al|||A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time|A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated With an Advagraf® or Prograf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up|Active, not recruiting||Phase 2|44|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 21:18:57.246975|2018-05-31 21:18:57.246975
NCT01614652|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-06-21|2012-06-06|2012-06-08|Estimate|||||||2017-06-21|2017-06-23|Actual|December 2012||2012-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PARACHUTE IV||A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System|Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease|Terminated||Phase 3|331|Actual|CardioKinetix, Inc||2||Company is closed|f||||t||||||||||2018-05-31 21:18:57.333218|2018-05-31 21:18:57.333218
NCT01614639|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-11-27|2012-06-07|2012-06-08|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2012|Actual|2012-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Brain Imaging Study of Acupuncture in Chronic Low Back Pain|A Physiological fMRI Study of Acupuncture and Perceptions of Pain in Chronic Low Back Pain Patients.|Completed||N/A|82|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 21:18:57.465006|2018-05-31 21:18:57.465006
NCT01614626|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-10-30|2012-06-06|2012-06-08|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2012|Actual|2012-11-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Alcohol's Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort|Alcohol & Zinc Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort|Active, not recruiting|||375|Anticipated|Boston Medical Center|||||f||||t|f|f||||Samples With DNA|"~     We are storing serum and plasma for future use, as well as dried blood spots for PEth~     testing.~   "|||2018-05-31 21:18:57.520204|2018-05-31 21:18:57.520204
NCT01614613|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|2013-06-30||2016-01-29|2012-06-06|2012-06-08|Estimate|2013-06-30|2013-09-09|Estimate||||2016-01-29|2016-02-29|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Comparison Evaluation of Blood Glucose Meter Systems in a Clinical Setting|Clinical Evaluation of Bayer G3 / Tatsu System and BGMs From Other Companies|Completed||N/A|146|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 21:18:57.745766|2018-05-31 21:18:57.745766
NCT01614600|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2013-09-27||2013-09-27|2012-06-06|2012-06-08|Estimate|2013-09-27|2013-12-04|Estimate||||2013-09-27|2013-12-04|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||This reporting group includes all enrolled and dispensed participants.|Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers|Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens Wearers|Completed||N/A|88|Actual|Alcon Research||1|||f||||t||||||||||2018-05-31 21:18:57.95919|2018-05-31 21:18:57.95919
NCT01614587|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-06-08|2012-06-07|2012-06-08|Estimate|||||||2017-06-08|2017-06-09|Actual|March 2012||2012-03-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition?|Do Patients With Early Post Operative Recurrence of Pelvic Organ Prolapse Have a Genetic Predisposition?|Completed|||50|Actual|Atlantic Health System|||2||f||||t||||||Samples With DNA|"~     DNA obtained from a buccal swab~   "|||2018-05-31 21:18:58.109046|2018-05-31 21:18:58.109046
NCT01614574|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2014-03-25||2014-07-08|2012-06-06|2012-06-08|Estimate|2014-07-08|2014-08-04|Estimate||||2014-07-08|2014-08-04|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease|A Multicenter, Open-Label Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease|Completed||Phase 3|6|Actual|Shire|All 6 enrolled patients received previous long-term treatment with the enzyme replacement therapy (ERT), imiglucerase. Key therapeutic parameters were expected to indicate stability after switching from imiglucerase.|1|||f||||f||||||||||2018-05-31 21:18:58.199493|2018-05-31 21:18:58.199493
NCT01614561|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-06|2012-06-06|2012-06-08|Estimate|||||||2012-06-06|2012-06-08|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|CEPHEUS||An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon|CEPHEUS Centralized Pan-Levant Survey on the Undertreatment of Hypercholesterolemia NIS-LT-CRE-2010/01 Version 1.0|Completed|||1000|Actual|AstraZeneca|||||f||||f||||||None Retained|"~     Blood specimens, serum, non-retained~   "|||2018-05-31 21:18:58.524832|2018-05-31 21:18:58.524832
NCT01614548|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-02|||2012-06-05|2012-06-05|2012-06-08|Estimate|||||||2012-06-05|2012-06-08|Estimate|January 2003||2003-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Management of Prostate Cancer in Central China|Comparisons of Management and Outcome of Prostate Cancer in Central China Between 2003 and 2008: A Multi-institutional Report|Completed|||789|Actual|Zhengzhou University|||1||f||||f||||||||||2018-05-31 21:18:58.583395|2018-05-31 21:18:58.583395
NCT01614535|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-07|2012-06-07|2012-06-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Comparison of the Effect Site Concentration of Remifentanil for Preventing Cough During Emergence Between Male and Female Patients With Thyroidectomy||Completed||N/A|46|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:18:58.652827|2018-05-31 21:18:58.652827
NCT01614522|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2015-01-13|2012-06-06|2012-06-08|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2|Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours Are Epidermal Growth Factor Receptor-2 (HER 2) Amplified or Co-expressing Epidermal Growth Factor Receptor-1 (HER-1) and HER-2.|Completed||Phase 2|24|Actual|Aslan Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:18:58.722586|2018-05-31 21:18:58.722586
NCT01614509|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|2012-08-31||2012-12-03|2012-06-07|2012-06-08|Estimate|2012-12-03|2012-12-04|Estimate||||2012-12-03|2012-12-04|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion||Completed||N/A|45|Actual|Yeungnam University College of Medicine|The limitation of our study include short duration of follow up (6 months) and small populations of study enroll (45 patients)|2|||f||||f||||||||||2018-05-31 21:18:58.812895|2018-05-31 21:18:58.812895
NCT01614496|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-09-23|2012-06-07|2012-06-08|Estimate|||||||2013-09-23|2013-09-24|Estimate||||June 2013|2013-06-30||||||||Interventional|||Rule-Based Closed Loop System for Type 1 Diabetes Control||Completed||N/A|||Corporacion Parc Tauli|||||f||||||||||||||2018-05-31 21:18:59.056257|2018-05-31 21:18:59.056257
NCT01614483|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2013-01-29|2012-06-05|2012-06-08|Estimate|||||||2013-01-29|2013-01-30|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CASSAVITA||Efficacy of Yellow Cassava to Improve Vitamin A Status of Kenyan School Children|Efficacy of Yellow Cassava to Improve Vitamin A Status of Mildly Deficient Primary School Children in Kenya: a Randomized Controlled Trial|Completed||N/A|341|Actual|Wageningen University||3|||f||||t||||||||||2018-05-31 21:18:59.106226|2018-05-31 21:18:59.106226
NCT01614470|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|2014-10-23||2014-10-23|2012-06-07|2012-06-08|Estimate|2014-10-23|2014-10-29|Estimate||||2014-10-23|2014-10-29|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|KONNECTION|Full Analysis Set (FAS) was defined as all randomized subjects who received at least 1 dose of study drug (ivacaftor or placebo).|Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation|A Phase 3, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Crossover Study With an Open-Label Period to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have a Non-G551D CFTR Gating Mutation|Completed||Phase 3|39|Actual|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-05-31 21:18:59.219278|2018-05-31 21:18:59.219278
NCT01614457|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|2015-01-31|2014-10-31|2015-01-31|2012-06-07|2012-06-08|Estimate|2015-01-31|2015-02-12|Estimate|2014-10-31|2014-11-07|Estimate|2015-01-31|2015-02-12|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|KONDUCT|Full Analysis Set (FAS) included all randomized subjects who received at least 1 dose of study drug (ivacaftor or placebo).|Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation|Completed||Phase 3|70|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 21:18:59.811807|2018-05-31 21:18:59.811807
NCT01614444|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-05-18|2012-06-05|2012-06-08|Estimate|||||||2017-05-18|2017-05-19|Actual|June 13, 2012|Actual|2012-06-13|May 2017|2017-05-31|March 7, 2017|Actual|2017-03-07|August 11, 2014|Actual|2014-08-11||Interventional|||Acupressure and Stress Resilience|Using Complementary and Alternative Medicine (CAM) to Promote Stress Resilience in Those With Co-Occurring Mild TBI and PTSD|Completed||N/A|60|Actual|VA Eastern Colorado Health Care System||2|||f||||||||||||||2018-05-31 21:19:00.372477|2018-05-31 21:19:00.372477
NCT01614431|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2012-06-19|2012-06-07|2012-06-08|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||N Acetyl Cysteine for Cystinosis Patients|N Acetyl Cysteine Can Decrease the Progression of Renal Disease in Cystinosis Patients|Completed||Phase 4|23|Actual|University of Sao Paulo||1|||f||||||||||||||2018-05-31 21:19:00.438047|2018-05-31 21:19:00.438047
NCT01614418|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-12-18|2012-06-07|2012-06-08|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Radiofrequency Ablation for Gastric Metaplasia and Dysplasia|Endoscopic Radiofrequency Ablation for Gastric Metaplasia and Dysplasia|Completed||Phase 1/Phase 2|10|Anticipated|The University of Hong Kong||1|||f||||f||||||||||2018-05-31 21:19:00.505171|2018-05-31 21:19:00.505171
NCT01614405|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2015-11-30|2012-06-06|2012-06-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|HAART||Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis|Randomized Controlled Pilot Study of Highly Active Anti-Retroviral Therapy for Patients With Primary Biliary Cirrhosis|Completed||N/A|13|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 21:19:00.579525|2018-05-31 21:19:00.579525
NCT01614392|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2012-06-05|2012-06-05|2012-06-07|Estimate|||||||2012-06-05|2012-06-07|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Lower Extremity Muscle and Function in the Elderly: Study 2|Lower Extremity Muscle and Function in the Elderly: Study 2|Completed||N/A|52|Actual|Tufts University||2|||f||||f||||||||||2018-05-31 21:19:00.662831|2018-05-31 21:19:00.662831
NCT01614379|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-04-11|2012-06-06|2012-06-07|Estimate|||||||2013-04-11|2013-04-12|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Non-enhanced Magnetic Resonance Angiography of Diabetic Ischemic Lower Limbs|Non-enhanced Magnetic Resonance Angiography of Diabetic Ischemic Lower Limbs|Withdrawn|||0|Actual|Aarhus University Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood sample less then 250ml to determine Hba1c (blood glucose level).~   "|||2018-05-31 21:19:00.795474|2018-05-31 21:19:00.795474
NCT01614366|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2015-11-11|2012-06-05|2012-06-07|Estimate|||||||2015-11-11|2015-11-13|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension|A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension|Completed||Phase 2|111|Actual|TSH Biopharm Corporation Limited||4|||f||||f||||||||||2018-05-31 21:19:00.869045|2018-05-31 21:19:00.869045
NCT01612208|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-05-21|2012-05-31|2012-06-05|Estimate|||||||2014-05-21|2014-05-23|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Observational|||MotionLoc Study, Femur Fractures|Healing of Distal Femur Fractures Stabilized With a Flexible Plating Construct Using MotionLoc Screws|Completed|||2|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 21:19:27.446557|2018-05-31 21:19:27.446557
NCT01614353|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-12-19|2012-06-06|2012-06-07|Estimate|||||||2012-12-19|2012-12-21|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Observational|||Medication-taking Preferences & Practices of Patients With Chronic Conditions|Medication-taking Preferences & Practices of Patients With Chronic Conditions|Unknown status|Recruiting||30|Anticipated|Washington State University|||1||f||||f||||||||||2018-05-31 21:19:00.991103|2018-05-31 21:19:00.991103
NCT01614340|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2017-11-01|2012-06-06|2012-06-07|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2012||2012-10-31|November 2017|2017-11-30|December 2015|Actual|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Treating Pain to Reduce Disability Among Older Home Health Patients|Treating Pain to Reduce Disability Among Older Home Health Patients|Completed||N/A|658|Actual|Visiting Nurse Service of New York||2|||f||||t||||||||||2018-05-31 21:19:01.089764|2018-05-31 21:19:01.089764
NCT01614327|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-09-14|2012-06-04|2012-06-07|Estimate|||||||2017-09-14|2017-09-18|Actual|August 2012||2012-08-31|September 2017|2017-09-30|February 24, 2015|Actual|2015-02-24|February 24, 2015|Actual|2015-02-24||Observational|||Computer-based Screening for Diabetic Retinopathy|Phase 0 Observational Study of a Computer-based Screening Algorithm for Detection of Diabetic Retinopathy|Completed|||19199|Actual|VisionQuest Biomedical LLC|||1||f||||f||||||||||2018-05-31 21:19:01.166483|2018-05-31 21:19:01.166483
NCT01614314|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-07|2012-06-06|2012-06-07|Estimate|||||||2012-06-07|2012-06-11|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dressing of Tunneled Central Venous Catheter|Dressing of Tunneled Central Venous Catheter: Preceptorship's Presence or Use of Auto-instructional Guide|Completed||N/A|35|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:19:01.257239|2018-05-31 21:19:01.257239
NCT01614301|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-05|2012-06-05|2012-06-07|Estimate|||||||2012-06-05|2012-06-07|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|May 2016|Anticipated|2016-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma|A Prospective Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial of Temsirolimus in Combination With Pioglitazone, Etoricoxib and Metronomic Low-dose Trofosfamide Versus Dacarbazine (DTIC) in Patients With Advanced Melanoma|Unknown status|Recruiting|Phase 1/Phase 2|136|Anticipated|University of Regensburg||2|||f||||t||||||||||2018-05-31 21:19:01.342068|2018-05-31 21:19:01.342068
NCT01614288|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-02-06|2012-06-04|2012-06-07|Estimate|||||||2013-02-06|2013-02-08|Estimate||||February 2013|2013-02-28||||||||Interventional|||High Tibial Osteotomy (HTO) With or Without Arthroscopy of the Knee Joint|A Randomized Clinical Trial to Compare the Effectiveness of High Tibial Osteotomy (HTO) With or Without Arthroscopy of the Knee Joint on Quality of Life, Function, Pain and Swelling for Patients With Medical Compartment Osteoarthritis of the Knee|Withdrawn||N/A|0|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 21:19:01.425484|2018-05-31 21:19:01.425484
NCT01614275|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-02-06|2012-06-05|2012-06-07|Estimate|||||||2018-02-06|2018-02-07|Actual|May 30, 2012|Actual|2012-05-30|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Using Web-based Technology to Expand and Enhance Applied Behavioral Analysis Programs for Children With Autism in Military Families|Using Technology to Expand and Enhance Applied Behavioral Analysis Programs for Children With Autism in Military Families|Active, not recruiting||N/A|66|Actual|University of Nebraska||4|||f||||f||||||||||2018-05-31 21:19:01.496344|2018-05-31 21:19:01.496344
NCT01614262|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-04-17|2012-06-05|2012-06-07|Estimate|||||||2017-04-17|2017-04-19|Actual|June 2012||2012-06-30|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Examining The Role of CGM in T2DM|Examining the Role of Continuous Glucose Monitoring (CGM) in Non-Insulin Treated Type 2 Diabetes|Completed||N/A|35|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:19:01.580652|2018-05-31 21:19:01.580652
NCT01614249|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|2015-11-25||2016-02-09|2012-06-05|2012-06-07|Estimate|2016-02-09|2016-03-08|Estimate||||2016-02-09|2016-03-08|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Omega-3 Supplementation and Depression Clinical Trial|Role of Omega-3 Fish Oil Fatty Acids on Depression Among HIV-seropositive Pregnant Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial|Completed||Phase 2/Phase 3|216|Actual|University of Nairobi|Omega-3 intake value based on international database due to absence in local food composition database. Cellular level EPA/DHA not reported due to technical problems with collected samples.|2|||f||||t||||||||||2018-05-31 21:19:01.66249|2018-05-31 21:19:01.66249
NCT01614236|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-06|2012-06-06|2012-06-07|Estimate|||||||2012-06-06|2012-06-07|Estimate|July 2012||2012-07-31|June 2012|2012-06-30||||August 2013|Anticipated|2013-08-31||Interventional|||Pre- Versus Post-Incisional Pregabalin for Postoperative Pain Control||Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 21:19:02.243949|2018-05-31 21:19:02.243949
NCT01614223|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-04-24|2012-06-04|2012-06-07|Estimate|||||||2014-04-24|2014-04-25|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis|A Randomized Double-Blind Clinical Trial to Investigate the Use of Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis|Unknown status|Recruiting|N/A|140|Anticipated|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 21:19:02.310718|2018-05-31 21:19:02.310718
NCT01614210|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2017-07-28||2018-05-10|2012-06-06|2012-06-07|Estimate|2017-11-14|2017-12-13|Actual||||2018-05-10|2018-05-15|Actual|August 2012||2012-08-31|May 2018|2018-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|POWER PIINC||Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance|Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance|Completed||Phase 2|52|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 21:19:02.378576|2018-05-31 21:19:02.378576
NCT01614197|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-05-31|2012-06-06|2012-06-07|Estimate|||||||2016-05-31|2016-06-02|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma|A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma|Recruiting||Phase 1|30|Anticipated|Therapeutic Advances in Childhood Leukemia Consortium||1|||f||||t||||||||No||2018-05-31 21:19:02.545378|2018-05-31 21:19:02.545378
NCT01614184|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-07-08|2012-06-04|2012-06-07|Estimate|||||||2013-07-08|2013-07-10|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer|Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Operable Breast Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 21:19:02.843806|2018-05-31 21:19:02.843806
NCT01614171|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-04-20|2012-06-05|2012-06-07|Estimate|||||||2017-04-20|2017-04-21|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|GHOPPG||Growth Hormone for Osteoporosis Pseudoglioma Syndrome|Trial of Growth Hormone for Osteoporosis Pseudoglioma Syndrome|Withdrawn||N/A|0|Actual|University of Maryland||1||it was never started because it was never funded|f||||t||||||||||2018-05-31 21:19:02.906457|2018-05-31 21:19:02.906457
NCT01614158|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-05-27|2012-06-06|2012-06-07|Estimate|||||||2014-05-27|2014-05-28|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|Pilot-SINN||Assessment of Visual Field-related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy|Pilot SINN; Assessment of Visual Field (vf)-Related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy (N-AION)|Completed|||16|Actual|University Hospital Tuebingen|||1||f||||f||||||||||2018-05-31 21:19:02.969476|2018-05-31 21:19:02.969476
NCT01614145|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-05-05|2012-06-05|2012-06-07|Estimate|||||||2017-05-05|2017-05-08|Actual|September 2007||2007-09-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Diagnostic Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples|Diagnostic Study Evaluating the Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis|Enrolling by invitation|||200|Anticipated|Heidelberg University|||2||f||||f||||||Samples With DNA|"~     Aspergillus DNA samples~   "|||2018-05-31 21:19:03.051287|2018-05-31 21:19:03.051287
NCT01614132|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-09-14|2012-06-06|2012-06-07|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2009||2009-01-31|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|NOA-07||Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults|Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-07)|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|University of Regensburg||1|||f||||f||||||||Undecided||2018-05-31 21:19:03.108275|2018-05-31 21:19:03.108275
NCT01614119|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-06-04|2012-06-04|2012-06-07|Estimate|||||||2012-06-04|2012-06-07|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CERVOX||Cerebral Responses During Exercise in Hypoxia|Evaluation of the Cerebral Responses to Exercise in Hypoxia|Completed||N/A|30|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 21:19:03.199434|2018-05-31 21:19:03.199434
NCT01614106|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2018-04-20|2012-06-04|2012-06-07|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2013||2013-01-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users|Project RETAIN: Providing Integrated Care for HIV-Infected Crack Cocaine Users|Active, not recruiting||N/A|360|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 21:19:03.257043|2018-05-31 21:19:03.257043
NCT01614093|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2017-04-14||2017-09-21|2012-06-04|2012-06-07|Estimate|2017-08-24|2017-09-21|Actual||||2017-09-21|2017-10-23|Actual|June 2012||2012-06-30|September 2017|2017-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia|Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia|Completed||Phase 4|24|Actual|University of Maryland||2|||f||||t|t|f||||||||2018-05-31 21:19:03.31882|2018-05-31 21:19:03.31882
NCT01614080|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-12-18|2012-06-04|2012-06-07|Estimate|||||||2014-12-18|2014-12-19|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|OPHELIE||Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA|Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA in the Administered Rt-PA|Completed|||700|Actual|University Hospital, Lille|||2||f||||t||||||||||2018-05-31 21:19:03.469645|2018-05-31 21:19:03.469645
NCT01614067|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-07-17|2012-06-04|2012-06-07|Estimate|||||||2015-07-17|2015-07-21|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|DOS/DOR||Delayed Start to Ovarian Stimulation|Delayed Start to Ovarian Stimulation Improves Oocyte Maturation and Quality: A Randomized Trial|Terminated||N/A|26|Actual|University of California, San Francisco||2||Slow enrollment resulted in withdraw of funding|f||||f||||||||||2018-05-31 21:19:03.520752|2018-05-31 21:19:03.520752
NCT01614054|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2014-03-14|2012-06-04|2012-06-07|Estimate|||||||2014-03-14|2014-03-17|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|N-PATCH||Nicotine Replacement Provided at a Tertiary Care Hospital|A Patient-centered Approach to Behavioral Modification in a Tertiary-care University-affiliated Hospital and the Incidence of Smoking Cessation|Completed||N/A|100|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 21:19:03.580979|2018-05-31 21:19:03.580979
NCT01614041|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2016-10-13|2012-06-06|2012-06-07|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|TACGAD||Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder|Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial|Recruiting||Phase 4|300|Anticipated|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:19:04.640819|2018-05-31 21:19:04.640819
NCT01614028|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-04-08|2012-06-05|2012-06-07|Estimate|||||||2013-04-08|2013-04-09|Estimate||||April 2013|2013-04-30||||||||Interventional|||Total Hip Arthroplasty Using Small Direct Anterior Incision: The Role of Short Femoral Stem||Unknown status|Recruiting|N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 21:19:04.714829|2018-05-31 21:19:04.714829
NCT01614015|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-10-17|2012-06-05|2012-06-07|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BOOST||Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial|Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial|Completed||Phase 2|328|Actual|Oregon Research Institute||2|||f||||t||||||||||2018-05-31 21:19:04.778865|2018-05-31 21:19:04.778865
NCT01614002|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2015-06-03|2012-06-06|2012-06-07|Estimate|||||||2015-06-03|2015-06-04|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region.|Completed|||371|Actual|Onkovis GmbH|||1||f||||t||||||||||2018-05-31 21:19:04.854309|2018-05-31 21:19:04.854309
NCT01613989|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-08-20|2012-06-05|2012-06-07|Estimate|||||||2014-08-20|2014-08-21|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|November 2014|Anticipated|2014-11-30|November 2013|Actual|2013-11-30||Interventional|NAVEOS||Total Hip Prosthesis Assisted by Computer|Total Hip Prosthesis Assisted by Computer Based on Pre-operative EOS Imaging|Unknown status|Active, not recruiting|N/A|78|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 21:19:04.942088|2018-05-31 21:19:04.942088
NCT01613976|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-01-13|2012-06-06|2012-06-07|Estimate|||||||2015-01-13|2015-01-14|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (Vidaza®) in Adult Japanese Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)|Completed||Phase 1|10|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:19:05.008627|2018-05-31 21:19:05.008627
NCT01613963|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-06-05|2012-06-05|2012-06-07|Estimate|||||||2012-06-05|2012-06-07|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Causes of Visual Loss in Retinal Disease|Observational Study of Visual Outcomes in Retinal Disease|Unknown status|Enrolling by invitation||2000|Anticipated|Royal Surrey County Hospital|||1||f||||f||||||||||2018-05-31 21:19:05.172297|2018-05-31 21:19:05.172297
NCT01613950|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-02-13|2012-06-06|2012-06-07|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2012||2012-12-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer|A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2|Completed||Phase 1|18|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:19:05.263827|2018-05-31 21:19:05.263827
NCT01613937|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-11-17|2012-06-05|2012-06-07|Estimate|||||||2014-11-17|2014-11-19|Estimate|December 2009||2009-12-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2011|Actual|2011-09-30||Interventional|||Community Approach to Reduce the Risks of Diabetes After Gestational Diabetes Mellitus|Dulce Mothers: A Community Approach to Reduce the Risks of Developing Diabetes After Gestational Diabetes|Completed||N/A|67|Actual|Scripps Whittier Diabetes Institute||1|||f||||t||||||||||2018-05-31 21:19:05.351385|2018-05-31 21:19:05.351385
NCT01613924|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-12-02|2012-06-04|2012-06-07|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Handheld Acne Heat Device|Efficacy of a Handheld Heat Based Device for the Spot Treatment of Mild to Moderate Acne Vulgaris: A Controlled Study to Determine Time to Resolution of Individual Inflammatory Lesions Using an Over-the-counter Acne Heat Device.|Withdrawn||Phase 4|0|Actual|University of British Columbia||2||Lack of funding and resources|f||||f||||||||||2018-05-31 21:19:05.420659|2018-05-31 21:19:05.420659
NCT01613911|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-12-04|2012-06-06|2012-06-07|Estimate|||||||2014-12-04|2014-12-08|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Study of Human Sensory Perception|A Combined fMRI and Electrophysiological Study of Human Sensory Perception|Completed|||6|Actual|Swedish Medical Center|||1||f||||f||||||||||2018-05-31 21:19:05.507595|2018-05-31 21:19:05.507595
NCT01613898|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-06-06|2012-06-06|2012-06-07|Estimate|||||||2012-06-06|2012-06-07|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|June 2015|Anticipated|2015-06-30|May 2013|Anticipated|2013-05-31||Observational|CTX||Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis|Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous Xanthomatosis|Unknown status|Recruiting||17|Anticipated|Sheba Medical Center|||1||f||||f||||||Samples Without DNA|"~     Lipid and lipoprotein profiles~   "|||2018-05-31 21:19:05.593445|2018-05-31 21:19:05.593445
NCT01613885|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-04-03|2012-06-05|2012-06-07|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2010||2010-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Understanding and Diagnosing Allergic Disease in Twins|Understanding and Diagnosing Allergic Disease in Twins|Recruiting|||200|Anticipated|Stanford University|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:19:05.70931|2018-05-31 21:19:05.70931
NCT01613872|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-09-30|2012-06-05|2012-06-07|Estimate|||||||2014-09-30|2014-10-01|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||The Effects of Mindfulness Based Stress Reduction on Patients With Traumatic Brain Injury|The Effects of Mindfulness Based Stress Reduction on Patients With Traumatic Brain Injury|Completed||N/A|8|Actual|Spaulding Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 21:19:05.798208|2018-05-31 21:19:05.798208
NCT01613859|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-05-25|2012-06-04|2012-06-07|Estimate|||||||2016-05-25|2016-05-27|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Measurement of Cardiac Output and Intravascular Volume Status in Children Using COstatus (SH)|Measurement of Cardiac Output and Intravascular Volume Status in Critically Ill Children Using an Ultrasound Dilution Method (COstatus)|Completed|||9|Actual|Transonic Systems Inc.|||||f||||||||||||||2018-05-31 21:19:05.863435|2018-05-31 21:19:05.863435
NCT01613846|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-04-19|2012-06-06|2012-06-07|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2012||2012-05-31|April 2017|2017-04-30||||October 30, 2016|Actual|2016-10-30||Interventional|||Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)|Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma|Completed||Phase 3|544|Anticipated|Technische Universität München||2|||f||||||||||||||2018-05-31 21:19:05.946274|2018-05-31 21:19:05.946274
NCT01613833|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-10-06|2012-06-05|2012-06-07|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2012||2012-03-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Serum and Synovium Protease Inhibitor Levels in Primary and Secondary Osteoarthritic Joints|Evaluation of Serum and Synovium Protease Inhibitor Levels in Primary and Secondary Osteoarthritic Joints, and Comparison for Patients Undergoing Joint Replacement|Suspended|||40|Anticipated|Scuderi, Gaetano J., M.D.|||2|need new PI, i moved|f||||f||||||Samples With DNA|"~     1. 2cc whole blood to be collected from patient on date of total knee arthroplasty~        2. Joint aspirate harvested and collected intraoperatively during total knee arhtroplasty~   "|||2018-05-31 21:19:06.108853|2018-05-31 21:19:06.108853
NCT01613820|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2018-02-15|2012-06-05|2012-06-07|Estimate|||||||2018-02-15|2018-02-19|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder|Combination of Anticholinergic and Glutamatergic Effects in Treatment-resistant Major Depressive Disorder. A Pilot Study|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||3||Lack of funding|f||||t||||||||||2018-05-31 21:19:06.286277|2018-05-31 21:19:06.286277
NCT01613807|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-06|2012-06-06|2012-06-07|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes|Phase 4 Humalog® Mix50/50(tm) for the Treatment of Insulin Requiring Gestational Diabetes|Completed||Phase 4|40|Actual|Sansum Diabetes Research Institute||2|||f||||t||||||||||2018-05-31 21:19:06.367747|2018-05-31 21:19:06.367747
NCT01613794|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-01-13|2012-06-06|2012-06-07|Estimate|||||||2017-01-13|2017-01-16|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|START||Rosuvastatin Use to Improve the Coagulation Profile in Patients With Venous Thrombosis|Prospective Randomized Controlled, Open Label, Clinical Trial to Study if Rosuvastatin Use Improves the Coagulation Profile in Patients With Venous Thrombosis|Completed||N/A|255|Actual|Leiden University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 21:19:06.484066|2018-05-31 21:19:06.484066
NCT01613781|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-12-24|2012-06-06|2012-06-07|Estimate|||||||2013-12-24|2013-12-25|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery|Determination of Target of Adequate Partial Neuromuscular Blockade With Sevoflurane Anesthesia for Electrophysiologic Monitoring During Microvascular Decompression Surgery|Completed||N/A|61|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:19:06.568176|2018-05-31 21:19:06.568176
NCT01613768|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-02-20|2012-06-06|2012-06-07|Estimate|||||||2018-02-20|2018-02-22|Actual|May 8, 2012|Actual|2012-05-08|February 2018|2018-02-28|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer|Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers|Completed||Phase 2|29|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 21:19:06.673044|2018-05-31 21:19:06.673044
NCT01613755|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-04-26|2012-06-06|2012-06-07|Estimate|||||||2013-04-26|2013-04-29|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|MetDipy||Metformin-Dipyridamole Interaction Trial|The Effect of Dipyridamole on the Pharmacokinetics of Metformin|Completed||Phase 4|18|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:19:06.756975|2018-05-31 21:19:06.756975
NCT01613742|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-11-21|2012-06-06|2012-06-07|Estimate|||||||2013-11-21|2013-11-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:19:06.87911|2018-05-31 21:19:06.87911
NCT01613729|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-09-22|2012-06-06|2012-06-07|Estimate|||||||2012-09-22|2012-09-25|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|Cor16||Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin|An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin|Unknown status|Enrolling by invitation|Phase 4|2000|Anticipated|D16 Pharma & Biotec Ltd.||2|||f||||t||||||||||2018-05-31 21:19:06.926243|2018-05-31 21:19:06.926243
NCT01613716|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|2018-03-12||2018-04-17|2012-06-06|2012-06-07|Estimate|2018-04-17|2018-05-16|Actual||||2018-04-17|2018-05-16|Actual|July 2012|Actual|2012-07-31|April 2018|2018-04-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|OPERA||Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)|Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)|Completed||Phase 4|30|Actual|The Cleveland Clinic||1|||f||||t||||||||No||2018-05-31 21:19:07.024906|2018-05-31 21:19:07.024906
NCT01613703|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-05-31|2012-06-06|2012-06-07|Estimate|||||||2013-05-31|2013-06-03|Estimate|August 2012||2012-08-31|May 2013|2013-05-31||||March 2013|Actual|2013-03-31||Interventional|||ONO-2952 Single-dose PET Study in Healthy Adult Subjects|Open-Label, Single-Center, Single Dose Positron Emission Topography (PET) Using [11C]PBR28 to Evaluate Brain Translocator Protein 18KDa (TSPO) Occupancy of ONO-2952 in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Ono Pharmaceutical Co. Ltd||1|||f||||||||||||||2018-05-31 21:19:07.281821|2018-05-31 21:19:07.281821
NCT01613690|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-05|2012-06-05|2012-06-07|Estimate|||||||2012-06-05|2012-06-07|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment|An Open Label, Non-randomized, Parallel-group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of a Single Dose of NVA237 in Subjects With Mild, Moderate, Severe and End-stage Renal Impairment With That in Matched Healthy Control Subjects|Completed||Phase 1|48|Actual|Novartis||5|||f||||||||||||||2018-05-31 21:19:07.351753|2018-05-31 21:19:07.351753
NCT01613677|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-04-19|2012-06-06|2012-06-07|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2015||2015-11-30|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer|Phase II, Open Label, Non-randomized, Trial of BKM120 as Palliative Treatment for Metastatic or Locally Advanced Cervical Cancer After Failure to Platinum Based Regimen|Withdrawn||Phase 2|0|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:19:07.431118|2018-05-31 21:19:07.431118
NCT01613664|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-01-30|2012-06-06|2012-06-07|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|TISSEEL||Efficiency of TISSEEL for Sleeve Gastrectomy Complications|Randomized Prospective Clinical Study Evaluating the Usefulness of Fibrin Glue (TISSEEL® KIT) to Prevent Gastric Fistula, Intra Abdominal Haemorrhage and Intra Abdominal Loco Regional Collections After Laparoscopic Sleeve Gastrectomy|Recruiting||Phase 3|600|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 21:19:07.495871|2018-05-31 21:19:07.495871
NCT01613651|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-09-13|2012-06-06|2012-06-07|Estimate|||||||2017-09-13|2017-09-14|Actual|August 24, 2012|Actual|2012-08-24|September 2017|2017-09-30|September 11, 2017|Actual|2017-09-11|September 11, 2017|Actual|2017-09-11||Interventional|||Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer|A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients With Prostate Cancer|Completed||Phase 3|191|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 21:19:07.578768|2018-05-31 21:19:07.578768
NCT01613638|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2018-04-06|2012-06-06|2012-06-07|Estimate|||||||2018-04-06|2018-04-09|Actual|October 2012||2012-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PENEW||Pregnancy Environment and Newborn Malformations|"Congenital Malformations and Intrauterine Pollutants Exposure (Alcohol, Solvents and Pesticides) in Brittany. Population Based Case-control Study Short Title : Malformations and Environment Acronym : PENEW for Pregnancy Environment and Newborn Malformations"|Recruiting||N/A|5000|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 21:19:07.656495|2018-05-31 21:19:07.656495
NCT01613625|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-08-28|2012-06-05|2012-06-07|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Interest Of Renal Elastography In Children As A Diagnostic Tool Of Renal Fibrosis: Confrontation To Histological Features Of Renal Biopsies|Interest Of Renal Elastography In Children As A Diagnostic Tool Of Renal Fibrosis: Confrontation To Histological Features Of Renal Biopsies|Unknown status|Active, not recruiting|N/A|100|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 21:19:07.789904|2018-05-31 21:19:07.789904
NCT01613612|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-08-12|2012-06-05|2012-06-07|Estimate|||||||2012-08-12|2012-08-14|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH)|Control Study of Implantation of Enriched Bone Marrow Cells for the Treatment of Avascular Necrosis of Femoral Head|Unknown status|Enrolling by invitation|Phase 2/Phase 3|60|Anticipated|Guangdong General Hospital||2|||f||||f||||||||||2018-05-31 21:19:07.940469|2018-05-31 21:19:07.940469
NCT01613599|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2016-07-06||2017-08-10|2012-06-06|2012-06-07|Estimate|2016-07-06|2016-08-17|Estimate||||2017-08-10|2017-08-14|Actual|June 20, 2012|Actual|2012-06-20|August 2017|2017-08-31|April 28, 2017|Actual|2017-04-28|July 13, 2015|Actual|2015-07-13||Observational||Safety population included all participants who received any dose of rituximab and whose safety data was verifiable.|An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis|Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab|Completed|||100|Actual|Genentech, Inc.|||1||f||||t||||||||||2018-05-31 21:19:08.036986|2018-05-31 21:19:08.036986
NCT01613586|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-03-26|2012-06-05|2012-06-07|Estimate|||||||2014-03-26|2014-03-28|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|AMARANTH||A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Subjects With Bladder Pain Syndrome / Interstitial Cystitis|Completed||Phase 2|287|Actual|Astellas Pharma Inc||4|||f||||t||||||||||2018-05-31 21:19:08.439235|2018-05-31 21:19:08.439235
NCT01613573|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-13|2012-06-05|2012-06-07|Estimate|||||||2012-06-13|2012-06-14|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|Phase 1||Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children|A Phase 1, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Pegylated Somatropin(PEG Somatropin) in GHD Children|Completed||Phase 1|12|Actual|GeneScience Pharmaceuticals Co., Ltd.|||||f||||t||||||||||2018-05-31 21:19:08.634952|2018-05-31 21:19:08.634952
NCT01613560|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2017-02-24|2012-06-06|2012-06-07|Estimate|||||||2017-02-24|2017-02-27|Actual|June 2012||2012-06-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy|Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy|Recruiting||Phase 2|404|Anticipated|Peking University||3|||f||||t||||||||||2018-05-31 21:19:08.703469|2018-05-31 21:19:08.703469
NCT01613547|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2014-05-20|2012-06-05|2012-06-07|Estimate|||||||2014-05-20|2014-05-21|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Routine Antibiotic Use in the Outpatient Treatment of Severely Malnourished Children Without Complications|The Effect of Routine Antibiotic Use in the Outpatient Treatment of Severely Malnourished Children Without Complications: Maradi, Niger|Completed||N/A|2412|Anticipated|Epicentre||2|||f||||f||||||||||2018-05-31 21:19:08.835201|2018-05-31 21:19:08.835201
NCT01613534|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-05|2012-06-05|2012-06-07|Estimate|||||||2012-06-05|2012-06-07|Estimate|June 2003||2003-06-30|June 2012|2012-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Combined Therapy in Radiation Proctopathy|Argon Plasma Coagulation Plus Placebo or Oral Sucralfate for Chronic Radiation Proctopathy: a Randomized Placebo Controlled Trial|Completed||Phase 4|122|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 21:19:08.906943|2018-05-31 21:19:08.906943
NCT01613521|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-03-12|2012-06-05|2012-06-07|Estimate|||||||2014-03-12|2014-03-13|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer|Tumor Perfusion and Hypoxia Assessed by DCE-MRI and 18F-FMISO PET as Biomarkers of Treatment Response in Cervical Cancer|Terminated||N/A|3|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 21:19:08.982443|2018-05-31 21:19:08.982443
NCT01613508|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-01-22|2012-06-06|2012-06-07|Estimate|||||||2017-01-22|2017-01-24|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Randomized Study of Approaches in Total Hip Arthroplasty|A Randomized Clinical Trial of Direct Anterior Approach and Mini-Posterior Approach Total Hip Arthroplasty|Active, not recruiting||N/A|116|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:19:09.050164|2018-05-31 21:19:09.050164
NCT01613495|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-06-04|2012-06-04|2012-06-07|Estimate|||||||2012-06-04|2012-06-07|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|November 2010|Actual|2010-11-30|March 2009|Actual|2009-03-31||Interventional|||Ghrelin Suppression by Octreotide in Prader-Willi|Ghrelin Suppression by Sandostatin LAR® Depot (Octreotide Acetate for Injectable Suspension) in Patients With Prader-Willi Syndrome|Completed||N/A|2|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 21:19:09.131473|2018-05-31 21:19:09.131473
NCT01613482|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-06|2012-06-06|2012-06-07|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|TSARINE||TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention|Interest of the Prophylactic Cerebral Radiotherapy in the Metastatic Breast Cancer Expressing HER2/NEU Treated by Trastuzumab|Terminated||Phase 3|13|Actual|Centre Oscar Lambret||2||Lack of enrollment|f||||f||||||||||2018-05-31 21:19:09.205655|2018-05-31 21:19:09.205655
NCT01613469|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-04-01|2012-06-05|2012-06-07|Estimate|||||||2015-04-01|2015-04-03|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer|Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer|Unknown status|Recruiting|Phase 2|35|Anticipated|Marks, John, M.D.|||||f||||f||||||||||2018-05-31 21:19:09.301198|2018-05-31 21:19:09.301198
NCT01613456|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-05-13|2012-06-06|2012-06-07|Estimate|||||||2015-05-13|2015-05-14|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome|Effect of S.Cerevisiae vs Placebo on the Improvement of Gastrointestinal Disorders,Especially During Irritable Bowel Syndrome. Randomized, Double-blind Study|Completed||N/A|364|Actual|Lesaffre International||2|||f||||||||||||||2018-05-31 21:19:09.388091|2018-05-31 21:19:09.388091
NCT01613443|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-04-04|2012-06-05|2012-06-07|Estimate|||||||2017-04-04|2017-04-05|Actual|June 2012||2012-06-30|April 2017|2017-04-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|||Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices|Time-dependent ex Vivo Influence of Rivaroxaban on Point-of-care Devices|Completed|||100|Actual|Cardioangiologisches Centrum Bethanien|||4||f||||f||||||||||2018-05-31 21:19:09.447486|2018-05-31 21:19:09.447486
NCT01613430|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-04-24|2012-06-05|2012-06-07|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2012||2012-06-30|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|COACH||Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors|Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors (COACH)|Completed||N/A|1106|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:19:09.496341|2018-05-31 21:19:09.496341
NCT01613417|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2015-04-28||2015-06-04|2012-06-05|2012-06-07|Estimate|2015-05-15|2015-06-03|Estimate||||2015-06-04|2015-07-01|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|TRUTH|Per Protocol|Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain|Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH)|Completed||Phase 4|229|Actual|Bracco Diagnostics, Inc|Histologic confirmation of disease available for only 139/198 patients in the PP analysis. Of these, 128 patients had confirmed brain tumors and were available for the analyses of diagnostic performance (tumor detection and tumor characterization).|2|||f||||f||||||||||2018-05-31 21:19:09.589569|2018-05-31 21:19:09.589569
NCT01613404|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2016-01-20|2012-06-06|2012-06-07|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|PROSTARRT||An Observational Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis|A Prospective, Observational, Randomized Comparative Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis|Completed|||248|Actual|Janssen Inc.|||2||f||||t||||||||||2018-05-31 21:19:10.407419|2018-05-31 21:19:10.407419
NCT01613391|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-08|2012-06-06|2012-06-07|Estimate|||||||2012-06-08|2012-06-11|Estimate|July 2011||2011-07-31|June 2012|2012-06-30||||February 2012|Actual|2012-02-29||Observational|||Effect of Roux-en-Y Gastric Bypass Versus Laparoscopic Adjustable Gastric Band Operations on Resistin, Apelin and Visfatin Peptides|Effect of Roux-en-Y Gastric Bypass Versus Laparoscopic Adjustable Gastric Band Operations on Resistin, Apelin and Visfatin Peptides|Completed|||30|Actual|Istanbul University|||2||f||||||||||||||2018-05-31 21:19:10.528484|2018-05-31 21:19:10.528484
NCT01613378|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|2016-01-14||2016-08-10|2012-06-05|2012-06-07|Estimate|2016-08-10|2016-10-04|Estimate||||2016-08-10|2016-10-04|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra)|A Multi-National, Multi-Center Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Who Are Treated With Tocilizumab|Completed|||200|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:19:10.632837|2018-05-31 21:19:10.632837
NCT01613365|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-08-06|2012-06-06|2012-06-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CHLORHEX||Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections|Oropharyngeal and Nasopharyngeal Decontamination With Chlorhexidine Gluconate in the Reduction of the Postoperative Morbidity and Mortality After Major Pulmonary Resections: a Multicentric, Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 3|474|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 21:19:11.022413|2018-05-31 21:19:11.022413
NCT01613352|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-05|2012-06-05|2012-06-07|Estimate|||||||2012-06-05|2012-06-07|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Feasibility of Ambulatory Surgery for Early Breast Cancer|Same Day Discharge After Surgery for Early Breast Cancer - a Feasible Option|Completed||N/A|100|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 21:19:11.095296|2018-05-31 21:19:11.095296
NCT01613339|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2013-06-07||2013-12-04|2012-06-04|2012-06-07|Estimate|2013-12-04|2013-12-30|Estimate||||2013-12-04|2013-12-30|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Body Awareness Therapy for People With Stroke|Body Awareness Therapy for People With Stroke|Completed||N/A|46|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 21:19:11.198068|2018-05-31 21:19:11.198068
NCT01613326|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2014-01-10||2014-04-22|2012-06-06|2012-06-07|Estimate|2014-04-22|2014-04-23|Estimate||||2014-04-22|2014-04-23|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|GLOW5||Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Randomized, Blinded, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of NVA237 (50 µg o.d.) Compared to Tiotropium (18 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|657|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:19:11.482902|2018-05-31 21:19:11.482902
NCT01613313|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|2016-02-10||2016-08-25|2012-06-05|2012-06-07|Estimate|2016-02-10|2016-03-09|Estimate||||2016-08-25|2016-10-06|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma|A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma|Completed||Phase 2|14|Actual|Gerut, Zachary, M.D.||4|||f||||f||||||||No||2018-05-31 21:19:12.227155|2018-05-31 21:19:12.227155
NCT01613300|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-10-27|2012-06-05|2012-06-07|Estimate|||||||2017-10-27|2017-10-30|Actual|May 2012||2012-05-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients|Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation|Active, not recruiting||Phase 2|33|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||No||2018-05-31 21:19:12.567078|2018-05-31 21:19:12.567078
NCT01613287|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2013-12-06|2012-06-06|2012-06-07|Estimate|||||||2013-12-06|2013-12-09|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension|A Clinical Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension|Completed||N/A|12|Actual|Miltenyi Biotec GmbH||1|||f||||t||||||||||2018-05-31 21:19:12.65464|2018-05-31 21:19:12.65464
NCT01613274|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2014-04-21|2012-06-05|2012-06-07|Estimate|||||||2014-04-21|2014-04-22|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||The Effect of Gum Chewing on Bowel Motility in Post-operative Colon Resection Patients|The Effect of Gum Chewing on Bowel Motility in Post-operative Colon Resection Patients|Completed||Phase 3|80|Actual|Allina Health System||2|||f||||f||||||||||2018-05-31 21:19:12.73257|2018-05-31 21:19:12.73257
NCT01613261|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2013-10-31|2012-06-04|2012-06-07|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|||Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies|Withdrawn||Phase 1|0|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:19:12.801985|2018-05-31 21:19:12.801985
NCT01613248|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2016-08-08||2016-08-08|2012-06-04|2012-06-07|Estimate|2016-08-08|2016-09-30|Estimate||||2016-08-08|2016-09-30|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All Subjects as Treated Population included all randomized participants who received at least 1 dose of study treatment.|A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine|Completed||Phase 2|834|Actual|Allergan||6|||f||||f||||||||||2018-05-31 21:19:12.916963|2018-05-31 21:19:12.916963
NCT01613235|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-11-02|2012-06-06|2012-06-07|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2010||2010-08-31|November 2017|2017-11-30|December 10, 2015|Actual|2015-12-10|January 2015|Actual|2015-01-31||Interventional|HIMALAIA||Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage|Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage|Terminated||Phase 3|26|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||As advised by the DSMB the study was stopped due to slow recruitment.|f||||t||||||||||2018-05-31 21:19:13.889084|2018-05-31 21:19:13.889084
NCT01613222|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-08|2012-06-05|2012-06-07|Estimate|||||||2012-06-08|2012-06-11|Estimate|June 2012||2012-06-30|June 2012|2012-06-30||||||||Interventional|||SpO2 System Accuracy Testing|SpO2 System Accuracy Testing|Unknown status|Recruiting|N/A|100|Anticipated|GE Healthcare||1|||f||||f||||||||||2018-05-31 21:19:13.970035|2018-05-31 21:19:13.970035
NCT01613209|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-05-02|2012-06-04|2012-06-07|Estimate|||||||2016-05-02|2016-05-03|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|Sevicontrol1||Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine|Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial|Completed||Phase 3|83|Actual|Institut für Pharmakologie und Präventive Medizin||1|||f||||t||||||||No||2018-05-31 21:19:14.07249|2018-05-31 21:19:14.07249
NCT01613196|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-03-27|2012-06-04|2012-06-07|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2012|Actual|2012-05-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|September 2016|Actual|2016-09-30||Interventional|TUBOGTEP||Positron Emission Tomography in Extrapulmonary Tuberculosis|Evaluation of Positron Emission Tomography in Extrapulmonary Tuberculosis|Completed||N/A|55|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||Undecided||2018-05-31 21:19:14.166945|2018-05-31 21:19:14.166945
NCT01613183|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-06-04|2012-06-04|2012-06-07|Estimate|||||||2012-06-04|2012-06-07|Estimate|May 2012||2012-05-31|June 2012|2012-06-30||||||||Interventional|||Exploratory Study of Effective Core Formula of Chinese Medicine to Treat Primary Insomnia||Unknown status|Recruiting|N/A|2||China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 21:19:14.238009|2018-05-31 21:19:14.238009
NCT01613170|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-04-18|2012-06-04|2012-06-07|Estimate|||||||2017-04-18|2017-04-20|Actual|April 2012||2012-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Premarin Versus Toviaz for Treatment of Overactive Bladder|A Combined Treatment Program for the Symptoms of Urinary Urgency and Frequency With Toviaz and Premarin Vaginal Cream|Recruiting||Phase 4|90|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 21:19:14.316254|2018-05-31 21:19:14.316254
NCT01613157|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-06-04|2012-06-04|2012-06-07|Estimate|||||||2012-06-04|2012-06-07|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression||Completed|||88|Actual|Canadian Immunodeficiency Research Collaborative|||||f||||||||||||||2018-05-31 21:19:14.408528|2018-05-31 21:19:14.408528
NCT01613144|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2016-01-15|2012-06-04|2012-06-07|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|EVOLVE||OsseoScrew Versus Fenestrated Pedicle Screws Augmented With Polymethylmethacrylate|Expandable Pedicle Screws Versus Fenestrated Pedicle Screws Augmented With Polymethylmethacrylate (PMMA): Complications and Clinical Outcomes in Patients With Osteoporosis or Poor Bone Quality|Unknown status|Active, not recruiting||90|Actual|Alphatec Spine, Inc.|||2||f||||f||||||||||2018-05-31 21:19:14.467943|2018-05-31 21:19:14.467943
NCT01613131|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2015-08-11||2015-10-29|2012-06-05|2012-06-06|Estimate|2015-10-29|2015-12-02|Estimate||||2015-10-29|2015-12-02|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression|Effectiveness of Perimenopausal Hormone Therapy in Suppression of Ovulation, Stabilization of Reproductive Hormones and Symptom Control|Completed||N/A|39|Actual|University of Colorado, Denver|The main limitation was the sample size, which is consistent with a pilot study, and which can only inform the design of future research.|2|||f||||t||||||||||2018-05-31 21:19:14.55096|2018-05-31 21:19:14.55096
NCT01613118|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2018-03-16|2012-06-05|2012-06-06|Estimate|||||||2018-03-16|2018-03-20|Actual|December 2013||2013-12-31|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|June 2016|Actual|2016-06-30||Interventional|DUET||Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis|Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study|Active, not recruiting||Phase 2|100|Anticipated|Retrophin, Inc.||4|||f||||t||||||||||2018-05-31 21:19:14.896602|2018-05-31 21:19:14.896602
NCT01613105|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-06-24|2012-06-05|2012-06-06|Estimate|||||||2013-06-24|2013-06-26|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Diabetes Treatment With Glucobay in Combination With Sulfonylurea|Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Sulfonylurea Under Daily Life Treatment Conditions|Completed|||4564|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:19:15.112322|2018-05-31 21:19:15.112322
NCT01613092|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-10-09|2012-06-05|2012-06-06|Estimate|||||||2014-10-09|2014-10-10|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Prevention of Arrhythmia Device Infection Trial (PADIT)|Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study|Completed||Phase 4|241|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-05-31 21:19:15.178985|2018-05-31 21:19:15.178985
NCT01613079|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-08-02|2012-06-04|2012-06-06|Estimate|||||||2013-08-02|2013-08-05|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TRIFRA||Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis|Evaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.|Completed||Phase 2/Phase 3|201|Actual|Peking Union Medical College Hospital||3|||f||||t||||||||||2018-05-31 21:19:15.253389|2018-05-31 21:19:15.253389
NCT01613066|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|May 2013|Anticipated|2013-05-31|November 2012|Anticipated|2012-11-30||Interventional|||Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies|Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Ospedale Santa Croce-Carle Cuneo||1|||f||||f||||||||||2018-05-31 21:19:15.318297|2018-05-31 21:19:15.318297
NCT01613053|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-04-23|2012-06-04|2012-06-06|Estimate|||||||2015-04-23|2015-04-24|Estimate||||April 2015|2015-04-30||||||||Expanded Access|MACS2226||Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination|Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination|No longer available|||||Novartis|||||f||||f||||||||||2018-05-31 21:19:15.411616|2018-05-31 21:19:15.411616
NCT01613040|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-11-01|2012-06-04|2012-06-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers|A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects.|Completed||Phase 1|169|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:19:15.482843|2018-05-31 21:19:15.482843
NCT01613027|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2016-08-31||2016-08-31|2012-06-04|2012-06-06|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational||Intention-to Treat population, defined as all enrolled participants who received at least one dose of rituximab.|An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis|A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)|Completed|||135|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:19:15.580529|2018-05-31 21:19:15.580529
NCT01613014|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2016-09-29||2017-02-15|2012-06-04|2012-06-06|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|February 2013||2013-02-28|February 2017|2017-02-28|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional||144 represents the modified intention to treat population (mITT) - took at least one dose of medication.|ABT-436 for Alcohol Dependence|A Phase 2, Double-Blind, Randomized, Placebo Controlled Trial to Assess the Efficacy of ABT-436 for Alcohol Dependence|Completed||Phase 2|150|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||t||||||||||2018-05-31 21:19:15.949582|2018-05-31 21:19:15.949582
NCT01613001|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-10-15|2012-06-05|2012-06-06|Estimate|||||||2014-10-15|2014-10-16|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force Readiness||Completed|||67904|Actual|Mike O'Callaghan Military Hospital|||1||f||||f||||||||||2018-05-31 21:19:16.217879|2018-05-31 21:19:16.217879
NCT01612988|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2018-04-26|2012-06-05|2012-06-06|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2012|Actual|2012-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|December 2015|Actual|2015-12-31||Interventional|BOMP||Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL|Phase II Salvage Treatment With Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in Relapsed B-cell Chronic Lymphocytic Leukemia (B-CLL)|Terminated||Phase 2|74|Actual|French Innovative Leukemia Organisation||1||Other drugs others studies|f||||t||||||||||2018-05-31 21:19:16.269317|2018-05-31 21:19:16.269317
NCT01612975|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2018-02-13|2012-06-04|2012-06-06|Estimate|||||||2018-02-13|2018-02-15|Actual|April 2014||2014-04-30|September 2016|2016-09-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection|The Effect of Perioperative Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection|Terminated||Phase 2|7|Actual|McMaster University||2||Recruitment futile|f||||f||||||||||2018-05-31 21:19:16.344806|2018-05-31 21:19:16.344806
NCT01612962|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-02-05|2012-06-05|2012-06-06|Estimate|||||||2015-02-05|2015-02-06|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Diagnostic Tests to Help Determine Osteomyelitis|Diagnostic Tests to Help Determine Osteomyelitis: an Analysis and Comparison of Clinical Signs, Microbiology, Pathology and Radiology.|Terminated|||196|Actual|Georgetown University|||1||f||||f||||||||||2018-05-31 21:19:16.426111|2018-05-31 21:19:16.426111
NCT01612949|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-11-02|2012-06-05|2012-06-06|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2012||2012-05-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Facial Analysis to Classify Difficult Intubation|Comparison of a Computerized Image Analysis to Conventional Airway Examination Techniques to Predict Difficult Endotracheal Intubation|Recruiting|||1000|Anticipated|Wake Forest University Health Sciences|||4||f||||f|f|||||||Undecided||2018-05-31 21:19:16.624278|2018-05-31 21:19:16.624278
NCT01612936|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-09-14|2012-06-05|2012-06-06|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2012||2012-09-30|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MGH-001||T Cell Effector and Regulatory Mechanisms in Asthma|T Cell Effector and Regulatory Mechanisms in Asthma|Completed||Phase 1|168|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:19:16.700123|2018-05-31 21:19:16.700123
NCT01612923|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-08-25|2012-06-04|2012-06-06|Estimate|||||||2013-08-25|2013-08-27|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians|Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians|Completed||Phase 3|1180|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 21:19:16.775774|2018-05-31 21:19:16.775774
NCT01612910|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-02-10|2012-06-04|2012-06-06|Estimate|||||||2014-02-10|2014-02-12|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery|A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive, Invasive Breast Cancer, Who Have Residual Disease Following Surgical Resection After Neoadjuvant Chemotherapy|Withdrawn||Phase 2|0|Actual|Barbara Ann Karmanos Cancer Institute||1||Research cancelled.|f||||t||||||||||2018-05-31 21:19:16.840346|2018-05-31 21:19:16.840346
NCT01612897|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-03-23|2012-06-05|2012-06-06|Estimate|||||||2015-03-23|2015-03-24|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CAAC||Study of the Effectiveness of a Computer Decision Support System to Improve Physicians' Screening for Autism|Computer Assisted Autism Care (CAAC)|Completed||N/A|368|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 21:19:16.900661|2018-05-31 21:19:16.900661
NCT01612884|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2017-12-29||2018-03-28|2012-06-04|2012-06-06|Estimate|2018-03-28|2018-04-26|Actual||||2018-03-28|2018-04-26|Actual|August 2011||2011-08-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)|Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)|Terminated||Phase 4|67|Actual|Indiana University||2||Slow enrollment|f||||||||||||||2018-05-31 21:19:16.965331|2018-05-31 21:19:16.965331
NCT01612871|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2018-03-02|2012-06-05|2012-06-06|Estimate|||||||2018-03-02|2018-03-05|Actual|June 27, 2012|Actual|2012-06-27|March 2018|2018-03-31|January 28, 2016|Actual|2016-01-28|January 28, 2016|Actual|2016-01-28||Interventional|MIRHO||Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer|Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer? Pilot Study.|Completed||Phase 4|39|Actual|Institut Claudius Regaud||1|||f||||f||||||||||2018-05-31 21:19:17.309598|2018-05-31 21:19:17.309598
NCT01612858|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2016-05-12||2016-05-12|2012-06-05|2012-06-06|Estimate|2016-05-12|2016-06-20|Estimate||||2016-05-12|2016-06-20|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Metabolic Abnormalities in HIV-infected Persons|Metabolic Abnormalities in HIV-infected Persons|Completed||Phase 4|20|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-05-31 21:19:17.386566|2018-05-31 21:19:17.386566
NCT01612845|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|May 2009|Actual|2009-05-31||Interventional|PRP-Fibrin||Effect of Platelet-rich Fibrin on Rotator Cuff Repair|Platelet-Rich Fibrin for Arthroscopically Repaired Massive Rotator Cuff Tears: A Prospective Randomized Pilot Clinical Trial|Completed||Phase 2|28|Actual|Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 21:19:17.615857|2018-05-31 21:19:17.615857
NCT01612832|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2012||2012-06-30|June 2012|2012-06-30||||June 2013|Anticipated|2013-06-30||Interventional|||Pregabalin for Post-craniotomy Pain Control|Peri-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Elective Neurosurgical Patients: A Randomized, Comparative, Placebo-controlled, Double Blind Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 21:19:17.700776|2018-05-31 21:19:17.700776
NCT01612819|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-03-30|2012-06-04|2012-06-06|Estimate|||||||2017-03-30|2017-03-31|Actual|April 2012|Actual|2012-04-30|March 2017|2017-03-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|||DXR Stent(Previous Cilotax) Implantation Registry|Evaluation of Effectiveness and Safety of DXR(Previous Cilotax) Stent in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study (IRIS-CILOTAX)|Terminated|||451|Actual|CardioVascular Research Foundation, Korea||||No more enrollment|f||||f||||||||No|This is not a publicly funded trial.|2018-05-31 21:19:17.779602|2018-05-31 21:19:17.779602
NCT01612806|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-08-07|2012-06-05|2012-06-06|Estimate|||||||2017-08-07|2017-08-08|Actual|June 2011||2011-06-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Multi-center, Prospective, Randomized Study With PriMatrix and PriMatrix Ag for the Treatment of Venous Leg Ulcers|A Multi-center, Prospective, Randomized Study With PriMatrix Dermal Repair Scaffold, PriMatrix Ag Antimicrobial Dermal Repair Scaffold, and Standard of Care for the Treatment of Venous Leg Ulcers|Terminated||N/A|31|Actual|Integra LifeSciences Corporation||3||Site selection|f||||f||||||||||2018-05-31 21:19:17.877356|2018-05-31 21:19:17.877356
NCT01612793|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2015-03-11|2012-06-04|2012-06-06|Estimate|||||||2015-03-11|2015-03-12|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Vagus Nerve Stimulation for Management of Bronchoconstriction in Patients Hospitalized With COPD Exacerbations|Non-Invasive Vagus Nerve Stimulation With the AlphaCore Device for Management of Bronchoconstriction in Patients Hospitalized With COPD|Terminated|||4|Actual|ElectroCore LLC|||1||f||||t||||||Samples Without DNA|"~     Complete CBC and blood gases will be drawn at different time points to establish the medical~     condition of the subjects.~   "|||2018-05-31 21:19:17.962878|2018-05-31 21:19:17.962878
NCT01612780|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2014-05-20|2012-06-04|2012-06-06|Estimate|||||||2014-05-20|2014-05-22|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study|Trans-Nasal Maxillary Multi-Sinus Balloon Dilation Study|Completed||N/A|81|Actual|Entellus Medical, Inc.||1|||f||||f||||||||||2018-05-31 21:19:18.051615|2018-05-31 21:19:18.051615
NCT01612767|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2016-12-27||2018-01-04|2012-06-05|2012-06-06|Estimate|2017-04-17|2017-05-30|Actual||||2018-01-04|2018-01-29|Actual|November 2012||2012-11-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|September 2015|Actual|2015-09-30||Interventional|BIOHELIX-I||BIOHELIX-I Bare Metal Stent Study|The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent|Completed||Phase 2/Phase 3|329|Actual|Biotronik, Inc.||1|||f||||t||||||||||2018-05-31 21:19:18.153693|2018-05-31 21:19:18.153693
NCT01612754|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|||Prospective Trial on Noise Reduction in Surgical Operating Theaters|Noise Reduction Programme by Work Rules and Technical Devices (i.e.SoundEar-TM)for Surgical Theathres|Completed||N/A|16|Actual|Hannover Medical School||3|||f||||t||||||||||2018-05-31 21:19:18.913799|2018-05-31 21:19:18.913799
NCT01612741|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-07-07|2012-06-04|2012-06-06|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Diabetes Treatment With Glucobay in Combination With Metformin|Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Metformin Under Daily Life Treatment Conditions|Completed|||19509|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:19:18.989907|2018-05-31 21:19:18.989907
NCT01612728|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-02-11|2012-06-05|2012-06-06|Estimate|||||||2013-02-11|2013-02-12|Estimate|October 2013||2013-10-31|February 2013|2013-02-28|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|AIA||Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer|Aromatase Inhibitor-Induced Arthralgia: A Proposed Management Algorithm|Withdrawn||Phase 2|0|Actual|Baylor Breast Care Center||2||The grant application for this project was rejected.|f||||f||||||||||2018-05-31 21:19:19.057581|2018-05-31 21:19:19.057581
NCT01612715|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-03-19|2012-06-05|2012-06-06|Estimate|||||||2015-03-19|2015-03-20|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Analysis of Fel d 1-specific T Cells After Airway Allergen Challenge in Asthma|Analysis of Fel d 1-specific T Cells After Airway Allergen Challenge in Asthma:Frequency and Phenotype and Trafficking of Cat Allergen-specific T-cells in Blood, Bone Marrow and Bronchoalveolar Lavage Fluid (BALF) Following Segmental Allergen Challenge in Allergic Asthma.|Unknown status|Recruiting||48|Anticipated|Hamilton Health Sciences Corporation|||1||f||||f||||||||||2018-05-31 21:19:19.220322|2018-05-31 21:19:19.220322
NCT01612702|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|2012-06-06||2013-05-21|2012-06-05|2012-06-06|Estimate|2013-04-12|2013-05-21|Estimate||||2013-05-21|2013-05-27|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety of Single, Low-dose Dexamethasone in Patients After Total Knee Arthroplasty|The Use of a Single, Low-dose Dexamethasone in Total Knee Arthroplasty|Completed||Phase 4|291|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:19:19.303696|2018-05-31 21:19:19.303696
NCT01612689|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-08-06|2012-06-05|2012-06-06|Estimate|||||||2014-08-06|2014-08-07|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|October 2012|Actual|2012-10-31||Interventional|||3-Dimensional Accelerometer Sub-Study|3-Dimensional Accelerometer Sub-Study for Patients Participating in the E-30 Study: Heart Rate Changes in Subjects With Epilepsy During an Epilepsy Monitoring Unit Admission|Completed||N/A|16|Actual|Cyberonics, Inc.||1|||f||||f||||||||||2018-05-31 21:19:19.532425|2018-05-31 21:19:19.532425
NCT01612676|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2016-06-27|2014-11-03|2017-02-20|2012-06-05|2012-06-06|Estimate|2016-11-21|2017-01-16|Estimate|2014-11-03|2014-11-10|Estimate|2017-02-20|2017-03-23|Actual|June 2012||2012-06-30|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Full analysis set (FAS) was the primary dataset of interest. FAS comprised of all patients who were dosed.|Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock|An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.|Completed||Phase 2|31|Actual|Ferring Pharmaceuticals|There were no limitations or caveats in this trial|1|||f||||t||||||||||2018-05-31 21:19:19.649907|2018-05-31 21:19:19.649907
NCT01612663|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Effect of Distal Needling on Knee Pain Using Acupuncture Techniques|Comparison of Different Acupuncture Methods on Knee Pain|Unknown status|Not yet recruiting|N/A|80|Anticipated|Hadassah Medical Organization||4|||f||||t||||||||||2018-05-31 21:19:21.127233|2018-05-31 21:19:21.127233
NCT01612650|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2018-03-21|2012-06-04|2012-06-06|Estimate|||||||2018-03-21|2018-03-23|Actual|February 24, 2012|Actual|2012-02-24|March 2018|2018-03-31|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|TOMOSEIN||Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis|Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis|Completed||N/A|1069|Actual|Centre Oscar Lambret||3|||f||||f|f|f||||||No||2018-05-31 21:19:21.213673|2018-05-31 21:19:21.213673
NCT01612637|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2016-02-02|2012-06-05|2012-06-06|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Can Pelvic Floor Muscle Training Reduce my Prolapse|Can Pelvic Floor Muscle Training Reduce my Prolapse? A Randomised Controlled Trial Comparing the Effect of Pelvic Floor Muscle Training and Lifestyle Advice on Pelvic Organ Prolapse|Completed||N/A|108|Actual|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 21:19:21.282004|2018-05-31 21:19:21.282004
NCT01612624|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|May 2012||2012-05-31|May 2012|2012-05-31||||||||Observational|||Prospective Study on Changes in Acromegaly|FACIAL AND HAND ANALYSIS, SLEEP APNEA AND SPEECH IN PATIENTS WITH ACROMEGALY: A PROSPECTIVE STUDY TO INVESTIGATE CHANGES IN CRANIOFACIAL AND HAND CHARACTERISTICS, SLEEP APNEA AND SPEECH DURING TREATMENT AND AFTER REMISSION|Unknown status|Recruiting||60|Anticipated|Radboud University|||||f||||f||||||||||2018-05-31 21:19:21.343027|2018-05-31 21:19:21.343027
NCT01612611|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|||||Observational|||Safety Study of Shenmai(a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Shenmai (a Chinese Medicine Injection) Used in China|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||1||f||||t||||||||||2018-05-31 21:19:21.387966|2018-05-31 21:19:21.387966
NCT01612598|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-01-29|2012-06-05|2012-06-06|Estimate|||||||2014-01-29|2014-01-31|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|||Palliative Care Intervention in Patients With Solid Tumors Participating in Phase I Clinical Trials|Feasibility of a Palliative Care Intervention for Patients on Phase 1 Clinical Trials|Completed||N/A|16|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 21:19:21.446366|2018-05-31 21:19:21.446366
NCT01612585|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-07|2012-06-03|2012-06-06|Estimate|||||||2012-06-07|2012-06-11|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||Safety Study of Dengzhanxixin (a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Dengzhanxixin (a Chinese Medicine Injection) Used in China|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||||||2018-05-31 21:19:21.598358|2018-05-31 21:19:21.598358
NCT01612572|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals|A Registry Study on Safety Surveillance of Xiyanping (a Chinese Medicine Injection) Used in China|Unknown status|Active, not recruiting||20000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||||||2018-05-31 21:19:21.646146|2018-05-31 21:19:21.646146
NCT01612559|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-03|2012-06-03|2012-06-06|Estimate|||||||2012-06-03|2012-06-06|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|RSCMI-Ⅱ||Safety Study of Kudiezi (a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Kudiezi (a Chinese Medicine Injection) Used in China|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||||||2018-05-31 21:19:21.699666|2018-05-31 21:19:21.699666
NCT01612546|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2017-11-27||2018-01-08|2012-06-05|2012-06-06|Estimate|2017-11-27|2017-12-27|Actual||||2018-01-08|2018-02-01|Actual|November 2012||2012-11-30|January 2018|2018-01-31|January 15, 2015|Actual|2015-01-15|January 15, 2015|Actual|2015-01-15||Interventional|||Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery|Pilot Trial of CRLX101 in the Treatment of Patients With Advanced Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma|Completed||Phase 2|10|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 21:19:21.779777|2018-05-31 21:19:21.779777
NCT01612533|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-05|2012-06-05|2012-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||Safety Study of Shenfu (a Chinese Medicine Injection) Used in Hospitals in China|A Registry Study on Safety Surveillance of Shenfu (a Chinese Medicine Injection) Used in China|Unknown status|Active, not recruiting||20000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||||||2018-05-31 21:19:22.062146|2018-05-31 21:19:22.062146
NCT01612520|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-02-02|2012-06-05|2012-06-06|Estimate|||||||2015-02-02|2015-02-03|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Telecoaching of People With Type 2 Diabetes in Primary Care||Completed||N/A|574|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 21:19:22.115512|2018-05-31 21:19:22.115512
NCT01612507|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-08-31|2012-06-04|2012-06-05|Estimate|||||||2017-08-31|2017-09-05|Actual|July 2012||2012-07-31|August 2017|2017-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess Safety, Tolerability and Pharmacokinetics of Ceftaroline in Healthy Subjects|A Phase I, Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ceftaroline After Different Intravenous Dose Regimens of Ceftaroline Fosamil to Healthy Subjects|Completed||Phase 1|41|Actual|Pfizer||4|||f||||||||||||||2018-05-31 21:19:22.168951|2018-05-31 21:19:22.168951
NCT01612494|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2013-06-17||2014-02-20|2012-06-03|2012-06-05|Estimate|2014-02-20|2014-03-21|Estimate||||2014-02-20|2014-03-21|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Hypertonic Saline as Therapy for Pediatric Concussion|Hypertonic Saline as Therapy for Pediatric Concussion: A Randomized Controlled Trial in the Emergency Department|Completed||Phase 1/Phase 2|44|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:19:22.248198|2018-05-31 21:19:22.248198
NCT01612481|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2016-07-28|2012-06-04|2012-06-05|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma|Phase II Study Evaluating Strategies of Lung Surveillance of Patients Operated of High Grade Soft Tissue Sarcoma: Chest Radiograph Versus Chest CT|Terminated||Phase 2|11|Actual|Centre Oscar Lambret||2||lack of enrollment|f||||f||||||||No||2018-05-31 21:19:22.410637|2018-05-31 21:19:22.410637
NCT01612468|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2016-01-26|2012-06-04|2012-06-05|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Liraglutide in Type 1 Diabetes|Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients|Completed||Phase 4|100|Actual|Steno Diabetes Center||2|||f||||t||||||||||2018-05-31 21:19:22.473148|2018-05-31 21:19:22.473148
NCT01612455|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-07-19|2012-06-01|2012-06-05|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2012||2012-07-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|LINC||Linking Infectious and Narcology Care in Russia|Linking Russian Narcology & HIV Care to Enhance Treatment, Retention, & Outcomes|Completed||N/A|349|Actual|Boston Medical Center||2|||f||||f|f|f||||||||2018-05-31 21:19:23.525242|2018-05-31 21:19:23.525242
NCT01612442|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2012-06-03|2012-06-03|2012-06-05|Estimate|||||||2012-06-03|2012-06-05|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Integrated Education Intervention to Improve Infant and Young Child Nutrition and Growth in Ghana||Completed||N/A|367|Actual|McGill University||3|||f||||f||||||||||2018-05-31 21:19:23.593537|2018-05-31 21:19:23.593537
NCT01612429|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2016-11-09|2012-06-04|2012-06-05|Estimate|||||||2016-11-09|2016-11-10|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CarRAAT||Carbamylation in Renal Disease-modulation With Amino Acid Therapy|Amino Acid Therapy to Modify Protein Carbamylation in End Stage Renal Disease|Completed||Early Phase 1|23|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 21:19:23.654717|2018-05-31 21:19:23.654717
NCT01612416|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-03|2012-06-03|2012-06-05|Estimate|||||||2012-06-03|2012-06-05|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Spectral Domain Optical Coherence Tomography Analysis for Glaucoma|Comparison of Ganglion Cell and Retinal Nerve Fiber Layer Thickness in Primary Open Angle Glaucoma and Normal Tension Glaucoma With Spectral Domain OCT|Completed||N/A|169|Actual|Inonu University||3|||f||||f||||||||||2018-05-31 21:19:23.721855|2018-05-31 21:19:23.721855
NCT01612403|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-05|2012-06-04|2012-06-05|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|supplement||Study the Effect of Oral Zinc Supplementation on High Molecular Weight Zinc Binding Protein in Semen|Study the Effect of Oral Zinc Supplementation on High Molecular Weight Zinc Binding Protein in Semen|Completed|||37|Actual|Babylon University|||1||f||||t||||||||||2018-05-31 21:19:23.826375|2018-05-31 21:19:23.826375
NCT01612390|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-02|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Observational|||Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor|Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor|Unknown status|Not yet recruiting||180|Anticipated|Ain Shams University|||3||f||||t||||||||||2018-05-31 21:19:23.894696|2018-05-31 21:19:23.894696
NCT01610622|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-05-25|2012-06-01|2012-06-04|Estimate|||||||2016-05-25|2016-05-27|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|CH||Estimation of Cardiac Output in Neonatal ICU Using an Ultrasound Dilution Technique|Estimation of Cardiac Output in Neonatal ICU Using an Ultrasound Dilution Technique|Completed|||7|Actual|Transonic Systems Inc.|||||f||||||||||||||2018-05-31 21:19:48.492821|2018-05-31 21:19:48.492821
NCT01612377|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-09-10|2012-06-01|2012-06-05|Estimate|||||||2012-09-10|2012-09-11|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|||Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis|A Phase II, Double-blind, Controlled, Multi-center, Randomized, Long Term Safety Trial of z102 and Prednisone (5 mg or 7.5 mg) in Patients With Moderate to Severe Rheumatoid Arthritis|Terminated||Phase 2|18|Actual|Zalicus||3||missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg|f||||f||||||||||2018-05-31 21:19:23.959061|2018-05-31 21:19:23.959061
NCT01612364|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-06-01|2012-06-01|2012-06-05|Estimate|||||||2012-06-01|2012-06-05|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||RCT :Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb|Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:19:24.03144|2018-05-31 21:19:24.03144
NCT01612351|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2017-09-11||2018-03-21|2012-06-01|2012-06-05|Estimate|2017-09-11|2017-10-13|Actual||||2018-03-21|2018-04-23|Actual|June 2012||2012-06-30|March 2018|2018-03-31|November 2031|Anticipated|2031-11-30|November 2016|Actual|2016-11-30||Interventional|||Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery|Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches|Active, not recruiting||Phase 2|40|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:19:24.232115|2018-05-31 21:19:24.232115
NCT01612338|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2015-07-31|2012-06-01|2012-06-05|Estimate|||||||2015-07-31|2015-08-03|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives|Interventions to Increase Screening Utilization by Breast Cancer Survivors and Their High Risk Female Relatives: Using Cancer Surveillance and the Michigan Genomics Academic-Practice Partnership|Completed||N/A|1290|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:19:24.664723|2018-05-31 21:19:24.664723
NCT01612325|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2015-08-26|2012-06-01|2012-06-05|Estimate|||||||2015-08-26|2015-08-27|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|HEPAR-2||Radioactive Holmium Microspheres for the Treatment of Unresectable Liver Metastases|Radioactive Holmium Microspheres for the Treatment of Patients With Unresectable Liver Metastases; a Single Center, Interventional, Non-randomized, Phase II (HEPAR II) Trial|Completed||Phase 2|56|Actual|UMC Utrecht||1|||f||||t||||||||||2018-05-31 21:19:24.946442|2018-05-31 21:19:24.946442
NCT01612312|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-05-01|2012-06-01|2012-06-05|Estimate|||||||2017-05-01|2017-05-02|Actual|March 2011||2011-03-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|June 2013|Actual|2013-06-30||Interventional|||Thrombus Aspiration in ThrOmbus Containing culpRiT Lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI)|Thrombus Aspiration in ThrOmbus Containing culpRiT Lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI)|Completed||Phase 4|400|Anticipated|University of Leipzig||2|||f||||t||||||||||2018-05-31 21:19:25.252035|2018-05-31 21:19:25.252035
NCT01612299|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-08-04|2012-06-01|2012-06-05|Estimate|||||||2017-08-04|2017-08-07|Actual|May 2012||2012-05-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients|Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients|Withdrawn||N/A|0|Actual|University of Kentucky||2||Funding was withdrawn for this study by the sponsor.|f||||t||||||||||2018-05-31 21:19:25.530849|2018-05-31 21:19:25.530849
NCT01612286|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2014-02-16|2012-06-04|2012-06-05|Estimate|||||||2014-02-16|2014-02-19|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|May 2014|Anticipated|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma|A Phase II Clinical Study of Endostar Combination With Chemotherapy in the Metastatic Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 21:19:25.797018|2018-05-31 21:19:25.797018
NCT01612273|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-03-04|2012-06-04|2012-06-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||The Effect of Triflusal on Peripheral Microcirculation Dysfunction|The Effect of Triflusal on Peripheral Microcirculation Dysfunction: A Double-Blind, Randomized, Controlled, Crossover Study.|Completed||Phase 4|92|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:19:26.090929|2018-05-31 21:19:26.090929
NCT01612260|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-01-07|2012-06-04|2012-06-05|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat|Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial|Unknown status|Recruiting|Phase 4|460|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 21:19:26.38672|2018-05-31 21:19:26.38672
NCT01612247|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|February 2014|Anticipated|2014-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy|Low Dose Metronomic Cyclophosphamide and Methotrexate Chemotherapy in Combination With Aspirin in Patients With Stage II-III Breast Cancer Who Fail to Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy|Unknown status|Recruiting|N/A|13|Anticipated|University of Vermont|||||f||||t||||||||||2018-05-31 21:19:26.961084|2018-05-31 21:19:26.961084
NCT01612234|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-11-30|2012-06-04|2012-06-05|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Saturated Fat Versus Monounsaturated Fat and Insulin Action|Palmitate Metabolism and Insulin Resistance|Completed||N/A|70|Actual|University of Vermont||2|||f||||f||||||||||2018-05-31 21:19:27.035625|2018-05-31 21:19:27.035625
NCT01612221|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2017-03-07||2017-06-29|2012-06-04|2012-06-05|Estimate|2017-06-29|2017-07-31|Actual||||2017-06-29|2017-07-31|Actual|September 2012||2012-09-30|June 2017|2017-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo|A Phase II Placebo-controlled Intervention Trial of Oral N-acetylcysteine (NAC) for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo|Completed||Phase 2|100|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 21:19:27.128772|2018-05-31 21:19:27.128772
NCT01612195|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-02|||2013-05-16|2012-06-04|2012-06-05|Estimate|||||||2013-05-16|2013-05-17|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|March 2009|Actual|2009-03-31||Interventional|||Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula|Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula|Completed||Phase 2|46|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-05-31 21:19:27.534563|2018-05-31 21:19:27.534563
NCT01612182|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|||||Observational|||The Incidence of Extended-spectrum β-lactamase (ESBL) Klebsiella Pneumonia in Patient on Renal Replacement Therapy||Completed|||1289|Actual|Inje University|||2||f||||||||||||||2018-05-31 21:19:27.615201|2018-05-31 21:19:27.615201
NCT01612169|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2016-03-10|2012-06-04|2012-06-05|Estimate|||||||2016-03-10|2016-03-14|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CTN0049||Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users|NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users|Completed||N/A|801|Actual|Columbia University||3|||f||||t||||||||Yes|Information about the study and the de-identified study data will be available at https://datashare.nida.nih.gov/ within 18 months of the date the data are locked, as per the procedures of the National Drug Abuse Treatment Clinical Trials Network.|2018-05-31 21:19:27.694743|2018-05-31 21:19:27.694743
NCT01612156|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2015-01-07||2015-01-16|2012-05-31|2012-06-05|Estimate|2015-01-16|2015-01-19|Estimate||||2015-01-16|2015-01-19|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Lubricant Versus Lidocaine Gel for Pain Control During Urodynamics|Use of 2% Lidocaine Gel Versus Water Based Lubrication: Is There a Difference in Pain During and After Multi-channel Urodynamics?|Completed||N/A|90|Actual|University of Southern California|Our patient population represented a predominantly Latina/Hispanic population, and our results might not be generalizable to other populations.|2|||f||||f||||||||||2018-05-31 21:19:27.799823|2018-05-31 21:19:27.799823
NCT01612143|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2016-11-01|2012-06-01|2012-06-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers|A Randomized, Open-label, Single Dose, Cross-over Study to Investigate the Relative Bioavailability of Setrobuvir (STV) Tablet Formulation Versus the Reference Setrobuvir Capsule Formulation Following Oral Administration With or Without a High Fat Meal in Healthy Subjects|Completed||Phase 1|40|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:19:28.047551|2018-05-31 21:19:28.047551
NCT01612130|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-05|2012-06-04|2012-06-05|Estimate|||||||2012-06-05|2012-06-06|Estimate|March 2003||2003-03-31|June 2012|2012-06-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Valerian for Conscious Sedation in Patients Submitted to Impacted Lower Third Molars Surgery|Valeriana Officinalis L. for Conscious Sedation in Patients Submitted to Impacted Lower Third Molars Surgery: A Randomized, Double-Blind, Placebo-Controlled Crossover Study|Completed||N/A|20|Actual|Federal University of the Valleys of Jequitinhonha and Mucuri||2|||f||||f||||||||||2018-05-31 21:19:28.118787|2018-05-31 21:19:28.118787
NCT01612117|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-05-27|2012-06-04|2012-06-05|Estimate|||||||2014-05-27|2014-05-28|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) in Invasive Cardiology|"Is Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) the Renal Troponin in Invasive Cardiology?"|Completed|||244|Actual|University of Freiburg|||1||f||||f||||||Samples Without DNA|"~     urinary samples~   "|||2018-05-31 21:19:28.178032|2018-05-31 21:19:28.178032
NCT01612104|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-12-04|2012-06-04|2012-06-05|Estimate|||||||2015-12-04|2015-12-07|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|July 2013|Actual|2013-07-31||Interventional|||Psychological First Aid With Children in a High Risk Group - a Repeated Single Case Design|Psychological First Aid With Children in a High Risk Group - a Repeated Single Case Design|Completed||Phase 1|11|Actual|Uni Research||1|||f||||f||||||||||2018-05-31 21:19:28.230899|2018-05-31 21:19:28.230899
NCT01612091|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-10-24|2012-06-04|2012-06-05|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2013||2013-11-30|October 2017|2017-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||The Monitoring Messenger: Mobile Patient Monitoring for the Pediatric Intensive Care Unit|The Monitoring Messenger: Mobile Patient Monitoring for the Pediatric Intensive Care Unit|Withdrawn||N/A|0|Actual|University of British Columbia||2||Replaced with updated protocol as H16-02361|f||||f||||||||||2018-05-31 21:19:28.289764|2018-05-31 21:19:28.289764
NCT01612078|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2013-03-11|2012-06-01|2012-06-05|Estimate|||||||2013-03-11|2013-03-13|Estimate|June 2012||2012-06-30|March 2013|2013-03-31||||February 2013|Actual|2013-02-28||Interventional|OH||Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients|A Double-blind, Randomized and Placebo-controlled Study to Evaluate the Efficacy and Safety of L-threo-3,4-dihydroxyphenylserine (Droxidopa) on Orthostatic Hypotension Treatment in Hemodialysis Patients|Terminated||Phase 3|25|Actual|TSH Biopharm Corporation Limited||2|||f||||t||||||||||2018-05-31 21:19:28.35234|2018-05-31 21:19:28.35234
NCT01612065|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2013-04-10|2012-06-04|2012-06-05|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Optimum Misoprostol Dose Prior to Office Hysteroscopy|The Optimum Dose of Vaginal Misoprostol Prior to Office Hysteroscopy: Double Blind Randomized Controlled Trial|Completed||Phase 3|132|Actual|Cairo University||2|||f||||||||||||||2018-05-31 21:19:28.408168|2018-05-31 21:19:28.408168
NCT01612052|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-02-18|2012-06-02|2012-06-05|Estimate|||||||2013-02-18|2013-02-20|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|October 2013|Anticipated|2013-10-31|March 2013|Anticipated|2013-03-31||Interventional|||Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)|Double Blinded Prospective Randomized Controlled Trial Comparing Cefazolin Plus Vancomycin Versus Cefazolin Plus Daptomycin for Vascular Surgery Prophylaxis|Unknown status|Recruiting|Phase 4|200|Anticipated|CAMC Health System||2|||f||||f||||||||||2018-05-31 21:19:28.570248|2018-05-31 21:19:28.570248
NCT01612039|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01||2016-04-20|2016-09-26|2012-06-04|2012-06-05|Estimate||||2016-09-26|2016-09-28|Estimate|2016-09-26|2016-09-28|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis|A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis|Completed||Phase 2|112|Actual|Telsar Pharma Inc.||2|||f||||t||||||||No||2018-05-31 21:19:28.655488|2018-05-31 21:19:28.655488
NCT01612026|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Observational|||Ultrasound Versus Fluoroscopically-guided Arterial Access in Non-cardiac Vascular Patients|Ultrasound Versus Fluoroscopically-guided Arterial Access in Non-cardiac Vascular Patients|Unknown status|Active, not recruiting||1052|Anticipated|CAMC Health System|||2||f||||f||||||||||2018-05-31 21:19:28.724071|2018-05-31 21:19:28.724071
NCT01612013|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Intravenous High Dose NAC and Sodium Bicarbonate for the Prevention of Contrast-induced Acute Injury|Intravenous High Dose of N-acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-induced Acute Injury: a Randomized Controlled Trial|Completed||N/A|500|Actual|Federal University of São Paulo||4|||f||||f||||||||||2018-05-31 21:19:28.802824|2018-05-31 21:19:28.802824
NCT01612000|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2014-12-19||2015-10-26|2012-06-04|2012-06-05|Estimate|2015-10-26|2015-11-25|Estimate||||2015-10-26|2015-11-25|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|PSC25|Healthy adults 18-49 years of age with no prior vaccination with H5 pandemic influenza|Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults|Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years|Completed||Phase 1/Phase 2|341|Actual|Protein Sciences Corporation||4|||f||||f||||||||||2018-05-31 21:19:28.922148|2018-05-31 21:19:28.922148
NCT01611987|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2017-04-25|2012-06-02|2012-06-05|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2012||2012-09-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|MStep||The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis|The Role of Exercise in Modifying Outcomes for People With Multiple Sclerosis|Active, not recruiting||N/A|240|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 21:19:29.58086|2018-05-31 21:19:29.58086
NCT01611974|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|2015-11-13||2015-11-13|2012-06-01|2012-06-05|Estimate|2015-11-13|2015-12-17|Estimate||||2015-11-13|2015-12-17|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||The Intent-to-Treat Safety population, defined as all randomized participants who received at least 1 dose of study drug.|Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients|A Phase 2, Randomized Study to Assess the Safety and Anti-cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections That Are Resistant or Refractory to Treatment With Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients|Completed||Phase 2|120|Actual|Shire||3|||f||||t||||||||||2018-05-31 21:19:29.892294|2018-05-31 21:19:29.892294
NCT01611961|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-09-27|2012-05-31|2012-06-05|Estimate|||||||2014-09-27|2014-09-30|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients|A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Docetaxel Lipid Microsphere for Injection in Cancer Patients Receiving Chemotherapy|Unknown status|Recruiting|Phase 1|35|Anticipated|Shenyang Pharmaceutical University||2|||f||||t||||||||||2018-05-31 21:19:31.040632|2018-05-31 21:19:31.040632
NCT01611948|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2017-02-06||2017-03-29|2012-06-04|2012-06-05|Estimate|2017-02-06|2017-03-27|Actual||||2017-03-29|2017-05-01|Actual|May 2011||2011-05-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Treatment for Cannabis Withdrawal and Dependence|Pharmacological Treatment of Cannabis Withdrawal and Dependence|Completed||Phase 2|70|Actual|The Scripps Research Institute||2|||f||||f||||||||No||2018-05-31 21:19:31.139121|2018-05-31 21:19:31.139121
NCT01611935|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-06-14|2012-06-04|2012-06-05|Estimate|||||||2017-06-14|2017-06-16|Actual|May 1, 2013|Actual|2013-05-01|June 2017|2017-06-30|September 6, 2016|Actual|2016-09-06|September 6, 2016|Actual|2016-09-06||Interventional|AVERTShock||AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock|AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock|Completed||Phase 2|100|Actual|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 21:19:31.337745|2018-05-31 21:19:31.337745
NCT01611922|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|BURNABY||Optimization of Assessment and Grading for Lid Wiper Epitheliopathy|Optimization of Assessment and Grading for Lid Wiper Epitheliopathy|Completed|||57|Actual|Alcon Research|||3||f||||f||||||||||2018-05-31 21:19:31.426399|2018-05-31 21:19:31.426399
NCT01611909|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-06-18|2012-05-31|2012-06-05|Estimate|||||||2012-06-18|2012-06-20|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|||Citriodiol® and Impetigo|A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo.|Unknown status|Not yet recruiting|Phase 2/Phase 3|30|Anticipated|Royal North Shore Hospital||3|||f||||f||||||||||2018-05-31 21:19:31.511344|2018-05-31 21:19:31.511344
NCT01611896|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-10-27|2012-05-31|2012-06-05|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|GRASS||Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism|GRAves Selenium Supplementation Trial (GRASS) - an Investigator-initiated Randomised, Blinded, Multicentre Clinical Trial of Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism|Recruiting||N/A|492|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:19:31.601377|2018-05-31 21:19:31.601377
NCT01611883|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|2014-12-09||2017-03-31|2012-06-01|2012-06-05|Estimate|2014-12-09|2014-12-17|Estimate||||2017-03-31|2017-05-05|Actual|July 2, 2012|Actual|2012-07-02|March 2017|2017-03-31|January 16, 2014|Actual|2014-01-16|January 16, 2014|Actual|2014-01-16||Interventional|||A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)|Examination of the Effect of Ezetimibe on Glucose Metabolism - Randomized, Double-blind, Placebo-controlled Study in Type 2 Diabetes Mellitus Patients With Hypercholesterolemia - Phase 4, Protocol No. 367 (Also Known as SCH 58235, P06541)|Completed||Phase 4|152|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:19:31.732366|2018-05-31 21:19:31.732366
NCT01611870|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|AVAPS-AE COPD||AVAPS-AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD)Patients|Engineering Validation of the AVAPS-AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD)Patients|Unknown status|Recruiting|N/A|20|Anticipated|Philips Respironics||1|||f||||f||||||||||2018-05-31 21:19:32.072628|2018-05-31 21:19:32.072628
NCT01611857|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|2016-08-09||2016-10-03|2012-06-01|2012-06-05|Estimate|2016-10-03|2016-11-23|Estimate||||2016-10-03|2016-11-23|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||In the Tivantinib + FOLFOX Dose Expansion 34 patients were enrolled; only 32 were treated. Two dropped out prior to treatment. The Intent-to-Treat (ITT) population includes all 34 patients. Safety assessment was based on the population that received at least one dose of drug (N = 32); the efficacy assessments used the ITT population (N = 34).|Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach|A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)|Completed||Phase 1/Phase 2|49|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 21:19:32.164661|2018-05-31 21:19:32.164661
NCT01611844|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-07-30|2012-05-31|2012-06-05|Estimate|||||||2013-07-30|2013-07-31|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional|TB Dermatest||Optimization of Tuberculosis Intradermal Skin Test|Optimization of Tuberculosis Intradermal Skin Test: TB Dermatest WP 3.1|Completed||N/A|59|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:19:32.899894|2018-05-31 21:19:32.899894
NCT01611831|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|July 2012|Anticipated|2012-07-31||Interventional|ACTGROUP||Efficacy of Acceptance and Commitment Therapy (ACT) in Group in Fibromyalgia|Efficacy of Acceptance and Commitment Therapy (ACT) in Group in Fibromyalgia: a Randomized, Controlled Study.|Unknown status|Active, not recruiting|N/A|80|Anticipated|Hospital Miguel Servet||2|||f||||f||||||||||2018-05-31 21:19:33.172957|2018-05-31 21:19:33.172957
NCT01611818|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-08-08|2012-05-31|2012-06-05|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2012||2012-09-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Low Intensity Versus Self-guided Internet-delivered Psychotherapy for Major Depression|Low Intensity Versus Self-guided Internet-delivered Psychotherapy for Major Depression: a Multicenter, Controlled, Randomised Study|Completed||N/A|300|Actual|Hospital Miguel Servet||3|||f||||f||||||||||2018-05-31 21:19:33.527925|2018-05-31 21:19:33.527925
NCT01611805|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-06-13|2012-05-31|2012-06-05|Estimate|||||||2017-06-13|2017-06-14|Actual|July 22, 2010|Actual|2010-07-22|June 2017|2017-06-30|October 6, 2010|Actual|2010-10-06|October 6, 2010|Actual|2010-10-06||Interventional|||Japanese Phase I of GSK1605786|A Placebo-Controlled, Four-Period Crossover, Single Ascending Oral Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of the CCR9 Receptor Antagonist GSK1605786 in Japanese Healthy Male Subject|Completed||Phase 1|30|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 21:19:33.851022|2018-05-31 21:19:33.851022
NCT01611792|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|2017-02-20||2017-10-16|2012-06-04|2012-06-05|Estimate|2017-07-19|2017-08-21|Actual||||2017-10-16|2017-10-18|Actual|March 2003||2003-03-31|October 2017|2017-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional||Based on subjects who completed the 10 week treatment protocol|Effects and Mechanisms of Specific Trunk Exercises in Low Back Pain|Effects and Mechanisms of Specific Trunk Exercises in Low Back Pain|Completed||N/A|58|Actual|University of Vermont||2|||f||||f||||||||No||2018-05-31 21:19:34.140714|2018-05-31 21:19:34.140714
NCT01611779|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2016-11-09||2017-01-10|2012-06-04|2012-06-05|Estimate|2016-11-09|2017-01-06|Estimate||||2017-01-10|2017-02-24|Actual|May 2012||2012-05-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|FAST|Patients with obstructive sleep apnea were enrolled in the trial. Subjects meeting the inclusion and exclusion criteria were invited to participate in the trial. Subjects were treated with the the Encore System, and followed at 1 week, and then at 1, 3, and 12 months.|FAST as a Treatment for Obstructive Sleep Apnea|Functional Advancement and Suspension of the Tongue (FAST) as a Treatment for Obstructive Sleep Apnea|Terminated||Phase 4|5|Actual|Siesta Medical, Inc.||1||Slow enrollment|f||||f||||||||No||2018-05-31 21:19:35.471269|2018-05-31 21:19:35.471269
NCT01611766|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2018-02-24|2012-06-04|2012-06-05|Estimate|||||||2018-02-24|2018-02-27|Actual|January 2011||2011-01-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|January 2021|Anticipated|2021-01-31||Interventional|||Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?|Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial|Recruiting||Phase 3|356|Anticipated|Shanghai Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 21:19:36.316256|2018-05-31 21:19:36.316256
NCT01611753|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2012-05-31|2012-05-31|2012-06-05|Estimate|||||||2012-05-31|2012-06-05|Estimate|April 2004||2004-04-30|May 2012|2012-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Red Blood Cell Transfusion Improves Perfusion Parameters in Septic Shock Patients With Hypoperfusion|Red Blood Cell Transfusion Improves Perfusion Parameters in Septic Shock Patients With Hypoperfusion: a Prospective Randomized Study|Completed||N/A|46|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:19:36.722069|2018-05-31 21:19:36.722069
NCT01611740|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-08-28|2012-06-01|2012-06-05|Estimate|||||||2017-08-28|2017-08-29|Actual|May 2012||2012-05-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Observational|CARESS_PREMI||Contribution of Real Time Analyses of CARdio-RESpiratory Signals to the Diagnosis of Infection in PREterM Infants|Contribution of Computerized Real Time Analyses of Cardio-respiratory Signals to the Diagnosis of Infection in Preterm Infants|Recruiting|||500|Anticipated|Rennes University Hospital|||1||f||||f||||||||||2018-05-31 21:19:36.950314|2018-05-31 21:19:36.950314
NCT01611727|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-07-10|2012-06-04|2012-06-05|Estimate|||||||2012-07-10|2012-07-12|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|Cisplatin||Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients|Phase II Open-Label, Non-Randomized Trial of Cisplatin Chemotherapy in Patients With BRCA1-Positive Metastatic Breast Cancer|Completed||Phase 2|20|Actual|Pomeranian Medical University Szczecin||1|||f||||f||||||||||2018-05-31 21:19:37.040352|2018-05-31 21:19:37.040352
NCT01611714|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2016-01-28|2012-06-01|2012-06-05|Estimate|||||||2016-01-28|2016-01-29|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EDIT||Equity in Diagnostic Imaging Trial|Equity in Diagnostic Imaging Trial (EDIT)|Completed||N/A|181|Actual|Icahn School of Medicine at Mount Sinai||4|||f||||f||||||||||2018-05-31 21:19:37.109744|2018-05-31 21:19:37.109744
NCT01611701|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-06-01|2012-06-01|2012-06-05|Estimate|||||||2012-06-01|2012-06-05|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||Cryoballoon Ablation of Pulmonary Veins After Failed RF Ablation in Patients With Paroxysmal AF|Cryoballoon Ablation of Pulmonary Veins After Failed Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation|Completed||Phase 3|80|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 21:19:37.180898|2018-05-31 21:19:37.180898
NCT01611688|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-02-23|2012-06-01|2012-06-05|Estimate|||||||2017-02-23|2017-02-27|Actual|June 4, 2012|Actual|2012-06-04|February 2017|2017-02-28|June 17, 2013|Actual|2013-06-17|June 17, 2013|Actual|2013-06-17||Interventional|||First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis|First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis|Completed||Phase 1|36|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:19:37.245236|2018-05-31 21:19:37.245236
NCT01611675|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2017-04-04|2012-06-01|2012-06-05|Estimate|||||||2017-04-04|2017-04-06|Actual|July 2012||2012-07-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma|Leflunomide in Combination With Vemurafenib in Patients With V600 Mutant Metastatic Melanoma|Terminated||Phase 1|3|Actual|Massachusetts General Hospital||1||Adverse Events|f||||t||||||||||2018-05-31 21:19:37.323687|2018-05-31 21:19:37.323687
NCT01611662|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2016-12-27||2017-02-21|2012-06-04|2012-06-05|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|May 2012||2012-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Interventional||The tumor in patients was graded by TNM staging where T refers to the stage of primary tumor, n refers to the regional lymph nodes, M refers to distant metastasis. T0 - no evidence of primary tumor; N0- no regional lymph nodes; M0-no distant metastasis|Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer|Phase II Trial of Neoadjuvant Dose Dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer|Terminated||Phase 2|32|Actual|Fox Chase Cancer Center||1||Extreme Toxicity|f||||t||||||||||2018-05-31 21:19:37.406228|2018-05-31 21:19:37.406228
NCT01611649|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2015-04-20|2012-06-01|2012-06-05|Estimate|||||||2015-04-20|2015-04-21|Estimate|March 2012||2012-03-31|April 2015|2015-04-30||||September 2013|Actual|2013-09-30||Interventional|REBECA||Effect of a Mix of Dairy Lipids and Plant Oils in Infant Formula on Omega-3 Fatty Acid in Red Blood Cells|Profilo Degli Acidi Grassi Omega-3 Dei Globuli Rossi in Neonati Sani Alimentati Con Una Formula Per l'Infanzia Contenente Una Miscela di Grassi Del Latte e Oli Vegetali|Completed||Phase 2|117|Actual|Lactalis||4|||f||||t||||||||||2018-05-31 21:19:37.68256|2018-05-31 21:19:37.68256
NCT01611636|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2015-08-17|2012-06-04|2012-06-05|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study|Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study|Recruiting|||200000|Anticipated|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-05-31 21:19:37.745447|2018-05-31 21:19:37.745447
NCT01611623|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-03-29|2012-05-31|2012-06-05|Estimate|||||||2013-03-29|2013-04-02|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies|A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies or Non-Hodgkin's Lymphoma|Completed||Phase 1|9|Actual|Esanex Inc.||1|||f||||f||||||||||2018-05-31 21:19:37.798496|2018-05-31 21:19:37.798496
NCT01611610|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-03-04|2012-06-01|2012-06-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe)|Clinical Assessment of Spinal Muscular Atrophy Type II and III|Completed||N/A|4|Actual|Institut de Myologie, France||2|||f||||f||||||||||2018-05-31 21:19:37.917703|2018-05-31 21:19:37.917703
NCT01611597|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-04-18|2012-06-01|2012-06-05|Estimate|||||||2013-04-18|2013-04-19|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Pre-Acti||Continuous Measurement of the Activity for Clinical Evaluation at Home, for Non-ambulant Neuromuscular Patients|Continuous Measurement of the Activity for Clinical Evaluation at Home, for Non-ambulant Neuromuscular Patients|Completed||N/A|8|Actual|Institut de Myologie, France|||||f||||f||||||||||2018-05-31 21:19:37.981276|2018-05-31 21:19:37.981276
NCT01611584|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-11-11|2012-06-04|2012-06-05|Estimate|||||||2014-11-11|2014-11-13|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer|A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|Dartmouth-Hitchcock Medical Center||1||PI left institution|f||||t||||||||||2018-05-31 21:19:38.078952|2018-05-31 21:19:38.078952
NCT01611571|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2013-08-20||2014-01-15|2012-06-04|2012-06-05|Estimate|2014-01-15|2014-03-04|Estimate||||2014-01-15|2014-03-04|Estimate|December 2003||2003-12-31|January 2014|2014-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|RPM||Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis|Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis|Completed||Phase 3|31|Actual|Columbia University||3|||f||||f||||||||||2018-05-31 21:19:38.175073|2018-05-31 21:19:38.175073
NCT01611558|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2016-03-07||2017-10-05|2012-05-31|2012-06-05|Estimate|2016-03-21|2016-04-19|Estimate||||2017-10-05|2017-11-07|Actual|August 21, 2012|Actual|2012-08-21|October 2017|2017-10-31|July 8, 2019|Anticipated|2019-07-08|November 3, 2014|Actual|2014-11-03||Interventional||All participants who received at least 1 dose of study drug|Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer|A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects|Active, not recruiting||Phase 2|49|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 21:19:38.604375|2018-05-31 21:19:38.604375
NCT01611545|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-06-09|2012-06-04|2012-06-05|Estimate|||||||2015-06-09|2015-06-11|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Pharmacogenomics and Effective Treatment With Clopidogrel|Can Pharmacogenomic Testing Improve Response and Avoid Adverse Effects With Clopidogrel Therapy? A Biospecimen Bank for Genetic and Genomic Investigation of Clopidogrel.|Completed|||130|Actual|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples With DNA|"~     blood or buccal samples~   "|||2018-05-31 21:19:38.988533|2018-05-31 21:19:38.988533
NCT01611532|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-01|2012-06-01|2012-06-05|Estimate|||||||2012-06-01|2012-06-05|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||An Observational Study of the Role of Intra-abdominal Pressure Monitoring in Patients With Acute Pancreatitis|An Observational Study of the Role of Intra-abdominal Pressure Monitoring in Patients With Acute Pancreatitis|Completed|||218|Actual|NHS Greater Glasgow and Clyde|||1||f||||f||||||||||2018-05-31 21:19:39.061717|2018-05-31 21:19:39.061717
NCT01611519|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2016-09-12|2012-06-04|2012-06-05|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Early or Late Foley Removal After Thoracotomy|Optimal Timing of Foley Catheter Removal in Patients Undergoing Thoracic Surgery With Epidural Analgesia: A Randomized, Controlled Trial|Completed|||375|Actual|Mayo Clinic|||2||f||||f||||||||No||2018-05-31 21:19:39.115155|2018-05-31 21:19:39.115155
NCT01611506|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2013-01-08|2012-06-01|2012-06-05|Estimate|||||||2013-01-08|2013-01-09|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer|Integration of Cetuximab, in Combination With Local Radiotherapy, in Perioperative Chemotherapy of Resectable and Locally Advanced Gastric Cancer. A Pilot Phase Ib-trial|Terminated||Phase 1/Phase 2|1|Actual|Centre Hospitalier Universitaire Vaudois||1||"Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in~   advanced gastric cancer in the overall patient population)"|f||||t||||||||||2018-05-31 21:19:39.169203|2018-05-31 21:19:39.169203
NCT01611493|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-01|2012-06-01|2012-06-05|Estimate|||||||2012-06-01|2012-06-05|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|September 2013|Anticipated|2013-09-30|November 2012|Anticipated|2012-11-30||Interventional|OCPTI||Osseotite Certain Prevail for the Preservation of Crestal Bone|A Prospective, Randomized-Controlled Evaluation of the Osseotite CP4 Certain Prevail Tapered Implant for the Preservation of Crestal Bone|Unknown status|Recruiting|Phase 3|40|Anticipated|CES University||2|||f||||f||||||||||2018-05-31 21:19:39.232521|2018-05-31 21:19:39.232521
NCT01611480|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2013-06-25|2012-06-04|2012-06-05|Estimate|||||||2013-06-25|2013-06-26|Estimate||||June 2013|2013-06-30||||January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head||Completed||Phase 2|||Moberg Pharma AB|||||f||||||||||||||2018-05-31 21:19:39.298817|2018-05-31 21:19:39.298817
NCT01611467|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2016-03-25|2012-06-01|2012-06-05|Estimate|||||||2016-03-25|2016-03-28|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|AME/FE||A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects|A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects|Completed||Phase 1|18|Actual|Celgene Corporation||3|||f||||f||||||||||2018-05-31 21:19:39.343278|2018-05-31 21:19:39.343278
NCT01611454|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-09-23|2012-06-01|2012-06-05|Estimate|||||||2014-09-23|2014-09-25|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|PREFER-II||New Fabric Attenuation Device in Endovascular Interventional Radiology II (PREFER II)|Prospective Randomized Evaluation of a New Fabric Attenuation Device in Endovascular Interventional Radiology II (PREFER II)|Completed||N/A|150|Actual|Baptist Health South Florida||2|||f||||f||||||||||2018-05-31 21:19:39.402312|2018-05-31 21:19:39.402312
NCT01611441|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-26|2012-06-04|2012-06-05|Estimate|||||||2012-06-26|2012-06-27|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Investigation of Specific Protein/Markers in Patients With Osteoarthritis of the Knee Having a Total Knee Replacement|Investigation of Biomarkers in an Exploratory Study in Patients With Osteoarthritis of the Knee Undergoing Total Knee Replacement Surgery|Completed|||125|Actual|AstraZeneca|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum, urine, synovial fluid, synovial membrane, cartilage~   "|||2018-05-31 21:19:39.515575|2018-05-31 21:19:39.515575
NCT01611428|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-05-31|2012-05-31|2012-06-05|Estimate|||||||2012-05-31|2012-06-05|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Absolute Bioavailability Study With Ipragliflozin|A Single Dose, Open-label, Randomized Two-period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Ipragliflozin|Completed||Phase 1|14|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:19:39.574776|2018-05-31 21:19:39.574776
NCT01611415|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-05-31|2012-05-31|2012-06-05|Estimate|||||||2012-05-31|2012-06-05|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Drug to Drug Interaction Study With Ipragliflozin and Furosemide|A Clinical Pharmacological Study to Assess Pharmacodynamic and Pharmacokinetic Interactions Between Furosemide and Ipragliflozin in Healthy Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:19:39.639258|2018-05-31 21:19:39.639258
NCT01611402|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2018-04-04|2012-06-01|2012-06-05|Estimate|||||||2018-04-04|2018-04-05|Actual|May 29, 2012||2012-05-29|April 6, 2016|2016-04-06|April 6, 2016||2016-04-06|||||Observational|||Gene Expression in HIV and Tuberculosis Co-infection|Transcriptional Signature of HIV And TB Co-Infection|Completed|||96|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:19:39.706324|2018-05-31 21:19:39.706324
NCT01611389|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-04|2012-06-04|2012-06-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Minimizing Ventricular Pacing|Minimizing Right Ventricular Pacing in Dual-chamber Pacemaker Patients With Sinus Node Disease and First Degree Atrioventricular Block.|Unknown status|Recruiting|N/A|60|Anticipated|Military Institute of Medicine, Poland||2|||f||||f||||||||||2018-05-31 21:19:39.758189|2018-05-31 21:19:39.758189
NCT01611376|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2013-08-16|2012-06-04|2012-06-05|Estimate|||||||2013-08-16|2013-08-19|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Impedance Cardiography During Major Abdominal Surgery|Comparison of Cardiac Output Derived From Flotrac/Vigileo and Impedance Cardiography During Major Abdominal Surgery|Completed||Phase 4|11|Actual|Inje University|||||f||||f||||||||||2018-05-31 21:19:39.822983|2018-05-31 21:19:39.822983
NCT01611363|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-08-21|2012-05-31|2012-06-05|Estimate|||||||2017-08-21|2017-08-22|Actual|October 27, 2011|Actual|2011-10-27|August 2017|2017-08-31|February 3, 2012|Actual|2012-02-03|February 3, 2012|Actual|2012-02-03||Interventional|||A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin|An Exploratory Study to Investigate the Effects of Ipragliflozin (ASP1941) on Glucose Homeostasis and Urinary Glucose Excretion in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1|44|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:19:39.873861|2018-05-31 21:19:39.873861
NCT01611350|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-06-02|2012-06-02|2012-06-05|Estimate|||||||2012-06-02|2012-06-05|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Testing New Marketing Models for Improved Cookstoves - Uganda|Behavior Change Interventions to Improve the Acquisition and Correct Use of Improved Cookstoves|Unknown status|Recruiting|N/A|3500|Anticipated|University of California, Berkeley||5|||f||||t||||||||||2018-05-31 21:19:39.937315|2018-05-31 21:19:39.937315
NCT01611337|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-09-18|2012-05-31|2012-06-04|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2012||2012-06-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry|Insight in Persons Presenting Schizophrenia or Related Troubles During Hospitalization in Psychiatry|Completed||N/A|205|Actual|Centre Hospitalier Esquirol||1|||f||||f||||||||||2018-05-31 21:19:40.019327|2018-05-31 21:19:40.019327
NCT01611324|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-12-09|2012-05-31|2012-06-04|Estimate|||||||2012-12-09|2012-12-11|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|EASE||Painless Local Infiltration Anesthesia|Efficacy of Alkalinised 2% Mepivacaine for Local Infiltration Anesthesia, in Ambulatory Phlebectomy|Completed||Phase 4|100|Actual|Campus Bio-Medico University||2|||f||||t||||||||||2018-05-31 21:19:40.080872|2018-05-31 21:19:40.080872
NCT01611311|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-10-31|2012-05-31|2012-06-04|Estimate|||||||2013-10-31|2013-11-01|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Young and Elderly Healthy Male/Female Volunteers (Randomized, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)|Completed||Phase 1|40|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:19:41.126661|2018-05-31 21:19:41.126661
NCT01611298|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2014-04-01|2012-05-31|2012-06-04|Estimate|||||||2014-04-01|2014-04-03|Estimate|March 2008||2008-03-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|November 2012|Actual|2012-11-30||Interventional|TAR||Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR|Transfer of Donor-Derived Humoral Immunity Following Allogeneic Hematopoietic Stem Cell Transplantation|Completed||N/A|14|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 21:19:41.195866|2018-05-31 21:19:41.195866
NCT01611285|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-06-08|2012-05-31|2012-06-04|Estimate|||||||2017-06-08|2017-06-09|Actual|November 2010||2010-11-30|June 2017|2017-06-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|||Uphold Versus Robotic Surgery for Pelvic Prolapse Repair: A Decision Analytic Approach|Uphold Versus Robotic Surgery for Pelvic Prolapse Repair: A Decision Analytic Approach|Completed|||20|Actual|Atlantic Health System|||2||f||||f||||||||||2018-05-31 21:19:41.276448|2018-05-31 21:19:41.276448
NCT01611272|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-07-11|2012-05-31|2012-06-04|Estimate|||||||2017-07-11|2017-07-13|Actual|April 30, 2013|Actual|2013-04-30|July 2017|2017-07-31|July 20, 2016|Actual|2016-07-20|July 20, 2016|Actual|2016-07-20||Observational|||A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta|A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta|Completed|||3402|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 21:19:41.345062|2018-05-31 21:19:41.345062
NCT01611259|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|2016-06-21||2017-06-19|2012-05-31|2012-06-04|Estimate|2017-06-19|2017-11-06|Actual||||2017-06-19|2017-11-06|Actual|May 2012||2012-05-31|June 2017|2017-06-30|February 2015|Actual|2015-02-28|May 2014|Actual|2014-05-31||Interventional||Two of the enrolled patients withdrew their consent prior to study treatment and did not experience adverse events due to other study procedures. These 2 patients were therefore excluded from intent-to-treat (ITT) and per-protocol (PP) efficacy assessments, safety assessments and listing of baseline characteristics.|Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue|Phase II Trial of Rituximab Plus Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|Completed||Phase 2|50|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||No||2018-05-31 21:19:41.459168|2018-05-31 21:19:41.459168
NCT01611246|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-07-21|2012-05-31|2012-06-04|Estimate|||||||2017-07-21|2017-07-24|Actual|May 1, 2012|Actual|2012-05-01|July 2017|2017-07-31|August 1, 2012|Actual|2012-08-01|August 1, 2012|Actual|2012-08-01||Observational|||Earset Healthy Volunteer Study|Performance of the Acclarent Iontophoresis System With Earset (IPSES) in Healthy Volunteers|Completed|||22|Actual|Acclarent|||1||f||||f||||||||||2018-05-31 21:19:41.775579|2018-05-31 21:19:41.775579
NCT01611233|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-10-17|2012-05-31|2012-06-04|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2012||2012-09-30|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|February 2022|Anticipated|2022-02-28||Observational|||Massachusetts General Hospital Evaluation of DePuy ASR Hip System|Clinical Follow-up of ASR Patients Post-Recall|Active, not recruiting|||1950|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:19:41.857458|2018-05-31 21:19:41.857458
NCT01611220|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2015-12-07|2012-05-30|2012-06-04|Estimate|||||||2015-12-07|2015-12-09|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|RePAN||Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa|Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa: A Randomized Control Trial|Unknown status|Recruiting|Phase 2|80|Anticipated|Villa Garda Hospital||2|||f||||t||||||||||2018-05-31 21:19:41.969427|2018-05-31 21:19:41.969427
NCT01611207|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2013-05-17|2012-06-01|2012-06-04|Estimate|||||||2013-05-17|2013-05-20|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|ISAW||Evaluate the Efficacy of the Treatment of Iatrogenic Subcutaneous Abdominal Wounds (ISAW) After Surgery by Application of Negative Pressure Wound Therapy (NPWT) in Comparison to Standard Conventional Wound Therapy (SCWT) of the Clinical Routine|Randomised Controlled Study to Evaluate the Efficacy of the Treatment of Iatrogenic Subcutaneous Abdominal Wounds (ISAW) After Surgery by Application of Negative Pressure Wound Therapy (NPWT) in Comparison to Standard Conventional Wound Therapy (SCWT) of the Clinical Routine.|Terminated||N/A|12|Actual|University of Witten/Herdecke||2||"The patient recruitment was behind target, no successful completion of the planned patient~   numbers within trial period could be expected"|f||||t||||||||||2018-05-31 21:19:42.078682|2018-05-31 21:19:42.078682
NCT01611194|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-10-11|2012-05-30|2012-06-04|Estimate|||||||2017-10-11|2017-10-12|Actual|September 11, 2012|Actual|2012-09-11|October 2017|2017-10-31|January 29, 2016|Actual|2016-01-29|January 2015|Actual|2015-01-31||Interventional|BIMA||mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms|Brain Injury and Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms After Mild Traumatic Brain Injury (BIMA) Protocol|Completed||N/A|71|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-05-31 21:19:42.204134|2018-05-31 21:19:42.204134
NCT01611181|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-03-28|2012-05-31|2012-06-04|Estimate|||||||2014-03-28|2014-03-31|Estimate|May 2006||2006-05-31|March 2014|2014-03-31|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|||Iron Substitution After Total Knee Arthroplasty|Iron Substitution After Total Knee Arthroplasty - a Randomized Study|Completed||Phase 1|72|Actual|Northern Orthopaedic Division, Denmark||3|||f||||f||||||||||2018-05-31 21:19:42.281857|2018-05-31 21:19:42.281857
NCT01611168|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-05-17|2012-05-30|2012-06-04|Estimate|||||||2017-05-17|2017-05-19|Actual|April 2012|Actual|2012-04-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Remedies4D||REMEDIES4D: REdesigning MEDication Intensification Effectiveness Study for Diabetes|Redesigning Medication Intensification Effectiveness Study for Diabetes|Completed||N/A|240|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 21:19:42.355539|2018-05-31 21:19:42.355539
NCT01610986|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-06-03|2012-05-30|2012-06-04|Estimate|||||||2014-06-03|2014-06-04|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|LactEx||Effects of Glucose-fructose Drinks During Training on Lactate Transport|Effects of Glucose-fructose Drinks During Training on Lactate Transport and Oxidation and on Endurance Performance|Completed||N/A|17|Actual|University of Lausanne||2|||f||||f||||||||||2018-05-31 21:19:43.66758|2018-05-31 21:19:43.66758
NCT01611155|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2018-02-05|2012-06-01|2012-06-04|Estimate|||||||2018-02-05|2018-02-06|Actual|February 2012|Actual|2012-02-29|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy|A Pilot Randomized, Placebo-controlled, Double Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy|Active, not recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:19:42.419274|2018-05-31 21:19:42.419274
NCT01611142|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-06-13|2012-06-01|2012-06-04|Estimate|||||||2016-06-13|2016-06-14|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)|Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)|Completed||Phase 2|38|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-05-31 21:19:42.491637|2018-05-31 21:19:42.491637
NCT01611129|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-04-16|2012-05-31|2012-06-04|Estimate|||||||2013-04-16|2013-04-17|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Internet-based Pre-fitting Counseling of Persons With Hearing Impairment|Use of the 'Patient Journey' Model in the Internet-based Pre-fitting Counseling of a Person With Hearing Impairment: A Randomized Controlled Trial|Completed||N/A|80|Actual|Linkoeping University||2|||f||||t||||||||||2018-05-31 21:19:42.659918|2018-05-31 21:19:42.659918
NCT01611116|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-08-16|2012-05-31|2012-06-04|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2012||2012-05-31|August 2017|2017-08-31|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|TOR-AML||Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia|A Double-blind, Placebo-controlled, Randomized, Multicenter Phase II Trial to Assess the Efficacy of Temsirolimus Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML|Completed||Phase 2|33|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-05-31 21:19:42.739694|2018-05-31 21:19:42.739694
NCT01611103|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-08-31|2012-05-31|2012-06-04|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Cognitive Effects of Transcranial Direct Current Stimulation in Older Adults|Cognitive Effects of Transcranial Direct Current Stimulation in Older Adults|Completed||N/A|43|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:19:42.819317|2018-05-31 21:19:42.819317
NCT01611090|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2018-02-07|2012-05-31|2012-06-04|Estimate|||||||2018-02-07|2018-02-08|Actual|September 19, 2012|Actual|2012-09-19|February 2018|2018-02-28|January 19, 2019|Anticipated|2019-01-19|January 19, 2019|Anticipated|2019-01-19||Interventional|||A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Active, not recruiting||Phase 3|579|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 21:19:42.927947|2018-05-31 21:19:42.927947
NCT01611077|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-02-20|2012-05-31|2012-06-04|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2012||2012-01-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|Sevicontrol-2||Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg|Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial|Completed||Phase 4|88|Actual|Institut für Pharmakologie und Präventive Medizin||1|||f||||t||||||||Undecided||2018-05-31 21:19:43.235965|2018-05-31 21:19:43.235965
NCT01611064|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-05-27|2012-05-30|2012-06-04|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ReTAP||A Study Investigating Ways to Make Local Anaesthetic Hand Surgery Less Painful - Reducing Tourniquet Associated Pain|A Randomised Controlled Trial to Investigate Whether Oxygen Supplementation Can Extend the Time Tolerated or Reduce the Pain Associated With an Upper Limb Tourniquet for Hand Surgery Under Local Anaesthetic|Completed||N/A|50|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 21:19:43.322843|2018-05-31 21:19:43.322843
NCT01611051|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2013-01-05|2012-05-31|2012-06-04|Estimate|||||||2013-01-05|2013-01-08|Estimate|March 2012||2012-03-31|January 2013|2013-01-31||||January 2013|Actual|2013-01-31||Interventional|||A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy||Completed||Phase 3|330|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:19:43.393477|2018-05-31 21:19:43.393477
NCT01611038|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-09-11|2012-05-30|2012-06-04|Estimate|||||||2017-09-11|2017-09-12|Actual|October 2011||2011-10-31|September 2017|2017-09-30|June 2015|Actual|2015-06-30|July 2013|Actual|2013-07-31||Interventional|||Methylselenocysteine Effects on Circadian Rhythm|Chemoprevention of Breast and Prostate Cancers in Shift Workers by Dietary Methylselenocysteine: Effects on Circadian Rhythm and Estrogen Receptor-B Cycling|Completed||N/A|100|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 21:19:43.460732|2018-05-31 21:19:43.460732
NCT01611025|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-01|||2012-06-01|2012-06-01|2012-06-04|Estimate|||||||2012-06-01|2012-06-04|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|||||Observational|||Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time|The Impact on the Hospital's Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic, Using Antibiotic Utilization and Hospital Susceptibility Data Over Time|Unknown status|Active, not recruiting||30000|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f||||||||||2018-05-31 21:19:43.516153|2018-05-31 21:19:43.516153
NCT01611012|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-07-02|2012-06-01|2012-06-04|Estimate|||||||2014-07-02|2014-07-03|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|AIR||The Development of a Clinical Test to Assess the Inflammatory Phenotype of Asthma|The Development of a Clinical Test to Assess the Inflammatory Phenotype of Asthma|Completed|||115|Actual|UMC Utrecht|||||f||||f||||||Samples Without DNA|"~     Leukocytes in peripheral blood, serum samples for protein profiling and sputum samples.~   "|||2018-05-31 21:19:43.556652|2018-05-31 21:19:43.556652
NCT01610999|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-05-05|2012-05-31|2012-06-04|Estimate|||||||2017-05-05|2017-05-09|Actual|July 2013||2013-07-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation|Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation|Terminated||Phase 1|7|Actual|Tufts Medical Center||3||Unavailability of study article|f||||t|t|f||||||No||2018-05-31 21:19:43.609798|2018-05-31 21:19:43.609798
NCT01610973|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-10-07|2012-06-01|2012-06-04|Estimate|||||||2016-10-07|2016-10-10|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparison of Two Techniques in Achieving Corneal Graft|Comparison of Manual and Automated Techniques in Achieving Posterior Lamellar Transplantation of the Cornea|Completed||N/A|40|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 21:19:43.725844|2018-05-31 21:19:43.725844
NCT01610960|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-05-30|2012-06-01|2012-06-04|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Three Noninvasive Ventilation Modes: a Physiological Study in Healthy Volunteers|Comparison of Helmet NEXT, Helmet Standard and Facemask for Noninvasive Ventilation: a Physiological Study in Healthy Volunteers|Completed||N/A|13|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:19:43.881918|2018-05-31 21:19:43.881918
NCT01610947|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2018-05-09|2012-05-30|2012-06-04|Estimate|||||||2018-05-09|2018-05-15|Actual|May 14, 2012|Actual|2012-05-14|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SPACING||Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity|Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity: a Randomized Controlled Trial|Active, not recruiting||N/A|398|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:19:43.969307|2018-05-31 21:19:43.969307
NCT01610934|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-09-04|2012-06-01|2012-06-04|Estimate|||||||2013-09-04|2013-09-05|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)|Phase 2 Study: A Double-blind, Randomised, Clinical Cross-over Trial to Investigate the Treatment Potential of Liraglutide Compared to Glimepiride in MODY Patients|Completed||Phase 2/Phase 3|15|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 21:19:44.038992|2018-05-31 21:19:44.038992
NCT01610921|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-07-10|2012-05-30|2012-06-04|Estimate|||||||2014-07-10|2014-07-11|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|impact||Determining the Optimal Adenosine Provocation Test|Determining the Optimal Dry Powder Adenosine Provocation Test to Assess Small Airways Disease|Completed||N/A|11|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 21:19:44.132564|2018-05-31 21:19:44.132564
NCT01610908|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-05-26|2012-06-01|2012-06-04|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|January 2017|Anticipated|2017-01-31|August 2016|Anticipated|2016-08-31||Interventional|MultiSETS||Multicenter Schroth Exercise Trial for Scoliosis|A Multicenter Randomized Controlled Trial to Compare the Effect of Schroth Exercises to Standard Care on Curve Characteristics, Posture, and Quality Of Life in Adolescents With Idiopathic Scoliosis|Unknown status|Recruiting|Phase 2|258|Anticipated|University of Alberta||3|||f||||f||||||||||2018-05-31 21:19:44.228782|2018-05-31 21:19:44.228782
NCT01610895|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-06-01|2012-06-01|2012-06-04|Estimate|||||||2012-06-01|2012-06-04|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|BP||Split Dose Polyethylene Glycol (PEG) + Clear Fluids Versus Split Dose PEG + Low-Residue Diet|A Randomized Prospective Trial Comparing Split Dose Polyethylene Glycol-Based Lavage With Clear Fluids Versus Split Dose Polyethylene Glycol-Based Lavage With a Low-Residue Diet in Preparation of Patients for Colonoscopy.|Unknown status|Recruiting|N/A|345|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 21:19:44.345454|2018-05-31 21:19:44.345454
NCT01610882|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-10-24|2012-05-31|2012-06-04|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2012||2012-05-31|October 2017|2017-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Panda||Panda: Evaluation of a Smartphone-based Perioperative Pain Assessment Tool|Panda: Evaluation of a Smartphone-based Perioperative Pain Assessment Tool|Completed||N/A|144|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 21:19:44.444771|2018-05-31 21:19:44.444771
NCT01610869|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2017-05-03|2012-05-31|2012-06-04|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2014||2014-08-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|METRO-BIBF||Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer|Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer|Active, not recruiting||Phase 2|124|Anticipated|University College, London||2|||f||||t||||||||No||2018-05-31 21:19:44.530752|2018-05-31 21:19:44.530752
NCT01610856|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-06-01|2012-06-01|2012-06-04|Estimate|||||||2012-06-01|2012-06-04|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Single Dose Versus Split Dose Polyethylene Glycol-based Colonic Lavage for Colonoscopy|A Randomized Prospective Trial Comparing Single Dose Polyethylene Glycol-based Lavage Versus Split Dose Polyethylene Glycol-based Lavage in the Preparation of Patients Undergoing Colonoscopy|Completed||N/A|250|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 21:19:44.632394|2018-05-31 21:19:44.632394
NCT01610843|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2018-05-23|2012-06-01|2012-06-04|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2011||2011-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|WISE||Worldwide Sarcoidosis Research Study|Worldwide Sarcoidosis Research Study|Recruiting|||10000|Anticipated|University of Iowa|||||f||||f|f|f||||Samples With DNA|"~     Saliva samples will be collected and processed at the University of Iowa.~   "|No||2018-05-31 21:19:44.737515|2018-05-31 21:19:44.737515
NCT01610830|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-04-22|2012-06-01|2012-06-04|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|July 2014|Anticipated|2014-07-31|January 2013|Actual|2013-01-31||Observational|||Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura|Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura|Unknown status|Recruiting||120|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||Samples With DNA|"~     Blood and urine analysis - Skin and kidney biopsies~   "|||2018-05-31 21:19:44.820334|2018-05-31 21:19:44.820334
NCT01610817|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-01-22|2012-06-01|2012-06-04|Estimate|||||||2015-01-22|2015-01-26|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|InPAct||Impact of a Procedure for the Information and Active Participation of the Patient in the Primary Care Prescription of Antihypertensives|Impact of a Procedure for the Information and Active Participation of the Patient in the Primary Care Prescription of Antihypertensives : InPAct Study (Information for Participating Actively in Cardiovascular Treatment)|Completed|||1100|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 21:19:44.896262|2018-05-31 21:19:44.896262
NCT01610804|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-01|2012-06-01|2012-06-04|Estimate|||||||2012-06-01|2012-06-04|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Observational|||Choroidal Thickness Measurements During Central Serous Chorioretinopathy (CSCR) Treatment|Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology|Completed|||18|Actual|University Hospital Regensburg|||2||f||||f||||||||||2018-05-31 21:19:44.977177|2018-05-31 21:19:44.977177
NCT01610791|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2014-05-07||2014-07-08|2012-06-01|2012-06-04|Estimate|2014-07-08|2014-07-10|Estimate||||2014-07-08|2014-07-10|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Intention-to-treat (ITT) population, defined as participants who received at least one dose of tocilizumab (baseline) and for whom data for at least one follow-up variable were available.|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)|A Single Arm, Open Label Study to Assess the Safety, Tolerability and Efficacy of Tocilizumab in Active Rheumatoid Arthritis Patients With Inadequate Response to the DMARDs (REMISSION Study)|Completed||Phase 3|121|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-05-31 21:19:45.108555|2018-05-31 21:19:45.108555
NCT01610778|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2013-12-17|2012-05-31|2012-06-04|Estimate|||||||2013-12-17|2013-12-19|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of 5-Aminolevulinic Acid on Glucose Metabolism|A Randomized, Double-blind, Cross-over Study to Assess Efficacy of 5-Aminolevulinic Acid in Type 2 Diabetic Patients on Medication.|Completed||N/A|35|Anticipated|Hiroshima University||2|||f||||f||||||||||2018-05-31 21:19:45.879418|2018-05-31 21:19:45.879418
NCT01610765|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-06-06|2012-06-01|2012-06-04|Estimate|||||||2016-06-06|2016-06-07|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)|A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)|Withdrawn||Phase 1/Phase 2|0|Actual|University of Alabama at Birmingham||2||Study terminated because unable to obtain access to study drug for study population.|f||||t||||||||||2018-05-31 21:19:45.953001|2018-05-31 21:19:45.953001
NCT01610752|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2018-02-14|2012-05-31|2012-06-04|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2012||2012-12-31|February 2018|2018-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Personalized Management of Body Weight During Pregnancy|Expecting Success: Personalized Management of Body Weight During Pregnancy|Completed||N/A|54|Actual|Pennington Biomedical Research Center||3|||f||||t||||||||||2018-05-31 21:19:46.065724|2018-05-31 21:19:46.065724
NCT01610739|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-07-17|2012-06-01|2012-06-04|Estimate|||||||2012-07-17|2012-07-19|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Carpal Tunnel Release Effects on Median Nerve Perfusion|Effect of Carpal Tunnel Release on Median Nerve Perfusion Using SPY Scope Imaging|Unknown status|Not yet recruiting|N/A|50|Anticipated|Henry Ford Health System||1|||f||||f||||||||||2018-05-31 21:19:46.146692|2018-05-31 21:19:46.146692
NCT01610726|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-11-03|2012-05-31|2012-06-04|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2012||2012-02-29|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Economic and Clinical Evaluation of Enhanced Recovery in Colorectal Surgery|Economic and Clinical Evaluation of Enhanced Recovery in Colorectal Surgery|Completed||N/A|484|Actual|Haukeland University Hospital||2|||f||||t||||||||Yes||2018-05-31 21:19:46.224057|2018-05-31 21:19:46.224057
NCT01610713|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2012-07-18||2013-06-13|2012-06-01|2012-06-04|Estimate|2012-08-21|2012-09-19|Estimate||||2013-06-13|2013-06-24|Estimate|May 2001||2001-05-31|June 2013|2013-06-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis|Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension|Completed||Phase 3|154|Actual|GW Pharmaceuticals Ltd.||1|||f||||f||||||||||2018-05-31 21:19:46.32735|2018-05-31 21:19:46.32735
NCT01610700|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2012-07-18||2013-06-13|2012-06-01|2012-06-04|Estimate|2012-08-21|2012-09-19|Estimate||||2013-06-13|2013-06-24|Estimate|May 2001||2001-05-31|June 2013|2013-06-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients|Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension|Completed||Phase 3|160|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 21:19:47.01669|2018-05-31 21:19:47.01669
NCT01610687|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2012-07-11||2013-06-18|2012-06-01|2012-06-04|Estimate|2012-07-11|2012-08-17|Estimate||||2013-06-18|2013-06-24|Estimate|July 2001||2001-07-31|June 2013|2013-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis|A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension|Completed||Phase 3|137|Actual|GW Pharmaceuticals Ltd.||1|||f||||f||||||||||2018-05-31 21:19:47.810261|2018-05-31 21:19:47.810261
NCT01610674|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-01|2012-06-01|2012-06-04|Estimate|||||||2012-06-01|2012-06-04|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|July 2012|Anticipated|2012-07-31||Interventional|||Developing and Testing an Implementation Strategy to Improve Perioperative Diabetes Care|Perioperative Diabetes Care: Developing and Testing an Implementation Strategy in Terms of Effectiveness, Experiences and Costs|Unknown status|Enrolling by invitation|N/A|800|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 21:19:48.088117|2018-05-31 21:19:48.088117
NCT01610661|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-04-24|2012-06-01|2012-06-04|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2012||2012-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|April 2015|Actual|2015-04-30||Interventional|||Dietary Carbohydrate Type and Cardiovascular Disease (CVD) Risk Indicators|Dietary Carbohydrate Type and CVD Risk Indicators|Active, not recruiting||N/A|10|Anticipated|Tufts University||3|||f||||f||||||||||2018-05-31 21:19:48.232173|2018-05-31 21:19:48.232173
NCT01610648|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-04-20|2012-06-01|2012-06-04|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|May 2013|Actual|2013-05-31||Observational|||Improving the STOP-Bang Screening Questionnaire for Patients With Sleep Apnea|Improving the Sensitivity and Specificity of the STOP-Bang Screening Questionnaire for Patients With Obstructive Sleep Apnea|Completed|||258|Actual|Tufts Medical Center|||1||f||||f||||||||||2018-05-31 21:19:48.306033|2018-05-31 21:19:48.306033
NCT01610635|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-06-09|2012-06-01|2012-06-04|Estimate|||||||2015-06-09|2015-06-10|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|INTERVAL||INTERVAL Study: To Determine Whether the Interval Between Blood Donations in England Can be Safely and Acceptably Decreased|A Randomised Trial to Determine Whether the Interval Between Blood Donations in England Can be Safely and Acceptably Decreased|Unknown status|Active, not recruiting|N/A|50000|Anticipated|University of Cambridge||6|||f||||t||||||||||2018-05-31 21:19:48.378066|2018-05-31 21:19:48.378066
NCT01610609|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-09-26|2012-06-01|2012-06-04|Estimate|||||||2014-09-26|2014-09-29|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Reducing Disparities in Primary Prevention of Cardiovascular Disease|Center for Advancing Equity in Clinical Preventive Services Project 2: Reducing Disparities in Primary Prevention of Cardiovascular Disease|Completed||N/A|646|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 21:19:48.552882|2018-05-31 21:19:48.552882
NCT01610596|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2016-03-10|2013-06-04|2016-04-11|2012-06-01|2012-06-04|Estimate|2016-03-10|2016-04-11|Estimate|2013-06-04|2013-06-12|Estimate|2016-04-11|2016-05-13|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Baseline analyses are based on the Safety population. All participants enrolled in the study who were dispensed and applied test article at least once.|A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis|A Double-blind, Randomized, Multicenter, Vehicle-Controlled Parallel Group Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment|Completed||Phase 2|72|Actual|Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 21:19:48.647306|2018-05-31 21:19:48.647306
NCT01610583|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2018-05-23|2012-05-31|2012-06-04|Estimate|||||||2018-05-23|2018-05-24|Actual|May 24, 2012||2012-05-24|February 23, 2015|2015-02-23|February 23, 2015||2015-02-23|||||Observational|||Testing Spanish-language Genetic Literacy|Development of a Tool to Assess Spanish-Language Genetic Literacy|Completed|||117|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:19:49.277738|2018-05-31 21:19:49.277738
NCT01610570|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2015-11-25||2018-02-03|2012-05-31|2012-06-04|Estimate|2016-01-15|2016-02-15|Estimate||||2018-02-03|2018-03-02|Actual|May 10, 2012|Actual|2012-05-10|December 2017|2017-12-31|May 21, 2014|Actual|2014-05-21|May 21, 2014|Actual|2014-05-21||Interventional|||Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma|Phase I/II Trial of Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript (Phase II)|Terminated||Phase 1/Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||4||Study was closed to enrollment before dose level one was completed.|f||||f|t|f||||||No||2018-05-31 21:19:49.381908|2018-05-31 21:19:49.381908
NCT01610557|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2016-02-11||2016-08-18|2012-05-31|2012-06-04|Estimate|2016-03-24|2016-04-27|Estimate||||2016-08-18|2016-08-19|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||"Participants with both eyes enrolled are counted twice (by eye), once for each of the treatment sequences to which an eye was assigned randomly.~Although 56 participants enrolled, 6 participants had two eyes enrolled for a total of 62 eyes."|Ranibizumab and Bevacizumab for Diabetic Macular Edema|A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME)|Completed||Phase 2|56|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||t||||||||No||2018-05-31 21:19:50.200368|2018-05-31 21:19:50.200368
NCT01610544|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-06-30|2012-05-31|2012-06-04|Estimate|||||||2017-06-30|2017-07-02|Actual|May 10, 2012||2012-05-10|December 10, 2012|2012-12-10|December 10, 2012|Actual|2012-12-10|December 10, 2012|Actual|2012-12-10||Interventional|||18F FLT Imaging Studies of Treatment Response for Lung Cancer and Thymoma|A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:19:51.171117|2018-05-31 21:19:51.171117
NCT01610531|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2013-09-18|2012-06-01|2012-06-04|Estimate|||||||2013-09-18|2013-09-19|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||COPARIME: Pilot Study of a Target Detection of Malignant Melanoma|COPARIME: Pilot Study of a Target Detection of Malignant Melanoma|Recruiting||N/A|7700|Anticipated|Nantes University Hospital|||||f||||t||||||||||2018-05-31 21:19:51.229861|2018-05-31 21:19:51.229861
NCT01610518|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-06-01|2012-06-01|2012-06-04|Estimate|||||||2012-06-01|2012-06-04|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||The Glycemic Response Elicited by Beta-glucans of Different Physical Properties and Form|The Glycemic Response Elicited by Beta-glucans of Different Physical Properties and Form|Completed||N/A|15|Actual|Guelph Food Research Centre||6|||f||||f||||||||||2018-05-31 21:19:51.366512|2018-05-31 21:19:51.366512
NCT01610505|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-06-13|2012-06-01|2012-06-04|Estimate|||||||2017-06-13|2017-06-15|Actual|May 2012||2012-05-31|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|May 2017|Actual|2017-05-31||Interventional|GOAL||A Study of the KineSpring System Versus High Tibial Osteotomy Surgery for Medial Compartment Knee Osteoarthritis Treatment|Global, Prospective, Multi-Center, Non-randomized, Controlled Non-inferiority Trial to Evaluate Symptom Relief in Patients With Medial Knee Osteoarthritis Treated With the KineSpring® Knee Implant for Load Reduction Compared to HTO|Active, not recruiting||N/A|227|Actual|Moximed||2|||f||||f||||||||||2018-05-31 21:19:51.447591|2018-05-31 21:19:51.447591
NCT01610492|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2015-05-11||2017-09-12|2012-05-31|2012-06-04|Estimate|2015-05-11|2015-06-01|Estimate||||2017-09-12|2017-10-13|Actual|July 1, 2012||2012-07-01|September 2017|2017-09-30|September 14, 2016|Actual|2016-09-14|September 24, 2014|Actual|2014-09-24||Interventional|||A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy|BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy|Completed||Phase 2|14|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 21:19:51.709469|2018-05-31 21:19:51.709469
NCT01610479|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-08-02|2012-05-30|2012-06-04|Estimate|||||||2017-08-02|2017-08-04|Actual|June 2012||2012-06-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors|A Phase 1 Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors|Completed||Phase 1|120|Anticipated|Taiho Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:19:53.707669|2018-05-31 21:19:53.707669
NCT01610466|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-11-16|2012-05-30|2012-06-04|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Design and Validation of a Simulation-based Training Curriculum for Laparoscopic Bariatric Surgery|Design and Validation of a Simulation-based Training Curriculum for Laparoscopic Bariatric Surgery|Completed||N/A|24|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:19:53.844981|2018-05-31 21:19:53.844981
NCT01610453|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2016-04-25||2016-04-26|2012-06-01|2012-06-04|Estimate|2016-04-26|2016-04-27|Estimate||||2016-04-26|2016-04-27|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Prediction of Delivery With Transperineal Ultrasound in Women With Prolonged Labour. Multicentre Study|Prediction of Mode of Delivery With Transperineal Ultrasound in Women With Prolonged First Stage of Labour. A Multicentre Study|Completed|||150|Actual|Helse Stavanger HF|||1||f||||t||||||||||2018-05-31 21:19:53.994412|2018-05-31 21:19:53.994412
NCT01610440|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-11-28|2012-06-01|2012-06-04|Estimate|||||||2012-11-28|2012-11-30|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|October 2013|Anticipated|2013-10-31|March 2013|Anticipated|2013-03-31||Interventional|||Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy|Phase I/II Study of Stem Cell Therapy in Patients With Duchenne Muscular Dystrophy|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Shenzhen Beike Bio-Technology Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:19:54.259207|2018-05-31 21:19:54.259207
NCT01610427|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-10-09|2012-05-31|2012-06-04|Estimate|||||||2014-10-09|2014-10-13|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects|Optimizing the Quality of Samples for CMI in Antiretroviral Therapy (ART)-naïve Human Deficiency Virus Type 1 (HIV-1)-Infected Subjects|Completed||N/A|22|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 21:19:54.32397|2018-05-31 21:19:54.32397
NCT01610414|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2017-11-03||2017-12-20|2012-05-31|2012-06-04|Estimate|2017-12-20|2018-01-23|Actual||||2017-12-20|2018-01-23|Actual|July 13, 2012|Actual|2012-07-13|December 2017|2017-12-31|February 1, 2017|Actual|2017-02-01|November 4, 2016|Actual|2016-11-04||Interventional|||Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A|Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A|Completed||Phase 3|1877|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:19:54.509954|2018-05-31 21:19:54.509954
NCT01610401|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-05-17|2012-06-01|2012-06-04|Estimate|||||||2013-05-17|2013-05-20|Estimate|May 2012||2012-05-31|February 2012|2012-02-29|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MetFMD||The Metformin-FMD Trial|Can Metformin Prevent Endothelial Ischemia and Reperfusion Injury? The Metformin-FMD Trial|Completed||Phase 4|26|Actual|Radboud University||4|||f||||f||||||||||2018-05-31 21:19:56.275043|2018-05-31 21:19:56.275043
NCT01610388|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-06-09|2012-05-31|2012-06-04|Estimate|||||||2017-06-09|2017-06-12|Actual|September 13, 2011|Actual|2011-09-13|June 2017|2017-06-30|January 26, 2012|Actual|2012-01-26|January 26, 2012|Actual|2012-01-26||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects|Completed||Phase 1|61|Actual|GlaxoSmithKline||7|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:19:56.42751|2018-05-31 21:19:56.42751
NCT01610375|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-04-03|2012-06-01|2012-06-04|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2012||2012-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2014|Actual|2014-03-31||Interventional|TEACUP||Telephone Follow-up After Treatment for Endometrial Cancer|Telephone Follow-up After Treatment for Endometrial Cancer.|Active, not recruiting||N/A|280|Anticipated|Queensland Centre for Gynaecological Cancer||1|||f||||f||||||||No||2018-05-31 21:19:56.543367|2018-05-31 21:19:56.543367
NCT01610362|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2018-04-05|2012-05-30|2012-06-04|Estimate|||||||2018-04-05|2018-04-09|Actual|June 2012||2012-06-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response|Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response|Completed||N/A|50|Actual|Queen Saovabha Memorial Institute||2|||f||||f||||||||||2018-05-31 21:19:56.602282|2018-05-31 21:19:56.602282
NCT01610349|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-03-11|2012-05-30|2012-06-04|Estimate|||||||2013-03-11|2013-03-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:19:56.660529|2018-05-31 21:19:56.660529
NCT01610336|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-07-29|2012-06-01|2012-06-04|Estimate|||||||2017-07-29|2017-08-01|Actual|April 5, 2012|Actual|2012-04-05|July 2017|2017-07-31|March 30, 2018|Anticipated|2018-03-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment|A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment|Active, not recruiting||Phase 2|161|Actual|Novartis||1|||f||||f|t|f|||t|||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:19:56.694261|2018-05-31 21:19:56.694261
NCT01610323|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-07-25|2012-06-01|2012-06-04|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|InterGOFIT||Fitness Improvement in Obese, Pregnant Women: an Intervention Trial|Fitness Improvement in Obese, Pregnant Women: an Intervention Trial (InterGOFIT)|Completed||N/A|50|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 21:19:56.873618|2018-05-31 21:19:56.873618
NCT01610310|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-06-12|2012-05-31|2012-06-04|Estimate|||||||2014-06-12|2014-06-13|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers|A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profile, Safety, and Tolerability of Peginterferon Beta-1a (BIIB017) Delivered by Pre-filled Syringe (PFS) or Autoinjector in Healthy Volunteers|Completed||Phase 1|55|Actual|Biogen||2|||f||||f||||||||||2018-05-31 21:19:56.979948|2018-05-31 21:19:56.979948
NCT01610297|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2016-04-21||2016-09-12|2012-06-01|2012-06-04|Estimate|2016-06-09|2016-07-21|Estimate||||2016-09-12|2016-10-24|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Post Hematopoietic Stem Cell Transplantation|A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation.|Completed||Phase 4|27|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:19:57.084477|2018-05-31 21:19:57.084477
NCT01610128|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-01-05|2012-05-30|2012-06-01|Estimate|||||||2017-01-05|2017-01-06|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|UCT-D||Development of an Urticaria Control Test|UCT - Development of an Instrument to Assess Disease Control in Patients With Chronic Urticaria (Urticaria Control Test)|Completed|||508|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 21:20:00.31355|2018-05-31 21:20:00.31355
NCT01610284|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-10-16|2012-06-01|2012-06-04|Estimate|||||||2017-10-16|2017-10-18|Actual|August 7, 2012|Actual|2012-08-07|October 2017|2017-10-31|November 8, 2017|Anticipated|2017-11-08|November 8, 2017|Anticipated|2017-11-08||Interventional|BELLE-2||Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor|A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment|Active, not recruiting||Phase 3|1149|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:19:57.378423|2018-05-31 21:19:57.378423
NCT01610271|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-04-16|2012-06-01|2012-06-04|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ABS||Air Barrier System for the Prevention of Surgical Site Infection|Air Barrier System to Reduce Contamination of Wounds During Surgery|Completed||N/A|300|Actual|Nimbic Systems, LLC||2|||f||||t||||||||||2018-05-31 21:19:57.813198|2018-05-31 21:19:57.813198
NCT01610258|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-12-03|2012-05-31|2012-06-01|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|ICAR||Maternal Plasmatic Regulatory T Cells and Th17 as Possible Diagnosis Markers of Acute Chorioamnionitis|Contribution of the Study of Maternal Plasmatic Regulator T Cells and Th17 for the Diagnosis of Acute Chorioanmionitis Among Women Hospitalized for Premature Rupture of Fetal Membranes (PPROM) Between 24 and 34 Gestation Weeks|Unknown status|Recruiting|N/A|120|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||f||||||||||2018-05-31 21:19:57.889343|2018-05-31 21:19:57.889343
NCT01610245|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30||2018-03-27|2018-03-27|2012-05-30|2012-06-01|Estimate||||2018-03-27|2018-03-29|Actual|2018-03-27|2018-03-29|Actual|March 2013||2013-03-31|March 2018|2018-03-31|April 16, 2015|Actual|2015-04-16|March 2015|Actual|2015-03-31||Interventional|||Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza|Completed||Phase 3|1941|Actual|Romark Laboratories L.C.||4|||f||||f||||||||||2018-05-31 21:19:57.986928|2018-05-31 21:19:57.986928
NCT01610232|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-05-31|2012-05-31|2012-06-01|Estimate|||||||2012-05-31|2012-06-01|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Infrared-LED During Physical Training for Rehabilitation, Physical Performance and Body Aesthetics|Effects of Infrared-LED Illumination Applied During Treadmill Training in Postmenopausal Women|Completed||Phase 1|45|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 21:19:58.351935|2018-05-31 21:19:58.351935
NCT01610219|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-05-31|2012-05-31|2012-06-01|Estimate|||||||2012-05-31|2012-06-01|Estimate|August 2008||2008-08-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Lifestyle Modification for Type 2 Diabetes Prevention in Overweight Youth|Lifestyle Modification for Type 2 Diabetes Prevention in Overweight Youth|Completed||N/A|52|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 21:19:58.434021|2018-05-31 21:19:58.434021
NCT01610206|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2018-05-01|2012-05-31|2012-06-01|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2012|Actual|2012-09-30|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer|A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Active, not recruiting||Phase 2|148|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 21:19:58.497871|2018-05-31 21:19:58.497871
NCT01610193|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-08-22|2012-05-30|2012-06-01|Estimate|||||||2013-08-22|2013-08-23|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Observational|||The Value of Pancreatic Stone Protein in Predicting Acute Appendicitis|The Value of Pancreatic Stone Protein in Predicting Acute Appendicitis in Patients Presenting at the Emergency Department With Abdominal Pain|Unknown status|Recruiting||245|Anticipated|University of Zurich|||1||f||||t||||||Samples Without DNA|"~     Whole blood and serum or plasma of 245 patients.~   "|||2018-05-31 21:19:58.586018|2018-05-31 21:19:58.586018
NCT01610180|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-09-25|2012-05-31|2012-06-01|Estimate|||||||2012-09-25|2012-09-26|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)|Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)|Unknown status|Recruiting|Phase 2|26|Anticipated|Fondazione Progetto Ematologia||1|||f||||t||||||||||2018-05-31 21:19:58.670721|2018-05-31 21:19:58.670721
NCT01610167|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2013-02-20||2013-08-08|2012-05-31|2012-06-01|Estimate|2013-08-08|2013-10-14|Estimate||||2013-08-08|2013-10-14|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Intent to treat (ITT).|NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r)Sensitivity Relief Study|NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r) for the Treatment of Dentin Hypersensitivity.|Completed||N/A|151|Actual|Dentsply International||3|||f||||f||||||||||2018-05-31 21:19:58.746115|2018-05-31 21:19:58.746115
NCT01610154|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2016-11-27||2017-04-05|2012-05-31|2012-06-01|Estimate|2017-02-16|2017-04-04|Actual||||2017-04-05|2017-05-11|Actual|October 2012||2012-10-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|||Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics― the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics||Completed||Phase 4|85|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||1|||f||||t||||||||||2018-05-31 21:19:59.984591|2018-05-31 21:19:59.984591
NCT01610141|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-10-07|2012-05-31|2012-06-01|Estimate|||||||2013-10-07|2013-10-09|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients|Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients|Unknown status|Recruiting|Phase 4|500|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 21:20:00.217415|2018-05-31 21:20:00.217415
NCT01610115|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-05-30|2012-05-30|2012-06-01|Estimate|||||||2012-05-30|2012-06-01|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||HBV DNA Levels During Pregnancy in Chronic Hepatitis B|Serial HBV DNA Levels During Pregnancy in Patients With Chronic Hepatitis B: a Prospective Observational Follow-up Study|Unknown status|Recruiting||100|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||||||2018-05-31 21:20:00.37068|2018-05-31 21:20:00.37068
NCT01610102|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-02-04|2012-05-31|2012-06-01|Estimate|||||||2015-02-04|2015-02-05|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||PROGRESS-AMS 1.0 Clinical Long Term Follow-Up|Clinical Performance and Angiographic Results of Coronary Stenting With Absorbable Metal Stents, Clinical Long Term Follow-Up|Completed|||55|Actual|Biotronik AG|||||f||||f||||||||||2018-05-31 21:20:00.438436|2018-05-31 21:20:00.438436
NCT01610089|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-03-18|2012-05-31|2012-06-01|Estimate|||||||2015-03-18|2015-03-20|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|NOASSD||Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)|RDCRN 5110, Nitric Oxide Flux and Ureagenesis in Argininosuccinate Synthetase Deficiency (ASSD)(Citrullinemia I)(Version 24Feb12, NIH Approved 4/5/2012)|Completed||N/A|6|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 21:20:01.275202|2018-05-31 21:20:01.275202
NCT01610076|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2015-08-22||2016-04-07|2012-05-31|2012-06-01|Estimate|2016-03-15|2016-04-04|Estimate||||2016-04-07|2016-05-13|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Code Status Video in the Intensive Care Unit: Video Assisted Patient Education|Pilot Study to Determine Effectiveness and Acceptance of a Code Status Video in the ICU|Completed||Phase 1/Phase 2|208|Actual|Mayo Clinic|In this study the patient outcomes were not addressed as the primary outcome was patient and family knowledge of CPR.|2|||f||||f||||||||||2018-05-31 21:20:01.386152|2018-05-31 21:20:01.386152
NCT01610063|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2016-08-18||2017-02-10|2012-05-30|2012-06-01|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|January 2009|Actual|2009-01-31|February 2017|2017-02-28|May 2013|Actual|2013-05-31|November 2011|Actual|2011-11-30||Interventional|||Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting|A Pilot Study for the Evaluation of the Clinic-wide Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting|Completed||N/A|227|Actual|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 21:20:01.771491|2018-05-31 21:20:01.771491
NCT01610050|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-11-09|2012-05-31|2012-06-01|Estimate|||||||2014-11-09|2014-11-11|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase I Study of LFA102 in Japanese Patients|A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Japanese Patients With Castration-resistant Prostate Cancer or Advanced Breast Cancer|Completed||Phase 1|14|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:20:02.352557|2018-05-31 21:20:02.352557
NCT01610037|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2016-02-01||2016-05-09|2012-05-30|2012-06-01|Estimate|2016-05-09|2016-06-15|Estimate||||2016-05-09|2016-06-15|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||The RAN included all randomized patients regardless of whether or not they actually received study medication.|Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation|A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation|Completed||Phase 3|1215|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:20:02.638305|2018-05-31 21:20:02.638305
NCT01610024|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-06-25|2012-05-30|2012-06-01|Estimate|||||||2013-06-25|2013-06-26|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Northern Board Beet Breathlessness Trial||Unknown status|Recruiting|Phase 1|8|Anticipated|Northern Health and Social Care Trust||1|||f||||f||||||||||2018-05-31 21:20:04.136939|2018-05-31 21:20:04.136939
NCT01610011|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|2015-05-11||2015-09-25|2012-05-31|2012-06-01|Estimate|2015-09-25|2015-10-27|Estimate||||2015-09-25|2015-10-27|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Subjects eligible to undergo magnetic resonance spectroscopy scans and consume a glycine-enriched beverage, who completed both procedures.|Acute Glycine Pharmacodynamic Study|Acute Glycine Pharmacodynamic Study|Completed||N/A|21|Actual|Mclean Hospital|This trial was limited by small sample sizes, especially in the GLDC mutation group, since this is a rare genetic mutation.|1|||f||||f||||||||||2018-05-31 21:20:04.223389|2018-05-31 21:20:04.223389
NCT01609998|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-10-15|2012-05-31|2012-06-01|Estimate|||||||2013-10-15|2013-10-16|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents|Open-Label, Dose-Escalation, Phase I Study of the Prime-Boost Investigational 2012/13 Seasonal Influenza DNA Vaccine, VRC-FLUDNA063-00-VP, Followed by the 2012/2013 Seasonal TIV Compared to TIV Prime-Boost in Children/Adolescents Ages 6-17|Completed||Phase 1|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 21:20:04.422728|2018-05-31 21:20:04.422728
NCT01609985|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2013-06-28|2012-05-30|2012-06-01|Estimate|||||||2013-06-28|2013-07-01|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Cutaneous Heart Sounds Data Collection During Cardiac Resynchronization Therapy (CRT) Optimization Study|Cutaneous Heart Sounds Data Collection During CRT Optimization Study|Completed|||52|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-05-31 21:20:04.52572|2018-05-31 21:20:04.52572
NCT01609972|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-06-30|2012-05-31|2012-06-01|Estimate|||||||2015-06-30|2015-07-02|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|June 2015|Anticipated|2015-06-30|May 2015|Actual|2015-05-31||Interventional|SENZA-RCT||Comparison of Senza to Commercial Spinal Cord Stimulation for the Treatment of Chronic Pain|Multi-Center, Prospective, Randomized, Controlled Clinical Trial to Demonstrate Non-Inferiority of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Pain as Compared to Commercially Available SCS Devices|Unknown status|Active, not recruiting|N/A|356|Anticipated|Nevro Corp||2|||f||||t||||||||||2018-05-31 21:20:04.589466|2018-05-31 21:20:04.589466
NCT01609959|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-10-28|2012-05-30|2012-06-01|Estimate|||||||2013-10-28|2013-10-30|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|NARA||New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering|Effects of the New Angiotensin II Receptor Blocker Azilsartan Versus Valsartan on Blood Pressure in Japanese Patients With Hypertension|Completed||Phase 4|70|Actual|Nara Medical University||2|||f||||t||||||||||2018-05-31 21:20:04.659213|2018-05-31 21:20:04.659213
NCT01609946|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2018-03-30|2012-05-31|2012-06-01|Estimate|||||||2018-03-30|2018-04-02|Actual|June 2012||2012-06-30|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Realtime-Elastography (RTE) and Thyroid Nodules|Evaluation of Realtime-Elastography for Differentiation of Thyroid Nodules: a Multicenter Study|Completed||N/A|602|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-05-31 21:20:04.732934|2018-05-31 21:20:04.732934
NCT01609933|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-05-12|2012-05-30|2012-06-01|Estimate|||||||2017-05-12|2017-05-15|Actual|December 18, 2012|Actual|2012-12-18|May 2017|2017-05-31|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study|An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination With Peginterferon α-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study|Completed||Phase 2|32|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:20:04.819012|2018-05-31 21:20:04.819012
NCT01609920|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-11-09|2012-05-30|2012-06-01|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Nodal Staging in Breast Cancer With MRL|Non-invasive Nodal Staging in Breast Cancer With Magnetic Resonance Imaging Lymphography Using Gadofosveset|Terminated||N/A|97|Actual|Maastricht University Medical Center||1||Manufacturer recently halted production of gadofosveset.|f||||f||||||||||2018-05-31 21:20:04.986763|2018-05-31 21:20:04.986763
NCT01609907|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-05-31|2012-05-31|2012-06-01|Estimate|||||||2012-05-31|2012-06-01|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan in Healthy Male Volunteer|Completed||Phase 1|30|Actual|Yuhan Corporation||6|||f||||f||||||||||2018-05-31 21:20:05.066286|2018-05-31 21:20:05.066286
NCT01609894|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-08-10|2012-05-30|2012-06-01|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2013||2013-08-31|August 2016|2016-08-31||||June 2018|Anticipated|2018-06-30||Interventional|IFO||Individualized Fortification of Breast Milk|Individualized Fortification of Breast Milk With Fat, Carbohydrate and Protein for Preterm Infants|Recruiting||N/A|112|Anticipated|McMaster Children's Hospital||2|||f||||t||||||||||2018-05-31 21:20:05.173208|2018-05-31 21:20:05.173208
NCT01609881|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-02-20|2012-05-29|2012-06-01|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2012|Actual|2012-03-31|February 2017|2017-02-28|October 19, 2016|Actual|2016-10-19|October 19, 2016|Actual|2016-10-19||Interventional|Prostaglandin||The Role of Prostaglandins in the Progression of Diabetic Retinopathy|The Role of Prostaglandins in the Progression of Diabetic Retinopathy and the Therapeutic Efficacy of Topical Ketorolac (Acuvail)|Withdrawn||Phase 1|0|Actual|Vanderbilt University Medical Center||2||Due to lack of funding|f||||f||||||||||2018-05-31 21:20:05.378083|2018-05-31 21:20:05.378083
NCT01609868|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2018-01-29|2012-05-31|2012-06-01|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2012|Actual|2012-06-30|January 2018|2018-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of a Liquid Protein Modular on Growth and Outcomes in the NICU|The Effect of a Liquid Protein Modular on Growth and Outcomes in the NICU|Completed||N/A|60|Actual|University of Nebraska||2|||f||||f|f|f||||||||2018-05-31 21:20:05.451393|2018-05-31 21:20:05.451393
NCT01609855|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-31|2012-05-31|2012-06-01|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate?|Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study|Unknown status|Recruiting|Phase 4|400|Anticipated|Valduce Hospital||2|||f||||f||||||||||2018-05-31 21:20:05.505842|2018-05-31 21:20:05.505842
NCT01609842|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2018-04-10|2012-05-29|2012-06-01|Estimate|||||||2018-04-10|2018-04-11|Actual|January 20, 2014|Actual|2014-01-20|April 2018|2018-04-30|March 30, 2020|Anticipated|2020-03-30|October 31, 2017|Actual|2017-10-31||Interventional|||Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence|Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence|Active, not recruiting||N/A|2500|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 21:20:05.592714|2018-05-31 21:20:05.592714
NCT01609829|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-05-31|2012-05-31|2012-06-01|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||iCOMtrain, Development and Evaluation of a Combined Training of Technical and Non-Technical Skills During the Management of Simulated Incidents in Intensive Care||Unknown status|Recruiting||200|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 21:20:05.6875|2018-05-31 21:20:05.6875
NCT01609816|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-07-12|2012-05-30|2012-06-01|Estimate|||||||2017-07-12|2017-07-13|Actual|May 2012||2012-05-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma|Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.|Recruiting||Phase 1/Phase 2|30|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 21:20:05.754901|2018-05-31 21:20:05.754901
NCT01609803|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2016-05-16|2012-05-30|2012-06-01|Estimate|||||||2016-05-16|2016-05-18|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma|Tissue Microarray Studies of the 12q13-q14 Amplicon in Alveolar Rhabdomyosarcoma|Completed|||99|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tissue samples~   "|||2018-05-31 21:20:05.86458|2018-05-31 21:20:05.86458
NCT01609790|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2016-10-25||2018-02-05|2012-05-30|2012-06-01|Estimate|2017-01-09|2017-02-27|Actual||||2018-02-05|2018-03-07|Actual|June 4, 2012|Actual|2012-06-04|February 2018|2018-02-28||||October 2, 2015|Actual|2015-10-02||Interventional||All eligible patients.|Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors|Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma|Active, not recruiting||Phase 2|137|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:20:06.006548|2018-05-31 21:20:06.006548
NCT01609777|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-05-29|2012-05-29|2012-06-01|Estimate|||||||2012-05-29|2012-06-01|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|HandSAFE||HandSAFE - Development and Evaluation of a Handover Tool for Doctors and Nurses|HandSAFE - Development and Evaluation of a Handover Tool for Doctors and Nurses|Unknown status|Not yet recruiting|N/A|80|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 21:20:07.351137|2018-05-31 21:20:07.351137
NCT01609751|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-03-01|2012-05-31|2012-06-01|Estimate|||||||2016-03-01|2016-03-02|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|LACTOPRoD||Prevention of Diverticulitis by Taking a Daily Probiotic|Does a Daily Dose of the Probiotic Lactobacillus Casei Shirota Prevent Acute Episodes of Diverticulitis (LACTOPRoD) - a Pilot Study|Completed||N/A|26|Actual|University of Surrey||1|||f||||t||||||||||2018-05-31 21:20:07.528692|2018-05-31 21:20:07.528692
NCT01609738|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2016-04-07|2012-05-31|2012-06-01|Estimate|||||||2016-04-07|2016-04-08|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum|Left Ventricular Septum Pacing in Patients by Transvenous Approach Through the Inter-ventricular Septum - Feasibility, Long-term Lead Stability and Safety|Completed|||12|Actual|Maastricht University Medical Center|||2||f||||t||||||||||2018-05-31 21:20:07.612821|2018-05-31 21:20:07.612821
NCT01609725|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-06-08|2012-05-29|2012-06-01|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|PerioCardio||Periodontal Therapy in Coronary Artery Patients|Impact of Periodontal Therapy in Flow-mediated Dilation and Serum Levels of Cardiovascular Risk Biomarkers in Coronary Artery Disease Patients: 12 Months Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 21:20:07.71539|2018-05-31 21:20:07.71539
NCT01609712|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-06-03|2012-05-31|2012-06-01|Estimate|||||||2012-06-03|2012-06-05|Estimate|May 2012||2012-05-31|June 2012|2012-06-30||||||||Observational|||Osteoporotic Vertebral Compression Fractures: Can Kyphoplasty Improve Lung Function? A Prospective Evaluation|Osteoporotic Vertebral Compression Fractures: Can Kyphoplasty Improve Lung Function? A Prospective Evaluation|Unknown status|Recruiting||30|Anticipated|University Hospital, Bonn|||1||f||||f||||||||||2018-05-31 21:20:07.866045|2018-05-31 21:20:07.866045
NCT01609699|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-05-31|2012-05-31|2012-06-01|Estimate|||||||2012-05-31|2012-06-01|Estimate|August 2012||2012-08-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effectiveness Study of the UltraShape® Contour I-Y for Non-Invasive Reduction in Abdominal Circumference|A Baseline Controlled Study to Evaluate the Effectiveness of the UltraShape® Contour I - Y System for Non-Invasive Reduction in Abdominal Circumference|Unknown status|Not yet recruiting|N/A|30|Anticipated|UltraShape||2|||f||||f||||||||||2018-05-31 21:20:07.983039|2018-05-31 21:20:07.983039
NCT01609686|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-02-01|2012-05-31|2012-06-01|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||Pharmacokinetics of Tranexamic Acid in Patients With Varying Renal Function Undergoing Cardiac Surgery With the Use of Cardiopulmonary Bypass|Pharmacokinetics of Tranexamic Acid in Patients With Varying Renal Function Undergoing Cardiac Surgery With the Use of Cardiopulmonary Bypass|Completed|||49|Actual|University Health Network, Toronto|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 21:20:08.071066|2018-05-31 21:20:08.071066
NCT01609673|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-06-11|2012-05-31|2012-06-01|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of Everolimus in de Novo Renal Transplant Recipients|Evaluation of the Early Conversion From a Calcineurin Inhibitor-based Immunosuppressive Regimen to Everolimus in de Novo Renal Transplant Recipients, a Multicenter Experience|Terminated||N/A|1|Actual|Fundação Instituto Mineiro de Estudo Pesquisa Em Nefrologi||2||"The inclusion of proposed sample turned to be infeasible due to Ethical Non-approval of 2~   research sites and another site no transplant activity since 2012."|f||||t||||||||||2018-05-31 21:20:08.133051|2018-05-31 21:20:08.133051
NCT01609660|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2016-09-09|2012-05-31|2012-06-01|Estimate|||||||2016-09-09|2016-09-12|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|||Impact of Probiotics on the Intestinal Microbiota|Impact of Probiotics on the Intestinal Microbiota and Its Association With Postoperative Outcome After Colorectal Surgery|Completed||Phase 4|33|Actual|Federal University of Minas Gerais||2|||f||||f||||||||Yes|Scientific publications|2018-05-31 21:20:08.202676|2018-05-31 21:20:08.202676
NCT01609647|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-12-21|2012-05-30|2012-06-01|Estimate|||||||2014-12-21|2014-12-23|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PRAISE-HPR||Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention|Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention|Completed||Phase 3|76|Actual|Dong-A University||2|||f||||t||||||||||2018-05-31 21:20:08.357667|2018-05-31 21:20:08.357667
NCT01609634|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-08-03|2012-05-31|2012-06-01|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2012|Actual|2012-07-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|August 2016|Actual|2016-08-31||Interventional|Venus||New Infant Formula Trial in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety|A Randomised, Controlled, Double-blind Trial to Investigate the Effects of a New Infant Formula in Healthy Term Subjects on Growth, Body Composition, Tolerance and Safety.|Active, not recruiting||N/A|541|Actual|Danone Asia Pacific Holdings Pte, Ltd.||3|||f||||t||||||||No||2018-05-31 21:20:08.444157|2018-05-31 21:20:08.444157
NCT01609621|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2016-12-19|2012-05-31|2012-06-01|Estimate|||||||2016-12-19|2016-12-20|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|||Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions|Tibiopedal Access for Crossing of Infrainguinal Artery Occlusions|Completed|||199|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 21:20:08.516419|2018-05-31 21:20:08.516419
NCT01609608|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2012-05-30|2012-05-30|2012-06-01|Estimate|||||||2012-05-30|2012-06-01|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Whole-Body Vibration for Functional Constipation|Whole-Body Vibration for Functional Constipation: A Single-Center, Single-Blinded, Randomized, Controlled Trial|Completed||N/A|26|Actual|Changhua Christian Hospital||2|||f||||t||||||||||2018-05-31 21:20:08.584881|2018-05-31 21:20:08.584881
NCT01609595|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2013-03-12|2012-05-31|2012-06-01|Estimate|||||||2013-03-12|2013-03-13|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|ST20-P2T||Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand|An Open Label Academic Phase 2 Study of SDMB in Subjects in Thailand With Beta Thalassemia Intermedia|Completed||Phase 2|10|Actual|Boston University||1|||f||||t||||||||||2018-05-31 21:20:08.70376|2018-05-31 21:20:08.70376
NCT01609426|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-03-24|2012-05-30|2012-06-01|Estimate|||||||2017-03-24|2017-03-27|Actual|September 2012|Actual|2012-09-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|NEPHROVIR-2||Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome|Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome|Completed|||351|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     DNA Peripheral Blood Mononuclear Cells Plasma~   "|||2018-05-31 21:20:13.647289|2018-05-31 21:20:13.647289
NCT01609582|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2015-07-24||2015-10-15|2012-05-31|2012-06-01|Estimate|2015-07-24|2015-08-21|Estimate||||2015-10-15|2015-10-19|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||The randomized set included all randomized participants.|Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects With Type 2 Diabetes and With Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events|Terminated||Phase 3|3207|Actual|Takeda||2||Due to potential concerns about liver safety (See Detailed Description)|f||||t||||||||||2018-05-31 21:20:08.869847|2018-05-31 21:20:08.869847
NCT01609569|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2013-02-20|2012-05-31|2012-06-01|Estimate|||||||2013-02-20|2013-02-22|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Observational|||Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.|Utility of Pro-calcitonin as an Indicator of Ischemia in Patients Undergoing Percutaneous Coronary Intervention With Subsequent Coronary Complications.|Unknown status|Active, not recruiting||100|Anticipated|Saint Michael's Medical Center|||1||f||||f||||||||||2018-05-31 21:20:11.146831|2018-05-31 21:20:11.146831
NCT01609556|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-12-19|2012-05-31|2012-06-01|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2012||2012-05-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|IMGN-0401||First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors|Active, not recruiting||Phase 1|205|Anticipated|ImmunoGen, Inc.||1|||f||||f||||||||||2018-05-31 21:20:11.345594|2018-05-31 21:20:11.345594
NCT01609543|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2015-12-29||2015-12-29|2012-05-30|2012-06-01|Estimate|2015-12-29|2016-02-01|Estimate||||2015-12-29|2016-02-01|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Intent-to-treat (ITT) population included all enrolled participants.|A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations|Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations|Completed||Phase 4|62|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:20:11.447982|2018-05-31 21:20:11.447982
NCT01609530|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2018-03-20|2012-05-31|2012-06-01|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2012||2012-01-31|March 2018|2018-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy|Randomized Double Blind Study Comparing Liquid Nitrogen Cryotherapy With Nd:YAG in the Treatment of Verruca Vulgaris|Terminated||N/A|31|Actual|Saint Joseph Mercy Health System||2||Unable to accrue the projected number of patients required.|f||||t||||||||No||2018-05-31 21:20:11.706661|2018-05-31 21:20:11.706661
NCT01609517|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-10-29|2012-05-31|2012-06-01|Estimate|||||||2014-10-29|2014-10-30|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Influence of Body-mass Index on the Outcome of Spinal Anesthesia for Total Knee Replacement Arthroplasty|The Influence of Body-mass Index on the Outcome of Spinal Anesthesia for Total Knee Replacement Arthroplasty|Completed|||209|Actual|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 21:20:11.853453|2018-05-31 21:20:11.853453
NCT01609504|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2012-05-29|2012-05-29|2012-06-01|Estimate|||||||2012-05-29|2012-06-01|Estimate|April 1997||1997-04-30|May 2012|2012-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|ELRRvsLTME||ELRR by TEM Versus Laparoscopic TME in iT2N0M0 SMALL LOW RECTAL CANCER|Randomized Controlled Clinical Trial: Endoluminal Loco-regional Resection (ELRR) by Transanal Endoscopic Microsurgery (TEM) Versus Laparoscopic Total Mesorectal Excision (LTME) in it2n0m0 Small Low Rectal Cancer|Completed||Phase 3|283|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:20:11.954178|2018-05-31 21:20:11.954178
NCT01609491|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2015-12-09|2012-05-30|2012-06-01|Estimate|||||||2015-12-09|2015-12-10|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Phenylephrine Versus Norepinephrine in Ophthalmic Surgery|Comparison of the Effects of Phenylephrine and Norepinephrine on Hemodynamics and Tissue Oxygenation in Patients Undergoing Ophthalmic Surgery|Completed||N/A|60|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 21:20:12.046903|2018-05-31 21:20:12.046903
NCT01609478|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2014-06-27||2015-01-15|2012-05-29|2012-06-01|Estimate|2014-08-27|2014-09-09|Estimate||||2015-01-15|2015-01-27|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma|A Multicenter, Randomized, Double-blind, Placebo-controlled, 12-week Treatment, Parallel-group Study to Assess the Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate (75 and 150 µg o.d.) in Patients With Persistent Asthma|Completed||Phase 2|335|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:20:12.182124|2018-05-31 21:20:12.182124
NCT01609465|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-05-29|2012-05-29|2012-06-01|Estimate|||||||2012-05-29|2012-06-01|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Prognostic Models for People With Stable Coronary Artery Disease|Prognostic Models for People With Stable Coronary Artery Disease|Unknown status|Active, not recruiting||300000|Anticipated|University College, London|||1||f||||t||||||||||2018-05-31 21:20:13.451508|2018-05-31 21:20:13.451508
NCT01609452|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2015-07-28|2012-05-29|2012-06-01|Estimate|||||||2015-07-28|2015-07-30|Estimate|December 2015||2015-12-31|July 2015|2015-07-31||||June 2016|Anticipated|2016-06-30||Interventional|||MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP|MONICA-SC: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With Immune Thrombocytopenic Purpura (ITP)|Withdrawn||Phase 2/Phase 3|0|Actual|Anthera Pharmaceuticals||2|||f||||||||||||||2018-05-31 21:20:13.515172|2018-05-31 21:20:13.515172
NCT01609439|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2016-09-14|2012-05-29|2012-06-01|Estimate|||||||2016-09-14|2016-09-16|Estimate||||May 2012|2012-05-31||||||||Interventional|||Preoperative Vitamin D for Post-thyroidectomy Hypocalcemia|Pre-operative Vitamin D Supplementation to Reduce Post-operative Hypocalcemia in Patients Undergoing Total Thyroidectomy: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 21:20:13.579681|2018-05-31 21:20:13.579681
NCT01609413|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-31|2012-05-31|2012-06-01|Estimate|||||||2012-05-31|2012-06-01|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|COMCAL||The COMparison of CALcium Bioavailability Between AlgaeCal® and a Proprietary Supplement|A Human Crossover Study to Compare the Bioavailability of Calcium From AlgaeCal® Versus a Proprietary Calcium Dietary Supplement|Completed||Phase 1|20|Actual|SPRIM Advanced Life Sciences, SprimItalia||2|||f||||t||||||||||2018-05-31 21:20:13.717918|2018-05-31 21:20:13.717918
NCT01609400|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-02-26|2012-05-30|2012-06-01|Estimate|||||||2015-02-26|2015-02-27|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||An Extension of CTN 31GB0607 to Evaluate Long Term Safety of NASHA Treatment in the Breast||Completed|||11|Actual|Q-Med AB|||1||f||||f||||||||||2018-05-31 21:20:13.77472|2018-05-31 21:20:13.77472
NCT01609387|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2016-05-02|2012-05-29|2012-06-01|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Postoperative Vitamin Supplementation in Morbidly Obese Patient (VITAAL Study)|Postoperative Vitamin Supplementation in Morbidly Obese Patient|Completed||Phase 4|300|Actual|Rijnstate Hospital||6|||f||||f||||||||||2018-05-31 21:20:13.949323|2018-05-31 21:20:13.949323
NCT01609374|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-09-25|2012-05-29|2012-06-01|Estimate|||||||2017-09-25|2017-09-26|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Restore CLINICAL TRIAL|Prospective, Non-Randomized, Concurrently Controlled, Multi-Center Study to Evaluate the Safety and Effectiveness of the Spinal Kinetics™ M6-C Artificial Cervical Disc Compared to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Symptomatic Cervical Radiculopathy|Active, not recruiting||Phase 3|258|Actual|Spinal Kinetics||2|||f||||t||||||||||2018-05-31 21:20:14.029136|2018-05-31 21:20:14.029136
NCT01609361|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-08-18|2012-05-29|2012-06-01|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|REHAB||Benefit of Rehabilitation Program in Colorectal Surgery|Benefit of Rehabilitation Program in Colorectal Laparoscopic Surgery|Completed||N/A|270|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:20:14.117111|2018-05-31 21:20:14.117111
NCT01609348|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2017-10-16||2018-01-04|2012-05-29|2012-06-01|Estimate|2018-01-04|2018-01-31|Actual||||2018-01-04|2018-01-31|Actual|April 2012||2012-04-30|January 2018|2018-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|DIADs-3||Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)|Venlafaxine for Depression in Alzheimer's Disease|Completed||N/A|5|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:20:14.192143|2018-05-31 21:20:14.192143
NCT01609335|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-08-07|2012-05-29|2012-05-31|Estimate|||||||2014-08-07|2014-08-08|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults|Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults (30-49yo)|Completed||Phase 1|41|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:20:14.480954|2018-05-31 21:20:14.480954
NCT01609322|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2013-12-19|2012-05-30|2012-05-31|Estimate|||||||2013-12-19|2013-12-23|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Exposure Therapy for Fear of Falling in Older Adults|Exposure Therapy for Fear of Falling in Older Adults|Completed||Phase 2|40|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:20:14.533544|2018-05-31 21:20:14.533544
NCT01609309|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-01-26|2012-05-29|2012-05-31|Estimate|||||||2015-01-26|2015-01-27|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)|Multicenter Study on Comparison of Long-term Outcome Between Laparoscopic and Open Distal Subtotal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 3|1056|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 21:20:14.699547|2018-05-31 21:20:14.699547
NCT01609296|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-01-20|2012-05-29|2012-05-31|Estimate|||||||2017-01-20|2017-01-24|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|April 2016|Actual|2016-04-30||Interventional|||IN.PACT Global Clinical Study|The IN.PACT Global Clinical Study for the Treatment of Comprehensive Superficial Femoral and/or Popliteal Artery Lesions Using the IN.PACT Admiral™ Drug-Eluting Balloon.|Active, not recruiting||N/A|1535|Actual|Medtronic Endovascular||1|||f||||f||||||||||2018-05-31 21:20:14.847853|2018-05-31 21:20:14.847853
NCT01609283|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2018-01-10|2012-05-29|2012-05-31|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2012||2012-05-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis|A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis|Active, not recruiting||Phase 1|27|Actual|Mayo Clinic||1|||f||||t|t|f||||||No||2018-05-31 21:20:15.075857|2018-05-31 21:20:15.075857
NCT01609270|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2015-04-21|2012-05-29|2012-05-31|Estimate|||||||2015-04-21|2015-04-23|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|CardioRoot||CardioRoot Post-Marketing Surveillance Registry|CardioRoot Post-Marketing Surveillance Registry|Unknown status|Recruiting|N/A|50|Anticipated|Maquet Cardiovascular||1|||f||||f||||||||||2018-05-31 21:20:15.158049|2018-05-31 21:20:15.158049
NCT01609257|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2015-12-08||2017-07-20|2012-05-29|2012-05-31|Estimate|2016-07-18|2016-08-15|Estimate||||2017-07-20|2017-08-21|Actual|July 16, 2012|Actual|2012-07-16|July 2017|2017-07-31|March 18, 2014|Actual|2014-03-18|March 1, 2014|Actual|2014-03-01||Interventional|||Norovirus Bivalent-Vaccine Efficacy Study|Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease|Completed||Phase 1/Phase 2|132|Actual|Takeda||2|||f||||t||||||||||2018-05-31 21:20:15.295238|2018-05-31 21:20:15.295238
NCT01609244|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2016-01-06|2012-05-29|2012-05-31|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|CSA-FKKG||Bilevel Versus Servoventilation in Complex Sleep Apnea|Bilevel Versus Servoventilation in Complex Sleep Apnea|Completed||N/A|30|Actual|Krankenhaus Kloster Grafschaft||2|||f||||f||||||||||2018-05-31 21:20:16.06008|2018-05-31 21:20:16.06008
NCT01609231|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-01-06|2012-05-30|2012-05-31|Estimate|||||||2015-01-06|2015-01-07|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)|A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination With Irinotecan Versus Cetuximab and Irinotecan for Patients With Metastatic Rectal Cancers (mRC) Expressing High IGF-1/Low IGF-2 Levels|Completed||Phase 2|11|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:20:16.1357|2018-05-31 21:20:16.1357
NCT01609218|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-10-04|2012-05-29|2012-05-31|Estimate|||||||2012-10-04|2012-10-08|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of LY2140023 in Healthy Participants|A Study to Evaluate the Impact of Activated Charcoal on the Absorption of LY2140023 in Healthy Subjects|Completed||Phase 1|18|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:20:16.195241|2018-05-31 21:20:16.195241
NCT01609205|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2018-04-24|2012-05-30|2012-05-31|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2012||2012-10-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|Muscara||Doppler Evaluation in RA Patients After Adalimumab.|Doppler Quantitative Evaluation and Follow-up Over 12 Months in RA Patients With Moderate and High Disease Activity Who Are Candidates for Biologic add-on Therapy With Adalimumab|Completed||Phase 4|60|Actual|Karolinska Institutet||1|||f||||t||||||||No||2018-05-31 21:20:16.251515|2018-05-31 21:20:16.251515
NCT01609192|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2013-08-06|2012-05-29|2012-05-31|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|HYDREP||Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated|Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated.|Completed||Phase 4|50|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 21:20:16.310381|2018-05-31 21:20:16.310381
NCT01609179|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-11-13|2012-05-29|2012-05-31|Estimate|||||||2012-11-13|2012-11-14|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||IPI-926 Extension Protocol for Continuation of Treatment With IPI-926|IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol|Completed||N/A|9|Actual|Infinity Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:20:16.498914|2018-05-31 21:20:16.498914
NCT01609166|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-05-22|2012-05-29|2012-05-31|Estimate|||||||2014-05-22|2014-05-23|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome|Placebo-controlled Trial to Determine the Effectiveness of a 3% Allopurinol-base Topical Agent for Prevention of Capecitabine-induced Hand-foot Syndrome|Completed||Phase 2|60|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 21:20:16.571579|2018-05-31 21:20:16.571579
NCT01609153|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2018-05-11|2012-05-29|2012-05-31|Estimate|||||||2018-05-11|2018-05-14|Actual|June 2012||2012-06-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|COMBINE||Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy|A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients. - COMBINE|Recruiting||Phase 4|399|Anticipated|Heinrich-Heine University, Duesseldorf||3|||f||||t||||||||||2018-05-31 21:20:16.656814|2018-05-31 21:20:16.656814
NCT01609140|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2016-11-01|2012-05-29|2012-05-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease|A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease|Completed||Phase 2|248|Actual|Genentech, Inc.||6|||f||||||||||||||2018-05-31 21:20:16.795444|2018-05-31 21:20:16.795444
NCT01609127|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-05-31|2012-05-29|2012-05-31|Estimate|||||||2012-05-31|2012-06-01|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|July 2014|Anticipated|2014-07-31|September 2013|Anticipated|2013-09-30||Interventional|||Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer|A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|213|Anticipated|Genta Incorporated||3|||f||||f||||||||||2018-05-31 21:20:16.93795|2018-05-31 21:20:16.93795
NCT01609114|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-05-08|2012-05-29|2012-05-31|Estimate|||||||2013-05-08|2013-05-10|Estimate|April 2012||2012-04-30|May 2013|2013-05-31||||July 2016|Anticipated|2016-07-31||Observational|||Irradiation Modulates the Pharmacokinetics of Anticancer Drugs for Head and Neck Cancer|Irradiation Modulates the Pharmacokinetics of Anticancer Drugs for Head and Neck Cancer|Unknown status|Active, not recruiting||30|Actual|Far Eastern Memorial Hospital|||2||f||||t||||||||||2018-05-31 21:20:17.006123|2018-05-31 21:20:17.006123
NCT01609101|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-04-03|2012-05-29|2012-05-31|Estimate|||||||2014-04-03|2014-04-04|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Oropharyngeal Space in Videolaryngoscopy|Oropharyngeal Space in Videolaryngoscopy: a Randomised Crossover Trial Measuring Remaining Space Adjacent to the Videolaryngoscope Blade|Completed||N/A|489|Actual|Catharina Ziekenhuis Eindhoven||7|||f||||t||||||||||2018-05-31 21:20:17.054187|2018-05-31 21:20:17.054187
NCT01609088|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-07-23|2012-05-29|2012-05-31|Estimate|||||||2013-07-23|2013-07-24|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Completed||N/A|24|Actual|Boston University||1|||f||||f||||||||||2018-05-31 21:20:17.13869|2018-05-31 21:20:17.13869
NCT01609075|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-11-01|2012-05-29|2012-05-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)|Use of Bevacizumab in the Treatment of Metastatic Colorectal Cancer (mCRC) in Italy: an Observational Cohort Study|Completed|||437|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:20:17.199906|2018-05-31 21:20:17.199906
NCT01609062|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2015-11-12||2015-12-24|2012-05-29|2012-05-31|Estimate|2015-12-24|2016-02-01|Estimate||||2015-12-24|2016-02-01|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome|A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|Terminated||Phase 2|25|Actual|BioMarin Pharmaceutical||2|||f||||t||||||||||2018-05-31 21:20:18.392127|2018-05-31 21:20:18.392127
NCT01608880|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2014-09-08|2012-05-30|2012-05-31|Estimate|||||||2014-09-08|2014-09-10|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis|Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis|Completed||N/A|154|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 21:20:22.273109|2018-05-31 21:20:22.273109
NCT01609049|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-04-11|2012-05-29|2012-05-31|Estimate|||||||2017-04-11|2017-04-12|Actual|December 7, 2011|Actual|2011-12-07|April 2017|2017-04-30|June 22, 2015|Actual|2015-06-22|June 22, 2015|Actual|2015-06-22||Observational|STANDART||An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis|Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Clinical Practice|Completed|||1496|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:20:20.130779|2018-05-31 21:20:20.130779
NCT01609036|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-11-01|2012-05-29|2012-05-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma|An Observational Phase IV Non Interventional Study in Patients With Advanced Follicular Lymphoma (III-IV) Evaluating the Safety of Maintenance Therapy With Rituximab After 8 Cycles of Rituximab in Combination With Chemotherapy as Induction Therapy in Previously Untreated Patients in Greece.|Terminated|||3|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:20:20.36418|2018-05-31 21:20:20.36418
NCT01609023|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2017-03-28||2017-03-28|2012-05-29|2012-05-31|Estimate|2017-03-28|2017-06-14|Actual||||2017-03-28|2017-06-14|Actual|April 2012||2012-04-30|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|CaLLypso|Intent-to-treat (ITT) population included all eligible participants.|A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia|A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia|Completed|||67|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:20:20.453406|2018-05-31 21:20:20.453406
NCT01609010|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2014-05-23||2014-08-29|2012-05-29|2012-05-31|Estimate|2014-05-23|2014-06-25|Estimate||||2014-08-29|2014-09-08|Estimate|October 2002||2002-10-31|August 2014|2014-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Intent to treat (ITT) population included all randomized participants.|A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma|Rituximab (Mabthera®) as Single Agent and in Combination With Interferon Alfa-2a (Roferon-A®), a Phase-III Randomized Trial in Patients With Follicular or Other CD20+ Low-grade (Indolent) Lymphoma|Completed||Phase 3|313|Actual|Hoffmann-La Roche|Nonserious AEs presented in this record include all AEs reported during the study, not just nonserious events, and information is presented by SOC as AE data by preferred term were not available within specified parameters (with 5% threshold).|2|||f||||||||||||||2018-05-31 21:20:20.763643|2018-05-31 21:20:20.763643
NCT01608997|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-05-29|2012-05-29|2012-05-31|Estimate|||||||2012-05-29|2012-05-31|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Postoperative Multiparameter Outcomes During the Six Months After Rotator Cuff Repair||Unknown status|Not yet recruiting||50|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 21:20:21.250014|2018-05-31 21:20:21.250014
NCT01608984|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2013-07-15|2012-05-30|2012-05-31|Estimate|||||||2013-07-15|2013-07-16|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|RIPCON||Effects of Remote Ischemic PreConditioning in Off-pump Versus On-pump Coronary Artery Bypass Grafting(RIPCON)|Effects of Remote Ischemic PreConditioning in Off-pump Versus On-pump Coronary|Unknown status|Recruiting|Phase 1|100|Anticipated|Heinrich-Heine University, Duesseldorf||4|||f||||t||||||||||2018-05-31 21:20:21.299514|2018-05-31 21:20:21.299514
NCT01608971|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2015-03-17||2017-02-22|2012-05-30|2012-05-31|Estimate|2015-11-18|2015-11-20|Estimate||||2017-02-22|2017-03-27|Actual|January 2011||2011-01-31|February 2017|2017-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|PROTT||Protamine in Cardiac Surgery and Haemostasis|The Effects of Heparin Level Based Versus Weight Based Protamine Dosing on Protamine Demand, Markers of Haemostasis, Blood Product Utilization and Perioperative Blood Loss in Patients Undergoing Extended Cardiac Surgery Cardiac Surgery|Completed|||30|Actual|Heart and Diabetes Center North-Rhine Westfalia|small study cohort||2||f||||f||||||||No||2018-05-31 21:20:21.486608|2018-05-31 21:20:21.486608
NCT01608958|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-03-25|2012-05-29|2012-05-31|Estimate|||||||2016-03-25|2016-03-28|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||IV vs IM Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage|Intravenous and Intramuscular Administration of Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage|Completed||N/A|653|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 21:20:21.754239|2018-05-31 21:20:21.754239
NCT01608945|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-05-30|2012-05-30|2012-05-31|Estimate|||||||2012-05-30|2012-05-31|Estimate|April 2008||2008-04-30|May 2012|2012-05-31||||||||Observational|||Prospective Randomized Study of Glucocorticoids in the Impact of the Liver Function and the Prognosis After Hepatectomy of HCC||Suspended|||60|Actual|Eastern Hepatobiliary Surgery Hospital|||1||f||||||||||||||2018-05-31 21:20:21.840351|2018-05-31 21:20:21.840351
NCT01608932|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-10-27|2012-05-29|2012-05-31|Estimate|||||||2015-10-27|2015-10-28|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Life-long Monitoring of Frail Patients With Chronic Diseases|RENEWING HEALTH - Telemonitoring of Elderly and Frail Patients With Multiple Chronic Diseases in Veneto Region|Completed||N/A|152|Actual|Regione Veneto||2|||f||||t||||||||||2018-05-31 21:20:21.902369|2018-05-31 21:20:21.902369
NCT01608919|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-08-07|2012-05-30|2012-05-31|Estimate|||||||2015-08-07|2015-08-10|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection|Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection.|Terminated||N/A|4|Actual|University of Colorado, Denver||1||Sara Cheng, MD has left the University of Colorado and we have closed this study.|f||||f||||||||||2018-05-31 21:20:21.999194|2018-05-31 21:20:21.999194
NCT01608906|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-05-19|2012-05-30|2012-05-31|Estimate|||||||2014-05-19|2014-05-20|Estimate|May 2007||2007-05-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery|Efficacy of Low Dose Intravenous Heparin in Preventing Thromboembolism in the SICU.|Completed||N/A|113|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 21:20:22.074552|2018-05-31 21:20:22.074552
NCT01608893|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2017-10-24|2012-05-30|2012-05-31|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2012||2012-05-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Carvedilol for Prevention of Paroxysmal Atrial Fibrillation|Carvedilol for Prevention of Paroxysmal Atrial Fibrillation|Recruiting||N/A|300|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 21:20:22.150774|2018-05-31 21:20:22.150774
NCT01608867|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-07-25|2012-05-29|2012-05-31|Estimate|||||||2017-07-25|2017-07-27|Actual|June 2012||2012-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|August 2016|Actual|2016-08-31||Interventional|||A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors|Completed||Phase 1|26|Actual|OncoMed Pharmaceuticals, Inc.|||||f||||f||||||||||2018-05-31 21:20:22.376823|2018-05-31 21:20:22.376823
NCT01608854|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-06-08|2012-05-29|2012-05-31|Estimate|||||||2016-06-08|2016-06-10|Estimate|November 2008||2008-11-30|June 2016|2016-06-30|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Observational|||Comparison of Antibiotic Protocols in Spine Patients With Postoperative Drains|Prospective, Randomized Study of the Utilization of Antibiotics and Drains in Spinal Surgery|Completed|||539|Actual|New York University School of Medicine|||2||f||||f||||||||||2018-05-31 21:20:22.44393|2018-05-31 21:20:22.44393
NCT01608841|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2015-02-14|2012-05-30|2012-05-31|Estimate|||||||2015-02-14|2015-02-18|Estimate|July 2005||2005-07-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib|The Role of Epidermal Growth Factor Receptor (EGFR) Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib|Unknown status|Recruiting|Phase 2|88|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 21:20:22.548562|2018-05-31 21:20:22.548562
NCT01608828|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2017-05-02|2012-05-30|2012-05-31|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Assessing the Functional and Psychosocial Impact of Strabismus in Asian Children Using the AS-20 and IXTQ Questionnaires|Assessing the Functional and Psychosocial Impact of Strabismus in Asian Children Using the AS-20 and IXTQ Questionnaires|Completed|||120|Actual|Singapore National Eye Centre|||||f||||f||||||||||2018-05-31 21:20:22.628834|2018-05-31 21:20:22.628834
NCT01608815|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|2014-03-07||2014-04-15|2012-05-28|2012-05-31|Estimate|2014-04-15|2014-05-12|Estimate||||2014-04-15|2014-05-12|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects|Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects|Completed||Phase 3|200|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:20:22.702349|2018-05-31 21:20:22.702349
NCT01608802|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2014-06-09|2012-05-30|2012-05-31|Estimate|||||||2014-06-09|2014-06-10|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|TOPCare||Outcomes for Antiretroviral Therapy Patients Receiving Palliative Care|Phase 3 Trial of Palliative Care for HIV Patients on Antiretroviral Therapy|Completed||Phase 2/Phase 3|240|Actual|King's College London||2|||f||||t||||||||||2018-05-31 21:20:23.103053|2018-05-31 21:20:23.103053
NCT01608789|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2018-01-24|2012-05-28|2012-05-31|Estimate|||||||2018-01-24|2018-01-25|Actual|August 27, 2012|Actual|2012-08-27|January 2018|2018-01-31|June 5, 2018|Anticipated|2018-06-05|June 28, 2016|Actual|2016-06-28||Interventional|||Virtue® European Study|Virtue® Male Sling European Study|Active, not recruiting||N/A|123|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 21:20:23.166496|2018-05-31 21:20:23.166496
NCT01608776|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-10-06|2012-05-30|2012-05-31|Estimate|||||||2014-10-06|2014-10-08|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs|Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs|Terminated||Phase 4|13|Actual|Celleration, Inc.||2||Enrollment delays, business re-allocation of resources|f||||t||||||||||2018-05-31 21:20:23.323535|2018-05-31 21:20:23.323535
NCT01608763|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2014-12-05|2012-05-29|2012-05-31|Estimate|||||||2014-12-05|2014-12-09|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||What is the Active Ingredient in Personalized Feedback Interventions for Problem Drinkers? A Randomized Controlled Trial|What is the Active Ingredient in Personalized Feedback Interventions for Problem Drinkers? A Randomized Controlled Trial|Completed||N/A|804|Actual|Centre for Addiction and Mental Health||4|||f||||f||||||||||2018-05-31 21:20:23.416044|2018-05-31 21:20:23.416044
NCT01608750|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2012-05-30|2012-05-30|2012-05-31|Estimate|||||||2012-05-30|2012-05-31|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia|The Efficacy of Pantoprazole Treatment in Patients With Functional Dyspepsia: Randomised, Double-blind, Placebo-controlled Trial.|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Bezmialem Vakif University||2|||f||||t||||||||||2018-05-31 21:20:23.471567|2018-05-31 21:20:23.471567
NCT01608737|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2013-02-23|2012-05-29|2012-05-31|Estimate|||||||2013-02-23|2013-02-26|Estimate|September 2012||2012-09-30|February 2013|2013-02-28||||October 2015|Anticipated|2015-10-31||Interventional|||A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection|A Phase III, Randomised, Double-blind and Placebo-controlled Study of Once Daily BI 201335 for 12 or 24 Weeks in Combination With Pegylated interferon-a and Ribavirin in Treatment-naive and Prior Relapser Patients With Genotype 1 Chronic Hepatitis C Infection|Withdrawn||Phase 3|0|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 21:20:23.543219|2018-05-31 21:20:23.543219
NCT01608724|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|2015-05-14||2015-12-31|2012-05-30|2012-05-31|Estimate|2015-12-31|2016-02-02|Estimate||||2015-12-31|2016-02-02|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SUNSHINE|Per-protocoal analysis set (PPS), including patients who took at least 1 dose of study drug, had baseline and post-baseline efficacy records, and had no major protocol deviations.|The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus|A Multicenter, Single Arm, Cohort Study to Evaluate the Efficacy and Safety of Saxagliptin 5mg, Once Daily for 24 Weeks, in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|2165|Actual|AstraZeneca|This was a single-arm study and thus potential placebo effect was unable to be adjusted in any efficacy analyses.|1|||f||||f||||||||||2018-05-31 21:20:23.622423|2018-05-31 21:20:23.622423
NCT01608711|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-05-15|2012-05-29|2012-05-31|Estimate|||||||2017-05-15|2017-05-16|Actual|August 7, 2012|Actual|2012-08-07|May 2017|2017-05-31|November 16, 2015|Actual|2015-11-16|November 16, 2015|Actual|2015-11-16||Interventional|||A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002|An Open-Label Phase 2 Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002|Completed||Phase 2|2|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:20:23.958139|2018-05-31 21:20:23.958139
NCT01608698|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-04-07|2012-05-30|2012-05-31|Estimate|||||||2015-04-07|2015-04-09|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Comparison of Body Weight Change During Contraception With Belara and Yasmin|A Comparison of Body Weight Changing and Side Effects Between Treatment With 30 mcg Ethinylestradiol/2 mg Chlormadinone Acetate (Belara®) and 30 mcg Ethinylestradiol/3 mg Drospirenone (Yasmin®): A Randomized Control Trial|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 21:20:24.048221|2018-05-31 21:20:24.048221
NCT01608685|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-05-30|2012-05-30|2012-05-31|Estimate|||||||2012-05-30|2012-05-31|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients|Interferon Gamma Release Assays Versus Tuberculin Skin Testing for the Detection of Latent Tuberculosis Infection in Renal Transplant Recipients|Completed|||205|Actual|Ligue Pulmonaire Genevoise|||1||f||||f||||||||||2018-05-31 21:20:24.129262|2018-05-31 21:20:24.129262
NCT01608672|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2013-11-04||2013-11-04|2012-05-29|2012-05-31|Estimate|2013-11-04|2013-12-23|Estimate||||2013-11-04|2013-12-23|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®||Completed|||207|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:20:24.203671|2018-05-31 21:20:24.203671
NCT01608659|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2012-06-25||2012-06-25|2012-05-29|2012-05-31|Estimate|2012-06-25|2012-08-01|Estimate||||2012-06-25|2012-08-01|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A||Completed|||110|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:20:24.367271|2018-05-31 21:20:24.367271
NCT01608646|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2012-05-28|2012-05-28|2012-05-31|Estimate|||||||2012-05-28|2012-05-31|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|August 2018|Anticipated|2018-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer|Study of Dihydropyrimidine Dehydrogenase for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer|Recruiting||Phase 2|200|Anticipated|Xijing Hospital||1|||f||||f||||||||||2018-05-31 21:20:24.540057|2018-05-31 21:20:24.540057
NCT01608633|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2013-09-03|2012-05-30|2012-05-31|Estimate|||||||2013-09-03|2013-09-04|Estimate|March 2012||2012-03-31|September 2013|2013-09-30||||April 2013|Actual|2013-04-30||Interventional|||Effects of Spray and Stretch on Postneedling Soreness and Sensitivity After Dry Needling of a Latent Myofascial Trigger Point.||Completed||Phase 2|70|Actual|CEU San Pablo University||2|||f||||||||||||||2018-05-31 21:20:24.61354|2018-05-31 21:20:24.61354
NCT01608620|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2016-05-15|2012-05-28|2012-05-31|Estimate|||||||2016-05-15|2016-05-17|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2014|Actual|2014-09-30||Observational|||Meta-analyses of Total and Individual Fructose-containing Sugars and Incident Cardiometabolic Disease|The Relation of Total and Individual Fructose-containing Sugars With Incident Cardiometabolic Diseases: A Series of Systematic Reviews and Meta-analyses of Prospective Observational Studies|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 21:20:24.672226|2018-05-31 21:20:24.672226
NCT01608607|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-05-26|2012-05-28|2012-05-31|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|September 2014|Actual|2014-09-30||Observational|||Meta-analysis of Fructose-Containing Sugar Sweetened Beverages (SSBs) and Weight Change|Effect of Fructose-containing Sugar Sweetened Beverages (SSBs) on Body Weight: A Systematic Review and Meta-analysis of Controlled Feeding Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development|Unknown status|Active, not recruiting||1|Actual|University of Toronto|||||f||||f||||||||||2018-05-31 21:20:24.744186|2018-05-31 21:20:24.744186
NCT01608594|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2018-03-13|2012-05-30|2012-05-31|Estimate|||||||2018-03-13|2018-03-15|Actual|May 21, 2013|Actual|2013-05-21|March 2018|2018-03-31|February 27, 2017|Actual|2017-02-27|February 14, 2017|Actual|2017-02-14||Interventional|||Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma|Neoadjuvant Combination Biotherapy With Ipilimumab (3 mg/kg or 10 mg/kg) and High Dose IFN-Α2B in Patients With Locally/Regionally Advanced/Recurrent Melanoma: a Randomized Safety, Efficacy and Biomarker Study|Completed||Phase 1|30|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:20:24.812179|2018-05-31 21:20:24.812179
NCT01608581|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-06-01|2012-05-28|2012-05-31|Estimate|||||||2012-06-01|2012-06-05|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Development and Evaluation of an Adult Burn Prevention Program|Development and Evaluation of an Adult Burn Prevention Program|Completed||N/A|1637|Actual|The University of Queensland||1|||f||||f||||||||||2018-05-31 21:20:24.88299|2018-05-31 21:20:24.88299
NCT01608568|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-05-31|2012-05-30|2012-05-31|Estimate|||||||2012-05-31|2012-06-01|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|August 2013|Anticipated|2013-08-31|August 2012|Anticipated|2012-08-31||Interventional|Quill RALSC||Affixing Polypropylene Mesh Using Barbed Suture (Quill™ SRS) During Robotic Assisted Laparoscopic Sacrocolpopexy|AFFIXING POLYPROPYLENE MESH USING BARBED SUTURE (QUILL™ SRS) DURING ROBOTIC ASSISTED LAPAROSCOPIC SACROCOLPOPEXY RANDOMIZED CONTROLLED TRIAL|Unknown status|Recruiting|N/A|32|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:20:24.956768|2018-05-31 21:20:24.956768
NCT01608555|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2012-07-23|2012-05-30|2012-05-31|Estimate|||||||2012-07-23|2012-07-24|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis|Tobramycin 300 mg o.d. Aerosol in in Adult Patients With Cystic Fibrosis: Pilot Study on Antimicrobial Activity|Completed||Phase 4|10|Anticipated|University of Milan||1|||f||||t||||||||||2018-05-31 21:20:25.046582|2018-05-31 21:20:25.046582
NCT01608542|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-12-18|2012-05-30|2012-05-31|Estimate|||||||2012-12-18|2012-12-19|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects|A Phase I, Open-label Study to Assess the Pharmacokinetics of Oral Fostamatinib in Healthy Japanese Subjects After Single and Multiple Doses|Completed||Phase 1|24|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:20:25.113341|2018-05-31 21:20:25.113341
NCT01608529|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2013-05-16|2012-05-26|2012-05-31|Estimate|||||||2013-05-16|2013-05-17|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|FB||Feel Breathe, Restriction Device Ventilatory Nasal|Phase 1: Effects of a Restriction Device Ventilatory Nasal Flow on Pulmonary Ventilation and Gas Exchange During Exercise|Completed||Phase 1|27|Actual|University of Cadiz||1|||f||||f||||||||||2018-05-31 21:20:25.171944|2018-05-31 21:20:25.171944
NCT01608516|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2016-11-13|2012-05-28|2012-05-31|Estimate|||||||2016-11-13|2016-11-15|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Multimodal Imaging Assessment of the Inflammatory Atheromatous Plaque|Multimodal Assessment of the Inflammatory Atheromatous Plaque : Comparison Between 68Ga-NODAGA-RGD PET/CT, 18F-FDG PET/CT, MRI AND US|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Lausanne Hospitals||1|||f||||f||||||||No||2018-05-31 21:20:25.23894|2018-05-31 21:20:25.23894
NCT01608334|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-05-29|2012-05-29|2012-05-31|Estimate|||||||2012-05-29|2012-05-31|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Intrathecal Fentanyl or Sufentanil in 1 mg Bupivacaine Spinal Anesthesia for TURP in Elderly Patients||Completed||N/A|56|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:20:27.287386|2018-05-31 21:20:27.287386
NCT01608503|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2013-04-20|2012-05-30|2012-05-31|Estimate|||||||2013-04-20|2013-04-23|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SCVLD||Lung Deflation in Pediatric Subclavian Vein Catheterization|The Effect of Lung Deflation on the Position of the Pleura in Mechanically Ventilated Infants During Subclavian Vein Cannulation: an Ultrasound Study|Completed||N/A|41|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 21:20:25.299748|2018-05-31 21:20:25.299748
NCT01608490|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|2017-04-25||2017-06-07|2012-05-30|2012-05-31|Estimate|2017-06-07|2017-06-27|Actual||||2017-06-07|2017-06-27|Actual|October 2012||2012-10-31|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|December 2015|Actual|2015-12-31||Interventional|RENEW||Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study|Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study|Active, not recruiting||N/A|315|Actual|PneumRx, Inc.||2|||f||||t||||||||Undecided||2018-05-31 21:20:25.48031|2018-05-31 21:20:25.48031
NCT01608477|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2018-01-12|2012-05-28|2012-05-31|Estimate|||||||2018-01-12|2018-01-16|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2015|Actual|2015-10-31||Observational|BRIGHT||Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation|Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation|Active, not recruiting|||1365|Actual|University of Basel|||||f||||f|f|f||||||No||2018-05-31 21:20:26.428872|2018-05-31 21:20:26.428872
NCT01608464|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2017-10-29|2012-05-30|2012-05-31|Estimate|||||||2017-10-29|2017-10-31|Actual|May 2012||2012-05-31|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer|A Trial Comparing Pre-operative Chemo-radiotherapy With Cisplatin and Fluorouracil Versus Chemotherapy With Docetaxel and Irinotecan in PET Non Responders Resectable Cancer Esophagus: a Multicenter Study|Terminated||Phase 2|170|Actual|King Faisal Specialist Hospital & Research Center||2||poor accrual|f||||t||||||||Undecided||2018-05-31 21:20:26.517818|2018-05-31 21:20:26.517818
NCT01608451|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2018-01-16|2012-05-30|2012-05-31|Estimate|||||||2018-01-16|2018-01-17|Actual|September 2007||2007-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer|Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer.|Active, not recruiting||Phase 3|800|Anticipated|Tata Memorial Hospital||4|||f||||t||||||||||2018-05-31 21:20:26.603565|2018-05-31 21:20:26.603565
NCT01608438|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-08-24|2012-05-28|2012-05-31|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2013||2013-02-28|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BMI||Motor Learning in a Customized Body-Machine Interface|Motor Learning in a Customized Body-Machine Interface for Persons With Paralysis|Recruiting||N/A|46|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 21:20:26.687637|2018-05-31 21:20:26.687637
NCT01608425|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-06-04|2012-05-28|2012-05-31|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|November 2013|Anticipated|2013-11-30|June 2013|Anticipated|2013-06-30||Interventional|Telesaar||Ulcer Monitoring in Diabetes Mellitus|Impact Assessment by Introducing Telemedicine Consultations for Treatment of Diabetic Patients With Foot Ulcers in Region of Southern Denmark - Randomized Prospective Study|Unknown status|Recruiting|Phase 2|400|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 21:20:26.771812|2018-05-31 21:20:26.771812
NCT01608412|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-30|2012-05-30|2012-05-31|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2012||2012-02-29|August 2011|2011-08-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus|An Open-label Randomized Controlled Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus 3 Months After Kidney Transplantation.|Unknown status|Recruiting|Phase 4|120|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 21:20:26.851542|2018-05-31 21:20:26.851542
NCT01608399|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2017-05-25|2012-05-28|2012-05-31|Estimate|||||||2017-05-25|2017-05-30|Actual|March 2012|Actual|2012-03-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Clinical Trial of the Effectiveness of Metacognitive Therapy in the Treatment of Patients With Major Depressive Disorder|A Randomized Controlled Trial of the Effectiveness of Metacognitive Therapy (MCT) in the Treatment of Patients With Major Depressive Disorder (MDD)|Completed||N/A|40|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 21:20:26.918388|2018-05-31 21:20:26.918388
NCT01608386|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2015-08-05|2012-05-26|2012-05-31|Estimate|||||||2015-08-05|2015-08-06|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|AA+IVC||A Study of Anterior Approach Combined With Infrahepatic Inferior Vena Cava Clamping|Anterior Approach Combined With Infrahepatic Inferior Vena Cava Clamping Right Hepatic Resection for Large Hepatocellular Carcinoma: A Prospective Randomized Controlled Study|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 21:20:26.992522|2018-05-31 21:20:26.992522
NCT01608373|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2013-08-01|2012-05-30|2012-05-31|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||The Effect of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation on Pain After Laparoscopic Cholecystectomy|Comparison of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation for Effective Pain Relief After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-blind, Placebo-controlled Study|Unknown status|Recruiting|Phase 4|83|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||3|||f||||t||||||||||2018-05-31 21:20:27.072393|2018-05-31 21:20:27.072393
NCT01608360|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2014-03-17|2012-05-30|2012-05-31|Estimate|||||||2014-03-17|2014-03-19|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effect of Intravenous Lidocaine on Pain After Thyroidectomy|Intravenous Lidocaine for Effective Pain Relief After Thyroidectomy: a Prospective, Randomized, Double-blind, Placebo-controlled Study|Unknown status|Recruiting|Phase 4|56|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||f||||||||||2018-05-31 21:20:27.153037|2018-05-31 21:20:27.153037
NCT01608347|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-26|||2017-01-23|2012-05-30|2012-05-31|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2010|Actual|2010-01-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|LMWH-APAN||Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies|Low Molecular Weight Heparin for Treatment of Recurrent Miscarriage With Negative Antiphospholipid Antibodies: a Randomized Controlled Trial|Completed||Phase 4|228|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 21:20:27.230244|2018-05-31 21:20:27.230244
NCT01608321|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2016-12-12||2017-04-10|2012-05-25|2012-05-31|Estimate|2017-04-10|2017-04-11|Actual||||2017-04-10|2017-04-11|Actual|September 2012||2012-09-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|rTMS||rTMS for the Treatment of Chronic Pain in GW1 Veterans|rTMS for the Treatment of Chronic Pain in GW1 Veterans|Terminated||Phase 3|17|Actual|VA Office of Research and Development||2||Did not meet recruitment goals|f||||t||||||||No|Trial discontinued before an adequate number of subjects was tested.|2018-05-31 21:20:27.430476|2018-05-31 21:20:27.430476
NCT01608308|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2015-06-12||2015-09-25|2012-05-29|2012-05-31|Estimate|2015-08-05|2015-09-04|Estimate||||2015-09-25|2015-10-16|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|IVAPAP|In total 62 subjects were enrolled. Two subjects were dropped due to pretrreatment medical and billing issues;therefore, in total 60 subjects were dosed.|Intraoperative and Post-operative Analgesic Effect of IV Acetaminophen for Sinus Surgery|A Double Blind, Randomized, Placebo-controlled Study to Investigate the Effectiveness of IV Acetominophen Administered During Functional Endoscopic Sinus Surgery in Reducing the Use of Opiates to Treat Postoperative Pain|Completed||N/A|62|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 21:20:27.757533|2018-05-31 21:20:27.757533
NCT01608295|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2017-02-01||2018-04-12|2012-05-25|2012-05-31|Estimate|2017-03-28|2017-05-09|Actual||||2018-04-12|2018-05-10|Estimate|July 2012||2012-07-31|April 2018|2018-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Vilazodone for Treatment of Geriatric Depression|A Pilot Study of Double-blind Comparison of Vilazodone to Paroxetine in Geriatric Depression|Completed||Phase 4|65|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:20:28.080085|2018-05-31 21:20:28.080085
NCT01608282|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-06-27|2012-05-29|2012-05-31|Estimate|||||||2017-06-27|2017-06-29|Actual|October 2012|Actual|2012-10-31|June 2017|2017-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|OPEN||Internet Intervention to Improve Physical Activity in Early Knee Osteoarthritis|Capitalizing on the Teachable Moment: the OPEN (Osteoarthritis Physical Activity & Exercise Net) for Improving Physical Activity in Early Knee Osteoarthritis|Terminated||N/A|75|Actual|University of British Columbia||2||Unable to reach recruitment target|f||||f||||||||No||2018-05-31 21:20:28.36184|2018-05-31 21:20:28.36184
NCT01608269|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-04-27|2012-05-29|2012-05-31|Estimate|||||||2017-04-27|2017-04-28|Actual|November 2010||2010-11-30|May 2012|2012-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|EPZSwitch||Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy|Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy|Completed||Phase 4|30|Anticipated|Therapeutic Concepts||1|||f||||f||||||||||2018-05-31 21:20:28.43922|2018-05-31 21:20:28.43922
NCT01608256|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-05-29|2012-05-29|2012-05-31|Estimate|||||||2012-05-29|2012-05-31|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|June 2014|Anticipated|2014-06-30|July 2013|Anticipated|2013-07-31||Observational|MCI||Driving Ability Among People With Mild Cognitive Impairment|Assessing the Effect of MCI on Driving Ability by Using on Road Driving Test. The Relationship Between Their Driving Outcome and Their Cognitive Decline Will be Examined|Unknown status|Not yet recruiting||60|Anticipated|Tel Aviv University|||2||f||||f||||||||||2018-05-31 21:20:28.505612|2018-05-31 21:20:28.505612
NCT01608243|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-06-30|2012-05-25|2012-05-31|Estimate|||||||2014-06-30|2014-07-01|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts|Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma|Completed||Phase 1|94|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-05-31 21:20:28.563922|2018-05-31 21:20:28.563922
NCT01608230|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-11-17|2012-05-25|2012-05-31|Estimate|||||||2014-11-17|2014-11-18|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|HuTS||Human Tumor Sequencing Project|Human Tumor Sequencing Project|Completed|||35|Actual|Scripps Translational Science Institute|||||f||||f||||||||||2018-05-31 21:20:28.630406|2018-05-31 21:20:28.630406
NCT01608217|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-06-26|2012-05-25|2012-05-31|Estimate|||||||2014-06-26|2014-06-30|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Delta-THC in Dementia|Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia|Completed||Phase 2|50|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:20:28.672863|2018-05-31 21:20:28.672863
NCT01608204|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-06-10|2012-05-29|2012-05-30|Estimate|||||||2013-06-10|2013-06-11|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Busulfan Pharmacokinetic Analysis and GST Pharmacogenetic Profile in Adults Undergoing Hematological Stem Cell Transplantation||Completed|||63|Actual|Rambam Health Care Campus|||||f||||f||||||Samples With DNA|"~     Peripheral Blood was used for DNA extraction~   "|||2018-05-31 21:20:28.752869|2018-05-31 21:20:28.752869
NCT01608191|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2016-02-01|2012-05-29|2012-05-30|Estimate|||||||2016-02-01|2016-02-02|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|LCD-KBT||Obesity Treatment With LCD in Primary Health Care|Obesity Treatment With LCD(Low Calorie Diet) in Primary Health Care - Long Term Effects With or Without Internet Based CBT (Cognitive Behavioral Therapy) , for Weight Stability|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Örebro County Council||2|||f||||f||||||||No||2018-05-31 21:20:28.804195|2018-05-31 21:20:28.804195
NCT01608178|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2018-05-18|2012-05-25|2012-05-30|Estimate|||||||2018-05-18|2018-05-21|Actual|April 27, 2012||2012-04-27|December 16, 2013|2013-12-16|December 16, 2013||2013-12-16|||||Observational|||Taurine Therapy for SSADH Deficiency|Succinic Semialdehyde Dehydrogenase Deficiency: Physiological Markers of Taurine Therapy|Completed|||7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:20:29.00759|2018-05-31 21:20:29.00759
NCT01608165|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2015-12-04|2012-05-29|2012-05-30|Estimate|||||||2015-12-04|2015-12-07|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|CONSERVE||A Feasibility Study for a Multicentre Randomised Controlled Trial to Compare Surgery With Needle Ablation Techniques in People With Small Renal Masses (4cm)|CONSERVE: a Feasibility Study for a Multicentre Randomised Controlled Trial to Compare Surgery (Partial Nephrectomy) With Needle Ablation Techniques (Radiofrequency Ablation/Cryotherapy) for the Treatment of People With Small Renal Masses (4cm)|Completed||N/A|17|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||3|||f||||t||||||||||2018-05-31 21:20:29.065318|2018-05-31 21:20:29.065318
NCT01608152|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2018-05-03|2012-05-29|2012-05-30|Estimate|||||||2018-05-03|2018-05-07|Actual|February 2013|Actual|2013-02-28|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Using Game Mechanics to Improve Outcomes Among Stem Cell Transplant Survivors|Using Game Mechanics to Improve Outcomes Among Stem Cell Transplant Survivors|Active, not recruiting|||40|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 21:20:29.139253|2018-05-31 21:20:29.139253
NCT01608139|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-10-17|2012-05-29|2012-05-30|Estimate|||||||2012-10-17|2012-10-19|Estimate|November 2012||2012-11-30|October 2012|2012-10-31||||November 2022|Anticipated|2022-11-30||Interventional|||Study of Curcumin, Vorinostat, and Sorafenib|Pilot Study of Curcumin, Vorinostat, and Sorafenib in Patients With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:20:29.20705|2018-05-31 21:20:29.20705
NCT01608126|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-05-29|2012-05-29|2012-05-30|Estimate|||||||2012-05-29|2012-05-30|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Medial Cervical Block for Carotid Endarterectomy Comparison With Standard Method|A Comparison of Medial Cervical Plexus Block Versus Combined (Superficial and Deep) Cervical Plexus Block for Carotid Endarterectomy: A Prospective, Randomized Single Blind Study|Completed||N/A|100|Actual|Masaryk Hospital Krajská zdravotní a.s.||2|||f||||f||||||||||2018-05-31 21:20:29.275595|2018-05-31 21:20:29.275595
NCT01608113|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-05-25|2012-05-25|2012-05-30|Estimate|||||||2012-05-25|2012-05-30|Estimate|September 2011||2011-09-30|May 2012|2012-05-31||||||||Observational|||Long-term Follow-up of Subfoveal Neovascular AMD||Unknown status|Recruiting||70|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-05-31 21:20:29.342366|2018-05-31 21:20:29.342366
NCT01608100|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2014-12-03||2015-03-04|2012-05-29|2012-05-30|Estimate|2015-03-04|2015-03-17|Estimate||||2015-03-04|2015-03-17|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Evaluation of a New Cardiac Biomarker Assay|Design Validation Protocol for the Evaluation of ARCHITECT STAT High Sensitive Troponin I Assay|Completed||Phase 3|1101|Actual|Abbott Diagnostics Division|Some tube types and some time points may not have been obtained for each subject. Every attempt was made to collect all tube types within the time point windows described.|1|||f||||f||||||||||2018-05-31 21:20:29.433133|2018-05-31 21:20:29.433133
NCT01608087|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-05-15|2012-05-25|2012-05-30|Estimate|||||||2013-05-15|2013-05-16|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects|Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study|Completed||Phase 1|91|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:20:30.113724|2018-05-31 21:20:30.113724
NCT01608074|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-07-19|2012-05-29|2012-05-30|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2011|Actual|2011-12-31|July 2017|2017-07-31|October 2025|Anticipated|2025-10-31|October 2019|Anticipated|2019-10-31||Interventional|Fimbriectomy||Radical Fimbriectomy for Young BRCA Mutation Carriers|Radical Fimbriectomy for Young BRCA Mutation Carriers at Risk of Pelvic Serous Carcinoma|Active, not recruiting||N/A|123|Actual|Centre Oscar Lambret||1|||f||||t|f|f||||||No||2018-05-31 21:20:30.188319|2018-05-31 21:20:30.188319
NCT01608061|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-02-14|2012-05-29|2012-05-30|Estimate|||||||2017-02-14|2017-02-16|Actual|May 2012||2012-05-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|June 2015|Actual|2015-06-30||Interventional|ADvance||ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease|A Twelve Month Double-blind Randomized Controlled Feasibility Study to Evaluate the Safety, Efficacy and Tolerability of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease|Active, not recruiting||N/A|50|Anticipated|Functional Neuromodulation Ltd||2|||f||||t||||||||||2018-05-31 21:20:30.297363|2018-05-31 21:20:30.297363
NCT01608048|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-03-29|2012-05-29|2012-05-30|Estimate|||||||2014-03-29|2014-04-01|Estimate|May 2014||2014-05-31|November 2012|2012-11-30|February 2017|Anticipated|2017-02-28|April 2016|Anticipated|2016-04-30||Interventional|||Transcutaneous Electrical Acupoint Stimulation to Improve Pregnancy Rates for Women Undergoing in Vitro Fertilization|Transcutaneous Electrical Acupoint Stimulation to Improve Pregnancy Rates for Women Undergoing in Vitro Fertilization|Unknown status|Not yet recruiting|N/A|384|Anticipated|Huazhong University of Science and Technology||3|||f||||t||||||||||2018-05-31 21:20:30.383844|2018-05-31 21:20:30.383844
NCT01608035|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2016-05-18|2012-05-29|2012-05-30|Estimate|||||||2016-05-18|2016-05-20|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Sciatic Perineural Versus Stump Catheter for Below Knee Amputation|Ultrasound Guided Sciatic Perineural Catheter vs Surgically Placed Sciatic Stump Catheter for Below Knee Amputations: Is There A Difference in Patient Outcomes|Completed||Early Phase 1|29|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 21:20:30.465051|2018-05-31 21:20:30.465051
NCT01608022|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-09-05|2012-05-25|2012-05-30|Estimate|||||||2016-09-05|2016-09-07|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus||Completed||Phase 2|48|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 21:20:30.540815|2018-05-31 21:20:30.540815
NCT01608009|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-03-09|2012-05-25|2012-05-30|Estimate|||||||2017-03-09|2017-03-10|Actual|July 2012||2012-07-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Interventional|PAZPET-1||[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer|Phase 1b Exploratory Study of [18F]Fluciclatide-PET as a Marker of Angiogenic Response to Combination Therapy With the Pan-VEGF Inhibitor, Pazopanib, and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer|Completed||Phase 1|16|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 21:20:30.608343|2018-05-31 21:20:30.608343
NCT01607996|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-05-25|2012-05-25|2012-05-30|Estimate|||||||2012-05-25|2012-05-30|Estimate|July 2005||2005-07-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|August 2010|Actual|2010-08-31||Interventional|||Effect of Epidural Anesthesia on Pancreatic Perfusion and Clinical Outcome in Patients With Severe Acute Pancreatitis|Phase 1 Study of Epidural Anesthesia on Pancreatic Perfusion and Clinical Outcome in Patients With Severe Acute Pancreatitis|Completed||Phase 1|35|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 21:20:30.697825|2018-05-31 21:20:30.697825
NCT01607983|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2018-05-01|2012-05-25|2012-05-30|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2012||2012-06-30|May 2018|2018-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients|The Effect of Selective Pulmonary Vasodilation on Ventricular Afterload and Ventricular-arterial Coupling in Patients With Fontan Physiology and Validation of Echocardiographic Measures of Systolic and Diastolic Function.|Withdrawn||Phase 3|0|Actual|University of California, San Francisco||1||Poor accrual|f||||f|t|f|||f|||Undecided||2018-05-31 21:20:30.762654|2018-05-31 21:20:30.762654
NCT01607970|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-25|2012-05-25|2012-05-30|Estimate|||||||2012-05-25|2012-05-30|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making|Double-blind, Placebo-controlled, Randomized Study: Oxytocin Modulation of Startle Reactivity to Social Stimuli and Moral Decision Making|Completed||Phase 1|80|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 21:20:30.832186|2018-05-31 21:20:30.832186
NCT01607957|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-10-05|2012-05-25|2012-05-30|Estimate|||||||2017-10-05|2017-10-06|Actual|June 17, 2012|Actual|2012-06-17|October 2017|2017-10-31|May 23, 2016|Actual|2016-05-23|January 24, 2014|Actual|2014-01-24||Interventional|RECOURSE||Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies|Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies|Completed||Phase 3|800|Actual|Taiho Oncology, Inc.||2|||f||||t||||||||||2018-05-31 21:20:30.932718|2018-05-31 21:20:30.932718
NCT01607944|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-12-02|2012-05-25|2012-05-30|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Incretins and Metabolism|The Extrapancreatic Metabolic Effects of Incretin Hormones|Completed|||20|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 21:20:31.221667|2018-05-31 21:20:31.221667
NCT01607931|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-08-11|2012-05-25|2012-05-30|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Exercise, Glucose Kinetics, and the Incretin Effect|The Effects of Acute Exercise on Glucose Kinetics, Beta-cell Function and the Incretin Effect in Subjects Representative of the Whole Glucose Tolerance Continuum|Completed||N/A|12|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 21:20:31.277445|2018-05-31 21:20:31.277445
NCT01607918|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-10-27|2012-05-25|2012-05-30|Estimate|||||||2013-10-27|2013-10-29|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|THC||Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy|Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial|Unknown status|Recruiting|Phase 4|1300|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 21:20:31.339436|2018-05-31 21:20:31.339436
NCT01607905|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2018-02-28|2012-05-25|2012-05-30|Estimate|||||||2018-02-28|2018-03-02|Actual|June 2012||2012-06-30|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety Study of KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer|A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Advanced or Metastatic Solid Tumor Malignancies|Completed||Phase 1|189|Actual|Karyopharm Therapeutics Inc||1|||f||||f||||||||Yes||2018-05-31 21:20:31.427296|2018-05-31 21:20:31.427296
NCT01607892|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2018-02-28|2012-05-25|2012-05-30|Estimate|||||||2018-02-28|2018-03-02|Actual|June 2012||2012-06-30|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer|A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 in Patients With Advanced Hematological Malignancies|Completed||Phase 1|285|Actual|Karyopharm Therapeutics Inc||1|||f||||f||||||||Yes||2018-05-31 21:20:31.4992|2018-05-31 21:20:31.4992
NCT01607879|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-02-14|2012-05-25|2012-05-30|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2014||2014-03-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation|Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy|Recruiting||Phase 2|80|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||||2018-05-31 21:20:31.663275|2018-05-31 21:20:31.663275
NCT01607866|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2016-11-07|2012-05-25|2012-05-30|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Quadrant Versus Superficial Parotidectomy|Quadrant Parotidectomy Versus Superficial Parotidectomy for Treatment of Pleomorphic Adenoma|Withdrawn||Phase 2/Phase 3|0|Actual|Mansoura University||2||Lack of enrollment of eligible patients for randomization.|f||||f||||||||||2018-05-31 21:20:31.769834|2018-05-31 21:20:31.769834
NCT01607853|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2013-11-04||2015-03-25|2012-05-25|2012-05-30|Estimate|2013-11-04|2013-12-24|Estimate||||2015-03-25|2015-04-14|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris|A Phase IIa Exploratory Study Evaluating the Anti-psoriatic Effect of Daivobet® Gel Applied Then Removed After 10 Minutes, Daivobet® Gel Applied Then Removed After 20 Minutes, Daivobet® Gel Applied for 24 Hours and Daivobet® Gel Vehicle Applied for 24 Hours|Completed||Phase 2|24|Actual|LEO Pharma|"In this small exploratory trial the subjects received all 4 investigational products on small dermal test sites.~Regarding Adverse Events, only local dermal reactions could be potentially attributed to a specific investigational product."|1|||f||||f||||||||||2018-05-31 21:20:31.893927|2018-05-31 21:20:31.893927
NCT01607840|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-08-31|2012-05-25|2012-05-30|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Transcranial Direct Current Stimulation in Individuals With Schizophrenia|Effects of Transcranial Direct Current Stimulation in Individuals With Schizophrenia|Completed||N/A|11|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 21:20:32.728031|2018-05-31 21:20:32.728031
NCT01607827|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2012-06-18|2012-05-29|2012-05-30|Estimate|||||||2012-06-18|2012-06-19|Estimate|April 2004||2004-04-30|June 2012|2012-06-30|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Colorectal Polypectomy Upon Insertion And Withdrawal Or Upon Withdrawal Only?|Colorectal Polypectomy Upon Insertion And Withdrawal Or Upon Withdrawal Only?|Completed||N/A|400|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 21:20:32.794149|2018-05-31 21:20:32.794149
NCT01607814|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-30|2012-05-29|2012-05-30|Estimate|||||||2012-05-30|2012-05-31|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Observational|||Oxidative Stress and Haemostasis Abnormalities in Cirrhosis|Oxidative Stress and Haemostasis Abnormalities in Cirrhosis|Unknown status|Recruiting||200|Anticipated|University of Roma La Sapienza|||2||f||||t||||||Samples Without DNA|"~     Plasma, serum and urine samples~   "|||2018-05-31 21:20:32.856654|2018-05-31 21:20:32.856654
NCT01607801|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-01-30|2012-05-29|2012-05-30|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|UMBI-REC||Effect of Reoperation for Recurrence After Open Umbilical Hernia Repair|Effect of Reoperation for Recurrence After Open Surgery for Small Umbilical Hernia With Sutured Mesh or Plastic Surgery. A National Hernia Database Study.|Completed|||4847|Actual|Zealand University Hospital|||4||f||||t||||||||||2018-05-31 21:20:32.925456|2018-05-31 21:20:32.925456
NCT01607606|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-29|2012-05-29|2012-05-30|Estimate|||||||2012-05-29|2012-05-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:20:35.484565|2018-05-31 21:20:35.484565
NCT01607788|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2012-05-29|2012-05-29|2012-05-30|Estimate|||||||2012-05-29|2012-05-30|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|December 2017|Anticipated|2017-12-31|||||Observational|ProLit||Prospective Liver Tumor (ProLiT) Database|Prospective Database of Liver Transplantation for Hepatocellular Carcinoma|Unknown status|Recruiting||500|Anticipated|University of Geneva, Switzerland|||||f||||f||||||||||2018-05-31 21:20:32.980037|2018-05-31 21:20:32.980037
NCT01607775|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-06-04|2012-05-24|2012-05-30|Estimate|||||||2012-06-04|2012-06-05|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Palcage||In-house Produced PMMA- Versus PEEK-cages|Clinical Characterization of In-house Produced PMMA-cages in Patients With Cervical Pathology|Completed||Phase 1/Phase 2|88|Actual|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 21:20:33.053437|2018-05-31 21:20:33.053437
NCT01607762|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-04-08|2012-05-25|2012-05-30|Estimate|||||||2013-04-08|2013-04-09|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics|Comparison of Single-Dose Plasma and Blood Concentrations of Aripiprazole, Olanzapine, Quetiapine, Paliperidone and Risperidone After Capillary and Venous Blood Sample Collection|Completed||Phase 1|31|Actual|Janssen Research & Development, LLC||5|||f||||f||||||||||2018-05-31 21:20:33.110555|2018-05-31 21:20:33.110555
NCT01607749|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2012-06-17|2012-05-29|2012-05-30|Estimate|||||||2012-06-17|2012-06-19|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Study for Asthma Education in Primary Schools|Asthma Educational Intervention on Physical Education Teachers in Primary Schools|Unknown status|Active, not recruiting|Phase 3|4506|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||t||||||||||2018-05-31 21:20:33.288597|2018-05-31 21:20:33.288597
NCT01607736|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-05-29|2012-05-29|2012-05-30|Estimate|||||||2012-05-29|2012-05-30|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pilot Study of Virtual Gait Training in Older Adults|Pilot Study of Effects of Virtual Gait Training on Walking Stability in Older Adults|Completed||N/A|12|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:20:33.367615|2018-05-31 21:20:33.367615
NCT01607723|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2014-12-02|2012-05-24|2012-05-30|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|May 2012|Actual|2012-05-31||Interventional|||"NAVA-PAV Study: a Cross-over Comparative Study of 2 Advanced Modes"|"Comparison of Two New Ventilatory Modes: NAVA vs PAV+: a Randomized Controlled Cross-over Study: the NAVA-PAV Study"|Completed||Phase 3|13|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:20:33.43313|2018-05-31 21:20:33.43313
NCT01607710|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-09-04|2012-05-29|2012-05-30|Estimate|||||||2014-09-04|2014-09-05|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|fMRI||Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)|Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)|Completed|||55|Actual|Hartford Hospital|||2||f||||f||||||||||2018-05-31 21:20:33.497035|2018-05-31 21:20:33.497035
NCT01607697|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-06-13|2012-05-29|2012-05-30|Estimate|||||||2015-06-13|2015-06-16|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With PD|Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With Parkinson's Disease (PD)|Completed||Phase 2|42|Actual|University Hospital, Antwerp||2|||f||||f||||||||||2018-05-31 21:20:33.552284|2018-05-31 21:20:33.552284
NCT01607684|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2012-09-03|2012-05-24|2012-05-30|Estimate|||||||2012-09-03|2012-09-05|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis|Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis|Completed||Phase 2|50|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-05-31 21:20:33.621735|2018-05-31 21:20:33.621735
NCT01607671|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2015-05-22|2012-05-29|2012-05-30|Estimate|||||||2015-05-22|2015-05-25|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%|Can Urgent Reduction of Intraocular Pressure With Ophthalmic Timolol Improve Recovery From Non-arteritic Anterior Ischemic Optic Neuropathy (NAION): a Randomized Study.|Withdrawn||Phase 1|0|Actual|Fraser Health||2||Unable to recruit participants from recruiting sites.|f||||f||||||||||2018-05-31 21:20:33.688405|2018-05-31 21:20:33.688405
NCT01607658|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-10-11|2012-05-29|2012-05-30|Estimate|||||||2017-10-11|2017-10-12|Actual|May 2012||2012-05-31|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder|A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Efficacy and Safety of TBS-2 Intranasal Testosterone Gel in Women With Acquired Female Orgasmic Disorder|Completed||Phase 2|253|Actual|Acerus Pharmaceuticals Corporation||4|||f||||f||||||||||2018-05-31 21:20:33.775286|2018-05-31 21:20:33.775286
NCT01607645|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2016-10-13||2017-02-14|2012-05-29|2012-05-30|Estimate|2017-02-14|2017-03-31|Actual||||2017-02-14|2017-03-31|Actual|July 2012||2012-07-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS|Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML.|Terminated||Phase 2|7|Actual|Fred Hutchinson Cancer Research Center|Early termination due to similar competing protocol, which made statistical evaluation of primary endpoint and any meaningful evaluation of secondary time points not feasible.|2||The study was terminated early because there were other competing protocols.|f||||f||||||||Yes||2018-05-31 21:20:33.929743|2018-05-31 21:20:33.929743
NCT01607632|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-24|2012-05-24|2012-05-30|Estimate|||||||2012-05-24|2012-05-30|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Loving-kindness Meditation for Posttraumatic Stress Disorder (PTSD)|An Open Pilot Study of Loving-Kindness Meditation for PTSD|Completed||N/A|42|Actual|Seattle Institute for Biomedical and Clinical Research||1|||f||||f||||||||||2018-05-31 21:20:35.346257|2018-05-31 21:20:35.346257
NCT01607619|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2013-01-24|2012-05-29|2012-05-30|Estimate|||||||2013-01-24|2013-01-28|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Anatabine on Elevated Blood Levels of C-reactive Protein|A 12-week Multi-site Trial of the Dietary Supplement Anatabine (RCP006) to Determine the Effects on Peripheral Markers of Inflammation in Patients With Elevated Levels of C-reactive Protein (CRP)|Completed||N/A|117|Actual|Roskamp Institute Inc.|||||f||||t||||||||||2018-05-31 21:20:35.419049|2018-05-31 21:20:35.419049
NCT01607593|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2013-09-26||2013-12-11|2012-05-24|2012-05-30|Estimate|2013-09-26|2013-12-04|Estimate||||2013-12-11|2014-01-13|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients|A Retrospective And Multicenter Survey To Investigate The Dosage, Efficacy And Safety Of Sertraline In Posttraumatic Stress Disorder Patients|Completed|||123|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:20:35.546111|2018-05-31 21:20:35.546111
NCT01607580|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-01-03|2012-05-29|2012-05-30|Estimate|||||||2014-01-03|2014-01-07|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)|Risk Stratification-directed Low-dose Glucocorticoid Prophylaxis for Acute GVHD After Unmanipulated Haploidentical Blood and Marrow Transplantation——a Randomized, Controlled, Clinical Trial|Unknown status|Active, not recruiting|N/A|145|Actual|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 21:20:35.900124|2018-05-31 21:20:35.900124
NCT01607554|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2018-03-14||2018-04-23|2012-05-24|2012-05-30|Estimate|2018-03-14|2018-04-13|Actual||||2018-04-23|2018-05-22|Actual|April 2012||2012-04-30|March 2018|2018-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer|A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression|Terminated||Phase 1/Phase 2|2|Actual|New Mexico Cancer Care Alliance|Early termination leading to no subjects analyzed. There will be no publication, as the original PI has left employment with the institution.|1||Inadequate enrollment (2 subjects in 4 years)|f||||t||||||||No||2018-05-31 21:20:35.998274|2018-05-31 21:20:35.998274
NCT01607541|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-06-08|2012-05-29|2012-05-30|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|BCAP||Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV|Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV|Completed||Phase 2/Phase 3|3400|Actual|New York University||2|||f||||t||||||||||2018-05-31 21:20:36.262043|2018-05-31 21:20:36.262043
NCT01607528|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2016-05-04|2012-05-24|2012-05-30|Estimate|||||||2016-05-04|2016-05-05|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|PIC||Influence of Probiotics on Infections in Cirrhosis|Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections|Completed||N/A|92|Actual|Medical University of Graz||2|||f||||t||||||||Undecided||2018-05-31 21:20:36.341855|2018-05-31 21:20:36.341855
NCT01607515|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2015-09-07|2012-05-29|2012-05-30|Estimate|||||||2015-09-07|2015-09-09|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Non Invasive Measurement of Cardiac Index by Impedance Cardiography|Non Invasive Measurement of Cardiac Index by Impedance Cardiography|Completed||N/A|89|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 21:20:36.423828|2018-05-31 21:20:36.423828
NCT01607502|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2017-08-08|2012-05-29|2012-05-30|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2010||2010-07-31|August 2017|2017-08-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Observational|||Database for Clinical and Anamnestic Data in Pulmonary Hypertension|Database for Clinical and Anamnestic Data in Pulmonary Hypertension|Recruiting|||900|Anticipated|Medical University of Graz|||1||f||||f||||||Samples With DNA|"~     Blood samples are collected and stored anonymously in our biobank if patients give their~     informed consent containing the option of DNA analysis.~   "|||2018-05-31 21:20:36.506449|2018-05-31 21:20:36.506449
NCT01607489|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2017-07-12|2012-05-29|2012-05-30|Estimate|||||||2017-07-12|2017-07-17|Actual|June 2011||2011-06-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography|Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Pilot Study|Completed||N/A|25|Actual|Medical University of Graz||1|||f||||f||||||||No||2018-05-31 21:20:36.57395|2018-05-31 21:20:36.57395
NCT01607476|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2016-08-02||2017-03-21|2012-05-24|2012-05-30|Estimate|2016-09-12|2016-11-01|Estimate||||2017-03-21|2017-04-18|Actual|July 2012||2012-07-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|December 2014|Actual|2014-12-31||Interventional|||Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)|Bridging Study of C11 PiB and F18 Flutemetamol Brain PET|Completed||Phase 2|89|Actual|Mayo Clinic||3|||f||||t||||||||Undecided|This study was funded by an industrial partner (GE) and discussions with the company about sharing the data will be entertained after first publications.|2018-05-31 21:20:36.654147|2018-05-31 21:20:36.654147
NCT01607463|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-05-24|2012-05-24|2012-05-30|Estimate|||||||2012-05-24|2012-05-30|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Venous Cannulation|The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Venous Cannulation|Completed||N/A|100|Actual|Kyungpook National University||2|||f||||f||||||||||2018-05-31 21:20:36.950701|2018-05-31 21:20:36.950701
NCT01607450|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2015-11-16||2016-01-19|2012-05-24|2012-05-30|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Modulation of Human Myocardial Metabolism by GLP-1 Dose Response|Modulation of Human Myocardial Metabolism by GLP-1 Dose Response|Completed||Phase 2/Phase 3|33|Actual|Indiana University|This was a dose-finding study of myocardial responses to systemically infused GLP-1. After ascertaining no detectable response in controls with low dose, we completed mid dose studies. Finding an important difference there we did not do the high dose|4|||f||||t||||||||||2018-05-31 21:20:37.038069|2018-05-31 21:20:37.038069
NCT01607437|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-05-29|2012-05-29|2012-05-30|Estimate|||||||2012-05-29|2012-05-30|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|Howell||Clinical Follow-up After ACL Reconstruction|10-year Follow-up After ACL Reconstruction With Howells Guide, Transtibial Drilling and Hamstrings Graft|Completed|||96|Actual|Bergen Knee Group|||||f||||f||||||||||2018-05-31 21:20:37.636926|2018-05-31 21:20:37.636926
NCT01607424|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2015-09-02|2012-05-29|2012-05-30|Estimate|||||||2015-09-02|2015-09-03|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|RECOS||Specific Cognitive Remediation for Schizophrenia|Specific Versus General Cognitive Remediation for Schizophrenia|Completed||N/A|151|Actual|Hôpital le Vinatier||2|||f||||f||||||||||2018-05-31 21:20:37.701923|2018-05-31 21:20:37.701923
NCT01607411|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2013-05-30||2014-08-07|2012-05-24|2012-05-30|Estimate|2013-08-22|2013-08-26|Estimate||||2014-08-07|2014-08-11|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model|A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model|Completed||Phase 3|55|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:20:37.804664|2018-05-31 21:20:37.804664
NCT01607398|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2014-03-06||2014-04-24|2012-05-24|2012-05-30|Estimate|2014-04-24|2014-05-26|Estimate||||2014-04-24|2014-05-26|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease|A 12-week Randomised, Double-blind, Parallel-group Study to Evaluate the Anti-inflammatory Effects of ADOAIR® 50/250mcg Twice Daily Compared With Placebo Twice Daily in Japanese Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|56|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:20:38.27715|2018-05-31 21:20:38.27715
NCT01607385|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-07-24|2012-05-24|2012-05-30|Estimate|||||||2017-07-24|2017-07-26|Actual|May 18, 2012|Actual|2012-05-18|July 2017|2017-07-31|December 3, 2012|Actual|2012-12-03|December 3, 2012|Actual|2012-12-03||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.|A Single Blind, Randomized, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Parameters of Repeat Doses of GSK2330672 in Healthy Volunteers, Given Alone and With a Single Day of Dosing With GSK1614235|Completed||Phase 1|56|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:20:38.792277|2018-05-31 21:20:38.792277
NCT01607372|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-01-27|2012-05-24|2012-05-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies|A Randomized, Double Blind, Placebo-controlled Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies|Completed||Phase 2|18|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:20:39.008877|2018-05-31 21:20:39.008877
NCT01607359|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-04-20|2012-05-24|2012-05-30|Estimate|||||||2017-04-20|2017-04-24|Actual|May 2012||2012-05-31|December 2016|2016-12-31|April 20, 2017|Actual|2017-04-20|October 2012|Actual|2012-10-31||Observational|||Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation|Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation|Withdrawn|||0|Actual|William Beaumont Hospitals|||2|Withdrawn: It was decided not to proceed with the study at this time.|f||||f||||||||||2018-05-31 21:20:39.43953|2018-05-31 21:20:39.43953
NCT01607346|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2017-07-11||2018-05-17|2012-05-24|2012-05-30|Estimate|2017-08-28|2017-09-26|Actual||||2018-05-17|2018-05-22|Actual|March 27, 2013|Actual|2013-03-27|May 2018|2018-05-31|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|||An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures|An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures|Terminated||Phase 4|10|Actual|GlaxoSmithKline|The study was terminated after 10 of 100 subjects had been enrolled. Statistical analyses were not performed as the sample size enrolled was too small to allow for these analyses to be meaningful. The data are presented as summary statistics only.|1|||f||||f||||||||||2018-05-31 21:20:39.737267|2018-05-31 21:20:39.737267
NCT01607333|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-03-26|2012-05-24|2012-05-30|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide|WEUKBRE5557: IMI PROTECT (Work Package 2): Use of Antiepileptics and Risk of Suicidality|Completed|||1|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 21:20:41.001386|2018-05-31 21:20:41.001386
NCT01607320|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-04-14||2018-02-22|2012-05-29|2012-05-30|Estimate|2015-05-12|2015-06-01|Estimate||||2018-02-22|2018-03-20|Actual|June 2012||2012-06-30|February 2018|2018-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PCOS||Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome|Effect of Raloxifene on Ovulation in Women With Polycystic Ovarian Syndrome.|Terminated||N/A|3|Actual|Greenville Health System||2||Over budget, slow recruitment, and personnel change|f||||t||||||||||2018-05-31 21:20:41.327258|2018-05-31 21:20:41.327258
NCT01607307|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2013-12-17|2012-05-29|2012-05-30|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2016|Anticipated|2016-08-31|December 2013|Actual|2013-12-31||Interventional|JAPAN-PD||Daikenchuto for Intestinal Dysmotility and Prevention of Postoperative Paralytic Ielus After Pancreaticoduodenectomy|Effect of Daikenchuto (TJ-100) on Intestinal Dysmotility and For the Prevention of Postoperative Paralytic Ileus in Patients Undergoing Pancreaticoduodenectomy: A Multicenter, Randomized, Placebo-Controlled Phase II Trial|Unknown status|Active, not recruiting|Phase 2|220|Anticipated|Wakayama Medical University||2|||f||||t||||||||||2018-05-31 21:20:42.003921|2018-05-31 21:20:42.003921
NCT01607294|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26||2015-08-13|2015-08-27|2012-05-29|2012-05-30|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes|Completed||Phase 2|60|Actual|Esperion Therapeutics||2|||f||||f||||||||||2018-05-31 21:20:42.353876|2018-05-31 21:20:42.353876
NCT01607281|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-06-10|2012-05-29|2012-05-30|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||The Ability of Anesthesiologists Identifying Internal Jugular Vein Bilaterally by Anatomic Landmarks|The Ability of Anesthesiologists Identifying Internal Jugular Vein by Anatomic Landmark Technique|Completed|||50|Actual|Diskapi Teaching and Research Hospital|||1||f||||f||||||||||2018-05-31 21:20:42.59897|2018-05-31 21:20:42.59897
NCT01607268|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-01-16|2012-05-24|2012-05-30|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Magnetic Resonance Spectroscopy in Autonomic Failure|Proton Magnetic Resonance Spectroscopy in Primary Autonomic Failure|Terminated|||6|Actual|Vanderbilt University Medical Center|||2|Could not enroll enough participants, and lost funding.|f||||f||||||||||2018-05-31 21:20:42.85378|2018-05-31 21:20:42.85378
NCT01607255|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-10-03|2012-05-24|2012-05-30|Estimate|||||||2017-10-03|2017-10-06|Actual|May 16, 2013|Actual|2013-05-16|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|||Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT)|Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method|Completed||Phase 4|480|Actual|VA Office of Research and Development||3|||f||||t|t|f|||f|||No||2018-05-31 21:20:43.19399|2018-05-31 21:20:43.19399
NCT01607229|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-24|2012-05-24|2012-05-30|Estimate|||||||2012-05-24|2012-05-30|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Multi-frequency Bioelectrical Impedance for Estimating Total Body Water by Deuterium Dilution|Utility of Multi-frequency Bioelectrical Impedance Compared to Deuterium Dilution for Assessment of Total Body Water|Completed|||25|Actual|University of Southern California|||1||f||||t||||||||||2018-05-31 21:20:43.853977|2018-05-31 21:20:43.853977
NCT01607216|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-05-02|2012-05-24|2012-05-30|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2011||2011-08-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies|Prematurity and Respiratory Outcome Program: Single Center Study of Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies|Completed|||277|Actual|University of Rochester|||2||f||||t||||||Samples With DNA|"~     Several types of biospecimens are to be collected:~      Cord Blood Tracheal Aspirates Urine Stool Saliva Blood~      DNA collection is optional.~   "|||2018-05-31 21:20:44.108925|2018-05-31 21:20:44.108925
NCT01607203|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|2013-12-30||2015-02-03|2012-05-24|2012-05-30|Estimate|2015-02-03|2015-02-19|Estimate||||2015-02-03|2015-02-19|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist|Randomised Controlled Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist|Completed||Phase 4|120|Actual|AZ Jan Palfijn Gent||2|||f||||t||||||||||2018-05-31 21:20:44.379605|2018-05-31 21:20:44.379605
NCT01607190|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-09-13|2012-05-24|2012-05-30|Estimate|||||||2017-09-13|2017-09-14|Actual|November 2012||2012-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|April 2016|Actual|2016-04-30||Observational|C-Tracer||Biomarkers of Diabetic Retinopathy Progression|Biomarkers of Diabetic Retinopathy Progression.|Active, not recruiting|||200|Anticipated|Association for Innovation and Biomedical Research on Light and Image|||1||f||||f||||||||||2018-05-31 21:20:45.326669|2018-05-31 21:20:45.326669
NCT01607177|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-11-12|2012-05-25|2012-05-28|Estimate|||||||2013-11-12|2013-11-14|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Do Text Message Reminders Increase Preoperative Exercise in Obesity Surgery Candidates?|Text Messaging to Improve Adherence to Prehabilitation in Patients Undergoing Bariatric Surgery: a Randomised Controlled Trial|Completed||Phase 3|102|Actual|University of Auckland, New Zealand||2|||f||||||||||||||2018-05-31 21:20:45.568819|2018-05-31 21:20:45.568819
NCT01607164|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-05-21|2012-05-25|2012-05-28|Estimate|||||||2015-05-21|2015-05-25|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|DPC-R||Healthy Mood Internet Recruitment Study|Depression Prevention and Management Project|Completed||N/A|1226|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 21:20:45.86096|2018-05-31 21:20:45.86096
NCT01607151|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-08-04|2012-05-25|2012-05-28|Estimate|||||||2015-08-04|2015-08-05|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2015|Actual|2015-06-30||Interventional|TTM-ICH||Safety and Feasibility Study of Targeted Temperature Management After ICH|Safety and Feasibility of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 21:20:45.96137|2018-05-31 21:20:45.96137
NCT01607138|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2012-05-25|2012-05-25|2012-05-28|Estimate|||||||2012-05-25|2012-05-28|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|June 2013|Anticipated|2013-06-30||Observational|||Speech and Swallowing Characteristics of Patients After Laryngectomy and the Effect on Quality of Life|Speech and Swallowing Characteristics of Patients After Laryngectomy and the Effect on Quality of Life|Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 21:20:46.025562|2018-05-31 21:20:46.025562
NCT01607125|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-09-24|2012-05-25|2012-05-28|Estimate|||||||2013-09-24|2013-09-25|Estimate|July 2012||2012-07-31|September 2013|2013-09-30||||September 2013|Actual|2013-09-30||Interventional|||Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Exploratory Study Investigating the Effects of [Vortioxetine] Lu AA21004 on Cognition and BOLD fMRI Signals in Subjects Remitted From Depression and Controls|Completed||Phase 1|96|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 21:20:46.082147|2018-05-31 21:20:46.082147
NCT01607112|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2013-07-25||2013-11-14|2012-05-24|2012-05-28|Estimate|2013-11-14|2013-12-06|Estimate||||2013-11-14|2013-12-06|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and Above|Completed||Phase 3|119|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:20:46.166367|2018-05-31 21:20:46.166367
NCT01607099|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-11-13|2012-05-25|2012-05-28|Estimate|||||||2014-11-13|2014-11-14|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||Sodium Picosulfate Plus Magnesium Citrate Versus Macrogol 4000 in the Bowel Cleansing Procedure: a Comparison of Efficiency and Compatibility|Sodium Picosulfate Plus Magnesium Citrate Versus Macrogol 4000 in the Bowel Cleansing Procedure: a Comparison of Efficiency and Compatibility|Completed||N/A|220|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 21:20:47.461182|2018-05-31 21:20:47.461182
NCT01607086|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-08-01|2012-05-24|2012-05-28|Estimate|||||||2017-08-01|2017-08-03|Actual|July 11, 2008|Actual|2008-07-11|August 2017|2017-08-31|July 18, 2008|Actual|2008-07-18|July 18, 2008|Actual|2008-07-18||Interventional|||Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo|A Randomised, Double-blind Study in Healthy Volunteers to Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:20:47.541318|2018-05-31 21:20:47.541318
NCT01607073|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-03-24|2012-05-25|2012-05-28|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Verapamil as Therapy for Children and Young Adults With Dravet Syndrome|Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome|Completed||Phase 2|2|Actual|Gillette Children's Specialty Healthcare||1|||f||||t||||||||||2018-05-31 21:20:47.647835|2018-05-31 21:20:47.647835
NCT01607060|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-01-05|2012-05-25|2012-05-28|Estimate|||||||2015-01-05|2015-01-07|Estimate|September 2008||2008-09-30|October 2012|2012-10-31||||April 2012|Actual|2012-04-30||Interventional|||Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.|Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.|Completed||Phase 3|88|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:20:47.755496|2018-05-31 21:20:47.755496
NCT01607047|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2018-03-19|2012-05-25|2012-05-28|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2010||2010-12-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|September 2012|Actual|2012-09-30||Observational|LEPTO||French West Indies Leptospirosis Study|Utility of Quantitative Polymerase Chain Reaction to Predict Clinical Outcome of Leptospirosis in French West Indies|Active, not recruiting|||150|Actual|University Hospital Center of Martinique|||||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells, plasma, DNA~   "|||2018-05-31 21:20:47.835869|2018-05-31 21:20:47.835869
NCT01607034|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-11-24|2012-05-25|2012-05-28|Estimate|||||||2014-11-24|2014-11-25|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food Effects|An Open-Label, Randomized, Crossover Study to Assess the Bioavailability of Dexpramipexole Administered in Soft Food and Water, and in Intact Tablet Form in the Fasted and Fed States in Healthy Volunteers|Completed||Phase 1|24|Actual|Knopp Biosciences||4|||f||||f||||||||||2018-05-31 21:20:47.893969|2018-05-31 21:20:47.893969
NCT01607021|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-08-14|2012-05-25|2012-05-28|Estimate|||||||2015-08-14|2015-08-17|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection|Pharmacogenomics Study on IL28B Genetic Variants for Prediction of Drug Response in Chinese Children With HCV Infection.|Unknown status|Recruiting||200|Anticipated|Beijing 302 Hospital|||1||f||||t||||||||||2018-05-31 21:20:47.962213|2018-05-31 21:20:47.962213
NCT01607008|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-11-18|2012-05-25|2012-05-28|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|NA_00067284||MRI for Assessing Prostate Cancer Response|Multiparametric MRI for Assessing Radiotherapy Treatment Response of Prostate Cancer|Unknown status|Recruiting|N/A|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-05-31 21:20:48.043089|2018-05-31 21:20:48.043089
NCT01606995|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-01-19|2012-05-25|2012-05-28|Estimate|||||||2017-01-19|2017-01-23|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|XANTUS||Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation|Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation|Completed|||6784|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:20:48.121641|2018-05-31 21:20:48.121641
NCT01606982|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-02-15|2012-05-24|2012-05-28|Estimate|||||||2017-02-15|2017-02-17|Actual||||February 2017|2017-02-28||||||||Expanded Access|||Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|Approved for marketing|||||Astellas Pharma Inc|||||||||||||||||||2018-05-31 21:20:48.211152|2018-05-31 21:20:48.211152
NCT01606969|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2018-05-16|2012-05-25|2012-05-28|Estimate|||||||2018-05-16|2018-05-21|Actual|June 2012||2012-06-30|May 2018|2018-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution|Randomized Controlled Trial to Comparison of Epinephrine-lidocaine Solution and Dexmedetomidine -Lidocaine Solution for the Effect on Hemodynamic Response Due to Scalp Infiltration in Patients Undergoing Craniotomy|Completed||N/A|52|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:20:48.270326|2018-05-31 21:20:48.270326
NCT01606956|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-03-04|2012-05-23|2012-05-28|Estimate|||||||2014-03-04|2014-03-05|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Comparison of Two Different Methods of Partial Inflation of Cuff for Facile Insertion of Laryngeal Mask Airway in Adult Patients|The Comparison of Two Different Methods of Partial Inflation of Cuff for Facile Insertion of Laryngeal Mask Airway in Adult Patients|Completed||N/A|80|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:20:48.339453|2018-05-31 21:20:48.339453
NCT01606943|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-05-25|2012-05-25|2012-05-28|Estimate|||||||2012-05-25|2012-05-28|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|CPOAADCP||Clinical Profiles and Outcomes of Acute Aortic Dissection in the Chinese Patients|The Study of The Chinese Registry of Acute Aortic Dissection and Clinical Study of Acute Aortic Dissection in Chinese Patients|Completed|||2000|Actual|Xijing Hospital|||||f||||t||||||||||2018-05-31 21:20:48.398388|2018-05-31 21:20:48.398388
NCT01606930|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-05-23|2012-05-23|2012-05-28|Estimate|||||||2012-05-23|2012-05-28|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Pilot Study to Improve Patient-Doctor Communication|A Pilot Study to Improve Patient-Doctor Communication|Completed||N/A|106|Actual|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 21:20:48.45586|2018-05-31 21:20:48.45586
NCT01606917|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2012-05-25|2012-05-25|2012-05-28|Estimate|||||||2012-05-25|2012-05-28|Estimate|October 2004||2004-10-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|LÄTTA||Interventions for Lifestyle Changes to Promote Weight Reduction, a Randomized Controlled Trial in Primary Health Care|Interventions for Lifestyle Changes to Promote Weight Reduction, a Randomized Controlled Trial in Primary Health Care|Completed||N/A|133|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 21:20:48.529552|2018-05-31 21:20:48.529552
NCT01606904|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2018-05-04|2012-05-23|2012-05-28|Estimate|||||||2018-05-04|2018-05-11|Actual|May 2012||2012-05-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CognObe||The Effect of CBT- Based Weight Loss Program on Obesity|The Effect of CBT- Based Weight Loss Program on Eating Behavior, Weight Loss Result and Risk for Coronary Heart Diseases and Type 2 Diabetes|Completed||N/A|62|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 21:20:48.599799|2018-05-31 21:20:48.599799
NCT01606891|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-03-29|2012-05-25|2012-05-28|Estimate|||||||2017-03-29|2017-03-31|Actual|June 2012||2012-06-30|March 2017|2017-03-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|NET-Works||NET-Works:Community Preschooler Obesity Prevention|Linking Primary Care, Communities and Families to Prevent Obesity Among Preschoolers|Completed||N/A|534|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 21:20:48.67728|2018-05-31 21:20:48.67728
NCT01606878|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-12-04|2012-05-24|2012-05-28|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2013||2013-03-31|December 2017|2017-12-31||||October 2018|Anticipated|2018-10-31||Interventional|||Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma|A Phase 1 Study of Crizotinib (IND#105573) in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma|Active, not recruiting||Phase 1|65|Anticipated|Children's Oncology Group||4|||f||||t||||||||||2018-05-31 21:20:48.741544|2018-05-31 21:20:48.741544
NCT01606865|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-10-22|2012-05-25|2012-05-28|Estimate|||||||2014-10-22|2014-10-23|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|BIANCA||Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery|Does Platelet Inhibition Predict Surgery Related Bleeding in Patients Undergoing Non-Cardiac Surgery During Dual Antiplatelet Therapy|Completed|||207|Actual|Medical University of Graz|||1||f||||f||||||||||2018-05-31 21:20:48.861255|2018-05-31 21:20:48.861255
NCT01606852|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|2017-11-22||2018-02-13|2012-05-23|2012-05-28|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|March 2013||2013-03-31|February 2018|2018-02-28|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|PCS||Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients|Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients|Completed||Phase 1/Phase 2|15|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 21:20:48.919501|2018-05-31 21:20:48.919501
NCT01606839|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-02-18|2012-05-24|2012-05-28|Estimate|||||||2014-02-18|2014-02-19|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Noninvasive Measurement of Cardiac Output in Pulmonary Hypertension Using Inert Gas Rebreathing|Noninvasive Measurement of Cardiac Output in Pulmonary Hypertension Using Inert Gas Rebreathing|Completed|||34|Actual|Medical University of Graz|||||f||||f||||||||||2018-05-31 21:20:49.096463|2018-05-31 21:20:49.096463
NCT01606826|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-09-25|2012-05-25|2012-05-28|Estimate|||||||2017-09-25|2017-09-26|Actual|October 2012||2012-10-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Observational|SARP||Severe Asthma Research Program|Severe Asthma Research Program|Active, not recruiting|||715|Actual|Milton S. Hershey Medical Center|||1||f||||t||||||Samples With DNA|"~     Blood: CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA; Urine; EBC; Sputum: Supernatant, Cell~     Pellet; Bronch: BAL, Bronchial Brushings, Bronchial Biopsy~   "|Yes||2018-05-31 21:20:49.238512|2018-05-31 21:20:49.238512
NCT01606813|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2016-12-06|2012-05-25|2012-05-28|Estimate|||||||2016-12-06|2016-12-08|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Impact of Integrating an Internet Weight Control Program Into Primary Care|The Impact of Integrating an Internet Weight Control Program Into Primary Care|Completed||N/A|611|Actual|Milton S. Hershey Medical Center||3|||f||||t||||||||||2018-05-31 21:20:49.337746|2018-05-31 21:20:49.337746
NCT01606800|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2016-01-26||2017-03-10|2012-05-24|2012-05-28|Estimate|2016-01-26|2016-02-23|Estimate||||2017-03-10|2017-04-10|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|START 4|All Treated Population, which included all participants who received at least one dose of study medication after RVR.|Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)|Randomized Open Label Study to Assess the Efficacy and Safety of Short Course Therapy (24 Weeks) With Peginterferon Alpha-2b and Ribavirin for Chronic Hepatitis C (Genotype 4) Patients Who Achieve a Rapid Virological Response (HCV -RNA Undetectable at Week 4 of Treatment)|Terminated||Phase 4|45|Actual|Merck Sharp & Dohme Corp.|This Trial was prematurely terminated due to the availability of more promising treatment for HCV participants and the change in treatment guidelines, which will offer the patient a better treatment opportunity.|2||The trial was terminated due to change in new standard of therapy during the study period.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:20:49.446842|2018-05-31 21:20:49.446842
NCT01606787|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2018-02-21|2012-05-25|2012-05-28|Estimate|||||||2018-02-21|2018-02-22|Actual|May 22, 2012|Actual|2012-05-22|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes|Phase 3 Trial of Intravenous Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes|Completed||Phase 3|210|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:20:49.713956|2018-05-31 21:20:49.713956
NCT01606774|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-02-03|2012-05-25|2012-05-28|Estimate|||||||2017-02-03|2017-02-06|Estimate|July 2012||2012-07-31|February 2017|2017-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Modernized Approach to Prenatal Care in Low Risk Women|A Modernized Approach to Prenatal Care in Low Risk Women|Completed||N/A|4|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 21:20:49.837964|2018-05-31 21:20:49.837964
NCT01606761|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2017-11-24|2016-01-18|2018-02-23|2012-05-24|2012-05-28|Estimate|2018-01-19|2018-02-05|Actual|2016-01-18|2016-02-10|Estimate|2018-02-23|2018-03-23|Actual|August 6, 2012|Actual|2012-08-06|February 2018|2018-02-28|January 12, 2016|Actual|2016-01-12|March 17, 2015|Actual|2015-03-17||Interventional|||A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy|Completed||Phase 3|878|Actual|Janssen Research & Development, LLC||3|||f||||t|t|||||||||2018-05-31 21:20:50.041265|2018-05-31 21:20:50.041265
NCT01606748|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2015-12-21|2014-04-25|2017-04-21|2012-05-24|2012-05-28|Estimate|2016-07-15|2016-08-26|Estimate|2014-04-25|2014-05-13|Estimate|2017-04-21|2017-05-23|Actual|August 2012||2012-08-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2013|Actual|2013-06-30||Interventional||All participants who received at least one dose of study drug.|A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin|An Open-Label, Non-controlled, Non-randomized Sequential Design, Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin in Patients With Advanced Solid Cancers|Completed||Phase 2|35|Actual|Eli Lilly and Company||1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 21:20:53.642284|2018-05-31 21:20:53.642284
NCT01606735|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2014-09-02||2014-09-17|2012-05-25|2012-05-28|Estimate|2014-09-17|2014-09-22|Estimate||||2014-09-17|2014-09-22|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety of IBI-10090 in Ocular Surgery Patients|A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Ocular Surgery|Completed||Phase 2|172|Actual|ICON Bioscience Inc||3|||f||||f||||||||||2018-05-31 21:20:55.111642|2018-05-31 21:20:55.111642
NCT01606722|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-07-10|2012-05-25|2012-05-28|Estimate|||||||2013-07-10|2013-07-11|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|MonDar||Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy|Relation Between Darunavir Levels and Virological Efficacy, Integrated Proviral ADN and Resistance Mutations in HIV-infected Patients on Treatment With Darunavir/Ritonavir Monotherapy|Completed|||150|Actual|Hospitales Universitarios Virgen del Rocío|||1||f||||t||||||Samples Without DNA|"~     Blood samples (plasma and PBMC)~   "|||2018-05-31 21:20:55.456751|2018-05-31 21:20:55.456751
NCT01606709|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2012-05-25|2012-05-25|2012-05-28|Estimate|||||||2012-05-25|2012-05-28|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Interventional|||Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation|A Prospective Comparison of Transcriptional Profiling of Luteal Phase Endometrial Biopsies After Induction of Oocyte Maturation With a Gonadotropin Releasing Hormone (GnRH) Agonist or Human Chorionic Gonadotropins (hCG)|Unknown status|Enrolling by invitation|N/A|20|Anticipated|UConn Health||2|||f||||t||||||||||2018-05-31 21:20:55.523855|2018-05-31 21:20:55.523855
NCT01606696|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-07-15|2012-05-25|2012-05-28|Estimate|||||||2015-07-15|2015-07-16|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|November 2012|Actual|2012-11-30||Interventional|HIIT||Higher Intensity Interval Training in Cardiac Rehabilitation|Practical Use of Higher Intensity Interval Exercise in Cardiac Rehabilitation to Improve Aerobic Fitness|Completed||N/A|49|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 21:20:55.601115|2018-05-31 21:20:55.601115
NCT01606683|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-02-02|2012-05-24|2012-05-28|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional|||Impact of Infant Feeding on Newborn Metabolomic Profile|Impact of Infant Feeding on Newborn Metabolomic Profile|Completed||N/A|30|Actual|Heinz Italia SpA||3|||f||||f||||||||||2018-05-31 21:20:55.662091|2018-05-31 21:20:55.662091
NCT01606670|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|2015-04-01||2018-03-09|2012-05-23|2012-05-28|Estimate|2015-04-28|2015-04-29|Estimate||||2018-03-09|2018-04-04|Estimate|May 2012||2012-05-31|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|NEUPAD|Baseline Characteristics refer to the Safety Set, including all enrolled patients who had applied the rotigotine transdermal patch at least once.|Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease|A Multicenter, Non-interventional Study With Neupro® to Evaluate the Perception of Pain Associated With Idiopathic Parkinson's Disease|Completed|||93|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 21:20:55.753698|2018-05-31 21:20:55.753698
NCT01606657|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-05-01|2012-05-23|2012-05-28|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2010||2010-08-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional|||Irrigation Versus no Irrigation for Cutaneous Abscess|Is Routine Irrigation of Cutaneous Abscesses Necessary?|Completed||N/A|201|Actual|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 21:20:56.019797|2018-05-31 21:20:56.019797
NCT01606644|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2012-05-25|2012-05-25|2012-05-28|Estimate|||||||2012-05-25|2012-05-28|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue|Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue.|Unknown status|Recruiting|Phase 3|60|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 21:20:56.090881|2018-05-31 21:20:56.090881
NCT01606631|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-05-23|2012-05-23|2012-05-28|Estimate|||||||2012-05-23|2012-05-28|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Role of Beta-blockers in the Prevention on the Arisen of a Severe Sepsis (TESS)|Evaluation of the Protective Role of Beta-blockers Prescribed in a Chronic Way on the Arisen of a Severe Septic Syndrome or a Toxic Shock at Patients Having a Community Infection|Completed|||2444|Actual|Rennes University Hospital|||2||f||||f||||||Samples Without DNA|"~     Non applicable.~   "|||2018-05-31 21:20:56.23935|2018-05-31 21:20:56.23935
NCT01606618|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2016-06-14|2012-05-23|2012-05-28|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|ESTIME||Self-esteem and Neuro-urological Follow-up in Patients With Spina Bifida or Spinal Cord Injury|Analysis of Psychosocial Determinants of Observance of Monitoring Neuro-urological in Spina-bifida Adult Patients and in Spinal Cord Injury Patients: a Prospective, Comparative, Multicenter With Parallel Groups Study|Recruiting|||330|Anticipated|Rennes University Hospital|||2||f||||f||||||||||2018-05-31 21:20:56.321657|2018-05-31 21:20:56.321657
NCT01606605|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-01-12|2012-05-23|2012-05-25|Estimate|||||||2013-01-12|2013-01-15|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma|Retrospective Analysis of Diffuse Large B-cell Lymphoma: Identification of Factors Associated With Treatment Resistance Via Gene Expression Profile|Completed|||350|Actual|Samsung Medical Center|||1||f||||f||||||Samples With DNA|"~     Parrafin-embedded tissue blocks~   "|||2018-05-31 21:20:56.460336|2018-05-31 21:20:56.460336
NCT01606592|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-08-18|2012-05-23|2012-05-25|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2010|Actual|2010-01-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Psychotherapy Outcome and Self-selection Effects in Panic Disorder|Phase 2/3 Study of Panic Control Treatment vs Panic-Focussed Psychodynamic Psychotherapy Under Randomized and Self-Selection Conditions|Active, not recruiting||N/A|216|Actual|Region Skane||5|||f||||t||||||||||2018-05-31 21:20:56.51879|2018-05-31 21:20:56.51879
NCT01606579|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-08-16|2012-05-23|2012-05-25|Estimate|||||||2017-08-16|2017-08-17|Actual|July 2012||2012-07-31|May 2017|2017-05-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|||Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies|An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies|Completed||Phase 1/Phase 2|49|Actual|Prism Pharma Co., Ltd.||5|||f||||f||||||||||2018-05-31 21:20:56.588534|2018-05-31 21:20:56.588534
NCT01606566|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-09-27|2012-05-23|2012-05-25|Estimate|||||||2016-09-27|2016-09-28|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of PC-A11 in Patients With Recurrent Head and Neck Squamous Cell Carcinoma|An Open-label, Single Arm, Multi-centre, Phase II Study to Evaluate the Safety and Efficacy of PC-A11 With Superficial and Interstitial Laser Light Application in Patients With Recurrent Head and Neck Squamous Cell Carcinoma Unsuitable for Surgery and Radiotherapy|Terminated||Phase 2|26|Actual|PCI Biotech AS||1||Business reasons|f||||t||||||||||2018-05-31 21:20:56.664492|2018-05-31 21:20:56.664492
NCT01606553|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-02-15|2012-05-23|2012-05-25|Estimate|||||||2016-02-15|2016-02-17|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|INCA||Inspiratory Muscle Training in Patients With Chronic Heart Failure|The INCA Study: Inspiratory Muscle Training in Patients With Chronic Heart Failure|Completed||N/A|22|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 21:20:56.758519|2018-05-31 21:20:56.758519
NCT01606540|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-09-14|2012-05-23|2012-05-25|Estimate|||||||2017-09-14|2017-09-15|Actual|June 2012||2012-06-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Non-steroid Antiinflammatory Drugs to Heal Colles Fracture|The Influence of Non-steroid Antiinflammatory Drugs (NSAID) to Heal Colles Fracture.|Active, not recruiting||N/A|192|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:20:56.831261|2018-05-31 21:20:56.831261
NCT01606527|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-05-23|2012-05-23|2012-05-25|Estimate|||||||2012-05-23|2012-05-25|Estimate|July 2012||2012-07-31|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||NSAID RCT for Prevention of Altitude Sickness|Prospective, Double-blind, Randomized, Placebo-controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness|Unknown status|Not yet recruiting|Phase 2|300|Anticipated|Naval Health Research Center||2|||f||||f||||||||||2018-05-31 21:20:57.053544|2018-05-31 21:20:57.053544
NCT01606514|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-10-03|2012-05-23|2012-05-25|Estimate|||||||2014-10-03|2014-10-06|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Web-based Intervention for Disaster-Affected Youth and Families|Web-based Intervention for Disaster-Affected Youth and Families|Completed||N/A|2000|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-05-31 21:20:57.138763|2018-05-31 21:20:57.138763
NCT01606501|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-06-12|2012-05-23|2012-05-25|Estimate|||||||2017-06-12|2017-06-14|Actual|May 2012||2012-05-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|OUTLET||Outcomes Following Severe Distal Tibia, Ankle and/or Foot Trauma: Comparison of Limb Salvage Versus Transtibial Amputation Protocol|Outcomes Following Severe Distal Tibia, Ankle and/or Foot Trauma: Comparison of Limb Salvage Versus Transtibial Amputation Protocol (OUTLET Study)|Unknown status|Active, not recruiting||664|Actual|Major Extremity Trauma Research Consortium|||2||f||||t||||||||||2018-05-31 21:20:57.204966|2018-05-31 21:20:57.204966
NCT01606488|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2018-05-14|2012-05-24|2012-05-25|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2012||2012-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Brain Beta-Amyloid on Postoperative Cognition|Effects of Brain Beta Amyloid on Postoperative Cognition and 18F-AV-45-A14: Clinical Evaluation of Florbetapir F 18 (18F-AV-45)|Recruiting||Phase 4|100|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:20:57.305348|2018-05-31 21:20:57.305348
NCT01606475|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-02-27|2012-05-24|2012-05-25|Estimate|||||||2017-02-27|2017-03-01|Actual||||February 2017|2017-02-28||||||||Expanded Access|EXAX||Islet Transplant for Type 1 or Surgical Diabetes|Human Alloislet Transplant for Type 1 or Surgical Diabetes Mellitus With Complications|No longer available|||||University of Minnesota - Clinical and Translational Science Institute|||||||||||||||||||2018-05-31 21:20:57.385299|2018-05-31 21:20:57.385299
NCT01606462|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-12-02|2012-05-24|2012-05-25|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Oxytocin and Social Cognition|Double-blind, Placebo-controlled, Randomized Study: Oxytocin and OXTR-genotypes Influence Behavioral and Neural Social Reactions|Completed||Phase 1|153|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 21:20:57.451644|2018-05-31 21:20:57.451644
NCT01606449|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-24|2012-05-24|2012-05-25|Estimate|||||||2012-05-24|2012-05-25|Estimate|January 1980||1980-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Follow-up of Patients Operated Upon for Type II-IV Hiatal Hernia|Thirty-year Follow-up of a Case Series of Patients Operated Upon for Type II-IV Hiatal Hernia|Completed|||100|Actual|University of Bologna|||3||f||||f||||||||||2018-05-31 21:20:57.587752|2018-05-31 21:20:57.587752
NCT01606436|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-09-28|2012-05-23|2012-05-25|Estimate|||||||2012-09-28|2012-10-01|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia|A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:20:57.663492|2018-05-31 21:20:57.663492
NCT01606423|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-23|2012-05-23|2012-05-25|Estimate|||||||2012-05-23|2012-05-25|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants|The Effect of LY2409021 on Blood Glucose Concentrations During Hyperglucagonaemia in Healthy Male Subjects|Completed||Phase 1|21|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 21:20:57.749865|2018-05-31 21:20:57.749865
NCT01606410|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2013-11-19|2012-05-23|2012-05-25|Estimate|||||||2013-11-19|2013-11-20|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Impact of Age and Fitness on Reperfusion Injury and Ischemic Preconditioning to Prevent This Injury|The Impact of Age and Fitness on Endothelial Reperfusion Injury and the Ability of Ischemic Preconditioning to Prevent This Injury|Completed|||30|Actual|Radboud University|||4||f||||f||||||||||2018-05-31 21:20:57.818493|2018-05-31 21:20:57.818493
NCT01606397|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-23|2012-05-23|2012-05-25|Estimate|||||||2012-05-23|2012-05-25|Estimate|March 2008||2008-03-31|May 2012|2012-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes|The Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Doses of LY2409021 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|50|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 21:20:57.891205|2018-05-31 21:20:57.891205
NCT01606384|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-24|2012-05-24|2012-05-25|Estimate|||||||2012-05-24|2012-05-25|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|NAPA||Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder|A Double-blind, Placebo-controlled Study Evaluating the Pharmacodynamic Effects of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) on Hypothalamic-pituitary-adrenal Axis Function in Outpatients With Major Depressive Disorder|Completed||Phase 2|100|Actual|Sanofi||3|||f||||||||||||||2018-05-31 21:20:57.96428|2018-05-31 21:20:57.96428
NCT01606371|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-23|2012-05-23|2012-05-25|Estimate|||||||2012-05-23|2012-05-25|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2409021 After Escalating Single Oral Dose Administration in Healthy Subjects and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|32|Actual|Eli Lilly and Company||11|||f||||f||||||||||2018-05-31 21:20:58.050576|2018-05-31 21:20:58.050576
NCT01606358|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-08-08|2012-05-24|2012-05-25|Estimate|||||||2014-08-08|2014-08-11|Estimate||||August 2014|2014-08-31||||May 2016|Anticipated|2016-05-31||Observational|IClyCO||Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer|IClyCO Influence of Chemotherapy (Carboplatin and Taxol) on the ex Vivo Expansion and Functional Capacity of Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer|Withdrawn|||0|Actual|Rennes University Hospital|||1||f||||f||||||Samples Without DNA|"~     The VGAMMA9VDELTA2 T cells will be isolated from peripheral blood mononuclear cells of~     patients with ovarian cancer.~   "|||2018-05-31 21:20:58.129945|2018-05-31 21:20:58.129945
NCT01606345|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-04-21|2012-05-24|2012-05-25|Estimate|||||||2016-04-21|2016-04-22|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma|Phase I Dose Escalation and Landmark Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (UTUC) Following Endoscopic Resection|Completed||Phase 1|4|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 21:20:58.195939|2018-05-31 21:20:58.195939
NCT01606332|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2013-06-10|2012-05-24|2012-05-25|Estimate|||||||2013-06-10|2013-06-11|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Indwelling Interscalene Nerve Catheters in Surgical Management of Idiopathic Adhesive Capsulitis|Indwelling Interscalene Nerve Catheters in Surgical Management of Idiopathic Adhesive Capsulitis|Unknown status|Recruiting|N/A|40|Anticipated|OAD Orthopaedics||2|||f||||f||||||||||2018-05-31 21:20:58.280724|2018-05-31 21:20:58.280724
NCT01606319|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2016-09-13||2016-11-17|2012-05-24|2012-05-25|Estimate|2016-11-17|2017-01-16|Estimate||||2016-11-17|2017-01-16|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|AVICA||Acetaminophen Versus Ibuprofen in Children With Asthma|Acetaminophen vs. Ibuprofen in Children With Asthma|Completed||Phase 3|300|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 21:20:58.37745|2018-05-31 21:20:58.37745
NCT01606306|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2016-09-15||2017-01-27|2012-05-24|2012-05-25|Estimate|2017-01-27|2017-03-16|Actual||||2017-01-27|2017-03-16|Actual|February 2013||2013-02-28|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|INFANT|All randomized participants|Individualized Therapy For Asthma in Toddlers|Individualized Therapy For Asthma in Toddlers|Completed||Phase 3|300|Actual|Milton S. Hershey Medical Center||6|||f||||t||||||||||2018-05-31 21:20:58.773643|2018-05-31 21:20:58.773643
NCT01606293|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2018-01-09|2012-05-24|2012-05-25|Estimate|||||||2018-01-09|2018-01-11|Actual|May 24, 2012|Actual|2012-05-24|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix|Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix|Recruiting|||60|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 21:20:59.688299|2018-05-31 21:20:59.688299
NCT01606280|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-01-20|2012-05-23|2012-05-25|Estimate|||||||2014-01-20|2014-01-22|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation|Reporting of Amyloidosis Stem Cell Transplantation Outcomes|Completed|||400|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 21:20:59.759061|2018-05-31 21:20:59.759061
NCT01606267|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2018-04-19|2012-05-24|2012-05-25|Estimate|||||||2018-04-19|2018-04-23|Actual|December 2010|Actual|2010-12-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Evaluation of Integrated Community Case Management in Ethiopia|Independent Prospective Evaluation of Integrated Community Case Management and Development and Implementation of a Method for Real-time Mortality Monitoring in the Oromia Region, Ethiopia|Completed||N/A|607770|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:20:59.816368|2018-05-31 21:20:59.816368
NCT01606254|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2013-03-04||2013-05-28|2012-05-23|2012-05-25|Estimate|2013-03-04|2013-04-18|Estimate||||2013-05-28|2013-06-05|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia|A Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia|Completed||Phase 2|56|Actual|Janssen Pharmaceutical K.K.||4|||f||||f||||||||||2018-05-31 21:20:59.962469|2018-05-31 21:20:59.962469
NCT01606241|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-08-28|2012-05-24|2012-05-25|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2012||2012-07-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer|Active, not recruiting||Phase 1|24|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:21:01.391718|2018-05-31 21:21:01.391718
NCT01606228|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2012-08-03||2012-09-19|2012-05-23|2012-05-25|Estimate|2012-09-19|2012-10-22|Estimate||||2012-09-19|2012-10-22|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia|An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly-Dosed Paliperidone ER Among Treatment-Naïve and Newly Diagnosed Patients With Schizophrenia|Completed||Phase 3|188|Actual|Janssen Pharmaceutica||1|||f||||f||||||||||2018-05-31 21:21:01.504971|2018-05-31 21:21:01.504971
NCT01606215|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-08-26|2012-05-23|2012-05-25|Estimate|||||||2016-08-26|2016-08-29|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|STREAMS||Stem Cells in Rapidly Evolving Active Multiple Sclerosis|Stem Cells in Rapidly Evolving Active Multiple Sclerosis|Completed||Phase 1/Phase 2|19|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 21:21:01.767848|2018-05-31 21:21:01.767848
NCT01606202|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2012-07-19||2012-08-28|2012-05-23|2012-05-25|Estimate|2012-08-28|2012-09-28|Estimate||||2012-08-28|2012-09-28|Estimate|July 2002||2002-07-31|August 2012|2012-08-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury|A Randomised, Double Blind, Placebo Controlled, Parallel Group Comparative Study of the Efficacy, Safety and Tolerability of Sublingual Cannabis Based Medicine Extracts and Placebo in Patients With Intractable Neuropathic Pain Associated With Spinal Cord Injury|Completed||Phase 3|116|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 21:21:01.850145|2018-05-31 21:21:01.850145
NCT01606189|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2012-07-12||2014-02-18|2012-05-24|2012-05-25|Estimate|2012-10-24|2012-11-19|Estimate||||2014-02-18|2014-03-17|Estimate|December 2001||2001-12-31|June 2013|2013-06-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain|A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury.|Completed||Phase 3|48|Actual|GW Pharmaceuticals Ltd.||3|||f||||f||||||||||2018-05-31 21:21:02.530578|2018-05-31 21:21:02.530578
NCT01606176|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2012-07-19||2012-08-28|2012-05-23|2012-05-25|Estimate|2012-07-19|2012-08-24|Estimate||||2012-08-28|2012-09-03|Estimate|March 2002||2002-03-31|August 2012|2012-08-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin|A Multi Centre Randomised, Double Blind, Placebo Controlled, Parallel Group Comparison of the Effects of Cannabis Based Medicine Standardised Extracts Over 4 Weeks, in Patients With Chronic Refractory Pain Due to Multiple Sclerosis or Other Defects of Neurological Function.|Completed||Phase 3|70|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 21:21:03.133742|2018-05-31 21:21:03.133742
NCT01606163|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-01-01|2012-05-24|2012-05-25|Estimate|||||||2014-01-01|2014-01-03|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose Escalation Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male Adults|Completed||Phase 1|36|Actual|Green Cross Corporation||4|||f||||f||||||||||2018-05-31 21:21:03.637115|2018-05-31 21:21:03.637115
NCT01606150|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2016-10-20||2016-10-20|2012-05-24|2012-05-25|Estimate|2016-10-20|2016-12-13|Estimate||||2016-10-20|2016-12-13|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain|Lumbar Punctures in Neonates: Improving Success Rates and Minimizing Pain|Terminated||N/A|5|Actual|Georgetown University|This study proved to be very difficult to execute in a busy NICU due to clinical practice biases and technical difficulties in establishing masked treatment. The Investigator left the Fellowship program before any results could be analyzed.|2||Investigator left the insititution|f||||t||||||||No|THERE IS NO DATA TO SHARE|2018-05-31 21:21:03.7068|2018-05-31 21:21:03.7068
NCT01606137|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2012-07-19||2013-06-13|2012-05-23|2012-05-25|Estimate|2012-07-19|2012-08-23|Estimate||||2013-06-13|2013-06-24|Estimate|February 2002||2002-02-28|June 2013|2013-06-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Study of the Long-term Safety of Sativex Use|A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.|Completed||Phase 3|507|Actual|GW Pharmaceuticals Ltd.||1|||f||||f||||||||||2018-05-31 21:21:03.865299|2018-05-31 21:21:03.865299
NCT01606124|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2017-08-28||2017-09-27|2012-05-24|2012-05-25|Estimate|2017-08-28|2017-09-28|Actual||||2017-09-27|2017-10-27|Actual|June 2012||2012-06-30|May 2017|2017-05-31|May 21, 2015|Actual|2015-05-21|May 21, 2015|Actual|2015-05-21||Interventional|||Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer|Randomized Phase II Trial of Polyphenon E vs.Placebo in Patients at High Risk of Recurrent Colonic Neoplasia|Terminated||Phase 2|39|Actual|Mayo Clinic||2||pending expiration of the supply of study agent.|f||||t||||||||||2018-05-31 21:21:04.487201|2018-05-31 21:21:04.487201
NCT01606111|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-02-09|2012-05-23|2012-05-25|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|CAPTAIN||The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery|A Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury|Unknown status|Active, not recruiting|Phase 4|800|Anticipated|Ever Neuro Pharma GmbH||2|||f||||t||||||||||2018-05-31 21:21:04.707453|2018-05-31 21:21:04.707453
NCT01606098|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2018-03-13|2012-05-24|2012-05-25|Estimate|||||||2018-03-13|2018-03-14|Actual|July 2012|Actual|2012-07-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|December 2018|Anticipated|2018-12-31||Interventional|CAIRO4||The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer|The Role of Surgery of the Primary Tumour With Few or Absent Symptoms in Patients With Synchronous Unresectable Metastases of Colorectal Cancer, a Randomized Phase III Study. A Study of the Dutch Colorectal Cancer Group (DCCG)|Recruiting||Phase 3|360|Anticipated|Dutch Colorectal Cancer Group||2|||f||||t||||||||Undecided||2018-05-31 21:21:04.851946|2018-05-31 21:21:04.851946
NCT01606085|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2014-04-22|2012-05-24|2012-05-25|Estimate|||||||2014-04-22|2014-04-24|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|QUALITYHF-DM||Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes|Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes|Completed||N/A|141|Actual|Emory University||2|||f||||f||||||||||2018-05-31 21:21:05.054921|2018-05-31 21:21:05.054921
NCT01606072|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2015-08-27|2012-05-23|2012-05-25|Estimate|||||||2015-08-27|2015-08-28|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||Perioperative Use of Desmopressin (DDAVP) in Breast Cancer|Perioperative Administration of Desmopressin to Subjects With Breast Cancer: A Phase IIa, Dose-Escalation Study|Completed||Phase 2|21|Actual|Laboratorio Elea S.A.C.I.F. y A.||1|||f||||f||||||||||2018-05-31 21:21:05.145329|2018-05-31 21:21:05.145329
NCT01606059|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-10-11|2012-05-23|2012-05-25|Estimate|||||||2016-10-11|2016-10-12|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|DW0919-1003||Phase 1 Study of DW-0919 & DW-0920 in Healthy Male Volunteers Under Fasting Condition|A Randomized, Open Label, 2-treatment, 2-sequence, Cross-over Study to Compare the Safety and Pharmacokinetics of DW-0919 and DW-0920 After Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:21:05.217546|2018-05-31 21:21:05.217546
NCT01606046|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-06-19|2012-05-24|2012-05-25|Estimate|||||||2012-06-19|2012-06-21|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Comparison of the Effects of Vapocoolant Spray and EMLA Cream on Pain During Needle Electromyography|Comparison of the Effects of Vapocoolant Spray and Topical Anesthetic Cream on Pain During Needle Electromyography: a Randomized Controlled Clinical Trial|Completed||Phase 4|99|Actual|The Catholic University of Korea||3|||f||||f||||||||||2018-05-31 21:21:05.287027|2018-05-31 21:21:05.287027
NCT01606033|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-07-27|2012-05-24|2012-05-25|Estimate|||||||2016-07-27|2016-07-28|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|IPSY||Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating|Psychological and Emotional Impacts of Participation in Oncologic Clinical Trials|Completed||N/A|125|Actual|Centre Oscar Lambret||4|||f||||f||||||||No||2018-05-31 21:21:05.360112|2018-05-31 21:21:05.360112
NCT01606020|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-08-21|2012-05-23|2012-05-25|Estimate|||||||2012-08-21|2012-08-22|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PrivSom||Sleep Deprivation : Effects on Driving Performance and Central Fatigue|Effects of Sleep Deprivation on Driving Performance and Central Fatigue|Completed||N/A|12|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 21:21:05.448109|2018-05-31 21:21:05.448109
NCT01606007|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2014-12-19||2017-03-29|2012-05-24|2012-05-25|Estimate|2015-09-22|2015-10-20|Estimate||||2017-03-29|2017-05-15|Actual|July 2012||2012-07-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy With Saxagliptin and Dapagliflozin Added to Metformin Compared to Add-On Therapy With Saxagliptin in Combination With Metformin or Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.|Completed||Phase 3|1282|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 21:21:05.555304|2018-05-31 21:21:05.555304
NCT01605994|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-06-26|2012-05-24|2012-05-25|Estimate|||||||2014-06-26|2014-06-27|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects|Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043|Completed||Phase 1|115|Actual|Bristol-Myers Squibb||11|||f||||f||||||||||2018-05-31 21:21:06.406237|2018-05-31 21:21:06.406237
NCT01605981|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-04-19|2012-05-24|2012-05-25|Estimate|||||||2017-04-19|2017-04-20|Actual|February 2014||2014-02-28|June 2014|2014-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|MACS1881||Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.|A Phase II, Non Randomized, Open Label, Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.|Withdrawn||Phase 4|0|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:21:06.518606|2018-05-31 21:21:06.518606
NCT01605968|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-07-12|2012-05-24|2012-05-25|Estimate|||||||2017-07-12|2017-07-14|Actual|June 2012||2012-06-30|July 2017|2017-07-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||A Comparative Efficacy and Safety Study Between Two Silver Containing Dressings In Post-Op Wound Healing|A Comparative Efficacy and Safety Study Between BCT Silver Bandage and Aquacel® Ag. Dressing In Obstetrical and Gynecological Post-Op Wound Healing|Terminated||N/A|38|Actual|Bio-medical Carbon Technology Co., Ltd.||2||The rate of subject recruitment is too slow.|f||||f||||||||||2018-05-31 21:21:06.612724|2018-05-31 21:21:06.612724
NCT01605955|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-05-23|2012-05-23|2012-05-25|Estimate|||||||2012-05-23|2012-05-25|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|||||Observational|||Fingertip Pulse Oximeter Clinical Test||Completed|||10|Actual|Andon Health Co., Ltd|||2||f||||||||||||||2018-05-31 21:21:06.693814|2018-05-31 21:21:06.693814
NCT01605942|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2015-06-11||2015-06-11|2012-05-23|2012-05-25|Estimate|2015-06-11|2015-07-01|Estimate||||2015-06-11|2015-07-01|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery||Terminated||Phase 1|8|Actual|Allergan||2||Study terminated due to corporate decision.|f||||f||||||||||2018-05-31 21:21:06.746928|2018-05-31 21:21:06.746928
NCT01605929|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-12-04|2012-05-23|2012-05-25|Estimate|||||||2015-12-04|2015-12-07|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Clinical Evaluation of the Ultrasound-Guided Retroclavicular Brachial Plexus Block|Clinical Evaluation of the Ultrasound-Guided Retroclavicular Brachial Plexus Block|Withdrawn||N/A|0|Actual|Brigham and Women's Hospital||1||withdrawn before IRB approval|f||||f||||||||||2018-05-31 21:21:07.059863|2018-05-31 21:21:07.059863
NCT01605916|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2016-04-06||2016-09-08|2012-05-24|2012-05-25|Estimate|2016-06-03|2016-07-14|Estimate||||2016-09-08|2016-10-21|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional||All subjects who received selumetinib were included into the baseline analysis population.|Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer|A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)|Completed||Phase 1|33|Actual|AstraZeneca||5|||f||||||||||||||2018-05-31 21:21:07.172289|2018-05-31 21:21:07.172289
NCT01605903|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2018-02-23||2018-03-25|2012-05-24|2012-05-25|Estimate|2018-02-23|2018-03-26|Estimate||||2018-03-25|2018-04-24|Actual|May 3, 2012|Actual|2012-05-03|March 2018|2018-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional||Race and Ethnicity not collected|Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy|Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy|Completed||Phase 2|741|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||Undecided||2018-05-31 21:21:08.274044|2018-05-31 21:21:08.274044
NCT01605890|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2016-07-11|2012-05-23|2012-05-25|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VIH-2||Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients|ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients|Completed||Phase 2|32|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 21:21:08.461718|2018-05-31 21:21:08.461718
NCT01605877|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|2015-05-08||2015-06-08|2012-05-23|2012-05-25|Estimate|2015-05-26|2015-06-09|Estimate||||2015-06-08|2015-07-07|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||This analysis population includes all implanted subjects.|AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0] in Japan|Clinical Investigation of AcrySof® IQ ReSTOR® Multifocal Intraocular Lens Model SN6AD2|Completed||N/A|70|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:21:08.568605|2018-05-31 21:21:08.568605
NCT01605864|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2014-03-20|2012-05-23|2012-05-25|Estimate|||||||2014-03-20|2014-03-24|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CAP||Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia|Ceftaroline Fosamil Versus Standard of Care for Community Acquired Bacterial Pneumonia (CABP): Clinical Outcomes Among Hospitalized Adults at a Single United States Hospital|Completed||Phase 3|12|Actual|Albany Medical College|||||f||||f||||||||||2018-05-31 21:21:09.601904|2018-05-31 21:21:09.601904
NCT01605851|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2014-04-22|2012-05-24|2012-05-25|Estimate|||||||2014-04-22|2014-04-24|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||GORE® Septal Occluder European Union Clinical Evaluation|GORE® Septal Occluder EU Clinical Evaluation: A Study to Evaluate Clinical Success and Performance in the Treatment of Transcatheter Closure of Patent Foramen Ovale (PFO)|Completed||N/A|150|Actual|W.L.Gore & Associates||1|||f||||f||||||||||2018-05-31 21:21:09.661549|2018-05-31 21:21:09.661549
NCT01605838|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2015-01-12|2012-05-23|2012-05-25|Estimate|||||||2015-01-12|2015-01-14|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|June 2013|Anticipated|2013-06-30||Observational|REG01||Noninvasive Monitoring of Cerebral Blood Flow Autoregulation in Patients With Traumatic Brain Injury (TBI)|Pilot (Feasibility) Study of New Portable Monitor for Continuous Assessment of Cerebral Blood Flow (CBF) Autoregulation in Patients With Moderate to Severe Traumatic Brain Injury (TBI)|Withdrawn|||0|Actual|Advanced Brain Monitoring, Inc.||||A series of administrative delays on all sides involved, combined with funding problems.|f||||f||||||||||2018-05-31 21:21:09.78632|2018-05-31 21:21:09.78632
NCT01605825|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2014-01-28||2015-12-18|2012-05-23|2012-05-25|Estimate|2014-01-28|2014-03-10|Estimate||||2015-12-18|2016-01-22|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||Safety Population: The Safety Population consists of all randomized subjects who took at least one dose of investigational product.|A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke|A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke|Completed||Phase 2|83|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-05-31 21:21:09.866803|2018-05-31 21:21:09.866803
NCT01605812|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2015-01-07|2012-05-24|2012-05-25|Estimate|||||||2015-01-07|2015-01-09|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|||Evaluate Capsular Apposition to Intraocular Lens|Phase 1 Evaluate Capsular Apposition to Intraocular Lens in Subjects With High Myopia by Ultra-long Scan Depth Optical Coherence Tomography; Phase 2 Evaluate Capsular Apposition to Different Types of Intraocular Lens in Subjects|Unknown status|Recruiting||150|Anticipated|Wenzhou Medical University|||2||f||||t||||||||||2018-05-31 21:21:10.248069|2018-05-31 21:21:10.248069
NCT01605799|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|2015-11-13||2016-01-22|2012-05-24|2012-05-25|Estimate|2015-11-13|2015-12-17|Estimate||||2016-01-22|2016-02-23|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||IOK Treatment Study|A Novel PTSD Treatment for Veterans Who Killed in War|Completed||Phase 2|33|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 21:21:10.325614|2018-05-31 21:21:10.325614
NCT01605786|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-05-22|2012-05-22|2012-05-25|Estimate|||||||2012-05-22|2012-05-25|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|PEBS-POC1||Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)|Phase I and IIa Trial for Assessment of Safety, Immunogenicity (Phase Ia) and Efficacy (Phase IIa) Against Sporozoite Challenge of P. Falciparum Pre-Erythrocytic and Blood Stage (PfPEBS-LSP) Malaria Vaccine Candidate|Unknown status|Recruiting|Phase 1/Phase 2|36|Anticipated|Vac4All||3|||f||||t||||||||||2018-05-31 21:21:10.584369|2018-05-31 21:21:10.584369
NCT01605773|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-02-17|2012-05-24|2012-05-25|Estimate|||||||2017-02-17|2017-02-20|Actual|November 8, 2001||2001-11-08|February 2017|2017-02-28|March 13, 2003|Actual|2003-03-13|March 13, 2003|Actual|2003-03-13||Interventional|||Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes|Repaglinide Versus Glyburide: Comparitive Effect on Postprandial Lipemia: An Open-labeled, Randomized, Parallel Group Study in Patients With Type 2 Diabetes|Completed||Phase 4|51|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:21:10.710036|2018-05-31 21:21:10.710036
NCT01605760|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-21|2012-05-21|2012-05-25|Estimate|||||||2012-05-21|2012-05-25|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||House Dust Mite SLIT in Elderly Patients|House Dust Mite Sublingual Immunotherapy: a Double-blind, Placebo Control Study in Elderly Patients.|Completed||Phase 4|111|Actual|Medical University of Silesia||2|||f||||t||||||||||2018-05-31 21:21:10.774649|2018-05-31 21:21:10.774649
NCT01605747|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-11-12|2012-05-23|2012-05-25|Estimate|||||||2013-11-12|2013-11-13|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|January 2013|Actual|2013-01-31||Interventional|||Study of Culturelle in the Prophylaxis of Infection and Diarrhea|A Blinded Placebo Controlled Clinical Outcomes Study of Culturelle® in the Prophylaxis of Infection and Diarrhea|Terminated||Phase 2|20|Actual|Shriners Hospitals for Children||2||Study was stopped due to inavailability of subjects meeting eligibility criteria.|f||||||||||||||2018-05-31 21:21:10.838566|2018-05-31 21:21:10.838566
NCT01605734|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-05-21|2012-05-21|2012-05-25|Estimate|||||||2012-05-21|2012-05-25|Estimate|July 2012||2012-07-31|May 2012|2012-05-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma|Phase II Trail of TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 2|120|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||t||||||||||2018-05-31 21:21:10.899609|2018-05-31 21:21:10.899609
NCT01605721|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-05-21|2012-05-21|2012-05-25|Estimate|||||||2012-05-21|2012-05-25|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|April 2015|Anticipated|2015-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Efficacy and Safety of Xience in Coronary arEry Disease aLL-comers After stENTing Using the PRIME Platform (EXCELLENT-PRIME Registry)||Unknown status|Recruiting|Phase 4|2000|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 21:21:10.997256|2018-05-31 21:21:10.997256
NCT01604499|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-10-02|2012-05-22|2012-05-23|Estimate|||||||2015-10-02|2015-10-06|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Building on a Point-of-purchase Intervention to Encourage Healthy Food Choices|Building on a Point-of-purchase Intervention to Encourage Healthy Food Choices|Completed||N/A|2672|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 21:21:31.80722|2018-05-31 21:21:31.80722
NCT01605708|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12||2013-09-27|2013-09-27|2012-05-23|2012-05-25|Estimate||||2013-09-27|2013-10-28|Estimate|2013-09-27|2013-10-28|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis|Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Dose Study of the Clinical Activity, Safety, Tolerability and Pharmacokinetics of a Single IV Dose of REGN846 in Refractory Moderate-to-Severe Pruritus in Adult Patients With Moderate-to-Severe Atopic Dermatitis|Terminated||Phase 1/Phase 2|19|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:21:11.08115|2018-05-31 21:21:11.08115
NCT01605695|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2013-11-23|2012-05-21|2012-05-25|Estimate|||||||2013-11-23|2013-11-26|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Observational|||Normal Human Plasma Level of iNOS Study|Determination of the Normal Human Plasma Level of Inducible Nitric Oxide Synthase (iNOS) Using the PliNOSa Test|Completed|||100|Actual|Research & Diagnostic Antibodies|||1||f||||f||||||Samples Without DNA|"~     heparinized plasma samples~   "|||2018-05-31 21:21:11.35835|2018-05-31 21:21:11.35835
NCT01605682|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-21|2012-05-21|2012-05-25|Estimate|||||||2012-05-21|2012-05-25|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Multi Dose Effects of a Berry Extract Upon Moodand Cognition in Healthy Young Adults|Multi Dose Effects of a Berry Extract Upon Mood, Attention and Memory in Healthy Young Adults.|Completed||N/A|36|Actual|Northumbria University||4|||f||||f||||||||||2018-05-31 21:21:11.436144|2018-05-31 21:21:11.436144
NCT01605669|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2013-05-17||2016-08-17|2012-05-21|2012-05-25|Estimate|2013-11-01|2013-11-05|Estimate||||2016-08-17|2016-09-23|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|Cassette||Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography|Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography|Completed|||50|Actual|United States Naval Medical Center, San Diego|Patients with significant concomitant valvular disease were not evaluated. The software does not provide immediate feedback on the severity of the stenosis. Multiple early recordings had artifact noise rquiring modificaiton of recording techniques.||1||f||||f||||||||No||2018-05-31 21:21:11.525293|2018-05-31 21:21:11.525293
NCT01605656|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-03-28|2012-05-21|2012-05-25|Estimate|||||||2016-03-28|2016-03-29|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women|A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women|Completed|||188|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 21:21:11.7|2018-05-31 21:21:11.7
NCT01605643|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-12-15|2012-05-23|2012-05-25|Estimate|||||||2017-12-15|2017-12-19|Actual|March 2012|Actual|2012-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Observational|MAW||Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women: Phase 1|Completed|||150|Actual|Mayo Clinic|||||f||||t||||||Samples With DNA|"~     urine and serum specimen samples collected from mother and infant pairs~   "|||2018-05-31 21:21:11.775666|2018-05-31 21:21:11.775666
NCT01605630|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-12-15|2012-05-21|2012-05-25|Estimate|||||||2017-12-15|2017-12-19|Actual|March 2012||2012-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|July 2016|Actual|2016-07-31||Interventional|||Family Cancer Literacy to Promote Mammography Screening Among Navajo Women|Family Cancer Literacy to Promote Mammography Screening Among Navajo Women|Completed||Phase 1|40|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:21:11.84313|2018-05-31 21:21:11.84313
NCT01605617|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2013-09-24||2013-12-16|2012-05-21|2012-05-25|Estimate|2013-12-16|2014-02-05|Estimate||||2013-12-16|2014-02-05|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate|Prospective Randomized Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate|Terminated||Phase 4|4|Actual|Mayo Clinic|The study was terminated due to a low recruitment rate prior to subjects completing treatment.|2||Low recruitment rate, and study patients were removed prior to completion|f||||f||||||||||2018-05-31 21:21:11.982562|2018-05-31 21:21:11.982562
NCT01605604|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-07-26|2012-05-21|2012-05-25|Estimate|||||||2012-07-26|2012-07-27|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Effectiveness of Buddhist Intergrated Group Intervention on Minefulness in Adolescents|Department of Orthopedic Surgery, Faculty of Medicine Siriraj Hospital|Completed||N/A|40|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 21:21:12.263623|2018-05-31 21:21:12.263623
NCT01605591|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2014-09-04|2012-05-21|2012-05-25|Estimate|||||||2014-09-04|2014-09-08|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Different Bending Mode for Double-lumen Endotracheal Tube Intubation|Comparison of Different Bending Mode for Double-lumen Endotracheal Tube Intubation|Completed||N/A|66|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:21:12.330168|2018-05-31 21:21:12.330168
NCT01605578|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-05-21|2012-05-21|2012-05-25|Estimate|||||||2012-05-21|2012-05-25|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2014|Anticipated|2014-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Description of Abdominal and Gluteo-femoral Subcutaneous Adipose Tissue Cell Population in Women - GLUTAB|Description Des Populations Cellulaires Des Tissus Adipeux Sous-cutanés Abdominaux et glutéo-fémoraux Chez la Femme.|Unknown status|Recruiting|N/A|20|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||||||||||||2018-05-31 21:21:12.426699|2018-05-31 21:21:12.426699
NCT01605565|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-05-21|2012-05-21|2012-05-25|Estimate|||||||2012-05-21|2012-05-25|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Functional Analysis by Dynamic Imaging of the Respiratory Epithelium in Infants With Cystic Fibrosis|Analyse Fonctionnelle Par Imagerie Dynamique de l'épithélium Respiratoire Chez Des Nourrissons Atteints de Mucoviscidose|Unknown status|Recruiting|N/A|30|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 21:21:12.496638|2018-05-31 21:21:12.496638
NCT01605552|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2016-01-27||2016-03-23|2012-05-21|2012-05-25|Estimate|2016-01-27|2016-02-24|Estimate||||2016-03-23|2016-04-21|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BtB-Heart||Beating the Blues for Your Heart|Computer-Based Depression Treatment to Reduce Coronary Artery Disease Risk|Completed||Phase 2|29|Actual|Indiana University|"Missing data precluded analysis of one secondary outcome variables: Tumor Necrosis Factor-Alpha (TNF-a).~Due to the very small sample of randomized patients, conclusions should not be drawn from the results of this pilot trial."|2|||f||||t||||||||||2018-05-31 21:21:12.585298|2018-05-31 21:21:12.585298
NCT01605539|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2015-09-28||2016-10-05|2012-05-21|2012-05-25|Estimate|2016-10-05|2016-11-28|Estimate||||2016-10-05|2016-11-28|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans|Cannabidiol as Treatment Intervention for Opioid Relapse|Completed||Phase 2|10|Actual|Hurd,Yasmin, Ph.D.||3|||f||||t||||||||||2018-05-31 21:21:12.850811|2018-05-31 21:21:12.850811
NCT01605526|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2016-11-01|2012-05-21|2012-05-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma|A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma|Completed||Phase 1|23|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:21:13.322367|2018-05-31 21:21:13.322367
NCT01605513|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2016-01-23|2012-05-23|2012-05-25|Estimate|||||||2016-01-23|2016-01-26|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PEG-IFN-SA||Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease|Phase I Clinical Trial of PEG-IFN-SA in HCV Disease: Evidence for Drug Safety, Tolerance, and Antiviral Activity|Completed||Phase 1/Phase 2|80|Actual|First Hospital of Jilin University||1|||f||||t||||||||||2018-05-31 21:21:13.390486|2018-05-31 21:21:13.390486
NCT01605500|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-02-18|2012-05-21|2012-05-25|Estimate|||||||2016-02-18|2016-02-19|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Utility of the Audible Alert in Current Generation Medtronic Implantable Cardioverter-defibrillators|Investigation of the Utility of the Audible Alert in Current Generation Medtronic ICDs|Completed|||100|Actual|Englewood Hospital and Medical Center|||1||f||||f||||||||||2018-05-31 21:21:13.451455|2018-05-31 21:21:13.451455
NCT01605487|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2014-10-14|2012-05-21|2012-05-25|Estimate|||||||2014-10-14|2014-10-15|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Interventional|PAFCUTIII||Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria|Double-blind, Three-way Cross-over, Placebo-controlled Study to Assess the Efficacy, Safety and Mechanisms of Treatment With Rupatadine 20 mg and 40 mg in Cold Contact Urticaria (CCU)|Completed||Phase 2|24|Actual|Charite University, Berlin, Germany||6|||f||||f||||||||||2018-05-31 21:21:13.503446|2018-05-31 21:21:13.503446
NCT01605474|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-05-23|2012-05-23|2012-05-25|Estimate|||||||2012-05-23|2012-05-25|Estimate|April 2012||2012-04-30|May 2012|2012-05-31||||July 2014|Anticipated|2014-07-31||Interventional|||Patient Satisfaction of Cervical Ripening in an Outpatient Setting|Safety, Efficacy, and Patient Satisfaction of Cervical Ripening With Transcervical Use of the Foley Catheter in an Outpatient Setting|Unknown status|Recruiting|N/A|800|Anticipated|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 21:21:13.567176|2018-05-31 21:21:13.567176
NCT01605461|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2016-01-21||2016-02-22|2012-05-21|2012-05-25|Estimate|2016-02-22|2016-03-21|Estimate||||2016-02-22|2016-03-21|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Treated set which included all subjects who were dispensed study medication and were documented to have taken the dose of investigational treatment|Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers|Metabolite Profile, Excretion Balance and Pharmacokinetics of BI 207127 NA Combined With [14C]-BI 207127 NA in Healthy Adult Male Volunteers After an 800 mg Single Oral Solution Dose; a Phase I, Single-arm, Open-label Trial|Completed||Phase 1|12|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 21:21:13.644133|2018-05-31 21:21:13.644133
NCT01605448|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2012-05-21|2012-05-21|2012-05-24|Estimate|||||||2012-05-21|2012-05-24|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment|Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment|Completed||N/A|14|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 21:21:13.951976|2018-05-31 21:21:13.951976
NCT01605435|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-01-15|2012-05-23|2012-05-24|Estimate|||||||2013-01-15|2013-01-16|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Ghrelin Dose Finding In Frail Elderly|Ghrelin In Frail Elderly Subcutaneous Dose Finding Study|Completed||Phase 2|6|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 21:21:14.027131|2018-05-31 21:21:14.027131
NCT01605422|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2015-05-26|2012-05-22|2012-05-24|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|September 2013|Actual|2013-09-30||Observational|||Meta-analyses of the Effect of Dietary Pulses on Acute Postprandial Metabolic Control|Effect of Dietary Pulses on Acute Postprandial Glycemia and Food Intake Regulation: A Systematic Review and Meta-analyses|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 21:21:14.126306|2018-05-31 21:21:14.126306
NCT01605409|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2018-03-23|2012-05-23|2012-05-24|Estimate|||||||2018-03-23|2018-03-26|Estimate|November 2014||2014-11-30|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|ECPB4OHCA||Emergency Cardiopulmonary Bypass for Cardiac Arrest|Emergency Cardiopulmonary Bypass After Cardiac Arrest With Ongoing Cardiopulmonary Resuscitation - a Pilot Randomized Trial|Recruiting||N/A|40|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:21:14.250513|2018-05-31 21:21:14.250513
NCT01605396|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2018-04-18|2012-05-22|2012-05-24|Estimate|||||||2018-04-18|2018-04-19|Actual|July 4, 2012|Actual|2012-07-04|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|February 19, 2014|Actual|2014-02-19||Interventional|||A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)|A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients|Terminated||Phase 2|80|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:21:14.356392|2018-05-31 21:21:14.356392
NCT01605383|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2017-07-07|2012-05-23|2012-05-24|Estimate|||||||2017-07-07|2017-07-11|Actual|July 2012||2012-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head|"A Pilot Clinical Trial of ex Vivo Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue (XCEL-MT-OSTEO- ALPHA) in Osteonecrosis of the Femoral Head"|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Banc de Sang i Teixits||2|||f||||f||||||||||2018-05-31 21:21:14.484181|2018-05-31 21:21:14.484181
NCT01604876|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2016-10-05|2012-05-23|2012-05-24|Estimate|||||||2016-10-05|2016-10-06|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|LightPD||Effect of Bright Light on Mood and Sleep in Parkinson's Disease|Effect of Bright Light on Mood and Sleep in Parkinson's Disease|Active, not recruiting||N/A|83|Actual|VU University Medical Center||2|||f||||f||||||||Undecided|Data may be shared on reasonable request|2018-05-31 21:21:28.486834|2018-05-31 21:21:28.486834
NCT01605370|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|2014-04-04||2014-05-08|2012-05-23|2012-05-24|Estimate|2014-04-04|2014-05-07|Estimate||||2014-05-08|2014-05-19|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Inapprop|The study was terminated early due to the difficulty in identifying subjects satisfying the inclusion criteria. Only 1 subject was enrolled.|Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?|Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?|Terminated||Phase 4|1|Actual|Mayo Clinic|The study was terminated early due to the difficulty in identifying subjects satisfying the inclusion criteria. Only 1 subject was enrolled.|2||Difficulty in identifying subjects satisfying the inclusion criteria.|f||||f||||||||||2018-05-31 21:21:14.564305|2018-05-31 21:21:14.564305
NCT01605357|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2016-12-09|2012-05-23|2012-05-24|Estimate|||||||2016-12-09|2016-12-12|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|||Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury|A Randomized, Open Label Clinical Trial of Sustained Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury|Withdrawn||Phase 1/Phase 2|0|Actual|Massachusetts General Hospital||2||Never started.|f||||t||||||||||2018-05-31 21:21:14.8203|2018-05-31 21:21:14.8203
NCT01605344|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-02-26|2012-05-23|2012-05-24|Estimate|||||||2014-02-26|2014-02-27|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI|A Prospective, Randomized, Crossover Evaluation of the Effect of Atorvastatin on the Pharmacokinetics of Irinotecan in Colorectal Cancer Patients Receiving FOLFIRI|Withdrawn||Phase 1|0|Actual|UNC Lineberger Comprehensive Cancer Center||2||Study was withdrawn due to lack of patient enrollment.|f||||t||||||||||2018-05-31 21:21:14.891782|2018-05-31 21:21:14.891782
NCT01605331|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-10-03|2012-05-23|2012-05-24|Estimate|||||||2012-10-03|2012-10-05|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)||Completed||Phase 4|132|Actual|LG Life Sciences||1|||f||||||||||||||2018-05-31 21:21:14.974363|2018-05-31 21:21:14.974363
NCT01605318|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2016-03-18|2012-05-23|2012-05-24|Estimate|||||||2016-03-18|2016-03-21|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer|A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14-SN38, Antibody-Drug Conjugate) in Patients With Colorectal Cancer.|Unknown status|Recruiting|Phase 1/Phase 2|104|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 21:21:15.041817|2018-05-31 21:21:15.041817
NCT01605305|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-05-23|2012-05-23|2012-05-24|Estimate|||||||2012-05-23|2012-05-24|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer|Phase II Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer|Completed||Phase 2|60|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 21:21:15.159284|2018-05-31 21:21:15.159284
NCT01605292|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2014-12-29||2015-02-25|2012-05-22|2012-05-24|Estimate|2015-02-25|2015-02-26|Estimate||||2015-02-25|2015-02-26|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|RAUST||Radial Artery Access With Ultrasound Trial|Radial Artery Access With Ultrasound Trial|Completed||N/A|698|Actual|University of California, Irvine|Blinding was not possible in this study. We cannot exclude a bias in the performance, measurement, or recording of the procedure or clinical data. Time to prepare the US probe was not included in the time to access.|2|||f||||f||||||||||2018-05-31 21:21:15.225495|2018-05-31 21:21:15.225495
NCT01605279|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2015-03-06|2012-05-23|2012-05-24|Estimate|||||||2015-03-06|2015-03-09|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Dobutamine Versus Placebo for Low Superior Vena Cava Flow in Newborns|Randomised Double Blind Clinical Trial of Dobutamine Versus Placebo for Low Superior Vena Cava Flow Treatment in Low Birth Weight Infants: Systematic Assessment of Cerebral and Systemic Hemodynamics Effects|Completed||Phase 2|127|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||2|||f||||t||||||||||2018-05-31 21:21:15.700801|2018-05-31 21:21:15.700801
NCT01605266|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-11-06|2012-05-22|2012-05-24|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2011||2011-01-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|INSIGHT||INSIGHT (Insight Into Nephrotic Syndrome)|INSIGHT (Insight Into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics)|Recruiting|||1000|Anticipated|The Hospital for Sick Children|||1||f||||f||||||Samples With DNA|"~     Blood is drawn for DNA, serum, plasma, buffy coat and whole blood. Urine and toenail~     clippings are also collected.~   "|No||2018-05-31 21:21:15.777398|2018-05-31 21:21:15.777398
NCT01605253|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2016-04-14|2012-05-22|2012-05-24|Estimate|||||||2016-04-14|2016-04-15|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Eszopiclone for the Treatment of Posttraumatic Stress Disorder|Eszopiclone for the Treatment of PTSD|Completed||Phase 4|81|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 21:21:15.864229|2018-05-31 21:21:15.864229
NCT01605240|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-07-24|2012-05-23|2012-05-24|Estimate|||||||2013-07-24|2013-07-25|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|August 2014|Anticipated|2014-08-31|December 2013|Anticipated|2013-12-31||Interventional|||Ibuprofen Versus Codeine. Is One Better for Post-operative Pain Relief Following Reduction of Paediatric Forearm Fractures?|Ibuprofen vs. Codeine. Is One Better for Post-operative Pain Relief Following Reduction of Paediatric Forearm Fractures?|Unknown status|Recruiting|N/A|50|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 21:21:15.945659|2018-05-31 21:21:15.945659
NCT01605227|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|2017-05-23||2018-02-14|2012-05-23|2012-05-24|Estimate|2018-02-14|2018-03-14|Actual||||2018-02-14|2018-03-14|Actual|July 2012||2012-07-31|February 2018|2018-02-28|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|COMET-1||Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100|A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100|Completed||Phase 3|1028|Actual|Exelixis||2|||f||||t||||||||||2018-05-31 21:21:16.08421|2018-05-31 21:21:16.08421
NCT01605214|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2018-01-17|2012-05-23|2012-05-24|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2015||2015-10-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung Transplant|Measurement of Extravascular Lung Water to Detect and Predict Primary Graft Dysfunction Following Lung Transplant|Recruiting|||60|Anticipated|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 21:21:19.779637|2018-05-31 21:21:19.779637
NCT01605201|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2018-01-02|2012-05-23|2012-05-24|Estimate|||||||2018-01-02|2018-01-03|Actual|May 2012||2012-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Interventional|Nose2Knee||Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage|Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage in the Knee After Traumatic Injury - a Phase I Clinical Trial-|Active, not recruiting||Phase 1|18|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 21:21:20.074039|2018-05-31 21:21:20.074039
NCT01605188|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2016-01-27|2012-05-23|2012-05-24|Estimate|||||||2016-01-27|2016-01-28|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Predictors of Non-response and Loss of Response in IBD Patients Treated With Anti-TNF|Predictors of Non-response and Loss of Response in IBD Patients Treated With Anti-TNF.|Completed|||132|Actual|Evangelismos Hospital|||||f||||t||||||Samples With DNA|"~     Whole blood Serum Bowel mucosal tissue~   "|||2018-05-31 21:21:20.335018|2018-05-31 21:21:20.335018
NCT01605175|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2015-11-15|2012-05-22|2012-05-24|Estimate|||||||2015-11-15|2015-11-17|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Predictors of Mucosal Healing in Inflammatory Bowel Disease (IBD) Patients Treated With Anti-TNF|Predictors of Tissue Healing in Inflammatory Bowel Disease Patients Treated With Anti-TNF|Completed|||21|Actual|Evangelismos Hospital|||||f||||t||||||Samples With DNA|"~     Whole blood Serum Bowel mucosal tissue~   "|||2018-05-31 21:21:20.555777|2018-05-31 21:21:20.555777
NCT01605162|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22||2016-06-22|2016-07-25|2012-05-23|2012-05-24|Estimate||||2016-06-22|2016-06-27|Estimate|2016-07-25|2016-07-28|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma|Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma|Terminated||Phase 2|8|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 21:21:20.81067|2018-05-31 21:21:20.81067
NCT01605149|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-03-25|2012-05-23|2012-05-24|Estimate|||||||2014-03-25|2014-03-27|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Type 1 Diabetes Mellitus Bone Mineral Density in Childhood and Adolescence|Type 1 DM Bone Mineral Density in Childhood and Adolescence|Completed|||60|Actual|Creighton University|||1||f||||f||||||||||2018-05-31 21:21:21.056439|2018-05-31 21:21:21.056439
NCT01605136|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-03-21|2012-05-22|2012-05-24|Estimate|||||||2013-03-21|2013-03-22|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Phase III Confirmatory Study in Erythropoietic Protoporphyria|A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)|Unknown status|Active, not recruiting|Phase 3|93|Actual|Clinuvel Pharmaceuticals Limited||2|||f||||t||||||||||2018-05-31 21:21:21.213784|2018-05-31 21:21:21.213784
NCT01605123|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2017-02-24|2012-05-23|2012-05-24|Estimate|||||||2017-02-24|2017-02-28|Actual|April 2007|Actual|2007-04-30|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Longitudinal Assessment of Cardiovascular and Metabolic Parameters in Obese and Lean Children|Leipzig Artherobesity Childhood Cohort|Recruiting|||200|Anticipated|University of Leipzig|||4||f||||f||||||Samples With DNA|"~     Serum samples, samples from oral glucose tolerance tests (oGTT), EDTA/DNA samples, primary~     cells (endothelial progenitor cells), peripheral blood mononuclear cells), urine~   "|No||2018-05-31 21:21:21.84772|2018-05-31 21:21:21.84772
NCT01605110|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2012-12-03|2012-05-22|2012-05-24|Estimate|||||||2012-12-03|2012-12-05|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|BLEPH||Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing|Effects of HBOT for Edema/Ecchymosis After Upper Eyelid Blepharoplasty (Single Site Study)|Unknown status|Enrolling by invitation|N/A|164|Anticipated|Restorix Research Institute, LLLP||2|||f||||t||||||||||2018-05-31 21:21:22.152655|2018-05-31 21:21:22.152655
NCT01605097|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2016-02-19|2012-05-23|2012-05-24|Estimate|||||||2016-02-19|2016-02-22|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2013|Actual|2013-12-31||Interventional|Dosepainting||High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule|High Dose Rate Prostate (HDR) Brachytherapy Dose Escalation to Dominant Intra-prostatic Nodule for Patients With Intermediate and High Risk Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|15|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 21:21:22.434797|2018-05-31 21:21:22.434797
NCT01605084|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-12-03|2012-05-23|2012-05-24|Estimate|||||||2012-12-03|2012-12-04|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|SUPPRESS||Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone|An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone|Withdrawn||Phase 3|0|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 21:21:22.76226|2018-05-31 21:21:22.76226
NCT01605071|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2017-03-31|2012-05-23|2012-05-24|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2011||2011-09-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|November 2015|Actual|2015-11-30||Interventional|TEMPUS||Timing Estrogen After MenoPaUSe|Time Past Menopause, Duration of Estrogen Deficiency, and Insulin Action|Completed||N/A|55|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 21:21:23.079065|2018-05-31 21:21:23.079065
NCT01605058|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-05-25|2012-05-23|2012-05-24|Estimate|||||||2012-05-25|2012-05-30|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Observational|||Visual Performance With a Trifocal Intraocular Lens|Visual Performance Adn Quality of Vision Evaluation After Implantation of a Trifocal Intraocular Lens|Unknown status|Not yet recruiting||30|Anticipated|BMI Southend Hospital|||||f||||t||||||||||2018-05-31 21:21:23.423325|2018-05-31 21:21:23.423325
NCT01605045|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-10-11|2012-05-22|2012-05-24|Estimate|||||||2012-10-11|2012-10-15|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Screening for Coronary Artery Disease Using Fluoroscopy During Coronary Angiography|Efficacy of Fluoroscopy-save Function During Cardiac Catheterization|Completed||Phase 4|50|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 21:21:23.639864|2018-05-31 21:21:23.639864
NCT01604707|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2016-10-03|2012-05-21|2012-05-24|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Medical Yoga for Patients With Stress-related Symptoms and Diagnoses|Medical Yoga for Patients With Stress-related Symptoms and Diagnoses in Primary Health Care - a Randomized Controlled Trial|Completed||N/A|44|Actual|Region Örebro County||2|||f||||f||||||||No||2018-05-31 21:21:30.544802|2018-05-31 21:21:30.544802
NCT01605032|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-01-11|2012-05-22|2012-05-24|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2012||2012-02-29|January 2016|2016-01-31||||January 2017|Anticipated|2017-01-31||Interventional|||Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase II Study Assessing the Efficacy and Toxicity of PK--directed Intravenous Busulfan in Combination With High--Dose Melphalan and Bortezomib as Conditioning Regimen for First--Line Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma|Unknown status|Active, not recruiting|Phase 2|42|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 21:21:23.93581|2018-05-31 21:21:23.93581
NCT01605019|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-04-06|2012-05-23|2012-05-24|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery|A Multi-Center Clinical Pilot-Study to Evaluate the Performance of CoSeal in Reducing Post-Op Bleeding, Air Micro Emboli, and Cardiac Tissue Adhesions in Patients With Left Ventricular Assist Devices (LVADs)|Terminated||N/A|4|Actual|The Methodist Hospital System||2||funding for study stopped|f||||f||||||||||2018-05-31 21:21:24.269653|2018-05-31 21:21:24.269653
NCT01605006|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2016-04-12|2012-05-23|2012-05-24|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis|HDE Post-Approval Study (PAS) of NeuRx DPS for ALS|Unknown status|Active, not recruiting|N/A|97|Actual|Synapse Biomedical||1|||f||||f||||||||||2018-05-31 21:21:24.627544|2018-05-31 21:21:24.627544
NCT01604993|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-03-07|2012-05-22|2012-05-24|Estimate|||||||2014-03-07|2014-03-10|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|DNAB||Acute Effect of Nitrate From Natural Dietary Sources on Arterial Stiffness and Blood Pressures in Healthy Individuals|Acute Effect of Nitrate Supplementation From Natural Dietary Sources on Arterial Stiffness and Aortic and Brachial Blood Pressures: a Double-blind, Placebo-controlled, Randomized, Crossover Clinical Trial in Healthy Adults|Completed||Phase 2|31|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:21:24.811686|2018-05-31 21:21:24.811686
NCT01604980|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2018-01-05|2012-05-23|2012-05-24|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Determination of Protein Requirements in Elderly Female Subjects >75 Yrs Old|Use of Indicator Amino Acid Oxidation Technique to Determine Protein Requirement of Elderly Female Subjects >75 Years Old|Completed||N/A|14|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 21:21:24.922001|2018-05-31 21:21:24.922001
NCT01604967|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-05-11|2012-05-23|2012-05-24|Estimate|||||||2015-05-11|2015-05-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:21:26.630525|2018-05-31 21:21:26.630525
NCT01604954|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-08-31|2012-05-22|2012-05-24|Estimate|||||||2015-08-31|2015-09-01|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|May 2013|Actual|2013-05-31||Interventional|MENU||Does Food Labeling Influence Long-term Food Intake and Eating-related Variables in Women?|Does Food Labeling Influence Long-term Food Intake and Eating-related Variables in Women?|Completed||N/A|160|Actual|Laval University||2|||f||||f||||||||||2018-05-31 21:21:26.848688|2018-05-31 21:21:26.848688
NCT01604941|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|2015-06-04||2015-07-22|2012-05-23|2012-05-24|Estimate|2015-07-22|2015-08-17|Estimate||||2015-07-22|2015-08-17|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Safety Set, defined as all participants who had taken at least 1 BID dose of investigational product.|Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy|A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy|Terminated||Phase 2|32|Actual|Shire|This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.|1||"This study was terminated due to treatment stop resulting in an inability to draw conclusions~   from the data. Evaluation of nonclinical rat findings is ongoing."|f||||t||||||||||2018-05-31 21:21:27.224776|2018-05-31 21:21:27.224776
NCT01604928|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2017-02-14|2012-05-22|2012-05-24|Estimate|||||||2017-02-14|2017-02-16|Actual|April 2004||2004-04-30|February 2017|2017-02-28|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|Blossom||Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder|A Randomized, Double-blind, Parallel Group, Proof of Concept Study of YM178 in Comparison With Placebo and Tolterodine in Patients With Symptomatic Overactive Bladder|Completed||Phase 2|260|Actual|Astellas Pharma Inc||4|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 21:21:28.088535|2018-05-31 21:21:28.088535
NCT01604915|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2013-07-05|2012-05-23|2012-05-24|Estimate|||||||2013-07-05|2013-07-09|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Comparison of Dexamethasone Added to Ropivacaine and Ropivacaine Alone in Caudal Analgesia in Children Undergoing Orchiopexy|Comparison of Analgesic Effect of Dexamethasone Added to Ropivacaine and Ropivacaine Alone in Caudal Analgesia on Postoperative Pain Control in Pediatric Patients Undergoing Orchiopexy|Completed||N/A|80|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:21:28.229108|2018-05-31 21:21:28.229108
NCT01604902|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-08-22|2012-05-23|2012-05-24|Estimate|||||||2014-08-22|2014-08-25|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|January 2016|Anticipated|2016-01-31|March 2015|Anticipated|2015-03-31||Observational|||miRNAs and mRNAs in Psoriasis|miRNAs and mRNAs in Psoriasis During Treatment With Biological Drugs.|Unknown status|Recruiting||10|Anticipated|University of Aarhus|||1||f||||t||||||Samples With DNA|"~     tissue: 4mm skin pinch biopsies for mRNA and miRNA extration.~   "|||2018-05-31 21:21:28.307248|2018-05-31 21:21:28.307248
NCT01604889|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09||2017-05-02|2018-01-15|2012-05-22|2012-05-24|Estimate||||2014-12-23|2015-01-09|Estimate|2018-01-15|2018-01-17|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|December 27, 2016|Actual|2016-12-27|December 27, 2016|Actual|2016-12-27||Interventional|||A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma|A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma|Terminated||Phase 1/Phase 2|136|Actual|Incyte Corporation||5||"Further development of this compound with ipilimumab in the treatment of melanoma is no longer~   being pursued."|f||||f||||||||||2018-05-31 21:21:28.391656|2018-05-31 21:21:28.391656
NCT01604863|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-10-29|2012-05-22|2012-05-24|Estimate|||||||2012-10-29|2012-11-01|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies|Multi-Center, Open-Label Phase 1B Study to Evaluate the Safety and Tolerability of HGS1036 in Combination With Paclitaxel and Carboplatin, Cisplatin and Etoposide, or Docetaxel in Subjects With Advanced Solid Malignancies|Suspended||Phase 1|54|Anticipated|GlaxoSmithKline||3||Study suspended prior to enrollment|f||||f||||||||||2018-05-31 21:21:28.580977|2018-05-31 21:21:28.580977
NCT01604850|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2014-03-31||2014-05-09|2012-05-22|2012-05-24|Estimate|2014-03-31|2014-05-01|Estimate||||2014-05-09|2014-05-28|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|FUSION|Participants in the Safety Analysis Set (randomized and received at least 1 dose of study drug) were analyzed for baseline characteristics.|Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)|A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection|Completed||Phase 3|202|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:21:28.697603|2018-05-31 21:21:28.697603
NCT01604837|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-12-24|2012-05-23|2012-05-24|Estimate|||||||2013-12-24|2013-12-25|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Optimal Oblique and Axial Angle of Fluoroscope for Superior Hypogastric Plexus Block|The Optimal Oblique and Axial Angle of Fluoroscope for Superior Hypogastric Plexus Block|Completed|||268|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 21:21:29.416763|2018-05-31 21:21:29.416763
NCT01604824|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22||2015-01-24|2015-01-24|2012-05-22|2012-05-24|Estimate||||2015-01-24|2015-01-30|Estimate|2015-01-24|2015-01-30|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|September 2016|Anticipated|2016-09-30|May 2014|Actual|2014-05-31||Interventional|||A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene|A Phase 2 Pilot Study With a Randomized Double-Blind Treatment Phase to Evaluate the Pharmacodynamics and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia and Gain-of-Function Mutations in 1 or Both Alleles of the PCSK9 Gene or Loss-of-Function Mutations in 1 or More Alleles of the Apolipoprotein B Gene|Unknown status|Active, not recruiting|Phase 2|23|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:21:29.494251|2018-05-31 21:21:29.494251
NCT01604811|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-01-14|2012-05-23|2012-05-24|Estimate|||||||2014-01-14|2014-01-15|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|PERMIN||Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)|Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study|Completed||Phase 4|206|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 21:21:29.601175|2018-05-31 21:21:29.601175
NCT01604798|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-22|2012-05-22|2012-05-24|Estimate|||||||2012-05-22|2012-05-24|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer|Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer|Completed|||547|Actual|Fudan University|||2||f||||t||||||Samples Without DNA|"~     All fasting blood samples were prepared without anticoagulant and left to clot at room~     temperature for 1.5 h. The serum was then isolated by centrifugation at 3000 g for 10 min at~     room temperature and stored at -80℃. All samples were subjected to one freeze-thaw cycle.~   "|||2018-05-31 21:21:29.735198|2018-05-31 21:21:29.735198
NCT01604785|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2016-08-16|2012-05-23|2012-05-24|Estimate|||||||2016-08-16|2016-08-18|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Low-dose Propofol for Pediatric Migraine|Low-dose Propofol for Abortive Therapy of Pediatric Migraine in the Emergency Department|Completed||Phase 2/Phase 3|74|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 21:21:29.824153|2018-05-31 21:21:29.824153
NCT01604772|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|2015-06-04||2018-03-21|2012-05-22|2012-05-24|Estimate|2015-06-04|2015-06-26|Estimate||||2018-03-21|2018-04-20|Actual|July 23, 2012|Actual|2012-07-23|March 2018|2018-03-31||||October 24, 2013|Actual|2013-10-24||Interventional|||Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma|A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:21:29.939713|2018-05-31 21:21:29.939713
NCT01604759|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2017-01-30|2012-05-23|2012-05-24|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PolProbe||Polarized Reflectance Spectroscopy for Oral Lesions|Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions|Completed||Phase 1|40|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 21:21:30.203577|2018-05-31 21:21:30.203577
NCT01604746|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2015-10-07|2012-05-22|2012-05-24|Estimate|||||||2015-10-07|2015-10-09|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801|Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801)|Completed||Phase 3|1146|Actual|Ology Bioservices||1|||f||||t||||||||||2018-05-31 21:21:30.26597|2018-05-31 21:21:30.26597
NCT01604733|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-23|2012-05-23|2012-05-24|Estimate|||||||2012-05-23|2012-05-24|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|CEPHEUS||Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|Completed|||1000|Actual|AstraZeneca|||1||f||||f||||||None Retained|"~     blood sample~   "|||2018-05-31 21:21:30.331812|2018-05-31 21:21:30.331812
NCT01604720|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-01-13|2012-05-22|2012-05-24|Estimate|||||||2015-01-13|2015-01-14|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Observational|||Sample Size Definition in Cochrane Hepato-Biliary Trials|Review: Analysis of the Sample Size Definitions in the Randomized Clinical Trials Included in Systematic Reviews of the Hepato-biliary Group of the Cochrane Collaboration|Unknown status|Recruiting||250|Anticipated|Azienda Ospedaliera di Lecco|||||f||||f||||||||||2018-05-31 21:21:30.380725|2018-05-31 21:21:30.380725
NCT01604694|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2014-05-09|2012-05-23|2012-05-24|Estimate|||||||2014-05-09|2014-05-12|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|TAPlastie||Ultrasound-guided Transversus Abdominis Plane Block for Analgesia After Abdominoplasty|Ultrasound-guided Transversus Abdominis Plane Block for Analgesia After Abdominoplasty: Randomized- Controlled- Trial Double Blind Monocentric Study, Against Placebo|Completed||Phase 4|52|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 21:21:30.614448|2018-05-31 21:21:30.614448
NCT01604681|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-05-23|2012-05-23|2012-05-24|Estimate|||||||2012-05-23|2012-05-24|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Supplementation With Flaxseed Oil in the State of Rio de Janeiro|The Effect of Flaxseed Oil Supplementation on Biomarkers, Quality of Life and Cognitive Function in Hypertensive and Dyslipidemic Subjects With or Without the C677T and A1298C Polymorphisms in MTHFR Gene in Different Municipalities of Rio de Janeiro|Unknown status|Recruiting|N/A|200|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 21:21:30.685902|2018-05-31 21:21:30.685902
NCT01604668|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2013-08-19|2012-05-23|2012-05-24|Estimate|||||||2013-08-19|2013-08-21|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring|Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring.|Completed|||10|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-05-31 21:21:30.767812|2018-05-31 21:21:30.767812
NCT01604655|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2016-03-07|2012-05-23|2012-05-24|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|PERFECT||ProspEctive First Evaluation in Chest Pain Trial|ProspEctive Randomized First Evaluation in Chest Pain Trial|Completed||N/A|411|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 21:21:30.827943|2018-05-31 21:21:30.827943
NCT01604642|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2018-03-29|2012-05-23|2012-05-24|Estimate|||||||2018-03-29|2018-04-02|Actual|May 2012||2012-05-31|March 2018|2018-03-31|January 1, 2016|Actual|2016-01-01|March 2014|Actual|2014-03-31||Interventional|||Role of Activin A (ActA) in the Human Cancer Cachexia|Role of Activin A (ActA) in the Human Cancer Cachexia|Completed||N/A|150|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 21:21:30.906858|2018-05-31 21:21:30.906858
NCT01604629|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2015-11-16|2012-05-21|2012-05-24|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|REDES-TNF||Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF|Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial.|Completed||Phase 4|120|Actual|Spanish Clinical Pharmacology Society||2|||f||||t||||||||||2018-05-31 21:21:30.984938|2018-05-31 21:21:30.984938
NCT01604616|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-22|2012-05-22|2012-05-23|Estimate|||||||2012-05-22|2012-05-23|Estimate|January 1998||1998-01-31|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|||||Observational|||Short Term Postoperative Tamponade Using Perfluorocarbon Liquid for Giant Retinal Tears|Short Term Postoperative Tamponade Using Perfluorocarbon Liquid for Giant Retinal Tears|Unknown status|Recruiting||40|Anticipated|Ziv Hospital|||2||f||||t||||||||||2018-05-31 21:21:31.128341|2018-05-31 21:21:31.128341
NCT01604603|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2013-11-04|2012-05-22|2012-05-23|Estimate|||||||2013-11-04|2013-11-06|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||The Clinical and Biochemical Characteristics in Women With Different Menstrual Pattern||Completed|||470|Actual|Taipei Medical University WanFang Hospital|||4||f||||f||||||||||2018-05-31 21:21:31.216793|2018-05-31 21:21:31.216793
NCT01604590|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-04-10|2012-05-22|2012-05-23|Estimate|||||||2015-04-10|2015-04-13|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|||Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme|Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease|Completed|||13|Actual|Medical University of South Carolina|||1||f||||f||||||||||2018-05-31 21:21:31.284123|2018-05-31 21:21:31.284123
NCT01604577|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-07-26|2012-05-22|2012-05-23|Estimate|||||||2014-07-26|2014-07-29|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Targeting Social Determinants to Improve Chronic Kidney Disease Care|Targeting Social Determinants to Improve Chronic Kidney Disease Care|Completed||N/A|273|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 21:21:31.367238|2018-05-31 21:21:31.367238
NCT01604564|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-07-28|2012-05-21|2012-05-23|Estimate|||||||2016-07-28|2016-07-29|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|KOPOF||Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients|KOPOF Registry (Patients Characteristics, Operative Data, Postoperative Outcome, Functional Postoperative Recovery ) of Patients in Which a Pouch Has Been Created Due to Colitis Ulcerosa (CU) or Familial Adenomatous Polyposis(FAP)|Recruiting|||200|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||No||2018-05-31 21:21:31.456604|2018-05-31 21:21:31.456604
NCT01604551|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-31|2012-05-21|2012-05-23|Estimate|||||||2012-05-31|2012-06-01|Estimate|May 2003||2003-05-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|||||Observational|||Membrane Shedding During Septic Shock|Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance|Completed|||100|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 21:21:31.541523|2018-05-31 21:21:31.541523
NCT01604538|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-21|2012-05-21|2012-05-23|Estimate|||||||2012-05-21|2012-05-23|Estimate|March 2006||2006-03-31|May 2012|2012-05-31||||||||Observational|IPER||Italian Pulmonary Embolism Registry - IPER|Italian Pulmonary Embolism Registry|Completed|||1700|Actual|University Of Perugia|||1||f||||f||||||||||2018-05-31 21:21:31.594393|2018-05-31 21:21:31.594393
NCT01604525|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-21|2012-05-21|2012-05-23|Estimate|||||||2012-05-21|2012-05-23|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|RealU||Tailored Web and Peer Email Cessation Counseling for College Smokers|RealU: Tailored Web and Peer Email Cessation Counseling for College Smokers|Completed||N/A|1699|Actual|University of Michigan||3|||f||||t||||||||||2018-05-31 21:21:31.648926|2018-05-31 21:21:31.648926
NCT01604512|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2018-04-02|2012-05-22|2012-05-23|Estimate|||||||2018-04-02|2018-04-03|Actual|May 2012||2012-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression|Enhancing Brain Lesions After Radiation Therapy: A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression|Recruiting||N/A|150|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:21:31.712957|2018-05-31 21:21:31.712957
NCT01604486|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-10-01|2012-05-22|2012-05-23|Estimate|||||||2015-10-01|2015-10-02|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Natural Ischaemic Preconditioning Before First Myocardial Infarction|Natural Ischaemic Preconditioning Before First Myocardial Infarction: an Analysis of Prospectively Collected UK Electronic Primary Care Records Linked to the National Registry of Acute Coronary Syndromes|Completed|||16000|Actual|London School of Hygiene and Tropical Medicine|||4||f||||t||||||||||2018-05-31 21:21:31.873001|2018-05-31 21:21:31.873001
NCT01604473|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2018-01-04|2012-05-22|2012-05-23|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2010||2010-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|EFAVF||Endothelial Function and Arterio-Venous Fistula Maturation|Endothelial Function and Arterio-Venous Fistula Maturation|Active, not recruiting|||54|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-05-31 21:21:31.934847|2018-05-31 21:21:31.934847
NCT01604460|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2013-02-08|2012-05-21|2012-05-23|Estimate|||||||2013-02-08|2013-02-11|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part V|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part V|Completed||Phase 4|275|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 21:21:32.011222|2018-05-31 21:21:32.011222
NCT01604447|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-02-23|2012-05-21|2012-05-23|Estimate|||||||2015-02-23|2015-02-24|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part IV|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part IV|Completed||Phase 4|118|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 21:21:32.080946|2018-05-31 21:21:32.080946
NCT01604434|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-11-20|2012-05-21|2012-05-23|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2012||2012-06-30|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part III|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part III|Recruiting||N/A|118|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 21:21:32.158448|2018-05-31 21:21:32.158448
NCT01604421|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-11-20|2012-05-21|2012-05-23|Estimate|||||||2017-11-20|2017-11-22|Actual|February 2013||2013-02-28|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part II|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part II|Recruiting||N/A|182|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 21:21:32.239911|2018-05-31 21:21:32.239911
NCT01604408|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2018-03-24|2014-04-14|2018-03-24|2012-05-21|2012-05-23|Estimate|2018-03-24|2018-04-25|Actual|2014-04-14|2014-05-07|Estimate|2018-03-24|2018-04-25|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional||All participants enrolled in the study.|A Study in Older Participants Who Have Fallen and Have Muscle Weakness|A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness|Completed||Phase 2|201|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 21:21:32.35198|2018-05-31 21:21:32.35198
NCT01604395|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-03-21|2012-05-22|2012-05-23|Estimate|||||||2016-03-21|2016-03-23|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Observational|LGS||Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA and ISS in Children|An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. / Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA and ISS in Children|Recruiting|||2000|Anticipated|LG Life Sciences|||1||f||||t||||||||||2018-05-31 21:21:33.156251|2018-05-31 21:21:33.156251
NCT01604382|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2012-05-22|2012-05-22|2012-05-23|Estimate|||||||2012-05-22|2012-05-23|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|||Early Mobilization After Total Knee Arthroplasty|A Randomized Study of Whether General or Regional Anesthesia for Patients Undergoing Elective Total Knee Arthroplasty Could Effect Length of Hospital Stay|Completed||N/A|60|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 21:21:33.254425|2018-05-31 21:21:33.254425
NCT01604369|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-10-05|2012-05-22|2012-05-23|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CASTAF||Cryoablation as Standard Treatment of Atrial Flutter|Cryoablation as Standard Treatment of Atrial Flutter - Long Term Efficacy and Patient Content|Completed||N/A|193|Actual|Karolinska University Hospital||1|||f||||t||||||||||2018-05-31 21:21:33.335751|2018-05-31 21:21:33.335751
NCT01604356|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-03-03|2012-05-22|2012-05-23|Estimate|||||||2014-03-03|2014-03-04|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa|Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa|Completed||Phase 1|19|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 21:21:33.409285|2018-05-31 21:21:33.409285
NCT01604343|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2017-10-17|2016-06-08|2017-12-08|2012-05-21|2012-05-23|Estimate|2017-12-08|2018-01-11|Actual|2016-06-08|2016-06-10|Estimate|2017-12-08|2018-01-11|Actual|August 15, 2012|Actual|2012-08-15|December 2017|2017-12-31|December 6, 2016|Actual|2016-12-06|September 2, 2015|Actual|2015-09-02||Interventional|||A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis Despite DMARD Therapy|Completed||Phase 3|1670|Actual|Janssen Research & Development, LLC|The short pure placebo-controlled period (through Week 18) and the EE at Week 18 and LE at Week 40 for participants in the placebo group might have affected the ability to directly compare safety between sirukumab and placebo groups through Week 52.|3|||f||||t|t|||||||||2018-05-31 21:21:33.664255|2018-05-31 21:21:33.664255
NCT01604330|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-10-02|2012-05-22|2012-05-23|Estimate|||||||2017-10-02|2017-10-03|Actual|May 29, 2012|Actual|2012-05-29|September 2017|2017-09-30|October 2015|Actual|2015-10-31|September 2014|Actual|2014-09-30||Interventional|BACLOVILLE||Baclofen for the Treatment of Alcohol Drinkers|Alcohol Treatment: Pragmatic Therapeutic Trial Randomized, Double-blind for a Year in Ambulatory Care of Baclofen Versus Placebo.|Completed||Phase 2/Phase 3|323|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 21:21:37.937348|2018-05-31 21:21:37.937348
NCT01604317|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-11-20|2012-05-21|2012-05-23|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2012||2012-06-30|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part I|Randomized Evaluation of the Use of Plastic Bags to Prevent Neonatal Hypothermia in Developing Countries-Part I|Recruiting||N/A|182|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 21:21:38.030454|2018-05-31 21:21:38.030454
NCT01604304|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-08-26|2012-05-22|2012-05-23|Estimate|||||||2014-08-26|2014-08-27|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CALIX-1||Flexible urétéroscopy Versus Extracorporeal Shockwave Lithotripsy in Renal Calculi|Flexible urétéroscopy Versus Extracorporeal Shockwave Lithotripsy in 5 to 20 mm Renal Calculi, Efficacity Prospective Randomized Trial|Completed||N/A|30|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:21:38.11842|2018-05-31 21:21:38.11842
NCT01604291|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-02-15|2012-05-21|2012-05-23|Estimate|||||||2017-02-15|2017-02-17|Actual|May 2012||2012-05-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C|Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients|Completed|||959|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:21:38.217675|2018-05-31 21:21:38.217675
NCT01604278|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2014-07-28||2014-11-12|2012-05-21|2012-05-23|Estimate|2014-11-12|2014-11-14|Estimate||||2014-11-12|2014-11-14|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|GLOW6|The baseline characteristics table was based on the safety set.|Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Multi-center, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of the Co-administration of NVA237 + Indacaterol Once Daily vs. Indacaterol Once Daily in Patients With Moderate to Severe COPD|Completed||Phase 3|449|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:21:38.376469|2018-05-31 21:21:38.376469
NCT01604265|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2012-07-18||2013-06-13|2012-05-22|2012-05-23|Estimate|2012-08-21|2012-09-19|Estimate||||2013-06-13|2013-06-24|Estimate|March 2002||2002-03-31|June 2013|2013-06-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis|A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis.|Completed||Phase 3|66|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 21:21:39.127858|2018-05-31 21:21:39.127858
NCT01604252|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-07-25|2012-05-21|2012-05-23|Estimate|||||||2017-07-25|2017-07-28|Actual|June 20, 2012|Actual|2012-06-20|June 2017|2017-06-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC)|A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients|Terminated|||503|Actual|Genentech, Inc.|||1|"The study was terminated early by the Sponsor due to the high rate of discontinuation of~   subjects unrelated to patient safety."|f||||||||||Samples With DNA|"~     optional blood sample~   "|||2018-05-31 21:21:39.724455|2018-05-31 21:21:39.724455
NCT01604239|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2013-11-11|2012-05-22|2012-05-23|Estimate|||||||2013-11-11|2013-11-13|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis|A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of 'Shinbaro Capsule' Compared With Historical Data of 'Celebrex Capsule' in Patients With Osteoarthritis|Completed||Phase 4|761|Actual|Green Cross Corporation||1|||f||||f||||||||||2018-05-31 21:21:40.19387|2018-05-31 21:21:40.19387
NCT01604226|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-07-08|2012-05-22|2012-05-23|Estimate|||||||2014-07-08|2014-07-09|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Predicting Bispectral Index Values by Estimated Effect-site Concentration of Propofol and Remifentanil Displayed on the Target-centered Infusion Pump|Predicting Bispectral Index Values by Estimated Effect-site Concentration of Propofol and Remifentanil Displayed on the Target-centered Infusion Pump|Unknown status|Recruiting||100|Anticipated|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 21:21:40.284345|2018-05-31 21:21:40.284345
NCT01604213|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-04-17|2012-05-22|2012-05-23|Estimate|||||||2016-04-17|2016-04-19|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|VAAST||Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease|Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease|Completed||Phase 4|60|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:21:40.355636|2018-05-31 21:21:40.355636
NCT01604200|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2013-08-26|2012-05-22|2012-05-23|Estimate|||||||2013-08-26|2013-08-27|Estimate||||August 2013|2013-08-31||||||||Observational|Dental-PROBE||Dental PROBE (Dental Practice suRvey of Office Blood Pressure mEasurement)|A Mixed Methods Study to Assess How to Engage Dentists in Blood Pressure Screening|Withdrawn|||0|Actual|Sunnybrook Health Sciences Centre|||1|Funding unsuccessful|f||||f||||||||||2018-05-31 21:21:40.442241|2018-05-31 21:21:40.442241
NCT01604187|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-10-12|2012-05-22|2012-05-23|Estimate|||||||2017-10-12|2017-10-13|Actual|April 2012||2012-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|Abstral||Procedural Pain Treatment With Transmucosal Sublingual Fentanyl Tablet in Colonoscopy Patients|Procedural Pain Treatment With Transmucosal Sublingual Fentanyl Tablet in Colonoscopy Patients|Recruiting||Phase 4|200|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 21:21:40.508643|2018-05-31 21:21:40.508643
NCT01604174|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-23|2012-05-22|2012-05-23|Estimate|||||||2012-05-23|2012-05-24|Estimate|November 2008||2008-11-30|May 2012|2012-05-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|REHABITIC||Interactive Virtual Telerehabilitation After Total Knee Arthroplasty|Effectiveness of an Interactive Virtual Telerehabilitation System in Patients After Total Knee Arthroplasty. A Randomized Controlled Trial|Completed||N/A|140|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 21:21:40.577007|2018-05-31 21:21:40.577007
NCT01603992|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2018-04-04|2012-05-19|2012-05-23|Estimate|||||||2018-04-04|2018-04-05|Actual|November 8, 2005||2005-11-08|May 3, 2012|2012-05-03|May 3, 2012||2012-05-03|||||Observational|||Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms|Quitting Marijuana Use: Self-Report Study of Quitting Strategies and Withdrawal Symptoms|Completed|||822|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:21:42.650687|2018-05-31 21:21:42.650687
NCT01604161|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-07-02|2012-05-21|2012-05-23|Estimate|||||||2015-07-02|2015-07-03|Estimate|May 2005||2005-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|NordiPAD||Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome|A Multicentre, Open Label, Non-interventional Study to Evaluate on Long-term Safety and Efficacy of Norditropin® Formulation in Child Patients With GHD or Turner Short Stature Without Closure of Epiphyseal Discs.|Completed|||2016|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:21:40.643878|2018-05-31 21:21:40.643878
NCT01604148|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-22|2012-05-22|2012-05-23|Estimate|||||||2012-05-22|2012-05-23|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Retrospective Review a Comprehensive Case Database of HoLEP Procedure Performed by a Single Surgeon|Retrospective Review of a Comprehensive Case Database of HoLEP (Holmium Laser Enucleation of Prostate) Procedure Performed by a Single Surgeon|Completed|||300|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 21:21:40.770543|2018-05-31 21:21:40.770543
NCT01604135|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-04-22|2012-05-21|2012-05-23|Estimate|||||||2016-04-22|2016-04-25|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|CXL-RCT||Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial|Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial|Recruiting||Phase 3|200|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 21:21:40.833753|2018-05-31 21:21:40.833753
NCT01604122|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2016-07-14||2017-03-01|2012-05-22|2012-05-23|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|April 18, 2012|Actual|2012-04-18|March 2017|2017-03-31|July 18, 2016|Actual|2016-07-18|July 27, 2015|Actual|2015-07-27||Observational||All participants who were enrolled in the study and completed the survey.|Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers|Cross-sectional, Non-interventional Burden Of Disease (Bod) Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (Ttr-fap) Or Transthyretin Cardiomyopathy (ttr-cm) And Caregivers|Completed|||1|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 21:21:40.96885|2018-05-31 21:21:40.96885
NCT01604109|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|2013-06-10||2013-06-10|2012-05-22|2012-05-23|Estimate|2013-06-10|2013-08-15|Estimate||||2013-06-10|2013-08-15|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of CPP-ACP Paste on Dental Caries in Primary Teeth|Effect of CPP-ACP Paste on Dental Caries in Primary Teeth: A Randomized Trial|Completed||Phase 2|296|Actual|Thammasat University|This one year study was performed on high caries risk pre-school children who enrolled in government nursery schools in central part of Thailand.|2|||f||||f||||||||||2018-05-31 21:21:41.593468|2018-05-31 21:21:41.593468
NCT01604096|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-22|2012-05-22|2012-05-23|Estimate|||||||2012-05-22|2012-05-23|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|LOCAAL||Controlled Trial to Evaluate a Local Information Campaign on Antibiotic Prescribing in Italy|Doctors and Local Media: a Synergy for Public Health Information? A Controlled Trial to Evaluate the Effects of a Multifaceted Campaign on Antibiotic Prescribing|Completed||Phase 2|||Regional Health and Social Care Agency, Italy||2|||f||||f||||||||||2018-05-31 21:21:41.78214|2018-05-31 21:21:41.78214
NCT01604083|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2016-04-08|2012-05-21|2012-05-23|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|ETPOS||European Transfusion Practice and Outcome Study|European Transfusion Practice and Outcome Study A Multi-central Evaluation of Standard of Transfusion Care and Clinical Outcome for Elective Surgical Patients. Observational Study.|Completed|||6066|Actual|European Society of Anaesthesiology|||||f||||f||||||||||2018-05-31 21:21:41.850762|2018-05-31 21:21:41.850762
NCT01604070|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-07-02|2012-05-22|2012-05-23|Estimate|||||||2014-07-02|2014-07-03|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|||Study to Evaluate Safety, of NextraTM in Surgery to Fuse the Proximal-interphalangeal- Joints|Randomized Multi-Center Post Market Clinical Study to Evaluate the Safety and Performance of NextraTM for Use in Foot Surgery to Fuse the Proximal-interphalangeal- Joints|Completed|||98|Actual|eMedtrain Inc.|||2||f||||t||||||||||2018-05-31 21:21:41.93125|2018-05-31 21:21:41.93125
NCT01604057|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-05-21|2012-05-21|2012-05-23|Estimate|||||||2012-05-21|2012-05-23|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass|A Parallel Group Study to Evaluate the Effect of Six Weeks of Treatment With Nasal Spray (NS) ZT-034, Compared to Subcutaneous (SC) Forteo and Placebo, on Bone Formation, as Assessed by Stimulation of Serum P1NP Levels in Postmenopausal Women With Low Bone Mass|Unknown status|Active, not recruiting|Phase 2|130|Actual|Azelon Pharmaceuticals||5|||f||||f||||||||||2018-05-31 21:21:41.991407|2018-05-31 21:21:41.991407
NCT01604044|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-09-04|2012-05-22|2012-05-23|Estimate|||||||2014-09-04|2014-09-05|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial.||Completed||Phase 1|579|Actual|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 21:21:42.201804|2018-05-31 21:21:42.201804
NCT01604031|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2016-02-05|2012-05-22|2012-05-23|Estimate|||||||2016-02-05|2016-02-08|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|TAIL||Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide|Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide|Terminated||Phase 1|2|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 21:21:42.267125|2018-05-31 21:21:42.267125
NCT01604018|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-05-23|2012-05-22|2012-05-23|Estimate|||||||2012-05-23|2012-05-24|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||An Optional Two Year Follow Up Study to Study CP005A|An Optional Two Year Follow Up Study to Evaluate the Continued Efficacy of Cat-PAD ToleroMune Peptide Immunotherapy in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber|Completed|||51|Actual|Circassia Limited|||3||f||||f||||||||||2018-05-31 21:21:42.348561|2018-05-31 21:21:42.348561
NCT01604005|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2018-01-26|2012-05-21|2012-05-23|Estimate|||||||2018-01-26|2018-01-29|Actual|July 2012||2012-07-31|January 2018|2018-01-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|PIT||PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma|PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention|Terminated||Phase 3|375|Actual|The Christie NHS Foundation Trust||2||"CI Decision:That once the last patient has reached 1 year follow-up, no further follow up needs~   to be completed on patients recruited in PIT"|f||||f||||||||||2018-05-31 21:21:42.437103|2018-05-31 21:21:42.437103
NCT01603979|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2015-04-06|2012-05-22|2012-05-23|Estimate|||||||2015-04-06|2015-04-08|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors|A Phase 1 Open-label, Multiple Dose, Dose Escalation Study of Monoclonal Antibody AV-203 Administered in Subjects With Metastatic or Advanced Solid Tumors|Completed||Phase 1|24|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:21:42.721569|2018-05-31 21:21:42.721569
NCT01603966|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2012-07-14|2012-05-22|2012-05-23|Estimate|||||||2012-07-14|2012-07-17|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Low Dose Aspirin Studied With the AggreGuide|Low Dose Aspirin Study With the AggreGuide|Completed|||13|Actual|Aggredyne, Inc.|||||f||||f||||||None Retained|"~     whole blood~   "|||2018-05-31 21:21:42.802283|2018-05-31 21:21:42.802283
NCT01603953|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2014-11-17|2012-05-22|2012-05-23|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Observational|BIVA||Bioelectrical Impedance Vector Analysis in Cirrhotic Patients|Malnutrition Assessed Through Bioelectrical Impedance Vector Analysis is Related to Poor Prognosis in Cirrhosis|Completed|||250|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||f||||||||||2018-05-31 21:21:42.864716|2018-05-31 21:21:42.864716
NCT01603940|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|2015-08-18||2015-12-29|2012-05-22|2012-05-23|Estimate|2015-10-09|2015-11-11|Estimate||||2015-12-29|2016-02-01|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CONTROL||Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine|Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.|Completed||Phase 4|30|Actual|Hospital Universitario Pedro Ernesto||2|||f||||f||||||||||2018-05-31 21:21:42.931273|2018-05-31 21:21:42.931273
NCT01603927|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-22|2012-05-22|2012-05-23|Estimate|||||||2012-05-22|2012-05-23|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Observational|DISCARD2||Detect InSpect ChAracterise Resect and Discard 2|Detect InSpect ChAracterise Resect and Discard 2|Unknown status|Not yet recruiting||2500|Anticipated|South Tyneside NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 21:21:43.191576|2018-05-31 21:21:43.191576
NCT01603914|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2012-08-28|2012-05-22|2012-05-23|Estimate|||||||2012-08-28|2012-08-29|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|CARB||Central Venous Catheter Replacement Strategies in Adult Patients With Major Burn Injury|Comparison of Three Strategies for Changing of Central Venous Catheters in Patients With Serious Burns for the Prevention of Catheter-associated Bacteremia: Randomized Clinical Trial|Unknown status|Recruiting|N/A|1120|Anticipated|Hospital Universitario Getafe||3|||f||||t||||||||||2018-05-31 21:21:43.291622|2018-05-31 21:21:43.291622
NCT01603901|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2012-05-22|2012-05-22|2012-05-23|Estimate|||||||2012-05-22|2012-05-23|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|August 2012|Anticipated|2012-08-31||Interventional|||Regulated Negative Pressure-Assisted Wound Therapy Device||Unknown status|Not yet recruiting|N/A|10|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 21:21:43.443576|2018-05-31 21:21:43.443576
NCT01603888|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2017-11-26|2012-05-22|2012-05-23|Estimate|||||||2017-11-26|2017-11-28|Actual|January 2013||2013-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|January 2015|Actual|2015-01-31||Observational|||Molecular Forms of Plasma and Urinary B-type Natriuretic Peptide and Its N-terminal Prohormone in Health and Disease in Pediatric Cardiology||Completed|||60|Actual|Hadassah Medical Organization|||3||f||||||||||||||2018-05-31 21:21:43.501959|2018-05-31 21:21:43.501959
NCT01603875|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2014-01-03||2014-01-03|2012-05-20|2012-05-23|Estimate|2014-01-03|2014-02-25|Estimate||||2014-01-03|2014-02-25|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV|Immune Response in Adults to Pre-exposure Rabies Vaccination and Simulated Post-exposure Rabies Booster Vaccination With a New Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA®) : a Randomized Controlled Trial With Purified Vero-cell Rabies Vaccine (PVRV)|Completed||N/A|105|Actual|Queen Saovabha Memorial Institute||3|||f||||t||||||||||2018-05-31 21:21:43.571764|2018-05-31 21:21:43.571764
NCT01603862|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-04-25|2012-05-20|2012-05-23|Estimate|||||||2014-04-25|2014-04-28|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ThinkingFit||ThinkingFit: Combined Physical, Cognitive and Social Treatment in Mild Cognitive Impairment (MCI)|Piloting a Complex Intervention Involving Physical Exercise, Cognitive Training and Socialising to Delay the Onset of Dementia in Mild Cognitive Impairment|Completed||N/A|128|Anticipated|North Essex Partnership NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 21:21:43.855939|2018-05-31 21:21:43.855939
NCT01603849|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-03-01|2012-05-20|2012-05-23|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2012||2012-05-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|PCI||Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis|Randomized Phase II Trial of Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma Clinical Stage IIIB and IV With High Risk of Brain Metastasis|Active, not recruiting||N/A|128|Anticipated|Instituto Nacional de Cancerologia de Mexico||2|||f||||t||||||||No||2018-05-31 21:21:43.920037|2018-05-31 21:21:43.920037
NCT01603836|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-20|2012-05-20|2012-05-23|Estimate|||||||2012-05-20|2012-05-23|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2010|Actual|2010-03-31||Interventional|||Study Confirms or Refutes the Hypothesis That the Autologous Bone Marrow Concentrate Together With the Allograft is a Better Alternative for the Posterolateral Fusion in Spine Surgery Than the Allograft Alone|Allograft Alone Versus Allograft With Bone Marrow Concentrate for the Healing of the Instrumented Posterolateral Lumbar Fusion|Completed||N/A|80|Actual|Hospital Znojmo||1|||f||||f||||||||||2018-05-31 21:21:43.979874|2018-05-31 21:21:43.979874
NCT01603784|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-08-29|2012-05-18|2012-05-23|Estimate|||||||2014-08-29|2014-09-03|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|August 2012|Actual|2012-08-31||Interventional|EXACT||Combining Exercise and Cognitive Training to Improve Everyday Function|Combining Exercise and Cognitive Training to Improve Everyday Function|Completed||Phase 3|96|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-05-31 21:21:44.041131|2018-05-31 21:21:44.041131
NCT01603771|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-08-29|2012-05-18|2012-05-23|Estimate|||||||2014-08-29|2014-09-03|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|NAC||Neural Activation and Connectivity in Response to Exercise and Cognitive Training|Neural Activation and Connectivity in Response to Exercise and Cognitive Training|Completed|||24|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-05-31 21:21:44.107603|2018-05-31 21:21:44.107603
NCT01603758|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-05-05|2012-05-21|2012-05-23|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Physiological Study of Human Cholesterol Metabolism and Excretion|Reverse Cholesterol Transport in Humans|Completed||Phase 1|132|Actual|Washington University School of Medicine||2|||f||||f||||||||Undecided|Data will be shared subject to IRB and HIPAA restrictions.|2018-05-31 21:21:44.162356|2018-05-31 21:21:44.162356
NCT01603732|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-04-03|2012-05-21|2012-05-23|Estimate|||||||2017-04-03|2017-04-04|Actual|January 2010||2010-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||"Association Between a Mother's Exposure to Strep Throat and Her Baby's Developing Heart Disease"|Evaluation of Maternal B-hemolytic Streptococcal Pharyngeal Exposure in Pregnancies Affected by Congenital Heart Disease(CHD)|Completed|||397|Actual|Washington University School of Medicine|||4||f||||f||||||Samples With DNA|"~     Confirmation of maternal ß-hemolytic streptococcal & enterovirus infection(s) will be~     determined from nose and rectal swabs & blood samples assayed for standard marker antibodies~     to ß-hemolytic streptococcal & enterovirus exposure.~   "|||2018-05-31 21:21:44.228448|2018-05-31 21:21:44.228448
NCT01603719|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2015-12-17|2012-05-18|2012-05-23|Estimate|||||||2015-12-17|2015-12-18|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|May 2016|Anticipated|2016-05-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety of an Infant Formula With Milkfat and Prebiotics|Safety and Efficacy of an Infant Starter Formula With Prebiotics (GOS) and a Higher Content of Beta-palmitate on Stool Characteristics, Food Tolerance, Calcium Uptake, and Incidence of Infectious Disease in the First Year of Life|Unknown status|Active, not recruiting|N/A|102|Anticipated|Waldkrankenhaus Protestant Hospital, Spandau||2|||f||||f||||||||||2018-05-31 21:21:44.312106|2018-05-31 21:21:44.312106
NCT01603563|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-04-23|2012-05-18|2012-05-23|Estimate|||||||2015-04-23|2015-04-24|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Stepped Care for Young Children After Trauma|Stepped Care for Young Children After Trauma|Completed||Phase 1/Phase 2|63|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 21:21:44.371738|2018-05-31 21:21:44.371738
NCT01603550|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-10-05|2012-05-21|2012-05-23|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Brain Energy and Cognition|Brain Energy and Cognition|Completed||N/A|31|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||Undecided||2018-05-31 21:21:44.449072|2018-05-31 21:21:44.449072
NCT01603537|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-18|2012-05-18|2012-05-23|Estimate|||||||2012-05-18|2012-05-23|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|May 2012|Anticipated|2012-05-31||Observational|||The Impact of Prehospital Trauma Life Support (PHTLS) on Outcome of Traffic Injury|Impact of Prehospital Trauma Life Support (PHTLS) Training of Ambulance Caregivers on Outcome of Traffic Injury Victims|Unknown status|Active, not recruiting||40000|Anticipated|Uppsala University Hospital|||2||f||||f||||||||||2018-05-31 21:21:44.648991|2018-05-31 21:21:44.648991
NCT01603524|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2015-06-01|2012-05-21|2012-05-23|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RCT-OMSC-PC||"Integrating the Ottawa Model for Smoking Cessation Into Primary Care Practice"|"Integrating the Ottawa Model for Smoking Cessation Into Routine Primary Care Practice: A Cluster Randomized Controlled Trial"|Completed||N/A|15|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 21:21:44.711516|2018-05-31 21:21:44.711516
NCT01603511|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2013-04-04|2012-05-21|2012-05-23|Estimate|||||||2013-04-04|2013-04-08|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Heat Donation Through the Head or Torso on Mild Hypothermic Rewarming|Effectiveness of Heat Donation Through the Head or Torso on Mild Hypothermic Rewarming|Completed||N/A|7|Actual|University of Manitoba|||||f||||f||||||||||2018-05-31 21:21:44.7775|2018-05-31 21:21:44.7775
NCT01603498|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-21|2012-05-21|2012-05-23|Estimate|||||||2012-05-21|2012-05-23|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery|Preemptive Effect of Dexamethasone and Methylprednisolone on Pain, Swelling and Trismus After Third Molar Surgery: a Split-mouth Randomized Triple-blind Clinical Trial|Completed||N/A|18|Actual|Federal University of the Valleys of Jequitinhonha and Mucuri||2|||f||||t||||||||||2018-05-31 21:21:44.841398|2018-05-31 21:21:44.841398
NCT01603407|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2018-03-02|2012-05-21|2012-05-23|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2013||2013-01-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|FOR-DMD||Finding the Optimum Regimen for Duchenne Muscular Dystrophy|Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen|Active, not recruiting||Phase 3|196|Actual|University of Rochester||3|||f||||t||||||||No||2018-05-31 21:21:44.959756|2018-05-31 21:21:44.959756
NCT01603823|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|August 2008||2008-08-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|February 2010|Actual|2010-02-28||Observational|||Angiographie and OCT in Macula and Retinal Diseases||Completed|||30|Actual|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 21:21:45.174395|2018-05-31 21:21:45.174395
NCT01603810|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31||||||||Observational|||Evaluating In Vivo OCT Imaging for Periocular Basal Cell Carcinoma|An Investigation of the Correlation Between OCT and Histology in Defining the Margins of Periocular Basal Cell Carcinoma|Unknown status|Not yet recruiting||||Maidstone & Tunbridge Wells NHS Trust|||1||f||||||||||||||2018-05-31 21:21:45.241363|2018-05-31 21:21:45.241363
NCT01603797|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2012-10-02|2012-05-21|2012-05-22|Estimate|||||||2012-10-02|2012-10-03|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Guided Internet-delivered Acceptance and Commitment Therapy for Chronic Pain Patients|Guided Internet-delivered Acceptance and Commitment Therapy for Chronic Pain Patients: a Randomized Controlled Trial|Completed||N/A|76|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 21:21:45.315811|2018-05-31 21:21:45.315811
NCT01603745|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome||Unknown status|Recruiting|Phase 1|10|Anticipated|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 21:21:45.410656|2018-05-31 21:21:45.410656
NCT01603095|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2018-03-16|2012-05-18|2012-05-22|Estimate|||||||2018-03-16|2018-03-20|Actual|April 2012||2012-04-30|March 2018|2018-03-31|February 2025|Anticipated|2025-02-28|October 2024|Anticipated|2024-10-31||Observational|||A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia|A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia|Enrolling by invitation|||350|Anticipated|BioMarin Pharmaceutical|||1||f||||f||||||||||2018-05-31 21:21:53.316144|2018-05-31 21:21:53.316144
NCT01603706|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-10-18|2012-05-20|2012-05-22|Estimate|||||||2017-10-18|2017-10-19|Actual|May 2012||2012-05-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|RAISE-CRT||Radial Strain ECHO-Guided Implantation of Cardiac Resynchronization Therapy|Radial Strain Imaging-Guided Lead Placement for Improving Response to Cardiac Resynchronization Therapy in Patients With Ischemic Cardiomyopathy: A Randomized Clinical Trial|Completed||N/A|172|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:21:45.502051|2018-05-31 21:21:45.502051
NCT01603693|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-11-26|2012-05-20|2012-05-22|Estimate|||||||2017-11-26|2017-11-28|Actual|February 2012|Actual|2012-02-29|March 2012|2012-03-31|February 21, 2013|Actual|2013-02-21|February 21, 2013|Actual|2013-02-21||Interventional|||Bone Quality and Quantity Following Guided Bone Regeneration Prior to Dental Implant Placement|Bone Quality and Quantity Following Guided Bone Regeneration With Bio-Oss Alone or Combined With BondBone, Prior to Dental Implant Placement|Completed||N/A|13|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:21:45.609336|2018-05-31 21:21:45.609336
NCT01603680|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2015-08-03|2012-05-20|2012-05-22|Estimate|||||||2015-08-03|2015-08-04|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Distribution Circumferential Versus Non Circumferential of Mepivacaine in the Median and Ulnar Nerves|Circumferential Versus Not Circumferential Distribution of Mepivacaine Around the Median and Ulnar Nerves in the Carpal Tunnel Surgery. Randomized Clinical Trial, Double Blinded.|Completed||Phase 4|124|Actual|Complexo Hospitalario Universitario de A Coruña||2|||f||||t||||||||||2018-05-31 21:21:45.681014|2018-05-31 21:21:45.681014
NCT01603667|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2016-11-03|2012-05-20|2012-05-22|Estimate|||||||2016-11-03|2016-11-04|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Pass||PG2 Injection 500 mg in Acute Stroke Study (Pass)|PG2 Injection 500 mg in Acute Stroke Study (Pass): A Randomized, Double-Blind, Placebo-Controlled Study of PG2 Injection 500 mg in Patients With Treatment Started Within 3-6 Hrs of the Onset of Acute Ischemic Stroke|Completed||Phase 2|86|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 21:21:45.760448|2018-05-31 21:21:45.760448
NCT01603654|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Sodium Picosulphate/Magnesium Citrate and Low-volume PEG -Ascorbic Acid as Preparation for Colonoscopy|A Randomized Controlled Trial Comparing the Efficacy and Acceptability of Sodium Picosulphate/Magnesium Citrate With Low-volume PEG -Ascorbic Acid as Preparation for Colonoscopy.|Completed||Phase 4|300|Actual|ASST Fatebenefratelli Sacco||2|||f||||f||||||||||2018-05-31 21:21:45.838223|2018-05-31 21:21:45.838223
NCT01603641|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-10-05|2012-05-21|2012-05-22|Estimate|||||||2017-10-05|2017-10-09|Actual|November 30, 2012|Actual|2012-11-30|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity|BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study|Active, not recruiting||Phase 3|350|Anticipated|Allergan||1|||f||||t||||||||||2018-05-31 21:21:45.923165|2018-05-31 21:21:45.923165
NCT01603628|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-09-01|2012-05-21|2012-05-22|Estimate|||||||2017-09-01|2017-09-06|Actual|September 11, 2012|Actual|2012-09-11|September 2017|2017-09-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||BOTOX® Treatment in Pediatric Lower Limb Spasticity|BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study|Completed||Phase 3|384|Actual|Allergan||3|||f||||t||||||||||2018-05-31 21:21:46.072111|2018-05-31 21:21:46.072111
NCT01603615|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-10-01|2012-05-21|2012-05-22|Estimate|||||||2017-10-01|2017-10-03|Actual|October 30, 2012|Actual|2012-10-30|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity|BOTOX® Treatment in Pediatric Upper Limb Spasticity: Open-label Study|Active, not recruiting||Phase 3|213|Anticipated|Allergan||1|||f||||t||||||||||2018-05-31 21:21:46.209801|2018-05-31 21:21:46.209801
NCT01603602|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-09-01|2012-05-21|2012-05-22|Estimate|||||||2017-09-01|2017-09-06|Actual|July 12, 2012||2012-07-12|September 2017|2017-09-30|July 6, 2017|Actual|2017-07-06|June 29, 2017|Actual|2017-06-29||Interventional|||BOTOX® Treatment in Pediatric Upper Limb Spasticity|BOTOX® Treatment in Pediatric Upper Limb Spasticity: Double-blind Study|Completed||Phase 3|235|Actual|Allergan||3|||f||||t||||||||||2018-05-31 21:21:46.475618|2018-05-31 21:21:46.475618
NCT01603589|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2013-11-27|2012-05-21|2012-05-22|Estimate|||||||2013-11-27|2013-11-28|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Comparison of Minimal Versus Conventional Extracorporeal Circulation in Coronary Surgery|Research on Remote End-organ Protection, Clinical Outcome and Quality of Life With Implementation of the Novel Minimal Extracorporeal Circulation Circuit in Open Heart Surgery|Unknown status|Recruiting|N/A|150|Anticipated|AHEPA University Hospital||2|||f||||f||||||||||2018-05-31 21:21:46.633604|2018-05-31 21:21:46.633604
NCT01603576|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-11-14|2012-05-19|2012-05-22|Estimate|||||||2016-11-14|2016-11-16|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Study of a Suprachoroidal Retinal Prosthesis|Safety and Feasibility Study of a Prototype Suprachoroidal Retinal Prosthesis for Vision Restoration|Completed||N/A|3|Actual|Center for Eye Research Australia||1|||f||||||||||||||2018-05-31 21:21:46.719153|2018-05-31 21:21:46.719153
NCT01603485|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-09-18|2012-05-21|2012-05-22|Estimate|||||||2012-09-18|2012-09-19|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects|Open-Label, Randomized, Crossover Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-Release Lersivirine (UK-453,061) 500 mg in Healthy Subjects|Completed||Phase 1|16|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:21:46.790727|2018-05-31 21:21:46.790727
NCT01603472|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2013-07-26|2012-05-21|2012-05-22|Estimate|||||||2013-07-26|2013-07-29|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Markers of Bone Disease in Children on Parenteral Nutrition|Markers of Parenteral Nutrition (PN) Associated Metabolic Bone Disease in Children on Long-Term PN for Intestinal Failure.|Completed|||38|Actual|The Hospital for Sick Children|||2||f||||f||||||||||2018-05-31 21:21:46.858414|2018-05-31 21:21:46.858414
NCT01603277|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2015-01-12||2015-01-30|2012-05-18|2012-05-22|Estimate|2015-01-30|2015-02-02|Estimate||||2015-01-30|2015-02-02|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|KB003-04||Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids|A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids|Completed||Phase 2|160|Actual|Humanigen, Inc.||2|||f||||t||||||||||2018-05-31 21:21:51.65286|2018-05-31 21:21:51.65286
NCT01603459|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2016-07-26|2015-09-10|2017-03-27|2012-05-21|2012-05-22|Estimate|2016-12-09|2017-02-03|Estimate|2015-09-10|2015-09-29|Estimate|2017-03-27|2017-04-26|Actual|May 2012||2012-05-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The safety evaluation set (SES) is the subset of all subjects who were exposed to study medication at least once.|Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm|Prospective, Open-label, Non-randomized, Single-arm, Multi-center Dose Titration Study to Investigate the Safety and Efficacy of NT 201 in Subjects Deemed to Require Total Body Doses of 800 U of NT 201 During the Course of the Study for the Treatment of Upper and Lower Limb Spasticity of the Same Body Side Due to Cerebral Causes|Completed||Phase 3|155|Actual|Merz Pharmaceuticals GmbH||1|||f||||t||||||||||2018-05-31 21:21:46.976091|2018-05-31 21:21:46.976091
NCT01603446|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2013-12-13|2012-05-21|2012-05-22|Estimate|||||||2013-12-13|2013-12-17|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome|Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome.|Completed||Phase 2|7|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 21:21:50.090846|2018-05-31 21:21:50.090846
NCT01603433|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-04-29|2012-05-18|2012-05-22|Estimate|||||||2016-04-29|2016-05-03|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2012|Actual|2012-07-31||Interventional|||The Sapheon Closure System Feasibility Study|The Sapheon Closure System Feasibility Study|Completed||N/A|38|Actual|Medtronic Endovascular||1|||f||||t||||||||No||2018-05-31 21:21:50.154183|2018-05-31 21:21:50.154183
NCT01603420|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|2015-07-31||2016-02-11|2012-05-18|2012-05-22|Estimate|2015-07-31|2015-08-31|Estimate||||2016-02-11|2016-03-14|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer|Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy With or Without Chemotherapy for High Risk Adenocarcinoma of the Prostate|Terminated||Phase 2/Phase 3|2|Actual|Proton Collaborative Group||2||enrollment goals not met|f||||t||||||||||2018-05-31 21:21:50.235453|2018-05-31 21:21:50.235453
NCT01603394|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2014-06-06||2014-06-06|2012-05-18|2012-05-22|Estimate|2014-06-06|2014-07-08|Estimate||||2014-06-06|2014-07-08|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia|A Phase 4 Multicenter, Open-Label, Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia|Terminated||Phase 4|9|Actual|Pfizer|Outcome measure PCS was removed in protocol amendment1. Study stopped due to low enrolment and not safety. Efficacy analyses were not performed; safety results are described. Overall risk-benefit of pregabalin has not changed due to trial termination|1||See termination reason in detailed description.|f||||f||||||||||2018-05-31 21:21:50.781815|2018-05-31 21:21:50.781815
NCT01603381|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2016-10-02|2012-05-18|2012-05-22|Estimate|||||||2016-10-02|2016-10-04|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effect of Family History on Insomnia During Sobriety in Alcoholics|The Effect of Family History on Insomnia During Sobriety in Alcoholics|Completed||N/A|22|Actual|Corporal Michael J. Crescenz VA Medical Center||2|||f||||f||||||||||2018-05-31 21:21:51.016373|2018-05-31 21:21:51.016373
NCT01603368|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-10-09|2012-05-21|2012-05-22|Estimate|||||||2017-10-09|2017-10-10|Actual|June 2012|Actual|2012-06-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PROPEL||Prophylactic Probiotics to Extremely Low Birth Weight Prematures|Prophylactic Probiotics to Extremely Low Birth Weight Prematures|Completed||Phase 2|134|Actual|Ostergotland County Council, Sweden||2|||f||||t||||||||||2018-05-31 21:21:51.086075|2018-05-31 21:21:51.086075
NCT01603355|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2016-07-07|2012-05-21|2012-05-22|Estimate|||||||2016-07-07|2016-07-11|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis|An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression|Terminated||Phase 1/Phase 2|3|Actual|Oregon Health and Science University||1||insufficient enrollment|f||||||||||||||2018-05-31 21:21:51.161365|2018-05-31 21:21:51.161365
NCT01603342|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2016-11-23|2012-05-21|2012-05-22|Estimate|||||||2016-11-23|2016-11-25|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers|A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers|Completed||Phase 1|18|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:21:51.224618|2018-05-31 21:21:51.224618
NCT01603329|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-10-22|2012-05-18|2012-05-22|Estimate|||||||2015-10-22|2015-10-23|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Increasing Medication Adherence Through Physician Incentives and Messaging|Increasing Medication Adherence Through Physician Incentives and Messaging|Completed||N/A|734|Actual|National Bureau of Economic Research, Inc.||11|||f||||f||||||||||2018-05-31 21:21:51.292795|2018-05-31 21:21:51.292795
NCT01603316|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2018-04-04|2012-05-18|2012-05-22|Estimate|||||||2018-04-04|2018-04-05|Actual|May 8, 2012|Actual|2012-05-08|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Food: A Three-Arm Study Examining Food Insecurity Interventions|Food: A Three-Arm Randomized Controlled Study Examining Food Insecurity Interventions|Recruiting||Phase 2|120|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 21:21:51.376166|2018-05-31 21:21:51.376166
NCT01603303|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-08-15|2012-05-18|2012-05-22|Estimate|||||||2017-08-15|2017-08-18|Actual|December 5, 2012|Actual|2012-12-05|August 2017|2017-08-31|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||Preventing Sexual Dysfunction With Aromatase Inhibitors|Preventing Sexual Dysfunction in Women on Aromatase Inhibitors|Completed||Phase 2|187|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 21:21:51.471687|2018-05-31 21:21:51.471687
NCT01603290|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-05-18|2012-05-18|2012-05-22|Estimate|||||||2012-05-18|2012-05-22|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|||Change of Fatigue and Physical Fitness in Hospitalized Hematology Patients|Change of Fatigue and Physical Fitness and Their Related Factors in Hospitalized Hematology Patients|Unknown status|Enrolling by invitation||130|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 21:21:51.579039|2018-05-31 21:21:51.579039
NCT01603264|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-12-15|2012-05-18|2012-05-22|Estimate|||||||2012-12-15|2012-12-18|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-05280014 And Trastuzumab Sourced From US And EU Administered To Healthy Male Volunteers|Completed||Phase 1|105|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:21:52.217472|2018-05-31 21:21:52.217472
NCT01603251|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2013-04-17|2012-05-21|2012-05-22|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ACTIVE||Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission|A Double Blind Randomized Controlled Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission|Completed||Phase 1/Phase 2|120|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-05-31 21:21:52.298201|2018-05-31 21:21:52.298201
NCT01603238|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444|An Open Label, Single-Dose, Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444|Completed||Phase 1|6|Actual|LG Life Sciences||1|||f||||||||||||||2018-05-31 21:21:52.373403|2018-05-31 21:21:52.373403
NCT01603225|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2018-04-03|2012-05-21|2012-05-22|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2015||2015-10-31|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|October 2020|Anticipated|2020-10-31||Observational|||Transcranial Direct Current Stimulation and Autism|The Use of Transcranial Direct Current Stimulation (tDCS) to Improve Communicative Efforts, Speech, Language and Related Cognitive Functions in Individuals With Autism|Recruiting|||40|Anticipated|Johns Hopkins University|||1||f||||t||||||||||2018-05-31 21:21:52.442858|2018-05-31 21:21:52.442858
NCT01603212|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-07-06|2012-05-21|2012-05-22|Estimate|||||||2017-07-06|2017-07-11|Actual|July 18, 2013|Actual|2013-07-18|July 2017|2017-07-31|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|||Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor|Systemic Therapy of Metastatic Melanoma With Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor|Completed||Phase 1/Phase 2|6|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:21:52.523344|2018-05-31 21:21:52.523344
NCT01603199|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2016-06-07|2012-05-21|2012-05-22|Estimate|||||||2016-06-07|2016-06-08|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|||High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis|Impact of a High-protein High-fiber Diet on the Nutritional Status of Patients With Primary Biliary Cirrhosis|Completed||N/A|36|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||||2018-05-31 21:21:52.611985|2018-05-31 21:21:52.611985
NCT01603186|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-07-05|2012-05-21|2012-05-22|Estimate|||||||2012-07-05|2012-07-09|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fed Condition|A Randomized, Open Label, Two-Treatment, Two-Period, Two-Sequence, Crossover, Single Dose, Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg With Seroquel® 25 mg in Normal, Healthy, Adult, Human Subjects, Under Fed Condition|Completed||Phase 1|54|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:21:52.679694|2018-05-31 21:21:52.679694
NCT01603173|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg Under Fasting Condition|A Randomized, Open Label, Two-Treatment, Two-Period, Two-Sequence, Crossover, Single Dose, Bioequivalence Study of Quetiapine Fumarate Tablets 25 mg With Seroquel® 25 mg in Normal, Healthy, Adult, Human Subjects, Under Fasting Condition|Completed||Phase 1|54|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:21:52.754112|2018-05-31 21:21:52.754112
NCT01603160|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-03-04|2012-05-18|2012-05-22|Estimate|||||||2015-03-04|2015-03-05|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Improving Emergency Department Management of Adults With Sickle Cell Disease|Improving Emergency Department Management of Adults With Sickle Cell Disease|Completed|||715|Actual|Duke University|||1||f||||t||||||||||2018-05-31 21:21:52.836054|2018-05-31 21:21:52.836054
NCT01603147|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2014-05-12|2012-05-21|2012-05-22|Estimate|||||||2014-05-12|2014-05-13|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety Study of Ch-mAb7F9 for Methamphetamine Abuse|A Phase Ia, Double-blind, Randomized, Placebo-controlled, Ascending IV Single-dose Study to Evaluate the Safety and Pharmacokinetics of ch mAb7F9 in Healthy Subjects|Completed||Phase 1|42|Actual|InterveXion Therapeutics, LLC||2|||f||||t||||||||||2018-05-31 21:21:52.920353|2018-05-31 21:21:52.920353
NCT01603134|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition|A Randomized, Open Label, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Comparative Bioequivalence Study of Allopurinol 300 mg Tablets USP With Zyloprim® 300 mg in Normal, Healthy, Adult, Human Male Subjects Under Fasting Condition.|Completed||Phase 1|32|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:21:52.982582|2018-05-31 21:21:52.982582
NCT01603121|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|2015-03-22||2016-08-10|2012-05-18|2012-05-22|Estimate|2016-08-10|2016-08-18|Estimate||||2016-08-10|2016-08-18|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All subjects enrolled into the study were included in the baseline analysis.|Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus|A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (9 mg/kg) Administration in Subjects With Type 1 Diabetes Mellitus|Terminated||Phase 1/Phase 2|1|Actual|Eastern Virginia Medical School|Early termination due to difficulty recruiting subjects.|2||Unable to enroll sufficient number of subjects|f||||t||||||||||2018-05-31 21:21:53.073222|2018-05-31 21:21:53.073222
NCT01603108|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-04-21|2012-05-21|2012-05-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|Rifaximin||Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant|Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients With Chronic Hepatitis C Virus Infection|Active, not recruiting||Phase 2|59|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 21:21:53.250061|2018-05-31 21:21:53.250061
NCT01603082|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|2015-06-01||2015-11-09|2012-05-21|2012-05-22|Estimate|2015-11-09|2015-12-11|Estimate||||2015-11-09|2015-12-11|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Randomized Analysis Set, defined as all participants who signed informed consent, who provided demographic and/or baseline screening assessments, and who were randomized into the study regardless of the participant's randomization and treatment status in the study.|Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients|A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention|Completed||Phase 4|343|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:21:53.501936|2018-05-31 21:21:53.501936
NCT01603069|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-07-18|2012-05-18|2012-05-22|Estimate|||||||2013-07-18|2013-07-19|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease|A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease|Completed||Phase 2|51|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:21:54.087569|2018-05-31 21:21:54.087569
NCT01603056|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2015-09-07||2016-03-29|2012-05-18|2012-05-22|Estimate|2016-03-29|2016-04-29|Estimate||||2016-03-29|2016-04-29|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Full Analysis Set|Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis|A Randomised, Double-blind, Placebo-controlled Phase III Multicentre Clinical Trial Investigating the Efficacy and Safety of Pangramin SLIT HDM-mix in Chinese Population With House Dust Mite Induced Rhinitis With or Without Asthma.|Completed||Phase 3|617|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-05-31 21:21:54.231199|2018-05-31 21:21:54.231199
NCT01603043|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|2013-12-03||2013-12-03|2012-05-21|2012-05-22|Estimate|2013-12-03|2014-01-20|Estimate||||2013-12-03|2014-01-20|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)|A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-of-Concept Study of Intravitreal AL-78898A in Patients With Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)|Terminated||Phase 2|10|Actual|Alcon Research||2||Management Decision|f||||t||||||||||2018-05-31 21:21:54.695651|2018-05-31 21:21:54.695651
NCT01603030|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-05-21|2012-05-21|2012-05-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|||Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation|Efficacy of Moxifloxacin 0.5%/Prednisolone 1% Fixed Combination Compared With Individual Administration of Moxifloxacin 0.5% and Prednisolone 1% in the Prevention of Post Operative Inflammation in Patients Having Lasik Surgery|Unknown status|Not yet recruiting|Phase 3|66|Anticipated|Adapt Produtos Oftalmológicos Ltda.||2|||f||||t||||||||||2018-05-31 21:21:54.907223|2018-05-31 21:21:54.907223
NCT01603017|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-17|2012-05-17|2012-05-21|Estimate|||||||2012-05-17|2012-05-21|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis|Nuclear Magnetic Resonance Therapy in Knee Osteoarthrosis: A Double Blind Ranomised Controlled Trial|Completed||N/A|100|Actual|NHS Grampian||2|||f||||t||||||||||2018-05-31 21:21:54.987691|2018-05-31 21:21:54.987691
NCT01603004|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-09-25|2012-05-17|2012-05-21|Estimate|||||||2017-09-25|2017-09-26|Actual|May 2012|Actual|2012-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors|A Pilot Study to Identify Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors|Recruiting|||30|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:21:55.06935|2018-05-31 21:21:55.06935
NCT01602991|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-09-22|2012-05-17|2012-05-21|Estimate|||||||2015-09-22|2015-09-24|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|EGScan||Clinic-based Nasopharyngoesophagogastroscopy Following Bariatric Surgery|Sensitivity, Specificity, and Positive and Negative Predictive Values of Clinic-based Nasopharyngoesophagogastroscopy Following Bariatric Surgery|Withdrawn||N/A|0|Actual|McMaster University||||difficulty obtaining funding|f||||f||||||||||2018-05-31 21:21:55.138621|2018-05-31 21:21:55.138621
NCT01602978|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2018-02-02|2012-05-17|2012-05-21|Estimate|||||||2018-02-02|2018-02-05|Actual|February 2010||2010-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Pleth||Comparison of Pulse Hemoglobin and Pleth Variability Index|Comparison of Pulse Hemoglobin and Pleth Variability Index to Standard Methods of Guiding Intraoperative Fluid and Transfusion Management During Major Surgical Procedures.|Active, not recruiting|||240|Actual|Loma Linda University|||||f||||f||||||||||2018-05-31 21:21:55.1906|2018-05-31 21:21:55.1906
NCT01602965|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|2017-02-03||2017-04-20|2012-05-17|2012-05-21|Estimate|2017-04-20|2017-08-02|Actual||||2017-04-20|2017-08-02|Actual|September 2012||2012-09-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Effectiveness Between Nutritional Counseling Monthly Phone Call Versus Self Help Informative Booklet|Personalized Nutritional Program Plus a Nutritional Counseling Monthly Phone Call Versus a Personalized Nutritional Program With Self Help Informative Booklet|Completed||N/A|40|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 21:21:55.234352|2018-05-31 21:21:55.234352
NCT01602952|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-03-08|2012-05-17|2012-05-21|Estimate|||||||2017-03-08|2017-03-10|Actual|July 2008||2008-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2012|Actual|2012-10-31||Interventional|||Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI|A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)|Active, not recruiting||Phase 1/Phase 2|85|Actual|Il-Yang Pharm. Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:21:55.423594|2018-05-31 21:21:55.423594
NCT01602939|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2016-08-26|2012-05-17|2012-05-21|Estimate|||||||2016-08-26|2016-08-29|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis|Subcutaneous Cladribine Plus Pegylated Interpheron Alfa-2a in Advanced Systemic Mastocytosis With D816V and Other Exon 17 KIT Mutations.|Recruiting||Phase 2/Phase 3|10|Anticipated|Hospital Virgen de la Salud||1|||f||||f||||||||Undecided||2018-05-31 21:21:55.493231|2018-05-31 21:21:55.493231
NCT01602926|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-08-24|2012-05-17|2012-05-21|Estimate|||||||2012-08-24|2012-08-28|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|September 2018|Anticipated|2018-09-30|September 2015|Anticipated|2015-09-30||Interventional|Minibunion||Prospective Trial of Minimally Invasive Surgery Versus Standard Surgery for Correction of Hallux Valgus|Randomized Prospective Trial of Minimally Invasive Surgery Versus Standard Surgery for Correction of Hallux Valgus.|Recruiting||N/A|100|Anticipated|Henry DeGroot, M.D.||2|||f||||f||||||||||2018-05-31 21:21:55.640149|2018-05-31 21:21:55.640149
NCT01602913|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-06-30|2012-05-17|2012-05-21|Estimate|||||||2014-06-30|2014-07-02|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine|Incident Type II Diabetes Mellitus Among Patients Exposed to the Combination of Pravastatin and Paroxetine|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 21:21:55.706928|2018-05-31 21:21:55.706928
NCT01602900|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-06-19|2012-05-17|2012-05-21|Estimate|||||||2017-06-19|2017-06-20|Actual|November 22, 2011|Actual|2011-11-22|June 2017|2017-06-30|April 12, 2012|Actual|2012-04-12|April 12, 2012|Actual|2012-04-12||Interventional|||Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)|Completed||Phase 1|8|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:21:55.761555|2018-05-31 21:21:55.761555
NCT01602887|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-11-08|2012-05-17|2012-05-21|Estimate|||||||2012-11-08|2012-11-12|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Relative Bioavailability Study|A Single Dose Open-Label Relative Bioavailability Study Comparing Two Capsule And A Solution Formulation Of PD-0332991 To The PD-0332991 Isethionate Capsule In Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 21:21:55.839815|2018-05-31 21:21:55.839815
NCT01602874|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2013-02-21|2012-05-17|2012-05-21|Estimate|||||||2013-02-21|2013-02-22|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia|Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years|Withdrawn||Phase 3|0|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:21:55.914384|2018-05-31 21:21:55.914384
NCT01602861|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-01-23|2012-05-18|2012-05-21|Estimate|||||||2014-01-23|2014-01-24|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|SPIREN||The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity|The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity|Unknown status|Enrolling by invitation|Phase 4|170|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 21:21:55.986395|2018-05-31 21:21:55.986395
NCT01602848|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2018-04-30|2012-05-18|2012-05-21|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2009||2009-08-31|April 2018|2018-04-30|November 1, 2013|Actual|2013-11-01|September 2011|Actual|2011-09-30||Interventional|||A Patient Centered Intervention to Improve Health and Reduce Medicaid Costs|A Patient Centered Intervention to Improve Health and Reduce Medicaid Costs|Completed||N/A|200|Actual|New York City Health and Hospitals Corporation||2|||f||||f||||||||||2018-05-31 21:21:56.075174|2018-05-31 21:21:56.075174
NCT01602835|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-02-10|2012-05-18|2012-05-21|Estimate|||||||2014-02-10|2014-02-11|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Human Urine Sample Collection for Alport Nephropathy Biomarker Studies|Human Urine Sample Collection for Alport Nephropathy Biomarker Studies|Terminated|||80|Actual|Novartis|||||f||||t||||||None Retained|"~     urine~   "|||2018-05-31 21:21:56.157991|2018-05-31 21:21:56.157991
NCT01602822|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2013-03-06|2012-05-17|2012-05-21|Estimate|||||||2013-03-06|2013-03-07|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|BMS PEP||Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV|A Phase IV Open-label Evaluation of Safety, Tolerability and Patient Acceptance of Atazanavir Boosted With Ritonavir Combined With a Fixed-dose Formulation of Tenofovir DF and Emtricitabine for Non-occupational Prophylaxis Following Potential Exposure to HIV-1|Terminated||Phase 4|11|Actual|Fenway Community Health||1||Grade 3 elevation in liver function tests|f||||f||||||||||2018-05-31 21:21:56.204673|2018-05-31 21:21:56.204673
NCT01602809|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-10-26|2012-05-18|2012-05-21|Estimate|||||||2017-10-26|2017-10-27|Actual|April 30, 2012||2012-04-30|October 25, 2017|2017-10-25|October 25, 2017||2017-10-25|||||Observational|||Microvessels and Heart Problems in Sickle Cell Disease|Microvascular and Cardiac Dysfunction in Sickle Cell Disease|Completed|||65|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:21:56.290795|2018-05-31 21:21:56.290795
NCT01602796|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-05-18|2012-05-18|2012-05-21|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ITACA||Effectiveness of Intervention on Reducing the Prevalence of Smoking Among Adolescents|Effectiveness of a Complex Intervention on Reducing the Prevalence of Smoking Among Adolescents: a Cluster Randomized Control Trial|Unknown status|Recruiting|N/A|2226|Anticipated|Fundació d'investigació Sanitària de les Illes Balears||2|||f||||f||||||||||2018-05-31 21:21:56.354146|2018-05-31 21:21:56.354146
NCT01602783|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-03-17|2012-05-18|2012-05-21|Estimate|||||||2014-03-17|2014-03-18|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||11C Acetate Imaging Post Prostatectomy|Use of 11C Acetate Imaging for Improved Prediction of the Effectiveness of Salvage Pelvic Radiation Post Prostatectomy: A Pilot Study|Terminated||N/A|2|Actual|Massachusetts General Hospital||1||Slow accrual; no further funding|f||||t||||||||||2018-05-31 21:21:56.435919|2018-05-31 21:21:56.435919
NCT01602770|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2018-05-14|2012-05-18|2012-05-21|Estimate|||||||2018-05-14|2018-05-16|Actual|July 27, 2015|Actual|2015-07-27|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|April 14, 2018|Actual|2018-04-14||Observational|||Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy|Prospective, Non-interventional, 2-year Post-authorization Safety Study for QLAIRA®|Active, not recruiting|||1|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:21:56.48715|2018-05-31 21:21:56.48715
NCT01602757|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-10-15|2012-05-17|2012-05-21|Estimate|||||||2012-10-15|2012-10-17|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetic Study of Synera in Healthy Volunteers|An Open-Label Pharmacokinetic Study of the Synera Patch Applied for 2-, 4-, and 12-hours and a Lidocaine/Tetracaine Patch Without Heat Applied for 4 Hours in Healthy Adult Volunteers|Completed||Phase 1|12|Actual|ZARS Pharma Inc.||1|||f||||f||||||||||2018-05-31 21:21:56.550754|2018-05-31 21:21:56.550754
NCT01602744|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2013-11-24||2014-03-23|2012-05-18|2012-05-21|Estimate|2014-01-23|2014-03-12|Estimate||||2014-03-23|2014-04-16|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|STOPP|All residents in the geriatric facility (382) were recruited for the trial. 23 were excluded for not fulfilling study entry criteria. The final study group was comprised of 359 residents. Residents were randomized to recieve either STOPP/START screening (intervention, n=183) or usual care (control, n=176).|The Use of STOPP/START Criteria for Medication Intervention Among Elderly Population Living in a Geriatric Hospital|The Use of STOPP/START Criteria for Medication Intervention and the Risk of Falls, Hospitalization, Functioning and Quality of Life Among Elderly Population Living in a Geriatric Hospital in Israel and Comparison to Beers|Completed||N/A|382|Actual|Wolfson Medical Center|The limitations of the study were that it was conducted in a single geriatric center. This precludes the possibility of generalizing its findings to other older segments of the community.|2|||f||||f||||||||||2018-05-31 21:21:56.614426|2018-05-31 21:21:56.614426
NCT01602731|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2015-04-22||2015-10-07|2012-05-17|2012-05-21|Estimate|2015-10-07|2015-11-06|Estimate||||2015-10-07|2015-11-06|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|TARGET||Targeted Intervention to Improve Medication Adherence in Cognitively Impaired Patients With HF (TARGET)|Targeted Intervention to Improve Medication Adherence in Cognitively Impaired Patients With Heart Failure|Completed||N/A|45|Actual|VA Office of Research and Development|Low enrollment in the study reflects the fact that many patients with HF do not admit the need for assistance with their medications. Patients should first be tested for the presence of cognitive impairment and baseline medication adherence problems.|1|||f||||f||||||||||2018-05-31 21:21:56.887569|2018-05-31 21:21:56.887569
NCT01602718|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2016-11-16|2012-05-17|2012-05-21|Estimate|||||||2016-11-16|2016-11-17|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Physical Activity and Functioning in Home Dialysis Patients|Physical Activity and Functioning in Home Dialysis Patients|Completed||N/A|120|Actual|University of Utah||3|||f||||f||||||||||2018-05-31 21:21:57.08286|2018-05-31 21:21:57.08286
NCT01602705|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-10-05|2012-05-17|2012-05-21|Estimate|||||||2014-10-05|2014-10-07|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EFIPPS||Effective Feedback to Improve Primary Care Prescribing Safety|Effective Feedback to Improve Primary Care Prescribing Safety (EFIPPS): a Randomised Controlled Trial Using ePrescribing Data|Completed||N/A|262|Actual|University of Dundee||3|||f||||f||||||||||2018-05-31 21:21:57.154018|2018-05-31 21:21:57.154018
NCT01602692|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-10-06|2012-05-17|2012-05-21|Estimate|||||||2015-10-06|2015-10-08|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||A Comparison of Tumescence in Breast Reduction Surgery|A Comparison of Tumescence in Breast Reduction Surgery|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 21:21:57.230514|2018-05-31 21:21:57.230514
NCT01602679|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2018-01-18|2012-05-18|2012-05-21|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2012||2012-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)|Acute Effects of Progesterone on LH Pulses During the Follicular Phase|Active, not recruiting||Phase 1|36|Anticipated|University of Virginia||2|||f||||t|t|f||||||Undecided|We do not have current plans to share IPD|2018-05-31 21:21:57.307452|2018-05-31 21:21:57.307452
NCT01602666|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2018-01-22|2012-05-18|2012-05-21|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2012||2012-05-31|January 2018|2018-01-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|||Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors|Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)|Recruiting||Phase 2|247|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 21:21:57.39878|2018-05-31 21:21:57.39878
NCT01602653|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-18|2012-05-18|2012-05-21|Estimate|||||||2012-05-18|2012-05-21|Estimate|November 2008||2008-11-30|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Extracorporeal Shock-wave Therapy for Supraspinatus Calcifying Tendonitis: a Randomized Clinical Trial Comparing Two Different Energy Levels|Extracorporeal Shock-wave Therapy for Supraspinatus Calcifying Tendonitis: a Randomized Clinical Trial Comparing Two Different Energy Levels|Completed||N/A|46|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:21:57.878508|2018-05-31 21:21:57.878508
NCT01602640|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-05-17|2012-05-17|2012-05-21|Estimate|||||||2012-05-17|2012-05-21|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Comparison of Morphine and Fentanyl/Midazolam in Intensive Care Unit|Sedation and Analgesia in Intensive Care: Comparison of Morphine and Fentanyl/Midazolam|Completed||N/A|90|Actual|Clínica de Los Andes IPS||2|||f||||f||||||||||2018-05-31 21:21:57.961185|2018-05-31 21:21:57.961185
NCT01602627|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2013-02-06|2012-05-18|2012-05-21|Estimate|||||||2013-02-06|2013-02-07|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies|A Phase I Dose Escalation, Single Center, Open-Label Study of AUY922 Administered IV on a Once-Weekly Schedule in Adult Patients 75 Years of Age or Older With Advanced Solid Malignancies|Terminated||Phase 1|2|Actual|Case Comprehensive Cancer Center||1||Slow accrual|f||||t||||||||||2018-05-31 21:21:58.074198|2018-05-31 21:21:58.074198
NCT01602614|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-05-23|2012-05-17|2012-05-21|Estimate|||||||2017-05-23|2017-05-25|Actual|April 2013||2013-04-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|Gan Premie||Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection|Evaluation of the Pharmacokinetics and Pharmacodynamics of Ganciclovir in Premature Infants Receiving Treatment for Cytomegalovirus Infection|Recruiting|||32|Anticipated|University of Alabama at Birmingham|||4||f||||t||||||Samples Without DNA|"~     Remnant blood will be retained for future CMV studies if subjects/subject families consent to~     future use. IRB approval for any future studies of remnant specimens will be required.~   "|||2018-05-31 21:21:58.177964|2018-05-31 21:21:58.177964
NCT01602601|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-09-21|2012-05-17|2012-05-21|Estimate|||||||2017-09-21|2017-09-25|Actual|April 9, 2012|Actual|2012-04-09|September 2017|2017-09-30|June 11, 2012|Actual|2012-06-11|June 11, 2012|Actual|2012-06-11||Observational|||A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723|A Study to Test the Possibility of Cross Reaction of the Antibodies Induced by the ELAPRASE (R) to GSK2788723 ELAPRASE is a Trade Mark Owned by a Third Party|Completed|||10|Actual|GlaxoSmithKline|||1||f||||f||||||Samples With DNA|"~     blood samples will be collected and serum will be analyzed and retained~   "|||2018-05-31 21:21:58.316645|2018-05-31 21:21:58.316645
NCT01602588|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-05-02|2012-05-17|2012-05-21|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2013||2013-05-31|May 2018|2018-05-31|November 2017|Actual|2017-11-30|October 2016|Actual|2016-10-31||Interventional|HCQ||A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)|A Randomised Phase 2 Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)|Completed||Phase 2|54|Actual|University College, London||2|||f||||t||||||||||2018-05-31 21:21:58.405811|2018-05-31 21:21:58.405811
NCT01602575|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2018-05-07|2012-05-17|2012-05-21|Estimate|||||||2018-05-07|2018-05-14|Actual|January 2013||2013-01-31|May 2018|2018-05-31|March 20, 2018|Actual|2018-03-20|March 20, 2016|Actual|2016-03-20||Interventional|||Neuroimaging and Biomarkers in Chronic Visceral Pain|Neuroimaging Biomarkers of Mind-Body Treatment Response in Chronic Visceral Pain|Completed||N/A|119|Actual|University of California, Los Angeles||1|||f||||t||||||||Yes|Neuroimaging data will be shared after initial analysis and publication at pain.ucla.edu to members of the Pain repository|2018-05-31 21:21:58.506655|2018-05-31 21:21:58.506655
NCT01602562|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2014-01-09||2016-11-18|2012-05-17|2012-05-21|Estimate|2014-01-09|2014-02-24|Estimate||||2016-11-18|2017-01-09|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients|A Multicenter, Open-label Study to Evaluate Preventive Efficacy for Herpes Simplex Virus Infection and Safety of 256U87 (Valaciclovir Hydrochloride) in Adult and Pediatric Hematopoietic Stem Cell Transplantation Patients|Completed||Phase 3|40|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:21:58.658303|2018-05-31 21:21:58.658303
NCT01602549|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2016-12-12||2016-12-12|2012-05-17|2012-05-21|Estimate|2016-12-12|2017-02-06|Estimate||||2016-12-12|2017-02-06|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||"The GSK962040 data include 37 subjects who received the 50-mg dose and 1 subject who received the 125-mg dose in the baseline description."|A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying|Completed||Phase 2|58|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:21:59.633483|2018-05-31 21:21:59.633483
NCT01602536|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2015-12-04|2012-05-17|2012-05-21|Estimate|||||||2015-12-04|2015-12-08|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Twitter-enabled Mobile Messaging for Smoking Relapse Prevention|Twitter-enabled Mobile Messaging for Smoking Relapse Prevention|Completed||N/A|280|Actual|University of California, Irvine||2|||f||||f||||||||||2018-05-31 21:22:02.120274|2018-05-31 21:22:02.120274
NCT01602523|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-12-06|2012-05-18|2012-05-21|Estimate|||||||2012-12-06|2012-12-07|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|April 2014|Anticipated|2014-04-30||Interventional|||Effect of Symbicort on Sleep Quality in Patients With Emphysema|Effect of Symbicort on Sleep Quality in Patients With Emphysema|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Temple University||2|||f||||f||||||||||2018-05-31 21:22:02.207992|2018-05-31 21:22:02.207992
NCT01602510|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2016-09-19||2016-11-29|2012-05-17|2012-05-21|Estimate|2016-11-29|2017-01-23|Estimate||||2016-11-29|2017-01-23|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Lamotrigine Phase III Study in Bipolar I Disorder|A Fixed-Dose Study of Lamotrigine Versus Placebo in the Long Term Prevention of Relapse and/or Recurrence of a Manic, Hypomanic, Mixed or Depressive Episode in Adult Subjects With Bipolar I Disorder|Completed||Phase 3|265|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:22:02.330314|2018-05-31 21:22:02.330314
NCT01602497|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-05-18|2012-05-18|2012-05-21|Estimate|||||||2012-05-18|2012-05-21|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder|A Sham-controlled Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Patients|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:22:03.009105|2018-05-31 21:22:03.009105
NCT01602484|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2013-02-15||2017-03-14|2012-05-17|2012-05-21|Estimate|2017-03-14|2017-03-31|Actual||||2017-03-14|2017-03-31|Actual|October 2011||2011-10-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Application Time of Plaster-of-Paris Splint Packs Compared to Bulk Supplies Following Standard Orthopaedic Procedure|Application Time of Plaster-of-Paris Splint Packs Compared to Bulk Supplies Following Standard Orthopaedic Procedure|Completed||N/A|50|Actual|Brigham and Women's Hospital|Splinting for one patient was interrupted secondary to airway issues unrelated to the study, so this subject was excluded from the study.|2|||f||||t|f|t|f|f||||No||2018-05-31 21:22:03.098575|2018-05-31 21:22:03.098575
NCT01602471|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2013-07-26||2013-07-26|2012-05-17|2012-05-21|Estimate|2013-07-26|2013-09-27|Estimate||||2013-07-26|2013-09-27|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Five participants enrolled, four complete and one withdrawal prior to receiving the investigational prodcut. Study was terminated early by the sponsor.|[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis|An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis|Terminated||Phase 2|5|Actual|Siemens Molecular Imaging||1||Sponsor decided to develop the product in collaboration|f||||f||||||||||2018-05-31 21:22:03.387028|2018-05-31 21:22:03.387028
NCT01602458|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-05-13|2012-05-17|2012-05-21|Estimate|||||||2014-05-13|2014-05-14|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Randomized Control Trial for Preventative Scar Management|The Use of Pressure and Silicone in Children With Skin Grafts After Traumatic Skin Injury: A Randomized Control Trial for Preventative Scar Management|Completed||N/A|12|Actual|Seton Healthcare Family||2|||f||||t||||||||||2018-05-31 21:22:03.550881|2018-05-31 21:22:03.550881
NCT01602445|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-05-09|2012-05-17|2012-05-21|Estimate|||||||2017-05-09|2017-05-11|Actual|July 2012||2012-07-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|REMARK||Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism|Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study|Completed|||700|Anticipated|Ottawa Hospital Research Institute|||1||f||||f||||||Samples With DNA|"~     Serum specimens Optional DNA banking~   "|Undecided||2018-05-31 21:22:03.639279|2018-05-31 21:22:03.639279
NCT01602432|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2014-09-08|2012-05-17|2012-05-21|Estimate|||||||2014-09-08|2014-09-10|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients|Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients|Completed|||143|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-05-31 21:22:03.730241|2018-05-31 21:22:03.730241
NCT01602419|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2018-01-26|2012-05-17|2012-05-21|Estimate|||||||2018-01-26|2018-01-29|Actual|October 2012|Actual|2012-10-31|August 2017|2017-08-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease|Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease|Completed|||120|Actual|Octapharma|||1||f||||f||||||Samples Without DNA|"~     Serum Samples~   "|||2018-05-31 21:22:03.813181|2018-05-31 21:22:03.813181
NCT01602406|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-05-29|2012-05-18|2012-05-21|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 21, 2012|Actual|2012-09-21|May 2018|2018-05-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|||Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer|A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer|Completed||Phase 1|64|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 21:22:03.903845|2018-05-31 21:22:03.903845
NCT01602393|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17||2014-01-07|2014-01-07|2012-05-17|2012-05-21|Estimate||||2014-01-07|2014-02-06|Estimate|2014-01-07|2014-02-06|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CT04 POLEP||Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase|A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment|Completed||Phase 2|51|Actual|Chiesi USA||3|||f||||f||||||||||2018-05-31 21:22:03.985195|2018-05-31 21:22:03.985195
NCT01602380|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2017-03-23||2018-04-16|2012-05-17|2012-05-21|Estimate|2017-04-07|2017-05-17|Actual||||2018-04-16|2018-04-17|Actual|October 17, 2012|Actual|2012-10-17|April 2018|2018-04-30|March 31, 2022|Anticipated|2022-03-31|April 11, 2016|Actual|2016-04-11||Interventional|FALCON|The intention to treat (ITT) analysis set included all randomised patients.|A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.|A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.|Active, not recruiting||Phase 3|462|Actual|AstraZeneca|This study consists of a primary analysis and a survival follow-up phase. Only results for the primary analysis phase are currently reported. The OS results data will be presented at a later date once the survival follow-up phase is completed.|2|||f||||||||||||||2018-05-31 21:22:04.218869|2018-05-31 21:22:04.218869
NCT01602367|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17||2015-09-23|2015-09-23|2012-05-18|2012-05-21|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects With Inadequately Controlled Hypertension|Terminated||Phase 2|7|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 21:22:05.010983|2018-05-31 21:22:05.010983
NCT01602354|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-06-27|2012-05-18|2012-05-21|Estimate|||||||2012-06-27|2012-06-28|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Observational|||Endotoxin in Gram-negative Septic Shock|Endotoxin Activity Assay as a Prognostic Factor in Gram-negative Septic Shock|Unknown status|Recruiting||20|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:22:05.151941|2018-05-31 21:22:05.151941
NCT01602341|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2017-01-11|2013-06-14|2017-01-12|2012-05-17|2012-05-21|Estimate|2017-01-12|2017-03-06|Actual|2013-06-21|2013-07-01|Estimate|2017-01-12|2017-03-06|Actual|August 2012||2012-08-31|January 2017|2017-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Intent-to-treat (ITT) population included all participants who were randomized and received study drug.|Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Four-Week, Bilateral Study of the Safety and Efficacy of Two Concentrations of AN2728 Ointment Administered Once or Twice a Day in Adolescents With Atopic Dermatitis|Completed||Phase 2|86|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:22:05.254011|2018-05-31 21:22:05.254011
NCT01602328|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-08-05|2012-05-17|2012-05-21|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|ACT-AKI||A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects|Terminated||Phase 2|156|Actual|AlloCure Inc.||2|||f||||t||||||||||2018-05-31 21:22:05.721416|2018-05-31 21:22:05.721416
NCT01602315|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2017-05-08||2018-04-19|2012-05-17|2012-05-18|Estimate|2018-04-19|2018-05-21|Actual||||2018-04-19|2018-05-21|Actual|November 12, 2012|Actual|2012-11-12|April 2018|2018-04-30|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional||Full Analysis Set (FAS) consisted of all patients who received at least one dose of either BYL719 or Cetuximab in Phase Ib and Phase II Arm 3, and all randomized patients in Phase II Scheme 1, Arm 1 and Arm 2.|A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|Terminated||Phase 1/Phase 2|179|Actual|Novartis|Recruitment of new patients who were resistant to both platinum & cetuximab into Arm 3 was halted due to slow enrollment. The study was terminated early and health authorities were informed.|7||early termination due to Sponsor decision (slow recruitment)|f||||f|t|f||||||No||2018-05-31 21:22:05.994053|2018-05-31 21:22:05.994053
NCT01602302|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2018-03-28|2012-05-17|2012-05-18|Estimate|||||||2018-03-28|2018-03-30|Actual|June 2012||2012-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|RA-BioStop||Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis|Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis|Recruiting||Phase 4|110|Anticipated|Medical University of Graz||1|||f||||t||||||||||2018-05-31 21:22:09.39162|2018-05-31 21:22:09.39162
NCT01602289|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2015-06-04|2012-05-16|2012-05-18|Estimate|||||||2015-06-04|2015-06-08|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of LY2875358 in Japanese Participants With Advanced Cancer|A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies|Completed||Phase 1|17|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:22:09.477333|2018-05-31 21:22:09.477333
NCT01602276|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-12-12|2012-05-16|2012-05-18|Estimate|||||||2017-12-12|2017-12-14|Actual|February 2012||2012-02-29|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||The Effect of tDCS on Subcortical Brain Functioning|The Effect of Transcranial Direct Current Stimulation on Subcortical Brain Functioning|Enrolling by invitation||N/A|150|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:22:09.547325|2018-05-31 21:22:09.547325
NCT01602263|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-12-05|2012-05-16|2012-05-18|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2009||2009-01-31|December 2017|2017-12-31|December 2030|Anticipated|2030-12-31|January 2025|Anticipated|2025-01-31||Observational|||Transcranial Direct Current Stimulation (tDCS) and Cognitive Processing|Transcranial Direct Current Stimulation (tDCS)and Cognitive Processing|Active, not recruiting|||300|Anticipated|Johns Hopkins University|||4||f||||t||||||||||2018-05-31 21:22:09.611413|2018-05-31 21:22:09.611413
NCT01602250|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-12-20|2012-05-16|2012-05-18|Estimate|||||||2016-12-20|2016-12-21|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|TOXALIP||Local Anaesthetics Toxicity and Intralipid®|Prevention of Systemic Toxicity Induced by Levobupivacaine and Ropivacaine by Intralipid®|Completed||Phase 2|16|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||t||||||||||2018-05-31 21:22:09.683501|2018-05-31 21:22:09.683501
NCT01602237|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2017-08-11|2012-05-16|2012-05-18|Estimate|||||||2017-08-11|2017-08-14|Actual|February 2012|Actual|2012-02-29|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2012|Actual|2012-12-31||Observational|Baker2012||Preventing Respiratory Health Problems in Bakery Employees|Preventing Respiratory Health Problems in Bakery Employees.|Completed|||253|Actual|Haukeland University Hospital|||1||f||||f||||||Samples Without DNA|"~     Serum, Nasal lavage fluid (without cells)~   "|||2018-05-31 21:22:09.761492|2018-05-31 21:22:09.761492
NCT01602224|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16||2014-09-29|2014-11-25|2012-05-17|2012-05-18|Estimate||||2014-09-29|2014-10-08|Estimate|2014-11-25|2014-12-12|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma|Completed||Phase 2|181|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 21:22:09.84165|2018-05-31 21:22:09.84165
NCT01602211|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-09-01|2012-05-16|2012-05-18|Estimate|||||||2017-09-01|2017-09-06|Actual|May 14, 2013|Actual|2013-05-14|September 2017|2017-09-30|November 28, 2016|Actual|2016-11-28|November 28, 2016|Actual|2016-11-28||Interventional|INSPIRE||INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant|INSPIRE for Survivorship After Transplant: A Multicenter Randomized Controlled Trial of an Internet and Social-Media Program for Long-Term Hematopoietic Cell Transplantation Survivors|Completed||Phase 3|1600|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 21:22:10.106825|2018-05-31 21:22:10.106825
NCT01602198|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2017-01-09||2017-01-09|2012-05-16|2012-05-18|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|June 2011||2011-06-30|December 2016|2016-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients|24-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Exelon® [Rivastigmine] Transdermal Patch in 120 APOE e4 Positive Amnestic MCI Patients|Terminated||N/A|1|Actual|The Cleveland Clinic||2||Study revised to use a different study medication and patient population.|f||||f||||||||No|No data to share.|2018-05-31 21:22:10.206668|2018-05-31 21:22:10.206668
NCT01602185|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2017-10-10|2012-05-16|2012-05-18|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|September 7, 2016|Actual|2016-09-07|June 2014|Actual|2014-06-30||Interventional|NMDA||Study of NMDA Antagonists and Neuropathic Pain|Antagonists NMDA in Relay to Ketamine in Neuropathic Pain|Completed||Phase 2|7|Actual|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 21:22:10.586605|2018-05-31 21:22:10.586605
NCT01602172|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-07-15|2012-05-17|2012-05-18|Estimate|||||||2015-07-15|2015-07-17|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Health Behavior Change for Hospitalized Veterans|Trial of Nurse-delivered Alcohol Brief Intervention for Hospitalized Veterans|Unknown status|Active, not recruiting|N/A|426|Anticipated|VA Office of Research and Development||3|||f||||f||||||||||2018-05-31 21:22:10.683745|2018-05-31 21:22:10.683745
NCT01602159|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-10-05|2012-05-17|2012-05-18|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2009|Actual|2009-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ROBUST||Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)|Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)|Recruiting||N/A|70|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:22:10.778242|2018-05-31 21:22:10.778242
NCT01602146|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-11-09|2012-05-16|2012-05-18|Estimate|||||||2012-11-09|2012-11-12|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|CHAMONIX2||Problems Associated With Ultramarathon|Acute and Chronic Problems Associated With the Practice of Mountain Ultramarathon|Completed|||35|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 21:22:10.860467|2018-05-31 21:22:10.860467
NCT01602133|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-10-24|2012-05-17|2012-05-18|Estimate|||||||2012-10-24|2012-10-25|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|ECLIPSE||Assessment of Ultrasound-guided Inserted Peripheral Intravenous Catheter|A Clinical Assessment of an Ultrasound-guided Inserted Peripheral Intravenous Catheter|Unknown status|Recruiting|N/A|29|Anticipated|Prodimed SAS||1|||f||||t||||||||||2018-05-31 21:22:10.918308|2018-05-31 21:22:10.918308
NCT01602120|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2018-05-30|2012-05-16|2012-05-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 29, 2012|Actual|2012-05-29|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|November 8, 2017|Actual|2017-11-08||Interventional|||An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy|A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies|Completed||Phase 2|159|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 21:22:10.997072|2018-05-31 21:22:10.997072
NCT01602107|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-11-06|2012-05-17|2012-05-18|Estimate|||||||2017-11-06|2017-11-07|Actual|November 2011||2011-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|SUIPT||The Effect of Pre-operative Pelvic Floor Muscle Exercise on Surgical Outcomes in Women With Stress Urinary Incontinence|Optimizing Treatment Outcomes for Women With Stress Urinary Incontinence Through the Identification of Factors Contributing to Successful Interventions|Completed||N/A|176|Actual|Queen's University||2|||f||||t||||||||||2018-05-31 21:22:11.447862|2018-05-31 21:22:11.447862
NCT01602094|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-05-17|2012-05-17|2012-05-18|Estimate|||||||2012-05-17|2012-05-18|Estimate|July 2012||2012-07-31|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Observational|||Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors|Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors|Unknown status|Not yet recruiting||550|Anticipated|Queen Saovabha Memorial Institute|||2||f||||f||||||Samples Without DNA|"~     Each participant will be taken blood sample approximately 8 ml. The blood sample will be~     centrifuged and kept as serum. The serum will be kept under - 20 degree Celsius. Then, all~     serum will be tested by ELISA.~   "|||2018-05-31 21:22:11.531731|2018-05-31 21:22:11.531731
NCT01602081|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-02-10|2012-05-17|2012-05-18|Estimate|||||||2015-02-10|2015-02-11|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|LIFT+Graft||Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula|Ligation of the Intersphincteric Fistula Tract With Tissue Graft Placement for Treatment of Persistent Trans-sphincteric Anal Fistula|Completed|||28|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 21:22:11.602709|2018-05-31 21:22:11.602709
NCT01602068|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2014-11-18||2018-05-17|2012-05-16|2012-05-18|Estimate|2018-05-17|2018-05-21|Actual||||2018-05-17|2018-05-21|Actual|May 2012||2012-05-31|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Patients planning to undergo a unilateral, posterior IOL.|Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL|A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens|Completed||Phase 2|45|Actual|Eyegate Pharmaceuticals, Inc.|The surgical procedure eliminates or washes out any remaining study drug product from the ocular tissue which becomes inflamed post-surgery. Exploratory study with multiple efficacy & safety parameters were evaluated.|2|||f||||f||||||||||2018-05-31 21:22:11.69313|2018-05-31 21:22:11.69313
NCT01602055|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-17|2012-05-16|2012-05-18|Estimate|||||||2012-05-17|2012-05-21|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects||Completed||Phase 1|24|Actual|PT Novell Pharmaceutical Laboratories||2|||f||||t||||||||||2018-05-31 21:22:11.909592|2018-05-31 21:22:11.909592
NCT01602042|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-12-03|2012-05-17|2012-05-18|Estimate|||||||2012-12-03|2012-12-04|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Adaptive Portable Essential Tremor Monitor|Phase II Study: Adaptive Portable Essential Tremor Monitor|Completed|||20|Actual|Great Lakes NeuroTechnologies Inc.|||||f||||||||||||||2018-05-31 21:22:11.977126|2018-05-31 21:22:11.977126
NCT01602029|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-11-08|2012-05-17|2012-05-18|Estimate|||||||2014-11-08|2014-11-11|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ROSES||Randomized Double Blind Placebo Control Study in Patients With Schizophrenia|Randomized Double Blind Placebo Controlled Study of Ondansetron and Simvastatis Added to Treatment as Usual in Patients With Schizophrenia|Completed||Phase 2|303|Actual|Pakistan Institute of Living and Learning||4|||f||||t||||||||||2018-05-31 21:22:12.126765|2018-05-31 21:22:12.126765
NCT01602016|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2016-11-04||2017-09-13|2012-05-17|2012-05-18|Estimate|2016-11-04|2016-11-07|Estimate||||2017-09-13|2017-10-17|Actual|May 2012||2012-05-31|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||The study sponsor (UAMS) was unable to completely monitor the study or resolve outstanding queries. The study data cannot be fully validated by the sponsor. The study was placed on Full Clinical Hold by the FDA and terminated by the sponsor as a result of investigator non-compliance.|A Folinic Acid Intervention for Autism Spectrum Disorders|A Folinic Acid Intervention for ASD: Links to Folate Receptor-alpha Autoimmunity & Redox Metabolism|Terminated||Phase 2|99|Actual|University of Arkansas||3||Non-compliance|f||||f||||||||||2018-05-31 21:22:12.354688|2018-05-31 21:22:12.354688
NCT01602003|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-17|2012-05-17|2012-05-18|Estimate|||||||2012-05-17|2012-05-18|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|June 2011|Actual|2011-06-30||Interventional|||Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes|A Multicenter, Multinational, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone|Completed||Phase 3|425|Actual|LG Life Sciences||3|||f||||||||||||||2018-05-31 21:22:12.617294|2018-05-31 21:22:12.617294
NCT01601990|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-17|2012-05-17|2012-05-18|Estimate|||||||2012-05-17|2012-05-18|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes|A Multicenter, Multinational, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes|Completed||Phase 3|189|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 21:22:12.710104|2018-05-31 21:22:12.710104
NCT01601977|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2015-05-03||2016-07-11|2012-05-17|2012-05-18|Estimate|2016-07-11|2016-08-18|Estimate||||2016-07-11|2016-08-18|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|AVAPS-AE|Study participants had a pre-existing diagnosis of COPD-OSA and were established on NIV for at least 6 months prior to study enrollement. Patients needed to be clinically stable prior to trial initiation.|Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients|Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease: A Non-randomised Pilot Study|Completed||Phase 2/Phase 3|10|Actual|Guy's and St Thomas' NHS Foundation Trust|Non-randomised controlled study|2|||f||||f||||||||Undecided||2018-05-31 21:22:12.802741|2018-05-31 21:22:12.802741
NCT01601964|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2015-08-06|2012-05-17|2012-05-18|Estimate|||||||2015-08-06|2015-08-07|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|VEGF||Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy|Vascular Endothelial Growth Factor Levels in Ectopic Pregnancy|Completed|||30|Actual|Bagcilar Training and Research Hospital|||2||f||||f||||||||||2018-05-31 21:22:13.114627|2018-05-31 21:22:13.114627
NCT01601951|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2014-03-14|2012-05-16|2012-05-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Outcomes Data of Bone Marrow Stem Cells to Treat Hip and Knee Osteoarthritis|Autologous Bone Marrow Concentrate Database Outcomes Research Project|Completed|||12|Actual|Regenerative Pain Center, Illinois|||2||f||||f||||||||||2018-05-31 21:22:13.182542|2018-05-31 21:22:13.182542
NCT01601938|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2016-03-03|2012-05-17|2012-05-18|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|SEREAL||Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients|Effects of Selenium Replacement on Prognosis of Severe Sepsis and Septic Shock Patients and Their Initial Serum Selenium Level: a Randomized, Double-blind Placebo Controlled Phase 2 Study|Withdrawn||Phase 2|0|Actual|Seoul National University Hospital||2||We failed to obtain study drugs from the company|f||||t||||||||||2018-05-31 21:22:13.248669|2018-05-31 21:22:13.248669
NCT01601925|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-01-23|2012-05-16|2012-05-18|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block|Distances From Cricoid Cartilage to the Targets of Stellate Ganglion Block|Unknown status|Recruiting|N/A|42|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 21:22:13.330052|2018-05-31 21:22:13.330052
NCT01601912|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2014-01-13|2012-05-16|2012-05-18|Estimate|||||||2014-01-13|2014-01-14|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders|Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders: a Randomized Controlled Clinical Trial for the Treatment of Central Sensitization|Completed|||59|Actual|Vrije Universiteit Brussel|||2||f||||f||||||||||2018-05-31 21:22:13.390458|2018-05-31 21:22:13.390458
NCT01601899|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|CHRU01||Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients|Molecular, Biochemical and Clinical Differences Between Stavudine and Tenofovir, Each Combined With Lamivudine and Efavirenz in South African HIV-infected Patients|Terminated||Phase 4|60|Actual|University of Witwatersrand, South Africa||3||DSMB decision to begin closeout process in view of April 2010 SA HAART guideline|f||||t||||||||||2018-05-31 21:22:13.466696|2018-05-31 21:22:13.466696
NCT01601886|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-17|2012-05-17|2012-05-18|Estimate|||||||2012-05-17|2012-05-18|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Observational|||Delivery Room Practice Change Following the Initiation of the NICHD SUPPORT Trial|Delivery Room Practice Change Following the Initiation of the NICHD SUPPORT Trial|Completed|||3843|Actual|University of Texas Southwestern Medical Center|||3||f||||f||||||||||2018-05-31 21:22:13.544642|2018-05-31 21:22:13.544642
NCT01601873|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2018-05-01|2012-05-16|2012-05-18|Estimate|||||||2018-05-01|2018-05-03|Actual|November 9, 2012|Actual|2012-11-09|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Interventional|PRICE||Propaten Randomized Investigation on Cost-benefit and Efficacy|A Randomized Controlled Comparative Study on Efficacy and Cost-effectiveness of Heparin-bonded Versus Non-heparin-bonded Polytetrafluroethylene Hemodialysis Access Grafts.|Active, not recruiting||N/A|200|Actual|The University of Texas Health Science Center, Houston||2|||f||||t|f|t|f|f|f|||Undecided|De-identified data will be available following institutional review board approval|2018-05-31 21:22:13.602604|2018-05-31 21:22:13.602604
NCT01601860|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-06-04|2012-05-16|2012-05-18|Estimate|||||||2013-06-04|2013-06-05|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|July 2014|Anticipated|2014-07-31|June 2013|Anticipated|2013-06-30||Interventional|||The Maternal and Perinatal Outcomes Associated With the Use of Non-pharmacological in Labor|Evaluation of Maternal and Perinatal Outcomes Associated With the Use of Non-pharmacological in Parturients in Active Phase of Labor|Unknown status|Recruiting|Phase 4|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:22:13.849621|2018-05-31 21:22:13.849621
NCT01601847|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-07-10|2012-05-17|2012-05-18|Estimate|||||||2017-07-10|2017-07-12|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|D-Wheeze||Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy|Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy|Active, not recruiting||Phase 4|300|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-05-31 21:22:13.932202|2018-05-31 21:22:13.932202
NCT01601834|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-07-03|2012-05-16|2012-05-18|Estimate|||||||2012-07-03|2012-07-04|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Pf-06273340 In Healthy Volunteers|Completed||Phase 1|20|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 21:22:14.024435|2018-05-31 21:22:14.024435
NCT01601821|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2013-04-29||2013-04-29|2012-05-16|2012-05-18|Estimate|2013-04-29|2013-06-19|Estimate||||2013-04-29|2013-06-19|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids|An Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids With Further CSA Elimination In The Rapamune Arm With The Introduction Of MMF|Completed||Phase 4|245|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:22:14.144539|2018-05-31 21:22:14.144539
NCT01601808|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Interventional|ViP||Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma|A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma|Unknown status|Recruiting|Phase 2|120|Anticipated|University of Liverpool||2|||f||||t||||||||||2018-05-31 21:22:15.056937|2018-05-31 21:22:15.056937
NCT01601795|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-01-28|2012-05-17|2012-05-18|Estimate|||||||2014-01-28|2014-01-29|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Sevoflurane and Isoflurane - During Cardiopulmonary Bypass With the MECC System (Minimized Extracorporeal Circuit)|Sevoflurane and Isoflurane - Cardioprotective Effects, Hemodynamic Stability and Pharmacokinetics During Cardiopulmonary Bypass With the MECC System|Completed||Phase 4|30|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 21:22:15.188935|2018-05-31 21:22:15.188935
NCT01601782|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2013-12-10||2017-12-19|2012-05-17|2012-05-18|Estimate|2014-08-18|2014-08-19|Estimate||||2017-12-19|2018-01-19|Actual|August 2009||2009-08-31|December 2017|2017-12-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional||Patients were randomly evaluated without pre-selection of gender or race|Impact of Volume Imaging Using Diagnostic Ultrasound|Impact of Volume Imaging With Ultrasound|Terminated||N/A|16|Actual|University of Michigan|16 patients were studied as part of a pilot project to determine if 3D ultrasound offers any benefit over routine standard ultrasound imaging of the extremity. The study was terminated after evaluating 16 subjects.|1||It was determined that the volume imaging was not working.|f||||f||||||||||2018-05-31 21:22:15.511085|2018-05-31 21:22:15.511085
NCT01601769|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|VITOM||Tissue Sparing Therapy of Female Precancerous Genital Lesions With VITOM|Development of a Tissue Sparing Procedure for the Diagnosis and Therapy of Female Precancerous Genital Lesions Combining Endoscopic and Ultrasound Technics.|Unknown status|Active, not recruiting|N/A|300|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 21:22:15.856226|2018-05-31 21:22:15.856226
NCT01601756|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|NavRevKnie||Joint Line Reconstruction in Navigated Total Knee Arthroplasty Revision|Joint Line Reconstruction in Navigated Total Knee Arthroplasty Revision|Unknown status|Recruiting|N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 21:22:15.919103|2018-05-31 21:22:15.919103
NCT01601743|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-01-26|2012-05-16|2012-05-18|Estimate|||||||2015-01-26|2015-01-27|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Exercise as a Behavioral Treatment for Cocaine Dependence|Exercise as a Behavioral Treatment for Cocaine Dependence|Completed||N/A|24|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 21:22:15.983107|2018-05-31 21:22:15.983107
NCT01601730|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Modafinil - Escitalopram Study for Cocaine Dependence|Combination Therapy With Modafinil and Escitalopram for the Treatment of Cocaine Dependence|Completed||Phase 1|68|Actual|Baylor College of Medicine||4|||f||||t||||||||||2018-05-31 21:22:16.050592|2018-05-31 21:22:16.050592
NCT01601717|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||RTI-336 as a Treatment for Methamphetamine Dependence|RTI-336 for Methamphetamine Dependence|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||2|||t||||t||||||||||2018-05-31 21:22:16.121534|2018-05-31 21:22:16.121534
NCT01601704|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2016-12-11||2017-02-24|2012-05-16|2012-05-18|Estimate|2017-02-24|2017-02-27|Actual||||2017-02-24|2017-02-27|Actual|June 2012||2012-06-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR|Terminated||Phase 3|8910|Actual|Orexigen Therapeutics, Inc|The study was terminated early. Outcome measures data is based on the 50% interim analysis, designated as the primary analysis. Safety data is based on all available data at the time of database lock, which occurred after the 50% interim analysis.|2|||f||||t||||||||||2018-05-31 21:22:16.27016|2018-05-31 21:22:16.27016
NCT01601691|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2014-11-04||2014-11-13|2012-05-16|2012-05-18|Estimate|2014-11-13|2014-11-14|Estimate||||2014-11-13|2014-11-14|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Protection of Rectum From High Radiation Doses|Protection of Rectum From High Radiation Doses|Completed||N/A|10|Actual|University of Oulu||1|||f||||f||||||||||2018-05-31 21:22:18.473733|2018-05-31 21:22:18.473733
NCT01601678|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2018-05-17|2012-05-16|2012-05-18|Estimate|||||||2018-05-17|2018-05-18|Actual|December 2013||2013-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2015|Actual|2015-12-31||Interventional|POEM||Endoscopic Versus Laparoscopic Myotomy for Treatment of Idiopathic Achalasia: A Randomized, Controlled Trial|Endoscopic Versus Laparoscopic Myotomy for Treatment of Idiopathic Achalasia: A Randomized, Controlled Trial|Active, not recruiting||N/A|240|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-05-31 21:22:18.60626|2018-05-31 21:22:18.60626
NCT01601665|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-08-03|2012-05-16|2012-05-18|Estimate|||||||2015-08-03|2015-08-04|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Post Approval Study of the AcrySof® IQ Toric Intraocular Lens (IOL) Models SN6AT6-SN6AT9|Post Approval Study of the AcrySof® IQ Toric High Cylinder Power IOL Models SN6AT6-SN6AT9|Completed|||477|Actual|Alcon Research|||2||f||||f||||||||||2018-05-31 21:22:18.800901|2018-05-31 21:22:18.800901
NCT01601652|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2018-03-27|2012-05-17|2012-05-18|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2011||2011-11-30|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis|Open Label, Compassionate Use Protocol of an Intravenous Fish Oil Emulsion in Infants With Cholestasis|Enrolling by invitation||Phase 1/Phase 2|5|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 21:22:18.873164|2018-05-31 21:22:18.873164
NCT01601639|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-01-24|2012-05-17|2012-05-18|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Endoscopic Band Ligation Versus Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial|Endoscopic Band Ligation vs Argon Plasma Coagulation for the Treatment of Gastric Antral Vascular Ectasia: a Randomized Clinical Trial|Completed||Phase 3|30|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 21:22:18.933304|2018-05-31 21:22:18.933304
NCT01601457|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-01-12|2012-05-16|2012-05-18|Estimate|||||||2017-01-12|2017-01-13|Estimate|September 2002||2002-09-30|January 2017|2017-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction|A Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Efficacy and Safety of Activated Recombinant Coagulation Factor VII (rFVIIa, NovoSeven®) in Patients With Major Fractures of Pelvis or Pelvis and Acetabulum Undergoing Repair Surgery|Completed||Phase 2|48|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:22:21.547258|2018-05-31 21:22:21.547258
NCT01601626|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2018-01-10||2018-02-07|2012-05-17|2012-05-18|Estimate|2018-02-07|2018-02-13|Actual||||2018-02-07|2018-02-13|Actual|July 13, 2013|Actual|2013-07-13|February 2018|2018-02-28|June 28, 2017|Actual|2017-06-28|January 19, 2017|Actual|2017-01-19||Interventional||All randomized participants were included.|Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV|A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifampin-Based Tuberculosis Treatment Versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen With Rifabutin-Based Tuberculosis Treatment With or Without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIV|Terminated||Phase 2|71|Actual|AIDS Clinical Trials Group|The study was terminated after 71 of 471 participants enrolled. Therefore, the study was under-powered and formal statistical comparisons between study arms were not undertaken as originally planned. Instead, summaries within study arm were provided.|3||The study was stopped early due to feasibility concerns.|f||||t||||||||||2018-05-31 21:22:19.024846|2018-05-31 21:22:19.024846
NCT01601613|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-01-10|2012-05-15|2012-05-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2001||2001-07-31|January 2017|2017-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombinant Factor VIIa (NovoSeven®) and Standard Haemostatic Replacement Therapy in Patients With Dengue Haemorrhagic Fever|Completed||Phase 2|28|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:22:20.306142|2018-05-31 21:22:20.306142
NCT01601600|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-11-16|2012-05-17|2012-05-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults|A Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults With Mobility Limitations|Completed||Phase 2|40|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:22:20.39729|2018-05-31 21:22:20.39729
NCT01601587|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-12-21|2012-05-15|2012-05-18|Estimate|||||||2017-12-21|2017-12-26|Actual|May 2012|Actual|2012-05-31|December 2017|2017-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Introduction Seminar About Patient Participation and Treatment Options Decisional Preferences|Introduction Seminar About Patient Participation, Treatment Options and Decisional Preferences for Psychiatric Outpatients on Waiting List|Completed||N/A|52|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 21:22:20.474665|2018-05-31 21:22:20.474665
NCT01601574|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2014-10-14|2012-05-17|2012-05-18|Estimate|||||||2014-10-14|2014-10-15|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|T2D||Weight Loss Study for People With Type 2 Diabetes|Effects on Glycemic Control and Weight of a Modified Commercial Weight Control Program for People With Type 2 Diabetes|Completed||Phase 3|563|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:22:20.552824|2018-05-31 21:22:20.552824
NCT01601561|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-05-17|2012-05-17|2012-05-18|Estimate|||||||2012-05-17|2012-05-18|Estimate|June 2010||2010-06-30|May 2012|2012-05-31||||December 2012|Anticipated|2012-12-31||Interventional|||The Effect of Insulin on Protein Metabolism After Cardiac Surgery|The Effect of Insulin on Protein Metabolism After Cardiac Surgery|Unknown status|Recruiting|N/A|30|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 21:22:20.651094|2018-05-31 21:22:20.651094
NCT01601548|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-11-29|2012-05-17|2012-05-18|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2012||2012-07-31|November 2017|2017-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy|Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy|Completed||N/A|45|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||f||||||||||2018-05-31 21:22:20.715782|2018-05-31 21:22:20.715782
NCT01601535|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2018-03-28|2012-05-16|2012-05-18|Estimate|||||||2018-03-28|2018-03-30|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 26, 2018|Actual|2018-03-26||Interventional|||Study of MLN8237 in Combination With Irinotecan and Temozolomide|Phase I/II Study of MLN8237 in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma|Active, not recruiting||Phase 1/Phase 2|44|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||1|||f||||t||||||||||2018-05-31 21:22:20.7865|2018-05-31 21:22:20.7865
NCT01601522|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2015-04-13|2012-05-16|2012-05-18|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Peanut Allergy Oral Immunotherapy Desensitization|Peanut Allergy Oral Immunotherapy Desensitization|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 21:22:20.86951|2018-05-31 21:22:20.86951
NCT01601509|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2012-05-17|2012-05-17|2012-05-18|Estimate|||||||2012-05-17|2012-05-18|Estimate|April 2010||2010-04-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|NTD||Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and|Randomized Placebo-controlled Cross-over Trial of the Effect of Nasal Tramazoline With Dexamethasone in Obstructive Sleep Apnoea Patients|Completed||N/A|23|Actual|University of Athens||2|||f||||f||||||||||2018-05-31 21:22:20.934364|2018-05-31 21:22:20.934364
NCT01601496|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-01-15|2012-05-16|2012-05-18|Estimate|||||||2014-01-15|2014-01-16|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PERFECTION||Evaluation of FUSION™ Vascular Graft for Above Knee Targets|Study of PERipheral Bypass GraFting: ProspECTive Evaluation of FUSION™ Vascular Graft for Above Knee Targets(PERFECTION)|Completed||N/A|117|Actual|Maquet Cardiovascular||1|||f||||f||||||||||2018-05-31 21:22:20.999802|2018-05-31 21:22:20.999802
NCT01601483|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2014-04-24|2012-05-17|2012-05-18|Estimate|||||||2014-04-24|2014-04-28|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration|Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration|Terminated||Phase 2/Phase 3|22|Actual|MacuCLEAR, Inc.||2||Unmasked without Sponsor's prior knowledge or authorization by the PI.|f||||f||||||||||2018-05-31 21:22:21.073908|2018-05-31 21:22:21.073908
NCT01601470|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2015-07-11||2015-10-06|2012-05-16|2012-05-18|Estimate|2015-08-25|2015-09-28|Estimate||||2015-10-06|2015-10-07|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension|An Open Label, Three-period, Single Sequence Study to Evaluate the Pharmacokinetic Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension|Completed||Phase 2|28|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:22:21.281696|2018-05-31 21:22:21.281696
NCT01601444|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Detection of Pleural Effusion by Internal Thoracic Impedance Method|Detection of Pleural Effusion by Internal Thoracic Impedance Method|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 21:22:21.615158|2018-05-31 21:22:21.615158
NCT01601431|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-04-24|2012-05-17|2012-05-18|Estimate|||||||2017-04-24|2017-04-26|Actual|March 29, 2012|Actual|2012-03-29|April 2017|2017-04-30|February 2, 2015|Actual|2015-02-02|February 2, 2015|Actual|2015-02-02||Interventional|||The Utility of Cap Colonoscopy in Increasing Adenoma Detection Rate|The Utility of Cap Colonoscopy in Increasing Adenoma Detection Rate|Terminated||N/A|440|Actual|Texas Tech University Health Sciences Center, El Paso||2||Study was inactivated by the IRB since PI left institution.|f||||t||||||||No||2018-05-31 21:22:21.669603|2018-05-31 21:22:21.669603
NCT01601418|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|October 2001||2001-10-31|May 2012|2012-05-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Effect of Single Doses of YF476 on Stomach Acidity|Double-blind, Placebo-controlled, Single-dose, 5-way Crossover Study of the Effect of YF476 (1, 5, 25 & 100 mg) on Pentagastrin-induced Gastric Acid Output in Healthy Volunteers|Completed||Phase 1|12|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 21:22:21.745669|2018-05-31 21:22:21.745669
NCT01601405|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|October 2001||2001-10-31|May 2012|2012-05-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Effect of Repeated Doses of YF476 on Stomach Acidity|Open Study of the Effect of Repeated Doses of YF476 on Pentagastrin-induced Gastric Acid Output in Healthy Volunteers|Completed||Phase 1|10|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 21:22:21.799456|2018-05-31 21:22:21.799456
NCT01601392|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-05-16|2012-05-16|2012-05-18|Estimate|||||||2012-05-16|2012-05-18|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Interventional|tDCS||Anodal and Cathodal Transcranial Direct Current Stimulation in Stroke Recovery|Effect of Anodal Versus Cathodal Transcranial Direct Current Stimulation on Stroke Recovery: a Pilot Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|40|Actual|Assiut University||3|||f||||||||||||||2018-05-31 21:22:21.853615|2018-05-31 21:22:21.853615
NCT01601379|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-05-25|2012-05-17|2012-05-18|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|PROFILE||Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.|Symptoms of Gastroesophageal Reflux Disease (GERD): Classification of Adult Subjects Suffering From Typical GERD Symptoms and Description of the Most Frequent Symptom Profiles and Characteristics - European Observational Study|Completed|||7964|Actual|Janssen-Cilag International NV|||||f||||f||||||||||2018-05-31 21:22:21.920427|2018-05-31 21:22:21.920427
NCT01601366|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-11-20|2012-05-16|2012-05-18|Estimate|||||||2017-11-20|2017-11-22|Actual|April 2012|Actual|2012-04-30|November 2017|2017-11-30|April 2015|Actual|2015-04-30|April 2013|Actual|2013-04-30||Interventional|LNGIUSAD||LNG-IUS for Treatment of Dysmenorrhea|Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial|Completed||Phase 2|62|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 21:22:21.972802|2018-05-31 21:22:21.972802
NCT01601353|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-10-10|2012-05-16|2012-05-18|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction|Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile Dysfunction|Active, not recruiting||N/A|30|Actual|Tissue Genesis, LLC||2|||f||||t||||||||||2018-05-31 21:22:22.033829|2018-05-31 21:22:22.033829
NCT01601340|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-12|||2015-03-17|2012-05-17|2012-05-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Effects of HQK-1001 in Patients With Sickle Cell Disease|A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease|Terminated||Phase 2|77|Actual|HemaQuest Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 21:22:22.099204|2018-05-31 21:22:22.099204
NCT01601327|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-17|2012-05-17|2012-05-18|Estimate|||||||2012-05-17|2012-05-18|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effects of Medications in Patients With Hypogonadism|Effects of Three Different Medications on Metabolic Parameters and Testicular Volume in Patients With Hypogonadotropic Hypogonadism-Last Three Years Experience|Completed||Phase 4|119|Actual|Gulhane School of Medicine||2|||f||||t||||||||||2018-05-31 21:22:23.253552|2018-05-31 21:22:23.253552
NCT01601314|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-01-12|2012-05-15|2012-05-18|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MAGNA||Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients|Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients|Completed||Phase 3|55|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 21:22:23.3246|2018-05-31 21:22:23.3246
NCT01601301|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-01-31|2012-05-17|2012-05-18|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2012||2012-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PINS||Post-Market Study of the Ellipse PRECICE Intramedullary Limb Lengthening System|A Post-Market Prospective Evaluation of the Performance and Safety of the Ellipse PRECICE Intramedullary Limb Lengthening System|Active, not recruiting||N/A|32|Actual|Ellipse Technologies, Inc.||1|||f||||f||||||||||2018-05-31 21:22:23.392452|2018-05-31 21:22:23.392452
NCT01601288|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-11-06|2012-05-16|2012-05-17|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2012||2012-05-31|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital|Prospective Database of All Patients Who Have Undergone Pulmonary Function Testing at Singapore General Hospital|Recruiting|||25000|Anticipated|Singapore General Hospital|||||f||||f||||||||||2018-05-31 21:22:23.47258|2018-05-31 21:22:23.47258
NCT01601275|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-11-06|2012-05-16|2012-05-17|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2012||2012-05-31|November 2017|2017-11-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|||Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection|Prospective Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection Treated at Singapore General Hospital|Recruiting|||4000|Anticipated|Singapore General Hospital|||||f||||f||||||||||2018-05-31 21:22:23.543145|2018-05-31 21:22:23.543145
NCT01601262|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-07-25|2012-05-16|2012-05-17|Estimate|||||||2012-07-25|2012-07-26|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|January 2015|Anticipated|2015-01-31|July 2014|Anticipated|2014-07-31||Interventional|||Efficacy & Safety of a 2nd Series of Low Intensity Shock Waves for ED on Partial Responders to First Treatment|Efficacy and Safety of a Second Series of Low Intensity Extracorporeal Shock Wave Therapy (LI-ESWT) Treatment for Erectile Dysfunction Patients Who Were Partial Responders to the Initial Treatment.|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 21:22:23.607417|2018-05-31 21:22:23.607417
NCT01601249|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-08-19|2012-05-16|2012-05-17|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Improving IVF Embryo Quality Grading Using Polarized Light|A Prospective Comparison Between Conventional IVF Embryo Grading and Polscope Based Grading|Withdrawn||Phase 1|0|Actual|Hadassah Medical Organization||2||PI moved from Hadassah|f||||f||||||||||2018-05-31 21:22:23.696965|2018-05-31 21:22:23.696965
NCT01601236|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2017-05-18||2017-07-21|2012-05-16|2012-05-17|Estimate|2017-06-23|2017-07-24|Actual||||2017-07-21|2017-08-21|Actual|May 2012||2012-05-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional||All randomized subjects|Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.|Completed||Phase 2|34|Actual|Mallinckrodt|Groups 5 & 6 were closed when 2 of the 1st 4 subjects met predefined tolerability criteria. Enrollment terminated early at 34/40 subjects due to slow recruitment.16 of 34 subjects discontinued prior to collecting primary endpoint data at week 36.|6|||f||||||||||||||2018-05-31 21:22:23.959636|2018-05-31 21:22:23.959636
NCT01601223|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-10-13|2012-05-16|2012-05-17|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Observational|LAS VEGAS||Local Assessment of Ventilatory Management During General Anesthesia for Surgery|Local Assessment of Ventilatory Management During General Anesthesia for Surgery - a Prospective Observational Multi-center Cohort Study|Completed|||10690|Actual|European Society of Anaesthesiology|||1||f||||f||||||||||2018-05-31 21:22:25.112455|2018-05-31 21:22:25.112455
NCT01601210|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2016-10-24|2012-05-15|2012-05-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder|Placebo-Controlled Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study|Completed||Early Phase 1|32|Actual|University of Utah||4|||f||||t||||||||Yes||2018-05-31 21:22:25.318384|2018-05-31 21:22:25.318384
NCT01601197|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2012-10-23|2012-05-15|2012-05-17|Estimate|||||||2012-10-23|2012-10-24|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|||A Study of Two Injection Techniques to Reduce Pain in Infants Undergoing Immunization|A Study of Two Injection Techniques Added to Proven Strategies to Reduce Pain in One- to Twelve-month Old Infants Undergoing Immunization|Unknown status|Recruiting|Phase 3|120|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 21:22:25.38245|2018-05-31 21:22:25.38245
NCT01601184|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2018-03-02|2012-05-16|2012-05-17|Estimate|||||||2018-03-02|2018-03-05|Actual|June 2012||2012-06-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway|An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway|Recruiting||Phase 1/Phase 2|38|Anticipated|Centre Leon Berard||3|||f||||t||||||||||2018-05-31 21:22:25.464235|2018-05-31 21:22:25.464235
NCT01601171|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2016-07-06|2012-05-16|2012-05-17|Estimate|||||||2016-07-06|2016-07-07|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome)|The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome)|Recruiting|||2000|Anticipated|Centre Hospitalier Universitaire Vaudois|||2||f||||f||||||Samples With DNA|"~     whole blood, serum/plasma, white blood cells, DNA~   "|||2018-05-31 21:22:25.639624|2018-05-31 21:22:25.639624
NCT01601158|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2014-01-08|2012-05-16|2012-05-17|Estimate|||||||2014-01-08|2014-01-09|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Umbilical Cord Blood Therapy for Children With Global Developmental Delay|Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Children With Global Developmental Delay|Completed||N/A|10|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 21:22:25.715187|2018-05-31 21:22:25.715187
NCT01601145|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-08-21|2012-05-16|2012-05-17|Estimate|||||||2012-08-21|2012-08-22|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Probiotic on the Plaque pH. A Randomized Double Blind Interventional Study||Completed||Phase 4|192|Actual|Università degli Studi di Sassari||2|||f||||f||||||||||2018-05-31 21:22:25.78119|2018-05-31 21:22:25.78119
NCT01601132|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2013-03-07||2013-04-18|2012-05-15|2012-05-17|Estimate|2013-04-18|2013-06-17|Estimate||||2013-04-18|2013-06-17|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Drug Interaction Study of Colchicine and Theophylline|An Open-Label, One Sequence, Pharmacokinetic Drug Interaction Study of Colchicine and Theophylline in Healthy Subjects|Completed||Phase 4|30|Actual|Takeda||2|||f||||f||||||||||2018-05-31 21:22:25.864661|2018-05-31 21:22:25.864661
NCT01601119|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2015-05-28|2012-05-16|2012-05-17|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients|The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients|Completed|||545|Actual|Merck KGaA|||2||f||||f||||||||||2018-05-31 21:22:26.149423|2018-05-31 21:22:26.149423
NCT01601106|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-05-18|2012-05-16|2012-05-17|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2011||2011-09-30|May 2012|2012-05-31||||May 2013|Anticipated|2013-05-31||Interventional|SILENCE||Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease|A Phase I/II, Single-Center, Randomized, Placebo-Controlled Study Evaluating the Therapeutic Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) in Subjects With Severe Inflamed Carotid or Aortic Atherosclerosis Plaques|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||||||||||||2018-05-31 21:22:26.211846|2018-05-31 21:22:26.211846
NCT01601093|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-06-03|2012-05-16|2012-05-17|Estimate|||||||2013-06-03|2013-06-05|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|November 2013|Anticipated|2013-11-30|August 2013|Anticipated|2013-08-31||Interventional|CAZ-SBT||Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection|Unknown status|Recruiting|Phase 2|288|Anticipated|Xiangbei Welman Pharmaceutical Co., Ltd||3|||f||||t||||||||||2018-05-31 21:22:26.367797|2018-05-31 21:22:26.367797
NCT01601080|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2014-02-03|2012-05-16|2012-05-17|Estimate|||||||2014-02-03|2014-02-04|Estimate|April 2012||2012-04-30|February 2014|2014-02-28||||October 2012|Actual|2012-10-31||Observational|READER||An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device|REbiSmart™ Retrospective ADherencE Review (READER) An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device|Completed|||230|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 21:22:26.445309|2018-05-31 21:22:26.445309
NCT01601067|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-04-10|2012-05-15|2012-05-17|Estimate|||||||2018-04-10|2018-04-11|Actual|January 21, 2013|Actual|2013-01-21|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Integrated Alcohol Disorder and PTSD Treatment|Integrated Alcohol Disorder and PTSD Treatment|Completed||Phase 2|119|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|"Final data sets underlying all publications resulting from the proposed research will be shared outside VA.~A de-identified, anonymized dataset will be created and shared. Requests for access must be made in writing signed by a requestor from the United States and include an email address for delivery and an assurance that the recipient will not attempt to identify or re-identify any individual. The request should reference the publication underlying the request.~One or more data sets without personal identifiers will be generated during the data analysis phase of this study. The data sets will include all data underlying any publications generated by this study and therefore these will be sufficient to reproduce or verify any published findings.~Any HIPAA identifiers, or combinations of variables that could be used for re-identification, will be excluded, as will any proprietary information. The plan excludes access to individually identifiable or proprietary data."|2018-05-31 21:22:26.50056|2018-05-31 21:22:26.50056
NCT01601054|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-04-17|2012-05-15|2012-05-17|Estimate|||||||2016-04-17|2016-04-19|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SALIF||Supplemental Anterior Lumbar Interbody Fusion (ALIF) in Spinal Deformity|Supplemental Anterior Lumbar Interbody Fusion in Posterior Instrumented Fusion in Surgical Treatment of Spinal Deformities. A Randomized Study|Completed||N/A|30|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 21:22:26.56142|2018-05-31 21:22:26.56142
NCT01601041|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2016-11-21|2012-05-15|2012-05-17|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Role of Residual Urine and Asymptomatic Prostatitis in the Development of Urinary Tract Infections in Spinal Cord Injury|Role of Residual Urine and Asymptomatic Prostatitis in the Development of Lower Urinary Tract Infections in Spinal Cord Injury Patients - a Prospective Study|Completed|||60|Actual|Swiss Paraplegic Centre Nottwil|||2||f||||f||||||||||2018-05-31 21:22:26.678518|2018-05-31 21:22:26.678518
NCT01601028|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|||2013-10-16|2012-05-15|2012-05-17|Estimate|||||||2013-10-16|2013-10-17|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome|Phase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome|Completed||Phase 3|39|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:22:26.757807|2018-05-31 21:22:26.757807
NCT01601015|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-05-16|2012-05-16|2012-05-17|Estimate|||||||2012-05-16|2012-05-17|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Effectiveness of the Treatment of Tension-type Headache With Manual and Manipulative Therapy|Effectiveness of the Treatment of Tension-type Headache With Manual and Manipulative Therapy in the Perception of Pain and Cervical Motion: a Double-blind, Randomized, Placebo-controlled Clinical Trial.|Completed||N/A|84|Actual|University of Valencia||4|||f||||t||||||||||2018-05-31 21:22:26.836232|2018-05-31 21:22:26.836232
NCT01601002|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2016-04-20|2012-05-16|2012-05-17|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression|Does LEPR Polymorphism Predict Variability in Weight Gain Induced by Mirtazapine in the Treatment of Late Life Depression?|Completed||Phase 4|19|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 21:22:26.922267|2018-05-31 21:22:26.922267
NCT01600989|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2014-04-24|2012-05-15|2012-05-17|Estimate|||||||2014-04-24|2014-04-25|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|MitoSepsis||Mitochondrial Function of Immune Cells in Sepsis|Mitochondrial Function of Immune Cells in Severe Sepsis and Septic Shock - a Prospective Observational Cohort Study|Completed|||60|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||Samples With DNA|"~     Serum, isolated B-cells, T-cells, Monocytes~   "|||2018-05-31 21:22:26.99376|2018-05-31 21:22:26.99376
NCT01600976|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2013-11-08|2012-05-16|2012-05-17|Estimate|||||||2013-11-08|2013-11-11|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment|A Phase I Study to Assess the Safety and Pharmacokinetics of Telaprevir (VX-950) in Subjects With Moderate and Severe Hepatic Impairment|Completed||Phase 1|24|Actual|Janssen Infectious Diseases BVBA||3|||f||||f||||||||||2018-05-31 21:22:27.07024|2018-05-31 21:22:27.07024
NCT01600963|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-11-30|2012-05-16|2012-05-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|November 2022|Anticipated|2022-11-30|July 2016|Anticipated|2016-07-31||Interventional|||A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis|A Phase III Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Efficacy and Safety of TMC207 in Subjects With Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB)|Withdrawn||Phase 3|0|Actual|Janssen Infectious Diseases BVBA||2||PhIII program revised; TMC207-C210 cancelled|f||||t||||||||||2018-05-31 21:22:27.162615|2018-05-31 21:22:27.162615
NCT01600950|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2014-10-03||2014-10-03|2012-05-15|2012-05-17|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All randomized participants.|A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus|Pharmacodynamics of LY2963016 Compared to LANTUS® in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|20|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:22:27.342671|2018-05-31 21:22:27.342671
NCT01600937|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-03-22|2012-05-16|2012-05-17|Estimate|||||||2017-03-22|2017-03-24|Actual|October 2012||2012-10-31|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|IDES-2||Italian Diabetes and Exercise Study 2|Italian Diabetes and Exercise Study 2 - A Long-term Behavioural Intervention for Adoption and Maintenance of a Physically Active Lifestyle|Completed||N/A|300|Actual|Metabolic Fitness Association, Italy||2|||f||||f||||||||||2018-05-31 21:22:27.573157|2018-05-31 21:22:27.573157
NCT01600924|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-03-22|2012-05-16|2012-05-17|Estimate|||||||2017-03-22|2017-03-24|Actual|September 2016|Actual|2016-09-30|March 2017|2017-03-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Observational|SAMBA||Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes|Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes|Recruiting|||500|Anticipated|Metabolic Fitness Association, Italy|||||f||||f||||||Samples Without DNA|"~     Whole blood, plasma, serum and urine samples~   "|No||2018-05-31 21:22:27.665475|2018-05-31 21:22:27.665475
NCT01600911|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-05-17|2012-05-16|2012-05-17|Estimate|||||||2012-05-17|2012-05-18|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Establish a Vegetable Signature Database From Human Metabolomics Responses|Establish a Vegetable Signature Database From Human Metabolomics Responses|Unknown status|Active, not recruiting|N/A|50|Anticipated|National Health Research Institutes, Taiwan|||||f||||f||||||||||2018-05-31 21:22:27.747651|2018-05-31 21:22:27.747651
NCT01600898|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-05-02|2012-05-16|2012-05-17|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2012||2012-03-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|DELPHI-2||Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers|Screening and Risk Factors of Pulmonary Arterial Hypertension in BMPR2 Mutation Asymptomatic Carriers|Completed|||57|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||||||2018-05-31 21:22:27.796854|2018-05-31 21:22:27.796854
NCT01600885|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2014-08-29||2017-07-20|2012-05-16|2012-05-17|Estimate|2014-10-22|2014-10-28|Estimate||||2017-07-20|2017-08-21|Actual|August 2008||2008-08-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|GuaKet|Baseline population is the number of participants who started the study|The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects|The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects|Completed||N/A|16|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:22:27.858698|2018-05-31 21:22:27.858698
NCT01600872|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2013-11-04|2012-05-16|2012-05-17|Estimate|||||||2013-11-04|2013-11-06|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Oxidative Stress and Bisphenol A (BPA) Impact With Polycystic Ovary Syndrome (PCOS)|Oxidative Stress and BPA Impact With PCOS|Unknown status|Recruiting||300|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 21:22:28.054899|2018-05-31 21:22:28.054899
NCT01600859|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2016-12-29|2012-05-15|2012-05-17|Estimate|||||||2016-12-29|2016-12-30|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease|Completed||Phase 1|65|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 21:22:28.105554|2018-05-31 21:22:28.105554
NCT01600846|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-07-27|2012-05-16|2012-05-17|Estimate|||||||2017-07-27|2017-07-28|Actual|December 2012||2012-12-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Pharmacogenetic Testing in Primary Care|Delivery of Pharmacogenetic Testing in a Primary Care Setting|Completed|||400|Anticipated|Duke University|||||f||||t||||||||||2018-05-31 21:22:28.223954|2018-05-31 21:22:28.223954
NCT01600833|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2013-11-06|2012-05-16|2012-05-17|Estimate|||||||2013-11-06|2013-11-07|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The Association of Ferrtin and Homocysteine Etc. With RI and MS in Polycystic Ovary Syndrome (PCOS)|To Association of Serum Ferrtin and Homocysteine Levels With Insulin Resistence and Metabolic Syndrome in Women With Polycystic Ovary Syndrome|Completed|||539|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 21:22:28.277554|2018-05-31 21:22:28.277554
NCT01600820|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2016-12-06|2012-05-16|2012-05-17|Estimate|||||||2016-12-06|2016-12-07|Estimate|February 2005||2005-02-28|December 2016|2016-12-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Spain)|A Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Study on the Effects of a Fermented Dairy Product Enriched With Phytosterols Over Blood Cholesterol Levels of Hypercholesterolemic Adult Subjects|Completed||N/A|126|Actual|Danone Research||3|||f||||f||||||||||2018-05-31 21:22:28.33872|2018-05-31 21:22:28.33872
NCT01600807|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-06-25|2012-05-15|2012-05-17|Estimate|||||||2013-06-25|2013-06-26|Estimate||||June 2013|2013-06-30||||||||Interventional|||OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas|Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas|Withdrawn||Phase 1/Phase 2|0|Actual|Dana-Farber Cancer Institute||2||"Study was pending major changes and was on hold, pending activation; administratively~   withdrawn; will be submitted as a new protocol if study is revised."|f||||t||||||||||2018-05-31 21:22:28.394094|2018-05-31 21:22:28.394094
NCT01600794|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-16|2012-05-16|2012-05-17|Estimate|||||||2012-05-16|2012-05-17|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|||||Observational|||To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization|To Evaluate The Androgens and Ovary Function Impact on The Pregnancy Outcome in In Vitro Fertilization|Suspended|||1000|Anticipated|Taipei Medical University WanFang Hospital|||1||f||||f||||||||||2018-05-31 21:22:28.533528|2018-05-31 21:22:28.533528
NCT01600781|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2015-02-08|2012-05-16|2012-05-17|Estimate|||||||2015-02-08|2015-02-10|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic Leukemia|Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed on the Nutritional Status, Gut Microbiota and Quality of Life of Children With Acute Lymphocytic Leukemia: an Egyptian Pilot Study|Completed||N/A|120|Actual|Children's Cancer Hospital Egypt 57357||2|||f||||t||||||||||2018-05-31 21:22:28.577748|2018-05-31 21:22:28.577748
NCT01600768|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2012-05-16|2012-05-16|2012-05-17|Estimate|||||||2012-05-16|2012-05-17|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of Extended Intravenous of Beta-lactams in the Treatment of Serious Gram-negative Infections in Critically Ill Patients||Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||||||||||||2018-05-31 21:22:28.650398|2018-05-31 21:22:28.650398
NCT01600755|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-11-29|2012-05-15|2012-05-17|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2012||2012-05-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous Cell Therapy for Treatment of Fecal Incontinence|A Prospective Nonrandomized Study of Autologous Muscle Derived Cell (AMDC) Transplantation for Treatment of Fecal Incontinence|Recruiting||Phase 1/Phase 2|50|Anticipated|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 21:22:28.726491|2018-05-31 21:22:28.726491
NCT01600742|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-01-07|2012-05-16|2012-05-17|Estimate|||||||2014-01-07|2014-01-09|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis|Vorinostat and Concomitant Whole Brain Radiation Therapy in Patients With Brain Metastases: A Randomized, Double-blind, Placebo-controlled, Phase II Study|Terminated||Phase 2|4|Actual|National Taiwan University Hospital||2||Sponsor stops to provide the study drug.|f||||t||||||||||2018-05-31 21:22:28.804061|2018-05-31 21:22:28.804061
NCT01600729|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2013-07-12||2013-09-27|2012-05-15|2012-05-17|Estimate|2013-07-12|2013-09-17|Estimate||||2013-09-27|2013-09-30|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Reliability of the Facial Wrinkle Scale in Japanese Subjects||Completed|||66|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:22:28.888442|2018-05-31 21:22:28.888442
NCT01600716|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2016-02-17|2015-04-29|2016-05-11|2012-05-15|2012-05-17|Estimate|2016-02-17|2016-03-22|Estimate|2015-06-15|2015-07-13|Estimate|2016-05-11|2016-06-15|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|April 2014|Actual|2014-04-30||Interventional|||Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)||Completed||Phase 3|144|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:22:29.066542|2018-05-31 21:22:29.066542
NCT01600703|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2014-03-24||2017-01-20|2012-05-16|2012-05-17|Estimate|2014-04-02|2014-05-05|Estimate||||2017-01-20|2017-01-23|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans|Sitagliptin (®Januvia) Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans|Completed||Phase 2/Phase 3|21|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:22:29.483495|2018-05-31 21:22:29.483495
NCT01600690|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2013-08-12|2012-05-16|2012-05-17|Estimate|||||||2013-08-12|2013-08-13|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SStatin-EPC||Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients|Evaluation of the Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients. A Controlled Randomized Study|Completed||Phase 4|34|Actual|University of Padova||2|||f||||f||||||||||2018-05-31 21:22:29.679005|2018-05-31 21:22:29.679005
NCT01600677|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2016-01-14||2016-08-18|2012-05-15|2012-05-17|Estimate|2016-08-18|2016-08-26|Estimate||||2016-08-18|2016-08-26|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|EMMA-RCT||Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions|Determining the Impact of a Medication Delivery Unit on Medication Adherence Immediately Following Hospitalization of Adults With Common Cardiac Conditions|Terminated||N/A|11|Actual|University of Pittsburgh|We terminated the study early after exhausting all possible approaches to increasing participant enrollment.|2||Terminated on 2/28/13, low enrollment; last participant med visit 5/13/13.|f||||t||||||||||2018-05-31 21:22:29.765395|2018-05-31 21:22:29.765395
NCT01600664|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2014-05-04|2012-05-16|2012-05-17|Estimate|||||||2014-05-04|2014-05-06|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||"The Effect of the Use of Computer Game- My Diabetic Friend in Children With Type 1 Diabetes"|"Randomized Controlled Trial to Evaluate the Effect of 3 Months Use With Interactive Computer Game- My Diabetic Friend-Comparing to Conventional Diabetes Education on Metabolic Control, Quality of Life and Diabetes Knowledge in Children With Type 1 Diabetes."|Completed||N/A|30|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 21:22:29.97411|2018-05-31 21:22:29.97411
NCT01600651|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-10-01|2012-05-15|2012-05-17|Estimate|||||||2013-10-01|2013-10-07|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|DAMAGE||Diffuse Acute Respiratory Distress Syndrome (ARDS), Recruitment Maneuver, and sRAGE (DAMAGE Study)|Effects Of A Recruitment Maneuver On Plasma Levels of sRAGE, The Soluble Form of The Receptor For Advanced Glycation End Products, In Patients With Diffuse Acute Respiratory Distress Syndrome (ARDS)|Completed||Phase 4|24|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 21:22:30.051669|2018-05-31 21:22:30.051669
NCT01600638|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-06-20|2012-05-16|2012-05-17|Estimate|||||||2017-06-20|2017-06-22|Actual|April 2012||2012-04-30|April 2012|2012-04-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature|Non-Invasive Reduction of Fat in the Flanks of Patients With Sharp Body Curvature|Completed||N/A|25|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 21:22:30.119639|2018-05-31 21:22:30.119639
NCT01600625|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2014-03-04|2012-05-16|2012-05-17|Estimate|||||||2014-03-04|2014-03-05|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction||Completed||N/A|46|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 21:22:30.175462|2018-05-31 21:22:30.175462
NCT01600612|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2013-05-30|2012-05-16|2012-05-17|Estimate|||||||2013-05-30|2013-05-31|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial|Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial|Unknown status|Recruiting|N/A|300|Anticipated|Sohag University||3|||f||||t||||||||||2018-05-31 21:22:30.230754|2018-05-31 21:22:30.230754
NCT01600599|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-05-17|2012-05-16|2012-05-17|Estimate|||||||2012-05-17|2012-05-18|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|LATA||Reducing Post Operative Bleeding Following Cabg|Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial|Completed||N/A|40|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 21:22:30.312075|2018-05-31 21:22:30.312075
NCT01600391|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-12-02|2012-05-16|2012-05-17|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|VCTpilot||Visual Cues for Gait Training Post-stroke|Visual Cue Training to Improve Walking and Turning After Stroke: a Pilot Study|Completed||N/A|60|Actual|University of Salford||3|||f||||t||||||||||2018-05-31 21:22:32.444669|2018-05-31 21:22:32.444669
NCT01600586|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2015-12-11||2018-04-04|2012-05-14|2012-05-17|Estimate|2018-04-04|2018-05-07|Actual||||2018-04-04|2018-05-07|Actual|April 2012||2012-04-30|April 2018|2018-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||NICU infants|A Clinical Trial of A Pacifier-Activated Music Player|A Pacifier-Activated Music Player With Mother's Voice Improves Oral Feeding in Preterm Infants|Completed||N/A|100|Actual|Vanderbilt University Medical Center|PI left Vanderbilt, data obtained from publication http://pediatrics.aappublications.org/content/133/3/462.full|2|||f||||f||||||||||2018-05-31 21:22:30.410923|2018-05-31 21:22:30.410923
NCT01600573|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2016-10-10|2012-05-16|2012-05-17|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)|A Phase I/II Study of Pazopanib and Weekly Topotecan in Patients With Platinum-resistant or Intermediate-sensitive Recurrent Ovarian Cancer|Recruiting||Phase 1/Phase 2|68|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||No||2018-05-31 21:22:30.679192|2018-05-31 21:22:30.679192
NCT01600560|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-04-17|2012-05-16|2012-05-17|Estimate|||||||2017-04-17|2017-04-18|Actual|May 2012|Actual|2012-05-31|April 2017|2017-04-30|July 5, 2016|Actual|2016-07-05|November 9, 2015|Actual|2015-11-09||Observational|||Facilitating Completion of HPV Vaccination|Facilitating the Completion of the 3-Dose Series of HPV Vaccination in Males and Females|Completed|||223|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 21:22:30.82587|2018-05-31 21:22:30.82587
NCT01600547|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-12-05|2012-05-14|2012-05-17|Estimate|||||||2014-12-05|2014-12-08|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Observational|OFOS||Odense Fallers and Osteoporosis Study|Odense Fallers and Osteoporosis Study|Completed|||322|Actual|University of Southern Denmark|||3||f||||t||||||||||2018-05-31 21:22:30.876636|2018-05-31 21:22:30.876636
NCT01600534|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2014-09-10|2012-05-16|2012-05-17|Estimate|||||||2014-09-10|2014-09-12|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||GooDMoMS: A Multimodel Pregnancy and Postpartum Intervention for Gestational Diabetics|GooDMomS: A Multimodel Pregnancy and Postpartum Intervention for Gestational Diabetics|Completed||N/A|24|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:22:30.937132|2018-05-31 21:22:30.937132
NCT01600521|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2015-04-07|2012-05-15|2012-05-17|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2004||2004-11-30|April 2015|2015-04-30|March 2012|Actual|2012-03-31|April 2011|Actual|2011-04-30||Interventional|||A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications|A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications|Completed||N/A|1748|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 21:22:31.002962|2018-05-31 21:22:31.002962
NCT01600508|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-06-15|2012-05-16|2012-05-17|Estimate|||||||2016-06-15|2016-06-17|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Videoconference in Stoma Out-patient Clinic|. A Randomized Controlled Trial Comparing Videoconference and Outpatient Stoma Care|Completed||N/A|110|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 21:22:31.133052|2018-05-31 21:22:31.133052
NCT01600495|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2012-05-16||2015-09-18|2012-05-16|2012-05-17|Estimate|2014-02-02|2014-03-17|Estimate||||2015-09-18|2015-10-05|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Transcutaneous Electrical Nerve Stimulation for Pain Relief During the Active Phase of Labor|Effects of Transcutaneous Nerve Electrical Stimulation for Pain Relief in Nulliparous Women in Active Phase of Labor|Completed||Phase 4|46|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:22:31.248315|2018-05-31 21:22:31.248315
NCT01600482|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|2017-05-16||2017-07-24|2012-05-16|2012-05-17|Estimate|2017-07-24|2017-08-23|Actual||||2017-07-24|2017-08-23|Actual|May 2012||2012-05-31|July 2017|2017-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)|Clinical Investigation Plan (CIP) for Safety and Efficacy Study of Arterial Closure Device (CELT ACD). Clinical Investigation Plan No.: CIP-TS-003|Completed||N/A|241|Actual|Vasorum Ltd||2|||f||||t||||||||||2018-05-31 21:22:31.60395|2018-05-31 21:22:31.60395
NCT01600469|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-06-03|2012-05-15|2012-05-17|Estimate|||||||2013-06-03|2013-06-04|Estimate|January 2012||2012-01-31|April 2011|2011-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease|NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease|Completed||Phase 2|86|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:22:31.960313|2018-05-31 21:22:31.960313
NCT01600456|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2016-03-03|2012-05-15|2012-05-17|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|OPT||Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline|Optimizing PTSD Treatment: PE Versus PE Plus Sertraline|Unknown status|Active, not recruiting|Phase 3|150|Actual|Case Western Reserve University||4|||f||||t||||||||||2018-05-31 21:22:32.034466|2018-05-31 21:22:32.034466
NCT01600443|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-01-31|2012-05-15|2012-05-17|Estimate|||||||2014-01-31|2014-02-03|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Comparison of Microtrauma in Urethra After Usage of Different Catheters|A Randomized Cross-over Study on Urethral Microtrauma After Intermittent Catheterization.|Terminated||N/A|21|Actual|Wellspect HealthCare||6||Planned interim analysis showed study was underpowered|f||||||||||||||2018-05-31 21:22:32.116541|2018-05-31 21:22:32.116541
NCT01600430|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-02-08|2012-05-15|2012-05-17|Estimate|||||||2017-02-08|2017-02-10|Actual|June 2012||2012-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Vitamin D Supplementation for Extremely Preterm Infants|Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial|Completed||Phase 2/Phase 3|100|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-05-31 21:22:32.192629|2018-05-31 21:22:32.192629
NCT01600417|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-11-21|2012-05-15|2012-05-17|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Investigation of Lumbo-sacral Instability Using Custom Made Table - a Pilot Study|Radiologic Presentation of Lumbo-sacral Instability Using a Custom Made Table - a Pilot Study|Terminated|||4|Actual|Swiss Paraplegic Centre Nottwil|||1|principal investigator has left the institution|f||||f||||||||||2018-05-31 21:22:32.283401|2018-05-31 21:22:32.283401
NCT01600404|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-11-16|2012-05-15|2012-05-17|Estimate|||||||2015-11-16|2015-11-17|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Effects of Antimuscarinics on Cognition in Spinal Cord Injury|Effects of Antimuscarinic Drugs on the Cognition of Patients With Acute Spinal Cord Injury|Completed|||32|Actual|Swiss Paraplegic Centre Nottwil|||2||f||||f||||||||||2018-05-31 21:22:32.349092|2018-05-31 21:22:32.349092
NCT01600378|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-11-06|2012-05-16|2012-05-17|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2012||2012-05-31|November 2017|2017-11-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases|Prospective Data Collection of Clinical, Pulmonary Function, Radiological, Bronchoscopic and Fibered Confocal Fluorescence Microscopy Imaging, and Pathological Characteristics in Patients With Diffuse Parenchymal Lung Diseases|Recruiting|||500|Anticipated|Singapore General Hospital|||||f||||f||||||||||2018-05-31 21:22:32.546499|2018-05-31 21:22:32.546499
NCT01600365|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-05-15|2012-05-15|2012-05-17|Estimate|||||||2012-05-15|2012-05-17|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus|"Prospective, Interventional, Randomized, Double-masked With the Use of Ganciclovir Gel 0.3% for Treatment of Conjunctivitis Caused by Adenovirus."|Unknown status|Not yet recruiting|Phase 3|22|Anticipated|Adapt Produtos Oftalmológicos Ltda.||2|||f||||t||||||||||2018-05-31 21:22:32.609932|2018-05-31 21:22:32.609932
NCT01600352|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-11-06|2012-05-16|2012-05-17|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2012||2012-05-31|November 2017|2017-11-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Specific Autoantibody Testing in Patients With Interstitial Lung Disease|To Evaluate the Clinical Utility of Specific Autoantibody Testing in Patients With Interstitial Lung Disease|Completed|||20|Actual|Singapore General Hospital|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 21:22:32.676139|2018-05-31 21:22:32.676139
NCT01600339|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2015-05-10|2012-05-16|2012-05-17|Estimate|||||||2015-05-10|2015-05-12|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)|A Single Arm, Multicenter, Open-label Phase II Trial of Cabazitaxel as Second Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Completed||Phase 2|19|Actual|Rambam Health Care Campus||1|||f||||t||||||||||2018-05-31 21:22:32.733692|2018-05-31 21:22:32.733692
NCT01600326|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2017-02-20||2017-02-20|2012-05-16|2012-05-17|Estimate|2017-02-20|2017-04-05|Actual||||2017-02-20|2017-04-05|Actual|July 2010|Actual|2010-07-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection|A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection Versus Tenotomy for Treatment of Gluteus Minimus and Medius Tendinosis|Completed||Phase 2|30|Actual|University of Michigan|Two limitations include the small sample size and the retrospective nature of the long term secondary patient outcome.|2|||f||||t|t|f|||f|||No||2018-05-31 21:22:32.803839|2018-05-31 21:22:32.803839
NCT01600313|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-05-16|2012-05-16|2012-05-17|Estimate|||||||2012-05-16|2012-05-17|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|May 2010|Actual|2010-05-31||Interventional|||Effect of Low Calorie Diet With Rice Bran Oil on Cardiovascular Risk Factors in Hyperlipidemic Patients|Effect of Low Calorie Diet With Rice Bran Oil on Cardiovascular Risk Factors in Hyperlipidemic Patients|Unknown status|Active, not recruiting|N/A|50|Anticipated|Qazvin University Of Medical Sciences||1|||f||||t||||||||||2018-05-31 21:22:33.044017|2018-05-31 21:22:33.044017
NCT01600300|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-15|2012-05-15|2012-05-17|Estimate|||||||2012-05-15|2012-05-17|Estimate|August 2002||2002-08-31|May 2012|2012-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration|A Double-Blind, Placebo-Controlled Feasibility Study to Evaluate the Efficacy of TESMAC™ (Transcutaneous Electrical Stimulation of the Macula)|Completed||Phase 1/Phase 2|40|Actual|Acuity Medical International, Inc.||2|||f||||||||||||||2018-05-31 21:22:33.125988|2018-05-31 21:22:33.125988
NCT01600287|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2012-12-22||2013-07-10|2012-05-16|2012-05-17|Estimate|2013-07-10|2013-08-09|Estimate||||2013-07-10|2013-08-09|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Closed Loop Propofol Administration in Pediatric Cardiac Surgery|Evaluation of Closed Loop Anaesthesia Delivery System for Propofol Anaesthesia in Pediatric Cardiac Surgery|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research|anesthesiologist could get visual impression of his performance.|2|||f||||f||||||||||2018-05-31 21:22:33.228929|2018-05-31 21:22:33.228929
NCT01600274|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-15|2012-05-15|2012-05-17|Estimate|||||||2012-05-15|2012-05-17|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Bioavailability Study With Oral Single Dose Administration of Ethinylestradiol and Dienogest|Characterisation of Relative Bioavailability and Assessment of Bioequivalence of a Newly Developed Ethinylestradiol/Dienogest IR Formulation in Comparison With a Marketed Reference Product (Valette®)|Completed||N/A|20|Actual|Pharbil Waltrop GmbH|||||f||||t||||||||||2018-05-31 21:22:33.64236|2018-05-31 21:22:33.64236
NCT01600261|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-06-27|2012-05-16|2012-05-17|Estimate|||||||2012-06-27|2012-06-28|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||iCam Clinical Validation Study|iCam Clinical Validation Study|Completed|||131|Actual|Optovue|||1||f||||f||||||||||2018-05-31 21:22:33.692835|2018-05-31 21:22:33.692835
NCT01600248|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-08-19|2012-05-14|2012-05-17|Estimate|||||||2015-08-19|2015-08-21|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Online Chronic Pain Therapy for Adults|Online Chronic Pain Therapy for Adults|Completed||N/A|25|Actual|University of Manitoba||1|||f||||t||||||||||2018-05-31 21:22:33.742544|2018-05-31 21:22:33.742544
NCT01600235|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2017-04-24|2012-05-16|2012-05-17|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2012||2012-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Efficacy of Therapeutic INduced HYPERTENSION in Acute Non-cardioembolic Ischemic Stroke (SETIN-HYPERTENSION)|Safety and Efficacy of Therapeutic Induced Hypertension in Patients With Acute Non-cardioembolic Ischemic Stroke: A Multicenter, Randomized, Open Label, Prospective, Phase 3 Study|Recruiting||Phase 3|170|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:22:33.86187|2018-05-31 21:22:33.86187
NCT01600222|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2015-11-13||2016-07-28|2012-05-16|2012-05-17|Estimate|2016-07-28|2016-09-16|Estimate||||2016-07-28|2016-09-16|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris|A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris|Completed||Phase 2|37|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 21:22:33.972282|2018-05-31 21:22:33.972282
NCT01600027|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-03-15|2012-05-15|2012-05-16|Estimate|||||||2015-03-15|2015-03-17|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Dexmedetomidine Addition to Fascia Iliaca Compartment Block|Effects of Dexmedetomidine Addition to Bupivacaine on the Quality of Fascia Iliaca Compartment Block (FICB) in Children Undergoing Femur Fracture Surgery|Completed||Phase 1|28|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 21:22:35.899594|2018-05-31 21:22:35.899594
NCT01600209|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2015-05-12|2012-05-14|2012-05-17|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|||Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing|Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing|Completed|||674|Actual|Exact Sciences Corporation|||1||f||||f||||||Samples With DNA|"~     Provide anonymous, clinically characterized specimens for bio-repository for future~     colorectal cancer-related test development.~   "|||2018-05-31 21:22:34.405989|2018-05-31 21:22:34.405989
NCT01600196|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2012-05-15|2012-05-15|2012-05-16|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2006||2006-01-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2009|Actual|2009-07-31||Interventional|||Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus|Surgical Resection Versus Best Supportive Care for Resectable Hepatocellular Carcinoma Invading the First Branch of Portal Vein|Completed||Phase 4|126|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:22:34.500437|2018-05-31 21:22:34.500437
NCT01600183|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-15|2012-05-15|2012-05-16|Estimate|||||||2012-05-15|2012-05-16|Estimate|August 2012||2012-08-31|May 2012|2012-05-31||||August 2013|Anticipated|2013-08-31||Interventional|||Safety and Efficacy of the Universal Neonatal Foot Orthosis in the Treatment of Metatarsus Adductus (MTA)|Safety and Efficacy of the Universal Neonatal Foot Orthosis in the Treatment of Metatarsus Adductus (MTA)|Unknown status|Not yet recruiting|N/A|50|Anticipated|Unfo Ltd.||2|||f||||f||||||||||2018-05-31 21:22:34.593407|2018-05-31 21:22:34.593407
NCT01600170|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-12-08|2012-05-15|2012-05-16|Estimate|||||||2017-12-08|2017-12-12|Actual|January 2013||2013-01-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)|Statin Modulation of Monocyte/Macrophage Activation for HAND Treatment|Completed||Phase 4|11|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:22:34.675509|2018-05-31 21:22:34.675509
NCT01600157|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-12|||2018-01-22|2012-05-15|2012-05-16|Estimate|||||||2018-01-22|2018-01-24|Actual|April 2013||2013-04-30|January 2018|2018-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Ambulant Laparoscopic Nephrectomy; Are There Limiting Factors|Ambulant Laparoscopic Nephrectomy|Completed||N/A|62|Actual|Zealand University Hospital||1|||f||||t||||||||||2018-05-31 21:22:34.7568|2018-05-31 21:22:34.7568
NCT01600144|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2014-08-06|2012-05-14|2012-05-16|Estimate|||||||2014-08-06|2014-08-07|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||August 2014||2014-08-31||Observational|||Data Collection for CAD Evaluation||Unknown status|Recruiting||100|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 21:22:34.840365|2018-05-31 21:22:34.840365
NCT01600131|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-05-02|2012-05-15|2012-05-16|Estimate|||||||2018-05-02|2018-05-03|Actual|June 22, 2015|Actual|2015-06-22|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|January 31, 2020|Anticipated|2020-01-31||Interventional|RESCUE||RESCUE Stroke Caregiver Website to Enhance Discharge Planning|Utilizing the RESCUE Stroke Caregiver Website to Enhance Discharge Planning|Recruiting||N/A|240|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 21:22:34.914076|2018-05-31 21:22:34.914076
NCT01600118|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-10-09|2012-05-14|2012-05-16|Estimate|||||||2015-10-09|2015-10-12|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Shock Waves on Dental Parameters|Effect of Low-energy Extracorporeal Shock Waves on Periodontal and Endodontic Parameters|Completed||Phase 2/Phase 3|72|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:22:35.007132|2018-05-31 21:22:35.007132
NCT01600105|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-10-20|2012-05-15|2012-05-16|Estimate|||||||2017-10-20|2017-10-24|Actual|May 2010||2010-05-31|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)|Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests|Completed||Phase 4|266|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f|t|f||||||||2018-05-31 21:22:35.103754|2018-05-31 21:22:35.103754
NCT01600092|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2015-03-09||2017-02-17|2012-05-14|2012-05-16|Estimate|2015-03-09|2015-03-19|Estimate||||2017-02-17|2017-03-22|Actual|April 2013||2013-04-30|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)|A Double-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq™|Completed||Phase 3|1020|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:22:35.202401|2018-05-31 21:22:35.202401
NCT01600079|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-10-19|2012-05-15|2012-05-16|Estimate|||||||2017-10-19|2017-10-20|Actual|May 15, 2012|Actual|2012-05-15|October 2017|2017-10-31|October 30, 2023|Anticipated|2023-10-30|October 30, 2023|Anticipated|2023-10-30||Observational|||ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)|Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™|Active, not recruiting|||30000|Anticipated|Merck Sharp & Dohme Corp.|||2||f||||t||||||||||2018-05-31 21:22:35.567526|2018-05-31 21:22:35.567526
NCT01600066|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-12-02|2012-05-14|2012-05-16|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Erectile Dysfunction in Severe Obstructive Sleep Apnea: Effects of CPAP Therapy|Erectile Dysfunction in Severe Obstructive Sleep Apnea : Effects of CPAP Therapy|Completed|||200|Actual|University of Giessen|||||f||||t||||||Samples Without DNA|"~     blood specimens for the determination of lipids and glucose~   "|||2018-05-31 21:22:35.626177|2018-05-31 21:22:35.626177
NCT01600053|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2015-12-16||2016-10-24|2012-05-14|2012-05-16|Estimate|2016-10-24|2016-12-15|Estimate||||2016-10-24|2016-12-15|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia|A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 2|11|Actual|University of California, San Diego||1||interim analysis showed that the trial will not meet the interim endpoint.|f||||t||||||||||2018-05-31 21:22:35.678171|2018-05-31 21:22:35.678171
NCT01600040|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-05-04|2012-05-15|2012-05-16|Estimate|||||||2018-05-04|2018-05-07|Actual|May 2013||2013-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix|Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix With Metastases to Regional Lymph Nodes|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:22:35.83904|2018-05-31 21:22:35.83904
NCT01598818|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-07-03|2012-05-14|2012-05-15|Estimate|||||||2012-07-03|2012-07-04|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||First-Sight Refractive Error Correction in the Developing World|First-Sight Refractive Error Correction in the Developing World|Completed|||150|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 21:22:55.295665|2018-05-31 21:22:55.295665
NCT01600014|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2015-12-17|2015-04-07|2016-04-04|2012-05-15|2012-05-16|Estimate|2016-04-04|2016-05-09|Estimate|2015-05-06|2015-05-25|Estimate|2016-04-04|2016-05-09|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp|Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp|Completed||Phase 3|463|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 21:22:35.973982|2018-05-31 21:22:35.973982
NCT01600001|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-10-29|2012-05-15|2012-05-16|Estimate|||||||2013-10-29|2013-10-30|Estimate||||October 2013|2013-10-31||||||||Interventional|||A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)|A Randomized, Double-blind, Placebo-controlled, Phase II Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)|Completed||Phase 2|75|Anticipated|Kissei Pharmaceutical Co., Ltd.||5|||f||||f||||||||||2018-05-31 21:22:36.353591|2018-05-31 21:22:36.353591
NCT01599988|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-01-15|2012-05-14|2012-05-16|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Study to Compare Milk Protein Isolate (MPI) With Caseinate in Terms of Protein Utilization|A Randomised, Double-blinded Study to Compare Milk Protein Isolate (MPI)With Caseinate in Terms of Protein Utilization in Healthy Elderly Subjects|Completed||Phase 2/Phase 3|24|Actual|University College Cork||2|||f||||f||||||||||2018-05-31 21:22:36.408905|2018-05-31 21:22:36.408905
NCT01599975|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-14|2012-05-14|2012-05-16|Estimate|||||||2012-05-14|2012-05-16|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Interventional|||A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV|Phase III, Placebo-Controlled, Double-Blind Crossover Study of Slow-Release Methylphenidate (Concerta ™) for Treatment of HIV Associated Neurocognitive Disorder|Unknown status|Recruiting|Phase 3|40|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:22:36.46455|2018-05-31 21:22:36.46455
NCT01599962|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-10-02|2012-05-15|2012-05-16|Estimate|||||||2012-10-02|2012-10-03|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Mira-Basel||Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects|Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects|Completed||Phase 2|40|Actual|University of Basel||2|||f||||t||||||||||2018-05-31 21:22:36.561533|2018-05-31 21:22:36.561533
NCT01599949|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-05-27|2012-05-15|2012-05-16|Estimate|||||||2016-05-27|2016-06-01|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy|A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy|Completed||Phase 2|120|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:22:36.620959|2018-05-31 21:22:36.620959
NCT01599936|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-03-18|2012-05-14|2012-05-16|Estimate|||||||2016-03-18|2016-03-22|Estimate|April 2004||2004-04-30|March 2016|2016-03-31|June 2007|Actual|2007-06-30|October 2006|Actual|2006-10-31||Interventional|||Open Label Clinical Trial of Anascorp® in Pediatric Patients With Scorpion Sting Envenomation|Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation|Completed||Phase 3|50|Actual|Instituto Bioclon S.A. de C.V.||1|||f||||f||||||||||2018-05-31 21:22:37.71658|2018-05-31 21:22:37.71658
NCT01599923|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-14|2012-05-14|2012-05-16|Estimate|||||||2012-05-14|2012-05-16|Estimate|May 2005||2005-05-31|May 2012|2012-05-31|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|||Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation|Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation|Completed||Phase 3|29|Actual|Instituto Bioclon S.A. de C.V.||1|||f||||f||||||||||2018-05-31 21:22:37.794592|2018-05-31 21:22:37.794592
NCT01599910|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-01-04|2012-05-15|2012-05-16|Estimate|||||||2017-01-04|2017-01-05|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Scribes in the Emergency Department|The Effect of Scribes in the Emergency Department|Withdrawn|||0|Actual|Beth Israel Deaconess Medical Center||||Funding not received|f||||f||||||||||2018-05-31 21:22:37.864244|2018-05-31 21:22:37.864244
NCT01599897|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-09-14|2012-05-14|2012-05-16|Estimate|||||||2017-09-14|2017-09-15|Actual|August 2012||2012-08-31|September 2017|2017-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults|Completed||Phase 1|60|Actual|IDRI||6|||f||||t||||||||||2018-05-31 21:22:37.923942|2018-05-31 21:22:37.923942
NCT01599884|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2012-05-15|2012-05-15|2012-05-16|Estimate|||||||2012-05-15|2012-05-16|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||N-Acetylcysteine for Patients With COPD and ChronicBronchitis|Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-1|Unknown status|Not yet recruiting|N/A|65|Anticipated|Minnesota Veterans Medical Research and Education Foundation||2|||f||||f||||||||||2018-05-31 21:22:37.989249|2018-05-31 21:22:37.989249
NCT01599871|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-08-28|2012-05-15|2012-05-16|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2011||2011-01-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|ASSET||Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease|Multicenter 52 Weeks Double Blind Placebo-controlled Trial for the Assessment of Theophylline on Top of Combination Therapy in Severe COPD|Completed||Phase 3|70|Actual|Hospital Son Espases||2|||f||||f||||||||||2018-05-31 21:22:38.078754|2018-05-31 21:22:38.078754
NCT01599858|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-05-14|2012-05-14|2012-05-16|Estimate|||||||2012-05-14|2012-05-16|Estimate|August 1996||1996-08-31|May 2012|2012-05-31|October 1996|Actual|1996-10-31|October 1996|Actual|1996-10-31||Interventional|||Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers|YF476: Effects of Repeated Dosing at 2 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Omeprazole in Healthy Volunteers|Completed||Phase 1|49|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 21:22:38.165353|2018-05-31 21:22:38.165353
NCT01599845|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|||2012-05-14|2012-05-14|2012-05-16|Estimate|||||||2012-05-14|2012-05-16|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Observational|Nanoexposure||The Differential Pattern of Deposition of Nano Particles in the Airways of Exposed Workers|The Differential Pattern of Deposition of Nano Particles in the Airways of Exposed Workers (Nanoexposure)|Unknown status|Not yet recruiting||60|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 21:22:38.313818|2018-05-31 21:22:38.313818
NCT01599832|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2016-10-25||2017-05-08|2012-05-15|2012-05-16|Estimate|2017-05-08|2017-06-08|Actual||||2017-05-08|2017-06-08|Actual|June 2012||2012-06-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer|DCE-MRI as Pazopanib Biomarker in Metastatic Renal Cancer|Terminated||N/A|20|Actual|University of Chicago||1||Poor accrual|f||||f||||||||||2018-05-31 21:22:38.395935|2018-05-31 21:22:38.395935
NCT01599819|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-10-19|2012-05-15|2012-05-16|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2011||2011-09-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||BAX 855 Dose-Escalation Safety Study|BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A|Completed||Phase 1|19|Actual|Shire||2|||f||||t||||||||||2018-05-31 21:22:38.649856|2018-05-31 21:22:38.649856
NCT01599806|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|2015-11-04||2017-08-31|2012-05-15|2012-05-16|Estimate|2016-02-03|2016-03-02|Estimate||||2017-08-31|2017-09-06|Actual|October 2012||2012-10-31|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Safety analysis set|Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)|A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults|Completed||Phase 3|641|Actual|Pfizer||2|||f||||||||||||||2018-05-31 21:22:38.949226|2018-05-31 21:22:38.949226
NCT01599793|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-01-31|2012-05-15|2012-05-16|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2012||2012-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib on Bone Metastases in Patients With Castrate Resistant Prostate Cancer|A Phase II Study of MRI Based Functional Imaging for the Evaluation of Bone Metastasis in Men With Castrate Resistant Prostate Cancer Receiving XL184|Active, not recruiting||Phase 2|17|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 21:22:41.846828|2018-05-31 21:22:41.846828
NCT01599780|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-04-16|2012-05-15|2012-05-16|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2010||2010-01-31|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Language Development in Preterm Children|On- and Off-line Measures of Language Development in Preterm Children|Completed|||100|Anticipated|Stanford University|||2||f||||f||||||||||2018-05-31 21:22:41.916552|2018-05-31 21:22:41.916552
NCT01599767|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2018-01-04|2012-05-14|2012-05-16|Estimate|||||||2018-01-04|2018-01-05|Actual|December 2011||2011-12-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Spaulding-Harvard Model System: Effects of Transcranial Direct Current Stimulation (tDCS) on Chronic Pain in Spinal Cord Injury|Spaulding-Harvard Spinal Cord Injury (SH-SCI) Study: Effects of tDCS on Chronic Pain in Spinal Cord Injury.|Completed||N/A|46|Actual|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 21:22:41.974143|2018-05-31 21:22:41.974143
NCT01599754|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2018-05-04|2012-05-14|2012-05-16|Estimate|||||||2018-05-04|2018-05-10|Estimate|April 2012||2012-04-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|March 2018|Actual|2018-03-31||Interventional|ATLAS||Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients|Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC|Terminated||Phase 3|722|Actual|SFJ Pharmaceuticals, Inc.||2||Primary endpoint did not reach statistical significance|f||||t||||||||||2018-05-31 21:22:42.047645|2018-05-31 21:22:42.047645
NCT01599741|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2013-09-27||2014-01-16|2012-05-15|2012-05-16|Estimate|2014-01-16|2014-03-05|Estimate||||2014-01-16|2014-03-05|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||X-ray Dose Reduction Study for Endovascular Interventional Radiology|Clinical Validation and Evaluation of X-ray Image Processing for Endovascular Digital Subtraction Angiography and Intervention|Completed||N/A|51|Actual|Philips Healthcare||2|||f||||f||||||||||2018-05-31 21:22:42.338555|2018-05-31 21:22:42.338555
NCT01599728|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-06-24|2012-05-15|2012-05-16|Estimate|||||||2013-06-24|2013-06-25|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Urocortins in Patients With Heart Failure|Urocortins 2 & 3-Effects on Forearm Arterial Blood Flow in Patients With Heart Failure|Completed||N/A|22|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 21:22:42.481816|2018-05-31 21:22:42.481816
NCT01599715|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-05-10|2012-05-14|2012-05-16|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TULIP||Translating Unique Learning for Incontinence Prevention|Translating Unique Learning for Incontinence Prevention for Women Over the Age of 55|Completed||Phase 2|647|Actual|University of Michigan||2|||f||||t||||||||Yes|Manuscript preparation for data dissemination is currently in progress.|2018-05-31 21:22:42.553907|2018-05-31 21:22:42.553907
NCT01599702|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-04-28|2012-05-15|2012-05-16|Estimate|||||||2015-04-28|2015-04-29|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|IBD-02||Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease|A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease (PROMISE)|Completed||Phase 3|21|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 21:22:42.6316|2018-05-31 21:22:42.6316
NCT01599689|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-04-21|2012-05-15|2012-05-16|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Pilot and Feasibility Study of a Mirrors Intervention for Reducing Delirium in Older Cardiac Surgical Patients|Can an Evidence-based Mirrors Intervention Reduce Postoperative Delirium in Older Cardiac Surgical Patients? A Pilot and Feasibility Cluster Randomised Controlled Trial|Completed||N/A|223|Actual|Papworth Hospital NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:22:42.708039|2018-05-31 21:22:42.708039
NCT01599676|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-07-31|2012-05-15|2012-05-16|Estimate|||||||2016-07-31|2016-08-02|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CITREX||Citrulline, Exercise Training and Muscle Strength in the Elderly|"Effect of Citrulline Supplementation on Muscle Strength in Elderly Institutionalized Subjects Undergoing an Exercise Training Programme. "|Completed||N/A|91|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 21:22:42.974865|2018-05-31 21:22:42.974865
NCT01599663|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-12-05|2012-05-15|2012-05-16|Estimate|||||||2017-12-05|2017-12-06|Actual|May 2012||2012-05-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|May 2017|Actual|2017-05-31||Interventional|||Pain Management of Intensive Care Unit Patients|Pain Management of Intensive Care Unit (ICU) Patients. An Intervention Study to Evaluate the Effect of Systematic Pain Management of Various Groups of ICU Patients.|Active, not recruiting||N/A|720|Anticipated|Ostfold Hospital Trust||2|||f||||t||||||||No||2018-05-31 21:22:43.054428|2018-05-31 21:22:43.054428
NCT01599650|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2016-05-26||2016-09-21|2012-05-14|2012-05-16|Estimate|2016-09-21|2016-11-10|Estimate||||2016-09-21|2016-11-10|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|BRIGHTER||Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion|A 24-month, Phase IIIb, Open-label, Randomized, Active Controlled, 3-arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy or With Adjunctive Laser Photocoagulation in Comparison to Laser Photocoagulation in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion|Completed||Phase 3|455|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:22:43.192596|2018-05-31 21:22:43.192596
NCT01599637|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2014-09-10||2015-03-11|2012-05-15|2012-05-16|Estimate|2014-10-30|2014-11-03|Estimate||||2015-03-11|2015-03-31|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment|A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Determine the Mode of Action of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)|Completed||Phase 2|40|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:22:44.554747|2018-05-31 21:22:44.554747
NCT01599624|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2016-08-17|2012-05-15|2012-05-16|Estimate|||||||2016-08-17|2016-08-19|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SRTS||Stress Resilience Training System|Stress Resilience Training System|Completed||N/A|68|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||No||2018-05-31 21:22:46.294635|2018-05-31 21:22:46.294635
NCT01599611|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-15|2012-05-15|2012-05-16|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study|Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study|Completed|||128|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 21:22:46.358587|2018-05-31 21:22:46.358587
NCT01599598|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2016-08-17|2012-05-14|2012-05-16|Estimate|||||||2016-08-17|2016-08-19|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Coherence Training for Military Personnel|Coherence Training for Military Personnel|Completed||N/A|192|Actual|United States Naval Medical Center, San Diego||2|||f||||f||||||||No||2018-05-31 21:22:46.426357|2018-05-31 21:22:46.426357
NCT01599585|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2016-12-12||2017-03-28|2012-05-14|2012-05-16|Estimate|2017-03-28|2017-06-16|Actual||||2017-03-28|2017-06-16|Actual|May 2012||2012-05-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|January 2015|Actual|2015-01-31||Interventional|||A Randomized Controlled Trial of In-Home Tele-Behavioral Health Care Utilizing Behavioral Activation for Depression|A Randomized Controlled Trial of In-Home Tele-behavioral Health Care Utilizing Behavioral Activation for Depression|Completed||N/A|121|Actual|National Center for Telehealth and Technology||2|||f||||t||||||||No||2018-05-31 21:22:46.501659|2018-05-31 21:22:46.501659
NCT01599572|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-05-19|2012-05-15|2012-05-16|Estimate|||||||2015-05-19|2015-05-21|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Zinc Supplementation on Serum Zinc Level in Nursing Home Elderly|Zinc Intervention in Nursing Home Elderly|Completed||Phase 1|31|Actual|Tufts University||1|||f||||f||||||||||2018-05-31 21:22:46.946515|2018-05-31 21:22:46.946515
NCT01599559|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-08-22|2012-05-15|2012-05-16|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2011||2011-11-30|July 2017|2017-07-31|May 2025|Anticipated|2025-05-31|May 2017|Actual|2017-05-31||Interventional|||Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma|IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)|Recruiting||N/A|540|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||2|||f||||||||||||||2018-05-31 21:22:47.15733|2018-05-31 21:22:47.15733
NCT01599546|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-04-16|2012-05-15|2012-05-16|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2012||2012-01-31|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Reading in Preterm and Full-term Children: Neural Basis and Prediction|Reading in Preterm and Full-term Children: Neural Basis and Prediction|Completed|||100|Actual|Stanford University|||2||f||||f||||||||||2018-05-31 21:22:47.550759|2018-05-31 21:22:47.550759
NCT01599533|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-10-17|2012-05-14|2012-05-16|Estimate|||||||2016-10-17|2016-10-18|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm|Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm : Prevalence, Description of the Different Thoracic Aortic Phenotypes by Aortic Volumetric Numerized Imaging and Their Relationship With Epidemiologic, Clinical, Biological and Genetic Factors|Recruiting||N/A|500|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 21:22:47.611567|2018-05-31 21:22:47.611567
NCT01599520|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-03-27|2012-05-14|2012-05-16|Estimate|||||||2018-03-27|2018-03-29|Actual|January 9, 2012|Actual|2012-01-09|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|September 1, 2016|Actual|2016-09-01||Interventional|||Stress Management Training for Latinas Receiving Chemotherapy|Stress Management Training for Latinas Receiving Chemotherapy|Active, not recruiting||N/A|140|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||||2018-05-31 21:22:47.689205|2018-05-31 21:22:47.689205
NCT01599507|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2014-02-27|2012-05-14|2012-05-16|Estimate|||||||2014-02-27|2014-03-03|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of FG-4592 in Subjects With Chronic Kidney Disease in China|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose Ranging Safety and Efficacy Study of FG 4592 in Non-dialysis Chronic Kidney Disease (CKD) Subjects With Anemia|Completed||Phase 2|91|Actual|FibroGen||2|||f||||f||||||||||2018-05-31 21:22:47.764304|2018-05-31 21:22:47.764304
NCT01599494|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-10-30|2012-05-14|2012-05-16|Estimate|||||||2015-10-30|2015-11-02|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)|A Multi-center, Open-label, Randomized Trial in India to Investigate the Efficacy and Safety of a Single Injection of MK-8962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as a Reference (Phase III, Protocol No. MK-8962-029-00 [Also Known as SCH900962, P07056])|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:22:47.843854|2018-05-31 21:22:47.843854
NCT01599481|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-08-19|2012-05-14|2012-05-16|Estimate|||||||2015-08-19|2015-08-20|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CAREER||Career Management to Improve Education, Employment and Retention for People With Anxiety and Depression|Effectiveness and Cost Effectiveness of Individual Career Management for People With Anxiety and Depression: A Randomised Controlled Trial|Completed||Phase 2|261|Actual|South London and Maudsley NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:22:47.919919|2018-05-31 21:22:47.919919
NCT01599468|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-21|2012-05-15|2012-05-16|Estimate|||||||2012-05-21|2012-05-22|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Can Tranexamic Acid Reduce Bleeding After Post Partum Hemorrhage in Cesarean Section Delivery|Effects of Tranexamic Acid on Post Partum Hemorrhage by Uterine Atony After Cesarean Section Delivery: a Randomized, Placebo Controlled Trial.|Completed||Phase 4|74|Actual|Hédi Chaker Hospital||2|||f||||f||||||||||2018-05-31 21:22:47.991965|2018-05-31 21:22:47.991965
NCT01599455|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-08-02|2012-05-15|2012-05-16|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2012||2012-05-31|August 2017|2017-08-31|May 2022|Anticipated|2022-05-31|May 2019|Anticipated|2019-05-31||Observational|||Baseline Cardiovascular Measurements in Pediatric Spinal Cord Injury|Cardiovascular Measurements at Baseline and During Cystometry in Pediatric Spinal Cord Injury|Recruiting|||315|Anticipated|Shriners Hospitals for Children|||3||f||||f||||||||No||2018-05-31 21:22:48.072306|2018-05-31 21:22:48.072306
NCT01599442|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2014-04-04|2012-05-15|2012-05-16|Estimate|||||||2014-04-04|2014-04-07|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|August-1||Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia|Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia|Terminated|||123|Actual|GWT-TUD GmbH||||recrution number was not reached|f||||f||||||||||2018-05-31 21:22:48.135927|2018-05-31 21:22:48.135927
NCT01599429|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2014-09-24|2012-05-14|2012-05-16|Estimate|||||||2014-09-24|2014-09-25|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Observational|TEP-FLT-LMA||Study of the Predictive Marker FLT in Patients Suffering From AML|Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy|Unknown status|Recruiting||24|Anticipated|Centre de recherche du Centre hospitalier universitaire de Sherbrooke|||||f||||t||||||||||2018-05-31 21:22:48.188783|2018-05-31 21:22:48.188783
NCT01599416|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-01-04|2012-05-15|2012-05-16|Estimate|||||||2018-01-04|2018-01-05|Actual|June 2011|Actual|2011-06-30|April 2012|2012-04-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Influence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative|Randomized, Double-blind, Placebo-controlled Study ,Oral U-relax in the Influence of the Vaginal Environment Health Promotion, and the HPV DNA Test Index Change From Positive to Negative on the HPV Infection Women|Completed||N/A|80|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:22:48.251487|2018-05-31 21:22:48.251487
NCT01599403|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-02-09|2012-05-14|2012-05-16|Estimate|||||||2017-02-09|2017-02-13|Actual|April 2012|Actual|2012-04-30|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Thoracic Blocks Versus Thoracic Epidural and Patient Controlled Anesthesia in Traumatic Rib Fracture Patients|Comparative Effectiveness of Continuous Thoracic Paravertebral Blocks Versus Thoracic Epidural and Continuous Intercostal Blocks Versus Patient-Controlled Anesthesia in Traumatic Rib Fracture Patients|Completed||N/A|50|Actual|Brigham and Women's Hospital||4|||f||||f||||||||||2018-05-31 21:22:48.316552|2018-05-31 21:22:48.316552
NCT01599390|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-02-21|2012-05-14|2012-05-16|Estimate|||||||2013-02-21|2013-02-25|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Influenza Burden Assessment in the United States, July1997 - up to April 2009|Burden of Influenza in the United States, July 1997 up to April 2009|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:22:48.378732|2018-05-31 21:22:48.378732
NCT01599377|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-07-08|2012-05-14|2012-05-16|Estimate|||||||2012-07-08|2012-07-10|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Tofacitinib Bioequivalence Study Comparing Tablets And Capsules|Phase 1, Open-Label, Randomized, Single-Dose, Cross-Over, Bioequivalence Study Comparing Tablets (5 And 10 Mg) And Capsules (5 And 10 Mg) Of Tofacitinib Under Fasted Conditions In Healthy Volunteers|Completed||Phase 1|50|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:22:48.612031|2018-05-31 21:22:48.612031
NCT01599364|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-08-14|2012-05-15|2012-05-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|April 2016|Actual|2016-04-30||Interventional|ATLAS||Atazanavir/r + Lamivudine Dual Therapy|Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression|Active, not recruiting||Phase 4|266|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||No||2018-05-31 21:22:48.698335|2018-05-31 21:22:48.698335
NCT01599351|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-15|2012-05-15|2012-05-16|Estimate|||||||2012-05-15|2012-05-16|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography Between Prone and Left Lateral Decubitus|Different Radiation Exposures to Patient and Endoscopists Between Performing ERCP in Patients Lying Prone and Left Lateral Decubitus|Completed||Phase 4|40|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 21:22:48.798682|2018-05-31 21:22:48.798682
NCT01599338|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-31|2012-05-15|2012-05-16|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients|Influence du Victoza (Liraglutide,Analogue GLP-1) Sur Les Performances Gustatives, le Rassasiement Sensoriel spécifique, le Liking et le Wanting Chez Les Patients diabétiques de Type 2.|Completed||N/A|30|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||f||||||||||2018-05-31 21:22:48.874743|2018-05-31 21:22:48.874743
NCT01599325|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2016-01-29||2018-03-01|2012-05-15|2012-05-16|Estimate|2016-01-29|2016-02-29|Estimate||||2018-03-01|2018-03-29|Actual|July 24, 2012|Actual|2012-07-24|March 2018|2018-03-31|March 28, 2018|Anticipated|2018-03-28|January 29, 2015|Actual|2015-01-29||Interventional||ITT includes all participants who had been screened and enrolled into the study.|Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome|A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Chinese Subjects With Higher-Risk Myelodysplastic Syndromes|Active, not recruiting||Phase 2|72|Actual|Celgene||1|||f||||f||||||||||2018-05-31 21:22:49.008758|2018-05-31 21:22:49.008758
NCT01599312|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-02-08|2012-05-15|2012-05-16|Estimate|||||||2015-02-08|2015-02-10|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Forces on Teeth During Videolaryngoscopy|Forces Exerted on Upper and Lower Teeth During Intubation: a Randomized, Cross-over Trial Comparing Indirect Videolaryngoscopy to Direct Videolaryngoscopy.|Completed||N/A|100|Actual|Catharina Ziekenhuis Eindhoven||4|||f||||f||||||||||2018-05-31 21:22:49.804337|2018-05-31 21:22:49.804337
NCT01599299|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2014-03-05|2012-05-15|2012-05-16|Estimate|||||||2014-03-05|2014-03-06|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Comparison of the Right and Left Internal Jugular Vein Using Ultrasound|Comparison of the Diameter, Cross-sectional Area and Position of the Left and Right Internal Jugular Vein in Adults Using Ultrasound|Completed|||100|Actual|Catharina Ziekenhuis Eindhoven|||1||f||||t||||||||||2018-05-31 21:22:49.885546|2018-05-31 21:22:49.885546
NCT01599286|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-10-05|2012-05-14|2012-05-16|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2012|Actual|2012-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia|Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia|Recruiting||Phase 2|114|Anticipated|Children's Research Institute||2|||f||||t||||||||No|This is a blinded study, the individual participant data will not be shared|2018-05-31 21:22:49.96494|2018-05-31 21:22:49.96494
NCT01599273|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-01-26|2012-05-13|2012-05-16|Estimate|||||||2015-01-26|2015-01-28|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections||Completed||Phase 4|50|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:22:50.07601|2018-05-31 21:22:50.07601
NCT01599260|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-05-29|2012-05-14|2012-05-15|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 2012|Actual|2012-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Resistance Exercise in Rheumatic Disease|Resistance Exercise in Rheumatic Disease|Suspended||N/A|10|Anticipated|Johns Hopkins University||1||Funding ended. Trying to secure more funds|f||||f||||||||||2018-05-31 21:22:50.135781|2018-05-31 21:22:50.135781
NCT01599247|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-08-07|2012-05-14|2012-05-15|Estimate|||||||2014-08-07|2014-08-08|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Natural History of Hopelessness, Suicidality, and Optimism in Psychiatric Inpatients Following Discharge|Natural History of Hopelessness, Suicidality, and Optimism in Psychiatric Inpatients Following Discharge|Completed|||46|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:22:50.193304|2018-05-31 21:22:50.193304
NCT01599234|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2012-07-11||2013-06-13|2012-05-14|2012-05-15|Estimate|2012-07-11|2012-08-16|Estimate||||2013-06-13|2013-06-24|Estimate|March 2005||2005-03-31|June 2013|2013-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis|A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis.|Completed||Phase 3|337|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 21:22:50.261679|2018-05-31 21:22:50.261679
NCT01599221|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-09-10|2012-05-14|2012-05-15|Estimate|||||||2012-09-10|2012-09-11|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|July 2012|Actual|2012-07-31||Observational|||Observational Retrospective and Prospective Study on the Treatment of Femoral Fractures With EBA2|Observational Retrospective and Prospective Study on the Treatment of Lateral Proximal Femoral Fractures With Medical Device EBA2|Unknown status|Active, not recruiting||40|Anticipated|Citieffe S.r.l|||1||f||||f||||||||||2018-05-31 21:22:50.853393|2018-05-31 21:22:50.853393
NCT01599208|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-01-24|2012-05-14|2012-05-15|Estimate|||||||2018-01-24|2018-01-25|Actual|August 2012||2012-08-31|January 2018|2018-01-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Facilitating Associative Memory Via Deep Transcranial Magnetic Stimulation to the Medial Temporal Lobe|Facilitating Associative Memory Via Deep Transcranial Magnetic Stimulation to the Medial Temporal Lobe|Withdrawn||Early Phase 1|0|Actual|Brainsway||6||no IRB|f||||t||||||||||2018-05-31 21:22:50.935618|2018-05-31 21:22:50.935618
NCT01599195|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2017-01-31|2012-05-14|2012-05-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2010|Actual|2010-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|September 2014|Actual|2014-09-30||Observational|||Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis|Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis|Terminated|||18|Actual|Albert Einstein Healthcare Network|||1|Enrollment did not progress as anticipated|f||||f||t|f|f|f|||No||2018-05-31 21:22:50.998798|2018-05-31 21:22:50.998798
NCT01599182|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-06-22|2012-05-13|2012-05-15|Estimate|||||||2015-06-22|2015-06-23|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer|Metabolic Effects of Treatment in Intermediate and High-Risk Prostate Cancer|Completed|||9|Actual|University of Waterloo|||2||f||||f||||||Samples Without DNA|"~     Measurements related to glucose, lipid and immune metabolism will be measured.~   "|||2018-05-31 21:22:51.063784|2018-05-31 21:22:51.063784
NCT01599169|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2013-04-21|2012-05-13|2012-05-15|Estimate|||||||2013-04-21|2013-04-23|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of the Efficacy and Tolerance of B-Back® on the Burnout Syndrome|Evaluation of the Efficacy and Tolerance of B-Back® on the Burnout Syndrome. Double-blind, Randomized, Monocentric Trial With Two Parallel Groups (B-Back® Verum Versus B-Back® Placebo)|Completed||N/A|87|Actual|Université Victor Segalen Bordeaux 2||2|||f||||f||||||||||2018-05-31 21:22:51.118835|2018-05-31 21:22:51.118835
NCT01599156|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2013-01-14|2012-05-13|2012-05-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Reflexology for Chronic Constipation|Reflexology for Patients Suffering From Chronic Constipation- a Phase II B, Single Armed, Open Label Study.|Unknown status|Recruiting|Phase 2|40|Anticipated|Shaare Zedek Medical Center||1|||f||||f||||||||||2018-05-31 21:22:51.252378|2018-05-31 21:22:51.252378
NCT01599143|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-13|2012-05-13|2012-05-15|Estimate|||||||2012-05-13|2012-05-15|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|mbsr||Identifying Therapeutic Factors in an 8-Week (30 Hour) Mindfulness-Based Stress Reduction (MBSR) Program|Identifying Therapeutic Factors in an 8-Week (30 Hour) Mindfulness-Based Stress Reduction (MBSR) Program|Completed||Phase 1|135|Actual|North York General Hospital||1|||f||||f||||||||||2018-05-31 21:22:51.328619|2018-05-31 21:22:51.328619
NCT01599130|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-14|2012-05-14|2012-05-15|Estimate|||||||2012-05-14|2012-05-15|Estimate|July 2012||2012-07-31|May 2012|2012-05-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss|The Efficacy of Peg-interferon α-2a in HBeAg (+) Chronic Hepatitis B Patients Who Have Been Treated by Entecavir for 48 Weeks But Without HBeAg Loss|Unknown status|Not yet recruiting|N/A|60|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 21:22:51.396409|2018-05-31 21:22:51.396409
NCT01599117|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2013-01-30|2012-05-14|2012-05-15|Estimate|||||||2013-01-30|2013-01-31|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Interventional|||A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF]|Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial]|Unknown status|Recruiting|Phase 3|52|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:22:51.487916|2018-05-31 21:22:51.487916
NCT01599104|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|2015-07-11||2015-09-25|2012-05-13|2012-05-15|Estimate|2015-07-11|2015-08-06|Estimate||||2015-09-25|2015-10-16|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension|Completed||Phase 3|1161|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:22:51.625112|2018-05-31 21:22:51.625112
NCT01599091|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-09-08|2012-05-14|2012-05-15|Estimate|||||||2013-09-08|2013-09-10|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Characterizing Gingival and Periodontal Ligament Fibroblasts Reaction to Infection With the Bacteria Porphyromonas Gingivalis|Characterizing Gingival and Periodontal Ligament Fibroblasts Reaction to Infection With the Perio- Pathogenic Bacteria Porphyromonas Gingivalis|Unknown status|Recruiting||100|Anticipated|Hadassah Medical Organization|||1||f||||f||||||Samples With DNA|"~     Anyway extracted teeth and gingiva. Patients undergoing tooth extraction will be asked~     permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for~     further basic research.~   "|||2018-05-31 21:22:52.110307|2018-05-31 21:22:52.110307
NCT01599078|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2012-05-13|2012-05-13|2012-05-15|Estimate|||||||2012-05-13|2012-05-15|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|PacTAP||Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention|Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention (PacTAP Study): A Double Blind, Randomized Control Study|Unknown status|Recruiting|N/A|100|Anticipated|Midwest Cardiovascular Research Foundation||2|||f||||t||||||||||2018-05-31 21:22:52.177875|2018-05-31 21:22:52.177875
NCT01599065|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2013-10-18|2012-05-14|2012-05-15|Estimate|||||||2013-10-18|2013-10-21|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|MAGNET||"Comparison of a MAGNET Protocol Versus off-on Protocol for Patients With Implantable Cardioverter Defibrillators"|"Comparison of a MAGNET Protocol Versus off-on Protocol for Patients With Implantable Cardioverter Defibrillators Undergoing Procedures Requiring Electrocautery"|Completed|||80|Actual|Midwest Heart Foundation|||2||f||||f||||||||||2018-05-31 21:22:52.267964|2018-05-31 21:22:52.267964
NCT01599052|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-10-24|2012-05-14|2012-05-15|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2011||2011-03-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Social Cognition in Children Treated for a Brain Tumour|Social Cognition in Children Treated for a Brain Tumour: A Prospective Longitudinal Multi-Centre Study|Active, not recruiting|||113|Anticipated|University Medical Center Groningen|||3||f||||f||||||||||2018-05-31 21:22:52.332998|2018-05-31 21:22:52.332998
NCT01599039|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2016-09-26|2012-05-14|2012-05-15|Estimate|||||||2016-09-26|2016-09-27|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2014|Actual|2014-01-31||Observational|||Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema|Prospective Controlled Study Comparing the Effectiveness and Specificity of Inverse Water Volumetry Versus Bio-impedance Spectroscopy in the Assessment of Early Recognition of Breast Cancer Related Lymphoedema.|Completed|||80|Actual|Nij Smellinghe Hosptial|||3||f||||f||||||||||2018-05-31 21:22:52.394434|2018-05-31 21:22:52.394434
NCT01599026|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-05-14|2012-05-14|2012-05-15|Estimate|||||||2012-05-14|2012-05-15|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Observational|||Cardiac Septal Hypertrophy in the Fetus of Diabetic Mother and Its Effect on Postnatal Cardiac Function|Cardiac Septal Hypertrophy in the Fetus of Diabetic Mother and Its Effect on Postnatal Cardiac Function|Unknown status|Enrolling by invitation||120|Anticipated|Ain Shams Maternity Hospital|||||f||||||||||||||2018-05-31 21:22:52.451695|2018-05-31 21:22:52.451695
NCT01599013|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-12-07|2012-05-11|2012-05-15|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|JASINT1||JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin|Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|69|Actual|Pierre Fabre Medicament||2|||f||||t||||||||||2018-05-31 21:22:52.500239|2018-05-31 21:22:52.500239
NCT01599000|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2012-08-14|2012-05-11|2012-05-15|Estimate|||||||2012-08-14|2012-08-16|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Artemether-Lumefantrine Clinical Effectiveness Study|Artemether-Lumefantrine Clinical Effectiveness Study|Completed||Phase 4|159|Actual|Papua New Guinea Institute of Medical Research||2|||f||||f||||||||||2018-05-31 21:22:52.573859|2018-05-31 21:22:52.573859
NCT01598805|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-11-15|2012-05-14|2012-05-15|Estimate|||||||2012-11-15|2012-11-16|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Increased Rate of Prophylaxis Against Venous Thromboembolism Due to eAlerts|Increased Rate of Prophylaxis Against Venous Thromboembolism Due to eAlerts|Completed||N/A|10000|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 21:22:55.357662|2018-05-31 21:22:55.357662
NCT01598987|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2016-11-30||2017-04-13|2012-05-11|2012-05-15|Estimate|2016-11-30|2017-01-24|Estimate||||2017-04-13|2017-05-16|Actual|October 2012||2012-10-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Full analysis set (FAS): consisted of all patients enrolled into the study, including patients who did not receive any everolimus, but were followed beyond baseline.|Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.|A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.|Completed||Phase 3|56|Actual|Novartis|Based on DMC recommendation, enrolment was terminated and patients below 7 years were converted form study medication to local standard of care but patients were followed up until Month 24.|1|||f||||t||||||||||2018-05-31 21:22:52.662936|2018-05-31 21:22:52.662936
NCT01598974|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-11-27|2012-05-14|2012-05-15|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2012|Actual|2012-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|LBP||Back Pain Response to Different Acupuncture Methods|Brain Plasticity Underlying Back Pain Response to Different Acupuncture Methods|Completed||N/A|151|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 21:22:53.398981|2018-05-31 21:22:53.398981
NCT01598961|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-12|||2013-12-24|2012-05-12|2012-05-15|Estimate|||||||2013-12-24|2013-12-25|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery|Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery|Completed||N/A|150|Actual|Samsung Medical Center||3|||f||||t||||||||||2018-05-31 21:22:53.674158|2018-05-31 21:22:53.674158
NCT01598948|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-12|||2015-09-01|2012-05-12|2012-05-15|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|MICA||Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis|Effect of Mipomersen on LDL-Cholesterol Levels in Patients With Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis|Completed||Phase 3|17|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 21:22:53.809196|2018-05-31 21:22:53.809196
NCT01598935|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-06-12|2012-05-11|2012-05-15|Estimate|||||||2013-06-12|2013-06-13|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||Post-exercise Protein Intake for Active Children|Double Blind Controlled Trial of Protein in Active Children|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|McMaster University||4|||f||||f||||||||||2018-05-31 21:22:53.911021|2018-05-31 21:22:53.911021
NCT01598922|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2016-03-14|2012-05-11|2012-05-15|Estimate|||||||2016-03-14|2016-03-16|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|October 2015|Actual|2015-10-31||Interventional|iCBT||Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function|Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function|Unknown status|Active, not recruiting|N/A|108|Anticipated|Mclean Hospital||3|||f||||f||||||||||2018-05-31 21:22:54.021654|2018-05-31 21:22:54.021654
NCT01598909|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-12|||2015-08-21|2012-05-12|2012-05-15|Estimate|||||||2015-08-21|2015-08-25|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ARINE||Efficacy of Arnica D1 Ointment After Upper Blepharoplasty|Efficacy of Arnica D1 Ointment After Upper Blepharoplasty: a Randomized, Double-blind Placebo-controlled Study|Completed||N/A|136|Actual|Isala||3|||f||||f||||||||||2018-05-31 21:22:54.11291|2018-05-31 21:22:54.11291
NCT01598896|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-04-26|2012-05-14|2012-05-15|Estimate|||||||2017-04-26|2017-04-27|Actual|May 2012||2012-05-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|DCCS||Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia|Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia|Recruiting||Phase 2/Phase 3|18|Anticipated|Mclean Hospital||3|||f||||f||||||||||2018-05-31 21:22:54.21124|2018-05-31 21:22:54.21124
NCT01598883|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-12-13|2012-05-11|2012-05-15|Estimate|||||||2016-12-13|2016-12-14|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||"Understanding Heparin Resistance in Cardiac Surgery"|"Understanding Heparin Resistance in Cardiac Surgery: Altered Heparin Responsiveness and Its Association With Acute Inflammatory Reactions"|Completed||Phase 1|504|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:22:54.336902|2018-05-31 21:22:54.336902
NCT01598870|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2015-01-13|2012-05-11|2012-05-15|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Observational|ARSDIASP||Diagnosis of Spontaneous Bacterial Peritonitis|Redefinition of Diagnostic Criteria for Spontaneous Bacterial Peritonitis: Assessment of Accuracy of Available Tests and of Reference Standard|Unknown status|Recruiting||100|Anticipated|Azienda Ospedaliera di Lecco|||1||f||||f||||||Samples With DNA|"~     Blood and ascitic fluid samples stored at -80°C~   "|||2018-05-31 21:22:54.416547|2018-05-31 21:22:54.416547
NCT01598857|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2015-07-28|2012-05-14|2012-05-15|Estimate|||||||2015-07-28|2015-07-30|Estimate|December 2014||2014-12-31|July 2015|2015-07-31||||June 2015|Anticipated|2015-06-30||Interventional|BIANCA-SC||BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis|Withdrawn||Phase 2|0|Actual|Anthera Pharmaceuticals||2|||f||||||||||||||2018-05-31 21:22:54.522972|2018-05-31 21:22:54.522972
NCT01598844|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-12-12|2012-05-11|2012-05-15|Estimate|||||||2017-12-12|2017-12-13|Actual|May 2012||2012-05-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|September 2015|Actual|2015-09-30||Observational|JUPITER||Longterm Safety and Performance of the JenaValve|"The JenaValve EvalUation of Long Term Performance and Safety In PaTients With SEvere Aortic Stenosis oR Aortic Insufficiency"|Active, not recruiting|||210|Actual|JenaValve Technology GmbH|||2||f||||f||||||||||2018-05-31 21:22:54.595943|2018-05-31 21:22:54.595943
NCT01598831|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2018-03-22|2012-05-14|2012-05-15|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2012||2012-08-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|August 2018|Anticipated|2018-08-31||Interventional|||Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy.|Active, not recruiting||Phase 3|814|Actual|Asahi Kasei Pharma America Corporation||2|||f||||t||||||||||2018-05-31 21:22:54.797605|2018-05-31 21:22:54.797605
NCT01598792|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2016-05-17|2012-05-11|2012-05-15|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|REALISTIC:||Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer|REALISTIC: A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Genotype 16 Target Antigens (ADXS11-001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma|Terminated||Phase 1|2|Actual|University of Liverpool||||"Patient 2 suffered DLT post-vaccination. The vaccine manufacturers withdrew support for the~   study on commercial grounds."|f||||t||||||||||2018-05-31 21:22:55.435117|2018-05-31 21:22:55.435117
NCT01598779|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2014-12-09||2015-12-18|2012-05-11|2012-05-15|Estimate|2015-12-18|2015-12-21|Estimate||||2015-12-18|2015-12-21|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||Women age 15–45 attending an outpatient consultation at clinics of the investigators or at University of Buenos Aires, with a lesion suspected of being HPV related.|Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population|Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population|Completed|||150|Actual|University of Buenos Aires|||||f||||t||||||Samples With DNA|"~     Biopsy specimens will be held in a formol 10% solution and will be sent to the pathologist. A~     portion of each sample will be processed for histological analysis, which will be performed~     by one pathologist. The remainder of each specimen will be saved to extract DNA for PCR~     analysis~   "|||2018-05-31 21:22:55.50112|2018-05-31 21:22:55.50112
NCT01598766|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2013-02-04|2012-05-11|2012-05-15|Estimate|||||||2013-02-04|2013-02-05|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|May 2020|Anticipated|2020-05-31|May 2013|Anticipated|2013-05-31||Interventional|||General Investigative MRI Protocol|General Investigational Protocol for EXCELART VANTAGE ZGV/XGV/AGV/ ATLAS/XGV/ZGV TITAN/XGV VANTAGE TITAN 3T|Recruiting||Phase 1|100|Anticipated|Toshiba America Medical Systems, Inc.||1|||f||||||||||||||2018-05-31 21:22:55.626294|2018-05-31 21:22:55.626294
NCT01598753|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-05-04|2012-05-10|2012-05-15|Estimate|||||||2018-05-04|2018-05-07|Actual|May 2012||2012-05-31|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|COMBAT-FM||Combined Behavioral and Analgesic Trial for Fibromyalgia|Phase 3 Double Blind Randomized Study Comparing Drug Treatment (Tramadol Versus Placebo) and Behavioral Health Treatments (Cognitive Behavior Therapy Versus Health Education)for Patients With Fibromyalgia|Active, not recruiting||Phase 3|250|Anticipated|University of Washington||4|||f||||t||||||||||2018-05-31 21:22:55.684278|2018-05-31 21:22:55.684278
NCT01598740|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2013-03-22||2013-07-12|2012-05-11|2012-05-15|Estimate|2013-03-22|2013-05-08|Estimate||||2013-07-12|2013-07-19|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease|A Phase 1, Open-label, Randomized, Crossover Study to Assess the Safety, Tolerability, and Efficacy of CLP With and Without Spironolactone in Adults With Heart Failure|Completed||Phase 1|18|Actual|Sorbent Therapeutics||2|||f||||f||||||||||2018-05-31 21:22:55.744864|2018-05-31 21:22:55.744864
NCT01598727|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-08-23|2012-05-14|2012-05-15|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics|A Phase I Feasibility Study of Intra-operative Near Infra-red Fluorescent Imaging in Thyroid/Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics|Completed||Phase 1|10|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 21:22:55.958372|2018-05-31 21:22:55.958372
NCT01598714|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-08-23|2012-05-11|2012-05-15|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Comparison of Patient Satisfaction Between 3 Types Dressing Shoes|A Comparison of Patient Satisfaction Between Darco, Podalux and Standard Dressing Shoes Following Forefoot Surgery|Unknown status|Recruiting|N/A|90|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 21:22:56.018685|2018-05-31 21:22:56.018685
NCT01598701|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2016-11-07|2012-05-10|2012-05-15|Estimate|||||||2016-11-07|2016-11-09|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||Intravenous Acetaminophen in Craniotomy|The Opioid-Sparing and Analgesic Effects of IV Acetaminophen in Craniotomy: A Prospective, Randomized, Placebo-Controlled, Double-Blind Study|Active, not recruiting||Phase 4|100|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||Undecided||2018-05-31 21:22:56.086529|2018-05-31 21:22:56.086529
NCT01598688|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-05-28|2012-05-10|2012-05-15|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Cyclosporine (CSA) Level in Blood Samples Collected From Different Lines|Monitoring of Cyclosporine Serum Levels in Hematopoietic Stem Cell Transplantation|Completed||N/A|32|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:22:57.175596|2018-05-31 21:22:57.175596
NCT01598675|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-04-18|2012-05-10|2012-05-15|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Error Based Learning for Restoring Gait Symmetry Post-Stroke|Error Based Learning for Restoring Gait Symmetry Post-Stroke|Completed||Phase 1|48|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 21:22:57.259658|2018-05-31 21:22:57.259658
NCT01598662|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-05-14|2012-05-14|2012-05-15|Estimate|||||||2012-05-14|2012-05-15|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|March 2014|Anticipated|2014-03-31|June 2013|Anticipated|2013-06-30||Interventional|IUD||Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement|Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement: A Randomized, Controlled Trial|Unknown status|Active, not recruiting|N/A|70|Anticipated|University of Louisville||2|||f||||t||||||||||2018-05-31 21:22:57.345651|2018-05-31 21:22:57.345651
NCT01598649|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2013-10-28|2012-05-10|2012-05-15|Estimate|||||||2013-10-28|2013-10-29|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Intervention With Lupin Protein-enriched Foods in Hypercholesterolemic Subjects|Influence of Intervention With Lupin Protein-enriched Foods on Cardiovascular Risk Factors in Hypercholesterolemic Subjects|Completed||N/A|72|Actual|University of Jena||3|||f||||t||||||||||2018-05-31 21:22:57.438424|2018-05-31 21:22:57.438424
NCT01598636|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-12-04|2012-05-10|2012-05-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|LTT-HVDB||The Lateral Tibial Tunnel in ACL Surgery|The Lateral Tibial Tunnel in Anterior Cruciate Ligament Surgery. A Clinical and Ct-graphic Study.to Evaluate the Concept|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 21:22:57.531669|2018-05-31 21:22:57.531669
NCT01598623|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-11-22|2012-05-14|2012-05-15|Estimate|||||||2013-11-22|2013-11-25|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|February 2014|Anticipated|2014-02-28||Interventional|OXY-S-01||Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients|A Randomized Trial Administering Oxytocin vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia and Schizo-affective Disorder|Unknown status|Not yet recruiting|Phase 2|48|Anticipated|Sheba Medical Center||4|||f||||f||||||||||2018-05-31 21:22:57.615904|2018-05-31 21:22:57.615904
NCT01598610|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|2013-05-30||2016-01-29|2012-05-13|2012-05-15|Estimate|2013-05-30|2013-07-30|Estimate||||2016-01-29|2016-02-29|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Performance Evaluation of an Investigational Blood Glucose Monitoring System|Performance of the CONTOUR® PLUS Blood Glucose Monitoring System With CONTOUR® PLUS Strip|Completed||N/A|220|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 21:22:58.522278|2018-05-31 21:22:58.522278
NCT01598597|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-05-07|2012-05-11|2012-05-15|Estimate|||||||2015-05-07|2015-05-08|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)|An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin|Completed|||276|Actual|Genentech, Inc.|||1||f||||||||||Samples With DNA|"~     saliva, optional blood~   "|||2018-05-31 21:22:58.722173|2018-05-31 21:22:58.722173
NCT01598584|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2015-09-24|2012-05-14|2012-05-15|Estimate|||||||2015-09-24|2015-09-28|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer|A Phase II/III Prospective Randomized Placebo-control Trail Compare Mirtazapine Plus Gemcitabine With Gemcitabine in Metastasis Pancreatic Cancer|Withdrawn||Phase 2/Phase 3|0|Actual|Tianjin Medical University Cancer Institute and Hospital||2||Gemcitabine is not the first choice for most pancreatic cancer patients nowdays|f||||t||||||||||2018-05-31 21:22:58.844338|2018-05-31 21:22:58.844338
NCT01598571|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-08-21|2012-05-14|2012-05-15|Estimate|||||||2012-08-21|2012-08-22|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose|A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib With Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers|Completed||Phase 1|37|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:22:58.923282|2018-05-31 21:22:58.923282
NCT01598558|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-10-03|2012-05-14|2012-05-15|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT|Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT|Withdrawn||N/A|0|Actual|Stanford University||1||Accrual issues - Low Accrual|f||||t||||||||||2018-05-31 21:22:59.09357|2018-05-31 21:22:59.09357
NCT01598545|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2014-12-09||2014-12-09|2012-05-14|2012-05-15|Estimate|2014-12-09|2014-12-17|Estimate||||2014-12-09|2014-12-17|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Hydromorphone and C-section|Determination of the ED50 of Intrathecal Hydromorphone for Post-cesarean Section Pain Relief|Completed||Phase 2|20|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:22:59.190052|2018-05-31 21:22:59.190052
NCT01598532|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|2016-05-16||2016-08-23|2012-05-10|2012-05-15|Estimate|2016-07-12|2016-08-22|Estimate||||2016-08-23|2016-09-30|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|LED|Population was Males and Females, ages 18 to 65 years who sustained a mild traumatic brain injury at least 6 months prior to study participation|Effects of LEDs on Memory in TBI Patients|Treatment of Cognitive Dysfunction in Mild TBI With Transcranial Light Emitting Diodes- An Open Protocol, Pilot Study|Completed||N/A|22|Actual|Spaulding Rehabilitation Hospital|Small sample size & Open Protocol|1|||f||||f||||||||No||2018-05-31 21:22:59.387924|2018-05-31 21:22:59.387924
NCT01598519|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-05-10|2012-05-10|2012-05-15|Estimate|||||||2012-05-10|2012-05-15|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||School-based Comprehensive Suicide Intervention in Shanghai, China||Unknown status|Recruiting|N/A|3000|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||||2018-05-31 21:22:59.645582|2018-05-31 21:22:59.645582
NCT01598506|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2014-11-04||2017-12-14|2012-05-14|2012-05-15|Estimate|2014-11-04|2014-11-10|Estimate||||2017-12-14|2018-01-12|Actual|September 2013||2013-09-30|December 2017|2017-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Intrathecal Hydromorphone for Labor Analgesia|Determination of the ED50 of Intrathecal Hydromorphone in Laboring Women Using the Up-and-down Sequential Allocation Method|Completed||Phase 2|22|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:22:59.727299|2018-05-31 21:22:59.727299
NCT01598493|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-07-12|2012-05-13|2012-05-15|Estimate|||||||2017-07-12|2017-07-13|Actual|May 2012||2012-05-31|July 2017|2017-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Deep Dermal Burn|To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Deep Dermal Burn|Completed||N/A|30|Actual|Bio-medical Carbon Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:22:59.863267|2018-05-31 21:22:59.863267
NCT01598480|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-07-12|2012-05-13|2012-05-15|Estimate|||||||2017-07-12|2017-07-13|Actual|May 2012||2012-05-31|July 2017|2017-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Superficial Dermal Burn|To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Superficial Dermal Burn|Completed||N/A|30|Actual|Bio-medical Carbon Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:22:59.933233|2018-05-31 21:22:59.933233
NCT01598467|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-02-15|2012-05-14|2012-05-15|Estimate|||||||2018-02-15|2018-02-21|Estimate|August 2011||2011-08-31|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|PARSEC||Prospective Assessment of Robotic Sacrocolpopexy: a European Multicentric Cohort (PARSEC)|Prospective Interventional Study on Robotic Sacrocolpopexy: a European Multicentric Cohort (PARSEC)|Recruiting||N/A|300|Anticipated|Cork University Hospital||1|||f||||f||||||||||2018-05-31 21:22:59.998941|2018-05-31 21:22:59.998941
NCT01597271|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-06-22|2012-05-11|2012-05-14|Estimate|||||||2012-06-22|2012-06-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:23:23.092261|2018-05-31 21:23:23.092261
NCT01598454|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-07-27|2012-05-11|2012-05-15|Estimate|||||||2015-07-27|2015-07-29|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|March 2014|Actual|2014-03-31||Interventional|||Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides|Phase 1 Study on the Use of Racotumomab Anti-idiotype Antibody in Patients With Pediatric Malignancies That Express N-glycolylated Gangliosides and Are Resistant to Conventional Treatment.|Completed||Phase 1|15|Actual|Laboratorio Elea S.A.C.I.F. y A.||1|||f||||f||||||||||2018-05-31 21:23:00.076675|2018-05-31 21:23:00.076675
NCT01598441|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2016-11-20|2012-05-14|2012-05-15|Estimate|||||||2016-11-20|2016-11-22|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)|Multi-centre, Randomized Study of Iloprost Inhaled in Preventing and Treating Reactive Pulmonary Hypertension (RPH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Diseases (CHD)|Completed||Phase 3|8|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 21:23:00.14351|2018-05-31 21:23:00.14351
NCT01598428|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2014-06-17||2015-01-14|2012-05-14|2012-05-15|Estimate|2015-01-14|2015-01-26|Estimate||||2015-01-14|2015-01-26|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Anterior Capsule Polishing Effect on Effective Lens Position|Effect of Anterior Capsule Polishing on Effective Lens Position After Cataract Surgery|Completed||N/A|20|Actual|Shandong University||1|||f||||f||||||||||2018-05-31 21:23:00.330502|2018-05-31 21:23:00.330502
NCT01598415|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-10-16|2012-05-10|2012-05-15|Estimate|||||||2014-10-16|2014-10-17|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II|A Two Part Protocol to Assess, Using Double Blind Placebo Control, the Safety, Tolerability, and Pharmacokinetics of Ascending Single Doses of a New Intra-articular Administration Formulation of SAR113945 (IKK Inhibitor) Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose in Patients With Knee Osteoarthritis.|Completed||Phase 2|130|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:23:00.561418|2018-05-31 21:23:00.561418
NCT01598402|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2013-07-12|2012-05-14|2012-05-15|Estimate|||||||2013-07-12|2013-07-15|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|PANTAP||Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia|Efficacy and Cost Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Locally Advanced Head and Neck Cancer to Prevent Aspiration Pneumonia. A Randomized Phase II-III Study|Unknown status|Recruiting|Phase 2/Phase 3|106|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 21:23:00.651005|2018-05-31 21:23:00.651005
NCT01598389|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-10|2012-05-10|2012-05-15|Estimate|||||||2012-05-10|2012-05-15|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Eating Behaviors Among Weight-Discordant Siblings|Eating Behaviors Among Weight-Discordant Siblings|Completed||N/A|94|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 21:23:00.765261|2018-05-31 21:23:00.765261
NCT01598376|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-05-14|2012-05-14|2012-05-15|Estimate|||||||2012-05-14|2012-05-15|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||A Prospective Double-blind Interventional Study of Tissue Reaction to Polyglycolic Acid Sutures in Human Skin|A Prospective Double-blind Interventional Study of Tissue Reaction to Polyglycolic Acid Sutures in Human Skin|Completed||N/A|42|Actual|The Royal Bournemouth Hospital||2|||f||||f||||||||||2018-05-31 21:23:00.837967|2018-05-31 21:23:00.837967
NCT01598363|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-11-01|2012-05-14|2012-05-15|Estimate|||||||2012-11-01|2012-11-02|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers||Completed||Phase 1|32|Actual|Reata Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 21:23:00.924438|2018-05-31 21:23:00.924438
NCT01598350|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2013-11-12||2013-11-12|2012-05-14|2012-05-15|Estimate|2013-11-12|2013-12-30|Estimate||||2013-11-12|2013-12-30|Estimate|January 2010||2010-01-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Gait in Children With Down Syndrome While Wearing Orthoses|Using Anthropometric Measurements to Predict Orthotic Influence on Gait Parameters in Children With Down Syndrome|Completed||N/A|6|Actual|University of Puget Sound|small number of subject recruited.|1|||f||||f||||||||||2018-05-31 21:23:01.006137|2018-05-31 21:23:01.006137
NCT01598337|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-14|2012-05-14|2012-05-15|Estimate|||||||2012-05-14|2012-05-15|Estimate|April 2011||2011-04-30|May 2012|2012-05-31||||December 2013|Anticipated|2013-12-31||Interventional|||The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency|The Effect Of Antiplatelets Therapy, Tirafiban, Prasugrel, And Aspirin On Saphenous Vein Coronary Artery Bypass Graft Patency|Unknown status|Recruiting|Phase 3|200|Anticipated|Prince Sultan Cardiac Center, Adult Cardiology Department.||4|||f||||t||||||||||2018-05-31 21:23:01.175082|2018-05-31 21:23:01.175082
NCT01598324|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2013-08-10|2012-05-12|2012-05-15|Estimate|||||||2013-08-10|2013-08-13|Estimate|July 2012||2012-07-31|August 2013|2013-08-31||||April 2013|Actual|2013-04-30||Observational|||Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder|Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder|Terminated|||1|Actual|Mclean Hospital|||3|Clinical trial from which subjects were recruited closed to enrollment|f||||f||||||||||2018-05-31 21:23:01.267104|2018-05-31 21:23:01.267104
NCT01598311|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2018-01-31||2018-03-05|2012-05-11|2012-05-15|Estimate|2018-01-31|2018-02-27|Actual||||2018-03-05|2018-03-29|Actual|May 16, 2012|Actual|2012-05-16|March 2018|2018-03-31|August 25, 2015|Actual|2015-08-25|July 26, 2015|Actual|2015-07-26||Interventional||The baseline analysis population includes all randomized and treated participants with a confirmed CDAD diagnosis (microbiological modified intent-to-treat [mMITT] population).|A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)|A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea|Completed||Phase 3|608|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 21:23:01.362417|2018-05-31 21:23:01.362417
NCT01598298|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2018-01-31||2018-03-06|2012-05-11|2012-05-15|Estimate|2018-01-31|2018-02-28|Actual||||2018-03-06|2018-04-02|Actual|June 2013||2013-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|April 2017|Actual|2017-04-30||Interventional||Eligible patients|S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy|A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer|Active, not recruiting||Phase 3|299|Actual|Southwest Oncology Group||2|||f||||t||||||||Yes|https://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-05-31 21:23:01.918298|2018-05-31 21:23:01.918298
NCT01598285|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-06-07|2012-05-14|2012-05-15|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer|A Combined Genome-Wide Association Study (GWAS) and microRNA (miRNA) Profiling Approach for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer|Unknown status|Active, not recruiting||200|Anticipated|Spanish Breast Cancer Research Group|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 21:23:03.628592|2018-05-31 21:23:03.628592
NCT01598272|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-12-10|2012-05-14|2012-05-15|Estimate|||||||2014-12-10|2014-12-11|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Pharmanex||Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women|A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Center Study on the Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women.|Completed||Phase 4|95|Actual|Pharmanex||2|||f||||t||||||||||2018-05-31 21:23:03.682675|2018-05-31 21:23:03.682675
NCT01598259|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-06-27|2012-05-14|2012-05-15|Estimate|||||||2016-06-27|2016-06-28|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Sleep6||Randomized Controlled Trial to Assess Efficacy of Melatonin for Children During Burn Rehabilitation|Randomized Controlled Trial to Assess Efficacy of Melatonin for Children During Burn Rehabilitation|Terminated||Phase 2|10|Actual|Shriners Hospitals for Children||2||lack or enrollment, funding depletion|f||||t||||||||No|given low level of enrollment and hence, randomization (n=3), no plans to provide data|2018-05-31 21:23:03.745774|2018-05-31 21:23:03.745774
NCT01598246|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2018-03-29|2012-05-14|2012-05-15|Estimate|||||||2018-03-29|2018-04-02|Actual|May 2012|Actual|2012-05-31|March 2018|2018-03-31|June 30, 2013|Actual|2013-06-30|June 30, 2013|Actual|2013-06-30||Observational|RIPE||Study to Evaluate Causes of Failure to Extubate|Prospective Observational Study on Factors Influencing Re-Intubation Following a Planned Extubation (RIPE) in a Pediatric Intensive Care Unit: Identifying Targets for a Quality Improvement Initiative|Completed|||500|Actual|Montefiore Medical Center|||2||f||||f||||||||||2018-05-31 21:23:03.797301|2018-05-31 21:23:03.797301
NCT01598233|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-12-16|2012-05-11|2012-05-15|Estimate|||||||2014-12-16|2014-12-18|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Intragastric Balloon on Bone, Metabolic and Respiratory Parameters|Effects of Intragastric Balloon on Bone, Metabolic and Respiratory Parameters|Completed||Phase 3|50|Actual|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 21:23:03.845857|2018-05-31 21:23:03.845857
NCT01598220|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-05-17|2012-05-11|2012-05-15|Estimate|||||||2012-05-17|2012-05-18|Estimate|September 2002||2002-09-30|May 2012|2012-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|CACREPS||Computer Assisted Cognitive Remediation Program in Schizophrenia|Efficacy Study of a Computer Cognitive Remediation Program in Patients With Schizophrenia|Completed||N/A|135|Actual|Consorci Sanitari de Terrassa||2|||f||||t||||||||||2018-05-31 21:23:03.977978|2018-05-31 21:23:03.977978
NCT01598207|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2016-03-21||2017-04-26|2012-05-14|2012-05-15|Estimate|2017-04-26|2017-04-28|Actual||||2017-04-26|2017-04-28|Actual|February 2011||2011-02-28|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain||Completed||Phase 4|13|Actual|University of Iowa||2|||f||||||||||||||2018-05-31 21:23:04.064809|2018-05-31 21:23:04.064809
NCT01598194|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-07-07|2012-05-14|2012-05-15|Estimate|||||||2017-07-07|2017-07-11|Actual|January 30, 2012|Actual|2012-01-30|July 2017|2017-07-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||Comparison of a Novel 22-gauge Core Biopsy Needle|Prospective Comparison of a Novel 22-gauge Core Biopsy Needle With Reverse Bevel Design to a Standard Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) Needle for Diagnosis of Solid Pancreatic Mass Lesions|Completed||N/A|60|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-05-31 21:23:04.306594|2018-05-31 21:23:04.306594
NCT01598181|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-02-15|2012-05-11|2012-05-15|Estimate|||||||2017-02-15|2017-02-16|Actual|December 2011||2011-12-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia|Transcranial Direct Current Stimulation (tDCS) as Treatment Method for Pain in Fibromyalgia|Completed||N/A|70|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 21:23:04.374124|2018-05-31 21:23:04.374124
NCT01598168|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2016-03-24|2012-05-11|2012-05-15|Estimate|||||||2016-03-24|2016-03-25|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia|Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia|Terminated||Phase 3|22|Actual|McMaster University||1||slow recruitment|f||||t||||||||||2018-05-31 21:23:04.442618|2018-05-31 21:23:04.442618
NCT01598155|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-12-07|2012-05-11|2012-05-15|Estimate|||||||2014-12-07|2014-12-09|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Effect of Supragingival Control Versus Supra- and Subgingival Control in the Periodontal Health During the Maintenance|The Effect of Supragingival Biofilm Control, and the Combination of Supra and Subgingival Biofilm Control in Periodontal Health of Patients Participating in a Periodontal Preventive Maintenance Program - A Randomized Clinical Trial.|Unknown status|Active, not recruiting|N/A|70|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 21:23:04.515634|2018-05-31 21:23:04.515634
NCT01598142|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-05-14|2012-05-14|2012-05-15|Estimate|||||||2012-05-14|2012-05-15|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Single-operator Wire-guided Endoscopic Retrograde Cholangiopancreatography Cannulation Technique|Single-operator Wire-guided ERCP Cannulation Technique: a Single-center Randomized Controlled Study|Completed||N/A|465|Actual|Zhejiang University||2|||f||||t||||||||||2018-05-31 21:23:04.642257|2018-05-31 21:23:04.642257
NCT01598129|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2014-06-11||2016-10-21|2012-05-10|2012-05-15|Estimate|2014-10-01|2014-10-02|Estimate||||2016-10-21|2016-10-24|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers|Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours|Completed||Phase 1|12|Actual|Targovax ASA||1|||f||||t||||||||||2018-05-31 21:23:04.735228|2018-05-31 21:23:04.735228
NCT01598116|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-03-21|2012-05-10|2012-05-15|Estimate|||||||2018-03-21|2018-03-22|Actual|December 2010||2010-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas|A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas.|Active, not recruiting|||60|Anticipated|Ohio State University|||2||f||||f||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 21:23:04.959845|2018-05-31 21:23:04.959845
NCT01598103|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-04-26|2012-05-14|2012-05-15|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions|A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy|Terminated||Phase 2|9|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:23:05.055983|2018-05-31 21:23:05.055983
NCT01598090|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09||2017-03-02|2017-03-03|2012-05-11|2012-05-15|Estimate||||2017-03-02|2017-03-03|Actual|2017-03-03|2017-03-06|Actual|June 2012||2012-06-30|March 2017|2017-03-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|PEDESTAL||Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir|A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin|Completed||Phase 3|646|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-05-31 21:23:05.191537|2018-05-31 21:23:05.191537
NCT01598077|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-04-21|2012-05-14|2012-05-15|Estimate|||||||2014-04-21|2014-04-23|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer|A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer|Completed||Phase 1|54|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:23:05.401161|2018-05-31 21:23:05.401161
NCT01598064|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2014-07-14||2014-09-09|2012-05-14|2012-05-15|Estimate|2014-08-25|2014-09-05|Estimate||||2014-09-09|2014-09-18|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Probiotics for Liver Cirrhosis With Portal Hypertension|Clinical Trial of Probiotics in Preventing Complication Related to Portal Hypertension in Cirrhotic Patients|Completed||N/A|49|Actual|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 21:23:05.487553|2018-05-31 21:23:05.487553
NCT01598051|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-05-16|2012-05-11|2012-05-15|Estimate|||||||2018-05-16|2018-05-18|Actual|May 31, 2012|Actual|2012-05-31|May 2018|2018-05-31|March 31, 2017|Actual|2017-03-31|June 9, 2016|Actual|2016-06-09||Observational|||Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan|Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)|Completed|||741|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:23:06.212454|2018-05-31 21:23:06.212454
NCT01598038|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-07-27|2012-05-14|2012-05-15|Estimate|||||||2017-07-27|2017-07-28|Actual|April 2012||2012-04-30|July 2017|2017-07-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma|Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma|Terminated||N/A|41|Actual|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 21:23:06.280167|2018-05-31 21:23:06.280167
NCT01598025|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2018-03-19||2018-03-19|2012-05-10|2012-05-15|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|May 2, 2012|Actual|2012-05-02|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|||Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor|Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor|Terminated||N/A|3|Actual|Memorial Sloan Kettering Cancer Center||2||Closed due to poor accrual|f||||||||||||||2018-05-31 21:23:06.366902|2018-05-31 21:23:06.366902
NCT01598012|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2013-08-26|2012-05-14|2012-05-15|Estimate|||||||2013-08-26|2013-08-27|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea|The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea|Completed||Phase 4|40|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 21:23:06.746972|2018-05-31 21:23:06.746972
NCT01597999|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2013-01-21|2012-05-14|2012-05-15|Estimate|||||||2013-01-21|2013-01-23|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|July 2012|Actual|2012-07-31||Interventional|||Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer|Accuracy of Magnetic Resonance Imaging (MRI) in Predicting Aggressiveness of Early Breast Cancer According to Molecular Subtypes Identified by ER PR and HER-2 Status|Unknown status|Recruiting|Phase 4|60|Anticipated|Mahidol University||1|||f||||f||||||||||2018-05-31 21:23:06.831245|2018-05-31 21:23:06.831245
NCT01597986|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-07-12|2012-05-11|2012-05-15|Estimate|||||||2012-07-12|2012-07-16|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone|A Phase 1, Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:23:06.912012|2018-05-31 21:23:06.912012
NCT01597973|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-02-14|2012-05-10|2012-05-15|Estimate|||||||2018-02-14|2018-02-16|Estimate|October 2012||2012-10-31|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|August 2020|Anticipated|2020-08-31||Interventional|||Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli|Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli|Recruiting||Phase 3|444|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 21:23:06.998656|2018-05-31 21:23:06.998656
NCT01597960|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-11-10|2012-05-14|2012-05-15|Estimate|||||||2016-11-10|2016-11-11|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|YACHT||Yoga And Cardiovascular Health Trial|Yoga And Cardiovascular Health Trial|Completed||N/A|80|Actual|Imperial College London||2|||f||||t||||||||Undecided||2018-05-31 21:23:07.123262|2018-05-31 21:23:07.123262
NCT01597947|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-01-18|2012-05-11|2012-05-15|Estimate|||||||2013-01-18|2013-01-21|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|||||Interventional|||A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers|A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) ACHN-975 in Normal Healthy Volunteers|Completed||Phase 1|50|Actual|Achaogen, Inc.||2|||f||||||||||||||2018-05-31 21:23:07.199477|2018-05-31 21:23:07.199477
NCT01597934|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-01-30|2012-05-14|2012-05-15|Estimate|||||||2014-01-30|2014-01-31|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Antiviral Efficacy of Switching to ETV Plus TDF|A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation|Unknown status|Active, not recruiting|Phase 4|104|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 21:23:07.269918|2018-05-31 21:23:07.269918
NCT01597921|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-08-08|2012-05-11|2012-05-14|Estimate|||||||2012-08-08|2012-08-09|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer|Phase II, Double Blinded, Randomized Study of R1 and R2 (Waterjel) Verses Aloe Vera Jell for the Prevention and Treatment of Radiation Induced Dermatitis in Breast Cancer Patients|Terminated|||50|Actual|Water-Jel|||1|The study was stopped due to unbalanced side effects|f||||f||||||||||2018-05-31 21:23:07.356082|2018-05-31 21:23:07.356082
NCT01597908|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2014-12-01||2018-04-30|2012-05-10|2012-05-14|Estimate|2014-12-01|2014-12-04|Estimate||||2018-04-30|2018-05-30|Actual|June 4, 2012|Actual|2012-06-04|April 2018|2018-04-30|March 18, 2019|Anticipated|2019-03-18|April 17, 2014|Actual|2014-04-17||Interventional|COMBI-v||Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma|A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma|Active, not recruiting||Phase 3|704|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:23:07.501806|2018-05-31 21:23:07.501806
NCT01597895|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-09-18|2012-05-10|2012-05-14|Estimate|||||||2012-09-18|2012-09-19|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects|Open-Label, Randomized, Fixed-Sequence, Crossover Study to Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects|Completed||Phase 1|14|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 21:23:08.692092|2018-05-31 21:23:08.692092
NCT01597882|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-02-16|2012-05-11|2012-05-14|Estimate|||||||2014-02-16|2014-02-19|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Improving Monitoring of Patients Receiving Case Management|Improved Targeting of Admission Avoidance Interventions in Older People With Long-term Conditions:An Observational,Longitudinal Study Exploring the Feasibility of Measures of Strength as a Monitoring Aid in Patients Receiving Case Management|Completed|||114|Actual|University of Southampton|||1||f||||f||||||||||2018-05-31 21:23:08.766193|2018-05-31 21:23:08.766193
NCT01597869|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2013-01-01|2012-05-10|2012-05-14|Estimate|||||||2013-01-01|2013-01-03|Estimate|April 2012||2012-04-30|January 2013|2013-01-31||||January 2013|Anticipated|2013-01-31||Observational|||Safety of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration : A Prospective Study|Safety of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration : A Prospective Study|Unknown status|Recruiting||300|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-05-31 21:23:08.829043|2018-05-31 21:23:08.829043
NCT01597856|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-01-30|2012-05-11|2012-05-14|Estimate|||||||2018-01-30|2018-02-01|Actual|March 18, 2013|Actual|2013-03-18|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|September 30, 2017|Actual|2017-09-30||Interventional|SBIRT-PTSD||Evaluation and Treatment of Substance Abuse in Veterans With PTSD Disability Claims|Evaluation and Treatment of Substance Use in Veterans With PTSD Disability Claims|Completed||Phase 1|172|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 21:23:08.887604|2018-05-31 21:23:08.887604
NCT01597843|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2014-09-08||2015-04-06|2012-05-11|2012-05-14|Estimate|2014-09-08|2014-09-12|Estimate||||2015-04-06|2015-04-28|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional||We included the mean number of post members across the three data collection times as our best measure of participants|Veterans Service Organizations and My HealtheVet (MHV)|Working With Veterans Organizations to Encourage Use of My HealtheVet|Completed||N/A|282|Actual|VA Office of Research and Development|Response rates on surveys were lower than expected. One of the first round intervention posts almost certainly did not deliver anything resembling the planned educational intervention at any point.|3|||f||||f||||||||||2018-05-31 21:23:08.974196|2018-05-31 21:23:08.974196
NCT01597830|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2016-04-04|2012-05-10|2012-05-14|Estimate|||||||2016-04-04|2016-04-06|Estimate|July 2007||2007-07-31|April 2016|2016-04-30||||August 2013|Actual|2013-08-31||Interventional|||The Effects of Specialized Footwear in Osteoarthritis|The Effects of Specialized Footwear in Osteoarthritis|Completed||N/A|200|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 21:23:09.274664|2018-05-31 21:23:09.274664
NCT01597817|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-12-08|2012-05-11|2012-05-14|Estimate|||||||2014-12-08|2014-12-09|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|2ndDermisII||Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis|A Randomized Controlled Trial of the Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis|Completed||Phase 2|78|Actual|Universidade do Porto||2|||f||||f||||||||||2018-05-31 21:23:09.357907|2018-05-31 21:23:09.357907
NCT01597804|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2016-04-26|2012-05-10|2012-05-14|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2014|Actual|2014-02-28||Interventional|||Bathing Bundle Regimen in Reducing Gynecological Surgical Site Infection in Patients Undergoing Surgery|"A Bathing Bundle Regimen to Reduce the Risk of Gynecological Surgical Site Infection"|Completed||N/A|435|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 21:23:09.468522|2018-05-31 21:23:09.468522
NCT01597791|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2017-09-12||2018-03-27|2012-05-11|2012-05-14|Estimate|2017-09-12|2017-10-10|Actual||||2018-03-27|2018-04-25|Actual|March 22, 2012|Actual|2012-03-22|March 2018|2018-03-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Combined Spinal Epidural Urinary Retention|Do Women Receiving Low Dose Combined Spinal Epidural for Labor Analgesia Exhibit Less Bacteriuria Using a Urinary Retention Protocol Versus Routine Urinary Catheter Placement?|Terminated||N/A|56|Actual|Northwestern University|The study was terminated early because of difficulty using the ultrasound device to estimate urinary bladder capacity and residual levels.|2||Change in procedure.US technically challenging.|f||||f||||||||No||2018-05-31 21:23:09.544621|2018-05-31 21:23:09.544621
NCT01597778|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-03-20|2012-05-10|2012-05-14|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2012|Actual|2012-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Double Cord Versus Haploidentical (BMT CTN 1101)|A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients With Hematologic Malignancies (BMT CTN #1101)|Recruiting||Phase 3|410|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 21:23:09.794703|2018-05-31 21:23:09.794703
NCT01597765|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-05-13|2012-05-10|2012-05-14|Estimate|||||||2012-05-13|2012-05-15|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients|Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients|Completed||N/A|60|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 21:23:09.984485|2018-05-31 21:23:09.984485
NCT01597752|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-11-29|2012-05-10|2012-05-14|Estimate|||||||2012-11-29|2012-11-30|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Biological Standardization of Blomia Tropicalis Allergen Extract|Biological Standardization of Blomia Tropicalis Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units|Completed||Phase 2|20|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 21:23:10.081137|2018-05-31 21:23:10.081137
NCT01597739|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-04-07|2012-05-10|2012-05-14|Estimate|||||||2014-04-07|2014-04-08|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy|A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy|Completed||Phase 2|96|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 21:23:10.161323|2018-05-31 21:23:10.161323
NCT01597726|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2013-11-06|2012-05-11|2012-05-14|Estimate|||||||2013-11-06|2013-11-07|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cervical Priming Before Dilation & Evacuation|Cervical Priming Before Dilation & Evacuation: a Randomized Controlled Trial|Completed||N/A|159|Actual|Ibis Reproductive Health||2|||f||||f||||||||||2018-05-31 21:23:10.264865|2018-05-31 21:23:10.264865
NCT01597713|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-05-28|2012-05-10|2012-05-14|Estimate|||||||2015-05-28|2015-05-29|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects|Completed||Phase 1|83|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:23:10.331463|2018-05-31 21:23:10.331463
NCT01597700|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-06-19|2012-05-10|2012-05-14|Estimate|||||||2017-06-19|2017-06-20|Actual|January 13, 2012|Actual|2012-01-13|June 2017|2017-06-30|January 30, 2012|Actual|2012-01-30|January 30, 2012|Actual|2012-01-30||Interventional|||Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.|A RANDOMIZED, BALANCED, OPEN LABEL, CROSSOVER, TWO PERIOD, TWO TREATMENT, TWO SEQUENCE, SINGLE DOSE, BIOEQUIVALENCE STUDY OF ACOTRAL® EZETIMIBE 10 MG TABLETS CONTAINING EZETIMIBE MANUFACTURED BY LABORATORIOS PHOENIX S.A.I.C.F, ARGENTINA AND ZETIA® EZETIMIBE 10 MG TABLETS OF MERCK/SCHERING - PLOUGH PHARMACEUTICALS, USA IN HEALTHY ADULT HUMAN MALE SUBJECTS UNDER FASTING CONDITION|Completed||Phase 1|52|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:23:10.561234|2018-05-31 21:23:10.561234
NCT01597687|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-11-07|2012-05-10|2012-05-14|Estimate|||||||2013-11-07|2013-11-11|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pertussis Infection in Adolescents and Adults With Prolonged Cough|Bordetella Pertussis Infection Among Adolescents and Adults With Prolonged Cough|Completed||N/A|337|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 21:23:10.646215|2018-05-31 21:23:10.646215
NCT01597674|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-05-11|2012-05-11|2012-05-14|Estimate|||||||2012-05-11|2012-05-14|Estimate|April 1997||1997-04-30|May 2012|2012-05-31|June 1997|Actual|1997-06-30|June 1997|Actual|1997-06-30||Interventional|||Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers|A Double-blind, Placebo-controlled, Parallel-group Study of the Effect of 5, 10 and 25 mg Daily of YF476 for 14 Days on 24-hour Ambulatory Gastric pH and Plasma Gastrin Concentrations in Healthy Volunteers|Completed||Phase 1|49|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 21:23:10.729087|2018-05-31 21:23:10.729087
NCT01597661|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2014-07-03|2012-05-10|2012-05-14|Estimate|||||||2014-07-03|2014-07-08|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Bupropion & Cardio Birth Defect (Slone)|Bupropion and Cardiac Birth Defects (Slone Epidemiology Center)|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:23:10.791876|2018-05-31 21:23:10.791876
NCT01597648|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-05-17|2012-05-10|2012-05-14|Estimate|||||||2012-05-17|2012-05-21|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™|A Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ Administered Concurrently in Healthy Adult Subjects|Completed||Phase 1|42|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:23:10.864742|2018-05-31 21:23:10.864742
NCT01597635|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2017-07-23|2015-03-19|2017-08-31|2012-05-10|2012-05-14|Estimate|2017-08-31|2017-09-28|Actual|2015-03-19|2015-04-08|Estimate|2017-08-31|2017-09-28|Actual|September 1, 2012||2012-09-01|August 2017|2017-08-31|October 6, 2014|Actual|2014-10-06|October 1, 2014|Actual|2014-10-01||Interventional|||The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury|A Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2586881 in Patients With Acute Lung Injury|Completed||Phase 2|44|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:23:11.504288|2018-05-31 21:23:11.504288
NCT01597622|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-05-14|2012-05-10|2012-05-14|Estimate|||||||2018-05-14|2018-05-15|Actual|June 11, 2012|Actual|2012-06-11|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115|BEL114333, a Multicenter, Continuation Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase III Study BEL113750 in Northeast Asia or Completed the Open-label Extension of HGS1006-C1115 in Japan|Active, not recruiting||Phase 3|420|Anticipated|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:23:16.390456|2018-05-31 21:23:16.390456
NCT01597609|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-06-16|2012-05-10|2012-05-14|Estimate|||||||2017-06-16|2017-06-20|Actual|May 22, 2008|Actual|2008-05-22|June 2017|2017-06-30|March 4, 2010|Actual|2010-03-04|March 4, 2010|Actual|2010-03-04||Interventional|||A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects|A Single-blind, Randomised, Placebo-controlled, Parallel Group, Incomplete Block Design, Benchmark Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects|Completed||Phase 1|60|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:23:16.512289|2018-05-31 21:23:16.512289
NCT01597596|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2015-09-25||2015-12-14|2012-05-10|2012-05-14|Estimate|2015-12-14|2016-01-18|Estimate||||2015-12-14|2016-01-18|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease|A Phase 3/4, Prospective, Multinational, Open-label, Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease|Terminated||Phase 4|4|Actual|Sanofi||2||Study was stopped due to approved label expansion of alglucosidase alfa.|f||||t||||||||||2018-05-31 21:23:16.61129|2018-05-31 21:23:16.61129
NCT01597583|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2013-12-09|2012-05-11|2012-05-14|Estimate|||||||2013-12-09|2013-12-10|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||MobileMedMinder: A Networked Aide for Medication Compliances|MobileMedMinder: A Networked Aide for Medication Compliances|Completed||N/A|50|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 21:23:17.049673|2018-05-31 21:23:17.049673
NCT01597570|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-07-23|2012-05-10|2012-05-14|Estimate|||||||2017-07-23|2017-07-25|Actual|May 2012||2012-05-31|July 2017|2017-07-31|December 10, 2012|Actual|2012-12-10|December 10, 2012|Actual|2012-12-10||Interventional|||Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System|Clinical Evaluation of Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable Vascular Access Closure System and Perclose® ProGlide Suture-Mediated Closure System; Randomized, Comparative Study|Terminated||Phase 3|52|Actual|Taewoong Medical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:23:17.110251|2018-05-31 21:23:17.110251
NCT01597557|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-07-18|2012-05-10|2012-05-14|Estimate|||||||2014-07-18|2014-07-21|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|MICA||Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial|Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial|Completed||N/A|256|Actual|State University of New York at Buffalo||2|||f||||t||||||||||2018-05-31 21:23:17.184784|2018-05-31 21:23:17.184784
NCT01597544|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-07-20|2012-05-11|2012-05-14|Estimate|||||||2017-07-20|2017-07-21|Actual|July 2012||2012-07-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Post-operative Voiding Dysfunction: the Preferred Method for Catheterization|Post-operative Voiding Dysfunction: the Preferred Method for Catheterization|Active, not recruiting||N/A|150|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 21:23:17.263099|2018-05-31 21:23:17.263099
NCT01597531|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-01-31|2012-05-11|2012-05-14|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 2012||2012-06-30|January 2018|2018-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding|LIRAGLUTIDE AND ORLISTAT TREATMENT FOR PERSISTENT TYPE 2 DIABETES AFTER GASTRIC BANDING: A PILOT STUDY|Terminated||Phase 4|1|Actual|East Carolina University||3||Difficulty recruiting patients|f||||f||||||||||2018-05-31 21:23:17.480642|2018-05-31 21:23:17.480642
NCT01597518|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-03-09|2012-05-11|2012-05-14|Estimate|||||||2018-03-09|2018-03-12|Actual|August 2013||2013-08-31|March 2018|2018-03-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|RISCIS||Riluzole in Spinal Cord Injury Study|A Multi-Center, Randomized, Placebo Controlled, Double-Blinded, Trial of Efficacy and Safety of Riluzole in Acute Spinal Cord Injury|Recruiting||Phase 2/Phase 3|351|Anticipated|AOSpine North America Research Network||2|||f||||t||||||||||2018-05-31 21:23:17.789439|2018-05-31 21:23:17.789439
NCT01597505|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2018-01-18||2018-02-26|2012-05-11|2012-05-14|Estimate|2018-02-26|2018-02-28|Actual||||2018-02-26|2018-02-28|Actual|May 16, 2012|Actual|2012-05-16|February 2018|2018-02-28|March 20, 2015|Actual|2015-03-20|March 20, 2015|Actual|2015-03-20||Interventional|||Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)|A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea|Completed||Phase 3|606|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 21:23:18.813901|2018-05-31 21:23:18.813901
NCT01597492|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2016-04-28||2016-07-11|2012-05-10|2012-05-14|Estimate|2016-07-11|2016-07-25|Estimate||||2016-07-11|2016-07-25|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 4|79|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:23:20.893669|2018-05-31 21:23:20.893669
NCT01597479|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2015-05-06||2016-02-19|2012-05-10|2012-05-14|Estimate|2016-02-19|2016-03-21|Estimate||||2016-02-19|2016-03-21|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Patients undergoing Ambulatory TRA|Ultrasound Guided Distal Peripheral Nerve Blocks and Postoperative Pain.|Effectiveness of Distal Peripheral Nerve Blocks on Postoperative Pain Management After Ambulatory Thumb Resection Arthroplasty.|Completed||Phase 4|52|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|We could included another group: distal blocks with 0,125% levobupivacaine+ 4mg dexamethasone; register patient satisfaction with anesthetic technique or patient risks factors for nausea and vomiting.|2|||f||||t||||||||Undecided||2018-05-31 21:23:21.286062|2018-05-31 21:23:21.286062
NCT01597466|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2016-11-02|2012-05-10|2012-05-14|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Epidrum-Tho||Epidrum for Thoracic Epidural Analgesia|A Comparison Study of Two Different Techniques for Identifying the Epidural Space in Patients Requiring Thoracic Epidural Analgesia: a Prospective Multicentric Randomized Study|Completed||N/A|46|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 21:23:21.500868|2018-05-31 21:23:21.500868
NCT01597453|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2016-02-19|2012-05-10|2012-05-14|Estimate|||||||2016-02-19|2016-02-22|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|December 2035|Anticipated|2035-12-31|December 2015|Actual|2015-12-31||Interventional|NOR-SYS||NOR-SYS: The Norwegian Stroke in the Young Study|NOR-SYS: The Norwegian Stroke in the Young Study Young Ischemic Stroke and Family Risk Factors|Active, not recruiting||N/A|1062|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 21:23:21.564712|2018-05-31 21:23:21.564712
NCT01597440|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2016-06-20||2017-03-15|2012-05-11|2012-05-14|Estimate|2017-03-15|2017-04-26|Actual||||2017-03-15|2017-04-26|Actual|September 2012||2012-09-30|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||One participant, infant under 1 month old, with organic acidemia.|Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia|Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia|Terminated||Phase 2|1|Actual|Children's Research Institute||2||insufficient enrollment|f||||t||||||||No|A single participant was enrolled before the study closed. There are no analyses and if data are shared, this may compromise the confidentiality of this single participant from a very rare disease.|2018-05-31 21:23:21.632151|2018-05-31 21:23:21.632151
NCT01597427|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-10|2012-05-10|2012-05-14|Estimate|||||||2012-05-10|2012-05-14|Estimate|March 2009||2009-03-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|April 2011|Actual|2011-04-30||Interventional|||Reduction of Pulmonary Artery Pressure in Patients Subjected to Cardiac Surgery|Intravenous Clonidine Does Not Reduce Pulmonary Artery Pressure in Patients Subjected to Cardiac|Completed||Phase 2|29|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:23:21.819207|2018-05-31 21:23:21.819207
NCT01597414|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-01-24|2012-05-10|2012-05-14|Estimate|||||||2018-01-24|2018-01-25|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1|Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group|Active, not recruiting||Phase 2|80|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 21:23:21.891522|2018-05-31 21:23:21.891522
NCT01597401|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-01-04|2012-05-11|2012-05-14|Estimate|||||||2018-01-04|2018-01-08|Actual|May 12, 2012|Actual|2012-05-12|January 2018|2018-01-31|June 7, 2013|Actual|2013-06-07|June 7, 2013|Actual|2013-06-07||Interventional|||A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease|A Phase 1, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating, Single Oral Doses of Aes-103 in Subjects With Stable Sickle Cell Disease|Completed||Phase 1|19|Actual|Shire||3|||f||||f||||||||||2018-05-31 21:23:22.173942|2018-05-31 21:23:22.173942
NCT01597388|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-07-25|2012-05-10|2012-05-14|Estimate|||||||2017-07-25|2017-07-26|Actual|May 8, 2012|Actual|2012-05-08|July 2017|2017-07-31|December 12, 2017|Anticipated|2017-12-12|August 4, 2016|Actual|2016-08-04||Interventional|||AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer|A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer.|Active, not recruiting||Phase 1|99|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 21:23:22.305739|2018-05-31 21:23:22.305739
NCT01597375|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2018-04-17|2012-05-11|2012-05-14|Estimate|||||||2018-04-17|2018-04-19|Actual|August 31, 2012|Actual|2012-08-31|April 2018|2018-04-30|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|Aspirin||Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)|Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)|Completed||Phase 2|95|Actual|Brigham and Women's Hospital||2|||f||||t|t|f||||||||2018-05-31 21:23:22.40106|2018-05-31 21:23:22.40106
NCT01597362|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-11|2012-05-11|2012-05-14|Estimate|||||||2012-05-11|2012-05-14|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Three Laparoscopic Access Techniques||Completed||N/A|608|Actual|Campus Bio-Medico University||3|||f||||f||||||||||2018-05-31 21:23:22.50246|2018-05-31 21:23:22.50246
NCT01597349|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09||2014-01-27|2014-01-27|2012-05-11|2012-05-14|Estimate||||2014-01-27|2014-02-28|Estimate|2014-01-27|2014-02-28|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection|An Exploratory, Randomized, Placebo Controlled, Double Blind, Parallel Arm Dose Ranging Study to Determine the Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection|Completed||Phase 2|208|Actual|Cerecor Inc||3|||f||||f||||||||||2018-05-31 21:23:22.569953|2018-05-31 21:23:22.569953
NCT01597336|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-02-03|2012-05-11|2012-05-14|Estimate|||||||2015-02-03|2015-02-04|Estimate|June 2009||2009-06-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Treatment of Abdominal Abscesses With or Without Fibrinolysis|Treatment of Abdominal Abscesses With or Without Fibrinolysis|Completed||N/A|92|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 21:23:22.715262|2018-05-31 21:23:22.715262
NCT01597323|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-10-29|2012-05-10|2012-05-14|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|September 2012|Actual|2012-09-30||Observational|||Safety & Efficacy Evaluation of a Radiofrequency & Laser/Light System for Improvement of Skin Texture|Safety and Efficacy Evaluation of the eTWO System for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction|Unknown status|Recruiting||150|Anticipated|Candela Corporation|||1||f||||f||||||Samples With DNA|"~     Optional biopsy, for consenting subjects, of facial skin tissue from areas directly in front~     of ear (Pre-Auricular)~   "|||2018-05-31 21:23:22.789424|2018-05-31 21:23:22.789424
NCT01597310|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-11-24|2012-05-10|2012-05-14|Estimate|||||||2014-11-24|2014-11-25|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study|An Open-Label Study to Assess the Effect of Dexpramipexole (BIIB050) on the Pharmacokinetics of Warfarin in Healthy Volunteers|Completed||Phase 1|15|Actual|Knopp Biosciences||2|||f||||f||||||||||2018-05-31 21:23:22.849339|2018-05-31 21:23:22.849339
NCT01597297|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-01-05|2012-05-11|2012-05-14|Estimate|||||||2017-01-05|2017-01-09|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|MOBILE||Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis|Completed||Phase 2|132|Actual|Biogen||2|||f||||f||||||||||2018-05-31 21:23:22.925841|2018-05-31 21:23:22.925841
NCT01597284|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-02-09|2012-05-11|2012-05-14|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2012||2012-02-29|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Oral Therapies in Oncology: Cognitive Function and Compliance|Oral Therapies in Oncology: Cognitive Function and Compliance|Terminated|||129|Actual|Centre Francois Baclesse||||Loss of recruitment|f||||f||||||||||2018-05-31 21:23:23.045568|2018-05-31 21:23:23.045568
NCT01597258|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-03-26|2012-05-10|2012-05-14|Estimate|||||||2018-03-26|2018-03-27|Actual|May 2012|Actual|2012-05-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Xalkori For Nsclc (Regulatory Post Marketing Commitment Plan)|Completed|||2044|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:23:23.126666|2018-05-31 21:23:23.126666
NCT01597245|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2016-04-20|2015-01-16|2017-12-06|2012-05-10|2012-05-14|Estimate|2016-08-27|2016-10-20|Estimate|2015-01-16|2015-01-29|Estimate|2017-12-06|2018-01-02|Actual|May 2012||2012-05-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|March 2014|Actual|2014-03-31||Interventional|UNCOVER-2||A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis|Active, not recruiting||Phase 3|1224|Actual|Eli Lilly and Company||5|||f||||t||||||||||2018-05-31 21:23:23.2815|2018-05-31 21:23:23.2815
NCT01597232|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2016-01-11|2012-05-10|2012-05-11|Estimate|||||||2016-01-11|2016-01-12|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|WCPTS||Clinic Trial for West China Perioperative Transfusion Score (WCPTS)|Effect of West China Perioperative Transfusion Score (WCPTS) on Red Blood Cells Transfusion in Patients Undergoing Major Surgery: a Prospective, Multicenter, Randomized Controlled Trial|Enrolling by invitation||Phase 3|3000|Anticipated|West China Hospital||3|||f||||t||||||||||2018-05-31 21:23:26.864846|2018-05-31 21:23:26.864846
NCT01597219|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-05-03|2012-05-10|2012-05-11|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2013||2013-03-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|UK-Haplo||Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers|A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies|Recruiting||Phase 2|78|Anticipated|University College, London||2|||f||||t||||||||Undecided||2018-05-31 21:23:26.945189|2018-05-31 21:23:26.945189
NCT01597206|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-02-09|2012-05-10|2012-05-11|Estimate|||||||2017-02-09|2017-02-13|Actual|January 2014||2014-01-31|January 2016|2016-01-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|SDA-RCT||Interventions for Patients With a Shortened Dental Arch|Outcomes of Interventions for Patients With a Reduced Posterior Dental Arch: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|50|Actual|University of the Western Cape||2|||f||||t||||||||Yes|By publishing the results in a reputable (peer reviewed and accredited) journal|2018-05-31 21:23:27.031155|2018-05-31 21:23:27.031155
NCT01597193|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2018-03-22|2012-05-09|2012-05-11|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 30, 2012|Actual|2012-04-30|March 2018|2018-03-31|January 22, 2018|Actual|2018-01-22|December 15, 2015|Actual|2015-12-15||Interventional|||Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer|A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer|Completed||Phase 1|101|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:23:27.095521|2018-05-31 21:23:27.095521
NCT01597180|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-03-04|2012-05-10|2012-05-11|Estimate|||||||2014-03-04|2014-03-05|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir|Pharmacokinetics, Pharmacodynamics and Genital Tract Viral Shedding in HIV+ Women Using Combined Oral Contraceptives and Raltegravir|Withdrawn|||0|Actual|University of North Carolina, Chapel Hill||||Could not find subjects who met all the enrollment criteria so the study was stopped.|f||||f||||||||||2018-05-31 21:23:27.332747|2018-05-31 21:23:27.332747
NCT01597167|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2016-01-19|2012-05-10|2012-05-11|Estimate|||||||2016-01-19|2016-01-21|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Magnesium Sulfate Versus 5% Dextrose With Treatment Resistant Depression|A Double-blinded Randomized Study of IV Infusion of Magnesium Sulfate Versus 5% Dextrose in a Crossover Design in Male and Female Volunteers With Treatment Resistant Depression|Completed||N/A|21|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 21:23:27.394688|2018-05-31 21:23:27.394688
NCT01597154|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-07-28|2012-05-10|2012-05-11|Estimate|||||||2014-07-28|2014-07-29|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|BDT||Lifestyle Therapy for Youth With Type 2 Diabetes|Beating Diabetes Together: A Randomized Controlled Trial for Intensive Lifestyle Therapy for Youth With Type 2 Diabetes|Completed||N/A|15|Actual|University of Manitoba||2|||f||||||||||||||2018-05-31 21:23:27.475719|2018-05-31 21:23:27.475719
NCT01597141|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2015-10-22||2016-01-07|2012-05-09|2012-05-11|Estimate|2016-01-07|2016-02-08|Estimate||||2016-01-07|2016-02-08|Estimate|May 2003||2003-05-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|EDIP||Psychosis: Early Detection, Intervention and Prevention|Psychosis: Early Detection, Intervention and Prevention|Completed||N/A|100|Actual|Maine Medical Center||2|||f||||t||||||||||2018-05-31 21:23:27.560658|2018-05-31 21:23:27.560658
NCT01597128|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2016-06-24||2017-01-26|2012-05-10|2012-05-11|Estimate|2017-01-26|2017-03-16|Actual||||2017-01-26|2017-03-16|Actual|March 2011||2011-03-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Flex HD||Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or Contaminated Cases|Feasibility Study of The Use of FLEX HD® Surgical Implant or STRATTICE® Reconstructive Tissue Matrix in The Closure of Abdominal Wall Defects With Component Separation in Clean or Contaminated Cases|Completed||N/A|35|Actual|University of Kentucky|This is a Prospective Quasi-experimental study. Patients were randomized in the traditional sense.|2|||f||||t||||||||||2018-05-31 21:23:27.813442|2018-05-31 21:23:27.813442
NCT01597115|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2015-05-25|2012-05-10|2012-05-11|Estimate|||||||2015-05-25|2015-05-27|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ENHANCE||ENhancing Maturation of Autogenous Arteriovenous Hemodialysis Access by Aggressive surveillaNCe With Duplex and Endovascular Treatment|ENhancing Maturation of Autogenous Arteriovenous Hemodialysis Access by Aggressive surveillaNCe With Duplex and Endovascular Treatment|Completed||N/A|150|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:23:28.303686|2018-05-31 21:23:28.303686
NCT01597102|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-01-09|2012-05-09|2012-05-11|Estimate|||||||2013-01-09|2013-01-11|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|dARICULtx||Cerebrovascular Autoregulation During and After Liver Transplantation|Cerebrovascular Autoregulation During and After Liver Transplantation|Unknown status|Active, not recruiting||20|Anticipated|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-05-31 21:23:28.36673|2018-05-31 21:23:28.36673
NCT01597089|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-05-02|2012-05-10|2012-05-11|Estimate|||||||2018-05-02|2018-05-03|Actual|September 1, 2012||2012-09-01|May 1, 2018|2018-05-01|May 1, 2018||2018-05-01|||||Observational|||Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples|Detection of Respiratory Viruses in Upper and Lower Respiratory Tract Specimens Using a Rapid Multiplex PCR|Terminated|||35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:23:28.435534|2018-05-31 21:23:28.435534
NCT01597076|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-12-02|2012-05-10|2012-05-11|Estimate|||||||2014-12-02|2014-12-04|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effect of an Iridoid Enriched Beverage on Skin Autofluorescence||Completed||Phase 1|34|Actual|Tahitian Noni International, Inc.||1|||f||||t||||||||||2018-05-31 21:23:28.49023|2018-05-31 21:23:28.49023
NCT01597063|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2016-04-18|2012-05-10|2012-05-11|Estimate|||||||2016-04-18|2016-04-20|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|February 2014|Actual|2014-02-28||Observational|||Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies|A Clinical Study to Evaluate the Relative Clinical Specificity Performance of the SEQureDx Trisomy Test in Pregnant Women at Low Risk for Fetal Chromosomal Aneuploidy|Completed|||3333|Actual|Sequenom, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood specimens will be collected and processed to plasma. DNA will be extracted from~     the plasma.~   "|Yes|Upon analysis of collected samples and submission for publication, data will be shared as per journal requirements.|2018-05-31 21:23:28.564327|2018-05-31 21:23:28.564327
NCT01597050|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2016-04-28||2016-06-15|2012-05-10|2012-05-11|Estimate|2016-04-28|2016-06-08|Estimate||||2016-06-15|2016-07-14|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|SKINDLE||Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Patients With Active Cutaneous Discoid Lesions|Completed||Phase 2|54|Actual|Rigel Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:23:28.666909|2018-05-31 21:23:28.666909
NCT01597037|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-10-14|2012-05-10|2012-05-11|Estimate|||||||2017-10-14|2017-10-17|Actual|June 2011||2011-06-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|September 2017|Actual|2017-09-30||Interventional|||Aphasia Rehabilitation: Modulating Cues, Feedback & Practice|Aphasia Rehabilitation: Modulating Cues, Feedback & Practice|Active, not recruiting||N/A|16|Actual|Shirley Ryan AbilityLab||4|||f||||f||||||||||2018-05-31 21:23:29.189516|2018-05-31 21:23:29.189516
NCT01597024|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2016-05-19|2012-05-09|2012-05-11|Estimate|||||||2016-05-19|2016-05-20|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|F4H||Full4Health: Understanding Food-gut-brain Axis Across the Lifecourse|Full4Health: Neuro-gut Interactions in Humans Across the Lifecourse|Completed||N/A|718|Actual|University of Aberdeen||2|||f||||f||||||||||2018-05-31 21:23:29.263349|2018-05-31 21:23:29.263349
NCT01597011|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-03-17|2012-05-10|2012-05-11|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Long-term Follow-up After Laparoscopic Inguinal Hernia Repair Using Tisseel for Mesh Fixation|Long-term Follow-up After Laparoscopic Inguinal Hernia Repair Using Tisseel for Mesh Fixation|Completed|||2340|Actual|Herlev Hospital|||2||f||||f||||||||||2018-05-31 21:23:29.334524|2018-05-31 21:23:29.334524
NCT01596998|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-10|2012-05-10|2012-05-11|Estimate|||||||2012-05-10|2012-05-11|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Plasma Concentrations of Levobupivacaine With and Without Epinephrine in Transversus Abdominis Plane Blocks|Comparison of Plasma Concentrations of Levobupivacaine With and Without Epinephrine for Transversus Abdominis Plane Block Under Ultrasound.|Completed||Phase 4|11|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 21:23:29.424185|2018-05-31 21:23:29.424185
NCT01596985|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-11|2012-05-10|2012-05-11|Estimate|||||||2012-05-11|2012-05-14|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Ovarian Endometrioma Ablation Using Plasma Energy Versus Cystectomy|Prospective, Monocentric Study Comparing Cystectomy to PlasmaJet Ablation in the Surgical Management of Ovarian Endometriomas|Unknown status|Recruiting|Phase 2|50|Anticipated|Plasma Surgical Inc||2|||f||||f||||||||||2018-05-31 21:23:29.494691|2018-05-31 21:23:29.494691
NCT01596972|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2014-05-15||2014-06-27|2012-05-09|2012-05-11|Estimate|2014-06-27|2014-07-01|Estimate||||2014-06-27|2014-07-01|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location|The Role of a Semi-Quantitative Urine Pregnancy Test and Pregnancy Questionnaire After Uterine Evacuation for Undesired Pregnancy of Uncertain Location: A Pilot Randomized Controlled Trial|Completed||N/A|51|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-05-31 21:23:29.594972|2018-05-31 21:23:29.594972
NCT01596959|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-10-11|2012-05-10|2012-05-11|Estimate|||||||2017-10-11|2017-10-13|Actual|January 2012||2012-01-31|May 2012|2012-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Contact-CTI Study: Use of Tissue Contact Data to Guide Atrial Flutter Ablation|The Contact-CTI Study - Does Assessment of Tissue Contact During Ablation of Atrial Flutter Improve Outcomes?|Completed||Phase 4|101|Actual|Oxford University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 21:23:29.893344|2018-05-31 21:23:29.893344
NCT01596946|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-10|2012-05-10|2012-05-11|Estimate|||||||2012-05-10|2012-05-11|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Home-sampling in Partner Notification of Chlamydia|Home-sampling as a Tool in a Chlamydia Trachomatis Partner Notification Context. A Multi-centre Cluster-randomized Controlled Trial.|Completed||N/A|633|Actual|Ostergotland County Council, Sweden||2|||f||||f||||||||||2018-05-31 21:23:29.969867|2018-05-31 21:23:29.969867
NCT01596933|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-03-09|2012-05-09|2012-05-11|Estimate|||||||2015-03-09|2015-03-10|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|NUTRIOM||Effect of Omega-3 Supplements on the Prevention of Cachexia in Head and Neck Cancer Treated With Radio(Chemo)Therapy|Multi-centric, Placebo-controlled Trial of Omega-3 Fatty Acid Supplementation in Weight Maintenance and Preservation of Lean Body Mass, in (Pre)Cachectic Head and Neck Cancer Patients, Undergoing Curative Radio(Chemo)Therapy|Completed||Phase 2/Phase 3|91|Actual|General Hospital Groeninge||2|||f||||t||||||||||2018-05-31 21:23:30.043232|2018-05-31 21:23:30.043232
NCT01596205|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-09|2012-05-09|2012-05-10|Estimate|||||||2012-05-09|2012-05-10|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||The Efficacy of Robot Assisted Group Cognitive Training in Elderly Adults Without Cognitive Impairment|The Efficacy of Robot Assisted Group Cognitive Training in Elderly Adults Without Cognitive Impairment|Completed||N/A|85|Actual|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 21:23:36.856648|2018-05-31 21:23:36.856648
NCT01596920|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-04-07|2012-05-10|2012-05-11|Estimate|||||||2014-04-07|2014-04-09|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|DFU||Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers|A Multicenter, Adaptive Design, Randomized, Single-Blind Study With an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Grafix® for the Treatment of Chronic Diabetic Foot Ulcers|Completed||Phase 4|97|Actual|Osiris Therapeutics||2|||f||||f||||||||||2018-05-31 21:23:30.120714|2018-05-31 21:23:30.120714
NCT01596907|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-09-22|2012-05-10|2012-05-11|Estimate|||||||2015-09-22|2015-09-24|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Treatment of Low Metabolic Rate Following Bariatric Surgery|Treatment of Low Metabolic Rate and Low Weight Loss Rate Following Bariatric Surgery|Completed||N/A|218|Actual|Oregon Weight Loss Surgery, LLC||2|||f||||f||||||||||2018-05-31 21:23:30.207963|2018-05-31 21:23:30.207963
NCT01596894|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-08-08|2012-05-09|2012-05-11|Estimate|||||||2017-08-08|2017-08-10|Actual|October 2012||2012-10-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease|A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's Disease, Using 2 Months Antibiotic Course of Azithromycin Combined With Metronidazole vs. Metronidazole Alone.|Completed||Phase 4|73|Actual|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 21:23:30.282107|2018-05-31 21:23:30.282107
NCT01596881|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2018-04-10|2012-05-10|2012-05-11|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2012||2012-04-30|April 2018|2018-04-30|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Observational|OCT in MS||Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis|Using OCT to Capture Retinal Microvascular Changes Associated With MS|Completed|||101|Actual|Oregon Health and Science University|||2||f||||||||||||||2018-05-31 21:23:30.355556|2018-05-31 21:23:30.355556
NCT01596868|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-10-29|2012-05-09|2012-05-11|Estimate|||||||2013-10-29|2013-10-30|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China|A Randomized, Phase II Trial Comparing Induction Chemotherapy Gemcitabine Plus Cisplatin With Docetaxel Plus Cisplatin Followed by Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma in Northwest China|Completed||Phase 2|60|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 21:23:30.414426|2018-05-31 21:23:30.414426
NCT01596855|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-01-31|2012-05-09|2012-05-11|Estimate|||||||2013-01-31|2013-02-04|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China|A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)|Completed||Phase 2|96|Actual|FibroGen||2|||f||||f||||||||||2018-05-31 21:23:30.489014|2018-05-31 21:23:30.489014
NCT01596842|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2015-02-20||2015-03-08|2012-05-09|2012-05-11|Estimate|2015-03-08|2015-03-10|Estimate||||2015-03-08|2015-03-10|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Hemodialysis patients|Effect of Omega-3 Fatty Acid on Vitamin D Activation|Effect of Omega-3 Fatty Acid on Vitamin D Activation in Hemodialysis Patients|Completed||Phase 4|17|Actual|Dong-A University||2|||f||||t||||||||||2018-05-31 21:23:30.568737|2018-05-31 21:23:30.568737
NCT01596829|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-01-21|2012-05-09|2012-05-11|Estimate|||||||2016-01-21|2016-01-22|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Probiotic Formula on Reducing the Risk for Antibiotic-associated Diarrhoea|Effect of Probiotic Formula on Reducing the Risk for Antibiotic-associated Diarrhoea|Terminated||Phase 2/Phase 3|258|Actual|Danisco||2||low incidence|f||||f||||||||No|Terminated prematurely.|2018-05-31 21:23:30.755082|2018-05-31 21:23:30.755082
NCT01596816|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2017-10-23|2012-05-09|2012-05-11|Estimate|||||||2017-10-23|2017-10-25|Actual|August 2010||2010-08-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|September 2016|Actual|2016-09-30||Interventional|CKNO-PRO||Hypofractionated Stereotactic Boost in Prostate Cancer|Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study|Active, not recruiting||Phase 2|76|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 21:23:30.819235|2018-05-31 21:23:30.819235
NCT01596803|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-05-09|2012-05-09|2012-05-11|Estimate|||||||2012-05-09|2012-05-11|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|April 2013|Anticipated|2013-04-30||Interventional|FSHD||Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD)|Effects of Antioxidants Supplementation on Muscular Function of Patients Affected by Facioscapulohumeral Dystrophy (FSHD)|Unknown status|Recruiting|N/A|54|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:23:30.898759|2018-05-31 21:23:30.898759
NCT01596790|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-12-03|2012-05-09|2012-05-11|Estimate|||||||2014-12-03|2014-12-04|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|||COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer|Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment|Unknown status|Recruiting|Phase 2|168|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 21:23:31.130473|2018-05-31 21:23:31.130473
NCT01596777|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2016-10-25|2012-05-09|2012-05-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|LOP-MNTX-2009||Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects|Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects|Completed||Phase 1|15|Actual|University Medicine Greifswald||5|||f||||f||||||||||2018-05-31 21:23:31.209076|2018-05-31 21:23:31.209076
NCT01596764|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-09|2012-05-09|2012-05-11|Estimate|||||||2012-05-09|2012-05-11|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.|Effects of Extended Release Methylnaltrexone Bromide (150 mg b.i.d.) in Comparison to Extended Release Naloxone Hydrochloride (20 mg b.i.d.) on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time in Healthy Subjects.|Completed||Phase 1|16|Actual|University Medicine Greifswald||4|||f||||f||||||||||2018-05-31 21:23:31.308272|2018-05-31 21:23:31.308272
NCT01596751|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-05-30|2012-05-09|2012-05-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2012||2012-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|July 5, 2017|Actual|2017-07-05||Interventional|||Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer|Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|68|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:23:31.413977|2018-05-31 21:23:31.413977
NCT01596738|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2012-05-09|2012-05-09|2012-05-11|Estimate|||||||2012-05-09|2012-05-11|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Tranexamic Acid in On-pump CABG With Premature Clopidogrel Cessation|Tranexamic Acid in Patients Receiving Primary and Isolated On-pump CABG With Premature Clopidogrel Cessation to Reduce Postoperative Bleeding and Transfusion|Completed||N/A|120|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 21:23:31.528787|2018-05-31 21:23:31.528787
NCT01596725|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-02-05|2012-05-10|2012-05-11|Estimate|||||||2014-02-05|2014-02-06|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|||A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2|A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 2.|Completed||Phase 1|333|Actual|Novavax||6|||f||||t||||||||||2018-05-31 21:23:31.603784|2018-05-31 21:23:31.603784
NCT01596712|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-11-20|2012-05-09|2012-05-11|Estimate|||||||2012-11-20|2012-11-22|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Following Subcutaneous Injections of QGE031 in Japanese Atopic Male Subjects|Completed||Phase 1|209|Actual|Novartis||4|||f||||||||||||||2018-05-31 21:23:31.763689|2018-05-31 21:23:31.763689
NCT01596699|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-05-02|2012-05-09|2012-05-11|Estimate|||||||2017-05-02|2017-05-04|Actual|July 2012||2012-07-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation|A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation|Suspended||N/A|31|Anticipated|University of California, San Francisco||2||Triggering of futility rule, requires study modification|f||||t||||||||||2018-05-31 21:23:31.879427|2018-05-31 21:23:31.879427
NCT01596686|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-12-23|2012-05-09|2012-05-11|Estimate|||||||2013-12-23|2013-12-24|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Comparison of Preparation Regimens for Colonoscopy||Completed||N/A|184|Actual|Clinical Hospital Colentina||2|||f||||t||||||||||2018-05-31 21:23:31.975722|2018-05-31 21:23:31.975722
NCT01596673|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-11-20|2012-05-09|2012-05-11|Estimate|||||||2012-11-20|2012-11-21|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Abuse Potential of the Hydrocodone Bitartrate Extended-Release Tablet in Healthy, Nondependent, Recreational Opioid Users|Completed||Phase 1|100|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-05-31 21:23:32.06334|2018-05-31 21:23:32.06334
NCT01596660|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-09|2012-05-09|2012-05-11|Estimate|||||||2012-05-09|2012-05-11|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|TAPBLOCK||Transversus Abdominis Bilateral Plane Block in Total Laparoscopic Hysterectomy : A Randomized Controlled Trial|Transversus Abdominis Bilateral Plane Block in Total Laparoscopic Hysterectomy : A Randomized Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|CES University||2|||f||||t||||||||||2018-05-31 21:23:32.167493|2018-05-31 21:23:32.167493
NCT01596647|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-05-12|2012-05-10|2012-05-11|Estimate|||||||2015-05-12|2015-05-14|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors|A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of TKI258 on the Pharmacokinetics of Caffeine, Diclofenac, Omeprazole and Midazolam Administered as a Four-drug Cocktail in Patients With Advanced Solid Tumors, Excluding Breast Cancer|Completed||Phase 1|39|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:23:32.256575|2018-05-31 21:23:32.256575
NCT01596634|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-05-25|2012-05-10|2012-05-11|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2013|Actual|2013-01-31|April 2017|2017-04-30|October 10, 2015|Actual|2015-10-10|August 2015|Actual|2015-08-31||Interventional|||Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy|A Pilot Study of Bovine Lactoferrin in Patients With Colorectal Carcinoma Receiving Oxaliplatin-Based Chemotherapy and Self-Reported Taste Disturbances|Completed||N/A|12|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 21:23:32.343277|2018-05-31 21:23:32.343277
NCT01596621|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2018-03-23|2012-05-09|2012-05-11|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 6, 2012|Actual|2012-08-06|March 2018|2018-03-31|April 28, 2017|Actual|2017-04-28|June 18, 2015|Actual|2015-06-18||Interventional|||Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment|An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment|Completed||Phase 3|102|Actual|Teva Pharmaceutical Industries||1|||f||||t|f|f||||||||2018-05-31 21:23:32.422524|2018-05-31 21:23:32.422524
NCT01596608|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-04-11|2012-05-09|2012-05-11|Estimate|||||||2018-04-11|2018-04-13|Actual|February 2012||2012-02-29|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Interventional|||Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder|Efficacy and Tolerability of Magnetic Seizure Therapy (MST) as an Alternative to Electroconvulsive Therapy (ECT) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder|Recruiting||N/A|250|Anticipated|Centre for Addiction and Mental Health||1|||f||||t||||||||||2018-05-31 21:23:32.526592|2018-05-31 21:23:32.526592
NCT01596595|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-11-28|2012-05-09|2012-05-11|Estimate|||||||2017-11-28|2017-11-30|Actual|April 2013|Actual|2013-04-30|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|LSS of 4-SITE||Longitudinal Surveillance Study of the 4-SITE Lead/Header System|Longitudinal Surveillance Study of the 4-SITE Lead/Header System|Active, not recruiting|||1820|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 21:23:32.626265|2018-05-31 21:23:32.626265
NCT01596582|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2017-01-23||2017-03-20|2012-05-09|2012-05-11|Estimate|2017-03-20|2017-03-21|Actual||||2017-03-20|2017-03-21|Actual|April 2012||2012-04-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening|Impact of Risk Stratification on Shared Decision-Making for Colorectal Cancer Screening|Completed||N/A|352|Actual|Boston Medical Center|Single institution setting; lack of provider education about the utility of risk stratification into their decision-making.|2|||f||||f|f|f||||||No||2018-05-31 21:23:32.801781|2018-05-31 21:23:32.801781
NCT01596569|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-11-27|2012-05-09|2012-05-11|Estimate|||||||2017-11-27|2017-11-29|Actual|May 2012||2012-05-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|COST-TBI||Combined Transcranial Magnetic Stimulation and Cognitive Treatment in Blast Traumatic Brain Injury|Combining Cognitive Treatment With Noninvasive Brain Stimulation in Blast TBI|Active, not recruiting||N/A|24|Anticipated|Boston Medical Center||2|||f||||f||||||||No||2018-05-31 21:23:33.26918|2018-05-31 21:23:33.26918
NCT01596556|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2014-05-08|2012-05-09|2012-05-11|Estimate|||||||2014-05-08|2014-05-09|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Smoking on Thermoregulation|The Effect of Smoking on Thermoregulation|Completed||N/A|16|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:23:33.345561|2018-05-31 21:23:33.345561
NCT01596543|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2014-05-08|2012-05-09|2012-05-11|Estimate|||||||2014-05-08|2014-05-09|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Partial and Complete Sleep Deprivation on Heat Tolerance|Thr Effect of Partial and Complete Sleep Deprivation on Heat Tolerance|Completed||N/A|12|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 21:23:33.563167|2018-05-31 21:23:33.563167
NCT01596530|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-12-13|2012-05-09|2012-05-11|Estimate|||||||2012-12-13|2012-12-17|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|CHIVE||Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment|A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status|Terminated||Phase 1|3|Actual|AstraZeneca||2||All AstraZeneca sponsored clinical trials of AZD8931 have been halted|f||||||||||||||2018-05-31 21:23:33.636639|2018-05-31 21:23:33.636639
NCT01596517|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-12|2012-05-09|2012-05-11|Estimate|||||||2012-05-12|2012-05-15|Estimate|June 2003||2003-06-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C|Efficacy and Effectiveness of Combination Therapy With Pegylated Interferon Alfa-2a and Ribavirin in Korean Patients With Chronic Hepatitis C|Completed||Phase 4|272|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:23:33.724566|2018-05-31 21:23:33.724566
NCT01596504|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2016-08-22|2015-04-21|2016-08-22|2012-05-09|2012-05-11|Estimate|2016-08-22|2016-10-14|Estimate|2015-04-21|2015-05-07|Estimate|2016-08-22|2016-10-14|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin|An Open-label, Randomized, Three-parallel-group Study on Pharmacodynamic Effects of 8-week QD Treatment With Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin|Completed||Phase 2|142|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:23:33.838096|2018-05-31 21:23:33.838096
NCT01596491|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-12-19|2012-05-09|2012-05-11|Estimate|||||||2012-12-19|2012-12-20|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Study of Possible Changes in QST After Application of Capsaicin on Patients With Peripheral Neuropathic Pain|Kind and Duration of Possible Changes of the Sensory Profiles After the Topical Application of Capsaicin (8%) in Patients With Peripheral Neuropathic Pain|Completed|||20|Actual|Ruhr University of Bochum|||2||f||||f||||||||||2018-05-31 21:23:34.615658|2018-05-31 21:23:34.615658
NCT01596478|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-01-10|2012-05-09|2012-05-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effectiveness of Therapy Treatment|Effectiveness of Cognitive-Motivational Behaviour Therapy in Community|Unknown status|Recruiting|N/A|150|Anticipated|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-05-31 21:23:34.704438|2018-05-31 21:23:34.704438
NCT01596465|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-10|2012-05-10|2012-05-11|Estimate|||||||2012-05-10|2012-05-11|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of Two Teaching Techniques to Teach Cardiac Auscultation to Physicians|Self-Directed Study Using MP3 Players Versus Multimedia Lecture to Improve Auscultation Proficiency of Physicians: A Randomized, Controlled Trial.|Completed||N/A|83|Actual|The Reading Hospital and Medical Center||2|||f||||t||||||||||2018-05-31 21:23:34.795221|2018-05-31 21:23:34.795221
NCT01596452|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-08|2012-05-10|2012-05-11|Estimate|||||||2013-12-08|2013-12-10|Estimate|June 2012||2012-06-30|December 2013|2013-12-31||||May 2015|Anticipated|2015-05-31||Observational|||Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology||Unknown status|Recruiting||31|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-05-31 21:23:34.867544|2018-05-31 21:23:34.867544
NCT01596439|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-10|2012-05-10|2012-05-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2013||2013-06-30|December 2013|2013-12-31||||May 2014|Anticipated|2014-05-31||Observational|||A Prospective Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive Function of Breast Cancer Patients||Unknown status|Recruiting||100|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 21:23:34.9273|2018-05-31 21:23:34.9273
NCT01596426|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-08-15|2012-05-09|2012-05-11|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2018|Anticipated|2018-07-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years|An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 2 to 5 Years)|Not yet recruiting||Phase 1|16|Anticipated|Kyowa Kirin Pharmaceutical Development Ltd||2|||f|||||f|f||||||||2018-05-31 21:23:34.989602|2018-05-31 21:23:34.989602
NCT01596413|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-06-07|2012-05-09|2012-05-11|Estimate|||||||2017-06-07|2017-06-08|Actual||||June 2017|2017-06-30||||||||Interventional|||Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years|An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)|Not yet recruiting||Phase 1|16|Anticipated|Kyowa Kirin Pharmaceutical Development Ltd||2|||f||||||||||||||2018-05-31 21:23:35.061122|2018-05-31 21:23:35.061122
NCT01596400|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-07-11|2012-05-09|2012-05-11|Estimate|||||||2017-07-11|2017-07-13|Actual|May 2012||2012-05-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years|An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)|Completed||Phase 1|19|Actual|Kyowa Kirin Pharmaceutical Development Ltd||2|||f||||||||||||||2018-05-31 21:23:35.137533|2018-05-31 21:23:35.137533
NCT01596387|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-10|2012-05-10|2012-05-11|Estimate|||||||2012-05-10|2012-05-11|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients|Validation of a Pharmacokinetic Pharmacodynamic Model to Administer Propofol in Obese Patients|Completed||Phase 4|20|Actual|Pontificia Universidad Catolica de Chile||1|||f||||t||||||||||2018-05-31 21:23:35.21954|2018-05-31 21:23:35.21954
NCT01596374|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-10|2012-05-10|2012-05-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|August 2011||2011-08-31|December 2013|2013-12-31||||July 2014|Anticipated|2014-07-31||Observational|||Clinical Relevance of ROS (V-ros UR2 Sarcoma Virus Oncogene Homolog) Aberrations in Solid Tumours||Unknown status|Recruiting||2000|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 21:23:35.290746|2018-05-31 21:23:35.290746
NCT01596361|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-10|2012-05-10|2012-05-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|August 2011||2011-08-31|December 2013|2013-12-31||||August 2014|Anticipated|2014-08-31||Observational|||Verification of a Pharmacogenetic Approach to Customizing Chemotherapy to Asians||Unknown status|Recruiting||750|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 21:23:35.354625|2018-05-31 21:23:35.354625
NCT01596348|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-05-10|2012-05-10|2012-05-11|Estimate|||||||2012-05-10|2012-05-11|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Exercise Perceptions and Preferences Among Rheumatoid Arthritis Patients|Perceived Exercise Benefits, Barriers and Preferences Among Swiss Rheumatoid Arthritis Patients|Completed|||120|Actual|University of Lausanne|||1||f||||f||||||||||2018-05-31 21:23:35.423967|2018-05-31 21:23:35.423967
NCT01596335|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-04-09|2012-05-10|2012-05-11|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease|To Evaluate the Efficacy and Safety of TA-650 in Comparison With a Control Drug Polyethylene Glycol-treated Human Immunoglobulin (VGIH) in Patients With Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin (IVIG).|Completed||Phase 3|31|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 21:23:35.478445|2018-05-31 21:23:35.478445
NCT01596322|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-10-29|2012-05-10|2012-05-11|Estimate|||||||2017-10-29|2017-10-31|Actual|September 2004|Actual|2004-09-30|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|UARTO||International HIV Antiretroviral Adherence, Resistance and Survival|Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Uganda|Completed|||750|Actual|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     plasma, buffy coat, saliva~   "|||2018-05-31 21:23:35.551401|2018-05-31 21:23:35.551401
NCT01596309|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2013-06-17|2012-05-09|2012-05-10|Estimate|||||||2013-06-17|2013-06-18|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Cocoa Extract-enriched Meals and Cardiovascular Risk in Older Population|Study of the Effect of Ready-cooked Meals Containing Cocoa Extract, as a Potential Functional Ingredient, on Cardiovascular Risk Markers in Older Population|Completed||N/A|50|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-05-31 21:23:35.61168|2018-05-31 21:23:35.61168
NCT01596296|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-10-29|2012-05-09|2012-05-10|Estimate|||||||2017-10-29|2017-10-31|Actual|May 2012||2012-05-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Foley Catheter Versus Dinoprostone Vaginal Insert for Induction of Labor in Parous Women at Term: A Randomized Trial||Recruiting||N/A|154|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:23:35.845814|2018-05-31 21:23:35.845814
NCT01596283|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2017-05-02||2017-09-19|2012-05-09|2012-05-10|Estimate|2017-09-19|2017-10-18|Actual||||2017-09-19|2017-10-18|Actual|April 2012||2012-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection|A Prospective Randomized Controlled Clinical Trial of Standard Compared to Goal-directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection|Completed||Phase 3|135|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:23:35.939584|2018-05-31 21:23:35.939584
NCT01596270|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-10-24|2012-05-09|2012-05-10|Estimate|||||||2014-10-24|2014-10-27|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma|A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma|Completed||Phase 1|49|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:23:36.307299|2018-05-31 21:23:36.307299
NCT01596257|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2018-01-31|2012-05-09|2012-05-10|Estimate|||||||2018-01-31|2018-02-01|Actual|May 2012|Actual|2012-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation|Randomized Phase II Trial of Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation|Active, not recruiting||Phase 2|72|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:23:36.381372|2018-05-31 21:23:36.381372
NCT01596244|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-11-07|2012-05-09|2012-05-10|Estimate|||||||2012-11-07|2012-11-08|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|April 2011|Actual|2011-04-30||Interventional|||Jordan Diabetes Microclinic Project|Pilot and Expansion Project for the Jordan Diabetes Microclinic Project|Completed||N/A|2400|Actual|Microclinic International||1|||f||||f||||||||||2018-05-31 21:23:36.456439|2018-05-31 21:23:36.456439
NCT01596231|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2014-10-15||2014-10-15|2012-05-09|2012-05-10|Estimate|2014-10-15|2014-10-21|Estimate||||2014-10-15|2014-10-21|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|May 2013|Actual|2013-05-31||Interventional|KUDZU||Kudzu Treatment for Alcohol Abuse|Isoflavone (Kudzu) Extract Effects on Alcohol Drinking: Single Dose Pretreatment Study|Completed||Phase 2|20|Actual|Mclean Hospital||2|||f||||f||||||||||2018-05-31 21:23:36.530301|2018-05-31 21:23:36.530301
NCT01596218|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-03-21|2012-05-09|2012-05-10|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Brentuximab Vedotin for Steroid Refractory GvHD|Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft vs. Host Disease (GvHD)|Completed||Phase 1|34|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 21:23:36.775992|2018-05-31 21:23:36.775992
NCT01596192|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-09|2012-05-09|2012-05-10|Estimate|||||||2012-05-09|2012-05-10|Estimate|May 2012||2012-05-31|February 2012|2012-02-29|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Observational|PETGVHD-001||PETCT for Diagnosing and Monitoring Acute GVHD|The Sensitivity and Specificity of 18F-Fluorodeoxyglucose Positron Emission Tomography -Computed Tomography for the Diagnosis and Monitoring of Acute Graft vs. Host Disease|Unknown status|Not yet recruiting||30|Anticipated|Rabin Medical Center|||1||f||||f||||||Samples Without DNA|"~     Levels of HGF, IL8, IL2R and TNFR1 will be measured at the onset of GVHD and prior to the~     second PET-CT. Five cc blood will be drawn twice from each patient and will be collected in~     an EDTA containing tube.~   "|||2018-05-31 21:23:36.914277|2018-05-31 21:23:36.914277
NCT01596179|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-04-16|2012-05-09|2012-05-10|Estimate|||||||2015-04-16|2015-04-17|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TENN||Technology Enhanced Nurse Navigator Trial (TENN Trial)|Technology Enhanced Nurse Navigator Trial (TENN Trial) Phase III Randomized Controlled Trial|Completed||Phase 3|101|Actual|Mercy Medical Center||2|||f||||f||||||||||2018-05-31 21:23:36.983261|2018-05-31 21:23:36.983261
NCT01596166|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-01-21|2012-05-08|2012-05-10|Estimate|||||||2015-01-21|2015-01-26|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|EDMigraine-4||Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department|Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department|Completed||Phase 4|56|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:23:37.046826|2018-05-31 21:23:37.046826
NCT01596153|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-11-17|2012-05-09|2012-05-10|Estimate|||||||2014-11-17|2014-11-18|Estimate||||November 2014|2014-11-30||||||||Interventional|||Probiotics in Hospitalized Patients Study|Randomized Double-blind, Placebo-Controlled Trial Comparing the the Effect of Enhance Probiotic (EP, Go Live Rx,) Versus Placebo (Pl) on the Incidence of Clostridium Difficile Associated Diarrhea (CDAD) or Antibiotic-Associated Diarrhea (AAD)in Hospitalized Patients Initiated on Antibiotics|Withdrawn||N/A|0|Actual|South Shore Hospital||2||The study was not initiated|f||||f||||||||||2018-05-31 21:23:38.263036|2018-05-31 21:23:38.263036
NCT01596140|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-04-02|2012-05-09|2012-05-10|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2012|Actual|2012-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer|A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination With an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects With Advanced Cancer|Active, not recruiting||Phase 1|114|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 21:23:38.329396|2018-05-31 21:23:38.329396
NCT01596127|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2018-02-28||2018-04-26|2012-05-08|2012-05-10|Estimate|2018-02-28|2018-03-27|Actual||||2018-04-26|2018-05-24|Actual|January 24, 2013|Actual|2013-01-24|April 2018|2018-04-30|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System|Safety and Efficacy of Intrathecal Rituximab in Patients With Lymphoid Malignancies Involving the Central Nervous System|Terminated||Phase 1/Phase 2|4|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 21:23:38.429057|2018-05-31 21:23:38.429057
NCT01596114|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-08-23|2012-05-09|2012-05-10|Estimate|||||||2017-08-23|2017-08-24|Actual|June 2012||2012-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|EURO-SKI||European Stop Tyrosine Kinase Inhibitor Study|Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukemia After Stopping TKI|Active, not recruiting||Phase 3|800|Actual|European LeukemiaNet||1|||f||||t||||||||||2018-05-31 21:23:38.648053|2018-05-31 21:23:38.648053
NCT01596101|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-08-10|2012-05-09|2012-05-10|Estimate|||||||2014-08-10|2014-08-12|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Observational|Sleep4||Circadian Rhythm of Melatonin in Burns|Role of Circadian Rhythm of Melatonin on Sleep-related Disturbances Postburn|Completed|||86|Actual|Shriners Hospitals for Children|||2||f||||t||||||||||2018-05-31 21:23:38.881033|2018-05-31 21:23:38.881033
NCT01596088|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2015-02-27||2015-03-18|2012-05-09|2012-05-10|Estimate|2015-02-27|2015-03-13|Estimate||||2015-03-18|2015-04-07|Estimate||||March 2015|2015-03-31||||January 2014|Actual|2014-01-31||Interventional|||A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents|A Multicenter, Open Label, Single-arm Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents|Completed||Phase 1/Phase 2|2|Actual|Kissei Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:23:38.952656|2018-05-31 21:23:38.952656
NCT01596075|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-09-09|2012-05-09|2012-05-10|Estimate|||||||2012-09-09|2012-09-11|Estimate|July 2012||2012-07-31|September 2012|2012-09-30||||July 2015|Anticipated|2015-07-31||Interventional|||Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation|Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 21:23:39.110614|2018-05-31 21:23:39.110614
NCT01596062|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2014-03-17||2014-06-26|2012-05-08|2012-05-10|Estimate|2014-06-26|2014-07-25|Estimate||||2014-06-26|2014-07-25|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|IDEALE||Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)|Prospective, Multicenter, Randomized, Open-label, Phase 2, Lasting 12 Weeks, Evaluating the Pharmacodynamics, Efficacy and Safety of Basiliximab in de Novo Adult Renal Transplant Patients at Low Risk Receiving Either a Cumulative Dose of Basiliximab of 40 or 80 mg in Combination With Cyclosporine Microemulsion, or a Cumulative Dose of 80 mg of Basiliximab Without Calcineurin Inhibitor, With Additional Follow-up of 12 Weeks|Completed||Phase 2|16|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:23:39.241163|2018-05-31 21:23:39.241163
NCT01596049|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-08-17|2012-05-09|2012-05-10|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2012||2012-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||The Efficacy of a Self-fixating Mesh in Unilateral Open Inguinal Hernia Repair|The Efficacy of a Self-fixating Mesh in Unilateral Open Inguinal Hernia Repair, in Comparison to the Standard Treatment in the Literature|Terminated|||7|Actual|Rambam Health Care Campus|||1|recruitment was not going well.|f||||f||||||||||2018-05-31 21:23:40.022295|2018-05-31 21:23:40.022295
NCT01596036|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-11-13|2012-05-09|2012-05-10|Estimate|||||||2012-11-13|2012-11-14|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|ENROLL||Readiness for Behavior Change After a Heart Attack|Stages of Change Through the Cardiac Rehabilitation Experience After a Recent Hospitalization|Completed||N/A|150|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 21:23:40.181713|2018-05-31 21:23:40.181713
NCT01596023|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-01-14|2012-05-09|2012-05-10|Estimate|||||||2014-01-14|2014-01-15|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of Breathe NIOV System on Work of Breathing in Chronic Obstructive Lung Disease Patients|Evaluation of Effect of Breathe Ventilation System on Work of Breathing in COPD Patients|Completed||N/A|14|Actual|Breathe Technologies, Inc.||1|||f||||f||||||||||2018-05-31 21:23:40.269989|2018-05-31 21:23:40.269989
NCT01596010|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-03-17|2012-05-09|2012-05-10|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Investigation of 2 Different Oral Formulations of Estradiol and Norethisterone in Healthy Women|Single Dose, Double-blind, Two-way Cross-over Bioequivalence Trial With 2 Different Oral Formulations of Estradiol and Norethisterone|Completed||Phase 1|44|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:23:40.353353|2018-05-31 21:23:40.353353
NCT01595997|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2013-01-07|2012-05-09|2012-05-10|Estimate|||||||2013-01-07|2013-01-08|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|2011-00500-15||Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris|A Multi-center, Double-blinded, Randomized, Placebo-controlled, Intra-individual Comparison, Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris|Completed||Phase 1/Phase 2|20|Anticipated|Delenex Therapeutics AG||2|||f||||t||||||||||2018-05-31 21:23:40.439758|2018-05-31 21:23:40.439758
NCT01595984|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2016-06-23|2012-05-09|2012-05-10|Estimate|||||||2016-06-23|2016-06-24|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|CIME||Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)|Randomized, Multicenter, Open-label, Comparative Study of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI), Associating Myfortic ® and Neoral ® Compared to a CNI-free Treatment, Combining Myfortic ® and Certican ® , in Adult Patients With de Novo Renal Transplant|Active, not recruiting||Phase 3|90|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 21:23:40.52993|2018-05-31 21:23:40.52993
NCT01595971|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-05-12|2012-05-09|2012-05-10|Estimate|||||||2017-05-12|2017-05-15|Actual|August 12, 2010|Actual|2010-08-12|September 2016|2016-09-30|December 16, 2011|Actual|2011-12-16|December 16, 2011|Actual|2011-12-16||Interventional|RESPIRANET||Distance Education Versus Usual Care Qualification in Asthma Care|Distance Education Versus Usual Care in the Qualification of Asthma Care: A Cluster Randomized Clinical Trial - RESPIRANET|Completed||N/A|467|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 21:23:40.627905|2018-05-31 21:23:40.627905
NCT01595958|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2014-04-30|2012-05-09|2012-05-10|Estimate|||||||2014-04-30|2014-05-01|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CYRUS||Cyclosporine A in Cardiac Arrest|CYclosporine A in Non-shockable Out-of-hospital Cardiac Arrest ResUScitation|Completed||Phase 3|796|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 21:23:40.711355|2018-05-31 21:23:40.711355
NCT01595945|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-02-04|2012-05-09|2012-05-10|Estimate|||||||2015-02-04|2015-02-05|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Effect of Caloric Restriction and Gastric Bypass on Resting Metabolic Rate|Effect of Caloric Restriction and Gastric Bypass on Resting Metabolic Rate in Obese Subjects|Terminated||N/A|75|Anticipated|KiloCoach e.U.||2|||f||||f||||||||||2018-05-31 21:23:40.785871|2018-05-31 21:23:40.785871
NCT01595932|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-09|2012-05-09|2012-05-10|Estimate|||||||2012-05-09|2012-05-10|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children|Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children. A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 4|52|Actual|Azienda Policlinico Umberto I||2|||f||||t||||||||||2018-05-31 21:23:40.856311|2018-05-31 21:23:40.856311
NCT01595919|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-06-14|2012-05-08|2012-05-10|Estimate|||||||2012-06-14|2012-06-15|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Comparison of Beverages Consumed Within a Meal to Satiation on Meal-time Food Intake and Post-meal Appetite and Glycemic Response in Healthy Young Adults||Completed||N/A|26|Actual|University of Toronto||5|||f||||t||||||||||2018-05-31 21:23:40.920427|2018-05-31 21:23:40.920427
NCT01595906|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-05-14|2012-05-09|2012-05-10|Estimate|||||||2012-05-14|2012-05-15|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|February 2013|Anticipated|2013-02-28|October 2012|Anticipated|2012-10-31||Interventional|||The Affect of a Ventilated Helmet on Physiological Load|The Affect of a Ventilated Helmet System on Human Physiological Load|Unknown status|Not yet recruiting|N/A|12|Anticipated|Medical Corps, Israel Defense Force||1|||f||||f||||||||||2018-05-31 21:23:40.983294|2018-05-31 21:23:40.983294
NCT01595893|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-06-10|2012-05-09|2012-05-10|Estimate|||||||2016-06-10|2016-06-13|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|VitD-PLE_2012||Vitamin D Supplementation in Polymorphic Light Eruption|Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial|Terminated||Phase 3|8|Actual|Medical University of Graz||2||Difficulties in recruiting the planned number of patients|f||||f||||||||||2018-05-31 21:23:41.056516|2018-05-31 21:23:41.056516
NCT01595880|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-02-02|2012-05-09|2012-05-10|Estimate|||||||2015-02-02|2015-02-03|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone in Healthy Male Volunteers|Completed||Phase 1|29|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 21:23:41.136003|2018-05-31 21:23:41.136003
NCT01595867|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-06-07|2012-05-08|2012-05-10|Estimate|||||||2012-06-07|2012-06-08|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo|A Randomized, Double-Blind, Placebo-Controlled, 3 Way Crossover Study Evaluating The Relative Abuse Potential Of Crushed Embeda Compared To Morphine Sulfate Controlled Release Tablets (Crushed) And Placebo In Non-Dependent, Recreational Opioid Users Following Intranasal Administration|Completed||Phase 1|33|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:23:41.212709|2018-05-31 21:23:41.212709
NCT01595854|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2013-06-18||2013-06-18|2012-05-09|2012-05-10|Estimate|2013-06-18|2013-08-22|Estimate||||2013-06-18|2013-08-22|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran|Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor (Part 1 and 2, Open, Non-randomised, 2 Parallel Groups) and Assessment of Ticagrelor Interaction Potential With Dabigatran (Part 3, Open, Randomised, Two-period Cross-over) in Healthy Male Subjects|Completed||Phase 1|36|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:23:41.348554|2018-05-31 21:23:41.348554
NCT01595841|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2018-03-05|2012-05-08|2012-05-10|Estimate|||||||2018-03-05|2018-03-07|Actual|December 2011||2011-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|SAVE||Sirolimus Use in Angioplasty for Vascular Access Extension|A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy|Recruiting||Phase 2|36|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:23:41.65055|2018-05-31 21:23:41.65055
NCT01595828|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2013-07-19|2012-05-08|2012-05-10|Estimate|||||||2013-07-19|2013-07-22|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CAPITAIN||Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome|An Open Label Study of the Chronic and Acute Effects of Pitavastatin on Monocyte Phenotype, Endothelial Dysfunction and HDL Atheroprotective Function in Subjects With Metabolic Syndrome (CAPITAIN)|Completed||Phase 1|14|Actual|Kowa Research Europe||1|||f||||f||||||||||2018-05-31 21:23:41.766814|2018-05-31 21:23:41.766814
NCT01595815|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-01-06|2012-05-09|2012-05-10|Estimate|||||||2014-01-06|2014-01-08|Estimate|May 2007||2007-05-31|January 2014|2014-01-31|April 2016|Anticipated|2016-04-30|September 2011|Actual|2011-09-30||Interventional|||Successful Pregnancy and Delivery After AOA|Successful Pregnancy and Delivery After AOA in Couples With Repeated Complete Fertilization Failure or Low Fertilization Rates|Unknown status|Active, not recruiting|N/A|100|Anticipated|Maria Fertility Hospital||2|||f||||t||||||||||2018-05-31 21:23:41.878995|2018-05-31 21:23:41.878995
NCT01595802|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2016-02-23|2012-05-09|2012-05-10|Estimate|||||||2016-02-23|2016-02-25|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|March 2013|Actual|2013-03-31||Interventional|||Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm|A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler as an Aid to Diagnosing Vasospasm|Completed||N/A|72|Actual|Jan Medical, Inc.||2|||f||||f||||||||No||2018-05-31 21:23:41.956677|2018-05-31 21:23:41.956677
NCT01595789|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-03-04|2012-05-09|2012-05-10|Estimate|||||||2017-03-04|2017-03-07|Actual|May 2012||2012-05-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|AddHope2||The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes|Adding Liraglutide to the Backbone Therapy of Biguanide in Patients With Coronary Artery Disease and Newly Diagnosed Type-2 Diabetes|Completed||Phase 4|41|Actual|Haugaard, Steen Bendix, M.D., DMSc||2|||f||||t||||||||||2018-05-31 21:23:42.042273|2018-05-31 21:23:42.042273
NCT01595776|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-06-13|2012-05-08|2012-05-10|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Autologous Endothelial Progenitor Cells (EPCs) From Peripheral Blood in the Treatment of Critical Limb Ischemia|Autologous Immunomagnetic Selected cd133+ Cells in the Treatment of No-option Critical Limb Ischemia: Clinical and Ceus Assessed Results.|Completed||Phase 1/Phase 2|8|Actual|IRCCS Policlinico S. Matteo||1|||f||||t||||||||||2018-05-31 21:23:42.141218|2018-05-31 21:23:42.141218
NCT01595763|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-08|2012-05-08|2012-05-10|Estimate|||||||2012-05-08|2012-05-10|Estimate|November 2011||2011-11-30|April 2011|2011-04-30||||||||Observational|||Diagnostic Approach of Deep Vein Thrombosis in Primary Care|Orientación Diagnóstica de la Trombosis Venosa Profunda en la Atención Primaria. Estudio de Coste Efectividad|Unknown status|Recruiting||20|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||Samples Without DNA|"~     blood to calculate the value of Dimer D~   "|||2018-05-31 21:23:42.217133|2018-05-31 21:23:42.217133
NCT01595750|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-05-09|2012-05-09|2012-05-10|Estimate|||||||2012-05-09|2012-05-10|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|REVASC||Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Roflumilast on Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Spanish Research Center for Respiratory Diseases||2|||f||||f||||||||||2018-05-31 21:23:42.291721|2018-05-31 21:23:42.291721
NCT01595737|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-03-11|2012-05-08|2012-05-10|Estimate|||||||2015-03-11|2015-03-12|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery|Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery|Completed||Phase 4|30|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 21:23:42.373997|2018-05-31 21:23:42.373997
NCT01595724|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-07-09|2012-05-09|2012-05-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Observational|DIVA||Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life|Study to Characterize Patients Treated With Visanne for Their Endometriosis Under Real-life Practice Conditions and Evaluate Their Quality of Life at Baseline and After 6 Months of Treatment With Visanne.|Completed|||3006|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:23:42.439334|2018-05-31 21:23:42.439334
NCT01595711|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2018-01-26|2012-05-08|2012-05-10|Estimate|||||||2018-01-26|2018-01-29|Actual|March 7, 2012|Actual|2012-03-07|January 2018|2018-01-31|September 7, 2013|Actual|2013-09-07|September 7, 2013|Actual|2013-09-07||Observational|D3C||Prediction of Chronic Pain by the Pain Monitor|Prediction of the Occurrence of Chronic Pain After Thoracotomy by Measuring Preoperative Skin Conductance (Pain Monitor Device)|Terminated|||6|Actual|Hopital Foch|||1|Difficulties of recrutment|f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 21:23:42.533543|2018-05-31 21:23:42.533543
NCT01595698|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-06-08|2012-05-09|2012-05-10|Estimate|||||||2012-06-08|2012-06-12|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Schizophrenia and Physical Exercise|Schizophrenia and Physical Exercise: Effect of 20 Weeks of Training in Symptoms and Concentration in Serum IGF-1 and BDNF|Completed||N/A|11|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:23:42.624371|2018-05-31 21:23:42.624371
NCT01595685|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-01-24|2012-05-09|2012-05-10|Estimate|||||||2017-01-24|2017-01-26|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TERESA||Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B|A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment|Completed||Phase 3|98|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:23:42.701632|2018-05-31 21:23:42.701632
NCT01595672|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-05-08|2012-05-08|2012-05-10|Estimate|||||||2012-05-08|2012-05-10|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Interventional|EHVCVVHSAP||Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis|Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis: Single-center, Randomized, Controlled Trial|Unknown status|Recruiting|N/A|56|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 21:23:42.797663|2018-05-31 21:23:42.797663
NCT01595659|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2018-01-23|2012-05-08|2012-05-10|Estimate|||||||2018-01-23|2018-01-25|Actual|September 30, 2011|Actual|2011-09-30|January 2018|2018-01-31|June 3, 2015|Actual|2015-06-03|June 3, 2015|Actual|2015-06-03||Interventional|||Influence of Alcohol and Peer Passengers on Risky Driving Behavior in Young Adults|Influence of Alcohol and Peer Passengers on Risky Driving Behavior in Young Adults|Completed||N/A|240|Actual|Centre de recherche du Centre hospitalier universitaire de Sherbrooke||3|||f||||f|f|f||||||No||2018-05-31 21:23:42.887453|2018-05-31 21:23:42.887453
NCT01595646|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2017-04-17||2018-04-23|2012-05-09|2012-05-10|Estimate|2018-01-05|2018-02-01|Actual||||2018-04-23|2018-05-22|Actual|November 2011|Actual|2011-11-30|April 2018|2018-04-30|March 12, 2015|Actual|2015-03-12|March 12, 2015|Actual|2015-03-12||Interventional|SL120||Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)|Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)|Completed||Phase 2|37|Actual|Wake Forest University Health Sciences||3|||f||||t|t|f||||||No|There is no plan to share individual participant data with other researchers.|2018-05-31 21:23:42.970605|2018-05-31 21:23:42.970605
NCT01595633|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2012-05-09|2012-05-09|2012-05-10|Estimate|||||||2012-05-09|2012-05-10|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy|Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance|Unknown status|Recruiting|Phase 4|124|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 21:23:43.412998|2018-05-31 21:23:43.412998
NCT01595620|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-11-29|2012-05-09|2012-05-10|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2011||2011-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cannabinoid Modulation of Pain|Cannabinoid Modulation of Pain|Active, not recruiting||N/A|120|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 21:23:43.495789|2018-05-31 21:23:43.495789
NCT01595607|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-02-23|2012-05-08|2012-05-10|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Avocado Consumption on Vascular Health|The Influence of Daily Consumption of Avocado on Biomarkers of Vascular Health|Completed||N/A|60|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 21:23:43.557602|2018-05-31 21:23:43.557602
NCT01595594|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-07-15|2012-05-08|2012-05-10|Estimate|||||||2014-07-15|2014-07-16|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics|Effect of a PDT Protocol With Multiple Applications as an Adjuvant on the Non Surgical Treatment of Periodontal Disease in Patients With Type 2 Diabetes. A Clinical and Laboratorial Study in Humans|Completed||Phase 3|30|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 21:23:43.615955|2018-05-31 21:23:43.615955
NCT01595581|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-12-03|2012-05-09|2012-05-10|Estimate|||||||2013-12-03|2013-12-05|Estimate|April 2012||2012-04-30|December 2013|2013-12-31||||April 2014|Anticipated|2014-04-30||Interventional|TACL||Testosterone Administration and ACL Reconstruction in Men|The Effects of Acute Testosterone Administration in Men on Muscle Mass, Strength, and Physical Function Following ACL Reconstructive Surgery|Unknown status|Recruiting|Phase 3|14|Anticipated|University of Southern California||2|||f||||f||||||||||2018-05-31 21:23:43.675253|2018-05-31 21:23:43.675253
NCT01595568|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-07-18|2012-05-08|2012-05-10|Estimate|||||||2012-07-18|2012-07-19|Estimate|February 2012||2012-02-29|July 2012|2012-07-31||||July 2012|Anticipated|2012-07-31||Interventional|||Prevention and Reduction of Alcohol and Drug Problems in a Clinical Psychiatric Youth Population||Unknown status|Recruiting|N/A|60|Anticipated|St. Justine's Hospital||4|||f||||f||||||||||2018-05-31 21:23:43.753034|2018-05-31 21:23:43.753034
NCT01595555|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-08-07|2012-05-09|2012-05-10|Estimate|||||||2012-08-07|2012-08-08|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effectiveness of Stress Free Now: an Internet-based Mindfulness Program for Stress Management|Effectiveness of an Internet-based Mindfulness Program for Stress Management|Completed||N/A|684|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 21:23:43.825377|2018-05-31 21:23:43.825377
NCT01595542|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-03-12|2012-05-08|2012-05-10|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A School Health Center Intervention to Increase Adolescent Vaccination|A School Health Center Intervention to Increase Adolescent Vaccination|Completed||N/A|3417|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:23:43.925029|2018-05-31 21:23:43.925029
NCT01595529|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-03-22|2012-05-08|2012-05-10|Estimate|||||||2018-03-22|2018-03-23|Actual|May 18, 2012|Actual|2012-05-18|October 22, 2013|2013-10-22|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||"The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children"|"Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children"|Recruiting||Phase 2|746|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 21:23:43.986631|2018-05-31 21:23:43.986631
NCT01595516|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2017-10-24|2012-05-08|2012-05-10|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2012||2012-02-29|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)|Nebivolol and Endothelial Regulation of Fibrinolysis|Completed||Phase 4|54|Actual|University of Colorado, Boulder||3|||f||||t||||||||||2018-05-31 21:23:44.132663|2018-05-31 21:23:44.132663
NCT01595503|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-07-15|2012-05-08|2012-05-10|Estimate|||||||2013-07-15|2013-07-16|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Transcranial Magnetic Stimulation for the Treatment of Auditory Hallucinations in Schizophrenia|Functional Targeting of Transcranial Magnetic Stimulation for the Treatment of Refractory Auditory Hallucinations in Schizophrenia|Completed||N/A|5|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:23:44.204434|2018-05-31 21:23:44.204434
NCT01595490|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-01-27|2012-05-08|2012-05-10|Estimate|||||||2014-01-27|2014-01-29|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza|A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza|Completed||N/A|121|Actual|The Center for Mind-Body Medicine||2|||f||||f||||||||||2018-05-31 21:23:44.272745|2018-05-31 21:23:44.272745
NCT01595477|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-01-27|2012-05-08|2012-05-10|Estimate|||||||2014-01-27|2014-01-29|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Mind-Body Skills Groups for the Treatment of War-Related Trauma in Children in Gaza|A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Children in Gaza|Completed||N/A|114|Actual|The Center for Mind-Body Medicine||2|||f||||f||||||||||2018-05-31 21:23:44.359581|2018-05-31 21:23:44.359581
NCT01595464|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-01-27|2012-05-08|2012-05-10|Estimate|||||||2014-01-27|2014-01-29|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza|A Randomized Controlled Study of Mind-Body Skills Groups for the Treatment of War-Related Trauma in Adults in Gaza|Completed||N/A|148|Actual|The Center for Mind-Body Medicine||2|||f||||f||||||||||2018-05-31 21:23:44.439849|2018-05-31 21:23:44.439849
NCT01595451|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-11-27|2012-05-08|2012-05-10|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2012|Actual|2012-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Brain Mechanisms of Acupuncture Treatment in Chronic Low Back Pain|Brain Mechanisms of Acupuncture Treatment in Chronic Low Back Pain|Completed||N/A|79|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 21:23:44.520446|2018-05-31 21:23:44.520446
NCT01595438|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2015-10-28||2017-08-31|2012-05-08|2012-05-10|Estimate|2016-03-08|2016-03-09|Estimate||||2017-08-31|2017-09-06|Actual|October 2012||2012-10-31|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Safety analysis set|Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)|A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults|Completed||Phase 3|598|Actual|Pfizer||2|||f||||||||||||||2018-05-31 21:23:44.716042|2018-05-31 21:23:44.716042
NCT01595425|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-12-11|2012-05-09|2012-05-10|Estimate|||||||2012-12-11|2012-12-12|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bioequivalence Study Comparing D961H Sachet and D961H Capsule in Japanese Healthy Male Subjects|A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Bioequivalence Study Comparing a Pellets Based Sachet Formulation of D961H 20 mg and a Commercial HPMC Capsule of D961H 20 mg After Repeated Oral Administration in Japanese Healthy Male Subjects|Completed||Phase 1|71|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:23:47.643521|2018-05-31 21:23:47.643521
NCT01595412|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-10-20|2012-05-09|2012-05-10|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2010|Actual|2010-01-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|LaProS||An International Double Cohort Study to Compare Laparoscopic Ventral Rectopexy With Laparoscopic Resection Rectopexy|Laparoscopic Rectal Prolapse Surgery Study. An International, Double Cohort Study to Determine the Optimal Treatment for Rectal Prolapse.|Terminated||N/A|2|Actual|The Cleveland Clinic||2||2 patients enrolled lost of follow-up after completing 1st year visits.PI decided to close|f||||t||||||||No||2018-05-31 21:23:47.798761|2018-05-31 21:23:47.798761
NCT01595399|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-09-23|2012-05-08|2012-05-10|Estimate|||||||2013-09-23|2013-09-24|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation|Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation|Unknown status|Recruiting|Phase 4|70|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:23:47.917474|2018-05-31 21:23:47.917474
NCT01595386|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2015-01-28||2015-10-12|2012-05-08|2012-05-10|Estimate|2015-10-12|2015-11-10|Estimate||||2015-10-12|2015-11-10|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass|Effect of Postoperative Hydrocortisone on Cardiovascular and Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass|Completed||N/A|40|Actual|University of Alabama at Birmingham|small, single-center trial; included subjects from more than one surgeon; all patients received preoperative and rescue steroids; definition of low cardiac output syndrome although appropriate must ultimately be arbitrary.|2|||f||||t||||||||||2018-05-31 21:23:48.037336|2018-05-31 21:23:48.037336
NCT01595373|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-01-15|2012-05-08|2012-05-10|Estimate|||||||2013-01-15|2013-01-16|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Local Metabolic Effects of Ghrelin in Skeletal Muscle and Adipose Tissue|Local Metabolic Effects of Ghrelin: A Clinical Microdialysis Study|Completed||Early Phase 1|10|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:23:48.579048|2018-05-31 21:23:48.579048
NCT01595360|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-09-13|2012-05-09|2012-05-10|Estimate|||||||2013-09-13|2013-09-16|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction|A Phase 1, Randomized, Open, Controlled, Comparative Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction|Completed||Phase 1|24|Actual|Thrombotargets Europe S.L||2|||f||||t||||||||||2018-05-31 21:23:48.644318|2018-05-31 21:23:48.644318
NCT01595347|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-05-08|2012-05-08|2012-05-10|Estimate|||||||2012-05-08|2012-05-10|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|September 2013|Anticipated|2013-09-30||Interventional|PrevenUP||Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care|Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care.A Cluster Randomized Clinical Trial.|Unknown status|Enrolling by invitation|Phase 4|410|Actual|Andaluz Health Service||2|||f||||f||||||||||2018-05-31 21:23:48.706388|2018-05-31 21:23:48.706388
NCT01595334|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-05-24|2012-05-08|2012-05-10|Estimate|||||||2012-05-24|2012-05-25|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|November 2012|Anticipated|2012-11-30|September 2012|Anticipated|2012-09-30||Interventional|LH/M2-Oocyte||Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity|Is it Possible to Obtain Higher Yield of Mature M2 Oocytes by Establishing Appropriate Levels of LH During Controlled Ovarian Hyperstimulation (COH) in Antagonist Cycles for In-vitro Fertilization-embryo Transfer (IVF-ET)/ Intracytoplasmic Sperm Injection (ICSI)?|Unknown status|Recruiting|N/A|300|Anticipated|Southern Cross Fertility Centre||2|||f||||t||||||||||2018-05-31 21:23:49.787387|2018-05-31 21:23:49.787387
NCT01595321|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2017-10-05|2012-05-09|2012-05-10|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2012||2012-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|||Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas|Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated With Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas|Active, not recruiting||N/A|19|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 21:23:49.887977|2018-05-31 21:23:49.887977
NCT01595308|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-05-10|2012-05-09|2012-05-10|Estimate|||||||2012-05-10|2012-05-14|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers|A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers|Completed||Phase 1|12|Actual|POM Wonderful LLC||1|||f||||f||||||||||2018-05-31 21:23:49.960375|2018-05-31 21:23:49.960375
NCT01595295|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-04-04|2012-05-08|2012-05-10|Estimate|||||||2017-04-04|2017-04-05|Actual|February 2009|Actual|2009-02-28|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Registry on Hypomethylating Agents in Myeloid Neoplasms|Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelominocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)|Recruiting|||1500|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie|||1||f||||f||||||Samples With DNA|"~     From some patients with myeloid neoplasms blood or tissue samples will be stored for further~     analyses. These samples will also be obtained from patients, who are not or not yet treated~     with hypomethylating agents, to comprise a control.~   "|||2018-05-31 21:23:50.065045|2018-05-31 21:23:50.065045
NCT01595282|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2014-05-15||2014-06-30|2012-05-08|2012-05-10|Estimate|2014-06-30|2014-07-02|Estimate||||2014-06-30|2014-07-02|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage|Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage: a Randomized Clinical Trial.|Completed||N/A|94|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-05-31 21:23:50.165717|2018-05-31 21:23:50.165717
NCT01595269|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2012-05-08|2012-05-08|2012-05-10|Estimate|||||||2012-05-08|2012-05-10|Estimate|April 2007||2007-04-30|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|eHealthDM||The Clinical and Economic Impacts of e-Heath on Diabetes|The Clinical and Economic Impacts of e-Heath on Diabetes|Completed||N/A|79|Actual|Pacaud, Danièle, M.D.||3|||f||||f||||||||||2018-05-31 21:23:50.507619|2018-05-31 21:23:50.507619
NCT01595256|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2014-10-13|2012-05-08|2012-05-10|Estimate|||||||2014-10-13|2014-10-15|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Exploration the Effect of Walking Program in Patients With Colorectal Cancer|Exploration the Effect of Individualized Home-based Walking Program on Muscle Strength and Fatigue in Patients With Colorectal Cancer Both During and After Treatment|Completed||N/A|237|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 21:23:50.588643|2018-05-31 21:23:50.588643
NCT01595243|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-12-26|2012-05-08|2012-05-10|Estimate|||||||2012-12-26|2012-12-27|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|February 2013|Anticipated|2013-02-28|July 2012|Actual|2012-07-31||Interventional|||Effects of Telephone Consultations on Discharged Liver Cancer|Effects of Telephone Follow- up Consultations on Discharged Liver Cancer Following Non-surgical Treatment|Unknown status|Recruiting|N/A|254|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 21:23:50.661833|2018-05-31 21:23:50.661833
NCT01595230|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-06-28|2012-05-09|2012-05-10|Estimate|||||||2017-06-28|2017-06-29|Actual|May 2012||2012-05-31|June 2017|2017-06-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Internal Hernias After Gastric Bypass Can be Prevented Safely With Primary Closure of All Mesenteric Defects With Clips|Randomized Controlled Trial: Internal Hernias After Gastric Bypass Can be Prevented Safely With Primary Closure of All Mesenteric Defects With Clips|Active, not recruiting||N/A|405|Actual|Region Zealand||2|||f||||f||||||||||2018-05-31 21:23:50.747225|2018-05-31 21:23:50.747225
NCT01595217|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-05-14|2012-05-08|2012-05-09|Estimate|||||||2017-05-14|2017-05-16|Actual|March 2012|Actual|2012-03-31|May 2017|2017-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||MRCP Diagnoses EHCC Better When Combined DWI|The Incremental Value of 3T Diffusion-Weighted MRI in Diagnosing Extrahepatic Cholangiocarcinoma|Completed||N/A|99|Actual|China Medical University, China||2|||f||||t|f|t|f|f|t|||No||2018-05-31 21:23:50.839604|2018-05-31 21:23:50.839604
NCT01595204|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-20|2012-05-08|2012-05-09|Estimate|||||||2012-05-20|2012-05-22|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|MITO13||Validation of a Laparoscopic Score to Predict the Chance of Optimal Cytoreduction in Advanced Ovarian Cancer Patients|Olympia-MITO13-validation of a Laparoscopic Score to Predict the Chance of Optimal Cytoreduction in Advanced Ovarian Cancer Patients: an Open-label Prospective Multicentric-trial.|Completed||N/A|163|Actual|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 21:23:50.932362|2018-05-31 21:23:50.932362
NCT01595191|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-08|2012-05-08|2012-05-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||"Bach Music in Preterm Infants: No Mozart Effect on Resting Energy Expenditure"|"Bach Music in Preterm Infants: No Mozart Effect on Resting Energy Expenditure"|Completed||N/A|12|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 21:23:51.001421|2018-05-31 21:23:51.001421
NCT01595178|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-07|2012-05-07|2012-05-09|Estimate|||||||2012-05-07|2012-05-09|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Combination SBIRT for Emergency Department Patients Who Drink and Smoke|Development of a Combined Screening and Intervention Program for Emergency Department Patients Who Both Drink and Smoke|Unknown status|Not yet recruiting|Early Phase 1|50|Anticipated|Yale University|||||f||||f||||||||||2018-05-31 21:23:51.068908|2018-05-31 21:23:51.068908
NCT01595165|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-07-05|2012-05-08|2012-05-09|Estimate|||||||2012-07-05|2012-07-09|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Transversus Abdominis Plane Block and Postoperative Pain After Laparoscopic Cholecystectomy|Effect of Subcostal Transversus Abdominis Plane Block on Early Postoperative Pain in Laparoscopic Cholecystectomy: Randomized, Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|Soonchunhyang University Hospital||2|||f||||t||||||||||2018-05-31 21:23:51.142591|2018-05-31 21:23:51.142591
NCT01595152|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2012-05-14|2012-05-08|2012-05-09|Estimate|||||||2012-05-14|2012-05-16|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms|Solifenacin Succinate vs. Fesoterodine A Comparison Trial for the Treatment of Bothersome Urgency Symptoms|Unknown status|Recruiting|N/A|60|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 21:23:51.226117|2018-05-31 21:23:51.226117
NCT01595139|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-02-03|2012-05-08|2012-05-09|Estimate|||||||2016-02-03|2016-02-05|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||MicroRNAs in Patients With Neurofibromatosis Type 1|MicroRNAs as Disease Markers for Central Nervous System Tumors in Patients With Neurofibromatosis Type 1|Completed|||9|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||Undecided||2018-05-31 21:23:51.319214|2018-05-31 21:23:51.319214
NCT01595126|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-02-03|2012-05-08|2012-05-09|Estimate|||||||2016-02-03|2016-02-05|Estimate|December 2011||2011-12-31|February 2016|2016-02-29||||December 2018|Anticipated|2018-12-31||Observational|||Longitudinal Study of Biomarkers|A Longitudinal Study of Biomarkers in Pediatric Patients With Central Nervous System Tumors|Recruiting|||100|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||f||||||||||2018-05-31 21:23:51.386126|2018-05-31 21:23:51.386126
NCT01595113|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-11-13|2012-05-08|2012-05-09|Estimate|||||||2013-11-13|2013-11-15|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|||Safety Study of Clinical Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction|A Follow-up Observational Study of Safety of Clinical Trial Conducted With Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction|Completed|||40|Anticipated|Pharmicell Co., Ltd.|||||f||||t||||||||||2018-05-31 21:23:51.449963|2018-05-31 21:23:51.449963
NCT01595100|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2016-02-04|2012-05-08|2012-05-09|Estimate|||||||2016-02-04|2016-02-08|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|Waist||Anthropometric Assessment of Abdominal Obesity and Health Risk in Children and Adolescents|Anthropometric Assessment of Abdominal Obesity and Health Risk in Children and Adolescents|Completed|||423|Actual|Pennington Biomedical Research Center|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:23:51.490477|2018-05-31 21:23:51.490477
NCT01595087|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-11-12|2012-05-08|2012-05-09|Estimate|||||||2014-11-12|2014-11-14|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)|A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)|Completed||Phase 1/Phase 2|28|Actual|DexTech Medical AB||1|||f||||t||||||||||2018-05-31 21:23:51.566729|2018-05-31 21:23:51.566729
NCT01595074|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-09-19|2012-05-08|2012-05-09|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 2012||2012-05-31|August 2013|2013-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy|The Identification, Validation and Implemention of Prognostic and/or Predictive Biomarkers for Adjuvant Chemotherapy in Early Stage Non-Small Cell Lung Cancer (NSCLC)|Not yet recruiting|||950|Anticipated|National Cancer Institute (NCI)|||1||f||||||||||||||2018-05-31 21:23:51.726115|2018-05-31 21:23:51.726115
NCT01595061|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-05-04|2012-05-08|2012-05-09|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 2, 2012|Actual|2012-07-02|May 2018|2018-05-31||||September 30, 2019|Anticipated|2019-09-30||Interventional|||Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva|A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)|Recruiting||Phase 2|52|Anticipated|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 21:23:51.878309|2018-05-31 21:23:51.878309
NCT01595035|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-04-05|2012-05-08|2012-05-09|Estimate|||||||2017-04-05|2017-04-06|Actual|May 2012||2012-05-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2015|Actual|2015-10-31||Interventional|||A Clinical Trial of a Psycho-educational Intervention to Improve Pain Management After Day Surgery|A Randomized Clinical Trial of a Psycho-educational Intervention to Improve Pain Management After Day Surgery|Active, not recruiting||N/A|200|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 21:23:52.43773|2018-05-31 21:23:52.43773
NCT01595022|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-04-02|2012-05-08|2012-05-09|Estimate|||||||2015-04-02|2015-04-03|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||FR01 and FR20 IUS (Intrauterine System) Wearing Study|A Multi-center, Single-blinded, Randomized, Controlled, Parallel-group Study to Evaluate the Wearing Comfort of Two Different Placebo Intrauterine Systems FR01 and FR20 Compared to a Placebo T-frame Intrauterine System for 3 Cycles in Healthy Women Aged 18-40 Years|Completed||Phase 1|90|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:23:52.504261|2018-05-31 21:23:52.504261
NCT01595009|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-03-21|2012-05-08|2012-05-09|Estimate|||||||2017-03-21|2017-03-24|Actual|June 19, 2012|Actual|2012-06-19|March 2017|2017-03-31|August 9, 2016|Actual|2016-08-09|August 9, 2016|Actual|2016-08-09||Interventional|||Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors|Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors|Completed||Phase 4|15|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:23:52.581556|2018-05-31 21:23:52.581556
NCT01594996|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-10-31|2012-05-08|2012-05-09|Estimate|||||||2017-10-31|2017-11-01|Actual|April 24, 2012|Actual|2012-04-24|October 2017|2017-10-31|March 27, 2014|Actual|2014-03-27|March 27, 2014|Actual|2014-03-27||Observational|EUDUS||European Drug Utilization Study|A Multinational, Multicenter, Retrospective, Observational Drug Utilisation Study of Seroquel Extended Release (XR) Prescribed by Psychiatrists as Treatment for Major Depressive Disorder (MDD) in Selected Countries in the European Union (EU)|Completed|||814|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 21:23:52.665977|2018-05-31 21:23:52.665977
NCT01590693|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-02|2012-05-02|2012-05-03|Estimate|||||||2012-05-02|2012-05-03|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Botulinum Toxin A for Idiopathic Toe-walking|Botulinum Toxin A Does Not Improve Cast Treatment for Idiopathic Toe-walking- a Prospective Randomized Trial.|Completed||N/A|52|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:24:49.098193|2018-05-31 21:24:49.098193
NCT01594983|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07||2015-10-05|2015-10-05|2012-05-08|2012-05-09|Estimate||||2015-10-05|2015-10-28|Estimate|2015-10-05|2015-10-28|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia|A Multicenter, Randomized, Active Comparator, Placebo Controlled, Double-blind Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia|Completed||Phase 2|58|Actual|Novartis||6|||f||||f||||||||||2018-05-31 21:23:52.732631|2018-05-31 21:23:52.732631
NCT01594970|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2014-01-27||2014-01-27|2012-05-08|2012-05-09|Estimate|2014-01-27|2014-03-12|Estimate||||2014-01-27|2014-03-12|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)||Completed||Phase 4|800|Actual|Allergan||3|||f||||f||||||||||2018-05-31 21:23:52.962253|2018-05-31 21:23:52.962253
NCT01594957|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-05-23|2012-05-08|2012-05-09|Estimate|||||||2013-05-23|2013-05-27|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment|An Open-label, Single Dose, Parallel-group Study to Evaluate the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.|Completed||Phase 1|53|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:23:53.3204|2018-05-31 21:23:53.3204
NCT01594944|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-08|2012-05-08|2012-05-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|May 2012||2012-05-31|May 2012|2012-05-31||||||||Observational|||Fetal Orbital Measurements by 3D Ultrasound||Unknown status|Not yet recruiting||250|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 21:23:53.412921|2018-05-31 21:23:53.412921
NCT01594931|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-08|2012-05-08|2012-05-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|July 2005||2005-07-31|May 2012|2012-05-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria|A Randomised, Multi-Centre, Phase II, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 2|477|Actual|Medicines for Malaria Venture||3|||f||||t||||||||||2018-05-31 21:23:53.463602|2018-05-31 21:23:53.463602
NCT01594918|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-07-20|2012-05-07|2012-05-09|Estimate|||||||2017-07-20|2017-07-21|Actual|June 2012||2012-06-30|July 2017|2017-07-31|June 23, 2017|Actual|2017-06-23|August 2016|Actual|2016-08-31||Interventional|||Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer|A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy|Completed||Phase 1|25|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:23:53.570909|2018-05-31 21:23:53.570909
NCT01594905|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2014-01-30|2012-05-08|2012-05-09|Estimate|||||||2014-01-30|2014-01-31|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection|A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 21:23:53.672557|2018-05-31 21:23:53.672557
NCT01594892|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-08-06|2012-05-07|2012-05-09|Estimate|||||||2015-08-06|2015-08-07|Estimate|April 2012||2012-04-30|August 2015|2015-08-31||||January 2015|Actual|2015-01-31||Interventional|DOSIS||Fractionated Radiosurgery for Painful Spinal Metastases|Dose-intensified Image-Guided Fractionated Radiosurgery for Spinal Metastases (DOSIS)|Unknown status|Active, not recruiting|Phase 2|60|Actual|Wuerzburg University Hospital||2|||f||||t||||||||||2018-05-31 21:23:53.825048|2018-05-31 21:23:53.825048
NCT01594879|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-08|2012-05-08|2012-05-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer|Treatment With Medroxyprogesterone Acetate(MPA) Plus Levonorgestrel-releasing Intrauterine System(LNG-IUS) in Young Women With Early Stage Endometrial Cancer: Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2009)|Unknown status|Recruiting|Phase 2|39|Anticipated|Korean Gynecologic Oncology Group||1|||f||||f||||||||||2018-05-31 21:23:53.985312|2018-05-31 21:23:53.985312
NCT01594866|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-12-07|2012-05-08|2012-05-09|Estimate|||||||2015-12-07|2015-12-08|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|LEADERS||Lexapro®'s Efficacy After Dose Escalation in Remission Study|A Double-blinded 6-week Prospective Study to Evaluate the Remission Rate According to Dose of Escitalopram (Lexapro®) in Patients With Major Depressive Disorder: a Preliminary Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:23:54.066097|2018-05-31 21:23:54.066097
NCT01594853|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-01-08|2012-05-08|2012-05-09|Estimate|||||||2015-01-08|2015-01-09|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy|Exercise Study of Function and Pathology for Women With X-ALD|Completed||N/A|31|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||f||||||||||2018-05-31 21:23:54.151938|2018-05-31 21:23:54.151938
NCT01594840|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2014-03-24|2012-05-08|2012-05-09|Estimate|||||||2014-03-24|2014-03-26|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Changing Chat: Diaper Tips to Improve Language Development|Changing Chat: Diaper Tips to Improve Language Development|Completed||N/A|70|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 21:23:54.247266|2018-05-31 21:23:54.247266
NCT01594827|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-01-08|2012-05-08|2012-05-09|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|PMEP||Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)|Persistent MRSA Eradication Protocol (PMEP)|Completed||Phase 2|29|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:23:54.30818|2018-05-31 21:23:54.30818
NCT01594814|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-12-12|2012-05-08|2012-05-09|Estimate|||||||2014-12-12|2014-12-15|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|PPRA||Patients' Perspective on Radiofrequency Catheter Ablation of AVRT and AVNRT|Patients' Perspective on Radiofrequency Catheter Ablation of AVRT and AVNRT - a Quality of Life, Utility and Willingness to Pay Study (PPRA Study)|Completed|||82|Actual|Institute of Cardiology, Warsaw, Poland|||1||f||||t||||||||||2018-05-31 21:23:54.40893|2018-05-31 21:23:54.40893
NCT01594801|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2013-03-12|2012-05-08|2012-05-09|Estimate|||||||2013-03-12|2013-03-13|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Testing the Effect of the InsuPad Device in Daily Life Conditions|Testing the Effect of the InsuPad Device in Daily Life Conditions - The InsuPad in Daily Life Study|Completed||N/A|145|Actual|Insuline Medical Ltd.||2|||f||||f||||||||||2018-05-31 21:23:54.481567|2018-05-31 21:23:54.481567
NCT01594788|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-08|2012-05-08|2012-05-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|December 2012||2012-12-31|||||Observational|||Neutrophil Gelatinase-associated Lipocalin as a New Biomarker to Detect Acute Kidney Injury in Postoperative Cardiac Surgery|NGAL as a Marker of Acute Kidney Injury After Cardiac Surgery. Observational Study|Unknown status|Recruiting||340||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t||||||||||2018-05-31 21:23:54.553262|2018-05-31 21:23:54.553262
NCT01594775|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2014-02-24|2012-05-08|2012-05-09|Estimate|||||||2014-02-24|2014-02-25|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Oxytocin, Couple Interaction and Wound Healing||Completed||Phase 1|160|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 21:23:54.609071|2018-05-31 21:23:54.609071
NCT01594762|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2017-04-14||2017-05-19|2012-05-08|2012-05-09|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|June 2014||2014-06-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|OneStep-2||Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers|A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers|Completed||Phase 3|200|Actual|Dipexium Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 21:23:54.681155|2018-05-31 21:23:54.681155
NCT01594749|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|2015-08-26||2017-02-17|2012-05-07|2012-05-09|Estimate|2015-08-26|2015-09-25|Estimate||||2017-02-17|2017-03-22|Actual|September 2012||2012-09-30|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The Baseline analysis population is consistent with the Intent-to-Treat (ITT) population, i.e., all randomized participants who received ≥1 dose of study drug within the assigned treatment regimen. Note: One participant with missing source documentation in the Fosaprepitant Regimen was excluded from the ITT population.|Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy|Completed||Phase 3|1015|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:23:55.147335|2018-05-31 21:23:55.147335
NCT01594736|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-08-03|2012-05-08|2012-05-09|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2012||2012-04-30|August 2017|2017-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ORSIRO_OCT||ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography|Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography|Completed||Phase 4|30|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 21:23:55.642927|2018-05-31 21:23:55.642927
NCT01594723|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01||2015-09-03|2018-03-09|2012-05-07|2012-05-09|Estimate||||2015-09-03|2015-09-18|Estimate|2018-03-09|2018-03-14|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2015|Actual|2015-03-31||Interventional|||A Study of LY2784544 in Participants With Myeloproliferative Neoplasms|A Phase 2 Study of LY2784544 in Patients With Myeloproliferative Neoplasms|Active, not recruiting||Phase 2|110|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:23:55.73467|2018-05-31 21:23:55.73467
NCT01594710|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-28|||2015-10-12|2012-05-07|2012-05-09|Estimate|||||||2015-10-12|2015-10-14|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Observational|||Risk Factor Analysis for Developing Metabolic Syndrome in Korean Adults||Completed|||1800|Actual|Korea University|||1||f||||t||||||||||2018-05-31 21:23:55.882586|2018-05-31 21:23:55.882586
NCT01594697|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-10|2012-05-08|2012-05-09|Estimate|||||||2012-05-10|2012-05-11|Estimate||||May 2012|2012-05-31||||||||Interventional|||Metformin in Pregnancy in Women With Polycystic Ovary Syndrome||Completed||N/A|60|Actual|Catholic University of the Sacred Heart||1|||f||||||||||||||2018-05-31 21:23:55.945828|2018-05-31 21:23:55.945828
NCT01594684|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-06-16|2012-05-08|2012-05-09|Estimate|||||||2012-06-16|2012-06-19|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|June 2016|Anticipated|2016-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries|Cotavance™ Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study|Unknown status|Recruiting|Phase 2/Phase 3|112|Anticipated|Klinikum Rosenheim||3|||f||||f||||||||||2018-05-31 21:23:56.020701|2018-05-31 21:23:56.020701
NCT01594671|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-12-18|2012-05-07|2012-05-09|Estimate|||||||2012-12-18|2012-12-19|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|TRANEXTOP||Tranexamic Acid for Unilateral Total Knee Arthroplasty|Prevention of Postoperative Blood Loss: Randomised Multicentre Parallel Clinical Trial That Assess the Topical and Intravenous Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.|Completed||Phase 3|150|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||3|||f||||f||||||||||2018-05-31 21:23:56.129481|2018-05-31 21:23:56.129481
NCT01594658|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-09-30|2012-05-07|2012-05-09|Estimate|||||||2012-09-30|2012-10-02|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Observational|VUTEF||Venous Ulcer Treatment With Foam Versus Conservative Treatment|Prospective Random Study for Handling Venous Ulcer With Conservative Treatment (Dressings Alone) and Foam Sclerotherapy Versus Conservative Treatment|Completed|||46|Actual|Hospital Occidente de Kennedy|||2||f||||f||||||||||2018-05-31 21:23:56.211561|2018-05-31 21:23:56.211561
NCT01594645|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-08-19|2012-05-07|2012-05-09|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Clinical Impact of Selecting Acrosome Reacted Spermatozoa for ICSI|The Impact of Selecting Acrosome Reacted Spermatozoa for ICSI- a Prospective RCT|Withdrawn||Phase 1|0|Actual|Hadassah Medical Organization||2||PI moved from Hadassah|f||||f||||||||||2018-05-31 21:23:56.290123|2018-05-31 21:23:56.290123
NCT01594632|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-09-19|2012-05-07|2012-05-09|Estimate|||||||2017-09-19|2017-09-21|Actual|January 2011||2011-01-31|September 2017|2017-09-30|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|||Safety,Effectiveness and Acceptability of Sino-implant II in DR|A Study to Evaluate the Contraceptive Effectiveness, Safety and Acceptability of Sino-implant II|Completed||N/A|650|Actual|FHI 360||2|||f||||t||||||||Undecided||2018-05-31 21:23:56.358239|2018-05-31 21:23:56.358239
NCT01594619|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2014-10-13|2012-05-08|2012-05-09|Estimate|||||||2014-10-13|2014-10-15|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol|An Open-label, Sequential, 3-period Study to Assess the Effects of Diltiazem on the Pharmacokinetics of Naloxegol in Healthy Subjects|Completed||Phase 1|44|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:23:56.437716|2018-05-31 21:23:56.437716
NCT01594606|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-12-08|2012-05-08|2012-05-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|||Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth|RCT of an Animal-Assisted Intervention With Adjudicated Youth|Completed||Phase 3|150|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 21:23:56.520071|2018-05-31 21:23:56.520071
NCT01594593|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-11-16|2012-05-07|2012-05-09|Estimate|||||||2012-11-16|2012-11-19|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Acceptance-Based Treatment for Prostate Cancer Distress|Pilot Study of an Acceptance and Commitment Therapy Workshop for Distress and Decision Making in Early Stage Prostate Cancer in Veterans|Completed||N/A|24|Actual|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-05-31 21:23:56.585414|2018-05-31 21:23:56.585414
NCT01594580|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-12-09|2012-05-08|2012-05-09|Estimate|||||||2015-12-09|2015-12-10|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Contamination of Hospital Scrubs|A Novel Agent to Decrease Contamination of Hospital Scrubs|Completed||N/A|111|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 21:23:56.644554|2018-05-31 21:23:56.644554
NCT01594567|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-09-21|2012-05-07|2012-05-09|Estimate|||||||2015-09-21|2015-09-23|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Meta-analyses of Dietary Pulses and Cardiometabolic Risk|Effect of Dietary Pulses on Cardiometabolic Risk in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 21:23:56.703473|2018-05-31 21:23:56.703473
NCT01594554|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-05-08|2012-05-07|2012-05-09|Estimate|||||||2012-05-08|2012-05-10|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|September 2016|Anticipated|2016-09-30|April 2016|Anticipated|2016-04-30||Observational|||A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.|A 5-year Observational Follow-up Study to Describe Treatment Patterns and Outcomes in Real World Clinical Practice for Patients of Newly Confirmed HCV Infection in China (2012-2016)|Unknown status|Recruiting||600|Anticipated|Peking University People's Hospital|||1||f||||f||||||Samples With DNA|"~     Samples with HCV RNA~   "|||2018-05-31 21:23:56.772988|2018-05-31 21:23:56.772988
NCT01594541|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-03-21|2012-05-08|2012-05-09|Estimate|||||||2014-03-21|2014-03-24|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|August 2013|Actual|2013-08-31||Observational|||A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired Patients|Hyperhomocysteinemia in a Mild Cognitive Impairment and Dementia Population: the Effect of Treatment With Cerefolin NAC® in a Naturalistic Community-based Dementia Practice|Unknown status|Active, not recruiting||700|Anticipated|Pamlab, Inc.|||2||f||||f||||||||||2018-05-31 21:23:56.836557|2018-05-31 21:23:56.836557
NCT01594528|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2014-05-13|2012-05-07|2012-05-09|Estimate|||||||2014-05-13|2014-05-14|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Behavior During Experimentally Induced Pain|Behavior During Experimentally Induced Pain|Completed||N/A|15|Actual|Centre Hospitalier Esquirol||1|||f||||f||||||||||2018-05-31 21:23:56.895858|2018-05-31 21:23:56.895858
NCT01594515|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2015-11-11||2015-11-11|2012-05-08|2012-05-09|Estimate|2015-11-11|2015-12-15|Estimate||||2015-11-11|2015-12-15|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken at least 1 dose of the investigational treatment.|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers (a Partially Randomised, Partially Single-blind, Placebo-controlled Phase I Study)|Completed||Phase 1|70|Actual|Boehringer Ingelheim|BI 1015550 high dose 24mg was originally planned as 26 mg but reduced due to PK interim analysis results of previous dose group.|10|||f||||||||||||||2018-05-31 21:23:57.01428|2018-05-31 21:23:57.01428
NCT01594502|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-11-01|2012-05-07|2012-05-09|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2011||2011-09-30|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|November 2018|Anticipated|2018-11-30||Observational|||Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies|R01 CA155301: Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies|Active, not recruiting|||300|Anticipated|University of Illinois at Chicago|||6||f||||f||||||Samples Without DNA|"~     Biopsy tissue (Year 2 and Year 4) already collected in REDUCE trial~   "|||2018-05-31 21:23:57.955193|2018-05-31 21:23:57.955193
NCT01594489|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2012-10-26|2012-05-08|2012-05-09|Estimate|||||||2012-10-26|2012-10-30|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Aminophylline and Contrast Induced Nephropathy in Acute Myocardial Infarction|Effect of Aminophylline on Contrast Induced Acute Kidney Injury in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty|Completed||Phase 4|250|Actual|Ospedale Misericordia e Dolce||2|||f||||t||||||||||2018-05-31 21:23:58.054254|2018-05-31 21:23:58.054254
NCT01594476|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-10-14|2012-05-08|2012-05-09|Estimate|||||||2014-10-14|2014-10-16|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Early Postpartum Intrauterine Device (IUD) Placement|Early Versus Standard Interval Postpartum Intrauterine Device (IUD) Placement at 3 Weeks or 6 Weeks Following Delivery: A Prospective Randomized Trial|Terminated||Phase 4|201|Actual|Oregon Health and Science University||2||Incomplete study enrollment prior to depletion of funding|f||||t||||||||||2018-05-31 21:23:58.127939|2018-05-31 21:23:58.127939
NCT01594463|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-05-10|2012-05-08|2012-05-09|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|RECRET||Routine Ultrasound Screening in the Third Trimester|Third Trimester Routine Ultrasound in Low-risk Pregnancies : Comparison of Two Timing Periods Procedure for Screening Intrauterine Growth Restriction|Completed||N/A|3760|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 21:23:58.218465|2018-05-31 21:23:58.218465
NCT01590680|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2016-09-23|2012-05-02|2012-05-03|Estimate|||||||2016-09-23|2016-09-27|Estimate||||September 2016|2016-09-30||||||||Expanded Access|||Expanded Access Protocol Using I131-MIBG|An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma|Available|||||Jubilant DraxImage Inc.|||||||||||||||||||2018-05-31 21:24:49.171862|2018-05-31 21:24:49.171862
NCT01594450|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2017-03-02|2012-05-07|2012-05-09|Estimate|||||||2017-03-02|2017-03-03|Actual|May 2012|Actual|2012-05-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|SIMBIOSE||Biological Meshes in Infected Fields: a Randomized Controlled Trial|Use of Biological Mesh Versus Standard Wound Care in Infected Incisional Ventral Hernias: a Multicenter Randomized Controlled Trial, the SIMBIOSE Study|Active, not recruiting||Phase 3|110|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||Undecided||2018-05-31 21:23:58.297929|2018-05-31 21:23:58.297929
NCT01594437|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2014-03-19|2012-05-08|2012-05-09|Estimate|||||||2014-03-19|2014-03-21|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody|Phase 1 Study of TCN-202 (Human Anti-Cytomegalovirus Monoclonal Antibody) in Healthy Adult Volunteers|Completed||Phase 1|48|Actual|Theraclone Sciences, Inc.||2|||f||||t||||||||||2018-05-31 21:23:58.393224|2018-05-31 21:23:58.393224
NCT01594424|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|2015-07-08||2016-07-25|2012-05-07|2012-05-09|Estimate|2015-07-08|2015-08-05|Estimate||||2016-07-25|2016-08-25|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation|A Phase I/II Trial of Tocilizumab + Intravenous Immunoglobulin (IVIG) as Agents to Reduce Donor-Specific Anti-HLA Antibodies (DSA) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Kidney Transplantation|Completed||Phase 1/Phase 2|10|Actual|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 21:23:58.489765|2018-05-31 21:23:58.489765
NCT01594411|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2013-09-03||2018-02-21|2012-05-08|2012-05-09|Estimate|2014-04-15|2014-04-23|Estimate||||2018-02-21|2018-03-22|Actual|April 2012||2012-04-30|February 2018|2018-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Observational|IMPACT-PCP|Sequentially enrolled subjects meeting the inclusion/exclusion criteria and have a resulted CORUS CAD test.|PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis|Investigation of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Primary Care Practice Pattern|Completed|||251|Actual|CardioDx|"Prospective design may have influenced the diagnostic strategy; but historical controls had a similar diagnostic strategy.~Possible Selection bias; we believe these pts are typical of each practice. Appropriateness of care not evaluated"||1||f||||f||||||Samples Without DNA|"~     One 2.5 mL PAXgene (PreAnalytiXTM) (for RNA preservation) tube will be filled with~     approximately 7.5 ml of blood and sent to CardioDx, Inc. for analysis.~   "|||2018-05-31 21:23:58.677008|2018-05-31 21:23:58.677008
NCT01594398|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2016-06-29|2012-05-07|2012-05-09|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|ENCORE110||Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer|A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer|Completed||Phase 1|14|Actual|Syndax Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:23:58.902492|2018-05-31 21:23:58.902492
NCT01594385|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2014-05-10||2017-10-17|2012-05-07|2012-05-09|Estimate|2017-04-24|2017-05-30|Actual||||2017-10-17|2017-11-20|Actual|April 2010||2010-04-30|October 2017|2017-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|OASIT||Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients|Seprafilm in Open Abdomens: a Prospective Evaluation of Wound and Adhesion Characteristics in Trauma Damage Control (OASIT)|Completed||N/A|30|Actual|St. Luke's Hospital and Health Network, Pennsylvania||2|||f||||t||||||||No|Currently, the only available data is de-identified dataset without any linkages to the original data. Data storage currently past record-keeping requirements. Study was permanently closed in June 2014.|2018-05-31 21:23:59.025511|2018-05-31 21:23:59.025511
NCT01594372|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-05-07|2012-05-07|2012-05-09|Estimate|||||||2015-05-07|2015-05-08|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparison of Laparoscopic to Vaginal Surgical Repair for Uterine Prolapse|Randomized Trial Comparing Vaginal Hysterectomy to Laparoscopic Supracervical Hysterectomy With Vault Suspension for Symptomatic Uterine Prolapse|Terminated||N/A|14|Actual|Brigham and Women's Hospital||2||"Laproscopic procedure not offered at this time; will not be offered for the foreseeable, thus~   we are unable to randomize participants between the two arms."|f||||f||||||||||2018-05-31 21:23:59.342217|2018-05-31 21:23:59.342217
NCT01594359|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-11-30|2012-05-07|2012-05-09|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Nutrition Study of Effect of High Iron Beans on Iron Status|Efficacy of Iron Biofortified Beans in Improving the Iron Status of Rwandan Adolescent Girls: A Randomized Control Trial|Completed||N/A|300|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 21:23:59.406601|2018-05-31 21:23:59.406601
NCT01594346|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-05-08|2012-05-08|2012-05-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|September 2000||2000-09-30|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Multicenter Vitamin E Trial in Aging Persons With Down Syndrome||Completed||Phase 3|349|Actual|New York State Institute for Basic Research||2|||f||||t||||||||||2018-05-31 21:23:59.497276|2018-05-31 21:23:59.497276
NCT01594333|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-04-03|2012-05-07|2012-05-09|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2013||2013-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CIRT||Cardiovascular Inflammation Reduction Trial|A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome|Active, not recruiting||Phase 3|7000|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 21:23:59.645302|2018-05-31 21:23:59.645302
NCT01594320|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-02-05|2012-05-07|2012-05-09|Estimate|||||||2014-02-05|2014-02-06|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|August 2013|Actual|2013-08-31|July 2012|Actual|2012-07-31||Interventional|||A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1|A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 1.|Completed||Phase 1|333|Actual|Novavax||6|||f||||t||||||||||2018-05-31 21:24:00.535728|2018-05-31 21:24:00.535728
NCT01594307|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2012-05-08|2012-05-08|2012-05-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|April 2012|Actual|2012-04-30|||||Observational|||Blood Pressure Monitor Clinical Test (Cuff Range: 13.5 Cm-22cm)||Completed|||85|Actual|Andon Health Co., Ltd|||2||f||||f||||||||||2018-05-31 21:24:00.632114|2018-05-31 21:24:00.632114
NCT01594294|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2014-06-27||2014-06-27|2012-05-07|2012-05-09|Estimate|2014-06-27|2014-07-25|Estimate||||2014-06-27|2014-07-25|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ID11-56|This analysis population includes all participants who completed the study as per the protocol.|An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues|EVALUATION OF THE EFFECTS OF CLEAR CARE® / AOSEPT® PLUS HYDROGEN PEROXIDE SOLUTION ON THE EYELID TISSUES - Part III: COMPARATIVE EVALUATION WITH RENU® MPS OVER 3 MONTH OF WEAR - CONTROL EVALUATION WITH AIR OPTIX® AQUA and ACUVUE® 2®|Completed||N/A|100|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 21:24:00.710567|2018-05-31 21:24:00.710567
NCT01594281|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2018-04-18|2012-05-07|2012-05-09|Estimate|||||||2018-04-18|2018-04-19|Actual|December 11, 2012|Actual|2012-12-11|April 2018|2018-04-30|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|PRIDE||Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)|Multicenter Randomized Open-label Three-arms Controlled 12 Months Clinical Proof of Concept Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy|Completed||Phase 4|107|Actual|Novartis||3|||f|||||f|f||||||No||2018-05-31 21:24:00.961855|2018-05-31 21:24:00.961855
NCT01594268|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-03-17|2012-05-07|2012-05-09|Estimate|||||||2017-03-17|2017-03-21|Actual|March 2012||2012-03-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CERKI||A Prospective, Open Label Study of CERtican in KIdney Transplantation|A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients|Completed||Phase 4|54|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:24:01.059229|2018-05-31 21:24:01.059229
NCT01594255|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-05-07|2012-05-07|2012-05-09|Estimate|||||||2012-05-07|2012-05-09|Estimate|July 2009||2009-07-31|May 2012|2012-05-31||||September 2009|Actual|2009-09-30||Interventional|||CAEB071 Thorough QTc Study in Healthy Volunteers|A Randomized, Partially Blinded, 4-period, Crossover Study to Assess the Effects of Single-dose AEB071 Administration (300 and 900 mg) on Electrocardiographic QT Intervals Compared to Placebo in Healthy Volunteers|Completed||Phase 1|100|Actual|Novartis||4|||f||||||||||||||2018-05-31 21:24:01.115935|2018-05-31 21:24:01.115935
NCT01594242|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-09-23|2012-05-08|2012-05-09|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2012||2012-04-30|September 2016|2016-09-30||||June 2015|Actual|2015-06-30||Interventional|||Autophagy Induction After Bortezomib for Myeloma|A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma|Active, not recruiting||Early Phase 1|11|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:24:01.174809|2018-05-31 21:24:01.174809
NCT01594229|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-01-03|2012-05-07|2012-05-09|Estimate|||||||2018-01-03|2018-01-05|Actual|June 6, 2012|Actual|2012-06-06|January 2018|2018-01-31|October 26, 2020|Anticipated|2020-10-26|October 26, 2020|Anticipated|2020-10-26||Interventional|||A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|60|Actual|AbbVie||1|||f||||f|t|f|||f|||No||2018-05-31 21:24:01.227651|2018-05-31 21:24:01.227651
NCT01594216|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2016-09-23|2012-05-08|2012-05-09|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2012||2012-04-30|September 2016|2016-09-30||||April 2016|Actual|2016-04-30||Interventional|||Ruxolitinib in Estrogen Receptor Positive Breast Cancer|A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer)|Active, not recruiting||Phase 2|29|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:24:01.319993|2018-05-31 21:24:01.319993
NCT01594203|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-07|2012-05-07|2012-05-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|May 2013|Anticipated|2013-05-31|November 2012|Anticipated|2012-11-30||Observational|||Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma||Unknown status|Not yet recruiting||30|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 21:24:01.383822|2018-05-31 21:24:01.383822
NCT01594190|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-05-08|2012-05-07|2012-05-08|Estimate|||||||2012-05-08|2012-05-09|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|||Physical Activity Immediately After Acute Cerebral Ischemia|Physical Activity Immediately After Acute Cerebral Ischemia: Too Little or Too Much - a Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|250|Anticipated|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-05-31 21:24:01.452026|2018-05-31 21:24:01.452026
NCT01594177|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2014-03-12|2012-05-07|2012-05-08|Estimate|||||||2014-03-12|2014-03-13|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|DAFNE||Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy|Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy|Completed||Phase 2|65|Actual|German Breast Group||1|||f||||t||||||||||2018-05-31 21:24:01.512003|2018-05-31 21:24:01.512003
NCT01594164|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-10-19|2012-05-07|2012-05-08|Estimate|||||||2012-10-19|2012-10-22|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Clinical Study to Assess Change in Upper Airway Geometry Between Upright and Supine Position|Clinical Study to Assess Change in Upper Airway Geometry Between Upright and Supine Position|Completed||Phase 1|20|Actual|FLUIDDA nv|||||f||||f||||||||||2018-05-31 21:24:01.580406|2018-05-31 21:24:01.580406
NCT01594151|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-10-19|2012-05-07|2012-05-08|Estimate|||||||2012-10-19|2012-10-22|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Modelling of the Upper Airway in Children With Controlled Asthma|Modelling of the Upper Airway in Children With Controlled Asthma|Completed||Phase 2|20|Actual|FLUIDDA nv|||||f||||f||||||||||2018-05-31 21:24:01.627384|2018-05-31 21:24:01.627384
NCT01594138|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2017-02-13|2012-05-07|2012-05-08|Estimate|||||||2017-02-13|2017-02-15|Actual|September 2009||2009-09-30|February 2017|2017-02-28|July 2014|Actual|2014-07-31|November 2011|Actual|2011-11-30||Observational|||Linguistic Characteristics of Suicidal Patients in the Emergency Department|Linguistic Characteristics of Suicidal Patients in the ED (Emergency Department)|Completed|||60|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f|f|f||||||No|There is no plan to make individual participant data available.|2018-05-31 21:24:01.683147|2018-05-31 21:24:01.683147
NCT01590485|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-01-28|2012-05-01|2012-05-03|Estimate|||||||2013-01-28|2013-01-29|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Evaluation of the Effect of Saffron (Crocus Sativus) on Pain Control After Root Canal Therapy in Teeth With Vital Pulps||Completed||N/A|36|Actual|Zahedan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:24:50.879985|2018-05-31 21:24:50.879985
NCT01594125|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2015-11-17||2016-01-11|2012-05-07|2012-05-08|Estimate|2015-11-17|2015-12-22|Estimate||||2016-01-11|2016-02-12|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma|An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma.|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:24:01.766063|2018-05-31 21:24:01.766063
NCT01594112|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-03-16|2012-05-07|2012-05-08|Estimate|||||||2017-03-16|2017-03-17|Actual|March 15, 2012|Actual|2012-03-15|March 2017|2017-03-31|April 1, 2015|Actual|2015-04-01|September 27, 2013|Actual|2013-09-27||Observational|THORN||Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.|Inappropriate Therapies and Home Monitoring® in Implantable Cardioverter Defibrillators (ICD)|Completed|||512|Actual|Biotronik SE & Co. KG|||1||f||||t|f|f||||||No||2018-05-31 21:24:03.483614|2018-05-31 21:24:03.483614
NCT01594099|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-05-06|2012-05-06|2012-05-08|Estimate|||||||2012-05-06|2012-05-08|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|March 2014|Anticipated|2014-03-31|October 2013|Anticipated|2013-10-31||Interventional|||Concurrent Chemoradiotherapy for Cervical Cancer in Elderly Women|Weekly Cisplatin or Weekly Liposome Paclitaxel Concurrent Radiation Therapy in Treating Elderly People With Cervical Cancer|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|Health Science Center of Xi’an Jiaotong University||3|||f||||t||||||||||2018-05-31 21:24:03.720103|2018-05-31 21:24:03.720103
NCT01594086|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2013-07-14|2012-05-06|2012-05-08|Estimate|||||||2013-07-14|2013-07-16|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Green Tea Consumption on Homocysteine Metabolism and Cognitive Dysfunction|Effects of Green Tea Consumption on Homocysteine Metabolism and Cognitive Dysfunction in Elderly: An Exploratory Clinical Study|Completed||N/A|15|Anticipated|University of Shizuoka||1|||f||||f||||||||||2018-05-31 21:24:03.799697|2018-05-31 21:24:03.799697
NCT01594073|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-08-13|2012-05-07|2012-05-08|Estimate|||||||2017-08-13|2017-08-16|Actual|April 2012||2012-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|BIOMARKERICD||Evaluation of Novel Biomarkers to Improve Risk Stratification and Patient Selection in Implantable Cardioverter-defibrillator (ICD) Therapy|Evaluation of Novel Biomarkers to Improve Risk Stratification and Patient Selection in ICD Therapy|Active, not recruiting|||500|Anticipated|Hannover Medical School|||||f||||f||||||Samples With DNA|"~     Serum, plasma (EDTA, heparin), monocytes, DNA~   "|||2018-05-31 21:24:03.871127|2018-05-31 21:24:03.871127
NCT01594060|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2018-02-27|2012-05-07|2012-05-08|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2012||2012-06-30|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards|A Randomized, Comparative Study of Basal-bolus Insulin Versus Conventional Sliding-scale Regular Insulin Therapy in Management of Non-critically Ill Patients Hospitalized in the Medical Ward.|Completed||Phase 4|36|Actual|HaEmek Medical Center, Israel||2|||f|||||f|f||||||||2018-05-31 21:24:03.938456|2018-05-31 21:24:03.938456
NCT01594047|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2012-05-15|2012-05-07|2012-05-08|Estimate|||||||2012-05-15|2012-05-16|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone|Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone|Unknown status|Recruiting|N/A|96|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||4|||f||||f||||||||||2018-05-31 21:24:03.999309|2018-05-31 21:24:03.999309
NCT01594034|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-05-11|2012-05-07|2012-05-08|Estimate|||||||2012-05-11|2012-05-14|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Effects of Hemoperitoneum Driven Carbon Monoxide on Post-Traumatic Stability and Platelet Aggregation|Effects of Hemoperitoneum Driven Carbon Monoxide on Post-Traumatic Stability|Completed|||9|Actual|The University of Texas Health Science Center at San Antonio|||1||f||||f||||||||||2018-05-31 21:24:04.086144|2018-05-31 21:24:04.086144
NCT01594021|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2016-10-28|2012-05-05|2012-05-08|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|NICOM-MAP||Efficacy of Preemptive Volume Loading to Prevent Arterial Hypotension During Induction of General Anesthesia|Efficacy of Preemptive Volume Loading to Prevent Arterial Hypotension During Induction of General Anesthesia|Terminated||Phase 4|17|Actual|Hopital Foch||2||Difficulty of realization of the study|f||||f||||||||||2018-05-31 21:24:04.151777|2018-05-31 21:24:04.151777
NCT01594008|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-03-20|2012-05-04|2012-05-08|Estimate|||||||2015-03-20|2015-03-24|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|FL89||The Effects of Antioxidants in Blueberry Powder on Inflammation Induced by a Single High Fat Meal.|Does Blueberry Intake Alleviate Postprandial Lipemia-induced Inflammation?|Completed||N/A|43|Actual|USDA, Western Human Nutrition Research Center|||||f||||f||||||||||2018-05-31 21:24:04.230128|2018-05-31 21:24:04.230128
NCT01593995|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2014-11-02|2012-05-07|2012-05-08|Estimate|||||||2014-11-02|2014-11-04|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|||EGF Ointment for Erlotinib Skin Lesion|Phase II Trial of Epidermal Growth Factor Ointment for Patients With Erlotinib Related Skin Effects|Completed||Phase 2|52|Actual|Dong-A University Hospital||1|||f||||t||||||||||2018-05-31 21:24:04.297011|2018-05-31 21:24:04.297011
NCT01593982|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-05-22|2012-05-07|2012-05-08|Estimate|||||||2012-05-22|2012-05-23|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|August 2012|Anticipated|2012-08-31||Interventional|rTMSinADHD||Repetitive Transcranial Magnetic Stimulation in Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts|Effect of Repetitive Transcranial Magnetic Stimulation on Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 21:24:04.378938|2018-05-31 21:24:04.378938
NCT01593969|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-08-15|2012-05-07|2012-05-08|Estimate|||||||2014-08-15|2014-08-18|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|Njugu Plus||A Trial of n-3 PUFA-Enriched Ready to Use Therapeutic Food for Childhood Severe Malnutrition|A Randomised Controlled Trial of n-3 Polyunsaturated Fatty Acid-Enriched Therapeutic Food for Childhood Severe Malnutrition|Completed||Phase 2|60|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 21:24:04.469011|2018-05-31 21:24:04.469011
NCT01593956|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-05-22|2012-05-07|2012-05-08|Estimate|||||||2013-05-22|2013-05-23|Estimate|March 2012||2012-03-31|May 2013|2013-05-31||||July 2013|Anticipated|2013-07-31||Interventional|||Influence of Transcranial Direct Current Stimulation on Cortical Plasticity in Concussed Athletes|Influence of Anodal Transcranial Direct Current Stimulation on Cortical Plasticity in Concussed Athletes and Healthy Volunteers|Unknown status|Recruiting|N/A|30|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:24:04.636338|2018-05-31 21:24:04.636338
NCT01593943|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-12-03|2012-05-07|2012-05-08|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CHARM||Gender Equity-Focused, Male-Centered Family Planning for Rural India|Gender Equity-Focused, Male-Centered Family Planning for Rural India|Completed||Phase 3|2162|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:24:04.711119|2018-05-31 21:24:04.711119
NCT01593930|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2013-01-28|2012-05-07|2012-05-08|Estimate|||||||2013-01-28|2013-01-29|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Evaluation of the Success Rate of Pulpal Anesthesia in Mandibular First Molar Following Infiltration of 4% Articaine Alone and as Supplemental Injection After Inferior Alveolar Nerve Block||Completed||N/A|60|Actual|Zahedan University of Medical Sciences||4|||f||||f||||||||||2018-05-31 21:24:04.777714|2018-05-31 21:24:04.777714
NCT01593917|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-11-16|2012-05-04|2012-05-08|Estimate|||||||2017-11-16|2017-11-20|Actual|June 2012||2012-06-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Long Term Follow Up Study of the St. Jude Medical Trifecta Valve|Long Term Follow Up Study of the St. Jude Medical Trifecta™ Valve|Active, not recruiting|||329|Actual|St. Jude Medical|||1||f||||t||||||||||2018-05-31 21:24:04.917917|2018-05-31 21:24:04.917917
NCT01593904|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2012-05-06|2012-05-06|2012-05-08|Estimate|||||||2012-05-06|2012-05-08|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|||||Observational|VERIFYMS||Venous Irregularities, Flow and Perfusion in MS Study|Venous Irregularities, Flow and Perfusion in MS Study|Unknown status|Recruiting||400|Anticipated|Synergy Health Concepts, Inc.|||||f||||t||||||||||2018-05-31 21:24:05.004247|2018-05-31 21:24:05.004247
NCT01593891|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2012-05-06|2012-05-06|2012-05-08|Estimate|||||||2012-05-06|2012-05-08|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|||||Observational|Resrch_Reg_2||Radiographic and Intravascular (IVUS) Evaluation of Venous Morphology During CCSVI Treatment|Radiographic and Intravascular (IVUS) Evaluation of Venous Morphology During CCSVI Treatment|Unknown status|Active, not recruiting||45|Actual|Synergy Health Concepts, Inc.|||||f||||t||||||||||2018-05-31 21:24:05.075347|2018-05-31 21:24:05.075347
NCT01593878|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-03-24|2012-05-07|2012-05-08|Estimate|||||||2014-03-24|2014-03-26|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Media Background and Test Performance||Withdrawn||N/A|0|Actual|Seattle Children's Hospital||2|||f||||||||||||||2018-05-31 21:24:05.133299|2018-05-31 21:24:05.133299
NCT01593865|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2012-08-17|2012-05-07|2012-05-08|Estimate|||||||2012-08-17|2012-08-21|Estimate|April 2012||2012-04-30|August 2012|2012-08-31||||June 2014|Anticipated|2014-06-30||Observational|CATHEXIS||The Catholic University BIMA Grafting Study|Observational, Case-Control, Propensity-Matched Study of Bilateral Versus Monolateral Internal Mammary Artery Grafting for Severe Coronary Artery Disease. Assessment of Feasibility of Systematic Bilateral Mammary Artery Grafting and Early/Late Clinical Outcomes|Unknown status|Recruiting||1000|Anticipated|Catholic University, Italy|||2||f||||||||||||||2018-05-31 21:24:05.192642|2018-05-31 21:24:05.192642
NCT01593852|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2013-12-09||2014-02-17|2012-05-07|2012-05-08|Estimate|2013-12-09|2014-01-29|Estimate||||2014-02-17|2014-03-18|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||X-ray Dose Reduction in Electrophysiology|X-ray Dose Reduction in Electrophysiology|Completed||N/A|136|Actual|Philips Healthcare||2|||f||||f||||||||||2018-05-31 21:24:05.295877|2018-05-31 21:24:05.295877
NCT01593839|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-05-07|2012-05-07|2012-05-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Observational|||Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism|Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism|Unknown status|Recruiting||6|Anticipated|Oslo University Hospital|||||f||||t||||||Samples Without DNA|"~     Interstitial~   "|||2018-05-31 21:24:05.626104|2018-05-31 21:24:05.626104
NCT01593826|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-11-21|2012-05-04|2012-05-08|Estimate|||||||2012-11-21|2012-11-22|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler|Pharmacokinetic Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 320/9 Microg/Inhalation and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|72|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 21:24:05.697648|2018-05-31 21:24:05.697648
NCT01593813|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-05-07|2012-05-07|2012-05-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|PQ||Repair or Not Repair Pronator Quadratus in the Volar Plating of Distal Radial Fracture Are Functional Outcomes Differ ?|Repair or Not Repair Pronator Quadratus in the Volar Plating of Distal Radial Fracture-Are Functional Outcomes Differ ?|Unknown status|Active, not recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 21:24:05.761839|2018-05-31 21:24:05.761839
NCT01593800|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2016-04-05|2012-05-06|2012-05-08|Estimate|||||||2016-04-05|2016-04-06|Estimate|May 2012||2012-05-31|February 2012|2012-02-29|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|PLI||The Effect of Probiotics on Lactose Intolerance|The Effect of Probiotics on Lactose Intolerance|Completed||N/A|60|Actual|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 21:24:05.808698|2018-05-31 21:24:05.808698
NCT01593787|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2015-07-08||2015-08-07|2012-05-07|2012-05-08|Estimate|2015-08-07|2015-08-13|Estimate||||2015-08-07|2015-08-13|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction|A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction|Completed||Phase 3|32|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:24:05.887826|2018-05-31 21:24:05.887826
NCT01593774|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2013-04-08|2012-05-07|2012-05-08|Estimate|||||||2013-04-08|2013-04-09|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Melatonin for Prevention of Metabolic Side Effects of Olanzapine|Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.|Completed||Phase 2|36|Actual|Guilan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:24:06.248567|2018-05-31 21:24:06.248567
NCT01593761|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2012-12-27|2012-05-06|2012-05-08|Estimate|||||||2012-12-27|2012-12-31|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|CG400549||Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus|Phase 2a, Repeated-dose, Open-label, Single-arm Study of CG400549 for the Treatment of Complicated Acute Bacterial Skin and Skin Structure Infection (cABSSSI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)|Completed||Phase 2|20|Actual|CrystalGenomics, Inc.||1|||f||||f||||||||||2018-05-31 21:24:06.410703|2018-05-31 21:24:06.410703
NCT01593748|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2018-05-17|2012-05-07|2012-05-08|Estimate|||||||2018-05-17|2018-05-21|Actual|May 2012||2012-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2, 2018|Anticipated|2018-11-02||Interventional|||A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma|A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma|Active, not recruiting||Phase 2|90|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:24:06.504396|2018-05-31 21:24:06.504396
NCT01593735|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-01-21|2012-05-04|2012-05-08|Estimate|||||||2015-01-21|2015-01-22|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2748 in Hepatitis C-Infected Participants|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 21:24:06.602083|2018-05-31 21:24:06.602083
NCT01593722|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|2015-12-02||2016-09-20|2012-05-05|2012-05-08|Estimate|2016-09-20|2016-11-09|Estimate||||2016-09-20|2016-11-09|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis|Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection|Completed||Phase 4|155|Actual|National Institutes of Health Clinical Center (CC)|Small number of subjects analyzed|2|||f||||t||||||||||2018-05-31 21:24:06.754836|2018-05-31 21:24:06.754836
NCT01593709|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2018-04-03|2012-05-05|2012-05-08|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 15, 2012||2012-05-15|March 27, 2018|2018-03-27||||||||Observational|||Volunteer Screening for Vaccine and Antivirals Clinical Trials|Screening of Volunteers for Clinical Trials of Investigational and Licensed Vaccines, Antiviral Products, or Live Virus Challenge Studies|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:24:07.107011|2018-05-31 21:24:07.107011
NCT01593696|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2018-05-18|2012-05-05|2012-05-08|Estimate|||||||2018-05-18|2018-05-21|Actual|April 12, 2012||2012-04-12|April 9, 2018|2018-04-09|October 2, 2017|Actual|2017-10-02|November 11, 2016|Actual|2016-11-11||Interventional|||Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma|Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies|Completed||Phase 1|53|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:24:07.189724|2018-05-31 21:24:07.189724
NCT01593683|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2013-07-09|2012-05-07|2012-05-08|Estimate|||||||2013-07-09|2013-07-10|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||Waitlist-controlled Trial of a Psychological Education Program for Nurses|Waitlist-controlled Trial of a Psychological Education Program for Nurses|Unknown status|Active, not recruiting|N/A|42|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:24:07.273678|2018-05-31 21:24:07.273678
NCT01593670|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|2017-03-29||2017-12-03|2012-05-07|2012-05-08|Estimate|2017-05-17|2017-06-14|Actual||||2017-12-03|2017-12-05|Actual|March 2013||2013-03-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|October 2015|Actual|2015-10-31||Interventional|||Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes|Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS)|Terminated||Phase 2|9|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 21:24:07.370046|2018-05-31 21:24:07.370046
NCT01593657|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2017-07-28|2012-05-04|2012-05-08|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2012|Actual|2012-05-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Mindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery|Mindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery|Completed||N/A|10|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 21:24:07.636196|2018-05-31 21:24:07.636196
NCT01593644|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-06|||2012-09-06|2012-05-07|2012-05-08|Estimate|||||||2012-09-06|2012-09-07|Estimate|June 2011||2011-06-30|September 2012|2012-09-30||||March 2013|Anticipated|2013-03-31||Interventional|||Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler|Phase 2, Monocentric, Single Blind Study, Comparing the Efficacy and Tolerance of a Dipyridamole/Adenosine Combination Given Intravenously, as a Slow Bolus and at Low Doses to Adenosine Alone for Coronary Flow Reserve Assessment (in Patients With Stable Ischemic Heart Disease) Using Transthoracic Echodoppler|Unknown status|Recruiting|Phase 2|75|Anticipated|Adenobio N.V||1|||f||||f||||||||||2018-05-31 21:24:07.705197|2018-05-31 21:24:07.705197
NCT01593631|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-05-07|2012-05-07|2012-05-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Acid Lactase in Combination With Yoghurt Bacteria for Improvement of Lactose Digestion in Lactose Malabsorbers|A Combination of Yoghurt Bacteria and Acid Lactase From Aspergillus Oryzae Improves Lactose Digestion in Lactose Malabsorbers More Reliably Than Preparations Containing Acid Lactase or Yoghurt Bacteria Alone|Completed||N/A|24|Actual|Vitacare Gmbh & Co. KG||5|||f||||||||||||||2018-05-31 21:24:07.806285|2018-05-31 21:24:07.806285
NCT01593618|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-11-29|2012-05-07|2012-05-08|Estimate|||||||2017-11-29|2017-12-02|Actual|August 2007||2007-08-31|November 2017|2017-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Empowering Cancer Survivors Through Information Technology|Empowering Cancer Survivors Through Information Technology|Completed||N/A|53|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||f||||||||||2018-05-31 21:24:07.875882|2018-05-31 21:24:07.875882
NCT01593605|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2013-09-18|2012-05-07|2012-05-08|Estimate|||||||2013-09-18|2013-09-20|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Resveratrol-Leucine Metabolite Synergy in Pre-diabetes|Resveratrol-Leucine Metabolite Synergy in Pre-diabetes|Completed||N/A|36|Actual|Vanderbilt University||3|||f||||t||||||||||2018-05-31 21:24:07.944268|2018-05-31 21:24:07.944268
NCT01593592|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|2015-03-07||2015-07-19|2012-05-07|2012-05-08|Estimate|2015-07-19|2015-08-17|Estimate||||2015-07-19|2015-08-17|Estimate|June 2012||2012-06-30|July 2015|2015-07-31||||January 2013|Actual|2013-01-31||Interventional||All were dyspeptic patients|Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients|Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients: a Double Blind Placebo Controlled Randomized Clinical Trial|Completed||N/A|70|Actual|Zagazig University|no limitations|2|||f||||t||||||||||2018-05-31 21:24:08.033538|2018-05-31 21:24:08.033538
NCT01593579|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-12-18|2012-05-07|2012-05-08|Estimate|||||||2014-12-18|2014-12-23|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Observational|||Autonomic Phenotype Before and After Akt Inhibition|Autonomic Phenotype Before and After Akt Inhibition: Akt Therapy for Melanoma Sub-study|Withdrawn|||0|Actual|Vanderbilt University|||1|Planned parent study never enrolled|f||||f||||||||||2018-05-31 21:24:08.233805|2018-05-31 21:24:08.233805
NCT01593566|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-04-08|2012-05-07|2012-05-08|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|FNB for ACLR||Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction|Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction|Completed||Phase 4|100|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 21:24:08.291572|2018-05-31 21:24:08.291572
NCT01593553|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-11-17|2012-05-07|2012-05-08|Estimate|||||||2017-11-17|2017-11-20|Actual|March 2012||2012-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden|Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden.|Active, not recruiting||N/A|7173|Actual|Karolinska University Hospital||2|||f||||||||||||||2018-05-31 21:24:08.361435|2018-05-31 21:24:08.361435
NCT01593540|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-28|||2012-05-07|2012-05-07|2012-05-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Clinical Examination of Metal Free Interdental Brushes|Clinical Efficacy and Patient Acceptance of Metal and Metal-Free Interdental Brushes: A Controlled Prospective Randomized Study|Completed||Phase 4|39|Actual|University of Freiburg||2|||f||||f||||||||||2018-05-31 21:24:08.424219|2018-05-31 21:24:08.424219
NCT01593527|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-04-19|2012-05-04|2012-05-08|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2012||2012-09-30|August 2013|2013-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease|A Randomized Double-blind Active-controlled Trial of Canakinumab Versus Triamcinolone Acetonide on Reducing the Proportion of Patients With Any New Gouty Arthritis Flare(s) in Patients With Chronic Kidney Disease|Withdrawn||Phase 3|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:24:08.486364|2018-05-31 21:24:08.486364
NCT01593514|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-11-29|2012-05-04|2012-05-08|Estimate|||||||2016-11-29|2016-11-30|Estimate|December 2012||2012-12-31|November 2016|2016-11-30||||April 2013|Actual|2013-04-30||Interventional|||Understanding the Immune Response to Two Different Meningitis Vaccines|A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine|Completed||Phase 4|20|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 21:24:08.545197|2018-05-31 21:24:08.545197
NCT01593501|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2016-10-31|2012-05-07|2012-05-08|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional|||How Does Magnesium Status Influence Calcium Homeostasis?|How Does Magnesium Status Influence Calcium Homeostasis?|Completed||Phase 4|39|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 21:24:08.71048|2018-05-31 21:24:08.71048
NCT01593488|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2017-03-28|2012-05-04|2012-05-08|Estimate|||||||2017-03-28|2017-03-29|Actual|March 2012||2012-03-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|CILI||Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children|Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement|Recruiting||Phase 2|31|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 21:24:08.798058|2018-05-31 21:24:08.798058
NCT01593475|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-01-01|2012-05-04|2012-05-08|Estimate|||||||2018-01-01|2018-01-03|Actual|September 5, 2011|Actual|2011-09-05|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma|A Phase II Study of Induction Chemotherapy With Gemcitabine and Cisplatin Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Pancreatic Carcinoma|Completed||Phase 2|44|Actual|National Cancer Center, Korea||1|||f||||f||||||||No||2018-05-31 21:24:08.883769|2018-05-31 21:24:08.883769
NCT01593462|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-01-20|2012-05-04|2012-05-08|Estimate|||||||2017-01-20|2017-01-24|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparative Effectiveness of MR Enterography|Comparative Effectiveness of MR Enterography, Enteric Ultrasound, and Ultrasound Elastography Imaging in the Evaluation of Pediatric Small Bowel Crohn Disease|Completed||N/A|30|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 21:24:09.004679|2018-05-31 21:24:09.004679
NCT01593449|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-04-11|2012-05-07|2012-05-08|Estimate|||||||2013-04-11|2013-04-15|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Community-based Social Networking Intervention to Increase Walking in Dog Owners|A Community-based Social Networking Intervention to Increase Walking in Dog Owners|Completed||Phase 1|107|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 21:24:09.068159|2018-05-31 21:24:09.068159
NCT01593436|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-04-30|2012-05-07|2012-05-08|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2011|Actual|2011-07-31|April 2018|2018-04-30|July 2015|Actual|2015-07-31|November 2011|Actual|2011-11-30||Interventional|||Mindfulness and RelaxationTraining for Insomnia (MRTI) on Postmenopausal Women: a Randomized Clinical Trial.|The Effects of Mindfulness and RelaxationTraining for Insomnia (MRTI) on Postmenopausal Women: a Randomized Clinical Trial.|Completed||N/A|54|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:24:09.130634|2018-05-31 21:24:09.130634
NCT01593423|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-11-15|2012-05-04|2012-05-08|Estimate|||||||2016-11-15|2016-11-17|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Food Security and Nutrition in Rural Cambodia|Integration of Small-scale Aquaculture With Homestead Food Production for Improved Household Food Security and Nutrition in Rural Cambodia|Completed||N/A|900|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 21:24:09.197081|2018-05-31 21:24:09.197081
NCT01593410|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-09-18|2012-05-07|2012-05-08|Estimate|||||||2017-09-18|2017-09-20|Actual|August 1, 2010|Actual|2010-08-01|September 2017|2017-09-30|January 3, 2013|Actual|2013-01-03|January 3, 2013|Actual|2013-01-03||Interventional|||Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma|A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|194|Actual|Celgene||1|||f||||f||||||||||2018-05-31 21:24:09.257195|2018-05-31 21:24:09.257195
NCT01593397|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2017-12-27|2012-05-04|2012-05-08|Estimate|||||||2017-12-27|2017-12-29|Actual|November 2011||2011-11-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity|Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity|Completed||Phase 1|100|Actual|Stanford University||1|||f||||t||||||||Yes|pharmacokinetic models will be published after data analysis and study completion|2018-05-31 21:24:09.384141|2018-05-31 21:24:09.384141
NCT01593384|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2016-02-15|2012-05-07|2012-05-08|Estimate|||||||2016-02-15|2016-02-17|Estimate|April 2012||2012-04-30|February 2016|2016-02-29||||February 2013|Actual|2013-02-28||Observational|||Prospective Chart-Review: Impact of Combination - Digital Breast Tomosynthesis + Digital Mammography|To Determine the Clinical Impact of the Combination of Digital Breast Tomosynthesis and Digital Mammography on Screening for Breast Cancer|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||Funding unavailable|f||||f||||||||||2018-05-31 21:24:09.476675|2018-05-31 21:24:09.476675
NCT01593371|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2012-05-08|2012-05-07|2012-05-08|Estimate|||||||2012-05-08|2012-05-09|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients|Comparing Effects of Metformin and Pioglitazone on Regulation of Serum Adipokines in Newly Diagnosed Type 2 Diabetes Patients|Completed||N/A|98|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:24:09.550824|2018-05-31 21:24:09.550824
NCT01593358|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-05|||2012-05-05|2012-05-05|2012-05-08|Estimate|||||||2012-05-05|2012-05-08|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|January 2014|Anticipated|2014-01-31|||||Observational|||Venous Obstruction in Neurodegenerative Disorders Research Registry|Venous Obstruction in Neurodegenerative Disorders Research Registry|Unknown status|Recruiting||2000|Anticipated|Synergy Health Concepts, Inc.|||||f||||t||||||||||2018-05-31 21:24:09.62238|2018-05-31 21:24:09.62238
NCT01593345|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-12-18|2012-05-05|2012-05-08|Estimate|||||||2015-12-18|2015-12-21|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Self-management of Chronic Mobility Limitations in MUHC Seniors|Promotion of Self-management of Chronic Mobility Limitations Among Vulnerable Seniors at the MUHC: Training the New Generation of Canadian Physiotherapists for This Role. Addendum: Planning Physiotherapy Services for Persons Treated at the MUHC for Cancer: A Needs Assessment|Completed||N/A|60|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 21:24:09.689413|2018-05-31 21:24:09.689413
NCT01593332|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-07|||2012-05-05|2012-05-05|2012-05-08|Estimate|||||||2012-05-05|2012-05-08|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis||Completed||Phase 4|44|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:24:09.778422|2018-05-31 21:24:09.778422
NCT01593319|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-04-17|2012-05-07|2012-05-08|Estimate|||||||2015-04-17|2015-04-21|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Is Regional Anesthesia of the Hip Preferable Over Traditional Analgesia in the Acute Stage of the Management of Patients With a Fracture of the Hip||Terminated||Phase 4|37|Actual|Landstinget i Värmland||2|||f||||t||||||||||2018-05-31 21:24:09.869207|2018-05-31 21:24:09.869207
NCT01593306|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-05-07|2012-05-07|2012-05-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|February 2013|Anticipated|2013-02-28|October 2012|Anticipated|2012-10-31||Interventional|||Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix||Unknown status|Recruiting|Phase 3|80|Anticipated|Indira Gandhi Medical College||2|||f||||t||||||||||2018-05-31 21:24:09.95565|2018-05-31 21:24:09.95565
NCT01593293|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-05-05|2012-05-05|2012-05-08|Estimate|||||||2012-05-05|2012-05-08|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Interventional|ACE||Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer|A Randomized, Open-label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 3|266|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:24:10.051948|2018-05-31 21:24:10.051948
NCT01593280|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-07|2012-05-07|2012-05-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|May 2012||2012-05-31|May 2012|2012-05-31||||February 2013|Anticipated|2013-02-28||Interventional|||TAP Catheters Versus Intrathecal Morphine for Cesarean Section|Quality of Recovery Following Administration of Transverse Abdominus Plane (TAP) Catheter as Compared to Intrathecal Morphine After Cesarean Delivery Under Spinal Anesthesia: a Prospective, Randomized Trial|Unknown status|Recruiting|N/A|80|Anticipated|Stamford Anesthesiology Services, PC||2|||f||||t||||||||||2018-05-31 21:24:10.143832|2018-05-31 21:24:10.143832
NCT01593267|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2017-08-09|2012-05-04|2012-05-08|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2002||2002-11-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|April 15, 2017|Actual|2017-04-15||Interventional|BRAT||Barrow Ruptured Aneurysm Trial|Barrow Ruptured Aneurysm Study|Active, not recruiting||N/A|500|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||No||2018-05-31 21:24:10.237507|2018-05-31 21:24:10.237507
NCT01593254|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2018-05-22|2012-05-07|2012-05-08|Estimate|||||||2018-05-22|2018-05-23|Actual|October 29, 2012|Actual|2012-10-29|May 2018|2018-05-31|February 17, 2022|Anticipated|2022-02-17|November 8, 2017|Actual|2017-11-08||Interventional|DASCERN||Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib|An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib|Active, not recruiting||Phase 2|288|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 21:24:10.327649|2018-05-31 21:24:10.327649
NCT01593241|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-04-12|2012-05-07|2012-05-08|Estimate|||||||2018-04-12|2018-04-17|Actual|June 15, 2012|Actual|2012-06-15|April 2018|2018-04-30|September 2038|Anticipated|2038-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Therapy De-escalation in Seminoma Stage IIA/B|Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma|Recruiting||Phase 2|115|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||No||2018-05-31 21:24:10.52332|2018-05-31 21:24:10.52332
NCT01593228|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30||2017-09-12|2017-09-12|2012-05-04|2012-05-08|Estimate||||2017-09-12|2017-09-19|Actual|2017-09-12|2017-09-19|Actual|May 2012||2012-05-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial|International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study|Completed||Phase 3|37|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:24:10.676379|2018-05-31 21:24:10.676379
NCT01593215|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2014-10-31||2015-01-07|2012-05-04|2012-05-08|Estimate|2015-01-07|2015-01-09|Estimate||||2015-01-07|2015-01-09|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|YOH1||Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant|Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant|Completed||Phase 2|50|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 21:24:10.783217|2018-05-31 21:24:10.783217
NCT01593202|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2018-04-30|2012-05-04|2012-05-08|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2012||2012-01-31|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Long Term Efficacy of DBT-A in Adolescents With Repetitive Self-harming and Suicidal Behaviours|Long Term Efficacy of Dialectical Behaviour Therapy vs Enhanced Usual Care for Adolescents With Self-Harming and Suicidal Behaviours|Active, not recruiting||N/A|77|Actual|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 21:24:11.06796|2018-05-31 21:24:11.06796
NCT01593189|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-10-13|2012-05-07|2012-05-08|Estimate|||||||2015-10-13|2015-10-15|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy Trial of the Kids in Transition to School (KITS) Program for Children With Developmental Disabilities and Behavioral Problems|A Randomized Efficacy Trial of the Kids in Transition to School (KITS) Program for Children With Developmental Disabilities and Behavioral Problems|Completed||N/A|209|Actual|Oregon Social Learning Center||2|||f||||f||||||||||2018-05-31 21:24:11.165269|2018-05-31 21:24:11.165269
NCT01593176|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-05-04|2012-05-04|2012-05-08|Estimate|||||||2015-05-04|2015-05-06|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|RSA||Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures|Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures|Unknown status|Recruiting||30|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:24:11.321404|2018-05-31 21:24:11.321404
NCT01593163|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-05-04|2012-05-04|2012-05-08|Estimate|||||||2012-05-04|2012-05-08|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus|Randomised Controlled Clinical Trial of Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus: a Pilot Study|Completed||Phase 3|49|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||2|||f||||t||||||||||2018-05-31 21:24:11.428875|2018-05-31 21:24:11.428875
NCT01593150|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-02-02|2012-05-07|2012-05-08|Estimate|||||||2015-02-02|2015-02-03|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation|Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation.|Completed||N/A|141|Actual|Odense University Hospital||3|||f||||||||||||||2018-05-31 21:24:11.536418|2018-05-31 21:24:11.536418
NCT01593137|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-07-01|2012-05-04|2012-05-07|Estimate|||||||2013-07-01|2013-07-02|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|ADELANTE||A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes|A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes|Withdrawn||Phase 4|0|Actual|Fundación Fernández-Cruz||2||Lack of patients with the criteria established in the protocol.|f||||f||||||||||2018-05-31 21:24:11.642339|2018-05-31 21:24:11.642339
NCT01593124|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-03-30|2012-05-04|2012-05-07|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Biomarkers||Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation|Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation|Completed||Phase 2|20|Actual|CONRAD||3|||f||||f||||||||||2018-05-31 21:24:11.741439|2018-05-31 21:24:11.741439
NCT01593111|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-02-02|2012-05-04|2012-05-07|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ERA||Comparative Effectiveness of Environmental Intervention and Standard Care in Ability to Reduce Pharmacologic Therapy for Asthma|Comparative Effectiveness of Environmental Intervention and Standard Care in Ability to Reduce Pharmacologic Therapy for Asthma|Completed||N/A|243|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 21:24:11.856671|2018-05-31 21:24:11.856671
NCT01593098|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2017-04-20|2012-05-04|2012-05-07|Estimate|||||||2017-04-20|2017-04-21|Actual|May 2010||2010-05-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|AN||A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)|A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)|Recruiting|||600|Anticipated|Chinese University of Hong Kong|||2||f||||f||||||Samples With DNA|"~     colonic biopsies, blood, stool~   "|||2018-05-31 21:24:11.95269|2018-05-31 21:24:11.95269
NCT01593085|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-02-05|2012-05-04|2012-05-07|Estimate|||||||2013-02-05|2013-02-06|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|DECAPAL||Evaluation of States in Major Depressive Patients With Cancer, Hospitalized in a Hospital Palliative|Evaluation of States in Major Depressive Patients With Cancer, Hospitalized in a Hospital Palliative|Completed|||55|Actual|Centre Francois Baclesse|||1||f||||f||||||||||2018-05-31 21:24:12.04224|2018-05-31 21:24:12.04224
NCT01593072|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-01-23|2012-05-04|2012-05-07|Estimate|||||||2013-01-23|2013-01-24|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers|Withdrawn||Phase 1|0|Actual|Sarepta Therapeutics||2||Terminated for convenience of the Government due to funding constraits|f||||t||||||||||2018-05-31 21:24:12.123413|2018-05-31 21:24:12.123413
NCT01592565|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-01-26|2012-05-03|2012-05-07|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2010||2010-08-31|January 2017|2017-01-31||||December 2014|Actual|2014-12-31||Interventional|EXACT||Exercise Cardiac Magnetic Resonance Imaging Accuracy for Cardiovascular Stress Testing|An In-state Multi-center Evaluation of Treadmill Exercise Stress Cardiac Magnetic Resonance|Completed||N/A|227|Actual|Ohio State University|||||f||||t||||||||||2018-05-31 21:24:20.899176|2018-05-31 21:24:20.899176
NCT01593059|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2014-04-25|2012-05-04|2012-05-07|Estimate|||||||2014-04-25|2014-04-28|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|||BIOFLOW-III Romania Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Romania|Terminated|||13|Actual|Biotronik Vertriebs-GmbH|||1|low enrollment|f||||f||||||||||2018-05-31 21:24:12.218629|2018-05-31 21:24:12.218629
NCT01593046|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2014-02-06|2012-05-03|2012-05-07|Estimate|||||||2014-02-06|2014-02-10|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects|A Randomized, Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects|Completed||Phase 1|43|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-05-31 21:24:12.305271|2018-05-31 21:24:12.305271
NCT01593033|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-01-11|2012-05-03|2012-05-07|Estimate|||||||2013-01-11|2013-01-14|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effectiveness of Micronutrient Supplementation and Fish Oil + Micronutrient Supplementation in the Treatment of Environmental Enteropathy|Randomized, Double-blind, Placebo-controlled Trial Evaluating the Impact of Micronutrient Supplementation and Fish Oil + Micronutrient Supplementation in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children|Completed||N/A|225|Actual|Washington University School of Medicine||3|||f||||||||||||||2018-05-31 21:24:12.431996|2018-05-31 21:24:12.431996
NCT01593020|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2018-05-08|2012-05-04|2012-05-07|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2012|Actual|2012-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2|A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2|Active, not recruiting||Phase 2|162|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:24:12.524425|2018-05-31 21:24:12.524425
NCT01593007|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-06-12|2012-05-04|2012-05-07|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Inspiratory Muscular Training|REGIONAL LUNG VENTILATION DISTRIBUTION AMONG INDIVIDUALS WITH CHRONIC HEART FAILURE AFTER AN INSPIRATORY MUSCLE TRAINING PROGRAMM: A RANDOMIZED CONTROLLED CLINICAL TRIAL|Completed||N/A|19|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 21:24:12.65344|2018-05-31 21:24:12.65344
NCT01592994|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2014-12-03|2012-05-04|2012-05-07|Estimate|||||||2014-12-03|2014-12-04|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|RHANI Wives||Enhancing HIV Risk Reduction Among Indian Women With Risky Husbands|Enhancing HIV Risk Reduction Among Indian Women With Risky Husbands|Completed||Phase 2|220|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:24:12.737764|2018-05-31 21:24:12.737764
NCT01592981|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-11-16|2012-05-04|2012-05-07|Estimate|||||||2017-11-16|2017-11-17|Actual|January 2013||2013-01-31|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|March 2017|Actual|2017-03-31||Interventional|R2W||Randomised Trial in Waldenstrom's Macroglobulinaemia|Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstrőm's Macroglobulinaemia (WM): a Randomized Phase II Trial|Active, not recruiting||Phase 2|60|Actual|University College, London||2|||f||||t||||||||||2018-05-31 21:24:12.81228|2018-05-31 21:24:12.81228
NCT01592968|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2018-01-09|2012-05-04|2012-05-07|Estimate|||||||2018-01-09|2018-01-11|Actual|August 2, 2012|Actual|2012-08-02|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Prospective Phase III Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy|A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases|Recruiting||Phase 3|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 21:24:12.934611|2018-05-31 21:24:12.934611
NCT01592955|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-06-15|2012-05-04|2012-05-07|Estimate|||||||2015-06-15|2015-06-16|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU)|Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound With the EyeOP1 Medical Device.|Completed||Phase 4|84|Actual|EyeTechCare||1|||f||||t||||||||||2018-05-31 21:24:13.025571|2018-05-31 21:24:13.025571
NCT01592942|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-03-07|2012-05-04|2012-05-07|Estimate|||||||2017-03-07|2017-03-08|Actual|August 2012||2012-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2016|Actual|2016-10-31||Interventional|||Mesh Fixation in Lichtenstein Hernioplasty|A Randomized Multi-center Study of Tissue Glue Fixation of Optilene™ Mesh With Histoacryl™ or Self-gripping Parietex ProGrip™ Compared to Conventional Non-absorbable Suture Fixation of Ultrapro™ Mesh|Recruiting||N/A|650|Anticipated|Kuopio University Hospital||3|||f||||f||||||||||2018-05-31 21:24:13.183908|2018-05-31 21:24:13.183908
NCT01592929|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2017-10-02|2012-05-04|2012-05-07|Estimate|||||||2017-10-02|2017-10-04|Actual|September 2012||2012-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation With Scans and Pharyngometry of the Possible Changes in Upper Airway Geometry Induced by Using Different Mouthpieces.|Assessment of the Effect of the Shape of an Inhaler's Mouthpiece on Upper Airway Geometry, Using Functional Respiratory Imaging and Pharyngometry.|Completed||N/A|12|Actual|FLUIDDA nv|||||f||||f||||||||||2018-05-31 21:24:13.282947|2018-05-31 21:24:13.282947
NCT01592916|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2018-02-01|2012-05-04|2012-05-07|Estimate|||||||2018-02-01|2018-02-02|Estimate|May 10, 2012|Actual|2012-05-10|February 2018|2018-02-28|November 23, 2012|Actual|2012-11-23|November 23, 2012|Actual|2012-11-23||Observational|||Acute Effects of Exercise in Women With Fibromyalgia (FM)|Acute Effects of Exercise in Women With FM|Completed|||55|Actual|Göteborg University|||2||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-05-31 21:24:13.352772|2018-05-31 21:24:13.352772
NCT01592760|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2015-12-21||2017-02-08|2012-05-03|2012-05-07|Estimate|2016-12-13|2017-02-08|Estimate||||2017-02-08|2017-03-17|Actual|May 2012||2012-05-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Air-Q® SP Versus Air-Q® and I-gel: A Randomized Clinical Trial|Comparison of the Air-Q® Self-Pressurizing (SP) Intubating Laryngeal Airway With the Air-Q® Intubating Laryngeal Airway and I-gel for Airway Maintenance in Adults Under General Anesthesia|Completed||N/A|225|Actual|University of Wisconsin, Madison||3|||f||||f||||||||No|Not applicable. There is no plan to make individual participant data available to other researchers.|2018-05-31 21:24:17.017422|2018-05-31 21:24:17.017422
NCT01592903|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2016-08-30|2012-05-04|2012-05-07|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Somatic Stem Cells in Leiomyomas?|Identification and Characterization of Putative Leiomyoma Stem Cells.|Completed|||16|Actual|Igenomix|||1||f||||f||||||Samples With DNA|"~     PHASE 1:SAMPLE COLLECTION Duration: From the first month to 36th month approximately. PHASE~     2: CELL PREPARATION PROTOCOL Duration: From the first month to 12th month PHASE 3: ISOLATION~     OF PUTATIVE SOMATIC STEM CELLS Duration: From the third month (March 2010) to 12th month~     PHASE 4: CELL CULTURE Duration: From the sixth month to 18th month PHASE 5: ENDOCRINE~     CHARACTERIZATION Duration:From the 18th month to 36th month Biospecimen Retention Samples~     With DNA - samples retained, with potential for extraction of DNA from at least one of the~     types of samples retained (e.g., frozen tissue, whole blood) Biospecimen Description Samples~     of human leiomyomas obtained from patients with symptomatic uterine fibroids.~   "|||2018-05-31 21:24:13.426846|2018-05-31 21:24:13.426846
NCT01592890|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2016-11-01|2012-05-04|2012-05-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers|Single-centre, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Dose of 14C-labeled RO4917523 and an Intravenous Tracer Dose of 13C-labeled RO4917523 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:24:13.487621|2018-05-31 21:24:13.487621
NCT01592877|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-07-30|2012-05-04|2012-05-07|Estimate|||||||2012-07-30|2012-07-31|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|||A Comparative Study of the Performance of a New Type Non-contact Patient Monitor|Clinical Test of Ultra-Wideband Non-contact Heart Rate and Breath Rate Monitor|Unknown status|Recruiting||50|Anticipated|Holux Technology, Inc.|||||f||||t||||||||||2018-05-31 21:24:13.549932|2018-05-31 21:24:13.549932
NCT01592864|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2013-05-16||2014-02-06|2012-05-03|2012-05-07|Estimate|2014-02-06|2014-03-10|Estimate||||2014-02-06|2014-03-10|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity|Completed||Phase 3|120|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:24:13.608685|2018-05-31 21:24:13.608685
NCT01592851|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2013-04-05||2014-05-01|2012-05-03|2012-05-07|Estimate|2014-05-01|2014-06-03|Estimate||||2014-05-01|2014-06-03|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Short Term Relief From Dentinal Hypersensitivity|Completed||Phase 3|113|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:24:13.852027|2018-05-31 21:24:13.852027
NCT01592838|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-03-30|2012-05-03|2012-05-07|Estimate|||||||2015-03-30|2015-04-01|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccination Introduction in Belgium|Feasibility Pilot Study Assessing the Impact on the Quality of Hospital Care After the Introduction of Rotavirus Vaccination in Belgium|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:24:15.529932|2018-05-31 21:24:15.529932
NCT01592825|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-06-23|2012-05-04|2012-05-07|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2009||2009-09-30|June 2017|2017-06-30|May 2021|Anticipated|2021-05-31|May 2011|Actual|2011-05-31||Observational|PiA||PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors|PiA Trial: a Cross-sectional, Multicenter, Consecutive Cohort Evaluating the Distribution of uPA/PAI-1 Versus St. Gallen Algorithm in >1000 Prospectively Included Patients|Active, not recruiting|||1000|Anticipated|Martin-Luther-Universität Halle-Wittenberg|||||f||||f||||||Samples With DNA|"~     Tumor specimen frozen Tumor specimen formalin fixed~   "|||2018-05-31 21:24:15.597922|2018-05-31 21:24:15.597922
NCT01592812|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-03-15|2012-05-04|2012-05-07|Estimate|||||||2013-03-15|2013-03-18|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Arterial Inflow and Muscle Ischemia During Calf Stimulation With the Veinoplus Device|Investigation of the Arterial Effects of the Veinoplus(r) Stimlator Device.|Completed||Phase 4|15|Actual|University Hospital, Angers||1|||f||||t||||||||||2018-05-31 21:24:15.650532|2018-05-31 21:24:15.650532
NCT01592799|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-05-03|2012-05-03|2012-05-07|Estimate|||||||2012-05-03|2012-05-07|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in Spain|Burden of Influenza-related Hospitalizations and ER Visits in Children in Spain|Completed||N/A|501|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 21:24:15.715997|2018-05-31 21:24:15.715997
NCT01592786|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2014-07-15||2014-07-15|2012-05-04|2012-05-07|Estimate|2014-07-15|2014-08-07|Estimate||||2014-07-15|2014-08-07|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional||A total of 906 patients were enrolled in the open-label study. Of these, 903 patients received at least 1 dose of open-label treatment to comprise the Safety Population. 868 patients in the Safety Population also had at least 1 post–Visit 1 assessment of the SRS total raw score to comprise the Intent to Treat (ITT) population|An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)|An Open-Label Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)|Completed||Phase 2|906|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 21:24:15.84735|2018-05-31 21:24:15.84735
NCT01592773|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2015-01-30||2015-01-30|2012-05-04|2012-05-07|Estimate|2015-01-30|2015-02-16|Estimate||||2015-01-30|2015-02-16|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional||Demographic summaries were provided based on the 747 patients who received at least 1 dose of investigational product in the extension study (Safety Population).|Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)|An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)|Terminated||Phase 2|747|Actual|Forest Laboratories||1||"Terminated because primary efficacy parameter failed to demonstrate statistically significant~   difference between memantine and placebo in controlled trials"|f||||f||||||||||2018-05-31 21:24:16.457031|2018-05-31 21:24:16.457031
NCT01592747|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2013-10-31|2012-05-04|2012-05-07|Estimate|||||||2013-10-31|2013-11-04|Estimate|September 2012||2012-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine|A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated With Memantine|Completed||Phase 2|480|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 21:24:18.276963|2018-05-31 21:24:18.276963
NCT01592734|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-05-04|2012-05-04|2012-05-07|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children|Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children. A Controlled Double Blind Randomized Study vs a Standard PEG-EL Laxative|Completed||Phase 4|96|Actual|Azienda Policlinico Umberto I||2|||f||||t||||||||||2018-05-31 21:24:18.993902|2018-05-31 21:24:18.993902
NCT01592721|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-03-06|2012-05-03|2012-05-07|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2013||2013-04-30|March 2018|2018-03-31|November 2024|Anticipated|2024-11-30|January 2024|Anticipated|2024-01-31||Interventional|||Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma|Safety and Efficacy of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|42|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 21:24:19.196907|2018-05-31 21:24:19.196907
NCT01592708|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2014-07-14||2014-08-15|2012-05-03|2012-05-07|Estimate|2014-07-14|2014-08-06|Estimate||||2014-08-15|2014-08-20|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery|A Prospective Evaluation of an Anesthesia Protocol to Reduce Post-operative and Post-discharge Nausea and Vomiting in a High Risk Orthognathic Surgery Population|Completed||N/A|233|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 21:24:19.368521|2018-05-31 21:24:19.368521
NCT01592695|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2017-04-14||2017-06-20|2012-05-03|2012-05-07|Estimate|2017-06-20|2017-07-19|Actual||||2017-06-20|2017-07-19|Actual|June 2012||2012-06-30|June 2017|2017-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Tailored Tobacco Quitline for Rural Veterans|Tailored Tobacco Cessation Program for Rural Veterans With Comorbid Depression, Alcoholism or Obesity|Completed||Phase 2|63|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 21:24:19.663831|2018-05-31 21:24:19.663831
NCT01592682|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-06-01|2012-05-03|2012-05-07|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Creating Smokefree Living Together for Chinese Household Pairs|"Creating Smokefree Living Together: Smokefree Counseling Intervention for Chinese Smokers and Household Nonsmokers"|Completed||N/A|410|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 21:24:20.083243|2018-05-31 21:24:20.083243
NCT01592669|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-05-04|2012-05-04|2012-05-07|Estimate|||||||2012-05-04|2012-05-07|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Passive Leg Raising Attenuates and Delays Tourniquet Deflation-induced Hypotension and Tachycardia|The Effect of Passive Leg Raising or Experimental Clinical Practices on the Prevention of Hypotension Following Tourniquet Release in Total Knee Arthroplasty Patients|Completed||N/A|35|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 21:24:20.169199|2018-05-31 21:24:20.169199
NCT01592656|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2014-01-15|2012-05-04|2012-05-07|Estimate|||||||2014-01-15|2014-01-16|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Long-term Effects of Non-invasive Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients|Long-term Effects of Non-invasive Ventilation in Hypercapnic COPD Patients.|Terminated||Phase 2|40|Anticipated|FLUIDDA nv||2||Lack of budget|f||||f||||||||||2018-05-31 21:24:20.403516|2018-05-31 21:24:20.403516
NCT01592643|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2018-04-22|2012-05-03|2012-05-07|Estimate|||||||2018-04-22|2018-04-24|Actual|March 2012||2012-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|Nexis-CS0032||Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain|Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain|Active, not recruiting||Phase 4|30|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 21:24:20.51459|2018-05-31 21:24:20.51459
NCT01592630|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2016-12-05|2012-05-03|2012-05-07|Estimate|||||||2016-12-05|2016-12-06|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effectiveness of Transverse Abdominus Plane Catheter Blocks to Patient-controlled Analgesia in Laparoscopic Colon Resections|Effectiveness of Adding Transverse Abdominus Plane (TAP) Catheter Blocks to Patient-controlled Analgesia (PCA) in Laparoscopic Colon Resections: a Prospective, Randomized Controlled Study|Withdrawn||Phase 3|0|Actual|Stamford Hospital||2||Investigator Left Institution|f||||t||||||||||2018-05-31 21:24:20.589606|2018-05-31 21:24:20.589606
NCT01592617|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-08-11|2012-05-04|2012-05-07|Estimate|||||||2015-08-11|2015-08-13|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer|Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|Shiga University||1|||f||||t||||||||||2018-05-31 21:24:20.671241|2018-05-31 21:24:20.671241
NCT01592604|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-08-23|2012-05-03|2012-05-07|Estimate|||||||2013-08-23|2013-08-26|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||An Optimal Treatment for Avulsion Fractures of the Base of Fith Metatarsal Bone|An Optimal Treatment for Avulsion Fractures of the Base of Fith Metatarsal Bone. A Level I Prospective Randomised Control Trial|Completed||N/A|60|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:24:20.751349|2018-05-31 21:24:20.751349
NCT01592578|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2013-04-25|2012-05-03|2012-05-07|Estimate|||||||2013-04-25|2013-04-29|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||The Research of the Evaluation of Clinical Procedures in Gastroesophageal Varices in Patients With Liver Cirrhosis|A Randomized Controlled Trial of Ligation Versus Ligation Plus Sclerotherapy in Addition to Cyanoacrylate in Patients With Gastroesophageal Varices|Unknown status|Recruiting|N/A|96|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 21:24:20.826195|2018-05-31 21:24:20.826195
NCT01592552|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-03-01|2012-05-04|2012-05-07|Estimate|||||||2016-03-01|2016-03-03|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery|A Multi-Center Longitudinal Biorepository Study to Provide Biospecimens & Clinical Data From Neurological Disease Patients To Approved Pre-Clinical And Clinical Investigators for Drug & Biomarker Studies|Completed|||20|Actual|Sanguine Biosciences|||2||f||||f||||||||||2018-05-31 21:24:20.998068|2018-05-31 21:24:20.998068
NCT01592539|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-02-25|2012-05-04|2012-05-07|Estimate|||||||2015-02-25|2015-02-26|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls|Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls|Completed|||78|Actual|Creighton University|||2||f||||f||||||||||2018-05-31 21:24:21.0608|2018-05-31 21:24:21.0608
NCT01592526|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2016-01-28|2012-05-04|2012-05-07|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|January 2013|Actual|2013-01-31||Interventional|||Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers|Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers|Completed||Early Phase 1|23|Actual|Rigshospitalet, Denmark||4|||f||||t||||||||||2018-05-31 21:24:21.114048|2018-05-31 21:24:21.114048
NCT01592513|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-05-03|2012-05-03|2012-05-07|Estimate|||||||2012-05-03|2012-05-07|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||Effect of BIS Monitoring on Propofol Usage During Elective Bronchoscopy|Effect of BIS Monitoring on Propofol Usage During Elective Bronchoscopy|Unknown status|Recruiting|N/A|80|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 21:24:21.214392|2018-05-31 21:24:21.214392
NCT01592500|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02||2015-01-08|2015-11-10|2012-05-03|2012-05-07|Estimate||||2015-03-12|2015-04-01|Estimate|2015-11-10|2015-12-09|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children|Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children|Completed||Phase 2|53|Actual|Opko Biologics||4|||f||||t||||||||||2018-05-31 21:24:21.283489|2018-05-31 21:24:21.283489
NCT01592487|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2014-02-11|2012-05-03|2012-05-07|Estimate|||||||2014-02-11|2014-02-12|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Effects of a Breakfast and Snack on Cognitive Function in Preadolescents||Withdrawn|||0|Actual|University of Arkansas|||2|Study never started, and there are no plans to initiate.|f||||t||||||||||2018-05-31 21:24:21.358178|2018-05-31 21:24:21.358178
NCT01592474|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2014-07-08|2012-05-04|2012-05-07|Estimate|||||||2014-07-08|2014-07-09|Estimate|October 2005||2005-10-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|August 2011|Actual|2011-08-31||Observational|||Evaluation of Brain Atrophy in CIS Patients on Avonex|Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNβ-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy)|Completed|||180|Actual|University at Buffalo|||||f||||f||||||||||2018-05-31 21:24:21.514168|2018-05-31 21:24:21.514168
NCT01592461|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2016-08-04|2012-05-04|2012-05-07|Estimate|||||||2016-08-04|2016-08-08|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Starting Treatment With Agonist Replacement Therapies Follow-up Study|START Follow-up Study (NIDA CTN Protocol 0050)|Completed|||877|Actual|University of California, Los Angeles|||||f||||f||||||||Yes|Deidentified data will be shared via NIDA Clinical Trials Network Website|2018-05-31 21:24:21.609672|2018-05-31 21:24:21.609672
NCT01592448|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-11-17|2012-05-03|2012-05-07|Estimate|||||||2014-11-17|2014-11-18|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Investigation of Efficacy of Improved Acetaminophen Labeling|Consumer Understanding and Use of Non-Prescription Analgesics, Investigation of Efficacy of Improved Acetaminophen Labeling|Completed|||662|Actual|Northwestern University|||3||f||||t||||||||||2018-05-31 21:24:21.66878|2018-05-31 21:24:21.66878
NCT01592435|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2016-09-14||2017-03-09|2012-05-04|2012-05-07|Estimate|2017-01-20|2017-03-09|Actual||||2017-03-09|2017-04-06|Actual|April 2011||2011-04-30|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|LLI-MSE|76 subjects participated from both sites. 76 image sets were reconstructed with Cedara Accustitch software and the same 76 image sets were reconstructed with Carestream DR LLI software.|Carestream Digital Radiography Long Length Imaging Software Data Collection Protocol|Carestream Digital Radiography Long Length Imaging Manual Stitch Editor Software Data Collection|Completed|||76|Actual|Carestream Health, Inc.|||1||f||||f||||||||No||2018-05-31 21:24:21.743731|2018-05-31 21:24:21.743731
NCT01592422|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-07-02|2012-05-03|2012-05-07|Estimate|||||||2012-07-02|2012-07-03|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer|Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|People's Hospital of Guangxi||2|||f||||t||||||||||2018-05-31 21:24:21.90996|2018-05-31 21:24:21.90996
NCT01592409|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-07-18|2012-05-04|2012-05-07|Estimate|||||||2017-07-18|2017-07-19|Actual|July 2012||2012-07-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Cannabis Effects on Driving-related Skills of Young Drivers|Acute and Residual Effects of Cannabis on Young Drivers' Performance of Driving-related Skills|Completed||N/A|99|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 21:24:21.989365|2018-05-31 21:24:21.989365
NCT01592396|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2016-10-03||2017-01-20|2012-05-03|2012-05-07|Estimate|2016-11-22|2017-01-20|Estimate||||2017-01-20|2017-03-06|Actual|June 2012||2012-06-30|January 2017|2017-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Pharmacokinetic (PK) population included all participants who received the investigational product and had at least 1 detectable post dosing tralokinumab (CAT-354) serum concentration.|A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma|A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of Tralokinumab in Adolescents With Asthma|Completed||Phase 1|30|Actual|MedImmune LLC|Dose-normalized AUC(0-infinity) and dose-normalized Cmax were not evaluated as they were not relevant for single-dose study.|1|||f||||f||||||||||2018-05-31 21:24:22.107231|2018-05-31 21:24:22.107231
NCT01592383|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-05-10|2012-05-04|2012-05-07|Estimate|||||||2017-05-10|2017-05-12|Actual|June 2012||2012-06-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma|Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations|Completed||Phase 2|2|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 21:24:22.357758|2018-05-31 21:24:22.357758
NCT01592370|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2018-05-21|2012-05-04|2012-05-07|Estimate|||||||2018-05-21|2018-05-23|Actual|June 27, 2012|Actual|2012-06-27|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|June 14, 2020|Anticipated|2020-06-14||Interventional|||An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma|Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies|Recruiting||Phase 1/Phase 2|375|Anticipated|Bristol-Myers Squibb||5|||f||||f|t|f||||||||2018-05-31 21:24:22.466744|2018-05-31 21:24:22.466744
NCT01592357|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2013-03-18|2012-05-03|2012-05-07|Estimate|||||||2013-03-18|2013-03-19|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||The Effects of Tai Chi in Older Patients With Cardiovascular Disease|The Effects of Tai Chi in Older Patients With Cardiovascular Disease|Unknown status|Active, not recruiting|N/A|200|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 21:24:22.660399|2018-05-31 21:24:22.660399
NCT01592344|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2016-01-16||2016-03-11|2012-05-04|2012-05-07|Estimate|2016-02-15|2016-03-14|Estimate||||2016-03-11|2016-04-11|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional||Adults having severe intractable chronic pain of peripheral nerve origin were enrolled and all were included in the 94 intent-to-treat analysis.|Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy|Prospective, Multi-Center, Randomized, Double-Blinded, Study to Assess Safety and Efficacy of the Bioness® StimRouter™ Neuromodulation System in Patients With Chronic Pain of Peripheral Nerve Origin|Completed||N/A|94|Actual|Bioness Inc|The device was designed for treatment of mononeuritis excluding the face. For this reason, mononeuropathies of the face were excluded.|2|||f||||f||||||||||2018-05-31 21:24:22.762954|2018-05-31 21:24:22.762954
NCT01592331|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-11-01|2012-05-03|2012-05-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Single Dose, Placebo-Controlled, Parallel Group Study to Investigate the Pharmacodynamic and Pharmacokinetic Behavior of RO5508887 in Plasma and Cerebral Spinal Fluid Following Oral Administration in Healthy Volunteers|Completed||Phase 1|42|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:24:23.087742|2018-05-31 21:24:23.087742
NCT01592318|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-11-01|2012-05-03|2012-05-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers|An Up to Two-Part Relative Bioavailability Study of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets as Compared to the Reference Phase 2 Ad Hoc Combination Tablets in Healthy Adult Volunteers|Completed||Phase 1|42|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:24:23.144399|2018-05-31 21:24:23.144399
NCT01592305|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-11-01|2012-05-03|2012-05-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir|A Study to Evaluate the Potential Drug-Drug Interaction Between Danoprevir When Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:24:23.209397|2018-05-31 21:24:23.209397
NCT01592292|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2016-05-03||2016-07-06|2012-05-03|2012-05-07|Estimate|2016-07-06|2016-08-22|Estimate||||2016-07-06|2016-08-22|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||The intent to treat (ITT) set included participants who offered end-point results among the participants who received the study drugs after enrollment and met all inclusion/exclusion criteria.|An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy|A Non-interventional Study for Relative Efficacy Outcome of Rituximab Treatment in RA Patients Who Have Inadequate Response or Have Been Intolerant to a First Anti-TNF Agent|Completed|||90|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 21:24:23.296573|2018-05-31 21:24:23.296573
NCT01592279|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-03|2012-05-03|2012-05-07|Estimate|||||||2012-05-03|2012-05-07|Estimate|June 2012||2012-06-30|April 2012|2012-04-30||||June 2014|Anticipated|2014-06-30||Interventional|||GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients||Unknown status|Not yet recruiting|Phase 4|124|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:24:23.922342|2018-05-31 21:24:23.922342
NCT01592266|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-05-03|2012-05-03|2012-05-07|Estimate|||||||2012-05-03|2012-05-07|Estimate|October 2012||2012-10-31|April 2012|2012-04-30||||October 2013|Anticipated|2013-10-31||Observational|AML F18-FLT||F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)|F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML|Unknown status|Not yet recruiting||10|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 21:24:23.982567|2018-05-31 21:24:23.982567
NCT01592253|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-06-22|2012-05-04|2012-05-07|Estimate|||||||2012-06-22|2012-06-25|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient|Investigation of the Safety and Immunologic Biomarker After Conversion From Calcineurin Inhibitor to Rapamune in Stable Renal Transplant Recipient|Unknown status|Recruiting|N/A|50|Anticipated|Seoul St. Mary's Hospital|||||f||||f||||||||||2018-05-31 21:24:24.042362|2018-05-31 21:24:24.042362
NCT01592240|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2017-10-27|2014-10-14|2017-10-27|2012-05-04|2012-05-07|Estimate|2017-10-27|2017-12-05|Actual|2014-10-14|2014-10-23|Estimate|2017-10-27|2017-12-05|Actual|July 2012|Actual|2012-07-31|October 2017|2017-10-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional||Full analysis set (FAS) included all participants who were randomized.|Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin|A Phase 2b Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose-ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Monthly And Twice Monthly Subcutaneous Dosing For Six Months In Hypercholesterolemic Subjects On A Statin|Completed||Phase 2|354|Actual|Pfizer|There were no limitations or caveats in this study.|2|||f||||f||||||||||2018-05-31 21:24:24.19393|2018-05-31 21:24:24.19393
NCT01592227|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-11-20|2012-05-03|2012-05-07|Estimate|||||||2014-11-20|2014-11-24|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Compare Two Paracetamol Formulations.|A Pharmacokinetic Study Investigating the Rate and Extent of Absorption of Paracetamol and an Adjuvant From Two Different Paracetamol Formulations.|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:24:26.515199|2018-05-31 21:24:26.515199
NCT01592214|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2016-09-01|2012-05-03|2012-05-07|Estimate|||||||2016-09-01|2016-09-05|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73|A Two-Part Phase I Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XF-73 for Decolonization of Staphylococcus Aureus: A Previously Investigated 0.5 mg/g Viscosified Gel Formulation Versus a Modified Formulation|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-05-31 21:24:26.656767|2018-05-31 21:24:26.656767
NCT01592201|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2014-06-24|2012-05-03|2012-05-07|Estimate|||||||2014-06-24|2014-06-25|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug|An Open-label, Prospective, Randomized and Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug|Terminated||Phase 4|13|Actual|Janssen Korea, Ltd., Korea||2||This study was early terminated due to insufficient enrollment required for hypothesis testing.|f||||f||||||||||2018-05-31 21:24:26.745164|2018-05-31 21:24:26.745164
NCT01592188|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2013-11-13|2012-05-03|2012-05-07|Estimate|||||||2013-11-13|2013-11-14|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Cognitively-Based Compassion Training and Mindfulness Attention Training Program|Cognitively-Based Compassion Training and Mindfulness Attention Training for Elementary School Students|Completed||Phase 3|53|Actual|Emory University||2|||f||||t||||||||||2018-05-31 21:24:26.868906|2018-05-31 21:24:26.868906
NCT01592175|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-05-03|2012-05-03|2012-05-07|Estimate|||||||2012-05-03|2012-05-07|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Magnetoencephalography (MEG), Attention and Conscience|Spatio-temporal Dynamic of the Relationship Between Spatial Attention and Visual Awareness|Unknown status|Recruiting||8|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-05-31 21:24:26.946788|2018-05-31 21:24:26.946788
NCT01592162|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2016-11-02|2012-05-04|2012-05-07|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PropofolRemi||Comparison of Different Propofol Formulations With or Without Remifentanil|Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Remifentanil|Completed||Phase 4|409|Actual|Hopital Foch||9|||f||||f||||||||||2018-05-31 21:24:27.024373|2018-05-31 21:24:27.024373
NCT01592149|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2015-02-10|2012-05-03|2012-05-07|Estimate|||||||2015-02-10|2015-02-11|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|March 2014|Actual|2014-03-31||Observational|SPLASH||Survey of Prevalence of Loss of Appetite in Subject With Health Disorders|Survey of Prevalence of Loss of Appetite in Subject With Health Disorders.|Completed|||16629|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:24:27.118012|2018-05-31 21:24:27.118012
NCT01592136|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2018-02-05|2012-05-04|2012-05-07|Estimate|||||||2018-02-05|2018-02-06|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Expanded Access Program of Ponatinib|Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia|Approved for marketing|||||Takeda|||||||||||||||||||2018-05-31 21:24:27.21368|2018-05-31 21:24:27.21368
NCT01592123|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-03|2012-05-03|2012-05-07|Estimate|||||||2012-05-03|2012-05-07|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|||||Observational|||Effects of Nasal Septal Surgery on Sleep Quality, Daytime and Dream Anxiety|Evaluation of Benefits of Nasal Septal Surgery on Subjective Sleep Quality, Daytime and Dream Anxiety|Completed|||68|Actual|Ataturk Training and Research Hospital|||1||f||||f||||||||||2018-05-31 21:24:27.347738|2018-05-31 21:24:27.347738
NCT01592110|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2013-07-23|2012-05-04|2012-05-07|Estimate|||||||2013-07-23|2013-07-25|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia|A Pilot, Open-Label, Non-Randomized, Single Ascending Dose, Safety and Pharmacokinetic Trial With Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|40|Actual|Zogenix, Inc.||4|||f||||t||||||||||2018-05-31 21:24:27.460325|2018-05-31 21:24:27.460325
NCT01592097|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-04-30|2012-05-04|2012-05-07|Estimate|||||||2018-04-30|2018-05-03|Actual|June 2012||2012-06-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS|A Non-randomized, Exploratory, Study to Assess Clinical Response to Gilenya® (Fingolimod) in a Cohort of Relapsing Remitting Hispanic MS Forms|Completed|||51|Actual|University of Southern California|||||f||||f||||||Samples With DNA|"~     DNA will be extracted from isolated cells; the remaining cells will be cryopreserved for any~     duplicate analyses.~   "|||2018-05-31 21:24:27.550063|2018-05-31 21:24:27.550063
NCT01592084|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-05-03|2012-05-03|2012-05-07|Estimate|||||||2012-05-03|2012-05-07|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis|Cohort Study of the Relationship of Hyperlipidemia and Statin Therapy on Survival and Disease Progresssion in Amyotrophic Lateral Sclerosis|Completed|||267|Actual|The Methodist Hospital System|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:24:27.618037|2018-05-31 21:24:27.618037
NCT01592071|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2012-08-23||2014-02-14|2012-05-01|2012-05-07|Estimate|2014-02-14|2014-03-31|Estimate||||2014-02-14|2014-03-31|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||IgG-mediated Food Test for Weight Loss|Eliminating IgG-mediated Reactive Foods From the Diet and Its Effect on Body Composition and Quality of Life in Overweight Persons|Completed||N/A|120|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 21:24:27.708084|2018-05-31 21:24:27.708084
NCT01592058|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-07-30|2012-05-02|2012-05-04|Estimate|||||||2012-07-30|2012-07-31|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|BMI||Weight Change Among Users of Three Progestin-Only Methods of Contraception Over a 12-Month Time Period|Weight Change Among Users of Three Progestin-Only Methods of Contraception Over a 12-Month Time Period|Completed|||427|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 21:24:27.977774|2018-05-31 21:24:27.977774
NCT01590667|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-07-25|2012-05-01|2012-05-03|Estimate|||||||2012-07-25|2012-07-27|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Litramine on Fat Excretion|Double-blind, Randomized, Placebo-controlled, Crossover Clinical Investigation to Evaluate the Effect of Litramine on Fecal Fat Excretion in Healthy Subjects|Completed||Phase 4|20|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 21:24:49.23422|2018-05-31 21:24:49.23422
NCT01592045|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2015-06-03||2015-08-20|2012-05-02|2012-05-04|Estimate|2015-08-20|2015-09-23|Estimate||||2015-08-20|2015-09-23|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Twenty-eight subjects were enrolled in this study with all subjects receiving at least one dose of study therapy.|ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma|A Comparative Pharmacokinetic and Safety Study of Chimeric Monoclonal Antibody ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-2 (IL-2) and Isotretinoin in High Risk Neuroblastoma Patients Following Myeloablative Therapy|Completed||Phase 1/Phase 2|28|Actual|United Therapeutics||2|||f||||t||||||||||2018-05-31 21:24:28.082307|2018-05-31 21:24:28.082307
NCT01592032|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-02-18|2012-05-02|2012-05-04|Estimate|||||||2015-02-18|2015-02-19|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|January 2015|Actual|2015-01-31||Interventional|CONAN||Concentration of Antimicrobials in Catheter-lock Solutions|Concentration and Antibiotic Activity in Antibiotic Lock Solutions|Unknown status|Active, not recruiting|Phase 4|125|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||5|||f||||t||||||||||2018-05-31 21:24:28.654769|2018-05-31 21:24:28.654769
NCT01592019|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-12-12|2012-05-02|2012-05-04|Estimate|||||||2012-12-12|2012-12-13|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products|Use of Dermal Microdialysis to Evaluate the Effect of Skin Properties and Application Site on the Topical Bioequivalence of Diclofenac: The Main Study|Completed||Early Phase 1|6|Actual|University of Florida||4|||f||||||||||||||2018-05-31 21:24:28.742331|2018-05-31 21:24:28.742331
NCT01592006|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2015-01-05||2016-05-11|2012-05-02|2012-05-04|Estimate|2015-01-05|2015-01-12|Estimate||||2016-05-11|2016-06-15|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients|A Pilot Study on the Efficicay and Safety of Pegylated Interferon, Ribavirin and Telaprevir in Recurrent Hepatitis C Virus (HCV) Infection in Orthotopic Liver Transplant (OLT) Recipients.|Terminated||Phase 4|3|Actual|University of Chicago||1||Low accrual|f||||f||||||||||2018-05-31 21:24:28.810007|2018-05-31 21:24:28.810007
NCT01591993|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-11-28|2012-05-02|2012-05-04|Estimate|||||||2012-11-28|2012-11-29|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Determination of Sensitive Skin and Its Biophysical Response in a Latin-American Population|Determination of Sensitive Skin in a Mexican Population by Lactic Acid Testing and Its Analysis Through Biophysical Measures|Completed||Phase 4|260|Actual|Universidad Autonoma de San Luis Potosí||2|||f||||f||||||||||2018-05-31 21:24:28.947024|2018-05-31 21:24:28.947024
NCT01591980|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-02-18|2012-05-02|2012-05-04|Estimate|||||||2014-02-18|2014-02-19|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Effects of Perioperative Pregabalin for Post-Craniotomy Pain|Effects of Perioperative Low-dose Pregabalin on Post-craniotomy Pain: A Two-centre Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|St. Michael's Hospital, Toronto||3||"Pfizer Canada and the SMH ORA could not come into an agreement on responsibility to be the~   Importer of Record for the trial."|f||||t||||||||||2018-05-31 21:24:29.013522|2018-05-31 21:24:29.013522
NCT01591967|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-02|2012-05-02|2012-05-04|Estimate|||||||2012-05-02|2012-05-04|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Measure the Effects of Specific Thoracic Chiropractic Adjustments on Blood Pressure and Pulse Rate|A Randomized Controlled Trial to Measure the Effects of Specific Thoracic Chiropractic Adjustments on Blood Pressure and Pulse Rate|Completed||Phase 1|290|Actual|Spinal Missions, Inc., LLC||3|||f||||t||||||||||2018-05-31 21:24:29.103542|2018-05-31 21:24:29.103542
NCT01591954|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2016-08-02||2016-10-07|2012-05-02|2012-05-04|Estimate|2016-10-07|2016-12-01|Estimate||||2016-10-07|2016-12-01|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Feasibility Study of a Modular Video Augmentation System for Image-Guided Skull Base Surgery|A Feasibility/Pilot Study of a Modular Video Augmentation System for Image-Guided Endoscopic Skull Base Surgery|Terminated||N/A|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||3rd party proprietary software issue|f||||t||||||||||2018-05-31 21:24:29.158402|2018-05-31 21:24:29.158402
NCT01591941|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-05-03|2012-05-02|2012-05-04|Estimate|||||||2012-05-03|2012-05-07|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effectiveness of a Novel Warm-up in Decreasing Risk Factors for ACL Injury in Female Youth Soccer Players|The Effectiveness of a Novel Warm-up in Decreasing Risk Factors for Anterior Cruciate Ligament Injury in Female Youth Soccer Players|Completed||Phase 2|20|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 21:24:29.26225|2018-05-31 21:24:29.26225
NCT01591928|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2017-05-08|2012-05-03|2012-05-04|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2012||2012-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study|Heterotaxy Syndrome and Intestinal Rotation Abnormalities - A Prospective Study|Completed|||40|Actual|University of Alberta|||1||f||||f||||||||No||2018-05-31 21:24:29.320523|2018-05-31 21:24:29.320523
NCT01591915|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2016-04-29|2012-05-03|2012-05-04|Estimate|||||||2016-04-29|2016-05-02|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer|A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer|Enrolling by invitation||N/A|150|Actual|Skaraborg Hospital||3|||f||||f||||||||||2018-05-31 21:24:29.371008|2018-05-31 21:24:29.371008
NCT01591902|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2016-08-12|2012-05-02|2012-05-04|Estimate|||||||2016-08-12|2016-08-15|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|September 2024|Anticipated|2024-09-30|December 2023|Anticipated|2023-12-31||Interventional|||Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®|A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes|Recruiting||Phase 4|648|Anticipated|Theratechnologies||2|||f||||t||||||||||2018-05-31 21:24:29.429534|2018-05-31 21:24:29.429534
NCT01591889|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-01-19|2012-05-03|2012-05-04|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2009||2009-09-30|January 2018|2018-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions|Completed||Phase 1|28|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:24:30.507054|2018-05-31 21:24:30.507054
NCT01591876|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-02-28|2012-05-02|2012-05-04|Estimate|||||||2013-02-28|2013-03-01|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|July 2013|Anticipated|2013-07-31||Interventional|||Exercise and Vascular Function in Haemodialysis Patients|The Effect of an Intra-dialytic Aerobic Exercise Intervention on Vascular Function in People Undergoing Maintenance Haemodialysis Therapy for Chronic Kidney Disease Stage 5. An Exploratory Study|Unknown status|Recruiting|Phase 2|50|Anticipated|Queen Margaret University||2|||f||||f||||||||||2018-05-31 21:24:30.577986|2018-05-31 21:24:30.577986
NCT01591863|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2015-03-05||2017-08-10|2012-05-02|2012-05-04|Estimate|2015-03-05|2015-03-17|Estimate||||2017-08-10|2017-09-11|Actual|June 15, 2012|Actual|2012-06-15|August 2017|2017-08-31|March 7, 2014|Actual|2014-03-07|March 7, 2014|Actual|2014-03-07||Interventional|||Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|Completed||Phase 2|38|Actual|Optimer Pharmaceuticals LLC||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:24:30.670457|2018-05-31 21:24:30.670457
NCT01591850|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2016-11-01|2012-05-03|2012-05-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers|A Randomized, Single-center, Open-label, One-sequence, Two-period Crossover Study in 3 Parts to Investigate the Effects of Multiple Doses of Ketoconazole (Part 1), Rifampicin (Part 2), and Ritonavir-boosted Atazanavir (Part 3) on the PK of a Single Dose of RO5093151 in Healthy Female & Male Subjects|Completed||Phase 1|51|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:24:30.869031|2018-05-31 21:24:30.869031
NCT01591837|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|2013-06-06||2017-10-23|2012-05-03|2012-05-04|Estimate|2013-10-25|2013-11-18|Estimate||||2017-10-23|2017-11-27|Actual|May 2012||2012-05-31|October 2017|2017-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2012/2013 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)|Completed||Phase 4|120|Actual|Seqirus||2|||f||||||||||||||2018-05-31 21:24:30.958522|2018-05-31 21:24:30.958522
NCT01591824|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2016-02-06|2012-05-02|2012-05-04|Estimate|||||||2016-02-06|2016-02-09|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|Pold-LBP||Study of Effectiveness of Pold in Chronic Nonspecific Low Back Pain|Effectiveness of Resonant Oscillation, According to the Pold Concept in Chronic Nonspecific Low Back Pain|Completed||N/A|50|Actual|Omphis Foundation||2|||f||||f||||||||||2018-05-31 21:24:32.032209|2018-05-31 21:24:32.032209
NCT01591811|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-07-19|2012-05-02|2012-05-04|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2012||2012-04-30|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost|Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost|Active, not recruiting||Phase 3|433|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 21:24:32.114258|2018-05-31 21:24:32.114258
NCT01591798|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-05-03|2012-05-02|2012-05-04|Estimate|||||||2012-05-03|2012-05-07|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|December 2017|Anticipated|2017-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy Study of Robotic Surgery for Rectal Cancer|Clinical Assessment of Laparoscopic and Robotic Surgery for Rectal Cancer - Randomized Phase II Trial|Unknown status|Recruiting|Phase 2|146|Anticipated|National Cancer Center, Korea||2|||f||||||||||||||2018-05-31 21:24:32.194681|2018-05-31 21:24:32.194681
NCT01591785|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-07-08|2012-05-02|2012-05-04|Estimate|||||||2015-07-08|2015-07-10|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Treatment of Staphylococcus Aureus Colonization in Hand Eczema|An Investigator-Initiated Study: Treatment of Staphylococcus Aureus Colonization in Hand Eczema Decreases Severity of Disease|Completed||N/A|60|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 21:24:32.284566|2018-05-31 21:24:32.284566
NCT01591772|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2018-05-01|2012-05-02|2012-05-04|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2012||2012-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer|Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer|Active, not recruiting|||36|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 21:24:32.387272|2018-05-31 21:24:32.387272
NCT01591759|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-04-22|2012-05-02|2012-05-04|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI)|A Pilot Trial of Citicoline in Individuals With mTBI|Withdrawn||Phase 2|0|Actual|Mclean Hospital||2||Our citicoline supply expired and the exact product has discontinued.|f||||f||||||||||2018-05-31 21:24:32.547715|2018-05-31 21:24:32.547715
NCT01591746|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2017-10-17|2012-05-02|2012-05-04|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2012|Actual|2012-08-31|October 2017|2017-10-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction|Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial|Completed||Phase 3|141|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 21:24:32.63033|2018-05-31 21:24:32.63033
NCT01591733|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2018-03-02||2018-03-28|2012-05-02|2012-05-04|Estimate|2018-03-28|2018-04-30|Actual||||2018-03-28|2018-04-30|Actual|May 2012|Actual|2012-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|March 2017|Actual|2017-03-31||Interventional|||FOLFIRINOX + RT for Pancreatic Cancer|Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer|Active, not recruiting||Phase 2|48|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:24:32.749479|2018-05-31 21:24:32.749479
NCT01591720|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-05-02|2012-05-02|2012-05-04|Estimate|||||||2012-05-02|2012-05-04|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TAYLOR2||Tailored Internet-delivered Cognitive Behaviour Therapy in Primary Care|Effectiveness Testing of a Tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Symptoms of Depression, Anxiety and Comorbid Problems|Completed||N/A|64|Actual|Linkoeping University||1|||f||||f||||||||||2018-05-31 21:24:33.218678|2018-05-31 21:24:33.218678
NCT01591707|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2018-05-21|2012-05-02|2012-05-04|Estimate|||||||2018-05-21|2018-05-23|Actual|July 2012||2012-07-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Evaluating a Social and Communication Intervention for Preschoolers|Evaluating a Social and Communication Intervention for Preschoolers|Recruiting||N/A|700|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||Yes|Individual participant data for teachers will be shared with the Delaware Autism Program to determine feasibility of model implementation. Child participant data will not be shared.|2018-05-31 21:24:33.290307|2018-05-31 21:24:33.290307
NCT01591694|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2018-04-05|2012-05-02|2012-05-04|Estimate|||||||2018-04-05|2018-04-06|Actual|April 2012||2012-04-30|April 2018|2018-04-30|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Observational|||National Child Traumatic Stress Network (NCTSN) Quality Improvement Initiative Database|National Child Traumatic Stress Network (NCTSN) Quality Improvement Initiative Database|Completed|||4193|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|||4||f||||f||||||||||2018-05-31 21:24:33.363752|2018-05-31 21:24:33.363752
NCT01591681|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2014-03-11||2016-08-26|2012-05-02|2012-05-04|Estimate|2014-06-04|2014-06-05|Estimate||||2016-08-26|2016-08-30|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||There were 45 participants who could use the Continuous Glucose Monitoring device and met a minimum amount of nocturnal hypoglycemia as well as successfully completed the run-in phase of system use at home for 5 nights to verify the ability to use it properly.|Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study|Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension: An Outpatient Pilot Feasibility and Efficacy Study|Completed||Phase 2|49|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 21:24:33.454477|2018-05-31 21:24:33.454477
NCT01591668|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-08-12|2012-05-02|2012-05-04|Estimate|||||||2013-08-12|2013-08-13|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C|A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 1|51|Actual|Gilead Sciences||8|||f||||t||||||||||2018-05-31 21:24:33.929199|2018-05-31 21:24:33.929199
NCT01591655|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02||2013-11-22|2013-11-22|2012-05-02|2012-05-04|Estimate||||2013-11-22|2013-12-17|Estimate|2013-11-22|2013-12-17|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery.|Completed||Phase 3|363|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 21:24:34.016802|2018-05-31 21:24:34.016802
NCT01591642|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-05-02|2012-05-02|2012-05-04|Estimate|||||||2012-05-02|2012-05-04|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Physical Activity, Functional Fitness and Quality of Life After Coronary Artery Bypass Grafting||Completed|||315|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 21:24:34.08916|2018-05-31 21:24:34.08916
NCT01591629|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-11-28|2012-05-02|2012-05-04|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effects of ∆-9-THC and Naloxone in Humans|Assessment of Cannabinoid-opiate Interactions in Humans With a Cannabis Use Disorder and Healthy Subjects|Active, not recruiting||Phase 1|56|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 21:24:34.139235|2018-05-31 21:24:34.139235
NCT01591616|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2014-02-20||2014-02-20|2012-05-02|2012-05-04|Estimate|2014-02-20|2014-04-03|Estimate||||2014-02-20|2014-04-03|Estimate|April 2010||2010-04-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel|A Phase 4 Pediatric Study to Assess the Pharmacokinetics and Safety of Oraqix Gel in Healthy Children and Adolescent Volunteers Following Tooth Extraction|Completed||Phase 4|16|Actual|Dentsply International||1|||f||||f||||||||||2018-05-31 21:24:34.251844|2018-05-31 21:24:34.251844
NCT01591603|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-07-17|2012-05-02|2012-05-04|Estimate|||||||2015-07-17|2015-07-20|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Perineural Catheter Depth for the Continuous Popliteal Nerve Block Using Ultrasound Guidance and Dermabond|Comparison of Perineural Catheter Depth for the Continuous Popliteal Nerve Block Using Ultrasound Guidance and Dermabond|Completed||N/A|83|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 21:24:35.074136|2018-05-31 21:24:35.074136
NCT01591590|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2016-09-06|2012-05-02|2012-05-04|Estimate|||||||2016-09-06|2016-09-07|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|CORIOLAN||Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer|Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer|Recruiting||Phase 2|53|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 21:24:35.140145|2018-05-31 21:24:35.140145
NCT01591577|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2017-08-17|2012-05-03|2012-05-04|Estimate|||||||2017-08-17|2017-08-22|Actual|December 7, 2012|Actual|2012-12-07|August 2017|2017-08-31|December 7, 2019|Anticipated|2019-12-07|December 7, 2018|Anticipated|2018-12-07||Interventional|||Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme|Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme|Recruiting||Phase 2|70|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:24:35.237816|2018-05-31 21:24:35.237816
NCT01591564|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-03-30|2012-05-03|2012-05-04|Estimate|||||||2015-03-30|2015-03-31|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Interpersonal Psychotherapy in Youth With Severe Mood Dysregulation-Pilot|Interpersonal Psychotherapy in Youth With Severe Mood Dysregulation-Pilot|Completed||N/A|3|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 21:24:35.301052|2018-05-31 21:24:35.301052
NCT01591551|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2014-01-28|2012-05-02|2012-05-04|Estimate|||||||2014-01-28|2014-01-29|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness|NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness|Completed||Phase 4|37|Actual|Cornerstone Health Care, PA||1|||f||||f||||||||||2018-05-31 21:24:35.369297|2018-05-31 21:24:35.369297
NCT01591538|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-05-28|2012-05-03|2012-05-04|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|MARC||Multi-Antibiotic Resistance Carriage in Gut Flora|Prevalence Study Evaluating the Acquisition of Carriage of Resistant Bacteria in the Gut Flora in Volunteers From French Armed Forces Coming Back From External Operations|Completed|||272|Actual|Da Volterra|||1||f||||f||||||Samples Without DNA|"~     Stool~   "|||2018-05-31 21:24:35.428478|2018-05-31 21:24:35.428478
NCT01591525|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-05-03|2012-05-03|2012-05-04|Estimate|||||||2012-05-03|2012-05-04|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Diabetes Mellitus Community Based Screening in Minority Populations|Diabetes Mellitus Community Based Screening in Minority Populations|Unknown status|Not yet recruiting||100|Anticipated|Ethnicity and Disease Community Empowerment Center|||4||f||||||||||||||2018-05-31 21:24:35.57269|2018-05-31 21:24:35.57269
NCT01591512|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-03-04|2012-05-03|2012-05-04|Estimate|||||||2015-03-04|2015-03-06|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer|A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell|Terminated|||4|Actual|Fujirebio Diagnostics, Inc.||||Decision was made by Sponsor to stop the trial.|f||||||||||Samples Without DNA|"~     Collection of whole blood and urine.~   "|||2018-05-31 21:24:35.657685|2018-05-31 21:24:35.657685
NCT01591499|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2013-12-30||2016-01-07|2012-05-02|2012-05-04|Estimate|2016-01-07|2016-02-08|Estimate||||2016-01-07|2016-02-08|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|INNOVATION|Population of patients having evaluated at least one lens (N=138)|Clinical Evaluation of Biofinity Multifocal Compared With Air Optix Aqua Multifocal and With PureVision Multifocal|Clinical Evaluation of the Biofinity Multifocal Lens Compared With the Air Optix Aqua Multifocal Lens and With PureVision Multifocal Lens (INNOVATION PRESBYOPIA Study)|Completed||Phase 4|142|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 21:24:35.737698|2018-05-31 21:24:35.737698
NCT01591486|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-08-10|2012-05-02|2012-05-04|Estimate|||||||2015-08-10|2015-08-13|Estimate|January 1995||1995-01-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|2NA3NANC||Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding|A Long-term Prospective Cohort Study of Testing for Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding With Low-dose Aspirin|Completed|||904|Actual|Chinese University of Hong Kong|||3||f||||f||||||||||2018-05-31 21:24:36.336161|2018-05-31 21:24:36.336161
NCT01591473|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02||2017-02-22|2017-02-22|2012-05-02|2012-05-04|Estimate||||2017-02-22|2017-02-23|Actual|2017-02-22|2017-02-23|Actual|April 2012|Actual|2012-04-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|||Safety Study of FluMist With and Without Ampligen|A Phase I/II, Two-Staged, Single-Center, Randomized, Double-Blind, Antibody Titer Study to Assess Immunogenicity and Safety of FluMist® Intranasal Influenza Vaccine Administered With and Without a TLR-3 Agonist, Ampligen®.|Terminated||Phase 1/Phase 2|55|Actual|Hemispherx Biopharma||6||The CDC indicated nasal spray flu vaccine should not be used during 2016-2017|f||||t||||||||Undecided||2018-05-31 21:24:36.402094|2018-05-31 21:24:36.402094
NCT01591460|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2015-07-10||2016-11-01|2012-05-02|2012-05-04|Estimate|2015-07-10|2015-08-07|Estimate||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||All-Treated Population: All enrolled participants who received at least one dose of study medication.|A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C|An International, Multicenter, Open-Label Study Evaluating Sustained Virological Response and Safety With Boceprevir in Triple Combination Therapy With Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-Naïve Patients With Genotype 1 Chronic Hepatitis C|Completed||Phase 4|165|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:24:36.567975|2018-05-31 21:24:36.567975
NCT01591447|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02||2014-02-06|2017-03-01|2012-05-02|2012-05-04|Estimate||||2014-02-06|2014-03-10|Estimate|2017-03-01|2017-03-03|Actual|May 2012||2012-05-31|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea|An Open-Label Study to Evaluate the Efficacy and Safety of a Single-Dose of Oral CEM-101 in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea|Completed||Phase 2|60|Actual|Cempra Inc||2|||f||||f||||||||||2018-05-31 21:24:37.756805|2018-05-31 21:24:37.756805
NCT01591434|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2013-07-29|2012-05-02|2012-05-04|Estimate|||||||2013-07-29|2013-07-30|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Evaluate the Performance of AQUACEL® Extra™ in Venous Leg Ulcers|An Open Randomised Comparative Study to Evaluate the Performance of AQUACEL® Extra™ in Venous Leg Ulcers|Completed||Phase 3|65|Actual|ConvaTec Inc.||2|||f||||f||||||||||2018-05-31 21:24:37.902497|2018-05-31 21:24:37.902497
NCT01591421|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2018-03-21|2012-05-03|2012-05-04|Estimate|||||||2018-03-21|2018-03-22|Actual|May 1, 2012|Actual|2012-05-01|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|September 30, 2015|Actual|2015-09-30||Interventional|||P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.|Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.|Active, not recruiting||Phase 1/Phase 2|22|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||Yes||2018-05-31 21:24:37.981566|2018-05-31 21:24:37.981566
NCT01591408|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2016-08-23||2016-10-27|2012-05-03|2012-05-04|Estimate|2016-10-27|2016-12-20|Estimate||||2016-10-27|2016-12-20|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||EEG Biofeedback Therapy as an Adjunct Treatment for PTSD|Placebo-controlled Study of EEG Biofeedback Therapy as an Adjunct Treatment for PTSD, Evaluating Symptoms and EEG Dynamics|Completed||N/A|68|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||No||2018-05-31 21:24:38.092534|2018-05-31 21:24:38.092534
NCT01591395|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-05-04|2012-05-02|2012-05-04|Estimate|||||||2012-05-04|2012-05-07|Estimate|August 2010||2010-08-31|May 2012|2012-05-31||||December 2012|Anticipated|2012-12-31||Interventional|||Prospective Randomized Trial Comparing Three-port and Single-port TEP Repair in Adults|Prospective Randomized Trial Comparing the Short-term and Long-term Outcomes of Three-port and Single-port TEP Repair in Adults|Unknown status|Recruiting|N/A|100|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||t||||||||||2018-05-31 21:24:38.256323|2018-05-31 21:24:38.256323
NCT01590888|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2015-11-17||2016-06-07|2012-05-01|2012-05-03|Estimate|2016-06-07|2016-07-18|Estimate||||2016-06-07|2016-07-18|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|Reach2HD||Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease|Completed||Phase 2|109|Actual|Prana Biotechnology Limited||3|||f||||t||||||||||2018-05-31 21:24:43.095428|2018-05-31 21:24:43.095428
NCT01591382|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2017-02-01||2017-02-01|2012-05-02|2012-05-04|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|September 2008||2008-09-30|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional||Baseline characteristics are based on the total number of participants who completed the study.|Efficacy Study of Ketamine for Postoperative Pain in Opioid Dependent Patients|Hydromorphone PCA or Hydromorphone PCA With Ketamine for Acute Postoperative Pain Relief in Opioid-Dependent Chronic Pain Patients|Completed||Phase 4|64|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:24:38.347642|2018-05-31 21:24:38.347642
NCT01591369|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2013-08-13|2012-05-03|2012-05-04|Estimate|||||||2013-08-13|2013-08-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:24:38.597077|2018-05-31 21:24:38.597077
NCT01591356|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2018-03-12|2012-05-02|2012-05-04|Estimate|||||||2018-03-12|2018-03-14|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery|EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial|Recruiting||Phase 1|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:24:38.627515|2018-05-31 21:24:38.627515
NCT01591343|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2018-02-21|2012-05-03|2012-05-04|Estimate|||||||2018-02-21|2018-02-23|Actual|June 2012||2012-06-30|February 2018|2018-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma|Prospective Study to Evaluate the Safety of a 4-month Treatment With Depigoid® Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml) in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Mild Persistent or Intermittent Asthma|Terminated||Phase 2|8|Actual|Laboratorios Leti, S.L.||1||Study halted by Sponsor|f||||t||||||||||2018-05-31 21:24:38.690654|2018-05-31 21:24:38.690654
NCT01591330|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-07-02|2012-05-02|2012-05-04|Estimate|||||||2012-07-02|2012-07-03|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of LY2140023 in Healthy Males and Females|A Particle Size Study of 3 Different Particle Size Test Tablet Formulations Compared to the Reference Tablet Formulation in Healthy Subjects|Completed||Phase 1|35|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 21:24:38.772244|2018-05-31 21:24:38.772244
NCT01591317|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2012-09-04||2012-09-04|2012-05-02|2012-05-04|Estimate|2012-09-04|2012-10-04|Estimate||||2012-09-04|2012-10-04|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of Prasugrel in Korean Healthy Male Volunteers|Single and Multiple Dose Pharmacokinetics and Pharmacodynamics of Prasugrel (LY640315) in Korean Healthy Male Subjects|Completed||Phase 1|30|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:24:38.87858|2018-05-31 21:24:38.87858
NCT01591304|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2017-11-21|2012-05-02|2012-05-03|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2011||2011-08-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne|Feasibility Study: Evaluation of the Safety and Effectiveness of the Ulthera® System for the Treatment of Moderate to Severe Facial Acne|Completed||N/A|24|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 21:24:39.277322|2018-05-31 21:24:39.277322
NCT01591291|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-05-02|2012-05-02|2012-05-03|Estimate|||||||2012-05-02|2012-05-03|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Pharmacogenetic Treatments for Alcoholism|1/2 - Pharmacogenetic Treatments for Alcoholism|Unknown status|Not yet recruiting|Phase 2/Phase 3|256|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 21:24:39.35676|2018-05-31 21:24:39.35676
NCT01591278|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2014-11-11|2012-05-01|2012-05-03|Estimate|||||||2014-11-11|2014-11-13|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||MTA and Biodentine in Pulpotomized Primary Molars|Clinical and Radiographic Outcomes of MTA and Biodentine in Pulpotomized Primary Molars. A Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|Universitat Internacional de Catalunya||2|||f||||f||||||||||2018-05-31 21:24:39.447329|2018-05-31 21:24:39.447329
NCT01591265|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2018-05-07|2012-05-01|2012-05-03|Estimate|||||||2018-05-07|2018-05-14|Actual|May 2014||2014-05-31|May 2018|2018-05-31|March 25, 2015|Actual|2015-03-25|March 25, 2015|Actual|2015-03-25||Interventional|SIXES||SIXES: Should I eXtract Every Six? A Study of the Extraction of Permanent Molar Teeth in Children.|SIXES: Should I eXtract Every Six? A Randomized Clinical Trial of the Extraction of First Permanent Molar Teeth in Children|Terminated||N/A|7|Actual|University of Dundee||2||Poor recruitment|f||||t||||||||||2018-05-31 21:24:39.523128|2018-05-31 21:24:39.523128
NCT01591252|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2016-05-31|2012-05-01|2012-05-03|Estimate|||||||2016-05-31|2016-06-02|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|||Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)|Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)|Completed|||200|Anticipated|University of Alabama at Birmingham|||||f||||t||||||||||2018-05-31 21:24:39.587709|2018-05-31 21:24:39.587709
NCT01591239|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2016-08-31|2012-05-01|2012-05-03|Estimate|||||||2016-08-31|2016-09-02|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Home-Based Program to Help Parents of Drug Abusing Adolescents|Parents as Interventionists for Moderate Drug Abusing Adolescents|Completed||N/A|286|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-05-31 21:24:39.640611|2018-05-31 21:24:39.640611
NCT01591226|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-11-21|2012-05-01|2012-05-03|Estimate|||||||2016-11-21|2016-11-22|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Caffeine and Sodium Citrate Ingestion|Effects of Caffeine and Sodium Citrate Ingestion in 1500m Wheelchair Racing Athletes|Completed||N/A|9|Actual|Swiss Paraplegic Centre Nottwil||4|||f||||f||||||||||2018-05-31 21:24:39.709715|2018-05-31 21:24:39.709715
NCT01591213|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2015-01-12|2012-05-02|2012-05-03|Estimate|||||||2015-01-12|2015-01-13|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||St. Jude Cancer Education for Children Program: The Feasibility of Teacher Delivery (Pilot Study)|St. Jude Cancer Education for Children Program: The Feasibility of Teacher Delivery (Pilot Study)|Completed|||426|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 21:24:39.784725|2018-05-31 21:24:39.784725
NCT01590875|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2017-02-01||2017-10-05|2012-05-01|2012-05-03|Estimate|2017-03-22|2017-05-03|Actual||||2017-10-05|2017-11-06|Actual|May 2012||2012-05-31|October 2017|2017-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation|Validation of the Durability of the Adenosine Effect in Verification of Pulmonary Vein Isolation|Completed||N/A|20|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 21:24:44.692515|2018-05-31 21:24:44.692515
NCT01591200|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2016-09-14|2012-05-01|2012-05-03|Estimate|||||||2016-09-14|2016-09-15|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis|A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis|Completed||Phase 2|40|Actual|Stempeutics Research Pvt Ltd||4|||f||||t||||||||||2018-05-31 21:24:39.868304|2018-05-31 21:24:39.868304
NCT01591187|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2015-03-04|2012-05-02|2012-05-03|Estimate|||||||2015-03-04|2015-03-05|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Observational|||The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease|The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease|Completed|||77|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||||||2018-05-31 21:24:40.016157|2018-05-31 21:24:40.016157
NCT01591174|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-02-02|2012-05-02|2012-05-03|Estimate|||||||2015-02-02|2015-02-04|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|GHR||Ghrelin and Gastric Emptying in Children With Functional Dyspepsia|Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia|Unknown status|Active, not recruiting||45|Anticipated|Children's Mercy Hospital Kansas City|||3||f||||f||||||Samples Without DNA|"~     breath specimen blood plasma~   "|||2018-05-31 21:24:40.077765|2018-05-31 21:24:40.077765
NCT01591161|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02||2013-11-22|2013-11-22|2012-05-02|2012-05-03|Estimate||||2013-11-22|2013-12-17|Estimate|2013-11-22|2013-12-17|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|Completed||Phase 3|369|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 21:24:40.141198|2018-05-31 21:24:40.141198
NCT01591148|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2017-12-27|2012-05-02|2012-05-03|Estimate|||||||2017-12-27|2017-12-29|Actual|January 2011||2011-01-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects|A High Resolution Pharmacokinetic/Pharmacodynamic Model of Propofol in Morbidly Obese Subjects|Completed||Phase 1|30|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 21:24:40.196212|2018-05-31 21:24:40.196212
NCT01591135|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-02-01|2012-05-02|2012-05-03|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2012||2012-04-30|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma|A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma|Active, not recruiting||Phase 3|436|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 21:24:40.343653|2018-05-31 21:24:40.343653
NCT01591122|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2018-05-03|2012-05-02|2012-05-03|Estimate|||||||2018-05-03|2018-05-04|Actual|March 27, 2012|Actual|2012-03-27|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 3|313|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 21:24:40.448435|2018-05-31 21:24:40.448435
NCT01591109|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-05-02|2012-05-02|2012-05-03|Estimate|||||||2012-05-02|2012-05-03|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||A Reversal in the Vascularity of Metastatic Liver Tumors From Colorectal Cancer After the Cessation of Anti-VEGF Therapy|A Reversal in the Vascularity of Metastatic Liver Tumors in Patients With Colorectal Cancer After the Cessation of Anti-VEGF Therapy: A Study Using Contrast-enhanced Ultrasonography and Histological Techniques.|Completed|||20|Actual|NHO - Matsumoto Medical Center|||2||f||||t||||||Samples Without DNA|"~     formalin fixed oarafin embedded block of liver specimen~   "|||2018-05-31 21:24:40.589202|2018-05-31 21:24:40.589202
NCT01591096|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2017-06-08||2018-04-26|2012-05-02|2012-05-03|Estimate|2018-04-26|2018-05-25|Actual||||2018-04-26|2018-05-25|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|TIPS||Thrombolysis in Pediatric Stroke (TIPS)|Thrombolysis in Pediatric Stroke (TIPS)|Terminated||Phase 1|1|Actual|Seattle Children's Hospital|Early termination due to lack of participant accrual.|1||Lack of patient accrual|f||||t||||||||No||2018-05-31 21:24:40.663067|2018-05-31 21:24:40.663067
NCT01591083|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-10-11|2012-05-02|2012-05-03|Estimate|||||||2015-10-11|2015-10-14|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DDE||The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers|The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses|Completed||Phase 4|474|Actual|National Cheng-Kung University Hospital||3|||f||||t||||||||||2018-05-31 21:24:40.885158|2018-05-31 21:24:40.885158
NCT01591070|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-08-07|2012-05-02|2012-05-03|Estimate|||||||2012-08-07|2012-08-08|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis|Phase 4 Study of Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis|Completed||Phase 4|104|Actual|Pusan National University Hospital||3|||f||||f||||||||||2018-05-31 21:24:40.965443|2018-05-31 21:24:40.965443
NCT01591057|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-11-22|2012-05-02|2012-05-03|Estimate|||||||2012-11-22|2012-11-27|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|BIOFAV||Effect of Fruit and Vegetable Intake on Markers of Fruit and Vegetable Consumption|Effect of Increased Fruit and Vegetable Intake on Biomarkers of Fruit and Vegetable Consumption|Completed||N/A|30|Anticipated|Queen's University, Belfast||3|||f||||t||||||||||2018-05-31 21:24:41.046929|2018-05-31 21:24:41.046929
NCT01590862|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-10-31|2012-05-02|2012-05-03|Estimate|||||||2016-10-31|2016-11-01|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators|ON/OFF Stimulation and Reward Motivation in Patients With Deep Brain Stimulators|Recruiting|||60|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 21:24:44.923938|2018-05-31 21:24:44.923938
NCT01591044|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2016-05-17||2016-08-05|2012-05-02|2012-05-03|Estimate|2016-08-05|2016-09-29|Estimate||||2016-08-05|2016-09-29|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SITAR|For the purpose of analysis, participants randomized to the two different dosage levels of the placebo were considered a single Arm/Group.|A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients With Mild to Moderate Allergic Asthma|Completed||Phase 2|301|Actual|Rigel Pharmaceuticals||3|||f||||f||||||||No||2018-05-31 21:24:41.162285|2018-05-31 21:24:41.162285
NCT01591031|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-02-13|2012-05-02|2012-05-03|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Laryngeal Injuries After Anesthesia Induction With Sevoflurane and After Anesthesia Induction With Rocuronium|Laryngeal Injuries After Anesthesia Induction With Sevoflurane and After Anesthesia Induction With Rocuronium. A Randomized, Prospective, Controlled Trial|Completed||N/A|60|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 21:24:41.534394|2018-05-31 21:24:41.534394
NCT01591018|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2016-07-24||2016-07-24|2012-05-02|2012-05-03|Estimate|2016-07-24|2016-09-08|Estimate||||2016-07-24|2016-09-08|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|SONORESCUE|In total, 120 of 214 screened patients fulfilled the inclusion criteria. Subjects were allocated to the sonolysis or control group randomly and equally.|SONOlysis in Risk REduction of Symptomatic and Silent Brain infarCtions dUring Cardiac surgEry|Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring|Completed||Phase 3|120|Actual|University Hospital Ostrava||2|||f||||t||||||||Undecided||2018-05-31 21:24:41.617457|2018-05-31 21:24:41.617457
NCT01591005|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2015-12-22||2016-07-24|2012-05-02|2012-05-03|Estimate|2016-07-24|2016-09-08|Estimate||||2016-07-24|2016-09-08|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|SONOBUSTER|In total, 242 of the 495 screened patients fulfilled the inclusion criteria. Subjects were randomly and equally allocated to the sonolysis or control group. Clinical and procedural variables were well balanced between the groups|SONOlysis in Prevention of Brain Infarctions dUring Carotid Stenting and caroTid EndaRterectomy|Risk Reduction of Symptomatic and Silent Brain Infarctions During Carotid Endarterectomy and Carotid Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring|Completed||Phase 3|242|Actual|University Hospital Ostrava|Serial follow-up MRI was not done. A software package for mapping of brain infarction volume was not used. Single-centre investigation with mandatory use of brain protection device during carotid stenting and shunt during carotid endarterectomy.|4|||f||||t||||||||Undecided||2018-05-31 21:24:42.024934|2018-05-31 21:24:42.024934
NCT01590992|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-08-21|2012-05-02|2012-05-03|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2012||2012-05-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Globus Sensations With Psychotherapy|Psychotherapy and Psychobiology of Somatoform Disorders (Globus Sensations): A Randomized Controlled Trial|Active, not recruiting||Phase 2/Phase 3|175|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:24:42.418999|2018-05-31 21:24:42.418999
NCT01590979|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2016-09-08||2017-02-01|2012-05-01|2012-05-03|Estimate|2017-02-01|2017-03-23|Actual||||2017-02-01|2017-03-23|Actual|April 2012||2012-04-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation|Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation Rates in Post-Operative Cardiac Surgery Patients|Terminated||N/A|54|Actual|Northwell Health|Due to insufficient accrual rate the study was stopped before the recruitment total was met. Thus, a major limitation is small sample size.|2||The study was terminated due to slow rate of accrual resulting in a sample size.|f||||t||||||||No||2018-05-31 21:24:42.500536|2018-05-31 21:24:42.500536
NCT01590966|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2014-12-04|2012-05-02|2012-05-03|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|SCINTRA||Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis|Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis|Unknown status|Recruiting|Phase 3|20|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 21:24:42.702691|2018-05-31 21:24:42.702691
NCT01590953|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-02|2012-05-02|2012-05-03|Estimate|||||||2012-05-02|2012-05-03|Estimate|May 2012||2012-05-31|May 2012|2012-05-31||||||||Observational|||A Study of the Effects of an Employee Wellness Program||Unknown status|Recruiting||80|Anticipated|Ochsner Health System|||||f||||f||||||||||2018-05-31 21:24:42.78438|2018-05-31 21:24:42.78438
NCT01590940|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-05-03|2012-05-02|2012-05-03|Estimate|||||||2012-05-03|2012-05-04|Estimate|April 2012||2012-04-30|May 2012|2012-05-31||||April 2013|Anticipated|2013-04-30||Observational|||Use of Parietex Plug and Patch Hernia System in Open Inguinal Hernia Repair|Use of Parietex Plug-and-patch Hernia Mesh in Elective Open Inguinal Hernia Repair: A Pilot Investigation|Unknown status|Recruiting||50|Anticipated|Owen Drive Surgical Clinic of Fayetteville|||1||f||||||||||||||2018-05-31 21:24:42.828755|2018-05-31 21:24:42.828755
NCT01590927|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-05-02|2012-05-02|2012-05-03|Estimate|||||||2012-05-02|2012-05-03|Estimate|August 2012||2012-08-31|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|February 2013|Anticipated|2013-02-28||Observational|||Reliability and Validation of 3-D Electromagnetic Tracking During Pelvic Floor Muscle (PFM) Activation - a Pilot Study|Reliability and Validation of 3-D Electromagnetic Tracking During Pelvic Floor Muscle (PFM) Activation - a Pilot Study|Unknown status|Not yet recruiting||20|Anticipated|Moser, Helene|||1||f||||f||||||||||2018-05-31 21:24:42.8976|2018-05-31 21:24:42.8976
NCT01590914|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2013-03-08|2012-05-02|2012-05-03|Estimate|||||||2013-03-08|2013-03-11|Estimate|January 2008||2008-01-31|March 2013|2013-03-31||||January 2014|Anticipated|2014-01-31||Interventional|||Brain Activation in Response to Appetitive Cues Pre- and Post- Bariatric Surgery|Brain Activation in Response to Appetite Cues Pre- and Post- Bariatric Surgery|Unknown status|Enrolling by invitation|N/A|120|Anticipated|New York Obesity and Nutrition Research Center||4|||f||||f||||||||||2018-05-31 21:24:42.954019|2018-05-31 21:24:42.954019
NCT01590901|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2013-06-04|2012-05-01|2012-05-03|Estimate|||||||2013-06-04|2013-06-05|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects|The Pharmacokinetics and Safety Study of Probucol by Multiple Administration in Healthy Male Subjects|Completed||Phase 1|12|Actual|Otsuka Beijing Research Institute||1|||f||||t||||||||||2018-05-31 21:24:43.010003|2018-05-31 21:24:43.010003
NCT01590849|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-02|2012-05-02|2012-05-03|Estimate|||||||2012-05-02|2012-05-03|Estimate|January 2011||2011-01-31|May 2012|2012-05-31||||May 2012|Anticipated|2012-05-31||Interventional|||Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone|Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone|Unknown status|Active, not recruiting|Phase 3|69|Actual|Instituto do Coracao||2|||f||||t||||||||||2018-05-31 21:24:45.021181|2018-05-31 21:24:45.021181
NCT01590836|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2017-02-09|2012-05-02|2012-05-03|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2012||2012-04-30|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes|Completed||Phase 1|22|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:24:45.165848|2018-05-31 21:24:45.165848
NCT01590823|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-10-31|2012-05-02|2012-05-03|Estimate|||||||2012-10-31|2012-11-01|Estimate|July 2012||2012-07-31|April 2012|2012-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients|Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients|Completed||Phase 1|10|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 21:24:45.245155|2018-05-31 21:24:45.245155
NCT01590810|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2016-03-03||2017-03-30|2012-05-02|2012-05-03|Estimate|2016-05-17|2016-06-27|Estimate||||2017-03-30|2017-05-03|Actual|May 7, 2012|Actual|2012-05-07|March 2017|2017-03-31|February 5, 2013|Actual|2013-02-05|January 24, 2013|Actual|2013-01-24||Interventional|||A Single Rising Dose Study of MK-8150 (MK-8150-001)|A Single Rising Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150|Completed||Phase 1|34|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 21:24:45.441872|2018-05-31 21:24:45.441872
NCT01590797|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2015-01-16||2017-03-23|2012-05-02|2012-05-03|Estimate|2015-01-16|2015-01-27|Estimate||||2017-03-23|2017-04-21|Actual|July 10, 2012|Actual|2012-07-10|March 2017|2017-03-31|June 25, 2014|Actual|2014-06-25|June 11, 2014|Actual|2014-06-11||Interventional|||A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy, Alone or in Combination With Metformin|Completed||Phase 3|467|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:24:47.228162|2018-05-31 21:24:47.228162
NCT01590784|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-07-27|2012-05-01|2012-05-03|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Observational|||Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS)|The Reliability and Validity of the Thai Version of Calgary Depression Scale for Schizophrenia (CDSS)|Completed|||60|Actual|Chiang Mai University|||||f||||f||||||||||2018-05-31 21:24:47.492523|2018-05-31 21:24:47.492523
NCT01590771|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2015-04-16||2017-03-23|2012-05-02|2012-05-03|Estimate|2015-04-16|2015-05-04|Estimate||||2017-03-23|2017-04-21|Actual|July 9, 2012|Actual|2012-07-09|March 2017|2017-03-31|June 24, 2014|Actual|2014-06-24|June 10, 2014|Actual|2014-06-10||Interventional|||A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy, Alone or in Combination With Metformin|Completed||Phase 3|498|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:24:47.564332|2018-05-31 21:24:47.564332
NCT01590758|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2017-04-14||2017-05-19|2012-05-02|2012-05-03|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|June 2014||2014-06-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|OneStep-1||Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers|A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers|Completed||Phase 3|189|Actual|Dipexium Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 21:24:48.097651|2018-05-31 21:24:48.097651
NCT01590745|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-01-30|2012-05-01|2012-05-03|Estimate|||||||2018-01-30|2018-01-31|Actual|June 2012|Actual|2012-06-30|January 2018|2018-01-31|January 3, 2018|Actual|2018-01-03|February 2017|Actual|2017-02-28||Interventional|CTS||Ultrasound Therapy for Carpal Tunnel Syndrome (CTS)|A Randomised Controlled Double Blind Trial Of Therapeutic Ultrasound in Carpal Tunnel Syndrome (CTS)|Completed||N/A|40|Actual|East Kent Hospitals University NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:24:48.601566|2018-05-31 21:24:48.601566
NCT01590732|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-05-07|2012-05-02|2012-05-03|Estimate|||||||2018-05-07|2018-05-08|Actual|October 9, 2012|Actual|2012-10-09|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02||Interventional|||Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma|Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma|Completed||Phase 1|22|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:24:48.690246|2018-05-31 21:24:48.690246
NCT01590719|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02||2016-07-08|2016-08-04|2012-05-02|2012-05-03|Estimate||||2016-07-08|2016-07-12|Estimate|2016-08-04|2016-08-09|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative Gastroesophageal Cancer|Completed||Phase 2|123|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:24:48.79098|2018-05-31 21:24:48.79098
NCT01590706|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2014-04-01|2012-05-01|2012-05-03|Estimate|||||||2014-04-01|2014-04-02|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Observational|||A Study of Characterizing Cognitive Decline and Functional Cardiac Senescence in Healthy Korean Volunteers|An Association Study of Characterizing Cognitive Decline and Functional Cardiac Senescence Profile Through the Association of Biomarkers and Clinical Outcomes in Healthy Middle Aged and Elderly Korean Volunteers|Completed|||116|Anticipated|Korea Institute of Oriental Medicine|||||f||||t||||||Samples With DNA|"~     Samples for single nucleotide polymorphism, and for cardiac enzyme level detection~   "|||2018-05-31 21:24:48.910067|2018-05-31 21:24:48.910067
NCT01590654|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-12-18|2012-05-02|2012-05-03|Estimate|||||||2013-12-18|2013-12-20|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection|A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection|Completed||Phase 1|51|Actual|Gilead Sciences||8|||f||||t||||||||||2018-05-31 21:24:49.304933|2018-05-31 21:24:49.304933
NCT01590641|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-11-13|2012-05-02|2012-05-03|Estimate|||||||2013-11-13|2013-11-14|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B|A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection|Completed||Phase 1|49|Actual|Gilead Sciences||8|||f||||t||||||||||2018-05-31 21:24:49.399899|2018-05-31 21:24:49.399899
NCT01590628|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2018-01-16|2012-05-02|2012-05-03|Estimate|||||||2018-01-16|2018-01-17|Actual|April 2012||2012-04-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pilot Study Evaluating Safety & Efficacy of a DCBT: NiCord® & UNM CBU to Patients With Hemaglobinopathies After Myeloablative Therapy|Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hemoglobinopathies|Recruiting||Phase 1/Phase 2|15|Anticipated|Gamida Cell ltd||1|||f||||t||||||||||2018-05-31 21:24:49.506235|2018-05-31 21:24:49.506235
NCT01590615|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2017-04-20|2012-05-02|2012-05-03|Estimate|||||||2017-04-20|2017-04-24|Actual|April 26, 2012|Actual|2012-04-26|April 2017|2017-04-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04|1 Year|Observational [Patient Registry]|||Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy|Observational, Post-marketing Renal Safety Surveillance Registry in Subjects With Chronic Hepatitis B (HBV) Infection With Decompensated Liver Disease Receiving Nucleotide/Side Therapy|Completed|||54|Actual|Gilead Sciences|||1||f||||f||f||||||||2018-05-31 21:24:49.662288|2018-05-31 21:24:49.662288
NCT01590602|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-09-14|2012-05-02|2012-05-03|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2011||2011-11-30|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|JHD||REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN)|REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN)|Completed|||78|Actual|European Huntington's Disease Network|||1||f||||f||||||||||2018-05-31 21:24:49.766907|2018-05-31 21:24:49.766907
NCT01590589|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-09-14|2012-05-02|2012-05-03|Estimate|||||||2017-09-14|2017-09-15|Actual|June 2004||2004-06-30|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|REGISTRY||REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)|REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)|Completed|||10000|Actual|European Huntington's Disease Network|||1||f||||f||||||Samples With DNA|"~     -  DNA from whole blood~        -  DNA~        -  Lymphoblastoid cell lines~        -  Urine~   "|||2018-05-31 21:24:49.874376|2018-05-31 21:24:49.874376
NCT01590576|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2016-09-05|2012-05-02|2012-05-03|Estimate|||||||2016-09-05|2016-09-07|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||Population-based Estimates of Medical Comorbidities in Women With Lower Urinary Tract Symptoms or Pelvic Organ Prolapse||Completed|||2500|Actual|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 21:24:50.107478|2018-05-31 21:24:50.107478
NCT01590563|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2013-11-05||2015-10-12|2012-05-02|2012-05-03|Estimate|2015-10-12|2015-11-09|Estimate||||2015-10-12|2015-11-09|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study to Evaluate the Safety and Initial Efficacy of a Novel Intrauterine Device|A Study to Evaluate the Safety and Initial Efficacy of a Spherical Copper Intrauterine Contraceptive Device the IUB(tm)|Completed||Phase 1|15|Actual|Ocon Medical Ltd.||1|||f||||f||||||||||2018-05-31 21:24:50.168205|2018-05-31 21:24:50.168205
NCT01590550|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|2016-02-02||2017-01-09|2012-05-01|2012-05-03|Estimate|2016-02-02|2016-03-01|Estimate||||2017-01-09|2017-02-27|Actual|May 2012||2012-05-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|January 2014|Actual|2014-01-31||Observational|||Observational Study of Citrate Based Dialysis in Pediatric Patients Receiving Hemodialysis|A Prospective Study of Citrate Based Dialysate in Pediatric Patients Receiving Intermittent Hemodialysis|Completed|||18|Actual|Loma Linda University|No control group||1||f||||f||||||||No|Mean data will be presented|2018-05-31 21:24:50.338184|2018-05-31 21:24:50.338184
NCT01590537|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-10-15|2012-05-02|2012-05-03|Estimate|||||||2015-10-15|2015-10-16|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Observational|Mirabel||Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction|Prospective Multicentre Non-interventional Comparative Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction|Completed|||2348|Actual|Bayer|||2||f||||f||||||||||2018-05-31 21:24:50.499166|2018-05-31 21:24:50.499166
NCT01590524|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-10-07|2012-05-02|2012-05-03|Estimate|||||||2014-10-07|2014-10-08|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Feasibility Study on the Effect of Complementary Methods as Supportive Interventions for Parents of Children With Cancer|Randomized Control Trial for the Effect of Guided Imagery and Progressive Muscle Relaxation in Reducing Anxiety for Parents of Hospitalized Children With Cancer|Completed||N/A|52|Actual|Cyprus University of Technology||2|||f||||t||||||||||2018-05-31 21:24:50.567945|2018-05-31 21:24:50.567945
NCT01590511|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-12-03|2012-05-02|2012-05-03|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|IVT NonVent||Echocardiographic Prediction of Fluid Responsiveness After a Mini-fluid Challenge in Non-ventilated Patients With Shock|Echocardiographic Prediction of Fluid Responsiveness After a Mini-fluid Challenge in Non-ventilated Patients With Shock|Completed|||71|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 21:24:50.635525|2018-05-31 21:24:50.635525
NCT01590498|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-05-03|2012-05-01|2012-05-03|Estimate|||||||2012-05-03|2012-05-04|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Radiotherapy vs Observation for CRPC|Salvage Radiotherapy vs Observation for Castration Resistant Prostate Cancer in Central China|Unknown status|Recruiting||2000|Anticipated|Zhengzhou University|||2||f||||f||||||Samples Without DNA|"~     the biopsy specimens of prostate tissue~   "|||2018-05-31 21:24:50.809017|2018-05-31 21:24:50.809017
NCT01590472|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-11-03|2012-05-01|2012-05-03|Estimate|||||||2017-11-03|2017-11-07|Actual|June 2011||2011-06-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Do Your Genes Put You at a Higher Risk of Developing Mesothelioma|Consortium for the Sharing of Germ Line DNA and Tissue From Subjects With Mesothelioma|Completed|||69|Actual|Wake Forest University Health Sciences|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:24:50.959917|2018-05-31 21:24:50.959917
NCT01590459|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27||2015-10-23|2015-10-23|2012-05-01|2012-05-03|Estimate||||2015-10-23|2015-11-20|Estimate|2015-10-23|2015-11-20|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate|A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension|Completed||Phase 2|359|Actual|Vertex Pharmaceuticals Incorporated||5|||f||||t||||||||||2018-05-31 21:24:51.082779|2018-05-31 21:24:51.082779
NCT01590446|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-06-07|2012-05-02|2012-05-03|Estimate|||||||2012-06-07|2012-06-11|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers|A Phase 1, Two-Part, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMN 111 Administered to Healthy Adult Volunteers|Completed||Phase 1|74|Anticipated|BioMarin Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:24:51.336877|2018-05-31 21:24:51.336877
NCT01590433|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2018-01-22|2012-05-02|2012-05-03|Estimate|||||||2018-01-22|2018-01-24|Actual|March 2012||2012-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Weight Loss With Exenatide Treatment|A Prospective Study of Patterns, Predictors, and Mechanisms of Weight Loss With Exenatide Treatment in Overweight and Obese Women Without Diabetes|Active, not recruiting||Phase 4|300|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t|t|f||||||No||2018-05-31 21:24:51.419044|2018-05-31 21:24:51.419044
NCT01590420|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-02|2012-05-02|2012-05-03|Estimate|||||||2012-05-02|2012-05-03|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|March 2014|Anticipated|2014-03-31|March 2011|Actual|2011-03-31||Interventional|||Cost-utility Study of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome Patients|Cost-utility Study of CPAP Treatment in Obstructive Sleep Apnea Patients|Unknown status|Recruiting|Phase 4|1000|Anticipated|Associação Fundo de Incentivo à Pesquisa||1|||f||||t||||||||||2018-05-31 21:24:51.511755|2018-05-31 21:24:51.511755
NCT01590407|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2017-10-27|2012-05-02|2012-05-03|Estimate|||||||2017-10-27|2017-10-31|Actual|December 31, 2011|Actual|2011-12-31|October 2017|2017-10-31|February 28, 2013|Actual|2013-02-28|February 28, 2013|Actual|2013-02-28||Interventional|||First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002200 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection|Completed||Phase 1|71|Actual|Alios Biopharma Inc.||2|||f||||f||f||||||||2018-05-31 21:24:51.652578|2018-05-31 21:24:51.652578
NCT01590394|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2017-09-18||2017-09-18|2012-05-01|2012-05-03|Estimate|2017-09-18|2017-10-17|Actual||||2017-09-18|2017-10-17|Actual|September 2012||2012-09-30|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.|Prospective Evaluation of Luminal Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.|Terminated||N/A|3|Actual|Mayo Clinic|The study was terminated early due to difficulty in enrolling subjects and transporting the scope for sterilization.|1||Difficulty in enrolling subjects and transporting scope for sterilization|f||||f||||||||||2018-05-31 21:24:51.732532|2018-05-31 21:24:51.732532
NCT01590381|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Observational|||Assessment of HBV Vaccine Immunity After 18 Years|Assessment of the Immune Status of New Health Care Workers in the Israel Defense Forces (IDF) Vaccinated in Infancy Against Hepatitis B Virus (HBV), Before and After a Booster Dose.|Unknown status|Recruiting||545|Anticipated|Medical Corps, Israel Defense Force|||10||f||||f||||||Samples Without DNA|"~     blood samples from study subjects vaccinated at infancy, before and after booster dose.~   "|||2018-05-31 21:24:51.867843|2018-05-31 21:24:51.867843
NCT01590368|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-02|2012-05-01|2012-05-02|Estimate|||||||2012-05-02|2012-05-04|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||A Comparative Wear Test of Two Adhesives on the Unilect ™ Biotab Short Term Monitoring Electrode|A Comparative Wear Test of Two Adhesives on the Unilect ™ Biotab Short Term Monitoring Electrode|Unknown status|Not yet recruiting|Phase 3|20|Anticipated|ConvaTec Inc.||2|||f||||f||||||||||2018-05-31 21:24:51.931261|2018-05-31 21:24:51.931261
NCT01590355|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2017-08-03|2012-05-01|2012-05-02|Estimate|||||||2017-08-03|2017-08-04|Actual|June 2012||2012-06-30|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|ORATOR||A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)|A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)|Active, not recruiting||Phase 2|68|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 21:24:52.02018|2018-05-31 21:24:52.02018
NCT01590342|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2017-09-05|2012-05-01|2012-05-02|Estimate|||||||2017-09-05|2017-09-06|Actual|May 2012||2012-05-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|AINEP-1||Diclofenac for Submassive PE|Efficacy of Diclofenac for Patients With Acute Submassive Pulmonary Embolism: a Randomized Clinical Trial|Terminated||Phase 2/Phase 3|34|Actual|Ministry of Health, Spain||2||Low recruitment rate|f||||t||||||||||2018-05-31 21:24:52.106739|2018-05-31 21:24:52.106739
NCT01590329|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Use of Epidermal Expansion System for Epidermal Grafting on Hypopigmented Skin and Surgical Wounds|A Proof of Concept Cases Series on the Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Hypopigmented Skin and Surgical Wounds|Unknown status|Recruiting|N/A|12|Anticipated|Momelan Technologies||1|||f||||f||||||||||2018-05-31 21:24:52.177807|2018-05-31 21:24:52.177807
NCT01590134|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-02-03|2012-05-01|2012-05-02|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|December 2015|Anticipated|2015-12-31|December 2012|Actual|2012-12-31||Interventional|||The Efficacy and Safety of Iron Supplementation|Pilot Studies on the Efficacy and Safety of Dietary Iron Supplementation|Unknown status|Active, not recruiting|N/A|18|Actual|Imperial College London||3|||f||||f||||||||||2018-05-31 21:24:53.870408|2018-05-31 21:24:53.870408
NCT01590316|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-04-10|2012-05-01|2012-05-02|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2012||2012-06-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2013|Actual|2013-12-31||Interventional|SafeBoosC||SafeBoosC - a Phase II Trial|SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants|Completed||N/A|165|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||Yes|Archieving anonymized data at Danish Data Archieve|2018-05-31 21:24:52.259009|2018-05-31 21:24:52.259009
NCT01590303|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Interventional|||Outcome Following Vitamin C Administration in Sepsis|A Pilot Study Examining the Efficacy of Vitamin C Administration in Septic Patients.|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:24:52.33241|2018-05-31 21:24:52.33241
NCT01590290|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|April 2012||2012-04-30|April 2012|2012-04-30||||April 2013|Anticipated|2013-04-30||Interventional|||Randomized Controlled Cluster Trial of Resident Pay for Performance and Cardiovascular Outcomes|Randomized Controlled Cluster Trial of Resident Pay for Performance and Cardiovascular Outcomes|Unknown status|Recruiting|Phase 3|38|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 21:24:52.415226|2018-05-31 21:24:52.415226
NCT01590277|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2017-12-06|2012-04-30|2012-05-02|Estimate|||||||2017-12-06|2017-12-08|Actual|July 1, 2012|Actual|2012-07-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans|Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans|Recruiting||Phase 2|49|Anticipated|VA Office of Research and Development||4|||f||||f|t|f|||f|||Undecided||2018-05-31 21:24:52.486617|2018-05-31 21:24:52.486617
NCT01590264|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2012-09-17||2013-02-25|2012-05-01|2012-05-02|Estimate|2013-02-25|2013-04-02|Estimate||||2013-02-25|2013-04-02|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||rTMS Bimodal Treatment For Tinnitus: A Pilot Study|rTMS Bimodal Treatment For Patients With Subjective Idiopathic Tinnitus: A Pilot Study|Completed||N/A|5|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 21:24:52.568401|2018-05-31 21:24:52.568401
NCT01590251|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-09-23|2012-04-30|2012-05-02|Estimate|||||||2015-09-23|2015-09-25|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Yoga||Yoga for Pain and Opioid Dependence|Yoga for Pain and Opioid Dependence|Completed||Phase 1/Phase 2|8|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:24:52.700421|2018-05-31 21:24:52.700421
NCT01590238|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|2016-09-22||2016-12-29|2012-05-01|2012-05-02|Estimate|2016-09-22|2016-11-10|Estimate||||2016-12-29|2017-02-15|Actual|May 2012||2012-05-31|December 2016|2016-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)|Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)|Completed||Phase 3|15|Actual|The New York Eye & Ear Infirmary||1|||f||||f||||||||||2018-05-31 21:24:52.765017|2018-05-31 21:24:52.765017
NCT01590225|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2015-02-20|2012-05-01|2012-05-02|Estimate|||||||2015-02-20|2015-02-23|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)|A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 21:24:52.877935|2018-05-31 21:24:52.877935
NCT01590212|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2013-07-31||2014-03-05|2012-05-01|2012-05-02|Estimate|2014-01-30|2014-03-05|Estimate||||2014-03-05|2014-04-02|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Two participants withdrew and two were unable to be contacted.|Mellow Bumps RCT - Antenatal Intervention for Vulnerable Women|Antenatal Parenting Support for Women Vulnerable in Pregnancy: an Exploratory Randomised Controlled Trial of Mellow Bumps|Completed||N/A|35|Actual|University of Glasgow|Participants lived in one health board area and one community health care partnership (CHCP) in the west of Scotland. Midwives may have approached only those potential participants who were thought to be likely to take part in the group programmes.|3|||f||||f||||||||||2018-05-31 21:24:52.962392|2018-05-31 21:24:52.962392
NCT01590199|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2018-05-11|2012-04-30|2012-05-02|Estimate|||||||2018-05-11|2018-05-16|Actual|May 18, 2012|Actual|2012-05-18|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|December 31, 2018|Anticipated|2018-12-31||Interventional|MACS2002||Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs|"Extension Study to the Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study"|Active, not recruiting||Phase 1|18|Actual|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 21:24:53.453391|2018-05-31 21:24:53.453391
NCT01590186|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2014-03-28|2012-04-30|2012-05-02|Estimate|||||||2014-03-28|2014-03-31|Estimate|October 2002||2002-10-31|March 2014|2014-03-31|January 2004|Actual|2004-01-31|April 2003|Actual|2003-04-30||Observational|||Examination and Treatment of Pain in Front Foot|Examination and Treatment of Pain in Front Foot|Completed|||40|Actual|Northern Orthopaedic Division, Denmark|||||f||||f||||||||||2018-05-31 21:24:53.523177|2018-05-31 21:24:53.523177
NCT01590173|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2016-07-17|2012-05-01|2012-05-02|Estimate|||||||2016-07-17|2016-07-19|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles|Addition of Prednisolone and Heparin in Patients With Repeated Implantation Failures: a Prospective Clinical Study|Completed||Phase 2/Phase 3|86|Actual|National and Kapodistrian University of Athens||2|||f||||||||||||||2018-05-31 21:24:53.569816|2018-05-31 21:24:53.569816
NCT01590160|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2017-10-31|2012-05-01|2012-05-02|Estimate|||||||2017-10-31|2017-11-01|Actual|August 2013||2013-08-31|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|MESO-02||Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma|A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma|Active, not recruiting||Phase 1/Phase 2|27|Actual|University College, London||2|||f||||t||||||||||2018-05-31 21:24:53.644261|2018-05-31 21:24:53.644261
NCT01590147|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2017-11-02|2012-05-01|2012-05-02|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2011||2011-06-30|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SIPS||Supportive Intervention Programs Study|Supportive Intervention Programs to Lessen Treatment Related Symptoms|Completed||N/A|15|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 21:24:53.709185|2018-05-31 21:24:53.709185
NCT01590121|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-05-28|2012-05-01|2012-05-02|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|Flying and HHT||Hereditary Haemorrhagic Telangiectasia Flight Safety Study|A Questionnaire Based Study to Evaluate the Safety of Flying in Hereditary Haemorrhagic Telangiectasia (HHT)|Completed|||145|Actual|Imperial College London|||1||f||||f||||||||||2018-05-31 21:24:53.957648|2018-05-31 21:24:53.957648
NCT01590108|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2016-02-15|2012-05-01|2012-05-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|EXAP||The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects|The Apelin-APJ System in Idiopathic Pulmonary Arterial Hypertension and Healthy Volunteers; Tissue Location and Cardiopulmonary Response.|Completed||Phase 1|12|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 21:24:54.203125|2018-05-31 21:24:54.203125
NCT01590095|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2016-10-27|2012-05-01|2012-05-02|Estimate|||||||2016-10-27|2016-10-28|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||WASH Benefits Bangladesh|WASH Benefits Bangladesh: A Cluster Randomized Controlled Trial of the Benefits of Water, Sanitation, Hygiene Plus Nutrition Interventions on Child Growth|Active, not recruiting||N/A|5040|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||7|||f||||t||||||||||2018-05-31 21:24:54.318362|2018-05-31 21:24:54.318362
NCT01590082|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-11-10|2012-04-30|2012-05-02|Estimate|||||||2015-11-10|2015-11-13|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Doxycycline, Temozolomide and Ipilimumab in Melanoma|Phase I / II Study of the Combination of Doxycycline With Temozolomide and Ipilimumab in Patients With Metastatic Melanoma|Terminated||Phase 1/Phase 2|12|Actual|M.D. Anderson Cancer Center||1||Accrual slow due to alternate trials and treatment options.|f||||f||||||||||2018-05-31 21:24:54.433938|2018-05-31 21:24:54.433938
NCT01590069|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2018-04-18|2012-04-30|2012-05-02|Estimate|||||||2018-04-18|2018-04-20|Actual|June 2012|Actual|2012-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Aerosol IL-2 for Pulmonary Metastases|Phase I/II Study of Aerosol Interleukin-2 for Pulmonary Metastases|Active, not recruiting||Phase 1/Phase 2|56|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:24:54.542303|2018-05-31 21:24:54.542303
NCT01590056|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Emotional and Cognitive Subthalamic Nucleus in Deep Brain Stimulation Treated Parkinson Patients|Mapping and Manipulating the Motor, Emotional and Cognitive Territories of the Subthalamic Area in Deep Brain Stimulation Treated Parkinson Patients|Unknown status|Recruiting||20|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 21:24:54.6374|2018-05-31 21:24:54.6374
NCT01590043|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-09-06|2012-04-30|2012-05-02|Estimate|||||||2012-09-06|2012-09-07|Estimate|May 2012||2012-05-31|July 2012|2012-07-31||||May 2013|Anticipated|2013-05-31||Observational|||Identifying Saliva Markers in Inflammatory Bowel Disease||Unknown status|Recruiting||160|Anticipated|Hadassah Medical Organization|||3||f||||||||||Samples With DNA|"~     Whole saliva~   "|||2018-05-31 21:24:54.719655|2018-05-31 21:24:54.719655
NCT01590030|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-02|2012-05-01|2012-05-02|Estimate|||||||2012-05-02|2012-05-03|Estimate|September 2004||2004-09-30|May 2012|2012-05-31|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Interventional|||Ovarian Mesial Incision: a New Safe and Fertility-sparing Technique|Mesial Incision for Laparoscopic Dermoid Cystectomy: a New Safe and Fertility-sparing Technique|Completed||N/A|67|Actual|University Magna Graecia||2|||f||||f||||||||||2018-05-31 21:24:54.797716|2018-05-31 21:24:54.797716
NCT01590017|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2018-04-20|2012-05-01|2012-05-02|Estimate|||||||2018-04-20|2018-04-24|Actual|April 1, 2014|Actual|2014-04-01|April 2018|2018-04-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer|Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer|Completed||Phase 2|41|Actual|AIDS Malignancy Consortium||1|||f||||f|f|f|||f|||Undecided||2018-05-31 21:24:54.867114|2018-05-31 21:24:54.867114
NCT01590004|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-05-18|2012-05-01|2012-05-02|Estimate|||||||2015-05-18|2015-05-19|Estimate|August 2012||2012-08-31|May 2015|2015-05-31||||March 2016|Anticipated|2016-03-31||Observational|||Technical Description of Cooled Radiofrequency Ablation of Lumbar Medial Branches for the Treatment of Lumbar Facet Pain|Technical Description of Cooled Radiofrequency Ablation of Lumbar Medial Branches for the Treatment of Lumbar Facet Pain|Unknown status|Recruiting||10|Anticipated|MAPS Applied Research Center|||||f||||t||||||||||2018-05-31 21:24:54.943153|2018-05-31 21:24:54.943153
NCT01589991|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-10-25|2012-05-01|2012-05-02|Estimate|||||||2013-10-25|2013-10-28|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Anticaries Potential and Fluorosis Risk From Different Fluoride Toothpastes|Anticaries Potential and Fluorosis Risk From Different Fluoride Toothpastes|Completed||Phase 1|24|Actual|University of Campinas, Brazil||4|||f||||f||||||||||2018-05-31 21:24:55.003011|2018-05-31 21:24:55.003011
NCT01589978|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2016-01-25||2018-05-29|2012-05-01|2012-05-02|Estimate|2016-03-30|2016-05-03|Estimate||||2018-05-29|2018-05-31|Estimate|May 2012||2012-05-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|August 2014|Actual|2014-08-31||Interventional|||PROMUS Element Plus US Post-Approval Study|A U.S. Post-Approval Study of the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System|Active, not recruiting||Phase 4|2681|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 21:24:55.128281|2018-05-31 21:24:55.128281
NCT01589965|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|February 2010|Actual|2010-02-28||Interventional|||The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence in Lesotho|The Impact of Short-term Financial Incentives on Sexual Behavior and HIV Incidence Among Youth: Evidence From a Randomized Controlled Field Trial in Lesotho|Unknown status|Active, not recruiting|Early Phase 1|5000|Anticipated|Bocconi University||3|||f||||t||||||||||2018-05-31 21:24:56.114239|2018-05-31 21:24:56.114239
NCT01589952|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Interventional|Bangabandhu||Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)|Pilot Study of First Line Combination Treatment With Low Dose Pegylated Interferon and Entecavir in Treatment-naïve Patients With Chronic Hepatitis B.|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||1|||f||||f||||||||||2018-05-31 21:24:56.174352|2018-05-31 21:24:56.174352
NCT01589939|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-05-13|2012-05-01|2012-05-02|Estimate|||||||2016-05-13|2016-05-17|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Observational|PTV||Reduced Planning Target Volume (PTV) Margins for the Treatment of Prostate Cancer Using the Calypso 4D Localization System|Reduced PTV Margins for the Treatment of Prostate Cancer With IMRT Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study|Unknown status|Active, not recruiting||40|Anticipated|U.S. Army Medical Research Acquisition Activity|||||f||||t||||||||||2018-05-31 21:24:56.243761|2018-05-31 21:24:56.243761
NCT01589926|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|July 2012||2012-07-31|May 2012|2012-05-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Bi-Level Positive Airway Ventilation for Acute Chest Syndrome|Early Bi-Level Positive Airway Pressure (BLPAP) Ventilation for Acute Chest Syndrome (ACS) - a Double-Blind Randomized Controlled Pilot Study|Unknown status|Not yet recruiting|N/A|60|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 21:24:56.293063|2018-05-31 21:24:56.293063
NCT01589913|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-05-08|2012-05-01|2012-05-02|Estimate|||||||2017-05-08|2017-05-10|Actual|May 2012||2012-05-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2015|Actual|2015-11-30||Interventional|REACH-ICD||REmote Web Assisted Care for Heart Failure Patients With Implantable Cardioverter Defibrillators|Remote Care for Reducing Cardiac Fear, Fear of Dying, Depression, and Increasing Quality of Life in ICD‐Patients With Cardiac Insufficiency/at Risk for Fatal Cardiac Arrhythmia.|Active, not recruiting||N/A|118|Actual|Wuerzburg University Hospital||2|||f||||t||||||||No||2018-05-31 21:24:56.363542|2018-05-31 21:24:56.363542
NCT01589900|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-02|2012-05-01|2012-05-02|Estimate|||||||2012-05-02|2012-05-03|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|December 2006|Actual|2006-12-31||Observational|||Identification the Expression of Sox2 in Colorectal Cancer Tissues|The Role of Sox2 in Tumor Genesis and Migration in Colorectal Cancer|Completed|||136|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 21:24:56.437431|2018-05-31 21:24:56.437431
NCT01589874|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-04-30|2012-04-30|2012-05-02|Estimate|||||||2012-04-30|2012-05-02|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|March 2012|Actual|2012-03-31||Observational|||Anemia of Inflammation: Investigation on Impaired Iron Regulation in Acutely Ill Patients and Their Clinical Outcome|Anemia of Inflammation: Investigation on Impaired Iron Regulation in Acutely Ill Patients and Their Clinical Outcome|Unknown status|Recruiting||100|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||1||f||||t||||||Samples With DNA|"~     serum, buffy coat~   "|||2018-05-31 21:24:57.483506|2018-05-31 21:24:57.483506
NCT01589861|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-03-27|2012-04-30|2012-05-02|Estimate|||||||2017-03-27|2017-03-28|Actual|December 2011||2011-12-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PIKHER2||Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer|A Phase Ib/II Open-label Study Evaluating Safety and Efficacy of Oral BKM120 in Combination With Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Locally Advanced, Recurrent and Metastatic Breast Cancer. PIKHER2/IPC 2011-001|Suspended||Phase 1/Phase 2|106|Anticipated|Institut Paoli-Calmettes||1||Data analysis|f||||t||||||||||2018-05-31 21:24:57.556915|2018-05-31 21:24:57.556915
NCT01589848|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-07-02|2012-04-30|2012-05-02|Estimate|||||||2013-07-02|2013-07-03|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|VWD||Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador|Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador|Completed|||81|Actual|Universidad del Azuay|||1||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 21:24:57.624796|2018-05-31 21:24:57.624796
NCT01589835|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2014-03-04|2012-05-01|2012-05-02|Estimate|||||||2014-03-04|2014-03-05|Estimate|July 2012||2012-07-31|March 2014|2014-03-31||||October 2013|Actual|2013-10-31||Interventional|FLIP||Preventing Diabetes in Those at Risk by Having a Facilitator and Family Doctor Encourage Healthy Activity and Eating Habits|Preventing Diabetes With Facilitated Lifestyle Intervention Prescriptions.Phase 2: Pilot Study|Completed||Phase 2|59|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 21:24:57.683587|2018-05-31 21:24:57.683587
NCT01589822|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2014-07-16||2015-02-24|2012-05-01|2012-05-02|Estimate|2015-02-24|2015-02-25|Estimate||||2015-02-24|2015-02-25|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional||Subjects enrolled who consented and were randomized into the study or assigned to the non-randomized portion and had the investigational product applied were included in the analysis sets. The Safety Set consists of 125 subjects treated with EVICEL (41 Non- Randomized) and 89 subjects treated with Standard of Care.|The EVICEL® Gastrointestinal Study|A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques|Completed||Phase 2|214|Actual|Ethicon, Inc.||3|||f||||t||||||||||2018-05-31 21:24:57.77658|2018-05-31 21:24:57.77658
NCT01589809|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-06-30|2012-04-30|2012-05-02|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2012||2012-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Nicotinamide in Friedreich's Ataxia|Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in Friedreich's Ataxia|Active, not recruiting||Phase 2|40|Anticipated|Imperial College London||1|||f||||f||||||||||2018-05-31 21:24:58.647157|2018-05-31 21:24:58.647157
NCT01589796|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-04-30|2012-04-30|2012-05-02|Estimate|||||||2012-04-30|2012-05-02|Estimate|April 2012||2012-04-30|April 2012|2012-04-30||||February 2013|Anticipated|2013-02-28||Interventional|||Medial Versus Traditional Approach to US-guided TAP Blocks for Open Inguinal Hernia Repair|Effect of Medial vs Traditional Approach to US-guided Transverse Abdominis Plane (TAP) Blocks on Analgesia After Open Inguinal Hernia Repair|Unknown status|Recruiting|N/A|100|Anticipated|Stamford Anesthesiology Services, PC||2|||f||||t||||||||||2018-05-31 21:24:58.728472|2018-05-31 21:24:58.728472
NCT01589783|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2015-07-26|2012-04-30|2012-05-02|Estimate|||||||2015-07-26|2015-07-28|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|||Vitamin D During Pregnancy|Evaluation of the Influence of Education, Knowledge and Existing Guidelines on the Consumption of Vitamin D During Pregnancy.|Completed|||764|Actual|Hadassah Medical Organization|||2||f||||f||||||||||2018-05-31 21:24:58.824283|2018-05-31 21:24:58.824283
NCT01589770|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-11-30|2012-04-30|2012-05-02|Estimate|||||||2017-11-30|2017-12-04|Actual|August 2012||2012-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Inflammation and the Heart|Inflammation and the Heart|Active, not recruiting|||345|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||Samples With DNA|"~     serum plasma DNA RNA~   "|||2018-05-31 21:24:58.893288|2018-05-31 21:24:58.893288
NCT01589068|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-01-14|2012-04-27|2012-05-01|Estimate|||||||2013-01-14|2013-01-15|Estimate|January 2007||2007-01-31|January 2013|2013-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs||Suspended||N/A|300|Anticipated|Mclean Hospital||3||Clinical studies stopped, pending funding.|f||||f||||||||||2018-05-31 21:25:07.739051|2018-05-31 21:25:07.739051
NCT01589757|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-05-19|2012-05-01|2012-05-02|Estimate|||||||2016-05-19|2016-05-20|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|GIinGDM||MAIN STUDY: Low Glycaemic Index (GI) Diet in the Management of GDM SUB-STUDY: The Breast Milk Sub-Study|The Effect of a Low GI Diet on Maternal and Neonatal Markers of Glycaemic Control and Postpartum Diabetes Risk SUBSTUDY The Effect of a Low GI Diet on Postpartum Markers of Oxidation in Breast Milk of Women With Gestational Hyperglycaemia|Completed||Phase 2/Phase 3|99|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 21:24:58.970508|2018-05-31 21:24:58.970508
NCT01589744|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-10-17|2012-04-30|2012-05-02|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|HEMOGYN||Proof of Concept Study of a Sucker Hemostatic Intra Uterine in Postpartum Hemorrhage After Abruptio Placenta Assisted|Vacuum Device for Hemostasis in Obstetrics and Gynecology: Proof of Concept Study in the Post Partum Hemorrhage|Terminated||N/A|1|Actual|University Hospital, Grenoble||1||Non adequation between the medical device and the study population|f||||t||||||||||2018-05-31 21:24:59.091462|2018-05-31 21:24:59.091462
NCT01589731|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-30|2012-05-02|Estimate|||||||2012-04-30|2012-05-02|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Observational|ImmuneBLG||Polymerized Beta-lactoglobulin Comparative Immunoreactivity|Study of the Immunoreactivity of Native and Polymerized Beta-lactoglobulin in Children and Adults With Cow's Milk Allergy and/or Intolerance|Completed|||114|Actual|University of Campinas, Brazil|||3||f||||f||||||||||2018-05-31 21:24:59.161142|2018-05-31 21:24:59.161142
NCT01589718|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2014-03-04|2012-04-30|2012-05-02|Estimate|||||||2014-03-04|2014-03-05|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|No-Crunch01||A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy|A Phase III Randomized 1:1, Masked, Study of the Safety, Tolerability, and Efficacy of Intravitreal Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Adjuvant Management of TRD and Vit Hem Associated With PDR|Withdrawn||Phase 3|0|Actual|Greater Houston Retina Research||2||No patients were enrolled|f||||t||||||||||2018-05-31 21:24:59.222678|2018-05-31 21:24:59.222678
NCT01589705|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-07-29|2012-05-01|2012-05-02|Estimate|||||||2012-07-29|2012-07-31|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease|Endothelial Dysfunction in Patients With Polycystic Kidney Disease|Terminated|||150|Actual|TC Erciyes University|||1|Patients recruitment and analysis were terminated|f||||f||||||||||2018-05-31 21:24:59.398781|2018-05-31 21:24:59.398781
NCT01589692|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2018-05-23|2012-05-01|2012-05-02|Estimate|||||||2018-05-23|2018-05-25|Actual|April 2012|Actual|2012-04-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2018|Actual|2018-02-28||Interventional|WRIST||A Clinical Trial for the Surgical Treatment of Elderly Distal Radius Fractures|A Clinical Trial for the Surgical Treatment of Elderly Distal Radius Fractures. The Wrist and Radius Injury Surgical Trial (WRIST)|Active, not recruiting||N/A|304|Actual|University of Michigan||4|||f||||t|f|f||||||||2018-05-31 21:24:59.517942|2018-05-31 21:24:59.517942
NCT01589679|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-08-08|2012-04-30|2012-05-02|Estimate|||||||2013-08-08|2013-08-12|Estimate|April 2012||2012-04-30|August 2013|2013-08-31||||May 2016|Anticipated|2016-05-31||Interventional|Bunionectomy||Contracture Reduction Following Bunionectomy: a Longitudinal, Controlled Trial|Contracture Reduction Following Bunionectomy: a Longitudinal, Controlled Trial|Terminated||N/A|40|Actual|Dynasplint Systems, Inc.||2||Unrelated to Trial|f||||f||||||||||2018-05-31 21:24:59.633881|2018-05-31 21:24:59.633881
NCT01589666|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-02-06|2012-04-30|2012-05-02|Estimate|||||||2017-02-06|2017-02-07|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Interventional|||Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers|Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers|Completed||Phase 1|27|Actual|Entegrion, Inc.||1|||f||||t||||||||||2018-05-31 21:24:59.702952|2018-05-31 21:24:59.702952
NCT01589653|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2016-06-29||2017-06-08|2012-04-30|2012-05-02|Estimate|2016-06-29|2016-08-09|Estimate||||2017-06-08|2017-07-11|Actual|May 26, 2012|Actual|2012-05-26|June 2017|2017-06-30|July 9, 2015|Actual|2015-07-09|July 9, 2015|Actual|2015-07-09||Interventional|||Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients|A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin|Completed||Phase 4|155|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:24:59.802172|2018-05-31 21:24:59.802172
NCT01589640|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Observational|||Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance|Phase 4 Study Accessing Patient Satisfaction and Tear Osmolarity While Using Blink Tears, Blink Gel Tears and Systane Balance|Unknown status|Not yet recruiting||60|Anticipated|Ophthalmic Consultants of Connecticut|||3||f||||f||||||||||2018-05-31 21:25:00.138879|2018-05-31 21:25:00.138879
NCT01589627|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-30|2012-05-02|Estimate|||||||2012-04-30|2012-05-02|Estimate||||April 2012|2012-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Wrist Extension Dynasplint (WED) Distal Radius Fracture|Contracture Reduction Following Distal Radius Fracture|Unknown status|Not yet recruiting|N/A|50|Anticipated|Dynasplint Systems, Inc.||2|||f||||||||||||||2018-05-31 21:25:00.231395|2018-05-31 21:25:00.231395
NCT01589614|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-08-16|2012-04-30|2012-05-02|Estimate|||||||2012-08-16|2012-08-17|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study To Investigate The Effect Of Erythromycin On The Pharmacokinetics Of PH-797804|A Phase 1, Randomised, Open Label, Two Sequence, Two Treatment, Two Way Crossover Study to Estimate the Steady-state Effect of Erythromycin on the Single Dose Pharmacokinetics of Ph-797804 in Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:25:00.300788|2018-05-31 21:25:00.300788
NCT01589601|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|2017-02-27||2017-04-28|2012-04-30|2012-05-02|Estimate|2017-04-28|2017-07-24|Actual||||2017-04-28|2017-07-24|Actual|August 2012||2012-08-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PAL-HF||Palliative Care in Heart Failure|Palliative Care in Heart Failure (PAL-HF)|Completed||N/A|150|Actual|Duke University||2|||f||||t||||||||||2018-05-31 21:25:00.412977|2018-05-31 21:25:00.412977
NCT01589588|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-10-09|2012-04-30|2012-05-02|Estimate|||||||2015-10-09|2015-10-12|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Administration of Oxygen to Cluster Headache Patients||Completed||N/A|57|Actual|Danish Headache Center||4|||f||||||||||||||2018-05-31 21:25:00.782677|2018-05-31 21:25:00.782677
NCT01589575|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-03-30|2012-05-01|2012-05-02|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|StressRéa||Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives|Evaluation of the Impact of Symptoms of Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives|Completed|||208|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 21:25:00.843426|2018-05-31 21:25:00.843426
NCT01589562|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-01-21|2012-04-30|2012-05-02|Estimate|||||||2013-01-21|2013-01-23|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fed Condition|A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of DW-ES(B) and Megace® Under Fed Conditions in Healthy Male Volunteers|Completed||Phase 1|28|Anticipated|Daewon Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:25:01.001145|2018-05-31 21:25:01.001145
NCT01589549|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-06-08|2012-04-30|2012-05-02|Estimate|||||||2015-06-08|2015-06-09|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mesenchymal Stromal Cells for Acute Graft Versus Host Disease|A Phase 2 Trial of Standard of Care Treatment Versus Mesenchymal Stromal Cell Therapy Together With Standard of Care for the Treatment of de Novo Acute Graft Versus Host Disease Following Allogeneic Bone Marrow Transplantation|Unknown status|Recruiting|Phase 2|66|Anticipated|Royal Perth Hospital||2|||f||||t||||||||||2018-05-31 21:25:01.071475|2018-05-31 21:25:01.071475
NCT01589536|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|SINKO||Social Medical Progression of Coronary Heart Disease With Associated Psychosocial Comorbidity -Interval Rehabilitation.|Improvement of the Social Medical Progression of Coronary Heart Disease With Associated Psychosocial Comorbidity by the Use of Interval Rehabilitation.|Unknown status|Recruiting|N/A|480|Anticipated|Clinic Roderbirken||2|||f||||t||||||||||2018-05-31 21:25:01.22436|2018-05-31 21:25:01.22436
NCT01589523|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-12-06|2012-04-30|2012-05-02|Estimate|||||||2016-12-06|2016-12-08|Estimate|February 2006||2006-02-28|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis|Conjugated Cholic Acid for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-Chain Conjugation|Enrolling by invitation||Phase 3|20|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 21:25:01.309944|2018-05-31 21:25:01.309944
NCT01589510|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2014-01-21||2014-05-15|2012-05-01|2012-05-02|Estimate|2014-05-15|2014-06-13|Estimate||||2014-05-15|2014-06-13|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)||Completed|||419|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:25:01.406947|2018-05-31 21:25:01.406947
NCT01589497|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2017-01-24||2018-03-12|2012-05-01|2012-05-02|Estimate|2017-03-24|2017-04-04|Actual||||2018-03-12|2018-04-06|Actual|June 30, 2015||2015-06-30|March 2018|2018-03-31|February 10, 2016|Actual|2016-02-10|January 28, 2016|Actual|2016-01-28||Interventional||Intent to treat: All enrolled 69 participants were included in the baseline characteristics.|Essentiality of INH in TB Therapy|Essentiality of Isoniazid in Tuberculosis Therapy|Completed||Phase 2|69|Actual|AIDS Clinical Trials Group||4|||f||||t||||||||||2018-05-31 21:25:01.844606|2018-05-31 21:25:01.844606
NCT01589484|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|2014-12-05||2014-12-17|2012-05-01|2012-05-02|Estimate|2014-12-05|2014-12-12|Estimate||||2014-12-17|2015-01-07|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones|Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones: Results From a Prospective Multifactorial Analysis|Completed||N/A|104|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 21:25:03.257181|2018-05-31 21:25:03.257181
NCT01589471|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2018-02-09|2012-04-30|2012-05-02|Estimate|||||||2018-02-09|2018-02-12|Actual|May 2012||2012-05-31|May 2015|2015-05-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||The Value of Botox-A for Management of Low Anterior Resection Syndrome|The Value of Botox-A Administered as a Single Intra-rectal Injection for the Management of Low Anterior Resection Syndrome: A Phase II Study|Completed||Phase 2|23|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 21:25:03.385537|2018-05-31 21:25:03.385537
NCT01589458|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Fluoride Availability in Saliva After Use of Sodium Fluoride or Monofluorophosphate Toothpastes|Fluoride Availability in Saliva After Use of NaF or MFP Toothpastes|Completed||Phase 1|12|Actual|University of Campinas, Brazil||3|||f||||f||||||||||2018-05-31 21:25:03.453096|2018-05-31 21:25:03.453096
NCT01589445|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|2012-05-05||2014-02-26|2012-05-01|2012-05-02|Estimate|2014-01-08|2014-02-27|Estimate||||2014-02-26|2014-02-28|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|T2DMCT||Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects|Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.|Completed||Phase 4|77|Actual|University of Dhaka|The sample size was relatively small for more detailed analysis, treatment period was also short and there was a possibility of confounding by the use of non-study medication.|2|||f||||t||||||||||2018-05-31 21:25:03.542442|2018-05-31 21:25:03.542442
NCT01589432|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-01-02|2012-04-30|2012-05-02|Estimate|||||||2013-01-02|2013-01-03|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy|A Randomized, Double-blind, Placebo and Active-controlled Study of the Electrophysiological Effects of ABT-639 on Spontaneous Activity in C-Nociceptors in Patients With Painful Diabetic Peripheral Neuropathy|Completed||Phase 2|39|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 21:25:04.066678|2018-05-31 21:25:04.066678
NCT01589419|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2017-11-16|2012-04-30|2012-05-02|Estimate|||||||2017-11-16|2017-11-20|Actual|June 2012||2012-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer|An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)|Completed||Phase 1|32|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:25:04.150695|2018-05-31 21:25:04.150695
NCT01589406|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|||2012-05-01|2012-05-01|2012-05-02|Estimate|||||||2012-05-01|2012-05-02|Estimate|June 2012||2012-06-30|April 2012|2012-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||Quality of Life and Sexuality in Women With Gynaecological Cancer|Quality of Life and Sexuality in Women With Gynaecological Cancer|Unknown status|Not yet recruiting||100|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 21:25:04.25445|2018-05-31 21:25:04.25445
NCT01589393|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-03-20|2012-04-28|2012-05-02|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2010||2010-09-30|April 2012|2012-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|OPTTTICH||OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)|OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)|Completed||N/A|52|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 21:25:04.311246|2018-05-31 21:25:04.311246
NCT01589380|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|||2012-04-30|2012-04-29|2012-05-01|Estimate|||||||2012-04-30|2012-05-02|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|May 2013|Anticipated|2013-05-31||Interventional|ALFA||A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)|Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis|Unknown status|Recruiting|Phase 4|100|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:25:04.387743|2018-05-31 21:25:04.387743
NCT01589367|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2018-04-17|2012-04-29|2012-05-01|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2012||2012-05-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer|Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer|Recruiting||Phase 2|208|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 21:25:04.500354|2018-05-31 21:25:04.500354
NCT01589354|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|||2012-04-30|2012-04-29|2012-05-01|Estimate|||||||2012-04-30|2012-05-02|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery|Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery|Unknown status|Not yet recruiting|N/A|60|Anticipated|NHS Grampian||2|||f||||f||||||||||2018-05-31 21:25:04.59268|2018-05-31 21:25:04.59268
NCT01589341|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-29|||2016-05-17|2012-04-29|2012-05-01|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2012||2012-04-30|May 2016|2016-05-31||||August 2012|Actual|2012-08-31||Observational|||Studying Chromosomes in Samples From Younger Patients With Neuroblastoma|Prognostic Impact of Segmental Chromosome Aberrations in Non MYCN Amplified Neuroblastomas in Different Age Groups|Completed|||300|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tumor tissue~   "|||2018-05-31 21:25:04.66665|2018-05-31 21:25:04.66665
NCT01589328|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2018-01-01|2012-04-30|2012-05-01|Estimate|||||||2018-01-01|2018-01-03|Actual|March 15, 2012|Actual|2012-03-15|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|EPADE-PB||Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB|Randomized Controlled Trials for the Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB|Completed||N/A|288|Actual|National Cancer Center, Korea||2|||f||||f||||||||No||2018-05-31 21:25:04.745673|2018-05-31 21:25:04.745673
NCT01589315|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-29|2012-04-29|2012-05-01|Estimate|||||||2012-04-29|2012-05-01|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|FEAST||Focal Electroconvulsive Therapy for Depression|Focal Electrical Administered Seizure Therapy (FEAST) for Major Depression|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 21:25:04.814824|2018-05-31 21:25:04.814824
NCT01589302|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-03-20|2012-04-27|2012-05-01|Estimate|||||||2017-03-20|2017-03-21|Actual|May 21, 2012|Actual|2012-05-21|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|July 28, 2016|Actual|2016-07-28||Interventional|||PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia|A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)|Active, not recruiting||Phase 2|78|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:25:04.907387|2018-05-31 21:25:04.907387
NCT01589289|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-01-15|2012-04-28|2012-05-01|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|Nidiag-Neuro||Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC|Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo|Completed||Phase 3|352|Actual|Institute of Tropical Medicine, Belgium||1|||f||||f||||||||||2018-05-31 21:25:05.004591|2018-05-31 21:25:05.004591
NCT01589276|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-04-28|2012-04-28|2012-05-01|Estimate|||||||2012-04-28|2012-05-01|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Observational|||Risk Factors and Results of Emergency Ventral Hernia Repair|Risk Factors and Results of Emergency Ventral Hernia Repair|Completed|||10976|Actual|Zealand University Hospital|||2||f||||f||||||||||2018-05-31 21:25:05.08727|2018-05-31 21:25:05.08727
NCT01589263|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2018-04-30|2012-04-27|2012-05-01|Estimate|||||||2018-04-30|2018-05-01|Actual|June 1, 2012|Actual|2012-06-01|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 28, 2018|Anticipated|2018-08-28||Interventional|||Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With Benign Prostatic Hyperplasia and Lower Urinary Track Symptoms (BPH)|OnabotulinumtoxinA (onaBoNT-A) vs Oral Tamsulosin for BPH & LUTS (#02-10-10-05)|Recruiting||Phase 2|74|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||f|||No||2018-05-31 21:25:05.165133|2018-05-31 21:25:05.165133
NCT01589250|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-30|2012-05-01|Estimate|||||||2012-04-30|2012-05-01|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Observational|||Risk Scoring Systems in Upper GI-haemorrhage|Risk Scoring Systems in Upper GI-haemorrhage|Completed|||831|Actual|Odense University Hospital|||||f||||f||||||||||2018-05-31 21:25:05.333491|2018-05-31 21:25:05.333491
NCT01589055|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-03-18|2012-04-27|2012-05-01|Estimate|||||||2013-03-18|2013-03-19|Estimate|April 2005||2005-04-30|March 2013|2013-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||IV Nicotine Induced Changes in Hormone Function, Mood States and Behavior|IV Nicotine Induced Changes in Hormone Function, Mood States and Behavior|Suspended||N/A|180|Anticipated|Mclean Hospital||3|||f||||f||||||||||2018-05-31 21:25:07.82002|2018-05-31 21:25:07.82002
NCT01589237|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2016-06-17||2016-09-26|2012-04-30|2012-05-01|Estimate|2016-09-26|2016-11-15|Estimate||||2016-09-26|2016-11-15|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Full analysis set (FAS) – All subjects in the extension study who were in full analysis set in either study LCQ908A2212/NCT01146522 or LCQ908B2302/NCT01514461.|Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.|An Open Label, 52-week, Safety and Tolerability Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.|Terminated||Phase 3|38|Actual|Novartis|As the anticipated benefit from the continued participation of patients in 18 month extension (Part B) was not supported by results of the December 2014 interim analysis, Novartis decided to terminate the Part B to be effective as of May 31, 2015.|1||"Interim analysis suggested that size of benefit anticipated from continued participation of~   patients in Part B no longer supported trial extension beyond Part A"|f||||f||||||||||2018-05-31 21:25:05.450474|2018-05-31 21:25:05.450474
NCT01589224|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-10-12|2012-04-28|2012-05-01|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 2012||2012-05-31|April 2012|2012-04-30||||August 2012|Actual|2012-08-31||Observational|||Risk Factor Analysis for Coronary Atherosclerosis Measured by MDCT||Completed|||150|Actual|Korea University|||1||f||||t||||||||||2018-05-31 21:25:06.720704|2018-05-31 21:25:06.720704
NCT01589211|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-30|2012-05-01|Estimate|||||||2012-04-30|2012-05-01|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|November 2012|Anticipated|2012-11-30||Interventional|BISQUITS||Brief Intervention Study for Quitting Smoking||Unknown status|Enrolling by invitation|N/A|800|Anticipated|Heidelberg University||3|||f||||f||||||||||2018-05-31 21:25:06.78249|2018-05-31 21:25:06.78249
NCT01589198|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2017-03-27|2012-04-30|2012-05-01|Estimate|||||||2017-03-27|2017-03-29|Actual|January 2012||2012-01-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma|Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma|Completed|||110|Actual|National Jewish Health|||||f||||f||||||Samples Without DNA|"~     Blood and lung samples will be retained for RNA purposes.~   "|||2018-05-31 21:25:06.872794|2018-05-31 21:25:06.872794
NCT01589185|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2016-09-21|2012-04-28|2012-05-01|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, Efficacy and Pharmacodynamics of KBSA301 in Severe Pneumonia (S. Aureus)|Completed||Phase 1/Phase 2|48|Actual|Aridis Pharmaceuticals, Inc.||5|||f||||t||||||||||2018-05-31 21:25:06.987137|2018-05-31 21:25:06.987137
NCT01589172|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2015-05-28|2012-04-30|2012-05-01|Estimate|||||||2015-05-28|2015-05-29|Estimate|May 2012||2012-05-31|May 2015|2015-05-31||||||||Observational|||Evaluating the Use of Thromboelastography to Diagnose Coagulopathy After Traumatic Brain Injury|Evaluating the Use of Thromboelastography to Diagnose and Monitor Coagulopathy Associated With Pediatric Traumatic Brain Injury|Unknown status|Recruiting||40|Anticipated|University of California, San Diego|||1||f||||f||||||||||2018-05-31 21:25:07.155477|2018-05-31 21:25:07.155477
NCT01589159|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-28|||2017-02-24|2012-04-30|2012-05-01|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes|A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes|Completed||Phase 2|54|Actual|Peking University||1|||f||||t||||||||||2018-05-31 21:25:07.251323|2018-05-31 21:25:07.251323
NCT01589146|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-28|||2012-04-28|2012-04-28|2012-05-01|Estimate|||||||2012-04-28|2012-05-01|Estimate|September 2010||2010-09-30|April 2012|2012-04-30||||December 2012|Anticipated|2012-12-31||Interventional|PRO-LAPS I||ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.|ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.|Unknown status|Recruiting|Phase 3|400|Anticipated|University Of Perugia||2|||f||||f||||||||||2018-05-31 21:25:07.317424|2018-05-31 21:25:07.317424
NCT01589133|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-05-29|2012-04-28|2012-05-01|Estimate|||||||2013-05-29|2013-05-30|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Surgiscreen Registration|A Multi-center Clinical Study for Assessment of the Consistency of the Results of Human Irregular Antibody Screening With Surgiscreen and Serascan Diana 3|Completed|||3109|Actual|Johnson & Johnson Medical, China|||||f||||f||||||Samples Without DNA|"~     Plasma or Serum left after routine clinical testing.~   "|||2018-05-31 21:25:07.385139|2018-05-31 21:25:07.385139
NCT01589120|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-28|||2012-05-01|2012-04-28|2012-05-01|Estimate|||||||2012-05-01|2012-05-02|Estimate|April 2012||2012-04-30|May 2012|2012-05-31||||April 2014|Anticipated|2014-04-30||Interventional|VIDEO-HF||Using Videos to Facilitate Advance Care Planning for Patients With Heart Failure|Using Videos to Facilitate Advance Care Planning for Patients With Heart Failure|Unknown status|Recruiting|N/A|248|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:25:07.44497|2018-05-31 21:25:07.44497
NCT01589107|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-28|||2012-05-01|2012-04-30|2012-05-01|Estimate|||||||2012-05-01|2012-05-02|Estimate|December 2011||2011-12-31|May 2012|2012-05-31||||December 2012|Anticipated|2012-12-31||Interventional|||A Randomized Controlled Trial of a Video Decision Making Aid to Obtain Informed Consent in the Surgical Intensive Care Unit|A Randomized Controlled Trial of a Video Decision Making Aid to Obtain Informed Consent in the Surgical Intensive Care Unit|Unknown status|Recruiting|N/A|52|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:25:07.525697|2018-05-31 21:25:07.525697
NCT01589094|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2018-05-01|2012-04-27|2012-05-01|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2012||2012-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer|Phase II Study of Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer|Active, not recruiting||Phase 2|46|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:25:07.592946|2018-05-31 21:25:07.592946
NCT01589081|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-01-14|2012-04-27|2012-05-01|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2008||2008-09-30|January 2013|2013-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect|Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect|Suspended||N/A|45|Anticipated|Mclean Hospital||2||Clinical studies are stopped, pending funding.|f||||f||||||||||2018-05-31 21:25:07.674453|2018-05-31 21:25:07.674453
NCT01589029|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2015-11-23|2012-04-27|2012-05-01|Estimate|||||||2015-11-23|2015-11-24|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ILARIS||A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)|A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)|Terminated||Phase 1|6|Actual|Triemli Hospital||1||The results of the interim analysis showed that the primary endpoint was not met|f||||t||||||||||2018-05-31 21:25:08.052749|2018-05-31 21:25:08.052749
NCT01589016|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-09-18|2012-04-30|2012-05-01|Estimate|||||||2013-09-18|2013-09-19|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Activin A and Inhibin A in Predicting Outcome of Pregnancies of Unknown Location After Assisted Reproductive Technology|Single Determination of Serum Activin A and Inhibin A in Predicting the Outcome of Pregnancies of Unknown Location (PUL) After IVF and Oocyte Donation.|Completed|||96|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA|||3||f||||f||||||None Retained|"~     Blood samples are to be taken at the time of the first ultrasound examination and stored at~     -20ºC. Inhibin A and activin A to be determined by ELISA. β-hCG and P were also determined~     using Microparticle Enzyme Inmunoassay (MEIA).~   "|||2018-05-31 21:25:08.113946|2018-05-31 21:25:08.113946
NCT01589003|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-30|2012-05-01|Estimate|||||||2012-04-30|2012-05-01|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|February 2013|Anticipated|2013-02-28|October 2012|Anticipated|2012-10-31||Interventional|||The Impact of Milk-products Differing in Their Glycaemic Properties on the Behaviour of Infants|An Intervention Study to Consider the Impact of Milk-products Differing in Their Glycaemic Properties on the Behaviour of Infants.|Unknown status|Recruiting|N/A|70|Anticipated|International Medical University||2|||f||||t||||||||||2018-05-31 21:25:08.170228|2018-05-31 21:25:08.170228
NCT01588990|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2017-08-10|2012-04-30|2012-05-01|Estimate|||||||2017-08-10|2017-08-14|Actual|June 26, 2012|Actual|2012-06-26|July 2017|2017-07-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|ASCENT||A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer|An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™) [ASCENT]|Completed||Phase 4|128|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:25:08.241162|2018-05-31 21:25:08.241162
NCT01588977|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-08-02|2012-04-30|2012-05-01|Estimate|||||||2016-08-02|2016-08-04|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Observational|||Subchondral Microfracture of Tibia After Arthroscopic Anterior Cruciate Ligament Surgery Reconstruction|Subchondral Microfracture of Tibia After Arthroscopic Anterior Cruciate Ligament Surgery Reconstruction With Two Different Drilling Techniques. Correlation With Postoperative Pain|Completed|||43|Actual|Hospital Ambroise Paré Paris|||3||f||||f||||||||||2018-05-31 21:25:08.337108|2018-05-31 21:25:08.337108
NCT01588964|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-28|2012-04-28|2012-05-01|Estimate|||||||2012-04-28|2012-05-01|Estimate|March 2005||2005-03-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|IPHC||IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer|Surgery and Intraperitoneal Hyperthermic Chemotherapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer .|Completed||Phase 2|30|Actual|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 21:25:08.386742|2018-05-31 21:25:08.386742
NCT01588951|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2017-05-01||2017-05-01|2012-04-30|2012-05-01|Estimate|2017-05-01|2017-06-05|Actual||||2017-05-01|2017-06-05|Actual|August 2013|Actual|2013-08-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior|Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior|Terminated||Phase 2/Phase 3|10|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||f||||||||No||2018-05-31 21:25:08.524623|2018-05-31 21:25:08.524623
NCT01588938|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-05-13|2012-04-27|2012-05-01|Estimate|||||||2016-05-13|2016-05-17|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|September 2016|Anticipated|2016-09-30||Observational|||External Immobilization Compared to Limited Immobilization Using a Novel Real-time Localization System of the Prostate||Unknown status|Active, not recruiting||20|Anticipated|U.S. Army Medical Research Acquisition Activity|||||f||||t||||||||||2018-05-31 21:25:08.875549|2018-05-31 21:25:08.875549
NCT01588925|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-10-02|2012-04-27|2012-05-01|Estimate|||||||2014-10-02|2014-10-03|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|January 2014|Actual|2014-01-31|February 2013|Actual|2013-02-28||Interventional|||Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation|Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation|Completed||Phase 2|18|Actual|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 21:25:08.935194|2018-05-31 21:25:08.935194
NCT01588912|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-27|2012-05-01|Estimate|||||||2012-04-30|2012-05-02|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|TETRA||Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir|A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients|Unknown status|Recruiting|Phase 4|104|Anticipated|Pusan National University Yangsan Hospital||2|||f||||f||||||||||2018-05-31 21:25:09.008847|2018-05-31 21:25:09.008847
NCT01588899|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2015-10-21|2012-04-27|2012-05-01|Estimate|||||||2015-10-21|2015-10-22|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||China Clinical Trial for Therapeutic MR-HIFU Ablation of Uterine Fibroids|China Clinical Trial for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Completed||N/A|107|Actual|Philips Healthcare||1|||f||||t||||||||||2018-05-31 21:25:09.115145|2018-05-31 21:25:09.115145
NCT01588886|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2017-02-15|2012-04-30|2012-05-01|Estimate|||||||2017-02-15|2017-02-16|Actual|March 2012||2012-03-31|November 2013|2013-11-30|August 2015|Actual|2015-08-31|June 2012|Actual|2012-06-30||Observational|||Proton Pump Inhibitor Use is Associated With High Risk of Pneumonia in Chronic Kidney Disease Patients|Institute of Emergency and Critical Care Medicine , School of Yang-Ming University|Completed|||9000|Actual|Far Eastern Memorial Hospital|||2||f||||t||||||||||2018-05-31 21:25:09.178091|2018-05-31 21:25:09.178091
NCT01588873|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-05-03|2012-04-27|2012-05-01|Estimate|||||||2012-05-03|2012-05-04|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Contraceptive Pill and Hormonal Vaginal Ring in Women With Polycystic Ovary Syndrome|The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).|Recruiting||Phase 4|42|Anticipated|University of Oulu||2|||f||||f||||||||||2018-05-31 21:25:09.232621|2018-05-31 21:25:09.232621
NCT01588860|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-30|2012-05-01|Estimate|||||||2012-04-30|2012-05-01|Estimate|January 2011||2011-01-31|December 2010|2010-12-31||||December 2011|Actual|2011-12-31||Observational|||Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma|Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma|Unknown status|Active, not recruiting||100|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||Samples Without DNA|"~     Fixed tissue in the paraffin embedded blocks~   "|||2018-05-31 21:25:09.594758|2018-05-31 21:25:09.594758
NCT01588847|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2014-12-10|2012-04-30|2012-05-01|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Anesthesia and Cancer Recurrence im Malignant Melanoma|Long-term Outcome After Radical Lymph Node Dissection of Malignant Melanoma. Comparison Between Regional Versus General Anesthesia With Respect to Impact of Perioperative Immunoediting and Validation of New Potential Predictive Biomarkers|Recruiting||N/A|230|Anticipated|University Hospital Muenster||2|||f||||f||||||||||2018-05-31 21:25:09.650614|2018-05-31 21:25:09.650614
NCT01588834|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-05-19|2012-04-27|2012-05-01|Estimate|||||||2016-05-19|2016-05-20|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Histology of Functional Density in Premenopausal Breast|Pilot Study to Examine Histological Characteristics of Mammographic Density With Molecular Breast Imaging: Part 2 - Premenopausal Women|Completed|||23|Actual|Mayo Clinic|||||f||||t||||||Samples Without DNA|"~     core biopsy samples from mammographically dense breast tissue~   "|||2018-05-31 21:25:09.739754|2018-05-31 21:25:09.739754
NCT01588821|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|2017-12-11||2017-12-11|2012-04-27|2012-05-01|Estimate|2017-12-11|2018-01-10|Actual||||2017-12-11|2018-01-10|Actual|June 2012||2012-06-30|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|January 2017|Actual|2017-01-31||Interventional|||Cabozantinib in Advanced Solid Malignancies|Phase II Trial of Cabozantinib (XL184) in Patients With Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases|Active, not recruiting||Phase 2|37|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:25:09.823348|2018-05-31 21:25:09.823348
NCT01588808|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-07-09|2012-04-27|2012-05-01|Estimate|||||||2013-07-09|2013-07-10|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|IM-PRO||Immobilization and Protein Supplementation (IM-PRO)|The Impact of Dietary Protein Supplementation and Age on Muscle Mass Loss During Short Term One-legged Knee Immobilization|Completed||N/A|35|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 21:25:10.216701|2018-05-31 21:25:10.216701
NCT01588795|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-05-30|2012-04-27|2012-05-01|Estimate|||||||2016-05-30|2016-06-01|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DERENEDIAB||Renal Denervation in Diabetic Nephropathy|Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria|Completed||Phase 4|25|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:25:10.300234|2018-05-31 21:25:10.300234
NCT01588782|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-11-23|2012-04-27|2012-05-01|Estimate|||||||2012-11-23|2012-11-27|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone (JNJ-589485) Following Administration of Abiraterone Acetate (JNJ-212082) Tablets in Healthy Male Subjects|Completed||Phase 1|20|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:25:10.393329|2018-05-31 21:25:10.393329
NCT01588769|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-06-03|2012-04-30|2012-05-01|Estimate|||||||2016-06-03|2016-06-06|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|ALECSAT-GBM||A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients|A Phase I Study to Investigate Tolerability and Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-cells (ALECSAT) Administered to Patients With Glioblastoma Multiforme (GBM)|Completed||Phase 1|23|Actual|CytoVac A/S||1|||f||||f||||||||Undecided||2018-05-31 21:25:10.477488|2018-05-31 21:25:10.477488
NCT01588756|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-02-27|2012-04-27|2012-05-01|Estimate|||||||2017-02-27|2017-03-01|Actual|October 2010|Actual|2010-10-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|AcSDKP-NH2||Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)|Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)|Completed||Phase 1/Phase 2|100|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:25:10.556315|2018-05-31 21:25:10.556315
NCT01588743|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-04-30|2012-04-30|2012-05-01|Estimate|||||||2012-04-30|2012-05-01|Estimate|October 2008||2008-10-31|April 2012|2012-04-30||||December 2012|Anticipated|2012-12-31||Interventional|||Effects of Short-term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes Patients|Effects of Short-term Intensive Insulin Therapy on Insulin Resistance and Insulin Secretion in Newly Diagnosed Lean and Obese Type 2 Diabetes Patients|Unknown status|Active, not recruiting|N/A|130|Anticipated|China-Japan Friendship Hospital|||||f||||||||||||||2018-05-31 21:25:10.641124|2018-05-31 21:25:10.641124
NCT01588730|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-08-08|2012-04-27|2012-05-01|Estimate|||||||2013-08-08|2013-08-12|Estimate|June 2011||2011-06-30|August 2013|2013-08-31||||June 2015|Anticipated|2015-06-30||Interventional|||Dynamic and Static Splinting as a Treatment for Plantar Faciiopathy|Dynamic and Static Splinting as a Treatment for Plantar Faciiopathy|Terminated||Phase 4|26|Actual|Dynasplint Systems, Inc.||2|||f||||t||||||||||2018-05-31 21:25:10.707632|2018-05-31 21:25:10.707632
NCT01588717|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-08-24|2012-04-27|2012-05-01|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|AIDES-G||Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)|A Pilot Study to Measure and Treat Antidepressant-Induced Excessive Sweating With Glycopyrrolate (AIDES-G)|Terminated||Phase 1|5|Actual|Thomas Jefferson University||1||PI left institution|f||||f||||||||||2018-05-31 21:25:10.793201|2018-05-31 21:25:10.793201
NCT01588704|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-01-21|2012-04-30|2012-05-01|Estimate|||||||2015-01-21|2015-01-22|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma|A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma|Completed||Phase 2|42|Actual|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 21:25:10.872161|2018-05-31 21:25:10.872161
NCT01588691|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-03-20|2012-04-27|2012-05-01|Estimate|||||||2015-03-20|2015-03-23|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|TBI||Traumatic Brain Injury Peripheral Nerve Study|A Feasibility Study to Examine the Efficacy of C2-C3 Dermatomal Peripheral Nerve Stimulation in Cognitive Improvements Following Persistent Impairment After Traumatic Brain Injury|Completed||Phase 1|3|Actual|St. Jude Medical||3|||f||||f||||||||||2018-05-31 21:25:10.947494|2018-05-31 21:25:10.947494
NCT01588678|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-04-02|2012-04-27|2012-05-01|Estimate|||||||2015-04-02|2015-04-03|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas|A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas|Completed||Phase 1|32|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 21:25:11.014043|2018-05-31 21:25:11.014043
NCT01588665|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-01-30|2012-04-30|2012-05-01|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2012||2012-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2015|Actual|2015-06-30||Observational|||Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy|Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy|Active, not recruiting|||23|Actual|Cornell University|||1||f||||f||||||Samples With DNA|"~     -  A total of 45 mL maternal blood sample is collected at five study visits during~          pregnancy~        -  At delivery, an additional 10 mL maternal blood sample, a 30 mL cord blood, and the~          placenta are collected~   "|No||2018-05-31 21:25:11.084336|2018-05-31 21:25:11.084336
NCT01588639|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2015-01-11|2012-04-30|2012-05-01|Estimate|||||||2015-01-11|2015-01-13|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Observational|SEAS||To Evaluate Clinical Outcome and Injection Compliance of Scilin|A Prospective Multi-centre, Non-randomized, Open-label, Non-interventional Study to Evaluate the Safety, Efficacy and Injection Compliance of Scilin N, Scilin R or Scilin M30 in Chinese Type 2 Diabetes Mellitus (T2DM)|Completed|||2683|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:25:11.155977|2018-05-31 21:25:11.155977
NCT01588626|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-07-12|2012-04-30|2012-05-01|Estimate|||||||2012-07-12|2012-07-13|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study to Assess the Pharmacokinetics of AZD6140 After Single Dose in Healthy Japanese Male Volunteers|A Phase I, Single Centre, Open Study to Assess the Pharmacokinetics of Oral AZD6140 After Single Dose in Healthy Japanese Male Volunteers|Completed||Phase 1|12|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 21:25:11.244916|2018-05-31 21:25:11.244916
NCT01588600|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-04-20|2012-04-27|2012-05-01|Estimate|||||||2016-04-20|2016-04-21|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Fiber on Satiety|Effects of Fiber on Satiety and Food Intake in Men and Women|Completed||N/A|90|Actual|Ingredion Incorporated||3|||f||||f||||||||||2018-05-31 21:25:11.306762|2018-05-31 21:25:11.306762
NCT01588587|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-10-17|2012-04-27|2012-05-01|Estimate|||||||2012-10-17|2012-10-19|Estimate|October 2012||2012-10-31|April 2012|2012-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients|Effect of DPP-IV Inhibitors on Occurence of Cancers and the Mechanism Using AGE and RAGE in Patients With Type 2 Diabetes|Unknown status|Not yet recruiting||500|Anticipated|Nagaoka Red Cross Hospital|||1||f||||f||||||||||2018-05-31 21:25:11.362376|2018-05-31 21:25:11.362376
NCT01588574|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-09-05|2012-04-27|2012-05-01|Estimate|||||||2014-09-05|2014-09-08|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia||Completed||Phase 2|60|Actual|Medy-Tox||2|||f||||t||||||||||2018-05-31 21:25:11.607432|2018-05-31 21:25:11.607432
NCT01588561|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2016-11-29||2017-07-31|2012-04-27|2012-05-01|Estimate|2017-07-31|2017-08-31|Actual||||2017-07-31|2017-08-31|Actual|October 2005||2005-10-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Nicotine Related Brain Activity: The Influence of Smoking History and Blood Nicotine Levels|Nicotine Related Brain Activity: The Influence of Smoking History and Blood Nicotine Levels, an Exploratory Study|Completed||N/A|15|Actual|Mclean Hospital|Small number of subjects completed due to a large shortage of Nicotine Bitartrate (the chemical used to create our IV Nicotine). We were unable to receive new nicotine shipments from 4/14 -2/15.Without this nicotine it was impossible to run subjects.|2|||f||||t||||||||Undecided||2018-05-31 21:25:11.713357|2018-05-31 21:25:11.713357
NCT01588548|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2015-07-24||2015-10-06|2012-04-30|2012-05-01|Estimate|2015-07-24|2015-08-19|Estimate||||2015-10-06|2015-11-04|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma|Completed||Phase 1|43|Actual|AstraZeneca||1|||f||||t||||||||||2018-05-31 21:25:12.026004|2018-05-31 21:25:12.026004
NCT01588535|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27||2013-12-03|2015-04-13|2012-04-27|2012-05-01|Estimate||||2013-12-03|2013-12-27|Estimate|2015-04-13|2015-05-04|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis Media|Phase 2, Multicenter, Placebo-controlled, Double-masked, Randomized Study to Demonstrate Reliability and Validity of FAECC Scale (Modified FLACC) to Evaluate Relief of Pain in Subjects With Acute Otitis Media Aged >/=2 Months to <5 Years|Completed||Phase 2|38|Actual|Arbor Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:25:13.1636|2018-05-31 21:25:13.1636
NCT01588522|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-04-21|2012-04-27|2012-05-01|Estimate|||||||2017-04-21|2017-04-25|Actual|July 2012||2012-07-31|July 2016|2016-07-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease|Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease|Completed||Phase 1|30|Anticipated|Berg, LLC||1|||f||||t||||||||||2018-05-31 21:25:13.275506|2018-05-31 21:25:13.275506
NCT01588509|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-06-02|2012-04-27|2012-05-01|Estimate|||||||2017-06-02|2017-06-05|Actual|March 30, 2012|Actual|2012-03-30|May 2017|2017-05-31|November 21, 2012|Actual|2012-11-21|November 21, 2012|Actual|2012-11-21||Interventional|||Transition From Alendronate to Romosozumab (AMG 785)|An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate|Completed||Phase 1|60|Actual|Amgen||2|||f||||f||||||||||2018-05-31 21:25:13.368017|2018-05-31 21:25:13.368017
NCT01588496|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2015-08-28|2014-05-02|2017-02-07|2012-04-27|2012-05-01|Estimate|2015-08-28|2015-10-02|Estimate|2014-05-02|2014-05-20|Estimate|2017-02-07|2017-03-15|Actual|April 2012||2012-04-30|February 2017|2017-02-28||||January 2014|Actual|2014-01-31||Interventional|TESLA||Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities|2-part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part A - Open-label, Single-arm, Multicenter Pilot Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part B - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia|Completed||Phase 2/Phase 3|58|Actual|Amgen||3|||f||||t||||||||||2018-05-31 21:25:13.489936|2018-05-31 21:25:13.489936
NCT01588483|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-05-02|2012-04-26|2012-05-01|Estimate|||||||2018-05-02|2018-05-03|Actual|March 1, 2012|Actual|2012-03-01|May 2018|2018-05-31||||March 2022|Anticipated|2022-03-31||Observational|ATACT||Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis|Prospective Study for the Follow-up of Aortic Diameter in Patients With Arteritis Temporalis / Giant Cell Arteritis.|Recruiting|||150|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 21:25:14.363175|2018-05-31 21:25:14.363175
NCT01588470|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2016-02-17||2017-10-31|2012-04-30|2012-05-01|Estimate|2017-10-31|2017-12-06|Actual||||2017-10-31|2017-12-06|Actual|June 2006||2006-06-30|October 2017|2017-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)|Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM) - Role of Intramyocellular Lipid Content and Mitochondrial Dysfunction in Myocardial Insulin Resistance and Their Correction With Pioglitazone|Completed||Phase 4|130|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||No|IPD data will not be available for other researchers. However, a manuscript describing the study results is under review for publication in the medical literature|2018-05-31 21:25:14.445786|2018-05-31 21:25:14.445786
NCT01588457|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-03-21|2012-04-30|2012-05-01|Estimate|||||||2017-03-21|2017-03-23|Actual|June 2011||2011-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SMART||Sequential Multiple Assignment Treatment for Bipolar Disorder|Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder|Completed||Phase 4|110|Actual|The University of Texas Health Science Center at San Antonio||6|||f||||t||||||||||2018-05-31 21:25:14.646258|2018-05-31 21:25:14.646258
NCT01588444|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2014-10-01||2015-10-01|2012-04-30|2012-05-01|Estimate|2014-10-01|2014-10-06|Estimate||||2015-10-01|2015-10-22|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||patietns requring tooth extraction adn ridge preservation|Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft|Histological Comparison of Healing Following Tooth Extraction With Ridge Preservation Using Cortical Versus Cancellous Freeze Dried Bone Allograft|Completed||N/A|40|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 21:25:14.749009|2018-05-31 21:25:14.749009
NCT01588431|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-03-06|2012-04-30|2012-05-01|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2011||2011-12-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Interventional|||Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer|A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer (CTRC# 11-36)|Active, not recruiting||Phase 2|33|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 21:25:15.020373|2018-05-31 21:25:15.020373
NCT01588418|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2015-10-28||2017-10-19|2012-04-26|2012-05-01|Estimate|2017-04-17|2017-05-25|Actual||||2017-10-19|2017-11-24|Actual|July 2010||2010-07-31|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||We studied male subjects with impaired fasting glucose or newly diagnosed type 2 diabetes.|Acute Effect of Exenatide on Brain Glucose Metabolism|Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function|Completed||Phase 4|15|Actual|The University of Texas Health Science Center at San Antonio|Our study has several potential limitations. It included only men. During OGTT it is difficult to evaluate the separate contributions of glucose and insulin.|2|||f||||f||||||||No||2018-05-31 21:25:15.089817|2018-05-31 21:25:15.089817
NCT01588405|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2015-08-20||2016-04-08|2012-04-26|2012-05-01|Estimate|2016-04-08|2016-05-16|Estimate||||2016-04-08|2016-05-16|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Remodulin® to Oral Treprostinil Transition|A Multicenter, Open-Label Study of the Safety and Tolerability of Transitioning From Remodulin® to Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 2|33|Actual|United Therapeutics||1|||f||||f||||||||||2018-05-31 21:25:15.329608|2018-05-31 21:25:15.329608
NCT01588392|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2014-07-22|2012-04-26|2012-05-01|Estimate|||||||2014-07-22|2014-07-23|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|STEP||Short bouTs of Exercise for Preschool-age Children|Effects of Short Bouts of Physical Activity in Low-income Preschool-age Children|Completed||N/A|323|Actual|University of Massachusetts, Amherst||2|||f||||f||||||||||2018-05-31 21:25:15.705632|2018-05-31 21:25:15.705632
NCT01588379|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-12-05|2012-04-26|2012-05-01|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|MAGNET||Mothers and Girls Dancing Together Trial|Effects of an Afro-centric Dance Program for African-American Daughters and Mothers|Completed||N/A|152|Actual|University of Massachusetts, Amherst||3|||f||||f||||||||||2018-05-31 21:25:16.020545|2018-05-31 21:25:16.020545
NCT01588366|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-09-10|2012-04-27|2012-05-01|Estimate|||||||2013-09-10|2013-09-11|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Effects of LY2409021 on the Liver|Effects of LY2409021 on Hepatic Metabolism in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|36|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:25:16.092839|2018-05-31 21:25:16.092839
NCT01588353|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2016-07-03||2017-02-14|2012-04-27|2012-04-30|Estimate|2016-12-21|2017-02-14|Actual||||2017-02-14|2017-03-21|Actual|May 2012||2012-05-31|February 2017|2017-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CORD-J||Collagenase Option for Reduction of Dupuytren's Contracture in Japan|Phase III Study of AK160 in Patients With Dupuytren's Contracture|Completed||Phase 3|104|Actual|Asahi Kasei Pharma Corporation||1|||f||||||||||||||2018-05-31 21:25:16.191781|2018-05-31 21:25:16.191781
NCT01588340|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-05-29|2012-04-27|2012-04-30|Estimate|||||||2015-05-29|2015-06-01|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||MRI Hydronephrosis Study|Comparison of Rapid Protocol Noncontrast MRI vs. Ultrasound in the Evaluation of Pediatric Hydronephrosis|Withdrawn||N/A|0|Actual|University of Michigan||2||PI leaving institution|f||||t||||||||||2018-05-31 21:25:16.53595|2018-05-31 21:25:16.53595
NCT01588327|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-04-27|2012-04-27|2012-04-30|Estimate|||||||2012-04-27|2012-04-30|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||A Prospective Pharmacodynamic Study of Dabigatran|A Prospective Pharmacodynamic Study of Dabigatran Using Peak and Trough Coagulation Test Results in Patients on Therapeutic Doses of Dabigatran|Completed|||65|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|||2018-05-31 21:25:16.67812|2018-05-31 21:25:16.67812
NCT01588314|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-08-16|2012-04-27|2012-04-30|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2012||2012-04-30|August 2017|2017-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease|Placebo Controlled Trial Evaluating Gabapentin for the Treatment of Small Fiber Neuropathic Pain in Patients With Fabry Disease|Withdrawn||Phase 2|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||No patients were enrolled. No data & no study results to report.|f||||f||||||||||2018-05-31 21:25:16.727627|2018-05-31 21:25:16.727627
NCT01588301|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-09-11|2012-04-27|2012-04-30|Estimate|||||||2014-09-11|2014-09-12|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|APACHE-2||Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention|Attitudes to Different Strategies Among Women Not Attending Cervical Cancer Screening: Further Invitation by Mail or Kit for Self-collected Vaginal Sample|Completed||Early Phase 1|5998|Actual|University Hospital, Tours||3|||f||||f||||||||||2018-05-31 21:25:16.804043|2018-05-31 21:25:16.804043
NCT01588288|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-10-07|2012-04-27|2012-04-30|Estimate|||||||2016-10-07|2016-10-10|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Galectins||Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter|Diagnosis Interest of Galectin 3 Dosage in Nodular and Multinodular Goiter Pretreatment|Completed||N/A|193|Actual|University Hospital, Rouen||1|||f||||t||||||||||2018-05-31 21:25:16.865578|2018-05-31 21:25:16.865578
NCT01588275|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2018-05-14|2012-04-27|2012-04-30|Estimate|||||||2018-05-14|2018-05-15|Actual|May 24, 2012|Actual|2012-05-24|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|REST||MRA Therapy Versus CPAP Therapy in Moderate OSAS|Cost-effectiveness of obstRuctivE Sleep Apnea Therapy (REST Study): Comparison of MRA Therapy Versus CPAP Therapy in Moderate OSAS|Completed||N/A|86|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 21:25:16.935674|2018-05-31 21:25:16.935674
NCT01588262|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-10-12|2012-04-26|2012-04-30|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Early Rehabilitation of Cancer Patients|Early Rehabilitation of Cancer Patients|Completed||N/A|300|Actual|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 21:25:17.013376|2018-05-31 21:25:17.013376
NCT01588249|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-10-09|2012-04-27|2012-04-30|Estimate|||||||2012-10-09|2012-10-11|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection|A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection|Terminated||N/A|80|Anticipated|Zarbee's Inc.||2||Revisiting product options|f||||||||||||||2018-05-31 21:25:17.081707|2018-05-31 21:25:17.081707
NCT01588236|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-10-05|2012-04-27|2012-04-30|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of KYG0395 on Primary Dysmenorrhea|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Further Assess the Efficacy, Safety and Dose Response of KYG0395 in the Treatment of Primary Dysmenorrhea|Completed||Phase 2|280|Actual|Jiangsu Kanion Pharmaceutical Co., Ltd||3|||f||||f||||||||||2018-05-31 21:25:17.14877|2018-05-31 21:25:17.14877
NCT01588223|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2014-03-26|2012-04-27|2012-04-30|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Non Invasive Diagnostic of Endometrial Receptivity|A Non Invasive Diagnostic of Endometrial Receptivity Based on Lipidomic Profile on Endometrial Fluid.|Completed||N/A|40|Actual|Igenomix||1|||f||||f||||||||||2018-05-31 21:25:17.243685|2018-05-31 21:25:17.243685
NCT01588210|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-05-17|2012-04-27|2012-04-30|Estimate|||||||2012-05-17|2012-05-18|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|March 2008|Actual|2008-03-31||Interventional|||Fluoride Concentration in Inter-proximal Fluid From Dental Sealants|Fluoride Concentration in Inter-proximal Fluid From Dental Sealants.|Completed||N/A|2776|Actual|Università degli Studi di Sassari||3|||f||||f||||||||||2018-05-31 21:25:17.297793|2018-05-31 21:25:17.297793
NCT01588197|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-05-03|2012-04-26|2012-04-30|Estimate|||||||2016-05-03|2016-05-04|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Real-Time fMRI Feedback Effects on Pain Perception|Real-Time fMRI Feedback Effects on Pain Perception|Unknown status|Active, not recruiting|N/A|30|Anticipated|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 21:25:17.366201|2018-05-31 21:25:17.366201
NCT01588184|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-05-10|2012-04-26|2012-04-30|Estimate|||||||2018-05-10|2018-05-14|Actual|July 19, 2012|Actual|2012-07-19|May 2018|2018-05-31|October 18, 2018|Anticipated|2018-10-18|October 18, 2018|Anticipated|2018-10-18||Interventional|||An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study|A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study|Active, not recruiting||Phase 4|93|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:25:17.443779|2018-05-31 21:25:17.443779
NCT01588171|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-03-17|2012-04-27|2012-04-30|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum|Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial|Completed||N/A|7020|Actual|Hawler Medical University||3|||f||||f||||||||||2018-05-31 21:25:17.721655|2018-05-31 21:25:17.721655
NCT01588158|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2016-01-11||2017-02-02|2012-04-27|2012-04-30|Estimate|2016-03-15|2016-04-14|Estimate||||2017-02-02|2017-03-14|Actual|July 2012||2012-07-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Patient Satisfaction With Pain Relief After Ambulatory Hand Surgery|Satisfaction With Pain Relief After Carpal Tunnel Release Surgery|Terminated||Phase 4|7|Actual|Massachusetts General Hospital||2||"The PI of this study is leaving the institution and enrollment was progressing slowly so we~   decided to close the study."|f||||f||||||||||2018-05-31 21:25:17.830664|2018-05-31 21:25:17.830664
NCT01588145|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-04-23|2012-04-27|2012-04-30|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2012||2012-03-31|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients|Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation|Completed||Phase 1/Phase 2|273|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 21:25:18.125399|2018-05-31 21:25:18.125399
NCT01588132|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-26|2012-04-26|2012-04-30|Estimate|||||||2012-04-26|2012-04-30|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Anfibatide Phase 1 Clinical Trial in Healthy Volunteers|First Assessment of the Glycoprotein Ib-IV-V Complex Antagonist Anfibatide in Healthy Human Volunteers|Completed||Phase 1|94|Actual|Lee's Pharmaceutical Limited||11|||f||||f||||||||||2018-05-31 21:25:18.195082|2018-05-31 21:25:18.195082
NCT01588119|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-01-19|2012-04-26|2012-04-30|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|NOAC||Register for New Oral Anticoagulants|Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants|Recruiting|||3500|Anticipated|GWT-TUD GmbH|||4||f||||f||||||||||2018-05-31 21:25:18.260102|2018-05-31 21:25:18.260102
NCT01588106|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|2017-01-19||2017-01-19|2012-04-27|2012-04-30|Estimate|2017-01-19|2017-03-09|Actual||||2017-01-19|2017-03-09|Actual|June 2012||2012-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Observational|CONGO||Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients|Evaluation of the Impact of the CONTOUR® USB Blood Glucose Monitoring System With Integrated Data Management on Glycaemic Control in Insulin-treated Diabetic Patients|Completed|||154|Actual|GWT-TUD GmbH|||2||f||||f||||||||||2018-05-31 21:25:18.340472|2018-05-31 21:25:18.340472
NCT01588093|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2012-04-27|2012-04-27|2012-04-30|Estimate|||||||2012-04-27|2012-04-30|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations|Insulin-like Growth Factor (IGF-I) Induced Muscle Glucose Uptake and Interstitial IGF-1 Concentrations.|Completed||N/A|8|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 21:25:18.605743|2018-05-31 21:25:18.605743
NCT01588080|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-05-25|2012-04-27|2012-04-30|Estimate|||||||2015-05-25|2015-05-27|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Comparison Between Infant Flow SiPAP and Noninvasive NAVA in the Neonatal Intensive Care Unit|A Pilot Study Comparing Infant Flow SiPAP to Noninvasive NAVA|Completed||N/A|21|Actual|Fraser Health||2|||f||||f||||||||||2018-05-31 21:25:18.676298|2018-05-31 21:25:18.676298
NCT01588067|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2015-07-06|2012-04-26|2012-04-30|Estimate|||||||2015-07-06|2015-07-08|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|PAD||Effectiveness of Medical Therapy, Endovascular Therapy, and Surgery for Peripheral Arterial Disease|Effectiveness of Medical Therapy, Endovascular Therapy, and Surgery for Peripheral Arterial Disease.|Completed|||271|Actual|Kaiser Permanente|||3||f||||f||||||||||2018-05-31 21:25:18.74992|2018-05-31 21:25:18.74992
NCT01588054|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-10-10|2012-04-26|2012-04-30|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2012||2012-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PCD||Prospective Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity|Prospective Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study|Enrolling by invitation|||100|Actual|International Spine Study Group Foundation|||1||f||||f||||||||||2018-05-31 21:25:18.817773|2018-05-31 21:25:18.817773
NCT01588041|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-05-14|2012-04-27|2012-04-30|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2009||2009-09-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|MIOCT||Intraoperative OCT Guidance of Intraocular Surgery|Intraoperative OCT Guidance of Intraocular Surgery|Enrolling by invitation|||802|Anticipated|Duke University|||8||f||||t||||||||Yes|"All findings resulting from the MIOCT study will be prepared for publication in peer-reviewed journals and posted on PubMed Central once accepted. We are also strong advocates of open-access publishing whenever possible; one of the MPIs (Prof. Izatt) is the founding editor-in-chief of the Optical Society of America's (OSA) newest on-line, open-access journal Biomedical Optics Express (http://www.opticsinfobase.org/boe/home.cfm). We are supportive of efforts by publishers and professional societies to develop technologies for on-line publishing of entire experimental datasets. We have published such datasets using OSA's Interactive Science Publishing technology in the recent past (http://midas.osa.org/midaspub/item/view/1123).~We will archive experimental results and findings from the proposed project for at least the duration of the project, and make the underlying datasets available to other researchers upon request."|2018-05-31 21:25:18.908025|2018-05-31 21:25:18.908025
NCT01588015|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-05-16|2012-04-26|2012-04-30|Estimate|||||||2018-05-16|2018-05-17|Actual|August 2012||2012-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant|A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant|Active, not recruiting||Phase 1|36|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 21:25:19.011239|2018-05-31 21:25:19.011239
NCT01588002|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-11-01|2012-04-26|2012-04-30|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers|A Study to Evaluate the Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir When Administered Together in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:25:19.115696|2018-05-31 21:25:19.115696
NCT01587989|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2015-06-22||2015-06-22|2012-04-26|2012-04-30|Estimate|2015-06-22|2015-07-17|Estimate||||2015-06-22|2015-07-17|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Intent to treat (ITT) population: all randomized participants who received at least 1 dose of study treatment.|A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate|A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) Versus Tocilizumab Monotherapy in Patients With Mild to Moderate Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 < 4,5 and >2,6)|Completed||Phase 3|77|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:25:19.196163|2018-05-31 21:25:19.196163
NCT01587976|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-03-27|2012-04-26|2012-04-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|June 2011||2011-06-30|September 2013|2013-09-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|HQOL||Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases|Health Related Quality of Life After Surgery and Oncological Treatment of Colorectal Liver Metastases A Prospective Multicenter Study|Unknown status|Recruiting||100|Anticipated|Haukeland University Hospital|||||f||||f||||||||||2018-05-31 21:25:19.571917|2018-05-31 21:25:19.571917
NCT01587963|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|2016-10-07||2017-03-31|2012-04-27|2012-04-30|Estimate|2017-03-31|2017-05-11|Actual||||2017-03-31|2017-05-11|Actual|February 2013||2013-02-28|March 2017|2017-03-31|April 2015|Actual|2015-04-30|February 2014|Actual|2014-02-28||Interventional|VitC||High Dose Vitamin C in the Critically Ill Patient|The Efficacy of High Dose Vitamin C in the Critically Ill Patient Population|Terminated||Phase 2|11|Actual|Rutgers, The State University of New Jersey|Early termination leading to small number of subjects analyzed|2||PI's add. responsibilities and time commitment prevent him from completing trial|f||||t||||||||No||2018-05-31 21:25:19.652735|2018-05-31 21:25:19.652735
NCT01587950|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2013-03-21||2015-04-09|2012-04-26|2012-04-30|Estimate|2015-04-09|2015-04-28|Estimate||||2015-04-09|2015-04-28|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity|An Exploratory Study Investigating the Effects of a Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity|Completed||Phase 1|12|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:25:19.916149|2018-05-31 21:25:19.916149
NCT01587937|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2014-11-17|2012-04-26|2012-04-30|Estimate|||||||2014-11-17|2014-11-19|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Hospital Wide Roll-Out of Antimicrobial Stewardship|Hospital Wide Roll-Out of Antimicrobial Stewardship: A Stepped Wedge Randomized Controlled Trial|Completed||N/A|19220|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:25:20.430509|2018-05-31 21:25:20.430509
NCT01587924|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2017-08-14|2015-04-27|2017-10-12|2012-04-26|2012-04-30|Estimate|2017-08-14|2017-09-12|Actual|2015-04-27|2015-05-14|Estimate|2017-10-12|2017-11-14|Actual|May 23, 2012|Actual|2012-05-23|August 2017|2017-08-31|May 27, 2013|Actual|2013-05-27|May 27, 2013|Actual|2013-05-27||Interventional||The intent to treat (ITT) population included all randomized participants who received at least one dose of the study drug, had a baseline and at least one corresponding on treatment laboratory assessment.|4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease|A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease|Completed||Phase 2|80|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:25:20.594797|2018-05-31 21:25:20.594797
NCT01587911|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-08-10|2012-04-27|2012-04-30|Estimate|||||||2017-08-10|2017-08-14|Actual|May 2008||2008-05-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|May 2009|Actual|2009-05-31||Interventional|CMP2||Casinomacropeptide and Satiety|Characterization of the Physiological and Subjective Satiety Response to Preloads Varying in Bioactive Dairy Proteins|Completed||N/A|20|Actual|University of California, Davis||6|||f||||f||||||||||2018-05-31 21:25:21.868651|2018-05-31 21:25:21.868651
NCT01587898|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2017-08-15|2015-04-27|2017-10-09|2012-04-26|2012-04-30|Estimate|2017-10-09|2017-11-09|Actual|2015-04-27|2015-05-14|Estimate|2017-10-09|2017-11-09|Actual|May 17, 2012|Actual|2012-05-17|August 2017|2017-08-31|May 7, 2013|Actual|2013-05-07|May 7, 2013|Actual|2013-05-07||Interventional|||4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis|A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis|Completed||Phase 2|72|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:25:22.134983|2018-05-31 21:25:22.134983
NCT01587885|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|2013-04-04||2015-02-20|2012-04-26|2012-04-30|Estimate|2013-04-04|2013-05-22|Estimate||||2015-02-20|2015-03-11|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)|Protocol PT 11-29: Randomized, Open-label, Cross-over Pilot Study to Evaluate and Compare Two Omeprazole Containing Products for Relief of Frequent Heartburn|Completed||Phase 4|48|Actual|Bayer||2|||f||||f||||||||||2018-05-31 21:25:25.589781|2018-05-31 21:25:25.589781
NCT01587872|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2014-04-11|2012-04-26|2012-04-30|Estimate|||||||2014-04-11|2014-04-14|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Double-balloon Colonoscopy to Increase Colonoscopy Completion Rate|Double-balloon Colonoscopy to Increase Cecal Intubation Rate in Technically Difficult Colonoscopies|Terminated||N/A|62|Anticipated|Sorlandet Hospital HF||1||"Slow patient recruitment, not enough patients willing to participate within the prespecified~   time frame."|f||||f||||||||||2018-05-31 21:25:25.944336|2018-05-31 21:25:25.944336
NCT01587859|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-04-27|2012-04-27|2012-04-30|Estimate|||||||2012-04-27|2012-04-30|Estimate|January 1995||1995-01-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|SEHH||Short Esophagus in Type II-IV Hiatus Hernia|Frequency of True Short Esophagus in Type II-IV Hiatus Hernia|Completed|||34|Actual|University of Bologna|||1||f||||f||||||||||2018-05-31 21:25:26.030462|2018-05-31 21:25:26.030462
NCT01587846|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-10-02|2012-04-26|2012-04-30|Estimate|||||||2012-10-02|2012-10-03|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|June 2013|Anticipated|2013-06-30||Interventional|||Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children|Lactobacillus Reuteri in Treatment of Functional Abdominal Pain and Chronic Constipation in Children - Randomized, Double Blind, Placebo Controlled Study|Unknown status|Recruiting|Phase 3|300|Anticipated|Sisters of Mercy University Hospital||4|||f||||f||||||||||2018-05-31 21:25:26.113508|2018-05-31 21:25:26.113508
NCT01587833|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-07-03|2012-04-26|2012-04-30|Estimate|||||||2014-07-03|2014-07-08|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture|WEUKBRE5559: IMI PROTECT (Work Package 2): Use of Benzodiazepines and Risk of Hip/Femur Fracture|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 21:25:26.197079|2018-05-31 21:25:26.197079
NCT01587105|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2016-04-22||2017-10-10|2012-04-25|2012-04-27|Estimate|2016-12-28|2017-02-20|Actual||||2017-10-10|2017-11-13|Actual|October 2010||2010-10-31|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 2014|Actual|2014-09-30||Interventional|I3CN||Improving Care for Children With Complex Needs|Improving Care for Children With Complex Needs (I3CN) Study|Completed||N/A|331|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 21:25:33.416515|2018-05-31 21:25:33.416515
NCT01587820|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-12-04|2012-04-26|2012-04-30|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer|A Pilot/ Feasibility Study Comparing Response Rates of Intra-arterial and Intravenous Cisplatin Chemotherapy, Combined With Radiation, in Patients With Locally Advanced Carcinoma of the Oral Cavity and Oropharynx|Terminated||Early Phase 1|1|Actual|Southern Illinois University||2||lack of enrollment|f||||t||||||||||2018-05-31 21:25:26.253221|2018-05-31 21:25:26.253221
NCT01587807|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-07-24|2012-04-26|2012-04-30|Estimate|||||||2017-07-24|2017-07-26|Actual|March 28, 2012|Actual|2012-03-28|July 2017|2017-07-31|November 19, 2012|Actual|2012-11-19|November 19, 2012|Actual|2012-11-19||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057|A Two-part, Randomised, Placebo-controlled Study to Investigatethe Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single Doses of Inhaled GSK1995057 in Healthy Subjects|Completed||Phase 1|53|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 21:25:26.330081|2018-05-31 21:25:26.330081
NCT01587794|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2012-04-26|2012-04-26|2012-04-30|Estimate|||||||2012-04-26|2012-04-30|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Topographic Changes of Retinal Layers After Resolution of Acute Retinal Detachment|Topographic Changes of Retinal Layers After Resolution of Acute Retinal|Completed|||21|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 21:25:26.411785|2018-05-31 21:25:26.411785
NCT01587781|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-08-17|2012-04-27|2012-04-30|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2011||2011-11-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery|Prophylactic Use of Enoxaparin in Morbidly Obese Adolescents During Bariatric Surgery|Active, not recruiting|||12|Anticipated|Children's Research Institute|||||f||||t||||||||||2018-05-31 21:25:26.458226|2018-05-31 21:25:26.458226
NCT01587768|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-12-08|2012-04-26|2012-04-30|Estimate|||||||2014-12-08|2014-12-10|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics|WEUKBRE5555: IMI PROTECT (Work Package 2): The Risk of Acute Liver Injury Associated With the Use of Antibiotics|Completed|||1|Actual|GlaxoSmithKline|||3||f||||||||||||||2018-05-31 21:25:26.502264|2018-05-31 21:25:26.502264
NCT01587755|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-03-06|2012-04-26|2012-04-30|Estimate|||||||2015-03-06|2015-03-09|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PSO-TOP||Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)|Optimising Outpatient Care in Mild to Moderate Psoriasis by a Newly Developed 'Topical Treatment Optimising Programme' - an International Study Using Daivobet®/Dovobet® Gel|Completed||Phase 4|1852|Actual|Reich, Kristian, M.D.||2|||f||||f||||||||||2018-05-31 21:25:26.566394|2018-05-31 21:25:26.566394
NCT01587742|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-12-18|2012-04-26|2012-04-30|Estimate|||||||2014-12-18|2014-12-23|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Observational|||IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer|IMI PROTECT (Work Package 2): Calcium Channel Blocker Treatments and Cancer Risk|Completed|||1|Actual|GlaxoSmithKline|||5||f||||f||||||||||2018-05-31 21:25:27.790811|2018-05-31 21:25:27.790811
NCT01587729|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-03-26|2012-04-26|2012-04-30|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||IMI PROTECT(WP2): Antidepressants & Fractures|IMI PROTECT (Work Package 2): Use of Antidepressants and Risk of Hip and/or Hip/Femur Fracture|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 21:25:27.857405|2018-05-31 21:25:27.857405
NCT01587716|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-07-24|2012-04-26|2012-04-30|Estimate|||||||2017-07-24|2017-07-26|Actual|April 23, 2012|Actual|2012-04-23|July 2017|2017-07-31|July 30, 2012|Actual|2012-07-30|July 30, 2012|Actual|2012-07-30||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.|A Randomised, Double-blind, Placebo Controlled, Inhaled Single Escalating and Repeat Dose Study Using an Aqueous Droplet Inhaler to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:25:27.936672|2018-05-31 21:25:27.936672
NCT01587703|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2018-05-10|2012-04-26|2012-04-30|Estimate|||||||2018-05-10|2018-05-11|Actual|March 28, 2012|Actual|2012-03-28|May 2018|2018-05-31|December 14, 2018|Anticipated|2018-12-14|April 13, 2018|Actual|2018-04-13||Interventional|||A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers|A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers|Active, not recruiting||Phase 1|195|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 21:25:28.056972|2018-05-31 21:25:28.056972
NCT01587690|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-11-19|2012-04-27|2012-04-30|Estimate|||||||2013-11-19|2013-11-20|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells|Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells|Completed|||24|Actual|Rutgers, The State University of New Jersey|||3||f||||f||||||Samples With DNA|"~     peripheral blood~   "|||2018-05-31 21:25:28.167464|2018-05-31 21:25:28.167464
NCT01587677|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2016-10-05|2012-04-26|2012-04-30|Estimate|||||||2016-10-05|2016-10-06|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Observational|LAM FLISA||Evaluation of a LAM FLISA for the Diagnosis of Tuberculosis|Diagnostic Evaluation of a Urine and Plasma Based LAM FLISA for the Diagnosis of Infection With Mycobacterium Tuberculosis|Completed|||92|Actual|Research Center Borstel|||4||f||||f||||||Samples Without DNA|"~     Urine and EDTA plasma~   "|||2018-05-31 21:25:28.230757|2018-05-31 21:25:28.230757
NCT01587664|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-04-07|2012-04-26|2012-04-30|Estimate|||||||2017-04-07|2017-04-11|Actual|May 2012||2012-05-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||NewBreez Safety and Efficacy Evaluation|Safety and Efficacy Evaluation of the NewBreez Intra-laryngeal Prosthesis|Terminated||N/A|2|Actual|ProTiP Medical||1||Due to lack of recruitment and loss of the French principal investigator.|f||||f||||||||No||2018-05-31 21:25:28.3812|2018-05-31 21:25:28.3812
NCT01587651|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|2014-02-11||2014-03-26|2012-04-27|2012-04-30|Estimate|2014-03-26|2014-04-29|Estimate||||2014-03-26|2014-04-29|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|SWAP-2||Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease|A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents|Completed||Phase 4|110|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 21:25:28.499695|2018-05-31 21:25:28.499695
NCT01587625|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-08-04|2012-04-27|2012-04-30|Estimate|||||||2017-08-04|2017-08-07|Actual|August 2013||2013-08-31|August 2017|2017-08-31|October 8, 2016|Actual|2016-10-08|June 9, 2016|Actual|2016-06-09||Interventional|OxyHighLow||High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour|High Dose Versus Low Dose Oxytocin for Augmentation of Delayed Labour|Completed||N/A|1376|Actual|Göteborg University||2|||f||||t||||||||Yes|Data for primary and secondary outcome measures from the two groups will be submitted to the Swedish National Data Service (Svensk Nationell Datatjänst, SND), a national authority responsible for administrating sharing of research data.|2018-05-31 21:25:29.499545|2018-05-31 21:25:29.499545
NCT01587612|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2014-03-28|2012-04-26|2012-04-30|Estimate|||||||2014-03-28|2014-03-31|Estimate|August 2003||2003-08-31|March 2014|2014-03-31|March 2004|Actual|2004-03-31|December 2003|Actual|2003-12-31||Observational|||Study of Quantification of Hyperpronation|Study of Quantification of Hyperpronation|Completed|||80|Actual|Northern Orthopaedic Division, Denmark|||||f||||f||||||||||2018-05-31 21:25:29.586787|2018-05-31 21:25:29.586787
NCT01587599|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-27|2012-04-27|2012-04-30|Estimate|||||||2012-04-27|2012-04-30|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Pharmaceutical Care of Patients With Impaired Mobility in a Model-region of Decreasing Supply of Medical Services|Pharmaceutical Care of Elderly Diabetes-patients With Impaired Mobility in a Model-region of Decreasing Supply of Medical Services in North-eastern Germany|Unknown status|Active, not recruiting|Phase 4|54|Anticipated|Foerderinitiative Pharmazeutische Betreuung e.V.||2|||f||||f||||||||||2018-05-31 21:25:29.648799|2018-05-31 21:25:29.648799
NCT01587586|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-04-27|2012-04-27|2012-04-30|Estimate|||||||2012-04-27|2012-04-30|Estimate|October 2011||2011-10-31|April 2012|2012-04-30||||December 2013|Anticipated|2013-12-31||Interventional|||Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With HCV Genotype 1 Infection|An Open-label, Randomized, Active Control Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 + Ribavirin in Treatment-Naïve Subjects With HCV Genotype 1 Infection|Unknown status|Recruiting|Phase 2|208|Anticipated|PharmaEssentia||4|||f||||f||||||||||2018-05-31 21:25:29.816275|2018-05-31 21:25:29.816275
NCT01587573|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-04-10|2012-04-27|2012-04-30|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2012|Actual|2012-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer|Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma|Recruiting|||370|Anticipated|PeriRx|||1||f||||t||||||Samples With DNA|"~     cell free saliva~   "|Undecided||2018-05-31 21:25:29.914084|2018-05-31 21:25:29.914084
NCT01587560|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-08-29|2012-04-27|2012-04-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Comparison Between a Pyrocarbon and a CoCr Shoulder Resurfacing Implant||Active, not recruiting||N/A|80|Anticipated|Danderyd Hospital||2|||f||||t||||||||||2018-05-31 21:25:30.021789|2018-05-31 21:25:30.021789
NCT01587547|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-05-07|2012-04-26|2012-04-30|Estimate|||||||2013-05-07|2013-05-08|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Observational|EmbryoSure||Amino Acid Profiling of Spent Culture Medium|Amino Acid Profiling of Spent Culture Medium to Retrospectively Determine Individual Embryo Selection Criteria for Improved Clinical IVF Outcome|Terminated|||10|Actual|Origio A/S|||1|ORIGIO a/s acquired by Cooper Surgical Inc. who decided to withdraw from the project|f||||t||||||Samples Without DNA|"~     Spent culture medium from the individual embryos~   "|||2018-05-31 21:25:30.105532|2018-05-31 21:25:30.105532
NCT01587534|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-04-13|2012-04-26|2012-04-30|Estimate|||||||2015-04-13|2015-04-15|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)|Phase 2 Study of Randomized Controlled Trial of Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer|Completed||Phase 2|67|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 21:25:30.169188|2018-05-31 21:25:30.169188
NCT01587521|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-07-27|2012-04-27|2012-04-30|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia|Prevalence of and Factors Associated With Metabolic Syndrome in Patients With Schizophrenia|Completed|||80|Actual|Chiang Mai University|||||f||||f||||||||||2018-05-31 21:25:30.251975|2018-05-31 21:25:30.251975
NCT01587508|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-04-29|2012-04-26|2012-04-30|Estimate|||||||2016-04-29|2016-05-03|Estimate|May 2013||2013-05-31|April 2012|2012-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago|A Phase III, Randomized, Single-Blind, Superiority Study Comparing The Efficacy And Tolerability Of A New Drug Containing The Combination Meloxicam And Cyclobenzaprine And The Same Components Alone In The Treatment Of Acute Lumbago|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||3||"The comparator product was withdrawn from the brazilian market not being possible to conduct~   the design regarding initially planned."|f||||f||||||||||2018-05-31 21:25:30.31796|2018-05-31 21:25:30.31796
NCT01587495|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2015-05-19|2012-04-26|2012-04-30|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pharmacokinetics and Safety of Ertapenem in the Postpartum Period|Pharmacokinetics and Safety of Ertapenem in the Postpartum Period|Terminated||Phase 1|3|Actual|Duke University||1||study terminated due to low subject accrual|f||||f||||||||||2018-05-31 21:25:30.426798|2018-05-31 21:25:30.426798
NCT01587482|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-05-19|2012-04-26|2012-04-30|Estimate|||||||2016-05-19|2016-05-20|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|December 2012|Actual|2012-12-31||Observational|PLAISIR||PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis|PacLitaxel Eluting Balloon Application In Sfa In Stent Restenosis|Completed|||53|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 21:25:30.51816|2018-05-31 21:25:30.51816
NCT01587469|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2018-02-02|2012-04-26|2012-04-30|Estimate|||||||2018-02-02|2018-02-06|Actual|May 2012|Actual|2012-05-31|February 2018|2018-02-28|February 21, 2014|Actual|2014-02-21|February 21, 2014|Actual|2014-02-21||Observational|||Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects|Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects|Completed|||992|Actual|Cepheid|||1||f||||||||||None Retained|"~     Samples of sputum may be retained~   "|||2018-05-31 21:25:30.61965|2018-05-31 21:25:30.61965
NCT01587092|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2013-11-14|2012-04-25|2012-04-27|Estimate|||||||2013-11-14|2013-11-18|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Workstation Pilot Study|WorkStation Pilot Study|Completed||N/A|41|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:25:33.834634|2018-05-31 21:25:33.834634
NCT01587456|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2016-06-15|2012-04-27|2012-04-30|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|ARTEOS2||Arteos II Study: Relationship Between Osteoporosis and Arterial Rigidity Within Fractured Patients Cohort|Relationship Between Osteoporosis and Arterial Rigidity Within Fractured Patients Cohort.|Recruiting|||300|Anticipated|Central Hospital, Nancy, France|||||f||||t||||||Samples With DNA|"~     Serum, Plasma and DNA~   "|Undecided||2018-05-31 21:25:30.690523|2018-05-31 21:25:30.690523
NCT01587443|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-04-14|2012-04-27|2012-04-30|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2012||2012-01-31|April 2015|2015-04-30||||April 2015|Actual|2015-04-30||Observational|||Comparison of Outcomes Between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population|A Comparison of Patient-Reported, Economic and Clinical Outcomes Between Hemodialysis and Peritoneal Dialysis Patients in a Multi-Ethnic Asian Population|Unknown status|Active, not recruiting||200|Anticipated|National University, Singapore|||2||f||||f||||||||||2018-05-31 21:25:30.768407|2018-05-31 21:25:30.768407
NCT01587430|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2014-04-04|2012-04-27|2012-04-30|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|January 2015|Anticipated|2015-01-31|April 2014|Anticipated|2014-04-30||Interventional|||3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia|Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance|Unknown status|Active, not recruiting|Phase 4|245|Anticipated|National Research Center for Hematology, Russia||2|||f||||t||||||||||2018-05-31 21:25:30.926752|2018-05-31 21:25:30.926752
NCT01587417|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-10-31|2012-04-27|2012-04-30|Estimate|||||||2013-10-31|2013-11-01|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL|A Randomised, Double-blind, Placebo-controlled Trial in Healthy Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 2.5 mg to 360 mg of BI 187004 CL|Completed||Phase 1|72|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:25:31.018438|2018-05-31 21:25:31.018438
NCT01587404|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-08-18|2012-04-26|2012-04-30|Estimate|||||||2015-08-18|2015-08-19|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Catheter Contact Force and Electrograms|Relationship Between Catheter Contact Force and Electrogram Characteristics in Fibrillating Human Atrial Myocardium|Unknown status|Recruiting|Phase 4|55|Anticipated|Barts & The London NHS Trust||2|||f||||||||||||||2018-05-31 21:25:31.088966|2018-05-31 21:25:31.088966
NCT01587391|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-10-30|2012-04-27|2012-04-30|Estimate|||||||2013-10-30|2013-10-31|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX|A Randomised, Double-blind, Placebo-controlled Trial in Healthy Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 2.5 mg to 160 mg of BI 163538 XX|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:25:31.185933|2018-05-31 21:25:31.185933
NCT01587378|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-10-05|2012-04-27|2012-04-30|Estimate|||||||2017-10-05|2017-10-06|Actual|October 2012|Actual|2012-10-31|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|August 2017|Actual|2017-08-31||Interventional|PregMet2||Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome|A Prospective, Randomized, Double-blind, Multi-centre Study, Where the Possible Effect of Metformin to Prevent Late Miscarriage and Preterm Delivery is Studied in Women With Polycystic Ovary Syndrome (PCOS)|Completed||N/A|489|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 21:25:31.293292|2018-05-31 21:25:31.293292
NCT01587365|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-09-02|2012-04-27|2012-04-30|Estimate|||||||2013-09-02|2013-09-04|Estimate|May 2012||2012-05-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins|Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-962476 in Healthy Subjects and in Patients With Hypercholesterolemia on Statin Therapy|Completed||Phase 1|66|Actual|Bristol-Myers Squibb||8|||f||||f||||||||||2018-05-31 21:25:31.454856|2018-05-31 21:25:31.454856
NCT01587352|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-05-01|2012-04-26|2012-04-30|Estimate|||||||2018-05-01|2018-05-02|Actual|April 20, 2012|Actual|2012-04-20|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Vorinostat in Treating Patients With Metastatic Melanoma of the Eye|A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma|Active, not recruiting||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:25:31.57946|2018-05-31 21:25:31.57946
NCT01587339|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-09-12|2012-04-26|2012-04-30|Estimate|||||||2013-09-12|2013-09-16|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Observational|||Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy|Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy|Completed|||6498|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:25:31.691672|2018-05-31 21:25:31.691672
NCT01587326|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-05-13|2012-04-27|2012-04-30|Estimate|||||||2012-05-13|2012-05-15|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|BAFH||The Effects of Escitalopram on Cytokines|The Effects of Escitalopram on Cytokines in Depressive Patients|Unknown status|Recruiting|N/A|25|Anticipated|Beitou Armed Forces Hospital, Taipei, Taiwan||1|||f||||t||||||||||2018-05-31 21:25:31.779915|2018-05-31 21:25:31.779915
NCT01587313|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-08-04|2012-04-27|2012-04-30|Estimate|||||||2015-08-04|2015-08-06|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers|A Four-arm, Single Dose, Two-Period, Pharmacokinetic Study of BiDil SR and IR Capsules and Commercial BiDil Tablets|Completed||Phase 1|36|Actual|Arbor Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 21:25:31.868019|2018-05-31 21:25:31.868019
NCT01587300|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2018-01-17|2012-04-27|2012-04-30|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2011||2011-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Neuroblastoma Biology Study|N2004-05: Neuroblastoma Biology Study|Recruiting|||500|Anticipated|New Approaches to Neuroblastoma Therapy Consortium|||||f||||t||||||Samples With DNA|"~     The biospecimen includes blood and bone marrow and their derivatives (e.g., DNA, RNA, plasma,~     lymphocytes) as well as tumors.~   "|||2018-05-31 21:25:31.949313|2018-05-31 21:25:31.949313
NCT01587287|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-28|2012-04-25|2012-04-30|Estimate|||||||2012-04-28|2012-05-01|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|||A Comprehensive Assessment of Anterior Corneal Power by Different Devices|A Comprehensive Assessment of the Precision and Agreement of Anterior Corneal Power Measurements Obtained Using Different Devices|Completed|||35|Actual|Wenzhou Medical University|||1||f||||t||||||||||2018-05-31 21:25:32.058381|2018-05-31 21:25:32.058381
NCT01587274|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2014-10-09|2012-04-27|2012-04-30|Estimate|||||||2014-10-09|2014-10-10|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|January 2015|Anticipated|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||A Randomized Study of Three Medication Regimens for Acute Low Back Pain|A Randomized Three-armed Comparative Effectiveness Study of Various Medications for Musculoskeletal Low Back Pain: Defining the Added Benefit of Muscle Relaxants and Opioids.|Unknown status|Active, not recruiting|Phase 4|323|Anticipated|Montefiore Medical Center||3|||f||||t||||||||||2018-05-31 21:25:32.131746|2018-05-31 21:25:32.131746
NCT01587261|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2016-01-12|2012-04-27|2012-04-30|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2017||2017-06-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Vitamin C for Severe Thermal Injuries|Prospective Placebo-Controlled Double-Blinded Trial for High-Dose Vitamin C Administration During the Acute Resuscitative Phase of Severe Thermal Injuries|Unknown status|Not yet recruiting|Phase 2|54|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 21:25:32.220282|2018-05-31 21:25:32.220282
NCT01587248|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-26|2012-04-26|2012-04-30|Estimate|||||||2012-04-26|2012-04-30|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|HMRM||Use of Harmonic in Breast Surgery|Harmonic Scalpel vs. Electrocautery Dissection in Modified Radical Mastectomy: A Randomized Controlled Trial|Completed||Phase 3|152|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 21:25:32.310814|2018-05-31 21:25:32.310814
NCT01587235|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2014-12-29|2012-04-27|2012-04-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|VYCTORY||A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)|A Multicenter, Open-label, 6 Week Study to Evaluate the Efficacy and Safety of Algorithm Based Intensive Treatment With Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Patients.|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:25:32.402541|2018-05-31 21:25:32.402541
NCT01587222|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2015-09-10|2012-04-27|2012-04-30|Estimate|||||||2015-09-10|2015-09-11|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|July 2014|Actual|2014-07-31||Interventional|||Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure||Unknown status|Recruiting|Phase 2|15|Anticipated|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 21:25:32.477271|2018-05-31 21:25:32.477271
NCT01587209|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2016-08-18|2012-04-27|2012-04-30|Estimate|||||||2016-08-18|2016-08-22|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Microparticles in Scuba Divers With Decompression Sickness|Phase 1 Study Investigating Alterations of Circulating Microparticles in Scuba Divers With Decompression Sickness|Completed|||1|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 21:25:32.550935|2018-05-31 21:25:32.550935
NCT01587196|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-09-29|2012-04-25|2012-04-30|Estimate|||||||2017-09-29|2017-10-03|Actual|January 2012||2012-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|fMRI CURE||CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery|CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery - Prescription Opiates/Medication|Enrolling by invitation||Phase 2|72|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 21:25:32.612585|2018-05-31 21:25:32.612585
NCT01587183|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2013-08-20|2012-04-27|2012-04-30|Estimate|||||||2013-08-20|2013-08-21|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|RAPT||Running Against Prehypertension Trial (RAPT): A Pilot Trial|Running Against Prehypertension Trial (RAPT): A Pilot Randomized Controlled Trial|Completed||N/A|22|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 21:25:32.688816|2018-05-31 21:25:32.688816
NCT01587170|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-11-30|2012-04-25|2012-04-30|Estimate|||||||2012-11-30|2012-12-03|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Observational|||Effects of Zolmitriptan on Sensory Transmission After Spinal Cord Injury|Phase 2: Effects of Zolmitriptan on Sensory Afferent Transmission After Spinal Cord Injury|Completed|||13|Actual|University of Alberta|||2||f||||||||||||||2018-05-31 21:25:32.760522|2018-05-31 21:25:32.760522
NCT01587157|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-25|2012-04-25|2012-04-30|Estimate|||||||2012-04-25|2012-04-30|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Capnography During Percutaneous Transhepatic Cholangiodrainage (PTCD) (HepaBreath)||Completed||Phase 3|20|Actual|Technische Universität München||1|||f||||f||||||||||2018-05-31 21:25:32.82214|2018-05-31 21:25:32.82214
NCT01587144|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-07-20|2012-04-27|2012-04-30|Estimate|||||||2016-07-20|2016-07-22|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)|An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme|Terminated||Phase 2|18|Actual|Spectrum Pharmaceuticals, Inc||2||Sponsor's decision|f||||t||||||||||2018-05-31 21:25:32.883013|2018-05-31 21:25:32.883013
NCT01587131|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-04-16|2012-04-26|2012-04-27|Estimate|||||||2015-04-16|2015-04-17|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||DNA-based Influenza Vaccine in the Elderly|Phase I, Open Label Study of a DNA Vaccine's Ability to Increase the Immune Response to the Trivalent Seasonal Influenza Vaccine in the Elderly|Completed||Phase 1|50|Actual|University of Manitoba||3|||f||||t||||||||||2018-05-31 21:25:33.096949|2018-05-31 21:25:33.096949
NCT01587118|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2016-07-18||2016-10-12|2012-04-26|2012-04-27|Estimate|2016-10-12|2016-12-05|Estimate||||2016-10-12|2016-12-05|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder|An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder|Completed||Phase 4|18|Actual|Tuscaloosa Research & Education Advancement Corporation|"This study was limited by both the small number of subjects enrolled and its open-label design.~Average dose of asenapine was 13.6 ± 6.4 mg/d; at 12-weeks 15.9 ± 4.9 mg/d."|1|||f||||f||||||||No|No sharing of individual participant data|2018-05-31 21:25:33.207534|2018-05-31 21:25:33.207534
NCT01587079|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2016-05-23|2013-10-22|2016-05-23|2012-04-26|2012-04-27|Estimate|2016-05-23|2016-06-30|Estimate|2013-10-22|2013-11-14|Estimate|2016-05-23|2016-06-30|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional||ITT/Safety Population|Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double Blind, (Test Products), Chronic Dosing (7 Days), Four Period, Eight Treatment , Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Five Doses of PT003, One Dose of PT001 and One Dose of PT005 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide 18 µg, Open Label) as Active Control|Completed||Phase 2|159|Actual|Pearl Therapeutics, Inc.||8|||f||||f||||||||||2018-05-31 21:25:33.960637|2018-05-31 21:25:33.960637
NCT01587066|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-26|2012-04-26|2012-04-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|September 2011|Anticipated|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression||Withdrawn||Phase 4|0|Actual|Naju National Hospital||2|||f||||f||||||||||2018-05-31 21:25:34.853597|2018-05-31 21:25:34.853597
NCT01587053|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-02-06|2012-04-25|2012-04-27|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2012|Actual|2012-04-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Anti Vitamin K Therapeutic Education|Anti Vitamin K Therapeutic Education With INR Self Measure Device Within Children From 0 to 18 Years|Terminated|||57|Actual|University Hospital, Montpellier|||1|Difficulty recruiting|f||||t||||||||||2018-05-31 21:25:34.916479|2018-05-31 21:25:34.916479
NCT01587040|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2018-03-01|2012-04-26|2012-04-27|Estimate|||||||2018-03-01|2018-03-02|Actual|July 20, 2012|Actual|2012-07-20|March 2018|2018-03-31|June 6, 2018|Anticipated|2018-06-06|June 6, 2018|Anticipated|2018-06-06||Interventional|||Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen|International, Multicenter, Open-label, Treatment-extension Study for Subjects Who Completed a Phase 1 or Phase 2 Parental Study to Continue Receiving Treatment With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen|Active, not recruiting||Phase 1/Phase 2|150|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 21:25:34.979592|2018-05-31 21:25:34.979592
NCT01587027|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2013-08-07||2016-12-22|2012-04-26|2012-04-27|Estimate|2014-05-12|2014-06-09|Estimate||||2016-12-22|2017-02-10|Actual|December 2011||2011-12-31|December 2016|2016-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Participants must be healthy non-smoking adult male and female volunteers between the ages of 18 and 40 years, with a BMI of 18-30 kg/m2.|Safety Evaluation of Aminophylline and Methazolamide|The Safety Evaluation of Aminophylline and Methazolamide When Administered Orally Alone and in Combination to Healthy Volunteers|Completed||Phase 1|16|Actual|Poudre Valley Health System||2|||f||||t||||||||No||2018-05-31 21:25:35.081193|2018-05-31 21:25:35.081193
NCT01587014|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2014-03-17||2017-01-03|2012-04-26|2012-04-27|Estimate|2014-03-17|2014-04-21|Estimate||||2017-01-03|2017-02-20|Actual|February 2012||2012-02-29|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|Prima-Temp|ICU patients|Safety and Feasibility of Prima-Temp Thermometer Patch|Safety and Feasibility of Prima-Temp Thermometer Patch in Determining Baseline Temperatures of Research Subjects in a Hospital Intensive Care Unit (ICU)|Completed|||26|Actual|Poudre Valley Health System|||||f||||f||||||||No||2018-05-31 21:25:35.314512|2018-05-31 21:25:35.314512
NCT01587001|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2016-03-21||2017-03-27|2012-04-26|2012-04-27|Estimate|2016-06-15|2016-07-26|Estimate||||2017-03-27|2017-04-26|Actual|November 2011||2011-11-30|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis|The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis|Completed||N/A|17|Actual|National Jewish Health||2|||f||||t||||||||No||2018-05-31 21:25:35.611527|2018-05-31 21:25:35.611527
NCT01586988|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2016-11-23|2012-04-25|2012-04-27|Estimate|||||||2016-11-23|2016-11-28|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|IMAGE||A Parenting and Self-Care Intervention for HIV Infected Mothers|A Parenting Intervention for HIV+ Moms: The IMAGE Program|Completed||N/A|124|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:25:35.865548|2018-05-31 21:25:35.865548
NCT01586975|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2015-06-29||2015-12-02|2012-04-26|2012-04-27|Estimate|2015-10-27|2015-12-03|Estimate||||2015-12-02|2015-12-31|Estimate|July 2007||2007-07-31|December 2015|2015-12-31|December 2011|Actual|2011-12-31|April 2010|Actual|2010-04-30||Interventional|||Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events|Multiphase Study to Determine if Platelet Function Analysis Results Correlate With Ischemic Events and Bleeding Complications|Completed||Phase 2/Phase 3|93|Actual|Northwestern University||3|||f||||f||||||||||2018-05-31 21:25:35.942521|2018-05-31 21:25:35.942521
NCT01586962|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2013-04-25||2013-08-06|2012-04-25|2012-04-27|Estimate|2013-08-06|2013-08-07|Estimate||||2013-08-06|2013-08-07|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI|An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection|Completed||Phase 3|56|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:25:36.32727|2018-05-31 21:25:36.32727
NCT01586949|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-09-22|2012-04-25|2012-04-27|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effectiveness of a Well-being Web-based Intervention|A Randomized Controlled Trial of the Effectiveness of the Web-based Well-being Intervention Daily Challenge|Completed||N/A|1503|Actual|MeYou Health, LLC||2|||f||||f||||||||||2018-05-31 21:25:36.485951|2018-05-31 21:25:36.485951
NCT01586936|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-02-23|2012-04-25|2012-04-27|Estimate|||||||2017-02-23|2017-02-27|Actual|March 10, 1999|Actual|1999-03-10|February 2017|2017-02-28|March 9, 2010|Actual|2010-03-09|March 9, 2010|Actual|2010-03-09||Observational|||Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors|Special Survey of Production of Antibody Against Coagulation|Completed|||9|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:25:36.569505|2018-05-31 21:25:36.569505
NCT01586923|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-04-06|2012-04-25|2012-04-27|Estimate|||||||2016-04-06|2016-04-08|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Interventional|TOTAL||RBC Transfusion in Severe Anemia With Lactic Acidosis|A Prospective Study of RBC Transfusion in Children With Severe Anemia|Completed||Phase 3|290|Actual|Massachusetts General Hospital||2|||f||||t||||||||No|Data published|2018-05-31 21:25:36.637089|2018-05-31 21:25:36.637089
NCT01586910|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2018-04-26|2012-04-26|2012-04-27|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2012|Actual|2012-04-30|April 2018|2018-04-30|November 2026|Anticipated|2026-11-30|July 2018|Anticipated|2018-07-31||Interventional|SURTAVI||Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).|Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)|Active, not recruiting||N/A|2500|Anticipated|Medtronic Cardiovascular||2|||f||||t||||||||||2018-05-31 21:25:36.727512|2018-05-31 21:25:36.727512
NCT01586897|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2015-07-08||2015-12-08|2012-04-26|2012-04-27|Estimate|2015-11-04|2015-12-09|Estimate||||2015-12-08|2016-01-11|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care|The Medication Metronome Project|Completed||N/A|52|Actual|Massachusetts General Hospital|Study participants did not embrace this method of non-visit based care, with only 660 medication prescriptions using the Medication Metronome ordering option (21% of possible orders).|2|||f||||f||||||||||2018-05-31 21:25:36.926879|2018-05-31 21:25:36.926879
NCT01586884|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2014-09-08|2012-04-25|2012-04-27|Estimate|||||||2014-09-08|2014-09-09|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Determine the Safety and Feasibility of Utilizing the CD Leycom Pressure/Conductance Catheter to Determine Optimal LV Pacing Site|Study to Determine the Safety and Feasibility of Utilizing the CD Leycom Pressure/Conductance Catheter to Determine Optimal LV Pacing Site|Withdrawn||Phase 1|0|Actual|Lancaster General Hospital||1|||f||||t||||||||||2018-05-31 21:25:37.22016|2018-05-31 21:25:37.22016
NCT01586871|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-09-01|2012-04-25|2012-04-27|Estimate|||||||2017-09-01|2017-09-05|Actual|March 2012||2012-03-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|August 2016|Actual|2016-08-31||Observational|||Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network|Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network|Completed|||27|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 21:25:37.301786|2018-05-31 21:25:37.301786
NCT01586858|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-10-25|2012-04-25|2012-04-27|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|May 15, 2014|Actual|2014-05-15|May 15, 2014|Actual|2014-05-15||Observational|RAVELOS||Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study|Rituximab for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (RAVE) Long-Term Follow-Up Study|Terminated|||67|Actual|Johns Hopkins University|||1|Loss of Funding|f||||f||||||||||2018-05-31 21:25:37.53458|2018-05-31 21:25:37.53458
NCT01586845|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2014-01-16|2012-04-26|2012-04-27|Estimate|||||||2014-01-16|2014-01-20|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|INSPIRE||Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation|A Phase III, Randomized, Multicentre, Open-Label, Concentration-Controlled, Safety and Efficacy Study of Voclosporin and Tacrolimus in Renal Transplantation|Withdrawn||Phase 3|0|Actual|Aurinia Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 21:25:37.627139|2018-05-31 21:25:37.627139
NCT01586832|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-10-13|2012-04-25|2012-04-27|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Stocking of a Busy Emergency Department|Stocking of a Busy Emergency Department|Completed|||565|Actual|Lehigh Valley Hospital|||1||f||||f||||||||No|However, the overall study results were published in JONA, vol 44, issue 11, November, 2014.|2018-05-31 21:25:37.702224|2018-05-31 21:25:37.702224
NCT01586819|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2017-04-12||2017-08-08|2012-04-26|2012-04-27|Estimate|2017-08-08|2017-09-11|Actual||||2017-08-08|2017-09-11|Actual|September 2011|Actual|2011-09-30|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A|Treatment of Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: A Split-face, Rater-blinded Randomized Control Trial|Completed||Phase 3|26|Actual|Loyola University|There are no limitations or caveats to disclose.|2|||f||||f||||||||No||2018-05-31 21:25:37.781751|2018-05-31 21:25:37.781751
NCT01586806|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2016-05-03||2016-10-07|2012-04-26|2012-04-27|Estimate|2016-05-03|2016-06-09|Estimate||||2016-10-07|2016-11-28|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction|Postoperative Analgesia Comparing Subsartorial Saphenous Nerve Block With and Without Dexamethasone in ACL Reconstruction|Completed||Phase 4|195|Actual|Hospital for Special Surgery, New York||3|||f||||t||||||||||2018-05-31 21:25:38.019743|2018-05-31 21:25:38.019743
NCT01586793|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-05-26|2012-04-25|2012-04-27|Estimate|||||||2015-05-26|2015-05-28|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar Depression|A Randomized Trial Comparing the Effectiveness and Tolerability of High and Low Frequency Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar Depression: An Exploratory Study|Completed||Phase 2/Phase 3|8|Actual|Douglas Mental Health University Institute||2|||f||||f||||||||||2018-05-31 21:25:38.44375|2018-05-31 21:25:38.44375
NCT01586780|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-25|2012-04-25|2012-04-27|Estimate|||||||2012-04-25|2012-04-27|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Metabolic Effects of a Pre-meal Protein Drink With or Without Added Amino Acids at a Subsequent Composite Meal|Effects of Pre-meal Drinks With Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite Meal|Completed||N/A|14|Actual|Lund University||7|||f||||f||||||||||2018-05-31 21:25:38.547981|2018-05-31 21:25:38.547981
NCT01586767|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2018-02-13|2012-04-25|2012-04-27|Estimate|||||||2018-02-13|2018-02-14|Actual|July 2011||2011-07-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy|A Phase II Study of Intensity-Modulated or Proton Radiation Therapy for Locally Advanced Sinonasal Malignancy|Active, not recruiting||Phase 2|39|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:25:38.641602|2018-05-31 21:25:38.641602
NCT01586754|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-26|2012-04-26|2012-04-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Observational|||Subclinical Organ Damage in Overweight and Obese Patients: Does Presence of Metabolic Syndrome Matter?||Unknown status|Active, not recruiting||100|Actual|Goztepe Training and Research Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood will be drawn from patients for routine biochemical analyses for glucose, urea,~     creatinine, liver function tests, thyroid function tests, electrolytes and homocysteine and~     also glucose tolerance test. Spot urine samples will be drawn for assessment of~     microalbuminuria.~   "|||2018-05-31 21:25:38.744341|2018-05-31 21:25:38.744341
NCT01586741|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-04-25|2012-04-25|2012-04-27|Estimate|||||||2012-04-25|2012-04-27|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate Two Different Surgical Methods for Treatment for Abdominal Wall Diastasis|A Prospective Randomized Study to Evaluate Two Different Surgical Methods for Treatment for Abdominal Wall Diastasis|Unknown status|Active, not recruiting|N/A|96|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 21:25:38.826713|2018-05-31 21:25:38.826713
NCT01586728|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-06-12|2012-04-26|2012-04-27|Estimate|||||||2015-06-12|2015-06-15|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|MUCOXY||Oxygen Therapy in Cystic Fibrosis|Indication and Benefits of Nocturnal Oxygen Therapy in Cystic Fibrosis|Terminated||N/A|8|Actual|Assistance Publique - Hôpitaux de Paris||2||lack of inclusion in the study|f||||f||||||||||2018-05-31 21:25:38.913635|2018-05-31 21:25:38.913635
NCT01586715|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-25|2012-04-25|2012-04-27|Estimate|||||||2012-04-25|2012-04-27|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Interventional|||Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)|A Phase IIa Clinical Trial to Study the Treatment of the Extremely Complex and Conventional Treatment Resistant Perianal Fistulae With Autologous Stem Cells From Lipoaspirate|Unknown status|Recruiting|Phase 2|10|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 21:25:38.99421|2018-05-31 21:25:38.99421
NCT01586702|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-11-02|2012-04-26|2012-04-27|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2011||2011-09-30|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|INSPiRE-TMS||Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients|Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients (INSPiRE-TMS) A Randomized Trial Comparing a Patient Centered Support Program Versus Conventional Car|Active, not recruiting||N/A|2082|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 21:25:39.087907|2018-05-31 21:25:39.087907
NCT01586689|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-01-11|2012-04-26|2012-04-27|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2006||2006-09-30|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Evaluating Alternative Aftercare Models for Ex-offenders|Evaluating Alternative Aftercare Models for Ex-offenders|Completed||Phase 2|270|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-05-31 21:25:39.179702|2018-05-31 21:25:39.179702
NCT01586676|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-01-10|2012-04-25|2012-04-27|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional|||Effectiveness of Motivational Interviewing Supervision in Community Programs|Effectiveness of Motivational Interviewing Supervision in Community Programs|Completed||Phase 2/Phase 3|450|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-05-31 21:25:39.255587|2018-05-31 21:25:39.255587
NCT01586663|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-27|2012-04-26|2012-04-27|Estimate|||||||2012-04-27|2012-05-01|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Serial Night Time Position Splint on Systemic Sclerosis|Evaluation of Serial Night Time Position Splint on Range of Motion for Patients With Systemic Sclerosis|Unknown status|Recruiting|Phase 3|76|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:25:39.353459|2018-05-31 21:25:39.353459
NCT01586650|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2017-02-14|2012-04-25|2012-04-27|Estimate|||||||2017-02-14|2017-02-15|Actual|July 2011||2011-07-31|February 2017|2017-02-28|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Effects of Aerobic Training in Patients With Ankylosing Spondylitis||Completed||Phase 3|70|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:25:39.447516|2018-05-31 21:25:39.447516
NCT01586637|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-04-25|2012-04-25|2012-04-27|Estimate|||||||2012-04-25|2012-04-27|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Art Therapy to Treat Women With Fibromyalgia|Assessment of Art Therapy Program for Women With Fibromyalgia: Randomized, Controlled, Blinded Study|Completed||Phase 2|80|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:25:39.540647|2018-05-31 21:25:39.540647
NCT01586624|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-10-13|2012-04-26|2012-04-27|Estimate|||||||2017-10-13|2017-10-16|Actual|December 2011||2011-12-31|May 2016|2016-05-31||||September 2018|Anticipated|2018-09-30||Interventional|||A Phase I Trial of Vandetanib (ZD6474) and Selumetinib (AZD6244)for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)|A Cancer Research UK Phase I Dose Escalation Trial of Oral VEGFR and EGFR Inhibitor, Vandetanib in Combination With the Oral MEK Inhibitor, Selumetinib (VanSel-1) in Solid Tumours (Dose Escalation) and NSCLC (Expansion Cohort).|Active, not recruiting||Phase 1|61|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 21:25:39.638453|2018-05-31 21:25:39.638453
NCT01586611|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-10-01|2012-04-25|2012-04-27|Estimate|||||||2014-10-01|2014-10-02|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|Panc001||A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer|A Multicentre, Randomized, Open Label, Phase III Study of Gemcitabine Versus FOLFOX in the First Line Setting for Metastatic Pancreatic Cancer Patients Using Human Equilibrative Nucleoside Transporter 1 (hENT1) Biomarker Testing.|Unknown status|Recruiting|Phase 3|175|Anticipated|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-05-31 21:25:39.72097|2018-05-31 21:25:39.72097
NCT01586598|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-04-25|2012-04-25|2012-04-27|Estimate|||||||2012-04-25|2012-04-27|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Sensory Retraining Facilitates Sensory Recovery After Mandibular Nerve Injury|Sensory Retraining Exercise Facilitates Sensory Recovery After Bilateral Sagittal Split Osteotomy - a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|80|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:25:39.805126|2018-05-31 21:25:39.805126
NCT01586585|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2013-10-23|2012-04-26|2012-04-27|Estimate|||||||2013-10-23|2013-10-24|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|BTFL2012||Back to Functional Life Following Cardiac Surgery|Patient Rehabilitation Post Cardiac Surgery Based on Their Pre-op Status|Withdrawn|||0|Actual|Carmel Medical Center|||1||f||||f||||||||||2018-05-31 21:25:39.876449|2018-05-31 21:25:39.876449
NCT01586572|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-06-26|2012-04-26|2012-04-27|Estimate|||||||2015-06-26|2015-06-29|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SIAD||Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3|Comparison of Immunogenicity of Type 1 mOPV Administered at Short Intervals With Type 1 mOPV1 and Type 1 & 3 bOPV Oral Polio Vaccine Given at Standard Intervals in Pakistan:A Randomized Trial|Completed||N/A|1000|Actual|Aga Khan University||4|||f||||f||||||||||2018-05-31 21:25:39.932239|2018-05-31 21:25:39.932239
NCT01586559|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-26|2012-04-26|2012-04-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|January 2011|Actual|2011-01-31||Observational|||Evaluation of the Long-term Stability of Sheath Plication Using Absorbable Sutures in Patients With Diastasis of the Recti Muscles: an Ultrasonography Study|Evaluation of the Long-term Stability of Sheath Plication Using Absorbable Sutures in Patients With Diastasis of the Recti Muscles: an Ultrasonography Study|Completed|||65|Actual|Bulovka Hospital|||2||f||||||||||||||2018-05-31 21:25:40.034297|2018-05-31 21:25:40.034297
NCT01586546|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-26|2012-04-26|2012-04-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||A Pilot Study To Assess Guidance in and Subsequent Use of Mind-Body Techniques on the Quality of Life of Cancer Patients|Quality of Life Outcomes Following Mind-body Skills Training for Cancer Patients That Are Facilitated Either Face-to-face or Online: A Pilot Study|Unknown status|Not yet recruiting|N/A|32|Anticipated|Absenger Cancer Education Foundation||4|||f||||f||||||||||2018-05-31 21:25:40.085562|2018-05-31 21:25:40.085562
NCT01586533|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2014-01-07|2012-04-26|2012-04-27|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2012||2012-06-30|January 2014|2014-01-31||||April 2014|Anticipated|2014-04-30||Interventional|||Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis|A Phase II Double-blind, Randomized, Comparator-controlled Study of the Safety and Efficacy of Zoenasa™ Rectal Gel (Mesalamine Plus N-acetylcysteine) in Subjects With Left-sided Ulcerative Colitis|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|Altheus Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 21:25:40.164428|2018-05-31 21:25:40.164428
NCT01586520|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-09-14|2012-04-25|2012-04-26|Estimate|||||||2017-09-14|2017-09-15|Actual|April 2011||2011-04-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|October 2014|Actual|2014-10-31||Observational|||Diagnosing Thyroid Cancer Using a Blood Test|Diagnosing Thyroid Cancer Using a Blood Test|Completed|||400|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||2||f||||t||||||Samples With DNA|"~     serum, DNA and RNA~   "|||2018-05-31 21:25:40.467142|2018-05-31 21:25:40.467142
NCT01586507|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-08-28|2012-04-25|2012-04-26|Estimate|||||||2012-08-28|2012-08-29|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of ULTRAM ER at Two Dose Levels in Adolescents With Pain|A Single Dose Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER at Two Dose Levels in Adolescents Twelve to Seventeen Years Old, Inclusive, With Pain|Completed||Phase 1|38|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 21:25:40.540423|2018-05-31 21:25:40.540423
NCT01586494|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-08-28|2012-04-25|2012-04-26|Estimate|||||||2012-08-28|2012-08-29|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER in Children With Pain|A Single Dose Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER at Two Dose Levels in Children Seven to Eleven Years Old, Inclusive, With Pain|Completed||Phase 1|37|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 21:25:40.615628|2018-05-31 21:25:40.615628
NCT01586481|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2013-11-13|2012-04-25|2012-04-26|Estimate|||||||2013-11-13|2013-11-14|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|SANIBA||Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers|Effectiveness and Safety of an Off- Loading Shoe to Improve Healing and Prevention of Recurrence of Neuropathic Diabetic Plantar Foot Ulcers of the Fore Foot: a Prospective Randomised Pilot Study|Completed||Phase 3|33|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:25:40.68547|2018-05-31 21:25:40.68547
NCT01586468|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-25|2012-04-25|2012-04-26|Estimate|||||||2012-04-25|2012-04-26|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS|A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS|Completed||Phase 2|60|Actual|Nuvo Research GmbH||2|||f||||f||||||||||2018-05-31 21:25:40.770592|2018-05-31 21:25:40.770592
NCT01586455|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-12-20|2012-04-25|2012-04-26|Estimate|||||||2017-12-20|2017-12-22|Actual|April 2013||2013-04-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|HPDSC||Human Placental-Derived Stem Cell Transplantation|A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders|Active, not recruiting||Phase 1|43|Actual|New York Medical College||4|||f||||t||||||||||2018-05-31 21:25:40.929061|2018-05-31 21:25:40.929061
NCT01586442|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-03-27|2012-04-25|2012-04-26|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2012||2012-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2015|Actual|2015-03-31||Interventional|SNOW||Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes|A Comparison of the Effects of Selective and Non Selective Mineralocorticoid Antagonism on Glucose Homeostasis and Lipid Profile of Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes.|Active, not recruiting||Phase 3|62|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 21:25:41.038552|2018-05-31 21:25:41.038552
NCT01586429|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2012-04-25|2012-04-25|2012-04-26|Estimate|||||||2012-04-25|2012-04-26|Estimate||||February 2011|2011-02-28||||||||Observational|||Ultrasound Guided Femoral Nerve Block Catheter Analgesia Compared With Epidural Analgesia for Patients With Knee OA (Osteoarthritis) Who Underwent Unilateral Total Knee Replacement||Unknown status|Recruiting||||King Saud University|||2||f||||||||||||||2018-05-31 21:25:41.138275|2018-05-31 21:25:41.138275
NCT01586416|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-09-21|2012-04-25|2012-04-26|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|September 2014|Actual|2014-09-30||Interventional|||Intervention to Increase Chemotherapy Tolerance in Elderly Cancer Patients|Intervention to Increase Chemotherapy Tolerance in Elderly Cancer Patients|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:25:41.239773|2018-05-31 21:25:41.239773
NCT01586403|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2018-05-21|2012-04-25|2012-04-26|Estimate|||||||2018-05-21|2018-05-23|Actual|July 2012|Actual|2012-07-31|May 2018|2018-05-31|September 2028|Anticipated|2028-09-30|September 2028|Anticipated|2028-09-30||Interventional|||Transfer of Genetically Engineered Lymphocytes in Melanoma Patients|Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study|Active, not recruiting||Phase 1|14|Actual|Loyola University||4|||f||||t||||||||No||2018-05-31 21:25:41.3393|2018-05-31 21:25:41.3393
NCT01586390|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-24|2012-04-24|2012-04-26|Estimate|||||||2012-04-24|2012-04-26|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Functional Treatment for Acute Ankle Sprains: Softcast Wrap Versus MOKcast|Functional Treatment for Acute Ankle Sprains: Softcast Wrap Versus MOKcast. A Prospective Randomized Single-centre Trial|Completed||Phase 2|100|Actual|Spaarne Gasthuis||2|||f||||f||||||||||2018-05-31 21:25:41.44873|2018-05-31 21:25:41.44873
NCT01586377|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-07-02|2012-04-24|2012-04-26|Estimate|||||||2013-07-02|2013-07-03|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Near-infrared Spectroscopic Measurement in Complex Regional Pain Syndrome|Near-infrared Spectroscopic Measurement of Tissue Oxygen Saturation and the Vascular Occlusion Test in Complex Regional Pain Syndrome|Completed|||20|Actual|Lawson Health Research Institute|||2||f||||t||||||||||2018-05-31 21:25:41.550021|2018-05-31 21:25:41.550021
NCT01586364|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2013-03-20||2018-04-19|2012-04-24|2012-04-26|Estimate|2013-05-21|2013-06-28|Estimate||||2018-04-19|2018-05-21|Actual|May 8, 2006|Actual|2006-05-08|April 2018|2018-04-30|December 22, 2008|Actual|2008-12-22|November 21, 2008|Actual|2008-11-21||Interventional|||Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus|Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310|Completed||Phase 3|301|Actual|Shionogi Inc.||1|||f|||||t|f||||||||2018-05-31 21:25:41.720446|2018-05-31 21:25:41.720446
NCT01586351|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-04-21|2012-04-25|2012-04-26|Estimate|||||||2016-04-21|2016-04-22|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2014|Actual|2014-02-28||Observational|||Rotator Cuff Reconstruction With Xenologous Dermis-patch Augmentation and ACP® - Injection|Arthroscopic Rotator Cuff Reconstruction With Xenologous Dermis-patch Augmentation and ACP® - Injection in Patients Over 60 Years (ACP = Autologous Conditioned Plasma)|Completed|||20|Actual|Schulthess Klinik|||1||f||||f||||||||||2018-05-31 21:25:42.441198|2018-05-31 21:25:42.441198
NCT01586338|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2016-01-27||2016-01-27|2012-04-24|2012-04-26|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)|A Multicenter, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Synvisc® (Hylan G-F 20) in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)|Completed||Phase 4|237|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:25:42.678463|2018-05-31 21:25:42.678463
NCT01586325|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-07-10|2012-04-24|2012-04-26|Estimate|||||||2014-07-10|2014-07-11|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients|A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Asian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens|Unknown status|Recruiting|Phase 1|18|Anticipated|Janssen R&D Ireland||3|||f||||f||||||||||2018-05-31 21:25:43.000299|2018-05-31 21:25:43.000299
NCT01586312|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2014-09-24||2015-09-26|2012-04-24|2012-04-26|Estimate|2014-11-04|2014-11-06|Estimate||||2015-09-26|2015-10-16|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|MSV_allo||Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells|Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Mesenchymal Stromal Cells From Valladolid|Completed||Phase 1/Phase 2|30|Actual|Red de Terapia Celular||2|||f||||t||||||||||2018-05-31 21:25:43.114275|2018-05-31 21:25:43.114275
NCT01586299|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-11-13|2012-04-25|2012-04-26|Estimate|||||||2014-11-13|2014-11-14|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||NSAIDs Treatment in Children With Pleuropneumonia|The Role of Non Steroidal Anti Inflammatory Drugs in the Treatment of Pleuropneumonia in Children. a Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 21:25:43.532685|2018-05-31 21:25:43.532685
NCT01586286|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2014-05-21|2012-04-24|2012-04-26|Estimate|||||||2014-05-21|2014-05-22|Estimate|July 2012||2012-07-31|May 2014|2014-05-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||A Study Examining the Use of Vaginal Nifedipine With Pelvic Floor Physical Therapy for Levator Myalgia and Pelvic Pain|Does Adjunctive Treatment With Vaginal Nifedipine Result in Symptomatic Improvement in Patients With Levator Myalgia and Pelvic Floor Pain Who Are Undergoing Pelvic Floor Physical Therapy?|Withdrawn||N/A|0|Actual|Vanderbilt University||2||No patients were recruited over a 12 month period|f||||f||||||||||2018-05-31 21:25:43.605242|2018-05-31 21:25:43.605242
NCT01586273|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-04-03|2012-04-24|2012-04-26|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2012||2012-09-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases|Magnetic Resonance-guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study|Terminated||N/A|20|Actual|Philips Healthcare||1|||f||||t||||||||||2018-05-31 21:25:43.687355|2018-05-31 21:25:43.687355
NCT01586260|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-04-25|2012-04-25|2012-04-26|Estimate|||||||2017-04-25|2017-04-27|Actual|June 2012|Actual|2012-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission|A Phase II Preventative Trial of DFMO as a Single Agent in Patients With High Risk Neuroblastoma in Remission|Active, not recruiting||Phase 2|89|Actual|Spectrum Health Hospitals||1|||f||||t||||||||||2018-05-31 21:25:44.792163|2018-05-31 21:25:44.792163
NCT01586247|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-26|2012-04-24|2012-04-26|Estimate|||||||2012-04-26|2012-04-27|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||The Effect of a Prebiotic, Probiotic and Synbiotic on the Gut Microbiota and Immune Response of Older Volunteers (GOS)|A Double-blind, Placebo-controlled, Randomized Crossover Study of a Prebiotic (Galacto-oligosaccharides, GOS), Probiotic (B.Lactis, BI07) and Synbiotic (GOS + BI07) on the Gut Microbiota and Immune Response of Older Volunteers|Completed||N/A|40|Actual|University of Reading||4|||f||||f||||||||||2018-05-31 21:25:44.909125|2018-05-31 21:25:44.909125
NCT01586234|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-04-12|2012-04-24|2012-04-26|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2012||2012-01-31|April 2018|2018-04-30|August 31, 2014|Actual|2014-08-31|August 31, 2014|Actual|2014-08-31||Interventional|DSAEK||OCT-guided DSAEK Graft Shaping and Smoothing|Randomized Clinical Trial of OCT-guided DSAEK Graft Shaping and Smoothing|Terminated||N/A|6|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 21:25:44.998757|2018-05-31 21:25:44.998757
NCT01586221|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2017-07-19|2012-04-24|2012-04-26|Estimate|||||||2017-07-19|2017-07-21|Actual|January 1, 2012|Actual|2012-01-01|July 2017|2017-07-31|May 1, 2017|Actual|2017-05-01|May 2016|Actual|2016-05-31||Interventional|MT/PT||Music Therapy/Physical Therapy Intervention to Enhance Well-being and Functional Recovery Post-stroke|A Collaborative Music Therapy/Physical Therapy Intervention to Enhance Well-being and Functional Recovery Post-stroke|Completed||N/A|30|Actual|New York University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 21:25:45.075592|2018-05-31 21:25:45.075592
NCT01586208|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-03-10|2012-04-25|2012-04-26|Estimate|||||||2013-03-10|2013-03-12|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Refractory Status Epilepticus Treatment Study|Refractory Status Epilepticus: Plasmatic Levels Monitorization Utility|Completed||Phase 3|5|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 21:25:45.156279|2018-05-31 21:25:45.156279
NCT01586195|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|2016-07-07||2017-04-24|2012-04-24|2012-04-26|Estimate|2017-04-24|2017-05-25|Actual||||2017-04-24|2017-05-25|Actual|October 31, 2011|Actual|2011-10-31|April 2017|2017-04-30|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional||Intent to treat (ITT) population defined as all enrolled participants who received any amount of study drug.|Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E|An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E|Terminated||Phase 2|31|Actual|Genentech, Inc.||1||Recruitment challenges|f||||t||||||||||2018-05-31 21:25:45.262173|2018-05-31 21:25:45.262173
NCT01586182|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-09-02|2012-04-25|2012-04-26|Estimate|||||||2015-09-02|2015-09-04|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|April 2012|Actual|2012-04-30||Interventional|||Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma|Stereotactic Boost for Poor-Prognosis Oropharyngeal Squamous Cell Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Dana-Farber Cancer Institute||1||Local IRB closed the study due to poor accural.|f||||t||||||||||2018-05-31 21:25:45.708369|2018-05-31 21:25:45.708369
NCT01586169|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-24|2012-04-24|2012-04-26|Estimate|||||||2012-04-24|2012-04-26|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|AZIVAL||Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination|A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali|Completed||N/A|3000|Actual|Centre d'Appui à la lutte contre la Maladie|||||f||||t||||||||||2018-05-31 21:25:45.785766|2018-05-31 21:25:45.785766
NCT01586156|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2017-08-16||2017-11-04|2012-04-25|2012-04-26|Estimate|2017-11-04|2017-11-30|Actual||||2017-11-04|2017-11-30|Actual|December 2012||2012-12-31|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PAHTCH||PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)|Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure|Completed||N/A|30|Actual|The Cleveland Clinic|We thought that there would be a possible limitation of hypotension that might limit dosage|2|||f||||t||||||||||2018-05-31 21:25:45.902245|2018-05-31 21:25:45.902245
NCT01586143|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-07-04|2012-04-25|2012-04-26|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PARAJUG||Clinical Study Comparing the Efficacy of Transbuccal Paracetamol 125 mg Versus Paracetamol Injection 1g in Slow Infusion IV in Patients With Acute Pain|Clinical Study Comparing the Efficacy of Transbuccal Paracetamol 125 mg Versus Paracetamol Injection 1g in Slow Infusion IV in Patients With Acute Pain|Completed||Phase 3|43|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 21:25:46.493902|2018-05-31 21:25:46.493902
NCT01586130|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-01-11|2012-04-24|2012-04-26|Estimate|||||||2013-01-11|2013-01-14|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|August 2014|Anticipated|2014-08-31||Interventional|ISOGO||Assessing the Impact of Isokinetic Muscular Strengthening in Eccentric Mode in the Medical Treatment of Knee Osteoarthritis|Assessing the Impact of Isokinetic Muscular Strengthening in Eccentric Mode in the Medical Treatment of Knee Osteoarthritis.|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 21:25:46.562465|2018-05-31 21:25:46.562465
NCT01586117|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2013-08-14|2012-04-24|2012-04-26|Estimate|||||||2013-08-14|2013-08-15|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity|A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity|Unknown status|Recruiting|Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 21:25:46.638706|2018-05-31 21:25:46.638706
NCT01586104|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2013-09-23|2012-04-25|2012-04-26|Estimate|||||||2013-09-23|2013-09-24|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|September 2015||2015-09-30|September 2013|Actual|2013-09-30||Interventional|||Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases|Cardiac-Sparing Whole Lung IMRT in Children and Young Adults With Lung Metastases: A Feasibility Study|Completed||N/A|20|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||t||||||||||2018-05-31 21:25:46.710313|2018-05-31 21:25:46.710313
NCT01586091|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-24|2012-04-24|2012-04-26|Estimate|||||||2012-04-24|2012-04-26|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|LAWAF||Safety Study of Levocetirizine and Fexofenadine|Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response|Completed||Phase 1|18|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 21:25:46.888731|2018-05-31 21:25:46.888731
NCT01586065|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-06-10|2012-04-25|2012-04-26|Estimate|||||||2016-06-10|2016-06-14|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes|Use of CGM in Adolescents With Poorly-controlled Type 1 Diabetes|Completed||N/A|10|Actual|Nemours Children's Clinic||2|||f||||f||||||||No||2018-05-31 21:25:46.999775|2018-05-31 21:25:46.999775
NCT01586052|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-04-07|2012-04-25|2012-04-26|Estimate|||||||2014-04-07|2014-04-08|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1|A Phase 1 Clinical Research of Erythropoietin Therapy for Children With Cerebral Palsy: Safety and Efficacy|Completed||Phase 1|11|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 21:25:47.082579|2018-05-31 21:25:47.082579
NCT01584908|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-12-31|2012-04-24|2012-04-25|Estimate|||||||2014-12-31|2015-01-01|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Observational|||Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients|Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients(AdVEnTR)|Completed|||68|Actual|University of Alberta|||||f||||f||||||||||2018-05-31 21:26:04.838714|2018-05-31 21:26:04.838714
NCT01586039|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-03-08|2012-04-25|2012-04-26|Estimate|||||||2017-03-08|2017-03-10|Actual|August 2012||2012-08-31|March 2017|2017-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep|Investigating the Effects of Evening Light Exposure on Melatonin Suppression, Alertness and Nocturnal Sleep.|Completed||N/A|36|Actual|Brigham and Women's Hospital||2|||f||||f||f||||||||2018-05-31 21:25:47.164883|2018-05-31 21:25:47.164883
NCT01586026|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2014-07-10||2016-07-13|2012-04-25|2012-04-26|Estimate|2016-07-13|2016-08-23|Estimate||||2016-07-13|2016-08-23|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|DISTAL|Post-infusional chemotherapy subjects that had Bard implanted ports with distally valved catheters.|Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters|A Retrospective Study to Extend the Maximum Maintenance Flushing Interval for Ports With Distally Valved Catheters|Terminated|||171|Actual|C. R. Bard|||3|Insufficient number of adverse events|f||||f||||||||No|Study was terminated due to limited number of adverse events recorded.|2018-05-31 21:25:47.271766|2018-05-31 21:25:47.271766
NCT01586013|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-25|2012-04-25|2012-04-26|Estimate|||||||2012-04-25|2012-04-26|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ke0agedep||the Effect Site Equilibration Time of Propofol is Age Dependant|Importance of Age as Covariable in the Requirements to Determine the Drug Plasma -Site Effect Equilibration Time for TCI Propofol Pharmacokinetic Models|Completed||Phase 4|45|Actual|Universidad del Desarrollo||1|||f||||t||||||||||2018-05-31 21:25:47.541238|2018-05-31 21:25:47.541238
NCT01586000|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2016-02-19|2012-04-24|2012-04-26|Estimate|||||||2016-02-19|2016-02-22|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women|A Dose-finding Study to Evaluate the Effect of a Contraceptive Vaginal Ring, Releasing Nestorone® and Estradiol, on Cycle Control, Ovulation Inhibition, and Pharmacokinetics in Normal Cycling Women|Completed||Phase 2|197|Actual|Health Decisions||3|||f||||||||||||||2018-05-31 21:25:47.637243|2018-05-31 21:25:47.637243
NCT01585987|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2015-07-15||2016-04-15|2012-04-25|2012-04-26|Estimate|2015-10-19|2015-11-18|Estimate||||2016-04-15|2016-05-17|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|July 2014|Actual|2014-07-31||Interventional||All participants randomized to a treatment arm are summarized.|An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy|A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer|Completed||Phase 2|143|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 21:25:47.763051|2018-05-31 21:25:47.763051
NCT01585974|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-10-18|2012-04-25|2012-04-26|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Observational|TURCOS||Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma|Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma|Completed|||151|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:25:48.614044|2018-05-31 21:25:48.614044
NCT01585961|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|2015-01-13||2015-01-20|2012-04-25|2012-04-26|Estimate|2015-01-20|2015-01-26|Estimate||||2015-01-20|2015-01-26|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|SFAF|Enrolled patients|NAVISTAR® THERMOCOOL® SF Catheter: Observational Study|NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population|Completed|||511|Actual|Biosense Webster, Inc.|||1||f||||f||||||||||2018-05-31 21:25:48.708543|2018-05-31 21:25:48.708543
NCT01585948|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-05-03|2012-04-25|2012-04-26|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2009||2009-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|May 2013|Actual|2013-05-31||Observational|||Study of the Effect of Diabetes on the Incidence and the Extent of Coronary Artery Disease|The Role of Newer and Traditional Risk Factors in the Development, Extent and Manifestation of Coronary Artery Disease|Active, not recruiting|||1000|Anticipated|University of Ioannina|||3||f||||f||||||Samples With DNA|"~     Includes retaining blood samples for DNA analyses and biochemical markers.~   "|||2018-05-31 21:25:49.300627|2018-05-31 21:25:49.300627
NCT01585935|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2018-01-06|2012-04-24|2012-04-26|Estimate|||||||2018-01-06|2018-01-09|Actual|June 2012||2012-06-30|January 2018|2018-01-31|November 13, 2017|Actual|2017-11-13|June 2015|Actual|2015-06-30||Interventional|||Preventing Cholestasis Using SMOFLipid®|Preventing Cholestasis in Premature Infants Using SMOFLipid®|Completed||Phase 4|230|Actual|Medical University of Vienna||2|||f||||f||||||||Yes|After publication of the trial, we currently plan to share IPD upon personal request.|2018-05-31 21:25:49.374484|2018-05-31 21:25:49.374484
NCT01585922|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-09-10|2012-04-25|2012-04-26|Estimate|||||||2012-09-10|2012-09-11|Estimate|July 2012||2012-07-31|September 2012|2012-09-30||||July 2013|Anticipated|2013-07-31||Interventional|||Noninvasive Positive Pressure Ventilation in Moderate Acute Respiratory Distress Syndrome||Unknown status|Recruiting|N/A|200|Anticipated|Beijing Hospital||2|||f||||||||||||||2018-05-31 21:25:49.469601|2018-05-31 21:25:49.469601
NCT01585909|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-08-28|2012-04-24|2012-04-26|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2011||2011-07-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Intestinal Brush Border Enzyme Function in Critically Ill Patients|Evaluation of Intestinal Brush Border Enzyme Function in Patients With SIRS and Septic Shock Compared to Control Patients|Completed||N/A|39|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 21:25:49.553605|2018-05-31 21:25:49.553605
NCT01585896|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-03-13|2012-04-24|2012-04-26|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2012|Actual|2012-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Self-Help Group for the Treatment of Hoarding Disorder|Self-Help Group for the Treatment of Hoarding Disorder|Recruiting||N/A|60|Anticipated|University of Miami||1|||f||||f||||||||||2018-05-31 21:25:49.654849|2018-05-31 21:25:49.654849
NCT01585883|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-03-04|2012-04-24|2012-04-26|Estimate|||||||2016-03-04|2016-03-08|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Self-Management Intervention for Breathlessness in Lung Cancer|A Pilot Trial of a Self-Management Intervention for Breathlessness in Lung Cancer|Unknown status|Active, not recruiting|N/A|56|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:25:49.737576|2018-05-31 21:25:49.737576
NCT01585675|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-08-29|2012-04-25|2012-04-26|Estimate|||||||2017-08-29|2017-08-30|Actual|November 2005||2005-11-30|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|||Specimen Banking From Patients With Lung Cancer|Specimen Banking From Patients With Lung Cancer|Recruiting|||1000|Anticipated|University of Colorado, Denver|||1||f||||t||||||Samples With DNA|"~     Tissue, blood, urine, and sputum, breath~   "|||2018-05-31 21:25:52.170591|2018-05-31 21:25:52.170591
NCT01585870|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2015-10-26|2012-04-24|2012-04-26|Estimate|||||||2015-10-26|2015-10-27|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination|A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors|Completed||Phase 1|40|Actual|Bayer||1|||f||||f||||||||||2018-05-31 21:25:49.965294|2018-05-31 21:25:49.965294
NCT01585857|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-12-03|2012-04-24|2012-04-26|Estimate|||||||2014-12-03|2014-12-04|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||ADIPOA - Clinical Study|A Phase I, Prospective, Bi-centric,Single -Arm, Open-label, Dose-escalating Clinical Trial to Evaluate the Safety of a Single Injection of Autologous Adipose Derived Mesenchymal Stromal Cells in the Treatment of Severe Osteoarthritis of the Knee Joint|Completed||Phase 1|18|Actual|University Hospital, Montpellier||3|||f||||t||||||||||2018-05-31 21:25:50.063981|2018-05-31 21:25:50.063981
NCT01585844|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-25|2012-04-25|2012-04-26|Estimate|||||||2012-04-25|2012-04-26|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|SAPSS||Sleep Apnea in Pregnancy Screening Study|Obstructive Sleep Apnea in Pregnancy:Epidemiology and Maternal/ Neonatal Morbidity|Completed|||182|Actual|MetroHealth Medical Center|||2||f||||f||||||Samples With DNA|"~     urine serum~   "|||2018-05-31 21:25:50.137913|2018-05-31 21:25:50.137913
NCT01585831|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-12-13|2012-04-25|2012-04-26|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2012||2012-03-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|TestoXXY/KS||Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome|Psychological and Motor Effects of Testosterone Therapy in Adolescents With XXY/Klinefelter Syndrome|Completed||N/A|47|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 21:25:50.212413|2018-05-31 21:25:50.212413
NCT01585818|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2014-01-15|2012-04-25|2012-04-26|Estimate|||||||2014-01-15|2014-01-17|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31||Interventional|DIDM||Dietary Intervention in Diabetes Mellitus (DIDM)- Intermediate and Acute Effects|Nutrition Studies and Dietary Intervention in Individuals With Type 2 Diabetes Mellitus of Chinese, Malay and Indian Ethnicity|Unknown status|Recruiting|Phase 2|160|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 21:25:50.387439|2018-05-31 21:25:50.387439
NCT01585805|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2018-05-02|2012-04-25|2012-04-26|Estimate|||||||2018-05-02|2018-05-03|Actual|April 18, 2012|Actual|2012-04-18|May 2018|2018-05-31||||November 30, 2018|Anticipated|2018-11-30||Interventional|||Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)|Recruiting||Phase 2|107|Anticipated|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-05-31 21:25:50.495336|2018-05-31 21:25:50.495336
NCT01585792|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-04-15|2012-04-25|2012-04-26|Estimate|||||||2013-04-15|2013-04-16|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Double Blind Comparative Study of TAK-875||Completed||Phase 3|80|Actual|Takeda||4|||f||||||||||||||2018-05-31 21:25:50.676519|2018-05-31 21:25:50.676519
NCT01585779|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2017-03-21||2017-05-04|2012-04-24|2012-04-26|Estimate|2017-05-04|2017-05-10|Actual||||2017-05-04|2017-05-10|Actual|May 2012||2012-05-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|Contour3D||Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial|Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial|Completed|||64|Actual|Medtronic Cardiovascular|||2||f||||f||||||||||2018-05-31 21:25:50.768584|2018-05-31 21:25:50.768584
NCT01585766|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2016-08-15|2012-04-24|2012-04-26|Estimate|||||||2016-08-15|2016-08-16|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Interventional|||Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis|A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis|Completed||Phase 1|56|Actual|MedImmune LLC||7|||f||||t||||||||||2018-05-31 21:25:51.590264|2018-05-31 21:25:51.590264
NCT01585753|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-01-18|2012-04-25|2012-04-26|Estimate|||||||2016-01-18|2016-01-20|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MARCH VE||MARCH Vascular Endothelium Substudy|Maraviroc Switch Vascular Endothelium (VE) Substudy: a Substudy of MARCH|Completed|||34|Actual|Kirby Institute|||3||f||||t||||||||||2018-05-31 21:25:51.723597|2018-05-31 21:25:51.723597
NCT01585740|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-06-13|2012-04-24|2012-04-26|Estimate|||||||2012-06-13|2012-06-14|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Ringer's Lactate Versus Normal Saline in Caesarean Section|Effect of Ringer's Lactate on Maternal and Neonatal pH in Caesarean Section at Mulago Hospital, a Randomized Trial|Completed||N/A|500|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 21:25:51.81422|2018-05-31 21:25:51.81422
NCT01585727|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-08-15|2012-04-25|2012-04-26|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2012||2012-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|NEUROS||Intraoperative Monitoring of the Pelvic Autonomic Nerves|Continuous Intraoperative Monitoring of the Pelvic Autonomic Nerves During Total Mesorectal Excision (TME) for the Prevention of Urogenital and Anorectal Dysfunction in Patients With Rectal Cancer.|Recruiting||N/A|188|Anticipated|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 21:25:51.895708|2018-05-31 21:25:51.895708
NCT01585701|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-02-22|2012-04-25|2012-04-26|Estimate|||||||2017-02-22|2017-02-23|Actual|May 2012||2012-05-31|January 2017|2017-01-31||||May 2017|Anticipated|2017-05-31||Interventional|||Phase I Study of AT13148, a Novel AGC Kinase Inhibitor|A Cancer Research UK Phase I First in Man Study of the Novel AGC Kinase Inhibitor AT13148 Given Orally in Patients With Advanced Solid Tumours.|Recruiting||Phase 1|40|Anticipated|Cancer Research UK|||||f||||f||||||||||2018-05-31 21:25:51.991449|2018-05-31 21:25:51.991449
NCT01585688|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-09-03|2012-04-24|2012-04-26|Estimate|||||||2015-09-03|2015-09-07|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|||Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL|A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 21:25:52.068524|2018-05-31 21:25:52.068524
NCT01584921|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-11-04|2012-04-24|2012-04-25|Estimate|||||||2013-11-04|2013-11-05|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|EPO 2012||Renal Effects of Erythropoietin in Humans|Renal Effects of Erythropoietin in Humans|Completed||Phase 1|16|Actual|University of Copenhagen||3|||f||||t||||||||||2018-05-31 21:26:04.730388|2018-05-31 21:26:04.730388
NCT01585662|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-24|2012-04-24|2012-04-26|Estimate|||||||2012-04-24|2012-04-26|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Prospective Random Comparing Study on EUS-guided Pseudocyst Drainage by Naso-pancreatic Tube and Stents|Random Comparing Study on Two Different EUS-guided Pseudocyst Drainage Methods--Modified Naso-pancreatic Tube Drainage and Stents Drainage|Unknown status|Recruiting|Phase 4|30|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 21:25:52.248897|2018-05-31 21:25:52.248897
NCT01585649|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-05-17|2012-04-23|2012-04-26|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|June 2014|Actual|2014-06-30||Interventional|||PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma|Multicenter, Open-label Study to Assess the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100µg/kg XM22 in 21 Children With Ewing Family of Tumors or Rhabdomyosarcoma|Completed||Phase 1|21|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-05-31 21:25:52.332557|2018-05-31 21:25:52.332557
NCT01585636|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-08-16|2012-04-23|2012-04-26|Estimate|||||||2013-08-16|2013-08-19|Estimate|September 2006||2006-09-30|August 2013|2013-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers|A Phase Ia, Randomized, Placebo-Controlled, Single-Dose, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of SQ109 in Normal, Healthy Male and Female Volunteers|Completed||Phase 1|62|Actual|Sequella, Inc.||8|||f||||f||||||||||2018-05-31 21:25:52.420336|2018-05-31 21:25:52.420336
NCT01585623|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-03-21|2012-04-23|2012-04-26|Estimate|||||||2013-03-21|2013-03-22|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Drug Interaction Study of SAR302503 in Patients With Solid Tumor|An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors|Completed||Phase 1|16|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:25:52.485287|2018-05-31 21:25:52.485287
NCT01585610|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2015-05-13|2012-04-25|2012-04-26|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|August 2015|Anticipated|2015-08-31||Interventional|ABLE||Motivating Smokers With Mobility Impairments to Quit Smoking|Motivating Smokers With Mobility Impairments to Quit Smoking|Unknown status|Active, not recruiting|Phase 3|560|Anticipated|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 21:25:52.553736|2018-05-31 21:25:52.553736
NCT01585597|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|2014-01-07||2014-07-07|2012-04-24|2012-04-26|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ReCCLAIM||Reperfusion With Cooling in Cerebral Acute Ischemia|Phase 1 Study of Mild Induced Hypothermia After Endovascular Revascularization in Acute Ischemic Stroke of the Anterior Circulation|Completed||Phase 1|20|Actual|Emory University||1|||f||||f||||||||||2018-05-31 21:25:52.637932|2018-05-31 21:25:52.637932
NCT01585584|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2015-08-22||2015-08-22|2012-04-23|2012-04-26|Estimate|2015-08-22|2015-09-21|Estimate||||2015-08-22|2015-09-21|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|LeeG3||Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment|Triple-Therapy With PegInterferon α-2b + Ribavirin + Boceprevir in Patients With HCV Genotype 3 Who Previously Failed Treatment With PegInterferon α + Ribavirin|Completed||Phase 3|11|Actual|University of Calgary|Small sample size (n=11)|1|||f||||t||||||||||2018-05-31 21:25:52.891581|2018-05-31 21:25:52.891581
NCT01585571|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-02-08|2012-04-23|2012-04-26|Estimate|||||||2017-02-08|2017-02-10|Actual|April 2012||2012-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Balance and Posture in Adults With Cerebral Palsy|Observational Study of Balance and Posture in Adults With Cerebral Palsy|Active, not recruiting|||80|Actual|Temple University|||2||f||||f||||||||||2018-05-31 21:25:53.137276|2018-05-31 21:25:53.137276
NCT01585558|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2013-03-20||2018-04-19|2012-04-23|2012-04-26|Estimate|2013-05-21|2013-06-28|Estimate||||2018-04-19|2018-05-21|Actual|May 16, 2006|Actual|2006-05-16|April 2018|2018-04-30|September 18, 2008|Actual|2008-09-18|August 19, 2008|Actual|2008-08-19||Interventional|||Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus|Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310.|Completed||Phase 3|180|Actual|Shionogi Inc.||3|||f||||||||||||||2018-05-31 21:25:53.2628|2018-05-31 21:25:53.2628
NCT01585545|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2018-04-16|2012-04-23|2012-04-26|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2013||2013-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers|Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers|Recruiting|||500|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     lung cance tissue~   "|||2018-05-31 21:25:55.534847|2018-05-31 21:25:55.534847
NCT01585532|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2015-11-03|2012-04-23|2012-04-26|Estimate|||||||2015-11-03|2015-11-05|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Observational|||Alere Mycobacterium Tuberculosis Urine Study|Evaluation of Various Methods for the Detection of Mycobacterium Tuberculosis Nucleic Acid|Completed|||60|Actual|Research Center Borstel|||2||f||||f||||||Samples Without DNA|"~     Urine Sputum Blood~   "|||2018-05-31 21:25:55.688529|2018-05-31 21:25:55.688529
NCT01585519|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-10-23|2012-04-23|2012-04-26|Estimate|||||||2017-10-23|2017-10-24|Actual|April 2012||2012-04-30|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|October 2013|Actual|2013-10-31||Interventional|APPS||A Study Examining Effects of Apples/ Apple Products on Heart Disease Risk|Effect of Increased Whole Apple Consumption, Apple Extract and Freeze-dried Apple Products on Biomarkers of Cardiovascular Disease Risk: a Randomised Intervention in Participants at Increased Risk of Cardiovascular Disease|Completed||N/A|50|Anticipated|Queen's University, Belfast||5|||f||||t||||||||||2018-05-31 21:25:55.7433|2018-05-31 21:25:55.7433
NCT01585506|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2018-02-06|2012-04-23|2012-04-26|Estimate|||||||2018-02-06|2018-02-07|Actual|September 20, 2010|Actual|2010-09-20|February 2018|2018-02-28|December 20, 2010|Actual|2010-12-20|December 20, 2010|Actual|2010-12-20||Observational|||Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues|Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues|Completed|||3618|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:25:55.831304|2018-05-31 21:25:55.831304
NCT01585493|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-10-26|2012-04-23|2012-04-26|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||CHANGE -it is About Life|CHANGE.A Randomized Clinical Trial of Health Promoting Programme Versus Standard Treatment for Patients With Schizophrenia|Completed||Phase 3|428|Actual|Mental Health Services in the Capital Region, Denmark||3|||f||||f||||||||||2018-05-31 21:25:55.923686|2018-05-31 21:25:55.923686
NCT01585480|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-03-13|2012-04-24|2012-04-25|Estimate|||||||2017-03-13|2017-03-14|Actual|November 2010||2010-11-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|Go!||"Preventing Obesity in the Worksite: A Multi-Message, Multi-Step Approach"|"Preventing Obesity in the Worksite: A Multi-Message, Multi-Step Approach"|Completed||N/A|499|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-05-31 21:25:56.011509|2018-05-31 21:25:56.011509
NCT01585467|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-05-05|2012-04-24|2012-04-25|Estimate|||||||2015-05-05|2015-05-07|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Anterior Shoulder Dislocation|Selective Radiography in Anterior Shoulder Dislocation: Prospective Validation Rule of Decision Rules Derived in Fresno and Quebec|Completed|||300|Actual|University of California, San Francisco|||||f||||f||||||||||2018-05-31 21:25:56.09747|2018-05-31 21:25:56.09747
NCT01585454|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2018-04-24|2012-04-24|2012-04-25|Estimate|||||||2018-04-24|2018-04-25|Actual|March 27, 2012||2012-03-27|January 20, 2016|2016-01-20|January 20, 2016||2016-01-20|||||Observational|||Healthy Lifestyle in Pregnancy|Healthy Lifestyle in Pregnancy|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:25:56.156312|2018-05-31 21:25:56.156312
NCT01585441|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|2014-10-29||2014-11-25|2012-04-24|2012-04-25|Estimate|2014-11-25|2014-12-04|Estimate||||2014-11-25|2014-12-04|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Finasteride for Chronic Central Serous Chorioretinopathy|Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated early due to lack of enrollment.|2||This study was terminated early due to lack of enrollment.|f||||t||||||||||2018-05-31 21:25:56.239912|2018-05-31 21:25:56.239912
NCT01585428|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|2017-02-01||2018-02-07|2012-04-24|2012-04-25|Estimate|2017-02-01|2017-03-23|Actual||||2018-02-07|2018-03-07|Actual|April 13, 2012|Actual|2012-04-13|February 2018|2018-02-28|August 1, 2016|Actual|2016-08-01|April 9, 2016|Actual|2016-04-09||Interventional|||Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers|A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers|Completed||Phase 2|29|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f||||||No||2018-05-31 21:25:57.847097|2018-05-31 21:25:57.847097
NCT01585415|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2018-04-12|2012-04-24|2012-04-25|Estimate|||||||2018-04-12|2018-04-13|Actual|April 9, 2012||2012-04-09|July 21, 2016|2016-07-21|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||Vemurafenib and White Blood Cell Therapy for Advanced Melanoma|A Pilot Trial of the Combination of Vemurafenib With Adoptive Cell Therapy in Patients With Metastatic Melanoma|Terminated||Phase 1|12|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:25:58.340658|2018-05-31 21:25:58.340658
NCT01585402|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2018-05-23|2012-04-24|2012-04-25|Estimate|||||||2018-05-23|2018-05-24|Actual|April 11, 2012||2012-04-11|January 8, 2018|2018-01-08|March 20, 2020|Anticipated|2020-03-20|March 20, 2020|Anticipated|2020-03-20||Interventional|||Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)|An Open-label, Non-Randomized, Single-Arm Pilot Study to Evaluate the Effectiveness of Etidronate Treatment for Arterial Calcifications Due to Deficiency in CD73 (ACDC)|Recruiting||Phase 1|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:25:58.436216|2018-05-31 21:25:58.436216
NCT01585389|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-05-17|2012-04-24|2012-04-25|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2012||2012-04-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Gene Expression and Location in Samples From Patients With Brain Tumors|Expression and Subcellular Localization of NEIL3 in Tumors|Completed|||10|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:25:58.539465|2018-05-31 21:25:58.539465
NCT01585376|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-05-17|2012-04-24|2012-04-25|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma|Study Recurrency Testing of Mutations Identified in WGS of Pediatric Rhabdomyosarcoma|Completed|||58|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:25:58.612417|2018-05-31 21:25:58.612417
NCT01585350|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-08-11|2012-04-24|2012-04-25|Estimate|||||||2016-08-11|2016-08-12|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|MEL58||A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients|A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients, With Evaluation of the Injection Site Microenvironment|Completed||Phase 1|53|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 21:25:58.778042|2018-05-31 21:25:58.778042
NCT01585337|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-07-07|2012-04-23|2012-04-25|Estimate|||||||2015-07-07|2015-07-08|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|February 2016|Anticipated|2016-02-29||Observational|||Trunk Forward Ability in Patients With Lumbar Fusion|Joint Coordination Changes During Functional Activities After Lumbar Fusion|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 21:25:58.871715|2018-05-31 21:25:58.871715
NCT01585324|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|2015-06-25||2015-06-25|2012-04-24|2012-04-25|Estimate|2015-06-25|2015-07-24|Estimate||||2015-06-25|2015-07-24|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Intent-to-treat (ITT) analysis population included all enrolled participants who received at least 1 dose of study drug.|A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)|Open, Multicenter Phase IV Study, Evaluating Drop of Hemoglobin in Association to the Rate of Sustained Virological Response in Chronic Hepatitis C Patients Treated With Ribavirin (Copegus®) in Combination With Standard Treatment (ANECO)|Completed||Phase 4|30|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:25:58.960796|2018-05-31 21:25:58.960796
NCT01585311|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Observational|||Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)|Impact of Prolonged Tachycardia on Cardiovascular Morbidity and Outcome After Subarachnoid Hemorrhage (SAH)|Unknown status|Enrolling by invitation||400|Anticipated|Columbia University|||1||f||||f||||||||||2018-05-31 21:25:59.247359|2018-05-31 21:25:59.247359
NCT01585298|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-02-28|2012-04-24|2012-04-25|Estimate|||||||2017-02-28|2017-03-01|Actual|June 29, 2012|Actual|2012-06-29|February 2017|2017-02-28|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|START||STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)|A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 4|6996|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:25:59.383592|2018-05-31 21:25:59.383592
NCT01585285|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-08-02|2012-04-24|2012-04-25|Estimate|||||||2017-08-02|2017-08-04|Actual|July 2012||2012-07-31|August 2017|2017-08-31|June 2028|Anticipated|2028-06-30|June 2019|Anticipated|2019-06-30||Interventional|AMI-PONT||Coronary Artery Bypass Grafting Strategies for the Anterolateral Territory: a Prospective Randomized Clinical Trial|Composite Arterial and Venous Grafting Strategy Versus Conventional Coronary Artery Bypass Grafting for the Anterolateral Territory: a Prospective Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||Yes|Manuscripts, Abstracts, Presentations|2018-05-31 21:26:00.042502|2018-05-31 21:26:00.042502
NCT01585272|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2016-06-24||2018-04-16|2012-04-24|2012-04-25|Estimate|2016-09-22|2016-11-10|Estimate||||2018-04-16|2018-04-18|Actual|August 2012||2012-08-31|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia|A 52-week, Prospective, Multi-center, Open-label Study to Assess the Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Patients With Alzheimer's Dementia in a Controlled Titration Schedule|Completed||Phase 4|121|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:26:00.198444|2018-05-31 21:26:00.198444
NCT01585259|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-06-02|2012-04-24|2012-04-25|Estimate|||||||2016-06-02|2016-06-03|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Anfibatide Phase Ib-IIa Clinical Trial|A Multi-center, Randomized, Double-blind, Multi-dose Group, Parallel Group and Placebo Controlled Phase Ib-IIa Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin for Injection for the Treatment of Patients With Non-ST Segment Elevation Myocardial Infarction (NSTEMI).|Completed||Phase 1/Phase 2|90|Anticipated|Lee's Pharmaceutical Limited||2|||f||||t||||||||||2018-05-31 21:26:00.565124|2018-05-31 21:26:00.565124
NCT01585246|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2016-05-04||2017-07-13|2012-04-23|2012-04-25|Estimate|2017-06-16|2017-07-14|Actual||||2017-07-13|2017-08-11|Actual|October 2011||2011-10-31|July 2017|2017-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Saw Palmetto: Symptom Management for Men During Radiation Therapy|Saw Palmetto Use During Radiation Therapy for Symptom Management Among Prostate Cancer Patients|Completed||Phase 1/Phase 2|48|Actual|Michigan State University||3|||f||||t||||||||Undecided||2018-05-31 21:26:00.663328|2018-05-31 21:26:00.663328
NCT01585233|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-01-19|2012-04-24|2012-04-25|Estimate|||||||2015-01-19|2015-01-21|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|60|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 21:26:01.17675|2018-05-31 21:26:01.17675
NCT01585220|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold|A Randomized, Multi-center, Double Masked, Matched Pairs, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Injection With Neuramis as Compared to Restylane® in Correction of Nasolabial Fold|Unknown status|Recruiting|Phase 3|69|Anticipated|Medy-Tox||2|||f||||f||||||||||2018-05-31 21:26:01.306169|2018-05-31 21:26:01.306169
NCT01585207|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|2017-04-19||2018-01-17|2012-04-24|2012-04-25|Estimate|2018-01-17|2018-01-19|Actual||||2018-01-17|2018-01-19|Actual|July 2012||2012-07-31|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder|Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder|Completed||Phase 1/Phase 2|4|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 21:26:01.481669|2018-05-31 21:26:01.481669
NCT01585194|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-05-21|2012-04-24|2012-04-25|Estimate|||||||2018-05-21|2018-05-23|Actual|November 2012|Actual|2012-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma|Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma|Recruiting||Phase 2|39|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:26:01.768294|2018-05-31 21:26:01.768294
NCT01585181|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-03-12|2012-04-24|2012-04-25|Estimate|||||||2015-03-12|2015-03-17|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200|A Phase 1 Randomized, Double-Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the LIve Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae Serotype 01 Inaba CVD 103-HgR Vaccine Strain|Completed||Phase 1|66|Actual|PaxVax, Inc.||2|||f||||f||||||||||2018-05-31 21:26:01.906563|2018-05-31 21:26:01.906563
NCT01585168|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2017-11-03||2018-04-26|2012-04-24|2012-04-25|Estimate|2018-04-26|2018-05-25|Actual||||2018-04-26|2018-05-25|Actual|December 2011||2011-12-31|April 2018|2018-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CTNA||Functional Neuroimaging of Alcoholism Vulnerability (PIT)|Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity and Pavlovian-to-Instrumental Transfer (PIT)|Completed||Phase 2|71|Actual|Yale University||4|||f||||t|t|f||||||||2018-05-31 21:26:02.04505|2018-05-31 21:26:02.04505
NCT01585155|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-05-10|2012-04-24|2012-04-25|Estimate|||||||2015-05-10|2015-05-12|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis|Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Ulcerative Colitis.|Completed||Phase 3|21|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 21:26:02.632972|2018-05-31 21:26:02.632972
NCT01585142|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2015-01-15|2012-04-24|2012-04-25|Estimate|||||||2015-01-15|2015-01-16|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Growth of Infants Fed With BabyNes System|Assessment of Growth of Infants Fed With BabyNes System (Single-serve Formulas, Adaptative System)|Completed||N/A|33|Actual|Nestlé||1|||f||||f||||||||||2018-05-31 21:26:02.727089|2018-05-31 21:26:02.727089
NCT01585129|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2018-01-25||2018-04-23|2012-04-24|2012-04-25|Estimate|2018-04-23|2018-05-22|Actual||||2018-04-23|2018-05-22|Actual|September 2010||2010-09-30|April 2018|2018-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TUPAC||Treatment Utility of Postpartum Antibiotics in Chorioamnionitis|Treatment Utility of Postpartum Antibiotics in Chorioamnionitis|Terminated||Phase 4|80|Actual|Washington University School of Medicine||2||Futility in patient enrollment|f||||t||||||||||2018-05-31 21:26:02.815424|2018-05-31 21:26:02.815424
NCT01585103|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-10-09|2012-04-24|2012-04-25|Estimate|||||||2017-10-09|2017-10-11|Actual|December 2012||2012-12-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Cytosponge Protocol IRB 11-006429|Cytosponge Protocol|Recruiting||N/A|120|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:26:03.196423|2018-05-31 21:26:03.196423
NCT01585090|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate||||April 2012|2012-04-30||||||||Interventional|||Effect of Ankle Position and Pelvic Floor Muscle Force With Relaxation of Pelvic Floor Muscles Syndrome||Withdrawn||Phase 2/Phase 3|0|Actual|Mashhad University of Medical Sciences||3|||f||||t||||||||||2018-05-31 21:26:03.279172|2018-05-31 21:26:03.279172
NCT01585077|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-01-13|2012-04-24|2012-04-25|Estimate|||||||2014-01-13|2014-01-15|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|ChallengeIII||Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge|Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites.|Completed||Phase 1/Phase 2|16|Actual|Malaria Vaccine and Drug Development Center||2|||f||||f||||||||||2018-05-31 21:26:03.369206|2018-05-31 21:26:03.369206
NCT01585064|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|August 2006||2006-08-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|||Optimization of Treatment With Adalimumab (Humira)|Optimization of Treatment With Adalimumab (HUMIRA): A Multi-center, Randomized, Single Blind, Controlled Clinical Trial|Completed|||309|Actual|Lawson Health Research Institute|||3||f||||t||||||||||2018-05-31 21:26:03.470666|2018-05-31 21:26:03.470666
NCT01585051|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D|Effect of Administration of 25(OH) Vitamin on Mean 24 Hour Blood Pressure and HBA1c Levels in Patients With Stable Type 2 Diabetes Mellitus|Completed||Phase 3|51|Actual|Kantonsspital Baselland Bruderholz||2|||f||||f||||||||||2018-05-31 21:26:03.565435|2018-05-31 21:26:03.565435
NCT01585038|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2015-06-11||2015-07-27|2012-04-24|2012-04-25|Estimate|2015-06-11|2015-07-02|Estimate||||2015-07-27|2015-08-14|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress|A Randomized Controlled Trial Comparing Efavirenz With Rilpivirine on Changes in Endothelial Function, Inflammatory Markers, and Oxidative Stress in HIV-uninfected Healthy Volunteers|Completed||Phase 4|40|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 21:26:03.656243|2018-05-31 21:26:03.656243
NCT01585025|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-09-05|2012-04-24|2012-04-25|Estimate|||||||2014-09-05|2014-09-08|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|OBADIAH1||Obeticholic Acid in Bile Acid Diarrhoea|Obeticholic Acid Treatment in Patients With Bile Acid Diarrhoea: an Open-label, Pilot Study of Mechanisms, Safety and Symptom Response.|Completed||Phase 2|28|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 21:26:04.01787|2018-05-31 21:26:04.01787
NCT01585012|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-05-04|2012-04-24|2012-04-25|Estimate|||||||2015-05-04|2015-05-06|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Ib2C||Usability Study of the Focus Touch™ Conception System: Semen Collection|Phase 2 Human Factors Usability Study of the Focus Touch™ Conception System: Semen Collection|Completed||Early Phase 1|30|Actual|Rinovum Women's Health, Inc.||1|||f||||t||||||||||2018-05-31 21:26:04.108925|2018-05-31 21:26:04.108925
NCT01584999|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-05-21|2012-04-23|2012-04-25|Estimate|||||||2012-05-21|2012-05-23|Estimate|February 2011||2011-02-28|May 2012|2012-05-31||||February 2012|Actual|2012-02-29||Interventional|||Effects on Septic Patient's Microcirculation of the Transfusion of Different Types of Concentrated RBCs.|Effects on the Septic Patient's Microcirculation of the Transfusion of Three Different Types of Concentrated Red Blood Cells.|Completed||Phase 4|30|Actual|Università Politecnica delle Marche||3|||f||||f||||||||||2018-05-31 21:26:04.178526|2018-05-31 21:26:04.178526
NCT01584986|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|May 2008||2008-05-31|April 2012|2012-04-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease|Autologous Stem Cell Therapy for the Treatment of Patients With Peripheral Artery Disease|Completed||Phase 2|22|Actual|Salus Ltd.||2|||f||||f||||||||||2018-05-31 21:26:04.341176|2018-05-31 21:26:04.341176
NCT01584973|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|April 2012||2012-04-30|April 2012|2012-04-30||||||||Observational|||Changes in Inter-joint Coordination and Muscle Activation After Cruciate Ligament Injury of the Knee Joint|Changes in Inter-joint Coordination and Muscle Activation After Cruciate Ligament Injury of the Knee Joint|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 21:26:04.412396|2018-05-31 21:26:04.412396
NCT01584960|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-11-29|2012-04-24|2012-04-25|Estimate|||||||2013-11-29|2013-12-02|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Effect of Endurance Training in Patients With Prostate Cancer|The Effect of Endurance Training on PSA Doubling Time, Body Composition, Insulin Sensitivity and Inflammation in Patients With Prostate Cancer|Completed||N/A|30|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 21:26:04.47985|2018-05-31 21:26:04.47985
NCT01584947|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2016-02-17|2012-04-24|2012-04-25|Estimate|||||||2016-02-17|2016-02-19|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional|||Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain|Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Oral Mucosal Pain in Burning Mouth Syndrome, Sjögrens Syndrome and Lichen Planus.|Terminated||Phase 2|31|Actual|Hvidovre University Hospital||2||Because of a very slow patient recruitment.|f||||t||||||||||2018-05-31 21:26:04.549642|2018-05-31 21:26:04.549642
NCT01584934|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-12-04|2012-04-24|2012-04-25|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Sodium Oxybate in Patients With Chronic Fatigue Syndrome.|The Effect of Sodium Oxybate in Patients With Chronic Fatigue Syndrome.|Unknown status|Recruiting|Phase 4|65|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 21:26:04.630655|2018-05-31 21:26:04.630655
NCT01584895|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-08-17|2012-04-24|2012-04-25|Estimate|||||||2015-08-17|2015-08-19|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|RehabVAD||Cardiac Rehabilitation in Patients With Continuous Flow Left Ventricular Assist Devices:Rehab VAD Trial|Cardiac Rehabilitation in Patients With Continuous Flow Left Ventricular Assist Devices:Rehab VAD Trial|Completed||N/A|26|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 21:26:04.901143|2018-05-31 21:26:04.901143
NCT01584882|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-07-15|2012-04-24|2012-04-25|Estimate|||||||2014-07-15|2014-07-17|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|July 2012|Actual|2012-07-31|April 2011|Actual|2011-04-30||Interventional|CATI||Computer-Assisted Tobacco Interventions in Dental Offices|Computer-Assisted Guidance for Tobacco Dependence Interventions in Dental Offices|Completed||N/A|548|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-05-31 21:26:04.987454|2018-05-31 21:26:04.987454
NCT01584869|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2015-01-28|2012-04-24|2012-04-25|Estimate|||||||2015-01-28|2015-01-29|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Emergency Capsule Endoscopy in Severe GI-bleeding|Emergency Capsule Endoscopy in Severe GI-bleeding|Completed||Phase 2/Phase 3|20|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 21:26:05.062102|2018-05-31 21:26:05.062102
NCT01584856|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-25|2012-04-24|2012-04-25|Estimate|||||||2012-04-25|2012-04-26|Estimate|May 2006||2006-05-31|April 2012|2012-04-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Small Dense Low-density Lipoprotein in Patients With Prediabetes and Type 2 Diabetes||Unknown status|Active, not recruiting||60|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 21:26:05.17155|2018-05-31 21:26:05.17155
NCT01584843|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2014-06-26||2015-07-02|2012-04-23|2012-04-25|Estimate|2014-07-03|2014-08-01|Estimate||||2015-07-02|2015-07-24|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|July 2013|Actual|2013-07-31||Interventional|||Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus|A Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus|Completed||Phase 3|41|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 21:26:05.285787|2018-05-31 21:26:05.285787
NCT01584830|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2016-02-05|2012-04-24|2012-04-25|Estimate|||||||2016-02-05|2016-02-08|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2013|Actual|2013-11-30||Interventional|CONCUR||Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy|A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy|Completed||Phase 3|204|Actual|Bayer||2|||f||||t||||||||||2018-05-31 21:26:06.852079|2018-05-31 21:26:06.852079
NCT01584817|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2013-12-01|2012-04-24|2012-04-25|Estimate|||||||2013-12-01|2013-12-03|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Repeated Instruction by Telephone on the Day Before Colonoscopy to Patients Undergoing Colonoscopy|A Repeated Instruction by Telephone on the Day Before Colonoscopy Improves the Quality of Bowel Preparation and Colonoscopy Procedure : a Prospective Randomized, Controlled Trial|Completed||N/A|605|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 21:26:06.957677|2018-05-31 21:26:06.957677
NCT01584804|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-11-15|2012-04-24|2012-04-25|Estimate|||||||2012-11-15|2012-11-19|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Effects of Su-Huang Antitussive Capsule on Cough Variant Asthma|Randomised, Double-blinded, Placebo-Controlled Study of Therapeutic Effect of Su-Huang Antitussive Capsule on Cough Variant Asthma(CVA)|Unknown status|Recruiting|Phase 4|60|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 21:26:07.113819|2018-05-31 21:26:07.113819
NCT01584791|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|October 2010||2010-10-31|April 2012|2012-04-30||||February 2012|Actual|2012-02-29||Interventional|||Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting||Completed||Phase 4|148|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:26:07.205009|2018-05-31 21:26:07.205009
NCT01584778|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-25|2012-04-24|2012-04-25|Estimate|||||||2012-04-25|2012-04-26|Estimate|January 2002||2002-01-31|April 2012|2012-04-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Observational|||Behçet's Disease and Eosinophil Cationic Protein|The Serum Eosinophil Cationic Protein Levels in Behçet's Disease and Its Relation to the Clinical Activity|Completed|||47|Actual|Cukurova University|||3||f||||f||||||||||2018-05-31 21:26:07.286908|2018-05-31 21:26:07.286908
NCT01584765|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2014-07-03|2012-04-23|2012-04-25|Estimate|||||||2014-07-03|2014-07-08|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Rechallenge, Potential Drug Induced Liver Injury (Kaiser)|Rechallenge Analysis: Detection of Potential Drug-Induced Liver Injury Using Kaiser California Database|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 21:26:07.383491|2018-05-31 21:26:07.383491
NCT01584752|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-11-21|2012-04-24|2012-04-25|Estimate|||||||2014-11-21|2014-11-24|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|November 2015|Anticipated|2015-11-30|December 2014|Anticipated|2014-12-31|12 Months|Observational [Patient Registry]|||Gore-BioA Fistula Plug to Treat Transsphincteric Fistulas|Clinical Multicenter Study of the Efficacy of Gore-BioA Fistula Plug in High Transsphincteric Perianal Fistulas|Terminated|||60|Actual|Central Finland Hospital District|||1||f||||f||||||||||2018-05-31 21:26:07.497025|2018-05-31 21:26:07.497025
NCT01584739|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-11-30|2012-04-24|2012-04-25|Estimate|||||||2012-11-30|2012-12-03|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase I, Single Centre, Double-Blind, Randomised, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD8683 in Healthy Volunteers and COPD Patients|Terminated||Phase 1|30|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:26:07.619982|2018-05-31 21:26:07.619982
NCT01584726|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2014-01-27|2012-04-24|2012-04-25|Estimate|||||||2014-01-27|2014-01-28|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31||Interventional|||Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma|Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)|Unknown status|Recruiting|N/A|400|Anticipated|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 21:26:07.741954|2018-05-31 21:26:07.741954
NCT01584713|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2012-04-23|2012-04-23|2012-04-25|Estimate|||||||2012-04-23|2012-04-25|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|July 2012|Anticipated|2012-07-31||Interventional|HULPUTC||Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)|A Phase II Clinical Trial to Study the Feasibility and Safety of Stromal Vascular Derived From Adipose Tissue for the Treatment of Enterocutaneous Fistula|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 21:26:07.870228|2018-05-31 21:26:07.870228
NCT01584700|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2016-08-22|2012-04-23|2012-04-25|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|REACH-Pilot||Renal Artery Denervation in Chronic Heart Failure|Renal Artery Denervation in Chronic Heart Failure- Pilot|Completed||Phase 1|7|Actual|Imperial College London||1|||f||||t||||||||Undecided|waiting|2018-05-31 21:26:07.983459|2018-05-31 21:26:07.983459
NCT01584687|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|June 2012||2012-06-30|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||mRNA Expression as a Biomarker of Omalizumab Response|mRNA Expression as a Biomarker of Xolair (Omalizumab) Response|Unknown status|Not yet recruiting|Phase 4|6|Anticipated|Instituto de Investigação em Imunologia||1|||f||||t||||||||||2018-05-31 21:26:08.099057|2018-05-31 21:26:08.099057
NCT01584674|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2013-05-15|2012-04-23|2012-04-25|Estimate|||||||2013-05-15|2013-05-17|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Clinical Trial Evaluating the Safety and Efficacy of the KLOX Biophotonic System in Moderate to Severe Acne|A Prospective Clinical Trial Evaluating the Efficacy of the KLOX Biophotonic System (KLOX KLGA0105-01 and KLOX THERA LAMP) On Moderate to Severe Acne|Completed||Phase 3|98|Actual|KLOX Technologies Inc.||2|||f||||f||||||||||2018-05-31 21:26:08.199439|2018-05-31 21:26:08.199439
NCT01584661|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|July 2012||2012-07-31|April 2012|2012-04-30||||August 2013|Anticipated|2013-08-31||Observational|||The Continuity of Nutritional Care Among Elderly Patients|The Continuity of Nutritional Care From the Hospital to the Community and Its Impact on Health and Functional Indicators Among Elderly Patients|Unknown status|Not yet recruiting||||Bait Balev Hospital|||1||f||||t||||||||||2018-05-31 21:26:08.296365|2018-05-31 21:26:08.296365
NCT01584648|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2014-04-10||2018-04-11|2012-04-23|2012-04-25|Estimate|2014-07-24|2014-08-15|Estimate||||2018-04-11|2018-05-14|Actual|May 4, 2012|Actual|2012-05-04|April 2018|2018-04-30|July 13, 2018|Anticipated|2018-07-13|August 26, 2013|Actual|2013-08-26||Interventional|||A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma|A Phase III, Randomized, Double-blinded Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to Dabrafenib and Placebo as First-line Therapy in Subjects With Unresectable (Stage IIIC) or Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma|Active, not recruiting||Phase 3|422|Actual|Novartis||2|||f||||t|t|f||||||||2018-05-31 21:26:08.446062|2018-05-31 21:26:08.446062
NCT01584635|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-10-27|2012-04-23|2012-04-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|POEM||The Role That Peroral Endoscopic Myotomy (POEM) Could Play in the Treatment of Achalasia|Peroral Endoscopic Myotomy (POEM) for Treatment of Achalasia|Completed||N/A|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:26:09.834611|2018-05-31 21:26:09.834611
NCT01584622|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-06-27|2012-04-23|2012-04-25|Estimate|||||||2013-06-27|2013-07-01|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|CADENCE||Clinical Evaluation of the CADenceTM System in Detection of Coronary Artery Diseases|Clinical Evaluation of the CADence System in Detection of Coronary Artery Diseases|Withdrawn||N/A|0|Actual|AUM Cardiovascular, Inc.|||||f||||f||||||||||2018-05-31 21:26:09.970956|2018-05-31 21:26:09.970956
NCT01584609|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-03-01|2012-04-24|2012-04-25|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2012||2012-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke|A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke|Completed||Phase 2/Phase 3|230|Anticipated|Penumbra Inc.||2|||f||||t||||||||||2018-05-31 21:26:10.076366|2018-05-31 21:26:10.076366
NCT01584596|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2016-02-04|2012-04-23|2012-04-25|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Steps Ahead, Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population|Steps Ahead, Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population|Completed||Phase 1/Phase 2|129|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 21:26:10.233626|2018-05-31 21:26:10.233626
NCT01584583|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|April 2012|Actual|2012-04-30|||||Observational|||Blood Pressure Monitor Clinical Test (Cuff Range: 22 Cm-36cm)||Completed|||85|Actual|Andon Health Co., Ltd|||2||f||||f||||||||||2018-05-31 21:26:10.336246|2018-05-31 21:26:10.336246
NCT01584570|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2014-07-13|2012-04-23|2012-04-25|Estimate|||||||2014-07-13|2014-07-15|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||The Effects of Dexmedetomidine and Tracheal Intubation on Heart Rate Variability and QTc Interval||Unknown status|Recruiting|N/A|66|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 21:26:10.403997|2018-05-31 21:26:10.403997
NCT01584557|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-09-26|2012-04-23|2012-04-25|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|Secret of CHF||Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management|A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management|Completed||Phase 3|250|Actual|Cardiovascular Clinical Science Foundation||2|||f||||t||||||||||2018-05-31 21:26:10.527569|2018-05-31 21:26:10.527569
NCT01584544|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2015-04-07||2015-04-17|2012-04-23|2012-04-25|Estimate|2015-04-17|2015-04-20|Estimate||||2015-04-17|2015-04-20|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer|Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients|Completed||Phase 1|24|Actual|Chinese Academy of Medical Sciences||5|||f||||t||||||||||2018-05-31 21:26:10.745475|2018-05-31 21:26:10.745475
NCT01584531|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23||2016-06-28|2017-06-22|2012-04-23|2012-04-25|Estimate||||2016-06-28|2016-06-30|Estimate|2017-06-22|2017-06-26|Actual|May 2012||2012-05-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|ONTARGET||Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome|A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification|Completed||Phase 2|82|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 21:26:11.354824|2018-05-31 21:26:11.354824
NCT01584518|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2016-01-04||2016-04-28|2012-04-23|2012-04-25|Estimate|2016-02-25|2016-03-28|Estimate||||2016-04-28|2016-05-27|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||B-type Natriuretic Peptide as a Surrogate Marker Guiding Post-operative Fluid Off-loading|B-type Natriuretic Peptide (BNP) as a Surrogate Marker Guiding Post-operative Fluid Off-loading|Completed||N/A|50|Actual|Creighton University||2|||f||||t||||||||||2018-05-31 21:26:11.47632|2018-05-31 21:26:11.47632
NCT01584505|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-03-28|2012-04-24|2012-04-25|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2012||2012-04-30|March 2017|2017-03-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|CARSAF||Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD|Randomized, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study To Evaluate The Cardiac Safety Of Two Doses Of CHF5993 BID Delivered Via HFA PMDI Both Combined With CHF1535 BID Delivered Via HFA PMDI Versus CHF1535 BID Delivered Via HFA PMDI In Patients With Moderate To Severe COPD|Completed||Phase 2|191|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 21:26:11.680148|2018-05-31 21:26:11.680148
NCT01584492|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-03-28|2012-04-24|2012-04-25|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2011||2011-12-31|March 2017|2017-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PAED3||Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children|Double Blind, Double Dummy, Cross-over Study to Compare the Bronchodilator Effect of CHF1535 pMDI (Fixed Combination of Beclometasone 50 µg + Formoterol 6 µg) Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children|Completed||Phase 2|59|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||t||||||||||2018-05-31 21:26:11.76606|2018-05-31 21:26:11.76606
NCT01584479|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2014-06-13||2015-06-17|2012-04-24|2012-04-25|Estimate|2015-06-17|2015-07-09|Estimate||||2015-06-17|2015-07-09|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||See Giannobile et al 2013 manuscript included|Periodontal Disease Prevention Study|Periodontal Disease Prevention Study:A Retrospective Cohort Study to Assess the Effect of Genetics and Dental Preventive Care on Periodontal Disease|Completed|||5117|Actual|University of Michigan|||4||f||||f||||||Samples With DNA|"~     buccal swabs~   "|||2018-05-31 21:26:11.845432|2018-05-31 21:26:11.845432
NCT01584466|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2014-01-27|2012-04-23|2012-04-25|Estimate|||||||2014-01-27|2014-01-29|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study|Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study|Withdrawn||N/A|0|Actual|University of Maryland||1|||f||||f||||||||||2018-05-31 21:26:12.307848|2018-05-31 21:26:12.307848
NCT01584453|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2017-11-28|2012-04-24|2012-04-25|Estimate|||||||2017-11-28|2017-11-29|Actual|April 2012|Actual|2012-04-30|July 2015|2015-07-31|January 2016|Actual|2016-01-31|November 2013|Actual|2013-11-30||Interventional|NITRITE-AMI||Safety and Effectiveness of Intra-coronary Nitrite in Acute Myocardial Infarction|A Randomised, Double-blind, Placebo-controlled Trial Assessing the Safety and Efficacy of Intracoronary Nitrite Infusion During Acute Myocardial Infarction|Completed||Phase 2|80|Actual|Barts & The London NHS Trust||2|||f||||t||||||||||2018-05-31 21:26:12.456638|2018-05-31 21:26:12.456638
NCT01584440|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23||2018-01-08|2018-01-08|2012-04-24|2012-04-25|Estimate||||2018-01-08|2018-01-11|Actual|2018-01-08|2018-01-11|Actual|June 2012||2012-06-30|January 2018|2018-01-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients|A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.|Completed||Phase 2|220|Actual|Avanir Pharmaceuticals||2|||f||||t||||||||||2018-05-31 21:26:12.559355|2018-05-31 21:26:12.559355
NCT01584427|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-06-06|2012-04-24|2012-04-25|Estimate|||||||2013-06-06|2013-06-07|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ButCoIns||ButCoIns - Metabolic Effects of Resistent Starch and Arabinoxylans in Subjects With Metabolic Syndrome|ButCoIns - Metabolic Effects of Resistent Starch and Arabinoxylans in Subjects With Metabolic Syndrome|Completed||N/A|22|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 21:26:12.729901|2018-05-31 21:26:12.729901
NCT01584414|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|April 2010|Actual|2010-04-30|||||Observational|||Evaluation of the Zetiq Histological and Cytological Staining Technique for the Detection Cervical Cancer|Evaluation of the Zetiq Histological and Cytological Staining Technique for the Detection Cervical Cancer|Completed|||210|Actual|Meir Medical Center|||2||f||||||||||||||2018-05-31 21:26:12.821589|2018-05-31 21:26:12.821589
NCT01584401|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2012-04-24|2012-04-24|2012-04-25|Estimate|||||||2012-04-24|2012-04-25|Estimate|May 2012||2012-05-31|April 2012|2012-04-30||||||||Observational|||Temperature Measurement Using a Non Invasive Device||Unknown status|Not yet recruiting||500|Anticipated|Medisim Ltd|||||f||||f||||||||||2018-05-31 21:26:12.882164|2018-05-31 21:26:12.882164
NCT01584388|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|2015-12-14||2017-05-31|2012-04-24|2012-04-25|Estimate|2017-05-31|2017-07-02|Actual||||2017-05-31|2017-07-02|Actual|April 2012||2012-04-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional||Covient sample|Rituximab in IgG4-RD: A Phase 1-2 Trial|Rituximab (RTX) for IgG4-related Disease (IgG4-RD): a Prospective,Open-label Trial|Completed||Phase 1/Phase 2|30|Actual|Massachusetts General Hospital||1|||f||||t|t|f||||||||2018-05-31 21:26:12.956457|2018-05-31 21:26:12.956457
NCT01584375|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2014-10-30|2012-04-24|2012-04-25|Estimate|||||||2014-10-30|2014-10-31|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|||The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions|The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions in Preterm Infant Less Than 30 Weeks of Gestation: a Multicenter Randomized Control Trial|Terminated||N/A|71|Actual|King Abdul Aziz General Hospital||2||Due to low patient recruitment|f||||f||||||||||2018-05-31 21:26:13.263774|2018-05-31 21:26:13.263774
NCT01584362|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-08-29|2012-04-24|2012-04-25|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|OXFEND-02||Single Ascending Dose Safety Study of Oxfendazole|Phase I Study of Oxfendazole (Toward the Treatment of Neurocysticercosis)|Withdrawn||Phase 1|0|Actual|Johns Hopkins Bloomberg School of Public Health||7||study conducted under Clinical Trials Agreement as NIAID registration NCT02234570|f||||f||||||||||2018-05-31 21:26:13.350135|2018-05-31 21:26:13.350135
NCT01584336|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2014-02-05|2012-04-22|2012-04-24|Estimate|||||||2014-02-05|2014-02-06|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|March 2014|Anticipated|2014-03-31|February 2014|Actual|2014-02-28||Interventional|KLASS-03||Laparoscopy-assisted Total Gastrectomy for Clinical Stage I Gastric Cancer (KLASS-03)|Prospective Multi-center Study of Laparoscopy-assisted Total Gastrectomy for Clinical Stage I Gastric Cancer (KLASS-03)|Unknown status|Recruiting|Phase 2|168|Anticipated|Soonchunhyang University Hospital||1|||f||||t||||||||||2018-05-31 21:26:15.175861|2018-05-31 21:26:15.175861
NCT01584323|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-22|2012-04-22|2012-04-24|Estimate|||||||2012-04-22|2012-04-24|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes|Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes|Unknown status|Recruiting|N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 21:26:15.599705|2018-05-31 21:26:15.599705
NCT01584310|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2016-04-10|2012-04-22|2012-04-24|Estimate|||||||2016-04-10|2016-04-12|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|STAMP2||Validation of the STAMP Screening Tool|Validation of the STAMP Screening Tool For Pediatric Nutritional Risk To Be Used in the Ambulatory Setting.|Completed||N/A|60|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 21:26:15.751987|2018-05-31 21:26:15.751987
NCT01584297|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2015-01-19|2012-04-22|2012-04-24|Estimate|||||||2015-01-19|2015-01-21|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|GreKo||Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary|Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.|Terminated||Phase 2|6|Actual|Grupo Español de Tumores Huérfanos e Infrecuentes||1||Insufficient recruitment rate|f||||f||||||||||2018-05-31 21:26:15.821947|2018-05-31 21:26:15.821947
NCT01584284|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2015-08-21|2012-04-22|2012-04-24|Estimate|||||||2015-08-21|2015-08-25|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer|Phase I Trial Of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiotherapy in Patients With Locoregionally Advanced Head and Neck Carcinoma|Completed||Phase 1|19|Actual|Genelux Corporation|||||f||||t||||||||||2018-05-31 21:26:15.907819|2018-05-31 21:26:15.907819
NCT01584271|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-07-07|2012-04-23|2012-04-24|Estimate|||||||2013-07-07|2013-07-09|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)|Phase II 3 Arm Double Blinded Clinical Study Evaluating the Pain Killing and Healing Time of Botanical Ear Drops, Ear Comfort(TM), in Severe External Ear Infection (AOE) Patients, Compared to Dex-Otic(R) and Otidin(R)|Unknown status|Recruiting|Phase 2|75|Anticipated|Assuta Hospital Systems||3|||f||||t||||||||||2018-05-31 21:26:15.97848|2018-05-31 21:26:15.97848
NCT01584258|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-22|||2015-04-24|2012-04-22|2012-04-24|Estimate|||||||2015-04-24|2015-04-27|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|September 2026|Anticipated|2026-09-30|September 2021|Anticipated|2021-09-30||Interventional|PACE||Prostate Advances in Comparative Evidence|International Randomised Study of Laparoscopic Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Early Stage Organ-Confined Prostate Cancer|Recruiting||Phase 3|1716|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:26:16.208531|2018-05-31 21:26:16.208531
NCT01584245|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-09-15|2012-04-23|2012-04-24|Estimate|||||||2014-09-15|2014-09-16|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of the Efficacy of an Amino Acid Based Formula in Infants|Evaluation of the Efficacy of an Amino Acid Based Formula in Infants|Terminated||N/A|32|Actual|Mead Johnson Nutrition||||Enough participants enrolled to provide adequate statistical power|f||||f||||||||||2018-05-31 21:26:16.339161|2018-05-31 21:26:16.339161
NCT01584232|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2014-10-03|2013-09-27|2014-10-14|2012-04-23|2012-04-24|Estimate|2014-10-14|2014-10-20|Estimate|2013-09-27|2013-10-28|Estimate|2014-10-14|2014-10-20|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||All randomized participants who received at least 1 dose of LY2189265 or insulin glargine.|A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus|A Phase 3 Study of LY2189265 Compared to Insulin Glargine in Patients With Type 2 Diabetes Mellitus on a Sulfonylurea and/or Biguanide|Completed||Phase 3|361|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:26:16.484799|2018-05-31 21:26:16.484799
NCT01584219|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-05-07|2012-04-23|2012-04-24|Estimate|||||||2012-05-07|2012-05-08|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||The Role of Placental Myeloid Cells During Gestation, Labor and Disease|The Role of Placental Myeloid Cells During Gestation, Labor and Disease|Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||4||f||||f||||||||||2018-05-31 21:26:17.280951|2018-05-31 21:26:17.280951
NCT01584206|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2016-03-09|2012-04-23|2012-04-24|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|August 2013|Actual|2013-08-31||Interventional|STAIR7002||Sitosterolemia Metabolism|Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe|Unknown status|Active, not recruiting|N/A|8|Actual|University of Manitoba||1|||f||||t||||||||||2018-05-31 21:26:17.38108|2018-05-31 21:26:17.38108
NCT01584193|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2015-06-23|2012-04-21|2012-04-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Ultrasound-guided Subclavian Vein Puncture Versus Cephalic Vein Dissection for Venous Access Port Implantation|Ultrasound-guided Subclavian Vein Puncture Versus Cephalic Vein Dissection for Totally Implantable Venous Access Port Implementation: a Single-center Controlled Randomized Superiority Trial|Withdrawn||N/A|0|Actual|University of Lausanne Hospitals||2||Logistical reasons (institutional reorganization of ambulatory surgery)|f||||f||||||||||2018-05-31 21:26:17.468858|2018-05-31 21:26:17.468858
NCT01584180|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2012-08-14|2012-04-21|2012-04-24|Estimate|||||||2012-08-14|2012-08-15|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|iCOOL 3||A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Brain.Pad (iCOOL 3)|iCOOL 3 (Induction of COOLing 3): A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Brain.Pad|Completed||Phase 2|20|Anticipated|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 21:26:17.547669|2018-05-31 21:26:17.547669
NCT01584167|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2013-06-21|2012-04-21|2012-04-24|Estimate|||||||2013-06-21|2013-06-24|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|iCOOL 2||A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Flex.Pads (iCOOL 2)|iCOOL 2 (Induction of COOLing 2): A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. EMCOOLS Flex.Pads|Unknown status|Recruiting|Phase 2|20|Anticipated|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 21:26:17.710076|2018-05-31 21:26:17.710076
NCT01584154|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2015-09-03|2012-04-23|2012-04-24|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|CRYOABLATE||Comparative Study Between Cryoablation and Radiofrequency Ablation in the Treatment of Supraventricular Tachycardia|CRYOthermy and Radiofrequency ABLation For AVNRT TrEatment|Unknown status|Recruiting|Phase 4|520|Anticipated|Princess Margaret Hospital, Hong Kong||2|||f||||f||||||||||2018-05-31 21:26:17.813011|2018-05-31 21:26:17.813011
NCT01584141|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2017-10-18|2012-04-21|2012-04-24|Estimate|||||||2017-10-18|2017-10-19|Actual|July 5, 2011||2011-07-05|July 10, 2017|2017-07-10||||||||Observational|||Study of Lymphoma in Asia|A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph)|Recruiting|||13600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:26:17.935011|2018-05-31 21:26:17.935011
NCT01584128|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2017-05-02|2012-04-23|2012-04-24|Estimate|||||||2017-05-02|2017-05-05|Actual|April 2012||2012-04-30|May 2017|2017-05-31|March 1, 2013|Actual|2013-03-01|March 1, 2013|Actual|2013-03-01||Observational|||Oxidized Regenerated Cellulose to Decrease Vaginal Cuff Complications|Use of Structured Non-woven Absorbable Hemostat (or Oxidized Regenerated Cellulose) to Decrease Vaginal Cuff Dehiscence Rate in Laparoscopic Hysterectomy|Completed|||101|Actual|Milton S. Hershey Medical Center|||1||f||||t||||||||||2018-05-31 21:26:18.0314|2018-05-31 21:26:18.0314
NCT01584115|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-21|||2012-04-24|2012-04-23|2012-04-24|Estimate|||||||2012-04-24|2012-04-25|Estimate|July 2012||2012-07-31|April 2012|2012-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)|Phase I Clinical Trial of a Therapeutic Vaccine for Malignancies, Comprising the Tumor Antigen NY-ESO-1 in Combination With the Adjuvant MPLA of Bordetella Pertussis. Evaluation of Toxicity and Immunogenicity|Unknown status|Not yet recruiting|Phase 1/Phase 2|15|Anticipated|Instituto de Investigação em Imunologia||1|||f||||t||||||||||2018-05-31 21:26:18.128003|2018-05-31 21:26:18.128003
NCT01584102|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-04-23|2012-04-23|2012-04-24|Estimate|||||||2012-04-23|2012-04-24|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Randomized Controlled Trial Targeting Obesity-related Behaviors|Better Together Healthy Caswell County: Randomized Controlled Trial Targeting Obesity-related Behaviors|Completed||N/A|91|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-05-31 21:26:18.280092|2018-05-31 21:26:18.280092
NCT01584076|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-03-21|2012-04-23|2012-04-24|Estimate|||||||2018-03-21|2018-03-23|Actual|August 2012|Actual|2012-08-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Treatment of Residual Amblyopia With Donepezil|Recovery From Amblyopia With Cholinesterase Inhibitors|Recruiting||Phase 1|20|Anticipated|Boston Children’s Hospital||1|||f||||f||||||||No||2018-05-31 21:26:18.410949|2018-05-31 21:26:18.410949
NCT01584063|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-04-23|2012-04-23|2012-04-24|Estimate|||||||2012-04-23|2012-04-24|Estimate|February 2004||2004-02-29|April 2012|2012-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|Healthy MOMs||Healthy Mothers on the Move||Completed||N/A|276|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:26:18.558947|2018-05-31 21:26:18.558947
NCT01584050|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-08-09|2012-04-23|2012-04-24|Estimate|||||||2012-08-09|2012-08-10|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate|Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate|Completed||N/A|150|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 21:26:18.646987|2018-05-31 21:26:18.646987
NCT01584037|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2014-04-17|2012-04-23|2012-04-24|Estimate|||||||2014-04-17|2014-04-21|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30|12 Months|Observational [Patient Registry]|||Adenovirus Vaccine Pregnancy Registry|Adenovirus Vaccine Pregnancy Registry|Withdrawn|||0|Actual|Teva Pharmaceutical Industries|||1||f||||t||||||||||2018-05-31 21:26:18.730757|2018-05-31 21:26:18.730757
NCT01584024|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-04-09|2012-04-20|2012-04-24|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2013||2013-03-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Resin Infiltration to Arrest Early Tooth Decay|Radiographic Progression of Early Caries Lesions After Resin Infiltration|Completed||N/A|42|Actual|University of Michigan||2|||f||||f||||||||Undecided||2018-05-31 21:26:18.804252|2018-05-31 21:26:18.804252
NCT01584011|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-05-07|2012-04-23|2012-04-24|Estimate|||||||2012-05-07|2012-05-08|Estimate|January 2010||2010-01-31|April 2012|2012-04-30||||December 2015|Anticipated|2015-12-31||Observational|||Taste Disorders in Middle Ear Disease and After Middle Ear Surgery|Taste Disorders in Middle Ear Disease and After Middle Ear Surgery|Unknown status|Recruiting||310|Anticipated|Uppsala University|||1||f||||t||||||Samples Without DNA|"~     Samples of nerve tissue~   "|||2018-05-31 21:26:18.893098|2018-05-31 21:26:18.893098
NCT01583998|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-05-21|2012-04-20|2012-04-24|Estimate|||||||2012-05-21|2012-05-23|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|e-MBC||Electronic-Measurement Based Care for Major Depressive Disorder|Electronic-Measurement Based Care (e-MBC) for Major Depressive Disorder (MDD)|Unknown status|Active, not recruiting|N/A|80|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 21:26:18.989588|2018-05-31 21:26:18.989588
NCT01583985|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-06-07|2012-04-23|2012-04-24|Estimate|||||||2017-06-07|2017-06-08|Actual|June 1, 2013|Actual|2013-06-01|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|January 31, 2017|Actual|2017-01-31||Interventional|SPACE||Strategies for Prescribing Analgesics Comparative Effectiveness Trial|Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) Trial|Completed||N/A|265|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 21:26:19.066535|2018-05-31 21:26:19.066535
NCT01583972|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-14|||2014-08-22|2012-04-23|2012-04-24|Estimate|||||||2014-08-22|2014-08-26|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function|Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function|Completed||N/A|300|Actual|USDA, Western Human Nutrition Research Center||2|||f||||t||||||||||2018-05-31 21:26:19.143603|2018-05-31 21:26:19.143603
NCT01583959|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-02-05|2012-04-21|2012-04-24|Estimate|||||||2014-02-05|2014-02-07|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|FOLVARI||Study of Different Doses of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis|Randomized Trial of 10 mg Versus 30 mg Per Week of Folic Acid in Combination With Methotrexate in Rheumatoid Arthritis|Completed||Phase 4|100|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 21:26:19.24798|2018-05-31 21:26:19.24798
NCT01583946|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2016-06-07|2012-04-23|2012-04-24|Estimate|||||||2016-06-07|2016-06-09|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|LIFT||Temporally-Oriented Subjective Well-being Across Transitions—Resources & Outcomes|Temporally-Oriented Subjective Well-being Across Transitions—Resources & Outcomes|Completed|||793|Actual|University of Pittsburgh|||8||f||||t||||||||||2018-05-31 21:26:19.338616|2018-05-31 21:26:19.338616
NCT01583933|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-04-26|2012-04-23|2012-04-24|Estimate|||||||2012-04-26|2012-04-27|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|May 2012|Anticipated|2012-05-31|January 2012|Actual|2012-01-31||Interventional|retainer||Essix Retainer vs Hawley Retainer|PHASE 3 STUDY OF THE EFFECTIVITY OF TWO RETAINERS IN THE DENTAL AND OCCLUSAL STABILITY|Unknown status|Recruiting|Phase 3|46|Anticipated|CES University||2|||f||||f||||||||||2018-05-31 21:26:19.410662|2018-05-31 21:26:19.410662
NCT01583920|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-02-16|2012-04-23|2012-04-24|Estimate|||||||2018-02-16|2018-02-19|Actual|July 2012||2012-07-31|February 2018|2018-02-28|July 2028|Anticipated|2028-07-31|July 2028|Anticipated|2028-07-31||Interventional|||Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer|Pilot Study of Focal Salvage HDR Prostate Brachytherapy|Recruiting||Phase 1/Phase 2|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 21:26:19.519741|2018-05-31 21:26:19.519741
NCT01583907|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-04-24|2012-04-23|2012-04-24|Estimate|||||||2012-04-24|2012-04-25|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Observational|||Nutrition in Children With Food Allergy||Unknown status|Recruiting||70|Anticipated|Federico II University|||1||f||||f||||||Samples Without DNA|"~     blood sampling to measure laboratory parameters useful to asses nutritional status~   "|||2018-05-31 21:26:19.603521|2018-05-31 21:26:19.603521
NCT01583894|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2014-12-18||2015-03-09|2012-04-23|2012-04-24|Estimate|2014-12-18|2014-12-30|Estimate||||2015-03-09|2015-03-11|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|MAP|Patients suffering from chronic intractable pain of the trunk and/or limbs for a duration of at least 6 months|Multiple Areas of Pain (MAP)|Multiple Areas of Pain (MAP): Epidemiology of Multisite Pain in the Chronic Pain Population|Completed|||828|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 21:26:19.775118|2018-05-31 21:26:19.775118
NCT01583881|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2015-10-30|2012-04-23|2012-04-24|Estimate|||||||2015-10-30|2015-11-02|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|DIASTOLE||Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction|Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction|Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 21:26:19.917103|2018-05-31 21:26:19.917103
NCT01583868|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-08-10|2012-04-23|2012-04-24|Estimate|||||||2012-08-10|2012-08-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:26:20.017418|2018-05-31 21:26:20.017418
NCT01583855|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-05-03|2012-04-20|2012-04-24|Estimate|||||||2018-05-03|2018-05-09|Actual|March 1, 2012||2012-03-01|March 2017|2017-03-31|February 28, 2015|Actual|2015-02-28|February 28, 2015|Actual|2015-02-28||Interventional|MAST-AF||Manual vs Amigo SmartTouch Atrial Fibrillation Study|Manual vs Amigo SmartTouch Atrial Fibrillation Study|Completed||N/A|50|Actual|University of Leicester||2|||f||||t||||||||||2018-05-31 21:26:20.068633|2018-05-31 21:26:20.068633
NCT01583842|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-12-07|2012-04-23|2012-04-24|Estimate|||||||2017-12-07|2017-12-11|Actual|June 2012||2012-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study|124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study|Recruiting||N/A|20|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:26:20.16503|2018-05-31 21:26:20.16503
NCT01583829|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-07-06|2012-04-23|2012-04-24|Estimate|||||||2017-07-06|2017-07-07|Actual|May 2009||2009-05-31|July 2017|2017-07-31|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|CATS||Study of Computer Attention Training Programs in Schools for Children With Attention Deficit/Hyperactivity Disorder|Randomized Control Trial of Two Computer-Based Attention Training Programs in Schools for Children With Attention Deficit/Hyperactivity Disorder (ADHD)|Completed||N/A|104|Actual|Tufts Medical Center||3|||f||||t||||||||||2018-05-31 21:26:20.289551|2018-05-31 21:26:20.289551
NCT01583816|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2015-12-14|2012-04-20|2012-04-24|Estimate|||||||2015-12-14|2015-12-15|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|||Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions|Prospective, Randomized, Partly Blinded, in Part Placebo-controlled, Multicenter, Dose-finding Trial Exploring Safety, Tolerability and Efficacy of a Topical Resiquimod Gel in Patients With Multiple Actinic Keratosis Lesions|Completed||Phase 2|218|Actual|Spirig Pharma Ltd.||5|||f||||f||||||||||2018-05-31 21:26:20.398352|2018-05-31 21:26:20.398352
NCT01583803|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-12-20|2012-04-23|2012-04-24|Estimate|||||||2016-12-20|2016-12-21|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|January 2014|Actual|2014-01-31||Observational|||Sex Differences in Oral Bacteria|Investigation of the Sex Differences in Oral Microbiota and Their Effect on Circulating Nitrite Levels|Active, not recruiting|||24|Anticipated|Queen Mary University of London|||2||f||||f||||||Samples Without DNA|"~     Urine, saliva and plasma~   "|||2018-05-31 21:26:20.510049|2018-05-31 21:26:20.510049
NCT01583790|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2018-01-24|2012-04-23|2012-04-24|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2012||2012-01-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Factors Influencing the Positive Outcome of Bariatric Surgery for Morbidly Obese Patients|A Prospective Trial for Laparoscopic Adjustable Gastric Banding in Morbidly Obese Patients: Report on Weight Loss, Metabolic Changes and Quality of Life|Recruiting|||2000|Anticipated|Assuta Hospital Systems|||1||f||||f||||||||||2018-05-31 21:26:20.588863|2018-05-31 21:26:20.588863
NCT01583777|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-07-20|2012-04-23|2012-04-24|Estimate|||||||2016-07-20|2016-07-22|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer|A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Belinostat in Patients With Advanced Cancer|Completed||Phase 1|6|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 21:26:20.702975|2018-05-31 21:26:20.702975
NCT01583751|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-04-23|2012-04-23|2012-04-24|Estimate|||||||2012-04-23|2012-04-24|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|videosinus||Videoendoscopic Pilonidal Sinus Surgery|Videoendoscopic Pilonidal Sinus Surgery. A New Technique|Unknown status|Recruiting|Phase 1|60|Anticipated|SB Istanbul Education and Research Hospital||1|||f||||f||||||||||2018-05-31 21:26:20.783297|2018-05-31 21:26:20.783297
NCT01583738|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2014-10-29|2012-04-20|2012-04-24|Estimate|||||||2014-10-29|2014-10-30|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of V0251 in Acute Vertigo||Completed||Phase 2|132|Actual|Pierre Fabre Medicament||2|||f||||t||||||||||2018-05-31 21:26:20.923045|2018-05-31 21:26:20.923045
NCT01583725|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-01-10|2012-04-23|2012-04-24|Estimate|||||||2014-01-10|2014-01-14|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|||fMRI and Appetite-Related Hormones Pre and Post Obesity Surgery|Functional Brain Imaging and Appetite-Related Hormones Pre and Post Obesity Surgery|Unknown status|Enrolling by invitation|N/A|160|Anticipated|New York Obesity and Nutrition Research Center||5|||f||||t||||||||||2018-05-31 21:26:21.04161|2018-05-31 21:26:21.04161
NCT01583712|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2015-07-19|2012-04-23|2012-04-24|Estimate|||||||2015-07-19|2015-07-21|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Endomicroscopy and Graft-versus-host Disease|Diagnosis of Acute Gastrointestinal Graft-versus-Host Disease by Early Endomicroscopic Features of the Small Intestine|Unknown status|Recruiting|N/A|40|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 21:26:21.149651|2018-05-31 21:26:21.149651
NCT01583699|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2015-07-19|2012-04-23|2012-04-24|Estimate|||||||2015-07-19|2015-07-21|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Endomicroscopy and Gastric MALT-lymphoma|Confocal Laser Endomicroscopy as Diagnostic Tool for Gastrointestinal MALT-lymphoma|Completed||N/A|50|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 21:26:21.26536|2018-05-31 21:26:21.26536
NCT01583686|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-05-26|2012-04-20|2012-04-24|Estimate|||||||2018-05-26|2018-05-30|Actual|April 2, 2012||2012-04-02|May 21, 2018|2018-05-21|December 31, 2029|Anticipated|2029-12-31|December 4, 2028|Anticipated|2028-12-04||Interventional|||CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer|Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes|Recruiting||Phase 1/Phase 2|136|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:26:21.368651|2018-05-31 21:26:21.368651
NCT01583673|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2015-10-20|2012-04-23|2012-04-24|Estimate|||||||2015-10-20|2015-10-21|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Growth of Infants Fed an Amino Acid Infant Formula|Assessment of Growth of Infants Fed an Amino Acid Based Formula|Completed||N/A|225|Actual|Nestlé||2|||f||||t||||||||||2018-05-31 21:26:21.532676|2018-05-31 21:26:21.532676
NCT01583660|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-04-21|2012-04-21|2012-04-24|Estimate|||||||2012-04-21|2012-04-24|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Observational|||Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture|Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture|Unknown status|Recruiting||800|Anticipated|Beijing Army General Hospital|||||f||||t||||||Samples Without DNA|"~     Peripheral blood serum~   "|||2018-05-31 21:26:21.622467|2018-05-31 21:26:21.622467
NCT01583647|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2013-10-07||2015-11-02|2012-04-23|2012-04-24|Estimate|2013-10-07|2013-12-04|Estimate||||2015-11-02|2015-11-03|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)|A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia|Terminated||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||2||"In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a~   significant increase in incidence of some types of non-fatal SAEs."|f||||f||||||||||2018-05-31 21:26:21.701422|2018-05-31 21:26:21.701422
NCT01583634|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2014-10-02|2012-04-20|2012-04-24|Estimate|||||||2014-10-02|2014-10-03|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Accuracy of Oximeters With Hypoxia and Methemoglobin or Carboxyhemoglobin|Accuracy of Oximeters With Hypoxia and Methemoglobin or Carboxyhemoglobin|Completed|||9|Actual|Mespere Lifesciences Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 21:26:21.861461|2018-05-31 21:26:21.861461
NCT01583621|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-02-08|2012-04-23|2012-04-24|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2011||2011-11-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|November 2012|Actual|2012-11-30||Interventional|D-SUNNY||Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)|Vitamin D Supplementation in Overweight/Obese African American Adults and Youth (D-SUNNY)|Completed||N/A|74|Actual|Augusta University||4|||f||||||||||||||2018-05-31 21:26:21.961059|2018-05-31 21:26:21.961059
NCT01583608|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2016-12-08|2012-04-20|2012-04-24|Estimate|||||||2016-12-08|2016-12-09|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|March 2013|Actual|2013-03-31||Observational|ASSURE||ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease|ABSORB: Initial Clinical Experience With the Everolimus-eluting Bioresorbable Vascular Scaffold (BVS) System in the Treatment of de Novo Native Coronary Artery Lesions - a Surveillance Registry|Completed|||183|Actual|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|||||f||||t||||||||||2018-05-31 21:26:22.034691|2018-05-31 21:26:22.034691
NCT01583595|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-04-01|2012-04-23|2012-04-24|Estimate|||||||2013-04-01|2013-04-04|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease|Determining the Relationships Between Self-efficacy for Walking Ability, Gate Speed and Physical Activity in Patients With Chronic Lung Disease|Completed|||70|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 21:26:22.210723|2018-05-31 21:26:22.210723
NCT01583582|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-01-30|2012-04-20|2012-04-24|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MARE||Antihypertensive Effect and Safety of Peptides Derived From Coldwater Shrimp|Assessment on Antihypertensive Effect and Safety of Bioactive Peptides Derived From Coldwater Shrimp (Pandalus Borealis) in Healthy Subjects With Mild or Moderate Hypertension|Completed||Phase 2|74|Actual|Marealis AS||3|||f||||f||||||||||2018-05-31 21:26:22.286395|2018-05-31 21:26:22.286395
NCT01583569|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-10-05|2012-04-23|2012-04-24|Estimate|||||||2015-10-05|2015-10-07|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Complex Dynamic Systems in Mood Disorders|Complex Dynamic Systems in Mood Disorders|Completed|||20|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 21:26:22.384006|2018-05-31 21:26:22.384006
NCT01583556|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-04-06|2012-04-20|2012-04-24|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Optional Follow-up Visits for Common, Low-risk Arm Fractures|Optional Follow-up Visits for Common, Low-risk Arm Fractures|Completed|||120|Actual|Massachusetts General Hospital|||2||f||||t||||||None Retained|"~     n.a.~   "|||2018-05-31 21:26:22.458831|2018-05-31 21:26:22.458831
NCT01583543|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2016-03-09||2017-04-11|2012-04-23|2012-04-24|Estimate|2017-04-11|2017-05-19|Actual||||2017-04-11|2017-05-19|Actual|May 2012||2012-05-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Interventional|||Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma|Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy|Completed||Phase 2|12|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 21:26:22.556882|2018-05-31 21:26:22.556882
NCT01583530|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2012-05-22||2013-08-01|2012-04-23|2012-04-24|Estimate|2012-07-25|2012-08-28|Estimate||||2013-08-01|2013-08-07|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of Belimumab Administered Subcutaneously to Healthy Subjects|A Randomized, Parallel-Group, Open-Label Study to Evaluate the Absolute Bioavailability, Pharmacokinetics, Tolerability and Safety of a High Concentration Formulation of Belimumab (HGS1006), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Healthy Subjects|Completed||Phase 1|118|Actual|Human Genome Sciences Inc.||6|||f||||f||||||||||2018-05-31 21:26:22.844642|2018-05-31 21:26:22.844642
NCT01583517|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2014-10-08|2012-04-23|2012-04-24|Estimate|||||||2014-10-08|2014-10-10|Estimate|September 1997||1997-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|April 2012|Actual|2012-04-30||Interventional|||ERCP in Idiopathic Recurrent Acute Pancreatitis|Defining the Role of ERCP in the Evaluation and Treatment of Idiopathic Recurrent Acute Pancreatitis|Completed||N/A|89|Actual|Indiana University||4|||f||||f||||||||||2018-05-31 21:26:23.99887|2018-05-31 21:26:23.99887
NCT01583504|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-04-23|2012-04-23|2012-04-24|Estimate|||||||2012-04-23|2012-04-24|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Interventional|||High Volume Saline Injections for Achilles Tendinopathy|A Double Blind, Randomised Controlled Trial of High Volume Saline Injections for Chronic Midportion Achilles Tendinopathy|Unknown status|Recruiting|N/A|44|Anticipated|Leeds Comunity Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 21:26:24.080736|2018-05-31 21:26:24.080736
NCT01583491|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-04-24|2012-04-23|2012-04-24|Estimate|||||||2012-04-24|2012-04-25|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Interventional|||Evaluation of Platelet Rich Fibrin on Reduction of Periodontal Problems After Surgical Removal of Mandibular Third Molar|Evaluation of Platelet Rich Fibrin Efficacy on Reduction of Periodontal Problems|Unknown status|Active, not recruiting|Phase 4|30|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:26:24.175746|2018-05-31 21:26:24.175746
NCT01583478|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2014-09-27|2012-04-23|2012-04-24|Estimate|||||||2014-09-27|2014-09-30|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids|An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids|Unknown status|Recruiting|Phase 4|15|Anticipated|The Maas Clinic||5|||f||||f||||||||||2018-05-31 21:26:24.243494|2018-05-31 21:26:24.243494
NCT01583465|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-23|2012-04-23|2012-04-24|Estimate|||||||2012-04-23|2012-04-24|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Aquamantys||Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty|Open Label, Randomized, Blinded Study to Evaluate the Efficacy of Aquamantys System for Reducing the Transfusion Requirements Associated With the Anterior-Supine Intermuscular (ASI) Approach for Total Hip Arthroplasty (THA)|Completed||N/A|200|Actual|Joint Implant Surgeons, Inc.||2|||f||||t||||||||||2018-05-31 21:26:24.345422|2018-05-31 21:26:24.345422
NCT01583452|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|2015-03-19||2015-06-27|2012-04-20|2012-04-24|Estimate|2015-06-27|2015-07-23|Estimate||||2015-06-27|2015-07-23|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Chewing Gum Use to Reduce Post-operative Ileus in Pediatric Patients|Use of Chewing Gum to Reduce Postoperative Ileus in Pediatric Patients After Gastrointestinal Surgery|Completed||Phase 1|41|Actual|Instituto Tecnologico y de Estudios Superiores de Monterey|We had a small number of participants because of time limitations. We included only patients with diagnosis of appendicitis and post-op appendectomy.|2|||f||||t||||||||||2018-05-31 21:26:24.441857|2018-05-31 21:26:24.441857
NCT01583439|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-03-18|2012-04-23|2012-04-24|Estimate|||||||2015-03-18|2015-03-19|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||The Mochudi Prevention Project ART Protocol|An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 ≥ 250 Cells/mm3 and HIV Virus Load ≥ 50,000 cp/mL|Terminated||N/A|11|Actual|Harvard School of Public Health||||Low Accrual.|f||||t||||||||||2018-05-31 21:26:24.765586|2018-05-31 21:26:24.765586
NCT01583426|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-10-11|2012-04-23|2012-04-24|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GeparSepto||Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)|A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)|Active, not recruiting||Phase 3|1200|Anticipated|German Breast Group||2|||f||||t||||||||||2018-05-31 21:26:24.843486|2018-05-31 21:26:24.843486
NCT01583413|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-10-10|2012-04-23|2012-04-24|Estimate|||||||2013-10-10|2013-10-11|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||CDC Prevention Epicenters Wake Up and Breathe Collaborative|CDC Prevention Epicenters Wake Up and Breathe Collaborative|Completed||N/A|3342|Actual|Harvard Pilgrim Health Care||1|||f||||f||||||||||2018-05-31 21:26:24.954683|2018-05-31 21:26:24.954683
NCT01583400|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2014-09-17|2012-04-20|2012-04-24|Estimate|||||||2014-09-17|2014-09-18|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial|Development and Evaluation of Enhanced Digital Health Coaching Program for Depressive Symptoms to Support Collaborative Depression Treatment in Primary Care: The RESPECT-D-E (Enhanced) Trial|Completed||N/A|131|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 21:26:25.062848|2018-05-31 21:26:25.062848
NCT01583387|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-10-07|2012-04-23|2012-04-24|Estimate|||||||2016-10-07|2016-10-10|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Water Intake on the DNA Adducts Formation|Proof of Concept of the Effect of Water Intake on the DNA Adducts Formation|Completed||N/A|65|Actual|Danone Research||2|||f||||||||||||||2018-05-31 21:26:25.16653|2018-05-31 21:26:25.16653
NCT01583374|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2015-02-24||2018-04-20|2012-04-23|2012-04-24|Estimate|2015-03-05|2015-03-17|Estimate||||2018-04-20|2018-04-24|Actual|May 2, 2012|Actual|2012-05-02|April 2018|2018-04-30|October 2, 2018|Anticipated|2018-10-02|February 24, 2014|Actual|2014-02-24||Interventional|POSTURE|Modified Intent to Treat (mITT) were all participants who were randomized and received at least one dose of investigational product (IP)|Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis|A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS|Active, not recruiting||Phase 3|490|Actual|Celgene||3|||f||||t||||||||||2018-05-31 21:26:25.281677|2018-05-31 21:26:25.281677
NCT01583361|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-23|2012-04-23|2012-04-24|Estimate|||||||2012-04-23|2012-04-24|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|January 2017|Anticipated|2017-01-31|September 2014|Anticipated|2014-09-30||Interventional|RESONANCE||SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer|Phase III, Randomized, Multicenter, Controlled Evaluation of S‐1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients|Unknown status|Recruiting|Phase 3|772|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 21:26:25.914408|2018-05-31 21:26:25.914408
NCT01583348|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-04-28|2012-04-23|2012-04-24|Estimate|||||||2013-04-28|2013-04-30|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Observational|||Technical Feasibility of Routine Intraoperative Cholangiography During Elective Rigid-hybrid Transvaginal Natural Orifice Transluminal Endoscopic Cholecystectomy|An Open Case Series About Technical Feasibility of Routine Intraoperative Cholangiography (IOC) During Elective Rigid-hybrid Transvaginal Natural Orifice Transluminal Endoscopic Cholecystectomy (tvNCC)|Completed|||33|Actual|Cantonal Hosptal, Baselland|||1||f||||f||||||||||2018-05-31 21:26:25.996367|2018-05-31 21:26:25.996367
NCT01583335|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2015-01-27|2012-04-20|2012-04-24|Estimate|||||||2015-01-27|2015-01-28|Estimate|May 2009||2009-05-31|January 2015|2015-01-31|December 2020|Anticipated|2020-12-31|August 2012|Actual|2012-08-31||Interventional|||The Healthy Start Project: Primary Prevention of Overweight in Preschool Children Predisposed to Future Overweight|Prevention of Weight Gain Among Normal Weight, High Risk, Pre-school Children - a Randomized Controlled Interventions Study.|Active, not recruiting||N/A|1100|Anticipated|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 21:26:26.067181|2018-05-31 21:26:26.067181
NCT01583322|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-03-15|2012-04-23|2012-04-24|Estimate|||||||2016-03-15|2016-03-17|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|CHIVA||Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer|Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum|Completed||Phase 2|188|Actual|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-05-31 21:26:26.149792|2018-05-31 21:26:26.149792
NCT01583309|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-04-23|2012-04-23|2012-04-24|Estimate|||||||2012-04-23|2012-04-24|Estimate|November 2003||2003-11-30|April 2012|2012-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|ECTDP||Effects of Convective Therapies in Dialysis Patients|Effects of Convective Therapies in Dialysis Patients|Completed||Phase 3|146|Actual|A. Manzoni Hospital||3|||f||||f||||||||||2018-05-31 21:26:26.353242|2018-05-31 21:26:26.353242
NCT01583296|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2018-02-15|2012-04-23|2012-04-24|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2010||2010-07-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LUCHAR||LUCHAR - Latinos Using Counseling for Help With Asthma and Anxiety Reduction|Adaptation of a Behavioral Treatment for Latinos With Panic Disorder and Asthma|Completed||N/A|53|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 21:26:26.502806|2018-05-31 21:26:26.502806
NCT01583283|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2018-04-30|2012-04-20|2012-04-24|Estimate|||||||2018-04-30|2018-05-01|Actual|July 12, 2012|Actual|2012-07-12|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 30, 2018|Anticipated|2018-08-30||Interventional|||Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma|A Phase I/II, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|38|Actual|Celgene||1|||f||||f||||||||Yes|Clinical Study Report|2018-05-31 21:26:26.589101|2018-05-31 21:26:26.589101
NCT01583270|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2013-06-18|2012-04-23|2012-04-24|Estimate|||||||2013-06-18|2013-06-19|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Arabinoxylan and Rye Kernels on Second Meal Responses|Effect of Arabinoxylan and Rye Kernels on Second Meal Responses in Subjects With the Metabolic Syndrome|Completed||N/A|15|Actual|Aarhus University Hospital||4|||f||||f||||||||||2018-05-31 21:26:26.674832|2018-05-31 21:26:26.674832
NCT01583257|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2015-05-14|2012-04-20|2012-04-23|Estimate|||||||2015-05-14|2015-05-15|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pilot Study: Active Video Gaming to Facilitate Physical Activity and Quality of Life in Kidney Transplant Recipients|Pilot Study: Active Video Gaming to Facilitate Physical Activity and Quality of Life in Kidney Transplant Recipients|Completed||Phase 1/Phase 2|10|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 21:26:26.756851|2018-05-31 21:26:26.756851
NCT01583244|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-05-10|2012-04-20|2012-04-23|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Korean Post-marketing Surveillance for Orencia®|Korean Post-marketing Surveillance for Orencia®|Completed|||701|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 21:26:26.810709|2018-05-31 21:26:26.810709
NCT01583231|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-12-18|2012-04-19|2012-04-23|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy of the Brushless Scrub|Efficacy of the Brushless Scrub|Completed||N/A|100|Actual|Winthrop University Hospital||2|||f||||f||||||||||2018-05-31 21:26:26.945868|2018-05-31 21:26:26.945868
NCT01583218|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2017-07-19||2017-09-18|2012-04-19|2012-04-23|Estimate|2017-09-18|2017-09-20|Actual||||2017-09-18|2017-09-20|Actual|March 2012||2012-03-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|APEX|All randomized subjects|Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)|(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients|Completed||Phase 3|7513|Actual|Portola Pharmaceuticals||2|||f||||t||||||||||2018-05-31 21:26:27.132995|2018-05-31 21:26:27.132995
NCT01583205|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-11-07|2012-04-19|2012-04-23|Estimate|||||||2014-11-07|2014-11-10|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Coping Effectiveness Training for ALS|Coping Effectiveness Training for Recently Diagnosed ALS Patients and Care Partners|Withdrawn||N/A|0|Actual|Research Foundation for Mental Hygiene, Inc.||1||The study was not funded.|f||||f||||||||||2018-05-31 21:26:29.542254|2018-05-31 21:26:29.542254
NCT01583192|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2014-06-06|2012-04-19|2012-04-23|Estimate|||||||2014-06-06|2014-06-09|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Chloridehexidine Versus Povidine Jodine Both Soluted in Alcohol in Forefoot Surgery|Prospective Study of Chloridehexidine/Alcohol Versus Jodine/Povidine in Forefoot Surgery|Completed||Phase 3|52|Actual|St. Antonius Hospital||2|||f||||f||||||||||2018-05-31 21:26:29.617418|2018-05-31 21:26:29.617418
NCT01583179|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-01-06|2012-04-19|2012-04-23|Estimate|||||||2016-01-06|2016-01-08|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|March 2014|Actual|2014-03-31||Interventional|||Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution|Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution|Terminated||N/A|22|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 21:26:29.828293|2018-05-31 21:26:29.828293
NCT01583166|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-10-30|2012-04-19|2012-04-23|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2012||2012-03-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|URINE&ME||Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial|Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial|Completed||N/A|50|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 21:26:29.910461|2018-05-31 21:26:29.910461
NCT01583153|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-04-13|2012-04-19|2012-04-23|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HIHO||The HIHO Study: Hospital Inpatient vs Home Rehabilitation After Total Knee Replacement|Randomised Controlled Trial Comparing Hospital Inpatient vs Home Rehabilitation After Total Knee|Completed||N/A|165|Actual|South West Sydney Local Health District||2|||f||||t||||||||||2018-05-31 21:26:30.010617|2018-05-31 21:26:30.010617
NCT01583140|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-01-24|2012-04-19|2012-04-23|Estimate|||||||2013-01-24|2013-01-28|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Seamos Saludables - Physical Activity Intervention Study for Latinas|Culturally and Linguistically Adapted Physical Activity Intervention for Latinas (Seamos Saludables)|Completed||N/A|312|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:26:30.098747|2018-05-31 21:26:30.098747
NCT01583127|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-02-23|2012-04-20|2012-04-23|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2002||2002-09-30|February 2016|2016-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Examining Variation in the Impact of School-Wide Positive Behavioral Interventions and Supports (PBIS)|Examining Variation in the Impact of School-Wide Positive Behavioral Interventions and Supports (PBIS)|Completed||N/A|32986|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:26:30.176937|2018-05-31 21:26:30.176937
NCT01583114|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-02-23|2012-04-19|2012-04-23|Estimate|||||||2016-02-23|2016-02-24|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PRECARDIA||PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors|Preventive Effect of ACE Inhibitor Perindopril)on the Onset or Progression of Left Ventricular Dysfoction in Subjects at a Preclinical Stage From Families With Dilated Cardiomyopathy|Terminated||Phase 3|6|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2||recruitement problem|f||||t||||||||||2018-05-31 21:26:30.265443|2018-05-31 21:26:30.265443
NCT01583101|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2016-12-08||2017-04-10|2012-04-19|2012-04-23|Estimate|2017-02-02|2017-03-23|Actual||||2017-04-10|2017-05-15|Actual|April 2012||2012-04-30|April 2017|2017-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Child Health Improvement Through Computer Automation (CHICA) Highlighting Study|Increasing Prompt Response Rates in the CHICA System|Completed||N/A|2237|Actual|Indiana University||2|||f||||f||||||||No||2018-05-31 21:26:30.458697|2018-05-31 21:26:30.458697
NCT01583088|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2015-12-21|2012-04-20|2012-04-23|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|RespiStimALS||Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation|Can Diaphragm Pacing Delay Non Invasive Ventilation in Amyotrophic Lateral Sclerosis ? a Randomized Controlled Study|Terminated||Phase 3|74|Actual|Assistance Publique - Hôpitaux de Paris||2||"in the absence of benefits and because of a statistically significant excess mortality in the~   group of patients receiving active stimulation."|f||||t||||||||||2018-05-31 21:26:30.694907|2018-05-31 21:26:30.694907
NCT01583075|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-04-23|2012-04-20|2012-04-23|Estimate|||||||2012-04-23|2012-04-24|Estimate|December 2009||2009-12-31|April 2012|2012-04-30||||March 2011|Actual|2011-03-31||Interventional|||Pulmonary Vein Ablation of Atrial Fibrillation Using Magnetic Navigation: Single Ring Versus Circumferential Techniques|"Pulmonary Vein Ablation With Magnetic Navigation in Patients With Therapy-refractory Symptomatic Atrial Fibrillation: Comparison of Single Ring and Circumferential Ablation Techniques"|Completed||N/A|80|Actual|University Medical Center Goettingen||2|||f||||f||||||||||2018-05-31 21:26:30.780793|2018-05-31 21:26:30.780793
NCT01583062|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-07-12|2012-04-20|2012-04-23|Estimate|||||||2013-07-12|2013-07-15|Estimate|January 2006||2006-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures|Duration of Postoperative Antibiotic Prophylaxis in Facial Fractures (Mandibular Fractures, Zygomaticoorbital Fractures, Isolated Orbital Blow-out Fractures and LeFort I/II/III Fractures): 1 Day vs. 5 Days: a Prospective, Randomized, Double Blind and Placebo Controlled Study (Phase IV)|Terminated||Phase 4|217|Actual|University Hospital Inselspital, Berne||2||Limited number of patients|f||||t||||||||||2018-05-31 21:26:30.866373|2018-05-31 21:26:30.866373
NCT01583049|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-09-08|2012-04-20|2012-04-23|Estimate|||||||2017-09-08|2017-09-11|Actual|March 2012|Actual|2012-03-31|September 2017|2017-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Post Authorisation Safety Study of Triaxis as a 5th Dose in 4-6 Year Old Spanish Children|Observational Post Authorisation Safety Study to Describe the Safety Profile of the Diphtheria, Tetanus, Acellular Pertussis Combination Vaccine, Reduced Antigen Content (Triaxis) as a 5th Dose in 4-6 Year Old Spanish Children|Completed|||556|Actual|Sanofi|||||f||||f||||||||||2018-05-31 21:26:30.979319|2018-05-31 21:26:30.979319
NCT01583036|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2018-05-17|2012-04-19|2012-04-23|Estimate|||||||2018-05-17|2018-05-21|Actual|January 16, 2012|Actual|2012-01-16|May 2018|2018-05-31|April 17, 2012|Actual|2012-04-17|April 17, 2012|Actual|2012-04-17||Interventional|||An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed|An Interaction Study to Assess the Effect of the Ezogabine/Retigabine and the Main Metabolite NAMR on the Pharmacokinetics of Digoxin in Healthy Volunteers|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:26:31.080332|2018-05-31 21:26:31.080332
NCT01583023|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2014-03-31|2012-04-19|2012-04-23|Estimate|||||||2014-03-31|2014-04-01|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression|Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression|Unknown status|Not yet recruiting|Phase 4|45|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-05-31 21:26:31.200593|2018-05-31 21:26:31.200593
NCT01583010|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2012-04-20|2012-04-20|2012-04-23|Estimate|||||||2012-04-20|2012-04-23|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Improvement of Needle Visibility in Ultrasound Guided Regional Anaesthesia|"Improvement of Needle Visibility in In-line Regional Anaesthesia by Advanced Needle Visualization Technology ®"|Unknown status|Recruiting|N/A|100|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:26:31.30099|2018-05-31 21:26:31.30099
NCT01582997|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-11-08|2012-04-19|2012-04-23|Estimate|||||||2017-11-08|2017-11-13|Actual|May 11, 2012|Actual|2012-05-11|November 2017|2017-11-30|April 16, 2015|Actual|2015-04-16|August 1, 2014|Actual|2014-08-01||Interventional|||A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors|An Open-label, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of GSK2118436 in Japanese Subjects With BRAF V600 Mutation Positive Solid Tumors|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:26:31.426792|2018-05-31 21:26:31.426792
NCT01582984|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-21|2012-04-19|2012-04-23|Estimate|||||||2012-04-21|2012-04-24|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Patient Understanding and Satisfaction in Informed Consent for Total Knee Arthroplasty|Patient Understanding and Satisfaction in Informed Consent for Total Knee Arthroplasty|Completed||N/A|176|Actual|Minneapolis Veterans Affairs Medical Center||3|||f||||f||||||||||2018-05-31 21:26:31.519284|2018-05-31 21:26:31.519284
NCT01582971|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2017-03-21||2018-03-20|2012-04-19|2012-04-23|Estimate|2017-08-15|2017-10-02|Actual||||2018-03-20|2018-04-18|Actual|April 17, 2012||2012-04-17|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 1, 2016|Actual|2016-05-01||Interventional|||Home-Based Symptom Management Via Reflexology for Breast Cancer Patients|Home-Based Symptom Management Via Reflexology for Breast Cancer Patients|Completed||N/A|256|Actual|Michigan State University||2|||f||||t||||||||No||2018-05-31 21:26:31.608525|2018-05-31 21:26:31.608525
NCT01582958|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-14|||2015-10-06|2012-04-20|2012-04-23|Estimate|||||||2015-10-06|2015-10-08|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of OMT on Patients With COPD: Correlating Pulmonary Function Tests With Biochemical Alterations|The Effect of Osteopathic Manipulative Treatment on Patients With Chronic Obstructive Pulmonary Disease:Correlating Pulmonary Function Tests With Biochemical Alterations|Completed||N/A|45|Actual|Michigan State University||3|||f||||f||||||||||2018-05-31 21:26:32.072985|2018-05-31 21:26:32.072985
NCT01582945|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2017-03-02||2017-04-18|2012-04-19|2012-04-23|Estimate|2017-04-18|2017-04-20|Actual||||2017-04-18|2017-04-20|Actual|April 2012||2012-04-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Ketamine Infusion for Treatment-resistant Major Depressive Disorder|N-methyl-D-aspartate Antagonist (Ketamine) Infusion for Treatment-resistant Major Depressive Disorder With Suicidal Ideation|Completed||N/A|14|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:26:32.38549|2018-05-31 21:26:32.38549
NCT01582932|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2018-05-18|2012-04-19|2012-04-23|Estimate|||||||2018-05-18|2018-05-22|Actual|April 2013||2013-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis|A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis|Recruiting||Phase 1|75|Anticipated|Mayne Pharma International Pty Ltd||1|||f||||f|t|||||||||2018-05-31 21:26:33.038634|2018-05-31 21:26:33.038634
NCT01582919|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-03-31|2012-04-20|2012-04-23|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2012|Actual|2012-09-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AMIMAGE 2||Neuroimaging Markers of Alzheimer Disease: a Longitudinal Population Study|STUDY OF IMAGING MARKERS IN THE VERY EARLY STAGES OF DEMENTIA AMONG RETIRED RURAL FARM IN THE GIRONDE AND PARTICIPATING IN THE AMI COHORT EPIDEMIOLOGY: A LONGITUDINAL STUDY.|Completed||N/A|304|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 21:26:33.198933|2018-05-31 21:26:33.198933
NCT01582906|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-11-21|2012-04-20|2012-04-23|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2011|Actual|2011-08-31|November 2017|2017-11-30|April 2015|Actual|2015-04-30|March 2014|Actual|2014-03-31||Observational|||A Survivorship Care Plan for Gynaecological Cancer Patients|Does a Post Treatment Survivorship Care Plan Improve Gynaecological Cancer Patient's Quality of Life and Self Efficacy? A Mixed Methods Pilot Study.|Completed|||150|Actual|Royal Marsden NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 21:26:33.283846|2018-05-31 21:26:33.283846
NCT01582893|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-04-04|2012-04-19|2012-04-23|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2012||2012-04-30|April 2017|2017-04-30|July 2013|Actual|2013-07-31|October 2012|Actual|2012-10-31||Interventional|PERCI||Permeability Enhancement to Reduce Chronic Inflammation|Permeability Enhancement to Reduce Chronic Inflammation|Completed||N/A|50|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 21:26:33.347528|2018-05-31 21:26:33.347528
NCT01582880|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2017-03-21||2017-09-14|2012-04-19|2012-04-23|Estimate|2017-06-28|2017-07-24|Actual||||2017-09-14|2017-09-18|Actual|March 2012||2012-03-31|September 2017|2017-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis|The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis|Completed||Phase 1/Phase 2|1|Actual|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||No||2018-05-31 21:26:33.44482|2018-05-31 21:26:33.44482
NCT01582867|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-04-19|2012-04-19|2012-04-23|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2012||2012-05-31|March 2017|2017-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SOCRATHE||HemoControl System Activated in Hemodiafiltration Treatments|Studio Cross-Over Controllato Randomizzato Sul Dispositivo ArTis Con Hemocontrol in Emodiafiltrazione - SOCRATHE|Completed||N/A|7|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 21:26:33.785262|2018-05-31 21:26:33.785262
NCT01582854|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|2016-01-23||2016-01-23|2012-04-20|2012-04-23|Estimate|2016-01-23|2016-02-22|Estimate||||2016-01-23|2016-02-22|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ARTEMIDA||Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)|A 12-month, International, Parallel Group, Randomised, Multi-centre, Double-blind, Placebo-controlled Trial to Examine the Effect of Actovegin® Treatment Given First Intravenously and Subsequently Orally Over 6 Months, in Subjects With Post-stroke Cognitive Impairment (PSCI).|Completed||Phase 3|503|Actual|Takeda||2|||f||||f||||||||||2018-05-31 21:26:33.920993|2018-05-31 21:26:33.920993
NCT01582841|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-08-29|2012-04-20|2012-04-23|Estimate|||||||2016-08-29|2016-08-31|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|HNPCC||Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting|Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting|Completed||N/A|247|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 21:26:34.995851|2018-05-31 21:26:34.995851
NCT01582828|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2016-07-06|2012-04-20|2012-04-23|Estimate|||||||2016-07-06|2016-07-07|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|SHAFT||Serial Hybrid Atrial Fibrillation Ablation|Serial Hybrid Atrial Fibrillation Ablation|Recruiting||N/A|162|Anticipated|Medisch Spectrum Twente||2|||f||||f||||||||||2018-05-31 21:26:35.107084|2018-05-31 21:26:35.107084
NCT01582815|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2015-06-15|2012-04-20|2012-04-23|Estimate|||||||2015-06-15|2015-06-16|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms|A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults With Major Depressive Disorder With Anxiety Symptoms|Completed||Phase 2|121|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 21:26:35.214103|2018-05-31 21:26:35.214103
NCT01582802|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-01-30|2012-04-19|2012-04-23|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2011||2011-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||Determinants of Neonatal Anemia in Women Carrying Multiples|Determinants of Neonatal Iron Homeostasis in Women Carrying Multiples|Active, not recruiting|||350|Anticipated|Cornell University|||1||f||||f||||||Samples With DNA|"~     maternal and cord blood, placental tissue and RNA~   "|No||2018-05-31 21:26:35.331777|2018-05-31 21:26:35.331777
NCT01582789|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2016-02-25||2016-03-30|2012-04-19|2012-04-23|Estimate|2016-03-30|2016-05-04|Estimate||||2016-03-30|2016-05-04|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||All subjects prior to dispense of first set of study lenses|Comparative Study of Two Marketed Spherical Soft Contact Lenses|Comparative Study of Two Marketed Spherical Soft Contact Lenses|Completed||Phase 4|61|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 21:26:35.398916|2018-05-31 21:26:35.398916
NCT01582776|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-03-06|2012-04-20|2012-04-23|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2012||2012-10-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma|A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|317|Actual|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 21:26:35.841226|2018-05-31 21:26:35.841226
NCT01582763|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-01-04|2012-04-20|2012-04-23|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|June 2017|Anticipated|2017-06-30||Observational|IGOS||International Guillain-Barré Syndrome Outcome Study|International GBS Outcome Study (IGOS): A Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).|Recruiting|||4000|Anticipated|Erasmus Medical Center|||4||f||||f||||||Samples With DNA|"~     serum, cerebrospinal fluid, samples with DNA~   "|Undecided||2018-05-31 21:26:36.03704|2018-05-31 21:26:36.03704
NCT01582750|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2013-09-17|2012-04-19|2012-04-23|Estimate|||||||2013-09-17|2013-09-19|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|December 2015|Anticipated|2015-12-31|September 2014|Anticipated|2014-09-30||Observational|||Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy|Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy|Unknown status|Recruiting||40|Anticipated|Chinese Academy of Medical Sciences|||1||f||||f||||||||||2018-05-31 21:26:36.64782|2018-05-31 21:26:36.64782
NCT01582737|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2018-05-03|2012-04-20|2012-04-23|Estimate|||||||2018-05-03|2018-05-08|Actual|May 30, 2012|Actual|2012-05-30|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Xarelto [SPAF] Post-marketing Surveillance in Japan|Special Drug Use Investigation of Xarelto [SPAF]|Active, not recruiting|||11311|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:26:36.734909|2018-05-31 21:26:36.734909
NCT01582724|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2015-08-03|2012-04-19|2012-04-23|Estimate|||||||2015-08-03|2015-08-04|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|AKUD||Effectiveness of Additional Self-care Acupressure for Women With Menstrual Pain Compared to Usual Care Alone|Randomized Pragmatic Trial for Women With Menstrual Pain Comparing Additional Self-care Acupressure to Usual Care Alone|Completed||N/A|220|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:26:36.82069|2018-05-31 21:26:36.82069
NCT01582711|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2015-07-30|2012-04-19|2012-04-23|Estimate|||||||2015-07-30|2015-08-03|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|iAdhere||Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT|TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.|Completed||Phase 3|1002|Actual|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 21:26:36.90092|2018-05-31 21:26:36.90092
NCT01582698|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2015-06-23|2012-04-20|2012-04-23|Estimate|||||||2015-06-23|2015-06-24|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||TBE Seropersistence up to 10 Years After First Booster in Adults|Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults|Completed||Phase 4|243|Actual|Baxter Healthcare Corporation||1|||f||||t||||||||||2018-05-31 21:26:37.039002|2018-05-31 21:26:37.039002
NCT01582685|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2014-12-01|2012-04-19|2012-04-23|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Exercise in Breast Cancer Survivors|Exercise in Breast Cancer Survivors: Analysis of Angiogenic Profile|Withdrawn||N/A|0|Actual|University of Mississippi Medical Center||2||no patients enrolled|f||||f||||||||||2018-05-31 21:26:37.13222|2018-05-31 21:26:37.13222
NCT01582672|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-06-06|2012-04-20|2012-04-23|Estimate|||||||2017-06-06|2017-06-07|Actual|November 2012||2012-11-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|ADAPT||Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma|An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)|Active, not recruiting||Phase 3|450|Anticipated|Argos Therapeutics||2|||f||||t||||||||No||2018-05-31 21:26:37.219826|2018-05-31 21:26:37.219826
NCT01582659|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2014-12-04|2012-04-19|2012-04-20|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Outpatient Treatment of Constipation in Children|Outpatient Treatment of Constipation in Children - a Randomized Interventions Study|Completed||N/A|239|Actual|Vejle Hospital||3|||f||||f||||||||||2018-05-31 21:26:37.619417|2018-05-31 21:26:37.619417
NCT01582646|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-09-07|2012-04-19|2012-04-20|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|Bêtapain||Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain|Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain|Terminated||Phase 2|20|Actual|University Hospital, Strasbourg, France||2||difficulty of recruitment|f||||f||||||||||2018-05-31 21:26:37.710238|2018-05-31 21:26:37.710238
NCT01582633|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-06-20|2012-04-19|2012-04-20|Estimate|||||||2012-06-20|2012-06-21|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|||Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine|Assessment of Dose-sparing of Pandemic A/California/7/2009 H1N1 Influenza Vaccine Administered Intradermally by Needle-free Disposable-syringe Jet Injector (DSJI)|Unknown status|Not yet recruiting|Phase 2/Phase 3|300|Anticipated|University of Sao Paulo General Hospital||4|||f||||f||||||||||2018-05-31 21:26:37.787557|2018-05-31 21:26:37.787557
NCT01582620|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|Telestroke||Telestroke in Nordland Hospital. A Study of a Telemedicine Network in Rural Hospitals|Telestroke in Nordland Hospital: Improved Treatment of Cerebral Stroke in Small Hospitals|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital of North Norway|||||f||||f||||||||||2018-05-31 21:26:37.873334|2018-05-31 21:26:37.873334
NCT01582607|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-14|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Interventional|||Subarachnoid Administration of Levobupivacaine for Cesarean Section|Intrathecal Plain Bupivacaine, Ropivacaine and Levo-bupivacaine With or Without Fentanyl for Elective c Section.|Unknown status|Recruiting|Phase 2/Phase 3|130|Anticipated|University of Patras||6|||f||||t||||||||||2018-05-31 21:26:37.963558|2018-05-31 21:26:37.963558
NCT01582594|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2013-06-27|2012-04-19|2012-04-20|Estimate|||||||2013-06-27|2013-06-28|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Observational|||A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection|A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection|Terminated|||795|Actual|Johnson & Johnson Medical, China||||Sponsor's decision|f||||f||||||Samples With DNA|"~     A minimum of 1000 qualified specimens shall be collected, including at least 350 anti-HCV~     seropositive specimens.~      To further evaluate RIBA test specificity in HAV IgG positive, HBsAg positive, HEV IgG~     positive and anti-HIV positive specimens, approximately 30 specimens of each viral infection~     will be included in the study.~      A minimum of 60 matched plasma and serum specimens will be collected to evaluate the~     applicability of the investigational product on different types of samples, including at~     least 30% of anti-HCV seropositive specimens.~   "|||2018-05-31 21:26:38.06699|2018-05-31 21:26:38.06699
NCT01582581|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2015-04-29|2012-04-19|2012-04-20|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|iTAD||Study of Technology-assisted Treatment of Adolescent Depression|Information Technology Enabled Treatment of Adolescent Depression|Completed||N/A|45|Actual|iHope Network, Inc.||2|||f||||t||||||||||2018-05-31 21:26:38.210299|2018-05-31 21:26:38.210299
NCT01582568|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-02-17|2012-04-19|2012-04-20|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|EUS||EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment|EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment|Terminated|||1|Actual|Baylor College of Medicine|||1|Not enough subjects to reach accrual goals.|f||||t||||||||No||2018-05-31 21:26:38.296666|2018-05-31 21:26:38.296666
NCT01582555|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|June 2012||2012-06-30|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Postoperative Nasal Irrigation Using Mucolytic Agents|Postoperative Nasal Irrigation Using Mucolytic Agents in Patients Undergoing Endoscopic Sinus Surgery|Unknown status|Not yet recruiting|N/A|44|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 21:26:38.384319|2018-05-31 21:26:38.384319
NCT01582542|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction|Usage of Desmopressin fo Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Orthotopic Bladder Reconstruction|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 21:26:38.492136|2018-05-31 21:26:38.492136
NCT01582529|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2018-02-27|2012-04-19|2012-04-20|Estimate|||||||2018-02-27|2018-03-01|Actual|June 2012|Actual|2012-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||SVRII Family Factors Study|The Impact of Family Factors on Developmental and Psychosocial Outcomes in Children With Hypoplastic Left Heart Syndrome (HLHS) at 6 Years of Age - Pediatric Heart Network Single Ventricle Reconstruction Extension (SVR II) Ancillary Study|Active, not recruiting|||187|Actual|Medical College of Wisconsin|||||f||||t||||||||||2018-05-31 21:26:38.579999|2018-05-31 21:26:38.579999
NCT01582516|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2015-03-06|2012-04-19|2012-04-20|Estimate|||||||2015-03-06|2015-03-09|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma|A Phase I/II Trial of a Conditionally Replication-competent Adenovirus (Delta-24-rgd) Administered by Convection Enhanced Delivery in Patients With Recurrent Glioblastoma|Completed||Phase 1/Phase 2|20|Actual|Erasmus Medical Center||1|||f||||t||||||||||2018-05-31 21:26:38.666229|2018-05-31 21:26:38.666229
NCT01582503|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19||2016-08-09|2016-11-01|2012-04-19|2012-04-20|Estimate||||2016-08-09|2016-08-11|Estimate|2016-11-01|2016-11-02|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Dosing Regimens of MEMP1972A in Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA)|Completed||Phase 2|578|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 21:26:38.753241|2018-05-31 21:26:38.753241
NCT01582490|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2014-04-29||2014-05-31|2012-04-19|2012-04-20|Estimate|2014-05-31|2014-07-02|Estimate||||2014-05-31|2014-07-02|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||19 subjects were enrolled, 9 in the Infiltration - EXPAREL group and 10 in the Instillation - EXPAREL group.|Study of EXPAREL in Patients Undergoing Breast Augmentation|Evaluation of the Safety and Efficacy of EXPAREL® (Bupivacaine Liposome Injectable Suspension) When Administered Via Infiltration Versus Instillation in Subjects Undergoing Bilateral Augmentation Mammoplasty|Completed||Phase 4|19|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 21:26:39.045675|2018-05-31 21:26:39.045675
NCT01582477|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2013-02-26||2013-05-05|2012-04-19|2012-04-20|Estimate|2013-05-05|2013-06-10|Estimate||||2013-05-05|2013-06-10|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|TAP||TAP-patients With Robotic Assisted Lap Prostatectomy|Evaluation of the Safety and Efficacy of EXPAREL When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) for Prolonged Postsurgical Analgesia in Subjects Undergoing Robot-assisted Laparoscopic Prostatectomy|Completed||Phase 4|24|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 21:26:39.491749|2018-05-31 21:26:39.491749
NCT01582464|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-05-06|2012-04-19|2012-04-20|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|AAIU-PHOA||Addressing Attitudes to Improve Use of Protective Headwear in Older Adults|Effect of Social Marketing on Attitudes Towards Protective Headwear in Older Adults to Reduce Traumatic Brain Injury|Completed|||37|Actual|University of California, Los Angeles|||1||f||||f||||||||No|all data shared will be de-identified|2018-05-31 21:26:39.780161|2018-05-31 21:26:39.780161
NCT01582451|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2018-03-17|2014-04-14|2018-03-17|2012-04-19|2012-04-20|Estimate|2018-03-17|2018-04-20|Actual|2014-04-14|2014-05-07|Estimate|2018-03-17|2018-04-20|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|IMAGINE 5|All randomized participants.|A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus|A Comparison of LY2605541 Versus Insulin Glargine Alone or in Combination With Pre-study Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin: An Open-Label, Randomized Study The IMAGINE 5 Study|Completed||Phase 3|466|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 21:26:39.885799|2018-05-31 21:26:39.885799
NCT01582438|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-03-07|2012-04-19|2012-04-20|Estimate|||||||2017-03-07|2017-03-10|Actual|November 2012||2012-11-30|March 2017|2017-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Expanded Access|||An Open Label Access Study For Subjects Who Completed A1481156|A Local, Multicentre, Open Label Access Study, To Provide Sildenafil Therapy For Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil For Subjects In India|No longer available|||||Pfizer|||||f||||||||||||||2018-05-31 21:26:41.143371|2018-05-31 21:26:41.143371
NCT01582425|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-06-28|2012-04-19|2012-04-20|Estimate|||||||2012-06-28|2012-07-02|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Drug Interaction Study of Isavuconazole and Methadone|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Methadone in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:26:41.240494|2018-05-31 21:26:41.240494
NCT01582412|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2015-08-31|2012-04-19|2012-04-20|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Drug Interaction Study of Isavuconazole and Digoxin|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Digoxin in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:26:41.363253|2018-05-31 21:26:41.363253
NCT01582399|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-12-07|2012-04-19|2012-04-20|Estimate|||||||2012-12-07|2012-12-10|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240|A Phase 1 Single-Dose, Parallel Group, Randomized, Open-Label Study to Determine the Absolute Bioavailability of ASKP1240 After Intravenous and Subcutaneous Administration in Healthy Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:26:41.493791|2018-05-31 21:26:41.493791
NCT01582386|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-09-26|2012-04-19|2012-04-20|Estimate|||||||2017-09-26|2017-09-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:26:41.587541|2018-05-31 21:26:41.587541
NCT01582373|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2014-12-01|2012-04-19|2012-04-20|Estimate|||||||2014-12-01|2014-12-03|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|May 2013|Actual|2013-05-31||Interventional|||Pilot Study to Assess the Efficacy of Cognitive-behavioral Couple Therapy for Provoked Vestibulodynia|Pilot Study to Assess the Efficacy of an Experimental 12-week Cognitive-behavioral Couple Therapy in the Treatment of Provoked Vestibulodynia|Completed||N/A|9|Actual|Université de Montréal||1|||f||||f||||||||||2018-05-31 21:26:41.644441|2018-05-31 21:26:41.644441
NCT01582360|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2015-10-14|2012-04-19|2012-04-20|Estimate|||||||2015-10-14|2015-10-16|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|PharmacoCRRT||2012_PharmacoCRRT-study:Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT)|Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT) or Without CRRT|Unknown status|Recruiting||640|Anticipated|Oslo University Hospital|||8||f||||t||||||||||2018-05-31 21:26:41.740603|2018-05-31 21:26:41.740603
NCT01582347|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18||2015-08-07|2017-01-19|2012-04-19|2012-04-20|Estimate||||2015-08-07|2015-08-24|Estimate|2017-01-19|2017-01-20|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Transfer of Subjects From Subutex/Suboxone to RBP-6300|A Randomized, Double-blind, Double-dummy, Active-drug-controlled, Parallel-group, Multicentre Acceptability and Safety Study of the Transfer From Subutex/Suboxone to RBP-6300 in Opioid-dependent Subjects|Completed||Phase 2|143|Actual|Indivior Inc.||2|||f||||t||||||||||2018-05-31 21:26:41.86456|2018-05-31 21:26:41.86456
NCT01582334|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-12-22|2012-04-19|2012-04-20|Estimate|||||||2017-12-22|2017-12-26|Actual|March 31, 2013|Actual|2013-03-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS ARG||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina|"Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Argentina"|Completed|||68|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 21:26:42.043086|2018-05-31 21:26:42.043086
NCT01582321|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-06-12|2012-04-19|2012-04-20|Estimate|||||||2017-06-12|2017-06-14|Actual|March 2012||2012-03-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Investigation of the Influence of Gender on Cardiovascular Function|Investigation of the Influence of Gender on Cardiovascular Function and Inflammation|Completed||Early Phase 1|56|Anticipated|Queen Mary University of London||4|||f||||f||||||||||2018-05-31 21:26:42.117804|2018-05-31 21:26:42.117804
NCT01582308|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2013-12-04||2017-04-28|2012-04-19|2012-04-20|Estimate|2013-12-04|2014-01-22|Estimate||||2017-04-28|2017-05-30|Actual|June 21, 2012|Actual|2012-06-21|April 2017|2017-04-30|December 14, 2012|Actual|2012-12-14|December 4, 2012|Actual|2012-12-04||Interventional|||A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)|A Study to Assess and Compare the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:26:42.236388|2018-05-31 21:26:42.236388
NCT01582295|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-05-23|2012-04-19|2012-04-20|Estimate|||||||2017-05-23|2017-05-25|Actual|June 2012|Actual|2012-06-30|May 2017|2017-05-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease|Dose Finding Pilot Study of Cabozantinib (XL184) Administered Orally as Monotherapy for the Treatment of Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With Bone Disease|Completed||Phase 1|4|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:26:42.7362|2018-05-31 21:26:42.7362
NCT01582282|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2012-10-03||2012-11-08|2012-04-19|2012-04-20|Estimate|2012-10-03|2012-11-02|Estimate||||2012-11-08|2012-11-15|Estimate|May 1988||1988-05-31|November 2012|2012-11-30|January 1990|Actual|1990-01-31|January 1990|Actual|1990-01-31||Interventional|||Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects|A Clinical Study to Determine the Ability of Metamucil to Reduce Fasting Blood Glucose and HbA1c Levels in Type II NIDDM|Terminated||Phase 4|37|Actual|Procter and Gamble||3||due to slow enrollment|f||||f||||||||||2018-05-31 21:26:42.82481|2018-05-31 21:26:42.82481
NCT01582269|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19||2014-09-29|2017-11-16|2012-04-19|2012-04-20|Estimate||||2014-09-29|2014-10-08|Estimate|2017-11-16|2017-11-20|Actual|April 2012||2012-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2014|Actual|2014-07-31||Interventional|||A Study in Recurrent Glioblastoma (GB)|A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 2|180|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:26:43.422691|2018-05-31 21:26:43.422691
NCT01582256|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2012||2012-08-31|April 2012|2012-04-30|July 2015|Anticipated|2015-07-31|||||Observational|||Behavior, Neuropsychology, Neuroimage and Electrophysiology in Autistic Individuals With and Without CNVs|Behavior, Neuropsychology, Neuroimage and Electrophysiology in Autistic Individuals With and Without Copy Number Variation and Their Unaffected Siblings|Unknown status|Not yet recruiting||132|Anticipated|National Taiwan University Hospital|||6||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-05-31 21:26:43.548795|2018-05-31 21:26:43.548795
NCT01582243|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2016-09-15||2016-09-15|2012-04-19|2012-04-20|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Baseline characteristics used the Intent to Treat (ITT) population: all enrolled patients who took at least one tablet of vildagliptin plus metformin 50/500 mg, and had Baseline and at least one post treatment evaluation for efficacy measurement|Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients|A Prospective, Open-label, Interventional Study to Assess the HbA1c Change an 24-hr Glucose Fluctuation After Vildagliptin Plus Metformain (SPC) Treatment in Metformin Monotherapy Uncontrolled Type 2 Diabetes Mellitus Patients|Completed||Phase 4|40|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:26:43.630205|2018-05-31 21:26:43.630205
NCT01582230|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2013-08-29|2012-04-19|2012-04-20|Estimate|||||||2013-08-29|2013-08-30|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus|A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|293|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:26:43.84983|2018-05-31 21:26:43.84983
NCT01580826|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|March 2006||2006-03-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|February 2010|Actual|2010-02-28||Interventional|||Pasteurization of Mother's Own Milk for Preterm Infants|Pasteurization of Mother's Own Milk for Preterm Infants : a Randomized Trial.|Completed||N/A|303|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 21:27:01.482701|2018-05-31 21:27:01.482701
NCT01582217|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2015-12-22|2012-04-18|2012-04-20|Estimate|||||||2015-12-22|2015-12-23|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|TRIAGE||Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition|TRIAGE: Patients Undergoing Percutaneous Coronary Interventions to Improve Clinical Outcomes Through Optimal Platelet Inhibition|Completed|||318|Actual|Icahn School of Medicine at Mount Sinai|||3||f||||t||||||||||2018-05-31 21:26:43.951468|2018-05-31 21:26:43.951468
NCT01582204|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2018-05-30|2012-04-18|2012-04-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2012||2012-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma|Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma|Active, not recruiting||N/A|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:26:44.013112|2018-05-31 21:26:44.013112
NCT01582191|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-08-02|2012-04-19|2012-04-20|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2012|Actual|2012-05-31|August 2017|2017-08-31|May 2026|Anticipated|2026-05-31|May 2026|Anticipated|2026-05-31||Interventional|||A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer|A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer|Recruiting||Phase 1|174|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:26:44.085236|2018-05-31 21:26:44.085236
NCT01582178|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2013-06-02||2013-09-19|2012-04-19|2012-04-20|Estimate|2013-06-02|2013-08-01|Estimate||||2013-09-19|2013-09-20|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Warm Water Versus Room Temperature Water Immersion Colonoscopy|Warm Water Versus Room Temperature Water Immersion Colonoscopy - a Prospective, Randomized, Double-blind, Single-center Trial|Completed||N/A|212|Actual|Vitkovice Hospital||2|||f||||f||||||||||2018-05-31 21:26:44.162449|2018-05-31 21:26:44.162449
NCT01582165|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2016-09-26|2012-04-19|2012-04-20|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance|Microvascular Resistance in Women With Chest Pain and no or Minimal Coronary Artery Disease|Completed||Phase 4|66|Actual|Oslo University Hospital||2|||f||||f||||||||Undecided|Analyses of the study will start within a few weeks or months. Publication planned in 2017|2018-05-31 21:26:45.477094|2018-05-31 21:26:45.477094
NCT01582152|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-03-30|2012-04-18|2012-04-20|Estimate|||||||2016-03-30|2016-04-01|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma|Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma|Completed||Phase 1/Phase 2|12|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 21:26:45.567916|2018-05-31 21:26:45.567916
NCT01582139|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2014-06-27||2014-07-28|2012-04-18|2012-04-20|Estimate|2014-07-28|2014-08-15|Estimate||||2014-07-28|2014-08-15|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker|Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker|Completed||N/A|12|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 21:26:45.677043|2018-05-31 21:26:45.677043
NCT01582126|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-03-26|2012-04-19|2012-04-20|Estimate|||||||2015-03-26|2015-03-27|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Group Balance Training for People With Multiple Sclerosis|Group Balance Training for People With Multiple Sclerosis|Completed||N/A|87|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 21:26:45.950181|2018-05-31 21:26:45.950181
NCT01582113|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-05-24|2012-04-19|2012-04-20|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2012||2012-06-30|May 2017|2017-05-31|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|||Cognizin Citicoline Dosing in a Healthy Adolescent Male Population||Completed||N/A|84|Actual|University of Utah||3|||f||||t||||||||||2018-05-31 21:26:46.041725|2018-05-31 21:26:46.041725
NCT01582100|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2014-11-05||2014-11-05|2012-04-19|2012-04-20|Estimate|2014-11-05|2014-11-13|Estimate||||2014-11-05|2014-11-13|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||two subjects with GERD and nausea|Reletex for Nausea in GERD Patients|Reletex ™ Band as an Adjunct to Standard Therapy in Patients With GERD, Nausea With or Without Vomiting- A Pilot Study|Terminated||N/A|2|Actual|Northwestern University|The study was terminated due to low enrollment. One subject withdrew due to minor wrist discomfort and the other withdrew after determining the study schedule was undesirable.|1||study was terminated by investigator due to low enrollment|f||||f||||||||||2018-05-31 21:26:46.217489|2018-05-31 21:26:46.217489
NCT01582087|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-05-10|2012-04-18|2012-04-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Observational|||Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure|Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure|Unknown status|Active, not recruiting||20|Anticipated|The University of Texas Medical Branch, Galveston|||1||f||||t||||||Samples Without DNA|"~     Samples previously collected for diagnostic use which could include blood, urine, bile,~     cerebral spinal fluid, feces, liver tissue, brain tissue.~   "|||2018-05-31 21:26:46.360259|2018-05-31 21:26:46.360259
NCT01582074|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2018-04-04|2012-04-19|2012-04-20|Estimate|||||||2018-04-04|2018-04-05|Actual|July 5, 2011||2011-07-05|December 14, 2017|2017-12-14||||||||Observational|||The Ultrasound Study of Tamoxifen|The Ultrasound Study of Tamoxifen|Completed|||247|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:26:46.434275|2018-05-31 21:26:46.434275
NCT01582061|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-01-11|2012-04-19|2012-04-20|Estimate|||||||2018-01-11|2018-01-16|Actual|August 16, 2011|Actual|2011-08-16|January 2018|2018-01-31|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Interventional|||An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.|An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).|Completed||Phase 3|104|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:26:46.529563|2018-05-31 21:26:46.529563
NCT01581879|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|November 2004||2004-11-30|April 2012|2012-04-30|January 2005|Actual|2005-01-31|November 2004|Actual|2004-11-30||Interventional|||Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|38|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:26:48.593897|2018-05-31 21:26:48.593897
NCT01582048|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2018-05-02|2012-04-19|2012-04-20|Estimate|||||||2018-05-02|2018-05-08|Actual|April 2012||2012-04-30|May 2018|2018-05-31|August 17, 2016|Actual|2016-08-17|August 17, 2016|Actual|2016-08-17||Interventional|||Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning|Multicenter Phase II Study of Peritransplantation Immunosuppression Using ATG, Rituximab, Sirolimus and Mycophenolate Mofetil in Patient Receiving Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning With Fludarabine and Treosulfan|Terminated||Phase 2|9|Actual|University Hospital Tuebingen||||slow enrollment|f||||t||||||||||2018-05-31 21:26:46.751207|2018-05-31 21:26:46.751207
NCT01582035|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2014-02-14|2012-04-19|2012-04-20|Estimate|||||||2014-02-14|2014-02-17|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir|A Phase I, Open Label Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC647055 Given in Combination With Telaprevir|Completed||Phase 1|7|Actual|Janssen R&D Ireland||2|||f||||f||||||||||2018-05-31 21:26:46.842411|2018-05-31 21:26:46.842411
NCT01582022|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate||||April 2012|2012-04-30||||||||Interventional|||Evaluation of The Effect of Bupivacaine (Marcaine) in Reducing Early Post Tonsillectomy Pain|The Effect of Bupivacaine (Marcaine) in Reducing Early Post Tonsillectomy Pain|Unknown status|Not yet recruiting|Phase 4|||King Saud University||2|||f||||t||||||||||2018-05-31 21:26:46.969366|2018-05-31 21:26:46.969366
NCT01582009|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2017-04-07||2017-05-17|2012-04-19|2012-04-20|Estimate|2017-04-07|2017-05-17|Actual||||2017-05-17|2017-06-14|Actual|March 2010||2010-03-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional||All treated and eligible patients|Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate|A Phase I/II Study of the HDAC Inhibitor LBH-589 in Combination With the mTOR Inhibitor Everolimus (RAD001) in Metastatic Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|26|Actual|Roswell Park Cancer Institute||1||pts off study, PI left institute|f||||t||||||||||2018-05-31 21:26:47.065844|2018-05-31 21:26:47.065844
NCT01581996|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2017-05-08|2012-04-19|2012-04-20|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2012||2012-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Fosrenol and Phosphorus Balance - Lanthanum Carbonate|Effect of Lanthanum Carbonate (Fosrenol) on Fecal Phosphorus Excretion and Phosphorus Balance|Completed||N/A|9|Actual|Los Angeles Biomedical Research Institute||1|||f||||t||||||||||2018-05-31 21:26:47.536323|2018-05-31 21:26:47.536323
NCT01581983|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2015-07-09|2012-04-18|2012-04-20|Estimate|||||||2015-07-09|2015-07-13|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Mindfulness Meditation Format Pilot Study|Mindfulness Meditation Format Pilot Study|Completed||Phase 1|8|Actual|Oregon Health and Science University||2|||f||||||||||||||2018-05-31 21:26:47.632114|2018-05-31 21:26:47.632114
NCT01581970|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2015-07-15|2012-04-19|2012-04-20|Estimate|||||||2015-07-15|2015-07-16|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer|Potentiation of Cetuximab by Tregs Depletion With Metronomic Cyclophosphamide in Metastatic Squamous Cell Cancers of Head and Neck|Completed||Phase 2|8|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 21:26:47.724019|2018-05-31 21:26:47.724019
NCT01581957|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2014-06-26|2012-04-18|2012-04-20|Estimate|||||||2014-06-26|2014-06-27|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|SPIRIT||Pilot Study on Gastro-intestinal (GI) Enteral Nutrition (EN) Tolerance in Intensive Care Unit Patients|A Pilot Study to Evaluate the Effect of a Specific Enteral Formulation Designed to Improve Gastrointestinal Tolerance in the Critically Ill Patient|Completed||N/A|90|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 21:26:47.8291|2018-05-31 21:26:47.8291
NCT01581944|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-04-18|2012-04-18|2012-04-20|Estimate|||||||2012-04-18|2012-04-20|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Gonadotropin-releasing Hormone Agonist Prior to Myomectomy|Phase 3 Study of Experience With a Gonadotropin-releasing Hormone Agonist Prior to Myomectomy - Comparison of 2 Versus 3 Monthly Doses.|Completed||Phase 3|68|Actual|Mt. Hope Maternity Hospital||3|||f||||t||||||||||2018-05-31 21:26:47.924713|2018-05-31 21:26:47.924713
NCT01581931|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2013-06-14||2013-06-14|2012-04-19|2012-04-20|Estimate|2013-06-14|2013-08-20|Estimate||||2013-06-14|2013-08-20|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets|Bioequivalence of Metformin Under Fed Conditions After Administration of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Male and Female Volunteers, (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:26:48.043435|2018-05-31 21:26:48.043435
NCT01581918|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-23|2012-04-19|2012-04-20|Estimate|||||||2012-04-23|2012-04-24|Estimate|December 2011||2011-12-31|April 2012|2012-04-30||||March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting|PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF CARBAMAZEPINE FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING.|Unknown status|Recruiting|Phase 2|43|Anticipated|Faculdade de Medicina do ABC|||||f||||t||||||||||2018-05-31 21:26:48.325569|2018-05-31 21:26:48.325569
NCT01581905|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-01-19|2012-04-18|2012-04-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution|A Randomized Controlled Trial Comparing Conventional Laparoscopic Hysterectomy With Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution|Terminated||N/A|98|Actual|Milton S. Hershey Medical Center||2||Trial was redesigned as a new trial|f||||f||||||||||2018-05-31 21:26:48.399359|2018-05-31 21:26:48.399359
NCT01581892|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2015-08-24|2012-04-19|2012-04-20|Estimate|||||||2015-08-24|2015-08-25|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Use of Adult Bone Marrow Mononuclear Cells in Patients With Long Bone Nonunion|Treatment of Long Bone Nonunion With Autologous Bone Marrow Stem Cells. Phase I/II Study|Completed||Phase 1/Phase 2|7|Actual|Hospital Universitario Central de Asturias||1|||f||||f||||||||||2018-05-31 21:26:48.50458|2018-05-31 21:26:48.50458
NCT01581866|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|November 2004||2004-11-30|April 2012|2012-04-30|January 2005|Actual|2005-01-31|November 2004|Actual|2004-11-30||Interventional|||Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|56|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:26:48.669923|2018-05-31 21:26:48.669923
NCT01581853|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2016-10-05|2012-04-19|2012-04-20|Estimate|||||||2016-10-05|2016-10-06|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily|Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily|Completed||Phase 4|21|Actual|Hospital Universitari de Bellvitge||1|||f||||f||||||||||2018-05-31 21:26:48.73193|2018-05-31 21:26:48.73193
NCT01581840|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2016-08-02|2012-04-19|2012-04-20|Estimate|||||||2016-08-02|2016-08-03|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|June 2020|Anticipated|2020-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus|Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus|Recruiting||Phase 1/Phase 2|45|Anticipated|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-05-31 21:26:48.81519|2018-05-31 21:26:48.81519
NCT01581827|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-04-05|2012-04-18|2012-04-20|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2009||2009-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2015|Actual|2015-12-31||Observational|SHF-L||SCREEN-HFL (SCReening Evaluation of the Evolution of New Heart Failure) - a Longitudinal Study|SCREEN-HFL (SCReening Evaluation of the Evolution of New Heart Failure) - a Longitudinal Study|Completed|||3000|Actual|Monash University|||1||f||||f||||||Samples Without DNA|"~     Blood samples to measure BNP and NT-proBNP~   "|||2018-05-31 21:26:48.959079|2018-05-31 21:26:48.959079
NCT01581814|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome||Completed||Phase 3|99|Actual|Catholic University of the Sacred Heart||3|||f||||t||||||||||2018-05-31 21:26:49.102489|2018-05-31 21:26:49.102489
NCT01581801|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-02-04|2012-04-19|2012-04-20|Estimate|||||||2017-02-04|2017-02-07|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||Bariatric Surgery and Reactive Hypoglycemia|RANDOMIZED CLINICAL STUDY COMPARING THE EFFECT OF ROUX-en-Y GASTRIC BYPASS AND SLEEVE GASTRECTOMY ON REACTIVE HYPOGLYCEMIA|Completed||N/A|120|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 21:26:49.18814|2018-05-31 21:26:49.18814
NCT01581788|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Bioequivalence Study of Divalproex Sodium ER Tablets, 500 mg Under Fed Conditions|Open Label, Balanced, Randomized, Single-dose, Crossover Oral Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's and Depakote ER 500 mg Tablets of Abbott Laboratories, in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:26:49.271076|2018-05-31 21:26:49.271076
NCT01581775|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's Under Fasting Conditions|Open Label, Balanced, Randomized, Single-dose, Crossover Oral Bioequivalence Study of Divalproex Sodium ER Tablets 500 mg of Dr. Reddy's and Depakote ER 500 mg Tablets of Abbott Laboratories, in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:26:49.349362|2018-05-31 21:26:49.349362
NCT01581762|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2016-10-11|2012-04-19|2012-04-20|Estimate|||||||2016-10-11|2016-10-12|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||EUS-FNA With 22G Procore Needles vs 22G Conventional Needles|Prospective Comparative Study on Endoscopic Ultrasonography (EUS) - Guided Fine-Needle Aspiration (FNA) Using the 22G Conventional Needles or Procore Needles Without Immediate On-site Cytopathologic Examination|Completed||Phase 3|42|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:26:49.439667|2018-05-31 21:26:49.439667
NCT01581749|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-03-22|2012-04-19|2012-04-20|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer|Prospective Evaluation of Truebeam STX Stereotactic Body Radiosurgery for Low and Intermediate Risk Prostate Cancer|Recruiting||Phase 4|50|Anticipated|Main Line Health||1|||f||||f||||||||||2018-05-31 21:26:49.526973|2018-05-31 21:26:49.526973
NCT01581736|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2017-11-22|2012-04-18|2012-04-20|Estimate|||||||2017-11-22|2017-11-27|Actual|April 2012||2012-04-30|November 2017|2017-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Molecular Regulation of Muscle Glucose Metabolism|Molecular Regulation of Muscle Glucose Metabolism|Terminated||Phase 1|48|Actual|Mayo Clinic||1||PI job change|f||||f||||||||||2018-05-31 21:26:49.607947|2018-05-31 21:26:49.607947
NCT01581723|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2015-02-02|2012-04-19|2012-04-20|Estimate|||||||2015-02-02|2015-02-04|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor|Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|150|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:26:49.691549|2018-05-31 21:26:49.691549
NCT01581710|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2017-07-31||2018-03-14|2012-04-19|2012-04-20|Estimate|2018-03-14|2018-04-12|Actual||||2018-03-14|2018-04-12|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional||Measure Analysis Population Description: two participants did not complete the second set test due to symptom aggravation|Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.|A Double-blind, Randomized, Cross-over Design Study to Compare the Lung Function Measure of Montelukast Versus Placebo in Children With Mild Persistent Asthma|Completed||N/A|32|Actual|CHA University||3|||f||||f||||||||No||2018-05-31 21:26:49.807937|2018-05-31 21:26:49.807937
NCT01581697|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate||||April 2012|2012-04-30||||||||Interventional|||Impact of Consumption of Oats in Lipid Profile of Children and Adolescents With Dyslipidemia|Impact of Consumption of Oats in Lipid Profile of Children and Adolescents With Dyslipidemia at the Outpatient Clinic of Reference in Preventive Pediatric Cardiology at the Institute of Cardiology of Rio Grande do Sul|Unknown status|Recruiting|Phase 1/Phase 2|||Instituto de Cardiologia do Rio Grande do Sul||1|||f||||||||||||||2018-05-31 21:26:50.122563|2018-05-31 21:26:50.122563
NCT01581684|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2014-03-13||2017-07-05|2012-04-19|2012-04-20|Estimate|2014-03-13|2014-04-17|Estimate||||2017-07-05|2017-08-15|Actual|April 1, 2012|Actual|2012-04-01|July 2017|2017-07-31|August 1, 2012|Actual|2012-08-01|August 1, 2012|Actual|2012-08-01||Interventional|||Safety Tolerability and Pharmacokinetic of BI 411034|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 411034 (PIB) in Healthy Male Volunteers (Randomised, Single-blind, Placebocontrolled Within Dose Groups, Phase I Study)|Completed||Phase 1|62|Actual|Boehringer Ingelheim||9|||f||||||||||||||2018-05-31 21:26:50.228566|2018-05-31 21:26:50.228566
NCT01581671|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-06-24|2012-04-18|2012-04-20|Estimate|||||||2014-06-24|2014-06-25|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|April 2012|Actual|2012-04-30||Observational|||Non-Invasive EndoPAT Increases Diagnostic Yield of CAD by Coronary Angiography|Non-Invasive Peripheral Arterial Tonometry (EndoPAT) Increases Diagnostic Yield of Coronary Artery Disease by Coronary Angiography|Completed|||201|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 21:26:50.998114|2018-05-31 21:26:50.998114
NCT01581658|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2014-05-16||2017-07-04|2012-04-19|2012-04-20|Estimate|2014-05-16|2014-06-17|Estimate||||2017-07-04|2017-08-14|Actual|April 1, 2012|Actual|2012-04-01|July 2017|2017-07-31|November 1, 2012|Actual|2012-11-01|November 1, 2012|Actual|2012-11-01||Interventional|||Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes|A Phase I, Open-label, Parallel-group Study to Investigate Pharmacokinetics, Pharmacodynamics and Safety of a Single 25 mg Dose of Empagliflozin in Japanese Type 2 Diabetes Patients With Different Degrees of Renal Impairment in Comparison to Type 2 Diabetes Patients With Normal Renal Function|Completed||Phase 1|32|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:26:51.056095|2018-05-31 21:26:51.056095
NCT01581645|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2015-12-30|2012-04-19|2012-04-20|Estimate|||||||2015-12-30|2015-12-31|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Mobilaser Study to Help With People Who Are Having Problems With Their Gait|Increasing Mobility in Parkinsonian Patients With Freezing of Gait and Gait Hypokinesia With an Adjustable, Attachable Laser (Mobilaser)|Completed||Early Phase 1|11|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:26:51.353269|2018-05-31 21:26:51.353269
NCT01581632|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-09-22|2012-04-18|2012-04-20|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Assessment of Coronary Plaque Composition|Assessment of Coronary Plaque Composition Using Near Infrared Spectroscopy During Inhibition of LpPLA2 Activity|Completed||N/A|39|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 21:26:51.415645|2018-05-31 21:26:51.415645
NCT01581619|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2017-08-29||2017-12-01|2012-04-18|2012-04-20|Estimate|2017-08-29|2017-09-26|Actual||||2017-12-01|2017-12-04|Actual|May 2012||2012-05-31|December 2017|2017-12-31|August 2024|Anticipated|2024-08-31|August 2016|Actual|2016-08-31||Interventional|||External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks|A Phase I Study of Once-Daily External-Beam Partial-Breast Irradiation (PBI) for Selected Patients With Early Invasive N0 or Non-Invasive Breast Cancer|Active, not recruiting||N/A|54|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 21:26:51.490692|2018-05-31 21:26:51.490692
NCT01581606|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-11-02|2012-04-18|2012-04-20|Estimate|||||||2017-11-02|2017-11-06|Actual|April 30, 2013|Actual|2013-04-30|November 2017|2017-11-30|April 7, 2014|Actual|2014-04-07|April 4, 2014|Actual|2014-04-04||Observational|||Evaluation of TeleOphthalmology in AMD-TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes|Evaluation of TeleOphthalmology in Age-related Macular Degeneration (AMD) - TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes.|Completed|||169|Actual|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 21:26:51.95617|2018-05-31 21:26:51.95617
NCT01581593|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-09-12|2012-04-19|2012-04-20|Estimate|||||||2013-09-12|2013-09-13|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)|Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects With Primary Immunodeficiency (PID).|Unknown status|Active, not recruiting|Phase 3|50|Anticipated|Kedrion S.p.A.||1|||f||||t||||||||||2018-05-31 21:26:52.036749|2018-05-31 21:26:52.036749
NCT01581580|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2018-05-22|2012-04-19|2012-04-20|Estimate|||||||2018-05-22|2018-05-23|Actual|July 12, 2011||2011-07-12|May 11, 2018|2018-05-11|March 1, 2021|Anticipated|2021-03-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Deep Brain Stimulation Surgery for Movement Disorders|Deep Brain Stimulation Surgery for Movement Disorders|Recruiting||N/A|200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:26:52.155468|2018-05-31 21:26:52.155468
NCT01581567|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2018-03-27|2012-04-19|2012-04-20|Estimate|||||||2018-03-27|2018-03-29|Actual|July 15, 2011||2011-07-15|February 9, 2018|2018-02-09||||||||Observational|||Neuroimmunology Branch Repository|NIB Repository Protocol|Completed|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:26:52.247733|2018-05-31 21:26:52.247733
NCT01581554|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2018-03-27|2012-04-19|2012-04-20|Estimate|||||||2018-03-27|2018-03-29|Actual|April 28, 2011||2011-04-28|February 26, 2018|2018-02-26||||||||Observational|||Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B|Withdrawal of Therapy After Long-Term Oral Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B|Active, not recruiting|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:26:52.337322|2018-05-31 21:26:52.337322
NCT01581541|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|2017-07-28||2017-09-06|2012-04-19|2012-04-20|Estimate|2017-09-06|2017-10-04|Actual||||2017-09-06|2017-10-04|Actual|April 26, 2011|Actual|2011-04-26|September 2017|2017-09-30|September 3, 2014|Actual|2014-09-03|September 3, 2014|Actual|2014-09-03||Interventional|||PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment|Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma|Terminated||Phase 1|17|Actual|National Institutes of Health Clinical Center (CC)||1||The study closed prematurely due to discontinuation of drug supply.|f||||f|t|f||||||No||2018-05-31 21:26:52.47367|2018-05-31 21:26:52.47367
NCT01581528|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-05-17|2012-04-19|2012-04-20|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2012||2012-04-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia|Metabolic Pathways in T-Cell Acute Lymphoblastic Leukemia (T-ALL)|Completed|||15|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:26:54.382123|2018-05-31 21:26:54.382123
NCT01581515|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-04-17|2012-04-17|2012-04-20|Estimate|||||||2012-04-17|2012-04-20|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|ANCHOR||Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation|2-phased Randomized Comparison Between PromusTMElementTM Versus Xience PRIME® Stent|Unknown status|Recruiting|Phase 4|100|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 21:26:54.473432|2018-05-31 21:26:54.473432
NCT01581502|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-08-31|2012-04-18|2012-04-20|Estimate|||||||2015-08-31|2015-09-02|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Observational|SAMURAI-NVAF||SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)|Stroke Acute Management With Urgent Risk-factor Assessment and Improvement (SAMURAI) Study on Anticoagulant Therapy in Nonvalvular Atrial Fibrillation (NVAF)|Unknown status|Active, not recruiting||1000|Anticipated|Ministry of Health, Labour and Welfare, Japan|||1||f||||f||||||||||2018-05-31 21:26:54.575412|2018-05-31 21:26:54.575412
NCT01581489|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-06-11|2012-04-18|2012-04-20|Estimate|||||||2015-06-11|2015-06-12|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Early Versus Delayed Cord Clamping at Term: Neurodevelopmental Outcomes in Swedish Infants at 4 Years of Age|Early Versus Delayed Cord Clamping at Term: Neurodevelopmental Outcomes in Swedish Infants at 4 Years of Age|Completed|||263|Actual|Uppsala University|||2||f||||f||||||||||2018-05-31 21:26:54.665708|2018-05-31 21:26:54.665708
NCT01581476|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-01-10|2012-04-19|2012-04-20|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2009||2009-01-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|AdDIT||Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial|Randomised, Double Blind, Placebo Controlled Trial of Angiotensin Converting Enzyme Inhibitors and Statins in the Prevention of Long Term Complications in Young People With Type 1 Diabetes|Completed||Phase 3|443|Actual|University of Cambridge||4|||f||||t||||||||||2018-05-31 21:26:54.834631|2018-05-31 21:26:54.834631
NCT01581463|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-08-03|2012-04-19|2012-04-20|Estimate|||||||2012-08-03|2012-08-06|Estimate|April 2012||2012-04-30|August 2012|2012-08-31||||August 2012|Actual|2012-08-31||Interventional|||A Study of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects|Phase 1 Single-Dose Study of the Pharmacokinetics of Sustained-Release Liothyronine Sodium (T3) in Healthy Subjects|Completed||Phase 1|12|Actual|Ipe, LLC||1|||f||||t||||||||||2018-05-31 21:26:54.933825|2018-05-31 21:26:54.933825
NCT01581450|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-04-19|2012-04-19|2012-04-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Hyperalgesia and Pain|Evaluation of Antihyperalgesic and Analgesic Effects of 35% Nitrous Oxide in a Human Model of Electrically Evoked Hyperalgesia and Pain|Completed||Phase 1|20|Actual|Air Liquide Santé International||2|||f||||||||||||||2018-05-31 21:26:54.989817|2018-05-31 21:26:54.989817
NCT01581437|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2015-06-05||2016-03-09|2012-04-18|2012-04-20|Estimate|2016-03-09|2016-03-11|Estimate||||2016-03-09|2016-03-11|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CONFIRM|48 patients with persistent AF, 7=longstanding AF, 23 paroxysmal AF|Recording for Potential AF Drivers and Patient Specific Atrial Anatomy & Atrial Electrogram Maps|Recording for Potential AF Drivers and Patient Specific Atrial Anatomy and Atrial Electrogram Maps Using an FDA Approved 64-Pole Basket Catheter (CONFIRM)|Completed||N/A|78|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 21:26:55.079072|2018-05-31 21:26:55.079072
NCT01581424|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-05-01|2012-04-18|2012-04-20|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2010||2010-10-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|July 2020|Anticipated|2020-07-31||Observational|LDN6702||Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study|Natural History and Structural Functional Relationships in Fabry Renal Disease Natural History, Structural Functional Relationships and Determinants of Renal Structural Responses (Changes) With Enzyme Replacement Therapy in Fabry Disease|Recruiting|||50|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples Without DNA|"~     Serum and Plasma samples as well as urine samples from an overnight collection.~   "|||2018-05-31 21:26:55.332366|2018-05-31 21:26:55.332366
NCT01581411|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-18|2012-04-18|2012-04-20|Estimate|||||||2012-04-18|2012-04-20|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion|Phase 1 Trial of Intra-Ophthalmic Artery Thrombolysis for Treating Recent Severe Central Retinal Vein Occlusion|Unknown status|Recruiting|Phase 1|5|Anticipated|Weill Medical College of Cornell University||1|||f||||||||||||||2018-05-31 21:26:55.433162|2018-05-31 21:26:55.433162
NCT01581398|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-10-06|2012-04-18|2012-04-20|Estimate|||||||2014-10-06|2014-10-07|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients|A Phase 3, Randomized, Multi-center, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Combination With Ribavirin in Chinese Chronic Hepatitis C Patients|Completed||Phase 3|770|Actual|Xiamen Amoytop Biotech Co., Ltd.||4|||f||||t||||||||||2018-05-31 21:26:55.552065|2018-05-31 21:26:55.552065
NCT01581385|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2018-05-07|2012-04-18|2012-04-20|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2012||2012-04-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive, Diagnostic Atherosclerosis Imaging|Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive, Diagnostic Atherosclerosis Imaging; Independent Scientist: ARFI and RWI Ultrasound for Improved Atherosclerosis Imaging|Active, not recruiting|||25|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples Without DNA|"~     Plaque specimens extracted during clinically indicated carotid endarterectomy surgery will be~     sectioned and histochemically processed.~   "|||2018-05-31 21:26:55.720719|2018-05-31 21:26:55.720719
NCT01581372|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-04-25|2012-04-18|2012-04-20|Estimate|||||||2015-04-25|2015-04-28|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|RxACT||A Community Based Approach to Dyslipidemia Management: Pharmacist Prescribing to Achieve Cholesterol Targets|A Community Based Approach to Dyslipidemia Management: Pharmacist Prescribing to Achieve Cholesterol Targets (RxACT Study)|Completed||N/A|100|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:26:55.784809|2018-05-31 21:26:55.784809
NCT01581359|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-10-21|2012-04-18|2012-04-20|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|ENDOFIV||The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis|A Comparative Study, Randomized, Blinded, About the Effect of Pre-treatment With GnRH Analogues Versus Placebo in Infertile Patients With Endometriosis Undergoing in Vitro Fertilization Treatment|Completed||Phase 4|200|Actual|Instituto de Investigacion Sanitaria La Fe||2|||f||||t||||||||||2018-05-31 21:26:55.853436|2018-05-31 21:26:55.853436
NCT01581346|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-04-18|2012-04-18|2012-04-20|Estimate|||||||2012-04-18|2012-04-20|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|POSITIVE||Exercise Study in Patients With Lung Cancer|Pilot Study to Establish an Exercise Intervention in Patients With Lung Cancer|Completed||Phase 2|40|Actual|German Cancer Research Center||1|||f||||f||||||||||2018-05-31 21:26:55.956377|2018-05-31 21:26:55.956377
NCT01581333|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-10-31|2012-04-19|2012-04-20|Estimate|||||||2017-10-31|2017-11-01|Actual|April 2012||2012-04-30|October 2017|2017-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|HOWLONG||Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia|Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia|Completed||Phase 4|157|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f||||||||||2018-05-31 21:26:56.02506|2018-05-31 21:26:56.02506
NCT01581320|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2016-10-31|2012-04-18|2012-04-20|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|DIOS||Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis|A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R206 and Bonviva for the Improvement of Vitamin D in Postmenopausal Women With Osteoporosis|Completed||Phase 3|201|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 21:26:56.102727|2018-05-31 21:26:56.102727
NCT01581307|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2016-11-09||2017-01-20|2012-04-19|2012-04-20|Estimate|2016-11-09|2017-01-06|Estimate||||2017-01-20|2017-03-03|Actual|April 2012||2012-04-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional||All participants. Outcome Measures may reference participants evaluable at time of analysis.|Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets|A Phase II Clinical Trial Evaluating Overall Survival With Therasphere® In Conjunction With 2nd-Line FOLFOX In Patients With Gemcitabine-Refractory Pancreatic Carcinoma With Liver Metastases|Completed||Phase 2|9|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 21:26:56.187503|2018-05-31 21:26:56.187503
NCT01581294|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-08-06|2012-04-19|2012-04-20|Estimate|||||||2016-08-06|2016-08-09|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|NOR-DMARD||The Norwegian Antirheumatic Drug Register|Long-term Safety and Effectiveness of Disease Modifying Therapies in Inflammatory Arthropathies: a Multicentre, Phase IV, Longitudinal Observational Study|Recruiting|||15000|Anticipated|Diakonhjemmet Hospital|||||f||||t||||||Samples With DNA|"~     Samples (including serum, plasma and full blood) for biomarker or DNA/RNA discovery and~     validation will be collected and stored in a freezer at -70 C at visits at baseline and at~     the 3-month assessment.~   "|||2018-05-31 21:26:56.646457|2018-05-31 21:26:56.646457
NCT01581281|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2016-11-16||2017-07-11|2012-04-18|2012-04-20|Estimate|2017-07-11|2017-08-10|Actual||||2017-07-11|2017-08-10|Actual|June 2012||2012-06-30|July 2017|2017-07-31|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Interventional|CHAMP||The Childhood and Adolescent Migraine Prevention Study|Amitriptyline and Topiramate in the Prevention of Childhood Migraine|Terminated||Phase 3|488|Actual|Children's Hospital Medical Center, Cincinnati||3||Interim assessment provided sufficient data to answer study questions|f||||t||||||||Yes|De-identified datasets and associated documentation will be submitted to NINDS for archiving and public access, consistent with current NINDS data sharing policy.|2018-05-31 21:26:56.77854|2018-05-31 21:26:56.77854
NCT01581255|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-09-10|2012-04-18|2012-04-20|Estimate|||||||2012-09-10|2012-09-12|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||The Effect of High Frequency Oscillation on Biological Markers of Lung Injury|The Effect of High Frequency Oscillation on Biological Markers of Lung Injury|Terminated|||2|Actual|Canadian Critical Care Trials Group|||2|Parent study (OSCILLATE) stopped by the Data Monitoring Committee|f||||f||||||Samples Without DNA|"~     Blood samples will be drawn to measure the following biomarkers of ventilator-induced lung~     injury: IL-1β, IL-6, IL-8, IL-10, IFN-γ, TGF-β, TNF-α, VEGF, sICAM-1, surfactant protein D~     (SP-D), Krebs von den Lungen protein (KL-6), Clara cell 16 kD protein (CC16), Angiopoietin-1,~     Angiopoietin-2, and vWF.~   "|||2018-05-31 21:26:57.485682|2018-05-31 21:26:57.485682
NCT01581242|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-09-16|2012-04-19|2012-04-20|Estimate|||||||2012-09-16|2012-09-18|Estimate|April 2012||2012-04-30|September 2012|2012-09-30||||June 2012|Actual|2012-06-30||Interventional|BKP-1003-101||A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Three-sequence, Three-period, Three-treatment Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects|Completed||Phase 1|42|Anticipated|Bukwang Pharmaceutical||3|||f||||f||||||||||2018-05-31 21:26:57.564663|2018-05-31 21:26:57.564663
NCT01581229|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-07-05|2012-04-19|2012-04-20|Estimate|||||||2012-07-05|2012-07-09|Estimate|June 2012||2012-06-30|July 2012|2012-07-31||||June 2013|Anticipated|2013-06-30||Interventional|||Early Use of Noninvasive Positive Pressure Ventilation for Intro-pulmonary Acute Lung Injury||Unknown status|Recruiting|N/A|200|Anticipated|Beijing Hospital||2|||f||||f||||||||||2018-05-31 21:26:57.651701|2018-05-31 21:26:57.651701
NCT01581216|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2015-08-10|2012-04-18|2012-04-20|Estimate|||||||2015-08-10|2015-08-11|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Fatigue Before and After Exercise in Patients With Advanced Cancer Stage|The Use of Physical Activity to Control Fatigue and Improve the Quality of Life in Patients With Advanced Cancer Stage|Unknown status|Recruiting|N/A|50|Anticipated|Barretos Cancer Hospital||3|||f||||f||||||||||2018-05-31 21:26:57.748833|2018-05-31 21:26:57.748833
NCT01581203|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18||2015-09-23|2015-09-23|2012-04-19|2012-04-20|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|October 2013|Actual|2013-10-31||Interventional|Hallmark DUAL||Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)|A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection|Completed||Phase 3|748|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 21:26:57.872345|2018-05-31 21:26:57.872345
NCT01581190|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-14|||2012-04-18|2012-04-18|2012-04-20|Estimate|||||||2012-04-18|2012-04-20|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bananas as an Energy Source During Exercise: a Metabolomics Approach|Comparison of Bananas and Gatorade on Performance and Exercise-induced Inflammation, Oxidative Stress, and Changes in Immune Function in Endurance Athletes|Completed||N/A|14|Actual|Appalachian State University||1|||f||||f||||||||||2018-05-31 21:26:58.165778|2018-05-31 21:26:58.165778
NCT01581177|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17||2017-04-17|2017-05-18|2012-04-18|2012-04-20|Estimate||||2017-04-17|2017-04-19|Actual|2017-05-18|2017-05-19|Actual|April 2012||2012-04-30|May 2017|2017-05-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation|A Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Crossover Dose-ranging Study of A006 in Adult Asthma Patients|Completed||Phase 2|23|Actual|Amphastar Pharmaceuticals, Inc.||7|||f||||f||||||||||2018-05-31 21:26:58.242702|2018-05-31 21:26:58.242702
NCT01581164|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-05-07|2012-04-18|2012-04-20|Estimate|||||||2015-05-07|2015-05-08|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation|Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation|Completed|||12|Actual|University of California, San Francisco|||1||f||||t||||||Samples With DNA|"~     Serum will be collected and stored for immunologic analysis after vaccination. Samples will~     be cryopreserved. No cell lines will be created using samples procured on this protocol.~   "|||2018-05-31 21:26:58.342246|2018-05-31 21:26:58.342246
NCT01581151|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2015-02-19|2012-04-19|2012-04-20|Estimate|||||||2015-02-19|2015-02-20|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion|Dexamethasone Implant With Rescue Ranibizumab for Treating Macular Edema Secondary to Retinal Vein Occlusion|Unknown status|Recruiting|N/A|30|Anticipated|Wills Eye||2|||f||||f||||||||||2018-05-31 21:26:58.412629|2018-05-31 21:26:58.412629
NCT01581138|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17||2014-07-02|2014-07-02|2012-04-17|2012-04-20|Estimate||||2014-07-02|2014-07-04|Estimate|2014-07-02|2014-07-04|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C|A Multicenter, Randomized, Open-label, Phase 2b Study to Evaluate the Efficacy and Safety of Two Regimens of All-oral Triple Therapy (VX-222 in Combination With Telaprevir [Incivek™] and Ribavirin [Copegus®]) in Treatment-Naïve Subjects With Genotype 1a Chronic Hepatitis C|Completed||Phase 2|64|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 21:26:58.503412|2018-05-31 21:26:58.503412
NCT01581125|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-07-15|2012-04-18|2012-04-19|Estimate|||||||2016-07-15|2016-07-18|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Sleep Duration Required to Restore Performance During Chronic Sleep Restriction|Sleep Duration Required to Restore Performance During Chronic Sleep Restriction|Completed||N/A|19|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:26:58.605629|2018-05-31 21:26:58.605629
NCT01581112|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2013-09-17|2012-04-18|2012-04-19|Estimate|||||||2013-09-17|2013-09-18|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Microbial Community Transplantation on the Armpit/Foot|Microbial Community Transplantation on the Armpit/Foot in Order to Reduce the Malodour Generation on Armpit/Foot|Completed||N/A|4|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 21:26:58.675164|2018-05-31 21:26:58.675164
NCT01581099|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-05-01|2012-04-17|2012-04-19|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2013||2013-04-30|May 2017|2017-05-31|April 20, 2017|Actual|2017-04-20|March 2016|Actual|2016-03-31||Observational|ADIII||"Effect of Bariatric Surgery Digestive Adaptations III on Cardiovascular Risk"|"Effect of Bariatric Surgery Digestive Adaptations III on Clinical, Laboratory and Cardiovascular Risk Factors"|Completed|||30|Actual|University of Sao Paulo|||3||f||||f||||||Samples Without DNA|"~     Whole blood samples will be retained for future exams.~   "|||2018-05-31 21:26:58.745611|2018-05-31 21:26:58.745611
NCT01581086|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-06-20|2012-04-18|2012-04-19|Estimate|||||||2017-06-20|2017-06-21|Actual|January 2012||2012-01-31|May 2016|2016-05-31|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Observational|VAST||Vascular Subphenotypes of Lung Disease in HIV & COPD|Identify and Characterize Populations at Risk for Developing Pulmonary Arterial Hypertension (PAH)|Completed|||30|Actual|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 21:26:58.82132|2018-05-31 21:26:58.82132
NCT01581073|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2018-04-17|2012-04-18|2012-04-19|Estimate|||||||2018-04-17|2018-04-18|Actual|February 16, 2012|Actual|2012-02-16|April 2018|2018-04-30|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|PREDICT||PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease|Prevention of End Stage Kidney Disease by Darbepoetin Alfa In CKD Patients With Non-diabetic Kidney Disease|Completed||Phase 3|476|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||||||||||||2018-05-31 21:26:58.879646|2018-05-31 21:26:58.879646
NCT01581060|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2014-05-15|2012-04-18|2012-04-19|Estimate|||||||2014-05-15|2014-05-16|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours|A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours|Terminated||Phase 1/Phase 2|41|Actual|Wilex||1||Study terminated for business reasons|f||||f||||||||||2018-05-31 21:26:58.959481|2018-05-31 21:26:58.959481
NCT01581047|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2014-12-04|2012-04-18|2012-04-19|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|AMOCEF||Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units|Pharmacokinetics of Small Spectrum Beta-lactam Antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) in Patients on Intensive Care Units|Unknown status|Recruiting||60|Anticipated|University Hospital, Ghent|||2||f||||f||||||Samples Without DNA|"~     8 serum samples will be taken per patient.~   "|||2018-05-31 21:26:59.022393|2018-05-31 21:26:59.022393
NCT01581034|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-07-31|2012-04-18|2012-04-19|Estimate|||||||2013-07-31|2013-08-01|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PADMA 28||Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery Disease|A Randomized, Placebo-controlled, Double-blinded Trial on the Effect of PADMA 28 on Endothelial Function, Biomarkers and the Autonomic Nervous System in Patients With Coronary Artery Disease|Completed||Phase 2|80|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 21:26:59.088959|2018-05-31 21:26:59.088959
NCT01581021|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2013-04-14||2013-12-13|2012-04-18|2012-04-19|Estimate|2013-12-13|2014-02-03|Estimate||||2013-12-13|2014-02-03|Estimate|August 2005||2005-08-31|December 2013|2013-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pedicle Screw Usage in Conventional Fixation Pattern Constructs Compared to Thoracic Hook Constructs in Scoliosis|Pedicle Screw Usage in Conventional Fixation Pattern Constructs Compared to Thoracic Hook Constructs in Adolescent Idiopathic Scoliosis Patients and Neuromuscular Ambulators|Completed||N/A|58|Actual|University of Mississippi Medical Center|The design of this study is a computer-generated randomized trial. Initially, the first 3 participants were not computer-randomized and therefore, these subjects had to be removed from the study.|2|||f||||f||||||||||2018-05-31 21:26:59.247502|2018-05-31 21:26:59.247502
NCT01580267|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2014-04-24|2012-04-17|2012-04-18|Estimate|||||||2014-04-24|2014-04-28|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Hepcidin and Anemia in Trauma|Hepcidin and Anemia in Trauma|Completed|||74|Actual|University of Michigan|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:27:08.706773|2018-05-31 21:27:08.706773
NCT01581008|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2014-11-03||2015-04-27|2012-04-17|2012-04-19|Estimate|2014-11-03|2014-11-11|Estimate||||2015-04-27|2015-05-15|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|CASA||Improving Symptoms and Quality of Life in Chronic Heart Failure: Pilot Study|Implementing Collaborative Care to Alleviate Symptoms and Adjust to Heart Failure: A Pilot Study|Completed||N/A|31|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 21:26:59.526223|2018-05-31 21:26:59.526223
NCT01580995|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2016-06-13||2016-08-01|2012-04-17|2012-04-19|Estimate|2016-08-01|2016-09-21|Estimate||||2016-08-01|2016-09-21|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|HSV1/HCV||Herpes Simplex Type 1 Suppression in Hepatitis C|HSV-1 Suppression in HCV Infected Veterans Who Are Seronegative for HSV-2|Completed||Phase 2|19|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 21:26:59.753096|2018-05-31 21:26:59.753096
NCT01580982|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2018-01-17|2012-04-18|2012-04-19|Estimate|||||||2018-01-17|2018-01-19|Actual|January 23, 2012|Actual|2012-01-23|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer|Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung and Other Thoracic Cancers|Recruiting|||175|Anticipated|University of Colorado, Denver|||||f||||f||||||Samples With DNA|"~     Tumor tissue will be acquired from either archival or de novo biopsy material~   "|Undecided||2018-05-31 21:26:59.975847|2018-05-31 21:26:59.975847
NCT01580969|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-02-28|2012-04-18|2012-04-19|Estimate|||||||2018-02-28|2018-03-02|Actual|July 6, 2012|Actual|2012-07-06|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|January 12, 2018|Actual|2018-01-12||Interventional|RAMBO||Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma|A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in Patients With Recurrent gliOma (RAMBO)|Active, not recruiting||Phase 1/Phase 2|22|Actual|University of Utah||1|||f||||t|t|f|||f|||||2018-05-31 21:27:00.114482|2018-05-31 21:27:00.114482
NCT01580956|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2013-05-28|2012-04-18|2012-04-19|Estimate|||||||2013-05-28|2013-05-29|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||"VARIABLE-PSV Study"|"Evaluation a New Ventilatory Modes: VARIABLE-PSV: a Randomized Controlled Cross-over Study: the  VARIABLE-PSV Study"|Completed||Phase 3|20|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:27:00.214615|2018-05-31 21:27:00.214615
NCT01580943|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-20|2012-04-18|2012-04-19|Estimate|||||||2012-04-20|2012-04-24|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Two Commercially Available Chlorhexidine Mouthrinses Non-alcohol Base|Efficacy of Two Commercially Available Chlorhexidine Mouthrinses Non-alcohol Base - a Randomized Clinical Trial|Completed||Phase 1/Phase 2|50|Actual|Universidade do Porto||2|||f||||t||||||||||2018-05-31 21:27:00.308746|2018-05-31 21:27:00.308746
NCT01580930|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-19|2012-04-17|2012-04-19|Estimate|||||||2012-04-19|2012-04-20|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|START||Changes in Habitual Physical Activity and Inactivity|Changes in Physical Activity and Inactivity During a 12-week Exercise Training and/or Sedentary Time Intervention|Completed||N/A|57|Actual|University of Massachusetts, Amherst||4|||f||||f||||||||||2018-05-31 21:27:00.43548|2018-05-31 21:27:00.43548
NCT01580917|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2016-12-14|2012-04-18|2012-04-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|ILH||Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control: a Pilot Study|Dynamic Plantar Microvascular Skin Response to Compressive Loads in At-risk Diabetic and Healthy Control|Completed|||18|Actual|Temple University|||2||f||||f||||||||||2018-05-31 21:27:00.552618|2018-05-31 21:27:00.552618
NCT01580904|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2016-03-11||2016-12-19|2012-04-17|2012-04-19|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|September 2009||2009-09-30|December 2016|2016-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|IPCD||Impact of Pharmaceutical Care in Diabetics Patients|Popular Pharmacy of Brazil: Impact of Pharmaceutical Care in Diabetics Patients|Completed||N/A|100|Actual|Universidade Estadual da Paraiba||2|||f||||t||||||||No||2018-05-31 21:27:00.676999|2018-05-31 21:27:00.676999
NCT01580891|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2014-05-05|2012-04-18|2012-04-19|Estimate|||||||2014-05-05|2014-05-06|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis|Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design Study to Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis.|Completed||Phase 1|1053|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 21:27:00.996976|2018-05-31 21:27:00.996976
NCT01580878|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-05-03|2012-04-18|2012-04-19|Estimate|||||||2017-05-03|2017-05-05|Actual|January 2012||2012-01-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis|A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.|Completed||Phase 1|707|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 21:27:01.078661|2018-05-31 21:27:01.078661
NCT01580865|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2015-11-02|2012-04-17|2012-04-19|Estimate|||||||2015-11-02|2015-11-04|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis|Comparison Between Tacrolimus and Mycophenolate Mofetil for Induction of Remission in Lupus Nephritis|Unknown status|Recruiting|N/A|90|Anticipated|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 21:27:01.183624|2018-05-31 21:27:01.183624
NCT01580852|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|July 2012||2012-07-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||The Effects of Immersion in Dead Sea Water on Glucose Levels in Type 2 Diabetes Mellitus Patients|The Effects of Immersion in Dead Sea Water on Glucose Levels in Type 2 Diabetes Mellitus Patients|Unknown status|Not yet recruiting|N/A|40|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 21:27:01.278622|2018-05-31 21:27:01.278622
NCT01580839|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-12-20|2012-04-17|2012-04-19|Estimate|||||||2017-12-20|2017-12-22|Actual|December 6, 2012|Actual|2012-12-06|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|EXTEND||EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)|Extending the Time for Thrombolysis in Emergency Neurological Deficits|Recruiting||Phase 3|200|Anticipated|Neuroscience Trials Australia||2|||f||||t||||||||||2018-05-31 21:27:01.364823|2018-05-31 21:27:01.364823
NCT01580813|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-11-01|2012-04-17|2012-04-19|Estimate|||||||2017-11-01|2017-11-06|Actual|June 2011||2011-06-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|AcT2||Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes|Effects of Serum Fatty Acid Lowering on Insulin Sensitivity, Cardiovascular Function, And Exercise Capacity in Non-Insulin Dependent Diabetes|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||2|||f||||t||f||||||||2018-05-31 21:27:01.569988|2018-05-31 21:27:01.569988
NCT01580800|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-02-28|2012-04-17|2012-04-19|Estimate|||||||2018-02-28|2018-03-02|Actual|September 2011||2011-09-30|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|September 2021|Anticipated|2021-09-30||Observational|||National Breast Cancer and Lymphedema Registry|National Breast Cancer and Lymphedema Registry|Suspended|||1000|Anticipated|Stanford University|||1|Low enrollment and follow-up participation|f||||t||||||||Undecided||2018-05-31 21:27:01.660694|2018-05-31 21:27:01.660694
NCT01580787|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Interventional|||Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment|Functional Improvement in Patients With Parkinson's Disease After Training in Real or Virtual Environment|Completed||N/A|32|Actual|Sao Camilo University Center||2|||f||||t||||||||||2018-05-31 21:27:01.764426|2018-05-31 21:27:01.764426
NCT01580774|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-08-28|2012-04-17|2012-04-19|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2012||2012-07-31|August 2017|2017-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Effect of Post-discharge Phone Calls on Patient Outcomes|Effect of Post-discharge Phone Calls on Patient Outcomes for General Internal Medicine Patients Discharged From a Teaching Hospital.|Completed|||334|Actual|Mount Sinai Hospital, Canada|||2||f||||f||||||||||2018-05-31 21:27:01.881765|2018-05-31 21:27:01.881765
NCT01580761|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2018-05-14|2012-04-17|2012-04-19|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2012||2012-07-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Sleep Restriction and Obesity|Sleep Restriction and Obesity|Recruiting||N/A|20|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:27:01.955339|2018-05-31 21:27:01.955339
NCT01580748|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients||Unknown status|Not yet recruiting|Phase 2|25|Anticipated|Seoul National University Bundang Hospital||1|||f||||||||||||||2018-05-31 21:27:02.037297|2018-05-31 21:27:02.037297
NCT01580735|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-08-16|2012-04-18|2012-04-19|Estimate|||||||2015-08-16|2015-08-18|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer|A Phase 2, Multicenter, Open-label, Single-arm Study of ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer|Completed||Phase 2|40|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 21:27:02.198551|2018-05-31 21:27:02.198551
NCT01580722|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Comparison of Early Versus Delay Reconstruction in Anterior Cruciate Ligament Tearing|Study of Surgical Methods for Anterior Cruciate Ligament Tearing|Completed||Phase 2|202|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:27:02.286411|2018-05-31 21:27:02.286411
NCT01580709|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2016-09-19|2012-04-18|2012-04-19|Estimate|||||||2016-09-19|2016-09-20|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Endoscopic Retrograde Cholangiopancreatography (ERCP) Based Sampling of Indeterminate Bile Duct Strictures|Optimizing the Role of ERCP in Evaluating Indeterminate Bile Duct Strictures|Completed||N/A|48|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:27:02.374112|2018-05-31 21:27:02.374112
NCT01580696|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2018-05-01|2012-04-17|2012-04-19|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2012||2012-04-30|April 2018|2018-04-30|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer|Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients|Completed||Phase 1/Phase 2|51|Actual|San Antonio Military Medical Center||4|||f||||f||||||||||2018-05-31 21:27:02.445901|2018-05-31 21:27:02.445901
NCT01580683|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2015-05-11|2012-04-17|2012-04-19|Estimate|||||||2015-05-11|2015-05-13|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Vitamin C and Atrial Fibrillation After Cardiac Surgery|Effect of Ascorbic Acid on the Incidence of Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery|Withdrawn||Phase 3|0|Actual|Regional Hospital of Scranton||2||No funding obtained to support patient recruitment|f||||t||||||||||2018-05-31 21:27:02.554449|2018-05-31 21:27:02.554449
NCT01580670|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-04-09|2012-04-17|2012-04-19|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease|Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease|Completed||Phase 3|14|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 21:27:02.644201|2018-05-31 21:27:02.644201
NCT01580657|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-17|2012-04-17|2012-04-19|Estimate|||||||2012-04-17|2012-04-19|Estimate|September 2006||2006-09-30|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics|Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics|Completed||N/A|1728|Actual|Medical College of Wisconsin||6|||f||||f||||||||||2018-05-31 21:27:02.716633|2018-05-31 21:27:02.716633
NCT01580644|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-19|2012-04-18|2012-04-19|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers|Bioavailability Study of Two Formulations of the Isopropyl Malonate Prodrug of GLPG0187 in Healthy Male Subjects|Completed||Phase 1|12|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 21:27:02.794386|2018-05-31 21:27:02.794386
NCT01580631|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-01-16|2012-04-18|2012-04-19|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Narrow Band Imaging Project on Barrett's Esophagus|Assessment of a Consensus Driven Narrow Band Imaging (NBI) Pattern Classification System in Barrett's Esophagus (BE)|Recruiting|||50|Anticipated|Midwest Biomedical Research Foundation|||2||f||||f||||||||||2018-05-31 21:27:02.870265|2018-05-31 21:27:02.870265
NCT01580618|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2013-06-24||2015-01-02|2012-04-18|2012-04-19|Estimate|2015-01-02|2015-01-06|Estimate||||2015-01-02|2015-01-06|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy|TNK for Loculated Pleural Effusions in Patients With Malignancy|Terminated||Phase 2/Phase 3|20|Actual|Kaiser Permanente|Results are limited due to the small numbers of patients enrolled|2||Unable to accrue patients at a reasonable rate|f||||f||||||||||2018-05-31 21:27:02.974259|2018-05-31 21:27:02.974259
NCT01580605|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2014-04-29|2012-04-18|2012-04-19|Estimate|||||||2014-04-29|2014-04-30|Estimate|July 2003||2003-07-31|April 2014|2014-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin|Prospective, Longitudinal and National Follow-up Program of Adult Patients With Somatotropic Hormone Deficiency for Whom Substituting Treatment by Norditropin SimpleXx Was Started|Completed|||331|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:27:03.218664|2018-05-31 21:27:03.218664
NCT01580592|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|2015-10-27||2017-02-23|2012-04-18|2012-04-19|Estimate|2016-01-18|2016-02-15|Estimate||||2017-02-23|2017-04-07|Actual|April 2012||2012-04-30|February 2017|2017-02-28|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|CUTEX|Intention-to-treat|Cold Urticaria Treatment With Xolair|A Two-center, Double Blind, Placebo-controlled Study in Parallel Design to Assess the Efficacy and Safety of 150 and 300 mg Omalizumab in Subjects With Antihistamine-resistant Cold Contact Urticaria (CCU)|Completed||Phase 2|31|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 21:27:03.285948|2018-05-31 21:27:03.285948
NCT01580579|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-03-01|2012-04-18|2012-04-19|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2012||2012-07-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer Treated With Chemoradiation|Clinical, Biochemical, Dosimetric and Functional Respiratory Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer (Stages IIIa and IIIb) Treated With Chemotherapy and Radiotherapy|Completed|||62|Actual|Instituto Nacional de Cancerologia de Mexico|||1||f||||f||||||||Yes||2018-05-31 21:27:04.644246|2018-05-31 21:27:04.644246
NCT01580566|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-04-09|2012-04-18|2012-04-19|Estimate|||||||2017-04-09|2017-04-11|Actual|March 2012||2012-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Renal Acute MI Study|Renal Structural, Functional and Cytokine Responses to Acute Myocardial Injury in Man|Recruiting|||160|Anticipated|Monash University|||4||f||||f||||||Samples With DNA|"~     Blood samples to measure bio-markers~   "|||2018-05-31 21:27:04.713006|2018-05-31 21:27:04.713006
NCT01580553|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-04-26|2012-04-18|2012-04-19|Estimate|||||||2012-04-26|2012-04-27|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure|The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart Failure —A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study|Completed||Phase 2/Phase 3|268|Actual|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 21:27:04.796746|2018-05-31 21:27:04.796746
NCT01580540|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2015-08-03|2012-04-17|2012-04-19|Estimate|||||||2015-08-03|2015-08-04|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Head to Head Study Epi proColon and FIT|Comparison of the Performance of the Epi proColon and Fecal ImmunochemicalTest Post Colonoscopy in Subjects With Colorectal Cancer and Pre Colonoscopy in Subjects From a Guideline-Eligible Screening Population|Completed|||336|Actual|Epigenomics, Inc|||2||f||||f||||||Samples With DNA|"~     Plasma~   "|||2018-05-31 21:27:04.893492|2018-05-31 21:27:04.893492
NCT01580527|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-04-17|2012-04-17|2012-04-19|Estimate|||||||2012-04-17|2012-04-19|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|Nutri-DPC||Postoperative Artificial Nutrition After Pancreaticoduodenectomy|A Prospective, Multicentric, Randomized Trial Comparing Early Enteral Nutrition Versus Parenteral Nutrition After Pancreaticoduodenectomy|Unknown status|Recruiting|N/A|220|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:27:05.161373|2018-05-31 21:27:05.161373
NCT01580514|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|EMPIRE||Myocardial Protection of Exenatide in AMI|Cardioprotective Effects of Exenatide in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention ; Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study|Completed||Phase 4|127|Actual|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 21:27:05.270914|2018-05-31 21:27:05.270914
NCT01580501|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2014-01-27|2012-04-18|2012-04-19|Estimate|||||||2014-01-27|2014-01-28|Estimate|March 2012||2012-03-31|January 2014|2014-01-31||||March 2013|Actual|2013-03-31||Interventional|||PDE Inhibitors in DMD Study (Acute Dosing Study)|Functional Muscle Ischemia and PDE5 Inhibition in Duchenne Muscular Dystrophy: Acute Dosing Study|Completed||Phase 1|12|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 21:27:05.386564|2018-05-31 21:27:05.386564
NCT01580488|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2013-08-19||2013-11-08|2012-04-18|2012-04-19|Estimate|2013-11-08|2013-12-30|Estimate||||2013-11-08|2013-12-30|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris|A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris|Completed||Phase 1|24|Actual|LEO Pharma|This was an exploratory study in which each of the 24 subjects received all 6 treatments on 2 cm diameter dermal test sites. Regarding Adverse Events, only local dermal reactions could be potentially attributed to a specific treatment.||||f||||f||||||||||2018-05-31 21:27:05.49327|2018-05-31 21:27:05.49327
NCT01580475|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|June 2010|Actual|2010-06-30|September 2008|Actual|2008-09-30||Interventional|||Training, Detraining, Retraining and Glycemic Control in Patients With Type 2 Diabetes|Training, Detraining and Retraining Effects on Glycemic Control and Physical Fitness in Patients With Type 2 Diabetes|Completed||N/A|13|Actual|Democritus University of Thrace||1|||f||||f||||||||||2018-05-31 21:27:05.873767|2018-05-31 21:27:05.873767
NCT01580462|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2012-04-18|2012-04-18|2012-04-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|June 2012|Anticipated|2012-06-30||Observational|ADHERENCE||The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes|The ADHERENCE Index - the Indicator of Effective Coping With the Requirements of the Disease of Children and Adolescents With Type 1 Diabetes. Prospective Study|Unknown status|Recruiting||200|Anticipated|Institution of Mother and Child, Warsaw, Poland|||1||f||||||||||||||2018-05-31 21:27:05.958156|2018-05-31 21:27:05.958156
NCT01580436|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2014-10-23|2012-04-18|2012-04-19|Estimate|||||||2014-10-23|2014-10-24|Estimate|August 2011||2011-08-31|October 2014|2014-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery|Prospective, Randomized Evaluation of Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery|Unknown status|Recruiting|N/A|300|Anticipated|Hasselt University||2|||f||||t||||||||||2018-05-31 21:27:06.060735|2018-05-31 21:27:06.060735
NCT01580423|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2013-05-24||2013-05-24|2012-04-18|2012-04-19|Estimate|2013-05-24|2013-07-19|Estimate||||2013-05-24|2013-07-19|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SP-RLB||The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing|The Role of Substance P on Perception of Breathlessness|Completed||N/A|16|Actual|Dartmouth-Hitchcock Medical Center|"single dose of aprepitant used~clinical diagnosis of chronic bronchitis phenotype of chronic obstructive pulmonary disease"|2|||f||||t||||||||||2018-05-31 21:27:06.143654|2018-05-31 21:27:06.143654
NCT01580410|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2017-12-21||2018-02-22|2012-04-17|2012-04-19|Estimate|2018-02-22|2018-03-21|Actual||||2018-02-22|2018-03-21|Actual|May 2009||2009-05-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|October 2015|Actual|2015-10-31||Interventional|||Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix|A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After HIPEC With Oxaliplatin or Mitomycin C in Patients With Appendiceal Tumors|Completed||Phase 2|136|Actual|Wake Forest University Health Sciences|The worst adverse event of each type was recorded for the course of treatment.|2|||f||||f|t|f||||||||2018-05-31 21:27:06.468262|2018-05-31 21:27:06.468262
NCT01580397|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-06-27|2012-04-18|2012-04-19|Estimate|||||||2013-06-27|2013-06-28|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer|A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy|Completed||Phase 2|14|Actual|CytRx||1|||f||||f||||||||||2018-05-31 21:27:07.355874|2018-05-31 21:27:07.355874
NCT01580384|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-03-02|2012-04-18|2012-04-19|Estimate|||||||2015-03-02|2015-03-03|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome||Completed|||90|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:27:07.45753|2018-05-31 21:27:07.45753
NCT01580371|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2016-10-04|2012-04-17|2012-04-19|Estimate|||||||2016-10-04|2016-10-06|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|CKD-581||Safety and Pharmacokinetic Profile of CKD-581|Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-581 in Patients With Lymphoma or Multiple Myeloma Failed to Standard Therapy|Completed||Phase 1|39|Actual|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||No||2018-05-31 21:27:07.555816|2018-05-31 21:27:07.555816
NCT01580358|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-06-19|2012-04-17|2012-04-19|Estimate|||||||2012-06-19|2012-06-21|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||Therapeutic Effects of Traditional Chinese Medicine, Shen-Mai San in Cancer Patient Undergoing Chemotherapy or Radiotherapy|Changhua Christian Hospital|Unknown status|Recruiting|N/A|60|Anticipated|Changhua Christian Hospital||2|||f||||t||||||||||2018-05-31 21:27:07.637135|2018-05-31 21:27:07.637135
NCT01580345|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-02-20|2012-04-18|2012-04-19|Estimate|||||||2017-02-20|2017-02-23|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 9, 2016|Actual|2016-12-09|December 6, 2016|Actual|2016-12-06||Interventional|DHANI||Effect of Docosa-Hexanoic Acid (DHA) Supplements During Pregnancy on Newborn Outcomes in India.|Effect of Docosa-Hexanoic Acid (DHA) Supplements During Pregnancy on Newborn Outcomes in India (DHANI)|Completed||Phase 3|600|Actual|Centre for Chronic Disease Control, India||2|||f||||t||||||||No||2018-05-31 21:27:07.72125|2018-05-31 21:27:07.72125
NCT01580332|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2014-07-22|2012-04-18|2012-04-19|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Observational|ISRUSAL01||Non-Invasive Biomarkers For Early Detection Of Lung Cancers|NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF LUNG CANCERS: ELEMENT 1: NON-RANDOMIZED PHASE II EVALUATION AND VALIDATION IN NEWLY DIAGNOSED LUNG CANCER PATIENTS|Completed|||50|Anticipated|Baptist Cancer Institute|||||f||||f||||||Samples With DNA|"~     serum; sputum~   "|||2018-05-31 21:27:07.796036|2018-05-31 21:27:07.796036
NCT01580319|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2012-05-07|2012-04-18|2012-04-19|Estimate|||||||2012-05-07|2012-05-09|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity|Outpatient Strategy of Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity|Terminated||N/A|27|Actual|Instituto de Cardiologia do Rio Grande do Sul||2||Difficulty in selecting the sample and follow-up lost.|f||||f||||||||||2018-05-31 21:27:07.852092|2018-05-31 21:27:07.852092
NCT01580306|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2015-07-03||2015-07-03|2012-04-18|2012-04-19|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment|Pharmacokinetics, Safety and Tolerability of BI 201335 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase I Trial|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:27:07.945989|2018-05-31 21:27:07.945989
NCT01580293|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28||2015-06-09|2018-03-26|2012-04-18|2012-04-19|Estimate||||2015-06-09|2015-07-08|Estimate|2018-03-26|2018-03-29|Actual|April 23, 2012|Actual|2012-04-23|March 2018|2018-03-31|January 15, 2019|Anticipated|2019-01-15|June 13, 2014|Actual|2014-06-13||Interventional|PROTECT-VIII||A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A|A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A|Active, not recruiting||Phase 2/Phase 3|141|Actual|Bayer||4|||f||||t|t|f||||||||2018-05-31 21:27:08.406084|2018-05-31 21:27:08.406084
NCT01580280|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2014-11-12|2012-04-17|2012-04-19|Estimate|||||||2014-11-12|2014-11-14|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Manual Therapy and Exercise in Patients With Cervicogenic Headache|Effect of Upper Cervical and Upper Thoracic Thrust Manipulation Versus Mobilization and Exercise in Patients With Cervicogenic Headache|Completed||N/A|112|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||t||||||||||2018-05-31 21:27:08.593029|2018-05-31 21:27:08.593029
NCT01580254|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-04-17|2012-04-17|2012-04-18|Estimate|||||||2012-04-17|2012-04-18|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|LATANOPROST||Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma|Phase 4 Study to Evaluate Efficacy And Safety of Three Different Preparations of Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma|Unknown status|Recruiting|Phase 4|120|Anticipated|University of Cantanzaro||3|||f||||f||||||||||2018-05-31 21:27:08.768681|2018-05-31 21:27:08.768681
NCT01580241|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-08-21|2012-04-17|2012-04-18|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2010||2010-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2015|Actual|2015-07-31||Observational|||Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer|Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma|Active, not recruiting|||60|Anticipated|University of Oklahoma|||4||f||||f||||||||||2018-05-31 21:27:08.865513|2018-05-31 21:27:08.865513
NCT01580228|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-02-17|2012-04-17|2012-04-18|Estimate|||||||2017-02-17|2017-02-23|Actual|August 2012||2012-08-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)|A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia|Completed||Phase 3|44|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 21:27:08.92009|2018-05-31 21:27:08.92009
NCT01580215|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-12-21|2012-04-17|2012-04-18|Estimate|||||||2017-12-21|2017-12-26|Actual|July 2012||2012-07-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|LIVE||Long Term Follow up Investigation of Endobronchial Valves in Emphysema|Long Term Follow up Investigation of Endobronchial Valves in Emphysema|Terminated|||628|Actual|Pulmonx, Inc.|||1|Inability to reach desired recruitment goal; Sponsor executed other RCTs|f||||t||||||||||2018-05-31 21:27:08.991126|2018-05-31 21:27:08.991126
NCT01580202|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-06-28|2012-04-17|2012-04-18|Estimate|||||||2017-06-28|2017-06-29|Actual|April 2012||2012-04-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine|A Randomized, Open Labeled, Multicenter Study Comparing Entecavir Versus Lamivudine as Antiviral Prophylaxis for Patients With Hepatitis B Infection Undergoing Cytotoxic Chemotherapy for Malignant Tumors|Completed||Phase 3|180|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:27:09.059783|2018-05-31 21:27:09.059783
NCT01580189|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-12-07|2012-04-17|2012-04-18|Estimate|||||||2015-12-07|2015-12-08|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|October 2012|Actual|2012-10-31||Interventional|||Whole Milk Versus Whey Protein Supplement and Resistance Exercise|Effects of Whole Milk Versus Whey Protein Supplementation With Resistance Exercise on Body Composition, Muscle Hypertrophy and Strength Changes in Healthy Individuals|Completed||N/A|32|Actual|University of Manitoba||3|||f||||t||||||||||2018-05-31 21:27:09.156289|2018-05-31 21:27:09.156289
NCT01580176|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2013-12-19|2012-04-17|2012-04-18|Estimate|||||||2013-12-19|2013-12-20|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|ContAssGlu||Continuous GlucoseMonitor for Measurement of Blood Glucose Level|A Prospective Clinical Trial on Agreement to Evaluate the GlucoseMonitor, a Novel Device for Continuous Assessment of Blood Glucose Levels, in Comparison With the RAPIDLab® 1265 Blood Gas Analyser (ContAssGlu)|Completed||N/A|100|Actual|University Hospital Heidelberg||1|||f||||f||||||||||2018-05-31 21:27:09.25273|2018-05-31 21:27:09.25273
NCT01580163|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2015-11-16|2012-04-17|2012-04-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After Detoxification|Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After Detoxification|Completed||N/A|554|Actual|Shanghai Mental Health Center||3|||f||||f||||||||||2018-05-31 21:27:09.320153|2018-05-31 21:27:09.320153
NCT01580150|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-16|2012-04-16|2012-04-18|Estimate|||||||2012-04-16|2012-04-18|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SOMA||Effects of Berries on Post-meal Blood Sugar|Effects of Berries on Postprandial Glycemic Responses to Sucrose and Starch|Completed||N/A|20|Actual|University of Eastern Finland||2|||f||||f||||||||||2018-05-31 21:27:09.412126|2018-05-31 21:27:09.412126
NCT01580137|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2013-10-29|2012-04-17|2012-04-18|Estimate|||||||2013-10-29|2013-10-30|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|April 2014|Anticipated|2014-04-30|April 2012|Actual|2012-04-30||Observational|||Acute Upper Respiratory Tract Infection - When is Bacteria Involved?|Acute Upper Respiratory Tract Infection - When is Bacteria Involved?|Unknown status|Active, not recruiting||48|Anticipated|Oulu University Hospital|||2||f||||f||||||||||2018-05-31 21:27:09.488484|2018-05-31 21:27:09.488484
NCT01580124|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2016-01-26|2012-04-17|2012-04-18|Estimate|||||||2016-01-26|2016-01-27|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|CHASE-AF||CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study|CatHeter Ablation of perSistEnd Atrial Fibrillation: Pulmonary Vein Isolation Versus Defragmentation. The CHASE-AF Study.|Completed||N/A|150|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 21:27:09.562733|2018-05-31 21:27:09.562733
NCT01580111|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-04-17|2012-04-17|2012-04-18|Estimate|||||||2012-04-17|2012-04-18|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Effect of Blood Storage Age on the Resolution of Lactic Acidosis in Children With Severe Malarial Anemia at Mulago Hospital|Effect of Blood Storage Age on the Resolution of Lactic Acidosis in Children With Severe Malarial Anemia at Mulago Hospital|Completed||N/A|74|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 21:27:09.63897|2018-05-31 21:27:09.63897
NCT01580098|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2015-04-08||2015-08-21|2012-04-17|2012-04-18|Estimate|2015-08-21|2015-09-23|Estimate||||2015-08-21|2015-09-23|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|RenewingHealth||Medium-term Health Coaching and Life-long Monitoring in Diabetes Mellitus|Regions of Europe Working Together for Health (Renewing Health)|Completed||N/A|193|Actual|Landeskrankenanstalten-Betriebsgesellschaft||3|||f||||t||||||||||2018-05-31 21:27:09.735056|2018-05-31 21:27:09.735056
NCT01580085|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-17|2012-04-17|2012-04-18|Estimate|||||||2012-04-17|2012-04-18|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Obstructive Sleep Apnea in Pulmonary Embolism|Obstructive Sleep Apnea is Prevalent in Patients With Pulmonary Embolism|Completed|||75|Actual|University of Gaziantep|||2||f||||f||||||||||2018-05-31 21:27:10.227224|2018-05-31 21:27:10.227224
NCT01580072|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2015-04-08||2015-07-01|2012-04-17|2012-04-18|Estimate|2015-06-25|2015-07-01|Estimate||||2015-07-01|2015-07-23|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|RenewingHealth||Telemonitoring of Patients With COPD in Carinthia|REgions of Europe WorkiNg toGether for HEALTH (Renewing Health)|Completed||N/A|65|Actual|Landeskrankenanstalten-Betriebsgesellschaft||3|||f||||||||||||||2018-05-31 21:27:10.328124|2018-05-31 21:27:10.328124
NCT01580046|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-10-14|2012-04-17|2012-04-18|Estimate|||||||2013-10-14|2013-10-16|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|RIPE||Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction|Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction—a Multicentre, Single Blind, Randomized Controlled, Prospective Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|Peking University First Hospital||2|||f||||f||||||||||2018-05-31 21:27:10.784708|2018-05-31 21:27:10.784708
NCT01580033|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2013-05-07|2012-04-17|2012-04-18|Estimate|||||||2013-05-07|2013-05-08|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine|Immunogenicity and Safety Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Aged 3-5 Months: A Phase 3 Clinical Trial|Completed||Phase 3|900|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 21:27:10.909831|2018-05-31 21:27:10.909831
NCT01580020|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2015-09-28||2016-04-11|2012-04-17|2012-04-18|Estimate|2016-04-11|2016-05-17|Estimate||||2016-04-11|2016-05-17|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO|An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18)|Completed||Phase 4|175|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:27:11.023993|2018-05-31 21:27:11.023993
NCT01580007|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2015-02-12|2012-04-17|2012-04-18|Estimate|||||||2015-02-12|2015-02-13|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)|Clinical Trial of Oral Phenylbutyrate and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis in Bangladesh: a Pilot Study|Completed||Phase 2|288|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 21:27:11.868403|2018-05-31 21:27:11.868403
NCT01579994|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2018-02-23|2012-04-17|2012-04-18|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2012|Actual|2012-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers|A Phase I Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers|Active, not recruiting||Phase 1|55|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:27:11.96247|2018-05-31 21:27:11.96247
NCT01579981|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-02-09|2012-04-17|2012-04-18|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2012||2012-04-30|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Importance of GLP-1 in Post RYGB Improvement in Glycaemic Control Type 2 Diabetic Subjects|The Exaggerated Glucagon-like Peptide-1 Response is Important for the Improved β-cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes|Completed||N/A|9|Actual|Hvidovre University Hospital|||||f||||f||||||||||2018-05-31 21:27:12.031341|2018-05-31 21:27:12.031341
NCT01579968|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-02-23|2012-04-17|2012-04-18|Estimate|||||||2017-02-23|2017-02-24|Actual|March 10, 1999|Actual|1999-03-10|February 2017|2017-02-28|March 9, 2010|Actual|2010-03-09|March 9, 2010|Actual|2010-03-09||Observational|||Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery|Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery|Completed|||86|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:27:12.10508|2018-05-31 21:27:12.10508
NCT01579955|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-02-22|2012-04-17|2012-04-18|Estimate|||||||2017-02-22|2017-02-24|Actual|March 10, 1999|Actual|1999-03-10|February 2017|2017-02-28|March 9, 2010|Actual|2010-03-09|March 9, 2010|Actual|2010-03-09||Observational|||Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice|Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice|Completed|||321|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:27:12.169334|2018-05-31 21:27:12.169334
NCT01579942|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-03-02|2012-04-17|2012-04-18|Estimate|||||||2017-03-02|2017-03-06|Actual|April 2012||2012-04-30|March 2017|2017-03-31||||||||Observational|||Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression|Potential Use Of Brain Network Activation Analysis Using Evoked Response Potentials to Diagnose Major Depression and Assess Response to Antidepressant Treatment|Terminated|||70|Anticipated|Massachusetts General Hospital|||2|The study was ultimately not funded by the sponsor. No subjects were enrolled.|f||||f||||||||||2018-05-31 21:27:12.366333|2018-05-31 21:27:12.366333
NCT01579929|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-08-14|2012-04-17|2012-04-18|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2012||2012-04-30|August 2017|2017-08-31|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)|A Phase I Trial of the Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)|Completed||Phase 1|19|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:27:12.436741|2018-05-31 21:27:12.436741
NCT01579916|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2013-12-16||2013-12-16|2012-04-17|2012-04-18|Estimate|2013-12-16|2014-02-03|Estimate||||2013-12-16|2014-02-03|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|Completed||Phase 4|303|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 21:27:12.534519|2018-05-31 21:27:12.534519
NCT01579903|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-02-07|2012-04-16|2012-04-18|Estimate|||||||2013-02-07|2013-02-08|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)|An Open-Label, Randomized, Two-period Crossover Study To Compare Relative Bioavailability of Two Formulations of Moroctocog Alfa (Af-cc) In Subjects With Moderately Severe Or Severe Hemophilia A (FVIII:C </=2%)|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:27:13.00643|2018-05-31 21:27:13.00643
NCT01579890|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2012-04-17|2012-04-16|2012-04-18|Estimate|||||||2012-04-17|2012-04-19|Estimate||||April 2012|2012-04-30||||||||Expanded Access|||Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis|A Non-blinded, Non-placebo Controlled, Compassionate Use, Open Treatment, Open-ended Program of the Safety of Pennsaid Topical Lotion (Diclofenac) in the Treatment of Osteo or Rheumatoid Arthritis|Approved for marketing|||||Mallinckrodt|||||f||||||||||||||2018-05-31 21:27:13.092692|2018-05-31 21:27:13.092692
NCT01579877|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-05-12|2012-04-16|2012-04-18|Estimate|||||||2013-05-12|2013-05-14|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Interventional|||Treatment of Xerostomia by Herbal Preparation|Efficacy of Yukmijihwang-tang on Xerostomia in the Elderly: A Randomized,Double-blind, Placebo-controlled, Two-center Trial|Unknown status|Recruiting|N/A|96|Anticipated|Korea Health Industry Development Institute||2|||f||||f||||||||||2018-05-31 21:27:13.148912|2018-05-31 21:27:13.148912
NCT01579864|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-11-02|2012-04-17|2012-04-18|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Broncho-SR||Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia|Interventional Rigid Bronchoscopy Under General Anesthesia: Influence of the Muscle Relaxant, Succinylcholine or Rocuronium, on the Quality of the Surgical Procedure|Terminated||Phase 4|6|Actual|Hopital Foch||2||recent publication (Ghezel-Ahmadi. Thorac Cardiovasc Surg. 2014 Nov 21)|f||||f||||||||||2018-05-31 21:27:13.246955|2018-05-31 21:27:13.246955
NCT01579851|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-05-19|2012-04-17|2012-04-18|Estimate|||||||2017-05-19|2017-05-22|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|Sugammadex2||Recovery After Sugammadex(Propofol vs Sevoflurane)|Recovery After Sugammadex(TIVA Using Propofol vs Inhalation Anesthesia Using Sevoflurane)|Completed||Phase 4|71|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 21:27:13.316429|2018-05-31 21:27:13.316429
NCT01579838|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-04-17|2012-04-17|2012-04-18|Estimate|||||||2012-04-17|2012-04-18|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||An Open Label Study of the Effects of Eculizumab in CD59 Deficiency|An Open Label Study of the Effects of Eculizumab in CD59 Deficiency|Unknown status|Recruiting|Phase 1/Phase 2|5|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 21:27:13.394481|2018-05-31 21:27:13.394481
NCT01579825|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-04-24|2012-04-17|2012-04-18|Estimate|||||||2013-04-24|2013-04-25|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh|Evaluation of the Effect of Buffer on the Immune Response to Oral Poliovirus Vaccine in Bangladesh: a Randomized Controlled Trial|Completed||N/A|300|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:27:13.492142|2018-05-31 21:27:13.492142
NCT01579812|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2018-02-28||2018-05-24|2012-04-16|2012-04-18|Estimate|2018-05-24|2018-05-25|Actual||||2018-05-24|2018-05-25|Actual|October 2011||2011-10-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients|A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Completed||Phase 2|90|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:27:13.592399|2018-05-31 21:27:13.592399
NCT01579799|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2015-05-27|2012-04-16|2012-04-18|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||The Effect of L-lysine on Human Gastrointestinal Secretion: A Dose-finding Study Applying Magnetic Resonance Imaging (MRI)||Completed||N/A|6|Actual|University of Zurich||4|||f||||||||||||||2018-05-31 21:27:13.910226|2018-05-31 21:27:13.910226
NCT01579786|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-02-19|2012-04-16|2012-04-18|Estimate|||||||2014-02-19|2014-02-20|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|December 2012|Actual|2012-12-31||Interventional|||Treatment of Post Operative Pain in Thyroid Surgery Patients: Perspective Study Acupuncture Versus Drugs|The Treatment of Post Operative Pain in Thyroid Surgery Patients: Perspective Study Acupuncture Versus Pharmacological Treatment|Unknown status|Active, not recruiting|N/A|121|Actual|University of Padova||2|||f||||t||||||||||2018-05-31 21:27:13.988432|2018-05-31 21:27:13.988432
NCT01579773|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-12-08|2012-04-16|2012-04-18|Estimate|||||||2014-12-08|2014-12-10|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|DEXA||Comparison of Body Composition & Weight Change in Users of Progestin-only Contraception During the First Year of Use|Comparison of Body Composition & Weight Change in Users of Progestin-only Contraception During the First Year of Use|Completed|||345|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 21:27:14.063444|2018-05-31 21:27:14.063444
NCT01579760|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2018-04-30|2012-04-17|2012-04-18|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2012||2012-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intravitreal Aflibercept Injection for Radiation Retinopathy|Treatment of Radiation Retinopathy With Intravitreal Aflibercept Injection 2.0mg|Active, not recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:27:14.122041|2018-05-31 21:27:14.122041
NCT01579747|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2013-08-19||2013-12-18|2012-04-17|2012-04-18|Estimate|2013-10-29|2013-12-19|Estimate||||2013-12-18|2014-01-24|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Does Ultrasound Improve Procedural Time in the Lateral Popliteal Approach to the Sciatic Nerve in Obese Patients|Does Ultrasound Improve Procedural Time in the Lateral Popliteal Approach to the Sciatic Nerve in Obese Patients|Completed||Phase 4|25|Actual|University of New Mexico|We attempted to minimize performance bias by only involving staff anesthesiologists with years of experience in peripheral nerve blockade using both guidance modalities.|2|||f||||f||||||||||2018-05-31 21:27:14.210933|2018-05-31 21:27:14.210933
NCT01579734|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-01-30|2012-04-17|2012-04-18|Estimate|||||||2018-01-30|2018-01-31|Actual|March 2002||2002-03-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|HOT||Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users|The HOT Study: Hormone Replacement Therapy Opposed by Low Dose Tamoxifen. A Phase III Trial of Breast Cancer Prevention With Low Dose Tamoxifen in HRT Users.|Active, not recruiting||Phase 3|1884|Actual|European Institute of Oncology||2|||f||||t||||||||||2018-05-31 21:27:14.453441|2018-05-31 21:27:14.453441
NCT01579721|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-02-03|2012-04-17|2012-04-18|Estimate|||||||2013-02-03|2013-02-05|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Prospective Randomized Study of SILS Versus CLS for Rectal Cancer|Prospective Randomized Study of Single Incision Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer|Completed||Phase 4|40|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 21:27:14.640486|2018-05-31 21:27:14.640486
NCT01579708|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-12-20|2012-04-17|2012-04-18|Estimate|||||||2017-12-20|2017-12-21|Actual|September 2011||2011-09-30|December 2017|2017-12-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|Preschool_PSI!||Evaluation of the Program SI! for Preschool Education: A School-Based Randomized Controlled Trial|Evaluation of the Program SI! for Preschool Education: A School-Based Randomized Controlled Trial|Completed||Phase 3|2060|Actual|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III||2|||f||||||||||||||2018-05-31 21:27:14.709273|2018-05-31 21:27:14.709273
NCT01579695|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2016-08-12|2012-04-16|2012-04-18|Estimate|||||||2016-08-12|2016-08-15|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|March 2030|Anticipated|2030-03-31|December 2029|Anticipated|2029-12-31||Observational|||Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®|A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®|Recruiting|||3190|Anticipated|Theratechnologies|||2||f||||t||||||||||2018-05-31 21:27:14.777294|2018-05-31 21:27:14.777294
NCT01579682|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2016-04-12|2012-04-16|2012-04-18|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Adaptive Family Treatment for Adolescent Anorexia Nervosa|Adaptive Family Treatment for Adolescent Anorexia Nervosa|Completed||N/A|90|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 21:27:14.923942|2018-05-31 21:27:14.923942
NCT01579669|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2015-08-18||2015-10-30|2012-04-16|2012-04-18|Estimate|2015-10-30|2015-12-07|Estimate||||2015-10-30|2015-12-07|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Baseline characteristics are presented for the autistic participants who completed the pre-intervention survey and the primary care providers who completed the PCP survey.|Partnering With Autistic Adults to Improve Healthcare|Partnering With Autistic Adults to Develop Tools to Improve Primary Healthcare|Completed||N/A|237|Actual|Oregon Health and Science University|This study was designed as a single-arm trial to assess feasibility and acceptability and to explore potential mechanisms of action. As such, there was no control group. PCPs are not a separate arm, but were included to assess acceptability.|1|||f||||f||||||||||2018-05-31 21:27:15.08262|2018-05-31 21:27:15.08262
NCT01579656|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2014-03-06|2012-04-16|2012-04-18|Estimate|||||||2014-03-06|2014-03-07|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Effect of Flax, Poppy, Sesame & Salba on Postprandial Blood Glucose Response, Vascular, Appetite & Sensory Parameters|The Effects of Four Commonly Consumed Seeds (Flax, Poppy, Sesame & Salba) on Postprandial Blood Glucose Response, Vascular, Appetite and Sensory Parameters in Healthy Individuals|Completed||Phase 1|21|Actual|St. Michael's Hospital, Toronto||5|||f||||f||||||||||2018-05-31 21:27:15.503657|2018-05-31 21:27:15.503657
NCT01579643|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-04-12|2012-04-16|2012-04-18|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2012||2012-01-31|April 2018|2018-04-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|LALAK||OCT-guided LALAK in Children|Randomized Clinical Trial of OCT-guided Laser-assisted Lamellar Anterior Keratoplasty in Children|Terminated||N/A|1|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 21:27:15.605497|2018-05-31 21:27:15.605497
NCT01579630|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2014-04-03|2012-04-17|2012-04-18|Estimate|||||||2014-04-03|2014-04-04|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy|An Open Label, Randomized, Multicenter, Phase II Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Advanced (Stage IV) EGFR Mutation Negative or T790M Single Mutation Nonsquamous NSCLC Who Respond to 4 Cycles of Pemetrexed/ Platinum as First-line Therapy|Unknown status|Active, not recruiting|Phase 2/Phase 3|52|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 21:27:15.840368|2018-05-31 21:27:15.840368
NCT01579617|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-12-16|2012-04-16|2012-04-18|Estimate|||||||2016-12-16|2016-12-19|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|eSiHLE||e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls|e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls|Completed||N/A|637|Actual|Tulane University||2|||f||||f||||||||No||2018-05-31 21:27:16.221129|2018-05-31 21:27:16.221129
NCT01579604|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-02-02|2012-04-16|2012-04-18|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2012||2012-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Nerve Transfer Reconstruction in the Tetraplegic Upper Extremity|Early Nerve Reconstruction Approach in Tetraplegic Patients With Dysfunctional Upper Extremity: a Randomized Controlled Trial.|Recruiting||Phase 4|10|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 21:27:16.594961|2018-05-31 21:27:16.594961
NCT01579591|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-17|2012-04-17|2012-04-18|Estimate|||||||2012-04-17|2012-04-18|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Interventional|||VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer|A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in Increasing the Pathological Major Response Rate in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy|Unknown status|Recruiting|Phase 3|160|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 21:27:16.95865|2018-05-31 21:27:16.95865
NCT01579578|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2014-03-20||2014-09-11|2012-04-17|2012-04-18|Estimate|2014-09-11|2014-09-12|Estimate||||2014-09-11|2014-09-12|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer|A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE)|Terminated||Phase 2|39|Actual|AstraZeneca||2||AstraZeneca sponsored trials of AZD8931 have been halted|f||||||||||||||2018-05-31 21:27:17.118368|2018-05-31 21:27:17.118368
NCT01579565|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2014-07-02|2013-07-10|2017-05-19|2012-04-16|2012-04-18|Estimate|2014-08-05|2014-08-22|Estimate|2013-07-10|2013-07-12|Estimate|2017-05-19|2017-06-14|Actual|April 2012||2012-04-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|OMS302-ILR-004||Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Pharmacokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|Completed||Phase 3|416|Actual|Omeros Corporation||2|||f||||f||||||||||2018-05-31 21:27:17.686038|2018-05-31 21:27:17.686038
NCT01579552|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-08-08|2012-04-17|2012-04-18|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2010||2010-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer|EMPOWER Study: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer|Active, not recruiting||Phase 3|360|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:27:18.157379|2018-05-31 21:27:18.157379
NCT01579539|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2017-12-28|2012-04-16|2012-04-18|Estimate|||||||2017-12-28|2017-12-29|Actual|June 2013||2013-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy|The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy|Recruiting||Phase 3|24|Anticipated|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 21:27:18.306653|2018-05-31 21:27:18.306653
NCT01579526|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2012-05-16|2012-04-17|2012-04-18|Estimate|||||||2012-05-16|2012-05-17|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers|A Randomized, Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers|Completed||Phase 1|40|Actual|Cerecor Inc||4|||f||||f||||||||||2018-05-31 21:27:18.616075|2018-05-31 21:27:18.616075
NCT01579513|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-01-08|2012-04-16|2012-04-18|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2012||2012-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass|Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass|Active, not recruiting||N/A|190|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:27:18.866954|2018-05-31 21:27:18.866954
NCT01579500|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-04-23|2012-04-16|2012-04-18|Estimate|||||||2013-04-23|2013-04-25|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients|The Effect of Botulinum Toxin A in Post Spinal Cord Injury Neuropathic Pain|Completed||Phase 4|40|Actual|Catholic University of Korea Saint Paul's Hospital||2|||f||||t||||||||||2018-05-31 21:27:19.188593|2018-05-31 21:27:19.188593
NCT01579487|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-06-20|2012-04-16|2012-04-18|Estimate|||||||2017-06-20|2017-06-22|Actual|March 2012||2012-03-31|March 2012|2012-03-31|February 2013|Actual|2013-02-28|April 2012|Actual|2012-04-30||Interventional|JUNO||Extended Follow-Up Study for Subjects Who Participated in 2010 Study|Non-Invasive Reduction of Abdominal Fat Utilizing the JUNO Applicator|Completed||N/A|10|Actual|Zeltiq Aesthetics|||||f||||f||||||||No||2018-05-31 21:27:19.451028|2018-05-31 21:27:19.451028
NCT01579474|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2015-07-03||2015-07-03|2012-04-17|2012-04-18|Estimate|2015-07-03|2015-08-03|Estimate||||2015-07-03|2015-08-03|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||FAS (All patients who were randomized and received at least 1 dose of the trial medication)|Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial|Safety, Efficacy and Pharmacokinetics of BI 201335 NA in Patient With Genotype 1 Chronic Hepatitis C Virus Infection in Combination With Pegylated Interferon Alfa-2b and Ribavirin - Cohort 1 for Treatment-naive Patients: Randomised, Double-blind Part of BI 201335 NA for 12 or 24 Weeks - Cohort 2 for Treatment-experienced Patients: Open-label Part of BI 201335 NA for 24 Weeks|Completed||Phase 3|131|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:27:19.65468|2018-05-31 21:27:19.65468
NCT01579461|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-09-04|2012-04-17|2012-04-18|Estimate|||||||2013-09-04|2013-09-05|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects|An Open Label Single Dose Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of YM178 Compared With Healthy Subjects|Completed||Phase 1|32|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 21:27:21.521025|2018-05-31 21:27:21.521025
NCT01579448|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2013-09-24|2012-04-16|2012-04-18|Estimate|||||||2013-09-24|2013-09-25|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Boost||Evaluation of a Boosting Regimen With Oral Cholera Vaccine|A Open Labeled Controlled Trial to Evaluate the Immune Response of a Boosting Regimen With Shanchol™, a Killed Whole Cell Oral Cholera Vaccine (WC-OCV), in Previously Immunized Adults and Children in Eastern Kolkata, India|Completed||Phase 4|426|Actual|International Vaccine Institute||3|||f||||t||||||||||2018-05-31 21:27:21.598503|2018-05-31 21:27:21.598503
NCT01579435|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-04-10|2012-04-16|2012-04-18|Estimate|||||||2013-04-10|2013-04-11|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ELECTRE||Experimental Therapeutics in Essential Tremor Using Transcranial Direct Current Stimulation|Thérapeutique expérimentale du Tremblement Essentiel Par la Stimulation Trans-crânienne Par Courant Direct (tDCS) du Cortex cérébelleux et du Cortex Moteur. Etude Exploratoire.|Completed||N/A|12|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 21:27:21.676446|2018-05-31 21:27:21.676446
NCT01579422|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-01-11|2012-04-16|2012-04-18|Estimate|||||||2016-01-11|2016-01-12|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Social Cognitive Training for Psychosis: Treatment Development|Social Cognitive Training for Psychosis: Phase I Treatment Development|Completed||Phase 1|77|Actual|Yale University||1|||f||||f||||||||||2018-05-31 21:27:21.759132|2018-05-31 21:27:21.759132
NCT01579409|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2012-04-16|2012-04-16|2012-04-18|Estimate|||||||2012-04-16|2012-04-18|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|NUTRIVASC||The Impact of the French PNNS Guidelines on Vascular Function Following a Standardised Breakfast.|The Impact of the French National Program for Nutrition and Health Guidelines on Vascular Function Following a Standardised Breakfast:The Nutri-Vasc Study|Unknown status|Enrolling by invitation|Phase 4|94|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 21:27:21.93533|2018-05-31 21:27:21.93533
NCT01579396|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-04-04|2012-04-16|2012-04-18|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2012||2012-04-30|April 2017|2017-04-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|HICOSIRS||High Cut Off Dialysis in Systemic Inflammatory Response Syndrome Patients After Cardiac Surgery|The Effects of High-cutoff (HCO) Hemofiltration in the Immediate Postoperative Period on Systemic Inflammatory Response Syndrome (SIRS) and Renal Recovery in Cardiac Surgery Patients With a High Risk for Renal Failure. (HICOSIRS)|Withdrawn||N/A|0|Actual|Baxter Healthcare Corporation||2||Study halted prematurely, prior to enrollment of first patient, due to recruiting problems.|f||||f||||||||||2018-05-31 21:27:22.002557|2018-05-31 21:27:22.002557
NCT01579383|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-04-25|2012-04-16|2012-04-18|Estimate|||||||2013-04-25|2013-04-26|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Safety Tolerability and Pharmacokinetics of ALD403|A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection|Completed||Phase 1|104|Actual|Alder Biopharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 21:27:22.086647|2018-05-31 21:27:22.086647
NCT01579370|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2015-11-15|2012-04-16|2012-04-18|Estimate|||||||2015-11-15|2015-11-17|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)|A Four-arm Prospective, Multicenter Study to Assess the Efficacy, Effectiveness, and Feasibility of Enhanced Terminal Room Disinfection With Chlorine and UV Light Using Clinical and Microbiologic Outcomes|Completed||N/A|21395|Actual|Duke University||4|||f||||f||||||||||2018-05-31 21:27:22.168642|2018-05-31 21:27:22.168642
NCT01579357|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-03-06|2012-04-17|2012-04-18|Estimate|||||||2015-03-06|2015-03-09|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetics and Metabolic Activation of Capecitabine|Pharmacokinetics and Metabolic Activation of Capecitabine When Given Concomitantly With Oxaliplatin and the Monoclonal Antibody Cetuximab|Completed||Phase 2|24|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||t||||||||||2018-05-31 21:27:22.27918|2018-05-31 21:27:22.27918
NCT01579344|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2012-04-16|2012-04-15|2012-04-17|Estimate|||||||2012-04-16|2012-04-18|Estimate|January 2012||2012-01-31|April 2012|2012-04-30||||March 2014|Anticipated|2014-03-31||Interventional|||Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma|Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma|Unknown status|Enrolling by invitation|N/A|100|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:27:22.353689|2018-05-31 21:27:22.353689
NCT01579331|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2012-11-25|2012-04-15|2012-04-17|Estimate|||||||2012-11-25|2012-11-27|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|DCT||Reliability of Dynamic Contour Tonometry (DCT)|Study of Test-retest Reliability of Dynamic Contour Tonometry and Its Correlation With Goldmann Applanation Tonometry|Completed||Phase 4|102|Actual|University of Cantanzaro||1|||f||||f||||||||||2018-05-31 21:27:22.420238|2018-05-31 21:27:22.420238
NCT01579318|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|2017-11-27||2018-01-01|2012-04-16|2012-04-17|Estimate|2018-01-01|2018-01-03|Actual||||2018-01-01|2018-01-03|Actual|June 8, 2012|Actual|2012-06-08|January 2018|2018-01-31|June 3, 2014|Actual|2014-06-03|June 3, 2014|Actual|2014-06-03||Interventional|CTCL|All enrolled participants|Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma|A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma|Terminated||Phase 2|2|Actual|OncoSec Medical Incorporated|Study enrollment was prematurely terminated under protocol version 6.0. No patients signed informed consent under version 7.0. Two (2) of the targeted 27 patients were enrolled. Thus, a formal statistical analysis was not performed.|1||Due to company resource constraints|f||||t||||||||||2018-05-31 21:27:22.514405|2018-05-31 21:27:22.514405
NCT01579305|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2014-06-27||2015-04-30|2012-04-16|2012-04-17|Estimate|2014-07-10|2014-08-05|Estimate||||2015-04-30|2015-05-19|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional||Baseline characteristics are based on the “modified Intent-to-Treat” population: subjects randomized to receive treatment and treated.|Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-L® for Lip Volume Enhancement||Completed||N/A|285|Actual|Allergan||2|||f||||||||||||||2018-05-31 21:27:22.771309|2018-05-31 21:27:22.771309
NCT01579292|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2014-07-16|2012-04-16|2012-04-17|Estimate|||||||2014-07-16|2014-07-17|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Mobile Based Diabetes Prevention Program|mDPP Pilot RCT of a Motivational Mobile Diabetes Prevention Program (mDPP)|Completed||N/A|61|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:27:23.010273|2018-05-31 21:27:23.010273
NCT01579279|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-09-24|2012-04-16|2012-04-17|Estimate|||||||2013-09-24|2013-09-26|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain|Terminated||Phase 2|1|Actual|AbbVie||5||Study Stopped|f||||t||||||||||2018-05-31 21:27:23.10228|2018-05-31 21:27:23.10228
NCT01579266|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-14|||2018-03-21|2012-04-14|2012-04-17|Estimate|||||||2018-03-21|2018-03-22|Actual|March 21, 2012||2012-03-21|October 25, 2016|2016-10-25|October 25, 2016||2016-10-25|||||Observational|||Validating a New Writer s Cramp Scale|Validating a New Writer's Cramp Scale|Completed|||16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:27:23.278932|2018-05-31 21:27:23.278932
NCT01579253|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2012-12-17|2012-04-15|2012-04-17|Estimate|||||||2012-12-17|2012-12-18|Estimate|April 2012||2012-04-30|December 2012|2012-12-31||||||||Observational|||Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients|Untersuchungen Zur Verlaufskontrolle Bei Re-Bestrahlung Von Glioblastompatienten Mittels Kombinierter [18F]FET-PET-Kernspintomographie|Unknown status|Recruiting||10|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||f||||||||||2018-05-31 21:27:23.342196|2018-05-31 21:27:23.342196
NCT01579240|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-16|2012-04-16|2012-04-17|Estimate|||||||2012-04-16|2012-04-17|Estimate|February 2006||2006-02-28|December 2006|2006-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Internet Intervention Promotes Physical Activity in Sedentary Older Adults|Internet Intervention Promotes Physical Activity|Completed||N/A|368|Actual|Oregon Center for Applied Science, Inc.||1|||f||||f||||||||||2018-05-31 21:27:23.419024|2018-05-31 21:27:23.419024
NCT01579227|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-01-25|2012-04-16|2012-04-17|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2012||2012-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|TOP/OTOP||Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound|Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound.|Active, not recruiting|||101|Anticipated|Ohio State University|||6||f||||f||||||Samples With DNA|"~     Tissue biopsy will be collected twice in the study period.~   "|||2018-05-31 21:27:23.490727|2018-05-31 21:27:23.490727
NCT01579045|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2014-08-28||2015-05-05|2012-04-13|2012-04-17|Estimate|2014-09-29|2014-10-03|Estimate||||2015-05-05|2015-05-21|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Twenty-four subjects were screened, enrolled and completed each of the two arms of the study. No subjects were deemed ineligible on screening.|Effect of Head and Gaze Position on Soft Toric Contact Lens Performance|Effect of Head and Gaze Position on Soft Toric Contact Lens Performance|Completed||N/A|24|Actual|Johnson & Johnson Vision Care, Inc.||12|||f||||f||||||||||2018-05-31 21:27:25.695471|2018-05-31 21:27:25.695471
NCT01579214|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2017-05-05||2017-12-08|2012-04-16|2012-04-17|Estimate|2017-10-17|2017-12-08|Actual||||2017-12-08|2018-01-04|Actual|July 2012||2012-07-31|December 2017|2017-12-31|April 2015|Actual|2015-04-30|December 2013|Actual|2013-12-31||Interventional||Participants enrolled in the trial were in HIV care and had low CD4 count results requiring a prompt return to clinic as advised by a study clinician.|Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda|Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda|Completed||N/A|183|Actual|Massachusetts General Hospital|"Non-randomized allocation for primary analysis~Single site study~Requires validation in implementation study"|2|||f||||f||||||||||2018-05-31 21:27:23.602593|2018-05-31 21:27:23.602593
NCT01579201|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-02-12|2012-04-16|2012-04-17|Estimate|||||||2013-02-12|2013-02-15|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery|ED90 Determination of Carbetocin for the Prevention of Postpartum Uterine Atony in Women Undergoing an Elective Cesarean Delivery|Unknown status|Recruiting|Phase 4|40|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||||2018-05-31 21:27:23.952182|2018-05-31 21:27:23.952182
NCT01579188|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-18|2012-04-16|2012-04-17|Estimate|||||||2012-04-18|2012-04-19|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|LucaVax||Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer|A Double-blind, Multicenter, Randomized Phase III Study of the Telomerase Vaccine, GV1001 Administered After Curative Intent Chemo-radiotherapy in Patients With Inoperable Stage III Non-small Cell Lung Cancer Compared to Best Supportive Care|Unknown status|Not yet recruiting|Phase 3|600|Anticipated|Kael-GemVax Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:27:24.049313|2018-05-31 21:27:24.049313
NCT01579175|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-03-13|2012-04-16|2012-04-17|Estimate|||||||2013-03-13|2013-03-14|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|GumGyn||The Effect of Gum Chewing on Postoperative Ileus After Gynecologic Surgery|The Effect of Gum Chewing on Postoperative Ileus After Gynecologic Surgery.|Completed||Phase 1/Phase 2|294|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:27:24.127134|2018-05-31 21:27:24.127134
NCT01579162|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2017-10-09|2012-04-13|2012-04-17|Estimate|||||||2017-10-09|2017-10-11|Actual|January 2012||2012-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|Repro||Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation|Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation|Active, not recruiting||N/A|40|Anticipated|HepQuant, LLC||5|||f||||f||||||||||2018-05-31 21:27:24.209127|2018-05-31 21:27:24.209127
NCT01579149|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2015-03-19|2012-04-13|2012-04-17|Estimate|||||||2015-03-19|2015-03-23|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent|A Phase 1, Randomized, Single-center, Single-dose, Double-blind, Placebo-controlled Pharmacokinetic, Safety, and Pharmacodynamic Study of Subcutaneous Injection of 160 μg/kg, 240 μg/kg, and 400 μg/kg Plerixafor in Healthy Adult Volunteers of Japanese Descent|Completed||Phase 1|24|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:27:24.296505|2018-05-31 21:27:24.296505
NCT01579136|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-12-20|2012-04-13|2012-04-17|Estimate|||||||2012-12-20|2012-12-24|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Do Home Monitors Improve Blood Pressure Control?||Terminated||N/A|26|Actual|Exempla Saint Joseph Hospital||2||Lack of subjects|f||||f||||||||||2018-05-31 21:27:24.381335|2018-05-31 21:27:24.381335
NCT01579123|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-01-17|2012-04-16|2012-04-17|Estimate|||||||2018-01-17|2018-01-19|Actual|February 2012||2012-02-29|January 2018|2018-01-31|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|||Laser Atherectomy Versus Angioplasty for the Treatment of Critical Limb Ischemia|Prospective Trial Comparing Laser Atherectomy to Angioplasty With/Without Stenting for Infrageniculate Peripheral Disease|Completed||N/A|200|Anticipated|Baylor Research Institute||2|||f||||t||||||||||2018-05-31 21:27:24.457732|2018-05-31 21:27:24.457732
NCT01579110|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-18|2012-04-14|2012-04-17|Estimate|||||||2012-04-18|2012-04-19|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.|Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||t||||||||||2018-05-31 21:27:24.54167|2018-05-31 21:27:24.54167
NCT01579097|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-01-31|2012-04-16|2012-04-17|Estimate|||||||2013-01-31|2013-02-01|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation|A Randomized, Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-Chamber Parenteral Nutrition Formulation (Oliclinomel N4)|Completed||Phase 3|458|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 21:27:24.623951|2018-05-31 21:27:24.623951
NCT01579084|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2013-09-12||2013-09-12|2012-04-16|2012-04-17|Estimate|2013-09-12|2013-11-15|Estimate||||2013-09-12|2013-11-15|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea||Completed||Phase 1|64|Actual|Allergan||10|||f||||f||||||||||2018-05-31 21:27:24.72137|2018-05-31 21:27:24.72137
NCT01579071|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2015-02-08|2012-04-14|2012-04-17|Estimate|||||||2015-02-08|2015-02-10|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor|A Randomized, Controlled, Double-blind Trial of the Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor|Completed||Phase 4|110|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 21:27:25.528675|2018-05-31 21:27:25.528675
NCT01579058|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-14|||2014-05-08|2012-04-14|2012-04-17|Estimate|||||||2014-05-08|2014-05-09|Estimate|July 2012||2012-07-31|May 2014|2014-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|BLAST||Effect of Bisoprolol on Progression of Aortic Stenosis|A Randomized Trial of Beta-blocker Therapy in Aortic Stenosis|Terminated||Phase 4|150|Anticipated|Asan Medical Center||2||The sponsor discontinued to support the study.|f||||t||||||||||2018-05-31 21:27:25.594073|2018-05-31 21:27:25.594073
NCT01578720|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-10-26|2012-04-13|2012-04-17|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2012||2012-06-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|April 2014|Actual|2014-04-30||Interventional|||Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome|Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)|Active, not recruiting||Phase 1|5|Anticipated|Retina Research Institute, LLC||1|||f||||f||||||||||2018-05-31 21:27:32.909539|2018-05-31 21:27:32.909539
NCT01579032|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-16|2012-04-16|2012-04-17|Estimate|||||||2012-04-16|2012-04-17|Estimate|January 2004||2004-01-31|February 2012|2012-02-29||||January 2012|Actual|2012-01-31||Observational|||PULSE WAVE ANALYSIS AND VELOCITY IN PATIENTS WITH CHRONIC RENAL FAILURE|PULSE WAVE ANALYSIS AND VELOCITY IN PATIENTS WITH CHRONIC RENAL FAILURE: A CROSS-SECTIONAL OBSERVATIONAL STUDY TO ASSESS ASSOCIATION WITH LEFT VENTRICULAR HYPERTROPY, UREMIC TOXINS AND INFLAMMATION.|Completed|||90|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 21:27:25.938472|2018-05-31 21:27:25.938472
NCT01579019|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2016-11-01|2012-04-16|2012-04-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment||Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:27:26.005632|2018-05-31 21:27:26.005632
NCT01579006|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2015-12-08||2016-02-04|2012-04-16|2012-04-17|Estimate|2015-12-08|2016-01-14|Estimate||||2016-02-04|2016-03-07|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Full Analysis Set (FAS) population included all recruited participants who received at least one dose of TCZ.|Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|A Multi National, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (Actemra)|Completed|||184|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:27:26.14469|2018-05-31 21:27:26.14469
NCT01578993|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2014-05-21||2016-02-18|2012-04-16|2012-04-17|Estimate|2014-05-21|2014-06-24|Estimate||||2016-02-18|2016-03-16|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Observational|PRISM-1||Observational Study of Complications Related to Use of Peripherally Inserted Central Catheters|A Phase IV, Prospective Clinical Evaluation of Complications Related to the Use of Peripherally Inserted Central Catheters (PICC) - An Observational Baseline Multicenter Study.|Completed|||101|Actual|Teleflex|Further comparative studies standarizing the management of PICC line flushing solutions and type if PICC line required to provide comparative and evidence based clinical practice recommendations.||||f||||f||||||||||2018-05-31 21:27:26.913953|2018-05-31 21:27:26.913953
NCT01578980|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2014-08-08||2014-09-05|2012-04-13|2012-04-17|Estimate|2014-08-08|2014-08-25|Estimate||||2014-09-05|2014-09-16|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Outpatient Control-to-Range: System and Monitoring Testing|Outpatient Control-to-Range: System and Monitoring Testing|Completed||N/A|20|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 21:27:27.051392|2018-05-31 21:27:27.051392
NCT01578967|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2017-09-11||2018-03-26|2012-04-13|2012-04-17|Estimate|2017-09-11|2017-10-12|Actual||||2018-03-26|2018-04-25|Actual|April 2012||2012-04-30|March 2018|2018-03-31|August 10, 2021|Anticipated|2021-08-10|August 10, 2016|Actual|2016-08-10||Interventional||One patient was not evaluable due to change in diagnosis during ABVD treatment (HL --> gray zone lymphoma).|Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma|LCCC 1115: A Pilot Feasibility Trial of Induction Chemotherapy With ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients With Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)|Active, not recruiting||N/A|41|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:27:27.231674|2018-05-31 21:27:27.231674
NCT01578954|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-03-20|2012-04-16|2012-04-17|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2012||2012-06-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|August 3, 2016|Actual|2016-08-03||Interventional|||Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction|LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy|Active, not recruiting||Phase 1|26|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:27:27.710443|2018-05-31 21:27:27.710443
NCT01578941|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-10-31|2012-04-13|2012-04-17|Estimate|||||||2012-10-31|2012-11-01|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine||Completed||Phase 4|12|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 21:27:27.79895|2018-05-31 21:27:27.79895
NCT01578928|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2015-03-02|2012-04-16|2012-04-17|Estimate|||||||2015-03-02|2015-03-03|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers|A Phase I, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous (s.c.) Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to a Matched Control Group of Healthy Volunteers|Completed||Phase 1|50|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:27:27.879457|2018-05-31 21:27:27.879457
NCT01578915|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2017-05-14|2012-04-13|2012-04-17|Estimate|||||||2017-05-14|2017-05-16|Actual|May 2011||2011-05-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A Case Control Study of Women With Multiple Sexual Partners|A Case Control Study of Women With Multiple Sexual Partners Attending the Jefferson County Department of Health Sexually Transmitted Diseases Clinic|Completed|||213|Actual|University of Alabama at Birmingham|||2||f||||f|f|f||||||No||2018-05-31 21:27:27.948651|2018-05-31 21:27:27.948651
NCT01578902|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2014-12-19|2012-04-13|2012-04-17|Estimate|||||||2014-12-19|2014-12-23|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2008|Actual|2008-04-30||Interventional|pHART3||Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer|Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer (pHART 3)|Completed||Phase 1/Phase 2|84|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 21:27:28.035716|2018-05-31 21:27:28.035716
NCT01578889|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2016-12-12|2012-04-13|2012-04-17|Estimate|||||||2016-12-12|2016-12-13|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|September 2014|Actual|2014-09-30||Interventional|||Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults|A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an IL-12 pDNA Enhanced HIV-1 Multiantigen pDNA Vaccine Delivered Intramuscularly With Electroporation, With an HIV-1 rVSV Vaccine Boost, in Healthy HIV-Uninfected Adult Participants|Completed||Phase 1|100|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-05-31 21:27:28.114663|2018-05-31 21:27:28.114663
NCT01578876|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2012-04-17|2012-04-16|2012-04-17|Estimate|||||||2012-04-17|2012-04-19|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||Extracorporeal Cardiac Shock Wave Therapy (CSWT) for Treatment of Coronary Artery Disease|To Prove up the Effect of CSWT in Vivo and to Evaluate the Feasibility and Efficiency of CSWT for Treatment of CAD and to Establish the Inclusion and Exclusion Criteria and Summarize the Methodological Outlines of CSWT in China.|Completed||Phase 3|55|Actual|Kunming Medical University||3|||f||||t||||||||||2018-05-31 21:27:28.226802|2018-05-31 21:27:28.226802
NCT01578863|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-04-13|2012-04-16|2012-04-17|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Predictors of Success in an Intervention Program for the Treatment of Childhood Obesity|Predictors of Success in a Multidisciplinary Intervention Program for Obese Children and Adolescence|Completed||N/A|176|Actual|Meir Medical Center||3|||f||||f||||||||||2018-05-31 21:27:28.301369|2018-05-31 21:27:28.301369
NCT01578850|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2016-02-16||2016-05-25|2012-04-12|2012-04-17|Estimate|2016-05-25|2016-07-06|Estimate||||2016-05-25|2016-07-06|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||The Full Analysis Set for Period 2 (Double Blind FAS) included all randomized participants who met the period 2 DAS28-ESR inclusion criteria, had at least one dose of study drug during Period 2 (ie, ETN, MTX or placebo) and have at least one valid efficacy (DAS28-ESR) evaluation after randomization.|Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening|A Randomized, Double-blind Placebo-controlled Study Of The Maintenance Of Efficacy Of Etanercept Plus Dmard(s) Compared With Dmard(s) Alone In Subjects With Rheumatoid Arthritis After Achieving An Adequate Response With Etanercept Plus Dmard(s)|Completed||Phase 4|491|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:27:28.466784|2018-05-31 21:27:28.466784
NCT01578837|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2014-02-18|2012-04-13|2012-04-17|Estimate|||||||2014-02-18|2014-02-19|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|R-KAT||Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes|Efficacy and Safety of Combined Rg3-enriched Korean Red Ginseng (Panax Ginseng C.A. Meyer) and American Ginseng (Panax Quinquefolius) as Poly-therapy in the Management of Concomitant Hypertension in Type 2 Diabetes|Unknown status|Recruiting|Phase 1/Phase 2|90|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:27:30.513193|2018-05-31 21:27:30.513193
NCT01578824|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-06-12|2012-04-15|2012-04-17|Estimate|||||||2013-06-12|2013-06-13|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients|Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients|Completed||N/A|26|Actual|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 21:27:30.608671|2018-05-31 21:27:30.608671
NCT01578811|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-03-14|2012-04-15|2012-04-17|Estimate|||||||2013-03-14|2013-03-18|Estimate|August 2011||2011-08-31|December 2010|2010-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis||Completed||Phase 2|102|Actual|SK Chemicals Co.,Ltd.||3|||f||||t||||||||||2018-05-31 21:27:30.699294|2018-05-31 21:27:30.699294
NCT01578798|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-10-29|2012-04-16|2012-04-17|Estimate|||||||2013-10-29|2013-10-30|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Detection of Immune Changes as a Result of Surgical Trauma in Human Subject|Detection of Immune Changes as a Result of Surgical Trauma in Human Subject|Completed|||50|Actual|Stanford University|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 21:27:30.764656|2018-05-31 21:27:30.764656
NCT01578785|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2014-02-19||2014-02-19|2012-04-15|2012-04-17|Estimate|2014-02-19|2014-04-02|Estimate||||2014-02-19|2014-04-02|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|GLOW||An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate 20mg/0.5ml New Formulation Administered Daily by Subcutaneous Injection|Terminated||Phase 3|178|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 21:27:30.871812|2018-05-31 21:27:30.871812
NCT01578772|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2014-09-04||2014-12-02|2012-04-15|2012-04-17|Estimate|2014-12-02|2014-12-08|Estimate||||2014-12-02|2014-12-08|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||HIV-infected individual >50 years old with HIV-1 RNA <50 copies /mL on stable ART and >=1 CVD risk factor.|A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease|Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease|Completed||Phase 2|17|Actual|University of California, Los Angeles|Given the limited size of the study population, the study was underpowered.|1|||f||||f||||||||||2018-05-31 21:27:32.458097|2018-05-31 21:27:32.458097
NCT01578759|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-04-21|2012-04-15|2012-04-17|Estimate|||||||2017-04-21|2017-04-25|Actual|April 2012||2012-04-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function|Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function|Completed||N/A|30|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:27:32.621733|2018-05-31 21:27:32.621733
NCT01578746|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-06-13|2012-04-13|2012-04-17|Estimate|||||||2013-06-13|2013-06-14|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison Between Anterior and Direct Lateral Approach in Total Hip Arthroplasty|Comparison Between Minimally Invasive Anterior Approach and Direct Lateral Approach in Total Hip Arthroplasty - A Prospective Randomized Trial|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Sorlandet Hospital HF||2|||f||||t||||||||||2018-05-31 21:27:32.708315|2018-05-31 21:27:32.708315
NCT01578733|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-08-16|2012-04-16|2012-04-17|Estimate|||||||2013-08-16|2013-08-19|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Determination of Protein Requirement in Elderly Female Subjects 65-75 Yrs Old|Use of Indicator Amino Acid Oxidation Technique to Determine Protein Requirement of Elderly Female Subjects 65-75 Yrs Old|Completed||N/A|14|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 21:27:32.805601|2018-05-31 21:27:32.805601
NCT01578707|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2015-06-23||2018-04-26|2012-04-13|2012-04-17|Estimate|2015-09-11|2015-10-12|Estimate||||2018-04-26|2018-05-25|Actual|June 2012|Actual|2012-06-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2013|Actual|2013-11-30||Interventional|RESONATE™||A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Active, not recruiting||Phase 3|391|Actual|Pharmacyclics LLC.||2|||f||||t||||||||||2018-05-31 21:27:33.146773|2018-05-31 21:27:33.146773
NCT01578694|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-03-23|2012-04-13|2012-04-17|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2007|Actual|2007-07-31|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Characterization of Proteoglycan Depletion in Femoroacetabular Impingement With T1ρ Magnetic Resonance Imaging (MRI)|Characterization of Proteoglycan Depletion in Femoroacetabular Impingement With T1ρ MRI|Completed||N/A|26|Actual|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||||2018-05-31 21:27:33.982139|2018-05-31 21:27:33.982139
NCT01578681|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2017-11-13|2012-04-16|2012-04-17|Estimate|||||||2017-11-13|2017-11-14|Actual|September 2011||2011-09-30|November 2017|2017-11-30|March 2017|Actual|2017-03-31|September 2011|Actual|2011-09-30||Interventional|ELTGOLBQ||ELTGOL and Bronchiectasis. Respiratory Therapy|Multicenter Randomized Placebo-controlled Trial to Evaluate the Efficacy of the ELTGOL Technique in the Drainage of Secretions in Patients With Bronchiectasis|Completed||N/A|44|Actual|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta||2|||f||||f||||||||||2018-05-31 21:27:34.045859|2018-05-31 21:27:34.045859
NCT01578668|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-01-23|2012-04-16|2012-04-17|Estimate|||||||2015-01-23|2015-01-26|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases|Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases|Completed||Phase 2|69|Actual|Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 21:27:34.119542|2018-05-31 21:27:34.119542
NCT01578655|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09||2016-10-07|2016-10-11|2012-04-16|2012-04-17|Estimate||||2016-10-11|2016-10-12|Estimate|2016-10-11|2016-10-12|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|AFFINITY||Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer|A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)|Completed||Phase 3|630|Actual|Achieve Life Sciences||2|||f||||t||||||||||2018-05-31 21:27:34.25223|2018-05-31 21:27:34.25223
NCT01578642|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2014-02-11|2012-04-15|2012-04-17|Estimate|||||||2014-02-11|2014-02-12|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease|A Feasibility Study: An Evaluation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 2|24|Actual|EndoStim Inc.||1|||f||||f||||||||||2018-05-31 21:27:34.532325|2018-05-31 21:27:34.532325
NCT01578629|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-03-20|2012-04-13|2012-04-17|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2012||2012-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|NUTRITION||NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event|Human Blood Outcomes Following Tocotrienol Supplementation - NUTRITION Phase I and Phase IIA|Active, not recruiting||Phase 1/Phase 2|210|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 21:27:34.629015|2018-05-31 21:27:34.629015
NCT01578616|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-08-05|2012-04-14|2012-04-17|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Endothelial Dysfunction and Plaque Vulnerability|Association of Endothelial Function With Plaque Vulnerability Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome|Completed|||100|Actual|Yokohama City University Medical Center|||2||f||||f||||||||||2018-05-31 21:27:34.712266|2018-05-31 21:27:34.712266
NCT01578603|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-05-09|2012-04-14|2012-04-17|Estimate|||||||2012-05-09|2012-05-10|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Two Sugar Substituted Chewing Gums on Caries and Gingivitis Variables|Effects of Two Sugar Substituted Chewing Gums Plus Tooth Brushing on Different Caries and Gingivitis Related Variables: a Double Blind, Randomized Controlled Clinical Trial|Completed||Phase 4|130|Actual|Universidad de Antioquia||2|||f||||f||||||||||2018-05-31 21:27:34.817284|2018-05-31 21:27:34.817284
NCT01578590|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-11-26|2012-04-16|2012-04-17|Estimate|||||||2014-11-26|2014-12-02|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Meat-Milk||Post-exercise Recovery After Dietary Protein Ingestion in Healthy Young Men (Meat-Milk Study)|Post-exercise Recovery After Dietary Protein Ingestion in Healthy Young Men|Completed||N/A|12|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:27:34.933925|2018-05-31 21:27:34.933925
NCT01578577|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2015-03-26|2012-04-16|2012-04-17|Estimate|||||||2015-03-26|2015-03-30|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|NAMES||Northwestern University and Access Community Health Network Medication Education Study|EHR-based Health Literacy Strategy to Promote Medication Therapy Management|Unknown status|Active, not recruiting|N/A|1680|Anticipated|Northwestern University||3|||f||||t||||||||||2018-05-31 21:27:35.046771|2018-05-31 21:27:35.046771
NCT01578564|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2016-06-21|2012-04-13|2012-04-17|Estimate|||||||2016-06-21|2016-06-23|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel|Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel|Completed||Phase 1|23|Actual|Soricimed Biopharma Inc||1|||f||||t||||||||||2018-05-31 21:27:35.138664|2018-05-31 21:27:35.138664
NCT01578551|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2016-10-12|2012-04-13|2012-04-17|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|November 2019|Anticipated|2019-11-30|November 2015|Actual|2015-11-30||Interventional|NA_00052073||A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.|A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma|Active, not recruiting||Phase 2|60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 21:27:35.217734|2018-05-31 21:27:35.217734
NCT01578538|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-16|2012-04-16|2012-04-17|Estimate|||||||2012-04-16|2012-04-17|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|hernia||Safety of Mesh Used Repairs in Emergency Abdominal Wall Hernias. Prospective Randomized Multicenter Trial|Mesh Used Repairs in Emergency Abdominal Wall Hernias|Unknown status|Recruiting|N/A|200|Anticipated|SB Istanbul Education and Research Hospital||2|||f||||f||||||||||2018-05-31 21:27:35.320422|2018-05-31 21:27:35.320422
NCT01578525|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2015-10-29|2012-04-13|2012-04-17|Estimate|||||||2015-10-29|2015-10-30|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Medication Safety of Elderly Patients in Hospital and Ambulatory Setting|Medication Safety of Elderly Patients in Hospital and Ambulatory Setting Considering the Transitions of Care for Home-cared Patients and Nursing Home Residents|Completed||N/A|61|Actual|RWTH Aachen University||2|||f||||||||||||||2018-05-31 21:27:35.436465|2018-05-31 21:27:35.436465
NCT01578512|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-16|2012-04-16|2012-04-17|Estimate|||||||2012-04-16|2012-04-17|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|August 2012|Anticipated|2012-08-31||Interventional|SPARK||SPARK a Healthy and Fit Lifestyle|SPARK a Healthy and Fit Lifestyle|Unknown status|Recruiting|N/A|45|Anticipated|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 21:27:35.507728|2018-05-31 21:27:35.507728
NCT01578499|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2017-12-09|2017-02-02|2018-02-19|2012-04-13|2012-04-17|Estimate|2018-02-19|2018-03-16|Actual|2017-02-02|2017-02-03|Estimate|2018-02-19|2018-03-16|Actual|June 11, 2012|Actual|2012-06-11|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|May 31, 2016|Actual|2016-05-31||Interventional||Safety population included participants who received at least 1 dose of study drug, analyzed according to the actual treatment received (n=66,62). Intent-to-treat population (ITT) population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment (n=64,64).|A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)|A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma|Active, not recruiting||Phase 3|131|Actual|Takeda||2|||f||||t|t|f||||||||2018-05-31 21:27:35.69277|2018-05-31 21:27:35.69277
NCT01578486|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2016-10-20||2018-04-05|2012-04-13|2012-04-17|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|June 2011||2011-06-30|April 2018|2018-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Salsalate as an Adjunctive Treatment for Patients With Schizophrenia|Salsalate as an Adjunctive Treatment for Patients With Schizophrenia|Completed||Phase 4|17|Actual|University of Massachusetts, Worcester||1|||f||||f||||||||||2018-05-31 21:27:36.84802|2018-05-31 21:27:36.84802
NCT01578473|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-03-26|2012-04-16|2012-04-17|Estimate|||||||2018-03-26|2018-03-29|Actual|May 23, 2013|Actual|2013-05-23|March 2018|2018-03-31|November 13, 2017|Actual|2017-11-13|July 7, 2013|Actual|2013-07-07||Interventional|PD+||Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease|An Open-Label, Nine-Month Randomized Controlled Study of Testosterone (Testopel) Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease|Completed||Phase 1|75|Actual|Men's Health Boston||2|||f||||t||||||||||2018-05-31 21:27:37.108626|2018-05-31 21:27:37.108626
NCT01578460|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-03-09|2012-04-13|2012-04-17|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2012|Actual|2012-05-31|March 2017|2017-03-31|August 29, 2014|Actual|2014-08-29|August 29, 2014|Actual|2014-08-29||Interventional|HMHB||Healthy Moms, Healthy Babies|Healthy Moms, Healthy Babies: A Strategy to Improve the Care and OUtcome of Diabetes in Pregnancy in On-Reserve First Nations Women|Completed||N/A|18|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:27:37.219165|2018-05-31 21:27:37.219165
NCT01578447|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2014-09-16|2012-04-13|2012-04-17|Estimate|||||||2014-09-16|2014-09-18|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda|Acceptability of Depo-subQ Provera 104 in Uniject Versus Intramuscular Depo-Provera Among HIV-positive Women and Family Planning Providers in Rakai, Uganda|Completed||N/A|356|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 21:27:37.29999|2018-05-31 21:27:37.29999
NCT01578434|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-17|2012-04-16|2012-04-17|Estimate|||||||2012-04-17|2012-04-19|Estimate|November 2007||2007-11-30|April 2012|2012-04-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|ROCAVINR||Role of Calcium And Vitamin D In Nutritional Rickets And It's Management|Role of Calcium And Vitamin D In Nutritional Rickets And It's Management|Completed||Phase 4|67|Actual|Lady Hardinge Medical College||3|||f||||f||||||||||2018-05-31 21:27:37.376346|2018-05-31 21:27:37.376346
NCT01578421|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2013-08-06|2012-04-16|2012-04-17|Estimate|||||||2013-08-06|2013-08-07|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser|Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser|Completed||N/A|31|Actual|Kantonsspital Aarau||3|||f||||f||||||||||2018-05-31 21:27:37.437727|2018-05-31 21:27:37.437727
NCT01578408|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-05-28|2012-04-13|2012-04-17|Estimate|||||||2015-05-28|2015-05-29|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|December 2023|Anticipated|2023-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Cemented Versus Uncemented Stems in Total Hip Arthroplasty in Patients With Femoral Neck Fractures|Corail-SP Study - A Prospective Randomized Comparison Between Cemented and Uncemented Hydroxyapatite Coated Prosthesis Stems in Total Hip Arthroplasty in Patients With Femoral Neck Fractures|Recruiting||N/A|100|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 21:27:37.516808|2018-05-31 21:27:37.516808
NCT01578395|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-12-05|2012-04-13|2012-04-16|Estimate|||||||2012-12-05|2012-12-06|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Impact of Antioxidant Agents on the Number of DNA Double-strand Breaks After Radiation-based Cardiac Examinations|Randomized, Double-blinded, Placebo-controlled, Single Center, and Prospective Phase II Clinical Trial to Analyze the Effects of Antioxidant Agents on DNA Double-strand Breaks in Patients After Radiation-based Cardiac Examinations|Completed||Phase 2|102|Actual|University of Zurich||3|||f||||t||||||||||2018-05-31 21:27:37.594574|2018-05-31 21:27:37.594574
NCT01578226|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-13|2012-04-13|2012-04-16|Estimate|||||||2012-04-13|2012-04-16|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Observational|||Procalcitonin in Cirrhotic Patients at High Risk for Sepsis|Role of Procalcitonin (PCT) for the Diagnosis of Sepsis in Ascitic Cirrhotic Patients|Completed|||75|Actual|University of Modena and Reggio Emilia|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:27:39.713468|2018-05-31 21:27:39.713468
NCT01578382|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-10-27|2012-04-13|2012-04-16|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)|Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU): A Comparison of Martorell HYTILU, Calciphylaxis and Venous Ulcer (Control)|Recruiting|||50|Anticipated|University of Zurich|||3||f||||f||||||Samples With DNA|"~     Blood serum (2 tubes); blood plasma in citrate (2 tubes); blood plasma in heparin (2 tubes)~     Diseased skin tissue in formalin for paraffin embedded H-E histology; Diseased skin tissue~     snap frozen Diseased skin tissue in RNA later tube (1 tube)~   "|||2018-05-31 21:27:37.681766|2018-05-31 21:27:37.681766
NCT01578369|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-04-13|2012-04-13|2012-04-16|Estimate|||||||2012-04-13|2012-04-16|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effect of Pelvic Floor Muscle Training Included in General Fitness Classes During Pregnacy|Pelvic Floor Muscle Training Included in General Fitness Classes is Effective in Primary Prevention of Urinary Incontince in Pregnancy. A Randomized Controlled Trial|Completed||N/A|169|Actual|Universidad Politecnica de Madrid||2|||f||||f||||||||||2018-05-31 21:27:37.831834|2018-05-31 21:27:37.831834
NCT01578356|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2014-12-04|2012-04-13|2012-04-16|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery|Oncological and Functional Outcomes After Radical Prostatectomy for Prostate Cancer: Comparing Open With Robot-assisted Surgery|Unknown status|Recruiting||50|Anticipated|University Hospital, Ghent|||2||f||||f||||||||||2018-05-31 21:27:37.922593|2018-05-31 21:27:37.922593
NCT01578343|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-04-13|2012-04-13|2012-04-16|Estimate|||||||2016-04-13|2016-04-15|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|ZOLINZA||Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma|A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma|Terminated||Phase 2|20|Actual|Samsung Medical Center||1||"we collected data of a total of 19 patients for an interim analysis. but there are less than 7~   responses out of the initial 19 patients."|f||||f||||||||Yes|we will share collected data with principal investigator in Korea|2018-05-31 21:27:38.008605|2018-05-31 21:27:38.008605
NCT01578330|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2016-04-29||2016-04-29|2012-04-13|2012-04-16|Estimate|2016-04-29|2016-06-07|Estimate||||2016-04-29|2016-06-07|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720|A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine|Completed||Phase 4|42|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:27:38.117929|2018-05-31 21:27:38.117929
NCT01578317|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-05-17|2012-04-13|2012-04-16|Estimate|||||||2018-05-17|2018-05-18|Actual|March 20, 2012||2012-03-20|April 5, 2018|2018-04-05|May 22, 2014|Actual|2014-05-22|May 22, 2014|Actual|2014-05-22||Interventional|||Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant|Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine|Completed||N/A|49|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:27:38.439499|2018-05-31 21:27:38.439499
NCT01578304|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-13|2012-04-13|2012-04-16|Estimate|||||||2012-04-13|2012-04-16|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder|Phase IV Study to Evaluate the Efficacy and Safety Imidafenacin Versus Fesoterodine in Patients With Overactive Bladder|Completed||Phase 4|207|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 21:27:38.5316|2018-05-31 21:27:38.5316
NCT01578291|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-12-07|2012-04-13|2012-04-16|Estimate|||||||2017-12-07|2017-12-11|Actual|December 2011|Actual|2011-12-31|December 2017|2017-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram|Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram|Terminated||N/A|21|Actual|Johns Hopkins University||3||"Recruitment was not on target, evised AAP guidelines may have contributed to the decrease in~   the number of potential participants"|f||||f||||||||||2018-05-31 21:27:38.612701|2018-05-31 21:27:38.612701
NCT01578278|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18||2013-08-23|2014-04-04|2012-04-13|2012-04-16|Estimate||||2014-04-04|2014-05-01|Estimate|2014-04-04|2014-05-01|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis||Completed||Phase 2|606|Actual|Bausch & Lomb Incorporated||4|||f||||f||||||||||2018-05-31 21:27:38.691796|2018-05-31 21:27:38.691796
NCT01578265|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-13|2012-04-13|2012-04-16|Estimate|||||||2012-04-13|2012-04-16|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Ondansetron Tablets USP 8 mg With Zofran® 8 mg in Normal, Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:27:38.765674|2018-05-31 21:27:38.765674
NCT01578252|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-13|2012-04-13|2012-04-16|Estimate|||||||2012-04-13|2012-04-16|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Ondansetron Tablets USP 8 mg With Zofran® 8 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:27:38.841233|2018-05-31 21:27:38.841233
NCT01578239|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2017-08-29||2017-12-11|2012-04-13|2012-04-16|Estimate|2017-08-29|2017-10-02|Actual||||2017-12-11|2018-01-09|Actual|September 2012||2012-09-30|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|July 2015|Actual|2015-07-31||Interventional|NETTER-1|All patients who were randomized in the study.|A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours|A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours|Active, not recruiting||Phase 3|231|Actual|Advanced Accelerator Applications||2|||f||||t||||||||||2018-05-31 21:27:38.957003|2018-05-31 21:27:38.957003
NCT01578213|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-01-24|2012-04-13|2012-04-16|Estimate|||||||2018-01-24|2018-01-25|Actual|November 2011||2011-11-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|ISAV||Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients|Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV)|Active, not recruiting||Phase 4|100|Anticipated|University of Milano Bicocca||1|||f||||f||||||||||2018-05-31 21:27:39.785293|2018-05-31 21:27:39.785293
NCT01578200|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-05-02|2012-04-13|2012-04-16|Estimate|||||||2018-05-02|2018-05-03|Actual|December 24, 2011||2011-12-24|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|LANDMARK||Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study|Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate on Cardiovascular Mortality and Morbidity in Patients With Chronic Kidney Disease on Hemodialysis (CKD5D)|Active, not recruiting||Phase 3|2309|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||||||||||||2018-05-31 21:27:39.880225|2018-05-31 21:27:39.880225
NCT01578187|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2013-04-04||2013-11-27|2012-04-13|2012-04-16|Estimate|2013-08-04|2013-10-11|Estimate||||2013-11-27|2013-12-25|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|OHR6-LCU||Hair2Go Label Comprehension and Usability Study|Evaluating Label Comprehension and Usability of the Hair2Go System|Completed||N/A|63|Actual|Syneron Medical||1|||f||||t||||||||||2018-05-31 21:27:39.957023|2018-05-31 21:27:39.957023
NCT01578174|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-01-16|2012-04-13|2012-04-16|Estimate|||||||2018-01-16|2018-01-17|Actual|April 2012||2012-04-30|January 2018|2018-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Effect of Dexmedetomidine in the Management of Pain After Uterine Artery Embolization||Completed||N/A|66|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 21:27:40.118815|2018-05-31 21:27:40.118815
NCT01578161|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-04-13|2012-04-13|2012-04-16|Estimate|||||||2012-04-13|2012-04-16|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Interventional|||The Effect of Dexmedetomidine on Emergence Agitation in Children Undergoing a Surgery Under Desflurane Anesthesia|The Effect of Dexmedetomidine on Emergence Agitation in Children Undergoing a Surgery Under Desflurane Anesthesia|Unknown status|Recruiting|Phase 4|116|Anticipated|Seoul National University Hospital||4|||f||||f||||||||||2018-05-31 21:27:40.174379|2018-05-31 21:27:40.174379
NCT01578148|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2013-04-23|2012-04-13|2012-04-16|Estimate|||||||2013-04-23|2013-04-24|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Noxipoint Therapy Versus Standard Physical Therapy Using Electrical Stimulation for Chronic Pain|Noxipoint Therapy vs. Standard Physical Therapy Using Electrical Stimulation for Chronic Pain|Completed||N/A|34|Actual|Pain Cure Center, California||2|||f||||t||||||||||2018-05-31 21:27:40.257716|2018-05-31 21:27:40.257716
NCT01578135|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2017-07-31|2012-04-13|2012-04-16|Estimate|||||||2017-07-31|2017-08-01|Actual|March 19, 2007|Actual|2007-03-19|July 2017|2017-07-31|April 28, 2022|Anticipated|2022-04-28|April 28, 2022|Anticipated|2022-04-28||Observational|||French National Registry of Children Born Small for Gestational Age Treated With Somatropin|French National Longitudinal Prospective Follow-up of Children Born Small for Gestational Age and Treated With Norditropin SimpleXx (French Health Authorities Commitment)|Active, not recruiting|||400|Anticipated|Novo Nordisk A/S|||2||f||||f|t|f||||||||2018-05-31 21:27:40.407417|2018-05-31 21:27:40.407417
NCT01578122|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-03-27|2012-04-13|2012-04-16|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2012|Actual|2012-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|CELEST||Elastic Compression Stockings for Prevention of Post-thrombotic Syndrome|Evaluation of the Efficacy of Elastic Compression in Preventing Post-thrombotic Syndrome. Randomised Non-inferiority Study for Ankle Pressure Targeted at 25 mm Hg Versus 35 mm Hg|Active, not recruiting||N/A|350|Actual|Laboratoires Innothera||2|||f||||t||||||||||2018-05-31 21:27:40.506337|2018-05-31 21:27:40.506337
NCT01578109|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-05-24|2012-04-13|2012-04-16|Estimate|||||||2018-05-24|2018-05-25|Actual|January 13, 2012|Actual|2012-01-13|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia|A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-transplant Remission Maintenance|Active, not recruiting||N/A|45|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 21:27:40.751007|2018-05-31 21:27:40.751007
NCT01578096|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2015-08-20|2012-04-12|2012-04-16|Estimate|||||||2015-08-20|2015-08-21|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|CALMS-D||Stress Management Among Latinos With Type 2 Diabetes|Stress Management Among Latinos With Type 2 Diabetes Mellitus|Completed||N/A|107|Actual|Yale University||2|||f||||||||||||||2018-05-31 21:27:40.853496|2018-05-31 21:27:40.853496
NCT01578083|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2013-02-25|2012-04-13|2012-04-16|Estimate|||||||2013-02-25|2013-02-26|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|CICI||Chemotherapy-Induced Cognitive Impairment|The Neurobiology of Chemotherapy-Induced Cognitive Impairment|Completed|||28|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-05-31 21:27:40.935139|2018-05-31 21:27:40.935139
NCT01578070|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2013-08-29|2012-04-12|2012-04-16|Estimate|||||||2013-08-29|2013-08-30|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|VSG-2011-101||Single-center Study Evaluating the Safety and Efficacy of Viscogel® as Adjuvant in Act-HIB® Vaccine|A Single-centre Study Evaluating the Safety of ViscoGel® and Its Safety and Efficacy as an Adjuvant in Act-HIB® Vaccine Administered by Intramuscular Injection to Healthy Volunteers in a Single-blind Randomised, Parallel-group Design|Completed||Phase 1/Phase 2|130|Actual|Viscogel AB||5|||f||||t||||||||||2018-05-31 21:27:41.009778|2018-05-31 21:27:41.009778
NCT01578057|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2014-02-14|2012-04-12|2012-04-16|Estimate|||||||2014-02-14|2014-02-17|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol|A Randomized, Double-mask, Four-period Crossover Study in Healthy Subjects to Evaluate the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol|Completed||Phase 1|28|Actual|Vanda Pharmaceuticals||4|||f||||f||||||||||2018-05-31 21:27:41.095389|2018-05-31 21:27:41.095389
NCT01578044|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|2015-04-27||2015-05-28|2012-04-12|2012-04-16|Estimate|2015-05-28|2015-06-15|Estimate||||2015-05-28|2015-06-15|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation|Pilot Intervention to Improve Adherence to Dabigatran for Patients With Atrial Fibillation|Completed||N/A|12|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 21:27:41.191263|2018-05-31 21:27:41.191263
NCT01578031|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2017-04-12||2017-04-12|2012-04-12|2012-04-16|Estimate|2017-04-12|2017-05-18|Actual||||2017-04-12|2017-05-18|Actual|March 2009||2009-03-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PISA||The Effects of Treating Obese and Lean Patients With Sleep Apnea|Responses to CPAP Treatment in Obese and Lean Sleep Apnea Patients|Completed||N/A|450|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 21:27:41.455468|2018-05-31 21:27:41.455468
NCT01578018|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-08-08|2012-04-12|2012-04-16|Estimate|||||||2012-08-08|2012-08-10|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Tumor Markers in Lung Cancer: DCAMLK-1LK-1|Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study|Completed||N/A|49|Actual|University of Oklahoma||2|||f||||f||||||||||2018-05-31 21:27:41.841955|2018-05-31 21:27:41.841955
NCT01578005|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-05-30|2012-04-12|2012-04-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 2011||2011-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|OPTIVUS||IVUS Assessment of Atheroma Burden After Acute Coronary Syndrome|Intravascular Ultrasound (IVUS) Assessment of the Atherosclerotic Plaque Causing an Acute Coronary Syndrome: One-year Changes Under Optimal Secondary Prevention Drug Treatment|Recruiting|||150|Anticipated|University Hospital, Toulouse|||||f||||f||||||Samples With DNA|"~     bioanalysis on DNA, searching genes involving coronary disease~   "|No||2018-05-31 21:27:41.936921|2018-05-31 21:27:41.936921
NCT01577992|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2013-11-08|2012-04-12|2012-04-16|Estimate|||||||2013-11-08|2013-11-11|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|MSA-DOUL||Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy|Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy|Completed||N/A|42|Actual|University Hospital, Toulouse||3|||f||||f||||||||||2018-05-31 21:27:42.031184|2018-05-31 21:27:42.031184
NCT01577979|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2015-02-24|2012-04-13|2012-04-16|Estimate|||||||2015-02-24|2015-02-26|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Adolescent Vaccination in the Medical Home: Established and Innovative Strategies|Adolescent Vaccination in the Medical Home: Established and Innovative Strategies|Completed||N/A|34581|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 21:27:42.109796|2018-05-31 21:27:42.109796
NCT01577966|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2016-07-19||2016-10-16|2012-04-12|2012-04-16|Estimate|2016-10-16|2016-12-08|Estimate||||2016-10-16|2016-12-08|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma|A Pilot Study to Determine the Effect of Sulfasalazine on Glutamate Levels Detected by Magnetic Resonance Spectroscopy(MRS) in Patients With Glioma|Completed||N/A|9|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 21:27:42.20081|2018-05-31 21:27:42.20081
NCT01577953|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2014-04-28|2012-04-12|2012-04-16|Estimate|||||||2014-04-28|2014-04-29|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma|Phase-Ib Study in Male Patients With Stable Allergic Asthma With Airway Hyperresponsiveness to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation - A Randomised, Double-blind, Placebo-controlled, Parallel-group (Per Dose Level) Dose-escalation Study in Asthmatic Patients|Completed||Phase 1|24|Actual|Sterna Biologicals GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 21:27:42.353926|2018-05-31 21:27:42.353926
NCT01577940|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-05-03|2012-04-13|2012-04-16|Estimate|||||||2012-05-03|2012-05-04|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Method Study: Bilateral TAP Block With 24 Hours Infusion|Method Study of Bilateral Transversus Abdominis Plane (TAP) Block With 24 Hours Infusion. Extent of Sensory Block, Analgetic Effect and Lung Function in Healthy Volunteers|Completed||Phase 4|8|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 21:27:42.433232|2018-05-31 21:27:42.433232
NCT01577927|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-06-04|2012-04-13|2012-04-16|Estimate|||||||2014-06-04|2014-06-05|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|UTIR||Feasibility Study of a Home Rehabilitative Network to Treat Prolonged Weaned Patients|Feasibility and Efficacy of a Home Rehabilitative Network for Prolonged Weaned Patients Discharged From a Weaning Unit|Completed||N/A|60|Actual|Fondazione Salvatore Maugeri||2|||f||||t||||||||||2018-05-31 21:27:42.505183|2018-05-31 21:27:42.505183
NCT01577914|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-07-05|2012-04-12|2012-04-16|Estimate|||||||2012-07-05|2012-07-09|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Carvedilol Tablets USP 12.5 mg With Coreg® 12.5 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|42|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:27:42.58413|2018-05-31 21:27:42.58413
NCT01577901|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-08-14|2012-04-12|2012-04-16|Estimate|||||||2012-08-14|2012-08-15|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Consumer in Stream and Container Collected Study|Consumer in Stream and Container Collected Study|Completed||N/A|168|Actual|SPD Development Company Limited|||||f||||f||||||||||2018-05-31 21:27:42.651306|2018-05-31 21:27:42.651306
NCT01577888|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2014-08-06|2012-04-13|2012-04-16|Estimate|||||||2014-08-06|2014-08-08|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Feasibility Study of the Shockwave Lithoplasty System|Safety and Feasibility Study of the Shockwave Lithoplasty System|Completed||N/A|6|Actual|Shockwave Medical, Inc.||1|||f||||t||||||||||2018-05-31 21:27:42.7199|2018-05-31 21:27:42.7199
NCT01577875|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-11-18|2012-04-12|2012-04-16|Estimate|||||||2014-11-18|2014-11-20|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Narrow Band Imaging With or Without Magnifying Colonoscopy|A Prospective Clinical Study to Evaluate Narrow Band Imaging and Magnifying Colonoscopy for the Histologic Prediction of Colorectal Polyps|Completed||N/A|122|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:27:42.784483|2018-05-31 21:27:42.784483
NCT01577862|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-12|2012-04-12|2012-04-16|Estimate|||||||2012-04-12|2012-04-16|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|CoRAb||Colistin and Rifampicin for MDR-Acinetobacter|Randomised, Open-Label Clinical Trial on The Efficacy of Colistin Plus Rifampicin Treatment Versus Colistin Alone for Severe Infections Due to Multidrug-Resistant Acinetobacter Baumannii|Completed||Phase 3|210|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||||2018-05-31 21:27:42.857497|2018-05-31 21:27:42.857497
NCT01577849|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2016-10-31|2012-04-13|2012-04-16|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers|Randomized, Open-label Crossover Study to Evaluate Comparative Pharmacokinetics of Vitamin D3 Between DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 Tablet) and a 24,000 IU Vitamin D3 in Healthy Adult Volunteers|Completed||Phase 1|36|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 21:27:42.93003|2018-05-31 21:27:42.93003
NCT01577836|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2016-05-19|2012-04-13|2012-04-16|Estimate|||||||2016-05-19|2016-05-20|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|RoboProstate||Medico-economic Comparison of Robot-assisted Radical Prostatectomy Versus Radical Prostatectomy Via Laparotomy|Medico-economic Comparison of Robot-assisted Radical Prostatectomy Using the da Vinci System Versus Radical Prostatectomy Via Laparotomy|Unknown status|Active, not recruiting||90|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 21:27:42.988809|2018-05-31 21:27:42.988809
NCT01577823|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-04-08|2012-04-12|2012-04-16|Estimate|||||||2013-04-08|2013-04-09|Estimate||||April 2013|2013-04-30||||||||Interventional|||Utility of Indwelling Catheter in Orthopaedic Patients Receiving Spinal Anesthesia||Completed||N/A|||Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-05-31 21:27:43.063371|2018-05-31 21:27:43.063371
NCT01577810|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-06-06|2012-04-12|2012-04-16|Estimate|||||||2013-06-06|2013-06-07|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Near Infrared Spectroscopy (NIRS) for Heart Failure Assessment.|Near Infrared Spectroscopy (NIRS) for Heart Failure Assessment in the Outpatient Setting|Unknown status|Recruiting|N/A|100|Anticipated|Phoenix Children's Hospital|||||f||||f||||||||||2018-05-31 21:27:43.116802|2018-05-31 21:27:43.116802
NCT01577797|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-07-08|2012-04-12|2012-04-16|Estimate|||||||2013-07-08|2013-07-10|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence|A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence|Completed||Phase 1|25|Actual|New Leaf Treatment Center||2|||f||||f||||||||||2018-05-31 21:27:43.252221|2018-05-31 21:27:43.252221
NCT01577784|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-03-11|2012-04-13|2012-04-16|Estimate|||||||2014-03-11|2014-03-12|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Pazopanib in Second-line Therapy in Renal Cell Carcinoma|A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor|Unknown status|Active, not recruiting|Phase 2|27|Anticipated|Associació per a la Recerca Oncologica, Spain||1|||f||||f||||||||||2018-05-31 21:27:43.32347|2018-05-31 21:27:43.32347
NCT01577771|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-03-03|2012-04-13|2012-04-16|Estimate|||||||2017-03-03|2017-03-06|Actual|February 2013||2013-02-28|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|PCV13-Bobo||Immunogenicity and Reactogenicity of PCV13 Among Infants and Children in Burkina Faso|Immunogenicity and Reactogenicity of 13-valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers and Children in Bobo-Dioulasso, Burkina Faso: a Phase 4 Randomized Trial|Completed||Phase 4|663|Actual|Agence de Médecine Préventive, France||5|||f||||f||||||||||2018-05-31 21:27:43.412912|2018-05-31 21:27:43.412912
NCT01577758|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|2015-02-12||2016-09-06|2012-04-13|2012-04-16|Estimate|2016-06-13|2016-07-25|Estimate||||2016-09-06|2016-09-07|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Safety population included all participants who received at least 1 dose of study drug. A total of 41 participants participated in the study. There were 3 participants who participated in both phases of the study and are only counted once.|Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C|An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C|Completed||Phase 1|41|Actual|Takeda||1|||f||||f||||||||||2018-05-31 21:27:43.573084|2018-05-31 21:27:43.573084
NCT01577745|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2017-01-23||2017-03-21|2012-04-12|2012-04-16|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|April 2012||2012-04-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Safety Population included all participants who received at least one dose of MEDI0639.|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors|A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|58|Actual|MedImmune LLC|OMs relationship modulation of DLL4-Notch signaling pathway in tumor and clinical response analysis was not conducted due to low number of evaluable tumor samples and low response rate. Study was terminated early due to lack of clinical activity.|6|||f||||f||||||||||2018-05-31 21:27:44.818205|2018-05-31 21:27:44.818205
NCT01577732|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2014-04-03||2017-04-24|2012-04-12|2012-04-16|Estimate|2014-04-03|2014-05-05|Estimate||||2017-04-24|2017-06-05|Actual|December 8, 2012||2012-12-08|April 2017|2017-04-30|April 9, 2013|Actual|2013-04-09|April 9, 2013|Actual|2013-04-09||Interventional|||Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers|Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers|Completed||Phase 3|321|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:27:46.644915|2018-05-31 21:27:46.644915
NCT01577719|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-06-08|2012-04-12|2012-04-16|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2009||2009-06-30|June 2016|2016-06-30||||November 2012|Actual|2012-11-30||Interventional|SAHARA-Pilot||South Asian HeArt Risk Assessment Project - Pilot|South Asian HeArt Risk Assessment Project - Pilot|Active, not recruiting||N/A|400|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 21:27:46.822841|2018-05-31 21:27:46.822841
NCT01577706|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2014-09-25||2017-03-24|2012-04-13|2012-04-16|Estimate|2017-03-24|2017-04-04|Actual||||2017-03-24|2017-04-04|Actual|June 2013|Actual|2013-06-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CEBRA2|Healthy male volunteers receiving drug and undergoing 1H-MRSI scanning|Spectroscopic Imaging at 4T: A Drug Challenge Study|Spectroscopic Imaging of GABA and Glutamate/Glutamine in Healthy Volunteers at 4T: A Double Blind, Crossover Drug Challenge Study|Terminated||N/A|7|Actual|Mclean Hospital||3||lack of enrollment|f||||f||||||||Undecided|At present, there is no plan to share IPD data.|2018-05-31 21:27:47.909459|2018-05-31 21:27:47.909459
NCT01577693|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2018-05-17|2012-04-12|2012-04-16|Estimate|||||||2018-05-17|2018-05-21|Actual|May 12, 2011|Actual|2011-05-12|May 2018|2018-05-31|August 31, 2011|Actual|2011-08-31|August 31, 2011|Actual|2011-08-31||Interventional|ARI115148||Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects|An Open-label, Single Dose, Randomized, Two-period Crossover Study to Investigate the Bioavailability of a Novel Dosage Form of Dutasteride in Healthy Male Subjects|Completed||Phase 1|35|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:27:48.338625|2018-05-31 21:27:48.338625
NCT01577680|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-07-24|2012-04-12|2012-04-16|Estimate|||||||2017-07-24|2017-07-25|Actual|March 5, 2012|Actual|2012-03-05|July 2017|2017-07-31|June 29, 2012|Actual|2012-06-29|June 29, 2012|Actual|2012-06-29||Interventional|||A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers|An Open-label, Non-randomized, Pharmacokinetic and Safety Study of Single Dose GSK573719 + GW643444 (VI) Combination and Repeat Doses of GSK573719 in Healthy Subjects and in Subjects With Moderate Hepatic Impairment|Completed||Phase 1|18|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:27:48.443255|2018-05-31 21:27:48.443255
NCT01577667|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-12-05|2012-04-12|2012-04-16|Estimate|||||||2012-12-05|2012-12-06|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|Intellivent||Intellivent Versus Conventional Ventilation|Comparative Monocenter RCT Comparing Safety and Efficacy of an Automated Closed-loop Oxygenation and Ventilation(IntelliVent® System - HAMILTON MEDICAL AG) With Non-automated Conventional Ventilation and Oxygenation|Completed||Phase 3|80|Actual|Hamilton Medical AG||2|||f||||t||||||||||2018-05-31 21:27:48.599043|2018-05-31 21:27:48.599043
NCT01577654|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-08-03|2012-04-12|2012-04-16|Estimate|||||||2015-08-03|2015-08-04|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2013|Actual|2013-12-31||Interventional|TARGET||Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer|A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC|Completed||Phase 2|203|Actual|Endocyte||3|||f||||t||||||||||2018-05-31 21:27:48.76807|2018-05-31 21:27:48.76807
NCT01577628|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2016-02-23||2016-03-23|2012-04-12|2012-04-16|Estimate|2016-02-23|2016-03-24|Estimate||||2016-03-23|2016-04-21|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis|Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis|Terminated||N/A|2|Actual|Cosmetique Active International||2||Sponsor Decision|f||||f||||||||No||2018-05-31 21:27:48.886558|2018-05-31 21:27:48.886558
NCT01577615|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-11-10|2012-04-13|2012-04-16|Estimate|||||||2015-11-10|2015-11-13|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PEPI||Patterned Experience for Preterm Infants|Patterned Experience for Preterm Infants|Completed||N/A|121|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 21:27:49.124591|2018-05-31 21:27:49.124591
NCT01577602|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2013-03-13|2012-04-13|2012-04-16|Estimate|||||||2013-03-13|2013-03-14|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Standard Medication Reconciliation Protocol in the Primary Care Office-based Setting|Standard Medication Reconciliation Protocol in the Primary Care Office-based Setting: A Focused Investigation of Two Interventions|Completed||N/A|424|Actual|The Cleveland Clinic||4|||f||||f||||||||||2018-05-31 21:27:49.197807|2018-05-31 21:27:49.197807
NCT01577589|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-09-01|2012-04-13|2012-04-16|Estimate|||||||2017-09-01|2017-09-05|Actual|April 2012||2012-04-30|September 2017|2017-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects|A Phase I, Single-center, 2-part, Randomized, 2-way Crossover Study to Assess the Local Tolerability and Safety (Multiple-dose) and to Assess the Pharmacokinetics, Safety, and Tolerability (Single-dose) of Ceftaroline in Healthy Subjects When Ceftaroline Fosamil is Diluted in Various Infusion Volume|Completed||Phase 1|34|Actual|Pfizer||6|||f||||||||||||||2018-05-31 21:27:49.271902|2018-05-31 21:27:49.271902
NCT01577576|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2015-11-27|2012-04-13|2012-04-16|Estimate|||||||2015-11-27|2015-11-30|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|MediaSport||Mechanical Stress Effects on the Cardiovascular Adaptations of Peripheral Arterial Calcifications Among Athletes|Morphological, Biomechanical and Functional Properties of the Arterial Wall of Athletes: Impact and Consequences of Mechanical Stress on the Cardiovascular Adaptations of Peripheral Arterial Calcifications|Terminated|||56|Actual|Centre Hospitalier Universitaire de Nīmes|||3|Inclusion curve too slow.|f||||f||||||Samples Without DNA|"~     A non-fasting venous blood sample is required for the following cofactors:~        -  serum protein~        -  serum calcium~        -  phosphorus~        -  PTH~        -  Vitamin D2 and D3~      Left-over serum will be stored in the Nîmes University Hospital Sérotheque (serum~     collection).~   "|||2018-05-31 21:27:49.369596|2018-05-31 21:27:49.369596
NCT01577563|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-05-13|2012-04-13|2012-04-16|Estimate|||||||2013-05-13|2013-05-14|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|RATIONAL||Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS).|Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis Receiving Treatment With Non- Steroidal Anti- Inflammatory Drugs.|Completed|||5383|Actual|AstraZeneca|||||f||||||||||||||2018-05-31 21:27:49.514549|2018-05-31 21:27:49.514549
NCT01577550|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-11-15|2012-04-12|2012-04-16|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|||Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis|Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)|Completed||Phase 1|39|Actual|AbbVie||4|||f||||||||||||||2018-05-31 21:27:49.690059|2018-05-31 21:27:49.690059
NCT01577537|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12||2012-10-17|2013-10-27|2012-04-12|2012-04-16|Estimate||||2012-10-19|2012-10-25|Estimate|2013-10-27|2013-11-20|Estimate|March 2012||2012-03-31|October 2013|2013-10-31||||December 2012|Actual|2012-12-31||Interventional|||A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis|Completed||Phase 3|251|Actual|Starpharma Pty Ltd||2|||f||||t||||||||||2018-05-31 21:27:49.913587|2018-05-31 21:27:49.913587
NCT01577524|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-07-13|2012-04-12|2012-04-16|Estimate|||||||2016-07-13|2016-07-14|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Use of Diluted Povidone Iodine Irrigation in Spine Surgery|The Use of Diluted Povidone Iodine Irrigation in Spine Surgery|Terminated||Phase 2|58|Actual|Attabib, Najmedden, M.D.||2||"We had very low recruitment rates that would have resulted in several years being added to the~   study to achieve an appropriate sample size."|f||||f||||||||||2018-05-31 21:27:50.006783|2018-05-31 21:27:50.006783
NCT01577511|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-06-16|2012-04-13|2012-04-16|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2012||2012-06-30|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|October 2015|Actual|2015-10-31||Observational|||Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer|Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer: Molecular Characterization and Implications for Therapeutic Strategies|Active, not recruiting|||60|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples Without DNA|"~     Peroperative blood sample plus primary and metastatic tumor biopsies.~   "|||2018-05-31 21:27:50.105077|2018-05-31 21:27:50.105077
NCT01577498|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-06-09|2012-04-12|2012-04-13|Estimate|||||||2016-06-09|2016-06-10|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|March 2014|Actual|2014-03-31|April 2013|Actual|2013-04-30||Observational|AGE-ADO||Age Estimation of Adolescents for Legal Purposes|Age Estimation of Adolescents for Legal Purposes: Determining the Medical Response|Completed|||500|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-05-31 21:27:50.186052|2018-05-31 21:27:50.186052
NCT01577485|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2013-01-03|2012-04-12|2012-04-13|Estimate|||||||2013-01-03|2013-01-04|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||LGG/BB12-pastille Study|LGG/BB12-pastille Study|Completed||Phase 1|60|Actual|University of Turku||2|||f||||f||||||||||2018-05-31 21:27:50.254267|2018-05-31 21:27:50.254267
NCT01577472|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-01-25|2012-04-12|2012-04-13|Estimate|||||||2018-01-25|2018-01-26|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|CANTAPOR||Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol|Prospective Randomized Phase IV Study Comparing the Effect of Adding Clomiphencitrate Versus Placebo to a High Dose Versus a Minimal Dose GnRH Antagonist Protocol on the Number of Oocytes Collected From Women That Are Poor Responders|Completed||Phase 4|117|Actual|University Hospital, Basel, Switzerland||4|||f||||t||||||||||2018-05-31 21:27:50.327092|2018-05-31 21:27:50.327092
NCT01577459|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-10-04|2012-04-12|2012-04-13|Estimate|||||||2017-10-04|2017-10-06|Actual|April 23, 2012|Actual|2012-04-23|October 2017|2017-10-31|June 15, 2012|Actual|2012-06-15|June 15, 2012|Actual|2012-06-15||Interventional|||A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response|A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response to Pseudoephedrine Concurrent With Placebo or TR 701 FA|Completed||Phase 1|18|Actual|Trius Therapeutics LLC||2|||f||||f||||||||||2018-05-31 21:27:50.414494|2018-05-31 21:27:50.414494
NCT01577446|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-10-15|2012-04-12|2012-04-13|Estimate|||||||2016-10-15|2016-10-18|Estimate|January 2008||2008-01-31|October 2016|2016-10-31||||August 2012|Actual|2012-08-31||Interventional|NARROW-CRT||Narrow QRS Ischemic Patients Treated With Cardiac Resynchronization Therapy (NARROW CRT)|Narrow QRS Ischemic Patients Treated With Cardiac Resynchronization Therapy|Completed||N/A|120|Actual|Ospedale Santa Maria di Loreto Mare||2|||f||||||||||||||2018-05-31 21:27:50.502245|2018-05-31 21:27:50.502245
NCT01577433|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-12-06|2012-04-12|2012-04-13|Estimate|||||||2016-12-06|2016-12-07|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|SSI||Driveline Silicone Skin Interface Registry|Driveline Silicone Skin Interface (SSI) Registry|Active, not recruiting|||400|Anticipated|St. Jude Medical|||2||f||||f||||||||||2018-05-31 21:27:50.581154|2018-05-31 21:27:50.581154
NCT01577420|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-04-12|2012-04-12|2012-04-13|Estimate|||||||2012-04-12|2012-04-13|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||Reflexology: An Intervention for Advanced Breast Cancer|Reflexology: An Intervention for Advanced Breast Cancer|Completed||N/A|451|Actual|Michigan State University||3|||f||||t||||||||||2018-05-31 21:27:50.683883|2018-05-31 21:27:50.683883
NCT01577407|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-12-10|2012-04-12|2012-04-13|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|Nefopel||Non Opioid Treatment for Experimental Dyspnea|Non Opioid Treatment for Experimental Dyspnea|Completed||Phase 3|15|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:27:50.792027|2018-05-31 21:27:50.792027
NCT01577394|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-05-20|2012-04-12|2012-04-13|Estimate|||||||2016-05-20|2016-05-23|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|OculoMacl||Oculomotor Testing in the Differential Diagnosis of Dementia|Oculomotor Recording in the Contribution to the Early Differential Diagnosis of Dementia With Lewy Bodies and Alzheimer's Disease|Completed||Phase 3|65|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 21:27:50.865115|2018-05-31 21:27:50.865115
NCT01577381|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2015-12-09|2015-11-06|2016-02-16|2012-04-11|2012-04-13|Estimate|2016-02-16|2016-03-16|Estimate|2015-11-06|2015-12-07|Estimate|2016-02-16|2016-03-16|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration|A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration|Terminated||Phase 2|10|Actual|Pfizer|The study was terminated early due to an organizational decision, which was not based on safety or efficacy concerns. As only 10 participants enrolled at the time of termination, there were not enough subjects or data to perform meaningful analyses.|2||See termination reason in detailed description.|f||||t||||||||||2018-05-31 21:27:51.010853|2018-05-31 21:27:51.010853
NCT01577368|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-09-19|2012-04-12|2012-04-13|Estimate|||||||2014-09-19|2014-09-22|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional|PiperTazo||Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa|Efficacy and Safety of Piperacillin-Tazobactam Continuous Infusion vs Intermittent Infusion for Complicated or Nosocomial Pseudomonas Aeruginosa Infection or Suspected Infection|Completed||Phase 3|76|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f||||||||||2018-05-31 21:27:52.025855|2018-05-31 21:27:52.025855
NCT01577355|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-07-02|2012-04-11|2012-04-13|Estimate|||||||2012-07-02|2012-07-03|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of LY2784544 in Healthy Male Subjects|Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects|Completed||Phase 1|8|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:27:52.118925|2018-05-31 21:27:52.118925
NCT01577342|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-04-12|2012-04-12|2012-04-13|Estimate|||||||2012-04-12|2012-04-13|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora|Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora|Completed||N/A|56|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:27:52.201509|2018-05-31 21:27:52.201509
NCT01577329|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2016-11-22||2017-04-21|2012-04-12|2012-04-13|Estimate|2017-04-21|2017-08-02|Actual||||2017-04-21|2017-08-02|Actual|October 2011||2011-10-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|May 2013|Actual|2013-05-31||Interventional|||Mindfulness Mediation Intervention in Chronic Obstructive Pulmonary Disease (COPD)|Mindfulness Mediation Intervention in COPD|Completed||N/A|41|Actual|University of Michigan||2|||f||||f||||||||Undecided||2018-05-31 21:27:52.299968|2018-05-31 21:27:52.299968
NCT01577316|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-04-12|2012-04-12|2012-04-13|Estimate|||||||2012-04-12|2012-04-13|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|VACINFL2011||Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women|Clinical Trial to Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women|Unknown status|Not yet recruiting|Phase 2/Phase 3|240|Anticipated|Instituto Nacional de Salud Publica, Mexico||2|||f||||t||||||||||2018-05-31 21:27:52.554934|2018-05-31 21:27:52.554934
NCT01577303|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-10-29|2012-04-11|2012-04-13|Estimate|||||||2016-10-29|2016-11-01|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Treatment of Social Phobia With Cognitive Bias Modification|Reduction of Social Phobia Symptoms With Internet-Based Cognitive Bias Modification|Completed||N/A|129|Actual|Umeå University||6|||f||||f||||||||||2018-05-31 21:27:52.650482|2018-05-31 21:27:52.650482
NCT01577290|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-10-29|2012-04-11|2012-04-13|Estimate|||||||2016-10-29|2016-11-01|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Interventional|||An Internet-administered, Mindfulness Training Program for the Treatment of Anxiety|An Internet-administered, Mindfulness Training Program for the Treatment of Anxiety|Completed||N/A|91|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 21:27:52.761062|2018-05-31 21:27:52.761062
NCT01577277|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-03-03|2012-04-11|2012-04-13|Estimate|||||||2017-03-03|2017-03-06|Actual|May 2011||2011-05-31|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||OPUS School Meal Study - Cross Sectional Analyses From Baseline Investigations|OPUS(Optimal Well-being, Development and Health for Danish Children Through a Healthy New Nordic Diet) School Meal Study - - Cross Sectional Analyses From Baseline Investigations|Completed|||834|Actual|University of Copenhagen|||||f||||f||||||Samples With DNA|"~     serum and white cells~   "|||2018-05-31 21:27:52.860173|2018-05-31 21:27:52.860173
NCT01577264|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-11-09|2012-04-12|2012-04-13|Estimate|||||||2015-11-09|2015-11-10|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)|Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring|Terminated|||199|Actual|UCB Pharma|||1|"Study is replaced by some Risk Manag. Activities covering the whole Russian Federation. Primary~   objectives could not be met due to critical missing information."|f||||f||||||||||2018-05-31 21:27:52.952564|2018-05-31 21:27:52.952564
NCT01577251|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2016-09-23|2012-04-12|2012-04-13|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2008||2008-06-30|September 2016|2016-09-30||||June 2018|Anticipated|2018-06-30||Observational|||Registry and Biosample Repository|Registry and Biosample Repository|Recruiting|||2500|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:27:53.093787|2018-05-31 21:27:53.093787
NCT01577238|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12||2012-10-17|2013-10-27|2012-04-12|2012-04-13|Estimate||||2012-10-19|2012-10-25|Estimate|2013-10-27|2013-11-20|Estimate|March 2012||2012-03-31|October 2013|2013-10-31||||December 2012|Actual|2012-12-31||Interventional|||A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis|Completed||Phase 3|250|Actual|Starpharma Pty Ltd||2|||f||||t||||||||||2018-05-31 21:27:53.157405|2018-05-31 21:27:53.157405
NCT01577225|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2017-04-24|2012-04-12|2012-04-13|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2011||2011-11-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|OPOV||OPSITE Post-Op Visible Wound Dressings in Treatment of Surgical Incisions|A Prospective, Open, Randomised Controlled Trial to Compare OPSITE Post-Op Visible Wound Dressings With Standard Therapy in the Treatment of Surgical Incisions.|Completed||N/A|100|Actual|Smith & Nephew Medical (Shanghai) Ltd||2|||f||||f||||||||No||2018-05-31 21:27:53.231835|2018-05-31 21:27:53.231835
NCT01577212|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-11-06|2012-04-12|2012-04-13|Estimate|||||||2015-11-06|2015-11-09|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|IDEAL-VMAT||Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy|Individualized Dose Escalation for Non-small Cell Lung Cancer (NSCLC) Using Volumetric Modulated Arc Therapy (VMAT)|Terminated||Phase 2|6|Actual|Radboud University||1||Lack of accrual|f||||t||||||||||2018-05-31 21:27:53.313993|2018-05-31 21:27:53.313993
NCT01577199|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-12-15|2012-04-11|2012-04-13|Estimate|||||||2016-12-15|2016-12-16|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|CLOVANT||RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders|Randomized Prospective Controlled Non-inferiority Trial of Low-dose Clomiphene Based Antagonist Protocol vs. High Dose Gonadotropin/Antagonist Protocol for IVF Poor Responders|Withdrawn||Phase 4|0|Actual|Weill Medical College of Cornell University||2||no subjects recruited|f||||f||||||||No||2018-05-31 21:27:53.380176|2018-05-31 21:27:53.380176
NCT01577186|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2013-12-02||2013-12-02|2012-04-12|2012-04-13|Estimate|2013-12-02|2014-01-17|Estimate||||2013-12-02|2014-01-17|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)|Symptomatic Remission and Social Function in Patients Treated With Paliperidone ER|Completed||Phase 4|480|Actual|Johnson & Johnson Taiwan Ltd|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.|1|||f||||f||||||||||2018-05-31 21:27:53.456679|2018-05-31 21:27:53.456679
NCT01577173|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11||2016-07-12|2016-11-01|2012-04-11|2012-04-13|Estimate||||2016-07-12|2016-07-14|Estimate|2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck|A Phase II, Open-Label, Randomized Study of MEDH7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Progressed During or Following Platinum-based Chemotherapy|Completed||Phase 2|122|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 21:27:53.790852|2018-05-31 21:27:53.790852
NCT01577160|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2013-11-25||2013-11-25|2012-04-12|2012-04-13|Estimate|2013-11-25|2014-01-14|Estimate||||2013-11-25|2014-01-14|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia|An Open Label, Prospective, Non-Comparative Study to Evaluate Flexible Dose of Paliperidone ER and Clinical Response in the Treatment of Subjects With Schizophrenia|Completed||Phase 4|353|Actual|Johnson & Johnson Taiwan Ltd|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.|1|||f||||f||||||||||2018-05-31 21:27:53.995944|2018-05-31 21:27:53.995944
NCT01577147|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-12-20|2012-04-12|2012-04-13|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2012|Actual|2012-01-31|November 2016|2016-11-30|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|EPS||Early Pregnancy Sample Collection Study|Generic Protocol for the Collection of Early Pregnancy Urines|Completed||N/A|4025|Actual|SPD Development Company Limited||1|||f||||f||||||||||2018-05-31 21:27:54.391593|2018-05-31 21:27:54.391593
NCT01577134|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-03-26|2012-04-12|2012-04-13|Estimate|||||||2015-03-26|2015-03-31|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional|PREFER||Personal Resources of Elderly People With Multimorbidity|Personal Resources of Elderly People With Multimorbidity: Fortification of Effective Health Behaviour|Completed||N/A|310|Actual|German Centre of Gerontology||3|||f||||t||||||||||2018-05-31 21:27:54.466277|2018-05-31 21:27:54.466277
NCT01577121|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-10-20|2012-04-12|2012-04-13|Estimate|||||||2014-10-20|2014-10-21|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|INDOGEST||Evaluation of the Use of Indomethacin as Co-treatment in Women With Preterm Labor and High Risk of Intraamniotic Inflammation|Evaluation of the Utility of Indomethacin as Support Treatment in Women With Preterm Labor With Intact Membranes and High Risk of Intraamniotic Inflammation|Completed||Phase 2|16|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 21:27:54.552364|2018-05-31 21:27:54.552364
NCT01577108|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2016-03-06||2017-02-13|2012-04-12|2012-04-13|Estimate|2017-02-13|2017-03-31|Actual||||2017-02-13|2017-03-31|Actual|April 2011||2011-04-30|February 2017|2017-02-28|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Interventional|||Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women|Oral Probiotics Lactobacillus Rhamnosus GR-1 and Lactobacillus Reuteri RC-14 Reduce Group B Streptococci Colonization in Pregnant Women|Completed||N/A|110|Actual|China Medical University Hospital||2|||f||||t||||||||No||2018-05-31 21:27:54.768371|2018-05-31 21:27:54.768371
NCT01577095|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-04-12|2012-04-12|2012-04-13|Estimate|||||||2012-04-12|2012-04-13|Estimate|April 2006||2006-04-30|April 2012|2012-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy|A Randomized Controlled Trial Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy on Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|49|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 21:27:55.02207|2018-05-31 21:27:55.02207
NCT01577082|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2017-03-28|2012-04-12|2012-04-13|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2012||2012-04-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients|A 12-week, Multinational, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of CHF 1535 200/6µg Versus Beclomethasone Dipropionate in Adult Asthmatic Patients Not Adequately Controlled on High Dose of Inhaled Corticosteroids or on Medium Dose of Inhaled Corticosteroids Plus Long-acting β2 Agonists|Completed||Phase 3|542|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 21:27:55.121188|2018-05-31 21:27:55.121188
NCT01577069|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2016-06-21|2012-04-12|2012-04-13|Estimate|||||||2016-06-21|2016-06-22|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|GENUPI||Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir|Predictive Factors of the Treatment Failure in HCV Mono-infected Patients Treated With Pegylated-interferon/Ribavirin/Telaprevir.|Completed|||73|Anticipated|Association HGE CHU Bordeaux Sud|||||f||||f||||||||||2018-05-31 21:27:55.210509|2018-05-31 21:27:55.210509
NCT01577056|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-11|2012-04-11|2012-04-13|Estimate|||||||2012-04-11|2012-04-13|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|FIFH||Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils|Effect of Fish Oil Supplementation on Postprandial Lipid Metabolism in Familial Hypercholesterolaemia|Unknown status|Not yet recruiting|N/A|30|Anticipated|The University of Western Australia||2|||f||||f||||||||||2018-05-31 21:27:55.275883|2018-05-31 21:27:55.275883
NCT01577043|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-04-12|2012-04-12|2012-04-13|Estimate|||||||2012-04-12|2012-04-13|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Efficacy of Racecadotril in Acute Watery Diarrhea in Children|Efficacy of Racecadotril in the Management of Acute Watery Diarrhea in Children|Completed||Phase 4|52|Actual|Centro Pediatrico Albina de Patino||2|||f||||f||||||||||2018-05-31 21:27:55.360262|2018-05-31 21:27:55.360262
NCT01577030|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-02-10|2012-04-11|2012-04-13|Estimate|||||||2014-02-10|2014-02-12|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness|Hypotensive Effects of Conventional Dairy Products: Role of Arterial Stiffness|Completed||N/A|49|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 21:27:55.452377|2018-05-31 21:27:55.452377
NCT01577017|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-06-13|2012-04-11|2012-04-13|Estimate|||||||2012-06-13|2012-06-14|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|May 2009|Actual|2009-05-31||Interventional|||The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)|Study On The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)|Completed||Phase 3|150|Actual|University of Science Malaysia||1|||f||||t||||||||||2018-05-31 21:27:55.52957|2018-05-31 21:27:55.52957
NCT01577004|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-04-11|2012-04-11|2012-04-13|Estimate|||||||2012-04-11|2012-04-13|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?|Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?|Completed||N/A|40|Actual|Université de Sherbrooke||1|||f||||t||||||||||2018-05-31 21:27:55.591235|2018-05-31 21:27:55.591235
NCT01576991|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2013-08-09|2012-04-11|2012-04-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Telomeres and Reproduction in Women|Telomeres and Reproduction in Women|Completed|||145|Actual|University of South Florida|||1||f||||t||||||Samples With DNA|"~     Blood, Follicle cells, and or polar body of eggs~   "|||2018-05-31 21:27:55.659149|2018-05-31 21:27:55.659149
NCT01576978|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-04-11|2012-04-11|2012-04-13|Estimate|||||||2012-04-11|2012-04-13|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Hatha Yoga Exercises in Pelvic and Lumbar Back Pain in Pregnant Woman|Hatha Yoga Exercises in Pelvic and Lumbar Back Pain in Pregnant Woman|Completed||N/A|60|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 21:27:55.722221|2018-05-31 21:27:55.722221
NCT01576965|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2017-03-10|2012-04-11|2012-04-13|Estimate|||||||2017-03-10|2017-03-14|Actual|April 2012||2012-04-30|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial|Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial|Completed||N/A|160|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||||2018-05-31 21:27:55.783427|2018-05-31 21:27:55.783427
NCT01576952|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2016-04-26|2014-06-19|2016-06-02|2012-04-12|2012-04-13|Estimate|2016-06-02|2016-07-13|Estimate|2014-06-19|2014-06-23|Estimate|2016-06-02|2016-07-13|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ISV-303|Modified Intent-to-Treat: subjects who were randomized into the trial, underwent cataract surgery, and received at least one dose of study drug.|Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects|A Randomized Double-Masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects|Completed||Phase 3|268|Actual|InSite Vision||2|||f||||||||||||||2018-05-31 21:27:55.865383|2018-05-31 21:27:55.865383
NCT01576939|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2016-12-08||2017-05-16|2012-04-11|2012-04-13|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|August 2011||2011-08-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|January 2014|Actual|2014-01-31||Interventional|||Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer|A Feasibility Study of IMRT (Intensity Modulated Radiotherapy) Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer Patients|Completed||N/A|30|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 21:27:56.062315|2018-05-31 21:27:56.062315
NCT01576926|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-04-11|2012-04-11|2012-04-13|Estimate|||||||2012-04-11|2012-04-13|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Observational|||Evolution of Swallowing in Patients Undergoing Lateral Pharyngoplasty With Preservation Stylopharyngeal Muscle|Evolution of Swallowing in Patients Undergoing Lateral Pharyngoplasty With Preservation Stylopharyngeal Muscle|Completed|||1|Actual|Hospital do Servidor Publico Estadual|||1||f||||t||||||||||2018-05-31 21:27:56.248169|2018-05-31 21:27:56.248169
NCT01576913|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2014-11-22|2012-04-11|2012-04-13|Estimate|||||||2014-11-22|2014-11-25|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Music Pacing in Pediatric Exercise Testing|Music Pacing in Pediatric Exercise Testing|Completed||N/A|20|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:27:56.306308|2018-05-31 21:27:56.306308
NCT01576900|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-11-19|2012-04-11|2012-04-13|Estimate|||||||2014-11-19|2014-11-20|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia||Completed|||124|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 21:27:56.361379|2018-05-31 21:27:56.361379
NCT01576887|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-11-01|2012-04-11|2012-04-13|Estimate|||||||2012-11-01|2012-11-02|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|October 2013|Anticipated|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis||Withdrawn||Phase 2|0|Actual|Reata Pharmaceuticals, Inc.||2||IDMC recommendation for safety concerns|f||||||||||||||2018-05-31 21:27:56.431773|2018-05-31 21:27:56.431773
NCT01576874|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2018-01-29|2012-04-11|2012-04-13|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|SCOR-III||The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking|The Gender-Sex Hormone Interface With Craving & Stress-Related Changes in Smoking|Completed||N/A|180|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:27:56.518722|2018-05-31 21:27:56.518722
NCT01576861|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-10-17|2012-04-12|2012-04-13|Estimate|||||||2012-10-17|2012-10-18|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure||Completed||Phase 2|28|Actual|Federico II University||2|||f||||||||||||||2018-05-31 21:27:56.680977|2018-05-31 21:27:56.680977
NCT01576848|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-04-12|2012-04-12|2012-04-13|Estimate|||||||2012-04-12|2012-04-13|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PRO-CARB||Impact of Carbohydrate Co-ingestion on the Post-prandial Anabolic Response of Protein in Young and Elderly Men|Impact of Carbohydrate Co-ingestion on the Post-prandial Anabolic Response of Protein in Young and Elderly Men|Completed||N/A|48|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 21:27:56.775388|2018-05-31 21:27:56.775388
NCT01576835|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2015-08-24|2012-04-11|2012-04-13|Estimate|||||||2015-08-24|2015-08-26|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|REACT||Renal Artery Contrast-Free Trial|Comparison of Non-contrast Renal Artery Magnetic Resonance Angiography With Contrast-enhanced CT Angiography|Completed|||75|Actual|Central Coast Cardiovascular Research|||||f||||t||||||||||2018-05-31 21:27:56.884838|2018-05-31 21:27:56.884838
NCT01576822|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-10-29|2012-04-12|2012-04-13|Estimate|||||||2012-10-29|2012-10-30|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Sauna Detoxification Study: Pilot Feasibility|Complementary and Alternative Medicine Detoxification: Safety and Efficacy|Completed||Phase 1|10|Actual|Bastyr University||2|||f||||t||||||||||2018-05-31 21:27:56.974461|2018-05-31 21:27:56.974461
NCT01576809|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2013-04-17||2013-10-18|2012-04-11|2012-04-12|Estimate|2013-10-18|2013-11-11|Estimate||||2013-10-18|2013-11-11|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)|An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection|Completed||Phase 3|51|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:27:57.084852|2018-05-31 21:27:57.084852
NCT01576796|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-07-27|2012-04-11|2012-04-12|Estimate|||||||2016-07-27|2016-07-28|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|March 2016|Actual|2016-03-31||Interventional|RTEP-5||Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer|Phase II Study of the Efficacy and Safety of a Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Identified by F-miso PET/CT in Patients With Stage III Non-small-cell Lung Cancer (NSCLC) Not Amenable to Curative Surgical Resection Who Are Candidate for Curative Radio-chemotherapy|Active, not recruiting||Phase 2|75|Anticipated|Centre Henri Becquerel|||||f||||f||||||||||2018-05-31 21:27:57.279632|2018-05-31 21:27:57.279632
NCT01576783|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-07-11|2012-04-11|2012-04-12|Estimate|||||||2017-07-11|2017-07-14|Actual|April 2012||2012-04-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|April 2017|Actual|2017-04-30||Interventional|||Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes|Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes|Active, not recruiting||Phase 4|377|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 21:27:57.360562|2018-05-31 21:27:57.360562
NCT01576770|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-11|2012-04-11|2012-04-12|Estimate|||||||2012-04-11|2012-04-12|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|January 2013|Anticipated|2013-01-31|October 2012|Anticipated|2012-10-31||Interventional|Synera patch||In Children, Does Using a Synera Patch Decrease Pain When Injecting Propofol at Anesthesia Induction?|In Children, Does the Use of Synera Patch for Local Analgesia Before Vascular Access Reduce Pain Associated With Propofol Injection for Anesthesia Induction?|Unknown status|Recruiting|Phase 4|80|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 21:27:57.452751|2018-05-31 21:27:57.452751
NCT01576757|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-06-28|2012-04-10|2012-04-12|Estimate|||||||2017-06-28|2017-07-02|Actual|April 2011||2011-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Harvest, Isolation and Culture of Cardiac Stem Cells From Endomyocardial Biopsies|Harvest, Isolation and Culture of Cardiac Stem Cells From Endomyocardial Biopsies|Enrolling by invitation|||30|Anticipated|University of Louisville|||1||f||||f||||||Samples With DNA|"~     Biopsy samples are taken at the time of right heart catheterization. They are frozen in a GMP~     facility at the University of Louisville. The tissue is shipped either to the Institue of~     Molecular Caridology, Louisville, KY or shipped overnight to the Brigham and Women's Hospital~     in Boston, MA. The tissue is enzymatically dissociated, and cardiac stem cells are isolated~     and maintained in culture for 6-8 passages (point of clinical utility). During that time~     period, experimentation is carried out to charcterize the biological attributes of these cell~     populations. After this experimentation is complete, the cultures are destroyed in accordance~     with the biohazard handling policies of the individual institution.~   "|||2018-05-31 21:27:57.55514|2018-05-31 21:27:57.55514
NCT01576744|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-06-01|2012-04-10|2012-04-12|Estimate|||||||2012-06-01|2012-06-04|Estimate|March 2010||2010-03-31|June 2012|2012-06-30||||June 2012|Anticipated|2012-06-30||Observational|FHE4||Serum Biomarker HE4 During IVF Treatment|Serum Concentration of HE4, a New Marker for Ovarian Cancer, Changes Little Throughout IVF Stimulation|Unknown status|Active, not recruiting||20|Actual|Turku University Hospital|||||f||||f||||||Samples Without DNA|"~     Repeated serum samples~   "|||2018-05-31 21:27:57.619156|2018-05-31 21:27:57.619156
NCT01576731|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-03-31|2012-04-11|2012-04-12|Estimate|||||||2015-03-31|2015-04-01|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|RAL-PEP||Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)|Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir|Completed||Phase 4|240|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 21:27:57.672026|2018-05-31 21:27:57.672026
NCT01576718|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2017-02-28|2015-03-19|2018-05-04|2012-04-10|2012-04-12|Estimate|2017-02-28|2017-04-12|Actual|2015-03-19|2015-04-09|Estimate|2018-05-04|2018-05-08|Actual|April 2012||2012-04-30|May 2018|2018-05-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional||Intent to treat analysis set|A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications|A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High Dose Inhaled Corticosteroid Therapy|Completed||Phase 2|889|Actual|Teva Pharmaceutical Industries||6|||f||||f||||||||||2018-05-31 21:27:57.874053|2018-05-31 21:27:57.874053
NCT01576705|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2018-03-06|2012-04-11|2012-04-12|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2012|Actual|2012-04-30|March 2018|2018-03-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|ACTHYF||Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children|Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children|Completed||Phase 3|175|Actual|Institut Jerome Lejeune||4|||f||||t||||||||||2018-05-31 21:28:00.708361|2018-05-31 21:28:00.708361
NCT01576692|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2018-02-19|2012-04-11|2012-04-12|Estimate|||||||2018-02-19|2018-02-20|Actual|April 2012||2012-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2014|Actual|2014-10-31||Interventional|||Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma|A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma|Active, not recruiting||Phase 1|34|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|t|t|f||||||2018-05-31 21:28:00.86999|2018-05-31 21:28:00.86999
NCT01576679|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2018-05-03|2012-04-11|2012-04-12|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2012||2012-03-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-Abdominal Collections in Children - A Prospective Study|A Double Blind, Randomized Controlled Trial Examining the Efficacy of the Use of Tissue Plasminogen Activator (tPA) in Intra-abdominal Collections in Children - a Prospective Study|Suspended||Phase 3|50|Anticipated|The Hospital for Sick Children||2||Final analysis, drafting final report.|f||||t||||||||No||2018-05-31 21:28:00.963394|2018-05-31 21:28:00.963394
NCT01576666|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-02-18|2012-04-11|2012-04-12|Estimate|||||||2016-02-18|2016-02-22|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors|A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors|Completed||Phase 1|120|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:28:01.055167|2018-05-31 21:28:01.055167
NCT01576653|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-09-20|2012-04-11|2012-04-12|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2011||2011-06-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL|Prospective Clinical Evaluation of Bata-D-Glucan Assay for Diagnosis of Invasive Fungal Infection in Blood and Bronchoalveolar Lavage|Recruiting||N/A|100|Anticipated|Medical University of Graz||2|||f||||f||||||||||2018-05-31 21:28:01.18478|2018-05-31 21:28:01.18478
NCT01576640|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2015-05-19|2012-04-11|2012-04-12|Estimate|||||||2015-05-19|2015-05-21|Estimate|December 2005||2005-12-31|May 2015|2015-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia|An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia|Terminated||Phase 4|17|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:28:01.2771|2018-05-31 21:28:01.2771
NCT01576627|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-01-03|2012-04-11|2012-04-12|Estimate|||||||2013-01-03|2013-01-04|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|||Zinc Absorption From Zinc Citrate, Zinc Gluconate and Zinc Oxide|Zinc Absorption From Zinc Supplements Comparing Zinc Citrate to Zinc Gluconate and Zinc Oxide in Young Adults|Completed||N/A|15|Actual|Swiss Federal Institute of Technology||3|||f||||f||||||||||2018-05-31 21:28:01.362982|2018-05-31 21:28:01.362982
NCT01576614|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2013-09-24|2012-04-11|2012-04-12|Estimate|||||||2013-09-24|2013-09-26|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||The Role of Off-shift Robotic Telerounding Between Physicians and Nurses in the Surgical Intensive Care Unit|A Prospective Randomized Study on the Role of Off-shift Robotic Telerounding on the Collaboration Between Physicians and Nurses in the Surgical Intensive Care Unit|Completed|||35|Actual|Lahey Clinic|||2||f||||f||||||||||2018-05-31 21:28:01.43706|2018-05-31 21:28:01.43706
NCT01576601|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-12-07|2012-04-11|2012-04-12|Estimate|||||||2017-12-07|2017-12-11|Actual|August 2011|Actual|2011-08-31|December 2017|2017-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||The Management of Postoperative Craniotomy Pain in Pediatric Patients|The Management of Postoperative Craniotomy Pain in Pediatric Patients: A Prospective Cohort Study|Completed|||81|Actual|Johns Hopkins University|||3||f||||f||||||||||2018-05-31 21:28:01.511737|2018-05-31 21:28:01.511737
NCT01576588|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-12-09|2012-04-11|2012-04-12|Estimate|||||||2014-12-09|2014-12-10|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||Rituximab in Pretreated Elderly or Unfit B-CLL Patients|Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients With Chronic B Lymphocytic Leukemia|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Vilnius University||1|||f||||f||||||||||2018-05-31 21:28:01.581201|2018-05-31 21:28:01.581201
NCT01576575|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-12-11|2012-04-11|2012-04-12|Estimate|||||||2017-12-11|2017-12-13|Actual|June 2010||2010-06-30|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BUP||Buprenorphine Disposition and Clinical Effects|Influence of CYP3A Modulation on Buprenorphine Disposition and Clinical Effects|Recruiting||N/A|25|Anticipated|Washington University School of Medicine||7|||f||||t||||||||||2018-05-31 21:28:01.683277|2018-05-31 21:28:01.683277
NCT01576562|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-08-07|2012-04-11|2012-04-12|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2014|Actual|2014-02-28|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) Implantation|Implantable Cardioverter Defibrillator (ICD) Function During Ventricular Assist Device (VAD) Implantation|Completed|||37|Actual|Virginia Commonwealth University|||1||f||||f||||||||||2018-05-31 21:28:01.780409|2018-05-31 21:28:01.780409
NCT01576549|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2018-03-24|2013-09-27|2018-03-24|2012-04-11|2012-04-12|Estimate|2018-03-24|2018-04-26|Actual|2013-09-27|2013-10-28|Estimate|2018-03-24|2018-04-26|Actual|May 2012||2012-05-31|March 2018|2018-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Participants who received at least one dose of study drug (LY2127399).|A Study of LY2127399 in Rheumatoid Arthritis|An Exploratory Open-Label Biomarker Study of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Synovial Biopsies|Terminated||Phase 2|2|Actual|Eli Lilly and Company|Due to early termination of the trial (February 2013 in conjunction with the FLEX RA program), no participant had outcome measure data analyzed. Participants who received study treatment had disposition, demographic, and adverse event data reported.|1||Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773).|f||||f||||||||||2018-05-31 21:28:01.857466|2018-05-31 21:28:01.857466
NCT01576536|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2018-01-23|2012-04-11|2012-04-12|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Genetic Variation in Platelet Aggregation|Genetic Variation in Platelet Aggregation|Active, not recruiting|||118|Actual|Vanderbilt University Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood samples for DNA and plasma/serum for subsequent biomarker analysis if required.~   "|||2018-05-31 21:28:02.165752|2018-05-31 21:28:02.165752
NCT01576523|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10||2014-01-28|2017-07-27|2012-04-10|2012-04-12|Estimate||||2014-01-28|2014-02-28|Estimate|2017-07-27|2017-07-28|Actual|April 2012||2012-04-30|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route|An Open-label, Cross-over, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of the Subcutaneous Administration of a Human Plasma-derived C1-esterase Inhibitor in Subjects With Hereditary Angioedema|Completed||Phase 1/Phase 2|18|Actual|CSL Behring||6|||f||||||||||||||2018-05-31 21:28:02.243306|2018-05-31 21:28:02.243306
NCT01576510|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-06-23|2012-04-11|2012-04-12|Estimate|||||||2014-06-23|2014-06-24|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||fMRI Predictors of Treatment Response in Posttraumatic Stress Disorder (PTSD)|Brain Circuitry and Psychosocial Predictors of PTSD|Completed||N/A|95|Actual|Research Foundation for Mental Hygiene, Inc.||2|||f||||f||||||||||2018-05-31 21:28:02.358551|2018-05-31 21:28:02.358551
NCT01576497|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2014-05-28|2012-04-11|2012-04-12|Estimate|||||||2014-05-28|2014-05-29|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Optimal Number of To-and-fro Motion in EUS-guided Fine Needle Aspiration for Pancreatic Masses|Optimal Number of To-and-fro Motion in EUS-guided Fine Needle Aspiration for Pancreatic Masses in Terms of Suction or Without Suction: Prospective Randomized Single Blinded Trial|Completed||Phase 3|193|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:28:02.434839|2018-05-31 21:28:02.434839
NCT01576484|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27||2018-02-04|2018-02-04|2012-04-10|2012-04-12|Estimate||||2015-01-24|2015-01-30|Estimate|2018-02-04|2018-02-09|Actual|March 2012||2012-03-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia|A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia|Completed||Phase 2|58|Actual|Regeneron Pharmaceuticals||1|||f||||t||||||||||2018-05-31 21:28:02.512999|2018-05-31 21:28:02.512999
NCT01576471|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2017-04-03||2017-05-30|2012-04-11|2012-04-12|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|July 2012||2012-07-31|April 2017|2017-04-30|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|TRUST-I||Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo|A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease|Completed||Phase 2|250|Actual|Coronado Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 21:28:02.627057|2018-05-31 21:28:02.627057
NCT01576458|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-04-11|2012-04-11|2012-04-12|Estimate|||||||2012-04-11|2012-04-12|Estimate|January 1998||1998-01-31|April 2012|2012-04-30|December 1998|Actual|1998-12-31|December 1998|Actual|1998-12-31||Interventional|||Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy|Randomised Placebo-controlled Study of Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy|Completed||Phase 3|20|Actual|Turku University Hospital||2|||f||||t||||||||||2018-05-31 21:28:03.104271|2018-05-31 21:28:03.104271
NCT01576445|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-10|2012-04-10|2012-04-12|Estimate|||||||2012-04-10|2012-04-12|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Functional Outcome in Two Types of Total Knee Replacement Surgery for People With Osteoarthritis|Randomised Controlled Trial to Compare the Speed of Recovery and Functional Outcome Following Total Knee Replacement (TKR) Using a Quadriceps Sparing Approach to the Knee Against a Standard Medial Parapatellar Surgical Exposure|Completed||Phase 2|30|Actual|Queen Margaret University||2|||f||||f||||||||||2018-05-31 21:28:03.172371|2018-05-31 21:28:03.172371
NCT01576432|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-04-10|2012-04-10|2012-04-12|Estimate|||||||2012-04-10|2012-04-12|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Non-pharmacological Analgesia During Heel Prick|Non-pharmacological Analgesia During Heel Prick: A Randomized, Controlled Trial|Terminated||N/A|136|Actual|Puerta de Hierro University Hospital||4||The data showed that pain was higher for our standardized method of sampling|f||||f||||||||||2018-05-31 21:28:03.239194|2018-05-31 21:28:03.239194
NCT01576419|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-10|2012-04-10|2012-04-12|Estimate|||||||2012-04-10|2012-04-12|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients|Double Blinded, Randomized, Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis Patients|Completed||Phase 3|309|Actual|PMG Pharm Co., Ltd||2|||f||||t||||||||||2018-05-31 21:28:03.317931|2018-05-31 21:28:03.317931
NCT01576406|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-05-04|2012-04-10|2012-04-12|Estimate|||||||2017-05-04|2017-05-08|Actual|July 19, 2012|Actual|2012-07-19|May 2017|2017-05-31|June 10, 2016|Actual|2016-06-10|June 10, 2016|Actual|2016-06-10||Interventional|||Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients|A Phase I Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Crizotinib In Advanced Cancer Patients|Completed||Phase 1|70|Anticipated|Pfizer||5|||f||||f||||||||||2018-05-31 21:28:03.398037|2018-05-31 21:28:03.398037
NCT01576393|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2015-09-20|2012-04-10|2012-04-12|Estimate|||||||2015-09-20|2015-09-22|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|||Adolescent Involvement in Parental Substance Abuse Treatment|Adolescent Involvement in Parental Substance Abuse Treatment: Evaluation of EBFT|Completed||Phase 1/Phase 2|183|Anticipated|Ohio State University||3|||f||||f||||||||||2018-05-31 21:28:03.560578|2018-05-31 21:28:03.560578
NCT01576380|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-02-23|2012-04-10|2012-04-12|Estimate|||||||2017-02-23|2017-02-27|Actual|June 2012||2012-06-30|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients|A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments|Completed||Phase 2|11|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:28:03.727696|2018-05-31 21:28:03.727696
NCT01576367|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2016-06-22||2016-06-22|2012-04-10|2012-04-12|Estimate|2016-06-22|2016-08-03|Estimate||||2016-06-22|2016-08-03|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease|An Open-label Extension Study to Assess Efficacy, Safety and Tolerability of Canakinumab and the Efficacy and Safety of Childhood Vaccinations in Patients With Cryopyrin Associated Periodic Syndromes (CAPS)|Completed||Phase 3|17|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:28:03.838213|2018-05-31 21:28:03.838213
NCT01576185|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-05-13|2012-04-11|2012-04-12|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia|Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents|Completed|||10|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-05-31 21:28:05.917272|2018-05-31 21:28:05.917272
NCT01576354|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-12-03|2012-04-11|2012-04-12|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|FAMPKIN||Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis|A Phase IIb, Double-blind, Randomized, Mono-center, Placebo-controlled Study With Crossover Design Characterizing the Effects of Prolonged-release Fampridine Treatment on Ambulatory Function in Patients With Multiple Sclerosis Using Detailed Gait Analysis Based on Kinematic and Kinetic Parameters|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|University of Zurich||2|||f||||||||||||||2018-05-31 21:28:04.17464|2018-05-31 21:28:04.17464
NCT01576341|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2017-04-03||2017-04-04|2012-04-11|2012-04-12|Estimate|2017-04-04|2017-06-19|Actual||||2017-04-04|2017-06-19|Actual|April 2012||2012-04-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|SENSE|Safety population: The safety population consists of all patients that received at least one dose of study drug|HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)|Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of HX575 Epoetin Alfa in the Treatment of Anemia Associated With Chronic Kidney Disease in Pre-dialysis and Dialysis Patients|Completed||Phase 3|417|Actual|Sandoz||1|||f||||f||||||||||2018-05-31 21:28:04.289105|2018-05-31 21:28:04.289105
NCT01576328|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2018-03-05|2012-04-10|2012-04-12|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2012||2012-04-30|March 2018|2018-03-31|October 2015|Actual|2015-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes|A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin|Completed||Phase 1/Phase 2|61|Actual|Mesoblast, Ltd.||3|||f||||t||||||||||2018-05-31 21:28:04.797285|2018-05-31 21:28:04.797285
NCT01576315|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-04-11|2012-04-11|2012-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|ATCF||ATCF (Azole Therapy in Cystic Fibrosis)|Efficacy of Itraconazole and of Voriconazole in Patients With Cystic Fibrosis and Presenting With Persistent Positive Sputums for Aspergillus.|Completed||Phase 2|11|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 21:28:04.914148|2018-05-31 21:28:04.914148
NCT01576302|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2014-12-08|2012-04-10|2012-04-12|Estimate|||||||2014-12-08|2014-12-10|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Diaphragmatic Breathing and Muscle Relaxation for Rumination|Diaphragmatic Breathing and Progressive Muscle Relaxation: Behavioral Interventions for Gastrointestinal Rumination|Completed||Phase 3|13|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:28:05.007722|2018-05-31 21:28:05.007722
NCT01576289|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2012-07-23|2012-04-11|2012-04-12|Estimate|||||||2012-07-23|2012-07-24|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|histoGERD||Analysis of Biopsies From the Upper Gastrointestinal Tract|Clinical Evaluation and Histological Analysis of Biopsies From the Upper Gastrointestinal Tract of Patients With and Without Symptoms of Reflux Disease (histoGERD Trial)|Completed|||600|Anticipated|Medical University of Graz|||1||f||||f||||||Samples With DNA|"~     Biopsy specimens (formalin fixed and paraffin embedded) which are routinely obtained during~     the endoscopic procedure are retained according to legal requirements.~   "|||2018-05-31 21:28:05.084123|2018-05-31 21:28:05.084123
NCT01576276|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2018-02-08||2018-04-27|2012-04-10|2012-04-12|Estimate|2018-04-27|2018-05-28|Estimate||||2018-04-27|2018-05-28|Estimate|April 2012|Actual|2012-04-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects|A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects|Completed||N/A|51|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:28:05.160874|2018-05-31 21:28:05.160874
NCT01576263|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-04-09|2012-04-11|2012-04-12|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||Autologous Blood Transfusion After Local Infiltration|Autologous Blood Transfusion After Local Infiltration Analgesia With Ropivacaine in Total Knee and Hip Arthroplasty|Completed|||52|Actual|Northern Orthopaedic Division, Denmark|||2||f||||f||||||Samples Without DNA|"~     Venous blood to collect an analysis of total ropivacaine concentrations.~   "|||2018-05-31 21:28:05.407415|2018-05-31 21:28:05.407415
NCT01576250|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2015-05-27|2012-04-10|2012-04-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Lowered Physical Activity on Insulin Sensitivity and Lipid and Glucose Metabolism|The Effect of Lowered Physical Activity (Induced by Lower Limb Suspension (ULLS)) on Insulin Sensitivity and Lipid and Glucose Metabolism|Completed||N/A|13|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 21:28:05.473034|2018-05-31 21:28:05.473034
NCT01576237|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2015-02-24|2012-04-11|2012-04-12|Estimate|||||||2015-02-24|2015-02-26|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Multinational Haemapheresis Vigilance Study|Open Prospective Multi-national Long-term Study to Register Adverse Events Related to Hemaphereses by Means of an Internet-based Haemapheresis Vigilance Questionnaire|Unknown status|Active, not recruiting||50000|Anticipated|DGTI - Haemapheresis Vigilance Working Party|||1||f||||t||||||||||2018-05-31 21:28:05.545747|2018-05-31 21:28:05.545747
NCT01576224|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2017-01-23|2012-04-10|2012-04-12|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|E-MOB||Early Mobilization After Volar Plate Osteosynthesis of Distal Radius Fractures|Early Mobilization After Volar Plate Osteosynthesis of Distal Radius Fractures. A Prospective Randomized Study.|Completed||N/A|100|Actual|Zealand University Hospital||2|||f||||t||||||||No||2018-05-31 21:28:05.607861|2018-05-31 21:28:05.607861
NCT01576211|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-05-17|2012-04-11|2012-04-12|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2012||2012-04-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor|Investigating the Frequency of Loss of Imprinting Across a Birth Cohort and the Link DNA Methylation Plays|Completed|||40|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     blood and tissue~   "|||2018-05-31 21:28:05.774431|2018-05-31 21:28:05.774431
NCT01576198|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-07-13|2012-04-11|2012-04-12|Estimate|||||||2016-07-13|2016-07-14|Estimate|April 2012||2012-04-30|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Studying Biomarkers in Samples From Younger Patients With Wilms Tumor|Validation of Copy Number Changes by MLPA as Predictors of Relapse in Wilms Tumor|Completed|||2227|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:28:05.841552|2018-05-31 21:28:05.841552
NCT01576172|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2018-04-24|2012-04-11|2012-04-12|Estimate|||||||2018-04-24|2018-04-25|Actual|March 30, 2012|Actual|2012-03-30|March 2018|2018-03-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer|A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 2|148|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:28:06.011195|2018-05-31 21:28:06.011195
NCT01576159|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|2012-05-02||2015-06-09|2012-04-11|2012-04-12|Estimate|2015-06-09|2015-06-10|Estimate||||2015-06-09|2015-06-10|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Serum Cartilage Oligomeric Matrix Protein Levels After 12 Weeks of Different Exercises|The Effect of Mechanical Loading During Sports Exercises on Degradation of Human Articular Cartilage|Completed||Early Phase 1|48|Actual|Middle East Technical University||4|||f||||t||||||||||2018-05-31 21:28:06.147769|2018-05-31 21:28:06.147769
NCT01576146|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2017-03-01|2015-07-21|2017-03-01|2012-04-10|2012-04-12|Estimate|2017-03-01|2017-04-13|Actual|2015-07-21|2015-08-11|Estimate|2017-03-01|2017-04-13|Actual|March 2012||2012-03-31|March 2017|2017-03-31|May 1, 2014|Actual|2014-05-01|May 1, 2014|Actual|2014-05-01||Interventional||Baseline was defined as the baseline of the parent study, 20120331.|Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism|A Multicenter Open-label Extension Study to Assess the Long-term Safety and Efficacy of KAI-4169 (Also Known as AMG 416) in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Patients With Secondary Hyperparathyroidism|Terminated||Phase 2|30|Actual|KAI Pharmaceuticals||1||Study was terminated early to allow subjects to roll over to study NCT02102204.|f||||f|t|f||||||||2018-05-31 21:28:06.544795|2018-05-31 21:28:06.544795
NCT01576133|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-08-16|2012-04-10|2012-04-12|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2012||2012-04-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|CAPABLE||Reducing Disability Via a Bundled Bio-Behavioral-Environmental Approach|Reducing Disability Via a Bundled Bio-Behavioral-Environmental Approach|Completed||Phase 2|300|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:28:06.898045|2018-05-31 21:28:06.898045
NCT01576120|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2014-10-05||2014-10-05|2012-04-10|2012-04-12|Estimate|2014-10-05|2014-10-09|Estimate||||2014-10-05|2014-10-09|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|RD-207||Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients|Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study|Completed||Phase 1/Phase 2|40|Actual|Given Imaging Ltd.||2|||f||||f||||||||||2018-05-31 21:28:06.973135|2018-05-31 21:28:06.973135
NCT01576107|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-04-22|2012-04-10|2012-04-12|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||MOTIVACTION - Study|Motivational Intervention Enhancing Physical Activity In Oncology Patients (MOTIVACTION)|Completed||N/A|76|Actual|German Cancer Research Center||2|||f||||||||||||||2018-05-31 21:28:07.166215|2018-05-31 21:28:07.166215
NCT01576094|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2012-04-11|2012-04-11|2012-04-12|Estimate|||||||2012-04-11|2012-04-12|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Two Inodilators Postsurgery in Neonates|Phase I Study of Two Inodilators in Neonates Undergoing Cardiovascular Surgery|Completed||Phase 1/Phase 2|20|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||2|||f||||t||||||||||2018-05-31 21:28:07.243595|2018-05-31 21:28:07.243595
NCT01576081|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-08-15|2012-04-11|2012-04-12|Estimate|||||||2012-08-15|2012-08-16|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|HEP||"The Novel Unloading Device HEPHAISTOS and Its Effects Upon Bone, Muscle and Vasculature"|The Effects of a 56day Unilateral Muscular Unloading Intervention With a Novel Device That Allows Normal Ambulation While Reducing Muscle Activation Drastically, on Muscles, Bones and Vessels.|Completed||N/A|11|Actual|DLR German Aerospace Center||1|||f||||t||||||||||2018-05-31 21:28:07.32542|2018-05-31 21:28:07.32542
NCT01576068|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-04-11|2012-04-11|2012-04-12|Estimate|||||||2012-04-11|2012-04-12|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|July 2012|Anticipated|2012-07-31||Interventional|FARMAEPOC||Chronic Obstructive Pulmonary Disease Case Finding in Community-pharmacies by Spirometry|Efficiency of COPD Case Finding Program by Spirometry in High-risk Customers of Urban Community Pharmacies|Unknown status|Active, not recruiting|Early Phase 1|3600|Anticipated|Col·legi de Farmacèutics de la Província de Barcelona||1|||f||||f||||||||||2018-05-31 21:28:07.396123|2018-05-31 21:28:07.396123
NCT01576055|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2016-08-24||2017-09-08|2012-04-10|2012-04-12|Estimate|2016-08-24|2016-10-19|Estimate||||2017-09-08|2017-10-09|Actual|April 2012||2012-04-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2015|Actual|2015-08-31||Interventional|TIGRIS|Per Protocol Population|Evaluation of the GORE TIGRIS Vascular Stent|Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries|Completed||N/A|267|Actual|W.L.Gore & Associates||2|||f||||t||||||||No||2018-05-31 21:28:07.493085|2018-05-31 21:28:07.493085
NCT01576042|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|2014-09-18||2014-10-06|2012-04-10|2012-04-12|Estimate|2014-09-18|2014-09-25|Estimate||||2014-10-06|2014-10-16|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|CALYPSO||Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator|Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL|Terminated||N/A|27|Actual|Duke University||2||"Main objectives of the study were met; consensus among investigators that continuing the study~   would not add new information beyond that already learned."|f||||t||||||||||2018-05-31 21:28:08.068285|2018-05-31 21:28:08.068285
NCT01576029|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2013-12-23|2012-04-11|2012-04-12|Estimate|||||||2013-12-23|2013-12-24|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SWITCH||Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer|Phase II Randomized Study of Continuing Treatment With Docetaxel Versus Switching to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in the First Line Treatment of Patients With Castration-Resistant Metastatic Prostate Cancer.|Completed||Phase 2|2|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:28:08.448984|2018-05-31 21:28:08.448984
NCT01576016|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-10-30|2012-04-10|2012-04-12|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2012||2012-03-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy of the Accent Magnetic Resonance Imaging™ (MRI) Pacemaker and Tendril MRI™ Lead|Accent Magnetic Resonance Imaging Pacemaker and Tendril Magnetic Resonance Imaging™ Lead Investigational Device Exemption Study|Active, not recruiting||N/A|800|Anticipated|St. Jude Medical||2|||f||||f||||||||||2018-05-31 21:28:08.655752|2018-05-31 21:28:08.655752
NCT01576003|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2015-07-28|2012-04-11|2012-04-12|Estimate|||||||2015-07-28|2015-07-29|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants|Efficacy of Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants|Completed||N/A|48|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-05-31 21:28:08.85859|2018-05-31 21:28:08.85859
NCT01575990|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-05-27|2012-04-10|2012-04-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|EPIC-D||Elders Preferences in Care Decisions|Improving Appropriate Colorectal Cancer Screening in Elderly Patients|Completed||N/A|424|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:28:08.960182|2018-05-31 21:28:08.960182
NCT01575977|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-04-26|2012-04-11|2012-04-12|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2011||2011-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Stress Analysis of Hip Dysplasia|Stress Analysis of Hip Dysplasia After Corrective Surgery|Enrolling by invitation|||24|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 21:28:09.052231|2018-05-31 21:28:09.052231
NCT01575964|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-04-26|2012-04-11|2012-04-12|Estimate|||||||2018-04-26|2018-04-30|Actual|January 2012||2012-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|FAI||Biomechanical Assessment of Femoroacetabular Impingement|Biomechanical Assessment of Femoroacetabular Impingement|Enrolling by invitation|||36|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 21:28:09.109066|2018-05-31 21:28:09.109066
NCT01575951|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2018-04-19|2012-04-10|2012-04-12|Estimate|||||||2018-04-19|2018-04-20|Actual|February 2010||2010-02-28|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|November 5, 2014|Actual|2014-11-05||Interventional|||Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection|Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection|Active, not recruiting||N/A|16|Actual|University of Utah||1|||f||||t|f|f||||||||2018-05-31 21:28:09.17958|2018-05-31 21:28:09.17958
NCT01575938|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-12-01|2012-04-10|2012-04-12|Estimate|||||||2017-12-01|2017-12-05|Actual|March 2012|Actual|2012-03-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|LifeSkills||HIV Prevention Intervention for Young Transgender Women|HIV Prevention Intervention for Young Transgender Women|Completed||N/A|300|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||3|||f||||t||||||||Undecided||2018-05-31 21:28:09.254199|2018-05-31 21:28:09.254199
NCT01575925|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2018-02-15|2012-04-11|2012-04-12|Estimate|||||||2018-02-15|2018-02-19|Actual|June 1, 2012|Actual|2012-06-01|February 2018|2018-02-28|June 11, 2021|Anticipated|2021-06-11|June 11, 2021|Anticipated|2021-06-11||Interventional|POM Renal||Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)|A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Impaired Renal Function|Active, not recruiting||Phase 1|25|Actual|Celgene||2|||f||||f||||||||||2018-05-31 21:28:09.346686|2018-05-31 21:28:09.346686
NCT01575912|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2017-01-31||2017-06-09|2012-04-10|2012-04-12|Estimate|2017-03-22|2017-05-03|Actual||||2017-06-09|2017-06-12|Actual|March 2012||2012-03-31|June 2017|2017-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Past Pain Experience and Perception of Experimental Pain|Past Pain Experience and Perception of Experimental Pain|Completed|||92|Actual|Centre Hospitalier Esquirol|||3||f||||f||||||||No||2018-05-31 21:28:09.465518|2018-05-31 21:28:09.465518
NCT01575899|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2012-04-19||2012-07-28|2012-04-11|2012-04-12|Estimate|2012-07-28|2012-08-31|Estimate||||2012-07-28|2012-08-31|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori|Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori.|Terminated||Phase 4|208|Actual|Buddhist Tzu Chi General Hospital|The limitation of this study is the local primary resistance of Hp to levofloxacin and to amoxicillin/clavulanate is unknown. We are currently engaged in an on-going investigation of the influence of CYP2C19 genotypes on this new regimen.|2||Early termination due to efficacy|f||||t||||||||||2018-05-31 21:28:09.711343|2018-05-31 21:28:09.711343
NCT01575886|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2012-04-10|2012-04-10|2012-04-12|Estimate|||||||2012-04-10|2012-04-12|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Enhancing Teachable Moment Communication for Smoking Cessation and Weight Management|Enhancing Teachable Moment Communication for Smoking Cessation and Weight|Unknown status|Enrolling by invitation|N/A|1152|Anticipated|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 21:28:10.105474|2018-05-31 21:28:10.105474
NCT01575873|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10||2017-05-17|2017-07-06|2012-04-11|2012-04-12|Estimate||||2017-05-17|2017-05-19|Actual|2017-07-06|2017-07-11|Actual|March 28, 2012|Actual|2012-03-28|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|June 21, 2016|Actual|2016-06-21||Interventional|GIOP||A Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids|A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals|Completed||Phase 3|795|Actual|Amgen||2|||f||||t||||||||||2018-05-31 21:28:10.20366|2018-05-31 21:28:10.20366
NCT01575860|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-04-26|2012-04-11|2012-04-12|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2012||2012-04-30|April 2016|2016-04-30||||April 2017|Anticipated|2017-04-30||Interventional|||Maintenance Lenalidomide in Lymphoma|Maintenance Lenalidomide in Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|28|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:28:10.399559|2018-05-31 21:28:10.399559
NCT01575847|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-01-03|2012-04-10|2012-04-12|Estimate|||||||2017-01-03|2017-01-04|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Observational|||Adduct Dipstick for Diagnosis of Acetaminophen Toxicity|Adduct Dipstick for Diagnosis of Acetaminophen Toxicity|Completed|||120|Anticipated|Arkansas Children's Hospital Research Institute|||2||f||||f||||||Samples Without DNA|"~     Acetaminophen Adduct Samples~   "|||2018-05-31 21:28:10.473788|2018-05-31 21:28:10.473788
NCT01575834|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04||2016-03-07|2017-05-09|2012-04-10|2012-04-12|Estimate||||2016-03-07|2016-04-04|Estimate|2017-05-09|2017-05-10|Actual|March 15, 2012|Actual|2012-03-15|April 2017|2017-04-30|December 28, 2016|Actual|2016-12-28|December 14, 2015|Actual|2015-12-14||Interventional|FRAME||Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis|A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis|Completed||Phase 3|7180|Actual|Amgen||2|||f||||t||||||||||2018-05-31 21:28:10.589028|2018-05-31 21:28:10.589028
NCT01575821|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2012-04-11|2012-04-11|2012-04-12|Estimate|||||||2012-04-11|2012-04-12|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Effect of Honey on Nocturnal Cough and Sleep Quality|The Effect of Honey on Nocturnal Cough and Sleep Quality: a Double-blind, Randomized,Placebo-controlled Study|Completed||N/A|300|Actual|Meir Medical Center||4|||f||||f||||||||||2018-05-31 21:28:12.018723|2018-05-31 21:28:12.018723
NCT01575808|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|2017-04-07||2017-07-26|2012-04-10|2012-04-11|Estimate|2017-07-26|2018-02-08|Actual||||2017-07-26|2018-02-08|Actual|April 2012||2012-04-30|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2014|Actual|2014-08-31||Interventional|VJH11-01||Multi-center Study for Stent Graft System for Peripheral Artery|The Utility of GP1101 Relative to Surgical Bypass in the Treatment of Femoral / Popliteal Arterial Symptomatic Peripheral Arterial Disease|Active, not recruiting||N/A|133|Actual|W.L.Gore & Associates||2|||f||||t||||||||No||2018-05-31 21:28:12.191301|2018-05-31 21:28:12.191301
NCT01575795|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2013-04-09|2012-04-10|2012-04-11|Estimate|||||||2013-04-09|2013-04-10|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI): a Multi-center Randomized Parallel Pharmacodynamic Study.|Completed||Phase 4|83|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 21:28:13.447093|2018-05-31 21:28:13.447093
NCT01575782|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-07-13|2012-04-10|2012-04-11|Estimate|||||||2017-07-13|2017-07-18|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|Chloroquine||Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer|Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer (SCLC) Patients: a Phase I Trial.|Terminated||Phase 1|5|Actual|Maastricht Radiation Oncology||1||Poor accrual|f||||f||||||||||2018-05-31 21:28:13.629811|2018-05-31 21:28:13.629811
NCT01575769|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2015-08-17||2017-08-02|2012-04-10|2012-04-11|Estimate|2015-12-03|2016-01-07|Estimate||||2017-08-02|2018-02-09|Actual|January 19, 2012|Actual|2012-01-19|August 2017|2017-08-31|December 3, 2013|Actual|2013-12-03|December 3, 2013|Actual|2013-12-03||Interventional||Safety Population included all participants who entered the study, took at least one dose of study drug, and with at least one safety follow-up, regardless of premature withdrawal.|An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis|Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From Poland and Russia Who Completed the Global, Multinational Trial (WA19977).|Terminated||Phase 3|41|Actual|Hoffmann-La Roche|The study was terminated prior to the planned final on-treatment efficacy assessments due to commercial availability of tocilizumab in Russia and Poland.|1||"The study was terminated prior to the planned final on-treatment efficacy assessments due to~   commercial availability of tocilizumab in Russia and Poland."|f||||||||||||||2018-05-31 21:28:13.772849|2018-05-31 21:28:13.772849
NCT01575756|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|2016-10-05||2018-03-06|2012-04-10|2012-04-11|Estimate|2016-10-05|2016-11-30|Estimate||||2018-03-06|2018-03-09|Actual|June 2013||2013-06-30|March 2018|2018-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Full analysis set: All randomised participants who received at least 1 infusion of study medication (Octafibrin/FIBRYGA® and/or any part of an infusion of Haemocomplettan® P/RiaSTAP(TM)) and for whom any post-treatment data were available.|Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap|A Prospective, Controlled, Randomised, Crossover Study Investigating the Pharmacokinetic Properties, Surrogate Efficacy and Safety of Octafibrin Compared to Haemocomplettan® P/RiaSTAPTM in Patients With Congenital Fibrinogen Deficiency|Completed||Phase 2|22|Actual|Octapharma||2|||f||||f||||||||||2018-05-31 21:28:14.543057|2018-05-31 21:28:14.543057
NCT01575743|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Effects of Aerobic Exercise on Occupational Burnout|Effects of Aerobic Exercise on Occupational Burnout|Completed||N/A|24|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:28:14.996941|2018-05-31 21:28:14.996941
NCT01575730|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2014-12-04|2012-04-10|2012-04-11|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Cytoreduction Followed by Normothermic Versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion (HIPEC): a Study in Peritoneal Carcinomatosis|Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer|Unknown status|Recruiting|Phase 2|24|Anticipated|University Hospital, Ghent||3|||f||||t||||||||||2018-05-31 21:28:15.056588|2018-05-31 21:28:15.056588
NCT01575717|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-10-22|2012-04-09|2012-04-11|Estimate|||||||2012-10-22|2012-10-24|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List|The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List|Unknown status|Recruiting|N/A|50|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-05-31 21:28:15.135748|2018-05-31 21:28:15.135748
NCT01575704|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-03-31|2012-04-10|2012-04-11|Estimate|||||||2015-03-31|2015-04-01|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|BISON||Physical Exercise Therapy in Pediatric Stem Cell Transplantation|Physical Exercise Therapy in Pediatric Stem Cell Transplantation (BISON- Bewegungstherapie in Der Pädiatrischen Stammzelltransplantation)|Completed||N/A|68|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 21:28:15.224547|2018-05-31 21:28:15.224547
NCT01575691|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|July 2005||2005-07-31|April 2012|2012-04-30|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Phase I 5-Azacytidine Plus VPA Plus ATRA|Phase I Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia|Completed||Phase 1|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:28:15.39094|2018-05-31 21:28:15.39094
NCT01575678|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-11-01|2012-04-10|2012-04-11|Estimate|||||||2012-11-01|2012-11-02|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||The Effect of Melatonin on Nocturnal Enuresis|The Effect of Melatonin on Nocturnal Enuresis|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:28:15.488849|2018-05-31 21:28:15.488849
NCT01575665|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2016-05-18|2012-04-10|2012-04-11|Estimate|||||||2016-05-18|2016-05-19|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|HVMASKE||Normalizing CO2 in Chronic Hyperventilation by a Novel Breathing Mask: A Pilot Study|CO2 Rebreathing by a Partial Rebreathing Mask as a Treatment of Chronic Idiopathic Hyperventilation - a Pilot Study|Completed||N/A|6|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 21:28:15.580409|2018-05-31 21:28:15.580409
NCT01575652|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effects of Aceis on Peritoneal Protein Loss and Solute Transport in pd Patients|Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients|Completed||Phase 4|43|Actual|Turkish Nephrology Association||2|||f||||f||||||||||2018-05-31 21:28:15.671393|2018-05-31 21:28:15.671393
NCT01575639|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2013-04-07|2012-04-10|2012-04-11|Estimate|||||||2013-04-07|2013-04-09|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Prednisolone in Infantile Spasms- High Dose Versus Usual Dose|Randomized Trial of High Dose (4mg/kg) Versus Usual Dose (2mg/kg) Oral Prednisolone in the Treatment of Infantile Spasms.|Completed||Phase 3|63|Actual|Lady Hardinge Medical College||2|||f||||||||||||||2018-05-31 21:28:15.756156|2018-05-31 21:28:15.756156
NCT01575626|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|May 2012||2012-05-31|April 2012|2012-04-30||||May 2013|Anticipated|2013-05-31||Interventional|||The Effect of Different Sevoflurane Concentrations on Intraocular Pressure in Patients Undergoing Ocular Surgery Under General Anesthesia||Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||4|||f||||||||||||||2018-05-31 21:28:15.844608|2018-05-31 21:28:15.844608
NCT01575613|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-11-26|2012-04-10|2012-04-11|Estimate|||||||2012-11-26|2012-11-27|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|REDHOT||Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission|Reducing the Burden of Malaria by Targeting Hotspots of Transmission and Improving Malaria Control Measures in the Highlands of Western Kenya: Simultaneous Rollout of Four Malaria Control Interventions and Evaluation by Cross-sectional Surveys|Completed||N/A|17506|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:28:15.942736|2018-05-31 21:28:15.942736
NCT01575600|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-05-08|2012-04-10|2012-04-11|Estimate|||||||2012-05-08|2012-05-10|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Intravenous Fluid Therapy on Postoperative Vomiting in Children Undergoing Otorhinolaryngological Surgery|Effect of Intravenous Fluid Therapy on Postoperative Vomiting in Children Undergoing Otorhinolaryngological Surgery|Completed||Phase 3|100|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 21:28:16.03851|2018-05-31 21:28:16.03851
NCT01575587|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-01-09|2012-04-10|2012-04-11|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Male Subjects|Completed||Phase 1|51|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 21:28:16.113801|2018-05-31 21:28:16.113801
NCT01575574|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-08-21|2012-04-10|2012-04-11|Estimate|||||||2016-08-21|2016-08-23|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PRIGA||Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis|Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis|Completed||Phase 4|74|Actual|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 21:28:16.191027|2018-05-31 21:28:16.191027
NCT01575561|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2016-07-11||2016-07-11|2012-04-10|2012-04-11|Estimate|2016-07-11|2016-08-22|Estimate||||2016-07-11|2016-08-22|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PERSISTExt||This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296|A Multi-center, Open Label, Flexible Dose, Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects With Bipolar I Disorder|Completed||Phase 3|377|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 21:28:16.292624|2018-05-31 21:28:16.292624
NCT01575548|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2018-05-24|2012-04-10|2012-04-11|Estimate|||||||2018-05-24|2018-05-25|Actual|August 8, 2012|Actual|2012-08-08|May 2018|2018-05-31||||August 1, 2022|Anticipated|2022-08-01||Interventional|||Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery|Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy|Active, not recruiting||Phase 3|128|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:28:16.856786|2018-05-31 21:28:16.856786
NCT01575535|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2015-03-05|2012-04-10|2012-04-11|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia|S0106B, Stem Cell Origin in AML: Prognostic and Therapeutic Implications|Completed|||100|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-05-31 21:28:17.934996|2018-05-31 21:28:17.934996
NCT01575522|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2015-11-12||2016-02-23|2012-04-10|2012-04-11|Estimate|2016-02-23|2016-03-21|Estimate||||2016-02-23|2016-03-21|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer|A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:28:18.004254|2018-05-31 21:28:18.004254
NCT01575509|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-06-14|2012-04-10|2012-04-11|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects|A Clinical, Randomized, Comparative Study of Effects of Berry and Grain Products on Postprandial Glycemic Response in Healthy Subjects|Completed||N/A|14|Actual|Clinical Life Sciences Ltd.|||||f||||f||||||||||2018-05-31 21:28:18.304426|2018-05-31 21:28:18.304426
NCT01575496|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-08-01|2012-04-10|2012-04-11|Estimate|||||||2012-08-01|2012-08-03|Estimate|April 2012||2012-04-30|August 2012|2012-08-31||||January 2015|Anticipated|2015-01-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) for the Treatment of Tinnitus|Transcranial Direct Current Stimulation (tDCS) for the Treatment of Chronic Subjective Tinnitus|Unknown status|Enrolling by invitation|Phase 2|40|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||||||||||||2018-05-31 21:28:18.390582|2018-05-31 21:28:18.390582
NCT01575483|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-08-07|2012-04-10|2012-04-11|Estimate|||||||2017-08-07|2017-08-08|Actual|March 1, 2012|Actual|2012-03-01|August 2017|2017-08-31|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Observational|||Korean Post-marketing Surveillance for Onglyza®|Korean Post-marketing Surveillance for Onglyza®|Completed|||3433|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:28:18.485098|2018-05-31 21:28:18.485098
NCT01575470|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06||2016-07-07|2016-07-11|2012-04-09|2012-04-11|Estimate||||2016-07-08|2016-07-12|Estimate|2016-07-11|2016-07-13|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells|Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells|Completed||Phase 1/Phase 2|25|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 21:28:18.576363|2018-05-31 21:28:18.576363
NCT01575457|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2015-04-05|2012-04-10|2012-04-11|Estimate|||||||2015-04-05|2015-04-07|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Interventional|HF||Harriet Lane Healthy Futures Program|The Harriet Lane Clinic Healthy Futures Program is to Increase Academic or Workforce Development Success Among Adolescents and Young Adults|Completed||N/A|202|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:28:18.671141|2018-05-31 21:28:18.671141
NCT01575444|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-12-08|2012-04-10|2012-04-11|Estimate|||||||2017-12-08|2017-12-12|Actual|June 2012||2012-06-30|December 2017|2017-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Cervical Cancer Screening Project Part C|Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative|Terminated|||10|Actual|University of Minnesota - Clinical and Translational Science Institute|||2|Investigator left University No results are possible|f||||f||||||Samples With DNA|"~     Home based or clinic based HPV test (Pap) collection~   "|||2018-05-31 21:28:18.755705|2018-05-31 21:28:18.755705
NCT01575431|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2013-03-06|2012-04-09|2012-04-11|Estimate|||||||2013-03-06|2013-03-07|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2014|Anticipated|2014-12-31||Observational|PROCREATION||Progenitor Cells Role in Restenosis and Atherosclerosis|PROgenitor Cells Role in Restenosis and Progression of Coronary ATherosclerosis After Percutaneous Coronary Intervention (PROCREATION) Study|Unknown status|Recruiting||200|Anticipated|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 21:28:18.834498|2018-05-31 21:28:18.834498
NCT01575418|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-05-06|2012-04-09|2012-04-11|Estimate|||||||2014-05-06|2014-05-08|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations|An Exploratory, Double-Blinded, Randomized, Pharmacokinetic and Safety Study of Three Rectally-Applied Tenofovir 1% Microbicide Gel Formulations|Completed||Phase 1|9|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:28:18.923421|2018-05-31 21:28:18.923421
NCT01575405|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2013-11-06|2012-04-09|2012-04-11|Estimate|||||||2013-11-06|2013-11-07|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally|A Randomized, Double Blind Phase 1 Safety, Acceptability, and Pharmacokinetic Study Comparing Three Formulations of Tenofovir 1% Gel Administered Rectally to HIV-1 Seronegative Adults|Completed||Phase 1|13|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:28:19.002242|2018-05-31 21:28:19.002242
NCT01575392|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Quality Assessment Creatinines in Plasma and Urine|Quality Assessment of Creatinines in Plasma and Urine|Completed|||181|Actual|Medical Research Foundation, The Netherlands|||1||f||||f||||||Samples Without DNA|"~     All patients presenting at the laboratory facility for a 24-hour creatinine clearance and~     patients in the dialysis population of the Isala Clinics who came for their periodical KT/V~     control, were informed about the study and asked to participate. From the 24-hour urine (and~     for peritoneal dialysis population also from the 24-hour peritoneal dialysate fluid) 4~     samples of 4 ml were collected. Moreover, extra blood samples (16 ml in total) were drawn on~     top of the samples that were necessary for the (routine) 24-hour creatinine clearance.~   "|||2018-05-31 21:28:19.07893|2018-05-31 21:28:19.07893
NCT01575366|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-08-16|2012-04-09|2012-04-11|Estimate|||||||2013-08-16|2013-08-19|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Movement Velocity Effect on Cortical Reorganization and Finger Function in Stroke|Movement Velocity Effect on Cortical Reorganization and Finger Function in Stroke|Completed||Phase 1|5|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 21:28:19.134503|2018-05-31 21:28:19.134503
NCT01575353|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2014-02-27|2012-04-10|2012-04-11|Estimate|||||||2014-02-27|2014-02-28|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|||Nasal High-flow Versus Venturi Mask Oxygen Therapy in the Post-extubation Period|Nasal High-flow Oxygen Therapy vs Standard Oxygen Therapy Via Venturi Mask in the Post-extubation Period|Completed||N/A|105|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 21:28:19.195338|2018-05-31 21:28:19.195338
NCT01575340|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2012-09-05|2012-04-10|2012-04-11|Estimate|||||||2012-09-05|2012-09-06|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Study to Assess the Effect of Consumption of Fish Oil Encapsulated on Inflammatory Markers in Colorectal Cancer|Markers of the Inflammatory Response (IL-1β, IL-10, IL-17A and TNF-α) in Patients With Colorectal Cancer in Chemotherapy Supplemented With Fish Oil|Completed||N/A|11|Actual|Universidade Federal de Santa Catarina||2|||f||||f||||||||||2018-05-31 21:28:19.260456|2018-05-31 21:28:19.260456
NCT01575327|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2018-03-13|2012-04-10|2012-04-11|Estimate|||||||2018-03-13|2018-03-14|Actual|July 2012||2012-07-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|FreeO2-rehab||Closed-loop System for Oxygen Delivery and Exercise in Chronic Obstructive Pulmonary Disease|Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Exercise Tolerance During Walk in Patients With COPD, Oxygen Therapy and Hypercapnia|Completed||N/A|15|Actual|AGIR à Dom||2|||f||||t||||||||||2018-05-31 21:28:19.325764|2018-05-31 21:28:19.325764
NCT01575314|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2016-02-01|2012-04-10|2012-04-11|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Interventional|||Cost-consequence Analysis of Parenchymal Stapling Device Versus Hand-sewing for Pulmonary Lobectomy in Lung Disease|Cost-consequence Analysis of Parenchymal Stapling Device Versus Hand-sewing for Pulmonary Lobectomy in Lung Disease: A Randomized Controlled Trial|Completed||N/A|53|Actual|Chiang Mai University||2|||f||||t||||||||No||2018-05-31 21:28:19.393665|2018-05-31 21:28:19.393665
NCT01575301|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2018-04-09|2012-04-09|2012-04-11|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2011||2011-03-31|April 2018|2018-04-30|December 11, 2015|Actual|2015-12-11|July 2015|Actual|2015-07-31||Interventional|DIRECTGLP||DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists|DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists|Completed||N/A|411|Actual|University of Dundee|||||f||||f||||||||||2018-05-31 21:28:19.611393|2018-05-31 21:28:19.611393
NCT01575288|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2015-12-09|2012-04-09|2012-04-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults|Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults|Completed||N/A|110|Actual|University of Colorado, Boulder||2|||f||||t||||||||||2018-05-31 21:28:19.687659|2018-05-31 21:28:19.687659
NCT01575275|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2014-08-26|2012-04-09|2012-04-11|Estimate|||||||2014-08-26|2014-08-28|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme|A Phase 2 Comparative Study of 5-Aminolevulinic Acid (5-ALA) and Intraoperative MRI (iMRI) to Enhance Completeness of Resection of Glioblastoma|Terminated||Phase 2|8|Actual|Case Comprehensive Cancer Center||1||Drugs unavailable|f||||t||||||||||2018-05-31 21:28:19.761208|2018-05-31 21:28:19.761208
NCT01575262|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|PAL||The Physical Activity Loyalty Card Scheme|The Physical Activity Loyalty Card Scheme: A Randomised Controlled Trial to Encourage Physical Activity|Completed||Phase 2/Phase 3|406|Actual|Queen's University, Belfast||2|||f||||t||||||||||2018-05-31 21:28:19.851467|2018-05-31 21:28:19.851467
NCT01575249|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|July 2012||2012-07-31|April 2012|2012-04-30|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Observational|ENIGMAS||Identification of Parameters in rapId-proGression Subgroup Patients With Moderate Aortic Stenosis|Prospective Study Focused on idEntification of cliNical, Biological and Imagistic Parameters in rapId-proGression Subgroup Patients With Moderate Aortic Stenosis|Unknown status|Not yet recruiting||200|Anticipated|Carol Davila University of Medicine and Pharmacy|||2||f||||t||||||Samples Without DNA|"~     standard blood count, c-reactive protein, urea, creatinin, hepatic standard biology, serum~     calcium, cholesterol and tryglicerides.~   "|||2018-05-31 21:28:19.918973|2018-05-31 21:28:19.918973
NCT01575236|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-08-06|2012-04-09|2012-04-11|Estimate|||||||2012-08-06|2012-08-08|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||A Randomized Non Crossover Study of the GuardianTM Versus SupremeTM Laryngeal Mask Airway|A Randomized Non Crossover Study of the GuardianTM Versus SupremeTM Laryngeal Mask Airway|Completed||Phase 3|120|Actual|Schulthess Klinik||2|||f||||t||||||||||2018-05-31 21:28:19.987055|2018-05-31 21:28:19.987055
NCT01575223|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2014-04-22|2012-04-09|2012-04-11|Estimate|||||||2014-04-22|2014-04-23|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|HVSI||Saline Irrigation After Surgery in Patients With Chronic Sinusitis|The HVSI STUDY: High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial|Completed||Phase 4|86|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 21:28:20.053999|2018-05-31 21:28:20.053999
NCT01575210|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2013-11-25|2012-04-09|2012-04-11|Estimate|||||||2013-11-25|2013-11-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:28:20.194271|2018-05-31 21:28:20.194271
NCT01575197|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2015-04-28||2015-05-13|2012-04-09|2012-04-11|Estimate|2015-05-13|2015-06-01|Estimate||||2015-05-13|2015-06-01|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All enrolled subjects who received at least one rotavirus vaccine dose and are IgA seronegative (< 20 U/mL) at 6 (Groups 1 and 3) or 10 (Group 2) weeks of age at baseline.|Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana|Immunogenicity of the Human Rotavirus Vaccine (Rotarix™) at Varying Schedules, Doses, and Ages in Rural Ghana|Completed||Phase 4|456|Actual|PATH||3|||f||||||||||||||2018-05-31 21:28:20.24893|2018-05-31 21:28:20.24893
NCT01575184|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-12|2012-04-10|2012-04-11|Estimate|||||||2012-04-12|2012-04-13|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Effect of Shoulder Traction on Size and Relative Position of Internal Jugular Vein to Carotid Artery|Effect of Shoulder Position and Head Rotation on Size and Relative Position of Internal Jugular Vein to Carotid Artery in Infants and Children|Unknown status|Recruiting|N/A|25|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:28:20.594189|2018-05-31 21:28:20.594189
NCT01575171|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-07-31|2012-04-10|2012-04-11|Estimate|||||||2015-07-31|2015-08-03|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Using Nudges to Implement Comparative Effectiveness|Using Nudges to Implement Comparative Effectiveness: Behavioral Economics and Statins|Completed|||19|Actual|New York University School of Medicine|||1||f||||t||||||||||2018-05-31 21:28:20.686953|2018-05-31 21:28:20.686953
NCT01575158|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|October 1997||1997-10-31|April 2012|2012-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Citalopram vs Clomipramine vs Placebo in Recurrent Depression||Completed||N/A|59|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 21:28:20.757335|2018-05-31 21:28:20.757335
NCT01575145|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2016-01-08|2012-04-09|2012-04-11|Estimate|||||||2016-01-08|2016-01-11|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Helping Hospitalized Patients Quit Smoking|Helping Hospitalized Patients Quit Smoking|Completed||Phase 4|600|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:28:20.828702|2018-05-31 21:28:20.828702
NCT01575132|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2013-12-10|2012-04-10|2012-04-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|September 2015|Anticipated|2015-09-30|April 2014|Anticipated|2014-04-30||Observational|||Deep Brain Stimulation Follow-up After 10 Years|STN-DBS Retrospective/Prospective Study With a Follow-up Time of Minimum 10 Years|Unknown status|Enrolling by invitation||15|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 21:28:20.902435|2018-05-31 21:28:20.902435
NCT01575106|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2017-01-06||2017-09-12|2012-04-09|2012-04-11|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|June 2012||2012-06-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Neurobiology of Expectancy and Pain Perception|A Brain Imaging Study of the Analgesic Effect of Lidocaine and the Hyperalgesic Effect of Capsaicin|Completed||N/A|38|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 21:28:21.051377|2018-05-31 21:28:21.051377
NCT01575093|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2012-07-04|2012-04-10|2012-04-11|Estimate|||||||2012-07-04|2012-07-06|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety Evaluation of Bowel Cleansing Regimen for PillCam® COLON 2 Capsule Endoscopy||Completed||Phase 1/Phase 2|25|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-05-31 21:28:21.200606|2018-05-31 21:28:21.200606
NCT01575080|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|2013-04-26||2016-01-29|2012-04-10|2012-04-11|Estimate|2013-04-26|2013-07-08|Estimate||||2016-01-29|2016-02-29|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Performance Evaluation of Blood Glucose Monitoring System Using ISO Study Design|Performance Evaluation of the Contour TS BGMS Using ISO/DIS 15197:2011 Section 8 Study Design and Performance Criteria|Completed||N/A|102|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 21:28:21.266638|2018-05-31 21:28:21.266638
NCT01575067|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-04-10|2012-04-10|2012-04-11|Estimate|||||||2012-04-10|2012-04-11|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Blood Pressure Monitor Clinical Test (Cuff Range: 22 Cm-42cm)||Completed|||85|Actual|Andon Health Co., Ltd|||2||f||||f||||||||||2018-05-31 21:28:21.44107|2018-05-31 21:28:21.44107
NCT01575054|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|2015-10-01||2016-08-22|2012-04-09|2012-04-11|Estimate|2015-12-29|2016-02-01|Estimate||||2016-08-22|2016-09-28|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|September 2014|Actual|2014-09-30||Interventional|||BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity||Completed||Phase 3|468|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:28:21.49372|2018-05-31 21:28:21.49372
NCT01575041|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-08-09|2012-04-09|2012-04-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|KaNa||The Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function|Study on the Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function in Untreated (Pre)Hypertensive Subjects|Completed||N/A|40|Actual|Wageningen University||3|||f||||f||||||||||2018-05-31 21:28:21.829245|2018-05-31 21:28:21.829245
NCT01575028|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2015-05-14||2015-07-29|2012-04-09|2012-04-10|Estimate|2015-05-14|2015-06-01|Estimate||||2015-07-29|2015-08-24|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Transversus Abdominis Plane (TAP) Versus Local Anesthetic for Lap Appendectomies|A Prospective, Double Blinded, Randomized Comparison of Transversus Abdominis Plane Block Versus Local Anesthetic Infiltration for Laparoscopic Appendectomy in the Pediatric Population|Terminated||Phase 2|3|Actual|Nationwide Children's Hospital||2||"The study was allowed to expire due to changes in standard care for the patient population~   within the NCH institution."|f||||t||||||||||2018-05-31 21:28:21.995972|2018-05-31 21:28:21.995972
NCT01575015|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2017-02-04|2012-04-09|2012-04-10|Estimate|||||||2017-02-04|2017-02-07|Estimate|May 2012||2012-05-31|February 2017|2017-02-28|December 11, 2015|Actual|2015-12-11|December 11, 2015|Actual|2015-12-11||Interventional|INCEPTION||Intraoperative Dialysis in Liver Transplantation|Intra-Operative Continuous Renal Replacement Therapy in Liver Transplantation: A Phase II Randomized Controlled Trial (INCEPTION)|Terminated||N/A|32|Actual|University of Alberta||2||Insufficient funding.|f||||f||||||||||2018-05-31 21:28:23.491122|2018-05-31 21:28:23.491122
NCT01575002|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-03-17|2012-04-09|2012-04-10|Estimate|||||||2017-03-17|2017-03-21|Actual|January 2012||2012-01-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) in Chronic Corneal Pain|Neural Correlates of Pain-related Cognitive Processing in Chronic Pain of the Cornea: an ERP and Electrical Stimulation Study.|Completed||N/A|26|Actual|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 21:28:23.792751|2018-05-31 21:28:23.792751
NCT01574989|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-04-24|2012-04-09|2012-04-10|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2011||2011-05-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of rTMS and tDCS on Motor Function in Stroke|Effects of Repetitive Transcranial Magnetic Stimulation and Transcranial DC Stimulation on Motor Function in Stroke Patients|Completed||N/A|14|Actual|Spaulding Rehabilitation Hospital||5|||f||||f|f|f||||||||2018-05-31 21:28:24.070412|2018-05-31 21:28:24.070412
NCT01574976|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2015-11-16|2012-04-09|2012-04-10|Estimate|||||||2015-11-16|2015-11-17|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Effect of Feedback and Practice on Probabilistic Decision Making in Attention Deficit and Hyperactivity Disorder|Effect of Feedback and Practice on Probabilistic Decision Making in Attention Deficit and Hyperactivity Disorder|Completed||N/A|80|Actual|Shaare Zedek Medical Center||4|||f||||f||||||||||2018-05-31 21:28:24.159096|2018-05-31 21:28:24.159096
NCT01574963|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-09|2012-04-09|2012-04-10|Estimate|||||||2012-04-09|2012-04-10|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Observational|||Graz Osteoprotegerin as a Risk Factor (GORF) Study|Graz Osteoprotegerin as a Risk Factor (GORF) Study: THE ROLE of OSTEOPROTEGERIN (OPG) and the RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-Kb LIGAND (RANKL) IN PATIENTS REQUIRING SURGERY FOR CORONARY HEART DISEASE|Unknown status|Recruiting||150|Anticipated|Medical University of Graz|||2||f||||t||||||||||2018-05-31 21:28:24.230181|2018-05-31 21:28:24.230181
NCT01574950|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-10-23|2012-04-09|2012-04-10|Estimate|||||||2015-10-23|2015-10-26|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Impact of Impaired Cerebral Autoregulation on Postoperative Delirium in Elderly Patients Undergoing Spine Surgery|The Impact of Impaired Cerebral Autoregulation on the Development of Postoperative Delirium in Elderly Patients Undergoing Spine Surgery|Completed|||99|Actual|Johns Hopkins University|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 21:28:24.298808|2018-05-31 21:28:24.298808
NCT01574937|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2018-02-06|2012-04-08|2012-04-10|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2012||2012-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|||XL-184+Abiraterone in Post-Chemo CRPC|A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer|Active, not recruiting||Phase 1|27|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||Undecided||2018-05-31 21:28:24.424363|2018-05-31 21:28:24.424363
NCT01574924|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-04-12|2012-04-07|2012-04-10|Estimate|||||||2012-04-12|2012-04-16|Estimate|April 2012||2012-04-30|April 2012|2012-04-30||||October 2018|Anticipated|2018-10-31||Observational|||Personality Change During Medical Residency|Personality Change During Medical Residency Across Different Medical Specialties|Not yet recruiting|||600|Anticipated|University of Coimbra|||1||f||||t||||||||||2018-05-31 21:28:24.520882|2018-05-31 21:28:24.520882
NCT01574911|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2012-04-19|2012-04-09|2012-04-10|Estimate|||||||2012-04-19|2012-04-20|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|||Validation of a New Method of Limb Volumetry|Development and Validation of a Limb Volumetry Technique Applicable in Daily Clinical Practice Using Self Positioning 3D Laser Scanning:Reproductibility and Comparison to the Reference Method|Unknown status|Recruiting||90|Anticipated|University Hospital, Montpellier|||3||f||||t||||||None Retained|"~     Validation study an innovative non-invasive diagnostic technique. Biomedical research~     conducted with the help of Montpellier University Hospital Clinical Investigation Center~     (CIC) for the recruitment of healthy controls, and vascular Medicine clinics for the~     recruitment of patients with chronic venous insufficiency or lymphedema~   "|||2018-05-31 21:28:24.620522|2018-05-31 21:28:24.620522
NCT01574898|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-07-06|2012-04-05|2012-04-10|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations|Pilot Pharmacokinetic Study of Three New Nicotine Lozenge Formulations (V0474) Versus Two Reference Formulations (V0018 B mg and Niquitin® Fresh Mint, 4mg) After Single Oral Administration in Healthy Male Smokers.|Completed||Phase 1|13|Actual|Pierre Fabre Medicament||5|||f||||||||||||||2018-05-31 21:28:24.940055|2018-05-31 21:28:24.940055
NCT01574885|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-11-07|2012-04-07|2012-04-10|Estimate|||||||2012-11-07|2012-11-08|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Interventional|||Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases|Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases|Terminated||Phase 2|45|Actual|Tecno Sun SRL||2|||f||||t||||||||||2018-05-31 21:28:25.197263|2018-05-31 21:28:25.197263
NCT01574872|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2014-11-17|2012-04-07|2012-04-10|Estimate|||||||2014-11-17|2014-11-18|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Interventional|||Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis|Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis|Withdrawn||Phase 2|0|Actual|Tecno Sun SRL||2||Changes in the sponsorship, design and locations of the study|f||||t||||||||||2018-05-31 21:28:25.318225|2018-05-31 21:28:25.318225
NCT01574859|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2013-03-30|2012-04-09|2012-04-10|Estimate|||||||2013-03-30|2013-04-02|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Observational|||Central Hypothyroidism and Cardiovascular Risk|Central Hypothyroidism and Cardiovascular Risk Factors|Completed|||200|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 21:28:25.4088|2018-05-31 21:28:25.4088
NCT01574846|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2014-10-15|2012-04-05|2012-04-10|Estimate|||||||2014-10-15|2014-10-16|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|Vantas||Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer|Prospective, Multicentre, Non-interventional (Observational) Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer.|Completed|||142|Actual|Orion Corporation, Orion Pharma|||1||f||||f||||||||||2018-05-31 21:28:25.495028|2018-05-31 21:28:25.495028
NCT01574833|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2012-04-09|2012-04-09|2012-04-10|Estimate|||||||2012-04-09|2012-04-10|Estimate|March 2007||2007-03-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Early Application of Pulsed Electromagnetic Field in the Treatment of Postoperative Delayed Union|Phase 4 Study of Early Applied Pulsed Electromagnetic Field in the Treatment of Postoperative Delayed Union of Long-bone Fractures|Completed||Phase 4|92|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||||2018-05-31 21:28:25.565191|2018-05-31 21:28:25.565191
NCT01574820|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-10|2012-04-07|2012-04-10|Estimate|||||||2012-04-10|2012-04-11|Estimate|November 2006||2006-11-30|April 2012|2012-04-30|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|||Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease|Role of Rosiglitazone Treatment and Secondary Prevention of Cardiovascular Events in Patients With Pre-Diabetes Mellitus and Coronary Artery Disease|Completed||Phase 3|105|Actual|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 21:28:25.639488|2018-05-31 21:28:25.639488
NCT01574807|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-07-09|2012-04-09|2012-04-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Lower Jaw Dental Injections|A Prospective, Randomized, Double-blind Study of the Anesthetic Efficacy of 3% Mepivacaine Plus 2% Lidocaine With 1:100,000 Epinephrine for Inferior Alveolar Nerve Blocks.|Completed||Phase 4|100|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 21:28:25.715508|2018-05-31 21:28:25.715508
NCT01574794|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2014-12-01|2012-04-09|2012-04-10|Estimate|||||||2014-12-01|2014-12-03|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||Exercise Intervention and Running Biomechanics in Older Adults|Changes in Running Gait Biomechanics Following an Intervention Program in Older Runners|Completed||N/A|105|Actual|University of Calgary||3|||f||||f||||||||||2018-05-31 21:28:25.797618|2018-05-31 21:28:25.797618
NCT01574781|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-06-28|2012-04-09|2012-04-10|Estimate|||||||2013-06-28|2013-07-02|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|NIPD||Non-invasive Prenatal Diagnostic Validation Study|Development of Non-invasive Prenatal Diagnostic Test Based on Fetal DNA Isolated From Maternal Blood|Completed|||1781|Actual|Natera, Inc.|||6||f||||f||||||Samples With DNA|"~     Maternal blood, paternal blood or cheek swab, paternal relative blood or cheek swab, fetal~     blood or tissue, POC tissue, and child cord blood or saliva.~   "|||2018-05-31 21:28:25.863526|2018-05-31 21:28:25.863526
NCT01574768|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2012-04-07|2012-04-07|2012-04-10|Estimate|||||||2012-04-07|2012-04-10|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|||LATERAL PHARYNGOPLASTY OUTCOMES IN THE TREATMENT OF SNORE AND OBSTRUCTIVE SLEEP APNEA|LATERAL PHARYNGOPLASTY OUTCOMES IN THE TREATMENT OF SNORE AND OBSTRUCTIVE SLEEP APNEA|Unknown status|Active, not recruiting|N/A|300|Anticipated|Hospital do Servidor Publico Estadual|||||f||||f||||||||||2018-05-31 21:28:25.947357|2018-05-31 21:28:25.947357
NCT01574755|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2013-06-29|2012-04-09|2012-04-10|Estimate|||||||2013-06-29|2013-07-02|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|ACHAT FU||Long Term Outcome of Argon Plasma Coagulation of Cervical Heterotopic Gastric Mucosa as an Alternative Treatment for Globus Sensations|Long Term Outcome of Argon Plasma Coagulation of Cervical Heterotopic Gastric Mucosa as an Alternative Treatment for Globus Sensations|Completed|||49|Actual|Technische Universität München|||||f||||f||||||Samples Without DNA|"~     biopsy of gastric inlet patches~   "|||2018-05-31 21:28:26.000219|2018-05-31 21:28:26.000219
NCT01574742|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-07-03|2012-04-09|2012-04-10|Estimate|||||||2012-07-03|2012-07-04|Estimate|June 2012||2012-06-30|April 2012|2012-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression|A Single Center, Open Label Study Assessing the Feasibility, Safety and Therapeutic Effect of Minocycline in Adult Patients With Diagnosis of Unipolar Depression.|Unknown status|Recruiting|Phase 1|30|Anticipated|Shalvata Mental Health Center||1|||f||||t||||||||||2018-05-31 21:28:26.048384|2018-05-31 21:28:26.048384
NCT01574729|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2012-06-27|2012-04-06|2012-04-10|Estimate|||||||2012-06-27|2012-06-28|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|rAd-p53||Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma|Phase II Study of Surgery Combined With Recombinant Adenoviral Human p53 Gene Therapy in Treatment Advanced Non-small-cell Carcinoma|Unknown status|Not yet recruiting|Phase 2|120|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||2|||f||||f||||||||||2018-05-31 21:28:26.133123|2018-05-31 21:28:26.133123
NCT01574716|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04||2016-11-04|2016-11-29|2012-04-09|2012-04-10|Estimate||||2016-11-29|2016-11-30|Estimate|2016-11-29|2016-11-30|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Interventional|SOURCE||Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE)|A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma|Completed||Phase 2|209|Actual|Morphotek||2|||f||||||||||||||2018-05-31 21:28:26.205276|2018-05-31 21:28:26.205276
NCT01574703|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2016-07-07||2016-10-31|2012-04-09|2012-04-10|Estimate|2016-10-31|2016-12-29|Estimate||||2016-10-31|2016-12-29|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CATS|The term Baseline visit refers to the Baseline (Week 0) visit of the parent study NCT01456936. The safety population included all participants who received at least one dose of study drug in NCT01456936 parent study. The below Baseline characteristics (age, gender) are presented for all participants who entered study NCT01574703.|Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.|A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders|Completed||Phase 4|4595|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 21:28:26.492376|2018-05-31 21:28:26.492376
NCT01574690|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-02-07|2012-04-09|2012-04-10|Estimate|||||||2013-02-07|2013-02-08|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Correlation of Physical Exam Versus Non-invasive Assessment Versus Invasive Assessment of Central Venous Pressure|Correlation of Physical Exam Versus Non-invasive Near-infrared Spectroscopy Versus Invasive Hemodynamic Assessment of Central Venous Pressure|Completed|||50|Actual|Mespere Lifesciences Inc.|||1||f||||f||||||||||2018-05-31 21:28:28.885746|2018-05-31 21:28:28.885746
NCT01574677|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2014-08-01|2012-04-06|2012-04-10|Estimate|||||||2014-08-01|2014-08-04|Estimate|June 2012||2012-06-30|August 2014|2014-08-31||||||||Observational|||Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test|Assessment of Septin9 Biomarker for Detection of Colorectal Cancer in Patients With Positive Fecal Immunochemical Test|Withdrawn|||0|Actual|Epigenomics, Inc|||1||f||||t||||||||||2018-05-31 21:28:28.972936|2018-05-31 21:28:28.972936
NCT01574664|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-12-10|2012-04-07|2012-04-10|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Observational|||Evaluation of RFID Localization System for Marking and Retrieving Breast Lesions|A Prospective, Single-Arm, Multicenter Clinical Study to Evaluate the Safety and Performance of the Health Beacons Radiofrequency Identification (RFID) Localization System for Marking and Retrieving Non-Palpable Breast Lesions|Unknown status|Active, not recruiting||60|Anticipated|Health Beacons|||1||f||||f||||||||||2018-05-31 21:28:29.039674|2018-05-31 21:28:29.039674
NCT01574651|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2014-03-27||2014-05-19|2012-04-06|2012-04-10|Estimate|2014-03-27|2014-04-29|Estimate||||2014-05-19|2014-05-22|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|QUANTIFY||The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment, Multicenter, Randomized, Parallel Group, Blinded Study to Assess the Efficacy and Safety of QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Using Tiotropium Plus Formoterol as Control|Completed||Phase 3|934|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:28:29.170399|2018-05-31 21:28:29.170399
NCT01574638|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2015-10-13|2012-04-06|2012-04-10|Estimate|||||||2015-10-13|2015-10-14|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults|Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers|Completed||Phase 1|44|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 21:28:29.992864|2018-05-31 21:28:29.992864
NCT01574625|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2018-04-24|2012-04-06|2012-04-10|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2001||2001-04-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|February 2018|Actual|2018-02-28||Observational|||Post-Approval Study for the MOSAIC® Bioprostheses|Post-Approval Study for the MOSAIC® Bioprostheses: A Long Term Follow Up Study.|Active, not recruiting|||178|Actual|Medtronic Cardiovascular|||1||f||||f||||||||||2018-05-31 21:28:30.100284|2018-05-31 21:28:30.100284
NCT01574612|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2014-02-25||2014-04-28|2012-04-05|2012-04-10|Estimate|2014-04-28|2014-05-22|Estimate||||2014-04-28|2014-05-22|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old|An Open Label Multi Center Phase III Subject/Caregiver Initiated Safety Study of Xerese(Acyclovir and Hydrocortisone)Cream 5%/1% in the Treatment of Recurrent Herpes Labialis in Children|Completed||Phase 3|54|Actual|Meda Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:28:30.174983|2018-05-31 21:28:30.174983
NCT01574599|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2017-03-21|2012-04-09|2012-04-10|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2012||2012-04-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Use of Repetitive Facilitative Exercise Program in Established Stroke|A Randomized Controlled Evaluation of a Repetitive Facilitative Exercise Program for Adults With an Established Stroke and Upper Extremity Impairment|Terminated||N/A|15|Actual|Mayo Clinic||2||poor subject recruitment|f||||f||||||||||2018-05-31 21:28:30.452782|2018-05-31 21:28:30.452782
NCT01574586|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2015-04-06|2012-04-06|2012-04-10|Estimate|||||||2015-04-06|2015-04-07|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|May 2014|Actual|2014-05-31||Interventional|BEGIN||Bifurcation Stenting Using 2 Link Stent Nobori Versus 3 Link Stent Xience|A Multicenter, Randomized Trial to Compare 2 Link Nobori and 3 Link Xience Stents in Bifurcation Stenting|Unknown status|Active, not recruiting|N/A|240|Anticipated|Kurashiki Central Hospital||2|||f||||||||||||||2018-05-31 21:28:30.542089|2018-05-31 21:28:30.542089
NCT01574573|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2018-01-16|2012-04-09|2012-04-10|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2009||2009-06-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study|Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study|Terminated||N/A|52|Actual|Midwest Biomedical Research Foundation||2||Closed due to lack of recruitment|f||||f||||||||||2018-05-31 21:28:30.626637|2018-05-31 21:28:30.626637
NCT01574560|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-08-05|2012-04-05|2012-04-10|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||P60 Program Project Grant-Outreach for Smoke-Free Homes|Community Outreach and Biomarker Feedback for Smoke-Free Homes|Completed||N/A|212|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 21:28:30.723484|2018-05-31 21:28:30.723484
NCT01574547|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2012-04-09|2012-04-09|2012-04-10|Estimate|||||||2012-04-09|2012-04-10|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|CSC||Risk Factors of Cat Scratch Colon Developing.|Risk Factors of Cat Scratch Colon Developing.|Completed|||10715|Actual|University Hospital of the Nuestra Señora de Candelaria|||2||f||||t||||||||||2018-05-31 21:28:30.80521|2018-05-31 21:28:30.80521
NCT01574534|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2018-01-25|2012-04-09|2012-04-10|Estimate|||||||2018-01-25|2018-01-26|Actual|April 2012||2012-04-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|BASKET-SMALL2||Basel Stent Kosten Effektivitäts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions|A Prospective, Randomized, Controlled, Open Label, Multicenter Trial to Test the Non-inferiority of Drug Eluting Balloon vs. Drug Eluting Stent Treatment in de Novo Stenoses of Small Native Vessels Regarding Efficacy and Safety|Recruiting||N/A|758|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:28:30.87398|2018-05-31 21:28:30.87398
NCT01574521|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2012-04-09|2012-04-09|2012-04-10|Estimate|||||||2012-04-09|2012-04-10|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|||Seroepidemiologic Study of Spermatozoal Transmission of Hepatitis B Virus (HBV)|A Fetal Seroepidemiologic Study in Hepatitis B Virus Transmitted Via Male Germ Line|Completed|||407|Actual|Taizhou Hospital|||3||f||||f||||||Samples With DNA|"~     whole blood, serum,amniotic fluid~   "|||2018-05-31 21:28:30.992113|2018-05-31 21:28:30.992113
NCT01574508|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2013-05-03|2012-04-08|2012-04-10|Estimate|||||||2013-05-03|2013-05-06|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|CAMACS||Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy||Unknown status|Recruiting|Phase 4|120|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 21:28:31.055573|2018-05-31 21:28:31.055573
NCT01574495|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-09-23|2012-04-08|2012-04-10|Estimate|||||||2015-09-23|2015-09-24|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|VREA||Evaluating Error Augmentation for Neurorehabilitation|Evaluating Error Augmentation for Neurorehabilitation|Completed||N/A|40|Actual|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 21:28:31.136946|2018-05-31 21:28:31.136946
NCT01574482|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2016-11-23|2012-04-07|2012-04-10|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Italy)|Effects of the Consumption of a Plant Sterols-enriched Dairy Fermented Product on Hypercholesterolemia Management in Hypercholesterolemic Adults|Completed||N/A|116|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 21:28:31.215633|2018-05-31 21:28:31.215633
NCT01574469|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-07|||2016-12-06|2012-04-07|2012-04-10|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2004||2004-09-30|December 2016|2016-12-31|August 2005|Actual|2005-08-31|December 2004|Actual|2004-12-31||Interventional|||Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (France)|Effect of Low-fat, Fermented Milk Enriched With Plant Sterols on Serum Lipid Profile in Moderate Hypercholesterolemia|Completed||N/A|194|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 21:28:31.283534|2018-05-31 21:28:31.283534
NCT01574456|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-12-09|2012-04-09|2012-04-10|Estimate|||||||2013-12-09|2013-12-10|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Blood-brain Barrier Permeability in Alzheimer's Disease||Completed|||39|Actual|Maastricht University Medical Center|||3||f||||||||||||||2018-05-31 21:28:31.339216|2018-05-31 21:28:31.339216
NCT01574443|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-11-02|2012-04-09|2012-04-10|Estimate|||||||2017-11-02|2017-11-06|Actual|August 22, 2011|Actual|2011-08-22|November 2017|2017-11-30|April 8, 2016|Actual|2016-04-08|May 11, 2015|Actual|2015-05-11||Observational|ECOG||Brain Dynamics in Different Stages of Arousal and Anesthesia|Brain Dynamics in Different Stages of Arousal and Anesthesia|Terminated|||5|Actual|Weill Medical College of Cornell University|||1|Feasibility issues for subject recruitment and PI left the institution|f||||f||||||||No||2018-05-31 21:28:31.40388|2018-05-31 21:28:31.40388
NCT01574430|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2016-08-15|2012-04-09|2012-04-10|Estimate|||||||2016-08-15|2016-08-16|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)|A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy|Completed||Phase 4|131|Anticipated|Peking University People's Hospital||2|||f||||f||||||||||2018-05-31 21:28:31.472312|2018-05-31 21:28:31.472312
NCT01574417|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-10-24|2012-04-05|2012-04-10|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Plant Stanols and Gene Expression Profile|The Effects of Plant Stanol Esters on Intestinal Mucosal Gene Expression Profiles and Microbiota Composition in Healthy Human Subjects|Completed||N/A|20|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:28:31.568162|2018-05-31 21:28:31.568162
NCT01574404|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-06-10|2012-04-06|2012-04-10|Estimate|||||||2015-06-10|2015-06-11|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|July 2012|Actual|2012-07-31||Interventional|Polar Body||Polar Body Biopsy for Preimplantation Genetic Screening|Polar Body Biopsy (PB) for Preimplantation Genetic Screening|Completed||N/A|33|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 21:28:31.655061|2018-05-31 21:28:31.655061
NCT01574391|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2015-04-13|2012-04-09|2012-04-10|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||A Comparison Study Of Two Different Techniques For Identifying The Epidural Space In Parturients In Labour|A COMPARISON STUDY OF TWO DIFFERENT TECHNIQUES FOR IDENTIFYING THE EPIDURAL SPACE IN PARTURIENTS IN LABOUR: A PILOT PROSPECTIVE RANDOMIZED STUDY.|Completed||N/A|300|Actual|National Maternity Hospital, Ireland||2|||f||||t||||||||||2018-05-31 21:28:31.738752|2018-05-31 21:28:31.738752
NCT01574378|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-04-08|2012-04-08|2012-04-10|Estimate|||||||2012-04-08|2012-04-10|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Effectiveness of Wound Closure Using V-Loc™ 90 Sutures in Lipoabdominoplasty Patients|Cost Effectiveness and Clinical Outcomes of Wound Closure Using V-Loc™ 90 Sutures.|Unknown status|Active, not recruiting|Phase 4|30|Actual|Grigoryants Medical Corporation||2|||f||||f||||||||||2018-05-31 21:28:31.811414|2018-05-31 21:28:31.811414
NCT01574365|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-02-28|2012-04-05|2012-04-10|Estimate|||||||2017-02-28|2017-03-03|Actual|February 2012||2012-02-29|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus|A Phase 2 Study of RTA 402 in CKD Patients With Type 2 Diabetes Mellitus|Terminated||Phase 2|53|Actual|Kyowa Hakko Kirin Co., Ltd||4|||f||||f||||||||||2018-05-31 21:28:31.873045|2018-05-31 21:28:31.873045
NCT01574352|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2014-07-02|2012-04-06|2012-04-10|Estimate|||||||2014-07-02|2014-07-03|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|July 2017|Anticipated|2017-07-31|July 2014|Actual|2014-07-31||Interventional|OOIS||The Odense Overweight Intervention Study|The Odense Overweight Intervention Study (OOIS): A Randomized Controlled Trial on Overweight Prevention in Children.|Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 21:28:31.97405|2018-05-31 21:28:31.97405
NCT01574339|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-03-17|2012-04-08|2012-04-10|Estimate|||||||2015-03-17|2015-03-18|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD|An Investigation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD)|Unknown status|Active, not recruiting|Phase 3|42|Actual|EndoStim Inc.||1|||f||||t||||||||||2018-05-31 21:28:32.152966|2018-05-31 21:28:32.152966
NCT01574326|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2016-06-14||2016-06-14|2012-04-06|2012-04-10|Estimate|2016-06-14|2016-07-25|Estimate||||2016-06-14|2016-07-25|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease|A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in Hyperphosphatemic Pediatric Patients With Chronic Kidney Disease|Completed||Phase 2|101|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 21:28:32.268435|2018-05-31 21:28:32.268435
NCT01574313|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2012-04-10|2012-04-08|2012-04-10|Estimate|||||||2012-04-10|2012-04-11|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|April 2011|Actual|2011-04-30||Interventional|||Effect of Stellate Ganglion Block on Meniere's Disease|Effect of Stellate Ganglion Block on Meniere's Disease|Completed||Phase 4|20|Actual|Chi Mei Medical Hospital||2|||f||||t||||||||||2018-05-31 21:28:32.914482|2018-05-31 21:28:32.914482
NCT01574300|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-03-16|2012-04-09|2012-04-10|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2010||2010-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CASTLE||Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network|Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network|Recruiting|||200|Anticipated|Addario Lung Cancer Medical Institute|||1||f||||f|f|f||||||Undecided||2018-05-31 21:28:33.036983|2018-05-31 21:28:33.036983
NCT01574287|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2017-11-01|2012-04-09|2012-04-10|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2012||2012-08-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas|Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC|Recruiting||N/A|12|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 21:28:33.122076|2018-05-31 21:28:33.122076
NCT01574274|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-09-25|2012-04-09|2012-04-10|Estimate|||||||2017-09-25|2017-09-27|Actual|April 2012||2012-04-30|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma|Randomized Study of Intravenous Calaspargase Pegol (SC-PEG Asparaginase) and Intravenous Oncaspar in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|Active, not recruiting||Phase 2|240|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 21:28:33.201913|2018-05-31 21:28:33.201913
NCT01574261|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2012-04-09|2012-04-09|2012-04-10|Estimate|||||||2012-04-09|2012-04-10|Estimate|March 2012||2012-03-31|April 2012|2012-04-30||||August 2012|Anticipated|2012-08-31||Interventional|||Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial||Unknown status|Recruiting|Early Phase 1|70|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 21:28:33.286928|2018-05-31 21:28:33.286928
NCT01574248|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2016-10-28||2016-12-22|2012-04-05|2012-04-10|Estimate|2016-12-22|2017-02-17|Actual||||2016-12-22|2017-02-17|Actual|August 2011||2011-08-31|December 2016|2016-12-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema|Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial|Terminated||Phase 4|33|Actual|Vanderbilt University Medical Center||2||DSMC recommended discontinuation for futility and feasibility|f||||t||||||||||2018-05-31 21:28:33.377974|2018-05-31 21:28:33.377974
NCT01574235|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2015-07-27|2012-04-09|2012-04-10|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2011||2011-10-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents|Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice|Completed|||2114|Actual|Hospira, now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-05-31 21:28:33.717266|2018-05-31 21:28:33.717266
NCT01574222|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2018-01-16|2012-04-05|2012-04-10|Estimate|||||||2018-01-16|2018-01-18|Actual|October 1, 2011|Actual|2011-10-01|January 2018|2018-01-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|VTNSCLC||A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer|Intratumoral Genetic Therapy for Lung Cancer|Terminated||Phase 1|1|Actual|VA Office of Research and Development||1||"Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome~   measure)"|f||||f||||||||No||2018-05-31 21:28:33.971497|2018-05-31 21:28:33.971497
NCT01574209|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-11-08|2012-04-05|2012-04-10|Estimate|||||||2012-11-08|2012-11-09|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|PPCD||Gut Peptides and Intestinal Permeability in Celiac Disease and Irritable Bowel Syndrome|Gut Peptides and Intestinal Permeability in Celiac Patients, Healthy Subjects and IBS Patients: a Comparative Study|Completed|||70|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|||3||f||||f||||||||||2018-05-31 21:28:34.062275|2018-05-31 21:28:34.062275
NCT01574196|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2015-03-30|2012-04-09|2012-04-10|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SALTO-SNA||Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood|"Assessment of Cardiac Autonomic Function in Adulthood After Chemotherapy or Radiotherapy in Childhood. Ancillary Study of the Long-term Follow-up of Childhood Cancer Survivors in the Rhône-Alpes and Auvergne Regions of France Study"|Completed|||83|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 21:28:34.137248|2018-05-31 21:28:34.137248
NCT01574183|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2015-09-21||2016-07-08|2012-04-06|2012-04-10|Estimate|2015-12-10|2016-01-14|Estimate||||2016-07-08|2016-08-10|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|||Vilazodone Treatment for Marijuana Dependence|Vilazodone Treatment for Marijuana Dependence|Completed||Phase 2|76|Actual|Medical University of South Carolina|Limitations included small sample size, significant attrition, and difficulty with UCT (urine cannabinoid test) interpretation due to long excretion half-life of cannabis in urine.|2|||f||||f||||||||||2018-05-31 21:28:34.22384|2018-05-31 21:28:34.22384
NCT01574170|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-03-02|2012-04-05|2012-04-10|Estimate|||||||2018-03-02|2018-03-05|Actual|June 18, 2012|Actual|2012-06-18|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|METAL3||Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival|Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival|Recruiting||Phase 4|270|Anticipated|Institut Claudius Regaud|||||f||||f||||||||||2018-05-31 21:28:34.490599|2018-05-31 21:28:34.490599
NCT01574157|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-11-15|2012-04-05|2012-04-10|Estimate|||||||2017-11-15|2017-11-17|Actual|November 5, 2012|Actual|2012-11-05|November 2017|2017-11-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.|Investigations of the Optimum Serum Bicarbonate Level in Renal Disease|Active, not recruiting||N/A|74|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 21:28:34.634972|2018-05-31 21:28:34.634972
NCT01574144|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-07-22|2012-04-06|2012-04-10|Estimate|||||||2013-07-22|2013-07-24|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Observational|READMIT-HF||REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)|Observational Study of Reducing 30-day Admissions in Post-discharge Subjects|Completed|||70|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||||2018-05-31 21:28:34.718762|2018-05-31 21:28:34.718762
NCT01574131|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-02-09|2012-04-09|2012-04-10|Estimate|||||||2016-02-09|2016-02-11|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients|Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients|Terminated||Phase 4|3|Actual|The University of Texas Medical Branch, Galveston||2||lost funding|f||||t||||||||||2018-05-31 21:28:34.79502|2018-05-31 21:28:34.79502
NCT01574118|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-01-22|2012-04-05|2012-04-10|Estimate|||||||2015-01-22|2015-01-26|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Enhancing Exposure Therapy for Post-traumatic Stress Disorder|Enhancing Exposure Therapy for PTSD: An Investigation of Non-Pharmacological Augmentation Strategies|Unknown status|Recruiting|Phase 2|54|Anticipated|University of Texas at Austin||3|||f||||f||||||||||2018-05-31 21:28:34.888209|2018-05-31 21:28:34.888209
NCT01574105|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2013-06-18||2014-07-03|2012-04-05|2012-04-10|Estimate|2014-07-03|2014-07-08|Estimate||||2014-07-03|2014-07-08|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients|Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients|Completed|||66|Actual|University of Saskatchewan|||2||f||||f||||||||||2018-05-31 21:28:35.024284|2018-05-31 21:28:35.024284
NCT01574092|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-08-21|2012-04-09|2012-04-10|Estimate|||||||2015-08-21|2015-08-24|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Interventional|||Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas|Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas|Completed||Phase 2|39|Actual|Hospital Sant Joan de Deu||1|||f||||f||||||||||2018-05-31 21:28:35.331623|2018-05-31 21:28:35.331623
NCT01574079|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2013-06-25||2014-09-04|2012-04-09|2012-04-10|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-04|2014-09-11|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Mirror Therapy on Lower Extremity Motor Control and Gait in Patients With Stroke|Effect of Mirror Therapy on Lower Extremity Motor Control and Gait in Patients With Stroke|Completed||N/A|33|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-05-31 21:28:35.457847|2018-05-31 21:28:35.457847
NCT01574066|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-08-01|2012-04-09|2012-04-10|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|PACSCAN||Chest CT-scan for the Diagnosis of Community-acquired Pneumonia|Chest CT-scan for the Diagnosis of Community-acquired Pneumonia in Patients Visiting the Emergency Department|Completed||N/A|339|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 21:28:35.70527|2018-05-31 21:28:35.70527
NCT01574053|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2018-05-14|2012-04-09|2012-04-10|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2012|Actual|2012-07-31|May 2018|2018-05-31|January 2062|Anticipated|2062-01-31|January 2062|Anticipated|2062-01-31|1 Year|Observational [Patient Registry]|||Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort|Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort|Recruiting|||15000|Anticipated|CHDI Foundation, Inc.|||||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:28:35.849637|2018-05-31 21:28:35.849637
NCT01574040|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-04-05|2012-04-05|2012-04-10|Estimate|||||||2012-04-05|2012-04-10|Estimate|February 2012||2012-02-29|April 2012|2012-04-30||||April 2012|Anticipated|2012-04-30||Interventional|LUDIC||The Lifestyle moDIfCation Study|A Before-and-after Study to Evaluate Effects of Low-cost Interventions for Promoting Healthy Lifestyle Modifications|Unknown status|Active, not recruiting|N/A|11000|Anticipated|UMC Utrecht||1|||f||||f||||||||||2018-05-31 21:28:36.711353|2018-05-31 21:28:36.711353
NCT01574027|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-04-05|2012-04-05|2012-04-10|Estimate|||||||2012-04-05|2012-04-10|Estimate|April 2008||2008-04-30|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Vitamin D in Colorectal Cancer Chemoprevention||Completed||Phase 2|55|Actual|University of Illinois at Chicago||2|||f||||||||||||||2018-05-31 21:28:36.839495|2018-05-31 21:28:36.839495
NCT01574001|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2013-05-14|2012-04-06|2012-04-10|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Smoking Cessation Interventions in Stroke Patients|Comparison of Smoking Cessation Interventions of Different Intensities in Patients With First Ever Ischemic Stroke.|Unknown status|Recruiting|N/A|240|Anticipated|Institute of Psychiatry and Neurology, Warsaw||3|||f||||t||||||||||2018-05-31 21:28:37.058115|2018-05-31 21:28:37.058115
NCT01573988|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-09-26|2012-04-06|2012-04-10|Estimate|||||||2012-09-26|2012-09-27|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SAFRAN||Satiety, Meal Frequency and Nutritional Aspects|Behavioural and Metabolic Consequences of Increasing Eating Frequency|Terminated||N/A|37|Actual|Hospices Civils de Lyon||2||Difficulties in recruiting of volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2|f||||f||||||||||2018-05-31 21:28:37.176824|2018-05-31 21:28:37.176824
NCT01573975|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-09|2012-04-09|2012-04-10|Estimate|||||||2012-04-09|2012-04-10|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori|Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori|Completed||Phase 4|345|Actual|Buddhist Tzu Chi General Hospital||3|||f||||t||||||||||2018-05-31 21:28:37.25656|2018-05-31 21:28:37.25656
NCT01573962|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2014-10-13|2012-04-09|2012-04-10|Estimate|||||||2014-10-13|2014-10-15|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury|A Sample Collection Study to Validate the Astute Medical NephroCheck Test in Critically Ill Subjects at Risk for Acute Kidney Injury|Completed|||420|Actual|Astute Medical, Inc.|||||f||||f||||||||||2018-05-31 21:28:37.373854|2018-05-31 21:28:37.373854
NCT01573949|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2013-06-20|2012-04-09|2012-04-10|Estimate|||||||2013-06-20|2013-06-24|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)|A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)|Completed||N/A|8|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 21:28:37.494498|2018-05-31 21:28:37.494498
NCT01573936|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-04-06|2012-04-06|2012-04-10|Estimate|||||||2012-04-06|2012-04-10|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Quality of Life in Adult Neurological Patients|The Influence of Rehabilitation on Quality of Life in Adult Patients With Neurological Disorders|Completed||N/A|70|Actual|Associação de Assistência a Criança Deficiente||1|||f||||t||||||||||2018-05-31 21:28:37.572337|2018-05-31 21:28:37.572337
NCT01573923|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2015-04-12|2012-04-09|2012-04-10|Estimate|||||||2015-04-12|2015-04-14|Estimate|July 2014||2014-07-31|April 2012|2012-04-30|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|LC||Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis|Clinical Trial of Umbilical Mesenchymal Stem Cells Transplantation for Liver Cirrhosis-Phase I/II|Unknown status|Recruiting|Phase 1/Phase 2|320|Anticipated|Alliancells Bioscience Corporation Limited||2|||f||||f||||||||||2018-05-31 21:28:37.648951|2018-05-31 21:28:37.648951
NCT01573910|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2015-04-27||2015-04-27|2012-04-09|2012-04-10|Estimate|2015-04-27|2015-05-12|Estimate||||2015-04-27|2015-05-12|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||This analysis population includes all participants who were administered study medication or potentially used study medication.|An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients|An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients|Completed||Phase 3|985|Actual|Alcon Research||2|||f||||t||||||||||2018-05-31 21:28:37.795925|2018-05-31 21:28:37.795925
NCT01573897|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2017-01-31|2012-04-09|2012-04-10|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|SAS-FOOT||Impact of Sleep Apnea on Diabetic Foot Wound|Influence of Sleep Apnea Syndrome and Its Treatment by Positive Airway Pressure Therapy on Transcutaneous Oxygen Tension (PtcO2)in Patients With Foot Wound or at Risk for Foot Wound|Recruiting|||60|Anticipated|AGIR à Dom|||2||f||||f||||||||Undecided||2018-05-31 21:28:38.033785|2018-05-31 21:28:38.033785
NCT01573884|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2012-04-06|2012-04-06|2012-04-10|Estimate|||||||2012-04-06|2012-04-10|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Observational|||Ex Vivo Exploratory Analysis in Healthy Full-term Infants|Ex Vivo Exploratory Analysis in Healthy Full-term Infants|Completed|||54|Actual|Abbott Nutrition|||||f||||f||||||||||2018-05-31 21:28:38.105365|2018-05-31 21:28:38.105365
NCT01573871|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2013-02-14|2012-04-06|2012-04-10|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula|Tolerance and Compliance of Infants Fed an Extensively Hydrolyzed Infant Formula|Completed||Phase 3|25|Actual|Abbott Nutrition||1|||f||||t||||||||||2018-05-31 21:28:38.163896|2018-05-31 21:28:38.163896
NCT01573858|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-02-01|2012-04-09|2012-04-10|Estimate|||||||2013-02-01|2013-02-05|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|PCOSAct||Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome|Effect of Acupuncture and Clomiphene Citrate on Live Birth in Anovulatory Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial (PCOSAct)|Unknown status|Recruiting|N/A|1000|Anticipated|Heilongjiang University of Chinese Medicine||4|||f||||t||||||||||2018-05-31 21:28:38.24079|2018-05-31 21:28:38.24079
NCT01573845|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-03-23|2012-04-05|2012-04-10|Estimate|||||||2015-03-23|2015-03-25|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional|||The GREEN Project Lunch Box Study|The GREEN (Growing Right: Eating Eco-Friendly & Nutritious) Project Lunch Box Study|Completed||N/A|979|Actual|Tufts University||3|||f||||f||||||||||2018-05-31 21:28:38.382982|2018-05-31 21:28:38.382982
NCT01573832|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2016-07-14|2012-04-05|2012-04-10|Estimate|||||||2016-07-14|2016-07-18|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|ICCP-WC||Integrated Client Care Project Trial: Wound Care Evaluation|Integrated Client Care Project Randomized Control Trial: Wound Care Evaluation|Completed||N/A|13999|Actual|Sunnybrook Health Sciences Centre||4|||f||||f||||||||||2018-05-31 21:28:38.453168|2018-05-31 21:28:38.453168
NCT01573819|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-06-13|2012-04-05|2012-04-10|Estimate|||||||2017-06-13|2017-06-15|Actual|November 24, 2011|Actual|2011-11-24|June 2017|2017-06-30|April 2, 2012|Actual|2012-04-02|April 2, 2012|Actual|2012-04-02||Interventional|||A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278|A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278|Completed||Phase 1|36|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:28:38.5244|2018-05-31 21:28:38.5244
NCT01573806|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-10-03|2012-04-05|2012-04-10|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2012||2012-10-31|October 2017|2017-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|PEPS||Pharmacology of Exenatide in Pediatric Sepsis|Phase 1-2 Study of the Pharmacology of Exenatide in Pediatric Sepsis|Withdrawn||Phase 1/Phase 2|0|Actual|Seattle Children's Hospital||2||No funding|f||||t||||||||||2018-05-31 21:28:38.616433|2018-05-31 21:28:38.616433
NCT01573793|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2014-03-24|2012-04-05|2012-04-10|Estimate|||||||2014-03-24|2014-03-26|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||Promoting Optimal Parenting (Bright Start)|Promoting Optimal Parenting|Unknown status|Recruiting|N/A|500|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 21:28:38.696843|2018-05-31 21:28:38.696843
NCT01573780|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2014-01-14|2012-04-09|2012-04-10|Estimate|||||||2014-01-14|2014-01-15|Estimate|April 2012||2012-04-30|January 2014|2014-01-31||||September 2013|Actual|2013-09-30||Interventional|||Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors|A Phase I Study of TL32711 In Combination With Gemcitabine in Patients With Advanced Solid Tumors|Terminated||Phase 1|21|Actual|Roswell Park Cancer Institute||1||Sponsor did not have funds to continue study|f||||f||||||||||2018-05-31 21:28:38.773591|2018-05-31 21:28:38.773591
NCT01573767|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2014-12-18||2016-11-18|2012-04-05|2012-04-10|Estimate|2015-04-02|2015-04-03|Estimate||||2016-11-18|2017-01-09|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children|A Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children Aged 5-11 Years With Asthma on a Background of Inhaled Corticosteroid Therapy|Completed||Phase 2|463|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:28:38.874409|2018-05-31 21:28:38.874409
NCT01573754|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-02-26|2012-04-06|2012-04-09|Estimate|||||||2018-02-26|2018-02-28|Actual|April 2003||2003-04-30|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda|A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435|Recruiting||Phase 2|100|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|t|f||||||Undecided|Through a NIH data repository at some future time.|2018-05-31 21:28:39.947945|2018-05-31 21:28:39.947945
NCT01573741|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-05-02|2012-04-06|2012-04-09|Estimate|||||||2012-05-02|2012-05-04|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||Study of Ketamine as an Antidepressant in Major Depressive Disorder|Department of AnesthesiologyJinling Hospital, Nanjing University School of Medicine, Nanjing, China|Unknown status|Recruiting|Phase 1/Phase 2|35|Anticipated|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 21:28:40.097541|2018-05-31 21:28:40.097541
NCT01573728|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2016-03-31|2012-04-05|2012-04-09|Estimate|||||||2016-03-31|2016-04-01|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|RED||Role of Exercise in Depression in Middle Aged and Older Adults|Role of Exercise in Depression Among Middle Aged and Older Adults|Completed||N/A|20|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 21:28:40.227565|2018-05-31 21:28:40.227565
NCT01573715|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-08-29|2012-04-06|2012-04-09|Estimate|||||||2014-08-29|2014-09-01|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS)|Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS|Unknown status|Recruiting|Phase 4|40|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 21:28:40.37531|2018-05-31 21:28:40.37531
NCT01573702|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-03-27|2012-04-05|2012-04-09|Estimate|||||||2018-03-27|2018-03-29|Actual|December 11, 2012|Actual|2012-12-11|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)|Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation Who Have Previously Progressed on an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)|Active, not recruiting||Phase 2|32|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:28:40.510047|2018-05-31 21:28:40.510047
NCT01573689|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-05-07|2012-04-06|2012-04-09|Estimate|||||||2013-05-07|2013-05-09|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Bereaving, But Not Alone : the Development and Actualization of a Mutual Aid Group for Children Who Have Lost a Parent.|Bereaving, But Not Alone : the Development and Actualization of a Mutual Aid Group for Children Who Have Lost a Parent.|Completed||N/A|4|Actual|Université de Montréal|||||f||||f||||||||||2018-05-31 21:28:40.674165|2018-05-31 21:28:40.674165
NCT01573676|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-04-06|2012-04-06|2012-04-09|Estimate|||||||2012-04-06|2012-04-09|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|July 2012|Anticipated|2012-07-31||Observational|OSA||The Influence of Bariatric Surgery on Patients With Obstructive Sleep Apnea (OSA)|The Influence of Bariatric Surgery on Patients With Obstructive Sleep Apnea (OSA)|Unknown status|Not yet recruiting||60|Anticipated|Hillel Yaffe Medical Center|||1||f||||f||||||||||2018-05-31 21:28:40.755568|2018-05-31 21:28:40.755568
NCT01573663|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-07-18|2012-04-06|2012-04-09|Estimate|||||||2012-07-18|2012-07-19|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Drug-Drug Interaction Study of Ambroxol and Levodropropizine|Open Label, Randomized, 3-sequence Crossover Study to Evaluate the Drug-drug Interaction Between Ambroxol HCl and Levodropropizine in Healthy Male Volunteers|Completed||Phase 1|21|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 21:28:40.826419|2018-05-31 21:28:40.826419
NCT01573650|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-10-17|2012-04-06|2012-04-09|Estimate|||||||2017-10-17|2017-10-18|Actual|March 2015||2015-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Optimization of Peripheral Nerve Reconstruction: A Non-inferiority Trial|Optimization of Peripheral Nerve Reconstruction: A Non-inferiority Trial|Recruiting|||48|Anticipated|University Hospital, Basel, Switzerland|||2||f||||t||||||||||2018-05-31 21:28:40.903429|2018-05-31 21:28:40.903429
NCT01573637|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2015-08-21|2012-04-06|2012-04-09|Estimate|||||||2015-08-21|2015-08-24|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women|Six Month, Double Blind, Placebo-controlled Trial of the Efficacy of Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women|Completed||Phase 3|78|Actual|Fundació Sant Joan de Déu||2|||f||||f||||||||||2018-05-31 21:28:41.03914|2018-05-31 21:28:41.03914
NCT01573624|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2017-05-18|2013-07-25|2017-09-07|2012-04-05|2012-04-09|Estimate|2017-07-14|2017-08-15|Actual|2013-07-25|2013-08-01|Estimate|2017-09-07|2017-10-06|Actual|April 3, 2012|Actual|2012-04-03|September 2017|2017-09-30|February 4, 2013|Actual|2013-02-04|February 4, 2013|Actual|2013-02-04||Interventional|ILA115938||Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma|A Multi-center, Randomized, Double-blind, Dose-ranging Study to Evaluate GSK573719 in Combination With Fluticasone Furoate, Fluticasone Furoate Alone, and an Active Control of Fluticasone Furoate/Vilanterol Combination in Subjects With Asthma|Completed||Phase 2|421|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:28:41.209525|2018-05-31 21:28:41.209525
NCT01573611|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-12-02|2012-04-05|2012-04-09|Estimate|||||||2014-12-02|2014-12-04|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|April 2013|Actual|2013-04-30||Interventional|||Impact of Grape Consumption on Brain Metabolism and Cognitive Function|Examining the Impact of Grape Consumption on Brain Metabolism and Cognitive Function in Patients With Mild Cognitive Impairment|Completed||Phase 1|12|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:28:42.078276|2018-05-31 21:28:42.078276
NCT01573598|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2015-05-15|2012-04-05|2012-04-09|Estimate|||||||2015-05-15|2015-05-18|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy of Vilazodone in Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder|Completed||Phase 4|1219|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 21:28:42.166727|2018-05-31 21:28:42.166727
NCT01573585|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2016-06-27|2012-04-05|2012-04-09|Estimate|||||||2016-06-27|2016-06-29|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|FAST||Fast Muscle Activation and Stepping Training (FAST) Post-stroke|Effectiveness of Fast Muscle Activation and Stepping Training (FAST) on Balance and Mobility Post-stroke|Recruiting||N/A|60|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 21:28:43.415511|2018-05-31 21:28:43.415511
NCT01573572|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2017-04-25|2012-04-05|2012-04-09|Estimate|||||||2017-04-25|2017-04-26|Actual|April 2010|Actual|2010-04-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|May 1, 2018|Anticipated|2018-05-01||Interventional|||Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium|A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection)Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.|Recruiting||Phase 4|125|Anticipated|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 21:28:43.504851|2018-05-31 21:28:43.504851
NCT01573559|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-04-05|2012-04-05|2012-04-09|Estimate|||||||2012-04-05|2012-04-09|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||ClearView Predicate Comparison Testing|ClearView Predicate Comparison Testing|Completed|||31|Actual|Epic Research & Diagnostics, Inc.|||1||f||||f||||||||||2018-05-31 21:28:43.598391|2018-05-31 21:28:43.598391
NCT01573546|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-04-17|2012-04-05|2012-04-09|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2011||2011-12-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2016|Actual|2016-12-31||Interventional|ENLIGHTEN||ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement|Lifestyle, CVD Risk, and Cognitive Impairment|Completed||N/A|160|Actual|Duke University||4|||f||||t||||||||||2018-05-31 21:28:43.661958|2018-05-31 21:28:43.661958
NCT01573533|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-10-09|2012-04-05|2012-04-09|Estimate|||||||2017-10-09|2017-10-11|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS|A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte β3 Integrin|Active, not recruiting||Phase 2|20|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:28:43.74926|2018-05-31 21:28:43.74926
NCT01573520|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2016-01-28|2012-04-05|2012-04-09|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|MEMS-cinac||Treatment Adhesion in Dialysis Patients Treated With Cinacalcet|A Randomized Trial Comparing an Integrated Care Approach Using Electronic Cinacalcet Adherence Data Versus Usual Care to Improve Secondary Hyperparathyroidism in Hemodialysis Patients|Completed||Phase 4|50|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 21:28:43.928792|2018-05-31 21:28:43.928792
NCT01573507|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2018-03-30|2012-04-06|2012-04-09|Estimate|||||||2018-03-30|2018-04-03|Actual|March 2012|Actual|2012-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LS_TCC||Lactate Therapy After Traumatic Brain Injury|Neuroprotective Role of Lactate Therapy in Humans With Traumatic Brain Injury|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||t||||||||No||2018-05-31 21:28:44.006918|2018-05-31 21:28:44.006918
NCT01573494|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2014-06-25|2012-04-05|2012-04-09|Estimate|||||||2014-06-25|2014-06-26|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|||Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma|Study of Circulating Tumor Cells Before and After Treatment in Patients With Metastatic Melanoma.|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 21:28:44.097685|2018-05-31 21:28:44.097685
NCT01573130|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2016-10-29|2012-04-04|2012-04-06|Estimate|||||||2016-10-29|2016-11-01|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Treating Depression With Physical Exercise|An Internet-administered, Therapist-supported Physical Exercise Program for the Treatment of Depression|Completed||N/A|128|Anticipated|Umeå University||2|||f||||f||||||||||2018-05-31 21:28:48.356767|2018-05-31 21:28:48.356767
NCT01573481|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-08-03|2012-04-05|2012-04-09|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|REVENTIL||Comparison of Two Ventilator Mode During the Night: New Strategy of Mechanical Ventilation Weaning|Pressure Controlled Ventilation Versus Pressure Support Ventilation During the Night: New Strategy of Mechanical Ventilation Weaning?|Completed||N/A|19|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 21:28:44.176425|2018-05-31 21:28:44.176425
NCT01573468|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-07-20|2012-04-06|2012-04-09|Estimate|||||||2012-07-20|2012-07-24|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|TESEGAST||Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer|A Randomized, Double-blind Study of Capecitabine Plus Tesetaxel Versus Capecitabine Plus Placebo as Second-line Therapy in Subjects With Gastric Cancer|Unknown status|Recruiting|Phase 2|580|Anticipated|Genta Incorporated||2|||f||||t||||||||||2018-05-31 21:28:44.26817|2018-05-31 21:28:44.26817
NCT01573442|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2018-04-12|2012-04-06|2012-04-09|Estimate|||||||2018-04-12|2018-04-13|Actual|August 2013|Actual|2013-08-31|April 2018|2018-04-30||||February 28, 2018|Actual|2018-02-28||Interventional|||Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment|Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias|Active, not recruiting||Phase 3|227|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 21:28:44.514403|2018-05-31 21:28:44.514403
NCT01573429|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-05-23|2012-04-05|2012-04-09|Estimate|||||||2018-05-23|2018-05-24|Actual|March 7, 2012||2012-03-07|February 5, 2018|2018-02-05|September 8, 2019|Anticipated|2019-09-08|September 8, 2019|Anticipated|2019-09-08||Interventional|||Bisphenol A Controlled Exposure Study|Bisphenol A (BPA) Pharmacokinetic (PK): Controlled Exposure Study|Recruiting||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:28:45.502177|2018-05-31 21:28:45.502177
NCT01573416|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-10-08|2012-04-05|2012-04-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||"Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care."|"Effectiveness of a Brief Intervention for Substances Consumption Linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A Randomized Control Trial in Chilean Primary Care."|Completed||Phase 3|400|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 21:28:45.595929|2018-05-31 21:28:45.595929
NCT01573403|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-02-12|2012-04-05|2012-04-09|Estimate|||||||2013-02-12|2013-02-13|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety of DLBS2411 in Healthy Volunteers|Effect of DLBS2411 on Gastric pH Regulation in Healthy Volunteers : Comparison With Placebo|Completed||Phase 1/Phase 2|54|Actual|Dexa Medica Group||3|||f||||f||||||||||2018-05-31 21:28:45.834765|2018-05-31 21:28:45.834765
NCT01573390|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-03-20|2012-04-05|2012-04-09|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2011||2011-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Non Invasive and Non-Contact Imaging Of Tissue Oxygenation and Vascular Reactivity|Non Invasive and Non-Contact Dual-modal Imaging Of Tissue Oxygenation and Vascular Reactivity Dynamic Imaging Of Tissue Metabolism and Vascular Function.|Active, not recruiting|||50|Anticipated|Ohio State University|||1||f||||f||||||None Retained|"~     there is no biospecimen collection require in this protocol.~   "|||2018-05-31 21:28:45.923989|2018-05-31 21:28:45.923989
NCT01573377|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2013-12-26|2012-04-06|2012-04-09|Estimate|||||||2013-12-26|2013-12-30|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial|Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial|Completed||N/A|40|Actual|Chongqing Medical University||2|||f||||t||||||||||2018-05-31 21:28:46.015944|2018-05-31 21:28:46.015944
NCT01573364|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2012-04-05|2012-04-05|2012-04-09|Estimate|||||||2012-04-05|2012-04-09|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Observational|Dist'air2||Prevalence and Reversibility of Lung Hyperinflation in Asthma|Evaluation of the Prevalence and the Reversibility of the Lung Hyperinflation in Uncontrolled Persistent Asthmatic Patients With Dyspnea|Completed|||450|Actual|Chiesi Farmaceutici S.p.A.|||||f||||f||||||||||2018-05-31 21:28:46.112798|2018-05-31 21:28:46.112798
NCT01573351|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05||2015-09-23|2015-09-23|2012-04-06|2012-04-09|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|Hallmark QUAD||Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)|A Phase 3, Open-Label Study With Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin With Chronic Hepatitis C Genotypes 1 or 4 Infection|Completed||Phase 3|398|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 21:28:46.208976|2018-05-31 21:28:46.208976
NCT01573338|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-04-25|2012-04-06|2012-04-09|Estimate|||||||2017-04-25|2017-04-26|Actual|February 25, 2013|Actual|2013-02-25|April 2017|2017-04-30|June 23, 2016|Actual|2016-06-23|March 25, 2016|Actual|2016-03-25||Interventional|||Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)|Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|43|Actual|Bayer||1|||f||||f||||||||||2018-05-31 21:28:46.463051|2018-05-31 21:28:46.463051
NCT01573325|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2012-12-26||2014-02-27|2012-04-05|2012-04-09|Estimate|2014-02-27|2014-02-28|Estimate||||2014-02-27|2014-02-28|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|LowMELD||HRQoL in the Low MELD Pre-tx Population|Health-Related Quality of Life in the Low Model for End-Stage Liver Disease (MELD) Pre Transplant Patient Candidate: A Pilot Study|Completed|||50|Actual|Northwestern University|The small sample size and convenience sampling were limitations of this study. Additionally, since subjects were recruited from only one site, generalizability of findings is limited.||||f||||f||||||||||2018-05-31 21:28:46.575453|2018-05-31 21:28:46.575453
NCT01573117|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2012-04-25|2012-04-04|2012-04-06|Estimate|||||||2012-04-25|2012-04-26|Estimate|September 2010||2010-09-30|April 2012|2012-04-30||||November 2011|Actual|2011-11-30||Interventional|iCOOL 1||A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill (iCOOL 1)|iCOOL 1 (Induction of COOLing 1): A Randomized Trial Comparing 2 Methods for Rapid Induction of Cooling in Stroke Patients, Cold Infusions vs. RhinoChill|Completed||Phase 2|20|Actual|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 21:28:48.464316|2018-05-31 21:28:48.464316
NCT01573312|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-01-09|2012-04-05|2012-04-09|Estimate|||||||2014-01-09|2014-01-10|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||H5N1 Vaccination With and Without AS03: Systems Biology Analysis|A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered With and Without AS03 Adjuvant: Standard & Systems Biology Analyses|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 21:28:46.722853|2018-05-31 21:28:46.722853
NCT01573299|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-12-16|2012-04-05|2012-04-09|Estimate|||||||2014-12-16|2014-12-17|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|SEVEL||Ischemic Stroke and Early Vertical Positioning (SEVEL)|Ischemic Stroke and Early Vertical Positioning, the SEVEL Study: a Randomised Controlled Trial Comparing the 3 Months Rankin Score Outcome in Ischemic Stroke Patients; in Whom Early or Delayed Mobilization is Performed|Terminated||N/A|167|Actual|Nantes University Hospital||2||"The required number of patients was not reached. The sites were not able to include more~   patients.Despite several actions the stop of the study has been decided"|f||||t||||||||||2018-05-31 21:28:46.79318|2018-05-31 21:28:46.79318
NCT01573286|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-12-19|2012-04-06|2012-04-09|Estimate|||||||2014-12-19|2014-12-23|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2014|Actual|2014-08-31||Interventional|GLP-2-01||Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure|Phase 1-2 Trial of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure|Terminated||Phase 1/Phase 2|13|Actual|Alberta Children's Hospital||2||GLP-2 Drug product stability concerns|f||||t||||||||||2018-05-31 21:28:46.87896|2018-05-31 21:28:46.87896
NCT01573273|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-01-31|2012-04-06|2012-04-09|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||Oxytocin in Cocaine Dependence||Completed||N/A|97|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:28:46.977634|2018-05-31 21:28:46.977634
NCT01573260|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2015-04-15||2015-12-21|2012-04-06|2012-04-09|Estimate|2015-12-21|2016-02-01|Estimate||||2015-12-21|2016-02-01|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|||Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease.|Tango for Treatment of Motor and Non-motor Manifestations in Parkinson's Disease: A Randomized Control Study.|Completed||Early Phase 1|33|Actual|McGill University Health Center|This was a relatively small study, and many of our negative results could be related to inadequate power. The higher baseline activity rate in the controls may have affected responsiveness to change.|2|||f||||t||||||||||2018-05-31 21:28:47.07253|2018-05-31 21:28:47.07253
NCT01573247|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2016-03-24|2012-04-05|2012-04-09|Estimate|||||||2016-03-24|2016-03-25|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia|A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients With Acute Myelogenous Leukemia (AML)|Terminated||Phase 1/Phase 2|25|Actual|Akinion Pharmaceuticals AB||1||"During the study two patients have experienced serious liver events related to AKN-028. The~   risk-benefit balance was judged to be negative."|f||||t||||||||||2018-05-31 21:28:47.52752|2018-05-31 21:28:47.52752
NCT01573234|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2014-01-10|2012-04-06|2012-04-09|Estimate|||||||2014-01-10|2014-01-13|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of MySkin Patch for the Healing of Cut Injuries and Abrasions|Efficacy of MySkin Patch for the Healing of Cut Injuries and Abrasions: a Randomised Controlled Trial|Completed||Phase 3|180|Actual|Associazione Infermieristica per lo studio delle Lesioni Cutanee||2|||f||||t||||||||||2018-05-31 21:28:47.619506|2018-05-31 21:28:47.619506
NCT01573221|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-01-04|2012-04-06|2012-04-09|Estimate|||||||2013-01-04|2013-01-07|Estimate||||January 2013|2013-01-31||||||||Observational|||Stroke and PMSI (Medicalisation Information Systems Programm)|Stroke and PMSI Evaluation of the Sensitivity and Specificity|Unknown status|Recruiting||||Centre Hospitalier Universitaire Dijon|||1||f||||f||||||||||2018-05-31 21:28:47.713744|2018-05-31 21:28:47.713744
NCT01573208|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-11-05|2012-04-06|2012-04-09|Estimate|||||||2017-11-05|2017-11-07|Actual|February 2011||2011-02-28|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Custom Guides for Total Knee Arthroplasty (TKA)|Prospective Cohort of FIRST TKA With Custom Guides|Recruiting||Phase 4|80|Anticipated|University of Lausanne Hospitals||1|||f||||||||||||||2018-05-31 21:28:47.794432|2018-05-31 21:28:47.794432
NCT01573195|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2014-12-16|2012-04-04|2012-04-06|Estimate|||||||2014-12-16|2014-12-18|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Merck IISP Stewardship Grant for Antibiotic Best Practices|Implementation of Antimicrobial Stewardship and Decision Support Into the EPIC Electronic Medical Record|Completed|||1285|Actual|University of Wisconsin, Madison|||1||f||||f||||||||||2018-05-31 21:28:47.875145|2018-05-31 21:28:47.875145
NCT01573182|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2018-05-03|2012-04-04|2012-04-06|Estimate|||||||2018-05-03|2018-05-10|Estimate|April 2012||2012-04-30|May 2018|2018-05-31|May 3, 2018|Actual|2018-05-03|May 3, 2018|Actual|2018-05-03||Interventional|VZV-Zostavax||Herpes Zoster Vaccine for Bone Marrow Transplant Donors|A Phase II Clinical Trial of Vaccination of Stem Cell Donors With Zostavax to Reduce the Incidence of Herpes Zoster in Transplant Recipients - A Pilot Study|Completed||Phase 2|8|Actual|University of Sydney||1|||f||||f||||||||||2018-05-31 21:28:47.949577|2018-05-31 21:28:47.949577
NCT01573169|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2017-10-10|2012-04-04|2012-04-06|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2012||2012-05-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PREVENTIHS||PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients|PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients|Recruiting||Phase 3|406|Anticipated|University Of Perugia||2|||f||||t||||||||||2018-05-31 21:28:48.047681|2018-05-31 21:28:48.047681
NCT01573156|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-01-08|2012-04-04|2012-04-06|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2013||2013-05-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|May 2014|Actual|2014-05-31||Interventional|KCM201||Vascular Targeted Photodynamic Therapy T1a Renal Tumours|Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial|Terminated||Phase 1/Phase 2|5|Actual|University of Oxford||1||Concerns about post VTP MRI results being conclusive|f||||t||||||||||2018-05-31 21:28:48.141213|2018-05-31 21:28:48.141213
NCT01573143|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-09-16|2012-04-04|2012-04-06|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|STICS||Statin Therapy In Cardiac Surgery|Statin Therapy In Cardiac Surgery|Completed||Phase 4|1922|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:28:48.241618|2018-05-31 21:28:48.241618
NCT01573104|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-05-26|2012-04-04|2012-04-06|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluating Novel Biomarkers in Acute Kidney Injury|Evaluating the Utility of Urinary Proteomics and Novel Biomarkers in Acute Kidney Injury|Completed||N/A|87|Actual|University of Glasgow||1|||f||||f||||||||||2018-05-31 21:28:48.549023|2018-05-31 21:28:48.549023
NCT01573091|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-02-22|2012-04-04|2012-04-06|Estimate|||||||2017-02-22|2017-02-24|Actual|December 2011||2011-12-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CRT-MORE||Cardiac Resynchronization Therapy Modular Registry|Cardiac Resynchronization Therapy Modular Registry|Completed|||500|Actual|University of Florence|||1||f||||||||||||No||2018-05-31 21:28:48.623632|2018-05-31 21:28:48.623632
NCT01573078|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2018-05-25|2012-04-04|2012-04-06|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2012||2012-05-31|May 2018|2018-05-31|January 28, 2015|Actual|2015-01-28|January 28, 2015|Actual|2015-01-28||Observational|||Psychology of Crohn's Disease|Will The Real Psychology Of Crohn's Disease Please Stand Up?|Completed|||50|Actual|University of British Columbia|||1||f||||||||||||||2018-05-31 21:28:48.716368|2018-05-31 21:28:48.716368
NCT01573065|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-08-09|2012-04-04|2012-04-06|Estimate|||||||2012-08-09|2012-08-10|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|May 2010|Actual|2010-05-31||Interventional|||HIV Testing and Brief Alcohol Intervention for Young Drinkers in the Emergency Department|Addressing HIV Risk in Young Unhealthy Alcohol Drinkers in the Emergency Department With Rapid HIV Testing and Brief Intervention|Completed||N/A|85|Actual|Yale University||1|||f||||f||||||||||2018-05-31 21:28:48.791403|2018-05-31 21:28:48.791403
NCT01573052|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-06-20|2012-04-04|2012-04-06|Estimate|||||||2012-06-20|2012-06-21|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal|Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment|Completed||Phase 4|27|Actual|VA Salt Lake City Health Care System||2|||f||||t||||||||||2018-05-31 21:28:48.860315|2018-05-31 21:28:48.860315
NCT01573039|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2014-04-03|2012-04-04|2012-04-06|Estimate|||||||2014-04-03|2014-04-04|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|July 2013|Actual|2013-07-31|November 2012|Actual|2012-11-30||Observational|||Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients|Definition of Cut Off for PCR - Quantitative and Antigenemia in the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients|Completed|||120|Actual|University of Sao Paulo General Hospital|||||f||||t||||||||||2018-05-31 21:28:48.936352|2018-05-31 21:28:48.936352
NCT01573026|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-05|2012-04-05|2012-04-06|Estimate|||||||2012-04-05|2012-04-06|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Observational|Genesis Dental||Five Year Survival Study Evaluating the Genesis Dental Implant System|Clinical Analysis of a Biomimetic Implant System: Five Year Survival Rates, Marginal Bone-level Changes, and Soft Tissue Aesthetics.|Unknown status|Active, not recruiting||120|Anticipated|Keystone Dental, Inc.|||||f||||f||||||||||2018-05-31 21:28:48.993012|2018-05-31 21:28:48.993012
NCT01573013|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-05-09|2012-04-04|2012-04-06|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Iron Fortification Trail Using NaFeEDTA in Iron Deficient Lead-exposed Children|Interactions of Lead Intoxication and Iron Deficiency in Morocco: The Effects of Iron Fortification With and Without NaEDTA on Lead Burden, Iron Status and Cognition in Children|Completed||N/A|457|Actual|Swiss Federal Institute of Technology||4|||f||||t||||||||||2018-05-31 21:28:49.056559|2018-05-31 21:28:49.056559
NCT01573000|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2012-04-12||2016-11-30|2012-04-03|2012-04-06|Estimate|2012-09-06|2012-10-05|Estimate||||2016-11-30|2017-01-18|Estimate|September 1998||1998-09-30|November 2016|2016-11-30|April 2010|Actual|2010-04-30|April 2001|Actual|2001-04-30||Interventional|||A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)|Phase II a Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 2|78|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:28:49.223193|2018-05-31 21:28:49.223193
NCT01572987|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-05-24|2012-04-04|2012-04-06|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2011||2011-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|ERADICATE||Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus|Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus|Terminated||N/A|12|Actual|Midwest Biomedical Research Foundation||2||Recruitment goals not being met|f||||t||||||||||2018-05-31 21:28:51.477882|2018-05-31 21:28:51.477882
NCT01572974|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-01-16|2012-04-04|2012-04-06|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2010||2010-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 2016|Actual|2016-09-30||Observational|||Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease|Quality of Life in Barrett's Esophagus and GERD:GERD Symptoms, Perception of Cancer Risk, and Actual Cancer Risk|Terminated|||89|Actual|Midwest Biomedical Research Foundation|||4|Lack of recruitment|f||||f||||||||||2018-05-31 21:28:51.582331|2018-05-31 21:28:51.582331
NCT01572961|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2016-02-11|2012-04-05|2012-04-06|Estimate|||||||2016-02-11|2016-02-12|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|May 2013|Actual|2013-05-31|March 2012|Actual|2012-03-31||Interventional|MICROTEC||Microvascular Function Assessment in Healthy Subjects|Amélioration Des Techniques d'étude de la Micro-cirulation cutanée Chez Des Sujets Sains|Completed||N/A|16|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 21:28:51.667319|2018-05-31 21:28:51.667319
NCT01572948|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|2015-05-29||2015-09-28|2012-04-04|2012-04-06|Estimate|2015-07-29|2015-07-31|Estimate||||2015-09-28|2015-10-19|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)|A Placebo-controlled Trial of Roflumilast (Daliresp) on Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|27|Actual|University of Alabama at Birmingham|small sample size and limited follow-up|2|||f||||f||||||||||2018-05-31 21:28:51.764915|2018-05-31 21:28:51.764915
NCT01572935|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-09-18|2012-04-04|2012-04-06|Estimate|||||||2012-09-18|2012-09-19|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Observational|||Body Weight Assessment in Swiss Primary School Children: Trend Analysis Over 10 Years|Body Weight Assessment in Swiss Primary School Children: Trend Analysis Over 10 Years|Completed|||2979|Actual|Swiss Federal Institute of Technology|||||f||||f||||||||||2018-05-31 21:28:52.098105|2018-05-31 21:28:52.098105
NCT01572909|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28||2015-11-11|2015-11-11|2012-04-04|2012-04-06|Estimate||||2015-11-11|2015-12-10|Estimate|2015-11-11|2015-12-10|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|EMBRACE||Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction|Completed||Phase 2|300|Actual|Stealth BioTherapeutics Inc.||2|||f||||t||||||||||2018-05-31 21:28:52.406639|2018-05-31 21:28:52.406639
NCT01572896|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-03-31|2012-04-04|2012-04-06|Estimate|||||||2017-03-31|2017-04-04|Actual|April 2012||2012-04-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||An Internet-based Self-management Program for Adolescents With Arthritis|An Internet-based Self-management Program for Adolescents With Arthritis: A Randomized Controlled Trial|Completed||N/A|333|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 21:28:52.581325|2018-05-31 21:28:52.581325
NCT01572883|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2014-10-15|2012-04-05|2012-04-06|Estimate|||||||2014-10-15|2014-10-16|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer|Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer|Completed|||175|Actual|Institute of Oncology Ljubljana|||||f||||f||||||||||2018-05-31 21:28:52.695414|2018-05-31 21:28:52.695414
NCT01572870|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2016-06-27|2012-04-05|2012-04-06|Estimate|||||||2016-06-27|2016-06-28|Estimate|December 2010||2010-12-31|June 2016|2016-06-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Observational|||Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients|Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients|Completed|||40|Actual|Rambam Health Care Campus|||3||f||||||||||||||2018-05-31 21:28:52.7746|2018-05-31 21:28:52.7746
NCT01572857|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2016-04-11|2012-04-04|2012-04-06|Estimate|||||||2016-04-11|2016-04-12|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|RCP-MM||Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma|Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma.|Unknown status|Recruiting||50|Anticipated|Rennes University Hospital|||2||f||||f||||||Samples Without DNA|"~     -  Proteinuria~        -  Albuminuria~        -  Urinary FLC (Freelite ™)~        -  Urine creatinine~   "|||2018-05-31 21:28:52.852131|2018-05-31 21:28:52.852131
NCT01572844|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|2017-06-23||2017-11-21|2012-04-05|2012-04-06|Estimate|2017-11-21|2017-11-29|Actual||||2017-11-21|2017-11-29|Actual|August 2012||2012-08-31|November 2017|2017-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis|Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis|Completed||Phase 2|3|Actual|George Washington University||2|||f||||t||||||||No||2018-05-31 21:28:52.955019|2018-05-31 21:28:52.955019
NCT01572831|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2015-05-22|2012-04-05|2012-04-06|Estimate|||||||2015-05-22|2015-05-25|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||PCT and Clinical Algorithm for Determination of Duration of Antibiotics|A Pilot Study to Evaluate a Procalcitonin-Based Algorithm for Duration of Antibiotic Therapy in Critically Ill Patients|Completed||Phase 3|1|Actual|Fraser Health||2|||f||||f||||||||||2018-05-31 21:28:53.266099|2018-05-31 21:28:53.266099
NCT01572818|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2016-06-14|2012-04-04|2012-04-06|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SAINPOS||Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients|Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients|Completed||N/A|13|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 21:28:53.341234|2018-05-31 21:28:53.341234
NCT01572805|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-10-10|2012-04-04|2012-04-06|Estimate|||||||2012-10-10|2012-10-11|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Evaluation of Melatonin's Effect on Pain and Blood Loss After Cesarean Section||Completed||Phase 1/Phase 2|120|Actual|Qazvin University Of Medical Sciences||3|||f||||t||||||||||2018-05-31 21:28:53.674972|2018-05-31 21:28:53.674972
NCT01572792|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|2016-12-23|2015-02-27|2017-03-09|2012-04-04|2012-04-06|Estimate|2017-03-09|2017-04-21|Actual|2015-02-27|2015-03-18|Estimate|2017-03-09|2017-04-21|Actual|April 2012||2012-04-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||The Extension Safety Population defined as all patients from the lead-in study (LAC-MD-31) who signed informed consent at Visit 1 of this extension study (last visit of the lead-in study) and who took at least 1 dose of double-blind investigational product in this extension study|Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Long-term, Randomized, Double-blind, Extension Study of the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|921|Actual|AstraZeneca|The objective of this extension study was to assess long-term safety and tolerability. Thus efficacy assessments were considered only supportive to the lead-in study (LAC-MD-31), and were not categorized as primary, secondary, or additional|5|||f||||f||||||||||2018-05-31 21:28:53.903305|2018-05-31 21:28:53.903305
NCT01572779|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-03-23|2012-04-04|2012-04-06|Estimate|||||||2015-03-23|2015-03-25|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study to Investigate the Effect of a New Postural Bio-feedback Device on Low Back Pain|A Multicentre, Cluster Randomised, Placebo-controlled, Open-label Pilot Study of Back Strain Monitor (BSM) With Feedback Compared With the BSM Without Feedback in Subjects With Moderate Lower Back Pain.|Completed||Phase 2|112|Actual|Pro-Active Medical Pty Ltd||2|||f||||t||||||||||2018-05-31 21:28:55.680236|2018-05-31 21:28:55.680236
NCT01572766|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-05|2012-04-05|2012-04-06|Estimate|||||||2012-04-05|2012-04-06|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Effect of Assessing Risk for Osteoporosis on Physician and Patient Behaviors|Impact of the FRAX Assessment on Physician and Patient Treatment Behavior|Completed||N/A|90|Actual|Duquesne University||2|||f||||f||||||||||2018-05-31 21:28:55.759655|2018-05-31 21:28:55.759655
NCT01572753|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-02-23|2012-04-04|2012-04-06|Estimate|||||||2017-02-23|2017-02-27|Actual|April 12, 2012|Actual|2012-04-12|February 2017|2017-02-28|September 8, 2012|Actual|2012-09-08|September 8, 2012|Actual|2012-09-08||Interventional|||Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects|A Single Centre, Multiple Dose, Open Label Randomised Trial to Evaluate the Effect of Post Dose Meal Timings and the Effect of Volume of Water With Dosing on the Pharmacokinetic Properties of Oral Semaglutide in Healthy Male Subjects|Completed||Phase 1|161|Actual|Novo Nordisk A/S||8|||f||||f||||||||||2018-05-31 21:28:55.832612|2018-05-31 21:28:55.832612
NCT01572740|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|2014-03-27||2018-01-11|2012-04-04|2012-04-06|Estimate|2014-04-24|2014-05-23|Estimate||||2018-01-11|2018-02-07|Actual|April 5, 2012|Actual|2012-04-05|January 2018|2018-01-31|March 27, 2013|Actual|2013-03-27|November 1, 2012|Actual|2012-11-01||Interventional|||Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes|A 36-week, Randomised, Multi-centre, Double-blind, Parallel Group Trial to Investigate the Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|257|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:28:55.946651|2018-05-31 21:28:55.946651
NCT01572727|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|2016-05-31||2017-01-27|2012-04-04|2012-04-06|Estimate|2016-12-01|2017-01-27|Estimate||||2017-01-27|2017-03-09|Actual|August 2012||2012-08-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BELLE-4|The Full Analysis Set (FAS) included all patients who were randomized to study treatment.|A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation|A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.|Completed||Phase 2/Phase 3|416|Actual|Novartis|Safety set: all randomized pts who received at least 1 dose of the study treatment (either buparlisib + paclitaxel or matching placebo + paclitaxel) & had at least 1 post-baseline safety assessment;13 of 416 pts didn't meet this criteria; safety =403|2|||f||||t||||||||||2018-05-31 21:28:56.700934|2018-05-31 21:28:56.700934
NCT01572714|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2016-07-12|2012-04-04|2012-04-06|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Examining the Effects of a Telehealth Self-management Intervention in Multiple Sclerosis|Examining the Effects of Physical Activity Promotion, Fatigue Management Education, and Social Support Using a Telehealth Intervention Approach Among Adults With Multiple Sclerosis|Active, not recruiting||N/A|215|Anticipated|Case Western Reserve University||3|||f||||f||||||||||2018-05-31 21:28:57.816708|2018-05-31 21:28:57.816708
NCT01572701|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-11-23|2012-04-04|2012-04-06|Estimate|||||||2015-11-23|2015-11-25|Estimate|January 2012||2012-01-31|November 2015|2015-11-30||||June 2012|Actual|2012-06-30||Interventional|||Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection|A Phase 1 Pilot Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection (PLND)|Completed||Phase 1|8|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:28:58.092961|2018-05-31 21:28:58.092961
NCT01572688|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-08-01|2012-04-04|2012-04-06|Estimate|||||||2012-08-01|2012-08-02|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|MM||Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma|A Multicenter, Single Arm, Open Label Study of Autologous Stem Cell Transplantation With High Dose Melphalan in Patients With Multiple Myeloma|Unknown status|Recruiting|N/A|60|Anticipated|Shandong Lanjin Pharmaceuticals Co.,Ltd||1|||f||||t||||||||||2018-05-31 21:28:58.172759|2018-05-31 21:28:58.172759
NCT01572675|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|2016-04-15||2016-04-15|2012-04-04|2012-04-06|Estimate|2016-04-15|2016-05-25|Estimate||||2016-04-15|2016-05-25|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|COXIBUS||A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)|Pharmacoepidemiological Study on the Use of Arcoxia® Under Actual Conditions of Use in France|Completed|||547|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-05-31 21:28:58.328163|2018-05-31 21:28:58.328163
NCT01572662|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-01-09|2012-04-05|2012-04-06|Estimate|||||||2018-01-09|2018-01-11|Actual|April 2012|Actual|2012-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning|Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 2|200|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 21:28:59.891769|2018-05-31 21:28:59.891769
NCT01572649|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2014-05-22|2012-04-04|2012-04-06|Estimate|||||||2014-05-22|2014-05-23|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Paediatric (10 - 17 Years Old) and Adult Patients With Type 2 Diabetes|Completed||Phase 1|24|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:28:59.989493|2018-05-31 21:28:59.989493
NCT01572636|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-12-03|2012-04-04|2012-04-06|Estimate|||||||2017-12-03|2017-12-05|Actual|March 28, 2012|Actual|2012-03-28|December 2017|2017-12-31|July 17, 2018|Anticipated|2018-07-17|July 17, 2018|Anticipated|2018-07-17||Observational|||Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome|MT2011-21C Laronidase (Aldurazyme TM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH).|Active, not recruiting|||20|Actual|Masonic Cancer Center, University of Minnesota|||1||f||||f||||||||||2018-05-31 21:29:00.082787|2018-05-31 21:29:00.082787
NCT01572623|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-05|2012-04-05|2012-04-06|Estimate|||||||2012-04-05|2012-04-06|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|ARMYDA-CARO||Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting|Efficacy of Two Different Pre-Intervention Therapeutic Strategies With Clopidogrel and Atorvastatin for the Prevention of Cerebral Damage During Carotid Artery Stenting. Armyda-Caro Randomized Trial.|Unknown status|Recruiting|Phase 4|150|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||||2018-05-31 21:29:00.141883|2018-05-31 21:29:00.141883
NCT01572610|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-02-28|2012-04-05|2012-04-06|Estimate|||||||2017-02-28|2017-03-03|Actual|February 2012|Actual|2012-02-29|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus|A Phase 2 GFR Measuring Study of RTA 402 in CKD Patients With Type 2 Diabetes Mellitus|Terminated||Phase 2|11|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 21:29:00.217194|2018-05-31 21:29:00.217194
NCT01572597|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-04-05|2012-04-05|2012-04-06|Estimate|||||||2012-04-05|2012-04-06|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy|Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy.|Unknown status|Recruiting|Phase 4|120|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||t||||||||||2018-05-31 21:29:00.275818|2018-05-31 21:29:00.275818
NCT01572584|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-12-18|2012-04-04|2012-04-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|LUS-PNXsize||Lung Ultrasound in the Evaluation of Pneumothorax Size|Accuracy of Lung Ultrasound in the Prediction of Pneumothorax Volume Assessed by CT Scan|Completed|||115|Actual|San Luigi Gonzaga Hospital|||||f||||f||||||||||2018-05-31 21:29:00.359317|2018-05-31 21:29:00.359317
NCT01572571|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-12-18|2012-04-05|2012-04-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|US-UHP||Ultrasound in Undifferentiated Hypotension|Focused Multiorgan Ultrasound in the Emergency Evaluation of Undifferentiated Hypotension|Completed|||100|Actual|San Luigi Gonzaga Hospital|||||f||||f||||||||||2018-05-31 21:29:00.551602|2018-05-31 21:29:00.551602
NCT01572558|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-10-15|2012-04-04|2012-04-06|Estimate|||||||2012-10-15|2012-10-17|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|CONSAPP Pilot||Conservative Treatment of Acute Appendicitis in Children|Conservative Treatment of Acute Appendicitis in Children Pilot Trial|Completed||N/A|51|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 21:29:00.619237|2018-05-31 21:29:00.619237
NCT01572545|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-01-15|2012-04-05|2012-04-06|Estimate|||||||2013-01-15|2013-01-17|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|DenoZol||Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass|Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial|Completed||N/A|91|Actual|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-05-31 21:29:00.711939|2018-05-31 21:29:00.711939
NCT01572532|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-08-18|2012-04-04|2012-04-06|Estimate|||||||2014-08-18|2014-08-20|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Maternal Genitourinary Infections and Adverse Perinatal Outcomes|Maternal Genitourinary Infections and Adverse Perinatal Outcomes in Sylhet District, Bangladesh|Unknown status|Recruiting|Phase 3|9000|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 21:29:00.814661|2018-05-31 21:29:00.814661
NCT01572519|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-06-22|2012-04-04|2012-04-06|Estimate|||||||2017-06-22|2017-06-23|Actual|June 1, 2012|Actual|2012-06-01|June 2017|2017-06-30|August 13, 2013|Actual|2013-08-13|August 13, 2013|Actual|2013-08-13||Interventional|||A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma|An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma|Completed||Phase 1|21|Actual|Janssen Research & Development, LLC||1|||f||||t||f||||||||2018-05-31 21:29:00.914495|2018-05-31 21:29:00.914495
NCT01572506|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-05-26|2012-04-05|2012-04-06|Estimate|||||||2018-05-26|2018-05-30|Actual|March 29, 2012||2012-03-29|May 23, 2018|2018-05-23|July 30, 2015|Actual|2015-07-30|July 30, 2015|Actual|2015-07-30||Interventional|||Mechanisms Accounting for Unexplained Anemia in the Elderly|Assessing Mechanisms Accounting for Unexplained Anemia in the Elderly|Completed||N/A|58|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 21:29:01.009643|2018-05-31 21:29:01.009643
NCT01572493|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-03-23|2012-04-05|2012-04-06|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 4, 2012||2012-04-04|March 9, 2018|2018-03-09|April 1, 2022|Anticipated|2022-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Continuous Infusion of rhIL-15 for Adults With Advanced Cancer|A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers|Recruiting||Phase 1|52|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 21:29:01.170685|2018-05-31 21:29:01.170685
NCT01572480|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2018-05-12|2012-04-05|2012-04-06|Estimate|||||||2018-05-12|2018-05-15|Actual|March 28, 2012||2012-03-28|December 17, 2017|2017-12-17|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma|Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Clinical and Correlative Study|Recruiting||Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:29:01.284691|2018-05-31 21:29:01.284691
NCT01572467|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2016-07-13|2012-04-05|2012-04-06|Estimate|||||||2016-07-13|2016-07-14|Estimate|April 2012||2012-04-30|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors|DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood|Completed|||50|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:29:01.388854|2018-05-31 21:29:01.388854
NCT01572454|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-12-24|2012-04-04|2012-04-06|Estimate|||||||2013-12-24|2013-12-25|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Dexmedetomidine and Remifentanil Infusion During CABG|The Comparison of Serum Potassium Concentration, Antiarrhythmic Effect, and Myocardial Protective Effect Between Dexmedetomidine and Remifentanil Infusion in Patients Undergoing Coronary Artery Bypass Surgery|Completed||N/A|77|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:29:01.488411|2018-05-31 21:29:01.488411
NCT01572441|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-02-23|2012-04-05|2012-04-06|Estimate|||||||2017-02-23|2017-02-24|Actual|September 2009||2009-09-30|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|PAIT||Parent-Adolescent Interactions and Adolescent Development|Responses During Parent-child Interactions and Alcohol Use Behavior in Adolescents.|Active, not recruiting|||250|Anticipated|George Mason University|||1||f||||t||||||Samples With DNA|"~     Retain saliva sample.~   "|No|We will make data from the proposed laboratory study available to other researchers, after de-identifying study data and after publishing the main manuscripts on the study.|2018-05-31 21:29:01.593217|2018-05-31 21:29:01.593217
NCT01572428|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-03-15|2012-04-04|2012-04-06|Estimate|||||||2017-03-15|2017-03-16|Actual|April 2011||2011-04-30|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|||Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon|Randomized Controlled Trial Comparing the Use of Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon|Active, not recruiting||N/A|950|Anticipated|Indiana University||2|||f||||f||||||||||2018-05-31 21:29:01.669237|2018-05-31 21:29:01.669237
NCT01572402|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-05-09|2012-04-04|2012-04-06|Estimate|||||||2012-05-09|2012-05-10|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Postprandial Insulin Secretion, Oxidative Stress and Gastrointestinal Peptides in Patients With Type 2 Diabetes Versus Healthy Subjects||Completed||N/A|100|Actual|Institute for Clinical and Experimental Medicine||2|||f||||t||||||||||2018-05-31 21:29:01.814446|2018-05-31 21:29:01.814446
NCT01572389|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2017-06-14||2017-06-14|2012-04-03|2012-04-06|Estimate|2017-06-14|2017-11-01|Actual||||2017-06-14|2017-11-01|Actual|November 1, 2012|Actual|2012-11-01|June 2017|2017-06-30|September 30, 2016|Actual|2016-09-30|June 24, 2016|Actual|2016-06-24||Interventional|||Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression|Behavioral Activation Therapy for Rural Veterans With Diabetes and Depression|Completed||N/A|225|Actual|VA Office of Research and Development||2|||f||||t|f|f||||||No||2018-05-31 21:29:01.903751|2018-05-31 21:29:01.903751
NCT01572376|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2015-08-24|2012-04-04|2012-04-06|Estimate|||||||2015-08-24|2015-08-25|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Autologous Bone Marrow Stem Cells in Pressure Ulcer Treatment|Treatment of Pressure Ulcers With Autologous Bone Marrow Stem Cells in Spinal Cord Injury Patients.Phase I/II Study.|Completed||Phase 1/Phase 2|30|Actual|Hospital Universitario Central de Asturias||1|||f||||f||||||||||2018-05-31 21:29:02.206542|2018-05-31 21:29:02.206542
NCT01572363|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-03-04|2012-04-05|2012-04-06|Estimate|||||||2014-03-04|2014-03-05|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Fontan Patients: Comprehensive Evaluation of Pulmonary Circulation and Ventricular Function|Fontan Patients: Comprehensive Evaluation of the Pulmonary Circulation to Identify Pulmonary Vascular Disease and Its Influence on Ventricular Hemodynamics.|Completed||N/A|10|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 21:29:02.268982|2018-05-31 21:29:02.268982
NCT01572350|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-04-04|2012-04-04|2012-04-06|Estimate|||||||2012-04-04|2012-04-06|Estimate|October 2010||2010-10-31|April 2011|2011-04-30||||October 2012|Anticipated|2012-10-31||Interventional|ALBA||Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema|Randomized Multicenter Clinical Trial of Three Parallel Groups to Estimate the Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema.|Unknown status|Recruiting|Phase 3|105|Anticipated|Hospital Universitario de Canarias||3|||f||||||||||||||2018-05-31 21:29:02.339259|2018-05-31 21:29:02.339259
NCT01572337|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-02-26|2012-04-03|2012-04-06|Estimate|||||||2018-02-26|2018-02-27|Actual|April 2012||2012-04-30|February 2018|2018-02-28|May 2020||2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|e-NIV||Early Non-invasive Ventilation Outside the Intensive Care Unit|Reducing the Need for Intensive Care Unit in Hospitalized Patients With Early Respiratory Failure Using the Non-invasive Ventilation Technique. A Multicentre Randomized Study.|Recruiting||Phase 4|520|Anticipated|Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-05-31 21:29:02.644475|2018-05-31 21:29:02.644475
NCT01572324|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-01-02|2012-04-04|2012-04-06|Estimate|||||||2017-01-02|2017-01-04|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas|Phase II Study of Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil in Patients With Unresectable Biliary Tract Carcinomas|Completed||Phase 2|37|Actual|Peking University||1|||f||||t||||||||||2018-05-31 21:29:02.742194|2018-05-31 21:29:02.742194
NCT01572311|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-10-24|2012-04-05|2012-04-06|Estimate|||||||2014-10-24|2014-10-28|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|HM2||Dual Task Aerobic Exercise for Older Adults With Cognitive Impairment (HM2)|Study of Community Based Dual Task and Aerobic Exercise Intervention on Cognition and Mobility in Older Adults Without Dementia|Completed||N/A|44|Actual|Parkwood Hospital, London, Ontario||2|||f||||f||||||||||2018-05-31 21:29:02.830849|2018-05-31 21:29:02.830849
NCT01572298|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|2014-10-01||2017-12-04|2012-04-05|2012-04-06|Estimate|2014-10-01|2014-10-06|Estimate||||2017-12-04|2018-01-02|Actual|April 2012||2012-04-30|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts|A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts.|Completed||N/A|34|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 21:29:02.922466|2018-05-31 21:29:02.922466
NCT01572285|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-04-05|2012-04-05|2012-04-06|Estimate|||||||2012-04-05|2012-04-06|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|May 2012|Anticipated|2012-05-31||Interventional|||Transforaminal Epidural Steroid Injection to Treat Hemiplegic Shoulder Pain|Transforaminal Epidural Steroid Injection to Treat Hemiplegic Shoulder Pain : A Randomized, Sham-Controlled, Proof of Principle Trial|Unknown status|Recruiting|N/A|20|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 21:29:03.123724|2018-05-31 21:29:03.123724
NCT01572272|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2016-11-01|2012-04-04|2012-04-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Comparison of Open Versus Masked Distal EtCO2 Monitoring of Neonates Ventilated With Conventional Ventilation|Comparison of Open Versus Masked Distal EtCO2 Monitoring of Neonates Ventilated With Conventional Ventilation. A Randomized, Multi-Center Study|Completed|||66|Actual|Medtronic - MITG|||2||f||||f||||||||||2018-05-31 21:29:03.207776|2018-05-31 21:29:03.207776
NCT01572259|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2015-11-16|2012-04-04|2012-04-06|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism|Assessment of the Role of the Growth Hormone (GH) Onthe Intestinal Triglyceride-rich-lipoproteins (TRL) Metabolism|Unknown status|Recruiting|Phase 3|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 21:29:03.334723|2018-05-31 21:29:03.334723
NCT01572246|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-02-23|2012-04-04|2012-04-06|Estimate|||||||2017-02-23|2017-02-24|Actual|May 2012||2012-05-31|August 2016|2016-08-31|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Observational|||Effects of Monopolar Electrocautery Use During Surgery on Implanted Cardiac Defibrillators|Effects of Surgical Monopolar Electrocautery and Optimal Electrosurgery Unit Return Pad Placement on Implantable Cardioverter Defibrillators Protocol|Completed|||167|Actual|Oregon Health and Science University|||3||f||||f||||||||||2018-05-31 21:29:03.42646|2018-05-31 21:29:03.42646
NCT01571349|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-24|2012-04-04|2012-04-05|Estimate|||||||2013-12-24|2013-12-25|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura|Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura|Completed|||20|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 21:29:17.172968|2018-05-31 21:29:17.172968
NCT01572233|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2012-12-26|2012-04-04|2012-04-06|Estimate|||||||2012-12-26|2012-12-27|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection|Effects of Personalized Physical Activity and Psycho-Education Program on Patients With Chronic Hepatitis C Infection|Recruiting||N/A|300|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 21:29:03.499472|2018-05-31 21:29:03.499472
NCT01572220|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-12-07|2012-04-05|2012-04-06|Estimate|||||||2017-12-07|2017-12-11|Actual|April 2012||2012-04-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|August 2014|Actual|2014-08-31||Interventional|SECURE||Stress Echo Ultrasound Contrast in an Urban Safety Net Hospital to Refine Ischemia Evaluation|Stress Echo Ultrasound Contrast in an Urban Safety Net Hospital to Refine Ischemia Evaluation|Completed||N/A|240|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||||2018-05-31 21:29:03.577247|2018-05-31 21:29:03.577247
NCT01572207|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2013-08-07||2015-01-22|2012-04-04|2012-04-06|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-22|2015-01-26|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Promoting Physical Activity Behavior in Persons With Multiple Sclerosis|Using Targeted Print-material to Promote Physical Activity Behavior in Adults With Multiple Sclerosis|Completed||N/A|30|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 21:29:03.665821|2018-05-31 21:29:03.665821
NCT01572194|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2018-04-20|2012-04-04|2012-04-06|Estimate|||||||2018-04-20|2018-04-23|Actual|April 2012||2012-04-30|May 2017|2017-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|MUCO-IRC||Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation (MUCO-IRC)|Predictive Value of PIIINP Urinary for the Development of Chronic Renal Failure in Patients With Cystic Fibrosis After Lung Transplantation.|Terminated||N/A|45|Actual|Nantes University Hospital||||no more recruitment in the centers|f||||f||||||||||2018-05-31 21:29:03.934735|2018-05-31 21:29:03.934735
NCT01572181|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-04-04|2012-04-04|2012-04-06|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2012|Actual|2012-04-30|April 2018|2018-04-30|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Interventional|FB4-PEDIA||Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens|Phase 2 Study of a Reduced-toxicity Myeloablative Conditionning Regimen Using Fludarabine and Full Doses of iv Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens|Completed||Phase 2|50|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 21:29:04.004688|2018-05-31 21:29:04.004688
NCT01572168|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-02-03|2012-04-04|2012-04-06|Estimate|||||||2016-02-03|2016-02-05|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Acupuncture for the Treatment of Cancer Related Fatigue|A Phase II Study of Acupuncture for the Treatment of Cancer Related Fatigue in Children and Adolescents With Central Nervous System Tumors|Terminated||Phase 2|7|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||1||slow accrual|f||||f||||||||||2018-05-31 21:29:04.104705|2018-05-31 21:29:04.104705
NCT01572155|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-12-03|2012-04-04|2012-04-06|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pilot Study: Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve|Pilot Study: Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve: Potential New Therapeutic Intervention to Shorten Postoperative Ileus|Completed||N/A|24|Actual|Katholieke Universiteit Leuven||3|||f||||f||||||||||2018-05-31 21:29:04.173701|2018-05-31 21:29:04.173701
NCT01572142|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-09-27|2012-04-05|2012-04-06|Estimate|||||||2017-09-27|2017-09-29|Actual|August 2010||2010-08-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|OLF||Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease|Hyposmia, Cholinergic Denervation and Incipient Cognitive Decline in PD|Completed|||74|Actual|University of Michigan|||1||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-05-31 21:29:04.245845|2018-05-31 21:29:04.245845
NCT01572129|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-04-04|2012-04-04|2012-04-06|Estimate|||||||2012-04-04|2012-04-06|Estimate|November 2011||2011-11-30|April 2012|2012-04-30||||May 2012|Anticipated|2012-05-31||Interventional|||Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy|Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial.|Unknown status|Recruiting|Phase 4|240|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||||2018-05-31 21:29:04.313036|2018-05-31 21:29:04.313036
NCT01572116|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2012-04-04|2012-04-04|2012-04-06|Estimate|||||||2012-04-04|2012-04-06|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Effect of Sufentanil on the Rate of Anesthesia|Comparison the Effect of Lidocaine (With Epinephrine) With and Without Sufentanil on the Rate of Anesthesia of Intra-ligamentary Injection in Teeth With Irreversible Pulpitis|Completed||Phase 2|60|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||||2018-05-31 21:29:04.391704|2018-05-31 21:29:04.391704
NCT01572103|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-04-04|2012-04-04|2012-04-06|Estimate|||||||2012-04-04|2012-04-06|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Coffee Effect in HCV-related Hepatitis|Coffee Consumption and Oxidative DNA Damage, Apoptosis and Collagen Synthesis in HCV-related Liver Disease: a Prospective Randomized Trial.|Completed||Phase 3|40|Actual|Azienda Ospedaliera di Padova||2|||f||||f||||||||||2018-05-31 21:29:04.457212|2018-05-31 21:29:04.457212
NCT01572090|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2016-10-24|2012-04-03|2012-04-05|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2006||2006-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Weight Loss Induced by Bariatric Surgery vs Conventional Treatment|Comparison of Weight Loss Induced by Bariatric Surgery vs Conventional Treatment on Body Composition, Adipokines, Gastro-intestinal Hormones and Cardiometabolic Risk Factors|Active, not recruiting||N/A|600|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||6|||f||||f||||||||No||2018-05-31 21:29:04.526528|2018-05-31 21:29:04.526528
NCT01572077|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2018-04-12|2012-04-03|2012-04-05|Estimate|||||||2018-04-12|2018-04-13|Actual|January 2011|Actual|2011-01-31|April 2018|2018-04-30|July 26, 2017|Actual|2017-07-26|December 31, 2016|Actual|2016-12-31||Interventional|RVMET||Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension|Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension|Completed||N/A|20|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||Undecided||2018-05-31 21:29:04.604506|2018-05-31 21:29:04.604506
NCT01572064|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-09-17|2012-04-04|2012-04-05|Estimate|||||||2012-09-17|2012-09-18|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Mrker||Magnetic Resonance Imaging in the Evaluation of Liver Fibrosis|Magnetic Resonance Imaging in the Evaluation of Hepatic Fibrosis: Search for MRI Biomarker|Completed||N/A|134|Actual|University of Nottingham|||||f||||f||||||||||2018-05-31 21:29:04.678068|2018-05-31 21:29:04.678068
NCT01572051|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-01-14|2012-04-04|2012-04-05|Estimate|||||||2015-01-14|2015-01-15|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|PARQVE||Project Osteoarthritis: Recovering Quality of Life Through Education|Project Osteoarthritis: Recovering Quality of Life Through Education|Completed||N/A|228|Actual|University of Sao Paulo General Hospital||8|||f||||f||||||||||2018-05-31 21:29:04.733793|2018-05-31 21:29:04.733793
NCT01572038|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2018-04-13|2012-04-04|2012-04-05|Estimate|||||||2018-04-13|2018-04-17|Actual|June 1, 2012|Actual|2012-06-01|April 2018|2018-04-30|September 28, 2019|Anticipated|2019-09-28|September 28, 2019|Anticipated|2019-09-28||Interventional|PERUSE||A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer|A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer|Active, not recruiting||Phase 3|1436|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:29:05.018086|2018-05-31 21:29:05.018086
NCT01572025|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-12-08|2012-04-04|2012-04-05|Estimate|||||||2015-12-08|2015-12-09|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|DITTO||Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging|Efficacy of Dehydroepiandrosterone to Overcome the Effect of Ovarian Aging - A Pilot Double Blinded Randomised Controlled Trial|Completed||Phase 3|60|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 21:29:05.689945|2018-05-31 21:29:05.689945
NCT01572012|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-01-22|2012-04-04|2012-04-05|Estimate|||||||2014-01-22|2014-01-24|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers|Phase 1 Open-Label Randomized 4 Period Crossover Study Comparing Safety, Tolerability and PK of Ondansetron Given Subcutaneously With Hylenex Recombinant and Given Alone Intramuscularly, Intravenously and Orally in Healthy Volunteers|Completed||Phase 1|12|Actual|Halozyme Therapeutics||4|||f||||f||||||||||2018-05-31 21:29:05.776722|2018-05-31 21:29:05.776722
NCT01571999|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-07-24|2012-04-03|2012-04-05|Estimate|||||||2017-07-24|2017-07-25|Actual|March 29, 2012|Actual|2012-03-29|July 2017|2017-07-31|June 22, 2012|Actual|2012-06-22|June 22, 2012|Actual|2012-06-22||Interventional|||Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment|A Single-blind, Non-randomized Pharmacokinetic and Safety Study of Single Dose of GSK573719 and GSK573719 + GW642444 Combination in Healthy Subjects and in Subjects With Severe Renal Impairment|Completed||Phase 1|17|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:29:05.860167|2018-05-31 21:29:05.860167
NCT01571986|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-02-26|2012-04-03|2012-04-05|Estimate|||||||2018-02-26|2018-02-27|Actual|February 2012||2012-02-29|February 2018|2018-02-28|May 2020||2020-05-31|May 2020|Anticipated|2020-05-31||Observational|Improving NIV||Improving Non-invasive Ventilation|Improving Non Invasive Ventilation|Recruiting|||750|Anticipated|Università Vita-Salute San Raffaele|||1||f||||f||||||||||2018-05-31 21:29:05.959932|2018-05-31 21:29:05.959932
NCT01571973|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-04-04|2012-04-04|2012-04-05|Estimate|||||||2012-04-04|2012-04-05|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|March 2012|Actual|2012-03-31||Interventional|depression||Evaluation of Pharmaceutical Care in Depressed Outpatients|EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL CARE (DÁDER PROGRAM) IN DEPRESSED OUTPATIENTS TREATED WITH PSYCHOTROPIC|Unknown status|Active, not recruiting|N/A|60|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:29:06.078859|2018-05-31 21:29:06.078859
NCT01571960|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-01-23|2012-04-03|2012-04-05|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|August 2014|Actual|2014-08-31||Interventional|||Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults|A Phase 1 Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost Vaccine Regimen of GEO-D03 DNA and MVA/HIV62B Vaccines in Healthy, HIV-1-Uninfected Vaccinia Naive Adult Participants|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 21:29:06.159417|2018-05-31 21:29:06.159417
NCT01571947|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-07-22|2012-04-04|2012-04-05|Estimate|||||||2014-07-22|2014-07-23|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2012|Actual|2012-06-30||Interventional|||Acute Effects of Dietary Fats and Carbohydrate in Subjects With Metabolic Syndrome|Acute Effects of Dietary Fats and Carbohydrate on Insulinaemia, Lipaemia, Inflammatory Responses and Gastrointestinal Peptide Secretion in Subjects With Metabolic Syndrome|Completed||N/A|30|Actual|Malaysia Palm Oil Board||4|||f||||t||||||||||2018-05-31 21:29:06.241497|2018-05-31 21:29:06.241497
NCT01571934|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-04-24|2012-04-04|2012-04-05|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2011||2011-11-30|April 2017|2017-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|PASs||Inhibitor Development in Patients With Hemophilia A Undergoing Surgery|Inhibitor Development in Patients With Hemophilia A Undergoing Surgery|Completed|||30|Actual|Emory University|||1||f||||f|f|f||||Samples With DNA|"~     Blood drawn during study includes 15 ml within 7 days prior to surgery and 15 ml drawn on~     post-operative days 1, 14 and 90.~      Samples for DNA storage will be generated from blood draw study samples.~   "|Undecided||2018-05-31 21:29:06.330782|2018-05-31 21:29:06.330782
NCT01571921|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-09-13|2012-04-03|2012-04-05|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|GEMM1a||Gamma-delta Tocotrienol as Potential Maintenance Treatment in Women With Metastatic Breast Cancer|Phase 1a: A Randomized, 2-period Cross-over Study to Compare the Bioavailability of Gamma-Delta Tocotrienol (GDT) With That of Tocotrienol Rich Fraction (TRF) in Twelve Healthy Subjects|Completed||Phase 1|12|Actual|Malaysia Palm Oil Board||2|||f||||||||||||||2018-05-31 21:29:06.527302|2018-05-31 21:29:06.527302
NCT01571908|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-07-17|2012-04-04|2012-04-05|Estimate|||||||2015-07-17|2015-07-20|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|MagInRoc||Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study|Rapid Sequence Intubation With Magnesium-rocuronium Compared With Succinylcholine - A Randomised Clinical Study|Completed||Phase 2|280|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 21:29:06.5992|2018-05-31 21:29:06.5992
NCT01571895|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2014-06-25|2012-04-04|2012-04-05|Estimate|||||||2014-06-25|2014-06-26|Estimate|July 2011||2011-07-31|June 2014|2014-06-30||||July 2012|Actual|2012-07-31||Interventional|||Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid|A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid.|Terminated||Phase 2|4|Actual|Dompé Farmaceutici S.p.A||1||Limited efficacy response observed at 1/3 enrollment at investigated dosage.|f||||t||||||||||2018-05-31 21:29:06.71364|2018-05-31 21:29:06.71364
NCT01571882|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-11-23|2012-04-04|2012-04-05|Estimate|||||||2016-11-23|2016-11-25|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Effects of Fermented Milk Product Enriched With Plant Sterols and Policosanols in Mild Hypercholesterolaemic Adults|Effects of the Consumption of a no Added Sugar Fermented Milk Product Enriched With Plant Sterols and Policosanols on Hypercholesterolaemia Management in Moderately Hypercholesterolaemic Adults|Completed||N/A|72|Actual|Danone Research||3|||f||||f||||||||||2018-05-31 21:29:06.824478|2018-05-31 21:29:06.824478
NCT01571869|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-12-06|2012-04-04|2012-04-05|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2005||2005-04-30|December 2016|2016-12-31|April 2006|Actual|2006-04-30|December 2005|Actual|2005-12-31||Interventional|||Pilot Study in the Cholesterol Absorption Reduction After Consumption of Low-fat, Drinkable Fermented Milk Enriched With Plant Sterols|Influence of a Meal on the Efficacy of Plant Sterol Given at Different Times of the Day in Management of Hypercholesterolemia|Completed||N/A|30|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 21:29:06.907539|2018-05-31 21:29:06.907539
NCT01571856|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-05-05|2012-04-04|2012-04-05|Estimate|||||||2013-05-05|2013-05-07|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants|Efficacy of Use of Zinc in the Treatment of Acute Diarrhea in Infants Under Six Months.|Completed||Phase 4|52|Actual|Centro Pediatrico Albina de Patino||2|||f||||f||||||||||2018-05-31 21:29:06.970209|2018-05-31 21:29:06.970209
NCT01571843|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-04-07|2012-04-03|2012-04-05|Estimate|||||||2015-04-07|2015-04-09|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Radius Loading in Primary Hyperparathyroidism|Effect of Mechanical Loading on Radius Bone Density and Microarchitecture in Primary Hyperparathyroidism|Completed||N/A|12|Actual|Columbia University||4|||f||||f||||||||||2018-05-31 21:29:07.042935|2018-05-31 21:29:07.042935
NCT01571830|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2015-08-05|2012-04-03|2012-04-05|Estimate|||||||2015-08-05|2015-08-06|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Improving Nutrient Intake and Growth in Children With Multiple Food Allergies|Improving Nutrient Intake and Growth in Children With Multiple Food Allergies|Completed|||43|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-05-31 21:29:07.124083|2018-05-31 21:29:07.124083
NCT01571817|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-08-07|2012-04-04|2012-04-05|Estimate|||||||2013-08-07|2013-08-09|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Pancreatic Islet Transplantation Into the Gastric Submucosa|Treatment of Type I Diabetes by Pancreatic Islet Transplantation Into The Gastric Submucosa|Unknown status|Enrolling by invitation|Phase 1|4|Anticipated|University of California, San Francisco|||||f||||f||||||||||2018-05-31 21:29:07.178314|2018-05-31 21:29:07.178314
NCT01571804|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2012-05-04|2012-04-03|2012-04-05|Estimate|||||||2012-05-04|2012-05-07|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Pregabalin Reduce the Sevoflurane Requirement|Does Pregabalin Reduce the Sevoflurane Requirement During Laparoscopic Cholecystectomy? Mansoura University Hospitals Experience.|Completed||Phase 2|42|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 21:29:07.227285|2018-05-31 21:29:07.227285
NCT01571791|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2015-03-15|2012-04-04|2012-04-05|Estimate|||||||2015-03-15|2015-03-17|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery|A Randomized Study of the Effects of Perioperative i.v. Ketorolac-lidocaine on the Hemodynamic Response in the Patients With Valvular Heart Diseases During Cesarean Delivery|Unknown status|Recruiting|Phase 2|90|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 21:29:07.293524|2018-05-31 21:29:07.293524
NCT01571778|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-11-30|2012-04-03|2012-04-05|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Hand Hygiene Before Non-sterile Glove Use|The Utility of Hand Hygiene Before Non-sterile Glove Use|Completed||N/A|230|Actual|University of Maryland||2|||f||||||||||||||2018-05-31 21:29:07.402831|2018-05-31 21:29:07.402831
NCT01571765|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-05-04|2012-04-04|2012-04-05|Estimate|||||||2015-05-04|2015-05-06|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|HCUM||MNCH Programming in Southwest Uganda Maternal and Child Health In Bushenyi and Rubirizi Districts, UGANDA|Scaling Up Maternal and Child Health In Bushenyi and Rubirizi Districts, UGANDA|Completed||N/A|10985|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 21:29:07.498502|2018-05-31 21:29:07.498502
NCT01571752|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-05-19|2012-04-04|2012-04-05|Estimate|||||||2018-05-19|2018-05-22|Actual|March 8, 2012||2012-03-08|April 27, 2018|2018-04-27||||||||Observational|||Health Outcomes by Neighborhood - Baltimore|Health Outcomes by Neighborhood - HON Study Baltimore|Recruiting|||1550|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:07.569916|2018-05-31 21:29:07.569916
NCT01571739|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-05-15|2012-04-04|2012-04-05|Estimate|||||||2018-05-15|2018-05-16|Actual|January 2, 2012||2012-01-02|May 20, 2014|2014-05-20|May 20, 2014||2014-05-20|||||Observational|||Determining Risk in Latent Tuberculosis|Risk Stratification in Latent Tuberculosis: PET/CT Findings in TB Contacts|Terminated|||18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:08.667311|2018-05-31 21:29:08.667311
NCT01571726|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-05-16|2012-04-04|2012-04-05|Estimate|||||||2018-05-16|2018-05-17|Actual|March 27, 2012||2012-03-27|April 16, 2014|2014-04-16|April 23, 2014|Actual|2014-04-23|April 23, 2014|Actual|2014-04-23||Interventional|||Imaging Studies and the Development of Multiple Myeloma|Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:08.73899|2018-05-31 21:29:08.73899
NCT01571713|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-10-14|2012-04-03|2012-04-05|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Side Effects of Pulmonary Hypertension Medications|Patient Reported Side Effects of Pulmonary Hypertension (PH) Medications|Recruiting|||100|Anticipated|Stanford University|||1||f||||t||||||||No||2018-05-31 21:29:08.80303|2018-05-31 21:29:08.80303
NCT01571700|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-10-14|2012-04-04|2012-04-05|Estimate|||||||2016-10-14|2016-10-17|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Investigation of Dysynchrony in Patients With Pulmonary Hypertension|Investigation of Dysynchrony in Patients With Pulmonary Hypertension|Recruiting|||100|Anticipated|Stanford University|||2||f||||t||||||||Yes|Publication|2018-05-31 21:29:08.865185|2018-05-31 21:29:08.865185
NCT01571687|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-04-03|2012-04-03|2012-04-05|Estimate|||||||2012-04-03|2012-04-05|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PLHARE||Pik Lenin High Altitude Research Expedition 2009|Pik Lenin High Altitude Research Expedition 2009, a Follow-up Project of the Muztagh Ata High Altitude Research Expedition 2005|Completed||N/A|30|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 21:29:08.942734|2018-05-31 21:29:08.942734
NCT01571674|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-05-13|2012-04-04|2012-04-05|Estimate|||||||2016-05-13|2016-05-17|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Validation of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation: A Randomized Clinical Trial|Validation of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation: A Randomized Clinical Trial|Completed||Phase 2/Phase 3|140|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 21:29:09.041185|2018-05-31 21:29:09.041185
NCT01571661|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-04-03|2012-04-03|2012-04-05|Estimate|||||||2012-04-03|2012-04-05|Estimate|September 2004||2004-09-30|April 2012|2012-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|A Double Blind, Randomized, Placebo Controlled, Single-dose Escalation, First-time-in-human Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|16|Actual|GlaxoSmithKline||8|||f||||f||||||||||2018-05-31 21:29:09.138849|2018-05-31 21:29:09.138849
NCT01571648|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-06-14|2012-04-04|2012-04-05|Estimate|||||||2013-06-14|2013-06-17|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes|A Phase 1, Multicenter, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Subjects With Myelodysplastic Syndromes|Completed||Phase 1|5|Actual|Celgene||1|||f||||f||||||||||2018-05-31 21:29:10.008338|2018-05-31 21:29:10.008338
NCT01571635|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03||2015-12-11|2018-05-14|2012-04-04|2012-04-05|Estimate||||2016-04-01|2016-05-02|Estimate|2018-05-14|2018-05-16|Actual|October 10, 2012|Actual|2012-10-10|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|July 2, 2015|Actual|2015-07-02||Interventional|||Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.|A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA.|Active, not recruiting||Phase 2|46|Actual|Celgene||6|||f||||f||||||||||2018-05-31 21:29:10.099608|2018-05-31 21:29:10.099608
NCT01571622|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-03-27|2012-04-03|2012-04-05|Estimate|||||||2014-03-27|2014-03-31|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|WheyGLP-1||Whey Protein on Posprandial Glucose, Insulin GLP-1, GIP and DPP4 in Type 2 Diabetes|Effect of Whey Protein Concentrate on Postprandial Glycemic Insulin, Active and Intact GLP-1and GIP, and DPP-4 Response in Type 2 Diabetic Patients|Completed||N/A|19|Actual|Tel Aviv University||2|||f||||t||||||||||2018-05-31 21:29:10.189692|2018-05-31 21:29:10.189692
NCT01571609|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2014-12-01|2012-04-04|2012-04-05|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|July 2013|Actual|2013-07-31||Interventional|||Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders|Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders|Completed||N/A|40|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:29:10.265863|2018-05-31 21:29:10.265863
NCT01571596|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23||2015-01-12|2016-06-10|2012-04-03|2012-04-05|Estimate||||2015-01-12|2015-01-26|Estimate|2016-06-10|2016-06-14|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|||An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia|An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia|Completed||Phase 1/Phase 2|23|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-05-31 21:29:10.348945|2018-05-31 21:29:10.348945
NCT01571583|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-06-29|2012-04-03|2012-04-05|Estimate|||||||2016-06-29|2016-06-30|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|REPLACE||An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation|Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects|Completed||Phase 3|74|Actual|Janssen-Cilag International NV||1|||f||||t||||||||||2018-05-31 21:29:10.442648|2018-05-31 21:29:10.442648
NCT01571570|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-06-24|2012-04-03|2012-04-05|Estimate|||||||2013-06-24|2013-06-25|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess Bioavailability & Food Effect of Different Liquid and Capsule Formulations of TMC435.|A Phase I, Open-Label, Randomized, 3-Panel, 3-way Crossover Trial in Healthy Adult Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of 2 Liquid Formulations or 2 Different Capsule Concept Formulations Compared ot the Phase III 150 mg Capsule, and to Assess the Effect of Food on the Bioavailability of TMC435 Following Administration of the Liquid Formulations.|Completed||Phase 1|72|Actual|Janssen R&D Ireland||9|||f||||f||||||||||2018-05-31 21:29:10.677648|2018-05-31 21:29:10.677648
NCT01571557|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|2015-06-22||2015-06-22|2012-04-03|2012-04-05|Estimate|2015-06-22|2015-07-20|Estimate||||2015-06-22|2015-07-20|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)||Completed|||573|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:29:10.797745|2018-05-31 21:29:10.797745
NCT01571544|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-01-03|2012-04-04|2012-04-05|Estimate|||||||2017-01-03|2017-01-04|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|November 2014|Actual|2014-11-30|April 2013|Actual|2013-04-30||Interventional|||The Use of Thermal Suits as Preventing Hypothermia During Surgery|The Use of Thermal Suits as Preventing Hypothermia During Surgery|Completed||Phase 4|100|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 21:29:11.013523|2018-05-31 21:29:11.013523
NCT01571518|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-04-03|2012-04-03|2012-04-05|Estimate|||||||2012-04-03|2012-04-05|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy|Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Sunchonhang University||2|||f||||t||||||||||2018-05-31 21:29:11.183264|2018-05-31 21:29:11.183264
NCT01571505|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-08-30|2012-04-03|2012-04-05|Estimate|||||||2017-08-30|2017-08-31|Actual|March 1, 2012|Actual|2012-03-01|August 2017|2017-08-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE)|Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA|Completed||Phase 1|372|Actual|International Vaccine Institute||2|||f||||f||||||||||2018-05-31 21:29:11.2761|2018-05-31 21:29:11.2761
NCT01571492|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-06-05|2012-04-04|2012-04-05|Estimate|||||||2017-06-05|2017-06-07|Actual|June 2009||2009-06-30|June 2017|2017-06-30|June 2015|Actual|2015-06-30|October 2010|Actual|2010-10-31||Interventional|||Continuous L2 Paravertebral Block Versus Continuous Lumbar Plexus Block for Postoperative Analgesia|Continuous L2 Paravertebral Block Versus Continuous Lumbar Plexus Block for Postoperative Analgesia After Total Hip Arthroplasty|Completed||N/A|60|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 21:29:11.365812|2018-05-31 21:29:11.365812
NCT01571479|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2012-04-03|2012-04-03|2012-04-05|Estimate|||||||2012-04-03|2012-04-05|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|April 2011|Actual|2011-04-30||Interventional|||The Feasibility and Safety of a Three-Port Laparoscopic Cholecystectomy Using a 2-mm Mini-Instrument|The Feasibility and Safety of a Three-Port Laparoscopic Cholecystectomy Using a 2-mm Mini-Instrument|Completed||N/A|133|Actual|Inje University||2|||f||||f||||||||||2018-05-31 21:29:11.439741|2018-05-31 21:29:11.439741
NCT01571466|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2015-03-31|2012-04-03|2012-04-05|Estimate|||||||2015-03-31|2015-04-01|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|2009-016578-34||A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART|A Double-blind Phase I Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART|Completed||Phase 1|30|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 21:29:11.516812|2018-05-31 21:29:11.516812
NCT01571453|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2014-10-06||2014-10-06|2012-04-03|2012-04-05|Estimate|2014-10-06|2014-10-13|Estimate||||2014-10-06|2014-10-13|Estimate|May 2012||2012-05-31|October 2014|2014-10-31||||October 2013|Actual|2013-10-31||Interventional||"The all-patients-treated set (APTS) comprises all randomized patients who took at least one dose of IMP.~Baseline age and gender is based on the APTS. Baseline efficacy outcome measures is based on the full-analysis set (FAS)."|Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries|Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries|Completed||Phase 3|437|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 21:29:11.617754|2018-05-31 21:29:11.617754
NCT01571440|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2014-02-07|2012-04-04|2012-04-05|Estimate|||||||2014-02-07|2014-02-10|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Soluble Corn Fiber and Calcium Utilization in Adolescents|The Effect of Soluble Corn Fiber on Calcium Utilization and Retention and Gut Microflora in Adolescents|Completed||N/A|24|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 21:29:12.115154|2018-05-31 21:29:12.115154
NCT01571427|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-08-08|2012-04-04|2012-04-05|Estimate|||||||2016-08-08|2016-08-10|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|conversation||Conversations as a Means to Delay the Onset of Alzheimer's Disease|Conversational Engagement as a Means to Delay Alzheimer's Disease Onset|Completed||Early Phase 1|96|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 21:29:12.211233|2018-05-31 21:29:12.211233
NCT01571414|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-04-02|2012-04-03|2012-04-05|Estimate|||||||2015-04-02|2015-04-03|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin|A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin|Completed||Phase 1|52|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 21:29:12.314414|2018-05-31 21:29:12.314414
NCT01571401|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-06-17|2012-04-04|2012-04-05|Estimate|||||||2013-06-17|2013-06-19|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TRACKS||Trying Activity in Kidney Cancer Survivors (TRACKS) Trial|Trying Activity in Kidney Cancer Survivors (TRACKS) Trial: A Randomized Controlled Trial Comparing the Effects of Supervised Physical Activity Versus Supervised Physical Activity Plus Behavioural Counselling|Completed||Phase 2|32|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 21:29:12.459944|2018-05-31 21:29:12.459944
NCT01571388|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-12-16|2012-04-04|2012-04-05|Estimate|||||||2013-12-16|2013-12-18|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study To Compare Pharmacokinetics Of Dacomitinib (PF-00299804) Between Healthy Subjects And Subjects With Mild And Moderate Hepatic Impairment|A Phase 1 Study To Evaluate The Single Dose Pharmacokinetics Of Dacomitinib (PF-00299804) In Subjects With Impaired Hepatic Function|Completed||Phase 1|25|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:29:12.565284|2018-05-31 21:29:12.565284
NCT01571375|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2018-02-26|2012-04-02|2012-04-05|Estimate|||||||2018-02-26|2018-02-27|Actual|June 2012||2012-06-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Observational|||The Effect of Different Emergency Medical Systems on the Prognosis of Traumatic Brain Injury - a Prospective Study|The Differences Between Out-of-hospital Severe Traumatic Brain Injury (TBI) Treatment in a Physician-staffed Versus Paramedic-staffed Emergency Medical Service (EMS) Unit and Its Effect on Patient Prognosis|Suspended|||400|Anticipated|Tampere University Hospital|||2||f||||f||||||||||2018-05-31 21:29:12.688982|2018-05-31 21:29:12.688982
NCT01571362|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|2016-10-06|2014-08-04|2017-02-17|2012-04-03|2012-04-05|Estimate|2017-02-17|2017-04-04|Actual|2014-08-04|2014-08-07|Estimate|2017-02-17|2017-04-04|Actual|June 2012||2012-06-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain|A Multicenter, 12 Week, Double-blind, Placebo-controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Subjects With Moderate To Severe Chronic Low Back Pain|Completed||Phase 3|410|Actual|Pfizer||2|||f||||f|t|f||||||||2018-05-31 21:29:13.453269|2018-05-31 21:29:13.453269
NCT01571336|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2016-09-26|2012-04-03|2012-04-05|Estimate|||||||2016-09-26|2016-09-27|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Observational|||Photodynamic Therapy of Actinic Keratoses With Alacare®|Non-interventional Observational Study on Photodynamic Therapy of Actinic Keratoses With Alacare®|Completed|||388|Actual|photonamic GmbH & Co. KG|||||f||||t||||||||||2018-05-31 21:29:17.255823|2018-05-31 21:29:17.255823
NCT01571323|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-10-10|2012-04-04|2012-04-05|Estimate|||||||2012-10-10|2012-10-11|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Combined Use of Oxytocin and Misoprostol Versus Oxytocin Infusion and Misoprostol Alone to Reduce Blood Loss at Cesarean Section||Completed||Phase 1/Phase 2|150|Actual|Qazvin University Of Medical Sciences||3|||f||||t||||||||||2018-05-31 21:29:17.315158|2018-05-31 21:29:17.315158
NCT01571310|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-10-10|2012-04-04|2012-04-05|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2012|Actual|2012-07-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|OB-B||Effect of Breakfast or Omission of Breakfast in T2D|Effect of Breakfast Omission on Postprandial Glycemia After Lunch and Dinner in T2D|Completed||N/A|30|Actual|Tel Aviv University||2|||f||||t||||||||||2018-05-31 21:29:17.47312|2018-05-31 21:29:17.47312
NCT01571297|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02||2014-11-06|2016-09-21|2012-04-04|2012-04-05|Estimate||||2014-11-06|2014-11-19|Estimate|2016-09-21|2016-09-23|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis|Completed||Phase 2|204|Actual|Motus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 21:29:17.553067|2018-05-31 21:29:17.553067
NCT01571284|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|2018-01-29||2018-03-19|2012-04-03|2012-04-05|Estimate|2018-01-29|2018-02-27|Actual||||2018-03-19|2018-04-17|Actual|May 30, 2012|Actual|2012-05-30|March 2018|2018-03-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional||Safety population defined as the participants who signed the informed consent form and received at least part of one dose of study treatment.|Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen|A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen|Completed||Phase 3|781|Actual|Sanofi||1|||f||||f|t|f||||||||2018-05-31 21:29:17.761715|2018-05-31 21:29:17.761715
NCT01571271|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-03-28|2012-04-03|2012-04-05|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2010||2010-01-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|EHLvlaser||Electrohydraulic Versus Laser Lithotripsy for Treatment of Difficult to Remove Biliary Stones|Electrohydraulic Versus Laser Lithotripsy for Treatment of Difficult to Remove Biliary Stones|Completed||N/A|25|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 21:29:19.425663|2018-05-31 21:29:19.425663
NCT01571258|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-04-04|2012-04-04|2012-04-05|Estimate|||||||2012-04-04|2012-04-05|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|Text4Diet||Text4Diet: A Text Messaging Program for Weight Loss|Text4Diet: A Text Messaging Program for Weight Loss|Completed||N/A|170|Actual|Santech, Inc||2|||f||||f||||||||||2018-05-31 21:29:19.662427|2018-05-31 21:29:19.662427
NCT01571245|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-12-14|2012-04-03|2012-04-05|Estimate|||||||2015-12-14|2015-12-15|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Predicting Treatment Response Using Psychophysiologic Reactivity Measures|Predicting Treatment Response Using Psychophysiologic Reactivity Measures|Completed|||9|Actual|Central Arkansas Veterans Healthcare System|||1||f||||f||||||||||2018-05-31 21:29:19.7502|2018-05-31 21:29:19.7502
NCT01571232|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|2017-04-26||2017-04-26|2012-04-04|2012-04-05|Estimate|2017-04-26|2017-05-31|Actual||||2017-04-26|2017-05-31|Actual|April 2012||2012-04-30|April 2017|2017-04-30|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|||Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema|Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.|Completed||Phase 2|20|Actual|Retina Macula Institute||2|||f||||f||||||||||2018-05-31 21:29:19.824152|2018-05-31 21:29:19.824152
NCT01571219|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-07-30|2012-04-03|2012-04-05|Estimate|||||||2017-07-30|2017-08-01|Actual|March 2012||2012-03-31|July 2017|2017-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1|An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-Administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab(Remicade or CP-P13) in Study CT-P13 3.1|Completed||Phase 3|302|Actual|Celltrion||1|||f||||f||||||||||2018-05-31 21:29:20.065458|2018-05-31 21:29:20.065458
NCT01571206|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-07-30|2012-04-04|2012-04-05|Estimate|||||||2013-07-30|2013-07-31|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||An Extension Study to Demonstrate the Equivalence of Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1|An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 1.1|Completed||Phase 1|174|Actual|Celltrion||1|||f||||f||||||||||2018-05-31 21:29:20.142345|2018-05-31 21:29:20.142345
NCT01571180|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-05-17|2012-04-04|2012-04-05|Estimate|||||||2017-05-17|2017-05-18|Actual|April 2012||2012-04-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|INOGMA||Influence of Obesity and Gastric Bypass on Medication Absorption|Influence of Obesity and Gastric Bypass on Medication Absorption: Prospective Follow-up of Patients|Active, not recruiting|||100|Anticipated|Katholieke Universiteit Leuven|||1||f||||t||||||||||2018-05-31 21:29:20.20842|2018-05-31 21:29:20.20842
NCT01571167|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2013-06-12|2012-04-03|2012-04-05|Estimate|||||||2013-06-12|2013-06-13|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Varenicline||Varenicline as a Treatment for Methamphetamine Dependence|A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline in Methamphetamine-Dependent Volunteers Receiving Methamphetamine|Completed||Phase 1|17|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 21:29:20.343655|2018-05-31 21:29:20.343655
NCT01571141|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-04-18|2012-04-03|2012-04-05|Estimate|||||||2012-04-18|2012-04-19|Estimate||||June 2011|2011-06-30||||||||Interventional|||Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||f||||||||||2018-05-31 21:29:20.463697|2018-05-31 21:29:20.463697
NCT01571128|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-03-14|2012-04-02|2012-04-05|Estimate|||||||2017-03-14|2017-03-15|Actual|November 2014|Actual|2014-11-30|March 2017|2017-03-31|March 23, 2016|Actual|2016-03-23|March 23, 2016|Actual|2016-03-23||Interventional|MP3-Youth||Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)|Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)|Completed||Phase 4|1215|Actual|New York University||5|||f||||f||||||||||2018-05-31 21:29:20.547163|2018-05-31 21:29:20.547163
NCT01571115|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2014-08-12|2012-04-02|2012-04-04|Estimate|||||||2014-08-12|2014-08-15|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|IER||Effects of Resistance Physical Exercise in Patients With Chronic Primary Insomnia|Effects of Resistance Physical Exercise in Patients With Chronic Primary|Completed||N/A|30|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 21:29:20.665054|2018-05-31 21:29:20.665054
NCT01571102|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2014-12-04|2012-04-02|2012-04-04|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Impact of Physiotherapy on Short-term Outcome After Meniscectomy|Study of Impact of Physiotherapy on Short-term Outcome After Meniscectomy.|Unknown status|Recruiting|N/A|180|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-05-31 21:29:20.755994|2018-05-31 21:29:20.755994
NCT01571089|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2015-05-19|2012-04-02|2012-04-04|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Anxiety Treatment Inspired by Dialectical Behavior Therapy (DBT)|Anxiety Treatment Inspired by Dialectical Behavior Therapy (DBT) - An Alternative for Patients Who Previously Received Exposure-based Treatment for Anxiety Without Sustained Improvements.|Completed||N/A|5|Actual|Örebro County Council||1|||f||||f||||||||||2018-05-31 21:29:20.86373|2018-05-31 21:29:20.86373
NCT01571076|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2014-07-10|2012-04-02|2012-04-04|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|February 2015|Anticipated|2015-02-28|September 2014|Anticipated|2014-09-30||Interventional|||Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor|Prospective and Randomized Study of the Use of Comparative Genomic Hybridization (CGH) Arrays to Study Embryo Aneuploidies in Female Advanced Age and Male Factor In Vitro Fertilization (IVF) Patients.|Unknown status|Recruiting|N/A|240|Anticipated|Igenomix||4|||f||||f||||||||||2018-05-31 21:29:20.936567|2018-05-31 21:29:20.936567
NCT01571063|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2016-10-24|2012-04-02|2012-04-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D||Completed||Phase 2|22|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 21:29:21.022808|2018-05-31 21:29:21.022808
NCT01571050|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-04-02|2012-04-02|2012-04-04|Estimate|||||||2012-04-02|2012-04-04|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Systemic Fluoride Bioavailability From Toothpastes Containing Calcium Carbonate or Silica as Abrasives||Completed||Phase 1|20|Actual|University of Campinas, Brazil||5|||f||||f||||||||||2018-05-31 21:29:21.096147|2018-05-31 21:29:21.096147
NCT01571037|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2014-02-28|2012-04-02|2012-04-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study|Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study|Completed||Phase 1|10|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 21:29:21.182509|2018-05-31 21:29:21.182509
NCT01571024|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-04-24|2012-04-02|2012-04-04|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2012||2012-05-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|||BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer|A Phase I Study of BKM120 With mFOLFOX6 in Patients With Advanced Solid Tumors With Expansion Cohort in Metastatic Pancreatic Cancers.|Completed||Phase 1|17|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:29:21.243133|2018-05-31 21:29:21.243133
NCT01571011|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-07-31|2012-04-03|2012-04-04|Estimate|||||||2015-07-31|2015-08-04|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CURB||Chicago Urban Resiliency Building (CURB)|Chicago Urban Resiliency Building (CURB): Phase 3 Clinical Trial in Primary Care to Engage Adolescents With a Web-based Depression Prevention Intervention|Completed||N/A|10|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 21:29:21.320861|2018-05-31 21:29:21.320861
NCT01570998|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2017-10-24|2012-04-02|2012-04-04|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2012||2012-05-31|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery|Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery|Recruiting||N/A|750|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:29:21.418123|2018-05-31 21:29:21.418123
NCT01570985|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-05-26|2012-04-02|2012-04-04|Estimate|||||||2015-05-26|2015-05-28|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Interventional|FSS||Treatment Study of Frozen Shoulder: Corticosteroid Injection in Joint Versus Wait and See Policy|Outcome in Shoulder Capsulitis (Frozen Shoulder) Between Corticosteroid and Corticosteroid With Distension Compared to Wait and See Policy, a Randomised Controlled Trial|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|University of Bergen||3|||f||||t||||||||||2018-05-31 21:29:21.591635|2018-05-31 21:29:21.591635
NCT01570972|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-04-24|2012-04-03|2012-04-04|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2010|Actual|2010-02-28|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis|Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis|Completed||N/A|103|Actual|University of Arizona||1|||f||||f||||||||||2018-05-31 21:29:21.679989|2018-05-31 21:29:21.679989
NCT01570959|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2018-01-19|2012-04-02|2012-04-04|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2007||2007-04-30|January 2018|2018-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions|A Two Period, Two Treatment, Two Way, Steady State Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Fasting Conditions|Completed||N/A|56|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 21:29:21.747705|2018-05-31 21:29:21.747705
NCT01570764|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2018-03-16|2012-04-02|2012-04-04|Estimate|||||||2018-03-16|2018-03-19|Actual|January 14, 2013|Actual|2013-01-14|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|SCLEROCYC||Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease|Intravenous Cyclophosphamide for the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease|Active, not recruiting||Phase 3|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 21:29:23.136346|2018-05-31 21:29:23.136346
NCT01570946|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2015-12-29|2012-04-02|2012-04-04|Estimate|||||||2015-12-29|2015-12-30|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Use of Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK|A Pragmatic and Scalable Strategy Using Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK|Completed||N/A|1171|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals||2|||f||||t||||||||||2018-05-31 21:29:21.801259|2018-05-31 21:29:21.801259
NCT01570933|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-12-06|2012-04-02|2012-04-04|Estimate|||||||2013-12-06|2013-12-09|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|NIVNAVA||Feasibility Study Over the NAVA Mode in Noninvasive Ventilation After Cardiac Surgery in Infants.|Feasibility Study Over the Neurally Adjusted Ventilatory Assist (NAVA) Mode in Noninvasive Ventilation After Cardiac Surgery in Infants.|Completed||Phase 4|10|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 21:29:21.868472|2018-05-31 21:29:21.868472
NCT01570920|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-04-02|2012-04-02|2012-04-04|Estimate|||||||2012-04-02|2012-04-04|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Regular Brisk Walking in Chronic Stroke Patients|Effects of Regular Brisk Walking in Chronic Stroke Patients|Completed||N/A|34|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-05-31 21:29:22.084111|2018-05-31 21:29:22.084111
NCT01570907|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2018-01-19|2012-04-02|2012-04-04|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2007||2007-06-30|January 2018|2018-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fasting Conditions|Completed||N/A|42|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 21:29:22.148407|2018-05-31 21:29:22.148407
NCT01570894|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2018-01-19|2012-04-02|2012-04-04|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2007||2007-07-31|January 2018|2018-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fed Conditions|Completed||N/A|42|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 21:29:22.208871|2018-05-31 21:29:22.208871
NCT01570881|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2012-04-03|2012-04-02|2012-04-04|Estimate|||||||2012-04-03|2012-04-05|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Association of Plasma Melatonin Levels With Delirium|Association of Plasma Melatonin Levels With Delirium After Sevoflurane Anesthesia|Completed|||33|Actual|Okayama University|||1||f||||f||||||||||2018-05-31 21:29:22.266543|2018-05-31 21:29:22.266543
NCT01570868|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2016-05-13|2012-04-02|2012-04-04|Estimate|||||||2016-05-13|2016-05-16|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)|Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase|Terminated||Phase 2|51|Actual|M.D. Anderson Cancer Center||1||Closed due to slow accrual|f||||f||||||||||2018-05-31 21:29:22.349535|2018-05-31 21:29:22.349535
NCT01570855|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2016-04-25|2012-04-02|2012-04-04|Estimate|||||||2016-04-25|2016-04-27|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|May 2014|Actual|2014-05-31||Observational|||Chemotherapy Resistance and Sensitivity Testing in Lung Tumors|Chemotherapy Resistance and Sensitivity Testing in Lung Tumors|Completed|||45|Actual|Marshall University|||||f||||f||||||||||2018-05-31 21:29:22.444733|2018-05-31 21:29:22.444733
NCT01570842|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2014-03-28|2012-04-03|2012-04-04|Estimate|||||||2014-03-28|2014-03-31|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury|The Role of Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury|Completed||N/A|100|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:29:22.498928|2018-05-31 21:29:22.498928
NCT01570829|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-12-25|2012-04-03|2012-04-04|Estimate|||||||2017-12-25|2017-12-27|Actual|December 2011||2011-12-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients|Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients|Completed||Phase 3|332|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 21:29:22.569234|2018-05-31 21:29:22.569234
NCT01570816|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2018-03-12|2012-04-02|2012-04-04|Estimate|||||||2018-03-12|2018-03-14|Actual|April 2012||2012-04-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Improving Ambulatory Community Access After Paralysis|Improving Ambulatory Community Access After Paralysis|Recruiting||Phase 1|6|Anticipated|Louis Stokes VA Medical Center||1|||f||||t||||||||||2018-05-31 21:29:22.734431|2018-05-31 21:29:22.734431
NCT01570803|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2018-03-13|2012-04-03|2012-04-04|Estimate|||||||2018-03-13|2018-03-15|Actual|January 2013|Anticipated|2013-01-31|March 2018|2018-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SENS-FP||Efficacy Between Different Two Self-Expanding Nitinol Stents For The Atherosclerotic Femoro-Popliteal Arterial Disease|Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)|Withdrawn||N/A|0|Actual|Korea University Guro Hospital||2||Study could not be initiated due to lack of research funding from the sponsors.|f||||t||||||||No||2018-05-31 21:29:22.841168|2018-05-31 21:29:22.841168
NCT01570790|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-12-04|2012-04-03|2012-04-04|Estimate|||||||2017-12-04|2017-12-06|Actual|May 2003||2003-05-31|December 2017|2017-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration|An Open Label, Pilot (Phase I/II), Dose-Escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration.|Completed||Phase 1/Phase 2|8|Actual|Johns Hopkins University||3|||||||f||||||||||2018-05-31 21:29:22.927905|2018-05-31 21:29:22.927905
NCT01570777|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-11-03|2012-04-02|2012-04-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|April 2018|Anticipated|2018-04-30|May 2014|Actual|2014-05-31||Interventional|DENER-HTN||Renal Denervation in Hypertension|Renal Denervation in Patients With Resistant Hypertension|Unknown status|Active, not recruiting|Phase 4|121|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:29:23.039476|2018-05-31 21:29:23.039476
NCT01570751|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|2015-10-16|2014-01-24|2017-01-24|2012-04-02|2012-04-04|Estimate|2015-10-16|2015-11-18|Estimate|2014-01-24|2014-02-24|Estimate|2017-01-24|2017-03-07|Actual|April 2012||2012-04-30|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||For 4 subjects baseline fasting plasma glucose (FPG) values were missing, hence did not contribute to the FPG summary.|A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin|A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin|Completed||Phase 3|145|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:29:23.26811|2018-05-31 21:29:23.26811
NCT01570738|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2018-03-04|2012-04-02|2012-04-04|Estimate|||||||2018-03-04|2018-03-06|Actual|July 2012||2012-07-31|March 2018|2018-03-31||||August 2018|Anticipated|2018-08-31||Observational|||Validation of Home Sleep Testing (WP200) Compared to an Overnight Sleep Testing in the Sleep Laboratory|Validation of Home Sleep Testing (WP200) Compared to an Overnight Sleep Testing in the Sleep Laboratory|Recruiting|||150|Anticipated|Itamar-Medical, Israel|||||f||||f||||||||||2018-05-31 21:29:23.696006|2018-05-31 21:29:23.696006
NCT01570725|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2012-04-02|2012-04-02|2012-04-04|Estimate|||||||2012-04-02|2012-04-04|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|VRSurg||Virtual Reality to Reduce Anxiety in Ambulatory Surgical Operations|A Portable Virtual Reality System as an Alternative Medical Treatment to Reduce Anxiety in Ambulatory Surgical Operations: a Randomized Controlled Study|Withdrawn||N/A|0|Actual|Istituto Auxologico Italiano||2||Difficulty in recruiting the selected subjects|f||||t||||||||||2018-05-31 21:29:23.758084|2018-05-31 21:29:23.758084
NCT01570712|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2014-08-29|2012-04-03|2012-04-04|Estimate|||||||2014-08-29|2014-09-01|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|February 2015|Anticipated|2015-02-28|August 2014|Anticipated|2014-08-31||Interventional|||"Evaluation of the Housing First Program in Patients With Severe Mental Disorders in France"|"Evaluation of the Housing First Program in Patients With Severe Mental Disorders in France: a Multicentric Randomized Controlled Study"|Unknown status|Recruiting|N/A|600|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 21:29:23.845224|2018-05-31 21:29:23.845224
NCT01570699|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-09-28|2012-04-02|2012-04-04|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|COM-ON||Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients|COMT Val158Met Polymorphism in Opiate-using Subjects Without Lifetime Opiate Dependence|Completed|||87|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||Samples With DNA|"~     We will compare polymorphism COMT between COM-ON patients and METHADOSE patients. Samples may~     be blood sample or salivary sample.~   "|||2018-05-31 21:29:23.91533|2018-05-31 21:29:23.91533
NCT01570686|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|2013-11-10||2014-01-15|2012-04-02|2012-04-04|Estimate|2013-11-10|2014-01-01|Estimate||||2014-01-15|2014-01-22|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||All Randomized patients (including one mis-randomized patient in Aliskiren:Fed arm).|8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension|An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension|Completed||Phase 4|589|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:29:24.000101|2018-05-31 21:29:24.000101
NCT01570673|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-06-11|2012-04-03|2012-04-04|Estimate|||||||2015-06-11|2015-06-12|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Group Versus Individual Urotherapy for Children|Group Versus Individual Urotehrapy in Children With Non-neurogenic Lower Urinary Tract Dysfunction|Completed||N/A|60|Actual|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 21:29:24.550643|2018-05-31 21:29:24.550643
NCT01570660|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-04-02|2012-04-02|2012-04-04|Estimate|||||||2012-04-02|2012-04-04|Estimate|February 2002||2002-02-28|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Phielix et al.: Hepatic Fat Content and Adipokines|Effects of Glimepiride Monotherapy Versus Combined Neteglinide-Pioglitazone Therapy on Insulin Sensitivity in Type 2 Diabetic Patients|Completed||N/A|24|Actual|German Diabetes Center||1|||f||||f||||||||||2018-05-31 21:29:24.658021|2018-05-31 21:29:24.658021
NCT01570647|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2013-10-08|2012-04-03|2012-04-04|Estimate|||||||2013-10-08|2013-10-09|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|StromaTorque||Automated Connective Tissue Torque Sensor|Automated Connective Tissue Torque Sensor|Completed|||165|Actual|Stromatec, Inc.|||5||f||||t||||||||||2018-05-31 21:29:24.746945|2018-05-31 21:29:24.746945
NCT01570634|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|2012-12-29||2013-02-03|2012-04-03|2012-04-04|Estimate|2013-02-03|2013-03-08|Estimate||||2013-02-03|2013-03-08|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Proof-of-Concept, Calcium Aluminosilicate Anti-Diarrheal (CASAD) for Treatment of Clostridium Difficile Infection|Proof-of-Concept, CASAD for Treatment of Clostridium Difficile Infection|Terminated||Phase 2|2|Actual|Salient Pharmaceuticals Incorporated|This study was terminated early for slow enrollment. Only 2 patients were enrolled during the open period. One of the two took less than 50% of the prescribed study drug. The results are not meaningful.|1||Study was stopped for slow enrollment - only 2 patients, no evaluable results|f||||t||||||||||2018-05-31 21:29:24.802792|2018-05-31 21:29:24.802792
NCT01570621|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|POEM||Personalized Peroral Endoscopic Myotomy for Achalasia|Personalized Peroral Endoscopic Myotomy for Achalasia|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||||f||||t||||||||||2018-05-31 21:29:24.969869|2018-05-31 21:29:24.969869
NCT01570608|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|March 2007||2007-03-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Lucentis KAV Study|Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy (Verteporfin) in Patients With Subfoveal Choroidal Neovascularisation Due to Age-Related Macular Degeneration - a Pilot Study|Completed||Phase 3|51|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||||2018-05-31 21:29:25.040807|2018-05-31 21:29:25.040807
NCT01570595|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-05-09|2012-04-02|2012-04-04|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|PSFW||Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV|A Pilot Study of Positively Smoke Free on the Web (PSFW) for HIV-infected Smokers|Completed||Phase 1/Phase 2|138|Actual|Georgetown University||2|||f||||||||||||||2018-05-31 21:29:25.100352|2018-05-31 21:29:25.100352
NCT01570582|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|A Phase II Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Unknown status|Active, not recruiting|Phase 2|314|Anticipated|Korean Gynecologic Oncology Group||1|||f||||f||||||||||2018-05-31 21:29:25.168169|2018-05-31 21:29:25.168169
NCT01570569|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-04-01|2012-04-01|2012-04-04|Estimate|||||||2012-04-01|2012-04-04|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Development of Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human|Development of High-throughput Minidose Inje Cocktail Method for Simultaneous Evaluating Five Cytochrome P450 Isoforms in Human|Completed||Phase 1|26|Actual|Inje University||5|||f||||f||||||||||2018-05-31 21:29:25.228008|2018-05-31 21:29:25.228008
NCT01570556|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|December 2011||2011-12-31|March 2012|2012-03-31||||December 2013|Anticipated|2013-12-31||Interventional|||Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients|Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients|Unknown status|Recruiting|Phase 4|120|Anticipated|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-05-31 21:29:26.286512|2018-05-31 21:29:26.286512
NCT01570543|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-09-27|2012-04-03|2012-04-04|Estimate|||||||2013-09-27|2013-10-01|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|MRI||MRI Scanning of People With MR Safe Orthopedic Implants That Are Made of Metal|Development of MR Systems, Accessories, and Software for Imaging Subjects With Metallic Orthopedic Implants.|Withdrawn|||0|Actual|GE Healthcare|||1|After over a year no subjects were identified|f||||f||||||||||2018-05-31 21:29:26.359193|2018-05-31 21:29:26.359193
NCT01570530|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-09-15|2012-04-02|2012-04-04|Estimate|||||||2014-09-15|2014-09-16|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|PROFACE||Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery|Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery|Terminated||Phase 3|90|Actual|Fundación General Universidad de Valladolid||2||End of finantial support|f||||f||||||||||2018-05-31 21:29:26.423641|2018-05-31 21:29:26.423641
NCT01570517|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-08-03|2012-04-02|2012-04-04|Estimate|||||||2016-08-03|2016-08-05|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Feasibility Trial of the DC Devices Interatrial Septal Device (IASD) System|Evaluation of the DC Devices IASD System in the Treatment of Patients With Heart Failure With Preserved Ejection Fraction|Completed||Phase 1/Phase 2|11|Actual|Corvia Medical||1|||f||||f||||||||||2018-05-31 21:29:26.498463|2018-05-31 21:29:26.498463
NCT01570504|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-05-24|2012-04-02|2012-04-04|Estimate|||||||2017-05-24|2017-05-25|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|STRONGTREAT||Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis|Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis|Active, not recruiting||Phase 3|312|Actual|Centro per le Malattie Tropicali||2|||f||||t||||||||No||2018-05-31 21:29:26.575225|2018-05-31 21:29:26.575225
NCT01570491|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-12-29|2012-04-02|2012-04-04|Estimate|||||||2016-12-29|2016-12-30|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Real-Time Ultrasound Guided Approach For Spinal Anesthesia||Active, not recruiting||N/A|40|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 21:29:26.660131|2018-05-31 21:29:26.660131
NCT01570478|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-03-28|2012-04-02|2012-04-04|Estimate|||||||2017-03-28|2017-03-29|Actual|July 2012||2012-07-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|NELSON||A Study in Patients With Asthma|A 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® NEXThaler® (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Inhalations b.i.d., Versus Seretide® Accuhaler® (Fluticasone 250 µg Plus Salmeterol 50 µg/Actuation), 1 Inhalation b.i.d., on Small Airway Derived Parameters in Patients With Asthma|Completed||Phase 3|108|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 21:29:26.833134|2018-05-31 21:29:26.833134
NCT01570465|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2018-02-20|2012-04-03|2012-04-04|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2012||2012-09-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|AML1411||Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients|Prospective Survey on Severe Infections During a Multicenter Study of Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia.|Recruiting|||237|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 21:29:26.936419|2018-05-31 21:29:26.936419
NCT01570452|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|September 2008|Actual|2008-09-30||Observational|MMP7||Matrilysin Expression in Different Stages of Colorectal Tumors|Matrilysin Expression in Different Stages of Colorectal Tumors|Completed|||38|Actual|University of Roma La Sapienza|||4||f||||f||||||Samples With DNA|"~     normal mucosa, cancer tissue, lymph nodes and serum from cancer patients serum from healty~     volunteers~   "|||2018-05-31 21:29:27.227135|2018-05-31 21:29:27.227135
NCT01570439|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-10|2012-04-03|2012-04-04|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2012||2012-01-31|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31||Observational|||To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore||Unknown status|Recruiting||10|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 21:29:27.301395|2018-05-31 21:29:27.301395
NCT01570426|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2018-01-16|2012-04-02|2012-04-04|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2007||2007-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BBPP||Brain Imaging and Computer Games in Children With Either Bipolar Disorder, ADHD, Anxiety or Healthy Controls|Brain/Behavior Alterations in Pediatric Psychopathology|Recruiting|||240|Anticipated|Bradley Hospital|||4||f||||f||||||Samples With DNA|"~     Spit samples are collected for DNA/RNA extraction.Genetic tests will be performed at the~     Brown University affiliated Molecular Genetics Laboratory located at the Providence VA~     Medical Center. For privacy purposes, all genetic samples will be assigned a study code~     number to ensure that there is no identifiable information with them. After this study is~     over, genetic samples will be disposed.~   "|||2018-05-31 21:29:27.363456|2018-05-31 21:29:27.363456
NCT01570400|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-10-29|2012-04-03|2012-04-04|Estimate|||||||2016-10-29|2016-11-01|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|SOFIE13a||Treatment of Social Phobia With Combined Cognitive Bias Modification and iCBT|Reduction of Social Phobia Symptoms With Combined Internet-Based Cognitive Bias Modification and Cognitive Behavioral Therapy|Completed||N/A|133|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 21:29:27.506979|2018-05-31 21:29:27.506979
NCT01570387|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-04-24|2012-04-02|2012-04-04|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2012|Actual|2012-06-30|April 2018|2018-04-30|February 2030|Anticipated|2030-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis|A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis|Active, not recruiting||Phase 1/Phase 2|27|Actual|Boston Medical Center||1|||f||||t|t|f||||||No||2018-05-31 21:29:27.593486|2018-05-31 21:29:27.593486
NCT01570374|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2016-10-31|2012-04-03|2012-04-04|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Internet-based Treatment of Generalized Anxiety Disorder|Internet-based Treatment of Generalized Anxiety Disorder|Completed||N/A|103|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 21:29:27.68091|2018-05-31 21:29:27.68091
NCT01570361|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-06-27|2012-04-03|2012-04-04|Estimate|||||||2017-06-27|2017-06-28|Actual|February 2012||2012-02-29|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ATTEST||Atrial Fibrillation Progression Trial|Atrial Fibrillation Progression Trial|Recruiting||Phase 4|330|Anticipated|Biosense Webster, Inc.||2|||f||||f||||||||||2018-05-31 21:29:27.804792|2018-05-31 21:29:27.804792
NCT01570348|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-08-02|2012-04-03|2012-04-04|Estimate|||||||2017-08-02|2017-08-04|Actual|July 2012||2012-07-31|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2018|Anticipated|2018-02-28||Interventional|CATS||Crohn's Allogeneic Transplant Study|Allogeneic Hematopoietic Cell Transplantation for Patients With Treatment-Refractory Crohn's Disease: A Phase 2 Study|Suspended||Phase 2|2|Actual|Fred Hutchinson Cancer Research Center||1||Temporarily closed to enrollment|f||||t||||||||||2018-05-31 21:29:28.159182|2018-05-31 21:29:28.159182
NCT01570335|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-12-01|2012-04-02|2012-04-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The SBAR Effect on Safety Attitudes in the Perinatal Department||Completed|||40|Actual|Far Eastern Memorial Hospital|||||f||||||||||||||2018-05-31 21:29:28.28424|2018-05-31 21:29:28.28424
NCT01570322|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2016-06-08|2012-04-02|2012-04-04|Estimate|||||||2016-06-08|2016-06-09|Estimate||||June 2016|2016-06-30||||||||Observational|||Determinants of Quality of Life Related to Health in Alzheimer Disease||Recruiting|||400|Anticipated|CHU de Reims|||||f||||f||||||||||2018-05-31 21:29:28.337328|2018-05-31 21:29:28.337328
NCT01570309|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2012-09-23||2013-08-05|2012-04-03|2012-04-04|Estimate|2013-08-05|2013-10-10|Estimate||||2013-08-05|2013-10-10|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vitamin D Repletion in Coronary Artery Disease|The Effects of Vitamin D Repletion on Endothelial Function and Inflammation in Patients With Coronary Artery Disease|Completed||N/A|96|Actual|New York City Health and Hospitals Corporation||2|||f||||f||||||||||2018-05-31 21:29:28.431371|2018-05-31 21:29:28.431371
NCT01570296|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-02-01|2012-04-03|2012-04-04|Estimate|||||||2018-02-01|2018-02-05|Actual|October 3, 2011|Actual|2011-10-03|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|February 22, 2016|Actual|2016-02-22||Interventional|BKM120||A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR|A Phase Ib Trial of Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa™) in Combination With BKM120, an Oral Pan-class I PI3K Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR|Active, not recruiting||Phase 1|38|Actual|National Cancer Centre, Singapore||1|||f||||f||||||||||2018-05-31 21:29:28.799703|2018-05-31 21:29:28.799703
NCT01570283|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27||2016-01-21|2018-05-23|2012-04-02|2012-04-04|Estimate||||2016-01-21|2016-02-15|Estimate|2018-05-23|2018-05-25|Actual|September 2012||2012-09-30|May 2018|2018-05-31|September 2017|Actual|2017-09-30|August 2016|Actual|2016-08-31||Interventional|ARMS||ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus|ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant|Completed||Phase 1/Phase 2|21|Actual|ViraCyte||1|||f||||t||||||||||2018-05-31 21:29:28.935001|2018-05-31 21:29:28.935001
NCT01570270|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Cheese Intake and Hypercholesterolemia||Completed||Phase 1/Phase 2|42|Actual|Azienda Ospedaliera Brotzu||1|||f||||f||||||||||2018-05-31 21:29:29.034541|2018-05-31 21:29:29.034541
NCT01570257|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2016-08-02|2012-04-03|2012-04-04|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2003||2003-09-30|March 2012|2012-03-31|October 2007|Actual|2007-10-31|December 2006|Actual|2006-12-31||Interventional|||A Trial of High and Low Pressure Level Settings on a Programmable Ventriculoperitoneal Shunt Valve for Idiopathic Normal Pressure Hydrocephalus|A Randomized Trial of High and Low Pressure Level Settings on a Programmable Ventriculoperitoneal Shunt Valve for Idiopathic Normal Pressure Hydrocephalus. Results of the Dutch Evaluation Program Strata Shunt (DEPSS) Trial|Completed||N/A|58|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 21:29:29.102266|2018-05-31 21:29:29.102266
NCT01570244|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|2015-07-03||2015-07-03|2012-04-02|2012-04-04|Estimate|2015-07-03|2015-08-03|Estimate||||2015-07-03|2015-08-03|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Drug-drug Interaction of BI 201335 and Microgynon|An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of 240 mg BI 201335 QD on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:29:29.203595|2018-05-31 21:29:29.203595
NCT01570231|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2012-07-26|2012-04-03|2012-04-04|Estimate|||||||2012-07-26|2012-07-27|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Feasibility, Safety and Efficacy of Remote Ischemic Preconditioning for Symptomatic Intracranial Arterial Stenosis in Octogenarians|Feasibility, Safety and Efficacy of RIPC for Symptomatic Intracranial Arterial Stenosis in Octogenarians|Completed||Phase 1|58|Actual|Capital Medical University||2|||f||||||||||||||2018-05-31 21:29:29.52848|2018-05-31 21:29:29.52848
NCT01570218|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2018-05-01|2012-04-01|2012-04-04|Estimate|||||||2018-05-01|2018-05-04|Actual|February 2010||2010-02-28|May 2018|2018-05-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy|Randomized Clinical Trial Testing Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy.|Completed||N/A|164|Actual|Universidade Federal de Goias||2|||f||||f|f|f||||||||2018-05-31 21:29:29.592747|2018-05-31 21:29:29.592747
NCT01570205|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers|The Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Male Volunteers in a Randomized, Double Blind, Placebo Controlled, Dose Escalating Phase I Study|Completed||Phase 1|24|Actual|Xigen SA||4|||f||||f||||||||||2018-05-31 21:29:29.754005|2018-05-31 21:29:29.754005
NCT01570192|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2016-12-22|2016-03-15|2017-09-01|2012-03-30|2012-04-04|Estimate|2017-03-08|2017-04-20|Actual|2016-03-15|2016-04-15|Estimate|2017-09-01|2017-09-29|Actual|September 2010||2010-09-30|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Number of patients enrolled in the study and who had a baseline BAL.|Clinical Trials to Reduce the Risk of Antimicrobial Resistance|Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation|Terminated||Phase 2|43|Actual|University of Florida||2||NIAID terminated the study due to low subject enrollment|f||||t|t|f||||||No||2018-05-31 21:29:29.848686|2018-05-31 21:29:29.848686
NCT01570179|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2013-01-23|2012-04-02|2012-04-04|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SugReBaCh-1||Sugammadex-dosing in Bariatric Patients|Sugammadex in Patients Undergoing Bariatric Surgery: An Equivalence Trial Comparing Real and Ideal Body Weight-based Dosing|Completed||Phase 3|34|Actual|Central Hospital, Nancy, France||4|||f||||t||||||||||2018-05-31 21:29:30.408826|2018-05-31 21:29:30.408826
NCT01570166|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-04-03|2012-04-03|2012-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma|Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|180|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:29:30.491065|2018-05-31 21:29:30.491065
NCT01570153|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-03-21|2012-04-02|2012-04-04|Estimate|||||||2014-03-21|2014-03-24|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Observational|BIONICS-HF||Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial|Biomarkers Plus Bioimpedance Vector Analysis to Predict Cardiorenal Syndrome Onset and Prognosis in Patients With Acutely Decompensated Heart Failure: Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial|Completed|||100|Actual|Massachusetts General Hospital|||1||f||||t||||||Samples Without DNA|"~     10 ml sample of blood will be draw into a tube containing ethylenediaminetetraacetic acid,~     spun for 15 minutes, and aliquoted to freezer tubes for biomarker measurement following the~     completition of the trial~   "|||2018-05-31 21:29:30.587269|2018-05-31 21:29:30.587269
NCT01570140|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2018-03-20|2012-04-01|2012-04-04|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2012|Actual|2012-05-31|March 2018|2018-03-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Observational|LSD||Large Scale Demonstrator, Webportal Diabetes|Large Scale Demonstrator, Webportal Diabetes|Completed|||350|Actual|Medical Research Foundation, The Netherlands|||1||f||||f||||||||||2018-05-31 21:29:30.676351|2018-05-31 21:29:30.676351
NCT01570127|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-04-05|2012-04-01|2012-04-04|Estimate|||||||2012-04-05|2012-04-06|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Efficacy and Safety Study of Individualized and Standardized Acupuncture Treatment for Low Back Pain|Clinical Trial to Evaluate and Compare the Efficacy and Safety of Individualized and Standardized Acupuncture for Low Back Pain Patients: Randomized, Double-blind, Controlled Study|Unknown status|Recruiting|Phase 2|276|Anticipated|Kyunghee University Medical Center||4|||f||||t||||||||||2018-05-31 21:29:30.745812|2018-05-31 21:29:30.745812
NCT01570114|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-30|2012-04-04|Estimate|||||||2012-03-30|2012-04-04|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||Covered Metallic Stent and Benign Colonic Strictures|EFFICACY OF A SELF EXPANDABLE FULLY COVERED METALLIC STENT IN THE TREATMENT OF BENIGN COLONIC STRICTURES|Completed|||43|Actual|Société Française d'Endoscopie Digestive|||1||f||||f||||||||||2018-05-31 21:29:30.842536|2018-05-31 21:29:30.842536
NCT01570101|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-04-29|2012-03-30|2012-04-04|Estimate|||||||2016-04-29|2016-05-03|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|July 2013|Actual|2013-07-31||Interventional|eSCOPE||European Sapheon™ Closure System Observational ProspectivE (eSCOPE) Study|"Post Market Study - European Observational Study of the Sapheon™ Closure System for the Definitive Treatment of Incompetent Great Saphenous Veins: A Prospective Single Arm Multicenter Clinical Observational Study"|Completed||N/A|70|Actual|Medtronic Endovascular||1|||f||||f||||||||No||2018-05-31 21:29:30.914411|2018-05-31 21:29:30.914411
NCT01570088|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2014-12-12|2012-03-30|2012-04-04|Estimate|||||||2014-12-12|2014-12-16|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioavailability of Folic Acid Fortified Bread|Bioavailability of Folic Acid and L-5-methyltetrahydrofolic Acid in Fortified Bread: a Randomized Placebo-controlled Trial|Completed||Phase 2|45|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 21:29:30.986533|2018-05-31 21:29:30.986533
NCT01570075|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-03-30|2012-03-30|2012-04-04|Estimate|||||||2012-03-30|2012-04-04|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria|Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria|Unknown status|Recruiting|Phase 4|180|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:29:31.052816|2018-05-31 21:29:31.052816
NCT01570062|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-04-10|2012-04-03|2012-04-04|Estimate|||||||2014-04-10|2014-04-14|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|CLEAR||Cardiovascular Effects of Aerosols in Residences Study|Subclinical Cardiovascular Health Benefits of Interventions to Reduce Exposure to Combustion-Derived Particulate Air Pollution|Completed||Phase 2|83|Actual|Simon Fraser University||2|||f||||t||||||||||2018-05-31 21:29:31.125776|2018-05-31 21:29:31.125776
NCT01570049|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-08-01|2012-03-30|2012-04-04|Estimate|||||||2012-08-01|2012-08-02|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma|A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma|Unknown status|Recruiting|Phase 3|100|Anticipated|Shandong Lanjin Pharmaceuticals Co.,Ltd||1|||f||||t||||||||||2018-05-31 21:29:31.198485|2018-05-31 21:29:31.198485
NCT01570036|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2018-04-05|2012-03-30|2012-04-04|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2013||2013-01-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax|Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence|Active, not recruiting||Phase 2|300|Anticipated|Cancer Insight, LLC||2|||f||||t||||||||||2018-05-31 21:29:31.279471|2018-05-31 21:29:31.279471
NCT01570023|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-10-09|2012-03-30|2012-04-04|Estimate|||||||2015-10-09|2015-10-12|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study of Tongue Strengthening for Swallowing Problems|Comparison Between Isometric Lingual Strengthening Exercises and Standard Clinical Care for the Treatment of Dysphagia|Completed||N/A|34|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 21:29:31.40515|2018-05-31 21:29:31.40515
NCT01570010|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-12-04|2012-03-30|2012-04-04|Estimate|||||||2015-12-04|2015-12-07|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|March 2040|Anticipated|2040-03-31|March 2040|Anticipated|2040-03-31||Interventional|NFS||Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors|Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors|Recruiting||N/A|500|Anticipated|University of Oslo||2|||f||||t||||||||||2018-05-31 21:29:31.485398|2018-05-31 21:29:31.485398
NCT01569997|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2015-08-21|2012-03-30|2012-04-04|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|IDEM||Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units|Interest of Systematic Tracking of Dementia Cases in Nursing Homes: Analysing the Contribution of MultiDisciplinary Team Meeting (MDTM) in Alzheimer's Disease and Related Diseases|Completed||N/A|1428|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 21:29:31.582764|2018-05-31 21:29:31.582764
NCT01569984|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-10-12|2012-03-30|2012-04-03|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SBRT-Avastin||Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis|An Open Label, Single-Centre, Phase II Study for Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy (SBRT) for Colorectal Liver Metastasis (SBRT Avastin)|Completed||Phase 2|11|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 21:29:31.843353|2018-05-31 21:29:31.843353
NCT01569971|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2014-06-23|2012-04-02|2012-04-03|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program|Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program|Completed|||55|Actual|St. Jude Children's Research Hospital|||3||f||||f||||||||||2018-05-31 21:29:31.914982|2018-05-31 21:29:31.914982
NCT01569958|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-10-08|2012-03-30|2012-04-03|Estimate|||||||2012-10-08|2012-10-10|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis|Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis|Unknown status|Recruiting|Phase 2|54|Anticipated|Università degli Studi 'G. d'Annunzio' Chieti e Pescara||2|||f||||t||||||||||2018-05-31 21:29:31.996513|2018-05-31 21:29:31.996513
NCT01569945|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2014-09-09|2012-03-30|2012-04-03|Estimate|||||||2014-09-09|2014-09-10|Estimate|September 2004||2004-09-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur||Completed||N/A|371|Actual|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-05-31 21:29:32.078205|2018-05-31 21:29:32.078205
NCT01569932|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-02-25|2012-03-30|2012-04-03|Estimate|||||||2013-02-25|2013-02-26|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|CFCC||Cognitive Changes in Adult Cancer Survivors|Cognitive and Functional Changes With Chemotherapy in Adult Cancer|Completed|||13|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 21:29:32.138512|2018-05-31 21:29:32.138512
NCT01569919|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2013-03-11|2012-03-30|2012-04-03|Estimate|||||||2013-03-11|2013-03-12|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|SKOPOS||A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma|A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma|Unknown status|Recruiting|Phase 2|26|Anticipated|Wales Cancer Trials Unit||1|||f||||t||||||||||2018-05-31 21:29:32.195925|2018-05-31 21:29:32.195925
NCT01569906|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-04-03|2012-03-30|2012-04-03|Estimate|||||||2012-04-03|2012-04-05|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Narrowband UVB for Children With Moderate to Severe Atopic Eczema|Narrowband Ultraviolet B Phototherapy in Children With Moderate to Severe Atopic Eczema- an Observational Prospective Controlled Study|Completed|||58|Actual|Royal Victoria Infirmary|||2||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-05-31 21:29:32.291227|2018-05-31 21:29:32.291227
NCT01569893|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-10-27|2012-03-30|2012-04-03|Estimate|||||||2015-10-27|2015-10-28|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Life-Long Monitoring of Diabetes Mellitus in Veneto Region|RENEWING HEALTH - Large Scale Pilot in Veneto Region: Life-long Monitoring of Diabetes Mellitus|Completed||N/A|598|Actual|Regione Veneto||2|||f||||t||||||||||2018-05-31 21:29:32.378767|2018-05-31 21:29:32.378767
NCT01569880|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-03-30|2012-03-30|2012-04-03|Estimate|||||||2012-03-30|2012-04-03|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Pre-flight Evaluation of Adult Patients With Cystic Fibrosis|Pre-flight Evaluation of Adult Patients With Cystic Fibrosis|Completed|||30|Actual|Oslo University Hospital|||||f||||f||||||||||2018-05-31 21:29:32.477373|2018-05-31 21:29:32.477373
NCT01569867|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-09-26|2012-03-30|2012-04-03|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|March 2022|Anticipated|2022-03-31|June 2020|Anticipated|2020-06-30||Observational|||Genetic Influence on Statin Pharmacokinetics|An Observational Study Investigating Genetic Influences on Statin Plasma Concentrations in Adults Taking Atorvastatin, Simvastatin, or Lovastatin|Recruiting|||800|Anticipated|Ohio State University|||1||f||||f||||||Samples With DNA|"~     Frozen plasma and frozen nuclear pellet~   "|||2018-05-31 21:29:32.538164|2018-05-31 21:29:32.538164
NCT01569854|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-09-26|2012-03-30|2012-04-03|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|March 2022|Anticipated|2022-03-31|March 2016|Anticipated|2016-03-31||Observational|||Genetic Influence on Statin Pharmacodynamics|An Observational Study Investigating Genetic Influences on Clinical Outcomes and Change in Carotid Intimal Thickness in Adults Taking Atorvastatin, Simvastatin, or Lovastatin|Withdrawn|||0|Actual|Ohio State University|||1|Insufficient recruitment|f||||f||||||Samples With DNA|"~     nuclear pellet~   "|||2018-05-31 21:29:32.60626|2018-05-31 21:29:32.60626
NCT01569841|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2015-10-16|2012-12-19|2016-01-21|2012-03-30|2012-04-03|Estimate|2015-10-16|2015-11-17|Estimate|2012-12-19|2012-12-24|Estimate|2016-01-21|2016-02-18|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes|A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes|Completed||Phase 3|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:29:32.684066|2018-05-31 21:29:32.684066
NCT01569828|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2015-07-30||2015-08-27|2012-03-30|2012-04-03|Estimate|2015-08-27|2015-09-29|Estimate||||2015-08-27|2015-09-29|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function|An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function|Completed||Phase 2|12|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:29:32.961397|2018-05-31 21:29:32.961397
NCT01569815|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2015-07-30||2015-09-25|2012-03-30|2012-04-03|Estimate|2015-07-30|2015-08-27|Estimate||||2015-09-25|2015-10-19|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function|An Open Label, Parallel-group Study to Determine Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Mild and Moderate Renal Impairment Compared to Matched Healthy Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:29:33.347679|2018-05-31 21:29:33.347679
NCT01569802|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-30|2012-04-03|Estimate|||||||2012-03-30|2012-04-03|Estimate|January 2012||2012-01-31|March 2012|2012-03-31||||||||Observational|||A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population|A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population|Unknown status|Recruiting||10000|Anticipated|Rose Imaging Specialists, P.A.|||1||f||||f||||||||||2018-05-31 21:29:34.000368|2018-05-31 21:29:34.000368
NCT01569789|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-04-14|2012-03-30|2012-04-03|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Auricular Vagus Nerve Stimulation on the Pro-inflammatory Cytokine Response in Healthy Adults|Effects of Auricular Vagus Nerve Stimulation on the Pro-inflammatory Cytokine Response in Healthy Adults|Completed||Phase 1|24|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 21:29:34.053216|2018-05-31 21:29:34.053216
NCT01569776|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2013-06-24|2012-03-30|2012-04-03|Estimate|||||||2013-06-24|2013-06-26|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Elemental Formula Hypoallergenicity|Evaluation of Hypoallergenicity of an Amino Acid-Based Infant Formula|Completed||N/A|37|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 21:29:34.110881|2018-05-31 21:29:34.110881
NCT01569763|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2016-04-01||2018-03-20|2012-03-30|2012-04-03|Estimate|2016-04-01|2016-05-05|Estimate||||2018-03-20|2018-04-18|Actual|March 2012||2012-03-31|March 2018|2018-03-31|March 2, 2018|Actual|2018-03-02|January 2015|Actual|2015-01-31||Interventional||Enrolled Subjects|Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation|Minerva Pivotal Study|Completed||N/A|153|Actual|Minerva Surgical, Inc.||2|||f||||t||||||||||2018-05-31 21:29:34.267352|2018-05-31 21:29:34.267352
NCT01569750|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-08-18|2012-03-30|2012-04-03|Estimate|||||||2017-08-18|2017-08-22|Actual|June 14, 2012|Actual|2012-06-14|August 2017|2017-08-31|September 4, 2014|Actual|2014-09-04|September 4, 2014|Actual|2014-09-04||Interventional|||A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma|A Phase 1b Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With CD20-Positive B-Cell Non Hodgkin Lymphoma (NHL)|Completed||Phase 1|33|Actual|Janssen Research & Development, LLC||1|||f||||t||f||||||||2018-05-31 21:29:34.684426|2018-05-31 21:29:34.684426
NCT01569737|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2018-02-15|2012-03-30|2012-04-03|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2012||2012-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ellipse II||Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella|Prospective Multicenter Observational Study to Assess Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella|Recruiting|||100|Anticipated|HRA Pharma|||1||f||||t||||||||||2018-05-31 21:29:34.822026|2018-05-31 21:29:34.822026
NCT01569724|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-07-19|2012-03-30|2012-04-03|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2012||2012-01-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|TgBEX||Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma|Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study|Completed||Phase 4|10|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 21:29:34.902091|2018-05-31 21:29:34.902091
NCT01569711|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2015-05-26|2012-03-30|2012-04-03|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|PRESTHYM||Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder|Preliminary Study Evaluating Deep Brain Stimulation of Nucleus Accumbens in Patients Suffering From Chronic and Resistant Major Depressive Disorder|Completed|||6|Actual|Rennes University Hospital|||1||f||||f||||||||||2018-05-31 21:29:34.990231|2018-05-31 21:29:34.990231
NCT01569698|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2016-09-06|2012-03-30|2012-04-03|Estimate|||||||2016-09-06|2016-09-07|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|June 2016|Actual|2016-06-30||Observational|EPURE||Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury|Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury|Unknown status|Recruiting||600|Anticipated|Rennes University Hospital|||1||f||||f||||||||||2018-05-31 21:29:35.112274|2018-05-31 21:29:35.112274
NCT01569685|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2015-03-03|2012-03-30|2012-04-03|Estimate|||||||2015-03-03|2015-03-04|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PTF3||The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy|The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy - a Randomised Clinical Study|Completed||Phase 4|207|Actual|Psychiatric Center Ballerup||2|||f||||t||||||||||2018-05-31 21:29:35.315916|2018-05-31 21:29:35.315916
NCT01569672|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-12-20|2012-03-30|2012-04-03|Estimate|||||||2017-12-20|2017-12-22|Actual|November 2006||2006-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2010|Actual|2010-12-31||Interventional|OPNRP||Ohio Patient Navigator Research Program|Ohio Patient Navigation Research Program|Active, not recruiting||N/A|941|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 21:29:35.399202|2018-05-31 21:29:35.399202
NCT01569659|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-12-08|2012-04-02|2012-04-03|Estimate|||||||2015-12-08|2015-12-09|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HDL||High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia|High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia|Completed||Phase 4|101|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:29:35.493094|2018-05-31 21:29:35.493094
NCT01569646|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-03-30|2012-03-30|2012-04-03|Estimate|||||||2012-03-30|2012-04-03|Estimate|April 2008||2008-04-30|March 2012|2012-03-31||||||||Observational|||Monocytosis and Culprit Vessel in STEMI Patients|Significance of Monocytosis and Culprit Vessel in Patients With Acute ST Elevation Myocardial Infarction|Completed|||226|Actual|Northwell Health|||||f||||t||||||||||2018-05-31 21:29:35.568216|2018-05-31 21:29:35.568216
NCT01569633|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-02-13|2012-03-30|2012-04-03|Estimate|||||||2015-02-13|2015-02-16|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|February 2014|Actual|2014-02-28||Interventional|||Use of Prokinetics in Early Enteral Feeding in Preterm Infants|Pilot Study for Use of Prokinetics in Early Enteral Feeding of Preterm Infants ; Double Blind; Cross Over Study Comparing Eryththromycin, Metoclopramide and Placebo|Terminated||N/A|3|Actual|East Tennessee State University||3||very poor enrollment|f||||t||||||||||2018-05-31 21:29:35.634992|2018-05-31 21:29:35.634992
NCT01569620|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-01-28|2012-03-30|2012-04-03|Estimate|||||||2016-01-28|2016-01-29|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Improving Colorectal Cancer Screening for Diverse Hispanics in Urban Primary Care|Improving Colorectal Cancer (CRC) Screening for Diverse Hispanics in an Urban Primary Care Setting|Completed||N/A|386|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-05-31 21:29:35.711501|2018-05-31 21:29:35.711501
NCT01569607|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2017-10-31||2017-12-13|2012-03-30|2012-04-03|Estimate|2017-12-13|2018-01-16|Actual||||2017-12-13|2018-01-16|Actual|March 8, 2012|Actual|2012-03-08|December 2017|2017-12-31|August 26, 2016|Actual|2016-08-26|August 26, 2016|Actual|2016-08-26||Interventional||Participants that were randomized to a study arm and received an intervention.|Structurally Reorganizing Motor Cortex in Stroke Patients Through Hebbian-type Stimulation|Structurally Reorganizing Motor Cortex in Stroke Patients Through Hebbian-type Stimulation|Completed||N/A|48|Actual|Emory University||2|||f||||f||||||||||2018-05-31 21:29:35.811959|2018-05-31 21:29:35.811959
NCT01569594|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-06-28|2012-03-30|2012-04-03|Estimate|||||||2017-06-28|2017-06-29|Actual|April 2012||2012-04-30|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||CorMatrix ECM for Carotid Repair Following Endarterectomy Registry|CorMatrix® ECM® for Carotid Repair Following Endarterectomy Registry|Completed|||230|Actual|Aziyo Biologics, Inc.|||1||f||||f||||||||||2018-05-31 21:29:36.121074|2018-05-31 21:29:36.121074
NCT01569581|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2013-03-10|2012-03-30|2012-04-03|Estimate|||||||2013-03-10|2013-03-12|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children|A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children|Completed||Phase 3|12000|Actual|Chinese Academy of Medical Sciences||8|||f||||t||||||||||2018-05-31 21:29:36.18275|2018-05-31 21:29:36.18275
NCT01569568|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2015-06-30||2017-04-12|2012-04-02|2012-04-03|Estimate|2017-04-12|2017-04-14|Actual||||2017-04-12|2017-04-14|Actual|September 2010||2010-09-30|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI|Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI|Completed|||49|Actual|Children's Research Institute|||2||f||||t||||||||Yes|Final data is on the UCDC website|2018-05-31 21:29:36.267997|2018-05-31 21:29:36.267997
NCT01569555|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-03-30|2012-03-30|2012-04-03|Estimate|||||||2012-03-30|2012-04-03|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Observational|||Significant Pathology Associated With Crossed Leg Sign|Crossed Leg Sign and it's Correlation With Significant Pathology|Unknown status|Not yet recruiting||400|Anticipated|Uelk, J. Daniel, D.O.|||||f||||t||||||||||2018-05-31 21:29:36.609125|2018-05-31 21:29:36.609125
NCT01569542|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-03-30|2012-03-30|2012-04-03|Estimate|||||||2012-03-30|2012-04-03|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Observational|||Crossed Leg Sign and it's Correlation With Significant Pathology|Crossed Leg Sign and it's Correlation With Significant Pathology|Unknown status|Not yet recruiting||400|Anticipated|Uelk, J. Daniel, D.O.|||||f||||t||||||||||2018-05-31 21:29:36.658669|2018-05-31 21:29:36.658669
NCT01569529|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2013-10-31||2017-02-28|2012-04-02|2012-04-03|Estimate|2014-04-11|2014-05-13|Estimate||||2017-02-28|2017-03-30|Actual|May 2012||2012-05-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Young Adult Smoker's Treatment Demand|Increasing Young Adult Smoker's Demand for Internet-based Cessation Treatment|Completed|||3070|Actual|University of Illinois at Chicago|||2||f||||t||||||||||2018-05-31 21:29:36.724837|2018-05-31 21:29:36.724837
NCT01569516|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-04-06|2012-03-30|2012-04-03|Estimate|||||||2012-04-06|2012-04-09|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|||Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease|A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease|Unknown status|Recruiting|Phase 2|288|Anticipated|Changchun Huayang High-tech Co., Ltd||4|||f||||t||||||||||2018-05-31 21:29:36.889766|2018-05-31 21:29:36.889766
NCT01569503|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2018-05-02|2012-04-02|2012-04-03|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2012|Actual|2012-03-31|August 2017|2017-08-31|May 30, 2017|Actual|2017-05-30|March 30, 2017|Actual|2017-03-30||Interventional|VNS||Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease|The Anti-inflammatory Effect of Vagus Nerve Stimulation (VNS): a New Approach in the Treatment of Crohn's Disease|Terminated||Phase 3|9|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 21:29:38.068932|2018-05-31 21:29:38.068932
NCT01569490|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-02-28|2012-03-30|2012-04-03|Estimate|||||||2017-02-28|2017-03-03|Actual|September 2012||2012-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|STQ FB||Striving to Quit: First Breath|Striving to Quit: First Breath Tobacco Cessation Research|Completed||N/A|3100|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 21:29:38.144674|2018-05-31 21:29:38.144674
NCT01569477|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2016-12-05|2012-03-30|2012-04-03|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|March 2013|Actual|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Striving to Quit-Wisconsin Tobacco Quit Line|Striving to Quit: Wisconsin Tobacco Quit Line Tobacco Cessation Research|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||2||Not able to recruit participants|f||||f||||||||Yes||2018-05-31 21:29:38.211028|2018-05-31 21:29:38.211028
NCT01569464|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2014-04-15||2014-08-13|2012-03-30|2012-04-03|Estimate|2014-08-13|2014-08-26|Estimate||||2014-08-13|2014-08-26|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|RESTORE|The demographics section consists of the Full Analysis Set (FAS), which includes all randomized, treated subjects having valid Baseline measurements for both primary efficacy variables.|Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)|A Phase 3B, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine and Its Effect on All-Day Functioning and Quality of Life in Subjects With Moderate to Severe Idiopathic Restless Legs Syndrome|Completed||Phase 3|150|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:29:38.31587|2018-05-31 21:29:38.31587
NCT01569451|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-06-03|2012-04-02|2012-04-03|Estimate|||||||2015-06-03|2015-06-08|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|GATEWAY II||Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy for MS|A Double Blinded, Placebo Controlled, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis|Completed||Phase 2|64|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 21:29:38.890249|2018-05-31 21:29:38.890249
NCT01569438|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2016-09-23||2017-04-14|2012-04-02|2012-04-03|Estimate|2016-11-16|2017-01-12|Estimate||||2017-04-14|2017-05-17|Actual|March 31, 2012|Actual|2012-03-31|April 2017|2017-04-30|May 31, 2014|Actual|2014-05-31|May 31, 2014|Actual|2014-05-31||Interventional||Titration Population|The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome||Completed||Phase 2|74|Actual|Afferent Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 21:29:39.040921|2018-05-31 21:29:39.040921
NCT01569425|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-04-07|2012-04-02|2012-04-03|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|June 2012|Actual|2012-06-30||Interventional|M-PCOS||Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome|Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome|Unknown status|Active, not recruiting|N/A|60|Anticipated|Tel Aviv University||2|||f||||t||||||||||2018-05-31 21:29:39.438531|2018-05-31 21:29:39.438531
NCT01569412|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2016-05-04|2012-03-30|2012-04-03|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Open Label, Dose Escalating Study With Ertumaxomab In Patients With HER-2/Neu Expressing Advanced Solid Tumors|Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Expressing (1+/SISH Positive, 2+ and 3+) Solid Tumors Progressing After Standard Therapy|Terminated||Phase 1/Phase 2|14|Actual|Krankenhaus Nordwest||1|||f||||||||||||||2018-05-31 21:29:39.508143|2018-05-31 21:29:39.508143
NCT01569399|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2015-02-05|2012-03-30|2012-04-03|Estimate|||||||2015-02-05|2015-02-06|Estimate|February 2011||2011-02-28|February 2015|2015-02-28||||February 2011|Actual|2011-02-28||Interventional|||Efficacity of rTMS in Alcohol Dependance|Evaluation de l'efficacité thérapeutique de la Stimulation magnétique transcrânienne répétée Sur le Traitement du Craving à l'Alcool et la prévention de la Rechute Alcoolique à 6 Mois Chez Les Sujets dépendants et Des Facteurs génétiques déterminant la réponse thérapeutique|Unknown status|Recruiting|N/A|150|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 21:29:39.585505|2018-05-31 21:29:39.585505
NCT01569386|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-04-02|2012-04-02|2012-04-03|Estimate|||||||2012-04-02|2012-04-03|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2007|Actual|2007-02-28||Interventional|LIPA||Low Intensity Physical Activity Leads to Improvement in Brachial-ankle Pulse Wave Velocity of Hemiplegics|Low Intensity Physical Activity Leads to Improvement in Brachial-ankle Pulse Wave Velocity in the Affected Leg of Hemiplegics|Completed||Phase 2|54|Actual|Gunma PAZ College||2|||f||||t||||||||||2018-05-31 21:29:39.667667|2018-05-31 21:29:39.667667
NCT01569373|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-10-17|2012-03-30|2012-04-03|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2012||2012-03-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)|Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD).|Withdrawn|||0|Actual|Mayo Clinic|||1|Resources needed to complete the study were not able to be obtained.|f||||f||||||||||2018-05-31 21:29:39.733721|2018-05-31 21:29:39.733721
NCT01569360|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2013-12-18|2012-03-30|2012-04-03|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Garchoise||Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord Injury|Randomised Open Study of the Efficiency and Tolerance of the Use of a Corset on the Respiratory Function of Spinal Cord Injury Patients|Withdrawn||Phase 3|0|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:29:39.87518|2018-05-31 21:29:39.87518
NCT01569347|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2016-12-07|2012-03-30|2012-04-03|Estimate|||||||2016-12-07|2016-12-08|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|PSYCHOCOKE||Clinical and Genetic Factors Associated With Psychotic Symptoms Among Cocaine Abusers|Multicentric Descriptive Cross-sectional Study Evaluating Cocaine Users in Treatment Center|Completed|||417|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||Samples With DNA|"~     -  Hair sampling: cocain and metabolit dosage (last 3 months)~        -  Blood sampling : plasmatic DBH activity, polymorphisms of several genes (DBH,D2R, DAT,~          COMT)~   "|||2018-05-31 21:29:39.95396|2018-05-31 21:29:39.95396
NCT01569334|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2014-08-28|2012-04-02|2012-04-03|Estimate|||||||2014-08-28|2014-08-29|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|November 2014|Anticipated|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasculopathy|Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasculopathy|Unknown status|Active, not recruiting|N/A|170|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 21:29:40.039436|2018-05-31 21:29:40.039436
NCT01569321|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-04-20|2012-04-02|2012-04-03|Estimate|||||||2015-04-20|2015-04-21|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Diagosis of Breast Carcinoma: Characterization of Breast Lesions With CLEARPEMSONIC : Feasibility Study|Diagosis of Breast Carcinoma: Characterization of Breast Lesions With CLEARPEMSONIC : Feasibility Study|Terminated||N/A|10|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 21:29:40.109439|2018-05-31 21:29:40.109439
NCT01569308|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-04-02|2012-04-02|2012-04-03|Estimate|||||||2012-04-02|2012-04-03|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Pulse Pressure Variation Helps to Predict Fluid Responsiveness in Patients Ventilated With Low Tidal Volumes|Pulse Pressure Variation Helps to Predict Fluid Responsiveness in Patients Ventilated With Low Tidal Volumes|Completed|||38|Actual|Hospital de Clinicas de Porto Alegre|||||f||||t||||||||||2018-05-31 21:29:40.181074|2018-05-31 21:29:40.181074
NCT01569295|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2017-12-18|2016-05-24|2018-01-29|2012-03-30|2012-04-03|Estimate|2018-01-29|2018-02-27|Actual|2016-05-24|2016-06-06|Estimate|2018-01-29|2018-02-27|Actual|June 26, 2012|Actual|2012-06-26|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 7, 2015|Actual|2015-10-07||Interventional|Tugela|The intent-to-treat (ITT) Analysis Set included all participants randomized in the study regardless of whether study drug was administered and with treatment group designated according to initial randomization.|A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 3|416|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 21:29:40.342326|2018-05-31 21:29:40.342326
NCT01569282|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-04-20|2012-03-30|2012-04-03|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|||Double Bypass Versus Stent-treatment in Irresectable Pancreatic Cancer|Double Bypass vs Stent Strategy in Peroperatively Diagnosed Irresectable Pancreatic Cancer - A Prospective Randomized Multicenter Study|Withdrawn||N/A|0|Actual|Göteborg University||2||Difficulties to recruit patients|f||||f||||||||||2018-05-31 21:29:41.732165|2018-05-31 21:29:41.732165
NCT01569269|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-04-02|2012-04-02|2012-04-03|Estimate|||||||2012-04-02|2012-04-03|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Reiki, Yoga, Meditation, on the Physical and Psychological Symptoms of Chemotherapy-Induced Peripheral Neuropathy|A Randomized, Four-Arm Study Comparing Reiki, Yoga, Meditation, or Patient Education Group for Addressing Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)|Completed||N/A|36|Actual|George Mason University||4|||f||||f||||||||||2018-05-31 21:29:41.833536|2018-05-31 21:29:41.833536
NCT01569256|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-04-03|2012-04-02|2012-04-03|Estimate|||||||2012-04-03|2012-04-04|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Ovarian Hyperstimulation Syndrome and Cabergoline|The Effect Of Cabergoline On Follicular Microenvironment Profile In Patients With High Risk Of Ohss|Completed||N/A|40|Actual|Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital||2|||f||||t||||||||||2018-05-31 21:29:41.920541|2018-05-31 21:29:41.920541
NCT01569243|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2014-02-04|2012-03-30|2012-04-03|Estimate|||||||2014-02-04|2014-02-06|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|TTM||Text to Move (TTM)Study|Using Activity Monitoring and Text Messaging For Behavior Change in a Diabetes Self-Management Program|Completed||Phase 2|126|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:29:41.991135|2018-05-31 21:29:41.991135
NCT01569230|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-04-02|2012-03-30|2012-04-03|Estimate|||||||2012-04-02|2012-04-04|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Efficacy and Safety Study of Individualized and Standardized Acupuncture Treatment for Knee Osteoarthritis|Clinical Trial to Evaluate and Compare the Efficacy and Safety of Individualized and Standardized Acupuncture for Knee Osteoarthritis Patients: Randomized, Single-blind, Controlled Study|Unknown status|Recruiting|N/A|250|Anticipated|DongGuk University||4|||f||||t||||||||||2018-05-31 21:29:42.084687|2018-05-31 21:29:42.084687
NCT01569217|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-04-28|2012-04-02|2012-04-03|Estimate|||||||2017-04-28|2017-05-01|Actual|June 2011||2011-06-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|DREM||Regional Distribution of Ventilation to Assess Respiratory Muscle Dysfunction|Construction of a Database to Identify Early Indicators of Respiratory Muscle Dysfunction in Neuromuscular Patients From the Optoelectronic Plethysmography Assessment of the Thoracoabdominal Motion|Enrolling by invitation|||200|Anticipated|Centre d'Investigation Clinique et Technologique 805|||2||f||||t||||||||||2018-05-31 21:29:42.179098|2018-05-31 21:29:42.179098
NCT01569204|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-05-10|2012-04-02|2012-04-03|Estimate|||||||2017-05-10|2017-05-11|Actual|October 2012||2012-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|March 2014|Actual|2014-03-31||Interventional|||Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma||Active, not recruiting||Phase 2|100|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 21:29:42.238924|2018-05-31 21:29:42.238924
NCT01569191|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2015-06-22||2017-07-24|2012-04-02|2012-04-03|Estimate|2017-07-24|2018-02-05|Actual||||2017-07-24|2018-02-05|Actual|March 2012||2012-03-31|July 2015|2015-07-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional||Subjects underwent skin prick and bilateral conjunctival challenge tests to confirm systemic and ocular allergic sensitivity to grass pollen|Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis|Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis|Completed||Phase 4|18|Actual|Aston University||4|||f||||f||||||||||2018-05-31 21:29:42.320651|2018-05-31 21:29:42.320651
NCT01569178|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-06-07|2012-04-02|2012-04-03|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2013||2013-09-30|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|BAMI||BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction|The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction.|Recruiting||Phase 3|350|Anticipated|Queen Mary University of London||2|||f||||t|f|f||||||||2018-05-31 21:29:42.642762|2018-05-31 21:29:42.642762
NCT01569165|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-30|2012-04-03|Estimate|||||||2012-03-30|2012-04-03|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Effect of Water Rinsing After Topical Fluoride Application on Dental Plaque pH|Effect of Water Rinsing After APF Application on Dental Plaque Acidogenicity|Completed||N/A|25|Actual|Mashhad University of Medical Sciences||5|||f||||f||||||||||2018-05-31 21:29:42.811415|2018-05-31 21:29:42.811415
NCT01569152|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2017-01-19||2017-03-14|2012-03-30|2012-04-02|Estimate|2017-01-19|2017-03-09|Actual||||2017-03-14|2017-04-12|Actual|May 2012||2012-05-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All randomized participants|Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial With a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Terminated||Phase 2|82|Actual|Merck Sharp & Dohme Corp.|This study was terminated early (12 September 2013) based on preliminary analysis of data. The results of this study need to be interpreted with caution given the small sample size (82 participants) resulting from the early termination of the study.|3|||f||||f||||||||||2018-05-31 21:29:42.929437|2018-05-31 21:29:42.929437
NCT01569139|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-10-01|2012-03-30|2012-04-02|Estimate|||||||2015-10-01|2015-10-02|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Comparison of Information Recorded in MINAP, GPRD and HES: a CALIBER Study|Comparison of the Information Recorded in the Myocardial Ischaemia National Audit Project, the General Practice Research Database and Hospital Episode Statistics: a CALIBER Study|Completed|||21000|Actual|London School of Hygiene and Tropical Medicine|||3||f||||t||||||||||2018-05-31 21:29:43.553182|2018-05-31 21:29:43.553182
NCT01569126|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2013-09-20||2014-01-14|2012-03-30|2012-04-02|Estimate|2013-09-20|2013-11-25|Estimate||||2014-01-14|2014-02-10|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||All randomized participants.|A Study of LY110140 in Healthy Japanese Male Participants|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY110140 in Healthy Japanese Male Subjects|Completed||Phase 1|56|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 21:29:43.625455|2018-05-31 21:29:43.625455
NCT01569113|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2013-06-12|2012-03-30|2012-04-02|Estimate|||||||2013-06-12|2013-06-13|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.|A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo.|Completed||Phase 4|76|Actual|HRA Pharma||2|||f||||f||||||||||2018-05-31 21:29:44.371172|2018-05-31 21:29:44.371172
NCT01569100|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-03-30|2012-03-30|2012-04-02|Estimate|||||||2012-03-30|2012-04-02|Estimate|December 2005||2005-12-31|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Atorvastatin After Aneurysmal Subarachnoid Hemorrhage|Atorvastatin Effect in Incidence and Ischemic Complications of Vasospasm After Subarachnoid Aneurysmal Hemorrhage: a Cohort Study|Completed|||278|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f||||f||||||||||2018-05-31 21:29:44.451253|2018-05-31 21:29:44.451253
NCT01569087|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2015-02-05||2016-10-24|2012-03-30|2012-04-02|Estimate|2016-08-31|2016-10-24|Estimate||||2016-10-24|2016-12-05|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer|Randomized Multicenter Open-label Phase II Clinical Study Comparing the Efficacy and Safety of the Single Dose of Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy|Completed||Phase 2|60|Actual|Biocad||3|||f||||f||||||||||2018-05-31 21:29:44.536141|2018-05-31 21:29:44.536141
NCT01569074|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2013-11-21||2014-02-27|2012-03-30|2012-04-02|Estimate|2014-02-27|2014-04-07|Estimate||||2014-02-27|2014-04-07|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|OSKIRA-Asia-1||Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis|(OSKIRA-Asia-1): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study in Asia Evaluating Efficacy and Safety of Fostamatinib in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate Therapy|Terminated||Phase 2|163|Actual|AstraZeneca||5||"AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to~   Rigel Pharmaceuticals."|f||||t||||||||||2018-05-31 21:29:45.213911|2018-05-31 21:29:45.213911
NCT01569061|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-03-29|2012-03-29|2012-04-02|Estimate|||||||2012-03-29|2012-04-02|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|PLTOAB||Painless Laser Therapy for Overactive Bladder|A Double-blind, Randomized, Sham-controlled, Multicenter Clinical Trial to Assess the Effectiveness of Therapeutic Class IV Laser LCT-1000TM Treatment for Overactive Bladder Syndrome.|Unknown status|Recruiting|N/A|200|Anticipated|Zipper Urogynecology Associates||2|||f||||f||||||||||2018-05-31 21:29:46.105946|2018-05-31 21:29:46.105946
NCT01569048|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2014-03-04|2012-03-29|2012-04-02|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Randomized Controlled Trial to Evaluate of Dexmedetomidine for the Effect on Operative Visibility in Patients Undergoing Endoscopic Sinus Surgery||Completed||Phase 4|66|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:29:46.171907|2018-05-31 21:29:46.171907
NCT01569035|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2012-09-20|2012-03-29|2012-04-02|Estimate|||||||2012-09-20|2012-09-21|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Warfarine in Unexplained Oligohydramnios|a Randomized Clinical Trial Using Oral Anti Coagulant in the Management of Unexplained Oligohydramnios|Completed||Phase 4|200|Actual|Woman's Health University Hospital, Egypt||1|||f||||t||||||||||2018-05-31 21:29:46.222249|2018-05-31 21:29:46.222249
NCT01569022|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2017-08-25||2017-11-03|2012-03-29|2012-04-02|Estimate|2017-11-03|2017-11-08|Actual||||2017-11-03|2017-11-08|Actual|November 1, 2012|Actual|2012-11-01|November 2017|2017-11-30|March 30, 2017|Actual|2017-03-30|October 30, 2016|Actual|2016-10-30||Interventional|||A Randomized Cross Over Trial of Two Treatments for Sleep Apnea in Veterans With Post-Traumatic Stress Disorder|A Randomized Cross Over Trial of Two Treatments for OSA in Veterans With PTSD|Completed||N/A|42|Actual|VA Office of Research and Development||2|||f||||f|f|t|f|f|f|||No||2018-05-31 21:29:46.286174|2018-05-31 21:29:46.286174
NCT01569009|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2013-07-24|2012-03-29|2012-04-02|Estimate|||||||2013-07-24|2013-07-25|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|PhAB||Physical Activity in Bronchiectasis|Patterns of Physical Activity Levels in Patients With Bronchiectasis: Cross Sectional Study Using Quantitative Methodology|Completed|||63|Actual|University of Ulster|||1||f||||t||||||||||2018-05-31 21:29:46.587605|2018-05-31 21:29:46.587605
NCT01568996|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2018-01-07|2012-03-29|2012-04-02|Estimate|||||||2018-01-07|2018-01-09|Actual|August 2012|Actual|2012-08-31|January 2018|2018-01-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions|A Pilot Study Evaluation of Sulforaphane in Atypical Nevi--Precursor Lesions: Assessment of STAT1 and STAT3 Risk Markers of Melanoma|Completed||Early Phase 1|17|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:29:46.659943|2018-05-31 21:29:46.659943
NCT01568983|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-06-29|2012-03-29|2012-04-02|Estimate|||||||2012-06-29|2012-07-03|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Effects of Polyphenol-rich Berry Juice on Blood Pressure in Hypertensive Subjects|The Effects of Polyphenol-rich Berry Juice on Blood Pressure and Additional CVD Related Parameters in Pre-hypertensive Subjects|Completed||Phase 3|153|Actual|University of Oslo||3|||f||||f||||||||||2018-05-31 21:29:46.739389|2018-05-31 21:29:46.739389
NCT01568970|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-06-12|2012-03-29|2012-04-02|Estimate|||||||2017-06-12|2017-06-14|Actual|January 2012|Actual|2012-01-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|June 2014|Actual|2014-06-30||Interventional|||Multidisciplinary Return-to-work Rehabilitation and Return-to Work Follow-up|Multidisciplinary Return-to-work Rehabilitation and Return-to-work Follow-up, a Randomized Study of Patients With Complex Symptom Disorders|Active, not recruiting||N/A|214|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-05-31 21:29:46.808355|2018-05-31 21:29:46.808355
NCT01568957|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2017-12-08|2012-03-29|2012-04-02|Estimate|||||||2017-12-08|2017-12-12|Actual|September 2011||2011-09-30|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|March 29, 2017|Actual|2017-03-29||Interventional|||Training Dual-Task Walking After Stroke|Training Dual-Task Walking After Stroke: Effects on Attentional and Locomotor Control|Completed||N/A|37|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:29:46.87834|2018-05-31 21:29:46.87834
NCT01568944|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2015-01-27|2012-03-29|2012-04-02|Estimate|||||||2015-01-27|2015-01-28|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Role of Infected Blood Dendritic Cells in Heart Disease Risk|Peripheral Blood Dendritic Cells and Periodontitis|Completed||N/A|19|Actual|Augusta University||2|||f||||t||||||||||2018-05-31 21:29:46.951347|2018-05-31 21:29:46.951347
NCT01568931|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2013-03-06|2012-03-30|2012-04-02|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|March 2017|Anticipated|2017-03-31|March 2015|Anticipated|2015-03-31||Interventional|DISSOLUTION||Local Thrombolytics Before Thrombectomy in STEMI|Local Delivery of thrombolytIcs Before Thrombectomy in patientS With ST-elevatiOn myocardiaL Infarction Undergoing Primary percuTaneous Coronary interventION - The DISSOLUTION Randomized Trial|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:29:47.039602|2018-05-31 21:29:47.039602
NCT01568918|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-11-07|2012-03-29|2012-04-02|Estimate|||||||2017-11-07|2017-11-09|Actual|May 2012||2012-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery|The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery|Recruiting||Phase 3|350|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 21:29:47.108755|2018-05-31 21:29:47.108755
NCT01568905|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|2015-12-02||2017-01-17|2012-03-29|2012-04-02|Estimate|2016-11-15|2017-01-12|Estimate||||2017-01-17|2017-03-01|Actual|February 2011||2011-02-28|January 2017|2017-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Daily cigarette smokers|Palatability of Experimental Cigarettes - Study 2|Palatability of Experimental Cigarettes|Completed||N/A|36|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 21:29:47.210352|2018-05-31 21:29:47.210352
NCT01568892|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2013-08-15||2014-01-02|2012-03-29|2012-04-02|Estimate|2014-01-02|2014-02-19|Estimate||||2014-01-02|2014-02-19|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|October 2012|Actual|2012-10-31||Interventional|VIKING-4||Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir|A Phase III Randomized, Double-blind Trial Investigating the Activity of Dolutegravir 50 mg BID vs Placebo Over 7 Days in HIV-1-infected Subjects With RAL/ELV Resistance, Followed by an Open-label Phase With an Optimized Background Regimen|Unknown status|Active, not recruiting|Phase 3|30|Actual|ViiV Healthcare||3|||t||||f||||||||||2018-05-31 21:29:47.626403|2018-05-31 21:29:47.626403
NCT01568879|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2015-03-04|2012-03-29|2012-04-02|Estimate|||||||2015-03-04|2015-03-06|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluating the Effectiveness of a Chronic Disease Management Program for Gout|Evaluating the Effectiveness of a Chronic Disease Management Program for Gout|Completed||N/A|104|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 21:29:48.424464|2018-05-31 21:29:48.424464
NCT01568866|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2015-11-06||2018-02-14|2012-03-30|2012-04-02|Estimate|2015-11-06|2015-12-11|Estimate||||2018-02-14|2018-03-14|Actual|June 20, 2012|Actual|2012-06-20|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|November 10, 2014|Actual|2014-11-10||Interventional|ENDEAVOR|Intent-to-treat population (all randomized participants)|Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients|A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma|Completed||Phase 3|929|Actual|Amgen||2|||f||||t||||||||||2018-05-31 21:29:48.566613|2018-05-31 21:29:48.566613
NCT01568853|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-04-05|2012-03-30|2012-04-02|Estimate|||||||2012-04-05|2012-04-06|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Prospective Study of The Complement Depletion in Patients With Severe Abdominal Sepsis|The Complement C3 Depletion in Patients With Severe Abdominal Sepsis: Risk Prediction and the Association With Down-regulated Adaptive Immunity|Completed||N/A|75|Actual|Jinling Hospital, China|||||f||||t||||||||||2018-05-31 21:29:50.153178|2018-05-31 21:29:50.153178
NCT01568840|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-03-29|2012-03-29|2012-04-02|Estimate|||||||2012-03-29|2012-04-02|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|February 2011||2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Global Postural Reeducation and Segmental Exercises in Patients With Scapular Dyskinesis and Cervicalgia|Effectiveness of Global Postural Reeducation and Segmental Exercises on Function, Pain, and Quality of Life of Patients With Scapular Dyskinesis and Cervicalgia: A Randomized Clinical Study|Completed||Phase 1|30||Irmandade da Santa Casa de Misericordia de Sao Paulo||2|||f||||t||||||||||2018-05-31 21:29:50.213768|2018-05-31 21:29:50.213768
NCT01568827|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2015-09-25||2016-09-26|2012-03-29|2012-04-02|Estimate|2016-02-17|2016-03-15|Estimate||||2016-09-26|2016-09-27|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||older obese and overweight males|Inflammation, Polyphenols, and Genetics|Inflammation, Polyphenols, and Genetics: A Pilot Study in Overweight and Obese Adult Males to Determine Whether Black-Raspberry Consumption Affects Markers of Inflammation in Study Participants Fed a High-Fat, High-Calorie Challenge Meal|Completed||Phase 1/Phase 2|10|Actual|Ohio State University||2|||f||||f||||||||No||2018-05-31 21:29:50.282752|2018-05-31 21:29:50.282752
NCT01568814|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-29|2012-04-02|Estimate|||||||2012-03-30|2012-04-03|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|LOWPEG||Low Volume PEG With Low Residue Test Meals Versus High Volume Split-dose PEG Bowel Preparation|Efficacy and Tolerability of Morning (AM) Only Low Volume (2L) PEG With Low Residue Test Meals Versus High Volume (4L) Split-dose (PM/AM) PEG Bowel Preparation With Standard Meals: A Prospective Randomized, Investigator Blinded Trial|Completed||Phase 3|188|Actual|Inje University||2|||f||||f||||||||||2018-05-31 21:29:50.610092|2018-05-31 21:29:50.610092
NCT01568801|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-04-15|2012-03-30|2012-04-02|Estimate|||||||2015-04-15|2015-04-16|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|SingaPACE||Evaluation of the Singapura Program of All Inclusive Care for the Elderly (SingaPACE) Demonstration Project|Evaluation of the Singapura Program of All Inclusive Care for the Elderly|Completed||N/A|80|Anticipated|National University, Singapore||2|||f||||f||||||||||2018-05-31 21:29:50.6716|2018-05-31 21:29:50.6716
NCT01568788|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-06-18|2012-03-29|2012-04-02|Estimate|||||||2012-06-18|2012-06-20|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine|Post-marketing Clinical Observation of Hualan's Inactivated Influenza Vaccine: A Single Center, Parallelled, Controlled, Randomised Clinical Trial|Completed||N/A|600|Actual|Hualan Biological Engineering, Inc.||3|||f||||t||||||||||2018-05-31 21:29:50.732137|2018-05-31 21:29:50.732137
NCT01568775|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-29|2012-03-29|2012-04-02|Estimate|||||||2012-03-29|2012-04-02|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects|An Open-label, Parallel Group, Single-sequence Study to Evaluate Pharmacokinetics, Safety, and Tolerability of a Single Dose Administration of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects|Completed||Phase 1|12|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:29:50.797361|2018-05-31 21:29:50.797361
NCT01568762|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-30|2012-04-02|Estimate|||||||2012-03-30|2012-04-02|Estimate|October 2010||2010-10-31|March 2012|2012-03-31||||July 2011|Actual|2011-07-31||Interventional|||To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma|A Randomized, Double-blind, Placebo Controlled Study to Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 (Sequential Administration of a Fixed Dose of VAK694 and Single Ascending Doses of QAX576) in Patients With Well-controlled Mild to Moderate Asthma|Completed||Phase 1|50|Actual|Novartis||4|||f||||||||||||||2018-05-31 21:29:50.855618|2018-05-31 21:29:50.855618
NCT01568749|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-11-20|2012-03-29|2012-04-02|Estimate|||||||2014-11-20|2014-11-24|Estimate|December 2008||2008-12-31|June 2014|2014-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations|A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations|Completed||Phase 1|14|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 21:29:50.915633|2018-05-31 21:29:50.915633
NCT01568736|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-30|2012-04-02|Estimate|||||||2012-03-30|2012-04-02|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|HIDS-MKD||B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency|B7 Coreceptor Molecules as Clinically-Relevant Surrogate Biomarkers in the Hyper IgD Syndrome (HIDS) Form of Mevalonate Kinase Deficiency (MKD)|Unknown status|Recruiting||10|Anticipated|Michigan Technological University|||||f||||t||||||Samples With DNA|"~     Blood Urine~   "|||2018-05-31 21:29:51.060254|2018-05-31 21:29:51.060254
NCT01568723|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-08-02|2012-03-30|2012-04-02|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2012||2012-01-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|BetrnetRF||Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation|Stem Cells And The Origins Of Barrett's Esophagus:Identification Of Novel Biomarkers And Gene Signatures In Barrett's Esophagus|Active, not recruiting|||125|Actual|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     biopsy samples, serum, plasma, buffycoat, cytology brushings~   "|No||2018-05-31 21:29:51.144666|2018-05-31 21:29:51.144666
NCT01568710|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2018-02-13|2012-03-30|2012-04-02|Estimate|||||||2018-02-13|2018-02-14|Actual|March 21, 2012||2012-03-21|December 28, 2017|2017-12-28||||||||Observational|||Blood Flow and Pain Crises in People With Sickle Cell Disease|Measurement of the Reactive Hyperemia Index in Sickle Cell Patients During Pain Crisis and After Recovery|Completed|||94|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:51.230205|2018-05-31 21:29:51.230205
NCT01568697|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2018-04-27|2012-03-30|2012-04-02|Estimate|||||||2018-04-27|2018-04-30|Actual|March 13, 2012||2012-03-13|June 13, 2017|2017-06-13||||||||Observational|||Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)|Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction|Recruiting|||650|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:51.307457|2018-05-31 21:29:51.307457
NCT01568684|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2018-05-19|2012-03-30|2012-04-02|Estimate|||||||2018-05-19|2018-05-22|Actual|March 12, 2012||2012-03-12|December 11, 2012|2012-12-11|December 11, 2012|Actual|2012-12-11|December 11, 2012|Actual|2012-12-11||Interventional|||Brain Imaging, Genetics and Treatment for Major Depression|Pharmacogenetics and Neuroimaging in Major Depressive Disorder (PAN-D)|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:51.388998|2018-05-31 21:29:51.388998
NCT01568671|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2018-05-08|2012-03-30|2012-04-02|Estimate|||||||2018-05-08|2018-05-09|Actual|March 14, 2012||2012-03-14|April 24, 2018|2018-04-24||||||||Observational|||Energy Expenditure Responses to Different Temperatures|Energy Expenditure Responses to Different Temperatures|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:51.524857|2018-05-31 21:29:51.524857
NCT01568658|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2018-05-08|2012-03-30|2012-04-02|Estimate|||||||2018-05-08|2018-05-09|Actual|March 14, 2012||2012-03-14|April 30, 2018|2018-04-30||||||||Observational|||Genetic and Physical Study of Childhood Nerve and Muscle Disorders|Clinical and Molecular Manifestations of Neuromuscular and Neurogenetic Disorders of Childhood|Recruiting|||5650|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:51.873509|2018-05-31 21:29:51.873509
NCT01568645|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2017-07-06|2012-03-30|2012-04-02|Estimate|||||||2017-07-06|2017-07-07|Actual|March 2, 2012||2012-03-02|December 11, 2012|2012-12-11|December 11, 2012|Actual|2012-12-11|December 11, 2012|Actual|2012-12-11||Interventional|||Imatinib and Carvedilol for High Blood Pressure in the Lungs in Adults With Sickle Cell Disease|A Pilot Study of Treatment of Adults With Sickle Cell Disease Associated Pulmonary Hypertension Based on Hemodynamic Stratification: Safety and Tolerability Study of Imatinib and Carvedilol|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:52.174178|2018-05-31 21:29:52.174178
NCT01568632|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-11-20|2012-03-30|2012-04-02|Estimate|||||||2012-11-20|2012-11-21|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|||||Interventional|||Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma|A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:29:52.455102|2018-05-31 21:29:52.455102
NCT01568619|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-01-15|2012-03-30|2012-04-02|Estimate|||||||2017-01-15|2017-01-18|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Validation of Electrical Cardiometry Versus Fick Method in Cardiac Output Measurement|Validation of Electrical Cardiometry Versus Fick Method to Measure Stroke Volume and Cardiac Output in Patients With or Suspected of Having Heart Failure|Completed|||30|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 21:29:52.72339|2018-05-31 21:29:52.72339
NCT01568606|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2012-03-30|2012-03-30|2012-04-02|Estimate|||||||2012-03-30|2012-04-02|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety of Body Composition Analysis in Heart Failure Patients With Implantable Cardioverter Defibrillators (ICDs)|Safety of Body Composition Analysis Using Bioimpedance in Heart Failure Patients With Implantable Cardioverter Defibrillators (ICDs)|Completed||N/A|20|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 21:29:52.958416|2018-05-31 21:29:52.958416
NCT01568593|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2014-10-07||2016-03-07|2012-03-29|2012-04-02|Estimate|2014-10-24|2014-10-27|Estimate||||2016-03-07|2016-04-04|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome|Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome|Completed||Phase 3|93|Actual|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 21:29:53.288059|2018-05-31 21:29:53.288059
NCT01568580|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-29|2012-03-29|2012-04-02|Estimate|||||||2012-03-29|2012-04-02|Estimate|December 2004||2004-12-31|March 2012|2012-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A|Open-label, Non-comparative, Multicenter, Phase III for Evaluation of Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Previously Treated Patients With Hemophilia A|Completed||Phase 3|71|Actual|Green Cross Corporation||1|||f||||f||||||||||2018-05-31 21:29:54.018099|2018-05-31 21:29:54.018099
NCT01568567|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-07-03|2012-03-29|2012-04-02|Estimate|||||||2012-07-03|2012-07-04|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|BSSII||Study to Demonstrate the Safety of a Novel Powder Formulation of Lactobacilli in Adults|To Demonstrate That a Novel Powder Formulation of Lactobacillus Reuteri DSM 17938 is Safe in Adults, a Randomized, Placebo Controlled Double-blind Study|Completed||Phase 1/Phase 2|32|Actual|Good Food Practice, Sweden||3|||f||||f||||||||||2018-05-31 21:29:54.27941|2018-05-31 21:29:54.27941
NCT01568554|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-05-04|2012-03-30|2012-04-02|Estimate|||||||2018-05-04|2018-05-08|Actual|December 2011||2011-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Clinical Diagnosis of Acute Porphyria|Clinical Diagnosis of Acute Porphyria|Recruiting|||600|Anticipated|University of California, San Francisco|||3||f||||t||||||||||2018-05-31 21:29:54.522196|2018-05-31 21:29:54.522196
NCT01568541|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-09-14|2012-03-30|2012-04-02|Estimate|||||||2012-09-14|2012-09-18|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|March 2009|Actual|2009-03-31|July 2008|Actual|2008-07-31||Interventional|F||Fluoride Intake From Toothbrushig With Children's or Regular Toothpastes|Fluoride Intake From Tooth Brushing With Children's and Regular Toothpastes: a Study With Preschooler Children|Completed||N/A|208|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 21:29:54.873624|2018-05-31 21:29:54.873624
NCT01568528|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-09-20|2012-03-29|2012-04-02|Estimate|||||||2017-09-20|2017-09-25|Actual|March 2013||2013-03-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Oxytocin as Adjunctive Treatment of Schizophrenia|Oxytocin as Adjunctive Treatment of Schizophrenia|Active, not recruiting||N/A|40|Anticipated|Emory University||2|||f||||t||||||||No||2018-05-31 21:29:55.193995|2018-05-31 21:29:55.193995
NCT01568515|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-10-31|2012-03-29|2012-04-02|Estimate|||||||2014-10-31|2014-11-04|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students|A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase HPV Vaccine Utilization and Adherence Among College Students in Eastern North Carolina.|Completed||Early Phase 1|283|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 21:29:55.498749|2018-05-31 21:29:55.498749
NCT01568502|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-30|2012-04-02|Estimate|||||||2012-03-30|2012-04-02|Estimate|January 2001||2001-01-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Dobutamine Stress Cardiac Magnetic Resonance Versus Echocardiography for the Assessment of Outcome. Are the Two Imaging Modalities Comparable?||Completed|||5008|Actual|University Hospital Heidelberg|||2||f||||f||||||||||2018-05-31 21:29:55.769918|2018-05-31 21:29:55.769918
NCT01568489|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-09-21|2012-03-30|2012-04-02|Estimate|||||||2015-09-21|2015-09-23|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis|A Randomized, Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of HL-009 Liposomal Gel in Adult Patients With Mild to Moderate Atopic Dermatitis|Completed||Phase 2|120|Actual|HanAll BioPharma Co., Ltd.||4|||f||||f||||||||||2018-05-31 21:29:56.029796|2018-05-31 21:29:56.029796
NCT01568476|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-12-01|2012-03-29|2012-04-02|Estimate|||||||2017-12-01|2017-12-05|Actual|July 2011||2011-07-31|December 2017|2017-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Does Interneural Local Anesthetic Spread at the Site of Sciatic Nerve Bifurcation Shorten Block Onset Time?|Does Interneural Local Anesthetic Spread at the Site of Sciatic Nerve Bifurcation Shorten Block Onset Time?|Completed||N/A|88|Actual|University Health Network, Toronto||2|||f||||||||||||||2018-05-31 21:29:56.297674|2018-05-31 21:29:56.297674
NCT01568450|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-01-25|2012-03-30|2012-04-02|Estimate|||||||2013-01-25|2013-01-28|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|GL2907-101||A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Crossover Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers|Completed||Phase 1|24|Actual|GL Pharm Tech Corporation||3|||f||||f||||||||||2018-05-31 21:29:56.97878|2018-05-31 21:29:56.97878
NCT01568437|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-12-07|2012-03-30|2012-04-02|Estimate|||||||2015-12-07|2015-12-09|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Transversus Abdominis Plane (TAP) Block in Laparoscopic Gastric-bypass Surgery|Is the Analgesic Effect of the Transversus Abdominis Plane (TAP) Block in Laparoscopic Gastric-bypass Surgery Useful?|Completed||Phase 3|70|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:29:57.243575|2018-05-31 21:29:57.243575
NCT01568424|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2017-03-03||2017-04-21|2012-03-30|2012-04-02|Estimate|2017-03-03|2017-04-17|Actual||||2017-04-21|2017-05-30|Actual|September 2009||2009-09-30|April 2017|2017-04-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|CMagRVAS|This study includes data from 25 consecutive patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.|CentriMag RVAS U.S. Post-approval Study Protocol|CentriMag RVAS U.S. Post-approval Study Protocol|Completed||N/A|25|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 21:29:57.482203|2018-05-31 21:29:57.482203
NCT01568411|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-03-05|2012-03-30|2012-04-02|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211|A Phase 1, Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211|Completed||Phase 1|20|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||||2018-05-31 21:29:57.7584|2018-05-31 21:29:57.7584
NCT01568398|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2014-02-07|2012-03-30|2012-04-02|Estimate|||||||2014-02-07|2014-02-10|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy||Completed||Phase 3|27|Actual|Takeda||1|||f||||||||||||||2018-05-31 21:29:57.814984|2018-05-31 21:29:57.814984
NCT01568385|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2014-02-07|2012-03-30|2012-04-02|Estimate|||||||2014-02-07|2014-02-10|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy||Completed||Phase 3|30|Actual|Takeda||1|||f||||||||||||||2018-05-31 21:29:57.886472|2018-05-31 21:29:57.886472
NCT01568372|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-10-03|2012-03-30|2012-04-02|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2010||2010-05-31|October 2017|2017-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy of a Nurse Telephone Follow-up on Pain Intensity After Removal of Tonsils in Children|Efficacy of a Nurse Telephone Follow-up on Post-tonsillectomy Pain Management and Complications in Children: A Randomized Clinical Trial|Completed||N/A|52|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 21:29:57.953102|2018-05-31 21:29:57.953102
NCT01568359|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2014-12-04|2012-03-30|2012-04-02|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors|Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.|Completed|||49|Actual|Emory University|||1||f||||f||||||Samples Without DNA|"~     Blood and urine samples obtained from subjects.~   "|||2018-05-31 21:29:58.042735|2018-05-31 21:29:58.042735
NCT01568346|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-08-01|2012-03-30|2012-04-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy|Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy|Terminated||Phase 3|9|Actual|Dana-Farber Cancer Institute||2||Slow Accural|f||||t||||||||No||2018-05-31 21:29:58.103082|2018-05-31 21:29:58.103082
NCT01568333|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-07-26|2012-03-30|2012-04-02|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia|A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia|Unknown status|Recruiting|Phase 2|30|Anticipated|Shandong University||1|||f||||t||||||||||2018-05-31 21:29:59.082983|2018-05-31 21:29:59.082983
NCT01568320|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29||2017-02-27|2018-05-03|2012-03-30|2012-04-02|Estimate||||2017-02-27|2017-02-28|Actual|2018-05-03|2018-05-08|Actual|August 2012||2012-08-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|February 2015|Actual|2015-02-28||Interventional|||Zenith® Dissection Clinical Trial|Use of the Zenith® Dissection Endovascular System in the Treatment of Patients With Acute, Complicated Type B Aortic Dissection|Active, not recruiting||N/A|73|Actual|Cook Group Incorporated||1|||t||||||||||||||2018-05-31 21:29:59.191928|2018-05-31 21:29:59.191928
NCT01568307|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2013-12-16|2012-03-29|2012-04-02|Estimate|||||||2013-12-16|2013-12-18|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|MDD||Major Depressive Disorder - Understanding The Link Between The Brain And The Heart|Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart|Unknown status|Recruiting|Phase 4|80|Anticipated|Baker IDI Heart and Diabetes Institute|||||f||||f||||||||||2018-05-31 21:29:59.291213|2018-05-31 21:29:59.291213
NCT01568294|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-08-19|2012-03-30|2012-04-02|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma|A Phase 1, Multicenter, Open-label, Dose-escalation Study in Japan to Determine the Tolerated Dose and to Evaluate the Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination With Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma|Completed||Phase 1|12|Actual|Celgene||1|||f||||f||||||||||2018-05-31 21:29:59.39582|2018-05-31 21:29:59.39582
NCT01568281|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-06-22|2012-03-29|2012-04-02|Estimate|||||||2012-06-22|2012-06-25|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bioequivalence Study Comparing Arimidex Tablet and Anastrozole ODF in Japanese Healthy Male Subjects|A Randomised, Open Label, Single Centre, 2 Way Crossover Bioequivalence Study Comparing Arimidex Tablet 1 mg and Anastrozole Orally Rapid Disintegration Film Formula 1 mg After Single Oral Administration in Japanese Healthy Male Subjects|Completed||Phase 1|58|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 21:29:59.47605|2018-05-31 21:29:59.47605
NCT01568268|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2013-12-24|2012-03-30|2012-04-02|Estimate|||||||2013-12-24|2013-12-25|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting|A Randomized, Double Blind, Multicenter Phase III Trial to Evaluate the Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting|Completed||Phase 3|384|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:30:00.358419|2018-05-31 21:30:00.358419
NCT01568255|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-11-17|2012-03-30|2012-04-02|Estimate|||||||2017-11-17|2017-11-21|Actual|March 2012||2012-03-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms|Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms|Recruiting||Phase 4|40|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||Yes||2018-05-31 21:30:00.457578|2018-05-31 21:30:00.457578
NCT01568242|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-29|2012-03-29|2012-04-02|Estimate|||||||2012-03-29|2012-04-02|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Changes in Vitreous Temperature During Phacoemulsification|Changes in Vitreous Temperature During Phacoemulsification|Unknown status|Recruiting|N/A|15|Anticipated|Asociación para Evitar la Ceguera en México||1|||f||||t||||||||||2018-05-31 21:30:00.544852|2018-05-31 21:30:00.544852
NCT01568229|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28||2014-05-13|2014-09-19|2012-03-29|2012-04-02|Estimate||||2014-05-13|2014-05-28|Estimate|2014-09-19|2014-10-01|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms|Terminated||Phase 2|111|Actual|Amgen||4||Toxic Epidermal Necrolysis|f||||f||||||||||2018-05-31 21:30:00.636733|2018-05-31 21:30:00.636733
NCT01568216|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27||2014-05-08|2015-07-08|2012-03-29|2012-04-02|Estimate||||2014-05-08|2014-05-23|Estimate|2015-07-08|2015-07-30|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms|"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms"|Terminated||Phase 2|121|Actual|Amgen||4||Toxic Epidermal Necrolysis|f||||f||||||||||2018-05-31 21:30:00.784951|2018-05-31 21:30:00.784951
NCT01568203|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-10-05|2012-03-29|2012-04-02|Estimate|||||||2012-10-05|2012-10-10|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia|Phase I, Randomized, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 579 in Healthy Adult Subjects and Patients With Stable Schizophrenia or Schizoaffective Disorder|Terminated||Phase 1|50|Actual|Amgen||2||Amgen decision (business)|f||||f||||||||||2018-05-31 21:30:01.023515|2018-05-31 21:30:01.023515
NCT01568190|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-01-05|2012-03-30|2012-04-02|Estimate|||||||2015-01-05|2015-01-06|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|AV-M-01||An Open Trial to Assess the Tolerability of AVANZ Mite Mix Immunotherapy|An Open Trial to Asses the Tolerability of AVANZ Mite Mix Immunotherapy|Completed||Phase 2/Phase 3|102|Actual|ALK-Abelló A/S||1|||f||||f||||||||||2018-05-31 21:30:01.112438|2018-05-31 21:30:01.112438
NCT01568177|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-11-17|2012-03-30|2012-04-02|Estimate|||||||2017-11-17|2017-11-21|Actual|February 2011||2011-02-28|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cardiac Autonomic Function in Women With Microvascular Coronary Dysfunction|Cardiac Autonomic Function in Women With Microvascular Coronary Dysfunction|Recruiting||N/A|60|Anticipated|Cedars-Sinai Medical Center||3|||f||||f||||||||Yes||2018-05-31 21:30:01.204626|2018-05-31 21:30:01.204626
NCT01568164|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-09-30|2012-03-30|2012-04-02|Estimate|||||||2016-09-30|2016-10-04|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CONFIGURE-HF||Safety and Efficacy Study of the BioVentrix PliCath HF System|Phase II Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy|Active, not recruiting||N/A|120|Anticipated|BioVentrix||1|||f||||t||||||||||2018-05-31 21:30:01.41616|2018-05-31 21:30:01.41616
NCT01568151|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-05-08|2012-03-29|2012-04-02|Estimate|||||||2017-05-08|2017-05-10|Actual|April 2009||2009-04-30|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2013|Actual|2013-12-31||Interventional|TIME||Testing Interventions to Motivate and Educate|Testing Interventions to Motivate and Educate|Active, not recruiting||N/A|551|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 21:30:01.717186|2018-05-31 21:30:01.717186
NCT01568138|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-04-02|2012-03-30|2012-04-02|Estimate|||||||2012-04-02|2012-04-03|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|March 2013|Anticipated|2013-03-31|August 2012|Anticipated|2012-08-31||Interventional|CONFIGURE-HF||Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy|This Study is a Multi-center, Prospective, Single-armed, Study Designed to Evaluate the Safety and Feasibility of the BioVentrix PliCath HF System for Left Ventricular (LV) Volume and Radius Reduction Through Scar Exclusion in Patients Whose Systolic HF is Due to Ischemic Cardiomyopathy.|Unknown status|Active, not recruiting|N/A|26|Actual|BioVentrix|||||f||||t||||||||||2018-05-31 21:30:01.860048|2018-05-31 21:30:01.860048
NCT01568125|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-30|2012-03-30|2012-04-02|Estimate|||||||2012-03-30|2012-04-02|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Effect of Incretin-related Drugs on Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus|Effect of Incretin-related Drugs on Energy and Contents of Dietary Intake in Japanese Patients With Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting||100|Anticipated|Nagaoka Red Cross Hospital|||1||f||||f||||||||||2018-05-31 21:30:02.01745|2018-05-31 21:30:02.01745
NCT01567605|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-04-17|2012-03-28|2012-03-30|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2012||2012-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bowel Care and Cardiovascular Function After Spinal Cord Injury|Bowel Care and Cardiovascular Function After Spinal Cord Injury|Recruiting||Phase 4|13|Anticipated|Simon Fraser University||2|||f||||f||||||||No||2018-05-31 21:30:12.675379|2018-05-31 21:30:12.675379
NCT01568112|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2016-05-04||2016-05-04|2012-03-30|2012-04-02|Estimate|2016-05-04|2016-06-13|Estimate||||2016-05-04|2016-06-13|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||All randomized and treated participants|Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate|A Randomized, Double-Blind, Phase 3b Study to Evaluate Effects of Aspirin or Dose Titration on Flushing and Gastrointestinal Events Following Oral Administration of BG00012 Dosed at 240 mg BID|Completed||Phase 3|173|Actual|Biogen||4|||f||||f||||||||||2018-05-31 21:30:02.608905|2018-05-31 21:30:02.608905
NCT01568099|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-08-14|2012-03-29|2012-04-02|Estimate|||||||2015-08-14|2015-08-17|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease|A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of Two Doses of AFFITOPE® PD01A Formulated With Adjuvant to Patients With Parkinson's Disease|Completed||Phase 1|32|Actual|Affiris AG||3|||f||||t||||||||||2018-05-31 21:30:05.873827|2018-05-31 21:30:05.873827
NCT01568086|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2013-11-05|2012-03-29|2012-04-02|Estimate|||||||2013-11-05|2013-11-06|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Observational|||Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A|Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A|Terminated|||16|Actual|Affiris AG|||2|The study could not be performed as planned for organizational reasons.|f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:30:05.937416|2018-05-31 21:30:05.937416
NCT01568073|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2014-11-26||2015-09-01|2012-03-30|2012-04-02|Estimate|2015-01-06|2015-01-08|Estimate||||2015-09-01|2015-09-18|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon"|"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study"|Completed||Phase 3|600|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 21:30:06.032422|2018-05-31 21:30:06.032422
NCT01568060|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-04-21|2012-03-29|2012-04-02|Estimate|||||||2016-04-21|2016-04-25|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea|Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus Vaccine, Infanrix-IPV When Administered According to the Approved Prescribing Information in Korea|Completed|||645|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:30:06.824284|2018-05-31 21:30:06.824284
NCT01568047|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2014-02-05||2015-11-23|2012-03-30|2012-04-02|Estimate|2014-12-19|2015-01-08|Estimate||||2015-11-23|2015-12-24|Estimate|February 2010||2010-02-28|November 2015|2015-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients|"Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (Wearing-off Phenomenon)"|Completed||Phase 2|40|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 21:30:06.931847|2018-05-31 21:30:06.931847
NCT01568034|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2014-02-05||2014-12-19|2012-03-30|2012-04-02|Estimate|2014-12-19|2015-01-12|Estimate||||2014-12-19|2015-01-12|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067|A Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 on the Levodopa Pharmacokinetics, Motor Response, and Erythrocyte Soluble Catechol-O-methyltransferase Activity in Parkinson's Disease Patients Concomitantly Treated With Levodopa/Dopa-decarboxylase Inhibitor|Completed||Phase 2|10|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 21:30:07.435016|2018-05-31 21:30:07.435016
NCT01568021|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2015-01-27||2015-01-27|2012-03-30|2012-04-02|Estimate|2015-01-27|2015-02-10|Estimate||||2015-01-27|2015-02-10|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)||Completed|||100|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:30:07.841997|2018-05-31 21:30:07.841997
NCT01568008|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2013-07-18||2013-07-18|2012-03-30|2012-04-02|Estimate|2013-07-18|2013-09-20|Estimate||||2013-07-18|2013-09-20|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)||Completed|||933|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:30:08.020393|2018-05-31 21:30:08.020393
NCT01567995|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-11-24|2012-03-29|2012-04-02|Estimate|||||||2017-11-24|2017-11-28|Actual|February 28, 2008|Actual|2008-02-28|November 2017|2017-11-30|February 10, 2009|Actual|2009-02-10|January 1, 2009|Actual|2009-01-01||Interventional|||Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety|Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate Cream in Patients With Eczema for Two Weeks to Evaluate the Efficacy and Safety|Completed||Phase 3|240|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:30:08.280719|2018-05-31 21:30:08.280719
NCT01567982|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2015-07-14|2012-03-28|2012-03-30|Estimate|||||||2015-07-14|2015-07-15|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|tDCSsmokers||Effects of Transcranial Direct Current Stimulation on Tobacco Withdrawal Symptoms|Phase 1 Study of Effects of tDCS on Tobacco Withdrawal Symptoms|Completed||Phase 1|60|Actual|Yale University||1|||f||||f||||||||||2018-05-31 21:30:08.375413|2018-05-31 21:30:08.375413
NCT01567969|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-10-12|2012-03-28|2012-03-30|Estimate|||||||2016-10-12|2016-10-14|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|FHDP||Family Health and Development Project|Family Health and Development Project: Intensive In-home Child and Adolescent Psychiatric Service (IICAPS) vs. Home-based Child Treatment Coordination (Home-based CTC) for Seriously Emotionally Disturbed Children|Completed||Phase 3|110|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:30:08.515195|2018-05-31 21:30:08.515195
NCT01567956|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2016-11-04|2012-03-29|2012-03-30|Estimate|||||||2016-11-04|2016-11-07|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study|Phase III Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment|Terminated||Phase 3|150|Actual|sigma-tau i.f.r. S.p.A.||2||Evidence of very low probability to success. No safety issues|f||||t||||||||No||2018-05-31 21:30:08.615092|2018-05-31 21:30:08.615092
NCT01567943|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2016-11-07||2017-01-05|2012-03-28|2012-03-30|Estimate|2016-11-07|2017-01-05|Estimate||||2017-01-05|2017-02-23|Actual|March 2012||2012-03-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|CMETG||Contingency Management of Alcohol Abuse in the Severely Mentally ILL|Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill|Completed||N/A|123|Actual|University of Washington||2|||f||||t||||||||No||2018-05-31 21:30:08.856124|2018-05-31 21:30:08.856124
NCT01567930|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-12-13|2012-03-28|2012-03-30|Estimate|||||||2012-12-13|2012-12-17|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Temsirolimus as Second-line Therapy in HCC|A Phase II Study of Temsirolimus as Second-line Therapy in Patients With Advanced, Unresectable Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|25|Anticipated|University of Tennessee Cancer Institute|||||f||||t||||||||||2018-05-31 21:30:09.105957|2018-05-31 21:30:09.105957
NCT01567917|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-03-29|2012-03-29|2012-03-30|Estimate|||||||2012-03-29|2012-03-30|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Observational|||Incidence of Venous Thromboembolism Following Surgery in Patients With Colorectal Cancer|Incidence of Venous Thromboembolism Following Surgery in Korean Patients With Colorectal Cancer; a Prospective Study|Unknown status|Recruiting||600|Anticipated|Seoul National University Bundang Hospital|||2||f||||f||||||||||2018-05-31 21:30:09.194475|2018-05-31 21:30:09.194475
NCT01567904|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28||2016-04-04|2016-04-04|2012-03-28|2012-03-30|Estimate||||2016-04-04|2016-05-03|Estimate|2016-04-04|2016-05-03|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of AVE5026 at Weight-adjusted Doses in Children With a Central Venous Line|An Open-label, Pharmacokinetic, Pharmacodynamic, and Tolerability Study of AVE5026 Administered at Weight-adjusted Doses to Patients Less Than 18 Years of Age With a Central Venous Line (CVL)|Terminated||Phase 2|2|Actual|Sanofi||5||"Decision from Sanofi to withdraw on a worldwide basis the Marketing Authorisation Applications~   for Semuloparin sodium in the adult indication"|f||||t||||||||||2018-05-31 21:30:09.275951|2018-05-31 21:30:09.275951
NCT01567891|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-01-09|2012-03-28|2012-03-30|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2013||2013-06-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||CT Antigen TCR-redirected T Cells for Ovarian Cancer.|A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Adaptimmune||1|||f||||t|t|f||||||||2018-05-31 21:30:09.36042|2018-05-31 21:30:09.36042
NCT01567878|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2014-12-01|2012-03-28|2012-03-30|Estimate|||||||2014-12-01|2014-12-02|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects|Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects|Completed|||80|Actual|University of Sao Paulo|||2||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 21:30:09.454075|2018-05-31 21:30:09.454075
NCT01567865|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2013-08-02|2012-03-28|2012-03-30|Estimate|||||||2013-08-02|2013-08-05|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Lot-to-lot Consistency Trial of JE Live Attenuated SA 14-14-2 Vaccine|A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Manufactured in a New Good Manufacturing Practices Facility and Non-inferiority With Respect to an Earlier Product.|Completed||Phase 4|||PATH||1|||f||||||||||||||2018-05-31 21:30:09.521884|2018-05-31 21:30:09.521884
NCT01567852|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2014-05-21||2014-12-15|2012-03-29|2012-03-30|Estimate|2014-12-15|2014-12-30|Estimate||||2014-12-15|2014-12-30|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time|The Use of Ketamine Versus Methohexital for Electroconvulsive Therapy: A Cross-Over Comparative Study on Patient Recovery and Re-Orientation Time|Completed||N/A|20|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 21:30:09.604065|2018-05-31 21:30:09.604065
NCT01567839|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2013-06-24||2013-11-07|2012-03-29|2012-03-30|Estimate|2013-11-07|2014-01-01|Estimate||||2013-11-07|2014-01-01|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional||No difference.|Testing the Anesthetic Effectiveness of Three Different Dental Local Anesthetics Injected Next to a Lower First Molar|Anesthetic Efficacy of 4% Articaine With 1:100,000 Epinephrine, 4% Prilocaine With 1:200,000 Epinephrine, and 4% Lidocaine With 1:100,000 Epinephrine as a Primary Buccal Infiltration in the Mandibular First Molar.|Completed||Phase 4|60|Actual|Ohio State University|No adverse events.|3|||f||||f||||||||||2018-05-31 21:30:09.957734|2018-05-31 21:30:09.957734
NCT01567826|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2016-05-10||2017-04-11|2012-03-29|2012-03-30|Estimate|2017-01-09|2017-02-27|Actual||||2017-04-11|2017-05-19|Actual|May 2010||2010-05-31|April 2017|2017-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|YELLOW||Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy|Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy. (YELLOW Trial)|Completed||Phase 4|87|Actual|Icahn School of Medicine at Mount Sinai|Limitations - small sample size and short duration of follow-up.|2|||f||||t||||||||||2018-05-31 21:30:10.201174|2018-05-31 21:30:10.201174
NCT01567813|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-11-28|2012-03-29|2012-03-30|Estimate|||||||2017-11-28|2017-11-30|Actual|June 23, 2011|Actual|2011-06-23|November 2017|2017-11-30|June 23, 2018|Anticipated|2018-06-23|June 23, 2018|Anticipated|2018-06-23||Observational|||Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)|Post-Licensure Observational Study of the Safety of GARDASIL™ in Males|Active, not recruiting|||44000|Anticipated|Merck Sharp & Dohme Corp.|||3||f||||t||||||||||2018-05-31 21:30:10.936757|2018-05-31 21:30:10.936757
NCT01567800|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-03-21|2012-03-28|2012-03-30|Estimate|||||||2018-03-21|2018-03-22|Actual|April 2012||2012-04-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Prostate Hypoxia FAZA|A Feasibility Study of Hypoxia Imaging in Patients With Prostate Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-05-31 21:30:10.996996|2018-05-31 21:30:10.996996
NCT01567774|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2013-05-03|2012-03-29|2012-03-30|Estimate|||||||2013-05-03|2013-05-06|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|June 2015|Anticipated|2015-06-30|March 2014|Anticipated|2014-03-31||Interventional|PEARL||Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity|Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:30:11.160395|2018-05-31 21:30:11.160395
NCT01567761|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-03-29|2012-03-29|2012-03-30|Estimate|||||||2012-03-29|2012-03-30|Estimate|May 2012||2012-05-31|March 2012|2012-03-31||||||||Observational|||The Effect of Two Different Artificial Respiration Methods on the Intraocular Pressure During Surgery Under General Anesthesia|A Prospective, Randomized and Double Blind Study on The Effect of Two Different Artificial Respiration Methods on the Intraocular Pressure During Surgery Under General Anesthesia|Unknown status|Not yet recruiting||50|Anticipated|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-05-31 21:30:11.304009|2018-05-31 21:30:11.304009
NCT01567748|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2014-12-03|2012-03-28|2012-03-30|Estimate|||||||2014-12-03|2014-12-05|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||In-human Validation of a Technique for Measuring Central Aortic Hemodynamics With Peripheral Arterial Waveforms|In-human Validation of a Technique for Measuring Central Aortic Hemodynamics With Peripheral Arterial Waveforms|Completed|||40|Actual|University of Alberta|||1||f||||t||||||||||2018-05-31 21:30:11.378409|2018-05-31 21:30:11.378409
NCT01567735|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2017-07-05|2012-03-28|2012-03-30|Estimate|||||||2017-07-05|2017-07-07|Actual|March 27, 2012|Actual|2012-03-27|July 2017|2017-07-31|March 20, 2014|Actual|2014-03-20|March 20, 2014|Actual|2014-03-20||Interventional|RESTORE||A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients|An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Subjects|Completed||Phase 3|107|Actual|Janssen R&D Ireland||1|||f||||t||f||||||||2018-05-31 21:30:11.476039|2018-05-31 21:30:11.476039
NCT01567722|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-11-15|2012-03-29|2012-03-30|Estimate|||||||2017-11-15|2017-11-17|Actual|July 2012||2012-07-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies|Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies|Recruiting|||300|Anticipated|AIDS Malignancy Consortium|||||f||||f||||||Samples With DNA|"~     Fresh-frozen tissue, Peripheral blood mononuclear cells~   "|Yes|Results will be submitted to dBGaP|2018-05-31 21:30:11.653781|2018-05-31 21:30:11.653781
NCT01567709|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2018-04-10|2012-03-29|2012-03-30|Estimate|||||||2018-04-10|2018-04-11|Actual|April 16, 2012|Actual|2012-04-16|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma|Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies|Completed||Phase 1|34|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:30:11.788575|2018-05-31 21:30:11.788575
NCT01567696|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-03-29|2012-03-29|2012-03-30|Estimate|||||||2012-03-29|2012-03-30|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Clinical, Radiographic and Laboratory Analysis of Failures of Joint Replacements|Defining the Inflammatory Cytokines in Patients With Adverse Reactions to Metal-on-Metal Hip Replacements|Unknown status|Recruiting||100|Anticipated|University of California, San Diego|||||f||||f||||||||||2018-05-31 21:30:11.922705|2018-05-31 21:30:11.922705
NCT01567683|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2012-05-25|2012-03-29|2012-03-30|Estimate|||||||2012-05-25|2012-05-28|Estimate||||May 2012|2012-05-31||||||||Interventional|Limsafe||A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects||Completed||Phase 1|||Moberg Pharma AB||1|||f||||||||||||||2018-05-31 21:30:11.997318|2018-05-31 21:30:11.997318
NCT01567670|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-29|2012-03-29|2012-03-30|Estimate|||||||2012-03-29|2012-03-30|Estimate|August 2011||2011-08-31|March 2012|2012-03-31||||June 2012|Anticipated|2012-06-30||Interventional|BED||Clinical Trial on Binge Eating Disorder, Treatment With Naloxone Spray|Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration|Unknown status|Active, not recruiting|Phase 2/Phase 3|138|Anticipated|Lightlake Sinclair Ltd.||2|||f||||t||||||||||2018-05-31 21:30:12.088566|2018-05-31 21:30:12.088566
NCT01567657|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-01-25|2012-03-29|2012-03-30|Estimate|||||||2013-01-25|2013-01-28|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety Study of Two Regimen for Sedation for Transesophageal Echocardiography|Phase II Study of Comparison of Two Sedation Regimen for Transesophageal Echocardiography in Point of View of Blood Pressure Response, Safety and Patient Comfort|Completed||Phase 2|200|Actual|Kantonsspital Münsterlingen||2|||f||||f||||||||||2018-05-31 21:30:12.170405|2018-05-31 21:30:12.170405
NCT01567644|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-04-01|2012-03-29|2012-03-30|Estimate|||||||2012-04-01|2012-04-03|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|September 2012|Anticipated|2012-09-30|April 2012|Anticipated|2012-04-30||Interventional|||Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris|Clinical Trial Evaluating the Treatment of Patients With Refractory Chronic Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device|Unknown status|Active, not recruiting|Phase 1|35|Anticipated|Medispec||1|||f||||f||||||||||2018-05-31 21:30:12.282553|2018-05-31 21:30:12.282553
NCT01567631|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-01-29|2012-03-29|2012-03-30|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LAHIGA||Classical Procedure Versus Intrahepatic Glisson's Approach|Laparoscopic Anatomical Hepatectomy With Intrahepatic Glisson's Approach Versus Laparoscopic Anatomical Hepatectomy With Classical Procedure|Unknown status|Recruiting|N/A|80|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 21:30:12.432995|2018-05-31 21:30:12.432995
NCT01567618|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2014-11-06|2012-03-28|2012-03-30|Estimate|||||||2014-11-06|2014-11-07|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|DaeMon||Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer|A Phase II Trial Evaluating Biweekly Docetaxel and DeGramont Regimen in First-Line Treatment of Unresectable or Metastatic Gastric Adenocarcinoma (DaeMon)|Completed||Phase 2|39|Actual|Sixth Affiliated Hospital, Sun Yat-sen University|||||f||||t||||||||||2018-05-31 21:30:12.553742|2018-05-31 21:30:12.553742
NCT01567592|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-04-01|2012-03-29|2012-03-30|Estimate|||||||2012-04-01|2012-04-03|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris|Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device|Suspended||Phase 1|20|Anticipated|Medispec||1|||f||||f||||||||||2018-05-31 21:30:12.818202|2018-05-31 21:30:12.818202
NCT01567579|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-05-15|2012-03-29|2012-03-30|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2009||2009-01-31|May 2017|2017-05-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease|An Evaluation of Routine Developmental Follow-Up in Infants and Children With Congenital Heart Disease|Recruiting|||1000|Anticipated|Medical College of Wisconsin|||||f||||f||||||||||2018-05-31 21:30:12.924023|2018-05-31 21:30:12.924023
NCT01567566|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-03-28|2012-03-28|2012-03-30|Estimate|||||||2012-03-28|2012-03-30|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|LBP-RCT||An Efficacy Study of Exercise Rehabilitation on Pain and Disability for Patients With Non-specific Low Back Pain|The Effect of Hip Stabilizer Muscle Strengthening on Pain and Disability for Patients With Non-specific Low Back Pain: an Outcome-based Randomized Controlled Trial|Unknown status|Recruiting|N/A|80|Anticipated|Running Injury Clinic||2|||f||||f||||||||||2018-05-31 21:30:13.049416|2018-05-31 21:30:13.049416
NCT01567553|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2015-10-27|2012-03-28|2012-03-30|Estimate|||||||2015-10-27|2015-10-28|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|USPIO-CIS||The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.|Early Neuroinflammatory Changes as a Prognostic Marker in Clinically Isolated Syndromes Patients.|Terminated|||37|Actual|Rennes University Hospital|||2|terminated ( Halted prematurely,expiration of investigationnal product)|f||||f||||||||||2018-05-31 21:30:13.190077|2018-05-31 21:30:13.190077
NCT01567540|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2014-01-17|2012-03-29|2012-03-30|Estimate|||||||2014-01-17|2014-01-20|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients|A Pilot Study to Evaluate the Clinical and Biological Tolerance of Sitagliptin With Pegylated Interferon alfa2a Plus Ribavirin Combination Therapy in Chronic Hepatitis C Patients|Terminated||Phase 1|3|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1||New treatments available, which prevents additional recruitment.|f||||t||||||||||2018-05-31 21:30:13.278002|2018-05-31 21:30:13.278002
NCT01567527|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26||2017-03-10|2017-03-10|2012-03-28|2012-03-30|Estimate||||2017-03-10|2017-03-13|Actual|2017-03-10|2017-03-13|Actual|August 2012||2012-08-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients|52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder|Completed||Phase 3|731|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 21:30:13.382576|2018-05-31 21:30:13.382576
NCT01567514|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-03-29|2012-03-29|2012-03-30|Estimate|||||||2012-03-29|2012-03-30|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Postoperative Pulpal Complications in Posterior Resin Composite Restorations Without Glass-ionomer Cement Lining|A 2-year Clinical Study on Postoperative Pulpal Complications Arising From the Absence of a Glass-ionomer Lining in Deep Occlusal Resin Composite Restorations|Completed||Phase 4|53|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 21:30:13.554867|2018-05-31 21:30:13.554867
NCT01567501|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-11-30|2012-03-29|2012-03-30|Estimate|||||||2012-11-30|2012-12-03|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal® 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fed Condition|Completed||Phase 1|28|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:30:13.82709|2018-05-31 21:30:13.82709
NCT01567488|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2018-01-02|2012-03-29|2012-03-30|Estimate|||||||2018-01-02|2018-01-03|Actual|June 8, 2011|Actual|2011-06-08|May 2017|2017-05-31|June 7, 2017|Actual|2017-06-07|September 1, 2014|Actual|2014-09-01||Interventional|EVERLAR||Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET|A Phase II Study on Everolimus, an mTOR Inhibitor (Oral Formulation), With Octreotide LAR® in Adult Patients With Advanced, Non-functioning, Well-differentiated Gastrointestinal Neuroendocrine Tumours (GI NET)|Completed||Phase 2|43|Actual|Grupo Espanol de Tumores Neuroendocrinos||1|||f||||t||||||||Undecided|As per Spanish local regulations|2018-05-31 21:30:14.120102|2018-05-31 21:30:14.120102
NCT01567475|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2016-03-14|2012-03-29|2012-03-30|Estimate|||||||2016-03-14|2016-03-15|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2013|Actual|2013-06-30||Interventional|(RAD001-R)||The Combination of Rad001 and Rituximab In Patients With Non-hodgkin's Lymphomas|A Phase I/II Study Investigating the Combination of RAD001 and Rituximab in Patients With Non-Hodgkin's Lymphomas|Completed||Phase 1|21|Actual|The Lymphoma Academic Research Organisation||1|||f||||f||||||||||2018-05-31 21:30:14.455331|2018-05-31 21:30:14.455331
NCT01567462|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2017-09-14||2017-11-09|2012-03-29|2012-03-30|Estimate|2017-11-09|2017-12-08|Actual||||2017-11-09|2017-12-08|Actual|September 2012|Actual|2012-09-30|October 2017|2017-10-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|PK Button|Participants who completed all study procedures per protocol.|PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors|PK Button Vaporization Electrode for Treatment of Bladder Tumors|Completed||N/A|95|Actual|Emory University||2|||f||||t||||||||||2018-05-31 21:30:15.023799|2018-05-31 21:30:15.023799
NCT01567449|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2012-03-28|2012-03-28|2012-03-30|Estimate|||||||2012-03-28|2012-03-30|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|March 2012|Actual|2012-03-31||Observational|||Risk Factors for Aneurysm Rebleeding|Risk Factors in Predicting Spontaneous Intracranial Aneurysm Rebleeding During Hospitalization|Unknown status|Recruiting||66|Anticipated|Fujian Medical University|||2||f||||t||||||||||2018-05-31 21:30:16.186056|2018-05-31 21:30:16.186056
NCT01567436|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-09-26|2012-03-28|2012-03-30|Estimate|||||||2012-09-26|2012-09-27|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||A Prospective Field Study: Introducing the Shang Ring in Routine Clinical Settings|A Prospective Study of Male Circumcision Using the Shang Ring in Routine Clinical Settings in Kenya & Zambia|Completed||Phase 4|1200|Actual|FHI 360|||||f||||f||||||||||2018-05-31 21:30:16.437824|2018-05-31 21:30:16.437824
NCT01567423|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-03-28|2012-03-28|2012-03-30|Estimate|||||||2012-03-28|2012-03-30|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria|Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008|Completed||N/A|301|Actual|Epicentre||2|||f||||f||||||||||2018-05-31 21:30:16.683795|2018-05-31 21:30:16.683795
NCT01567410|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2014-10-22|2012-03-28|2012-03-30|Estimate|||||||2014-10-22|2014-10-23|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of an E-learning Program for Assessing Pressure Ulcer Risk and Pressure Ulcer Classification - a Pilot Study|Randomized Controlled Trial to Evaluate the Effect of E-learning on Nurses Ability to Assess Patient Risk for Pressure Ulcers and Pressure Ulcer Classification|Completed||N/A|68|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 21:30:16.996992|2018-05-31 21:30:16.996992
NCT01567397|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2016-12-20|2012-03-29|2012-03-30|Estimate|||||||2016-12-20|2016-12-22|Estimate|December 2011||2011-12-31|December 2016|2016-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|ReDuCTO||Registry of Dupuytren's Contracture Treatment Outcomes|Registry of Dupuytren's Contracture Treatment Outcomes|Completed|||87|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-05-31 21:30:17.416043|2018-05-31 21:30:17.416043
NCT01567384|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-11-19|2012-03-28|2012-03-30|Estimate|||||||2013-11-19|2013-11-20|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies|A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies|Withdrawn||Phase 1|0|Actual|Emory University||1||The sponsor withdrew support for the study before any patients were enrolled.|f||||t||||||||||2018-05-31 21:30:17.661923|2018-05-31 21:30:17.661923
NCT01567371|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2016-03-16||2016-03-16|2012-03-29|2012-03-30|Estimate|2016-03-16|2016-04-15|Estimate||||2016-03-16|2016-04-15|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||LiDCO Monitor Study|Use of the LiDCORapid Monitor in Patients During Graded Phlebotomy and the Removal of Autologous Blood|Completed||N/A|30|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 21:30:17.956648|2018-05-31 21:30:17.956648
NCT01567358|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-06-18|2012-03-28|2012-03-30|Estimate|||||||2013-06-18|2013-06-19|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Repeated Dose, Active Control Drug, Parallel-group and Single-center Phase I Study of the Safety of Intravenous Administration of NI-071 in Comparison With Remicade® in Japanese Patients With Rheumatoid Arthritis Inadequately Treated With Methotrexate|Completed||Phase 1|14|Actual|Nichi-Iko Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:30:18.361677|2018-05-31 21:30:18.361677
NCT01567345|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-28|2012-03-28|2012-03-30|Estimate|||||||2012-03-28|2012-03-30|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|PITAC||Intrathecal Morphine Administration Using Implantable Pump With Continuous or Programmable Flow|Comparison of Two Types of Intrathecal Morphine Administration by Pump for Analgesia in Cancer Patients With Failure of Conventional Analgesic Therapy.|Completed||Phase 2|54|Actual|ICO Paul Papin||2|||f||||t||||||||||2018-05-31 21:30:18.443511|2018-05-31 21:30:18.443511
NCT01567332|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-08-05|2012-03-28|2012-03-30|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|rTMS||Evaluation of Walking After Repetitive Transcranial Magnetic Stimulation (rTMS) Inhibitory 1Hz in Vascular Hemiplegia|Evaluation of Walking After Repetitive Transcranial Magnetic Stimulation (rTMS) Inhibitory 1Hz in Vascular Hemiplegia.|Terminated||N/A|10|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 21:30:18.548302|2018-05-31 21:30:18.548302
NCT01567319|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-04-28|2012-03-28|2012-03-30|Estimate|||||||2017-04-28|2017-05-01|Actual|February 2012||2012-02-29|April 2017|2017-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Biological Standardization of D. Glomerata, L. Perenne, S. Cereale and O. Europaea Pollen Extracts|Biological Standardization of D. Glomerata, L. Perenne, S. Cereale and O. Europaea Pollen Extracts in Patients Sensitized to Them.|Completed||Phase 1|177|Actual|Roxall Medicina España S.A||3|||f||||f||||||||||2018-05-31 21:30:18.63896|2018-05-31 21:30:18.63896
NCT01567306|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-04-28|2012-03-29|2012-03-30|Estimate|||||||2017-04-28|2017-05-01|Actual|October 2011||2011-10-31|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense|Phase II, Multicenter, Randomized, Double Blind Study, With Subcutaneous Immunotherapy At Different Doses, in Parallel Groups and Placebo-Controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Phleum Pratense|Completed||Phase 2|151|Actual|Roxall Medicina España S.A||6|||f||||f||||||||||2018-05-31 21:30:18.750595|2018-05-31 21:30:18.750595
NCT01567280|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-01-19|2012-03-29|2012-03-30|Estimate|||||||2015-01-19|2015-01-21|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Observational|LIAISON||International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)|International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)|Completed|||8111|Actual|Chiesi Farmaceutici S.p.A.|||2||f||||t||||||||||2018-05-31 21:30:18.87175|2018-05-31 21:30:18.87175
NCT01567267|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-03-01|2012-03-29|2012-03-30|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2010||2010-02-28|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|||Evaluation of Educational Intervention to Teach Principles of Evidence-based Medicine (EbM) in Biology Classes|Phase II Study of a Short Term Educational Intervention for Upcoming Biology Teachers to Teach Principles of Evidence-based Medicine (EbM) in Biology Classes at High-school|Active, not recruiting||N/A|87|Actual|Goethe University||2|||f||||f||||||||||2018-05-31 21:30:18.930637|2018-05-31 21:30:18.930637
NCT01567254|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2015-01-01|2012-03-29|2012-03-30|Estimate|||||||2015-01-01|2015-01-05|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control|Subject: A Blinded Randomized Trial: the Effect of Guided Imagery in Children With Type 1 Diabetes Mellitus on Glucose Levels and on Glycemic Control|Completed||N/A|13|Actual|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 21:30:19.005873|2018-05-31 21:30:19.005873
NCT01567241|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-30|2012-03-29|2012-03-30|Estimate|||||||2012-03-30|2012-04-02|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2014|Anticipated|2014-03-31|August 2013|Anticipated|2013-08-31||Interventional|||Clinical Hypnosis During Insemination or Embryotransfer|Prospective Off-center Randomised Trial of Clinical Hypnosis Versus Relaxation Music|Unknown status|Recruiting|N/A|282|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 21:30:19.093842|2018-05-31 21:30:19.093842
NCT01567228|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-09-14|2012-03-29|2012-03-30|Estimate|||||||2015-09-14|2015-09-16|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CHICA GIS||Delivering Geospatial Intelligence to Health Care Providers|Delivering Geospatial Intelligence to Health Care Providers|Completed||N/A|1076|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 21:30:19.164624|2018-05-31 21:30:19.164624
NCT01567215|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-06-30|2012-03-28|2012-03-30|Estimate|||||||2014-06-30|2014-07-02|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Treatment of Granuloma Umbilical in Newborn Babies|Treatment of Granuloma Umbilical in Newborn Babies - Comparison of Treatment With Silver Nitrate Versus Alcohol Swaps Versus Steroid Creme Group IV|Completed||Phase 2|90|Actual|Hvidovre University Hospital||1|||f||||t||||||||||2018-05-31 21:30:19.254829|2018-05-31 21:30:19.254829
NCT01567202|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2015-05-19|2012-03-28|2012-03-30|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of DC Vaccination Against Glioblastoma|A Triple-blind Randomized Clinical Study of Vaccination With Dendritic Cells Loaded With Glioma Stem-like Cells Associated Antigens Against Brain Glioblastoma Multiform|Unknown status|Recruiting|Phase 2|100|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 21:30:19.327353|2018-05-31 21:30:19.327353
NCT01567189|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-03-28|2012-03-28|2012-03-30|Estimate|||||||2012-03-28|2012-03-30|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|CERC1||Cost-effectiveness of Outpatient Versus Hospital Cardiac Rehabilitation|Outpatient Cardiac Rehabilitation Versus Hospital. Cost-effectiveness Study|Unknown status|Not yet recruiting|N/A|138|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 21:30:19.409652|2018-05-31 21:30:19.409652
NCT01567176|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-01-17|2012-03-28|2012-03-30|Estimate|||||||2013-01-17|2013-01-18|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Sirt6||Circulating SIRT6 Expression, Effect on Aging Quality|Circulating Expression Measurement of a Sirtuin Protein Isoform, Sirt6, as an Early Marker of Aging Quality|Completed||N/A|60|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 21:30:19.477705|2018-05-31 21:30:19.477705
NCT01567163|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2014-05-16|2014-04-14|2014-10-03|2012-03-28|2012-03-30|Estimate|2014-05-16|2014-06-18|Estimate|2014-04-14|2014-05-07|Estimate|2014-10-03|2014-10-16|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|December 2012|Actual|2012-12-31||Interventional||All participants who received at least 1 dose of ramucirumab or docetaxel.|A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors|A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors|Completed||Phase 2|22|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:30:19.549389|2018-05-31 21:30:19.549389
NCT01567150|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|2015-09-22||2016-10-04|2012-03-28|2012-03-30|Estimate|2016-10-04|2016-11-25|Estimate||||2016-10-04|2016-11-25|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Wound Fluid Protease Levels During Use of Novel Wound Dressing|Wound Fluid Protease Levels During Use of Novel Wound Dressing|Completed||Phase 4|35|Actual|Hollister Incorporated||2|||f||||f||||||||No||2018-05-31 21:30:20.001874|2018-05-31 21:30:20.001874
NCT01567137|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2016-06-14|2012-03-29|2012-03-30|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2007||2007-11-30|June 2016|2016-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||MR Characterisation/Localisation of Breast Cancer|Using Magnetic Resonance Techniques to Improve the Characterisation and Localisation of Breast Cancer|Completed|||16|Actual|Institute of Cancer Research, United Kingdom|||||f||||f||||||||||2018-05-31 21:30:20.162898|2018-05-31 21:30:20.162898
NCT01567124|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2013-12-16|2012-03-29|2012-03-30|Estimate|||||||2013-12-16|2013-12-18|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Alleviating the Metabolic Side Effects of Antipsychotic Medications|A Randomised Trial Examining the Effectiveness of Sympathetic Nervous Inhibition in Alleviating the Metabolic Side Effects of Antipsychotic Medications in Patients With Schizophrenia|Unknown status|Recruiting|Phase 4|90|Anticipated|Baker IDI Heart and Diabetes Institute||2|||f||||f||||||||||2018-05-31 21:30:20.21802|2018-05-31 21:30:20.21802
NCT01567111|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-02-28|2012-03-28|2012-03-30|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2012||2012-02-29|February 2017|2017-02-28|December 2022|Anticipated|2022-12-31|August 2015|Actual|2015-08-31||Interventional|MIA||11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism|Functional Imaging With 11C-Metomidate Positron Emission Tomography Versus Adrenal Vein Sampling in Differential Diagnosis of Unilateral and Bilateral Aldosterone Secretion in Primary Aldosteronism|Active, not recruiting||N/A|40|Anticipated|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 21:30:20.328971|2018-05-31 21:30:20.328971
NCT01567098|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-05-28|2012-03-29|2012-03-30|Estimate|||||||2012-05-28|2012-05-30|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Single Incision Versus Conventional 3-Port Laparoscopic Appendectomy|Single Incision Versus Conventional 3-Port Laparoscopic Appendectomy: A Single Center Prospective Randomized Trial|Unknown status|Not yet recruiting|N/A|120|Anticipated|Hospital Authority, Hong Kong||2|||f||||f||||||||||2018-05-31 21:30:20.393562|2018-05-31 21:30:20.393562
NCT01567085|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-09-12|2012-03-28|2012-03-30|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2012||2012-05-31|September 2017|2017-09-30|May 24, 2017|Actual|2017-05-24|June 2015|Actual|2015-06-30||Interventional|||Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor|An Open-Label, Single-Arm, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Sensitized Recipients of a Kidney Transplant From a Deceased Donor.|Completed||Phase 2|80|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 21:30:20.474809|2018-05-31 21:30:20.474809
NCT01567072|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2016-09-03|2012-03-29|2012-03-30|Estimate|||||||2016-09-03|2016-09-07|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|CHIP||Non Steroidal Antiinflammatory Drugs Influence on Heal of Distal Radius Fracture|Non Steroidal Antiinflammatory Drugs Influence on Heal of Distal Radius Fracture|Completed||Phase 3|192|Actual|Aalborg Universitetshospital||3|||f||||t||||||||||2018-05-31 21:30:20.54941|2018-05-31 21:30:20.54941
NCT01567059|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28||2017-02-13|2017-02-13|2012-03-29|2012-03-30|Estimate||||2017-02-13|2017-02-15|Actual|2017-02-13|2017-02-15|Actual|May 2012||2012-05-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS|Completed||Phase 2|34|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 21:30:20.626018|2018-05-31 21:30:20.626018
NCT01567046|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-05-13|2012-03-27|2012-03-30|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas|Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)|Completed|||70|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 21:30:20.698119|2018-05-31 21:30:20.698119
NCT01567033|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2018-05-04|2012-03-27|2012-03-30|Estimate|||||||2018-05-04|2018-05-11|Actual|July 2011||2011-07-31|May 2018|2018-05-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|HEALTH||Healthy Eating and Active Living Taught at Home|Translating a Weight Loss Intervention Through a National Home Visiting Program|Completed||N/A|460|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 21:30:21.770779|2018-05-31 21:30:21.770779
NCT01567020|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2016-12-15||2016-12-15|2012-03-27|2012-03-30|Estimate|2016-12-15|2017-02-08|Estimate||||2016-12-15|2017-02-08|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|99 Years|Observational [Patient Registry]|CAPD Blast||Central Auditory Processing Deficits Associated With Blast Exposure|Central Auditory Processing Deficits Associated With Blast Exposure|Completed|||105|Actual|VA Office of Research and Development|||4||f||||f||||||None Retained|"~     None collected.~   "|Yes|Data sharing will be through an established data repository overseen by the VA Portland HCS IRB.|2018-05-31 21:30:21.854778|2018-05-31 21:30:21.854778
NCT01567007|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-27|2012-03-27|2012-03-30|Estimate|||||||2012-03-27|2012-03-30|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|April 2012|Anticipated|2012-04-30||Interventional|||Change in Physical Activity Levels in Women at Working Place|Impact of Different Interventions in Physical Activity Level and Co-morbidities in Women: Randomized, Controlled Study|Unknown status|Active, not recruiting|N/A|195|Actual|University of Sao Paulo General Hospital||4|||f||||t||||||||||2018-05-31 21:30:22.187017|2018-05-31 21:30:22.187017
NCT01566994|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-09-16|2012-03-27|2012-03-30|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparing Population Cessation Services|Comparing Population Cessation Services With Emphasis on Unmotivated Smokers|Completed||N/A|2500|Actual|University of Rhode Island||3|||f||||t||||||||||2018-05-31 21:30:22.261591|2018-05-31 21:30:22.261591
NCT01566981|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|2014-07-27||2014-10-28|2012-03-27|2012-03-30|Estimate|2014-10-28|2014-10-29|Estimate||||2014-10-28|2014-10-29|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|EHDI||E-health Care Process Support for Diabetes Type II Patients|E-support for Healthcare Processes - DIABETES|Completed||N/A|120|Actual|University of Primorska||2|||f||||f||||||||||2018-05-31 21:30:22.350683|2018-05-31 21:30:22.350683
NCT01566968|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-04-05|2012-03-27|2012-03-30|Estimate|||||||2012-04-05|2012-04-06|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|NEAT||Novel Endpoints in Cough Challenge Testing|Novel Endpoints in Cough Challenge Testing.|Completed|||98|Actual|Manchester University NHS Foundation Trust|||5||f||||f||||||||||2018-05-31 21:30:22.706984|2018-05-31 21:30:22.706984
NCT01566955|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-05-26|2012-03-27|2012-03-30|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TG-Adnex||Feasability Study of Removing the Ovaries and Fallopian Tubes|Feasability of Transgastric Adnexectomy|Completed||N/A|6|Actual|Heidelberg University||1|||f||||f||||||||||2018-05-31 21:30:22.797142|2018-05-31 21:30:22.797142
NCT01566942|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-03-27|2012-03-27|2012-03-30|Estimate|||||||2012-03-27|2012-03-30|Estimate|June 2012||2012-06-30|March 2012|2012-03-31|June 2017|Anticipated|2017-06-30|May 2014|Anticipated|2014-05-31||Interventional|||FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer|FOLFIRI or mFOLFOX6 as Adjuvant Chemotherapy Regiment After Neo-adjuvant Chemotherapy With FOLFIRI in Patients With Advanced Colorectal Cancer: a Randomized, Multicenter Clinical Trial|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:30:22.874321|2018-05-31 21:30:22.874321
NCT01566929|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2016-12-11|2012-03-27|2012-03-30|Estimate|||||||2016-12-11|2016-12-13|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|January 2016|Actual|2016-01-31||Interventional|||Weight Management Intervention for Obese Women and the Live Birth Outcome of in Vitro Fertilization (IVF)|Weight Management Interventions for Obese Women and the Live Birth Outcome of in Vitro Fertilization (IVF): a Randomized Controlled Trial|Active, not recruiting||N/A|317|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 21:30:22.946839|2018-05-31 21:30:22.946839
NCT01566916|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-02-10|2012-03-27|2012-03-29|Estimate|||||||2014-02-10|2014-02-12|Estimate||||February 2014|2014-02-28||||||||Interventional|||Medium Term Survivorship of Cementless THA Performed Using the Bone Preservation Tri-Lock Femoral Stem||Unknown status|Not yet recruiting|N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 21:30:23.096363|2018-05-31 21:30:23.096363
NCT01566903|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-04-13|2012-03-27|2012-03-29|Estimate|||||||2018-04-13|2018-04-17|Actual|June 5, 2012|Actual|2012-06-05|April 2018|2018-04-30|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Observational|NCE MRA||Neurovascular Non Contrast-Enhanced MR Angiography at 3T|Morphological and Dynamic Non Contrast-enhanced MR Angiography in the Exploration of Neurovascular Diseases|Completed|||80|Actual|Rennes University Hospital|||3||f||||||||||||||2018-05-31 21:30:23.17037|2018-05-31 21:30:23.17037
NCT01566890|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-11-08|2012-03-28|2012-03-29|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2012||2012-07-31|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 30, 2017|Anticipated|2017-12-30||Interventional|||Microvascular Blood Flow in Sickle Cell Anemia|Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia|Active, not recruiting||N/A|200|Anticipated|Blood Center of Wisconsin||5|||f||||t||||||||||2018-05-31 21:30:23.250217|2018-05-31 21:30:23.250217
NCT01566877|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2014-05-06|2012-03-28|2012-03-29|Estimate|||||||2014-05-06|2014-05-07|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Sarepta Therapeutics||2|||f||||t||||||||||2018-05-31 21:30:23.365816|2018-05-31 21:30:23.365816
NCT01566864|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-01-03|2012-03-27|2012-03-29|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2011|Actual|2011-04-30|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Multi-Method Health System Quality Improvement Intervention to Reduce Hypertension Disparities|Multi-Method Health System QI Intervention to Reduce Hypertension Disparities|Completed||N/A|66570|Actual|Johns Hopkins University||3|||f||||t||||||||No||2018-05-31 21:30:23.452177|2018-05-31 21:30:23.452177
NCT01566851|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-03-28|2012-03-28|2012-03-29|Estimate|||||||2012-03-28|2012-03-29|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Observational|||Application of EULAR Recommendations for Cardiovascular Risk Management in Patients With Rheumatoid Arthritis|Application of EULAR Recommendations for Cardiovascular Risk Management in Patients With Rheumatoid Arthritis in France in the Entire Population of the RSI (Other Branches of the Universal Healthcare Insurance Agency)|Unknown status|Not yet recruiting||7000|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||||||2018-05-31 21:30:23.541515|2018-05-31 21:30:23.541515
NCT01566838|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2016-01-04||2017-12-18|2012-03-27|2012-03-29|Estimate|2016-06-23|2016-08-04|Estimate||||2017-12-18|2017-12-20|Actual|October 2012||2012-10-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Continuous Subpleural Infusion of Bupivacaine|A Randomized Controlled Trial of Continuous Subpleural Infusion of Bupivacaine After Thoracoscopy|Completed||N/A|83|Actual|Inova Health Care Services|This study limited by a low power and reliance on patient self-reporting.|2|||f||||f||||||||||2018-05-31 21:30:23.636239|2018-05-31 21:30:23.636239
NCT01566825|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-03-27|2012-03-27|2012-03-29|Estimate|||||||2012-03-27|2012-03-29|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Influence of Amitriptyline on Learning in a Visual Discrimination Task|The Influence of Amitriptyline (Amitriptylin-CT 25 mg®) on Learning in a Visual Discrimination Task (Karni-Sagi-paradigm)|Completed||N/A|32|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 21:30:24.12659|2018-05-31 21:30:24.12659
NCT01566812|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-03-05|2012-03-27|2012-03-29|Estimate|||||||2017-03-05|2017-03-07|Actual|June 2012||2012-06-30|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|BRAVO||Effect of Breastfeeding Optimization on Early Vascular Development|BReast Feeding Attitude and Volume Optimization (BRAVO) Trial: A Randomized Breast Feeding Optimization Experiment|Active, not recruiting||N/A|1000|Actual|Indonesia University||2|||f||||f||||||||||2018-05-31 21:30:24.204467|2018-05-31 21:30:24.204467
NCT01566799|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-29|2012-03-27|2012-03-29|Estimate|||||||2012-03-29|2012-03-30|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Metformin Plus Neoadjuvant Chemotherapy in Breast Cancer|Clinical Phase II, Randomized, Double Blind Trial, to Evaluate the Efficacy of Metformin and Chemotherapy Versus Placebo Nad Chemotherapy in Neoadjuvant Setting for Locally Advanced Breast Cancer|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Instituto Nacional de Cancerologia de Mexico||1|||f||||t||||||||||2018-05-31 21:30:24.294809|2018-05-31 21:30:24.294809
NCT01566786|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-01-11|2012-03-27|2012-03-29|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2001||2001-08-31|January 2017|2017-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage|Randomised, Double-Blind, Placebo-Controlled, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage|Completed||Phase 2|48|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:30:24.378395|2018-05-31 21:30:24.378395
NCT01566773|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2017-05-12|2013-10-22|2017-10-10|2012-03-27|2012-03-29|Estimate|2017-10-10|2017-10-12|Actual|2013-10-22|2013-11-14|Estimate|2017-10-10|2017-10-12|Actual|March 2012||2012-03-31|October 2017|2017-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Intent to Treat (ITT) Population: Subjects who randomized and received at least 1 dose of study drug, and had both baseline and post-baseline efficacy data for that treatment.|PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD|A Randomized, Double Blind (Test Products and Placebo), Chronic Dosing (14 Days), Four Period, Eight Treatment, Placebo-Controlled, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Six Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide, Open Label) as An Active Control|Completed||Phase 2|140|Actual|Pearl Therapeutics, Inc.||8|||f||||f||||||||||2018-05-31 21:30:24.529501|2018-05-31 21:30:24.529501
NCT01566760|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-08-17|2012-03-27|2012-03-29|Estimate|||||||2016-08-17|2016-08-19|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study To Estimate The Effects Of Food On Drug Fesoterodine Fumarate And The Pharmacokinetics Of 5-Hydroxymethyl Tolterodine (5-HMT) In Healthy Volunteers|Open-Label, Single-Dose, Randomized, Crossover Study To Estimate The Effects Of Food On The Pharmacokinetics Of Two Fesoterodine Sustained-Release Beads-In-Capsule Formulations And To Estimate The Relative Bioavailability Of One Or Both Formulations Compared To Commercial Tablet Formulation In Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:30:25.794259|2018-05-31 21:30:25.794259
NCT01566747|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-05-30|2012-03-27|2012-03-29|Estimate|||||||2017-05-30|2017-05-31|Actual|March 2011||2011-03-31|May 2017|2017-05-31||||August 13, 2015|Actual|2015-08-13||Interventional|||Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5|A Phase II Study of Pazopanib in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC) Who Have Failed Prior Sunitinib Therapy|Active, not recruiting||Phase 2|43|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-05-31 21:30:25.861725|2018-05-31 21:30:25.861725
NCT01566734|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-10-12|2012-03-28|2012-03-29|Estimate|||||||2012-10-12|2012-10-15|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Effect of Cefazolin and Normal Saline Irrigation on Surgical Site Infections (SSIs)|Comparison of the Effect of Cefazolin and Normal Saline Irrigation With no Irrigation on the Incidence of Surgical Site Infections|Completed||N/A|200|Actual|Hormozgan University of Medical Sciences||3|||f||||t||||||||||2018-05-31 21:30:25.922913|2018-05-31 21:30:25.922913
NCT01566721|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2017-03-06||2018-04-06|2012-03-27|2012-03-29|Estimate|2017-03-06|2017-04-18|Actual||||2018-04-06|2018-04-10|Actual|May 17, 2012|Actual|2012-05-17|April 2018|2018-04-30|March 3, 2020|Anticipated|2020-03-03|March 10, 2015|Actual|2015-03-10||Interventional|SafeHER|Intent-to-Treat (ITT) Population: All participants enrolled into the study regardless of whether treatment was received.|A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer|Active, not recruiting||Phase 3|2577|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 21:30:26.176523|2018-05-31 21:30:26.176523
NCT01566552|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2014-01-21|2012-03-28|2012-03-29|Estimate|||||||2014-01-21|2014-01-22|Estimate|June 2014||2014-06-30|March 2012|2012-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis|Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India.|Unknown status|Not yet recruiting|Phase 4|1300|Anticipated|Banaras Hindu University||1|||f||||t||||||||||2018-05-31 21:30:30.796974|2018-05-31 21:30:30.796974
NCT01566708|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-04-24|2012-03-27|2012-03-29|Estimate|||||||2013-04-24|2013-04-25|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|September 2013|Anticipated|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Neuro-Music Therapy for Recent Onset Tinnitus: Evaluation of a Therapy Concept|Diagnostic and Interventional Study of Neuro-Music Therapy for Recent Onset Tinnitus: Evaluation of a Therapy Concept Using Psychological Assessment and Functional Neuroimaging|Unknown status|Active, not recruiting|N/A|60|Anticipated|German Center for Music Therapy Research||3|||f||||f||||||||||2018-05-31 21:30:28.196968|2018-05-31 21:30:28.196968
NCT01566695|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2018-05-22|2012-03-28|2012-03-29|Estimate|||||||2018-05-22|2018-05-24|Actual|April 26, 2013|Actual|2013-04-26|May 2018|2018-05-31|August 31, 2021|Anticipated|2021-08-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)|A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.|Active, not recruiting||Phase 3|217|Actual|Celgene||2|||f||||f||||||||||2018-05-31 21:30:28.331412|2018-05-31 21:30:28.331412
NCT01566682|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2018-02-13|2012-03-28|2012-03-29|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2012||2012-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Multi-Center Trial of the ProLung Test™|A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients With Pulmonary Lesions Suspicious for Lung Cancer|Active, not recruiting|||420|Actual|Fresh Medical Laboratories|||1||f||||f||||||||No||2018-05-31 21:30:28.691828|2018-05-31 21:30:28.691828
NCT01566669|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-09-20|2012-03-27|2012-03-29|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|PCEA||Efficacy and Safety of Parecoxib on Morphine Patient-controlled Epidural Analgesia (PCEA) After Gynecologic Surgery|A Multicenter, Randomised, Double-blinded, Placebo-controlled Trial Comparing the Efficacy and Safety of Intravenous Parecoxib Sodium on Morphine Patient-controlled Epidural Analgesia After Gynecologic Surgery|Completed||N/A|294|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 21:30:28.771254|2018-05-31 21:30:28.771254
NCT01566656|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2018-04-04|2012-03-27|2012-03-29|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2, 2012|Actual|2012-03-02|April 2018|2018-04-30|November 29, 2016|Actual|2016-11-29|November 29, 2016|Actual|2016-11-29||Interventional|TLI-ATG||Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies|Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies|Completed||Phase 2|15|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 21:30:28.860503|2018-05-31 21:30:28.860503
NCT01566643|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-04-04|2012-03-28|2012-03-29|Estimate|||||||2012-04-04|2012-04-05|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections|Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections|Unknown status|Recruiting|Phase 4|231|Anticipated|Buddhist Tzu Chi General Hospital||3|||f||||t||||||||||2018-05-31 21:30:28.953831|2018-05-31 21:30:28.953831
NCT01566630|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2015-08-06||2015-10-12|2012-03-27|2012-03-29|Estimate|2015-10-12|2015-11-05|Estimate||||2015-10-12|2015-11-05|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia|An Adaptive Multicentre, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Safety, PK and PD/Efficacy of RLX030 in Women With Pre-eclampsia|Terminated||Phase 2|3|Actual|Novartis||2||Novartis terminated this study due to internal, strategic decisions.|f||||||||||||||2018-05-31 21:30:29.077121|2018-05-31 21:30:29.077121
NCT01566617|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2016-01-20|2012-03-28|2012-03-29|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|ChagasCare||Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease|Impact of The Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial|Unknown status|Recruiting|N/A|88|Anticipated|Evandro Chagas Institute of Clinical Research||2|||f||||f||||||||||2018-05-31 21:30:29.56142|2018-05-31 21:30:29.56142
NCT01566604|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2014-06-03||2014-07-16|2012-03-27|2012-03-29|Estimate|2014-07-16|2014-08-08|Estimate||||2014-07-16|2014-08-08|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|GLOW7||Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease|A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|460|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:30:29.829757|2018-05-31 21:30:29.829757
NCT01566591|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-02-05|2012-03-28|2012-03-29|Estimate|||||||2017-02-05|2017-02-07|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression|A Prospective, Double Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Conjunction With Mood Stabilizers in Subjects With Bipolar Depression|Recruiting||Phase 3|120|Anticipated|Brainsway||2|||f||||t||||||||||2018-05-31 21:30:30.497696|2018-05-31 21:30:30.497696
NCT01566578|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-08-02|2012-03-27|2012-03-29|Estimate|||||||2012-08-02|2012-08-03|Estimate|April 2012||2012-04-30|August 2012|2012-08-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|EGFR||A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF|A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF|Unknown status|Recruiting|Phase 1|24|Anticipated|Ennar Pharmaceuticals AF||2|||f||||f||||||||||2018-05-31 21:30:30.635909|2018-05-31 21:30:30.635909
NCT01566565|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2013-02-22|2012-03-27|2012-03-29|Estimate|||||||2013-02-22|2013-02-26|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension|The Safety Evaluation of Theophylline and Bambuterol When Administered Orally Alone and in Combination to Healthy Volunteers|Completed||Phase 1|20|Actual|Norwegian Armed Forces Medical Service||2|||f||||t||||||||||2018-05-31 21:30:30.720307|2018-05-31 21:30:30.720307
NCT01566539|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2017-07-21||2017-09-08|2012-03-28|2012-03-29|Estimate|2017-09-08|2017-09-25|Actual||||2017-09-08|2017-09-25|Actual|April 2008||2008-04-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Biological Basis of Individual Variation in Social Cooperation|The Biological Basis of Individual Variation in Social Cooperation|Completed||N/A|707|Actual|Emory University||11|||f||||t||||||||||2018-05-31 21:30:30.905956|2018-05-31 21:30:30.905956
NCT01566526|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2013-03-27||2013-03-27|2012-03-28|2012-03-29|Estimate|2013-03-27|2013-05-27|Estimate||||2013-03-27|2013-05-27|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion||Completed|||26|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:30:31.844682|2018-05-31 21:30:31.844682
NCT01566513|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2015-01-22|2012-03-28|2012-03-29|Estimate|||||||2015-01-22|2015-01-26|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|Project PEP||Effectiveness and Cost Effectiveness of Peer Mentors in Reducing Hospital Use|Effectiveness and Cost Effectiveness of Peer Mentors in Reducing Hospital Use|Completed||N/A|285|Actual|Yale University||4|||f||||t||||||||||2018-05-31 21:30:32.031512|2018-05-31 21:30:32.031512
NCT01566500|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|2015-04-28||2015-07-29|2012-03-28|2012-03-29|Estimate|2015-07-29|2015-08-26|Estimate||||2015-07-29|2015-08-26|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||Adults with self-reported epilepsy.|Medication Adherence in Individuals With Epilepsy|Best Practices and Challenges in Medication Adherence for Individuals With Epilepsy|Completed|||140|Actual|Columbia University|||||f||||t||||||||||2018-05-31 21:30:32.101494|2018-05-31 21:30:32.101494
NCT01566487|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2012-03-28|2012-03-28|2012-03-29|Estimate|||||||2012-03-28|2012-03-29|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition|Randomized, Open-Label, Balanced, Two-treatment, Two-period, Two-sequence, Crossover, Multicentric Experimental Bioequivalence Study of Quetiapine Fumarate Film-coated Tablets 300 mg (Test)and Seroquel Film-coated Tablets 300 mg (Reference) Under Fasting Condition|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:30:32.204582|2018-05-31 21:30:32.204582
NCT01566474|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2013-01-23|2012-03-28|2012-03-29|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study|Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study|Unknown status|Recruiting|Phase 3|80|Anticipated|Aragon Institute of Health Sciences||2|||f||||t||||||||||2018-05-31 21:30:32.27041|2018-05-31 21:30:32.27041
NCT01566461|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2015-02-18||2018-01-04|2012-03-28|2012-03-29|Estimate|2015-06-18|2015-07-14|Estimate||||2018-01-04|2018-01-30|Actual|March 2012||2012-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|February 2014|Actual|2014-02-28||Interventional|INPACT SFA II|The randomized data (n=331) from both phases have been pooled and comprise the pivotal trial data.|IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)|Randomized Trial of IN.PACT (Paclitaxel) Admiral Drug-Coated Balloon (DCB) vs. Standard Percutaneous Transluminal Angioplasty (PTA) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)|Active, not recruiting||N/A|331|Actual|Medtronic Endovascular||2|||f||||t||||||||||2018-05-31 21:30:32.505388|2018-05-31 21:30:32.505388
NCT01566448|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-12-11|2012-03-27|2012-03-29|Estimate|||||||2015-12-11|2015-12-14|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash|Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash|Completed||Phase 2|30|Actual|West Virginia University||1|||f||||t||||||||||2018-05-31 21:30:33.414814|2018-05-31 21:30:33.414814
NCT01566435|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2015-09-08||2017-06-29|2012-03-27|2012-03-29|Estimate|2015-11-09|2015-12-14|Estimate||||2017-06-29|2017-07-31|Actual|August 9, 2012|Actual|2012-08-09|June 2017|2017-06-30|October 31, 2023|Anticipated|2023-10-31|October 31, 2013|Actual|2013-10-31||Interventional|||Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer|Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)|Active, not recruiting||Phase 2|30|Actual|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 21:30:33.554824|2018-05-31 21:30:33.554824
NCT01566422|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2018-04-18|2012-03-28|2012-03-29|Estimate|||||||2018-04-18|2018-04-20|Actual|June 2012|Actual|2012-06-30|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients|Comparative Effectiveness and Cost-Benefit Analysis of Vancomycin Powder in High Risk Spine Surgery Patients|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||2||unable to enroll any participants|f||||f||||||||||2018-05-31 21:30:34.337382|2018-05-31 21:30:34.337382
NCT01566409|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2016-08-04||2016-08-04|2012-03-28|2012-03-29|Estimate|2016-08-04|2016-09-28|Estimate||||2016-08-04|2016-09-28|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|||Maintenance Treatment for Children With Constipation|Maintenance Treatment With Polyethylene Glycol 3350 for Children With Constipation. A Randomized, Placebocontrolled Intervention Study|Completed||N/A|115|Actual|Vejle Hospital||2|||f||||f||||||||||2018-05-31 21:30:34.41384|2018-05-31 21:30:34.41384
NCT01566396|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-10-18|2012-03-28|2012-03-29|Estimate|||||||2012-10-18|2012-10-19|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles|Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles|Completed||N/A|32|Actual|Pollogen||1|||f||||f||||||||||2018-05-31 21:30:34.604401|2018-05-31 21:30:34.604401
NCT01566383|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-02-21|2012-03-28|2012-03-29|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2012||2012-03-31|February 2017|2017-02-28|August 27, 2013|Actual|2013-08-27|August 27, 2013|Actual|2013-08-27||Interventional|||Assessing Normal Multichannel Intraluminal Impedance (MII)-pH Parameters for Today's Population|Assessing Normal Multichannel Intraluminal Impedance (MII)-pH Parameters for Today's Population|Terminated||N/A|19|Actual|Vanderbilt University Medical Center||1||unable to meet recruitment goals|f||||f|f|f||||||No||2018-05-31 21:30:34.66971|2018-05-31 21:30:34.66971
NCT01566370|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2016-03-22||2016-11-17|2012-03-28|2012-03-29|Estimate|2016-03-22|2016-04-22|Estimate||||2016-11-17|2017-01-13|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ZNSBP|Heavy drinkers with bipolar disorder|Zonisamide for Heavy Drinkers With Bipolar Disorder|Zonisamide for Heavy Drinkers With Bipolar Disorder|Terminated||Phase 2|3|Actual|Yale University||2||recruitment infeasible|f||||t||||||||||2018-05-31 21:30:34.730811|2018-05-31 21:30:34.730811
NCT01566357|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2013-07-17|2012-03-28|2012-03-29|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Impact of Milk on Erosion/Abrasion of Enamel and Dentin - an in Situ Study|Impact of Milk and Casein Phosphopeptide-amorphous Calcium Phosphate on Erosion/Abrasion of Enamel and Dentin - an in Situ Study|Completed||N/A|15|Actual|University of Zurich||7|||f||||f||||||||||2018-05-31 21:30:35.022683|2018-05-31 21:30:35.022683
NCT01566344|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-04-09|2012-03-27|2012-03-29|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Reversal of Cardiomyopathy by Suppression of Frequent Premature Ventricular Complexes|Reversal of Cardiomyopathy by Suppression of Frequent Premature Ventricular Complexes - A Prospective Randomized Clinical Trial|Unknown status|Recruiting|N/A|70|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:30:35.097583|2018-05-31 21:30:35.097583
NCT01566331|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2014-05-19||2016-10-17|2012-03-26|2012-03-29|Estimate|2016-10-17|2016-12-12|Estimate||||2016-10-17|2016-12-12|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SDB||Safe Delivery Using a Belt on the Belly of Pregnant Woman|Safe Natural Delivery by Using a New Inflatable Ergonomic Three Chambers Belt|Completed||Phase 2|80|Actual|University of Padua||2|||f||||t||||||||No||2018-05-31 21:30:35.324473|2018-05-31 21:30:35.324473
NCT01566318|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-12-11|2012-03-28|2012-03-29|Estimate|||||||2016-12-11|2016-12-13|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Depression Agency-Based Collaboration|Depression Agency-Based Collaborative (Depression ABC)|Completed||N/A|104|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:30:35.545547|2018-05-31 21:30:35.545547
NCT01566305|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-03-27|2012-03-27|2012-03-29|Estimate|||||||2012-03-27|2012-03-29|Estimate|October 2010||2010-10-31|March 2012|2012-03-31||||July 2012|Anticipated|2012-07-31||Interventional|||Effects of Buttermilk on Serum LDL Cholesterol Concentrations|The Effects of Buttermilk With or Without Lutein-enriched Egg Yolk on the Serum LDL Cholesterol Concentration of Slightly Hypercholesterolaemic Volunteers|Unknown status|Active, not recruiting|N/A|108|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 21:30:35.617077|2018-05-31 21:30:35.617077
NCT01566292|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-03-27|2012-03-27|2012-03-29|Estimate|||||||2012-03-27|2012-03-29|Estimate|September 2009||2009-09-30|March 2012|2012-03-31||||September 2010|Actual|2010-09-30||Interventional|||"Intraprostatic Botulinum Toxin Type A Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy"|"Intraprostatic Botulinum Toxin Type A Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical Therapy: a Randomised, Double-blind, Controlled Trial Using Subjective and Objective Outcomes"|Completed||Phase 2/Phase 3|33|Actual|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 21:30:35.677944|2018-05-31 21:30:35.677944
NCT01566279|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2018-03-07|2012-03-28|2012-03-29|Estimate|||||||2018-03-07|2018-03-09|Actual|August 2012||2012-08-31|March 2018|2018-03-31|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|CPCT-03||A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03)|A Two Parts, Biomarker Study to Identify Genetic Aberrations Predictive for Response on Everolimus in Solid Tumors Without Regular Treatment Options (CPCT-03)|Completed||N/A|73|Actual|UMC Utrecht||1|||f||||f||||||||||2018-05-31 21:30:35.742018|2018-05-31 21:30:35.742018
NCT01566266|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2013-05-13|2012-03-27|2012-03-29|Estimate|||||||2013-05-13|2013-05-14|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Gut Flora and Lipid Metabolism||Completed||N/A|77|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:30:35.806466|2018-05-31 21:30:35.806466
NCT01566253|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2013-04-03|2012-03-28|2012-03-29|Estimate|||||||2013-04-03|2013-04-04|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Oral Self Medication Versus IV Administration of Pain Killers After Caesarian Delivery|Comparison of a Patient Controlled Oral Administration (PCOA) of Analgesic Protocol With an IV Administration After Planned Caesarian Section : Monocentric, Randomised and Controlled Study|Completed||Phase 4|80|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:30:35.943505|2018-05-31 21:30:35.943505
NCT01566240|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-12-14|2012-03-28|2012-03-29|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2012||2012-09-30|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|INTERLACE||Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer|A Phase III Multicentre Trial of Weekly Induction Chemotherapy Followed by Standard Chemoradiation Versus Standard Chemoradiation Alone in Patients With Locally Advanced Cervical Cancer|Recruiting||Phase 3|770|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 21:30:36.046529|2018-05-31 21:30:36.046529
NCT01566227|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-03-26|2012-03-26|2012-03-29|Estimate|||||||2012-03-26|2012-03-29|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Within-subject Comparison of Mandibular Overdentures Retained by 1,2,or 3 Implants|Within-subject Comparison of Mandibular Overdentures Retained by 1,2,or 3 Implants|Unknown status|Recruiting|N/A|30|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 21:30:36.220536|2018-05-31 21:30:36.220536
NCT01566214|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-09-01|2012-03-26|2012-03-29|Estimate|||||||2017-09-01|2017-09-05|Actual|April 30, 2012|Actual|2012-04-30|September 2017|2017-09-30|October 31, 2012|Actual|2012-10-31|June 30, 2012|Actual|2012-06-30||Interventional|VHPI||Vet-Harts Pilot Intervention for Veterans With Coronary Heart Disease|Representational Telehealth Nursing Intervention for Veterans With CHD|Completed||Phase 2|14|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 21:30:36.320761|2018-05-31 21:30:36.320761
NCT01566201|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2014-12-01|2012-03-28|2012-03-29|Estimate|||||||2014-12-01|2014-12-03|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|April 2012|Actual|2012-04-30||Interventional|||Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease|The Effect of Inhibition of Interleukin-1 Activity on Vascular and Left Ventricular Function in Patients With Coronary Artery Disease and Coexistent Rheumatoid Arthritis|Completed||N/A|80|Actual|University of Athens||2|||f||||t||||||||||2018-05-31 21:30:36.414051|2018-05-31 21:30:36.414051
NCT01566188|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2014-09-01|2012-03-26|2012-03-29|Estimate|||||||2014-09-01|2014-09-03|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CARDIOMEGA||Vascular Impact of Omega-3 in Metabolic Syndrome|Cardiovascular Impact of Omega-3 Dietary Supplement From Vegetal Origin in Hypertension Associated With Metabolic Syndrome|Completed||N/A|95|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 21:30:36.508959|2018-05-31 21:30:36.508959
NCT01566175|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2018-02-14|2012-03-27|2012-03-29|Estimate|||||||2018-02-14|2018-02-15|Actual|August 30, 2011|Actual|2011-08-30|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|Reducer||Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization|Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Angina Class 3-4 Who Are Not Candidates for Revascularization|Recruiting||N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 21:30:36.593944|2018-05-31 21:30:36.593944
NCT01566162|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2014-10-21||2014-11-12|2012-03-28|2012-03-29|Estimate|2014-11-12|2014-11-20|Estimate||||2014-11-12|2014-11-20|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Twelve Week, Open Label Extension Study in Patients With Schizophrenia|A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia|Completed||Phase 3|191|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 21:30:36.706226|2018-05-31 21:30:36.706226
NCT01566149|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2013-05-28||2017-03-17|2012-03-27|2012-03-29|Estimate|2013-05-28|2013-07-29|Estimate||||2017-03-17|2017-04-14|Actual|March 2012||2012-03-31|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)|An Open-Label Study to Assess the Safety and Tolerability of Zenhale® (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects With Persistent Asthma (Protocol No. 206-00 [P08212])|Completed||Phase 3|49|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:30:37.068539|2018-05-31 21:30:37.068539
NCT01566136|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2014-04-23|2012-03-28|2012-03-29|Estimate|||||||2014-04-23|2014-04-24|Estimate|August 2009||2009-08-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||An Inpatient Rehabilitation Model of Care Targeting Patients With Cognitive Impairment|An Inpatient Rehabilitation Model of Care Targeting Patients With Cognitive|Completed||Phase 2/Phase 3|198|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:30:37.295642|2018-05-31 21:30:37.295642
NCT01566123|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2018-05-11|2012-03-28|2012-03-29|Estimate|||||||2018-05-11|2018-05-17|Actual|March 2007||2007-03-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|||Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)|Clinical Phase I/II Trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in Patients With Retroperitoneal Soft Tissue Sarcoma|Active, not recruiting||Phase 1/Phase 2|37|Anticipated|University Hospital Heidelberg||1|||f||||t||||||||||2018-05-31 21:30:37.360036|2018-05-31 21:30:37.360036
NCT01566110|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-04-12|2012-03-27|2012-03-29|Estimate|||||||2017-04-12|2017-04-13|Actual|March 2012||2012-03-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CD-DIET||Celiac Disease and Diabetes- Dietary Intervention and Evaluation Trial|A Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Gluten-Free Diet in Patients With Asymptomatic Celiac Disease and Type 1 Diabetes, Celiac Disease and Diabetes - Dietary Intervention and Evaluation Trial (CD-DIET)|Active, not recruiting||N/A|50|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 21:30:37.421908|2018-05-31 21:30:37.421908
NCT01566097|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-03-25|2012-03-28|2012-03-29|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||Intervention Trial of Culturally-Appropriate Decision Aids for Smoking Cessation|Development and Application of Culturally-Appropriate Decision Aids for Smoking Cessation in Korea: a Single Arm Intervention Trial With Historical Control|Unknown status|Active, not recruiting|N/A|400|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:30:37.48922|2018-05-31 21:30:37.48922
NCT01566084|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|2014-05-20||2015-12-04|2012-03-28|2012-03-29|Estimate|2014-05-20|2014-06-20|Estimate||||2015-12-04|2016-01-07|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||11 Men and 6 post-menopausal women were enrolled.|Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults|Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults|Completed||N/A|17|Actual|University of Colorado, Boulder|Due to the complexity, burden, and, in some cases, invasiveness of the study design and procedures, only a limited number of subjects could be studied.|2|||f||||t||||||||||2018-05-31 21:30:37.560633|2018-05-31 21:30:37.560633
NCT01566071|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-06-08|2012-03-28|2012-03-29|Estimate|||||||2016-06-08|2016-06-09|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|||||Interventional|DRIVE COG||Ability to Drive of Early Stage Alzheimer Disease||Completed||N/A|60|Actual|CHU de Reims|||||f||||f||||||||||2018-05-31 21:30:37.867593|2018-05-31 21:30:37.867593
NCT01566058|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-04-29|2012-03-28|2012-03-29|Estimate|||||||2015-04-29|2015-04-30|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|January 2014|Actual|2014-01-31||Interventional|BBBox||Impact of the BB Box System on Postpartum Maternal Anxiety, Post Traumatic Stress and Mother-child Relationships|Pilot Study Evaluating the Impact of the BB Box System on Postpartum Maternal Anxiety, Post Traumatic Stress and the Establishment of a Mother-child Relationship in the Context of a Premature Birth|Completed||N/A|59|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 21:30:37.929171|2018-05-31 21:30:37.929171
NCT01566045|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-05-28|2012-03-27|2012-03-29|Estimate|||||||2013-05-28|2013-05-29|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer|MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer. A Phase III Study|Unknown status|Recruiting|N/A|980|Anticipated|Philips Healthcare||2|||f||||t||||||||||2018-05-31 21:30:38.007288|2018-05-31 21:30:38.007288
NCT01566032|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-07-05|2012-03-28|2012-03-29|Estimate|||||||2017-07-05|2017-07-07|Actual|January 2012||2012-01-31|July 2017|2017-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|DiVA||Digital Versus Analog Pleural Drainage in Patients With Pulmonary Air Leak|Digital Versus Analog Pleural Drainage in Patients With Pulmonary Air Leak|Completed|||30|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 21:30:38.094111|2018-05-31 21:30:38.094111
NCT01566019|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2016-07-11|2012-03-28|2012-03-29|Estimate|||||||2016-07-11|2016-07-12|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|MOSCATO 02||Molecular Screening for Cancer Treatment Optimization|Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment|Recruiting||N/A|1050|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 21:30:38.143679|2018-05-31 21:30:38.143679
NCT01566006|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-03-28|2012-03-28|2012-03-29|Estimate|||||||2012-03-28|2012-03-29|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|Myridian||Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration|Mycophenolate Mofetil (MMF) ,Carnitine and Phosphodiesterase Type 5 Inhibitor, Three Potential Treatments for Resistant Proteinuria and for Slowing the Deterioration of Diabetic Nephropathy in Patients With Type II Diabetes Mellitus|Unknown status|Not yet recruiting|N/A|80|Anticipated|The Nazareth Hospital, Israel||4|||f||||t||||||||||2018-05-31 21:30:38.208113|2018-05-31 21:30:38.208113
NCT01565993|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2012-03-28||2012-04-25|2012-03-27|2012-03-29|Estimate|2012-04-25|2012-05-25|Estimate||||2012-04-25|2012-05-25|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Use of Prophylactic Hemoclips in the Endoscopic Resection of Large Pedunculated Polyps|Is the Use of Prophylactic Hemoclips in the Endoscopic Resection of Large Pedunculated Polyps Useful? A Prospective and Randomized Study|Terminated||N/A|108|Actual|Hospital Severo Ochoa|Not to reach the sample size established previously in the initial design, implies bias and decreases the strength of the study.|2||The unexpected increase in morbidity of the hemoclip group|f||||f||||||||||2018-05-31 21:30:38.285917|2018-05-31 21:30:38.285917
NCT01565980|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2014-07-13||2014-11-14|2012-03-27|2012-03-29|Estimate|2014-11-14|2014-11-17|Estimate||||2014-11-14|2014-11-17|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Mindfulness Therapy for Individuals With Lung Cancer|A Mindfulness Intervention for Symptom Management in Lung Cancer|Completed||N/A|40|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 21:30:38.526995|2018-05-31 21:30:38.526995
NCT01565967|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-10-28|2012-03-28|2012-03-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Registry AutoLog Lipid Removal and Blood Component Characterization|Registry AutoLog Lipid Removal and Blood Component Characterization|Completed|||199|Actual|Medtronic Cardiovascular|||1||f||||f||||||Samples With DNA|"~     Whole blood and washed blood will be collected from each patient~   "|||2018-05-31 21:30:39.108513|2018-05-31 21:30:39.108513
NCT01565954|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2018-03-01|2012-03-27|2012-03-29|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2014||2014-01-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|SOMMEDREP||Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children|Systematic Evaluation of Sleep Respiratory Disorders During Sleep in Children With Sickle Cell Disease|Active, not recruiting|||62|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 21:30:40.15839|2018-05-31 21:30:40.15839
NCT01565941|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2017-11-03||2018-03-02|2012-03-27|2012-03-29|Estimate|2017-12-08|2017-12-11|Actual||||2018-03-02|2018-03-29|Actual|April 2012|Actual|2012-04-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|September 2016|Actual|2016-09-30||Interventional|HALF-PINT||Heart And Lung Failure - Pediatric INsulin Titration Trial|Heart And Lung Failure - Pediatric INsulin Titration Trial (HALF-PINT)|Completed||Phase 3|713|Actual|Boston Children’s Hospital||2|||f||||t||||||||Undecided||2018-05-31 21:30:40.26455|2018-05-31 21:30:40.26455
NCT01565928|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2018-04-16|2012-03-27|2012-03-29|Estimate|||||||2018-04-16|2018-04-17|Actual|January 24, 2012|Actual|2012-01-24|April 2018|2018-04-30|February 26, 2018|Actual|2018-02-26|July 1, 2013|Actual|2013-07-01||Interventional|||Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer|A Phase 1b, Open-label, Safety And Tolerability Study Of Oral Mdv3100 In Combination With Docetaxel In Men With Advanced Prostate Cancer|Completed||Phase 1|23|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:30:41.547767|2018-05-31 21:30:41.547767
NCT01565915|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2013-08-20|2012-03-27|2012-03-29|Estimate|||||||2013-08-20|2013-08-21|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety of Perlane-L in the Correction of Midface Volume Deficit||Unknown status|Active, not recruiting|N/A|221|Actual|Medicis Global Service Corporation||2|||f||||||||||||||2018-05-31 21:30:41.627102|2018-05-31 21:30:41.627102
NCT01565902|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2014-12-12||2018-02-27|2012-03-26|2012-03-29|Estimate|2014-12-12|2014-12-22|Estimate||||2018-02-27|2018-03-27|Actual|October 2012||2012-10-31|February 2018|2018-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetics of BAF312 in Patients With Hepatic Impairment|A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects.|Completed||Phase 1|40|Actual|Novartis||4|||f||||f||||||||||2018-05-31 21:30:41.713812|2018-05-31 21:30:41.713812
NCT01565889|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2014-08-28||2014-09-25|2012-03-28|2012-03-29|Estimate|2014-09-25|2014-10-01|Estimate||||2014-09-25|2014-10-01|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional||Safety Analysis Set: participants who enrolled and received at least one dose of study drug(s)|Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.|Part A: Drug Interaction Study Between GS-7977 and Antiretroviral Therapy (ARV) Combinations of Efavirenz, Tenofovir and Emtricitabine; Efavirenz, Zidovudine and Lamivudine; Atazanavir/Ritonavir, Tenofovir and Emtricitabine; Darunavir/Ritonavir, Tenofovir and Emtricitabine; Raltegravir, Tenofovir and Emtricitabine in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve HIV/HCV Co-infected Patients.|Completed||Phase 1/Phase 2|52|Actual|Gilead Sciences||6|||f||||f||||||||||2018-05-31 21:30:42.061308|2018-05-31 21:30:42.061308
NCT01565876|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2012-03-28|2012-03-28|2012-03-29|Estimate|||||||2012-03-28|2012-03-29|Estimate|December 2012||2012-12-31|March 2012|2012-03-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|minkal||Auxiliary Device to Alleviate Soldiers' Backload|Auxiliary Device to Alleviate Soldiers' Backload|Unknown status|Not yet recruiting|N/A|12|Anticipated|Medical Corps, Israel Defense Force||1|||f||||||||||||||2018-05-31 21:30:42.996081|2018-05-31 21:30:42.996081
NCT01565863|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-03-27|2012-03-27|2012-03-29|Estimate|||||||2012-03-27|2012-03-29|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|PGAP for Vets||Progressive Goal Attainment Program for Veterans|The Progressive Goal Attainment Program for Veterans Project|Unknown status|Recruiting|Phase 1|200|Anticipated|MDRC||2|||f||||f||||||||||2018-05-31 21:30:43.092281|2018-05-31 21:30:43.092281
NCT01565538|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2014-09-03||2014-09-11|2012-03-26|2012-03-28|Estimate|2014-09-11|2014-09-15|Estimate||||2014-09-11|2014-09-15|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma|A Randomized Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma|Completed||Phase 2|123|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 21:30:48.435258|2018-05-31 21:30:48.435258
NCT01565850|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2016-03-11|2013-11-25|2016-03-11|2012-03-27|2012-03-29|Estimate|2016-03-11|2016-04-11|Estimate|2013-11-25|2013-12-19|Estimate|2016-03-11|2016-04-11|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional||Safety Analysis Set: participants who were randomized and received at least one dose of study drug|D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults|Completed||Phase 2|153|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t||||||||||2018-05-31 21:30:43.230964|2018-05-31 21:30:43.230964
NCT01565837|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-01-28|2012-03-27|2012-03-29|Estimate|||||||2016-01-28|2016-02-01|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|SART||Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma|Phase II Evaluation of Concurrent Ipilimumab Therapy and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Malignant Melanoma|Unknown status|Recruiting|Phase 2|50|Anticipated|Comprehensive Cancer Centers of Nevada||1|||f||||t||||||||||2018-05-31 21:30:43.91653|2018-05-31 21:30:43.91653
NCT01565824|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-08-04|2012-03-28|2012-03-29|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2011||2011-11-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MODIAB-web||Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web)|Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web)|Completed||N/A|174|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 21:30:44.017592|2018-05-31 21:30:44.017592
NCT01565811|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2015-08-28|2012-03-27|2012-03-29|Estimate|||||||2015-08-28|2015-09-01|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|March 2012|Actual|2012-03-31||Observational|LN||Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis|Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis|Completed|||30|Actual|Gachon University Gil Medical Center|||1||f||||t||||||||||2018-05-31 21:30:44.083594|2018-05-31 21:30:44.083594
NCT01565798|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-03-23|2012-03-28|2012-03-29|Estimate|||||||2016-03-23|2016-03-24|Estimate|July 2010||2010-07-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy Of Copper To Reduce Acquisition Of Microbes and Healthcare-acquired Infections|Copper Antimicrobial Research Program: Environmental and Patient Sampling For Indicator Organisms To Determine The Efficacy Of Copper To Reduce Acquisition Of Microbes From The Patient Care Environment|Completed||N/A|614|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:30:44.150645|2018-05-31 21:30:44.150645
NCT01565785|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2015-11-16|2012-03-26|2012-03-29|Estimate|||||||2015-11-16|2015-11-17|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluating a New Way to Prepare Parents of Hospitalized Children for Discharge and Management of Child at Home|Self-Management Guided Discharge Teaching for Parents of Hospitalized Children: A Pilot Study|Completed||N/A|104|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 21:30:44.220029|2018-05-31 21:30:44.220029
NCT01565772|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-02-12|2012-03-28|2012-03-29|Estimate|||||||2016-02-12|2016-02-17|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer|A Phase I Trial of Hypofractionated Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer|Terminated||Phase 1|4|Actual|Massachusetts General Hospital||1||Slow accrual|f||||t||||||||||2018-05-31 21:30:44.288288|2018-05-31 21:30:44.288288
NCT01565759|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-02-11|2012-03-27|2012-03-29|Estimate|||||||2016-02-11|2016-02-12|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects|Investigation of the Effects of in Vivo Lithium Treatment on Gene Expression Levels Using Lymphoblastoid Cell Lines From Human Healthy Subjects|Recruiting||Phase 1|20|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 21:30:44.361903|2018-05-31 21:30:44.361903
NCT01565746|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-10-14|2012-03-27|2012-03-29|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|October 2012|Actual|2012-10-31||Interventional|||Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients|Uncontrolled, Open-label, Non-randomized Phase I Study to Investigate Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics of a Single Dose of BAY88-8223 in Japanese Patients With Castration-resistant Prostate Cancer and Bone Metastases|Completed||Phase 1|19|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:30:44.476263|2018-05-31 21:30:44.476263
NCT01565733|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-10-27|2012-03-26|2012-03-29|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes|Multicenter, Open Label, Non-randomized, Non-interventional Observational Study of Safety of Treatment Initiation With a Biphasic Insulin Aspart (NovoMix® 30) in Hospitalized Patients With Type 2 Diabetes Mellitus|Completed|||2223|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:30:44.570894|2018-05-31 21:30:44.570894
NCT01565720|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-07-05|2012-03-27|2012-03-29|Estimate|||||||2012-07-05|2012-07-09|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization|A Phase 1, Randomized, Double Blind, Placebo and Active Controlled, Parallel Study to Evaluate the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization in Healthy Adult Subjects|Completed||Phase 1|161|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 21:30:44.663453|2018-05-31 21:30:44.663453
NCT01565707|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|2016-12-05|2014-12-18|2017-02-27|2012-03-27|2012-03-29|Estimate|2016-12-05|2017-01-30|Estimate|2014-12-18|2015-01-07|Estimate|2017-02-27|2017-03-28|Actual|June 2012||2012-06-30|February 2017|2017-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|LION|Baseline values provided are based on the Safety Analysis Set (SAF) population and the Full Analysis Set (FAS). Population analysis is defined within each baseline measure.|A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug|A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in Pediatric Subjects From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)|Completed||Phase 3|189|Actual|Astellas Pharma Inc||4|||f||||t||||||||||2018-05-31 21:30:44.81126|2018-05-31 21:30:44.81126
NCT01565694|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27||2017-04-18|2018-04-04|2012-03-27|2012-03-29|Estimate||||2017-04-18|2017-04-19|Actual|2018-04-04|2018-04-06|Actual|August 14, 2012|Actual|2012-08-14|April 2018|2018-04-30|April 28, 2016|Actual|2016-04-28|April 28, 2016|Actual|2016-04-28||Interventional|||A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity|A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Patients From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)|Completed||Phase 3|76|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 21:30:46.466021|2018-05-31 21:30:46.466021
NCT01565681|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2012-12-07|2012-03-27|2012-03-29|Estimate|||||||2012-12-07|2012-12-10|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects|A Phase 1 Single Ascending Dose Study of ASKP1240 in Healthy Male and Female Volunteers|Completed||Phase 1|109|Actual|Astellas Pharma Inc||13|||f||||f||||||||||2018-05-31 21:30:46.602715|2018-05-31 21:30:46.602715
NCT01565668|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27||2017-04-06|2017-04-06|2012-03-27|2012-03-29|Estimate||||2017-04-06|2017-04-10|Actual|2017-04-06|2017-04-10|Actual|April 2012||2012-04-30|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)|Completed||Phase 2|76|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 21:30:46.702665|2018-05-31 21:30:46.702665
NCT01565655|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27||2014-12-01|2014-12-01|2012-03-27|2012-03-29|Estimate||||2014-12-01|2014-12-16|Estimate|2014-12-01|2014-12-16|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis|A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects|Completed||Phase 2|289|Actual|Astellas Pharma Inc||5|||f||||t||||||||||2018-05-31 21:30:46.82237|2018-05-31 21:30:46.82237
NCT01565642|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-03-01|2012-03-26|2012-03-28|Estimate|||||||2016-03-01|2016-03-02|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|GOC||Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia|Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia|Completed||N/A|302|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:30:46.93859|2018-05-31 21:30:46.93859
NCT01565629|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-10-25|2012-03-26|2012-03-28|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2012||2012-02-29|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|CCAL||Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders|Computer- Assisted Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders|Completed||N/A|40|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 21:30:47.011943|2018-05-31 21:30:47.011943
NCT01565616|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2017-08-29||2017-10-19|2012-03-26|2012-03-28|Estimate|2017-08-29|2017-09-29|Actual||||2017-10-19|2017-11-21|Actual|March 2012|Actual|2012-03-31|October 2017|2017-10-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|STRIDE|Individuals with severe sickle cell disease receiving hematopoietic cell transplantation (HCT) from a human leukocyte antigen (HLA)-identical sibling donor or an unrelated HLA-matched donor|Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease|A Phase II Study of Hematopoietic Stem Cell Therapy for Young Adults With Severe Sickle Cell Disease|Completed||Phase 2|22|Actual|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 21:30:47.10902|2018-05-31 21:30:47.10902
NCT01565603|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-03-29|2012-03-26|2012-03-28|Estimate|||||||2012-03-29|2012-03-30|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2011|Actual|2011-10-31||Observational|VALLOT 2011||Sleep and Cerebral Responses to High Altitude|Intolerance Mechanisms and Exercise Performance Limitation During a High Altitude Stay: Investigation of Sleep and Cerebral Responses|Unknown status|Active, not recruiting||12|Actual|University Hospital, Grenoble|||||f||||f||||||Samples Without DNA|"~     Venous blood~   "|||2018-05-31 21:30:47.60702|2018-05-31 21:30:47.60702
NCT01565590|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-01-30|2012-03-26|2012-03-28|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2012||2012-02-29|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage|Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage|Terminated||Phase 3|4|Actual|University of Cincinnati||2||Slow enrollment along with new competing studies, investigators decided to stop study|f||||t||||||||||2018-05-31 21:30:47.656548|2018-05-31 21:30:47.656548
NCT01565577|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2014-09-05|2012-03-26|2012-03-28|Estimate|||||||2014-09-05|2014-09-08|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|Exten MenbVac||Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)|Phase 3, Vaccinal Activity Assessment of MenBVac Against Nesseiria Menigitidis B:14,P1.7,16 Strain in Child Vaccinated With MenBVac®|Completed||Phase 3|117|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 21:30:47.726789|2018-05-31 21:30:47.726789
NCT01565564|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2015-05-21||2015-06-09|2012-03-27|2012-03-28|Estimate|2015-05-21|2015-06-09|Estimate||||2015-06-09|2015-07-07|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes|A Randomized Translational Study to Examine the Effects of Shared Care Versus Usual Care in Management of Gestational Diabetes in a Three-tier Prenatal Care Network in Tianjin, China|Completed||N/A|948|Actual|Tianjin Women and Children's Health Center|Exclusion of 242 women with GDM diagnosed from 10 Nov 2011 to 31 Jul 2012 due to potential contaminations due to logistic reasons.|2|||f||||t||||||||||2018-05-31 21:30:47.794398|2018-05-31 21:30:47.794398
NCT01565551|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|2014-01-03||2014-01-03|2012-03-26|2012-03-28|Estimate|2014-01-03|2014-02-17|Estimate||||2014-01-03|2014-02-17|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Observational|||Transforming Research and Clinical Knowledge in TBI Pilot|Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot|Completed|||650|Actual|University of California, San Francisco|Enrolling patients representative of the TBI population created challenges for follow-up (e.g. homelessness, substance abuse); limited access to research MRI scanner; lack of validated outcome measures for non-English-speaking and pediatric patients.||2||f||||f||||||Samples With DNA|"~     Whole blood for genetic analysis. Plasma for proteomic analysis.~   "|||2018-05-31 21:30:48.121153|2018-05-31 21:30:48.121153
NCT01565512|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2015-03-03|2012-03-27|2012-03-28|Estimate|||||||2015-03-03|2015-03-05|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort|Randomized Trial to Determine the Effect of Dorsal Penile Block on Post-Robotic Prostatectomy Foley Discomfort|Withdrawn||Phase 1/Phase 2|0|Actual|Columbia University||2||Lack of funding, PI left the institution, poor enrollment|f||||t||||||||||2018-05-31 21:30:48.827319|2018-05-31 21:30:48.827319
NCT01565499|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-02-13|2012-03-26|2012-03-28|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2012|Actual|2012-04-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2012|Actual|2012-12-31||Interventional|||Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer|Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer|Active, not recruiting||Phase 2|78|Anticipated|Spanish Breast Cancer Research Group||1|||f||||f||||||||||2018-05-31 21:30:48.904794|2018-05-31 21:30:48.904794
NCT01565486|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2012-12-04|2012-03-26|2012-03-28|Estimate|||||||2012-12-04|2012-12-05|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|August 2017|Anticipated|2017-08-31|January 2013|Anticipated|2013-01-31||Interventional|UCBEST||Safety and Efficacy Study of Ultrasonic Coagulation Device and Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated With the Harmonic ACE® Scalpel and LigaSure Precise™ Instrument During Conventional Thyroidectomy: A Single-blind Prospective Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|304|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 21:30:48.996566|2018-05-31 21:30:48.996566
NCT01565473|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2014-12-01|2012-03-26|2012-03-28|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||PET Study of Non-Motor Symptoms of Parkinson Disease|PET Study of Biochemistry and Metabolism of the CNS: Parkinson Disease|Completed|||242|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Whole blood Saliva~   "|||2018-05-31 21:30:49.089765|2018-05-31 21:30:49.089765
NCT01565460|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-03-29|2012-03-26|2012-03-28|Estimate|||||||2017-03-29|2017-03-30|Actual|February 2012||2012-02-29|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Bile and Bile Duct/Pancreatic Duct Brushings Database for Patients With Pancreato-biliary Stricture|Bile and Bile Duct/Pancreatic Duct Brushings Database for Patients With Pancreato-biliary Stricture|Completed|||200|Actual|The Cleveland Clinic|||1||f||||f||||||Samples With DNA|"~     Bile and bile duct/pancreatic duct brushings~   "|No||2018-05-31 21:30:49.161138|2018-05-31 21:30:49.161138
NCT01565447|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-10-14|2012-03-26|2012-03-28|Estimate|||||||2014-10-14|2014-10-16|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma Gait Parameters Study|Temporal and Spatial Gait Parameters of Children Undergoing Treatment for and Surviving Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma|Unknown status|Enrolling by invitation||200|Anticipated|Oregon Health and Science University|||1||f||||t||||||||||2018-05-31 21:30:49.225964|2018-05-31 21:30:49.225964
NCT01565434|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-06-08|2012-03-27|2012-03-28|Estimate|||||||2016-06-08|2016-06-09|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|April 2015|Actual|2015-04-30|||||Interventional|||Erythrocyte Complement Receptor 1 and Alzheimer Disease||Completed||N/A|200|Actual|CHU de Reims|||||f||||f||||||||||2018-05-31 21:30:49.282921|2018-05-31 21:30:49.282921
NCT01565421|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-04-18|2012-03-27|2012-03-28|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2008||2008-09-30|April 2017|2017-04-30|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients|A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression.|Withdrawn||Phase 2|0|Actual|NewLink Genetics Corporation||3||By previous sponsor|f||||t||||||||||2018-05-31 21:30:49.33403|2018-05-31 21:30:49.33403
NCT01565408|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-02-06|2012-03-26|2012-03-28|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2012||2012-03-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis|Safety and Tolerability of NNC0114-0006 Following Multiple s.c. Dosing at Escalating Dose Levels in Subjects With Rheumatoid Arthritis|Completed||Phase 1|32|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:30:49.415644|2018-05-31 21:30:49.415644
NCT01565395|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-02-03|2012-03-27|2012-03-28|Estimate|||||||2017-02-03|2017-02-07|Estimate|March 2012||2012-03-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Xeomin||Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)|Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)|Withdrawn||Phase 2|0|Actual|Beth Israel Deaconess Medical Center||2||Could not recruit ALS participants, hence ALS arm discontinued|f||||||||||||No||2018-05-31 21:30:49.489719|2018-05-31 21:30:49.489719
NCT01565382|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2012-04-06||2012-05-23|2012-03-27|2012-03-28|Estimate|2012-05-23|2012-06-27|Estimate||||2012-05-23|2012-06-27|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)|Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Evaluation of Inter-reader Reliability Using Images From Subjects With a Clinical Presentation of AD or MCI|Completed||N/A|40|Actual|Avid Radiopharmaceuticals|||||f||||f||||||||||2018-05-31 21:30:49.567786|2018-05-31 21:30:49.567786
NCT01565369|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2012-04-06||2012-05-03|2012-03-27|2012-03-28|Estimate|2012-05-03|2012-06-07|Estimate||||2012-05-03|2012-06-07|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Evaluation of Physician Training Methods to Read Florbetapir-PET Scans|Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Validation of Binary Image Rating Methodology Using Amyloid Histopathology at Autopsy as the Reference Standard.|Completed||N/A|35|Actual|Avid Radiopharmaceuticals|||||f||||f||||||||||2018-05-31 21:30:49.688873|2018-05-31 21:30:49.688873
NCT01565356|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2012-04-06||2012-05-03|2012-03-27|2012-03-28|Estimate|2012-05-03|2012-06-07|Estimate||||2012-05-03|2012-06-07|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of PET Scan Timing Relative to AV-45 Injection Time|Comparison of PET Images Acquired at 30 Min and 50 Min Post Injection of 18F-AV-45 in Healthy Volunteers and Alzheimer's Disease Patients|Completed||N/A|41|Actual|Avid Radiopharmaceuticals|||||f||||f||||||||||2018-05-31 21:30:49.811547|2018-05-31 21:30:49.811547
NCT01565343|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2012-04-06||2012-05-08|2012-03-27|2012-03-28|Estimate|2012-04-06|2012-05-02|Estimate||||2012-05-08|2012-05-10|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers|Test-retest Reproducibility of 18F-AV-45 for Brain Imaging of Amyloid in Healthy Volunteers and Alzheimer's Disease Patients|Completed||Phase 1|25|Actual|Avid Radiopharmaceuticals||3|||f||||f||||||||||2018-05-31 21:30:50.028423|2018-05-31 21:30:50.028423
NCT01565330|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2012-04-06||2012-06-14|2012-03-27|2012-03-28|Estimate|2012-04-06|2012-05-02|Estimate||||2012-06-14|2012-06-18|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers|An Open Label, Parallel Group, Dose Comparison of Safety and Imaging Characteristics of 111 and 370 MBq (3 and 10 mCi) of 18F-AV-45 for Brain Imaging of Amyloid in Healthy Volunteers and Patients With Alzheimer's Disease (AD)|Completed||Phase 1|20|Actual|Avid Radiopharmaceuticals||4|||f||||f||||||||||2018-05-31 21:30:50.293526|2018-05-31 21:30:50.293526
NCT01565317|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-02-22|2012-03-27|2012-03-28|Estimate|||||||2016-02-22|2016-02-23|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Evaluating the Effect of Diabetes Control Through Intensive Lifestyle Modifications on Diabetic Peripheral Neuropathy|Evaluation of the Effect of Intensive Diabetes Control Through Non-Surgical Intensive Lifestyle Modifications and Weight Reduction on Diabetic Peripheral Neuropathy|Completed||N/A|50|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-05-31 21:30:50.596686|2018-05-31 21:30:50.596686
NCT01565304|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-09-22|2012-03-26|2012-03-28|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of the Effectiveness of the POWER Through Choices Program|Evaluation of the Effectiveness of the POWER Through Choices Program|Completed||N/A|1039|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 21:30:50.668775|2018-05-31 21:30:50.668775
NCT01565291|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|2012-04-06||2012-05-11|2012-03-27|2012-03-28|Estimate|2012-04-06|2012-05-03|Estimate||||2012-05-11|2012-05-18|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers|A Preliminary Evaluation of the Amyloid Binding Properties, Pharmacokinetics and Safety of 18F-AV-45 in Healthy Elderly Volunteers and Patients With Alzheimer's Disease|Completed||Early Phase 1|32|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-05-31 21:30:50.748181|2018-05-31 21:30:50.748181
NCT01565278|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-05-10|2012-03-26|2012-03-28|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Fish Oil for Patients With Liver Disease Due to Parenteral Nutrition|Effect of n-3 Polyunsaturated Fatty Acid Lipid Emulsion on Parenteral Nutrition Associated Liver Disease|Terminated||Phase 3|2|Actual|University Health Network, Toronto||2||No more eligible patients could be identified.|f||||f||||||||||2018-05-31 21:30:50.962224|2018-05-31 21:30:50.962224
NCT01565265|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-04-27|2012-03-25|2012-03-28|Estimate|||||||2017-04-27|2017-05-01|Actual|April 2012||2012-04-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|Pergoveris||Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression|Prospective Randomized Study Comparing Ovarian Stimulation With Pergoveris Supported by a GnRH Agonist in a Long Protocol Versus Multidose GnRH Antagonist Regimen in Young Infertile Women Treated With ICS|Completed||N/A|5|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 21:30:51.087279|2018-05-31 21:30:51.087279
NCT01565252|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2013-11-21|2012-03-27|2012-03-28|Estimate|||||||2013-11-21|2013-11-25|Estimate|April 2014||2014-04-30|February 2013|2013-02-28|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|PisNShMiGSL-01||Assessment of the Effect of n-3(Omega 3) Fortified Egg in Healthy Subjects|Assessment of the Effect of n-3(Omega 3) Fortified Egg Compared to Omega-6 Israeli Regular Egg on Metabolic, Inflammation and Other Physiologic Parameters Prospective, Crossover, Compared Study in Healthy Subjects|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 21:30:51.180678|2018-05-31 21:30:51.180678
NCT01565239|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-09-08|2012-03-26|2012-03-28|Estimate|||||||2014-09-08|2014-09-09|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|Fiix||Fiix-prothrombin Time for Monitoring Warfarin|"Clinical Outcome During Warfarin Anticoagulation Monitored With Fiix-INR Compared to Standard Monitoring With INR.A Prospective Randomized Double-blinded Trial."|Completed||Phase 2|1156|Actual|Landspitali University Hospital||2|||f||||t||||||||||2018-05-31 21:30:51.274152|2018-05-31 21:30:51.274152
NCT01565226|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2016-11-01|2012-03-27|2012-03-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Capnography in Neonates Ventilated With High Frequency Ventilation: Prospective, Observational Multi-Center Study|Capnography in Neonates Ventilated With High Frequency Ventilation: Prospective, Observational Multi-Center Study|Completed|||25|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-05-31 21:30:51.35708|2018-05-31 21:30:51.35708
NCT01565213|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-03-26|2012-03-26|2012-03-28|Estimate|||||||2012-03-26|2012-03-28|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2008|Actual|2008-09-30||Interventional|||Transdiagnostic Group Treatments for Patients With Common Mental Disorders in Primary Health Care|Transdiagnostic Group Treatments for Patients With Common Mental Disorders in Primary Health Care: A Randomized Controlled Trial|Completed||Phase 3|245|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 21:30:51.431517|2018-05-31 21:30:51.431517
NCT01565200|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-11-28|2012-03-26|2012-03-28|Estimate|||||||2017-11-28|2017-11-29|Actual|May 2012||2012-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ZEPHIR||HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1|Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients With Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1|Active, not recruiting||Phase 2|90|Actual|Jules Bordet Institute||1|||f||||f||||||||No||2018-05-31 21:30:51.510862|2018-05-31 21:30:51.510862
NCT01565187|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-05-10|2012-03-27|2012-03-28|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Development of a Psychosocial Assessment Database for Reconstructive Hand Transplantation|Development of a Psychosocial Assessment Database for Reconstructive Hand Transplantation|Unknown status|Enrolling by invitation||100|Anticipated|Mayo Clinic|||1||f||||f||||||None Retained|"~     No biospecimens to be gathered and used for this study.~   "|||2018-05-31 21:30:51.616974|2018-05-31 21:30:51.616974
NCT01565174|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-04-01|2012-03-27|2012-03-28|Estimate|||||||2012-04-01|2012-04-03|Estimate|October 2012||2012-10-31|April 2012|2012-04-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Observational|||The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis|The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis|Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples With DNA|"~     Samples of DNA will be taken from saliva of participants~   "|||2018-05-31 21:30:51.684352|2018-05-31 21:30:51.684352
NCT01565161|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2018-02-22|2012-03-27|2012-03-28|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2011|Actual|2011-06-30|February 2018|2018-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HH||Healthy Habits, Happy Homes: An Intervention to Improve Household Routines for Obesity Prevention|Healthy Habits, Happy Homes: An Intervention to Improve Household Routines for Obesity Prevention|Completed||N/A|117|Actual|Harvard Pilgrim Health Care||2|||f||||f||||||||||2018-05-31 21:30:51.766679|2018-05-31 21:30:51.766679
NCT01565148|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2016-10-11||2017-07-28|2012-03-26|2012-03-28|Estimate|2017-07-28|2017-08-30|Actual||||2017-07-28|2017-08-30|Actual|February 2012|Actual|2012-02-29|July 2017|2017-07-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|iDEAL||A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)|A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)|Terminated||Phase 2|185|Actual|Johns Hopkins University||4||Patient's disease progressed and Vision Dropped which led to exit from the study|f||||t||||||||||2018-05-31 21:30:51.867871|2018-05-31 21:30:51.867871
NCT01565135|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2018-01-16|2012-03-26|2012-03-28|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2012|Actual|2012-09-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|October 2015|Actual|2015-10-31||Interventional|||Immunization Delivery in Obstetrics and Gynecology Settings|Immunization Delivery in Obstetrics and Gynecology Settings|Active, not recruiting||N/A|225000|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 21:30:52.282732|2018-05-31 21:30:52.282732
NCT01565122|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-11-01|2012-03-26|2012-03-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)|An Observational, Non-interventional, Multi-national Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab|Completed|||51|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:30:52.347366|2018-05-31 21:30:52.347366
NCT01565109|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2012-12-20|2012-03-26|2012-03-28|Estimate|||||||2012-12-20|2012-12-21|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|March 2018|Anticipated|2018-03-31|March 2013|Anticipated|2013-03-31||Interventional|||NESC: Neoadjuvant Treatment Of Gastric Adenocarcinoma|Phase II Multicenter Study in the Preoperative Treatment of Gastric Adenocarcinoma Consisting of Chemotherapy Using Docetaxel-cisplatin-5FU + Lenograstim Followed by Chemoradiation Based 5FU and Oxaliplatin|Unknown status|Recruiting|Phase 2|34|Anticipated|Institut Sainte Catherine||1|||f||||t||||||||||2018-05-31 21:30:52.406361|2018-05-31 21:30:52.406361
NCT01565096|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-03-26|2012-03-26|2012-03-28|Estimate|||||||2012-03-26|2012-03-28|Estimate|November 2011||2011-11-30|March 2012|2012-03-31||||November 2012|Anticipated|2012-11-30||Interventional|||Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy|Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy|Unknown status|Recruiting|Phase 4|44|Anticipated|ikfe-CRO GmbH||2|||f||||f||||||||||2018-05-31 21:30:52.48098|2018-05-31 21:30:52.48098
NCT01565083|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2016-09-30||2016-09-30|2012-03-27|2012-03-28|Estimate|2016-09-30|2016-11-22|Estimate||||2016-09-30|2016-11-22|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|VELVET|Intent-to-treat (ITT) population included all participants enrolled into the study.|A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer|A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer|Completed||Phase 2|213|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:30:52.58818|2018-05-31 21:30:52.58818
NCT01565070|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2014-07-09|2012-03-27|2012-03-28|Estimate|||||||2014-07-09|2014-07-10|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic|Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic|Withdrawn||Phase 3|0|Actual|University of Chile||2||The local authorities did not authorize the use of biofreeze in Chile.|f||||t||||||||||2018-05-31 21:30:53.569369|2018-05-31 21:30:53.569369
NCT01565057|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-05-04|2012-03-26|2012-03-28|Estimate|||||||2012-05-04|2012-05-07|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Gastric Layering Study|A Study on the Effect of Gastric Layering and Emptying Induced by a Food Emulsion|Completed||N/A|10|Actual|Quadram Institute||1|||f||||t||||||||||2018-05-31 21:30:53.653207|2018-05-31 21:30:53.653207
NCT01565044|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-08-22|2012-03-27|2012-03-28|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2012||2012-03-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|AUTOTAB||Automatic Versus Intentional Movement Exercises to Enhance Arm Functions After Stroke|Automatic Versus Intentional Movement Exercises to Enhance Arm Functions After Stroke|Recruiting||N/A|32|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:30:53.723608|2018-05-31 21:30:53.723608
NCT01565031|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|||Prediction of Future Risk in Patients With Controlled Asthma|A Simple Prognostic Score for Future Risk Assessment in Patients With Controlled Asthma Who Undergo a Step-down Guidelines-based Strategy|Unknown status|Not yet recruiting||338|Anticipated|Hospital Universitario Lucus Augusti|||1||f||||f||||||||||2018-05-31 21:30:53.839089|2018-05-31 21:30:53.839089
NCT01565018|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-07-05|2012-03-26|2012-03-28|Estimate|||||||2012-07-05|2012-07-09|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects|Single-site, Open-label, Randomized, Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations|Completed||Phase 1|55|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:30:53.91782|2018-05-31 21:30:53.91782
NCT01565005|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-03-01|2012-03-26|2012-03-28|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2013|Actual|2013-10-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|MICROFANC||Microcephaly Genetic Deficiency in Neural Progenitors|Microcephaly Genetic Deficiency in Neural Progenitors: Genotyping, Phenotyping and Functional Neuro-anatomy and Neurobiology Comparative Primitive Microcephaly (MCPH) and the Fanconi Anemia (FA)|Completed|||98|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 21:30:54.037069|2018-05-31 21:30:54.037069
NCT01564992|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-06-27|2012-03-26|2012-03-28|Estimate|||||||2017-06-27|2017-06-28|Actual|May 2009||2009-05-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|DIGPD||Drug Interaction With Genes in Parkinson's Disease|Drug Interaction With Genes in Parkinson's Disease|Recruiting|||600|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     blood~   "|No||2018-05-31 21:30:54.109942|2018-05-31 21:30:54.109942
NCT01564979|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm|Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm|Unknown status|Not yet recruiting|Phase 2|26|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 21:30:54.186533|2018-05-31 21:30:54.186533
NCT01564966|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2012-03-28|2012-03-27|2012-03-28|Estimate|||||||2012-03-28|2012-03-29|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation|Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation|Completed|||46|Actual|Istanbul University|||1||f||||t||||||||||2018-05-31 21:30:54.421353|2018-05-31 21:30:54.421353
NCT01564953|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2015-05-31||2017-01-13|2012-03-27|2012-03-28|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|February 2012||2012-02-29|January 2013|2013-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Observational|||Magnesium is Associated With QoL in COPD: A Cross-sectional Study|Serum Magnesium and Nit Vitamin D is Associated With Better QoL in COPD: A Cross-sectional Study|Completed|||143|Actual|University of Aarhus|The cross-sectional design. Some data (e.g. number of exacerbations past one year and smoking history) were self-reported and therefore, a risk of recall-bias cannot be excluded.||||f||||f||||||Samples Without DNA|"~     Blood samples:~      p-creatinine p-potassium p-sodium p-albumine p-phosphate p-magnesium p-calcium-ion~     p-parathyrine p-25-hydroxy-vitamin D2 + D3~   "|Yes|Publish as paper in Scientific journal|2018-05-31 21:30:54.492983|2018-05-31 21:30:54.492983
NCT01564940|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Human Factors Usability Study of Ib2C Conception System|Human Factors Usability Study of Abbreviated Functional Use of the Intimate Bridge 2 Conception, Inc. Conception System|Completed|||15|Actual|Rinovum Women's Health, Inc.|||||f||||t||||||||||2018-05-31 21:30:54.650846|2018-05-31 21:30:54.650846
NCT01564927|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Physiological Changes Associated With Deqi During Electroacupuncture to Right LI4 and LI11|Physiological Changes Associated With Deqi During Electroacupuncture to Right LI4 and LI11|Unknown status|Recruiting|N/A|36|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 21:30:54.70072|2018-05-31 21:30:54.70072
NCT01564914|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2018-02-05|2012-03-26|2012-03-28|Estimate|||||||2018-02-05|2018-02-07|Actual|May 2012||2012-05-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|105GM201||A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma|A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab|Completed||Phase 2|22|Actual|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 21:30:54.803631|2018-05-31 21:30:54.803631
NCT01564901|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-11-01|2012-03-27|2012-03-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids|A Prospective Observational Study to Assess the Impact of RoActemra® on the Use of Glucocorticoids in Patients With Rheumatoid Arthritis Treated With the Standard of Care.|Completed|||23|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:30:54.88105|2018-05-31 21:30:54.88105
NCT01564888|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-02-16|2012-03-26|2012-03-28|Estimate|||||||2016-02-16|2016-02-18|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PROPHET-II||Prevention of Radial Artery Occlusion: Prophylactic Hyperperfusion Evaluation Trial|Prevention of Radial Artery Occlusion: Prophylactic Hyperperfusion Evaluation Trial|Completed||Phase 4|3000|Actual|Total Cardiovascular Solutions||2|||f||||f||||||||No||2018-05-31 21:30:54.949591|2018-05-31 21:30:54.949591
NCT01564875|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-03-26|2012-03-26|2012-03-28|Estimate|||||||2012-03-26|2012-03-28|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|HM-SIM4||Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia|Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4)|Unknown status|Active, not recruiting|Phase 4|122|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 21:30:55.008013|2018-05-31 21:30:55.008013
NCT01564862|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2015-01-13||2015-02-04|2012-03-26|2012-03-28|Estimate|2015-02-04|2015-02-05|Estimate||||2015-02-04|2015-02-05|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects With Major Depressive Disorder (MDD)|Completed||Phase 2|602|Actual|Takeda||3|||f||||f||||||||||2018-05-31 21:30:55.120492|2018-05-31 21:30:55.120492
NCT01564849|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2016-11-13|2012-03-27|2012-03-28|Estimate|||||||2016-11-13|2016-11-15|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||The Clinical Efficacy of Topical Nasal Pomegranate Fruit Extract for Patients With Chronic Rhinosinusitis|The Clinical Efficacy of Topical Nasal Pomegranate Fruit Extract (PFE) for Patients With Chronic Rhinitis, Chronic Sinusitis With or Without Nasal Polyps|Recruiting|||198|Anticipated|Hillel Yaffe Medical Center|||6||f||||f||||||||||2018-05-31 21:30:57.156416|2018-05-31 21:30:57.156416
NCT01564836|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2014-01-10|2012-03-27|2012-03-28|Estimate|||||||2014-01-10|2014-01-13|Estimate|June 2010||2010-06-30|January 2014|2014-01-31||||June 2015|Anticipated|2015-06-30||Interventional|||Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib|A Multi-center Study of the Discontinuation of Imatinib in Adult Patients With Ph+ CML in CP Who Have a Complete Molecular Response to Imatinib|Unknown status|Recruiting|N/A|50|Anticipated|Seoul St. Mary's Hospital||1|||f||||t||||||||||2018-05-31 21:30:57.23445|2018-05-31 21:30:57.23445
NCT01564823|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-03-15|2012-03-26|2012-03-28|Estimate|||||||2015-03-15|2015-03-17|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|APPRECIA||Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease|Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease|Completed||Phase 3|86|Actual|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa||2|||f||||f||||||||||2018-05-31 21:30:57.328049|2018-05-31 21:30:57.328049
NCT01564810|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-10-23|2012-03-27|2012-03-28|Estimate|||||||2012-10-23|2012-10-24|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|September 2015|Anticipated|2015-09-30|June 2012|Actual|2012-06-30||Interventional|||Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer|Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 4|150|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 21:30:57.47203|2018-05-31 21:30:57.47203
NCT01564797|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-03-04|2012-03-26|2012-03-28|Estimate|||||||2015-03-04|2015-03-06|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Partnership for a Hispanic Diabetes Prevention Program|Partnership for a Hispanic Diabetes Prevention Program|Completed||N/A|430|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 21:30:57.576708|2018-05-31 21:30:57.576708
NCT01564784|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2017-03-02||2017-12-14|2012-03-26|2012-03-28|Estimate|2017-12-14|2018-01-17|Actual||||2017-12-14|2018-01-17|Actual|August 2, 2012|Actual|2012-08-02|December 2017|2017-12-31|January 4, 2017|Actual|2017-01-04|March 8, 2016|Actual|2016-03-08||Interventional|||A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia|An Open-label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory Cd22-positive Acute Lymphoblastic Leukemia (All)|Completed||Phase 3|327|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:30:57.78114|2018-05-31 21:30:57.78114
NCT01564771|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2014-08-20|2012-03-27|2012-03-28|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|B1851065||Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.|Serotype Distribution of Chest X-ray Confirmed Pneumococcal Community Acquired Pneumonia in the Adult Population in Greece, Over 1 Year.|Completed|||320|Actual|Pfizer|||1||f||||f||||||Samples Without DNA|"~     Urine Samples~   "|||2018-05-31 21:30:59.403913|2018-05-31 21:30:59.403913
NCT01564758|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2012-06-27||2012-06-27|2012-03-26|2012-03-28|Estimate|2012-06-27|2012-08-06|Estimate||||2012-06-27|2012-08-06|Estimate|February 2004||2004-02-29|June 2012|2012-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Observational|A5951090||Post Marketing Surveillance Study on Linezolid|Post Marketing Surveillance on the Efficacy, Safety and Tolerability of Linezolid (Zyvox) in the Treatment of Gram Positive Infections|Completed|||99|Actual|Pfizer|Protocol did not indicate primary or secondary endpoints and all determination of primary or secondary endpoints were arbitrary.||1||f||||f||||||||||2018-05-31 21:30:59.55098|2018-05-31 21:30:59.55098
NCT01564745|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2014-02-03|2012-03-27|2012-03-28|Estimate|||||||2014-02-03|2014-02-04|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Extu-Cough||Cough Determinants in Mechanically Ventilated Patients|Cough Determinants in Mechanically Ventilated Patients: a Physiological Study|Unknown status|Recruiting|N/A|180|Anticipated|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 21:30:59.744044|2018-05-31 21:30:59.744044
NCT01564732|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2016-04-25||2016-06-03|2012-03-26|2012-03-28|Estimate|2016-04-25|2016-06-01|Estimate||||2016-06-03|2016-07-01|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding|Multicenter Prospective Randomized Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding|Terminated||N/A|17|Actual|Duke University||2||Sponsor withdrew funding.|f||||t||||||||||2018-05-31 21:30:59.850407|2018-05-31 21:30:59.850407
NCT01564719|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-02-09|2012-03-27|2012-03-28|Estimate|||||||2017-02-09|2017-02-13|Actual|October 2010|Actual|2010-10-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SpiritedLife||Study of a Holistic Health Program for United Methodist Clergy|A Randomized Multiple Baseline Intervention Study of Metabolic Syndrome, Mental Health, and Spiritual Well-Being of United Methodist Clergy in North Carolina|Completed||N/A|1114|Actual|Duke Clergy Health Initiative||3|||f||||f||||||||No||2018-05-31 21:31:00.135505|2018-05-31 21:31:00.135505
NCT01564706|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|2012-04-03||2012-05-11|2012-03-25|2012-03-28|Estimate|2012-04-03|2012-04-30|Estimate||||2012-05-11|2012-05-18|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of 18F-AV-45 in Healthy Volunteers|Positron Emission Tomography Whole Body Biodistribution Using 18F-AV-45|Completed||Phase 1|9|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 21:31:00.238283|2018-05-31 21:31:00.238283
NCT01564693|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|2015-04-23||2015-07-28|2012-03-27|2012-03-28|Estimate|2015-06-12|2015-07-09|Estimate||||2015-07-28|2015-08-18|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Observational|||Cancer Anorexia and the Central Nervous System|Neuroimaging of Hypothalamic Activity During Cancer Anorexia|Completed|||15|Actual|University of Roma La Sapienza|||3||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:31:00.467145|2018-05-31 21:31:00.467145
NCT01564680|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Lornoxicam vs. Paracetamol After Lower Abdominal Surgery|Intravenous Lornoxicam is More Effective Than Paracetamol as a Supplemental Analgesic After Lower Abdominal Surgery; A Randomized Controlled Trial|Completed||Phase 4|60|Actual|Dammam University||3|||f||||t||||||||||2018-05-31 21:31:00.760571|2018-05-31 21:31:00.760571
NCT01564667|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2016-01-13|2012-03-27|2012-03-28|Estimate|||||||2016-01-13|2016-01-14|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Attention Bias Modification Treatment for Warzone-Related Posttraumatic Stress Disorder (PTSD)|Attention Bias Modification Treatment for Warzone-Related PTSD: A Randomized Clinical Trial Magnetoencephalography Study|Completed||N/A|51|Actual|Creighton University||2|||f||||f||||||||||2018-05-31 21:31:00.835668|2018-05-31 21:31:00.835668
NCT01564654|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2013-04-17|2012-03-27|2012-03-28|Estimate|||||||2013-04-17|2013-04-19|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||A Retrospective Study of the iTotal CR Knee Replacement System|A Retrospective, Multi-Center Study to Evaluate the ConforMIS iTotal® CR (Cruciate Retaining) Total Knee Replacement System|Completed|||106|Actual|ConforMIS, Inc.|||1||f||||f||||||||||2018-05-31 21:31:00.912827|2018-05-31 21:31:00.912827
NCT01564641|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2017-07-13|2012-03-26|2012-03-28|Estimate|||||||2017-07-13|2017-07-17|Actual|May 2012|Actual|2012-05-31|July 2017|2017-07-31|March 2025|Anticipated|2025-03-31|August 2016|Actual|2016-08-31||Observational|||Study of the ConforMIS iDuo(R) G2|A Prospective, Multicenter Study of the ConforMIS iDuo(R) G2 Bicompartmental Knee Repair System|Active, not recruiting|||150|Anticipated|ConforMIS, Inc.|||1||f||||f|f|t|f|f|t|||No||2018-05-31 21:31:00.98959|2018-05-31 21:31:00.98959
NCT01564628|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-26|2012-03-26|2012-03-28|Estimate|||||||2012-03-26|2012-03-28|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Observational|||Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm|Data Acquisition for Optimization of Coronary Artery Disease Algorithm|Unknown status|Enrolling by invitation||250|Anticipated|Coloplast A/S|||3||f||||f||||||||||2018-05-31 21:31:01.06748|2018-05-31 21:31:01.06748
NCT01564615|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||AgION Catheter for Preventing Catheter-Related Bloodstream Infections|Reduction of Catheter-Related Bloodstream Infections in Preterm Infants by the Use of Catheters With the AgION Antimicrobial System|Completed||N/A|86|Actual|University of Florence||2|||f||||t||||||||||2018-05-31 21:31:01.137464|2018-05-31 21:31:01.137464
NCT01564602|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-03-28|2012-03-27|2012-03-28|Estimate|||||||2012-03-28|2012-04-02|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|||To Compare to 2-channel and Multiple-channel Single Port Laparoscopic-assisted Vaginal Hysterectomy|Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy|Unknown status|Recruiting|N/A|200|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f||||f||||||||||2018-05-31 21:31:01.228195|2018-05-31 21:31:01.228195
NCT01564589|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-08-25|2012-03-27|2012-03-28|Estimate|||||||2012-08-25|2012-08-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:31:01.30149|2018-05-31 21:31:01.30149
NCT01564576|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|Sugamadex||Neuromuscular Blockade and Surgical Conditions|The Influence of the Magnitude of Neuromuscular Blockade on the Surgical Conditions During Laparoscopic Sleeve Gastrectomy|Unknown status|Not yet recruiting|N/A|40|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:31:01.336638|2018-05-31 21:31:01.336638
NCT01564563|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-02-23|2012-03-27|2012-03-28|Estimate|||||||2017-02-23|2017-02-27|Actual|June 28, 2002|Actual|2002-06-28|February 2017|2017-02-28|October 27, 2003|Actual|2003-10-27|October 27, 2003|Actual|2003-10-27||Interventional|||Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation|A Multi-center, Randomized, Double-blind, Parallel Groups, Placebo-controlled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation (HSCT)|Terminated||Phase 2|11|Actual|Novo Nordisk A/S||3||Trial enrollment was prematurely terminated due to excessively slow patient recruitment|f||||f||||||||||2018-05-31 21:31:01.433179|2018-05-31 21:31:01.433179
NCT01564550|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-12-05|2012-03-23|2012-03-28|Estimate|||||||2014-12-05|2014-12-09|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism|The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism|Completed|||30|Actual|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 21:31:01.623139|2018-05-31 21:31:01.623139
NCT01564537|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2015-12-19||2018-04-27|2012-03-27|2012-03-28|Estimate|2015-12-19|2016-01-27|Estimate||||2018-04-27|2018-05-01|Actual|August 1, 2012|Actual|2012-08-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|October 1, 2014|Actual|2014-10-01||Interventional||Intent-to-Treat (ITT) population was defined as all randomized participants.|A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma|Active, not recruiting||Phase 3|722|Actual|Takeda||2|||f||||t||||||||||2018-05-31 21:31:01.783612|2018-05-31 21:31:01.783612
NCT01564524|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-10-24|2012-03-23|2012-03-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Effect of Concentrating Endogenous Stromal Cells in the Fat Graft|Structural Fat Grafting for Craniofacial Trauma: Effect of Concentrating Endogenous Stromal Cells in the Fat Graft|Terminated|||3|Actual|University of Pittsburgh||||Funding ended|f||||t||||||||||2018-05-31 21:31:03.380969|2018-05-31 21:31:03.380969
NCT01564511|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-09-09|2012-03-23|2012-03-27|Estimate|||||||2016-09-09|2016-09-12|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|||Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis|Effects of Electromechanical Gait Trainer on Endurance, Fatigue and Daily Life Autonomy in Patients With Multiple Sclerosis: a Randomized Control Trial|Completed||N/A|50|Actual|Universita di Verona||2|||f||||t||||||||||2018-05-31 21:31:03.456702|2018-05-31 21:31:03.456702
NCT01564498|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-10-24|2012-03-23|2012-03-27|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Purple Vegetables on Cardiovascular Disease (CVD) Risk Factors|A Pilot Study of the Effects of Replacing Orange Carrots and White Potatoes With Purple Varieties, on Risk Factors for Cardiovascular Disease|Recruiting||Phase 1|60|Anticipated|University of Guelph||4|||f||||f||||||||No||2018-05-31 21:31:03.529788|2018-05-31 21:31:03.529788
NCT01564485|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-12-07|2012-03-23|2012-03-27|Estimate|||||||2016-12-07|2016-12-08|Estimate|July 2008||2008-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CTRAD||Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome|Role of Cardiac CT in Risk Factor Control in Asymptomatic Patients With Diabetes|Completed||N/A|198|Actual|University of California, Irvine||2|||f||||t||||||||Undecided||2018-05-31 21:31:03.610078|2018-05-31 21:31:03.610078
NCT01564472|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-11-30|2012-03-23|2012-03-27|Estimate|||||||2012-11-30|2012-12-04|Estimate|February 2013||2013-02-28|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Observational|||Validation of Sleepware G3 Autoscoring Algorithm|Validation of Sleepware G3 Autoscoring Algorithm|Unknown status|Not yet recruiting||100|Anticipated|Philips Respironics|||1||f||||f||||||||||2018-05-31 21:31:03.681737|2018-05-31 21:31:03.681737
NCT01564459|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2016-05-02||2017-05-31|2012-03-23|2012-03-27|Estimate|2016-06-27|2016-08-10|Estimate||||2017-05-31|2017-06-26|Actual|March 26, 2012|Actual|2012-03-26|May 2017|2017-05-31|April 18, 2013|Actual|2013-04-18|April 18, 2013|Actual|2013-04-18||Interventional|||Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)|A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 in Patients With Painful Diabetic Neuropathy|Completed||Phase 2|170|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-05-31 21:31:03.746768|2018-05-31 21:31:03.746768
NCT01564446|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2014-03-26|2012-03-23|2012-03-27|Estimate|||||||2014-03-26|2014-03-27|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|April 2013|Actual|2013-04-30||Interventional|SMMRT||Interactive Medication Reconciliation By Secure Messaging|Interactive Medication Reconciliation by Secure Messaging|Unknown status|Active, not recruiting|Phase 1|152|Actual|VA Boston Healthcare System||1|||f||||t||||||||||2018-05-31 21:31:04.183501|2018-05-31 21:31:04.183501
NCT01564433|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-06-13|2012-03-23|2012-03-27|Estimate|||||||2012-06-13|2012-06-14|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Electromechanical Gait Trainer in Patients With Cerebral Palsy|The Effects of an Electromechanical Gait Trainer in Gait Impairments and Endurance in Patients With Cerebral Palsy: a Randomized Control Trial|Completed||Early Phase 1|20|Actual|Universita di Verona||2|||f||||t||||||||||2018-05-31 21:31:04.25772|2018-05-31 21:31:04.25772
NCT01564420|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-23|2012-03-23|2012-03-27|Estimate|||||||2012-03-23|2012-03-27|Estimate|January 2003||2003-01-31|March 2012|2012-03-31||||December 2006|Actual|2006-12-31||Observational|||Morphine Postoperative Analgesia and Pharmacokinetic/Pharmacodynamic Modeling|Pharmacokinetic/Pharmacodynamic Modeling of Morphine for Postoperative Analgesia Through a Patient Controlled Device After Coronary Artery Bypass Grafting. Intrathecal Morphine Significantly Reduces Drug Consumption|Completed|||36|Actual|University of Sao Paulo|||2||f||||f||||||Samples Without DNA|"~     For pharmacokinetic analysis, a serial of blood samples of patients was collected~     postoperatively after the extubation from a venous catheter (5mL each) into an EDTA tube (BD,~     Sao Paulo/Brazil) in the periods as follows: 0, 0.08, 0.25, 0.5, 1, 3, 6, 12, 18, 24 and 36~     hrs. Blood samples were centrifuged at 2800 g for 20 minutes, plasma was transferred to~     labeled polyethylene vials and frozen at -80ºC until drug plasma assay.~   "|||2018-05-31 21:31:04.345477|2018-05-31 21:31:04.345477
NCT01564407|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2016-02-18||2017-06-09|2012-03-23|2012-03-27|Estimate|2017-05-10|2017-05-12|Actual||||2017-06-09|2017-07-11|Actual|January 2011||2011-01-31|June 2017|2017-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures|A Phase I/II Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures|Terminated||Phase 1/Phase 2|15|Actual|University of Pittsburgh||5||Study Terminated due to lack of Funding|f||||t||||||||Undecided||2018-05-31 21:31:04.4248|2018-05-31 21:31:04.4248
NCT01564394|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2013-06-12||2015-11-09|2012-03-23|2012-03-27|Estimate|2015-07-22|2015-08-19|Estimate||||2015-11-09|2015-12-08|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Body Mind Training Project|Effects of Qigong on Fatigue & Quality of Life in Elderly Prostate Cancer Survivors|Completed||N/A|60|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 21:31:04.9138|2018-05-31 21:31:04.9138
NCT01564381|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2017-07-13|2012-03-23|2012-03-27|Estimate|||||||2017-07-13|2017-07-14|Actual|March 2012||2012-03-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women|Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women|Completed||Phase 1/Phase 2|64|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 21:31:05.23471|2018-05-31 21:31:05.23471
NCT01564368|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2017-03-16|2012-03-24|2012-03-27|Estimate|||||||2017-03-16|2017-03-20|Actual|August 2012||2012-08-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|July 2017|Anticipated|2017-07-31||Interventional|ACRIN6698||DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy|Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis)|Active, not recruiting||N/A|304|Anticipated|American College of Radiology Imaging Network||1|||f||||t||||||||Yes|See ACRIN data sharing Policy https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx|2018-05-31 21:31:05.315082|2018-05-31 21:31:05.315082
NCT01564355|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-12-01|2012-03-23|2012-03-27|Estimate|||||||2014-12-01|2014-12-03|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Postoperative Systemic Corticosteroids When Utilizing a Steroid-Eluting Spacer Following Endoscopic Sinus Surgery|The Role of Postoperative Systemic Corticosteroids When Utilizing a Steroid-Eluting Middle Meatal Spacer Following Endoscopic Sinus Surgery: A Randomized, Double-Blind, Placebo Controlled Trial|Completed||N/A|80|Actual|University of Calgary||2|||f||||||||||||||2018-05-31 21:31:05.410004|2018-05-31 21:31:05.410004
NCT01564342|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-23|2012-03-23|2012-03-27|Estimate|||||||2012-03-23|2012-03-27|Estimate|June 1994||1994-06-30|March 2012|2012-03-31|June 1996|Actual|1996-06-30|June 1996|Actual|1996-06-30||Interventional|||Tap Water Versus Normal Saline for Wound Irrigation|A Prospective Double-Blind Randomized Clinical Trial Comparing Tap Water Irrigation With Normal Saline for Wound Management|Completed||N/A|660|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 21:31:05.486903|2018-05-31 21:31:05.486903
NCT01564329|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-23|2012-03-23|2012-03-27|Estimate|||||||2012-03-23|2012-03-27|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|July 2013|Anticipated|2013-07-31|April 2013|Anticipated|2013-04-30||Interventional|||The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar|The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar|Unknown status|Recruiting|Phase 2|20|Anticipated|Simcere Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 21:31:05.555953|2018-05-31 21:31:05.555953
NCT01564134|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-07-09|2012-03-26|2012-03-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Dose of Hepatitis B Vaccines in Non/Low-response Populations|Effect of Dose of Hepatitis B Vaccines in Non/Low-response Populations|Completed||N/A|537|Actual|Centers for Disease Control and Prevention, China||4|||f||||t||||||||||2018-05-31 21:31:07.318487|2018-05-31 21:31:07.318487
NCT01564316|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2016-04-14|2012-03-23|2012-03-27|Estimate|||||||2016-04-14|2016-04-15|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients|Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients|Terminated|||22|Actual|Seoul National University Hospital|||1|The study has been terminated due to difficulties in gathering the patient samples.|f||||t||||||Samples With DNA|"~     serum:10ml~      WHO: neurodegeneration patients and control group include dementia patients visited the part~     of neurology.~   "|||2018-05-31 21:31:05.630279|2018-05-31 21:31:05.630279
NCT01564303|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-24|2012-03-24|2012-03-27|Estimate|||||||2012-03-24|2012-03-27|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|February 2013|Anticipated|2013-02-28|November 2012|Anticipated|2012-11-30||Interventional|||Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN)|Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study|Unknown status|Not yet recruiting|N/A|80|Anticipated|The Nazareth Hospital, Israel||4|||f||||t||||||||||2018-05-31 21:31:05.690587|2018-05-31 21:31:05.690587
NCT01564290|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-29|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|||Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children|Use of Probiotic Yogurt in the Treatment of Acute Diarrhea in Children: A Randomized Double-blind Trial|Completed||Phase 4|54|Actual|Centro Pediatrico Albina de Patino||2|||f||||f||||||||||2018-05-31 21:31:05.772508|2018-05-31 21:31:05.772508
NCT01564277|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2017-10-02||2017-12-11|2012-03-23|2012-03-27|Estimate|2017-12-06|2017-12-08|Actual||||2017-12-11|2018-01-09|Actual|September 29, 2011|Actual|2011-09-29|December 2017|2017-12-31|May 28, 2016|Actual|2016-05-28|May 28, 2015|Actual|2015-05-28||Interventional||All treated and eligible patients|Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies|Efficacy and Safety of Two Comparable Single Low Doses of Rasburicase Followed by Allopurinol in Adult Patients With Malignancy|Terminated||Phase 2|24|Actual|Roswell Park Cancer Institute||2||low accrual|f||||t||||||||||2018-05-31 21:31:05.859761|2018-05-31 21:31:05.859761
NCT01564264|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2014-08-29|2012-03-26|2012-03-27|Estimate|||||||2014-08-29|2014-09-03|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Sentinel Node Biopsy in Endometrial Cancer|Prospective Cohort Study Evaluating Identification Rate of Sentinel Node in the Management of Endometrial Cancer Utilizing a Combined Method of Cervical and Myometrial Injections|Unknown status|Recruiting|N/A|50|Anticipated|Hamilton Health Sciences Corporation||1|||f||||f||||||||||2018-05-31 21:31:06.46859|2018-05-31 21:31:06.46859
NCT01564251|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-02-06|2012-03-26|2012-03-27|Estimate|||||||2018-02-06|2018-02-07|Actual|March 23, 2012|Actual|2012-03-23|February 2018|2018-02-28|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma|An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma|Completed||Phase 1|104|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 21:31:06.541416|2018-05-31 21:31:06.541416
NCT01564238|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2018-05-03|2012-03-23|2012-03-27|Estimate|||||||2018-05-03|2018-05-09|Actual|January 1999||1999-01-31|May 2018|2018-05-31|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Effect of Sodium Intake on Calcium Retention in Girls|Effect of Sodium Intake on Calcium Retention in Black and White Adolescent Girls.|Completed||N/A|67|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 21:31:06.633475|2018-05-31 21:31:06.633475
NCT01564225|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-11-25|2012-03-26|2012-03-27|Estimate|||||||2013-11-25|2013-11-27|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200|A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200, an Ectodysplasin-A1 Replacement Molecule, in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Adults|Completed||Phase 1|6|Actual|Edimer Pharmaceuticals||1|||f||||t||||||||||2018-05-31 21:31:06.783928|2018-05-31 21:31:06.783928
NCT01564212|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-01-05|2012-03-26|2012-03-27|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2012||2012-03-31|January 2018|2018-01-31|February 23, 2017|Actual|2017-02-23|February 2017|Actual|2017-02-28||Interventional|||Quantitative Heat Loss With Laminar Air Flow||Completed||N/A|10|Actual|The Cleveland Clinic||4|||f||||f||||||||||2018-05-31 21:31:06.854539|2018-05-31 21:31:06.854539
NCT01564199|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-06-25|2012-03-23|2012-03-27|Estimate|||||||2012-06-25|2012-06-26|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SALBLOCK||Phase I Pharmacokinetic Study (SALBLOCK)|Effect of Charcoal on Gastrointestinal Absorption of Salmeterol and Fluticasone Propionate.|Completed||Phase 1|20|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 21:31:06.931291|2018-05-31 21:31:06.931291
NCT01564186|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2014-04-08|2012-03-24|2012-03-27|Estimate|||||||2014-04-08|2014-04-09|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Observational|||Characterization of Cardiac Hemodynamics During MultiSite Pacing|Characterization of Cardiac Hemodynamics by Pressure-Volume Loop Analysis During MultiPoint Pacing|Completed|||44|Actual|St. Jude Medical|||2||f||||t||||||||||2018-05-31 21:31:07.011024|2018-05-31 21:31:07.011024
NCT01564173|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2016-03-23|2012-03-24|2012-03-27|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Dependence of LV Hemodynamics on Pacing Site|Characterization of LV Hemodynamics During Epicardial and Endocardial Pacing|Completed|||13|Actual|St. Jude Medical|||1||f||||t||||||||||2018-05-31 21:31:07.070067|2018-05-31 21:31:07.070067
NCT01564160|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-11-30|2012-03-23|2012-03-27|Estimate|||||||2012-11-30|2012-12-03|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Assessment of PCSO-524 Relative to a Comparator Product|Assessment of the Acute and Chronic Bioavailability of Marine Lipid Fraction PCSO-524 Relative to a Comparator Product.|Completed||Early Phase 1|10|Anticipated|Nutrasource Diagnostics Inc.||2|||f||||f||||||||||2018-05-31 21:31:07.132497|2018-05-31 21:31:07.132497
NCT01564147|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-08-05|2012-03-23|2012-03-27|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ETP-PR||More Added Value of Therapeutic Education in the Management of Patients With Rheumatoid Arthritis (ETP-PR)|More Added Value of Therapeutic Education in the Management of Patients With Rheumatoid Arthritis|Terminated||N/A|62|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 21:31:07.232633|2018-05-31 21:31:07.232633
NCT01563419|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Clinical Usefulness of a Magnifier for Insulin Pen||Completed||N/A|50|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:31:13.714407|2018-05-31 21:31:13.714407
NCT01564121|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-08-29|2012-03-23|2012-03-27|Estimate|||||||2013-08-29|2013-08-30|Estimate|January 2006||2006-01-31|August 2013|2013-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Zometa||Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone Zométa|Phase 2 Study of the Effect of Zoledronate on Local Recurrence After Surgical Treatment of Giant Cell Tumors of Bone|Terminated||Phase 1/Phase 2|24|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 21:31:07.415093|2018-05-31 21:31:07.415093
NCT01564108|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-07-04|2012-03-23|2012-03-27|Estimate|||||||2016-07-04|2016-07-06|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema|An Exploratory Study of Ranibizumab (Lucentis) for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema Which Has Proven Refractory or Ineligible to Standard Treatment.|Completed||Phase 2|10|Actual|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 21:31:07.478434|2018-05-31 21:31:07.478434
NCT01564095|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-03-21|2012-03-23|2012-03-27|Estimate|||||||2017-03-21|2017-03-23|Actual|October 2011|Actual|2011-10-31|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TOP||TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion|TOP-Study (Tacrolimus Organ Perfusion): A Prospective Multicenter Trial for Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion|Terminated||Phase 2/Phase 3|25|Actual|Ludwig-Maximilians - University of Munich||2||Missing evidence of the effectiveness of the study medication|f||||t|t|f|||f|||No||2018-05-31 21:31:07.56736|2018-05-31 21:31:07.56736
NCT01564082|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-04-09|2012-03-23|2012-03-27|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of Early Endotracheal Tube Insertion With GlideScope Use|Comparison of Early Endotracheal Tube Insertion With GlideScope Use|Completed||N/A|160|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:31:07.667337|2018-05-31 21:31:07.667337
NCT01564069|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-03-05|2012-03-23|2012-03-27|Estimate|||||||2013-03-05|2013-03-06|Estimate|July 2009||2009-07-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Intrathecal Therapy for Chronic Non-Cancer Pain: An Analysis of Its Efficacy|Intrathecal Therapy for Chronic Non-Cancer Pain: An Analysis of Its Efficacy|Unknown status|Recruiting||90|Anticipated|Brigham and Women's Hospital|||3||f||||f||||||||||2018-05-31 21:31:07.737258|2018-05-31 21:31:07.737258
NCT01564056|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-11-06|2012-03-23|2012-03-27|Estimate|||||||2017-11-06|2017-11-07|Actual|March 2012||2012-03-31|November 2017|2017-11-30|March 2026|Anticipated|2026-03-31|March 2020|Anticipated|2020-03-31||Interventional|ASTER 70s||Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment|Adjuvant Systemic Treatment for Oestrogen-receptor (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) Multicentre Phase III Trial|Active, not recruiting||Phase 3|2000|Anticipated|UNICANCER||2|||f||||f||||||||||2018-05-31 21:31:07.814947|2018-05-31 21:31:07.814947
NCT01564043|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Internet Walking Program and Pedometer in Chronic Obstructive Pulmonary Disease||Completed||N/A|31|Actual|VA Boston Healthcare System||1|||f||||f||||||||||2018-05-31 21:31:08.226702|2018-05-31 21:31:08.226702
NCT01564030|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-11-08|2012-03-23|2012-03-27|Estimate|||||||2012-11-08|2012-11-12|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Gastric Ultrasound in Pregnant Women at Term|Qualitative Ultrasound Assessment of the Gastric Content of Pregnant Women at Term|Completed||N/A|32|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||3|||f||||f||||||||||2018-05-31 21:31:08.295627|2018-05-31 21:31:08.295627
NCT01564017|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-04-28|2012-03-26|2012-03-27|Estimate|||||||2017-04-28|2017-05-01|Actual|May 2012||2012-05-31|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract|Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Dermatophagoides Pteronyssinus.|Completed||Phase 2|150|Actual|Roxall Medicina España S.A||6|||f||||f||||||||||2018-05-31 21:31:08.392211|2018-05-31 21:31:08.392211
NCT01564004|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|September 2014|Anticipated|2014-09-30|February 2014|Anticipated|2014-02-28||Interventional|||Clinical Hypnosis Before External Cephalic Version (ECV)|Clinical Hypnosis Versus Neuro-linguistic Programming Before External Cephalic Version (ECV) - a Prospective Off-centre Randomised Controlled Trial|Unknown status|Recruiting|N/A|716|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 21:31:08.499496|2018-05-31 21:31:08.499496
NCT01563991|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2017-03-28|2012-03-26|2012-03-27|Estimate|||||||2017-03-28|2017-03-30|Actual|February 2007||2007-02-28|March 2017|2017-03-31|April 18, 2012|Actual|2012-04-18|April 18, 2012|Actual|2012-04-18||Interventional|||Impact of Perioperative Intravenous Fluid Utilization on Postoperative Outcomes|Impact of Perioperative Intravenous Fluid Utilization on Postoperative Outcomes Following Elective Open Colorectal Surgery|Completed||N/A|186|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 21:31:08.575584|2018-05-31 21:31:08.575584
NCT01563978|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|2013-11-08||2014-04-23|2012-03-23|2012-03-27|Estimate|2014-03-13|2014-04-14|Estimate||||2014-04-23|2014-05-08|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Oskira ABPM||Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis|OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis|Completed||Phase 2|266|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 21:31:08.755843|2018-05-31 21:31:08.755843
NCT01563965|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Carbohydrates and Proteins 3h Before Surgery|Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations|Completed||Phase 3|30|Actual|Federal University of Mato Grosso do Sul||2|||f||||t||||||||||2018-05-31 21:31:09.320472|2018-05-31 21:31:09.320472
NCT01563952|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|CTO||Impact of Intravascular Ultrasound(IVUS)-Guided Chronic Total Occlusion Intervention With Drug-eluting Stents|Impact of IVUS-guided Chronic Total Occlusion InterVention With DrUg-eluting Stents on Mid-term Angiographic and Clinical Outcomes (CTO-IVUS Study)|Unknown status|Recruiting|Phase 4|400|Anticipated|Yonsei University||4|||f||||t||||||||||2018-05-31 21:31:09.405455|2018-05-31 21:31:09.405455
NCT01563939|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-09-02|2012-03-23|2012-03-27|Estimate|||||||2015-09-02|2015-09-04|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour|Patient-controlled Intravenous Analgesia With Remifentanil Infusion for Labour: is Demand Bolus Required for Optimal Analgesia|Terminated||N/A|2|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||Difficult recruitment.|f||||f||||||||||2018-05-31 21:31:09.501636|2018-05-31 21:31:09.501636
NCT01563926|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-02-23|2012-03-24|2012-03-27|Estimate|||||||2017-02-23|2017-02-27|Actual|October 23, 2000|Actual|2000-10-23|February 2017|2017-02-28|October 10, 2002|Actual|2002-10-10|October 10, 2002|Actual|2002-10-10||Interventional|||Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency|An Open, Multi-Centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin Simplexx™ in Children With GH Deficiency|Completed||Phase 3|168|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:31:09.598386|2018-05-31 21:31:09.598386
NCT01563913|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2017-04-25||2017-09-21|2012-03-22|2012-03-27|Estimate|2017-09-21|2018-05-28|Estimate||||2017-09-21|2018-05-28|Estimate|October 2012||2012-10-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RLID-PD|Report on the participants that were randomized and completed visit 1.|Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids|Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids|Completed||Phase 1|33|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-05-31 21:31:09.706048|2018-05-31 21:31:09.706048
NCT01563900|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-04-16|2012-03-26|2012-03-27|Estimate|||||||2013-04-16|2013-04-18|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|February 2016|Anticipated|2016-02-29|February 2015|Anticipated|2015-02-28||Interventional|||Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea|Withdrawn||N/A|0|Actual|Northwestern University||2||Was unable to recruit subjects|f||||f||||||||||2018-05-31 21:31:10.111636|2018-05-31 21:31:10.111636
NCT01563887|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2015-12-04|2012-03-26|2012-03-27|Estimate|||||||2015-12-04|2015-12-07|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)|Identifying Driving Risk Factors in T1DM and Their Reduction Via Behavioral Intervention|Completed||N/A|568|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 21:31:10.18328|2018-05-31 21:31:10.18328
NCT01563874|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-04-04|2012-03-23|2012-03-27|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2, 2009||2009-06-02|June 19, 2017|2017-06-19||||||||Observational|||Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins|Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins|Completed|||130|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:31:10.255803|2018-05-31 21:31:10.255803
NCT01563861|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-12-19|2012-03-23|2012-03-27|Estimate|||||||2017-12-19|2017-12-21|Actual|February 2012||2012-02-29|December 2017|2017-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma|Determining the Cell of Origin and Prognostic Gene Signatures in SWOG Trials of Diffuse Large B-Cell Lymphoma|Completed|||397|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-05-31 21:31:10.31301|2018-05-31 21:31:10.31301
NCT01563848|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-09-21|2012-03-23|2012-03-27|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|June 2015|Actual|2015-06-30||Interventional|CIAFL||Cryoablation in Patients With Atrial Flutter|Cryoablation in Patients With Atrial Flutter|Unknown status|Recruiting|Phase 2|80|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 21:31:10.368304|2018-05-31 21:31:10.368304
NCT01563835|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2014-10-09|2012-03-23|2012-03-27|Estimate|||||||2014-10-09|2014-10-13|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Analgesia for 2nd Trimester Termination of Pregnancy|Analgesia for 2nd Trimester Termination of Pregnancy: a Randomized Controlled Trial of Intravenous Versus Epidural Patient Controlled Analgesia|Terminated||N/A|42|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||Recruitment difficulty|f||||f||||||||||2018-05-31 21:31:10.456268|2018-05-31 21:31:10.456268
NCT01563822|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-10-06|2012-03-23|2012-03-27|Estimate|||||||2012-10-06|2012-10-10|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Does Flushing the Uterine Cavity With Follicular Fluid After Ovum Pick-up Improve Implantation Rates in ICSI Cycles?|Phase I Study of the Effect of Flushing the Uterine Cavity With Follicular Fluid After Ovum Pick-up on Implantation Rates in ICSI Cycles|Completed||Phase 1|100|Actual|Kasr El Aini Hospital||2|||f||||t||||||||||2018-05-31 21:31:10.668077|2018-05-31 21:31:10.668077
NCT01563809|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-04-21|2012-03-23|2012-03-27|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Basal Androgens and LH Needing for Ovarian Stimulation for in Vitro Fertilization|The Relationship Between Basal Androgen Levels and the Needing of LH for Controlled Ovarian Stimulation for in Vitro Fertilization|Completed||Phase 3|400|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||4|||f||||f||||||||||2018-05-31 21:31:10.747046|2018-05-31 21:31:10.747046
NCT01563796|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-09-22|2012-03-23|2012-03-27|Estimate|||||||2015-09-22|2015-09-24|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|March 2014|Actual|2014-03-31||Observational|||Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer|A Multi-Center Study to Evaluate the Safety and Efficacy of a Urine DEK ELISA in Diagnosis of Subjects With Bladder Cancer|Unknown status|Active, not recruiting||1000|Anticipated|Medical Diagnostic Laboratories, LLC|||2||f||||f||||||None Retained|"~     urine~   "|||2018-05-31 21:31:10.821078|2018-05-31 21:31:10.821078
NCT01563783|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-01-08|2012-03-23|2012-03-27|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2017|Actual|2017-09-30||Interventional|TRUST||Post Market TRUST Study|The Trust (Treatment Results of Uterine Sparing Technologies) Study|Active, not recruiting||N/A|260|Anticipated|Acessa Health, Inc.||2|||f||||t||||||||||2018-05-31 21:31:10.886252|2018-05-31 21:31:10.886252
NCT01563770|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-05-23|2012-03-26|2012-03-27|Estimate|||||||2012-05-23|2012-05-24|Estimate|April 2012||2012-04-30|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)|A Double Blind, Randomized Placebo-controlled Cross-over Study on the Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen) in Patients With Hypertension and Hyperlipidemia.|Unknown status|Recruiting|N/A|20|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 21:31:10.989205|2018-05-31 21:31:10.989205
NCT01563757|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-10-28|2012-03-23|2012-03-27|Estimate|||||||2013-10-28|2013-10-29|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology|An Investigation Into The Potential Roles Of Vasoactive Intestinal Peptide And Substance P In The Pathophysiology Of Plastic Bronchitis And Protein Losing Enteropathy In Children With Palliated Single Ventricle Physiology|Completed|||20|Actual|Medical College of Wisconsin|||4||f||||f||||||||||2018-05-31 21:31:11.081663|2018-05-31 21:31:11.081663
NCT01563744|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2016-04-15|2012-03-23|2012-03-27|Estimate|||||||2016-04-15|2016-04-19|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||EGD-assisted Bowel Preparation for Colonoscopy|EGD-assisted Bowel Preparation for Colonoscopy|Completed||N/A|82|Actual|Rockford Gastroenterology Associates||2|||f||||f||||||||No||2018-05-31 21:31:11.146144|2018-05-31 21:31:11.146144
NCT01563731|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2018-04-06|2012-03-26|2012-03-27|Estimate|||||||2018-04-06|2018-04-09|Actual|April 2013||2013-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|ESH-CHL-SHOT||Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives|European Society of Hypertension and Chinese Hypertension League Stroke in Hypertension Optimal Treatment Trial|Recruiting||Phase 4|7500|Anticipated|Istituto Auxologico Italiano||6|||f||||t||||||||||2018-05-31 21:31:11.297383|2018-05-31 21:31:11.297383
NCT01563718|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-10-21|2012-03-23|2012-03-27|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pre-Release VIVITROL for Opioid Dependent Inmates|VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison|Completed||Phase 4|26|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 21:31:11.418125|2018-05-31 21:31:11.418125
NCT01563705|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-12-19|2012-03-26|2012-03-27|Estimate|||||||2012-12-19|2012-12-20|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|PRO GSDIII||Prospective Follow-up of Patients With Glycogen Storage Disease Type III|Prospective Follow-up of Patients With Glycogen Storage Disease Type III|Unknown status|Recruiting|N/A|30|Anticipated|Institut de Myologie, France|||||f||||f||||||||||2018-05-31 21:31:11.503909|2018-05-31 21:31:11.503909
NCT01563692|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-11-06|2012-03-26|2012-03-27|Estimate|||||||2015-11-06|2015-11-09|Estimate|March 2012||2012-03-31|November 2015|2015-11-30||||August 2012|Actual|2012-08-31||Observational|||Immune Response to Respiratory Syncytial Virus (RSV) in Health Care Workers|Analysis of the Immune Response to Respiratory Syncytial Virus (RSV) Infection in Health Care Personnel|Completed|||30|Actual|University of Oxford|||2||f||||f||||||Samples With DNA|"~     The humoral and cellular immune response to RSV exposure. To characterise these further some~     analysis of HLA typing my occur.~   "|||2018-05-31 21:31:11.581834|2018-05-31 21:31:11.581834
NCT01563679|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-05-23|2012-03-23|2012-03-27|Estimate|||||||2014-05-23|2014-05-28|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Analysis of Percutaneous Ablations for Cancer Treatment|Prospective Analysis of Percutaneous Ablations for Cancer Treatment|Completed|||26|Actual|Emory University|||||f||||t||||||||||2018-05-31 21:31:11.644035|2018-05-31 21:31:11.644035
NCT01563653|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-06-16|2012-03-23|2012-03-27|Estimate|||||||2017-06-16|2017-06-19|Actual|February 20, 2014|Actual|2014-02-20|June 2017|2017-06-30|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|IEUF||Development and Evaluation of a New Diagnostic Test in Female Urinary Stress Incontinence|Development and Evaluation of a New Diagnostic Test in Female Urinary Stress Incontinence|Terminated||N/A|7|Actual|Centre Hospitalier Universitaire de Nīmes||1||Not enough inclusions.|f||||t||||||||||2018-05-31 21:31:11.720141|2018-05-31 21:31:11.720141
NCT01563640|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-08-31|2012-03-22|2012-03-27|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|June 2013|Actual|2013-06-30||Interventional|DengueTools||Insecticidal School Uniforms for Dengue Prevention in Thailand|Can Insecticide-treated School Uniforms Reduce Dengue Infections in School-aged Children in Thailand|Terminated||N/A|1825|Actual|Umeå University||2||Insecticidal treatment of school uniforms did not last through a dengue season|f||||t||||||||||2018-05-31 21:31:11.807107|2018-05-31 21:31:11.807107
NCT01563627|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2016-05-31|2012-03-26|2012-03-27|Estimate|||||||2016-05-31|2016-06-01|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy|Serum Profile of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy: New Targets for Diagnosis and Prediction of Drug Resistance|Completed||N/A|70|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:31:11.882074|2018-05-31 21:31:11.882074
NCT01563614|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2016-04-18|2012-03-22|2012-03-27|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain|Safety and Efficacy of Liposomal Cytarabine in Combination With Radiotherapy (RT) and Lomustine for the Treatment of Leptomeningeal Metastasis From Malignant Melanoma|Terminated||Phase 1|1|Actual|University Hospital, Bonn||1||"No patients can be recruited for this trial anymore due to other therapeutical approaches that~   became available."|f||||f||||||||||2018-05-31 21:31:11.957547|2018-05-31 21:31:11.957547
NCT01563601|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-08-14|2012-03-23|2012-03-27|Estimate|||||||2012-08-14|2012-08-15|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|January 2018|Anticipated|2018-01-31|May 2016|Anticipated|2016-05-31||Interventional|||Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer|Withdrawn||Phase 3|0|Actual|Teva Pharmaceutical Industries||2||Business Decision|f||||t||||||||||2018-05-31 21:31:12.044094|2018-05-31 21:31:12.044094
NCT01563588|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2015-12-23|2012-03-23|2012-03-27|Estimate|||||||2015-12-23|2015-12-28|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2010|Actual|2010-10-31||Interventional|||Support and Rehabilitation Protocol for Non Metastatic Breast Cancer Patients in Complete Remission After Chemotherapy|Post Therapeutic Support and Rehabilitation Protocol in Hydrothermal Centers for Breast Cancer Patients in Complete Remission: a Multicenter Prospective Randomized Trial Testing the Intervention Versus Best Supportive Care|Terminated||N/A|251|Actual|Centre Jean Perrin||2||"Enrollment lasted longer than expected and expected number of patients could not be matched in~   time."|f||||f||||||||||2018-05-31 21:31:12.12937|2018-05-31 21:31:12.12937
NCT01563575|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-04-05|2012-03-23|2012-03-27|Estimate|||||||2016-04-05|2016-04-06|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|RP||WHO-HPH Recognition Project on Fast-Track Implementation of Clinical Health Promotion|WHO-HPH Recognition Project on Fast-Track Implementation of Clinical Health Promotion - a Multi-Centre RCT|Unknown status|Active, not recruiting|N/A|48|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 21:31:12.218898|2018-05-31 21:31:12.218898
NCT01563562|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-04-09|2012-03-23|2012-03-27|Estimate|||||||2013-04-09|2013-04-11|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function|A Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function|Completed||Phase 1|34|Actual|Reata Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 21:31:12.336752|2018-05-31 21:31:12.336752
NCT01563536|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2014-12-29|2013-04-25|2014-12-29|2012-03-23|2012-03-27|Estimate|2014-12-29|2015-01-08|Estimate|2013-04-25|2013-05-03|Estimate|2014-12-29|2015-01-08|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|June 2013|Actual|2013-06-30|April 2012|Actual|2012-04-30||Interventional|||Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects|An Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects|Completed||Phase 2|12|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 21:31:12.453996|2018-05-31 21:31:12.453996
NCT01563523|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-01-12|2012-03-23|2012-03-27|Estimate|||||||2017-01-12|2017-01-13|Estimate|March 2002||2002-03-31|January 2017|2017-01-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ Niastase®) in the Treatment of Bleeding in Severely Injured Trauma Subjects|Completed||Phase 2|283|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:12.92917|2018-05-31 21:31:12.92917
NCT01563510|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-10-08|2012-03-22|2012-03-27|Estimate|||||||2012-10-08|2012-10-10|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Research of the Key Technology and Standardization of Minimal Invasive Treatment for Hepatolithiasis|Comparison of Laparoscopic Versus Open Operation for Hepatolithiasis|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 21:31:13.03222|2018-05-31 21:31:13.03222
NCT01563497|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-03-23|2012-03-23|2012-03-27|Estimate|||||||2012-03-23|2012-03-27|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State|A Phase 1, Open-Label, Single Dose, Bioavailability Study In Healthy Volunteers Comparing PF-05089771 TS Tablet To PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And The Fed State|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:31:13.110312|2018-05-31 21:31:13.110312
NCT01563484|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-30|2012-03-26|2012-03-27|Estimate|||||||2012-03-30|2012-04-02|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media|Comparison of Liver and Renal Function After TACE for PHC With Iso-osmolar and Low-osmolar Contrast Media|Unknown status|Active, not recruiting||50|Anticipated|Southeast University, China|||2||f||||t||||||||||2018-05-31 21:31:13.179765|2018-05-31 21:31:13.179765
NCT01563471|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-01-12|2012-03-23|2012-03-27|Estimate|||||||2017-01-12|2017-01-13|Estimate|October 2001||2001-10-31|January 2017|2017-01-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers|Single-centre, Randomised, Placebo-controlled, Double-blind, Dose Escalation Trial Investigating Pharmacokinetics, Pharmacodynamics and Tolerability of Three Different Single Intravenous Doses of Activated Recombinant Factor VIIa (rFVIIa/NovoSeven®) in Healthy Caucasian and Japanese Subjects|Completed||Phase 1|39|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:31:13.240981|2018-05-31 21:31:13.240981
NCT01563458|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-01-12|2012-03-23|2012-03-27|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2001||2001-08-31|January 2017|2017-01-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Dose Exploratory Trial Evaluating the Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Reduction of Bleeding in Subjects Undergoing Orthotopic Liver Transplantation|Completed||Phase 2|208|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:31:13.319494|2018-05-31 21:31:13.319494
NCT01563445|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-01-12|2012-03-23|2012-03-27|Estimate|||||||2017-01-12|2017-01-13|Estimate|November 2001||2001-11-30|January 2017|2017-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage|Multi-center, Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of Activated Recombinant Factor VII (NovoSeven®) for Preventing Early Hematoma Growth in Acute Intracerebral Hemorrhage (ICH)|Completed||Phase 2|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:13.407385|2018-05-31 21:31:13.407385
NCT01563432|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Febuxostat Between TMX-67 40mg 2 Tablets and Feburic® 80mg 1 Tablet in Healthy Male Volunteers|Completed||Phase 1|30|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 21:31:13.621574|2018-05-31 21:31:13.621574
NCT01563406|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-08-14||2016-04-14|2012-03-26|2012-03-27|Estimate|2016-04-14|2016-04-18|Estimate||||2016-04-14|2016-04-18|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HUC-PHIN|140 participants, 149 separate MICU admissions, 509 hubs total. Each MICU admission is treated as a separate enrollment.|Hub Cleansing to Prevent Hub Infection|Hub Cleansing to Prevent Hub Infection|Completed||N/A|149|Actual|Rush University Medical Center|"Single MICU~Large number of eligible hubs not evaluated~Unbalanced hub collection among study arms~Studied hub contamination only; unable to collect catheter tips~Did not study central-line associated bloodstream infection itself"|4|||f||||f||||||||Yes|Rush University Medical Center adheres to the NIH Grant Policy on Sharing of Unique Research Resources including the Sharing of Biomedical Research Resources Principles and Guidelines for Recipients of NIH Grants and Contracts. Our response to requests for research resources from academic and other non-profit investigators will be timely and will be based on the Simple Letter Agreement for the Transfer of Materials as described in the Guidelines for Disseminating Research Resources Arising Out of NIH-Funded Research (Federal Register, Vol. 64, No 246, p.72094), and will not be more restrictive than the Uniform Biological Materials Transfer Agreement (UBMTA). Any intellectual property resulting from this study that can be patented will remain easily and widely available to the researchers in accordance with the NIH Principles and Guidelines. Distribution of resources to for-profit entities may occur under material transfer agreements or non-exclusive license arrangements.|2018-05-31 21:31:13.813485|2018-05-31 21:31:13.813485
NCT01563393|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-04-10|2012-03-22|2012-03-27|Estimate|||||||2016-04-10|2016-04-12|Estimate|May 2012||2012-05-31|April 2016|2016-04-30||||November 2016|Anticipated|2016-11-30||Interventional|STAMP||Validation of a STAMP in Hospitalized Children and the Effect of Its Use on the Awareness of the Medical Staff|Validation of a Nutritional Risk Screening Tool- STAMP in Hospitalized Children and the Effect of Its Use on the Awareness of the Medical Staff|Unknown status|Recruiting|N/A|464|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 21:31:14.539436|2018-05-31 21:31:14.539436
NCT01563380|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-26|2012-03-26|2012-03-27|Estimate|||||||2012-03-26|2012-03-27|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|PRPTKA2012||Role of Autologous Platelet Rich Plasma in Total Knee Arthroplasty|Efficacy of Autologous Platelet Rich Plasma on Blood Loss, Pain, Wound Healing and Functional Outcome After Total Knee Arthroplasty by a Single Surgeon A Randomized, Prospective, Controlled, Double-blinded Study|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 21:31:14.605743|2018-05-31 21:31:14.605743
NCT01563367|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2014-04-28|2012-03-22|2012-03-27|Estimate|||||||2014-04-28|2014-04-29|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|CABG-01||A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof|A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute CABG, Valve Replacement or a Combination Thereof|Completed||Phase 3|74|Actual|Pharmacosmos A/S||2|||f||||t||||||||||2018-05-31 21:31:14.770589|2018-05-31 21:31:14.770589
NCT01563354|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2018-05-28|2012-03-26|2012-03-27|Estimate|||||||2018-05-28|2018-05-30|Actual|August 16, 2013|Actual|2013-08-16|May 2018|2018-05-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|LUNA||3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial|Multicenter 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus - LUNA Trial|Active, not recruiting||Phase 2|124|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:31:14.880221|2018-05-31 21:31:14.880221
NCT01563341|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2018-03-23|2012-03-23|2012-03-26|Estimate|||||||2018-03-23|2018-03-27|Actual|April 2012||2012-04-30|March 2018|2018-03-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation|Tandem DBS for Parkinson's Disease: A Pilot Study Utilizing STN/GPi + Hypothalamic Stimulation|Enrolling by invitation||N/A|12|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f|t|||||2018-05-31 21:31:15.048558|2018-05-31 21:31:15.048558
NCT01563328|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-03-27|2012-03-22|2012-03-26|Estimate|||||||2017-03-27|2017-03-28|Actual|March 1, 2012||2012-03-01|March 2017|2017-03-31|May 1, 2012|Actual|2012-05-01|May 1, 2012|Actual|2012-05-01||Interventional|||A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).|A Phase I, Open Label, Randomized, Two Cohort, Two Period, Oneway Study to Evaluate the Effect of Boceprevir and Telaprevir onDolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697)|Completed||Phase 1|32|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 21:31:15.132995|2018-05-31 21:31:15.132995
NCT01563315|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-23|2012-03-23|2012-03-26|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|||Community-acquired Pneumonia in Buskerud County in Norway|Community-acquired Pneumonia: A Prospective Observational Study to Explore Etiology, Risk Factors and Potential Predictors for re- Admittance to Hospital and All-cause Mortality|Completed|||270|Actual|Vestre Viken Hospital Trust|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, plasma, blood culture, airways specimens, urine~   "|||2018-05-31 21:31:15.248396|2018-05-31 21:31:15.248396
NCT01563302|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2018-05-07|2012-03-22|2012-03-26|Estimate|||||||2018-05-07|2018-05-11|Actual|February 27, 2012|Actual|2012-02-27|May 2018|2018-05-31|March 23, 2016|Actual|2016-03-23|March 23, 2016|Actual|2016-03-23||Interventional|||Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers|A Phase 1/2 Study of ISIS 481464, an Antisense Oligonucleotide Inhibitor of STAT3, Administered to Patients With Advanced Cancers|Completed||Phase 1/Phase 2|64|Actual|Ionis Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:31:15.39458|2018-05-31 21:31:15.39458
NCT01563289|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2013-05-07|2012-03-23|2012-03-26|Estimate|||||||2013-05-07|2013-05-08|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries|A Randomised, Multicentre, Two-arm, Parallel Group, Double-blind, Placebo-controlled, Comparative Efficacy and Safety Clinical Study of Ibuprofen in Patients With Pain Related to Uncomplicated Ankle Injuries|Completed||Phase 3|62|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 21:31:15.508406|2018-05-31 21:31:15.508406
NCT01563276|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-23|2012-03-23|2012-03-26|Estimate|||||||2012-03-23|2012-03-26|Estimate|December 2011||2011-12-31|March 2012|2012-03-31||||||||Observational|||Postural Instability in Progressive Supranuclear Palsy|Postural Instability in Progressive Supranuclear Palsy: Why do Patients With PSP Fall?|Unknown status|Recruiting||40|Anticipated|Oregon Health and Science University|||3||f||||||||||||||2018-05-31 21:31:15.591149|2018-05-31 21:31:15.591149
NCT01563263|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-03-29|2012-03-22|2012-03-26|Estimate|||||||2016-03-29|2016-03-31|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43|A Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Recombinant Pseudomonas Vaccine Intensive Care Patients|Completed||Phase 2/Phase 3|803|Actual|Valneva Austria GmbH||2|||f||||t||||||||||2018-05-31 21:31:15.693871|2018-05-31 21:31:15.693871
NCT01563250|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-04-03|2012-03-23|2012-03-26|Estimate|||||||2013-04-03|2013-04-04|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|RACE||Improving the Management of Acute Coronary Syndromes in the Emergency Department|Improving the Management of Acute Coronary Syndromes in the Emergency Department Using a Rapid Acute Cardiac Evaluation Pathway|Completed||Phase 4|705|Actual|Integrated Medical Research LLC||2|||f||||f||||||||||2018-05-31 21:31:15.88023|2018-05-31 21:31:15.88023
NCT01563237|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-01-10|2012-03-23|2012-03-26|Estimate|||||||2017-01-10|2017-01-12|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant|Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) to Relieve Glaucoma Symptoms|Completed||Phase 2|72|Actual|InnFocus Inc.||1|||f||||f||||||||||2018-05-31 21:31:15.962011|2018-05-31 21:31:15.962011
NCT01563224|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2015-06-03|2012-03-22|2012-03-26|Estimate|||||||2015-06-03|2015-06-04|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||GABA-B Receptor Function in Healthy Volunteers|GABA-B Receptor Function in Healthy Volunteers: a Pilot, Double Blind Crossover Study of the Effects of 2 Doses of Baclofen and Placebo on Objective and Subjective Measurements of Brain Function|Completed||N/A|8|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 21:31:16.034702|2018-05-31 21:31:16.034702
NCT01563211|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2015-03-25|2012-03-22|2012-03-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Predictive Model of Therapy Outcomes in Breast Cancer Patients|Predictive Modelling of Short Term Outcomes Following Systemic Neo-adjuvant and Adjuvant Therapy in Breast Cancer Patients|Completed|||70|Actual|Imperial College London|||2||f||||f||||||Samples With DNA|"~     plasma/serum urine buffy coat - for purposes of DNA extraction~   "|||2018-05-31 21:31:16.096724|2018-05-31 21:31:16.096724
NCT01563198|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2017-04-12||2017-04-12|2012-03-22|2012-03-26|Estimate|2017-04-12|2017-04-14|Actual||||2017-04-12|2017-04-14|Actual|August 2011||2011-08-31|April 2017|2017-04-30|February 17, 2016|Actual|2016-02-17|July 2015|Actual|2015-07-31||Interventional||We obtained cumulative data from patients completion rates, thus no individual patient data on age, gender, ethnicity are available. MR departments per se do not have personal characteristics.|Reduction of Claustrophobia and Patient Motion After Training of MRI Personnel in Comfort TalkTM|Amelioration of Claustrophobia and Disruptive Patient Motion in MR Imaging|Completed||N/A|97712|Actual|Hypnalgesics, LLC||1|||f||||f||||||||No||2018-05-31 21:31:16.166136|2018-05-31 21:31:16.166136
NCT01563185|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2015-07-17||2015-11-19|2012-03-22|2012-03-26|Estimate|2015-11-19|2015-12-23|Estimate||||2015-11-19|2015-12-23|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis|A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis|Completed||Phase 4|12|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||f||||||||||2018-05-31 21:31:16.417606|2018-05-31 21:31:16.417606
NCT01563172|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-04-27||2018-01-11|2012-03-22|2012-03-26|Estimate|2017-07-31|2017-08-10|Actual||||2018-01-11|2018-02-07|Actual|January 1, 2009|Actual|2009-01-01|January 2018|2018-01-31|June 1, 2009|Actual|2009-06-01|June 1, 2009|Actual|2009-06-01||Interventional||Safety population: The overall Safety Population included all the participants who were randomized and used at least one of the treatment dentifrices during the study and had at least one safety assessment (e.g. assessment of adverse events [AEs] or had an oral soft tissue examination) after using the treatment dentifrices.|Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride|A Study to Measure the Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride Using an In Situ Caries Model|Completed||Phase 4|65|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 21:31:16.947387|2018-05-31 21:31:16.947387
NCT01563159|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2018-03-13|2012-03-22|2012-03-26|Estimate|||||||2018-03-13|2018-03-14|Actual|March 31, 2015|Actual|2015-03-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011|Assessing the Rotavirus Positive Test Results in 11 Hospitals in Belgium From 2005 to 2013: the RotaBIS Study (Rotavirus Belgian Impact Study)|Completed|||1|Actual|GlaxoSmithKline|||1||f|||||f|f||||||||2018-05-31 21:31:17.427924|2018-05-31 21:31:17.427924
NCT01563146|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2018-03-09|2012-03-22|2012-03-26|Estimate|||||||2018-03-09|2018-03-12|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007|Assessing the Number of Rotavirus Related Hospitalizations in 11 Hospitals in Belgium - Season 2006-2007|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:31:17.481928|2018-05-31 21:31:17.481928
NCT01563133|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-08-28|2012-03-23|2012-03-26|Estimate|||||||2017-08-28|2017-08-29|Actual|June 2012||2012-06-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2, 2016|Actual|2016-03-02||Interventional|CONTACT||Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas|Clinical Evaluation Of NCLE in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas|Active, not recruiting||N/A|330|Actual|Mauna Kea Technologies||1|||f||||f||||||||||2018-05-31 21:31:17.543266|2018-05-31 21:31:17.543266
NCT01563120|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2016-10-30|2012-03-23|2012-03-26|Estimate|||||||2016-10-30|2016-11-01|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus||Completed||Phase 4|108|Actual|HaEmek Medical Center, Israel||2|||f||||||||||||||2018-05-31 21:31:17.632862|2018-05-31 21:31:17.632862
NCT01563107|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-03-26|2012-03-23|2012-03-26|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2012||2012-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome|Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome|Active, not recruiting||N/A|40|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 21:31:17.691182|2018-05-31 21:31:17.691182
NCT01563094|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-10-24|2012-03-22|2012-03-26|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2003||2003-01-31|October 2016|2016-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Bone Accrual and Hormones in Response to Lactation|Bone Accrual and Hormones in Response to Lactation|Completed|||141|Actual|University of Virginia|||||f||||f||||||Samples Without DNA|"~     Blood samples.~   "|Yes|Deidentified IPD may be available by direct request of Principal Investigator.|2018-05-31 21:31:17.772005|2018-05-31 21:31:17.772005
NCT01563081|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2013-03-07||2017-01-16|2012-03-22|2012-03-26|Estimate|2013-04-25|2013-06-03|Estimate||||2017-01-16|2017-02-28|Actual|April 2012||2012-04-30|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics|A Multi-Center, Open-labelled Study to Evaluate the Safety of Levocetirizine Hydrochloride Oral Solution in Children Aged 6 Months to 2 Years With Allergic Rhinitis or Pruritus Associated With the Skin Diseases.|Completed||Phase 3|60|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:31:17.841748|2018-05-31 21:31:17.841748
NCT01563068|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2018-05-08|2012-03-22|2012-03-26|Estimate|||||||2018-05-08|2018-05-10|Estimate|April 2012|Actual|2012-04-30|May 2018|2018-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis|A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) With Plaque Psoriasis|Completed||Phase 1|18|Actual|Mayne Pharma International Pty Ltd||1|||f||||f|t|||||||||2018-05-31 21:31:19.237398|2018-05-31 21:31:19.237398
NCT01563055|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2015-05-28||2015-07-16|2012-03-22|2012-03-26|Estimate|2015-07-16|2015-08-10|Estimate||||2015-07-16|2015-08-10|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia|A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia|Completed||Phase 2|10|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:31:19.428156|2018-05-31 21:31:19.428156
NCT01563042|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-06-19|2012-03-22|2012-03-26|Estimate|||||||2017-06-19|2017-06-20|Actual|February 13, 2012|Actual|2012-02-13|June 2017|2017-06-30|May 23, 2012|Actual|2012-05-23|May 23, 2012|Actual|2012-05-23||Interventional|||A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunteers|An Exploratory First Time in Human (FTIH) Study Investigating the Pharmacokinetics (PK), Immunogenicity, Safety and Tolerability of GSK2434735 Administered as a Single Low Dose in Healthy Male Subjects|Completed||Phase 1|5|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:31:21.435938|2018-05-31 21:31:21.435938
NCT01563029|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2015-04-09||2017-04-25|2012-03-22|2012-03-26|Estimate|2015-04-09|2015-04-27|Estimate||||2017-04-25|2017-05-30|Actual|March 28, 2012|Actual|2012-03-28|April 2017|2017-04-30|September 24, 2014|Actual|2014-09-24|September 24, 2014|Actual|2014-09-24||Interventional|||A Dose-ranging Study of Fluticasone Furoate (FF)|A Dose-ranging Study of Fluticasone Furoate (FF) Inhalation Powder in Children Aged 5-11 Years With Asthma|Completed||Phase 2|597|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:31:21.619626|2018-05-31 21:31:21.619626
NCT01563016|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-23|2012-03-23|2012-03-26|Estimate|||||||2012-03-23|2012-03-26|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia|Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia: A Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|The University of Hong Kong||4|||f||||f||||||||||2018-05-31 21:31:22.850919|2018-05-31 21:31:22.850919
NCT01563003|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2015-04-01||2015-04-15|2012-03-22|2012-03-26|Estimate|2015-04-15|2015-04-17|Estimate||||2015-04-15|2015-04-17|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism|Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism|Completed||N/A|31|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 21:31:22.952321|2018-05-31 21:31:22.952321
NCT01562990|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2016-05-20|2012-03-23|2012-03-26|Estimate|||||||2016-05-20|2016-05-23|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|August 2014|Actual|2014-08-31||Interventional|||Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse|A Multi-center, Phase IB/II, Open Label, Single Arm Study of Inotuzumab Ozogamicin Plus Rituximab (R-CMC544) Alternating With Gemcitabine-oxaliplatin Plus Rituximab(R-GEMOX)in Patients Aged From 18 to 80 Years With CD20 and CD22 Positive Diffuse Large B-cell Lymphoma (DLBCL) in Relapse After/Refractory to 1ST or 2ND Line Treatment, Who Are no Candidates for Autologous Transplant.|Completed||Phase 1/Phase 2|11|Actual|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 21:31:23.236128|2018-05-31 21:31:23.236128
NCT01562977|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2017-10-27|2012-03-22|2012-03-26|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2011||2011-04-30|October 2017|2017-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|RGemOx||Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL|Prospective, Open-label, Multicentric, ph. II Study of R-GemOx and Dexametasone in Patients With Agressive Lymphomas Refractory or Relapsed to Previous Treatment and Non Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplanted|Completed||Phase 2|82|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||||||||||||2018-05-31 21:31:23.325712|2018-05-31 21:31:23.325712
NCT01562964|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-09-08|2012-03-23|2012-03-26|Estimate|||||||2015-09-08|2015-09-09|Estimate||||August 2015|2015-08-31||||||||Interventional|||Hypnotherapy in Patients With Chest Pain & Unobstructed Coronaries|The Impact of Hypnotherapy on Symptoms, Psychological Morbidity and Quality of Life in Postmenopausal Women With Chest Pain and Unobstructed Coronary Arteries|Withdrawn||N/A|0|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 21:31:23.529265|2018-05-31 21:31:23.529265
NCT01562951|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2016-05-03|2012-03-22|2012-03-26|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ADACAL||Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants|cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants|Terminated||Phase 3|15|Actual|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa||2||Not enough patient population according to selection criteria to complete the study|f||||f||||||||No||2018-05-31 21:31:23.621251|2018-05-31 21:31:23.621251
NCT01562938|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-10-04|2012-03-22|2012-03-26|Estimate|||||||2013-10-04|2013-10-07|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|CD-1092||MEDI-557 Adult Dosing|A Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of MEDI-557, a Humanized Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus (RSV), Administered to Healthy Adults|Completed||Phase 1|42|Actual|MedImmune LLC||3|||f||||f||||||||||2018-05-31 21:31:23.761688|2018-05-31 21:31:23.761688
NCT01562925|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2013-07-04|2012-03-23|2012-03-26|Estimate|||||||2013-07-04|2013-07-08|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|RenPro-II-WINE||Effect of Red Wine, White Wine and Beer on Contrast-Medium Induced Acute Kidney Injury|Randomized Controlled Study for Evaluation of the Impact of Red Wine, White Wine and Beer Intake on Contrast-Medium Induced Acute Kidney Injury|Completed||Phase 3|260|Actual|University of Cologne||4|||f||||t||||||||||2018-05-31 21:31:23.862263|2018-05-31 21:31:23.862263
NCT01562912|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2018-03-27|2012-03-22|2012-03-26|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2012||2012-02-29|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|CAPCOST||Efficiency Study Evaluating the Use of PVAC Catheter Technology for Performing Ablation in Pts With Atrial Fibrillation|The Prospective, Multicenter Canadian Atrial Fibrillation PVAC Cohort Study|Completed||N/A|230|Actual|Newmarket Electrophysiology Research Group Inc||2|||f||||f||||||||Undecided|to be determined|2018-05-31 21:31:23.950836|2018-05-31 21:31:23.950836
NCT01562899|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22||2017-02-14|2017-02-14|2012-03-23|2012-03-26|Estimate||||2017-02-14|2017-02-15|Actual|2017-02-14|2017-02-15|Actual|August 2012||2012-08-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors|A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors|Terminated||Phase 2|77|Actual|Array BioPharma||4||Study was withdrawn due to scientific and business considerations.|f||||||||||||||2018-05-31 21:31:24.039474|2018-05-31 21:31:24.039474
NCT01562886|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2014-05-19||2014-05-19|2012-03-23|2012-03-26|Estimate|2014-05-19|2014-06-19|Estimate||||2014-05-19|2014-06-19|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||The Rilpivirine Cerebrospinal-fluid (CSF) Study|A Phase I Pharmacokinetic Study to Assess the Cerebrospinal-fluid (CSF) Exposure of Rilpivirine in HIV-infected Subjects Switching From TDF/FTC/Nevirapine to TDF/FTC/Rilpivirine|Completed||Phase 1|14|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 21:31:24.157659|2018-05-31 21:31:24.157659
NCT01562873|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2016-10-05||2017-01-03|2012-03-22|2012-03-26|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|June 2012||2012-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional||The analysis dataset is comprised of all treated patients.|Ruxolitinib in Patients With Breast Cancer|Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer|Terminated||Phase 2|21|Actual|Dana-Farber Cancer Institute||2||Not enough responses to continue treatment.|f||||t||||||||No||2018-05-31 21:31:24.346974|2018-05-31 21:31:24.346974
NCT01562860|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2018-01-23|2012-03-22|2012-03-26|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2010||2010-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Influence of Pronator Teres Release on Treatment of Median Nerve Compression Neuropathy|The Influence of Pronator Teres Release in the Treatment of Median Nerve Compression Neuropathy: A Randomized Prospective Study|Recruiting||Phase 2|100|Anticipated|Christine M. Kleinert Institute for Hand and Microsurgery||2|||f||||f||||||||||2018-05-31 21:31:24.570413|2018-05-31 21:31:24.570413
NCT01562847|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-01-10|2012-03-23|2012-03-26|Estimate|||||||2014-01-10|2014-01-13|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Observational|AMICAN||Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib|Dynamics of ABL Mutations in Imatinib Failed Ph Positive or Bcr-Abl Positive CML CP or AP Patients Who Treated With Nilotinib as Second-line TKI Therapy (AMICAN-Prospective)in Asia|Unknown status|Active, not recruiting||125|Anticipated|Seoul St. Mary's Hospital|||1||f||||t||||||Samples Without DNA|"~     RNA analysis for mutation and Bcr-Abl gene quantification using mainly peripheral blood~   "|||2018-05-31 21:31:24.666705|2018-05-31 21:31:24.666705
NCT01562834|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-02-23|2012-03-23|2012-03-26|Estimate|||||||2017-02-23|2017-02-27|Actual|October 21, 1998|Actual|1998-10-21|February 2017|2017-02-28|December 1, 2002|Actual|2002-12-01|December 1, 2002|Actual|2002-12-01||Interventional|||Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients|Randomized Cross Over Double Blind Versus Placebo Trial Followed by an Open Phase Studying Effect of Norditropin® on Left Ventricular Mass of Growth Hormone Deficient Adult Patients|Completed||Phase 4|22|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:24.752443|2018-05-31 21:31:24.752443
NCT01562821|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-01-12|2012-03-23|2012-03-26|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2001||2001-07-31|January 2017|2017-01-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Safety and Efficacy of A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial Evaluating the Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Cirrhotic Patients Scheduled to Undergo Partial Hepatectomy Due to Liver Cancer or Benign Tumours|Completed||Phase 2|235|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:31:24.868362|2018-05-31 21:31:24.868362
NCT01562808|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-23|2012-03-23|2012-03-26|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|May 2010|Actual|2010-05-31||Interventional|||Change in Brain Metabolism and Cognitive Function by Aripiprazole|The Relationship Between D2 Occupancy and Change in Frontal Metabolism and Working Memory Induced by Aripiprazole|Completed||N/A|15|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 21:31:24.953197|2018-05-31 21:31:24.953197
NCT01562795|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-01-02|2012-03-23|2012-03-26|Estimate|||||||2014-01-02|2014-01-03|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease|Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease|Completed||N/A|48|Actual|Wenzhou Medical University||4|||f||||t||||||||||2018-05-31 21:31:25.010169|2018-05-31 21:31:25.010169
NCT01562782|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-07-20|2012-03-23|2012-03-26|Estimate|||||||2016-07-20|2016-07-21|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Change of Fructose to Fat in South Asians|Fructose-induced Hepatic De Novo Lipogenesis in South Asians|Active, not recruiting||N/A|36|Anticipated|The Rogosin Institute||1|||f||||f||||||||||2018-05-31 21:31:25.095684|2018-05-31 21:31:25.095684
NCT01562769|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-08-20|2012-03-23|2012-03-26|Estimate|||||||2015-08-20|2015-08-21|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|ISOL/STAND||Interest of Contact Precautions for Preventing Micro-organisms Acquisition in Patients Hospitalized in Infectious Disease Unit of University-affiliated Hospital in Rennes|Interest of Contact Precautions for Preventing Micro-organisms Acquisition in Patients Hospitalized in Infectious Disease Unit of University-affiliated Hospital in Rennes|Terminated|||400|Actual|Rennes University Hospital|||2|enrollment difficulties|f||||||||||||||2018-05-31 21:31:25.183304|2018-05-31 21:31:25.183304
NCT01562756|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2017-03-21||2017-05-05|2012-03-22|2012-03-26|Estimate|2017-05-05|2017-07-31|Actual||||2017-05-05|2017-07-31|Actual|February 2012||2012-02-29|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PRiSM||Patient Response to Spinal Manipulation - Pilot Study|Pilot for Patient Response to Spinal Manipulation (PRiSM)|Completed||N/A|6|Actual|Palmer College of Chiropractic||1|||f||||f||||||||No|Feasibility/pilot study|2018-05-31 21:31:25.336336|2018-05-31 21:31:25.336336
NCT01562743|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2014-02-03||2014-03-26|2012-03-22|2012-03-26|Estimate|2014-03-26|2014-04-23|Estimate||||2014-03-26|2014-04-23|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|RLS||A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome|An Open-label Long-term Extension Trial From Late Phase II of SPM 962 (243-07-003) in Patients With Restless Legs Syndrome|Completed||Phase 2|185|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:31:25.541283|2018-05-31 21:31:25.541283
NCT01562730|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-04-30|2012-03-23|2012-03-26|Estimate|||||||2012-04-30|2012-05-01|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Myovista iECG for Detecting Ischemic Heart Disease: Comparison With Computed Tomography Coronary Angiography|Incremental Value of Signal Processed Surface Electrocardiography (IECG) for Detecting Ischemic Heart Disease: Comparison With Computed Tomography Coronary Angiography (CTCA)|Unknown status|Recruiting||1000|Anticipated|Cardiocentro Ticino|||2||f||||f||||||||||2018-05-31 21:31:25.845413|2018-05-31 21:31:25.845413
NCT01562717|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2013-05-07|2012-03-23|2012-03-26|Estimate|||||||2013-05-07|2013-05-08|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries|A Randomised, Multicentre, Two-arm, Parallel Group, Double-blind, Placebo-controlled, Comparative Efficacy and Safety Clinical Study of Ibuprofen in Patients With Pain Related to Uncomplicated Ankle Injuries|Completed||Phase 3|62|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 21:31:25.942883|2018-05-31 21:31:25.942883
NCT01562704|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2013-01-11|2012-03-22|2012-03-26|Estimate|||||||2013-01-11|2013-01-14|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|IRMf||Visualisation of the Central Analgesic Effect of Paracetamol in Functional MRI|Visualisation of the Central Analgesic Effect of Paracetamol in Functional MRI|Completed||Phase 1|21|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 21:31:26.02188|2018-05-31 21:31:26.02188
NCT01562691|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-23|2012-03-23|2012-03-26|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Effect of Airway Integrated Nasal Packing With Different Material|Comparison of Nasal Packing Methods:Nasal Packing Was Done With Nasopore@, Airway-integrated Nasopore@ and Airway-integrated Vaseline Gauze|Completed||Phase 4|60|Actual|Chi Mei Medical Hospital||3|||f||||t||||||||||2018-05-31 21:31:26.097011|2018-05-31 21:31:26.097011
NCT01562678|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2015-12-22||2017-04-26|2012-03-23|2012-03-26|Estimate|2017-04-26|2017-05-31|Actual||||2017-04-26|2017-05-31|Actual|March 2012||2012-03-31|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI|Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI|Completed||Phase 4|28|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 21:31:26.185104|2018-05-31 21:31:26.185104
NCT01562665|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-05-23|2012-03-22|2012-03-26|Estimate|||||||2016-05-23|2016-05-24|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|Lung-EPICLIN/G||Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf|Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA|Completed|||25|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 21:31:26.407493|2018-05-31 21:31:26.407493
NCT01562652|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-03-23|2012-03-23|2012-03-26|Estimate|||||||2012-03-23|2012-03-26|Estimate||||March 2012|2012-03-31||||||||Interventional|||AposTherapy for Singaporean Patients With Knee Osteoarthritis (OA)||Completed||N/A|60|Actual|Apos Medical and Sports Technology Ltd.||1|||f||||||||||||||2018-05-31 21:31:26.48057|2018-05-31 21:31:26.48057
NCT01562639|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-10-30|2012-03-23|2012-03-26|Estimate|||||||2014-10-30|2014-10-31|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Nexium Capsules RE Maintenance Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation for Maintenance Therapy for Repeatedly Recurring/Relapsing Reflux Oesophagitis|Completed|||647|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 21:31:26.557285|2018-05-31 21:31:26.557285
NCT01562626|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-12-26|2012-03-22|2012-03-26|Estimate|||||||2017-12-26|2017-12-28|Actual|September 2012||2012-09-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors|A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|75|Anticipated|Anaeropharma Science, Inc.||1|||f||||||||||||||2018-05-31 21:31:26.690429|2018-05-31 21:31:26.690429
NCT01562613|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2014-03-27||2014-08-08|2012-03-23|2012-03-26|Estimate|2014-07-29|2014-07-30|Estimate||||2014-08-08|2014-08-12|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan|Stroke Estimation (According to Framingham Profile ParameterS) in Patients Under medicAtion Due to Essential Hypertension. (NASA)|Completed|||533|Actual|Abbott|No important limitations apply. Missing data and drop-out rate was very low; but some factors required for patient CV (cardiovascular) risk classification were unknown and may have resulted in CV risk underestimation in a limited number of patients.||1||f||||f||||||||||2018-05-31 21:31:26.791906|2018-05-31 21:31:26.791906
NCT01562600|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-06-20|2012-03-23|2012-03-26|Estimate|||||||2017-06-20|2017-06-21|Actual|April 19, 2012|Actual|2012-04-19|June 2017|2017-06-30|August 27, 2015|Actual|2015-08-27|August 27, 2015|Actual|2015-08-27||Observational|||Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation for Long-term Use Concerning Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer With NSAIDs|Completed|||1634|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 21:31:27.055461|2018-05-31 21:31:27.055461
NCT01562587|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-01-11|2012-03-23|2012-03-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2002||2002-09-30|January 2017|2017-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State|Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non-Bleeding State|Completed||Phase 1|18|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:27.153332|2018-05-31 21:31:27.153332
NCT01562574|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-01-11|2012-03-22|2012-03-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2002||2002-01-31|January 2017|2017-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease|A Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombi-nant Factor VIIa (rFVIIa/ NovoSeven®) With Standard Haemostatic Replacement Therapy, and Standard Haemostatic Replacement Ther-apy Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease|Completed||Phase 3|82|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:27.318587|2018-05-31 21:31:27.318587
NCT01562561|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-02-17|2012-03-23|2012-03-26|Estimate|||||||2017-02-17|2017-02-20|Actual|June 1, 2001|Actual|2001-06-01|February 2017|2017-02-28|December 20, 2002|Actual|2002-12-20|December 20, 2002|Actual|2002-12-20||Interventional|||Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes|Multi-centre, Multinational, Open-labelled, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled on Repaglinide, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime NPH Insulin Versus Twice Daily NPH Insulin|Completed||Phase 3|213|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:27.41079|2018-05-31 21:31:27.41079
NCT01562548|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2014-03-06||2014-05-01|2012-03-22|2012-03-26|Estimate|2014-05-01|2014-06-03|Estimate||||2014-05-01|2014-06-03|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Exploratory Efficacy Study of Guaifenesin in Upper Back Pain|A Proof of Principle Study to Explore the Utility of Guaifenesin in Upper Back Pain|Completed||N/A|78|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:31:27.542706|2018-05-31 21:31:27.542706
NCT01562535|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-23|2012-03-23|2012-03-26|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2012||2012-06-30|March 2012|2012-03-31|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Interventional|||A Clinical Trial of Pronation Versus Supination Maneuvers for the Reduction of the Pulled Elbow|A Randomized Clinical Trial of Pronation Versus Supination Maneuvers for the Reduction of the Pulled Elbow|Unknown status|Not yet recruiting|N/A|90|Anticipated|Instituto Tecnologico y de Estudios Superiores de Monterey||2|||f||||t||||||||||2018-05-31 21:31:28.34578|2018-05-31 21:31:28.34578
NCT01562522|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-03-22|2012-03-23|2012-03-26|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|EXPEDIENT||Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.|Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.|Terminated||Phase 2|6|Actual|Ipsen||2||Poor enrolment; only 6 subjects enrolled and they were all screen failures.|f||||f||||||||||2018-05-31 21:31:28.439817|2018-05-31 21:31:28.439817
NCT01562509|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-11-12|2012-03-22|2012-03-23|Estimate|||||||2014-11-12|2014-11-13|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||PEARL Study: Improvement of Non-Hodgkin's Lymphoma Care|Improvement of Hospital Care for Patients With Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|N/A|418|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 21:31:28.517343|2018-05-31 21:31:28.517343
NCT01562496|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-11-12|2012-03-22|2012-03-23|Estimate|||||||2014-11-12|2014-11-13|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The ParkCycle Study: Aerobic Exercise in PD|The ParkCycle Study: Effects of Aerobic Exercise on Cognitive and Adaptive Plasticity in Parkinson's Disease|Completed||N/A|35|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:31:28.604957|2018-05-31 21:31:28.604957
NCT01562483|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2014-10-27|2012-03-22|2012-03-23|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain|The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain; a Randomized, Double Blinded, Placebo-controlled, Experiment|Completed||Phase 2|36|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:31:28.690692|2018-05-31 21:31:28.690692
NCT01562470|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-03-23|2012-03-22|2012-03-23|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Clinical Trial to Assess the Efficacy and Safety of a Novel Cellulite Cream|Clinical Trial to Assess the Efficacy and Safety of a Novel Cellulite Cream in Reducing the Appearance of Cellulite in Human Subjects|Completed||Phase 1|23|Actual|Nutrasource Diagnostics Inc.||1|||f||||f||||||||||2018-05-31 21:31:28.775126|2018-05-31 21:31:28.775126
NCT01562457|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-05-11|2012-03-22|2012-03-23|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2005||2005-11-30|May 2016|2016-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State|A Randomised, Open-label, Multi-centre Trial Investigating the Intra-subject Variability of ROTEM® and TEG® Parameters Following Two Intravenous Administrations of the Same Dose of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Haemophilia Patients in a Non-bleeding State|Completed||Phase 1|30|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:31:28.848078|2018-05-31 21:31:28.848078
NCT01562444|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-03-21|2012-03-22|2012-03-23|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2012||2012-03-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules|A Phase IV, Open-label, Single-center Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules|Completed||Phase 4|206|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:31:28.923998|2018-05-31 21:31:28.923998
NCT01562431|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-01-23|2012-03-22|2012-03-23|Estimate|||||||2014-01-23|2014-01-24|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||The Signal-Trial: Evaluation of a Screening Tool for Psychosocial Problems in Cancer Genetics|The Signal-Trial: Evaluation of a Screening Tool for Psychosocial Problems in Cancer Genetics|Completed||N/A|246|Actual|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 21:31:28.997795|2018-05-31 21:31:28.997795
NCT01562418|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2012-03-22|2012-03-22|2012-03-23|Estimate|||||||2012-03-22|2012-03-23|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|February 2013|Anticipated|2013-02-28|March 2012|Anticipated|2012-03-31||Interventional|||Multi Dimensional System for Evaluating a Preventive Program for Upper Extremity Disorders Among Computer Operators|Multi Dimensional System for Evaluating a Preventive Program for Upper Extremity Disorders Among Computer Operators|Unknown status|Recruiting|N/A|108|Anticipated|Medical Corps, Israel Defense Force||3|||f||||f||||||||||2018-05-31 21:31:29.07424|2018-05-31 21:31:29.07424
NCT01562405|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2018-05-06|2012-03-22|2012-03-23|Estimate|||||||2018-05-06|2018-05-08|Actual|May 2012||2012-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2018|Actual|2018-05-31||Interventional|||Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma|Phase 1, Multicenter, Open-label, Dose-escalation Study of Sotatercept (ACE-011) in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1|34|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:31:29.164987|2018-05-31 21:31:29.164987
NCT01562392|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-02-26|2012-03-22|2012-03-23|Estimate|||||||2014-02-26|2014-02-27|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Berries and Vegetables on Cardiometabolic Risk Markers and Cognitive Functions|Effects of 5 w Daily Intake of Berries and Vegetables on Cardiometabolic Risk Markers and Cognitive Functions|Completed||N/A|40|Anticipated|Lund University||2|||f||||||||||||||2018-05-31 21:31:29.259525|2018-05-31 21:31:29.259525
NCT01562379|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-04-23|2012-03-22|2012-03-23|Estimate|||||||2015-04-23|2015-04-24|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Complementary Food Supplements for Reducing Childhood Undernutrition|Evaluation of Complementary Food Supplements For Reducing Childhood Undernutrition: The JiVitA-4 Study|Completed||Phase 2/Phase 3|5449|Actual|Johns Hopkins Bloomberg School of Public Health||5|||f||||t||||||||||2018-05-31 21:31:29.336022|2018-05-31 21:31:29.336022
NCT01562366|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-05-23|2012-03-22|2012-03-23|Estimate|||||||2017-05-23|2017-05-25|Actual|April 2012||2012-04-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Research Study to Compare the Addition of Topaz Micro Debridement to the Standard of Care Surgery|A Randomised, Controlled, Double-blind Clinical Investigation on the Efficacy and Safety of Radiofrequency Micro Debridement, Topaz, in Recalcitrant Greater Trochanteric Pain Syndrome (GTPS) vs. Standard of Care|Completed||N/A|66|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-05-31 21:31:29.428273|2018-05-31 21:31:29.428273
NCT01562353|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2013-09-13|2012-03-22|2012-03-23|Estimate|||||||2013-09-13|2013-09-16|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction|A Pilot Study to Determine the Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction in Patients Treated for Pain Using a Comparative Transcriptomic Analysis of Gene Expression in Peripheral Blood Cells|Unknown status|Recruiting||30|Anticipated|Analgesic Solutions|||2||f||||f||||||Samples With DNA|"~     One tube (2.5-5.0 mL) of blood will be drawn from each subject during the visit for mRNA~     testing~   "|||2018-05-31 21:31:29.502462|2018-05-31 21:31:29.502462
NCT01562340|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2015-05-26|2012-03-21|2012-03-23|Estimate|||||||2015-05-26|2015-05-28|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|POM Pilot||Pomegranate and Hemodialysis Pilot Trial|A Pilot Trial Assessing the Effect of Pomegranate Juice and Extract on Biomarkers of Oxidative Stress, Systemic Inflammation, and Monocyte Function in Hemodialysis Patients|Completed||N/A|24|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 21:31:29.567485|2018-05-31 21:31:29.567485
NCT01562327|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2016-06-29||2016-10-18|2012-03-22|2012-03-23|Estimate|2016-08-24|2016-10-18|Estimate||||2016-10-18|2016-11-29|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab Actemra|Completed|||50|Actual|Hoffmann-La Roche|||1||f||||t||||||||||2018-05-31 21:31:29.656622|2018-05-31 21:31:29.656622
NCT01562314|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2015-06-22||2015-07-17|2012-03-22|2012-03-23|Estimate|2015-07-17|2015-08-14|Estimate||||2015-07-17|2015-08-14|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|GWID10160||A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160)|A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis.|Completed||Phase 2|60|Actual|GW Research Ltd||2|||f||||f||||||||||2018-05-31 21:31:30.235501|2018-05-31 21:31:30.235501
NCT01562301|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2015-06-05|2012-03-21|2012-03-23|Estimate|||||||2015-06-05|2015-06-08|Estimate|June 2014||2014-06-30|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Interventional|||Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of the Combination of Carboplatin, Docetaxel, and Increasing Doses of Sublingual Anvirzel (Nerium Oleander) in Advance Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-05-31 21:31:31.271258|2018-05-31 21:31:31.271258
NCT01562288|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-08-07|2012-03-21|2012-03-23|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2012||2012-02-29|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab|Adjuvant Chemotherapy Combined With Trastuzumab in the Randomized Phase III Trial N9831 Actively Immunizes Patients Against Tumor Antigens|Active, not recruiting|||1576|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Serum and DNA extracted from peripheral blood mononuclear cell samples~   "|||2018-05-31 21:31:31.35626|2018-05-31 21:31:31.35626
NCT01562275|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2016-02-25||2016-02-25|2012-03-21|2012-03-23|Estimate|2016-02-25|2016-03-28|Estimate||||2016-02-25|2016-03-28|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||All enrolled participants.|A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|67|Actual|Genentech, Inc.|As per changes in the planned analysis, PFS and duration of response outcome measures were not analyzed as only few participants experienced a measurable response.|3|||f||||||||||||||2018-05-31 21:31:31.542549|2018-05-31 21:31:31.542549
NCT01562262|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-24|2012-03-22|2012-03-23|Estimate|||||||2012-03-24|2012-03-27|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|March 2012|Actual|2012-03-31||Observational|||Comparison of RT in Patients With Sleep Apnea With and Without Complaints of Daytime Sleepiness|Behavior of Psychomotor Vigilance Task Performance in Subjects With Obstructive Sleep Apnea With and Without Complaints of Daytime Sleepiness|Unknown status|Recruiting||30|Anticipated|Federal University of São Paulo|||3||f||||t||||||||||2018-05-31 21:31:35.823651|2018-05-31 21:31:35.823651
NCT01562249|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-21|2012-03-21|2012-03-23|Estimate|||||||2012-03-21|2012-03-23|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|February 2010|Actual|2010-02-28||Interventional|||Rehabilitative Management of Mastication|Rehabilitative Management of Mastication After Orthognathic Surgery: A Randomized Controlled Trial|Completed||Phase 2|17|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 21:31:35.930681|2018-05-31 21:31:35.930681
NCT01562236|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-22|2012-03-22|2012-03-23|Estimate|||||||2012-03-22|2012-03-23|Estimate|January 2000||2000-01-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|December 2002|Actual|2002-12-31||Observational|||Gender-specific aEEGs and Outcome in Preterms|Gender-related Differences in Early Amplitude-integrated Electroencephalography in Newborns < 30 Weeks' Gestational Age and Their Correlation With Neurodevelopment Outcome at Three Years Corrected Age|Completed|||148|Actual|Medical University of Vienna|||||f||||t||||||||||2018-05-31 21:31:36.044376|2018-05-31 21:31:36.044376
NCT01562223|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-03-16|2012-03-22|2012-03-23|Estimate|||||||2017-03-16|2017-03-20|Actual|August 2012||2012-08-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|A6701QIBA||Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer|Repeatability Assessment of Quantitative DCE-MRI and DWI: A Multicenter Study of Functional Imaging Standardization in the Prostate|Active, not recruiting||N/A|30|Anticipated|American College of Radiology Imaging Network||1|||f||||t||||||||Yes|"See ACRIN data Sharing Policy:~https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx"|2018-05-31 21:31:36.114531|2018-05-31 21:31:36.114531
NCT01562210|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2016-12-07|2012-03-22|2012-03-23|Estimate|||||||2016-12-07|2016-12-08|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|March 2020|Anticipated|2020-03-31|November 2017|Anticipated|2017-11-30||Interventional|olaparib||Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC|Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma|Recruiting||Phase 1|60|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 21:31:36.222727|2018-05-31 21:31:36.222727
NCT01562197|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-05-23|2012-03-21|2012-03-23|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2014||2014-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AxiGII||A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma|A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 2|52|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 21:31:36.352356|2018-05-31 21:31:36.352356
NCT01562184|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2015-11-30|2012-03-22|2012-03-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Investigating tDCS as a Treatment for Unipolar and Bipolar Depression|A Controlled Trial of Transcranial Direct Current Stimulation as a Treatment for Unipolar and Bipolar Depression|Completed||Phase 2/Phase 3|120|Actual|The University of New South Wales||2|||f||||t||||||||||2018-05-31 21:31:36.443828|2018-05-31 21:31:36.443828
NCT01562171|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2014-12-11|2012-03-21|2012-03-23|Estimate|||||||2014-12-11|2014-12-12|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|LEN-0-2012||Lentils as a Functional Food to Improve Glucose and Decrease Cardiovascular Risk|Lentils as a Functional Food to Improve Glucose Tolerance and Decrease Cardiovascular Disease Risk in Hypercholesterolemic Overweight Individuals|Completed||N/A|102|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:31:36.545116|2018-05-31 21:31:36.545116
NCT01562158|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-01-10|2012-03-22|2012-03-23|Estimate|||||||2017-01-10|2017-01-11|Estimate|April 2001||2001-04-30|January 2017|2017-01-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation|A Multi-centre, Randomised, Double-blind, Parallel Groups, Placebocontrolled Trial on Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Treatment of Bleeding in Patients Following Stem Cell Transplantation (SCT)|Completed||Phase 2|100|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:31:37.737813|2018-05-31 21:31:37.737813
NCT01562145|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-23|2012-03-21|2012-03-23|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Elevated Plasma Levels of TIMP-1 in Patients With Rotator Cuff Tear|Elevated Plasma Levels of TIMP-1 in Patients With Rotator Cuff Tear|Completed|||34|Actual|University Hospital, Linkoeping|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 21:31:37.900778|2018-05-31 21:31:37.900778
NCT01562132|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2015-07-31||2015-07-31|2012-03-21|2012-03-23|Estimate|2015-07-31|2015-08-31|Estimate||||2015-07-31|2015-08-31|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|SToP-Crypto||Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection|An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone|Terminated||Phase 2|6|Actual|Yale University||2||Stopped in accordance with pre-specified stopping rules for poor recruitment.|f||||t||||||||||2018-05-31 21:31:38.061572|2018-05-31 21:31:38.061572
NCT01562119|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2013-04-17|2012-03-22|2012-03-23|Estimate|||||||2013-04-17|2013-04-19|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|ADM||Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn|Long Term Evaluation of Human Acellular Dermal Matrix Allograft For Coverage of the Wound After Extensive Deep Burn|Unknown status|Active, not recruiting||30|Actual|Tang-Du Hospital|||||f||||t||||||Samples With DNA|"~     The skin with ADM inplant and the nomal skin as control group~   "|||2018-05-31 21:31:38.402441|2018-05-31 21:31:38.402441
NCT01562106|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-11-16|2012-03-21|2012-03-23|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|September 2015|Actual|2015-09-30||Interventional|||Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery|A Prospective Investigation of the Use of Fluorescence Imaging on the da Vinci Surgical System for Ultrastaging of Endometrial Cancer by Sentinel Node Assessment|Completed||N/A|123|Actual|Swedish Medical Center||1|||f||||f||||||||||2018-05-31 21:31:38.492679|2018-05-31 21:31:38.492679
NCT01562093|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-08-30|2012-03-21|2012-03-23|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Intranasal Corticosteroids on Pulmonary Symptoms in Asthmatics With Nasal Congestion|Effect of Intranasal Corticosteroids on Pulmonary Symptoms in Asthmatics With Nasal Congestion, a Randomized Controlled Trial|Terminated||N/A|14|Actual|St. Olavs Hospital||2||Investigational drugs no longer available|f||||f||||||||||2018-05-31 21:31:38.589061|2018-05-31 21:31:38.589061
NCT01562080|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2013-02-27|2012-03-22|2012-03-23|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|ARM-PLUS-LDL||Combined Effects of Bioactive Compounds in Lipid Profile|Combined Effects of Bioactive Compounds (ARMOLIPID PLUS ®) on Lipid Profile and Clinical Criteria of Metabolic Syndrome in Patients With Serum Elevated LDL-C|Completed||Phase 2/Phase 3|118|Actual|Rottapharm Spain||2|||f||||f||||||||||2018-05-31 21:31:38.685819|2018-05-31 21:31:38.685819
NCT01562067|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-03-22|2012-03-22|2012-03-23|Estimate|||||||2012-03-22|2012-03-23|Estimate|March 2012||2012-03-31|March 2011|2011-03-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Observational|||Sonographic Characteristics of Tumor Indices in Patients With Cervical Cancer During Chemo-radiotherpy|Sonographic Characteristics of Tumor Indices in Patients With Cervical Cancer During Chemo-radiotherpy|Unknown status|Not yet recruiting||40|Anticipated|Rambam Health Care Campus|||||f||||f||||||Samples Without DNA|"~     pap smear~   "|||2018-05-31 21:31:38.795279|2018-05-31 21:31:38.795279
NCT01562054|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-08-08|2012-03-22|2012-03-23|Estimate|||||||2012-08-08|2012-08-09|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|April 2012|Actual|2012-04-30|||||Observational|||Evaluation of a Rating Tool for Measuring General Surgeons' Non-technical Performance in the Operating Room|Evaluation of a Rating Tool for Measuring General Surgeons' Non-technical Performance in the Operating Room|Completed|||20|Anticipated|Herlev Hospital|||||f||||f||||||||||2018-05-31 21:31:38.877626|2018-05-31 21:31:38.877626
NCT01562041|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-04-15|2012-03-22|2012-03-23|Estimate|||||||2016-04-15|2016-04-19|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease|Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease|Terminated||Phase 2|11|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:31:38.93172|2018-05-31 21:31:38.93172
NCT01562028|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-01-23|2012-03-22|2012-03-23|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2012||2012-06-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|BELIEF||BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)|An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations|Active, not recruiting||Phase 2|110|Actual|European Thoracic Oncology Platform||1|||f||||t||||||||||2018-05-31 21:31:39.040616|2018-05-31 21:31:39.040616
NCT01562015|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2015-05-18|2012-03-21|2012-03-23|Estimate|||||||2015-05-18|2015-05-20|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|CHIARA||A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)|A Single Arm, Phase 2 Study of Ganetespib in Subjects With Advanced Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)|Completed||Phase 2|12|Actual|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-05-31 21:31:39.207758|2018-05-31 21:31:39.207758
NCT01562002|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-01-07|2012-03-22|2012-03-23|Estimate|||||||2015-01-07|2015-01-08|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome|Advanced Therapy for Ocular Surface Reconstruction. Allogenic Limbus Epithelial Stem-cell Transplant vs Bone Marrow Mesenchymal Stem-cell Transplant in Limbus Insufficiency Syndrome. Double-masked Randomized Trial|Completed||Phase 1/Phase 2|27|Actual|Instituto Universitario de Oftalmobiología Aplicada||2|||f||||||||||||||2018-05-31 21:31:39.273546|2018-05-31 21:31:39.273546
NCT01561989|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-02-03|2012-03-22|2012-03-23|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2011||2011-10-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|July 2013|Actual|2013-07-31||Interventional|||Cholecalciferol and Flu Vaccine in Treating Healthy Participants|Immune Responses to Influenza Vaccine Among Healthy Employees Working at Roswell Park Cancer Institute and the Relationship to Vitamin D Status|Terminated||N/A|211|Actual|Roswell Park Cancer Institute||2||low accrual|f||||t||||||||||2018-05-31 21:31:39.339475|2018-05-31 21:31:39.339475
NCT01561976|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-08-10||2017-09-13|2012-03-22|2012-03-23|Estimate|2017-09-13|2017-10-16|Actual||||2017-09-13|2017-10-16|Actual|January 30, 2012|Actual|2012-01-30|August 2017|2017-08-31|February 21, 2012|Actual|2012-02-21|February 21, 2012|Actual|2012-02-21||Interventional|||Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers|The Effect of Food on the Pharmacokinetics of Metformin Given Either as Metformin Hydrochloride SR 1000mg Tablet or as a Fixed Dose Combination of Metformin Hydrochloride SR 1000mg/Glimepiride 2mg Tablet in Healthy Indian Volunteers.|Completed||N/A|30|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:31:39.550955|2018-05-31 21:31:39.550955
NCT01561963|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-11-21|2012-03-22|2012-03-23|Estimate|||||||2016-11-21|2016-11-22|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast|A Phase 1, Open-label, Three-period, Fixed-sequence Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects|Completed||Phase 1|21|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 21:31:40.157337|2018-05-31 21:31:40.157337
NCT01561950|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-11-22|2012-03-22|2012-03-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2008||2008-05-31|November 2016|2016-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding|Use of Recombinant FVIIa to Mitigate Clopidogrel Anti-platelet Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial|Terminated||Phase 1|91|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:40.256002|2018-05-31 21:31:40.256002
NCT01561937|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-11-23|2012-03-22|2012-03-23|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment|Use of Recombinant FVIIa to Mitigate Warfarin Anticoagulation Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial|Completed||Phase 1|127|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:40.35267|2018-05-31 21:31:40.35267
NCT01560676|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-20|2012-03-20|2012-03-22|Estimate|||||||2012-03-20|2012-03-22|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|HEALTH[e]TEEN||Reducing Obesity and Type 2 Diabetes in High Risk Youth|A School-based Internet Obesity Prevention Program for Adolescents|Completed||Phase 2/Phase 3|384|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:31:55.025238|2018-05-31 21:31:55.025238
NCT01561924|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-11-22|2012-03-22|2012-03-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2005||2005-11-30|November 2016|2016-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography|An Exploratory Non-interventional Study of Ex-vivo Spiking Followed by Thromboelastography as a Method for Predicting the Efficacy of Recombinant Activated Human FVII (rFVIIa, NovoSeven®) in Adult Congenital Haemophilia A or B Patients With Inhibitors|Completed||Phase 1|17|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:31:40.45039|2018-05-31 21:31:40.45039
NCT01561911|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2014-12-01|2012-03-22|2012-03-23|Estimate|||||||2014-12-01|2014-12-02|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment|A Phase I Clinical Research Study Evaluating the Safety, Tolerability and Biological Effects of the Chimeric Anti-CD40 Monoclonal Antibody Chi Lob 7/4 Given Intravenously, Weekly for Four Weeks in the Treatment of Patients With Advanced Malignancies Refractory to Conventional Anti-cancer Treatment.|Completed||Phase 1|29|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 21:31:40.549471|2018-05-31 21:31:40.549471
NCT01561898|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|2012-08-08||2012-09-14|2012-03-22|2012-03-23|Estimate|2012-08-08|2012-09-10|Estimate||||2012-09-14|2012-09-28|Estimate|June 2006||2006-06-30|September 2012|2012-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Long-Term Study of JNS007ER in Patients With Schizophrenia|A Long-Term Study of JNS007ER in Patients With Schizophrenia|Completed||Phase 3|228|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 21:31:40.643446|2018-05-31 21:31:40.643446
NCT01561885|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2017-04-04|2012-03-22|2012-03-23|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2012||2012-03-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CHAMP-Path||Collaborative Healthcare Professionals Approach in Monitoring of Patient Centered Outcomes Through Pathways|A Pragmatic Randomized Controlled Trial of Patient-Centered Integrated Clinical Pathways Based Versus Usual Care in an Academic Center: National Guard Health Affairs Western Region Experience|Completed||N/A|341|Actual|King Abdullah International Medical Research Center||2|||f||||t||||||||||2018-05-31 21:31:40.924034|2018-05-31 21:31:40.924034
NCT01561872|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2015-02-12|2012-03-21|2012-03-23|Estimate|||||||2015-02-12|2015-02-13|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Observational|GET-BETTER||Assessment of an Automated Telesurveillance System on Serious Falls Prevention in an Elderly Suffering From Dementia Specialized Care Unit: the URCC|Assessment of an Automated Telesurveillance System on Serious Falls Prevention in an Elderly Suffering From Dementia Specialized Care Unit: the URCC. GET-BETTER Study (Geriatric Environmental Telecare - Behavioral Engineering Technology To Enhance Rehabilitation)|Completed|||350|Actual|University Hospital, Limoges|||2||f||||f||||||||||2018-05-31 21:31:40.994204|2018-05-31 21:31:40.994204
NCT01561859|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-08-18|2012-03-22|2012-03-23|Estimate|||||||2017-08-18|2017-08-22|Actual|June 2012||2012-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BICEPS||Brain Imaging, Cognitive Enhancement and Early Schizophrenia|Brain Imaging, Cognitive Enhancement and Early Schizophrenia|Active, not recruiting||N/A|102|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 21:31:41.047046|2018-05-31 21:31:41.047046
NCT01561846|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-03-22|2012-03-22|2012-03-23|Estimate|||||||2012-03-22|2012-03-23|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|CASU||Cheese Intake,CLA and Hypercholesterolemia|Randomized, Double Blind, Controlled, Cross Over Clinical Trial on Intake of CLA Enriched Cheese in Hypercholesterolemic Patients|Completed||Phase 1/Phase 2|42|Actual|Azienda Ospedaliera Brotzu||2|||f||||f||||||||||2018-05-31 21:31:41.12805|2018-05-31 21:31:41.12805
NCT01561833|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-02-18|2012-03-21|2012-03-23|Estimate|||||||2015-02-18|2015-02-19|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients|A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients|Completed||Phase 1|15|Actual|Yale University||1|||f||||t||||||||||2018-05-31 21:31:41.327425|2018-05-31 21:31:41.327425
NCT01561820|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-12-18|2012-03-21|2012-03-23|Estimate|||||||2017-12-18|2017-12-20|Actual|November 2011||2011-11-30|December 2017|2017-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Mild Cognitive Impairment, Buddy Supported Exercise/ My Buddy Study|Community-based, Buddy-supported Exercise in Patients With MCI: a Pilot Trial|Completed||N/A|15|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 21:31:41.418073|2018-05-31 21:31:41.418073
NCT01561807|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19||2014-01-08|2016-08-31|2012-03-21|2012-03-23|Estimate||||2014-01-08|2014-02-06|Estimate|2016-08-31|2016-09-02|Estimate|March 2012||2012-03-31|August 2016|2016-08-31||||October 2012|Actual|2012-10-31||Interventional|||A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus|A Phase 2a, Randomized, Double-Blind,Placebo-Controlled Study to Investigate the Effects of VX-787 Administered to Adult Volunteers Experimentally Inoculated With Live Influenza Virus|Completed||Phase 2|140|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||f||||||||||2018-05-31 21:31:41.490406|2018-05-31 21:31:41.490406
NCT01561794|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2015-04-24|2012-03-21|2012-03-23|Estimate|||||||2015-04-24|2015-04-27|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia|A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and TID) in Hospitalized Patients With Bacterial Pneumonia or Secondary Infection of Chronic Respiratory Disease With Severe Disease or a Poor Response to Other Antimicrobials|Completed||Phase 3|44|Actual|Bayer||1|||f||||f||||||||||2018-05-31 21:31:41.577151|2018-05-31 21:31:41.577151
NCT01561781|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-08-26|2012-03-22|2012-03-23|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Vandetanib||Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of Digoxin Administered Alone and in Combination With Vandetanib|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With a Single Dose of Vandetanib (CAPRELSA) 300 mg|Completed||Phase 1|14|Actual|Sanofi||1|||f||||||||||||||2018-05-31 21:31:41.69006|2018-05-31 21:31:41.69006
NCT01561599|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-02-18|2012-03-22|2012-03-23|Estimate|||||||2016-02-18|2016-02-22|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||Study on Delayed Graft Function Using Paired Kidneys|Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation From Donors After Cardiac Death|Unknown status|Active, not recruiting|Phase 2|12|Actual|Angion Biomedica Corp||2|||f||||t||||||||||2018-05-31 21:31:43.818394|2018-05-31 21:31:43.818394
NCT01561768|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02||2013-07-16|2013-07-16|2012-03-22|2012-03-23|Estimate||||2013-07-16|2013-07-18|Estimate|2013-07-16|2013-07-18|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults|A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-64) Adults|Completed||Phase 2|500|Actual|Novavax||5|||f||||f||||||||||2018-05-31 21:31:41.776214|2018-05-31 21:31:41.776214
NCT01561755|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2018-03-06||2018-04-10|2012-03-21|2012-03-23|Estimate|2018-04-10|2018-04-13|Actual||||2018-04-10|2018-04-13|Actual|February 2012||2012-02-29|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy|A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy|Terminated||Phase 4|12|Actual|Icahn School of Medicine at Mount Sinai|Recruitment difficult with the widespread availability of IVIG which can be prescribed in an “off-label” fashion, the low incidence of new HIVM cases and a reluctance of this patient population to undergo randomization.|2||Difficulty with enrollment|f||||f||||||||||2018-05-31 21:31:41.874705|2018-05-31 21:31:41.874705
NCT01561742|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-03-22|2012-03-22|2012-03-23|Estimate|||||||2012-03-22|2012-03-23|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Minocycline Augmentation in Schizophrenia|Minocycline Augmentation in Early-Course Schizophrenia|Unknown status|Recruiting|N/A|120|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 21:31:42.207231|2018-05-31 21:31:42.207231
NCT01561729|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-11-03|2012-03-22|2012-03-23|Estimate|||||||2014-11-03|2014-11-04|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity|Evaluation of RightBio Metrics', RightSpot pH Indicator, for Rapid Bedside Verification of Proper Nasogastric/ Orogastric Tube Placement in Emergency Department & Intensive Care Unit Patients|Unknown status|Recruiting|N/A|30|Anticipated|RightBio Metrics||1|||f||||f||||||||||2018-05-31 21:31:42.309958|2018-05-31 21:31:42.309958
NCT01561716|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|2012-03-29||2015-09-16|2012-03-21|2012-03-23|Estimate|2012-03-29|2012-04-25|Estimate||||2015-09-16|2015-10-01|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||An Evaluation of the Energy Expenditure From Wii Fit Games|Is the Wii Fit / Wii Fit Plus Good Enough? A Comparison of the Energy Expenditure From Interactive Physical Activity Promoting Technology to Walking and Running|Completed||N/A|30|Actual|University of Rochester|The lab staffs that administrated the tests were not blinded to the order of the randomization, nor were they blinded to the results of the test. Thus, our study is subjected to observer and measurement biases.|6|||f||||f||||||||||2018-05-31 21:31:42.421515|2018-05-31 21:31:42.421515
NCT01561703|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2015-10-28||2016-11-22|2012-03-21|2012-03-23|Estimate|2016-11-22|2017-01-19|Estimate||||2016-11-22|2017-01-19|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Interventional|||Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use|Postoperative Healthcare Utilization in Adenotonsillectomy Patients With Postoperative Antibiotic Administration Compared to Patients Without Antibiotic Administration|Completed||N/A|58|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 21:31:42.857391|2018-05-31 21:31:42.857391
NCT01561690|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21||2013-06-06|2013-06-06|2012-03-21|2012-03-23|Estimate||||2013-06-06|2013-06-14|Estimate|2013-06-06|2013-06-14|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of ARRY-502 in Patients With Persistent Asthma||Completed||Phase 2|184|Actual|Array BioPharma||2|||f||||f||||||||||2018-05-31 21:31:43.102373|2018-05-31 21:31:43.102373
NCT01561677|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-21|2012-03-21|2012-03-23|Estimate|||||||2012-03-21|2012-03-23|Estimate|September 2011||2011-09-30|March 2012|2012-03-31||||March 2014|Anticipated|2014-03-31||Interventional|||Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP)|Consequences of Obstructive Sleep Apnea Syndrome (OSAS) on the Outcome and the Survival After Ischemic Subtentorial Stroke. Impact of the Treatment With Continuous Positive Airway Pressure (CPAP)|Unknown status|Recruiting|N/A|300|Anticipated|University Hospital, Montpellier||5|||f||||f||||||||||2018-05-31 21:31:43.21282|2018-05-31 21:31:43.21282
NCT01561664|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-09-17|2012-03-21|2012-03-23|Estimate|||||||2015-09-17|2015-09-18|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|December 2013|Actual|2013-12-31|November 2011|Actual|2011-11-30||Interventional|||Inflammation Regulation in Obese Patients|Relations Between Obesity and Insulin Resistance: Role of Inflammation Regulatory Mechanisms in Obese Patients Without Associated Comorbidity|Completed||N/A|30|Actual|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 21:31:43.293765|2018-05-31 21:31:43.293765
NCT01561651|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2016-09-08|2012-03-21|2012-03-23|Estimate|||||||2016-09-08|2016-09-09|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|LAAOS III||Left Atrial Appendage Occlusion Study III|Left Atrial Appendage Occlusion Study III|Recruiting||N/A|4700|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 21:31:43.362501|2018-05-31 21:31:43.362501
NCT01561638|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-03-15|2012-03-21|2012-03-23|Estimate|||||||2015-03-15|2015-03-17|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Pulsed Radiofrequency Versus Pulsed Dose for Shoulder Pain|"Pulsed Radiofrequency Versus New Technique Pulsed Dose in Treatment of Chronic Shoulder Pain"|Completed||Phase 1/Phase 2|38|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 21:31:43.437737|2018-05-31 21:31:43.437737
NCT01561625|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-05-03|2012-03-21|2012-03-23|Estimate|||||||2013-05-03|2013-05-07|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|SIM||Signaling Pathway Activation After Exercise in Patients With Chronic Obstructive Pulmonary Disease|Signaling Pathway Activation in the Quadriceps of Patients With COPD After an Acute Bout of Resistance|Completed||N/A|21|Actual|Laval University|||||f||||t||||||||||2018-05-31 21:31:43.614936|2018-05-31 21:31:43.614936
NCT01561612|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-10-09|2012-03-22|2012-03-23|Estimate|||||||2013-10-09|2013-10-10|Estimate|June 1996||1996-06-30|October 2013|2013-10-31||||December 1998|Actual|1998-12-31||Interventional|PROBIT||Promotion of Breastfeeding Intervention Trial|Breastfeeding Promotion RCT and Child Metabolic Syndrome|Completed||N/A|17046|Actual|Harvard Pilgrim Health Care||2|||f||||f||||||||||2018-05-31 21:31:43.695877|2018-05-31 21:31:43.695877
NCT01561222|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-06-05|2012-03-21|2012-03-22|Estimate|||||||2015-06-05|2015-06-08|Estimate|July 2015||2015-07-31|June 2015|2015-06-30||||March 2016|Anticipated|2016-03-31||Interventional|||Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2||Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Taixing People's Hospital||2|||f||||||||||||||2018-05-31 21:31:48.421881|2018-05-31 21:31:48.421881
NCT01561586|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2017-10-17|2012-03-22|2012-03-23|Estimate|||||||2017-10-17|2017-10-18|Actual|March 2012|Actual|2012-03-31|October 2017|2017-10-31|March 2023|Anticipated|2023-03-31|March 2020|Anticipated|2020-03-31||Interventional|TACO||Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer|Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer|Recruiting||Phase 3|590|Anticipated|Korea Cancer Center Hospital||2|||f||||t||||||||||2018-05-31 21:31:43.917118|2018-05-31 21:31:43.917118
NCT01561573|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-04-21|2012-03-21|2012-03-23|Estimate|||||||2012-04-21|2012-04-24|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Ultrasound Assisted Distal Radius Fracture Reduction|Ultrasound Assisted Distal Radius Fracture Reduction|Unknown status|Recruiting|Phase 1/Phase 2|136|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 21:31:44.086761|2018-05-31 21:31:44.086761
NCT01561560|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2013-11-19||2013-11-19|2012-03-21|2012-03-23|Estimate|2013-11-19|2014-01-07|Estimate||||2013-11-19|2014-01-07|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||All participants enrolled and exposed to Test Article|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses|Completed||N/A|123|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:31:44.216778|2018-05-31 21:31:44.216778
NCT01561547|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-09-17|2012-03-22|2012-03-23|Estimate|||||||2016-09-17|2016-09-20|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|TRAKC||Trial of Repeated Analgesia With Kangaroo Care|Maternal Analgesia for Procedural Pain in Preterm Neonates: Does It Remain Efficacious?|Completed||Phase 3|242|Actual|IWK Health Centre||3|||f||||f||||||||No|Aggregate data will be available but no individual data will be provided.|2018-05-31 21:31:44.41914|2018-05-31 21:31:44.41914
NCT01561534|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-21|2012-03-21|2012-03-23|Estimate|||||||2012-03-21|2012-03-23|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Observational|||Vascularized Free Fibula Flap and Computer-guided Implant Surgery|Long-term Results of Mandibular/Maxillary Reconstruction With Vascularized Free Fibula Flap and Computer-guided Implant Surgery|Unknown status|Recruiting||5|Anticipated|University of Bari|||||f||||t||||||||||2018-05-31 21:31:44.507248|2018-05-31 21:31:44.507248
NCT01561521|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21||2013-07-16|2013-07-16|2012-03-22|2012-03-23|Estimate||||2013-07-16|2013-07-18|Estimate|2013-07-16|2013-07-18|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis||Completed||Phase 3|90|Actual|Akorn, Inc.||3|||f||||f||||||||||2018-05-31 21:31:44.5714|2018-05-31 21:31:44.5714
NCT01561508|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-12-21|2012-03-22|2012-03-23|Estimate|||||||2012-12-21|2012-12-24|Estimate|June 2012||2012-06-30|December 2012|2012-12-31||||April 2013|Anticipated|2013-04-30||Interventional|GABA||Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children|Double Blinded, Placebo Controlled Trial on the Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children|Withdrawn||Phase 2|0|Actual|University of Alabama at Birmingham||2||Unable to obtain IND currently|f||||f||||||||||2018-05-31 21:31:44.647738|2018-05-31 21:31:44.647738
NCT01561495|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2014-10-10|2012-03-22|2012-03-23|Estimate|||||||2014-10-10|2014-10-13|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Proton Radiotherapy for Extremity Soft Tissue Sarcoma|Proton Radiotherapy for Extremity Soft Tissue Sarcoma|Completed||Phase 2|124|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:31:44.731106|2018-05-31 21:31:44.731106
NCT01561482|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-07-20|2012-03-21|2012-03-23|Estimate|||||||2015-07-20|2015-07-22|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study of Metformin With Simvastatin for Men With Prostate Carcinoma|Open-Label Study Of Metformin In Combination With Simvastatin For Men With Prostate Carcinoma And A Rising Serum Prostate-Specific Antigen Level After Radical Prostatectomy And/Or Radiation Therapy|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||1||Study closed due to slow/low enrollment; no subjects were enrolled.|f||||t||||||||||2018-05-31 21:31:44.797959|2018-05-31 21:31:44.797959
NCT01561469|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2014-06-09||2014-06-09|2012-03-21|2012-03-23|Estimate|2014-06-09|2014-07-10|Estimate||||2014-06-09|2014-07-10|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||Analysis population included all participants who met the eligibility criteria for this study.|Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin|Multicenter, Retrospective, Observational Study to Evaluate Clinical and Economic Outcomes of Patients With MRSA Hospital-Acquired Pneumonia Treated With Linezolid Or Vancomycin|Completed|||188|Actual|Pfizer|Prioritization of endpoints as primary or secondary was not specified in protocol and was based on study team's inputs.||2||f||||f||||||||||2018-05-31 21:31:44.90371|2018-05-31 21:31:44.90371
NCT01561456|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-12-04|2012-03-21|2012-03-23|Estimate|||||||2013-12-04|2013-12-05|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung|Phase II, Randomized, Open-label Study of the IGF-1R Inhibitor AXL1717 Compared to Docetaxel in Patients With Previously Treated, Locally Advanced, or Metastatic Squamous Cell Carcinoma or Adenocarcinoma of the Lung|Completed||Phase 2|100|Actual|Axelar AB||2|||f||||t||||||||||2018-05-31 21:31:45.211182|2018-05-31 21:31:45.211182
NCT01561443|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2016-01-08|2012-03-22|2012-03-23|Estimate|||||||2016-01-08|2016-01-11|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|LINE||LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer|LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer|Completed|||153|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 21:31:45.361577|2018-05-31 21:31:45.361577
NCT01561430|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2018-03-24|2014-01-07|2018-05-16|2012-03-21|2012-03-23|Estimate|2018-05-16|2018-05-18|Actual|2014-01-07|2014-02-06|Estimate|2018-05-16|2018-05-18|Actual|March 2012||2012-03-31|May 2018|2018-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All enrolled participants.|Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease|Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease|Terminated||Phase 1/Phase 2|70|Actual|Eli Lilly and Company|Study was terminated early because of abnormal liver biochemical tests levels for 4 participants.|4||Study terminated due to abnormal liver biochemical tests in some participants.|f||||f||||||||||2018-05-31 21:31:45.502405|2018-05-31 21:31:45.502405
NCT01561417|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-01-18|2012-03-21|2012-03-23|Estimate|||||||2017-01-18|2017-01-19|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects|A Single-centre, Randomised, Double-blind, Two-way Cross-over Trial Investigating the Bio-equivalence in Healthy Male Subjects of NovoSeven (CP-rFVIIa) and a Formulation of NovoSeven Stable at 25°C (VII25)|Completed||Phase 1|28|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:31:46.642863|2018-05-31 21:31:46.642863
NCT01561404|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-04-27|2012-03-21|2012-03-23|Estimate|||||||2015-04-27|2015-04-28|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EXETOR||Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise|Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise.|Terminated||Phase 4|3|Actual|Hospital Universitari de Bellvitge||1||lack of potential patients|f||||f||||||||||2018-05-31 21:31:46.741869|2018-05-31 21:31:46.741869
NCT01561391|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-01-11|2012-03-21|2012-03-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 1998||1998-04-30|January 2017|2017-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery|An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery|Completed||Phase 4|36|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:31:46.845523|2018-05-31 21:31:46.845523
NCT01561378|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-01-13|2012-03-21|2012-03-23|Estimate|||||||2015-01-13|2015-01-14|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CNS-Elders||Cardiac Surgery Neuroprotection Study in Elders|Intranasal Insulin for Neuroprotection in Elderly Cardiac Surgery Patients|Completed||Phase 2|22|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 21:31:46.979159|2018-05-31 21:31:46.979159
NCT01561365|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-03-21|2012-03-21|2012-03-23|Estimate|||||||2012-03-21|2012-03-23|Estimate|October 2003||2003-10-31|March 2012|2012-03-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Applicability of the Ottawa Ankle Rules|Applicability of the Ottawa Ankle Rules to Exclude Fractures of the Ankle and Midfoot - Comparison to Orthopedic Residents Routine.|Completed||N/A|92|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:31:47.110877|2018-05-31 21:31:47.110877
NCT01561352|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-01-11|2012-03-22|2012-03-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2001||2001-09-30|January 2017|2017-01-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis|An Open Label Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven®) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy|Completed||Phase 2|7|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:31:47.23897|2018-05-31 21:31:47.23897
NCT01561326|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-21|2012-03-21|2012-03-23|Estimate|||||||2012-03-21|2012-03-23|Estimate|May 2005||2005-05-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|TC3||Facilitating Follow-Up Adherence for Abnormal Pap Smears|Facilitating Follow-Up Adherence for Abnormal Pap Smears|Completed||N/A|211|Actual|Fox Chase Cancer Center||3|||f||||t||||||||||2018-05-31 21:31:47.328966|2018-05-31 21:31:47.328966
NCT01561313|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|2013-11-08||2014-01-23|2012-03-21|2012-03-23|Estimate|2014-01-23|2014-02-20|Estimate||||2014-01-23|2014-02-20|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||63 participants received at least one dose of the study drug, and 62 participants were analyzed for injection site-related pain. 63 participants were analyzed for other safety analyses.|Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.|A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis.|Completed||Phase 2|64|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 21:31:47.427398|2018-05-31 21:31:47.427398
NCT01561300|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2016-12-21||2017-02-16|2012-03-22|2012-03-23|Estimate|2017-02-16|2017-04-05|Actual||||2017-02-16|2017-04-05|Actual|March 2012||2012-03-31|February 2017|2017-02-28|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Efficacy of Brooke Bond Black Tea Extract on Flow Mediated Dilation in Indian Males|Efficacy of Standardized Brooke Bond Black Tea Extract on Flow-Mediated Dilation After an Acute Dose as Well as After One Week of Consumption in Healthy Adult Indian Males|Completed||N/A|30|Actual|Unilever R&D||2|||f||||f||||||||No||2018-05-31 21:31:47.722094|2018-05-31 21:31:47.722094
NCT01561287|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2016-05-10|2012-03-22|2012-03-23|Estimate|||||||2016-05-10|2016-05-11|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Comparison of Dermal Autograft to AlloDerm in Breast Reconstruction|A Comparison of Dermal Autograft to Commercially Available Dermal Allograft in Breast Reconstruction|Completed||Phase 4|48|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 21:31:48.003162|2018-05-31 21:31:48.003162
NCT01561274|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2014-06-20|2012-03-22|2012-03-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|ET-50||ET 50 for Post Caesarean Section Spinal Hypotension|The Time Required to Remain Sitting After Spinal Anesthesia for 50% of Patients to Not Experience Hypotension|Completed||Phase 2|50|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 21:31:48.099584|2018-05-31 21:31:48.099584
NCT01561261|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2017-04-15|2012-03-22|2012-03-23|Estimate|||||||2017-04-15|2017-04-18|Actual|October 2012||2012-10-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|PACS||Predicting Acute Compartment Syndrome (PACS)|Predicting Acute Compartment Syndrome (PACS) Using Optimized Clinical Assessment, Continuous Pressure Monitoring, and Continuous Tissue Oximetry|Completed||N/A|194|Actual|Major Extremity Trauma Research Consortium|||||f||||t||||||||||2018-05-31 21:31:48.172578|2018-05-31 21:31:48.172578
NCT01561248|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-03-21|2012-03-21|2012-03-22|Estimate|||||||2012-03-21|2012-03-22|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|EHEC-PEG||Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis|Repetitive Intestinal Lavage Using Polyethylene Glycol Solution in Patients With EHEC O104:H4 Infection During the German 2011 Outbreak for Prevention of Severe Thrombocytopenia With Subsequently Following Therapeutic Plasmapheresis|Completed||N/A|33|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 21:31:48.238532|2018-05-31 21:31:48.238532
NCT01561235|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-06-20|2012-03-21|2012-03-22|Estimate|||||||2012-06-20|2012-06-21|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|Protein||Protein Dose-repsonse Effect on GLP-1, PYY and Appetite in Male Subjects|The Contribution of Gastrointestinal Appetite Hormones to Protein-induced|Completed||N/A|25|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 21:31:48.342146|2018-05-31 21:31:48.342146
NCT01561209|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-08-26|2012-03-21|2012-03-22|Estimate|||||||2017-08-26|2017-08-29|Actual|March 2012||2012-03-31|August 2017|2017-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Low Doses Amitriptyline & Chronic Neck Pain|Prospective Randomized & Controlled Study of the Role of Low Doses Amitriptyline in the Management of Chronic Neck Pain|Completed||Phase 4|212|Actual|St Joseph University, Beirut, Lebanon||2|||f||||f||||||||||2018-05-31 21:31:48.497124|2018-05-31 21:31:48.497124
NCT01561196|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-01-30|2012-03-21|2012-03-22|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Conventional Verses Ultrasound Guided Arteria Cannulation, With and Without Local Anesthesia|Conventional vs. Ultrasound Guided Arteria Cannulation, With and Without Local Anesthesia|Completed||Phase 3|20|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 21:31:48.565375|2018-05-31 21:31:48.565375
NCT01561183|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-04-26|2012-03-21|2012-03-22|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2012||2012-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|March 2014|Actual|2014-03-31||Interventional|||Vital Pulp Therapy (VPT) Using Calcium Enriched Mixture (CEM) to Treat Irreversible Pulpitis|Vital Pulp Therapy for Management of Irreversible Pulpitis in Human Permanent Teeth: A Randomized Clinical Trial.|Completed||N/A|302|Actual|Shahid Beheshti University of Medical Sciences||4|||f||||t||||||||||2018-05-31 21:31:48.632034|2018-05-31 21:31:48.632034
NCT01561170|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-04-09|2012-03-21|2012-03-22|Estimate|||||||2015-04-09|2015-04-10|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Electromagnetic Field Therapy to Improve Healing of Chronically Venous Ulcer|The Effect of Electromagnetic Field Therapy to Improve Healing of Chronically Venous Ulcer in Lower Extremities|Unknown status|Active, not recruiting||36|Anticipated|Northern Orthopaedic Division, Denmark|||1||f||||f||||||||||2018-05-31 21:31:48.714606|2018-05-31 21:31:48.714606
NCT01561157|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2018-02-14|2012-03-21|2012-03-22|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2010||2010-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Longitudinal Study of the Porphyrias|Longitudinal Study of the Porphyrias|Recruiting|||800|Anticipated|Icahn School of Medicine at Mount Sinai|||9||f||||t||||||Samples With DNA|"~     whole blood, plasma/serum, red blood cells, white cells, urine, stool, tissue, DNA~   "|||2018-05-31 21:31:48.786082|2018-05-31 21:31:48.786082
NCT01561144|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-01-29|2012-03-21|2012-03-22|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2011||2011-08-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|UMBRELLA||UMBRELLA - Incidence of Arrhythmias in Spanish Population With a Medtronic Implantable Cardiac Defibrillator Implant|UMBRELLA - Incidence of Arrhythmias in Spanish Population With a Medtronic ICD Implant|Terminated|||4648|Actual|Medtronic Bakken Research Center|||||f||||||||||||||2018-05-31 21:31:49.932375|2018-05-31 21:31:49.932375
NCT01561131|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2017-02-06|2012-03-20|2012-03-22|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 2012|Actual|2012-01-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|PROKA||The Effect of Protein and Calcium on Weight Change and Blood Lipid Profile|The Effect of Protein and Calcium on Weight Change and Blood Lipid Profile|Completed||N/A|223|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 21:31:50.120301|2018-05-31 21:31:50.120301
NCT01561118|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2017-11-06|2012-03-20|2012-03-22|Estimate|||||||2017-11-06|2017-11-07|Actual|September 2012||2012-09-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|DiaSport||DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis|DiaSport - Ausdauerorientiertes Trainingsprogramm Mit Kindern Und Jugendlichen an Der Dialyse (DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis)|Completed||N/A|66|Actual|University Hospital, Bonn||2|||f||||t||||||||||2018-05-31 21:31:50.211365|2018-05-31 21:31:50.211365
NCT01561105|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-26|2012-03-20|2012-03-22|Estimate|||||||2012-03-26|2012-03-28|Estimate|January 1999||1999-01-31|March 2012|2012-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|IMPACT||Improving Depression Care for Elders: Coordinating Center|This Was a Five-year Seven-site Trial to Study the Cost-effectiveness of a Population Based Disease Management Program for Late Life Depression in Primary Care.|Completed||N/A|1801|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:31:50.292301|2018-05-31 21:31:50.292301
NCT01561092|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-06-18|2012-03-20|2012-03-22|Estimate|||||||2012-06-18|2012-06-19|Estimate||||June 2012|2012-06-30||||||||Interventional|ESTIAS||Escitalopram Treatment In Acute Stroke|Efficacy of Escitalopram Treatment in Acute Stroke and the Role of SERT Genotype in Stroke|Withdrawn||Phase 4|0|Actual|University of Aarhus||2||Study medication could not be supplied. An alternative project will be conducted|f||||t||||||||||2018-05-31 21:31:50.464368|2018-05-31 21:31:50.464368
NCT01561079|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2017-03-08||2017-08-28|2012-03-21|2012-03-22|Estimate|2017-08-25|2017-08-28|Actual||||2017-08-28|2017-09-26|Actual|February 2012||2012-02-29|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Fetal and Infant Effects of Maternal Buprenorphine Treatment|Fetal and Infant Effects of Maternal Buprenorphine Treatment|Completed||Phase 2/Phase 3|127|Actual|Johns Hopkins University|Small sample size|1|||f||||t||||||||Undecided||2018-05-31 21:31:50.593341|2018-05-31 21:31:50.593341
NCT01561066|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2013-02-23|2012-03-21|2012-03-22|Estimate|||||||2013-02-23|2013-02-26|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Autologous Fibrin Glues for Fistulas Closure|Adjuvant Use of Autologous Platelet-rich Fibrin Glue in the Treatment of Fistulas and Anastomotic Leakages of the Digestive Tract|Completed||Phase 1|122|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 21:31:51.135223|2018-05-31 21:31:51.135223
NCT01561053|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-08-01|2012-03-21|2012-03-22|Estimate|||||||2017-08-01|2017-08-02|Actual|March 2012||2012-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AMBAR||A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease|A Multicenter, Randomized, Controlled Study To Evaluate The Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Plasmapheresis With Infusion of Human Albumin Combined With Intravenous Immunoglobulin In Patients With Mild-Moderate AD|Active, not recruiting||Phase 2/Phase 3|350|Anticipated|Grifols Biologicals Inc.||4|||f||||f||||||||||2018-05-31 21:31:51.235192|2018-05-31 21:31:51.235192
NCT01561040|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-03-22|2012-03-21|2012-03-22|Estimate|||||||2012-03-22|2012-03-26|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|ONIT||Oral Nutrition Impact on Tear Film|Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy|Unknown status|Recruiting|Phase 4|80|Anticipated|Eye and Vision Technologies and Research Institute||1|||f||||f||||||||||2018-05-31 21:31:51.378087|2018-05-31 21:31:51.378087
NCT01561027|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-10-12|2012-03-21|2012-03-22|Estimate|||||||2017-10-12|2017-10-13|Actual|April 30, 2011|Actual|2011-04-30|October 2017|2017-10-31|August 31, 2012|Actual|2012-08-31|June 30, 2012|Actual|2012-06-30||Interventional|||Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy|A Randomized, Double Blind, Cross-over Study to Evaluate the Safety and Efficacy of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy|Completed||Phase 2|82|Actual|Biogen||2|||f||||f||||||||||2018-05-31 21:31:51.51062|2018-05-31 21:31:51.51062
NCT01561014|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-04-17|2012-03-21|2012-03-22|Estimate|||||||2017-04-17|2017-04-19|Actual|April 2007|Actual|2007-04-30|April 2017|2017-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase I Study of Preoperative Chemoradiation With Oxaliplatin, 5-Fluorouracil, Erlotinib and Radiation Followed by Resection and Consolidative Erlotinib for Patients With Locally Advanced Cancer of the Esophagus and Gastroesophageal Junction|Completed||Phase 1|9|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-05-31 21:31:51.741464|2018-05-31 21:31:51.741464
NCT01561001|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-05-19|2012-03-21|2012-03-22|Estimate|||||||2015-05-19|2015-05-20|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant|24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Primary Open Angle Glaucoma Before and After Deep Sclerectomy With Collagen Implant|Terminated||N/A|3|Actual|Sensimed AG|||||f||||f||||||||||2018-05-31 21:31:51.885337|2018-05-31 21:31:51.885337
NCT01560988|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2017-02-15||2018-04-06|2012-03-21|2012-03-22|Estimate|2017-07-11|2017-08-09|Actual||||2018-04-06|2018-04-09|Actual|February 2013||2013-02-28|April 2018|2018-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Borage|Patients with physician diagnosed asthma between 18 and 65 years of age|Borage and Echium Seed Oils for Asthma|Treatment of Bronchial Asthma With Borage and Echium Seed Oils|Completed||Phase 3|62|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:31:51.975054|2018-05-31 21:31:51.975054
NCT01560975|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2014-11-18||2015-12-21|2012-03-20|2012-03-22|Estimate|2014-11-18|2014-11-24|Estimate||||2015-12-21|2016-01-27|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure|A Prospective, Explorative, Open Label Study to Assess the 24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Moderate to Severe Obstructive Sleep Apnea Syndrome Using Continuous Positive Airway Pressure With or Without Primary Open Angle Glaucoma|Completed||N/A|10|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 21:31:52.371726|2018-05-31 21:31:52.371726
NCT01560962|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-05-28|2012-03-20|2012-03-22|Estimate|||||||2013-05-28|2013-05-30|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis|Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis|Terminated||N/A|||Southern California Institute for Research and Education||4||research staffs unable to continue.|f||||||||||||||2018-05-31 21:31:52.594414|2018-05-31 21:31:52.594414
NCT01560949|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2018-03-19|2012-03-21|2012-03-22|Estimate|||||||2018-03-19|2018-03-20|Actual|June 14, 2012|Actual|2012-06-14|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas|A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas|Active, not recruiting||Phase 2|34|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:31:52.692039|2018-05-31 21:31:52.692039
NCT01560936|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-05-13|2012-03-20|2012-03-22|Estimate|||||||2013-05-13|2013-05-14|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU|Surveillance Study of Bacterial Contamination of the Parent's Cell Phone in the NICU and the Effectiveness of an Antimicrobial Gel in Reducing Transmission to the Hands|Completed|||50|Actual|Mednax Center for Research, Education, Quality and Safety|||||f||||f||||||||||2018-05-31 21:31:52.805586|2018-05-31 21:31:52.805586
NCT01560923|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2018-05-01|2012-03-21|2012-03-22|Estimate|||||||2018-05-01|2018-05-03|Actual|October 1, 2012|Actual|2012-10-01|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|April 2019|Anticipated|2019-04-30||Interventional|||Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer|A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer|Active, not recruiting||Phase 2|47|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-05-31 21:31:52.866167|2018-05-31 21:31:52.866167
NCT01560910|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-21|2012-03-21|2012-03-22|Estimate|||||||2012-03-21|2012-03-22|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Detection of Minimal Change Esophagitis by I-scan||Completed|||48|Actual|Maharaj Nakorn Chiang Mai Hospital|||||f||||f||||||||||2018-05-31 21:31:52.967293|2018-05-31 21:31:52.967293
NCT01560897|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-07-30|2012-03-21|2012-03-22|Estimate|||||||2012-07-30|2012-07-31|Estimate|January 2012||2012-01-31|July 2012|2012-07-31||||December 2012|Anticipated|2012-12-31||Interventional|PIL001||"Investigating Project of the Functional C13 Test Pilot Study"|Investigating Project of the Functional C13 Test|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 21:31:53.033654|2018-05-31 21:31:53.033654
NCT01560884|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-11-06|2012-03-21|2012-03-22|Estimate|||||||2013-11-06|2013-11-08|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SPI-014||Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb|A Double Blind, Dose-Ranging, Phase 1 Study In Healthy Volunteers to Assess Safety and the Phosphate Binding Capacity of Lanthanum Dioxycarbonate (SPI-014, Renazorb)|Completed||Phase 1|32|Actual|Spectrum Pharmaceuticals, Inc||4|||f||||f||||||||||2018-05-31 21:31:53.094491|2018-05-31 21:31:53.094491
NCT01560871|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2016-10-19|2012-03-20|2012-03-22|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of a Walking Program and Inspiratory Muscle Training on Individuals With Chronic Heart Failure|Effects of a Walking Program and Inspiratory Muscle Training on Individuals With Chronic Heart Failure - A Pilot Study|Recruiting||N/A|30|Anticipated|Texas Woman's University||2|||f||||t||||||||||2018-05-31 21:31:53.178779|2018-05-31 21:31:53.178779
NCT01560858|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-06-19|2012-03-21|2012-03-22|Estimate|||||||2013-06-19|2013-06-20|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State|A Retrospective Observational Study to Describe Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State, in Routine Clinical Practice in Spain.|Completed|||407|Actual|Ipsen|||||f||||f||||||||||2018-05-31 21:31:53.268184|2018-05-31 21:31:53.268184
NCT01560845|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-03-21|2012-03-21|2012-03-22|Estimate|||||||2012-03-21|2012-03-22|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|||ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis|Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Wenzhou Medical University||2|||f||||f||||||||||2018-05-31 21:31:53.326388|2018-05-31 21:31:53.326388
NCT01560832|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2014-03-04|2012-03-20|2012-03-22|Estimate|||||||2014-03-04|2014-03-05|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Descriptive Epidemiology of Clostridium Difficile Infection in Hospitalized Adult Patients in the Asia Pacific Region||Completed|||188|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 21:31:53.421999|2018-05-31 21:31:53.421999
NCT01560819|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2013-07-15||2013-12-04|2012-03-21|2012-03-22|Estimate|2013-10-07|2013-12-04|Estimate||||2013-12-04|2013-12-30|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|GMT||Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases|Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases|Completed||Phase 1|20|Actual|Spectrum Health Hospitals|This short-term pilot study is limited by its small sample size; therefore, studies with a larger sample size and longer follow-up period will be required to determine true efficacy of GMT in patients with ulcerative colitis (UC).|1|||f||||t||||||||||2018-05-31 21:31:53.594485|2018-05-31 21:31:53.594485
NCT01560806|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-03-20|2012-03-20|2012-03-22|Estimate|||||||2012-03-20|2012-03-22|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Intervention Study on Hypertension Management Combined With Health Promotion at Commune Level|Quasi-experimental Intervention Study on Hypertension Management Combined With Comprehensive Healthy Lifestyle Promotion at Commune Level|Completed||N/A|2400|Actual|Vietnam National Heart Institute||2|||f||||t||||||||||2018-05-31 21:31:54.034263|2018-05-31 21:31:54.034263
NCT01560793|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2014-09-22|2012-03-20|2012-03-22|Estimate|||||||2014-09-22|2014-09-23|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years|Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years|Completed||Phase 1|224|Actual|VaxInnate Corporation||1|||f||||t||||||||||2018-05-31 21:31:54.173311|2018-05-31 21:31:54.173311
NCT01560780|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-04-05|2012-03-20|2012-03-22|Estimate|||||||2018-04-05|2018-04-09|Actual|February 1, 2013|Actual|2013-02-01|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis|Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis|Active, not recruiting||Phase 3|84|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 21:31:54.280208|2018-05-31 21:31:54.280208
NCT01560767|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-03-20|2012-03-20|2012-03-22|Estimate|||||||2012-03-20|2012-03-22|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PAKA||Perioperative Analgesia for Knee Arthroplasty (PAKA)|Can Periarticular Knee Injection of Multimodal Agents Levobupivicaine, Morphine, Ketorolac and Adrenaline Improve Postoperative Pain and Function Following Primary Total Knee Arthroplasty?|Completed||Phase 4|46|Actual|University of Warwick||2|||f||||f||||||||||2018-05-31 21:31:54.366617|2018-05-31 21:31:54.366617
NCT01560754|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-09-28|2012-03-21|2012-03-22|Estimate|||||||2015-09-28|2015-09-29|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|NIC-PD||Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease|A Randomized, Placebo-controlled, Double-blind, Multi-center Trial to Assess the Disease-modifying Potential of Transdermal Nicotine in Early Parkinson's Disease in Germany and the USA|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|University of Vermont||2|||f||||t||||||||||2018-05-31 21:31:54.455679|2018-05-31 21:31:54.455679
NCT01560741|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-10-03|2012-03-21|2012-03-22|Estimate|||||||2012-10-03|2012-10-04|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|TeleMotiNIV||Telemedicine and Ventilator Titration in Chronic Respiratory Patients Initiating Non-invasive Ventilation|Randomized Trial Comparing Telemedicine Monitoring and Titration in Patients Initiating Non-invasive Ventilation With Usual Care (TELEMOTINIV Study)|Unknown status|Recruiting|Phase 1|128|Anticipated|Hospital Sao Joao||2|||f||||f||||||||||2018-05-31 21:31:54.586376|2018-05-31 21:31:54.586376
NCT01560728|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2016-03-15|2012-03-20|2012-03-22|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Bringing What Works to Youth in Corrections: A Trauma Intervention|Bringing What Works to Youth in Prison: An Evidence-Based Trauma Intervention|Completed||Phase 1/Phase 2|57|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 21:31:54.677925|2018-05-31 21:31:54.677925
NCT01560715|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-07-18|2012-03-20|2012-03-22|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2011||2011-06-30|July 2017|2017-07-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|RETICELL||Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa|Phase 2 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa|Completed||Phase 2|50|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 21:31:54.762301|2018-05-31 21:31:54.762301
NCT01560702|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-09-24|2012-03-21|2012-03-22|Estimate|||||||2013-09-24|2013-09-25|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers|Endoscopic Injection of Autologous Blood Versus Diluted Epinephrine for Control of Actively Bleeding Gastroduodenal Ulcers|Completed||N/A|100|Actual|Zagazig University||2|||f||||t||||||||||2018-05-31 21:31:54.847557|2018-05-31 21:31:54.847557
NCT01560689|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-09-06|2012-03-21|2012-03-22|Estimate|||||||2012-09-06|2012-09-07|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|alloforb||Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation|Open-labeled Trial to Evaluate the Therapeutic Effects of Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation|Completed||Phase 2|32|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:31:54.937313|2018-05-31 21:31:54.937313
NCT01560663|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2017-03-07|2012-03-21|2012-03-22|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2012||2012-01-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer|Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer|Recruiting|||185|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||f||||||||||2018-05-31 21:31:55.103345|2018-05-31 21:31:55.103345
NCT01560650|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2016-01-17|2012-03-21|2012-03-22|Estimate|||||||2016-01-17|2016-01-20|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Acute Kidney Injury|Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Cardiac Surgery Associated Acute Kidney Injury (CRITERIA STUDY)|Completed||Phase 4|211|Actual|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 21:31:55.191162|2018-05-31 21:31:55.191162
NCT01560637|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2017-11-16|2012-03-20|2012-03-22|Estimate|||||||2017-11-16|2017-11-20|Actual|May 2012||2012-05-31|November 2017|2017-11-30|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Interventional|||An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension|Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310|Recruiting||Phase 3|850|Anticipated|United Therapeutics||1|||f||||t||||||||||2018-05-31 21:31:55.324759|2018-05-31 21:31:55.324759
NCT01560624|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2018-04-10|2012-03-21|2012-03-22|Estimate|||||||2018-04-10|2018-04-11|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|FREEDOM-Ev||Trial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial Hypertension|A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy|Active, not recruiting||Phase 3|850|Anticipated|United Therapeutics||2|||f||||t||||||||||2018-05-31 21:31:55.913142|2018-05-31 21:31:55.913142
NCT01560611|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-21|2012-03-21|2012-03-22|Estimate|||||||2012-03-21|2012-03-22|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||||||Observational|||A New Non-invasive Marker to Detect Silent Hypoxia in Patients Undergoing Cardiac Surgery|The Somatic-to-cerebral Oxygen Saturation Gradient as a Non-invasive Index of Anaerobic Threshold in High-risk Cardiac Surgical Patient|Unknown status|Not yet recruiting||60|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 21:31:56.232616|2018-05-31 21:31:56.232616
NCT01560598|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-21|2012-03-21|2012-03-22|Estimate|||||||2012-03-21|2012-03-22|Estimate|June 2012||2012-06-30|March 2012|2012-03-31||||June 2013|Anticipated|2013-06-30||Observational|||Adipokines and the Risk of Reflux Esophagitis|Adipokines and the Risk of Reflux Esophagitis : Prospective Case-control Study|Unknown status|Not yet recruiting||600|Anticipated|Seoul National University Hospital|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:31:56.32296|2018-05-31 21:31:56.32296
NCT01560585|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-08-27|2012-03-21|2012-03-22|Estimate|||||||2014-08-27|2014-08-28|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease|Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease|Terminated||Phase 1/Phase 2|10|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-05-31 21:31:56.422188|2018-05-31 21:31:56.422188
NCT01560572|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-12-31|2012-03-20|2012-03-22|Estimate|||||||2014-12-31|2015-01-01|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Interventional|Allegro||Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen|Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen|Unknown status|Active, not recruiting|Phase 4|300|Anticipated|University Medical Center Groningen||3|||f||||t||||||||||2018-05-31 21:31:56.516652|2018-05-31 21:31:56.516652
NCT01560559|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-05-22|2012-03-20|2012-03-22|Estimate|||||||2015-05-22|2015-05-25|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TAMEO||Peroral Endoscopic Myotomy for Primary Esophageal Achalasia|Peroral Endoscopic Myotomy for Primary Esophageal Achalasia|Completed||Phase 3|16|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 21:31:56.609234|2018-05-31 21:31:56.609234
NCT01560546|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-11-13|2012-03-21|2012-03-22|Estimate|||||||2013-11-13|2013-11-14|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)|Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) - a Randomised, Doubleblinded and Placebocontrolled Trial of Men With Subnormal Testosterone Levels and T2DM.|Completed||Phase 4|43|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 21:31:56.702433|2018-05-31 21:31:56.702433
NCT01560533|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2014-01-29|2012-03-20|2012-03-22|Estimate|||||||2014-01-29|2014-01-30|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|CORCAN||Representation of the Body for Patients With Cancer|Representation of the Body and Treatment of Peritoneal Cancer by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - A Collaborative Approach Between Professionals of Health / Patients / Researchers|Completed||N/A|21|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:31:56.783109|2018-05-31 21:31:56.783109
NCT01560520|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-10-17|2012-03-20|2012-03-22|Estimate|||||||2012-10-17|2012-10-18|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Physical Activity Immediately After Acute Cerebral Ischemia|Physical Activity Immediately After Acute Cerebral Ischemia: Too Little or Too Much?|Completed|||100|Actual|Hillerod Hospital, Denmark|||1||f||||f||||||Samples Without DNA|"~     Interleukin (IL)-6, IL-1beta, Tumor Nekrosis Factor(TNF)-alpha, C-Reactive Proteine (CRP),~     IL-1ra, IL-10, fasting-insuline, fasting-glucose~   "|||2018-05-31 21:31:56.846579|2018-05-31 21:31:56.846579
NCT01560507|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2013-09-09||2014-12-05|2012-03-20|2012-03-22|Estimate|2013-09-09|2013-11-19|Estimate||||2014-12-05|2014-12-24|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|LiveForLife2||Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants|Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants|Terminated||Phase 2/Phase 3|19|Actual|Duke University|Early termination of the study because of recruitment difficulties lead to insufficient data collection and analysis of primary and secondary outcome measures.|3||Low Recruitment|f||||t||||||||||2018-05-31 21:31:56.928148|2018-05-31 21:31:56.928148
NCT01560494|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-20|2012-03-20|2012-03-22|Estimate|||||||2012-03-20|2012-03-22|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Validation of a Curriculum (STAC) for Technical Skill Acquisition in Minimally Invasive Surgery|Validation of a Structured Training and Assessment Curriculum (STAC) for Technical Skill Acquisition in Minimally Invasive Surgery. A Randomized Controlled Study|Completed||N/A|20|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:31:57.191101|2018-05-31 21:31:57.191101
NCT01560481|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2018-01-26|2012-03-20|2012-03-22|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2011||2011-12-31|January 2018|2018-01-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|NTC00940472||Clinical Trial to Evaluate Safety and pK Profile of Metformin Glycinate in Healthy Volunteers|Randomized Clinical Trial to Evaluate Safety, Tolerability and PK-PD Profile of Metformin Glycinate 620 mg,1240 mg, 2480 mg and Metformin Chlorhydrate 1000 mg of One Single Dose, Multiple Dose and After Food Intake.|Completed||Phase 1|49|Actual|Laboratorios Silanes S.A. de C.V.||7|||f||||f||||||||||2018-05-31 21:31:57.250616|2018-05-31 21:31:57.250616
NCT01560468|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2018-04-16|2012-03-20|2012-03-22|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2012||2012-03-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection|Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection|Terminated||Phase 1|10|Anticipated|Schiano, Thomas D., MD||1||Financial Reasons|f||||t||||||||||2018-05-31 21:31:57.3255|2018-05-31 21:31:57.3255
NCT01560455|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2016-03-11|2012-03-21|2012-03-22|Estimate|||||||2016-03-11|2016-03-14|Estimate|May 2011||2011-05-31|March 2016|2016-03-31||||September 2014|Actual|2014-09-30||Interventional|EBC TWO||European Bifurcation Club Trial - Two-stent Versus One-stent Technique for Large Bifurcation Lesions|The European Bifurcation Coronary Study; A Randomised Comparison Of Provisional T-Stenting Versus A Systematic Two Stent Strategy In Large Calibre True Bifurcations|Completed||Phase 3|200|Anticipated|Royal Sussex County Hospital||2|||f||||t||||||||||2018-05-31 21:31:57.386137|2018-05-31 21:31:57.386137
NCT01560442|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-01-11|2012-03-21|2012-03-22|Estimate|||||||2013-01-11|2013-01-14|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Observational|PUPIDOL||Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine|Pupillometry and Pain Thresholds Patients Substituted by Methadone and Buprenorphine.|Unknown status|Recruiting||100|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 21:31:57.448344|2018-05-31 21:31:57.448344
NCT01560429|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2013-06-12||2016-06-09|2012-03-21|2012-03-22|Estimate|2016-06-09|2016-07-21|Estimate||||2016-06-09|2016-07-21|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy of Patient Controlled Epidural Anesthesia Versus Continuous Epidural Analgesia for Post-thoracotomy Pain|Efficacy of Patient Controlled Epidural Anesthesia (PCEA) Versus Continuous Epidural Analgesia (CEA) for Post-thoracotomy Pain.|Completed||Phase 4|52|Actual|Queen's University||2|||f||||f||||||||No||2018-05-31 21:31:57.518585|2018-05-31 21:31:57.518585
NCT01560416|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-02-21|2012-03-20|2012-03-22|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2012||2012-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Fulvestrant With or Without Ganetespib in HR+ Breast Cancer|Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer|Active, not recruiting||Phase 2|50|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 21:31:57.829195|2018-05-31 21:31:57.829195
NCT01560403|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2014-12-16||2015-11-10|2012-03-20|2012-03-22|Estimate|2014-12-24|2014-12-25|Estimate||||2015-11-10|2015-12-08|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|STEPS3||A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021|A One-Year, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition-dependent Short Bowel Syndrome Who Completed Study CL0600-021|Completed||Phase 3|14|Actual|Shire|This study provided further long-term safety and efficacy data on the 14 US subjects who enrolled in the CL0600-020 and the CL0600-021 study. Given the small number of subjects in this study, only descriptive statistics were employed and presented.|1|||f||||t||||||||||2018-05-31 21:31:57.932208|2018-05-31 21:31:57.932208
NCT01560390|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2013-01-11|2012-03-20|2012-03-22|Estimate|||||||2013-01-11|2013-01-14|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|KetaRea||Use of Ketamine Associate With an Opioid for Sedation in ICU|Use of Ketamine Associate With an Opioid for Sedation in ICU : a Randomized Controlled Double Blind Study|Completed||Phase 4|164|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 21:31:58.246552|2018-05-31 21:31:58.246552
NCT01560377|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-06-30|2012-03-20|2012-03-22|Estimate|||||||2014-06-30|2014-07-01|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|PILLAR II||Perfusion Assessment in Laparoscopic Left Anterior Resection|Open Label Clinical Study to Demonstrate the Utility of Intra-operative Perfusion Assessment Using NIR Fluorescence Angiography With the PINPOINT® Endoscopic Fluorescence Imaging System and to Assess the Impact of PINPOINT on the Surgical Decision Making Process and on Surgical Outcomes in Laparoscopic Left Anterior Resection Procedures|Completed||Phase 1|147|Actual|Novadaq Technologies Inc.||1|||f||||f||||||||||2018-05-31 21:31:58.347679|2018-05-31 21:31:58.347679
NCT01560364|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2014-11-28|2012-03-20|2012-03-22|Estimate|||||||2014-11-28|2014-12-02|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|BEERT||Bundle Evaluation in Extra Renal Epuration, Incidence of Thrombosis|Bundle Evaluation in Extra Renal Epuration, Incidence of Thrombosis|Completed|||100|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 21:31:58.464807|2018-05-31 21:31:58.464807
NCT01560351|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-03-09|2012-03-21|2012-03-22|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|STIMJEU||Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study|Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study|Terminated||N/A|31|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 21:31:58.548252|2018-05-31 21:31:58.548252
NCT01560338|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2018-04-09|2012-03-21|2012-03-22|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|January 28, 2018|Actual|2018-01-28|January 2018|Actual|2018-01-31||Observational|HIP||Hypothermia's Impact on Pharmacology|Impact of Hypothermia on Midazolam and Morphine Pharmacokinetics|Completed|||41|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|Undecided||2018-05-31 21:31:58.629636|2018-05-31 21:31:58.629636
NCT01560325|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-09-15|2012-03-20|2012-03-22|Estimate|||||||2015-09-15|2015-09-16|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers|Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-516 Inj. Administered on A Twice-Weekly Schedule in Patients With Advanced Solid Cancers Failed to Standard Therapy|Completed||Phase 1|21|Actual|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||||2018-05-31 21:31:58.709566|2018-05-31 21:31:58.709566
NCT01560312|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-02-27|2012-03-21|2012-03-22|Estimate|||||||2014-02-27|2014-03-03|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PRAGUE-15||Renal Denervation in Refractory Hypertension|Renal Denervation - Hope for Patients With Refractory Hypertension?|Terminated||Phase 3|106|Actual|Charles University, Czech Republic||2||"Based on analysis of our data after the Symplicity-3 trial announcement, decision for study~   termination was done."|f||||f||||||||||2018-05-31 21:31:58.788991|2018-05-31 21:31:58.788991
NCT01560299|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-20|2012-03-20|2012-03-22|Estimate|||||||2012-03-20|2012-03-22|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients||Completed||N/A|150|Actual|Mashhad University of Medical Sciences||3|||f||||f||||||||||2018-05-31 21:31:58.870751|2018-05-31 21:31:58.870751
NCT01560286|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05||2017-08-17|2017-08-17|2012-03-20|2012-03-22|Estimate||||2017-08-17|2017-08-21|Actual|2017-08-17|2017-08-21|Actual|May 2012||2012-05-31|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks|A Phase II, Multi-center, Open-label, Dose-finding Study to Evaluate Safety, Efficacy and Tolerability of Subcutaneously (SC) Administered rAvPAL-PEG in Patients With PKU for 24 Weeks|Completed||Phase 2|24|Actual|BioMarin Pharmaceutical||2|||f||||t||||||||||2018-05-31 21:31:58.95503|2018-05-31 21:31:58.95503
NCT01560273|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2016-03-14|2012-03-20|2012-03-22|Estimate|||||||2016-03-14|2016-03-15|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Aspen Spinous Process Fixation System for Use in PLF in Patients With Spondylolisthesis|A Multi-Center Prospective Study Evaluation Aspen Spinous Process Fixation System for Use in Posterolateral Fusion (PLF) in Patients With Spondylolisthesis|Terminated|||25|Actual|Zimmer Biomet|||1|Will answer study question through other research means.|f||||f||||||||Undecided||2018-05-31 21:31:59.042899|2018-05-31 21:31:59.042899
NCT01560260|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2016-11-18||2016-11-18|2012-03-20|2012-03-22|Estimate|2016-11-18|2017-01-19|Estimate||||2016-11-18|2017-01-19|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors|A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors|Completed||Phase 2|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:31:59.161877|2018-05-31 21:31:59.161877
NCT01560247|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-04-03|2012-03-21|2012-03-22|Estimate|||||||2012-04-03|2012-04-05|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Observational|PRIISM2||Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry|Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry|Unknown status|Active, not recruiting||1000|Anticipated|MindFrame, Inc.|||1||f||||f||||||||||2018-05-31 21:31:59.467998|2018-05-31 21:31:59.467998
NCT01560234|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2015-07-30||2016-05-05|2012-03-21|2012-03-22|Estimate|2016-05-05|2016-06-06|Estimate||||2016-05-05|2016-06-06|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All available data were used for the baseline analysis|AZD8848 Single Ascending Dose Study|A Double-blind, Placebo-controlled, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD8848 in Healthy Subjects|Completed||Phase 1|47|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:31:59.571949|2018-05-31 21:31:59.571949
NCT01560221|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-12-10|2012-03-21|2012-03-22|Estimate|||||||2014-12-10|2014-12-11|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution|Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution|Completed||Phase 1|38|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:32:00.422419|2018-05-31 21:32:00.422419
NCT01560208|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-12-18|2012-03-21|2012-03-22|Estimate|||||||2012-12-18|2012-12-20|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|ACSIKS||The Asia Cornea Society Infectious Keratitis Study|The Asia Cornea Society Infectious Keratitis Study|Unknown status|Recruiting||6750|Anticipated|Asia Cornea Society|||||f||||f||||||Samples Without DNA|"~     Positive bacterial and fungal growth obtained from the cornea samples of ACSIKS patients will~     be retained and stored.~   "|||2018-05-31 21:32:00.503729|2018-05-31 21:32:00.503729
NCT01560195|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2012-11-04|2012-03-20|2012-03-22|Estimate|||||||2012-11-04|2012-11-06|Estimate|April 2012||2012-04-30|November 2012|2012-11-30||||January 2013|Anticipated|2013-01-31||Interventional|||A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy|A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) on the Incidence of Neutropenia in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated With Myelosuppressive Chemotherapy|Unknown status|Recruiting|Phase 3|150|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:32:00.591814|2018-05-31 21:32:00.591814
NCT01560182|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-03-22|2012-03-21|2012-03-22|Estimate|||||||2017-03-22|2017-03-24|Actual|May 2010||2010-05-31|March 2017|2017-03-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|TIGET-MLD||Gene Therapy for Metachromatic Leukodystrophy|A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Treatment of Metachromatic Leukodystrophy|Active, not recruiting||Phase 2|14|Anticipated|GlaxoSmithKline|||||f||||f||||||||||2018-05-31 21:32:00.756592|2018-05-31 21:32:00.756592
NCT01560169|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-10-09|2012-03-21|2012-03-22|Estimate|||||||2013-10-09|2013-10-10|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients|Clinical Evaluation of Three Celiac Disease-Specific Patient Reported Outcome Instruments in Established and Newly Diagnosed Celiac Disease Patients|Completed|||110|Actual|Alvine Pharmaceuticals Inc.|||2||f||||f||||||||||2018-05-31 21:32:00.85564|2018-05-31 21:32:00.85564
NCT01560156|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2014-01-10|2012-03-21|2012-03-22|Estimate|||||||2014-01-10|2014-01-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:32:00.94285|2018-05-31 21:32:00.94285
NCT01560143|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|2016-10-11||2016-12-16|2012-03-21|2012-03-22|Estimate|2016-10-11|2016-12-06|Estimate||||2016-12-16|2017-02-09|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects|Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects|Completed||Phase 4|12|Actual|University of Michigan|Small study sample size|1|||f||||f||||||||No|The data have been published as a manuscript J Antimicrob Chemother. 2014 Jan;69(1):190-9.|2018-05-31 21:32:00.992466|2018-05-31 21:32:00.992466
NCT01560130|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-04-23|2012-03-21|2012-03-22|Estimate|||||||2013-04-23|2013-04-24|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|SHARE||State-wide Health Approach to Increase Reach and Effectiveness: Study 2|Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies|Completed||Phase 3|300|Actual|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 21:32:01.178349|2018-05-31 21:32:01.178349
NCT01560117|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-01-08|2012-03-20|2012-03-22|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2004||2004-01-31|January 2018|2018-01-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma|Multicenter Study to Evaluate the Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy Und Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma|Completed||Phase 2|29|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie|||||f||||f|f|f||||||||2018-05-31 21:32:01.289086|2018-05-31 21:32:01.289086
NCT01560104|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29||2015-09-30|2015-09-30|2012-03-20|2012-03-22|Estimate||||2015-09-30|2015-10-21|Estimate|2015-09-30|2015-10-21|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer|Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|160|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 21:32:01.374852|2018-05-31 21:32:01.374852
NCT01560091|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-02-16|2012-03-21|2012-03-22|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2012||2012-03-31|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy|Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL|Withdrawn||Phase 3|0|Actual|Albert Einstein Healthcare Network||3||accrual of subjects did not occur as anticipated|f||||t|t|f||||||Undecided||2018-05-31 21:32:01.498841|2018-05-31 21:32:01.498841
NCT01560078|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-07-11|2012-03-21|2012-03-22|Estimate|||||||2013-07-11|2013-07-12|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Observational|||Efficacy Study of Thrice Weekly Directly Observed Treatment Short-Course Regimen in Tubercular Pleural Effusion|Evaluation of Efficacy of Thrice Weekly DOTS Regimen in Tubercular Pleural Effusion at 6 Months|Completed|||360|Actual|All India Institute of Medical Sciences, New Delhi|||||f||||f||||||||||2018-05-31 21:32:01.62092|2018-05-31 21:32:01.62092
NCT01560065|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-03-21|2012-03-21|2012-03-22|Estimate|||||||2012-03-21|2012-03-22|Estimate||||January 2012|2012-01-31||||||||Interventional|||Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing In Vitro Fertilization Cycles||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||3|||f||||||||||||||2018-05-31 21:32:01.698544|2018-05-31 21:32:01.698544
NCT01560052|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2018-01-29|2012-03-20|2012-03-21|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2012||2012-04-30|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|TESTING||Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)|Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study|Recruiting||N/A|500|Anticipated|The George Institute||2|||f||||t||||||||||2018-05-31 21:32:01.831855|2018-05-31 21:32:01.831855
NCT01560039|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Electroencephalography Based Neurofeedback in Chronic Neuropathic Pain|Voluntary Modulation of M1 Motor Cortex Activity Using EEG Neurofeedback for the Treatment of Resistant Chronic Neuropathic Pain - a Clinical and fMRI Study|Unknown status|Not yet recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||||||||||||2018-05-31 21:32:02.1296|2018-05-31 21:32:02.1296
NCT01560026|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2012-03-24|2012-03-20|2012-03-21|Estimate|||||||2012-03-24|2012-03-27|Estimate|August 2000||2000-08-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2011|Actual|2011-12-31||Observational|ECWOP||Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma|Study for Elevate the Feasibility of Ovarian Preservation With Endometrial Carcinoma|Unknown status|Recruiting||300|Anticipated|Taipei Veterans General Hospital, Taiwan|||2||f||||t||||||||||2018-05-31 21:32:02.242111|2018-05-31 21:32:02.242111
NCT01560013|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2012-03-20|2012-03-20|2012-03-21|Estimate|||||||2012-03-20|2012-03-21|Estimate|October 2012||2012-10-31|March 2012|2012-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent Patients|Brain Imaging Study on the Effects of Treatment With Naltrexone on Cue-induced Craving and Brain's Metabolic Changes in Alcohol and Cannabis-dependent Patients|Unknown status|Not yet recruiting|N/A|24|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 21:32:02.327906|2018-05-31 21:32:02.327906
NCT01560000|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-03-13|2012-03-20|2012-03-21|Estimate|||||||2013-03-13|2013-03-15|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Bran Fiber Type on Subjective and Objective Measures of Appetite|Effect of Bran Fiber Type on Subjective and Objective Measures of Appetite|Completed||N/A|40|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 21:32:02.461744|2018-05-31 21:32:02.461744
NCT01559987|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-01-18|2012-03-19|2012-03-21|Estimate|||||||2017-01-18|2017-01-20|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PAU2||Dental Plaque Removal Study|A Randomized Parallel Method Development Study Comparing Clinical to Subclinical Effects From Oral Cleaning Modalities|Completed||N/A|270|Actual|University of North Carolina, Chapel Hill||3|||f||||f|f|f||||||||2018-05-31 21:32:02.555593|2018-05-31 21:32:02.555593
NCT01559974|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2013-03-08|2012-03-19|2012-03-21|Estimate|||||||2013-03-08|2013-03-11|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Vitamin D and Walking Ability in Patients With Peripheral Artery Occlusive Disease|Phase 4 Study of 25-hydroxy-vitamin D in Patients With Peripheral Artery Occlusive Disease and Walking Ability|Terminated||Phase 4|4|Actual|University Hospital, Basel, Switzerland||2||Insufficient recruitment|f||||t||||||||||2018-05-31 21:32:02.638457|2018-05-31 21:32:02.638457
NCT01559961|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2013-06-24|2012-03-19|2012-03-21|Estimate|||||||2013-06-24|2013-06-26|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome|A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome|Completed||Phase 1|28|Actual|Trillium Therapeutics Inc.||1|||f||||t||||||||||2018-05-31 21:32:02.722622|2018-05-31 21:32:02.722622
NCT01559948|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2014-02-10|2012-03-19|2012-03-21|Estimate|||||||2014-02-10|2014-02-12|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effectiveness of the Compression Belt for Patients With Sacroiliac Joint Pain|A Randomized Clinical Trial of the Effectiveness of the Compression Belt for Patients With Sacroiliac Joint Pain|Completed||N/A|30|Actual|Texas Woman's University||2|||f||||f||||||||||2018-05-31 21:32:02.805762|2018-05-31 21:32:02.805762
NCT01559935|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-02-01||2018-04-27|2012-03-19|2012-03-21|Estimate|2017-02-01|2017-03-22|Actual||||2018-04-27|2018-05-01|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|June 7, 2016|Actual|2016-06-07||Interventional|CarBiRD|72 subjects started the Car Phase of the CarBiRD therapy. 58 subjects started the BiRD Phase of the CarBiRD therapy. 54 subjects started the Maintenance Phase of the CarBiRD therapy. A detailed explanation of those numbers is provided in the participant flow.|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma|A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|74|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-05-31 21:32:02.949995|2018-05-31 21:32:02.949995
NCT01559922|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2014-10-02||2016-12-21|2012-03-20|2012-03-21|Estimate|2016-12-21|2017-02-14|Actual||||2016-12-21|2017-02-14|Actual|February 2012||2012-02-29|December 2016|2016-12-31|February 2014|Actual|2014-02-28|April 2013|Actual|2013-04-30||Interventional|||Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction|A Phase 3 Randomized Placebo-Controlled Double-Blind Study of the Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction|Completed||Phase 3|175|Actual|Suneva Medical, Inc.||2|||f||||f||||||||No||2018-05-31 21:32:03.50147|2018-05-31 21:32:03.50147
NCT01559909|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2014-05-08|2012-03-20|2012-03-21|Estimate|||||||2014-05-08|2014-05-12|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Socket Wall Height With Vacuum Suspension for Above Knee Amputees|Effect of Brim Height Using Vacuum Assisted Technology With Transfemoral Amputees|Completed||Phase 1|10|Anticipated|Stony Brook University||1|||f||||f||||||||||2018-05-31 21:32:03.805324|2018-05-31 21:32:03.805324
NCT01559896|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-08-04|2012-03-20|2012-03-21|Estimate|||||||2014-08-04|2014-08-05|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Egg Protein Hydrolysate and Vascular Function|The Effect of Egg Protein Hydrolysate on Arterial Stiffness in Overweight or Moderately Obese Subjects With Impaired Glucose Tolerance or Diabetes Type 2|Completed||N/A|40|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 21:32:03.895046|2018-05-31 21:32:03.895046
NCT01559883|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-08-14|2012-03-19|2012-03-21|Estimate|||||||2014-08-14|2014-08-15|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Study on Thrombosis Therapy in German Cancer Patients|Study on Thrombosis Therapy in German Cancer Patients|Completed|||76|Actual|LEO Pharma|||1||f||||f||||||||||2018-05-31 21:32:03.96481|2018-05-31 21:32:03.96481
NCT01559870|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-11-10|2012-03-20|2012-03-21|Estimate|||||||2012-11-10|2012-11-14|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Observational|||Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac Surgery|Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac Surgery With Cardiopulmonary Bypass|Completed|||164|Actual|Khon Kaen University|||1||f||||f||||||Samples Without DNA|"~     whole blood taken from arterial line~   "|||2018-05-31 21:32:04.03072|2018-05-31 21:32:04.03072
NCT01559857|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2016-10-19||2017-03-30|2012-03-19|2012-03-21|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|November 2011||2011-11-30|March 2017|2017-03-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Pioglitazone in Patients With Mood Disorders|Pioglitazone Treatment for Insulin Resistant Patients With Mood Disorders|Completed||Phase 4|37|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 21:32:04.091581|2018-05-31 21:32:04.091581
NCT01559844|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2015-05-12||2016-06-16|2012-03-19|2012-03-21|Estimate|2015-05-12|2015-05-28|Estimate||||2016-06-16|2016-07-27|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional||Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug|Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant|An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant|Completed||Phase 2|61|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 21:32:05.478022|2018-05-31 21:32:05.478022
NCT01559831|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-03-07|2012-03-20|2012-03-21|Estimate|||||||2013-03-07|2013-03-08|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination|Immune Responses to Revaccination After Potentially Insufficient Priming With the Japanese Encephalitis Vaccine IXIARO Batch JEV09L37|Withdrawn||Phase 1|0|Actual|Valneva Austria GmbH||1|||f||||f||||||||||2018-05-31 21:32:06.849554|2018-05-31 21:32:06.849554
NCT01559818|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-03-04|2012-03-20|2012-03-21|Estimate|||||||2017-03-04|2017-03-07|Actual|February 2012||2012-02-29|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001|An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001|Active, not recruiting||Phase 1/Phase 2|12|Anticipated|Immodulon Therapeutics Ltd||1|||f||||f||||||||No||2018-05-31 21:32:06.922555|2018-05-31 21:32:06.922555
NCT01559805|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2016-03-23|2012-03-19|2012-03-21|Estimate|||||||2016-03-23|2016-03-25|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||Intervention to Improve Engagement in Care Among Newly Diagnosed HIV-positive Men|Efficacy Trial of a Brief Health Enhancement Intervention for Newly Diagnosed Men|Unknown status|Recruiting|N/A|440|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 21:32:07.023955|2018-05-31 21:32:07.023955
NCT01559792|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-03-20|2012-03-20|2012-03-21|Estimate|||||||2012-03-20|2012-03-21|Estimate|December 2011||2011-12-31|March 2012|2012-03-31||||December 2012|Anticipated|2012-12-31||Observational|||Band to Bypass - Metabolism Kinetics in Gastric Bypass and Banding|Gastric Banding to Bypass - Metabolism Kinetics in Gastric Bypass and Banding|Unknown status|Recruiting||18|Anticipated|Hvidovre University Hospital|||||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 21:32:07.124725|2018-05-31 21:32:07.124725
NCT01559779|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-06-09|2012-03-20|2012-03-21|Estimate|||||||2014-06-09|2014-06-10|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Observational|AB-CD-10||Effect of Gastric Bypass Surgery on Pancreatic Islets and Incretin Function|The Effect of Gastric Bypass Surgery on the Beta- and Alpha Cells Secretory Function and the Insulinotropic Effect of the Incretin Hormones|Completed|||11|Actual|Hvidovre University Hospital|||1||f||||f||||||Samples Without DNA|"~     Plasma and serum specimens are retained~   "|||2018-05-31 21:32:07.191309|2018-05-31 21:32:07.191309
NCT01559766|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-03-20|2012-03-20|2012-03-21|Estimate|||||||2012-03-20|2012-03-21|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Observational|||Dietary Vitamin A Requirement in Chinese Children and the New Technology of Dietary Assessment|Estimating Dietary Vitamin A Requirement in Chinese Children by Stable-isotope Dilution Technique|Completed|||403|Actual|Huazhong University of Science and Technology|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:32:07.258035|2018-05-31 21:32:07.258035
NCT01559753|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|January 1998||1998-01-31|March 2012|2012-03-31|November 2002|Actual|2002-11-30|September 2002|Actual|2002-09-30||Interventional|||Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment|Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia|Completed||Phase 4|225|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 21:32:07.329377|2018-05-31 21:32:07.329377
NCT01559740|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|July 2010||2010-07-31|March 2012|2012-03-31||||August 2010|Actual|2010-08-31||Interventional|||Transversus Abdominis Plane Blocks for Infants and Children for Postoperative Pain Control|Transversus Abdominis Plane Blocks for Infants and Children for Postoperative Pain Control: Is it the Concentration or Volume of Local Anesthetic Solution That Improves Analgesia?|Completed||Phase 2|36|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 21:32:07.524895|2018-05-31 21:32:07.524895
NCT01559727|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-08-27|2012-03-20|2012-03-21|Estimate|||||||2013-08-27|2013-08-28|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Dose-comparison Study of Prednisone in Heart Failure|Randomized Dose-comparison Study of Prednisone in Patients With Symptomatic Heart Failure|Completed||Phase 3|40|Actual|Hebei Medical University||4|||f||||t||||||||||2018-05-31 21:32:07.620108|2018-05-31 21:32:07.620108
NCT01559714|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2016-08-15|2012-03-20|2012-03-21|Estimate|||||||2016-08-15|2016-08-16|Estimate|April 2012||2012-04-30|August 2016|2016-08-31||||December 2020|Anticipated|2020-12-31||Observational|BE STRONG HCM||A Biomarker and MRI Study on Troponin Release After Exercise in Hypertrophic Cardiomyopathy|BE STRONG HCM: Biomarkers, Exercise Stress Testing, and mRi to Obtain New insiGhts in Hypertrophic CardioMyopathy Study|Active, not recruiting|||81|Actual|Heartcenter, University Medical Center St. Radboud|||2||f||||f||||||||||2018-05-31 21:32:07.720283|2018-05-31 21:32:07.720283
NCT01559701|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13||2012-10-01|2015-08-28|2012-03-19|2012-03-21|Estimate||||2012-10-01|2012-10-05|Estimate|2015-08-28|2015-09-11|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Long-term Safety of PF-00345439 (Oxycodone)|A Long-Term, Open-Label, Safety Study Of PTI-821 In Patients With Moderate To Severe Chronic Low Back Pain Or With Moderate To Severe Chronic Pain Due To Osteoarthritis Of The Hip Or Knee|Completed||Phase 3|823|Actual|Pain Therapeutics||1|||f||||f||||||||||2018-05-31 21:32:07.804993|2018-05-31 21:32:07.804993
NCT01559688|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2013-10-29|2012-03-19|2012-03-21|Estimate|||||||2013-10-29|2013-10-30|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Accelerated Resolution Therapy (ART) for Psychological Trauma||Completed||N/A|80|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 21:32:07.891035|2018-05-31 21:32:07.891035
NCT01559675|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2014-08-18||2018-02-28|2012-03-19|2012-03-21|Estimate|2014-08-18|2014-08-29|Estimate||||2018-02-28|2018-03-29|Actual|September 2010||2010-09-30|February 2018|2018-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||We assumed that patients treated with HDS would have no postural hypotension on POD1 95% of the time. The noninferiority margin was 10%. We calculated that a sample size of 118 patients (59 patients per study arm) was needed to establish clinical equivalency with a 1-sided α level of 0.05 and 80% power.|Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery|Randomized Controlled Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery|Completed||N/A|121|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 21:32:07.990176|2018-05-31 21:32:07.990176
NCT01559662|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-08-14|2012-03-19|2012-03-21|Estimate|||||||2012-08-14|2012-08-15|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Sugared Chewing Gum on Gastrointestinal Recovery After Major Colorectal Surgery|A Prospective Randomized Controlled Trial of Sugared Chewing Gum on Gastrointestinal Recovery After Major Colorectal Surgery in Patients Managed With Early Enteral Feeding|Completed||N/A|114|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 21:32:08.229322|2018-05-31 21:32:08.229322
NCT01559649|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2016-06-24||2016-06-24|2012-03-20|2012-03-21|Estimate|2016-06-24|2016-07-19|Estimate||||2016-06-24|2016-07-19|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Observational|SSST|N=250 stroke patients with data analyzed|Stroke Swallowing Screening Tool Validation|Development and Validation of a VA Stroke Swallowing Screening Tool|Completed|||284|Actual|VA Office of Research and Development|Large number of individuals excluded from participation due to stringent inclusion/exclusion criteria to ensure that stroke-related aspiration was being measured. Small number of women recruited. Inability to screen in the emergency department.||2||f||||f||||||None Retained|"~     no samples will be collected~   "|No||2018-05-31 21:32:08.322472|2018-05-31 21:32:08.322472
NCT01559636|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2015-10-13|2012-03-19|2012-03-21|Estimate|||||||2015-10-13|2015-10-15|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Diarrhea and Bivalent Oral Polio Vaccine Immunity|Effect of Diarrheal Disease on Bivalent Oral Polio Vaccine (bOPV) Immune Response in Infants in Nepal|Completed||N/A|699|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 21:32:08.983399|2018-05-31 21:32:08.983399
NCT01558050|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-09-13|2012-03-16|2012-03-20|Estimate|||||||2012-09-13|2012-09-17|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||the Effect of a Red Rice Nutrition Supplement on Cholesterol Levels|The Effect of a Commercially Available Red Rice Nutrition Supplement on Serum Lipids|Completed||Phase 4|52|Actual|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 21:32:29.578545|2018-05-31 21:32:29.578545
NCT01559623|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-12-15|2012-03-20|2012-03-21|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|February 2013|Actual|2013-02-28|December 2011|Actual|2011-12-31||Observational|||Colonization of the Female Urethra With Mycoplasma Hominis, Ureaplasma Urealyticum, Chlamydia Trachomatis, or Neisseria Gonorrhea in Patients With Lower Urinary Tract Symptoms||Completed|||766|Actual|University of Zurich|||||f||||||||||||||2018-05-31 21:32:09.072433|2018-05-31 21:32:09.072433
NCT01559610|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Preoperatively Orientation in Cardiac Surgery: Nurses Intervention on Patients Recovery|Preoperatively Orientation in Cardiac Surgery: Nurses Intervention on Patients Recovery|Completed||N/A|180|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 21:32:09.148394|2018-05-31 21:32:09.148394
NCT01559597|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-05-01|2012-03-19|2012-03-21|Estimate|||||||2013-05-01|2013-05-03|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparative Study of Two Tetanus Toxoid Vaccination Strategies: Cold Chain Versus Controlled Temperature Chain|Etude Comparative de Deux stratégies de Vaccination antitétanique en Situation réelle: Vaccin conservé en chaîne de Froid Versus en chaîne de température contrôlée.|Completed||N/A|2129|Actual|Epicentre||2|||f||||||||||||||2018-05-31 21:32:09.256186|2018-05-31 21:32:09.256186
NCT01559584|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-04-05|2012-03-19|2012-03-21|Estimate|||||||2014-04-05|2014-04-08|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata|A Clinical and Immunological Study of Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata: A Randomized Controlled Clinical Trial|Completed||N/A|40|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 21:32:09.351286|2018-05-31 21:32:09.351286
NCT01559571|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-04-27|2012-03-19|2012-03-21|Estimate|||||||2018-04-27|2018-04-30|Actual|May 2012||2012-05-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|||Registry for Severe ROP and Treatment on Visual Outcomes|Study Registry for Severe Retinopathy and Treatment on Visual Outcomes of Premature Neonates|Active, not recruiting|||324|Actual|Mednax Center for Research, Education, Quality and Safety|||||f||||f||||||||||2018-05-31 21:32:09.458667|2018-05-31 21:32:09.458667
NCT01559558|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Changes of Pad Weight Results and Urethral Pressure Profiles After Reduction of Cystocele by Vaginal Gauze Packing||Completed|||140|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 21:32:09.527336|2018-05-31 21:32:09.527336
NCT01559545|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-06-06|2012-03-20|2012-03-21|Estimate|||||||2013-06-06|2013-06-07|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||A Safety, Tolerability and Pharmacokinetic Study of Two Formulations of Metronidazole Versus Immediate Release Metronidazole in Patient With C. Difficile Colitis|A Randomized, Open Label, Active Control, Safety, Tolerability and Pharmacokinetics Study of Two Dr. Reddy's Formulations of Metronidazole Versus Immediate Release Metronidazole (Flagyl) in Patients With Mild to Moderate C. Difficile Associated Diarrhea (CDAD)|Completed||Phase 2|60|Actual|Dr. Reddy's Laboratories Limited||3|||f||||f||||||||||2018-05-31 21:32:09.601745|2018-05-31 21:32:09.601745
NCT01559532|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Observational|||Influence of Tourniquet Use and Surgery Duration on the Incidence of Deep Vein Thrombosis in Total Knee Arthroplasty|Influence of Tourniquet Use and Surgery Duration on the Incidence of Deep Vein Thrombosis in Total Knee Arthroplasty|Completed|||78|Actual|University of Sao Paulo General Hospital|||1||f||||f||||||||||2018-05-31 21:32:09.735946|2018-05-31 21:32:09.735946
NCT01559519|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-12-16|2012-03-19|2012-03-21|Estimate|||||||2013-12-16|2013-12-17|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy|Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt|Completed||Phase 4|20|Actual|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 21:32:09.809632|2018-05-31 21:32:09.809632
NCT01559506|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|2015-02-25||2015-03-16|2012-03-19|2012-03-21|Estimate|2015-03-16|2015-03-17|Estimate||||2015-03-16|2015-03-17|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Air Barrier System Device to Reduce Contamination in Posterior Spine Surgery|ABS to Reduce Contamination in Spine Surgery|Completed||N/A|41|Actual|Nimbic Systems, LLC||2|||f||||t||||||||||2018-05-31 21:32:09.900412|2018-05-31 21:32:09.900412
NCT01559493|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Fractional Flow Reserve (FFR) Versus Instant Wave-Free Ratio (iFR)|Comparison of Fractional Flow Reserve Versus Instant Wave-Free Ratio for Assessment of Coronary Artery Stenosis Severity in Routine Practice|Completed|||200|Actual|NHS National Waiting Times Centre Board|||1||f||||f||||||||||2018-05-31 21:32:10.137784|2018-05-31 21:32:10.137784
NCT01559480|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2015-04-08|2012-03-20|2012-03-21|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Postoperative Desogestrel for Endometriosis Related Pain|A Prospective Double Blind Randomized Controlled Trial to Study the Effectiveness of a Desogestrel for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis|Completed||N/A|40|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 21:32:10.229138|2018-05-31 21:32:10.229138
NCT01559467|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2017-07-03|2012-03-19|2012-03-21|Estimate|||||||2017-07-03|2017-07-05|Actual|April 2012||2012-04-30|July 2016|2016-07-31|June 19, 2017|Actual|2017-06-19|May 2017|Actual|2017-05-31||Interventional|CARMENTA||The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction|The Supplementary Role of Cardiovascular Magnetic Resonance Imaging and Computed Tomography Angiography to Routine Clinical Practice in Suspected Non-ST Elevation Myocardial Infarction - A Randomized Controlled Trial|Completed||N/A|300|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 21:32:10.323187|2018-05-31 21:32:10.323187
NCT01559454|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2016-01-22||2017-02-17|2012-03-20|2012-03-21|Estimate|2017-02-17|2017-02-20|Actual||||2017-02-17|2017-02-20|Actual|February 2012||2012-02-29|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients|A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients|Completed||Phase 4|19|Actual|State University of New York at Buffalo|Early termination due to human subject concerns|2|||f||||t||||||||Undecided|We are preparing a de-identified data set that could be shared.|2018-05-31 21:32:10.44445|2018-05-31 21:32:10.44445
NCT01559441|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2013-07-15|2012-03-19|2012-03-21|Estimate|||||||2013-07-15|2013-07-16|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Beetroot Juice and Postprandial Vascular Activity|The Effects of Beetroot Juice on Postprandial Vascular Activity After a High-fat Meal in Overweight and Slightly Obese Men|Completed||N/A|20|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:32:11.200645|2018-05-31 21:32:11.200645
NCT01559428|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-19|2012-03-19|2012-03-21|Estimate|||||||2012-03-19|2012-03-21|Estimate|May 2010||2010-05-31|March 2012|2012-03-31||||April 2012|Anticipated|2012-04-30||Interventional|||Phytosterols and Oxyphytosterol Concentrations|The Effects of Plant Sterol and Stanol Esters on Serum Oxyphytosterol Concentrations in Healthy Human Subjects|Unknown status|Active, not recruiting|N/A|48|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 21:32:11.316181|2018-05-31 21:32:11.316181
NCT01559415|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-12-22|2012-03-19|2012-03-21|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ADIPOSTRESS||An Adipocyte-Driven Mechanism For Weight Regain After Weight Loss: The Yo-Yo Effect|An Adipocyte-Driven Mechanism For Weight Regain After Weight Loss: The Yo-Yo Effect|Completed||N/A|58|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:32:11.421271|2018-05-31 21:32:11.421271
NCT01559402|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-08-31|2012-03-19|2012-03-21|Estimate|||||||2014-08-31|2014-09-03|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Oxygenation Test During General Anesthesia|Application of Protective Ventilation Improves Oxygenation During and After Anesthesia. Is it Possible That a Special Procedure, an Oxygenation Test, Can Replace Arterial Blood Gases When Evaluating Oxygenation?|Completed||N/A|40|Actual|Region Västmanland||3|||f||||t||||||||||2018-05-31 21:32:11.618777|2018-05-31 21:32:11.618777
NCT01559389|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-07-27|2012-03-19|2012-03-21|Estimate|||||||2017-07-27|2017-07-31|Actual|March 2012||2012-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|IIMPACT||Incontinence & Intimate Partners: Assessing the Contribution of Treatment|Incontinence & Intimate Partners: Assessing the Contribution of Treatment|Completed||N/A|69|Actual|Loyola University||1|||f||||f||||||||Yes||2018-05-31 21:32:11.732563|2018-05-31 21:32:11.732563
NCT01559376|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2017-08-25|2012-03-19|2012-03-21|Estimate|||||||2017-08-25|2017-08-28|Actual|February 2012||2012-02-29|March 2012|2012-03-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Observational|||Long Term Follow-up of Open Versus Endoscopic Radial Artery Harvest With CT Angiography|Long Term Follow-up of Open Versus Endoscopic Radial Artery Harvest With CT Angiography|Completed|||118|Anticipated|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 21:32:11.851135|2018-05-31 21:32:11.851135
NCT01559363|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2018-04-09|2012-03-19|2012-03-21|Estimate|||||||2018-04-09|2018-04-11|Actual|September 2012||2012-09-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 (Tesevatinib) in Subjects With ADPKD|A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|Kadmon Corporation, LLC||7|||f||||f||||||||||2018-05-31 21:32:11.956649|2018-05-31 21:32:11.956649
NCT01559350|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2016-04-13|2012-03-20|2012-03-21|Estimate|||||||2016-04-13|2016-04-15|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2022|Anticipated|2022-12-31|December 2015|Actual|2015-12-31||Observational|||Graft Patency Analysis of the Right Coronary Artery System|Graft Patency of the Right Coronary Artery System in OPCAB: Saphenous Vein Graft Versus Right Gastroepiploic Artery|Terminated|||50|Actual|Samsung Medical Center|||2|Poor recruiting rate|f||||t||||||||||2018-05-31 21:32:12.063597|2018-05-31 21:32:12.063597
NCT01559337|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-03-20|2012-03-20|2012-03-21|Estimate|||||||2012-03-20|2012-03-21|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|June 2009|Actual|2009-06-30||Interventional|||Nerve Transfer for Finger Sensory Reconstruction With Dorsal Branch of the Digital Nerve||Completed||N/A|17|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 21:32:12.149343|2018-05-31 21:32:12.149343
NCT01559324|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-07-08|2012-03-20|2012-03-21|Estimate|||||||2015-07-08|2015-07-09|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Electroconvulsive Therapy (ECT) for Elderly Patients With Major Depression|Randomized Controlled Comparison of Bifrontal and Right Unilateral ECT as to Effects on Depression, Global Cognitive Function and Biomarkers.|Completed||Phase 4|92|Actual|Diakonhjemmet Hospital||2|||f||||f||||||||||2018-05-31 21:32:12.241526|2018-05-31 21:32:12.241526
NCT01559311|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2016-09-07||2016-11-17|2012-03-19|2012-03-21|Estimate|2016-09-07|2016-10-31|Estimate||||2016-11-17|2017-01-09|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|ENHANCE|Age = (the year of visit - year of birth)|ENHANCE-Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction|Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction|Completed||N/A|98|Actual|St. Jude Medical|Sample size was not reached due to difficulty in enrollment.|3|||f||||f||||||||||2018-05-31 21:32:12.36316|2018-05-31 21:32:12.36316
NCT01559298|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-05-10|2012-03-20|2012-03-21|Estimate|||||||2017-05-10|2017-05-11|Actual|March 2012|Actual|2012-03-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|ARTE||Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial|Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)|Completed||Phase 4|178|Actual|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f||||f||||||||||2018-05-31 21:32:13.376239|2018-05-31 21:32:13.376239
NCT01559285|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-08-28|2012-03-20|2012-03-21|Estimate|||||||2017-08-28|2017-08-29|Actual|November 16, 2011|Actual|2011-11-16|August 2017|2017-08-31|April 19, 2013|Actual|2013-04-19|April 19, 2013|Actual|2013-04-19||Interventional|PNU||Effects of Epidurally Administered Ropivacaine Concentration on the Hemodynamic Parameters|Effects of Epidurally Administered Ropivacaine Concentration on the Hemodynamic Parameters|Completed||Phase 4|120|Actual|Pusan National University Hospital||3|||f||||f||||||||||2018-05-31 21:32:13.536569|2018-05-31 21:32:13.536569
NCT01559272|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-09-15|2012-03-19|2012-03-21|Estimate|||||||2017-09-15|2017-09-18|Actual|February 21, 2008|Actual|2008-02-21|September 2017|2017-09-30|May 24, 2014|Actual|2014-05-24|April 9, 2014|Actual|2014-04-09||Interventional|||A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia|Completed||Phase 1|328|Actual|Janssen Research & Development, LLC||4|||f||||f||f||||||||2018-05-31 21:32:13.659834|2018-05-31 21:32:13.659834
NCT01559259|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19||2014-07-25|2014-07-25|2012-03-19|2012-03-21|Estimate||||2014-07-25|2014-07-30|Estimate|2014-07-25|2014-07-30|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain|Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain|Completed||Phase 2|394|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:32:13.841041|2018-05-31 21:32:13.841041
NCT01559246|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-11-05|2012-03-19|2012-03-21|Estimate|||||||2012-11-05|2012-11-07|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Observational|TCEM||True Continuous ECG Monitoring (TCEM Study)|Comparison of Short Term Holter Monitoring vs. Long Term Zio(R)Patch True Continuous ECG Monitoring (TCEM Study)|Unknown status|Active, not recruiting||150|Anticipated|iRhythm Technologies, Inc.|||1||f||||f||||||||||2018-05-31 21:32:13.960265|2018-05-31 21:32:13.960265
NCT01559233|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2012-03-20|2012-03-20|2012-03-21|Estimate|||||||2012-03-20|2012-03-21|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Clinical Study to Determine Safety and Efficacy of FPlus for Wrinkle Treatment|Clinical Study to Determine Safety and Efficacy of FPlus for Wrinkle Treatment|Completed||N/A|69|Actual|Invasix||1|||f||||f||||||||||2018-05-31 21:32:14.061366|2018-05-31 21:32:14.061366
NCT01559220|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-03-28|2012-03-20|2012-03-21|Estimate|||||||2017-03-28|2017-03-30|Actual|March 2012||2012-03-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Deep Brain Stimulation for the Treatment of Alzheimer's Disease|Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease|Completed||N/A|3|Actual|Ohio State University||1|||f||||f|f|t|f|||||No||2018-05-31 21:32:14.171977|2018-05-31 21:32:14.171977
NCT01559207|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-03-25|2012-03-20|2012-03-21|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Reproducibility of Plasma Nucleosomes and Free DNA as Markers for Venous Thromboembolism|Reproducibility of Plasma Nucleosomes and Free DNA as Markers for Venous Thromboembolism|Completed|||120|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||Samples With DNA|"~     EDTA, CTAD and dry tubes; Biological collection at the Nîmes University Hospital.~   "|||2018-05-31 21:32:14.253368|2018-05-31 21:32:14.253368
NCT01559194|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2014-04-10|2012-03-19|2012-03-21|Estimate|||||||2014-04-10|2014-04-14|Estimate|May 2005||2005-05-31|April 2014|2014-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|LEAF||Low Fat Versus Protein Sparing Diet for Weight Loss & Impact on Biomarkers Associated With Breast Cancer Risk|A Randomized Comparison of a Low Fat or Low Carbohydrate Dietary Pattern for Weight Loss and Impact on Biomarkers Associated With Breast Cancer Risk in Overweight and Obese Premenopausal Women: Lifestyle Eating and Fitness|Completed||Phase 3|82|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:32:14.409384|2018-05-31 21:32:14.409384
NCT01559181|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2018-05-23|2012-03-20|2012-03-21|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2012||2012-04-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|EPICOM||Study of Offspring of Women With Type 1 Diabetes|Environmental Versus Genetic and Epigenetic Influences on Growth, Metabolism and Cognitive Function in Offspring of Mothers With Type 1 Diabetes|Completed|||584|Actual|Odense University Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum and plasma. Tissue biopsies from m. vastus lateralis and subcutaneous~     abdominal fat (only selected subgroup of participants)~   "|||2018-05-31 21:32:14.745999|2018-05-31 21:32:14.745999
NCT01559168|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-01-31|2012-03-20|2012-03-21|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|||Uphold Mesh for the Surgical Treatment of Uterine-predominant Prolapse|Clinical Evaluation of the Uphold Mesh for the Surgical Treatment of Uterine-predominant Prolapse: a Prospective, Multicenter Trial|Completed||N/A|121|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 21:32:15.039108|2018-05-31 21:32:15.039108
NCT01559155|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2018-05-04|2012-03-20|2012-03-21|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 5, 2013|Actual|2013-11-05|May 2018|2018-05-31|June 9, 2015|Actual|2015-06-09|June 9, 2015|Actual|2015-06-09||Observational|||Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid|Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid|Terminated|||14|Actual|Centre Hospitalier Universitaire de Nīmes|||3|recruitment difficulties|f||||f||||||Samples With DNA|"~     All left over plasma samples will be incorporated into the biological collection at the Nîmes~     University Hospital.~   "|||2018-05-31 21:32:15.384536|2018-05-31 21:32:15.384536
NCT01559142|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-04-02|2012-03-20|2012-03-21|Estimate|||||||2012-04-02|2012-04-04|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|April 2012|Anticipated|2012-04-30||Interventional|||Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease|Efficacy and Safety of Induction Therapy With Three Doses of Infliximab in Patients With Crohn Disease Aged 7-17 Years-multicenter Open Study. Efficacy and Safety of Two Regimens of Maintenance Therapy in Patients With Crohn Disease Aged 7-17 Years-multicenter Randomized Study|Unknown status|Active, not recruiting|Phase 3|100|Actual|Children's Memorial Health Institute, Poland||2|||f||||f||||||||||2018-05-31 21:32:15.511531|2018-05-31 21:32:15.511531
NCT01559129|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-04-05|2012-03-20|2012-03-21|Estimate|||||||2017-04-05|2017-04-06|Actual|August 9, 2012|Actual|2012-08-09|April 2017|2017-04-30|November 3, 2016|Actual|2016-11-03|November 3, 2016|Actual|2016-11-03||Interventional|||Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease|A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerablity, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease|Completed||Phase 2|23|Actual|Celgene||2|||f||||t||||||||||2018-05-31 21:32:15.605717|2018-05-31 21:32:15.605717
NCT01559116|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2015-06-19|2014-04-03|2015-06-19|2012-03-20|2012-03-21|Estimate|2015-06-19|2015-07-16|Estimate|2014-04-03|2014-04-30|Estimate|2015-06-19|2015-07-16|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Treated Set (TS): This patient set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease|Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg, 5/5 µg), Tiotropium (2.5 µg, 5 µg) and Olodaterol (5 µg) (Oral Inhalation, Delivered by the Respimat® Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM]|Completed||Phase 3|219|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 21:32:15.810213|2018-05-31 21:32:15.810213
NCT01559103|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2015-02-19|2012-03-20|2012-03-21|Estimate|||||||2015-02-19|2015-02-23|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients|A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (Anti-IL-6)|Terminated||Phase 1|39|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:32:17.015068|2018-05-31 21:32:17.015068
NCT01559090|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-03-07|2012-03-20|2012-03-21|Estimate|||||||2017-03-07|2017-03-09|Actual|April 20, 2012|Actual|2012-04-20|March 2017|2017-03-31|February 21, 2017|Actual|2017-02-21|August 19, 2014|Actual|2014-08-19||Interventional|||Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus|A Phase 2, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Intravenous Dose of MEDI-546, a Human Monoclonal Antibody Directed Against Type I Interferon Receptor (IFNAR), in Japanese Subjects With Active Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|20|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 21:32:17.101149|2018-05-31 21:32:17.101149
NCT01559077|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2013-01-14|2012-03-20|2012-03-21|Estimate|||||||2013-01-14|2013-01-15|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects|A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Healthy Volunteers|Completed||Phase 1|17|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:32:17.183364|2018-05-31 21:32:17.183364
NCT01559064|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|2013-03-21||2014-10-06|2012-03-20|2012-03-21|Estimate|2013-06-06|2013-06-10|Estimate||||2014-10-06|2014-10-13|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face|A Prospective, Observational Study of the Volumizing Effect of Open-Label Aesthetic Use of VOLUMA® in the Mid-Face Area|Completed|||115|Actual|Allergan|||3||f||||f||||||||||2018-05-31 21:32:17.254598|2018-05-31 21:32:17.254598
NCT01559051|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-11-21|2012-03-20|2012-03-21|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2014||2014-03-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Intra-venous and Inhalation Implantation of Autologous Adipose-Derived Stromal Vascular Fraction Cells in Patients With Chronic Obstructive Pulmonary Disease|Withdrawn||Phase 1/Phase 2|0|Actual|Ageless Regenerative Institute||1||company dissolved|f||||f||||||||Undecided||2018-05-31 21:32:17.520901|2018-05-31 21:32:17.520901
NCT01559038|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2018-05-25|2012-03-19|2012-03-21|Estimate|||||||2018-05-25|2018-05-30|Actual|February 16, 2012|Actual|2012-02-16|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|Complete-PsA||Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis|Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA)|Active, not recruiting|||474|Actual|AbbVie|||2||f||||f|f|f|||f|||Undecided||2018-05-31 21:32:17.619518|2018-05-31 21:32:17.619518
NCT01559025|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-05-13|2012-03-18|2012-03-20|Estimate|||||||2014-05-13|2014-05-14|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|March 2017|Anticipated|2017-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus|Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in Residual β-cell Function and Inflammatory Markers in New-onset Type 1 Diabetes Mellitus.|Unknown status|Recruiting|Phase 3|44|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:32:17.741774|2018-05-31 21:32:17.741774
NCT01559012|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2014-02-12||2014-03-31|2012-03-18|2012-03-20|Estimate|2014-03-31|2014-04-30|Estimate||||2014-03-31|2014-04-30|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CLONEMESI|"Baseline biophysical and demographic data were reported:~age, race, ethnicity, parity, HG in previous pregnancy, smoking, BMI, weight loss, concurrent diseases, concurrent treatment,gestational age at start of symptoms, gestational age at enrollment, PUQE score at enrollment"|Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum|The CLONEMESI Study: a Randomized Placebo-controlled Study With Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum.|Completed||Phase 3|13|Actual|Azienda Ospedaliera Città della Salute e della Scienza di Torino|"Efficacy and safety issues are represented by maternal exposure in a critical period for organogenesis and hypotensive effect of the drug.~Findings based on a very limited number of women limit the reliability of results"|2|||f||||f||||||||||2018-05-31 21:32:17.833329|2018-05-31 21:32:17.833329
NCT01558999|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18||2013-08-30|2014-07-22|2012-03-18|2012-03-20|Estimate||||2013-08-30|2013-09-13|Estimate|2014-07-22|2014-07-24|Estimate|March 2012||2012-03-31|July 2014|2014-07-31||||July 2012|Actual|2012-07-31||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye||Completed||Phase 2|150|Actual|Seikagaku Corporation||3|||f||||||||||||||2018-05-31 21:32:19.170631|2018-05-31 21:32:19.170631
NCT01558986|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-19|2012-03-19|2012-03-20|Estimate|||||||2012-03-19|2012-03-20|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Routine Preoperative Antibiotic Prophylaxis in Modified Radical Mastectomy|A Randomized, Double Blinded Placebo-Controlled Trial on the Routine Use of Preoperative Antibiotic Prophylaxis in Modified Radical Mastectomy|Completed||Phase 3|254|Actual|University of the Philippines||2|||f||||t||||||||||2018-05-31 21:32:19.232602|2018-05-31 21:32:19.232602
NCT01558973|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2016-11-28|2012-03-18|2012-03-20|Estimate|||||||2016-11-28|2016-11-30|Estimate|August 2005||2005-08-31|November 2016|2016-11-30||||December 2015|Actual|2015-12-31||Observational|||FMRI of Stress and Addictive Disorders|Functional Magnetic Resonance Imaging of Stress and Addictive Disorders|Completed|||108|Actual|Yale University|||6||f||||t||||||||||2018-05-31 21:32:19.319282|2018-05-31 21:32:19.319282
NCT01558960|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-08-19|2012-03-18|2012-03-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Intravitreal Injections of Melphalan for Retinoblastoma|Intravitreal Injections of Melphalan for Retinoblastoma|Terminated||N/A|10|Anticipated|Hadassah Medical Organization||1||Sufficient findings to draw conclusions|f||||f||||||||||2018-05-31 21:32:19.383386|2018-05-31 21:32:19.383386
NCT01558947|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-18|2012-03-18|2012-03-20|Estimate|||||||2012-03-18|2012-03-20|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer|Peri-operative Chemotherapy With ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the Treatment of Advanced Gastric Cancer: a Randomized, Multicenter, Parallel Control|Unknown status|Recruiting|Phase 2|2|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 21:32:19.462782|2018-05-31 21:32:19.462782
NCT01558934|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2018-02-22|2012-03-18|2012-03-20|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2012||2012-02-29|February 2018|2018-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Pilot Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients|A Pilot, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects|Completed||Phase 1|6|Actual|US WorldMeds LLC||1|||f||||f||||||||||2018-05-31 21:32:19.548571|2018-05-31 21:32:19.548571
NCT01558921|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2017-05-08|2012-03-19|2012-03-20|Estimate|||||||2017-05-08|2017-05-09|Actual|June 21, 2011|Actual|2011-06-21|May 2017|2017-05-31|June 8, 2022|Anticipated|2022-06-08|March 8, 2020|Anticipated|2020-03-08||Interventional|RAPIDO||Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial|Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.|Active, not recruiting||Phase 3|920|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 21:32:19.639221|2018-05-31 21:32:19.639221
NCT01558908|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-03-18|2012-03-18|2012-03-20|Estimate|||||||2012-03-18|2012-03-20|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Interventional|||Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia|Allogeneic,Unrelated, Menstrual Derived, Mesenchymal Stem Cell-Like, Endometrial Cells; Administered Intramuscular|Unknown status|Not yet recruiting|Phase 1/Phase 2|15|Anticipated|Medistem Inc.||1|||f||||||||||||||2018-05-31 21:32:19.901009|2018-05-31 21:32:19.901009
NCT01558895|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-03-20|2012-03-19|2012-03-20|Estimate|||||||2012-03-20|2012-03-21|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|||Infrared Ray Heat Treatment in Liver Cirrhosis Patients With Refractory Ascites|Infrared Ray Heat Treatment in Hepatic Area in Liver Cirrhosis Patients With Refractory Ascites|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|First People's Hospital of Foshan||2|||f||||t||||||||||2018-05-31 21:32:19.991697|2018-05-31 21:32:19.991697
NCT01558882|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2017-06-16|2012-03-18|2012-03-20|Estimate|||||||2017-06-16|2017-06-19|Actual|January 21, 2014|Actual|2014-01-21|June 2017|2017-06-30|November 28, 2014|Actual|2014-11-28|November 28, 2014|Actual|2014-11-28||Observational|||Impact of Essure Tubal Sterilization Devices on the Endometrium|Impact of Essure Tubal Sterilization Devices on the Endometrium|Terminated|||2|Actual|Centre Hospitalier Universitaire de Nīmes|||1|Trouble with recruting|f||||f||||||Samples With DNA|"~     All left over samples will be included in the hematology biological collection at the Nîmes~     University Hospital.~      Endometrial flushing samples will also be included in the Nîmes University Hospital biobank.~   "|||2018-05-31 21:32:20.099928|2018-05-31 21:32:20.099928
NCT01558869|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2017-05-06|2012-03-18|2012-03-20|Estimate|||||||2017-05-06|2017-05-09|Actual|April 2012||2012-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma|An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma|Completed||Phase 2|37|Actual|The University of Hong Kong||1|||f||||f||||||||||2018-05-31 21:32:20.203973|2018-05-31 21:32:20.203973
NCT01558856|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2016-10-12|2012-03-18|2012-03-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|HAVIR Bi||Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder|Prospective Randomized Trial Comparing Unilateral and Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder|Recruiting||N/A|55|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 21:32:20.294955|2018-05-31 21:32:20.294955
NCT01558843|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2012-03-27|2012-03-19|2012-03-20|Estimate|||||||2012-03-27|2012-03-28|Estimate|February 2012||2012-02-29|March 2012|2012-03-31||||||||Observational|SANI||Sodium Management in Acute Neurological Injury|Sodium Management in Patients With Acute Neurological Injury|Unknown status|Recruiting||400|Anticipated|Washington University School of Medicine|||4||f||||f||||||||||2018-05-31 21:32:20.406855|2018-05-31 21:32:20.406855
NCT01558830|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2012-03-20|2012-03-18|2012-03-20|Estimate|||||||2012-03-20|2012-03-21|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|July 2013|Anticipated|2013-07-31|April 2013|Anticipated|2013-04-30||Interventional|SARA||Safety of Amiodarone and Ranolazine Together in Patients With Angina|Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina|Unknown status|Recruiting|Phase 4|50|Anticipated|Cardiovascular Consultants of Nevada||2|||f||||t||||||||||2018-05-31 21:32:20.514861|2018-05-31 21:32:20.514861
NCT01558817|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-07-23|2012-03-19|2012-03-20|Estimate|||||||2014-07-23|2014-07-25|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation With Informed Assent||Completed||N/A|29|Actual|University of Vermont||2|||f||||t||||||||||2018-05-31 21:32:20.605135|2018-05-31 21:32:20.605135
NCT01558804|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-09-09|2012-03-16|2012-03-20|Estimate|||||||2016-09-09|2016-09-12|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|GRASP||GRoup A StrePtococcus|Gene Expression in Isolates of Group A Streptococci Recovered From Patients Who Are Carriers|Recruiting|||80|Anticipated|University of Wisconsin, Madison|||1||f||||f||||||Samples With DNA|"~     Throat swab specimens~   "|No||2018-05-31 21:32:20.67976|2018-05-31 21:32:20.67976
NCT01558791|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2014-11-03||2015-04-06|2012-03-16|2012-03-20|Estimate|2014-11-19|2014-11-26|Estimate||||2015-04-06|2015-04-28|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|TBI|All veterans screened for TBI|A Brief Educational Intervention to Improve Traumatic Brain Injury (TBI) Screening Outcomes|A Brief Educational Intervention to Improve TBI Screening Outcomes|Completed||Phase 1|1236|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 21:32:20.87727|2018-05-31 21:32:20.87727
NCT01558778|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-07-05|2012-03-19|2012-03-20|Estimate|||||||2012-07-05|2012-07-09|Estimate|May 2012||2012-05-31|July 2012|2012-07-31||||June 2012|Actual|2012-06-30||Interventional|||Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant|Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||1||device not available|f||||t||||||||||2018-05-31 21:32:21.366969|2018-05-31 21:32:21.366969
NCT01558765|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-11-12|2012-03-19|2012-03-20|Estimate|||||||2015-11-12|2015-11-13|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CopenHeartVR||CopenHeartVR - Integrated Rehabilitation of Patients After Heart Valve Surgery|CopenHeartVR - A Randomized Clinical Trial Investigating the Effect of Integrated Rehabilitation Versus Usual Care Without Physical Exercise After Heart Valve Surgery.|Completed||Phase 2|147|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:32:21.485133|2018-05-31 21:32:21.485133
NCT01558752|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-03-23|2012-03-19|2012-03-20|Estimate|||||||2018-03-23|2018-03-27|Actual|April 2010|Actual|2010-04-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Clinical Trial of a Metal on Poly Component Versus CORAIL Stem: A Bone Mineral Density Study|A Randomized Clinical Trial of a Modular Cementless Acetabular Metal on Poly Component Versus a Monoblock Cementless Titanium Shell With Ceramic on Ceramic Bearing and CORAIL Stem: A Bone Mineral Density Study|Active, not recruiting||N/A|88|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 21:32:21.575483|2018-05-31 21:32:21.575483
NCT01558739|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2015-01-26||2015-03-01|2012-03-19|2012-03-20|Estimate|2015-03-01|2015-03-03|Estimate||||2015-03-01|2015-03-03|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|MACS2030|All enrolled patients were included in the Full Analysis Set and the Safety Set.|Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)|A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)|Completed||Phase 4|48|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:32:21.692449|2018-05-31 21:32:21.692449
NCT01558726|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2012-03-17|2012-03-17|2012-03-20|Estimate|||||||2012-03-17|2012-03-20|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Case Management for Crack Users Who Seek Treatment in CAPSad in Brazil|Effectiveness of Case Management for Crack Users Who Seek Treatment in CAPSad in Six Brazilian Capitals|Unknown status|Recruiting|N/A|600|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 21:32:22.065297|2018-05-31 21:32:22.065297
NCT01558713|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-04-26|2012-03-19|2012-03-20|Estimate|||||||2012-04-26|2012-04-27|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Epidural Volume Extension and Intrathecal Use of Local Anesthetics in Cesarean Sections|Assessment of Sensory and Motor Block After Intrathecal Administration of Bupivacaine, Ropivacaine and Levo-bupivacaine Combined With Small Doses of Fentanyl, Followed by Administration of Normal Saline Epidurally:a Clinical Trial in Parturients Scheduled for C-section|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|University of Patras||6|||f||||f||||||||||2018-05-31 21:32:22.143376|2018-05-31 21:32:22.143376
NCT01558700|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2014-12-05||2014-12-16|2012-03-19|2012-03-20|Estimate|2014-12-16|2014-12-29|Estimate||||2014-12-16|2014-12-29|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Duloxetine in Osteoarthritis (OA) Pain|Brain Morphometries in OA Patients Treated With Duloxetine|Completed||Phase 4|40|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:32:22.24184|2018-05-31 21:32:22.24184
NCT01558687|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2014-02-03|2012-03-19|2012-03-20|Estimate|||||||2014-02-03|2014-02-04|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Cilengitide Imaging Trial in Glioblastoma|A Multi-center, Open-label, Randomized, Controlled Phase I Trial to Investigate the Effects of Cilengitide (EMD 121974) Using Dynamic MR and FET-PET Imaging as a Pharmacodynamic Measure of Response in Subjects With Newly Diagnosed Glioblastoma|Terminated||Phase 1|1|Actual|Merck KGaA||2||Discontinuation of development program|f||||f||||||||||2018-05-31 21:32:22.442576|2018-05-31 21:32:22.442576
NCT01558674|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2017-01-11||2017-03-27|2012-03-16|2012-03-20|Estimate|2017-01-11|2017-03-03|Actual||||2017-03-27|2017-04-27|Actual|May 2014||2014-05-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)|A Two Part, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7145 in Patients With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II)|Terminated||Phase 1|11|Actual|Merck Sharp & Dohme Corp.|Study terminated early due to lack of efficacy.|7||Lack of efficacy|f||||t||||||||||2018-05-31 21:32:22.614022|2018-05-31 21:32:22.614022
NCT01558661|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2017-07-17||2017-10-20|2012-03-16|2012-03-20|Estimate|2017-10-20|2017-11-28|Actual||||2017-10-20|2017-11-28|Actual|March 2012||2012-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|Completed||Phase 2|33|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:32:23.137114|2018-05-31 21:32:23.137114
NCT01558648|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-04-03|2012-03-19|2012-03-20|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer|Quality of Life Outcomes Following Minimally Invasive and Open Esophagectomy for Esophageal Cancer|Active, not recruiting|||265|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 21:32:23.491028|2018-05-31 21:32:23.491028
NCT01558635|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-04-28|2012-03-19|2012-03-20|Estimate|||||||2017-04-28|2017-05-02|Actual|September 2012||2012-09-30|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of the Cardioblate CryoFlex Surgical Ablation System in Subjects With Longstanding Persistent Atrial Fibrillation Requiring Mitral Valve Surgery|Cryo-AF Clinical Study|Completed||N/A|17|Actual|Medtronic Cardiovascular||1|||f||||f||||||||No||2018-05-31 21:32:23.577419|2018-05-31 21:32:23.577419
NCT01558622|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-03-22|2012-03-19|2012-03-20|Estimate|||||||2012-03-22|2012-03-23|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||May 2012|Anticipated|2012-05-31||Interventional|||Intraoperative Use of Dexketoprofen Trometamol, Pethidine Hcl, Tramadol Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication|Intraoperative Use of Dexketoprofen Trometamol, Tramadol Hcl, Pethidine Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication|Unknown status|Active, not recruiting|Phase 4|72|Anticipated|Kavaklıdere Umut Hospital||6|||f||||f||||||||||2018-05-31 21:32:23.667763|2018-05-31 21:32:23.667763
NCT01558609|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2012-03-19|2012-03-19|2012-03-20|Estimate|||||||2012-03-19|2012-03-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:32:23.759999|2018-05-31 21:32:23.759999
NCT01558596|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2016-10-12||2017-02-01|2012-03-16|2012-03-20|Estimate|2016-10-12|2016-12-06|Estimate||||2017-02-01|2017-03-22|Actual|September 2011||2011-09-30|February 2017|2017-02-28|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|CRIPES||Remote Ischemic Preconditioning Prior to Vascular Surgery|Cardiac Remote Ischemic Preconditioning Prior to Elective Major Vascular Surgery|Completed||Phase 1/Phase 2|201|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-05-31 21:32:23.810798|2018-05-31 21:32:23.810798
NCT01558583|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-04-21|2012-03-19|2012-03-20|Estimate|||||||2017-04-21|2017-04-25|Actual|July 2011||2011-07-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CARR2||Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making|A Comparison of the Effect of a Conjoint Analysis Based Values Clarification Exercise, Rating and Ranking Exercise, and Balance Sheet for Colorectal Cancer Screening and Prostate Cancer Screening Decision Making|Completed||N/A|1831|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 21:32:24.035201|2018-05-31 21:32:24.035201
NCT01558570|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2012-03-17|2012-03-17|2012-03-20|Estimate|||||||2012-03-17|2012-03-20|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin|Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin|Completed|||100|Actual|University of Maryland|||1||f||||f||||||Samples With DNA|"~     Laboratory Measures:~      Zonulin and gliadin antibodies will be sent to the lab of Dr. Alessio Fasano for assay.~      Genetic and Biochemical analysis will be sent for analysis and storage of blood sample at the~     Maryland Psychiatric Research Center Neurogenetics laboratory under the direction of Dr.~     Ikwunga Wonodi. Analysis will include kynurenic acid metabolites, inflammatory markers from~     Peripheral Blood Mononuclear Cells (PBMC) and future genetic analysis including but not~     limited to human leukocyte antigen (HLA) haplotypes (DQ2 and DQ8).~      Cytokines will be analyzed by the Cytokine Core Laboratory at the University of Maryland~     using Luminex Technology.~      Other standard laboratories will be done by Lab Corp or other contract laboratory.~   "|||2018-05-31 21:32:24.105983|2018-05-31 21:32:24.105983
NCT01558557|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-01-27|2012-03-19|2012-03-20|Estimate|||||||2014-01-27|2014-01-29|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Gluten Free Diet in People With Schizophrenia: A Pilot Study|Gluten Free Diet in People With Schizophrenia: A Pilot Study|Completed||N/A|3|Actual|University of Maryland||1|||f||||f||||||||||2018-05-31 21:32:24.165665|2018-05-31 21:32:24.165665
NCT01558544|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-02-20|2012-03-19|2012-03-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 1997|Actual|1997-04-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Cryopreservation of Ovarian Tissue|Cryopreservation of Ovarian Tissue for Potential In Vitro Maturation or Autologous Transplantation|Recruiting||N/A|100|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 21:32:24.229477|2018-05-31 21:32:24.229477
NCT01558531|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2015-02-02|2012-03-19|2012-03-20|Estimate|||||||2015-02-02|2015-02-03|Estimate|January 2010||2010-01-31|February 2015|2015-02-28||||December 2011|Actual|2011-12-31||Observational|DEBATE-ISR||Drug Eluting Balloon in Peripheral Intervention for In-Stent Restenosis|Drug Eluting Balloon in peripherAl inTErvention for In-Stent Restenosis: the DEBATE-ISR Study|Suspended|||44|Actual|Ospedale San Donato|||2|slow enrollment|f||||f||||||||||2018-05-31 21:32:24.304105|2018-05-31 21:32:24.304105
NCT01558518|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2013-07-09|2012-03-19|2012-03-20|Estimate|||||||2013-07-09|2013-07-11|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Handheld Echocardiography in Clinical Practice|Handheld Echocardiography in Clinical Practice|Completed|||200|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 21:32:24.36135|2018-05-31 21:32:24.36135
NCT01558505|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2013-01-26|2012-03-19|2012-03-20|Estimate|||||||2013-01-26|2013-01-29|Estimate|November 2010||2010-11-30|January 2013|2013-01-31||||September 2012|Actual|2012-09-30||Interventional|DEBATE-BTK||Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation|Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study|Completed||Phase 4|142|Actual|Ospedale San Donato||2|||f||||f||||||||||2018-05-31 21:32:24.404518|2018-05-31 21:32:24.404518
NCT01558492|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-02-28||2017-05-05|2012-03-16|2012-03-20|Estimate|2017-02-28|2017-04-12|Actual||||2017-05-05|2017-06-09|Actual|March 2011|Actual|2011-03-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|||Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer|A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel|Terminated||Phase 2|3|Actual|Weill Medical College of Cornell University||1||Poor accrual|f||||t||||||||No||2018-05-31 21:32:24.46308|2018-05-31 21:32:24.46308
NCT01558479|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-05-28|2012-03-16|2012-03-20|Estimate|||||||2017-05-28|2017-05-31|Actual|September 2009|Actual|2009-09-30|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|PaGeR||The Parkinson's Genetic Research Study|The Parkinson's Genetic Research Study (PaGeR)|Recruiting|||5000|Anticipated|University of Washington|||3||f||||f||||||Samples With DNA|"~     Blood or saliva~   "|||2018-05-31 21:32:24.594835|2018-05-31 21:32:24.594835
NCT01558466|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2012-09-23|2012-03-18|2012-03-20|Estimate|||||||2012-09-23|2012-09-25|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|June 2015|Anticipated|2015-06-30|November 2014|Anticipated|2014-11-30||Interventional|Sildeno||Sildenofil in Persistent Pulmonary Hypertension in Newborns|Early Combined Use of Inhaled Nitric Oxide and Oral Sildenafil on the Outcome of Pulmonary Hypertension in New Born Infants|Unknown status|Recruiting|Phase 3|100|Anticipated|Hamad Medical Corporation||2|||f||||f||||||||||2018-05-31 21:32:24.772232|2018-05-31 21:32:24.772232
NCT01558453|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2013-03-25|2012-03-19|2012-03-20|Estimate|||||||2013-03-25|2013-03-26|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Oxaliplatin for Children With Solid Tumors|Phase II Study With Oxaliplatin In Children With Relapsed/Refractory Solid Tumors|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Hospital Santa Marcelina||1|||f||||f||||||||||2018-05-31 21:32:24.871719|2018-05-31 21:32:24.871719
NCT01558440|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-07-26|2012-03-17|2012-03-20|Estimate|||||||2015-07-26|2015-07-28|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Rehabilitation of Malnourished Infants With F-100 or Diluted F-100|Rehabilitation of Severely Malnourished Infants Aged <6months: a Randomised, Controlled Comparison of Three Recovery Diets (Infant Formula, F-100 and Diluted F-100)|Completed||Phase 2|132|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||t||||||||||2018-05-31 21:32:24.938475|2018-05-31 21:32:24.938475
NCT01558427|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-06-01|2012-03-16|2012-03-20|Estimate|||||||2016-06-01|2016-06-02|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer|Salvage Treatment or Active Clinical Surveillance for Oligometastatic Prostate Cancer: a Randomized Phase II Trial|Active, not recruiting||Phase 2|54|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 21:32:25.005972|2018-05-31 21:32:25.005972
NCT01554566|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Metabolic Effects of Honey in Type 1 Diabetes Mellitus|Metabolic Effects of Honey in Type 1 Diabetes Mellitus: a Cross Over Randomised Controlled Pilot Study|Completed||Phase 2|20|Actual|Ain Shams University||1|||f||||t||||||||||2018-05-31 21:33:20.416404|2018-05-31 21:33:20.416404
NCT01558414|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2013-03-11|2012-03-19|2012-03-20|Estimate|||||||2013-03-11|2013-03-12|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional|||Single Incision Laparoscopic Surgery vs Flexible Single Incision Surgery for Cholecystectomy|Prospective Randomized Clinical Trial Comparing Single Incision Laparoscopic Surgery vs Flexible Single Incision Surgery on Cholecystectomy|Completed||Phase 3|60|Actual|Hospital Son Llatzer||3|||f||||f||||||||||2018-05-31 21:32:25.070064|2018-05-31 21:32:25.070064
NCT01558401|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-03-19|2012-03-19|2012-03-20|Estimate|||||||2012-03-19|2012-03-20|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Efficiency of Physical Activity on the Physical Condition of Elderly Women|Effects of an Adapted Physical Activity Program on the Physical Condition of Elderly Women: an Analysis of Efficiency|Completed||N/A|120|Actual|Universidade Federal de Sao Carlos||1|||f||||t||||||||||2018-05-31 21:32:25.146429|2018-05-31 21:32:25.146429
NCT01558388|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-16|2012-03-16|2012-03-20|Estimate|||||||2012-03-16|2012-03-20|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy|Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy|Unknown status|Recruiting|Phase 4|100|Anticipated|Università degli Studi di Brescia||2|||f||||f||||||||||2018-05-31 21:32:25.215568|2018-05-31 21:32:25.215568
NCT01558375|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-05-26|2012-03-19|2012-03-20|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Anakinra in Hidradenitis Suppurativa|A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa|Completed||Phase 2|20|Actual|University of Athens||2|||f||||t||||||||||2018-05-31 21:32:25.292443|2018-05-31 21:32:25.292443
NCT01558362|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-04-21|2012-03-19|2012-03-20|Estimate|||||||2017-04-21|2017-04-24|Actual|April 2012||2012-04-30|April 2017|2017-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|CMICE||A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers|A Phase 1 Study of Safety, Tolerance, Pharmacokinetics and Nuclear Medicine Imaging of 123I-CMICE-013 Administered Intravenously in Healthy Adult Volunteers|Completed||Phase 1|12|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 21:32:25.386478|2018-05-31 21:32:25.386478
NCT01558349|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-17|||2017-01-31|2012-03-19|2012-03-20|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques|Circulating Tumor Cells and Melanoma: Comparing the EPISPOT (EPithelial ImmunoSPOT) and CellSearch Techniques|Recruiting|||82|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 21:32:25.465287|2018-05-31 21:32:25.465287
NCT01558336|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2013-01-16|2012-03-19|2012-03-20|Estimate|||||||2013-01-16|2013-01-17|Estimate|August 2008||2008-08-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Schistosoma Haematobium Infections and Praziquantel|Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel|Completed||Phase 3|520|Actual|University of Khartoum||1|||f||||t||||||||||2018-05-31 21:32:25.545256|2018-05-31 21:32:25.545256
NCT01558323|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-01-14|2012-03-19|2012-03-20|Estimate|||||||2014-01-14|2014-01-15|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pharmacokinetics of LCQ908 in Patients With Renal Impairment|An Open-label, Parallel-group, Single Dose Study to Assess the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Renal Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.|Completed||Phase 1|58|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:32:25.620582|2018-05-31 21:32:25.620582
NCT01558310|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-07-17|2012-03-19|2012-03-20|Estimate|||||||2012-07-17|2012-07-18|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis|A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Yamauchi, Paul Steven, M.D., Ph.D.||2|||f||||f||||||||||2018-05-31 21:32:25.698487|2018-05-31 21:32:25.698487
NCT01558297|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2015-05-19||2015-06-03|2012-03-16|2012-03-20|Estimate|2015-05-19|2015-06-04|Estimate||||2015-06-03|2015-07-01|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Chi-square for categorical variables and ANOVAs for continuous variables.|Internet Treatment for Weight Loss in Primary Care|Internet Treatment for Weight Loss in Primary Care|Completed||N/A|89|Actual|Yale University|Treatment as Usual (TAU) was subsequently referred to as Usual Care (UC) when the study results were disseminated because the literature evolved regarding treatment terms. UC more accurately reflect the condition.|3|||f||||t||||||||||2018-05-31 21:32:25.797307|2018-05-31 21:32:25.797307
NCT01558284|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-02-04|2012-03-16|2012-03-20|Estimate|||||||2014-02-04|2014-02-05|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|Neu-P11||The Effect of Neu-P11 on Symptoms in Patients With D-IBS|Clinical Study on the Effect of Neu-P11 on Symptoms in Patients With Diarrhea- Irritable Bowel Syndrome (D-IBS)|Completed|||40|Actual|Ludwig-Maximilians - University of Munich|||||f||||t||||||||||2018-05-31 21:32:26.147415|2018-05-31 21:32:26.147415
NCT01558271|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2014-10-22|2014-04-25|2015-05-20|2012-03-16|2012-03-20|Estimate|2014-10-22|2014-10-30|Estimate|2014-04-25|2014-05-13|Estimate|2015-05-20|2015-05-22|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional||Participants who received at least 1 dose of study medication.|A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus|A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|492|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:32:26.307037|2018-05-31 21:32:26.307037
NCT01558258|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2015-04-08|2012-03-16|2012-03-20|Estimate|||||||2015-04-08|2015-04-10|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors|A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors|Completed||Phase 2|71|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 21:32:28.006008|2018-05-31 21:32:28.006008
NCT01558245|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-09-11|2012-03-16|2012-03-20|Estimate|||||||2013-09-11|2013-09-12|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis|Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis|Unknown status|Recruiting|Phase 2|99|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 21:32:28.088315|2018-05-31 21:32:28.088315
NCT01558232|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-07-05|2012-03-16|2012-03-20|Estimate|||||||2012-07-05|2012-07-09|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|Acute Effects||A Prospective Study to Evaluate Use of the Tibion Bionic Leg in Sub-Acute Post-stroke Patients|A Prospective, Experimental ABA Study to Evaluate Use of the Tibion Bionic Leg in Subacute Post-stroke Patients Undergoing Physical Therapy|Terminated||N/A|10|Actual|Tibion Bionics, Inc.||1||Study was terminated base on Sponsor's decision.|f||||f||||||||||2018-05-31 21:32:28.187232|2018-05-31 21:32:28.187232
NCT01558219|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2016-10-20|2012-03-19|2012-03-20|Estimate|||||||2016-10-20|2016-10-21|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ProstyII||Second-line Chemotherapy in Castration Resistant Prostate Cancer|Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containing Regimen|Completed||Phase 2|60|Actual|Tampere University Hospital||1|||f||||f||||||||||2018-05-31 21:32:28.282704|2018-05-31 21:32:28.282704
NCT01558206|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2012-03-16|2012-03-16|2012-03-20|Estimate|||||||2012-03-16|2012-03-20|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Observational|||Ultrasonography of Chest Versus Pulmonary Artery CT Angiography in Patients With Symptoms and Signs in Favor of PTE|Bedside Ultrasonography of Chest Versus Pulmonary Artery CT Angiography in the Patients Who Came to Emergency Department of Alzahra General Hospital With Respiratory Symptoms and Signs in Favor of Pulmonary Thromboemboli.|Unknown status|Enrolling by invitation||76|Anticipated|Isfahan University of Medical Sciences|||1||f||||t||||||||||2018-05-31 21:32:28.366963|2018-05-31 21:32:28.366963
NCT01558193|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-05-02|2012-03-19|2012-03-20|Estimate|||||||2017-05-02|2017-05-05|Actual|March 2011||2011-03-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Impact of Supplementation With Multi-vitamins/Minerals, With and Without Fatty Acids, on Impulsivity and Aggression|The Impact of Supplementation With Multi-vitamins/Minerals, With and Without Fatty Acids, on Impulsivity and Aggression|Completed||N/A|202|Actual|Swansea University||4|||f||||f||||||||||2018-05-31 21:32:28.451602|2018-05-31 21:32:28.451602
NCT01558180|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-02-02|2012-03-19|2012-03-20|Estimate|||||||2015-02-02|2015-02-03|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Telephone Care Management to Address Sleep Problems in Young Children With Autism|Telephone Care Management to Address Sleep Problems in Young Children With Autism|Completed||Phase 2|60|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 21:32:28.557169|2018-05-31 21:32:28.557169
NCT01558167|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2018-05-09|2012-03-16|2012-03-20|Estimate|||||||2018-05-09|2018-05-15|Actual|February 2011||2011-02-28|May 2018|2018-05-31|June 2015|Actual|2015-06-30|October 2013|Actual|2013-10-31||Interventional|CLL2P||A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia|A phaseI/II Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide (BRL) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|22|Actual|German CLL Study Group||1|||f||||f||||||||No||2018-05-31 21:32:28.633527|2018-05-31 21:32:28.633527
NCT01558154|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-16|2012-03-16|2012-03-20|Estimate|||||||2012-03-16|2012-03-20|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|July 2014|Anticipated|2014-07-31|March 2014|Anticipated|2014-03-31||Interventional|||Comparison of Treatment Effect of Chinese Medicine and Western Medicine on Depression in China and America|Comparison of Treatment Effect of Chinese Medicine and Western Medicine on Depression in China and America|Unknown status|Not yet recruiting|N/A|160|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||4|||f||||t||||||||||2018-05-31 21:32:28.733467|2018-05-31 21:32:28.733467
NCT01558141|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-06-10|2012-03-19|2012-03-20|Estimate|||||||2015-06-10|2015-06-11|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Follicular Flushing|Follicular Flushing on Cycle Outcomes in Poor Responders|Completed||N/A|50|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 21:32:28.825527|2018-05-31 21:32:28.825527
NCT01558128|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2017-02-16||2017-04-21|2012-03-16|2012-03-20|Estimate|2017-04-21|2017-05-23|Actual||||2017-04-21|2017-05-23|Actual|March 2012||2012-03-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery|Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery|Terminated||N/A|1|Actual|Weill Medical College of Cornell University||1||Insufficient Recruitment|f||||f||||||||No|There is no plan to share IPD|2018-05-31 21:32:28.902677|2018-05-31 21:32:28.902677
NCT01558115|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-04-07|2012-03-19|2012-03-20|Estimate|||||||2015-04-07|2015-04-09|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Denosumab in Primary Hyperparathyroidism|Denosumab in Primary Hyperparathyroidism|Completed||Phase 4|8|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 21:32:29.023164|2018-05-31 21:32:29.023164
NCT01558102|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-11-20|2012-03-16|2012-03-20|Estimate|||||||2013-11-20|2013-11-25|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|IntrePED||International Retrospective Study of Pipeline Embolization Device|International Retrospective Study of Pipeline Embolization Device|Completed|||793|Actual|ev3|||||f||||f||||||||||2018-05-31 21:32:29.102451|2018-05-31 21:32:29.102451
NCT01558089|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2016-05-25||2016-09-21|2012-03-19|2012-03-20|Estimate|2016-09-21|2016-11-11|Estimate||||2016-09-21|2016-11-11|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|EARLY RA||Good EULAR Response In Patients With Early Rheumatoid Arthritis|Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece|Completed|||76|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:32:29.185482|2018-05-31 21:32:29.185482
NCT01558076|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-09-21|2012-03-16|2012-03-20|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia|Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia|Unknown status|Recruiting||90|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||t||||||||||2018-05-31 21:32:29.424754|2018-05-31 21:32:29.424754
NCT01558063|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2016-12-20|2012-03-19|2012-03-20|Estimate|||||||2016-12-20|2016-12-22|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Ketamine in the Treatment of Depression|The Antidepressant Action of Ketamine: Brain Chemistry|Active, not recruiting||Phase 2|76|Anticipated|Columbia University||6|||f||||t||||||||Undecided||2018-05-31 21:32:29.50251|2018-05-31 21:32:29.50251
NCT01558037|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2013-04-03|2012-03-16|2012-03-20|Estimate|||||||2013-04-03|2013-04-05|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Observational|ViracorCMI||Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients|A Study to Correlate CMV-Specific Cell Mediated Immunity With Risk of CMV Disease and With Clinical Response to Therapy Following Solid Organ Transplantation|Completed|||113|Actual|Northwestern University|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 21:32:29.636309|2018-05-31 21:32:29.636309
NCT01558024|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2016-05-19|2012-03-19|2012-03-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|MACIVC||The Effects of Compression Stockings on Pressure Parameters in Patients With Chronic Venous Insufficiency|The Effects of Compression Stockings on Pressure Parameters in Patients With Chronic Venous Insufficiency|Completed|||111|Actual|Centre Hospitalier Universitaire de Nīmes|||6||f||||f||||||||||2018-05-31 21:32:29.698008|2018-05-31 21:32:29.698008
NCT01558011|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2016-05-03|2012-03-16|2012-03-20|Estimate|||||||2016-05-03|2016-05-04|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Interventional|||Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study|Using Genetic Polymorphisms of Drug Metabolism and Immunohistochemical Stain to Predict the Efficacy and Toxicity in Patients With Gastric Adenocarcinoma - A Phase II Study|Terminated||Phase 2|51|Actual|National Health Research Institutes, Taiwan||1||The budget issues.|f||||t||||||||||2018-05-31 21:32:29.762476|2018-05-31 21:32:29.762476
NCT01557998|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2018-01-12|2012-03-16|2012-03-20|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2012||2012-03-31|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|TLCIDU Kenya||Testing and Linkage to Care for Injecting Drug Users in Kenya|Testing and Linkage to Care for IDUs in Kenya|Active, not recruiting||N/A|8800|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:32:29.82948|2018-05-31 21:32:29.82948
NCT01557985|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-03-19|2012-03-19|2012-03-20|Estimate|||||||2013-03-19|2013-03-21|Estimate|July 2010||2010-07-31|March 2013|2013-03-31||||October 2011|Actual|2011-10-31||Interventional|||Single Dose Pharmacokinetics and Pharmacodynamics of Bupivacaine Following Transversus Abdominis Plane (TAP) Block in Neonates|Single Dose Pharmacokinetics and Pharmacodynamics of Bupivacaine Following Transversus Abdominis Plane (TAP) Block in Neonates|Completed||Phase 2|13|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||t||||||||||2018-05-31 21:32:30.931716|2018-05-31 21:32:30.931716
NCT01557972|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2012-03-16|2012-03-16|2012-03-20|Estimate|||||||2012-03-16|2012-03-20|Estimate|November 1999||1999-11-30|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Observational|||Long-term of 10 Years Results of a Prospective Longitudinal Study|Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients : Long-term (10 Years) Results of a Prospective Longitudinal Study|Unknown status|Active, not recruiting||400|Anticipated|Nagaoka Red Cross Hospital|||2||f||||f||||||||||2018-05-31 21:32:31.008594|2018-05-31 21:32:31.008594
NCT01557959|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2013-05-01||2018-02-01|2012-03-16|2012-03-20|Estimate|2013-06-26|2013-06-28|Estimate||||2018-02-01|2018-02-28|Actual|July 2007|Actual|2007-07-31|November 2013|2013-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Sequential Dose-Dense Chemotherapy and Dose-Intense Erlotinib for the Initial Treatment of Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|45|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-05-31 21:32:31.126448|2018-05-31 21:32:31.126448
NCT01557946|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2017-01-20||2017-08-10|2012-03-16|2012-03-20|Estimate|2017-08-10|2017-09-12|Actual||||2017-08-10|2017-09-12|Actual|March 2012||2012-03-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression|Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression|Completed||Phase 4|32|Actual|Mclean Hospital|"Modest sample size due to participant attrition and the cost and logistical challenges of the study design.~Multiple comparisons, increasing the likelihood of type I errors. Open-label design which leaves open the possibility of a placebo effect."|2|||f||||f||||||||No||2018-05-31 21:32:31.688022|2018-05-31 21:32:31.688022
NCT01557933|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-11-28|2012-03-16|2012-03-20|Estimate|||||||2012-11-28|2012-11-29|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Effects of Electroconvulsive Therapy (ECT) in Bipolar Depression|A Study of the Acute and Chronic Effects of Electroconvulsive Therapy on Glutamatergic Neurotransmission in Bipolar Depression|Withdrawn|||0|Actual|Mclean Hospital|||1|Due to a lack of participants, this study has been closed.|f||||f||||||||||2018-05-31 21:32:32.082407|2018-05-31 21:32:32.082407
NCT01557920|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2015-04-12||2016-08-01|2012-03-16|2012-03-20|Estimate|2016-03-21|2016-04-21|Estimate||||2016-08-01|2016-09-13|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||The Effects of General Anesthetics on Upper Airway Collapsibility in Healthy Subjects|The Effects of Sevoflurane, Propofol, and Carbon Dioxide 'Reversal' on Upper Airway Collapsibility in Healthy, Adult Subjects|Completed||Phase 4|18|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:32:32.163752|2018-05-31 21:32:32.163752
NCT01557907|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-07-25|2012-03-16|2012-03-20|Estimate|||||||2012-07-25|2012-07-26|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion|Multi-day (3) In-patient Evaluation of Intradermal vs Subcutaneous Basal/Bolus Insulin Infusion|Completed||Phase 1/Phase 2|23|Actual|Becton, Dickinson and Company||2|||f||||f||||||||||2018-05-31 21:32:32.473129|2018-05-31 21:32:32.473129
NCT01557894|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2013-10-09||2014-09-05|2012-03-16|2012-03-20|Estimate|2014-07-17|2014-08-12|Estimate||||2014-09-05|2014-09-17|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|iSOFIE-Ro||Internet Treatment for Social Phobia in Romania|Internet Treatment for Social Phobia in Romania: A Randomized Controlled Trial|Completed||N/A|76|Actual|Babes-Bolyai University|1) An active control condition matched for clients’ expectations, time, and therapist involvement was not included, 2)Due to personnel constrains, post-intervention SCID interviews were not blinded regarding the study conditions etc.|2|||f||||f||||||||||2018-05-31 21:32:32.565355|2018-05-31 21:32:32.565355
NCT01557881|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-08-12|2012-03-19|2012-03-20|Estimate|||||||2015-08-12|2015-08-14|Estimate|February 2012||2012-02-29|August 2015|2015-08-31||||April 2015|Actual|2015-04-30||Interventional|||Positron Emission Tomography/Magnetic Resonance Imaging in Patients|Evaluating Attenuation Correction Methods Applied to PET/MRI|Terminated||N/A|98|Actual|Case Comprehensive Cancer Center||1||Funding unavailable|f||||t||||||||||2018-05-31 21:32:32.972698|2018-05-31 21:32:32.972698
NCT01557868|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2014-01-07||2014-02-19|2012-03-16|2012-03-20|Estimate|2014-02-19|2014-04-02|Estimate||||2014-02-19|2014-04-02|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis|Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis|Completed||Phase 4|198|Actual|American Orthopaedic Society for Sports Medicine||2|||f||||f||||||||||2018-05-31 21:32:33.070443|2018-05-31 21:32:33.070443
NCT01557855|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-02-21|2012-03-19|2012-03-20|Estimate|||||||2018-02-21|2018-02-23|Actual|April 2012||2012-04-30|February 2018|2018-02-28|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|REGISTRY-I||Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease|Enhanced Assessment of Chest Pain and Related Symptoms in the Primary Care Setting Through the Use of a Novel Personalized Medicine Genomic Test: Results From a Prospective Registry Study.|Completed|||342|Actual|CardioDx|||||f||||f||||||||||2018-05-31 21:32:33.378923|2018-05-31 21:32:33.378923
NCT01557842|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2014-12-19||2017-05-13|2012-03-19|2012-03-20|Estimate|2014-12-19|2015-01-01|Estimate||||2017-05-13|2017-06-08|Actual|June 1, 2012|Actual|2012-06-01|May 2017|2017-05-31|March 19, 2014|Actual|2014-03-19|March 19, 2014|Actual|2014-03-19||Interventional|ASPIRE|All enrolled subjects|Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators|Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators|Terminated||Phase 4|15|Actual|Biosense Webster, Inc.|Please note that this study was terminated early and only 15 subjects were enrolled. As a result the reported results might be unreliable (unmonitored) and limited.|2|||f||||f||||||||||2018-05-31 21:32:33.492692|2018-05-31 21:32:33.492692
NCT01557829|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-04-03|2012-03-19|2012-03-20|Estimate|||||||2017-04-03|2017-04-04|Actual|February 2012||2012-02-29|April 2017|2017-04-30|March 2017|Actual|2017-03-31|January 2016|Actual|2016-01-31||Interventional|SNAP||Valeo OL Interbody Fusion Devices for Posterior Lumbar Interbody Fusion SNAP Trial|Clinical Study of the Amedica Corporation Valeo OL Interbody Fusion Devices for Posterior Lumbar Interbody Fusion|Completed||N/A|100|Actual|Amedica Corporation||2|||f||||t||||||||No||2018-05-31 21:32:33.93202|2018-05-31 21:32:33.93202
NCT01557816|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-03-21|2012-03-19|2012-03-20|Estimate|||||||2012-03-21|2012-03-22|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee|A Randomized, Double-Blind, Placebo-controlled Cross-over, Exploratory Trial of Naproxen to Evaluate Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee|Unknown status|Recruiting|N/A|70|Anticipated|Analgesic Solutions||2|||f||||t||||||||||2018-05-31 21:32:34.02617|2018-05-31 21:32:34.02617
NCT01557803|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-01-13|2012-03-19|2012-03-20|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Observational|IRIS||Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome|Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome in Lambaréné, Gabon|Completed|||107|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples Without DNA|"~     Plasma, Paxgene RNA tubes and urine~   "|||2018-05-31 21:32:34.133645|2018-05-31 21:32:34.133645
NCT01557790|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2016-09-23|2012-03-19|2012-03-20|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2012||2012-03-31|July 2016|2016-07-31||||February 2015|Actual|2015-02-28||Interventional|||Proton Radiotherapy for Stage I, IIA, and IIB Seminoma|A Phase II Study of Adjuvant Proton Radiation Therapy for the Treatment of Stage I, IIA and IIB Seminoma|Active, not recruiting||Phase 2|5|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:32:34.205621|2018-05-31 21:32:34.205621
NCT01557777|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16||2014-07-02|2014-07-02|2012-03-16|2012-03-20|Estimate||||2014-07-02|2014-07-04|Estimate|2014-07-02|2014-07-04|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)|An Extension Study of Navitoclax (ABT-263) in Subjects With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|17|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:32:34.273619|2018-05-31 21:32:34.273619
NCT01557764|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2013-07-02|2012-03-15|2012-03-19|Estimate|||||||2013-07-02|2013-07-04|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer|A Phase II Study of Lapatinib in Combination With Trastuzumab in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 21:32:34.389978|2018-05-31 21:32:34.389978
NCT01557751|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2018-02-19||2018-04-25|2012-03-16|2012-03-19|Estimate|2018-04-25|2018-05-24|Actual||||2018-04-25|2018-05-24|Actual|February 2010||2010-02-28|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|December 2016|Actual|2016-12-31||Interventional|||Acute Pain Genomic Study|Preliminary Studies for Whole Genome Association Study (WGAS) in Acute Perioperative Pain|Active, not recruiting||N/A|156|Actual|University of Pittsburgh||1|||f||||t||||||||Undecided||2018-05-31 21:32:34.468945|2018-05-31 21:32:34.468945
NCT01557738|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-06-24|2012-03-15|2012-03-19|Estimate|||||||2014-06-24|2014-06-25|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Role of Flavanols in Exercise and Aging|Acute and Long-term Effects of Dietary Flavanols on Local Control of Skeletal Muscle Blood Flow During Exercise in Young and Old Humans|Completed||N/A|20|Actual|University of Texas at Austin||4|||f||||f||||||||||2018-05-31 21:32:34.602633|2018-05-31 21:32:34.602633
NCT01557725|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-12-14|2012-03-16|2012-03-19|Estimate|||||||2015-12-14|2015-12-15|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|FETA||Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty.|Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty|Completed|||4924|Actual|Rigshospitalet, Denmark|||1||f||||t||||||||||2018-05-31 21:32:34.751945|2018-05-31 21:32:34.751945
NCT01557712|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-02-23|2012-03-16|2012-03-19|Estimate|||||||2017-02-23|2017-02-24|Actual|March 2012|Actual|2012-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|KETADEP||Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks|Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks.|Completed||Phase 3|25|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 21:32:34.833849|2018-05-31 21:32:34.833849
NCT01553682|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-06-24|2012-03-12|2012-03-14|Estimate|||||||2015-06-24|2015-06-25|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Project N-Liten- HIV Prevention for African American Women|Reducing Alcohol-Related HIV Risk in African American Females|Completed||N/A|560|Actual|Emory University||3|||f||||f||||||||||2018-05-31 21:33:30.348869|2018-05-31 21:33:30.348869
NCT01557699|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2014-06-14||2018-03-13|2012-03-16|2012-03-19|Estimate|2014-11-22|2014-12-01|Estimate||||2018-03-13|2018-03-14|Actual|March 2012||2012-03-31|March 2018|2018-03-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|PMV-001|60 healthy adult males of 18 to 45 years|A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices|An Open-Label, Randomized, Phase I Study in Healthy Male Adults to Evaluate the Safety of a Measles Vaccine (Dry Powder)Administered by Two Devices|Completed||Phase 1|60|Actual|Serum Institute of India Pvt. Ltd.||3|||f||||f||||||||||2018-05-31 21:32:34.929717|2018-05-31 21:32:34.929717
NCT01557686|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-16|2012-03-16|2012-03-19|Estimate|||||||2012-03-16|2012-03-19|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|PACE-AL||Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study|Patient Activation Through Counseling and Exercise - Acute Leukemia - Pilot Trial|Completed||Early Phase 1|20|Actual|Universitetshospitalernes Center for Sygepleje|||||f||||t||||||||||2018-05-31 21:32:35.375572|2018-05-31 21:32:35.375572
NCT01557673|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2013-05-03|2012-03-15|2012-03-19|Estimate|||||||2013-05-03|2013-05-06|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Bolus and Continuous Nasogastric Feeding on Small Bowel Water Content and Blood Flow|Effects of Bolus and Continuous Nasogastric Feeding on Small Bowel Water Content and Blood Flow|Completed||Phase 1/Phase 2|12|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 21:32:35.45894|2018-05-31 21:32:35.45894
NCT01557660|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-03-23|2012-03-15|2012-03-19|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2012||2012-06-30|March 2012|2012-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|INTREPID - OL||Inhaled Treprostinil for PAH: Open-label Extension|Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study|Withdrawn||Phase 3|0|Actual|United Therapeutics||1|||f||||t||||||||||2018-05-31 21:32:35.548976|2018-05-31 21:32:35.548976
NCT01557647|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-03-23|2012-03-15|2012-03-19|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2012||2012-06-30|March 2012|2012-03-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|INTREPID||Safety and Efficacy of Inhaled Treprostinil in Patients With PAH|Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil.|Withdrawn||Phase 3|0|Actual|United Therapeutics||2|||f||||t||||||||||2018-05-31 21:32:35.613002|2018-05-31 21:32:35.613002
NCT01557634|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2013-04-01|2012-03-15|2012-03-19|Estimate|||||||2013-04-01|2013-04-04|Estimate|December 2012||2012-12-31|March 2012|2012-03-31||||December 2013|Anticipated|2013-12-31||Interventional|||Closing the Loop in Young Children With Type 1 Diabetes|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of Overnight Closed-loop Insulin Delivery Using Diluted Insulin in Comparison With Closed-loop With Non-diluted Insulin in Children With Type 1 Diabetes Aged 2 to 6 Years|Unknown status|Recruiting|Phase 2|12|Anticipated|University of Cambridge||2|||f||||f||||||||||2018-05-31 21:32:35.686185|2018-05-31 21:32:35.686185
NCT01557621|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-12-15|2012-03-16|2012-03-19|Estimate|||||||2015-12-15|2015-12-16|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparative Effectiveness Trial of Two Reminder/Recall Methods to Increase Immunization Rates in Young Children|Center for Research in Implementation Science and Prevention (CRISP): Project 1: Comparative Effectiveness Trial of Two Reminder/Recall Methods to Increase Immunization Rates in Young Children|Completed||N/A|68000|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 21:32:35.792931|2018-05-31 21:32:35.792931
NCT01557608|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2016-03-29|2012-03-15|2012-03-19|Estimate|||||||2016-03-29|2016-03-31|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|CIN||Characterization and Treatment of Chemotherapy Neuropathy|Characterization of and Treatment for Chemotherapy-Induced Neuropathy|Unknown status|Active, not recruiting|Phase 2|131|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:32:35.889664|2018-05-31 21:32:35.889664
NCT01557595|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2014-04-08||2017-12-12|2012-03-15|2012-03-19|Estimate|2014-09-05|2014-09-12|Estimate||||2017-12-12|2017-12-13|Actual|September 2011||2011-09-30|December 2017|2017-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ADHD||Blue Wavelength Light-blocking Glasses in ADHD-Insomnia|Evening Use of Polarized Glasses Designed to Filter Out Blue Light in Attention Deficit Hyperactivity Disorder - Delayed Circadian Rhythm Disorder Patients|Completed||N/A|22|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 21:32:35.980981|2018-05-31 21:32:35.980981
NCT01557582|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2015-03-25||2015-03-25|2012-03-16|2012-03-19|Estimate|2015-03-25|2015-03-27|Estimate||||2015-03-25|2015-03-27|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional||Demographic information was not available for 2 patients. One subject failed to disclose metal in his abdomen and the other was due to user error.|Assessmet of Patients With PAH Right Ventricular Volume|Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Pulmonary Arterial Hypertension|Completed||N/A|103|Actual|VentriPoint Diagnostics Ltd.||1|||f||||f||||||||||2018-05-31 21:32:36.182796|2018-05-31 21:32:36.182796
NCT01557569|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2016-10-24||2016-12-16|2012-03-16|2012-03-19|Estimate|2016-10-24|2016-12-16|Estimate||||2016-12-16|2017-02-09|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|ATM|those that received at least one dose of study medication|Clinical Efficacy of Atomoxetine for Methamphetamine Dependence||Completed||Phase 1/Phase 2|20|Actual|University of Arkansas|Recruitment and retention was much more difficult than anticipated. Because of, this too few (3 in ATM and 1 in PLA) were retained through the residential stay to determine efficacy.|2|||f||||t||||||||||2018-05-31 21:32:36.494722|2018-05-31 21:32:36.494722
NCT01557556|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-05-10|2012-03-16|2012-03-19|Estimate|||||||2018-05-10|2018-05-11|Actual|February 24, 2012||2012-02-24|December 16, 2013|2013-12-16|December 16, 2013||2013-12-16|||||Observational|||Pexacerfont to Reduce Stress-induced Tobacco Craving|Pexacerfont for Reduction of Stress-induced Tobacco Craving, Nicotine Reinforcement, and Brain Activation in Humans|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:32:36.753919|2018-05-31 21:32:36.753919
NCT01557543|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-04-03|2012-03-16|2012-03-19|Estimate|||||||2018-04-03|2018-04-04|Actual|February 29, 2012||2012-02-29|March 27, 2018|2018-03-27|December 30, 2020|Anticipated|2020-12-30|July 25, 2017|Actual|2017-07-25||Interventional|||Stem Cell Injection to Treat Heart Damage During Open Heart Surgery|Preliminary Assessment of Direct Intra-Myocardial Injection of Autologous Bone Marrow-derived Stromal Cells on Patients Undergoing Revascularization for CAD With Depressed Left Ventricular Function|Active, not recruiting||Phase 1|24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:32:36.825329|2018-05-31 21:32:36.825329
NCT01557517|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-10-18|2012-03-16|2012-03-19|Estimate|||||||2017-10-18|2017-10-19|Actual|January 26, 2012||2012-01-26|August 24, 2017|2017-08-24|August 24, 2017|Actual|2017-08-24|June 9, 2017|Actual|2017-06-09||Interventional|||Clobetasol for Oral Graft-Versus-Host Disease|A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host-Disease|Completed||Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:32:36.893461|2018-05-31 21:32:36.893461
NCT01557504|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|2015-04-06||2017-04-06|2012-03-16|2012-03-19|Estimate|2015-05-06|2015-05-22|Estimate||||2017-04-06|2017-05-12|Actual|July 18, 2012|Actual|2012-07-18|April 2017|2017-04-30|April 29, 2014|Actual|2014-04-29|April 29, 2014|Actual|2014-04-29||Interventional|||A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)|A Study to Assess the Pharmacokinetics and the Ability for Pediatric Patients With Type 2 Diabetes to Swallow MK-0431A XR Tablets|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:32:37.002937|2018-05-31 21:32:37.002937
NCT01557491|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-16|2012-03-16|2012-03-19|Estimate|||||||2012-03-16|2012-03-19|Estimate|May 2012||2012-05-31|March 2012|2012-03-31||||November 2013|Anticipated|2013-11-30||Interventional|||Hair Regrowth After Bicoronal Incision|A Randomized Blinded Comparison of Hair Growth Following Either Bevelled or Standard Bi-coronal Scalp Incisions.|Unknown status|Not yet recruiting|N/A|26|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||||||||||||2018-05-31 21:32:37.494294|2018-05-31 21:32:37.494294
NCT01557478|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-01-06|2012-03-16|2012-03-19|Estimate|||||||2015-01-06|2015-01-08|Estimate|March 2012||2012-03-31|January 2015|2015-01-31||||September 2016|Anticipated|2016-09-30||Interventional|MIQOL-B||Melatonin as Adjuvant Therapy in Breast Cancer Patients|Melatonin in Improving the Quality of Life of Breast Cancer Patients and Reduction of Postoperative Pain and Chemotherapy Induced Toxicity|Unknown status|Active, not recruiting|Phase 2/Phase 3|166|Actual|Khon Kaen University||2|||f||||f||||||||||2018-05-31 21:32:37.587609|2018-05-31 21:32:37.587609
NCT01557465|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2015-04-06|2012-03-16|2012-03-19|Estimate|||||||2015-04-06|2015-04-08|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|MAS||Mechanical Alternans Study|Study of Mechanical Alternans for Prediction of Ventricular Tachyarrhythmias|Completed|||134|Actual|Johns Hopkins University|||||f||||f||||||||||2018-05-31 21:32:37.676573|2018-05-31 21:32:37.676573
NCT01557452|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-02-26|2012-03-16|2012-03-19|Estimate|||||||2014-02-26|2014-02-27|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis (JIA)|An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Polyarticular Course Juvenile Idiopathic Arthritis (Poly JIA) JIA|Terminated||N/A|1|Actual|Italfarmaco||1||"Previous study DSC/08/2357/36 did not show efficacy for Givinostat in JIA. Decision wasn't~   related to any tolerability concerns"|f||||f||||||||||2018-05-31 21:32:37.734617|2018-05-31 21:32:37.734617
NCT01557439|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-11-30|2012-03-16|2012-03-19|Estimate|||||||2012-11-30|2012-12-03|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Levocetirizine Dihydrochloride 5 mg Tablets With Xyzal® 5 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fasting Condition|Completed||Phase 1|28|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:32:37.805395|2018-05-31 21:32:37.805395
NCT01557426|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-04-28|2012-03-15|2012-03-19|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Soft Tissue Ultrasound of Infections|Soft Tissue Ultrasound of Infections|Completed||Phase 1|15|Actual|Rhode Island Hospital||1|||f||||f||||||||||2018-05-31 21:32:37.883404|2018-05-31 21:32:37.883404
NCT01557413|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-02-20|2012-03-16|2012-03-19|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2012|Actual|2012-02-29|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|HUMERUS||Randomised Study Between Intramedullary Locking Nails and Locking Plates for Treatment of Proximal Humerus Fractures|Randomised Study Between Intramedullary Locking Nails and Locking Plates for Treatment of Proximal Humerus Fractures in Patients After 40-year-old|Completed||N/A|80|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 21:32:37.990057|2018-05-31 21:32:37.990057
NCT01557400|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2018-01-16|2012-03-15|2012-03-19|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2012||2012-05-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and Canada|An Open-Label Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy|Active, not recruiting||Phase 3|95|Actual|PTC Therapeutics||1|||f||||f||||||||No||2018-05-31 21:32:38.092043|2018-05-31 21:32:38.092043
NCT01557387|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2014-12-27|2012-03-16|2012-03-19|Estimate|||||||2014-12-27|2014-12-30|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Real-time Diagnosis of Pseudopolyps During Colonoscopy|Real-time Diagnosis of Pseudopolyps During Colonoscopy Using Noninvasive Advanced Endoscopic Techniques - a Prospective Study|Completed|||75|Actual|University of Miami|||1||f||||f||||||||||2018-05-31 21:32:38.199525|2018-05-31 21:32:38.199525
NCT01557374|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-04-25|2012-03-16|2012-03-19|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2012||2012-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TOLEDO||TOward the Lowest Effective DOse of Abatacept or Tocilizumab|Tapering Abatacept or Tocilizumab in Rheumatoid Arthritis in Remission. An Evaluation of Disease Activity, Relapse Risk, Structural Progression and the Economic Impact of a Tapering Strategy|Active, not recruiting||Phase 4|232|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 21:32:38.277924|2018-05-31 21:32:38.277924
NCT01557361|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2014-09-11|2012-03-15|2012-03-19|Estimate|||||||2014-09-11|2014-09-12|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|STARRT-AKI||Standard Versus Accelerated Initiation of Dialysis in Acute Kidney Injury|STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI)|Completed||Phase 2|100|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 21:32:38.36841|2018-05-31 21:32:38.36841
NCT01557192|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-04-12|2012-03-15|2012-03-19|Estimate|||||||2016-04-12|2016-04-13|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|LFMS6tx||Low Field Magnetic Stimulation (LFMS) in Mood Disorders: 6 Treatments|Low Field Magnetic Stimulation in Mood Disorders in Six Visits|Suspended||Phase 1|200|Anticipated|Mclean Hospital||2||on hold indefinitely due to lack of funding|f||||f||||||||||2018-05-31 21:32:44.010455|2018-05-31 21:32:44.010455
NCT01557348|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2016-11-28||2016-11-28|2012-03-16|2012-03-19|Estimate|2016-11-28|2017-01-24|Estimate||||2016-11-28|2017-01-24|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||The primary effectiveness population included all participants who received at least one dose of a second biologic therapy at baseline (day of change in biologic therapy [<=Day 1]), had only one previous biologic therapy, and contributed for 24-week disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) for primary analysis.|An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor|A Global Multi-centre Observational Study in RA Patients Who Are Non Responders or Intolerant to a Single TNF Inhibitor.|Completed|||1239|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 21:32:38.517553|2018-05-31 21:32:38.517553
NCT01557335|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-15|2012-03-15|2012-03-19|Estimate|||||||2012-03-15|2012-03-19|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540|A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers|Completed||Phase 1|30|Actual|POZEN||2|||f||||f||||||||||2018-05-31 21:32:39.942117|2018-05-31 21:32:39.942117
NCT01557322|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2013-08-26||2013-08-26|2012-03-15|2012-03-19|Estimate|2013-08-26|2013-10-31|Estimate||||2013-08-26|2013-10-31|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)|Evaluation of the Clinical Characteristics, Real-world Treatment Pathways, and Outcomes of Patients With Moderate Rheumatoid Arthritis|Completed|||1754|Actual|Pfizer|Since this study was a retrospective registry analysis of de-identified participants’ data, only SAEs pre specified in analysis were reported with preferred terms and all other SAEs were reported under the preferred term Other Serious Event.||2||f||||f||||||||||2018-05-31 21:32:40.121647|2018-05-31 21:32:40.121647
NCT01557309|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-08-16|2012-03-16|2012-03-19|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Observational|||Clinical and Structural Outcome After Early Repair of the Traumatic Rotator Cuff Tear|Arthroscopic Repair of Traumatic Rotator Cuff Tears. A Prospective Trial|Completed|||60|Actual|Helsingborgs Hospital|||||f||||||||||Samples Without DNA|"~     Peroperatively retained rotator cuff biopsy.~   "|||2018-05-31 21:32:42.567549|2018-05-31 21:32:42.567549
NCT01557296|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2018-02-20|2012-03-16|2012-03-19|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2007||2007-09-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis|Comparing Treatment With Food of Small Particle Size and Food of Large Particle Size in Subjects With Diabetic Gastroparesis. Evaluation of Diagnostic Methods. Determination of the Motility of Gastric Emptying After Intervention|Recruiting||Phase 2|50|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 21:32:42.748759|2018-05-31 21:32:42.748759
NCT01557283|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2014-05-28||2014-05-28|2012-03-15|2012-03-19|Estimate|2014-05-28|2014-06-30|Estimate||||2014-05-28|2014-06-30|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|BEFLEX|Per protocol (PP) population included participants who completed at least 1 treatment cycle, for whom study conclusion was duly filled in, and who had not deviated from protocol.|An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria|An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria - Beflex Study|Completed|||140|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:32:42.865094|2018-05-31 21:32:42.865094
NCT01557270|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-12-03|2012-03-15|2012-03-19|Estimate|||||||2012-12-03|2012-12-04|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery|The Efficacy and Safety of Dexmedetomidine as an Additive to Ropivacaine for Interscalene Brachial Plexus Blocks for Shoulder Surgery|Completed||Phase 3|62|Actual|Paracelsus Medical University||2|||f||||t||||||||||2018-05-31 21:32:43.133074|2018-05-31 21:32:43.133074
NCT01557257|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-06-26|2012-03-15|2012-03-19|Estimate|||||||2012-06-26|2012-06-28|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pharmacokinetics Study of ALO-02 and OxyContin|An Open-label, Single-dose and Multiple-dose, Randomized, Crossover Study to Evaluate Pharmacokinetics, Safety and Tolerability After Administration of ALO-02 40 Mg Twice Daily Compared to ALO-02 80 Mg Once Daily and to Oxycontin 40 Mg Twice Daily in Healthy Volunteers|Completed||Phase 1|13|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:32:43.30831|2018-05-31 21:32:43.30831
NCT01557244|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2018-05-14|2012-03-15|2012-03-19|Estimate|||||||2018-05-14|2018-05-16|Actual|July 2, 2012|Actual|2012-07-02|May 2018|2018-05-31|November 13, 2019|Anticipated|2019-11-13|November 13, 2019|Anticipated|2019-11-13||Interventional|||A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition|A 24-week Randomized, Open-label, Study To Evaluate The Safety And Efficacy Of Fesoterodine In Subjects Aged 6 To 17 Years With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity)|Recruiting||Phase 3|192|Anticipated|Pfizer||5|||f||||t|t|f||||||||2018-05-31 21:32:43.462249|2018-05-31 21:32:43.462249
NCT01557231|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2018-03-27|2012-03-15|2012-03-19|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2012||2012-03-31|March 2018|2018-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Epidemiology of Osteoarthritis (OA) Pain|Epidemiology of OA Pain|Completed|||86|Actual|Northwestern University|||1||f||||f||||||||||2018-05-31 21:32:43.79835|2018-05-31 21:32:43.79835
NCT01557218|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2013-02-14|2012-03-15|2012-03-19|Estimate|||||||2013-02-14|2013-02-15|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Increasing the Variety of Vegetables and Fruits Served to Preschool Children at a Snack||Completed||N/A|61|Actual|Penn State University||8|||f||||f||||||||||2018-05-31 21:32:43.872342|2018-05-31 21:32:43.872342
NCT01557205|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-16|2012-03-16|2012-03-19|Estimate|||||||2012-03-16|2012-03-19|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Research and System Development on Functional 3D Optical Tomography for Skin Cell Imaging|Research and System Development on Functional 3D Optical Tomography for Skin Cell Imaging|Unknown status|Not yet recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||f||||||None Retained|"~     No biospecimen to be retained.~   "|||2018-05-31 21:32:43.96327|2018-05-31 21:32:43.96327
NCT01557179|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-03-16|2012-03-16|2012-03-19|Estimate|||||||2012-03-16|2012-03-19|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness|Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness. A Multicenter, Randomized, Controlled, Open-label, Parallel-group, Clinical Trial|Completed||Phase 2|144|Actual|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 21:32:44.088554|2018-05-31 21:32:44.088554
NCT01557166|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2015-01-22|2014-06-10|2017-09-29|2012-03-15|2012-03-19|Estimate|2015-01-22|2015-02-09|Estimate|2014-06-10|2014-06-19|Estimate|2017-09-29|2017-11-01|Actual|June 7, 2012|Actual|2012-06-07|September 2017|2017-09-30|June 17, 2013|Actual|2013-06-17|June 1, 2013|Actual|2013-06-01||Interventional|||Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea|Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial|Completed||Phase 3|359|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:32:44.17999|2018-05-31 21:32:44.17999
NCT01557153|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-16|2012-03-16|2012-03-19|Estimate|||||||2012-03-16|2012-03-19|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|VALUeD||Vascular Augmentation of Late-life Unremitted Depression (VALUeD)|Vascular Augmentation of Late-life Unremitted Depression (VALUeD)|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Gateshead Health NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:32:44.887939|2018-05-31 21:32:44.887939
NCT01557140|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-08-10|2012-03-16|2012-03-19|Estimate|||||||2015-08-10|2015-08-13|Estimate|May 2003||2003-05-31|August 2015|2015-08-31|December 2006|Actual|2006-12-31|March 2004|Actual|2004-03-31||Interventional|||A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy|A Randomized Trial of Carvedilol After Renin-angiotensin System Inhibition in Chronic Chagas Cardiomyopathy|Completed||Phase 4|42|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 21:32:45.00392|2018-05-31 21:32:45.00392
NCT01557127|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2017-03-24|2012-03-16|2012-03-19|Estimate|||||||2017-03-24|2017-03-28|Actual|November 1, 2011|Actual|2011-11-01|March 2017|2017-03-31|March 31, 2016|Actual|2016-03-31|May 16, 2014|Actual|2014-05-16||Observational|NEXST||"Nexavar Dosing in Renal Cancer Patients in Real-life Setting"|Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma|Completed|||205|Actual|Bayer|||1||f||||f||||||||No||2018-05-31 21:32:45.104423|2018-05-31 21:32:45.104423
NCT01557114|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-06-08|2012-03-16|2012-03-19|Estimate|||||||2016-06-08|2016-06-09|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|Mel-Ipi-Rx||Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma|A Dose Escalation Phase I Study of Radiotherapy Administered in Combination With Anti-CTLA4 Monoclonal Antibody (Ipilimumab) in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma|Terminated||Phase 1|19|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1||New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab|f||||t||||||||||2018-05-31 21:32:45.188582|2018-05-31 21:32:45.188582
NCT01557101|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2014-01-08|2012-03-15|2012-03-19|Estimate|||||||2014-01-08|2014-01-09|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|CRIBADO||Comparison Colon Capsule Endoscopy vs Optical Colonoscopy for Colorectal Cancer Screening in Familiar-Risk Population|Effectiveness of Colon Capsule Endoscopy as Colorectal Cancer Method of Screening in The Familiar-Risk Population|Completed||Phase 4|200|Actual|Hospital Universitario de Canarias||2|||f||||f||||||||||2018-05-31 21:32:45.272214|2018-05-31 21:32:45.272214
NCT01557088|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-09-22|2012-03-16|2012-03-19|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AIM 1 and II||Lp-PLA2 and Coronary Atherosclerosis in Humans|Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans|Completed||N/A|166|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 21:32:45.345505|2018-05-31 21:32:45.345505
NCT01557075|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-16|2012-03-16|2012-03-19|Estimate|||||||2012-03-16|2012-03-19|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|statin||Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation|Effects of High-dose Statin Treatments on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Drug-eluting Stents Implantation: a Randomized Controlled Study|Unknown status|Recruiting|Phase 4|2000|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 21:32:45.413222|2018-05-31 21:32:45.413222
NCT01557062|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-03-15|2012-03-15|2012-03-19|Estimate|||||||2012-03-15|2012-03-19|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Passive Body Heating, Sleep and Fibromyalgia|Passive Body Heating Improves The Sleep Pattern In Women Patients Fibromyalgia|Completed||N/A|25|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 21:32:45.513006|2018-05-31 21:32:45.513006
NCT01557049|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-15|2012-03-15|2012-03-19|Estimate|||||||2012-03-15|2012-03-19|Estimate|June 2008||2008-06-30|April 2010|2010-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|GPR||Global Postural Reeducation in Chronic Low Back Pain|Global Postural Reeducation in Chronic Low Back Pain: an Randomized Controlled Trial|Completed||N/A|61|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:32:45.603401|2018-05-31 21:32:45.603401
NCT01557036|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-01-19|2012-03-15|2012-03-19|Estimate|||||||2015-01-19|2015-01-21|Estimate|May 2012||2012-05-31|January 2015|2015-01-31||||May 2014|Actual|2014-05-31||Observational|ASPIRE||Aneurysm Study of Pipeline in an Observational Registry|Aneurysm Study of Pipeline in an Observational Registry|Terminated|||200|Actual|ev3|||1||f||||t||||||||||2018-05-31 21:32:45.68502|2018-05-31 21:32:45.68502
NCT01557023|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-09-19|2012-03-16|2012-03-19|Estimate|||||||2017-09-19|2017-09-21|Actual|July 1, 2013|Anticipated|2013-07-01|March 2012|2012-03-31|December 1, 2014|Anticipated|2014-12-01|December 1, 2014|Anticipated|2014-12-01||Interventional|||Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol||Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||2||Change Company strategy|f||||t||||||||||2018-05-31 21:32:45.7934|2018-05-31 21:32:45.7934
NCT01557010|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-02-19|2012-03-15|2012-03-19|Estimate|||||||2014-02-19|2014-02-21|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia|The Clinical Trial for Evaluation of Efficacy and Safety of DWP05195 in Postherpetic Neuralgia: Double-blind, Placebo-controlled, Randomized, Multi-center, Exploratory Clinical Trial|Completed||Phase 2|140|Actual|Daewoong Pharmaceutical Co. LTD.||4|||f||||||||||||||2018-05-31 21:32:45.860246|2018-05-31 21:32:45.860246
NCT01556997|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2015-07-28||2015-09-08|2012-03-15|2012-03-19|Estimate|2015-07-28|2015-08-25|Estimate||||2015-09-08|2015-09-28|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PATH||Perindopril Amlodipine for the Treatment of Hypertension|Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension|Completed||Phase 3|837|Actual|Symplmed Pharmaceuticals LLC||3|||f||||f||||||||||2018-05-31 21:32:45.942198|2018-05-31 21:32:45.942198
NCT01556984|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-06-12|2012-03-16|2012-03-19|Estimate|||||||2015-06-12|2015-06-16|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Observational|||Changes of Endothelial Function Before and After DSA in Patients With Diabetes|Changes of Endothelial Function Before and After DSA in Patients With Diabetes|Completed|||200|Anticipated|Wuhan General Hospital of Guangzhou Military Command|||2||f||||||||||||||2018-05-31 21:32:46.589417|2018-05-31 21:32:46.589417
NCT01556971|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-15|2012-03-15|2012-03-19|Estimate|||||||2012-03-15|2012-03-19|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Efficacy Study of Botox for Depression|A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD)|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Capital Clinical Research Associates, LLC||2|||f||||f||||||||||2018-05-31 21:32:46.661803|2018-05-31 21:32:46.661803
NCT01556958|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2013-08-16|2012-03-16|2012-03-19|Estimate|||||||2013-08-16|2013-08-19|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||WheezoMeter® Correlation Study|Prospective Comparative Study of WheezeRATE™ (Wz%) Readings With Spirometry, Symptoms, and Auscultatory Findings in Children With Wheezing.|Terminated|||19|Actual|iSonea|||3|Device revised|f||||||||||||||2018-05-31 21:32:46.748822|2018-05-31 21:32:46.748822
NCT01556945|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-05-01|2012-03-16|2012-03-19|Estimate|||||||2014-05-01|2014-05-02|Estimate|April 2001||2001-04-30|May 2014|2014-05-31||||February 2002|Actual|2002-02-28||Interventional|MAL019||Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S|Phase I/IIa Safety, Immunogenicity, and Preliminary Efficacy of an Administration Schedule of FMP1 and SmithKlineBeecham Biologicals' Candidate Malaria Vaccine RTS,S Each Adjuvanted With SBAS2, Given Concomitantly in Separate Injections|Completed||Phase 1/Phase 2|72|Actual|U.S. Army Medical Research and Materiel Command||5|||f||||f||||||||||2018-05-31 21:32:46.812404|2018-05-31 21:32:46.812404
NCT01556932|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2015-03-03||2015-10-15|2012-03-16|2012-03-19|Estimate|2015-10-15|2015-10-16|Estimate||||2015-10-15|2015-10-16|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional||Patients who were eligible were randomly assigned to two sequences: one group used ABH gel first and then the placebo; and the other group used the placebo first and then ABH gel. We assumed there was no carry-over effect from the first treatment to the second. In total, 22 patients were enrolled but 20 subjects completed the study.|"Randomized Trial of the Effectiveness of Topical ABH Gel vs. Placebo in Cancer Patients With Nausea"|"A Randomized Trial of the Effectiveness of Topical ABH Gel (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) Versus Placebo in Patients With Nausea"|Completed||N/A|22|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 21:32:46.908037|2018-05-31 21:32:46.908037
NCT01556919|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2017-11-29|2012-03-16|2012-03-19|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2012||2012-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Esophageal Monitoring Device for Assessing Mucosal Impedance|Development of an Esophageal Monitoring Device for the Assessment of Esophageal Epithelium Integrity With Mucosal Impedance|Recruiting|||750|Anticipated|Vanderbilt University Medical Center|||1||f||||f||f||||||||2018-05-31 21:32:47.281363|2018-05-31 21:32:47.281363
NCT01556906|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2013-01-18||2013-04-04|2012-03-16|2012-03-19|Estimate|2013-01-18|2013-02-22|Estimate||||2013-04-04|2013-04-10|Estimate|June 2003||2003-06-30|April 2013|2013-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor|A Phase II Open Label, Dose-Escalation Study to Determine the Safety, Tolerability and Efficacy of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor BMS-201038 in Patients With Homozygous Familial Hypercholeterolemia|Completed||Phase 2|6|Actual|Aegerion Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 21:32:47.398158|2018-05-31 21:32:47.398158
NCT01556893|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-10-23|2012-03-16|2012-03-19|Estimate|||||||2014-10-23|2014-10-27|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Creating LASIK Flaps With the LenSx Femtosecond Laser|Prospective, Single-center Clinical Trial of Subjects Scheduled to Undergo LASIK Surgery Requiring an Initial Corneal Flap.|Completed||Phase 1|20|Actual|Alcon LenSx, Inc.||1|||f||||f||||||||||2018-05-31 21:32:47.729998|2018-05-31 21:32:47.729998
NCT01556880|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-02-04|2012-03-15|2012-03-16|Estimate|||||||2014-02-04|2014-02-05|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|May 2010|Actual|2010-05-31||Interventional|||RCT of SMS for Drivers With Pre-DM|A Randomized Controlled Trial of Short Message Service by Cellular Phone for Professional Drivers With Pre-diabetes|Completed||N/A|104|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:32:47.790986|2018-05-31 21:32:47.790986
NCT01556867|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-08-05|2012-03-15|2012-03-16|Estimate|||||||2016-08-05|2016-08-08|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|NEOCORD||Evaluation of Two Strategies for Umbilical Cord Care : Dry Cord Care Versus Antiseptic on the Incidence of Omphalitis in Healthy Term Newborn|Evaluation of Two Strategies for Umbilical Cord Care : Dry Cord Care Versus Antiseptic on the Incidence of Omphalitis in Healthy Term Newborn|Terminated||N/A|8698|Actual|Nantes University Hospital||2|||f||||||||||||||2018-05-31 21:32:47.862349|2018-05-31 21:32:47.862349
NCT01556854|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-15|2012-03-15|2012-03-16|Estimate|||||||2012-03-15|2012-03-16|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|June 2014|Anticipated|2014-06-30|November 2013|Anticipated|2013-11-30||Observational|CER||Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke|Comparative Effectiveness of Different Neuroprotectants Among Patients With Acute Ischemic Stroke in Clinical Practice|Unknown status|Recruiting||20000|Anticipated|Ministry of Science and Technology of the People´s Republic of China|||||f||||||||||||||2018-05-31 21:32:47.937804|2018-05-31 21:32:47.937804
NCT01556841|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-12-14|2012-03-15|2012-03-16|Estimate|||||||2017-12-14|2017-12-15|Actual|November 2013||2013-11-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|TRIOC||The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer|A Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|97|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 21:32:48.003322|2018-05-31 21:32:48.003322
NCT01556828|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-06-22|2012-03-15|2012-03-16|Estimate|||||||2016-06-22|2016-06-24|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing|Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing|Terminated|||70|Actual|Stanford University|||||f||||t||||||Samples With DNA|"~     whole blood tissue~   "|||2018-05-31 21:32:48.104553|2018-05-31 21:32:48.104553
NCT01556815|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-04-24|2012-03-15|2012-03-16|Estimate|||||||2012-04-24|2012-04-25|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma|Phase II Trail of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||f||||||||||2018-05-31 21:32:48.239875|2018-05-31 21:32:48.239875
NCT01556802|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-15|2012-03-15|2012-03-16|Estimate|||||||2012-03-15|2012-03-16|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|January 2013|Anticipated|2013-01-31|November 2011|Actual|2011-11-30||Interventional|||Use of Minocicline in Patients With Stroke|Effect of Minocicline Use in Less Neurologic Sequels in Patients With Stroke|Unknown status|Recruiting|Phase 1|134|Anticipated|Hospital Universitario Hernando Moncaleano Perdomo||2|||f||||t||||||||||2018-05-31 21:32:48.320299|2018-05-31 21:32:48.320299
NCT01556789|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2018-05-14|2012-03-15|2012-03-16|Estimate|||||||2018-05-14|2018-05-17|Actual|March 2013||2013-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Phase 1 Study of ONT-10 in Patients With Solid Tumors|Phase 1 Study of ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients With Solid Tumors|Completed||Phase 1|85|Actual|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-05-31 21:32:48.402613|2018-05-31 21:32:48.402613
NCT01556776|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2018-05-09|2012-03-15|2012-03-16|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 20, 2012|Actual|2012-07-20|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|March 2016|Actual|2016-03-31||Interventional|||A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy|CLLM1-Protocol of the German CLL-Study Group (GCLLSG) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for High-risk Patients With Chronic Lymphocytic Leukemia Following First-line Therapy|Active, not recruiting||Phase 3|89|Actual|German CLL Study Group||2|||f||||t||||||||No||2018-05-31 21:32:48.4894|2018-05-31 21:32:48.4894
NCT01556763|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|2012-04-18||2012-05-21|2012-03-15|2012-03-16|Estimate|2012-05-21|2012-06-21|Estimate||||2012-05-21|2012-06-21|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia|A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics|Completed||Phase 1|21|Actual|FORUM Pharmaceuticals Inc||3|||f||||f||||||||||2018-05-31 21:32:48.594732|2018-05-31 21:32:48.594732
NCT01556750|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2013-02-27|2012-03-15|2012-03-16|Estimate|||||||2013-02-27|2013-03-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:32:49.189033|2018-05-31 21:32:49.189033
NCT01556737|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-10-30|2012-03-15|2012-03-16|Estimate|||||||2012-10-30|2012-10-31|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ISOII||Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women|Effect of Two Different Isoflavone Supplement Preparations on Gene-expression in Postmenopausal Women|Completed||N/A|72|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 21:32:49.231169|2018-05-31 21:32:49.231169
NCT01556724|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2016-03-23||2017-12-18|2012-03-15|2012-03-16|Estimate|2016-03-23|2016-04-25|Estimate||||2017-12-18|2018-01-17|Actual|January 2010||2010-01-31|December 2017|2017-12-31|December 2014|Actual|2014-12-31|May 2011|Actual|2011-05-31||Interventional|||A Comparison of Postoperative Analgesic Nerve Block Ropivacaine Concentrations|A Comparison of 0.1 and 0.2% Ropivacaine in Lumbar Plexus Catheters After Primary Total Hip Arthroplasty: a Comparison of Postoperative Analgesia and Motor Function.|Completed||N/A|41|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 21:32:49.328446|2018-05-31 21:32:49.328446
NCT01556711|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-12-07|2012-03-15|2012-03-16|Estimate|||||||2013-12-07|2013-12-10|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|B-AHEAD II||Assessment of Head Injury in the Emergency Department Using BrainScope® Ahead® Technology|Assessment of Head Injury in the Emergency Department: Clinical Validation of the BrainScope® Ahead™ Technology|Completed|||816|Actual|BrainScope Company, Inc.|||2||f||||f||||||||||2018-05-31 21:32:49.757969|2018-05-31 21:32:49.757969
NCT01556698|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-12-14|2012-03-15|2012-03-16|Estimate|||||||2017-12-14|2017-12-18|Actual|July 2011||2011-07-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris||Completed||Phase 1/Phase 2|||Novan, Inc.||2|||f||||||||||||||2018-05-31 21:32:49.8428|2018-05-31 21:32:49.8428
NCT01556685|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-09-12|2012-03-15|2012-03-16|Estimate|||||||2013-09-12|2013-09-16|Estimate|March 2011||2011-03-31|March 2012|2012-03-31||||October 2011|Actual|2011-10-31||Interventional|MATRIX||MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia|Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia|Completed||Phase 4|180|Actual|Biogen||2|||f||||f||||||||||2018-05-31 21:32:49.905628|2018-05-31 21:32:49.905628
NCT01556672|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2016-06-28|2012-03-15|2012-03-16|Estimate|||||||2016-06-28|2016-06-29|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Adalimumab-psoriasis and Small Bowel Lesions|Open-label Study on Small Bowel Lesions Suggestive of Crohn's Disease in Patients With Moderate to Severe Plaque Psoriasis Treated With Adalimumab|Completed||Phase 4|100|Actual|Innovaderm Research Inc.||1|||f||||f||||||||No||2018-05-31 21:32:49.987644|2018-05-31 21:32:49.987644
NCT01556659|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-19|2012-03-15|2012-03-16|Estimate|||||||2012-03-19|2012-03-20|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||LV Thrombus After Acute AMI: A Randomized Controlled Trial|Left Ventricular Thrombus Formation After Acute Myocardial Infarction - a Randomized Multi-center Trial Comparing Two Different Anti-thrombotic Regimens|Unknown status|Recruiting|N/A|250|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 21:32:50.098281|2018-05-31 21:32:50.098281
NCT01556646|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-02-06|2012-03-15|2012-03-16|Estimate|||||||2014-02-06|2014-02-07|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Tolvaptan on Cognitive Function in Cirrhosis|Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial|Completed||Phase 3|25|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||1|||f||||f||||||||||2018-05-31 21:32:50.177145|2018-05-31 21:32:50.177145
NCT01556633|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2015-11-30||2016-05-26|2012-03-15|2012-03-16|Estimate|2016-05-26|2016-07-07|Estimate||||2016-05-26|2016-07-07|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Safety population: All participants who received the study drug, whether prematurely withdrawn from the study or not, were included.|A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance|An Open Label, Prospective, Single Oral Dose Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Oseltamivir in Adult Subjects on Peritoneal Dialysis (PD) Using a Rapid Cycle Regimen to Simulate APD and in Adult Subjects With Creatinine Clearance From 10 to 30 mL/Min Not on Dialysis|Completed||Phase 1|16|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:32:50.274342|2018-05-31 21:32:50.274342
NCT01556620|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-03-15|2012-03-15|2012-03-16|Estimate|||||||2012-03-15|2012-03-16|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|NIRS||Is NIRS Able to Detect Ischemia Following Brain Insult|The New 4 Wavelengths EQUANOX NIRS Sensor: Correlation and Detection of Ischemic Episodes. An Observational Comparative Study Versus PtiO2|Completed|||8|Actual|Direction Centrale du Service de Santé des Armées|||||f||||f||||||||||2018-05-31 21:32:50.670457|2018-05-31 21:32:50.670457
NCT01556607|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-05-21|2012-03-15|2012-03-16|Estimate|||||||2012-05-21|2012-05-22|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma|A Double-Blind, Randomized, 3 Period Crossover, Single Ascending Dose Study to Assess the Safety, and Tolerability of Inhaled MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma|Completed||Phase 1|10|Anticipated|MicroDose Therapeutx, Inc||2|||f||||||||||||||2018-05-31 21:32:50.722431|2018-05-31 21:32:50.722431
NCT01556594|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|2013-03-18||2016-04-26|2012-03-15|2012-03-16|Estimate|2014-08-09|2014-08-13|Estimate||||2016-04-26|2016-05-25|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|AMG102|Healthy volunteers|Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia|Phase II Study to Investigate the Safety and Efficacy of 2 Dose Levels of a Novel Glucagon Formulation Compared to Commercially Available Glucagon in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia|Completed||Phase 2|18|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 21:32:50.782118|2018-05-31 21:32:50.782118
NCT01556581|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-09-11|2012-03-15|2012-03-16|Estimate|||||||2017-09-11|2017-09-12|Actual|February 2012|Actual|2012-02-29|September 2017|2017-09-30|December 2016|Actual|2016-12-31|July 27, 2016|Actual|2016-07-27||Interventional|COMPETE||Comparative Effectiveness of Early Physical Therapy Versus Usual Care for Low Back Pain|Effectiveness and Subsequent Healthcare Use Associated With Early Physical Therapy Access Compared With a Stepped Usual Care Approach for Treatment of Low Back Pain.|Completed||N/A|119|Actual|Madigan Army Medical Center||2|||f||||f||||||||Yes|Any data sharing must go through a Data Sharing Agreement through the Defense Health Agency|2018-05-31 21:32:51.251816|2018-05-31 21:32:51.251816
NCT01556568|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2015-12-28|2012-03-15|2012-03-16|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 2012||2012-02-29|December 2015|2015-12-31||||May 2017|Anticipated|2017-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy|An Open Label Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy|Withdrawn||Phase 2|0|Actual|Array BioPharma||1||Study was withdrawn due to scientific and business considerations.|f||||f||||||||||2018-05-31 21:32:51.352245|2018-05-31 21:32:51.352245
NCT01556555|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-03-15|2012-03-15|2012-03-16|Estimate|||||||2012-03-15|2012-03-16|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Observational|||Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)|Prospective Evaluation of the Clinical Utility of Peroral Cholangiopancreatoscopy With the Spyglass System in Patients With Sclerosing Cholangitis|Completed|||46|Actual|Karolinska University Hospital|||1||f||||f||||||||||2018-05-31 21:32:51.458623|2018-05-31 21:32:51.458623
NCT01556542|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-01-26|2012-03-14|2012-03-16|Estimate|||||||2013-01-26|2013-01-29|Estimate|November 2010||2010-11-30|January 2013|2013-01-31||||September 2012|Actual|2012-09-30||Interventional|DEBATE SFA||Drug Eluting Balloon in peripherAl inTErvention SFA|Drug Eluting Balloon in peripherAl inTErvention: the DEBATE SFA Study|Completed||Phase 4|104|Actual|Ospedale San Donato||2|||f||||f||||||||||2018-05-31 21:32:51.528454|2018-05-31 21:32:51.528454
NCT01556529|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-03-20|2012-03-14|2012-03-16|Estimate|||||||2012-03-20|2012-03-21|Estimate|June 2007||2007-06-30|March 2012|2012-03-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|CDRM_DMP||CDRM Study: Computer-assisted Diabetes Risk Management-for Secondary and Tertiary Prevention of T2DM Complications|CDRM Study: Computer-assisted Diabetes Risk Management-evaluation of a Medical Care Approach to Support Secondary and Tertiary Prevention of Type 2 Diabetes Mellitus and Its Complications|Completed||N/A|405|Actual|Philipps University Marburg Medical Center||2|||f||||t||||||||||2018-05-31 21:32:51.614588|2018-05-31 21:32:51.614588
NCT01556516|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2016-09-27|2012-03-15|2012-03-16|Estimate|||||||2016-09-27|2016-09-28|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|July 2016|Actual|2016-07-31|October 2014|Actual|2014-10-31||Observational|||Pregnancy and Birth Outcome in Women With Pompe Disease|Pregnancy and Birth Outcome in Women With Pompe Disease|Completed|||20|Actual|O & O Alpan LLC|||1||f||||f||||||||||2018-05-31 21:32:51.713238|2018-05-31 21:32:51.713238
NCT01556503|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-04-21|2012-03-14|2012-03-16|Estimate|||||||2016-04-21|2016-04-25|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis|Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis|Completed|||24|Actual|OHSU Knight Cancer Institute|||1||f||||f||||||||||2018-05-31 21:32:51.792352|2018-05-31 21:32:51.792352
NCT01556490|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2018-03-02|2012-03-14|2012-03-16|Estimate|||||||2018-03-02|2018-03-06|Actual|March 2012||2012-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|STOP-HCC||Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer|A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)|Active, not recruiting||Phase 3|526|Actual|BTG International Inc.||2|||f||||t||||||||||2018-05-31 21:32:51.914674|2018-05-31 21:32:51.914674
NCT01556477|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-14|2012-03-14|2012-03-16|Estimate|||||||2012-03-14|2012-03-16|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Interventional|||The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).|A Multicentre Open Randomized Phase II Study of the Efficacy and Safety of Azacitidine Alone or in Combination With Lenalidomide in High-risk Myeloid Disease (High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia) With a Karyotype Including Del(5q)|Unknown status|Recruiting|Phase 2|72|Anticipated|Nordic MDS Group||2|||f||||t||||||||||2018-05-31 21:32:52.137699|2018-05-31 21:32:52.137699
NCT01556464|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2018-03-26|2012-03-14|2012-03-16|Estimate|||||||2018-03-26|2018-03-29|Actual|February 2012||2012-02-29|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Initiation of Auto-adjusting CPAP for Newly Diagnosed OSA in Hospitalized Patients|Initiation of Auto-adjusting Continuous Positive Airway Pressure (CPAP) for Management of Newly Diagnosed Obstructive Sleep Apnea (OSA) in Hospitalized Patients: A Pilot Study|Withdrawn||N/A|0|Actual|MetroHealth Medical Center||2||Difficulty with enrollment. Study stopped after 5 patients and no data kept.|f||||f||||||||||2018-05-31 21:32:52.240524|2018-05-31 21:32:52.240524
NCT01556451|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2013-07-19||2017-03-14|2012-03-14|2012-03-16|Estimate|2013-07-19|2013-09-23|Estimate||||2017-03-14|2017-04-12|Actual|April 2012||2012-04-30|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)|An Open-label, Single-arm, Multi-center, Phase IV Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in Korea|Completed||Phase 4|180|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:32:52.333897|2018-05-31 21:32:52.333897
NCT01556438|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2016-02-09|2012-03-15|2012-03-16|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Study of LY2127399 in Japanese Participants With Relapsed or Refactory Multiple Myeloma|A Phase 1 Study of LY2127399 in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|10|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:32:52.500621|2018-05-31 21:32:52.500621
NCT01556425|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2018-01-16||2018-02-13|2012-03-14|2012-03-16|Estimate|2018-01-16|2018-02-13|Actual||||2018-02-13|2018-03-12|Actual|May 2012|Actual|2012-05-31|February 2018|2018-02-28|August 6, 2017|Actual|2017-08-06|December 12, 2016|Actual|2016-12-12||Interventional|||The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence|The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence|Completed||Phase 2|84|Actual|Johns Hopkins University|Small sample size|4|||f||||f|t|f|||f|||No|We will publish the results in a peer-reviewed journal.|2018-05-31 21:32:52.612518|2018-05-31 21:32:52.612518
NCT01556412|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2014-10-19|2012-03-15|2012-03-16|Estimate|||||||2014-10-19|2014-10-21|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Observational|||Endoscopic Ultrasound as an Early Diagnostic Tool for Primary Sclerosing Cholangitis|Pilot Study of Endoscopic Ultrasound as an Early Diagnostic Tool for Evaluation of Suspected Primary Sclerosing Cholangitis|Completed|||32|Actual|Tischendorf, Jens, M.D.|||1||f||||f||||||||||2018-05-31 21:32:53.126012|2018-05-31 21:32:53.126012
NCT01556399|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-11-14|2012-03-15|2012-03-16|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2011||2011-11-30|November 2017|2017-11-30|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Observational|DUO/AMP-LST||Endoscopic Characteristics of Duodenal and Ampullary Lesions|A Correlation of the Endoscopic Characteristics of Duodenal and Ampullary Laterally Spreading Tumours With Their Somatic or Germline Mutations.|Recruiting|||350|Anticipated|Western Sydney Local Health District|||1||f||||t||||||Samples With DNA|"~     Adenoma tissue sample and control regular tissue sample~   "|||2018-05-31 21:32:53.183397|2018-05-31 21:32:53.183397
NCT01556386|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-07-11|2012-03-15|2012-03-16|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 2006||2006-06-30|December 2013|2013-12-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|||Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia|Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia|Completed|||200|Anticipated|Seoul National University Hospital|||1||f||||f||||||Samples With DNA|"~     1. Candidate genes exhibit polymorphisms and encodes proteins that are involved in the~          pharmacokinetics and pharmacodynamics of antileukemic agents~             -  Priority was given to polymorphism that were demonstrated to be associated with~               phenotypes in both clinical and preclinical studies.~             -  Candidate genes : CYP3A4*1B, CYPA5*3, GSTM1 deletion, GSTP1 313, GSTT1 deletion,~               MDR exon 21, MDR exon 26, MTHFR 677, MTHFR 1298, NR3C1 1088, RFC 80, TPMT-1 238,~               TPMT-1 460, TPMT-1 719, VDR intron 8, VDR FokI, ITPA~        2. Blood sample at complete remission→DNA extraction~        3. Total-Plex (multiplex) PCR amplification~        4. Luminex system analysis~   "|||2018-05-31 21:32:53.244927|2018-05-31 21:32:53.244927
NCT01556373|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-02-10|2012-03-15|2012-03-16|Estimate|||||||2017-02-10|2017-02-13|Actual|February 2012||2012-02-29|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|IRIGA||Effects of Acute Systemic Inflammation on Arterial Stiffness and Microcirculation.|Effects of Acute Systemic Inflammation on Arterial Stiffness and Microcirculation.|Recruiting|||40|Anticipated|Rennes University Hospital|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:32:53.325111|2018-05-31 21:32:53.325111
NCT01556360|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-05-26|2012-03-15|2012-03-16|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2008||2008-07-31|May 2015|2015-05-31||||August 2014|Actual|2014-08-31||Observational|FEROS||Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study|Bone Status on Patients With Genetic Hemochromatosis : a 3 Years Descriptive and Evolutionary Study.|Completed|||100|Actual|Rennes University Hospital|||||f||||f||||||Samples With DNA|"~     -  serum~        -  urine~        -  DNA~   "|||2018-05-31 21:32:53.400367|2018-05-31 21:32:53.400367
NCT01556347|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2016-12-21|2012-03-15|2012-03-16|Estimate|||||||2016-12-21|2016-12-23|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Multi-Drug Desensitization Protocol for Heart Transplant Candidates|Multi-Drug Desensitization Protocol for Heart Transplant Candidates|Terminated||Phase 2|2|Actual|Providence Health & Services||1||Lack of efficacy|f||||t||||||||||2018-05-31 21:32:53.460784|2018-05-31 21:32:53.460784
NCT01555983|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2015-12-03||2017-03-20|2012-03-14|2012-03-16|Estimate|2016-01-13|2016-01-15|Estimate||||2017-03-20|2017-04-18|Actual|July 2012||2012-07-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Consented subjects with at least one study visit|Vaporized Cannabis and Spinal Cord Injury Pain|The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury|Completed||Phase 2/Phase 3|42|Actual|University of California, Davis||3|||f||||f||||||||Yes|email Barth Wilsey at bwilsey@ucsd.edu|2018-05-31 21:32:59.063534|2018-05-31 21:32:59.063534
NCT01556334|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-03-04|2012-03-15|2012-03-16|Estimate|||||||2014-03-04|2014-03-05|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PEACE||Erythromycin Versus Azithromycin in Preterm Premature Rupture of Membranes|Preterm Premature Rupture of Membranes: Erythromycin Versus Azithromycin a Randomized Trial Comparing Their Efficacy to Prolong Latency (PEACE Trial)|Withdrawn||Phase 3|0|Actual|Indiana University||2||Terminated before starting due to need for IND determined by FDA.|f||||t||||||||||2018-05-31 21:32:53.546641|2018-05-31 21:32:53.546641
NCT01556321|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-03-17|2012-03-15|2012-03-16|Estimate|||||||2016-03-17|2016-03-18|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Long-term Effects of Green Tea on Gut Flora, Fat Absorption, Body Composition and Resting Energy Expenditure|Long-term Effects of Green Tea on Gut Flora, Fat Absorption, Body Composition and Resting Energy Expenditure|Completed||N/A|70|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 21:32:53.618534|2018-05-31 21:32:53.618534
NCT01556308|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2014-07-28|2012-03-15|2012-03-16|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|October 2013|Actual|2013-10-31|March 2012|Actual|2012-03-31||Interventional|||Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara|Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara|Completed||N/A|6|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 21:32:53.691996|2018-05-31 21:32:53.691996
NCT01556295|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-16|2012-03-14|2012-03-16|Estimate|||||||2012-03-16|2012-03-19|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|August 2012|Anticipated|2012-08-31||Observational|||Gesture Behavior and Knowledge on Low Back Pain Among Nurses|Assessment of Gesture Behavior and Knowledge on Low Back Pain Among Nurses|Unknown status|Recruiting||100|Anticipated|Federal University of São Paulo|||2||f||||t||||||||||2018-05-31 21:32:53.780854|2018-05-31 21:32:53.780854
NCT01556282|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-05-23|2012-03-14|2012-03-16|Estimate|||||||2014-05-23|2014-05-28|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis|A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis|Completed||N/A|35|Actual|Emory University||1|||f||||f||||||||||2018-05-31 21:32:55.179597|2018-05-31 21:32:55.179597
NCT01556256|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-01-05|2012-03-15|2012-03-16|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents|Music Video for AYA-Parent Communication and Resilience|Completed||N/A|123|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 21:32:55.350021|2018-05-31 21:32:55.350021
NCT01556243|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2018-04-06|2012-03-15|2012-03-16|Estimate|||||||2018-04-06|2018-04-09|Actual|July 2012||2012-07-31|April 2018|2018-04-30||||July 2020|Anticipated|2020-07-31||Interventional|||Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer|Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)|Active, not recruiting||Phase 2|270|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 21:32:55.544168|2018-05-31 21:32:55.544168
NCT01556230|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2017-01-30|2012-03-14|2012-03-16|Estimate|||||||2017-01-30|2017-02-01|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PAPS||Prospective Study of Clinically Nonfunctioning Pituitary Adenomas|Prospective Study of Clinically Nonfunctioning Pituitary Adenomas|Recruiting|||350|Anticipated|Columbia University|||2||f||||f||||||Samples Without DNA|"~     Blood Serum and Plasma samples~   "|Undecided||2018-05-31 21:32:56.196478|2018-05-31 21:32:56.196478
NCT01556217|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2013-07-23|2012-03-15|2012-03-16|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers|A Double-blind, Placebo-controlled, Single Dose, Pharmacokinetic Study to Characterize the Central Brain Penetrance of JNJ-39393406 Using Cerebrospinal Fluid in Healthy Male and Female Subjects|Completed||Phase 1|12|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 21:32:56.283934|2018-05-31 21:32:56.283934
NCT01556204|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2016-05-16||2016-12-22|2012-03-14|2012-03-16|Estimate|2016-06-23|2016-08-04|Estimate||||2016-12-22|2017-02-14|Actual|March 2012||2012-03-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|LAROSE||Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a Prospective Randomized Controlled Trial|Laparoscopy vs. Robotic Surgery for Endometriosis (LAROSE): a Prospective Randomized Controlled Trial|Completed||N/A|73|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 21:32:56.468866|2018-05-31 21:32:56.468866
NCT01556191|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-09-19|2012-03-15|2012-03-16|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2012||2012-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|LADIE||Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR|Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer|Active, not recruiting||Phase 2|394|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||4|||f||||f||||||||||2018-05-31 21:32:56.762474|2018-05-31 21:32:56.762474
NCT01556178|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-02-03|2012-03-15|2012-03-16|Estimate|||||||2016-02-03|2016-02-05|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research|Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research|Completed|||5|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||f||||||Samples Without DNA|"~     whole blood and cerebrospinal fluid~   "|||2018-05-31 21:32:56.987631|2018-05-31 21:32:56.987631
NCT01556165|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2014-12-04||2014-12-22|2012-03-15|2012-03-16|Estimate|2014-12-22|2014-12-23|Estimate||||2014-12-22|2014-12-23|Estimate|April 2012||2012-04-30|December 2014|2014-12-31||||December 2013|Actual|2013-12-31||Interventional||The all-patients-treated set (APTS) comprises all randomised patients who took at least one dose of IMP.|Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China|Completed||Phase 3|130|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 21:32:57.095062|2018-05-31 21:32:57.095062
NCT01555788|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2014-12-02|2012-03-14|2012-03-15|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||DiaPort Closed-Loop Artificial Pancreas|Closed Loop Artificial Pancreas Using Intraperitoneal (IP) Insulin Via DiaPort®|Completed||Phase 2|10|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 21:33:00.742209|2018-05-31 21:33:00.742209
NCT01556152|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2012-11-09|2012-03-15|2012-03-16|Estimate|||||||2012-11-09|2012-11-12|Estimate||||November 2012|2012-11-30||||||||Interventional|||A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)|A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Neuropathy|Withdrawn||Phase 2|0|Actual|Glenmark Pharmaceuticals Ltd. India||3||"Due to new scientific evidence assessment, the study design was revised before the study~   started recruitment"|f||||t||||||||||2018-05-31 21:32:57.47295|2018-05-31 21:32:57.47295
NCT01556139|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2015-07-06|2012-03-15|2012-03-16|Estimate|||||||2015-07-06|2015-07-08|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|||Effectiveness of Respiratory Muscle Training by Spirotiger in Chronic Patients|Evaluation of the Effectiveness of Respiratory Muscle Training by the Technique of Hypocapnia Hyperpnea (Spirotiger) in COPD and CHF Patients|Unknown status|Active, not recruiting|N/A|40|Anticipated|Fondazione Salvatore Maugeri||2|||f||||t||||||||||2018-05-31 21:32:57.542674|2018-05-31 21:32:57.542674
NCT01556126|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2018-04-27|2012-03-15|2012-03-16|Estimate|||||||2018-04-27|2018-04-30|Actual|February 2012|Actual|2012-02-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2014|Actual|2014-07-31||Interventional|PARTICIPATE||Clinical Performance of CRE8 Drug Eluting Stent in All Comer Population|Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients|Active, not recruiting||N/A|1000|Anticipated|CID - Carbostent & Implantable Devices|||||f||||f||||||||||2018-05-31 21:32:57.625228|2018-05-31 21:32:57.625228
NCT01556113|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2017-04-26|2012-03-15|2012-03-16|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2012|Actual|2012-03-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease|The Genetic Effect on Omega 3 Fatty Acid Supplementation for the Treatment of Non Alcoholic Fatty Liver Disease in Obese Children and Adolescents|Completed||N/A|17|Actual|Yale University||2|||f||||t||||||||No||2018-05-31 21:32:57.7147|2018-05-31 21:32:57.7147
NCT01556100|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2017-02-06||2017-12-13|2012-03-14|2012-03-16|Estimate|2017-12-13|2017-12-15|Actual||||2017-12-13|2017-12-15|Actual|November 2011||2011-11-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression|Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression|Completed||Phase 2|40|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 21:32:57.885085|2018-05-31 21:32:57.885085
NCT01556087|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-09-09|2012-03-14|2012-03-16|Estimate|||||||2015-09-09|2015-09-10|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|February 2014|Actual|2014-02-28||Interventional|TRUST||Distress Tolerance and Buprenorphine|Distress Tolerance and Reducing Early Relapse in Buprenorphine Patients|Completed||Phase 3|59|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 21:32:58.043678|2018-05-31 21:32:58.043678
NCT01556074|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-08-01|2012-03-14|2012-03-16|Estimate|||||||2014-08-01|2014-08-04|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Evaluation of Yoga for Sleep Disturbances in Post Traumatic Stress Disorder (PTSD)|Evaluation of Yoga for Sleep Disturbances in Insomnia and Posttraumatic Stress Disorder|Completed||N/A|50|Actual|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 21:32:58.129425|2018-05-31 21:32:58.129425
NCT01556061|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2013-07-27||2014-04-25|2012-03-14|2012-03-16|Estimate|2014-04-25|2014-05-26|Estimate||||2014-04-25|2014-05-26|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison of Storz C-MAC and D-MAC Orotracheal Intubation Systems in Morbidly Obese Patients|Comparison of Storz C-MAC and D-MAC Orotracheal Intubation Systems in Morbidly Obese Patients - A Prospective Randomized Crossover Trial|Completed||Phase 4|50|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 21:32:58.233784|2018-05-31 21:32:58.233784
NCT01556048|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-12-01|2012-03-14|2012-03-16|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pilot Study of Behavioral Activation for Prolonged Grief||Completed||Phase 1|25|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 21:32:58.529422|2018-05-31 21:32:58.529422
NCT01556035|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-09-22|2012-03-15|2012-03-16|Estimate|||||||2016-09-22|2016-09-23|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|REV-LEG||Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma|A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid®) in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type) After First Line Treatment by Chemotherapy Plus Rituximab for the French Study Group of Cutaneous Lymphoma (GFELC)|Completed||Phase 2|19|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 21:32:58.621266|2018-05-31 21:32:58.621266
NCT01556022|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-10-26|2012-03-15|2012-03-16|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2015|Actual|2015-08-31||Interventional|ATHENA||Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia|Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization.|Completed||Phase 2|28|Actual|Cytori Therapeutics||2|||f||||t||||||||||2018-05-31 21:32:58.746394|2018-05-31 21:32:58.746394
NCT01556009|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-01-13|2012-03-15|2012-03-16|Estimate|||||||2016-01-13|2016-01-14|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Vismodegib||Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas|A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas|Completed||Phase 2|24|Actual|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-05-31 21:32:58.84612|2018-05-31 21:32:58.84612
NCT01555996|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2014-05-19|2012-03-15|2012-03-16|Estimate|||||||2014-05-19|2014-05-21|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Early Occupational Therapy for Delirium Prevention in Older Patients Admitted to Critical Care Unit|Early Occupational Therapy (OT) for Delirium Prevention in Older Patients Admitted to Critical Care Unit (CCU)|Completed||N/A|126|Actual|University of Chile||2|||f||||f||||||||||2018-05-31 21:32:58.94834|2018-05-31 21:32:58.94834
NCT01555970|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2014-10-23|2012-03-14|2012-03-16|Estimate|||||||2014-10-23|2014-10-24|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|NACTOC||Efficacy Study of add-on Therapy With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder|Serotonin Reuptake Inhibitor Augmentation With N-Acetylcysteine in Resistant Obsessive-compulsive Disorder: a Double-blind, Randomized and Controlled Study|Completed||Phase 2|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:32:59.274078|2018-05-31 21:32:59.274078
NCT01555957|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2018-03-15|2012-03-14|2012-03-16|Estimate|||||||2018-03-15|2018-03-16|Actual|February 2012||2012-02-29|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis|Effect of Lipid Intake on Direct Hyperbilirubinemia in Late Preterm and Term Infants With Gastrointestinal Surgical Problems.|Recruiting||Phase 3|40|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 21:32:59.356724|2018-05-31 21:32:59.356724
NCT01555944|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-04-22|2012-03-15|2012-03-16|Estimate|||||||2016-04-22|2016-04-25|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines|Screening and Management of Cardiovascular Risk in Belgian Women Aged > or = 65 Years With Metastatic Breast Cancer Before and After Anthracycline Treatment|Completed|||60|Actual|Teva Pharma|||||f||||f||||||||No||2018-05-31 21:32:59.425777|2018-05-31 21:32:59.425777
NCT01555931|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|2014-07-14||2014-08-21|2012-03-15|2012-03-16|Estimate|2014-08-21|2014-08-25|Estimate||||2014-08-21|2014-08-25|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PPIUD1|Baseline characteristics of women allocated to immediate or late LNG-IUS placement after delivery.|Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding|Immediate vs. 4-8 Week Postpartum Levonorgestrel-releasing Intrauterine System Placement: A Randomized Clinical Trial (Short Title: PPIUD1)|Completed||Phase 4|61|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:32:59.513582|2018-05-31 21:32:59.513582
NCT01555918|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2013-01-31|2012-03-14|2012-03-16|Estimate|||||||2013-01-31|2013-02-01|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers|A Phase I, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers|Completed||Phase 1|36|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 21:32:59.724742|2018-05-31 21:32:59.724742
NCT01555905|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-10-10|2012-03-15|2012-03-16|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2011||2011-04-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|RMST||Respiratory Muscle Strength in Patients With NMD|Respiratory Muscle Strength and Function in Patients With Neuromuscular Disease|Recruiting||N/A|30|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 21:32:59.797274|2018-05-31 21:32:59.797274
NCT01555892|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2018-01-18|2012-03-15|2012-03-16|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2013||2013-01-31|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|December 2018|Anticipated|2018-12-31||Interventional|GRALE||Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE|Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma|Recruiting||Phase 1|136|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 21:32:59.961141|2018-05-31 21:32:59.961141
NCT01555879|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-11-02|2012-03-14|2012-03-16|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2012||2012-03-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Real-world Clinical Efficacy of Abatacept in the T3 Data Registry|Abatacept in T3: A Characterization of Abatacept's Efficacy and Outcomes From a Real-Word Clinical Practice Information Hub on Novel Patient Sub-Groups|Completed|||200|Actual|Arthritis Northwest PLLC|||1||f||||f||||||||||2018-05-31 21:33:00.060806|2018-05-31 21:33:00.060806
NCT01555866|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2015-08-31|2012-03-14|2012-03-16|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.|A Phase 1 Open Label, 2 Part, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole|Completed||Phase 1|49|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 21:33:00.148883|2018-05-31 21:33:00.148883
NCT01555853|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2016-12-05|2012-03-13|2012-03-16|Estimate|||||||2016-12-05|2016-12-06|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma|A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma|Terminated||Phase 1|20|Actual|Washington University School of Medicine||4||"completed accrual to phase I but drug did not show activity, so halted before initiation of~   phase II"|f||||f||||||||||2018-05-31 21:33:00.247331|2018-05-31 21:33:00.247331
NCT01555840|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-12-17|2012-03-14|2012-03-15|Estimate|||||||2013-12-17|2013-12-19|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Comparative Study of the Magnetically Guided Capsule Endoscopy Versus High Definition Gastroscopy|"EVALUATION CLINIQUE D'UNE CAPSULE A GUIDAGE MAGNETIQUE POUR L'EXPLORATION GASTRIQUE Capsule Dirigée Versus Gastroscopie à Haute Définition"|Completed||N/A|189|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-05-31 21:33:00.370494|2018-05-31 21:33:00.370494
NCT01555827|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-11-09|2012-03-14|2012-03-15|Estimate|||||||2017-11-09|2017-11-13|Actual|March 12, 2012|Actual|2012-03-12|November 2017|2017-11-30|June 7, 2014|Actual|2014-06-07|June 7, 2014|Actual|2014-06-07||Interventional|SIGNAL||Retinal Neurodegenerative Signs in Alzheimer's Diseases|Retinal Neurodegenerative Signs in Alzheimer's Diseases|Completed||N/A|200|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 21:33:00.44375|2018-05-31 21:33:00.44375
NCT01555814|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2016-10-25|2012-03-14|2012-03-15|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen|Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes|Completed||N/A|56|Actual|University of Copenhagen||1|||f||||t||||||||||2018-05-31 21:33:00.533824|2018-05-31 21:33:00.533824
NCT01555801|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-01-23|2012-03-14|2012-03-15|Estimate|||||||2017-01-23|2017-01-25|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endoscopic Ultrasound Plus Submucosal Injection for Early Esophageal Cancer|Efficacy Study of Endoscopic Ultrasound Combining With Submucosal Saline Injection for Pretreatment Staging of T1a and T1b in Patients With Early Esophageal Cancer|Recruiting||N/A|80|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 21:33:00.63752|2018-05-31 21:33:00.63752
NCT01555775|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-01-15|2012-03-14|2012-03-15|Estimate|||||||2013-01-15|2013-01-16|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Compared Effect of a Fruit Milk Shake With a Protein-Carbohydrate Supplement on Recovery After Resistance Exercise|Compared Effect of a Fruit Milk Shake With a Protein-Carbohydrate Supplement on Muscle Damage, Inflammation, Oxidative Stress and Functional Recovery, After Resistance Exercise|Completed||N/A|13|Actual|Universidade do Porto||2|||f||||f||||||||||2018-05-31 21:33:00.846972|2018-05-31 21:33:00.846972
NCT01555762|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-11-01|2012-03-14|2012-03-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)|Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin ® Regimen for Metastatic Colorectal Cancer.|Completed|||403|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:33:01.016445|2018-05-31 21:33:01.016445
NCT01555749|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-02-23|2012-03-14|2012-03-15|Estimate|||||||2017-02-23|2017-02-27|Actual|March 12, 2012|Actual|2012-03-12|February 2017|2017-02-28|May 8, 2012|Actual|2012-05-08|May 8, 2012|Actual|2012-05-08||Interventional|||Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects|A Randomised, Double-blind, Placebo-controlled, Single Centre, Single Dose Trial, Assessing the Pharmacokinetics of NNC172-2021, Administered Subcutaneously at Two Different Dose Levels, in Healthy Japanese Subjects|Completed||Phase 1|8|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:33:01.290553|2018-05-31 21:33:01.290553
NCT01555736|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-19|2012-03-14|2012-03-15|Estimate|||||||2012-03-19|2012-03-21|Estimate|January 2003||2003-01-31|March 2012|2012-03-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Comparison of Perennial and Preseasonal Subcutaneous Immunotherapy|A Randomised Double-blind Clinical Trial for Evaluation of Efficacy and Safety of Perennial in Comparison to Preseasonal Grass/Rye Pollen Immunotherapy in Patients Suffering From Seasonal Allergic Rhinitis|Completed||Phase 4|120|Actual|Medical Universtity of Lodz||2|||f||||f||||||||||2018-05-31 21:33:01.373337|2018-05-31 21:33:01.373337
NCT01555723|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2015-09-29|2012-03-14|2012-03-15|Estimate|||||||2015-09-29|2015-10-01|Estimate||||September 2015|2015-09-30||||||||Observational|RELATES||Observational Study of Antiretroviral (ARV) Response in a Cohort of African Children Using Viral Load Monitoring|HIV (Human Immunodeficiency Virus) Subtype and ARV Response in African Children|Withdrawn|||0|Actual|University of Wisconsin, Madison||||New study created.|f||||f||||||Samples With DNA|"~     Plasma obtained fron participants~   "|||2018-05-31 21:33:01.453985|2018-05-31 21:33:01.453985
NCT01555710|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2013-05-20|2012-03-13|2012-03-15|Estimate|||||||2013-05-20|2013-05-21|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)|A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination With Carboplatin and Etoposide (PaCE) Chemotherapy Versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer. The MATISSE Study|Unknown status|Active, not recruiting|Phase 3|548|Anticipated|Ziopharm||2|||f||||t||||||||||2018-05-31 21:33:01.528048|2018-05-31 21:33:01.528048
NCT01555697|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-10-24|2012-03-14|2012-03-15|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2014||2014-07-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|Swerdlow-R34||Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia|Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia|Recruiting||Phase 1/Phase 2|60|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:33:01.688177|2018-05-31 21:33:01.688177
NCT01555684|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-12-01|2012-03-13|2012-03-15|Estimate|||||||2015-12-01|2015-12-02|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|December 2012|Anticipated|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients|The Effect of Percutaneous Venoplasty on Muscular Function, Mobility and Fatigue of Multiple Sclerosis (MS) Patients With Chronic Cerebrospinal Venous Insufficiency (CCSVI).|Withdrawn||N/A|0|Actual|University of Stirling||2|||f||||t||||||||||2018-05-31 21:33:01.765943|2018-05-31 21:33:01.765943
NCT01555671|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-12-13|2012-03-14|2012-03-15|Estimate|||||||2012-12-13|2012-12-17|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Study of the Effectiveness of Administration of Meperidine on the Length of Active Phase of Labor in Women|Is There Any Effect of Meperidine on the Length of Duration of Labor? A Prospective Randomized Controlled Trial.|Unknown status|Recruiting|Phase 4|440|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||t||||||||||2018-05-31 21:33:01.83697|2018-05-31 21:33:01.83697
NCT01555658|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-13|2012-03-13|2012-03-15|Estimate|||||||2012-03-13|2012-03-15|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|BILLION||Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial|Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial|Unknown status|Not yet recruiting|Phase 3|204|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:33:02.022972|2018-05-31 21:33:02.022972
NCT01555645|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-12-03|2012-03-14|2012-03-15|Estimate|||||||2015-12-03|2015-12-04|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||Stress Management in Breast Cancer Patients|How Can Health Care Help Female Breastcancer Patients Reduce Their Stress Symptoms? A Randomized Intervention Study With Stepped-care|Completed||N/A|466|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 21:33:02.132644|2018-05-31 21:33:02.132644
NCT01555632|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-06-17|2012-03-13|2012-03-15|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Atorvastatin Calcium in Preventing Metabolic Syndrome in Patients With Prostate Cancer Receiving Long-Term Androgen-Deprivation Therapy|A Pilot Study of Atorvastatin on Prevention of Metabolic Syndrome in Subjects With Prostate Cancer on Long Term Androgen-deprivation Therapy|Withdrawn||N/A|0|Actual|University of Nebraska||2||Other more favorable treatments are now available.|f||||t||||||||||2018-05-31 21:33:02.241219|2018-05-31 21:33:02.241219
NCT01555619|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-06-20|2012-03-14|2012-03-15|Estimate|||||||2017-06-20|2017-06-22|Actual|February 15, 2012||2012-02-15|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|Quad PAS||Quadripolar Pacing Post Approval Study|Quadripolar Pacing Post Approval Study|Active, not recruiting|||1971|Actual|St. Jude Medical|||1||f||||f|f|t|f|f||||No||2018-05-31 21:33:02.358073|2018-05-31 21:33:02.358073
NCT01555606|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2015-07-20|2012-03-14|2012-03-15|Estimate|||||||2015-07-20|2015-07-21|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis|A Multicenter, Observational, Noninterventional, Narrative Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis|Completed|||108|Actual|Janssen Biotech, Inc.|||1||f||||f||||||||||2018-05-31 21:33:02.600663|2018-05-31 21:33:02.600663
NCT01555593|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-10-28|2012-03-13|2012-03-15|Estimate|||||||2014-10-28|2014-10-29|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Prolonged Decubitus on Nitric Oxide Concentration in Chronic Obstructive Pulmonary Disease|Effect of Prolonged Decubitus on Bronchial Inflammation in COPD Patients Evaluated by Expired NO Concentration Assessment|Completed||Phase 4|30|Actual|University of Milan||1|||f||||t||||||||||2018-05-31 21:33:02.707829|2018-05-31 21:33:02.707829
NCT01555580|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis|A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Symptomatic Autoimmune Generalized Myasthenia Gravis|Unknown status|Not yet recruiting|Early Phase 1|12|Anticipated|Muscular Dystrophy Association||1|||f||||f||||||||||2018-05-31 21:33:02.786084|2018-05-31 21:33:02.786084
NCT01555567|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2015-04-26||2015-05-13|2012-03-13|2012-03-15|Estimate|2015-05-12|2015-05-14|Estimate||||2015-05-13|2015-06-08|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Electrical Stimulation and Eccentric Exercise for Anterior Cruciate Ligament (ACL) Injury|Quadriceps Inhibition After ACL Injury: Neuromuscular and Functional Consequences|Completed||N/A|43|Actual|University of Michigan||4|||f||||f||||||||||2018-05-31 21:33:02.90602|2018-05-31 21:33:02.90602
NCT01555554|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2018-05-14|2012-03-13|2012-03-15|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2012||2012-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)|Effect of Prophylactic, Perioperative Propranolol on Peri- and Postoperative Complications in Patients With Post Traumatic Stress Disorder|Recruiting||N/A|110|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:33:03.257657|2018-05-31 21:33:03.257657
NCT01555541|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2017-06-07|2012-03-13|2012-03-15|Estimate|||||||2017-06-07|2017-06-09|Actual|June 2012||2012-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma|A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma|Recruiting||Phase 2|24|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:33:03.356396|2018-05-31 21:33:03.356396
NCT01555528|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-12-22|2012-03-14|2012-03-15|Estimate|||||||2017-12-22|2017-12-26|Actual|April 30, 2012|Actual|2012-04-30|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS MEX||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Mexico|"Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Mexico"|Completed|||193|Actual|Merck KGaA|||1||f||||f||||||||||2018-05-31 21:33:03.466548|2018-05-31 21:33:03.466548
NCT01555515|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2016-09-12|2012-03-14|2012-03-15|Estimate|||||||2016-09-12|2016-09-13|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|||Epodure Therapy of Anemia in End Stage Renal Disease on Dialysis With Epodure Skin Implant|Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in End Stage Renal Disease (ESRD) Dialysis Patients Using EPODURE Biopump|Terminated||Phase 1/Phase 2|4|Actual|Medgenics Medical Israel Ltd.||1||New protocol to start with improved product|f||||f||||||||No|Early phase study.|2018-05-31 21:33:03.551738|2018-05-31 21:33:03.551738
NCT01555502|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2015-05-26|2012-03-13|2012-03-15|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Health Related Quality of Life After Video Assisted Thoracoscopic Lobectomy for Lung Cancer||Completed|||50|Actual|University of Alberta|||2||f||||t||||||||||2018-05-31 21:33:03.631188|2018-05-31 21:33:03.631188
NCT01555489|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2017-01-31|2012-03-13|2012-03-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca|Phase II, Open Label Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer|Completed||Phase 2|11|Actual|Thomas Jefferson University||1|||f||||t||||||||No||2018-05-31 21:33:03.703972|2018-05-31 21:33:03.703972
NCT01555476|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-07-06|2012-03-13|2012-03-15|Estimate|||||||2012-07-06|2012-07-10|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study to Test the Blood to See if a New Medicine is Likely to Provide Pain Relief Similar to a Product Already Sold in Stores|Bioequivalence Between an Ibuprofen Suspension and a Reference Formulation. A Study in Healthy Volunteers.|Completed||Phase 1|32|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 21:33:03.827563|2018-05-31 21:33:03.827563
NCT01555463|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2014-12-28||2015-12-28|2012-03-13|2012-03-15|Estimate|2015-01-25|2015-01-27|Estimate||||2015-12-28|2016-02-01|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea|A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea|Completed||Phase 3|961|Actual|Bayer||2|||f||||||||||||||2018-05-31 21:33:03.950847|2018-05-31 21:33:03.950847
NCT01555450|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-02-23|2012-03-13|2012-03-15|Estimate|||||||2015-02-23|2015-02-24|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PRADO||Study of Patient Navigation to Reduce Social Inequalities|The Patient Navigator to Reduce Social Inequalities. A French Interventional Trial in Public Health|Completed||N/A|28929|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 21:33:05.87476|2018-05-31 21:33:05.87476
NCT01555437|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-11-18|2012-03-14|2012-03-15|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Assessment of Capsule Endoscopy Scoring Index (CESI), Harvey-Bradshaw Index (HBI) and Biological Markers in Small Bowel Crohn's Disease (SBCD)|Assessment of Capsule Endoscopy Scoring Index, Clinical Disease Activity and Biological Markers in Small Bowel Crohn's Disease|Completed|||58|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     serum of small bowel Crohn's disease patients~   "|||2018-05-31 21:33:05.958396|2018-05-31 21:33:05.958396
NCT01555424|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Vitamin D Fortified Cheese and Well-being in the Institutionalized Elderly|Bioavailability of Casein-bound Vitamin D From Fortified Cheese and Its Effects on the Well-being of the Institutionalized Elderly|Unknown status|Active, not recruiting|N/A|28|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 21:33:06.01317|2018-05-31 21:33:06.01317
NCT01555411|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2018-05-01|2012-03-13|2012-03-15|Estimate|||||||2018-05-01|2018-05-07|Actual|September 2012||2012-09-30|May 2018|2018-05-31|December 2050|Anticipated|2050-12-31|May 2015|Actual|2015-05-31||Observational|ACE1950||Akershus Cardiac Examination (ACE) 1950 Study|Akershus Cardiac Examination 1950 Study - a Cohort Study on Cardio- and Cerebrovascular Disease in 62-65-year-old Subjects|Active, not recruiting|||3706|Actual|Vestre Viken Hospital Trust|||1||f||||t||||||Samples With DNA|"~     Blood samples, including for genetic testing, and urine.~   "|||2018-05-31 21:33:06.178803|2018-05-31 21:33:06.178803
NCT01555398|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-04-05|2012-03-14|2012-03-15|Estimate|||||||2013-04-05|2013-04-08|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of HIP0901 Capsule|Open-label, Randomized Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Fenofibric Acid for HIP0901 Capsule in Healthy Male Subjects|Completed||Phase 1|48|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 21:33:06.260705|2018-05-31 21:33:06.260705
NCT01555385|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2013-03-05|2012-03-14|2012-03-15|Estimate|||||||2013-03-05|2013-03-06|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|April 2012|Actual|2012-04-30||Interventional|AivoPro1||The Effects of Breakfast on Mental Workload|The Effects of Nutritive and Non-nutritive Breakfast on Subjective Mental Workload During Multitasking - a Pilot Study in Healthy Volunteers|Completed||N/A|13|Actual|Helsinki University||3|||f||||f||||||||||2018-05-31 21:33:06.330859|2018-05-31 21:33:06.330859
NCT01555372|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|May 2014|Anticipated|2014-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Treatment of Unstable Distal Clavicular Fractures (Neer 2b): Hook Plate vs Locking Plate|Treatment of Unstable Distal Clavicular Fractures (Neer 2b): Hook Plate vs Locking Plate|Unknown status|Not yet recruiting|N/A|40|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 21:33:06.401713|2018-05-31 21:33:06.401713
NCT01555359|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|February 2013|Anticipated|2013-02-28|||||Observational|||Telomerase Activity as a Marker For Mobilization Quality|Telomerase Activity Of CD34+ Cells - Marker For Mobilization Quality And Predictor For Engraftment After Autologous Hematopoietic Cell Transplantation|Unknown status|Recruiting||50|Anticipated|Rabin Medical Center|||1||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 21:33:06.491295|2018-05-31 21:33:06.491295
NCT01555346|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-04-18|2012-03-14|2012-03-15|Estimate|||||||2016-04-18|2016-04-20|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Observational|||Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies|A Clinical Study to Evaluate the Clinical Performance of the SEQureDx Trisomy 21 Test in the Detection of the Relative Quantity of Chromosome 21 in Circulating Cell-Free DNA Extracted From a Maternal Blood Sample Obtained From Pregnant Women With One or More High Risk Indicators for Fetal Chromosome 21 Aneuploidy|Completed|||3062|Actual|Sequenom, Inc.|||2||f||||f||||||Samples With DNA|"~     Whole blood specimens will be collected and processed to plasma. DNA will be extracted from~     the plasma.~   "|||2018-05-31 21:33:06.578712|2018-05-31 21:33:06.578712
NCT01555333|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-07-30|2012-03-13|2012-03-15|Estimate|||||||2013-07-30|2013-07-31|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|209FX303||An Open Label Extension Study in Subjects With Fragile X Syndrome|An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome|Terminated||Phase 3|357|Actual|Seaside Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 21:33:06.690983|2018-05-31 21:33:06.690983
NCT01555320|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2013-03-19|2012-03-13|2012-03-15|Estimate|||||||2013-03-19|2013-03-20|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|CACT-IHF||Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure|Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure (CACT-IHF) A Randomized, Double-blind, Multicenter, Placebo-controlled Trial|Unknown status|Recruiting|N/A|640|Anticipated|State Administration of Traditional Chinese Medicine of the People's Republic of China||2|||f||||t||||||||||2018-05-31 21:33:06.813093|2018-05-31 21:33:06.813093
NCT01555307|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2007||2007-06-30|January 2012|2012-01-31|April 2010|Actual|2010-04-30|May 2009|Actual|2009-05-31||Interventional|||Effectiveness of Exercise Programs Following Total Hip and Knee Joint Arthroplasty|Effectiveness of Exercise Programs Following Total Hip and Knee Joint Arthroplasty|Completed||N/A|82|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:33:07.049646|2018-05-31 21:33:07.049646
NCT01555294|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|May 2005||2005-05-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|NIMA||Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification|Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification: a Study in a Population-based Cohort and Familial Combined Hyperlipidemia|Completed|||1960|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 21:33:07.136766|2018-05-31 21:33:07.136766
NCT01555281|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-08-02|2012-03-13|2012-03-15|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2012||2012-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma|Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy - A Single Arm Phase I/II Trial|Active, not recruiting||Phase 1/Phase 2|33|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||No||2018-05-31 21:33:07.317553|2018-05-31 21:33:07.317553
NCT01555268|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-02-14|2012-03-13|2012-03-15|Estimate|||||||2017-02-14|2017-02-15|Actual|October 31, 2011|Actual|2011-10-31|February 2017|2017-02-28|August 3, 2016|Actual|2016-08-03|September 24, 2013|Actual|2013-09-24||Interventional|||Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia|A Phase lb Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients|Completed||Phase 1|24|Actual|Roswell Park Cancer Institute||2|||f||||f||||||||||2018-05-31 21:33:07.438054|2018-05-31 21:33:07.438054
NCT01555255|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2015-04-22|2012-03-14|2012-03-15|Estimate|||||||2015-04-22|2015-04-23|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|March 2012|Actual|2012-03-31||Observational|||Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria|Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria|Unknown status|Active, not recruiting||1205|Anticipated|Foundation for Innovative New Diagnostics, Switzerland|||||f||||f||||||Samples With DNA|"~     Red cell pellets, dried whole blood on filter paper, and fixed blood and placental tissue~   "|||2018-05-31 21:33:07.559102|2018-05-31 21:33:07.559102
NCT01555242|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-04-07|2012-03-14|2012-03-15|Estimate|||||||2015-04-07|2015-04-08|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Aneustat (OMN54) in Patients With Advanced Cancer and Lymphomas|A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas|Completed||Phase 1|22|Actual|Omnitura Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 21:33:07.6397|2018-05-31 21:33:07.6397
NCT01555229|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2015-09-16|2012-03-13|2012-03-15|Estimate|||||||2015-09-16|2015-09-17|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|ASPIRE||Effect of Intermittent Versus Continuous Subglottic Secretion Drainage on Tracheal Mucosa Damages|Randomized, Single Blind Study Comparing the Effect of Intermittent Versus Continuous Subglottic Secretion Drainage on Tracheal Mucosa Damages in Intensive Care Patients Requiring Prolonged Mechanical Ventilation|Terminated||Phase 3|80|Actual|Rennes University Hospital||2||Enrolment difficulties|f||||f||||||||||2018-05-31 21:33:07.720611|2018-05-31 21:33:07.720611
NCT01555216|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2016-05-25|2012-03-13|2012-03-15|Estimate|||||||2016-05-25|2016-05-27|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Continuous Tibial Nerve Block Versus Single Shot Tibial Nerve Block|A Randomized Comparison of a Continuous Posterior Tibial Nerve Block and Single Injection Posterior Tibial Nerve Block in Patients Undergoing Forefoot Surgery|Withdrawn||N/A|0|Actual|Northwestern University||2||Lack of participant recruitment|f||||f||||||||No||2018-05-31 21:33:07.819254|2018-05-31 21:33:07.819254
NCT01555203|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2015-04-27|2012-03-13|2012-03-15|Estimate|||||||2015-04-27|2015-04-28|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Multiple Health Behavior Change Internet Program for College Students|A Multiple Health Behavior Change Internet Program for College Students|Completed||Phase 2|1877|Actual|Pro-Change Behavior Systems||1|||f||||f||||||||||2018-05-31 21:33:07.926573|2018-05-31 21:33:07.926573
NCT01555190|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|January 2012||2012-01-31|March 2012|2012-03-31||||||||Interventional|||Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone|Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome|Unknown status|Recruiting|N/A|50||Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 21:33:08.041958|2018-05-31 21:33:08.041958
NCT01555177|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-11-03|2012-03-14|2012-03-15|Estimate|||||||2014-11-03|2014-11-04|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|OPTIMUS||Study of Coronary Plaque Rupture in Heart Attack Following Surgery Using Optical Coherence Tomography (OCT)|OCT Plaque and Thrombus IMaging in Patients Who Underwent Non-cardiac Surgery|Unknown status|Recruiting||60|Anticipated|Hamilton Health Sciences Corporation|||2||f||||t||||||||||2018-05-31 21:33:08.140539|2018-05-31 21:33:08.140539
NCT01555164|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2014-09-17|2014-01-17|2014-09-17|2012-03-13|2012-03-15|Estimate|2014-09-17|2014-09-23|Estimate|2014-01-17|2014-02-13|Estimate|2014-09-17|2014-09-23|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional||Safety Analysis Set: randomized participants who received at least one dose of study treatment.|A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|442|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:33:08.282148|2018-05-31 21:33:08.282148
NCT01555151|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2014-07-06||2015-04-10|2012-03-14|2012-03-15|Estimate|2014-07-06|2014-08-01|Estimate||||2015-04-10|2015-05-01|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma|A Randomized, Double-blind, Double-dummy, 4-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of Two Doses of Mometasone Furoate Delivered Via Concept1 or Twisthaler® in Adult and Adolescent Patients With Persistent Asthma|Completed||Phase 2|739|Actual|Novartis||4|||f||||f||||||||||2018-05-31 21:33:09.121394|2018-05-31 21:33:09.121394
NCT01555138|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|2015-02-10||2015-04-08|2012-03-14|2012-03-15|Estimate|2015-04-08|2015-04-28|Estimate||||2015-04-08|2015-04-28|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|INSTEAD||Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)|A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez® Breezhaler® 150 mcg o.d.) With Salmeterol/Fluticasone Propionate (Seretide® Accuhaler® 50 mcg/500 mcg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease|Completed||Phase 4|581|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:33:10.262943|2018-05-31 21:33:10.262943
NCT01555125|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-02-28|2012-03-14|2012-03-15|Estimate|||||||2017-02-28|2017-03-03|Actual|May 2012||2012-05-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|FEATURE||First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis|Completed||Phase 3|177|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:33:11.05427|2018-05-31 21:33:11.05427
NCT01555112|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2013-08-14|2012-03-14|2012-03-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy Study to Test Topical AS101 for External Genital Warts|A Phase I/II, Open Labeled, Uncontrolled, Single Center Study of Topical AS101 for External Genital Warts|Completed||Phase 1/Phase 2|12|Actual|BioMAS Ltd||1|||f||||t||||||||||2018-05-31 21:33:11.250228|2018-05-31 21:33:11.250228
NCT01555099|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2013-06-14|2012-03-14|2012-03-15|Estimate|||||||2013-06-14|2013-06-17|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol|A Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group,Multi-centre Study to Assess the Efficacy and Safety of Two Staggered Dose Levels of Inhaled Once Daily AZD5423 or Twice Daily Budesonide for 12 Weeks in COPD Patients on a Background Therapy of Formoterol.|Completed||Phase 2|353|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:33:11.357905|2018-05-31 21:33:11.357905
NCT01555086|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-01-23|2012-03-14|2012-03-15|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2011||2011-08-31|January 2017|2017-01-31||||August 2017|Anticipated|2017-08-31||Interventional|SEAL||Prospective Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy|Prospective Randomized Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy|Recruiting||N/A|500|Anticipated|Association of Urologic Oncology (AUO)||2|||f||||t||||||||||2018-05-31 21:33:11.541424|2018-05-31 21:33:11.541424
NCT01555073|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2014-09-11||2016-06-29|2012-03-13|2012-03-15|Estimate|2014-09-11|2014-09-18|Estimate||||2016-06-29|2016-07-28|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional||Baseline Analysis population description|Preemptive Analgesia Following Uterine Artery Embolization|A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization|Terminated||Phase 4|23|Actual|Northwestern University|Early termination due to lost of follow-up for primary outcome at 3 months|4||Subjects did not meet inclusion criteria|f||||f||||||||||2018-05-31 21:33:11.655476|2018-05-31 21:33:11.655476
NCT01555060|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-01-22|2012-03-13|2012-03-15|Estimate|||||||2014-01-22|2014-01-23|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|HEIRS||Hemoglobin and Iron Recovery Study|Hemoglobin and Iron Recovery Study|Completed||Phase 2|215|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-05-31 21:33:11.979395|2018-05-31 21:33:11.979395
NCT01555047|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2013-04-08|2012-03-14|2012-03-15|Estimate|||||||2013-04-08|2013-04-10|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Correlation Among Sperm DNA Fragmentation, Genitourinary Infection by Mycoplasma in Male and the Pregnancy Outcomes After IUI in Their Partner||Unknown status|Active, not recruiting|Phase 4|200|Anticipated|Nanjing Medical University||3|||f||||t||||||||||2018-05-31 21:33:12.06109|2018-05-31 21:33:12.06109
NCT01555034|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-04-13|2012-03-13|2012-03-15|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Movement Therapy and Childhood Obesity|The Effect of Movement Therapy on the Success in a Multidisciplinary Intervention for the Treatment of Childhood Obesity|Completed||N/A|26|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 21:33:12.140358|2018-05-31 21:33:12.140358
NCT01555021|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-02-10|2012-03-13|2012-03-15|Estimate|||||||2017-02-10|2017-02-13|Actual|December 2011||2011-12-31|February 2017|2017-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pharmacogenomics for Antidepressant Guidance and Education|Pharmacogenomics for Antidepressant Guidance and Education|Terminated||Phase 1|5|Actual|Massachusetts General Hospital||2||The study was an inpatient, but PI left inpatient at MGH on July 1, 2012|f||||f||||||||||2018-05-31 21:33:12.220255|2018-05-31 21:33:12.220255
NCT01555008|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-09-06|2012-03-13|2012-03-15|Estimate|||||||2013-09-06|2013-09-09|Estimate|March 2012||2012-03-31|September 2013|2013-09-30||||August 2013|Actual|2013-08-31||Interventional|||Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes Mellitus and Moderate to Severe Renal Impairment|Completed||Phase 1|31|Actual|Lexicon Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:33:12.310325|2018-05-31 21:33:12.310325
NCT01554995|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-11-13|2012-03-13|2012-03-15|Estimate|||||||2014-11-13|2014-11-17|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCB01-0371 in Healthy Male Subjects|Completed||Phase 1|70|Actual|LegoChem Biosciences, Inc||2|||f||||t||||||||||2018-05-31 21:33:12.500806|2018-05-31 21:33:12.500806
NCT01554982|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2015-09-24||2016-06-02|2012-03-13|2012-03-15|Estimate|2016-06-02|2016-07-13|Estimate||||2016-06-02|2016-07-13|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional||Note: two subjects randomized did not receive study drug, therefore not included in Safety Assessment Population|A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis|A Long-Term Safety Extension Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis|Completed||Phase 3|168|Actual|Keryx Biopharmaceuticals||1|||f||||t||||||||||2018-05-31 21:33:12.618155|2018-05-31 21:33:12.618155
NCT01554969|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2016-02-19|2012-03-14|2012-03-15|Estimate|||||||2016-02-19|2016-02-22|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer|Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer|Completed||Phase 1|16|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:33:13.230578|2018-05-31 21:33:13.230578
NCT01554956|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-07-26|2012-03-13|2012-03-15|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients|A Historically Controlled Phase II/III Study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed With Ligneous Conjunctivitis|Active, not recruiting||Phase 2/Phase 3|12|Anticipated|Kedrion S.p.A.||1|||f||||f||||||||||2018-05-31 21:33:13.338801|2018-05-31 21:33:13.338801
NCT01554592|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-05-30|2012-03-14|2012-03-15|Estimate|||||||2016-05-30|2016-06-01|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study|Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study.|Completed||N/A|13|Actual|The Alfred||2|||f||||f||||||||||2018-05-31 21:33:18.729523|2018-05-31 21:33:18.729523
NCT01554943|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-08-29|2012-03-14|2012-03-15|Estimate|||||||2013-08-29|2013-08-30|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients|Late Cardiac Evaluation of the Three Arm Belgian Trial A Phase III Randomized Trial Involving Node-positive Early Breast Cancer Patients With a Long Median Follow-up (~ 15 Years)|Completed||Phase 2|73|Actual|Jules Bordet Institute||3|||f||||f||||||||||2018-05-31 21:33:13.434299|2018-05-31 21:33:13.434299
NCT01554930|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|||Effectiveness and Safety of Chinese Medicine to Treat Hand, Foot, and Mouth Disease|A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease|Completed||N/A|230|Actual|Jiangxi Qingfeng Pharmaceutical Co. Ltd.||2|||f||||t||||||||||2018-05-31 21:33:13.57629|2018-05-31 21:33:13.57629
NCT01554917|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-02-22|2012-03-13|2012-03-15|Estimate|||||||2016-02-22|2016-02-23|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of Iguratimod in Patients With Active Rheumatoid Arthritis|A Phase IV Study of Iguratimod in Patients With Active Rheumatoid Arthritis (RA)|Completed||Phase 4|1759|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||No||2018-05-31 21:33:13.684424|2018-05-31 21:33:13.684424
NCT01554904|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2013-02-24||2013-04-29|2012-03-13|2012-03-15|Estimate|2013-04-29|2013-05-01|Estimate||||2013-04-29|2013-05-01|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Number completing study|Study Will Test the Theory That Training With the Facial-Flex Exercise Device Will Improve Snoring in Patients|Facial-Flex as a Treatment for Snoring|Completed||N/A|18|Actual|Facial Concepts, Inc.|This was not a sham controlled trial. The number of participants was somewhat limited.|1|||f||||f||||||||||2018-05-31 21:33:13.784979|2018-05-31 21:33:13.784979
NCT01554891|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2015-09-21||2016-03-02|2012-03-13|2012-03-15|Estimate|2016-03-02|2016-03-03|Estimate||||2016-03-02|2016-03-03|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Observational|SAFE-TBI||INTRuST Structured Assessment For Evaluation of TBI (SAFE-TBI)|Reliability and Initial Validation of the INTRuST Structured Assessment For Evaluation of TBI (SAFE-TBI)|Completed|||305|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|||3||f||||t||||||||||2018-05-31 21:33:14.012151|2018-05-31 21:33:14.012151
NCT01554878|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-09-30|2012-03-14|2012-03-15|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Observational|LOGIC||Observational Study on the Treatment of Knee Osteochondral Lesions of Grade III-IV|Observational Studies, Prospective, Multicenter, to Evaluate the Effect of Treatment of Knee Osteochondral Lesions of Outerbridge Grade III-IV|Completed|||20|Actual|Ettore Sansavini Health Science Foundation|||1||f||||f||||||||No||2018-05-31 21:33:14.302258|2018-05-31 21:33:14.302258
NCT01554865|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-07-27|2012-03-14|2012-03-15|Estimate|||||||2015-07-27|2015-07-29|Estimate|December 2010||2010-12-31|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Diet-induced Weight Loss in Obese Men|The Effects of Diet-induced Weight Loss on Metabolic and Inflammatory Profile, Endothelial, Sexual and Urinary Function, and Quality of Life in Obese Men|Completed||Phase 4|70|Actual|Changi General Hospital||2|||f||||f||||||||||2018-05-31 21:33:14.38453|2018-05-31 21:33:14.38453
NCT01554852|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2016-06-10|2012-03-14|2012-03-15|Estimate|||||||2016-06-10|2016-06-13|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|September 2017|Anticipated|2017-09-30||Interventional|Myeloma XI||Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients|Randomised Comparisons, in Myeloma Patients of All Ages, of Thalidomide, Lenalidomide, Carfilzomib and Bortezomib Induction Combinations, and of Lenalidomide and Combination Lenalidomide Vorinostat as Maintenance (Myeloma XI)|Active, not recruiting||Phase 3|4420|Actual|University of Leeds||2|||f||||t||||||||||2018-05-31 21:33:14.58719|2018-05-31 21:33:14.58719
NCT01554839|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-02-09|2012-03-13|2012-03-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Family of Heroes: an Evaluation of an Online Educational Tool|The Family of Heroes Program for Veterans and Their Families: An Evaluation of an Online Educational Tool for Helping Veterans.|Completed||N/A|206|Actual|Department of Veterans Affairs, New Jersey||2|||f||||f||||||||||2018-05-31 21:33:14.733778|2018-05-31 21:33:14.733778
NCT01554826|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-09-04|2012-03-14|2012-03-15|Estimate|||||||2012-09-04|2012-09-06|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|||Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)|A Double - Blind, Randomized, - Controlled Clinical Trial With Inactivated Influenza Vaccine (Split Virion)(0.25ml Formulation for Pediatric Use)|Completed||Phase 3|810|Actual|Hualan Biological Engineering, Inc.||2|||f||||t||||||||||2018-05-31 21:33:14.835076|2018-05-31 21:33:14.835076
NCT01554813|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-09-04|2012-03-14|2012-03-15|Estimate|||||||2012-09-04|2012-09-06|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Interventional|||Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)|A Single - Blind, Randomized, - Controlled Clinical Trial With Inactivated Influenza Vaccine (Split Virion) (0.5ml Formulation)|Completed||Phase 3|900|Actual|Hualan Biological Engineering, Inc.||3|||f||||t||||||||||2018-05-31 21:33:14.922664|2018-05-31 21:33:14.922664
NCT01554800|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-01-10|2012-03-14|2012-03-15|Estimate|||||||2013-01-10|2013-01-14|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease|An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease|Completed||Phase 1|16|Actual|Alphacore Pharma, LLC||1|||f||||f||||||||||2018-05-31 21:33:15.006341|2018-05-31 21:33:15.006341
NCT01554787|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-13|2012-03-13|2012-03-15|Estimate|||||||2012-03-13|2012-03-15|Estimate|January 2012||2012-01-31|March 2012|2012-03-31||||December 2013|Anticipated|2013-12-31||Interventional|||Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue||Unknown status|Recruiting|Phase 4|90|Anticipated|China Medical University Hospital||2|||f||||||||||||||2018-05-31 21:33:15.077337|2018-05-31 21:33:15.077337
NCT01554579|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2016-09-23||2017-04-14|2012-03-13|2012-03-15|Estimate|2017-01-10|2017-03-01|Actual||||2017-04-14|2017-05-17|Actual|March 31, 2012|Actual|2012-03-31|April 2017|2017-04-30|November 30, 2013|Actual|2013-11-30|November 30, 2013|Actual|2013-11-30||Interventional|||A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee||Completed||Phase 2|171|Actual|Afferent Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 21:33:19.091715|2018-05-31 21:33:19.091715
NCT01554774|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2015-02-06|2012-03-14|2012-03-15|Estimate|||||||2015-02-06|2015-02-09|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|PVR-COPD||Non-invasive Assessment of Pulmonary Vascular Resistance in Elderly Patients With Chronic Obstructive Pulmonary Disease|Observational Study of Comparison of Echocardiographic Markers of Right Ventricular Function and Electrocardiographic Signs of Chronic Cor Pulmonale in Elderly Patient With COPD|Completed|||60|Actual|Hospital Viamed Valvanera, Spain|||3||f||||t||||||||||2018-05-31 21:33:15.193452|2018-05-31 21:33:15.193452
NCT01554761|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-13|2012-03-13|2012-03-15|Estimate|||||||2012-03-13|2012-03-15|Estimate|February 2012||2012-02-29|March 2012|2012-03-31||||May 2012|Anticipated|2012-05-31||Interventional|||Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia|Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia|Unknown status|Recruiting|Phase 4|30|Anticipated|China Medical University, China|||||f||||t||||||||||2018-05-31 21:33:15.45153|2018-05-31 21:33:15.45153
NCT01554748|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2018-02-20|2012-03-13|2012-03-15|Estimate|||||||2018-02-20|2018-02-22|Actual|January 2008||2008-01-31|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Improvement of Implant Survival in Total Joint Arthroplasty of the Trapeziometacarpal Joint|Improvement of Implant Survival in Total Joint Arthroplasty of the Trapeziometacarpal Joint|Recruiting||N/A|400|Anticipated|Regional Hospital Holstebro||1|||f||||t||||||||||2018-05-31 21:33:15.751768|2018-05-31 21:33:15.751768
NCT01554735|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-07-27|2012-03-13|2012-03-15|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Lifestyle-modification Induced Weight Loss on Sexual and Urinary Function, and Quality of Life in Obese Men|The Effects of Lifestyle-modification Induced Weight Loss on Metabolic and Inflammatory Profile, Endothelial, Sexual and Urinary Function, and Quality of Life in Obese Men|Completed||Phase 4|70|Actual|Changi General Hospital||1|||f||||f||||||||||2018-05-31 21:33:16.077775|2018-05-31 21:33:16.077775
NCT01554722|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-13|2012-03-13|2012-03-15|Estimate|||||||2012-03-13|2012-03-15|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Needle Nerve Contact in Ultrasound Guided Femoral Block|Incidence of Intraneural Needle Insertion in Ultrasound Guided Femoral Block: Out of Plane Versus in Plane Approach|Unknown status|Recruiting|N/A|44|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 21:33:16.370824|2018-05-31 21:33:16.370824
NCT01554709|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2014-09-23|2012-03-13|2012-03-15|Estimate|||||||2014-09-23|2014-09-25|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Performance Study of the CardioGard Cannula|A Study to Collect Additional Information Related to the Safety and Performance of the CardioGard Cannula|Completed||Phase 2/Phase 3|71|Actual|CardioGard Medical Ltd.||2|||f||||f||||||||||2018-05-31 21:33:16.880987|2018-05-31 21:33:16.880987
NCT01554696|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13||2014-12-01|2014-12-01|2012-03-13|2012-03-15|Estimate||||2014-12-01|2014-12-16|Estimate|2014-12-01|2014-12-16|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate|A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate|Completed||Phase 2|379|Actual|Astellas Pharma Inc||5|||f||||t||||||||||2018-05-31 21:33:16.998102|2018-05-31 21:33:16.998102
NCT01554683|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-02-22|2012-03-13|2012-03-15|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2012||2012-02-29|February 2018|2018-02-28|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Seizure Activity in Alzheimer's Disease|Seizure-like Hippocampal Activity in Alzheimer's Disease Neurodegeneration|Completed||N/A|20|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||t||||||||||2018-05-31 21:33:17.134033|2018-05-31 21:33:17.134033
NCT01554670|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-18|2012-03-13|2012-03-15|Estimate|||||||2012-03-18|2012-03-20|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|RF||Radio-frequency (RF)-Based Plasma Micro-tenotomy for the Treatment of Shoulder Impingement Syndrome|A Prospective Randomized Controlled Study of Radio-frequency Treatment for Shoulder Impingement Syndrome|Completed||Phase 4|65|Actual|Beijing Hospital||2|||f||||f||||||||||2018-05-31 21:33:17.209176|2018-05-31 21:33:17.209176
NCT01554657|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Five Versus Seven Day Antibiotic Course for the Treatment of Pneumonia in the Intensive Care Unit||Completed||N/A|46|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:33:17.271168|2018-05-31 21:33:17.271168
NCT01554644|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-07-15|2012-03-13|2012-03-15|Estimate|||||||2013-07-15|2013-07-16|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients|A Randomized, Double-Blind Exploratory Pilot Study Comparing Prontosan(TM) Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients|Withdrawn||N/A|0|Actual|B. Braun Medical Inc.||2||Lack of Enrollment|f||||f||||||||||2018-05-31 21:33:17.412316|2018-05-31 21:33:17.412316
NCT01554631|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-06-13|2012-03-13|2012-03-15|Estimate|||||||2013-06-13|2013-06-14|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg|Randomized, Non-blinded, 3-fold Crossover Study to Investigate the Bioequivalence Between Glucobay ODT 100 mg Taken Without and With Water and the Glucobay Standard Tablet 100 mg Following Single Oral Dosing in Healthy Male Subjects|Completed||Phase 1|34|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:33:17.656608|2018-05-31 21:33:17.656608
NCT01554618|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2018-05-17|2012-03-13|2012-03-15|Estimate|||||||2018-05-17|2018-05-18|Actual|May 12, 2016|Actual|2016-05-12|May 2018|2018-05-31|June 29, 2023|Anticipated|2023-06-29|June 22, 2020|Anticipated|2020-06-22||Interventional|||Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes|A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes|Recruiting||Phase 3|77|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 21:33:18.03437|2018-05-31 21:33:18.03437
NCT01554605|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-14|2012-03-14|2012-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||||||Observational|||Gait Disturbances and Hips Bone Mineral Density||Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-05-31 21:33:18.558305|2018-05-31 21:33:18.558305
NCT01554553|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-05-10|2012-03-14|2012-03-15|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Longitudinal Sleeve Gastrectomy Study Comparing Posterior Crural Repair Versus No Repair|A Prospective Randomized Clinical Trial Comparing Patients Who Have Had Longitudinal Sleeve Gastrectomy With Posterior Crural Repair Versus Without Posterior Crural Repair|Active, not recruiting||N/A|100|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 21:33:20.501824|2018-05-31 21:33:20.501824
NCT01554540|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-07-17|2012-03-12|2012-03-15|Estimate|||||||2013-07-17|2013-07-18|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|February 2014|Anticipated|2014-02-28|October 2013|Anticipated|2013-10-31||Interventional|TIPPS||Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study|Pharmacodynamic and Pharmacokinetic Assessment of Treprostinil Iontophoresis on the Forearm and the Fingers|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 21:33:20.755845|2018-05-31 21:33:20.755845
NCT01554527|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-12-04|2012-03-14|2012-03-15|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2012||2012-03-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|||Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children|Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children|Completed||N/A|120|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:33:20.928817|2018-05-31 21:33:20.928817
NCT01554514|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2018-02-22|2012-03-13|2012-03-15|Estimate|||||||2018-02-22|2018-02-23|Actual|August 2012||2012-08-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura|Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency|Recruiting||Phase 2|20|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 21:33:21.030339|2018-05-31 21:33:21.030339
NCT01554501|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-11-28|2012-03-12|2012-03-15|Estimate|||||||2016-11-28|2016-11-30|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Role of Stress in Self-Control, Coping, and Emotion Regulation|The Role of Stress in Self-Control, Coping and Emotion Regulation|Completed|||855|Actual|Yale University|||1||f||||t||||||Samples With DNA|"~     Blood taken for understanding genetic factors.~   "|||2018-05-31 21:33:21.181943|2018-05-31 21:33:21.181943
NCT01554488|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-02-24|2012-03-12|2012-03-15|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|InFLOW||Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease|Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease|Terminated||N/A|58|Anticipated|VA Office of Research and Development||2||Low subject accrual|f||||t||||||||||2018-05-31 21:33:21.268707|2018-05-31 21:33:21.268707
NCT01554475|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-02-16|2012-03-12|2012-03-15|Estimate|||||||2015-02-16|2015-02-18|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction|Use of Alternative Medicine Among Patients With Dementia and Mild Cognitive Dysfunction|Completed|||151|Actual|University Hospital of North Norway|||||f||||f||||||||||2018-05-31 21:33:21.335855|2018-05-31 21:33:21.335855
NCT01554462|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2013-12-10|2012-03-12|2012-03-15|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Effects of EPA/DHA Supplementation on Cognitive Control in Children With ADHD|The Effects of Eicosapentaenoic Acid (EPA)/ Docosahexaenoic Acid (DHA) Supplementation on Cognitive Control in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|79|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 21:33:21.49041|2018-05-31 21:33:21.49041
NCT01554449|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2018-05-09|2012-03-12|2012-03-15|Estimate|||||||2018-05-09|2018-05-15|Actual|September 12, 2011|Actual|2011-09-12|May 2018|2018-05-31|July 12, 2016|Actual|2016-07-12|March 22, 2016|Actual|2016-03-22||Interventional|MARGAUT||Upper Arm Reahabilitation After Stroke and Video Game|Effect of Early Upper Arm Rehabilitation After Stroke Using Adaptative Video Games|Completed||N/A|62|Actual|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 21:33:21.571856|2018-05-31 21:33:21.571856
NCT01554436|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-12-30|2012-03-12|2012-03-15|Estimate|||||||2014-12-30|2014-12-31|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|||Neuropsychological Prognosis Factors of Smoking Cessation|Neuropsychological and Psychopathological Prognosis Factors of Smoking Cessation|Completed||Phase 4|135|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 21:33:21.657384|2018-05-31 21:33:21.657384
NCT01554423|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-07-18|2012-03-12|2012-03-15|Estimate|||||||2017-07-18|2017-07-19|Actual|July 2010||2010-07-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|January 31, 2017|Actual|2017-01-31||Interventional|SA R01||Four-Arm Randomized Control Trial of Brief MI Versus Couples-Based HIV/STI Prevention in South Africa|Four-Arm RCT of Brief MI vs. Couples-Based HIV/STI Prevention in South Africa|Completed||N/A|464|Actual|The City College of New York||4|||f||||t||||||||||2018-05-31 21:33:21.73788|2018-05-31 21:33:21.73788
NCT01554410|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-12-01|2012-03-14|2012-03-15|Estimate|||||||2014-12-01|2014-12-03|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma|A Phase I Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Escalating Gemcitabine for Locally Advanced Cervical Carcinoma|Unknown status|Recruiting|Phase 1|19|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 21:33:21.811112|2018-05-31 21:33:21.811112
NCT01554397|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-12-01|2012-03-14|2012-03-15|Estimate|||||||2014-12-01|2014-12-03|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer|Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma|Unknown status|Recruiting|Phase 2/Phase 3|425|Anticipated|University of California, San Diego||3|||f||||t||||||||||2018-05-31 21:33:21.91665|2018-05-31 21:33:21.91665
NCT01554384|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2013-06-04|2012-03-12|2012-03-15|Estimate|||||||2013-06-04|2013-06-06|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|TBNEATXpert||Trial of Point-of-treatment Xpert MTB/RIF Assay|Multicentre Randomised Control Trial of Point-of-treatment (Clinic-based) Xpert MTB/RIF Assay|Completed||N/A|1472|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 21:33:22.043832|2018-05-31 21:33:22.043832
NCT01552655|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-04-20|2012-03-09|2012-03-13|Estimate|||||||2015-04-20|2015-04-21|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|BREAC-AUT||Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT|Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT|Completed||N/A|101|Actual|Odense University Hospital||1|||f||||f||||||||||2018-05-31 21:33:45.519772|2018-05-31 21:33:45.519772
NCT01554371|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2018-01-25|2012-03-12|2012-03-15|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies|A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies|Recruiting||Phase 1/Phase 2|58|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||||2018-05-31 21:33:22.127016|2018-05-31 21:33:22.127016
NCT01554358|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2015-11-03|2012-03-12|2012-03-14|Estimate|||||||2015-11-03|2015-11-04|Estimate|August 2009||2009-08-31|November 2015|2015-11-30||||July 2011|Actual|2011-07-31||Interventional|GDM||Tianjin Gestational Diabetes Prevention Program (TGDPP)|Lifestyle and Genetic Factors on Diabetes Risk in Women With GDM After Delivery: Tianjin Gestational Diabetes Prevention Program (TGDPP)|Unknown status|Recruiting|N/A|1180|Anticipated|Tianjin Women and Children's Health Center||2|||f||||t||||||||||2018-05-31 21:33:22.244438|2018-05-31 21:33:22.244438
NCT01554345|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|June 2011||2011-06-30|March 2012|2012-03-31||||August 2012|Anticipated|2012-08-31||Interventional|||Effect of Vitamin E+Selenium on Kidney Function in Controlled Hypotension|Assessment of Preventive Effect of Vitamin E +Selenium on Acute Kidney Injury Through NGAL in Patients Undergoing Controlled Hypotension During Neurosurgery Operations|Unknown status|Recruiting|Phase 2|60|Anticipated|Tehran University of Medical Sciences|||||f||||t||||||||||2018-05-31 21:33:22.323981|2018-05-31 21:33:22.323981
NCT01554332|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-04-24|2012-03-12|2012-03-14|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2012||2012-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Motor Cortex Stimulation for Chronic Neuropathic Pain|A Clinical Evaluation for the Management of Patients With Chronic Neuropathic Pain With Cortical Stimulation|Active, not recruiting||N/A|38|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 21:33:22.42046|2018-05-31 21:33:22.42046
NCT01554319|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2012-11-22|2012-03-12|2012-03-14|Estimate|||||||2012-11-22|2012-11-27|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety, Tolerability, and Pharmacokinetics After Multiple Doses of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects|Phase-I Study in Healthy Male Subjects to Investigate Safety, Tolerability and Pharmacokinetics of Orally Inhaled Multiple Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation|Completed||Phase 1|36|Actual|Sterna Biologicals GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 21:33:22.489727|2018-05-31 21:33:22.489727
NCT01554306|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2016-10-28|2012-03-12|2012-03-14|Estimate|||||||2016-10-28|2016-10-31|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Measuring the Effects of Continuous Dopaminergic Stimulation on Nocturnal Movements in Parkinson's Disease|Observational Study on the Effecst of Continuous Dopaminergic Stimulation on Nocturnal Hypokinesia in Parkinson's Disease|Terminated|||2|Actual|Sleep Medicine Centre Kempenhaeghe|||1|difficulty to include enough subjects|f||||t||||||||||2018-05-31 21:33:22.55311|2018-05-31 21:33:22.55311
NCT01554293|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2013-05-15|2012-03-13|2012-03-14|Estimate|||||||2013-05-15|2013-05-16|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|||Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Phase I Study To Determine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers|Unknown status|Recruiting|Phase 1|48|Anticipated|Panacea Biotec Ltd||2|||f||||t||||||||||2018-05-31 21:33:23.684499|2018-05-31 21:33:23.684499
NCT01554280|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2014-12-03|2012-03-13|2012-03-14|Estimate|||||||2014-12-03|2014-12-05|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|CBE-001-SEOS||Fully Coated, Removable, Self-expanding Oesophageal Stents for Preventing Strictures Following Complete Barretts Excision.|Fully, Coated, Removable, Self-expanding Oesophageal Stents for the Prevention of Oesophageal Stricture Following Endoscopic Mucosal Resection of Short Segment Barrett's With High Grade Dysplasia and Early Cancer.|Completed||N/A|12|Actual|Western Sydney Local Health District||1|||f||||f||||||||||2018-05-31 21:33:23.804329|2018-05-31 21:33:23.804329
NCT01554267|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-05-12|2012-03-12|2012-03-14|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|May 2015|Anticipated|2015-05-31|January 2015|Anticipated|2015-01-31||Interventional|ICG||The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Mastectomy Skin Flap Viability|The Use of Laser-Assisted Indocyanine Green Dye Angiography to Predict Intraoperative Mastectomy Skin Flap Viability During Breast Reconstruction|Unknown status|Recruiting|N/A|45|Anticipated|Stony Brook University||1|||f||||f||||||||||2018-05-31 21:33:23.866779|2018-05-31 21:33:23.866779
NCT01554254|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-08-29|2012-03-12|2012-03-14|Estimate|||||||2016-08-29|2016-08-31|Estimate|March 2012||2012-03-31|August 2016|2016-08-31||||December 2013|Actual|2013-12-31||Interventional|||Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation|Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation|Withdrawn||Phase 2|0|Actual|Tarix Pharmaceuticals||1||Lack of enrollment|f||||||||||||||2018-05-31 21:33:23.940604|2018-05-31 21:33:23.940604
NCT01554241|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2015-01-23||2015-02-13|2012-03-13|2012-03-14|Estimate|2015-02-13|2015-02-18|Estimate||||2015-02-13|2015-02-18|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Elderly (>65 yr) clinically stable long-term stay nursing home residents with no contraindications or allergy to D, osteoporosis or a history of fractures and receiving over 800 IU/day D, treatment for severe D deficiency or investigational agent in the prior six months on no D or had stable D doses for over two months .|Optimizing Vitamin D in the Elderly|Optimizing Vitamin D in the Elderly|Completed||N/A|86|Actual|University of California, San Francisco||4|||f||||t||||||||||2018-05-31 21:33:24.046867|2018-05-31 21:33:24.046867
NCT01554228|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2016-12-20|2012-03-13|2012-03-14|Estimate|||||||2016-12-20|2016-12-21|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|Obesity||Change in Cognitive Function in Obese Patients After Bariatric Surgery - an Observational Study|Change in Cognitive Function in Obese Patients After Bariatric Surgery - an Observational Study|Active, not recruiting|||64|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 21:33:24.642946|2018-05-31 21:33:24.642946
NCT01554215|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-03-31|2012-03-13|2012-03-14|Estimate|||||||2016-03-31|2016-04-01|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|MP||Mom Power is an Attachment Based Parenting Program for Families and Their Children|Phase 1 of Mom Power: Attachment Based Parenting and Self-Care Skills Program|Completed||Phase 2|419|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:33:24.774669|2018-05-31 21:33:24.774669
NCT01554202|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-03-05|2012-03-13|2012-03-14|Estimate|||||||2013-03-05|2013-03-06|Estimate|January 2008||2008-01-31|March 2013|2013-03-31||||December 2021|Anticipated|2021-12-31||Interventional|IMAP||Multi-modal Neuroimaging in Alzheimer's Disease|Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging|Active, not recruiting||N/A|295|Anticipated|University Hospital, Caen||9|||f||||t||||||||||2018-05-31 21:33:24.869085|2018-05-31 21:33:24.869085
NCT01554189|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2015-07-20|2012-03-12|2012-03-14|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C Infected Males|Terminated||Phase 1|37|Actual|Merck Sharp & Dohme Corp.||11|||f||||f||||||||||2018-05-31 21:33:25.015009|2018-05-31 21:33:25.015009
NCT01554176|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2016-09-15||2017-08-29|2012-03-13|2012-03-14|Estimate|2016-09-15|2016-11-07|Estimate||||2017-08-29|2017-09-27|Actual|May 18, 2012|Actual|2012-05-18|August 2017|2017-08-31|September 3, 2013|Actual|2013-09-03|September 3, 2013|Actual|2013-09-03||Interventional|||Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)|A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder|Terminated||Phase 2|129|Actual|Merck Sharp & Dohme Corp.||5||Low Enrollment|f||||f||||||||||2018-05-31 21:33:25.129323|2018-05-31 21:33:25.129323
NCT01554163|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2013-09-25||2015-10-08|2012-03-12|2012-03-14|Estimate|2013-10-04|2013-12-04|Estimate||||2015-10-08|2015-10-09|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis|A Phase III, 12-Week, Randomized, Active-Comparator-Controlled, Parallel-Group, Double Blind Study in Korea to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis|Completed||Phase 3|239|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 21:33:25.628075|2018-05-31 21:33:25.628075
NCT01554150|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-07-18|2012-03-13|2012-03-14|Estimate|||||||2014-07-18|2014-07-21|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Randomised Controlled Trial of Method of Levels Cognitive Therapy|A Randomised Controlled Trial Comparing Method of Levels Cognitive Therapy With a Contact Service for Improving Outcomes in Primary Care|Completed||N/A|55|Actual|University of Manchester||2|||f||||f||||||||||2018-05-31 21:33:26.048077|2018-05-31 21:33:26.048077
NCT01554137|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-05-31|2012-03-12|2012-03-14|Estimate|||||||2016-05-31|2016-06-01|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Interests of Strengthening Isokinetic Upper Extremity Hemiparetic Sequelae in Patients|Interests of Strengthening Isokinetic Upper Extremity Hemiparetic Sequelae in Patients|Terminated||N/A|20|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:33:26.202437|2018-05-31 21:33:26.202437
NCT01554124|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-02-12|2012-03-13|2012-03-14|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NeoMero-2||Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis|Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Probable and Confirmed Meningitis: A European Multicenter Phase I-II Trial|Completed||Phase 1/Phase 2|51|Actual|PENTA Foundation||1|||f||||t||||||||||2018-05-31 21:33:26.267722|2018-05-31 21:33:26.267722
NCT01554111|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-09-23|2012-03-12|2012-03-14|Estimate|||||||2015-09-23|2015-09-25|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparing Bowel Preparation Regimens for Flexible Sigmoidoscopy|A Randomized Controlled Study Comparing PicoSalax, Versus PicoSalax and Fleet Enema Versus Fleet Enema Alone for Sigmoidoscopy|Completed||Phase 4|120|Actual|Queen's University||3|||f||||t||||||||||2018-05-31 21:33:26.357617|2018-05-31 21:33:26.357617
NCT01554098|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2014-03-27|2012-03-12|2012-03-14|Estimate|||||||2014-03-27|2014-03-28|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Comparison of Two Colonoscopic Withdrawal Techniques|A Comparison of Two Colonoscopic Withdrawal Techniques on Colonic Polyp Detection: an Open, Randomised, Cross Over Trial|Completed||Phase 4|130|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:33:26.453569|2018-05-31 21:33:26.453569
NCT01554085|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2017-10-27|2012-03-13|2012-03-14|Estimate|||||||2017-10-27|2017-10-31|Actual|December 31, 2011|Actual|2011-12-31|October 2017|2017-10-31|September 30, 2012|Actual|2012-09-30|September 30, 2012|Actual|2012-09-30||Interventional|||First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-002158 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection|Terminated||Phase 1|78|Actual|Alios Biopharma Inc.||2||"ALS-2158 showed insufficient antiviral activity to warrant proceeding with further clinical~   development."|f||||f||f||||||||2018-05-31 21:33:26.539697|2018-05-31 21:33:26.539697
NCT01554072|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2013-06-24|2012-03-13|2012-03-14|Estimate|||||||2013-06-24|2013-06-25|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|HBCOPD||Home-based in Chronic Obstructive Pulmonary Disease|Home-based Pulmonary Rehabilitation in COPD|Completed||N/A|30|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 21:33:26.630018|2018-05-31 21:33:26.630018
NCT01554059|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2014-11-07|2012-03-13|2012-03-14|Estimate|||||||2014-11-07|2014-11-10|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|May 2013|Actual|2013-05-31||Interventional|New Beat||Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients|Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma|Completed||Phase 2|25|Actual|Sixth Affiliated Hospital, Sun Yat-sen University|||||f||||t||||||||||2018-05-31 21:33:26.713448|2018-05-31 21:33:26.713448
NCT01554046|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-11|2012-03-11|2012-03-14|Estimate|||||||2012-03-11|2012-03-14|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Interventional|||The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)|The Effect of Methylphenidate (Ritalin IR) Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)|Recruiting||N/A|400|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 21:33:26.796059|2018-05-31 21:33:26.796059
NCT01554033|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2012-03-16|2012-03-13|2012-03-14|Estimate|||||||2012-03-16|2012-03-19|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN)|Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN).|Unknown status|Recruiting||200|Anticipated|Seoul National University Hospital|||2||f||||t||||||Samples With DNA|"~     serum-60ml urine-60ml Formation study of Lymphoblast and diagnosis of a Huntington gene~   "|||2018-05-31 21:33:26.8949|2018-05-31 21:33:26.8949
NCT01554020|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-03-11|2012-03-13|2012-03-14|Estimate|||||||2013-03-11|2013-03-12|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Blood Sugar Take Care and Glucose Metabolism|Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study|Withdrawn||Phase 2|0|Actual|NewChapter, Inc.||2||Change of CRO|f||||f||||||||||2018-05-31 21:33:26.998956|2018-05-31 21:33:26.998956
NCT01554007|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-10-25|2012-03-13|2012-03-14|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Clinical Course of Korean Crohn's Disease Cohort|Clinical Course of Crohn's Disease: a Prospective Multicenter Long-term Follow-up Study in Korea|Enrolling by invitation|||2000|Anticipated|Kyunghee University Medical Center|||1||f||||t||||||Samples With DNA|"~     Whole blood, DNA, and serum will be retained for central biobank~   "|No||2018-05-31 21:33:27.089063|2018-05-31 21:33:27.089063
NCT01553994|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-03-15|2012-03-12|2012-03-14|Estimate|||||||2013-03-15|2013-03-18|Estimate|June 2006||2006-06-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Effectiveness Study of Gardasil on Condyloma|Gardasil® Population-Based Condyloma Effectiveness Study In Swedish Women Including Condyloma Incidence Estimations For Swedish Men And Women|Completed|||500000|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 21:33:27.185568|2018-05-31 21:33:27.185568
NCT01553981|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2015-04-20|2012-03-13|2012-03-14|Estimate|||||||2015-04-20|2015-04-21|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma|A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma|Completed||Phase 3|40|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:33:27.271848|2018-05-31 21:33:27.271848
NCT01553968|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-09-19|2012-03-12|2012-03-14|Estimate|||||||2016-09-19|2016-09-20|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Effects of Acute Exercise on Acetylcarnitine Concentration in Endurance Trained and Untrained Subjects|Effects of Acute Exercise on Acetylcarnitine Concentration in Endurance Trained and Untrained Subjects|Completed||N/A|9|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:33:27.351856|2018-05-31 21:33:27.351856
NCT01553955|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-07-22|2012-03-13|2012-03-14|Estimate|||||||2013-07-22|2013-07-24|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy of Training in Manual Preparation of Platelet Rich Plasma|Efficacy of Training in Preparation of Platelet Rich Plasma Using a Standard Centrifuge and Manual Pipetting Methods|Completed||N/A|28|Actual|Peterson, Noel, N.D.|||||f||||t||||||||||2018-05-31 21:33:27.417139|2018-05-31 21:33:27.417139
NCT01553942|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2018-01-06|2012-03-12|2012-03-14|Estimate|||||||2018-01-06|2018-01-09|Actual|April 2012||2012-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Afatinib With CT and RT for EGFR-Mutant NSCLC|Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:33:27.473671|2018-05-31 21:33:27.473671
NCT01553929|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-08-13|2012-03-13|2012-03-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|March 2012|Actual|2012-03-31||Interventional|EPAC-M||Physical Training and Cognitive Activity on the Mild Cognitive Impairment (MCI) Patient|Physical Trainig and Cognitive Activity on the MCI Patient|Terminated||N/A|5|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 21:33:27.569951|2018-05-31 21:33:27.569951
NCT01553916|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2017-09-07||2017-10-09|2012-03-13|2012-03-14|Estimate|2017-10-09|2017-11-08|Actual||||2017-10-09|2017-11-08|Actual|April 26, 2012|Actual|2012-04-26|October 2017|2017-10-31|June 5, 2017|Actual|2017-06-05|September 12, 2016|Actual|2016-09-12||Interventional|||Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain|Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)|Completed||Phase 1/Phase 2|19|Actual|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 21:33:27.666838|2018-05-31 21:33:27.666838
NCT01553903|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-06-03|2012-03-12|2012-03-14|Estimate|||||||2013-06-03|2013-06-04|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|OXYTAM||Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not|Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not|Completed||Phase 4|29|Actual|Institut Claudius Regaud||4|||f||||f||||||||||2018-05-31 21:33:28.049902|2018-05-31 21:33:28.049902
NCT01553890|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|November 2012|Anticipated|2012-11-30||Interventional|SSc||Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples|Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at SSc Patients Compared Healthy Peoples|Unknown status|Not yet recruiting|N/A|30|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 21:33:28.134407|2018-05-31 21:33:28.134407
NCT01553877|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2013-01-01|2012-03-12|2012-03-14|Estimate|||||||2013-01-01|2013-01-03|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Development and Acceptability Testing of Ready-to-use-complementary Food Supplement (RUCFS) for Children in Bangladesh|Development and Acceptability Testing of Ready-to-use-complementary Food Supplement (RUCFS) for Children in Bangladesh|Completed||Phase 2/Phase 3|90|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||f||||||||||2018-05-31 21:33:28.215273|2018-05-31 21:33:28.215273
NCT01553669|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-05-14|2012-03-12|2012-03-14|Estimate|||||||2012-05-14|2012-05-15|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Reminiscence Therapy on Depression, Self Esteem, Life Satisfaction, and Loneliness of the Elderly|The Effects of Reminiscence Therapy on Depression, Self Esteem, Life Satisfaction, and Loneliness of the Elderly in China|Unknown status|Recruiting|Phase 2|60|Anticipated|Chinese Academy of Sciences||2|||f||||t||||||||||2018-05-31 21:33:30.435128|2018-05-31 21:33:30.435128
NCT01553851|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|2016-09-06||2016-10-31|2012-03-12|2012-03-14|Estimate|2016-10-31|2016-12-26|Estimate||||2016-10-31|2016-12-26|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer|A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer|Completed||Phase 2|20|Actual|Washington University School of Medicine|Small number of treated patients. Short duration of GSK1120212 administration. Biopsy limitations precluded analysis of all patients.|1|||f||||f||||||||||2018-05-31 21:33:28.324307|2018-05-31 21:33:28.324307
NCT01553838|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-08-18|2012-03-12|2012-03-14|Estimate|||||||2014-08-18|2014-08-19|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Prospective Study to Evaluate MRI Guided Biopsy Compared With Transrectal Ultrasound Guided Biopsy of the Prostate in Men With Increased PSA Values|A Prospective Study to Evaluate MRI Guided Biopsy Compared With Transrectal Ultrasound Guided Biopsy of the Prostate in Men With Increased PSA Values|Completed||N/A|185|Actual|Heinrich-Heine University, Duesseldorf||1|||f||||f||||||||||2018-05-31 21:33:28.78537|2018-05-31 21:33:28.78537
NCT01553825|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2017-08-18|2012-03-13|2012-03-14|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2012|Actual|2012-03-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Assessment of Patient Experience During Treatment for Cancer|Assessment of Patient Experience During Treatment for Cancer|Recruiting|||100|Anticipated|Stanford University|||1||f||||t||||||||||2018-05-31 21:33:28.851255|2018-05-31 21:33:28.851255
NCT01553812|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-12|2012-03-12|2012-03-14|Estimate|||||||2012-03-12|2012-03-14|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||The Assessment of Airway Resistance and Airtrapping in Elderly COPD Patients by Forced Oscillation Technique (FOT)|The Assessment of Airway Resistance and Airtrapping in Elderly COPD Patients by Forced Oscillation Technique (FOT)|Completed|||158|Actual|Kwong Wah Hospital|||||f||||f||||||||||2018-05-31 21:33:28.911625|2018-05-31 21:33:28.911625
NCT01553799|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-12|2012-03-12|2012-03-14|Estimate|||||||2012-03-12|2012-03-14|Estimate|April 2012||2012-04-30|March 2012|2012-03-31||||||||Observational|||Use of Ultrasound Technology to Check Proper Placement of Tracheal and Endobronchial Tubes||Unknown status|Not yet recruiting||40|Anticipated|King Saud University|||2||f||||||||||||||2018-05-31 21:33:28.957525|2018-05-31 21:33:28.957525
NCT01553786|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2018-05-23|2012-03-12|2012-03-14|Estimate|||||||2018-05-23|2018-05-24|Actual|November 2011|Actual|2011-11-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)|STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)|Recruiting||Phase 2|70|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||f||||||||||2018-05-31 21:33:29.017685|2018-05-31 21:33:29.017685
NCT01553773|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|July 2004||2004-07-31|March 2012|2012-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment|Hyaluronic Acid Concentration in Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment: Double-blind and Randomized Clinical Trial of Efficacy|Completed||Phase 2|30|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:33:29.197901|2018-05-31 21:33:29.197901
NCT01553760|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||The Use of an Anterior Chamber Maintainer as a Sole Fluid Source in Micro Incision Cataract Surgery as Compared to a Standard Phacoemulsification Procedure||Unknown status|Not yet recruiting|N/A|20|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 21:33:29.273379|2018-05-31 21:33:29.273379
NCT01553747|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08||2014-03-25|2015-04-26|2012-03-13|2012-03-14|Estimate||||2014-03-25|2014-04-21|Estimate|2015-04-26|2015-05-13|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome|Completed||Phase 3|1150|Actual|Furiex Pharmaceuticals, Inc||3|||f||||f||||||||||2018-05-31 21:33:29.390985|2018-05-31 21:33:29.390985
NCT01553734|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2016-08-30|2012-03-13|2012-03-14|Estimate|||||||2016-08-30|2016-08-31|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia?|Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia?|Completed|||148|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||No||2018-05-31 21:33:29.870218|2018-05-31 21:33:29.870218
NCT01553721|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2016-04-15|2012-03-12|2012-03-14|Estimate|||||||2016-04-15|2016-04-18|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)|A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)|Completed||Phase 2|63|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:33:29.933567|2018-05-31 21:33:29.933567
NCT01553708|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2012-07-01||2013-03-19|2012-03-11|2012-03-14|Estimate|2012-07-01|2012-08-09|Estimate||||2013-03-19|2013-03-25|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound|The Clinical Efficacy of Epidermal Growth Factor With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream on Acceleration of Partial Thickness Burn Wound Healing|Completed||Phase 2/Phase 3|34|Actual|Chulalongkorn University|Early termination leading to small numbers of subjects analyzed and all samples have 18-60 years of age, this data cannot be applied for pediatrics.|2|||f||||t||||||||||2018-05-31 21:33:30.035197|2018-05-31 21:33:30.035197
NCT01553695|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-07-28|2012-03-13|2012-03-14|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|February 2014|Actual|2014-02-28|March 2012|Actual|2012-03-31||Interventional|||Adults With Attention Deficit Hyperactivity Disorder (ADHD): Validation of a Clinical Interview and Screening Instruments in French|Validation of a Clinical Interview for a Diagnosis of ADHD in Adults. Cross-validity of Screening Instruments ADHD in Adults. Estimation of Prevalence in France|Completed||N/A|110|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 21:33:30.273515|2018-05-31 21:33:30.273515
NCT01553656|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-08-19|2012-03-12|2012-03-14|Estimate|||||||2015-08-19|2015-08-20|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer|Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|85|Anticipated|Exelixis||1|||f||||f||||||||||2018-05-31 21:33:30.51864|2018-05-31 21:33:30.51864
NCT01553643|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2010||2010-01-31|March 2012|2012-03-31||||November 2012|Anticipated|2012-11-30||Interventional|||A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis||Unknown status|Recruiting|Phase 4|80|Anticipated|China Medical University Hospital||2|||f||||||||||||||2018-05-31 21:33:30.619172|2018-05-31 21:33:30.619172
NCT01553630|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-11-10|2012-03-13|2012-03-14|Estimate|||||||2014-11-10|2014-11-11|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Reamed Locked Plating - Metaphyseal Fractures of the Distal Femur and Tibia|Reamed Locked Plating - Metaphyseal Fractures of the Distal Femur and Tibia|Terminated||N/A|6|Actual|Florida Orthopaedic Institute||2||Low enrollment.|f||||f||||||||||2018-05-31 21:33:30.735091|2018-05-31 21:33:30.735091
NCT01553617|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2014-06-25|2012-03-13|2012-03-14|Estimate|||||||2014-06-25|2014-06-26|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||VolulyteTM in Cardiac Surgery|Efficacy and Safety of Perioperative Infusion of 6 % Hydroxyethyl Starch 130/0.4 in an Isotonic Electrolyte Solution (VolulyteTM) vs. 5% HSA as Volume Replacement Therapy During Cardiac Surgery for Adult Patients|Completed||Phase 4|133|Actual|Fresenius Kabi||2|||f||||f||||||||||2018-05-31 21:33:30.831511|2018-05-31 21:33:30.831511
NCT01553604|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2016-02-10|2012-03-13|2012-03-14|Estimate|||||||2016-02-10|2016-02-11|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Dressing Wear Time After Breast Augmentation With Prosthesis|Influence of Dressing Wear Time on Skin Colonization After Breast Augmentation With Prosthesis: a Randomized Controlled Trial|Completed||N/A|80|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:33:30.912124|2018-05-31 21:33:30.912124
NCT01553591|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08||2014-03-25|2015-04-26|2012-03-13|2012-03-14|Estimate||||2014-03-25|2014-04-21|Estimate|2015-04-26|2015-05-13|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)|A Randomized, Double-blind, Placebo-controled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome|Completed||Phase 3|1282|Actual|Furiex Pharmaceuticals, Inc||3|||f||||f||||||||||2018-05-31 21:33:31.066443|2018-05-31 21:33:31.066443
NCT01553578|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2017-05-25|2012-03-13|2012-03-14|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2012||2012-02-29|May 2015|2015-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Healing Touch or Guided Imagery In Treating Pain, Fatigue, Nausea, and Anxiety in Patients Undergoing Chemotherapy|The Efficacy of Healing Touch Versus Guided Imagery on Pain, Fatigue, Nausea, and Anxiety in Patients' Receiving Outpatient Chemotherapy|Completed||N/A|244|Actual|Wake Forest University Health Sciences||3|||f||||f|f|f||||||||2018-05-31 21:33:31.5734|2018-05-31 21:33:31.5734
NCT01553565|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2014-08-13|2012-03-13|2012-03-14|Estimate|||||||2014-08-13|2014-08-15|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prospective Comparison of Cold Polypectomy and Conventional Polypectomy for Small Colorectal Polyps in Patients Taking Antithrombotic Agents||Completed||N/A|160|Anticipated|Showa Inan General Hospital||2|||f||||f||||||||||2018-05-31 21:33:31.687374|2018-05-31 21:33:31.687374
NCT01553552|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|SchistoVAN||Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal|Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status|Completed|||99|Actual|Biomedical Research Center EPLS|||2||f||||t||||||Samples Without DNA|"~     Whole blood Sera Urine Stool~   "|||2018-05-31 21:33:31.795548|2018-05-31 21:33:31.795548
NCT01553539|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2013-11-15||2018-02-27|2012-03-12|2012-03-14|Estimate|2013-12-10|2014-01-30|Estimate||||2018-02-27|2018-03-29|Actual|October 2009||2009-10-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery|A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas|Completed||Phase 2|20|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 21:33:31.907089|2018-05-31 21:33:31.907089
NCT01553526|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-08-29|2012-03-12|2012-03-14|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|March 2013|Actual|2013-03-31||Observational|BIOFLOW-III||BIOFLOW-III All-comers Orsiro Safety and Performance Registry|BIOTRONIK - Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III|Active, not recruiting|||1356|Actual|Biotronik AG|||1||f||||f||||||||||2018-05-31 21:33:32.321707|2018-05-31 21:33:32.321707
NCT01553513|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|June 2012||2012-06-30|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|QAEK||PET/CT for the Quantification of Atherosclerotic Plaque Inflammation|PET/CT for the Quantification of Atherosclerotic Plaque Inflammation in Patients With Coronary Heart Disease: The QAEK Trial|Unknown status|Not yet recruiting||140|Anticipated|Ludwig-Maximilians - University of Munich|||4||f||||f||||||Samples With DNA|"~     A 20 ml blood sample will be obtained from each patient. The following biomarkers will be~     assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol,~     triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP,~     resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin,~     fetuin, FGF21.~      ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum~     markers.~   "|||2018-05-31 21:33:32.486725|2018-05-31 21:33:32.486725
NCT01553500|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2014-04-01|2012-03-12|2012-03-14|Estimate|||||||2014-04-01|2014-04-02|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|GC-NASH||Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease|Study of the Efficacy and Tolerability of Glucomannan on Children Affected by NAFLD|Completed||Phase 2|66|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||||||||||||2018-05-31 21:33:32.590073|2018-05-31 21:33:32.590073
NCT01553487|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-08-13|2012-03-12|2012-03-14|Estimate|||||||2013-08-13|2013-08-14|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|Vib-Frx||Effects Of Unilateral Forearm Vibration On The Loss Of Muscle And Bone Of Contralateral Forearm|Effects Of Unilateral Forearm Vibration On The Loss Of Muscle Strength And Bone Of The Contralateral Forearm Due to Forearm/Elbow Fracture|Withdrawn||N/A|0|Actual|Bagcilar Training and Research Hospital||2||We did not found voluntary subjects|f||||f||||||||||2018-05-31 21:33:32.670693|2018-05-31 21:33:32.670693
NCT01553474|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-06-30|2012-03-13|2012-03-14|Estimate|||||||2017-06-30|2017-07-02|Actual|February 24, 2012||2012-02-24|February 5, 2013|2013-02-05|February 5, 2013||2013-02-05|||||Observational|||Blood and Saliva Sample Collection for AREDS 2|Blood and Saliva Sample Collection and Submission to the Age-Related Eye Disease Study 2 (AREDS2) Genetic Repository|Completed|||56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:33:32.743067|2018-05-31 21:33:32.743067
NCT01553461|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2018-05-26|2012-03-13|2012-03-14|Estimate|||||||2018-05-26|2018-05-30|Actual|February 2, 2012||2012-02-02|May 23, 2018|2018-05-23|October 20, 2036|Anticipated|2036-10-20|October 20, 2036|Anticipated|2036-10-20||Interventional|||Transplants With Unlicensed Preserved Cord Blood|A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications|Recruiting||Phase 1/Phase 2|500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:33:32.795141|2018-05-31 21:33:32.795141
NCT01553448|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2016-05-17|2012-03-13|2012-03-14|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2012||2012-03-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Gene Expression in Samples From Younger Patients With Neuroblastoma|The Role of Stroma-Derived Soluble TßRIII in Neuroblastoma|Completed|||75|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:33:32.871677|2018-05-31 21:33:32.871677
NCT01553435|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-04-12|2012-03-13|2012-03-14|Estimate|||||||2015-04-12|2015-04-14|Estimate|January 2011||2011-01-31|April 2015|2015-04-30||||January 2015|Actual|2015-01-31||Interventional|||Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients|Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients|Unknown status|Active, not recruiting|N/A|36|Anticipated|King Abdullah International Medical Research Center||2|||f||||t||||||||||2018-05-31 21:33:32.955761|2018-05-31 21:33:32.955761
NCT01553422|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-12-03|2012-03-13|2012-03-14|Estimate|||||||2012-12-03|2012-12-04|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava Before and After Fluid Therapy|Assessment of Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava by Emergency Ultrasonography Before and After Fluid Therapy|Completed||Phase 4|82|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:33:33.035257|2018-05-31 21:33:33.035257
NCT01553409|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-05-07|2012-03-13|2012-03-14|Estimate|||||||2014-05-07|2014-05-08|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Effect of Blood Donation on Blood Pressure, Iron Metabolism, Oxidative Stress|Prospective Observational Study on the Effects of Blood Donation on Blood Pressure, Iron Metabolism and Oxidative Stress|Completed|||300|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||Samples Without DNA|"~     regular blood donation is done and from blood, that is taken for blood tests by the blood~     donation center any there are made blood tests of lipid metabolism, iron metabolism and~     antioxidative stress~   "|||2018-05-31 21:33:33.096958|2018-05-31 21:33:33.096958
NCT01553396|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Observational|||Muscle Strength and Functional Autonomy of Elderly Women|Muscle Strength and Functional Autonomy of Normo-IGF-1 Elderly Women With Skeletal Muscle Dysfunctions|Completed|||35|Actual|Euro-American Network of Human Kinetics|||||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 21:33:33.152052|2018-05-31 21:33:33.152052
NCT01553383|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-04-05|2012-03-13|2012-03-14|Estimate|||||||2013-04-05|2013-04-08|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of Nasal Positive End Expiratory Pressure Valve to Dental Device as an Alternative Treatment for Obstructive Sleep Apnea|Comparison of Nasal Positive End Expiratory Pressure Valve to Dental Device as an Alternative Treatment for OSA|Completed||N/A|200|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:33:33.228326|2018-05-31 21:33:33.228326
NCT01553370|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||Randomized Controlled Trial of Milk Products and Physical Activity on Body Composition and Health in Overweight Young Males|Randomized Controlled Trial of Milk Products and Physical Activity on Body Composition and Health in Overweight Young Males|Unknown status|Not yet recruiting|N/A|54|Anticipated|Brock University||2|||f||||f||||||||||2018-05-31 21:33:33.284946|2018-05-31 21:33:33.284946
NCT01553357|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2012-03-13|2012-03-13|2012-03-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia|A Pilot Study of Lenalidomide and Dexamethasone in Patients With Primary Plasma Cell Leukemia|Completed||Phase 2|23|Actual|IRCCS Centro di Riferimento Oncologico della Basilicata|||||f||||t||||||||||2018-05-31 21:33:33.357795|2018-05-31 21:33:33.357795
NCT01553344|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-12-22|2012-03-12|2012-03-14|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Observational|OMSOST||Serum Sclerostin Level & Treatment of Vitamin D Deficiency|Serum Sclerostin Level in Patients With Vitamin D Deficiency|Completed|||26|Actual|Bagcilar Training and Research Hospital|||||f||||f||||||||||2018-05-31 21:33:33.420258|2018-05-31 21:33:33.420258
NCT01553331|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2014-12-10|2012-03-13|2012-03-14|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Day Case Laparoscopic Cholecystectomy: Fundus First With Ultrasonic Dissection or Conventional Diathermy Hook|Day Case Laparoscopic Cholecystectomy: Comparison of Fundus First With Ultrasonic Dissection or Conventional Diathermy Hook, Randomized Trial|Completed||N/A|169|Actual|Central Finland Hospital District||2|||f||||t||||||||||2018-05-31 21:33:33.520195|2018-05-31 21:33:33.520195
NCT01552993|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2016-04-21|2012-03-09|2012-03-13|Estimate|||||||2016-04-21|2016-04-22|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Registration and Treatment of Pain During Eye Examination of Prematurity|Registration and Treatment of Pain During Eye Examination of Prematurity|Terminated||N/A|5|Actual|St. Olavs Hospital||2||the chosen intervention was obviously ineffective|f||||f||||||||||2018-05-31 21:33:39.36536|2018-05-31 21:33:39.36536
NCT01553318|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2016-04-26||2016-09-28|2012-03-12|2012-03-14|Estimate|2016-09-28|2016-11-17|Estimate||||2016-09-28|2016-11-17|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|KetoforFMS||Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study|Novel Use of Ketotifen (Mast Cell Stabilizer) in Fibromyalgia: A Pilot Study|Completed||Phase 3|51|Actual|Indiana University|Just tested one dose (low dose). Would be better if we tested higher dosages|2|||f||||t||||||||||2018-05-31 21:33:33.606721|2018-05-31 21:33:33.606721
NCT01553305|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2013-07-03|2012-03-10|2012-03-14|Estimate|||||||2013-07-03|2013-07-04|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of the Effect of Supervised Exercise Programme in Patients With Rheumatoid Arthritis|The Effect of 6-weeks Supervised Exercise Programme Followed by 6-weeks Unsupervised Exercise Programme Versus 12 Weeks Unsupervised Exercise Programme in Patients With Rheumatoid Arthritis.|Completed||N/A|52|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 21:33:34.815769|2018-05-31 21:33:34.815769
NCT01553292|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2012-10-05||2013-06-18|2012-03-13|2012-03-14|Estimate|2013-06-18|2013-07-24|Estimate||||2013-06-18|2013-07-24|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ECALMIST||Early CPAP And Large Volume Minimally Invasive Surfactant (ECALMIST) in Preterm Infants With RDS|Feasibility of Using Early CPAP (Continuous Positive Airway Pressure) And Large Volume Minimal Invasive Surfactant Therapy (ECALMIST) in Preterm Infants With Respiratory Distress Syndrome (RDS)|Completed||N/A|21|Actual|University of Manitoba|This is non randomized interventional feasibility trial, small sample size and in one center|1|||f||||t||||||||||2018-05-31 21:33:34.922832|2018-05-31 21:33:34.922832
NCT01553279|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-02-27|2012-03-09|2012-03-14|Estimate|||||||2017-02-27|2017-03-01|Actual|March 2012||2012-03-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines|A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine|Completed||Phase 3|284|Actual|MCM Vaccines B.V.||2|||f||||f||||||||||2018-05-31 21:33:35.229448|2018-05-31 21:33:35.229448
NCT01553266|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-04-17|2012-03-13|2012-03-14|Estimate|||||||2017-04-17|2017-04-18|Actual|March 1, 2012|Actual|2012-03-01|December 2013|2013-12-31|April 12, 2017|Actual|2017-04-12|March 12, 2014|Actual|2014-03-12||Observational|||Mobile Diabetes Education Teams in Primary Care|Mobile Diabetes Education Teams in Primary Care|Completed|||900|Actual|Ryerson University|||2||f||||f||||||||||2018-05-31 21:33:35.329218|2018-05-31 21:33:35.329218
NCT01553253|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2014-06-16|2012-03-09|2012-03-14|Estimate|||||||2014-06-16|2014-06-17|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|FACTS1||From ACute To Chronic Postoperative Pain in Patients for Elective Cholecystectomy|From Acute To Chronic Postoperative Pain in Patients for Elective Cholecystectomy: The Significance of Components of Pain|Completed|||100|Actual|Odense University Hospital|||||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 21:33:35.408136|2018-05-31 21:33:35.408136
NCT01553240|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2017-01-12||2017-01-12|2012-03-13|2012-03-14|Estimate|2017-01-12|2017-01-13|Estimate||||2017-01-12|2017-01-13|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.|Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies|Neurocircuitry of Autism- fMRI and Transcranial Magnetic Stimulation Studies|Terminated||N/A|8|Actual|New York State Psychiatric Institute||1||Principal Investigator (Dr. Sporn) left the sponsoring institution.|f||||t||||||||||2018-05-31 21:33:35.577227|2018-05-31 21:33:35.577227
NCT01553227|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2012-11-26|2012-03-13|2012-03-14|Estimate|||||||2012-11-26|2012-11-27|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Treatment for Obstructive Sleep Apnea Hypopnea Syndrome and Obesity Hypoventilation Syndrome (OHS)|Effect of Auto-trilevel Ventilator on Patients With Obstructive Sleep Apnea Hypopnea Syndrome and Obesity|Completed||N/A|24|Actual|Nanjing Medical University||1|||f||||f||||||||||2018-05-31 21:33:35.727112|2018-05-31 21:33:35.727112
NCT01553214|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2018-03-28|2012-03-10|2012-03-14|Estimate|||||||2018-03-28|2018-03-29|Actual|March 7, 2012||2012-03-07|March 27, 2018|2018-03-27|January 1, 2030|Anticipated|2030-01-01|January 1, 2030|Anticipated|2030-01-01||Interventional|||Improving White Blood Cell Collection From Healthy Donors|Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone|Recruiting||Phase 1|1000|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 21:33:35.816582|2018-05-31 21:33:35.816582
NCT01553201|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2018-04-24|2012-03-13|2012-03-14|Estimate|||||||2018-04-24|2018-04-25|Actual|February 27, 2012||2012-02-27|April 10, 2018|2018-04-10|December 31, 2019|Anticipated|2019-12-31|January 1, 2019|Anticipated|2019-01-01||Interventional|||Botulinum Toxin for Pelvic Pain in Women With Endometriosis|The Effectiveness of Botulinum Toxin on Persistent Pelvic Pain in Women With Endometriosis|Recruiting||Phase 1/Phase 2|35|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:33:35.920748|2018-05-31 21:33:35.920748
NCT01553188|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2017-12-06|2012-03-10|2012-03-14|Estimate|||||||2017-12-06|2017-12-07|Actual|February 8, 2012||2012-02-08|July 17, 2017|2017-07-17|January 1, 2018|Anticipated|2018-01-01|April 20, 2017|Actual|2017-04-20||Interventional|||AMG 386 and Abiraterone for Advanced Prostate Cancer|A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer|Active, not recruiting||Phase 2|23|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 21:33:36.022589|2018-05-31 21:33:36.022589
NCT01553175|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2016-07-13|2012-03-10|2012-03-14|Estimate|||||||2016-07-13|2016-07-14|Estimate|March 2012||2012-03-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Studying Gene Expression in Samples From Patients With Rhabdoid Tumors|Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors|Completed|||25|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:33:36.135016|2018-05-31 21:33:36.135016
NCT01553162|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2016-05-17|2012-03-10|2012-03-14|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2012||2012-04-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Dexamethasone and Prednisone Sensitivity in Samples From Younger Patients With High-Risk B-Cell Precursor Acute Lymphoblastic Leukemia|B-precursor Acute Lymphoblastic Leukemia (ALL): Studying the Mechanisms Behind Dexamethasone and Prednisone Sensitivity in High-Risk Patients|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:33:36.210487|2018-05-31 21:33:36.210487
NCT01552460|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-04-02|2012-03-08|2012-03-13|Estimate|||||||2015-04-02|2015-04-03|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Brain Genomics Superstruct Project|Brain Genomics Superstruct Project|Completed|||61|Actual|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 21:33:47.804379|2018-05-31 21:33:47.804379
NCT01553149|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-10|||2018-05-23|2012-03-10|2012-03-14|Estimate|||||||2018-05-23|2018-05-24|Actual|March 19, 2012|Actual|2012-03-19|May 2018|2018-05-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma|A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas|Active, not recruiting||Phase 2|80|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:33:36.307414|2018-05-31 21:33:36.307414
NCT01553136|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-10-17||2018-02-09|2012-03-09|2012-03-13|Estimate|2018-02-09|2018-02-12|Actual||||2018-02-09|2018-02-12|Actual|September 2012||2012-09-30|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Varenicline Treatment of Alcohol Dependence in Smokers|1/2-Multi-site Study: Varenicline Treatment of Alcohol Dependent Smokers|Completed||Phase 2|131|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:33:36.680076|2018-05-31 21:33:36.680076
NCT01553123|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2013-02-05|2012-03-09|2012-03-13|Estimate|||||||2013-02-05|2013-02-07|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma|A Randomized, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate in Women With Anemia Associated With Uterine Leiomyomas|Withdrawn||Phase 3|0|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:33:37.185596|2018-05-31 21:33:37.185596
NCT01553110|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-02-28|2012-03-09|2012-03-13|Estimate|||||||2018-02-28|2018-03-01|Actual|March 2012||2012-03-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Observational|||An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms|An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms in Acute Rhinosinusitis.|Recruiting|||62|Anticipated|Virginia Commonwealth University|||2||f||||t|f|f||||Samples With DNA|"~     Nasal Secretions~   "|||2018-05-31 21:33:37.356871|2018-05-31 21:33:37.356871
NCT01553097|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-12-12|2012-03-09|2012-03-13|Estimate|||||||2014-12-12|2014-12-16|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty|Neurocognitive Impairment in Women With Early Stage Breast Cancer|Completed|||51|Actual|Virginia Commonwealth University|||3||f||||t||||||Samples Without DNA|"~     3 cc of blood in a BD Vacutainer® tube preserved with 5.4mg K2 EDTA for the cytokine assay~   "|||2018-05-31 21:33:37.445168|2018-05-31 21:33:37.445168
NCT01553084|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-10-30|2012-03-09|2012-03-13|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2012||2012-05-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|October 2017|Actual|2017-10-31||Interventional|NHLBI-RO1||A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers|A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers|Active, not recruiting||Phase 4|1500|Anticipated|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 21:33:37.535355|2018-05-31 21:33:37.535355
NCT01553071|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-12-11|2012-03-09|2012-03-13|Estimate|||||||2017-12-11|2017-12-13|Actual|November 2016||2016-11-30|December 2017|2017-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies|Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies|Recruiting||Phase 1|8|Anticipated|South Plains Oncology Consortium||1|||f||||t||||||||||2018-05-31 21:33:37.614858|2018-05-31 21:33:37.614858
NCT01553058|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2017-08-04||2018-04-23|2012-03-09|2012-03-13|Estimate|2018-04-23|2018-05-22|Actual||||2018-04-23|2018-05-22|Actual|July 2012||2012-07-31|April 2018|2018-04-30|October 27, 2016|Actual|2016-10-27|August 8, 2016|Actual|2016-08-08||Interventional|VIP||Vascular Inflammation in Psoriasis Trial (The VIP Trial)|A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease|Completed||Phase 4|97|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 21:33:37.742357|2018-05-31 21:33:37.742357
NCT01553045|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2014-12-02|2012-03-12|2012-03-13|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|May 2014|Actual|2014-05-31||Observational|SMURF||Reasons for Variations in Health Related Quality of Life and Symptom Burden in Patients With Atrial Fibrillation|Observational Study of the Variation in Health-related Quality of Life and Symptom Burden in Patients Accepted for Catheter Ablation of Atrial Fibrillation in Relation to Biomarkers, Intracardiac Pressures and Echocardiography.|Unknown status|Active, not recruiting||200|Anticipated|University Hospital, Linkoeping|||1||f||||t||||||Samples Without DNA|"~     Blood samples will be drawn from femoral vein, CS and LA (baseline sampling).~      Concerning sub-study: After the induction of AF and after the patient has maintained AF in 30~     minutes blood samples will be drawn in the exact same way as before the induction in the~     intervention group.~      Patients who are going to be randomized to control group after the baseline blood sampling,~     are going to be monitored in about 30 minutes to examine whether they maintain sinus rhythm~     (SR) under that time. No intervention, clinical or experimental is going to be made during~     that time. After those 30 minutes, blood samples are going to be drawn in the exact same way~     as before.~      Blood to be analyzed for biomarkers will be froozen to -70 degress and analyzed when the~     study is completed.~   "|||2018-05-31 21:33:38.939818|2018-05-31 21:33:38.939818
NCT01553032|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2013-08-01|2012-03-09|2012-03-13|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|HICARE||Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)|Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux®|Unknown status|Recruiting|Phase 4|500|Anticipated|University of Heidelberg Medical Center||2|||f||||t||||||||||2018-05-31 21:33:39.027873|2018-05-31 21:33:39.027873
NCT01553019|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-09-01|2012-03-09|2012-03-13|Estimate|||||||2017-09-01|2017-09-06|Actual|October 2011||2011-10-31|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|PC03||Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer|A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma|Completed||Phase 2|2|Actual|University of Florida||3|||f||||t|f|f||||||Undecided||2018-05-31 21:33:39.153847|2018-05-31 21:33:39.153847
NCT01553006|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-03-13|2012-03-12|2012-03-13|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|RS||Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis|A Comparison of Cefditoren Pivoxil 10 mg/kg/Day and Cefditoren Pivoxil 20 mg/kg/Day in Treatment of Childhood With Acute Rhinosinusitis|Unknown status|Recruiting|Phase 4|120|Anticipated|Thammasat University||2|||f||||t||||||||||2018-05-31 21:33:39.284298|2018-05-31 21:33:39.284298
NCT01552980|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-27|2012-03-12|2012-03-13|Estimate|||||||2012-03-27|2012-03-28|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|mSOX||Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma|A Phase II Trial Evaluate a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University|||||f||||t||||||||||2018-05-31 21:33:39.459899|2018-05-31 21:33:39.459899
NCT01552967|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-27|2012-03-09|2012-03-13|Estimate|||||||2012-03-27|2012-03-28|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|mXELOX||Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma|A Phase II Trial Evaluating a Modified Regimen of Oxaliplatin and Capecitabine in First-Line Treatment of Metastatic Colorectal Adenocarcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University|||||f||||t||||||||||2018-05-31 21:33:39.53362|2018-05-31 21:33:39.53362
NCT01552954|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2013-10-30||2014-12-10|2012-03-09|2012-03-13|Estimate|2014-12-10|2014-12-18|Estimate||||2014-12-10|2014-12-18|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|ESPECIAL||Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan|Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial|Completed||Phase 4|269|Actual|Seoul National University Bundang Hospital|The major limitation of this study is that we used a 24-hour volume urine collected at a single time point for each follow-up visit. Urine excretion can be influenced by the sodium intake of individual patients at certain point.|2|||f||||f||||||||||2018-05-31 21:33:39.645747|2018-05-31 21:33:39.645747
NCT01552941|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-10-28|2012-03-09|2012-03-13|Estimate|||||||2016-10-28|2016-11-01|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis|Pilot Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid Arthritis|Completed||N/A|18|Actual|SetPoint Medical Corporation||1|||f||||f||||||||No||2018-05-31 21:33:39.975489|2018-05-31 21:33:39.975489
NCT01552928|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2013-09-20||2014-03-12|2012-03-09|2012-03-13|Estimate|2013-11-21|2014-01-10|Estimate||||2014-03-12|2014-04-17|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, 4-Period Crossover Trial to Assess the Effect of Anagrelide Hydrochloride on QT/QTc Interval in Healthy Men and Women.|Completed||Phase 1|60|Actual|Shire||4|||f||||f||||||||||2018-05-31 21:33:40.069182|2018-05-31 21:33:40.069182
NCT01552915|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2014-12-03||2014-12-10|2012-03-09|2012-03-13|Estimate|2014-12-10|2014-12-11|Estimate||||2014-12-10|2014-12-11|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety Set: All subjects in the Randomized Set who took at least 1 dose of investigational product.|Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder|A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|464|Actual|Shire||3|||f||||f||||||||||2018-05-31 21:33:40.824005|2018-05-31 21:33:40.824005
NCT01552902|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2015-03-04||2015-03-04|2012-03-09|2012-03-13|Estimate|2015-03-04|2015-03-18|Estimate||||2015-03-04|2015-03-18|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||The Safety set consisted of all participants in the Randomized set (all screened participants for whom a randomization number was generated) who took at least 1 dose of investigational product.|Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder|A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|549|Actual|Shire||3|||f||||f||||||||||2018-05-31 21:33:41.405115|2018-05-31 21:33:41.405115
NCT01552889|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2017-01-25||2017-03-16|2012-03-09|2012-03-13|Estimate|2017-03-16|2017-04-27|Actual||||2017-03-16|2017-04-27|Actual|January 2012||2012-01-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|DOCS||Depression Outpatient Cardiology Screening Study|Randomized Controlled Trial of Screening for Depression in Cardiac Outpatients|Completed||N/A|201|Actual|Washington University School of Medicine||2|||f||||t||||||||No||2018-05-31 21:33:42.154767|2018-05-31 21:33:42.154767
NCT01552876|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2013-10-30||2015-05-06|2012-03-09|2012-03-13|Estimate|2014-08-14|2014-08-15|Estimate||||2015-05-06|2015-05-22|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||All enrolled subjects.|Comparative Clinical Evaluation of Soft Toric Lens Designs|Comparative Clinical Evaluation of Soft Toric Lens Designs|Completed||N/A|42|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 21:33:42.432051|2018-05-31 21:33:42.432051
NCT01552863|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-08-28|2012-03-09|2012-03-13|Estimate|||||||2015-08-28|2015-08-31|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers|Open-Label, Single-Dose, Randomized, Crossover Study To Evaluate The Pharmacokinetics Of Oxycodone Following Oral Administration Of PF-00345439 Under Fed Conditions In Healthy Volunteers|Completed||Phase 1|21|Actual|Pain Therapeutics||6|||f||||f||||||||||2018-05-31 21:33:42.63419|2018-05-31 21:33:42.63419
NCT01552850|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-08-28|2012-03-09|2012-03-13|Estimate|||||||2015-08-28|2015-08-31|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetics And Relative Bioavailability Study Of Oxycodone|An Open-Label, Single-Dose, Randomized, Crossover Pharmacokinetics And Relative Bioavailability Study Of Three Modified 40 Mg Oxycodone Formulations Compared With 40 Mg Pf-00345439 Capsule Formulation In Healthy Volunteers|Completed||Phase 1|18|Actual|Pain Therapeutics||5|||f||||f||||||||||2018-05-31 21:33:42.718567|2018-05-31 21:33:42.718567
NCT01552837|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-09|2012-03-09|2012-03-13|Estimate|||||||2012-03-09|2012-03-13|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology|Effects of Quetiapine on Ultrastructural Hippocampal and Neurochemical Changes in Patients With Bipolar Disorder: Searching for Antidepressant and Mood Stabilising Neurophysiology|Completed||N/A|33|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 21:33:42.795323|2018-05-31 21:33:42.795323
NCT01552824|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-05-09|2012-03-12|2012-03-13|Estimate|||||||2015-05-09|2015-05-12|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|June 2018|Anticipated|2018-06-30|May 2017|Anticipated|2017-05-31||Interventional|CYSTUO||Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions|Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions|Not yet recruiting||Phase 2|60|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 21:33:42.869408|2018-05-31 21:33:42.869408
NCT01552811|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-02-04|2012-03-12|2012-03-13|Estimate|||||||2014-02-04|2014-02-05|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Studies of Pancreatic Islet Mass by Positron Emission Tomography (PET)|Open Study to Investigate Pancreatic Islet Mass by Positron Emission Tomography Using the Tracer [11C]5-hydroxytryptophane|Completed|||20|Actual|Uppsala University Hospital|||2||f||||||||||||||2018-05-31 21:33:42.940765|2018-05-31 21:33:42.940765
NCT01552798|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2016-01-14|2012-03-09|2012-03-13|Estimate|||||||2016-01-14|2016-01-15|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Tarot Headache||Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache|A Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single Dose of Fast Release Aspirin 1000 mg and Acetaminophen 1000 mg in Tension Type Headache Pain|Terminated||Phase 3|9|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:33:42.988012|2018-05-31 21:33:42.988012
NCT01552785|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-06-21|2012-03-09|2012-03-13|Estimate|||||||2012-06-21|2012-06-22|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||A Comparison of Measurements of Peripheral Tissue Oxygenation by NONIN EQUANOX 7600, INVOS 5100c, and FORE-SIGHT||Completed|||10|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 21:33:43.077385|2018-05-31 21:33:43.077385
NCT01552772|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2014-09-02||2014-10-08|2012-03-09|2012-03-13|Estimate|2014-09-02|2014-09-09|Estimate||||2014-10-08|2014-10-10|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole|An Open-label, Safety and Tolerability Trial of Aripiprazole IM Depot Treatment Initiation in Adult Subjects With Schizophrenia Stabilized on Atypical Oral Antipsychotics Other Than Aripiprazole|Completed||Phase 1|60|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 21:33:43.138597|2018-05-31 21:33:43.138597
NCT01552759|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2013-03-08|2012-03-09|2012-03-13|Estimate|||||||2013-03-08|2013-03-11|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Appetite Hormones in Binge Eating Disorder|Appetite Hormones in Binge Eating Disorder|Completed||N/A|96|Actual|New York Obesity and Nutrition Research Center||3|||f||||t||||||||||2018-05-31 21:33:43.598967|2018-05-31 21:33:43.598967
NCT01552746|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2014-06-16|2012-03-09|2012-03-13|Estimate|||||||2014-06-16|2014-06-17|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|FACTS2||From ACute To Chronic Postoperative Shoulder Pain in Patients for Elective Lobectomy|From Acute to Chronic Postoperative Shoulder Pain in Patients for Elective Lobectomy|Completed|||60|Actual|Odense University Hospital|||||f||||f||||||||||2018-05-31 21:33:43.717993|2018-05-31 21:33:43.717993
NCT01552733|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2017-01-26|2012-03-12|2012-03-13|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 1, 2012|Actual|2012-03-01|January 2017|2017-01-31|March 16, 2016|Actual|2016-03-16|March 16, 2016|Actual|2016-03-16||Interventional|R-TEASE||Robotic Therapy Early After Stroke Events|Robotic Therapy Early After Stroke Events|Completed||N/A|80|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 21:33:43.792246|2018-05-31 21:33:43.792246
NCT01552720|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-12|2012-03-12|2012-03-13|Estimate|||||||2012-03-12|2012-03-13|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|CCMOCPAAD||Clinical Characteristics, Management and Outcomes of Chinese Patients With Acute Aortic Dissection|Clinical Investigation of Chinese Patients With Aortic Dissection|Unknown status|Recruiting||5000|Anticipated|Xijing Hospital|||||f||||t||||||||||2018-05-31 21:33:43.896422|2018-05-31 21:33:43.896422
NCT01552707|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-03-16|2012-03-08|2012-03-13|Estimate|||||||2017-03-16|2017-03-17|Actual|June 2012||2012-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Safety Study of Mesenchymal Stem Cells and Spinal Fusion|"Ex Vivo Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue for Spinal Fusion in Spine Degenerative Disease"|Active, not recruiting||Phase 1/Phase 2|62|Anticipated|Banc de Sang i Teixits||2|||f||||f||||||||||2018-05-31 21:33:43.980851|2018-05-31 21:33:43.980851
NCT01552694|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2015-02-05||2018-04-05|2012-03-12|2012-03-13|Estimate|2015-03-04|2015-03-05|Estimate||||2018-04-05|2018-05-08|Actual|October 2012||2012-10-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation|A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia for Reducing Inflammation and Increasing EPC Number in HIV Infected Men and Women With Insulin Resistance and Central Adiposity.|Completed||Phase 3|38|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 21:33:44.106533|2018-05-31 21:33:44.106533
NCT01552681|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2016-02-21||2016-03-22|2012-03-09|2012-03-13|Estimate|2016-03-22|2016-03-23|Estimate||||2016-03-22|2016-03-23|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional||The Modified Intent-to-Treat population included all randomized subjects who received at least one dose of either baminercept or placebo and had a screening stimulated salivary flow assessment|Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome|A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren's Syndrome (ASJ02)|Terminated||Phase 2|52|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Randomization was prematurely stopped in July 2014 due to study product expiration. 52 of the 72 planned subjects were randomized.|2||Expired experimental study agent, no additional supply available.|f||||t||||||||Yes|The plan is to share data in ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval.|2018-05-31 21:33:44.608954|2018-05-31 21:33:44.608954
NCT01552668|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-05-27|2012-03-12|2012-03-13|Estimate|||||||2014-05-27|2014-05-28|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Fidaxomicin to Prevent Clostridium Difficile Colonization|The Effect of a Twice Daily, 200 mg Dose of Oral Fidaxomicin Compared to Placebo on Risk of Acquiring C. Difficile and Developing C. Difficile Infection (CDI) in High Risk Patients|Withdrawn||Phase 4|0|Actual|Washington University School of Medicine||2||Study not performed|f||||f||||||||||2018-05-31 21:33:45.42217|2018-05-31 21:33:45.42217
NCT01552642|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-07-27|2012-03-12|2012-03-13|Estimate|||||||2015-07-27|2015-07-29|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children|An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children|Completed||Phase 3|77|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 21:33:45.585741|2018-05-31 21:33:45.585741
NCT01552629|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-02-20|2012-03-09|2012-03-13|Estimate|||||||2017-02-20|2017-02-23|Actual|January 5, 2012|Actual|2012-01-05|February 2017|2017-02-28|August 28, 2013|Actual|2013-08-28|August 28, 2013|Actual|2013-08-28||Interventional|||A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 2|22|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:33:45.65449|2018-05-31 21:33:45.65449
NCT01552616|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2013-04-05|2012-03-09|2012-03-13|Estimate|||||||2013-04-05|2013-04-09|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Performance of Muscle Activation for Critical Care Patients|Evaluation of Thermal-aided Muscle Activation in Intensive Care Unit (ICU) Patients - A PILOT Study|Terminated||N/A|5|Actual|Niveus Medical, Inc.||2||Enrollment|f||||f||||||||||2018-05-31 21:33:45.729601|2018-05-31 21:33:45.729601
NCT01552603|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|2014-09-08||2016-04-27|2012-03-09|2012-03-13|Estimate|2014-09-15|2014-09-17|Estimate||||2016-04-27|2016-06-03|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Artificial Pancreas Control System in an Inpatient Setting|Sensor-controlled Insulin- and Glucagon Delivery in Subjects With Type 1 Diabetes: Testing of an Automated System in a Supervised Inpatient Setting|Completed||Phase 2|14|Actual|Legacy Health System||1|||f||||t||||||||||2018-05-31 21:33:45.796236|2018-05-31 21:33:45.796236
NCT01552590|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-01-03|2012-03-09|2012-03-13|Estimate|||||||2013-01-03|2013-01-04|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|ECF||Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites|Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites|Unknown status|Recruiting|Phase 4|74|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:33:45.938722|2018-05-31 21:33:45.938722
NCT01552577|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-03-10|2012-03-12|2012-03-13|Estimate|||||||2016-03-10|2016-03-11|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|August 2015|Actual|2015-08-31||Observational|RETINA||The RETINA Project: Reliable Eye Tracking in Neurocognitive Assessment of Traumatic Brain Injury|Eye Tracking Indicators of Neurocognitive Status After Traumatic Brain Injury|Terminated|||183|Actual|Uniformed Services University of the Health Sciences|||2|Expiration of funding|f||||t||||||||||2018-05-31 21:33:47.024193|2018-05-31 21:33:47.024193
NCT01552564|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-10-27|2012-03-12|2012-03-13|Estimate|||||||2014-10-27|2014-10-28|Estimate|March 2012||2012-03-31|October 2014|2014-10-31||||January 2014|Actual|2014-01-31||Observational|Micro-AMI||The Microcirculation in Acute Myocardial Infarction (Micro-AMI)|The Microcirculation in Acute Myocardial Infarction (Micro-AMI)|Completed|||50|Actual|University of Bristol|||1||f||||t||||||||||2018-05-31 21:33:47.098443|2018-05-31 21:33:47.098443
NCT01552551|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-12-29|2012-03-12|2012-03-13|Estimate|||||||2015-12-29|2015-12-30|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Assessment and Referral Versus Exercise in Primary Prevention of Falls: PA Healthy Steps Program|Assessment and Referral Versus Exercise in Primary Prevention of Falls: PA Healthy Steps Program|Completed||N/A|189|Actual|University of Pittsburgh||3|||f||||t||||||||Yes|Deidentified research data will be made available to qualified investigators|2018-05-31 21:33:47.164995|2018-05-31 21:33:47.164995
NCT01552538|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2016-10-28|2012-03-09|2012-03-13|Estimate|||||||2016-10-28|2016-11-01|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Long Term Extension Study For SPM-005 Participants|Long Term Observational Study of the Safety and Efficacy of an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 1/Phase 2|18|Anticipated|SetPoint Medical Corporation||1|||f||||f||||||||No||2018-05-31 21:33:47.248734|2018-05-31 21:33:47.248734
NCT01552525|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-03-02|2012-03-08|2012-03-13|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||L-Arginine, Symmetrical and Asymmetrical Dimethylarginine (SDMA/ADMA) in Acute Kidney Injury (AKI)|Regulation of L-Arginine Und Its Derivatives of Asymmetrical and Symmetrical Dimethylarginine and L-NG Monomethylarginine (ADMA/SDMA/L-NMMA) in Acute Kidney Injury and Correlation to Cardiac, Renal and Vascular Function and Mortality|Completed|||300|Anticipated|Wuerzburg University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood and urine samples will be centrifuged. One ml aliquots of plasma, serum, urine and a~     whole blood sample will be stored at -80°C.~   "|||2018-05-31 21:33:47.322328|2018-05-31 21:33:47.322328
NCT01552512|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-03-08|2012-03-08|2012-03-13|Estimate|||||||2012-03-08|2012-03-13|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|NPPU||Nutributter Programming to Prevent Undernutrition: an Evaluation|Randomized Control Trial of Complementary Food to Prevent Undernutrition Among At-Risk Infants in Fort San Michel, Haiti|Unknown status|Active, not recruiting|N/A|612|Anticipated|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 21:33:47.390125|2018-05-31 21:33:47.390125
NCT01552499|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-08-13|2012-03-08|2012-03-13|Estimate|||||||2015-08-13|2015-08-17|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Parallel Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers|Completed||N/A|25|Actual|MiMedx Group, Inc.||2|||f||||||||||||||2018-05-31 21:33:47.473353|2018-05-31 21:33:47.473353
NCT01552486|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-11-02|2012-03-08|2012-03-13|Estimate|||||||2016-11-02|2016-11-03|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Chiropractic Spinal Manipulative Therapy for Acute Sciatica Secondary to Lumbar Disc Herniation|Biology and Clinical Outcomes of Chiropractic Spinal Manipulative Therapy in the Treatment of Patients With Acute Inflammatory Radiculopathy Secondary to Lumbar Disc Herniation: a Pilot Study|Active, not recruiting||N/A|40|Actual|Vancouver General Hospital||2|||f||||t||||||||||2018-05-31 21:33:47.625159|2018-05-31 21:33:47.625159
NCT01552473|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-10-24|2012-03-08|2012-03-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Brain Training to Enhance Frontal Lobe Reasoning|Brain Training to Enhance Frontal Lobe Reasoning in Soldiers and Civilian Adults With TBI|Completed||Phase 2|121|Actual|The University of Texas at Dallas||2|||f||||t||||||||||2018-05-31 21:33:47.709941|2018-05-31 21:33:47.709941
NCT01552447|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-03-14|2012-03-08|2012-03-13|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers|A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers.|Completed||N/A|98|Actual|MiMedx Group, Inc.||3|||f||||f||||||||Undecided||2018-05-31 21:33:47.874199|2018-05-31 21:33:47.874199
NCT01552434|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2018-03-26|2012-03-12|2012-03-13|Estimate|||||||2018-03-26|2018-03-29|Actual|March 2012|Actual|2012-03-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications|A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications|Recruiting||Phase 1|216|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 21:33:47.963931|2018-05-31 21:33:47.963931
NCT01552421|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-09-23|2012-03-09|2012-03-13|Estimate|||||||2013-09-23|2013-09-24|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|TRAVAKOL||The Effect of Transvaginal vs. Conventional Laparoscopic Cholecystectomy on the Postoperative Course|The Effect of Transvaginal vs. Conventional Laparoscopic Cholecystectomy on the Postoperative Course|Terminated||N/A|50|Anticipated|Herlev Hospital||2||For logistic reasons in the department and due to very low inclusion rates.|f||||t||||||||||2018-05-31 21:33:48.09367|2018-05-31 21:33:48.09367
NCT01552408|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-02-27|2012-03-09|2012-03-13|Estimate|||||||2017-02-27|2017-02-28|Actual|March 2012|Actual|2012-03-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|DAVE||Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)|A Phase I/II, Randomized, Study for Diabetic Macular Edema Using 0.3mg Ranibizumab Combined With Targeted PRP Monthly for 4 Months,Then PRN vs. 0.3mg Ranibizumab 4 Months Monotherapy, Then as Needed(DME-AntiVEgf) DAVE|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Greater Houston Retina Research||2|||f||||f||||||||No||2018-05-31 21:33:48.195666|2018-05-31 21:33:48.195666
NCT01552395|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-05-23|2012-03-09|2012-03-13|Estimate|||||||2016-05-23|2016-05-24|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia|A Prospective Safety Study in 24 Months Treatment of Nocturia With Minirin Melt in Clinical Practice in the Czech Republic|Completed|||4136|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 21:33:48.315133|2018-05-31 21:33:48.315133
NCT01552382|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-08-10|2012-03-12|2012-03-13|Estimate|||||||2016-08-10|2016-08-11|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|Vitop||Vitamin D, Cardiac Surgery and Outcome|Vitamin D and Clinical Outcome in Cardiac Surgical Patients|Completed|||4418|Actual|Heart and Diabetes Center North-Rhine Westfalia|||1||f||||f||||||||No||2018-05-31 21:33:48.437781|2018-05-31 21:33:48.437781
NCT01552369|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2018-03-30|2012-03-08|2012-03-13|Estimate|||||||2018-03-30|2018-04-03|Actual|October 29, 2012|Actual|2012-10-29|March 22, 2018|2018-03-22|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||"CMV Antiviral Prevention Strategies in D+R-Liver Transplants (CAPSIL)"|Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients|Active, not recruiting||Phase 4|205|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 21:33:48.503324|2018-05-31 21:33:48.503324
NCT01552356|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2018-05-23|2012-03-09|2012-03-13|Estimate|||||||2018-05-23|2018-05-24|Actual|March 19, 2012|Actual|2012-03-19|May 2018|2018-05-31||||December 31, 2015|Actual|2015-12-31||Interventional|||Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors|Pharmacokinetic-Driven Individualization of Pazopanib Therapy in Patients With Solid Tumors: A Phase I Study|Active, not recruiting||Phase 1|54|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:33:48.682058|2018-05-31 21:33:48.682058
NCT01552343|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2016-11-21|2013-05-31|2017-06-15|2012-03-09|2012-03-13|Estimate|2017-03-27|2017-05-05|Actual|2013-05-31|2013-06-10|Estimate|2017-06-15|2017-07-11|Actual|March 2012||2012-03-31|June 2017|2017-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|IMPACT||Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary|A Double-blind, Randomized, Placebo-controlled Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary|Completed||Phase 3|56|Actual|Ferring Pharmaceuticals|This was a patient reported outcome (PRO) validation study on a highly selective population (responders on active treatment and non-responsers on placebo from CS40/CS41) and not powered to look at efficacy.|4|||f||||f||||||||||2018-05-31 21:33:48.801704|2018-05-31 21:33:48.801704
NCT01552330|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-08-27|2012-03-08|2012-03-13|Estimate|||||||2013-08-27|2013-08-28|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pharmacokinetic Study of Primaquine and Pyronaridine-Artesunate in Healthy Subjects|Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Pyronaridine-Artesunate in Healthy Adult Subjects|Completed||Phase 1|17|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 21:33:49.323157|2018-05-31 21:33:49.323157
NCT01552317|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-12-02|2012-03-08|2012-03-13|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|OxCKD1||OxCKD1 -Empowering Healthy Lifestyle Choices in Chronic Kidney Disease|OxCKD1 - a Randomised Controlled Trial of the OxSalt1 Care Bundle to Help Renal Patients Learn How to Lower the Salt Content of Their Diets.|Completed||N/A|201|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 21:33:49.428067|2018-05-31 21:33:49.428067
NCT01552304|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-05-03|2012-03-08|2012-03-13|Estimate|||||||2017-05-03|2017-05-04|Actual|February 2012||2012-02-29|May 2016|2016-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Oxygen Supplementation Study in Obstructive Sleep Apnea (OSA) Patients|The Benefit and Risk of Oxygen Supplementation in Perioperative Management of Obstructive Sleep Apnea|Completed||N/A|196|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:33:49.499262|2018-05-31 21:33:49.499262
NCT01552291|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2018-02-12|2012-03-12|2012-03-13|Estimate|||||||2018-02-12|2018-02-13|Actual|May 2012||2012-05-31|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|February 10, 2018|Actual|2018-02-10||Interventional|Glutaminprojec||The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies|The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies - A Randomized, Placebo-controlled Pilot Study|Completed||Phase 4|42|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 21:33:49.583276|2018-05-31 21:33:49.583276
NCT01552265|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2018-04-24|2012-03-08|2012-03-13|Estimate|||||||2018-04-24|2018-04-25|Actual|February 2012||2012-02-29|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Observational|||Shanghai Mild Cognitive Impairment Cohort Study|Shanghai Cohort Study on Mild Cognitive Impairment for Early Detection of Alzheimer's Disease|Completed|||400|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||f||||||||||2018-05-31 21:33:49.664835|2018-05-31 21:33:49.664835
NCT01552252|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-08|2012-03-08|2012-03-13|Estimate|||||||2012-03-08|2012-03-13|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of an Apple Juice Drink With POs-Ca|Development and Evaluation of a Low Erosive Apple Juice Drink With Phosphoryl Oligosaccharides of Calcium (POs-Ca)|Completed||Early Phase 1|30|Actual|Tokyo Medical and Dental University||5|||f||||||||||||||2018-05-31 21:33:49.728052|2018-05-31 21:33:49.728052
NCT01552239|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-09-19|2012-03-12|2012-03-13|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2011||2011-08-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|PREMISS||Preoperative Radiotherapy for Sarcomas of the Extremities With Intensity-Modulation, Image-Guidance and Small Safety-margins|Phase II Study of Preoperative Radiotherapy for Sarcomas of the Extremities With Intensity-Modulation, Image-Guidance, Small Safety-margins and Brachytherapy Conditioned by Resection Margin|Recruiting||Phase 2|50|Anticipated|Technische Universität München||1|||f||||||||||||||2018-05-31 21:33:49.79139|2018-05-31 21:33:49.79139
NCT01552226|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2014-07-22|2012-03-08|2012-03-13|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Compare Preperitoneal Analgesia to Epidural Analgesia for Pain Control After Colon and Rectal Surgery|Prospective Randomized Clinical Trial to Compare Continuous Preperitoneal Analgesia to Continuous Epidural Analgesia for Pain Control After Colon and Rectal Surgery|Unknown status|Active, not recruiting|N/A|137|Anticipated|Saint Joseph Mercy Health System||2|||f||||f||||||||||2018-05-31 21:33:49.866198|2018-05-31 21:33:49.866198
NCT01552213|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-10-03|2012-03-08|2012-03-13|Estimate|||||||2017-10-03|2017-10-04|Actual|March 2012||2012-03-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|September 2014|Actual|2014-09-30||Interventional|||Early Screening and Treatment of Women With Prediabetes in Pregnancy|A Randomized Controlled Trial of Early Screening and Treatment of Women With Prediabetes in Pregnancy|Active, not recruiting||N/A|350|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 21:33:49.94075|2018-05-31 21:33:49.94075
NCT01552200|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-04-06|2012-03-08|2012-03-13|Estimate|||||||2014-04-06|2014-04-08|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Performance Evaluation of the NaviAid™ G-Eye System|Performance Evaluation of the NaviAid™ G-Eye System|Completed||N/A|126|Actual|Smart Medical Systems Ltd.||2|||f||||f||||||||||2018-05-31 21:33:50.025516|2018-05-31 21:33:50.025516
NCT01552187|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-06-29|2012-03-08|2012-03-13|Estimate|||||||2014-06-29|2014-07-01|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|COPPS-2||COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial)|COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial).|Unknown status|Active, not recruiting|Phase 3|360|Anticipated|Maria Vittoria Hospital||2|||f||||t||||||||||2018-05-31 21:33:50.104772|2018-05-31 21:33:50.104772
NCT01552174|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-08-31|2012-03-08|2012-03-13|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|MEIBUM||Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice||Completed|||185|Actual|Laboratoires Thea|||1||f||||f||||||||||2018-05-31 21:33:50.272785|2018-05-31 21:33:50.272785
NCT01552161|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-01-26|2012-03-12|2012-03-13|Estimate|||||||2014-01-26|2014-01-28|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|||Prevalence of Allergic Diseases and Atopy in Subjects With Coronary Artery Disease|Prevalence of Allergic Diseases and Atopy in Patients With Angiographically Confirmed Coronary Artery Disease|Completed|||300|Anticipated|Medical Universtity of Lodz|||2||f||||f||||||Samples With DNA|"~     Blood samples for total IgE, specific IgE and markers of inflammation.~   "|||2018-05-31 21:33:50.34973|2018-05-31 21:33:50.34973
NCT01552148|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-02-14|2012-03-12|2012-03-13|Estimate|||||||2014-02-14|2014-02-17|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Transversus Abdominis Plane Block for Laparoscopic Hysterectomy|Randomized, Controlled, Observer-blinded Study on the Efficacy of TAP Block With 0.375% Levobupivacaine in Terms of PCA Morphine Postoperative Consumption in Patients Undergoing Laparoscopic Hysterectomy|Completed||Phase 4|52|Actual|Istituti Ospitalieri di Cremona||2|||f||||||||||||||2018-05-31 21:33:50.438341|2018-05-31 21:33:50.438341
NCT01552135|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-05-29|2012-03-08|2012-03-13|Estimate|||||||2012-05-29|2012-05-30|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|May 2012|Actual|2012-05-31||Observational|||Pilot Study - Putative Penetration of Nanoparticles in Sunscreen in Intact or Sunburned Skin|Pilot Study - Does Nanoparticles in Sunscreen Penetrate Intact or Sunburned Skin?|Unknown status|Active, not recruiting||2|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 21:33:50.507767|2018-05-31 21:33:50.507767
NCT01552122|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-08-26|2012-03-09|2012-03-13|Estimate|||||||2015-08-26|2015-08-27|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)|A Phase III Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density, Tolerability, and Safety in the Treatment of Postmenopausal Women With Osteoporosis Previously Treated With Alendronate|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 21:33:50.580145|2018-05-31 21:33:50.580145
NCT01552109|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-10-03|2012-03-12|2012-03-13|Estimate|||||||2014-10-03|2014-10-07|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Observational|STAR||Stable Angina Observational Registry|STable Angina obseRvational Registry|Completed|||2079|Actual|Medtronic Vascular|||||f||||f||||||||||2018-05-31 21:33:50.670958|2018-05-31 21:33:50.670958
NCT01552096|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2014-03-15|2012-03-09|2012-03-13|Estimate|||||||2014-03-15|2014-03-18|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Tramadol Versus Lidocaine Infiltration for Tonsillectomy|A Comparative Study of the Effects of Pre-incisional Infiltration of Tramadol or Lidocaine on the Inflammatory Response After Tonsillectomy.|Completed||Phase 2|90|Actual|Dammam University||3|||f||||t||||||||||2018-05-31 21:33:50.732975|2018-05-31 21:33:50.732975
NCT01552083|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-03-12|2012-03-12|2012-03-13|Estimate|||||||2012-03-12|2012-03-13|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||A Community Pharmacist-led Intervention to Improve Screening of Sleep Apnea in Primary Care|A Community Pharmacist-led Intervention to Improve Screening of Sleep Apnea in Primary Care|Unknown status|Recruiting|N/A|400|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||||||||||||2018-05-31 21:33:50.816624|2018-05-31 21:33:50.816624
NCT01552070|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-09-13|2012-03-09|2012-03-13|Estimate|||||||2013-09-13|2013-09-17|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Recruitment on Extravascular Lung Water in Acute Respiratory Distress Syndrome (ARDS)|Impact of Alveolar Recruitment Maneuver on Extravascular Lung Water of Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome.|Completed||Phase 2|30|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:33:50.889555|2018-05-31 21:33:50.889555
NCT01552057|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2014-12-12||2015-01-07|2012-03-09|2012-03-13|Estimate|2014-12-12|2014-12-19|Estimate||||2015-01-07|2015-01-16|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Randomized participants who received at least 1 dose of study drug who had at least 1 post-baseline measurement of primary efficacy [Brief Pain Inventory (BPI) 24-hour average pain severity].|A Study of Duloxetine in Fibromyalgia|A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia|Completed||Phase 3|393|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:33:51.027951|2018-05-31 21:33:51.027951
NCT01552044|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2016-02-24|2012-03-08|2012-03-13|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis|Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois|Completed||Phase 1/Phase 2|17|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 21:33:51.942799|2018-05-31 21:33:51.942799
NCT01552031|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-03-03|2012-03-08|2012-03-13|Estimate|||||||2017-03-03|2017-03-06|Actual|November 2011||2011-11-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|||Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device|Monitoring COPD Patients at Home by a Forced Oscillation Technique Device|Recruiting|||80|Anticipated|Politecnico di Milano|||1||f||||f||||||||||2018-05-31 21:33:52.009691|2018-05-31 21:33:52.009691
NCT01552018|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-06-17|2012-03-08|2012-03-13|Estimate|||||||2014-06-17|2014-06-18|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|SAXATH||Saxagliptin and Atherosclerosis|Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.|Completed||Phase 4|12|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 21:33:52.087651|2018-05-31 21:33:52.087651
NCT01552005|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-06-06|2012-03-09|2012-03-13|Estimate|||||||2016-06-06|2016-06-07|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|DIAPAZON||Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France|Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France|Completed|||1000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:33:52.149226|2018-05-31 21:33:52.149226
NCT01551992|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-09-15|2012-03-12|2012-03-13|Estimate|||||||2014-09-15|2014-09-16|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|QUILL-LSC||Affixing Polypropylene Mesh Using Barbed Suture (Quill™ Srs) During Laparoscopic Sacrocolpopexy Randomized Controlled Trial (Quill Lsc)|Affixing Polypropylene Mesh Using Barbed Suture (Quill™ Srs) During Laparoscopic Sacrocolpopexy Randomized Controlled Trial|Completed||N/A|32|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 21:33:52.205014|2018-05-31 21:33:52.205014
NCT01551979|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2017-03-15||2018-03-14|2012-03-09|2012-03-13|Estimate|2017-05-01|2017-06-02|Actual||||2018-03-14|2018-04-12|Actual|February 2012||2012-02-29|March 2018|2018-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia|Therapeutic Efficacy of Cerebellar Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia|Completed||N/A|22|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 21:33:52.370671|2018-05-31 21:33:52.370671
NCT01551966|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-07-26|2012-03-12|2012-03-13|Estimate|||||||2013-07-26|2013-07-29|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PREVOCAP||Esophageal Capsule Endoscopy in Children|Evaluation of Wireless Capsule Endoscopy for the Detection and the Control of the Esophageal Varices in Children|Completed||N/A|100|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 21:33:52.742412|2018-05-31 21:33:52.742412
NCT01551953|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-02-23|2012-03-09|2012-03-13|Estimate|||||||2017-02-23|2017-02-27|Actual|February 2011||2011-02-28|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BEAM COPD||BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)|BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease|Completed||Phase 2|124|Actual|Beth Israel Deaconess Medical Center||3|||f||||t||||||||||2018-05-31 21:33:52.83288|2018-05-31 21:33:52.83288
NCT01551940|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2015-08-13|2012-03-12|2012-03-13|Estimate|||||||2015-08-13|2015-08-14|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ALS-TOX||Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea|Evaluation of Efficacy of Botulinum Toxin Type A in the Treatment of Sialorrhea in the Patient Affected by Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|18|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 21:33:52.921755|2018-05-31 21:33:52.921755
NCT01551927|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2014-02-17|2012-03-12|2012-03-13|Estimate|||||||2014-02-17|2014-02-19|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|TAPE||Patients Expectations for Future Examination and Treatment|What Are the Expectations for Future Examination and Treatment in Patients Undergoing Evaluation and Treatment of Coronary Heart Disease?|Completed|||754|Actual|Göteborg University|||||f||||f||||||Samples Without DNA|"~     Blood samples NtProBNP~   "|||2018-05-31 21:33:53.061959|2018-05-31 21:33:53.061959
NCT01551914|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-06-30|2012-03-12|2012-03-13|Estimate|||||||2014-06-30|2014-07-01|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|March 2015|Anticipated|2015-03-31|October 2014|Anticipated|2014-10-31||Interventional|FOThyr||Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy|Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy|Unknown status|Active, not recruiting|Phase 3|1350|Anticipated|Nantes University Hospital||2|||f||||||||||||||2018-05-31 21:33:53.136098|2018-05-31 21:33:53.136098
NCT01551901|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2014-09-18|2012-03-09|2012-03-13|Estimate|||||||2014-09-18|2014-09-19|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|LIFT||Luna Interbody System for Fusion Trial|LIFT: Luna Interbody System for Fusion Trial|Unknown status|Active, not recruiting|N/A|100|Anticipated|Benvenue Medical, Inc.||1|||f||||f||||||||||2018-05-31 21:33:53.212789|2018-05-31 21:33:53.212789
NCT01551888|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2016-10-04|2012-08-22|2016-12-22|2012-03-09|2012-03-13|Estimate|2016-10-04|2016-11-23|Estimate|2012-08-22|2012-08-30|Estimate|2016-12-22|2017-02-14|Actual|January 2012||2012-01-31|December 2016|2016-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 µg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 µg Via Foradil® Aerolizer® In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 2|24|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:33:53.302085|2018-05-31 21:33:53.302085
NCT01551875|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-07-08|2012-03-09|2012-03-13|Estimate|||||||2013-07-08|2013-07-09|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|Score-India||A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors|A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors in Asymptomatic Nationwide Indian Population (SCORE India)|Completed|||1200|Actual|AstraZeneca|||1||f||||t||||||||||2018-05-31 21:33:53.527649|2018-05-31 21:33:53.527649
NCT01551862|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-12|2012-03-12|2012-03-13|Estimate|||||||2012-03-12|2012-03-13|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Observational|||Complications in Lower Body Lifts|Prospective Study on Complications Following a Lower Body Lift After Massive Weight Loss|Completed|||50|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 21:33:53.6161|2018-05-31 21:33:53.6161
NCT01551849|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2017-07-19|2012-03-09|2012-03-13|Estimate|||||||2017-07-19|2017-07-21|Actual|January 1, 2012|Actual|2012-01-01|July 2017|2017-07-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|||Echocardiographic Assessment of Function During ECMO Support|Echocardiographic Assessment of Function During ECMO Support|Completed|||5|Actual|Nationwide Children's Hospital|||1||f||||f||||||||No|non-interventional trial|2018-05-31 21:33:53.679213|2018-05-31 21:33:53.679213
NCT01551836|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-03-08|2012-03-08|2012-03-13|Estimate|||||||2012-03-08|2012-03-13|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations|A Randomised, Two Way Crossover Study to Determine the Time at Which Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:33:53.739057|2018-05-31 21:33:53.739057
NCT01551823|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2016-07-31|2012-03-09|2012-03-13|Estimate|||||||2016-07-31|2016-08-02|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）|The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)（Children Forms of Drug）|Completed||Phase 3|1200|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:33:53.939898|2018-05-31 21:33:53.939898
NCT01551810|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-07-31|2012-03-09|2012-03-13|Estimate|||||||2016-07-31|2016-08-02|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|IVV||The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)|The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)|Completed||Phase 3|1200|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:33:54.033101|2018-05-31 21:33:54.033101
NCT01551797|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-12-06|2012-03-08|2012-03-13|Estimate|||||||2012-12-06|2012-12-10|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.|A Proof of Principal Study to Investigate the Pharmacokinetic Profiles of Sustained Release and Standard Paracetamol Formulations|Completed||Phase 1|14|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:33:54.112609|2018-05-31 21:33:54.112609
NCT01551784|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-10-14|2012-03-09|2012-03-13|Estimate|||||||2013-10-14|2013-10-16|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|SIRIUS||An Observational Study of Statin Treatment Induced HDL Changes|An Observational Study of Statin Treatment Induced HDL Changes - Effect on Cardiovascular Disease|Completed|||120000|Actual|AstraZeneca|||1||f||||f|||||||"~     Cholesterol values (HDL-C, LDL-C, TC)~   "|||2018-05-31 21:33:54.186163|2018-05-31 21:33:54.186163
NCT01551771|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2017-10-17|2012-03-08|2012-03-13|Estimate|||||||2017-10-17|2017-10-19|Actual|February 1, 2012|Actual|2012-02-01|October 2017|2017-10-31|April 12, 2012|Actual|2012-04-12|April 12, 2012|Actual|2012-04-12||Interventional|||GW824575 First Time in Human|A Single-centre, Masked, Placebo-controlled Four Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of the CC-chemokine Receptor 3 (CCR3) Antagonist, GW824575, Coadministered With or Without Food in Healthy Male Subjects|Terminated||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:33:54.260925|2018-05-31 21:33:54.260925
NCT01551758|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2016-09-05||2017-05-03|2012-03-12|2012-03-13|Estimate|2017-01-13|2017-03-07|Actual||||2017-05-03|2017-05-31|Actual|March 13, 2012|Actual|2012-03-13|May 2017|2017-05-31|November 24, 2015|Actual|2015-11-24|November 24, 2015|Actual|2015-11-24||Interventional|||A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)|A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) Compared With the Existing COPD Maintenance Therapy Alone in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|2802|Actual|GlaxoSmithKline||2|||f||||t|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:33:54.464653|2018-05-31 21:33:54.464653
NCT01551745|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2018-02-15||2018-03-29|2012-03-12|2012-03-13|Estimate|2018-03-29|2018-05-01|Actual||||2018-03-29|2018-05-01|Actual|March 2012||2012-03-31|March 2018|2018-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Salvage Ovarian FANG™ Vaccine + Bevacizumab|Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105|Completed||Phase 2|5|Actual|Gradalis, Inc.||1|||f||||t||||||||||2018-05-31 21:33:56.463796|2018-05-31 21:33:56.463796
NCT01551732|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2018-02-22|2012-03-08|2012-03-13|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2011||2011-07-31|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger|Anger Control Therapy (ACT) With RAGE-Control: An Outpatient Videogame-assisted Therapy for the Treatment of Anger|Active, not recruiting||N/A|40|Anticipated|Gonzalez-Heydrich, Joseph, M.D.||2|||f||||f||||||||||2018-05-31 21:33:56.626008|2018-05-31 21:33:56.626008
NCT01551719|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-12-28|2012-03-08|2012-03-13|Estimate|||||||2012-12-28|2012-12-31|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation|Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation|Withdrawn||N/A|0|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 21:33:56.705847|2018-05-31 21:33:56.705847
NCT01551706|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-07-03|2012-03-12|2012-03-13|Estimate|||||||2012-07-03|2012-07-04|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status|A Randomized, Double-blind, Placebo-controlled, Pilot Study to Evaluate the Effect of ENI Patented Whole Grape Extract on Antioxidant Status|Completed||Phase 1|26|Actual|Ethical Naturals, Inc.||2|||f||||t||||||||||2018-05-31 21:33:56.7741|2018-05-31 21:33:56.7741
NCT01551693|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2016-12-21||2017-03-01|2012-03-08|2012-03-13|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|September 2011||2011-09-30|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||The analysis dataset is comprised of all treated patients.|STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma|This Trial is an Open Label, Parallel Cohort, Phase II Study Evaluating the Efficacy of the Heat Shock Protein 90 (Hsp90) Inhibitor STA-9090 in Patients With Unresectable Stage III or Stage IV Melanoma Who Were Intolerant of, or Progressed on, Prior Tyrosine Kinase Inhibitor Treatment. Two Cohorts Will Enroll Concurrently. One Cohort Will be Composed of Patients With Melanoma Expressing a Mutation in the Protein BRAF and the Other Cohort Will be Composed of Patients With Melanoma Expressing Wild-type BRAF.|Terminated||Phase 2|3|Actual|Dana-Farber Cancer Institute|The study was terminated early due to weak accrual.|2||due to weak accrual|f||||t|t|f||||||No||2018-05-31 21:33:56.856994|2018-05-31 21:33:56.856994
NCT01551680|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-08-16|2012-03-12|2012-03-13|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2012||2012-09-30|August 2017|2017-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|RAPIBE||A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases|A Phase I Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib (BSI-201) in Multiple Non Operable Brain Metastases|Terminated||Phase 1|3|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1||end of study of this product|f||||t||||||||||2018-05-31 21:33:57.14728|2018-05-31 21:33:57.14728
NCT01551667|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-04-05|2012-03-12|2012-03-13|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|ORISA||Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds|Observational and Comparative Study on the Immune Response of Patients With Chronic, Staphylococcus Aureus-infected Wounds (Localized Infections Versus Bacteremia)|Completed|||69|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||Samples Without DNA|"~     Left over blood/serum/plasma specimens will be incorporated into the biobank at the~     Bacteriology Laboratory of the Nîmes University Hospital~   "|||2018-05-31 21:33:57.234125|2018-05-31 21:33:57.234125
NCT01551654|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-19|2012-03-12|2012-03-13|Estimate|||||||2012-03-19|2012-03-20|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Electrical Stimulation Over Acupuncture Points in Reduction of Rectal Discomfort Distension|Non-invasive Acu-point Stimulation (Acu-TENS) in Reduction of Discomfort Associated With Barostat-induced Rectal Distension - a Randomized Controlled Study|Completed||N/A|40|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:33:58.485368|2018-05-31 21:33:58.485368
NCT01551641|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-02-14|2012-03-12|2012-03-13|Estimate|||||||2016-02-14|2016-02-17|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer|A Phase II Clinical Trial on VEGF Expression Interfered by Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer|Unknown status|Recruiting|Phase 2|180|Anticipated|Changzhou No.2 People's Hospital||3|||f||||t||||||||||2018-05-31 21:33:58.571269|2018-05-31 21:33:58.571269
NCT01551628|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-07-27|2012-03-08|2012-03-13|Estimate|||||||2017-07-27|2017-07-31|Actual|April 2012||2012-04-30|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma|A Pilot Study of the Safety and Preliminary Efficacy of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma|Terminated||Phase 1|1|Actual|Bio-Cancer Treatment International Limited||1||slow patient recruitment|f||||t||||||||||2018-05-31 21:33:58.674144|2018-05-31 21:33:58.674144
NCT01551615|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2016-08-26|2012-03-12|2012-03-13|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Vandetanib||A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Metformin, an OCT2 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Oral Dose of Vandetanib (CAPRELSA) 800 mg|Completed||Phase 1|14|Actual|Sanofi||1|||f||||||||||||||2018-05-31 21:33:58.757359|2018-05-31 21:33:58.757359
NCT01551602|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-07-21|2012-03-12|2012-03-13|Estimate|||||||2016-07-21|2016-07-25|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Clinical Study of AK159 in Healthy Postmenopausal Women||Completed||Phase 1|132|Actual|Asahi Kasei Pharma Corporation||11|||f||||||||||||||2018-05-31 21:33:58.840869|2018-05-31 21:33:58.840869
NCT01551589|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2017-07-25|2012-03-08|2012-03-13|Estimate|||||||2017-07-25|2017-07-26|Actual|March 2012||2012-03-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer|Multicenter Prospective Randomized Phase III Trial Comparing Elective to Prophylactic Regional Lymph Node Irradiation for Thoracic Esophageal Cancer|Completed||N/A|220|Actual|The Second People's Hospital of Sichuan||2|||f||||t||||||||||2018-05-31 21:33:58.930566|2018-05-31 21:33:58.930566
NCT01551576|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-11-07|2012-03-09|2012-03-12|Estimate|||||||2017-11-07|2017-11-09|Actual|February 2014||2014-02-28|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study|Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study|Suspended|||20|Anticipated|Stanford University||||logistics|f||||t||||||||||2018-05-31 21:33:59.014629|2018-05-31 21:33:59.014629
NCT01551563|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-12-04|2012-03-09|2012-03-12|Estimate|||||||2017-12-04|2017-12-05|Actual|April 2012||2012-04-30|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|August 2018|Anticipated|2018-08-31||Observational|SUSI||Stavanger University Hospital Inflammatory Bowel Disease Trial|Management of Inflammatory Bowel Disease in the Stavanger Area - a Prospective Evaluation of Standardized Treatment Regimens on Disease Outcome With Focus on Mucosal Healing and Associations to Fatigue|Recruiting|||300|Anticipated|Helse Stavanger HF|||||f||||f||||||Samples With DNA|"~     Plasma and mucosal biopsies~   "|No||2018-05-31 21:33:59.184729|2018-05-31 21:33:59.184729
NCT01551550|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2018-04-23|2012-03-09|2012-03-12|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2013||2013-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|STEPS||Shunt Tube Exposure Prevention Study|Amniotic Membrane Versus Pericardium in Reducing Glaucoma Drainage Tube Exposure: A Randomized Clinical Trial|Active, not recruiting||N/A|96|Anticipated|Tissue Tech Inc.||2|||f||||t||||||||||2018-05-31 21:33:59.264065|2018-05-31 21:33:59.264065
NCT01551537|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-09-05|2012-03-08|2012-03-12|Estimate|||||||2013-09-05|2013-09-09|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka|Post-marketing Surveillance (PMS) of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) -16/18 Vaccine, Cervarix™ When Administered to Healthy Females According to the Prescribing Information in Sri Lanka|Withdrawn|||0|Actual|GlaxoSmithKline|||1|"Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it~   was concluded GSK will submit local PSURs"|f||||||||||||||2018-05-31 21:33:59.374404|2018-05-31 21:33:59.374404
NCT01551524|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-05-05|2012-03-09|2012-03-12|Estimate|||||||2015-05-05|2015-05-07|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Phase I Study of mPEG-R-Crisantaspase Given IV|A Dose Escalation Phase I Study of Asparec®(mPEG-R-Crisantaspase) Administered as Intravenous (IV) Infusion in Patients With Relapsed or Refractory Hematological Malignancies|Completed||Phase 1|36|Anticipated|Jazz Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:33:59.475115|2018-05-31 21:33:59.475115
NCT01551511|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2014-10-27|2012-03-07|2012-03-12|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain|Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design|Completed||Phase 2|29|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:33:59.586297|2018-05-31 21:33:59.586297
NCT01551498|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-10-29|2012-03-07|2012-03-12|Estimate|||||||2015-10-29|2015-11-02|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|ASAP||Evaluating the Dietary Supplement Anatabloc in Thyroid Health-ASAP (Antabloc Supplementation Autoimmune Prevention)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Potential Effects of the Dietary Supplement Anatabloc on Antithyroid Autoantibodies and Thyroid Function in Autoimmune Thyroiditis|Completed||Phase 2|165|Actual|Rock Creek Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:33:59.683372|2018-05-31 21:33:59.683372
NCT01551485|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-08-07|2012-03-07|2012-03-12|Estimate|||||||2012-08-07|2012-08-08|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement|Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement|Unknown status|Active, not recruiting|N/A|20|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:33:59.785024|2018-05-31 21:33:59.785024
NCT01551472|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-07-26|2012-03-08|2012-03-12|Estimate|||||||2017-07-26|2017-07-27|Actual|April 2012||2012-04-30|July 2017|2017-07-31|June 2024|Anticipated|2024-06-30|June 2020|Anticipated|2020-06-30||Observational|e-plus||Post Market Study of the 3DKnee™ With E-plus Insert|Prospective Multicenter Open Label Study Examining the Mid- and Long-term Safety and Efficacy of the 3DKnee™ System With Vitamin E UHMWPE Tibial Inserts (3DKnee™ With E-plus Insert)|Recruiting|||300|Anticipated|Encore Medical, L.P.|||1||f||||f||||||||||2018-05-31 21:33:59.866009|2018-05-31 21:33:59.866009
NCT01551459|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-07-25|2012-03-09|2012-03-12|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|SUAVE||A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma|A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma|Unknown status|Active, not recruiting|Phase 2|124|Anticipated|The Clatterbridge Cancer Centre NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:33:59.971332|2018-05-31 21:33:59.971332
NCT01551446|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-11-01|2012-03-07|2012-03-12|Estimate|||||||2012-11-01|2012-11-02|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|October 2013|Anticipated|2013-10-31|November 2012|Anticipated|2012-11-30||Interventional|||Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes|Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes|Withdrawn||Phase 1|0|Actual|Reata Pharmaceuticals, Inc.||1||IDMC recommendation for safety concerns|f||||||||||||||2018-05-31 21:34:00.060717|2018-05-31 21:34:00.060717
NCT01551433|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-08-17|2012-03-09|2012-03-12|Estimate|||||||2016-08-17|2016-08-18|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy|A Prospective Trial to Evaluate Whether Variations in Tissue Oxygenation Are Associated With Anastomotic Leak Rates After an Ivor Lewis Esophagectomy|Completed|||166|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:34:00.179996|2018-05-31 21:34:00.179996
NCT01551420|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-03-16|2012-03-07|2012-03-12|Estimate|||||||2018-03-16|2018-03-19|Actual|April 1, 2012|Actual|2012-04-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|December 19, 2017|Actual|2017-12-19||Observational|||Home Study of an Advanced Upper Limb Prosthesis|Home Study of an Advanced Upper Limb Prosthesis|Active, not recruiting|||100|Anticipated|VA Office of Research and Development|||1||f||||f|f|t|f|f|f|||No||2018-05-31 21:34:00.257655|2018-05-31 21:34:00.257655
NCT01551407|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-10-24|2012-03-07|2012-03-12|Estimate|||||||2012-10-24|2012-10-25|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Detection of Bladder Tumors After 30 Min Instillation of Hexvix|Open Prospective Within Patient, Phase IIa Study of Hexvix Flexible Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer After 30 Minutes Instillation of Hexvix in Patients With Known or Suspicion of Bladder Cancer|Terminated||Phase 2|38|Actual|Photocure||||slow inclusion rate|f||||f||||||||||2018-05-31 21:34:00.339342|2018-05-31 21:34:00.339342
NCT01551394|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-02-12|2012-03-07|2012-03-12|Estimate|||||||2015-02-12|2015-02-16|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NeoMero-1||Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis|Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Clinical or Confirmed Late-onset Sepsis : a European Multicenter Randomised Phase III Trial|Completed||Phase 3|272|Actual|PENTA Foundation||2|||f||||t||||||||||2018-05-31 21:34:00.504552|2018-05-31 21:34:00.504552
NCT01551381|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-06-14|2012-03-08|2012-03-12|Estimate|||||||2013-06-14|2013-06-17|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects|Double-blind, Controlled Study in Healthy and Type 2 Diabetic Subjects to Assess Safety, Tolerability and Pharmacokinetics of 28 Days EV-077 Treatment, and the Effects on Platelet Function, Vascular Inflammation and Oxidative Stress.|Terminated||Phase 2|33|Actual|Evolva SA||2||Interim review indicated that the dose selected was too high for diabetics|f||||t||||||||||2018-05-31 21:34:00.600383|2018-05-31 21:34:00.600383
NCT01551368|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-05-04|2012-03-07|2012-03-12|Estimate|||||||2016-05-04|2016-05-05|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|April 2014|Actual|2014-04-30||Interventional|nimodipine||Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients|Using Nimodipine, a Calcium Channel Blocker, to Prevent the LH Surge and Ovulation in Women Undergoing Assisted Reproduction|Terminated||Phase 2|12|Actual|Mount Sinai Hospital, Canada||2||small number of patients got recruited|f||||f||||||||||2018-05-31 21:34:00.698276|2018-05-31 21:34:00.698276
NCT01551355|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2014-08-04||2016-11-10|2012-03-07|2012-03-12|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Promoting Heart Health in Preschool Children|Evaluation of an Intervention to Promote Healthy Heart Habits in Pre-School Children|Completed||Phase 3|2279|Actual|Icahn School of Medicine at Mount Sinai|minimal participation of teachers in initial planning stage. small number of teachers evaluated has limited the statistical power in this group.|2|||f||||f||||||||||2018-05-31 21:34:00.804699|2018-05-31 21:34:00.804699
NCT01551342|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2014-03-20|2012-03-07|2012-03-12|Estimate|||||||2014-03-20|2014-03-21|Estimate|January 2012||2012-01-31|August 2013|2013-08-31||||||||Observational|||Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology|Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology|Unknown status|Recruiting||500|Anticipated|Zetiq Technologies|||1||f||||f||||||Samples With DNA|"~     urine samples~   "|||2018-05-31 21:34:01.309603|2018-05-31 21:34:01.309603
NCT01551329|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2015-12-01|2012-03-09|2012-03-12|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|KetamineDep||Ketamine for Depression and Alcohol Dependence|A Randomized Controlled Trial of the N-methyl-D-aspartate (NMDA) Receptor Antagonist Ketamine in Comorbid Depression and Alcohol Dependence.|Completed||Phase 1|5|Actual|Yale University||1|||f||||t||||||||||2018-05-31 21:34:01.421103|2018-05-31 21:34:01.421103
NCT01551316|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-05-17|2012-03-09|2012-03-12|Estimate|||||||2012-05-17|2012-05-21|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase Ib Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Repeated Administration, Intravenous MN-221 in Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||Phase 1|19|Actual|MediciNova||2|||f||||||||||||||2018-05-31 21:34:01.518473|2018-05-31 21:34:01.518473
NCT01551303|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2014-03-26||2014-05-29|2012-03-07|2012-03-12|Estimate|2014-05-29|2014-06-30|Estimate||||2014-05-29|2014-06-30|Estimate|February 2009||2009-02-28|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety|Effect of Intranasal Neuropeptide on Emotion Perception in Trait Anxiety|Completed||N/A|47|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:34:01.630164|2018-05-31 21:34:01.630164
NCT01551290|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2015-10-28|2012-03-07|2012-03-12|Estimate|||||||2015-10-28|2015-10-30|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis|Completed||Phase 3|99|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-05-31 21:34:01.863996|2018-05-31 21:34:01.863996
NCT01551277|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2012-03-09|2012-03-09|2012-03-12|Estimate|||||||2012-03-09|2012-03-12|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Use of Breath Stacking Technique on Regional Ventilation in Box Chest in Women With Morbid Obesity|Use of Breath Stacking Technique on Regional Ventilation in Box Chest in Women With Morbid Obesity: Clinical Trial Controlled and Randominzado|Completed||N/A|32|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 21:34:01.953678|2018-05-31 21:34:01.953678
NCT01551264|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2018-01-26|2012-03-07|2012-03-12|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2012||2012-05-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|FAB24||Duration of Brace Wear in Clubfoot Treatment - A Prospective Randomized Trial|Duration of Brace Wear in Clubfoot Treatment - A Prospective Randomized Trail|Active, not recruiting||N/A|124|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:34:02.020037|2018-05-31 21:34:02.020037
NCT01551095|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|2016-08-21||2017-03-02|2012-03-09|2012-03-12|Estimate|2016-08-21|2016-10-12|Estimate||||2017-03-02|2017-03-31|Actual|January 2012||2012-01-31|March 2017|2017-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J)|Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J): A Pilot Study|Terminated||Phase 2|7|Actual|Johns Hopkins University|Small number of patients and short follow-up|1||Proof of principle was achieved after inclusion of 7 patients|f||||t||||||||||2018-05-31 21:34:03.683956|2018-05-31 21:34:03.683956
NCT01551251|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-07-27|2012-03-09|2012-03-12|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2006||2006-01-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Tumor Associated Macrophage in Advanced Non-small Cell Lung Cancer|Tumor-Associated Macrophages Correlate With Response and Outcomes in Advanced Non-Small Cell Lung Cancer After First Line Treatment.|Completed|||107|Actual|Chang Gung Memorial Hospital|||2||f||||t||||||Samples With DNA|"~     All specimens were fixed in 10% buffered formalin and embedded in paraffin according to~     standard procedures. All of the tissues were fixed immediately after biopsy, with time from~     tissue acquisition to fixation as short as possible. Serial sections (4 μm thickness) placed~     on positively charged slides (Menzel-Glasser, German) were used for immuno-histochemistry.~   "|||2018-05-31 21:34:02.099194|2018-05-31 21:34:02.099194
NCT01551238|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-05-02|2012-03-07|2012-03-12|Estimate|||||||2013-05-02|2013-05-03|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Energy Expenditure, Sleep and Macronutrients|Energy Expenditure and Sleep in Response to Protein/Carbohydrate and Fat Ratio|Unknown status|Recruiting|N/A|40|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:34:02.161035|2018-05-31 21:34:02.161035
NCT01551225|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-01-11|2012-03-07|2012-03-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder|Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder|Completed||Phase 4|32|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 21:34:02.246791|2018-05-31 21:34:02.246791
NCT01551212|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-11-13|2012-03-09|2012-03-12|Estimate|||||||2017-11-13|2017-11-17|Actual|May 24, 2012|Actual|2012-05-24|November 2017|2017-11-30|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|HEPHAISTOS||Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients|A 12-month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate Efficacy/Safety and Evolution of Renal Function of Everolimus in Co-exposure With Tacrolimus in de Novo Liver Transplant Recipients|Completed||Phase 4|333|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:34:02.314232|2018-05-31 21:34:02.314232
NCT01551199|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2014-12-08||2017-01-04|2012-03-07|2012-03-12|Estimate|2015-01-12|2015-01-13|Estimate||||2017-01-04|2017-02-23|Actual|March 2012||2012-03-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1)|Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1)|Completed||Phase 1|7|Actual|VA Office of Research and Development||1|||f||||t||||||||No||2018-05-31 21:34:02.506643|2018-05-31 21:34:02.506643
NCT01551186|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2014-01-23|2012-03-06|2012-03-12|Estimate|||||||2014-01-23|2014-01-27|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria|The Use of the Probiotic, Lactobacillus Rhamnosus GG to Evaluate Colonization With Antimicrobial Resistant Bacteria in High Risk Patients|Completed||Phase 4|104|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 21:34:02.686517|2018-05-31 21:34:02.686517
NCT01551173|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2014-05-13||2015-08-10|2012-03-09|2012-03-12|Estimate|2014-05-13|2014-06-11|Estimate||||2015-08-10|2015-08-13|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Randomized Set (RAN)|Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD|Completed||Phase 4|436|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:34:02.800335|2018-05-31 21:34:02.800335
NCT01551160|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2016-11-23|2012-03-07|2012-03-12|Estimate|||||||2016-11-23|2016-11-25|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|IMPACT||Impact of a Communication and Team-working Intervention on Performance and Effectiveness of a Medical Emergency Team|Impact of a Communication and Team-working Intervention on Performance and Effectiveness of a Medical Emergency Team|Completed||N/A|1500|Actual|Lyell McEwin Hospital||1|||f||||f||||||||No||2018-05-31 21:34:03.195095|2018-05-31 21:34:03.195095
NCT01551147|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-04-29|2012-03-09|2012-03-12|Estimate|||||||2013-04-29|2013-04-30|Estimate|June 2012||2012-06-30|April 2013|2013-04-30||||April 2013|Actual|2013-04-30||Interventional|||A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma|A Double-blind, Placebo-controlled, Three-way Crossover Study to Compare the Safety and Efficacy of 8 Days of Therapy With ONO-6950 Versus Placebo and Montelukast (Singulair®) on Asthmatic Responses and Airway Hypersensitivity Following Allergen Challenge in Patients With Asthma|Completed||Phase 2|25|Actual|Ono Pharmaceutical Co. Ltd||3|||f||||f||||||||||2018-05-31 21:34:03.306021|2018-05-31 21:34:03.306021
NCT01551134|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2012-03-09|2012-03-09|2012-03-12|Estimate|||||||2012-03-09|2012-03-12|Estimate|January 2003||2003-01-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Is Laparoscopic Fundoplication Better Than Open Fundoplication in Children ?|IS Laparoscopic Fundoplication Superior to Open Fundoplication in Children - a Randomized Study|Terminated||N/A|88|Actual|Oslo University Hospital||2||Fewer patients than anticipated were referred|f||||f||||||||||2018-05-31 21:34:03.437126|2018-05-31 21:34:03.437126
NCT01551121|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-08-19|2012-03-07|2012-03-12|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Observational|TELEHPAD||Assessment of an Automated Telesurveillance System on the Incidence of Serious Falls in Nursing Homes|Assessment of an Automated Telesurveillance System on the Incidence of Serious Falls in Nursing Homes|Recruiting|||216|Anticipated|University Hospital, Limoges|||2||f||||f||||||||||2018-05-31 21:34:03.524903|2018-05-31 21:34:03.524903
NCT01551108|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-05-02|2012-03-08|2012-03-12|Estimate|||||||2016-05-02|2016-05-03|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Parent-targeted Mobile Phone Based Intervention to Increase Physical Activity in Children (P-Mobile)|Parent-targeted Mobile Phone Based Intervention to Increase Physical Activity in Children (P-Mobile)|Completed||N/A|27|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:34:03.595704|2018-05-31 21:34:03.595704
NCT01551082|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2016-07-13||2016-10-18|2012-03-09|2012-03-12|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational||patients older than 18 years old who underwent lung resection and were sent home with chest tubes|Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes|Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes|Terminated|||12|Actual|Alliance of Cardiothoracic and Vascular Surgeons|||1|Poor accrual|f||||t||||||||No||2018-05-31 21:34:03.823725|2018-05-31 21:34:03.823725
NCT01551069|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2014-05-12|2012-03-09|2012-03-12|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion|A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion|Completed||Phase 3|103|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:34:03.958327|2018-05-31 21:34:03.958327
NCT01551056|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2017-06-27|2015-04-30|2017-10-06|2012-03-08|2012-03-12|Estimate|2017-09-06|2017-10-03|Actual|2015-04-30|2015-05-19|Estimate|2017-10-06|2017-11-07|Actual|March 2012||2012-03-31|October 2017|2017-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|Completed||Phase 3|91|Actual|Aciex Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 21:34:04.102642|2018-05-31 21:34:04.102642
NCT01551043|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-09-27|2012-03-09|2012-03-12|Estimate|||||||2016-09-27|2016-09-29|Estimate|September 2010||2010-09-30|September 2016|2016-09-30||||May 2015|Actual|2015-05-31||Interventional|||Allo CART-19 Protocol|Pilot Study of Donor Lymphocyte Infusions Using Donor T Cells Engineered to Contain Anti-CD19 Attached To TCR And 4-1BB Signaling Domains in Patients With Relapsed CD19+ All After Allogeneic Stem Cell Transplantation|Completed||Phase 1|2|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 21:34:04.867606|2018-05-31 21:34:04.867606
NCT01551030|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2018-04-17|2012-03-08|2012-03-12|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium|Phase II Study of Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium|Active, not recruiting||Phase 2|35|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:34:04.940752|2018-05-31 21:34:04.940752
NCT01551017|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-04-21|2012-03-09|2012-03-12|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|June 2015|Anticipated|2015-06-30||Observational|FARP||Fast Track Recovery Knee Arthroplasty Project|Postoperative Cryotherapy: Fast Track Recovery Knee Arthroplasty Project|Unknown status|Recruiting||80|Anticipated|Medical University of Graz|||2||f||||f||||||||||2018-05-31 21:34:05.030229|2018-05-31 21:34:05.030229
NCT01551004|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-09-21|2012-03-08|2012-03-12|Estimate|||||||2017-09-21|2017-09-25|Actual|May 22, 2012|Actual|2012-05-22|September 26, 2014|2014-09-26|April 21, 2014|Actual|2014-04-21|April 7, 2014|Actual|2014-04-07||Interventional|||Phase I Trial of a Single Dose of CRS3123|Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults|Completed||Phase 1|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f|||||t|f|||f|||||2018-05-31 21:34:05.113238|2018-05-31 21:34:05.113238
NCT01550978|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2016-02-17|2012-03-07|2012-03-12|Estimate|||||||2016-02-17|2016-02-19|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluation of the Safety and Efficacy of the AnapnoGuard 100 System|The Safety of Using the AnapnoGuard 100 System in Intubated Critical Care Patients|Completed||N/A|60|Actual|Hospitech Respiration||2|||f||||f||||||||||2018-05-31 21:34:05.198719|2018-05-31 21:34:05.198719
NCT01550965|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2016-04-01||2016-09-14|2012-03-08|2012-03-12|Estimate|2016-09-14|2016-11-01|Estimate||||2016-09-14|2016-11-01|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|InspirAda|Intention to Treat (ITT) population: all participants who had received at least one dose of study drug and had data for at least one post-baseline assessment of any effectiveness measurement [up to and including Week 26] while receiving treatment with adalimumab.|A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting|An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting|Completed||Phase 3|463|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:34:05.311907|2018-05-31 21:34:05.311907
NCT01550952|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2016-01-29||2016-03-01|2012-03-07|2012-03-12|Estimate|2016-03-01|2016-03-31|Estimate||||2016-03-01|2016-03-31|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Interscalene Dynamometer Pilot Study|Interscalene Dynamometer Pilot Study|Completed|||10|Actual|Hospital for Special Surgery, New York|||||f||||||||||||||2018-05-31 21:34:05.922944|2018-05-31 21:34:05.922944
NCT01550939|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-07-31|2012-03-09|2012-03-12|Estimate|||||||2012-07-31|2012-08-01|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Time Study for Biometry Measurements With the Lenstar and IntraOcularLens (IOL) Master 500|A Single-Center, Open-Label, Randomized Clinical Study Measuring Time Needed for Testing Between the Haag-Streit Lenstar 900 Version i4 and the Carl Zeiss IOL Master 500 Instruments|Completed||Phase 4|61|Actual|Haag Streit USA||1|||f||||f||||||||||2018-05-31 21:34:06.124106|2018-05-31 21:34:06.124106
NCT01550926|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2013-01-24|2012-03-07|2012-03-12|Estimate|||||||2013-01-24|2013-01-28|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms|A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms|Completed||Phase 1|48|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:34:06.204199|2018-05-31 21:34:06.204199
NCT01550913|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2016-03-29|2012-03-09|2012-03-12|Estimate|||||||2016-03-29|2016-03-30|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Sober Network IPT for Perinatal Women With Comorbid Substance Use and Depression|Sober Network IPT for Perinatal Women With Comorbid Substance Use and Depression|Completed||Phase 1|59|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 21:34:06.280974|2018-05-31 21:34:06.280974
NCT01550900|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-04-04|2012-03-08|2012-03-12|Estimate|||||||2013-04-04|2013-04-05|Estimate|July 2013||2013-07-31|April 2013|2013-04-30||||July 2020|Anticipated|2020-07-31||Interventional|||Prospective Trial of Metformin - Chemoprevention Role|A Prospective Placebo-control Double-blind Randomized Trial of Metformin in Chemoprevention of Metachronous Colonic Neoplastic Polyps|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 21:34:06.366242|2018-05-31 21:34:06.366242
NCT01550887|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-08-10|2012-03-07|2012-03-12|Estimate|||||||2015-08-10|2015-08-13|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of Impulsivity on Cocaine and Crack Addicts|Evaluation of Impulsivity on Cocaine and Crack Addicts|Completed||N/A|60|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 21:34:06.442527|2018-05-31 21:34:06.442527
NCT01550874|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2018-01-31|2012-03-09|2012-03-12|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2, 2012|Actual|2012-04-02|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|STEP||STEP: Enhanced Physical Activity in Children and Youth With Epilepsy|STEP: Enhanced Physical Activity in Children and Youth With Epilepsy: Developing Evidence of Impacts on Health, Functioning, Psychological Wellbeing, and Quality of Life|Active, not recruiting||N/A|122|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 21:34:06.52294|2018-05-31 21:34:06.52294
NCT01550861|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-10-30|2012-03-07|2012-03-12|Estimate|||||||2017-10-30|2017-11-01|Actual|February 2012||2012-02-29|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|IVM||In Vitro Maturation (IVM) of Human Oocytes|IN VITRO MATURATION (IVM) OF HUMAN OOCYTES|Active, not recruiting||N/A|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 21:34:06.603048|2018-05-31 21:34:06.603048
NCT01550848|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-09-08|2012-03-07|2012-03-12|Estimate|||||||2015-09-08|2015-09-09|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|||A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer|A Phase II Study of Abraxane Combined With Gemcitabine in the Patients With Metastatic Breast Cancer|Completed||Phase 2|84|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 21:34:06.683045|2018-05-31 21:34:06.683045
NCT01550835|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-04-17|2012-03-07|2012-03-12|Estimate|||||||2015-04-17|2015-04-21|Estimate|February 2012||2012-02-29|April 2015|2015-04-30||||February 2016|Anticipated|2016-02-29||Interventional|||Impact of Aspiration Thrombectomy During Carotid Stenting|Impact of Aspiration Thrombectomy During Carotid Stenting on New Ischemic Lesions Identified by Diffusion-Weighted Magnetic Resonance Imaging|Unknown status|Recruiting|N/A|80|Anticipated|Fogarty Clinical Research Inc.||2|||f||||f||||||||||2018-05-31 21:34:06.760352|2018-05-31 21:34:06.760352
NCT01550822|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-03-09|2012-03-09|2012-03-12|Estimate|||||||2017-03-09|2017-03-13|Actual|April 2012||2012-04-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||HEALS (Healthy Eating And Lifestyle After Stroke)|HEALS (Healthy Eating And Lifestyle After Stroke): A Pilot Trial of a Multidisciplinary Lifestyle Intervention Program|Completed||N/A|100|Actual|Los Amigos Research and Education Institute||2|||f||||f||||||||||2018-05-31 21:34:06.859937|2018-05-31 21:34:06.859937
NCT01550809|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2012-06-05||2012-08-20|2012-03-07|2012-03-12|Estimate|2012-08-20|2012-08-29|Estimate||||2012-08-20|2012-08-29|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy|New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy: Feasibility of Insulin Dosing Based on Information From Continuous Glucose Monitoring|Completed||Phase 3|12|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||||2018-05-31 21:34:06.949054|2018-05-31 21:34:06.949054
NCT01550796|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2013-05-21|2012-03-09|2012-03-12|Estimate|||||||2013-05-21|2013-05-23|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Treatment of Chronic Bothersome Tinnitus Using Cognitive Training and D-cycloserine|Treatment of Chronic Bothersome Tinnitus Using Cognitive Training and D-cycloserine|Completed||Phase 2|37|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 21:34:07.194376|2018-05-31 21:34:07.194376
NCT01550783|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2018-04-16|2012-03-07|2012-03-12|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2012||2012-03-31|April 2018|2018-04-30|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening|Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS|Completed||N/A|1335|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 21:34:07.277857|2018-05-31 21:34:07.277857
NCT01550770|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-07-20|2012-03-09|2012-03-12|Estimate|||||||2012-07-20|2012-07-23|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Exploratory Study of Propofol and Fentanyl Pharmacodynamics|An Open Label, Exploratory Study of Propofol and Fentanyl Pharmacodynamics|Completed||Phase 1|20|Actual|Ethicon Endo-Surgery||1|||f||||||||||||||2018-05-31 21:34:07.360127|2018-05-31 21:34:07.360127
NCT01550757|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2017-05-16||2017-05-16|2012-03-07|2012-03-12|Estimate|2017-05-16|2017-10-11|Actual||||2017-05-16|2017-10-11|Actual|March 2012||2012-03-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2014|Actual|2014-09-30||Interventional|ARCH||Aligning Resources to Care for Homeless Veterans|Aligning Resources to Care for Homeless Veterans (ARCH)|Completed||N/A|382|Actual|VA Office of Research and Development|All AE and SAE monitoring was discussed with and approved by all regulatory authorities (IRB, DSMB, and research compliance officer).|4|||f||||f||||||||||2018-05-31 21:34:07.424745|2018-05-31 21:34:07.424745
NCT01550744|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2016-04-25||2016-12-15|2012-03-08|2012-03-12|Estimate|2016-09-19|2016-11-07|Estimate||||2016-12-15|2017-02-09|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|PSTELLAR|The “enrolled subject data set” was defined as all participants enrolled at Week 0 who received at least 1 dose of ustekinumab during the study.|"A Study of Ustekinumab to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis"|"A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis"|Completed||Phase 3|478|Actual|Janssen Biotech, Inc.||2|||f||||t||||||||||2018-05-31 21:34:07.918392|2018-05-31 21:34:07.918392
NCT01550731|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-07-26|2012-03-07|2012-03-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PREPARE||Preparing Older Veterans With Serious and Chronic Illness for Decision Making|Preparing Older Veterans With Serious and Chronic Illness for Decision Making|Completed||Early Phase 1|414|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 21:34:08.681045|2018-05-31 21:34:08.681045
NCT01550718|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-06-08|2012-03-07|2012-03-12|Estimate|||||||2015-06-08|2015-06-10|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial|Two Interventions for Early Stage Dementia: A Comparative Efficacy Trial|Completed||N/A|152|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 21:34:08.765094|2018-05-31 21:34:08.765094
NCT01550705|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2016-11-19||2016-11-19|2012-03-09|2012-03-12|Estimate|2016-11-19|2017-01-16|Estimate||||2016-11-19|2017-01-16|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|INHEPP||Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria|Quantification of the Effects of Isoniazid Treatment on Erythrocyte and Plasma Protoporphyrin IX Concentration and Plasma Aminolevulinic Acid in Patients With Erythropoietic Protoporphyria|Terminated||N/A|11|Actual|University of Utah||1||Interim analysis demonstrated the treatment was not effective|f||||t||||||||No||2018-05-31 21:34:08.850807|2018-05-31 21:34:08.850807
NCT01550679|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-07-19|2012-03-07|2012-03-12|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2010||2010-10-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Observational|MARKO||Early Detection of COPD Patients in GOLD 0 (Smokers) Population|Early Detection of COPD Patients in GOLD 0 (Smokers) Population|Recruiting|||600|Anticipated|Children's Hospital Srebrnjak|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, plasma~   "|||2018-05-31 21:34:09.017868|2018-05-31 21:34:09.017868
NCT01550666|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-01-08|2012-03-09|2012-03-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|MOVE||Treatment Development Targeting Severe and Persistent Negative Symptoms|Treatment Development Targeting Severe and Persistent Negative Symptoms|Completed||N/A|96|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 21:34:09.100722|2018-05-31 21:34:09.100722
NCT01550653|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-02-26|2012-03-07|2012-03-12|Estimate|||||||2014-02-26|2014-02-27|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Liraglutide Effects on Memory in Healthy Subjects|Liraglutide Effects on Memory in Healthy Subjects|Completed||Phase 1|40|Actual|University of Luebeck||2|||f||||t||||||||||2018-05-31 21:34:09.176655|2018-05-31 21:34:09.176655
NCT01550640|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-11-14|2012-03-09|2012-03-12|Estimate|||||||2014-11-14|2014-11-18|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia|Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia|Completed||N/A|149|Actual|Charles University, Czech Republic||2|||f||||f||||||||||2018-05-31 21:34:09.243707|2018-05-31 21:34:09.243707
NCT01550627|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-03-09|2012-03-09|2012-03-12|Estimate|||||||2012-03-09|2012-03-12|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Intravenous Fluid Supplementation on Serum Bilirubin and Cardiorespiratory Parameters in Preterm Infants During Phototherapy|Study of Possible Effects of Intravenous Fluid Supplementation on Serum Bilirubin Levels and Cardiorespiratory Parameters in Preterm Infants During Phototherapy|Completed||Early Phase 1|60|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 21:34:09.383399|2018-05-31 21:34:09.383399
NCT01550614|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-09-27|2012-03-07|2012-03-12|Estimate|||||||2016-09-27|2016-09-29|Estimate|March 2012||2012-03-31|September 2016|2016-09-30||||May 2016|Actual|2016-05-31||Interventional|ASPIRE||Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease|A Randomized, Controlled, Parallel Group, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Ad5FGF-4 Using SPECT Myocardial Perfusion Imaging in Patients With Stable Angina Pectoris|Terminated||Phase 3|11|Actual|Cardium Therapeutics||2|||f||||t||||||||No||2018-05-31 21:34:09.4781|2018-05-31 21:34:09.4781
NCT01550601|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-09|2012-03-09|2012-03-12|Estimate|||||||2012-03-09|2012-03-12|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Interventional|QUALISLEEVE||Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity|Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity: a Prospective,Controlled, Randomized, Multicentrique Study.|Unknown status|Recruiting|Phase 4|346|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:34:09.58341|2018-05-31 21:34:09.58341
NCT01550588|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2017-06-28|2012-03-07|2012-03-12|Estimate|||||||2017-06-28|2017-06-29|Actual|February 2012||2012-02-29|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO)|Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO|Recruiting||Phase 4|210|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:34:09.676478|2018-05-31 21:34:09.676478
NCT01550575|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2018-02-06|2012-03-07|2012-03-12|Estimate|||||||2018-02-06|2018-02-08|Actual|March 2012||2012-03-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|PRO||Precision Retrospective Outcomes|Precision Retrospective Outcomes|Recruiting|||2000|Anticipated|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 21:34:09.76771|2018-05-31 21:34:09.76771
NCT01550562|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2013-05-08|2012-03-07|2012-03-12|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effects of Programming Parameters on Back Pain Relief in Subthreshold Spinal Cord Stimulation|Precision™ High-Rate Sub-perception Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain|Terminated||N/A|1|Actual|Boston Scientific Corporation||3||"In >9 months only 1 patient enrolled. Study stopped because design was too cumbersome and~   subjects not willing to participate"|f||||f||||||||||2018-05-31 21:34:09.840162|2018-05-31 21:34:09.840162
NCT01550549|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2012-04-06||2012-05-03|2012-03-07|2012-03-12|Estimate|2012-05-03|2012-06-07|Estimate||||2012-05-03|2012-06-07|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans|Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans|Completed||N/A|151|Actual|Avid Radiopharmaceuticals|||||f||||f||||||||||2018-05-31 21:34:09.95351|2018-05-31 21:34:09.95351
NCT01550536|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-09|2012-03-09|2012-03-12|Estimate|||||||2012-03-09|2012-03-12|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Physical Activity and Basal Metabolic Rate in Postmenopausal Women|Aging and Basal Metabolic Rate in Postmenopausal Women: Effects of Long-Term and Short-Term Physical Activity|Completed||N/A|49|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:34:11.263258|2018-05-31 21:34:11.263258
NCT01550354|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-02-04|2012-03-06|2012-03-12|Estimate|||||||2014-02-04|2014-02-05|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparison Among Propofol, Alfentanil and Rocuronium as Adjunct to Sevoflurane Anesthesia for Endotracheal Intubation in Children With Frenectomy||Completed||N/A|114|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 21:34:12.918231|2018-05-31 21:34:12.918231
NCT01550523|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2013-12-02|2012-03-07|2012-03-12|Estimate|||||||2013-12-02|2013-12-03|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pilot Immunotherapy Trial for Recurrent Malignant Gliomas|Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurrent Malignant Glioma|Completed||Phase 1|12|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 21:34:11.358107|2018-05-31 21:34:11.358107
NCT01550510|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-01-31|2012-03-07|2012-03-12|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA|Phase I/II Study of Intravenous Ascorbic Acid in Combination With Irinotecan Versus Irinotecan Alone for Advanced Colorectal Cancer|Terminated||Phase 1/Phase 2|4|Actual|Thomas Jefferson University||1||Closed: low enrollment, many treatment options available for Colorectal Cancer|f||||t||||||||No||2018-05-31 21:34:11.447769|2018-05-31 21:34:11.447769
NCT01550497|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-12-17|2012-03-09|2012-03-12|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|LBPAIS||Spinal Stabilization Exercises for Low Back Pain in Adolescents With Idiopathic Scoliosis|Effectiveness of Spinal Stabilization Exercises for Low Back Pain in Adolescents With Idiopathic Scoliosis|Completed||N/A|45|Actual|Texas Scottish Rite Hospital for Children||2|||f||||t||||||||||2018-05-31 21:34:11.535333|2018-05-31 21:34:11.535333
NCT01550484|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06||2017-02-08|2017-02-08|2012-03-09|2012-03-12|Estimate||||2017-02-08|2017-02-09|Estimate|2017-02-08|2017-02-09|Estimate|April 2012||2012-04-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders|An Open Label, Multicenter Study, Evaluating the Safety and Efficacy of 18F-AV-133 PET Imaging to Identify Subjects With Dopaminergic Degeneration Among Subjects Presenting to a Movement Disorders Specialty Clinic With an Uncertain Diagnosis|Completed||Phase 2/Phase 3|170|Actual|Avid Radiopharmaceuticals|||||f||||f||||||||||2018-05-31 21:34:11.625239|2018-05-31 21:34:11.625239
NCT01550471|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2016-07-20|2012-03-07|2012-03-12|Estimate|||||||2016-07-20|2016-07-21|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis|A Study Evaluating the Effect of Omnaris Nasal Spray 200 mcg QD & Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 mcg BID & QVAR Inhalation Aerosol 40 mcg BID vs Placebo Nasal Spray QD & Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma & Allergic Rhinitis|Completed||Phase 4|25|Actual|West Penn Allegheny Health System||6|||f||||t||||||||||2018-05-31 21:34:11.832325|2018-05-31 21:34:11.832325
NCT01550458|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-01-23|2012-03-07|2012-03-12|Estimate|||||||2018-01-23|2018-01-24|Actual|February 2012||2012-02-29|January 2018|2018-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers|A Study of the Pharmacokinetic and Safety Profile of QID Dosing of Mibefradil in Normal Human Volunteers|Completed||Phase 1|30|Actual|Cavion, Inc.||2|||f||||f||||||||||2018-05-31 21:34:11.95241|2018-05-31 21:34:11.95241
NCT01550445|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-03-07|2012-03-07|2012-03-12|Estimate|||||||2012-03-07|2012-03-12|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|October 2009|Actual|2009-10-31||Interventional|||Steroid Withdrawal Immunosuppression After Renal Transplantation|Prospective Controlled Protocol for 3 Months Steroid Withdrawal With Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients|Unknown status|Recruiting|Phase 4|30|Anticipated|Ajou University School of Medicine||1|||f||||f||||||||||2018-05-31 21:34:12.067721|2018-05-31 21:34:12.067721
NCT01550432|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-05-24|2012-03-09|2012-03-12|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2011||2011-06-30|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation|Effects of GSH and N-Acetylcysteine on Inflammatory Markers Among Adults With CVD Risk|Completed||N/A|78|Actual|Stanford University||5|||f||||f|f|f||||||No||2018-05-31 21:34:12.252875|2018-05-31 21:34:12.252875
NCT01550419|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2013-02-24|2012-03-09|2012-03-12|Estimate|||||||2013-02-24|2013-02-26|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke|Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Shanghai Minhang Central Hospital||2|||f||||t||||||||||2018-05-31 21:34:12.371437|2018-05-31 21:34:12.371437
NCT01550406|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2016-06-06|2012-03-07|2012-03-12|Estimate|||||||2016-06-06|2016-06-08|Estimate|November 2011||2011-11-30|June 2016|2016-06-30||||April 2015|Actual|2015-04-30||Interventional|||Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy|Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study|Completed||Phase 4|150|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 21:34:12.504729|2018-05-31 21:34:12.504729
NCT01550393|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-07-07|2012-03-07|2012-03-12|Estimate|||||||2016-07-07|2016-07-11|Estimate|March 2012||2012-03-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Biomarkers in Urine Samples From Patients With Wilms Tumor|Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics|Completed|||100|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-05-31 21:34:12.635266|2018-05-31 21:34:12.635266
NCT01550380|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-07-28|2012-03-06|2012-03-12|Estimate|||||||2014-07-28|2014-07-29|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|BKM120||BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers|A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers|Withdrawn||Phase 2|0|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 21:34:12.720727|2018-05-31 21:34:12.720727
NCT01550367|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-12-22|2012-03-06|2012-03-12|Estimate|||||||2016-12-22|2016-12-23|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)|Inhibiting the Systemic Autophagic Syndrome - A Phase I/II Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC). A Cytokine Working Group (CWG) Study|Recruiting||Phase 1/Phase 2|39|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 21:34:12.797126|2018-05-31 21:34:12.797126
NCT01550315|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2018-03-26|2012-03-06|2012-03-09|Estimate|||||||2018-03-26|2018-03-27|Actual|April 2012||2012-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Dietary Sodium Intake on Vascular Endothelium|A Pilot Study of the Effect of Dietary Sodium Intake on Assessments of Vascular Endothelium|Active, not recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 21:34:13.239561|2018-05-31 21:34:13.239561
NCT01550302|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2017-03-23||2017-06-14|2012-03-06|2012-03-09|Estimate|2017-03-23|2017-05-04|Actual||||2017-06-14|2017-07-18|Actual|October 2013||2013-10-31|June 2017|2017-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SCPB||Superficial Cervical Plexus Block for Shoulder Pain After Lung Surgery|The Effect of Superficial Cervical Plexus Block on Post-Thoracotomy/Scopy Ipsilateral Shoulder Pain|Terminated||Phase 4|10|Actual|University of Washington||2||"Unable to continue enrollment due to lack of resources (research coordinator no longer~   available)."|f||||t||||||||||2018-05-31 21:34:13.467118|2018-05-31 21:34:13.467118
NCT01550289|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2016-09-14||2016-11-06|2012-03-08|2012-03-09|Estimate|2016-09-14|2016-11-03|Estimate||||2016-11-06|2016-12-28|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India|Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India.|Completed||Phase 2|189|Actual|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 21:34:13.980607|2018-05-31 21:34:13.980607
NCT01550276|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Tension-type Headache With Articulatory and Suboccipital Soft Tissue Therapy|Treatment of Tension-type Headache With Articulatory and Suboccipital Soft Tissue Therapy: a Double-blind, Randomized, Placebo-controlled Clinical Trial|Completed||N/A|84|Actual|University of Valencia||4|||f||||t||||||||||2018-05-31 21:34:15.099856|2018-05-31 21:34:15.099856
NCT01550263|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-10-04|2012-03-06|2012-03-09|Estimate|||||||2017-10-04|2017-10-05|Actual|January 2012||2012-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|Hip||Psychological Distress and Outcomes in Hip Preservation Patients|Pre-Operative Psychological Distress and Post-Operative Outcomes in Hip Preservation Patients|Active, not recruiting|||200|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 21:34:15.171405|2018-05-31 21:34:15.171405
NCT01550250|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2014-07-16|2012-03-07|2012-03-09|Estimate|||||||2014-07-16|2014-07-18|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Night-time Compression Systems for Breast Cancer Related Lymphedema|Feasibility of Night-time Compression Systems for Breast Cancer Related Lymphedema: a Pilot Study|Completed||Phase 1|30|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 21:34:15.216987|2018-05-31 21:34:15.216987
NCT01550237|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2018-02-06|2012-03-07|2012-03-09|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2012||2012-10-31|February 2018|2018-02-28|September 2025|Anticipated|2025-09-30|September 2015|Actual|2015-09-30||Interventional|RIC||Curative Image Guided Radiotherapy for Prostate Cancer|A Randomised, Two Centre Trial on Daily Cone-beam vs Standard Weekly Orthogonal Image Guided Radiotherapy (IGRT) for Prostate Cancer|Active, not recruiting||N/A|260|Actual|St. Olavs Hospital||2|||f||||t|f|f||||||||2018-05-31 21:34:15.372288|2018-05-31 21:34:15.372288
NCT01550224|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2018-05-16|2012-03-07|2012-03-09|Estimate|||||||2018-05-16|2018-05-21|Actual|May 1, 2013|Actual|2013-05-01|May 2018|2018-05-31|November 17, 2014|Actual|2014-11-17|November 17, 2014|Actual|2014-11-17||Interventional|||Phase 2 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML)|A Phase 2 Study of Temozolomide Plus Vorinostat in Patients With Relapse/Refractory Acute Myeloid Leukemia (AML)|Completed||Phase 2|23|Actual|Stanford University||2|||f||||t|t|f||||||No||2018-05-31 21:34:15.469996|2018-05-31 21:34:15.469996
NCT01550211|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-07|2012-03-07|2012-03-09|Estimate|||||||2012-03-07|2012-03-09|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||March 2014|Anticipated|2014-03-31||Observational|||Changes in Brain Synchronization During Perceptual and Linguistic Tasks in Schizophrenic Patients||Unknown status|Not yet recruiting||150|Anticipated|Shalvata Mental Health Center|||4||f||||t||||||||||2018-05-31 21:34:15.543636|2018-05-31 21:34:15.543636
NCT01550198|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-12-22|2012-03-07|2012-03-09|Estimate|||||||2017-12-22|2017-12-27|Actual|May 2013||2013-05-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|Edscini||Early Detection of Neonatal Shock|Early Detection of Shock in Critically Ill Newborn Infants. The Impact of Advanced Hemodynamic Monitoring|Suspended|||70|Anticipated|Radboud University|||1|Problems with availability of cardiac output monitoring system|f||||t||||||||||2018-05-31 21:34:15.635203|2018-05-31 21:34:15.635203
NCT01550185|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-04-04|2012-03-07|2012-03-09|Estimate|||||||2016-04-04|2016-04-06|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia|Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone in Relapsed/Refractory Patients With Acute Myeloid Leukemia|Terminated||Phase 1|10|Actual|Roswell Park Cancer Institute||1||Sponsor wanted study rewritten|f||||f||||||||||2018-05-31 21:34:15.739479|2018-05-31 21:34:15.739479
NCT01550172|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-10-24|2012-03-06|2012-03-09|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers|Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers|Completed||N/A|80|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 21:34:15.844003|2018-05-31 21:34:15.844003
NCT01550159|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-03-06|2012-03-06|2012-03-09|Estimate|||||||2012-03-06|2012-03-09|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Observational|||Correlation Between Markers of Neuronal Injury and Cognitive Dysfunction After Coronary Artery Bypass Surgery|Study of Correlation Between Serum Levels of Markers of Neuronal Injury and Cognitive Dysfunction After Coronary Artery Bypass Graft Surgery|Unknown status|Recruiting||88|Anticipated|University of Sao Paulo|||||f||||t||||||||||2018-05-31 21:34:15.928218|2018-05-31 21:34:15.928218
NCT01550146|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Single Dose of Dexamethasone in Femur Fractures|Effects of a Single Dose of Dexamethasone in Patients Undergoing Operative Fixation of Proximal Femur Fracture|Unknown status|Recruiting|Phase 4|40|Anticipated|Cork University Hospital||2|||f||||f||||||||||2018-05-31 21:34:16.005288|2018-05-31 21:34:16.005288
NCT01550133|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-10-04|2012-03-08|2012-03-09|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Effects of Food Form on Cephalic Phase Responses|Effects of Nutritive and Non-Nutritive Food Form and Learning on Cephalic Phase Responses|Active, not recruiting||N/A|60|Anticipated|Purdue University||8|||f||||f||||||||||2018-05-31 21:34:16.096937|2018-05-31 21:34:16.096937
NCT01550120|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-11-21|2012-03-08|2012-03-09|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Free Fatty Acids: Threshold Repeatability Study|Free Fatty Acids: Threshold Repeatability Study|Completed|||48|Anticipated|Purdue University|||||f||||f||||||||||2018-05-31 21:34:16.190456|2018-05-31 21:34:16.190456
NCT01550107|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2018-03-19|2012-03-08|2012-03-09|Estimate|||||||2018-03-19|2018-03-20|Actual|February 1, 2015|Actual|2015-02-01|March 2018|2018-03-31|September 20, 2017|Actual|2017-09-20|August 1, 2017|Actual|2017-08-01||Interventional|||Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'|A Prospective Study to Evaluate the Effect of Allopurinol on Muscle Energetics in Primary Sarcopenia|Completed||Phase 4|124|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 21:34:16.256217|2018-05-31 21:34:16.256217
NCT01550094|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2015-10-13|2012-03-07|2012-03-09|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Comparison of Two Injection Locations in Obese Patients Having Lower Leg/Foot Surgery|Evaluation of Ultrasound-Guided Popliteal Sciatic Nerve Blockade in the Severely and Morbidly Obese Populations|Completed|||60|Actual|Ochsner Health System|||||f||||f||||||||||2018-05-31 21:34:16.349851|2018-05-31 21:34:16.349851
NCT01550081|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2013-11-27|2012-03-07|2012-03-09|Estimate|||||||2013-11-27|2013-11-28|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|August 2012|Actual|2012-08-31||Interventional|||Target Heart Rate and Aerobic Interval Training|Exercise Intensity and Target Heart Rate During Aerobic Interval Training in Cardiac Rehabilitation|Completed||N/A|10|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 21:34:16.415087|2018-05-31 21:34:16.415087
NCT01550068|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-09-20|2012-03-08|2012-03-09|Estimate|||||||2017-09-20|2017-09-21|Actual|December 2012||2012-12-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Rheumatic Heart Disease School Project|A Population-Based Study of Prevalence of Rheumatic Heart Disease and Cardiovascular Outcomes Among Schoolchildren in Nepal|Recruiting|||5476|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 21:34:16.495365|2018-05-31 21:34:16.495365
NCT01550055|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-02-08|2012-03-07|2012-03-09|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2009||2009-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CRC009||Study of Cetuximab to Treat KRAS Wild Type Metastatic Colorectal Cancer|Phase II/III Trial of Cetuximab Plus Irinotecan Synchronously/Subsequently in Patients With KRAS Wild-type Metastatic Colorectal Cancer: an Randomized, Open-label, Multicenter, Prospective Study|Completed||Phase 2/Phase 3|512|Actual|Shanghai Zhangjiang Biotechnology Limited Company||2|||f||||t||||||||||2018-05-31 21:34:16.580071|2018-05-31 21:34:16.580071
NCT01550042|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-07-06|2012-03-07|2012-03-09|Estimate|||||||2016-07-06|2016-07-07|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2015|Actual|2015-04-30||Observational|SCARF||Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients|Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients|Active, not recruiting|||50|Actual|Medisch Spectrum Twente|||1||f||||t||||||||||2018-05-31 21:34:16.670677|2018-05-31 21:34:16.670677
NCT01550029|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-01-03|2012-03-08|2012-03-09|Estimate|||||||2014-01-03|2014-01-07|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Targeted Intervention for Bipolar Smokers|Targeted Intervention for Bipolar Smokers|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 21:34:16.74666|2018-05-31 21:34:16.74666
NCT01550016|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-10-10|2012-03-08|2012-03-09|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Observational|IDAMS||International Research Consortium on Dengue Risk Assessment, Management, and Surveillance|Clinical Evaluation of Dengue and Identification of Risk Factors for Severe Disease (WP1)|Completed|||7411|Actual|University of Heidelberg Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 21:34:16.832753|2018-05-31 21:34:16.832753
NCT01550003|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2018-03-23|2012-03-07|2012-03-09|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 2012|Actual|2012-03-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|PASCAL||Pediatric Arthritis Study of Certolizumab Pegol|A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)|Active, not recruiting||Phase 3|163|Actual|UCB Pharma||1|||f||||t||||||||||2018-05-31 21:34:16.925597|2018-05-31 21:34:16.925597
NCT01549990|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-01-26|2012-03-06|2012-03-09|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||A Comparison of Kidney Function After Nephrectomy in Living Donors Under Sevoflurane and Desflurane Anesthesia||Completed|||236|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 21:34:17.116289|2018-05-31 21:34:17.116289
NCT01549977|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2013-10-30||2013-10-30|2012-03-06|2012-03-09|Estimate|2013-10-30|2013-12-20|Estimate||||2013-10-30|2013-12-20|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina|A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Exercise Tolerance in Subjects With Chronic Stable Angina|Terminated||Phase 2|1|Actual|Takeda||2||Business Decision (please see below)|f||||t||||||||||2018-05-31 21:34:17.196259|2018-05-31 21:34:17.196259
NCT01549964|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2015-03-25||2016-04-20|2012-03-06|2012-03-09|Estimate|2016-04-20|2016-06-02|Estimate||||2016-04-20|2016-06-02|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes|Terminated||Phase 3|916|Actual|Takeda||4||Due to concerns about potential liver safety (See Detailed Description)|f||||t||||||||||2018-05-31 21:34:17.572055|2018-05-31 21:34:17.572055
NCT01549951|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2016-02-29||2016-04-24|2012-03-07|2012-03-09|Estimate|2016-04-24|2016-06-01|Estimate||||2016-04-24|2016-06-01|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Safety analysis set was defined as all participants who received at least 1 dose of any study drug.|Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 2|50|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:34:18.957666|2018-05-31 21:34:18.957666
NCT01549938|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-10-17|2012-03-07|2012-03-09|Estimate|||||||2012-10-17|2012-10-19|Estimate|May 2012||2012-05-31|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|CIPRIS||Cholecalciferol Intervention to Prevent Respiratory Infections Study|Cholecalciferol Intervention to Prevent Respiratory Infections Study: a Double-blind Randomised Controlled Trial to Evaluate the Efficacy of 20,000 IU/wk Cholecalciferol in Reducing Respiratory Tract Infection in a Cohort of Healthy Young Adults|Completed||Phase 2|32|Actual|Menzies Institute for Medical Research||2|||f||||t||||||||||2018-05-31 21:34:19.358759|2018-05-31 21:34:19.358759
NCT01549925|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2015-10-02||2015-12-21|2012-03-06|2012-03-09|Estimate|2015-12-21|2016-01-28|Estimate||||2015-12-21|2016-01-28|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Stand|A Prospective Randomized Surgical Trial Comparing the Efficacy of LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Standard Surgical Resection in Women With Stage IIIC or Stage IVA Epithelial Ovarian Cancer|Completed||N/A|50|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 21:34:19.456313|2018-05-31 21:34:19.456313
NCT01549912|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-08-05|2012-03-06|2012-03-09|Estimate|||||||2015-08-05|2015-08-06|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Results of Rotator Cuff Repair|Results of Rotator Cuff Repair Following Acute Shoulder Dislocation|Completed|||2|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 21:34:19.687275|2018-05-31 21:34:19.687275
NCT01549899|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2016-05-05|2012-03-06|2012-03-09|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparing Internet and In-Person Brief Cognitive Behavioral Therapy of Insomnia|Comparing Internet and In-Person Brief Cognitive Behavioral Therapy of Insomnia|Completed||Phase 3|187|Actual|University of North Texas, Denton, TX||3|||f||||t||||||||||2018-05-31 21:34:19.744031|2018-05-31 21:34:19.744031
NCT01549886|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-06-02|2012-03-08|2012-03-09|Estimate|||||||2015-06-02|2015-06-04|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma|A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma|Terminated||Phase 2|5|Actual|Spectrum Pharmaceuticals, Inc||2||Due to business reasons.|f||||f||||||||||2018-05-31 21:34:19.875466|2018-05-31 21:34:19.875466
NCT01549873|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2015-02-04||2015-02-24|2012-03-08|2012-03-09|Estimate|2015-02-24|2015-02-26|Estimate||||2015-02-24|2015-02-26|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Anesthesia During Neurophysiologic Monitoring in Scoliosis Patients|Anesthesia During Neurophysiologic Monitoring in Scoliosis Patients: Volatile Agents Versus Total Intravenous Anesthesia|Completed||N/A|30|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 21:34:19.983982|2018-05-31 21:34:19.983982
NCT01549860|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2015-04-27||2015-07-02|2012-03-08|2012-03-09|Estimate|2015-07-02|2015-07-30|Estimate||||2015-07-02|2015-07-30|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional||Eligible subjects randomized|Effects of Non Contact Low Frequency Ultrasound in Healing Venous Leg Ulcers|IN-BALANCE VLU Inflammation, Bacteria, & Angiogenesis Effects in Launching Venous Leg Ulcer Healing|Completed||N/A|156|Actual|Celleration, Inc.||2|||f||||t||||||||||2018-05-31 21:34:20.23202|2018-05-31 21:34:20.23202
NCT01549847|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2015-11-16|2012-03-08|2012-03-09|Estimate|||||||2015-11-16|2015-11-17|Estimate||||November 2015|2015-11-30||||February 2013|Anticipated|2013-02-28||Interventional|||A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome|A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Therapeutic Effect of the Association of L-carnitine and Piracetam as an Adjuvant Therapy in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome|Withdrawn||Phase 3|0|Actual|Biolab Sanus Farmaceutica||2||Study was not approved by Health Surveillance Agency|f||||f||||||||||2018-05-31 21:34:20.555697|2018-05-31 21:34:20.555697
NCT01549834|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07||2014-10-24|2014-10-24|2012-03-07|2012-03-09|Estimate||||2014-10-24|2014-10-31|Estimate|2014-10-24|2014-10-31|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|Completed||Phase 2|434|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 21:34:20.624899|2018-05-31 21:34:20.624899
NCT01549808|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|MIT||Early Mobilization in Intensive Therapy|Early Mobilisation in Intensive Therapy|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Region Zealand||1|||f||||f||||||||||2018-05-31 21:34:20.779303|2018-05-31 21:34:20.779303
NCT01549795|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-07-17|2012-03-08|2012-03-09|Estimate|||||||2012-07-17|2012-07-18|Estimate|January 2012||2012-01-31|July 2012|2012-07-31||||July 2013|Anticipated|2013-07-31||Interventional|||Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy|Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante|Unknown status|Recruiting|N/A|33|Anticipated|Azienda Ospedaliera di Padova|||||f||||t||||||||||2018-05-31 21:34:20.876664|2018-05-31 21:34:20.876664
NCT01549782|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|June 2005||2005-06-30|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Mixture of Prebiotics on Intestinal Microbiota of Patients Receiving Abdominal Radiotherapy.|Effect of a Mixture of Inulin and Fructo-oligosaccharide on Lactobacillus and Bifidobacterium Intestinal Microbiota of Patients Receiving Radiotherapy: a Randomised, Double-blind, Placebo-controlled Trial.|Completed||N/A|40|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 21:34:20.964905|2018-05-31 21:34:20.964905
NCT01549769|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-04-28|2012-03-08|2012-03-09|Estimate|||||||2014-04-28|2014-04-29|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes|A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes|Terminated||Phase 1|24|Actual|Reata Pharmaceuticals, Inc.||1||IDMC recommendation for safety concerns|f||||||||||||||2018-05-31 21:34:21.032013|2018-05-31 21:34:21.032013
NCT01549756|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||April 2012|Anticipated|2012-04-30||Observational|||Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers|Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers|Unknown status|Recruiting||30|Anticipated|Find A Cure Panel|||1||f||||f||||||||||2018-05-31 21:34:21.090117|2018-05-31 21:34:21.090117
NCT01549743|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-08|2012-03-07|2012-03-09|Estimate|||||||2012-03-08|2012-03-12|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||The Pharmacokinetic Interaction Between Celecoxib and Rebamipide|Clinical Trial to Assess the Pharmacokinetic Interaction Between Celecoxib and Rebamipide in Healthy Male Volunteers|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Hanlim Pharm. Co., Ltd.||3|||f||||||||||||||2018-05-31 21:34:21.152636|2018-05-31 21:34:21.152636
NCT01549730|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-09-19|2012-03-06|2012-03-09|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2011||2011-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Cervix Hypoxia FAZA|A Feasibility Study of Hypoxia Imaging in Patients With Cervix Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)|Recruiting||N/A|30|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 21:34:21.254044|2018-05-31 21:34:21.254044
NCT01549717|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2014-02-11|2012-03-07|2012-03-09|Estimate|||||||2014-02-11|2014-02-12|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|LISTEN||Feasibility And Efficacy Of Continuous In-Hospital Patient Monitoring|Feasibility And Efficacy Of Continuous In-Hospital Patient Monitoring|Completed||N/A|300|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 21:34:21.319175|2018-05-31 21:34:21.319175
NCT01549704|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-01-07|2012-03-08|2012-03-09|Estimate|||||||2013-01-07|2013-01-08|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Adductor-Canal-Blockade on High Pain Responders After Total Knee Arthroplasty|Effect of Adductor-Canal-Blockade on High Pain Responders the 1. or 2. Postoperative Day After Total Knee Arthroplasty|Completed||Phase 4|50|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 21:34:21.387104|2018-05-31 21:34:21.387104
NCT01549691|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2013-09-24|2012-03-06|2012-03-09|Estimate|||||||2013-09-24|2013-09-25|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PREMED||Reassessment of Premedication in Surgery|Assessment of Two Modes of Premedication in Surgery - PREMED Study|Completed||Phase 4|455|Anticipated|University Hospital, Angers||3|||f||||t||||||||||2018-05-31 21:34:21.469358|2018-05-31 21:34:21.469358
NCT01549678|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-07|2012-03-07|2012-03-09|Estimate|||||||2012-03-07|2012-03-09|Estimate|August 2010||2010-08-31|November 2010|2010-11-30|August 2012|Anticipated|2012-08-31|April 2012|Anticipated|2012-04-30||Interventional|||Plantar Fasciitis Foot Insole|Effect of Plantar Fasciitis Foot Insole|Unknown status|Recruiting|N/A|74|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:34:21.557907|2018-05-31 21:34:21.557907
NCT01549665|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-14|2012-03-06|2012-03-09|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|GVHD-MSC||Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease|Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-05-31 21:34:21.740232|2018-05-31 21:34:21.740232
NCT01549652|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-02-08|2012-03-08|2012-03-09|Estimate|||||||2016-02-08|2016-02-10|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|April 2015|Actual|2015-04-30||Interventional|||5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence|5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence|Unknown status|Active, not recruiting|N/A|76|Actual|Stanford University||2|||f||||||||||||||2018-05-31 21:34:21.80588|2018-05-31 21:34:21.80588
NCT01549639|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-07-18|2012-03-06|2012-03-09|Estimate|||||||2012-07-18|2012-07-19|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Blood Propofol Measurement During Anaesthesia Using Propofol Target Controlled Infusion|Use of a Novel Point of Care Device to Measure Blood Propofol Levels During Propofol Based General Anesthesia by Target Controlled Infusion Using the Marsh Model in Effect Site Mode|Completed|||50|Actual|University Hospital Birmingham NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 21:34:21.897325|2018-05-31 21:34:21.897325
NCT01549626|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Flaxseed Flour in Appetite Sensations, Lipid Profile and Pressure Levels Among Overweighed and Obese Women|Effects of Flaxseed Flour - Whole Brown Flaxseed Flour, Brown Defatted Flaxseed Flour and Golden Flaxseed Flour in Appetite Sensations Satiety, Lipid Profile, Pressure Levels and Associated Costs Among Overweighed and Obese Women|Completed||N/A|54|Actual|Universidade Federal do Rio de Janeiro||3|||f||||t||||||||||2018-05-31 21:34:21.963434|2018-05-31 21:34:21.963434
NCT01549613|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2014-07-07||2014-07-07|2012-03-06|2012-03-09|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||161 patients were screened;104 were initially enrolled. 3 patients were withdrawn prior to randomization; 1 patient was transferred to OR, 1 patient was admitted prior to randomization, 1 patient was prescribed a different antibiotic;1 patient was withdrawn not meet inclusion criteria. 39 patients in each treatment group completed follow-up.|Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections|Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections|Completed||Phase 4|104|Actual|University of Cincinnati||2|||f||||t||||||||||2018-05-31 21:34:22.037502|2018-05-31 21:34:22.037502
NCT01549236|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-08-27|2012-03-06|2012-03-09|Estimate|||||||2012-08-27|2012-08-29|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|August 2012|Actual|2012-08-31||Interventional|Pop PK Chagas||Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease|Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|Drugs for Neglected Diseases|||||f||||f||||||||||2018-05-31 21:34:25.735967|2018-05-31 21:34:25.735967
NCT01549600|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-10-27|2012-03-08|2012-03-09|Estimate|||||||2014-10-27|2014-10-28|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose|A Randomized, Controlled Study To Compare the Effects of 2 Types of Dietary Fiber, Psyllium and Microcrystalline Cellulose, on Glycemic Measures in Subjects With Pre-type 2 Diabetes|Completed||N/A|18|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 21:34:22.261971|2018-05-31 21:34:22.261971
NCT01549587|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-06-18|2012-03-06|2012-03-09|Estimate|||||||2015-06-18|2015-06-19|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|OHMOM||Oral Hygiene and Maternity Outcomes Multicenter Study (OHMOM)|A Randomized Controlled Clinical Trial to Evaluate Late First to Mid-Second Trimester Introduction of Advanced Daily Oral Hygiene on Gingivitis and Maternity Outcomes|Completed||N/A|746|Actual|Procter and Gamble||2|||f||||t||||||||||2018-05-31 21:34:22.327273|2018-05-31 21:34:22.327273
NCT01549574|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-25|||2012-06-01|2012-03-08|2012-03-09|Estimate|||||||2012-06-01|2012-06-05|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Drug Drug Interaction Study Of Crizotinib With Esomeprazole.|A Phase 1, Open Label, Single Dose, Randomized, Cross-Over Study To Estimate The Effect Of Esomeprazole On The Pharmacokinetics Of Crizotinib In Healthy Volunteers|Completed||Phase 1|16|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:34:22.49142|2018-05-31 21:34:22.49142
NCT01549561|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-04-07|2012-03-08|2012-03-09|Estimate|||||||2014-04-07|2014-04-08|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|KEEP2||Preventing Behavior and Health Problems in Foster Teens|Preventing Behavior and Health Problems in Foster Teens|Completed||N/A|259|Actual|Oregon Social Learning Center||3|||f||||f||||||||||2018-05-31 21:34:22.601237|2018-05-31 21:34:22.601237
NCT01549548|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-03-13|2012-03-08|2012-03-09|Estimate|||||||2013-03-13|2013-03-15|Estimate||||March 2013|2013-03-31||||||||Expanded Access|||Compassionate Use Ponatinib|Treatment Plan for the Compassionate Use of Ponatinib (AP24534) in Patients With Imatinib-, Dasatinib-, and Nilotinib- Resistant/Intolerant Philadelphia Chromosome Positive Leukemias.|No longer available|||||OHSU Knight Cancer Institute|||||||||||||||||||2018-05-31 21:34:22.685232|2018-05-31 21:34:22.685232
NCT01549535|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-11-22|2012-03-08|2012-03-09|Estimate|||||||2016-11-22|2016-11-25|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Polyp Detection With The Peerscope System™|Polyp Detection With The Peerscope System™: A Randomized Tandem Colonoscopy Study|Completed||Phase 2|197|Actual|PeerMedical Ltd.||2|||f||||||||||||||2018-05-31 21:34:22.744041|2018-05-31 21:34:22.744041
NCT01549522|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||April 2012|Anticipated|2012-04-30||Observational|||Qualitative Research for Stage 4 Liver Cancer Patients and Their Caregivers|Phase 1 0 Qualitative Research for Stage 4 Liver Cancer Patients and Their Caregivers.|Unknown status|Recruiting||30|Anticipated|Find A Cure Panel|||||f||||f||||||||||2018-05-31 21:34:22.824957|2018-05-31 21:34:22.824957
NCT01549509|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2014-10-15|2012-03-06|2012-03-09|Estimate|||||||2014-10-15|2014-10-17|Estimate|April 2007||2007-04-30|October 2014|2014-10-31|October 2009|Actual|2009-10-31|April 2008|Actual|2008-04-30||Interventional|||Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP Administered Alone or Administered as a Boost to a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda|Completed||Phase 1|18|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 21:34:22.904295|2018-05-31 21:34:22.904295
NCT01549496|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-01-07|2012-03-08|2012-03-09|Estimate|||||||2015-01-07|2015-01-09|Estimate|May 2012||2012-05-31|January 2015|2015-01-31||||September 2012|Anticipated|2012-09-30||Interventional|||A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers|A Drug Interaction Study Investigating the Effect of Boceprevir on the Pharmacokinetics of the Calcium Channel Blockers Amlodipine and Diltiazem and Vice Versa in Healthy Volunteers|Withdrawn||Phase 1|0|Actual|Ottawa Hospital Research Institute||1||Investigator left this hospital|f||||f||||||||||2018-05-31 21:34:22.987432|2018-05-31 21:34:22.987432
NCT01549483|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-01-15|2012-03-08|2012-03-09|Estimate|||||||2015-01-15|2015-01-16|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|ABHR||Small Airways Disease in Asymptomatic and Symptomatic Subjects With Airway Hyperresponsiveness (AHR)|Differences in Small Airways Disease Between Asymptomatic and Symptomatic Subjects With Airway Hyperresponsiveness|Completed|||45|Anticipated|University Medical Center Groningen|||3||f||||f||||||Samples With DNA|"~     Nasal epithelium brushes for mRNA expression~   "|||2018-05-31 21:34:23.086799|2018-05-31 21:34:23.086799
NCT01549470|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-12|2012-03-06|2012-03-09|Estimate|||||||2012-03-12|2012-03-13|Estimate||||March 2012|2012-03-31|March 2006|Actual|2006-03-31|||||Interventional|||Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, in Uninfected Adult Volunteers in Uganda|Completed||Phase 1|31|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 21:34:23.165857|2018-05-31 21:34:23.165857
NCT01549457|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-10-07|2012-03-08|2012-03-09|Estimate|||||||2015-10-07|2015-10-12|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment|The Effect of Weekly Text-message Communication on Treatment Completion Among Patients With Latent Tuberculosis Infection: a Randomised Controlled Trial (WelTel LTBI)|Unknown status|Active, not recruiting|Early Phase 1|350|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 21:34:23.25726|2018-05-31 21:34:23.25726
NCT01549444|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-10-21|2012-03-08|2012-03-09|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Observational|||Renin and Aldosterone Levels in the Preterm Neonate At Risk for Hypertension|Renin and Aldosterone Levels in the Preterm Neonate At Risk for Hypertension (RENAL HIT Study)|Completed|||76|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||Samples Without DNA|"~     Serum samples for Renin and Alsosterone, to be discarded when study is complete.~   "|||2018-05-31 21:34:23.338209|2018-05-31 21:34:23.338209
NCT01549431|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-12-20|2012-03-08|2012-03-09|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2012||2012-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|February 2016|Actual|2016-02-29||Interventional|||Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma|A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|22|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:34:23.414112|2018-05-31 21:34:23.414112
NCT01549418|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|September 2012||2012-09-30|March 2012|2012-03-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|ASAPOL||The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin|The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 4|760|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 21:34:23.492737|2018-05-31 21:34:23.492737
NCT01549405|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|2013-02-21||2013-04-01|2012-03-08|2012-03-09|Estimate|2013-04-01|2013-04-02|Estimate||||2013-04-01|2013-04-02|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Ultrasound-Guided Intercostal Nerve Block for Postoperative Pain Relief in Percutaneous Nephrolitotomy||Completed||N/A|40|Actual|Diskapi Teaching and Research Hospital||2|||f||||t||||||||||2018-05-31 21:34:23.578757|2018-05-31 21:34:23.578757
NCT01549392|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2014-04-02||2014-09-11|2012-03-06|2012-03-09|Estimate|2014-09-11|2014-09-15|Estimate||||2014-09-11|2014-09-15|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||patients with recurrent glioblastoma|Imaging Study of Glioblastomas Treated With Avastin|Feasibility Study of Magnetic Resonance Spectroscopy and Dynamic Enhanced Cat Scan Imaging in Glioblastomas Treated With and Without Avastin|Terminated||N/A|3|Actual|London Health Sciences Centre||2||insufficient accrual|f||||f||||||||||2018-05-31 21:34:23.829698|2018-05-31 21:34:23.829698
NCT01549379|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-10-14|2012-03-06|2012-03-09|Estimate|||||||2014-10-14|2014-10-15|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Dynamic Contrast Enhanced Computed Tomography (CT) for Head and Neck Cancer|Dynamic Contrast Enhanced Computed Tomography (DCE-CT) to Assess Lymph Node Metastases in Head and Neck Cancer: A Prospective Study|Terminated||N/A|1|Actual|Lawson Health Research Institute||2||Poor Accrual|f||||f||||||||||2018-05-31 21:34:24.002497|2018-05-31 21:34:24.002497
NCT01549366|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-03-05|2012-03-06|2012-03-09|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2012||2012-02-29|March 2018|2018-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparison of the Aspen Device Versus Pedicle Screws for Supplemental Posterior Fixation in Lumbar Interbody Fusion|A Multi-Center Prospective Randomized Study Comparing Supplemental Posterior Instrumentation, Aspen™ Spinous Process System Versus Pedicle Screw Fixation, in Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)|Completed||N/A|64|Actual|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-05-31 21:34:24.067635|2018-05-31 21:34:24.067635
NCT01549353|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-12-01|2012-03-06|2012-03-09|Estimate|||||||2012-12-01|2012-12-04|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Gum Chewing After Gynecologic Laparoscopy|Does Gum Chewing After Gynecologic Laparoscopy Stimulate Earlier Return of Bowel Motility?|Completed||N/A|200|Anticipated|Klinikum Klagenfurt am Wörthersee||1|||f||||f||||||||||2018-05-31 21:34:24.633913|2018-05-31 21:34:24.633913
NCT01549340|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2014-01-23||2017-01-18|2012-03-06|2012-03-09|Estimate|2014-01-23|2014-03-06|Estimate||||2017-01-18|2017-03-03|Actual|November 2011||2011-11-30|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)|Evaluation of Patient Initiation and Persistence With Advised Allergen Immunotherapy|Completed|||8790|Actual|ALK-Abelló A/S|||1||f||||f||||||||||2018-05-31 21:34:24.69617|2018-05-31 21:34:24.69617
NCT01549327|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-03-22|2012-03-06|2012-03-09|Estimate|||||||2016-03-22|2016-03-23|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of a Virtual Navigator on Colorectal Cancer Patient Empowerment|A Web-Based Person-Centred Navigation Tool for Newly Diagnosed Colorectal Cancer Patients: A Randomized Clinical Trial (RCT) to Assess Effects on Empowerment and Cost-Effectiveness (The TEN-C Study: Together to Enhance Navigation in Cancer)|Completed||N/A|129|Actual|McGill University||2|||f||||f||||||||No||2018-05-31 21:34:24.871705|2018-05-31 21:34:24.871705
NCT01549314|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2018-03-21|2012-03-06|2012-03-09|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2012||2012-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Cystic Fibrosis Related Bone Disease: the Role of CFTR|Cystic Fibrosis Related Bone Disease: the Role of CFTR|Active, not recruiting|||80|Actual|Massachusetts General Hospital|||3||f||||f||||||Samples Without DNA|"~     Plasma and urine~   "|||2018-05-31 21:34:24.955364|2018-05-31 21:34:24.955364
NCT01549301|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-06|2012-03-06|2012-03-09|Estimate|||||||2012-03-06|2012-03-09|Estimate|August 2012||2012-08-31|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Indústria e Comércio Ltda. Compared to Granulokine Produced by Produtos Roche Químicos e Farmacêuticos S/A.||Unknown status|Not yet recruiting|Phase 1|128|Anticipated|Azidus Brasil||4|||f||||||||||||||2018-05-31 21:34:25.074833|2018-05-31 21:34:25.074833
NCT01549288|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-04-07|2012-03-08|2012-03-09|Estimate|||||||2013-04-07|2013-04-09|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy|Evaluation of the Modified Atkins Diet in Children With Infantile Spasms Refractory to Hormonal Therapy: a Randomized Controlled Trial|Withdrawn||Phase 2/Phase 3|0|Actual|Lady Hardinge Medical College||2|||f||||||||||||||2018-05-31 21:34:25.210341|2018-05-31 21:34:25.210341
NCT01549275|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2013-07-15||2015-09-07|2012-03-06|2012-03-09|Estimate|2015-09-07|2015-10-08|Estimate||||2015-09-07|2015-10-08|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Observational|||Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration|Kaohsiung Medical University Hospital|Completed|||105|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||t||||||Samples With DNA|"~     cancer cells and cancer-associated fibroblasts~   "|||2018-05-31 21:34:25.318983|2018-05-31 21:34:25.318983
NCT01549262|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-08-04|2012-03-06|2012-03-09|Estimate|||||||2014-08-04|2014-08-05|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Clinical Validation of Embryo Cinematography|Clinical Validation of Embryo Culture and Selection by Morphokinetic Analysis; a Randomized Controlled Trial by Time-lapse System|Completed||N/A|843|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 21:34:25.599761|2018-05-31 21:34:25.599761
NCT01549249|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-11-12|2012-03-08|2012-03-09|Estimate|||||||2012-11-12|2012-11-14|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery|Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery|Completed||N/A|333|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 21:34:25.662133|2018-05-31 21:34:25.662133
NCT01549223|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|2017-02-24||2017-06-27|2012-03-08|2012-03-09|Estimate|2017-06-27|2017-06-29|Actual||||2017-06-27|2017-06-29|Actual|April 2011||2011-04-30|June 2017|2017-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Oxytocin And Uterotonic Agent Use For Cesarean Delivery|A Randomized Controlled Trial of Standardized Versus Conventional Oxytocin and Uterotonic Agent Use for Cesarean Delivery|Completed||Phase 4|60|Actual|Brigham and Women's Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 21:34:25.813663|2018-05-31 21:34:25.813663
NCT01549210|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-03-09|2012-03-08|2012-03-09|Estimate|||||||2013-03-09|2013-03-12|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|KING||Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of Life|Multicentre Prospective Observational Study for Identification of Determinants of Disability and Quality of Life in Patients With Gout.|Completed|||450|Actual|Italian Society for Rheumatology|||||f||||t||||||||||2018-05-31 21:34:27.073132|2018-05-31 21:34:27.073132
NCT01549197|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-11-19|2012-03-08|2012-03-09|Estimate|||||||2012-11-19|2012-11-20|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|CAESAR||Quality of Dying in the Intensive Care Unit: Validation of the CAESAR Scale|End-of-life in French Intensive Care Units: Perception of the Quality of Dying and Experience of Physicians, Nurses and Relatives. Validation of the CAESAR Scale|Completed|||475|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:34:27.168635|2018-05-31 21:34:27.168635
NCT01549184|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-20|2012-03-08|2012-03-09|Estimate|||||||2012-03-20|2012-03-21|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|HCQITP||Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia|Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia Among 40 Patients|Completed|||40|Actual|Henri Mondor University Hospital|||||f||||f||||||||||2018-05-31 21:34:27.372762|2018-05-31 21:34:27.372762
NCT01549171|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|November 2011|Actual|2011-11-30||Observational|||Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)|Pilot Study to Examine Iloprost Can Enhance Human Assisted Reproductive Technology Pregnancy Outcomes.|Unknown status|Recruiting||100|Anticipated|Fertility Specialists of Houston|||2||f||||f||||||||||2018-05-31 21:34:27.482614|2018-05-31 21:34:27.482614
NCT01549158|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-04-24|2012-03-08|2012-03-09|Estimate|||||||2013-04-24|2013-04-25|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure|Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure (CHF).|Terminated||Phase 4|8|Actual|Ferrer Internacional S.A.||3||Slow recruitment|f||||f||||||||||2018-05-31 21:34:27.629989|2018-05-31 21:34:27.629989
NCT01549145|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-08-28|2012-03-08|2012-03-09|Estimate|||||||2012-08-28|2012-08-29|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Sub-chronic Neurostimulation Delivered in the Middle Ear for Tinnitus Suppression||Completed||N/A|14|Actual|EstimME Ltd.||1|||f||||f||||||||||2018-05-31 21:34:27.841138|2018-05-31 21:34:27.841138
NCT01549132|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-08|2012-03-08|2012-03-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Observational|||Retinal Oximtery Following Treatment for Diabetic Maculopathy|Non-invasive Retinal Oximetry Using Oxymap in Patients With Diabetic Maculopathy Receiving Laser/Intravitreal Anti-VEGF Therapy|Unknown status|Not yet recruiting||45|Anticipated|East Kent Hospitals University NHS Foundation Trust|||||f||||f||||||||||2018-05-31 21:34:27.95581|2018-05-31 21:34:27.95581
NCT01549119|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2015-01-30|2012-03-06|2012-03-08|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|December 2014|Actual|2014-12-31|February 2013|Actual|2013-02-28||Interventional|||Phase I/IIa Dose-escalation Clinical Study of VAC-3S|Multicentre, Randomized, Placebo-controlled, Double-blind, Phase I/IIa Dose-escalation Clinical Study of a Therapeutic Vaccine (VAC-3S) Intended to Confer Protection Against Immunopathological Effects of HIV-1 in Infected Patients|Completed||Phase 1/Phase 2|33|Actual|InnaVirVax||5|||f||||t||||||||||2018-05-31 21:34:28.047856|2018-05-31 21:34:28.047856
NCT01549106|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-07-31|2012-03-06|2012-03-08|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2011||2011-08-31|July 2017|2017-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food and Ketoconazole on the Pharmacokinetics of IPI-145 When Administered to Healthy Adult Subjects|Completed||Phase 1|106|Actual|Verastem, Inc.||2|||f||||f||||||||||2018-05-31 21:34:28.159936|2018-05-31 21:34:28.159936
NCT01549093|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-03-22|2012-03-06|2012-03-08|Estimate|||||||2015-03-22|2015-03-24|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)|A Randomized, Open Label, Controlled Study About Endostar Continued Pumping or Injecting Into Vein Combining With Gemcitabine-Carboplatin Versus Gemcitabine-Carboplatin Alone to Treat Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 2|90|Anticipated|Hunan Province Tumor Hospital||3|||f||||t||||||||||2018-05-31 21:34:28.257929|2018-05-31 21:34:28.257929
NCT01549080|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Observational|thalessemia||Study of Effects of YisuiShengxueGranules on Thalassemia|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study of the Safety and Effects of YisuiShengxueGranules on Thalassemia Presenting the Syndrome of Deficiency of Liver/Kidney-yin, and Asthenia of Essence/Blood.|Completed|||2|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|||2||f||||t||||||Samples With DNA|"~     Peripheral blood and bone marrow cells~   "|||2018-05-31 21:34:28.477049|2018-05-31 21:34:28.477049
NCT01549067|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-13|2012-03-06|2012-03-08|Estimate|||||||2012-03-13|2012-03-14|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|Sprit||The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey|The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey|Unknown status|Recruiting||3700|Anticipated|Chinese Medical Doctor Association|||||f||||t||||||||||2018-05-31 21:34:28.679863|2018-05-31 21:34:28.679863
NCT01549054|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-10-31|2012-03-06|2012-03-08|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501|A Single-center, Randomized, Open-label, Two-part Study to Evaluate Bioavailability of Prototype Third-generation Formulations of E5501 Relative to Second-generation Tablet Formulation in Healthy Subjects|Completed||Phase 1|28|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 21:34:29.001785|2018-05-31 21:34:29.001785
NCT01549041|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2014-01-24||2014-04-23|2012-03-06|2012-03-08|Estimate|2014-04-23|2014-05-26|Estimate||||2014-04-23|2014-05-26|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|||Once-Daily Asenapine for Schizophrenia|A Randomized Comparison of Twice-Daily Versus Once-Daily Asenapine for Schizophrenia|Completed||Phase 4|30|Actual|Duke University|Small sample size Open label design|2|||f||||f||||||||||2018-05-31 21:34:29.150014|2018-05-31 21:34:29.150014
NCT01549028|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Osteoporosis in Chronic Obstructive Pulmonary Disease (COPD)|The Prevalence, Correlations and Effectiveness of Intervention of Osteoporosis in COPD Patients|Unknown status|Recruiting|N/A|60|Anticipated|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 21:34:29.518352|2018-05-31 21:34:29.518352
NCT01549015|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-06-25|2012-03-06|2012-03-08|Estimate|||||||2013-06-25|2013-06-26|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|||Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD) and Carriers of UCD Mutations to Evaluate Urea Cycle Function|Open, Prospective, Diagnostic, Multicentre Study in Healthy Subjects, Patients With Urea Cycle Disorders (UCD), and Carriers of UCD Mutations, to Evaluate in Vivo Ureagenesis Measured After a Single Application of Sodium [1,2-13C]-Acetate|Completed||N/A|37|Actual|Cytonet GmbH & Co. KG|||||f||||f||||||||||2018-05-31 21:34:29.587401|2018-05-31 21:34:29.587401
NCT01549002|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2015-02-02||2015-08-20|2012-03-06|2012-03-08|Estimate|2015-07-27|2015-08-21|Estimate||||2015-08-20|2015-08-28|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children|Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children|Completed||Phase 3|20|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 21:34:29.657559|2018-05-31 21:34:29.657559
NCT01548989|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2015-03-25|2012-03-06|2012-03-08|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Validation of a New Sexuality Questionnaire for Patients With Urinary Incontinence or Pelvic Organ Prolapse|Validation of a New Sexuality Questionnaire: a Tool for Evaluating the Sexuality of Patients With Urinary Incontinence or Pelvic Organ Prolapse|Completed|||25|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 21:34:30.041529|2018-05-31 21:34:30.041529
NCT01548976|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-03-25|2012-03-06|2012-03-08|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Validation of a French Version of the PISQ-R|Validation of a French Version of the PISQ-R: a Tool for Evaluating the Sexuality of Patients With Urinary Incontinence or Pelvic Organ Prolapse|Completed|||25|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 21:34:30.111288|2018-05-31 21:34:30.111288
NCT01548963|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-25|||2015-05-15|2012-03-06|2012-03-08|Estimate|||||||2015-05-15|2015-05-18|Estimate|January 2007||2007-01-31|May 2015|2015-05-31|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|||Perioperative Versus Postoperative Glycemia Control in Cardiac Surgery Patients|Perioperative Versus Postoperative Glycemia Control in Cardiac Surgery Patients|Completed||N/A|2384|Actual|Charles University, Czech Republic||2|||f||||f||||||||||2018-05-31 21:34:30.21109|2018-05-31 21:34:30.21109
NCT01548950|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-06-17|2012-03-05|2012-03-08|Estimate|||||||2015-06-17|2015-06-18|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|January 2014|Actual|2014-01-31||Interventional|||Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension|Combined Clinical and Surgical Approaches to Congenital Heart Disease Associated With Pulmonary Arterial Hypertension (PAH-CHD)|Unknown status|Recruiting|N/A|50|Anticipated|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-05-31 21:34:30.329298|2018-05-31 21:34:30.329298
NCT01548937|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2016-01-27|2012-03-06|2012-03-08|Estimate|||||||2016-01-27|2016-01-28|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Serotonin Transporter Density in Late-life Depression With and Without Dementia|Serotonin Transporter Density in Late-life Depression With and Without Dementia|Completed||Phase 2|39|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 21:34:30.455587|2018-05-31 21:34:30.455587
NCT01548924|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2014-01-07|2012-03-06|2012-03-08|Estimate|||||||2014-01-07|2014-01-08|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors|Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus Priming With BIBF 1120 BIBF 1120 Followed by Plus Paclitaxel in Breast Cancer With HER-2 Negative Correlative Proteomic Studies. and Dynamic Image|Terminated||Phase 1|24|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III||2||Drug toxicity|f||||t||||||||||2018-05-31 21:34:30.535795|2018-05-31 21:34:30.535795
NCT01548911|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-07-28|2012-03-06|2012-03-08|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2012||2012-05-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia|Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)|Withdrawn||Phase 2|0|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 21:34:30.670546|2018-05-31 21:34:30.670546
NCT01548898|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-03-06|2012-03-06|2012-03-08|Estimate|||||||2012-03-06|2012-03-08|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Efficacy of Laser Assisted Hair Removal in the Treatment of Acne Keloidalis Nuchae; a Pilot Study||Completed||Phase 4|16|Actual|Cairo University|||||f||||t||||||||||2018-05-31 21:34:30.796764|2018-05-31 21:34:30.796764
NCT01548885|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2013-03-27||2016-01-29|2012-03-06|2012-03-08|Estimate|2013-07-03|2013-08-06|Estimate||||2016-01-29|2016-02-29|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Per protocol|Comparison Evaluation of Blood Glucose Meter Systems|Evaluation of Blood Glucose Meter Systems - NACT Study|Completed||N/A|146|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 21:34:30.876235|2018-05-31 21:34:30.876235
NCT01548872|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-06|2012-03-06|2012-03-08|Estimate|||||||2012-03-06|2012-03-08|Estimate|December 2011||2011-12-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Comparison of the Effects of Crystalloid Cardioplegia and HTK Solution for Postoperative Troponin-I and CK-MB Levels After Pediatric Cardiac Surgery||Unknown status|Recruiting|Phase 4|60|Anticipated|Baskent University||2|||f||||t||||||||||2018-05-31 21:34:31.11923|2018-05-31 21:34:31.11923
NCT01548859|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2012-03-06|2012-03-06|2012-03-08|Estimate|||||||2012-03-06|2012-03-08|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Comparison of the Effects of Sevoflurane and Midazolam Used for the Maintenance of Anaesthesia on the Levels of Postoperative Cardiac Troponin I in Pediatric Cardiac Surgery||Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Baskent University||2|||f||||t||||||||||2018-05-31 21:34:31.264689|2018-05-31 21:34:31.264689
NCT01548846|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-03-12|2012-03-06|2012-03-08|Estimate|||||||2015-03-12|2015-03-13|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TOQUAL||Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract|Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract|Terminated||Phase 2|11|Actual|Centre Francois Baclesse||||lack of recrutment|f||||f||||||||||2018-05-31 21:34:31.341286|2018-05-31 21:34:31.341286
NCT01548833|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2013-04-22||2013-06-06|2012-03-07|2012-03-08|Estimate|2013-06-06|2013-06-24|Estimate||||2013-06-06|2013-06-24|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||All enrolled participants|Pre-Lens Tear Film Performance of Silicone Hydrogel Daily Disposable Contact Lenses|Randomized Cross-Over Evaluation of Silicone Hydrogel Daily Disposable Soft Contact Lenses|Completed||N/A|39|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 21:34:31.45963|2018-05-31 21:34:31.45963
NCT01548820|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2013-09-08|2012-03-06|2012-03-08|Estimate|||||||2013-09-08|2013-09-10|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|||Resistance to Lamivudine in HBV Egyptian Patients|Pretreatment and On-treatment Indicators of Virologic Breakthrough in Chronic HBV Egyptian Patients Receiving Lamivudine Therapy|Completed|||230|Actual|Ain Shams University|||1||f||||t||||||Samples With DNA|"~     blood samples +/- tissue biopsy~   "|||2018-05-31 21:34:31.639975|2018-05-31 21:34:31.639975
NCT01548807|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-09-23|2012-03-06|2012-03-08|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2010||2010-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy|Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy|Recruiting||Phase 1|33|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:34:31.70396|2018-05-31 21:34:31.70396
NCT01548794|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-04-21|2012-03-07|2012-03-08|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Recovery of Bupivacaine or Bupivacaine-Lidocaine Spinal Anesthesia and Infiltration Anesthesia in Herniorrhaphy|A Comparison of the Recovery Profiles of Bupivacaine or Bupivacaine Mixed With Lidocaine Spinal Anesthesia and Local Infiltration Anesthesia for Outpatient Herniorrhaphy|Completed||Phase 4|93|Actual|Diskapi Teaching and Research Hospital||3|||f||||f||||||||||2018-05-31 21:34:31.769477|2018-05-31 21:34:31.769477
NCT01548781|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2015-10-05|2012-03-05|2012-03-08|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Resistance to Participant-Supported Reaching on Workspace of the Hand in Severe Chronic Stroke|The Effect of Resistance to Participant-Supported Reaching on Workspace of the Hand in Severe Chronic Stroke|Completed||N/A|38|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:34:31.97893|2018-05-31 21:34:31.97893
NCT01548768|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-03-13|2012-03-07|2012-03-08|Estimate|||||||2017-03-13|2017-03-15|Actual|October 10, 2011|Actual|2011-10-10|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|RHYTHM||RHYTHM (Formerly Escape II Myocardium)|RHYTHM (RHeumatoid Arthritis studY of THe Myocardium): How Rheumatoid Arthritis (RA) and Tumor Necrosis Factor (TNF) Inhibitors Affect the Myocardial Structure and Function.|Recruiting||Phase 4|175|Anticipated|Columbia University||3|||f||||t|t|f||||||No||2018-05-31 21:34:32.058877|2018-05-31 21:34:32.058877
NCT01548755|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-12|2012-03-07|2012-03-08|Estimate|||||||2012-03-12|2012-03-13|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|January 2015|Anticipated|2015-01-31|||||Observational|||The Western Galilee Hospital in Nahariya Home Monitoring Registry|Workload Assessment of a Home Monitoring Based Follow up for Biotronik ICD and CRTD Patients.|Unknown status|Not yet recruiting||20|Anticipated|Western Galilee Hospital-Nahariya|||||f||||t||||||||||2018-05-31 21:34:32.254328|2018-05-31 21:34:32.254328
NCT01548742|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2015-09-29||2015-11-04|2012-03-05|2012-03-08|Estimate|2015-11-04|2015-12-10|Estimate||||2015-11-04|2015-12-10|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|VMP||Meditation Interventions for Treatment of PTSD in Veterans|Meditation Interventions for Treatment of PTSD in Veterans|Completed||N/A|116|Actual|VA Office of Research and Development|Initial analyses did not account for clustering effects. However, when we re-analyzed data using a multilevel model including a random effect for therapy group, we found that the results were essentially unchanged.|2|||f||||t||||||||||2018-05-31 21:34:32.364117|2018-05-31 21:34:32.364117
NCT01548729|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-03-16|2012-03-05|2012-03-08|Estimate|||||||2016-03-16|2016-03-17|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PIM||Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis|Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis : a Pilot Study|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|University Hospital, Strasbourg, France||1|||f||||t||||||||||2018-05-31 21:34:32.97119|2018-05-31 21:34:32.97119
NCT01548716|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Observational|||A Study of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients|A Cross-sectional Analysis of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients|Completed|||50|Actual|Winthrop University Hospital|||||f||||f||||||||||2018-05-31 21:34:33.13753|2018-05-31 21:34:33.13753
NCT01548352|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2018-04-04|2012-03-07|2012-03-08|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2010||2010-04-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||BAsel Syncope EvaLuation (BASEL IX) Study|BAsel Syncope EvaLuation (BASEL IX) Study|Recruiting|||720|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     EDTA Plasma; Heparin; Serum~   "|||2018-05-31 21:34:36.986844|2018-05-31 21:34:36.986844
NCT01548703|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-05-07|2012-03-06|2012-03-08|Estimate|||||||2012-05-07|2012-05-09|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of BCI 838 in Healthy Adult Subjects|Completed||Phase 1|30|Actual|BrainCells Inc.||3|||f||||f||||||||||2018-05-31 21:34:33.208383|2018-05-31 21:34:33.208383
NCT01548690|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2018-01-10|2012-03-07|2012-03-08|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2012||2012-06-30|January 2018|2018-01-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|STOP-ALF||Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure|A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure|Completed||Phase 2|47|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||Yes|De-identified data for the overall study will be shared once the study is completed.|2018-05-31 21:34:33.320188|2018-05-31 21:34:33.320188
NCT01548677|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2018-01-24|2012-03-05|2012-03-08|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2013||2013-04-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TREAT-CTC||Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer|"TRastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (TREAT CTC Trial)"|Completed||Phase 2|1317|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 21:34:33.48579|2018-05-31 21:34:33.48579
NCT01548664|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2014-02-25|2012-03-07|2012-03-08|Estimate|||||||2014-02-25|2014-02-27|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Utilization of Nintendo Wii™ in Outpatient Rehabilitation Following Total Knee Replacement|The Utilization of Nintendo Wii™ in Outpatient Rehabilitation Following Total Knee Replacement|Completed||Phase 2|50|Actual|St. John's Rehab Hospital||2|||f||||f||||||||||2018-05-31 21:34:33.677211|2018-05-31 21:34:33.677211
NCT01548651|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2018-01-16|2012-03-06|2012-03-08|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2012||2012-02-29|January 2018|2018-01-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation|Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients With Impaired Glucose Tolerance|Terminated||Phase 4|14|Actual|Baylor College of Medicine||2||difficulty with enrollment of subjects|f||||f||||||||||2018-05-31 21:34:33.765135|2018-05-31 21:34:33.765135
NCT01548638|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2013-10-30||2017-11-27|2012-03-07|2012-03-08|Estimate|2014-07-01|2014-07-02|Estimate||||2017-11-27|2017-12-26|Actual|February 2012||2012-02-29|November 2017|2017-11-30|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Galantamine on Smoking Abstinence|The Effect of the Acetylcholinesterase Inhibitor, Galantamine, on Short-term Abstinence|Completed||Phase 2|13|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 21:34:33.846087|2018-05-31 21:34:33.846087
NCT01548625|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|July 2007||2007-07-31|March 2012|2012-03-31||||November 2008|Actual|2008-11-30||Observational|||Cardiovascular Effects of Incremental Diesel Exhaust Inhalation in Middle-Aged Healthy GSTM1 Null Human Volunteers||Completed|||6|Actual|Environmental Protection Agency (EPA)|||1||f||||f||||||||||2018-05-31 21:34:34.072543|2018-05-31 21:34:34.072543
NCT01548612|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|December 2010|Actual|2010-12-31|June 2009|Actual|2009-06-30||Interventional|||Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia|Randomised Double Blind Placebo Controlled Study of Sodium Nitroprusside Added to Treatment as Usual in Patients With Schizophrenia|Completed||Phase 2|20|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:34:34.122289|2018-05-31 21:34:34.122289
NCT01548599|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2014-08-19|2012-03-07|2012-03-08|Estimate|||||||2014-08-19|2014-08-20|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Shamba||Shamba Maisha: Pilot Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya|Shamba Maisha: Pilot Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya|Completed||N/A|140|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:34:34.181224|2018-05-31 21:34:34.181224
NCT01548586|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-10-05|2012-03-05|2012-03-08|Estimate|||||||2012-10-05|2012-10-08|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Effect of Transcranial Direct Current Stimulation (tDCS) on the Excitability of the Diaphragmatic Primary Motor Cortex|Modulation de l'excitabilité Des Aires Corticales Motrices Primaires Correspondant Aux hémi Diaphragmes à l'Aide de la tDCS (Transcranial Direct Current Stimulation)|Completed||Phase 1|12|Actual|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||||2018-05-31 21:34:34.328636|2018-05-31 21:34:34.328636
NCT01548573|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|2017-04-04||2017-05-19|2012-03-07|2012-03-08|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment|Tandem Autotransplantation for Multiple Myeloma in Participants With Less Than 12 Months of Preceding Therapy, Incorporating Velcade (Bortezomib) With the Transplant Chemotherapy and During Maintenance|Terminated||Phase 2|19|Actual|University of Iowa|Enrollment halted prematurely. Study met stopping rules. Outcomes will not be tracked and published|1||Met study stopping rules|f||||t|t|f|||f|||No||2018-05-31 21:34:34.425498|2018-05-31 21:34:34.425498
NCT01548560|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-09-05|2012-03-05|2012-03-08|Estimate|||||||2017-09-05|2017-09-08|Actual|August 2012||2012-08-31|September 2017|2017-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Assessing the Safety of Dapivirine Gel and Film Formulations||Completed||Phase 1|60|Actual|International Partnership for Microbicides, Inc.||4|||f||||||||||||||2018-05-31 21:34:34.929594|2018-05-31 21:34:34.929594
NCT01548547|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|POISE||Patient Outcomes in Simulation Education (POISE) Intravenous (IV) and Lumbar Puncture (LP) Multi-institution Protocol|Patient Outcomes in Simulation Education (POISE) Intravenous (IV) and Lumbar Puncture (LP) Multi-institution Protocol|Completed||N/A|210|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 21:34:35.023776|2018-05-31 21:34:35.023776
NCT01548534|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-07-28|2012-03-05|2012-03-08|Estimate|||||||2015-07-28|2015-07-29|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DHALYA||A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer|A Phase III Randomized, Multicenter, Two Arms Double-blind Trial Versus Placebo, Evaluating the Interest of a Dietary Supplementation With Docosahexaenoic Acid (DHA) During Chemotherapy for Metastatic Breast Cancer|Terminated||Phase 3|65|Actual|University Hospital, Tours||2||Judicial liquidation of the society providing dietary supplementation.|f||||f||||||||||2018-05-31 21:34:35.122974|2018-05-31 21:34:35.122974
NCT01548521|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2017-02-21|2012-03-07|2012-03-08|Estimate|||||||2017-02-21|2017-02-23|Actual|July 2011||2011-07-31|February 2017|2017-02-28|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|OTBB||Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies|Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies and Effect on Suck and Food Intake.|Completed||Phase 1/Phase 2|5|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 21:34:35.2325|2018-05-31 21:34:35.2325
NCT01548508|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-05-10|2012-03-05|2012-03-08|Estimate|||||||2017-05-10|2017-05-11|Actual|July 2008||2008-07-31|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|EMSICA||Evaluation of Functionnal ElectromyoStimulation on Leg In Advanced Chronic Heart Failure After Hospitalisation for Acute Decompensation|Evaluation of Functionnal ElectromyoStimulation on Leg In Advanced Chronic Heart Failure After Hospitalisation for Acute Decompensation|Completed||N/A|46|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 21:34:35.366575|2018-05-31 21:34:35.366575
NCT01548495|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-03-08|2012-03-07|2012-03-08|Estimate|||||||2012-03-08|2012-03-09|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|September 2013|Anticipated|2013-09-30|May 2013|Anticipated|2013-05-31||Observational|MDS||Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients|Investigating Recombinant Human Erythropoietin (rHuEPO) Treatment Efficacy Depending on the Presence of Erythropoietin Autoantibodies in Myelodysplatic Syndrome (MDS) Patients|Unknown status|Not yet recruiting||100|Anticipated|Meir Medical Center|||4||f||||f||||||||||2018-05-31 21:34:35.454896|2018-05-31 21:34:35.454896
NCT01548482|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2015-10-05|2012-03-05|2012-03-08|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors With an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor|Completed||Phase 1|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:34:35.557046|2018-05-31 21:34:35.557046
NCT01548469|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-02-05|2012-03-07|2012-03-08|Estimate|||||||2013-02-05|2013-02-06|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study to Evaluate Clinical Efficacy and Safety of Bio Mineral Toothpaste in Patients With Mild Periodontitis|Single Blind, Randomized, Active-controlled Comparative Clinical Trial to Evaluate Clinical Efficacy and Safety Following the Application for 4 Weeks of Bio Mineral Toothpaste in Patients With Mild Periodontitis|Completed||Phase 4|60|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 21:34:35.645144|2018-05-31 21:34:35.645144
NCT01548456|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-05-16|2012-03-05|2012-03-08|Estimate|||||||2015-05-16|2015-05-19|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Nails Versus Plates for Femur Fractures in Dar es Salaam, Tanzania|Intramedullary Nailing Versus Plates for Femoral Shaft Fractures in Dar es Salaam, Tanzania With Minimum 1-Year Follow-up|Completed|||332|Actual|University of California, San Francisco|||2||f||||f||||||||||2018-05-31 21:34:35.726157|2018-05-31 21:34:35.726157
NCT01548443|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-02-05|2012-03-05|2012-03-08|Estimate|||||||2013-02-05|2013-02-06|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Medifoam H||"Study to Evaluate Clinical Efficacy and Safety of Medifoam H in Wound Healing"|The Wound Healing Efficacy and Safety of Medifoam H in Patients With Minor, Acute Trauma: a Single-center, Randomized, Active-controlled, Open-label, Phase IV|Completed||Phase 4|66|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 21:34:35.832927|2018-05-31 21:34:35.832927
NCT01548430|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-02-11|2012-03-07|2012-03-08|Estimate|||||||2015-02-11|2015-02-12|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Safety Study of TTP4000 in Subjects With Alzheimer's Disease|A Double-blind, Randomized, Placebo-controlled, Phase 1 Study of 2 Escalating, Single Subcutaneous Doses to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of TTP4000 in Subjects With Alzheimer's Disease With Mild Cognitive Impairment|Completed||Phase 1|8|Actual|vTv Therapeutics||3|||f||||f||||||||||2018-05-31 21:34:36.097285|2018-05-31 21:34:36.097285
NCT01548417|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2016-02-02||2016-05-24|2012-03-05|2012-03-08|Estimate|2016-04-12|2016-05-19|Estimate||||2016-05-24|2016-06-24|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists|Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists|Completed||Phase 2|56|Actual|The Scripps Research Institute||2|||f||||f||||||||No||2018-05-31 21:34:36.178283|2018-05-31 21:34:36.178283
NCT01548404|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05||2015-08-27|2015-08-27|2012-03-07|2012-03-08|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Study of REGN668/SAR231893 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|109|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 21:34:36.587512|2018-05-31 21:34:36.587512
NCT01548391|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|March 2012||2012-03-31|March 2012|2012-03-31||||||||Interventional|||A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects||Unknown status|Not yet recruiting|Phase 1|66|Anticipated|Biotoxtech Co., Ltd||9|||f||||t||||||||||2018-05-31 21:34:36.710035|2018-05-31 21:34:36.710035
NCT01548378|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-03-23|2012-03-05|2012-03-08|Estimate|||||||2015-03-23|2015-03-25|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|NL003CLI-II||Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia|Completed||Phase 2|200|Actual|Beijing Northland Biotech. Co., Ltd.||4|||f||||t||||||||||2018-05-31 21:34:36.814193|2018-05-31 21:34:36.814193
NCT01548365|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-09-20|2012-03-07|2012-03-08|Estimate|||||||2013-09-20|2013-09-23|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|ETI||Impact of an Infusion Therapy Nursing Expert Service on Length of Stay and Clinical Results of Venous Access Devices|Impact of an Infusion Therapy Nursing Expert Service on Length of Stay, Clinical Results of Venous Access Devices and Satisfaction on Patients With Long Intravenous Therapy Prescription.|Completed||N/A|82|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 21:34:36.899883|2018-05-31 21:34:36.899883
NCT01548339|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-12-29|2012-03-05|2012-03-08|Estimate|||||||2015-12-29|2015-12-30|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||Laparoscopic Cholecystectomy for Acute Cholecystitis After 72 Hours of Symptoms|Laparoscopic Cholecystectomy for Acute Cholecystitis: is the Rule of 72 Hours Still Actual?|Terminated||N/A|86|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 21:34:37.17527|2018-05-31 21:34:37.17527
NCT01548326|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-06|2012-03-06|2012-03-08|Estimate|||||||2012-03-06|2012-03-08|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine|Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine|Unknown status|Enrolling by invitation|Phase 4|52|Anticipated|Baqiyatallah Medical Sciences University||2|||f||||t||||||||||2018-05-31 21:34:37.262314|2018-05-31 21:34:37.262314
NCT01548313|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-01-30|2012-03-05|2012-03-08|Estimate|||||||2015-01-30|2015-02-02|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|May 2015|Anticipated|2015-05-31|May 2013|Actual|2013-05-31||Observational|MYMILK||The Role of Human Milk in Development of Breast Fed Child's Intestinal Microbiota|The Role of Human Milk in Development of Breast Fed Child's Intestinal Microbiota|Unknown status|Active, not recruiting||300|Anticipated|University of Ljubljana|||3||f||||f||||||Samples With DNA|"~     colostrum, meconium, milk, child's faeces, urine, venous blood~   "|||2018-05-31 21:34:37.377473|2018-05-31 21:34:37.377473
NCT01548300|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2018-02-07|2012-03-07|2012-03-08|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2011||2011-02-28|February 2018|2018-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|AIRCMD||Environmental Triggers Of Cardiometabolic Disease|Environmental Triggers Of Cardiometabolic Disease|Completed|||66|Actual|University of Maryland|||1||f||||f||||||||||2018-05-31 21:34:37.486716|2018-05-31 21:34:37.486716
NCT01548287|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|2015-01-26||2016-12-14|2012-03-05|2012-03-08|Estimate|2016-10-12|2016-12-05|Estimate||||2016-12-14|2017-02-07|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment|A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled|Completed||Phase 2|164|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 21:34:37.624408|2018-05-31 21:34:37.624408
NCT01548274|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells|Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells|Unknown status|Recruiting|N/A|20|Anticipated|Aichi Gakuin University|||||f||||t||||||||||2018-05-31 21:34:38.490645|2018-05-31 21:34:38.490645
NCT01548261|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Donating Oral Mucosal Cells for the Study of ex Vivo Culture of Cells Sheets||Unknown status|Recruiting||1|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     Donating oral mucosal cells for the study of ex vivo culture of cells sheets.~   "|||2018-05-31 21:34:38.596006|2018-05-31 21:34:38.596006
NCT01548248|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2017-01-30|2012-03-05|2012-03-08|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2006||2006-01-31|January 2017|2017-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Efficacy and Safety of Levemir® Used as Basal Insulin|An Observational 3-months Study to Evaluate Efficacy and Safety of Insulin Levemir® Used as Basal Insulin on the Glycaemic Control, Weight and Incidence of Hypoglycaemic Events in Insulin Treated Subjects With Type 1 or Type 2 Diabetes|Completed|||631|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:34:38.679909|2018-05-31 21:34:38.679909
NCT01548235|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2017-01-05|2012-03-05|2012-03-08|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2006||2006-02-28|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment|A Multicentre, Open Label, Non-randomised, Non-interventional, Observational Safety Study in Subjects With Type 2 Diabetes Mellitus, Starting or Switching to NovoMix® 30 Treatment|Completed|||423|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:34:38.782804|2018-05-31 21:34:38.782804
NCT01548222|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-08-23|2012-03-05|2012-03-08|Estimate|||||||2013-08-23|2013-08-27|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target|CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose Target|Completed|||20|Actual|Diabetes Care Center|||||f||||f||||||||||2018-05-31 21:34:38.882877|2018-05-31 21:34:38.882877
NCT01548209|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-01-30|2012-03-07|2012-03-08|Estimate|||||||2015-01-30|2015-02-02|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery|Effects of a Single Dose Dexmedetomidine on Postoperative Nausea and Vomiting (PONV) and Quality of Recovery 40 (QoR 40) in Breast Cancer Surgery|Completed||N/A|97|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:34:38.959608|2018-05-31 21:34:38.959608
NCT01548196|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2015-03-12|2012-03-07|2012-03-08|Estimate|||||||2015-03-12|2015-03-17|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Standard Percutaneous Nephrolithotomy Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL|A Prospective, Randomized Controlled Pilot Study Of Standard Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL|Completed||Phase 3|60|Actual|Duke University||4|||f||||t||||||||||2018-05-31 21:34:39.043486|2018-05-31 21:34:39.043486
NCT01548183|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2015-05-26|2012-03-07|2012-03-08|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|StARSS||Text-message Program to Reduce Risky Sexual Behavior in Young Adult Female Emergency Department (ED) Patients|Mobile Phone Text-message Program to Reduce Risky Sexual Behavior in Young Females Discharged From the Emergency Department|Completed||Phase 2|52|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:34:39.134577|2018-05-31 21:34:39.134577
NCT01548170|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib|A Phase I, Pilot, Dose Finding Clinical Trial to Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib for National Health System|Completed||Phase 1|12|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||5|||f||||f||||||||||2018-05-31 21:34:39.234796|2018-05-31 21:34:39.234796
NCT01548157|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-06-03|2012-03-05|2012-03-08|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule|A Randomized, Open Label, Single Dose, 2X2 Cross-over Study to Compare Pharmacokinetics Between Rosuvastatin 10mg and Omega-3 1g Co-administration and HCP1007 in Healthy Male Volunteers|Completed||Phase 1|28|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||t||||||||||2018-05-31 21:34:39.313665|2018-05-31 21:34:39.313665
NCT01548144|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2017-11-27|2012-03-07|2012-03-08|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2012|Actual|2012-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer|A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|364|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 21:34:39.418149|2018-05-31 21:34:39.418149
NCT01548131|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-03-15|2012-03-07|2012-03-08|Estimate|||||||2012-03-15|2012-03-16|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|LINNEA||A Randomized Longitudinal Trial About Treatment for Severe Fear of Childbirth|A Randomized Longitudinal Trial About Treatment for Severe Fear of Childbirth|Completed||N/A|370|Actual|Helsinki University Central Hospital||2|||f||||t||||||||||2018-05-31 21:34:39.547246|2018-05-31 21:34:39.547246
NCT01548118|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females|A Blind, Randomized and Placebo-controlled Clinical Trial With Recombinant HumanPapillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Health Women-Phase I|Unknown status|Enrolling by invitation|Phase 1|160|Actual|Shanghai Zerun Biotechnology Co.,Ltd||8|||f||||f||||||||||2018-05-31 21:34:39.636987|2018-05-31 21:34:39.636987
NCT01548105|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2014-10-15|2012-03-07|2012-03-08|Estimate|||||||2014-10-15|2014-10-17|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||Systemic Markers of Collagen Metabolism and Vitamin C in Smokers and Non-Smokers With Pelvic Organ Prolapse|Systemic Markers of Collagen Metabolism and Vitamin C in Smokers and Non-Smokers With Pelvic Organ Prolapse|Completed|||96|Actual|TriHealth Inc.|||4||f||||f||||||||||2018-05-31 21:34:39.739335|2018-05-31 21:34:39.739335
NCT01548092|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|December 2011||2011-12-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|July 2012|Anticipated|2012-07-31||Interventional|HULPCIR||Stromal Vascular Fraction (SVF) for Treatment of Recto-vaginal Fistula|A Phase II Clinical Trial to Study the Feasibility and Safety of Stromal Vascular Derived From Adipose Tissue for the Treatment of Recto-vaginal Fistula|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 21:34:39.845769|2018-05-31 21:34:39.845769
NCT01548079|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-12-02|2012-03-05|2012-03-08|Estimate|||||||2013-12-02|2013-12-03|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Ursodeoxycholic Acid in Bariatric Surgery|Effects of Ursodeoxycholic Acid on Hepatobiliary Detoxification/Elimination Mechanisms and Hepatic Fatty Acid/Triglyceride Metabolism in Morbidly Obese Patients.|Completed||N/A|40|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 21:34:39.957138|2018-05-31 21:34:39.957138
NCT01548066|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-10-05|2012-03-07|2012-03-08|Estimate|||||||2012-10-05|2012-10-08|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss|The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss|Completed||Phase 2|40|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:34:40.045598|2018-05-31 21:34:40.045598
NCT01548053|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-04-13|2012-03-05|2012-03-08|Estimate|||||||2017-04-13|2017-04-14|Actual|March 2012||2012-03-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|PC-DATA||The Primary Care - Dementia Assessment and Treatment Algorithm|A Study Evaluating the Effects of a Primary Care - Dementia Assessment Treatment Algorithm on the Quality of Care Provided to Older Adults With Dementia in Primary Care Settings|Completed||N/A|55|Actual|Queen's University|||||f||||f||||||||||2018-05-31 21:34:41.088612|2018-05-31 21:34:41.088612
NCT01548040|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-12-05||2018-03-16|2012-03-07|2012-03-08|Estimate|2018-03-14|2018-03-19|Actual||||2018-03-16|2018-04-11|Actual|March 2012||2012-03-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Controlled Study of Kneehab XP for Patients Undergoing Total Knee Replacement|A Randomised Controlled Study To Compare the Effects of a Standard Therapy Protocol With a 12-week Peri-Operative Program of Kneehab XP Compared to a Control Treatment in Patients Undergoing Total Knee Replacement|Completed||N/A|111|Actual|Theragen Inc.||2|||f||||f||||||||||2018-05-31 21:34:41.168313|2018-05-31 21:34:41.168313
NCT01548027|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2014-07-30|2012-03-07|2012-03-08|Estimate|||||||2014-07-30|2014-07-31|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|TAP||Surgical Transversus Abdominis Plane Block in Pediatric Patients|Efficacy of Surgical Transversus Abdominis Plane Block for Postoperative Pain Relief Following Abdominal Surgery in Pediatric Patients.|Completed||N/A|54|Actual|Mahidol University||3|||f||||t||||||||||2018-05-31 21:34:41.454617|2018-05-31 21:34:41.454617
NCT01548014|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|January 2016|Anticipated|2016-01-31|September 2012|Anticipated|2012-09-30||Interventional|||The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease|Reduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot Study|Unknown status|Recruiting|Phase 3|1|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-05-31 21:34:41.530102|2018-05-31 21:34:41.530102
NCT01548001|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2016-02-22|2012-03-05|2012-03-08|Estimate|||||||2016-02-22|2016-02-23|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis|Unknown status|Active, not recruiting|Phase 4|910|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||3|||f||||f||||||||Undecided||2018-05-31 21:34:41.599829|2018-05-31 21:34:41.599829
NCT01547988|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|October 2001||2001-10-31|March 2012|2012-03-31|August 2003|Actual|2003-08-31|February 2003|Actual|2003-02-28||Interventional|||Training Improves Balance Control|Improving Balance Control and Self-Reported Lower Extremity Function in Community Dwelling Older Adults - A Randomized Control Study|Completed||N/A|66|Actual|Boston University||2|||f||||f||||||||||2018-05-31 21:34:41.679697|2018-05-31 21:34:41.679697
NCT01547975|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2012-04-01|2012-03-07|2012-03-08|Estimate|||||||2012-04-01|2012-04-03|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Retrospective Analysis of Surgical Outcomes After Corneal Transplantation|Retrospective Analysis of Surgical Outcomes After Corneal Transplantation|Completed|||1000|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 21:34:41.853171|2018-05-31 21:34:41.853171
NCT01547962|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-04-06|2012-03-05|2012-03-08|Estimate|||||||2012-04-06|2012-04-09|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva|A Pilot Clinical Trial to Assess the Safety and Efficacy of Gintuit (TM) (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen) in Establishing a Functional Zone of Attached Gingiva|Completed||N/A|25|Actual|Organogenesis||2|||f||||f||||||||||2018-05-31 21:34:41.932788|2018-05-31 21:34:41.932788
NCT01547949|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-08-09|2012-03-05|2012-03-08|Estimate|||||||2012-08-09|2012-08-10|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults|Efficacy of Tart Cherry Juice in Reducing Muscle Injury and Biomarkers of Muscle Damage Among Healthy Adults|Completed||Phase 4|15|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 21:34:42.046152|2018-05-31 21:34:42.046152
NCT01547936|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Effect of Controlled Adverse Environment (CAE) on Tear Film Stability|A Single-Center Study Evaluating the Effect of the Controlled Adverse Environment (CAE) on Tear Film Stability Using the OPI 2.0 System, Ocular Protection Index (OPI), Tear Film Break-Up Time (TFBUT) and Mean Break up Area by Region (MBA) in Patients Diagnosed With Dry Eye Evaluated During Their Natural Blink Pattern|Completed|||33|Actual|ORA, Inc.|||||f||||f||||||||||2018-05-31 21:34:42.231134|2018-05-31 21:34:42.231134
NCT01547923|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-03-05|2012-03-05|2012-03-08|Estimate|||||||2012-03-05|2012-03-08|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|DPD côlon||Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines|The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study|Unknown status|Recruiting|Phase 3|2296|Anticipated|ICO Paul Papin||2|||f||||t||||||||||2018-05-31 21:34:42.31314|2018-05-31 21:34:42.31314
NCT01547910|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-08-19|2012-03-07|2012-03-08|Estimate|||||||2014-08-19|2014-08-21|Estimate|August 2007||2007-08-31|August 2014|2014-08-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children|Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children - a Randomized, Double Blind, Placebo Controlled, Multicenter Study|Completed||Phase 2|76|Actual|Children's Memorial Health Institute, Poland||2|||f||||t||||||||||2018-05-31 21:34:42.564965|2018-05-31 21:34:42.564965
NCT01547897|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2014-02-21|2012-03-05|2012-03-08|Estimate|||||||2014-02-21|2014-02-24|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria|A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer® NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria|Completed||Phase 2|76|Actual|NOXXON Pharma AG||2|||f||||f||||||||||2018-05-31 21:34:42.698075|2018-05-31 21:34:42.698075
NCT01547884|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-10-05|2012-03-06|2012-03-08|Estimate|||||||2017-10-05|2017-10-06|Actual|February 7, 2012||2012-02-07|August 31, 2017|2017-08-31||||||||Observational|||Effect of Filarial Infection on Immune Responses in Latent Tuberculosis|Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis|Recruiting|||4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:42.820361|2018-05-31 21:34:42.820361
NCT01547871|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-05-22|2012-03-06|2012-03-08|Estimate|||||||2018-05-22|2018-05-23|Actual|February 7, 2012||2012-02-07|April 14, 2016|2016-04-14|April 14, 2016||2016-04-14|||||Observational|||Infants With Spinal Muscular Atrophy Type I|A Pilot Study of the Natural History of Infants With Spinal Muscular Atrophy (SMA) Type 1|Terminated|||4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:42.894679|2018-05-31 21:34:42.894679
NCT01547858|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-04-04|2012-03-06|2012-03-08|Estimate|||||||2018-04-04|2018-04-05|Actual|February 9, 2012||2012-02-09|December 4, 2017|2017-12-04||||||||Observational|||Studying Blood Toxicity in Workers Exposed to Formaldehyde|A Cross-Sectional Study of Hematotoxicity in Workers Exposed to Formaldehyde|Completed|||708|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:42.976136|2018-05-31 21:34:42.976136
NCT01547845|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-04-04|2012-03-06|2012-03-08|Estimate|||||||2018-04-04|2018-04-05|Actual|February 10, 2012||2012-02-10|June 2, 2017|2017-06-02||||||||Observational|||Cancer Symptom Data From Multiple Treatment Centers|The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study|Completed|||2517|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:43.08616|2018-05-31 21:34:43.08616
NCT01547832|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-05-17|2012-03-06|2012-03-08|Estimate|||||||2018-05-17|2018-05-18|Actual|February 27, 2012||2012-02-27|September 22, 2017|2017-09-22||||||||Observational|||Mutations Associated With Parkinson s Disease|Metabolic Phenotyping of Subjects With Mutations Associated With Hereditary Parkinson's Disease|Completed|||42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:43.249964|2018-05-31 21:34:43.249964
NCT01547819|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-05-23|2012-03-06|2012-03-08|Estimate|||||||2018-05-23|2018-05-24|Actual|February 16, 2012||2012-02-16|December 18, 2013|2013-12-18|December 18, 2013||2013-12-18|||||Observational|||Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder|Imaging the GABAergic System Using 11C-flumazenil PET to Assess the Role of Mild Traumatic Brain Injury in the Development of Post Traumatic Stress Disorder|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:43.318943|2018-05-31 21:34:43.318943
NCT01547637|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-05-30|2012-03-07|2012-03-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 2012||2012-05-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Preventing the Obturator Nerve Reflex|Preventing the Obturator Nerve Reflex: A Comparison of Ultrasound Guided Obturator Nerve Block and Classic Anatomic Block Technique.|Completed||N/A|40|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 21:34:47.410737|2018-05-31 21:34:47.410737
NCT01547806|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2017-06-22||2018-02-06|2012-03-06|2012-03-08|Estimate|2017-07-27|2017-07-31|Actual||||2018-02-06|2018-03-07|Actual|February 22, 2012|Actual|2012-02-22|February 2018|2018-02-28|January 11, 2018|Actual|2018-01-11|June 17, 2014|Actual|2014-06-17||Interventional|||Collection of Transplant Stem Cells for Plasma Cell Myeloma|Mobilization and Collection of Autologous Stem Cell for Transplantation (ASCT) for Plasma Cell Myeloma (PCM)|Completed||Phase 2|49|Actual|National Institutes of Health Clinical Center (CC)|The sample size in outcome measure number 6 was inadequate. Results were not conclusive and the information is determined to be too preliminary to present. No conclusion should be drawn from the reported data for this outcome.|1|||f||||f|t|f||||||No||2018-05-31 21:34:43.404462|2018-05-31 21:34:43.404462
NCT01547793|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-06-30|2012-03-06|2012-03-08|Estimate|||||||2017-06-30|2017-07-02|Actual|January 26, 2012||2012-01-26|November 4, 2015|2015-11-04|November 4, 2015||2015-11-04|||||Observational|||Carbon Monoxide Levels and Sickle Cell Disease Severity|End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease|Completed|||106|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:43.795418|2018-05-31 21:34:43.795418
NCT01547780|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-04-27|2012-03-06|2012-03-08|Estimate|||||||2018-04-27|2018-04-30|Actual|January 20, 2012||2012-01-20|September 28, 2017|2017-09-28|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||Translocator Protein and Inflammation After Traumatic Brain Injury|PET Imaging of Translocator Protein in Subjects With Traumatic Brain Injury|Completed||Phase 1/Phase 2|52|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:43.866477|2018-05-31 21:34:43.866477
NCT01547767|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-05-22|2012-03-06|2012-03-08|Estimate|||||||2018-05-22|2018-05-23|Actual|February 1, 2012||2012-02-01|May 17, 2018|2018-05-17||||||||Observational|||Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy|Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy|Active, not recruiting|||2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:43.951319|2018-05-31 21:34:43.951319
NCT01547754|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-04-13|2012-03-06|2012-03-08|Estimate|||||||2018-04-13|2018-04-17|Actual|January 9, 2012||2012-01-09|August 25, 2014|2014-08-25|August 25, 2014||2014-08-25|||||Observational|||Mild Neurocognitive Disorder in HIV Infection of the Brain|Inflammation and Function of P-gp in HIV Infection of Brain|Terminated|||8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:34:44.034645|2018-05-31 21:34:44.034645
NCT01547741|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-10-21|2012-03-06|2012-03-08|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|May 2019|Anticipated|2019-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer|A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer|Active, not recruiting||Phase 3|1871|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-05-31 21:34:44.277931|2018-05-31 21:34:44.277931
NCT01547728|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2015-04-21||2015-07-13|2012-03-04|2012-03-08|Estimate|2015-07-13|2015-07-15|Estimate||||2015-07-13|2015-07-15|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery|Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery|Terminated||Phase 4|42|Actual|Mayo Clinic|The study was terminated because there were too many barriers to enroll participants.|1||Too many barriers to enroll participants.|f||||f||||||||||2018-05-31 21:34:45.886154|2018-05-31 21:34:45.886154
NCT01547715|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2014-12-18||2014-12-18|2012-03-05|2012-03-08|Estimate|2014-12-18|2014-12-31|Estimate||||2014-12-18|2014-12-31|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India|A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 75 Years of Age in India.|Completed||Phase 3|180|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:34:46.0715|2018-05-31 21:34:46.0715
NCT01547702|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2014-03-27|2012-03-05|2012-03-08|Estimate|||||||2014-03-27|2014-03-28|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Classroom-based Distance Intervention for Teachers of Children With Attention Deficit Hyperactivity Disorder|Randomized-controlled Trial of a Classroom-based Distance Intervention for Teachers of Elementary School-aged Children With ADHD|Completed||Phase 2|116|Actual|Dalhousie University||2|||f||||t||||||||||2018-05-31 21:34:46.970794|2018-05-31 21:34:46.970794
NCT01547689|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2016-02-18|2012-03-07|2012-03-08|Estimate|||||||2016-02-18|2016-02-22|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SEMAD||Safety and Efficiency of Umbilical Cord-derived Mesenchymal Stem Cells(UC-MSC) in Patients With Alzheimer's Disease|Open-Label, Single-Center, Self Control, Phase Ⅰ/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of UC-MSC in Patients With Alzheimer's Disease|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 21:34:47.076027|2018-05-31 21:34:47.076027
NCT01547676|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2015-03-25|2012-03-05|2012-03-08|Estimate|||||||2015-03-25|2015-03-27|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer|Prospective Randomized Comparison of Clamped Versus Unclamped Partial Nephrectomy|Terminated||N/A|28|Actual|University of Southern California||2||P.I. decided to terminate study due to multiple unresolved issues|f||||t||||||||||2018-05-31 21:34:47.134806|2018-05-31 21:34:47.134806
NCT01547663|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||A Comparison of Pain Scales in Patients With Disorder of Consciousness Following Craniotomy|A Comparison of Pain Scales in Patients With Disorder of Consciousness Following Craniotomy|Unknown status|Not yet recruiting||40|Anticipated|Mahidol University|||||f||||f||||||||||2018-05-31 21:34:47.21698|2018-05-31 21:34:47.21698
NCT01547650|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-13|2012-03-05|2012-03-08|Estimate|||||||2012-03-13|2012-03-14|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|February 2023|Anticipated|2023-02-28|February 2022|Anticipated|2022-02-28||Observational|||Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium|Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium|Active, not recruiting|||42|Anticipated|Nagaoka Red Cross Hospital|||1||f||||f||||||None Retained|"~     There is no biospeciment.~   "|||2018-05-31 21:34:47.283052|2018-05-31 21:34:47.283052
NCT01547624|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-03-10|2012-03-04|2012-03-08|Estimate|||||||2017-03-10|2017-03-13|Actual|February 2011||2011-02-28|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Neck Muscle Activation in Patients With Long Standing Problems After a Whiplash Trauma Registered With Ultrasound With Speckle Tracking||Completed||N/A|60|Anticipated|Linkoeping University||3|||f||||t||||||||Undecided||2018-05-31 21:34:47.519197|2018-05-31 21:34:47.519197
NCT01547611|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-03-05|2012-03-07|2012-03-08|Estimate|||||||2018-03-05|2018-03-06|Actual|January 2009||2009-01-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Outcome of Physiotherapy After Surgery for Cervical Disc Disease: a Prospective Multi-Centre Trial|Outcome of Physiotherapy After Surgery for Cervical Disc Disease: a Prospective Randomised Multi-Centre Trial|Completed||N/A|202|Actual|Linkoeping University||2|||f||||t||||||||No||2018-05-31 21:34:47.63826|2018-05-31 21:34:47.63826
NCT01547598|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2014-07-28||2014-07-28|2012-03-06|2012-03-08|Estimate|2014-07-28|2014-08-15|Estimate||||2014-07-28|2014-08-15|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction||Completed||Phase 4|135|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:34:47.75999|2018-05-31 21:34:47.75999
NCT01547585|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2015-03-10|2012-03-07|2012-03-08|Estimate|||||||2015-03-10|2015-03-17|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|SOY-LDL||A Human Trial to Assess the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Soy|A Randomized Controlled Trial to Determine the Low Density Lipoprotein Cholesterol (LDL-C) Lowering Effect of Whole Soy: a Dose Response Study|Completed||N/A|243|Actual|Guelph Food Research Centre||3|||f||||f||||||||||2018-05-31 21:34:48.125249|2018-05-31 21:34:48.125249
NCT01547572|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Psychological Preparation for Colorectal Surgery: Impact of Video Education|Psychological Preparation for Colorectal Surgery: Impact of Video Education. A Randomised Trial|Completed||N/A|60|Actual|Ihedioha, Ugo, M.D.||2|||f||||t||||||||||2018-05-31 21:34:48.246456|2018-05-31 21:34:48.246456
NCT01547559|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2014-10-20|2012-03-07|2012-03-08|Estimate|||||||2014-10-20|2014-10-21|Estimate|June 2007||2007-06-30|October 2014|2014-10-31||||November 2014|Anticipated|2014-11-30||Interventional|||Research for Prevention and Treatment of NSAIDs Related Gastrointestinal Side Effects|Evaluation of Preventive and Treatment Effects of Hp Eradication and Teprenone in Patients Taking NSAIDs|Unknown status|Active, not recruiting|N/A|369|Actual|Sun Yat-sen University||7|||f||||t||||||||||2018-05-31 21:34:48.343991|2018-05-31 21:34:48.343991
NCT01547546|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2016-11-01|2012-03-05|2012-03-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma|An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma|Completed||Phase 1|29|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 21:34:48.487096|2018-05-31 21:34:48.487096
NCT01547533|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-03-17|2012-03-07|2012-03-08|Estimate|||||||2015-03-17|2015-03-18|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|LACTBENZ||Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease|Study of Benznidazole Transfer Into Breastmilk in Lactating Women Treated for Chagas Disease|Completed|||10|Actual|Hospital de Niños R. Gutierrez de Buenos Aires|||1||f||||t||||||Samples Without DNA|"~     breastmilk; plasma~   "|||2018-05-31 21:34:48.549653|2018-05-31 21:34:48.549653
NCT01547520|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-03-07|2012-03-07|2012-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy|Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy, a Double-blind, Randomized Controlled Study|Completed||N/A|140|Actual|Dalin Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 21:34:48.604357|2018-05-31 21:34:48.604357
NCT01547507|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-05-29|2012-03-07|2012-03-08|Estimate|||||||2012-05-29|2012-05-30|Estimate|March 2012||2012-03-31|May 2012|2012-05-31||||December 2012|Anticipated|2012-12-31||Interventional|||Performance Evaluation of AirWay Medix Closed Suction System Compared With a Standard Closed Suction System|Performance Evaluation of AirWay Medix Closed Suction System Compared With a Standard Closed Suction System|Unknown status|Recruiting|N/A|26|Anticipated|Biovo Technologies Ltd||2|||f||||f||||||||||2018-05-31 21:34:48.671564|2018-05-31 21:34:48.671564
NCT01547494|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-05-13|2012-03-02|2012-03-07|Estimate|||||||2013-05-13|2013-05-14|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Nutritional Intervention for Migraines|A Nutritional Intervention for Migraines|Completed||N/A|16|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 21:34:48.899772|2018-05-31 21:34:48.899772
NCT01547481|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-05-14|2012-03-02|2012-03-07|Estimate|||||||2018-05-14|2018-05-17|Actual|December 2011||2011-12-31|May 2018|2018-05-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||MRI Study of Brain Activity in Healthy Adults and Individuals With Parkinsonism and Rapid Eye Movement Disorder.|Statistical Mapping of the Brain in Progressive Supranuclear Palsy, Essential Tremor, Parkinson Disease, Parkinsonism, and REM Behavior Disorder|Completed|||50|Actual|University of Alabama at Birmingham|||6||f||||f||||||||Yes|Patient data has now been collated as a de-identified dataset, that can be shared if requested.|2018-05-31 21:34:48.968511|2018-05-31 21:34:48.968511
NCT01547468|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-03-14|2012-03-02|2012-03-07|Estimate|||||||2013-03-14|2013-03-15|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||A Comparison of Two Pain Control Techniques on Deliruim in Hip Fracture Patients|Does Femoral Nerve Catheterization Reduce the Incidence of Post-Operative Delirium in Patients Presenting for Hip Fracture Repair?|Unknown status|Recruiting|N/A|270|Anticipated|Ochsner Health System||2|||f||||f||||||||||2018-05-31 21:34:49.035499|2018-05-31 21:34:49.035499
NCT01547455|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2013-07-24|2012-03-02|2012-03-07|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery|Anti-inflammatory and Renoprotective Effect of Pretreatment Loading Dose Atorvastatin in CABG|Completed||N/A|96|Actual|Peking Union Medical College||2|||f||||t||||||||||2018-05-31 21:34:49.120066|2018-05-31 21:34:49.120066
NCT01547442|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-01-31|2012-03-02|2012-03-07|Estimate|||||||2016-01-31|2016-02-02|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Artisan Aphakia Lens for the Correction of Aphakia in Children|Artisan Aphakia Lens for the Correction of Aphakia in Children|Recruiting||Phase 3|300|Anticipated|Ophtec USA||1|||f||||f||||||||||2018-05-31 21:34:49.214675|2018-05-31 21:34:49.214675
NCT01547429|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-01-31|2012-03-02|2012-03-07|Estimate|||||||2016-01-31|2016-02-02|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Artisan Aphakia Lens for the Correction of Aphakia (Secondary) in Adults|Artisan Aphakia Lens for the Correction of Aphakia in Adults|Recruiting||Phase 3|300|Anticipated|Ophtec USA||1|||f||||f||||||||||2018-05-31 21:34:49.298986|2018-05-31 21:34:49.298986
NCT01547416|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-07-09|2012-03-02|2012-03-07|Estimate|||||||2013-07-09|2013-07-11|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function|The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function After Robot-assisted Prostatectomy|Completed||Phase 4|50|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:34:49.44261|2018-05-31 21:34:49.44261
NCT01547403|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-01-14|2012-03-02|2012-03-07|Estimate|||||||2013-01-14|2013-01-15|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|CUSTOM||Customer Support Response Study|Evaluation of Customer Support Issues, Questions, or Alleged Complaints Regarding Use of Approved Commercially Distributed Scout DS Product in the Field|Withdrawn|||0|Actual|VeraLight, Inc.||||Protocol no longer meeting sponsor objectives|f||||f||||||||||2018-05-31 21:34:49.510519|2018-05-31 21:34:49.510519
NCT01547390|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2018-01-29||2018-04-11|2012-03-01|2012-03-07|Estimate|2018-04-11|2018-05-14|Actual||||2018-04-11|2018-05-14|Actual|March 2012||2012-03-31|April 2018|2018-04-30|July 20, 2015|Actual|2015-07-20|July 20, 2015|Actual|2015-07-20||Interventional|EPAPP||Early Prevention of Preeclampsia Study|Early Prediction and Aspirin for Prevention of Preeclampsia|Completed||N/A|104|Actual|Washington University School of Medicine|Study stopped due to poor enrollment after Aspirin was recommended by the US Preventive Task Force for the Prevention of Preeclampsia.|2|||f||||t||||||||||2018-05-31 21:34:49.590767|2018-05-31 21:34:49.590767
NCT01547377|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-03-02|2012-03-02|2012-03-07|Estimate|||||||2012-03-02|2012-03-07|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|||Zinc and Selenium Supplementation in Atherosclerosis|Effect of Zinc and Selenium Supplementation in Patients With Atherosclerosis Treated With Statins|Completed||N/A|76|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||||2018-05-31 21:34:49.972657|2018-05-31 21:34:49.972657
NCT01547364|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-04-27|2012-03-02|2012-03-07|Estimate|||||||2018-04-27|2018-04-30|Actual|February 2012||2012-02-29|April 2018|2018-04-30|November 2015|Actual|2015-11-30|October 2013|Actual|2013-10-31||Interventional|||Caudal Epidural Injection of Dextrose For Low Back Pain|Blinded Analgesic Effect and 1 Year Outcome of Caudal D5W Injection in All-Comers With Chronic Low Back Pain and Either Buttock or Leg Pain|Completed||Phase 2|35|Actual|Smigel, Liza, M.D.||2|||f||||t||||||||||2018-05-31 21:34:50.114729|2018-05-31 21:34:50.114729
NCT01547351|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2016-10-18|2012-03-02|2012-03-07|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|ARMS||Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire|Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire - A Phase 4 Pilot Study|Completed|||103|Actual|Mallinckrodt|||1||f||||||||||||||2018-05-31 21:34:50.202191|2018-05-31 21:34:50.202191
NCT01547338|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-04-13|2012-03-02|2012-03-07|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Photography or Video in Assessing Breast Reconstruction?|Comparison of Static Photography and Real Time Digital Video in the Assessment of Aesthetic Outcomes Following Breast Reconstruction|Completed|||35|Actual|NHS Greater Glasgow and Clyde|||1||f||||f||||||||||2018-05-31 21:34:50.307172|2018-05-31 21:34:50.307172
NCT01547325|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-03-09|2012-03-02|2012-03-07|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2012||2012-05-31|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of NanoDOX Hydrogel vs Placebo for Dehisced Surgical Wounds|Double-Blind, Single-Site, Pilot Study of NanoDOX Hydrogel Versus Placebo Hydrogel for Dehisced Surgical Wounds.|Withdrawn||N/A|0|Actual|NanoSHIFT LLC||2|||f||||f||||||||||2018-05-31 21:34:50.442274|2018-05-31 21:34:50.442274
NCT01547312|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2015-10-13|2012-03-02|2012-03-07|Estimate|||||||2015-10-13|2015-10-14|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)|A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-5172 in Participants With Chronic Hepatitis C|Withdrawn||Phase 1|0|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-05-31 21:34:50.527561|2018-05-31 21:34:50.527561
NCT01547299|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2015-03-30|2014-12-19|2017-11-19|2012-03-02|2012-03-07|Estimate|2015-03-30|2015-04-10|Estimate|2015-01-15|2015-01-27|Estimate|2017-11-19|2017-12-20|Actual|March 31, 2012|Actual|2012-03-31|November 2017|2017-11-30|November 30, 2013|Actual|2013-11-30|November 30, 2013|Actual|2013-11-30||Interventional|||Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer|A Randomized, Open-label, Phase 2 Study Of Mdv3100 As A Neoadjuvant Therapy For Patients Undergoing Prostatectomy For Localized Prostate Cancer|Completed||Phase 2|52|Actual|Pfizer||2|||f||||f||||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 21:34:50.665057|2018-05-31 21:34:50.665057
NCT01547286|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-05-08||2017-10-19|2012-03-02|2012-03-07|Estimate|2017-04-20|2017-04-25|Actual||||2017-10-19|2017-11-22|Actual|May 2012||2012-05-31|October 2017|2017-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||7 Subjects were enrolled and 5 subjects completed the study. Demographics and metacholine challenge test were obtained from all 7 subjects.|Imaging Study of the Lungs During an Allergic Asthma Attack|Redistribution of Pulmonary Perfusion During Bronchoconstriction in Asthma|Completed||N/A|7|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:34:51.419789|2018-05-31 21:34:51.419789
NCT01547273|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-09-26|2012-03-02|2012-03-07|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2012||2012-03-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Bone Grafts on Facial Gingival Profile in Maxillary Anterior Single Tooth Replacement|The Effect of Bone and Connective Tissue Grafts on Facial Gingival Profile in Single Maxillary Anterior Immediate Implant Placement and Provisionalization: A 1-Year Prospective Study|Active, not recruiting||N/A|30|Anticipated|Loma Linda University||3|||f||||f||||||||||2018-05-31 21:34:51.819067|2018-05-31 21:34:51.819067
NCT01547260|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2014-11-26|2012-03-02|2012-03-07|Estimate|||||||2014-11-26|2014-12-02|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Interventional|LENAGEM||Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer|Phase I/II Study of Lenalidomide and Gemcitabine as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|34|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 21:34:51.901347|2018-05-31 21:34:51.901347
NCT01547247|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|2012-12-20||2015-10-04|2012-03-03|2012-03-07|Estimate|2012-12-20|2013-01-28|Estimate||||2015-10-04|2015-10-23|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Cap-assisted Water Immersion Versus Water Immersion Colonoscopy|Cap-assisted Water Immersion Versus Water Immersion Minimal Sedation Colonoscopy - a Prospective, Randomized, Single-center Trial|Completed||N/A|208|Actual|Vitkovice Hospital|There were no complications recorded in the study.|2|||f||||f||||||||||2018-05-31 21:34:51.993363|2018-05-31 21:34:51.993363
NCT01547234|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-06-26|2012-03-06|2012-03-07|Estimate|||||||2016-06-26|2016-06-28|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis|Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis|Completed|||47|Actual|Carmel Medical Center|||||f||||f||||||||||2018-05-31 21:34:52.241536|2018-05-31 21:34:52.241536
NCT01547221|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2015-04-27|2012-03-03|2012-03-07|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients|Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients: a Randomized Controlled Trial|Completed||N/A|120|Actual|Khon Kaen Hospital||2|||f||||t||||||||||2018-05-31 21:34:52.312623|2018-05-31 21:34:52.312623
NCT01547208|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-09-29|2012-03-03|2012-03-07|Estimate|||||||2017-09-29|2017-10-02|Actual|September 2012||2012-09-30|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|PARTITA||Does Timing of VT Ablation Affect Prognosis in Patients With an Implantable Cardioverter-defibrillator?||Recruiting||N/A|590|Anticipated|IRCCS San Raffaele||2|||f||||f||||||||||2018-05-31 21:34:52.390946|2018-05-31 21:34:52.390946
NCT01547195|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-03-28|2012-03-03|2012-03-07|Estimate|||||||2012-03-28|2012-03-30|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|January 2012|Actual|2012-01-31||Interventional|ESTF||Effects of Swimming in the Treatment of Fibromyalgia|Assessment of the Effects of Swimming in the Treatment of Patients With Fibromyalgia.|Unknown status|Recruiting|Phase 1|75|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:34:52.639979|2018-05-31 21:34:52.639979
NCT01547182|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-11-02|2012-03-06|2012-03-07|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2012||2012-03-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|CLIP-II||Cooperative Lifestyle Programs (CLIP-II)|Cooperative Lifestyle Programs (CLIP-II)|Completed||N/A|249|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||No||2018-05-31 21:34:52.761563|2018-05-31 21:34:52.761563
NCT01547169|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-12-17|2012-03-06|2012-03-07|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SNIFF-LONG 21||Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days|Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days|Completed||Phase 2|60|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 21:34:52.851904|2018-05-31 21:34:52.851904
NCT01547156|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2016-03-09|2012-03-06|2012-03-07|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Mobile Sipoo - Telemonitoring With Combined With Active Assistance Technology|Mobile Sipoo a Randomized Controlled Trial|Completed||N/A|56|Actual|VTT Technical Research Centre of Finland||2|||f||||f||||||||||2018-05-31 21:34:52.954199|2018-05-31 21:34:52.954199
NCT01547143|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-01-09|2012-03-03|2012-03-07|Estimate|||||||2018-01-09|2018-01-10|Actual|March 2012||2012-03-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HELA2012||Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis|Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis (HLH) in Adult Patients|Terminated||N/A|12|Actual|Asan Medical Center||1||"The PI resigned the institute, and the rest investigators at the institute decided to terminate~   the study."|f||||f||||||||||2018-05-31 21:34:53.064561|2018-05-31 21:34:53.064561
NCT01547130|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|2015-01-17||2015-02-17|2012-03-03|2012-03-07|Estimate|2015-02-17|2015-03-04|Estimate||||2015-02-17|2015-03-04|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation|A Single Blind, Parallel Group, Randomized Controlled Trial Comparing Solution PEG Based Colon Preparation (HalfLytely) Versus Bolus Luke Warm Saline (Shudh) and Yoga Exercise for Large Bowel Cleansing Prior to Colonoscopy|Completed||Phase 1/Phase 2|133|Actual|Arya, Vijaypal, M.D., P.C.|Shudh Colon Cleanse (SCC) is suitable to only 30% of patients who are undergoing colonoscopy. A multi-center study is warranted to confirm these results.|2|||f||||t||||||||||2018-05-31 21:34:53.225486|2018-05-31 21:34:53.225486
NCT01547117|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2018-03-26|2012-03-06|2012-03-07|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2012||2012-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dietary Salt in Postural Tachycardia Syndrome|Dietary Salt in Postural Tachycardia Syndrome|Active, not recruiting||N/A|30|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 21:34:53.57306|2018-05-31 21:34:53.57306
NCT01547104|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-04-10|2012-03-02|2012-03-07|Estimate|||||||2012-04-10|2012-04-11|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus|Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 4|40|Anticipated|ikfe-CRO GmbH||2|||f||||f||||||||||2018-05-31 21:34:53.679404|2018-05-31 21:34:53.679404
NCT01547091|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-06-26|2012-03-03|2012-03-07|Estimate|||||||2013-06-26|2013-06-27|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|RA||Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis|Clinical Trial of Umbilical Cord-Derived Mesenchymal Stem Cells Transplantation for Rheumatoid Arthritis-Phase I/II|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Alliancells Bioscience Corporation Limited||3|||f||||f||||||||||2018-05-31 21:34:53.80014|2018-05-31 21:34:53.80014
NCT01547078|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2015-03-17|2012-03-02|2012-03-07|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Clinical Study of Lyophilized Plasma in Patients With Liver Disease|A Phase 2 Clinical Study of Lyophilized Plasma in Patients With Acquired Coagulopathy Due to Liver Disease|Withdrawn||Phase 2|0|Actual|HemCon Medical Technologies, Inc||2|||f||||t||||||||||2018-05-31 21:34:53.926342|2018-05-31 21:34:53.926342
NCT01547065|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2015-04-23|2012-03-06|2012-03-07|Estimate|||||||2015-04-23|2015-04-24|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Use of Transesophageal Echocardiography to Measure Intraoperative Renal Resistive Index and Predict Acute Renal Injury|Use of Transesophageal Echocardiography to Measure Intraoperative Renal Resistive Index and Predict Acute Renal Injury|Terminated|||13|Actual|Rutgers, The State University of New Jersey||||Enrollment lower than anticipated|f||||f||||||||||2018-05-31 21:34:53.98826|2018-05-31 21:34:53.98826
NCT01547052|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-05-10|2012-03-06|2012-03-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|August 2015|Actual|2015-08-31||Interventional|DBT-C||Adapting Dialectical Behavior Therapy for Children in Residential Care|Adapting Dialectical Behavior Therapy for Children in Residential Care: Pilot Randomized Clinical Trial With Children With Severe Emotional and Behavioral Dysregulation|Unknown status|Active, not recruiting|Phase 1/Phase 2|47|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-05-31 21:34:54.162613|2018-05-31 21:34:54.162613
NCT01547039|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-08|2012-03-02|2012-03-07|Estimate|||||||2012-03-08|2012-03-12|Estimate|June 2012||2012-06-30|March 2012|2012-03-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|||Platelet Reactivity and MES During CEA|Platelet Reactivity Testing in Association With Perioperative Microembolic Signals During Carotid Endarterectomy|Unknown status|Not yet recruiting||200|Anticipated|UMC Utrecht|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 21:34:54.319296|2018-05-31 21:34:54.319296
NCT01547026|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2013-02-12|2012-03-06|2012-03-07|Estimate|||||||2013-02-12|2013-02-13|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Self-regulation Strategies to Improve Exercise Behavior Among Schizophrenic Patients|Self-regulation Strategies to Improve Exercise Behavior: A Randomized Clinical Trial in Persons With Schizophrenia Spectrum Disorders|Completed||N/A|42|Actual|University of Konstanz||1|||f||||f||||||||||2018-05-31 21:34:54.387244|2018-05-31 21:34:54.387244
NCT01547013|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-10-12|2012-03-01|2012-03-07|Estimate|||||||2017-10-12|2017-10-16|Actual|February 2012||2012-02-29|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|February 2014|Actual|2014-02-28||Observational|NIRS||The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients|Phase II The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Trauma Patients|Active, not recruiting|||130|Anticipated|U.S. Army Medical Research and Materiel Command|||5||f||||f||||||||||2018-05-31 21:34:54.451861|2018-05-31 21:34:54.451861
NCT01547000|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-01-23|2012-03-06|2012-03-07|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Guanfacine in Children With Tic Disorders|Guanfacine in Children With Tic Disorders: A Multi-site Study|Completed||Phase 4|34|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:34:54.523757|2018-05-31 21:34:54.523757
NCT01546987|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2017-05-18|2012-03-03|2012-03-07|Estimate|||||||2017-05-18|2017-05-19|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31||||June 2020|Anticipated|2020-06-30||Interventional|||Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer|Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer|Active, not recruiting||Phase 3|239|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 21:34:54.633378|2018-05-31 21:34:54.633378
NCT01546974|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|February 2014|Anticipated|2014-02-28|November 2013|Anticipated|2013-11-30||Interventional|||Ventilator-associated Pneumonia (VAP) and Humidification System|Prospective Analysis of the Incidence of Ventilator-associated Pneumonia Related to the Humidification System: Heat and Moisture Exchanger Versus Heated Humidification|Unknown status|Recruiting|Phase 4|306|Anticipated|Hospital Sao Domingos||2|||f||||t||||||||||2018-05-31 21:34:55.031429|2018-05-31 21:34:55.031429
NCT01546961|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-01-04|2012-03-06|2012-03-07|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|KCP||Chloroquine Population Pharmacokinetics in Pre and Post-partum Women|The Population Pharmacokinetics of Chloroquine for the Treatment of Uncomplicated P.Vivax Malaria in Pre- and Post-partum Women.|Recruiting||N/A|160|Anticipated|University of Oxford||1|||f||||f||||||||||2018-05-31 21:34:55.105478|2018-05-31 21:34:55.105478
NCT01546948|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2018-05-27|2012-03-03|2012-03-07|Estimate|||||||2018-05-27|2018-05-30|Actual|August 2011|Actual|2011-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intraoperative Opioids and Postoperative Recovery After Hepatobiliary or Foregut Surgery|Intraoperative Opioids and Postoperative Recovery After Hepatobiliary or Foregut Surgery|Active, not recruiting||Phase 4|60|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 21:34:55.194742|2018-05-31 21:34:55.194742
NCT01546935|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-07-26|2012-03-06|2012-03-07|Estimate|||||||2013-07-26|2013-07-29|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One|SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study.|Withdrawn||Phase 2/Phase 3|0|Actual|University of Oxford||1||Study drugs (Oseltamivir suspension from Roche) were unavailable|f||||t||||||||||2018-05-31 21:34:55.277489|2018-05-31 21:34:55.277489
NCT01546922|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2014-04-25||2014-06-10|2012-03-01|2012-03-07|Estimate|2014-06-10|2014-07-14|Estimate||||2014-06-10|2014-07-14|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SUPREME CORT|The 47 participants completing both study periods were used for further analysis.|Hydrocortisone Replacement in Patients With Secondary Adrenal Insufficiency (SUPREME CORT)|A Randomized Double Blind Cross-over Study of the Effects of Low Dose and High Dose Hydrocortisone Replacement Therapy on Cognition, Quality of Life, Metabolic Profile and Somatosensation in Patients With Secondary Adrenal Insufficiency|Completed||Phase 4|63|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 21:34:55.434083|2018-05-31 21:34:55.434083
NCT01546909|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2017-09-08|2012-03-02|2012-03-07|Estimate|||||||2017-09-08|2017-09-11|Actual|February 2012|Actual|2012-02-29|September 2017|2017-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE|Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE|Completed||Phase 4|278|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:34:56.066676|2018-05-31 21:34:56.066676
NCT01546883|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-08-11||2015-09-10|2012-03-06|2012-03-07|Estimate|2015-09-10|2015-10-12|Estimate||||2015-09-10|2015-10-12|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DEPAF||Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation|Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation|Terminated||Phase 4|14|Actual|University of Utah||1||Not enough patients in time period allotted for study|f||||t||||||||||2018-05-31 21:34:56.377823|2018-05-31 21:34:56.377823
NCT01546870|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-03|||2016-06-16|2012-03-06|2012-03-07|Estimate|||||||2016-06-16|2016-06-20|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|CAS-POHT||Coronary Artery Study in Pediatric Heart Transplantation||Withdrawn|||0|Actual|Arkansas Children's Hospital Research Institute|||1|never approved by IRB|f||||f||||||||||2018-05-31 21:34:56.549642|2018-05-31 21:34:56.549642
NCT01546857|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-09-27|2012-03-01|2012-03-07|Estimate|||||||2016-09-27|2016-09-28|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Gabapentin on Orthopedic Pain|The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial|Terminated||Phase 4|34|Actual|Rutgers, The State University of New Jersey||2||No longer able to recruit subjects due to unavailability of orthopedic surgeon.|f||||f||||||||||2018-05-31 21:34:56.606729|2018-05-31 21:34:56.606729
NCT01546844|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-09-04|2012-03-02|2012-03-07|Estimate|||||||2012-09-04|2012-09-05|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|Care4Life||Mobile Health Technology as an Intervention for Diabetes Self-Management|Use of Mobile Health Technology as an Intervention for Type II Diabetes Self-Management|Unknown status|Enrolling by invitation|N/A|500|Anticipated|HealthInsight||2|||f||||f||||||||||2018-05-31 21:34:56.691814|2018-05-31 21:34:56.691814
NCT01546831|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-10-12|2012-03-01|2012-03-07|Estimate|||||||2016-10-12|2016-10-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:34:56.782844|2018-05-31 21:34:56.782844
NCT01546818|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2013-09-05|2012-03-01|2012-03-07|Estimate|||||||2013-09-05|2013-09-09|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|||Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients|A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 1|33|Actual|Sumagen|||||f||||f||||||||||2018-05-31 21:34:56.815514|2018-05-31 21:34:56.815514
NCT01546805|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-03-01|2012-03-01|2012-03-07|Estimate|||||||2012-03-01|2012-03-07|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm|The Effect of Zinc Supplementation on the Efficacy and Duration of Botulinum Toxin for the Treatment of Oculofacial Spasm Disorders|Unknown status|Not yet recruiting|N/A|40|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 21:34:56.979628|2018-05-31 21:34:56.979628
NCT01546792|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-01|2012-03-01|2012-03-07|Estimate|||||||2012-03-01|2012-03-07|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Lifestyle Intervention in Obstructive Sleep Apnoea|Effects of a Lifestyle Intervention on Quality of Life, Weight Loss and Cardiovascular Risk in Patients With Obstructive Sleep Apnoea Established on Continuous Positive Airway Pressure|Completed||Phase 2/Phase 3|60|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:34:57.092159|2018-05-31 21:34:57.092159
NCT01546779|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2012-03-01|2012-03-01|2012-03-07|Estimate|||||||2012-03-01|2012-03-07|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||The Use of Visual Feedback in Airway Clearance|"The Immediate Effect of Resistive Expiration Via Volumetric Incentive Spirometer on Lung Function in Patients With Cystic Fibrosis."|Completed||N/A|40|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 21:34:57.191176|2018-05-31 21:34:57.191176
NCT01546766|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-11-16|2012-03-06|2012-03-07|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)|Developing a Non-invasive Method and Device for Assessing the Degree of Midperipheral Retinal Ischemia in Diabetic Retinopathy.|Recruiting|||315|Anticipated|University of California, Los Angeles|||3||f||||f||||||||||2018-05-31 21:34:57.28023|2018-05-31 21:34:57.28023
NCT01546753|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-06-28|2012-03-06|2012-03-07|Estimate|||||||2017-06-28|2017-06-29|Actual|April 2012||2012-04-30|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|WOIT||Walnut Oral Immunotherapy for Tree Nut Allergy|Walnut Oral Immunotherapy for Tree Nut Allergy|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|University of Arkansas||2|||f||||t||||||||||2018-05-31 21:34:57.370581|2018-05-31 21:34:57.370581
NCT01546740|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Observational|||Prevalence of Glaucoma in the Israeli Arab Population|Glaucoma Prevalence in the Israeli Arab Population|Unknown status|Recruiting||15000|Anticipated|Ziv Hospital|||1||f||||t||||||||||2018-05-31 21:34:57.472065|2018-05-31 21:34:57.472065
NCT01546727|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2016-12-27|2012-03-06|2012-03-07|Estimate|||||||2016-12-27|2016-12-28|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|LAUNCH||Behavioral Treatment for Obese Preschoolers|Clinic and Home Family Based Behavioral Treatment for Obese Preschoolers|Completed||Phase 3|167|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-05-31 21:34:57.551919|2018-05-31 21:34:57.551919
NCT01546714|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2017-02-06|2012-03-06|2012-03-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 2011||2011-08-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|WSHP||Sexually Transmitted Infections Among African American Women Who Have Sex With Women|Sexually Transmitted Infections Among African American Women Who Have Sex With Women|Completed|||165|Actual|University of Alabama at Birmingham|||1||f||||f||||||Samples With DNA|"~     One vaginal swab and one endocervical swab to be stored for future studies.~   "|Yes|De-identified data will be shared with investigators at the Harvard School of Public Health for secondary data analysis.|2018-05-31 21:34:57.630932|2018-05-31 21:34:57.630932
NCT01546701|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-12-06|2012-03-06|2012-03-07|Estimate|||||||2012-12-06|2012-12-10|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Buprenorphine in Acute Renal Colic Pain Management||Completed||Phase 4|80|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:34:57.696051|2018-05-31 21:34:57.696051
NCT01546688|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2012-11-12||2016-01-06|2012-03-02|2012-03-07|Estimate|2013-01-02|2013-02-06|Estimate||||2016-01-06|2016-01-08|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|August 2011|Actual|2011-08-31|November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures|A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures|Terminated||Phase 4|41|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 21:34:57.768717|2018-05-31 21:34:57.768717
NCT01546675|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2014-10-17||2014-11-17|2012-03-01|2012-03-07|Estimate|2014-11-17|2014-11-24|Estimate||||2014-11-17|2014-11-24|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional||Cross-over design. Each subject participated under each condition. Total of 2 subjects.|Interface Kinematics of Transhumeral Prosthetic Sockets Using XROMM|Interface Kinematics of Transhumeral Prosthetic Sockets Using XROMM|Completed||N/A|2|Actual|VA Office of Research and Development|These results cannot be generalized outside of this small sample and may have been different if the intervention socket had been optimized. Additional research is needed to expand our understanding of the impact of prosthetic socket designs.|2|||f||||f||||||||||2018-05-31 21:34:59.210576|2018-05-31 21:34:59.210576
NCT01546662|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-02|2012-03-02|2012-03-07|Estimate|||||||2012-03-02|2012-03-07|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Interventional|EB-RH-02-11||A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.|A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.|Unknown status|Recruiting|N/A|54|Anticipated|Enovate Biolife Pvt Ltd||3|||f||||f||||||||||2018-05-31 21:34:59.563432|2018-05-31 21:34:59.563432
NCT01546649|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2015-10-22||2015-10-22|2012-03-01|2012-03-07|Estimate|2015-10-22|2015-11-26|Estimate||||2015-10-22|2015-11-26|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Full analysis set (FAS) included all randomized participants who had received at least a single dose of study treatment.|A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer||Completed||Phase 3|167|Actual|Takeda||2|||f||||||||||||||2018-05-31 21:34:59.739226|2018-05-31 21:34:59.739226
NCT01546636|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2013-07-16||2015-03-11|2012-03-06|2012-03-07|Estimate|2013-11-22|2013-12-17|Estimate||||2015-03-11|2015-03-31|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||The number of participants was determined by performing a sample size calculation.|The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position|The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position|Completed||Phase 4|70|Actual|NorthShore University HealthSystem Research Institute|There were no technical limitations to the trial|2|||f||||f||||||||||2018-05-31 21:35:01.491414|2018-05-31 21:35:01.491414
NCT01546623|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2015-04-02||2015-06-24|2012-03-01|2012-03-07|Estimate|2015-06-24|2015-07-21|Estimate||||2015-06-24|2015-07-21|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||The population included all participants who were randomized to treatment.|A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy|A Phase 3, Multi-center, Randomized, Open-label, Parallel-group, Comparative Study of TAP-144-SR (3M) to Evaluate Hormone Dynamics, Pharmacokinetics, Safety and Efficacy of TAP-144-SR (6M) 22.5 mg Subcutaneous Injection for 48 Weeks in Prostate Cancer Patients Previously Treated With Hormonal Therapy|Completed||Phase 3|160|Actual|Takeda||2|||f||||f||||||||||2018-05-31 21:35:01.990956|2018-05-31 21:35:01.990956
NCT01546610|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-08|2012-03-02|2012-03-07|Estimate|||||||2012-03-08|2012-03-09|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Rheumatoid Foot Insole|Effect of Rheumatoid Foot Insole|Unknown status|Recruiting|N/A|80|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:35:03.167589|2018-05-31 21:35:03.167589
NCT01546597|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-07-09|2012-03-02|2012-03-07|Estimate|||||||2012-07-09|2012-07-11|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine|A Phase 1, Open-Label, Single Cohort, Four-period Sequential Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|24|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 21:35:03.273499|2018-05-31 21:35:03.273499
NCT01546584|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-10-12|2012-03-01|2012-03-07|Estimate|||||||2016-10-12|2016-10-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:35:03.374233|2018-05-31 21:35:03.374233
NCT01546571|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2017-09-06|2012-03-01|2012-03-07|Estimate|||||||2017-09-06|2017-09-07|Actual|April 2012|Actual|2012-04-30|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|January 1, 2019|Anticipated|2019-01-01||Interventional|MAVIS||Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients|A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence|Active, not recruiting||Phase 3|1059|Anticipated|Polynoma LLC||2|||f||||f||||||||||2018-05-31 21:35:03.453504|2018-05-31 21:35:03.453504
NCT01546558|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-07-09|2012-03-06|2012-03-07|Estimate|||||||2012-07-09|2012-07-11|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg|A Phase 1, Open-label, Single Cohort, Two-Period Fixed Sequence Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg Twice Daily in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|25|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 21:35:03.720806|2018-05-31 21:35:03.720806
NCT01546545|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-12-12|2012-03-01|2012-03-07|Estimate|||||||2012-12-12|2012-12-17|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Insulin Variance Throughout the Day|Testing Whether Insulin Resistance Varies Throughout a Day A Pilot Study|Unknown status|Recruiting||10|Anticipated|Pennington Biomedical Research Center|||1||f||||f||||||Samples Without DNA|"~     IV Blood sample~   "|||2018-05-31 21:35:03.970831|2018-05-31 21:35:03.970831
NCT01546532|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02||2015-05-20|2015-05-20|2012-03-06|2012-03-07|Estimate||||2015-05-20|2015-06-15|Estimate|2015-05-20|2015-06-15|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Renal Hemodynamic Effects of RLX030 and Placebo Infused for 24 Hours in Subjects With Chronic Heart Failure (CHF)|Completed||Phase 2|118|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:35:04.041749|2018-05-31 21:35:04.041749
NCT01546519|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2015-10-13||2016-04-14|2012-03-02|2012-03-07|Estimate|2016-04-14|2016-05-23|Estimate||||2016-04-14|2016-05-23|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function|A Phase Ib Open-Label Pharmacokinetics and Safety Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function|Completed||Phase 1|31|Actual|Genentech, Inc.||5|||f||||f||||||||||2018-05-31 21:35:04.17234|2018-05-31 21:35:04.17234
NCT01546506|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2015-01-07|2012-03-02|2012-03-07|Estimate|||||||2015-01-07|2015-01-08|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|FLUMED||Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells|Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells|Completed||Phase 2|79|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 21:35:05.250604|2018-05-31 21:35:05.250604
NCT01546493|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-03-29|2012-03-01|2012-03-07|Estimate|||||||2018-03-29|2018-04-02|Actual|August 4, 2010|Actual|2010-08-04|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Hip Impingement - Understanding Cartilage Damage|Femoroacetabular Impingement: Correlating Hip Morphology to Changes in Cartilage and Subchondral Bone|Active, not recruiting||N/A|70|Actual|Ottawa Hospital Research Institute||3|||f||||f|f|f||||||||2018-05-31 21:35:05.501356|2018-05-31 21:35:05.501356
NCT01546480|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2014-06-16|2012-03-06|2012-03-07|Estimate|||||||2014-06-16|2014-06-17|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||From Acute to Chronic Postoperative Pain in Patients for Elective Cholecystectomy. Immunological Tests|From Acute to Chronic Postoperative Pain in Patients for Elective Cholecystectomy. Immunological Tests|Completed|||18|Actual|Odense University Hospital|||3||f||||f||||||Samples With DNA|"~     Whole blood Serum Plasma Cerebrospinal fluid Saliva~   "|||2018-05-31 21:35:05.63545|2018-05-31 21:35:05.63545
NCT01546467|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-03-01|2012-03-01|2012-03-07|Estimate|||||||2012-03-01|2012-03-07|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Cognitive Remediation in Early Phase Psychosis|Cognitive Remediation in Early Phase Psychosis|Unknown status|Recruiting|N/A|50|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 21:35:05.724353|2018-05-31 21:35:05.724353
NCT01546454|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|2014-04-11||2017-02-17|2012-03-01|2012-03-07|Estimate|2014-10-17|2014-10-23|Estimate||||2017-02-17|2017-03-22|Actual|February 2012||2012-02-29|February 2017|2017-02-28|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional||Healthy premenopausal women from the Portland, OR metro area|Relationship Between the Menstrual Cycle and Heart Disease in Women|Identification of the Menstrual Cycle-Associated Factors That Modulate Circulating Lipid Levels in Premenopausal Women|Completed||N/A|5|Actual|Oregon Health and Science University||3|||f||||f||||||||||2018-05-31 21:35:05.81037|2018-05-31 21:35:05.81037
NCT01546441|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||IMPACT Plus: The Integrated Complex Care Clinic|IMPACT Plus: The Integrated Complex Care Clinic|Unknown status|Not yet recruiting|N/A|350|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:35:06.008434|2018-05-31 21:35:06.008434
NCT01546428|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-06-17|2012-03-01|2012-03-07|Estimate|||||||2016-06-17|2016-06-20|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors|A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|44|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:35:06.08564|2018-05-31 21:35:06.08564
NCT01546415|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-10-27|2012-03-01|2012-03-07|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia|A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia|Completed||Phase 4|64|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:35:06.14575|2018-05-31 21:35:06.14575
NCT01546402|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2014-04-15||2014-06-17|2012-03-06|2012-03-07|Estimate|2014-06-17|2014-06-18|Estimate||||2014-06-17|2014-06-18|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema|Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema|Completed||Phase 4|20|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 21:35:06.218644|2018-05-31 21:35:06.218644
NCT01546389|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2013-09-12|2012-03-01|2012-03-07|Estimate|||||||2013-09-12|2013-09-13|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Sanaria™ PfSPZ Challenge Vaccine|A Phase I, Randomized Malaria Challenge Study of Intradermally-Administered Infectious (Replication-intact), Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) in Malaria-Naïve Adults|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-05-31 21:35:06.460187|2018-05-31 21:35:06.460187
NCT01546376|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|August 2009||2009-08-31|January 2009|2009-01-31||||||||Observational|||Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients|Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients|Unknown status|Recruiting||100|Anticipated|Rajavithi Hospital|||1||f||||f||||||||||2018-05-31 21:35:06.55995|2018-05-31 21:35:06.55995
NCT01546363|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-05-05|2012-03-01|2012-03-07|Estimate|||||||2017-05-05|2017-05-09|Actual|February 2012||2012-02-29|May 2017|2017-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer|Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer|Recruiting|||100|Anticipated|Stanford University|||2||f||||t||||||Samples With DNA|"~     Blood Tissue~   "|||2018-05-31 21:35:06.834375|2018-05-31 21:35:06.834375
NCT01546350|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2013-08-20|2012-03-06|2012-03-07|Estimate|||||||2013-08-20|2013-08-21|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH|Comparison of Standard ART Practice vs. Trophectoderm Biopsy, Array CGH Analysis, and Day-6 Replacement of a Single Euploid Embryo|Suspended||Phase 2|200|Anticipated|Reprogenetics||2||not enough patients recruited on time|f||||t||||||||||2018-05-31 21:35:06.962981|2018-05-31 21:35:06.962981
NCT01546337|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Observational|EPO||Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome|Search for Predictive Markers of Efficacy of Epoetin Beta (NEORECORMON) in the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Chemotherapy or Myelodysplastic Syndrome|Terminated|||30|Actual|Rennes University Hospital|||||f||||f||||||||||2018-05-31 21:35:07.081776|2018-05-31 21:35:07.081776
NCT01546324|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2013-08-08|2012-03-01|2012-03-07|Estimate|||||||2013-08-08|2013-08-12|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2012|Actual|2012-05-31||Observational|||Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing|Prenatal Diagnosis of Fetal DNA Isolated From Maternal Plasma|Completed|||16|Actual|Natera, Inc.|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:35:07.16793|2018-05-31 21:35:07.16793
NCT01546311|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-02|2012-03-02|2012-03-07|Estimate|||||||2012-03-02|2012-03-07|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Observational|PADS||Evaluation of a Pro-Active Dynamic Accommodating Socket||Unknown status|Recruiting||5|Anticipated|Infoscitex Corporation|||1||f||||||||||||||2018-05-31 21:35:07.259355|2018-05-31 21:35:07.259355
NCT01546298|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2017-06-06|2012-03-06|2012-03-07|Estimate|||||||2017-06-06|2017-06-08|Actual|January 2012||2012-01-31|June 2017|2017-06-30|November 2026|Anticipated|2026-11-30|November 2026|Anticipated|2026-11-30||Observational|||Immune Reactions in Contact Dermatitis Affected Skin|Analysis of Immune Reactions Occurring Upon Administration of Patch Tests and Contact Dermatitis Affected Skin|Enrolling by invitation|||120|Anticipated|Rockefeller University|||||f||||f||||||Samples With DNA|"~     Patch tests of skin~   "|Undecided||2018-05-31 21:35:07.348634|2018-05-31 21:35:07.348634
NCT01546285|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2013-01-16||2013-05-02|2012-03-02|2012-03-07|Estimate|2013-05-02|2013-06-21|Estimate||||2013-05-02|2013-06-21|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||B40 Non-Invasive Blood Pressure Equivalency Study|B40 Non-Invasive Blood Pressure Equivalency Study|Completed||N/A|66|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 21:35:07.451624|2018-05-31 21:35:07.451624
NCT01546272|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2016-03-07|2012-03-06|2012-03-07|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|May 2014|Actual|2014-05-31||Interventional|S2CARA||Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device|Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device|Completed||Phase 3|664|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 21:35:07.736356|2018-05-31 21:35:07.736356
NCT01546259|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-03-24|2012-03-02|2012-03-07|Estimate|||||||2016-03-24|2016-03-25|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Water Method in Low-body Mass Index (BMI) Female Patients With Unsedated Colonoscopy|Water Method With Water Exchange Versus Air Insufflation in Low-BMI Female Patients Undergoing Unsedated Colonoscopy: a Prospective Randomized, Controlled Trial|Withdrawn||N/A|0|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 21:35:07.873091|2018-05-31 21:35:07.873091
NCT01546246|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-03-24|2012-03-02|2012-03-07|Estimate|||||||2016-03-24|2016-03-25|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Water Method in Patients With Incomplete Colonoscopy|Water Method With Water Exchange Versus Air Insufflation in Patients With Incomplete Colonoscopy: a Prospective Randomized, Controlled Trial|Withdrawn||N/A|0|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 21:35:07.958159|2018-05-31 21:35:07.958159
NCT01546233|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-07-04|2012-03-06|2012-03-07|Estimate|||||||2016-07-04|2016-07-06|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|||Multidisciplinary Education in Lung Cancer Patients Who Receiving Chemotherapy Treatment|Outcome of Multidisciplinary Education Programme in Self-care in Fatigue Lung Cancer Patients Who Receiving Chemotherapy Treatment|Completed|||60|Actual|Rajavithi Hospital|||2||f||||f||||||||Yes|๋Journal of the medical association of Thailand|2018-05-31 21:35:08.066603|2018-05-31 21:35:08.066603
NCT01546220|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-03-24|2012-03-02|2012-03-07|Estimate|||||||2016-03-24|2016-03-25|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Water Method in Elder Patients With Unsedated Colonoscopy|Water Method With Water Exchange Versus Air Insufflation in Elder Patients Undergoing Unsedated Colonoscopy: a Prospective Randomized, Controlled Trial|Withdrawn||N/A|0|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 21:35:08.158778|2018-05-31 21:35:08.158778
NCT01546207|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2013-08-20||2016-06-28|2012-03-01|2012-03-07|Estimate|2014-03-24|2014-04-24|Estimate||||2016-06-28|2016-07-27|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|STRATUM VT||Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia|Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia|Terminated||N/A|4|Actual|Icahn School of Medicine at Mount Sinai|Early termination due to poor enrollment. Data analysis not done - there is not enough data for meaningful analysis.|1||low enrollment|f||||t||||||||No||2018-05-31 21:35:08.241242|2018-05-31 21:35:08.241242
NCT01546194|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2015-08-26||2016-03-30|2012-03-06|2012-03-07|Estimate|2015-08-26|2015-09-25|Estimate||||2016-03-30|2016-04-01|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||A Survey of Patient's Attitudes Towards Consent For Clinical Research In Anesthesiology|A Survey of Patient's Attitudes Towards Consent For Clinical Research In Anesthesiology|Completed|||200|Actual|NorthShore University HealthSystem Research Institute|||2||f||||f||||||||||2018-05-31 21:35:08.456825|2018-05-31 21:35:08.456825
NCT01546181|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2016-02-23|2012-03-06|2012-03-07|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|iPhot||Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases|Observational, Follow-up Study of Adaptive Optics Retinal Imaging in Controls and During Retinal or General Diseases|Unknown status|Recruiting||300|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||8||f||||t||||||||||2018-05-31 21:35:08.613865|2018-05-31 21:35:08.613865
NCT01546168|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2017-04-17||2018-01-19|2012-03-01|2012-03-07|Estimate|2018-01-19|2018-01-23|Actual||||2018-01-19|2018-01-23|Actual|November 2011||2011-11-30|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||17 roll-in patients and two pre-procedure withdrawals are removed from the analysis|Deviating the Esophagus in Atrial Fibrillation Ablation|Esophageal Deviation in Atrial Fibrillation Ablation: A Randomized Control Trial|Terminated||N/A|88|Actual|Icahn School of Medicine at Mount Sinai||2||Interim analysis: no statistically significant difference in the 2 study arms.|f||||t||||||||No||2018-05-31 21:35:08.711598|2018-05-31 21:35:08.711598
NCT01546155|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2017-01-06||2017-02-27|2012-03-01|2012-03-07|Estimate|2017-02-27|2017-04-11|Actual||||2017-02-27|2017-04-11|Actual|December 2011||2011-12-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|October 2012|Actual|2012-10-31||Interventional|||The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials|The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials|Completed||N/A|11|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:35:08.968338|2018-05-31 21:35:08.968338
NCT01546142|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2015-05-28|2014-05-30|2015-05-28|2012-03-01|2012-03-07|Estimate|2015-05-28|2015-06-15|Estimate|2014-05-30|2014-06-17|Estimate|2015-05-28|2015-06-15|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional||Intention-to-treat population|Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|516|Actual|Kythera Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 21:35:09.105519|2018-05-31 21:35:09.105519
NCT01546129|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|April 2012||2012-04-30|January 2012|2012-01-31||||December 2012|Anticipated|2012-12-31||Interventional|||Effect of Dianatal Obstetric Gel (Cross-linked Polyacrylic Acid) on Outcomes in Vaginal Delivery|Effect of Dianatal Obstetric Gel (Cross-linked Polyacrylic Acid) on Outcomes in Vaginal Delivery|Unknown status|Not yet recruiting|Phase 3|180|Anticipated|Rabin Medical Center||2|||f||||||||||||||2018-05-31 21:35:09.736874|2018-05-31 21:35:09.736874
NCT01546116|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-02-14|2012-03-01|2012-03-07|Estimate|||||||2014-02-14|2014-02-17|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2012|Actual|2012-02-29||Interventional|ALTER||Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)|Efficacy of Adefovir and Lamivudine Combination Therapy in Patients With Entecavir Resistance|Completed||Phase 4|20|Actual|Korea University||1|||f||||t||||||||||2018-05-31 21:35:09.820085|2018-05-31 21:35:09.820085
NCT01546103|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-01-22|2012-03-02|2012-03-07|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Vitamin D3 Supplementation Pilot Study|Pilot Study of Vitamin D3 Supplementation and Outcomes in Vitamin D Deficient Obese, African American Adolescents|Completed||N/A|39|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 21:35:09.926229|2018-05-31 21:35:09.926229
NCT01546090|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|||Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block|Effect of Preoperative Alprazolam on the Success of Inferior Alveolar Nerve Block for Teeth With Irreversible Pulpitis|Completed||Phase 4|60|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:35:10.034783|2018-05-31 21:35:10.034783
NCT01546077|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-11-09|2012-03-02|2012-03-07|Estimate|||||||2012-11-09|2012-11-12|Estimate|January 2012||2012-01-31|November 2012|2012-11-30||||March 2013|Anticipated|2013-03-31||Interventional|||Placement of Perineural Catheters in the Popliteal Region|Comparison of Techniques for Placement of Perineural Catheters in the Popliteal Region|Unknown status|Recruiting|Phase 4|40|Anticipated|Attikon Hospital||2|||f||||||||||||||2018-05-31 21:35:10.187583|2018-05-31 21:35:10.187583
NCT01546064|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2012-03-01|2012-03-01|2012-03-07|Estimate|||||||2012-03-01|2012-03-07|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity|Prospective and Randomized Trial on the Usefulness of T-Tube in the Bile Duct Anastomosis in Liver Transplantation Procedure.|Completed||N/A|200|Actual|Hospital Universitario La Fe||2|||f||||f||||||||||2018-05-31 21:35:10.284215|2018-05-31 21:35:10.284215
NCT01546051|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Food Effect of BCI-838; and, An Open-Label Minidose Bioavailability Study to Compare Several BCI-632 Pro-drug Candidates in Healthy Male Subjects|Completed||Phase 1|31|Actual|BrainCells Inc.||4|||f||||f||||||||||2018-05-31 21:35:10.478156|2018-05-31 21:35:10.478156
NCT01546038|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2017-12-11||2018-05-16|2012-03-01|2012-03-07|Estimate|2018-05-16|2018-05-23|Actual||||2018-05-16|2018-05-23|Actual|June 27, 2012|Actual|2012-06-27|May 2018|2018-05-31|October 17, 2019|Anticipated|2019-10-17|January 3, 2017|Actual|2017-01-03||Interventional|||A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase 1b/2 Study To Evaluate The Safety And Efficacy Of Pf-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-c Or Decitabine In Patients With Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome|Active, not recruiting||Phase 1|255|Actual|Pfizer||5|||f||||t||||||||||2018-05-31 21:35:11.070657|2018-05-31 21:35:11.070657
NCT01546025|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-03-02|2012-03-02|2012-03-07|Estimate|||||||2012-03-02|2012-03-07|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Brief Alcohol Intervention for School-to-Work Transitions|Brief Alcohol Intervention for School-to-Work Transitions|Completed||N/A|163|Actual|Brown University||2|||f||||||||||||||2018-05-31 21:35:19.51021|2018-05-31 21:35:19.51021
NCT01546012|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2015-08-31|2012-03-02|2012-03-07|Estimate|||||||2015-08-31|2015-09-02|Estimate||||August 2015|2015-08-31||||||||Interventional|||Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials||Withdrawn||N/A|0|Actual|Laboratoires Thea||2||Too difficult to select patient according to the investigator|f||||f||||||||||2018-05-31 21:35:19.578102|2018-05-31 21:35:19.578102
NCT01545999|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-02-11|2012-03-06|2012-03-07|Estimate|||||||2018-02-11|2018-02-13|Actual|March 2012||2012-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia|Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: a Combined Transcranial Magnetic Stimulation and Electroencephalography Study Across the Life Span|Active, not recruiting||N/A|72|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 21:35:19.712461|2018-05-31 21:35:19.712461
NCT01545986|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2012-03-01|2012-03-01|2012-03-07|Estimate|||||||2012-03-01|2012-03-07|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Comparative Analysis of Two Types of Exercise on Outcomes Following Total Knee Arthroplasty|A Comparative Analysis of High Velocity and Standard Low Velocity Exercise Training on Rehabilitation Outcomes Following Total Knee Arthroplasty|Completed||N/A|38|Actual|Helen Hayes Hospital||2|||f||||f||||||||||2018-05-31 21:35:19.788049|2018-05-31 21:35:19.788049
NCT01545973|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-02|2012-03-02|2012-03-07|Estimate|||||||2012-03-02|2012-03-07|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Understanding the Physiological Implications of Scanning Kelvin Probe Measurements|Measuring Skin Electrical Potential With the Kelvin Probe: Underlying Physiology|Suspended|||24|Anticipated|Massachusetts General Hospital|||1|Repair of minor software glitches|f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 21:35:19.870611|2018-05-31 21:35:19.870611
NCT01545960|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2012-03-02|2012-03-02|2012-03-07|Estimate|||||||2012-03-02|2012-03-07|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Evaluating Acupuncture Points With Scanning Kelvin Probe|Scanning Kelvin Probe Measurements of Acupuncture Point|Suspended|||24|Anticipated|Massachusetts General Hospital|||1|Adjusting minor software glitches|f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 21:35:20.097709|2018-05-31 21:35:20.097709
NCT01545947|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2016-11-04|2012-03-02|2012-03-07|Estimate|||||||2016-11-04|2016-11-08|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer|A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER|Completed||Phase 1|76|Actual|Celgene Corporation||3|||f||||f||||||||||2018-05-31 21:35:20.224445|2018-05-31 21:35:20.224445
NCT01545934|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2016-07-25|2012-03-02|2012-03-07|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|June 2021|Anticipated|2021-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Preventing Excessive Gestational Weight Gain in Obese Women|Preventing Excessive Gestational Weight Gain in Obese Women|Active, not recruiting||N/A|350|Anticipated|California Polytechnic State University-San Luis Obispo||2|||f||||t||||||||||2018-05-31 21:35:20.349661|2018-05-31 21:35:20.349661
NCT01545921|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-03-06|2012-03-06|2012-03-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|April 2014|Anticipated|2014-04-30|November 2013|Anticipated|2013-11-30||Interventional|CEOLE||Cancer End Of Life Evaluation|Evaluation and Validation of Quality Of Life Scales in Palliative Advanced Cancer|Unknown status|Recruiting|Phase 3|402|Anticipated|ICO Paul Papin||4|||f||||f||||||||||2018-05-31 21:35:20.496595|2018-05-31 21:35:20.496595
NCT01545908|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2015-03-17|2012-03-01|2012-03-07|Estimate|||||||2015-03-17|2015-03-19|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis|A Randomized Controlled Trial of Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis|Completed||Phase 2|130|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 21:35:20.625453|2018-05-31 21:35:20.625453
NCT01545882|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-07-22|2012-03-06|2012-03-07|Estimate|||||||2013-07-22|2013-07-23|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|October 2011|Actual|2011-10-31||Interventional|OTT 10-06||A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer|A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer|Terminated||Phase 2|5|Actual|Ottawa Hospital Research Institute||1||Negative study; Principal Investigator chose to prematurely terminate the study.|f||||f||||||||||2018-05-31 21:35:20.775227|2018-05-31 21:35:20.775227
NCT01545869|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2014-04-04|2012-03-06|2012-03-07|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy and Safety of Fractional Carbon Dioxide Laser for Treatment of Facial Freckles.|Efficacy and Safety of Fractional Carbon Dioxide Laser for Treatment of Facial Freckles|Completed||N/A|20|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 21:35:21.05686|2018-05-31 21:35:21.05686
NCT01545856|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-05-15|2012-03-01|2012-03-07|Estimate|||||||2017-05-15|2017-05-16|Actual|September 2011||2011-09-30|May 2017|2017-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Cardiovascular Events in Parkinson's Disease Patients|Background Incidence of Cardiovascular Ischaemic Events in Treated Parkinson's Disease Patients in the Impact Database|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:35:21.147364|2018-05-31 21:35:21.147364
NCT01545843|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2015-01-13||2017-11-07|2012-03-01|2012-03-07|Estimate|2015-01-19|2015-01-30|Estimate||||2017-11-07|2017-12-08|Actual|March 2009||2009-03-31|November 2017|2017-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression|Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression|Completed||Phase 2|68|Actual|University of Michigan|Sample is largely young, healthy adults|3|||f||||t||||||||||2018-05-31 21:35:21.478039|2018-05-31 21:35:21.478039
NCT01545830|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2016-08-30|2012-03-06|2012-03-07|Estimate|||||||2016-08-30|2016-09-01|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|MISURA||Metabolic Syndrome and Insulin Resistance at Allina|Randomized, Controlled Trial of Vitamin D Replenishment in Metabolic Syndrome|Completed||Phase 2|84|Actual|Allina Health System||2|||f||||f||||||||||2018-05-31 21:35:21.919175|2018-05-31 21:35:21.919175
NCT01545817|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-09-26|2012-03-01|2012-03-07|Estimate|||||||2017-09-26|2017-09-28|Actual|April 2012||2012-04-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|CATChEz||Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma|Continuous Access to Advanced and Metastatic Renal Cell Carcinoma Therapy With Everolimus Post Pazopanib Treatment|Terminated||Phase 2|74|Actual|Novartis||1||"Due to changes in the RCC treatment landscape, info gained is no longer clinically relevant to~   patients. Data collected is deemed sufficient to meet objectives."|f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:35:22.098013|2018-05-31 21:35:22.098013
NCT01545804|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-02-07|2012-03-06|2012-03-07|Estimate|||||||2017-02-07|2017-02-09|Estimate|August 2011|Actual|2011-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma|Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (HCC): a Phase II Clinical Trial|Completed||Phase 2|55|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 21:35:22.220794|2018-05-31 21:35:22.220794
NCT01545791|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-10-27|2012-03-06|2012-03-07|Estimate|||||||2016-10-27|2016-10-28|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|PREDICTIVE™||Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes|A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Patients Using Insulin Detemir for the Treatment of Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study - Predictable Results and Experience in Diabetes Through Intensification and Control to Target: An International Variability Evaluation|Completed|||1037|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:35:22.301478|2018-05-31 21:35:22.301478
NCT01545778|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-10-26|2012-03-06|2012-03-07|Estimate|||||||2012-10-26|2012-10-29|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)|Risk of Shopping Behavior of Tapentadol IR Immediate-Release (IR) Compared to Oxycodone IR Immediate-Release (IR)|Completed|||646620|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||2||f||||||||||||||2018-05-31 21:35:22.387802|2018-05-31 21:35:22.387802
NCT01545765|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2013-06-25||2013-06-25|2012-03-01|2012-03-07|Estimate|2013-06-25|2013-09-04|Estimate||||2013-06-25|2013-09-04|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||No sample size determination as a standard sample size for this type of study is about 30 subjects.|Anesthetic Effect Duration Assessment|Anesthetic Effect Duration Produced by Lidocaine 7% + Tetracaine 7% Cream on 2 Different Body Areas|Completed||Phase 4|30|Actual|Galderma|No limitation or caveat on this study|1|||f||||f||||||||||2018-05-31 21:35:22.485682|2018-05-31 21:35:22.485682
NCT01545752|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-07-11|2012-03-06|2012-03-07|Estimate|||||||2012-07-11|2012-07-12|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Comparing Interactive and Non-interactive CD-based Method|Comparing Interactive and Non-interactive CD-based Method in Teaching Medical Terminology|Terminated||Phase 2/Phase 3|180|Actual|Mashhad University of Medical Sciences||3|||f||||f||||||||||2018-05-31 21:35:22.712089|2018-05-31 21:35:22.712089
NCT01545739|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-10-15|2012-03-06|2012-03-07|Estimate|||||||2014-10-15|2014-10-16|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Evia/Entovis HF-T Master Study|Master Study of the Evia/Entovis HF-T Pacemaker|Completed|||122|Actual|Biotronik SE & Co. KG|||1||f||||f||||||||||2018-05-31 21:35:22.769708|2018-05-31 21:35:22.769708
NCT01545726|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-10-08|2012-03-01|2012-03-07|Estimate|||||||2013-10-08|2013-10-09|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma|A Double-blind, Placebo-controlled Study Examining the Effect of Orally Administered QAW039 on Sputum Eosinophil Levels and Other Efficacy Outcomes in Patients With Sputum Eosinophilia and Persistent Asthma|Completed||Phase 2|61|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:35:22.828456|2018-05-31 21:35:22.828456
NCT01545713|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-09-19|2012-03-06|2012-03-07|Estimate|||||||2017-09-19|2017-09-21|Actual|June 2011||2011-06-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|February 2012|Actual|2012-02-29||Observational|||Correlation of Donor-specific Anti-endothelial Cells|A Phase II, Prospective, Single-center Study: Correlation of Donor-specific Anti-precursor Endothelial Cells With Transplant Outcome for Recipients of Living-donor Kidney Transplants, Are Auto-antibodies Important.|Active, not recruiting|||16|Actual|Northwestern University|||1||f||||f||||||Samples Without DNA|"~     A total of 40 cc/3 tablespoons of blood will be drawn once.~   "|||2018-05-31 21:35:22.891131|2018-05-31 21:35:22.891131
NCT01545700|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2012-11-09||2013-01-15|2012-03-06|2012-03-07|Estimate|2012-12-07|2013-01-15|Estimate||||2013-01-15|2013-01-18|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery|Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery|Completed||Phase 4|200|Actual|NorthShore University HealthSystem Research Institute||6|||f||||f||||||||||2018-05-31 21:35:22.954461|2018-05-31 21:35:22.954461
NCT01545687|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-08-04|2012-03-01|2012-03-07|Estimate|||||||2017-08-04|2017-08-08|Actual|April 2012||2012-04-30|August 2017|2017-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy|A Phase III, Randomized, Double-Blind Study of Lactobacillus Brevis CD2 Lozenges Versus Placebo in the Prevention of Acute Oral Mucositis (OM) in Patients With Head and Neck Cancer Receiving Concurrent Radiotherapy and Chemotherapy|Withdrawn||Phase 3|0|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 21:35:23.541377|2018-05-31 21:35:23.541377
NCT01545674|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2018-03-28|2012-03-06|2012-03-07|Estimate|||||||2018-03-28|2018-03-30|Actual|January 2012||2012-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|April 2014|Actual|2014-04-30||Observational|PreNATUS||Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial|Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial (PreNATUS)|Active, not recruiting|||1000|Anticipated|Natera, Inc.|||1||f||||t||||||Samples With DNA|"~     Plasma Sample Prepared DNA~   "|No|A peer reviewed publication is planned from this study.|2018-05-31 21:35:23.656315|2018-05-31 21:35:23.656315
NCT01545661|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2012-12-21|2012-03-01|2012-03-07|Estimate|||||||2012-12-21|2012-12-24|Estimate|August 2009||2009-08-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|SINET||Utility of Sputum Induction and Novel Technologies to Improve TB Diagnosis in a High HIV Prevalence Primary Care Setting|A Randomised Control Trial of Sputum Induction, and New and Emerging Technologies in a High HIV Prevalence Primary Care Setting|Completed||N/A|517|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 21:35:24.013315|2018-05-31 21:35:24.013315
NCT01545648|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2017-11-27|2012-03-01|2012-03-07|Estimate|||||||2017-11-27|2017-11-29|Actual|November 2012||2012-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 29, 2014|Actual|2014-10-29||Interventional|||Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer|Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer|Active, not recruiting||Phase 2|45|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:35:24.105132|2018-05-31 21:35:24.105132
NCT01545635|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-03-22|2012-03-06|2012-03-07|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma|RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma|Terminated||Phase 3|100|Actual|Medical University Innsbruck||2||"The Interim analysis (100 patients) revealed a possible harm to patients randomised to the~   fresh frozen plasma (FFP) treatment arm."|f||||t||||||||||2018-05-31 21:35:24.226523|2018-05-31 21:35:24.226523
NCT01545622|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2017-08-30|2012-03-01|2012-03-07|Estimate|||||||2017-08-30|2017-08-31|Actual|March 2008|Actual|2008-03-31|August 2017|2017-08-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Observational|||Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease|Surgeon Compared to Nuclear Radiology Readers for Tc-99m Sestamibi Scans for Parathyroid Disease|Completed|||61|Actual|University of Arkansas|||||f||||f||||||||||2018-05-31 21:35:24.317325|2018-05-31 21:35:24.317325
NCT01545609|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2013-12-20|2012-03-06|2012-03-07|Estimate|||||||2013-12-20|2013-12-24|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|BC 2U||A Trial Assessing the Effectiveness of Text Messages in Improving Continuation of Birth Control|A Text Message Support System for Effective Continuation of a Birth Control Method in Female Adolescents: 'BC 2U'|Completed||Phase 1|220|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 21:35:24.383248|2018-05-31 21:35:24.383248
NCT01545596|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-05-23|2012-03-06|2012-03-07|Estimate|||||||2014-05-23|2014-05-26|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Will a Real Time Advisory for Double Low State Change Clinical Behavior and Impact Outcomes|A Randomized Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Double and Triple Low Combination of Mean Arterial Pressure, and Either End-tidal Anesthetic Concentration or Bispectral Index.|Completed||N/A|20237|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:35:24.566362|2018-05-31 21:35:24.566362
NCT01545583|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-09-18|2012-03-01|2012-03-07|Estimate|||||||2012-09-18|2012-09-19|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of LY3016859 in Healthy Volunteers|Study of the Safety, Tolerability and Pharmacokinetics of LY3016859 After Single Intravenous and Subcutaneous Dosing in Healthy Volunteers|Completed||Phase 1|56|Anticipated|Eli Lilly and Company||9|||f||||f||||||||||2018-05-31 21:35:24.712303|2018-05-31 21:35:24.712303
NCT01545570|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-07-24|2012-03-01|2012-03-06|Estimate|||||||2017-07-24|2017-07-25|Actual|November 7, 2011|Actual|2011-11-07|July 2017|2017-07-31|December 23, 2012|Actual|2012-12-23|December 23, 2012|Actual|2012-12-23||Interventional|||A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers|A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2374697 in Healthy Volunteers|Completed||Phase 1|82|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:35:24.82465|2018-05-31 21:35:24.82465
NCT01545557|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-03-24|2012-03-01|2012-03-06|Estimate|||||||2014-03-24|2014-03-26|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pan Facial Volume Restoration|Pan Facial Volume Restoration With a New Hyaluronic Acid Dermal Filler|Completed||Phase 4|60|Actual|Galderma||1|||f||||f||||||||||2018-05-31 21:35:24.987363|2018-05-31 21:35:24.987363
NCT01545544|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-02-06|2012-03-01|2012-03-06|Estimate|||||||2014-02-06|2014-02-07|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Observational|Lympho C||Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)|Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) in Patients With Hepatitis C Virus|Unknown status|Active, not recruiting||138|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||t||||||Samples With DNA|"~     whole blood and bone marrow~   "|||2018-05-31 21:35:25.091728|2018-05-31 21:35:25.091728
NCT01545531|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-12-30|2012-03-01|2012-03-06|Estimate|||||||2016-12-30|2017-01-04|Estimate|September 2008||2008-09-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance||Completed|||54|Actual|University of Washington|||1||f||||f||||||Samples Without DNA|"~     blood sample for iohexol level, serum creatinine, cystatin C, and hematocrit at baseline,~     prior to iohexol infusion, 2 hours and 5 hours post iohexol infusion.~   "|||2018-05-31 21:35:25.19476|2018-05-31 21:35:25.19476
NCT01545518|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2014-08-21||2014-08-21|2012-03-01|2012-03-06|Estimate|2014-08-21|2014-09-01|Estimate||||2014-08-21|2014-09-01|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional||18-50 years of age, both male and female|IVIG Treatment for Refractory Immune-Related Adult Epilepsy|IVIG Treatment for Refractory Immune-Related Adult Epilepsy|Terminated||Phase 2|20|Actual|Emory University|Study was terminated early. Subject eligibility for phase 2 not available.|1||Futility criteria, unable for Phase 2 of study, & phase 1 was terminated.|f||||f||||||||||2018-05-31 21:35:25.305842|2018-05-31 21:35:25.305842
NCT01545505|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-02-20|2012-03-01|2012-03-06|Estimate|||||||2013-02-20|2013-02-21|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|July 2014|Anticipated|2014-07-31|October 2013|Anticipated|2013-10-31||Interventional|||Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse|Early Diagnosis of Risk of Post-Traumatic Stress Disorder (PTSD) Relapse in Children and Their Families|Unknown status|Recruiting|N/A|120|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 21:35:25.592817|2018-05-31 21:35:25.592817
NCT01545492|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-03-01|2012-03-01|2012-03-06|Estimate|||||||2012-03-01|2012-03-06|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|CHIPS-Child||Testing the Developmental Origins Hypothesis|CHIPS-Child:Testing the Developmental Origins Hypothesis|Recruiting|||626|Anticipated|Children's & Women's Health Centre of British Columbia|||2||f||||t||||||Samples With DNA|"~     1. ~150 strands of hair~        2. Four buccal swabs~   "|||2018-05-31 21:35:25.724122|2018-05-31 21:35:25.724122
NCT01545479|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-03-01|2012-03-01|2012-03-06|Estimate|||||||2012-03-01|2012-03-06|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition|Renal Oxygen Content is Increased in Healthy Subjects After Angiotensin Converting Enzyme Inhibition|Completed||Phase 4|5|Actual|Instituto de Cardiologia do Rio Grande do Sul||1|||f||||f||||||||||2018-05-31 21:35:25.849334|2018-05-31 21:35:25.849334
NCT01545453|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01||2016-08-09|2016-11-01|2012-03-01|2012-03-06|Estimate||||2016-08-09|2016-08-11|Estimate|2016-11-01|2016-11-02|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication|Completed||Phase 2|205|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 21:35:25.999003|2018-05-31 21:35:25.999003
NCT01545440|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-03-03|2012-03-01|2012-03-06|Estimate|||||||2015-03-03|2015-03-05|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication|Completed||Phase 2|258|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 21:35:26.16785|2018-05-31 21:35:26.16785
NCT01545427|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-06|2012-03-01|2012-03-06|Estimate|||||||2012-03-06|2012-03-07|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma|A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma|Terminated||Phase 2|10|Actual|Lawson Health Research Institute||2||Frequent adverse events occurred early in treatment with poor tolerability.|f||||t||||||||||2018-05-31 21:35:26.487647|2018-05-31 21:35:26.487647
NCT01545414|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2015-02-12|2012-03-05|2012-03-06|Estimate|||||||2015-02-12|2015-02-13|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Internet-CBT (Cognitive Behavioral Therapy) for Depression and Anxiety in Parkinsons Disease|Internet-based CBT for Depression and Anxiety in Parkinson's Disease: a Pilot Study and Randomized Controlled Trial|Completed||Phase 3|150|Anticipated|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 21:35:26.639142|2018-05-31 21:35:26.639142
NCT01545401|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2014-09-18|2012-03-05|2012-03-06|Estimate|||||||2014-09-18|2014-09-19|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)|Empowering Primary Care Providers and Patients to Improve Chronic Disease Outcomes: The EMPOWER Participatory Action Research (EMPOWER - PAR)|Completed||Early Phase 1|1545|Actual|Ministry of Health, Malaysia||2|||f||||t||||||||||2018-05-31 21:35:26.716303|2018-05-31 21:35:26.716303
NCT01545388|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2014-02-10||2017-03-24|2012-03-05|2012-03-06|Estimate|2014-02-10|2014-03-26|Estimate||||2017-03-24|2017-04-24|Actual|February 23, 2012|Actual|2012-02-23|March 2017|2017-03-31|March 12, 2013|Actual|2013-03-12|March 12, 2013|Actual|2013-03-12||Interventional||All participants as treated population defined as all randomized participants.|Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)|A Phase III, Randomized, Placebo and Active-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of the Addition of Metformin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Sitagliptin Monotherapy|Completed||Phase 3|337|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:35:26.832337|2018-05-31 21:35:26.832337
NCT01545375|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2017-07-11||2017-08-11|2012-03-01|2012-03-06|Estimate|2017-08-11|2017-09-12|Actual||||2017-08-11|2017-09-12|Actual|May 21, 2012|Actual|2012-05-21|July 2017|2017-07-31|July 26, 2016|Actual|2016-07-26|July 26, 2016|Actual|2016-07-26||Interventional|||Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children|Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants|Completed||Phase 2|1806|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 21:35:27.513867|2018-05-31 21:35:27.513867
NCT01545362|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-01-11|2012-03-05|2012-03-06|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Effect of Preop Nutritional Status on Outcomes of Staged Bilateral Total Knee Arthroplasty|The Effect of Preop Nutritional Status on Outcomes of Staged Bilateral Total Knee Replacements Performed Within One Week|Completed|||50|Actual|Heekin Orthopedic Research Institute|||1||f||||f||||||||||2018-05-31 21:35:28.642771|2018-05-31 21:35:28.642771
NCT01545349|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-01-10|2012-03-05|2012-03-06|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|LAIV||Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine|Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine|Completed||Phase 1|30|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:35:28.750795|2018-05-31 21:35:28.750795
NCT01545336|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|2016-06-29||2016-09-20|2012-02-29|2012-03-06|Estimate|2016-06-29|2016-08-09|Estimate||||2016-09-20|2016-10-27|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|AIPH||Anastrozole in Patients With Pulmonary Arterial Hypertension|A Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial Hypertension|Completed||Phase 2|18|Actual|University of Pennsylvania|"Small sample size~No changes in echo parameters~Unclear mechanism for impact on 6MWD"|2|||f||||t||||||||||2018-05-31 21:35:28.857071|2018-05-31 21:35:28.857071
NCT01545323|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-10-18|2012-03-05|2012-03-06|Estimate|||||||2016-10-18|2016-10-19|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Gene Therapy for Netherton Syndrome|Phase I Study of Ex-vivo Lentiviral Gene Therapy for the Inherited Skin Disease Netherton Syndrome|Recruiting||Phase 1|5|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 21:35:29.290144|2018-05-31 21:35:29.290144
NCT01545310|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-09-14|2012-03-01|2012-03-06|Estimate|||||||2012-09-14|2012-09-18|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia|An Open-Label, Positron Emission Tomography (PET) Study to Evaluate the Brain 5 HT6 Receptor Occupancy by Single Doses of SLV354 in Healthy Male Subjects and Subjects With Stable Schizophrenia|Completed||Phase 1|18|Actual|Abbott||1|||f||||f||||||||||2018-05-31 21:35:29.563807|2018-05-31 21:35:29.563807
NCT01545297|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-07-05|2012-03-05|2012-03-06|Estimate|||||||2016-07-05|2016-07-07|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery|Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery: a Randomized Controlled Trial|Completed||N/A|50|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:35:29.683093|2018-05-31 21:35:29.683093
NCT01545284|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-07-23|2012-02-29|2012-03-06|Estimate|||||||2014-07-23|2014-07-24|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis|Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis|Completed||Phase 2/Phase 3|9|Actual|Innovaderm Research Inc.||1|||f||||f||||||||||2018-05-31 21:35:29.844762|2018-05-31 21:35:29.844762
NCT01545271|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-10-30|2012-02-29|2012-03-06|Estimate|||||||2014-10-30|2014-10-31|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|October 2013|Actual|2013-10-31||Interventional|CoolXenon2||Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth|Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth: A Randomised Pilot Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|32|Actual|University Hospitals Bristol NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:35:29.997063|2018-05-31 21:35:29.997063
NCT01545258|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-12-01|2012-03-05|2012-03-06|Estimate|||||||2016-12-01|2016-12-02|Estimate|March 2012||2012-03-31|December 2016|2016-12-31||||March 2013|Actual|2013-03-31||Interventional|||Exercise and Pain Sensitivity in Knee Osteoarthritis|Exercise and Changes in Pain Sensitivity in Patients With Knee Osteoarthritis|Completed||N/A|60|Actual|Frederiksberg University Hospital||2|||f||||||||||||||2018-05-31 21:35:30.164905|2018-05-31 21:35:30.164905
NCT01545245|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-12-05|2012-03-05|2012-03-06|Estimate|||||||2014-12-05|2014-12-08|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants|Cohort Study to Evaluate Effects of Prophylactic Treatment for Respiratory Syncytial (RS) Virus Infection in Respiratory Tract During Infancy on Subsequent Atopic Asthma in Preterm Infants|Completed|||343|Actual|Tokai University|||2||f||||f||||||Samples Without DNA|"~     The serum samples~   "|||2018-05-31 21:35:30.290557|2018-05-31 21:35:30.290557
NCT01545232|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|2015-04-22||2017-10-24|2012-03-05|2012-03-06|Estimate|2015-05-29|2015-06-03|Estimate||||2017-10-24|2017-11-30|Actual|August 2012||2012-08-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PROPPR||Pragmatic, Randomized Optimal Platelet and Plasma Ratios|Pragmatic, Randomized Optimal Platelet and Plasma Ratios|Completed||Phase 3|680|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 21:35:30.571279|2018-05-31 21:35:30.571279
NCT01545219|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-03-06|2012-02-29|2012-03-06|Estimate|||||||2012-03-06|2012-03-07|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|XOS||A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers|A Double-blind, Placebo-controlled, Randomized Crossover Study to Determine the Effects of Xylooligosaccharides (XOS), B. Lactis (BI07) and XOS + BI07 Upon the Gut Microbiota and Immune Response of Healthy Volunteers|Completed||N/A|44|Actual|University of Reading||4|||f||||f||||||||||2018-05-31 21:35:31.394972|2018-05-31 21:35:31.394972
NCT01545206|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|February 1997||1997-02-28|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Dose Reducing Door-to-balloon Time in ST-elevation Myocardial Infarction Cause Less Cost?|Better Quality With Less Cost? A Single Hospital Experience on Reducing Door-to-balloon Time in ST-elevation Myocardial Infarction|Completed|||215|Actual|Far Eastern Memorial Hospital|||1||f||||t||||||||||2018-05-31 21:35:31.557274|2018-05-31 21:35:31.557274
NCT01545193|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2015-03-17||2015-04-03|2012-03-05|2012-03-06|Estimate|2015-04-03|2015-04-06|Estimate||||2015-04-03|2015-04-06|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Observational|||The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade|The Effect of Age on the Incidence of Postoperative Residual Neuromuscular Blockade|Completed|||300|Actual|NorthShore University HealthSystem Research Institute|||2||f||||f||||||||||2018-05-31 21:35:31.744475|2018-05-31 21:35:31.744475
NCT01545180|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-11-21|2012-03-05|2012-03-06|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2012||2012-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|PH-HF||Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure|Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure.|Recruiting|||520|Anticipated|French Cardiology Society|||1||f||||f||||||Samples With DNA|"~     -  3 tubes of 6 blood for analysis of biomarkers~        -  2 tubes of 6 mL blood for DNA analysis~   "|||2018-05-31 21:35:32.044031|2018-05-31 21:35:32.044031
NCT01545167|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-09-14|2012-02-29|2012-03-06|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2008||2008-09-30|September 2017|2017-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|NAPS||The North American Pancreatitis Study|The North American Pancreatitis Study|Completed|||2980|Actual|University of Pittsburgh|||2||f||||t||||||Samples With DNA|"~     Blood samples and extracted biomarkers and genetic material.~   "|||2018-05-31 21:35:32.188126|2018-05-31 21:35:32.188126
NCT01545154|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-03-27|2012-03-05|2012-03-06|Estimate|||||||2014-03-27|2014-03-28|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer|Phase II Study of The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer|Completed|||17|Actual|University of Vermont Medical Center|||1||f||||||||||||||2018-05-31 21:35:32.306232|2018-05-31 21:35:32.306232
NCT01545141|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-01-24|2012-02-29|2012-03-06|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2012||2012-10-31|January 2018|2018-01-31|April 8, 2017|Actual|2017-04-08|April 8, 2016|Actual|2016-04-08||Interventional|||Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer|Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer|Terminated||Phase 1/Phase 2|23|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 21:35:32.374323|2018-05-31 21:35:32.374323
NCT01544777|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-03-23|2012-03-05|2012-03-06|Estimate|||||||2015-03-23|2015-03-25|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|751||Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study|Visual Quality Following Aspheric and Monovision Lens Implantation - a Comparative Clinical Study|Completed||N/A|42|Actual|Hoya Surgical Optics, Inc.||3|||f||||f||||||||||2018-05-31 21:35:36.375035|2018-05-31 21:35:36.375035
NCT01545128|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|January 2010|Actual|2010-01-31|||||Observational|||Impact of Pulmonary Rehabilitation on Direct Healthcare Costs in Chronic Obstructive Pulmonary Disease (COPD)|A Retrospective Case-control Study Comparing the Direrct Healthcare Costs of Conventionally Managed COPD Patients With Those Who Have Completed a Pulmonary Rehabilitation Programme|Completed|||70|Actual|East and North Hertfordshire NHS Trust|||||f||||f||||||||||2018-05-31 21:35:32.483307|2018-05-31 21:35:32.483307
NCT01545115|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-03-12|2012-02-29|2012-03-06|Estimate|||||||2012-03-12|2012-03-13|Estimate|October 2008||2008-10-31|March 2012|2012-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|AnoPalAnoVac||Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal|Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal|Completed|||410|Actual|Biomedical Research Center EPLS|||||f||||t||||||Samples Without DNA|"~     Sera, culture supernatants~   "|||2018-05-31 21:35:32.549562|2018-05-31 21:35:32.549562
NCT01545102|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-03-06|2012-02-29|2012-03-06|Estimate|||||||2012-03-06|2012-03-07|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure|Assessment of Exercise Intensity in Cardiac Rehabilitation Programmes for Patients With Chronic Heart Failure|Unknown status|Not yet recruiting||21|Anticipated|Eastbourne General Hospital|||||f||||f||||||||||2018-05-31 21:35:32.612374|2018-05-31 21:35:32.612374
NCT01545089|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2015-03-25|2012-02-29|2012-03-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Use of a Fabric Mattress Cover for Patient Comfort|Use of a Fabric Mattress Cover for Patient Comfort|Completed||N/A|174|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 21:35:32.674559|2018-05-31 21:35:32.674559
NCT01545076|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01||2017-09-20|2017-09-27|2012-03-05|2012-03-06|Estimate||||2017-09-20|2017-09-28|Actual|2017-09-27|2017-10-02|Actual|March 2012||2012-03-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)|Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study|Completed||Phase 3|172|Actual|CSL Behring||3|||f||||t||||||||||2018-05-31 21:35:32.751429|2018-05-31 21:35:32.751429
NCT01545063|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-07-18|2012-03-05|2012-03-06|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2012|Actual|2012-05-31|July 2017|2017-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|CAPANAH||CAre of Patients With PArenteral Nutrition At Home|Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate the Quality of Care for Adult Patients on Home Parenteral Nutrition (HPN)|Completed|||39|Actual|Katholieke Universiteit Leuven|||||f||||t|f|f||||||No||2018-05-31 21:35:33.41218|2018-05-31 21:35:33.41218
NCT01545050|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01||2015-07-24|2018-04-20|2012-03-05|2012-03-06|Estimate||||2015-07-24|2015-08-13|Estimate|2018-04-20|2018-04-24|Actual|June 2012||2012-06-30|April 2018|2018-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease|A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-945429 in Subjects With Moderate to Severe Crohn's Disease|Terminated||Phase 2|72|Actual|Vitaeris INC||9||due to sponsor decision|f||||t||||||||||2018-05-31 21:35:33.525635|2018-05-31 21:35:33.525635
NCT01545037|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-07-27|2012-03-05|2012-03-06|Estimate|||||||2017-07-27|2017-07-31|Actual|July 2012||2012-07-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome|Effect of Lactobacillus Acidophilus CL1285®, L. Casei LBC80R® and L. Rhamnosus CLR2® on Symptoms of Irritable Bowel Syndrome: a Double-blind, Randomized, Placebo-controlled Study|Completed||Phase 2|117|Actual|Bio-K Plus International Inc.||2|||f||||f||||||||||2018-05-31 21:35:33.794409|2018-05-31 21:35:33.794409
NCT01545024|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-13|2012-02-29|2012-03-06|Estimate|||||||2012-03-13|2012-03-14|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Observational|||Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus|Effect of DPP-IV Inhibitor on Glycemic Control and Autonomic Neuropathy in Adult Patients With Diabetes Mellitus|Unknown status|Recruiting||60|Anticipated|Nagaoka Red Cross Hospital|||1||f||||f||||||||||2018-05-31 21:35:33.889959|2018-05-31 21:35:33.889959
NCT01545011|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-09-18|2012-03-05|2012-03-06|Estimate|||||||2012-09-18|2012-09-19|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|IMT||Effects of Inspiratory Muscle Training on Dyspnea in Subjects With Chronic Obstructive Pulmonary Disease|Effects of Inspiratory Muscle Training Combined With a Pulmonary Rehabilitation Program Versus a Program of Pulmonary Rehabilitation Alone on Dyspnea: a Randomized Trial|Completed||N/A|38|Actual|University Hospital, Brest||2|||f||||f||||||||||2018-05-31 21:35:33.98432|2018-05-31 21:35:33.98432
NCT01544998|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2014-12-15||2018-02-22|2012-03-05|2012-03-06|Estimate|2015-02-17|2015-03-04|Estimate||||2018-02-22|2018-03-22|Actual|February 2012|Actual|2012-02-29|February 2018|2018-02-28|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional||Baseline analysis population description includes only those subjects who completed the study.|Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure|To Define the Role of PDEV in Mediating the Decreased GFR and Attenuated Renal Sodium and cGMP Excretory Response to Acute Saline Volume Expansion in PSD and PDD With Renal Dysfunction.|Completed||Phase 1/Phase 2|43|Actual|Mayo Clinic||2|||f||||t|t|f||||||||2018-05-31 21:35:34.09916|2018-05-31 21:35:34.09916
NCT01544985|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2015-12-21|2012-03-05|2012-03-06|Estimate|||||||2015-12-21|2015-12-22|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Trial of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Bladder Catheterization|A Randomized Double-blind Trial Comparing the Effect on Pain of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Bladder Catheterization|Completed||Phase 4|84|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 21:35:34.475489|2018-05-31 21:35:34.475489
NCT01544972|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-12-13|2012-03-05|2012-03-06|Estimate|||||||2012-12-13|2012-12-17|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants|Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen|Unknown status|Recruiting|Phase 4|80|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 21:35:34.564747|2018-05-31 21:35:34.564747
NCT01544959|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2016-10-25|2012-03-05|2012-03-06|Estimate|||||||2016-10-25|2016-10-27|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2013|Actual|2013-01-31||Interventional|PAINFree||Postoperative Analgesia Impact of Narcotic Free Anesthesia|The Impact on Postoperative Pain of Substituting Opioids by Beta Blockers for Peroperative Hemodynamic Control in Patients Undergoing Mastectomy|Active, not recruiting||N/A|84|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 21:35:34.661721|2018-05-31 21:35:34.661721
NCT01544946|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2015-12-21|2012-03-05|2012-03-06|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Trial of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Nasopharyngeal Aspiration|A Randomized Double-blind Trial Comparing the Effect on Pain of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Nasopharyngeal Aspiration|Completed||Phase 4|80|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 21:35:34.740038|2018-05-31 21:35:34.740038
NCT01544933|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|February 2011||2011-02-28|August 2011|2011-08-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||The Influence of the Ribs on the Gravity of Burst Thoracic Spine Fractures|The Influence of the Ribs on the Gravity of Burst Thoracic Spine Fractures|Completed|||2|Actual|Universidade de Passo Fundo|||2||f||||t||||||||||2018-05-31 21:35:34.809099|2018-05-31 21:35:34.809099
NCT01544920|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2016-04-22||2017-03-10|2012-03-05|2012-03-06|Estimate|2016-04-22|2016-05-30|Estimate||||2017-03-10|2017-04-10|Actual|May 2012||2012-05-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)|A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects|Completed||Phase 3|737|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:35:34.899831|2018-05-31 21:35:34.899831
NCT01544907|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-11-02|2012-02-29|2012-03-06|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2012||2012-01-31|November 2017|2017-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|DEBAPTA||Prospective Randomized Trial Comparing DEB Versus Conventional PTA for the Treatment of Hemodialysis AVF or AVG Stenoses|Prospective Randomized Trial Comparing Drug Eluting Balloon Angioplasty Versus Conventional Percutaneous Transluminal Angioplasty Balloon for the Treatment of Hemodialysis Arterio-Venous Fistula or Arterio-Venous Graft Stenoses|Completed||N/A|125|Actual|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 21:35:35.416515|2018-05-31 21:35:35.416515
NCT01544894|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-08-31|2012-02-29|2012-03-06|Estimate|||||||2012-08-31|2012-09-03|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis|Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis|Completed||Phase 4|80|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 21:35:35.508202|2018-05-31 21:35:35.508202
NCT01544881|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2013-01-24|2012-02-29|2012-03-06|Estimate|||||||2013-01-24|2013-01-25|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes|A Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Study in Subjects With Type 1 Diabetes Comparing Insulin Exposure & Response Following Inhalation of Technosphere Insulin Inhalation Powder Using the Gen2C Inhaler Vs Subcutaneous Rapid-Acting Analog|Completed||Phase 1|17|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-05-31 21:35:35.579612|2018-05-31 21:35:35.579612
NCT01544868|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-08-19|2012-03-05|2012-03-06|Estimate|||||||2014-08-19|2014-08-20|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|TEE||Total Energy Expenditure, Protein Kinetics, and Body Composition in Recovering Burn Children.|Total Energy Expenditure, Protein Kinetics and Body Composition During Recovery From Severe Burn Injury in Children.|Completed||N/A|12|Actual|Shriners Hospitals for Children||1|||f||||f||||||||||2018-05-31 21:35:35.658296|2018-05-31 21:35:35.658296
NCT01544855|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-02-27|2012-03-05|2012-03-06|Estimate|||||||2014-02-27|2014-03-03|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype?|Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype?|Completed||N/A|80|Actual|Université de Sherbrooke||1|||f||||t||||||||||2018-05-31 21:35:35.725534|2018-05-31 21:35:35.725534
NCT01544842|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2015-07-15|2012-03-05|2012-03-06|Estimate|||||||2015-07-15|2015-07-17|Estimate|August 2004||2004-08-31|December 2014|2014-12-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||Tacrolimus Ointment in Oral Lichen Planus|Comparison of Topical Tacrolimus, Triamcinolone and Placebo in the Treatment of Symptomatic Oral Lichen Planus|Terminated||N/A|28|Actual|University of Oulu||3||Lack of resources|f||||f||||||||||2018-05-31 21:35:35.783653|2018-05-31 21:35:35.783653
NCT01544829|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-11-30|2012-02-28|2012-03-06|Estimate|||||||2012-11-30|2012-12-03|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||The Acute Effect of 2 Different Serving Regimens of Theobromine on Physiological Effects|The Acute Effect of 2 Different Serving Regimens of Theobromine on Theobromine Concentration in the Blood & Physiological Effects|Completed||N/A|12|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 21:35:35.873749|2018-05-31 21:35:35.873749
NCT01544816|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2013-05-06|2012-02-29|2012-03-06|Estimate|||||||2013-05-06|2013-05-08|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluating the Effects of Snack Products on Energy||Completed||N/A|49|Actual|Mondelēz International, Inc.||3|||f||||f||||||||||2018-05-31 21:35:36.097829|2018-05-31 21:35:36.097829
NCT01544803|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||Randomized Controlled Trial of eScreen for Problematic Alcohol Use|Randomized Controlled Trial of eScreen for Problematic Alcohol Use|Completed||Phase 2|633|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 21:35:36.177261|2018-05-31 21:35:36.177261
NCT01544790|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2017-04-04|2012-03-05|2012-03-06|Estimate|||||||2017-04-04|2017-04-06|Actual|January 2012||2012-01-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ROBOT||Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy|Robot-assisted Minimally Invasive Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer. The ROBOT-trial: a Monocenter Randomized Controlled Trial.|Completed||Phase 3|112|Actual|UMC Utrecht||2|||f||||t||||||||Undecided||2018-05-31 21:35:36.283175|2018-05-31 21:35:36.283175
NCT01544764|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2013-12-16|2012-02-29|2012-03-06|Estimate|||||||2013-12-16|2013-12-18|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AFIX||Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina|Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX)|Completed||N/A|91|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 21:35:36.463091|2018-05-31 21:35:36.463091
NCT01544751|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-05-27|2012-03-05|2012-03-06|Estimate|||||||2014-05-27|2014-05-28|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin|Metformin Versus Atorvastatin in Nonalcoholic Hepatic Steatosis: a Randomized Study|Unknown status|Recruiting|N/A|150|Anticipated|University Magna Graecia||3|||f||||f||||||||||2018-05-31 21:35:36.558865|2018-05-31 21:35:36.558865
NCT01544738|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|November 2008||2008-11-30|February 2012|2012-02-29||||May 2009|Actual|2009-05-31||Interventional|||Sensory Stimulation Effect on Movement Speed in Patients With Parkinson Disease|Aponeurotic Stimulation Effect on Parkinson Bradykinesia|Completed||N/A|11|Actual|Université Libre de Bruxelles||2|||f||||||||||||||2018-05-31 21:35:36.653744|2018-05-31 21:35:36.653744
NCT01544725|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-11-30|2012-02-29|2012-03-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults|Ketamine-propofol Versus Ketamine Alone for Procedural Sedation in Adults : a Blinded, Randomized Controlled Trial|Completed||Phase 4|150|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 21:35:36.871627|2018-05-31 21:35:36.871627
NCT01544712|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|August 2004||2004-08-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Controlled Study of Stage 3 Osteonecrosis Treatment by Bone Marrow|Treatment of Stage 3 Osteonecrosis of the Femoral Head by Autologous Transplantation of Bone Marrow Cells: a Randomized, Controlled Double Blind Study|Completed||N/A|50|Actual|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 21:35:36.981307|2018-05-31 21:35:36.981307
NCT01544699|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2018-05-02|2012-03-05|2012-03-06|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2012|Actual|2012-01-31|May 2018|2018-05-31|January 2030|Anticipated|2030-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Impact of Non-invasive Brain Stimulation on Motor Recuperation|Impact of Non-invasive Brain Stimulation on Motor Recuperation|Active, not recruiting||N/A|200|Anticipated|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 21:35:37.072828|2018-05-31 21:35:37.072828
NCT01544686|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2015-12-08|2012-02-28|2012-03-06|Estimate|||||||2015-12-08|2015-12-09|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|COAT||Antimicrobial Catheter Securement Dressings for the Prevention of Cvc-related Bloodstream Infections in Cancer Patients|Chlorhexidine Containing Iv-securement Dressings for the Prevention of Central Venous Catheter-related Blood Stream Infections in Neutropenic Patients: a Randomized Trial|Completed||N/A|630|Actual|University of Cologne||2|||f||||t||||||||||2018-05-31 21:35:37.181703|2018-05-31 21:35:37.181703
NCT01544673|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-04-26|2012-02-29|2012-03-06|Estimate|||||||2012-04-26|2012-04-30|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males|An Open-label, Placebo-controlled Phase 1 Study to Evaluate the Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Male Subjects|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:35:37.333373|2018-05-31 21:35:37.333373
NCT01544660|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2014-04-15|2012-03-05|2012-03-06|Estimate|||||||2014-04-15|2014-04-16|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|Interscanner||Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research|Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research|Completed|||60|Actual|University of California, San Francisco|||2||f||||f||||||||||2018-05-31 21:35:37.463451|2018-05-31 21:35:37.463451
NCT01544647|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-08-13|2012-02-29|2012-03-06|Estimate|||||||2014-08-13|2014-08-15|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|January 2014|Actual|2014-01-31|May 2013|Actual|2013-05-31||Interventional|Nancythermal||Spa Therapy in Knee Osteoarthritis (OA): Nancy-thermal|Comparison of 2 Spa Therapy Protocols in Symptomatic Knee Osteoarthritis : a Randomised Trial|Completed||N/A|283|Actual|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 21:35:37.543171|2018-05-31 21:35:37.543171
NCT01544634|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2018-03-29|2012-02-29|2012-03-06|Estimate|||||||2018-03-29|2018-03-30|Actual|April 4, 2012|Actual|2012-04-04|March 2018|2018-03-31|May 25, 2013|Actual|2013-05-25|May 25, 2013|Actual|2013-05-25||Interventional|ANDA1||Beta Blocker Therapy in Mild to Moderate Asthmatics|Evaluation of Any Steroid Sparing Effect of Beta Blocker Therapy on Airway Hyper-responsiveness in Stable, Mild to Moderate Asthmatics|Completed||Phase 2|16|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 21:35:37.634353|2018-05-31 21:35:37.634353
NCT01544621|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2013-05-20|2012-02-29|2012-03-06|Estimate|||||||2013-05-20|2013-05-21|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|ESCAPE SMOKE||Escape Smoke Project: Non-Intervention Non-Drug Multicenter Study on the Real-life Effectiveness of Smoking Cessation in General Practice in Denmark|Escape Smoke Project: Non-Intervention Multicenter Study On the Real-Life Effectiveness of Smoking Cessation in General Practice in Denmark|Completed|||544|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:35:37.731221|2018-05-31 21:35:37.731221
NCT01544608|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2013-06-19|2012-02-29|2012-03-06|Estimate|||||||2013-06-19|2013-06-20|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|RECONNECT-S||Observe Real-life Allocation of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia|A Non- Interventional Study to Observe Real Life Usage of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia.|Completed|||1076|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 21:35:37.847258|2018-05-31 21:35:37.847258
NCT01544452|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-11-26|2012-03-05|2012-03-06|Estimate|||||||2014-11-26|2014-12-02|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Total Preoperative MR Diagnostic Evaluation Versus Standard Diagnostic Evaluation in Patients With Rectal Cancer|Prospective Randomized Study of Total Preoperative MR Diagnostic Evaluation Versus Standard Diagnostic Evaluation in Patients With Rectal Cancer|Terminated||N/A|75|Actual|Herlev Hospital||2||Lack of MR scanning capacity|f||||f||||||||||2018-05-31 21:35:42.392882|2018-05-31 21:35:42.392882
NCT01540357|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-09-26|2012-02-27|2012-02-28|Estimate|||||||2013-09-26|2013-09-27|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|January 2012|Actual|2012-01-31|October 2010|Actual|2010-10-31||Interventional|||Mindfulness-based Therapy in Chronic Tinnitus|Mindfulness-based Therapy For the Treatment of Chronic Tinnitus: A Randomized Controlled Pilot Study|Completed||N/A|36|Actual|University of Regensburg||2|||f||||f||||||||||2018-05-31 21:37:04.429653|2018-05-31 21:37:04.429653
NCT01544595|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-04-05|2012-02-29|2012-03-06|Estimate|||||||2018-04-05|2018-04-09|Actual|August 15, 2004|Actual|2004-08-15|April 2018|2018-04-30|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab|A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 4 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab|Completed||Phase 3|1150|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:35:37.994699|2018-05-31 21:35:37.994699
NCT01544582|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2016-05-24||2016-07-28|2012-02-28|2012-03-06|Estimate|2016-07-28|2016-09-16|Estimate||||2016-07-28|2016-09-16|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational||Analysis Population: All CHC genotype-1 participants included in study meeting eligibility criteria and receiving boceprevir plus peginterferon and ribavirin (PR), telaprevir plus PR, or PR alone.|Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)|An Observational Post-Authorization Safety Study (PASS) of Victrelis™ (Boceprevir) Among Chronic Hepatitis C Patients|Completed|||713|Actual|Merck Sharp & Dohme Corp.|This was a non-interventional study that collected data on both boceprevir and telaprevir treatment regimens within routine medical practice. No individual administration of any therapeutic or prophylactic agent was assigned in this protocol.||3||f||||f||||||||||2018-05-31 21:35:38.352428|2018-05-31 21:35:38.352428
NCT01544569|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-05-17|2012-02-29|2012-03-06|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2012||2012-03-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors|Endogenous DNA Transposition in Rhabdoid Tumors|Completed|||50|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:35:39.635474|2018-05-31 21:35:39.635474
NCT01544556|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Use of PrineoTM (Dermabond Protape) Skin Adhesive for Wound Closure Following Abdominoplasty|Use of PrineoTM (Dermabond Protape) Skin Adhesive for Wound Closure Following Abdominoplasty: An Open, Prospective, Controlled, Randomized Clinical Study|Completed|||1|Actual|Medical University of Graz|||2||f||||||||||||||2018-05-31 21:35:39.75519|2018-05-31 21:35:39.75519
NCT01544543|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|February 2010||2010-02-28|February 2012|2012-02-29||||||||Observational|VESALIO||Validation of HealthCare Standards in Chronic Obstructive Pulmonary Disease|Validation of HealthCare Standards in COPD|Completed|||600|Actual|Sociedad Española de Neumología y Cirugía Torácica|||1||f||||f||||||||||2018-05-31 21:35:39.870204|2018-05-31 21:35:39.870204
NCT01544530|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2018-02-05|2012-03-02|2012-03-06|Estimate|||||||2018-02-05|2018-02-07|Actual|March 2012||2012-03-31|February 2018|2018-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|COOLDonor||Cooling to Optimize Organ Life in Donor Study|Feasibility of Mild-to-moderate Therapeutic Hypothermia as an In-vivo Organ Preservation Strategy in Brain-dead Donors|Terminated||Phase 2|4|Actual|University of Pittsburgh||2||Lack of funding and other logistic reasons|f||||t||||||||||2018-05-31 21:35:39.959654|2018-05-31 21:35:39.959654
NCT01544517|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-03-05|2012-03-05|2012-03-06|Estimate|||||||2012-03-05|2012-03-06|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection|Five-day Concomitant Versus 10-day Sequential Therapy for Eradication of Helicobacter Pylori Infection: a Randomized Trial of Levofloxacin-based Regimens|Completed||Phase 3|180|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||||2018-05-31 21:35:40.049608|2018-05-31 21:35:40.049608
NCT01544504|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-05-25|2012-02-28|2012-03-06|Estimate|||||||2012-05-25|2012-05-28|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy|Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy|Withdrawn||Phase 1/Phase 2|0|Actual|ProCertus BioPharm, Inc||1||"The principal investigator withdrew from the study. The study was withdrawn because a qualified~   replacement was not available."|f||||f||||||||||2018-05-31 21:35:40.144615|2018-05-31 21:35:40.144615
NCT01544491|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-11-28|2012-03-05|2012-03-06|Estimate|||||||2017-11-28|2017-11-30|Actual|August 17, 2012|Actual|2012-08-17|November 2017|2017-11-30|October 5, 2018|Anticipated|2018-10-05|October 3, 2016|Actual|2016-10-03||Interventional|||Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients||Active, not recruiting||Phase 3|131|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:35:40.242084|2018-05-31 21:35:40.242084
NCT01544478|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|2017-06-08||2017-06-08|2012-02-29|2012-03-06|Estimate|2017-06-08|2017-07-07|Actual||||2017-06-08|2017-07-07|Actual|November 25, 2011|Actual|2011-11-25|June 2017|2017-06-30|August 27, 2016|Actual|2016-08-27|August 27, 2016|Actual|2016-08-27||Interventional|||V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)|A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women|Completed||Phase 4|1030|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|t|f|||t|||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:35:40.392172|2018-05-31 21:35:40.392172
NCT01544465|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-03-20|2012-02-28|2012-03-06|Estimate|||||||2014-03-20|2014-03-21|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Structured Physical Activity for Sleep Quality and Daytime Sleepiness in Patients With Parkinson's Disease|Effect of a Structured Physical Activity Program on Sleep Quality and Sleepiness in Parkinson's Disease|Terminated||N/A|1|Actual|Northwestern University||2||Difficulty recruiting, funding lapsed|f||||f||||||||||2018-05-31 21:35:42.148517|2018-05-31 21:35:42.148517
NCT01544439|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-05-15|2012-03-05|2012-03-06|Estimate|||||||2012-05-15|2012-05-17|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Occlusal Splint and Counseling to Temporomandibular Disorder|The Efficacy of Occlusal Stabilization Appliance Associated to Counseling in the Management of Myofascial Pain Chronic and in the Improvement of the Quality of Life of Patients With Temporomandibular Disorders|Unknown status|Recruiting|Phase 3|40|Anticipated|Federal University of Juiz de Fora||2|||f||||t||||||||||2018-05-31 21:35:42.545298|2018-05-31 21:35:42.545298
NCT01544426|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2014-12-27|2012-03-05|2012-03-06|Estimate|||||||2014-12-27|2014-12-30|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Office Hysteroscopy and Endometrial Snip Improve Intrauterine Insemination Outcome|Does Office Hysteroscopy and Endometrial Snip Improve IUI Outcome? : a Randomized Controlled Trial|Completed||Phase 3|332|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 21:35:42.737524|2018-05-31 21:35:42.737524
NCT01544413|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-12-14|2012-02-28|2012-03-05|Estimate|||||||2014-12-14|2014-12-16|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Quality Control Study of Laparoscopic Sentinel Node Biopsy in Early Gastric Cancer|Quality Control Study for Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy and Stomach Preserving Surgery in Early Gastric Cancer|Completed||N/A|112|Actual|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 21:35:42.846|2018-05-31 21:35:42.846
NCT01544400|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-08-05|2012-02-28|2012-03-05|Estimate|||||||2016-08-05|2016-08-08|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|TCA SHN||Description and Evaluation of Eating Disorders in Elite Athletes (TCA SHN)|Description and Evaluation of Eating Disorders in Elite Athletes|Terminated|||386|Actual|Nantes University Hospital|||||f||||||||||||||2018-05-31 21:35:42.942763|2018-05-31 21:35:42.942763
NCT01544387|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-02-26|2012-02-28|2012-03-05|Estimate|||||||2014-02-26|2014-02-28|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|BRAT||Preterm Premature Rupture of Membranes (PPROM): Bed Rest Versus Activity Trial|PPROM: Bed Rest Versus Activity Trial (BRAT)|Completed||N/A|36|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 21:35:43.981227|2018-05-31 21:35:43.981227
NCT01544374|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-06-07|2012-02-28|2012-03-05|Estimate|||||||2016-06-07|2016-06-09|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities|Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities|Completed||N/A|198|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 21:35:44.106555|2018-05-31 21:35:44.106555
NCT01544361|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2014-06-23||2014-06-23|2012-03-02|2012-03-05|Estimate|2014-06-23|2014-07-23|Estimate||||2014-06-23|2014-07-23|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers|A Phase 1, Randomized, Placebo-controlled, Single-dose Study to Evaluate the Safety of MEDI7814 in Adult Volunteers|Completed||Phase 1|125|Actual|MedImmune LLC|Analyses of PK parameters and immunogenicity were not performed as the clinical development of MEDI7814 had been discontinued because the indication was no longer being pursued.|5|||f||||f||||||||||2018-05-31 21:35:44.21884|2018-05-31 21:35:44.21884
NCT01544348|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2014-12-18||2014-12-18|2012-03-02|2012-03-05|Estimate|2014-12-18|2014-12-30|Estimate||||2014-12-18|2014-12-30|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Safety population included all participants who received any amount of investigational product and had safety data available.|A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL|A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE >= 30 IU/mL|Completed||Phase 1|295|Actual|MedImmune LLC||8|||f||||t||||||||||2018-05-31 21:35:44.65537|2018-05-31 21:35:44.65537
NCT01544335|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2018-03-20|2012-02-28|2012-03-05|Estimate|||||||2018-03-20|2018-03-21|Actual|December 2011||2011-12-31|March 2018|2018-03-31||||June 2018|Anticipated|2018-06-30||Observational|||Evaluation of BIS for Quantification of Lymphedema|Evaluation of the Validity of BIS as a Tool for Quantification of Lymphedema Through Comparison With Perometry and Self-Report|Recruiting|||200|Anticipated|Massachusetts General Hospital|||1||f||||t||||||||||2018-05-31 21:35:45.919355|2018-05-31 21:35:45.919355
NCT01544322|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2015-06-17|2012-03-02|2012-03-05|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|ME-344-001||Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors|Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors|Completed||Phase 1|24|Anticipated|MEI Pharma, Inc.|||||f||||t||||||||||2018-05-31 21:35:46.020194|2018-05-31 21:35:46.020194
NCT01544309|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2014-11-10||2015-03-04|2012-02-28|2012-03-05|Estimate|2015-03-04|2015-03-17|Estimate||||2015-03-04|2015-03-17|Estimate|March 2012||2012-03-31|March 2015|2015-03-31||||June 2014|Actual|2014-06-30||Interventional|LISTEN|Full analysis set (FAS) - All participants who received at least 1 dose of open-label study drug except the ones who had no HbA1c or non-HDL-C data or a protocol deviation of the administration of study drugs.|LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts|Study on Effect of Highly Potent Statins on Lipid Lowering Effect and Glucose Metabolism in Hypercholesterolemia Patients With Diabetes Mellitus|Completed||N/A|1049|Actual|Listen Trial Group||2|||f||||||||||||||2018-05-31 21:35:46.244614|2018-05-31 21:35:46.244614
NCT01544296|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-10-08|2012-03-02|2012-03-05|Estimate|||||||2013-10-08|2013-10-10|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Comparative Study of KHK6188|Phase II Study of KHK6188 (A Placebo-controlled, Double Blind, Crossover Study of KHK6188 in Postherpetic Neuralgia)|Completed||Phase 2|42|Anticipated|Kyowa Hakko Kirin Co., Ltd||3|||f||||f||||||||||2018-05-31 21:35:48.516595|2018-05-31 21:35:48.516595
NCT01544283|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-03-05|2012-02-28|2012-03-05|Estimate|||||||2012-03-05|2012-03-06|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Interventional|||Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome|Heated Lidocaine Patch Compared to Subacromial Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome, A Pilot|Unknown status|Recruiting|Phase 2|60|Anticipated|Injury Care Medical Center||2|||f||||f||||||||||2018-05-31 21:35:48.753|2018-05-31 21:35:48.753
NCT01544270|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-04-24|2012-02-28|2012-03-05|Estimate|||||||2013-04-24|2013-04-25|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|AivoPro2||The Effects of Dietary Factors on Physiological Subjective Stress Responses|The Effects of Dietary Factors on Physiological Subjective Stress Responses in Cronically Stressed Subjects: a Randomised Clinical Trial|Completed||N/A|101|Actual|Helsinki University||3|||f||||f||||||||||2018-05-31 21:35:48.876684|2018-05-31 21:35:48.876684
NCT01544257|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-02-28|2012-02-28|2012-03-05|Estimate|||||||2012-02-28|2012-03-05|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Osteopathic Manipulative Treatment on Length of Stay in Preterms|Effect of OMT on Length of Stay in a Population of Preterm Infants: RCT Study|Completed||Phase 4|100|Actual|European Institute for Evidence Based Osteopathic Medicine||2|||f||||t||||||||||2018-05-31 21:35:48.978226|2018-05-31 21:35:48.978226
NCT01544244|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-06-02|2012-03-02|2012-03-05|Estimate|||||||2016-06-02|2016-06-03|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Global Shoulder Concept (GSC) Method Versus Classic Physical Therapy for Shoulder Tendinitis|Comparison of the Global Shoulder Concept (GSC) Method Versus Classic Physical Therapy for Shoulder Tendinitis: a Prospective, Randomized Study|Terminated||N/A|40|Actual|Centre Hospitalier Universitaire de Nīmes||2||Inclusion curve too slow.|f||||f||||||||||2018-05-31 21:35:49.08473|2018-05-31 21:35:49.08473
NCT01544231|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2015-12-11|2012-02-28|2012-03-05|Estimate|||||||2015-12-11|2015-12-14|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis|Plasma Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels During Emergency Management of Rhabdomyolysis: Predicting Renal Failure|Completed|||197|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 21:35:49.330871|2018-05-31 21:35:49.330871
NCT01544218|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2017-06-19|2012-02-28|2012-03-05|Estimate|||||||2017-06-19|2017-06-21|Actual|September 2012||2012-09-30|June 2017|2017-06-30|June 30, 2016|Actual|2016-06-30|July 20, 2015|Actual|2015-07-20||Observational|||Validating NIAAA Screen Guide in YCMC|Validating NIAAA's Brief Screening Guide in Youth With Chronic Medical Conditions|Completed|||521|Actual|Boston Children’s Hospital|||1||f||||f||||||||||2018-05-31 21:35:49.497508|2018-05-31 21:35:49.497508
NCT01544205|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-12-13|2012-02-28|2012-03-05|Estimate|||||||2016-12-13|2016-12-15|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|NFD||Neurofeedback as a Treatment Tool for Depression|fMRI Based Neurofeedback as a Treatment Method for Depression|Completed||N/A|43|Actual|Cardiff University||2|||f||||||||||||||2018-05-31 21:35:49.616931|2018-05-31 21:35:49.616931
NCT01544192|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2012-03-02|2012-03-02|2012-03-05|Estimate|||||||2012-03-02|2012-03-05|Estimate|April 2008||2008-04-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|November 2009|Actual|2009-11-30||Interventional|||Impact of Oral Versatile Antioxidants on Glaucoma Progression|Impact of Oral Versatile Antioxidants on Glaucoma Progression:Comparative Early Results|Completed||Phase 3|60|Actual|Bagcilar Training and Research Hospital||5|||f||||f||||||||||2018-05-31 21:35:49.728556|2018-05-31 21:35:49.728556
NCT01544179|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-04-29||2018-02-20|2012-03-02|2012-03-05|Estimate|2016-01-19|2016-02-15|Estimate||||2018-02-20|2018-03-15|Actual|March 15, 2012|Actual|2012-03-15|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|May 5, 2014|Actual|2014-05-05||Interventional|IMPRESS||A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone|A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progressed on First Line IRESSA|Active, not recruiting||Phase 3|265|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 21:35:49.96404|2018-05-31 21:35:49.96404
NCT01544166|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2014-11-18||2015-06-03|2012-02-28|2012-03-05|Estimate|2014-11-18|2014-11-26|Estimate||||2015-06-03|2015-07-03|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)|Open-label, Multicenter, Pharmacokinetic, and Safety Study in Children (Term Newborn Infants to 23 Months of Age) Undergoing a Contrast-enhanced MRI With an Intravenous Injection of 0.1 mmol/kg BW Gadobutrol 1.0 M|Completed||Phase 1|44|Actual|Bayer|Results for Typical PK parameters were provided by the median value of the population together with the min-max range (individual PK). Typical PK parameter as described in study protocol was reflected by the Median PK parameter in the study report.|1|||f||||f||||||||||2018-05-31 21:35:51.515937|2018-05-31 21:35:51.515937
NCT01544153|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2016-10-25||2017-10-10|2012-02-28|2012-03-05|Estimate|2016-12-19|2017-02-10|Actual||||2017-10-10|2017-11-13|Actual|February 2012||2012-02-29|October 2017|2017-10-31|August 2017|Actual|2017-08-31|December 2015|Actual|2015-12-31||Interventional||Includes baseline characteristics of participants who completed participation in the full study.|Improving Adherence to Web-Based Cessation Programs: A Social Network Approach|Improving Adherence to Web-Based Cessation Programs: A Social Network Approach|Completed||N/A|5292|Actual|Truth Initiative||4|||f||||f||||||||No|No current plans, but interested researchers may contact Principal Investigator for additional discussion.|2018-05-31 21:35:53.378533|2018-05-31 21:35:53.378533
NCT01544140|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-08-26|2012-02-28|2012-03-05|Estimate|||||||2016-08-26|2016-08-29|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Vandetanib||Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination With a Single Dose of 800-mg Vandetanib (CAPRELSA)|Completed||Phase 1|16|Actual|Sanofi||1|||f||||||||||||||2018-05-31 21:35:54.410641|2018-05-31 21:35:54.410641
NCT01544127|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-03-14|2012-03-02|2012-03-05|Estimate|||||||2018-03-14|2018-03-15|Actual|July 30, 2012|Actual|2012-07-30|March 2018|2018-03-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|||Motivational Interviewing to Prevent Suicide in High Risk Veterans|Motivational Interviewing to Prevent Suicide in High Risk Veterans|Completed||N/A|132|Actual|VA Office of Research and Development||3|||f||||t|f|f|||f|||Undecided||2018-05-31 21:35:54.510057|2018-05-31 21:35:54.510057
NCT01544114|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2017-08-04|2016-02-11|2017-09-07|2012-02-28|2012-03-05|Estimate|2017-09-07|2017-10-04|Actual|2016-02-11|2016-03-14|Estimate|2017-09-07|2017-10-04|Actual|April 2012||2012-04-30|September 2017|2017-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)|A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)|Completed||Phase 4|46|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||f||||||||||2018-05-31 21:35:54.663634|2018-05-31 21:35:54.663634
NCT01544101|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-10-18|2012-03-02|2012-03-05|Estimate|||||||2012-10-18|2012-10-19|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Nutritional Intervention for Arthritis|A Nutritional Intervention for Arthritis|Completed||N/A|32|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 21:35:55.746016|2018-05-31 21:35:55.746016
NCT01544088|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-01-30|2012-02-28|2012-03-05|Estimate|||||||2018-01-30|2018-02-01|Actual|July 1, 2012|Actual|2012-07-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|August 23, 2017|Actual|2017-08-23||Interventional|GCBT||Group CBT for PTSD|Group CBT for Chronic PTSD: RCT With Veterans|Active, not recruiting||N/A|198|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|Data will be made available through Freedom of Information Act.|2018-05-31 21:35:55.850262|2018-05-31 21:35:55.850262
NCT01544075|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-06-02|2012-03-02|2012-03-05|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2012||2012-02-29|June 2015|2015-06-30||||September 2015|Anticipated|2015-09-30||Interventional|||Efficacy of Pain Neurophysiology Education in Combination With Psychologic Inoculation in Chronic Whiplash|Efficacy of Pain Neurophysiology Education in Combination With Psychologic Inoculation in Chronic Whiplash Associated Disorders : a Double-blind Randomised Controlled Trial|Unknown status|Enrolling by invitation|Early Phase 1|36|Anticipated|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 21:35:55.996272|2018-05-31 21:35:55.996272
NCT01544062|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2015-11-30||2016-05-12|2012-03-02|2012-03-05|Estimate|2016-05-12|2016-06-21|Estimate||||2016-05-12|2016-06-21|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|CarDolMev||IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery|Efficacy of Perioperative Intravenous Acetaminophen as an Adjunct Analgesic in Cardiac Surgery Patients|Completed||Phase 4|68|Actual|University of Washington|"several subjects received intraoperative hydromorphone while others only received intraoperative fentanyl~significantly greater proportion of females in the placebo group"|2|||f||||t||||||||No||2018-05-31 21:35:56.122194|2018-05-31 21:35:56.122194
NCT01544049|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-10-24|2012-03-02|2012-03-05|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2011||2011-12-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study|Patients Salpingectomy as a Method of Ovarian Cancer Prevention: A Descriptive Study|Active, not recruiting|||24|Actual|University of Washington|||1||f||||f||||||||||2018-05-31 21:35:56.918143|2018-05-31 21:35:56.918143
NCT01544036|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-12-18|2012-03-02|2012-03-05|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2012||2012-02-29|December 2013|2013-12-31||||February 2014|Anticipated|2014-02-28||Interventional|||Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram|Monitoring Renal Blood Flow Using Contrast Enhanced Ultrasound in Predicting Acute Kidney Injury After Exposure to Iodinated Contrast Agent|Unknown status|Recruiting|N/A|150|Anticipated|University of Virginia||1|||f||||||||||||||2018-05-31 21:35:57.190997|2018-05-31 21:35:57.190997
NCT01544023|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2015-11-30||2016-12-26|2012-03-02|2012-03-05|Estimate|2016-12-26|2017-02-16|Actual||||2016-12-26|2017-02-16|Actual|January 2010||2010-01-31|December 2016|2016-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||TiLoop® Bra for Breast Reconstruction|Multicenter Observational Study of Implant Based Breast Reconstruction Using a Titanium-coated Polypropylene Mesh|Completed|||207|Actual|University of Rostock|||1||f||||f||||||||||2018-05-31 21:35:57.602032|2018-05-31 21:35:57.602032
NCT01544010|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-05-26|2012-02-28|2012-03-05|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|STAR||Optimal TTM Tailoring for Population Cessation|Optimal TTM Tailoring for Population Cessation|Completed||N/A|3006|Actual|University of Rhode Island||5|||f||||t||||||||||2018-05-31 21:35:58.114979|2018-05-31 21:35:58.114979
NCT01543997|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-11-16|2012-03-02|2012-03-05|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Benefits of a Novel Sleep-focused Mind-body Program on Gulf War Illness (GWI) Symptoms|Investigating Clinical Benefits of a Novel Sleep-focused Mind-body Program on Gulf War Illness (GWI) Symptoms: An Exploratory Randomized Controlled Trial|Completed||Phase 2|75|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 21:35:58.438967|2018-05-31 21:35:58.438967
NCT01543984|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-11-19|2012-03-02|2012-03-05|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|||"Efficacy of Tailored Physical Activity in Health Care Workers"|"Efficacy of Tailored Physical Activity on the Number of Sick Days: a Randomized Controlled Trial in Health Care Workers That Have Experienced Pain Related to the Spine or Upper Body"|Completed||Phase 1/Phase 2|54|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 21:35:58.795768|2018-05-31 21:35:58.795768
NCT01543971|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2016-08-29|2012-02-27|2012-03-05|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)|Phase I Double-Blinded Comparison Study Using TXA127 and/or Neupogen to Increase Peripheral Blood Stem Cell (CD34+) Counts|Completed||Phase 1|18|Actual|Tarix Pharmaceuticals||3|||f||||f||||||||||2018-05-31 21:35:59.197826|2018-05-31 21:35:59.197826
NCT01543958|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|2013-09-23||2013-12-04|2012-02-29|2012-03-05|Estimate|2013-09-23|2013-11-25|Estimate||||2013-12-04|2013-12-30|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Sevelamer for Reducing Endotoxemia and Immune Activation|Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study|Completed||Phase 2|40|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-05-31 21:36:00.110287|2018-05-31 21:36:00.110287
NCT01543945|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-07-29|2012-03-02|2012-03-05|Estimate|||||||2012-07-29|2012-07-31|Estimate|March 2008||2008-03-31|July 2012|2012-07-31||||December 2011|Actual|2011-12-31||Interventional|||Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy||Completed||Phase 2|340|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 21:36:02.328111|2018-05-31 21:36:02.328111
NCT01543932|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-12-10|2012-03-02|2012-03-05|Estimate|||||||2013-12-10|2013-12-11|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|TRIPLETE RESET||High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients|Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation|Completed||Phase 3|81|Actual|University of Roma La Sapienza||3|||f||||t||||||||||2018-05-31 21:36:02.653865|2018-05-31 21:36:02.653865
NCT01543919|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28||2014-10-15|2014-10-15|2012-03-02|2012-03-05|Estimate||||2014-10-15|2014-10-27|Estimate|2014-10-15|2014-10-27|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide|A Phase 2B, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide|Completed||Phase 2|730|Actual|Pfizer||6|||f||||t||||||||||2018-05-31 21:36:02.950837|2018-05-31 21:36:02.950837
NCT01543906|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-12-11|2012-03-01|2012-03-05|Estimate|||||||2014-12-11|2014-12-15|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)|An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)|Completed||Phase 1|5|Actual|QLT Inc.||1|||f||||f||||||||||2018-05-31 21:36:03.564388|2018-05-31 21:36:03.564388
NCT01543893|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2013-06-27|2012-03-02|2012-03-05|Estimate|||||||2013-06-27|2013-06-28|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|IRMA05||Effect of Personal Versus Video Instruction in Elastic Resistance Exercise on Technical Execution (IRMA05)|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|Completed||N/A|38|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 21:36:03.851796|2018-05-31 21:36:03.851796
NCT01543880|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-04-28|2012-02-28|2012-03-05|Estimate|||||||2015-04-28|2015-04-29|Estimate|July 2003||2003-07-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|NordiWIN||Safety and Efficacy of Long-term Somatropin Treatment in Adults|Non-interventional Study of Safety and Efficacy of Long-term Somatropin Treatment in Adults|Completed|||752|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:36:04.000955|2018-05-31 21:36:04.000955
NCT01543867|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2015-03-27|2012-02-28|2012-03-05|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2001||2001-01-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|GrowthWIN II||Safety and Efficacy of Long-term Somatropin Treatment in Children|Non-interventional Study of the Safety and Efficacy of Long-term Somatropin Treatment in Children (GrowthWIN II / GrowthWIN II SGA)|Completed|||5442|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:36:04.097133|2018-05-31 21:36:04.097133
NCT01543854|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2014-08-04|2012-03-02|2012-03-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure|A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Hemodynamic Responses to Intravenous RLX030 Infusion in Subjects With Acute Heart Failure|Completed||Phase 2|71|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:36:04.293712|2018-05-31 21:36:04.293712
NCT01543841|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-04-16|2012-02-27|2012-03-05|Estimate|||||||2015-04-16|2015-04-17|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in Blood|A Laboratory Evaluation of Tie-2 Expressing Monocytes (TEMs) in Healthy Volunteers and Patients With Advanced Cancer|Completed|||20|Actual|University Health Network, Toronto|||2||f||||f||||||None Retained|"~     One tube of whole blood~   "|||2018-05-31 21:36:04.460786|2018-05-31 21:36:04.460786
NCT01543828|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2013-03-19||2013-05-06|2012-03-02|2012-03-05|Estimate|2013-03-19|2013-05-03|Estimate||||2013-05-06|2013-05-10|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Phase IV, Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory, Single-dose Crossover Study With Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 4|40|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:36:04.649545|2018-05-31 21:36:04.649545
NCT01543815|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2012-03-04|2012-03-02|2012-03-05|Estimate|||||||2012-03-04|2012-03-06|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|February 2009|Actual|2009-02-28||Interventional|WELL-ME||Well-Being Therapy by Personalized Mobile Technology Program for Psychological Distress and Promote Healthy Behaviors|Well-Being Therapy for Psychological Distress and Enhancing Healthy Behaviors With Personalized Mobile Technology in Cardiac Patients: a Randomized Controlled-trial Study Protocol|Completed||N/A|400|Actual|University of Bergamo||3|||f||||t||||||||||2018-05-31 21:36:04.948585|2018-05-31 21:36:04.948585
NCT01543802|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2015-05-26|2012-02-27|2012-03-05|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|June 2018|Anticipated|2018-06-30|June 2015|Anticipated|2015-06-30||Interventional|NOPASS||Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma|A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma|Recruiting||Phase 2|35|Anticipated|Heidelberg University||1|||f||||f||||||||||2018-05-31 21:36:05.03812|2018-05-31 21:36:05.03812
NCT01543789|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2015-06-02|2012-03-02|2012-03-05|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|FUN||The Flemish Umbilical Nitinol Mesh Trial, a Multicenter Trial|The Flemish Umbilical Nitinol Mesh Trial, a Multicenter Randomized Controlled Trial.|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 21:36:05.215429|2018-05-31 21:36:05.215429
NCT01543776|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2017-06-19|2012-03-02|2012-03-05|Estimate|||||||2017-06-19|2017-06-21|Actual|January 2012||2012-01-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|||Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer|A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer|Active, not recruiting||Phase 2|72|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 21:36:05.304334|2018-05-31 21:36:05.304334
NCT01543763|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2017-07-28|2012-02-27|2012-03-05|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2012||2012-05-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors|Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors|Active, not recruiting||Phase 1|52|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:36:05.558148|2018-05-31 21:36:05.558148
NCT01543750|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2014-02-07|2012-03-02|2012-03-05|Estimate|||||||2014-02-07|2014-02-10|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|4AP in EA2||4-Aminopyridine in Episodic Ataxia Type 2|Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2|Unknown status|Enrolling by invitation|Phase 2|20|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:36:05.67503|2018-05-31 21:36:05.67503
NCT01543737|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-02-11|2012-03-02|2012-03-05|Estimate|||||||2016-02-11|2016-02-12|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee|Single-blind Randomised Pragmatic Trial Comparing the Effectiveness of Two Hyaluronic Acid Viscosupplements, DUROLANE® (Single Injection) Versus HYALGAN® (Three Injections) for Symptomatic Tibiofemoral Osteoarthritis of the Knee.|Terminated||N/A|290|Actual|Bioventus LLC||2||post transfer of company ownership from Smith & Nephew to Bioventus LLC|f||||f||||||||Undecided||2018-05-31 21:36:05.797779|2018-05-31 21:36:05.797779
NCT01543724|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-02-08|2012-03-02|2012-03-05|Estimate|||||||2018-02-08|2018-02-09|Actual|June 1, 2015|Anticipated|2015-06-01|February 2018|2018-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder|A Multimodal Brain Imaging Study to Investigate Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder: Glycogen Synthase Kinase 3β Single Nucleotide Polymorphisms and Gray Matter Volume Increase Following Lithium Treatment in Bipolar Disorder|Withdrawn||Phase 4|0|Actual|Ewha Womans University||1||The research project has been cancelled before any participants were enrolled.|f||||||||||||||2018-05-31 21:36:05.916348|2018-05-31 21:36:05.916348
NCT01543711|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2013-06-05|2012-03-02|2012-03-05|Estimate|||||||2013-06-05|2013-06-06|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Long Term Follow-up of Persistent Pain, Sensory Disturbances and Lymphedema After Breast Cancer Treatment|Long Term Follow-up of Persistent Pain, Sensory Disturbances and Lymphedema After Breast Cancer Treatment|Completed|||2411|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 21:36:06.005844|2018-05-31 21:36:06.005844
NCT01543698|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2018-05-25|2012-03-02|2012-03-05|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2012||2012-05-31|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|September 14, 2017|Actual|2017-09-14||Interventional|||A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors|A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|179|Anticipated|Array BioPharma||2|||f||||f||||||||||2018-05-31 21:36:06.072717|2018-05-31 21:36:06.072717
NCT01543685|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2013-02-27||2014-01-02|2012-03-02|2012-03-05|Estimate|2013-11-21|2013-12-19|Estimate||||2014-01-02|2014-02-04|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Study of Indomethacin Capsules to Treat Pain Following Bunionectomy|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Indomethacin [Test] Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy|Completed||Phase 3|462|Actual|Iroko Pharmaceuticals, LLC||5|||f||||f||||||||||2018-05-31 21:36:06.305503|2018-05-31 21:36:06.305503
NCT01543672|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-03-12|2012-03-02|2012-03-05|Estimate|||||||2018-03-12|2018-03-13|Actual|November 22, 2011|Actual|2011-11-22|October 2017|2017-10-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|VOLUMES||Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously|VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study|Completed||Phase 1/Phase 2|60|Anticipated|The Netherlands Cancer Institute||2|||f||||t|f|f||||||||2018-05-31 21:36:07.360374|2018-05-31 21:36:07.360374
NCT01543659|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2018-02-23|2012-03-02|2012-03-05|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2012||2012-02-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer|A Phase I/II Study of Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|77|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:36:07.44605|2018-05-31 21:36:07.44605
NCT01543646|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-03-02|2012-03-02|2012-03-05|Estimate|||||||2012-03-02|2012-03-05|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|RIAL||Multiparametric MR for Rapid Imaging Assessment of the Liver|Rapid Imaging Assessment of the Liver Using Multiparametric Magnetic Resonance|Unknown status|Recruiting||60|Anticipated|University of Oxford|||1||f||||f||||||Samples With DNA|"~     Fresh frozen plasma, frozen serum, and whole blood for DNA analysis~   "|||2018-05-31 21:36:07.523623|2018-05-31 21:36:07.523623
NCT01543633|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-01-10|2012-03-02|2012-03-05|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2005||2005-08-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||EEG Studies of Induction and Recovery From Propofol Induced General Anesthesia|Electroencephalogram Studies of Induction and Recovery From Propofol Induced General Anesthesia|Active, not recruiting||N/A|20|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:36:07.598704|2018-05-31 21:36:07.598704
NCT01543620|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2014-12-08|2012-03-02|2012-03-05|Estimate|||||||2014-12-08|2014-12-09|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis|Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis|Unknown status|Recruiting||150|Anticipated|Foundation for the National Institutes of Health|||2||f||||f||||||Samples Without DNA|"~     urine and blood~   "|||2018-05-31 21:36:07.680008|2018-05-31 21:36:07.680008
NCT01543607|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2017-03-13||2017-03-13|2012-03-02|2012-03-05|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|February 2012|Actual|2012-02-29|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Endoscopic Therapy of Malignant Bile Duct Strictures|Endoscopic Therapy of Malignant Bile Duct Strictures: A Pilot Study|Terminated||N/A|1|Actual|Massachusetts General Hospital||1||Lack of enrollment|f||||t||||||||||2018-05-31 21:36:07.785229|2018-05-31 21:36:07.785229
NCT01543594|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-03-16|2012-03-02|2012-03-05|Estimate|||||||2018-03-16|2018-03-20|Actual|January 2009||2009-01-31|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|May 2020|Anticipated|2020-05-31||Observational|GISEA||Italian Registry of Arthritis on Biologic Therapy|Study of Efficacy and Safety of Biologic Drugs in the Therapy of Rheumatoid Arthritis and Spondyloarthritis|Recruiting|||10000|Anticipated|Gruppo Italiano Studio Early Arthritis|||||f||||t||||||||||2018-05-31 21:36:08.10304|2018-05-31 21:36:08.10304
NCT01543581|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2013-09-19||2014-09-24|2012-02-27|2012-03-05|Estimate|2014-09-24|2014-09-26|Estimate||||2014-09-24|2014-09-26|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|Erivedge||Vismodegib for Treatment of Basal Cell Carcinoma|Placebo-controlled, Double Blind Study to Assess Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery (MMS)|Completed||Phase 2|3|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 21:36:08.200052|2018-05-31 21:36:08.200052
NCT01543568|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2016-02-05||2016-11-03|2012-03-02|2012-03-05|Estimate|2016-11-03|2017-01-02|Estimate||||2016-11-03|2017-01-02|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|TURF||Study for Recalcitrant Age Related Macular Degeneration|AflibercepT for Subjects Who Are Incomplete Responders to mUltiple Intravitreal Injections of Ranibizumab, Anti-VegF (The TURF Study)|Completed||Phase 4|46|Actual|Greater Houston Retina Research||1|||f||||t||||||||||2018-05-31 21:36:08.38794|2018-05-31 21:36:08.38794
NCT01543555|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-12-30|2012-03-02|2012-03-05|Estimate|||||||2015-12-30|2015-12-31|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LOAD||Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose|Multicenter Randomized Controlled Trial of Loading Dose Statins for the Prevention of Cardiovascular Complications in High-Risk Non-Cardiac Surgery|Completed||Phase 3|648|Actual|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 21:36:08.631921|2018-05-31 21:36:08.631921
NCT01543542|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-05-05|2012-02-27|2012-03-05|Estimate|||||||2016-05-05|2016-05-06|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|TOMOSIBII||A Phase II Multi-institutional Study Assessing Simultaneous In-field Boost Helical Tomotherapy for 1-3 Brain Metastases|A Phase II Multi-institutional Study Assessing Simultaneous In-Field Boost Helical Tomotherapy for 1-3 Brain Metastases|Completed||Phase 2|91|Actual|Lawson Health Research Institute||1|||f||||t||||||||||2018-05-31 21:36:08.749178|2018-05-31 21:36:08.749178
NCT01543529|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2017-05-09|2012-02-28|2012-03-05|Estimate|||||||2017-05-09|2017-05-10|Actual|February 28, 2012|Actual|2012-02-28|May 2017|2017-05-31|June 4, 2012|Actual|2012-06-04|June 4, 2012|Actual|2012-06-04||Interventional|||A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers|A Single Center, Randomized, Double-blind, Single-dose, Four Period, Crossover Study to Investigate Pharmacodynamics and Pharmacokinetics of RO4917838 Alone or With Concomitant Administration of Alcohol in Healthy Volunteers|Completed||Phase 1|25|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:36:08.821956|2018-05-31 21:36:08.821956
NCT01543516|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-06-29|2012-03-02|2012-03-05|Estimate|||||||2012-06-29|2012-07-02|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||Cell Distribution in Induced Sputum in Patients With Asthma|Cell Distribution in Induced Sputum in Healthy Subjects and Patients With Asthma After Different Techniques for Sputum Induction|Completed|||40|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, and sputum~   "|||2018-05-31 21:36:08.880764|2018-05-31 21:36:08.880764
NCT01543503|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|2016-01-12||2016-01-12|2012-02-28|2012-03-05|Estimate|2016-01-12|2016-02-10|Estimate||||2016-01-12|2016-02-10|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational||Baseline characteristics were described for the safety population. All enrolled participants who received at least one dose of a TNF inhibitor or tocilizumab during the study were included in the safety population.|An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|A Global Comparative Observational Study In Rheumatoid Arthritis (RA) Patients Who Are Treated With A TNF Inhibitor Or Tocilizumab As The First Biologic Therapy|Completed|||1225|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:36:08.994636|2018-05-31 21:36:08.994636
NCT01543490|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2018-04-06|2012-03-02|2012-03-05|Estimate|||||||2018-04-06|2018-04-10|Actual|March 30, 2018|Actual|2018-03-30|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|ISV-305||Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects|A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis|Recruiting||Phase 3|550|Anticipated|InSite Vision||2|||f||||f|t|f||||||||2018-05-31 21:36:11.67683|2018-05-31 21:36:11.67683
NCT01543477|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-03-14|2012-02-27|2012-03-05|Estimate|||||||2018-03-14|2018-03-15|Actual|July 2010|Actual|2010-07-31|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|PASCO II||Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia|Post-authorisation Safety Cohort Observation Of Retacrit (tm) (Epoetin Zeta) Administered Subcutaneously For The Treatment Of Renal Anaemia (Pasco Ii)|Active, not recruiting|||4502|Actual|Pfizer|||1||f||||f||||||Samples Without DNA|"~     Pre-dose serum samples~   "|||2018-05-31 21:36:11.975405|2018-05-31 21:36:11.975405
NCT01543464|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2018-03-16|2012-03-02|2012-03-05|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2012||2012-05-31|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients|Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma|Terminated||Phase 2|41|Actual|Herlev Hospital||1||Diminished rectruitment|f||||t||||||||||2018-05-31 21:36:12.485461|2018-05-31 21:36:12.485461
NCT01543451|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21||2014-02-27|2014-02-27|2012-02-27|2012-03-05|Estimate||||2014-02-27|2014-03-26|Estimate|2014-02-27|2014-03-26|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea|Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846)Administered s.c. in the Prevention of Chemotherapy Induced Diarrhea(CID)|Completed||Phase 2|138|Actual|Helsinn Healthcare SA||2|||f||||t||||||||||2018-05-31 21:36:12.622867|2018-05-31 21:36:12.622867
NCT01543438|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-01-02|2012-03-02|2012-03-05|Estimate|||||||2013-01-02|2013-01-04|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Using Point-of-Care Video Prescriptions to Improve Aftercare Following Discharge From a Pediatric Emergency Department|Optimizing Emergency Aftercare With Mobile Video Prescriptions|Unknown status|Recruiting|N/A|5000|Anticipated|healthEworks LLC||2|||f||||t||||||||||2018-05-31 21:36:12.740882|2018-05-31 21:36:12.740882
NCT01543425|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-28|||2013-05-13|2012-03-02|2012-03-05|Estimate|||||||2013-05-13|2013-05-14|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Observational|HORMONES||Adrenocorticotropic Axis and Neuropathic Pain|Status of the Hypothalamic-pituitary-gonado- Adrenal Axis (HHSG) in Patients With Neuropathic Pain|Completed|||120|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||None Retained|"~     Day of inclusion: Blood sample for analysis of several hormones (cortisol, ACTH, SHBG, total~     testostérone et S-DHEA, βœstradiol et progestérone for women, LH, FSH).~      Day +1: salivary samples (at wake-up, 30 minutes after wake-up, at lunch, at 06:00 pm and~     before sleep).~      Day +2: salivary samples (at wake-up, 30 minutes after wake-up).~   "|||2018-05-31 21:36:12.842389|2018-05-31 21:36:12.842389
NCT01543412|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2012-03-02|2012-03-02|2012-03-05|Estimate|||||||2012-03-02|2012-03-05|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|SLAP||Second Line Chemotherapy for Advanced Pancreatic Cancer|Folfiri as Second-Line Chemotherapy for Advanced Pancreatic Cancer. A GISCAD Phase II Study|Completed||Phase 2|50|Actual|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||1|||f||||f||||||||||2018-05-31 21:36:12.939043|2018-05-31 21:36:12.939043
NCT01543399|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-04-02|2012-03-02|2012-03-05|Estimate|||||||2015-04-02|2015-04-03|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TDILA||Vascular Effect of Tibolone in the Brachial Artery|Vascular Effect of Tibolone Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery|Completed||N/A|60|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 21:36:13.063758|2018-05-31 21:36:13.063758
NCT01543386|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-07-04|2012-02-27|2012-03-05|Estimate|||||||2014-07-04|2014-07-08|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|CURCUMIN||Effects of Curcumin on Vascular Reactivity|Effects of Curcumin Loading Dose on Vascular Reactivity of Healthy Middle-aged Smokers|Completed||Phase 1/Phase 2|21|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 21:36:13.30894|2018-05-31 21:36:13.30894
NCT01543373|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2018-04-27|2012-02-27|2012-03-05|Estimate|||||||2018-04-27|2018-04-30|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|April 2014|Actual|2014-04-30|August 2013|Actual|2013-08-31||Interventional|DEMONSTRATE||Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS|Randomized Comparison Between a DES and a BMS to Assess Neointimal Coverage by OCT Evaluation|Completed||N/A|38|Actual|CID - Carbostent & Implantable Devices||2|||f||||f||||||||||2018-05-31 21:36:13.522778|2018-05-31 21:36:13.522778
NCT01543360|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-03-25|2012-03-02|2012-03-05|Estimate|||||||2015-03-25|2015-03-26|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Axillary Versus Subclavian Vein Strategies for Central Venous Catheterization Under Continuous Ultrasound Guidance|Comparison of Axillary Versus Subclavian Vein Strategies for Central Venous Catheterization Under Continuous Ultrasound Guidance: a Prospective, Randomized, Non-inferiority Study|Completed||N/A|132|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 21:36:13.685196|2018-05-31 21:36:13.685196
NCT01543347|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-01-28|2012-03-02|2012-03-05|Estimate|||||||2013-01-28|2013-01-29|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TEA||Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae|Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL) Producing and AmpC Hyperproducing Enterobacteriaceae in United Kingdom|Withdrawn||Phase 4|0|Actual|Belpharma s.a.||1||No patient has been included in 9 months because of strict incl/excl criteria|f||||f||||||||||2018-05-31 21:36:13.826174|2018-05-31 21:36:13.826174
NCT01543334|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-03-25|2012-02-27|2012-03-02|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|DALI||Antibiotic Concentrations Among Critically Ill Patients|Antibiotic Concentrations Among Critically Ill Patients|Completed|||98|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 21:36:14.030672|2018-05-31 21:36:14.030672
NCT01543321|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2017-09-11|2012-02-27|2012-03-02|Estimate|||||||2017-09-11|2017-09-12|Actual|May 14, 2012|Actual|2012-05-14|September 2017|2017-09-30|August 2017|Actual|2017-08-31|May 18, 2017|Actual|2017-05-18||Interventional|Xeladys||Xenazine in Late Dyskinetic Syndrome With Neuroleptics|Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial|Completed||Phase 3|54|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 21:36:14.296169|2018-05-31 21:36:14.296169
NCT01543308|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-05-16|2012-02-27|2012-03-02|Estimate|||||||2013-05-16|2013-05-20|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|October 2013|Anticipated|2013-10-31||Observational|||The Alteration of HDL Protein Composition in Patients With Coronary Heart Disease Before and After Statins Treatment|Phase 1 Study of Coronary Heart Disease Proteomics Research|Unknown status|Active, not recruiting||400|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||2||f||||f||||||Samples With DNA|"~     frozen in -80C~   "|||2018-05-31 21:36:14.472015|2018-05-31 21:36:14.472015
NCT01543295|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-07-27|2012-03-01|2012-03-02|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Evaluation of the Performance of Chembio's DPP(R) Syphilis Screen & Confirm Rapid Test System|Qualitative Evaluation of the DPP Syphilis Screen and Confirm Rapid Test to Detect the Presence of Antibodies Against Non-Treponemal and Treponema Pallidum Antigens in Fingerstick Whole Blood, Venous Whole Blood, Serum and Plasma Specimens.|Withdrawn|||0|Actual|Chembio Diagnostic Systems, Inc.|||3||f||||t||||||||||2018-05-31 21:36:14.55656|2018-05-31 21:36:14.55656
NCT01543282|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-08-02|2012-02-27|2012-03-02|Estimate|||||||2017-08-02|2017-08-03|Actual|December 2011||2011-12-31|February 2013|2013-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Endoscopic Ultrasonography (EUS) Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles|Randomized Controlled Study Comparing Endoscopic Ultrasonography Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles in Solid Lesions|Completed||N/A|120|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 21:36:14.679134|2018-05-31 21:36:14.679134
NCT01543269|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-11-20|2012-03-01|2012-03-02|Estimate|||||||2015-11-20|2015-11-24|Estimate|February 2010||2010-02-28|November 2015|2015-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers|A Randomized, Double Blind, Placebo Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYT1, a Selective Thyroid Receptor (TR) ß Agonist, Following the Oral Administrations in Healthy Volunteers.|Terminated||Phase 1|24|Actual|Cadila Healthcare Limited||2||Safety concerns|f||||t||||||||||2018-05-31 21:36:14.860762|2018-05-31 21:36:14.860762
NCT01543256|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2018-02-06|2012-02-27|2012-03-02|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2012||2012-09-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|||WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study|A Multi-Center, Prospective, Randomized Study Comparing Removable, Self-Expanding Metal Stents to Plastic Stents for the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis|Recruiting||Phase 4|164|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 21:36:14.959697|2018-05-31 21:36:14.959697
NCT01543243|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-06-11|2012-02-27|2012-03-02|Estimate|||||||2016-06-11|2016-06-14|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control|Application of Whole-body Vibration With Stochastic Resonance in Frail Elderly: The Effects on Postural Control: a Pilot Study|Completed||Phase 2|30|Actual|Bern University of Applied Sciences||2|||f||||f||||||||||2018-05-31 21:36:15.107974|2018-05-31 21:36:15.107974
NCT01543230|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2014-04-07|2012-02-27|2012-03-02|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||CoMplete™ Acetabular Hip System|Ceramic on Metal Total Hip System, CoMplete™ Acetabular Hip System|Terminated||N/A|58|Actual|DePuy Orthopaedics||1||Sponsor withdrew PMA|f||||f||||||||||2018-05-31 21:36:15.213825|2018-05-31 21:36:15.213825
NCT01543217|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-10-06|2012-02-27|2012-03-02|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Respiratory Disease Management|Use of a Respiratory Care Practitioner Disease Management (RCP-DM) Program for Patients Hospitalized With COPD|Completed||N/A|428|Actual|Barnes-Jewish Hospital||2|||f||||t||||||||||2018-05-31 21:36:15.320188|2018-05-31 21:36:15.320188
NCT01543204|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2016-05-18||2017-12-05|2012-02-27|2012-03-02|Estimate|2016-05-18|2016-06-27|Estimate||||2017-12-05|2017-12-29|Actual|February 1, 2012|Actual|2012-02-01|December 2017|2017-12-31|May 29, 2015|Actual|2015-05-29|May 29, 2015|Actual|2015-05-29||Interventional|||Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab|Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab|Terminated||Phase 4|64|Actual|Amgen||1||Business decision due to slow enrollment|f||||f||||||||||2018-05-31 21:36:15.474224|2018-05-31 21:36:15.474224
NCT01543191|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-07-18|2012-03-01|2012-03-02|Estimate|||||||2013-07-18|2013-07-19|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis|A Phase 1 Dose-escalation Study TO Evaluate the Safety and Tolerability of PUR118 and Placebo in Subjects With CF|Completed||Phase 1|10|Actual|Pulmatrix Inc.||2|||f||||f||||||||||2018-05-31 21:36:16.526803|2018-05-31 21:36:16.526803
NCT01543178|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2015-06-15||2017-12-08|2012-03-01|2012-03-02|Estimate|2015-06-15|2015-07-08|Estimate||||2017-12-08|2017-12-12|Actual|February 2012||2012-02-29|December 2017|2017-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|TARGET3|Baseline results were summarized for the safety population, defined as patients who received at least 1 dose of study drug. Results are presented for patients in the open-label period only (1943) and for patients who eventually were randomized to rifaximin (329) or placebo (308) (ie, participated in both open-label and double-blind periods).|Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study|A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)|Completed||Phase 3|2583|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||f||||||||||2018-05-31 21:36:16.672637|2018-05-31 21:36:16.672637
NCT01543165|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-12-13|2012-03-01|2012-03-02|Estimate|||||||2012-12-13|2012-12-17|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic|A Single Center, Prospective Randomized Double-blind Trial: Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic|Unknown status|Recruiting|Phase 4|111|Anticipated|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 21:36:17.602012|2018-05-31 21:36:17.602012
NCT01543152|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-10-06|2012-03-01|2012-03-02|Estimate|||||||2017-10-06|2017-10-10|Actual|December 2011||2011-12-31|October 2017|2017-10-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T|A Phase I, Open-Label Study to Assess the Effect of Escalating Doses of Cyclophosphamide on the Engraftment of SB-728-T in Aviremic HIV-Infected Subjects on HAART|Completed||Phase 1/Phase 2|26|Actual|Sangamo Therapeutics||5|||f||||t||||||||||2018-05-31 21:36:17.926301|2018-05-31 21:36:17.926301
NCT01543139|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-02-08|2012-02-27|2012-03-02|Estimate|||||||2018-02-08|2018-02-09|Actual|December 1, 2015|Anticipated|2015-12-01|February 2018|2018-02-28|April 30, 2017|Anticipated|2017-04-30|April 30, 2017|Anticipated|2017-04-30||Interventional|||Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression|A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-Containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression|Withdrawn||Phase 2|0|Actual|Ewha Womans University||3||The research project has been cancelled before any participants were enrolled.|f||||||||||||||2018-05-31 21:36:18.133981|2018-05-31 21:36:18.133981
NCT01543126|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-07-24|2012-02-27|2012-03-02|Estimate|||||||2013-07-24|2013-07-26|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer|A Prospective Study Assessing the Correlation Between Disease Prognosis and the Level of IL-6 and IL-8 Level in Blood and Pleural Effusion Before and After Chemotherapy in Patients With Metastatic Breast Cancer|Terminated|||9|Actual|Fudan University|||1|it's too slow to enroll suitable patients into this study|f||||f||||||Samples With DNA|"~     pleural effusion~   "|||2018-05-31 21:36:18.271687|2018-05-31 21:36:18.271687
NCT01543113|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-02-21|2012-03-01|2012-03-02|Estimate|||||||2014-02-21|2014-02-24|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|March 2012|Actual|2012-03-31||Interventional|KitMel||cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project|cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project|Completed||N/A|288|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 21:36:18.53288|2018-05-31 21:36:18.53288
NCT01543100|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2014-01-03|2012-03-01|2012-03-02|Estimate|||||||2014-01-03|2014-01-06|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PACMoG||Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy|Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy|Completed||N/A|60|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 21:36:19.129545|2018-05-31 21:36:19.129545
NCT01543087|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2018-04-30|2012-02-27|2012-03-02|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2012|Actual|2012-09-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose|A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086|Completed||Phase 3|698|Actual|Pfizer||1|||f||||t|t|f||||||||2018-05-31 21:36:19.53997|2018-05-31 21:36:19.53997
NCT01543074|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2015-06-01||2015-08-10|2012-03-01|2012-03-02|Estimate|2015-08-10|2015-09-10|Estimate||||2015-08-10|2015-09-10|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Dietary Histone Deacetylase Inhibitors (HDAC)|Dietary Histone Deacetylase (HDAC) Inhibitors|Terminated||N/A|23|Actual|Texas A&M University|Early termination (23/80) due to small numbers of subjects recruited.|4||Poor recruitment|f||||f||||||||||2018-05-31 21:36:20.147653|2018-05-31 21:36:20.147653
NCT01543061|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-09-26|2012-02-27|2012-03-02|Estimate|||||||2013-09-26|2013-09-27|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints|Evaluation of the Effect of Repeated Usage of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints|Completed||Phase 4|35|Anticipated|Optometric Technology Group Ltd||3|||f||||f||||||||||2018-05-31 21:36:21.543556|2018-05-31 21:36:21.543556
NCT01543048|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2017-08-22|2012-03-01|2012-03-02|Estimate|||||||2017-08-22|2017-08-24|Actual|March 6, 2012|Actual|2012-03-06|August 2017|2017-08-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Observational|SUIVICOL||Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization|Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization: Prospective Study With Virological Follow-up on 24 Months (SUIVICOL)|Terminated|||106|Actual|University Hospital, Bordeaux|||1|Lack of recruitment|f||||f||||||Samples With DNA|"~     Cervical samples~   "|||2018-05-31 21:36:22.000296|2018-05-31 21:36:22.000296
NCT01543035|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-12-11|2012-03-01|2012-03-02|Estimate|||||||2013-12-11|2013-12-12|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|ETRALL||Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs|Phase III Prospective Multicentric Trial Evaluating Etravirine for HIV Infected Patients in Need of Lipid Lowering Drugs: the ETRALL Trial|Completed||Phase 3|34|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 21:36:22.826828|2018-05-31 21:36:22.826828
NCT01543022|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-05-01|2012-03-01|2012-03-02|Estimate|||||||2013-05-01|2013-05-03|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|Symphony||Symphony: The Implantable Counter Pulsation Device (CPD) Safety and Feasibility Trial|First in Man Study - a Prospective, Multicenter, Single Arm Trial to Investigate the Safety and Feasibility of the Symphony Device|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Abiomed Inc.||1|||f||||t||||||||||2018-05-31 21:36:23.132837|2018-05-31 21:36:23.132837
NCT01543009|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2015-10-28|2012-03-01|2012-03-02|Estimate|||||||2015-10-28|2015-10-29|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|October 2015|Actual|2015-10-31||Interventional|||Use of Local Warming in Children Venipuncture|Use of Local Warming in Children to Facilitate Venipuncture. A Randomized Controlled Trial.|Suspended||Early Phase 1|72|Anticipated|University of Florence||2||Difficulty in recruiting|f||||t||||||||||2018-05-31 21:36:23.354971|2018-05-31 21:36:23.354971
NCT01542983|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2013-02-05|2012-03-01|2012-03-02|Estimate|||||||2013-02-05|2013-02-06|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy|Feasibility of Prophylactic Treatment of Sleep/Fatigue Before and During Chemotherapy for Breast Cancer|Completed||N/A|10|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:36:23.598389|2018-05-31 21:36:23.598389
NCT01542970|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-02|2012-03-01|2012-03-02|Estimate|||||||2012-03-02|2012-03-05|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PROOM-3||Can Supplementation With Lactobacillus Reuteri and Omega-3 Fatty Acids During Pregnancy and Lactation Reduce the Risk of Allergic Disease in Infancy?|Combined Dietary Supplementation With Lactobacillus Reuteri and Omega-3 PUFA During Pregnancy and Postnatally in Relation to Development of IgE-associated Disease During Infancy|Unknown status|Recruiting|N/A|496|Anticipated|Ostergotland County Council, Sweden||4|||f||||t||||||||||2018-05-31 21:36:24.005051|2018-05-31 21:36:24.005051
NCT01542957|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|2016-10-25||2017-02-17|2012-03-01|2012-03-02|Estimate|2016-10-25|2016-12-19|Estimate||||2017-02-17|2017-03-22|Actual|November 2011||2011-11-30|February 2017|2017-02-28|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention|Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention|Completed||N/A|128|Actual|University of Barcelona||2|||f||||f||||||||||2018-05-31 21:36:24.195134|2018-05-31 21:36:24.195134
NCT01542944|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2016-04-19|2012-03-01|2012-03-02|Estimate|||||||2016-04-19|2016-04-20|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||TevaGastrim for Stem Cell Mobilization Sibling Donors|TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Completed||Phase 2|24|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 21:36:24.842077|2018-05-31 21:36:24.842077
NCT01542931|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2017-08-16|2012-03-01|2012-03-02|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2008||2008-01-31|February 2012|2012-02-29|December 31, 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma|Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma|Completed||Phase 2/Phase 3|256|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 21:36:24.919999|2018-05-31 21:36:24.919999
NCT01542918|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-01-25|2012-03-01|2012-03-02|Estimate|||||||2018-01-25|2018-01-29|Actual|December 17, 2012|Actual|2012-12-17|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|April 7, 2016|Actual|2016-04-07||Interventional|||Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma|Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma|Active, not recruiting||Phase 1|14|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:36:25.124907|2018-05-31 21:36:25.124907
NCT01542905|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2015-05-23|2012-02-26|2012-03-02|Estimate|||||||2015-05-23|2015-05-27|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Stress Relief Effect of Korean Red Ginseng|Effects of Korean Red Ginseng on Stress Relief and Cognitive and Mental Function Enhancement Using Neuroimaging: Double-Blind, Randomized, Placebo-Controlled Clinical Trial|Completed||N/A|51|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:36:25.215878|2018-05-31 21:36:25.215878
NCT01542008|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-11-16|2012-02-24|2012-03-01|Estimate|||||||2017-11-16|2017-11-20|Actual|April 2012||2012-04-30|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|July 2017|Actual|2017-07-31||Interventional|CAE RCT||Treatment Adherence Enhancement in Bipolar Disorder|Treatment Adherence Enhancement in Bipolar Disorder|Active, not recruiting||N/A|184|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 21:36:39.354563|2018-05-31 21:36:39.354563
NCT01542892|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2014-11-14|2012-03-01|2012-03-02|Estimate|||||||2014-11-14|2014-11-18|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study)|Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study)|Completed||N/A|150|Actual|Tufts University||3|||f||||f||||||||||2018-05-31 21:36:25.288351|2018-05-31 21:36:25.288351
NCT01542879|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2018-04-17|2012-03-01|2012-03-02|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2012||2012-02-29|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Pilot Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer|Development of Radiation Free Whole Body MR Imaging Technique for Staging of Children With Cancer.|Recruiting||N/A|100|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 21:36:25.509597|2018-05-31 21:36:25.509597
NCT01542866|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2016-11-16|2012-03-01|2012-03-02|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)|A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-test Visual Function in Patients With AMD Treated With Ranibizumab|Completed||Phase 4|160|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:36:25.656494|2018-05-31 21:36:25.656494
NCT01542853|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-02-15|2012-03-01|2012-03-02|Estimate|||||||2013-02-15|2013-02-18|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|||||Observational|||The Value of PET/CT in Diagnosing Residual Disease in Patients With Spinal Infection|Preliminary Study. The Value of 18F-FDG PET/CT Compared to MRI in Diagnosing Residual Disease in Patients With Spondylodiscitis|Suspended|||10|Anticipated|Odense University Hospital||||problems with recruitment and funding|f||||||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:36:25.795473|2018-05-31 21:36:25.795473
NCT01542840|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2014-03-20|2012-02-27|2012-03-02|Estimate|||||||2014-03-20|2014-03-21|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Onset Time of Nerve Block: A Comparison of Two Injection Locations in Patients Having Lower Leg/ Foot Surgery|Onset Time of Ultrasound-Guided Popliteal Sciatic Nerve Block: Comparing Circumferential Injection of Local Anesthetic to Injection That Separates the Nerve in Its Two Components|Unknown status|Not yet recruiting||76|Anticipated|Ochsner Health System|||||f||||f||||||||||2018-05-31 21:36:25.86436|2018-05-31 21:36:25.86436
NCT01542827|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-09-22|2012-02-27|2012-03-02|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|IRMA04||Acute Effect of Topical Menthol on Neck Pain|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|Terminated||N/A|20|Anticipated|National Research Centre for the Working Environment, Denmark||2||Lack of resources to perform the study|f||||f||||||||||2018-05-31 21:36:25.948129|2018-05-31 21:36:25.948129
NCT01542814|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2013-10-23|2012-03-01|2012-03-02|Estimate|||||||2013-10-23|2013-10-25|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|3DM||Collection of FUJIFILM's 3Dimensional Mammograms|Acquisition of Mammography Images for Clinical Evaluation of FUJIFILM 3Dimensional Mammography|Completed|||600|Actual|Fujifilm Medical Systems USA, Inc.|||2||f||||f||||||||||2018-05-31 21:36:26.088663|2018-05-31 21:36:26.088663
NCT01542801|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2016-12-27|2012-03-01|2012-03-02|Estimate|||||||2016-12-27|2016-12-28|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|July 2015|Actual|2015-07-31||Interventional|||Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention|Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients|Completed||Phase 4|124|Actual|Korea University||2|||f||||t||||||||||2018-05-31 21:36:26.172558|2018-05-31 21:36:26.172558
NCT01542788|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2014-01-06||2014-05-08|2012-03-01|2012-03-02|Estimate|2014-01-06|2014-02-17|Estimate||||2014-05-08|2014-05-19|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|POSITRON|Participants in the Safety Analysis Set (randomized and received at least 1 dose of study drug) were analyzed for baseline characteristics.|Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 HCV Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon|Completed||Phase 3|278|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:36:26.404814|2018-05-31 21:36:26.404814
NCT01542775|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-03-01|2012-03-01|2012-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|January 2010||2010-01-31|February 2012|2012-02-29||||December 2011|Actual|2011-12-31||Interventional|||Effects of Exercise on sRAGE Levels and Cardiometabolic Risk Factors||Completed||N/A|80|Actual|Korea University||2|||f||||||||||||||2018-05-31 21:36:28.837759|2018-05-31 21:36:28.837759
NCT01542762|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-10-10|2012-03-01|2012-03-02|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|Pot-Cast||Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation|Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation: Determining the Balance Between Benefits and Risks|Completed||N/A|1500|Actual|Leiden University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 21:36:29.059598|2018-05-31 21:36:29.059598
NCT01542749|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-03-01|2012-03-01|2012-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|August 2010|Actual|2010-08-31||Observational|||Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer|Pilot Research Study to Asses Total Body Albumin Levels|Completed|||20|Actual|Daxor Corporation|||||f||||t||||||||||2018-05-31 21:36:29.178136|2018-05-31 21:36:29.178136
NCT01542736|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2017-09-19|2012-03-01|2012-03-02|Estimate|||||||2017-09-19|2017-09-21|Actual|May 2007||2007-05-31|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)|Feasibility of Using Concurrent Carboplatin and Reduced Dose Craniospinal Radiation (24Gy) for Metastatic Medulloblastoma, High-Risk Supratentorial PNET and Metastatic PNET|Completed||Phase 2|8|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 21:36:29.32687|2018-05-31 21:36:29.32687
NCT01541995|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2013-09-27|2012-02-29|2012-03-01|Estimate|||||||2013-09-27|2013-09-30|Estimate|April 2012||2012-04-30|September 2013|2013-09-30||||August 2013|Actual|2013-08-31||Observational|||Evaluation of Contrast Medium Enhanced Post-mortem CT in Virtual Autopsy||Completed|||50|Actual|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||Samples Without DNA|"~     Histology~   "|||2018-05-31 21:36:39.450336|2018-05-31 21:36:39.450336
NCT01542723|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-10-10|2012-03-01|2012-03-02|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|Pot-Kast||Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy|Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks|Completed||N/A|1500|Actual|Leiden University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 21:36:29.467821|2018-05-31 21:36:29.467821
NCT01542710|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-03-01|2012-03-01|2012-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Bimatoprost/Timolol Versus Travoprost/Timolol|Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study|Completed||N/A|80|Actual|Kasr El Aini Hospital||1|||f||||f||||||||||2018-05-31 21:36:29.572406|2018-05-31 21:36:29.572406
NCT01542697|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-02-27|2012-02-27|2012-03-02|Estimate|||||||2012-02-27|2012-03-02|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Effect of Intraperitoneal Nebulisation of Magnesium Sulphate for Analgesia Following Laparoscopic Cholecystectomy|Phase IV Recruiting|Unknown status|Recruiting|Phase 4|60|Anticipated|B.P. Koirala Institute of Health Sciences||2|||f||||f||||||||||2018-05-31 21:36:29.647569|2018-05-31 21:36:29.647569
NCT01542684|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2014-03-28||2014-03-28|2012-03-01|2012-03-02|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)|Phase II Study of Azacytidine Followed by GM-CSF in Patients With Low- or Intermediate-1- Risk Myelodysplastic Syndrome (MDS)|Terminated||Phase 2|8|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-05-31 21:36:29.751408|2018-05-31 21:36:29.751408
NCT01542671|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2016-03-31|2012-03-01|2012-03-02|Estimate|||||||2016-03-31|2016-04-04|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|CTL||Tailored Lifestyle Intervention in Obese Adults Within Primary Care Practice - Choose to Lose|Tailored Lifestyle Intervention in Obese Adults Within Primary Care Practice|Completed||N/A|200|Actual|Memorial Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 21:36:29.959792|2018-05-31 21:36:29.959792
NCT01542658|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2012-03-01|2012-03-01|2012-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Comparison of Robot-assisted Laparoscopic Myomectomy With Traditional Laparoscopic Myomectomy||Completed|||42|Actual|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 21:36:30.078484|2018-05-31 21:36:30.078484
NCT01542645|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|2014-03-26||2014-09-23|2012-03-01|2012-03-02|Estimate|2014-04-25|2014-05-26|Estimate||||2014-09-23|2014-10-02|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|November 2013|Actual|2013-11-30||Interventional|||The Effect of Choice of Intraoperative Opioid on Postoperative Pain|The Effect of Choice of Intraoperative Opioid on Postoperative Pain|Completed||Phase 4|164|Actual|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 21:36:30.152766|2018-05-31 21:36:30.152766
NCT01542632|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2014-12-31||2017-11-17|2012-03-01|2012-03-02|Estimate|2014-12-31|2015-01-09|Estimate||||2017-11-17|2017-11-21|Actual|February 1, 2012|Actual|2012-02-01|November 2017|2017-11-30|January 10, 2014|Actual|2014-01-10|January 1, 2014|Actual|2014-01-01||Interventional|||A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers|A Randomized, Phase 1b Study to Investigate the Safety and Immunogenicity of Various Schedules of Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers Between the Ages of 18 - 45 Years|Completed||Phase 1|140|Actual|Takeda||6|||f||||f||||||||||2018-05-31 21:36:30.435098|2018-05-31 21:36:30.435098
NCT01542619|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-26|||2017-04-19|2012-02-26|2012-03-02|Estimate|||||||2017-04-19|2017-04-21|Actual|March 2012||2012-03-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers|A Randomized, Placebo-controlled, Single Center, 5 Cohort Dose Escalation Trial to Investigate Safety and Pharmacokinetics of rVIIa-FP (CSL689) in Comparison to Placebo in Healthy Male Human Volunteers|Completed||Phase 1|40|Actual|CSL Behring||2|||f||||||||||||||2018-05-31 21:36:31.687507|2018-05-31 21:36:31.687507
NCT01542606|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-03-01|2012-03-01|2012-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2012||2012-03-31|November 2011|2011-11-30|November 2012|Anticipated|2012-11-30|September 2012|Anticipated|2012-09-30||Interventional|||Performance Proof of Product Developed to Detect Abnormal Vaginal pH|Performance Proof of The Norma-Sense Gen 3 - Wearing Study|Unknown status|Not yet recruiting|Phase 3|256|Anticipated|Common Sense||1|||f||||t||||||||||2018-05-31 21:36:31.785123|2018-05-31 21:36:31.785123
NCT01542593|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-04-29|2012-03-01|2012-03-02|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|URO-Y-2||Evaluating Ureteral Length Using Computed Tomography (CT)|Evaluation of Ureteral Length Measurement by Computed Tomography (CT) to Actual Ureteral Length Measured by Ureteral Catheterization|Completed||N/A|53|Actual|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 21:36:31.91971|2018-05-31 21:36:31.91971
NCT01542580|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-02-08|2012-02-27|2012-03-02|Estimate|||||||2018-02-08|2018-02-09|Actual|March 2012||2012-03-31|February 2018|2018-02-28|December 2029|Anticipated|2029-12-31|December 2021|Anticipated|2021-12-31||Observational|||A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee|A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee|Enrolling by invitation|||255|Anticipated|Zimmer Biomet|||5||f||||f||||||||No||2018-05-31 21:36:32.112244|2018-05-31 21:36:32.112244
NCT01542567|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-05-20|2012-03-01|2012-03-02|Estimate|||||||2012-05-20|2012-05-22|Estimate|May 2012||2012-05-31|May 2012|2012-05-31||||May 2014|Anticipated|2014-05-31||Interventional|DIC-2011||Efficacy of Diclofenac BCG Irrigations|Efficacy of Diclofenac Suppositories in Prevention of Immediate Side Effects of BCG Bladder Irrigations. A Double Blind Placebo Controlled Randomized Study|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Carmel Medical Center||2|||f||||f||||||||||2018-05-31 21:36:32.23805|2018-05-31 21:36:32.23805
NCT01542554|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-08-22|2012-02-27|2012-03-02|Estimate|||||||2012-08-22|2012-08-23|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effect of Low Glycaemic Index Diet on Blood Glucose Control in Chinese Type 2 Diabetic Patients|Effect of Low Glycaemic Index Diet on Blood Glucose Control in Chinese Type 2 Diabetic Patients: Randomized Controlled Trial|Unknown status|Recruiting|N/A|44|Anticipated|Hospital Authority, Hong Kong||2|||f||||f||||||||||2018-05-31 21:36:32.34603|2018-05-31 21:36:32.34603
NCT01542541|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2015-12-18||2017-11-15|2012-02-27|2012-03-02|Estimate|2015-12-18|2016-01-27|Estimate||||2017-11-15|2017-12-13|Actual|July 2011||2011-07-31|November 2017|2017-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans|A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans|Completed||N/A|68|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 21:36:32.488951|2018-05-31 21:36:32.488951
NCT01542528|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2016-09-08||2018-01-12|2012-03-01|2012-03-02|Estimate|2017-07-28|2017-09-25|Actual||||2018-01-12|2018-01-17|Actual|March 2012||2012-03-31|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|IBBS||Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)|Integrated Brain, Body and Social Intervention (IBBS) for Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|117|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:36:32.782004|2018-05-31 21:36:32.782004
NCT01542515|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-07-24|2012-03-01|2012-03-02|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Allograft Meniscal Arthroplasty for the Treatment of Basal Joint Arthritis of the Thumb|Allograft Meniscal Arthroplasty for the Treatment of Basal Joint Arthritis of the Thumb|Completed|||22|Actual|William Beaumont Hospitals|||1||f||||f||||||||||2018-05-31 21:36:33.628665|2018-05-31 21:36:33.628665
NCT01542502|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2014-08-19||2016-12-12|2012-03-01|2012-03-02|Estimate|2016-03-04|2016-04-07|Estimate||||2016-12-12|2017-02-06|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||This is a cross-over trial, so all patients have been treated with anakinra and with placebo at different times.|Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction|Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction|Completed||N/A|12|Actual|Virginia Commonwealth University|This is a pilot study to estimate the effects of targeted anti-inflammatory treatment on aerobic exercise capacity in patients with Heart Failure and Preserved Ejection Fraction. All findings should therefore be considered hypothesis generating.|2|||f||||f||||||||||2018-05-31 21:36:33.813515|2018-05-31 21:36:33.813515
NCT01542489|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-01-30|2012-02-24|2012-03-02|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2006||2006-10-31|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos|An Observational 3 Months Study to Evaluate the Effect of Insulin Levemir® on Glycaemic Control, Weight and Incidence of Hypoglycaemic Events in Insulin Treated Subjects With Type 1 or Type 2 Diabetes|Completed|||480|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 21:36:34.056141|2018-05-31 21:36:34.056141
NCT01542476|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-03-02|2012-02-24|2012-03-02|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2006||2006-08-31|March 2016|2016-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|CONFIDENCE||The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction|An Observational Study in Dutch Type 1 and Type 2 Diabetes Patients: The Impact of Initiation of/Switching to Levemir® on Emotional Well-being, Insulin Perceptions and Treatment Satisfaction - CONFIDENCE (Clinical ObservatioNs oF Levemir® In Dutch ExperieNCE)|Completed|||299|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:36:34.153239|2018-05-31 21:36:34.153239
NCT01542463|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-03-02|2012-02-24|2012-03-02|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2004||2004-09-30|March 2016|2016-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes|Levemir®: the Physiological Basal Insulin. Documentation of Safety Aspects, Glycaemic Control and Weight|Completed|||4464|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:36:34.244316|2018-05-31 21:36:34.244316
NCT01542450|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-01-26|2012-02-24|2012-03-02|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2002||2002-08-31|January 2017|2017-01-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes|A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single s.c. Doses of NN304 (Insulin Detemir) and NPH Human Insulin in Japanese Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|23|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:36:34.331666|2018-05-31 21:36:34.331666
NCT01542437|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-03-01|2012-02-24|2012-03-02|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2012||2012-01-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2014|Actual|2014-06-30||Interventional|NSCLC||Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer|Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2|Active, not recruiting||Phase 2|66|Actual|Instituto Nacional de Cancerologia de Mexico||1|||f||||t||||||||No||2018-05-31 21:36:34.424404|2018-05-31 21:36:34.424404
NCT01542424|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-01-30|2012-02-24|2012-03-02|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2006||2006-03-31|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia|Completed|||1889|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 21:36:34.538319|2018-05-31 21:36:34.538319
NCT01542411|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-25|||2012-03-01|2012-03-01|2012-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|April 2008||2008-04-30|February 2012|2012-02-29||||||||Observational|||Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment||Completed|||520|Actual|Yazd Medical University|||3||f||||t||||||||||2018-05-31 21:36:34.615946|2018-05-31 21:36:34.615946
NCT01542398|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-03-01|2012-03-01|2012-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Interventional|||A Family-based, Resilience-focused Intervention for War-affected Communities in North-eastern Democratic Republic of Congo|Title: Is a Family-based, Life Skills Focused Intervention Effective in Reducing Psychological Distress and Stigma and Improving Inter-personal Relations and Functioning Among Former LRA Abductees and Other War-affected Children in Their Community in Dungu, the Democratic Republic of Congo?|Unknown status|Enrolling by invitation|Phase 1|120|Anticipated|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 21:36:34.684646|2018-05-31 21:36:34.684646
NCT01542385|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-08-28|2012-03-01|2012-03-02|Estimate|||||||2017-08-28|2017-08-29|Actual|April 2014||2014-04-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|November 2017|Anticipated|2017-11-30||Interventional|PRIMACY||Primary Reperfusion Secondary Stenting Trial|Immediate vs. Delayed Stenting After Primary Percutaneous Reperfusion in ST Elevation Myocardial Infarction|Active, not recruiting||N/A|307|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 21:36:34.786415|2018-05-31 21:36:34.786415
NCT01541982|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2015-06-16|2012-02-24|2012-03-01|Estimate|||||||2015-06-16|2015-06-17|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Observational|||Virtual Autopsy for Quality Control on Intensive Care Medicine|Virtual Autopsy for Quality Control on Intensive Care Medicine|Completed|||160|Actual|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||||||2018-05-31 21:36:39.54759|2018-05-31 21:36:39.54759
NCT01542372|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2017-02-20||2017-04-10|2012-02-25|2012-03-02|Estimate|2017-04-10|2017-05-17|Actual||||2017-04-10|2017-05-17|Actual|April 2012|Actual|2012-04-30|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Patients who meet inclusion criteria for Step 1 such as PTSD and impairment.|Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD|Two Stepped Care Models for PTSD Among Cambodian Refugees With PTSD|Terminated||Phase 4|114|Actual|Massachusetts General Hospital|Owing to lack of recruitment sites the study was ended early. In addition, many more patients than anticipated had no PTSD after Step I and hence could not be randomized to participate in Step II. This greatly impacted on flow.|2||Inadequate flow of patients|f||||t|t|f|||t|||Undecided||2018-05-31 21:36:34.9241|2018-05-31 21:36:34.9241
NCT01542359|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2013-01-08|2012-02-25|2012-03-02|Estimate|||||||2013-01-08|2013-01-10|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effectiveness of Yoga on Ambulatory Blood Pressure in Patients With Pre- and Stage I Hypertension|Effectiveness of Yoga on Ambulatory Blood Pressure in Patients With Pre- and Stage I Hypertension|Completed||N/A|90|Actual|Long Island University||2|||f||||f||||||||||2018-05-31 21:36:35.235811|2018-05-31 21:36:35.235811
NCT01542346|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-25|||2013-07-11|2012-03-01|2012-03-02|Estimate|||||||2013-07-11|2013-07-15|Estimate|March 2012||2012-03-31|July 2013|2013-07-31||||||||Interventional|||Subcutaneous Adaption and Cosmetic Outcome Following Caesarean Delivery||Completed||N/A|116|Anticipated|Klinikum Klagenfurt am Wörthersee||1|||f||||||||||||||2018-05-31 21:36:35.318972|2018-05-31 21:36:35.318972
NCT01542333|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-05-17|2012-02-25|2012-03-02|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2012||2012-02-29|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Samples From Younger Patients With Wilms Tumor|Biological Analysis of Ethnic Variations in Wilms Tumor|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:36:35.393314|2018-05-31 21:36:35.393314
NCT01542320|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-03-05|2012-03-01|2012-03-02|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ProBoost||Effect of Probiotic Supplementation on Immune Function in Healthy Infants|Application of Therapeutic Microbiology to Improve Immunogenicity|Completed||N/A|15|Actual|Emory University||2|||f||||t||||||||||2018-05-31 21:36:35.467145|2018-05-31 21:36:35.467145
NCT01542307|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2016-10-16||2017-02-03|2012-02-29|2012-03-02|Estimate|2017-02-03|2017-03-27|Actual||||2017-02-03|2017-03-27|Actual|July 2012||2012-07-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Enrolled subjects|Normobaric Oxygen (NBO) Therapy in Acute Migraine|Normobaric Oxygen (NBO) Therapy in Acute Migraine|Completed||Phase 2|22|Actual|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 21:36:35.580239|2018-05-31 21:36:35.580239
NCT01542294|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2016-06-12|2012-02-25|2012-03-02|Estimate|||||||2016-06-12|2016-06-14|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|September 2014|Actual|2014-09-30||Interventional|||SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer|Phase I/II Study of Oral S-1 Plus f Oxaliplatin as an Adjuvant Chemotherapy After Curative Resection of Stage II-IV(M0) Gastric Cancer|Active, not recruiting||Phase 1/Phase 2|71|Actual|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:36:36.150024|2018-05-31 21:36:36.150024
NCT01542281|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-24|2012-02-24|2012-03-02|Estimate|||||||2012-02-24|2012-03-02|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer|Improving Outcomes in Patients With Hepatobiliary Cancers With a Nutritional and Physical Conditioning Pre-habilitation Program|Unknown status|Recruiting|N/A|64|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 21:36:36.236843|2018-05-31 21:36:36.236843
NCT01542268|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2012-03-05|2012-02-24|2012-03-02|Estimate|||||||2012-03-05|2012-03-06|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|IBS-PTX||Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)|Effect of Pentoxifylline on Tight Junctions of Intestinal Mucosa in Patients With Irritable Bowel Syndrome|Unknown status|Not yet recruiting|Phase 4|59|Anticipated|Hospital Universitario de Canarias||2|||f||||t||||||||||2018-05-31 21:36:36.3299|2018-05-31 21:36:36.3299
NCT01542255|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2014-08-28||2014-09-08|2012-02-24|2012-03-02|Estimate|2014-09-08|2014-09-09|Estimate||||2014-09-08|2014-09-09|Estimate|June 2010||2010-06-30|September 2014|2014-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||patients with metastatic melanoma|Metronomic Therapy in Patients With Metastatic Melanoma|Metronomic Therapy in Patients With Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine|Terminated||Phase 2|7|Actual|Dartmouth-Hitchcock Medical Center|terminated early due to difficulty with scheduling three times per week office treatment|1||Low accrual not allowing to support statistical endpoints|f||||t||||||||||2018-05-31 21:36:36.454643|2018-05-31 21:36:36.454643
NCT01542242|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-12-08|2012-02-24|2012-03-02|Estimate|||||||2015-12-08|2015-12-09|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Liraglutide Use in Prader-Willi Syndrome||Terminated||Phase 4|1|Actual|Vancouver General Hospital||1||Subject withdrew|f||||||||||||||2018-05-31 21:36:36.617451|2018-05-31 21:36:36.617451
NCT01542229|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2018-01-11|2012-02-24|2012-03-02|Estimate|||||||2018-01-11|2018-01-16|Actual|May 3, 2012|Actual|2012-05-03|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|PTSD/SMI||PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)|Improving PTSD Service Delivery for Veterans With Severe Mental Illness|Completed||N/A|134|Actual|VA Office of Research and Development||2|||f||||f|f|f||||||No||2018-05-31 21:36:36.726963|2018-05-31 21:36:36.726963
NCT01542216|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-11-04|2012-02-24|2012-03-02|Estimate|||||||2015-11-04|2015-11-05|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Evaluation of Nutrition and Metabolism in Breast Cancer Patients|Evaluation of Nutrition and Metabolism in Breast Cancer Patients|Withdrawn||N/A|0|Actual|University of Waterloo||2||Recruitment challenges|f||||f||||||||||2018-05-31 21:36:36.832597|2018-05-31 21:36:36.832597
NCT01542203|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-02-29|2012-02-29|2012-03-02|Estimate|||||||2012-02-29|2012-03-02|Estimate|March 2012||2012-03-31|January 2012|2012-01-31||||||||Observational|||Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer|Impact of Body Weight on the Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide in Breast Cancer Patients|Unknown status|Not yet recruiting||18|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||||2018-05-31 21:36:36.909339|2018-05-31 21:36:36.909339
NCT01542190|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2014-12-02|2012-02-24|2012-03-02|Estimate|||||||2014-12-02|2014-12-04|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery|A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery.|Completed||Phase 4|80|Anticipated|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 21:36:36.991547|2018-05-31 21:36:36.991547
NCT01542177|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2018-02-06|2012-03-01|2012-03-02|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2012||2012-02-29|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer|The Evaluation of Hypoxia Imaging in Patients With Pancreatic Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)|Recruiting|||30|Anticipated|University Health Network, Toronto|||1||f||||f||||||None Retained|"~     2 tubes of whole blood~   "|||2018-05-31 21:36:37.095593|2018-05-31 21:36:37.095593
NCT01542164|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2017-02-06|2012-02-24|2012-03-02|Estimate|||||||2017-02-06|2017-02-07|Estimate|June 2010|Actual|2010-06-30|February 2017|2017-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|KIFU/B266||Calcium Intake and Fat Excretion|Calcium Intake and Fat Excretion - an Observational Study|Completed|||158|Actual|University of Copenhagen|||||f||||f||||||Samples With DNA|"~     Whole blood, urine and faeces~   "|||2018-05-31 21:36:37.197426|2018-05-31 21:36:37.197426
NCT01542151|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-03-24|2012-02-24|2012-03-02|Estimate|||||||2015-03-24|2015-03-26|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Sleep, Fatigue, and Timing of Post-dates Inductions Among Nulliparas|Effects of Sleep, Fatigue, and Timing of Post-dates Inductions Among Nulliparas|Completed||N/A|72|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:36:37.285117|2018-05-31 21:36:37.285117
NCT01542138|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-11-27|2012-02-24|2012-03-02|Estimate|||||||2012-11-27|2012-11-29|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation|A Double Blind, Randomized Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation|Completed||Phase 4|28|Actual|Universidad Autonoma de San Luis Potosí||3|||f||||f||||||||||2018-05-31 21:36:37.392759|2018-05-31 21:36:37.392759
NCT01542125|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2015-06-05||2016-06-10|2012-02-29|2012-03-02|Estimate|2016-04-15|2016-05-23|Estimate||||2016-06-10|2016-07-12|Estimate|September 2008||2008-09-30|June 2016|2016-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Effect of Liposomal Lidocaine on Perceived Pain in Children During Percutaneous Interosseous Pin Removal in the Outpatient Setting|The Effect of Liposomal Lidocaine on Perceived Pain in Children During Percutaneous Interosseous Pin Removal in the Outpatient Setting: A Triple Blinded, Randomized Placebo-controlled Clinical Trial|Completed||Phase 4|281|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:36:37.535489|2018-05-31 21:36:37.535489
NCT01542112|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2013-03-05|2012-02-24|2012-03-02|Estimate|||||||2013-03-05|2013-03-06|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||An Innovational Model to Manage Patient Expectations and Improve Patient Satisfaction: An Intervention Study|An Innovational Model to Manage Patient Expectations and Improve Patient Satisfaction: An Intervention Study|Completed||N/A|835|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:36:37.785306|2018-05-31 21:36:37.785306
NCT01542099|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-04-19|2012-02-24|2012-03-02|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||The EC50 of Remifentanil Blunting Hemodynamic Response to Double Lumen Tube Intubation|The Effect Site Concentration of Remifentanil Blunting Hemodynamic Responses to Tracheal Intubation: Single Versus Double Lumen Tube|Completed||N/A|80|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:36:37.875815|2018-05-31 21:36:37.875815
NCT01542086|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-02-24|2012-02-24|2012-03-02|Estimate|||||||2012-02-24|2012-03-02|Estimate|September 2011||2011-09-30|February 2012|2012-02-29||||||||Interventional|CARE-CCTA||Comparison of the Cost-Effectiveness of Coronary CT Angiography Versus Myocardial SPECT in Patients With Intermediate Risk of Coronary Heart Disease|Comparison of the Cost-Effectiveness of Coronary CT Angiography Versus Myocardial SPECT in Patients With Intermediate Risk of Coronary Heart Disease|Unknown status|Recruiting|N/A|1050|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:36:37.946533|2018-05-31 21:36:37.946533
NCT01542073|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2017-04-06|2012-02-24|2012-03-01|Estimate|||||||2017-04-06|2017-04-07|Actual|February 2012||2012-02-29|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GRGDMI||68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction|68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Angiogenesis of Myocardial Infarction and the Comparison With Cardiac Perfusion and Metabolism|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 21:36:38.054548|2018-05-31 21:36:38.054548
NCT01542060|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-04-11|2012-02-24|2012-03-01|Estimate|||||||2012-04-11|2012-04-12|Estimate|January 2004||2004-01-31|April 2012|2012-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus|A Clinical Experience Programme to Collect Data on the Safety and Efficacy of NovoMix® 30 in the Treatment of Patients With Type 2 Diabetes in Jordan|Completed|||298|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:36:38.125976|2018-05-31 21:36:38.125976
NCT01542047|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-06-17|2012-02-29|2012-03-01|Estimate|||||||2015-06-17|2015-06-18|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies|A Phase I Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies|Terminated||Phase 1|3|Actual|New Mexico Cancer Care Alliance||1||Low rate of accrual|f||||t||||||||||2018-05-31 21:36:38.207145|2018-05-31 21:36:38.207145
NCT01542034|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2015-05-28|2014-05-30|2015-05-28|2012-02-24|2012-03-01|Estimate|2015-05-28|2015-06-15|Estimate|2014-05-30|2014-06-17|Estimate|2015-05-28|2015-06-15|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|REFINE-1|Intention-to-treat population|Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|506|Actual|Kythera Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 21:36:38.32875|2018-05-31 21:36:38.32875
NCT01542021|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2018-02-23|2012-02-29|2012-03-01|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2012|Actual|2012-02-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer|Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer|Active, not recruiting||N/A|41|Actual|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 21:36:39.180767|2018-05-31 21:36:39.180767
NCT01541969|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2015-04-18||2016-07-21|2012-02-24|2012-03-01|Estimate|2015-06-17|2015-06-18|Estimate||||2016-07-21|2016-08-22|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|RESET2||Evaluation of the CR Neuromodulation Treatment for Tinnitus|Systematic Evaluation of the Acoustic CR ® Neuromodulation Treatment for Tinnitus|Completed||Phase 2/Phase 3|100|Actual|Nottingham University Hospitals NHS Trust|Clinical Trial Protocol inadequately specified, particularly (i) device fitting, (ii) tolerance for pitch matching shifts and (iii) monitoring research audiologists after training. Specification of placebo algorithm is not evidenced by published data|2|||f||||t||||||||||2018-05-31 21:36:39.646092|2018-05-31 21:36:39.646092
NCT01541956|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-11-16|2012-02-24|2012-03-01|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)|An Open-labeled, Randomized, Multicenter, Prospective, Parallel Group, Interventional Study to Demonstrate the Effectiveness of 24 Weeks Treatment With Vildagliptin 50mg Bid as Add on to Metformin 500 mg Bid Compared to Metformin up to 1000 mg Bid in Chinese Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy .|Completed||Phase 4|3091|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:36:40.11944|2018-05-31 21:36:40.11944
NCT01541943|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2015-09-21|2012-02-24|2012-03-01|Estimate|||||||2015-09-21|2015-09-23|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia|A Phase 3, Randomized, Double- Blind, Multi-center, Double Dummy, Clinical Trial Comparing HL-040XC With Single Component Therapies(Atorvastatin, Losartan) to Assess the Efficacy and Safety of HL-040XC in Patients With Essential Hypertension and Hyperlipidemia|Completed||Phase 3|356|Actual|HanAll BioPharma Co., Ltd.||4|||f||||f||||||||||2018-05-31 21:36:40.259605|2018-05-31 21:36:40.259605
NCT01541930|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2013-11-13||2014-01-07|2012-02-29|2012-03-01|Estimate|2014-01-07|2014-02-06|Estimate||||2014-01-07|2014-02-06|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GK567|All patients who received the treatment at least once (Safety population) were included in all efficacy and safety analyses.|An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours|An Open, Uncontrolled Study Investigating the Safety and Efficacy of GK567 in the Deodorization of Malodorous Infected Cutaneous Fungating Neoplastic Tumours, Over 14 Days of Treatment|Completed||Phase 3|21|Actual|Galderma R&D||1|||f||||f||||||||||2018-05-31 21:36:40.405296|2018-05-31 21:36:40.405296
NCT01541917|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2016-11-21||2017-01-18|2012-02-24|2012-03-01|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|July 2012||2012-07-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|WebSMART||Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis|WebSMART: Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis|Completed||Phase 3|305|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||Yes|A deidentified dataset is available for secondary analyses per our Resource Sharing Plan.|2018-05-31 21:36:40.811314|2018-05-31 21:36:40.811314
NCT01541904|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-06-03|2012-02-29|2012-03-01|Estimate|||||||2013-06-03|2013-06-05|Estimate|March 2011||2011-03-31|June 2013|2013-06-30||||February 2012|Actual|2012-02-29||Interventional|PRO-118||Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis|STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRO-118 OPHTHALMIC SOLUTION IN ALLERGIC CONJUNCTIVITIS|Suspended||Phase 2|35|Anticipated|Laboratorios Sophia S.A de C.V.||5||Reformulation|f||||t||||||||||2018-05-31 21:36:41.41745|2018-05-31 21:36:41.41745
NCT01541891|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-02-29|2012-02-29|2012-03-01|Estimate|||||||2012-02-29|2012-03-01|Estimate|September 2011||2011-09-30|February 2012|2012-02-29||||February 2012|Actual|2012-02-29||Interventional|PRO-148||Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome|STUDY TO COMPARATIVE THE EFFICACY AND SAFETY OF PRO-148 OPHTHALMIC SOLUTION VS.SYSTANE® IN THE TREATMENT OF MILD-TO-MODERATE DRY EYE SYNDROME|Unknown status|Active, not recruiting|Phase 2|30|Actual|Laboratorios Sophia S.A de C.V.||2|||f||||t||||||||||2018-05-31 21:36:41.499488|2018-05-31 21:36:41.499488
NCT01541878|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-02-29|2012-02-29|2012-03-01|Estimate|||||||2012-02-29|2012-03-01|Estimate|January 2012||2012-01-31|February 2012|2012-02-29||||||||Observational|||Breast Cancer Registry in Thailand|Pilot Study of Breast Cancer Registry in Thailand|Unknown status|Recruiting||300|Anticipated|Siriraj Hospital|||||f||||f||||||||||2018-05-31 21:36:41.655489|2018-05-31 21:36:41.655489
NCT01541865|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2015-09-15||2015-10-23|2012-02-27|2012-03-01|Estimate|2015-09-15|2015-10-16|Estimate||||2015-10-23|2015-11-25|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|June 2015|Actual|2015-06-30|November 2013|Actual|2013-11-30||Interventional|REDUCE-HTN||Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter|Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter (REDUCE-HTN) - POST MARKET APPROVAL CLINICAL SURVEILLANCE STUDY|Completed||N/A|146|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 21:36:41.740069|2018-05-31 21:36:41.740069
NCT01541852|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-03-15|2012-02-29|2012-03-01|Estimate|||||||2015-03-15|2015-03-17|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|EVOLUTION||Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.|An Evaluation Of Losmapimod in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Systemic Inflammation Stratified Using Fibrinogen (EVOLUTION)|Completed||Phase 2|72|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:36:42.20275|2018-05-31 21:36:42.20275
NCT01541839|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2012-02-29|2012-02-29|2012-03-01|Estimate|||||||2012-02-29|2012-03-01|Estimate|February 2012||2012-02-29|February 2012|2012-02-29||||September 2012|Anticipated|2012-09-30||Interventional|||Comparison of a Septal Stapler to Suture Closure in Nasal Septoplasty|Randomized, Controlled Trial Comparing an Endoscopic Septal Stapler to Suture Closure in Primary Septoplasty|Unknown status|Active, not recruiting|N/A|16|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 21:36:42.281112|2018-05-31 21:36:42.281112
NCT01541826|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|2016-12-12||2017-04-12|2012-02-29|2012-03-01|Estimate|2017-04-12|2017-07-11|Actual||||2017-04-12|2017-07-11|Actual|February 2012||2012-02-29|April 2017|2017-04-30|December 2016|Actual|2016-12-31|August 2015|Actual|2015-08-31||Interventional|||Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers|The Effect of Chokeberry Polyphenols on Biomarkers of Cardiovascular Disease and Antioxidant Defenses in Former Smokers|Completed||N/A|62|Actual|University of Connecticut||3|||f||||f||||||||||2018-05-31 21:36:43.453154|2018-05-31 21:36:43.453154
NCT01541462|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-23|2012-02-23|2012-03-01|Estimate|||||||2012-02-23|2012-03-01|Estimate|October 2000||2000-10-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|June 2010|Actual|2010-06-30||Interventional|||Weaning From Prolonged Mechanical Ventilation|Weaning From Prolonged Mechanical Ventilation|Completed||N/A|500|Actual|RML Specialty Hospital||2|||f||||f||||||||||2018-05-31 21:36:48.467044|2018-05-31 21:36:48.467044
NCT01541813|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2015-03-09|2012-02-29|2012-03-01|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|HEPCIDEF||Rare Iron Overloads Except C282Y Homozygosity : Description and Characterization.|Clinical, Biological, Genetic and Functional Characterization of Rare Iron Overload Phenotypes Associated With Hepcidin Deficiency Except C282Y Homozygosity.|Terminated|||62|Actual|Rennes University Hospital|||1|rare overload and low recruitment|f||||||||||||||2018-05-31 21:36:44.842743|2018-05-31 21:36:44.842743
NCT01541800|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2016-02-03|2012-02-24|2012-03-01|Estimate|||||||2016-02-03|2016-02-05|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Circulating microRNAs as Disease Markers in Pediatric Cancers|A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers|Recruiting|||20|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||f||||||Samples Without DNA|"~     whole blood and cerebral spinal fluid~   "|||2018-05-31 21:36:44.955351|2018-05-31 21:36:44.955351
NCT01541774|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2014-01-29|2012-02-29|2012-03-01|Estimate|||||||2014-01-29|2014-01-31|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|EASE||Endovascular Atherectomy Safety and Effectiveness Study|A Prospective, Multicenter Clinical Evaluation of the Safety and Effectiveness of the Phoenix Atherectomy™ System in Atherectomy of the Peripheral Vasculature|Completed||Phase 3|128|Actual|AtheroMed, Inc||1|||f||||t||||||||||2018-05-31 21:36:45.044446|2018-05-31 21:36:45.044446
NCT01541761|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-10-11|2012-02-24|2012-03-01|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2012||2012-04-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Starting Early Obesity Prevention Program|RCT Testing the Effectiveness of an Early Obesity Prevention Program|Active, not recruiting||N/A|550|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 21:36:45.155258|2018-05-31 21:36:45.155258
NCT01541748|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2017-07-19|2012-02-24|2012-03-01|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2011||2011-11-30|July 2017|2017-07-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study|Axis™ Allograft Dermis for Female Pelvic Floor Repair: a Prospective Post Market Study|Active, not recruiting|||74|Actual|Coloplast A/S|||1||f||||f||||||||||2018-05-31 21:36:45.234836|2018-05-31 21:36:45.234836
NCT01541735|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|2013-07-27||2014-01-07|2012-02-24|2012-03-01|Estimate|2014-01-07|2014-02-21|Estimate||||2014-01-07|2014-02-21|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|IBP||Pantoprazole on Insulin Secretion in Diabetes|Effect of Pantoprazole on Insulin Secretion in Patients With Type 2 Diabetes|Completed||Phase 2/Phase 3|14|Actual|Coordinación de Investigación en Salud, Mexico|The intervention time was short to evaluate a total change in the primary outcome variables|2|||f||||t||||||||||2018-05-31 21:36:45.319116|2018-05-31 21:36:45.319116
NCT01541722|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2015-10-01|2012-02-29|2012-03-01|Estimate|||||||2015-10-01|2015-10-02|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Observational|||Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders|Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders|Terminated|||10|Actual|Children's Research Institute||||DSMB suggested closure due to low enrollment|f||||t||||||||||2018-05-31 21:36:45.584261|2018-05-31 21:36:45.584261
NCT01541709|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2017-07-13|2012-02-24|2012-03-01|Estimate|||||||2017-07-13|2017-07-14|Actual|March 2012|Actual|2012-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation|A Phase II Study of Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation|Recruiting||Phase 2|44|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:36:45.670368|2018-05-31 21:36:45.670368
NCT01541696|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-03-06|2012-02-24|2012-03-01|Estimate|||||||2012-03-06|2012-03-07|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|December 2011|Actual|2011-12-31||Observational|||Exchangeable Zinc Pool Size and Zn Absorption From Sprinkles and Traditional Foods in Pakistani Infants /Toddlers|Exchangeable Zn Pool Size and Zn Absorption From Sprinkles and Traditional Foods in Pakistani Infants/Toddlers|Unknown status|Active, not recruiting||40|Actual|Aga Khan University|||2||f||||t||||||||||2018-05-31 21:36:45.881899|2018-05-31 21:36:45.881899
NCT01541683|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-08-05|2012-02-29|2012-03-01|Estimate|||||||2013-08-05|2013-08-07|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||The Effect of Mentholyptus Drops on the Palatability of PEG-Electrolyte Solution|The Effect of Mentholyptus Drops (Halls®) on the Palatability of PEG-Electrolyte Solution (FORTRANS®) in Colonoscopy Preparation: A Randomized Controlled Trial|Completed||N/A|99|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 21:36:46.108309|2018-05-31 21:36:46.108309
NCT01541670|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-10-19|2012-02-29|2012-03-01|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2011||2011-11-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis|A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis|Terminated||Phase 1|4|Actual|Shire||1|||f||||t||||||||||2018-05-31 21:36:46.188498|2018-05-31 21:36:46.188498
NCT01541657|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2018-01-24|2012-02-23|2012-03-01|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2011||2011-12-31|January 2018|2018-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|STARS||Sensory-Targeted Ankle Rehabilitation Strategies (STARS)|Sensory-Targeted Ankle Rehabilitation Strategies|Completed||Phase 2|80|Actual|University of Kentucky||4|||f||||t||||||||||2018-05-31 21:36:46.336177|2018-05-31 21:36:46.336177
NCT01541644|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|2015-04-21||2016-11-02|2012-02-23|2012-03-01|Estimate|2016-02-12|2016-03-11|Estimate||||2016-11-02|2016-12-29|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|June 2012|Actual|2012-06-30||Interventional|||1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma|A Pilot Study to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients|Completed||N/A|27|Actual|University of Maryland|TNSc results deemed invalid as original validation of TNSc was performed by 2 neuromuscular trained physicians & the TNSc in our trial was performed by a research nurse. The reliability & validity of research nurse's TNSc not established pre-trial.|1|||f||||t||||||||||2018-05-31 21:36:46.454429|2018-05-31 21:36:46.454429
NCT01541449|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-29|2012-02-29|2012-03-01|Estimate|||||||2012-02-29|2012-03-01|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|April 2012|Anticipated|2012-04-30|||||Observational|||Plaqenil Role in Prevention of Age Related Macular Degeneration|Observational Study Between People That Use Plaquenil and Those Who do Not in Prevention of AMD.|Unknown status|Recruiting||30|Anticipated|Ziv Hospital|||2||f||||t||||||||||2018-05-31 21:36:48.586044|2018-05-31 21:36:48.586044
NCT01541631|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-03-02|2012-02-29|2012-03-01|Estimate|||||||2012-03-02|2012-03-05|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes|Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania.|Unknown status|Not yet recruiting|N/A|2000|Anticipated|Catholic University of Health and Allied Sciences||4|||f||||f||||||||||2018-05-31 21:36:46.659087|2018-05-31 21:36:46.659087
NCT01541618|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-02-29|2012-02-29|2012-03-01|Estimate|||||||2012-02-29|2012-03-01|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis|A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis|Unknown status|Recruiting||15|Anticipated|MSDx, Inc.|||1||f||||f||||||Samples With DNA|"~     Blood remaining after the biomarker test is completed will be retained for possible~     evaluation of additional biomarkers~   "|||2018-05-31 21:36:46.785745|2018-05-31 21:36:46.785745
NCT01541605|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-06-09|2012-02-23|2012-03-01|Estimate|||||||2016-06-09|2016-06-10|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Methylphenidate for the Treatment of Acute Mania|International Randomised Double-blind Placebo-controlled Study on the Initial Treatment of Acute Mania With Methylphenidate|Completed||Phase 3|42|Actual|University of Leipzig||2|||f||||t||||||||||2018-05-31 21:36:46.89815|2018-05-31 21:36:46.89815
NCT01541592|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-11-24|2012-02-24|2012-03-01|Estimate|||||||2014-11-24|2014-11-26|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Does Class of Dietary Fat Affect Insulin Resistance?|Insulin Resistance and Dietary Fat|Completed||N/A|24|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 21:36:47.023289|2018-05-31 21:36:47.023289
NCT01541579|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2016-11-30|2012-02-29|2012-03-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|July 2015|Actual|2015-07-31||Interventional|ADMIRE-CD||Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease|A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 104 Weeks.|Active, not recruiting||Phase 3|278|Anticipated|Cellerix||2|||f||||f||||||||||2018-05-31 21:36:47.16334|2018-05-31 21:36:47.16334
NCT01541566|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-02-25|2012-02-29|2012-03-01|Estimate|||||||2016-02-25|2016-02-26|Estimate|November 2007||2007-11-30|February 2016|2016-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|TELEBPMET||Blood Pressure Control and Compliance to Treatment in Hypertensive Patients With Metabolic Syndrome: a Study Based on Home Blood Pressure Telemonitoring and Assessment of Psychological Determinants|Blood Pressure Control and Compliance to Treatment in Hypertensive Patients With Metabolic Syndrome: a Study Based on Home Blood Pressure Telemonitoring|Completed|||254|Actual|Italian Institute of Telemedicine|||2||f||||f||||||||||2018-05-31 21:36:47.368093|2018-05-31 21:36:47.368093
NCT01541553|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2014-02-13||2016-07-26|2012-02-27|2012-03-01|Estimate|2014-02-13|2014-03-28|Estimate||||2016-07-26|2016-08-30|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp|A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp|Completed||Phase 3|367|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 21:36:47.504008|2018-05-31 21:36:47.504008
NCT01541540|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-10-06|2012-02-23|2012-03-01|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|REACH||e-Counseling Promotes Blood Pressure Reduction and Therapeutic Lifestyle Change in Hypertension|Reducing Risk With E-based Support for Adherence to Lifestyle Change in Hypertension|Completed||N/A|264|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 21:36:47.840354|2018-05-31 21:36:47.840354
NCT01541527|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-12-30|2012-02-23|2012-03-01|Estimate|||||||2014-12-30|2014-12-31|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Observational|||Non Neutralizing Antibodies: Prevalence and Characterization|Prevalence and Epitope Specificity of Non-neutralizing Antibodies in Haemophilia A Patients Without Inhibitors, Immunogenicity of B Domain: A Prospective Study|Withdrawn|||0|Actual|University Hospital, Montpellier|||1|Promoter's change|f||||f||||||||||2018-05-31 21:36:48.046471|2018-05-31 21:36:48.046471
NCT01541514|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-12-02|2012-02-23|2012-03-01|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|April 2012|Actual|2012-04-30||Observational|||Evaluating the Patient-Ventilator Synchrony During Mechanical Ventilation in Patients With Acute Lung Injury||Completed|||30|Actual|University of Chicago|||||f||||f||||||||||2018-05-31 21:36:48.132806|2018-05-31 21:36:48.132806
NCT01541501|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-09-02|2012-02-23|2012-03-01|Estimate|||||||2012-09-02|2012-09-05|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|||||Observational|||Comparison of Three Different No-contact Pachymetries|Phase 4 Study of Comparison Among 3 Different No-contact Instruments to Valuate Central Corneal Thickness|Unknown status|Recruiting||150|Anticipated|University of Cantanzaro|||1||f||||f||||||||||2018-05-31 21:36:48.198276|2018-05-31 21:36:48.198276
NCT01541488|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-10-30|2012-02-29|2012-03-01|Estimate|||||||2013-10-30|2013-10-31|Estimate|February 2012||2012-02-29|October 2013|2013-10-31||||May 2012|Actual|2012-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1 mg as Drinking Solution, and 5, 20, 60, 150, 300, 500 mg as Tablets) of BI 1021958 in Healthy Male Volunteers (Placebo-controlled, Randomised and Single Blind Within Dose Groups), Including Investigation of the Effect of Food on the Bioavailability of BI 1021958 (Open-label, Randomised, Two-way Cross-over)|Completed||Phase 1|66|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:36:48.280897|2018-05-31 21:36:48.280897
NCT01541475|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-04-09|2012-02-23|2012-03-01|Estimate|||||||2014-04-09|2014-04-10|Estimate|March 2009||2009-03-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder|Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder|Completed||Phase 4|60|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 21:36:48.3563|2018-05-31 21:36:48.3563
NCT01541436|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2017-10-20|2012-02-23|2012-03-01|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2012|Actual|2012-03-31|October 2017|2017-10-31|April 30, 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|||Remote Ischemic Preconditioning Mechanism Study|Remote Ischemic Preconditioning Effects on Central and Peripheral Sensitization in Healthy Volunteers-A Pilot Study|Completed||Early Phase 1|20|Actual|Wake Forest University Health Sciences||2|||f||||f|f|t|f|f|f|||||2018-05-31 21:36:48.758201|2018-05-31 21:36:48.758201
NCT01541423|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-10-20|2012-02-23|2012-03-01|Estimate|||||||2016-10-20|2016-10-24|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema|A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks|Completed|||83|Actual|Shire|||||f||||f||||||||||2018-05-31 21:36:48.973201|2018-05-31 21:36:48.973201
NCT01541410|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2013-07-12|2012-02-23|2012-03-01|Estimate|||||||2013-07-12|2013-07-15|Estimate|May 2010||2010-05-31|July 2013|2013-07-31||||August 2011|Actual|2011-08-31||Interventional|||Evaluation of the Vascutek Hybrid Graft for Use in the Replacement of the Aortic Arch and Concomitant Treatment of an Aneurysm/Dissection of the Descending Aorta in the Frozen Elephant Trunk Procedure||Completed||Phase 1/Phase 2|34|Actual|Vascutek Ltd.|||||f||||t||||||||||2018-05-31 21:36:49.099823|2018-05-31 21:36:49.099823
NCT01541397|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2015-06-11||2015-06-11|2012-02-23|2012-03-01|Estimate|2015-06-11|2015-07-07|Estimate||||2015-06-11|2015-07-07|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy|Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy|Terminated||N/A|6|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 21:36:49.27282|2018-05-31 21:36:49.27282
NCT01541384|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2017-07-12||2017-08-10|2012-02-23|2012-02-29|Estimate|2017-08-10|2017-08-11|Actual||||2017-08-10|2017-08-11|Actual|February 2012||2012-02-29|August 2017|2017-08-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Medication Adherence in Kidney Transplant Recipients Using Automated Reminders and Provider Notification|Medication Adherence in Kidney Transplant Recipients Using Automated Reminders and Provider Notification|Completed||N/A|120|Actual|University of Pennsylvania|The study did not assess clinical end points. Participants and study coordinators were not blinded to intervention arm.|3|||f||||f||||||||||2018-05-31 21:36:49.560659|2018-05-31 21:36:49.560659
NCT01541371|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2013-02-28||2013-07-03|2012-02-23|2012-02-29|Estimate|2013-07-03|2013-08-07|Estimate||||2013-07-03|2013-08-07|Estimate|July 2008||2008-07-31|July 2013|2013-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Non Acute Episode Subjects With Schizophrenia|Completed||Phase 3|405|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-05-31 21:36:49.913497|2018-05-31 21:36:49.913497
NCT01541358|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2017-02-14||2017-05-12|2012-02-23|2012-02-29|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|May 2012||2012-05-31|May 2017|2017-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer|Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer|Terminated||N/A|2|Actual|Stanford University|Low participant enrollment. The uptake of fluoride ions is better in bone remodeling processes, while purely bone lytic processes have a lower uptake, or no uptake at all, which is a limitation of F-18 NaF PET/CT bone scan.|1||Low accrual and no funding|f||||t||||||||No||2018-05-31 21:36:50.327033|2018-05-31 21:36:50.327033
NCT01541345|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2018-05-02|2012-02-23|2012-02-29|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2011||2011-02-28|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|February 2018|Actual|2018-02-28||Interventional|||Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2|A Phase III, Randomized, Controlled Clinical Trial of Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2|Active, not recruiting||Phase 3|24|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 21:36:50.542472|2018-05-31 21:36:50.542472
NCT01541332|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-03-08|2012-02-23|2012-02-29|Estimate|||||||2016-03-08|2016-03-10|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma|A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma|Unknown status|Active, not recruiting|Phase 1/Phase 2|70|Actual|Oncotherapeutics||1|||f||||f||||||||||2018-05-31 21:36:50.616545|2018-05-31 21:36:50.616545
NCT01541319|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-09-07|2012-02-23|2012-02-29|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|MARS||Mechanism and Repository Study for the Red Cell Storage Duration Study|Mechanism and Repository Study for the Red Cell Storage Duration Study|Completed|||92|Actual|New England Research Institutes|||4||f||||t||||||Samples With DNA|"~     plasma, pRBCs, PBMCs~   "|||2018-05-31 21:36:50.716912|2018-05-31 21:36:50.716912
NCT01541306|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2015-04-13|2012-02-28|2012-02-29|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||C-Type Natriuretic Peptide and Achondroplasia|C-Type Natriuretic Peptide and Achondroplasia|Completed|||91|Actual|Nemours Children's Clinic|||1||f||||f||||||Samples Without DNA|"~     Plasma and serum samples are stored for potential future research.~   "|||2018-05-31 21:36:50.900107|2018-05-31 21:36:50.900107
NCT01541293|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-05-13|2012-02-28|2012-02-29|Estimate|||||||2014-05-13|2014-05-14|Estimate|September 2012||2012-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Intrauterine Lidocaine for Laminaria|Intrauterine Lidocaine for Pain Control During Laminaria Insertion Prior to Dilation & Evacuation (D&E)|Completed||Phase 1|72|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:36:50.979652|2018-05-31 21:36:50.979652
NCT01541280|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2016-03-17|2012-02-23|2012-02-29|Estimate|||||||2016-03-17|2016-03-18|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|VIDAZA-DLI||VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome|Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome|Completed||Phase 2|30|Actual|Nantes University Hospital|||||f||||||||||||||2018-05-31 21:36:51.053219|2018-05-31 21:36:51.053219
NCT01541267|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2012-02-28|2012-02-28|2012-02-29|Estimate|||||||2012-02-28|2012-02-29|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|||The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria|The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria in Chronic Non-diabetic Kidney Disease: a Double-blind Cross-over Randomised Controlled Study|Completed||Phase 4|20|Actual|Medical University of Gdansk||3|||f||||t||||||||||2018-05-31 21:36:51.147751|2018-05-31 21:36:51.147751
NCT01541254|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2014-09-05||2014-09-06|2012-02-23|2012-02-29|Estimate|2014-09-06|2014-09-15|Estimate||||2014-09-06|2014-09-15|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|LVIS||Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device|A Feasibility Study of the MicroVention,Inc.(LVIS™) Neurovascular Self-Expanding Retrievable Stent System in the Treatment of Wide-Necked Intracranial Artery Aneurysms|Completed||Phase 2/Phase 3|30|Actual|Microvention-Terumo, Inc.||1|||f||||t||||||||||2018-05-31 21:36:51.232089|2018-05-31 21:36:51.232089
NCT01541241|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-02-28|2012-02-28|2012-02-29|Estimate|||||||2012-02-28|2012-02-29|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|May 2012|Anticipated|2012-05-31|January 2012|Actual|2012-01-31||Observational|IUD||Study About Patients Using Copper Intrauterine Device|Uterine Haemodynamic Changes in Patients With Copper Intrauterine Device Induced Bleeding|Unknown status|Recruiting||100|Anticipated|Egymedicalpedia|||1||f||||t||||||||||2018-05-31 21:36:51.439739|2018-05-31 21:36:51.439739
NCT01541228|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2013-09-02|2012-02-23|2012-02-29|Estimate|||||||2013-09-02|2013-09-04|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2011|Actual|2011-04-30||Interventional|||Photodynamic Treatment of Actinic Keratoses With Different Light Doses|Clinical Effect of Photodynamic Treatment When Treating Actinic Keratoses With Different Light Doses|Completed||N/A|38|Actual|Lithuanian University of Health Sciences||2|||f||||t||||||||||2018-05-31 21:36:51.561733|2018-05-31 21:36:51.561733
NCT01541215|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2018-05-25|2012-02-28|2012-02-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 13, 2012|Actual|2012-11-13|May 2018|2018-05-31|May 23, 2018|Actual|2018-05-23|November 15, 2017|Actual|2017-11-15||Interventional|Ellipse™||Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes|Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes|Completed||Phase 3|135|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 21:36:51.760109|2018-05-31 21:36:51.760109
NCT01541202|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-12-19|2012-02-23|2012-02-29|Estimate|||||||2017-12-19|2017-12-21|Actual|February 2012||2012-02-29|February 2012|2012-02-29|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure|Terminated||Phase 3|679|Actual|Zensun Sci. & Tech. Co., Ltd.||2||Sponsor has designed another study to replace the current study|f||||t||||||||||2018-05-31 21:36:52.119655|2018-05-31 21:36:52.119655
NCT01541189|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-03-17|2012-02-28|2012-02-29|Estimate|||||||2017-03-17|2017-03-21|Actual|February 2012||2012-02-29|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.|A 8-week, Multi Center(10),Single Arm, Open-labeled Prospective Study of Valsartan 160 mg in 200 Mild to Moderate Chinese Hypertension Patients Forced Titrated From 2-week Therapy of Valsartan 80 mg.|Completed||Phase 4|200|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:36:52.254432|2018-05-31 21:36:52.254432
NCT01541176|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-01-05|2012-02-28|2012-02-29|Estimate|||||||2016-01-05|2016-01-06|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|Astronef||Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation|Impact of the Absence of Steroids on the Evolution of Renal Function and on the Progression of Graft Fibrosis, Quantified by Numerical Method, in Patients With Renal Transplant|Unknown status|Active, not recruiting|Phase 4|193|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 21:36:52.34478|2018-05-31 21:36:52.34478
NCT01541163|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-10-31|2012-02-28|2012-02-29|Estimate|||||||2017-10-31|2017-11-01|Actual|September 2010||2010-09-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Observational|HISTORY||Heart and Ischemic STrOke Relationship studY|Assessment of Relationship Between Acute Ischemic Stroke and Heart Disease|Recruiting|||500|Anticipated|University Hospital Olomouc|||1||f||||t||||||||||2018-05-31 21:36:52.47152|2018-05-31 21:36:52.47152
NCT01541150|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-12-30|2012-02-23|2012-02-29|Estimate|||||||2014-12-30|2014-12-31|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|January 2017|Anticipated|2017-01-31|August 2015|Anticipated|2015-08-31||Interventional|||Impaired Decision Making in Pedophilic Offenders|Neuropsychological Approach of Pedophilic Behaviors, a Pilot Study in a Population of Inmates Pedophilic Offenders|Unknown status|Recruiting|Phase 4|128|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:36:52.567139|2018-05-31 21:36:52.567139
NCT01541137|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-02-28|2012-02-28|2012-02-29|Estimate|||||||2012-02-28|2012-02-29|Estimate|March 2004||2004-03-31|February 2012|2012-02-29|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||NSAIDs With Morphine-PCA Compared to Epidural Analgesia in Thoracotomy Pain|NSAID With IV-PCA Morphine is an Alternative to Thoracic Epidural Analgesia in Post-thoracotomy Pain|Completed||N/A|30|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 21:36:52.686405|2018-05-31 21:36:52.686405
NCT01541124|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2018-02-06|2012-02-28|2012-02-29|Estimate|||||||2018-02-06|2018-02-08|Actual|August 2008||2008-08-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Morphine as First Drug for Cancer Pain|Morphine as the First Drug for the Treatment of Cancer Pain|Completed||N/A|60|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 21:36:52.823642|2018-05-31 21:36:52.823642
NCT01541111|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2015-07-27|2012-02-28|2012-02-29|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Magnesium Associated With Morphine for Cancer Pain Relief|Evaluation of Analgesic Effect of Magnesiun Associated With Morphine for Cancer Pain Relief|Completed||N/A|40|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 21:36:52.900916|2018-05-31 21:36:52.900916
NCT01541098|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-03-17|2012-02-28|2012-02-29|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||A Clinical Study of Lyophilized Plasma in Patients on Warfarin|A Phase II Clinical Study of Lyophilized Plasma in Patients on Warfarin|Withdrawn||Phase 2|0|Actual|HemCon Medical Technologies, Inc||2|||f||||t||||||||||2018-05-31 21:36:53.004865|2018-05-31 21:36:53.004865
NCT01541085|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2013-11-25|2012-02-23|2012-02-29|Estimate|||||||2013-11-25|2013-11-26|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART|Ex Vivo Study of Immune-Reconstitution Kinetics in HIV-infected ARV-naive Subjects, With Advanced Disease, Starting a Darunavir/Ritonavir or Efavirenz Based HAART (IMMUNO Study)|Completed|||33|Actual|Janssen-Cilag S.p.A.|||2||f||||f||||||||||2018-05-31 21:36:53.103545|2018-05-31 21:36:53.103545
NCT01541072|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-10-31|2012-02-23|2012-02-29|Estimate|||||||2016-10-31|2016-11-01|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|PALM2||Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation|Lymphocyte Reconstitution in a Randomized Study After Administration of Pegfilgrastim Versus Filgrastim in Patients With B-cell Non-Hodgkin Lymphoma Treated With High-dose Chemotherapy and Autologous Peripheral Stem Cell Transplantation|Terminated||N/A|34|Actual|Centre Leon Berard||2||Number of enrolled patients was insufficient during planned inclusion time.|f||||f||||||||||2018-05-31 21:36:53.243717|2018-05-31 21:36:53.243717
NCT01541059|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-10-21|2012-02-23|2012-02-29|Estimate|||||||2015-10-21|2015-10-22|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|RopiMol||Postoperative Analgesia Following Wisdom Teeth Removal: Ropivacaine Versus Placebo|Postoperative Analgesia in Third Molar Surgery Under General Anesthesia: Ropivacaine Versus Placebo|Completed||Phase 4|100|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 21:36:53.629454|2018-05-31 21:36:53.629454
NCT01541046|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-11-19|2012-02-28|2012-02-29|Estimate|||||||2014-11-19|2014-11-20|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic|Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic: A Randomized Double-blind Controlled Trial|Completed||Phase 2|55|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 21:36:53.785618|2018-05-31 21:36:53.785618
NCT01541033|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-08-17|2012-02-28|2012-02-29|Estimate|||||||2016-08-17|2016-08-19|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Observational|||Biomarker of Children With Familial Autoimmune History|Biomarker Discovery In Children With Autism Plus Familial Autoimmune History|Completed|||58|Actual|Le Bonheur Children's Hospital|||3||f||||f||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 21:36:53.988599|2018-05-31 21:36:53.988599
NCT01541020|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-12-04|2012-02-23|2012-02-29|Estimate|||||||2013-12-04|2013-12-05|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Inspiratory Resistive Loading and Proprioceptive Postural Control|Inspiratory Resistive Loading and Proprioceptive Postural Control in Healthy Individuals and Individuals With Recurrent Low Back Pain|Completed|||40|Actual|Katholieke Universiteit Leuven|||2||f||||t||||||||||2018-05-31 21:36:54.173351|2018-05-31 21:36:54.173351
NCT01541007|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2015-10-30|2012-02-28|2012-02-29|Estimate|||||||2015-10-30|2015-11-02|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ConCab||A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer|A Randomized, Open Label, Multicenter, Phase II Trial Comparing The Conventional 3 Weekly Schedule Of Cabazitaxel With A Weekly Regimen In Patients With Metastatic Castration Resistant Prostate Cancer|Completed||Phase 2|100|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 21:36:54.417822|2018-05-31 21:36:54.417822
NCT01540994|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-04-27|2012-02-28|2012-02-29|Estimate|||||||2017-04-27|2017-05-01|Actual|January 2011||2011-01-31|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer|Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate|Recruiting||Phase 1/Phase 2|10|Anticipated|Sharp HealthCare||1|||f||||t||||||||||2018-05-31 21:36:54.603398|2018-05-31 21:36:54.603398
NCT01540981|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|2014-10-06||2015-01-06|2012-02-23|2012-02-29|Estimate|2014-12-11|2014-12-15|Estimate||||2015-01-06|2015-01-15|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Deep Tissue Injury Treatment With MIST Therapy Versus Standard Care: REVERSE DTI Study|Multi-Center Study of the Effects of MIST Therapy on the Treatment of Deep Tissue Injury|Terminated||N/A|12|Actual|Celleration, Inc.|Follow-up limited by discharge from hospital.|2||Lack of enrollment|f||||t||||||||||2018-05-31 21:36:54.766554|2018-05-31 21:36:54.766554
NCT01540968|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2015-06-25|2012-02-28|2012-02-29|Estimate|||||||2015-06-25|2015-06-26|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Nutrition and Physical Exercise Study|Influence of a Combined Intervention by Nutritional Support and Physical Exercise on Quality of Life in Cancer Out-patients Treated in Palliative Intention.|Completed||N/A|58|Actual|Kantonsspital Winterthur KSW||2|||f||||f||||||||||2018-05-31 21:36:55.408112|2018-05-31 21:36:55.408112
NCT01540955|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-04-08|2012-02-28|2012-02-29|Estimate|||||||2015-04-08|2015-04-10|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors|Cognitive Rehabilitation Group Intervention for Breast Cancer Survivors|Completed||Phase 2|48|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:36:55.590811|2018-05-31 21:36:55.590811
NCT01540942|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-03-20|2012-02-28|2012-02-29|Estimate|||||||2014-03-20|2014-03-21|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease|A Randomized, Controlled, Open-label Study to Investigate the Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease|Completed||N/A|91|Actual|Jinling Hospital, China||2|||f||||||||||||||2018-05-31 21:36:55.669756|2018-05-31 21:36:55.669756
NCT01540929|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2018-01-26|2012-02-23|2012-02-29|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2009||2009-09-30|January 2018|2018-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel|A Phase IV Post-licensure DOD Screening Accuracy Study in Military Personnel|Completed|||5001|Actual|Emergent BioSolutions|||1||f||||f||||||||||2018-05-31 21:36:55.765643|2018-05-31 21:36:55.765643
NCT01540916|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2015-11-07|2012-02-28|2012-02-29|Estimate|||||||2015-11-07|2015-11-10|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Respiratory Alterations of Acid-base Equilibrium: Acute and Chronic Renal Response|Respiratory Alterations of Acid-base Equilibrium: Acute and Chronic Renal Response|Unknown status|Active, not recruiting|N/A|50|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||||||||||||2018-05-31 21:36:55.845294|2018-05-31 21:36:55.845294
NCT01540903|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-09-09|2012-02-28|2012-02-29|Estimate|||||||2014-09-09|2014-09-10|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|August 2013|Actual|2013-08-31|September 2012|Actual|2012-09-30||Interventional|||Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults|Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites (PfSPZ Challenge)in Tanzanian Adults|Completed||Phase 1|30|Actual|Sanaria Inc.||3|||f||||t||||||||||2018-05-31 21:36:55.952051|2018-05-31 21:36:55.952051
NCT01540890|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-03-17|2012-02-28|2012-02-29|Estimate|||||||2014-03-17|2014-03-18|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational|||Impairment of Sleep and Pattern of Breathing Before and After Opioid Withdrawal in Comparison to Patients Without Opioid Withdrawal||Completed|||40|Actual|Ruhr University of Bochum|||3||f||||f||||||||||2018-05-31 21:36:56.068212|2018-05-31 21:36:56.068212
NCT01540877|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-02-28|2012-02-28|2012-02-29|Estimate|||||||2012-02-28|2012-02-29|Estimate|April 2011||2011-04-30|February 2012|2012-02-29||||September 2011|Actual|2011-09-30||Interventional|||A Human Experimental Model for Neuropathic Pain Using Combined Application of Capsaicin and Local Anesthetics||Completed||N/A|28|Actual|Ruhr University of Bochum||4|||f||||f||||||||||2018-05-31 21:36:56.154528|2018-05-31 21:36:56.154528
NCT01540864|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23||2015-08-19|2015-08-19|2012-02-28|2012-02-29|Estimate||||2015-08-19|2015-09-04|Estimate|2015-08-19|2015-09-04|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects|A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects|Terminated||Phase 2|126|Actual|High Point Pharmaceuticals, LLC.||3|||f||||f||||||||||2018-05-31 21:36:56.234246|2018-05-31 21:36:56.234246
NCT01540851|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2015-12-16||2018-01-16|2012-02-23|2012-02-29|Estimate|2016-01-22|2016-02-19|Estimate||||2018-01-16|2018-02-09|Actual|July 24, 2011|Actual|2011-07-24|January 2018|2018-01-31|May 10, 2014|Actual|2014-05-10|May 10, 2014|Actual|2014-05-10||Interventional|AViKA||Adding Value in Knee Arthroplasty Post-total Knee Replacement (TKR) Care Navigator Trial|Adding Value in Knee Arthroplasty Post TKR Care Navigator Trial|Completed||N/A|308|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:36:56.383198|2018-05-31 21:36:56.383198
NCT01540838|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-02-26|2012-02-28|2012-02-29|Estimate|||||||2017-02-26|2017-02-28|Actual|February 2012|Actual|2012-02-29|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|INFU/PARA||Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis|Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis, Especially of Pneumococcal Meningitis, in Angola.|Completed||Phase 4|375|Actual|Helsinki University||2|||f||||t||||||||Undecided|We are working on an agreement to share data with all the participants,|2018-05-31 21:36:56.667175|2018-05-31 21:36:56.667175
NCT01540825|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2016-11-23||2016-11-23|2012-02-23|2012-02-29|Estimate|2016-11-23|2017-01-20|Estimate||||2016-11-23|2017-01-20|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Treated set which included all randomised subjects who received 1 dose of the study drug.|First in Man Trial of BI 113608|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113608 in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)|Completed||Phase 1|80|Actual|Boehringer Ingelheim||11|||f||||||||||||||2018-05-31 21:36:56.859853|2018-05-31 21:36:56.859853
NCT01540812|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2018-03-19|2012-02-23|2012-02-29|Estimate|||||||2018-03-19|2018-03-20|Actual|February 2012|Actual|2012-02-29|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS||Recruiting|||200|Anticipated|PETHEMA Foundation|||1||f||||t||||||||||2018-05-31 21:36:57.890081|2018-05-31 21:36:57.890081
NCT01540799|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-05-23|2012-02-28|2012-02-29|Estimate|||||||2017-05-23|2017-05-25|Actual|February 2012||2012-02-29|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|Pathway M-1||Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache|Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache|Active, not recruiting||N/A|80|Anticipated|Autonomic Technologies, Inc.||2|||f||||t||||||||||2018-05-31 21:36:57.997233|2018-05-31 21:36:57.997233
NCT01540786|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-10-14|2012-02-23|2012-02-29|Estimate|||||||2014-10-14|2014-10-15|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics|"An Exploratory Study to Evaluate Bladder Contractions in the Storage Phase (Non Voiding Activities) and Related Bladder Sensation in Healthy Females and Untreated Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics"|Terminated||Phase 1|6|Actual|Astellas Pharma Inc||3||It was decided to discontinue the study due to insufficient recruitment|f||||t||||||||||2018-05-31 21:36:59.206623|2018-05-31 21:36:59.206623
NCT01540773|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2014-11-14||2017-11-13|2012-02-23|2012-02-29|Estimate|2017-01-31|2017-03-21|Actual||||2017-11-13|2017-11-22|Actual|October 2011||2011-10-31|November 2017|2017-11-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Single Low-Dose of Supplement Amino Acid|Growth Hormone 120 Minutes Following a Single Low-dose of Amino Acids in Healthy Subjects.|Completed||N/A|16|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:36:59.302257|2018-05-31 21:36:59.302257
NCT01540760|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-11-01|2012-02-23|2012-02-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of MCAF5352A in Healthy Volunteers|A Phase Ib, Single-Center, Randomized, Placebo-Controlled, Double-Blind Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers|Completed||Phase 1|23|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 21:36:59.508569|2018-05-31 21:36:59.508569
NCT01540747|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-02-23|2012-02-23|2012-02-29|Estimate|||||||2012-02-23|2012-02-29|Estimate||||January 2009|2009-01-31||||||||Interventional|||Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||||||||||||2018-05-31 21:36:59.579025|2018-05-31 21:36:59.579025
NCT01540734|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-11-20|2012-02-23|2012-02-29|Estimate|||||||2014-11-20|2014-11-24|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®|A Single Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Sustained Release Paracetamol Formulations|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:36:59.660669|2018-05-31 21:36:59.660669
NCT01540721|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-11-20|2012-02-23|2012-02-29|Estimate|||||||2014-11-20|2014-11-24|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend|A Single Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Different Sustained Released Paracetamol Formulations|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:36:59.727839|2018-05-31 21:36:59.727839
NCT01540708|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2018-05-17|2012-02-23|2012-02-29|Estimate|||||||2018-05-17|2018-05-18|Actual|January 16, 2012|Actual|2012-01-16|May 2018|2018-05-31|September 4, 2012|Actual|2012-09-04|September 4, 2012|Actual|2012-09-04||Interventional|||A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol|An Open-label, Randomised, Cross-over, Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation andROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol.|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:36:59.906766|2018-05-31 21:36:59.906766
NCT01540695|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2014-10-10|2012-02-23|2012-02-29|Estimate|||||||2014-10-10|2014-10-13|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H and E Histology|Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H&E Histology|Completed|||30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:37:00.208951|2018-05-31 21:37:00.208951
NCT01540682|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2017-07-27|2012-02-28|2012-02-29|Estimate|||||||2017-07-27|2017-07-28|Actual|February 2012||2012-02-29|July 2017|2017-07-31||||November 2015|Actual|2015-11-30||Interventional|||MLN8237 in Head and Neck Cancer|Phase I Study of MLN8237 in Combination With Cetuximab and Definitive Radiation in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 1|9|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:37:00.328697|2018-05-31 21:37:00.328697
NCT01540669|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-01-21|2012-02-28|2012-02-29|Estimate|||||||2016-01-21|2016-01-22|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PDX-Transit||Dose-Responsive Effect of Polydextrose on Whole Gut Transit Time|Dose-ranging Efficacy of 2-week Polydextrose Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebocontrolled Trial|Terminated||N/A|59|Actual|Danisco||4||Slow recruitment|f||||f||||||||No|Terminated|2018-05-31 21:37:00.730568|2018-05-31 21:37:00.730568
NCT01540656|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2013-05-23|2012-02-28|2012-02-29|Estimate|||||||2013-05-23|2013-05-24|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence|Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence|Unknown status|Active, not recruiting|Phase 3|39|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-05-31 21:37:00.853622|2018-05-31 21:37:00.853622
NCT01540643|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-01-19|2012-02-23|2012-02-29|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Zenith® Spiral-Z® AAA Iliac Leg Graft Post-market Registry|Zenith® Spiral-Z® AAA Iliac Leg Graft Post-market Registry|Completed|||600|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 21:37:00.986465|2018-05-31 21:37:00.986465
NCT01540630|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2017-10-17|2012-02-28|2012-02-29|Estimate|||||||2017-10-17|2017-10-19|Actual|March 31, 2012|Actual|2012-03-31|September 2017|2017-09-30|June 30, 2014|Actual|2014-06-30|March 31, 2014|Actual|2014-03-31||Interventional|||A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia|A Phase IIa Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients With Trigeminal Neuralgia|Completed||Phase 2|67|Actual|Biogen||2|||f||||t||||||||||2018-05-31 21:37:01.12203|2018-05-31 21:37:01.12203
NCT01540617|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-04-11|2012-02-28|2012-02-29|Estimate|||||||2014-04-11|2014-04-14|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||The Neural Basis of Lumbosacral Proprioceptive Impairment in Recurrent Low Back Pain|The Neural Basis of Lumbosacral Proprioceptive Impairment in Recurrent Low Back Pain|Completed|||36|Actual|Katholieke Universiteit Leuven|||2||f||||t||||||||||2018-05-31 21:37:01.239172|2018-05-31 21:37:01.239172
NCT01540604|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2012-10-01|2012-02-28|2012-02-29|Estimate|||||||2012-10-01|2012-10-02|Estimate||||October 2012|2012-10-31||||||||Interventional|||CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers|An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD|Completed||Phase 2|||RSPR Pharma AB||1|||f||||||||||||||2018-05-31 21:37:01.303947|2018-05-31 21:37:01.303947
NCT01540591|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-09-14|2012-02-28|2012-02-29|Estimate|||||||2016-09-14|2016-09-16|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|Intralipid||Intralipid for Repeated Implantation Failure|Does Intralipid Infusion Improve the Implantation Rate in Repeated Implantation Failure: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|200|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 21:37:01.369273|2018-05-31 21:37:01.369273
NCT01540578|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-05-17|2012-02-22|2012-02-29|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2012||2012-02-29|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia|OBSERVATIONAL: Replication Profiling as a Diagnostic Tool in B-cell Acute Lymphoblastic Leukemia (ALL)|Completed|||70|Actual|Children's Oncology Group|||1||f||||t||||||Samples With DNA|"~     Fresh and frozen bone marrow cells~   "|||2018-05-31 21:37:01.462533|2018-05-31 21:37:01.462533
NCT01540565|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2018-04-12|2012-02-22|2012-02-29|Estimate|||||||2018-04-12|2018-04-13|Actual|April 9, 2012|Actual|2012-04-09|November 2017|2017-11-30||||April 24, 2018|Anticipated|2018-04-24||Interventional|||Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (NSC#737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation|Active, not recruiting||Phase 2|51|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:37:01.59532|2018-05-31 21:37:01.59532
NCT01540552|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-01-24|2012-02-22|2012-02-29|Estimate|||||||2013-01-24|2013-01-25|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Natural History of Lung Nodules Seen on CT Scans From Participants at High-Risk of Developing Lung Cancer|Evolution of Undetermined Ld-CT Detected Lung Nodules Among a Randomized Phase II Trial With Inhaled Budesonide|Completed|||320|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 21:37:02.037582|2018-05-31 21:37:02.037582
NCT01540526|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-12-11|2012-02-27|2012-02-28|Estimate|||||||2014-12-11|2014-12-15|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib|Pharmacodynamic Study Using FLT-PET/CT in Patients With Prostate and Other Solid Malignancies Treated With an Interrupted High-dose Axitinib Schedule|Completed||Phase 1|24|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 21:37:02.264227|2018-05-31 21:37:02.264227
NCT01540513|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2017-08-17||2018-02-20|2012-02-22|2012-02-28|Estimate|2017-11-08|2017-12-11|Actual||||2018-02-20|2018-03-15|Actual|March 2012||2012-03-31|February 2018|2018-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404|PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404|Completed||N/A|12|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 21:37:02.369824|2018-05-31 21:37:02.369824
NCT01540500|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-02-14|2012-02-27|2012-02-28|Estimate|||||||2014-02-14|2014-02-17|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine|An Open-label, Single-sequence Study in Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP1A2 Inhibitor, Fluvoxamine|Completed||Phase 1|24|Actual|Vanda Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:37:02.848158|2018-05-31 21:37:02.848158
NCT01540487|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2013-06-06||2013-06-06|2012-02-27|2012-02-28|Estimate|2013-06-06|2013-08-06|Estimate||||2013-06-06|2013-08-06|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin|Characterisation of Fixed Dose Combination Tablets of Linagliptin 2.5 mg/Metformin 850 mg or Linagliptin 2.5 mg/Metformin 500 mg and Relative Oral Bioavailability Compared With Single Linagliptin 2.5 mg and Metformin 850 mg or 500 mg Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open Label, Randomised, Single-dose, Two-way Crossover, Phase I Study|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:37:02.948523|2018-05-31 21:37:02.948523
NCT01540474|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-01-14|2012-02-27|2012-02-28|Estimate|||||||2013-01-14|2013-01-15|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults|Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults|Completed||Phase 1|30|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-05-31 21:37:03.416532|2018-05-31 21:37:03.416532
NCT01540461|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-07-04|2012-02-27|2012-02-28|Estimate|||||||2014-07-04|2014-07-08|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)|A Phase 1 Study to Determine the Safety and Pharmacokinetics of Brivanib in Chinese Subjects With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 1|17|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 21:37:03.50211|2018-05-31 21:37:03.50211
NCT01540448|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-02-22|2012-02-22|2012-02-28|Estimate|||||||2012-02-22|2012-02-28|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|3DCT||Role of CT Angiography With Three-dimensional Reconstruction of Mesenteric Vessels in Planning and Performing of Laparoscopic Colorectal Resections||Completed||Phase 3|100|Actual|University of Roma La Sapienza||2|||f||||||||||||||2018-05-31 21:37:03.573494|2018-05-31 21:37:03.573494
NCT01540435|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-05-28|2012-02-22|2012-02-28|Estimate|||||||2013-05-28|2013-05-29|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PERIMAX||Perioperative Treatment of Resectable Liver Metastases|Perioperative FOLFOXIRI and Bevacizumab Compared With Postoperative FOLFOX in Patients With Resectable Liver Metastases From Colorectal Cancer (PERIMAX). A Randomized, Multidisciplinary DGAV(CAO-V/CALGP)/AIO Phase II Trial|Withdrawn||Phase 2|0|Actual|University of Regensburg||2||insufficient recruitment|f||||t||||||||||2018-05-31 21:37:03.661084|2018-05-31 21:37:03.661084
NCT01540422|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2015-03-12|2012-02-27|2012-02-28|Estimate|||||||2015-03-12|2015-03-17|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Study to Improve Long Term Vein Graft Patency After Coronary Bypass Surgery by Using a Novel Endoscopic Harvesting Technique|OPTION Trial: Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques|Completed|||93|Actual|Baylor Research Institute|||1||f||||f||||||||||2018-05-31 21:37:03.824263|2018-05-31 21:37:03.824263
NCT01540409|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2016-11-22|2012-02-27|2012-02-28|Estimate|||||||2016-11-22|2016-11-25|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|April 2016|Actual|2016-04-30||Interventional|||Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy|Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Who Participated in Study 4658-US-201|Active, not recruiting||Phase 2|12|Actual|Sarepta Therapeutics||1|||f||||f||||||||||2018-05-31 21:37:03.933555|2018-05-31 21:37:03.933555
NCT01540396|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-02-02|2012-02-22|2012-02-28|Estimate|||||||2016-02-02|2016-02-04|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|December 2014|Actual|2014-12-31|February 2013|Actual|2013-02-28||Interventional|GD2M||Gestational Diabetes Diagnostic Methods|GD2M Study:Gestational Diabetes Diagnostic Methods|Completed||N/A|47|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 21:37:04.063249|2018-05-31 21:37:04.063249
NCT01540383|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-09-25|2012-02-22|2012-02-28|Estimate|||||||2017-09-25|2017-09-26|Actual|April 2012||2012-04-30|September 2017|2017-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FCET2EC||Effectiveness of Intensive Aphasia Therapy Under Routine Clinical Conditions|From Controlled Experimental Trial to Everyday Communication: How Effective is Intensive Aphasia Therapy Under Routine Clinical Conditions?|Completed||N/A|156|Actual|University Hospital Muenster||2|||f||||t||||||||||2018-05-31 21:37:04.156517|2018-05-31 21:37:04.156517
NCT01540370|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2013-07-16||2013-07-16|2012-02-27|2012-02-28|Estimate|2013-07-16|2013-09-19|Estimate||||2013-07-16|2013-09-19|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)||Completed|||102|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:37:04.268985|2018-05-31 21:37:04.268985
NCT01540344|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2014-12-10|2012-02-27|2012-02-28|Estimate|||||||2014-12-10|2014-12-11|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|October 2017|Anticipated|2017-10-31|July 2015|Anticipated|2015-07-31||Interventional|COMBATAC||Combined Anticancer Treatment of Advanced Colon Cancer|Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|University of Regensburg||1|||f||||f||||||||||2018-05-31 21:37:04.53236|2018-05-31 21:37:04.53236
NCT01540331|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-27|2012-02-27|2012-02-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||Efficacy And Safety of Pneumatic Trabeculoplasty|Phase 4 Study to Evaluate Efficacy And Safety of Pneumatic Trabeculoplasty (PNT) in Subjects Affected by Primary Open Angle Glaucoma|Completed||Phase 4|27|Actual|University of Cantanzaro||1|||f||||f||||||||||2018-05-31 21:37:04.642221|2018-05-31 21:37:04.642221
NCT01540318|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-02-20|2012-02-27|2012-02-28|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2012||2012-02-29|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|February 2016|Actual|2016-02-29||Interventional|||Utility of Abdominal Ultrasound in the Evaluation of Children With Blunt Trauma|Utility of Abdominal Ultrasound in the Evaluation of Children With Blunt Trauma|Active, not recruiting||N/A|925|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 21:37:04.73357|2018-05-31 21:37:04.73357
NCT01540305|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-27|2012-02-27|2012-02-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy Study of Transcranial Magnetic Stimulation for Treatment of Obsessive-Compulsive Disorder|A Randomized Double-blind Trial of Repetitive Transcranial Magnetic Stimulation in Obsessive -Compulsive Disorder With Three Months Follow-up|Completed||Phase 2|22|Actual|University of Brasilia||2|||f||||f||||||||||2018-05-31 21:37:04.809246|2018-05-31 21:37:04.809246
NCT01540292|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-01-17|2012-02-27|2012-02-28|Estimate|||||||2013-01-17|2013-01-21|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders|Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|University Hospital of Liege||1|||f||||f||||||||||2018-05-31 21:37:04.897864|2018-05-31 21:37:04.897864
NCT01540279|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2015-03-17|2012-02-27|2012-02-28|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Clinical Outcome in View of Surgical Site Infection (SSI) With Antibacterial Skin Sutures|Do Antibacterial Skin Sutures Reduce Surgical Site Infections After Open Abdominal Surgery?|Terminated|||52|Actual|University Hospital, Basel, Switzerland|||2|insufficient enrollment|f||||||||||||||2018-05-31 21:37:04.980203|2018-05-31 21:37:04.980203
NCT01540266|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|2015-03-02||2015-03-17|2012-02-22|2012-02-28|Estimate|2015-03-17|2015-03-31|Estimate||||2015-03-17|2015-03-31|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|BACOP||Basel Discharge Communication Project|BACOP - Basel Discharge Communication Project - Study 3|Completed||N/A|242|Actual|University Hospital, Basel, Switzerland||6|||f||||t||||||||||2018-05-31 21:37:05.077129|2018-05-31 21:37:05.077129
NCT01540253|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-06-29|2012-02-27|2012-02-28|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic|A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors.|Completed||Phase 1|38|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 21:37:05.570497|2018-05-31 21:37:05.570497
NCT01540240|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-02-27|2012-02-27|2012-02-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|August 2011||2011-08-31|February 2012|2012-02-29||||December 2012|Anticipated|2012-12-31||Interventional|AZTlowdose||Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients|Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|136|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 21:37:05.66381|2018-05-31 21:37:05.66381
NCT01540227|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-04-04|2012-02-27|2012-02-28|Estimate|||||||2018-04-04|2018-04-06|Actual|September 2011|Actual|2011-09-30|April 2018|2018-04-30|November 10, 2016|Actual|2016-11-10|November 10, 2016|Actual|2016-11-10||Observational|||Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.|Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis. Do Low Serum Penicillin Levels Correlate With Treatment Failure?|Terminated|||25|Actual|Ottawa Hospital Research Institute|||1|Low enrollment.|f||||f||||||||||2018-05-31 21:37:05.786261|2018-05-31 21:37:05.786261
NCT01540214|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2013-01-04|2012-02-22|2012-02-28|Estimate|||||||2013-01-04|2013-01-07|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|SOAP||Study of Overactive Bladder in Women With Prolapse|Prevalence of Overactive Bladder (OAB) in Patients With Pelvic Organ Prolapse (POP) and Predictors of Symptoms of OAB After Surgical Correction of POP|Unknown status|Recruiting||100|Anticipated|Radboud University|||1||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-05-31 21:37:05.858276|2018-05-31 21:37:05.858276
NCT01540201|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-12-24|2012-02-27|2012-02-28|Estimate|||||||2013-12-24|2013-12-25|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing One-lung Ventilation for Lung Surgery|The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing One-lung Ventilation for Lung Surgery|Completed||N/A|110|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:37:05.983235|2018-05-31 21:37:05.983235
NCT01540188|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-02-16|2012-02-27|2012-02-28|Estimate|||||||2016-02-16|2016-02-18|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Development of a Family Intervention to Address Drug Use and HIV in Vietnam|Development of a Family Intervention to Address Drug Use and HIV in Vietnam|Completed||Phase 1/Phase 2|230|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:37:06.084696|2018-05-31 21:37:06.084696
NCT01540175|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2015-07-13|2012-02-27|2012-02-28|Estimate|||||||2015-07-13|2015-07-14|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|IROPAST||Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant|Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant|Completed|||31|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 21:37:06.209672|2018-05-31 21:37:06.209672
NCT01540162|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2015-08-12||2015-08-12|2012-02-22|2012-02-28|Estimate|2015-08-12|2015-09-10|Estimate||||2015-08-12|2015-09-10|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Observational|EMSUP||Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement|Open-labelled, Controlled, Parallel Group Study to Assess the Efficacy and Safety of MUTAFLOR in 3 Weeks Treatment for Immunity Improvement in Preterm Infants With 1 Year Follow-up Period|Completed|||62|Actual|Odessa National Medical University|||2||f||||f||||||||||2018-05-31 21:37:06.287604|2018-05-31 21:37:06.287604
NCT01540149|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-07-06|2012-02-27|2012-02-28|Estimate|||||||2016-07-06|2016-07-07|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|October 2014|Actual|2014-10-31||Observational|||Tel Aviv Sourasky MC Home Monitoring Clinic Registry|Tel Aviv Sourasky MC Home Monitoring Registry|Completed|||45|Actual|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||||No||2018-05-31 21:37:06.58431|2018-05-31 21:37:06.58431
NCT01540136|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-10-27|2012-02-27|2012-02-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|July 2016|Actual|2016-07-31|May 2014|Actual|2014-05-31||Interventional|||Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma|A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma|Completed||Phase 3|402|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:37:06.659509|2018-05-31 21:37:06.659509
NCT01540123|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-06-20|2012-02-27|2012-02-28|Estimate|||||||2016-06-20|2016-06-21|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Time Effects of a Berry Extract Upon Cerebral Blood Flow.|The Time Effects of a Berry Extract Upon Cerebral Blood Flow.|Completed||N/A|20|Actual|Northumbria University||2|||f||||t||||||||||2018-05-31 21:37:06.775575|2018-05-31 21:37:06.775575
NCT01540110|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-12-17|2012-02-22|2012-02-28|Estimate|||||||2017-12-17|2017-12-19|Actual|August 2010||2010-08-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses|Phase 2 Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses|Active, not recruiting||Phase 2|41|Anticipated|National Cancer Centre, Singapore||1|||f||||t||||||||||2018-05-31 21:37:06.874488|2018-05-31 21:37:06.874488
NCT01540084|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-27|2012-02-27|2012-02-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|December 2006||2006-12-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Cocktail Sedation Containing Propofol Versus Conventional Sedation for Endoscopic Retrograde Cholangiopancreatography (ERCP)|Cocktail Sedation Containing Propofol Versus Conventional Sedation for ERCP: a Prospective, Randomized Controlled Study|Completed||Phase 4|205|Actual|King Chulalongkorn Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:37:06.967375|2018-05-31 21:37:06.967375
NCT01540071|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2016-02-23|2012-02-22|2012-02-28|Estimate|||||||2016-02-23|2016-02-25|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer|A Phase II Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer|Completed||Phase 2|38|Actual|Io Therapeutics||1|||f||||t||||||||||2018-05-31 21:37:07.062582|2018-05-31 21:37:07.062582
NCT01540058|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-02-09|2012-02-22|2012-02-28|Estimate|||||||2016-02-09|2016-02-10|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|March 2016|Anticipated|2016-03-31||Interventional|GEFCAPI04||Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP|A Randomised Phase III Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With Carcinoma of an Unknown Primary (CUP)|Unknown status|Recruiting|Phase 3|223|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 21:37:07.146868|2018-05-31 21:37:07.146868
NCT01540045|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2013-07-23||2015-03-06|2012-02-22|2012-02-28|Estimate|2015-03-06|2015-03-18|Estimate||||2015-03-06|2015-03-18|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Observational||We invited to participate 72 patients with NSCLC newly diagnosed, but only 40 patients completed their baseline evaluation and their follow up after two cycles of chemotherapy using paclitaxel (175 mg/m2) and cisplatin (75 mg/m2). The main reason of exclusion was death followed by not returning to the institution.|Effect of Chemotherapy With Paclitaxel/Cisplatin on Development Dysgeusia in Non Small Cell Lung Cancer|Effect of Chemotherapy With Paclitaxel and Cisplatin on Development Dysgeusia in Non-small Cell Lung Cancer Patients|Completed|||40|Actual|Instituto Nacional de Cancerologia de Mexico|No analysis of serum zinc was performed and a small number of subjects analyzed.||1||f||||t||||||||||2018-05-31 21:37:07.297594|2018-05-31 21:37:07.297594
NCT01540032|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-02-22|2012-02-22|2012-02-28|Estimate|||||||2012-02-22|2012-02-28|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Low Salicylate Diet in Aspirin Exacerbated Respiratory Disease||Unknown status|Not yet recruiting|N/A|80|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 21:37:07.889438|2018-05-31 21:37:07.889438
NCT01540019|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2012-02-22|2012-02-22|2012-02-28|Estimate|||||||2012-02-22|2012-02-28|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Paullinia Cupana for Anorexia in Oncologic Patients|Guarana (Paullinia Cupana) for Anorexia Related to Cancer|Unknown status|Recruiting|Phase 1/Phase 2|35|Anticipated|Faculdade de Medicina do ABC||1|||f||||f||||||||||2018-05-31 21:37:07.981752|2018-05-31 21:37:07.981752
NCT01540006|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2017-10-17|2012-02-27|2012-02-28|Estimate|||||||2017-10-17|2017-10-18|Actual|January 2009||2009-01-31|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Outpatient Cardiac Rehabilitation in Austria||Completed|||1200|Actual|Paracelsus Medical University|||||f||||f||||||||||2018-05-31 21:37:08.129108|2018-05-31 21:37:08.129108
NCT01539993|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2014-05-23|2012-02-27|2012-02-28|Estimate|||||||2014-05-23|2014-05-28|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Prospective Liver Study|Prospective Analysis of Liver Cancer Treatment and Interventions|Completed|||400|Actual|Emory University|||1||f||||f||||||||||2018-05-31 21:37:08.195762|2018-05-31 21:37:08.195762
NCT01539980|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2015-03-10||2015-04-01|2012-02-22|2012-02-28|Estimate|2015-04-01|2015-04-02|Estimate||||2015-04-01|2015-04-02|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Clinical Study on Silk Sericin Wound Dressing for Split-thickness Skin Graft Donor Sites Treatment|Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment|Completed||Phase 1/Phase 2|30|Actual|Chulalongkorn University||1|||f||||t||||||||||2018-05-31 21:37:08.269878|2018-05-31 21:37:08.269878
NCT01539967|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-04-05|2012-02-22|2012-02-28|Estimate|||||||2012-04-05|2012-04-06|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|GASTROMANCH||Impact of the Residual Gastric Volume in Laparoscopic Sleeve Gastrectomy's Failure|Is the Residual Gastric Volume After Sleeve Gastrectomy an Objective Criterion to Adapt the Treatment Strategy After Failure?|Completed||N/A|90|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||f||||||||||2018-05-31 21:37:08.471144|2018-05-31 21:37:08.471144
NCT01539954|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-10-06|2012-02-22|2012-02-28|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|cASCA||Computerized Alcohol Screening for Children and Adolescents|Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care|Withdrawn|||0|Actual|Boston Children’s Hospital|||1|The project was not funded.|f||||f||||||||No||2018-05-31 21:37:08.573385|2018-05-31 21:37:08.573385
NCT01539941|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-08-03|2012-02-27|2012-02-28|Estimate|||||||2015-08-03|2015-08-04|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD in Routine Care|Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD in Routine Care|Completed||Phase 1|14|Actual|The National Center on Addiction and Substance Abuse at Columbia University||1|||f||||t||||||||||2018-05-31 21:37:08.688166|2018-05-31 21:37:08.688166
NCT01539928|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-06-24|2012-02-27|2012-02-28|Estimate|||||||2013-06-24|2013-06-25|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Observational|DILUCE||Dual PET/CT Imaging in Lung Cancer|Dual PET/CT Imaging in Lung Cancer (Danish Title: En og Tre Timers FDG-PET/CT Ved Lungecancer)|Unknown status|Recruiting||216|Anticipated|Odense University Hospital|||1||f||||t||||||Samples With DNA|"~     Fresh frozen sample of primary lung cancer tumor~   "|||2018-05-31 21:37:08.77105|2018-05-31 21:37:08.77105
NCT01539915|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-02-27|2012-02-27|2012-02-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|April 2007||2007-04-30|February 2012|2012-02-29||||November 2007|Actual|2007-11-30||Interventional|||Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients|A Single Center, Open Label Exploratory Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Topically Administered BCT194 in Dermal Interstitial Fluid in Psoriatic Patients Using Open Flow Microperfusion|Completed||Phase 1|12|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:37:08.839419|2018-05-31 21:37:08.839419
NCT01539902|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-03-05|2012-02-22|2012-02-28|Estimate|||||||2012-03-05|2012-03-06|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|hUC-MSC-SLE||Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis|A Randomized, Double Blind, Parallel Group, Placebo Controlled Research of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis|Unknown status|Recruiting|Phase 2|25|Anticipated|CytoMed & Beike||2|||f||||t||||||||||2018-05-31 21:37:08.920156|2018-05-31 21:37:08.920156
NCT01539889|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-09-30|2012-02-27|2012-02-28|Estimate|||||||2014-09-30|2014-10-01|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|||Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation|Phase-I Study of Radiolabeled DFH-12 (PulmoBind) for Molecular Imaging of the Pulmonary Circulation|Completed||Phase 1|20|Actual|Montreal Heart Institute||1|||f||||t||||||||||2018-05-31 21:37:09.022403|2018-05-31 21:37:09.022403
NCT01539876|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2014-03-24|2012-02-22|2012-02-28|Estimate|||||||2014-03-24|2014-03-26|Estimate||||March 2014|2014-03-31||||||||Interventional|TNFactor||Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel|Assessing Serial Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neo-adjuvant Taxane Chemotherapy|Withdrawn||Phase 1|0|Actual|Lawson Health Research Institute||1||Disease Site Team changed research focus unlikely to have sufficient support to complete study|f||||f||||||||||2018-05-31 21:37:09.103733|2018-05-31 21:37:09.103733
NCT01539863|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2017-08-15|2012-02-27|2012-02-28|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2012||2012-03-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Chiropractic Maintenance Care of Persistent or Recurrent Low Back Pain|Chiropractic Maintenance Care of Persistent or Recurrent Low Back Pain. A Randomized Controlled Trial With 1 Year Follow up|Completed||N/A|321|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:37:09.169208|2018-05-31 21:37:09.169208
NCT01539850|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-02-27|2012-02-27|2012-02-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102|Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102. A Prospective Multicenter Study|Completed||N/A|34|Actual|IntraPace, Inc|||||f||||f||||||||||2018-05-31 21:37:09.228452|2018-05-31 21:37:09.228452
NCT01539837|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-10-16|2012-02-27|2012-02-28|Estimate|||||||2012-10-16|2012-10-17|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|DeferipronPD||A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease|A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease|Unknown status|Recruiting|Phase 2|36|Anticipated|Imperial College London||3|||f||||t||||||||||2018-05-31 21:37:09.298719|2018-05-31 21:37:09.298719
NCT01539824|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-12-01|2012-02-27|2012-02-28|Estimate|||||||2016-12-01|2016-12-02|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer|A Phase II, Single Arm, Investigative Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Patients With Previously Treated Colorectal Cancer|Completed||Phase 2|12|Actual|Immodulon Therapeutics Ltd||1|||f||||t||||||||No||2018-05-31 21:37:09.414443|2018-05-31 21:37:09.414443
NCT01539811|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|2015-04-13||2015-04-13|2012-02-27|2012-02-28|Estimate|2015-04-13|2015-04-27|Estimate||||2015-04-13|2015-04-27|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Diabetic Foot Infection Antibiotic Study|Surgical Management of Diabetic Foot Infections - The Role of Post-Operative Antibiotics|Terminated||N/A|2|Actual|Greenville Health System||2||Principal investigator decided to terminate the study.|f||||f||||||||||2018-05-31 21:37:09.637976|2018-05-31 21:37:09.637976
NCT01539798|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-02-27|2012-02-27|2012-02-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Body Composition and Serum Biochemistry After Intravenous Infusion or Oral Intake of Saline in Healthy Volunteers|Changes in Body Composition, Hematological Parameters, and Serum Biochemistry and After Rapid Intravenous Infusion or Oral Intake of 2L of 0.9% Saline Solution in Young Healthy Volunteers. A Randomized Cross-over Study|Completed||N/A|10|Actual|Federal University of Mato Grosso do Sul||2|||f||||t||||||||||2018-05-31 21:37:09.889224|2018-05-31 21:37:09.889224
NCT01539785|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2014-08-21|2012-02-27|2012-02-28|Estimate|||||||2014-08-21|2014-08-22|Estimate|September 2012||2012-09-30|August 2014|2014-08-31||||September 2018|Anticipated|2018-09-30||Interventional|HORSE||Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence|Surgery Plus Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Versus Surgery Alone in Patients With Platinum-sensitive First Recurrence of Ovarian Cancer: a Prospective Randomized Multicenter Trial.|Recruiting||N/A|158|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 21:37:10.022881|2018-05-31 21:37:10.022881
NCT01539772|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2017-01-23|2012-02-27|2012-02-28|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping|PITT0112: Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping|Active, not recruiting|||85|Actual|Cooperative International Neuromuscular Research Group|||1||f||||t||||||||||2018-05-31 21:37:10.142811|2018-05-31 21:37:10.142811
NCT01539759|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2015-06-16||2017-09-12|2012-02-21|2012-02-27|Estimate|2015-06-16|2015-07-09|Estimate||||2017-09-12|2017-10-13|Actual|March 2012||2012-03-31|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|IUD@CSD||Immediate Postplacental Insertion of IUDs at Time of Cesarean Delivery: A Randomized Clinical Trial|Immediate Postplacental Insertion of Intrauterine Devices at Time of Cesarean Delivery: A Randomized Clinical Trial|Completed||N/A|112|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:37:10.275832|2018-05-31 21:37:10.275832
NCT01539746|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-01-30|2012-02-24|2012-02-27|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|SIMPLIFy TAVI||Transcatheter Aortic Valve Implantation Without Predilation|Use of the Self-Expanding Medtronic CoreValve Prosthesis Without Predilation in Patients With Severely IMPaired Left-VentrIcular Ejection Fraction for TAVI Trial - The SIMPLIFy TAVI Trial|Unknown status|Recruiting|N/A|110|Anticipated|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 21:37:10.687659|2018-05-31 21:37:10.687659
NCT01539733|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2017-04-06|2012-02-24|2012-02-27|Estimate|||||||2017-04-06|2017-04-07|Actual|March 2010||2010-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer|Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer|Completed||N/A|101|Actual|VU University Medical Center||2|||f||||f||||||||||2018-05-31 21:37:10.833245|2018-05-31 21:37:10.833245
NCT01539720|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-01-26|2012-02-24|2012-02-27|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LIFE||Levonorgestrel Intrauterine System For Emergency Contraception|Levonorgestrel Intrauterine System For Emergency Contraception: a Randomized Control Trial|Recruiting||N/A|532|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:37:10.923455|2018-05-31 21:37:10.923455
NCT01539707|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-10-29|2012-02-22|2012-02-27|Estimate|||||||2012-10-29|2012-10-31|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder|A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO)|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:37:11.053167|2018-05-31 21:37:11.053167
NCT01539694|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-09-28|2012-02-22|2012-02-27|Estimate|||||||2012-09-28|2012-10-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:37:11.158387|2018-05-31 21:37:11.158387
NCT01539681|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2016-02-16|2012-02-22|2012-02-27|Estimate|||||||2016-02-16|2016-02-18|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Observational|STELLA||Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy|Sorafenib Treatment Modalities for HEpatoceLLular Carcinoma Patients in ItAly|Completed|||234|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:37:11.200289|2018-05-31 21:37:11.200289
NCT01539668|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2014-02-25|2012-02-24|2012-02-27|Estimate|||||||2014-02-25|2014-02-26|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2012|Actual|2012-12-31||Observational|careHPV||Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas|CareHPV - Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas|Completed|||5079|Actual|Barretos Cancer Hospital|||1||f||||f||||||Samples With DNA|"~     Cervical cell samples (cytology)~   "|||2018-05-31 21:37:11.293909|2018-05-31 21:37:11.293909
NCT01539655|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-04-28|2012-02-22|2012-02-27|Estimate|||||||2017-04-28|2017-05-02|Actual|February 2012||2012-02-29|April 2017|2017-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Vandetanib||Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib|A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects When a Single Oral Dose of Vandetanib 300 mg is Administered Alone and in Combination With Omeprazole or Ranitidine|Completed||Phase 1|34|Actual|Sanofi||4|||f||||||||||||||2018-05-31 21:37:11.377331|2018-05-31 21:37:11.377331
NCT01539642|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|2013-10-24||2015-09-30|2012-02-24|2012-02-27|Estimate|2014-01-30|2014-02-03|Estimate||||2015-09-30|2015-10-20|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery|Completed||Phase 3|172|Actual|AcelRx Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:37:11.491744|2018-05-31 21:37:11.491744
NCT01539629|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-12-04|2012-02-24|2012-02-27|Estimate|||||||2012-12-04|2012-12-05|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Observational|ELEVATE 3||ELEVATE (Evaluation of Left Ventricular Autothreshold) 3.0|Evaluation of Left Ventricular Autothreshold|Completed|||50|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 21:37:11.768339|2018-05-31 21:37:11.768339
NCT01539122|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2018-03-16|2012-02-24|2012-02-27|Estimate|||||||2018-03-16|2018-03-20|Actual|April 2012||2012-04-30|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|TMGlenoid||Clinical Experience With the Zimmer Trabecular Metal (TM) Glenoid in Total Shoulder Arthroplasty|A Multi-Centre, Randomized Controlled Study on the Zimmer TM Glenoid Component Compared to Cemented Glenoid Component|Active, not recruiting||N/A|104|Anticipated|Joint Preservation Centre of BC||2|||f||||f||||||||||2018-05-31 21:37:20.953266|2018-05-31 21:37:20.953266
NCT01539616|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-10-25|2012-02-24|2012-02-27|Estimate|||||||2013-10-25|2013-10-28|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia|A Multicentric Prospective Randomized Double Blind Parallel Group Active Controlled Study to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia|Completed||Phase 2|109|Actual|Cadila Healthcare Limited||4|||f||||t||||||||||2018-05-31 21:37:11.850988|2018-05-31 21:37:11.850988
NCT01539603|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-06-11|2012-02-24|2012-02-27|Estimate|||||||2015-06-11|2015-06-12|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|DEBfirst||Comparison of Drug Eluting Balloon and Drug Eluting Stent|Comparison of Drug-Eluting Balloon First and Then Bare Metal Stent With Drug-eluting Stent for Treatment of de Novo Lesions (DEB First): A Randomized Controlled Single Center Clinical Trial|Completed||Phase 2|180|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 21:37:11.975315|2018-05-31 21:37:11.975315
NCT01539590|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|2014-10-29||2014-11-07|2012-02-22|2012-02-27|Estimate|2014-10-29|2014-11-04|Estimate||||2014-11-07|2014-11-21|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack|A Phase 2 Pilot Study to Evaluate the Safety and Activity of BB3 as an Adjunct to Percutaneous Coronary Intervention (PCI) in Subjects Presenting With Acute ST Segment Elevation Myocardial Infarction (STEMI)|Terminated||Phase 2|5|Actual|Angion Biomedica Corp|Five subjects were enrolled into the study; 3 subjects were randomized to BB3 and 2 subjects to placebo. All the 3 subjects randomized to BB3 discontinued the study prematurely. The 2 subjects randomized to placebo completed study treatment.|2|||f||||t||||||||||2018-05-31 21:37:12.091703|2018-05-31 21:37:12.091703
NCT01539577|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2016-04-18|2012-02-22|2012-02-27|Estimate|||||||2016-04-18|2016-04-20|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||A Long-Term Safety Study of OZURDEX® in Clinical Practice||Completed|||875|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:37:12.350765|2018-05-31 21:37:12.350765
NCT01539564|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-06-25|2012-02-21|2012-02-27|Estimate|||||||2014-06-25|2014-06-26|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Arestin - Use in Subjects With Peri-Implantitis|Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects With Peri-Implantitis|Completed||Phase 3|215|Actual|OraPharma||2|||f||||f||||||||||2018-05-31 21:37:12.432168|2018-05-31 21:37:12.432168
NCT01539551|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-11-12|2012-02-24|2012-02-27|Estimate|||||||2012-11-12|2012-11-14|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Investigation of the Role of Brain Natriuretic Peptide and Lactate in Early Goal-directed Therapy for Patients With Severe Sepsis and Septic Shock|Investigation of the Role of Brain Natriuretic Peptide and Lactate in Early Goal-directed Therapy for Patients With Severe Sepsis and Septic Shock|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     blood(serum/plasma)~   "|||2018-05-31 21:37:12.504192|2018-05-31 21:37:12.504192
NCT01539538|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|2013-11-25||2015-09-16|2012-02-24|2012-02-27|Estimate|2014-02-10|2014-03-27|Estimate||||2015-09-16|2015-10-01|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain|A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain|Completed||Phase 3|357|Actual|AcelRx Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:37:13.667417|2018-05-31 21:37:13.667417
NCT01539525|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2016-09-29||2017-03-02|2012-02-24|2012-02-27|Estimate|2017-03-02|2017-04-14|Actual||||2017-03-02|2017-04-14|Actual|September 5, 2011|Actual|2011-09-05|March 2017|2017-03-31|January 28, 2015|Actual|2015-01-28|January 28, 2015|Actual|2015-01-28||Interventional|ProjectSTART||Screening to Augment Referral to Treatment- Project START|Screening to Augment Referral to Treatment- Project START|Completed||N/A|439|Actual|Yale University|"Results may not be generalizable to populations differing from population from which sample was drawn.~Outcomes relied upon self-report, although we did try to verify through lab results for substance use and medical records/ provider for treatment."|3|||f||||f||||||||No|We will require data request with delineation of variables of interest. Only de-identified data will be released after evaluation of the request|2018-05-31 21:37:14.107597|2018-05-31 21:37:14.107597
NCT01539512|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|2014-10-09||2015-04-20|2012-02-24|2012-02-27|Estimate|2014-10-09|2014-10-16|Estimate||||2015-04-20|2015-05-07|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional||ITT Analysis Set: randomized participants with treatment group designated according to initial randomization.|A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia|Completed||Phase 3|220|Actual|Gilead Sciences|Following a recommendation by an independent Data Monitoring Committee (DMC), the study was stopped early due to highly statistically significant results for the primary efficacy endpoint of progression-free survival.|2|||f||||t||||||||||2018-05-31 21:37:15.230123|2018-05-31 21:37:15.230123
NCT01539499|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2017-08-30|2012-02-24|2012-02-27|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2010||2010-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Complications of Endocrine Surgery: Data From the United HealthSystem Consortium|Complications of Endocrine Surgery: Data From the United Health System Consortium|Completed|||1000|Actual|University of Arkansas|||||f||||f||||||||||2018-05-31 21:37:16.295407|2018-05-31 21:37:16.295407
NCT01539486|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2017-06-12|2012-02-24|2012-02-27|Estimate|||||||2017-06-12|2017-06-14|Actual|January 2010||2010-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Relationship of Preoperative Parathyroid Hormone (PTH) and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy|Relationship of Preoperative PTH and Ex-Vivo Gamma Counts in Minimally Invasive Parathyroidectomy|Active, not recruiting|||200|Anticipated|University of Arkansas|||||f||||f||||||||||2018-05-31 21:37:16.464262|2018-05-31 21:37:16.464262
NCT01539473|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2016-05-02|2012-02-24|2012-02-27|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge|A Phase 1, Blinded, Placebo-Controlled, Crossover TR-701 FA Study of Blood Pressure Response Post-Tyramine Challenge|Completed||Phase 1|30|Actual|Trius Therapeutics LLC||2|||f||||f||||||||||2018-05-31 21:37:16.647049|2018-05-31 21:37:16.647049
NCT01539460|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2017-05-11|2012-02-24|2012-02-27|Estimate|||||||2017-05-11|2017-05-12|Actual|February 2012||2012-02-29|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||A Minimally Invasive Surgery for Axillary Osmidrosis: Combined Liposuction With Subcutaneous Pruning|A Refined Minimally Invasive Procedure for Radical Treatment of Axillary Osmidrosis: Combined Tumescent Liposuction With Subcutaneous Pruning Through a Small Incision|Enrolling by invitation||N/A|30|Anticipated|Tang-Du Hospital||1|||f||||f||||||||||2018-05-31 21:37:16.744257|2018-05-31 21:37:16.744257
NCT01539447|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-10-04|2012-02-21|2012-02-27|Estimate|||||||2017-10-04|2017-10-05|Actual|January 2012||2012-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy|Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy|Active, not recruiting||Early Phase 1|342|Anticipated|University of Utah||2|||f||||t||||||||||2018-05-31 21:37:16.855081|2018-05-31 21:37:16.855081
NCT01539434|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-05-18|2012-02-24|2012-02-27|Estimate|||||||2017-05-18|2017-05-19|Actual|September 2010|Actual|2010-09-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|COPD||Behavioral Intervention to Maintain Physical Capacity and Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Behavioral Medicine Intervention to Maintain Physical Capacity and Level of Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 2|100|Anticipated|Uppsala University||2|||f||||t||||||||||2018-05-31 21:37:16.983135|2018-05-31 21:37:16.983135
NCT01539421|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-02-27|2012-02-21|2012-02-27|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Use of Wii Home Computer in Patients With Chronic Obstructive Pulmonary Disease: Effects on Quality of Life|The Use of Home Exercise Program Based on Interactive Entertainment Computer System in Patients With Moderate to Severe COPD: Its Feasibility and Effects on Exercise Performance, Physical Activity, Dyspnea, and Quality of Life|Completed||N/A|20|Actual|Saint Francis Care||1|||f||||f||||||||||2018-05-31 21:37:17.158816|2018-05-31 21:37:17.158816
NCT01539408|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-21|2012-02-21|2012-02-27|Estimate|||||||2012-02-21|2012-02-27|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion in Nigeria|Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion|Completed||Phase 1|90|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 21:37:17.286097|2018-05-31 21:37:17.286097
NCT01539395|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-02-24|2012-02-24|2012-02-27|Estimate|||||||2012-02-24|2012-02-27|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Observational|||A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis|A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis|Unknown status|Recruiting||65|Anticipated|MSDx, Inc.|||3||f||||f||||||Samples With DNA|"~     Blood remaining after testing for MSDx Complex-1 will be retained for evaluation for other MS~     biomarkers~   "|||2018-05-31 21:37:17.353153|2018-05-31 21:37:17.353153
NCT01539382|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-10-22|2012-02-24|2012-02-27|Estimate|||||||2015-10-22|2015-10-23|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Measuring and Treating Brain Oxygen Levels in Open Heart Surgery|Optimizing Cerebral Oxygenation in Cardiac Surgery|Completed||N/A|140|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:37:17.483254|2018-05-31 21:37:17.483254
NCT01539369|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2014-05-21|2012-02-24|2012-02-27|Estimate|||||||2014-05-21|2014-05-22|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|LWW||The Leeds Women's Wellbeing (LWW) Study|A Study to Investigate the Short and Long Term Effects of Two 12-week Healthy Eating Interventions on Body Weight, Body Composition, Appetite Control, Biomarkers of Health and Subjective Wellbeing in Overweight Women|Completed||N/A|80|Actual|University of Leeds||2|||f||||f||||||||||2018-05-31 21:37:17.583627|2018-05-31 21:37:17.583627
NCT01539356|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2016-03-15|2012-02-24|2012-02-27|Estimate|||||||2016-03-15|2016-03-16|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Observational|||Hepcidin Levels in Preterm Infants|Hepcidin Levels in Preterm Infants Receiving Blood Transfusion and During Sepsis.|Completed|||62|Actual|Meir Medical Center|||1||f||||f||||||||||2018-05-31 21:37:17.770415|2018-05-31 21:37:17.770415
NCT01539343|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-04-15|2012-02-24|2012-02-27|Estimate|||||||2016-04-15|2016-04-18|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)|Phase II Pilot Study to Estimate the Adverse Events Associated With the Lock Solution When Used to Salvage Central Venous Catheter (CVC) in the Setting of a Central Line Associated Bloodstream Infection (CLABSI)|Completed||Phase 2|31|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:37:17.861468|2018-05-31 21:37:17.861468
NCT01539330|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-10-31|2012-02-21|2012-02-27|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|VORTarget-site||Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy|Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy|Completed||Phase 4|9|Actual|Martin-Luther-Universität Halle-Wittenberg|||||f||||f||||||||||2018-05-31 21:37:17.968068|2018-05-31 21:37:17.968068
NCT01539317|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2015-06-05||2017-04-12|2012-02-21|2012-02-27|Estimate|2015-07-07|2015-08-04|Estimate||||2017-04-12|2017-04-14|Actual|December 2011||2011-12-31|April 2017|2017-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Therapy to Prevent Sexual Pain in Breast Cancer Survivors|Therapy to Prevent Sexual Pain in Menopausal Survivors of Breast Cancer|Completed||Phase 3|50|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-05-31 21:37:18.156212|2018-05-31 21:37:18.156212
NCT01539304|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-26|2012-02-24|2012-02-27|Estimate|||||||2012-02-26|2012-02-28|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||"Clinical Trial to Evaluate the Safety and Efficacy of CITUS Dry Syrup in Children With Perennial Allergic Rhinitis"|"Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of CITUS Dry Syrup in Children With Perennial Allergic Rhinitis: Double Blinded, Randomized, Placebo Controlled, Parallel Designed, Multi-centered, Phase III Study"|Completed||Phase 3|245|Actual|SamA Pharmaceutical Co., Ltd||2|||f||||||||||||||2018-05-31 21:37:18.799937|2018-05-31 21:37:18.799937
NCT01538979|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2015-12-17|2012-02-24|2012-02-27|Estimate|||||||2015-12-17|2015-12-18|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Phase II Study of Grass Pollen Allergy Vaccine BM32|Phase IIb Study on the Safety and Efficacy of BM32, a Recombinant Hypoallergenic Vaccine for Immunotherapy of Grass Pollen Allergy|Completed||Phase 2|181|Actual|Biomay AG||3|||f||||t||||||||||2018-05-31 21:37:23.260859|2018-05-31 21:37:23.260859
NCT01539291|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2018-05-04|2012-02-21|2012-02-27|Estimate|||||||2018-05-04|2018-05-08|Actual|October 3, 2012|Actual|2012-10-03|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116|A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 3|160|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 21:37:18.885159|2018-05-31 21:37:18.885159
NCT01539278|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-08-04|2012-02-21|2012-02-27|Estimate|||||||2015-08-04|2015-08-05|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Effect of Adenotonsillectomy on Quality of Life in Children With Mild Obstructive Sleep Apnea|Effect of Adenotonsillectomy on Quality of Life in Children With Mild Obstructive Sleep Apnea|Completed||N/A|113|Actual|Eastern Virginia Medical School||2|||f||||f||||||||||2018-05-31 21:37:19.149658|2018-05-31 21:37:19.149658
NCT01539265|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-10-29|2012-02-24|2012-02-27|Estimate|||||||2013-10-29|2013-10-30|Estimate||||October 2013|2013-10-31||||||||Interventional|||A Dose-finding Study of Silodosin in Patients With Urinary Calculi|A Randomized, Double-blind, Placebo-controlled, Phase II Study of Silodosin in Patients With Urinary Calculi|Completed||Phase 2|300||Kissei Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:37:19.329083|2018-05-31 21:37:19.329083
NCT01539252|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2016-12-07|2012-02-21|2012-02-27|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Examining the Impact of Using Two Dialysers in Parallel on Dialysis Adequacy in Hemodialysis Patients|Examining the Impact of Using Two Dialysers in Parallel on Dialysis Adequacy in Hemodialysis Patients|Completed||N/A|33|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 21:37:19.539351|2018-05-31 21:37:19.539351
NCT01539239|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-03-19|2012-02-24|2012-02-27|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2012||2012-01-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)|The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial|Active, not recruiting||N/A|1143|Actual|Ivantis, Inc.||2|||f||||t||||||||||2018-05-31 21:37:19.707118|2018-05-31 21:37:19.707118
NCT01539226|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21||2018-03-14|2018-03-14|2012-02-24|2012-02-27|Estimate||||2018-03-14|2018-03-16|Actual|2018-03-14|2018-03-16|Actual|March 2012||2012-03-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women|Completed||N/A|1950|Actual|International Partnership for Microbicides, Inc.||2|||f||||t||||||||No||2018-05-31 21:37:19.870971|2018-05-31 21:37:19.870971
NCT01539213|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2015-02-04|2012-02-21|2012-02-27|Estimate|||||||2015-02-04|2015-02-06|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|OFM ISF||Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg|An Exploratory Study to Investigate the Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid Using Open Flow Microperfusion After a Single Subcutaneous Administration of 300 mg in Healthy Subjects and Psoriatic Patients|Completed||Phase 1|16|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:37:19.991638|2018-05-31 21:37:19.991638
NCT01539200|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2014-03-25|2012-02-21|2012-02-27|Estimate|||||||2014-03-25|2014-03-26|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|NUDAL||Effects of Daily Nutritional Supplementation in Combination With a Eurhythmics Training (NUDAL)|Effects of 6-months Once Daily Nutritional Supplementation in Combination With a Once Weekly Jacques-Delacroze Eurhythmics Training (NUDAL) on Functionality, Probability of Independence and/or Functional Reserve Among Community-dwelling Seniors|Completed||Phase 3|80|Anticipated|Nestlé||2|||f||||f||||||||||2018-05-31 21:37:20.079656|2018-05-31 21:37:20.079656
NCT01539187|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-03-13|2012-02-24|2012-02-27|Estimate|||||||2015-03-13|2015-03-17|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|FAST-L||Fibroid Ablation Study - Large Fibroids|Symptom Effectiveness Study of VizAblate® Intrauterine Ultrasound-Guided RF Ablation (IUUSgRFA) in the Ablation of Large Uterine Fibroids|Terminated||N/A|6|Actual|Gynesonics||1||Investigational device changes|f||||f||||||||||2018-05-31 21:37:20.185695|2018-05-31 21:37:20.185695
NCT01539174|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-03-01|2012-02-21|2012-02-27|Estimate|||||||2016-03-01|2016-03-03|Estimate||||March 2016|2016-03-31||||||||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma|A Phase II Study of Rituximab Intense Dosing With CHOP-21 (RID-CHOP) in Patients With Previously Untreated High or High-Intermediate Risk IPI (3-5) Diffuse Large B-Cell Lymphoma (DLBCL)|Withdrawn||Phase 2|0|Actual|Fox Chase Cancer Center||1||No Funding Source and Competing Trials|f||||t||||||||||2018-05-31 21:37:20.313306|2018-05-31 21:37:20.313306
NCT01539161|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-10-10|2012-02-21|2012-02-27|Estimate|||||||2016-10-10|2016-10-12|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease|Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease|Terminated||Phase 4|12|Actual|Medtronic Cardiac Rhythm and Heart Failure||2||Extremely low enrollment rate|f||||f||||||||||2018-05-31 21:37:20.484251|2018-05-31 21:37:20.484251
NCT01539148|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-05-01|2012-02-24|2012-02-27|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Observational|IPTLD||A Five-Year Quality of Life Study for Cancer Patients|A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLDSM ) Chemotherapy and Nutrition Therapy in the Treatment of Cancer - The IPTLDSM QoL Broad Study|Unknown status|Recruiting||50|Anticipated|The Kotsanis Institute|||||f||||f||||||||||2018-05-31 21:37:20.598783|2018-05-31 21:37:20.598783
NCT01539135|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2015-04-30||2015-08-05|2012-02-21|2012-02-27|Estimate|2015-08-05|2015-08-13|Estimate||||2015-08-05|2015-08-13|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Influence of Endotracheal Tube Design on Fluid Leakage Into the Lungs During Surgery|The Influence of Endotracheal Tube Cuff Design on Intraoperative Microaspiration and Postoperative Respiratory Complications|Completed||N/A|80|Actual|Medtronic - MITG|This was a feasibility study and based on the results, we do not believe that a larger, multicenter randomized controlled trial would be appropriate. The study wasn’t powered to find any significant differences.|2|||f||||f||||||||||2018-05-31 21:37:20.671154|2018-05-31 21:37:20.671154
NCT01539109|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-01-04|2012-02-21|2012-02-27|Estimate|||||||2017-01-04|2017-01-05|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Directing Neuroplasticity to Improve Rehabilitative Outcomes of the Upper Limb in Incomplete Quadriplegia|Directing Neuroplasticity to Improve Rehabilitative Outcomes of the Upper Limb in Incomplete Quadriplegia|Recruiting||N/A|10|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No|We will not be sharing or releasing any study data to third parties outside the Cleveland Clinic|2018-05-31 21:37:21.037447|2018-05-31 21:37:21.037447
NCT01539096|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-01-04|2012-02-21|2012-02-27|Estimate|||||||2017-01-04|2017-01-05|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Brain Stimulation-aided Stroke Rehabilitation: Neural Mechanisms of Recovery|Brain Stimulation-aided Stroke Rehabilitation: Neural Mechanisms of Recovery|Recruiting||Phase 1/Phase 2|30|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No|We will not be sharing or releasing any study data to third parties outside the Cleveland Clinic.|2018-05-31 21:37:21.130944|2018-05-31 21:37:21.130944
NCT01539083|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2016-12-16||2018-02-07|2012-02-21|2012-02-27|Estimate|2016-12-16|2017-02-09|Estimate||||2018-02-07|2018-03-08|Actual|January 13, 2012|Actual|2012-01-13|February 2018|2018-02-28|January 9, 2018|Actual|2018-01-09|December 30, 2015|Actual|2015-12-30||Interventional|VCAT|Baseline population was defined as all enrolled participants who received at least 1 non-zero dose of any study drug in the induction phase.|Velcade (Bortezomib) Consolidation After Transplant|An Open-label, Randomised Trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma After Receiving Bortezomib, Cyclophosphamide, Dexamethasone (VCD) Induction and Autologous Stem Cell Transplant|Completed||Phase 3|256|Actual|Janssen Scientific Affairs, LLC||3|||f||||t|f|f||||||||2018-05-31 21:37:21.260859|2018-05-31 21:37:21.260859
NCT01539070|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2013-07-01||2014-03-19|2012-02-24|2012-02-27|Estimate|2014-03-19|2014-04-22|Estimate||||2014-03-19|2014-04-22|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Intervention for the Prevention of Obesity in Preschool|Design and Feasibility of a Clinical-based Intervention to Prevent Obesity in Preschool Children|Completed||N/A|306|Actual|Coordinación de Investigación en Salud, Mexico|35% of families did not complete follow-up at 3 months, our primary endpoint. To address the resulting bias from missing data we performed multiple imputation of missing information on covariates and behavioral and BMI outcomes.|2|||f||||f||||||||||2018-05-31 21:37:22.225996|2018-05-31 21:37:22.225996
NCT01539057|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2014-12-03|2012-02-21|2012-02-27|Estimate|||||||2014-12-03|2014-12-04|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|January 2015|Anticipated|2015-01-31|September 2013|Actual|2013-09-30||Interventional|FibstudLT||The Efficacy of the Administration of Fibrinogen in Liver Transplantation|A Multicenter, Placebo Controlled Study to Evaluate the Efficacy of the Administration of Fibrinogen on Blood Product Requirements in Liver Transplantation|Unknown status|Active, not recruiting|Phase 3|132|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 21:37:22.647414|2018-05-31 21:37:22.647414
NCT01539044|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-08-06|2012-02-24|2012-02-27|Estimate|||||||2015-08-06|2015-08-07|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ProjectO5Rs||Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal|Phase 4 Study of Optimal Relaxation With Rocuronium Infusion Followed by Rapid Reliable Reversal With Sugammadex: A Comparison With Conventional Practice|Completed||Phase 4|49|Actual|Hospital Sultanah Aminah Johor Bahru||2|||f||||t||||||||||2018-05-31 21:37:22.754713|2018-05-31 21:37:22.754713
NCT01539031|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-09-16|2012-02-24|2012-02-27|Estimate|||||||2015-09-16|2015-09-17|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease|Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease|Completed||Phase 3|351|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 21:37:22.860207|2018-05-31 21:37:22.860207
NCT01539018|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2015-08-03|2012-02-24|2012-02-27|Estimate|||||||2015-08-03|2015-08-05|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE|A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE|Terminated||Phase 2|77|Actual|Egyptian Society of Liver Cancer||2||After interim results data showed no evidence of a difference between both groups|f||||t||||||||||2018-05-31 21:37:23.012475|2018-05-31 21:37:23.012475
NCT01539005|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-02-01|2012-02-21|2012-02-27|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2009||2009-11-30|February 2017|2017-02-28|April 23, 2014|Actual|2014-04-23|April 23, 2014|Actual|2014-04-23||Observational|TRuTH||Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy|Is Tuberculosis Recurrence in Treated Tuberculosis-Human Immunodeficiency Virus (HIV) Co-Infected Patients Relapse or Re-infection?|Completed|||402|Actual|Centre for the AIDS Programme of Research in South Africa|||||f||||t||||||Samples With DNA|"~     Stored Plasma/Serum/PBMCs: Participants who consent to have additional samples stored for~     future testing will have serum, plasma and PBMCs stored . Possible uses of plasma include~     assessment of host genetics profiles, including HLA profile, additional viral load~     assays.Possible uses of serum include additional safety serology and evaluation of suspected~     IRIS on participants where indicated. The PBMCs will be used to test for IRIS/PR when~     suspected.~      Other potential tests that may be performed on the stored specimens include new generation~     assays of immunity.~      Stored Sputum Isolates :RFLP testing will be performed from stored bacterial isolates on all~     positive cultures in which recurrence is suspected and compared to the initial positive~     culture used to diagnose the TB initially.~   "|||2018-05-31 21:37:23.111254|2018-05-31 21:37:23.111254
NCT01538992|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-07-23|2012-02-21|2012-02-27|Estimate|||||||2013-07-23|2013-07-24|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||Renal Denervation in Patients With Advanced Heart Failure|Phase 3 Study of Renal Denervation That Improves Symptoms of Heart Failure and Enhances Life Quality in Advanced Heart Failure|Withdrawn||Phase 3|0|Actual|Bursa Postgraduate Hospital||2||we could not fined enough patients for the study|f||||f||||||||||2018-05-31 21:37:23.183927|2018-05-31 21:37:23.183927
NCT01538966|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-01-25|2012-02-24|2012-02-27|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acromegaly Combination Treatment Study|Comparison of Combination Low-Dose SRL + Daily Pegvisomant Therapy and High-Dose SRL + Weekly Pegvisomant Therapy|Recruiting||N/A|51|Anticipated|Cedars-Sinai Medical Center||3|||f||||t||||||||||2018-05-31 21:37:23.375621|2018-05-31 21:37:23.375621
NCT01538953|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-02-24|2012-02-24|2012-02-27|Estimate|||||||2012-02-24|2012-02-27|Estimate|March 2003||2003-03-31|February 2012|2012-02-29|January 2004|Actual|2004-01-31|December 2003|Actual|2003-12-31||Interventional|||Pakistan Flocculent Health Outcome Study|Pakistan Flocculent Health Outcome Study|Completed||N/A|8949|Actual|Centers for Disease Control and Prevention||5|||f||||f||||||||||2018-05-31 21:37:23.462972|2018-05-31 21:37:23.462972
NCT01538940|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-09-10|2012-02-24|2012-02-27|Estimate|||||||2012-09-10|2012-09-11|Estimate|November 2011||2011-11-30|September 2012|2012-09-30||||July 2013|Anticipated|2013-07-31||Interventional|||Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand|Randomized Controlled Trial to Compare the Immunogenicity of Intramuscular Versus Intradermal Trivalent Inactivated Split Virion Influenza Vaccine in HIV-infected Men Who Have Sex With Men in Bangkok, Thailand|Unknown status|Recruiting|Phase 4|480|Anticipated|Centers for Disease Control and Prevention||6|||f||||f||||||||||2018-05-31 21:37:23.565089|2018-05-31 21:37:23.565089
NCT01538927|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-12-22|2012-02-18|2012-02-24|Estimate|||||||2012-12-22|2012-12-25|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FS||Effect of Fibrin Sealant on Early Wound Healing|Evaluation of Early Wound Healing Following Use of Fibrin Sealant (FS) in Periodontal Surgery. A Controlled Randomized Clinical Trial.|Completed||Phase 4|15|Anticipated|Chhattisgarh Dental College and Research Institute||2|||f||||f||||||||||2018-05-31 21:37:23.634707|2018-05-31 21:37:23.634707
NCT01538914|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-04-19|2012-02-23|2012-02-24|Estimate|||||||2016-04-19|2016-04-20|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||Analgesic Effect of Intravenous Patient-Controlled Analgesia (IV PCA) Versus Paravertebral Block After Video Assisted Thoracic Surgery (VATS)|A Comparison Between the Analgesic Effect of Intravenous Patient-controlled Analgesia and of Paravertebral Block After Video Assisted Thoracoscopic Surgery|Completed||N/A|76|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:37:23.701008|2018-05-31 21:37:23.701008
NCT01538901|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2017-09-11|2012-02-23|2012-02-24|Estimate|||||||2017-09-11|2017-09-12|Actual|September 2012||2012-09-30|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AKtransplant||Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients|Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients|Terminated||Phase 4|10|Actual|Medical University of Vienna||2||prolonged recruitment phase|f||||t||||||||||2018-05-31 21:37:23.756875|2018-05-31 21:37:23.756875
NCT01538888|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-02-18|2012-02-18|2012-02-24|Estimate|||||||2012-02-18|2012-02-24|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|EWBVEPQL||Effects Whole Body Vibration in Ergospirometrics Parameters and Quality of Life|Effects Whole Body Vibration in Ergospirometrics Parameters, Strength And Quality of Life: A Randomised Controlled Trial|Completed||Phase 1/Phase 2|35|Actual|Universidade Federal de Pernambuco||1|||f||||t||||||||||2018-05-31 21:37:23.841726|2018-05-31 21:37:23.841726
NCT01538875|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2013-05-16|2012-02-23|2012-02-24|Estimate|||||||2013-05-16|2013-05-17|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy|Hydralazine vs. Labetalol for the Management of Hypertensive Crisis in Patients With Hypertensive Disorders of Pregnancy. A Randomized Controlled Trial.|Completed||Phase 3|261|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 21:37:23.929242|2018-05-31 21:37:23.929242
NCT01538862|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|2016-04-01||2017-05-30|2012-02-23|2012-02-24|Estimate|2017-03-13|2017-04-25|Actual||||2017-05-30|2017-06-23|Actual|February 2012||2012-02-29|May 2017|2017-05-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa|Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa|Completed||Phase 2|7|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||No||2018-05-31 21:37:24.028782|2018-05-31 21:37:24.028782
NCT01538849|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2014-07-08|2012-02-23|2012-02-24|Estimate|||||||2014-07-08|2014-07-10|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis|Randomized, Double-blind, Active-controlled, Multi-center Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis|Completed||Phase 2|154|Actual|Yuhan Corporation||5|||f||||f||||||||||2018-05-31 21:37:24.428134|2018-05-31 21:37:24.428134
NCT01538836|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-03-22|2012-02-20|2012-02-24|Estimate|||||||2017-03-22|2017-03-27|Actual|January 2012|Actual|2012-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|CRPS||Calorie Restriction, Protein Supplementation and Metabolic Health|Calorie Restriction and Metabolic Health|Completed||N/A|75|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 21:37:24.593553|2018-05-31 21:37:24.593553
NCT01538823|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2018-05-08|2012-02-23|2012-02-24|Estimate|||||||2018-05-08|2018-05-09|Actual|February 2012||2012-02-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|UP||Urine Proteome of Surgical Patients and Healthy Volunteers|Urine Proteome of Surgical Patients and Healthy Volunteers.|Active, not recruiting|||836|Actual|Washington University School of Medicine|||7||f||||t||||||||||2018-05-31 21:37:24.694426|2018-05-31 21:37:24.694426
NCT01538810|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-06-16|2012-02-23|2012-02-24|Estimate|||||||2016-06-16|2016-06-17|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarker Correlates of Radiologic Imaging|Biomarker Correlates of Radiologic Imaging|Completed|||751|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 21:37:24.830317|2018-05-31 21:37:24.830317
NCT01538797|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-20|2012-02-20|2012-02-24|Estimate|||||||2012-02-20|2012-02-24|Estimate|July 1996||1996-07-31|February 2012|2012-02-29|August 1996|Actual|1996-08-31|August 1996|Actual|1996-08-31||Interventional|||Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States|YF476: Effects of a Single Dose at 3 Dose Levels on 24-hour Ambulatory Gastric pH Compared With Placebo and Ranitidine in Healthy Volunteers|Completed||Phase 1|22|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 21:37:24.896875|2018-05-31 21:37:24.896875
NCT01538238|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-04-24|2012-02-20|2012-02-24|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2, 2012|Actual|2012-05-02|April 2017|2017-04-30|November 14, 2015|Actual|2015-11-14|February 28, 2015|Actual|2015-02-28||Interventional|||pazopanib_NCRCC,Ph2 STUDY||Completed||Phase 2|10|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 21:37:30.540639|2018-05-31 21:37:30.540639
NCT01538784|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-20|2012-02-20|2012-02-24|Estimate|||||||2012-02-20|2012-02-24|Estimate|May 1996||1996-05-31|February 2012|2012-02-29|June 1996|Actual|1996-06-30|June 1996|Actual|1996-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men|A Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of YF476, a Novel, Potent and Selective Gastrin/Cholecystokinin-B Antagonist, in Healthy Male Volunteers|Completed||Phase 1|15|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 21:37:24.966281|2018-05-31 21:37:24.966281
NCT01538771|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-06-18|2012-02-20|2012-02-24|Estimate|||||||2015-06-18|2015-06-19|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling|The Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion: Gauging Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction (ICEBERG).|Completed||Phase 2|80|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 21:37:25.070386|2018-05-31 21:37:25.070386
NCT01538758|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-07-11|2012-02-18|2012-02-24|Estimate|||||||2012-07-11|2012-07-12|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|BARB-01||Ultrasound Guided Needling Versus Ultrasound Guided Corticosteroid Injection Alone, a Randomized Controlled Trial.|Treatment of Calcifying Tendinitis of the Shoulder: Ultrasound Guided Needling With Subacromial Corticosteroid Injection Versus Ultrasound Guided Subacromial Corticosteroid Injection Only, a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|80|Anticipated|Medisch Spectrum Twente||2|||f||||t||||||||||2018-05-31 21:37:25.181622|2018-05-31 21:37:25.181622
NCT01538745|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2013-01-28|2012-02-21|2012-02-24|Estimate|||||||2013-01-28|2013-01-29|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Interventional|||Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department|Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department|Unknown status|Recruiting|Phase 4|210|Anticipated|Brooke Army Medical Center||2|||f||||t||||||||||2018-05-31 21:37:25.314261|2018-05-31 21:37:25.314261
NCT01538732|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-03-19|2012-02-23|2012-02-24|Estimate|||||||2012-03-19|2012-03-20|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Lichen Planus Mucosae at USZ, Efficacy of Oral Alitretinoin|Single-Center, Prospective, Open Label, Single-arm Pilot Study Investigating the Efficacy and Safety of Alitretinoin in Patients Suffering From Severe Mucosal Lichen Planus.|Unknown status|Recruiting|Phase 2|20|Anticipated|University of Zurich|||||f||||t||||||||||2018-05-31 21:37:25.461253|2018-05-31 21:37:25.461253
NCT01538719|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|2018-01-05||2018-04-02|2012-02-23|2012-02-24|Estimate|2018-04-02|2018-05-01|Actual||||2018-04-02|2018-05-01|Actual|December 2011|Actual|2011-12-31|April 2018|2018-04-30|August 11, 2017|Actual|2017-08-11|January 2017|Actual|2017-01-31||Interventional|||IL1-TRAP, Rilonacept, in Systemic Sclerosis|Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial|Completed||Phase 1/Phase 2|24|Actual|Boston University||2|||f||||t|t|f||||||Undecided||2018-05-31 21:37:25.569015|2018-05-31 21:37:25.569015
NCT01538706|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-02-23|2012-02-23|2012-02-24|Estimate|||||||2012-02-23|2012-02-24|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Hospital-based Home Care for Children With Cancer|Hospital-based Home Care for Children With Cancer|Completed||N/A|75|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 21:37:25.896818|2018-05-31 21:37:25.896818
NCT01538693|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-05-15|2012-02-20|2012-02-24|Estimate|||||||2015-05-15|2015-05-19|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury|Molecular Markers of Neuroplasticity During High-Intensity Exercise in Subjects With Incomplete Spinal Cord Injury|Completed||N/A|30|Anticipated|Shirley Ryan AbilityLab||3|||f||||f||||||||||2018-05-31 21:37:26.017227|2018-05-31 21:37:26.017227
NCT01538680|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-03-23|2012-02-21|2012-02-24|Estimate|||||||2018-03-23|2018-03-26|Estimate||||March 2018|2018-03-31||||||||Expanded Access|CONSIGN||Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy|An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy|No longer available|||||Bayer|||||||||||||||||||2018-05-31 21:37:26.232636|2018-05-31 21:37:26.232636
NCT01538667|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-08-20|2012-02-21|2012-02-24|Estimate|||||||2014-08-20|2014-08-21|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases|Non-blinded, Single Dose, Single Centre Trial to Assess the Pulmonary Deposition as Well as Pharmacokinetics, Safety and Tolerability of 99mTc Labeled Ciprofloxacin When Delivered as a Single Dose From a Dry Powder Inhaler to Healthy Subjects With and Without Charcoal Block and Patients Suffering From Bronchiectasis and COPD|Completed||Phase 1|24|Actual|Bayer||4|||f||||f||||||||||2018-05-31 21:37:26.779651|2018-05-31 21:37:26.779651
NCT01538654|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-10-25|2012-02-23|2012-02-24|Estimate|||||||2017-10-25|2017-10-27|Actual|March 10, 2011|Actual|2011-03-10|October 2017|2017-10-31|December 20, 2012|Actual|2012-12-20|December 20, 2012|Actual|2012-12-20||Observational|EMF||Enteroprotein Modified Fast ( EMF )|Enteroprotein Modified Fast ( EMF ) : Clinical Safety and Efficacy. A Six Months Pilot RCT|Completed|||26|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||1||f||||f||||||||||2018-05-31 21:37:26.893156|2018-05-31 21:37:26.893156
NCT01538641|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-07-11|2012-02-23|2012-02-24|Estimate|||||||2012-07-11|2012-07-13|Estimate|October 2003||2003-10-31|July 2012|2012-07-31|December 2008|Actual|2008-12-31|August 2007|Actual|2007-08-31||Interventional|||Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas|Phase II Evaluation Of GROC (Gemcitabine- Rituximab-Oxaliplatin Combination) Given Every 14 Days For The Treatment Of Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|43|Actual|Auxilio Mutuo Cancer Center||1|||f||||t||||||||||2018-05-31 21:37:27.033341|2018-05-31 21:37:27.033341
NCT01538628|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-11-21|2012-02-23|2012-02-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||SpaceOAR System Pivotal Study|Evaluation of SpaceOAR™ System When Used to Create Space Between the Rectum and Prostate in Men Undergoing IG-IMRT for Localized Stage T1-T2 Prostate Cancer: A Randomized, Multicenter, Parallel Arm Controlled Clinical Study|Completed||Phase 3|222|Actual|Augmenix, Inc.||2|||f||||f||||||||||2018-05-31 21:37:27.092653|2018-05-31 21:37:27.092653
NCT01538615|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2017-01-30||2018-02-27|2012-02-20|2012-02-24|Estimate|2018-02-27|2018-03-01|Actual||||2018-02-27|2018-03-01|Actual|July 2010||2010-07-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|||Healthy Home Offerings Via the Mealtime Environment (HOME) Plus|Healthy Home Offerings Via the Mealtime Environment (HOME) Plus|Completed||N/A|413|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-05-31 21:37:27.263055|2018-05-31 21:37:27.263055
NCT01538602|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2012-02-23|2012-02-23|2012-02-24|Estimate|||||||2012-02-23|2012-02-24|Estimate||||February 2012|2012-02-29||||||||Observational|||Mean Platelet Volume and TXA2 Levels in Patients With Polycystic Ovary Syndrome (PCOS)||Completed|||||AGUNCO Obstetrics and Gynecology Centre|||2||f||||||||||||||2018-05-31 21:37:27.717098|2018-05-31 21:37:27.717098
NCT01538589|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-03-03|2012-02-20|2012-02-24|Estimate|||||||2016-03-03|2016-03-07|Estimate|December 2003||2003-12-31|March 2016|2016-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Special Survey for Patients With Type 1 or Type 2 Diabetes|Special Survey for Type 1 or Type 2 Diabetic Patients|Completed|||1582|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:37:27.806227|2018-05-31 21:37:27.806227
NCT01538576|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-03-03|2012-02-20|2012-02-24|Estimate|||||||2016-03-03|2016-03-07|Estimate|December 2003||2003-12-31|March 2016|2016-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Paediatric Subjects - Special Survey|Special Survey for Paediatric Subjects|Completed|||71|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:37:27.903815|2018-05-31 21:37:27.903815
NCT01538563|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-06-22|2012-02-23|2012-02-24|Estimate|||||||2017-06-22|2017-06-23|Actual|June 2006||2006-06-30|June 2017|2017-06-30|November 2011|Actual|2011-11-30|July 2010|Actual|2010-07-31||Interventional|||Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer|Phase I Dose Escalation Study of ON 01910.Na by 24 Hour Continuous Infusion Per Week in Patients With Advanced Cancer|Completed||Phase 1|42|Actual|Onconova Therapeutics, Inc.|||||f||||f||||||||||2018-05-31 21:37:27.973503|2018-05-31 21:37:27.973503
NCT01538550|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2018-02-07|2012-02-20|2012-02-24|Estimate|||||||2018-02-07|2018-02-08|Actual|March 2012||2012-03-31|February 2018|2018-02-28|December 2030|Anticipated|2030-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of a National Screening Programme for Bowel Cancer in Norway|Colorectal Cancer Screening in Norway: Pilot Study of a National Screening Programme With Randomised Comparison of Different Screening Strategies to Provide the Best Possible Service to the Population|Recruiting||N/A|140000|Anticipated|Norwegian Department of Health and Social Affairs||2|||f||||t||||||||||2018-05-31 21:37:28.069057|2018-05-31 21:37:28.069057
NCT01538537|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-06-22|2012-02-20|2012-02-24|Estimate|||||||2017-06-22|2017-06-23|Actual|August 2006||2006-08-31|June 2017|2017-06-30|January 2012|Actual|2012-01-31|October 2010|Actual|2010-10-31||Interventional|||Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer|Phase I Dose Escalation Study of ON 01910.Na by 3-day Continuous Infusion in Patients With Advanced Cancer|Completed||Phase 1|29|Actual|Onconova Therapeutics, Inc.|||||f||||f||||||||||2018-05-31 21:37:28.166856|2018-05-31 21:37:28.166856
NCT01538524|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-02-23|2012-02-23|2012-02-24|Estimate|||||||2012-02-23|2012-02-24|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|February 2014|Anticipated|2014-02-28|||||Observational|||Analysis of Patient Seeking Second Opinion Who Are Undergoing Full Mouth Orthodontic Treatment|Analysis of Patient Seeking Second Opinion Who Undergoing Full Mouth Orthodontic Treatment|Unknown status|Not yet recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 21:37:28.257823|2018-05-31 21:37:28.257823
NCT01538511|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-10-04|2012-02-20|2012-02-24|Estimate|||||||2017-10-04|2017-10-06|Actual|June 5, 2006|Actual|2006-06-05|October 2017|2017-10-31|March 13, 2007|Actual|2007-03-13|March 13, 2007|Actual|2007-03-13||Interventional|||Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers|A Two-centre, Randomised, Open-labelled, Four-week, Parallel-group Pharmacokinetics Trial in Japanese Type 2 Diabetic Subjects Characterising the Insulin Profile of Thrice Daily Regimen With Biphasic Insulin Aspart 70 (NN2000-Mix70) With Reference to That of Twice Daily Regimen With Biphasic Insulin Aspart 30 (NN-X14Mix30) and Physiological Insulin Profile in Japanese Healthy Volunteers|Completed||Phase 1|59|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:37:28.332214|2018-05-31 21:37:28.332214
NCT01538498|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2013-03-26|2012-02-23|2012-02-24|Estimate|||||||2013-03-26|2013-03-28|Estimate|April 2008||2008-04-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Observational|||Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer|A Clinical Trial to Develop a Peritoneal Carcinomatosis Index (PCI) in Ovarian|Completed|||134|Actual|National Cancer Center, Korea|||||f||||||||||||||2018-05-31 21:37:28.425674|2018-05-31 21:37:28.425674
NCT01538485|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-10-09|2012-02-20|2012-02-24|Estimate|||||||2012-10-09|2012-10-10|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Vitamin D Supplementation and Regulatory FoxP3+ T Cells in the GUT|Pilot Study to Assess the Effects of Vitamin D Supplementation on the Number of Regulatory FoxP3+ T Cells in the Gastrointestinal Mucosa in Healthy Women and Men: Step 3 in the Austrian Diabetes Prevention Programme|Completed||Phase 4|16|Actual|Medical University of Graz||1|||f||||t||||||||||2018-05-31 21:37:28.496583|2018-05-31 21:37:28.496583
NCT01538472|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|2014-09-04||2014-09-04|2012-02-23|2012-02-24|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-04|2014-09-11|Estimate|September 2003||2003-09-30|September 2014|2014-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma|Y Zevalin, BEAM and Rituximab In Autologous Stem Cell Transplantation (ASCT) For Lymphoma|Completed||Phase 1/Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:37:28.602224|2018-05-31 21:37:28.602224
NCT01538459|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2013-05-17|2012-02-23|2012-02-24|Estimate|||||||2013-05-17|2013-05-20|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block|Plasma Glucose Levels With Dexamethasone as Adjuvant to Interscalene Block|Withdrawn||Phase 3|0|Actual|Lifespan||2|||f||||f||||||||||2018-05-31 21:37:28.825593|2018-05-31 21:37:28.825593
NCT01538446|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-01-10|2012-02-23|2012-02-24|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ANTARCTIC||Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel|The ANTARCTIC Study - Assessment of a Normal Versus Tailored Dose of Prasugrel After Stenting in Patients Aged > 75 Years to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications|Completed||Phase 4|880|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:37:28.921102|2018-05-31 21:37:28.921102
NCT01538433|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2015-08-17|2012-02-23|2012-02-24|Estimate|||||||2015-08-17|2015-08-19|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy|A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy: an Observational Study|Completed|||603|Actual|Guangdong General Hospital|||1||f||||t||||||||||2018-05-31 21:37:29.019854|2018-05-31 21:37:29.019854
NCT01538420|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-04-18|2012-02-23|2012-02-24|Estimate|||||||2012-04-18|2012-04-19|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||GLPG0492 Pharmacodynamics|Assessment of the Muscle Protein Fractional Synthesis Rate Induced by Repeated Administrations of GLPG0492 to Healthy Male Subjects and Assessment of the Safety, Tolerability and Pharmacokinetics of Repeated Administrations of GLPG0492 to Healthy Postmenopausal Women.|Completed||Phase 1|26|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 21:37:29.081058|2018-05-31 21:37:29.081058
NCT01538407|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2014-01-21|2012-02-20|2012-02-24|Estimate|||||||2014-01-21|2014-01-22|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Strengthening Exercise and Quadriceps Force During Walking|A Study of Strengthening Exercise on Quadriceps Force During Walking|Completed||N/A|30|Actual|Frederiksberg University Hospital||2|||f||||f||||||||||2018-05-31 21:37:29.149345|2018-05-31 21:37:29.149345
NCT01538394|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2013-10-17|2012-02-23|2012-02-24|Estimate|||||||2013-10-17|2013-10-18|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|COMBIVAR||Clinical Trial to Evaluate the Efficacy of Smoking Cessation|Randomized Double-blind Trial of Two Parallel Groups Design to Evaluate the Efficacy of Smoking Cessation With Combined (Varenicline Plus Nicotine Patches) Versus Monotherapy (Varenicline Plus Placebo Patches)|Completed||Phase 4|322|Actual|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-05-31 21:37:29.207029|2018-05-31 21:37:29.207029
NCT01538381|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-10-11|2012-02-23|2012-02-24|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck|Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study.|Completed||Phase 2|30|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 21:37:29.377305|2018-05-31 21:37:29.377305
NCT01538368|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-02-23|2012-02-23|2012-02-24|Estimate|||||||2012-02-23|2012-02-24|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|||Magnetic Resonance Cholangio-pancreatography (MRCP) for Suspected Bilio-pancreatic Disease|Magnetic Resonance Cholangio-pancreatography (MRCP) for Suspected Bilio-pancreatic Disease: Should the Endoscopist Take a Second Look?|Completed|||155|Actual|Deutsche Klinik fuer Diagnostik|||||f||||f||||||||||2018-05-31 21:37:29.460358|2018-05-31 21:37:29.460358
NCT01538355|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-02-15|2012-02-23|2012-02-24|Estimate|||||||2015-02-15|2015-02-18|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|February 2013|Actual|2013-02-28||Interventional|IGEL||A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis|A Randomised Controlled Pilot Study to Compare the Effects of Prolonged Fasting and Ketogenic Low Glycemic Load Treatment on Health Related Quality of Life in Relapsing-remitting Multiple Sclerosis.|Completed||N/A|48|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 21:37:29.513379|2018-05-31 21:37:29.513379
NCT01538342|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2016-04-22|2012-02-23|2012-02-24|Estimate|||||||2016-04-22|2016-04-25|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis|Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis|Unknown status|Recruiting|N/A|170|Anticipated|Centre Hospitalier Universitaire de Nice||5|||f||||f||||||||||2018-05-31 21:37:29.591557|2018-05-31 21:37:29.591557
NCT01538329|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-05-06|2012-02-20|2012-02-24|Estimate|||||||2016-05-06|2016-05-09|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|PREMANDYSK||Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease|Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)|Unknown status|Recruiting|Phase 2|202|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 21:37:29.705632|2018-05-31 21:37:29.705632
NCT01538316|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-05-13|2012-02-20|2012-02-24|Estimate|||||||2012-05-13|2012-05-15|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|QUERGEN||Prostate Cancer Prevention Trial With Quercetin and Genistein|Clinical Trial on the Effectiveness of the Flavonoids Genistein and Quercetin in Men With Rising Prostate-specific Antigen|Unknown status|Recruiting|N/A|60|Anticipated|University of Hohenheim||3|||f||||f||||||||||2018-05-31 21:37:29.838646|2018-05-31 21:37:29.838646
NCT01538303|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-07-09|2012-02-23|2012-02-24|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|||Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome|Microvascular Dysfunction in AMI and Its Relation to Outcome|Unknown status|Recruiting||25|Anticipated|Catharina Ziekenhuis Eindhoven|||1||f||||f||||||||||2018-05-31 21:37:30.010124|2018-05-31 21:37:30.010124
NCT01538290|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-06-11|2012-02-23|2012-02-24|Estimate|||||||2012-06-11|2012-06-12|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|IMPRESS||Validating Non-invasive Measurements of Central Blood Pressure in Type 2 Diabetic Patients|Validating Non-invasive Measurements of Central Blood Pressure in Type 2 Diabetic|Completed|||34|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 21:37:30.106233|2018-05-31 21:37:30.106233
NCT01538277|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-10-27|2012-02-20|2012-02-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2012||2012-02-29|March 2012|2012-03-31|October 2016|Actual|2016-10-31|September 2014|Actual|2014-09-30||Interventional|CFC-PVAI||A Pilot Study of a Contact Force Catheter for Pulmonary Vein Antrum Isolation|A Pilot Study of a Contact Force Catheter for Pulmonary Vein Antrum Isolation (CFC-PVAI)|Completed||Phase 2|50|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:37:30.169175|2018-05-31 21:37:30.169175
NCT01538264|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2018-03-19|2012-02-23|2012-02-24|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2006||2006-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|Glioma||Blood Flow MRI for Monitoring Brain Tumors|Blood Flow MRI for Monitoring of Glioma Angiogenesis|Recruiting|||125|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||||No||2018-05-31 21:37:30.239797|2018-05-31 21:37:30.239797
NCT01538251|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-11-04|2012-02-23|2012-02-24|Estimate|||||||2016-11-04|2016-11-07|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis|Randomized Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine Hydrochloride Modified Release Tablets in Patients Affected by Mild Ulcerative Colitis Under Oral Stable Treatment|Terminated||Phase 3|147|Actual|sigma-tau i.f.r. S.p.A.||2||Evidence of very low probability to success. No safety issues.|f||||t||||||||No||2018-05-31 21:37:30.323863|2018-05-31 21:37:30.323863
NCT01538225|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2014-01-17|2012-02-23|2012-02-24|Estimate|||||||2014-01-17|2014-01-20|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|NS-MSS||Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity|Neurophysiologic Study on Effects of Sativex® on Spasticity in Progressive Multiple Sclerosis|Completed||Phase 3|45|Actual|Almirall, S.A.||2|||f||||t||||||||||2018-05-31 21:37:30.636406|2018-05-31 21:37:30.636406
NCT01538212|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-04-15|2012-02-23|2012-02-24|Estimate|||||||2016-04-15|2016-04-18|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|ACT||Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease|Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease|Completed|||55|Actual|Accera, Inc.|||||f||||f||||||||||2018-05-31 21:37:30.727745|2018-05-31 21:37:30.727745
NCT01538199|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2017-01-09||2017-10-24|2012-02-23|2012-02-24|Estimate|2017-10-24|2017-11-29|Actual||||2017-10-24|2017-11-29|Actual|February 2012||2012-02-29|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ELATED|TLT: 3 randomized participants completed less than 4 treatments so they were not included in analyses. 9 participants screen failed. 5 participants decided not to participate after the screen (time commitment, no longer interested, etc). 1 participant was discontinued by the investigator pre-treatment - discovered that primary diagnosis was PTSD.|Transcranial Laser Therapy for Major Depressive Disorder|Evaluation of LED Therapeutic Effect in Depression (ELATED): a Placebo-Controlled, Parallel Study of Efficacy, Tolerability and Acceptability of a Novel Approach in the Community|Completed||N/A|28|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:37:30.824853|2018-05-31 21:37:30.824853
NCT01538186|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-02-23|2012-02-23|2012-02-24|Estimate|||||||2012-02-23|2012-02-24|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Observational|||Treatment Of Coronary Bifurcation Lesions: Stentcovering Of The Side Branch With And Without PCI Of The Side Branch: A Retrospective Analysis Of All Consecutive Patients|Treatment Of Coronary Bifurcation Lesions: Stentcovering Of The Side Branch With And Without PCI Of The Side Branch: A Retrospective Analysis Of All Consecutive Patients|Completed|||98|Actual|Krankenhaus Hetzelstift|||2||f||||f||||||||||2018-05-31 21:37:31.460631|2018-05-31 21:37:31.460631
NCT01538173|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2015-11-30|2012-02-22|2012-02-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|||Increased Microcirculation for Preventing Postoperative Wound Infections in Patients Undergoing Reduction Mammoplasty|Prospective Study Investigating the Role of Increased Microcirculation for Preventing Postoperative Surgical Side Infections in Patients Undergoing Reduction Mammoplasty|Completed||Phase 4|334|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 21:37:31.519837|2018-05-31 21:37:31.519837
NCT01538160|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|rFVIIa||A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery||Unknown status|Not yet recruiting|N/A|15|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 21:37:31.586733|2018-05-31 21:37:31.586733
NCT01538147|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2018-01-02|2012-02-22|2012-02-23|Estimate|||||||2018-01-02|2018-01-04|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|November 30, 2017|Actual|2017-11-30||Observational|||Restless Leg Syndrome and Severe Preeclampsia|Association Between Restless Leg Syndrome and Severe Preeclampsia. A Case Control Study.|Completed|||310|Actual|Saint Thomas Hospital, Panama|||2||f||||f||||||||||2018-05-31 21:37:31.656707|2018-05-31 21:37:31.656707
NCT01538134|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2015-01-01|2012-02-22|2012-02-23|Estimate|||||||2015-01-01|2015-01-05|Estimate|June 2015||2015-06-30|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Observational|||Antiphospholipid Antibodies and Fetal Growth Restriction|Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study.|Unknown status|Not yet recruiting||90|Anticipated|Saint Thomas Hospital, Panama|||2||f||||f||||||||||2018-05-31 21:37:31.72336|2018-05-31 21:37:31.72336
NCT01538121|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2015-01-01|2012-02-19|2012-02-23|Estimate|||||||2015-01-01|2015-01-05|Estimate|June 2015||2015-06-30|January 2015|2015-01-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Observational|||Antiphospholipid Antibodies and Early Severe Preeclampsia.|Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study.|Unknown status|Not yet recruiting||310|Anticipated|Saint Thomas Hospital, Panama|||2||f||||f||||||||||2018-05-31 21:37:31.78172|2018-05-31 21:37:31.78172
NCT01538108|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|July 2012||2012-07-31|February 2012|2012-02-29|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Study of NMB (Company's Name) Drug Ejecting Balloon for Arteriovenous Fistulae|The Use of NMB Drug Ejecting Balloon for Arteriovenous (AV) Dialysis Fistulae|Unknown status|Not yet recruiting|N/A|40|Anticipated|N.M.B. Medical Applications Ltd||2|||f||||||||||||||2018-05-31 21:37:31.92582|2018-05-31 21:37:31.92582
NCT01538095|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2016-09-30|2012-02-19|2012-02-23|Estimate|||||||2016-09-30|2016-10-03|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors|A Phase 1 Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors|Completed||Phase 1|37|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:37:31.998779|2018-05-31 21:37:31.998779
NCT01538082|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-19|||2012-02-19|2012-02-19|2012-02-23|Estimate|||||||2012-02-19|2012-02-23|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|STREX||Role of the Stress in the Development of the Metabolic Syndrome|Role of Anxiety, Depression, Quality of Life and Stressful Vital Events in the Development of the Metabolic Syndrome. StreX Project.|Unknown status|Recruiting||738|Anticipated|Jordi Gol i Gurina Foundation|||2||f||||f||||||||||2018-05-31 21:37:32.113496|2018-05-31 21:37:32.113496
NCT01538069|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2013-08-06|2012-02-19|2012-02-23|Estimate|||||||2013-08-06|2013-08-09|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|CPAP||Heart Failure and Sleep Apnea: Exercise Training and Continuous Positive Airway Pressure|Comparison Between Exercise Training and CPAP Treatment for Patients With Heart Failure and Sleep Apnea.|Unknown status|Recruiting|N/A|80|Anticipated|Associação Fundo de Incentivo à Pesquisa||4|||f||||t||||||||||2018-05-31 21:37:32.1872|2018-05-31 21:37:32.1872
NCT01537328|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2018-01-12|2012-02-22|2012-02-23|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2011||2011-07-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|May 2016|Actual|2016-05-31||Interventional|PROG||Progressive Rehabilitation Following Total Knee Arthroplasty|Progressive Rehabilitation Following Total Knee Arthroplasty|Active, not recruiting||Phase 1|162|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 21:37:41.449254|2018-05-31 21:37:41.449254
NCT01538056|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2017-11-06|2012-02-18|2012-02-23|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2011||2011-03-31|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|PMEG||Physician Modified Endovascular Grafts|Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysm: An Investigator Initiated Study|Recruiting||N/A|150|Anticipated|University of Washington||1|||f||||t||||||||Undecided||2018-05-31 21:37:32.262748|2018-05-31 21:37:32.262748
NCT01538043|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-07-01|2012-02-22|2012-02-23|Estimate|||||||2014-07-01|2014-07-02|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Spa Therapy in Knee Osteoarthritis: Study on Cost/Effectiveness - Cost/Utility and Possible Mechanisms of Action|Spa Therapy in Knee Osteoarthritis: Study on Cost/Effectiveness - Cost/Utility and Possible Mechanisms of Action|Completed||Phase 4|100|Actual|University of Siena||2|||f||||t||||||||||2018-05-31 21:37:32.349221|2018-05-31 21:37:32.349221
NCT01538030|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-08-13|2012-02-22|2012-02-23|Estimate|||||||2012-08-13|2012-08-15|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Perinatal Outcome After Premature Rupture of Membranes|Perinatal Outcomes According to Amniotic Fluid Indez After Premature Rupture of Membranes. A Prospective Cohort Study.|Completed|||80|Actual|Saint Thomas Hospital, Panama|||2||f||||f||||||||||2018-05-31 21:37:32.457005|2018-05-31 21:37:32.457005
NCT01538017|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2016-10-03|2012-02-18|2012-02-23|Estimate|||||||2016-10-03|2016-10-04|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Injectable Collagenase and Percutaneous Needle Fasciotomy for Dupuytren's Contracture|Comparing Injectable Collagenase (CI) and Percutaneous Needle Fasciotomy (PNF) for Dupuytren's Contracture (DC) Affecting Proximal Interphalangeal Joints (PIP). A Randomised Controlled Trial|Completed||N/A|50|Actual|Regionshospitalet Silkeborg||2|||f||||f||||||||||2018-05-31 21:37:32.505394|2018-05-31 21:37:32.505394
NCT01538004|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-04-02|2012-02-22|2012-02-23|Estimate|||||||2014-04-02|2014-04-04|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|November 2014|Anticipated|2014-11-30|September 2014|Anticipated|2014-09-30||Observational|||Where Should Automated Blood Pressures be Done in Primary Care Offices?|Where Should Automated Blood Pressures be Done? RCT of BpTRU Measurement in Private or Non-private Areas of Primary Care Offices|Withdrawn|||0|Actual|North Toronto Primary Care Research Network|||2|Not funded|f||||f||||||||||2018-05-31 21:37:32.565545|2018-05-31 21:37:32.565545
NCT01537991|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-02-17|2012-02-17|2012-02-23|Estimate|||||||2012-02-17|2012-02-23|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|I-START||ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial|A Phase I/II Trial of Isotoxic Accelerated Radiotherapy in the Treatment of Patients With Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 1/Phase 2|121|Anticipated|Wales Cancer Trials Unit||3|||f||||t||||||||||2018-05-31 21:37:32.623721|2018-05-31 21:37:32.623721
NCT01537978|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-12-08|2012-02-17|2012-02-23|Estimate|||||||2014-12-08|2014-12-10|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Use of Interactive Gaming for Enhanced Function After Spinal Cord Injury|Use of Interactive Gaming After Spinal Cord Injury|Completed||Phase 1|21|Actual|VA Palo Alto Health Care System||1|||f||||f||||||||||2018-05-31 21:37:32.704474|2018-05-31 21:37:32.704474
NCT01537965|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-02-21|2012-02-17|2012-02-23|Estimate|||||||2014-02-21|2014-02-24|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|FIBRECHO||Evaluation of Innovative Ultrasonic Techniques for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Viral Hepatitis B or C||Completed||N/A|96|Actual|University Hospital, Grenoble|||||f||||t||||||||||2018-05-31 21:37:32.777526|2018-05-31 21:37:32.777526
NCT01537952|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Microbiologic Findings of Acute Facial Palsy in Children|Microbiologic Findings of Acute Facial Palsy in Children|Completed|||46|Actual|Helsinki University|||||f||||f||||||||||2018-05-31 21:37:32.835758|2018-05-31 21:37:32.835758
NCT01537939|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|ASUKI-Step||ASUKI Step Pedometer Worksite Intervention|ASUKI Step Pedometer Worksite Intervention|Completed||Phase 4|2018|Actual|Arizona State University||1|||f||||f||||||||||2018-05-31 21:37:33.897675|2018-05-31 21:37:33.897675
NCT01537926|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2017-05-01|2012-02-17|2012-02-23|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2012||2012-01-31|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|HALT||Hypertrophic Regression With N-Acetylcysteine in HCM|Pilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins Mutations|Completed||Phase 1|42|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 21:37:34.007474|2018-05-31 21:37:34.007474
NCT01537913|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-18|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|June 2010|Actual|2010-06-30|||||Observational|||FOUR Score in Children With Non-traumatic Impairment of Consciousness|Comparison of the Full Outline of UnResponsiveness (FOUR) Score With Glasgow Coma Scale (GCS) in Children With Non-traumatic Impairment of Consciousness.|Completed|||70|Actual|All India Institute of Medical Sciences, New Delhi|||||f||||f||||||||||2018-05-31 21:37:34.090115|2018-05-31 21:37:34.090115
NCT01537900|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2016-02-03||2017-03-01|2012-02-17|2012-02-23|Estimate|2016-02-03|2016-03-04|Estimate||||2017-03-01|2017-03-30|Actual|October 2013||2013-10-31|March 2017|2017-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)|A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients|Completed||Phase 1|4|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:37:34.149051|2018-05-31 21:37:34.149051
NCT01537887|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-06-25|2012-02-17|2012-02-23|Estimate|||||||2012-06-25|2012-06-27|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of LY2484595 on the Electrical Activity of the Heart|A Placebo- and Positive-Controlled Study of the Effect of LY2484595 on QT Interval in Healthy Subjects|Completed||Phase 1|72|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:37:34.345555|2018-05-31 21:37:34.345555
NCT01537341|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2013-07-18|2012-02-22|2012-02-23|Estimate|||||||2013-07-18|2013-07-19|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Asymmetric Locomotor Training in the Elderly to Restore Physical Function|Asymmetric Locomotor Training in the Elderly to Restore Physical Function|Withdrawn||N/A|0|Actual|University of Florida||2||Funding was not received for this study.|f||||f||||||||||2018-05-31 21:37:41.376475|2018-05-31 21:37:41.376475
NCT01537874|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-05-19|2012-02-22|2012-02-23|Estimate|||||||2014-05-19|2014-05-20|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||MassCONECT (Massachusetts Community Networks to Eliminate Cancer Disparities Through Education) 4 Kids: Promoting Smoke-free Homes|MassCONECT 4 Kids: Promoting Smoke-free Homes MassCONECT (Massachusetts Community Networks to Eliminate Cancer Disparities Through Education)|Completed||N/A|138|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 21:37:34.433294|2018-05-31 21:37:34.433294
NCT01537861|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-01-21|2012-02-17|2012-02-23|Estimate|||||||2015-01-21|2015-01-26|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma|A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma|Terminated||Early Phase 1|7|Actual|Washington University School of Medicine||1||Unexpected toxicity (2 early deaths)|f||||f||||||||||2018-05-31 21:37:34.611467|2018-05-31 21:37:34.611467
NCT01537848|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-02-23|2012-02-22|2012-02-23|Estimate|||||||2012-02-23|2012-02-24|Estimate|January 2002||2002-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Observational|||Retrospective Study of Endoscopic Ultrasound (EUS) Guided Transmural Drainage of Post-operative Abdominal Collections|Retrospective Study of Endoscopic Ultrasound Guided Transmural Drainage of Post-operative Collections|Completed|||43|Actual|Erasme University Hospital|||1||f||||f||||||||||2018-05-31 21:37:34.74707|2018-05-31 21:37:34.74707
NCT01537835|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2014-12-17||2015-02-09|2012-02-22|2012-02-23|Estimate|2015-02-09|2015-02-23|Estimate||||2015-02-09|2015-02-23|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Please note two participants in the standard scrub group and two participants in the antimicrobial scrub group A were excluded from analysis.|Bacterial Contamination of Healthcare Worker Uniforms|Bacterial Contamination of Healthcare Worker Uniforms: A Study of Antimicrobial Uniforms on Occupationally Acquired Bacterial Contamination: A Randomized Controlled Trial|Completed||N/A|109|Actual|Denver Health and Hospital Authority||3|||f||||f||||||||||2018-05-31 21:37:34.851811|2018-05-31 21:37:34.851811
NCT01537822|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2018-02-09|2012-02-17|2012-02-23|Estimate|||||||2018-02-09|2018-02-13|Actual|May 2011||2011-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|HM||The Hysteroscopic Morcellator (HM).|The Hysteroscopic Morcellator Versus the Bipolar Resectoscope for Removal of Lager Intrauterine Polyps, Removal of Submucous Myomas and Removal of Residual Placental Tissue: a Randomized Controlled Trial.|Recruiting||N/A|222|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 21:37:35.175966|2018-05-31 21:37:35.175966
NCT01537809|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2013-12-12|2012-02-17|2012-02-23|Estimate|||||||2013-12-12|2013-12-13|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors [The Daily D Health Study]|The Impact of Vitamin D Supplementation on Cardiometabolic Risk Factors in Schoolchildren|Completed||N/A|691|Actual|Tufts University||3|||f||||t||||||||||2018-05-31 21:37:35.295846|2018-05-31 21:37:35.295846
NCT01537796|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-08-04|2012-02-17|2012-02-23|Estimate|||||||2015-08-04|2015-08-05|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparison of a Technology-based System and an In-person Behavioral Weight Loss Intervention in the Severely Obese|Comparison of a Technology-based System and an In-person Behavioral Weight Loss Intervention in the Severely Obese|Completed||N/A|39|Actual|University of Pittsburgh||3|||f||||f||||||||||2018-05-31 21:37:35.393582|2018-05-31 21:37:35.393582
NCT01537783|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2017-01-23||2017-03-15|2012-02-17|2012-02-23|Estimate|2017-01-23|2017-03-13|Actual||||2017-03-15|2017-04-13|Actual|September 2011||2011-09-30|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Evaluation of a Staphylococcus Eradication Protocol for Patients Who Present to the ED With Cutaneous Abscess|A Randomized Trial to Evaluate a Staphylococcus Eradication Protocol for Patients Who Present to the Emergency Department With Cutaneous Abscess|Completed||Phase 4|50|Actual|Tufts Medical Center|There were so many lost to follow-up patients in the intervention group that it is difficult to draw conclusions from this study.|2|||f||||f||||||||||2018-05-31 21:37:35.518586|2018-05-31 21:37:35.518586
NCT01537770|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2015-09-10|2012-02-22|2012-02-23|Estimate|||||||2015-09-10|2015-09-11|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|VOPE||Vertebroplasty Compared With a Sham-procedure for Painful Acute Osteoporotic Vertebral Fractures|Prospective, Randomized Study for Comparison of Percutaneous Vertebroplasty Opposite - Infiltration of the Periost and Vertebral Body With Lidocaine - as Pain Palliative Treatment of Osteoporotic Vertebral Fractures of the Thoracic and Lumbar Spine|Completed||Phase 4|52|Actual|Sygehus Lillebaelt||2|||f||||t||||||||||2018-05-31 21:37:35.752361|2018-05-31 21:37:35.752361
NCT01537757|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2015-01-23|2012-02-17|2012-02-23|Estimate|||||||2015-01-23|2015-01-26|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])|An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535])|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 21:37:35.951567|2018-05-31 21:37:35.951567
NCT01537744|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-03-21|2012-02-22|2012-02-23|Estimate|||||||2017-03-21|2017-03-24|Actual|February 2012||2012-02-29|March 2017|2017-03-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma|Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma|Completed||Phase 1|18|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 21:37:36.097823|2018-05-31 21:37:36.097823
NCT01537731|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2013-10-08|2012-02-22|2012-02-23|Estimate|||||||2013-10-08|2013-10-09|Estimate|April 2009||2009-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Vaginal or Laparoscopic Hysterectomy, Persistent Postsurgical Pain|Chronic Pain After Vaginal or Laparoscopic Hysterectomy for Benign Conditions|Completed|||225|Anticipated|Tampere University Hospital|||1||f||||f||||||||||2018-05-31 21:37:36.170868|2018-05-31 21:37:36.170868
NCT01537718|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2013-07-16|2012-02-17|2012-02-23|Estimate|||||||2013-07-16|2013-07-17|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|DREAM||Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker|Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker|Completed||Phase 3|40|Actual|LivaNova||1|||f||||f||||||||||2018-05-31 21:37:36.341298|2018-05-31 21:37:36.341298
NCT01537705|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-17|2012-02-17|2012-02-23|Estimate|||||||2012-02-17|2012-02-23|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|Neuron012703||A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy|A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|Targeted Medical Pharma||1|||f||||f||||||||||2018-05-31 21:37:36.469438|2018-05-31 21:37:36.469438
NCT01537692|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol|A Randomized, Open-Label, 3-Period Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of BDP HFA Nasal Aerosol in Healthy Volunteers|Completed||Phase 1|30|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 21:37:36.590842|2018-05-31 21:37:36.590842
NCT01537679|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-11-23|2012-02-17|2012-02-23|Estimate|||||||2016-11-23|2016-11-28|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|August 2010|Actual|2010-08-31||Interventional|Meditation||Meditation to Reduce Caregiver Stress|Meditation or Relaxation Used to Reduce Stress Response and Improve Cognitive Functioning in Older Family Dementia Caregivers|Completed||N/A|40|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:37:36.663279|2018-05-31 21:37:36.663279
NCT01537666|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2013-10-30||2014-03-03|2012-02-17|2012-02-23|Estimate|2014-01-15|2014-03-04|Estimate||||2014-03-03|2014-03-31|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics|Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.|Completed||Phase 1|25|Actual|Savara Inc.||6|||f||||t||||||||||2018-05-31 21:37:36.766197|2018-05-31 21:37:36.766197
NCT01537653|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2013-12-05|2012-02-17|2012-02-23|Estimate|||||||2013-12-05|2013-12-06|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Subcutaneous Doses of SAR231893/REGN668 in Healthy Japanese Adult Male Subjects|Completed||Phase 1|32|Actual|Sanofi||5|||f||||||||||||||2018-05-31 21:37:37.4667|2018-05-31 21:37:37.4667
NCT01537640|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2013-12-05|2012-02-22|2012-02-23|Estimate|||||||2013-12-05|2013-12-06|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects|A Randomized, Double-Blind, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of Two Different SAR231893 Drug Products After Administration of a Single Subcutaneous Dose to Healthy Subjects|Completed||Phase 1|30|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:37:37.594695|2018-05-31 21:37:37.594695
NCT01537627|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-05-02|2012-02-22|2012-02-23|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2009||2009-11-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Long-term Physical Training in Chronic Obstructive Pulmonary Disease|Effects of a Long-term Physical Training Program on Pulmonary and Systemic Aspects in Patients With Chronic Obstructive Pulmonary Disease|Recruiting||N/A|82|Anticipated|Universidade Estadual de Londrina||2|||f||||f||||||||||2018-05-31 21:37:37.688215|2018-05-31 21:37:37.688215
NCT01537614|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2016-10-10|2012-02-22|2012-02-23|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2011||2011-10-31|October 2016|2016-10-31||||February 2013|Actual|2013-02-28||Interventional|COLI-VLM||Pharmacokinetic Study of Aerosolized Colimycin in Cystic Fibrosis||Completed||Phase 1|7|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 21:37:37.813652|2018-05-31 21:37:37.813652
NCT01537601|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2018-02-06|2012-02-22|2012-02-23|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2012|Actual|2012-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CIRCUP||CIRCumcision and Urinary Tract Infections in Boys With Posterior Urethral Valves|Effect of Circumcision on the Risk of Febrile Urinary Tract Infections in Children With Posterior Urethral Valves.|Active, not recruiting||N/A|92|Actual|Centre Hospitalier Universitaire de la Réunion||2|||f||||f||||||||||2018-05-31 21:37:37.892764|2018-05-31 21:37:37.892764
NCT01537588|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2015-03-09|2012-02-17|2012-02-23|Estimate|||||||2015-03-09|2015-03-10|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Changes in Muscle Morphology Resulting From Anterior Cruciate Ligament Reconstruction|Changes in Muscle Morphology Resulting From ACL Reconstruction: Impact on Strength and Function|Completed||N/A|30|Actual|Panam Clinic||3|||f||||f||||||||||2018-05-31 21:37:37.975903|2018-05-31 21:37:37.975903
NCT01537575|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-02-23|2012-02-22|2012-02-23|Estimate|||||||2012-02-23|2012-02-27|Estimate|January 2008||2008-01-31|February 2012|2012-02-29||||December 2009|Actual|2009-12-31||Interventional|||Intravenous Immunoglobulins for Post-Polio Syndrome||Completed||Phase 3|50|Actual|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f||||||||||2018-05-31 21:37:38.048576|2018-05-31 21:37:38.048576
NCT01537562|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|February 2007||2007-02-28|February 2012|2012-02-29|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||Intrauterine Contraception (IUC) After Medical Abortion|Early Versus Delayed Insertion of Intrauterine Contraception After Medical Abortion- a Randomized Controlled Trial|Completed||N/A|129|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 21:37:38.149631|2018-05-31 21:37:38.149631
NCT01537549|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2017-02-28||2017-04-24|2012-02-22|2012-02-23|Estimate|2017-02-28|2017-04-12|Actual||||2017-04-24|2017-05-30|Actual|September 14, 2010|Actual|2010-09-14|April 2017|2017-04-30|April 7, 2015|Actual|2015-04-07|September 24, 2013|Actual|2013-09-24||Interventional|||Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy|An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers|Completed||Phase 1/Phase 2|11|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 21:37:38.35649|2018-05-31 21:37:38.35649
NCT01537536|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-06-14|2012-02-17|2012-02-23|Estimate|||||||2013-06-14|2013-06-17|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|EndoTAG-1||Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer|An Open-label Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in Patients With HER2-negative Breast Cancer|Completed||Phase 2|18|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 21:37:38.573153|2018-05-31 21:37:38.573153
NCT01537523|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-17|2012-02-17|2012-02-23|Estimate|||||||2012-02-17|2012-02-23|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|||To Investigate the Effect of Early Community-care Program on Fracture Hip Patient|To Investigate the Effect of Early Community-care Program on Physical and Depressive Aspects for Discharged Hospital Patient Suffered From Hip Fracture.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Hong Kong Healthcare Volunteer Organization||2|||f||||f||||||||||2018-05-31 21:37:38.697594|2018-05-31 21:37:38.697594
NCT01537510|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-09-25|2012-02-17|2012-02-23|Estimate|||||||2013-09-25|2013-09-27|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|STAR||Study of Technology to Accelerate Research|Accelerating Adoption of Childhood Obesity Comparative Effectiveness Research|Completed||N/A|549|Actual|Harvard Pilgrim Health Care||3|||f||||||||||||||2018-05-31 21:37:38.807585|2018-05-31 21:37:38.807585
NCT01537497|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2012-07-06|2012-02-17|2012-02-23|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers|Phase 1 Four-Arm Parallel Group, Placebo-Controlled Study To Evaluate The Effects Of Single Doses Of PF- 05175157 At Three Dose Levels On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers|Completed||Phase 1|31|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 21:37:38.918237|2018-05-31 21:37:38.918237
NCT01537484|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-04-18|2012-02-17|2012-02-23|Estimate|||||||2017-04-18|2017-04-20|Actual|June 2012||2012-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EMBARK||Exploring Massage Benefits for Arthritis of the Knee|Multisite RCT Investigating the Efficacy of Massage in Osteoarthritis|Completed||N/A|222|Actual|Duke University||3|||f||||t||||||||||2018-05-31 21:37:38.995645|2018-05-31 21:37:38.995645
NCT01537471|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2013-01-15|2012-02-22|2012-02-23|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PPI||The Effects of Antihistamines on Pre-Pulse Inhibition|A Pilot Study of the Effects of Meclizine on Pre-Pulse Inhibition|Completed||Phase 1|117|Actual|Duke University||2|||f||||f||||||||||2018-05-31 21:37:39.077596|2018-05-31 21:37:39.077596
NCT01537458|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|March 2012||2012-03-31|February 2012|2012-02-29||||June 2012|Anticipated|2012-06-30||Observational|||Long-term Outcome After Isolated Tricuspid Valve Repair||Unknown status|Not yet recruiting||50|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 21:37:39.163923|2018-05-31 21:37:39.163923
NCT01537445|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|August 2015|Anticipated|2015-08-31|February 2015|Anticipated|2015-02-28||Observational|MERFAP||MR-Evaluation of Renal Function-After-Pancreas-transplantation|MR-Evaluation of Renal Function-After-Pancreas-transplantation|Unknown status|Not yet recruiting||40|Anticipated|Uppsala University|||1||f||||t||||||||||2018-05-31 21:37:39.23606|2018-05-31 21:37:39.23606
NCT01537432|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2015-12-01||2015-12-01|2012-02-17|2012-02-23|Estimate|2015-12-01|2016-01-05|Estimate||||2015-12-01|2016-01-05|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients|Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis|Completed||Phase 2|36|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:37:39.317074|2018-05-31 21:37:39.317074
NCT01537419|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2017-12-04||2018-01-08|2012-02-17|2012-02-23|Estimate|2018-01-08|2018-02-06|Actual||||2018-01-08|2018-02-06|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Attachment Based Family Therapy for Suicidal Adolescents|Attachment Based Family Therapy (ABFT) for Suicidal Adolescents|Completed||N/A|129|Actual|Drexel University||2|||f||||t||||||||||2018-05-31 21:37:39.613133|2018-05-31 21:37:39.613133
NCT01537406|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-03-07|2012-02-22|2012-02-23|Estimate|||||||2012-03-07|2012-03-09|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|BIMRT||Long Term Outcomes of Breast Intensity-Modulated Radiation Therapy|Long Term Outcomes of A Multicentre Controlled Clinical Trial of Breast Irradiation Using Intensity-Modulated Radiation Therapy|Unknown status|Enrolling by invitation||314|Anticipated|British Columbia Cancer Agency|||||f||||t||||||||||2018-05-31 21:37:40.085795|2018-05-31 21:37:40.085795
NCT01537393|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2018-03-14||2018-04-19|2012-02-22|2012-02-23|Estimate|2018-04-19|2018-04-23|Actual||||2018-04-19|2018-04-23|Actual|April 16, 2012|Actual|2012-04-16|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|CPTS|Analyses conducted at eye level. 1330 study eyes of 1090 participants underwent descemet stripping automated endothelial keratoplasty. 480 eyes completed bilateral surgery (240 participants), 1 participant had both eyes received cornea in 8-14 days group. 435 and 414 participants underwent unilateral surgery in 0-7 and 8-14 days groups.|Cornea Preservation Time Study|Effect of Corneal Preservation Time on Long-Term Graft Success|Completed||Phase 4|1174|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-05-31 21:37:40.184457|2018-05-31 21:37:40.184457
NCT01537380|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2017-07-18|2012-02-17|2012-02-23|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2012||2012-03-31|July 2017|2017-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Cefasleeve||Tissue and Plasma Pharmacokinetics of Cefazolin in Antibiotic Prophylaxis in Bariatric Surgery|Tissue and Plasma Pharmacokinetics of Cefazolin in Antibiotic Prophylaxis in Bariatric Surgery, an Open Label, Prospective, Single Center Trial|Completed||Phase 4|117|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 21:37:40.745393|2018-05-31 21:37:40.745393
NCT01537367|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2013-08-07||2013-08-22|2012-02-22|2012-02-23|Estimate|2013-08-19|2013-08-23|Estimate||||2013-08-22|2013-09-09|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Phase II|The transgendered particpants were all males at birth, so we added the transgendered to the male count in the gender field.|Intervention to Retain HIV-positive Patients in Medical Care|Intervention Trials to Retain HIV-positive Patients in Medical Care|Completed||N/A|1838|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 21:37:40.808621|2018-05-31 21:37:40.808621
NCT01537354|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-01-07|2012-02-22|2012-02-23|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2012||2012-06-30|January 2014|2014-01-31||||December 2013|Actual|2013-12-31||Interventional|||Comparison in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome|A Comparison of Immediate Changes in Pulmonary Compliance Between Curosurf and Survanta in Preterm Infants With Respiratory Distress Syndrome|Withdrawn||N/A|0|Actual|University of Michigan||2||Sponsor discontinued clinical trial before enrollment of subjects.|f||||f||||||||||2018-05-31 21:37:41.287577|2018-05-31 21:37:41.287577
NCT01537315|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2014-10-31||2014-11-18|2012-02-22|2012-02-23|Estimate|2014-11-18|2014-11-19|Estimate||||2014-11-18|2014-11-19|Estimate|February 2012||2012-02-29|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study|Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study|Terminated||Phase 2|8|Actual|University of Arkansas||2||lack of funding|f||||t||||||||||2018-05-31 21:37:41.54131|2018-05-31 21:37:41.54131
NCT01537302|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-03-05||2015-03-17|2012-02-22|2012-02-23|Estimate|2015-03-17|2015-03-18|Estimate||||2015-03-17|2015-03-18|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CONNECTII|All enrolled subjects.|Chronic Total Occlusion Crossing With the Ocelot System - CONNECT II|A Non-randomized Study of the Avinger Ocelot System Used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries|Completed||Phase 1|201|Actual|Avinger, Inc.||1|||f||||t||||||||||2018-05-31 21:37:41.833639|2018-05-31 21:37:41.833639
NCT01537289|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Pigtail Catheter Versus Chest Tube in the Management of Traumatic Pneumothorax|A Prospective Randomized Study of 14-French (14F) Pigtail Catheters Versus 28F Chest Tubes in Patients With Traumatic Pneumothorax: Impact on Tube-Site Pain and Failure Rate|Unknown status|Recruiting|Phase 3|38|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 21:37:42.152874|2018-05-31 21:37:42.152874
NCT01537276|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2012-02-22|2012-02-22|2012-02-23|Estimate|||||||2012-02-22|2012-02-23|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Improve Hysterosalpingographic Accuracy by Real-time Fluoroscopy|Improve Hysterosalpingographic Accuracy by Real-time Fluoroscopy|Completed||N/A|263|Actual|Taizhou Hospital||2|||f||||f||||||||||2018-05-31 21:37:42.251164|2018-05-31 21:37:42.251164
NCT01537263|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-04-05|2012-02-17|2012-02-23|Estimate|||||||2012-04-05|2012-04-06|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|PSAB||Ultrasound Perfusion Imaging After Aneurysmal Subarachnoid Hemorrhage|Ultrasound Perfusion Imaging After Aneurysmal Subarachnoid Hemorrhage|Unknown status|Recruiting||30|Anticipated|Asklepios Kliniken Hamburg GmbH|||1||f||||f||||||||||2018-05-31 21:37:42.318492|2018-05-31 21:37:42.318492
NCT01537250|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2018-01-23|2012-02-16|2012-02-23|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2009||2009-08-31|January 2018|2018-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)|A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)|Completed||Phase 2|192|Actual|TaiGen Biotechnology Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:37:42.386253|2018-05-31 21:37:42.386253
NCT01537237|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2014-11-24|2012-02-22|2012-02-23|Estimate|||||||2014-11-24|2014-11-25|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|November 2014|Actual|2014-11-30|August 2013|Actual|2013-08-31||Observational|3DATGvsCT||Comparison of Rotational Angiography/Electroanatomical Mapping Fusion Versus CT/Electroanatomical Mapping Fusion to Guide AF Ablation|Randomized Comparison of Rotational Angiography/Electroanatomical Mapping Fusion Versus CT/Electroanatomical Mapping Fusion to Guide AF Ablation|Completed|||37|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.|||2||f||||t||||||||||2018-05-31 21:37:42.503241|2018-05-31 21:37:42.503241
NCT01537224|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-11-30|2012-02-22|2012-02-23|Estimate|||||||2012-11-30|2012-12-03|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|EMOPHYSIO||Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information|Study of the Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information in Patients With Parkinson's Disease|Unknown status|Recruiting|N/A|25|Anticipated|Rennes University Hospital||1|||f||||||||||||||2018-05-31 21:37:42.631587|2018-05-31 21:37:42.631587
NCT01537211|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-04-03|2012-02-22|2012-02-23|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2011||2011-08-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CLEG||Functional Outcomes in Dysvascular Transfemoral Amputees|Microprocessor Knee Versus Mechanical Knee: Impact on Functional Outcomes in Dysvascular Transfemoral Amputees|Active, not recruiting||N/A|40|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 21:37:42.783359|2018-05-31 21:37:42.783359
NCT01537198|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2015-06-18||2015-06-18|2012-02-17|2012-02-23|Estimate|2015-06-18|2015-07-10|Estimate||||2015-06-18|2015-07-10|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Surveillance of Synagis in Korean Pediatric Patients|"Post-Marketing Surveillance of Synagis in Korean Pediatric Patients Under the New Drug Re-Examination"|Completed|||618|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 21:37:42.869529|2018-05-31 21:37:42.869529
NCT01537185|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2014-03-28||2014-05-06|2012-02-22|2012-02-23|Estimate|2014-05-06|2014-06-05|Estimate||||2014-05-06|2014-06-05|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|||Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults|A Phase 1 Randomized, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (SPWCV+Alum) in Healthy Adults|Completed||Phase 1|42|Actual|PATH||4|||f||||t||||||||||2018-05-31 21:37:43.172261|2018-05-31 21:37:43.172261
NCT01537172|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-12-07|2012-02-16|2012-02-23|Estimate|||||||2012-12-07|2012-12-10|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers|A Phase 1, Single Centre, Three-part, Randomised, Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Multiple Ascending Doses of Oral ONO-4053 and the Effects of Food in Healthy Males and Females|Completed||Phase 1|80|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 21:37:43.685638|2018-05-31 21:37:43.685638
NCT01537159|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-08-02|2012-02-22|2012-02-23|Estimate|||||||2017-08-02|2017-08-04|Actual|May 2012||2012-05-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||MRI Assessment of Leukemia Response to Therapy|Quantitative DCE-MRI as a Predictor of Therapeutic Response in Acute Leukemia|Recruiting|||30|Anticipated|OHSU Knight Cancer Institute|||1||f||||t||||||||||2018-05-31 21:37:43.767972|2018-05-31 21:37:43.767972
NCT01535105|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2013-03-13|2012-02-16|2012-02-17|Estimate|||||||2013-03-13|2013-03-14|Estimate|August 2012||2012-08-31|February 2012|2012-02-29|April 2017|Anticipated|2017-04-30|April 2013|Anticipated|2013-04-30||Observational|||Impairment in Glucose Homeostasis Among Obese Adolescents in High Risk Diabetes Prone Population - Jisr Az-Zarqa Village||Unknown status|Recruiting||300|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 21:38:21.778571|2018-05-31 21:38:21.778571
NCT01537146|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-01-21|2012-02-22|2012-02-23|Estimate|||||||2016-01-21|2016-01-22|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HTO_pains||Local Infiltration Versus Block Against Pains After High Tibial Osteotomy|Examination of the LIA (Local Infiltration) Versus Regional Blockade as Pain Management for Open-wedge High Tibial Osteotomy|Completed||Phase 4|60|Actual|Northern Orthopaedic Division, Denmark||2|||f||||t||||||||||2018-05-31 21:37:43.8613|2018-05-31 21:37:43.8613
NCT01537133|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2016-03-11||2016-11-17|2012-02-16|2012-02-23|Estimate|2016-11-17|2016-11-30|Estimate||||2016-11-17|2016-11-30|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment|Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment|Completed||N/A|84|Actual|Milton S. Hershey Medical Center||4|||f||||t||||||||||2018-05-31 21:37:44.056655|2018-05-31 21:37:44.056655
NCT01537120|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2013-09-25||2015-08-17|2012-02-16|2012-02-23|Estimate|2013-09-25|2013-12-03|Estimate||||2015-08-17|2015-08-19|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)|Evaluation of Continuous Glucose Monitoring as a Tool to Measure Glucoregulatory Effects of a Twice Daily Oral Insulin Secretagogue|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-05-31 21:37:44.895694|2018-05-31 21:37:44.895694
NCT01537107|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2018-02-05|2012-02-22|2012-02-23|Estimate|||||||2018-02-05|2018-02-06|Actual|March 5, 2012|Actual|2012-03-05|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery|Phase I Trial of The Combination of Vismodegib and Sirolimus|Suspended||Phase 1|32|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:37:45.223239|2018-05-31 21:37:45.223239
NCT01537094|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2013-12-11|2012-02-16|2012-02-23|Estimate|||||||2013-12-11|2013-12-13|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Vitamin C on Growth Hormone Secretion|The Effect of Vitamin C on Growth Hormone Secretion|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||3||Unable to obtain funding to initiate the study. No subjects were enrolled.|f||||f||||||||||2018-05-31 21:37:45.327253|2018-05-31 21:37:45.327253
NCT01537081|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2013-07-03||2013-10-22|2012-02-16|2012-02-22|Estimate|2013-07-03|2013-09-12|Estimate||||2013-10-22|2013-11-14|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional||Based on the Safety population, defined as all patients who received at least one dose of the study medication, excluding patients who later return all the dispensed study medication to the site unused.|Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections|Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy Mucinex (2400 mg/d) and Immediate-Release Guaifenesin (800 mg/d) in the Treatment of Symptoms of Acute Upper Respiratory Tract Infections For 7 Days|Completed||Phase 2/Phase 3|2810|Actual|Reckitt Benckiser LLC||3|||f||||f||||||||||2018-05-31 21:37:45.46961|2018-05-31 21:37:45.46961
NCT01537068|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-06-12||2017-09-07|2012-02-16|2012-02-22|Estimate|2017-09-07|2017-09-11|Actual||||2017-09-07|2017-09-11|Actual|February 2012|Actual|2012-02-29|September 2017|2017-09-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional||59 met inclusion criteria and started with study medication.|Desvenlafaxine vs. Placebo Treatment of Chronic Depression|Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression|Completed||Phase 4|59|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 21:37:46.064756|2018-05-31 21:37:46.064756
NCT01537055|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-01-30|2012-02-21|2012-02-22|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy|Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial|Unknown status|Recruiting|Phase 4|600|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 21:37:46.410603|2018-05-31 21:37:46.410603
NCT01537042|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2014-10-01||2014-10-31|2012-02-16|2012-02-22|Estimate|2014-10-31|2014-11-03|Estimate||||2014-10-31|2014-11-03|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||The baseline analysis population consisted of the Safety Set (SS), which is all subjects who were randomized and had at least 1 patch applied during the Treatment Period.|A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Polysomnography Study to Investigate Safety and Efficacy of the Rotigotine Transdermal Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis|Completed||Phase 3|30|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:37:46.554358|2018-05-31 21:37:46.554358
NCT01537029|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-03-27|2012-02-21|2012-02-22|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2012||2012-02-29|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide|Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide|Recruiting||Phase 4|18|Anticipated|Texas Tech University Health Sciences Center||1|||f||||f||||||||No||2018-05-31 21:37:47.389412|2018-05-31 21:37:47.389412
NCT01537016|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-07-04|2012-02-16|2012-02-22|Estimate|||||||2013-07-04|2013-07-08|Estimate|July 2013||2013-07-31|May 2013|2013-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test on DFU|WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test A Prospective, Multi Centre, Randomised, Clinical Study on Diabetic Foot Ulcers|Unknown status|Recruiting|N/A|250|Anticipated|Systagenix Wound Management||4|||f||||f||||||||||2018-05-31 21:37:47.495446|2018-05-31 21:37:47.495446
NCT01537003|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-07-04|2012-02-16|2012-02-22|Estimate|||||||2013-07-04|2013-07-08|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Interventional|||WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test|WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test A Prospective, Multi Centre, Randomised, Clinical Study on Venous Leg Ulcers|Unknown status|Recruiting|N/A|250|Anticipated|Systagenix Wound Management||4|||f||||f||||||||||2018-05-31 21:37:47.572512|2018-05-31 21:37:47.572512
NCT01536990|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-21|2012-02-21|2012-02-22|Estimate|||||||2012-02-21|2012-02-22|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Sensitivity to Change of the Lower Extremity Functional Scale in Patients With Stroke|Sensitivity to Change of the Lower Extremity Functional Scale and a Single-Item Functional Assessment Tool in Patients With Neurological Impairments Secondary to Stroke|Completed|||39|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 21:37:47.657451|2018-05-31 21:37:47.657451
NCT01536977|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-05-29|2012-02-21|2012-02-22|Estimate|||||||2014-05-29|2014-06-02|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase II Early Behavioral Intervention in BMT w/ Sleep Disturbance-Assess QOL+Fatigue+Cognitive f(x)|Early Behavioral Intervention in BMT Recipients With Sleep Disturbance: Assessing Its Impact on Quality of Life, Fatigue and Cognitive Function|Completed||N/A|29|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 21:37:47.711047|2018-05-31 21:37:47.711047
NCT01536964|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-04-02|2012-02-21|2012-02-22|Estimate|||||||2013-04-02|2013-04-04|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effect of Morphine on Prasugrel Absorption in STEMI Patients||Completed||Phase 4|12|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:37:47.795523|2018-05-31 21:37:47.795523
NCT01536951|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-03-10||2017-05-15|2012-02-16|2012-02-22|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|February 2012||2012-02-29|May 2017|2017-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Participants who received at least 1 dose of LY3009104, moxifloxacin, or placebo and had at least 1 postdose safety assessment.|A Study of LY3009104 in Healthy Participants|A Placebo-Controlled, Single Dose, Dose Escalation (Part A) and a Placebo- and Positive-Controlled Study of the Effect on the Electrocardiographic QT Interval of a Single Dose (Part B) of LY3009104 in Healthy Subjects|Completed||Phase 1|62|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:37:47.876558|2018-05-31 21:37:47.876558
NCT01536938|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2015-11-02|2013-10-22|2016-04-04|2012-02-16|2012-02-22|Estimate|2015-11-02|2015-12-09|Estimate|2013-10-22|2013-11-14|Estimate|2016-04-04|2016-05-09|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||LEO 90100 in the Treatment of Psoriasis Vulgaris||Completed||Phase 2|303|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 21:37:48.920193|2018-05-31 21:37:48.920193
NCT01536925|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-04-03|2012-02-21|2012-02-22|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2011||2011-12-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|YHO||Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects|Biobehavioral Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects|Completed|||21|Actual|Wayne State University|||||f||||t||||||||||2018-05-31 21:37:49.239526|2018-05-31 21:37:49.239526
NCT01536912|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-07-29|2012-02-21|2012-02-22|Estimate|||||||2015-07-29|2015-07-30|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|MMS||Medical Marijuana Use in HIV+ Patients: Probability Survey|Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients: Probability Survey|Completed|||218|Actual|Wayne State University|||||f||||f||||||||||2018-05-31 21:37:49.305267|2018-05-31 21:37:49.305267
NCT01536899|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-04-03|2012-02-21|2012-02-22|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2012||2012-02-29|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|MMC-1||Medical Marijuana Use in HIV+ Patients Prospective Cohort Study|Behavioral Economic Analysis of Medical Marijuana Use in HIV+ Patients Prospective Cohort Study|Completed|||119|Actual|Wayne State University|||||f||||f||||||||||2018-05-31 21:37:49.368241|2018-05-31 21:37:49.368241
NCT01536886|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2015-11-02|2013-10-22|2016-08-09|2012-02-21|2012-02-22|Estimate|2015-11-02|2015-12-09|Estimate|2013-10-22|2013-11-14|Estimate|2016-08-09|2016-09-19|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris|A Phase 2 Study Comparing Treatment With LEO 90100 With Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris.|Completed||Phase 2|376|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 21:37:49.446722|2018-05-31 21:37:49.446722
NCT01536873|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-01-16|2012-02-21|2012-02-22|Estimate|||||||2017-01-16|2017-01-18|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|DEAP||Dolutegravir Expanded Access Study|A Dolutegravir Open Label Protocol for HIV Infected, Adult and Adolescent Patients With Integrase Resistance|Recruiting||Phase 3|200|Anticipated|ViiV Healthcare|||||f||||f||||||||Undecided||2018-05-31 21:37:49.788222|2018-05-31 21:37:49.788222
NCT01536860|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2012-09-11||2013-11-05|2012-02-16|2012-02-22|Estimate|2013-11-05|2013-11-27|Estimate||||2013-11-05|2013-11-27|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Glycemic Response Testing|Glycaemic Response Testing|Completed||N/A|12|Actual|Mondelēz International, Inc.||3|||f||||f||||||||||2018-05-31 21:37:49.96|2018-05-31 21:37:49.96
NCT01536847|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-09-07|2012-02-16|2012-02-22|Estimate|||||||2012-09-07|2012-09-10|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Glycaemic Response Testing|Glycaemic Response Testing|Completed||N/A|12|Actual|Mondelēz International, Inc.||3|||f||||f||||||||||2018-05-31 21:37:50.152905|2018-05-31 21:37:50.152905
NCT01536834|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-10-10|2012-02-16|2012-02-22|Estimate|||||||2017-10-10|2017-10-11|Actual|June 2012||2012-06-30|February 2012|2012-02-29|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Safety & Performance Study of Verruca Treatment Device|A Pilot Clinical Investigation in Adults to Evaluate the Safety and Performance of a Class IIa Medical Device for the Treatment of Plantar Warts (Verrucas)|Completed||N/A|35|Actual|Reckitt Benckiser LLC||1|||f||||f|f|f||||||||2018-05-31 21:37:50.208114|2018-05-31 21:37:50.208114
NCT01536821|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-12-13|2012-02-21|2012-02-22|Estimate|||||||2013-12-13|2013-12-16|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PROGENI||PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)|PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study|Completed|||81|Actual|Indiana University|||||f||||t||||||Samples With DNA|"~     DNA, plasma and serum will be obtained and stored from a blood sample. In addition, a whole~     blood and urine samples will be obtained and stored.~   "|||2018-05-31 21:37:50.281302|2018-05-31 21:37:50.281302
NCT01536808|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-08-02|2012-02-21|2012-02-22|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2009||2009-04-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|R2D2||Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?|Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?|Completed||N/A|150|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 21:37:50.357117|2018-05-31 21:37:50.357117
NCT01536795|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-08-25|2012-02-21|2012-02-22|Estimate|||||||2016-08-25|2016-08-26|Estimate|October 2005||2005-10-31|August 2016|2016-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis|Topical Treatment of Old World Cutaneous Leishmaniasis With WR279396 (Paromomycin/Gentamicin Ointment): Efficacy and Tolerance of a Regimen Using an Occlusive Polyurethane Dressing|Completed||Phase 2|40|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-05-31 21:37:50.426547|2018-05-31 21:37:50.426547
NCT01536782|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2017-02-02|2012-02-20|2012-02-22|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2015|Actual|2015-02-28|February 2017|2017-02-28|February 2017|Anticipated|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Optimal Tube Feeding Method in Head and Neck Cancer Patients|The Optimal Tube Feeding Method in Head and Neck Cancer Patients: A Comparison Between Bolus, Gravity, and Tube Feeding Pump.|Suspended||N/A|60|Anticipated|Baylor Research Institute||3||PI left the company|f||||f||||||||||2018-05-31 21:37:50.505859|2018-05-31 21:37:50.505859
NCT01536769|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-11-11|2012-02-21|2012-02-22|Estimate|||||||2016-11-11|2016-11-15|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Observational|||Intestinal and Nasal Microbiota of Patients With Idiopathic Parkinson's Disease|Intestinal and Nasal Microbiota of Patients With Idiopathic Parkinson's Disease|Completed|||150|Actual|Helsinki University Central Hospital|||2||f||||f||||||Samples With DNA|"~     Nasal and oral bacterial swabs and stool samples~   "|||2018-05-31 21:37:50.596928|2018-05-31 21:37:50.596928
NCT01536756|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-23|2012-02-16|2012-02-22|Estimate|||||||2012-02-23|2012-02-27|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|May 2014|Anticipated|2014-05-31|October 2013|Anticipated|2013-10-31||Interventional|||Effectiveness of a Structured Physical Rehabilitation Program for Chinese Patients With Depressive Disorders|A Single Blind Randomized Controlled Study Investigating the Effectiveness of a Structured Physical Rehabilitation Program on the Physical Fitness and Negative Psychological Symptoms for Chinese Patients With Mild to Severe Depressive Disorders|Unknown status|Recruiting|N/A|84|Anticipated|Kowloon Hospital, Hong Kong||2|||f||||f||||||||||2018-05-31 21:37:51.748329|2018-05-31 21:37:51.748329
NCT01536743|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-06-12|2012-02-16|2012-02-22|Estimate|||||||2017-06-12|2017-06-14|Actual|December 15, 2011||2011-12-15|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression|A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression|Active, not recruiting||Phase 2|26|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:37:51.84318|2018-05-31 21:37:51.84318
NCT01536730|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-03-23|2012-02-21|2012-02-22|Estimate|||||||2015-03-23|2015-03-25|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Self-Guided Intervention to Promote Condom Use Among African American Males|A Self-Guided Intervention to Promote Condom Use Among African American Males|Completed||N/A|193|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 21:37:51.919423|2018-05-31 21:37:51.919423
NCT01536717|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-10-29|2012-02-21|2012-02-22|Estimate|||||||2017-10-29|2017-10-31|Actual|March 2012||2012-03-31|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery|Comparison of Periosteal and Subcutaneous Infusions of Articaine and Bupivacaine in Treatment of Acute Pain After Sternotomy|Terminated||Phase 4|36|Actual|Helsinki University Central Hospital||2||Withdrawal of principal investigator from clinical duties and organisational reasons|f||||f||||||||||2018-05-31 21:37:52.002275|2018-05-31 21:37:52.002275
NCT01536704|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2013-03-14||2013-03-14|2012-02-16|2012-02-22|Estimate|2013-03-14|2013-04-26|Estimate||||2013-03-14|2013-04-26|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Nicotine Lozenge Bioequivalence Study|A Single Dose Bioequivalence Study of 2 Different Doses of Mini Cherry Nicotine Lozenges|Completed||Phase 1|50|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:37:52.134194|2018-05-31 21:37:52.134194
NCT01536691|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2012-10-02|2012-02-16|2012-02-22|Estimate|||||||2012-10-02|2012-10-03|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|February 2013|Anticipated|2013-02-28|November 2012|Anticipated|2012-11-30||Interventional|ROAD||Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone|To Assess the Efficacy and Safety of Ramosetron, Aprepitant and Dexamethasone Therapy vs Ondansetron, Aprepitant and Dexamethasone Therapy for Preventing of Nausea and Vomiting in Highly Emetogenic Chemotherapy (ROAD Study)|Unknown status|Recruiting|Phase 3|338|Anticipated|Hallym University Medical Center||2|||f||||t||||||||||2018-05-31 21:37:52.683229|2018-05-31 21:37:52.683229
NCT01536678|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2013-02-07|2012-02-16|2012-02-22|Estimate|||||||2013-02-07|2013-02-11|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers|Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers: A Single-dose, Randomized, Open-label, Crossover Study|Completed||Phase 4|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:37:52.7865|2018-05-31 21:37:52.7865
NCT01536665|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-02-06|2012-02-16|2012-02-22|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2012||2012-02-29|February 2017|2017-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes|The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes|Completed||Phase 1|45|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:37:52.87611|2018-05-31 21:37:52.87611
NCT01536652|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-03-03|2012-02-16|2012-02-22|Estimate|||||||2016-03-03|2016-03-07|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|ProMix||Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes|Prandial Oriented NovoMix 30® - the Physiological Insulin Therapy of Diabetes Type 2|Completed|||4994|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:37:52.969168|2018-05-31 21:37:52.969168
NCT01536639|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-01-06|2012-02-16|2012-02-22|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2006||2006-01-31|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes|Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes|Completed|||454|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:37:53.064042|2018-05-31 21:37:53.064042
NCT01536626|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-02-22|2012-02-16|2012-02-22|Estimate|||||||2017-02-22|2017-02-24|Actual|June 9, 2006|Actual|2006-06-09|February 2017|2017-02-28|April 10, 2007|Actual|2007-04-10|April 10, 2007|Actual|2007-04-10||Observational|SWITCH||Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands|SWITCH Mixtard® 30 NovoLet® to NovoMix® 30 FlexPen®. An Observational Study|Completed|||211|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:37:53.188292|2018-05-31 21:37:53.188292
NCT01536613|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-03-03|2012-02-16|2012-02-22|Estimate|||||||2016-03-03|2016-03-07|Estimate|September 2004||2004-09-30|March 2016|2016-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Post Marketing Surveillance Study of Biphasic Insulin Aspart 30|NovoMix® 30 FlexPen, Post Marketing Surveillance Study|Completed|||5346|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:37:53.322144|2018-05-31 21:37:53.322144
NCT01536600|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-01-05|2012-02-21|2012-02-22|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2004||2004-09-30|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|PRESENT||Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix 30 as Monotherapy, or in Combination With OHAs, in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice|Completed|||33010|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:37:53.397568|2018-05-31 21:37:53.397568
NCT01536587|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2013-07-30||2014-03-13|2012-02-16|2012-02-22|Estimate|2014-01-02|2014-02-04|Estimate||||2014-03-13|2014-04-11|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ESAN||Effects of Salmeterol on Autonomic Nervous System|Effects of Bronchodilatation With Salmeterol on the Autonomic Nervous System|Completed||Phase 4|32|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:37:53.540914|2018-05-31 21:37:53.540914
NCT01536574|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2012-11-15||2017-01-16|2012-02-16|2012-02-22|Estimate|2012-11-15|2012-12-13|Estimate||||2017-01-16|2017-02-28|Actual|September 2010||2010-09-30|January 2017|2017-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528|An Open Label Extension Study With REQUIP PR for Subjects From Study ROP111528|Completed||Phase 3|295|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:37:54.522349|2018-05-31 21:37:54.522349
NCT01536561|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2012-02-23||2017-08-01|2012-02-16|2012-02-22|Estimate|2012-03-01|2012-03-30|Estimate||||2017-08-01|2017-08-31|Actual|April 24, 1990|Actual|1990-04-24|August 2017|2017-08-31|October 16, 2009|Actual|2009-10-16|July 2, 1997|Actual|1997-07-02||Interventional|||Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma|Phase I Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas|Completed||Phase 1|59|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:37:55.397792|2018-05-31 21:37:55.397792
NCT01536548|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-02-10|2012-02-21|2012-02-22|Estimate|||||||2017-02-10|2017-02-13|Actual|March 2012||2012-03-31|February 2017|2017-02-28|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Indicating Direction and Angle for Cannulating of AV-fistula in Hemodialysis Patients|Indicating Direction and Angle for Button-hole Cannulating of AV-fistula in Hemodialysis Patients - a Randomized Controlled Study|Completed||N/A|83|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 21:37:56.454614|2018-05-31 21:37:56.454614
NCT01536535|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-05-12|2012-02-16|2012-02-22|Estimate|||||||2017-05-12|2017-05-15|Actual|July 2012||2012-07-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|April 2016|Actual|2016-04-30||Interventional|PROTECT||Predicting Response to Standardized Pediatric Colitis Therapy|Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis.|Active, not recruiting||Phase 4|467|Actual|Connecticut Children's Medical Center||2|||f||||t||||||||Yes|Baseline data will plan to be shared two years after recruitment is complete (last initial visit) or within 6 months of publication date (whichever is first)|2018-05-31 21:37:56.603716|2018-05-31 21:37:56.603716
NCT01536522|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2017-05-12|2012-02-21|2012-02-22|Estimate|||||||2017-05-12|2017-05-15|Actual|October 2011||2011-10-31|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|AIR||Asthma Inflammation Research|Asthma Inflammation Research|Active, not recruiting||N/A|200|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 21:37:56.797718|2018-05-31 21:37:56.797718
NCT01536509|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-09-21|2012-02-21|2012-02-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|February 2012||2012-02-29|September 2016|2016-09-30||||July 2017|Anticipated|2017-07-31||Interventional|TEAM||Improving Medication Adherence in Pediatric Inflammatory Bowel Disease|Telehealth Enhancement of Adherence to Medication in Pediatric Inflammatory Bowel Disease|Active, not recruiting||Phase 3|140|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-05-31 21:37:56.907141|2018-05-31 21:37:56.907141
NCT01536496|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2015-06-16||2016-01-20|2012-02-16|2012-02-22|Estimate|2016-01-20|2016-02-17|Estimate||||2016-01-20|2016-02-17|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma|A Prospective, Randomized Comparison Of Rapid Thrombelastography (r-TEG) And Conventional Coagulation Testing For Guiding The Diagnosis And Haemostatic Resuscitation Of Trauma Patients At Risk For Post-Injury Coagulopathy|Completed||N/A|114|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||||2018-05-31 21:37:57.03039|2018-05-31 21:37:57.03039
NCT01536483|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-05-10|2012-02-16|2012-02-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|NEOTRANS||Effects of Recto-colic Enemas of Butyrate on the Digestive Disorders of Very Low Birth Weight Preterms <1250 Grams|Effects of Recto-colic Enemas of Butyrate on the Digestive Disorders of Very Low Birth Weight Preterms <1250 Grams. Clinical Trial Prospective, Monocentric, Randomized in Double-blinded.|Terminated||Phase 2/Phase 3|61|Actual|Nantes University Hospital||2||The second intermediary analysis showed no significant difference between both arms|f||||||||||||||2018-05-31 21:37:57.599637|2018-05-31 21:37:57.599637
NCT01536470|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-09-30|2012-02-21|2012-02-22|Estimate|||||||2016-09-30|2016-10-03|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|INPRESS||Intraoperative Noradrenaline to Control Arterial Pressure (INPRESS Study)|Effectiveness of Noradrenaline to Control Intraoperative Arterial Pressure in High-risk Surgical Patients: A Multicentre Prospective Randomized Controlled Trial|Completed||Phase 4|300|Actual|University Hospital, Clermont-Ferrand||2|||f||||f||||||||||2018-05-31 21:37:57.705217|2018-05-31 21:37:57.705217
NCT01536457|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2015-02-10|2012-02-16|2012-02-22|Estimate|||||||2015-02-10|2015-02-11|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Observational|||Reflux Disease Therapy in the Management of Childhood Asthma-data Entry and Analysis Only|Data Analysis of a Randomized, Double-Blind, Placebo- Controlled Study of Gastroesophageal Reflux Disease Therapy (Lansoprazole; Solutab™) in the Management of Childhood Asthma|Completed|||59|Actual|Children's Center for Digestive Health Care|||||f||||f||||||||||2018-05-31 21:37:57.811776|2018-05-31 21:37:57.811776
NCT01536444|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-21|2012-02-21|2012-02-22|Estimate|||||||2012-02-21|2012-02-22|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Use of the Epidermal Micrografts for Wound Healing After Mohs or Excisional Surgery for Skin Cancer|Use of the Epidermal Expansion System to Harvest and Place Suction Blister Epidermal Grafts on Wounds in Patients After Mohs or Excisional Surgery for Skin Cancer|Unknown status|Recruiting|N/A|12|Anticipated|Momelan Technologies||1|||f||||f||||||||||2018-05-31 21:37:57.881979|2018-05-31 21:37:57.881979
NCT01536431|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2015-07-27|2012-02-16|2012-02-22|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|MonoPepT1De||Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes|Phase 1b Study of Proinsulin (PI) Peptide Immunotherapy in New-Onset Type 1 Diabetes|Completed||Phase 1/Phase 2|27|Actual|Cardiff University||3|||f||||t||||||||||2018-05-31 21:37:57.97721|2018-05-31 21:37:57.97721
NCT01536418|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2017-04-06|2014-03-06|2018-01-25|2012-02-16|2012-02-22|Estimate|2017-07-19|2017-08-17|Actual|2014-03-06|2014-04-02|Estimate|2018-01-25|2018-01-29|Actual|November 11, 2011|Actual|2011-11-11|January 2018|2018-01-31|October 17, 2013|Actual|2013-10-17|October 17, 2013|Actual|2013-10-17||Interventional|SHIELD-4||An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease|A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Moderately-to-Severely Active Crohn's Disease|Terminated||Phase 3|255|Actual|GlaxoSmithKline||2|||f||||t|t|f||||||||2018-05-31 21:37:58.245304|2018-05-31 21:37:58.245304
NCT01536405|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2014-05-30||2017-03-15|2012-02-16|2012-02-22|Estimate|2014-05-30|2014-07-02|Estimate||||2017-03-15|2017-04-12|Actual|June 2012||2012-06-30|March 2017|2017-03-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)|A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)|Completed||Phase 3|1412|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:37:59.276658|2018-05-31 21:37:59.276658
NCT01536392|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-10-05|2012-02-16|2012-02-22|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2012|Actual|2012-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation|Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation|Active, not recruiting||Phase 3|150|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 21:38:00.033681|2018-05-31 21:38:00.033681
NCT01536379|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2016-10-05||2017-03-14|2012-02-16|2012-02-22|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|September 2013||2013-09-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study of Belimumab in the Prevention of Kidney Transplant Rejection|BEL114424: A Phase 2 Pilot, Multicentered, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in the Prevention of Allograft Rejection in Adult Subjects After Renal Transplantation|Completed||Phase 2|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:38:00.207603|2018-05-31 21:38:00.207603
NCT01536366|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2015-07-22||2015-07-22|2012-02-16|2012-02-22|Estimate|2015-07-22|2015-08-20|Estimate||||2015-07-22|2015-08-20|Estimate|June 2009||2009-06-30|July 2015|2015-07-31|January 2011|Actual|2011-01-31|July 2009|Actual|2009-07-31||Interventional|||Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide|Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers|Completed||Phase 1|27|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 21:38:01.561467|2018-05-31 21:38:01.561467
NCT01536353|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-11-24|2012-02-21|2012-02-22|Estimate|||||||2015-11-24|2015-11-25|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301|A Single Dose, Randomized, Open-label, 2x2 Crossover Study to Evaluate the Bioavailability and Safety of AGSAV301 Tablet in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Ahn-Gook Pharmaceuticals Co.,Ltd||2|||f||||||||||||||2018-05-31 21:38:01.849198|2018-05-31 21:38:01.849198
NCT01536340|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2015-05-22|2012-02-21|2012-02-22|Estimate|||||||2015-05-22|2015-05-25|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2012|Actual|2012-10-31||Observational|||Identifying Adverse Events After Discharge From a Community Hospital|Identifying Adverse Events After Discharge From a Community Hospital|Completed|||684|Actual|Florida State University|||||f||||f||||||||||2018-05-31 21:38:01.922251|2018-05-31 21:38:01.922251
NCT01536327|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2018-05-18|2012-02-21|2012-02-22|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2011||2011-09-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|BioMeta||Biomarker for Metachromatic Leukodystrophy Disease|Biomarker for Metachromatic Leukodystrophy Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||80|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA~     blood, sputum tube and a dry blood spot filter card are taken. To proof the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|No||2018-05-31 21:38:01.983594|2018-05-31 21:38:01.983594
NCT01536314|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-06-30|2012-02-16|2012-02-22|Estimate|||||||2014-06-30|2014-07-01|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|MEMANTINE||Prophylaxis of Neuropathic Pain by mémantine|Preventing the Development of Neuropathic Pain Post-mastectomy/Tumorectomy by Pre-emptive or Post-operative Memantine Administration|Completed||Phase 3|43|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 21:38:02.099728|2018-05-31 21:38:02.099728
NCT01536301|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2018-01-02|2012-02-21|2012-02-22|Estimate|||||||2018-01-02|2018-01-03|Actual|June 2012||2012-06-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|July 2016|Actual|2016-07-31||Interventional|||Oxycodone Versus Intravenous Morphine for Postoperative Analgesia After Hip Surgery|Evaluation of Oxycodone Hydrochloride Versus Intravenous Morphine Hydrochloride for Postoperative Analgesia After Hip Prosthetic Surgery|Completed||Phase 4|246|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||t||||||||||2018-05-31 21:38:02.201097|2018-05-31 21:38:02.201097
NCT01536288|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2012-02-21|2012-02-21|2012-02-22|Estimate|||||||2012-02-21|2012-02-22|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness|Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness.|Completed||Phase 2|125|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:38:02.363552|2018-05-31 21:38:02.363552
NCT01536275|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2017-06-21|2012-02-21|2012-02-22|Estimate|||||||2017-06-21|2017-06-22|Actual|June 2012||2012-06-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|PEPaNIC||Early Versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit|Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Paediatric Critically Ill Patients|Recruiting||N/A|1440|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 21:38:02.466768|2018-05-31 21:38:02.466768
NCT01536262|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|2015-06-19|2014-04-03|2015-06-19|2012-02-16|2012-02-22|Estimate|2015-06-19|2015-07-15|Estimate|2014-04-03|2014-04-30|Estimate|2015-06-19|2015-07-15|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Treated Set (TS): This patient set included all patients who received at least 1 dose of treatment.|Japan Long-term Safety for Tiotropium Plus Olodaterol|A Randomised, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed-dose Combination (2.5µg / 5µg, 5µg / 5µg ) and Olodaterol (5 µg) Delivered by the RESPIMAT Inhaler in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|122|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:38:02.595755|2018-05-31 21:38:02.595755
NCT01536249|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2014-11-24|2012-02-21|2012-02-22|Estimate|||||||2014-11-24|2014-11-25|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)|An Open-Label Study to Assess the Effect of Cimetidine on the Pharmacokinetics of Dexpramipexole (BIIB050) in Healthy Volunteers|Completed||Phase 1|14|Actual|Knopp Biosciences||2|||f||||||||||||||2018-05-31 21:38:02.977647|2018-05-31 21:38:02.977647
NCT01536236|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2015-03-20|2012-02-17|2012-02-20|Estimate|||||||2015-03-20|2015-03-23|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Spinal Cord Stimulation for Diabetic Polyneuropathy|A Randomized, Comparison Study of the Safety and Efficacy of Spinal Cord Stimulation Versus Standard of Care Medical Management in the Treatment of Diabetic Polyneuropathy|Withdrawn||N/A|0|Actual|St. Jude Medical||3|||f||||f||||||||||2018-05-31 21:38:03.055766|2018-05-31 21:38:03.055766
NCT01536223|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2013-03-03|2012-02-17|2012-02-20|Estimate|||||||2013-03-03|2013-03-05|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|February 2015|Anticipated|2015-02-28|December 2013|Anticipated|2013-12-31||Interventional|ESNCCT||Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma|Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study|Unknown status|Recruiting|Phase 3|400|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 21:38:03.13245|2018-05-31 21:38:03.13245
NCT01536210|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-02-15|2012-02-15|2012-02-20|Estimate|||||||2012-02-15|2012-02-20|Estimate|December 2011||2011-12-31|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|ADHD||Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)|Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks|Unknown status|Recruiting|Phase 3|144|Anticipated|Yuyu Pharma, Inc.||2|||f||||t||||||||||2018-05-31 21:38:03.209306|2018-05-31 21:38:03.209306
NCT01536197|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2014-06-02||2017-11-06|2012-02-15|2012-02-20|Estimate|2014-07-02|2014-07-03|Estimate||||2017-11-06|2017-12-18|Actual|September 2009|Actual|2009-09-30|November 2017|2017-11-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|RBtaste||Taste Perception Pre and Post Bariatric Surgery|Effect of Bariatric Surgery-induced Weight Loss on Taste Perception|Completed|||33|Actual|Washington University School of Medicine|||3||f||||t|f|f||||Samples With DNA|"~     Tongue tissue~   "|||2018-05-31 21:38:03.483574|2018-05-31 21:38:03.483574
NCT01536184|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2016-08-16||2016-08-16|2012-02-15|2012-02-20|Estimate|2016-08-16|2016-08-25|Estimate||||2016-08-16|2016-08-25|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Evaluating the Effectiveness of an Attachment-Focused Intervention in Preschool Children With FASD|Evaluating the Effectiveness of an Attachment-Focused Intervention in Preschool Children With Fetal Alcohol Spectrum Disorder (FASD) or At-risk for FASD: A Randomized Controlled Field Trial|Completed||N/A|12|Actual|University of Manitoba|While we set out to conduct an RCT to evaluate the effectiveness of COS delivered in a home-visiting model vs. a behavioral TAU intervention, the limitations we faced did not allow for this.|2|||f||||f||||||||No||2018-05-31 21:38:03.863739|2018-05-31 21:38:03.863739
NCT01536171|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2013-12-13||2014-03-17|2012-02-15|2012-02-20|Estimate|2014-03-17|2014-04-21|Estimate||||2014-03-17|2014-04-21|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational||Healthy young active adults|Peak Impact Forces and Metabolic Cost During Mid-Forefoot Striking in Shod Versus Barefoot Runners|Peak Impact Forces and Metabolic Cost During Mid-Forefoot Striking in Shod Versus Barefoot Runners: A Pilot Study|Completed|||22|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 21:38:04.381937|2018-05-31 21:38:04.381937
NCT01536158|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-12-24|2012-02-17|2012-02-20|Estimate|||||||2012-12-24|2012-12-27|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial|Oral Paracetamol Versus Oral Ibuprofen Treatment|Completed||Phase 4|80|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 21:38:04.54288|2018-05-31 21:38:04.54288
NCT01536145|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2013-01-18||2013-03-12|2012-02-15|2012-02-20|Estimate|2013-01-18|2013-02-28|Estimate||||2013-03-12|2013-03-15|Estimate|December 2003||2003-12-31|March 2013|2013-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||CP-751,871 Treatment For Patients With Multiple Myeloma|An Open Label Phase I Study Of CP-751,871 In Patients With Multiple Myeloma|Completed||Phase 1|47|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:38:04.656827|2018-05-31 21:38:04.656827
NCT01536132|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-02-13|2012-02-17|2012-02-20|Estimate|||||||2016-02-13|2016-02-17|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|October 2013|Actual|2013-10-31||Interventional|LION-HEART||Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients|Multicenter, Double-blind, Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of Intravenous Administration of Intermittent Doses of Levosimendan in Ambulatory Patients With Advanced CHF: the LION-HEART Study|Completed||Phase 4|70|Actual|Parc de Salut Mar||2|||f||||f||||||||No||2018-05-31 21:38:05.48317|2018-05-31 21:38:05.48317
NCT01536119|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2013-07-04||2013-12-18|2012-02-17|2012-02-20|Estimate|2013-12-18|2014-01-24|Estimate||||2013-12-18|2014-01-24|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|COSI|The baseline participants consisted of 214 participants 107*2=214 107 couples per group (107 mothers and 107 fathers).|Evaluating a Coparenting Breastfeeding Support Intervention|Evaluating the Effectiveness of a Coparenting Breastfeeding Support Intervention on Exclusive Breastfeeding Rates at 12 Weeks Postpartum|Completed||N/A|428|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 21:38:05.598732|2018-05-31 21:38:05.598732
NCT01536106|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-16|||2013-09-03|2012-02-17|2012-02-20|Estimate|||||||2013-09-03|2013-09-04|Estimate|December 2013||2013-12-31|September 2013|2013-09-30|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|AMIRST||Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients.|Intracoronary Infusion of Concentrated Autologous Bone Marrow Mononuclear Cells in Acute Myocardial Infarction Patients Utilizing a Novel Point-of-Care Device for Rapid-Delivery of Stem Cells (AMIRST)|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|TotipotentRX Cell Therapy Pvt. Ltd.||2|||f||||t||||||||||2018-05-31 21:38:06.017322|2018-05-31 21:38:06.017322
NCT01536093|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2014-07-17||2014-08-11|2012-02-15|2012-02-20|Estimate|2014-07-17|2014-08-12|Estimate||||2014-08-11|2014-08-13|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Oropharyngeal Administration of Colostrum to Extremely Low Gestational Age Newborns||Completed||Phase 2|48|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:38:06.121816|2018-05-31 21:38:06.121816
NCT01536080|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-02-15|2012-02-15|2012-02-20|Estimate|||||||2012-02-15|2012-02-20|Estimate|July 2008||2008-07-31|February 2012|2012-02-29||||||||Observational|||Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life|Comparison of Risk Factors, GERD Symptoms and PPI Responses in the Reflux Esophagitis, Non-erosive Reflux Disease and Functional Heartburn Using GERD Impact Scale Questionnaire|Completed|||207|Actual|Seoul National University Bundang Hospital|||3||f||||f||||||||||2018-05-31 21:38:06.462529|2018-05-31 21:38:06.462529
NCT01536067|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2016-05-03||2016-05-03|2012-02-15|2012-02-20|Estimate|2016-05-03|2016-06-10|Estimate||||2016-05-03|2016-06-10|Estimate|April 2012||2012-04-30|May 2016|2016-05-31||||April 2014|Actual|2014-04-30||Interventional||All treated and eligible patients|Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia|A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia|Terminated||Phase 2|3|Actual|Roswell Park Cancer Institute||1||funding was withdrawn|f||||t||||||||||2018-05-31 21:38:06.532217|2018-05-31 21:38:06.532217
NCT01536054|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-03-28|2012-02-15|2012-02-20|Estimate|||||||2018-03-28|2018-03-29|Actual|August 20, 2012|Actual|2012-08-20|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|April 21, 2015|Actual|2015-04-21||Interventional|||Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Active, not recruiting||Phase 1|7|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 21:38:07.026053|2018-05-31 21:38:07.026053
NCT01536041|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15||2014-01-21|2014-01-21|2012-02-17|2012-02-20|Estimate||||2014-01-21|2014-02-14|Estimate|2014-01-21|2014-02-14|Estimate|March 2012||2012-03-31|January 2014|2014-01-31||||November 2012|Actual|2012-11-30||Interventional|||A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients|A Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Safety and Efficacy of ONO-6950 20 mg and 200 mg QD Versus Placebo and Montelukast (Singulair) in Asthmatic Patients Who Experience Exercise-induced Bronchoconstriction|Completed||Phase 2|59|Actual|Ono Pharmaceutical Co. Ltd||4|||f||||f||||||||||2018-05-31 21:38:07.211351|2018-05-31 21:38:07.211351
NCT01536028|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2017-01-05|2012-02-15|2012-02-20|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes|A Double-blind, Randomised, Four-Period Crossover Trial Comparing the Pharmacodynamics and Pharmacokinetics After Single Dose of Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 50, Biphasic Insulin Aspart 70 and Insulin Aspart in Subjects With Type 1 Diabetes|Completed||Phase 1|32|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:38:07.314771|2018-05-31 21:38:07.314771
NCT01536015|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2014-07-07||2014-07-07|2012-02-15|2012-02-20|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|ROADMAP|The Analysis Population Description refers to the Safety Set (SS) which consists of all randomized subjects who received at least one dose of study medication.|Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction|Terminated||Phase 3|25|Actual|UCB Pharma||2||The study was stopped due to low enrollment.|f||||f||||||||||2018-05-31 21:38:07.42554|2018-05-31 21:38:07.42554
NCT01536002|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-05-26|2012-02-15|2012-02-20|Estimate|||||||2017-05-26|2017-05-31|Actual|June 7, 2011|Actual|2011-06-07|May 2017|2017-05-31|May 7, 2014|Actual|2014-05-07|May 7, 2014|Actual|2014-05-07||Interventional|||Pharmacokinetics of Propofol in Morbidly Obese Patients|Pharmacokinetics (PK) of Propofol in Bariatric (Morbidly Obese) Patients|Completed||Phase 4|69|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 21:38:08.048587|2018-05-31 21:38:08.048587
NCT01535989|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-06-06|2012-02-17|2012-02-20|Estimate|||||||2016-06-06|2016-06-07|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|IOSI-LND-001||Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma|A Phase I Study of Inotuzumab Ozogamicin (CMC-544) in Combination With Temsirolimus (CCI-779) in Patients With Relapsed or Refractory CD22-positive B-cell Non Hodgkin's Lymphomas|Completed||Phase 1|25|Actual|Oncology Institute of Southern Switzerland||1|||f||||t||||||||||2018-05-31 21:38:08.135418|2018-05-31 21:38:08.135418
NCT01535976|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2013-11-11||2014-02-18|2012-02-15|2012-02-20|Estimate|2014-02-18|2014-04-01|Estimate||||2014-02-18|2014-04-01|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Ketamine Infusion and Hypoventilation|The Effect of Ketamine in The Prevention of Hypoventilation in Patients With and Without a Positive Berlin Questionnaire Undergoing Deep Sedation|Completed||N/A|54|Actual|Northwestern University|We did not use depth of anesthesia monitor guided protocol due to controversial effects of ketamine of the correlation of processed EEG monitor and clinical levels of sedation. We did not use opioids as part of the protocol.|2|||f||||f||||||||||2018-05-31 21:38:08.230211|2018-05-31 21:38:08.230211
NCT01535963|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-02-20|2012-02-15|2012-02-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2012||2012-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Patient Satisfaction in Cutaneous Surgery|A Pilot Study of Patient Satisfaction After Cutaneous Surgery|Active, not recruiting|||354|Actual|Northwestern University|||1||f||||f||||||||||2018-05-31 21:38:08.473682|2018-05-31 21:38:08.473682
NCT01535950|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10||2016-03-22|2016-03-22|2012-02-15|2012-02-20|Estimate||||2016-03-22|2016-04-25|Estimate|2016-03-22|2016-04-25|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)|A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration|Completed||Phase 2|43|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:38:08.54442|2018-05-31 21:38:08.54442
NCT01535937|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-08-07|2012-02-15|2012-02-20|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2012|Actual|2012-02-29|August 2017|2017-08-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence||Terminated||Phase 1/Phase 2|55|Actual|New York State Psychiatric Institute||2||An analysis demonstrated that running the final participants was unnecessary.|f||||t||||||||||2018-05-31 21:38:08.642599|2018-05-31 21:38:08.642599
NCT01535924|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2018-04-02|2012-02-17|2012-02-20|Estimate|||||||2018-04-02|2018-04-03|Actual|February 9, 2012|Actual|2012-02-09|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|26|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 21:38:08.738096|2018-05-31 21:38:08.738096
NCT01535911|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2017-07-18|2012-02-15|2012-02-20|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2012||2012-04-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Ketones||Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors|Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors|Recruiting||N/A|12|Anticipated|Michigan State University|||||f||||t||||||||||2018-05-31 21:38:08.826324|2018-05-31 21:38:08.826324
NCT01535898|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2017-05-04|2012-02-15|2012-02-20|Estimate|||||||2017-05-04|2017-05-08|Actual|February 2012||2012-02-29|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers|Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers|Completed|||10|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:38:08.914172|2018-05-31 21:38:08.914172
NCT01535885|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-08-10|2012-02-15|2012-02-20|Estimate|||||||2017-08-10|2017-08-14|Actual|February 2012||2012-02-29|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ACE||Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus|A Phase I Study Of Using Multi-virus Cytotoxic T-cells Following T-cell Depleted Allogeneic Hematopoietic Progenitor Cell Transplantation For Prophylaxis Against Specific Pathogens- Epstein Barr Virus, Adenovirus, And Cytomegalovirus (ACE TRIAL)|Recruiting||Phase 1|18|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 21:38:09.007725|2018-05-31 21:38:09.007725
NCT01535872|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-06-14|2012-02-17|2012-02-20|Estimate|||||||2016-06-14|2016-06-15|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|October 2014|Actual|2014-10-31||Interventional|||Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients|Dehydroepiandrosterone Treatment for Poor Responders in IVF Patients: A Prospective Randomised Controlled Trial.|Active, not recruiting||Phase 3|280|Anticipated|KK Women's and Children's Hospital||2|||f||||t||||||||||2018-05-31 21:38:09.091402|2018-05-31 21:38:09.091402
NCT01535859|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2016-06-14|2012-02-17|2012-02-20|Estimate|||||||2016-06-14|2016-06-15|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers|A Randomised Controlled Trial of Cabergoline Prophylaxis for Ovarian Hyperstimulation Syndrome in IVF Cycles and Derivation of Biomarkers for OHSS.|Active, not recruiting||Phase 3|540|Anticipated|KK Women's and Children's Hospital||2|||f||||t||||||||||2018-05-31 21:38:09.16393|2018-05-31 21:38:09.16393
NCT01535846|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2013-04-24|2012-02-17|2012-02-20|Estimate|||||||2013-04-24|2013-04-25|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|Flaveur||Awakening to the Taste of Food Among Restrained Women|Awakening to the Taste of Food: What Are the Effects on Cognitions and Behaviors About Food and Eating Among Restrained Women?|Completed||N/A|50|Actual|Laval University||2|||f||||f||||||||||2018-05-31 21:38:09.25488|2018-05-31 21:38:09.25488
NCT01535833|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-05-10|2012-02-15|2012-02-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Robotic Assisted Sacral Colpopexy : A Prospective Study Assessing Outcomes With Learning Curves|Robotic Assisted Sacral Colpopexy : A Prospective Study Assessing Subjective and Objective Outcomes With Learning Curves in the Development of a New Pelvic Floor Robotics Program|Unknown status|Recruiting|N/A|100|Anticipated|Kaiser Permanente||1|||f||||t||||||||||2018-05-31 21:38:09.375732|2018-05-31 21:38:09.375732
NCT01535820|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2013-03-19|2012-02-15|2012-02-20|Estimate|||||||2013-03-19|2013-03-20|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women|A Bioequivalence Study to Evaluate the Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women|Completed||Phase 1|54|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 21:38:09.478843|2018-05-31 21:38:09.478843
NCT01535807|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-11-19||2015-11-19|2012-02-17|2012-02-20|Estimate|2015-11-19|2015-12-24|Estimate||||2015-11-19|2015-12-24|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|February 2013|Actual|2013-02-28||Interventional|CorMatrix||CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM|CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without CorMatrix's Extra Cellular Matrix (ECM)|Unknown status|Active, not recruiting|N/A|44|Actual|Inova Health Care Services||2|||f||||f||||||||||2018-05-31 21:38:09.697719|2018-05-31 21:38:09.697719
NCT01535794|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-08-07|2012-02-17|2012-02-20|Estimate|||||||2014-08-07|2014-08-08|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||HPV Vaccine Acceptability Among Young Men Who Have Sex With Men|Exploring the Potential for Social Network Site-delivered Interventions to Increase HPV Vaccine Uptake Among Men Who Have Sex With Men|Completed|||2000|Actual|Indiana University|||1||f||||t||||||||||2018-05-31 21:38:09.895578|2018-05-31 21:38:09.895578
NCT01535781|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2015-02-03|2012-02-15|2012-02-20|Estimate|||||||2015-02-03|2015-02-05|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?|Effect of Tranexamic Acid on Blood Loss and Transfusion Need in Patients Operated With a Short Intramedullary Nail, for Pertrochanteric Fractures .|Terminated||N/A|72|Actual|Hvidovre University Hospital||2||Recruiting slower than expected.|f||||t||||||||||2018-05-31 21:38:09.970548|2018-05-31 21:38:09.970548
NCT01535768|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2017-07-19|2012-02-15|2012-02-20|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2012||2012-02-29|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves|Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves|Recruiting||Phase 4|150|Anticipated|Credit Valley EyeCare||2|||f||||t||||||||||2018-05-31 21:38:10.086825|2018-05-31 21:38:10.086825
NCT01535755|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2013-07-15|2012-02-17|2012-02-20|Estimate|||||||2013-07-15|2013-07-16|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Protocol to Wean From Noninvasive Mechanical Ventilation|A Protocol to Wean From Noninvasive Mechanical Ventilation|Terminated||N/A|80|Actual|Chongqing Medical University||2||Enough patients has been enrolled.|f||||t||||||||||2018-05-31 21:38:10.21653|2018-05-31 21:38:10.21653
NCT01535742|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-06-27|2012-02-15|2012-02-20|Estimate|||||||2012-06-27|2012-06-29|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Ambu Aura-i and Air-Q Intubating Laryngeal Airways as a Conduit for Tracheal Intubation in Children|Prospective Randomized Comparison of the Ambu Aura-i and Air-Q Intubating Laryngeal Airways as a Conduit for Tracheal Intubation in Children|Completed||N/A|120|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||4|||f||||f||||||||||2018-05-31 21:38:10.303287|2018-05-31 21:38:10.303287
NCT01535729|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2015-10-01||2015-10-01|2012-02-15|2012-02-20|Estimate|2015-10-01|2015-10-29|Estimate||||2015-10-01|2015-10-29|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||Safety Analysis Set (SAF), included participants who received at least one dose of Tarceva®.|An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer|Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.|Completed|||465|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:38:10.468132|2018-05-31 21:38:10.468132
NCT01535716|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-04-16|2012-02-17|2012-02-20|Estimate|||||||2013-04-16|2013-04-17|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ECOMIII||Effects of a Goal-directed Hemodynamic Therapy Driven by ECOM on Morbidity and Mortality After Cardiac Surgery?|Does Goal-directed Hemodynamic Therapy Driven by Endotracheal Cardiac Output Monitoring System During Surgical Intervention Reduce Hospital Stay and Major Adverse Cardiac Events Following Cardiac Surgery?|Completed||Phase 4|100|Actual|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 21:38:12.392771|2018-05-31 21:38:12.392771
NCT01535703|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-04-03|2012-02-15|2012-02-20|Estimate|||||||2013-04-03|2013-04-04|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational|PANEX||Comparison of Cardiac Output Measurement Between Transpulmonary Thermodilution and Photoplethysmography|Comparison of Cardiac Output Measurement Between Invasive Method (Transpulmonary Thermodilution) and Non Invasive Method (Photoplethysmography) : an Observational Study|Completed|||50|Actual|University Hospital, Caen|||||f||||f||||||||||2018-05-31 21:38:12.478259|2018-05-31 21:38:12.478259
NCT01535690|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2012-02-17|2012-02-17|2012-02-20|Estimate|||||||2012-02-17|2012-02-20|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Interventional|||Photodynamic Therapy Associated With Full-mouth Ultrasonic Debridement in the Treatment of Severe Chronic Periodontitis|Photodynamic Therapy Associated With Full-mouth Ultrasonic Debridement in the Treatment of Severe Chronic Periodontitis: a Randomized-controlled Clinical Trial Running Title: Photodynamic Therapy Associated With Periodontal Debridement|Completed||N/A|22|Actual|Escola Bahiana de Medicina e Saude Publica||1|||f||||t||||||||||2018-05-31 21:38:12.546359|2018-05-31 21:38:12.546359
NCT01535677|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-07-08|2012-02-15|2012-02-20|Estimate|||||||2015-07-08|2015-07-09|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately|A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States|Completed||Phase 1|71|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 21:38:12.647614|2018-05-31 21:38:12.647614
NCT01535664|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2013-05-28||2013-08-08|2012-02-15|2012-02-20|Estimate|2013-08-08|2013-10-14|Estimate||||2013-08-08|2013-10-14|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)|An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS|Completed|||20|Actual|Acorda Therapeutics|||1||f||||f||||||||||2018-05-31 21:38:12.898903|2018-05-31 21:38:12.898903
NCT01535651|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2018-05-14|2012-02-17|2012-02-20|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2011||2011-09-30|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|TOP4ME||Using Social Media to Enhance the Impact of the Teen Outreach Program|Using Social Media to Enhance the Impact of the Teen Outreach Program|Completed||N/A|852|Actual|Colorado School of Public Health||2|||f||||f||||||||||2018-05-31 21:38:13.247125|2018-05-31 21:38:13.247125
NCT01535638|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2016-01-21||2016-03-09|2012-02-17|2012-02-20|Estimate|2016-03-09|2016-04-11|Estimate||||2016-03-09|2016-04-11|Estimate|February 2012||2012-02-29|March 2016|2016-03-31||||March 2012|Actual|2012-03-31||Interventional|||Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers|Relative Bioavailability of BI 207127 FF Tablets, BI 207127 FF Modified Tablets and BI 207127 TFII Tablets Administered Orally as Three Tablets (Single Dose) to Healthy Male Volunteers, an Open-label, Randomised Three-way Crossover Study|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:38:13.350807|2018-05-31 21:38:13.350807
NCT01535625|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-17|2012-02-17|2012-02-20|Estimate|||||||2012-02-17|2012-02-20|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Interventional|||Safety and Effectiveness of the Coronary Momo Stent|Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease|Unknown status|Recruiting|Phase 4|100|Anticipated|be Medical||1|||f||||t||||||||||2018-05-31 21:38:13.707529|2018-05-31 21:38:13.707529
NCT01535612|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2016-07-25|2012-02-17|2012-02-20|Estimate|||||||2016-07-25|2016-07-27|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Study of PaQ™ (a Simple Patch on Insulin Delivery Device) in Patients With Type 2 Diabetes Mellitus|A Study Evaluating the Feasibility of Use and Performance of PaQ™ in Patients With Type 2 Diabetes Mellitus Who Are Currently Treated With Basal/Bolus Insulin Therapy|Completed||N/A|20|Actual|CeQur Corporation||1|||f||||f||||||||Yes|Published in Diabetes Care - Volume 37, May 2014, pages 1476-1479|2018-05-31 21:38:13.815669|2018-05-31 21:38:13.815669
NCT01535599|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2014-05-19||2014-06-24|2012-02-16|2012-02-20|Estimate|2014-05-19|2014-06-18|Estimate||||2014-06-24|2014-07-08|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||This reporting group includes all randomized participants who were treated with study medication (686). Note: 6 participants were randomized in error and did not receive study medication (3 in AL-60371 and 3 in Vehicle). Additionally 1 participant randomized to Vehicle exited the study at Visit 2 without dosing the study medication.|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa|Completed||Phase 3|768|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:38:13.970269|2018-05-31 21:38:13.970269
NCT01535586|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-16|2012-02-16|2012-02-17|Estimate|||||||2012-02-16|2012-02-17|Estimate|April 2012||2012-04-30|February 2012|2012-02-29||||March 2015|Anticipated|2015-03-31||Interventional|||A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder||Unknown status|Not yet recruiting|Phase 4|42|Anticipated|The VA Western New York Healthcare System||2|||f||||f||||||||||2018-05-31 21:38:14.340732|2018-05-31 21:38:14.340732
NCT01535573|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-05-03|2012-02-14|2012-02-17|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2010||2010-12-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Citalopram for Cocaine Dependence|Clinical Trial of Serotonin Medication Combination in Cocaine Dependence|Completed||Phase 2|122|Actual|The University of Texas Health Science Center, Houston||3|||f||||t||||||||||2018-05-31 21:38:14.413288|2018-05-31 21:38:14.413288
NCT01535560|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|2013-10-18||2013-10-18|2012-02-15|2012-02-17|Estimate|2013-10-18|2013-12-10|Estimate||||2013-10-18|2013-12-10|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||This reporting group includes all randomized participants who received the study drug (ie, 548). Note: 1 participant in the Vehicle arm was randomized in error and did not receive the study drug.|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa|Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa|Completed||Phase 3|589|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:38:14.546233|2018-05-31 21:38:14.546233
NCT01535547|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-02-15|2012-02-15|2012-02-17|Estimate|||||||2012-02-15|2012-02-17|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Drug Interaction Study of Isavuconazole and Tacrolimus|Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Tacrolimus: A Phase 1, Open Label, Sequential Study in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:38:14.973495|2018-05-31 21:38:14.973495
NCT01535534|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2016-11-22|2012-02-16|2012-02-17|Estimate|||||||2016-11-22|2016-11-23|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|||||Observational|MaSep||Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis|Evaluation of Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis|Recruiting|||400|Anticipated|Universitätsmedizin Mannheim|||||f||||f||||||Samples Without DNA|"~     Peripheral blood samples~   "|||2018-05-31 21:38:15.094618|2018-05-31 21:38:15.094618
NCT01535521|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2013-06-19|2012-02-16|2012-02-17|Estimate|||||||2013-06-19|2013-06-20|Estimate||||June 2013|2013-06-30||||February 2013|Actual|2013-02-28||Interventional|SupPos||Sleep Positional Trainer for Positional Sleep Apnea After Mandibular Advancement Device (MAD) Therapy|Evaluation of Sleep Position Trainer for Positional Sleep Apnea Patients After Therapy With Mandibular Advancement Device (MAD)|Completed||N/A|||University Hospital, Antwerp||1|||f||||||||||||||2018-05-31 21:38:15.281702|2018-05-31 21:38:15.281702
NCT01535508|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2016-11-04|2012-02-16|2012-02-17|Estimate|||||||2016-11-04|2016-11-07|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Open Label Clinical Trial of Vitamin D in Children With Autism|Open Label Clinical Trial of Vitamin D Dosage Tolerability, and Effect on Behavioral Measures in Children With Autism|Completed||Phase 2/Phase 3|10|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:38:15.345682|2018-05-31 21:38:15.345682
NCT01535495|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-03-29|2012-02-14|2012-02-17|Estimate|||||||2017-03-29|2017-03-31|Actual|February 2012||2012-02-29|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Propranolol for Diabetic Retinopathy|Propranolol for Diabetic Retinopathy|Completed||Phase 1|9|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 21:38:15.423082|2018-05-31 21:38:15.423082
NCT01535482|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2017-06-07|2012-02-14|2012-02-17|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2011||2011-09-30|June 2017|2017-06-30|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||Cognitive Therapy for Suicidal Older Men|Cognitive Therapy for Suicidal Older Men|Completed||N/A|110|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:38:15.524901|2018-05-31 21:38:15.524901
NCT01535118|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2013-12-09||2017-01-18|2012-02-14|2012-02-17|Estimate|2013-12-09|2014-01-27|Estimate||||2017-01-18|2017-03-03|Actual|January 2012||2012-01-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|AIRS||A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)|National Allergies, Immunotherapy and RhinoConjunctivitis Survey in America|Completed|||2765|Actual|ALK-Abelló A/S|||1||f||||f||||||||||2018-05-31 21:38:21.325791|2018-05-31 21:38:21.325791
NCT01535469|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-04-19|2012-02-16|2012-02-17|Estimate|||||||2017-04-19|2017-04-20|Actual|July 1, 2012|Actual|2012-07-01|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ORCAS||Operational Research for Cryptococcal Antigen Screening|Operational Research for Cryptococcal Antigen Screening to Improve ART Survival|Completed||Phase 4|3049|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|f|f|||f|||Yes|After publication, data to be shared upon request to the Infectious Disease Institute Research Department as per the institutional data sharing policy.|2018-05-31 21:38:15.622197|2018-05-31 21:38:15.622197
NCT01535456|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2015-04-29|2012-02-14|2012-02-17|Estimate|||||||2015-04-29|2015-04-30|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||FLT-PET Imaging for MDS|A Pilot Study for Using 18F-FLT PET Imaging To Assess Response In Patients With Myelodysplastic Syndrome (MDS) Being Treated With 5-azacitidine|Terminated||N/A|1|Actual|University of Wisconsin, Madison||1||funding|f||||t||||||||||2018-05-31 21:38:15.765174|2018-05-31 21:38:15.765174
NCT01535443|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-02-24|2012-02-16|2012-02-17|Estimate|||||||2012-02-24|2012-02-27|Estimate|September 2011||2011-09-30|February 2012|2012-02-29||||February 2012|Actual|2012-02-29||Interventional|PRO-155||Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.|STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PRO-155 OPHTHALMIC SOLUTION 0.09% IN HEALTHY VOLUNTEERS.|Unknown status|Active, not recruiting|Phase 1|35|Actual|Laboratorios Sophia S.A de C.V.||1|||f||||t||||||||||2018-05-31 21:38:15.851322|2018-05-31 21:38:15.851322
NCT01535430|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-09-15|2012-02-14|2012-02-17|Estimate|||||||2017-09-15|2017-09-18|Actual|January 2012||2012-01-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Assessment of Eloquent Function in Brain Tumor Patients|Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors|Recruiting|||10|Anticipated|University of Nebraska|||||f||||f||||||||||2018-05-31 21:38:15.976667|2018-05-31 21:38:15.976667
NCT01535417|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2012-02-14|2012-02-14|2012-02-17|Estimate|||||||2012-02-14|2012-02-17|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Shinbaro Capsule|A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee|Completed||Phase 3|198|Actual|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 21:38:16.053038|2018-05-31 21:38:16.053038
NCT01535404|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-05-11|2012-02-14|2012-02-17|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|RIVELA||Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function Study|Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function (RIVELA) Study|Terminated||N/A|36|Actual|University Hospital, Geneva||2||Slow enrollment|f||||t||||||||||2018-05-31 21:38:16.135931|2018-05-31 21:38:16.135931
NCT01535391|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2018-03-21|2012-02-16|2012-02-17|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2012|Actual|2012-01-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|November 2014|Actual|2014-11-30||Interventional|CML0811||Nilotinib in PH+, BCR-, ABL+ CML Patients|The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+, BCR-, ABL+ Chronic Myeloid Leukemia (CML) in Early Chronic Phase: a Phase IIIb, Multicenter Study to Assess the Complete Molecular Response|Active, not recruiting||Phase 3|109|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 21:38:16.242219|2018-05-31 21:38:16.242219
NCT01535378|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2014-07-21|2012-02-14|2012-02-17|Estimate|||||||2014-07-21|2014-07-22|Estimate|March 2012||2012-03-31|July 2014|2014-07-31||||||||Observational|PARADYSAM||Interest of Behavioural Reeducation in Dysfunctions of Masticatory Apparatus. Relations Between Parafunctions and Dysfunctions of Mastixatory Apparatus|Interest of Behavioural Reeducation in Dysfunctions of Masticatory Apparatus. Relations Between Parafunctions and Dysfunctions of Mastixatory Apparatus|Completed|||32|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 21:38:16.382734|2018-05-31 21:38:16.382734
NCT01535365|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2010-11-05||2012-02-16|2012-02-16|2012-02-17|Estimate|2012-02-16|2012-02-17|Estimate||||2012-02-16|2012-02-17|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Heat Versus Ice in the Acute Management of Neck and Back Strain Injuries|Heat Versus Ice in the Acute Management of Neck and Back Strain Injuries|Completed||N/A|60|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 21:38:16.460019|2018-05-31 21:38:16.460019
NCT01535352|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2018-01-10|2012-02-16|2012-02-17|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2012||2012-09-30|January 2018|2018-01-31|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|Mom-NetRCT||Depressed Mothers in Rural Areas: Web-Facilitated Cognitive Behavioral Treatment|Depressed Mothers in Rural Areas: Web-Facilitated Cognitive Behavioral Treatment|Completed||N/A|266|Actual|Oregon Research Institute||2|||f||||t||||||||||2018-05-31 21:38:16.767159|2018-05-31 21:38:16.767159
NCT01535339|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2016-03-31|2012-02-14|2012-02-17|Estimate|||||||2016-03-31|2016-04-01|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion|Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Sport Concussion Assessment - Test Stability and Effect of Concussion|Completed|||114|Actual|ElMindA Ltd|||4||f||||f||||||||||2018-05-31 21:38:16.875396|2018-05-31 21:38:16.875396
NCT01535326|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|2014-03-16||2014-07-28|2012-02-16|2012-02-17|Estimate|2014-07-28|2014-08-15|Estimate||||2014-07-28|2014-08-15|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||patients underwent endoscopy by YHH|Comparing Water Immersion and Water Exchange Methods During Minimally Sedated Colonoscopy|Comparing Air Insufflation, Water Immersion and Water Exchange Methods During Minimal Sedated Colonoscopy, a Randomized, Controlled Trial|Completed||N/A|270|Actual|Dalin Tzu Chi General Hospital|Single center; single endoscopist|3|||f||||f||||||||||2018-05-31 21:38:16.96466|2018-05-31 21:38:16.96466
NCT01535313|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-02-16|2012-02-16|2012-02-17|Estimate|||||||2012-02-16|2012-02-17|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Comparison of a Powered Bone Marrow Biopsy Device With a Manual System|a Prospective Randomized Controlled Trial Comparing a Powered Bone Marrow Biopsy Device With a Manual System|Completed||N/A|60|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:38:17.500235|2018-05-31 21:38:17.500235
NCT01535300|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-14|2012-02-14|2012-02-17|Estimate|||||||2012-02-14|2012-02-17|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Ultrasound and Paediatric Endotracheal Tube Size|Role of Ultrasound Compared to Age-related Formulas for Uncuffed Endotracheal Intubation in a Paediatric Population|Completed|||50|Actual|Heidelberg University|||1||f||||f||||||||||2018-05-31 21:38:17.600172|2018-05-31 21:38:17.600172
NCT01535287|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-02-14|2012-02-14|2012-02-17|Estimate|||||||2012-02-14|2012-02-17|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia|The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia|Unknown status|Recruiting|Phase 4|130|Anticipated|University of Iowa||2|||f||||t||||||||||2018-05-31 21:38:17.692029|2018-05-31 21:38:17.692029
NCT01535274|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2014-09-19|2012-02-16|2012-02-17|Estimate|||||||2014-09-19|2014-09-23|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Ventilation Strategies, Anesthetic Techniques and Cerebral Oxygenation in the Beach Chair Position|The Influence of Basic Ventilation Strategies and Anesthetic Techniques on Cerebral Oxygenation in the Beach Chair Position|Completed||N/A|54|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:38:17.848155|2018-05-31 21:38:17.848155
NCT01535261|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2016-03-16||2016-09-21|2012-02-16|2012-02-17|Estimate|2016-04-27|2016-06-03|Estimate||||2016-09-21|2016-10-27|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CRYSTAL||Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion|A 24-month, Phase IIIb, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal|Completed||Phase 3|357|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:38:18.000417|2018-05-31 21:38:18.000417
NCT01535248|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-11-30|2012-02-14|2012-02-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Echo Detection of Endoscopic Retrograde Cholangiopancreatography (ERCP) Air Embolus|Echocardiographic Surveillance of Patients Undergoing Scheduled Endoscopic Retrograde Cholangiopancreatography for the Presence of Intracardiac Air Embolus|Completed|||17|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 21:38:18.713249|2018-05-31 21:38:18.713249
NCT01535235|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2016-03-01||2016-05-12|2012-02-14|2012-02-17|Estimate|2016-03-01|2016-03-31|Estimate||||2016-05-12|2016-06-16|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study|ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study|Completed||Phase 4|31|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:38:18.840516|2018-05-31 21:38:18.840516
NCT01535222|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2012-06-14||2012-06-14|2012-02-14|2012-02-17|Estimate|2012-06-14|2012-07-19|Estimate||||2012-06-14|2012-07-19|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery|A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective CABG Surgery|Completed||Phase 2|32|Actual|The Medicines Company||6|||f||||t||||||||||2018-05-31 21:38:19.266269|2018-05-31 21:38:19.266269
NCT01535209|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-02-16|2012-02-16|2012-02-17|Estimate|||||||2012-02-16|2012-02-17|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Stereotactic Radiotherapy of Resection Cavity For Single Brain Metastasis Versus Whole-Brain Radiotherapy After Resection|Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis|Unknown status|Recruiting|Phase 3|100|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 21:38:20.223944|2018-05-31 21:38:20.223944
NCT01535196|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-02-18|2012-02-16|2012-02-17|Estimate|||||||2014-02-18|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Vitamine D Treatment in Chronic Heart Failure|Effects of 25-OH-D3 Vitamin Substitution in Congestive Heart Failure. Controlled, Randomized, Double Blind Trial|Suspended||Phase 3|300|Anticipated|Semmelweis University||2||financial reasons|f||||t||||||||||2018-05-31 21:38:20.369168|2018-05-31 21:38:20.369168
NCT01535183|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2014-07-11|2012-02-16|2012-02-17|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents|Irinotecan, Vincristine, Etoposide, Carboplatin, and Cyclophosphamide for Refractory or Relapsed Brain Tumor in Children and Adolescents|Unknown status|Recruiting|Phase 2|40|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 21:38:20.557699|2018-05-31 21:38:20.557699
NCT01535170|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-02-14|2012-02-14|2012-02-17|Estimate|||||||2012-02-14|2012-02-17|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|LFasSDD||Bovine Lactoferrin as a Natural Regimen of Selective Decontamination of the Digestive Tract in Patients With Prolonged Mechanical Ventilation|Bovine Lactoferrin as a Natural Regimen of Selective Decontamination of the Digestive Tract in Patients With Prolonged Mechanical Ventilation|Unknown status|Recruiting|N/A|280|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 21:38:20.653904|2018-05-31 21:38:20.653904
NCT01535157|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2017-07-28|2012-02-16|2012-02-17|Estimate|||||||2017-07-28|2017-07-31|Actual|February 2012||2012-02-29|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer|Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|South Plains Oncology Consortium||1|||f||||t||||||||Undecided||2018-05-31 21:38:20.744183|2018-05-31 21:38:20.744183
NCT01535144|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-02-29|2012-02-14|2012-02-17|Estimate|||||||2012-02-29|2012-03-01|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparative Study of Osteosynthesis for Chevron Osteotomy of Hallux Valgus Using Degradable Versus Non-degradable Metallic Device||Completed||N/A|26|Actual|Syntellix AG||2|||f||||f||||||||||2018-05-31 21:38:20.920129|2018-05-31 21:38:20.920129
NCT01535131|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-11-06|2012-02-14|2012-02-17|Estimate|||||||2017-11-06|2017-11-08|Actual|February 2012||2012-02-29|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Furlow Palatoplasty With Tensor Tenopexy|Furlow Palatoplasty With Tensor Tenopexy for Otitis Media|Active, not recruiting||Phase 2|83|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 21:38:21.139001|2018-05-31 21:38:21.139001
NCT01535092|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-14|2012-02-14|2012-02-17|Estimate|||||||2012-02-14|2012-02-17|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Legalon SIL for the Treatment of HCV Recurrence in Liver Transplanted Patients|A Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Legalon SIL for the Treatment of HCV Recurrence of the Graft in Orthotopic Liver Transplant Patients|Terminated||Phase 2|14|Actual|Rottapharm||2||when realized that the target 60% of patients with SVR was no more achievable|f||||f||||||||||2018-05-31 21:38:21.875526|2018-05-31 21:38:21.875526
NCT01535079|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-11-09|2012-02-16|2012-02-17|Estimate|||||||2012-11-09|2012-11-12|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Acute Sore Throat Pain Study|Analgesic Profile of 3 New Ibuprofen Lozenges (V0498TA01A 15 mg, 25 mg, 35 mg) After Single Administration in Acute Sore Throat Pain|Completed||Phase 2|186|Actual|Pierre Fabre Medicament||5|||f||||||||||||||2018-05-31 21:38:22.004296|2018-05-31 21:38:22.004296
NCT01535066|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-12-13|2012-02-14|2012-02-17|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2012||2012-03-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|October 2017|Actual|2017-10-31||Interventional|||S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer|Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer|Active, not recruiting||N/A|228|Anticipated|Southwest Oncology Group||3|||f||||t||||||||||2018-05-31 21:38:22.14688|2018-05-31 21:38:22.14688
NCT01535053|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-08-23|2012-02-14|2012-02-17|Estimate|||||||2017-08-23|2017-08-24|Actual|June 18, 2012|Actual|2012-06-18|August 2017|2017-08-31||||May 31, 2018|Anticipated|2018-05-31||Interventional|||Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia|A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia|Active, not recruiting||Phase 3|384|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 21:38:22.394095|2018-05-31 21:38:22.394095
NCT01535040|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2015-01-12||2017-05-25|2012-02-14|2012-02-17|Estimate|2015-01-12|2015-01-26|Estimate||||2017-05-25|2017-06-20|Actual|August 2012||2012-08-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||All randomized participants|Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking|Randomized Placebo-Controlled Phase 2 Pilot Study of Memantine (Namenda) for Smoking Cessation Among Cancer Survivors|Completed||Phase 2|130|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||||2018-05-31 21:38:23.003094|2018-05-31 21:38:23.003094
NCT01535027|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-12-30|2012-02-14|2012-02-17|Estimate|||||||2012-12-30|2013-01-03|Estimate|March 2006||2006-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Confors||Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis|Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy|Completed||Phase 4|125|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 21:38:23.520385|2018-05-31 21:38:23.520385
NCT01535014|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-02-07|2012-02-16|2012-02-17|Estimate|||||||2017-02-07|2017-02-08|Estimate|December 2011||2011-12-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial of Safety and Efficiency of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients|Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficiency of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients|Completed||Phase 3|493|Actual|Materia Medica Holding||4|||f||||f||||||||||2018-05-31 21:38:23.615717|2018-05-31 21:38:23.615717
NCT01535001|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2015-12-19||2017-09-14|2012-02-16|2012-02-17|Estimate|2015-12-19|2016-01-27|Estimate||||2017-09-14|2017-10-16|Actual|February 2012||2012-02-29|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Structured Non-operative Treatment of Knee Osteoarthritis|Structured Non-operative Treatment of Knee Osteoarthritis - a Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up|Completed||N/A|100|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:38:23.768657|2018-05-31 21:38:23.768657
NCT01534975|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2017-03-10||2018-01-31|2012-02-16|2012-02-17|Estimate|2018-01-31|2018-03-01|Actual||||2018-01-31|2018-03-01|Actual|January 2012||2012-01-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Visipaque||Comparison of Contrast Agents During CT Angiography|A Prospective, Single-Center Double-Blind Randomized Study in Subjects Undergoing Coronary Computed Tomography Angiography (CCTA) Examination (VISIPAQUE Randomized Study)|Completed||N/A|513|Actual|Los Angeles Biomedical Research Institute|study was performed as outlined, sample sizes are appropriate, there were no technical problems.|4|||f||||f||||||||No||2018-05-31 21:38:24.261557|2018-05-31 21:38:24.261557
NCT01534962|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2014-07-29||2014-07-29|2012-02-16|2012-02-17|Estimate|2014-07-29|2014-08-19|Estimate||||2014-07-29|2014-08-19|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|RAFFAELLO|ITT-population (excluding 3 randomized patients who never started study drug)|Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging Phase II Study Assessing Ranolazine in the Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Non-permanent Atrial Fibrillation.|Completed||Phase 2|241|Actual|Menarini Group|Most of the Kaplan-Meier estimates could not be calculated due to the lower than expected number of observed events and the high variability of data.|4|||f||||f||||||||||2018-05-31 21:38:24.674582|2018-05-31 21:38:24.674582
NCT01534949|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-07-21|2012-02-14|2012-02-17|Estimate|||||||2014-07-21|2014-07-23|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|Triad-DLBCL||Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial|A Phase 1, Multicenter, Open-Label, Single-Arm Study to Evaluate the Initial Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CT-P10 Given in Combination With Dexamethasone, Cytosine Arabinoside, and Cisplatin (DHAP) in Patients With Diffuse Large B-Cell Lymphoma as Second-Line Chemotherapy|Terminated||Phase 1|1|Actual|Celltrion||1|||f||||t||||||||||2018-05-31 21:38:25.236854|2018-05-31 21:38:25.236854
NCT01534936|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-12-19|2012-02-16|2012-02-17|Estimate|||||||2012-12-19|2012-12-20|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|AFFECT||Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary|Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary.|Completed|||2153|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:38:25.320642|2018-05-31 21:38:25.320642
NCT01534923|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2018-01-19|2012-02-14|2012-02-17|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2012||2012-02-29|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Doctor-Patient Communication About Colorectal Cancer Screening|Doctor-Patient Communication About Colorectal Cancer Screening|Active, not recruiting|||225|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:38:25.443938|2018-05-31 21:38:25.443938
NCT01534910|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2015-02-20||2017-03-09|2012-02-16|2012-02-17|Estimate|2015-03-19|2015-04-03|Estimate||||2017-03-09|2017-04-20|Actual|May 2012||2012-05-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Garlic4||Effect of Aged Garlic Extract on Atherosclerosis|Effect of Aged Garlic Extract on Atherosclerosis|Completed||Phase 4|65|Actual|Los Angeles Biomedical Research Institute||2|||f||||f||||||||No||2018-05-31 21:38:25.641681|2018-05-31 21:38:25.641681
NCT01534897|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2015-06-23||2017-01-24|2012-02-14|2012-02-17|Estimate|2017-01-24|2017-03-15|Actual||||2017-01-24|2017-03-15|Actual|July 2012||2012-07-31|January 2017|2017-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436|Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436|Completed||N/A|10|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 21:38:25.882445|2018-05-31 21:38:25.882445
NCT01534884|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2015-05-20|2012-02-14|2012-02-17|Estimate|||||||2015-05-20|2015-05-22|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|Triad RA||Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis|Phase 1, Randomized, Controlled, Multicenter, 2-Arm, Parallel-Group, Double-Blind Study to Demonstrate the Equivalence of CT-P10 to MabThera With Respect to the Pharmacokinetic Profile in Patients With Rheumatoid Arthritis|Completed||Phase 1|154|Actual|Celltrion||2|||f||||t||||||||||2018-05-31 21:38:26.097853|2018-05-31 21:38:26.097853
NCT01534871|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-02-06|2012-02-14|2012-02-17|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Cardiac Rehabilitation on Cardiovascular Disease Risk in Rheumatoid Arthritis Patients|The Effects of a 12-week Cardiovascular Rehabilitation Exercise Program on Inflammatory Markers and Traditional Coronary Artery Disease Risk Factors in Patients With Rheumatoid Arthritis|Recruiting||N/A|60|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||No||2018-05-31 21:38:26.165695|2018-05-31 21:38:26.165695
NCT01534858|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2015-09-21|2012-02-14|2012-02-17|Estimate|||||||2015-09-21|2015-09-22|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Prospective, Descriptive Cohort Study With Prontosan® Wound Gel X in Partial and Full Thickness Burns Requiring Split Thickness Skin Grafts|A Prospective, Descriptive Cohort Study With Prontosan® Wound Gel X in Partial and Full Thickness Burns Requiring Split Thickness Skin Grafts|Completed||N/A|51|Actual|B. Braun Ltd. Centre of Excellence Infection Control||1|||f||||f||||||||||2018-05-31 21:38:26.327091|2018-05-31 21:38:26.327091
NCT01534845|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-07-07|2012-02-16|2012-02-17|Estimate|||||||2015-07-07|2015-07-09|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|February 2017|Anticipated|2017-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion|A Randomized Phase 2 Study to Evaluate the Efficacy Between Only Radiotherapy Versus CCRT With Temozolomide in Newly Diagnosed Grade III Gliomas Without 1p/19q Codeletion|Unknown status|Active, not recruiting|Phase 2|90|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:38:26.41387|2018-05-31 21:38:26.41387
NCT01534832|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-08-14|2012-02-14|2012-02-17|Estimate|||||||2012-08-14|2012-08-15|Estimate|April 2012||2012-04-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Innervision||Assessment of a New Surgical Smoke Clearing Technology in Laparoscopic Cholecystectomy|"Assessment of a New Surgical Smoke Clearing Technology, Innervision, in Laparoscopic Cholecystectomy"|Completed||Phase 1/Phase 2|30|Actual|Asalus Medical Instruments Limited||1|||f||||f||||||||||2018-05-31 21:38:26.493663|2018-05-31 21:38:26.493663
NCT01534819|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2018-02-05|2012-02-14|2012-02-17|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2012|Actual|2012-04-30|February 2018|2018-02-28|April 2024|Anticipated|2024-04-30|April 2020|Anticipated|2020-04-30||Observational|ANCHOR||ANCHOR (Aneurysm Treatment Using the Heli-FX Aortic Securement System Global Registry)|Aneurysm Treatment Using the Heli-FX Aortic Securement System Global Registry|Recruiting|||2000|Anticipated|Medtronic Endovascular|||2||f||||f||||||||No||2018-05-31 21:38:26.587722|2018-05-31 21:38:26.587722
NCT01534806|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-06-23|2012-02-16|2012-02-17|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2012||2012-01-31|June 2014|2014-06-30||||January 2012|Actual|2012-01-31||Interventional|||Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department|A Randomized Double Blinded Study Comparing Use of Prochlorperazine Versus Prochlorperazine and Ketorolac in the Treatment of Pediatric Migraine in the Emergency Department|Withdrawn||Phase 4|0|Actual|Akron Children's Hospital||2||Drug is backordered;|f||||t||||||||||2018-05-31 21:38:26.864578|2018-05-31 21:38:26.864578
NCT01534793|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2015-02-24|2012-02-16|2012-02-17|Estimate|||||||2015-02-24|2015-02-25|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|July 2014|Actual|2014-07-31|May 2013|Actual|2013-05-31||Observational|QUAPELLA||QUAPELLA (QUAlity of Prostate Enucleation by LUMENIS - Laser)|Observational Study Evaluating the Quality of Laser Enucleation of the Prostate Using a LUMENIS Laser Device|Completed|||100|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:38:26.94538|2018-05-31 21:38:26.94538
NCT01534780|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-02-18|2012-02-16|2012-02-17|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|April 2020|Anticipated|2020-04-30|April 2017|Anticipated|2017-04-30||Interventional|FS||3 Fixation Devices in Laparoscopic Ventral Herniotomy|A Controlled Randomized Study of Protack, Securestrap and Glubran Glue as Fixation Devices in Laparoscopic Ventral Herniotomy|Recruiting||Phase 2|75|Anticipated|Horsens Hospital||3|||f||||t||||||||||2018-05-31 21:38:27.043656|2018-05-31 21:38:27.043656
NCT01534754|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2012-02-14|2012-02-14|2012-02-17|Estimate|||||||2012-02-14|2012-02-17|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon|Mesalazine and/or Lactobacillus Casei in Maintaining Remission of Symptomatic Uncomplicated Diverticular Disease of the Colon: a Double-blind, Double-dummy, Placebo-controlled Study|Completed||Phase 4|250|Actual|Hospital Cristo Re||4|||f||||f||||||||||2018-05-31 21:38:27.144249|2018-05-31 21:38:27.144249
NCT01534741|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2014-04-08|2012-02-14|2012-02-17|Estimate|||||||2014-04-08|2014-04-09|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Comparison FX CorDiax 60 in Relation to the FX 60-Dialyzer|Investigation on the Middle Size Molecule Elimination Characteristics of the FX CorDiax 60 in Relation to the FX 60-Dialyzer|Completed||Phase 4|30|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 21:38:27.242861|2018-05-31 21:38:27.242861
NCT01534728|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2015-01-12|2012-02-16|2012-02-17|Estimate|||||||2015-01-12|2015-01-13|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|TETRA||Identification of Hepatitis C Virus (HCV) Specific T Cells|Identification of HCV Specific T Cells Using Tetramer Technology - TETRA Study|Completed|||40|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||Samples Without DNA|"~     PBMCs~   "|||2018-05-31 21:38:27.326605|2018-05-31 21:38:27.326605
NCT01534715|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-12-27|2012-02-16|2012-02-17|Estimate|||||||2017-12-27|2017-12-29|Actual|January 2012||2012-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia|A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia|Completed||Phase 1|49|Actual|ImmunoGen, Inc.||1|||f||||f||||||||No||2018-05-31 21:38:27.384083|2018-05-31 21:38:27.384083
NCT01534702|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-02-17|2012-02-16|2012-02-17|Estimate|||||||2012-02-17|2012-02-20|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|September 2015|Anticipated|2015-09-30|April 2013|Anticipated|2013-04-30||Interventional|CIARA||Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML|Phase I/II Study on Cytarabine and Idarubicin Combined With Escalating Doses of Clofarabine as Induction Therapy in Patients With Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10)|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Hannover Medical School||1|||f||||f||||||||||2018-05-31 21:38:27.458671|2018-05-31 21:38:27.458671
NCT01534689|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2015-07-13||2015-11-07|2012-02-16|2012-02-17|Estimate|2015-11-07|2015-12-11|Estimate||||2015-11-07|2015-12-11|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study of the Use of Low Level Laser Light Therapy to Treat Toenail Fungus|An Evaluation of the Effect of the Erchonia FX-405™ on Treating Toenail Onychomycosis Clinical Study|Completed||N/A|105|Actual|Erchonia Corporation||1|||f||||f||||||||||2018-05-31 21:38:27.728335|2018-05-31 21:38:27.728335
NCT01534676|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2016-08-11||2016-08-11|2012-02-16|2012-02-17|Estimate|2016-08-11|2016-10-05|Estimate||||2016-08-11|2016-10-05|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of Transfusion of Older Stored Red Cells|Harmful Effects of Transfusion of Older Stored Red Cells: Iron and Inflammation|Terminated||N/A|3|Actual|Columbia University||4||Difficulty recruiting donors and recipients, looking for alternative sites|f||||f||||||||Undecided||2018-05-31 21:38:27.924543|2018-05-31 21:38:27.924543
NCT01534663|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2014-07-05|2012-02-16|2012-02-17|Estimate|||||||2014-07-05|2014-07-08|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|GLUTFISH-HF||Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure|Effects of Glutamine and Fish Oil on Muscle Function in Heart Failure (GlutFish-HF)|Completed||Phase 2/Phase 3|31|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 21:38:28.381|2018-05-31 21:38:28.381
NCT01534650|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2017-02-22|2012-02-14|2012-02-17|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2012||2012-02-29|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Movement Disorder Quantification Algorithm Development||Completed|||17|Actual|Great Lakes NeuroTechnologies Inc.|||||f||||||||||||||2018-05-31 21:38:28.679323|2018-05-31 21:38:28.679323
NCT01534637|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|2012-08-29||2017-07-28|2012-02-16|2012-02-17|Estimate|2012-09-28|2012-10-30|Estimate||||2017-07-28|2017-08-28|Actual|August 2006||2006-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|December 2009|Actual|2009-12-31||Interventional|||Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer|A Feasibility Study to Discern the Tolerability of 5-FU/Gemcitabine Based Chemotherapy Concurrent With Upper Abdominal Radiation and the Utility of Aprepitant/5HT-3 Antagonist (EMEND) for the Prevention of ChemoRadiation-Induced Nausea and Vomiting (CRINV)|Completed||N/A|22|Actual|Wake Forest University Health Sciences||1|||f|||||t|f||||||||2018-05-31 21:38:28.918668|2018-05-31 21:38:28.918668
NCT01534624|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2018-05-15|2012-02-15|2012-02-16|Estimate|||||||2018-05-15|2018-05-16|Actual|February 7, 2012||2012-02-07|July 30, 2014|2014-07-30|July 30, 2014||2014-07-30|||||Observational|||Stem Cell Study of Genetics and Drug Addiction|Development of Induced Pluripotent Stem Cells Carrying Monoamine Transporter Polymorphisms|Completed|||49|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:38:29.780146|2018-05-31 21:38:29.780146
NCT01534598|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2018-05-30|2012-02-15|2012-02-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 23, 2012||2012-01-23|February 28, 2018|2018-02-28|April 29, 2019|Anticipated|2019-04-29|December 21, 2018|Anticipated|2018-12-21||Interventional|||FdCyd and THU for Advanced Solid Tumors|Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors|Recruiting||Phase 1|68|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:38:29.8932|2018-05-31 21:38:29.8932
NCT01534585|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2018-04-16|2012-02-15|2012-02-16|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2012||2012-02-29|April 2018|2018-04-30|February 2015|Actual|2015-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma|Phase Ⅰ/Ⅱ Study of Icotinib Hydrochloride Combined With Intensity-modulated Radiotherapy in Nasopharyngeal Cancer|Completed||Phase 1/Phase 2|48|Actual|Taizhou Hospital|||||f||||t||||||||||2018-05-31 21:38:30.00433|2018-05-31 21:38:30.00433
NCT01534572|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-02-15|2012-02-15|2012-02-16|Estimate|||||||2012-02-15|2012-02-16|Estimate|January 2006||2006-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|March 2006|Actual|2006-03-31||Interventional|||Significance of Synbiotics on Inflammation and Proliferation of Colonic Mucosa|Significance of Synbiotics on Inflammation and Proliferation of Colonic Mucosa|Completed||N/A|12|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 21:38:30.12623|2018-05-31 21:38:30.12623
NCT01534559|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-04-06|2012-02-15|2012-02-16|Estimate|||||||2016-04-06|2016-04-07|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MMC||Pharmacist-led Medicines Management Outpatient Service|A Pharmacist-led Medicines Management Outpatient Service for Patients at High Risk of Medication Related Problems|Unknown status|Recruiting|Phase 4|268|Anticipated|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 21:38:30.208964|2018-05-31 21:38:30.208964
NCT01534546|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-02-04|2012-02-15|2012-02-16|Estimate|||||||2016-02-04|2016-02-08|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection|A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection|Recruiting||Phase 3|1059|Anticipated|Peking University||3|||f||||t||||||||No||2018-05-31 21:38:30.299344|2018-05-31 21:38:30.299344
NCT01534533|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2012-07-26||2013-06-18|2012-02-15|2012-02-16|Estimate|2012-09-13|2012-10-15|Estimate||||2013-06-18|2013-07-22|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Lutein Supplementation on Subclinical Atherosclerosis|The Effects of Lutein Supplementation on Subclinical Atherosclerosis|Completed||Phase 2/Phase 3|192|Actual|Peking University||4|||f||||t||||||||||2018-05-31 21:38:30.421697|2018-05-31 21:38:30.421697
NCT01534520|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2016-05-20||2016-10-27|2012-02-13|2012-02-16|Estimate|2016-10-27|2016-12-22|Estimate||||2016-10-27|2016-12-22|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|LIVIIN|Randomization is blinded.|Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women|Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women: a Randomized Controlled Trial|Completed||N/A|61|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 21:38:31.074372|2018-05-31 21:38:31.074372
NCT01534507|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-08-12|2012-02-13|2012-02-16|Estimate|||||||2014-08-12|2014-08-13|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Small and Large Bowel Transit Tests Using MRI (Study 1)|Optimising Measurement of Small and Large Bowel Transit During MRI Scanning and Characterising IBS Subtypes and Their Response to Stress Using MRI (Study 1)|Completed|||108|Actual|University of Nottingham|||5||f||||f||||||Samples Without DNA|"~     Study 1: no samples Study 2: no samples~   "|||2018-05-31 21:38:31.32493|2018-05-31 21:38:31.32493
NCT01534494|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-02-06|2012-02-15|2012-02-16|Estimate|||||||2014-02-06|2014-02-10|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|March 2014|Anticipated|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence|Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|University of New Mexico||1|||f||||t||||||||||2018-05-31 21:38:31.390699|2018-05-31 21:38:31.390699
NCT01534481|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2017-11-07|2012-02-13|2012-02-16|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2012|Actual|2012-08-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Donor Milk vs. Formula in Extremely Low Birth Weight (ELBW) Infants|Neurodevelopmental Effects of Donor Human Milk vs. Preterm Formula in Extremely Low Birth Weight (ELBW) Infants|Recruiting||Phase 3|670|Anticipated|NICHD Neonatal Research Network||2|||f||||t||||||||Yes|NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov)|2018-05-31 21:38:31.465238|2018-05-31 21:38:31.465238
NCT01534468|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2015-12-14|2012-02-13|2012-02-16|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults|Evaluation of Priming by Pandemic Live Attenuated Influenza Vaccine (LAIV) on the Subsequent Response to Inactivated H7N7 Vaccine in Healthy Adults: A Non-Randomized, Open Label Study|Completed||Phase 1|45|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||f||||||||||2018-05-31 21:38:31.617438|2018-05-31 21:38:31.617438
NCT01534455|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2016-02-09|2012-02-13|2012-02-16|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)|A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab Pre-treated Patients With HER2-positive Metastatic Breast Cancer (E-VITA)|Terminated||Phase 2|43|Actual|German Breast Group||2||very slow patient recruitment and concerns about the actuality of the study design|f||||t||||||||||2018-05-31 21:38:31.69379|2018-05-31 21:38:31.69379
NCT01534442|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-12-06|2012-02-15|2012-02-16|Estimate|||||||2012-12-06|2012-12-07|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response|The Significances of Atropin Administration for the GLP-1 Potentiation of Glucose Induced Insulin Secretion and the Cephalic Insulin Response|Unknown status|Recruiting|N/A|10|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 21:38:31.897225|2018-05-31 21:38:31.897225
NCT01534429|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-07-07|2012-02-13|2012-02-16|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2011||2011-02-28|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||Quantitative Sensory Testing and Analysis of Post Inguinal Hernia Surgery Pain|Quantitative Sensory Testing and Neurophysiologic Analysis of Post-Herniorraphy Pain in Patients Undergoing Selective Neurectomy and Mesh Removal|Completed|||10|Actual|University of California, Los Angeles|||1||f||||f||||||||No||2018-05-31 21:38:31.984092|2018-05-31 21:38:31.984092
NCT01534416|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2017-04-17||2017-12-18|2012-02-13|2012-02-16|Estimate|2017-12-18|2017-12-20|Actual||||2017-12-18|2017-12-20|Actual|September 2011||2011-09-30|December 2017|2017-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Paracervical Block on Post Operative Pain in Laparoscopic Gynecologic Surgery|Use of Paracervical Block in Laparoscopic Gynecologic Surgery: A Randomized Controlled Trial|Completed||N/A|132|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 21:38:32.089554|2018-05-31 21:38:32.089554
NCT01534403|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13||2016-04-11|2016-04-11|2012-02-15|2012-02-16|Estimate||||2016-04-11|2016-05-06|Estimate|2016-04-11|2016-05-06|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects|A Phase 2, Multicenter, Open-label, Long-term, Extension Study to Assess the Safety of Epratuzumab Treatment in Japanese Subjects With Systemic Lupus Erythematosus|Completed||Phase 2|17|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 21:38:32.641159|2018-05-31 21:38:32.641159
NCT01534390|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2015-05-31|2012-02-13|2012-02-16|Estimate|||||||2015-05-31|2015-06-02|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2013|Actual|2013-04-30||Interventional|||Influence of In-line Microfilters on Systemic Inflammation in Adult Critically Ill Patients|The Influence of In-line Microfilters on Systemic Inflammation in Adult Critically Ill Patients: A Prospective, Randomized, Controlled Trial|Completed||Phase 2|504|Actual|University of Salzburg||2|||f||||f||||||||||2018-05-31 21:38:32.820194|2018-05-31 21:38:32.820194
NCT01534377|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2018-04-20|2012-02-13|2012-02-16|Estimate|||||||2018-04-20|2018-04-23|Actual|July 2011|Actual|2011-07-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|IPT||Interpersonal Psychotherapy for Adolescent Girls|Prevention of Depression in Maltreated and Nonmaltreated Adolescents|Active, not recruiting||N/A|328|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 21:38:33.113364|2018-05-31 21:38:33.113364
NCT01534364|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-03-24|2012-02-15|2012-02-16|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|CR_KCH||Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery|Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery|Completed||N/A|82|Actual|University of Cologne||2|||f||||t||||||||||2018-05-31 21:38:33.258498|2018-05-31 21:38:33.258498
NCT01534351|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2015-10-29||2017-05-26|2012-02-13|2012-02-16|Estimate|2015-10-29|2015-12-03|Estimate||||2017-05-26|2017-06-20|Actual|August 1, 2013|Actual|2013-08-01|May 2017|2017-05-31|November 18, 2013|Actual|2013-11-18|November 18, 2013|Actual|2013-11-18||Interventional|||Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)|A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia (BPH)|Terminated||Phase 3|1|Actual|Merck Sharp & Dohme Corp.|The trial was terminated for business reasons.|3||Business Reasons|f||||t||||||||||2018-05-31 21:38:33.367163|2018-05-31 21:38:33.367163
NCT01534338|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-12-10|2012-02-13|2012-02-16|Estimate|||||||2012-12-10|2012-12-11|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MAPS||Effect of Mindfulness Training on Sleep and Inflammation Among Older Adults With Sleep Problems|A Randomized Controlled Trial Testing the Effect of Mindfulness Practices Versus Sleep Education on Sleep and Inflammation Among Older Adults With Sleep Problems|Completed||Phase 1/Phase 2|48|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:38:33.734142|2018-05-31 21:38:33.734142
NCT01534325|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-01-21|2012-02-13|2012-02-16|Estimate|||||||2016-01-21|2016-01-22|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy Study for SD Device|Efficacy Study of SD Device for Overweight and Obesity Treatment|Unknown status|Recruiting|N/A|150|Anticipated|Beck Medical Ltd.||3|||f||||t||||||||||2018-05-31 21:38:33.835384|2018-05-31 21:38:33.835384
NCT01534312|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-11-20|2012-02-13|2012-02-16|Estimate|||||||2016-11-20|2016-11-22|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)|Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)|Completed||N/A|24|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:38:34.093064|2018-05-31 21:38:34.093064
NCT01534299|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2018-04-25|2012-02-15|2012-02-16|Estimate|||||||2018-04-25|2018-04-27|Actual|February 2012||2012-02-29|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|July 2018|Anticipated|2018-07-31||Observational|||Global SYMPLICITY Registry|Global proSpective registrY for syMPathetic renaL denervatIon in seleCted IndicatIons Through 3 Years Registry|Recruiting|||3000|Anticipated|Medtronic Vascular|||1||f||||f||||||||||2018-05-31 21:38:34.398526|2018-05-31 21:38:34.398526
NCT01534286|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-05-04|2012-02-13|2012-02-16|Estimate|||||||2016-05-04|2016-05-05|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics|A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics|Terminated||Phase 4|8|Actual|Targeted Medical Pharma||2||Unable to recruit patients|f||||f||||||||No|Too small data set to draw any conclusions|2018-05-31 21:38:34.701333|2018-05-31 21:38:34.701333
NCT01534273|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2012-08-09|2012-02-13|2012-02-16|Estimate|||||||2012-08-09|2012-08-10|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of LY2886721 in Healthy Participants|Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects|Completed||Phase 1|39|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 21:38:35.001201|2018-05-31 21:38:35.001201
NCT01534260|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2018-03-28|2012-02-15|2012-02-16|Estimate|||||||2018-03-28|2018-03-30|Actual|February 10, 2012|Actual|2012-02-10|March 2018|2018-03-31|February 13, 2017|Actual|2017-02-13|August 29, 2016|Actual|2016-08-29||Interventional|||Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype|Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype|Completed||Phase 1/Phase 2|37|Actual|Indiana University||1|||f||||t|t|f||||||||2018-05-31 21:38:35.288|2018-05-31 21:38:35.288
NCT01534247|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2017-09-01|2012-02-13|2012-02-16|Estimate|||||||2017-09-01|2017-09-05|Actual|February 2012||2012-02-29|September 2017|2017-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately|A Phase I, Open-Label, 3-way Crossover, Pharmacokinetic and Drug-Drug Interaction Study of Ceftazidime Avibactam (CAZ-AVI) and Metronidazole When Administered Alone and in Combination in Healthy Subjects|Completed||Phase 1|28|Actual|Pfizer||3|||f||||||||||||||2018-05-31 21:38:35.519497|2018-05-31 21:38:35.519497
NCT01534234|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2018-02-21|2012-02-13|2012-02-16|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2012||2012-01-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2015|Actual|2015-12-31||Interventional|RESPOND-CRT||Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D|Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D|Active, not recruiting||Phase 3|1039|Actual|LivaNova||2|||f||||t||t|t|||||||2018-05-31 21:38:35.62793|2018-05-31 21:38:35.62793
NCT01534221|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-02-15|2012-02-15|2012-02-16|Estimate|||||||2012-02-15|2012-02-16|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|COPERNICOS||The COOPerative Establishment for Necessary Investigation in Clinical Outcome After Stenting|Randomized Comparison of Outcome of Stenting in Unselected Patients in Everyday Clinical Practice|Not yet recruiting||Phase 4|5100|Anticipated|Zealand University Hospital||5|||f||||f||||||||||2018-05-31 21:38:35.949947|2018-05-31 21:38:35.949947
NCT01534208|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2014-06-27||2014-06-27|2012-02-15|2012-02-16|Estimate|2014-06-27|2014-07-24|Estimate||||2014-06-27|2014-07-24|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Safety population|Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism|An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism|Completed||Phase 3|499|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 21:38:36.345854|2018-05-31 21:38:36.345854
NCT01534195|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-07-10|2012-02-13|2012-02-16|Estimate|||||||2012-07-10|2012-07-12|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model|A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model|Completed||Phase 4|9|Actual|ORA, Inc.||2|||f||||f||||||||||2018-05-31 21:38:37.078926|2018-05-31 21:38:37.078926
NCT01534182|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2014-06-11||2014-08-07|2012-02-15|2012-02-16|Estimate|2014-08-07|2014-08-08|Estimate||||2014-08-07|2014-08-08|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|EPOC||Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)|A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT)|Completed||Phase 4|298|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:38:37.175125|2018-05-31 21:38:37.175125
NCT01534169|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-11-08|2012-02-15|2012-02-16|Estimate|||||||2012-11-08|2012-11-12|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|March 2012|Actual|2012-03-31||Interventional|||Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients|Function of Regulatory T Cells Improved by Treatment With an Intrathyroid Injection of Dexamethasone in Graves' Patients|Completed||Phase 1|50|Actual|Nanjing Medical University||1|||f||||t||||||||||2018-05-31 21:38:37.531335|2018-05-31 21:38:37.531335
NCT01534143|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2013-10-22||2017-03-08|2012-02-15|2012-02-16|Estimate|2013-10-25|2013-12-16|Estimate||||2017-03-08|2017-04-05|Actual|February 2012||2012-02-29|March 2017|2017-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant|A Pilot Study Using High Dose Busulfan and Bortezomib as Part of Allogeneic Transplant Conditioning Regimen for High Risk Multiple Myeloma Patients.|Terminated||Phase 2|1|Actual|Barbara Ann Karmanos Cancer Institute|Data was not collected, because funding was unavailable to continue study.|1||Data was not collected, because funding was unavailable to continue study.|f||||t||||||||||2018-05-31 21:38:37.615868|2018-05-31 21:38:37.615868
NCT01534130|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-08-06|2012-02-13|2012-02-16|Estimate|||||||2012-08-06|2012-08-07|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome|Acupuncture for the Sleep Disorder of Chronic Fatigue Syndrome|Unknown status|Recruiting|N/A|72|Anticipated|Chengdu University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 21:38:38.036289|2018-05-31 21:38:38.036289
NCT01534117|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-15|2012-02-15|2012-02-16|Estimate|||||||2012-02-15|2012-02-16|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|ASA/Plavix||Platelet Function Analysis in Head Trauma: ASA/Plavix|Platelet Function Analysis in Head Trauma: ASA/CLOPIDOGREL|Completed||N/A|97|Actual|Chang, Steve S., M.D.||2|||f||||t||||||||||2018-05-31 21:38:38.179201|2018-05-31 21:38:38.179201
NCT01534104|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2018-03-02|2012-02-15|2012-02-16|Estimate|||||||2018-03-02|2018-03-05|Actual|February 2012|Actual|2012-02-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning|Using Functional MRI and Diffusion Imaging of Eloquent Brain Areas to Optimize Brain Tumor Resection Planning|Recruiting||N/A|185|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:38:38.28845|2018-05-31 21:38:38.28845
NCT01534091|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-04-13|2012-02-15|2012-02-16|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Enhancing the Amount of Physical Activity Carried Out by Overweight Children at Leisure Time|Enhancing the Amount of Physical Activity Carried Out by Overweight Children at Leisure Time|Terminated||N/A|25|Actual|Meir Medical Center||3||Lack of cooperation by the participants|f||||f||||||||||2018-05-31 21:38:38.424946|2018-05-31 21:38:38.424946
NCT01534078|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2017-06-07||2018-01-23|2012-02-13|2012-02-16|Estimate|2017-08-01|2017-08-30|Actual||||2018-01-23|2018-02-20|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2015|Actual|2015-01-31||Interventional|||Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma|Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma|Completed||Phase 2|34|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:38:38.566257|2018-05-31 21:38:38.566257
NCT01534065|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-11-07|2012-02-13|2012-02-16|Estimate|||||||2016-11-07|2016-11-09|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Barricaid EU Post Market Study for Primary Lumbar Disc Herniation|A Multi-center, Post Marketing Surveillance Study to Monitor the Safety and Performance of the Barricaid® ARD in the Treatment of Back and Radicular Pain Caused by Primary Lumbar Disc Herniation|Completed||Phase 4|45|Actual|Intrinsic Therapeutics||1|||f||||t||||||||||2018-05-31 21:38:39.120417|2018-05-31 21:38:39.120417
NCT01534052|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2018-03-26||2018-03-26|2012-02-13|2012-02-16|Estimate|2018-03-26|2018-04-27|Actual||||2018-03-26|2018-04-27|Actual|November 8, 2011|Actual|2011-11-08|March 2018|2018-03-31|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional||The analysis population was the Safety Analysis Set (SAF), which consisted of participants who received at least one dose of enzalutamide during the extension study. This extension study’s baseline was considered the original baseline from the prior parent studies with enzalutamide.|A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100|A Phase 2 Open-label Extension Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100|Completed||Phase 2|52|Actual|Astellas Pharma Inc||1|||f||||f|t|f||||||Undecided||2018-05-31 21:38:39.206397|2018-05-31 21:38:39.206397
NCT01534039|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-09-23|2012-02-13|2012-02-16|Estimate|||||||2013-09-23|2013-09-24|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Clinical Comparison of Two Marketed Skin Barriers on Healthy Volunteers|Phase 4-A Clinical Comparison of a Marketed Moldable Skin Barrier Versus a Marketed Stretch-to-Fit Skin Barrier in Healthy Volunteers|Completed||Phase 4|60|Actual|Independent Nurse Consultants LLC||2|||f||||f||||||||||2018-05-31 21:38:39.535202|2018-05-31 21:38:39.535202
NCT01534026|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-05-30|2012-02-13|2012-02-16|Estimate|||||||2016-05-30|2016-06-01|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study|Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study|Completed||Phase 4|12|Actual|The Alfred||2|||f||||f||||||||||2018-05-31 21:38:39.596925|2018-05-31 21:38:39.596925
NCT01533987|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-02-15|2012-02-15|2012-02-16|Estimate|||||||2012-02-15|2012-02-16|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Juice Plus+® Supplementation on Endothelial Function in Overweight Men|Effects of Juice Plus+® Supplementation on Endothelial Function in Overweight Men: A Randomized, Controlled Trial|Completed||N/A|70|Actual|Griffin Hospital||2|||f||||f||||||||||2018-05-31 21:38:39.963922|2018-05-31 21:38:39.963922
NCT01533974|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2016-04-05||2016-05-13|2012-02-15|2012-02-16|Estimate|2016-04-05|2016-05-09|Estimate||||2016-05-13|2016-06-17|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|PATH||PATH Partnering to Achieve Tobacco-free Health|Acceptance & Commitment Therapy for Smoking Cessation (Aka PATH Study - Partnering to Achieve Tobacco-free Health)|Completed||Phase 1/Phase 2|450|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 21:38:40.052971|2018-05-31 21:38:40.052971
NCT01533961|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2015-09-17|2012-02-15|2012-02-16|Estimate|||||||2015-09-17|2015-09-18|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158|Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers|Completed||Phase 1|136|Actual|Drugs for Neglected Diseases||2|||f||||f||||||||||2018-05-31 21:38:40.24241|2018-05-31 21:38:40.24241
NCT01533948|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2018-01-09||2018-05-08|2012-02-15|2012-02-16|Estimate|2018-05-08|2018-05-09|Actual||||2018-05-08|2018-05-09|Actual|January 2012||2012-01-31|May 2018|2018-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||All treated and eligible patients|Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery|Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma|Terminated||Phase 2|25|Actual|Roswell Park Cancer Institute||1||low accrual|f||||t||||||||||2018-05-31 21:38:40.340477|2018-05-31 21:38:40.340477
NCT01533935|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2015-06-19|2014-04-30|2015-08-12|2012-02-15|2012-02-16|Estimate|2015-08-12|2015-09-15|Estimate|2014-04-30|2014-05-16|Estimate|2015-08-12|2015-09-15|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Treated Set (TS) : This patient set included all patients of the Randomised Set (RS : patients who signed the informed consent form and were also randomised, regardless of whether the patient was treated with study medication or not) who were dispensed study medication and were documented to have taken at least 1 dose of study medication.|Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.|A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 2]|Completed||Phase 3|291|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 21:38:40.70053|2018-05-31 21:38:40.70053
NCT01533922|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|2015-06-19|2014-04-30|2015-08-12|2012-02-15|2012-02-16|Estimate|2015-08-12|2015-09-15|Estimate|2014-04-30|2014-05-16|Estimate|2015-08-12|2015-09-15|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Treated Set (TS) : This patient set included all patients of the Randomised Set (RS : patients who signed the informed consent form and were also randomised, regardless of whether the patient was treated with study medication or not) who were dispensed study medication and were documented to have taken at least 1 dose of study medication.|Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients|A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 1]|Completed||Phase 3|295|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 21:38:42.430423|2018-05-31 21:38:42.430423
NCT01533909|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2014-12-02|2012-02-14|2012-02-15|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Observational|||Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients|Development of a Screening Tool to Detect and Stage Cachectic Cancer Patients|Completed|||56|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples Without DNA|"~     The blood sample that will be collected is part of the routine hospital assessment. The~     biomarkers that will be measured are albumine, creatine, CRP, hemoglobin and Lactate~     dehydrogenase (LDH).~   "|||2018-05-31 21:38:43.230641|2018-05-31 21:38:43.230641
NCT01533896|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Can a Brief Primary Care Intervention Affect Healthy Weight Habits|Can a Brief Primary Care Intervention Affect Healthy Weight Habits|Completed||N/A|221|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 21:38:43.324821|2018-05-31 21:38:43.324821
NCT01533883|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-08-28|2012-02-12|2012-02-15|Estimate|||||||2016-08-28|2016-08-30|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|July 2016|Actual|2016-07-31||Observational|||Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair|Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair|Active, not recruiting|||16|Actual|Edwards Lifesciences|||||f||||t||||||||||2018-05-31 21:38:43.436605|2018-05-31 21:38:43.436605
NCT01533870|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-10-13|2012-02-14|2012-02-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118|An Open-label, Fixed-sequence, 3-period, 3-treatment, Crossover Study to Assess the Effects of Rifampin on Pharmacokinetics of NKTR-118 in Healthy Subjects|Completed||Phase 1|22|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:38:43.527981|2018-05-31 21:38:43.527981
NCT01533857|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2013-08-12|2012-02-12|2012-02-15|Estimate|||||||2013-08-12|2013-08-13|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|November 2012|Actual|2012-11-30|February 2012|Actual|2012-02-29||Interventional|||Pharmacokinetic Behavior of Phenolic Acids Derived From Black Tea|Pharmacokinetic Behavior of Phenolic Acids Derived From Black Tea|Completed||N/A|12|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 21:38:43.642458|2018-05-31 21:38:43.642458
NCT01533844|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2015-03-03|2012-02-13|2012-02-15|Estimate|||||||2015-03-03|2015-03-04|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|DAISY||To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis|An Observational, Non-interventional Study to Determine the Role of Clostridium Difficile in the Pathogenesis of Disease Observed in Neonates and to Investigate the Feasibility of a Potential Study to Evaluate Safety, Efficacy and Pharmacokinetics of Fidaxomicin Oral Suspension in Neonates With Clostridium Difficile Associated Disease (CDAD)|Terminated|||1|Actual|Astellas Pharma Inc|||1|Terminated due to the fact that the required number of trial subjects was not met.|f||||f||||||Samples Without DNA|"~     Stool Sample~   "|||2018-05-31 21:38:43.726432|2018-05-31 21:38:43.726432
NCT01533831|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2013-02-12|2012-02-14|2012-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:38:43.812682|2018-05-31 21:38:43.812682
NCT01533818|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2014-06-02|2012-02-14|2012-02-15|Estimate|||||||2014-06-02|2014-06-03|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MAT-YI||Community Based Management of Fast Breathing in Infants Aged < 60 Days in Low-income Settlements of Karachi|Community Based Management of Fast Breathing in Infants Aged < 60 Days: A Double-Blind, Randomized Placebo-Controlled Trial in Low-income Settlements of Karachi|Terminated||Phase 4|963|Actual|Aga Khan University||2||"The study was stopped by DSMB based on high treatment failure rate in placebo compared to~   active drug."|f||||t||||||||||2018-05-31 21:38:43.846731|2018-05-31 21:38:43.846731
NCT01533805|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Effects of Different Techniques of the Method Pilates in Chronic Low Back Pain|Effects of Different Techniques of the Method Pilates in Chronic Low Back Pain in Women 46 to 60 Years|Unknown status|Not yet recruiting|N/A|40|Anticipated|Universidade Gama Filho||2|||f||||t||||||||||2018-05-31 21:38:43.91819|2018-05-31 21:38:43.91819
NCT01533792|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2012-02-15|2012-02-12|2012-02-15|Estimate|||||||2012-02-15|2012-02-17|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|EONSPT||Effect of Non-surgical Periodontal Treatment|Effect of Non-surgical Periodontal Treatment on Pregnant Women With Periodontitis: a Randomized Clinical Trial|Completed||Phase 2|40|Actual|Universidade Federal do Maranhão||2|||f||||f||||||||||2018-05-31 21:38:44.026094|2018-05-31 21:38:44.026094
NCT01533779|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy and Their Role in Antitumor Activity|Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy for Pediatric Hematological and Solid Tumors, and Its Relation to Other Neutrophil Functions and the Role of NETs in Antitumor Activity|Unknown status|Recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 21:38:44.095832|2018-05-31 21:38:44.095832
NCT01533766|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-02-15|2012-02-10|2012-02-15|Estimate|||||||2013-02-15|2013-02-18|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|OMEGA||A Safety, Efficacy Study of CombiflexOmega Versus SmofKabiven in Patients With Parenteral Nutrition|A Randomized, Open, Multicenter, Compared Phase III Trial to Evaluate the Safety, Efficacy of CombiflexOmega and SmofKabiven in Postoperative Patients Requiring Parenteral Nutrition|Completed||Phase 3|50|Anticipated|JW Pharmaceutical||2|||f||||||||||||||2018-05-31 21:38:44.302574|2018-05-31 21:38:44.302574
NCT01533753|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2014-08-25||2014-09-10|2012-02-14|2012-02-15|Estimate|2014-09-10|2014-09-15|Estimate||||2014-09-10|2014-09-15|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer|Randomized, Open-Label Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer|Terminated||Phase 2|5|Actual|University of Wisconsin, Madison|The study was terminated due to slow accrual. The data was uninterpretable due to the small numbers of subjects analyzed.|2||Slow accrual|f||||||||||||||2018-05-31 21:38:44.415861|2018-05-31 21:38:44.415861
NCT01533740|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2014-02-01|2012-02-10|2012-02-15|Estimate|||||||2014-02-01|2014-02-04|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients|Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy|Completed|||31|Actual|University of Rome Tor Vergata|||||f||||f||||||Samples With DNA|"~     whole blood sample~   "|||2018-05-31 21:38:44.957696|2018-05-31 21:38:44.957696
NCT01533727|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2013-12-05|2012-02-14|2012-02-15|Estimate|||||||2013-12-05|2013-12-09|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|||CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)|A Phase 2,Open-label Study of Autologous Cytokine-Induced Killer Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Sun Yat-sen University||2||"Few patients would like to participate ,since CIK cell transfusion was a new treatment and its~   efficacy was doubted."|f||||t||||||||||2018-05-31 21:38:45.103085|2018-05-31 21:38:45.103085
NCT01533714|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10||2014-08-25|2014-08-27|2012-02-10|2012-02-15|Estimate||||2014-08-27|2014-08-29|Estimate|2014-08-27|2014-08-29|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Long-term Safety and Efficacy of Olokizumab (CDP6038) With Active Rheumatoid Arthritis|Multi-center, Open-label, Follow-up Study to Assess the Long-term Safety and Efficacy of CDP6038 Administered Subcutaneously to Asian Subjects With Active Rheumatoid Arthritis Who Completed Study RA0083|Completed||Phase 2|103|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 21:38:45.185365|2018-05-31 21:38:45.185365
NCT01533701|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-10|2012-02-10|2012-02-15|Estimate|||||||2012-02-10|2012-02-15|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|FBS||Scalp Sampling for Fetal Surveillance|Biosampling for Markers of Hypoxia in Fetal Blood Scalp Sampling During Labor|Unknown status|Recruiting|N/A|60|Anticipated|Uppsala University Hospital|||||f||||f||||||||||2018-05-31 21:38:45.361878|2018-05-31 21:38:45.361878
NCT01533688|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-03-24|2012-02-10|2012-02-15|Estimate|||||||2017-03-24|2017-03-27|Actual|October 2011||2011-10-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Interventional|||Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients|Efficacy and Tolerability of Various Bowel Preparations in Diabetic Patients: A Randomized Controlled Trial|Active, not recruiting||N/A|244|Anticipated|University of Oklahoma||3|||f||||f||||||||||2018-05-31 21:38:45.462707|2018-05-31 21:38:45.462707
NCT01533675|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-05-09|2012-02-10|2012-02-15|Estimate|||||||2017-05-09|2017-05-10|Actual|May 2010||2010-05-31|May 2017|2017-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Comparison Study of the Tensile Strength of Sutures Used in Dermatologic Surgery on the Day of Suture Removal, Following Wound Care With Two Different Products|A Comparison Study of the Tensile Strength of Sutures Used in Dermatologic Surgery on the Day of Suture Removal, Following Wound Care With Two Different|Completed||N/A|40|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 21:38:45.575283|2018-05-31 21:38:45.575283
NCT01533662|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2014-06-20|2012-02-10|2012-02-15|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|PPSA||Prophylactic Phenylephrine Infusion for Preventing Hypotension During Spinal Anesthesia|Phase 2 Study Evaluating the Prophylactic Phenylephrine Infusion for Preventing Hypotension During Spinal Anesthesia for Lower Limb Orthopedic Surgery in the Elderly Patients|Completed||Phase 2|64|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 21:38:45.65602|2018-05-31 21:38:45.65602
NCT01533649|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-10|2012-02-10|2012-02-15|Estimate|||||||2012-02-10|2012-02-15|Estimate|April 2012||2012-04-30|February 2012|2012-02-29|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|PHOENICS||Personalizing Health Outcome in Epilepsy Now - An Introduction to Clinical Services|Pilot Trial: Personalizing Health Outcome in Epilepsy Now - An Introduction to Clinical Services|Unknown status|Not yet recruiting|N/A|30|Anticipated|University Health Network, Toronto||3|||f||||t||||||||||2018-05-31 21:38:45.739834|2018-05-31 21:38:45.739834
NCT01533636|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-05-09|2012-02-14|2012-02-15|Estimate|||||||2017-05-09|2017-05-11|Actual|July 2012||2012-07-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|CADET||CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment|CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment to Lung Mucin|Recruiting|||50|Anticipated|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     Samples of induced and expectorated sputum and blood for DNA and RNA extraction, plasma, and~     serum will be banked in the UCSF Airway Tissue Bank.~   "|||2018-05-31 21:38:45.847446|2018-05-31 21:38:45.847446
NCT01533623|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-06-19|2012-02-10|2012-02-15|Estimate|||||||2013-06-19|2013-06-20|Estimate||||June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The 1 Year Follow-up Objective Oral Appliance Compliance|The 1 Year Follow-up of Objective Measures of Oral Appliance Compliance for Treatment of Sleep-disordered Breathing (SDB): a Clinical Trial|Completed||N/A|51|Actual|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 21:38:45.919531|2018-05-31 21:38:45.919531
NCT01533610|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||The Efficacy of Stellate Ganglion Block as Post-traumatic Stress Disorder (PTSD) Therapy: A Pilot Study|The Efficacy of Stellate Ganglion Block as PTSD Therapy: A Pilot Study|Unknown status|Recruiting|Phase 2|12|Anticipated|Southern California Institute for Research and Education|||||f||||f||||||||||2018-05-31 21:38:46.006085|2018-05-31 21:38:46.006085
NCT01533597|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2015-01-11||2015-01-24|2012-02-10|2012-02-15|Estimate|2015-01-24|2015-01-27|Estimate||||2015-01-24|2015-01-27|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)|Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study|Completed||Phase 4|70|Actual|Soonchunhyang University Hospital|small study population|2|||f||||f||||||||||2018-05-31 21:38:46.133651|2018-05-31 21:38:46.133651
NCT01533584|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-09-09|2012-02-14|2012-02-15|Estimate|||||||2012-09-09|2012-09-11|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Evaluation of Nocturnal Hypertension and Correlation With Target-Organ Damage|Evaluation of Nocturnal Hypertension With 24-hour Ambulatory or Home Blood Pressure Measurement: Correlation With Target-Organ Damage|Unknown status|Recruiting||100|Anticipated|University of Athens|||||f||||f||||||||||2018-05-31 21:38:46.507011|2018-05-31 21:38:46.507011
NCT01533571|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2015-03-06|2012-02-14|2012-02-15|Estimate|||||||2015-03-06|2015-03-09|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Immediate Implant Placement in the Esthetic Zone|Immediate Implant Placement After Tooth Extraction in the Esthetic Zone: Extraction Socket Morphology-Guided Treatment Modalities and Esthetic Outcome|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Lithuanian University of Health Sciences||2|||f||||f||||||||||2018-05-31 21:38:46.590741|2018-05-31 21:38:46.590741
NCT01533558|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2013-08-28|2012-02-10|2012-02-15|Estimate|||||||2013-08-28|2013-08-29|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|CASCADE||Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates|Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates|Completed|||20|Actual|Radboud University|||1||f||||f||||||Samples Without DNA|"~     Plasma samples for determination of caspofungin~   "|||2018-05-31 21:38:46.783921|2018-05-31 21:38:46.783921
NCT01533545|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-04-15|2012-02-10|2012-02-15|Estimate|||||||2014-04-15|2014-04-16|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients|Effect of Epinephrine on Systemic Absorption of Mepivacaine Administered for Brachial Plexus Block in Patients With Chronic Renal Insufficiency|Terminated||N/A|16|Actual|Rigshospitalet, Denmark||2||Slow recruitment|f||||t||||||||||2018-05-31 21:38:46.917107|2018-05-31 21:38:46.917107
NCT01533532|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2014-05-29|2012-02-14|2012-02-15|Estimate|||||||2014-05-29|2014-05-30|Estimate||||May 2014|2014-05-31||||||||Interventional|||A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)|A Multicenter, Randomized, Placebo-controlled, Double-blind Phase II Study of KLH-2109 in Patients With Endometriosis(2)|Completed||Phase 2|100||Kissei Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 21:38:47.039781|2018-05-31 21:38:47.039781
NCT01533519|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-04-13|2012-02-10|2012-02-15|Estimate|||||||2016-04-13|2016-04-14|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)|A Dose Escalation Study of Intranasal Neuropeptide Y in PTSD|Completed||Phase 1|26|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:38:47.114471|2018-05-31 21:38:47.114471
NCT01533506|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-02-26|2012-02-14|2012-02-15|Estimate|||||||2013-02-26|2013-02-28|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Expanded Access|||Stiripentol in Dravet Syndrome|Compassionate Use of Stiripentol in Intractable Epilepsy Due to Dravet Syndrome|No longer available|||||Mayo Clinic|||||||||f||||||||||2018-05-31 21:38:47.231577|2018-05-31 21:38:47.231577
NCT01533493|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2013-11-04||2014-03-10|2012-02-10|2012-02-15|Estimate|2014-01-06|2014-02-21|Estimate||||2014-03-10|2014-04-08|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study|Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study|Completed||N/A|33|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:38:47.353666|2018-05-31 21:38:47.353666
NCT01533480|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-02-27|2012-02-10|2012-02-15|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2012||2012-01-31|February 2018|2018-02-28|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|||A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis|A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis|Completed||Phase 4|20|Actual|Lifelong Vision Foundation||2|||f||||f||||||||||2018-05-31 21:38:47.868148|2018-05-31 21:38:47.868148
NCT01533467|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-12|2012-02-12|2012-02-15|Estimate|||||||2012-02-12|2012-02-15|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Device Designed to Protect the Perineum During Labor|Study of Perineal Protection Device|Completed||Phase 2|1200|Actual|Helsingborgs Hospital||2|||f||||f||||||||||2018-05-31 21:38:47.955918|2018-05-31 21:38:47.955918
NCT01533454|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2016-01-03|2012-02-14|2012-02-15|Estimate|||||||2016-01-03|2016-01-05|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Randomized Incentive-Based Weight Loss Trial in Singapore|A Randomized Incentive-Based Weight Loss Trial in Singapore|Completed||N/A|161|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 21:38:48.04935|2018-05-31 21:38:48.04935
NCT01533441|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2014-04-07|2012-02-14|2012-02-15|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|SAFEK||Vitamin K2 Intervention in Patients With Vitamin K Antagonists|Study of the Effect of Food Vitamin K2 Intake in Association With a Fermented Dairy Product on Patients Treated With Vitamin K Antagonist (VKA)|Completed||Phase 2|50|Actual|Danisco||4|||f||||f||||||||||2018-05-31 21:38:48.289362|2018-05-31 21:38:48.289362
NCT01533428|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|2015-02-06||2015-10-12|2012-02-14|2012-02-15|Estimate|2015-03-03|2015-03-13|Estimate||||2015-10-12|2015-11-04|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|STEP|Safety Analysis Set|A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)|A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of QUTENZA® in Subjects With Painful Diabetic Peripheral Neuropathy|Completed||Phase 3|369|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||f||||||||||2018-05-31 21:38:48.452963|2018-05-31 21:38:48.452963
NCT01533415|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2013-04-05|2012-02-14|2012-02-15|Estimate|||||||2013-04-05|2013-04-09|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Use of Alpha-Stim Cranial-electrotherapy Stimulation (CES) in the Treatment of Anxiety|The Efficacy of Cranial-electrotherapy Stimulation (CES) Using Alpha-Stim Technology in The Treatment of Anxiety Disorders|Completed||Phase 4|115|Actual|Wyndhurst Counseling Center||2|||f||||f||||||||||2018-05-31 21:38:49.482717|2018-05-31 21:38:49.482717
NCT01533402|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2014-09-08|2012-02-10|2012-02-15|Estimate|||||||2014-09-08|2014-09-09|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Internet-delivered Cognitive Behavior Therapy (CBT) for Children Age 8-12 Years With Anxiety Disorders|Internet-delivered Cognitive Behavior Therapy (CBT) Treatment for Anxiety Disorders in Children Age 8-12 Years - a Randomised Controlled Trial|Completed||N/A|128|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:38:49.594612|2018-05-31 21:38:49.594612
NCT01533389|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2013-11-18|2012-02-10|2012-02-15|Estimate|||||||2013-11-18|2013-11-20|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|STONE||Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones|A 4-week, Double-blind, Randomized, Comparative and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones.|Completed||Phase 4|114|Actual|JW Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:38:49.710642|2018-05-31 21:38:49.710642
NCT01533376|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2018-04-24|2012-02-14|2012-02-15|Estimate|||||||2018-04-24|2018-04-25|Actual|February 2012||2012-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol|Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol|Recruiting||Phase 1|10|Anticipated|Wills Eye||2|||f||||t||||||||No||2018-05-31 21:38:49.811339|2018-05-31 21:38:49.811339
NCT01533363|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2012-02-11|2012-02-11|2012-02-15|Estimate|||||||2012-02-11|2012-02-15|Estimate|July 2000||2000-07-31|February 2012|2012-02-29|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study About Patient Comfort and Long-term Outcome After Stapled Hemorrhoidopexy|Patient Comfort After Stapled Hemorrhoidopexy Long Term Results of a Randomized Controlled Trial|Completed||Phase 3|130|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 21:38:49.972588|2018-05-31 21:38:49.972588
NCT01533051|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-05-07|2012-02-14|2012-02-15|Estimate|||||||2012-05-07|2012-05-08|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Observational|||Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B|Phase IV Study of Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B|Unknown status|Recruiting||100|Anticipated|Yonsei University|||1||f||||t||||||Samples Without DNA|"~     Initially, 30ml of heparinized peripheral blood will be obtained from each subjects. After~     then, 10ml of heparinized peripheral blood will be additionaly obtained at every 3 months~     follow-up visit.~   "|||2018-05-31 21:38:57.299836|2018-05-31 21:38:57.299836
NCT01533350|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-15|2012-02-14|2012-02-15|Estimate|||||||2012-02-15|2012-02-17|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase|Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase of Infertile Women With Natural Cycles|Completed|||28|Actual|Shen-Zhen City Maternity and Child Healthcare Hospital|||2||f||||t||||||Samples Without DNA|"~     The specimen was divided into three parts after washing with sterilized saline, and one was~     ﬁxed by 2.5% glutaraldehyde solution immediately ，then coated with palladium gold for~     electron microscopic examination;one was fixed by 2.5% glutaraldehyde arsenate ,then embedded~     in Epon for transmission electron microscopy ; one was ﬁxed by 4% formalin, then embedded in~     parafﬁn for immunohistochemical analysis.~   "|||2018-05-31 21:38:50.087664|2018-05-31 21:38:50.087664
NCT01533337|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|May 2009|Actual|2009-05-31||Interventional|||Use of the Free Dorsal Digital Flap Including Both Dorsal Branches of the Proper Digital Nerves for Reconstruction of Volar Soft Tissue Defect of Digits||Completed||N/A|12|Actual|The Second Hospital of Tangshan|||||f||||t||||||||||2018-05-31 21:38:50.175467|2018-05-31 21:38:50.175467
NCT01533324|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)|Phase II Study of S-1 Combined With Calcium Folinate to Treat Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|32|Anticipated|Second Military Medical University||1|||f||||t||||||||||2018-05-31 21:38:50.242804|2018-05-31 21:38:50.242804
NCT01533311|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Prevalence and Characteristics of Nonpolypoid Colorectal Neoplasms - A Chinese Cohort Study|Prevalence and Characteristics of Nonpolypoid Colorectal Neoplasms - A Chinese Cohort Study|Completed|||1342|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     All the lesions will be removed endoscopically or surgically and examined histologically by~     an independent gastrointestinal pathologist.~      Histological diagnosis is determined according to the World Health Organization (WHO)~     criteria.Pedunculated lesions are categorized according to Haggitt's classification.~   "|||2018-05-31 21:38:50.334319|2018-05-31 21:38:50.334319
NCT01533298|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-02-15|2012-02-10|2012-02-15|Estimate|||||||2013-02-15|2013-02-18|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|OMEGA||A Safety, Efficacy Study of CombiflexOmega Peri Versus SmofKabiven Peripheral in Patients With Parenteral Nutrition|A Randomized, Open, Multicenter, Compared Phase III Trial to Evaluate the Safety, Efficacy of CombiflexOmega Peri and SmofKabiven Peripheral in Postoperative Patients Requiring Parenteral Nutrition|Completed||Phase 3|50|Anticipated|JW Pharmaceutical||2|||f||||||||||||||2018-05-31 21:38:50.386714|2018-05-31 21:38:50.386714
NCT01533285|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-03-27|2012-02-10|2012-02-15|Estimate|||||||2014-03-27|2014-03-28|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients|A 2-way Crossover Study to Explore the Effect of an Inflammatory and Psychosocial Stressor and a Combination Thereof on the Mood and Cytokine Levels in Young and Elderly Healthy Female Subjects and Female Subjects With Major Depressive Disorder|Completed||Early Phase 1|40|Actual|Janssen Pharmaceutica N.V., Belgium||6|||f||||f||||||||||2018-05-31 21:38:50.480909|2018-05-31 21:38:50.480909
NCT01533272|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2015-03-31|2012-02-10|2012-02-15|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)|Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC|Completed||Phase 4|240|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 21:38:50.602802|2018-05-31 21:38:50.602802
NCT01533259|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2015-01-16|2013-11-19|2015-01-16|2012-02-10|2012-02-15|Estimate|2015-01-16|2015-01-26|Estimate|2013-11-19|2013-12-13|Estimate|2015-01-16|2015-01-26|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|November 2012|Actual|2012-11-30||Interventional||Safety Analysis Set: participants who received at least one dose of study drug.|Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients|A Phase 3B Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF) Single-Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Patients|Completed||Phase 3|48|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 21:38:50.723043|2018-05-31 21:38:50.723043
NCT01533246|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2015-03-02||2015-03-02|2012-02-10|2012-02-15|Estimate|2015-03-02|2015-03-13|Estimate||||2015-03-02|2015-03-13|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Patients that received treatment.|Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer|A Phase 2 Study of OSI-906 in Patients With Asymptomatic or Mildly Symptomatic (Non-Opioid Requiring) Metastatic Castrate Resistant Prostate Cancer (CRPC)|Completed||Phase 2|17|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:38:51.000419|2018-05-31 21:38:51.000419
NCT01533233|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-10-27|2012-02-11|2012-02-15|Estimate|||||||2013-10-27|2013-10-29|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Thoracoscopic Lobectomy Using Nonintubated Anesthesia Versus Intubated General Anesthesia for Lung Cancer Patients|Safety and Results of Thoracoscopic Lobectomy Using Nonintubated Anesthesia Versus Intubated General Anesthesia for Lung Cancer Patients.|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 21:38:51.339941|2018-05-31 21:38:51.339941
NCT01533038|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2015-10-22||2017-11-20|2012-02-14|2012-02-15|Estimate|2015-10-22|2015-11-26|Estimate||||2017-11-20|2017-12-19|Actual|February 2012||2012-02-29|November 2017|2017-11-30|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|BPH-6||BPH-6: Comparison of the UroLift System to TURP for Benign Prostatic Hyperplasia|BPH-6: A UroLift® System Post Market Multi-Center Randomized Study|Completed||N/A|80|Actual|NeoTract, Inc.||2|||f||||f||||||||No||2018-05-31 21:38:57.391152|2018-05-31 21:38:57.391152
NCT01533220|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-09-24|2012-02-10|2012-02-15|Estimate|||||||2013-09-24|2013-09-25|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal|A Randomized, Double-blind, Prospective, Monocentric, Superior Efficacy and Safety of Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal Due to Colds or Other Upper Respiratory Allergies|Unknown status|Active, not recruiting|Phase 3|212|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 21:38:51.457603|2018-05-31 21:38:51.457603
NCT01533207|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2017-08-23|2012-02-11|2012-02-15|Estimate|||||||2017-08-23|2017-08-24|Actual|June 4, 2012|Actual|2012-06-04|August 2017|2017-08-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery|A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma|Active, not recruiting||Phase 3|216|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 21:38:51.608564|2018-05-31 21:38:51.608564
NCT01533194|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2015-04-14|2012-02-11|2012-02-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1 Study of Reolysin Alone in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:38:52.670234|2018-05-31 21:38:52.670234
NCT01533181|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|2015-12-10||2015-12-10|2012-02-11|2012-02-15|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All participants|Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer|Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:38:52.79106|2018-05-31 21:38:52.79106
NCT01533168|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-05-17|2012-02-11|2012-02-15|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2012||2012-02-29|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia|Next-Generation Sequencing of Immunoglobulin Heavy Chain Variable Region to Identify Previously Undetectable Minimal Residual Disease in Children With Acute Lymphoblastic Leukemia With Prognostic Significance|Completed|||12|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     cell samples~   "|||2018-05-31 21:38:53.469939|2018-05-31 21:38:53.469939
NCT01533155|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2014-10-13|2012-02-14|2012-02-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118|A Randomized, 2-Part, Crossover, Single Center Study to Evaluate Effect of Quinidine on the Pharmacokinetics of NKTR-118 and the Concomitant Effect of Quinidine and NKTR-118 on Morphine-induced Miosis|Completed||Phase 1|214|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 21:38:53.533253|2018-05-31 21:38:53.533253
NCT01533142|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-02-17|2012-02-11|2012-02-15|Estimate|||||||2016-02-17|2016-02-19|Estimate|February 2012||2012-02-29|February 2016|2016-02-29||||December 2016|Anticipated|2016-12-31||Observational|FatWest||Bariatric Surgery on the West Coast of Norway (Vestlandet)|Bariatric Surgery on the West Coast of Norway (Vestlandet): Prospective Study of Overweight People Undergoing Bariatric Surgery|Unknown status|Recruiting||400|Anticipated|Helse Fonna|||2||f||||f||||||Samples With DNA|"~     Plasma, serum, urine and biopsi from fat~   "|||2018-05-31 21:38:53.625415|2018-05-31 21:38:53.625415
NCT01533129|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|August 2008||2008-08-31|February 2012|2012-02-29||||April 2011|Actual|2011-04-30||Interventional|||The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism|Phase 4 Study That Evaluates the Effects of Two Different Testosterone Replacement Regiments on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism.|Completed||Phase 4|106|Actual|Gulhane School of Medicine||2|||f||||f||||||||||2018-05-31 21:38:53.710082|2018-05-31 21:38:53.710082
NCT01533116|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-07-22||2015-10-14|2012-02-10|2012-02-15|Estimate|2015-10-14|2015-11-16|Estimate||||2015-10-14|2015-11-16|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide|Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects|Completed||Phase 1|52|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 21:38:53.816333|2018-05-31 21:38:53.816333
NCT01533103|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2013-08-20|2012-02-14|2012-02-15|Estimate|||||||2013-08-20|2013-08-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:38:55.578057|2018-05-31 21:38:55.578057
NCT01533090|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-11|2012-02-11|2012-02-15|Estimate|||||||2012-02-11|2012-02-15|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|LowVolumePEG||Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy|Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy|Completed||N/A|162|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 21:38:55.626809|2018-05-31 21:38:55.626809
NCT01533077|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-07-22||2015-11-18|2012-02-10|2012-02-15|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|||Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa|Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa in Healthy Subjects|Completed||Phase 1|18|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 21:38:55.741943|2018-05-31 21:38:55.741943
NCT01533064|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-11|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|||||Observational|||Response of Psychiatric Outpatients to the Great East Japan Earthquake|Response of Psychiatric Outpatients to the Great East Japan Earthquake|Completed|||328|Actual|Ashikaga Red Cross Hospital|||1||f||||t||||||||||2018-05-31 21:38:57.240393|2018-05-31 21:38:57.240393
NCT01533025|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Single Bundle Anterior Cruciate Ligament Reconstruction in Active Young Men|Single Bundle Anterior Cruciate Ligament Reconstruction in Active Young Men: Free Tendon Achilles Allograft vs. Bone-tendon Achilles Allograft|Completed||N/A|72|Actual|National Police Hospital||2|||f||||t||||||||||2018-05-31 21:38:57.653585|2018-05-31 21:38:57.653585
NCT01533012|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|November 2011||2011-11-30|February 2012|2012-02-29||||April 2012|Anticipated|2012-04-30||Interventional|||Initial Positioning of Left Sided Double Lumen Endobronchial Tubes Using Peak Inspiratory Pressures Difference Between Two Lungs|Initial Positioning of Left Sided Double Lumen Endobronchial Tubes Using Peak Inspiratory Pressures Difference Between Two Lungs|Unknown status|Recruiting|N/A|100|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 21:38:57.761762|2018-05-31 21:38:57.761762
NCT01532999|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2015-03-06||2015-04-06|2012-02-14|2012-02-15|Estimate|2015-04-06|2015-04-08|Estimate||||2015-04-06|2015-04-08|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD|A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD|Completed||N/A|254|Actual|VA Office of Research and Development|Limitations: PCGT may be more active than originally anticipated and is thus an active control rather than neutral control|2|||f||||t||||||||||2018-05-31 21:38:57.947301|2018-05-31 21:38:57.947301
NCT01532986|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-08-02|2012-02-10|2012-02-15|Estimate|||||||2017-08-02|2017-08-04|Actual|July 9, 2012|Actual|2012-07-09|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|January 31, 2017|Actual|2017-01-31||Interventional|CHAPS||"Randomized Trial to Test the Coordinated Care for Health Promotion and Activities in Parkinson's Disease Intervention in the Veterans Administration"|Improving Quality of Care in Parkinson's Disease: A Randomized Controlled Trial|Completed||N/A|345|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 21:38:58.516726|2018-05-31 21:38:58.516726
NCT01532973|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2016-10-03||2016-10-03|2012-02-10|2012-02-15|Estimate|2016-10-03|2016-11-23|Estimate||||2016-10-03|2016-11-23|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All enrolled participants who received at least one dose of study drug. Participants who received placebo in Part 1, 2, or 3 are grouped together regardless of HCV GT or randomly assigned panel. 2 Panels (Panel D in Part 1 and Panel H in Part 2) were planned but not performed. No participants were enrolled in either of these panels.|Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males|Completed||Phase 1|48|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 21:38:58.669954|2018-05-31 21:38:58.669954
NCT01532960|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2016-08-11|2012-02-14|2012-02-15|Estimate|||||||2016-08-11|2016-08-15|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Breast 41||Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer|A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage I-IV Breast Cancer|Terminated||Phase 1|11|Actual|University of Virginia||1||"Futility for immune responses to the vaccine. Also, a component of study drug was in short~   supply."|f||||t||||||||||2018-05-31 21:38:59.5385|2018-05-31 21:38:59.5385
NCT01532947|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2012-02-10|2012-02-10|2012-02-15|Estimate|||||||2012-02-10|2012-02-15|Estimate|January 2003||2003-01-31|February 2012|2012-02-29||||June 2005|Actual|2005-06-30||Interventional|||Randomized Controlled Trial of Fiber Post Restorations|Survival of Endodontically Treated and Restored Premolars: A Randomized Controlled Trial|Completed||N/A|360|Actual|University of Siena||2|||f||||f||||||||||2018-05-31 21:38:59.662579|2018-05-31 21:38:59.662579
NCT01532934|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2015-10-06||2016-10-19|2012-02-10|2012-02-15|Estimate|2016-10-19|2016-12-12|Estimate||||2016-10-19|2016-12-12|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Participants were adults in an urban pretrial jail diversion program in Upstate New York recruited between 2009 and 2014 subsequent to being charged with a crime.|The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention|The Impact of Psychopathic Traits on the Efficacy of a Brief Intervention for Substance Use|Completed||Phase 2|105|Actual|University of Rochester||2|||f||||t||||||||No||2018-05-31 21:38:59.738413|2018-05-31 21:38:59.738413
NCT01532921|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-04-28|2012-02-10|2012-02-15|Estimate|||||||2017-04-28|2017-05-02|Actual|September 2011||2011-09-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty|EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty|Completed|||85|Actual|Medtronic Cardiovascular|||1||f||||f||||||||No||2018-05-31 21:39:00.308383|2018-05-31 21:39:00.308383
NCT01532908|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10||2016-07-13|2017-04-24|2012-02-14|2012-02-15|Estimate||||2016-07-15|2016-07-19|Estimate|2017-04-24|2017-04-25|Actual|May 2012||2012-05-31|April 2017|2017-04-30|August 27, 2015|Actual|2015-08-27|August 27, 2015|Actual|2015-08-27||Interventional|MBL-HCV1||Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C|A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation|Terminated||Phase 2|10|Actual|MassBiologics||2||The study was terminated due to funding constraints|f||||f||||||||||2018-05-31 21:39:00.405266|2018-05-31 21:39:00.405266
NCT01532895|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2014-03-15|2012-02-14|2012-02-15|Estimate|||||||2014-03-15|2014-03-18|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Clinical Usefulness and Quality of Life of OROS Hydromorphone in Patients Who Have Not Been Treated With a Strong Opioid|Clinical Usefulness and Quality of Life of OROS Hydromorphone in Strong Opioid-Naïve Cancer Pain Patients; Multicenter, Prospective, Open-Label and Observational Study|Completed|||400|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 21:39:00.518191|2018-05-31 21:39:00.518191
NCT01532882|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2013-04-26|2012-02-14|2012-02-15|Estimate|||||||2013-04-26|2013-04-29|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|EDEN||Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs|Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups|Completed||Phase 3|378|Actual|Laboratoire Innotech International||2|||f||||f||||||||||2018-05-31 21:39:00.640214|2018-05-31 21:39:00.640214
NCT01532869|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2015-10-08||2016-08-02|2012-02-14|2012-02-15|Estimate|2015-10-08|2015-11-05|Estimate||||2016-08-02|2016-09-23|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|January 2014|Actual|2014-01-31||Interventional||Safety population included all participants who received any study drug and provided at least one post-dose safety assessment (withdrawal, adverse event [AE], death, laboratory assessment, vital signs).|A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis|A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis|Completed||Phase 3|87|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 21:39:00.799265|2018-05-31 21:39:00.799265
NCT01532856|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-14|2012-02-14|2012-02-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years|Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maintenance Therapy With Thalidomide + Prednisone Versus Thalidomide Alone in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65years.|Unknown status|Active, not recruiting|Phase 3|64|Actual|Grupo de Estudos Multicentricos em Onco-Hematologia||3|||f||||t||||||||||2018-05-31 21:39:02.035243|2018-05-31 21:39:02.035243
NCT01532843|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-01-22|2012-02-14|2012-02-15|Estimate|||||||2016-01-22|2016-01-25|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PEGON||Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B|Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B (PEGON-study)|Completed||Phase 4|82|Actual|Foundation for Liver Research||2|||f||||f||||||||No||2018-05-31 21:39:02.12012|2018-05-31 21:39:02.12012
NCT01532830|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2018-03-07|2016-02-23|2018-04-10|2012-02-10|2012-02-15|Estimate|2018-04-10|2018-05-11|Actual|2018-03-05|2018-03-06|Actual|2018-04-10|2018-05-11|Actual|February 2012|Actual|2012-02-29|April 2018|2018-04-30|July 25, 2012|Actual|2012-07-25|July 2012|Actual|2012-07-31||Interventional||Randomized population|Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine|Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine|Completed||N/A|30|Actual|ElectroCore LLC||1|||f||||||||||||No||2018-05-31 21:39:02.249847|2018-05-31 21:39:02.249847
NCT01532817|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|2018-03-07|2016-02-23|2018-04-06|2012-02-10|2012-02-15|Estimate|2018-04-06|2018-04-09|Actual|2018-01-18|2018-01-25|Actual|2018-04-06|2018-04-09|Actual|January 2012||2012-01-31|April 2018|2018-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Open label 30 patient population|Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device|Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore™ Device, for the Relief of Acute Bronchoconstriction Due to Asthma|Completed||N/A|30|Actual|ElectroCore LLC||1|||f||||f||||||||No||2018-05-31 21:39:02.573093|2018-05-31 21:39:02.573093
NCT01532804|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-08-16|2012-02-14|2012-02-15|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2011||2011-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|BEVATOMOX||2nd-line Treatment of Metastatic Colorectal Cancer|A Multicenter Randomized Phase 2 Trial to Evaluate the Triplet Combination of Raltitrexed, Oxaliplatin and Bevacizumab Versus FOLFOX6 Plus Bevacizumab in Second-line Treatment of Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|83|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||t||||||||||2018-05-31 21:39:02.783659|2018-05-31 21:39:02.783659
NCT01532791|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-08-10|2012-02-14|2012-02-15|Estimate|||||||2016-08-10|2016-08-12|Estimate|July 2004||2004-07-31|August 2016|2016-08-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Observational|||Natural History Study - Mitochondrial Disease|Mitochondrial Encephalomyopathies and Mental Retardation: Investigations of Clinical Syndromes Associated With MtDNA Point Mutations|Recruiting|||300|Anticipated|Columbia University|||2||f||||f||||||None Retained|"~     skin fibroblast blood urine buccal cells hair samples~   "|Yes|When applicable, manuscript(s) regarding data will be submitted for publication|2018-05-31 21:39:02.926192|2018-05-31 21:39:02.926192
NCT01532778|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-09-22|2012-02-13|2012-02-14|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|SensInFat||Saliva Modification Related to Fat Perception in Human|Perception Ortho-nasale du Gras Chez l'Homme Sain : Relations Entre Typages olfactométriques, Sensoriels et Composition de la Salive.|Completed|||40|Actual|Centre des Sciences du Goût et de l'Alimentation|||||f||||f||||||||No||2018-05-31 21:39:03.055024|2018-05-31 21:39:03.055024
NCT01532765|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-12-03|2012-02-13|2012-02-14|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|||Randomized Trial Comparing Epiretinal Membrane Surgery With and Without Internal Limiting Membrane Removal|A Multicentre Randomized Clinical Trial Comparing Epiretinal Membrane Surgery With and Without Internal Limiting Membrane Peeling|Unknown status|Recruiting|N/A|80|Anticipated|Sunnybrook Health Sciences Centre||4|||f||||f||||||||||2018-05-31 21:39:03.122238|2018-05-31 21:39:03.122238
NCT01532752|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2013-07-31|2012-02-09|2012-02-14|Estimate|||||||2013-07-31|2013-08-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:39:03.275675|2018-05-31 21:39:03.275675
NCT01532739|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2016-08-08|2012-02-10|2012-02-14|Estimate|||||||2016-08-08|2016-08-09|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Making Memory Better for Seniors With Mild Cognitive Impairment|Neuropsychological Intervention for a Seniors Mental Health Population With Mild Cognitive Impairment|Active, not recruiting||N/A|40|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 21:39:03.311699|2018-05-31 21:39:03.311699
NCT01532726|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2017-01-05|2012-02-10|2012-02-14|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)|A Non-Interventional, Prospective Study to Assess Seizure Control and Tolerability of Eslicarbazepine Acetate as Adjunctive Therapy to One Baseline Antiepileptic Drug, in Adults With Partial-Onset Seizures With or Without Secondary Generalization|Completed|||56|Actual|Bial - Portela C S.A.|||1||f||||f||||||||||2018-05-31 21:39:03.438008|2018-05-31 21:39:03.438008
NCT01532713|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-03-04|2012-02-09|2012-02-14|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Oxygen Administration on Regional Cerebral Oxygen Saturation (rSO2) in the Non-block Side After Stellate Ganglion Block||Completed||N/A|38|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 21:39:03.572991|2018-05-31 21:39:03.572991
NCT01532700|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2017-11-09|2012-02-13|2012-02-14|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2012||2012-02-29|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)||Completed||Phase 2|28|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 21:39:03.656704|2018-05-31 21:39:03.656704
NCT01532687|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-11-01|2012-02-13|2012-02-14|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2012||2012-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma|A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma|Recruiting||Phase 2|80|Anticipated|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-05-31 21:39:03.746564|2018-05-31 21:39:03.746564
NCT01532674|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-02-16|2012-02-09|2012-02-14|Estimate|||||||2012-02-16|2012-02-20|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy|Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy|Unknown status|Recruiting|Phase 4|40|Anticipated|University of Valencia||2|||f||||t||||||||||2018-05-31 21:39:03.881339|2018-05-31 21:39:03.881339
NCT01532661|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2014-11-17|2012-02-09|2012-02-14|Estimate|||||||2014-11-17|2014-11-18|Estimate|April 2008||2008-04-30|November 2014|2014-11-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|NOVO7||National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology|National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology|Completed|||114|Actual|University Hospital, Grenoble|||1||f||||t||||||||||2018-05-31 21:39:04.0482|2018-05-31 21:39:04.0482
NCT01532648|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-03-27|2012-02-13|2012-02-14|Estimate|||||||2014-03-27|2014-03-28|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA).||Completed||Phase 3|509|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 21:39:04.223021|2018-05-31 21:39:04.223021
NCT01532635|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2014-11-03||2016-10-19|2012-02-09|2012-02-14|Estimate|2014-11-03|2014-11-10|Estimate||||2016-10-19|2016-11-29|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using Two Related Donors|Terminated||Phase 2|4|Actual|Thomas Jefferson University|Study was terminated due to poor accrual. No reportable data has been collected.|1||Slow accrual|f||||t||||||||||2018-05-31 21:39:04.604385|2018-05-31 21:39:04.604385
NCT01532622|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2013-10-18|2012-02-13|2012-02-14|Estimate|||||||2013-10-18|2013-10-22|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Impact of Blueberries on Uric Acid and Quality of Life|Impact of Blueberries on Uric Acid and Quality of Life|Completed||N/A|30|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-05-31 21:39:05.139006|2018-05-31 21:39:05.139006
NCT01532609|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-09|2012-02-09|2012-02-14|Estimate|||||||2012-02-09|2012-02-14|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|MMT1||Methadone Maintenance and HIV Prevention: A Window of Opportunity in China|Methadone Maintenance and HIV Prevention: A Window of Opportunity in China Version|Completed||N/A|220|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:39:05.266355|2018-05-31 21:39:05.266355
NCT01532596|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-09|2012-02-09|2012-02-14|Estimate|||||||2012-02-09|2012-02-14|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|MIND||Mindfulness Meditation in Older Adults|The Effects of Mindfulness Meditation in Older Adults|Completed||Early Phase 1|40|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 21:39:05.348618|2018-05-31 21:39:05.348618
NCT01532583|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2012-12-12|2012-02-09|2012-02-14|Estimate|||||||2012-12-12|2012-12-13|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Observational|||The Outcome of the Transobturator Tape (TOT) Procedure|The Outcome of the Transobturator Tape (TOT) Procedure During the Follow-up of 6.5 Years|Completed|||139|Actual|Turku University Hospital|||1||f||||||||||||||2018-05-31 21:39:05.428069|2018-05-31 21:39:05.428069
NCT01532570|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2016-06-15||2016-10-25|2012-02-13|2012-02-14|Estimate|2016-10-25|2016-12-16|Estimate||||2016-10-25|2016-12-16|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions|To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650|Completed||Phase 3|18|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 21:39:05.577608|2018-05-31 21:39:05.577608
NCT01532544|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2016-04-21|2012-02-09|2012-02-14|Estimate|||||||2016-04-21|2016-04-22|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis|Double-blinded, Randomized Trial in Severe Pneumonia Patients With Severe Sepsis Investigating the Safety and Efficacy of Co-administration of Iloprost and Ascending Doses of Eptifibatide Compared to Low-molecular-weight Heparin|Terminated||Phase 2|5|Actual|Thrombologic ApS||2||Difficulty recruiting patients, company closed down|f||||t||||||||Undecided||2018-05-31 21:39:06.666595|2018-05-31 21:39:06.666595
NCT01532531|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-08-14|2012-02-13|2012-02-14|Estimate|||||||2012-08-14|2012-08-15|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||The Effects of Collateral Meridian Therapy for Knee Osteoarthritis Pain Management||Completed||N/A|28|Actual|Taichung Armed Forces General Hospital||2|||f||||t||||||||||2018-05-31 21:39:06.77768|2018-05-31 21:39:06.77768
NCT01532518|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-03-24|2012-02-09|2012-02-14|Estimate|||||||2014-03-24|2014-03-26|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance|A Multicenter, Open Label, Ascending 7 Day-Repeated Dose Study to Investigate Efficacy, Safety and Pharmacokinetics of Nepadutant In Infants With Feeding Intolerance|Completed||Phase 2|27|Actual|Menarini Group||3|||f||||f||||||||||2018-05-31 21:39:06.834024|2018-05-31 21:39:06.834024
NCT01531504|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-12-27|2012-02-10|2012-02-13|Estimate|||||||2012-12-27|2012-12-28|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||New Use of the ViKY Device for Uterus Positioning|Evaluation of Safety and Effectiveness of ViKY Device for Uterine Positioning|Completed||N/A|30|Actual|EndoControl||1|||f||||f||||||||||2018-05-31 21:39:23.693809|2018-05-31 21:39:23.693809
NCT01532505|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-02-13|2012-02-09|2012-02-14|Estimate|||||||2012-02-13|2012-02-15|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Effect of Vasopressin on Tissue Oxygen Saturation in Cardiac Surgery Patients During Cardiopulmonary Bypass|A Randomized Study Comparing Low Dose Vasopressin Infusion or Placebo on Near Infrared Spectroscopy Tissue Oxygen Saturation and the Vascular Occlusion Test in Cardiac Surgery Patients During Cardiopulmonary Bypass: A Pilot Study|Unknown status|Not yet recruiting||40|Anticipated|London Health Sciences Centre|||||f||||t||||||||||2018-05-31 21:39:06.906095|2018-05-31 21:39:06.906095
NCT01532492|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2014-04-30|2012-02-13|2012-02-14|Estimate|||||||2014-04-30|2014-05-01|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|WORC||Validation of the Western Ontario Rotator Cuff Index in Patients With Arthroscopic Rotator Cuff Repair|Validation of the Western Ontario Rotator Cuff Index in Patients With Arthroscopic Rotator Cuff Repair|Completed|||118|Actual|St. Antonius Hospital|||3||f||||f||||||||||2018-05-31 21:39:06.978061|2018-05-31 21:39:06.978061
NCT01532479|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-04-25|2012-02-09|2012-02-14|Estimate|||||||2017-04-25|2017-04-27|Actual|August 2015||2015-08-31|April 2017|2017-04-30|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Observational|SHOTGUN||Saliva, Hyperbaric Oxygen Therapy, & Gland Function: A Prospective Study|Saliva, Hyperbaric Oxygen Therapy, & Gland Function: A Prospective Study|Withdrawn|||0|Actual|Loma Linda University|||3||f||||f||||||||||2018-05-31 21:39:07.09802|2018-05-31 21:39:07.09802
NCT01532466|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-09|2012-02-09|2012-02-14|Estimate|||||||2012-02-09|2012-02-14|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||The Effect of Priming Intravenous Rocuronium on Fentanyl-Induced Coughing||Completed||N/A|260|Actual|Taichung Armed Forces General Hospital||2|||f||||t||||||||||2018-05-31 21:39:07.203043|2018-05-31 21:39:07.203043
NCT01532453|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2015-07-16||2015-12-03|2012-02-09|2012-02-14|Estimate|2015-12-03|2016-01-08|Estimate||||2015-12-03|2016-01-08|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients|Open, Multicentre, Randomised, Comparative, Prospective Trial With MD-3511356 Versus Standard Sun Protection Measures in Immunosuppressed Solid Organ Transplanted Patients for Prevention of UV-induced Carcinogenic Skin Alterations|Terminated||Phase 3|244|Actual|Spirig Pharma Ltd.|Trial was terminated early for futility reasons (outcome would not be changed, if trial pursued up completion) and potential “loss of chance” (which could neither be confirmed nor rejected at the time) for patients included in the MD 3511356 group.|2||"For futility reasons and potential loss of chance for MD 3511356 group"|f||||t||||||||||2018-05-31 21:39:07.32713|2018-05-31 21:39:07.32713
NCT01532440|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2013-07-31|2012-02-09|2012-02-14|Estimate|||||||2013-07-31|2013-08-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:39:07.726634|2018-05-31 21:39:07.726634
NCT01532427|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2018-04-05|2012-02-13|2012-02-14|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2012|Actual|2012-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31|2 Years|Observational [Patient Registry]|2011-AAR-004||ALFApump System Post Marketing Surveillance Registry|ALFApump System Post Marketing Surveillance Registry, In Support of the Following Indication: Automated Removal of Excess Peritoneal Fluid Into the Urinary Bladder in Patients With Cirrhosis or Malignancy, With Persistent or Refractory Ascites|Active, not recruiting|||100|Actual|Sequana Medical AG|||||f||||f||||||||||2018-05-31 21:39:07.79229|2018-05-31 21:39:07.79229
NCT01532414|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2014-06-13||2015-05-07|2012-02-13|2012-02-14|Estimate|2015-05-07|2015-05-27|Estimate||||2015-05-07|2015-05-27|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Analyses were conducted on the following populations: ITT (all subjects enrolled), mITT (all ITT subjects except site 09), PP (all ITT subjects who completed Week 12) and Safety (all subjects who received any study drug)|Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism|A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration|Completed||Phase 3|151|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 21:39:07.960453|2018-05-31 21:39:07.960453
NCT01532401|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-10-10|2012-02-13|2012-02-14|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2011||2011-03-31|February 2012|2012-02-29||||September 2014|Actual|2014-09-30||Interventional|PLADSEL||Oral Sodium Blood Pressure in Normal Weight, Overweight and Obese Volunteers|Simplification of the Test of Sensibility in the Salt: Preliminary Study at the Child and the Adult|Completed||Phase 2|51|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 21:39:08.603629|2018-05-31 21:39:08.603629
NCT01532388|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2013-06-13|2012-02-09|2012-02-14|Estimate|||||||2013-06-13|2013-06-14|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|April 2011|Actual|2011-04-30||Interventional|||Randomized Controlled Trial of eScreen for Problematic Drug Use|Randomized Controlled Trial of eScreen for Problematic Drug Use|Completed||Phase 2|202|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:39:08.699433|2018-05-31 21:39:08.699433
NCT01532375|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2012-02-13|2012-02-13|2012-02-14|Estimate|||||||2012-02-13|2012-02-14|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Kochujang, a Fermented Soybean-based Red Pepper Paste, Decreases Visceral Fat and Improves Blood Lipid Profiles in Overweight Adults|Kochujang Decreases Visceral Fat and Improves Lipids Profiles|Completed||Phase 2|60|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:39:08.847736|2018-05-31 21:39:08.847736
NCT01532362|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2016-01-12||2017-11-09|2012-02-09|2012-02-14|Estimate|2016-01-12|2016-02-11|Estimate||||2017-11-09|2017-12-11|Actual|November 2011||2011-11-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer|Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer|Terminated||N/A|1|Actual|Jonsson Comprehensive Cancer Center|Early termination of study when sponsor withdrew drug from market due to toxicities revealed from other studies.|2||Drug sponsor stopped drug manufacture due to toxicity issues from other studies|f||||t||||||||||2018-05-31 21:39:08.978172|2018-05-31 21:39:08.978172
NCT01532349|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2017-03-09||2017-05-16|2012-02-09|2012-02-14|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|May 2012||2012-05-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|D-fense||Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease|Cholecalciferol as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease|Completed||Phase 2|34|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:39:09.349622|2018-05-31 21:39:09.349622
NCT01532336|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2015-05-26|2012-02-09|2012-02-14|Estimate|||||||2015-05-26|2015-05-28|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|BAYnovation™||Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis|A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis|Completed||Phase 2|500|Actual|NovaBay Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:39:09.703901|2018-05-31 21:39:09.703901
NCT01532323|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-09-18|2012-02-09|2012-02-14|Estimate|||||||2013-09-18|2013-09-19|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ORALISENS||Oral Sphere: Salivary Markers and Food. A Prospective Study in Children Expressing Oral Disorders|Oral Sphere: Salivary Markers and Food. A Prospective Study in Children Expressing Oral Disorders|Completed||N/A|44|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:39:09.846036|2018-05-31 21:39:09.846036
NCT01532310|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-08-08|2012-02-09|2012-02-14|Estimate|||||||2017-08-08|2017-08-09|Actual|July 16, 2012|Actual|2012-07-16|August 2017|2017-08-31|November 26, 2021|Anticipated|2021-11-26|November 26, 2021|Anticipated|2021-11-26|9 Years|Observational [Patient Registry]|||Belimumab (BENLYSTA®) Pregnancy Registry|WEUKBRE6076: Belimumab (BENLYSTA) Pregnancy Registry Protocol|Recruiting|||500|Anticipated|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 21:39:09.92275|2018-05-31 21:39:09.92275
NCT01532297|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-06-05|2012-02-13|2012-02-14|Estimate|||||||2014-06-05|2014-06-06|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Application of Citrate Dialysate in Chronic Haemodialysis|Application of Citrate Dialysate in Chronic Haemodialysis|Completed||N/A|95|Actual|Fresenius Medical Care Deutschland GmbH||6|||f||||f||||||||||2018-05-31 21:39:10.057738|2018-05-31 21:39:10.057738
NCT01532284|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-01-12|2012-02-09|2012-02-14|Estimate|||||||2018-01-12|2018-01-16|Actual|February 2012||2012-02-29|January 2018|2018-01-31|September 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31||Interventional|ESTEEM||The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis|The Eshre Study Into The Evaluation of Oocyte Euploidy by Microarray Analysis|Completed||N/A|396|Actual|European Society of Human Reproduction and Embryology||2|||f||||t||||||||Undecided||2018-05-31 21:39:10.150969|2018-05-31 21:39:10.150969
NCT01532271|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2014-04-03|2012-02-09|2012-02-14|Estimate|||||||2014-04-03|2014-04-04|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Observational|||Comparison of Brain Network Activation (BNA™) Analysis, Clinical Symptoms and Neuro-cognitive Performance in Concussed Children and Young Adults|Comparison of Brain Network Activation Analysis (BNA™) Using Evoked Response Potentials, Clinical Symptoms and Neuro-cognitive Performance and Symptoms in Concussed Children, Young Adults and Matched Controls|Completed|||146|Actual|ElMindA Ltd|||2||f||||f||||||||||2018-05-31 21:39:10.239859|2018-05-31 21:39:10.239859
NCT01532258|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2013-07-29|2012-02-09|2012-02-14|Estimate|||||||2013-07-29|2013-07-30|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effectiveness of an Eight Week Online Mediterranean Based Diet|Effectiveness of an Eight Week Online Mediterranean Based Diet in an Overweight or Obese Outpatient Primary Care Population|Withdrawn||N/A|0|Actual|The Cleveland Clinic||3||Online program required re-design|f||||f||||||||||2018-05-31 21:39:10.322227|2018-05-31 21:39:10.322227
NCT01532245|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2018-05-08|2012-02-09|2012-02-14|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2011||2011-12-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Use of Constant-flow Technique for Determining the Lower Inflexion Point of Pressure-volume Curve and Intrinsic PEEP During One-lung Ventilation||Active, not recruiting||N/A|40|Anticipated|The Cleveland Clinic||3|||f||||||||||||||2018-05-31 21:39:10.43118|2018-05-31 21:39:10.43118
NCT01532232|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2015-12-22|2012-02-13|2012-02-14|Estimate|||||||2015-12-22|2015-12-23|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)|Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)|Terminated|||7|Actual|Memorial Sloan Kettering Cancer Center|||2|Lack of accrual|f||||||||||Samples Without DNA|"~     saliva samples~   "|||2018-05-31 21:39:10.590994|2018-05-31 21:39:10.590994
NCT01532219|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-04-23|2012-02-09|2012-02-14|Estimate|||||||2013-04-23|2013-04-24|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ATLAS||Internet-delivered Psychodynamic Therapy for Depression and Anxiety Disorders|Internet-delivered Psychodynamic Therapy for Depression and Anxiety Disorders: A Randomized Controlled Trial|Completed||N/A|100|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 21:39:10.671146|2018-05-31 21:39:10.671146
NCT01532206|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-03-24|2012-02-13|2012-02-14|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||IL-10 Levels and Remote Ischemic Preconditioning in Acute Myocardial Infarction|Interleukin-10 Levels and Remote Ischemic Preconditioning in Acute Myocardial Infarction.|Terminated||N/A|1|Actual|Johns Hopkins University||2||Lack of funding|f||||f||||||||||2018-05-31 21:39:10.781483|2018-05-31 21:39:10.781483
NCT01532193|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2015-08-25|2012-02-13|2012-02-14|Estimate|||||||2015-08-25|2015-08-26|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Embryo Culture Under Low Oxygen Tension on Pregnancy Rates|A Randomized Controlled Trial Evaluation the Effect of Low Oxygen Tension on the Pregnancy Rate After Day 3 Embryo Transfer in an Egg Donation Programme.|Completed||N/A|380|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 21:39:10.847842|2018-05-31 21:39:10.847842
NCT01532180|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-02-09|2012-02-09|2012-02-14|Estimate|||||||2012-02-09|2012-02-14|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of a Hypoglossal Nerve Implant for the Treatment of Obstructive Sleep Apnea (OSA)|A Pilot Study and Follow Up of the Use of a Hypoglossal Nerve Implant for Treatment of Obstructive Sleep Apnea|Completed||Phase 2/Phase 3|14|Actual|ImThera Medical, Inc.||1|||f||||f||||||||||2018-05-31 21:39:10.978873|2018-05-31 21:39:10.978873
NCT01532167|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-03-23|2012-02-13|2012-02-14|Estimate|||||||2012-03-23|2012-03-27|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis|Impact and Utility of Positron Emission Tomography (PET) for the Assessment of Inflammatory Activity Arteritis Versus Clinical Score and Laboratory Values in Takayasu Arteritis: a Cohort Study|Completed|||26|Actual|Instituto Nacional de Cardiologia Ignacio Chavez|||||f||||f||||||||||2018-05-31 21:39:11.038844|2018-05-31 21:39:11.038844
NCT01532154|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-10-17|2012-02-13|2012-02-14|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29|12 Weeks|Observational [Patient Registry]|||Fampridine Pregnancy Exposure Registry|Fampridine Pregnancy Exposure Registry|Terminated|||1|Actual|Biogen||||Due to low enrollment, registration closed in agreement with the Regulatory Agency|f||||f||||||||||2018-05-31 21:39:11.110624|2018-05-31 21:39:11.110624
NCT01532141|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2015-07-22||2015-07-22|2012-02-13|2012-02-14|Estimate|2015-07-22|2015-08-20|Estimate||||2015-07-22|2015-08-20|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional|||Effect of Rasagiline on BIA 9-1067 Pharmacokinetics|Effect of Rasagiline on BIA 9-1067 Pharmacokinetics in Healthy Subjects|Completed||Phase 1|25|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 21:39:11.278485|2018-05-31 21:39:11.278485
NCT01532128|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2015-07-22||2015-07-22|2012-02-13|2012-02-14|Estimate|2015-07-22|2015-08-20|Estimate||||2015-07-22|2015-08-20|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Interventional|||Effect of BIA 9-1067 on Rasagiline Pharmacokinetics|Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects|Completed||Phase 1|24|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 21:39:11.86766|2018-05-31 21:39:11.86766
NCT01532115|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-06-20|2012-02-13|2012-02-14|Estimate|||||||2012-06-20|2012-06-21|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|||Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women|A Randomized, Double-blind, Placebo-controlled and Open-label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women|Completed||Phase 1|64|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 21:39:12.374766|2018-05-31 21:39:12.374766
NCT01532102|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2018-05-29|2012-02-13|2012-02-14|Estimate|||||||2018-05-29|2018-05-30|Actual|February 28, 2012|Actual|2012-02-28|May 2018|2018-05-31|May 6, 2013|Actual|2013-05-06|May 6, 2013|Actual|2013-05-06||Interventional|||Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts|A Double-blind, Placebo Controlled, Randomized, Phase IIa Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Repeated Topical Applications Over 42 Days of AP611074 5% Gel in Condyloma Patients|Completed||Phase 1/Phase 2|24|Actual|Vaxart||2|||f||||f||||||||||2018-05-31 21:39:12.527011|2018-05-31 21:39:12.527011
NCT01532089|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-05-21|2012-02-09|2012-02-14|Estimate|||||||2018-05-21|2018-05-23|Actual|March 16, 2012|Actual|2012-03-16|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations|A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations|Active, not recruiting||Phase 2|112|Anticipated|Academic and Community Cancer Research United||2|||f||||t|t|f|||f|||||2018-05-31 21:39:12.658869|2018-05-31 21:39:12.658869
NCT01532076|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2014-09-16|2012-02-08|2012-02-13|Estimate|||||||2014-09-16|2014-09-17|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ROBUST||Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts|Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts Versus Acellular Bone Graft Substitutes for Augmentation in the Treatment of Proximal Humeral Fractures as Model for Fractures of Osteoporotic Bone - a Prospective Randomized First in Men Proof of Principle Trial|Terminated||Phase 2|8|Actual|University Hospital, Basel, Switzerland||2||Slow recruitment|f||||f||||||||||2018-05-31 21:39:12.882185|2018-05-31 21:39:12.882185
NCT01532063|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-04-20|2012-02-10|2012-02-13|Estimate|||||||2017-04-20|2017-04-21|Actual|October 2011||2011-10-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|FRIDA-Rea||Risk Factors of Difficult Intubation and Related Complications in Adults in Intensive Care Units: FRIDA-Rea|Risk Factors of Difficult Intubation and Related Complications in Adults in Intensive Care Units(ICU)|Completed||N/A|1400|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 21:39:13.028179|2018-05-31 21:39:13.028179
NCT01532050|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2014-04-01|2012-02-08|2012-02-13|Estimate|||||||2014-04-01|2014-04-02|Estimate|February 2012||2012-02-29|April 2014|2014-04-30||||December 2014|Anticipated|2014-12-31||Interventional|PROMAD||PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea|PROMAD : Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 21:39:13.119428|2018-05-31 21:39:13.119428
NCT01532037|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-06-20|2012-02-10|2012-02-13|Estimate|||||||2012-06-20|2012-06-21|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Self Help for Fatigue in Multiple Sclerosis|A Randomised Controlled Trial of Cognitive Behavioural Therapy Based Self Help for Fatigue in Multiple Sclerosis|Unknown status|Recruiting|N/A|96|Anticipated|University of Edinburgh||3|||f||||t||||||||||2018-05-31 21:39:13.186512|2018-05-31 21:39:13.186512
NCT01532024|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-01-19|2012-02-10|2012-02-13|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2014||2014-10-31|January 2016|2016-01-31||||May 2016|Anticipated|2016-05-31||Interventional|NAP||Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs|Phase 1 Exploratory Clinical Study of Microdosing NAP for Optical Molecular Imaging in Human Lungs in Healthy Volunteers and in Patients With Acute Lung Injury in Intensive Care|Unknown status|Recruiting|Early Phase 1|15|Anticipated|University of Edinburgh||3|||f||||t||||||||||2018-05-31 21:39:13.281129|2018-05-31 21:39:13.281129
NCT01532011|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-07-01|2012-02-09|2012-02-13|Estimate|||||||2016-07-01|2016-07-04|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Erlotinib in Combination With Pralatrexate in Advanced Malignancies|A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer|Completed||Phase 1|72|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:39:13.425527|2018-05-31 21:39:13.425527
NCT01531998|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2015-06-02||2015-06-02|2012-02-09|2012-02-13|Estimate|2015-06-02|2015-06-19|Estimate||||2015-06-02|2015-06-19|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)|An Open Label, Single-Arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Lenalidomide, Bortezomib, Dexamethasone and Siltuximab (CNTO 328) in Subjects With Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy|Completed||Phase 1/Phase 2|14|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:39:13.574842|2018-05-31 21:39:13.574842
NCT01531985|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-05-07|2012-02-09|2012-02-13|Estimate|||||||2012-05-07|2012-05-08|Estimate|April 2010||2010-04-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Urine and Serum Biomarkers for Early Detection of Acute Kidney Injury|Urine and Serum Biomarkers for Early Detection of Acute Kidney Injury Following Cardiopulmonary Bypass Surgery for Congenital Heart Disease in Children and Adults: A Pilot Study|Completed|||20|Actual|Medical College of Wisconsin|||||f||||f||||||Samples Without DNA|"~     Urine samples will be collected after the operation at 6 hours, 12 hours, 24 hours and 72~     hours. The urine samples will be collected from your/your child's urinary catheter if one is~     in place for your/your child's regular hospital care, or by urine collected in a cup if~     you/your child do not have a urinary catheter. This study requires one blood samples of about~     1 teaspoon, before surgery. The blood sample will be collected when other blood samples are~     drawn, to avoid extra needle sticks for blood. The extra blood collected, totaling about 1~     teaspoon, is a safe amount for children over 2 years old.~   "|||2018-05-31 21:39:13.938301|2018-05-31 21:39:13.938301
NCT01531972|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2013-12-06|2012-02-10|2012-02-13|Estimate|||||||2013-12-06|2013-12-09|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects|A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects|Completed||Phase 1|30|Actual|Sunovion||3|||f||||f||||||||||2018-05-31 21:39:14.018913|2018-05-31 21:39:14.018913
NCT01531959|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2017-02-23|2012-02-10|2012-02-13|Estimate|||||||2017-02-23|2017-02-27|Actual|April 2012||2012-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Midodrine for the Treatment of Refractory Hypotension|Midodrine for the Treatment of Refractory Hypotension in Patients Otherwise Ready for Discharge From the ICU|Recruiting||Phase 3|120|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:39:14.091633|2018-05-31 21:39:14.091633
NCT01531946|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2014-07-15|2012-02-10|2012-02-13|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2012||2012-01-31|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31||Observational|||Acute MRI in Transient Ischemic Attack|Acute MRI-techniques for the Detection of Ischemic Lesions After Transient Ischemic Attack|Unknown status|Recruiting||300|Anticipated|Bispebjerg Hospital|||||f||||f||||||||||2018-05-31 21:39:14.197585|2018-05-31 21:39:14.197585
NCT01531933|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-08-06|2012-02-09|2012-02-13|Estimate|||||||2012-08-06|2012-08-07|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|DIPPER-DM||Efficacy and Safety of DLBS3233 in Prediabetic Patients|Phase III Clinical Study : DLBS3233 in Primary Prevention of Type 2 Diabetes Mellitus [DIPPER-DM]|Completed||Phase 3|80|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 21:39:14.284729|2018-05-31 21:39:14.284729
NCT01531920|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-02-10|2012-02-10|2012-02-13|Estimate|||||||2012-02-10|2012-02-13|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel|A Phase 1 Study in Healthy Subjects to Determine the Safety, Tolerability, Psychomotor Function and Cognitive Effects of Perampanel When Administered With Alcohol|Completed||Phase 1|59|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 21:39:14.38625|2018-05-31 21:39:14.38625
NCT01531907|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-12-14|2012-02-08|2012-02-13|Estimate|||||||2012-12-14|2012-12-17|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Observational|GLP-2||Relationships Between GLP-2 and Markers of Bone Turnover Following Feeding|Relationships Between GLP-2 and Markers of Bone Turnover Following Feeding: the Influence of Obesity and Cellular Mechanisms of Action|Unknown status|Enrolling by invitation||30|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||2||f||||f||||||Samples Without DNA|"~     On completion of the study, serum and plasma aliquots will be moved to the Human Tissue~     Authority (HTA) licensed biorepository housed in the Centre for Biomedical Research.~   "|||2018-05-31 21:39:14.480007|2018-05-31 21:39:14.480007
NCT01531894|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2018-05-07|2012-02-09|2012-02-13|Estimate|||||||2018-05-07|2018-05-11|Actual|February 8, 2012|Actual|2012-02-08|May 2018|2018-05-31|June 5, 2018|Anticipated|2018-06-05|June 5, 2018|Anticipated|2018-06-05||Interventional|||Continuation Study of the Oral AKT Inhibitor GSK2110183|An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies|Recruiting||Phase 2|200|Anticipated|Novartis||3|||f||||t||||||||||2018-05-31 21:39:14.580757|2018-05-31 21:39:14.580757
NCT01531881|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-01-05|2012-02-10|2012-02-13|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2006||2006-03-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|January 2014|Actual|2014-01-31||Observational|||Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression|Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression|Active, not recruiting|||240|Actual|Roswell Park Cancer Institute|||||f||||t||||||Samples With DNA|"~     saliva, oral mucosal and tongue brushings.~   "|||2018-05-31 21:39:14.698125|2018-05-31 21:39:14.698125
NCT01531868|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-04-07|2012-02-08|2012-02-13|Estimate|||||||2016-04-07|2016-04-11|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Alternative Sensory Presentation Formats in Asymptomatic Carotid Stenosis|A Randomized Trial of Alternative Sensory Presentation Formats in Asymptomatic Carotid Stenosis|Withdrawn||N/A|0|Actual|Rhode Island Hospital||6|||f||||f||||||||||2018-05-31 21:39:14.744617|2018-05-31 21:39:14.744617
NCT01531855|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2014-08-01|2012-02-10|2012-02-13|Estimate|||||||2014-08-01|2014-08-04|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Post-exercise Insulin Reductions in Type 1 Diabetes|The Metabolic and Glycaemic Responses to Reductions in Rapid-acting Insulin Dose After Running Exercise in People With Type 1 Diabetes Mellitus.|Completed||N/A|13|Actual|Northumbria University||1|||f||||t||||||||||2018-05-31 21:39:14.856931|2018-05-31 21:39:14.856931
NCT01531842|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-02-08|2012-02-08|2012-02-13|Estimate|||||||2012-02-08|2012-02-13|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|August 2013|Anticipated|2013-08-31|February 2013|Anticipated|2013-02-28||Interventional|||A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye|Bacterial Resistance and Alterations in Conjunctival Flora Following Serial Intravitreal Injections|Unknown status|Recruiting|N/A|30|Anticipated|Mid Atlantic Retina||2|||f||||f||||||||||2018-05-31 21:39:14.959128|2018-05-31 21:39:14.959128
NCT01531829|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-02-11|2012-02-10|2012-02-13|Estimate|||||||2012-02-11|2012-02-14|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD|Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized，Multi-Center，Controlled Trial|Unknown status|Recruiting|Phase 4|460|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 21:39:15.087538|2018-05-31 21:39:15.087538
NCT01531816|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-11-04|2012-02-10|2012-02-13|Estimate|||||||2013-11-04|2013-11-05|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|WeeHab in PCCU||Early Rehabilitation in Critically Ill Children Pilot Study|Early Rehabilitation in Critically Ill Children, a Pilot Study|Completed||Phase 1|20|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 21:39:16.307715|2018-05-31 21:39:16.307715
NCT01531803|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2015-10-22|2012-02-10|2012-02-13|Estimate|||||||2015-10-22|2015-10-23|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Evaluate the Safety of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients|A Prospective, Randomized, Multi-Center, Controlled, Open-Label Study to Evaluate the Safety of Kedbumin 25% Compared to Normal Saline Solution in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients Undergoing Major Elective Surgery.|Terminated||Phase 2/Phase 3|3|Actual|Kedrion S.p.A.||2||"Per FDA CBER letter dated July 15, 2015, Kedrion SpA was released from the PMC to perform the~   study with Kedbumin 25 % in pediatric patients"|f||||t||||||||||2018-05-31 21:39:16.396424|2018-05-31 21:39:16.396424
NCT01531790|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-01-15|2012-02-10|2012-02-13|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients|A Phase I Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced NSCLC Patients|Completed||Phase 1|19|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:39:16.479166|2018-05-31 21:39:16.479166
NCT01531777|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2015-04-02|2012-02-10|2012-02-13|Estimate|||||||2015-04-02|2015-04-03|Estimate|April 2011||2011-04-30|February 2012|2012-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer|A Random, Open, Dose Finding and Pharmacokinetics/Pharmacodynamics(PK/PD) Phase II Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer|Completed||Phase 2|40|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:39:16.738114|2018-05-31 21:39:16.738114
NCT01531764|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-10-17|2012-02-10|2012-02-13|Estimate|||||||2013-10-17|2013-10-18|Estimate|July 2012||2012-07-31|February 2012|2012-02-29|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||BIBW 2992 (Afatinib) and Vinorelbine|Single-arm, Open-label, Multicentre Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) in Combination With Vinorelbine for the Treatment of Patients With Metastatic Breast Cancer With Intermediate HER2 Expression (HER2 2+ by Immunohistochemistry, Fluorescence In-situ Hybridisation (FISH) Negative) After Failure of First-line Therapy in the Metastatic Setting and Having Been Pre-treated With Anthracyclines|Terminated||Phase 2|2|Actual|University of Magdeburg||||The recruitment was discontinued because of failure to meet expected enrolment goals|f||||f||||||||||2018-05-31 21:39:16.905001|2018-05-31 21:39:16.905001
NCT01531751|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-03-20|2012-02-08|2012-02-13|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DIACAL||High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease|An Open Label Phase II Trial of Free Light Chain Removal by Extended High Cut-Off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End-Stage Renal Disease.|Withdrawn||Phase 2|0|Actual|IRCCS Policlinico S. Matteo||1|||f||||t||||||||||2018-05-31 21:39:17.192984|2018-05-31 21:39:17.192984
NCT01531738|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-11-01|2012-02-08|2012-02-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Investigation of the Effects of Bariatric Surgery on Taste Reward in Humans|Investigation of the Effects of Bariatric Surgery on Taste Reward in Humans|Recruiting|||20|Anticipated|Imperial College London|||3||f||||t||||||||No||2018-05-31 21:39:17.324738|2018-05-31 21:39:17.324738
NCT01531725|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2013-02-14||2013-03-19|2012-02-09|2012-02-13|Estimate|2013-02-14|2013-03-19|Estimate||||2013-03-19|2013-03-25|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|March 2009|Actual|2009-03-31|April 2008|Actual|2008-04-30||Interventional|MULTIBENE|197 patients were considered for baseline analysis. 5 patients with protocol violation were excluded.|MULTIcentric BElgium/NEtherlands PRO-Kinetic Safety and Efficacy Study|6 Months Evaluation of the BIOTRONIK PRO-Kinetic Coronary Stent System|Completed||N/A|202|Actual|Biotronik AG|"Limitations:~missing comparators~permission to conduct follow up visits by telephone~limited number of 197 patients allows an insight of the safety and efficacy of the device."|1|||f||||t||||||||||2018-05-31 21:39:17.445204|2018-05-31 21:39:17.445204
NCT01531712|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2017-08-28|2012-02-10|2012-02-13|Estimate|||||||2017-08-28|2017-08-29|Actual|February 10, 2011||2011-02-10|August 2017|2017-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable|Phase II Study of Neoadjuvant Treatment With Gemcitabine, Tarceva and Oxaliplatin Followed by Chemotherapy With Tarceva and Gemcitabine in Patients With Pancreas Adenocarcinoma With Borderline Resectability.|Terminated||Phase 2|6|Actual|Institut Català d'Oncologia||1||Due to a low recruitment rate since start of recruitment period.|f||||f||||||||||2018-05-31 21:39:17.756902|2018-05-31 21:39:17.756902
NCT01531699|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2012-12-10|2012-02-10|2012-02-13|Estimate|||||||2012-12-10|2012-12-11|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers|An Open-label Study to Assess the Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution (ALT005) Compared to Control (Sterile Saline) Following Dermal Administration in Healthy Volunteers|Completed||Phase 3|54|Actual|Altacor Ltd.||3|||f||||f||||||||||2018-05-31 21:39:17.882521|2018-05-31 21:39:17.882521
NCT01531686|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2016-12-05|2012-02-08|2012-02-13|Estimate|||||||2016-12-05|2016-12-07|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route|An Observational Study to Determine the Safety and Effectiveness of Intraosseous Vascular Access for the Delivery of CT Contrast Dye|Terminated|||8|Actual|Vidacare Corporation||||Slow rate of enrollment|f||||f||||||||||2018-05-31 21:39:18.003022|2018-05-31 21:39:18.003022
NCT01531673|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2018-03-14|2015-05-05|2018-03-14|2012-02-08|2012-02-13|Estimate|2018-03-14|2018-04-13|Actual|2015-05-05|2015-05-22|Estimate|2018-03-14|2018-04-13|Actual|February 2012||2012-02-29|March 2018|2018-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation|A Phase 2, Multicenter, Double-Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation|Completed||Phase 2|194|Actual|Vertex Pharmaceuticals Incorporated|Pharmacokinetic (PK) final data are not yet available. Once the data are available for PK endpoints, the posting will be updated to include the same.|13|||f||||t||||||||||2018-05-31 21:39:18.360956|2018-05-31 21:39:18.360956
NCT01531660|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-03-07|2012-02-10|2012-02-13|Estimate|||||||2012-03-07|2012-03-08|Estimate|April 2004||2004-04-30|March 2012|2012-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Active Over 45: A Step-up Jogging Program in Inactive Female Hospital Staff Aged 45+|Active Over 45: A Step-up Jogging Program in Inactive Female Hospital Staff Aged 45+: Feasability, Role of Motivation and Sustained Benefit|Completed||N/A|68|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 21:39:22.112422|2018-05-31 21:39:22.112422
NCT01531647|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-11-01|2012-02-10|2012-02-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers|A Study to Evaluate the Potential Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir When Given With Raltegravir in Healthy Adult Volunteers|Completed||Phase 1|20|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:39:22.219973|2018-05-31 21:39:22.219973
NCT01531634|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-08|2012-02-08|2012-02-13|Estimate|||||||2012-02-08|2012-02-13|Estimate||||February 2012|2012-02-29||||||||Interventional|||Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention|Promoting Recovery Processes in Women Diagnosed With Borderline Personality Disorder Using a Dynamic Cognitive Intervention|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||||2018-05-31 21:39:22.351466|2018-05-31 21:39:22.351466
NCT01531621|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2015-03-25|2012-02-10|2012-02-13|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|RAXO||A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland|A Population-based Prospective Study to Evaluate Clinical Behaviour, Resectability and Survival in 1st Line Metastatic Colorectal Cancer (CRC) Patients in Finland|Recruiting|||1000|Anticipated|Helsinki University Central Hospital|||1||f||||f||||||||||2018-05-31 21:39:22.461177|2018-05-31 21:39:22.461177
NCT01531608|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-04-20|2012-02-08|2012-02-13|Estimate|||||||2015-04-20|2015-04-22|Estimate|March 2011||2011-03-31|April 2015|2015-04-30||||February 2012|Actual|2012-02-29||Observational|Mel54||Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma|Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma Independent Of Fixed Gamma Camera Imaging|Completed|||20|Actual|University of Virginia|||||f||||t||||||||||2018-05-31 21:39:22.586394|2018-05-31 21:39:22.586394
NCT01531595|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2015-03-25|2012-02-08|2012-02-13|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer|Phase 2 Study of Bevacizumab in Combination With Alternating Xeliri and Xelox as First-line Treatment of Patients With Metastatic Colorectal Cancer|Recruiting||Phase 2|100|Anticipated|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 21:39:22.676449|2018-05-31 21:39:22.676449
NCT01531582|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2014-05-09|2012-02-08|2012-02-13|Estimate|||||||2014-05-09|2014-05-12|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Minocycline in the Treatment of Angelman Syndrome|The Efficacy of Minocycline in the Treatment of Angelman Syndrome|Unknown status|Active, not recruiting|N/A|25|Actual|University of South Florida||1|||f||||t||||||||||2018-05-31 21:39:22.811713|2018-05-31 21:39:22.811713
NCT01531569|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-10-25|2012-02-08|2012-02-13|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SOD||Single Oral Dose of BeneFlax to Healthy Young and Older Adults|Community Alliance for Quality of Life in Long Term Care: Single Oral Dose of BeneFlax to Healthy Young and Older Adults|Completed||Phase 2|22|Actual|University of Saskatchewan||1|||f||||f||||||||||2018-05-31 21:39:22.903295|2018-05-31 21:39:22.903295
NCT01531556|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-10|2012-02-10|2012-02-13|Estimate|||||||2012-02-10|2012-02-13|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||A Study of How Tutin and Hyenanchin, Two Toxins Found in Honey, Are Absorbed and Processed by the Body|An Open-label, Non-randomised Study to Investigate the Pharmacokinetics of Tutin and Hyenanchin, Following Single Dose Administration of Honey Containing Tutin and Hyenanchin to Healthy Male Subjects.|Unknown status|Recruiting|Phase 1|6|Anticipated|Food Standards Australia New Zealand|||||f||||||||||||||2018-05-31 21:39:23.057005|2018-05-31 21:39:23.057005
NCT01531543|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-10|2012-02-10|2012-02-13|Estimate|||||||2012-02-10|2012-02-13|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Prospective Comparison of Primary Abdominal Closure and Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis|Phase 4 Study of Primary Use of the Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis|Completed||Phase 4|57|Actual|The Faculty Hospital Na Bulovce||2|||f||||f||||||||||2018-05-31 21:39:23.174009|2018-05-31 21:39:23.174009
NCT01531530|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-01-14|2012-02-08|2012-02-13|Estimate|||||||2013-01-14|2013-01-15|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP|Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP|Completed||Phase 1|26|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 21:39:23.302957|2018-05-31 21:39:23.302957
NCT01531517|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-02-19|2012-02-10|2012-02-13|Estimate|||||||2015-02-19|2015-02-20|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|PED111||Study of the Efficacy of PedyPhar® Ointment on the Diabetic Foot Ulcers|Study of the Efficacy of Topical Application of Royal Jelly and Panthenol (PedyPhar® Ointment) on the Diabetic Foot Ulcers, An Open Label, Randomized, Non-placebo-controlled Study|Terminated||Phase 3|47|Actual|European Egyptian Pharmaceutical Industries||2||inability to recruit patients|f||||t||||||||||2018-05-31 21:39:23.579424|2018-05-31 21:39:23.579424
NCT01531491|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-02-12|2012-02-10|2012-02-13|Estimate|||||||2015-02-12|2015-02-16|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Hypercapnia on Emergence From General Anesthesia Under Propofol|Effects of Hypercapnia on Emergence From General Anesthesia Under Propofol: a Pilot Study|Completed||N/A|30|Actual|DongGuk University||2|||f||||t||||||||||2018-05-31 21:39:23.831421|2018-05-31 21:39:23.831421
NCT01531478|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-03-30|2012-02-08|2012-02-13|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SALTO||Long-term Follow-up of Childhood Cancer Survivors in the Rhône-Alpes and Auvergne Regions of France|Long-term Follow-up of Childhood Cancer Survivors in the Rhône-Alpes and Auvergne Regions of France|Completed|||147|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 21:39:23.929274|2018-05-31 21:39:23.929274
NCT01531465|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2013-06-03|2012-02-08|2012-02-13|Estimate|||||||2013-06-03|2013-06-04|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure|Pulmonary Function Testing in Infants With Respiratory Insufficiency While Receiving High Flow Nasal Cannula (HFNC) Versus Nasal Continuous Positive Airway Pressure (nCPAP)|Completed||N/A|20|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-05-31 21:39:24.081608|2018-05-31 21:39:24.081608
NCT01531452|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2014-12-03|2012-02-10|2012-02-13|Estimate|||||||2014-12-03|2014-12-04|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|November 2012|Actual|2012-11-30||Interventional|||The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer|a Phase II Study of Oxaliplatin Plus S-1 (SOX) as First-line Treatment for Patients With Advanced Gastric Cancer|Completed||Phase 2|43|Actual|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:39:24.173754|2018-05-31 21:39:24.173754
NCT01531439|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-07-18|2012-02-10|2012-02-13|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2011|Actual|2011-11-30|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|May 1, 2015|Actual|2015-05-01||Interventional|||Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery|Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery|Completed||N/A|84|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 21:39:24.277142|2018-05-31 21:39:24.277142
NCT01531426|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2013-02-22|2012-02-10|2012-02-13|Estimate|||||||2013-02-22|2013-02-25|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|CoCaHYp||Cerebral Oxygenation in Cardiac Arrest and Hypothermia|Cerebral Oxygen Saturation as Outcome Predictor in Cardiac Arrest Patients Undergoing Mild Therapeutic Hypothermia|Completed|||94|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 21:39:24.42964|2018-05-31 21:39:24.42964
NCT01531413|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-08|2012-02-08|2012-02-13|Estimate|||||||2012-02-08|2012-02-13|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|AppyO2||Oxygen Insufflation To Reduce Postoperative Abscess In Laparoscopic Appendectomy|Single-Blind, Randomized, Controlled Trial of Oxygen Insufflation to Reduce Incidence of Postoperative Abscess in Laparoscopic Appendectomy|Completed||N/A|100|Actual|Chang, Steve S., M.D.||1|||f||||t||||||||||2018-05-31 21:39:24.530195|2018-05-31 21:39:24.530195
NCT01531400|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2012-03-18|2012-02-10|2012-02-13|Estimate|||||||2012-03-18|2012-03-20|Estimate|December 2002||2002-12-31|March 2012|2012-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Investigation of Pain and Anxiety During Electrodiagnostic Examination Using Self-selected Music|Investigation of Pain and Anxiety During Electrodiagnostic Examination Using Self-selected Music|Completed||N/A|61|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:39:24.654684|2018-05-31 21:39:24.654684
NCT01531387|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2015-06-19||2016-01-13|2012-02-10|2012-02-13|Estimate|2015-11-04|2015-12-09|Estimate||||2016-01-13|2016-02-08|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|SCATE||Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)|Sparing Conversion to Abnormal TCD Elevation (SCATE) - a Phase III Clinical Trial to Compare Standard Care (Observation) With Alternative Therapy (Hydroxyurea) for Reducing the Risk of Converting to an Abnormal TCD Velocity in Children With Sickle Cell Anemia and Conditional Pre-treatment TCD Velocities.|Terminated||Phase 3|38|Actual|Children's Hospital Medical Center, Cincinnati||2||inability to reach a satisfactory endpoint with respect to adequate recruitment|f||||t||||||||||2018-05-31 21:39:24.78635|2018-05-31 21:39:24.78635
NCT01531374|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|2016-09-01||2018-05-07|2012-02-08|2012-02-10|Estimate|2017-06-29|2017-07-18|Actual||||2018-05-07|2018-05-09|Actual|February 2012||2012-02-29|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|November 2015|Actual|2015-11-30||Interventional||A total of 1658 Extreme Risk subjects were enrolled; 1257 Iliofemoral and 367 Non-Iliofemoral had an attempted implant procedure. A total of 1119 High Risk subjects were enrolled; however, 1108 subjects had an attempted implant procedure. The baseline data presented are for subjects with an attempted implant.|Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement|Medtronic CoreValve® Continued Access Study|Active, not recruiting||N/A|2777|Actual|Medtronic Cardiovascular||3|||f||||t||||||||||2018-05-31 21:39:25.443179|2018-05-31 21:39:25.443179
NCT01531361|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2018-05-11|2012-02-08|2012-02-10|Estimate|||||||2018-05-11|2018-05-16|Actual|February 6, 2012|Actual|2012-02-06|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer|A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 Inhibitor) in Combination With Vemurafenib (BRAF Inhibitor) in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|46|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 21:39:28.601561|2018-05-31 21:39:28.601561
NCT01531348|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-08-28|2012-02-08|2012-02-10|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2012||2012-02-29|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Feasibility and Safety of Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa|Feasibility and Safety of Adult Human Bone Marrow-Derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis Pigmentosa|Enrolling by invitation||Phase 1|10|Anticipated|Mahidol University||1|||f||||t||||||||||2018-05-31 21:39:28.682785|2018-05-31 21:39:28.682785
NCT01531335|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2013-12-16||2015-11-07|2012-02-08|2012-02-10|Estimate|2015-11-07|2015-12-11|Estimate||||2015-11-07|2015-12-11|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|RuRaL||Hypocaloric Nutrition in Critically Ill Patients|Effectiveness of Hypocaloric Nutrition Compared With Standard Care in Critically Ill Adults Patients, a Randomized Controlled Trial|Completed||Phase 3|80|Actual|Lafrancol S.A.|No surgical patients included Wide variety of patients Caloric needs were not estimated with a gold standard|2|||f||||t||||||||||2018-05-31 21:39:28.764011|2018-05-31 21:39:28.764011
NCT01531322|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-02-15|2012-02-08|2012-02-10|Estimate|||||||2012-02-15|2012-02-17|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects|A Phase 1 Open-label Study to Assess the Safety and Tolerability of a Single Dose of 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children and Infants|Completed||Phase 1|72|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:39:28.991642|2018-05-31 21:39:28.991642
NCT01531309|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03||2013-02-18|2013-03-06|2012-02-08|2012-02-10|Estimate||||2013-02-18|2013-02-22|Estimate|2013-03-06|2013-03-14|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pharmacokinetics of Agomelatine in Patients With Liver Impairment|An Open-label, Parallel-group Study to Compare the Pharmacokinetics, Safety and Tolerability of a Single Sublingual 1 mg Dose of AGO178 in Subjects With Mild and Moderate Hepatic Impairment With That in Matched Healthy Control Subjects|Completed||Phase 1/Phase 2|32|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:39:29.076475|2018-05-31 21:39:29.076475
NCT01531296|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2016-01-13|2012-02-08|2012-02-10|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||To Assess Rotation for Femoral Version and Tibial Torsion|Correlation Between MRI and Clinical Measurements of Lower Extremity Rotational Profile: Reliability of MRI to Assess Rotation for Femoral Version and Tibial Torsion|Completed|||37|Actual|University of Utah|||||f||||f||||||||||2018-05-31 21:39:29.144124|2018-05-31 21:39:29.144124
NCT01531283|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-11-13|2012-02-09|2012-02-10|Estimate|||||||2012-11-13|2012-11-14|Estimate|February 2011||2011-02-28|November 2012|2012-11-30||||April 2013|Anticipated|2013-04-30||Interventional|UAG||Deacylated Ghrelin and Beta Cell Function|Impact of Unacylated Ghrelin on Beta-cell Function in Humans|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Cincinnati||4|||f||||t||||||||||2018-05-31 21:39:29.197832|2018-05-31 21:39:29.197832
NCT01531257|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2018-04-12|2012-02-09|2012-02-10|Estimate|||||||2018-04-12|2018-04-17|Actual|April 2010||2010-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|"Mini-Kidney"||Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients|Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients|Recruiting|||1000|Anticipated|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Urine Collection: Approximately one cup of urine (200 mL) will be taken for research tests on~     the day of a routine care biopsy, if possible.~      Blood Draws: About 1.5 tablespoons of blood (20.5 mL) will be taken for research tests before~     the biopsy.~      Kidney Biopsy: A kidney biopsy is a procedure to remove and examine a small piece of kidney~     tissue. For this study, one biopsy will be taken from the new kidney and used specifically~     for research. The biopsy will be done at the same time as the biopsies done for routine care.~     If there are any complications during the routine care biopsies, the tissue for this research~     study will not be taken.~   "|||2018-05-31 21:39:29.406544|2018-05-31 21:39:29.406544
NCT01531244|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-07-17|2012-02-08|2012-02-10|Estimate|||||||2014-07-17|2014-07-18|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma|A Phase I/II Study of Isolated Limb Infusion and Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma|Withdrawn||Phase 1/Phase 2|0|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 21:39:29.495366|2018-05-31 21:39:29.495366
NCT01531231|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2013-07-23|2012-02-08|2012-02-10|Estimate|||||||2013-07-23|2013-07-24|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Observational|||Typical Daily Experiences, Ischemia and Repolarization in Coronary Artery Disease|Typical Daily Emotions, Ischemia and Repolarization in Coronary Artery Disease|Unknown status|Recruiting||300|Anticipated|University of Arizona|||4||f||||f||||||||||2018-05-31 21:39:29.573176|2018-05-31 21:39:29.573176
NCT01531218|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-07-03|2012-02-09|2012-02-10|Estimate|||||||2014-07-03|2014-07-04|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Concisus2012||Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea|Randomized, Double-Blind, Placebo-Controlled Trial Of Azithromycin In Campylobacter Concisus Positive Patients With Diarrhea|Completed||Phase 3|100|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:39:29.642373|2018-05-31 21:39:29.642373
NCT01531205|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2014-07-08||2014-11-04|2012-02-09|2012-02-10|Estimate|2014-08-04|2014-08-05|Estimate||||2014-11-04|2014-11-05|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional||All participants|Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA|Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Failure With Biopsy Proven Local Recurrence After Initial Definitive Radiotherapy|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|Study was closed early due to low accrual. Investigators had planned to follow 25 participants from On Study through End of Follow-up, up to 10 years.|1||low accrual|f||||t||||||||||2018-05-31 21:39:29.726732|2018-05-31 21:39:29.726732
NCT01531192|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2013-07-13|2012-02-09|2012-02-10|Estimate|||||||2013-07-13|2013-07-16|Estimate|June 2012||2012-06-30|February 2012|2012-02-29|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants|Zekai Tahir Burak Maternity Teaching Hospital, Ankara/Turkey|Completed||Phase 4|300|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 21:39:30.021035|2018-05-31 21:39:30.021035
NCT01531179|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2013-05-08|2012-02-09|2012-02-10|Estimate|||||||2013-05-08|2013-05-13|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Lactobacillus Reuteri for Prevention of Necrotizing Enterocolitis in Very Low-birth Weight Infants|Role Of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis in Very Low Birth Weight Infants|Completed||Phase 3|400|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 21:39:30.104477|2018-05-31 21:39:30.104477
NCT01531166|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-08-16|2012-02-09|2012-02-10|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Observational|||A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon|An Observational, Multi-Center, Cohort Study Evaluating the Antiviral Efficacy, Safety, and Tolerability in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon-alpha 2a (Pegasys®): TRACES STUDY|Completed|||500|Actual|Yonsei University|||1||f||||t||||||||||2018-05-31 21:39:30.183455|2018-05-31 21:39:30.183455
NCT01531140|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||PEG Versus PEG+Bisacodyl Versus Sennosides for Colon Cleansing Before Colonoscopy|High-volume Polyethylene Glycol Solution (PEG) Versus Low-volume PEG Plus Stimulant Laxative Versus Sennosides for Colon Cleansing Before Colonoscopy: a Randomized, Single Blinded Study|Completed||Phase 4|240|Actual|Medical University of Warsaw||3|||f||||f||||||||||2018-05-31 21:39:30.337802|2018-05-31 21:39:30.337802
NCT01531127|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Executive Function in Learning in Children With Attention Deficit Hyperactivity Disorder (ADHD) Receiving Medical Treatment Alone Compared to Children Receiving Additional Treatment to Improve Learning Strategies||Unknown status|Not yet recruiting||30|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 21:39:30.419016|2018-05-31 21:39:30.419016
NCT01531114|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-06-27|2012-02-09|2012-02-10|Estimate|||||||2017-06-27|2017-06-28|Actual|May 2013||2013-05-31|June 2017|2017-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|RESET 2D||PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus|Prasugrel Or Ticagrelor In ST-Elevation Myocardial Infarction Patients With Diabetes Mellitus|Completed||Phase 3|50|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:39:30.474805|2018-05-31 21:39:30.474805
NCT01531101|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-10-09|2012-02-09|2012-02-10|Estimate|||||||2017-10-09|2017-10-10|Actual|January 2012||2012-01-31|October 2017|2017-10-31|September 2028|Anticipated|2028-09-30|September 2020|Anticipated|2020-09-30||Interventional|FEST-IT||First Experimental Study of Transference Work - In Teenagers (FEST-IT)|First Experimental Study of Transference Work - In Teenagers|Recruiting||N/A|100|Anticipated|Sykehuset i Vestfold HF||2|||f||||f||||||||Undecided||2018-05-31 21:39:30.550624|2018-05-31 21:39:30.550624
NCT01531088|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-01-04|2012-02-09|2012-02-10|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes|Enhancing the Detection and Management of Adverse Drug Events in the Nursing Home|Completed||N/A|36|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:39:30.67887|2018-05-31 21:39:30.67887
NCT01531075|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-06-06|2012-02-09|2012-02-10|Estimate|||||||2012-06-06|2012-06-07|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|HBV VIP||Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease|Assessment of Hepatitis B Vaccination Efficacy in Patients With Inflammatory Bowel Diseases|Unknown status|Recruiting|N/A|75|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 21:39:30.743633|2018-05-31 21:39:30.743633
NCT01531062|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-08|2012-02-08|2012-02-10|Estimate|||||||2012-02-08|2012-02-10|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Nigella Sativa on Lipid Profiles in Elderly|Effect of Nigella Sativa on Lipid Profiles in Elderly: a Randomized Double-blinded Clinical Trial|Completed||Phase 2|96|Actual|Indonesia University||2|||f||||t||||||||||2018-05-31 21:39:30.834507|2018-05-31 21:39:30.834507
NCT01531049|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2017-06-02|2012-02-09|2012-02-10|Estimate|||||||2017-06-02|2017-06-05|Actual|May 2012||2012-05-31|June 2017|2017-06-30|September 2, 2016|Actual|2016-09-02|December 31, 2015|Actual|2015-12-31||Interventional|||Smoking Habits and Smoking Cessation in Young Adults|Smoking Cessation in Young Adults in Northern Finland|Completed||Phase 2/Phase 3|300|Actual|University of Oulu||4|||f||||f||||||||||2018-05-31 21:39:31.193811|2018-05-31 21:39:31.193811
NCT01531036|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2016-02-24|2012-02-09|2012-02-10|Estimate|||||||2016-02-24|2016-02-25|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||3D Breast Ultrasound Elastography in Patients Under Neoadjuvant Chemotherapy|Imagerie 3D d'élasticité du Sein Par échographie Ultrarapide au Cours d'un Traitement Par chimiothérapie néoadjuvante.|Completed||N/A|33|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 21:39:31.275029|2018-05-31 21:39:31.275029
NCT01531023|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-10-28|2012-02-09|2012-02-10|Estimate|||||||2016-10-28|2016-10-31|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Treatment of Extended Spectrum Betalactamase Producing Bacteria Causing Urinary Tract Infections in General Practice|What is the Outcome of Treatment of Urinary Tract Infections Caused by Bacteria Producing Extended Spectrum Betalactamase in a Primary Care Setting?|Completed|||168|Actual|University of Oslo|||2||f||||f||||||Samples With DNA|"~     Urinesamples~   "|||2018-05-31 21:39:31.34687|2018-05-31 21:39:31.34687
NCT01531010|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-08|2012-02-08|2012-02-10|Estimate|||||||2012-02-08|2012-02-10|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pressure-limited Ventilation Versus Volume-targeted Ventilation in Preterm Newborns|Randomised Controlled Trial of Pressure-limited Ventilation Versus Volume-targeted Ventilation in Prematurely Born Infants|Completed||N/A|40|Actual|King's College London||2|||f||||f||||||||||2018-05-31 21:39:31.416393|2018-05-31 21:39:31.416393
NCT01530997|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2017-03-30||2017-07-10|2012-02-07|2012-02-10|Estimate|2017-07-10|2017-08-09|Actual||||2017-07-10|2017-08-09|Actual|November 2011||2011-11-30|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|November 2014|Actual|2014-11-30||Interventional||Sixty-nine patients were eligible for enrollment, of whom 45 were accrued. One patient had a cerebrovascular accident during de-intensified CRT and was taken off the study leaving 44 patients included in the baseline characteristics.|De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca|Phase II Study of De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma|Active, not recruiting||Phase 2|45|Actual|UNC Lineberger Comprehensive Cancer Center|Per the protocol, affiliate sites will only report grade 3/4 and all fatal (grade 5) toxicities. 1/2 toxicities were not reported for affiliate sites.|1|||f||||t||||||||||2018-05-31 21:39:31.52348|2018-05-31 21:39:31.52348
NCT01530984|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2015-10-01|2012-02-07|2012-02-10|Estimate|||||||2015-10-01|2015-10-05|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ipilimumab and GMCSF Immunotherapy for Prostate Cancer|Anti-CTLA4 Blockade Alone or Combined With Systemic GM-CSF for Prostate Cancer Immunotherapy|Withdrawn||Phase 2|0|Actual|University of California, San Francisco||2||Unable to execute contract|f||||t||||||||||2018-05-31 21:39:32.226146|2018-05-31 21:39:32.226146
NCT01530971|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2013-07-01|2012-02-09|2012-02-10|Estimate|||||||2013-07-01|2013-07-02|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect of Maternal and Neonatal Oxygenation|Effects of Neonate and Maternal Oxygenation in Low-dose Oxygen Supplement by Oxygen Cannula or Non- Supplement in Elective Cesarean Section: a Randomized Controlled Trial|Completed||Phase 3|325|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 21:39:32.319616|2018-05-31 21:39:32.319616
NCT01530958|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-10-26|2012-02-09|2012-02-10|Estimate|||||||2016-10-26|2016-10-28|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|KARE||Kidney Awareness Registry and Education|The Kidney Awareness Registry and Education Study|Recruiting||Phase 3|100|Anticipated|University of California, San Francisco||4|||f||||t||||||||Undecided|Data may be available upon contact of study PI.|2018-05-31 21:39:32.396562|2018-05-31 21:39:32.396562
NCT01530945|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2015-09-02|2012-02-09|2012-02-10|Estimate|||||||2015-09-02|2015-09-04|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease|Mapping Multidimensional Illness Trajectories of Patients With ESKD|Completed|||227|Actual|University of North Carolina, Chapel Hill|||||f||||||||||||||2018-05-31 21:39:32.481202|2018-05-31 21:39:32.481202
NCT01530932|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-10-20|2012-02-09|2012-02-10|Estimate|||||||2014-10-20|2014-10-21|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Immune Activation, Hypoxia and Vasoreaction in Sepsis of Pulmonary Versus Abdominal Origin|Immune Activation, Hypoxia and Vasoreaction in Sepsis of Pulmonary Versus Abdominal Origin|Completed|||20|Anticipated|Universitätsmedizin Mannheim|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 21:39:32.540267|2018-05-31 21:39:32.540267
NCT01530919|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-05-01|2012-02-07|2012-02-10|Estimate|||||||2017-05-01|2017-05-04|Actual|September 1998||1998-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|December 2009|Actual|2009-12-31||Observational|MIRP||Minimally Invasive Radioguided Parathyroidectomy|Minimally Invasive Radioguided Parathyroidectomy|Completed|||856|Actual|University of Louisville|||1||f||||f||||||Samples With DNA|"~     Small portion of abnormal parathyroid gland that is removed during surgery is frozen and~     stored for future research.~   "|||2018-05-31 21:39:32.598957|2018-05-31 21:39:32.598957
NCT01530906|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2014-12-02|2012-02-07|2012-02-10|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|rTMS&bulimia||Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) in Bulimia|Efficiency of rTMS in Bulimia: a Controlled Randomized Study|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:39:32.689506|2018-05-31 21:39:32.689506
NCT01530893|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2014-02-27|2012-02-07|2012-02-10|Estimate|||||||2014-02-27|2014-02-28|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|FASTCHECK||Flavonoids, Blood Pressure and Blood Vessel Function|Are the Cardiovascular Responses of Individuals at Mild to Moderate Cardiovascular Risk Influenced by Dietary Flavonoid Sub-class and Dietary Form?|Completed||N/A|64|Actual|University of East Anglia||4|||f||||f||||||||||2018-05-31 21:39:32.775928|2018-05-31 21:39:32.775928
NCT01530880|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|2017-07-14||2017-08-15|2012-02-08|2012-02-10|Estimate|2017-08-15|2017-08-28|Actual||||2017-08-15|2017-08-28|Actual|October 2012||2012-10-31|August 2017|2017-08-31|March 17, 2016|Actual|2016-03-17|March 17, 2016|Actual|2016-03-17||Interventional||Includes subjects from both arms as this information is only available for all subjects and not per arm.|Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage|Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage|Terminated||Phase 4|35|Actual|Columbia University||2||PI no longer at institution|f||||f||||||||||2018-05-31 21:39:32.861163|2018-05-31 21:39:32.861163
NCT01530867|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2013-06-05|2012-02-09|2012-02-10|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Physician-Patient Communication Project|Physician-Patient Communication Project|Completed|||456|Actual|University of California, Los Angeles|||||f||||t||||||||||2018-05-31 21:39:33.046156|2018-05-31 21:39:33.046156
NCT01530854|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-03-15|2012-02-09|2012-02-10|Estimate|||||||2017-03-15|2017-03-17|Actual|February 2008||2008-02-29|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Plasma Free Fatty Acids in Risk Assessment of Sepsis in the Emergency Department: A Prospective Pilot Study|Plasma Free Fatty Acids in Risk Assessment of Sepsis in the Emergency Department: A Prospective Pilot Study|Completed|||74|Actual|The Cleveland Clinic|||2||f||||f||||||Samples With DNA|"~     Blood samples (10 cc. total) are to be collected in non-heparinized tubes upon initial~     presentation to the ED as well as 3-6hours and 24(+/-3) hours after the initial blood draw.~     The 3-6hour and 24-hour blood draw will be optional depending on patient location and the~     availability of study personnel. The plasma samples will be aliquoted and frozen at -70°C for~     later assays. These samples will be assayed for plasma FFA, plasma glucose, plasma insulin,~     and future cytokines including IL-1 and TNF.~   "|||2018-05-31 21:39:33.10531|2018-05-31 21:39:33.10531
NCT01530841|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-03-08|2012-02-09|2012-02-10|Estimate|||||||2017-03-08|2017-03-10|Actual|July 2012||2012-07-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy|Prospective Randomized Controlled Single Blind Study of Efficacy and Tolerance of AVAPS Mode Compared to Bilevel Pressure Ventilation un Adult Patients With Myotonic Dystrophy|Completed||N/A|32|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||||2018-05-31 21:39:33.166021|2018-05-31 21:39:33.166021
NCT01530828|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2013-08-07|2012-02-09|2012-02-10|Estimate|||||||2013-08-07|2013-08-09|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|August 2014|Anticipated|2014-08-31|September 2013|Anticipated|2013-09-30||Observational|||IRT in Infants With Intestinal Perforation|Immunoreactive Trypsinogen in Infants With Intestinal Perforation|Unknown status|Recruiting||300|Anticipated|Children's Hospitals and Clinics of Minnesota|||1||f||||f||||||||||2018-05-31 21:39:33.385575|2018-05-31 21:39:33.385575
NCT01530815|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Bupivicaine to Reduce Postoperative Pain in Laparoscopic Ventral Hernia Repair|Intraoperative Local Anesthesia for Management of Postoperative Pain Following Laparoscopic Ventral Hernia Repair: a Prospective Double-blind Randomized Trial|Unknown status|Recruiting|N/A|80|Anticipated|Chang, Steve S., M.D.||1|||f||||t||||||||||2018-05-31 21:39:33.467661|2018-05-31 21:39:33.467661
NCT01530802|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|December 2009||2009-12-31|||||Interventional|||Temporary Clipping of the Uterine Arteries During Laparoscopic Myomectomy|Reduction of Intraoperative Blood Loss During Laparoscopic Myomectomy by Temporary Clipping of the Uterine Arteries|Completed||N/A|166|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:39:33.561014|2018-05-31 21:39:33.561014
NCT01530789|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2015-08-05|2012-02-09|2012-02-10|Estimate|||||||2015-08-05|2015-08-06|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Paramedical Consultation in Telemedicine|Evaluation of Paramedical Consultation in Type 1 Diabetic Patients in Telemedicine|Terminated|||50|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|||||f||||||||||||||2018-05-31 21:39:33.632978|2018-05-31 21:39:33.632978
NCT01530776|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-05-17|2012-02-09|2012-02-10|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2012||2012-01-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Healthy4Baby: Preventing Postpartum Weight Retention Among Low-Income, Black Women|Preventing Postpartum Weight Retention Among Low-Income, Black Women|Completed||Phase 2|66|Actual|Temple University||2|||f||||f||||||||||2018-05-31 21:39:33.69156|2018-05-31 21:39:33.69156
NCT01530763|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2015-01-12|2012-02-08|2012-02-10|Estimate|||||||2015-01-12|2015-01-13|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)|A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization|Completed||Phase 2/Phase 3|161|Actual|Forest Laboratories||2|||f||||t||||||||||2018-05-31 21:39:33.786412|2018-05-31 21:39:33.786412
NCT01530750|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2012-08-31|2012-02-09|2012-02-10|Estimate|||||||2012-08-31|2012-09-03|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|February 2014|Anticipated|2014-02-28|February 2013|Anticipated|2013-02-28||Observational|||READ-POAF Pilot Studies Postoperative Atrial Fibrillation After Cardiac Surgery|READ-POAF Pilot Study. The Use of the Reveal XT as Device for Postoperative Atrial Fibrillation Detection After Cardiac Surgery|Unknown status|Recruiting||40|Anticipated|Catharina Ziekenhuis Eindhoven|||1||f||||f||||||||||2018-05-31 21:39:34.000491|2018-05-31 21:39:34.000491
NCT01530737|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-01-06|2012-02-07|2012-02-10|Estimate|||||||2015-01-06|2015-01-07|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery|Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery|Completed||Phase 3|18|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 21:39:34.084113|2018-05-31 21:39:34.084113
NCT01530724|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2015-09-29|2012-02-09|2012-02-10|Estimate|||||||2015-09-29|2015-09-30|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CENTRAL||Diet and Body Composition|Effect of Weight-loss Diet Strategies and Exercise on Dynamics of Body Fat Depots and Metabolic Rate|Completed||Phase 3|224|Actual|Ben-Gurion University of the Negev||2|||f||||t||||||||||2018-05-31 21:39:34.164847|2018-05-31 21:39:34.164847
NCT01530711|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-08-17|2012-02-09|2012-02-10|Estimate|||||||2016-08-17|2016-08-18|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|AMELIORATE||Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response|Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response|Active, not recruiting||Phase 4|40|Anticipated|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-05-31 21:39:34.237654|2018-05-31 21:39:34.237654
NCT01530698|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2017-04-13|2012-02-09|2012-02-10|Estimate|||||||2017-04-13|2017-04-17|Actual|April 2010||2010-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients|Single-step Antigen Loading and TLR Activation of Dendritic Cells by mRNA Electroporation for Vaccination in Stage III and IV Melanoma Patients|Completed||Phase 1/Phase 2|28|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:39:34.318507|2018-05-31 21:39:34.318507
NCT01530685|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|August 2012|Anticipated|2012-08-31|April 2012|Anticipated|2012-04-30||Interventional|||Gycabiane and Glycemic Control of Prediabetic Subjects|Effect of Glycabiane, a Dietary Supplement, on Glycemic Control of Prediabetic Subjects|Unknown status|Recruiting|Phase 3|60|Anticipated|Pileje||2|||f||||||||||||||2018-05-31 21:39:34.397844|2018-05-31 21:39:34.397844
NCT01530672|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2014-10-27|2012-02-09|2012-02-10|Estimate|||||||2014-10-27|2014-10-28|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|MBIO||Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test|Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test|Completed||N/A|2900|Actual|PATH||1|||f||||f||||||||||2018-05-31 21:39:34.486718|2018-05-31 21:39:34.486718
NCT01530659|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-11-27|2012-02-07|2012-02-10|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2012||2012-01-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa|Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density|Active, not recruiting||Phase 2|30|Anticipated|Neurotech Pharmaceuticals||1|||f||||t||||||||||2018-05-31 21:39:34.566987|2018-05-31 21:39:34.566987
NCT01530646|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2015-06-06|2012-02-07|2012-02-10|Estimate|||||||2015-06-06|2015-06-09|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Impact of Whey and Soy Protein Ingestion in Conjunction With Energy Restriction in Overweight/Obese Individuals|Molecular Events Underpinning Changes in Tissue Metabolism With Whey and Soy Ingestion in Energy Restriction in Overweight/Obese Adults|Completed||N/A|42|Actual|McMaster University||3|||f||||t||||||||||2018-05-31 21:39:34.660678|2018-05-31 21:39:34.660678
NCT01530620|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|December 2004||2004-12-31|February 2012|2012-02-29|July 2006|Actual|2006-07-31|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity|Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial|Completed||Phase 3|66|Actual|APOGEPHA Arzneimittel GmbH||2|||f||||f||||||||||2018-05-31 21:39:34.748446|2018-05-31 21:39:34.748446
NCT01530607|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-02-24|2012-02-09|2012-02-10|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer|Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer|Completed||Phase 3|416|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||||||||||||2018-05-31 21:39:34.837833|2018-05-31 21:39:34.837833
NCT01530061|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-08-16|2012-02-07|2012-02-09|Estimate|||||||2012-08-16|2012-08-20|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|April 2013|Anticipated|2013-04-30|August 2012|Actual|2012-08-31||Interventional|||The Satiating Effect of Eggs in Children|The Satiating Effect of Eggs in Children|Unknown status|Active, not recruiting|N/A|30|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:39:41.264739|2018-05-31 21:39:41.264739
NCT01530594|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-02-24|2012-02-09|2012-02-10|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma|Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma|Completed||Phase 3|440|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||||||||||||2018-05-31 21:39:34.894944|2018-05-31 21:39:34.894944
NCT01530581|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-01-04|2012-02-09|2012-02-10|Estimate|||||||2016-01-04|2016-01-05|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|||Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation|A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies|Completed||Phase 3|230|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||||||||||||2018-05-31 21:39:34.974345|2018-05-31 21:39:34.974345
NCT01530568|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-01-06|2012-02-09|2012-02-10|Estimate|||||||2015-01-06|2015-01-07|Estimate|August 2010||2010-08-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Gene Xpert Diagnosis of TB Using Tracheal Aspirates From Intensive Care Unit (ICU) Patients|A Randomised Control Trial of a Standardised and User-friendly Real-time PCR Assay for the Diagnosis of TB Using Tracheal Aspirates Obtained From Patients in the ICU|Completed||N/A|341|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 21:39:35.054688|2018-05-31 21:39:35.054688
NCT01530555|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-02-24|2012-02-09|2012-02-10|Estimate|||||||2016-02-24|2016-02-25|Estimate|April 2008||2008-04-30|February 2012|2012-02-29|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia|Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia|Completed||Phase 2|35|Actual|King Faisal Specialist Hospital & Research Center||1|||f||||||||||||||2018-05-31 21:39:35.125024|2018-05-31 21:39:35.125024
NCT01530542|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-02-22|2012-02-07|2012-02-10|Estimate|||||||2012-02-22|2012-02-24|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers|Open-Label, Single-Dose, Randomized, 5-Period, 5-Way Crossover Study To Evaluate The Dose Proportionality And The Effects Of Food On The Bioavailability Of Acurox Tablets In Healthy Volunteers|Completed||Phase 1|35|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:39:35.1834|2018-05-31 21:39:35.1834
NCT01530529|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-04-29|2012-02-07|2012-02-10|Estimate|||||||2012-04-29|2012-05-01|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999|A Phase 1, Cross-Over, Single-Dose, Open-Label Study to Estimate the Relative Bioavailability of a Modified-Release Formulation of PF-05180999 Under Fed and Fasted Conditions in Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 21:39:35.279266|2018-05-31 21:39:35.279266
NCT01530516|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-02-01|2012-02-08|2012-02-10|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2012|Actual|2012-10-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Crossbow Versus Forsus Springs in Mild to Moderate Class II Malocclusion Cases|3D Changes Comparing the Crossbow Appliance and Later Full Fixed Brackets Against Simultaneous Use of Full Fixed Brackets Plus Forsus Springs Among Mild to Moderate Class II Malocclusion Cases: A Randomized Clinical Trial.|Active, not recruiting||N/A|54|Actual|University of Alberta, Graduate Orthodontic Program||2|||f||||f||||||||No||2018-05-31 21:39:35.370338|2018-05-31 21:39:35.370338
NCT01530503|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2016-02-24|2012-02-09|2012-02-10|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|BIT-2||Second Line Therapy in Advanced Biliary Tract Cancer|A Randomized Phase II Trial of Second Line Therapy in Advanced Biliary Tract Cancer: Capecitabine or Capecitabine Plus Mitomycin C|Completed||Phase 2|52|Actual|IRCCS San Raffaele||2|||f||||t||||||||||2018-05-31 21:39:35.436136|2018-05-31 21:39:35.436136
NCT01530490|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|August 2008|Actual|2008-08-31||Interventional|||Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention|Prevention of Ovarian Hyperstimulation Syndrome in GnRH Agonist IVF Cycles: Randomized Study Comparing Hydroxyethyl Starch Versus Cabergoline and Hydroxyethyl Starch|Completed||Early Phase 1|80|Actual|Hospital de Cruces||2|||f||||t||||||||||2018-05-31 21:39:35.518044|2018-05-31 21:39:35.518044
NCT01530477|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2013-06-26||2016-08-08|2012-02-09|2012-02-10|Estimate|2014-09-23|2014-09-25|Estimate||||2016-08-08|2016-09-16|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DXA P&A||DXA Precision and Accuracy Comparison Study|DXA Precision and Accuracy Comparison Study|Terminated||N/A|82|Actual|GE Healthcare||3||Early termination due to inability to meet enrollment for >350lb weight class|f||||f||||||||||2018-05-31 21:39:35.590956|2018-05-31 21:39:35.590956
NCT01530464|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2013-09-01||2013-11-28|2012-02-07|2012-02-10|Estimate|2013-11-28|2014-01-16|Estimate||||2013-11-28|2014-01-16|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|GQ01||The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers|The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers|Completed||Phase 1|18|Actual|Duke University||3|||f||||||||||||||2018-05-31 21:39:35.992472|2018-05-31 21:39:35.992472
NCT01530451|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2015-02-02|2012-02-09|2012-02-10|Estimate|||||||2015-02-02|2015-02-04|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients|Prospective, Randomized, Double-blind Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients|Terminated||Phase 3|9|Actual|Chinese University of Hong Kong||2||Insufficient funding|f||||f||||||||||2018-05-31 21:39:36.437008|2018-05-31 21:39:36.437008
NCT01530438|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-04-08|2012-02-09|2012-02-10|Estimate|||||||2014-04-08|2014-04-09|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Interventional|SLAMEM||Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis|Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis : Neuropsychological, Imaging and Neuropathological Study|Unknown status|Recruiting|N/A|90|Anticipated|University Hospital, Caen||3|||f||||||||||||||2018-05-31 21:39:36.507937|2018-05-31 21:39:36.507937
NCT01530425|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Observational|Wheels||Outcome Measures for Pediatric Wheelchairs in Low-resource Settings|Development of a Suite of Outcomes Measures Suitable for Use in Low-resource Settings to Compare Pediatric Wheelchairs Within the Framework of the International Classification of Function, Disability and Health|Unknown status|Recruiting||20|Anticipated|Bethany Relief and Rehabilitation International Inc.|||2||f||||t||||||||||2018-05-31 21:39:36.58442|2018-05-31 21:39:36.58442
NCT01530412|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-02-09|2012-02-09|2012-02-10|Estimate|||||||2012-02-09|2012-02-10|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Long Term Evaluation of Activity Levels Post Pulmonary Rehabilitation|Long Term Evaluation of Activity Levels Post Pulmonary Rehabilitation: 1 Year Follow-up|Completed||N/A|65|Actual|Beaumont Hospital||2|||f||||f||||||||||2018-05-31 21:39:36.729061|2018-05-31 21:39:36.729061
NCT01530399|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2015-11-04||2015-11-04|2012-02-07|2012-02-09|Estimate|2015-11-04|2015-12-10|Estimate||||2015-11-04|2015-12-10|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery|A Phase II, Double-blind, Parallel Group, Dose-selection Study to Compare Antifibrinolytic MDCO-2010 vs. Placebo and Tranexamic Acid in Reducing Blood Loss in Patients Undergoing Primary Cardiac Surgery|Terminated||Phase 2|44|Actual|The Medicines Company||6||Safety|f||||t||||||||||2018-05-31 21:39:36.86055|2018-05-31 21:39:36.86055
NCT01530386|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-08-16|2012-02-07|2012-02-09|Estimate|||||||2012-08-16|2012-08-20|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects|A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects|Completed||Phase 1|25|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 21:39:37.522347|2018-05-31 21:39:37.522347
NCT01530373|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-02-15|2012-02-07|2012-02-09|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2012||2012-02-29|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|July 2021|Anticipated|2021-07-31||Interventional|||Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients|A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy|Recruiting||Phase 2|110|Anticipated|University of Arkansas||2|||f||||t||||||||||2018-05-31 21:39:37.619329|2018-05-31 21:39:37.619329
NCT01530360|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-12-07|2012-02-07|2012-02-09|Estimate|||||||2012-12-07|2012-12-10|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|SafeBoosC-p||Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants|Safeguarding the Brains of Our Smallest Children - a Pilot Study|Completed||Phase 1|10|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 21:39:37.742033|2018-05-31 21:39:37.742033
NCT01530347|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-05-09|2012-02-08|2012-02-09|Estimate|||||||2018-05-09|2018-05-15|Actual|March 2012|Actual|2012-03-31|May 2018|2018-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Non Invasive Breath Based Acetone-meter- Easy Check|Assessing Feasibility of Non-invasive Breath Based Acetone Meter -Easy Check- Relative to Finger Capillary Blood Glucose and Beta Hydroxybutyrate Reference|Terminated||Phase 1|6|Actual|Rabin Medical Center||1||Per sponsor decision to stop the development of the study device|f||||f||||||||||2018-05-31 21:39:37.816644|2018-05-31 21:39:37.816644
NCT01530334|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2015-07-27||2016-01-26|2012-02-07|2012-02-09|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ICARUS|The overall number of patients was 61 (FAS population). FAS population was defined as all screened patients enrolled in the study|Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment|A Phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Who Responded to Gefitinib in 1st Line and Progressed After 2nd Line Chemotherapy|Completed||Phase 2|61|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 21:39:37.911778|2018-05-31 21:39:37.911778
NCT01530321|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-09-07|2012-02-06|2012-02-09|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CGH D-R||Cervicogenic Headache Dose-Response|Dose-Response of Manipulation for Cervicogenic Headache|Completed||Phase 1/Phase 2|256|Actual|University of Western States||4|||f||||t||||||||||2018-05-31 21:39:38.173153|2018-05-31 21:39:38.173153
NCT01530308|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-11-25|2012-02-06|2012-02-09|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|HARPOON||Haloperidol Prophylaxis in Older Emergency Department Patients|Early Pharmacological Intervention to Prevent Delirium: Haloperidol Prophylaxis in Older Emergency Department Patients|Completed||Phase 4|242|Actual|VU University Medical Center||2|||f||||t||||||||||2018-05-31 21:39:38.24792|2018-05-31 21:39:38.24792
NCT01530295|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2012-02-07|2012-02-07|2012-02-09|Estimate|||||||2012-02-07|2012-02-09|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer|Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant in Patients With High Risk Locallized Prostate Cancer|Unknown status|Recruiting|N/A|70|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:39:38.506525|2018-05-31 21:39:38.506525
NCT01530282|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-08|2012-02-08|2012-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|ERNI||Non-invasive Measurements of Elastance and Resistance|Non-invasive Respiratory Mechanics Assessment During Spontaneous / Assisted Breathing: The ERNI (Elastance, Resistance, Non Invasive Measurements) Study|Unknown status|Not yet recruiting|Phase 2|15|Anticipated|University of Turin, Italy||1|||f||||f||||||||||2018-05-31 21:39:38.591647|2018-05-31 21:39:38.591647
NCT01530269|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2017-04-03|2012-02-07|2012-02-09|Estimate|||||||2017-04-03|2017-04-05|Actual|April 2012||2012-04-30|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma|C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma|Recruiting||Phase 2|300|Anticipated|Phoenix Molecular Imaging||1|||f||||f||||||||No||2018-05-31 21:39:38.657254|2018-05-31 21:39:38.657254
NCT01530256|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06||2014-06-23|2018-04-16|2012-02-07|2012-02-09|Estimate||||2014-06-23|2014-06-25|Estimate|2018-04-16|2018-04-18|Actual|March 2012|Actual|2012-03-31|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ALD518-010||Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)|An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in Subjects With Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Terminated||Phase 1/Phase 2|3|Actual|Vitaeris INC||1||The trial was terminated in line with the endpoint committee charter.|f||||t||||||||||2018-05-31 21:39:38.745228|2018-05-31 21:39:38.745228
NCT01530243|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2015-01-21||2015-02-15|2012-02-06|2012-02-09|Estimate|2015-02-15|2015-03-02|Estimate||||2015-02-15|2015-03-02|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms|Phase One of Study on Urinary Stent Complications and Treatment|Completed||Phase 2/Phase 3|104|Actual|Urmia University of Medical Sciences|Applying stents with the same size and length|4|||f||||t||||||||||2018-05-31 21:39:38.839873|2018-05-31 21:39:38.839873
NCT01530230|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-10|2012-02-08|2012-02-09|Estimate|||||||2012-02-10|2012-02-13|Estimate|November 2005||2005-11-30|February 2012|2012-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||ST- Depression on Electrocardiogram During Caesarean Section in Regional Anaesthesia in Women With Preeclampsia|Randomised Study on Cardiac Effects of Oxytocin During Caesarean Section in Preeclamptic Women|Completed||N/A|25|Actual|Uppsala University Hospital||2|||f||||||||||||||2018-05-31 21:39:39.12625|2018-05-31 21:39:39.12625
NCT01530217|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-02-08|2012-02-08|2012-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Assessing of Tooth Sensitivity Using Ibuprofen Before in Office-tooth Bleaching|Assessing of Tooth Sensitivity Using Ibuprofen Before in Office-tooth Bleaching: a Randomized, Triple-blind Clinical Trial|Completed||N/A|30|Actual|Universidade Estadual de Ponta Grossa|||||f||||t||||||||||2018-05-31 21:39:39.223301|2018-05-31 21:39:39.223301
NCT01530204|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-10-26|2012-02-08|2012-02-09|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|RAPID||RAPID: Reducing Pain; Preventing Depression|RAPID: Reducing Pain; Preventing Depression|Completed||Phase 4|135|Anticipated|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:39:39.296485|2018-05-31 21:39:39.296485
NCT01530191|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2013-10-15|2012-02-06|2012-02-09|Estimate|||||||2013-10-15|2013-10-16|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Factors Affecting Perioperative Outcomes|Factors Affectign Perioperative Outcomes After Surgery for Pelvic Organ Prolapse|Withdrawn|||0|Actual|University of Oklahoma|||2|No subject accrual|f||||f||||||||||2018-05-31 21:39:39.36885|2018-05-31 21:39:39.36885
NCT01530178|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-06-22|2012-02-08|2012-02-09|Estimate|||||||2015-06-22|2015-06-23|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Sitagliptin Dose Determination Study|Sitagliptin Dose Determination Study in Type 1 Diabetes|Completed||Phase 4|7|Actual|Albert Einstein College of Medicine, Inc.||4|||f||||t||||||||||2018-05-31 21:39:39.437586|2018-05-31 21:39:39.437586
NCT01530165|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-01-03|2012-02-07|2012-02-09|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|PDPP||(Pakistan Diabetes Prevention Program PDPP)|A Translation Randodomized Trial of Culturally Specific and Cost Effective Life Style Intervention for the Prevention of Type 2 Diabetes in Pakistan|Unknown status|Active, not recruiting|N/A|20000|Anticipated|Aga Khan University||2|||f||||t||||||||||2018-05-31 21:39:39.538409|2018-05-31 21:39:39.538409
NCT01530152|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-06-18|2012-02-07|2012-02-09|Estimate|||||||2012-06-18|2012-06-19|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Method Evaluation Study of Truview Picture Capture Device(PCD) Versus MacIntosh Laryngoscope|Method Evaluation Study of Truview PCD Versus MacIntosh Laryngoscope|Completed||N/A|56|Actual|Aalborg Universitetshospital|||||f||||f||||||||||2018-05-31 21:39:39.596282|2018-05-31 21:39:39.596282
NCT01530139|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-02-25|2012-02-08|2012-02-09|Estimate|||||||2016-02-25|2016-02-26|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|Food4Me||Strategies for Personalised Nutrition|Personalised Nutrition: An Integrative Analysis of Opportunities and Challenges|Completed||N/A|1607|Actual|Newcastle University||4|||f||||f||||||||Yes|Data will be available upon request from the Project leader Professor Mike Gibney and Professor John Mathers.|2018-05-31 21:39:39.65928|2018-05-31 21:39:39.65928
NCT01530126|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-01-06|2012-02-08|2012-02-09|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2000||2000-01-31|January 2016|2016-01-31|January 2007|Actual|2007-01-31|January 2005|Actual|2005-01-31||Interventional|||Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain|Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain|Completed||N/A|180|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 21:39:40.827027|2018-05-31 21:39:40.827027
NCT01530113|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-02-08|2012-02-08|2012-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Observational|CSA-V-LD||Childhood Sexual Abuse, Vaginismus and Labor Dystocia|Childhood Sexual Abuse, Vaginismus and Labor Dystocia: Towards a Theoretical Model|Unknown status|Not yet recruiting||2000|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-05-31 21:39:40.905748|2018-05-31 21:39:40.905748
NCT01530100|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2014-12-01|2012-02-08|2012-02-09|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Observational|||Lower Laser Therapy in Orthognathics Surgery|Lower Laser Therapy in Orthognathics Surgery - Double Blind Study.|Completed|||10|Actual|Universidade Federal de Goias|||||f||||f||||||||||2018-05-31 21:39:40.976491|2018-05-31 21:39:40.976491
NCT01530087|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|2015-09-22||2016-02-22|2012-02-08|2012-02-09|Estimate|2016-02-22|2016-03-22|Estimate||||2016-02-22|2016-03-22|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Preliminary Evaluation of CASTLE Barrier Prototype UK|Peristomal Skin Irritation: A Preliminary Evaluation of the CASTLE Barrier Prototype for People With Intestinal Stomas|Terminated||N/A|3|Actual|Hollister Incorporated||1||Inability of site to recruit/enroll target population|f||||f||||||||||2018-05-31 21:39:41.046094|2018-05-31 21:39:41.046094
NCT01530074|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-08|2012-02-08|2012-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Quantitative Sensory Testing of the Lower Lip After Inferior Alveolar Nerve Block, and Evaluation of the Role of the Contra-lateral Inferior Alveolar Nerve||Unknown status|Not yet recruiting|N/A|60|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 21:39:41.195354|2018-05-31 21:39:41.195354
NCT01530048|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-10-14|2012-02-07|2012-02-09|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)|A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial, Assessing the Bioequivalence Between Insulin Aspart 100 U/mL and Insulin Aspart 200 U/mL in Healthy Individuals|Completed||Phase 1|34|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:39:41.346212|2018-05-31 21:39:41.346212
NCT01530035|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-05-04|2012-02-08|2012-02-09|Estimate|||||||2017-05-04|2017-05-05|Actual|March 2011||2011-03-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Cardiovascular and Muscular Adaptations to Recreational Soccer and Strength Training in Elderly Healthy 65-75-year-old Men|Cardiovascular and Muscular Adaptations to Recreational Soccer and Strength Training in Elderly Healthy 65-75-year-old Men|Completed||N/A|41|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 21:39:41.539173|2018-05-31 21:39:41.539173
NCT01530022|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2014-01-23|2012-02-08|2012-02-09|Estimate|||||||2014-01-23|2014-01-24|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects|A Multicenter, Randomized, Double-blind, Double-dummy, 2-period Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects|Completed||Phase 1|60|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:39:41.626064|2018-05-31 21:39:41.626064
NCT01530009|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-07-24|2012-02-07|2012-02-09|Estimate|||||||2017-07-24|2017-07-26|Actual|January 2012||2012-01-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children|The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children|Active, not recruiting||N/A|26|Anticipated|Nationwide Children's Hospital||2|||f||||t||||||||Undecided||2018-05-31 21:39:41.735292|2018-05-31 21:39:41.735292
NCT01529996|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-09-14|2012-02-08|2012-02-09|Estimate|||||||2012-09-14|2012-09-17|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness|Comparison of the Efficacy Between Pulsed Dye Laser (PDL) and the Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness: A Pilot, Prospective Randomized Trial.|Completed||N/A|16|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:39:41.841815|2018-05-31 21:39:41.841815
NCT01529983|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2018-02-20|2012-02-07|2012-02-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2012||2012-02-29|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fractional Laser vs. Ultrasound for Periorbital Wrinkles|A Comparison of 1550-nm Fractional Photothermolysis Versus Intense Focused Ultrasound for Treatment of Periorbital Wrinkles: A Pilot, Prospective Randomized Control Trial|Active, not recruiting||N/A|20|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 21:39:41.916134|2018-05-31 21:39:41.916134
NCT01529970|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-08|2012-02-08|2012-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|January 2012||2012-01-31|February 2012|2012-02-29||||||||Observational|||Genetic Study in Young Onset Parkinson's Disease||Unknown status|Active, not recruiting||60|Anticipated|China Medical University Hospital|||2||f||||||||||||||2018-05-31 21:39:42.001364|2018-05-31 21:39:42.001364
NCT01529957|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-16|2012-02-08|2012-02-09|Estimate|||||||2012-02-16|2012-02-20|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion|A Phase I Clinical Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion|Completed||Phase 1|176|Actual|TaiGen Biotechnology Co., Ltd.||10|||f||||f||||||||||2018-05-31 21:39:42.075824|2018-05-31 21:39:42.075824
NCT01529944|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2014-04-29|2012-02-08|2012-02-09|Estimate|||||||2014-04-29|2014-04-30|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658|Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial|Completed||Phase 3|22|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:39:42.193879|2018-05-31 21:39:42.193879
NCT01529931|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-10-13|2012-02-06|2012-02-09|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|OHR-8-FU-1Y||Long Term Efficiency of the Hair2Go Device|Follow Up Study: The Effect Of Hair2Go Maintenance Treatments on Long Term Hair Removal|Completed||N/A|5|Actual|Syneron Medical||1|||f||||f||||||||No|Only 5 subjects enrolled into this protocol. Data was combined with OHR2-1Y protocol and reported under that study.|2018-05-31 21:39:42.272674|2018-05-31 21:39:42.272674
NCT01529918|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-08|2012-02-08|2012-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Detecting Diabetes Sooner With a Risk Survey for the Family Doctor:Comparing Internet and Traditional Methods of Communication for Patients and Doctors|e-Diabetes:Uptake, Patient Preferences and Clinical Outcomes Regarding Self-screening and Clinical Follow-up Using Web-based Technologies in a Large Team-based Primary Care Setting|Unknown status|Active, not recruiting|N/A|2000|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 21:39:42.34591|2018-05-31 21:39:42.34591
NCT01529905|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2012-02-08|2012-02-08|2012-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|June 1999||1999-06-30|June 2005|2005-06-30|June 2014|Anticipated|2014-06-30|September 2009|Actual|2009-09-30||Observational|||Longitudinal Study of People Presenting for First Treatment of a Mood Disorder|Longitudinal Study of Individuals Presenting With a First Treated Episode of Depression of Mania (First Episode Project)|Unknown status|Recruiting||200|Anticipated|McMaster University|||||f||||||||||||||2018-05-31 21:39:42.408692|2018-05-31 21:39:42.408692
NCT01529892|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-05-29|2012-02-08|2012-02-09|Estimate|||||||2013-05-29|2013-05-31|Estimate||||May 2013|2013-05-31||||||||Interventional|||The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine|An Open-Label Study to Evaluate the Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine in Healthy Adults|Withdrawn||Phase 4|0|Actual|California Pacific Medical Center Research Institute||2|||f||||t||||||||||2018-05-31 21:39:42.478164|2018-05-31 21:39:42.478164
NCT01529879|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-03-30|2012-02-08|2012-02-09|Estimate|||||||2017-03-30|2017-03-31|Actual|August 2011||2011-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Polaris||Assessment of the Effect of an Implant System With a Novel Abutment Attachment Design on Crestal Bone Preservation|A Prospective Randomized-Controlled Evaluation of an Implant System With a Novel Abutment Attachment Design for the Preservation of Crestal Bone|Completed||N/A|49|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 21:39:42.542319|2018-05-31 21:39:42.542319
NCT01529866|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-03-30|2012-02-08|2012-02-09|Estimate|||||||2017-03-30|2017-03-31|Actual|August 2011||2011-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Bridge||Study of the Integration Success of an Implant System With a Novel Abutment Attachment Design in Immediate Loading Cases|A Prospective Randomized-controlled Study of the Integration Success Rate of an Implant System With a Novel Abutment Attachment in Cases Loaded Immediately|Completed||N/A|60|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 21:39:42.711392|2018-05-31 21:39:42.711392
NCT01529853|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06||2016-01-22|2016-01-22|2012-02-08|2012-02-09|Estimate||||2016-01-22|2016-02-15|Estimate|2016-01-22|2016-02-15|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)|Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Repeated Doses of SAR156597 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 1/Phase 2|24|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 21:39:42.806317|2018-05-31 21:39:42.806317
NCT01529840|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2017-01-17|2012-02-08|2012-02-09|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 1990||1990-06-30|January 2017|2017-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome|Norditropin Treatment in Subjects With Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit|Completed||Phase 3|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:39:42.929883|2018-05-31 21:39:42.929883
NCT01529827|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2017-06-30||2017-09-08|2012-02-08|2012-02-09|Estimate|2017-06-30|2017-07-02|Actual||||2017-09-08|2017-09-12|Actual|February 28, 2012|Actual|2012-02-28|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|May 28, 2015|Actual|2015-05-28||Interventional||All treated and eligible patients|Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation|Active, not recruiting||Phase 2|94|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 21:39:43.067417|2018-05-31 21:39:43.067417
NCT01529814|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-03-30|2012-02-08|2012-02-09|Estimate|||||||2017-03-30|2017-03-31|Actual|July 2011||2011-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Comet||Assessment of Integration Success of an Implant System With a Novel Abutment Attachment Design in Early Loaded Cases|A Prospective Randomized-controlled Study of the Integration Success Rate of an Implant System With a Novel Abutment Attachment in Cases Loaded Early|Completed||N/A|49|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 21:39:43.411847|2018-05-31 21:39:43.411847
NCT01529801|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-03-30|2012-02-08|2012-02-09|Estimate|||||||2017-03-30|2017-03-31|Actual|February 2011||2011-02-28|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|Luna||Assessment of the Effect of a Novel Surface Roughness Treatment on Dental Implants on Integration Success|A Prospective Randomized-controlled Study of the Effect of Surface Topographies on Implant Integration Rates and Clinical Success|Completed||N/A|80|Actual|Zimmer Biomet||3|||f||||f||||||||No||2018-05-31 21:39:43.507978|2018-05-31 21:39:43.507978
NCT01529788|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-09-29|2012-02-08|2012-02-09|Estimate|||||||2014-09-29|2014-09-30|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2012|Actual|2012-09-30||Interventional|||Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study|"A Double Blinded Randomized Controlled Trial to Compare the Efficacy, Time to Onset, and Duration of Two Botulinum Type A Exotoxins (Onabotulinum Toxin A and Abobotulinum Toxin A) in the Treatment of Crow's Feet."|Completed||Phase 4|90|Actual|The Maas Clinic||1|||f||||f||||||||||2018-05-31 21:39:43.597312|2018-05-31 21:39:43.597312
NCT01529775|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-03-28|2012-02-08|2012-02-09|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2010||2010-11-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Bolivar||Randomized Study of Osseotite Certain Tapered Prevails vs. Osseotite Certain Tapered|A Prospective Randomized-controlled Evaluation of the Osseotite Certain Tapered Prevail Implant for the Preservation of Crestal Bone|Completed||N/A|92|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 21:39:43.698879|2018-05-31 21:39:43.698879
NCT01529762|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-03-20|2012-02-08|2012-02-09|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|Carrera||Observational Study of Osseotite Certain Tapered Implants in Immediate Loading Cases|A Prospective, Observational Study of Immediate Loading Cases Using Osseotite Certain Tapered Implants|Completed|||47|Actual|Zimmer Biomet|||1||f||||f||||||||No||2018-05-31 21:39:43.790804|2018-05-31 21:39:43.790804
NCT01529749|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2016-02-18|2012-02-08|2012-02-09|Estimate|||||||2016-02-18|2016-02-19|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|January 2015|Actual|2015-01-31|March 2012|Actual|2012-03-31||Interventional|||Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated|Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation|Completed||Phase 4|48|Actual|Hospital Clinic of Barcelona||4|||f||||f||||||||||2018-05-31 21:39:43.861398|2018-05-31 21:39:43.861398
NCT01529736|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2017-03-20|2012-02-07|2012-02-09|Estimate|||||||2017-03-20|2017-03-21|Actual|December 2010||2010-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Pegasus||Randomized Study of Integration Success of Osseotite Dental Implants Placed Using Different Insertion Procedures|Prospective Randomized-controlled Study of the Integration Success of Osseotite Implants Placed With Different Insertion Procedures|Completed||N/A|60|Actual|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-05-31 21:39:43.939122|2018-05-31 21:39:43.939122
NCT01529723|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-04-07|2012-02-08|2012-02-09|Estimate|||||||2016-04-07|2016-04-11|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|||Validity of a New Stroke Dysphagia Screening Tool|Validity of a New Stroke Dysphagia Screening Tool|Withdrawn|||0|Actual|Rhode Island Hospital|||||f||||f||||||||||2018-05-31 21:39:44.007833|2018-05-31 21:39:44.007833
NCT01529710|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-02-19|2012-02-08|2012-02-09|Estimate|||||||2015-02-19|2015-02-20|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PHAR0211||Safety and Efficacy of Mirazid for Schistosomiasis Treatment|Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study|Completed||Phase 3|200|Actual|Pharco Pharmaceuticals||2|||f||||t||||||||||2018-05-31 21:39:44.061332|2018-05-31 21:39:44.061332
NCT01529697|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-01-11|2012-02-08|2012-02-09|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|INCA||Prospective Study of the Feedback From an Adherence Monitor on Asthma Control|Prospective Study of the Feedback From an Adherence Monitor on Asthma Control|Completed||N/A|220|Actual|Beaumont Hospital||2|||f||||f||||||||||2018-05-31 21:39:44.131062|2018-05-31 21:39:44.131062
NCT01529684|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-04-12|2012-02-08|2012-02-09|Estimate|||||||2013-04-12|2013-04-15|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism, and Excretion of 14C-OSI-906 in Subjects With Advanced Solid Tumors With an Optional Treatment Phase|Completed||Phase 1|5|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:39:44.196041|2018-05-31 21:39:44.196041
NCT01529671|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-12-10|2012-02-06|2012-02-09|Estimate|||||||2012-12-10|2012-12-12|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee|An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of Pf-05089771 In Healthy Subjects And In Subjects With Osteoarthritis Of The Knee|Completed||Phase 1|80|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:39:44.262272|2018-05-31 21:39:44.262272
NCT01529658|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-10-25|2012-02-08|2012-02-09|Estimate|||||||2016-10-25|2016-10-27|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Renal Hypothermia During Partial Nephrectomy|A Randomized Controlled Trial of Renal Hypothermia During Partial Nephrectomy|Active, not recruiting||N/A|184|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||No||2018-05-31 21:39:44.432417|2018-05-31 21:39:44.432417
NCT01529645|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2014-04-30||2016-03-03|2012-02-08|2012-02-09|Estimate|2014-09-16|2014-09-18|Estimate||||2016-03-03|2016-04-04|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional||Analysis was done on the all enrolled set, ie, all subjects who have signed an informed consent, undergone screening procedures and were randomized.|Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years|Phase I, Randomized, Controlled, Observer-Blind, Dose-Ranging Study of Acellular Pertussis and Tetanus-Diptheria-Acellular Pertussis Booster Vaccine in Adults Ages 18 to 40 Years.|Completed||Phase 1|420|Actual|Novartis||10|||f||||||||||||||2018-05-31 21:39:44.584437|2018-05-31 21:39:44.584437
NCT01529632|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2013-12-02||2014-01-16|2012-02-08|2012-02-09|Estimate|2014-01-16|2014-02-12|Estimate||||2014-01-16|2014-02-12|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BEACON||Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Study to Compare the Efficacy and Safety of Once Daily QVA149 Versus the Once Daily Concurrent Administration of QAB149 Plus NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|193|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:39:46.280678|2018-05-31 21:39:46.280678
NCT01529619|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-11-16|2012-02-08|2012-02-09|Estimate|||||||2016-11-16|2016-11-18|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors|A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-23) Switched From Cholinesterase Inhibitors (Donepezil, Galantamine)|Completed||Phase 4|52|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:39:46.749971|2018-05-31 21:39:46.749971
NCT01529606|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2014-09-23|2012-02-08|2012-02-09|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Cold Plasma for Dental Restoration and Caries Prevention|Development of a Miniature Plasma Brush for Dental Clinical Applications|Completed||Phase 1/Phase 2|102|Actual|Nanova, Inc||2|||f||||t||||||||||2018-05-31 21:39:46.876689|2018-05-31 21:39:46.876689
NCT01529593|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2018-01-05|2012-02-08|2012-02-09|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Temsirolimus in Combination With Metformin in Patients With Advanced Cancers|Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers|Recruiting||Phase 1|104|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:39:46.972039|2018-05-31 21:39:46.972039
NCT01529580|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2018-05-21|2012-02-08|2012-02-09|Estimate|||||||2018-05-21|2018-05-22|Actual|January 2012||2012-01-31|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||School-Age Children With Autism With Limited Expressive Language Skills|School-Age Children With Autism With Limited Expressive Language Skills: An Intervention Study|Completed||N/A|13|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||3|||f||||f||||||||||2018-05-31 21:39:47.056051|2018-05-31 21:39:47.056051
NCT01529567|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2013-02-14|2012-02-08|2012-02-09|Estimate|||||||2013-02-14|2013-02-15|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cognitive Behavioral Therapy With Our Without Exposure Therapy for Irritable Bowel Syndrome||Completed||N/A|311|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:39:47.125602|2018-05-31 21:39:47.125602
NCT01529554|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2018-02-05|2012-02-08|2012-02-09|Estimate|||||||2018-02-05|2018-02-06|Actual|January 8, 2015|Actual|2015-01-08|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CLEVER-ACS||Controlled Level EVERolimus in Acute Coronary Syndromes|Phase I-II Randomized Prospective Double-blind Multi-center Trial on the Effects of a Short Course of Oral Everolimus on Infarct Size, Left Ventricular Remodeling and Inflammation in Patients With Acute ST-Elevation Myocardial Infarction|Recruiting||Phase 1/Phase 2|150|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 21:39:47.186903|2018-05-31 21:39:47.186903
NCT01529541|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2014-05-12|2012-02-08|2012-02-09|Estimate|||||||2014-05-12|2014-05-14|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|CWP-DIANA-302||Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone|A Multicenter, Randomized, Double-blind, Double Dummy, Active-controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate the Efficacy and Safety of CWP-0403 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DM Insufficiently Controlled With Metformin Alone|Completed||Phase 3|200|Anticipated|JW Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:39:47.283766|2018-05-31 21:39:47.283766
NCT01529528|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2013-01-02|2012-02-08|2012-02-09|Estimate|||||||2013-01-02|2013-01-04|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|CWP-DIANA-301||A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients|A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients|Completed||Phase 3|117|Actual|JW Pharmaceutical||3|||f||||f||||||||||2018-05-31 21:39:47.356026|2018-05-31 21:39:47.356026
NCT01529515|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2015-04-07||2016-05-02|2012-02-08|2012-02-09|Estimate|2015-05-18|2015-06-18|Estimate||||2016-05-02|2016-05-11|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia|A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia|Completed||Phase 3|509|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 21:39:47.447613|2018-05-31 21:39:47.447613
NCT01529502|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2016-10-26||2017-04-17|2012-02-07|2012-02-08|Estimate|2017-02-08|2017-03-29|Actual||||2017-04-17|2017-05-22|Actual|March 2012||2012-03-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting|Effects of Stored Red Blood Cell Transfusion in Overweight Subjects With Endothelial Dysfunction: Influence of Inhaled Nitric Oxide (iNO)|Completed||Phase 2|14|Actual|Massachusetts General Hospital||3|||f||||t||||||||No||2018-05-31 21:39:48.232767|2018-05-31 21:39:48.232767
NCT01529489|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-06|2012-02-06|2012-02-08|Estimate|||||||2012-02-06|2012-02-08|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|BVPS-123||Effect of Two Physical Training Programs on Oxygen Uptake and Heart Rate On-kinetics in Patients COPD|Effect of the Combined (Aerobic/Resisted) and Interval Physical Training on Oxygen Uptake and Heart Rate On-kinetics Responses in Patients With Moderate to Very Severe COPD: Double-blind, Randomized, Controlled Trial|Completed||N/A|40|Actual|Universidade Federal de Sao Carlos||4|||f||||f||||||||||2018-05-31 21:39:48.604535|2018-05-31 21:39:48.604535
NCT01529476|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-06-17|2012-02-06|2012-02-08|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP|A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)|Completed||Phase 3|540|Actual|TaiGen Biotechnology Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:39:48.779327|2018-05-31 21:39:48.779327
NCT01529463|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-02-28|2012-02-06|2012-02-08|Estimate|||||||2013-02-28|2013-03-01|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Observational|||Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients|Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients|Completed|||21|Actual|Saint Francis Care|||1||f||||f||||||||||2018-05-31 21:39:48.947339|2018-05-31 21:39:48.947339
NCT01529450|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2016-03-11||2016-11-23|2012-02-06|2012-02-08|Estimate|2016-09-14|2016-11-02|Estimate||||2016-11-23|2017-01-16|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Participants with evaluable data are included for Baseline Characteristics|Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors|A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothened Inhibitor(s)|Completed||N/A|11|Actual|Stanford University||2|||f||||t||||||||No||2018-05-31 21:39:49.028269|2018-05-31 21:39:49.028269
NCT01529437|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-11-24|2012-02-06|2012-02-08|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2005||2005-01-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|SLIT||Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies|Phase 1 Single Center, Randomized, Controlled Study Using Sublingual Immunotherapy for Timothy Grass and Dust Mite Allergies|Completed||Phase 1|31|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 21:39:49.342483|2018-05-31 21:39:49.342483
NCT01529424|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06||2016-06-14|2016-06-14|2012-02-07|2012-02-08|Estimate||||2016-06-14|2016-06-16|Estimate|2016-06-14|2016-06-16|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia|Completed||Phase 2|89|Actual|Ionis Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-05-31 21:39:49.419177|2018-05-31 21:39:49.419177
NCT01529411|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2014-12-17|2012-02-07|2012-02-08|Estimate|||||||2014-12-17|2014-12-18|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|December 2014|Actual|2014-12-31|February 2013|Actual|2013-02-28||Interventional|MAJA||Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer|Randomized Phase II Study of Vinflunine as Maintenance Monotherapy in Patients With Advanced or Metastatic Urothelial Cancer That Obtains Clinical Benefit of the First Line With Cisplatin-gemcitabine Combination|Completed||Phase 2|86|Actual|Spanish Oncology Genito-Urinary Group||2|||f||||f||||||||||2018-05-31 21:39:49.515108|2018-05-31 21:39:49.515108
NCT01529398|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-08|2012-02-06|2012-02-08|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Sensorimotor Training Versus Resistance Training in Patients With Knee Osteoarthritis|Efficacy of a Sensorimotor Training in Patients With Knee Osteoarthritis: a Randomized Clinical Trial|Completed||Phase 2/Phase 3|96|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 21:39:49.627649|2018-05-31 21:39:49.627649
NCT01529385|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|2016-04-07||2016-05-13|2012-02-07|2012-02-08|Estimate|2016-05-13|2016-06-22|Estimate||||2016-05-13|2016-06-22|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Mild Compression Sock for Control of Lower Extremity Edema in Individuals With Diabetes|Efficacy of a Mild Compression Diabetic Sock Versus A Non- Compression Diabetic Sock in the Control of Lower Extremity Edema in Patients With Diabetes: A Randomized Controlled Trial|Completed||N/A|80|Actual|Rosalind Franklin University of Medicine and Science||2|||f||||f||||||||No||2018-05-31 21:39:49.723857|2018-05-31 21:39:49.723857
NCT01529372|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-04-04|2012-02-06|2012-02-08|Estimate|||||||2016-04-04|2016-04-06|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|February 2015|Actual|2015-02-28||Interventional|REALISE||REnAL denervatIon by ultraSound Transcatheter Emission|REnAL denervatIon by ultraSound Transcatheter Emission|Unknown status|Active, not recruiting|N/A|20|Actual|ReCor Medical, Inc.||1|||f||||f||||||||||2018-05-31 21:39:50.204336|2018-05-31 21:39:50.204336
NCT01529359|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-02-06|2012-02-06|2012-02-08|Estimate|||||||2012-02-06|2012-02-08|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Irritable Bowel Syndrome and Lactibiane Tolerance|Effect of Lactibiane Tolerance on Symptoms Severity of Irritable Bowel Syndrome|Unknown status|Recruiting|Phase 3|94|Anticipated|Pileje||2|||f||||f||||||||||2018-05-31 21:39:50.428036|2018-05-31 21:39:50.428036
NCT01529346|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13||2018-02-05|2018-02-05|2012-02-06|2012-02-08|Estimate||||2018-02-05|2018-02-09|Actual|2018-02-05|2018-02-09|Actual|December 2011||2011-12-31|February 2018|2018-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy Of PF-05089771 In Treating Postoperative Dental Pain|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study Assessing The Efficacy Of Single Doses Of PF-05089771 For The Treatment Of Postoperative Dental Pain Using Ibuprofen 400 mg As Positive Control|Completed||Phase 2|235|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:39:50.539976|2018-05-31 21:39:50.539976
NCT01529333|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-06|2012-02-06|2012-02-08|Estimate|||||||2012-02-06|2012-02-08|Estimate|May 2012||2012-05-31|February 2012|2012-02-29|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Middle-Ear Implant With MET V Transducer (Aka MET V System)|Middle Ear Implant With MET V for Mixed Hearing Loss|Unknown status|Not yet recruiting|N/A|130|Anticipated|Otologics LLC|||||f||||f||||||||||2018-05-31 21:39:50.643367|2018-05-31 21:39:50.643367
NCT01529320|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2016-05-11|2012-02-06|2012-02-08|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers|Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study).|Completed||Phase 1|18|Actual|Fundacion IMIM||1|||f||||f||||||||||2018-05-31 21:39:50.708012|2018-05-31 21:39:50.708012
NCT01529307|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-12-10|2012-02-06|2012-02-08|Estimate|||||||2012-12-10|2012-12-12|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||First in Human Trial of TAS266 in Patients With Advanced Solid Tumors|A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors|Terminated||Phase 1|6|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:39:50.770096|2018-05-31 21:39:50.770096
NCT01529294|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2013-03-13|2012-02-06|2012-02-08|Estimate|||||||2013-03-13|2013-03-14|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers|Open-label, Single-dose, Parallel-group Study to Compare the PKs of Iloperidone in Subjects With Mild or Moderate Hepatic Impairment With That in Matched Healthy Control Subjects|Completed||Phase 1|90|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:39:50.841104|2018-05-31 21:39:50.841104
NCT01529281|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-06|2012-02-06|2012-02-08|Estimate|||||||2012-02-06|2012-02-08|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids|Exercise-induced Muscle Damage is Reduced in Resistance Trained Athletes by Branch Chain Amino Acids|Completed||N/A|12|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 21:39:50.906833|2018-05-31 21:39:50.906833
NCT01529268|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2017-04-10||2017-08-02|2012-02-06|2012-02-08|Estimate|2017-08-02|2017-09-05|Actual||||2017-08-02|2017-09-05|Actual|June 2012||2012-06-30|August 2017|2017-08-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|CyNCh||Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children|Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)|Completed||Phase 2/Phase 3|169|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||Yes|Public use database deposited with the NIDDK Central Repository|2018-05-31 21:39:51.087148|2018-05-31 21:39:51.087148
NCT01529255|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2014-06-17|2012-02-06|2012-02-08|Estimate|||||||2014-06-17|2014-06-19|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|EFFORT-Ex||EFFORT Extension Study|A 3-year, Open-label, Multi-center Extension Trial of Telbivudine Therapy for Patients Previously Treated in EFFORT Clinical Trial|Unknown status|Active, not recruiting|Phase 4|576|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 21:39:52.116095|2018-05-31 21:39:52.116095
NCT01529242|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-02-15|2012-02-06|2012-02-08|Estimate|||||||2017-02-15|2017-02-16|Actual|February 2014|Actual|2014-02-28|February 2017|2017-02-28|October 20, 2016|Actual|2016-10-20|August 2016|Actual|2016-08-31||Interventional|||Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment|A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Acute Cutaneous Rash|Terminated||Phase 3|17|Actual|EMS||2||By sponsor decision due to difficulty of recruitment|f||||t|f|f||||||||2018-05-31 21:39:52.21508|2018-05-31 21:39:52.21508
NCT01529229|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-01-14|2012-02-06|2012-02-08|Estimate|||||||2015-01-14|2015-01-15|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment|A Double-blind, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Children (2-12 Years) With Moderate - Severe Persistent Allergic Rhinitis|Completed||Phase 3|210|Actual|EMS||2|||f||||t||||||||||2018-05-31 21:39:52.291095|2018-05-31 21:39:52.291095
NCT01529216|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-03-15|2012-02-06|2012-02-08|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|RUBY||Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus|An Advanced Configuration (The Third Generation) of the DIAMOND System for the Treatment of T2DM Patients - A Randomized, Double Blind Study|Completed||N/A|2|Actual|Metacure||2|||f||||f||||||||||2018-05-31 21:39:52.380093|2018-05-31 21:39:52.380093
NCT01529203|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2014-03-24||2014-09-16|2012-02-07|2012-02-08|Estimate|2014-03-24|2014-04-25|Estimate||||2014-09-16|2014-09-29|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|FIRST||Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range|Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range|Completed||Phase 3|60|Actual|Galderma||1|||f||||f||||||||||2018-05-31 21:39:52.466684|2018-05-31 21:39:52.466684
NCT01529190|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pregabalin on Interleukin-6 Levels in Living Donor Kidney|Effect of Preoperative Pregabalin on Pain Intensity and Interleukin-6 Levels in Living Donor Kidney|Completed||Phase 2|40|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:39:52.643542|2018-05-31 21:39:52.643542
NCT01529177|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2015-08-05|2012-02-07|2012-02-08|Estimate|||||||2015-08-05|2015-08-07|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|||Metformin for the Treatment of Unexplained Oligozspermia|Metformin for the Treatment of Unexplained Oligozspermia and Azoospermia|Unknown status|Recruiting|Phase 4|600|Anticipated|The Egyptian IVF-ET Center||2|||f||||t||||||||||2018-05-31 21:39:52.71287|2018-05-31 21:39:52.71287
NCT01529164|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2013-11-26|2012-02-07|2012-02-08|Estimate|||||||2013-11-26|2013-11-27|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer|Phase II Study of Recombinant Endostatin Combined With Modified FOLFOX6 in Advanced Colorectal Cancer|Unknown status|Recruiting|Phase 2|51|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:39:52.817563|2018-05-31 21:39:52.817563
NCT01529151|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-06-08|2012-02-03|2012-02-08|Estimate|||||||2015-06-08|2015-06-10|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effectiveness of Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT) in Individuals With Vertigo|Effectiveness of Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT) Alone or in Combination on Balance and Visual Function in Individuals With Vertigo and Somatic Dysfunction|Completed||N/A|26|Actual|Western University of Health Sciences||4|||f||||t||||||||||2018-05-31 21:39:53.017631|2018-05-31 21:39:53.017631
NCT01529138|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-04-10|2012-02-06|2012-02-08|Estimate|||||||2015-04-10|2015-04-13|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of Axitinib and Temsirolimus in Solid Tumors|Phase I Study of Axitinib and Temsirolimus in Solid Tumors|Completed||Phase 1|13|Actual|Emory University||2|||f||||t||||||||||2018-05-31 21:39:53.112216|2018-05-31 21:39:53.112216
NCT01529125|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2014-01-22|2012-02-07|2012-02-08|Estimate|||||||2014-01-22|2014-01-23|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|ARMAM||Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV|ART Pharmacokinetics, Mitochondrial Integrity, and Antioxidant Capacity in Severely Malnourished HIV-infected Malawian Children|Completed|||42|Actual|Washington University School of Medicine|||3||f||||f||||||||||2018-05-31 21:39:53.185558|2018-05-31 21:39:53.185558
NCT01529112|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2016-02-17|2015-10-05|2017-08-28|2012-02-06|2012-02-08|Estimate|2016-02-17|2016-03-15|Estimate|2016-02-17|2016-02-18|Estimate|2017-08-28|2017-09-26|Actual|November 2011|Actual|2011-11-30|August 2017|2017-08-31|June 27, 2015|Actual|2015-06-27|January 21, 2014|Actual|2014-01-21||Interventional|||A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) Versus BSC Alone in Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Who Have Failed at Least Two Systemic Anticancer Regimens|Completed||Phase 2|135|Actual|Eisai Inc.||2|||f||||t||||||||||2018-05-31 21:39:53.303827|2018-05-31 21:39:53.303827
NCT01529099|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-05-27|2012-02-06|2012-02-08|Estimate|||||||2016-05-27|2016-05-30|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|||Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM|A Prospective, Non-comparative, Single Centre Study to Determine the Performance & Survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM.|Completed||Phase 4|64|Actual|DePuy International||1|||f||||f||||||||||2018-05-31 21:39:54.313592|2018-05-31 21:39:54.313592
NCT01529086|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-08-22|2012-02-07|2012-02-08|Estimate|||||||2016-08-22|2016-08-23|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||For Cause Prostate Biopsy in REDUCE Population Trial|Determining the Likelihood of Prostate Cancer Detection in Men Taking Dutasteride When Biopsy is Performed 'for Cause'.|Completed|||6608|Actual|The Cleveland Clinic|||2||f||||f||||||||No||2018-05-31 21:39:54.456873|2018-05-31 21:39:54.456873
NCT01529073|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2015-01-13|2012-02-06|2012-02-08|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection|Phase II Clinical Trial to Evaluate the Antiviral Activity of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in Individuals With Chronic Hepatitis Due to HCV Genotype 4 and Coinfected by HIV|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|Andaluz Health Service||1|||f||||t||||||||||2018-05-31 21:39:54.557109|2018-05-31 21:39:54.557109
NCT01529060|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-01-31|2012-02-07|2012-02-08|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|MSUD||Phenylbutyrate Therapy for Maple Syrup Urine Disease|A Double-Blind, Randomized, Placebo-Controlled Trial of Phenylbutyrate in the Treatment of Maple Syrup Urine Disease|Active, not recruiting||Phase 2/Phase 3|20|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 21:39:54.657376|2018-05-31 21:39:54.657376
NCT01529047|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2013-12-10|2012-02-07|2012-02-08|Estimate|||||||2013-12-10|2013-12-11|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling|RTC of Web Versus In-Person SUD and Comorbidity Treatment|Unknown status|Enrolling by invitation|Phase 2|375|Anticipated|University of Washington||3|||f||||t||||||||||2018-05-31 21:39:54.753935|2018-05-31 21:39:54.753935
NCT01529034|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03||2018-03-15|2018-03-15|2012-02-07|2012-02-08|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|July 2012|Actual|2012-07-31|March 2018|2018-03-31||||April 2017|Actual|2017-04-30||Interventional|||Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters|An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters|Terminated||Phase 3|175|Actual|Proximagen, LLC||1|||f||||||||||||||2018-05-31 21:39:54.8743|2018-05-31 21:39:54.8743
NCT01529021|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Reducing Children's Distress Towards Flu Vaccinations||Completed|||57|Actual|University of Calgary|||2||f||||t||||||||||2018-05-31 21:39:55.060947|2018-05-31 21:39:55.060947
NCT01528839|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|March 2004||2004-03-31|February 2012|2012-02-29|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression|Supraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled Study.|Completed||Phase 2/Phase 3|74|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 21:39:58.136288|2018-05-31 21:39:58.136288
NCT01529008|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-10-19|2012-02-06|2012-02-08|Estimate|||||||2017-10-19|2017-10-20|Actual|November 2011||2011-11-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head|Phase 3, Pivotal, Multicentre, Randomised, Double-blind Controlled Study to Evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head|Recruiting||Phase 3|118|Anticipated|Bone Therapeutics S.A||2|||f||||t||||||||||2018-05-31 21:39:55.134801|2018-05-31 21:39:55.134801
NCT01528995|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-06-20|2012-02-07|2012-02-08|Estimate|||||||2016-06-20|2016-06-21|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|KISS||Treatment of Fecal Incontinence After Obstetric Anal Sphincter Injuries|A Blinded Randomized Controlled Clinical Trial Comparing Sacral Nerve Modulation and Anal Bulking Injections as Treatment for Fecal Incontinence After Obstetric Anal Sphincter Injuries (OASIS).|Completed||N/A|68|Actual|University Hospital of North Norway||3|||f||||t||||||||||2018-05-31 21:39:55.399565|2018-05-31 21:39:55.399565
NCT01528982|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-10-24|2012-02-07|2012-02-08|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2008||2008-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Susceptibility to Pathological Gambling|Susceptibility to Pathological Gambling|Active, not recruiting||N/A|588|Actual|University of Chicago||3|||f||||t||||||||||2018-05-31 21:39:55.505173|2018-05-31 21:39:55.505173
NCT01528969|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-03-30||2015-07-14|2012-02-05|2012-02-08|Estimate|2015-07-14|2015-08-10|Estimate||||2015-07-14|2015-08-10|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Effect of Xylitol on Oral Microbiota in Children|The Effect of the Frequent Xylitol Chewing Gum Use on the Oral Microbiota in Children With High MS Counts|Completed||Phase 1/Phase 2|122|Actual|Kuwait University||2|||f||||f||||||||||2018-05-31 21:39:55.60153|2018-05-31 21:39:55.60153
NCT01528956|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2016-05-17|2012-02-05|2012-02-08|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2012||2012-02-29|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Genes in Samples From Younger Patients With Adrenocortical Tumor|Using New Approaches for Genomics Studies in Pediatric Adrenocortical Tumors: Whole Genome Sequencing; Deep Sequencing; miRNA; methDNA and SNP 6.0|Completed|||10|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:39:55.861241|2018-05-31 21:39:55.861241
NCT01528943|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|March 2012||2012-03-31|February 2012|2012-02-29||||March 2013|Anticipated|2013-03-31||Interventional|||Effect of Prostacyclin on Haemostasis in Abdominal Surgery|The Effect of Prostacyclin on Haemostasis as Evaluated by Thrombelastography and Endothelial Markers in Patients Undergoing Major Abdominal Surgery. A Pilot Study|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 21:39:55.914526|2018-05-31 21:39:55.914526
NCT01528930|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-12-14|2012-02-05|2012-02-08|Estimate|||||||2012-12-14|2012-12-17|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease|Inhaled Amikacin for Treatment of Intractable Nontuberculous Mycobacterial Lung Disease|Withdrawn||Phase 2|0|Actual|Samsung Medical Center||1||"Although this study was approved at the Institutional Review Board, Korea Food & Drug~   Administration (KFDA) did not approve this study due to safety concern."|f||||f||||||||||2018-05-31 21:39:55.976374|2018-05-31 21:39:55.976374
NCT01528917|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-07-19|2012-02-07|2012-02-08|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Observational|||An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype|An Observational Study of the Clinical Characteristics and Disease Progression of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype|Completed|||49|Actual|Alexion Pharmaceuticals|||||f||||f||||||||No||2018-05-31 21:39:56.044403|2018-05-31 21:39:56.044403
NCT01528904|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-02-05|2012-02-05|2012-02-08|Estimate|||||||2012-02-05|2012-02-08|Estimate|January 2001||2001-01-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Observational|||Maternal Autoimmune Thyroid Disease and Fetal Thyroxin|Fetal Thyroid Hormones Concentration In Hyperthyroid or Hypothyroid Pregnant Women|Completed|||83|Actual|University of Belgrade|||3||f||||t||||||||||2018-05-31 21:39:56.118996|2018-05-31 21:39:56.118996
NCT01528891|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2015-09-16||2018-03-06|2012-02-07|2012-02-08|Estimate|2015-10-21|2015-11-25|Estimate||||2018-03-06|2018-03-08|Actual|January 2012||2012-01-31|March 2018|2018-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation|Dexmedetomidine as a Rapid Bolus for Treatment and Prophylactic Prevention of Emergence Agitation in Anesthetized Children|Completed||Phase 3|418|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 21:39:56.19427|2018-05-31 21:39:56.19427
NCT01528878|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2018-04-13||2018-04-13|2012-02-03|2012-02-08|Estimate|2018-04-13|2018-05-15|Actual||||2018-04-13|2018-05-15|Actual|April 2009||2009-04-30|April 2018|2018-04-30|January 28, 2016|Actual|2016-01-28|August 18, 2014|Actual|2014-08-18||Interventional|||Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases|A Dose-finding, Safety and Preliminary Efficacy Study of Stereotactic Radiosurgery for Hepato-cellular Carcinoma and Metastatic Disease to the Liver.|Completed||N/A|30|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:39:57.603592|2018-05-31 21:39:57.603592
NCT01528865|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-03-10|2012-02-07|2012-02-08|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||August 2017|Anticipated|2017-08-31||Interventional|||Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma|A Phase I/II Study of Safety and Efficacy of Lamivudine (EPIVIR®) and Tenofovir Disoproxil Fumarate (VIREAD®) Used to Lower the Plasma Level of Viral RNA of HERV-K(HML2) in Patients With Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|University of Michigan Cancer Center||1||Funding was removed.|f||||t||||||||||2018-05-31 21:39:57.963759|2018-05-31 21:39:57.963759
NCT01528852|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|CHX-Pemba||Chlorhexidine Cordcare for Reduction in Neonatal Mortality and Omphalitis|Efficacy of Use of Chlorhexidine to Clean Umbilical Cord of Neonates in First 10 Days for Reduction in Neonatal Mortality and Omphalitis - A Community Based Randomized, Double Masked Controlled Trial in Pemba Tanzania|Unknown status|Recruiting|Phase 3|28000|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-05-31 21:39:58.043424|2018-05-31 21:39:58.043424
NCT01527786|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2015-01-26|2012-02-03|2012-02-07|Estimate|||||||2015-01-26|2015-01-28|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine|A Pilot Study of Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine|Completed||Phase 3|25|Actual|BC Women's Hospital & Health Centre||1|||f||||f||||||||||2018-05-31 21:40:11.979711|2018-05-31 21:40:11.979711
NCT01528826|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|NVBOX||Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial|A Prospective Phase II Trial of Vinorelbine Plus Oxaliplatin in Pretreated Metastatic Triple-negative Breast Cancer|Unknown status|Recruiting|Phase 2|35|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 21:39:58.3272|2018-05-31 21:39:58.3272
NCT01528813|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2013-08-05|2012-02-07|2012-02-08|Estimate|||||||2013-08-05|2013-08-07|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis|AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE|Unknown status|Recruiting|Phase 2|30|Anticipated|Brasilia University Hospital||2|||f||||f||||||||||2018-05-31 21:39:58.43941|2018-05-31 21:39:58.43941
NCT01528800|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-07-24|2012-02-07|2012-02-08|Estimate|||||||2017-07-24|2017-07-25|Actual|November 2012||2012-11-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|iPACKHD||Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients|Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialyis Patients: iPACKHD Study|Recruiting||Phase 2|80|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||f||||||||||2018-05-31 21:39:58.536521|2018-05-31 21:39:58.536521
NCT01528787|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|2018-01-22|2014-02-17|2018-03-19|2012-02-07|2012-02-08|Estimate|2018-01-22|2018-02-21|Estimate|2014-03-17|2014-04-14|Estimate|2018-03-19|2018-04-18|Actual|March 2012||2012-03-31|June 2016|2016-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of AR-13324 in Patients With Elevated Intraocular Pressure|A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of Three Doses of AR-13324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure|Completed||Phase 2|85|Actual|Aerie Pharmaceuticals||4|||f||||f||||||||||2018-05-31 21:39:58.647755|2018-05-31 21:39:58.647755
NCT01528774|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2017-07-24|2012-02-07|2012-02-08|Estimate|||||||2017-07-24|2017-07-26|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|CTC||Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers|Culture and Characterization of Circulating Tumor Cells (CTC) From Patients With Malignant Melanoma and Other Cancers|Completed|||150|Actual|Comprehensive Cancer Centers of Nevada|||5||f||||f||||||Samples With DNA|"~     Whole blood (up to 40 cc) collected in four 7.5 - 10 ml tubes. Serum samples may be stored~     frozen in a coded, de-identified format until DNA or RNA is extracted for assays to allow for~     batch processing. Samples will be consumed in the course of the research studies. Viable~     tumor cells may be grown as long-term cell lines.~   "|||2018-05-31 21:39:59.279703|2018-05-31 21:39:59.279703
NCT01528761|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-11-06|2012-02-04|2012-02-08|Estimate|||||||2017-11-06|2017-11-08|Actual|August 15, 2011|Actual|2011-08-15|April 2017|2017-04-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||Prosocial Behavior and Volunteerism to Promote Physical Activity in Older Adults|Prosocial Behavior and Volunteerism to Promote Physical Activity in Older Adults|Completed||N/A|317|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 21:39:59.360401|2018-05-31 21:39:59.360401
NCT01528748|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2016-10-25|2012-02-04|2012-02-08|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|December 2015|Actual|2015-12-31||Observational|||Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence|Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence|Active, not recruiting|||8|Actual|University of Virginia|||1||f||||f||||||||||2018-05-31 21:39:59.433672|2018-05-31 21:39:59.433672
NCT01528735|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|2016-01-21|2014-04-30|2016-03-14|2012-02-06|2012-02-08|Estimate|2016-03-14|2016-04-13|Estimate|2014-04-30|2014-05-16|Estimate|2016-03-14|2016-04-13|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Treated Set which included all patients who were dispensed study medication and were documented to have taken at least one dose of study medication.|This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C|An Open-label, Ascending Dose, Phase II Study to Evaluate Tolerability, Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA in Combination With BI 201335 NA and Ribavirin for 8 Weeks in Treatment-naïve Japanese Patients With Genotype 1chronic Hepatitis C Virus Infection|Completed||Phase 2|25|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:39:59.619377|2018-05-31 21:39:59.619377
NCT01528722|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Randomized Control Trial of Intraperitoneal Bupivacaine During Cholecystectomy|Double Blind Sham Controlled Randomised Trial of Intraperitoneal Bupivacaine During Acute Laparoscopic Cholecystectomy|Completed||N/A|42|Actual|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||f||||||||||2018-05-31 21:40:01.166391|2018-05-31 21:40:01.166391
NCT01528709|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2018-01-24|2012-02-07|2012-02-08|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2012||2012-03-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ACTIVE||Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)|Aggressive Cholesterol Therapy to Inhibit Vein Graft Events (ACTIVE Trial): Does High-Dose Postoperative Statin Therapy Improve Graft Patency After Coronary Bypass?|Completed||Phase 3|173|Actual|Boca Raton Regional Hospital||2|||f||||f|t|f|||f|||Undecided||2018-05-31 21:40:01.246527|2018-05-31 21:40:01.246527
NCT01528696|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2016-12-22||2017-02-15|2012-02-07|2012-02-08|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|February 2012||2012-02-29|February 2017|2017-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Silver Impregnated Dressings to Reduce Wound Complications in Obese Patients at Cesarean Section|Silver Impregnated Dressings to Reduce Wound Complications in Obese Patients at Cesarean Section|Terminated||Phase 4|37|Actual|University of Michigan||2||Insufficient Recruitment|f||||f||||||||||2018-05-31 21:40:01.340205|2018-05-31 21:40:01.340205
NCT01528683|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-31|||2018-05-11|2012-02-07|2012-02-08|Estimate|||||||2018-05-11|2018-05-17|Actual|December 2012|Actual|2012-12-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|PANDORA||Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer|Phase I/II Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Recurrent Rectal Cancer|Completed||N/A|14|Actual|University Hospital Heidelberg||1|||f||||t||||||||||2018-05-31 21:40:01.721129|2018-05-31 21:40:01.721129
NCT01528670|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-05-11|2012-02-07|2012-02-08|Estimate|||||||2018-05-11|2018-05-17|Actual|May 2019|Anticipated|2019-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|MIRANDA||Monitoring of Patients Treated With Particle Therapy Using Positron-Emission-Tomography (PET): The MIRANDA Study|Monitoring of Patients Treated With Particle Therapy Using Positron-Emission-Tomography (PET): The MIRANDA Study.|Withdrawn|||0|Actual|University Hospital Heidelberg|||8|Administrative barriers|f||||f||||||||||2018-05-31 21:40:01.96021|2018-05-31 21:40:01.96021
NCT01528657|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2015-10-21|2012-02-06|2012-02-08|Estimate|||||||2015-10-21|2015-10-22|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|VIPERS||Ventricular Pace Suppression Versus Intrinsic Rhythm Support Study||Completed||N/A|230|Actual|Biotronik SE & Co. KG||2|||f||||f||||||||||2018-05-31 21:40:02.053824|2018-05-31 21:40:02.053824
NCT01528644|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2013-02-28|2012-02-07|2012-02-08|Estimate|||||||2013-02-28|2013-03-01|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Iron & Alginate Study|Study to Measure the Absorption of Iron From Ferrous Gluconate Incorporated Into Alginate Beads.|Completed||N/A|16|Actual|University of East Anglia||4|||f||||f||||||||||2018-05-31 21:40:02.272352|2018-05-31 21:40:02.272352
NCT01528631|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-07-24|2012-02-07|2012-02-08|Estimate|||||||2012-07-24|2012-07-25|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||The Effects of D-Fagomine on Glycaemic Response to Sucrose in Men|Randomized Controlled Double-blind Nutritional Intervention Trial to Evaluate the Effects of D-fagomine on Glycaemic Response to Sucrose in Men|Completed||N/A|12|Actual|Bioglane||2|||f||||f||||||||||2018-05-31 21:40:02.384766|2018-05-31 21:40:02.384766
NCT01528618|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-01-09|2012-02-04|2012-02-08|Estimate|||||||2016-01-09|2016-01-12|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma|A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)|Unknown status|Active, not recruiting|Phase 3|362|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:40:02.486088|2018-05-31 21:40:02.486088
NCT01528605|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|2014-07-20||2014-08-18|2012-02-04|2012-02-08|Estimate|2014-08-18|2014-08-29|Estimate||||2014-08-18|2014-08-29|Estimate|June 2010||2010-06-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional||4 participants was excluded during the analysis since they did not finish the intervention.|Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration|The Effects of Lutein and Zeaxanthin Supplementations on Early Age-related Macular Degeneration|Completed||N/A|168|Actual|Peking University||6|||f||||t||||||||||2018-05-31 21:40:02.594451|2018-05-31 21:40:02.594451
NCT01528592|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2013-11-06||2018-04-02|2012-02-04|2012-02-08|Estimate|2013-11-06|2013-12-24|Estimate||||2018-04-02|2018-05-03|Actual|June 2011||2011-06-30|April 2018|2018-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Patients with Parkinson's disease on dopaminergic therapy.|PharmacoMRI of Parkinson Disease|A Pilot Study of the Drug Effects on Brain Connectivity of Parkinson's Disease|Completed||N/A|18|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 21:40:03.114846|2018-05-31 21:40:03.114846
NCT01528579|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|||2017-03-06|2012-02-07|2012-02-08|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2011||2011-03-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Different Exercise Programs for People With Chronic Whiplash Associated Disorders|Effects of Different Exercise Programs for People With Chronic Whiplash Associated Disorders: a Prospective Randomized Study|Completed||N/A|216|Actual|Linkoeping University||3|||f||||t||||||||||2018-05-31 21:40:03.292435|2018-05-31 21:40:03.292435
NCT01528566|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-02-03|2012-02-03|2012-02-08|Estimate|||||||2012-02-03|2012-02-08|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Tai Chi on Osteoarthritic Knee Pain in Elders With Mild Dementia|Effect of Tai Chi on Osteoarthritic Knee Pain in Elders With Mild Dementia|Completed||N/A|55|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 21:40:03.381307|2018-05-31 21:40:03.381307
NCT01528553|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-02-03|2012-02-03|2012-02-08|Estimate|||||||2012-02-03|2012-02-08|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Stapling Versus 8plate for Correction of Genu Valgus|Stapling Versus 8plate for Correction of Genu Valgus. A Randomised Clinical Study|Unknown status|Active, not recruiting|N/A|20|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:40:03.473822|2018-05-31 21:40:03.473822
NCT01528540|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2015-09-08|2012-02-04|2012-02-08|Estimate|||||||2015-09-08|2015-09-09|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a Randomized Control Trial|Evaluation of Efficacy of Combination of Pregabalin and Antioxidant in Reducing Pain in Chronic Pancreatitis: a RCT|Completed||N/A|87|Actual|Asian Institute of Gastroenterology, India||2|||f||||t||||||||||2018-05-31 21:40:03.559585|2018-05-31 21:40:03.559585
NCT01528514|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|September 2011|Actual|2011-09-30||Interventional|CUPID||Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study|The Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study|Unknown status|Recruiting|Phase 3|200|Anticipated|Thailand Research Fund||2|||f||||t||||||||||2018-05-31 21:40:03.637317|2018-05-31 21:40:03.637317
NCT01528501|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2013-04-30|2012-02-07|2012-02-08|Estimate|||||||2013-04-30|2013-05-01|Estimate|June 2009||2009-06-30|December 2012|2012-12-31||||February 2013|Actual|2013-02-28||Interventional|HDAC||Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)|An Open-label, Uncontrolled Phase II Trial of HDAC-Inhibitor LBH589 in Patients With Chemo-refractory Metastatic Gastric Cancer Overexpressing Histone Deacetylases (HDACs) - CLBH589BDE03T|Terminated||Phase 2|28|Anticipated|Technische Universität München||1||medical/ethical reasons|f||||||||||||||2018-05-31 21:40:03.710433|2018-05-31 21:40:03.710433
NCT01528488|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2013-11-04|2012-02-07|2012-02-08|Estimate|||||||2013-11-04|2013-11-05|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC|A Randomized, Double-blind, Prospective Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in Non-small Cell Lung Cancer|Completed||Phase 2/Phase 3|118|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 21:40:03.76963|2018-05-31 21:40:03.76963
NCT01526395|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2013-04-01|2012-02-01|2012-02-03|Estimate|||||||2013-04-01|2013-04-04|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital|Decreasing the Use of Unmodified ECT in an Indian Hospital|Completed||N/A|99|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:40:31.180682|2018-05-31 21:40:31.180682
NCT01528475|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-12-16|2012-02-03|2012-02-08|Estimate|||||||2016-12-16|2016-12-19|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Initiation of Cooling by EMS to Promote Adoption of In-hospital Hypothermia in Cardiac Arrest Survivors|Initiation of Cooling by Emergency Medical Services to Promote the Adoption of In-hospital Therapeutic Hypothermia in Cardiac Arrest Survivors: the ICE-PACS Trial|Completed||N/A|585|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 21:40:03.858377|2018-05-31 21:40:03.858377
NCT01528462|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2014-11-21|2012-02-07|2012-02-08|Estimate|||||||2014-11-21|2014-11-24|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|SMARTIES||Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke|Does Acute Management of Sleep Disorders Improve Outcomes After Non-disabling Cerebrovascular Events?|Completed|||97|Actual|Sunnybrook Health Sciences Centre|||1||f||||f||||||||||2018-05-31 21:40:03.951836|2018-05-31 21:40:03.951836
NCT01528449|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-09-11|2012-02-07|2012-02-08|Estimate|||||||2017-09-11|2017-09-12|Actual|December 2011||2011-12-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Babesia Testing in Blood Donors|Blood Donation Screening for Babesia Microti by Real-time Polymerase Chain Reaction (PCR) and by Indirect Flourescent Antibody (IFA) Assays|Completed||Phase 3|90116|Actual|Imugen||2|||f||||f||||||||||2018-05-31 21:40:04.041637|2018-05-31 21:40:04.041637
NCT01528436|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-07-17|2012-02-03|2012-02-08|Estimate|||||||2012-07-17|2012-07-18|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Umbilical Cord Blood Therapy for Cerebral Palsy|Umbilical Cord Blood Therapy for Cerebral Palsy: a Randomized,Double-blind, Placebo-controlled Trial|Completed||Phase 2|37|Actual|Bundang CHA Hospital||2|||f||||f||||||||||2018-05-31 21:40:04.166964|2018-05-31 21:40:04.166964
NCT01528423|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-06-14|2012-02-07|2012-02-08|Estimate|||||||2012-06-14|2012-06-15|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|XtremeCT||Evaluation of the XtremeCT Device for the Assessment of Bone|Evaluation of the XtremeCT Device for the Assessment of Bone|Completed|||180|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||6||f||||f||||||Samples Without DNA|"~     Serum samples taken for measurement of PINP, CTX, PTH, calcium, creatinine, albumin,~     testosterone, IGF-1, IGFBP-3 and SHBG~   "|||2018-05-31 21:40:04.241666|2018-05-31 21:40:04.241666
NCT01528410|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-06-12|2012-02-07|2012-02-08|Estimate|||||||2017-06-12|2017-06-14|Actual|August 17, 2012|Actual|2012-08-17|June 2017|2017-06-30|September 21, 2016|Actual|2016-09-21|September 21, 2016|Actual|2016-09-21||Interventional|||ALFApump System Versus Standard of Care in Ascites Treatment|ALFApump® System Versus Large Volume Paracentesis in the Treatment of Refractory Ascites. A Multicentre Randomised Controlled Study.|Completed||Phase 3|58|Actual|Sequana Medical AG||2|||f||||t||||||||||2018-05-31 21:40:04.312774|2018-05-31 21:40:04.312774
NCT01528397|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-07|2012-02-07|2012-02-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|September 2009|Actual|2009-09-30||Interventional|||Reconstruction of Proper Digital Nerve Defects in the Thumb Using a Pedicled Nerve Graft||Completed||N/A|14|Actual|The Second Hospital of Tangshan|||||f||||t||||||||||2018-05-31 21:40:04.461184|2018-05-31 21:40:04.461184
NCT01528384|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-14|||2014-04-08|2012-02-07|2012-02-08|Estimate|||||||2014-04-08|2014-04-09|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient|A Phase 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient and Have Failed Prior Systemic Therapy|Completed||Phase 1|8|Actual|Polaris Group|||||f||||f||||||||||2018-05-31 21:40:04.52564|2018-05-31 21:40:04.52564
NCT01528371|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-10-01|2012-02-07|2012-02-08|Estimate|||||||2012-10-01|2012-10-03|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Midazolam on White-coat Hypertensive Dental Patients|The Effect of Low Dose of Midazolam on Blood Pressure and Anxiety Scale in White-coat Hypertensive Dental Patients|Completed||N/A|40|Anticipated|Okayama University||2|||f||||f||||||||||2018-05-31 21:40:04.603624|2018-05-31 21:40:04.603624
NCT01528358|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2018-03-08|2012-02-07|2012-02-08|Estimate|||||||2018-03-08|2018-03-09|Actual|April 4, 2012|Actual|2012-04-04|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Tissue Near InfraRed Spectroscopy (NIRS) in Critically Ill Patients|Tissue NIRS in the Assessment and Management of Critically Ill Patients|Suspended|||672|Actual|Lawson Health Research Institute|||2||f||||f||||||Samples Without DNA|"~     Blood: inflammatory markers~   "|Undecided||2018-05-31 21:40:04.694391|2018-05-31 21:40:04.694391
NCT01528345|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2016-04-01||2016-05-26|2012-02-07|2012-02-08|Estimate|2016-05-26|2016-07-11|Estimate||||2016-05-26|2016-07-11|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Full Analysis Set (FAS): Consisted of all randomized patients. Following the intent-to-treat principle, patients were analyzed according to the treatment and stratum to which they were assigned at randomization.|Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer|A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy|Terminated||Phase 2|97|Actual|Novartis||2||Slow and low enrollment|f||||t||||||||||2018-05-31 21:40:04.800829|2018-05-31 21:40:04.800829
NCT01528332|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2013-09-09||2014-02-07|2012-02-03|2012-02-08|Estimate|2013-11-20|2014-01-08|Estimate||||2014-02-07|2014-03-12|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PAINCT02||Blue Light Device for Pain Therapy|A Prospective, Randomized, Controlled, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Blue Light Therapy for Relief of Chronic Musculoskeletal Back Pain|Completed||Phase 3|171|Actual|Philips Light and Health||2|||f||||f||||||||||2018-05-31 21:40:05.409644|2018-05-31 21:40:05.409644
NCT01528319|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|2014-01-26||2014-07-14|2012-02-03|2012-02-08|Estimate|2014-07-14|2014-08-04|Estimate||||2014-07-14|2014-08-04|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|MG-1||Open-Label Study for Shoulder Dislocation Using MG-1|Open Clinical Trial of Arthroscopic Bankart Repair Using MG-1 for Dislocation of the Shoulder|Completed||N/A|24|Actual|Johnson & Johnson K.K. Medical Company||1|||f||||f||||||||||2018-05-31 21:40:05.720493|2018-05-31 21:40:05.720493
NCT01528306|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-05-15|2012-02-03|2012-02-08|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|||A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa|An Exploratory, Cross-Over Study of the Safety of HP802-247 Applied to Open Wounds of Subjects With Dystrophic Epidermolysis Bullosa|Withdrawn||Phase 2|0|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 21:40:05.93161|2018-05-31 21:40:05.93161
NCT01528293|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2015-04-14||2016-12-21|2012-02-03|2012-02-08|Estimate|2015-04-30|2015-05-18|Estimate||||2016-12-21|2017-02-10|Actual|July 2012||2012-07-31|December 2016|2016-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations|A Prospective, Randomized, Comparative Effectiveness Trial of the ActiV.A.C.+ Compression Therapy Versus Compression Therapy Alone for the Treatment of Chronic Venous Ulcerations|Terminated||N/A|2|Actual|Georgetown University|Enrollment was insufficient to support statistical analyses. Three subjects were screened and only one completed the study. The study was terminated due to insufficient enrollment.|2||slow recruitment - unable to meet enrollment goals|f||||f||||||||No||2018-05-31 21:40:06.021176|2018-05-31 21:40:06.021176
NCT01528280|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2018-01-09|2012-02-03|2012-02-08|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|September 2014|Actual|2014-09-30||Interventional|||Humoral and Cellular Response in Shift Workers|Vaccination Against Hepatitis A Virus in Shift Workers: Evaluation of the Humoral and Cellular Immune Response|Completed||N/A|34|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 21:40:06.225981|2018-05-31 21:40:06.225981
NCT01528267|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2013-12-19|2012-02-03|2012-02-07|Estimate|||||||2013-12-19|2013-12-20|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Bronchoscopic Lung Volume Reduction Using Blood|A Randomised, Double Blind, Sham Controlled Trial of Autologous Blood Lung Volume Reduction|Completed||Phase 2|10|Actual|Chelsea and Westminster NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:40:06.295928|2018-05-31 21:40:06.295928
NCT01528254|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2018-01-18|2012-02-03|2012-02-07|Estimate|||||||2018-01-18|2018-01-23|Actual|November 3, 2011|Actual|2011-11-03|January 2018|2018-01-31|April 18, 2019|Anticipated|2019-04-18|April 18, 2019|Anticipated|2019-04-18||Interventional|||VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus|A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin & Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus|Active, not recruiting||Phase 4|2005|Actual|Novartis||2|||f|||||f|f||||||No||2018-05-31 21:40:06.388391|2018-05-31 21:40:06.388391
NCT01528241|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-03|2012-02-03|2012-02-07|Estimate|||||||2012-02-03|2012-02-07|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)|A Multi-center, Open-label Study in Elderly Healthy Volunteers and Elderly Patients With Major Depressive Disorder to Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)|Completed||Phase 1|42|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:40:06.955569|2018-05-31 21:40:06.955569
NCT01528228|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2017-01-27|2012-02-03|2012-02-07|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|TENS||Effects of TENS Therapy Following Arthroscopic Knee Surgery|Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Postoperative Pain and Function Following Arthroscopic Knee Surgery: A Prospective Randomized Clinical Trial Pilot Study|Completed||N/A|20|Actual|A.T. Still University of Health Sciences||2|||f||||f||||||||||2018-05-31 21:40:07.037824|2018-05-31 21:40:07.037824
NCT01528215|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|2016-03-15||2017-02-03|2012-02-03|2012-02-07|Estimate|2016-03-15|2016-04-14|Estimate||||2017-02-03|2017-03-14|Actual|November 2011||2011-11-30|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2014|Actual|2014-12-31||Interventional|||Multicenter Study Comparing OsseoSpeed TX With OsseoSpeed EV.|An Open, Prospective, Randomized, Multicenter Study Comparing OsseoSpeed™ EV With OsseoSpeed™ TX in Partially Edentulous Maxillae and Mandibles. A 5-year Follow-up Study.|Active, not recruiting||N/A|120|Actual|Dentsply Sirona Implants||2|||f||||||||||||||2018-05-31 21:40:07.117346|2018-05-31 21:40:07.117346
NCT01528202|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-03|2012-02-03|2012-02-07|Estimate|||||||2012-02-03|2012-02-07|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Tart Cherries and Melatonin Content|Effect of Tart Cherry Juice (Prunus Cerasus) on Melatonin Levels and Sleep Quality|Completed||N/A|20|Actual|Northumbria University||4|||f||||f||||||||||2018-05-31 21:40:07.351776|2018-05-31 21:40:07.351776
NCT01528189|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2018-04-02|2012-02-06|2012-02-07|Estimate|||||||2018-04-02|2018-04-03|Actual|February 2012||2012-02-29|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of High Dose Insulin on Infectious Complications Following Major Surgery|Effect of Hyperinsulinemic Normoglycemic Clamp (HINC) on Infectious Complications Following Major Abdominal Surgery. A Randomized Controlled Trial.|Recruiting||N/A|540|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 21:40:07.458295|2018-05-31 21:40:07.458295
NCT01528176|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-13|2012-02-06|2012-02-07|Estimate|||||||2012-02-13|2012-02-14|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Vitamin D Metabolism in Chronic Kidney Disease Patients|Vitamin D Metabolism in Chronic Kidney Disease Patients With Vitamin D Deficiency Treated With Cholecalciferol|Unknown status|Active, not recruiting|N/A|70|Actual|Memphis VA Medical Center||1|||f||||t||||||||||2018-05-31 21:40:07.57709|2018-05-31 21:40:07.57709
NCT01528163|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2017-06-12|2012-02-06|2012-02-07|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2012||2012-02-29|June 2017|2017-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|RACATREX||Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Therapy.|Completed||Phase 2|101|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 21:40:07.66038|2018-05-31 21:40:07.66038
NCT01528150|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|2015-12-02||2018-03-08|2012-02-06|2012-02-07|Estimate|2016-07-19|2016-08-31|Estimate||||2018-03-08|2018-04-04|Estimate|February 2012||2012-02-29|March 2018|2018-03-31|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30|12 Months|Observational [Patient Registry]|TendrilMRI™||Safety and Efficacy Study of Tendril MRI™ Leads in Standard Bradycardia Pacing Indication|Clinical Investigation to Assess the Safety and Efficacy of the Tendril MRI™ Leads, as a Part of the Accent MRI™ System, in Patients With Standard Bradycardia Pacing Indication.|Completed|||466|Actual|St. Jude Medical|||1||f||||f|f|f||||||No||2018-05-31 21:40:07.791145|2018-05-31 21:40:07.791145
NCT01527799|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-02-03|2012-02-06|2012-02-07|Estimate|||||||2016-02-03|2016-02-04|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Exercise Capacity in Pediatric Sickle Cell Anemia|The Physiologic Assessment of Exercise Capacity in Pediatric Sickle Cell Anemia|Completed|||60|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||t||||||Samples Without DNA|"~     Plasma is collected and stored to be analyzed~   "|||2018-05-31 21:40:11.909096|2018-05-31 21:40:11.909096
NCT01528137|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2016-07-30|2012-02-03|2012-02-07|Estimate|||||||2016-07-30|2016-08-02|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|July 2013|Actual|2013-07-31|August 2012|Actual|2012-08-31||Interventional|||Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer|A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC)|Terminated||Phase 1|4|Actual|Stanford University||1||Negative data from another trial led to termination of this trial by sponsor.|f||||t||||||||||2018-05-31 21:40:07.982812|2018-05-31 21:40:07.982812
NCT01528124|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-05-21|2012-02-03|2012-02-07|Estimate|||||||2012-05-21|2012-05-22|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of LY3025876 in Healthy Volunteers|A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3025876 in Healthy Subjects|Completed||Phase 1|63|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:40:08.074956|2018-05-31 21:40:08.074956
NCT01528111|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03||2015-08-31|2015-08-31|2012-02-03|2012-02-07|Estimate||||2015-08-31|2015-09-14|Estimate|2015-08-31|2015-09-14|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|A Phase 1/2a, Randomized, Parallel-group, Double-masked, Vehicle-controlled, Dose-frequency Escalation Study to Evaluate the Safety, Tolerability, and Intraocular Pressure (IOP)-Lowering Efficacy of Topically Administered LX7101 in Subjects Diagnosed With Primary Open-angle Glaucoma (POAG) or Ocular Hypertension (OHT)|Completed||Phase 1/Phase 2|63|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 21:40:08.148904|2018-05-31 21:40:08.148904
NCT01528098|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-20|2012-02-03|2012-02-07|Estimate|||||||2012-02-20|2012-02-22|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Observational|PEG||Comparison of Bowel Cleansing Methods for Colonoscopy in Hospitalized Patients|Efficacy of Bisacodyl Given as Part of a Polyethylene Glycol-based Bowel Preparation Prior to Colonoscopy in Hospitalized Patients|Unknown status|Not yet recruiting||600|Anticipated|Kangbuk Samsung Hospital|||2||f||||t||||||||||2018-05-31 21:40:08.215675|2018-05-31 21:40:08.215675
NCT01528085|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2015-09-29|2012-02-03|2012-02-07|Estimate|||||||2015-09-29|2015-09-30|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|November 2018|Anticipated|2018-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Nilotinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting||Phase 2|79|Actual|Johann Wolfgang Goethe University Hospital|||||f||||t||||||||||2018-05-31 21:40:08.275847|2018-05-31 21:40:08.275847
NCT01528072|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-07-14|2012-02-06|2012-02-07|Estimate|||||||2016-07-14|2016-07-15|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Dynesys Spinal System Post Market 522 Study|Post Market Surveillance for the Dynesys Spinal System, Assessing Safety and Fusion.|Unknown status|Recruiting|N/A|168|Anticipated|Zimmer Biomet||1|||f||||t||||||||Undecided||2018-05-31 21:40:08.467639|2018-05-31 21:40:08.467639
NCT01528059|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-06|2012-02-06|2012-02-07|Estimate|||||||2012-02-06|2012-02-07|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|March 2013|Anticipated|2013-03-31|February 2012|Anticipated|2012-02-29||Interventional|||Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes|A Prospective Randomised Study Comparing Billroth II With Roux-en-Y Reconstruction After Radical Distal Subtotal Gastrectomy for Gastric Cancer Comorbid With Type 2 Diabetes|Unknown status|Recruiting|Phase 2/Phase 3|110|Anticipated|Xiamen University||2|||f||||t||||||||||2018-05-31 21:40:08.565708|2018-05-31 21:40:08.565708
NCT01528046|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2018-01-09|2012-02-06|2012-02-07|Estimate|||||||2018-01-09|2018-01-11|Actual|April 25, 2012|Actual|2012-04-25|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Metformin in Children With Relapsed or Refractory Solid Tumors|A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors|Recruiting||Phase 1|25|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t|t|f|||f|||||2018-05-31 21:40:08.637602|2018-05-31 21:40:08.637602
NCT01528033|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-08-08|2012-02-06|2012-02-07|Estimate|||||||2017-08-08|2017-08-10|Actual|August 2011||2011-08-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|SAWHI||Treatment Study of Vacuum Assisted Closure for Postsurgical Subcutaneous Abdominal Wound Healing Impairments|Treatment of Subcutaneous Abdominal Wound Healing Impairment After Surgery Without Fascial Dehiscence by Vacuum Assisted Closure™(SAWHI-V.A.C.® Study) Versus Standard Conventional Wound Therapy|Recruiting||N/A|550|Anticipated|University of Witten/Herdecke||2|||f||||t||||||||||2018-05-31 21:40:08.780222|2018-05-31 21:40:08.780222
NCT01528020|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-05-16|2012-02-06|2012-02-07|Estimate|||||||2016-05-16|2016-05-17|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Interventional|CARES||Collaborative Adolescent Research on Emotions and Suicide|Treatment of Suicidal and Self-Injurious Adolescents With Emotional Dysregulation|Completed||N/A|173|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 21:40:08.886339|2018-05-31 21:40:08.886339
NCT01528007|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2013-12-04|2012-02-06|2012-02-07|Estimate|||||||2013-12-04|2013-12-05|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention|Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial|Completed||Phase 4|100|Actual|National Institute for Health and Welfare, Finland||2|||f||||f||||||||||2018-05-31 21:40:10.079222|2018-05-31 21:40:10.079222
NCT01527994|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-04-13|2012-02-03|2012-02-07|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|||Aprepitant Effects in Intravenous Heroin Dependence|Clinical Laboratory Evaluations of Aprepitant for the Treatment of Opioid Dependence: Inpatient Test|Completed||Phase 1|64|Actual|New York University||2|||f||||t||||||||||2018-05-31 21:40:10.157488|2018-05-31 21:40:10.157488
NCT01527981|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-03|2012-02-03|2012-02-07|Estimate|||||||2012-02-03|2012-02-07|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Cognitive Behavioral Therapy (CBT) for Adherence and Depression in Type 1 Diabetes|CBT for Adherence and Depression in Type 1 Diabetes|Completed||Phase 2|9|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:40:10.267629|2018-05-31 21:40:10.267629
NCT01527968|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2016-07-22|2012-02-06|2012-02-07|Estimate|||||||2016-07-22|2016-07-26|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Epsilon Aminocaproic Acid Vs. Tranexamic Acid Vs. Placebo for Prevention of Blood Loss in Total Knee Arthroplasty|A Prospective, Randomized, Double Blind, Double-Dummy Study Comparing the Safety and Efficacy of Epsilon Aminocaproic Acid (eACA) Versus Tranexamic Acid (TXA) Versus Placebo for Prevention of Blood Loss in Total Knee Arthroplasty|Active, not recruiting||N/A|54|Actual|Heekin Orthopedic Research Institute||3|||f||||f||||||||||2018-05-31 21:40:10.345547|2018-05-31 21:40:10.345547
NCT01527955|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-06|2012-02-06|2012-02-07|Estimate|||||||2012-02-06|2012-02-07|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|||Kelee® Meditation: A Distinctive and Effective Therapeutic Intervention for Stress, Anxiety, and Depression|Troubleshooting the Mind Through Kelee® Meditation: A Distinctive and Effective Therapeutic Intervention for Stress, Anxiety, and Depression|Completed||N/A|47|Actual|University of California, San Diego|||||f||||f||||||||||2018-05-31 21:40:10.423478|2018-05-31 21:40:10.423478
NCT01527942|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2015-03-17||2015-11-13|2012-02-06|2012-02-07|Estimate|2015-11-13|2015-12-17|Estimate||||2015-11-13|2015-12-17|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Intravenous Acetaminophen Use With Bariatric Surgery on Morbidly Obese Patients|Effect of Intravenous Acetaminophen on Postoperative Pain of Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery: A Randomized, Placebo-Controlled Trial|Terminated||N/A|34|Actual|Saint Francis Care||2||Study Terminated per Principal Investigator's request|f||||t||||||||||2018-05-31 21:40:10.520183|2018-05-31 21:40:10.520183
NCT01527929|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2013-12-03|2012-02-06|2012-02-07|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment|An Open-label Pharmacokinetic and Safety Study of Cabazitaxel in Patients With Solid Tumors With Moderately and Severely Impaired and With Normal Renal Function|Completed||Phase 1|25|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:40:10.794082|2018-05-31 21:40:10.794082
NCT01527916|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03||2014-11-06|2014-11-06|2012-02-03|2012-02-07|Estimate||||2014-11-06|2014-11-19|Estimate|2014-11-06|2014-11-19|Estimate|February 2012||2012-02-29|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|438|Actual|AbbVie||5|||f||||t||||||||||2018-05-31 21:40:10.99884|2018-05-31 21:40:10.99884
NCT01527903|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-08-16|2012-02-06|2012-02-07|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ICU||A Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation in the Intensive Care Unit|Sedation of Surgical Patients in the Intensive Care Unit: A Randomized Comparison Between Propofol-Remifentanil and Midazolam-Remifentanil Sedation|Completed||Phase 4|77|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:40:11.151026|2018-05-31 21:40:11.151026
NCT01527890|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-02-02|2012-02-02|2012-02-07|Estimate|||||||2012-02-02|2012-02-07|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Observational|||Effect of Intravenous Patient-controlled Analgesia (IV-PCA) With Fentanyl in Adults for Acute Postoperative Pain Control||Unknown status|Recruiting||2000|Anticipated|Yonsei University|||||f||||||||||||||2018-05-31 21:40:11.241387|2018-05-31 21:40:11.241387
NCT01527877|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-10-04|2012-02-06|2012-02-07|Estimate|||||||2012-10-04|2012-10-08|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|August 2014|Anticipated|2014-08-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck|An Open Label, Single Arm, Multicenter Phase II Study of BKM120 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy|Unknown status|Recruiting|Phase 2|53|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 21:40:11.322526|2018-05-31 21:40:11.322526
NCT01527864|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2012-02-06|2012-02-06|2012-02-07|Estimate|||||||2012-02-06|2012-02-07|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or With Pegylated Endostatin for Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|300|Anticipated|Protgen Ltd||2|||f||||t||||||||||2018-05-31 21:40:11.424837|2018-05-31 21:40:11.424837
NCT01527851|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2018-05-04|2012-02-06|2012-02-07|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2012||2012-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Excess Skin and Physical Activity|Impact of Excess Skin on the Practice of Physical Activity in Women Who Underwent Bariatric Surgery and Exploration of the Benefits of Plastic Surgery|Active, not recruiting|||30|Anticipated|Université de Sherbrooke|||||f||||f||||||||||2018-05-31 21:40:11.580111|2018-05-31 21:40:11.580111
NCT01527838|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-09-09|2012-02-03|2012-02-07|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit|A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies|Completed||Phase 1|10|Actual|Fate Therapeutics||1|||f||||t||||||||||2018-05-31 21:40:11.635833|2018-05-31 21:40:11.635833
NCT01527825|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-01-09|2012-02-02|2012-02-07|Estimate|||||||2015-01-09|2015-01-12|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women|Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women: a Randomized Controlled Trial|Completed||Phase 3|800|Actual|University of Witwatersrand, South Africa||3|||f||||t||||||||||2018-05-31 21:40:11.722925|2018-05-31 21:40:11.722925
NCT01527812|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-03-31|2012-02-03|2012-02-07|Estimate|||||||2012-03-31|2012-04-03|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Optimal Positioning of Local Anaesthetic in Femoral Nerve Block Prior to Hip Surgery|Optimal Positioning of Local Anaesthetic in Femoral Nerve Block Prior to Operative Fixation of Fractured Neck of Femur|Completed||N/A|60|Actual|Cork University Hospital||3|||f||||f||||||||||2018-05-31 21:40:11.81465|2018-05-31 21:40:11.81465
NCT01527773|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-08-09|2012-02-06|2012-02-07|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2011||2011-05-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|TOPDOCS||Phenotypes and Vascular Damage in Chronic Obstructive Pulmonary Disease (COPD)|The Obstructive Pulmonary Disease Outcomes Cohort of Switzerland (TOP DOCS): Phenotypes and Vascular Damage in COPD|Completed|||313|Actual|University of Zurich|||1||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 21:40:12.05085|2018-05-31 21:40:12.05085
NCT01527760|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-14|2012-02-03|2012-02-07|Estimate|||||||2012-02-14|2012-02-16|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension|Effectiveness of Viscum Album Mother Tincture as an Anti-hypertensive in Essential Hypertension. One Group Pretest Posttest Design|Completed||N/A|37|Actual|Fr Muller Homoeopathic Medical College|||||f||||t||||||||||2018-05-31 21:40:12.226774|2018-05-31 21:40:12.226774
NCT01527747|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-10-13|2012-02-06|2012-02-07|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Effects of DPP-4 Inhibition on Triglycerides|Effects of Dipeptidyl Peptidase-4 Inhibition With Saxagliptin on Fasting and Postprandial Triglyceride Concentrations|Unknown status|Recruiting|Phase 4|30|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 21:40:12.318664|2018-05-31 21:40:12.318664
NCT01527734|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-02-07|2012-02-06|2012-02-07|Estimate|||||||2012-02-07|2012-02-08|Estimate|December 2011||2011-12-31|February 2012|2012-02-29||||January 2012|Actual|2012-01-31||Interventional|||Comparison Study of Liquid and Lyophilized Formulations of Subcutaneous Tetrodotoxin (TTX) in Healthy Volunteers|COMPARISON OF THE PHARMACOKINETICS AND SAFETY OF LIQUID (30 µg) AND LYOPHILIZED TETRODOTOXIN (15 µg AND 30 µg) FOLLOWING SINGLE AND TWICE DAILY SUBCUTANEOUS DOSE ADMINISTRATION TO HEALTHY VOLUNTEERS—DETERMINATIONS IN BLOOD AND URINE|Completed||Phase 1|44|Actual|Wex Pharmaceuticals Inc.||2|||f||||||||||||||2018-05-31 21:40:12.43649|2018-05-31 21:40:12.43649
NCT01527721|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2017-01-14|2012-02-06|2012-02-07|Estimate|||||||2017-01-14|2017-01-18|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus|Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CXL Combined With Photorefractive Keratectomy (PRK) in Keratoconus.|Completed||N/A|32|Actual|Democritus University of Thrace||2|||f||||f||||||||||2018-05-31 21:40:12.529577|2018-05-31 21:40:12.529577
NCT01527708|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-03|2012-02-03|2012-02-07|Estimate|||||||2012-02-03|2012-02-07|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas|Repeatability, Reliability and Reproducibility of Pentacam-derived Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Cross-linked Corneas|Completed|||129|Actual|Democritus University of Thrace|||3||f||||t||||||||||2018-05-31 21:40:12.619994|2018-05-31 21:40:12.619994
NCT01527695|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-01-30|2012-02-03|2012-02-07|Estimate|||||||2013-01-30|2013-01-31|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||PET Study in Parkinson's Disease Patients|A Phase IIA, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment With Oral AZD3241 on Microglia Activation, as Measured by Positron Emission Tomography (PET), in Patients With Parkinson's Disease|Completed||Phase 2|24|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:40:12.752681|2018-05-31 21:40:12.752681
NCT01527682|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2015-08-31|2012-02-02|2012-02-07|Estimate|||||||2015-08-31|2015-09-01|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma|Efficacy and Safety of Prostaglandin Analogue and Carbonic Anhydrase Inhibitor for the Treatment of Pediatric Glaucoma|Unknown status|Active, not recruiting|Phase 2|69|Actual|Azienda Ospedaliera Spedali Civili di Brescia||1|||f||||t||||||||||2018-05-31 21:40:12.874407|2018-05-31 21:40:12.874407
NCT01527669|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-07-09|2012-02-02|2012-02-07|Estimate|||||||2012-07-09|2012-07-11|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects|The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects.|Completed||Phase 4|12|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 21:40:12.971744|2018-05-31 21:40:12.971744
NCT01527656|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-01-05|2012-02-02|2012-02-07|Estimate|||||||2017-01-05|2017-01-06|Estimate|December 2003||2003-12-31|January 2017|2017-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects|Single-Centre, Randomised, Balanced, Double-Blind, Cross-Over Trial Investigating the Bioequivalence of Formulation 2 and Formulation 4 of Biphasic Insulin Aspart 70 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:40:13.086526|2018-05-31 21:40:13.086526
NCT01527643|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-02-22|2012-02-02|2012-02-07|Estimate|||||||2017-02-22|2017-02-24|Actual|November 11, 2003|Actual|2003-11-11|February 2017|2017-02-28|December 17, 2003|Actual|2003-12-17|December 17, 2003|Actual|2003-12-17||Interventional|||Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects|Single-Centre, Randomised, Balanced, Double- Blind, Cross-Over Trial Investigating the Bioequivalence of Formulation 2 and Formulation 4 of Biphasic Insulin Aspart 50 in Healthy Male Subjects|Completed||Phase 1|30|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:40:13.186722|2018-05-31 21:40:13.186722
NCT01527630|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-02-22|2012-02-02|2012-02-07|Estimate|||||||2017-02-22|2017-02-24|Actual|November 16, 2002|Actual|2002-11-16|February 2017|2017-02-28|January 8, 2003|Actual|2003-01-08|January 8, 2003|Actual|2003-01-08||Interventional|||Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects|A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Testing the Bioequivalence of Two Formulations of NN-X14Mix50 in Healthy Japanese Subjects|Completed||Phase 1|30|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:40:13.267228|2018-05-31 21:40:13.267228
NCT01527617|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2016-06-01|2012-02-02|2012-02-07|Estimate|||||||2016-06-01|2016-06-02|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Effect of Chronic Consumption of a Cranberry Beverage on Inflammation and Oxidative Stress|The Effect of Chronic Consumption of a Cranberry Beverage on Inflammation and Oxidative Stress in Healthy But Overweight/Obese Subjects: A Randomized Clinical Trial|Completed||N/A|79|Actual|Tufts University||2|||f||||||||||||||2018-05-31 21:40:13.349617|2018-05-31 21:40:13.349617
NCT01527604|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2014-11-18|2012-02-02|2012-02-07|Estimate|||||||2014-11-18|2014-11-19|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Avenanthramide-enriched Oats on Inflammation|Effects of Avenanthramide-enriched Oats on Inflammation in Obese Adults With Central Adiposity: A Randomized Clinical Trial|Completed||N/A|16|Actual|Tufts University||2|||f||||||||||||||2018-05-31 21:40:13.424693|2018-05-31 21:40:13.424693
NCT01527591|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-11-30|2012-02-06|2012-02-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2012||2012-02-29|November 2015|2015-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)|Safety And Long-Term Immunogenicity Of The 13-Valent Pneumococcal Conjugate Vaccine In Children Who Are Solid Organ Transplant Recipients|Recruiting||N/A|45|Anticipated|University of California, Los Angeles|||||f||||f||||||||||2018-05-31 21:40:13.502643|2018-05-31 21:40:13.502643
NCT01527578|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-05-08|2012-02-06|2012-02-07|Estimate|||||||2014-05-08|2014-05-12|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Observational|||Simons Variation in Individuals Project, Functional Common Acquisition Protocol|Functional Common Acquisition Protocol Phase of the Simons VIP|Completed|||120|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-05-31 21:40:13.579392|2018-05-31 21:40:13.579392
NCT01527565|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-02-22|2012-02-02|2012-02-07|Estimate|||||||2017-02-22|2017-02-24|Actual|January 20, 2003|Actual|2003-01-20|February 2017|2017-02-28|February 26, 2003|Actual|2003-02-26|February 26, 2003|Actual|2003-02-26||Interventional|||Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects|A Single-Centre, Randomised, Balanced, Double-Blind, Cross-Over Trial Investigating the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects|Completed||Phase 1|30|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:40:13.63216|2018-05-31 21:40:13.63216
NCT01527552|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-02-22|2012-02-02|2012-02-07|Estimate|||||||2017-02-22|2017-02-24|Actual|November 5, 2002|Actual|2002-11-05|February 2017|2017-02-28|December 18, 2002|Actual|2002-12-18|December 18, 2002|Actual|2002-12-18||Interventional|||Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects|A Single-Centre, Randomised, Balanced, Double-Blind, Cross-Over Trial Investigating the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects|Completed||Phase 1|30|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:40:13.714592|2018-05-31 21:40:13.714592
NCT01527539|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-02-22|2012-02-02|2012-02-07|Estimate|||||||2017-02-22|2017-02-24|Actual|November 23, 2001|Actual|2001-11-23|February 2017|2017-02-28|October 12, 2004|Actual|2004-10-12|October 12, 2004|Actual|2004-10-12||Interventional|||Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes|A Multi-centre, Non-comparative, Open-labelled, Extension Trial to Assess the Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes (Extension to BIAsp-1237)|Completed||Phase 3|25|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:40:13.788183|2018-05-31 21:40:13.788183
NCT01527526|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2015-06-03|2012-02-06|2012-02-07|Estimate|||||||2015-06-03|2015-06-04|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|DMPA||Depot-medroxyprogesterone Acetate (DMPA) Contraceptive Method and Metabolism|Prospective Study for Evaluation of the Insulin Resistance, Lipid Metabolism and Sub Clinical Cardiovascular Disease in Women Who Initiate the Depot-medroxyprogesterone Acetate (DMPA) Contraceptive Method With in Follow-up for Two Years|Completed|||54|Actual|University of Campinas, Brazil|||||f||||f||||||Samples Without DNA|"~     Serum samples for determination of lipid profile, insulin, glucose, coagulation factors,~     neuropeptide Y and factors related to bone mineral density.~   "|||2018-05-31 21:40:13.860239|2018-05-31 21:40:13.860239
NCT01527513|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|2014-01-10||2014-10-23|2012-02-03|2012-02-07|Estimate|2014-10-23|2014-10-24|Estimate||||2014-10-23|2014-10-24|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|March 2012|Actual|2012-03-31||Interventional|||Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures|Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures: an add-on, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Clinical Trial|Completed||Phase 2|123|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 21:40:13.951599|2018-05-31 21:40:13.951599
NCT01527500|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-03-16|2012-02-06|2012-02-07|Estimate|||||||2016-03-16|2016-03-17|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)|A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration|Completed||Phase 2|158|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:40:14.800318|2018-05-31 21:40:14.800318
NCT01527487|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2016-03-18||2016-10-03|2012-02-06|2012-02-07|Estimate|2016-07-15|2016-08-26|Estimate||||2016-10-03|2016-11-04|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|September 2014|Actual|2014-09-30||Interventional||Analysis population for ErC includes 10 lead-in and 44 randomized patients.|Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer|A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer|Completed||Phase 2|76|Actual|SCRI Development Innovations, LLC||2|||f||||t||||||||||2018-05-31 21:40:15.130931|2018-05-31 21:40:15.130931
NCT01527474|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-09|2012-02-03|2012-02-07|Estimate|||||||2012-02-09|2012-02-10|Estimate|April 2008||2008-04-30|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Escitalopram in the Treatment of Postpartum Depression|An Open-label Study of Escitalopram in the Treatment of Postpartum Depression|Completed||N/A|20|Actual|BC Women's Hospital & Health Centre|||||f||||f||||||||||2018-05-31 21:40:15.617093|2018-05-31 21:40:15.617093
NCT01527461|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2013-06-02|2012-02-06|2012-02-07|Estimate|||||||2013-06-02|2013-06-04|Estimate|February 2012||2012-02-29|June 2013|2013-06-30||||||||Observational|||Identifying Unique Scent Signature of Lung Cancer Through Body Odor||Unknown status|Recruiting||100|Anticipated|Sheba Medical Center|||2||f||||f||||||Samples Without DNA|"~     sweat samples~   "|||2018-05-31 21:40:15.692341|2018-05-31 21:40:15.692341
NCT01527448|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-09|2012-02-03|2012-02-07|Estimate|||||||2012-02-09|2012-02-10|Estimate|April 2008||2008-04-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II|An Open Label Dose Titration Study of Quetiapine XR in the Treatment of Postpartum Depression in Nonlactating Women Diagnosed With Bipolar Disorder (BD), Type II.|Completed||N/A|26|Actual|BC Women's Hospital & Health Centre||1|||f||||f||||||||||2018-05-31 21:40:15.778361|2018-05-31 21:40:15.778361
NCT01527435|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-04-05|2012-02-06|2012-02-07|Estimate|||||||2016-04-05|2016-04-06|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ARMD||Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD)|Zeaxanthin as an Adjuvant to Combination Therapy for Treatment of Choroidal Neovascularization (CNV) in Exudative Age Related Macular Degeneration (ARMD)|Completed|||200|Actual|The Retina Center of St. Louis County, PC|||||f||||f||||||||||2018-05-31 21:40:15.851128|2018-05-31 21:40:15.851128
NCT01527422|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2012-02-03|2012-02-03|2012-02-07|Estimate|||||||2012-02-03|2012-02-07|Estimate|January 2006||2006-01-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|CHOP-R||Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL|"Protocol CCAM 05-02  Phase I-II Study of Dose Dense of PEG Filgrastim and GM-CSF as Support for Dose Desnse CHOP-R Front Line Therapy for Aggressive Non Hodgkin's Lymphoma"|Completed||Phase 1/Phase 2|60|Actual|Auxilio Mutuo Cancer Center|||||f||||t||||||||||2018-05-31 21:40:15.906784|2018-05-31 21:40:15.906784
NCT01527409|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-02-06|2012-02-06|2012-02-07|Estimate|||||||2012-02-06|2012-02-07|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||The Efficacy of Health Partnership Program for Cancer Patients|The Efficacy of Health Partnership Program for Cancer Patients|Unknown status|Recruiting|N/A|248|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 21:40:16.032701|2018-05-31 21:40:16.032701
NCT01527396|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2015-10-27|2012-02-06|2012-02-07|Estimate|||||||2015-10-27|2015-10-28|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Observational|PALME||Prospective, Observational Study of Low-risk Criteria for Node Metastasis in Endometrial Cancer|Multi-center Prospective Observational Study for the Validation of Preoperative Low-risk Criteria for Lymph Node Metastasis in Endometrial Cancer|Completed|||529|Actual|National Cancer Center, Korea|||||f||||t||||||||||2018-05-31 21:40:16.230349|2018-05-31 21:40:16.230349
NCT01527383|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2018-01-22|2012-02-02|2012-02-07|Estimate|||||||2018-01-22|2018-01-23|Actual|February 21, 2012|Actual|2012-02-21|January 2018|2018-01-31|February 26, 2013|Actual|2013-02-26|February 26, 2013|Actual|2013-02-26||Interventional|||A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)|A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease|Completed||Phase 2|354|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:40:16.305525|2018-05-31 21:40:16.305525
NCT01527370|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2013-11-11||2017-03-14|2012-02-02|2012-02-07|Estimate|2013-11-11|2013-12-30|Estimate||||2017-03-14|2017-04-12|Actual|October 2012||2012-10-31|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)|A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in India|Completed||Phase 3|250|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:40:16.408705|2018-05-31 21:40:16.408705
NCT01527357|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26||2014-04-14|2014-06-06|2012-02-06|2012-02-07|Estimate||||2014-05-07|2014-05-23|Estimate|2014-06-06|2014-06-18|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|FINISH-3||Phase 3 Study of Fibrocaps™ in Surgical Bleeding|A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Hemostasis|Completed||Phase 3|719|Actual|Mallinckrodt||2|||f||||t||||||||||2018-05-31 21:40:16.644848|2018-05-31 21:40:16.644848
NCT01527344|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2014-05-08|2012-02-06|2012-02-07|Estimate|||||||2014-05-08|2014-05-09|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|CAV-OCT-IVUS||Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography|Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography as Compared to Intravascular Ultrasound-Virtual Histology|Completed|||82|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 21:40:16.810787|2018-05-31 21:40:16.810787
NCT01527331|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-04-28|2012-02-06|2012-02-07|Estimate|||||||2012-04-28|2012-05-01|Estimate|June 2011||2011-06-30|April 2012|2012-04-30||||December 2012|Anticipated|2012-12-31||Interventional|||A ProspectiveTrial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer||Unknown status|Recruiting|N/A|150|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:40:16.915151|2018-05-31 21:40:16.915151
NCT01527318|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-05-13|2012-02-06|2012-02-07|Estimate|||||||2013-05-13|2013-05-14|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|NLSDM||The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)|The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)|Completed||Phase 4|6|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 21:40:17.022801|2018-05-31 21:40:17.022801
NCT01527305|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2014-12-24|2012-02-06|2012-02-07|Estimate|||||||2014-12-24|2014-12-25|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PREVAIL||A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia|An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia|Completed||Phase 4|212|Actual|Johnson & Johnson Pte Ltd||1|||f||||f||||||||||2018-05-31 21:40:17.120761|2018-05-31 21:40:17.120761
NCT01527292|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-04-04|2012-02-06|2012-02-07|Estimate|||||||2017-04-04|2017-04-06|Actual|February 2012|Actual|2012-02-29|January 2016|2016-01-31|September 2, 2015|Actual|2015-09-02|May 2, 2015|Actual|2015-05-02||Interventional|||Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis|Randomized Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis|Terminated||Phase 2|3|Actual|James Graham Brown Cancer Center||2||Unable to enroll|f||||t||||||||||2018-05-31 21:40:17.26064|2018-05-31 21:40:17.26064
NCT01527279|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2015-05-21|2012-02-06|2012-02-07|Estimate|||||||2015-05-21|2015-05-22|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|AnPAF||Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation|Clinical Efficacy of Antazoline in Rapid Cardioversion of Paroxysmal Atrial Fibrillation - a Single Centre, Randomized, Double-blind, Placebo-controlled Study (the AnPAF Study)|Completed||Phase 4|74|Actual|Institute of Cardiology, Warsaw, Poland||2|||f||||t||||||||||2018-05-31 21:40:17.344662|2018-05-31 21:40:17.344662
NCT01527266|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-10-16|2012-02-02|2012-02-06|Estimate|||||||2012-10-16|2012-10-17|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|CHO rinse||Carbohydrate Mouth-rinse|The Impact of a Sucrose Mouth-rinse in the Fasted and Fed-state on Time Trial Performance|Unknown status|Recruiting|N/A|15|Anticipated|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 21:40:17.496853|2018-05-31 21:40:17.496853
NCT01527253|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-05-22|2012-02-02|2012-02-06|Estimate|||||||2014-05-22|2014-05-23|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Effect of a Synergistic Food Basket on Metabolic Syndrome Risk|Effects of a Synergistic Food Basket on Markers of Metabolic Syndrome Risk in Healthy Mature Women|Completed||N/A|52|Actual|Lund University||2|||f||||f||||||||||2018-05-31 21:40:17.623341|2018-05-31 21:40:17.623341
NCT01527240|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-05-15|2012-02-02|2012-02-06|Estimate|||||||2014-05-15|2014-05-16|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|December 2013|Actual|2013-12-31|October 2009|Actual|2009-10-31||Interventional|CsAStroke||Neuroprotection Impact of Cyclosporin A in Cerebral Infarction|Cyclosporin A Combined to Intravenous Thrombolysis. Multicenter Randomized Placebo-controlled|Completed||Phase 2|126|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 21:40:17.753924|2018-05-31 21:40:17.753924
NCT01527227|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-02-02|2012-02-02|2012-02-06|Estimate|||||||2012-02-02|2012-02-06|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|||Parentification Among Children Whose Parents Cope With a Serious Mental Illness|Parentification Among Children Whose Parents Cope With a Serious Mental Illness|Unknown status|Recruiting||130|Anticipated|Hillel Yaffe Medical Center|||1||f||||f||||||||||2018-05-31 21:40:17.841382|2018-05-31 21:40:17.841382
NCT01527214|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2013-08-05|2012-02-03|2012-02-06|Estimate|||||||2013-08-05|2013-08-07|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of Direct Referral for Fast CT Scan in Early Lung Cancer Detection in General Practice|The Effect of Direct Referral for Fast CT Scan in Early Lung Cancer Detection in General Practice. Clinical, Randomised Trial|Completed||N/A|650|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:40:17.914797|2018-05-31 21:40:17.914797
NCT01527201|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-10-14|2012-02-01|2012-02-06|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The ChAMP (Chondral Lesions And Meniscus Procedures) Trial|Design of a Randomized Controlled Trial Examining the Effects of Arthroscopic Debridement on Chondral Lesions in Patients Undergoing Partial Meniscectomy: The ChAMP (Chondral Lesions And Meniscus Procedures) Trial|Completed||N/A|190|Actual|State University of New York at Buffalo||2|||f||||t||||||||||2018-05-31 21:40:18.134205|2018-05-31 21:40:18.134205
NCT01527188|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2013-08-01|2012-02-03|2012-02-06|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite (HDM) Tablets in Allergic Rhinitis Environment Exposure Chamber Model|A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase II Study to Assess the Efficacy and Safety of 100IR, 300IR and 500IR Sublingual Tablets of House Dust Mite Allergen for the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber Model|Completed||Phase 2|355|Actual|Stallergenes Greer||4|||f||||f||||||||||2018-05-31 21:40:18.246011|2018-05-31 21:40:18.246011
NCT01527175|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2012-03-30|2012-02-01|2012-02-06|Estimate|||||||2012-03-30|2012-04-02|Estimate|November 2011||2011-11-30|March 2012|2012-03-31||||February 2012|Actual|2012-02-29||Interventional|SuCVC||Ultrasound-guided Subclavian Venous Catheterization in Children|Comparision of Ultrasound-guided Supraclavicular and Infraclavicular Approach for Central Venous Catheterization in Children|Completed||N/A|98|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:40:18.372117|2018-05-31 21:40:18.372117
NCT01527162|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2015-11-16||2016-02-03|2012-02-01|2012-02-06|Estimate|2016-02-03|2016-02-04|Estimate||||2016-02-03|2016-02-04|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|SAFO|ages 3.0 to 5.8 years, mean age 4.3 years, spastic diplegia cerebral palsy, all wearing current AFO bilaterally to enhance walking activity|Orthotics in Ambulatory Cerebral Palsy|Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy|Completed||Phase 3|11|Actual|Seattle Children's Hospital||2|||f||||f||||||||No||2018-05-31 21:40:18.450026|2018-05-31 21:40:18.450026
NCT01527149|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-01-25|2012-02-03|2012-02-06|Estimate|||||||2018-01-25|2018-01-29|Actual|December 6, 2011|Actual|2011-12-06|January 2018|2018-01-31|October 5, 2021|Anticipated|2021-10-05|October 5, 2020|Anticipated|2020-10-05||Interventional|||Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma|Active, not recruiting||Phase 2|37|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 21:40:18.717692|2018-05-31 21:40:18.717692
NCT01527136|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-01-11|2012-02-03|2012-02-06|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2012||2012-01-31|January 2016|2016-01-31||||October 2014|Actual|2014-10-31||Interventional|||Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery|A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients With Advanced Cancers|Completed||Phase 1|25|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 21:40:18.907767|2018-05-31 21:40:18.907767
NCT01527123|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-07-24|2012-02-02|2012-02-06|Estimate|||||||2017-07-24|2017-07-26|Actual|February 28, 2012|Actual|2012-02-28|July 2017|2017-07-31|June 1, 2012|Actual|2012-06-01|June 1, 2012|Actual|2012-06-01||Interventional|||A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris|A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:40:19.073204|2018-05-31 21:40:19.073204
NCT01526928|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-07-26|2012-02-02|2012-02-06|Estimate|||||||2016-07-26|2016-07-28|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients|A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral Rociletinib in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1/Phase 2|605|Anticipated|Clovis Oncology, Inc.||1|||f||||f||||||||||2018-05-31 21:40:23.306277|2018-05-31 21:40:23.306277
NCT01527110|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2017-07-11||2018-02-20|2012-02-02|2012-02-06|Estimate|2018-02-20|2018-02-21|Estimate||||2018-02-20|2018-02-21|Estimate|January 1, 2012||2012-01-01|July 2017|2017-07-31|March 29, 2013|Actual|2013-03-29|March 1, 2013|Actual|2013-03-01||Interventional|||A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection|An Open-label, Multi-centre, Single Arm Study to Evaluate the Safety and Efficacy of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Confirmed Influenza Infection (NAI115215)|Completed||Phase 3|21|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:40:19.274552|2018-05-31 21:40:19.274552
NCT01527097|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2015-11-16|2012-02-03|2012-02-06|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Influence of Atorvastatin on Psoriasis Severity and Endothelial Function|Atorvastatin to Reduce Psoriasis Severity and Improve Endothelial Function in Patients With Severe Psoriasis and Non-Elevated LDL Levels: A Randomized, Double Blind, Placebo-Controlled Study.|Withdrawn||Phase 3|0|Actual|Rabin Medical Center||2||"We strongly feel that the ability to recruit the required number of patients is very low and~   thus decided to stop the study."|f||||f||||||||||2018-05-31 21:40:20.497503|2018-05-31 21:40:20.497503
NCT01527084|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2014-11-08|2012-02-03|2012-02-06|Estimate|||||||2014-11-08|2014-11-11|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Timing of Surgical Intervention After Percutaneous Catheter Drainage in STEP UP Approach for Severe Acute Pancreatitis|Timing of Surgical Intervention After Percutaneous Catheter Drainage in STEP UP Approach for Severe Acute Pancreatitis: a Randomized Controlled Stud|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 21:40:20.586181|2018-05-31 21:40:20.586181
NCT01527058|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-04-05|2012-02-01|2012-02-06|Estimate|||||||2017-04-05|2017-04-07|Actual|December 2011||2011-12-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GRGDLC||68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients|Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-BNOTA-PRGD2 in Healthy Volunteers and Lung Cancer Patients|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 21:40:20.688757|2018-05-31 21:40:20.688757
NCT01527045|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-02-08|2012-02-02|2012-02-06|Estimate|||||||2018-02-08|2018-02-12|Actual|September 25, 2012|Actual|2012-09-25|February 2018|2018-02-28||||October 26, 2018|Anticipated|2018-10-26||Interventional|||Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies|Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation|Recruiting||Phase 2|100|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 21:40:20.772701|2018-05-31 21:40:20.772701
NCT01527032|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-03-24|2012-02-02|2012-02-06|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2002||2002-09-30|July 2011|2011-07-31|September 2005|Actual|2005-09-30|||||Interventional|||Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis|Risk-adapted Therapy for AL Amyloidosis|Completed||Phase 2|||FDA Office of Orphan Products Development|||||||||||||||||||2018-05-31 21:40:20.881609|2018-05-31 21:40:20.881609
NCT01527019|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-07-24|2012-02-02|2012-02-06|Estimate|||||||2015-07-24|2015-07-27|Estimate|October 2012||2012-10-31|February 2012|2012-02-29||||October 2012|Actual|2012-10-31||Interventional|CECI||Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)|A Phase III Non-Inferiority Open-label Multicenter Randomized Clinical Trial to Compare CEPHALOSPORIN to NORFLOXACIN in the Treatment of Acute Cystitis|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||3||the company suspended the persecution of this combination|f||||t||||||||||2018-05-31 21:40:21.050701|2018-05-31 21:40:21.050701
NCT01527006|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2015-07-31||2016-06-13|2012-02-02|2012-02-06|Estimate|2015-07-31|2015-08-28|Estimate||||2016-06-13|2016-07-12|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|||Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs|An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy|Completed||Phase 2|63|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 21:40:21.246394|2018-05-31 21:40:21.246394
NCT01526980|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-01-04|2012-02-01|2012-02-06|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2002||2002-05-31|January 2017|2017-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes|A Single-Centre, Randomised, Open-Labelled, Two-Period, Crossover Trial In Subjects With Type 2 Diabetes Comparing the Glycaemic Control of Two Treatment Regimens: A Thrice Daily Regimen With Biphasic Insulin Aspart 70 and - 30 and a Twice Daily Regimen With Biphasic Human Insulin 30|Completed||Phase 2|31|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:40:22.875853|2018-05-31 21:40:22.875853
NCT01526967|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-12-14|2012-02-02|2012-02-06|Estimate|||||||2012-12-14|2012-12-17|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|OSMOSE||Observational Evaluation of the Peristomal Skin Condition in Ostomates|Observational Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™ Skin Barriers|Unknown status|Active, not recruiting||2000|Anticipated|ConvaTec Inc.|||2||f||||f||||||||||2018-05-31 21:40:22.971299|2018-05-31 21:40:22.971299
NCT01526954|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-12-03|2012-02-02|2012-02-06|Estimate|||||||2013-12-03|2013-12-05|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Cohera TissuGlu® Surgical Adhesive in the Management of Wound Drainage|A Prospective, Randomized, Controlled, Single-blind, Multicenter Clinical Trial Evaluating the Safety and Efficacy of the Cohera TissuGlu® Surgical Adhesive in the Management of Wound Drainage as Compared to the Standard of Care Closure Techniques Following Abdominoplasty|Completed||Phase 2/Phase 3|150|Actual|Cohera Medical, Inc.||2|||f||||||||||||||2018-05-31 21:40:23.137824|2018-05-31 21:40:23.137824
NCT01526941|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-01-04|2012-02-01|2012-02-06|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2001||2001-05-31|January 2017|2017-01-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes|A Double-blind, Randomised, Two-Period Crossover Trial Comparing the Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Insulin Aspart 70 in Subjects With Type 1 Diabetes|Completed||Phase 1|27|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:40:23.219029|2018-05-31 21:40:23.219029
NCT01526915|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-04-06|2012-02-02|2012-02-06|Estimate|||||||2017-04-06|2017-04-07|Actual|September 2011||2011-09-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|OCN/PRF||Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates|Contribution of Platelet Rich Fibrin (PRF) After Tooth Avulsion in the Prevention of Healing Delay and of Jawbone Osteochemonecrosis Induced by Bisphosphonates|Suspended||N/A|270|Anticipated|Centre Hospitalier Régional Metz-Thionville||2|||f||||t||||||||||2018-05-31 21:40:23.570182|2018-05-31 21:40:23.570182
NCT01526902|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2013-11-01||2014-03-07|2012-02-02|2012-02-06|Estimate|2014-02-03|2014-03-06|Estimate||||2014-03-07|2014-04-07|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Proclear 1-D Multifocal Nondispensing Study|Proclear 1-D Multifocal Nondispensing Study|Completed||N/A|49|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 21:40:23.696736|2018-05-31 21:40:23.696736
NCT01526889|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01||2017-12-12|2017-12-12|2012-02-03|2012-02-06|Estimate||||2017-12-12|2017-12-14|Actual|2017-12-12|2017-12-14|Actual|October 8, 2012|Actual|2012-10-08|December 2017|2017-12-31|August 24, 2017|Actual|2017-08-24|February 16, 2017|Actual|2017-02-16||Interventional|||Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,|A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy|Completed||Phase 2|24|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:40:23.935806|2018-05-31 21:40:23.935806
NCT01526876|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-07-13|2012-02-03|2012-02-06|Estimate|||||||2017-07-13|2017-07-17|Actual|November 2011||2011-11-30|July 2017|2017-07-31|December 19, 2012|Actual|2012-12-19|November 2012|Actual|2012-11-30||Interventional|||The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients|Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury|Withdrawn||Phase 4|0|Actual|Columbia University||1||Terminated by Sponsor|f||||f||||||||||2018-05-31 21:40:24.057178|2018-05-31 21:40:24.057178
NCT01526863|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-01-15|2012-02-03|2012-02-06|Estimate|||||||2015-01-15|2015-01-16|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Hydrolyzed Egg and Tolerance Induction|Assessment of the Effect of an HA Egg Administration for 6 Months on the Tolerance Induction to Egg in Children Allergic to Egg as Compared to a Placebo|Completed||N/A|29|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 21:40:24.130989|2018-05-31 21:40:24.130989
NCT01526850|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-08-01|2012-02-02|2012-02-06|Estimate|||||||2012-08-01|2012-08-03|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|MSCsTcGVHD||Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease|Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:40:24.208674|2018-05-31 21:40:24.208674
NCT01526837|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2017-07-11|2012-02-02|2012-02-06|Estimate|||||||2017-07-11|2017-07-12|Actual|October 2011||2011-10-31|July 2017|2017-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence|A Dose-Escalating Phase I Study for Safety and Tolerability of Bevacizumab in Collagen Delivery Vehicle Administered Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence|Terminated||Phase 1|1|Actual|Brain & Spine Surgeons of New York||1||Investigators decision|f||||f||||||||||2018-05-31 21:40:24.301254|2018-05-31 21:40:24.301254
NCT01526824|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-01|2012-02-01|2012-02-06|Estimate|||||||2012-02-01|2012-02-06|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Lovaza's Effect on Clopidogrel in a Neuro Population|The Effects of Polyunsaturated Omega-3 Fatty Acids (Lovaza) on Patients Taking Clopidogrel +/- Aspirin Who Have Suffered an Ischemic Stroke/TIA and/or Are Candidates for Neuroendovascular Stenting.|Unknown status|Recruiting|Early Phase 1|60|Anticipated|Millard Fillmore Gates Hospital||2|||f||||f||||||||||2018-05-31 21:40:24.416994|2018-05-31 21:40:24.416994
NCT01526811|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2018-01-04|2012-02-01|2012-02-06|Estimate|||||||2018-01-04|2018-01-08|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)|Post-market Study on Endurant™ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms|Active, not recruiting|||180|Actual|Medtronic Endovascular|||1||f||||f||||||||||2018-05-31 21:40:24.543277|2018-05-31 21:40:24.543277
NCT01526798|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-04-19|2012-02-02|2012-02-06|Estimate|||||||2017-04-19|2017-04-20|Actual|March 2012||2012-03-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CIEPO-PILOT||Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off Hemodialysis|Improvement of EPO-resistance in HD Patients With Chronic Inflammation by High Cut-off Hemodialysis - Pilot Study (CIEPO-PILOT)|Completed||N/A|24|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 21:40:25.700033|2018-05-31 21:40:25.700033
NCT01526785|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|2015-09-29||2015-11-09|2012-02-03|2012-02-06|Estimate|2015-09-29|2015-10-27|Estimate||||2015-11-09|2015-12-08|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Full analysis population defined as all participants who receive at least 1 infusion of 4000 L alglucosidase alfa during the study.|A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease|A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale|Terminated||Phase 4|113|Actual|Sanofi||1||Terminated due to approved label expansion|f||||t||||||||||2018-05-31 21:40:25.878476|2018-05-31 21:40:25.878476
NCT01526772|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-11-03|2012-02-01|2012-02-06|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2011||2011-09-30|April 2017|2017-04-30|July 7, 2014|Actual|2014-07-07|July 7, 2014|Actual|2014-07-07||Observational|||A Prospective Study Evaluating The Utility of Transnasal Endoscopy With Roux en Y Gastric Bypass|A Prospective Study Evaluating The Utility of Transnasal Endoscopy With Roux en Y Gastric Bypass Referred for Upper Endoscopy|Completed|||11|Actual|Wake Forest University Health Sciences|||1||f||||f||||||||||2018-05-31 21:40:26.986512|2018-05-31 21:40:26.986512
NCT01526759|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2012-03-09|2012-02-01|2012-02-06|Estimate|||||||2012-03-09|2012-03-12|Estimate|December 2011||2011-12-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|FLiTS||Fiber Longer Term Study on Energy Intake|The Effect of 2 Weeks of Supplementation of a High-gelling, High-viscous Dietary Fibre on Energy Intake|Completed||N/A|35|Actual|Wageningen University||2|||f||||t||||||||||2018-05-31 21:40:27.066612|2018-05-31 21:40:27.066612
NCT01526746|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-02-14|2012-02-03|2012-02-06|Estimate|||||||2014-02-14|2014-02-17|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function|An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment With That in Matched Control Subjects With Relatively Normal Renal Function|Completed||Phase 1|32|Actual|Vanda Pharmaceuticals||3|||f||||f||||||||||2018-05-31 21:40:27.137278|2018-05-31 21:40:27.137278
NCT01526733|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2014-09-23||2014-09-23|2012-02-03|2012-02-06|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|August 2012|Actual|2012-08-31||Interventional||All enrolled participants.|Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase|A Phase 4, Randomized, Double-Blind, 2-Way Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) With, Compared to Without, Pretreatment With Recombinant Human Hyaluronidase (rHuPH20)|Completed||Phase 4|25|Actual|Halozyme Therapeutics||2|||f||||f||||||||||2018-05-31 21:40:27.383724|2018-05-31 21:40:27.383724
NCT01526720|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-02-03|2012-02-03|2012-02-06|Estimate|||||||2012-02-03|2012-02-06|Estimate|October 2003||2003-10-31|February 2012|2012-02-29|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|VNDS||The Verona Newly Diagnosed Type 2 Diabetes Study|The Verona Newly Diagnosed Type 2 Diabetes Study. Construction of a Biobank of Diabetes Related Genotypes and Phenotypes|Recruiting|||1500|Anticipated|Universita di Verona|||2||f||||t||||||Samples With DNA|"~     Whole blood Serum Plasma Urine~   "|||2018-05-31 21:40:28.052312|2018-05-31 21:40:28.052312
NCT01526707|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2014-10-08|2012-02-02|2012-02-06|Estimate|||||||2014-10-08|2014-10-10|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Use of FKBP51 in the Identification of Non-adherence to Inhaled Corticosteroids in Difficult Asthma|The Use of FKBP51 in the Identification of Non-adherence to Inhaled Corticosteroids in Difficult Asthma|Completed||N/A|40|Actual|Belfast Health and Social Care Trust||1|||f||||t||||||||||2018-05-31 21:40:28.155837|2018-05-31 21:40:28.155837
NCT01526694|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-07-14|2012-02-03|2012-02-06|Estimate|||||||2016-07-14|2016-07-15|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|December 2015|Actual|2015-12-31||Interventional|||Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs|Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs|Recruiting||Phase 2|30|Anticipated|Azienda Ospedaliera di Bolzano||1|||f||||f||||||||||2018-05-31 21:40:28.255059|2018-05-31 21:40:28.255059
NCT01526681|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-01-24|2012-02-02|2012-02-06|Estimate|||||||2016-01-24|2016-01-26|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|RANGER||Registry of Avance Nerve Graft Evaluating Utilization and Outcomes for the Reconstruction of Peripheral Nerve Discontinuities|Registry Study: A Multicenter, Retrospective Study of Avance Nerve Graft Utilization, Evaluations and Outcomes in Peripheral Nerve Injury Repair|Recruiting|||500|Anticipated|AxoGen, Inc|||2||f||||f||||||||Yes||2018-05-31 21:40:28.37821|2018-05-31 21:40:28.37821
NCT01526668|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-02-20|2012-02-03|2012-02-06|Estimate|||||||2016-02-20|2016-02-23|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|POSTHYSTREC||Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy|A Randomized Study Comparing Four Different Postoperative Follow-up Strategies for Improved Postoperative Recovery After Benign Hysterectomy|Unknown status|Recruiting|N/A|600|Anticipated|University Hospital, Linkoeping||4|||f||||t||||||||||2018-05-31 21:40:28.521384|2018-05-31 21:40:28.521384
NCT01526655|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2016-02-20|2012-02-01|2012-02-06|Estimate|||||||2016-02-20|2016-02-23|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|||Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer|A Randomized Open Controlled Trial Comparing Robot Assisted Laparoscopic Hysterectomy and Abdominal Hysterectomy for Endometrial Cancer in a Fast Track Program|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 21:40:28.633465|2018-05-31 21:40:28.633465
NCT01526642|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2017-08-21|2012-02-03|2012-02-06|Estimate|||||||2017-08-21|2017-08-22|Actual|December 2011||2011-12-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|NIVOLD||Home Non-invasive Ventilation for Chronic Obstructive Pulmonary Disease Patients|Home Non-invasive Ventilation Versus Long-term Oxygen Therapy in COPD Survivors of Acute Hypercapnic Respiratory Failure. A Multicenter Randomized Controlled Trial|Terminated||N/A|12|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 21:40:28.741462|2018-05-31 21:40:28.741462
NCT01526629|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2017-02-14||2017-04-18|2012-02-03|2012-02-06|Estimate|2017-04-18|2017-06-29|Actual||||2017-04-18|2017-06-29|Actual|May 2011||2011-05-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Full Automaticity and Remote Follow-up|Identification of Implantable Cardioverter Defibrillator Patients With Remote Follow up That Requires an Onsite Visit|Completed|||354|Actual|Medtronic Bakken Research Center|||1||f||||f||||||||||2018-05-31 21:40:28.806123|2018-05-31 21:40:28.806123
NCT01526616|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-02-03|2012-02-03|2012-02-06|Estimate|||||||2012-02-03|2012-02-06|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Spironolactone Plus Metformin in Polycystic Ovary Syndrome|Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study|Completed||N/A|56|Actual|University Magna Graecia||2|||f||||f||||||||||2018-05-31 21:40:28.988988|2018-05-31 21:40:28.988988
NCT01526603|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-03-22|2012-02-01|2012-02-06|Estimate|||||||2018-03-22|2018-03-23|Actual|March 28, 2012|Actual|2012-03-28|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||High Dose Chemotherapy and Autologous Transplant for Neuroblastoma|High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Rescue for Neuroblastoma: Standard of Care Considerations|Recruiting||N/A|20|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||f|f|f||||||||2018-05-31 21:40:29.103229|2018-05-31 21:40:29.103229
NCT01526590|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2015-06-03|2012-02-03|2012-02-06|Estimate|||||||2015-06-03|2015-06-04|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Contrast Enhanced Endoscopic Ultrasound for Vascular Involvement in Pancreatic Lesions|A Pilot Study of the Effects of Contrast Enhanced Endoscopic Ultrasound on Determining Vascular Involvement in Pancreatic Lesions|Withdrawn||N/A|0|Actual|University of Vermont||1||Lack of support|f||||f||||||||||2018-05-31 21:40:29.238599|2018-05-31 21:40:29.238599
NCT01526577|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-04-09|2012-02-03|2012-02-06|Estimate|||||||2012-04-09|2012-04-10|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Study of LC23-1306 in Healthy Male Subjects|A Dose Blocked-randomized, Double-blind, Active and Placebo Controlled, Single and Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect|Unknown status|Recruiting|Phase 1|96|Anticipated|LG Life Sciences||3|||f||||t||||||||||2018-05-31 21:40:29.337678|2018-05-31 21:40:29.337678
NCT01526564|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-11-07|2012-02-01|2012-02-06|Estimate|||||||2013-11-07|2013-11-11|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Clinical Study on Acetyl-L-Carnitine|Phase III Study of Acetyl-L-Carnitine (ALC) Hydrochloride Enteric-coated Tablets in Treatment of Peripheral Sensory Neuropathy in Anti-cancer Chemotherapeutics Induce|Completed||Phase 3|239|Actual|Lee's Pharmaceutical Limited||2|||f||||t||||||||||2018-05-31 21:40:29.458587|2018-05-31 21:40:29.458587
NCT01526551|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2015-02-19||2015-02-19|2012-02-03|2012-02-06|Estimate|2015-02-19|2015-03-06|Estimate||||2015-02-19|2015-03-06|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Compare the Impact of a School Based HPV Program on Vaccination Uptake and Completion Rates|A Study to Compare the Impact of a School Based HPV Vaccination Program on Vaccination Uptake and Completion Rates Among High School Students in Rural, Southeastern Kentucky|Completed||N/A|935|Actual|Lake Cumberland District Health Department||1|||f||||f||||||||||2018-05-31 21:40:29.643997|2018-05-31 21:40:29.643997
NCT01526538|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2015-09-10||2016-12-22|2012-02-03|2012-02-06|Estimate|2016-12-22|2017-02-15|Actual||||2016-12-22|2017-02-15|Actual|September 2011||2011-09-30|December 2016|2016-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Improving Learning-based Treatment of Cocaine Dependence With Medication|Improving Learning-based Treatment of Cocaine Dependence With Medication|Completed||Phase 2|52|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:40:29.858358|2018-05-31 21:40:29.858358
NCT01526525|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2014-02-20|2012-02-03|2012-02-06|Estimate|||||||2014-02-20|2014-02-21|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Perioperative Electroacupuncture on Postoperative Analgesia in Prostatectomy|Effect of Perioperative Electroacupuncture With Tramadol and Ketamine on Postoperative Analgesia in Prostatectomy: a Randomized Placebo-controlled Trial|Completed||Phase 4|70|Actual|G.Gennimatas General Hospital||2|||f||||f||||||||||2018-05-31 21:40:30.097645|2018-05-31 21:40:30.097645
NCT01526512|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2012-02-05|2012-02-03|2012-02-06|Estimate|||||||2012-02-05|2012-02-07|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer||Unknown status|Recruiting|Phase 2|72|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 21:40:30.208951|2018-05-31 21:40:30.208951
NCT01526499|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2012-02-05|2012-02-03|2012-02-06|Estimate|||||||2012-02-05|2012-02-07|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer||Unknown status|Recruiting|Phase 2|60|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 21:40:30.349432|2018-05-31 21:40:30.349432
NCT01526486|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2015-05-04|2012-02-03|2012-02-06|Estimate|||||||2015-05-04|2015-05-06|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer|Videoscopic Versus Open Inguinal Lymphadenectomy for Sentinel Node Positive Cutaneous Malignancies and Genitourinary Staging Procedures|Completed||N/A|29|Actual|Emory University||2|||f||||f||||||||||2018-05-31 21:40:30.458718|2018-05-31 21:40:30.458718
NCT01526473|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-03-28|2012-02-01|2012-02-06|Estimate|||||||2018-03-28|2018-03-29|Actual|February 2012|Actual|2012-02-29|March 2018|2018-03-31|December 2017|Actual|2017-12-31|March 2016|Actual|2016-03-31||Interventional|||A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901|A Phase I Study To Evaluate The Antitumor Activity And Safety Of DUKE-002-VRP(HUHER2-ECD+TM), An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region, In Patient With Locally Advanced Or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer|Completed||Phase 1|22|Actual|Duke University||1|||f||||f||||||||||2018-05-31 21:40:30.55985|2018-05-31 21:40:30.55985
NCT01526460|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-03-05|2012-02-02|2012-02-03|Estimate|||||||2014-03-05|2014-03-06|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|STATIPLAT||Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention|Prospective, Randomized, Single Center, Open Label Study Designed to Evaluate the Effect on Platelet Reactivity in Response to High Doses of Atorvastatin or Rosuvastatin Administered Before Percutaneous Coronary Intervention (PCI)|Completed||Phase 2|146|Actual|IRCCS San Raffaele||3|||f||||f||||||||||2018-05-31 21:40:30.642313|2018-05-31 21:40:30.642313
NCT01526447|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-02-20|2012-02-01|2012-02-03|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2012||2012-02-29|February 2017|2017-02-28|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|CranioS||Effects of Craniosacral Therapy on Chronic Neck Pain|Effects of Craniosacral Therapy on Chronic Neck Pain: A Randomized Controlled Trial|Completed||N/A|54|Actual|Universität Duisburg-Essen||2|||f||||t||||||||||2018-05-31 21:40:30.738725|2018-05-31 21:40:30.738725
NCT01526434|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2014-03-18|2012-02-01|2012-02-03|Estimate|||||||2014-03-18|2014-03-19|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|SONAR-12||Health-related Quality of Life and Patient-reported Outcomes in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol|An Open-label, Observational 12-week Study to Assess Health-related Quality of Life and Patient-reported Outcomes in Patients With Rheumatoid Arthritis Treated With Certolizumab Pegol|Completed|||81|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 21:40:30.853637|2018-05-31 21:40:30.853637
NCT01526421|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-12-18|2012-02-01|2012-02-03|Estimate|||||||2012-12-18|2012-12-20|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Incentives-1||Use of Incentives to Engage Drug Users in HIV Therapy|A Randomized Clinical Trial Evaluating the Role of Contingent Reinforcement in the Engagement of and Retention of Drug Users in HAART Programs - Part 1|Completed||N/A|301|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 21:40:30.964637|2018-05-31 21:40:30.964637
NCT01526408|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-08-27|2012-02-02|2012-02-03|Estimate|||||||2015-08-27|2015-08-28|Estimate|December 2011||2011-12-31|October 2013|2013-10-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|Famvir||Famvir for Treatment of Hearing in Unilateral Meniere's Disease|Treatment of Hearing Fluctuation in Unilateral Meniere's Disease: A Randomized, Placebo-controlled Clinical Trial of Famciclovir|Terminated||Phase 3|11|Actual|House Research Institute||2||HRI no longer conducting research.|f||||f||||||||||2018-05-31 21:40:31.075092|2018-05-31 21:40:31.075092
NCT01526382|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2015-04-30|2012-02-01|2012-02-03|Estimate|||||||2015-04-30|2015-05-04|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PiCCO||Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory Distress Syndrome|Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory|Completed||Phase 1/Phase 2|350|Actual|Jinhua Central Hospital||2|||f||||||||||||||2018-05-31 21:40:31.275215|2018-05-31 21:40:31.275215
NCT01526369|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-05-30|2012-02-02|2012-02-03|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2012||2012-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2015|Actual|2015-11-30||Interventional|TH V THL||A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer|A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer|Terminated||Phase 3|75|Actual|Cancer Trials Ireland||2|||f||||||||||||||2018-05-31 21:40:31.368612|2018-05-31 21:40:31.368612
NCT01526356|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2015-06-09|2012-02-02|2012-02-03|Estimate|||||||2015-06-09|2015-06-11|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Treatment||Topical Rapamycin to Erase Angiofibromas in TSC|Phase II Study of Topical Rapamycin to Erase Angiofibromas in TSC-Multicenter Evaluation of a Novel Therapy|Completed||Phase 2|177|Actual|The University of Texas Health Science Center, Houston||3|||f||||t||||||||||2018-05-31 21:40:31.540721|2018-05-31 21:40:31.540721
NCT01526343|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2017-05-08||2017-08-01|2012-02-02|2012-02-03|Estimate|2017-08-01|2017-08-03|Actual||||2017-08-01|2017-08-03|Actual|June 2011||2011-06-30|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Medtronic Reveal XT Study|A Comparison of Traditional Arrhythmia Assessment With the Use of Continuous Monitoring to Quantify Postoperative Arrhythmia Burden Following Surgical Treatment of Atrial Fibrillation- Medtronic Reveal XT Study|Completed||Phase 2|47|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 21:40:31.667534|2018-05-31 21:40:31.667534
NCT01526330|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-05-27|2012-02-01|2012-02-03|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease|A Double-blind, Randomized, Parallel, Placebo Controlled, Phase I/II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH14618 Following Single Intradiscal Injection in Patients With Degenerative Disc Disease|Completed||Phase 1/Phase 2|48|Actual|Yuhan Corporation||4|||f||||t||||||||||2018-05-31 21:40:31.847694|2018-05-31 21:40:31.847694
NCT01526317|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-07-31|2012-02-01|2012-02-03|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers|A Randomized, Open Label, Cross-over Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers|Completed||Phase 1|36|Actual|Yuhan Corporation||6|||f||||f||||||||||2018-05-31 21:40:31.931866|2018-05-31 21:40:31.931866
NCT01526304|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-02|2012-02-02|2012-02-03|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|||||Observational|||The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers|A Cross-Sectional Study To Investigate The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers|Unknown status|Recruiting||150|Anticipated|University of Zurich|||||f||||f||||||Samples Without DNA|"~     Whole Blood~   "|||2018-05-31 21:40:32.120721|2018-05-31 21:40:32.120721
NCT01526291|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-02-06|2012-01-31|2012-02-03|Estimate|||||||2018-02-06|2018-02-08|Actual|August 2011||2011-08-31|February 2018|2018-02-28||||||||Observational|PROWL-1||Patient-Reported Outcomes With LASIK:PROWL-1|Patient-Reported Outcomes With LASIK:PROWL-1|Completed|||550|Anticipated|Food and Drug Administration (FDA)|||||f||||t||||||||||2018-05-31 21:40:32.186329|2018-05-31 21:40:32.186329
NCT01526278|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-02-13|2012-02-01|2012-02-03|Estimate|||||||2012-02-13|2012-02-14|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|YY_PK_2011||Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women|Pharmacokinetics of a Single Oral Dose of Maxmarvil® in Healthy Postmenopausal Women Without a Previous History of Fractures|Unknown status|Recruiting|Phase 1|20|Anticipated|Yuyu Pharma, Inc.||1|||f||||t||||||||||2018-05-31 21:40:32.259381|2018-05-31 21:40:32.259381
NCT01526265|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-05-10|2012-02-02|2012-02-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures|Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures|Completed||N/A|2185|Anticipated|University of Pennsylvania||5|||f||||t||||||||||2018-05-31 21:40:32.393519|2018-05-31 21:40:32.393519
NCT01526252|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-04-21|2012-02-02|2012-02-03|Estimate|||||||2017-04-21|2017-04-24|Actual|December 2011||2011-12-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|July 2012|Actual|2012-07-31||Observational|STE Normal||Reference Population for Speckle Tracking Imaging|Establishing a Reference Population for Normal Left Ventricular Function Parameters to Validate the Use of Two Dimensional Speckle Tracking Imaging Software in the Scar Study|Completed|||91|Actual|Ottawa Heart Institute Research Corporation|||||f||||f||||||||No|The objective of the trial was to establish a normal database for comparison. The database has not produced a specific study result. There is no publication as the sample size was not adequate.|2018-05-31 21:40:32.512735|2018-05-31 21:40:32.512735
NCT01526239|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-02-02|2012-02-02|2012-02-03|Estimate|||||||2012-02-02|2012-02-03|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Reminding Patients of the Important of Colorectal Cancer Screening Results in Patient-Initiated Promoting Colorectal Cancer Screening Via Colonoscopy|Patient-Reminder Results in Patient-Initiated Promoting Colorectal Cancer Screening Via Colonoscopy|Completed||N/A|274|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 21:40:32.596608|2018-05-31 21:40:32.596608
NCT01526226|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2017-06-23|2012-01-31|2012-02-03|Estimate|||||||2017-06-23|2017-06-26|Actual|February 2012||2012-02-29|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Patient Comfort During High Flow Nasal Cannula Versus Nasal Continuous Airway Pressure (CPAP)|Patient Comfort During High Flow Nasal Cannula (HFNC)Versus Nasal Continuous Airway Pressure (CPAP): a Cross Over Randomised Trial|Completed||N/A|24|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 21:40:32.659306|2018-05-31 21:40:32.659306
NCT01526213|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2012-03-03||2017-04-21|2012-02-02|2012-02-03|Estimate|2012-12-29|2013-02-04|Estimate||||2017-04-21|2017-05-30|Actual|September 2009||2009-09-30|December 2012|2012-12-31|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|||Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?|Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?|Completed||N/A|18|Actual|University of North Carolina, Chapel Hill||6|||f||||f||||||||||2018-05-31 21:40:32.749448|2018-05-31 21:40:32.749448
NCT01526200|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-02-02|2012-02-02|2012-02-03|Estimate|||||||2012-02-02|2012-02-03|Estimate|October 2007||2007-10-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Observational|CEIOUSCLM||Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases|Factors Influencing the Impact of Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases|Completed|||127|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 21:40:33.225737|2018-05-31 21:40:33.225737
NCT01526187|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2014-10-13|2012-02-02|2012-02-03|Estimate|||||||2014-10-13|2014-10-15|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Observational|VOYAG-R||Travel in the Tropics and Acquisition of Multidrug-resistant Bacteria (VOYAG-R)|Acquisition of Multidrug-resistant Bacteria After Travel in the Tropics : Prevalence, Determinants and Length of Carriage|Completed|||750|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples Without DNA|"~     Stool~   "|||2018-05-31 21:40:33.319787|2018-05-31 21:40:33.319787
NCT01526174|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2013-10-10|2012-02-02|2012-02-03|Estimate|||||||2013-10-10|2013-10-14|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|AIED||Intratympanic Injection for Autoimmune Inner Ear Disease|Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial|Terminated||Phase 1/Phase 2|16|Actual|House Research Institute||2||House Research no longer conducting research.|f||||f||||||||||2018-05-31 21:40:33.397821|2018-05-31 21:40:33.397821
NCT01526161|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-02-02|2012-02-02|2012-02-03|Estimate|||||||2012-02-02|2012-02-03|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|January 2011|Actual|2011-01-31|June 2010|Actual|2010-06-30||Interventional|MASCOT||Management of Asthma in School-age Children on Therapy|Management of Asthma in School-age Children on Therapy|Completed||Phase 4|229|Actual|University Hospital of North Staffordshire||3|||f||||t||||||||||2018-05-31 21:40:33.515693|2018-05-31 21:40:33.515693
NCT01526148|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2015-07-30||2017-07-18|2012-01-31|2012-02-03|Estimate|2015-10-01|2015-10-30|Estimate||||2017-07-18|2017-08-16|Actual|January 2012||2012-01-31|July 2017|2017-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Gao Bipolar Spectrum Lithium/Quetiapine Study|Comparative Safety, Tolerability, and Effectiveness of Lithium Versus Quetiapine in Patients Across the Spectrum of Bipolar Disorder|Terminated||Phase 4|42|Actual|University Hospitals Cleveland Medical Center||2||Ran out of funding|f||||t||||||||||2018-05-31 21:40:33.640879|2018-05-31 21:40:33.640879
NCT01526135|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2018-05-06|2012-02-02|2012-02-03|Estimate|||||||2018-05-06|2018-05-08|Actual|January 2012|Actual|2012-01-31|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|March 2018|Actual|2018-03-31||Interventional|||Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma|Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma|Active, not recruiting||Phase 3|490|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 21:40:34.087172|2018-05-31 21:40:34.087172
NCT01526122|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2014-09-29|2012-02-01|2012-02-03|Estimate|||||||2014-09-29|2014-10-01|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetics & Safety Study of Clopidogrel 75mg and Aspirin 100mg Coadministration|A PhaseⅠ Study to Compare the Pharmacokinetic Characteristics and Safety After Oral Administration of G0041(75/100mg) With Those of Clopidogrel 75mg & Aspirin 100mg Coadministration in Healthy Male Volunteers|Completed||Phase 1|65|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:40:34.263919|2018-05-31 21:40:34.263919
NCT01526109|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-12-03|2012-02-02|2012-02-03|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Strength Training and Whole Body Vibration in Healthy Elderly|Effect of Strength Training and Whole Body Vibration on Cognitive Function, Behavioral and Functional Capacity in Healthy Elderly.|Withdrawn||N/A|0|Actual|Universidade Gama Filho||3||The study was finished since the University has been closed|f||||t||||||||||2018-05-31 21:40:34.339607|2018-05-31 21:40:34.339607
NCT01526096|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-03-07|2012-01-31|2012-02-03|Estimate|||||||2018-03-07|2018-03-09|Actual|July 12, 2011|Actual|2011-07-12|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Stem Cell Transplantation for Patients With Multiple Myeloma|Pilot Study T Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Patients With Multiple Myeloma|Recruiting||Phase 1|30|Anticipated|University of Chicago||3|||f||||f|t|t|t|f||||||2018-05-31 21:40:34.458184|2018-05-31 21:40:34.458184
NCT01526083|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-05-04|2012-02-02|2012-02-03|Estimate|||||||2012-05-04|2012-05-07|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males|Single-center, Open-label, Randomized 2-way Crossover Study of the Effect of Lacosamide 200 mg Twice Daily on the Single-dose Pharmacokinetics and Pharmacodynamics of Warfarin (25 mg) in Healthy Male Volunteers|Completed||Phase 1|16|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:40:34.55821|2018-05-31 21:40:34.55821
NCT01526070|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2014-11-17|2012-02-01|2012-02-03|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration|Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Standard Therapy for Exudative Age-Related Macular Degeneration|Completed|||142|Actual|Stanford University|||1||f||||f||||||||||2018-05-31 21:40:34.664845|2018-05-31 21:40:34.664845
NCT01526057|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01||2014-09-09|2014-09-09|2012-02-02|2012-02-03|Estimate||||2014-09-09|2014-09-18|Estimate|2014-09-09|2014-09-18|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|REFLECTIONS||A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)|A Randomized, Double-Blind, Study Comparing The Pharmacokinetics And Pharmacodynamics, And Assessing The Safety Of PF-05280586 And Rituximab In Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate Who Have Had An Inadequate Response To One Or More TNF Antagonist Therapies|Completed||Phase 1/Phase 2|222|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 21:40:34.764689|2018-05-31 21:40:34.764689
NCT01526044|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-06-26|2012-02-01|2012-02-03|Estimate|||||||2012-06-26|2012-06-27|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|RESCUEII||Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients|Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients; a Randomized Controlled Trial (RESCUEII)|Completed||N/A|178|Actual|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||||2018-05-31 21:40:35.063678|2018-05-31 21:40:35.063678
NCT01526031|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-02-01|2012-02-01|2012-02-03|Estimate|||||||2012-02-01|2012-02-03|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Bee Venom Acupuncture for the Treatment of Frozen Shoulder|Randomized Controlled Double Blind Study of Bee Venom Therapy on Adhesive Capsulitis of the Shoulder|Completed||Phase 2|68|Actual|Kyunghee University Medical Center||3|||f||||f||||||||||2018-05-31 21:40:35.164798|2018-05-31 21:40:35.164798
NCT01526018|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-08-14|2012-02-02|2012-02-03|Estimate|||||||2014-08-14|2014-08-18|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||The Bottle Study: Infant Weight Gain During Use of Novel Versus Typical Infant Feeding Bottles||Terminated|||5|Actual|University of Alabama at Birmingham|||1|Inadequate recruitment|f||||f||||||||||2018-05-31 21:40:35.298478|2018-05-31 21:40:35.298478
NCT01526005|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2015-01-26|2012-02-01|2012-02-03|Estimate|||||||2015-01-26|2015-01-27|Estimate|March 2012||2012-03-31|January 2015|2015-01-31||||January 2014|Actual|2014-01-31||Observational|||Brain Nicotine Receptor Density & Response to Nicotine Patch|Brain Nicotine Receptor Density & Response to Nicotine Patch|Completed|||50|Actual|Brentwood Biomedical Research Institute|||2||f||||f||||||||||2018-05-31 21:40:35.397894|2018-05-31 21:40:35.397894
NCT01525992|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-04-16|2012-02-02|2012-02-03|Estimate|||||||2014-04-16|2014-04-17|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||A Community Pharmacy-based Program to Improve Management of Diabetes|A Community Pharmacy-based Intervention on Type 2 Diabetic Patients to Improve Medications Adherence and Disease Outcomes; a Randomized Controlled Trial.|Completed||N/A|101|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:40:35.508604|2018-05-31 21:40:35.508604
NCT01525979|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-06-04|2012-02-01|2012-02-03|Estimate|||||||2015-06-04|2015-06-08|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Comparative Efficacy Research of Uni- vs Bi-lateral Arm Training Poststroke|Comparative Efficacy Research of Uni- vs Bi-lateral Arm Training Poststroke: Task-Related or Robotic|Completed||N/A|42|Actual|Chang Gung Memorial Hospital||5|||f||||f||||||||||2018-05-31 21:40:35.596615|2018-05-31 21:40:35.596615
NCT01525966|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2018-05-04|2012-02-01|2012-02-03|Estimate|||||||2018-05-04|2018-05-08|Actual|February 15, 2012||2012-02-15|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer|Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast Cancer|Recruiting||Phase 2|69|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 21:40:35.756148|2018-05-31 21:40:35.756148
NCT01525953|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-02-01|2012-02-01|2012-02-03|Estimate|||||||2012-02-01|2012-02-03|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|CRCRT-EC||Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis|Predictors of Survival for Complete Clinical Responders to Definite Chemoradiation or Radiation Therapy for Esophageal Cancer|Completed|||110|Actual|Centre Oscar Lambret|||||f||||f||||||||||2018-05-31 21:40:35.956175|2018-05-31 21:40:35.956175
NCT01525940|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2015-11-09|2012-02-02|2012-02-03|Estimate|||||||2015-11-09|2015-11-10|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy|PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy|Completed||N/A|100|Actual|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-05-31 21:40:36.049801|2018-05-31 21:40:36.049801
NCT01525927|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2015-08-28||2017-11-20|2012-02-02|2012-02-03|Estimate|2015-08-28|2015-09-30|Estimate||||2017-11-20|2017-12-19|Actual|August 2010||2010-08-31|November 2017|2017-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||data was not collected for Baseline Characteristics due to premature termination of this study|Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity|Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders|Terminated||Phase 2|2|Actual|Northwell Health|Study terminated , PI left the institution, no data analyzed|2||Principal Investigator left institution. IRB approval lapsed.|f||||t||||||||||2018-05-31 21:40:36.150619|2018-05-31 21:40:36.150619
NCT01525914|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2012-02-02|2012-02-02|2012-02-03|Estimate|||||||2012-02-02|2012-02-03|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Response of Patients on Surveillance for Prostate Cancer to Dutasteride|Assessment of Response of Patients on Surveillance for Favorable Risk Prostate Cancer to Dutasteride|Completed|||100|Actual|Sunnybrook Health Sciences Centre|||1||f||||f||||||Samples With DNA|"~     prostate biopsy tissue stored on site~   "|||2018-05-31 21:40:36.441331|2018-05-31 21:40:36.441331
NCT01525901|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-01-10|2012-02-01|2012-02-03|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)|A Double-Blind Placebo-Controlled Crossover Trial of Insulin-Like Growth Factor-1 (IGF-1) in Children and Adolescents With 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)|Completed||Phase 2|20|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:40:36.529955|2018-05-31 21:40:36.529955
NCT01525888|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-06-04|2012-02-02|2012-02-03|Estimate|||||||2015-06-04|2015-06-08|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Renin-angiotensin-aldosterone System (RAAS) Blockade and Contrast Induced Nephropathy||Completed||N/A|100|Actual|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 21:40:36.701957|2018-05-31 21:40:36.701957
NCT01525875|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-01-19|2012-02-01|2012-02-03|Estimate|||||||2016-01-19|2016-01-20|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)|Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)|Completed||Phase 2|44|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:40:36.81646|2018-05-31 21:40:36.81646
NCT01525862|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2013-02-12|2012-02-02|2012-02-03|Estimate|||||||2013-02-12|2013-02-13|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||XprESS Maxillary Balloon Dilation Study|XprESS Maxillary Sinus Balloon Dilation Study|Completed||N/A|30|Anticipated|Entellus Medical, Inc.|||||f||||f||||||||||2018-05-31 21:40:36.928173|2018-05-31 21:40:36.928173
NCT01525849|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2016-11-01||2017-01-04|2012-02-02|2012-02-03|Estimate|2017-01-04|2017-02-24|Actual||||2017-01-04|2017-02-24|Actual|December 2011||2011-12-31|January 2017|2017-01-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|REMODEL|All treated participants|Randomized Evaluation of Maxillary Antrostomy Versus Ostial Dilation Efficacy Through Long-Term Follow-Up|Randomized Evaluation of Maxillary Antrostomy Versus Ostial Dilation Efficacy Through Long-Term Follow-Up|Completed||N/A|151|Actual|Entellus Medical, Inc.||2|||f||||f||||||||No||2018-05-31 21:40:37.013286|2018-05-31 21:40:37.013286
NCT01525836|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-04-18|2012-02-02|2012-02-03|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP|Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.|Completed||Phase 3|123|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 21:40:37.521339|2018-05-31 21:40:37.521339
NCT01525823|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-06-13|2012-02-01|2012-02-03|Estimate|||||||2012-06-13|2012-06-14|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|NHV||Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin|Effects of Metformin on Glucose Homeostasis Following Administration of BMS-754807 in Healthy Volunteer Subjects|Completed||Phase 1|26|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 21:40:37.615373|2018-05-31 21:40:37.615373
NCT01525810|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2015-03-25|2012-02-01|2012-02-03|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial|A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in Which Peginterferon Lambda-1a (BMS-914143) Was Administered for the Treatment of Chronic Hepatitis C|Completed|||218|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 21:40:37.7936|2018-05-31 21:40:37.7936
NCT01525797|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2015-03-13|2012-02-01|2012-02-03|Estimate|||||||2015-03-13|2015-03-17|Estimate|October 2002||2002-10-31|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Blood Draw Study for Liver Transplant Patients|Immunomonitoring of Transplant Patients|Unknown status|Active, not recruiting||200|Anticipated|Baylor Research Institute|||2||f||||f||||||||||2018-05-31 21:40:37.981725|2018-05-31 21:40:37.981725
NCT01525784|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-02-01|2012-02-01|2012-02-03|Estimate|||||||2012-02-01|2012-02-03|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Observational|||Affect of RT-CGMS as Part of Clinical Care in Type 1 Diabetes Mellitus Patients|Prospective Short and Long Term Follow up of Pediatric Diabetes Mellitus Patients Receiving RT-CGMS as Part of National Clinical Care|Unknown status|Not yet recruiting||300|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||||2018-05-31 21:40:38.069708|2018-05-31 21:40:38.069708
NCT01525771|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-06-26|2012-02-01|2012-02-03|Estimate|||||||2015-06-26|2015-06-29|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|XPID||Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer|A Phase I-II Study of Systemic Capecitabine, Cisplatin and Intraperitoneal Docetaxel (XPID) in Patients With Advanced Stomach Cancer With Peritoneal Seeding|Completed||Phase 1/Phase 2|37|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:40:38.18335|2018-05-31 21:40:38.18335
NCT01525758|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-08-12|2012-02-02|2012-02-03|Estimate|||||||2013-08-12|2013-08-13|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of SI000413 in Knee Osteoarthritis Patients|Eight-week, Multi-centre, Dose-response, Double Blind, Placebo-controlled, Randomized, Parallel-group, PhaseⅡ Trial to Evaluate Efficacy and Safety of SI000413 in Patients With Knee Osteoarthritis|Unknown status|Recruiting|Phase 2|152|Anticipated|Dong-A ST Co., Ltd.||4|||f||||f||||||||||2018-05-31 21:40:39.270699|2018-05-31 21:40:39.270699
NCT01525745|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2015-09-03||2017-01-23|2012-02-02|2012-02-03|Estimate|2016-07-18|2016-08-29|Estimate||||2017-01-23|2017-03-06|Actual|January 2012||2012-01-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis|Randomized Ph II Study of Stereotactic Body Radiotherapy (SBRT) Versus Conventional Radiation for Spine Metastasis|Terminated||Phase 2|6|Actual|Beth Israel Deaconess Medical Center||2||Local IRB decision due to poor accrual|f||||t||||||||||2018-05-31 21:40:39.357479|2018-05-31 21:40:39.357479
NCT01525732|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-04-27|2012-02-02|2012-02-03|Estimate|||||||2017-04-27|2017-05-01|Actual|June 2010||2010-06-30|April 2017|2017-04-30|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|POEM||Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Esophageal Motility Disorders|Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders|Completed||N/A|50|Actual|Chinese University of Hong Kong||1|||f||||||||||||||2018-05-31 21:40:39.583786|2018-05-31 21:40:39.583786
NCT01525719|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-02|2012-02-02|2012-02-03|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|CRAD001T||Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma|A Phase II Single Arm Study to Evaluate the Safety and Efficacy of RAD001 as Monotherapy in Treatment naïve Advanced Cholangiocarcinoma|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Ratchavithi Hospital||1|||f||||f||||||||||2018-05-31 21:40:39.69947|2018-05-31 21:40:39.69947
NCT01525706|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-11-01|2012-02-02|2012-02-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm|EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm|Terminated||Phase 1|1|Actual|Lawson Health Research Institute||1||Poor recruitment|f||||f||||||||||2018-05-31 21:40:39.829915|2018-05-31 21:40:39.829915
NCT01525693|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2013-02-13|2012-02-02|2012-02-03|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2012||2012-04-30|February 2012|2012-02-29|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Observational|NEW2D||Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China|Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in China (NEW2D STUDY) A Study Of China Cardiometabolic Registries (CCMR)|Unknown status|Active, not recruiting||5000|Anticipated|China Cardiometabolic Registries|||1||f||||f||||||||||2018-05-31 21:40:39.936574|2018-05-31 21:40:39.936574
NCT01525173|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2013-10-07||2013-10-07|2012-01-31|2012-02-02|Estimate|2013-10-07|2013-12-04|Estimate||||2013-10-07|2013-12-04|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension||Completed||Phase 4|137|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:40:55.886642|2018-05-31 21:40:55.886642
NCT01525680|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2013-11-27|2012-02-02|2012-02-03|Estimate|||||||2013-11-27|2013-11-28|Estimate|April 2011||2011-04-30|November 2013|2013-11-30||||September 2015|Anticipated|2015-09-30||Interventional|||A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure|"Improving PTSD Outcomes in OIF/OEF Returnees: A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure Therapy"|Unknown status|Recruiting|N/A|60|Anticipated|Bronx VA Medical Center||2|||f||||f||||||||||2018-05-31 21:40:40.164808|2018-05-31 21:40:40.164808
NCT01525667|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2015-01-01||2015-09-07|2012-02-02|2012-02-03|Estimate|2015-02-05|2015-02-23|Estimate||||2015-09-07|2015-09-21|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Interventional|||Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty|A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty|Completed||Phase 1/Phase 2|20|Actual|Pluristem Ltd.||3|||f||||t||||||||||2018-05-31 21:40:40.287077|2018-05-31 21:40:40.287077
NCT01525654|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-11-29|2012-02-02|2012-02-03|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2009||2009-03-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PARASS||Patient Rheumatoid Arthritis Social Support Study|Rheumatoid Arthritis Patient-to-Patient Connection Program|Active, not recruiting||N/A|65|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:40:40.933751|2018-05-31 21:40:40.933751
NCT01525641|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2015-06-04||2015-07-17|2012-02-01|2012-02-03|Estimate|2015-07-17|2015-08-14|Estimate||||2015-07-17|2015-08-14|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||Safety set: included all patients who had received treatment with Mirapex®-LA Tablets except those who were found to have no observation after enrolment, invalid registration, or invalid contract.|Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease|Special Survey on Long-term Drug Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease|Completed|||615|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 21:40:41.064499|2018-05-31 21:40:41.064499
NCT01525628|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2016-01-21||2016-05-04|2012-02-01|2012-02-03|Estimate|2016-05-04|2016-06-10|Estimate||||2016-05-04|2016-06-10|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional||The treated set (TRT) included all patients who were dispensed trial medication and were documented to have taken at least one dose of trial drug.|Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients|A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the Pharmacokinetics of Tenofovir, Raltegravir, Caffeine (the Probe Drug Substrate for CYP1A2), Tolbutamide (the Probe Drug Substrate for CYP2C9) and Midazolam (the Probe Drug Substrate for CYP3A4) in Treatment naïve Patients and Prior Treatment Relapse or Partial Responder Patients With Genotype 1 Chronic Hepatitis C Infection|Completed||Phase 1|72|Actual|Boehringer Ingelheim|BI decided to stop the further development of the interferon-free combination therapy for Hepatitis C in December 2013 so the recruitment was stopped after 7 patients had entered Group E also PK analyses for Groups C to E were not performed.|5|||f||||||||||||||2018-05-31 21:40:41.789401|2018-05-31 21:40:41.789401
NCT01525615|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2015-06-19|2014-04-03|2016-07-28|2012-02-01|2012-02-03|Estimate|2015-08-12|2015-09-15|Estimate|2014-04-03|2014-04-30|Estimate|2016-07-28|2016-08-29|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Treated set included all randomised patients who were dispensed study medication and were documented to have taken any dose of study medication.|A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Effect of 12 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg and 5/5 µg) Delivered by the Respimat® Inhaler, on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD)[Torracto (TM)]|Completed||Phase 3|404|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:40:44.128746|2018-05-31 21:40:44.128746
NCT01525602|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-04-04|2012-02-02|2012-02-03|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2012||2012-05-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|||Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|74|Actual|Plexxikon||3|||f||||f||||||||||2018-05-31 21:40:44.959402|2018-05-31 21:40:44.959402
NCT01525589|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-11-27|2012-02-02|2012-02-03|Estimate|||||||2017-11-27|2017-11-28|Actual|December 2012||2012-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer|A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer|Active, not recruiting||Phase 2|111|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 21:40:45.047801|2018-05-31 21:40:45.047801
NCT01525576|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-07-30|2012-02-02|2012-02-03|Estimate|||||||2012-07-30|2012-07-31|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Booster as an Adjunct to Internet-based Cognitive Behavior Therapy (CBT)|Efficacy of an Internet-based Booster Program for Obsessive-compulsive Disorder: A Randomized Controlled Trial|Completed||Phase 2|98|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:40:45.122465|2018-05-31 21:40:45.122465
NCT01525563|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|2014-12-17||2014-12-17|2012-02-02|2012-02-03|Estimate|2014-12-17|2014-12-29|Estimate||||2014-12-17|2014-12-29|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study|Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study|Completed|||1000|Actual|Abbott|||1||f||||f||||||||||2018-05-31 21:40:45.218393|2018-05-31 21:40:45.218393
NCT01525550|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2017-03-08||2018-03-30|2012-01-31|2012-02-03|Estimate|2017-04-07|2017-05-19|Actual||||2018-03-30|2018-05-02|Actual|June 6, 2012|Actual|2012-06-06|March 2018|2018-03-31|June 29, 2018|Anticipated|2018-06-29|March 19, 2016|Actual|2016-03-19||Interventional||Full analysis set (FAS) included all participants who were enrolled into the study regardless of whether participants received study drug or not.|A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors|A Single-arm Open-label International Multi-center Study Of The Efficacy And Safety Of Sunitinib Malate (su011248, Sutent (Registered)) In Patients With Progressive Advanced Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors|Active, not recruiting||Phase 4|106|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:40:46.574976|2018-05-31 21:40:46.574976
NCT01525537|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-06-14|2012-02-02|2012-02-03|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|February 2010|Actual|2010-02-28||Interventional|||Surgical Pleth Index (SPI) Guided Analgesia During Sevoflurane Anesthesia|Comparison of Surgical Pleth Index Guided Analgesia With Standard Clinical Practise During Balanced Anesthesia|Completed||N/A|82|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 21:40:51.488482|2018-05-31 21:40:51.488482
NCT01525524|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2014-09-07|2012-02-02|2012-02-03|Estimate|||||||2014-09-07|2014-09-09|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|||Treatment of Major Depressive Disorder Post Stroke With Transcranial Direct Current Stimulation|Treatment of Major Depressive Disorder Post Stroke With Transcranial Direct Current Stimulation (TDCS): Randomized, Double-Blind, Clinical Trial|Completed||Phase 2|48|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:40:51.565343|2018-05-31 21:40:51.565343
NCT01525511|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-08-27|2012-01-31|2012-02-03|Estimate|||||||2013-08-27|2013-08-28|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects|Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects|Completed||Phase 1|16|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 21:40:51.640753|2018-05-31 21:40:51.640753
NCT01525498|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2013-10-15|2012-01-31|2012-02-03|Estimate|||||||2013-10-15|2013-10-16|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Foley Catheterization Following Sacrocolpopexy|Urinary Bladder Catheterization Following Sacrocolpopexy|Withdrawn|||0|Actual|University of Oklahoma|||2|No subject accrual|f||||f||||||||||2018-05-31 21:40:51.708233|2018-05-31 21:40:51.708233
NCT01525485|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-06-08|2012-01-31|2012-02-03|Estimate|||||||2016-06-08|2016-06-09|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|Estim||Vaginal Electrical Stimulation Versus Neuromodulation|Vaginal Electrical Stimulation Versus Sacral Neuromodulation for the Treatment of Refractory Overactive Bladder: A Pilot Study|Completed|||34|Actual|University of Oklahoma|||2||f||||f||||||||||2018-05-31 21:40:51.780824|2018-05-31 21:40:51.780824
NCT01525472|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2015-02-05|2012-02-01|2012-02-03|Estimate|||||||2015-02-05|2015-02-06|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|June 2015|Anticipated|2015-06-30||Observational|SENAPID||Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects|Accelerated Aging of the Cells of Visceral Adipose Tissue in Morbid Obese Subjects: Involvement in Diseases Associated With Obesity (Viellissement accéléré Des Cellules du Tissu Adipeux viscéral Chez Les obèses Morbides: Implication Dans Les Pathologies associées à l'obésité)|Unknown status|Recruiting||225|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||Samples Without DNA|"~     adipose tissue~   "|||2018-05-31 21:40:51.84806|2018-05-31 21:40:51.84806
NCT01525459|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-02-06|2012-01-31|2012-02-03|Estimate|||||||2012-02-06|2012-02-07|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Observational|||Gene Expression, Immunological Status and Metabolome in Glioma Patients|Monitoring and Analysis of Gene Expression, Immunological Status and Metabolome in Peripheral Blood Mononuclear Cells and Their Specific Subpopulations (CD4+ T Cells and CD56+ NK Cells) in Surgically Treated Glioma Patients|Unknown status|Recruiting||16|Anticipated|National Institute of Biology, Slovenia|||1||f||||f||||||Samples With DNA|"~     Whole blood, blood plasma, peripheral blood mononuclear cells, CD4+ T cells, CD56+ NK cells~   "|||2018-05-31 21:40:51.906076|2018-05-31 21:40:51.906076
NCT01525446|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-02-12|2012-01-31|2012-02-03|Estimate|||||||2016-02-12|2016-02-17|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer|Proton Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable, Peripheral Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Pilot Study|Terminated||Early Phase 1|7|Actual|Massachusetts General Hospital||1||Slow accrual|f||||t||||||||||2018-05-31 21:40:51.99969|2018-05-31 21:40:51.99969
NCT01525433|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-09-26|2012-02-02|2012-02-03|Estimate|||||||2017-09-26|2017-09-28|Actual|September 2011||2011-09-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|September 2015|Actual|2015-09-30||Interventional|||Cervical Cancer Screening Among Hispanic Women|Cervical Cancer Screening and Adherence to Follow-up Among Hispanic Women|Active, not recruiting||N/A|451|Actual|Fred Hutchinson Cancer Research Center||3|||f||||f||||||||||2018-05-31 21:40:52.071965|2018-05-31 21:40:52.071965
NCT01525420|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2014-03-10||2014-05-07|2012-02-02|2012-02-03|Estimate|2014-03-10|2014-04-16|Estimate||||2014-05-07|2014-05-26|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|TALK||Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy|Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy|Completed||N/A|121|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 21:40:52.138714|2018-05-31 21:40:52.138714
NCT01525407|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2017-04-11||2017-07-18|2012-02-02|2012-02-03|Estimate|2017-07-18|2017-08-17|Actual||||2017-07-18|2017-08-17|Actual|May 2012||2012-05-31|July 2017|2017-07-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation|Donor Statin Treatment for Prevention of Severe Acute GVHD After Myeloablative Hematopoietic Cell Transplantation|Completed||Phase 2|83|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 21:40:52.522435|2018-05-31 21:40:52.522435
NCT01525394|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-03-03|2012-01-31|2012-02-02|Estimate|||||||2015-03-03|2015-03-04|Estimate|December 2010||2010-12-31|April 2012|2012-04-30||||August 2011|Actual|2011-08-31||Interventional|||A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval|A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval|Completed||Phase 1|52|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 21:40:52.894548|2018-05-31 21:40:52.894548
NCT01525381|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2016-03-29|2012-02-01|2012-02-02|Estimate|||||||2016-03-29|2016-03-31|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Observational|||Strategies to Improve Asthma and Treatment of Asthma in Canadians|Strategies to Improve Diagnosis and Treatment of Asthma in Canadians|Completed|||701|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 21:40:52.967471|2018-05-31 21:40:52.967471
NCT01525368|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2014-11-11|2012-01-31|2012-02-02|Estimate|||||||2014-11-11|2014-11-13|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|OutPreC MCI||Outcome Predictors of a Cognitive Intervention in aMCI|Outcome Predictors of a Complex Cognitive Intervention in Amnestic Mild Cognitive Impairment (aMCI)|Completed|||110|Actual|Ludwig-Maximilians - University of Munich|||2||f||||f||||||||||2018-05-31 21:40:53.02701|2018-05-31 21:40:53.02701
NCT01525355|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-11-03|2012-02-01|2012-02-02|Estimate|||||||2017-11-03|2017-11-07|Actual|October 2010|Actual|2010-10-31|April 2017|2017-04-30|June 7, 2016|Actual|2016-06-07|June 7, 2016|Actual|2016-06-07||Observational|||EUS Prior to ERCP in the Positive Setting of Positive Intraoperative Cholangiogram (IOC) During Cholecystectomy|"A Prospective Study Evaluation the Role of EUS Prior to ERCP in the Positive Setting of Positive Intraoperative Cholangiogram (IOC) During Cholecystectomy"|Completed|||34|Actual|Wake Forest University Health Sciences|||1||f||||f||||||||||2018-05-31 21:40:53.087293|2018-05-31 21:40:53.087293
NCT01525329|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-01-03|2012-01-31|2012-02-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease|Combination Therapy With 5-Fluorouracil and Photodynamic Therapy for the Treatment of Post-transplant Premalignant Skin Disease|Terminated||Phase 3|19|Actual|The Cleveland Clinic||2||study drug no longer available in the United States|f||||t||||||||No|there is no plan to share individual participant data with other researchers.|2018-05-31 21:40:53.262456|2018-05-31 21:40:53.262456
NCT01525316|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-01-16|2012-02-01|2012-02-02|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|NEOLACTO||Lactoferrin for Prevention of Sepsis in Infants|Lactoferrin for Prevention of Sepsis in Infants|Completed||Phase 3|414|Actual|Universidad Peruana Cayetano Heredia||2|||f||||t||||||||||2018-05-31 21:40:53.402372|2018-05-31 21:40:53.402372
NCT01525303|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2013-01-14|2012-01-30|2012-02-02|Estimate|||||||2013-01-14|2013-01-16|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Effects of Aerobic Exercise Within a Behavioral Treatment Program for Chronic Headaches|Additive Effects of Aerobic Exercise to a Standard Behavioral Self-Management Program for Chronic Headaches|Completed||N/A|5|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-05-31 21:40:53.545488|2018-05-31 21:40:53.545488
NCT01525290|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-07-18|2012-02-01|2012-02-02|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2012||2012-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|WAKE-UP||Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke|Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke: a Randomised, Double-blind, Placebo-controlled Trial|Active, not recruiting||Phase 3|501|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-05-31 21:40:53.629563|2018-05-31 21:40:53.629563
NCT01525277|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-04-11|2012-02-01|2012-02-02|Estimate|||||||2014-04-11|2014-04-14|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|June 2014|Anticipated|2014-06-30||Observational|||The Side of Implantable Central Vascular Catheters and Complications|The Side of Implantable Central Vascular Catheters and Complications in Cancer Patients: A Randomization Observational Study|Unknown status|Recruiting||246|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 21:40:53.786704|2018-05-31 21:40:53.786704
NCT01525264|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2016-08-17|2012-02-01|2012-02-02|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Breast Cancer Screening Intervention|Korean Immigrants & Mammography—Culture-Specific Health Intervention (KIM-CHI)|Completed||N/A|434|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 21:40:53.901905|2018-05-31 21:40:53.901905
NCT01525251|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|August 2009||2009-08-31|January 2012|2012-01-31||||||||Observational|NCMM||Nurse Case Manager Model on Neuroblastoma Caregiver's Uncertainty|The Effect of Nurse Case Manager Model on Caregiver's Adaptation of Disease Uncertainty About Their Child With Neuroblastoma|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 21:40:54.011703|2018-05-31 21:40:54.011703
NCT01525238|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2016-09-29||2017-04-26|2012-01-31|2012-02-02|Estimate|2016-09-29|2016-11-21|Estimate||||2017-04-26|2017-05-30|Actual|July 1, 2012|Actual|2012-07-01|April 2017|2017-04-30|September 1, 2014|Actual|2014-09-01|September 1, 2014|Actual|2014-09-01||Interventional||All treated participants|PK Study of Dapagliflozin in Pediatric Subjects With T2DM|A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus|Completed||Phase 1|53|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 21:40:54.138861|2018-05-31 21:40:54.138861
NCT01525225|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2014-08-11||2015-05-27|2012-01-31|2012-02-02|Estimate|2014-08-11|2014-08-26|Estimate||||2015-05-27|2015-06-22|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All participants who received at least one dose of study drug.|Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM|Evaluation of the Pharmacokinetics of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus Following Oral Administration of Saxagliptin and Metformin XR Fixed Dose Combination Tablet and Co-Administration of Saxagliptin and Glucophage® (Metformin) IR Tablets|Terminated||Phase 1|4|Actual|AstraZeneca|Due to the small number of participants (2), the primary endpoints, pharmacokinetic parameters, were not calculated.|1||Release of Post Marketing Requirement for this study. Terminated November 2013.|f||||f||||||||||2018-05-31 21:40:55.143908|2018-05-31 21:40:55.143908
NCT01525212|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2013-06-19|2012-01-31|2012-02-02|Estimate|||||||2013-06-19|2013-06-21|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients|Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 21:40:55.376085|2018-05-31 21:40:55.376085
NCT01525199|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-04-11|2012-01-31|2012-02-02|Estimate|||||||2014-04-11|2014-04-14|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|IDENTIFY||Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.|Study of Cases and Controls on Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.|Completed|||450|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-05-31 21:40:55.703736|2018-05-31 21:40:55.703736
NCT01525186|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Observational|||Observational Study of Parental Feeding Practices to Improve Child's Food Intake and Weight Status|The Relationship of Parental Feeding Control Practices to Food Intake of 3-5Yr Children in Families With Limited Incomes|Completed|||660|Actual|Michigan State University|||||f||||t||||||||||2018-05-31 21:40:55.797486|2018-05-31 21:40:55.797486
NCT01525160|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-04-08|2012-02-01|2012-02-02|Estimate|||||||2014-04-08|2014-04-10|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Observational|||New Markers to Measure Clotting in Patients With the Obstructive Sleep Apnoea Hypopnoea Syndrome|Novel Biomarkers for Haemostasis in Patients With the Obstructive Sleep Apnoea Hypopnoea Syndrome|Completed|||66|Actual|Hywel Dda Health Board|||||f||||f||||||Samples Without DNA|"~     Frozen aliquots of citrated plasma~   "|||2018-05-31 21:40:56.130066|2018-05-31 21:40:56.130066
NCT01525147|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-07-08|2012-01-30|2012-02-02|Estimate|||||||2014-07-08|2014-07-10|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers|A Block-randomized, Double-blind, Placebo-controlled, Single-dose Escalating, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers|Completed||Phase 1|49|Actual|Yuhan Corporation||5|||f||||t||||||||||2018-05-31 21:40:56.22803|2018-05-31 21:40:56.22803
NCT01525134|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|April 2012|Anticipated|2012-04-30|February 2012|Anticipated|2012-02-29||Interventional|||Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis|Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects|Unknown status|Active, not recruiting|N/A|504|Actual|Tuberculosis Clinical Diagnostics Research Consortium|||||f||||f||||||||||2018-05-31 21:40:56.441928|2018-05-31 21:40:56.441928
NCT01525121|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Expiratory Rib Cage Compression in Mechanically Ventilated Patients|Expiratory Rib Cage Compression Does Not Improve Secretion Clearance and Respiratory Mechanics in Mechanically Ventilated Patients|Completed||N/A|20|Actual|Centro Universitário Augusto Motta||2|||f||||f||||||||||2018-05-31 21:40:56.530827|2018-05-31 21:40:56.530827
NCT01525108|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2013-06-10|2012-02-01|2012-02-02|Estimate|||||||2013-06-10|2013-06-11|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||A Home-based Blood Pressure Monitoring Program to Promote Better Management of Hypertension|A Home-based Blood Pressure Measurement Program in Hypertensive Patients to Promote Medications Adherence and Blood Pressure Status.|Completed||N/A|196|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:40:56.626953|2018-05-31 21:40:56.626953
NCT01525095|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-06-06|2012-02-01|2012-02-02|Estimate|||||||2014-06-06|2014-06-09|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|DIRECT||Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)|Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)-Part 1 (Prospective Collection and Freezing of Whole Blood Specimens)|Completed|||700|Anticipated|T2 Biosystems|||2||f||||f||||||Samples With DNA|"~     Whole Blood specimens, in addition to bacterial and fungal species isolates~   "|||2018-05-31 21:40:56.73083|2018-05-31 21:40:56.73083
NCT01525082|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2018-04-17|2012-02-01|2012-02-02|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2012||2012-12-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors|A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors|Active, not recruiting||Phase 2|20|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 21:40:56.851161|2018-05-31 21:40:56.851161
NCT01525069|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2018-03-22|2012-01-30|2012-02-02|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 3, 2012|Actual|2012-04-03|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma|Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma|Recruiting||Phase 1|57|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f|||No||2018-05-31 21:40:56.990221|2018-05-31 21:40:56.990221
NCT01525056|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-09-08|2012-01-31|2012-02-02|Estimate|||||||2014-09-08|2014-09-09|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Nodes Using Pet-Ct, CT-Perfusion and 3T MRI|Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Node Metastases Using PET-CT, CT-Perfusion and 3T MRI: A Prospective Feasibility Study|Completed||Phase 2|30|Actual|London Health Sciences Centre||1|||f||||f||||||||||2018-05-31 21:40:57.117766|2018-05-31 21:40:57.117766
NCT01525043|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2014-03-04|2012-01-31|2012-02-02|Estimate|||||||2014-03-04|2014-03-05|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow|Randomized, Parallel-Group, Open Label, Dose Finding Study to Evaluate the Efficacy of Synera Patch Compared to Naproxen Sodium for the Treatment of Lateral and Medial Epicondylitis of the Elbow|Completed||Phase 4|78|Actual|International Clinical Research Institute||3|||f||||f||||||||||2018-05-31 21:40:57.197744|2018-05-31 21:40:57.197744
NCT01525017|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2015-10-09|2012-01-31|2012-02-02|Estimate|||||||2015-10-09|2015-10-12|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer|A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intratumorally in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1|12|Actual|Immunicum AB||1|||f||||t||||||||||2018-05-31 21:40:57.330384|2018-05-31 21:40:57.330384
NCT01525004|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-08-12|2012-01-30|2012-02-02|Estimate|||||||2016-08-12|2016-08-16|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients|Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine in Pediatric Solid Organ Transplant Patients|Completed||Phase 1|38|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 21:40:57.402664|2018-05-31 21:40:57.402664
NCT01524991|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-09-06|2012-01-31|2012-02-02|Estimate|||||||2017-09-06|2017-09-07|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|July 15, 2017|Actual|2017-07-15||Interventional|||First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma|Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148|Active, not recruiting||Phase 2|36|Anticipated|Hoosier Cancer Research Network||1|||f||||t||||||||||2018-05-31 21:40:57.514603|2018-05-31 21:40:57.514603
NCT01524978|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2017-08-22||2017-10-17|2012-01-31|2012-02-02|Estimate|2017-10-17|2017-11-20|Actual||||2017-10-17|2017-11-20|Actual|April 12, 2012|Actual|2012-04-12|October 2017|2017-10-31|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional||Intent-to-treat (ITT) population included all participants enrolled in the study irrespective of whether they had received study medication or not.|A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers|An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers|Completed||Phase 2|208|Actual|Hoffmann-La Roche||7|||f|||||t|f||||||||2018-05-31 21:40:57.667208|2018-05-31 21:40:57.667208
NCT01524965|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|||2017-01-03|2012-01-31|2012-02-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Effect of the Timing of Postoperative Mobilisation After Locking Plate Osteosynthesis of Fractures of the Surgical Neck of the Humerus|The Effect of the Timing of Postoperative Mobilisation After Locking Plate Osteosynthesis of Fractures of the Surgical Neck of the Humerus.|Recruiting||N/A|100|Anticipated|Helsinki University||2|||f||||f||||||||||2018-05-31 21:40:59.311397|2018-05-31 21:40:59.311397
NCT01524952|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-01-31|2012-01-31|2012-02-02|Estimate|||||||2012-01-31|2012-02-02|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||The Effect of Combined Thermal and Electrical Muscle Stimulation (cTEMS) on Obesity|The Effect of Combined Thermal and Electrical Muscle Stimulation (cTEMS) on Cardiorespiratory Fitness and Adipose Tissue in Obese Individuals|Completed||N/A|12|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 21:40:59.403358|2018-05-31 21:40:59.403358
NCT01524939|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-09-19|2012-01-31|2012-02-02|Estimate|||||||2012-09-19|2012-09-20|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||"Study of Combined Therapy of Aspirin and IVIG-SN in Kawasaki Disease"|"Multicenter, Single-arm, Phase IV Study to Evaluate the Efficacy, Safety of Combined Therapy of Aspirin and High Dose IVIG-SN in Pediatric Patients With Kawasaki Disease"|Completed||Phase 4|45|Actual|Green Cross Corporation||1|||f||||f||||||||||2018-05-31 21:40:59.498235|2018-05-31 21:40:59.498235
NCT01524926|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-01-18|2012-01-31|2012-02-02|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2012||2012-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 6, 2017|Actual|2017-12-06||Interventional|CREATE||CREATE: Cross-tumoral Phase 2 With Crizotinib|"Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET (CREATE)"|Active, not recruiting||Phase 2|582|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||6|||f||||t||||||||||2018-05-31 21:40:59.589349|2018-05-31 21:40:59.589349
NCT01524913|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|2017-01-12||2017-03-27|2012-01-31|2012-02-02|Estimate|2017-03-27|2017-05-05|Actual||||2017-03-27|2017-05-05|Actual|January 2012||2012-01-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional||The Baseline Analysis Population includes all participants who met eligibility criteria, were randomized to a study arm, and received their assigned study treatment.|A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint (TMJ) Dysfunction|A Double Blind Randomised Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint Dysfunction|Completed||Phase 4|102|Actual|Emory University||3|||f||||t||||||||||2018-05-31 21:40:59.745173|2018-05-31 21:40:59.745173
NCT01524900|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2015-05-15||2015-06-01|2012-01-31|2012-02-02|Estimate|2015-06-01|2015-06-02|Estimate||||2015-06-01|2015-06-02|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||Patients from the Treated Set (TS): This patient set includes all HIV-1 infected patients who were dispensed Viramune® and were documented to have taken at least one dose of Viramune®and of a antiretroviral combination partner.|Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice|Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice|Completed|||398|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 21:41:00.500347|2018-05-31 21:41:00.500347
NCT01524887|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-02-03||2017-10-19|2012-01-31|2012-02-02|Estimate|2015-03-18|2015-03-31|Estimate||||2017-10-19|2017-11-24|Actual|January 2012||2012-01-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||The baseline analysis population comprises treated subjects (=safety analysis set).|Phase 3 IGIV, 10% in Alzheimer´s Disease|A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease|Terminated||Phase 3|508|Actual|Shire|The primary and secondary outcome measures were originally planned to be assessed at 18 months. However, as the study was terminated early, an analysis was completed at 9 months instead, in a subset of subjects who had received 9 months of treatment.|3||"The study was terminated because the first Phase 3 did not demonstrate efficacy on the~   co-primary endpoints. The known safety profile remained unchanged."|f||||t||||||||||2018-05-31 21:41:01.110687|2018-05-31 21:41:01.110687
NCT01524874|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2012-01-31|2012-01-31|2012-02-02|Estimate|||||||2012-01-31|2012-02-02|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|CEDARS||Comparative Effectiveness of Vitamin D and Repletion Strategies|A Comparative Effectiveness Trial of High-quality Vitamin D3 Nutritional Supplements to Replete Serum Vitamin D|Completed||N/A|66|Actual|Bastyr University||3|||f||||f||||||||||2018-05-31 21:41:01.998741|2018-05-31 21:41:01.998741
NCT01524861|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-01-26|2012-01-30|2012-02-02|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy|Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies.|Completed||Phase 4|90|Actual|"University of Campania Luigi Vanvitelli"||3|||f||||t||||||||||2018-05-31 21:41:02.247869|2018-05-31 21:41:02.247869
NCT01524848|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2017-05-09|2012-01-30|2012-02-02|Estimate|||||||2017-05-09|2017-05-10|Actual|February 2012||2012-02-29|May 2016|2016-05-31|November 2016|Actual|2016-11-30|January 2015|Actual|2015-01-31||Interventional|PAGIST||Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib|Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group|Completed||Phase 2|72|Anticipated|Scandinavian Sarcoma Group||1|||f||||t||||||||||2018-05-31 21:41:02.344813|2018-05-31 21:41:02.344813
NCT01520194|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2016-05-08|2012-01-25|2012-01-27|Estimate|||||||2016-05-08|2016-05-10|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|GWburden||The Psychosocial and Economic Burden of Genital Warts|The Psychosocial and Economic Burden of Genital Warts for Women Attending Six Reproductive Health Clinics in Brazil|Completed|||224|Actual|BEMFAM-Bem Estar Familiar|||2||f||||t||||||||No||2018-05-31 21:42:08.957574|2018-05-31 21:42:08.957574
NCT01524835|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-03-23|2012-01-31|2012-02-02|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2010||2010-08-31|March 2017|2017-03-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Live Lung Donor Cross-sectional Cohort Study|Live Lung Donor Cross-sectional Cohort Study|Completed|||192|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 21:41:02.482663|2018-05-31 21:41:02.482663
NCT01524822|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-03-30|2012-01-31|2012-02-02|Estimate|||||||2018-03-30|2018-04-02|Actual|January 23, 2012||2012-01-23|February 15, 2018|2018-02-15||||||||Observational|||The Effects of Chronic Exposure to Low-Level Blasts|Experienced Breacher Study: Evaluation of the Effects From Chronic Exposure to Low-Level Blast|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:41:02.610228|2018-05-31 21:41:02.610228
NCT01524809|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2017-01-04|2012-01-31|2012-02-02|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2001||2001-01-31|January 2017|2017-01-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes|A Single-Centre, Randomised, Double-Blind, 2- Period Crossover Trial Investigating the Steady State Pharmacokinetics of Biphasic Insulin Aspart 30 and Biphasic Insulin Aspart 70 in Subjects With Type 1 Diabetes|Completed||Phase 1|26|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:41:02.689989|2018-05-31 21:41:02.689989
NCT01524796|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2015-03-11||2015-03-25|2012-01-30|2012-02-02|Estimate|2015-03-25|2015-03-31|Estimate||||2015-03-25|2015-03-31|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|NEP-TUNE|Safety analysis set included all participants who received at least one dose of the drug under study.|NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark|NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions In Denmark|Completed|||128|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:41:02.79428|2018-05-31 21:41:02.79428
NCT01524783|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2016-03-26||2017-11-06|2012-02-01|2012-02-02|Estimate|2016-11-01|2016-12-28|Estimate||||2017-11-06|2017-12-08|Actual|March 30, 2012|Actual|2012-03-30|November 2017|2017-11-30|December 28, 2020|Anticipated|2020-12-28|November 28, 2014|Actual|2014-11-28||Interventional|RADIANT-4|The full analysis set (FAS) consists of all randomized patients. Following the intent-to-treat principle, patients were analyzed according to the treatment arm and stratification factors they were assigned to at randomization.|Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)|A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin|Active, not recruiting||Phase 3|302|Actual|Novartis|Two patients randomized to everolimus were not treated due to withdrawal of consent and protocol deviation and one patient randomized to everolimus inadvertently received placebo treatment.|2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:41:03.19935|2018-05-31 21:41:03.19935
NCT01524770|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|2014-10-03||2014-10-21|2012-01-31|2012-02-02|Estimate|2014-10-21|2014-10-22|Estimate||||2014-10-21|2014-10-22|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Participants who received at least 1 dose of dulaglutide.|A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe|Comparative Pharmacokinetics of Dulaglutide After Administration Via an Auto-injector and a Manual Syringe in Healthy Subjects|Completed||Phase 1|50|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:41:05.953413|2018-05-31 21:41:05.953413
NCT01524757|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|He-ppi||Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis|Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis|Unknown status|Not yet recruiting|N/A|48|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:41:06.260724|2018-05-31 21:41:06.260724
NCT01524744|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus||Unknown status|Enrolling by invitation|Phase 2|40|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:41:06.3864|2018-05-31 21:41:06.3864
NCT01524731|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2014-09-02|2012-02-01|2012-02-02|Estimate|||||||2014-09-02|2014-09-04|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||The Effect of Prophylactic Antiemetic Dexamethasone on Plasma Cortisol Levels|The Effect of Prophylactic Antiemetic Dexamethasone on Plasma Cortisol Levels After Gynecologic Laparotomy|Completed||N/A|63|Anticipated|McGill University Health Center||3|||f||||t||||||||||2018-05-31 21:41:06.576594|2018-05-31 21:41:06.576594
NCT01524718|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-09-02|2012-02-01|2012-02-02|Estimate|||||||2012-09-02|2012-09-05|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|October 2012|Anticipated|2012-10-31||Interventional|||Internal Fixation of Hip Fractures Using Intraoperative Simultaneous Two Axis View||Unknown status|Not yet recruiting|N/A|60|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 21:41:06.722373|2018-05-31 21:41:06.722373
NCT01524705|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-09-16|2012-02-01|2012-02-02|Estimate|||||||2014-09-16|2014-09-18|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|FLAT-SUGAR||FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)|FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR|Completed||Phase 4|102|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 21:41:06.856682|2018-05-31 21:41:06.856682
NCT01524692|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2017-10-25||2018-04-04|2012-01-30|2012-02-02|Estimate|2018-04-04|2018-05-07|Actual||||2018-04-04|2018-05-07|Actual|March 2012||2012-03-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|ACC||Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma|A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.|Completed||Phase 2|35|Actual|University of Virginia||1|||f||||t||||||||||2018-05-31 21:41:07.082416|2018-05-31 21:41:07.082416
NCT01524679|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-03-01|2012-01-31|2012-02-02|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2012||2012-08-31|March 2018|2018-03-31|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|PADD-ON||Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen|A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys®)180 μg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B|Completed||Phase 2|170|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 21:41:07.455264|2018-05-31 21:41:07.455264
NCT01524666|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2018-02-27|2012-02-01|2012-02-02|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2012||2012-02-29|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy|Nutritional Supplementation With Agmatine Sulfate During Small Fiber Neuropathy|Recruiting|||15|Anticipated|JFK Medical Center|||||f||||f||||||Samples Without DNA|"~     Skin Biopsy~   "|||2018-05-31 21:41:07.605954|2018-05-31 21:41:07.605954
NCT01524653|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-12-02|2012-01-30|2012-02-02|Estimate|||||||2017-12-02|2017-12-05|Actual|March 2012||2012-03-31|December 2017|2017-12-31|September 1, 2016|Actual|2016-09-01|July 1, 2016|Actual|2016-07-01||Interventional|DISOLVE||Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)|Impact of Rosuvastatin on Risk Markers of Venous Thromboembolism During Systemic Therapy for Advanced Cancer|Completed||Phase 2|30|Anticipated|University of Vermont||2|||f||||t||||||||||2018-05-31 21:41:07.700662|2018-05-31 21:41:07.700662
NCT01524640|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2015-05-01|2012-02-01|2012-02-02|Estimate|||||||2015-05-01|2015-05-04|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Bridging Study for Killed Oral Cholera Vaccine in Ethiopia|A Randomized, Double-blind, Controlled Trial to Evaluate the Safety and Immunogenicity of Killed Bivalent (o1 and o139) Whole-cell Based Oral Cholera Vaccine (Shanchol®) in Healthy Individuals in Ethiopia|Completed||Phase 4|216|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-05-31 21:41:07.844513|2018-05-31 21:41:07.844513
NCT01524627|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2017-04-21||2017-08-15|2012-01-30|2012-02-02|Estimate|2017-08-15|2017-08-17|Actual||||2017-08-15|2017-08-17|Actual|December 2011||2011-12-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|VSMK||Effects of Varenicline on Smoking Reminders|Characterizing a Cue-vulnerable Pharmaco-responsive Endophenotype in Smokers|Completed||Phase 2|124|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 21:41:07.941833|2018-05-31 21:41:07.941833
NCT01524614|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-01-15|2012-01-30|2012-02-02|Estimate|||||||2017-01-15|2017-01-18|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety Study of Continuous Positive Airway Pressure Via a Nasal Mask|Effect of Continuous Positive Airway Pressure Ventilation Through Nasal Mask on Upper Airway Patency During Induction of Anesthesia|Completed||N/A|80|Actual|Massachusetts General Hospital||4|||f||||t||||||||||2018-05-31 21:41:08.413469|2018-05-31 21:41:08.413469
NCT01524601|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-10-11|2012-02-01|2012-02-02|Estimate|||||||2012-10-11|2012-10-12|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|RITA||The Rosuvastatin In TrAnsplant Recipients Study|The RITA-study -- An Open Study to Evaluate the Blood Lipid Lowering Effect of Rosuvastatin Versus Fluvastatin and the Bilateral Interaction Between Everolimus and Rosuvastatin in Renal Transplant Recipients|Completed||Phase 4|20|Actual|University of Oslo School of Pharmacy||1|||f||||f||||||||||2018-05-31 21:41:08.526223|2018-05-31 21:41:08.526223
NCT01524588|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2012-10-19|2012-01-30|2012-02-02|Estimate|||||||2012-10-19|2012-10-22|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||C Terminal Variants of FSH Receptor|C Terminal Peptide Variants of the Fsh Receptor in Women Involved in an Assisted Reproduction Programm : Mechanistic Approach|Completed|||814|Actual|University Hospital, Tours|||||f||||f||||||||||2018-05-31 21:41:08.683196|2018-05-31 21:41:08.683196
NCT01524575|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-01-30|2012-01-30|2012-02-02|Estimate|||||||2012-01-30|2012-02-02|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|July 2013|Anticipated|2013-07-31||Interventional|||Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1|Phase II Study of Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (Excision Repair Cross-complementation Group 1)|Unknown status|Recruiting|Phase 2|50|Anticipated|University of Hawaii||2|||f||||t||||||||||2018-05-31 21:41:08.758691|2018-05-31 21:41:08.758691
NCT01524562|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2018-04-04|2012-02-01|2012-02-02|Estimate|||||||2018-04-04|2018-04-05|Actual|December 20, 2011||2011-12-20|March 6, 2018|2018-03-06||||||||Observational|||HIV Accelerated Liver Disease in Uganda|HIV-Accelerated Liver Disease in Uganda|Completed|||786|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:41:08.839139|2018-05-31 21:41:08.839139
NCT01524549|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2018-05-26|2012-02-01|2012-02-02|Estimate|||||||2018-05-26|2018-05-30|Actual|January 17, 2012||2012-01-17|May 21, 2018|2018-05-21||||||||Observational|||Blood Vessel Study|The Role of the Functionally Relevant Single Nucleotide Polymorphisms CYP2J2 -50G>T (CYP2J2 7) and EPHX2 9846A>G (EPHX2 K55R) in Human Endothelial Function|Completed|||178|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:41:08.908834|2018-05-31 21:41:08.908834
NCT01524536|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2018-05-08|2012-02-01|2012-02-02|Estimate|||||||2018-05-08|2018-05-09|Actual|November 23, 2011||2011-11-23|April 23, 2018|2018-04-23|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Steroid Treatment for Hypereosinophilic Syndrome|Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes|Recruiting||Phase 4|100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:41:08.976956|2018-05-31 21:41:08.976956
NCT01524523|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2017-06-30|2012-02-01|2012-02-02|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2, 2011||2011-12-02|June 27, 2013|2013-06-27|June 27, 2013||2013-06-27|||||Observational|||Bone Marrow Aspiration Pain Study|Biochemical and Genetic Mechanisms of Acute Clinical Pain During Bone Marrow Aspiration|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:41:09.053435|2018-05-31 21:41:09.053435
NCT01524510|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-05-27|2012-02-01|2012-02-02|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2011||2011-02-28|May 2015|2015-05-31||||April 2016|Anticipated|2016-04-30||Interventional|||Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients|Open, Prospective Study for the Validation of the Predictive Value of Upper Airway Segmentation and CFD Analysis on Outcome Parameters of the Mandibular Replacement Appliance (MRA) Therapy in Obstructive Sleep Apnea Hypopnea Syndrome OSAHS) Patients|Unknown status|Recruiting|Phase 4|40|Anticipated|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 21:41:09.119817|2018-05-31 21:41:09.119817
NCT01524497|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2014-10-14|2012-01-30|2012-02-02|Estimate|||||||2014-10-14|2014-10-16|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression|A Clinical Study on Efficacy And Safety of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression A Multicenter, Randomized, Double-Blind, Parallel Controlled Study|Completed||Phase 2/Phase 3|382|Actual|Lee's Pharmaceutical Limited||2|||f||||t||||||||||2018-05-31 21:41:09.204983|2018-05-31 21:41:09.204983
NCT01524484|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2014-10-21|2012-02-01|2012-02-02|Estimate|||||||2014-10-21|2014-10-22|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Observational|QoQ||Quality of Quality Data|Quality of Quality Data - A Retrospective Study on Routine Quality Data Reporting in Anesthesia|Completed|||255|Actual|Klinik Hirslanden, Zurich|||2||f||||f||||||||||2018-05-31 21:41:09.295033|2018-05-31 21:41:09.295033
NCT01524471|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2010||2010-07-31|January 2012|2012-01-31||||March 2012|Anticipated|2012-03-31||Interventional|||Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders||Unknown status|Recruiting|Phase 2|20|Anticipated|Chinese University of Hong Kong||1|||f||||||||||||||2018-05-31 21:41:09.371545|2018-05-31 21:41:09.371545
NCT01524458|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2010||2010-07-31|October 2010|2010-10-31||||||||Interventional|POEM||Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders|Prospective Study on the Feasibility and Effectiveness of Per-Oral Endoscopic Myotomy (P.O.E.M.) for Treatment of Primary Esophageal Motility Disorders|Unknown status|Recruiting|Phase 1/Phase 2|8|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 21:41:09.474129|2018-05-31 21:41:09.474129
NCT01524445|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-06-11|2012-02-01|2012-02-02|Estimate|||||||2012-06-11|2012-06-12|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|||||Observational|||Retrospective Survey of Re-treatment With Bortezomib|Retrospective Evaluation of Re-Treatment With Bortezomib in Subjects With First Relapse After Bortezomib First-Line Therapy|Completed|||35|Actual|Janssen Pharmaceutica N.V., Belgium|||1||f||||f||||||||||2018-05-31 21:41:09.589629|2018-05-31 21:41:09.589629
NCT01524432|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-03-31|2012-02-01|2012-02-02|Estimate|||||||2013-03-31|2013-04-02|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis|Phase III Study in Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis|Completed||Phase 1|42|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 21:41:09.686551|2018-05-31 21:41:09.686551
NCT01524419|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-05-02|2012-01-30|2012-02-02|Estimate|||||||2012-05-02|2012-05-03|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Observational|||Women's Involvement In Decision Making At Labor And Its Effect on Their Perceived Labor Process|Women's Involvement In Decision Making At Labor And Its Effect on Their Perceived Labor Process|Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||f||||||||||2018-05-31 21:41:09.762971|2018-05-31 21:41:09.762971
NCT01524406|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2014-07-14|2012-01-30|2012-02-02|Estimate|||||||2014-07-14|2014-07-15|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety Study of HPP593 in Subjects During and After Limb Immobilization|A Randomized, Double-blind, Placebo Controlled, Phase I Study to Evaluate the Safety and Tolerability of 28 Day Treatment With HPP593 Capsules in Healthy Volunteers During and After Limb Immobilization|Terminated||Phase 1|24|Actual|High Point Pharmaceuticals, LLC.||2|||f||||f||||||||||2018-05-31 21:41:09.858467|2018-05-31 21:41:09.858467
NCT01524393|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2012-02-01|2012-02-01|2012-02-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|January 1990||1990-01-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Observational|||Risk of Pulmonary and Venous Thromboembolism in Pregnancies After in Vitro Fertilization|Estimation of the Risk of Pulmonary Embolism and Venous Thromboembolism in Pregnancy After in Vitro Fertilization.|Completed|||140458|Actual|Danderyd Hospital|||1||f||||f||||||||||2018-05-31 21:41:09.948225|2018-05-31 21:41:09.948225
NCT01524380|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2016-07-10|2012-02-01|2012-02-02|Estimate|||||||2016-07-10|2016-07-12|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Ginkgo Biloba Extract for Schizophrenia|A Double-blind and Randomized Trial of Ginkgo Biloba Extract Added to Risperidone in Treatment-naive First-episode Schizophrenia|Completed||N/A|124|Actual|Beijing HuiLongGuan Hospital||2|||f||||t||||||||||2018-05-31 21:41:10.040078|2018-05-31 21:41:10.040078
NCT01524367|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2015-02-04|2012-01-27|2012-02-02|Estimate|||||||2015-02-04|2015-02-06|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery|Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery|Completed||Phase 4|74|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:41:10.117486|2018-05-31 21:41:10.117486
NCT01524354|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-09-11|2012-01-30|2012-02-01|Estimate|||||||2012-09-11|2012-09-12|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Depth of Anesthesia in Cardiac Surgery|Monitoring of Anesthetic Depth During Surgical Correction of Acquired Valvular Disorders|Completed||N/A|28|Actual|Northern State Medical University||2|||f||||f||||||||||2018-05-31 21:41:10.18321|2018-05-31 21:41:10.18321
NCT01524341|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2013-05-09|2012-01-30|2012-02-01|Estimate|||||||2013-05-09|2013-05-13|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection|A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection|Completed||Phase 2|27|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:41:10.249587|2018-05-31 21:41:10.249587
NCT01524328|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-01-30|2012-01-30|2012-02-01|Estimate|||||||2012-01-30|2012-02-01|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. A Cross Sectional Study in Norway.|Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease. A Cross Sectional Study in Norway.|Completed|||460|Actual|Oslo University Hospital|||||f||||f||||||||||2018-05-31 21:41:10.409031|2018-05-31 21:41:10.409031
NCT01524315|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2013-05-14|2012-01-31|2012-02-01|Estimate|||||||2013-05-14|2013-05-16|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery|Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery - a Pilot Study|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:41:10.471573|2018-05-31 21:41:10.471573
NCT01524302|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2015-10-12||2016-03-14|2012-01-31|2012-02-01|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|||Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia|Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)|Completed||Phase 4|12|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 21:41:10.578755|2018-05-31 21:41:10.578755
NCT01524289|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-10-27|2012-01-30|2012-02-01|Estimate|||||||2017-10-27|2017-10-30|Actual|February 3, 2012|Actual|2012-02-03|October 2017|2017-10-31|October 20, 2018|Anticipated|2018-10-20|February 12, 2014|Actual|2014-02-12||Interventional|REALIZE||Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)|A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia|Active, not recruiting||Phase 3|306|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:41:10.884498|2018-05-31 21:41:10.884498
NCT01524276|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-09-13|2012-01-30|2012-02-01|Estimate|||||||2017-09-13|2017-09-15|Actual|January 2012||2012-01-31|September 2017|2017-09-30|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|PSR||Product Surveillance Registry|Medtronic Product Surveillance Registry|Recruiting|||55000|Anticipated|Medtronic|||||f||||f||||||||||2018-05-31 21:41:11.024782|2018-05-31 21:41:11.024782
NCT01524263|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-01-30|2012-01-30|2012-02-01|Estimate|||||||2012-01-30|2012-02-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:41:11.438193|2018-05-31 21:41:11.438193
NCT01524250|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-09-01|2012-01-30|2012-02-01|Estimate|||||||2015-09-01|2015-09-02|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Optic Neuritis Recovery After Oral or IV Corticosteroids|Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial|Completed||Phase 2/Phase 3|51|Actual|London Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:41:11.477279|2018-05-31 21:41:11.477279
NCT01524237|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2013-07-31|2012-01-30|2012-02-01|Estimate|||||||2013-07-31|2013-08-02|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of LY2979165 and LY2140023 in Healthy Volunteers|Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects|Completed||Phase 1|52|Anticipated|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 21:41:11.555836|2018-05-31 21:41:11.555836
NCT01524224|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2016-02-08|2012-01-30|2012-02-01|Estimate|||||||2016-02-08|2016-02-09|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2012|Actual|2012-11-30||Interventional|||A Dose-Escalation Study in Participants With Advanced Cancer|A Phase 1 Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, in Patients With Advanced Cancer|Completed||Phase 1|32|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:41:11.643376|2018-05-31 21:41:11.643376
NCT01524211|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-10-31|2012-01-31|2012-02-01|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2012||2012-01-31|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|||Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms|Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms|Recruiting||Phase 2|125|Anticipated|Lee, W. Anthony, M.D. FACS||1|||f||||f||||||||No||2018-05-31 21:41:11.731837|2018-05-31 21:41:11.731837
NCT01524198|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2013-11-02||2014-02-12|2012-01-30|2012-02-01|Estimate|2013-12-20|2014-02-13|Estimate||||2014-02-12|2014-03-13|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room|The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room|Completed||Phase 2/Phase 3|945|Actual|King Saud University||2|||f||||t||||||||||2018-05-31 21:41:11.812478|2018-05-31 21:41:11.812478
NCT01524185|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2018-04-06|2012-01-31|2012-02-01|Estimate|||||||2018-04-06|2018-04-09|Actual|February 2009||2009-02-28|April 2018|2018-04-30|January 8, 2016|Actual|2016-01-08|January 8, 2016|Actual|2016-01-08||Interventional|||FamilyLive Feasibility and Effectiveness Study|FamilyLive Feasibility and Effectiveness Study|Withdrawn||Early Phase 1|0|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2||There were not enough eligible families and trained clinicians to conduct RCT.|f||||f||||||||||2018-05-31 21:41:12.033195|2018-05-31 21:41:12.033195
NCT01524172|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2018-04-05|2012-01-31|2012-02-01|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2009||2009-01-31|April 2018|2018-04-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Yoga Based Psychotherapy Group Feasibility and Efficacy Study|Yoga Based Psychotherapy Group Feasibility and Efficacy Study|Completed||Early Phase 1|20|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||||2018-05-31 21:41:12.111871|2018-05-31 21:41:12.111871
NCT01524159|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-09-20|2012-01-30|2012-02-01|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|BRCARDIO||Bromelain and Cardiovascular Risk Factors in Diabetes|Bromelain and Cardiovascular Risk Factors in Diabetes|Completed||N/A|72|Actual|Hebei Yiling Hospital||2|||f||||t||||||||||2018-05-31 21:41:12.288088|2018-05-31 21:41:12.288088
NCT01524146|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2017-02-16|2012-01-31|2012-02-01|Estimate|||||||2017-02-16|2017-02-20|Actual|November 2011||2011-11-30|February 2017|2017-02-28|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01||Observational|PDTRegistry||Photodynamic Therapy (PDT) Cholangiocarcinoma Registry|To Establish a Multicenter Registry to Evaluate the Impact of Photodynamic Therapy in the Management of Patients With Unresectable Cholangiocarcinoma.|Recruiting|||200|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD Sharing|2018-05-31 21:41:12.398395|2018-05-31 21:41:12.398395
NCT01524133|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2017-12-06||2018-01-30|2012-01-27|2012-02-01|Estimate|2018-01-30|2018-02-28|Actual||||2018-01-30|2018-02-28|Actual|November 2011||2011-11-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|PROGrESS||PROlonGed ExpoSure Sertraline|Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF).|Completed||Phase 4|223|Actual|VA Ann Arbor Healthcare System||3|||f||||t||||||||||2018-05-31 21:41:12.528602|2018-05-31 21:41:12.528602
NCT01524120|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-01-23|2012-01-29|2012-02-01|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Endoscopy and Endomicroscopy for Assessment of Mucosal Healing in Inflammatory Bowel Disease (IBD)||Unknown status|Not yet recruiting||96|Anticipated|University of Erlangen-Nürnberg Medical School|||4||f||||t||||||Samples With DNA|"~     Biopsies were taken from every patient for subsequent histological analysis.~   "|||2018-05-31 21:41:12.983493|2018-05-31 21:41:12.983493
NCT01524107|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2016-12-18|2012-01-30|2012-02-01|Estimate|||||||2016-12-18|2016-12-20|Estimate|January 2012||2012-01-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Observational|||Complications: Urgent C Section VS Elective C Section|Comparison of Maternal and Fetal Complications After Urgent Caesarian Section for Prolapsed Cord Versus Elective Caesarian Section.|Recruiting|||240|Anticipated|Hadassah Medical Organization|||2||f||||f||||||||||2018-05-31 21:41:13.108861|2018-05-31 21:41:13.108861
NCT01524094|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-31|2012-01-31|2012-02-01|Estimate|||||||2012-01-31|2012-02-01|Estimate|June 2003||2003-06-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis|A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.|Completed||Phase 3|49|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 21:41:13.190277|2018-05-31 21:41:13.190277
NCT01524081|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-02-07|2012-01-31|2012-02-01|Estimate|||||||2012-02-07|2012-02-08|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures|Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis|Completed||Phase 3|187|Actual|The Faculty Hospital Na Bulovce||6|||f||||f||||||||||2018-05-31 21:41:13.300387|2018-05-31 21:41:13.300387
NCT01524068|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-01-04|2012-01-31|2012-02-01|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations|A Multicenter, Open-Label, Phase II Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:41:13.414673|2018-05-31 21:41:13.414673
NCT01524055|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-11-25|2012-01-27|2012-02-01|Estimate|||||||2013-11-25|2013-11-26|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||CO2 Insufflation During Single-Balloon-Enteroscopy|CO2 Insufflation During Single-Balloon-Enteroscopy|Completed||Phase 3|107|Actual|University Hospital Muenster||2|||f||||||||||||||2018-05-31 21:41:13.507738|2018-05-31 21:41:13.507738
NCT01524042|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-29|2012-01-29|2012-02-01|Estimate|||||||2012-01-29|2012-02-01|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|||Patient Satisfaction With Novel Double Pants Compared to Conventional Single Pants for Outpatient Colonoscopy|Patient Satisfaction With Novel Double Pants Compared to Conventional Single Pants for Outpatient Colonoscopy: Prospective Randomized Study|Unknown status|Enrolling by invitation|N/A|160|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 21:41:13.61219|2018-05-31 21:41:13.61219
NCT01524029|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2012-01-31|2012-01-31|2012-02-01|Estimate|||||||2012-01-31|2012-02-01|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Observational|||Digital Breast Tomosynthesis Versus Digital Mammography: A National Multicenter Trial|Digital Breast Tomosynthesis vs. Digital Mammography: A National Multicenter Trial|Unknown status|Recruiting||600|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 21:41:13.924913|2018-05-31 21:41:13.924913
NCT01524016|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2017-04-05|2012-01-29|2012-02-01|Estimate|||||||2017-04-05|2017-04-07|Actual|December 2011||2011-12-31|July 2014|2014-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia|68Ga-DOTATATE PET/CT for Detection and Evaluation of the Causative Tumor of Oncogenic Osteomalacia|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 21:41:14.200259|2018-05-31 21:41:14.200259
NCT01524003|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2015-05-06|2012-01-29|2012-02-01|Estimate|||||||2015-05-06|2015-05-08|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|CHICAPS||Chinese Cancer Prevention Study(CHICAPS)|Chinese Cancer Prevention Study(CHICAPS) Mass Population Based Cervical Cancer Screening|Completed||N/A|8382|Actual|Preventive Oncology International, Inc.||2|||f||||f||||||||||2018-05-31 21:41:14.307021|2018-05-31 21:41:14.307021
NCT01523990|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-12-18|2012-01-29|2012-02-01|Estimate|||||||2014-12-18|2014-12-19|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|April 2012|Actual|2012-04-30||Interventional|||A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients|A Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of Single and Multiple Ascending Oral Doses of TG-2349, and Followed by a Dose-Ranging Study in Hepatitis C Genotype 1 Infected Patients|Completed||Phase 1|135|Actual|TaiGen Biotechnology Co., Ltd.||27|||f||||f||||||||||2018-05-31 21:41:14.400467|2018-05-31 21:41:14.400467
NCT01523977|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2018-02-02|2012-01-30|2012-02-01|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2011||2011-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|January 2017|Actual|2017-01-31||Interventional|CRAD001NUS175T||Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL|A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting||Phase 1|42|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-05-31 21:41:14.549687|2018-05-31 21:41:14.549687
NCT01523964|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2013-08-09||2013-10-16|2012-01-31|2012-02-01|Estimate|2013-10-16|2013-12-09|Estimate||||2013-10-16|2013-12-09|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls|A Phase I, Multi-Center, Controlled, Prospective Correlative Study of Electrical Impedance Myography in Males With Duchenne Muscular Dystrophy and In Healthy Males|Completed||N/A|92|Actual|Dart Therapeutics. LLC||4|||f||||f||||||||||2018-05-31 21:41:14.643566|2018-05-31 21:41:14.643566
NCT01523951|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-29|||2012-03-19|2012-01-31|2012-02-01|Estimate|||||||2012-03-19|2012-03-20|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|LACCA||Topical Local Anaesthesia and Cooling During Capsaicin 8% Patch Application|A Comparison of Topical Local Anaesthesia and Cooling to Reduce the Burning Pain During Capsaicin 8% Patch Application|Completed|||12|Actual|Medical University of Vienna|||1||f||||f||||||Samples Without DNA|"~     Skin biopsy~   "|||2018-05-31 21:41:14.935075|2018-05-31 21:41:14.935075
NCT01523938|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2016-08-09|2012-01-30|2012-02-01|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|April 2014|Actual|2014-04-30||Interventional|HYPNOC||Influence of Perioperative Hypnotherapy on Postoperative Improvement in Cognitive Performance|Influence of Perioperative Hypnotherapy on Postoperative Improvement in Cognitive Performance. A Randomized-controlled Open Clinical Monocentric Interventional Study.|Terminated||N/A|72|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:41:14.997743|2018-05-31 21:41:14.997743
NCT01523925|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-02-10|2012-01-30|2012-02-01|Estimate|||||||2015-02-10|2015-02-11|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Combined Behavioral Approaches With Functional Electrical Therapy in Stroke Rehabilitation|Combined Behavioral Approaches With Functional Electrical Therapy in Stroke Rehabilitation: Effects on Motor Control, Motor Impairment, Daily Function and Community Reintegration|Withdrawn||N/A|0|Actual|Chang Gung Memorial Hospital||5|||f||||f||||||||||2018-05-31 21:41:15.066195|2018-05-31 21:41:15.066195
NCT01523912|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2016-02-18|2012-01-29|2012-02-01|Estimate|||||||2016-02-18|2016-02-22|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Radiofrequency Ablation for the Treatment of Gastric Dysplasia|Ablation of Gastric Dysplastic Mucosa by a Novel Endoscopic Radiofrequency Device.|Completed||Phase 4|10|Actual|Hospital Sao Joao||1|||f||||f||||||||||2018-05-31 21:41:15.14419|2018-05-31 21:41:15.14419
NCT01523899|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2017-02-23||2017-08-04|2012-01-31|2012-02-01|Estimate|2017-08-04|2017-09-06|Actual||||2017-08-04|2017-09-06|Actual|May 2011||2011-05-31|August 2017|2017-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses|A Randomized Clinical Trial Comparing Use of Rapid Molecular Testing for Staphylococcus Aureus for Patients With Cutaneous Abscesses in the Emergency Department With Standard of Care.|Completed||N/A|252|Actual|George Washington University||2|||f||||f||||||||No||2018-05-31 21:41:15.212061|2018-05-31 21:41:15.212061
NCT01523886|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2014-01-16||2014-03-16|2012-01-30|2012-02-01|Estimate|2014-03-16|2014-04-21|Estimate||||2014-03-16|2014-04-21|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Muscle Relaxation-study|Optimization of Surgical Conditions During Laparoscopic Cholecystectomy With Deep or Moderate Neuromuscular Blockade|Completed||Phase 4|49|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 21:41:15.535215|2018-05-31 21:41:15.535215
NCT01523873|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2015-12-14||2017-01-10|2012-01-30|2012-02-01|Estimate|2015-12-14|2016-01-22|Estimate||||2017-01-10|2017-02-24|Actual|November 2008||2008-11-30|January 2017|2017-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)|Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)|Completed|||35921|Actual|Guerbet|||||f||||||||||||||2018-05-31 21:41:15.836681|2018-05-31 21:41:15.836681
NCT01523860|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-02-29|2012-01-30|2012-02-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FLE09||Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma|Brief Induction Chemoimmunotherapy With Rituximab + Bendamustine + Mitoxantrone Followed by Rituximab in Elderly Patients With Advanced Stage Previously Untreated Follicular Lymphoma|Completed||Phase 2|76|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 21:41:16.118781|2018-05-31 21:41:16.118781
NCT01523847|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-08-03|2012-01-30|2012-02-01|Estimate|||||||2016-08-03|2016-08-04|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|HD0803||A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)|A Phase II Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)|Completed||Phase 2|50|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 21:41:16.249796|2018-05-31 21:41:16.249796
NCT01523834|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-08-03|2012-01-30|2012-02-01|Estimate|||||||2016-08-03|2016-08-04|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|FIL_PanAL10||Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT|A Phase II Study of Oral Panobinostat in Adult Patients With Diffuse Large B-cell Lymphoma Relapsed/Refractory After High-dose Chemotherapy With Autologous Stem Cell Transfusion (ASCT) or Not Eligible for ASCT|Completed||Phase 2|35|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||t||||||||||2018-05-31 21:41:16.376899|2018-05-31 21:41:16.376899
NCT01523821|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2017-05-22|2012-01-30|2012-02-01|Estimate|||||||2017-05-22|2017-05-24|Actual|October 11, 2013|Actual|2013-10-11|May 2017|2017-05-31|January 15, 2017|Actual|2017-01-15|January 15, 2017|Actual|2017-01-15||Interventional|||Alpha 1 Anti-Trypsin in Treating Patients With Acute Graft-Versus-Host Disease|Treatment of Steroid Non-responsive Acute GVHD With Alpha 1 Antitrypsin (AAT). A Phase I/II Study|Completed||Phase 1/Phase 2|14|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 21:41:16.471456|2018-05-31 21:41:16.471456
NCT01523808|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-03-07|2012-01-30|2012-02-01|Estimate|||||||2013-03-07|2013-03-08|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer|Phase I, Dose Escalation Clinical Trial of GRASPA (Red Blood Cells Encapsulating L-Asparaginase) in Patients With Pancreatic Carcinoma|Completed||Phase 1|12|Actual|ERYtech Pharma||4|||f||||t||||||||||2018-05-31 21:41:16.567281|2018-05-31 21:41:16.567281
NCT01523795|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-01-31|2012-01-31|2012-02-01|Estimate|||||||2012-01-31|2012-02-01|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||PRESENCE 2: Predicting Sedentary Entertainment Choices and Effects|PRESENCE 2: Predicting Sedentary Entertainment Choices and Effects|Completed||N/A|120|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 21:41:16.634796|2018-05-31 21:41:16.634796
NCT01523782|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-03-07|2012-01-30|2012-02-01|Estimate|||||||2013-03-07|2013-03-08|Estimate|April 2009||2009-04-30|March 2013|2013-03-31|October 2012|Actual|2012-10-31|January 2011|Actual|2011-01-31||Interventional|||Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia|An Escalating Dose Phase IIa Study of L-Asparaginase Encapsulated in Erythrocytes (GRASPA®) in Association With Polychemotherapy During Induction Phase for Treatment of Elderly Patients With Acute Lymphoblastic Leukaemia (ALL), Aged 55 Years and Over, With Philadelphia Chromosome-negative (ALL Ph-)|Completed||Phase 2|30|Actual|ERYtech Pharma||3|||f||||t||||||||||2018-05-31 21:41:16.712741|2018-05-31 21:41:16.712741
NCT01523600|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-05-10|2012-01-27|2012-02-01|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|March 2014|Actual|2014-03-31||Interventional|VAREX||Whole Body Vibration Training Among Older People Using Sheltered Housing|Effect of Whole Body Vibration Training on Physical Functioning and Risk of Falling in Older People Using Sheltered Housing|Terminated||Phase 4|130|Actual|UKK Institute||2||Lack of funding|f||||f||||||||||2018-05-31 21:41:18.713476|2018-05-31 21:41:18.713476
NCT01523769|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2012-01-30|2012-01-30|2012-02-01|Estimate|||||||2012-01-30|2012-02-01|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants|The Efficacy of Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants Born Between 24 and 28 6/7 Weeks Gestation, a Randomized Controlled Trial.|Completed||N/A|113|Actual|Eastern Virginia Medical School||2|||f||||t||||||||||2018-05-31 21:41:16.81795|2018-05-31 21:41:16.81795
NCT01523756|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2013-11-21||2014-01-28|2012-01-30|2012-02-01|Estimate|2014-01-28|2014-03-10|Estimate||||2014-01-28|2014-03-10|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Clinical Investigation of New Ostomy Appliances|An Open-labelled Randomized Cross-over and Controlled Exploratory Investigation Comparing Several Variants of a Newly Developed Ostomy Appliance With Regard to Performance in 20 Patients With Ileostomy|Completed||N/A|20|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 21:41:16.918515|2018-05-31 21:41:16.918515
NCT01523743|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2013-08-06||2016-08-23|2012-01-30|2012-02-01|Estimate|2014-04-28|2014-05-22|Estimate||||2016-08-23|2016-09-30|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional||The ITT population consistsed of 118 subjects.|Quality of Life Intermittent Catheter Study|Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters|Completed||Phase 4|125|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 21:41:17.124396|2018-05-31 21:41:17.124396
NCT01523730|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2015-09-08|2012-01-30|2012-02-01|Estimate|||||||2015-09-08|2015-09-09|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|rTMSsmokelab||Effects of rTMS on Cigarette Smoking and Cognition in Schizophrenia|Effects of Repetitive Transcranial Magnetic Stimulation on Cigarette Smoking and Cognitive Function in Smokers With and Without Schizophrenia|Completed||N/A|27|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 21:41:17.329105|2018-05-31 21:41:17.329105
NCT01523717|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-03-13|2012-01-30|2012-02-01|Estimate|||||||2015-03-13|2015-03-17|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|MOSES||Procalcitonin Monitoring Sepsis Study|Procalcitonin Decrease Over 72 Hours and Outcome in Patients With Severe Sepsis or Septic Shock|Completed|||858|Actual|Brahms AG|||||f||||||||||Samples Without DNA|"~     EDTA plasma and serum samples~   "|||2018-05-31 21:41:17.413706|2018-05-31 21:41:17.413706
NCT01523704|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-02-03|2012-01-30|2012-02-01|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 2012||2012-01-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy Study of IPG Patient With Home Monitoring|Comparison of the Safety and Efficacy of the Management of Pacemaker Patients Followed-up Via Home Monitoring vs. Conventional In-Office Follow-up|Completed||N/A|1333|Actual|Biotronik Japan, Inc.||2|||f||||||||||||||2018-05-31 21:41:17.488659|2018-05-31 21:41:17.488659
NCT01523691|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-03-10|2012-01-30|2012-02-01|Estimate|||||||2017-03-10|2017-03-14|Actual|August 2011||2011-08-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Repeating Patterns of Sleep Restriction and Recovery|Repeating Patterns of Sleep Restriction and Recovery - do we Get Used to it?|Completed||N/A|17|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 21:41:17.552573|2018-05-31 21:41:17.552573
NCT01523678|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2017-07-28|2012-01-30|2012-02-01|Estimate|||||||2017-07-28|2017-07-31|Actual|February 2012||2012-02-29|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|May 2014|Actual|2014-05-31||Interventional|||Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers|Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers|Active, not recruiting||Phase 2|108|Anticipated|Belgian Gynaecological Oncology Group||1|||f||||||||||||||2018-05-31 21:41:17.623627|2018-05-31 21:41:17.623627
NCT01523665|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2013-11-26|2012-01-30|2012-02-01|Estimate|||||||2013-11-26|2013-11-27|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Blood Glucose Control in Intensive Care Patients Using the Space GlucoseControl System|Evaluation of Blood Glucose Control in Intensive Care Patients Using the Space GlucoseControl System|Completed|||508|Actual|B. Braun Melsungen AG|||||f||||f||||||||||2018-05-31 21:41:17.712394|2018-05-31 21:41:17.712394
NCT01523652|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-01-30|2012-01-30|2012-02-01|Estimate|||||||2012-01-30|2012-02-01|Estimate|November 2007||2007-11-30|January 2012|2012-01-31|November 2008|Actual|2008-11-30|||||Observational|||Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients|Studio Pilota Farmacocinetico-clinico Sulla Somministrazione di Eparina a Basso Peso Molecolare e Dosaggio Sierico di HGF Nelle Pazienti Operate Affette da Patologie Ginecologiche|Completed|||29|Actual|Azienda Ospedaliera San Giovanni Battista|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:41:17.779165|2018-05-31 21:41:17.779165
NCT01523639|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-03-07|2012-01-30|2012-02-01|Estimate|||||||2014-03-07|2014-03-10|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|May 2014|Anticipated|2014-05-31|November 2013|Actual|2013-11-30||Interventional|G-LUCAS||A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis|A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type, Metastatic Colorectal Cancer|Terminated||Phase 2|8|Actual|Austrian Breast & Colorectal Cancer Study Group||2||"Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013.~   ABCSG guaranteed completed treatment period for ethical reasons."|f||||t||||||||||2018-05-31 21:41:17.836466|2018-05-31 21:41:17.836466
NCT01523626|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2018-02-04|2012-01-30|2012-02-01|Estimate|||||||2018-02-04|2018-02-06|Actual|April 2011||2011-04-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|REACT-2||A Multicenter, Randomized Study of Early Assessment by CT Scanning in Severely Injured Trauma Patients|Randomized Study of Early Assessment by CT Scanning in Trauma Patients|Completed||N/A|1083|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 21:41:17.926734|2018-05-31 21:41:17.926734
NCT01523613|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2017-07-15||2017-09-05|2012-01-31|2012-02-01|Estimate|2017-09-05|2017-10-03|Actual||||2017-09-05|2017-10-03|Actual|November 2011||2011-11-30|September 2017|2017-09-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|ROCK||High-strength Glass-ionomer Dental Restorations|Clinical Performance of High-Viscous Glass-Ionomer Restorative Systems In Class II Lesions|Completed||N/A|93|Actual|University of Michigan|Current study was not designed to investigate wear behavior as final surface treatment was different between the two materials.|3|||f||||f||||||||Undecided||2018-05-31 21:41:18.156952|2018-05-31 21:41:18.156952
NCT01523587|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2014-10-06||2018-01-04|2012-01-30|2012-02-01|Estimate|2014-11-20|2014-11-21|Estimate||||2018-01-04|2018-01-08|Actual|March 5, 2012|Actual|2012-03-05|January 2018|2018-01-31|November 29, 2017|Actual|2017-11-29|August 27, 2013|Actual|2013-08-27||Interventional||All patients who were randomised, regardless of whether they received investigational treatment, are defined as the Randomised Set.|LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy|LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy|Completed||Phase 3|795|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:41:18.99282|2018-05-31 21:41:18.99282
NCT01523574|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2012-01-29|2012-01-29|2012-02-01|Estimate|||||||2012-01-29|2012-02-01|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis|Randomized, Placebo Controlled Study of Vitamin E for Oxaliplatin-induced Neuropathy Prophylaxis|Completed||Phase 2|38|Actual|Faculdade de Medicina do ABC||2|||f||||t||||||||||2018-05-31 21:41:20.135745|2018-05-31 21:41:20.135745
NCT01523561|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-07-14|2012-01-31|2012-02-01|Estimate|||||||2015-07-14|2015-07-15|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Interventional|||Influencing Adolescent Girls´ With Creative Dance Twice Weekly|Influencing Adolescent Girls With Internalizing Problems With Creative Dance Twice Weekly. A Randomised, Controlled Study|Completed||Phase 3|150|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 21:41:20.247762|2018-05-31 21:41:20.247762
NCT01523548|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2017-06-08|2012-01-31|2012-02-01|Estimate|||||||2017-06-08|2017-06-09|Actual|July 2012||2012-07-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CO in PAH||Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension|Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension|Withdrawn||Phase 1/Phase 2|0|Actual|University of Illinois at Chicago||1||Lack of funding and subject acuity|f||||t||||||||||2018-05-31 21:41:20.322099|2018-05-31 21:41:20.322099
NCT01523535|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2017-04-12|2012-01-30|2012-02-01|Estimate|||||||2017-04-12|2017-04-14|Actual|August 2011|Actual|2011-08-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|September 2014|Actual|2014-09-30||Interventional|||Repeated Challenge of Insufficient Sleep: Endothelial Effects|Repeated Challenge of Insufficient Sleep: Effects on Endothelial Function|Active, not recruiting||N/A|52|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 21:41:20.413476|2018-05-31 21:41:20.413476
NCT01523522|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-10-22|2012-01-31|2012-02-01|Estimate|||||||2015-10-22|2015-10-23|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|MIAS||Autologous Myoblast Intrasphincteric Injection for Fecal Incontinence|Etude de l'efficacité et de la sécurité d'Injections Intra-sphinctériennes de Myoblastes Autologues Chez Des Patients Atteints d'Incontinence Anale sévère Par Insuffisance sphinctérienne|Completed||Phase 2/Phase 3|24|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 21:41:20.4963|2018-05-31 21:41:20.4963
NCT01523509|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-06-15|2012-01-31|2012-02-01|Estimate|||||||2016-06-15|2016-06-17|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Use of Radiographic Contrast to Detect Dental Caries|The Use of Radiographic Contrast to Differentiate Cavitated From Non-cavitated Dental Caries|Completed||Phase 1|33|Actual|Creighton University||1|||f||||f||||||||||2018-05-31 21:41:20.577442|2018-05-31 21:41:20.577442
NCT01523496|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2017-10-24||2018-02-05|2012-01-31|2012-02-01|Estimate|2018-01-09|2018-02-06|Actual||||2018-02-05|2018-03-08|Actual|December 2011||2011-12-31|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||A total of 190 subjects were enrolled, including 102 HIV-infected subjects: 66 on vitamin D supplementation dose, 36 on vitamin D control dose and 88 healthy controls: 58 on vitamin D supplementation dose, 30 on vitamin D control dose. By design, groups were well matched for age, sex and race.|Vitamin D Supplementation in HIV Youth|Vitamin D Supplementation and HIV-related Complications in Children and Young Adults|Completed||Phase 2/Phase 3|190|Actual|University Hospitals Cleveland Medical Center|Limitations to this study include the lack of adherence measures to study drug such as pill counts and the small sample size.|2|||f||||t||||||||||2018-05-31 21:41:20.664417|2018-05-31 21:41:20.664417
NCT01523483|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2015-04-21|2012-01-31|2012-02-01|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Vaginal Progesterone for Prevention of Preterm Birth After an Episode of Preterm Labor|Vaginal Progesterone for Prevention of Preterm Birth After an Episode of Preterm Labor|Completed||N/A|30|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 21:41:21.062688|2018-05-31 21:41:21.062688
NCT01523470|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-14|||2012-01-31|2012-01-31|2012-02-01|Estimate|||||||2012-01-31|2012-02-01|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Withdrawal of Non-invasive Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Acute Hypercapnic Respiratory Failure|A Pilot Randomised Controlled Trial of Withdrawal of Non-invasive Ventilation in COPD Patients With Acute Hypercapnic Respiratory Failure|Completed||Phase 3|60|Actual|United Christian Hospital||2|||f||||t||||||||||2018-05-31 21:41:22.242266|2018-05-31 21:41:22.242266
NCT01523457|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2016-09-01||2017-08-28|2012-01-31|2012-02-01|Estimate|2017-08-28|2017-08-30|Actual||||2017-08-28|2017-08-30|Actual|October 2011||2011-10-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|FOLFIRINOX|75 patients, including 44 with MPC and 31 with LAPC, were enrolled. The demographics and disease characteristics of the 37 evaluable patients in the MPC cohort in this study are presented here. Seven of 44 patients with MPC were excluded from efficacy analysis due to voluntary withdrawal.|Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer|Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer|Completed||Phase 2|75|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:41:22.36039|2018-05-31 21:41:22.36039
NCT01523444|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2015-07-14|2012-01-27|2012-02-01|Estimate|||||||2015-07-14|2015-07-16|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|November 2017|Anticipated|2017-11-30|February 2016|Anticipated|2016-02-29||Interventional|||Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings|Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings|Withdrawn||Phase 3|0|Actual|Treatment Research Institute||3||Study not funded.|f||||t||||||||||2018-05-31 21:41:22.882026|2018-05-31 21:41:22.882026
NCT01523275|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-05-12|2012-01-31|2012-02-01|Estimate|||||||2016-05-12|2016-05-16|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Study of Mitomycin-C Application in Laryngotracheal Stenosis|A Randomized Study of Mitomycin-C Application in the Endoscopic Surgical Treatment of Patients With Laryngotracheal Stenosis|Recruiting||N/A|60|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:41:25.536116|2018-05-31 21:41:25.536116
NCT01523431|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-03-29|2012-01-29|2012-02-01|Estimate|||||||2017-03-29|2017-03-30|Actual|March 8, 2012|Actual|2012-03-08|March 2017|2017-03-31|April 27, 2016|Actual|2016-04-27|November 23, 2015|Actual|2015-11-23||Interventional|||Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients|Influence of Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype on Clinical Outcomes and Pharmacokinetics in Chinese Patients With Metastatic Colorectal Cancer|Completed||Phase 2/Phase 3|583|Actual|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||3|||f||||f|t|f|||f|||||2018-05-31 21:41:22.958409|2018-05-31 21:41:22.958409
NCT01523418|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2016-02-02|2012-01-30|2012-02-01|Estimate|||||||2016-02-02|2016-02-04|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|XYRIS||Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)|Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery or Hip or Knee in Indian Patients|Withdrawn|||0|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:41:23.060119|2018-05-31 21:41:23.060119
NCT01523405|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2014-09-05|2012-01-30|2012-02-01|Estimate|||||||2014-09-05|2014-09-08|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|INSIGHT||A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM|A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)|Completed|||4911|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:41:23.256914|2018-05-31 21:41:23.256914
NCT01523392|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2014-09-22||2014-09-30|2012-01-30|2012-02-01|Estimate|2014-09-22|2014-09-26|Estimate||||2014-09-30|2014-10-08|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Randomized Analysis Set for demography (N=34) - included all patients who signed informed consent and were randomized into the study.|A Pharmacodynamic Study With Ticagrelor in African American Patients|A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease|Completed||Phase 4|50|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:41:23.456913|2018-05-31 21:41:23.456913
NCT01523379|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-04-24|2012-01-31|2012-02-01|Estimate|||||||2012-04-24|2012-04-25|Estimate||||April 2012|2012-04-30||||||||Expanded Access|||Efficacy of Parecoxib on Patients With CRPS|Efficiacy of the Selctive COX-2-inhibitor Parecoxibe on the Pathological Low Pressure Pain Threshold (PPT) of Patients With Complex Regional Pain Syndrome (CRPS)|No longer available|||||Ruhr University of Bochum|||||f||||||||||||||2018-05-31 21:41:23.97853|2018-05-31 21:41:23.97853
NCT01523366|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|2014-05-10||2014-08-14|2012-01-30|2012-02-01|Estimate|2014-07-03|2014-08-05|Estimate||||2014-08-14|2014-08-18|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Randomized Analysis Set for demography (N=40) - included all patients who signed informed consent and were randomized into the study. Pharmacodynamic (PD) Analysis Set for outcomes (N=38) - included all patients for whom PD data was available with no major protocol deviations thought to significantly affect the PD of ticagrelor or clopidogrel|A Pharmacodynamic Study With Ticagrelor in Hispanic Patients|A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Hispanic Patients With Stable Coronary Artery Disease|Completed||Phase 4|53|Actual|AstraZeneca|Total N for the secondary outcome analysis after multiple doses and for PK measures was not the same for 2 hours, 8 hours and end of dosing. Only the first time point total N can be reported via the form. Row titles indicate N's where they differ.|2|||f||||f||||||||||2018-05-31 21:41:24.071211|2018-05-31 21:41:24.071211
NCT01523353|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2013-12-16|2012-01-30|2012-02-01|Estimate|||||||2013-12-16|2013-12-17|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Prehabilitation in Liver Surgery|Feasibility Study of Preoperative Exercise Intervention in the Resection of Colorectal Liver Metastasis.|Completed||Phase 1|37|Actual|Aintree University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:41:24.547527|2018-05-31 21:41:24.547527
NCT01523340|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-01-30|2012-01-28|2012-02-01|Estimate|||||||2013-01-30|2013-01-31|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|MENTOR||A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response|Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib|Unknown status|Recruiting||200|Anticipated|Chonnam National University Hospital|||1||f||||t||||||Samples Without DNA|"~     NSCLC tumor tissue for c-MET expression by immuohistochemistry c-MET amplification by silver~     in situ hybridization EGFR mutation by realtime PCR~   "|||2018-05-31 21:41:24.642704|2018-05-31 21:41:24.642704
NCT01523327|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-01-31|2012-01-31|2012-02-01|Estimate|||||||2012-01-31|2012-02-01|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|October 2012|Anticipated|2012-10-31|November 2011|Actual|2011-11-30||Observational|||Study of Association Between Maternal Uric Acid , Maternal and Fetal Outcome in Pregnant Women With Hypertension|Association of Maternal Uric Acid With Maternal Condition and Fetal Outcome in Pregnant Women With Hypertension|Unknown status|Recruiting||80|Anticipated|Ain Shams Maternity Hospital|||2||f||||t||||||||||2018-05-31 21:41:24.745864|2018-05-31 21:41:24.745864
NCT01523314|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-28|||2012-01-31|2012-01-31|2012-02-01|Estimate|||||||2012-01-31|2012-02-01|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|February 2013|Anticipated|2013-02-28|August 2012|Anticipated|2012-08-31||Interventional|DECEDE||Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema|Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema|Unknown status|Not yet recruiting|Phase 2/Phase 3|40|Anticipated|King Saud University||2|||f||||t||||||||||2018-05-31 21:41:24.846009|2018-05-31 21:41:24.846009
NCT01523301|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2015-10-12||2015-11-16|2012-01-31|2012-02-01|Estimate|2015-11-16|2015-12-18|Estimate||||2015-11-16|2015-12-18|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Baseline Characteristics refer to the Randomized Set (RS), which consists of all randomized subjects.|Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients|Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients|Completed||Phase 4|380|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:41:24.959523|2018-05-31 21:41:24.959523
NCT01523288|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2012-01-31|2012-01-31|2012-02-01|Estimate|||||||2012-01-31|2012-02-01|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||The Intestinal Function in People With Prader-Willi Syndrome|The Intestinal Function in People With Prader-Willi Syndrome|Completed|||21|Actual|Aarhus University Hospital|||2||f||||t||||||||||2018-05-31 21:41:25.449697|2018-05-31 21:41:25.449697
NCT01523262|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-01-12|2012-01-31|2012-02-01|Estimate|||||||2015-01-12|2015-01-14|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Preventing Myocardial Ischemia by Preconditioning in Elective Operation for Abdominal Aortic Aneurysm|The Effect of Preconditioning to Prevent Perioperative Myocardial Ischemia in Elective Operation of Abdominal Aortic Aneurysm|Unknown status|Recruiting|Phase 1|200|Anticipated|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 21:41:25.626084|2018-05-31 21:41:25.626084
NCT01523249|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2014-09-26|2012-01-31|2012-02-01|Estimate|||||||2014-09-26|2014-09-30|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Observational|||Three-Dimensional Ultrasound (3D US) in Parturients|Three-Dimensional Ultrasound (3D US) for Epidural Needle Insertion in Parturients|Completed|||20|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 21:41:25.710556|2018-05-31 21:41:25.710556
NCT01523236|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-01-27|2012-01-27|2012-02-01|Estimate|||||||2012-01-27|2012-02-01|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Furoate Anhydrous, 50 Mcg/Actuation Nasal Spray (Teva Pharmaceuticals USA) Compared to Nasonex® (Mometasone Furoate Monohydrate) 50 Mcg/Actuation Nasal Spray (Schering) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|Completed||Phase 1/Phase 2|800|Actual|Teva Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 21:41:25.784925|2018-05-31 21:41:25.784925
NCT01523223|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-11-17|2012-01-31|2012-02-01|Estimate|||||||2016-11-17|2016-11-18|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies|A Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation|Active, not recruiting||Phase 1|16|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 21:41:25.86394|2018-05-31 21:41:25.86394
NCT01523210|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-07|||2012-11-12|2012-01-28|2012-02-01|Estimate|||||||2012-11-12|2012-11-14|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle|Influence of Physiotherapy on the Spastic Musculus Biceps Brachii Under Routine Botulinum Toxin Injection. - An Explorative MRI Study|Completed|||5|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 21:41:25.946845|2018-05-31 21:41:25.946845
NCT01523197|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-11-26|2012-01-28|2012-02-01|Estimate|||||||2012-11-26|2012-11-27|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Auto-trilevel Ventilator for Patients With Overlap Syndrome|Effect of Auto-Trilevel Ventilation on Patients With Overlap Syndrome|Completed||N/A|17|Actual|Nanjing Medical University||1|||f||||f||||||||||2018-05-31 21:41:26.013306|2018-05-31 21:41:26.013306
NCT01523184|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27||2014-07-01|2014-07-02|2012-01-31|2012-02-01|Estimate||||2014-07-01|2014-07-03|Estimate|2014-07-02|2014-07-04|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation|A Phase II, Single-Center, Randomized, Parallel Group, Multiple Administration, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation|Completed||Phase 2|57|Actual|SK Life Science||4|||f||||f||||||||||2018-05-31 21:41:26.081987|2018-05-31 21:41:26.081987
NCT01523171|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27||2016-02-17|2016-02-17|2012-01-31|2012-02-01|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|JAKARTA2||Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib|A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis|Completed||Phase 2|97|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:41:26.16147|2018-05-31 21:41:26.16147
NCT01523158|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-09-21|2012-01-31|2012-02-01|Estimate|||||||2012-09-21|2012-09-25|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Mechanisms of Allergen Immunotherapy|An Open Study to Investigate the Effects of Injection Immunotherapy on Allergen-specific T and B Cell Responses in Adult Patients With Seasonal Allergic Rhinitis.|Terminated||N/A|2|Actual|Royal Sussex County Hospital||1||R and D approval not forthcoming|f||||f||||||||||2018-05-31 21:41:26.366066|2018-05-31 21:41:26.366066
NCT01523145|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-04-18|2012-01-31|2012-02-01|Estimate|||||||2016-04-18|2016-04-19|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|||CopenHeartRFA - Integrated Rehabilitation of Patients Treated for Atrial Fibrillation With Radio Frequency Ablation|CopenHeartRFA - A Randomized Clinical Trial Investigating the Effect and Meaning of Integrated Rehabilitation Versus Usual Follow-up of Patients Treated for Atrial Fibrillation With Radio Frequency Ablation|Completed||N/A|210|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 21:41:26.439175|2018-05-31 21:41:26.439175
NCT01523132|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-04-05|2012-01-27|2012-02-01|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms|Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms|Completed|||545|Actual|Rigshospitalet, Denmark|||1||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 21:41:26.523033|2018-05-31 21:41:26.523033
NCT01523119|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-02-08|2012-01-31|2012-02-01|Estimate|||||||2012-02-08|2012-02-09|Estimate|July 2006||2006-07-31|February 2012|2012-02-29|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fed Conditions|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Ondansetron 8 mg Orally Disintegrating Tablets of Ohm Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals USA) With Zofran 8 mg ODT® Orally Disintegrating Tablets (Containing 8 mg of Ondansetron) Manufactured by Cardinal Health, UK for GlaxoSmithKline USA, in Healthy, Adult, Human, Male Subjects Under Fed Condition.|Completed||N/A|35|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:41:26.60674|2018-05-31 21:41:26.60674
NCT01523106|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2014-01-16|2012-01-28|2012-02-01|Estimate|||||||2014-01-16|2014-01-17|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||L-carnitine to Treat Fatigue Associated With Crohn's Disease|L-carnitine to Treat Fatigue Associated With Crohn's Disease|Withdrawn||N/A|0|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:41:26.679182|2018-05-31 21:41:26.679182
NCT01523093|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-02-08|2012-01-31|2012-02-01|Estimate|||||||2012-02-08|2012-02-09|Estimate|July 2006||2006-07-31|February 2012|2012-02-29|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence Study of Ondansetron Orally Disintegrating Tablets 8mg Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Ondansetron 8 mg Orally Disintegrating Tablets of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc,) With Zofran ODT® 8 mg Orally Disintegrating Tablets (Containing 8 mg of Ondansetron) of GlaxoSmithKline in Healthy, Adult, Human, Male Subjects Under Fasting Condition.|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:41:26.747469|2018-05-31 21:41:26.747469
NCT01523080|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-02-08|2012-01-31|2012-02-01|Estimate|||||||2012-02-08|2012-02-09|Estimate|May 2006||2006-05-31|February 2012|2012-02-29|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fasting Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gel Tabs (Containing Acetaminophen 650 mg) of OHM Laboratories Inc. (Subsidiary of Ranbaxy) With Tylenol 8 Hour Extended Release Gel Tabs (Containing Acetaminophen 650 mg) of McNeil Consumer & Speciality Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fasting Condition|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:41:26.82656|2018-05-31 21:41:26.82656
NCT01523067|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2013-01-03|2012-01-31|2012-02-01|Estimate|||||||2013-01-03|2013-01-04|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension|Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Adult Subjects With Stage 1 or Stage 2 Essential Hypertension|Completed||Phase 1|68|Actual|PhaseBio Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 21:41:26.908386|2018-05-31 21:41:26.908386
NCT01523054|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-01-30|2012-01-30|2012-02-01|Estimate|||||||2012-01-30|2012-02-01|Estimate|February 2000||2000-02-29|January 2012|2012-01-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Metoprolol in Acute Myocardial Infarction. A PK/PD Study|A Pharmacokinetic and Pharmacodynamic Study Comparing Metoprolol IR and Metoprolol CR/XL Subsequent to Initial Treatment With Intravenous and/or Oral Metoprolol in Patients With Suspected Acut Myocardial Infarction|Completed||Phase 1|27|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:41:27.015123|2018-05-31 21:41:27.015123
NCT01523041|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-02-22|2012-01-27|2012-02-01|Estimate|||||||2017-02-22|2017-02-24|Actual|November 3, 1999|Actual|1999-11-03|February 2017|2017-02-28|November 30, 1999|Actual|1999-11-30|November 30, 1999|Actual|1999-11-30||Interventional|||Comparison of Two Formulations of Biphasic Insulin Aspart 70|A Randomised, Double Blind, Single Centre, Three Period Crossover Trial Testing the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 and Characterising the Pharmacokinetics of Biphasic Insulin Aspart 50 in Healthy Male Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:41:27.086291|2018-05-31 21:41:27.086291
NCT01523028|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2013-06-04|2012-01-27|2012-02-01|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Influence of Breakfast Consumption on Chlorogenic Acid Metabolism in Humans||Completed||N/A|14|Actual|Nestlé||3|||f||||t||||||||||2018-05-31 21:41:27.167131|2018-05-31 21:41:27.167131
NCT01523015|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2013-02-02|2012-01-31|2012-02-01|Estimate|||||||2013-02-02|2013-02-05|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|December 2020|Anticipated|2020-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction|Efficacy and Safety Study of the Combined Modality Therapy in Patients With Potentially Resectable, Locally Advanced Adenocarcinoma of the Esophago-gastric Junction With Preoperative Chemo- and Chemoradiation Followed by Surgical Resection|Recruiting||Phase 2/Phase 3|100|Anticipated|Medical University of Lublin||2|||f||||t||||||||||2018-05-31 21:41:27.225197|2018-05-31 21:41:27.225197
NCT01523002|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2013-01-25|2012-01-31|2012-02-01|Estimate|||||||2013-01-25|2013-01-28|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Drug Interaction Study of Pyronaridine-artesunate and Metoprolol and Pyronaridine-artesunate Re-dosing Study in Healthy Volunteers|Open-label, Drug Interaction Study of Pyramax (Pyronaridine:Artesunate) and Metoprolol in Healthy Volunteers and Pyramax Re-dosing Study in Healthy Volunteers|Completed||Phase 1|56|Actual|Medicines for Malaria Venture||2|||f||||t||||||||||2018-05-31 21:41:27.347641|2018-05-31 21:41:27.347641
NCT01522989|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-05-03|2012-01-27|2012-02-01|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2011||2011-12-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies|A Phase I Study of the CDK4/6 Inhibitor PD-0332991, 5-Fluorouracil, and Oxaliplatin in Patients With Advanced Solid Tumor Malignancies|Active, not recruiting||Phase 1|37|Actual|Georgetown University||1|||f||||t||||||||||2018-05-31 21:41:27.433896|2018-05-31 21:41:27.433896
NCT01522976|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|2016-02-18||2018-05-23|2012-01-27|2012-02-01|Estimate|2016-02-18|2016-03-22|Estimate||||2018-05-23|2018-05-24|Actual|March 1, 2012|Actual|2012-03-01|May 2018|2018-05-31||||June 1, 2015|Actual|2015-06-01||Interventional||Analysis includes eligible patients only.|Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia|A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)|Active, not recruiting||Phase 2|282|Actual|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-05-31 21:41:27.642083|2018-05-31 21:41:27.642083
NCT01522963|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2017-02-13||2017-07-20|2012-01-27|2012-02-01|Estimate|2017-06-08|2017-07-11|Actual||||2017-07-20|2017-08-21|Actual|December 2011||2011-12-31|July 2017|2017-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Only those that completed the entire cross-over study were included in the analysis|Medicinal Nicotine for Preventing Stress Induced Craving and Withdrawal Symptoms|Medicinal Nicotine for Preventing Stress Induced Craving and Withdrawal Symptoms|Completed||N/A|98|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 21:41:29.771902|2018-05-31 21:41:29.771902
NCT01522274|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-07-28|2012-01-27|2012-01-31|Estimate|||||||2017-07-28|2017-08-01|Actual|January 2012||2012-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|QFH||Quit Smoking With Nicotine Patch and Exercise/Health Education (Females Only)|Efficacy of Brisk Walking as a Smoking Cessation Treatment Adjunct Among Women|Completed||N/A|113|Actual|Brown University||2|||f||||f||||||||||2018-05-31 21:41:39.253105|2018-05-31 21:41:39.253105
NCT01522950|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-03-13|2012-01-30|2012-02-01|Estimate|||||||2017-03-13|2017-03-14|Actual|May 2010||2010-05-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|EVIDENCE||A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function|A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease|Completed||Phase 2|75|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 21:41:30.192099|2018-05-31 21:41:30.192099
NCT01522937|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2017-01-18||2017-01-18|2012-01-27|2012-02-01|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|October 2009||2009-10-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer|A Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer|Completed||Phase 2|94|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:41:30.304933|2018-05-31 21:41:30.304933
NCT01522924|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2013-01-07||2017-04-12|2012-01-27|2012-02-01|Estimate|2013-08-19|2013-08-22|Estimate||||2017-04-12|2017-05-23|Actual|February 2012||2012-02-29|April 2017|2017-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||There were 94 dental students who provided linkable surveys. There were 42 in the intervention group and 52 in the control group.|Tobacco Dependence Treatment Education for Dental Students|Tobacco Dependence Treatment Education for Dental Students Using Standardized Patients|Completed||N/A|94|Actual|University of Louisville|One participant in the intervention group did not provide gender information. The total number of participants in the intervention group did not equal the number of male and female participants.|2|||f||||f||||||||No||2018-05-31 21:41:30.718257|2018-05-31 21:41:30.718257
NCT01522911|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-01-30|2012-01-30|2012-02-01|Estimate|||||||2012-01-30|2012-02-01|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage|Interventional Study to Investigate the Effects of Percutaneous Closure of the Left Atrial Appendage on Atrial and Brain Natriuretic Peptide Secretion|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of Leipzig||1|||f||||f||||||||||2018-05-31 21:41:31.069579|2018-05-31 21:41:31.069579
NCT01522898|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-12-07|2012-01-27|2012-02-01|Estimate|||||||2017-12-07|2017-12-11|Actual|March 2013||2013-03-31|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|CAAN-AF||Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)|Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation|Recruiting||N/A|590|Anticipated|University of Adelaide||2|||f||||t||||||||||2018-05-31 21:41:31.15233|2018-05-31 21:41:31.15233
NCT01522885|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2014-08-19|2012-01-27|2012-02-01|Estimate|||||||2014-08-19|2014-08-21|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|KatGuide||KatGuide Method Versus Conventional Method at Insertion of Chest Tube|KatGuide-trial. KatGuide Method Versus Conventional Method at Insertion of Chest Tube. A Randomized, Parallel Group, Controlled Trial.|Completed||Phase 3|109|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:41:31.366825|2018-05-31 21:41:31.366825
NCT01522872|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2016-06-01|2012-01-27|2012-02-01|Estimate|||||||2016-06-01|2016-06-02|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma|A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|98|Anticipated|Threshold Pharmaceuticals||4|||f||||||||||||||2018-05-31 21:41:31.455605|2018-05-31 21:41:31.455605
NCT01522859|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-27|2012-01-27|2012-02-01|Estimate|||||||2012-01-27|2012-02-01|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Telehealth Monitoring in Chronic Obstructive Pulmonary Disease|The Efficacy of Telehealth Monitoring in the Management of Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|110|Actual|South Eastern Health and Social Care Trust||2|||f||||f||||||||||2018-05-31 21:41:31.547821|2018-05-31 21:41:31.547821
NCT01522846|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-08-28|2012-01-27|2012-02-01|Estimate|||||||2013-08-28|2013-08-29|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Heparin Solution and INTEM/HEPTEM Analysis|Influence by Heparinized Flush Solution of the Radial Artery Catheter: INTEM and HEPTEM Analysis.|Completed|||25|Actual|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 21:41:31.833772|2018-05-31 21:41:31.833772
NCT01522833|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2016-03-04|2012-01-27|2012-02-01|Estimate|||||||2016-03-04|2016-03-07|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer|Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting|Completed|||27|Actual|SCRI Development Innovations, LLC|||2||f||||f||||||Samples With DNA|"~     Tissue-testing will be performed or test results will be reviewed to identify EGFR-wt and~     EGFR mutation positive advanced non small cell lung cancer (NSCLC) patient cases with an~     erlotinib-treatment duration of six months or longer (as 2nd/3rd line and/or maintenance~     single-agent therapy) in a community-based setting.~      Biopsy specimens from enrolled patient cases who are EGFR-wt will be evaluated via~     exploratory genetic analysis for correlated biomarkers.~   "|||2018-05-31 21:41:31.91652|2018-05-31 21:41:31.91652
NCT01522820|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2016-10-03|2012-01-30|2012-02-01|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors|A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors|Completed||Phase 1|18|Actual|Roswell Park Cancer Institute||5|||f||||f||||||||||2018-05-31 21:41:31.993072|2018-05-31 21:41:31.993072
NCT01522807|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2012-01-27|2012-01-27|2012-02-01|Estimate|||||||2012-01-27|2012-02-01|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study Of Three PF-05190457 Formulations In Healthy Volunteers|A Phase I, Cross-Over, Single Dose, Double-Blind Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-05190457 In Healthy Adult Volunteers|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:41:32.113201|2018-05-31 21:41:32.113201
NCT01522794|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2014-11-07|2012-01-27|2012-02-01|Estimate|||||||2014-11-07|2014-11-10|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model|Randomized Double Blind Placebo Controlled PK/PD Study on the Effects of a Single Intravenous Dose of NOX-H94 on Serum Iron During Experimental Human Endotoxemia|Completed||Phase 1|24|Actual|NOXXON Pharma AG||2|||f||||t||||||||||2018-05-31 21:41:32.198582|2018-05-31 21:41:32.198582
NCT01522781|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-27|2012-01-27|2012-02-01|Estimate|||||||2012-01-27|2012-02-01|Estimate|October 1998||1998-10-31|January 2012|2012-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||10 Year Outcome of Total Knee Replacement (TKR) Using Sigma Prosthesis|10 Year Outcome of Total Knee Replacement (TKR) Using Sigma Prosthesis|Completed|||234|Actual|NHS Fife|||||f||||f||||||||||2018-05-31 21:41:32.275596|2018-05-31 21:41:32.275596
NCT01522768|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2018-05-08|2012-01-30|2012-02-01|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2012|Actual|2012-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer|A Phase II Study of Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab Refractory Advanced Esophagogastric Cancer|Recruiting||Phase 2|48|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:41:32.329711|2018-05-31 21:41:32.329711
NCT01522755|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-07-26|2012-01-27|2012-02-01|Estimate|||||||2012-07-26|2012-07-27|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Predictive Factors of a Successful Implant of the CapsureFix MRI Model 5086|Predictive Factors of a Successful Implant of the CapsureFix MRI Model 5086|Unknown status|Recruiting||700|Anticipated|Medtronic Bakken Research Center|||1||f||||f||||||||||2018-05-31 21:41:32.519264|2018-05-31 21:41:32.519264
NCT01522742|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-03-15|2012-01-30|2012-02-01|Estimate|||||||2017-03-15|2017-03-17|Actual|February 2012||2012-02-29|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|MMAPPS||Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study|Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study|Terminated|||29|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma, serum.~   "|||2018-05-31 21:41:32.608974|2018-05-31 21:41:32.608974
NCT01522729|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-01-27|2012-01-27|2012-02-01|Estimate|||||||2012-01-27|2012-02-01|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Impact of Muscle Afferent Feedback During Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Impact of Somatosensory Feedback on Peripheral Muscle Fatigue and Exercise Tolerance in Patients With COPD|Completed||N/A|8|Actual|Laval University||2|||f||||t||||||||||2018-05-31 21:41:32.693631|2018-05-31 21:41:32.693631
NCT01522716|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-05-30|2012-01-27|2012-02-01|Estimate|||||||2016-05-30|2016-06-01|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease|Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease|Unknown status|Active, not recruiting|Phase 1|11|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 21:41:32.787733|2018-05-31 21:41:32.787733
NCT01522703|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2016-08-08||2016-11-24|2012-01-27|2012-02-01|Estimate|2016-11-24|2017-01-19|Estimate||||2016-11-24|2017-01-19|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Whole Sprouts on Airway Allergic Inflammation|Dietary Interventions and Asthma Treatment: A Pilot Study of the Effects of Whole Sprouts on Airway Allergic Inflammation|Completed||N/A|51|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:41:32.866221|2018-05-31 21:41:32.866221
NCT01522690|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-04-14|2012-01-27|2012-02-01|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ACCELERIX||Assessment of Accelerometric Measurement Devices for Gait Analysis|Assessment of Accelerometric Measurement Devices for Gait Analysis|Completed||N/A|300|Anticipated|Institut de Myologie, France|||||f||||f||||||||||2018-05-31 21:41:33.153169|2018-05-31 21:41:33.153169
NCT01522677|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-11-30|2012-01-30|2012-01-31|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer|A Phase I/II Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, Irvine||1||Slow accrual|f||||t||||||||||2018-05-31 21:41:33.215857|2018-05-31 21:41:33.215857
NCT01522664|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2016-11-01|2012-01-27|2012-01-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma|Completed||Phase 1|53|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 21:41:33.309306|2018-05-31 21:41:33.309306
NCT01522651|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18||2014-08-07|2014-08-08|2012-01-27|2012-01-31|Estimate||||2014-08-07|2014-08-11|Estimate|2014-08-08|2014-08-12|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)|A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation|Completed||Phase 2|134|Actual|Gilead Sciences||5|||f||||f||||||||||2018-05-31 21:41:33.403241|2018-05-31 21:41:33.403241
NCT01522638|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-01-27|2012-01-27|2012-01-31|Estimate|||||||2012-01-27|2012-01-31|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Observational|||Advanced Characterization of Autosomal Dominant Optic Atrophy|Cross Sectional Study of Autosomal Dominant Opticus Atrophy|Unknown status|Enrolling by invitation||50|Anticipated|Glostrup University Hospital, Copenhagen|||2||f||||f||||||||||2018-05-31 21:41:33.595972|2018-05-31 21:41:33.595972
NCT01522625|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2017-03-20|2012-01-30|2012-01-31|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2012||2012-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Tenofovir in Chronic Hepatitis B With Mild ALT Elevation|Efficacy of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients With High Viral Load But Slight Aminotransferase Elevation|Active, not recruiting||Phase 4|160|Anticipated|E-DA Hospital||2|||f||||f||||||||||2018-05-31 21:41:33.668074|2018-05-31 21:41:33.668074
NCT01520181|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2015-10-06|2012-01-26|2012-01-27|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment||Completed||N/A|200|Anticipated|Meir Medical Center|||||f||||||||||||||2018-05-31 21:42:09.022801|2018-05-31 21:42:09.022801
NCT01522612|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-06-09|2012-01-30|2012-01-31|Estimate|||||||2016-06-09|2016-06-10|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Colorectal Cancer (CRC) Cetuximab Elderly Frail|Treatment of Patients With KRAS Wild Type Advanced Colorectal Cancer (CRC) With 5-Fluorouracil (5-FU) or 5- FU Plus an Epidermal Growth Factor Receptor (EGFR) Inhibitor (Cetuximab) Based on a Comprehensive Geriatric Assessment (CGA).|Terminated||Phase 2|5|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||poor accrual|f||||t||||||||||2018-05-31 21:41:33.763496|2018-05-31 21:41:33.763496
NCT01522599|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-06-16|2012-01-26|2012-01-31|Estimate|||||||2014-06-16|2014-06-17|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ELP||Flow-flow ECCO2-R and 4 ml/kg Tidal Volume vs. 6 ml/kg Tidal Volume to Enhance Protection From VILI in Acute Lung Injury|Flow-flow ECCO2-R and 4 ml/kg Tidal Volume vs. 6 ml/kg Tidal Volume to Enhance Protection From Ventilator Induced Lung Injury in Acute Lung Injury (ELP)|Terminated||Phase 3|230|Actual|University of Turin, Italy||2||Financial hardship|f||||t||||||||||2018-05-31 21:41:33.869822|2018-05-31 21:41:33.869822
NCT01522586|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2014-02-12|2012-01-30|2012-01-31|Estimate|||||||2014-02-12|2014-02-13|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Phase 1 Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031|Terminated||Phase 1|74|Actual|Daewoong Pharmaceutical Co. LTD.||2||change development strategy|f||||t||||||||||2018-05-31 21:41:33.945198|2018-05-31 21:41:33.945198
NCT01522573|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-02-16|2012-01-30|2012-01-31|Estimate|||||||2017-02-16|2017-02-20|Actual|November 2011||2011-11-30|February 2017|2017-02-28|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|EUSERCPReg||T-EUS for Gastrointestinal Disorders: A Multicenter Registry|Therapeutic Endoscopic Ultrasound (T-EUS) Guided Procedures in the Management of Gastrointestinal Disorders: A Multicenter Registry.|Recruiting|||1000|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-05-31 21:41:34.007302|2018-05-31 21:41:34.007302
NCT01522560|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2018-02-07|2012-01-30|2012-01-31|Estimate|||||||2018-02-07|2018-02-09|Actual|July 2011||2011-07-31|August 2017|2017-08-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Evaluation of Multiscore Feedback in Professionalism for Anesthesia||Completed||N/A|28|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 21:41:34.090818|2018-05-31 21:41:34.090818
NCT01522547|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2013-12-24|2012-01-27|2012-01-31|Estimate|||||||2013-12-24|2013-12-25|Estimate|August 2007||2007-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|October 2012|Actual|2012-10-31||Interventional|SCD-001||Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease|A Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Effect on Induction of Fetal Hemoglobin of CC-4047 In Subjects With Sickle Cell Disease|Completed||Phase 1|12|Anticipated|Celgene||5|||f||||f||||||||||2018-05-31 21:41:34.15279|2018-05-31 21:41:34.15279
NCT01522534|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2012-01-30|2012-01-30|2012-01-31|Estimate|||||||2012-01-30|2012-01-31|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|BPOP||Randomized Double Blind Controlled Trial Comparing a Blind Sciatic Nerve Block in the Popliteal Fossa to Intravenous Morphine for Traumatic Severe Acute Pain in the Prehospital Setting||Unknown status|Recruiting|Phase 3|66|Anticipated|Centre Hospitalier de la Région d'Annecy||2|||f||||t||||||||||2018-05-31 21:41:34.352487|2018-05-31 21:41:34.352487
NCT01522521|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2015-10-01|2012-01-30|2012-01-31|Estimate|||||||2015-10-01|2015-10-02|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study of AK156 in Primary Osteoporosis Patients|Phase 3 Study of AK156 in Primary Osteoporosis Patients|Completed||Phase 3|600|Anticipated|Asahi Kasei Pharma Corporation||2|||f||||||||||||||2018-05-31 21:41:34.472832|2018-05-31 21:41:34.472832
NCT01522508|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-06-14|2012-01-30|2012-01-31|Estimate|||||||2012-06-14|2012-06-15|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Observational|||Evaluation of Analgesia Nociception Index (ANI) During Propofol/Remifentanil and Sevoflurane/Remifentanil Anesthesia|Detection of Nociceptive Stimulation by Analgesia Nociception Index (ANI) During Anesthesia With Propofol or Sevoflurane and Varying Remifentanil Concentrations.|Unknown status|Recruiting||50|Anticipated|University of Schleswig-Holstein|||2||f||||f||||||||||2018-05-31 21:41:34.599112|2018-05-31 21:41:34.599112
NCT01522495|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-07-27|2012-01-30|2012-01-31|Estimate|||||||2016-07-27|2016-07-28|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging|Pilot Study for: Eye vs. Spy - A Prospective, Randomized Study Evaluating Patient Outcomes With the Use of SPY Imaging During Amputations or Debridements|Recruiting||N/A|160|Anticipated|Georgetown University||4|||f||||t||||||||||2018-05-31 21:41:34.677682|2018-05-31 21:41:34.677682
NCT01522482|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-01-31|2012-01-30|2012-01-31|Estimate|||||||2012-01-31|2012-02-02|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|||Apolipoprotein (APO)E Genotype, Meal Fatty Acids, Postprandial Lipaemia|Effects of Meal Fatty Acid Composition on Postprandial Lipaemia in Men According to APOE Genotype|Completed||N/A|31|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 21:41:34.777274|2018-05-31 21:41:34.777274
NCT01522469|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2015-03-18|2012-01-30|2012-01-31|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations|A Phase II Study of Crenolanib Besylate in Subjects With Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations|Completed||Phase 2|20|Actual|Arog Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 21:41:34.848702|2018-05-31 21:41:34.848702
NCT01522456|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2013-03-11||2015-08-10|2012-01-27|2012-01-31|Estimate|2015-08-10|2015-08-18|Estimate||||2015-08-10|2015-08-18|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel|Split-face Tolerability Comparison Between Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Versus Retin-A Micro® (Tretinoin Gel) Microsphere, 0.1% in Subjects With Acne Vulgaris|Completed||Phase 4|73|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-05-31 21:41:35.030642|2018-05-31 21:41:35.030642
NCT01519986|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-24|2012-01-24|2012-01-27|Estimate|||||||2012-01-24|2012-01-27|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|VITD_100484||The Effect of Fat on Vitamin D Absorption|The Effect of Fat on Vitamin D Absorption After a Single Oral Dose|Completed||N/A|64|Actual|Federal University of Rio Grande do Sul||3|||f||||t||||||||||2018-05-31 21:42:11.171456|2018-05-31 21:42:11.171456
NCT01522443|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2017-05-23||2018-04-23|2012-01-27|2012-01-31|Estimate|2018-04-23|2018-05-23|Actual||||2018-04-23|2018-05-23|Actual|March 2012||2012-03-31|April 2018|2018-04-30|January 13, 2015|Actual|2015-01-13|October 2014|Actual|2014-10-31||Interventional|COMET-2||Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer|A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer|Terminated||Phase 3|119|Actual|Exelixis|Enrollment was stopped before planned study population size of 246 was reached (only 119 enrolled).|2||Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.|f||||t||||||||||2018-05-31 21:41:36.081489|2018-05-31 21:41:36.081489
NCT01522430|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-01-27|2012-01-27|2012-01-31|Estimate|||||||2012-01-27|2012-01-31|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|DEPART||Study of Catheter Based Renal Denervation Therapy in Hypertension|DENERVATION OF RENAL SYMPATHETIC ACTIVITY AND HYPERTENSION STUDY|Unknown status|Recruiting|Phase 3|120|Anticipated|Erasme University Hospital||2|||f||||t||||||||||2018-05-31 21:41:37.109706|2018-05-31 21:41:37.109706
NCT01522417|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2018-03-09|2012-01-30|2012-01-31|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2012||2012-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|SAVI-PCI||Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention|A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention|Recruiting||Phase 2|550|Anticipated|Medicure||3|||f||||f||||||||||2018-05-31 21:41:37.190856|2018-05-31 21:41:37.190856
NCT01522404|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-10-06|2012-01-27|2012-01-31|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2012||2012-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|October 2017|Actual|2017-10-31||Interventional|ATX-001||Effects of Atomoxetine in Mild Cognitive Impairment|A 6 Month, Phase II Randomized, Double-Blind, Placebo Controlled, Flexible Dosing, Crossover Trial of Atomoxetine in Subjects With Mild Cognitive Impairment.|Active, not recruiting||Phase 2|39|Actual|Emory University||2|||f||||t||||||||||2018-05-31 21:41:37.28517|2018-05-31 21:41:37.28517
NCT01522391|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-01-27|2012-01-27|2012-01-31|Estimate|||||||2012-01-27|2012-01-31|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060|A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060|Completed||Phase 1/Phase 2|41|Actual|DermaGen AB||2|||f||||||||||||||2018-05-31 21:41:37.364785|2018-05-31 21:41:37.364785
NCT01522378|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2017-04-24|2012-01-30|2012-01-31|Estimate|||||||2017-04-24|2017-04-26|Actual|February 2012||2012-02-29|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging|Cardiac Resynchronization and MIBG Imaging|Terminated||Phase 1|14|Actual|Mayo Clinic||1||The study was terminated because the funding was withdrawn.|f||||f|t|f|||t|||No||2018-05-31 21:41:37.426628|2018-05-31 21:41:37.426628
NCT01522365|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-01-30|2012-01-27|2012-01-31|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2011||2011-11-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|June 2017|Actual|2017-06-30||Interventional|XiCC||XiVE® CAD/CAM Bridges (Abutment-supported/ Implant-supported)|A Randomized, Prospective, International, Multi-center Clinical Study to Evaluate the Peri-implant Tissue Outcome of Abutment-supported XiVE® CAD/CAM Supra-structures and Directly Implant-supported XiVE® CAD/CAM Supra-structures (Split-mouth) in Partly Edentulous Human Subjects.|Active, not recruiting||N/A|20|Anticipated|Dentsply Implants Manufacturing GmbH||2|||f||||f||||||||No||2018-05-31 21:41:37.495505|2018-05-31 21:41:37.495505
NCT01522352|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-09-02|2012-01-27|2012-01-31|Estimate|||||||2013-09-02|2013-09-04|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Comparison Between Three Types of Stented Pericardial Aortic Valves|Comparison of Short and Mid-term Hemodynamic Performance Between Three Types of Stented Pericardial Aortic Valves|Unknown status|Recruiting|N/A|165|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 21:41:37.565546|2018-05-31 21:41:37.565546
NCT01522339|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2013-08-08||2014-09-23|2012-01-27|2012-01-31|Estimate|2014-09-23|2014-09-25|Estimate||||2014-09-23|2014-09-25|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|NICU MRI||Pilot Study: Safety of a Customized MRI System for Neonatal Imaging|Pilot Study: Safety of a Customized MRI System for Neonatal Imaging|Completed||N/A|15|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 21:41:37.637015|2018-05-31 21:41:37.637015
NCT01522326|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2016-09-12|2012-01-27|2012-01-31|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness|Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen|Recruiting||N/A|300|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 21:41:37.785016|2018-05-31 21:41:37.785016
NCT01522313|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-10-08|2012-01-27|2012-01-31|Estimate|||||||2012-10-08|2012-10-10|Estimate|January 2006||2006-01-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|NEPHRANEST||Influence of Perioperative Kidney Function on Postoperative Outcome|Retrospective Data Analysis of the Impact of Perioperative Kidney Function on Postoperative Outcome|Completed|||39369|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 21:41:38.990901|2018-05-31 21:41:38.990901
NCT01522300|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-11-20|2012-01-27|2012-01-31|Estimate|||||||2013-11-20|2013-11-21|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité Tomos Study- Contribution of Tomosynthesis In Locoregional Pretherapeutic Staging of a Breast Tumor: Multicentricity Search|Etude Tomos- Apport de la Tomosynthèse Dans le Bilan d'Extension locorégional préthérapeutique d'Une Tumeur du Sein : Recherche de multicentricité|Terminated||Phase 2|81|Actual|Centre Jean Perrin||||No more inclusions since august 2013|f||||f||||||||||2018-05-31 21:41:39.070218|2018-05-31 21:41:39.070218
NCT01522287|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2014-03-13|2012-01-27|2012-01-31|Estimate|||||||2014-03-13|2014-03-14|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Computer Assisted Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Comprehensive Stepped-Care Approach|Computer Assisted CBT for OCD: A Comprehensive Stepped-Care Approach|Completed||Phase 1|88|Actual|Center for Psychological Consultation||3|||f||||t||||||||||2018-05-31 21:41:39.146139|2018-05-31 21:41:39.146139
NCT01522261|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-04-17|2012-01-27|2012-01-31|Estimate|||||||2015-04-17|2015-04-20|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|MBP||The Surgical Benefit and Pt.Tolerability Between Two Different Bowel Cleansing Regimens Performed Prior to Pelvic Reconstructive Surgery. Does One Bowel Cleansing Regimen Improve the Surgeons Visual Field Significantly Better Than the Other.|The Use of Mechanical Bowel Preparation in Pelvic Reconstructive Surgery (MBP)|Unknown status|Recruiting|Phase 1|176|Anticipated|Boston Urogynecology Associates||2|||f||||f||||||||||2018-05-31 21:41:39.377218|2018-05-31 21:41:39.377218
NCT01522248|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2015-09-17|2012-01-30|2012-01-31|Estimate|||||||2015-09-17|2015-09-18|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study|A Pilot Study to Examine the Early Cytokine Responses After Inactivated Influenza Vaccination in Adults 18-50.|Completed||N/A|20|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:41:39.479437|2018-05-31 21:41:39.479437
NCT01522235|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2017-04-14||2017-06-02|2012-01-27|2012-01-31|Estimate|2017-06-02|2017-07-02|Actual||||2017-06-02|2017-07-02|Actual|February 2012||2012-02-29|June 2017|2017-06-30|September 2015|Actual|2015-09-30|May 2014|Actual|2014-05-31||Interventional|||Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy|A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy.|Completed||Phase 2/Phase 3|6|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||Yes|The investigators will adhere to the NIH Grant Policy on Sharing of Unique Research Resources including the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.|2018-05-31 21:41:39.582155|2018-05-31 21:41:39.582155
NCT01522222|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-12-28|2012-01-27|2012-01-31|Estimate|||||||2015-12-28|2015-12-29|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PEEP||Study to Determine if Using Ventilation During Open Heart Surgery Improves Lung Outcomes|Effect of Continuous Mechanical Ventilation During Cardiopulmonary Bypass on The Lung Mechanics: A Prospective Evaluation|Completed||N/A|40|Actual|Aurora BayCare Medical Center||2|||f||||f||||||||||2018-05-31 21:41:40.033322|2018-05-31 21:41:40.033322
NCT01522209|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-01-14|2012-01-27|2012-01-31|Estimate|||||||2015-01-14|2015-01-15|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|CEIOUS-Liver||Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging|Value of Contrast Enhanced Intraoperative Ultrasound Compared to Preoperative CEUS, CT and MRT in the Treatment of Colorectal Liver Metastases.|Completed||N/A|59|Actual|Asklepios Kliniken Hamburg GmbH|||||f||||t||||||||||2018-05-31 21:41:40.127196|2018-05-31 21:41:40.127196
NCT01522196|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18||2014-01-30|2014-01-30|2012-01-27|2012-01-31|Estimate||||2014-01-30|2014-03-04|Estimate|2014-01-30|2014-03-04|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|IMPACTS-2||A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.|A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects.|Terminated||Phase 2|2|Actual|Anthera Pharmaceuticals||2||change in company plans|f||||f||||||||||2018-05-31 21:41:40.238844|2018-05-31 21:41:40.238844
NCT01522183|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2018-05-21|2012-01-27|2012-01-31|Estimate|||||||2018-05-21|2018-05-22|Actual|April 2012||2012-04-30|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31|10 Years|Observational [Patient Registry]|||Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry|An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With aTypical Hemolytic-Uremic Syndrome (aHUS Registry)|Recruiting|||2000|Anticipated|Alexion Pharmaceuticals|||||f||||f||||||||No||2018-05-31 21:41:40.346106|2018-05-31 21:41:40.346106
NCT01522170|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-02-22|2012-01-27|2012-01-31|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2012|Actual|2012-03-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31|5 Years|Observational [Patient Registry]|LTFU||aHUS Observational Long Term Follow-Up|An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study|Terminated|||94|Actual|Alexion Pharmaceuticals||||"Remaining patients were offered a similar observational study (Alexion M11-001) to allow for~   robust, high quality data collection in a larger, single database"|f||||f||||||||||2018-05-31 21:41:40.625823|2018-05-31 21:41:40.625823
NCT01522157|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2013-11-29|2012-01-30|2012-01-31|Estimate|||||||2013-11-29|2013-12-02|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Randomized Cross-over Trial of the Postprandial Effects of Three Different Diets in Patients With Type 2 Diabetes|A Randomized Cross-over Trial of the Postprandial Effects of Three Different Diets in Patients With Type 2 Diabetes|Completed||N/A|19|Actual|Vårdcentralen Lyckorna||1|||f||||||||||||||2018-05-31 21:41:40.841229|2018-05-31 21:41:40.841229
NCT01522144|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-01-27|2012-01-27|2012-01-31|Estimate|||||||2012-01-27|2012-01-31|Estimate|July 2006||2006-07-31|January 2012|2012-01-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||An Electronic Decision Support Tool to Improve Outpatient Asthma Care|EHR Decision Support to Improve Outpatient Asthma Care|Completed||N/A|1030|Actual|Agency for Healthcare Research and Quality (AHRQ)||1|||f||||f||||||||||2018-05-31 21:41:40.917602|2018-05-31 21:41:40.917602
NCT01522131|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2014-01-14||2014-05-13|2012-01-26|2012-01-31|Estimate|2014-05-13|2014-06-12|Estimate||||2014-05-13|2014-06-12|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Laser Use on Guided Tissue Regeneration in Treatment of Molar Teeth With Class 2 Furcation Affected by Periodontitis|Treatment of Class II Furcation Defects in the Maxillary and Mandibular Molars With Bioresorbable Collagen Membrane and Laser|Completed||N/A|33|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 21:41:41.036909|2018-05-31 21:41:41.036909
NCT01522118|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-02-25|2012-01-30|2012-01-31|Estimate|||||||2013-02-25|2013-02-26|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||MR-guided Focused Ultrasound Treatment of Prostate Cancer: Focal Therapy for Locally Non-Advanced Disease|Focal Therapy With Magnetic Resonance Guided Focused Ultrasound Treatment of Locally Non-Advanced Prostate Cancer: Phase 1 Study|Completed||Phase 1|12|Actual|University of Roma La Sapienza||1|||f||||f||||||||||2018-05-31 21:41:41.303344|2018-05-31 21:41:41.303344
NCT01520740|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2013-11-13|2012-01-26|2012-01-30|Estimate|||||||2013-11-13|2013-11-14|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|CV+/-||Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema|Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema|Terminated||Phase 4|100|Anticipated|Aeris Therapeutics||2|||f||||f||||||||||2018-05-31 21:42:02.641986|2018-05-31 21:42:02.641986
NCT01522105|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-06-07|2012-01-26|2012-01-31|Estimate|||||||2017-06-07|2017-06-08|Actual|April 2012|Actual|2012-04-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Daptomycin in Pediatric Patients With Bacterial Meningitis|Evaluation of Cerebrospinal Fluid Concentration of Daptomycin (Cubicin¬) in Pediatric Patients With Gram-positive Bacterial Meningitis, Concurrently Receiving Standard Antimicrobial Therapy|Recruiting||Phase 1|5|Anticipated|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 21:41:41.395555|2018-05-31 21:41:41.395555
NCT01522092|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2017-03-28|2012-01-30|2012-01-31|Estimate|||||||2017-03-28|2017-03-29|Actual||||March 2017|2017-03-31||||||||Interventional|||Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|The Effect of Escitalopram on Exacerbation Rates and Quality of Life in Patients With Anxiety Associated With Severe COPD|Withdrawn||Phase 3|0|Actual|Hull and East Yorkshire Hospitals NHS Trust||1||Study was not given ethical approval- a alternative protocol required|f||||f||||||||||2018-05-31 21:41:41.494218|2018-05-31 21:41:41.494218
NCT01522079|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-26|2012-01-26|2012-01-31|Estimate|||||||2012-01-26|2012-01-31|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Spinal Muscular Atrophy and Cardiac Autonomic Function|Spinal Muscular Atrophy and Cardiac Autonomic Function|Completed||N/A|9|Actual|Centro Universitário Augusto Motta||1|||f||||t||||||||||2018-05-31 21:41:41.581064|2018-05-31 21:41:41.581064
NCT01522066|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-12-17|2012-01-26|2012-01-31|Estimate|||||||2014-12-17|2014-12-19|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Catheter-over Needle: Outpatient Study|Comparison of the Effectiveness of Single-shot Local Anesthetic Delivery Versus Double-shot Local Anesthetic Delivery Via a Perineural Catheter|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 21:41:41.657414|2018-05-31 21:41:41.657414
NCT01522053|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-12-17|2012-01-26|2012-01-31|Estimate|||||||2014-12-17|2014-12-19|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Catheter-over-needle: Inpatient Study|Comparison of the Catheter-over-needle and Catheter-through-needle Methods for Continuous Delivery of Local Anesthetic During Peripheral Nerve Blockade|Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 21:41:41.7504|2018-05-31 21:41:41.7504
NCT01522040|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2017-03-29|2012-01-26|2012-01-31|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2012||2012-01-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Pilot Study of Magnesium Infusions in Pediatric Asthma|A Pilot Study of Magnesium Infusions (Drips) for Moderate-to-Severe Pediatric Asthma Exacerbations|Withdrawn||Phase 2/Phase 3|0|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 21:41:41.823584|2018-05-31 21:41:41.823584
NCT01522027|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-12-17|2012-01-26|2012-01-31|Estimate|||||||2014-12-17|2014-12-19|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Electrically Guided Needle Insertion: ICU Study|Use of Nerve Stimulation Technology to Aid in Percutaneous Tracheostomy in Intensive Care Patients.|Unknown status|Active, not recruiting|N/A|20|Anticipated|University of Alberta||1|||f||||f||||||||||2018-05-31 21:41:41.907121|2018-05-31 21:41:41.907121
NCT01522014|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2013-02-19|2012-01-26|2012-01-31|Estimate|||||||2013-02-19|2013-02-21|Estimate|November 1997||1997-11-30|February 2012|2012-02-29|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||Randomized Clinical Trial of Ceramic Bearing Primary Total Hip Arthroplasty|Five-Year Outcome of Ceramic on Ceramic Bearing Versus Ceramic on Crossfire® Highly Cross-Linked Polyethylene Bearing in Primary Total Hip Arthroplasty: A Randomized Trial|Completed||Phase 4|92|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:41:41.975015|2018-05-31 21:41:41.975015
NCT01522001|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2015-05-28|2012-01-26|2012-01-31|Estimate|||||||2015-05-28|2015-05-29|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SHARED-REHAB||Shared Care Rehabilitation After Acute Coronary Syndrome|Shared Care Rehabilitation After Acute Coronary Syndrome|Completed||Phase 4|212|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:41:42.050104|2018-05-31 21:41:42.050104
NCT01521988|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2018-05-25|2012-01-26|2012-01-31|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2012|Actual|2012-06-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|PAF CRIOBLAF||Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation|Prevention of Atrial Fibrillation by Combined Right Isthmus Ablation and cryoBalloon Pulmonary Vein Isolation in Patients With Typical Atrial Flutter|Completed||N/A|76|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 21:41:42.129492|2018-05-31 21:41:42.129492
NCT01521975|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-10-22|2012-01-30|2012-01-31|Estimate|||||||2017-10-22|2017-10-24|Actual|January 1, 2011|Actual|2011-01-01|January 2011|2011-01-31|May 30, 2014|Actual|2014-05-30|February 28, 2014|Actual|2014-02-28||Interventional|STEN||A Two-year Study of Telbivudine in HBeAg Negative Hepatitis|A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy|Completed||Phase 4|360|Actual|Third Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 21:41:42.212458|2018-05-31 21:41:42.212458
NCT01521962|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2013-11-12|2012-01-30|2012-01-31|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study of Combination Therapy With SYR-322|A Phase 3 Study to Investigate the Efficacy and Safety of SYR-322 When Used in Combination With Insulin Preparation in Subjects With Type 2 Diabetes in Japan|Completed||Phase 3|67|Actual|Takeda||2|||f||||||||||||||2018-05-31 21:41:42.289663|2018-05-31 21:41:42.289663
NCT01521949|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-03-15|2012-01-30|2012-01-31|Estimate|||||||2018-03-15|2018-03-19|Actual|November 4, 2011|Actual|2011-11-04|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|December 25, 2013|Actual|2013-12-25||Interventional|||Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA|A Phase 2 Study Acai Juice Product in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising Prostate Specific Antigen (PSA)|Completed||Phase 2|21|Actual|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 21:41:42.483752|2018-05-31 21:41:42.483752
NCT01521936|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2015-06-18|2012-01-26|2012-01-31|Estimate|||||||2015-06-18|2015-06-19|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|March 2013|Actual|2013-03-31||Interventional|||Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy|Vitamin D3 Supplementation in Acute Myeloid Leukemia: Pharmacokinetic Study|Terminated||Phase 2|4|Actual|Roswell Park Cancer Institute||2||Lack of funding|f||||t||||||||||2018-05-31 21:41:42.575064|2018-05-31 21:41:42.575064
NCT01521923|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2016-07-06||2018-03-14|2012-01-26|2012-01-31|Estimate|2016-11-10|2017-01-10|Estimate||||2018-03-14|2018-04-10|Actual|January 2012||2012-01-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|C-early|Baseline refers to Baseline from Period 1. Only subjects who entered Period 2 are included. Characteristics refer to the Safety Set 2 (SS2).|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis|Completed||Phase 3|359|Actual|UCB Pharma||3|||f||||f||||||||||2018-05-31 21:41:42.747317|2018-05-31 21:41:42.747317
NCT01521910|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-30|2012-01-30|2012-01-31|Estimate|||||||2012-01-30|2012-01-31|Estimate|April 1995||1995-04-30|January 2012|2012-01-31|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|LPD||Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy|Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy|Completed||N/A|82|Actual|Steno Diabetes Center||2|||f||||f||||||||||2018-05-31 21:41:44.098831|2018-05-31 21:41:44.098831
NCT01521897|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2015-12-14||2015-12-14|2012-01-26|2012-01-31|Estimate|2015-12-14|2016-01-20|Estimate||||2015-12-14|2016-01-20|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|January 2013|Actual|2013-01-31||Observational||In total, 1143 participants were enrolled in this study. Of the 1143 participants, 23 participants were excluded from the baseline analysis for the reasons of protocol violation and lost to follow-up.|Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)|Prevenar Special Use-result Surveillance (Multi-center, Prospective Observational Safety Surveillance For Prevenar In Japan)|Completed|||1143|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:41:44.217049|2018-05-31 21:41:44.217049
NCT01521884|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2015-02-03||2015-02-03|2012-01-30|2012-01-31|Estimate|2015-02-03|2015-02-19|Estimate||||2015-02-03|2015-02-19|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational||Intention to treat (ITT) population included all participants for whom the primary endpoint or one of the secondary endpoints could be determined at baseline. Here “N” (Overall Number of Baseline Participants) includes participants with non-missing baseline data.|Study Looking at Longitudinal Changes in Fatigue and Health Status in Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous Anti-TNF-α Therapy|Longitudinal Changes In Fatigue And Health Status (aims2) In Ra Patients Treated With Sc Anti-tnf-alpha Therapy|Completed|||62|Actual|Pfizer|Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.||1||f||||f||||||||||2018-05-31 21:41:45.397432|2018-05-31 21:41:45.397432
NCT01521871|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2013-12-13||2014-11-03|2012-01-26|2012-01-31|Estimate|2014-11-03|2014-11-04|Estimate||||2014-11-03|2014-11-04|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|TG-CYANO||Tissue Glue (Cyanoacrylate) Versus Conventional Suture in Kidney Donors|A Prospective, Randomised Study on Tissue Glue (Cyanoacrylate) Versus Conventional Suture for Skin Closure in Laparoscopic Living Donor Nephrectomy|Completed||Phase 4|64|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 21:41:45.797349|2018-05-31 21:41:45.797349
NCT01521858|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-08-28|2012-01-26|2012-01-31|Estimate|||||||2013-08-28|2013-08-29|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||THRA_hematologic Variables|Relations Between Hematologic Variables and Postoperative Bleeding in Total Hip Replacement Arthroplasty|Completed|||73|Actual|Seoul National University Bundang Hospital|||||f||||f||||||||||2018-05-31 21:41:46.160311|2018-05-31 21:41:46.160311
NCT01521845|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2012-05-31||2012-12-06|2012-01-30|2012-01-31|Estimate|2012-06-04|2012-07-09|Estimate||||2012-12-06|2012-12-10|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)|Phase 3 Study of Poly Unsaturated Fatty Acids of Omega 3 as an Anti Platelet Agent on Biomarkers of Cardiac Necrosis Including CKMB and Troponin I and Inflammation Marker CRP|Completed||Phase 3|104|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:41:46.207811|2018-05-31 21:41:46.207811
NCT01521832|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-02-06|2012-01-30|2012-01-31|Estimate|||||||2012-02-06|2012-02-07|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Escalating Dose Study in Healthy Volunteers With SEN0014196|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196|Completed||Phase 1|88|Actual|Siena Biotech S.p.A.||11|||f||||f||||||||||2018-05-31 21:41:46.578495|2018-05-31 21:41:46.578495
NCT01521819|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-10-24|2012-01-30|2012-01-31|Estimate|||||||2012-10-24|2012-10-25|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration|A Pilot, Single-center, Interventional Clinical Trial in Which Subjects With Vascularized Pigment Epithelial Detachment (V-PED) Secondary to AMD With Serous Component Superior to 50% of the Lesion Will Receive Low Voltage Stereotactic Radiotherapy (IRay®) Treatment and Lucentis Treatment as Needed.|Unknown status|Active, not recruiting|N/A|12|Anticipated|Oraya Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 21:41:46.675695|2018-05-31 21:41:46.675695
NCT01521806|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-01-26|2012-01-26|2012-01-31|Estimate|||||||2012-01-26|2012-01-31|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|September 2013|Anticipated|2013-09-30|January 2012|Anticipated|2012-01-31||Interventional|||Effects of Dietary Fiber on Insulin Sensitivity|Effects of Dieatry Fiber on Insulin Sensitivity in Pre- and Post-menopausal Women|Unknown status|Not yet recruiting|N/A|40|Anticipated|Ingredion Incorporated||3|||f||||f||||||||||2018-05-31 21:41:46.761229|2018-05-31 21:41:46.761229
NCT01521793|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-07-25|2012-01-30|2012-01-31|Estimate|||||||2014-07-25|2014-07-28|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)|An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01)|Completed||Phase 1|27|Actual|QLT Inc.|||||f||||t||||||||||2018-05-31 21:41:46.869216|2018-05-31 21:41:46.869216
NCT01521780|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2013-08-14||2015-10-30|2012-01-26|2012-01-31|Estimate|2013-08-14|2013-10-28|Estimate||||2015-10-30|2015-11-02|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)|A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials|Terminated||Phase 1|12|Actual|Merck Sharp & Dohme Corp.|The study was terminated early.|3|||f||||f||||||||||2018-05-31 21:41:46.948319|2018-05-31 21:41:46.948319
NCT01521767|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-26|2012-01-26|2012-01-31|Estimate|||||||2012-01-26|2012-01-31|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pharmacokinetics and Relative Bioavailability Study|A Single-Dose Pharmacokinetics And Relative Bioavailability Study Of Tolterodine From Two Microspheres In Powder Blend Extended Release Formulations Compared To The Commercial Extended Release Capsules|Completed||Phase 1|16|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:41:47.218574|2018-05-31 21:41:47.218574
NCT01521754|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-01-18|2012-01-30|2012-01-31|Estimate|||||||2018-01-18|2018-01-23|Actual|March 6, 2012|Actual|2012-03-06|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|MORE||Product Surveillance Registry- Deep Brain Stimulation for Epilepsy|Medtronic Registry for Epilepsy (MORE)|Active, not recruiting|||192|Actual|MedtronicNeuro|||2||f||||t||||||||||2018-05-31 21:41:47.313188|2018-05-31 21:41:47.313188
NCT01521741|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2017-04-05|2012-01-26|2012-01-31|Estimate|||||||2017-04-05|2017-04-07|Actual|August 2009||2009-08-31|April 2017|2017-04-30|December 2023|Anticipated|2023-12-31|August 2019|Anticipated|2019-08-31||Observational|||Prospective Analysis of Symptoms and Lymphedema in Patients Following Treatment for Breast Cancer|Prospective Analysis of Symptoms, Functionality and Quality of Life Questionnaires to Evaluate Lymphedema in Patients Following Treatment for Breast Cancer.|Recruiting|||2500|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||No||2018-05-31 21:41:47.416615|2018-05-31 21:41:47.416615
NCT01521728|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-04-18|2012-01-26|2012-01-31|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)|Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)|Completed||N/A|60|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 21:41:47.489704|2018-05-31 21:41:47.489704
NCT01521715|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-08-22|2012-01-26|2012-01-31|Estimate|||||||2017-08-22|2017-08-23|Actual|January 24, 2012|Actual|2012-01-24|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30||Interventional|FLIPPER||First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma|A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma|Completed||Phase 4|44|Actual|iOMEDICO AG||1|||f||||f||||||||No||2018-05-31 21:41:47.566155|2018-05-31 21:41:47.566155
NCT01521702|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-03-19|2012-01-26|2012-01-31|Estimate|||||||2015-03-19|2015-03-20|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|NEOPAC||NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer|Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study|Completed||Phase 3|2|Actual|Institut Paoli-Calmettes||2|||f||||f||||||||||2018-05-31 21:41:47.636961|2018-05-31 21:41:47.636961
NCT01521689|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-03-19|2012-01-26|2012-01-31|Estimate|||||||2015-03-19|2015-03-20|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|LLCRlowdoz||Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment|Phase II Study of Tolerance and Efficacy of Subcutanous Low Doses Rituximab Given as Consolidation Treatment to Chronic Lymphocytic Leukaemia (CLL) Patients Responding to Induction Therapy|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 21:41:47.704776|2018-05-31 21:41:47.704776
NCT01521676|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-09-01|2012-01-30|2012-01-31|Estimate|||||||2017-09-01|2017-09-05|Actual|December 2010||2010-12-31|September 2017|2017-09-30|December 2029|Anticipated|2029-12-31|December 2019|Anticipated|2019-12-31||Interventional|BC-BIO||Predictive Clinical and Biological Parameters in Breast Cancer|Research of Predictive Clinical and Biological Parameters in Breast Cancer|Recruiting||N/A|750|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 21:41:47.782613|2018-05-31 21:41:47.782613
NCT01521663|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23||2013-09-27|2017-01-31|2012-01-26|2012-01-31|Estimate||||2015-09-08|2015-09-22|Estimate|2017-01-31|2017-02-01|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)|A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of IPX159 in the Treatment of Moderate to Severe Restless Legs Syndrome (RLS)|Completed||Phase 2|159|Actual|IMPAX Laboratories, Inc.||2|||f||||f|t|f||||||No||2018-05-31 21:41:47.989123|2018-05-31 21:41:47.989123
NCT01521650|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2018-01-17|2012-01-28|2012-01-31|Estimate|||||||2018-01-17|2018-01-18|Actual|January 2012||2012-01-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Probiotics Against Pathogenic Bacteria in Connection With Anaesthesia|Probiotics for Reduction of Colonisation With Pathogenic Bacteria in the Oropharynx in Connection With Anaesthesia|Active, not recruiting||N/A|102|Anticipated|Region Skane||2|||f||||f||||||||Yes|Results are intended to be published in a scientific journal|2018-05-31 21:41:48.135318|2018-05-31 21:41:48.135318
NCT01521637|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-08-17|2012-01-26|2012-01-31|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2012||2012-01-31|August 2015|2015-08-31||||April 2015|Actual|2015-04-30||Interventional|||The Efficacy of Neuromuscular Electrical Stimulation to Attenuate Muscle Loss|The Efficacy of Neuromuscular Electrical Stimulation to Attenuate Skeletal Muscle Loss in ICU Patients|Completed||N/A|15|Anticipated|Hasselt University||2|||f||||f||||||||||2018-05-31 21:41:48.219557|2018-05-31 21:41:48.219557
NCT01521624|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-01-28|2012-01-27|2012-01-30|Estimate|||||||2012-01-28|2012-01-31|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients|Comparing Effects of Metformin Plus Life Style Modification Compared With Life Style Modification Alone in Lowering Parameters of Oxidative Stress in Newly Diagnosed Type 2 Diabetes Patients|Completed||N/A|108|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:41:48.27695|2018-05-31 21:41:48.27695
NCT01521442|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-12-18|2012-01-25|2012-01-30|Estimate|||||||2014-12-18|2014-12-19|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|||Mindful Yoga Therapy as an Adjunctive Treatment for PTSD Among OEF/OIF Veterans|Mindful Yoga Therapy as an Adjunctive Treatment for PTSD Among OEF/OIF Veterans: A Pilot Study|Withdrawn||Phase 1/Phase 2|0|Actual|VA Connecticut Healthcare System||2||Did not have funding or resources to carry out study|f||||f||||||||||2018-05-31 21:41:50.311668|2018-05-31 21:41:50.311668
NCT01521611|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-10-14|2012-01-26|2012-01-30|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2002||2002-03-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy|Radiolabelled Anti-CD66 Monoclonal Antibody in the Conditioning Regimen Prior to Haematopoietic Stem Cell Transplantation: Phase I Study in Patients With Poor-risk Disease.|Recruiting||Phase 1/Phase 2|55|Anticipated|University Hospital Southampton NHS Foundation Trust||1|||f||||f||||||||Yes|Trial still recruiting. Data will be summarised upon completion of study.|2018-05-31 21:41:48.333082|2018-05-31 21:41:48.333082
NCT01521598|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26||2013-07-12|2015-05-18|2012-01-26|2012-01-30|Estimate||||2013-07-17|2013-07-22|Estimate|2015-05-18|2015-06-11|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Tolerability of SKL11197 for the Pain of Diabetic Peripheral Neuropathy|Completed||Phase 2|128|Actual|SK Life Science||2|||f||||f||||||||||2018-05-31 21:41:48.408707|2018-05-31 21:41:48.408707
NCT01521585|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2015-11-24|2012-01-26|2012-01-30|Estimate|||||||2015-11-24|2015-11-25|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase II Safety and Tolerability Study With SEN0014196|A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196|Completed||Phase 2|144|Actual|Siena Biotech S.p.A.||3|||f||||f||||||||||2018-05-31 21:41:48.55309|2018-05-31 21:41:48.55309
NCT01521572|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-01-31|2012-01-27|2012-01-30|Estimate|||||||2012-01-31|2012-02-02|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|January 2012|Anticipated|2012-01-31||Interventional|||Effect of the Salbutamol on Mechanical Properties of Respiratory System|Effect of the Use of Salbutamol on the Mechanical Properties of the Respiratory System of Healthy Individuals, Smokers and COPD Patients|Unknown status|Recruiting|N/A|200|Anticipated|Rio de Janeiro State University||1|||f||||t||||||||||2018-05-31 21:41:48.623918|2018-05-31 21:41:48.623918
NCT01521559|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2014-11-05|2014-07-10|2014-11-05|2012-01-26|2012-01-30|Estimate|2014-11-05|2014-11-13|Estimate|2014-07-10|2014-07-14|Estimate|2014-11-05|2014-11-13|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|VIBRANT|Full analysis set (FAS): All enrolled subjects who received any investigational product, had a baseline best corrected visual acuity (BCVA) assessment, and at least 1 post-baseline BCVA assessment.|Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)|A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion|Completed||Phase 3|183|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:41:48.740903|2018-05-31 21:41:48.740903
NCT01521546|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2015-04-21||2016-10-04|2012-01-26|2012-01-30|Estimate|2015-05-07|2015-05-27|Estimate||||2016-10-04|2016-11-08|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|E-SCAR DMD|Males with Duchenne Muscular Dystrophy|Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy|Early Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular Dystrophy|Completed||N/A|42|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 21:41:49.20724|2018-05-31 21:41:49.20724
NCT01521533|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2015-10-05|2012-01-26|2012-01-30|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma|A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bortezomib and Dexamethasone (VD) in Previously Treated Patients With Multiple Myeloma (MM)|Completed||Phase 2|28|Actual|NOXXON Pharma AG||1|||f||||t||||||||||2018-05-31 21:41:49.404449|2018-05-31 21:41:49.404449
NCT01521520|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-04-06|2012-01-26|2012-01-30|Estimate|||||||2017-04-06|2017-04-10|Actual|January 2012||2012-01-31|April 2017|2017-04-30||||||||Observational|||Imaging of Type 1 Diabetes Progression|Ferumoxytol Enhanced Magnetic Resonance Imaging of Type 1 Diabetes Progression|Active, not recruiting|||65|Anticipated|Massachusetts General Hospital|||4||f||||f||||||||||2018-05-31 21:41:49.504547|2018-05-31 21:41:49.504547
NCT01521507|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2015-02-04||2015-02-04|2012-01-26|2012-01-30|Estimate|2015-02-04|2015-02-23|Estimate||||2015-02-04|2015-02-23|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye|Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye|Completed||N/A|200|Actual|TearScience, Inc.||2|||f||||f||||||||||2018-05-31 21:41:49.607481|2018-05-31 21:41:49.607481
NCT01521494|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-11-29|2012-01-26|2012-01-30|Estimate|||||||2012-11-29|2012-12-03|Estimate||||January 2012|2012-01-31||||||||Interventional|||PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia||Completed||Phase 2|150|Anticipated|Kissei Pharmaceutical Co., Ltd.||5|||f||||f||||||||||2018-05-31 21:41:50.05674|2018-05-31 21:41:50.05674
NCT01521481|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2014-02-03|2012-01-27|2012-01-30|Estimate|||||||2014-02-03|2014-02-04|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|U-IFB||Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery|Analgesic Efficacy of Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery.|Completed||Phase 4|87|Actual|Azienda Ospedaliera San Gerardo di Monza||2|||f||||t||||||||||2018-05-31 21:41:50.122348|2018-05-31 21:41:50.122348
NCT01521468|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-12-08|2012-01-27|2012-01-30|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PACIFIC||Comparison of Cardiac Imaging Techniques for Diagnosing Coronary Artery Disease|Prospective Comparison of Cardiac PET/CT, SPECT/CT Perfusion Imaging and CT Coronary Angiography With Invasive Coronary Angiography|Completed|||210|Actual|VU University Medical Center|||||f||||t||||||Samples With DNA|"~     Urine and whole blood.~   "|||2018-05-31 21:41:50.186176|2018-05-31 21:41:50.186176
NCT01521455|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2013-08-22|2012-01-26|2012-01-30|Estimate|||||||2013-08-22|2013-08-23|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients|A Phase I, Randomized, Open, Multi-center, Cross Over Study to Evaluate the Therapeutic Equivalence of Repeated Dose of HCP0910 250/50 μg to SeretideTM 250 DiskusTM in Asthmatic Patients|Completed||Phase 1|56|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 21:41:50.244528|2018-05-31 21:41:50.244528
NCT01521429|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2017-05-03|2012-01-25|2012-01-30|Estimate|||||||2017-05-03|2017-05-05|Actual|August 2009||2009-08-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Longitudinal Study of Bone Disease in Children With Mucopolysaccharidoses (MPS) I, II, and VI|Longitudinal Study of Bone and Endocrine Disease in Children With MPS I, II, and VI: A Multicenter Study of the Lysosomal Disease Network.|Active, not recruiting|||55|Actual|Los Angeles Biomedical Research Institute|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, white cells for DNA extraction, and urine will be retained.~   "|||2018-05-31 21:41:50.489036|2018-05-31 21:41:50.489036
NCT01521416|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2013-08-29|2012-01-26|2012-01-30|Estimate|||||||2013-08-29|2013-09-02|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Cost of Illness Associated With Influenza in the UK|The Cost of Illness Associated With Influenza in the UK|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:41:50.561895|2018-05-31 21:41:50.561895
NCT01521403|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2018-05-02|2012-01-27|2012-01-30|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2012||2012-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Is it Effective to Treat Patients With Blastocystis Hominis Infection?|Is it Effective to Treat Patients With Blastocystis Hominis Infection? A Double-blind Placebo Controlled Randomized Trial|Active, not recruiting||Phase 4|200|Anticipated|University of Lausanne Hospitals||2|||f||||t||||||||No||2018-05-31 21:41:50.625127|2018-05-31 21:41:50.625127
NCT01521390|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-06-19|2012-01-26|2012-01-30|Estimate|||||||2017-06-19|2017-06-20|Actual|October 12, 2011|Actual|2011-10-12|June 2017|2017-06-30|December 16, 2011|Actual|2011-12-16|December 16, 2011|Actual|2011-12-16||Interventional|||Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.|Randomized, Double-blind, 5 Period Cross Over Study Assessing Lung Function in Healthy Volunteers Following Single Inhalations of GSK573719 Inhalation Powder From Two Configurations of the Novel Dry Powder Inhaler|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:41:50.703726|2018-05-31 21:41:50.703726
NCT01521377|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-06-09|2012-01-26|2012-01-30|Estimate|||||||2017-06-09|2017-06-12|Actual|December 19, 2011|Actual|2011-12-19|June 2017|2017-06-30|June 5, 2012|Actual|2012-06-05|June 5, 2012|Actual|2012-06-05||Interventional|||QTc Study GSK573719+GW642444|A Randomised, Placebo-controlled, Incomplete Block, Four Period Crossover , Repeat Dose Study to Evaluate the Effect of the Inhaled GSK573719/Vilanterol Combination and GSK573719 Monotherapy on Electrocardiographic Parameters, With Moxifloxacin as a Positive Control, in Healthy Subjects.|Completed||Phase 1|100|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:41:50.8115|2018-05-31 21:41:50.8115
NCT01521364|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2013-01-17||2013-05-27|2012-01-25|2012-01-30|Estimate|2013-05-27|2013-07-01|Estimate||||2013-05-27|2013-07-01|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients|The Pharmacokinetic Effect of Clarithromycin on the AUC0-12h of Linezolid in Multidrug-resistant and Extensively Drug-resistant Tuberculosis (MDR/XDR-TB) Patients|Completed||Phase 4|7|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 21:41:50.924707|2018-05-31 21:41:50.924707
NCT01521351|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2015-05-26|2012-01-27|2012-01-30|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Natural History of Carotid Atherosclerosis|A Prospective Natural History Study of Carotid Atherosclerosis|Unknown status|Recruiting||700|Anticipated|University of Athens|||4||f||||f||||||||||2018-05-31 21:41:51.21517|2018-05-31 21:41:51.21517
NCT01521338|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2018-04-30|2012-01-27|2012-01-30|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|GOAL- e2||G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2)|G551D Observational Study (GOAL)-Expanded to Additional Genotypes and Extended for Long Term Follow up (GOAL-e2)|Active, not recruiting|||120|Actual|University of Alabama at Birmingham|||||f||||f||||||Samples With DNA|"~     Blood, Sputum, Urine~   "|||2018-05-31 21:41:51.33698|2018-05-31 21:41:51.33698
NCT01521325|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2016-09-28|2012-01-27|2012-01-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers|A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers|Completed||Phase 1|6|Actual|Morphotek||1|||f||||f||||||||||2018-05-31 21:41:51.47758|2018-05-31 21:41:51.47758
NCT01521312|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-02-02|2012-01-25|2012-01-30|Estimate|||||||2015-02-02|2015-02-03|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ACCES||ACute and Chronic Effects of Saxagliptin|A Randomized, Double Blind, Placebo Controlled, Pilot Study to Evaluate ACute and Chronic Effects of Saxagliptin on Impaired Glucose Tolerance and micro-and Macro-vascular Integrators|Completed||Phase 2|24|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:41:51.572794|2018-05-31 21:41:51.572794
NCT01521299|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2012-08-24|2012-01-25|2012-01-30|Estimate|||||||2012-08-24|2012-08-28|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors|A Phase I Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors|Withdrawn||Phase 1|0|Actual|Dartmouth-Hitchcock Medical Center||||Insufficient population of eligible patients.|f||||t||||||||||2018-05-31 21:41:51.747112|2018-05-31 21:41:51.747112
NCT01521286|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2015-09-24|2012-01-27|2012-01-30|Estimate|||||||2015-09-24|2015-09-28|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Observational|||Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain|Population Based Surveillance to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain|Completed|||552|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:41:51.858814|2018-05-31 21:41:51.858814
NCT01521273|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-11-07|2012-01-27|2012-01-30|Estimate|||||||2012-11-07|2012-11-08|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Iron Absorption From Biofortified Beans With Different Levels of Phytic Acid|A Multiple Meal Study to Evaluate the Role of Phytic Acid From Beans on Human Iron Absorption|Completed||N/A|25|Actual|Swiss Federal Institute of Technology||6|||f||||f||||||||||2018-05-31 21:41:51.955724|2018-05-31 21:41:51.955724
NCT01521260|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2013-05-03||2013-06-28|2012-01-25|2012-01-30|Estimate|2013-06-28|2013-07-02|Estimate||||2013-06-28|2013-07-02|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Implant Surface Decontamination in Peri-implantitis Treatment|Microbiological and Clinical Evaluation of Different Implant Surface Decontaminating Procedures in the Surgical Treatment of Peri-implantitis; a Double Blind Placebo Controlled Randomized Clinical Study|Completed||N/A|30|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 21:41:52.043093|2018-05-31 21:41:52.043093
NCT01521247|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-09-08|2012-01-25|2012-01-30|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|||Implementation of a Pediatric-to-adult Asthma Transition Program||Completed||N/A|30|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 21:41:52.284183|2018-05-31 21:41:52.284183
NCT01521234|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-05-11|2012-01-25|2012-01-30|Estimate|||||||2015-05-11|2015-05-13|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Using Wireless-technology for Feedback of Daily Walking Activity Post-stroke|Using Wireless Technology in Clinical Practice: Does Feedback of Daily Walking Activity Improve Walking Outcomes of Individuals Receiving Rehabilitation Post-stroke?|Completed||N/A|63|Actual|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-05-31 21:41:52.361975|2018-05-31 21:41:52.361975
NCT01521221|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2012-01-25|2012-01-25|2012-01-30|Estimate|||||||2012-01-25|2012-01-30|Estimate|April 2012||2012-04-30|January 2012|2012-01-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Assessment of Hand-grip in the Prevention of Postural Orthostatic Hypotension|Assessment of Hand-grip in the Prevention of Postural Orthostatic Hypotension|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 21:41:52.437638|2018-05-31 21:41:52.437638
NCT01521208|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2012-02-03|2012-01-27|2012-01-30|Estimate|||||||2012-02-03|2012-02-06|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Interventional|LUCAT||LUCAS Chest Compressor Versus Manual Chest Compression in Out-of-hospital Sudden Cardiac Arrest. LUCAT Trial|LUcas Continuous Chest Compressions in Out-of-hospital Cardiac Arrest Treatment. The LUCAT Trial|Unknown status|Recruiting|Phase 3|400|Anticipated|Sistema d’Emergències Mèdiques||2|||f||||f||||||||||2018-05-31 21:41:52.511571|2018-05-31 21:41:52.511571
NCT01521195|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-08-15|2012-01-25|2012-01-30|Estimate|||||||2013-08-15|2013-08-16|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Oxygen Consumption In Critically Ill Children|A Pilot Study of the Relationship Between Oxygen Delivery and Consumption During Extracorporeal Membrane Oxygenation.|Unknown status|Recruiting|Phase 2|10|Anticipated|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 21:41:52.603755|2018-05-31 21:41:52.603755
NCT01521182|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-09-19|2012-01-26|2012-01-30|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of the Consumption of a Fermented Dairy Drink on the Immune Function||Completed||N/A|550|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 21:41:52.671957|2018-05-31 21:41:52.671957
NCT01521169|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-10-26|2012-01-26|2012-01-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Long-term Effectiveness Study on Cholesterol-reducing Activity|Clinical Study for Evaluating the Plasma Cholesterol-reducing Activity of a Plant Sterol-enriched Yoghurt Drink - Effectiveness and Long-term Safety Study|Completed||N/A|138|Actual|Danone Research||3|||f||||f||||||||||2018-05-31 21:41:52.727358|2018-05-31 21:41:52.727358
NCT01521156|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-10-26|2012-01-26|2012-01-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||Effect of the Consumption of a Fermented Dairy Product Enriched With Plant Sterols|Cholesterol Lowering Effects of a Drinkable Low Fat Dairy Product Enriched With Plant Sterols|Completed||N/A|128|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 21:41:52.787269|2018-05-31 21:41:52.787269
NCT01521143|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2016-11-16||2016-12-09|2012-01-25|2012-01-30|Estimate|2016-12-09|2016-12-14|Estimate||||2016-12-09|2016-12-14|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CANVAS|"Part A - Safety population: All randomized participants who received at least 1 dose of Cvac or placebo.~Part B - Safety population: All randomized participants who received at least 1 dose of Cvac (Cvac group) or were evaluated at least once (observational standard of care group)."|Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment|A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-glutathione S-transferase] Coupled to Oxidized Polymannose) as Maintenance Treatment in Patients With Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-line Chemotherapy (A) and Patients With EOC in Second Remission (B)|Terminated||Phase 2|91|Actual|Prima BioMed Ltd||4||"The study was terminated due to company restructuring and changes in drug development~   priorities."|f||||t||||||||||2018-05-31 21:41:52.973906|2018-05-31 21:41:52.973906
NCT01521130|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2017-11-09|2012-01-26|2012-01-30|Estimate|||||||2017-11-09|2017-11-14|Actual|January 2012||2012-01-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|FIRST||Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children|Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children|Completed||Phase 1|108|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-05-31 21:41:53.596438|2018-05-31 21:41:53.596438
NCT01521117|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-25|2012-01-25|2012-01-30|Estimate|||||||2012-01-25|2012-01-30|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Interventional|||The Effect of Donepezil on Gait and Balance in Parkinson's Disease|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease|Unknown status|Recruiting|Phase 4|12|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 21:41:53.667208|2018-05-31 21:41:53.667208
NCT01521104|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-01-27|2012-01-27|2012-01-30|Estimate|||||||2012-01-27|2012-01-30|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Value of Narrow Band Imaging in Stratifying Patients for Endoscopic Resection or Surgery|The Value of NBI in Stratifying Patients for Endoscopic Resection or Surgery|Completed|||565|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     All the lesions will be removed endoscopically or surgically and examined histologically by~     an independent gastrointestinal pathologist.~      Histological diagnosis is determined according to the World Health Organization (WHO)~     criteria.Pedunculated lesions are categorized according to Haggitt's classification.~   "|||2018-05-31 21:41:53.747821|2018-05-31 21:41:53.747821
NCT01521091|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-27|2012-01-27|2012-01-30|Estimate|||||||2012-01-27|2012-01-30|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Comparison of Diagnostic Accuracy for Predicting Histology of Colorectal Lesions|Comparison of Diagnostic Accuracy for Predicting Histology of Colorectal Lesions Using Magnifying Colonoscopy With Narrow Band Imaging, Indigo Carmine, and Acetic Acid Staining|Completed|||565|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     All the lesions will be removed endoscopically or surgically and examine histologically by an~     independent gastrointestinal pathologist.~      Histological diagnosis is determined according to the World Health Organization (WHO)~     criteria. Pedunculated lesions are categorized according to Haggitt's classification.~   "|||2018-05-31 21:41:53.882053|2018-05-31 21:41:53.882053
NCT01521078|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2012-05-24|2012-01-26|2012-01-30|Estimate|||||||2012-05-24|2012-05-25|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Web-based Personalized Feedback for University Students|Randomized Controlled Trial of a Brief Personalized Feedback Intervention in University Students|Completed||N/A|425|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 21:41:54.021458|2018-05-31 21:41:54.021458
NCT01521065|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-04-24|2012-01-25|2012-01-30|Estimate|||||||2013-04-24|2013-04-26|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|October 2016|Anticipated|2016-10-31|October 2014|Anticipated|2014-10-31||Interventional|ENDEAVOUR||An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|A Multicenter, Open-label Study to Evaluate the Clinical and Economic Benefits of Low Voltage Stereotactic Radiotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|Unknown status|Recruiting|Phase 2|500|Anticipated|Oraya Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 21:41:54.074747|2018-05-31 21:41:54.074747
NCT01521052|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-01-27|2012-01-27|2012-01-30|Estimate|||||||2012-01-27|2012-01-30|Estimate|January 2012||2012-01-31|January 2012|2012-01-31||||December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for Treatment of Major Depressive Episode in the Elderly||Unknown status|Not yet recruiting|Phase 2|27|Anticipated|Shalvata Mental Health Center||1|||f||||t||||||||||2018-05-31 21:41:54.146303|2018-05-31 21:41:54.146303
NCT01521039|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-02-23|2012-01-25|2012-01-30|Estimate|||||||2018-02-23|2018-02-26|Actual|February 13, 2012|Actual|2012-02-13|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease|Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease|Recruiting|||240|Anticipated|Ohio State University Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 21:41:54.206037|2018-05-31 21:41:54.206037
NCT01521026|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|2013-07-01||2013-11-15|2012-01-25|2012-01-30|Estimate|2013-11-15|2013-12-11|Estimate||||2013-11-15|2013-12-11|Estimate|September 2003||2003-09-30|November 2013|2013-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Cognitive Training for Patients With Schizophrenia|Cognitive Training for Patients With Schizophrenia|Completed||Phase 2|69|Actual|University of California, San Diego|"small sample size~relatively short follow-up period~significant dropout rate~did not use an active control condition that matched CCT for therapist time or group involvement"|2|||f||||t||||||||||2018-05-31 21:41:54.310926|2018-05-31 21:41:54.310926
NCT01521013|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-04-07|2012-01-25|2012-01-30|Estimate|||||||2015-04-07|2015-04-08|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DIRECT-sc||Effectiveness of a Self-care Intervention for Depression in Primary Care Patients With Chronic Physical Illnesses|Effectiveness of a Supported Self-Care Intervention for Depression Compared to an Unsupported Intervention in Older Adults With Chronic Physical Illnesses (DIRECT-sc)|Completed||N/A|223|Actual|McGill University||2|||f||||||||||||||2018-05-31 21:41:54.537633|2018-05-31 21:41:54.537633
NCT01521000|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2012-01-25|2012-01-25|2012-01-30|Estimate|||||||2012-01-25|2012-01-30|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|L-Dex||The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient|The Use of Bioimpedance to Determine Pre-Clinical Lymphedema in the Post-Operative Breast Cancer Patient|Unknown status|Recruiting|N/A|200|Anticipated|Main Line Health||2|||f||||f||||||||||2018-05-31 21:41:55.681745|2018-05-31 21:41:55.681745
NCT01520987|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|2015-07-22||2016-05-12|2012-01-26|2012-01-30|Estimate|2016-05-12|2016-06-20|Estimate||||2016-05-12|2016-06-20|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects|Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Compare the Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|105|Actual|Bial - Portela C S.A.||8|||f||||t||||||||||2018-05-31 21:41:55.797957|2018-05-31 21:41:55.797957
NCT01520974|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-05-01|2012-01-27|2012-01-30|Estimate|||||||2012-05-01|2012-05-02|Estimate|January 2012||2012-01-31|May 2012|2012-05-31||||August 2012|Anticipated|2012-08-31||Interventional|||Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)|ProBiora3 Oral Care Probiotics Usage|Unknown status|Recruiting|N/A|48|Anticipated|Oragenics, Inc.||2|||f||||f||||||||||2018-05-31 21:41:56.709102|2018-05-31 21:41:56.709102
NCT01520961|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-02-06|2012-01-26|2012-01-30|Estimate|||||||2015-02-06|2015-02-09|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|AYNF||Functional Recovery After Partial Hip Arthroplasty: Anterior or Posterolateral Approach?|Approach Your Neck Fracture|Completed|||82|Actual|Hospital Ambroise Paré Paris|||2||f||||f||||||||||2018-05-31 21:41:56.814954|2018-05-31 21:41:56.814954
NCT01520948|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2018-01-08|2012-01-26|2012-01-30|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2012||2012-09-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|BETTUR PD||Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease|Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease|Completed||Phase 3|53|Actual|Atlanta VA Medical Center||2|||f||||f||||||||||2018-05-31 21:41:56.896621|2018-05-31 21:41:56.896621
NCT01520935|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-09-06|2012-01-26|2012-01-30|Estimate|||||||2012-09-06|2012-09-10|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Influenza Burden Assessment in the United Kingdom, 1996-2008|Burden of Influenza in the United Kingdom, 1996-2008|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:41:56.968718|2018-05-31 21:41:56.968718
NCT01520922|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2013-10-10||2016-11-22|2012-01-26|2012-01-30|Estimate|2013-10-24|2013-12-16|Estimate||||2016-11-22|2017-01-19|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|February 2013|Actual|2013-02-28||Interventional|||Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)|A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)|Completed||Phase 2|99|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:41:57.14249|2018-05-31 21:41:57.14249
NCT01520909|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2014-08-21||2015-02-19|2012-01-26|2012-01-30|Estimate|2014-09-25|2014-09-29|Estimate||||2015-02-19|2015-03-10|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PETIT2||Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.|A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP|Completed||Phase 3|92|Actual|GlaxoSmithKline||3|||f||||t||||||||||2018-05-31 21:41:58.95105|2018-05-31 21:41:58.95105
NCT01520896|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2014-10-13|2012-01-26|2012-01-30|Estimate|||||||2014-10-13|2014-10-15|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118|An Open-label, 1-sequence, 3-period, 3-treatment, Crossover Study to Assess the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118 in Healthy Subjects|Completed||Phase 1|22|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:42:01.402232|2018-05-31 21:42:01.402232
NCT01520883|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2013-05-24|2012-01-25|2012-01-30|Estimate|||||||2013-05-24|2013-05-27|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Observational|||Evaluation of Decisional Conflict and Needs Assessment in Asthma Management|Decisional Conflict and Needs Assessment in Shared Decision Making in Asthma Management|Completed|||50|Actual|Laval University|||1||f||||f||||||||||2018-05-31 21:42:01.486733|2018-05-31 21:42:01.486733
NCT01520870|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2018-03-14|2012-01-26|2012-01-30|Estimate|||||||2018-03-14|2018-03-16|Actual|February 2012||2012-02-29|March 2018|2018-03-31|March 9, 2017|Actual|2017-03-09|April 2015|Actual|2015-04-30||Interventional|||Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.|Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of PF299804, a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation|Completed||Phase 2|49|Actual|Grupo Español de Investigación en Neurooncología||1|||f||||f||||||||||2018-05-31 21:42:01.556941|2018-05-31 21:42:01.556941
NCT01520857|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-03-15|2012-01-25|2012-01-30|Estimate|||||||2017-03-15|2017-03-16|Actual|October 2011||2011-10-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Spinal Versus General Anesthesia for Transabdominal Preperitoneal (TAPP) Repair of Inguinal Hernia|A Controlled Randomized Trial Comparing Spinal Versus General Anesthesia for Transabdominal Preperitoneal (TAPP) Repair of Inguinal Hernia|Completed||N/A|140|Actual|Larissa University Hospital||2|||f||||f||||||||||2018-05-31 21:42:01.65779|2018-05-31 21:42:01.65779
NCT01520844|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-03-21|2012-01-26|2012-01-30|Estimate|||||||2017-03-21|2017-03-22|Actual|February 2012||2012-02-29|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|February 2018|Anticipated|2018-02-28||Interventional|CODEX||"the ANRS CO21  Extreme  Cohort (CODEX)"|Multicentric Cohort of HIV Patient With Extrem Profil|Recruiting||N/A|300|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 21:42:01.749473|2018-05-31 21:42:01.749473
NCT01520831|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-01-03|2012-01-25|2012-01-30|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 1999||1999-04-30|January 2017|2017-01-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects|A Randomised, Four-period Cross-over Trial in Healthy Subjects, Investigating the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, Biphasic Insulin Aspart 50, Biphasic Insulin Aspart 70 and Soluble Insulin Aspart|Completed||Phase 1|35|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:42:01.862337|2018-05-31 21:42:01.862337
NCT01520818|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-01-03|2012-01-25|2012-01-30|Estimate|||||||2017-01-03|2017-01-04|Estimate|March 2000||2000-03-31|January 2017|2017-01-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes|A Multinational, Randomised, Open-labelled, Parallel Group Four Months Comparison of Twice Daily Biphasic Human Insulin 30 and Thrice Daily Biphasic Insulin Aspart 50 and 70 in Subjects With Type 1 or Type 2 Diabetes|Completed||Phase 3|666|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:42:01.965813|2018-05-31 21:42:01.965813
NCT01520805|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2016-12-27|2012-01-26|2012-01-30|Estimate|||||||2016-12-27|2016-12-29|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome|A Phase 2a Open-Label Clinical Trial Evaluating Efficacy & Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents|Withdrawn||Phase 2|0|Actual|Rafael Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 21:42:02.136234|2018-05-31 21:42:02.136234
NCT01520792|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2013-05-13|2012-01-26|2012-01-30|Estimate|||||||2013-05-13|2013-05-14|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Paracetamol and Pharmacogenetic|Paracétamol and Pharmacogenetic in Healthy Volunteers|Completed||Phase 1|100|Actual|University Hospital, Clermont-Ferrand||1|||f||||f||||||||||2018-05-31 21:42:02.206531|2018-05-31 21:42:02.206531
NCT01520779|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2013-09-29|2012-01-26|2012-01-30|Estimate|||||||2013-09-29|2013-10-01|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Recurrence of Hepatocellular Carcinoma|Risk Factors for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation|Completed|||99|Actual|Ain Shams University|||2||f||||t||||||||||2018-05-31 21:42:02.27157|2018-05-31 21:42:02.27157
NCT01520766|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-30|2012-01-26|2012-01-30|Estimate|||||||2012-01-30|2012-01-31|Estimate|January 2003||2003-01-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|April 2004|Actual|2004-04-30||Interventional|||Prefabricated Endodontic Posts: Glass Fiber Versus Titanium - A Randomized Controlled Pilot- Trial||Completed||Phase 4|91|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:42:02.32718|2018-05-31 21:42:02.32718
NCT01520753|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-01-03|2012-01-25|2012-01-30|Estimate|||||||2017-01-03|2017-01-04|Estimate|March 1999||1999-03-31|January 2017|2017-01-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes|A Randomised, Double-blind, 4-week, Crossover Trial on Two Treatment Regimens With Biphasic Insulin Aspart 70 and 50 in Patients With Type 2 Diabetes|Completed||Phase 3|16|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:42:02.549732|2018-05-31 21:42:02.549732
NCT01520727|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2014-12-29||2014-12-29|2012-01-26|2012-01-30|Estimate|2014-12-29|2015-01-08|Estimate||||2014-12-29|2015-01-08|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|April 2009|Actual|2009-04-30|December 2007|Actual|2007-12-31||Interventional|||A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects|A Single Oral Ascending Dose Study to Investigate the Safety, Pharmacokinetics and Catechol-O-methyltransferase (COMT) Inhibition Profiles of BIA 9-1067 in Healthy Male Subjects|Completed||Phase 1|64|Actual|Bial - Portela C S.A.||9|||f||||f||||||||||2018-05-31 21:42:02.772671|2018-05-31 21:42:02.772671
NCT01520714|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2013-08-09||2014-04-30|2012-01-26|2012-01-30|Estimate|2014-04-30|2014-05-26|Estimate||||2014-04-30|2014-05-26|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|EXPECT||Effect of Posture on Left Ventricular (LV) Transvenous Lead Capture Thresholds (EXPECT)|Effect of Posture on LV Transvenous Lead Capture Thresholds (EXPECT)|Terminated||N/A|11|Actual|Baylor Research Institute|Early termination leading to small numbers of subjects; Non-efficacy of treatment leading to no data summary and analysis.|2||Lower enrollment rate than expected|f||||f||||||||||2018-05-31 21:42:03.359225|2018-05-31 21:42:03.359225
NCT01520701|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-07-13|2012-01-26|2012-01-30|Estimate|||||||2017-07-13|2017-07-14|Actual|February 2012||2012-02-29|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|February 2018|Anticipated|2018-02-28||Interventional|IPAC||Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy|Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy|Recruiting||Phase 3|125|Anticipated|Centre Francois Baclesse||2|||f||||f||||||||||2018-05-31 21:42:03.63992|2018-05-31 21:42:03.63992
NCT01520688|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-07-20|2012-01-26|2012-01-30|Estimate|||||||2016-07-20|2016-07-21|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth|A Randomized, Cross Over Study Evaluating the Effect of Flovent Discus 100 mcg BID vs QVAR 80 mcg BID vs Pulmicort Flexhaler 180 mcg BID on Short Term Growth in Pediatric Subjects With Asthma|Completed||Phase 4|32|Actual|West Penn Allegheny Health System||6|||f||||t||||||||||2018-05-31 21:42:03.747972|2018-05-31 21:42:03.747972
NCT01520675|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-06-27|2012-01-26|2012-01-30|Estimate|||||||2017-06-27|2017-06-28|Actual|July 2010|Actual|2010-07-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Endoscopic Versus Surgical Treatment of Chronic Pancreatitis|Endoscopic Versus Surgical Treatment of Chronic Pancreatitis - A Randomized Controlled Trial|Active, not recruiting||N/A|50|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 21:42:03.857865|2018-05-31 21:42:03.857865
NCT01520662|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-01-26|2012-01-26|2012-01-30|Estimate|||||||2012-01-26|2012-01-30|Estimate|September 2007||2007-09-30|January 2012|2012-01-31|August 2010|Actual|2010-08-31|July 2008|Actual|2008-07-31||Interventional|||Impact of a Wellness Portal on The Delivery of Patient-Centered Preventive Care|Impact of a Wellness Portal on The Delivery of Patient-Centered Preventive Care|Completed||N/A|540|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||t||||||||||2018-05-31 21:42:03.944297|2018-05-31 21:42:03.944297
NCT01520649|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-04-01|2012-01-27|2012-01-30|Estimate|||||||2014-04-01|2014-04-02|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects|A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects|Completed||Phase 1|26|Actual|Neuralstem Inc.||2|||f||||t||||||||||2018-05-31 21:42:04.06732|2018-05-31 21:42:04.06732
NCT01520636|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-05-02|2012-01-25|2012-01-30|Estimate|||||||2017-05-02|2017-05-05|Actual|July 2012||2012-07-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|AMOBES||Active MOBility Early After Stroke : What Should be the Best Physiotherapy Early After Stroke ?|What Should be the Best Physiotherapy Early After Stroke ?|Completed||Phase 3|104|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:42:04.209875|2018-05-31 21:42:04.209875
NCT01520623|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2015-04-09|2012-01-25|2012-01-30|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||Complement and Graft-versus-host Disease|Role of Complement System in Human Allogeneic Haematopoietic Stem Cell Transplantation|Completed||N/A|70|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 21:42:04.295484|2018-05-31 21:42:04.295484
NCT01520610|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2016-09-14|2012-01-25|2012-01-30|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|May 2016|Actual|2016-05-31|November 2014|Actual|2014-11-30||Observational|||TAKO-TSUBO Cardiomyopathy and Genetic|Genetic Polymorphisms in Catecholamine Pathway Responsible for the Tako-TSUBO Cardiomyopathy Susceptibly (TAKO-GENE)|Completed|||530|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples With DNA|"~     20 ml of blood sample will be collected from all patients enrolled in order to DNA analysis.~   "|||2018-05-31 21:42:04.372002|2018-05-31 21:42:04.372002
NCT01520597|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-04-27|2012-01-25|2012-01-30|Estimate|||||||2018-04-27|2018-04-30|Actual|November 1, 2009||2009-11-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|MONALISA||National Study on Listeriosis and Listeria|Multicentric Observational NAtional Study on LISteriosis and ListeriA|Recruiting|||1200|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-05-31 21:42:04.445614|2018-05-31 21:42:04.445614
NCT01520584|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-14|||2012-01-25|2012-01-25|2012-01-30|Estimate|||||||2012-01-25|2012-01-30|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2016|Anticipated|2016-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Supplement Intake in Infertile Men;the Effect on Sperm Parameters,Fertilization Rate and Embryo Quality|Vitamins ,Minerals and Amino Acids Supplement Intake in Infertile Men;the Effect on Sperm Parameters,Fertilization Rate and Embryo Quality. A Double Blind Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||||2018-05-31 21:42:04.538834|2018-05-31 21:42:04.538834
NCT01520571|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-01-25|2012-01-25|2012-01-30|Estimate|||||||2012-01-25|2012-01-30|Estimate|January 2000||2000-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2001|Actual|2001-12-31||Interventional|||Do We Need Computer Assistance To Improve the Survival of Primary Total Knee Arthroplasty. A Minimum Ten Years Follow-up||Completed||Phase 4|520|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 21:42:04.612602|2018-05-31 21:42:04.612602
NCT01520389|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-03-20|2012-01-24|2012-01-30|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2012||2012-01-31|March 2018|2018-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment|A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors|Completed||Phase 1|112|Actual|Merrimack Pharmaceuticals||3|||f||||||||||||||2018-05-31 21:42:07.306956|2018-05-31 21:42:07.306956
NCT01520558|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2017-04-18||2017-05-30|2012-01-25|2012-01-30|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|December 2012||2012-12-31|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|March 2016|Actual|2016-03-31||Interventional|||CNDO-109-AANK for AML in First Complete Remission (CR1)|A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)|Active, not recruiting||Phase 1/Phase 2|12|Actual|Coronado Biosciences, Inc.||3|||f||||f||||||||||2018-05-31 21:42:04.71547|2018-05-31 21:42:04.71547
NCT01520545|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-04-13|2012-01-25|2012-01-30|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2012||2012-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump|Study to Assess the Safety of 3 mg/mL Gablofen® (Baclofen Injection) Delivered by Intrathecal Administration Using the Synchromed® II Programmable Infusion System|Completed||Phase 3|153|Actual|Piramal Critical Care, Ltd.||1|||f||||f||||||||No||2018-05-31 21:42:05.306014|2018-05-31 21:42:05.306014
NCT01520532|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2012-12-10||2013-09-10|2012-01-27|2012-01-30|Estimate|2013-02-12|2013-03-14|Estimate||||2013-09-10|2013-09-19|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ERACE||Evaluation of the Incidence of Cerebral Lesions Post Pulmonary Vein Ablation Catheter (PVAC)|Evaluate Reduction in Asymptomatic Cerebral Embolism|Completed||N/A|60|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||f||||||||||2018-05-31 21:42:05.379295|2018-05-31 21:42:05.379295
NCT01520519|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2018-03-22|2012-01-27|2012-01-30|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 2012|Actual|2012-02-29|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients|A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:42:05.524091|2018-05-31 21:42:05.524091
NCT01520506|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2015-07-31||2015-08-14|2012-01-27|2012-01-30|Estimate|2015-08-14|2015-09-16|Estimate||||2015-08-14|2015-09-16|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|RAPID||Rapid Renal Sympathetic Denervation for Resistant Hypertension|Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot™ Ablation System|Completed||Phase 2|50|Actual|Medtronic Endovascular||1|||f||||f||||||||||2018-05-31 21:42:05.598893|2018-05-31 21:42:05.598893
NCT01520493|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2018-03-06|2012-01-27|2012-01-30|Estimate|||||||2018-03-06|2018-03-07|Actual|June 2011||2011-06-30|March 2018|2018-03-31|March 2015|Actual|2015-03-31|August 2013|Actual|2013-08-31||Interventional|||Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension|Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension|Completed||N/A|20|Actual|Laval University||1|||f||||f||||||||||2018-05-31 21:42:05.957997|2018-05-31 21:42:05.957997
NCT01520480|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-01-29|2012-01-27|2012-01-30|Estimate|||||||2012-01-29|2012-01-31|Estimate|January 1999||1999-01-31|January 2012|2012-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Pathological Subtrochanteric Fractures in 194 Patients|Pathological Subtrochanteric Fractures in 194 Patients. A Comparison of Outcome After Surgical Treatment of Pathological and Non-pathological Fractures.|Completed|||281|Actual|Karolinska University Hospital|||2||f||||f||||||||||2018-05-31 21:42:06.026469|2018-05-31 21:42:06.026469
NCT01520467|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2016-08-23|2012-01-27|2012-01-30|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|July 2016|Actual|2016-07-31||Interventional|ANASILPRA||Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome|Efficacy and Tolerance of Treatment With an Aromatase Inhibitor (Anastrozole) to Limit the Progression of Bone Maturation Related to Pathological Adrenarche in Children With Silver-Russell or Prader-Willi Syndrome|Active, not recruiting||N/A|27|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:42:06.089133|2018-05-31 21:42:06.089133
NCT01520454|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2015-12-29||2018-05-08|2012-01-27|2012-01-30|Estimate|2017-03-16|2017-04-26|Actual||||2018-05-08|2018-05-10|Estimate|November 2011||2011-11-30|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Increased Free Fatty Acids on Leptin Function|Differential Effects of Oral and Intravenous Lipid Administration on Leptin Signaling|Completed||N/A|26|Actual|Beth Israel Deaconess Medical Center||4|||f||||f||||||||||2018-05-31 21:42:06.183098|2018-05-31 21:42:06.183098
NCT01520441|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-06-01|2012-01-27|2012-01-30|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)|H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol # 05-09-30-03)|Withdrawn||Early Phase 1|0|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 21:42:06.65195|2018-05-31 21:42:06.65195
NCT01520428|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-09-26|2012-01-26|2012-01-30|Estimate|||||||2012-09-26|2012-09-27|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Interventions to Prevent Adolescents With Type 1 Diabetes From Long-term Complications|Interventions to Prevent Adolescents With Type 1 Diabetes From Long-term Complications. A Multicenter Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|120|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:42:06.81058|2018-05-31 21:42:06.81058
NCT01520415|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2013-07-26|2012-01-24|2012-01-30|Estimate|||||||2013-07-26|2013-07-29|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial Examining the Short and Long-term Effect of Myofascial Trigger Points Injection in Low Back Pain Patients|A Prospective, Randomized, Double-blind, Clinical Trial of Trigger Point Injection Therapy for the Treatment of Myofascial Pain Syndrome|Completed||Phase 2|40|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 21:42:06.919692|2018-05-31 21:42:06.919692
NCT01520402|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2012-10-24||2013-02-06|2012-01-24|2012-01-30|Estimate|2013-01-07|2013-02-07|Estimate||||2013-02-06|2013-02-12|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Genetic Response to Warfarin in Healthy Subjects|Quantitative Pharmacogenomics of the Anticoagulant Response to Warfarin in Healthy Subjects|Completed||N/A|35|Actual|Icahn School of Medicine at Mount Sinai|Small number of subjects, which prevented detection of modest effects; relied on self-reported race and self-reported adherance to vitamin K restricted diet without objective markers such as ancestry informative markers and serum vitamin k levels.|1|||f||||t||||||||||2018-05-31 21:42:07.035058|2018-05-31 21:42:07.035058
NCT01520376|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2015-08-11|2012-01-25|2012-01-27|Estimate|||||||2015-08-11|2015-08-13|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|ADPHA-EPOC||Anxiety and Depression in Patients Hospitalizes for an Acute Exacerbation of COPD|A Prospective Randomized Trial to Asses the Efficacy of an Early Psychiatric Counseling Compared to Usual Care in a Cohort of Patients Hospitalized for an Acute Exacerbation of COPD in Prevention of Re-exacerbation|Completed||N/A|169|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||t||||||||||2018-05-31 21:42:07.404963|2018-05-31 21:42:07.404963
NCT01520363|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25||2018-01-24|2018-01-25|2012-01-26|2012-01-27|Estimate||||2018-01-24|2018-01-26|Actual|2018-01-25|2018-01-29|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|October 26, 2016|Actual|2016-10-26|October 26, 2016|Actual|2016-10-26||Interventional|PCTDMRTT||Placebo Controlled Trial of Dextromethorphan in Rett Syndrome|Placebo Controlled Trial of Dextromethorphan in Rett Syndrome|Completed||Phase 2|57|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||t||||||||No||2018-05-31 21:42:07.490389|2018-05-31 21:42:07.490389
NCT01520350|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-07-28|2012-01-25|2012-01-27|Estimate|||||||2014-07-28|2014-07-29|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study|Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study|Terminated||Phase 3|2|Actual|Douglas Mental Health University Institute||2||recruitment issues|f||||f||||||||||2018-05-31 21:42:07.570444|2018-05-31 21:42:07.570444
NCT01520337|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-02-10|2012-01-26|2012-01-27|Estimate|||||||2014-02-10|2014-02-11|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Observational|||Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy|Polyp Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Subjects Undergoing Outpatients Colonoscopy|Completed|||170|Actual|Cosmo Technologies Ltd|||1||f||||t||||||Samples Without DNA|"~     mucosal biopsy~   "|||2018-05-31 21:42:07.779346|2018-05-31 21:42:07.779346
NCT01520324|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2014-01-27|2012-01-26|2012-01-27|Estimate|||||||2014-01-27|2014-01-29|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy|Intraepithelial Neoplasia Detection Rate After Single Oral Dose of Methylene Blue MMX Modified Release Tablets Administered to Patients With Long Standing Ulcerative Colitis Undergoing Colonoscopy.|Completed|||50|Actual|Cosmo Technologies Ltd|||1||f||||t||||||Samples Without DNA|"~     mucosal biopsy~   "|||2018-05-31 21:42:07.840778|2018-05-31 21:42:07.840778
NCT01520311|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2016-06-28|2012-01-26|2012-01-27|Estimate|||||||2016-06-28|2016-06-29|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The eSVS® Mesh Post-Marketing Trial|Post-market Study to Evaluate Post-implant Patency Rates of the eSVS Mesh in the Treatment of Saphenous Vein Graphs During Coronary Artery Bypass Grafting Versus Saphenous Vein Grafts Without the eSVS Mesh Via Coronary Angiography and Duplex Ultra-Sonography Results|Terminated||N/A|8|Actual|Kips Bay Medical, Inc.||1||Company closed|f||||f||||||||||2018-05-31 21:42:07.917159|2018-05-31 21:42:07.917159
NCT01520298|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2014-09-29|2012-01-24|2012-01-27|Estimate|||||||2014-09-29|2014-09-30|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients|Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients|Withdrawn||Phase 3|0|Actual|Lancaster General Hospital||2||Difficulty in recruiting subjects for the trial.|f||||f||||||||||2018-05-31 21:42:07.996496|2018-05-31 21:42:07.996496
NCT01520285|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2014-10-14|2012-01-24|2012-01-27|Estimate|||||||2014-10-14|2014-10-16|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|Zanidip||Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension|A Multi-center, Randomized, Open-label, Parallel-group Clinical Study to Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for the Treatment of Patients With Mild-to-Moderate Hypertension|Completed||Phase 4|281|Actual|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 21:42:08.079316|2018-05-31 21:42:08.079316
NCT01520272|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2018-04-04|2012-01-26|2012-01-27|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2, 2012||2012-01-02|June 28, 2017|2017-06-28|June 28, 2017||2017-06-28|||||Observational|||HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda|Immunogenicity of Bivalent HPV Vaccine Among Partially Vaccinated Young Adolescent Girls in Uganda|Completed|||376|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:42:08.147465|2018-05-31 21:42:08.147465
NCT01520259|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2018-04-04|2012-01-26|2012-01-27|Estimate|||||||2018-04-04|2018-04-05|Actual|January 10, 2012||2012-01-10|February 6, 2018|2018-02-06||||||||Observational|||Initial Study of Gallbladder Cancer in Chile|A Pilot Study of Gallbladder Cancer in Chile|Completed|||446|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:42:08.226382|2018-05-31 21:42:08.226382
NCT01520246|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-07-07|2012-01-26|2012-01-27|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2012||2012-01-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia|Signaling in Tumorigenesis and Immunity|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     tissue, blood, and bodily fluids~   "|||2018-05-31 21:42:08.418073|2018-05-31 21:42:08.418073
NCT01520233|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2016-05-13|2012-01-26|2012-01-27|Estimate|||||||2016-05-13|2016-05-17|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma|Genome Based Outcome Prediction in High Risk Neuroblastoma|Completed|||100|Actual|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:42:08.487068|2018-05-31 21:42:08.487068
NCT01520220|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2017-04-10|2012-01-26|2012-01-27|Estimate|||||||2017-04-10|2017-04-12|Actual|June 11, 2012|Actual|2012-06-11|April 2017|2017-04-30|February 24, 2017|Actual|2017-02-24|June 26, 2015|Actual|2015-06-26||Interventional|||Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms|A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms|Completed||Phase 1|100|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 21:42:08.571625|2018-05-31 21:42:08.571625
NCT01520207|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2017-09-20||2017-10-18|2012-01-25|2012-01-27|Estimate|2017-09-20|2017-10-19|Actual||||2017-10-18|2017-11-21|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Interventional|||Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension|Pilot Study of Intravenous Mannitol During Hemodialysis Initiation to Reduce the Occurrence of Intra-dialytic Hypotension.|Active, not recruiting||Phase 2|52|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:42:08.71594|2018-05-31 21:42:08.71594
NCT01520168|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-03-12|2012-01-26|2012-01-27|Estimate|||||||2012-03-12|2012-03-13|Estimate|October 2003||2003-10-31|March 2012|2012-03-31|March 2012|Anticipated|2012-03-31|July 2011|Actual|2011-07-31||Observational|||Composix Kugel Mesh Recall Leaves Unresolved Problems of Patient Management|The 2005 Composix Kugel Mesh Recall Leaves Unresolved Problems of Patient Management: Taking Stock After 5-year Follow up|Suspended|||21|Actual|University of Wuerzburg||||Because of the product recall 2005/2006.|f||||f||||||Samples Without DNA|"~     Explanted meshes~   "|||2018-05-31 21:42:09.076303|2018-05-31 21:42:09.076303
NCT01520155|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-12-20|2012-01-26|2012-01-27|Estimate|||||||2013-12-20|2013-12-23|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|CASTLE||CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)|CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE): Studie Zur Detektion Des kardiovaskulären Risikos in Patienten Mit Systemischem Lupus Erythematodes|Completed|||90|Actual|Johann Wolfgang Goethe University Hospital|||3||f||||f||||||Samples Without DNA|"~     Every participant will provide 20 ml Serum for further laboratory analysis~   "|||2018-05-31 21:42:09.14866|2018-05-31 21:42:09.14866
NCT01520142|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2013-06-21|2012-01-24|2012-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants|A Two-Part, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Subjects Employing the Intravenous Endotoxin-Induced Model of Acute Inflammation|Completed||Phase 1|19|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 21:42:09.235636|2018-05-31 21:42:09.235636
NCT01520129|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-01-28|2012-01-26|2012-01-27|Estimate|||||||2016-01-28|2016-01-29|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pilot Study of Interpersonal and Social Rhythm Therapy for Subthreshold Bipolar|Pilot Study of Interpersonal and Social Rhythm Therapy for Subthreshold Bipolar|Completed||N/A|16|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 21:42:09.297467|2018-05-31 21:42:09.297467
NCT01520116|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-10-30|2012-01-25|2012-01-27|Estimate|||||||2012-10-30|2012-11-01|Estimate|January 2012||2012-01-31|October 2012|2012-10-31||||December 2012|Anticipated|2012-12-31||Interventional|||Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension|A Phase 1/2a Randomized, Investigator-masked, Placebo- and Active-controlled, Dose-ranging Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension|Unknown status|Active, not recruiting|Phase 1/Phase 2|180|Anticipated|Altheos, Inc.||8|||f||||f||||||||||2018-05-31 21:42:09.368506|2018-05-31 21:42:09.368506
NCT01520103|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-08-08|2012-01-26|2012-01-27|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2012|Actual|2012-01-31|August 2017|2017-08-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|VicTORia||Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer|Randomized Phase II Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer|Completed||Phase 2|139|Actual|AIO-Studien-gGmbH||2|||f||||f||||||||||2018-05-31 21:42:09.453458|2018-05-31 21:42:09.453458
NCT01520090|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-01-26|2012-01-26|2012-01-27|Estimate|||||||2012-01-26|2012-01-27|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Observational|||Egyptian Women Knowledge and Use of Different Contraceptive Methods|Egyptian Women Knowledge and Use of Different Contraceptive Methods|Unknown status|Recruiting||1200|Anticipated|Ain Shams University|||||f||||f||||||||||2018-05-31 21:42:09.528055|2018-05-31 21:42:09.528055
NCT01520077|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-03-16|2012-01-26|2012-01-27|Estimate|||||||2015-03-16|2015-03-17|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Vytorin in the Treatment of Alopecia Areata|A Pilot Study To Evaluate the Efficacy of Vytorin (Simvastatin +Ezetimibe) In the Treatment of Alopecia Areata|Completed||Phase 1|29|Actual|University of Miami||1|||f||||t||||||||||2018-05-31 21:42:09.589571|2018-05-31 21:42:09.589571
NCT01520064|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2013-11-13|2012-01-25|2012-01-27|Estimate|||||||2013-11-13|2013-11-14|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30|2 Years|Observational [Patient Registry]|||Post Market Registry Study of the AeriSeal System|Post Market Registry Study of the AeriSeal System|Terminated|||25|Anticipated|Aeris Therapeutics|||||f||||f||||||||||2018-05-31 21:42:10.642409|2018-05-31 21:42:10.642409
NCT01520051|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2012-02-06|2012-01-25|2012-01-27|Estimate|||||||2012-02-06|2012-02-07|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|MATERIAL||Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations|The Efficacy of Mepolizumab Treatment on Rhinovirus Induced Asthma Exacerbations|Unknown status|Recruiting|Phase 3|48|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 21:42:10.738511|2018-05-31 21:42:10.738511
NCT01520038|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-07-31|2012-01-25|2012-01-27|Estimate|||||||2017-07-31|2017-08-02|Actual|January 2012||2012-01-31|July 2017|2017-07-31||||December 2013|Actual|2013-12-31||Interventional|||Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer|Feasibility and Phase 1/II Trial of Adjuvant Radiation Therapy for the Treatment of Urothelial Bladder Cancer Using Proton Therapy or IMRT|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:42:10.83528|2018-05-31 21:42:10.83528
NCT01520025|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2017-04-21|2012-01-24|2012-01-27|Estimate|||||||2017-04-21|2017-04-24|Actual|December 2011||2011-12-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Multi-modality Imaging of Ischemia With 18F-FDG PET and CTA|Direct Imaging of Ischemia With 18F-FDG PET Imaging Combined With Coronary Anatomy From CT Coronary Angiography|Terminated||Phase 4|18|Actual|Ottawa Heart Institute Research Corporation||1||Continued recruitment of study participants was not feasible|f||||f||||||||||2018-05-31 21:42:10.90628|2018-05-31 21:42:10.90628
NCT01520012|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-07-23|2012-01-24|2012-01-27|Estimate|||||||2012-07-23|2012-07-24|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Food Effect on Pharmacokinetics of YH4808 in Healthy Male Subjects|Clinical Trial to Investigate the Influence of Food on Safety/Tolerability and Pharmacokinetics of YH4808 After Oral Administration in Healthy Male Subjects|Completed||Phase 1|44|Actual|Yuhan Corporation||5|||f||||t||||||||||2018-05-31 21:42:11.019094|2018-05-31 21:42:11.019094
NCT01519999|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-03-01|2012-01-24|2012-01-27|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2012||2012-05-31|March 2018|2018-03-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|CRCS-WISDM||Colorectal Cancer Screening With Improved Shared Decision Making|Colorectal Cancer Screening With Improved Shared Decision Making (CRCS-WISDM)|Completed||N/A|206721|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 21:42:11.088165|2018-05-31 21:42:11.088165
NCT01519973|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2017-04-21|2012-01-24|2012-01-27|Estimate|||||||2017-04-21|2017-04-24|Actual|August 2008||2008-08-31|April 2017|2017-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|OSCARS||Optimization of SPECT Imaging|Optimization of SPECT Cardiac Imaging Through Compensation for Attenuation, Resolution Loss and Scatter - The OSCARS|Terminated||N/A|64|Actual|Ottawa Heart Institute Research Corporation||1||Recruitment base changed due to change in clinical acquisition procedures|f||||f||||||||No|This trial has concluded and the investigators have published from the available data.|2018-05-31 21:42:12.052012|2018-05-31 21:42:12.052012
NCT01519960|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2016-07-08||2018-05-01|2012-01-24|2012-01-27|Estimate|2016-07-08|2016-08-17|Estimate||||2018-05-01|2018-05-03|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|July 2015|Actual|2015-07-31||Interventional||Full Analysis Population: All participants who were randomized into the study and who were included in any of the study analyses.|A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B|A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children With HBeAg Positive Chronic Hepatitis B|Active, not recruiting||Phase 3|165|Actual|Hoffmann-La Roche|Results presented above include final analyses of the primary endpoint and most secondary endpoints. Group D had not reached FU Week 24 at time of analysis, so basic safety data were reported. New/updated data will be reported in the final results.|4|||f||||||||||||||2018-05-31 21:42:12.288691|2018-05-31 21:42:12.288691
NCT01519947|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-11-01|2012-01-24|2012-01-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis|Comparative Study to Assess the Effect of the Altitude on Dose Requirements of Methoxy Polyethylene Glycol-epoetin Beta to Correct Haemoglobin Levels in Chronic Renal Anemia in Pre-dialysis and Dialysis Patients|Completed||Phase 4|86|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:42:15.422328|2018-05-31 21:42:15.422328
NCT01519934|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2013-12-30||2017-11-10|2012-01-26|2012-01-27|Estimate|2014-03-19|2014-04-23|Estimate||||2017-11-10|2017-12-18|Actual|October 2011||2011-10-31|November 2017|2017-11-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Observational||Subjects who had received a dual depth Ulthera treatment to the face and upper neck prior to enrollment and met all entrance criteria.|A Retrospective Study to Evaluate the Effectiveness of the Ulthera System|Retrospective Evaluation of the Ulthera System for Lifting and Tightening of the Face and Neck|Completed|||48|Actual|Merz North America, Inc.|||1||f||||f||||||||||2018-05-31 21:42:15.524757|2018-05-31 21:42:15.524757
NCT01519921|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2015-12-17||2016-03-22|2012-01-24|2012-01-27|Estimate|2015-12-17|2016-01-25|Estimate||||2016-03-22|2016-04-21|Estimate|October 2005||2005-10-31|March 2016|2016-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional||Baseline characteristics were analysed on Intent-to-treat (ITT) population which included all participants who received at least one dose of study drug. The ITT and the safety populations were identical.|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.|An Open Label Phase IV Multicenter Study for Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Patients With HBeAg Positive Chronic Hepatitis B|Completed||Phase 4|150|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:42:15.771063|2018-05-31 21:42:15.771063
NCT01519908|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-11-30|2012-01-26|2012-01-27|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|MARC||Markers and Response to Cardiac Resynchronization Therapy|Markers and Response to Cardiac Resynchronization Therapy|Completed|||240|Actual|University Medical Center Groningen|||||f||||t||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 21:42:16.151091|2018-05-31 21:42:16.151091
NCT01519895|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2015-04-14|2012-01-24|2012-01-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Effectiveness of Telephone Intervention for Colorectal Cancer Caregivers|Effectiveness of Telephone-based Intervention on Distress, Burden and Quality of Life of Chinese Caregivers of Colorectal Cancer Patients|Completed||Phase 2|140|Actual|Hospital Authority, Hong Kong||2|||f||||f||||||||||2018-05-31 21:42:16.237346|2018-05-31 21:42:16.237346
NCT01519882|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2013-12-10||2014-01-29|2012-01-26|2012-01-27|Estimate|2013-12-10|2014-01-28|Estimate||||2014-01-29|2014-03-03|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|REFRESH-PD||Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease|A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease.|Terminated||Phase 4|1|Actual|UCB Pharma|"Despite many attempts by study sites to recruit subjects, only 1 subject was randomized by Oct 2012. The decision to terminate the study was taken in Nov 2012. The subject completed in Jan 2013.~No planned efficacy/safety analyses were performed."|2||Due to major recruitment issues, a decision was made to terminate this trial|f||||f||||||||||2018-05-31 21:42:16.404256|2018-05-31 21:42:16.404256
NCT01519869|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-12-04|2012-01-26|2012-01-27|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2012||2012-03-31|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma|Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Trial Protocol|Active, not recruiting||N/A|28|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-05-31 21:42:16.68767|2018-05-31 21:42:16.68767
NCT01519856|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2016-01-28|2012-01-26|2012-01-27|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2009||2009-06-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|PIR-008/K||PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy|Efficacy and Safety of Long-term Therapy With Piribedil (CLARIUM) in Patients With M. Parkinson Under Consideration of Quality of Life Parameters and Cognitive Function|Completed|||908|Actual|Desitin Arzneimittel GmbH|||1||f||||f||||||||||2018-05-31 21:42:16.786418|2018-05-31 21:42:16.786418
NCT01519843|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-05-12|2012-01-24|2012-01-27|Estimate|||||||2017-05-12|2017-05-15|Actual|September 2010||2010-09-30|May 2017|2017-05-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Post Stroke Motor Learning|Post-stroke Procedural Learning: From Neural Substrates to Therapeutic Modulation by Non-invasive Brain Stimulation|Recruiting||N/A|100|Anticipated|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 21:42:16.85943|2018-05-31 21:42:16.85943
NCT01519830|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-02-27|2012-01-26|2012-01-27|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ISUB||Iron Substitution in Blood Donors|Significance of Iron Deficiency in Transfusion Medicine: Effects of Iron Substitution on Fatigue Und General Well Being in Healthy Blood Donors|Completed||Phase 4|405|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 21:42:16.941826|2018-05-31 21:42:16.941826
NCT01519817|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2017-02-27||2018-01-02|2012-01-26|2012-01-27|Estimate|2017-05-30|2017-07-31|Actual||||2018-01-02|2018-01-29|Actual|January 5, 2012|Actual|2012-01-05|January 2018|2018-01-31|September 1, 2016|Actual|2016-09-01|March 3, 2016|Actual|2016-03-03||Interventional|||Cancer Vaccine Targeting Brachyury Protein in Tumors|An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors|Completed||Phase 1|34|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||No||2018-05-31 21:42:17.098874|2018-05-31 21:42:17.098874
NCT01519804|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19||2016-06-29|2016-09-01|2012-01-24|2012-01-27|Estimate||||2016-06-29|2016-07-01|Estimate|2016-09-01|2016-09-02|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|January 2014|Actual|2014-01-31||Interventional|||A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (Metmab) in Combination With Paclitaxel + Cisplatin or Carboplatin as First-Line Treatment for Patients With Stage IIIb (T4 Disease) or IV Squamous Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|108|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 21:42:19.057704|2018-05-31 21:42:19.057704
NCT01519791|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2015-07-08||2018-03-14|2012-01-24|2012-01-27|Estimate|2015-08-19|2015-09-22|Estimate||||2018-03-14|2018-04-10|Actual|January 2012||2012-01-31|March 2018|2018-03-31|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|C-early|Baseline Charactersitics refer to the Randomized Set (RS).|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis|Completed||Phase 3|880|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:42:19.288982|2018-05-31 21:42:19.288982
NCT01519778|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-02-27|2014-04-02|2017-03-21|2012-01-26|2012-01-27|Estimate|2015-02-27|2015-03-12|Estimate|2014-04-02|2014-04-30|Estimate|2017-03-21|2017-04-18|Actual|February 1, 2012|Actual|2012-02-01|March 2017|2017-03-31|August 1, 2012|Actual|2012-08-01|August 1, 2012|Actual|2012-08-01||Interventional|||A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study|Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients|Completed||Phase 2|200|Actual|Trius Therapeutics LLC||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:42:21.45701|2018-05-31 21:42:21.45701
NCT01519765|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2016-03-04||2016-08-03|2012-01-24|2012-01-27|Estimate|2016-08-03|2016-09-27|Estimate||||2016-08-03|2016-09-27|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||73 participants were recruited to the study. 5 participants were excluded.|Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor|Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor: Randomized Control Trial|Terminated||Phase 4|73|Actual|University of California, Los Angeles|Limitations to the trial were termination of study due to poor recruitment, leading to small numbers of subjects analyzed.|2||Poor Enrollment|f||||t||||||||||2018-05-31 21:42:22.252834|2018-05-31 21:42:22.252834
NCT01519752|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-01-19|2012-01-24|2012-01-27|Estimate|||||||2014-01-19|2014-01-22|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site, Study Comparing Oxiconazole Nitrate Cream 1% (Taro Pharmaceuticals,Inc) to Oxistat® (Oxiconazole Nitrate Cream) Cream 1% (PharmaDerma) in the Treatment of Tinea Pedis|Completed||Phase 1|661|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 21:42:23.66966|2018-05-31 21:42:23.66966
NCT01519739|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-07-19|2012-01-26|2012-01-27|Estimate|||||||2016-07-19|2016-07-20|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|||Clinical Evaluation of Mediguide System in Cardiac Resynchronization Therapy (CRT) Implants|Clinical Evaluation of Mediguide System in CRT Implants|Completed||N/A|15|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 21:42:23.742617|2018-05-31 21:42:23.742617
NCT01519726|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-24|2012-01-24|2012-01-27|Estimate|||||||2012-01-24|2012-01-27|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|MEMO||CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug|CYP3A4 Metabolism Before and After Surgery Induced Weight Loss in Morbidly Obese Patients Using Midazolam as a Model Drug|Unknown status|Recruiting|Phase 4|20|Anticipated|St. Antonius Hospital||1|||f||||||||||||||2018-05-31 21:42:23.808794|2018-05-31 21:42:23.808794
NCT01519713|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2013-04-04||2013-05-22|2012-01-24|2012-01-27|Estimate|2013-05-22|2013-05-28|Estimate||||2013-05-22|2013-05-28|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects|Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects|Completed||Phase 3|200|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:42:23.910105|2018-05-31 21:42:23.910105
NCT01519700|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2015-03-25||2015-04-14|2012-01-24|2012-01-27|Estimate|2015-03-25|2015-04-07|Estimate||||2015-04-14|2015-05-06|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PIONEER|The safety set consists of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment|Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim|A Randomized, Double-blind, Parallel-group, Multi-center Phase III Study Comparing the Efficacy and Safety of EP2006 and Neupogen® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy|Completed||Phase 3|218|Actual|Sandoz||2|||f||||t||||||||||2018-05-31 21:42:24.436308|2018-05-31 21:42:24.436308
NCT01519687|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-26|2012-01-26|2012-01-27|Estimate|||||||2012-01-26|2012-01-27|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout|Open-Label, Inpatient Study of Levotofisopam 50 mg TID Administered for 7 Days to Men and Postmenopausal Women With Hyperuricemia and Gout|Unknown status|Recruiting|Phase 2|20|Anticipated|Pharmos||1|||f||||f||||||||||2018-05-31 21:42:25.189516|2018-05-31 21:42:25.189516
NCT01519674|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2014-10-17||2017-01-10|2012-01-24|2012-01-27|Estimate|2014-11-05|2014-11-10|Estimate||||2017-01-10|2017-02-24|Actual|June 2012||2012-06-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|SIT2MIX||Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin|A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin|Completed||Phase 4|582|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:42:25.342687|2018-05-31 21:42:25.342687
NCT01519661|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2014-12-17||2015-02-08|2012-01-26|2012-01-27|Estimate|2015-02-08|2015-02-10|Estimate||||2015-02-08|2015-02-10|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis|A Single Arm, Open-label, Multicenter, Phase IV Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis|Completed||Phase 4|157|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:42:26.201394|2018-05-31 21:42:26.201394
NCT01519648|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2014-06-18||2014-07-18|2012-01-26|2012-01-27|Estimate|2014-06-18|2014-07-18|Estimate||||2014-07-18|2014-07-25|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Observational|||A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation|A Russian Prospective Observational Study of Invasive Fungal Infections in Patients With Acute Leukemia and Hematopoietic Stem Cell Transplantation|Completed|||808|Actual|National Hematological Society, Russia|||2||f||||f||||||||||2018-05-31 21:42:26.661986|2018-05-31 21:42:26.661986
NCT01519635|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-27|2012-01-24|2012-01-27|Estimate|||||||2012-01-27|2012-01-31|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension|Effect of Aliskiren 300mg and Hydrochlorothiazide 25mg on Kidney Oxygenation in Patients With Stage 1 and 2 Hypertension: a BOLD-MRI Study|Unknown status|Recruiting|Phase 4|36|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 21:42:26.876682|2018-05-31 21:42:26.876682
NCT01519622|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-26|2012-01-26|2012-01-27|Estimate|||||||2012-01-26|2012-01-27|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Impact of Disease on the Concept of End-of-life Decisions of the Elderly in the Community||Unknown status|Not yet recruiting||88|Anticipated|Meir Medical Center|||1||f||||t||||||||||2018-05-31 21:42:26.973968|2018-05-31 21:42:26.973968
NCT01519609|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2012-11-20|2012-01-26|2012-01-27|Estimate|||||||2012-11-20|2012-11-21|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Trial Comparing Moviprep and Phosphoral as Bowel Prep Before Colonoscopy|Double Blind Randomised Trial Comparing Moviprep and Phosphoral as Bowel Prep Before|Completed||N/A|400|Actual|Randers Regional Hospital||2|||f||||f||||||||||2018-05-31 21:42:27.047317|2018-05-31 21:42:27.047317
NCT01519596|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2018-05-24|2012-01-24|2012-01-27|Estimate|||||||2018-05-24|2018-05-25|Actual|October 2012||2012-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy|Minimizing Physical Function Decline in Older Adults Receiving Chemotherapy|Active, not recruiting||N/A|70|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 21:42:27.102642|2018-05-31 21:42:27.102642
NCT01519583|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-05-04|2012-01-24|2012-01-27|Estimate|||||||2015-05-04|2015-05-05|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||WalkMore Walking Interventions for Overweight/Obese Postmenopausal Women|Title: Comparative Effectiveness of Pedometer-Based Walking Interventions: WalkMore|Unknown status|Active, not recruiting|N/A|120|Anticipated|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 21:42:27.17926|2018-05-31 21:42:27.17926
NCT01519570|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-24|2012-01-24|2012-01-27|Estimate|||||||2012-01-24|2012-01-27|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates|Use of an Electronic Medical Record to Improve Standard Practice in the Primary Care Setting: A Randomized-Controlled Study of Herpes Zoster Vaccination Rates|Completed||N/A|2589|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 21:42:27.26125|2018-05-31 21:42:27.26125
NCT01519557|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-03-03|2012-01-24|2012-01-27|Estimate|||||||2015-03-03|2015-03-04|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders|Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders|Completed||Early Phase 1|68|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 21:42:27.334635|2018-05-31 21:42:27.334635
NCT01519544|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-04-22|2012-01-26|2012-01-27|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|July 2012|Actual|2012-07-31||Interventional|||Comparison of Temazepam and Acetazolamide to Treat Difficulty Sleeping at High Altitude|Treatment of High-altitude Sleep Disturbance: A Double-blind Comparison of Temazepam Versus Acetazolamide.|Completed||N/A|34|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:42:27.411954|2018-05-31 21:42:27.411954
NCT01519531|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-12-04|2012-01-24|2012-01-27|Estimate|||||||2012-12-04|2012-12-06|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects|A Randomized, Double-blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects|Completed||Phase 1|48|Actual|Madrigal Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:42:27.681278|2018-05-31 21:42:27.681278
NCT01519518|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-04-07||2015-04-24|2012-01-24|2012-01-27|Estimate|2015-04-07|2015-04-22|Estimate||||2015-04-24|2015-05-13|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|HEAT-PPCI||How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention|A Randomised Controlled Trial to Compare Unfractionated Heparin Versus Bivalirudin in the Treatment of Patients With a Clinical Diagnosis of ST-Segment Elevation Myocardial Infarction Events - For Planned Management With Primary PCI|Completed||Phase 4|1829|Actual|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:42:27.760783|2018-05-31 21:42:27.760783
NCT01519505|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-26|2012-01-26|2012-01-27|Estimate|||||||2012-01-26|2012-01-27|Estimate|March 2005||2005-03-31|January 2012|2012-01-31|March 2012|Anticipated|2012-03-31|March 2006|Actual|2006-03-31||Interventional|DE-PLAN-CAT||Diabetes in Europe - Prevention Using Lifestyle, Physical Activity and Nutritional Intervention in Catalonia|Diabetes in Europe - Prevention Using Lifestyle, Physical Activity and Nutritional Intervention in Catalonia(DE-PLAN-CAT).|Unknown status|Active, not recruiting|N/A|2082|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 21:42:27.993617|2018-05-31 21:42:27.993617
NCT01519492|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-08-03|2012-01-24|2012-01-27|Estimate|||||||2012-08-03|2012-08-07|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci|A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci|Completed||Phase 2|103|Actual|Affinium Pharmaceuticals, Ltd||1|||f||||f||||||||||2018-05-31 21:42:28.091801|2018-05-31 21:42:28.091801
NCT01519479|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-03-27|2012-01-26|2012-01-27|Estimate|||||||2015-03-27|2015-03-31|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Palliative Care for Heart Failure Patients|An Examination of Palliative Care as Standard Practice for Heart Failure Patients|Completed||N/A|232|Actual|Abbott Northwestern Hospital||2|||f||||f||||||||||2018-05-31 21:42:28.200582|2018-05-31 21:42:28.200582
NCT01519466|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2015-11-12||2016-03-03|2012-01-24|2012-01-27|Estimate|2016-03-03|2016-04-01|Estimate||||2016-03-03|2016-04-01|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||A total of 55 subjects consented and enrolled into the study. Six of these withdrew before randomisation or failed screening. Forty-nine (49) subjects were randomised and completed the study.|Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study|Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study|Completed||N/A|55|Actual|Abbott Diabetes Care||2|||f||||f||||||||||2018-05-31 21:42:28.35829|2018-05-31 21:42:28.35829
NCT01519453|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-03-01|2012-01-26|2012-01-27|Estimate|||||||2018-03-01|2018-03-05|Actual|September 2011||2011-09-30|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|November 2017|Actual|2017-11-30||Interventional|ABC-HS||Reducing Asthma Morbidity In High Risk Minority Preschool Children|Reducing Asthma Morbidity In High Risk Minority Preschool Children NA_00046455|Active, not recruiting||N/A|401|Actual|Johns Hopkins University||2|||f||||t|f|f||||||No|We will not be sharing individual participant data with other researchers|2018-05-31 21:42:28.751392|2018-05-31 21:42:28.751392
NCT01519440|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-10-21|2012-01-26|2012-01-27|Estimate|||||||2012-10-21|2012-10-23|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Observational|||Randomized Comparison of Sharp Versus Blunt Techniques at Cesarean|Unintended Extension of the Lower Segment Uterine Incision at Cesarean Delivery;A Randomized Comparison of Sharp Versus Blunt Techniques|Completed|||1076|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital|||2||f||||||||||||||2018-05-31 21:42:28.836|2018-05-31 21:42:28.836
NCT01519427|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2013-11-27||2014-05-16|2012-01-25|2012-01-27|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||2 consented patients were not eligible for the trial|Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib|A Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600-Mutant Advanced Melanoma Whose Disease Has Progressed on Prior Therapy With a Selective BRAF Inhibitor (i.e., Vemurafenib, Dabrafenib, LGX818)|Terminated||Phase 2|2|Actual|National Cancer Institute (NCI)|Because this study terminated early due to slow accrual, data were available for only the two eligible patients that enrolled before study closure.|1||Study terminated due to slow accrual|f||||t||||||||||2018-05-31 21:42:28.923276|2018-05-31 21:42:28.923276
NCT01519414|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2017-04-24|2012-01-25|2012-01-27|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2012||2012-01-31|April 2017|2017-04-30||||August 14, 2015|Actual|2015-08-14||Interventional|||Tivantinib in Treating Patients With Metastatic Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of ARQ 197 (Tivantinib) in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer|Active, not recruiting||Phase 2|78|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 21:42:29.184543|2018-05-31 21:42:29.184543
NCT01519401|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-01-23|2012-01-23|2012-01-26|Estimate|||||||2012-01-23|2012-01-26|Estimate|February 2010||2010-02-28|January 2012|2012-01-31|July 2011|Actual|2011-07-31|||||Interventional|||Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.|Clinical Efficacy and Metabolic Impact of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Normal-weight Women With Polycystic Ovary Syndrome: a Randomized Study.|Completed||N/A|||Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 21:42:29.31558|2018-05-31 21:42:29.31558
NCT01519388|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-07-09|2012-01-25|2012-01-26|Estimate|||||||2013-07-09|2013-07-10|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|May 2013|Actual|2013-05-31|February 2012|Actual|2012-02-29||Interventional|OPTIDEG||Evaluation of the Impact on Swallowing of Non Invasive Ventilation|Evaluation of Nasal Ventilation on Optimizing Swallowing in Ventilated Neuromuscular Patients|Completed||N/A|10|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 21:42:29.388863|2018-05-31 21:42:29.388863
NCT01519375|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-05-28|2012-01-25|2012-01-26|Estimate|||||||2012-05-28|2012-05-30|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|CONVOY||Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)|Cross-sectional, Observational Real Life Study on NSAIDs Treated Patients With Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis: Assessment of Patient Adherence to PPI Treatment|Completed|||102|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:42:29.473708|2018-05-31 21:42:29.473708
NCT01519362|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-25|2012-01-25|2012-01-26|Estimate|||||||2012-01-25|2012-01-26|Estimate|October 2011||2011-10-31|January 2012|2012-01-31||||||||Observational|||A Woman Suffered From Leukocytopenia and Widespread Migration After Polyacrylamide Hydrogel (PAAG) Injection in Epicranial Aponeurosis||Completed|||1|Actual|First Hospital of Jilin University|||||f||||f||||||||||2018-05-31 21:42:29.538962|2018-05-31 21:42:29.538962
NCT01519349|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2017-11-21|2012-01-25|2012-01-26|Estimate|||||||2017-11-21|2017-11-24|Actual|January 2012||2012-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis|Phase I Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis.|Completed||Phase 1|15|Actual|Nationwide Children's Hospital||3|||f||||t||||||||||2018-05-31 21:42:29.578713|2018-05-31 21:42:29.578713
NCT01519336|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-11-01|2012-01-24|2012-01-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers|A Study to Evaluate the Potential Drug-Drug Interaction Between Darunavir and Danoprevir When Administered Together With Low-Dose Ritonavir in Healthy Volunteers|Completed||Phase 1|40|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:42:29.642784|2018-05-31 21:42:29.642784
NCT01519323|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2016-06-17||2016-08-25|2012-01-24|2012-01-26|Estimate|2016-06-17|2016-07-28|Estimate||||2016-08-25|2016-10-10|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations|An Open-label, Multicenter, Single-arm, Phase I Dose-escalation With Efficacy Tail Extension Study of Vemurafenib (RO5185426) in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations|Terminated||Phase 1|6|Actual|Hoffmann-La Roche|The study was prematurely terminated on 18 December 2015 by the Sponsor due to recruitment challenges and therefore low enrollment.|1||Study was terminated due to low enrollment.|f||||t||||||||||2018-05-31 21:42:29.71807|2018-05-31 21:42:29.71807
NCT01519310|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-03-01|2012-01-25|2012-01-26|Estimate|||||||2016-03-01|2016-03-03|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Glory||Gut Flora Dependent Metabolism of Dietary Phosphatidylcholine and Cardiovascular Disease|Gut Flora Dependent Metabolism of Dietary Phosphatidylcholine and Cardiovascular Disease|Completed||Early Phase 1|4|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 21:42:30.139112|2018-05-31 21:42:30.139112
NCT01519297|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-01-19|2012-01-25|2012-01-26|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2012||2012-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Preeclampsia: A Marker for Future Cardiovascular Risk in Women|Preeclampsia: A Marker for Future Cardiovascular Risk in Women|Recruiting||N/A|150|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 21:42:30.219344|2018-05-31 21:42:30.219344
NCT01519284|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2015-07-22||2015-07-22|2012-01-23|2012-01-26|Estimate|2015-07-22|2015-08-20|Estimate||||2015-07-22|2015-08-20|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|June 2011|Actual|2011-06-30|February 2010|Actual|2010-02-28||Interventional|||Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic|A Double-blind, Randomised, Placebo- and Active-controlled Multiple-dose Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetics Following a Levodopa/Carbidopa 100/25 mg Single-dose in Healthy Subjects|Completed||Phase 1|82|Actual|Bial - Portela C S.A.||5|||f||||f||||||||||2018-05-31 21:42:30.322371|2018-05-31 21:42:30.322371
NCT01519271|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2016-05-24||2017-02-22|2012-01-23|2012-01-26|Estimate|2017-02-22|2017-04-07|Actual||||2017-02-22|2017-04-07|Actual|December 2011||2011-12-31|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Mild Cognitive Impairment in Parkinson's Disease|A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease|Completed||Phase 4|28|Actual|University of Pennsylvania|"The small sample size may have limited our power to detect a treatment effect.~When the study was conducted, the maximum strength of the rivastigmine patch was 9.5 mg/24 h. Since then, a higher dose has been approved by the FDA."|2|||f||||f||||||||||2018-05-31 21:42:30.866589|2018-05-31 21:42:30.866589
NCT01519258|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2013-09-13|2012-01-23|2012-01-26|Estimate|||||||2013-09-13|2013-09-16|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Mechanical Ventilation With Neurally-Adjusted Ventilatory Assist in Patients With ARDS|Performance of NAVA as Lung Protective Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome|Unknown status|Recruiting|N/A|20|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 21:42:31.100881|2018-05-31 21:42:31.100881
NCT01519245|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2012-12-06||2013-05-27|2012-01-25|2012-01-26|Estimate|2013-05-27|2013-07-02|Estimate||||2013-05-27|2013-07-02|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery|Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery|Completed||Phase 3|44|Actual|University of Saskatchewan|"Small sample size~Low-risk CABG patients enrolled only~Break in protocol, with pre-pump TXA not given to 2 participants, and post-pump TXA given to 8 participants~Short study period, with no long-term follow-up data"|2|||f||||f||||||||||2018-05-31 21:42:31.195439|2018-05-31 21:42:31.195439
NCT01519232|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2015-05-14|2012-01-23|2012-01-26|Estimate|||||||2015-05-14|2015-05-18|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|June 2012|Actual|2012-06-30||Observational|||A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)|A Pilot Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary SPECT|Completed|||23|Actual|University of Michigan Cancer Center|||1||f||||t||||||||||2018-05-31 21:42:32.797453|2018-05-31 21:42:32.797453
NCT01519219|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2018-05-30|2012-01-25|2012-01-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2003||2003-01-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|IC-Green||Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation|Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation|Recruiting|||240|Anticipated|University of Michigan Cancer Center|||1||f||||t||||||||||2018-05-31 21:42:32.866715|2018-05-31 21:42:32.866715
NCT01519206|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2014-03-20||2017-11-10|2012-01-25|2012-01-26|Estimate|2014-05-22|2014-06-02|Estimate||||2017-11-10|2017-12-11|Actual|August 2011||2011-08-31|November 2017|2017-11-30|March 2013|Actual|2013-03-31|February 2012|Actual|2012-02-29||Interventional|||Lifting and Tightening of the Face and Neck Following an Increased Density Treatment|Evaluation of the Efficacy and Safety of the Ulthera® System for Lifting and Tightening of the Face and Neck Following an Increased Density Treatment.|Completed||N/A|32|Actual|Merz North America, Inc.|3-D digital imaging was not completed, thus quantitative measure of submental skin lift was not obtained.|1|||f||||f||||||||||2018-05-31 21:42:32.965544|2018-05-31 21:42:32.965544
NCT01519193|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-11-06|2012-01-23|2012-01-26|Estimate|||||||2012-11-06|2012-11-07|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Treatment of Aggressive Behavior and Post-Traumatic Stress Disorder|Treatment of Aggressive Behavior and Post-Traumatic Stress Disorder in Former Street Children and Vulnerable Children in Burundi With Narrative Exposure Therapy for Violent Offenders|Completed||Phase 2|42|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 21:42:33.265787|2018-05-31 21:42:33.265787
NCT01519180|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2014-09-05|2012-01-25|2012-01-26|Estimate|||||||2014-09-05|2014-09-08|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Antro-pyloro-duodenal Motility in Idiopathic Gastroparesis|Study of the Antro-pyloro-duodenal Motor Dysfunction in Idiopathic Gastroparesis|Completed|||32|Actual|University Hospital, Rouen|||2||f||||t||||||||||2018-05-31 21:42:33.339011|2018-05-31 21:42:33.339011
NCT01519167|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-05-05||2017-03-16|2012-01-24|2012-01-26|Estimate|2015-08-07|2015-08-14|Estimate||||2017-03-16|2017-03-20|Actual|October 2012||2012-10-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety Evaluable Population: All subjects who receive any amount of study drug. All safety analyses will be performed on this population.|Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation|Phase IV, Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation|Completed||Phase 4|91|Actual|Hospira, now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-05-31 21:42:33.545978|2018-05-31 21:42:33.545978
NCT01519154|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-11-26|2012-01-25|2012-01-26|Estimate|||||||2014-11-26|2014-12-02|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Sedation MRI - Propofol Versus Propofol-Ketamin in Children|Untersuchung Unterschiedlicher Sedationstechniken für Elektive Magnetresonanztomographie (MRT)-Diagnostik Bei Kindern Anhand Klinischer Und MRT-basierter Outcomeparameter (Propofol Versus Propofol-Ketamin)|Completed||Phase 3|347|Actual|University Children's Hospital, Zurich||2|||f||||t||||||||||2018-05-31 21:42:34.208855|2018-05-31 21:42:34.208855
NCT01519141|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-05-03|2012-01-23|2012-01-26|Estimate|||||||2017-05-03|2017-05-05|Actual|July 2003||2003-07-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection|Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases|Active, not recruiting|||400|Anticipated|University of California, San Francisco|||2||f||||f||||||||||2018-05-31 21:42:34.316858|2018-05-31 21:42:34.316858
NCT01519128|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2013-03-01|2012-01-23|2012-01-26|Estimate|||||||2013-03-01|2013-03-04|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin|A Phase I, Open Label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Effect of Steady-state TMC278 on the Pharmacokinetics of a Single Dose of Digoxin|Completed||Phase 1|22|Actual|Janssen R&D Ireland||2|||f||||f||||||||||2018-05-31 21:42:34.38599|2018-05-31 21:42:34.38599
NCT01519115|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-01-09|2012-01-23|2012-01-26|Estimate|||||||2015-01-09|2015-01-13|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ACF||Comparison of Outcomes Between Early Physical Therapy Intervention and Usual Care Following Anterior Cervical Fusion Surgery|A Comparison of Clinic Outcomes Between Early Physical Therapy Intervention and Usual Care in Individuals Following Anterior Cervical Fusion|Completed||N/A|40|Actual|Texas Woman's University||2|||f||||t||||||||||2018-05-31 21:42:34.524462|2018-05-31 21:42:34.524462
NCT01519102|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-12-07|2012-01-25|2012-01-26|Estimate|||||||2012-12-07|2012-12-10|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CLASS02||Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting|An Open-label, Randomized Two-way, Cross-over Study to Compare Meal-and-carbohydrate-announcement Strategy Versus Meal-announcement Strategy During Closed-loop Regulation of Glucose Levels in a Morning Meal in Adults With Type-1 Diabetes.|Completed||Phase 2|12||Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 21:42:34.631123|2018-05-31 21:42:34.631123
NCT01519089|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2015-01-08||2015-08-06|2012-01-25|2012-01-26|Estimate|2015-08-06|2015-08-13|Estimate||||2015-08-06|2015-08-13|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis|A Phase 3, Multi Site, Randomized, Double Blind Study Of The Long-term Safety, Tolerability And Efficacy Of 2 Oral Doses Of Cp 690,550 In Subjects With Moderate To Severe Plaque Psoriasis And/or Psoriatic Arthritis|Completed||Phase 3|95|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:42:34.880649|2018-05-31 21:42:34.880649
NCT01519076|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2014-12-08|2012-01-23|2012-01-26|Estimate|||||||2014-12-08|2014-12-10|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||A Safety Evaluation of the Use of Magnetic-guided Iron Particles|A Feasibility Study: A Safety Evaluation of the Use of Magnetic-guided Iron Particles Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)|Terminated||Phase 1|7|Actual|Pulse Therapeutics||||Sponsor Request|f||||t||||||||||2018-05-31 21:42:38.320007|2018-05-31 21:42:38.320007
NCT01519063|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2017-05-16|2012-01-25|2012-01-26|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2012|Actual|2012-01-31|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|March 29, 2017|Actual|2017-03-29||Interventional|||Naltrexone and Memantine Effects on Alcohol Drinking Behaviors|Glutamate-opioid Interactions in Alcohol Drinking Behaviors|Completed||Phase 2|75|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:42:38.498106|2018-05-31 21:42:38.498106
NCT01519050|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-01-25|2012-01-25|2012-01-26|Estimate|||||||2012-01-25|2012-01-26|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||Predictors of Postoperative Left Ventricular Function in Patients Undergoing Mitral Valve Repair for Severe Degenerative Mitral Regurgitation||Unknown status|Recruiting||100|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 21:42:38.733436|2018-05-31 21:42:38.733436
NCT01519037|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-01-28|2012-01-24|2012-01-26|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|||Interaction Between a Calcimimetic Agent and the Renin Angiotensine Aldosterone System|Evaluation of the Interaction Between a Calcimimetic Agent (Cinacalcet) and the Renin Angiotensine Aldosterone System in Healthy Volunteers|Completed||N/A|18|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||Yes|Publication|2018-05-31 21:42:38.818171|2018-05-31 21:42:38.818171
NCT01519024|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-01-25|2012-01-25|2012-01-26|Estimate|||||||2012-01-25|2012-01-26|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Observational|||Postural Control in Breast Hypertrophy|Poorer Postural Control in Women With Breast Hypertrophy.|Completed|||28|Actual|University of Sao Paulo General Hospital|||2||f||||f||||||||||2018-05-31 21:42:38.910802|2018-05-31 21:42:38.910802
NCT01518842|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|||2017-07-18|2012-01-25|2012-01-26|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2011||2011-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|June 2014|Actual|2014-06-30||Interventional|RetinaCell||Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy|Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy|Active, not recruiting||N/A|30|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 21:42:41.413337|2018-05-31 21:42:41.413337
NCT01519011|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-03-24|2012-01-24|2012-01-26|Estimate|||||||2016-03-24|2016-03-25|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine|A PHASE 1, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND EFFECT OF FOOD OF A NEW TABLET FORMULATION OF ORAL AZACITIDINE, AND TO EVALUATE THE SAFETY AND EFFICACY OF ORAL AZACITIDINE IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA|Completed||Phase 1|34|Actual|Celgene Corporation||7|||f||||f||||||||||2018-05-31 21:42:38.978313|2018-05-31 21:42:38.978313
NCT01518998|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-06-29|2012-01-24|2012-01-26|Estimate|||||||2016-06-29|2016-07-01|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension||Completed||Phase 2|420|Actual|Boryung Pharmaceutical Co., Ltd||9|||f||||t||||||||||2018-05-31 21:42:39.217817|2018-05-31 21:42:39.217817
NCT01518985|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-04-17|2012-01-25|2012-01-26|Estimate|||||||2012-04-17|2012-04-19|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking|A Phase 1, Placebo-Controlled Trial to Evaluate the Impact of Intravenous (IV) Bendavia™ (MTP-131) on Endothelial Reactivity Dysfunction Induced by Cigarette Smoking|Completed||Phase 1|6|Actual|Stealth BioTherapeutics Inc.||2|||f||||f||||||||||2018-05-31 21:42:39.363578|2018-05-31 21:42:39.363578
NCT01518972|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-08-13|2012-01-25|2012-01-26|Estimate|||||||2012-08-13|2012-08-15|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder|A Placebo-Controlled Trial of Prazosin in Individuals With Co-occurring Alcohol Dependence and PTSD Seeking Abstinence|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|Seattle Institute for Biomedical and Clinical Research||2|||f||||t||||||||||2018-05-31 21:42:39.461399|2018-05-31 21:42:39.461399
NCT01518959|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-11-18|2012-01-25|2012-01-26|Estimate|||||||2014-11-18|2014-11-20|Estimate|January 2012||2012-01-31|November 2014|2014-11-30||||January 2017|Anticipated|2017-01-31||Interventional|D-HEM||The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases|Phase III, Controlled, Double-blind, Randomized Study of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases|Unknown status|Recruiting|Phase 3|50|Anticipated|Semmelweis University||2|||f||||f||||||||||2018-05-31 21:42:39.599738|2018-05-31 21:42:39.599738
NCT01518946|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2014-07-03||2014-10-10|2012-01-25|2012-01-26|Estimate|2014-07-03|2014-07-31|Estimate||||2014-10-10|2014-10-20|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Randomized Safety Analysis Set defined as all subjects who received at least 1 dose of randomized investigational product.|Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension|A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension|Completed||Phase 4|24|Actual|Shire||2|||f||||t||||||||||2018-05-31 21:42:39.712481|2018-05-31 21:42:39.712481
NCT01518933|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-03-04|2012-01-25|2012-01-26|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|LEG-SIL-LTX-02||Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of LEGALON SIL for the Treatment of HCV Recurrence in Stable Liver Transplanted Patients|Terminated||Phase 2|20|Actual|Rottapharm||2||when a blind review highlighted that at least 43% of patients had a virological response|f||||f||||||||||2018-05-31 21:42:40.241474|2018-05-31 21:42:40.241474
NCT01518920|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-04-01|2012-01-23|2012-01-26|Estimate|||||||2013-04-01|2013-04-04|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-04958242 In Subjects With Age-Related Sensorineural Hearing Loss|Completed||Phase 1|44|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:42:40.502872|2018-05-31 21:42:40.502872
NCT01518907|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2015-03-17|2012-01-24|2012-01-26|Estimate|||||||2015-03-17|2015-03-19|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)|A Phase 1b, Open-label, Dose-escalation Study of the Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy Commonly Known as Cellulite|Completed||Phase 1|99|Actual|Endo Pharmaceuticals||11|||f||||f||||||||||2018-05-31 21:42:40.650493|2018-05-31 21:42:40.650493
NCT01518894|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-05-05|2012-01-23|2012-01-26|Estimate|||||||2012-05-05|2012-05-08|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia|Completed||Phase 1|30|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:42:41.009811|2018-05-31 21:42:41.009811
NCT01518881|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-01-08|2012-01-25|2012-01-26|Estimate|||||||2014-01-08|2014-01-09|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion|A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability and Pharmacokinetics of TKM-100201 in Healthy Human Volunteers|Terminated||Phase 1|24|Actual|Arbutus Biopharma Corporation||2||Corporate decision to reformulate the investigational product.|f||||t||||||||||2018-05-31 21:42:41.1402|2018-05-31 21:42:41.1402
NCT01518868|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-08-10|2012-01-24|2012-01-26|Estimate|||||||2012-08-10|2012-08-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:42:41.234022|2018-05-31 21:42:41.234022
NCT01518855|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-24|2012-01-24|2012-01-26|Estimate|||||||2012-01-24|2012-01-26|Estimate|March 2004||2004-03-31|January 2012|2012-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension|Clinical Effect and Cost Effectiveness of Ca Antagonist in Combination With AII Receptor Antagonist in Patient With Essential Hypertension (PMS Study)|Completed||Phase 4|514|Actual|Bayer||2|||f||||f||||||||||2018-05-31 21:42:41.284022|2018-05-31 21:42:41.284022
NCT01518829|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2013-09-29|2012-01-24|2012-01-26|Estimate|||||||2013-09-29|2013-10-01|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Procalcitonin in Hepatocellular Carcinoma|Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment|Completed|||42|Actual|Ain Shams University|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:42:41.501388|2018-05-31 21:42:41.501388
NCT01518816|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-01-26|2012-01-25|2012-01-26|Estimate|||||||2012-01-26|2012-01-30|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Observational|||Role of Serum Total Antioxidant Level in Preterm Labor|the Role of Serum Total Antioxidant Level in Preterm Labor|Unknown status|Recruiting||70|Anticipated|Ain Shams Maternity Hospital|||2||f||||t||||||None Retained|"~     serum~   "|||2018-05-31 21:42:41.567063|2018-05-31 21:42:41.567063
NCT01518803|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-09-20|2012-01-25|2012-01-26|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Mediterranean-style Breakfast and Postprandial Lipid Disorders in Obese Pre-adolescents and Adults|Influence of a Mediterranean-style Breakfast on Postprandial Lipid Disorders and Inflammatory Processes in Obese Pre-adolescents and Adults|Completed||N/A|48|Actual|National Research Council, Spain||2|||f||||f||||||||||2018-05-31 21:42:41.725617|2018-05-31 21:42:41.725617
NCT01518790|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2016-02-09|2012-01-23|2012-01-26|Estimate|||||||2016-02-09|2016-02-10|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children|Evaluation of Short Course, Single-dose Polyethylene Glycol (PEG) 3350 Regimen for Colonoscopy Bowel Preparation in Children|Completed||N/A|50|Actual|Walter Reed National Military Medical Center||1|||f||||t||||||||||2018-05-31 21:42:41.809881|2018-05-31 21:42:41.809881
NCT01518777|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2017-02-08|2012-01-25|2012-01-26|Estimate|||||||2017-02-08|2017-02-09|Estimate|January 2012||2012-01-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Reducing Radioisotope Dose: the Half-Dose CZT Study|Reducing Radioisotope Dose in Regadenoson SPECT Myocardial Perfusion Imaging: Comparison of Half-Dose Scans Using a Novel Solid-State-Detector Dedicated Cardiac Camera to Full Dose Scans Acquired On Standard Equipment|Recruiting||N/A|50|Anticipated|The Methodist Hospital System||1|||f||||f||||||||Undecided|To be determined.|2018-05-31 21:42:41.906789|2018-05-31 21:42:41.906789
NCT01518764|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2014-11-24|2012-01-25|2012-01-26|Estimate|||||||2014-11-24|2014-11-25|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effects of Red Wine Polyphenols on Microvascular Dysfunction|The Effects of Red Wine Polyphenols on Microvascular Dysfunction|Completed||N/A|29|Actual|VU University Medical Center||2|||f||||||||||||||2018-05-31 21:42:42.046288|2018-05-31 21:42:42.046288
NCT01518751|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2015-09-29|2012-01-23|2012-01-26|Estimate|||||||2015-09-29|2015-09-30|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease - Evolution|Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease - Evolution A Monocentric Study to Investigate the Development of Symptoms of Autonomic Dysregulation in Parkinson`s Disease|Completed|||27|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 21:42:42.116379|2018-05-31 21:42:42.116379
NCT01518738|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2014-06-03|2012-01-23|2012-01-26|Estimate|||||||2014-06-03|2014-06-05|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Attention Training|Attention Training|Completed||N/A|94|Actual|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 21:42:42.209764|2018-05-31 21:42:42.209764
NCT01518725|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-04-27|2012-01-23|2012-01-26|Estimate|||||||2015-04-27|2015-04-29|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Vitamin D Supplementation on Muscle Power in Elite Cyclist|The Effect of Vitamin D Supplementation on Muscle Power in Elite Cyclist|Completed||Phase 4|103|Actual|Oklahoma State University||2|||f||||t||||||||||2018-05-31 21:42:42.327109|2018-05-31 21:42:42.327109
NCT01518712|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2012-08-28|2012-01-25|2012-01-26|Estimate|||||||2012-08-28|2012-08-29|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagl|Completed||Phase 1|64|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 21:42:42.428276|2018-05-31 21:42:42.428276
NCT01518699|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2013-07-22|2012-01-25|2012-01-26|Estimate|||||||2013-07-22|2013-07-23|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers|A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Male and Female Adult Subjects, Preceded by a Dose-Escalation Study to Determine the Supratherapeutic Dose of Ha44|Completed||Phase 1|81|Actual|Hatchtech Pty Ltd||6|||f||||f||||||||||2018-05-31 21:42:42.51684|2018-05-31 21:42:42.51684
NCT01518686|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-12-10|2012-01-25|2012-01-26|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2006||2006-06-30|December 2013|2013-12-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|Norm-Oct900||Age-related Normative Values for the Octopus 900 Perimeter|Normal Values for the Full Visual Field, Corrected for Age- and Reaction Time, Using Semi-automated Kinetic Testing on the Octopus 900 Perimeter|Completed||N/A|86|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 21:42:42.611353|2018-05-31 21:42:42.611353
NCT01518673|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2014-12-04|2012-01-25|2012-01-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Observational|PedCTBe||Low Dose Effects of X-rays in Pediatric Patients Undergoing a CT Examination.|National Study of Low Dose Effects of X-rays in Pediatric Patients Undergoing a CT Examination.|Unknown status|Recruiting||120|Anticipated|University Ghent|||1||f||||f||||||Samples With DNA|"~     Blood lymphocytes~   "|||2018-05-31 21:42:42.765409|2018-05-31 21:42:42.765409
NCT01518660|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-12-01|2012-01-25|2012-01-26|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Multiple Sclerosis and Progressive Resistance Training|Multiple Sclerosis - Inflammatory, Neurological and Muscular Adaptations to Progressive Resistance Training|Completed||N/A|35|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:42:42.920318|2018-05-31 21:42:42.920318
NCT01518647|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-05-08|2012-01-25|2012-01-26|Estimate|||||||2017-05-08|2017-05-09|Actual|January 25, 2012|Actual|2012-01-25|May 2017|2017-05-31|February 9, 2016|Actual|2016-02-09|August 25, 2015|Actual|2015-08-25||Interventional|Stress-4||Acceptance and Commitment Therapy for Patients With Multi-organ Bodily Distress Syndrome (Stress-4)|Treatment of Multi-organ Bodily Distress Syndrome. A Randomized Controlled Trial of the Effects of Acceptance and Commitment Therapy Given as Group Therapy or Workshop Compared to Standard Treatment (Stress-4)|Completed||N/A|180|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 21:42:42.986325|2018-05-31 21:42:42.986325
NCT01518634|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-05-08|2012-01-25|2012-01-26|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2012||2012-01-31|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional|Stress-3||Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome|Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3)|Completed||Phase 2|138|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:42:43.07944|2018-05-31 21:42:43.07944
NCT01518621|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-06-22|2012-01-25|2012-01-26|Estimate|||||||2017-06-22|2017-06-23|Actual|May 2012||2012-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|RadEr||Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer|Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer|Terminated||Phase 2|25|Actual|Oslo University Hospital||2||Slow accrual|f||||f||||||||||2018-05-31 21:42:43.159573|2018-05-31 21:42:43.159573
NCT01518608|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2012-01-25|2012-01-25|2012-01-26|Estimate|||||||2012-01-25|2012-01-26|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Alfentanil and the Elimination of Sympathetic Responses to Tracheal Intubation During Rapid Sequence Induction of Anesthesia: A Probability-based Approach|Alfentanil and the Elimination of Sympathetic Responses to Tracheal Intubation During Rapid Sequence Induction of Anesthesia: A Probability-based Approach|Completed||Phase 4|84|Actual|Oslo University Hospital|||||f||||f||||||||||2018-05-31 21:42:43.230809|2018-05-31 21:42:43.230809
NCT01518595|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2016-09-27|2012-01-25|2012-01-26|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2011||2011-10-31|September 2016|2016-09-30||||April 2014|Actual|2014-04-30||Interventional|||Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis|Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis - a Prospective Double Blind Randomized Controlled Clinical Study|Terminated||Phase 2|6|Actual|Medical University of Vienna||2||too slow patient recruitment|f||||||||||||||2018-05-31 21:42:43.322585|2018-05-31 21:42:43.322585
NCT01518582|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2016-06-27|2012-01-25|2012-01-26|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||GRANVIA®-C Cervical Disc Prosthesis Multicenter European Pilot Study|The GRANVIA®-C Cervical Disc Prosthesis to Treat Symptomatic Degenerative Disc Diseases|Completed|||70|Actual|Medicrea International|||1||f||||f||||||||||2018-05-31 21:42:43.431732|2018-05-31 21:42:43.431732
NCT01518569|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-01-25|2012-01-25|2012-01-26|Estimate|||||||2012-01-25|2012-01-26|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|ulistin||Ulinastatin's Anti-inflammatory Reaction in Cardiac Surgery|Effect of Ulinastatin on Postoperative Systemic Inflammatory Response in Cardiac Surgery|Completed||Phase 4|26|Actual|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 21:42:43.753895|2018-05-31 21:42:43.753895
NCT01518556|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2018-03-12|2012-01-25|2012-01-26|Estimate|||||||2018-03-12|2018-03-13|Actual|July 2011|Actual|2011-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|IDAML||Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia|Phase I/II Clinical Study of Idarubicin Dose Intensification for Remission Induction Therapy in Acute Myeloid Leukemia Patients Age of 65 Years or Less|Recruiting||Phase 1/Phase 2|67|Anticipated|Konkuk University Medical Center||1|||f||||t||||||||||2018-05-31 21:42:43.861221|2018-05-31 21:42:43.861221
NCT01518543|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2014-09-10|2012-01-25|2012-01-26|Estimate|||||||2014-09-10|2014-09-11|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Observational|||Follow-up of Patient Implanted With the Staple ASTUS®|Follow-up of Patient Implanted With the Staple ASTUS®|Terminated|||5|Actual|Integra LifeSciences Services|||1||f||||f||||||||||2018-05-31 21:42:43.955894|2018-05-31 21:42:43.955894
NCT01518530|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2013-05-07||2013-08-22|2012-01-25|2012-01-26|Estimate|2013-08-22|2013-10-29|Estimate||||2013-08-22|2013-10-29|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||One patient dropped out of the experiment due to lack of necessary documentation required for inclusion.|Tailored Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain||Completed||Phase 2|10|Actual|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 21:42:44.049534|2018-05-31 21:42:44.049534
NCT01518517|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2017-02-06|2012-01-25|2012-01-26|Estimate|||||||2017-02-06|2017-02-07|Estimate|December 2009|Actual|2009-12-31|March 2016|2016-03-31|October 2016|Actual|2016-10-31|September 2014|Actual|2014-09-30||Interventional|GRASPIVOTALL||GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia|Phase 2/3 Study Evaluating Efficacy and Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA)Versus Reference L-asparaginase Treatment in Combination With Standard Polychemotherapy in Patient With First Recurrence of Philadelphia Negative Acute Lymphoblastic Leukemia|Completed||Phase 2/Phase 3|80|Actual|ERYtech Pharma||2|||f||||t||||||||Undecided||2018-05-31 21:42:44.386415|2018-05-31 21:42:44.386415
NCT01518504|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-11-19|2012-01-25|2012-01-26|Estimate|||||||2012-11-19|2012-11-21|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effects of Thoracic Mobilization on Shoulder Range of Motion|Effects of Thoracic Mobilization on Shoulder Range of Motion|Completed||N/A|40|Actual|Creighton University||2|||f||||f||||||||||2018-05-31 21:42:44.715629|2018-05-31 21:42:44.715629
NCT01518491|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-06-21|2012-01-25|2012-01-26|Estimate|||||||2017-06-21|2017-06-23|Actual|April 2012||2012-04-30|June 2017|2017-06-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Open Label Trial of NanoDOX Hydrogel in Orthopedic Trauma Wounds With and Without Vacuum Assisted Closure Therapy|A Prospective, Randomized, Open Label Trial of NanoDOX™ Hydrogel Plus Vacuum Assisted Closure Therapy Versus Vacuum Assisted Closure Therapy Alone in Orthopedic Trauma Wounds.|Withdrawn||Phase 2|0|Actual|NanoSHIFT LLC||2|||f||||f||||||||||2018-05-31 21:42:44.7929|2018-05-31 21:42:44.7929
NCT01518478|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-02-27|2012-01-23|2012-01-26|Estimate|||||||2017-02-27|2017-03-01|Actual|November 2011||2011-11-30|February 2017|2017-02-28|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot|An Open Label Study in Adults With Atopic Dermatitis to Assess Variability in Immune Response to Fluzone® Intradermal Vaccine|Completed||Early Phase 1|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-05-31 21:42:44.86967|2018-05-31 21:42:44.86967
NCT01518465|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-11-27|2012-01-23|2012-01-26|Estimate|||||||2017-11-27|2017-11-29|Actual|January 9, 2012|Actual|2012-01-09|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|December 31, 2016|Actual|2016-12-31||Interventional|||Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma|A Phase 2 Study of Lenalidomide and Low-dose Dexamethasone in Combination With Dalteparin in Previously Untreated Multiple Myeloma|Terminated||Phase 2|13|Actual|University of Southern California||2||Insufficient Accrual|f||||t||||||||||2018-05-31 21:42:44.966747|2018-05-31 21:42:44.966747
NCT01518452|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2017-06-13|2012-01-25|2012-01-26|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2011|Actual|2011-04-30|June 2017|2017-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Computerized Working Memory Training in Very-low-birth-weight Children at Preschool Age|Computerized Working Memory Training Evaluated With Clinical Assessments and Quantitative EEG in Very-low-birth-weight (VLBW) Children at Preschool Age|Completed||N/A|20|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 21:42:45.081617|2018-05-31 21:42:45.081617
NCT01518439|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2013-07-18|2012-01-25|2012-01-26|Estimate|||||||2013-07-18|2013-07-19|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|January 2012|Actual|2012-01-31||Interventional|OPTICOUGH||Instrumental and Manual Increase of Couch in Neuromuscular Patients|Instrumental and Manual Increase of Couch in Neuromuscular Patients: Effects of Different Techniques on the Generated Flow|Completed||N/A|20|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 21:42:45.182156|2018-05-31 21:42:45.182156
NCT01518426|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-05-05|2012-01-25|2012-01-26|Estimate|||||||2014-05-05|2014-05-06|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|3Electrods||Evaluation of Evoked Potentials Recording Modalities in Healthy Volunteer Population|Evaluation of Evoked Potentials Recording Modalities in Healthy Volunteer Population.|Completed||Early Phase 1|10|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||t||||||||||2018-05-31 21:42:45.26217|2018-05-31 21:42:45.26217
NCT01518413|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2015-02-26|2012-01-25|2012-01-26|Estimate|||||||2015-02-26|2015-02-27|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors|Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors|Completed||Phase 1|17|Actual|Children's Research Institute||1|||f||||t||||||||||2018-05-31 21:42:45.342856|2018-05-31 21:42:45.342856
NCT01518400|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-04-30|2012-01-25|2012-01-26|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2009||2009-02-28|April 2018|2018-04-30|December 2050|Anticipated|2050-12-31|January 2050|Anticipated|2050-01-31||Observational|||LIFE Cancer Survivorship Database for Pediatric Cancer|A Research Database for Survivors of Childhood Cancer|Recruiting|||5000|Anticipated|Children's Hospital Los Angeles|||1||f||||f||||||||||2018-05-31 21:42:45.42735|2018-05-31 21:42:45.42735
NCT01518387|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-03-10|2012-01-25|2012-01-26|Estimate|||||||2016-03-10|2016-03-14|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients|Phase III Open Study of BAY 77 1931 (Lanthanum Carbonate) in Patients With Hyperphosphatemia Undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD)|Completed||Phase 3|43|Actual|Bayer||1|||f||||f||||||||||2018-05-31 21:42:45.511572|2018-05-31 21:42:45.511572
NCT01518374|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-06-09|2012-01-23|2012-01-26|Estimate|||||||2017-06-09|2017-06-12|Actual|December 2009||2009-12-31|June 2017|2017-06-30|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||Clinical Evaluation of Florbetapir F 18 (18F-AV-45)|Clinical Evaluation of Florbetapir F 18 (18F-AV-45)|Completed||Phase 2|1772|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 21:42:45.62032|2018-05-31 21:42:45.62032
NCT01518348|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-02-26|2012-01-23|2012-01-26|Estimate|||||||2013-02-26|2013-02-27|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|PREAII||Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents|Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents|Withdrawn||Phase 3|0|Actual|Allerderm||1||Study has been updated with new protocol number|f||||f||||||||||2018-05-31 21:42:45.739188|2018-05-31 21:42:45.739188
NCT01518335|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-05-08|2012-01-23|2012-01-26|Estimate|||||||2017-05-08|2017-05-10|Actual|June 2009||2009-06-30|May 2017|2017-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|PRP||Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department|A Double-Blind, Randomized, Placebo Controlled Study Evaluating the Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department.|Completed||N/A|38|Actual|Albert Einstein Healthcare Network||2|||f||||t||||||||No||2018-05-31 21:42:45.840754|2018-05-31 21:42:45.840754
NCT01518322|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|2013-03-16||2013-06-11|2012-01-25|2012-01-26|Estimate|2013-06-11|2013-08-30|Estimate||||2013-06-11|2013-08-30|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational||A total of 235 subjects were included in the All Subjects Population. 13 of the 235 subjects were missing the FeNO measurement.|Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms|An Observational, Multi-Center, Single-Visit Study to Assess the Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms|Completed|||235|Actual|Aerocrine AB|Physicians were blinded to FeNO results during the study, therefore asthma diagnoses and ICS prescriptions were made without knowledge of FeNO results.||1||f||||f||||||||||2018-05-31 21:42:45.916716|2018-05-31 21:42:45.916716
NCT01518309|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2017-04-18|2012-01-25|2012-01-26|Estimate|||||||2017-04-18|2017-04-19|Actual|November 2004||2004-11-30|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients||Completed||Phase 2|39|Actual|ACADIA Pharmaceuticals Inc.||1|||f||||||||||||||2018-05-31 21:42:46.116085|2018-05-31 21:42:46.116085
NCT01518296|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|||2013-03-28|2012-01-22|2012-01-25|Estimate|||||||2013-03-28|2013-03-29|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Rating Pelvic Organs Prolapse in Women According to the POPQ Method Before and After Emptying the Urinary Bladder|Rating the Degree of Pelvic Organs Prolapse in Women According to the POPQ Method Before and After Emptying the Urinary Bladder|Unknown status|Recruiting|N/A|80|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 21:42:46.17186|2018-05-31 21:42:46.17186
NCT01518283|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-06-29|2012-01-21|2012-01-25|Estimate|||||||2017-06-29|2017-07-02|Actual|May 2012||2012-05-31|November 2015|2015-11-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Study of Weekly Cabazitaxel for Advanced Prostate Cancer|"Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in Unfit Hormone-Refractory Patients Previously Treated With Docetaxel"|Completed||Phase 2|74|Actual|Spanish Oncology Genito-Urinary Group||1|||f||||f||||||||||2018-05-31 21:42:46.240213|2018-05-31 21:42:46.240213
NCT01518257|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2014-07-15|2014-01-27|2014-07-15|2012-01-23|2012-01-25|Estimate|2014-07-15|2014-08-07|Estimate|2014-01-27|2014-02-27|Estimate|2014-07-15|2014-08-07|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A as Treatment for Osteoarthritis Knee Pain||Completed||Phase 1/Phase 2|121|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:42:46.499837|2018-05-31 21:42:46.499837
NCT01518244|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2014-02-25||2015-07-17|2012-01-23|2012-01-25|Estimate|2014-02-25|2014-04-04|Estimate||||2015-07-17|2015-08-07|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||The analysis population includes all participants who received AZARGA® and with at least one on-therapy study visit (V2 or V3). Of the 50 enrolled, 1 participant discontinued after V1 and before V2.|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America|Completed||Phase 4|50|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:42:47.112701|2018-05-31 21:42:47.112701
NCT01518231|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|AHSCTIS||Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke|Phase 1 Study of Autologous Peripheral Hematopoietic Stem Cell Transplantation in Ischemic Stroke|Unknown status|Recruiting|Phase 1|40|Anticipated|Zhejiang Hospital||2|||f||||f||||||||||2018-05-31 21:42:47.308513|2018-05-31 21:42:47.308513
NCT01518218|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2015-04-09|2012-01-21|2012-01-25|Estimate|||||||2015-04-09|2015-04-13|Estimate|March 2006||2006-03-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|March 2007|Actual|2007-03-31||Interventional|||Effectiveness of Laying-on-of-hands for Sickle Cell Disease|Effectiveness of Laying-on-of-hands for Patients With Sickle Cell Disease in Africa|Completed||Phase 2|40|Actual|MOA Health Science Foundation||2|||f||||t||||||||||2018-05-31 21:42:47.431941|2018-05-31 21:42:47.431941
NCT01518205|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|||2017-01-02|2012-01-24|2012-01-25|Estimate|||||||2017-01-02|2017-01-04|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|HADIF||HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)|HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F): a RCTrial to Evaluate the Effect of LDL-apheresis on the Recovery of Diabetic Ulcers in Patients With Peripheral Vasculopathy Not Susceptible to Revascularization.|Completed||N/A|13|Actual|Universita di Verona||2|||f||||f||||||||No||2018-05-31 21:42:47.504604|2018-05-31 21:42:47.504604
NCT01518192|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2010-06-28||2011-12-18|2011-12-18|2012-01-25|Estimate|2011-12-18|2012-01-25|Estimate||||2011-12-18|2012-01-25|Estimate|June 2006||2006-06-30|December 2011|2011-12-31|January 2009|Actual|2009-01-31|November 2007|Actual|2007-11-30||Interventional|||Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome|Risk Factors for Failure of Erythema Migrans Treatment - Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Adult Patients With Erythema Migrans: Clinical and Microbiological Outcome.|Completed||Phase 4|544|Actual|University Medical Centre Ljubljana|Medical explanation besides Lyme disease of the symptoms in patients was based on history and physical examination, therefore some other medical explanations might have been missed. With regard to controls this was even more likely.|2|||f||||f||||||||||2018-05-31 21:42:47.651684|2018-05-31 21:42:47.651684
NCT01518179|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2018-01-24|2012-01-21|2012-01-25|Estimate|||||||2018-01-24|2018-01-25|Actual|April 2012||2012-04-30|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Compression Gloves for Distal Radius Fracture|The Effect of Wearing Made-to-Measure Compression Gloves on Rehabilitation Following DRF.|Recruiting||N/A|120|Anticipated|Clalit Health Services||2|||f||||f||||||||||2018-05-31 21:42:48.091928|2018-05-31 21:42:48.091928
NCT01518166|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-01-24|2012-01-21|2012-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH|A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential Influence on Intragastric pH|Completed||Phase 1|70|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:42:48.234178|2018-05-31 21:42:48.234178
NCT01518153|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2016-01-22||2016-02-18|2012-01-24|2012-01-25|Estimate|2016-02-18|2016-03-17|Estimate||||2016-02-18|2016-03-17|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)|Phase 2 Study of Planned Donor Lymphocyte Infusion After Reduced Intensity Allogeneic Stem Cell Transplantation|Terminated||Phase 2|16|Actual|M.D. Anderson Cancer Center||2||Objectives not met.|f||||f||||||||||2018-05-31 21:42:48.370517|2018-05-31 21:42:48.370517
NCT01518140|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-08-12|2012-01-23|2012-01-25|Estimate|||||||2013-08-12|2013-08-13|Estimate|December 2013||2013-12-31|August 2013|2013-08-31||||December 2019|Anticipated|2019-12-31||Interventional|||BiPAP-Vapotherm RCT|Novel Oxygen Delivery Modalities for Refractory Dyspnea in Patients With Advanced Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-05-31 21:42:48.865864|2018-05-31 21:42:48.865864
NCT01518127|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-07-18|2012-01-22|2012-01-25|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2011||2011-08-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|September 2013|Actual|2013-09-30||Interventional|AMDCELL||Intravitreal Bone Marrow-Derived Stem Cells in Patients With Macular Degeneration|Intravitreal Bone Marrow-Derived Stem Cells in Patients With Macular Degeneration|Completed||N/A|20|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 21:42:48.941939|2018-05-31 21:42:48.941939
NCT01518114|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-26|2012-01-24|2012-01-25|Estimate|||||||2012-01-26|2012-01-31|Estimate|December 2011||2011-12-31|January 2012|2012-01-31||||January 2013|Anticipated|2013-01-31||Interventional|||Exercise Training in Patients With Hypertrophic Cardiomyopathy||Unknown status|Recruiting|N/A|60|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:42:49.021946|2018-05-31 21:42:49.021946
NCT01518101|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|||2017-02-23|2012-01-24|2012-01-25|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2012||2012-01-31|February 2017|2017-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PREFER||Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications|A Randomized, Open-label, Cross-over Study to Evaluate Patient Preferences for Eucreas® Versus Victoza® as add-on to Metformin in Type 2 Diabetes Mellitus Patients Who Did Not Have Adequate Glycaemic Control With Metformin.|Completed||Phase 4|62|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:42:49.107311|2018-05-31 21:42:49.107311
NCT01518088|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2016-04-20|2012-01-24|2012-01-25|Estimate|||||||2016-04-20|2016-04-21|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of a Dietary Fiber on Fecal Microbiota and Metabolism|Effects of a Dietary Fiber on Human Gut Microbiota, Bioactive Metabolites and Blood Glucose Control|Completed||N/A|20|Actual|Ingredion Incorporated||3|||f||||f||||||||||2018-05-31 21:42:49.192593|2018-05-31 21:42:49.192593
NCT01518075|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2012-09-14|2012-01-21|2012-01-25|Estimate|||||||2012-09-14|2012-09-17|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Breathing-swallowing Interaction in Chronic Obstructive Pulmonary Disease Patients - Impact of Non Invasive Ventilation|Breathing-swallowing Interaction in Chronic Obstructive Pulmonary Disease (COPD) Patients Hospitalized in Intensive Care Unit for an Acute Exacerbation: Impact of Non Invasive Ventilation. Physiological Evaluation|Completed||N/A|16|Actual|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 21:42:49.249064|2018-05-31 21:42:49.249064
NCT01518062|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-01-17|2012-01-20|2012-01-25|Estimate|||||||2017-01-17|2017-01-18|Estimate|November 1989||1989-11-30|January 2017|2017-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome|Dose Response Trial of Biosynthetic Authentic Human Growth Hormone and Induction of Puberty With 17b Oestradiol in Girls With Turner's Syndrome|Completed||Phase 4|65|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:42:49.46904|2018-05-31 21:42:49.46904
NCT01518049|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2015-10-12|2012-01-21|2012-01-25|Estimate|||||||2015-10-12|2015-10-14|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Observational|||Clinical Validation of the Rating Scale for Psychotic Depression (RAS-PD)||Completed|||50|Actual|Aarhus University Hospital|||||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 21:42:49.569999|2018-05-31 21:42:49.569999
NCT01518036|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-02-27|2012-01-20|2012-01-25|Estimate|||||||2017-02-27|2017-02-28|Actual|September 14, 1987|Actual|1987-09-14|February 2017|2017-02-28|April 11, 2004|Actual|2004-04-11|April 11, 2004|Actual|2004-04-11||Interventional|||Use of Somatropin in Turner Syndrome|The Use of Norditropin® in Turner's Syndrome|Completed||Phase 3|57|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:42:49.656812|2018-05-31 21:42:49.656812
NCT01518023|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Long Term Diabetes Improvement After Cancer Gastrectomy and Colectomy|Long Term Diabetes Improvement After Cancer Gastrectomy and Colectomy|Completed|||240|Actual|University of Sao Paulo|||3||f||||f||||||||||2018-05-31 21:42:49.76035|2018-05-31 21:42:49.76035
NCT01518010|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|June 2012||2012-06-30|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Multi-player Online Video Games for Cognitive Rehabilitation|Multi-player Online Video Games for Cognitive Rehabilitation|Unknown status|Not yet recruiting|N/A|10|Anticipated|University of Portsmouth||1|||f||||f||||||||||2018-05-31 21:42:49.889441|2018-05-31 21:42:49.889441
NCT01517997|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-10-08|2012-01-20|2012-01-25|Estimate|||||||2013-10-08|2013-10-09|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|IDEAS-I||Infrapopliteal Drug Eluting Angioplasty Versus Stenting|Infrapopliteal Drug Eluting Angioplasty Versus Stenting for the Treatment of Long-segment Arterial Disease: The IDEAS-I Randomized Controlled Trial.|Completed||Phase 2/Phase 3|50|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 21:42:49.986105|2018-05-31 21:42:49.986105
NCT01517984|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2016-06-16||2017-08-10|2012-01-20|2012-01-25|Estimate|2016-10-07|2016-11-30|Estimate||||2017-08-10|2017-09-11|Actual|November 2010||2010-11-30|August 2017|2017-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Intent-to-treat|Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation|Immune Monitoring and Calcineurin Inhibitor (CNI) Withdrawal in Low Risk Recipients of Kidney Transplantation|Terminated||Phase 2|52|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|After meeting protocol stopping rules, this trial was closed to new enrollment and randomization. No additional prespecified withdrawal of tacrolimus was allowed. Those already enrolled or randomized were followed for up to 24 months post-transplant.|2||Absence of equipoise on the basis of predetermined stopping rules.|f||||t||||||||||2018-05-31 21:42:50.12162|2018-05-31 21:42:50.12162
NCT01517971|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-08-07|2012-01-20|2012-01-25|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2012||2012-01-31|August 2017|2017-08-31||||June 2100|Anticipated|2100-06-30||Observational|||Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer|Validation of Molecular Prognostic Tests in NSCLC|Recruiting|||1060|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue samples~   "|||2018-05-31 21:42:50.843854|2018-05-31 21:42:50.843854
NCT01517958|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2016-03-24|2012-01-24|2012-01-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates|The Use of Lung Ultrasound to Diagnose RDS vs. TTN in Neonates Greater Than or Equal to 28 Weeks Gestation|Completed|||36|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||t||||||||No||2018-05-31 21:42:50.955479|2018-05-31 21:42:50.955479
NCT01517945|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2018-04-06|2012-01-20|2012-01-25|Estimate|||||||2018-04-06|2018-04-09|Actual|January 2012||2012-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study|Attention and Interpretation Modification (AIM) for Fear of Breast Cancer Recurrence: An Intervention Development Study|Recruiting|||158|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||t||||||Samples Without DNA|"~     salvia~   "|||2018-05-31 21:42:51.107401|2018-05-31 21:42:51.107401
NCT01517932|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-22|||2013-03-18|2012-01-24|2012-01-25|Estimate|||||||2013-03-18|2013-03-20|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Dexmedetomidine on Stress Response and Postoperative Analgesia|Effects of Dexmedetomidine on Stress Response and Postoperative Analgesia in Patients Undergoing Thoracotomy During Anesthesia Recovery Period|Completed||Phase 4|60|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 21:42:51.259164|2018-05-31 21:42:51.259164
NCT01517919|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-09-08|2012-01-20|2012-01-25|Estimate|||||||2014-09-08|2014-09-09|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||"Peer-Led Self-Management Support in Real World Clinical and Community Settings"|"Peer-Led Self-Management Support in Real World Clinical and Community Settings"|Completed||N/A|241|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:42:52.417999|2018-05-31 21:42:52.417999
NCT01517893|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2015-02-19||2018-03-18|2012-01-20|2012-01-25|Estimate|2015-03-10|2015-03-12|Estimate||||2018-03-18|2018-04-17|Actual|January 2012||2012-01-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Clinical Trial of Simvastatin to Treat Generalized Vitiligo|A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo|Completed||Phase 2|15|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 21:42:52.602209|2018-05-31 21:42:52.602209
NCT01517880|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17||2016-06-14|2016-06-14|2012-01-20|2012-01-25|Estimate||||2016-06-14|2016-06-16|Estimate|2016-06-14|2016-06-16|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|GNE Myopathy||A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy|Completed||Phase 2|46|Actual|Ultragenyx Pharmaceutical Inc||3|||f||||t||||||||||2018-05-31 21:42:52.944354|2018-05-31 21:42:52.944354
NCT01517867|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2018-02-27||2018-04-03|2012-01-24|2012-01-25|Estimate|2018-02-27|2018-04-02|Actual||||2018-04-03|2018-05-03|Actual|September 2011|Actual|2011-09-30|April 2018|2018-04-30|September 2017|Actual|2017-09-30|February 2017|Actual|2017-02-28||Interventional|EPIC||Early Parenting Intervention Comparison|Comparing Two Parenting Programs for At-Risk Families|Completed||N/A|161|Actual|Johns Hopkins University||2|||f||||t||||||||No|No data sharing plan was developed.|2018-05-31 21:42:53.051373|2018-05-31 21:42:53.051373
NCT01517854|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2018-01-10|2012-01-20|2012-01-25|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 30, 2019|Anticipated|2019-12-30|November 2018|Anticipated|2018-11-30||Interventional|RePo1||Revatio Portal-Pulmonary Arterial Hypertension Trial|Revatio Portal-Pulmonary Arterial Hypertension Trial (RePo1 Trial): A Randomized, Double-blinded, Placebo-controlled, Multi-center Study to Evaluate the Effects of Sildenafil Citrate (Revatio) 20 mg TID on Patients With Portal Pulmonary Arterial Hypertension (PPAH)|Enrolling by invitation||Phase 2|44|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||||2018-05-31 21:42:53.519131|2018-05-31 21:42:53.519131
NCT01517841|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Observational|||Barriers to Peritoneal Dialysis Selection|Barriers to Selection and Initiation of Peritoneal Dialysis in the United States|Unknown status|Not yet recruiting||180|Anticipated|MetroHealth Medical Center|||1||f||||f||||||||||2018-05-31 21:42:53.644106|2018-05-31 21:42:53.644106
NCT01517828|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2014-12-02|2012-01-20|2012-01-25|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room|Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room.|Unknown status|Active, not recruiting|Phase 3|62|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:42:53.807825|2018-05-31 21:42:53.807825
NCT01517815|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2016-11-28|2012-01-24|2012-01-25|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients|Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients|Completed||N/A|50|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:42:53.991675|2018-05-31 21:42:53.991675
NCT01517802|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-05-03|2012-01-23|2012-01-25|Estimate|||||||2018-05-03|2018-05-04|Actual|March 28, 2012|Actual|2012-03-28|May 2018|2018-05-31|April 9, 2021|Anticipated|2021-04-09|April 9, 2021|Anticipated|2021-04-09||Interventional|||A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate|A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study|Active, not recruiting||Phase 3|32|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:42:54.111081|2018-05-31 21:42:54.111081
NCT01517789|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2015-03-04|2012-01-20|2012-01-25|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|VISUOPEV||Advantage of Using Intraoperative Visual Evoked Potentials to Preserve Visual Function During Surgical Procedures Near the Optical Pathways|Advantage of Using Intraoperative Visual Evoked Potentials to Preserve Visual Function During Surgical Procedures Near the Optical Pathways|Completed||N/A|40|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 21:42:54.293879|2018-05-31 21:42:54.293879
NCT01517776|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11||2015-05-26|2015-06-26|2012-01-20|2012-01-25|Estimate||||2015-06-26|2015-07-21|Estimate|2015-06-26|2015-07-21|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|HGG-CilMetro||Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents|Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group -|Terminated||Phase 2|28|Actual|Martin-Luther-Universität Halle-Wittenberg||1||due to an altered benefit/risk assessment.|f||||t||||||||||2018-05-31 21:42:54.389233|2018-05-31 21:42:54.389233
NCT01517763|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-09-28|2012-01-22|2012-01-25|Estimate|||||||2014-09-28|2014-09-30|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Comparison Study of the ICON™ Auto Series With and Without SensAwake™ and ThermoSmart™ and Conventional Continuous Positive Airway Pressure in Obstructive Sleep Apnea Patients||Terminated||N/A|25|Actual|Fisher and Paykel Healthcare||3||The site closed down, therefore the study has been terminated.|f||||f||||||||||2018-05-31 21:42:54.517236|2018-05-31 21:42:54.517236
NCT01517750|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2015-03-10||2015-06-21|2012-01-22|2012-01-25|Estimate|2015-06-21|2015-06-24|Estimate||||2015-06-21|2015-06-24|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study to Predict the Need for Humidification Use and Comparison of the Effect of ThermoSmart™ and no Humidification on Adherence||Completed||N/A|80|Actual|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-05-31 21:42:54.640872|2018-05-31 21:42:54.640872
NCT01517737|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-02-08|2012-01-24|2012-01-25|Estimate|||||||2012-02-08|2012-02-09|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Immunology of Failing Metal-on-Metal Hip Replacement|Immune Cell Involvement in the Tissue Response to Metallosis in Patients With Failed Metal-on-metal Hip Replacements|Unknown status|Recruiting||105|Anticipated|University of East Anglia|||||f||||t||||||Samples With DNA|"~     blood from all patients; joint fluid, soft tissue and bone on operated patients~   "|||2018-05-31 21:42:55.256784|2018-05-31 21:42:55.256784
NCT01517724|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-11-16|2012-01-20|2012-01-25|Estimate|||||||2017-11-16|2017-11-17|Actual|December 2009||2009-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|BCT||Bortezomib Consolidation Trial|Phase II Study of Bortezomib Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma|Active, not recruiting||Phase 2|40|Actual|University College, London||1|||f||||t||||||||||2018-05-31 21:42:55.337489|2018-05-31 21:42:55.337489
NCT01517711|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-01-12|2012-01-24|2012-01-25|Estimate|||||||2015-01-12|2015-01-14|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|September 2014|Actual|2014-09-30||Interventional|||Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)|A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium||2|||f||||t||||||||||2018-05-31 21:42:55.623643|2018-05-31 21:42:55.623643
NCT01517698|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20||2016-07-06|2016-07-06|2012-01-24|2012-01-25|Estimate||||2016-07-06|2016-07-11|Estimate|2016-07-06|2016-07-11|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of RO4917523 in Patients With Fragile X Syndrome|A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.|Completed||Phase 2|185|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:42:55.767841|2018-05-31 21:42:55.767841
NCT01517685|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-02-17|2012-01-24|2012-01-25|Estimate|||||||2016-02-17|2016-02-19|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Hallelujah Acres Omega 3 Fat Study|Hallelujah Acres Omega 3 Fat Study|Completed||N/A|13|Actual|Hallelujah Acres||1|||f||||f||||||||||2018-05-31 21:42:55.928247|2018-05-31 21:42:55.928247
NCT01517672|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-21|2012-01-21|2012-01-25|Estimate|||||||2012-01-21|2012-01-25|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Imaging Outcomes of Cognitive Behavioral Therapy (CBT) for Battered Women With Posttraumatic Stress Disorder|Neurobiology of Severe Psychological Trauma in Women|Completed||N/A|41|Actual|University of California, San Diego|||||f||||f||||||||||2018-05-31 21:42:56.015982|2018-05-31 21:42:56.015982
NCT01517659|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-06-20|2012-01-24|2012-01-25|Estimate|||||||2017-06-20|2017-06-22|Actual|November 2012||2012-11-30|November 2012|2012-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Non-Invasive Reduction of Fat in the Inner Thighs|Non-Invasive Reduction of Fat in the Inner Thighs With the Zeltiq Coolsculpting System|Completed||N/A|45|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 21:42:56.083331|2018-05-31 21:42:56.083331
NCT01517646|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-06-20|2012-01-24|2012-01-25|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2012||2012-02-29|January 2012|2012-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pilot Study of CoolTXT for Non-Invasive Fat Reduction|Pilot Study of CoolTXT for Non-Invasive Fat Reduction|Completed||N/A|18|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 21:42:56.163901|2018-05-31 21:42:56.163901
NCT01517633|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2012||2012-01-31|January 2012|2012-01-31||||January 2013|Anticipated|2013-01-31||Interventional|||Study of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine|Study of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine|Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-05-31 21:42:56.252767|2018-05-31 21:42:56.252767
NCT01517620|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2013-12-12|2012-01-24|2012-01-25|Estimate|||||||2013-12-12|2013-12-13|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy||Completed||Phase 4|38|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:42:56.325767|2018-05-31 21:42:56.325767
NCT01517607|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2015-09-30|2012-01-24|2012-01-25|Estimate|||||||2015-09-30|2015-10-01|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|MUKOSA||Mesalazine (PENTASA®) in Ulcerative Colitis|Mesalazine (PENTASA®) in Ulcerative Colitis: Correlation of the Information Level With Patient's Compliance in Everyday Practice|Completed|||506|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 21:42:56.455719|2018-05-31 21:42:56.455719
NCT01517594|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2013-10-18|2012-01-20|2012-01-25|Estimate|||||||2013-10-18|2013-10-21|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis|Tolerability of Pentasa® Sachet in Patients With Ulcerative Colitis Under Conditions of Standard Practice in the Czech Republic|Completed|||568|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 21:42:56.71206|2018-05-31 21:42:56.71206
NCT01517581|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Brown Fat Activity and White Fat Accumulation|Study on the Association Between Brown Adipose Tissue Activation and White Adipose Tissue Accumulation in Successfully Treated Pediatric Malignancy|Completed|||32|Actual|Children's Hospital Los Angeles|||1||f||||f||||||||||2018-05-31 21:42:56.801357|2018-05-31 21:42:56.801357
NCT01517568|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2017-01-25|2012-01-21|2012-01-25|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2006||2006-11-30|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Metabolism and Excretion of Liraglutide in Healthy Male Volunteers|A Single-Centre, Open Label Trial Investigating the Metabolites in Plasma, Urine and Faeces After a Single Subcutaneous Dose of [3H]-Liraglutide to Healthy Subjects|Completed||Phase 1|7|Anticipated|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:42:56.997718|2018-05-31 21:42:56.997718
NCT01517555|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2017-01-25|2012-01-21|2012-01-25|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2006||2006-10-31|January 2017|2017-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes|A Single Centre, Randomised, Double-blind, Placebo Controlled Trial to Evaluate the Possible Drug-drug Interaction Between Liraglutide and Paracetamol and the Effects of Liraglutide on Postprandial Glucose and Insulin, Gastric Emptying, Appetite Sensations and Energy Intake in Subjects With Type 2 Diabetes|Completed||Phase 1|18|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:42:57.079041|2018-05-31 21:42:57.079041
NCT01517542|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-08-12|2012-01-24|2012-01-25|Estimate|||||||2014-08-12|2014-08-15|Estimate|February 2010||2010-02-28|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of Effectiveness of Nutritional Counseling in Patients After Stroke|Evaluation on the Effectiveness of Nutritional Counseling on an Adapted DASH Diet in Patients After Stroke: a Randomized Clinical Trial|Unknown status|Recruiting|N/A|128|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 21:42:57.171397|2018-05-31 21:42:57.171397
NCT01517529|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-08-25||2015-10-20|2012-01-24|2012-01-25|Estimate|2015-08-27|2015-09-30|Estimate||||2015-10-20|2015-11-20|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational||chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin (RBV) therapy (NR)|Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations|Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy|Completed|||10|Actual|University of Cincinnati|||1||f||||f||||||Samples With DNA|"~     Blood lymphocytes from enrolled subjects will be retained until all investigations will be~     performed and publications are generated. After that remaining samples will be discarded~     properly according to the Biosafety instructions.~   "|||2018-05-31 21:42:57.276881|2018-05-31 21:42:57.276881
NCT01517516|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2016-01-12|2012-01-20|2012-01-25|Estimate|||||||2016-01-12|2016-01-14|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|MMI||Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.|A Magnetic Resonance Imaging (MRI) Study to Investigate Differences in the Structure and the Function of the Brain at Rest; Between Persons With Functional Pain Conditions Such as IBS or Vulvodynia, IBD and Healthy Controls|Completed|||165|Actual|University of California, Los Angeles|||2||f||||f||||||||||2018-05-31 21:42:57.488949|2018-05-31 21:42:57.488949
NCT01517503|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2012-12-02|2012-01-20|2012-01-25|Estimate|||||||2012-12-02|2012-12-04|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Acceptance and Commitment Therapy Versus Cognitive Therapy for the Treatment of Major Depressive Disorder|Acceptance and Commitment Therapy vs. Cognitive Therapy for the Treatment of Major Depressive Disorder|Unknown status|Recruiting|N/A|98|Anticipated|VU University of Amsterdam||2|||f||||t||||||||||2018-05-31 21:42:57.575294|2018-05-31 21:42:57.575294
NCT01517490|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2015-03-10|2012-01-24|2012-01-25|Estimate|||||||2015-03-10|2015-03-11|Estimate|August 2011||2011-08-31|March 2015|2015-03-31||||December 2016|Anticipated|2016-12-31||Observational|||Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes|Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes|Unknown status|Recruiting||100|Anticipated|Glostrup University Hospital, Copenhagen|||6||f||||f||||||||||2018-05-31 21:42:57.692847|2018-05-31 21:42:57.692847
NCT01517477|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-03-07|2012-01-24|2012-01-25|Estimate|||||||2018-03-07|2018-03-09|Actual|January 2012|Actual|2012-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects|A Prospective, Randomized, Controlled Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted With One, Two, or Three Trabecular Micro-Bypass Stents|Active, not recruiting||N/A|251|Anticipated|Glaukos Corporation||3|||f||||f||||||||Yes|18 month results published in Clinical Ophthalmology 2015:9 2313-2320.|2018-05-31 21:42:57.785475|2018-05-31 21:42:57.785475
NCT01517464|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-04-24|2012-01-20|2012-01-25|Estimate|||||||2017-04-24|2017-04-26|Actual|January 2012||2012-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SGT94-01||A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors|A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors|Completed||Phase 1|13|Actual|SynerGene Therapeutics, Inc.||1|||f||||t||||||||Undecided||2018-05-31 21:42:57.861577|2018-05-31 21:42:57.861577
NCT01517451|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-11-30|2012-01-20|2012-01-25|Estimate|||||||2017-11-30|2017-12-04|Actual|May 2013||2013-05-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Radiation and Androgen Ablation for Prostate Cancer|Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate|Active, not recruiting||Phase 1/Phase 2|105|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||Undecided||2018-05-31 21:42:57.934421|2018-05-31 21:42:57.934421
NCT01517438|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-20|2012-01-20|2012-01-25|Estimate|||||||2012-01-20|2012-01-25|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Serotonin Inhibitors on Patient-controlled Analgesia Related Nausea and Vomiting||Completed||N/A|21|Actual|Seoul National University Hospital|||||f||||||||||||||2018-05-31 21:42:58.007813|2018-05-31 21:42:58.007813
NCT01517425|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-09-05|2012-01-20|2012-01-25|Estimate|||||||2017-09-05|2017-09-07|Actual|November 2012||2012-11-30|September 2017|2017-09-30||||July 2020|Anticipated|2020-07-31||Observational|iPSC||Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells|Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells|Enrolling by invitation|||200|Anticipated|Scripps Translational Science Institute|||2||f||||f||||||||||2018-05-31 21:42:58.07097|2018-05-31 21:42:58.07097
NCT01517412|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2016-08-22|2014-05-06|2016-08-22|2012-01-20|2012-01-25|Estimate|2016-08-22|2016-10-14|Estimate|2014-05-06|2014-05-22|Estimate|2016-08-22|2016-10-14|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin|A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin|Completed||Phase 3|451|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 21:42:58.169343|2018-05-31 21:42:58.169343
NCT01517399|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2018-02-22|2012-01-20|2012-01-25|Estimate|||||||2018-02-22|2018-02-26|Actual|December 2011||2011-12-31|February 2018|2018-02-28|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects|A Phase 1, Open-Label, Single-Sequence Crossover Study Assessing the Effect of Tivantinib (ARQ 197) on the Pharmacokinetics of Omeprazole/S-Warfarin/Caffeine/Midazolam and Digoxin in Cancer Subjects|Completed||Phase 1|28|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 21:42:58.783207|2018-05-31 21:42:58.783207
NCT01517386|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-12-03|2012-01-24|2012-01-25|Estimate|||||||2012-12-03|2012-12-04|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|OTS-PS||Photonic Needle and Paravertebral Space Detection|Optical Tissue Stylet (OTS) - Descriptive Observational Study Into Paravertebral Space (PS) Detection in Humans|Completed|||10|Actual|Philips Healthcare|||1||f||||f||||||||||2018-05-31 21:42:58.888489|2018-05-31 21:42:58.888489
NCT01517217|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-20|2012-01-20|2012-01-25|Estimate|||||||2012-01-20|2012-01-25|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Effect of Postoperative Girdle Following Abdominal Surgery on Pulmonary Function, Mobilisation and Postoperative Pain|Randomised Trial Evaluating the Effect of Postoperative Girdle Following Major Abdominal Surgery|Unknown status|Recruiting|N/A|50|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:43:03.401612|2018-05-31 21:43:03.401612
NCT01517373|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2016-12-06|2014-04-21|2016-12-06|2012-01-20|2012-01-25|Estimate|2016-12-06|2017-01-31|Estimate|2014-04-21|2014-05-09|Estimate|2016-12-06|2017-01-31|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Baseline analysis population included all randomized participants who received at least 1 dose of study treatment.|Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin|A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Glimepiride In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Completed||Phase 2|304|Actual|Pfizer||5|||f||||t||||||||||2018-05-31 21:42:59.13602|2018-05-31 21:42:59.13602
NCT01517360|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2013-03-27|2012-01-19|2012-01-25|Estimate|||||||2013-03-27|2013-03-29|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pharmacological Approach to Improve the Outcome of Social Cognition Training|Pharmacological Approach to Improve the Outcome of Social Cognition Training|Completed||Phase 1|27|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||||2018-05-31 21:43:01.047633|2018-05-31 21:43:01.047633
NCT01517347|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2016-10-20|2012-01-20|2012-01-25|Estimate|||||||2016-10-20|2016-10-24|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation|Low Dose of Interleukin-2 Following Allogeneic Unmanipulated Blood and Marrow Transplantation in Treating Patients With Standard Risk Hematologic Malignancy|Terminated||N/A|90|Actual|Peking University People's Hospital||2||"Because the conditional power was 0.083, the Data and Safety Monitoring Board recommended~   halting the study due to futility after the 1st interim analysis."|f||||t||||||||||2018-05-31 21:43:01.111455|2018-05-31 21:43:01.111455
NCT01517334|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2015-08-25|2012-01-20|2012-01-25|Estimate|||||||2015-08-25|2015-08-26|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)|Multi-Center Phase 3 Trial of Minocycline HCl 1 mg Microspheres for the Use in Subjects With Peri-Implantitis: Clinical and Microbiological Evaluations|Completed||Phase 3|208|Actual|OraPharma||2|||f||||f||||||||||2018-05-31 21:43:01.172403|2018-05-31 21:43:01.172403
NCT01517321|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2013-07-07|2012-01-20|2012-01-25|Estimate|||||||2013-07-07|2013-07-09|Estimate||||July 2013|2013-07-31||||||||Interventional|||MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes|MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes|Completed||Phase 3|||Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-05-31 21:43:01.331512|2018-05-31 21:43:01.331512
NCT01517308|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-03-16|2012-01-24|2012-01-25|Estimate|||||||2012-03-16|2012-03-19|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C|24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C, RELAPSERS TO PEG-IFN + RIBAVIRIN TREATMENT. A RANDOMIZED CONTROLLED TRIAL|Withdrawn||Phase 3|0|Actual|Federico II University||2||"Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week~   regimen in this setting. It seems non-ethical to start this trial"|f||||f||||||||||2018-05-31 21:43:01.446179|2018-05-31 21:43:01.446179
NCT01517295|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2016-05-04||2016-06-17|2012-01-20|2012-01-25|Estimate|2016-06-17|2016-07-28|Estimate||||2016-06-17|2016-07-28|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients|Evaluating the Pharmacokinetic Profile of Hydromorphone in Chronic Pain Patients Taking Hydrocodone/APAP|Completed||Phase 4|30|Actual|NEMA Research, Inc.|Sensitivity of the lab test used to determine plasma hydromorphone concentrations was not sufficient. Failure to meet the lowest level of detection, all subjects plasma hydromorphone concentrations were recorded as zero at all time points.|2|||f||||t||||||||||2018-05-31 21:43:01.576865|2018-05-31 21:43:01.576865
NCT01517282|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2014-10-08||2014-11-09|2012-01-20|2012-01-25|Estimate|2014-10-08|2014-10-13|Estimate||||2014-11-09|2014-11-21|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional||All subjects who received 1 or more dose of placebo or MOR103 (safety population).|Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis|A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis|Completed||Phase 1/Phase 2|32|Actual|MorphoSys AG|Key limitations of this trial include its small sample size and limited duration. Efficacy assessments were not made in this study. Larger clinical trials will be required to evaluate the potential of MOR103 in treating patients with MS.|4|||f||||t||||||||||2018-05-31 21:43:01.994712|2018-05-31 21:43:01.994712
NCT01517269|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-03-06|2012-01-24|2012-01-25|Estimate|||||||2015-03-06|2015-03-09|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||PETS-D (Parent Education Thru Simulation-Diabetes)|PETS-D (Parent Education Thru Simulation-Diabetes)|Completed||Phase 3|191|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 21:43:03.13102|2018-05-31 21:43:03.13102
NCT01517256|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-20|2012-01-20|2012-01-25|Estimate|||||||2012-01-20|2012-01-25|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|LEAP||A Pilot Study Evaluating a Multidisciplinary Chronic Pain Group Therapy in a Primary Care Setting|Living Everyday Above-and-beyond Pain Research (LEAP): A Pilot Study Evaluating a Multidisciplinary Chronic Pain Group Therapy in a Primary Care Setting|Completed||Phase 3|60|Actual|McMaster University||2|||f||||||||||||||2018-05-31 21:43:03.194811|2018-05-31 21:43:03.194811
NCT01517243|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-01-26|2012-01-20|2012-01-25|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2010||2010-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase II Study of Alternating Sunitinib and Temsirolimus|Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus|Active, not recruiting||Phase 2|37|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 21:43:03.255978|2018-05-31 21:43:03.255978
NCT01517230|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-05-19|2012-01-20|2012-01-25|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Can Mass Media Campaigns Reduce Child Mortality|Can Mass Media Campaigns Reduce Child Mortality|Completed||N/A|100000|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 21:43:03.329009|2018-05-31 21:43:03.329009
NCT01517204|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2012-09-16|2012-01-20|2012-01-25|Estimate|||||||2012-09-16|2012-09-18|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Efficacy of Trachway (R) Intubating Stylet in the Insertion of the Double Lumen Endobronchial Tube|The Comparison of Direct Laryngoscope and Trachway (R) Intubating Stylet in the Insertion of the Double Lumen Endobronchial Tube|Completed||N/A|60|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:43:03.499493|2018-05-31 21:43:03.499493
NCT01517191|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-03-28|2012-01-20|2012-01-25|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2011||2011-11-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|SOS-VE01||Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults|Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults|Completed|||4197|Actual|Dalhousie University|||2||f||||f||||||Samples Without DNA|"~     Serum and Nasopharyngeal swabs~   "|||2018-05-31 21:43:03.571658|2018-05-31 21:43:03.571658
NCT01517178|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2015-03-03||2015-03-03|2012-01-20|2012-01-25|Estimate|2015-03-03|2015-03-13|Estimate||||2015-03-03|2015-03-13|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Multi-national, Safety and Performance Study of New Ostomy Product Compared to Standard Care|An Open-labelled, Randomised, Controlled, Comparative, Multi-national, Cross-over Study Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared to 2-piece Standard Care Ostomy Products|Terminated||Phase 3|33|Actual|Coloplast A/S|Early termination leading to small number of subjects analyzed.|2|||f||||f||||||||||2018-05-31 21:43:03.653501|2018-05-31 21:43:03.653501
NCT01517165|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-04-04|2012-01-24|2012-01-25|Estimate|||||||2018-04-04|2018-04-05|Actual|January 4, 2012||2012-01-04|February 2, 2015|2015-02-02|February 2, 2015|Actual|2015-02-02|February 2, 2015|Actual|2015-02-02||Interventional|||Pioglitazone to Treat Opioid Withdrawal Symptoms|Pioglitazone as an Aid During Buprenorphine Taper|Terminated||Phase 1|24|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:43:03.871657|2018-05-31 21:43:03.871657
NCT01517152|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-04-04|2012-01-24|2012-01-25|Estimate|||||||2018-04-04|2018-04-05|Actual|January 4, 2012||2012-01-04|October 2, 2017|2017-10-02||||||||Observational|||Testing a Spanish Version of a Patient Toxicity Questionnaire|Spanish Translation and Linguistic Validation of the Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Completed|||112|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:03.936912|2018-05-31 21:43:03.936912
NCT01517139|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-04-04|2012-01-24|2012-01-25|Estimate|||||||2018-04-04|2018-04-05|Actual|March 1, 2012||2012-03-01|July 28, 2017|2017-07-28||||||||Observational|||Diet and Nutrition Pilot Study for Chinese Adolescents and Their Mothers|Pilot Study to Test the Methods for the Diet, Nutrition and Physical Activity Feasibility Study of Early Life Determinants of Adult Cancers in a Chinese Cohort of Adolescents and Their Mothers|Completed|||278|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:03.992141|2018-05-31 21:43:03.992141
NCT01517126|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2017-10-18|2012-01-24|2012-01-25|Estimate|||||||2017-10-18|2017-10-19|Actual|January 6, 2012||2012-01-06|August 15, 2017|2017-08-15||||||||Observational|||Assessing Suicide Risk in Adolescents With Developmental Delays|Assessing Suicide Risk in Adolescents With Developmental Delays: Development of a Screening Tool|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:04.046583|2018-05-31 21:43:04.046583
NCT01517113|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-04-04|2012-01-24|2012-01-25|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2, 2012||2012-01-02|October 13, 2017|2017-10-13|October 13, 2017||2017-10-13|||||Observational|||Age-Related Changes in Body Composition|Age-Associated Changes in Regional Adiposity and Novel Cardiovascular Risk Factors|Terminated|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:04.157787|2018-05-31 21:43:04.157787
NCT01517100|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-04-04|2012-01-24|2012-01-25|Estimate|||||||2018-04-04|2018-04-05|Actual|January 5, 2012||2012-01-05|November 30, 2017|2017-11-30|October 6, 2014|Actual|2014-10-06|October 6, 2014|Actual|2014-10-06||Interventional|||The Role of Endocannabinoids in Insulin Production and Action|The Roles of Endocannabinoids in Insulin Secretion and Action|Completed||Phase 1|45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:04.215588|2018-05-31 21:43:04.215588
NCT01517087|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-03-27|2012-01-24|2012-01-25|Estimate|||||||2018-03-27|2018-03-29|Actual|January 9, 2012||2012-01-09|January 10, 2018|2018-01-10||||||||Observational|||Studying Motor Neuron Tests|Structural and Functional Brain Imaging Markers of Upper Motor Neuron Function|Recruiting|||55|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:04.281257|2018-05-31 21:43:04.281257
NCT01517074|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2014-05-12||2016-08-31|2012-01-24|2012-01-25|Estimate|2014-05-12|2014-06-10|Estimate||||2016-08-31|2016-09-02|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|ISAS||Sirolimus Injections for Autoimmune Scleritis|A Phase I/II Study to Investigate Subconjunctival Sirolimus for the Treatment of Active Autoimmune Non-Necrotizing Anterior Scleritis|Completed||Phase 1/Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 21:43:04.354469|2018-05-31 21:43:04.354469
NCT01517061|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-05-10|2012-01-24|2012-01-25|Estimate|||||||2018-05-10|2018-05-11|Actual|January 3, 2012||2012-01-03|July 30, 2014|2014-07-30|July 30, 2014||2014-07-30|||||Observational|||Genetics and Phantom Limb Pain|Integrative Genomic Analysis In Phantom Limb Pain|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:04.587386|2018-05-31 21:43:04.587386
NCT01517048|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-05-23|2012-01-24|2012-01-25|Estimate|||||||2018-05-23|2018-05-24|Actual|January 9, 2012||2012-01-09|December 12, 2014|2014-12-12|December 12, 2014||2014-12-12|||||Observational|||Brain-Derived Neurotrophic Factor in Obesity and Brain Function|Brain-Derived Neurotrophic Factor in Obesity and Neurocognitive Function|Completed|||93|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:43:04.682176|2018-05-31 21:43:04.682176
NCT01517035|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2018-03-16|2012-01-24|2012-01-25|Estimate|||||||2018-03-16|2018-03-19|Actual|January 13, 2012||2012-01-13|March 29, 2017|2017-03-29|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||Improving Blood Stem Cell Collection and Transplant Procedures|Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using Ex Vivo CD3, CD19 Depletion and CD34 Selection|Completed||Phase 1/Phase 2|43|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:43:04.765218|2018-05-31 21:43:04.765218
NCT01517022|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-10-12|2012-01-20|2012-01-25|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2010||2010-11-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis|Impact of a Package of Intensive Smoking-cessation Interventions Versus Smoking-cessation Advice on Outcomes in Smear-positive Patients With Pulmonary Tuberculosis; a Randomised Controlled Trial (STB_RCT).|Completed||Phase 3|800|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 21:43:04.846239|2018-05-31 21:43:04.846239
NCT01517009|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2013-06-25|2012-01-20|2012-01-25|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|DoCCS||A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer|A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer|Completed||Phase 2|50|Anticipated|Jeroen Bosch Ziekenhuis|||||f||||t||||||||||2018-05-31 21:43:04.921493|2018-05-31 21:43:04.921493
NCT01516996|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-03-18|2012-01-20|2012-01-25|Estimate|||||||2012-03-18|2012-03-20|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|March 2018|Anticipated|2018-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer|Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx|Unknown status|Recruiting|Phase 2|80|Anticipated|The Second People's Hospital of Sichuan||2|||f||||t||||||||||2018-05-31 21:43:04.985498|2018-05-31 21:43:04.985498
NCT01516983|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2014-02-13|2012-01-19|2012-01-25|Estimate|||||||2014-02-13|2014-02-17|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation|A Single Center, Open Label, Dose-Finding Study to Determine the Safety of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation.|Completed||Phase 1/Phase 2|15|Actual|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 21:43:05.08935|2018-05-31 21:43:05.08935
NCT01516970|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2016-06-20|2014-06-27|2017-06-21|2012-01-20|2012-01-25|Estimate|2016-08-16|2016-10-11|Estimate|2014-06-27|2014-06-30|Estimate|2017-06-21|2017-07-19|Actual|November 25, 2011|Actual|2011-11-25|June 2017|2017-06-30|September 28, 2013|Actual|2013-09-28|August 1, 2013|Actual|2013-08-01||Interventional|PEPDar|The safety population included all participants who received at least 1 dose of randomized HIV PEP.|Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)|HIV Postexposure Prophylaxis With Darunavir/r (PEPDar)|Completed||Phase 3|312|Actual|Janssen-Cilag G.m.b.H||2|||f||||f||f||||||||2018-05-31 21:43:05.181615|2018-05-31 21:43:05.181615
NCT01516957|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18||2016-03-14|2016-03-14|2012-01-19|2012-01-25|Estimate||||2016-03-14|2016-04-13|Estimate|2016-03-14|2016-04-13|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2012|Actual|2012-09-30||Interventional|||AMG 827 in Subjects With Psoriatic Arthritis|A Randomized, Double-blinded, Placebo-controlled, Multiple-dose Study With an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects With Psoriatic Arthritis.|Terminated||Phase 2|168|Actual|Amgen||4||Sponsor decision|f||||f||||||||||2018-05-31 21:43:05.675642|2018-05-31 21:43:05.675642
NCT01516944|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2017-10-05|2012-01-24|2012-01-25|Estimate|||||||2017-10-05|2017-10-09|Actual|February 2012||2012-02-29|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Perioperative Chemotherapy for Potentially Resectable Gastric Cancer|Perioperative Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin in Patients With Localized Advanced Gastric Cancer|Active, not recruiting||Phase 2/Phase 3|729|Anticipated|Hebei Medical University||3|||f||||f||||||||||2018-05-31 21:43:05.818433|2018-05-31 21:43:05.818433
NCT01516931|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2014-07-17|2012-01-19|2012-01-25|Estimate|||||||2014-07-17|2014-07-21|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Depression|A Study to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of the Symptoms of Depression.|Unknown status|Recruiting|Phase 3|540|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 21:43:05.919368|2018-05-31 21:43:05.919368
NCT01516918|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13||2014-10-09|2014-10-09|2012-01-19|2012-01-25|Estimate||||2014-10-09|2014-10-20|Estimate|2014-10-09|2014-10-20|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis|A Multicenter, Open-Label Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis|Completed||Phase 2|103|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||t||||||||||2018-05-31 21:43:06.038897|2018-05-31 21:43:06.038897
NCT01516905|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2018-02-08|2012-01-19|2012-01-25|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2011||2011-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 17, 2016|Actual|2016-05-17||Observational|||PET/CT Imaging of Malignant Brain Tumors With 124I-NM404|PET/CT Imaging of Malignant Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue 124I-NM404|Active, not recruiting|||19|Actual|University of Wisconsin, Madison|||1||f||||t||||||||||2018-05-31 21:43:06.244642|2018-05-31 21:43:06.244642
NCT01516892|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2016-11-09||2016-11-09|2012-01-20|2012-01-25|Estimate|2016-11-09|2017-01-06|Estimate||||2016-11-09|2017-01-06|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||All enrolled participants.|A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine||Completed||Phase 4|716|Actual|Allergan||1|||f||||f||||||||||2018-05-31 21:43:06.348775|2018-05-31 21:43:06.348775
NCT01516879|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2015-08-28|2014-05-15|2018-01-11|2012-01-20|2012-01-25|Estimate|2015-08-28|2015-09-29|Estimate|2014-05-15|2014-05-28|Estimate|2018-01-11|2018-02-07|Actual|January 5, 2012|Actual|2012-01-05|January 2018|2018-01-31|October 14, 2013|Actual|2013-10-14|October 14, 2013|Actual|2013-10-14||Interventional|DESCARTES||Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study|A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects|Completed||Phase 3|905|Actual|Amgen||2|||f||||t||||||||||2018-05-31 21:43:06.761932|2018-05-31 21:43:06.761932
NCT01516866|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2018-04-25|2012-01-19|2012-01-25|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2011|Actual|2011-11-30|April 2018|2018-04-30|January 1, 2018|Actual|2018-01-01|September 2015|Actual|2015-09-30||Observational|NaFl PET/CT||Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy|NaF PET/CT Repeatability, Responsiveness, and Response Assessment in Patients With Metastatic Castrate-resistant Prostate Cancer to Bone Treated With Either an Antimicrotubule Directed Agent or Androgen Receptor (AR)-Directed Therapies|Completed|||58|Actual|University of Wisconsin, Madison|||2||f||||t||||||||||2018-05-31 21:43:07.650681|2018-05-31 21:43:07.650681
NCT01516853|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2015-06-16|2012-01-19|2012-01-25|Estimate|||||||2015-06-16|2015-06-17|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Non-invasive Quantification of Liver Iron With MRI|Non-invasive Quantification of Liver Iron With MRI|Completed||N/A|50|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-05-31 21:43:07.821753|2018-05-31 21:43:07.821753
NCT01516840|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-01-17|2012-01-20|2012-01-25|Estimate|||||||2017-01-17|2017-01-18|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients|Randomized, Open-label (Double Blind Among Rivaroxaban Groups in the Initial 3 Weeks), Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism|Completed||Phase 3|60|Actual|Bayer||4|||f||||t||||||||||2018-05-31 21:43:07.891738|2018-05-31 21:43:07.891738
NCT01516827|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2017-10-25|2012-01-19|2012-01-25|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2012||2012-02-29|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TCT||Effectiveness of Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for Children With Post-traumatic Stress Disorder (TreatChildTrauma)|Effectiveness of Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT) for Children With Post-traumatic Stress Disorder|Completed||N/A|159|Actual|University of Ulm||2|||f||||t||||||||||2018-05-31 21:43:08.014534|2018-05-31 21:43:08.014534
NCT01516814|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2017-01-19|2012-01-20|2012-01-25|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients|Randomized, Open-label, Parallel-group, Active-controlled Study of Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism, With or Without Symptomatic Deep Vein Thrombosis|Completed||Phase 3|40|Actual|Bayer||3|||f||||t||||||||||2018-05-31 21:43:08.134855|2018-05-31 21:43:08.134855
NCT01516801|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Pragmatic Trial of the Effect of a Mailed Patient Flyer About Prostate Specific Antigen (PSA) Testing Prior to an Annual Exam|A Pragmatic Randomized Trial of the Effect of a Mailed Patient Flyer About PSA Testing Prior to an Annual Exam|Completed||N/A|303|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 21:43:08.305942|2018-05-31 21:43:08.305942
NCT01516788|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-09-08|2012-01-19|2012-01-25|Estimate|||||||2016-09-08|2016-09-12|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Photoprovocation Testing in Subjects With Cutaneous Lupus|Photoprovocation Testing in Subjects With Cutaneous Lupus|Recruiting||N/A|50|Anticipated|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 21:43:08.372442|2018-05-31 21:43:08.372442
NCT01516775|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-09-28|2012-01-24|2012-01-25|Estimate|||||||2012-09-28|2012-10-01|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Gastric pH in Intubated Children|Untersuchung Des Magen-pH in Intubationsanästhesie Bei Kindern|Completed||N/A|150|Actual|University Children's Hospital, Zurich||2|||f||||f||||||||||2018-05-31 21:43:08.453444|2018-05-31 21:43:08.453444
NCT01516762|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2014-07-11|2012-01-20|2012-01-25|Estimate|||||||2014-07-11|2014-07-14|Estimate||||July 2014|2014-07-31||||||||Expanded Access|||Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases|Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases|No longer available|||||Bayer|||||||||||||||||||2018-05-31 21:43:08.528513|2018-05-31 21:43:08.528513
NCT01516749|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|2014-07-11||2014-08-15|2012-01-19|2012-01-25|Estimate|2014-07-11|2014-08-06|Estimate||||2014-08-15|2014-08-20|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional||Eligible per protocol criteria|Anakinra as a Treatment for Hydradenitis Suppurativa|An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa|Completed||Phase 2|6|Actual|University of California, San Francisco|Limitations of the study include early termination leading to small numbers of subjects analyzed, and lack of control group.|1|||f||||f||||||||||2018-05-31 21:43:08.672944|2018-05-31 21:43:08.672944
NCT01516736|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2017-03-28|2014-11-20|2017-08-01|2012-01-24|2012-01-25|Estimate|2017-05-24|2017-06-28|Actual|2014-12-12|2015-01-05|Estimate|2017-08-01|2017-08-30|Actual|March 2012||2012-03-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|PROTECT2|Patient demographics (FAS set)|Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim|Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®|Completed||Phase 3|308|Actual|Sandoz||2|||f||||t||||||||Undecided||2018-05-31 21:43:08.911361|2018-05-31 21:43:08.911361
NCT01516723|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-03-27|2012-01-24|2012-01-25|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2012||2012-02-29|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|February 2016|Actual|2016-02-29||Interventional|PRISON-IV||Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions|Hybrid Sirolimus-eluting Stent With Bioresorbable Polymer Versus Everolimus-eluting Stent With Durable Polymer for Total Coronary Occlusions in Native Coronary Arteries (PRISON-IV)|Active, not recruiting||Phase 3|330|Anticipated|R&D Cardiologie||2|||f||||t||||||||||2018-05-31 21:43:09.774868|2018-05-31 21:43:09.774868
NCT01516710|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-01-04|2012-01-19|2012-01-25|Estimate|||||||2017-01-04|2017-01-06|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|December 2025|Anticipated|2025-12-31|April 2016|Actual|2016-04-30||Interventional|Oslo-CoMet||Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study|Prospective Randomized Study of Laparoscopic Versus Open Liver Resection for Colorectal Metastases|Active, not recruiting||N/A|280|Actual|Oslo University Hospital||2|||f||||f||||||||Yes|Not decided yet but results will be public no matter the outcome of the trial|2018-05-31 21:43:09.869779|2018-05-31 21:43:09.869779
NCT01516697|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-01-15|2012-01-19|2012-01-25|Estimate|||||||2017-01-15|2017-01-18|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Non-invasive Cardiac Output Monitoring in Obstetric Patients|Using Thoracic Electrical Bioimpedance to Measure Stroke Volume and Cardiac Output in Patients Under Spinal Anesthesia for Cesarean Section|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||unable to enrollment subjects due to early departure of study personele|f||||f||||||||||2018-05-31 21:43:09.961346|2018-05-31 21:43:09.961346
NCT01516684|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2018-01-24|2012-01-20|2012-01-25|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2012||2012-01-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures|A Randomized, Double Blind Trial of Pediatric Lumbar Puncture Under Sedation/Total Intravenous Anesthesia (TIVA) With and Without EMLA Cream|Suspended||Phase 2|40|Anticipated|Wake Forest University Health Sciences||2||Resource Issues|f||||f|t|f||||||||2018-05-31 21:43:10.022137|2018-05-31 21:43:10.022137
NCT01514084|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2014-04-21|2012-01-17|2012-01-20|Estimate|||||||2014-04-21|2014-04-23|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Cosmetic Outcomes and Patient Satisfaction After Facial Laceration Repair in the Emergency Department||Completed|||160|Anticipated|Children's Hospitals and Clinics of Minnesota|||4||f||||||||||||||2018-05-31 21:43:52.120282|2018-05-31 21:43:52.120282
NCT01516671|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-11-11|2012-01-24|2012-01-25|Estimate|||||||2013-11-11|2013-11-13|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Neuroinflammation and Bispectral Index After Subarachnoid Hemorrhage|Pilot Study on the Role of Neuroinflammation in the Pathophysiology of Subarachnoid Hemorrhage and the Value of the Bilateral Bispectral Index for Early Diagnosis of Cerebral Ischemia After Subarachnoid Hemorrhage.|Unknown status|Active, not recruiting||40|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||f||||||Samples With DNA|"~     Cerebrospinal fluid Blood~   "|||2018-05-31 21:43:10.115214|2018-05-31 21:43:10.115214
NCT01516658|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2018-03-05|2012-01-24|2012-01-25|Estimate|||||||2018-03-05|2018-03-07|Actual|June 2012|Actual|2012-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|March 2017|Actual|2017-03-31||Interventional|HYBRID||HYdrogel Coil Versus Bare Platinum Coil in Recanalization Imaging Data Study|Efficacy of Hydrogel Coil on Endovascular Treatment for Intracranial Aneurysms; Multi-center, Prospective, Randomized, Open-label Blind-endpoint Trial|Active, not recruiting||Phase 4|431|Actual|Kobe City General Hospital||2|||f||||t||||||||||2018-05-31 21:43:10.175956|2018-05-31 21:43:10.175956
NCT01516645|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-03-14|2012-01-24|2012-01-25|Estimate|||||||2017-03-14|2017-03-16|Actual|January 2012|Actual|2012-01-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors|Phase 1, Open-Label, Dose Escalation Study of Anti-CD98 Monoclonal Antibody KHK2898 as Monotherapy in Subjects With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy Is Available|Terminated||Phase 1|14|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 21:43:10.249255|2018-05-31 21:43:10.249255
NCT01516632|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2016-03-29||2016-04-28|2012-01-24|2012-01-25|Estimate|2016-04-28|2016-06-06|Estimate||||2016-04-28|2016-06-06|Estimate|June 2009||2009-06-30|April 2016|2016-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SMS USA||Smoking Cessation Via Text Messaging: Feasibility Testing of Stop My Smoking USA|Smoking Cessation Via Text Messaging: Feasibility Testing of SMS USA|Completed||N/A|164|Actual|Center for Innovative Public Health Research|The main limitation of the study is its small sample size. Also, it is unclear how young adult smokers recruited on Craigslist compared with young adult smokers who would be recruited through other ways.|2|||f||||f||||||||No||2018-05-31 21:43:10.327771|2018-05-31 21:43:10.327771
NCT01516619|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|September 2014|Anticipated|2014-09-30|November 2013|Anticipated|2013-11-30||Interventional|ProRom||Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia|Pilot Phase II Trial on Safety and Activity of Secondary Prophylaxis With Romiplostim in Patients With Non-Hodgkin Lymphoma and Chemotherapy-induced Thrombocytopenia|Unknown status|Recruiting|Phase 2|20|Anticipated|IRCCS San Raffaele||1|||f||||f||||||||||2018-05-31 21:43:11.043428|2018-05-31 21:43:11.043428
NCT01516606|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-19|2012-01-19|2012-01-25|Estimate|||||||2012-01-19|2012-01-25|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|HD-K||Salvage Therapy With High Dose Oral Clarithromycin in Relapsed or Refractory Extranodal Marginal Zone Lymphoma|Phase II Clinical Trial on the Activity of Salvage Therapy With High Dose Oral Clarithromycin in Patients With Relapsed or Refractory Extranodal Marginal Zone Lymphoma|Unknown status|Recruiting|Phase 2|19|Anticipated|IRCCS San Raffaele||1|||f||||f||||||||||2018-05-31 21:43:11.152017|2018-05-31 21:43:11.152017
NCT01516593|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|August 2015|Anticipated|2015-08-31|April 2013|Anticipated|2013-04-30||Interventional|CARMEN||Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma|Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma|Unknown status|Recruiting|Phase 2|19|Anticipated|IRCCS San Raffaele||1|||f||||f||||||||||2018-05-31 21:43:11.259467|2018-05-31 21:43:11.259467
NCT01516580|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-06-13|2012-01-24|2012-01-25|Estimate|||||||2017-06-13|2017-06-14|Actual|December 2011||2011-12-31|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|June 13, 2017|Actual|2017-06-13||Interventional|||Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients|Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial|Active, not recruiting||Phase 3|482|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 21:43:11.371069|2018-05-31 21:43:11.371069
NCT01516567|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-08-01|2012-01-24|2012-01-25|Estimate|||||||2017-08-01|2017-08-02|Actual|December 1, 2011|Actual|2011-12-01|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2016|Actual|2016-04-30||Interventional|||Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation|Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase II Trial of DA-EPOCH-Rituximab in PMLBL|Active, not recruiting||Phase 2|47|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||t||||||||||2018-05-31 21:43:11.574122|2018-05-31 21:43:11.574122
NCT01516554|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-07-04|2012-01-24|2012-01-25|Estimate|||||||2014-07-04|2014-07-08|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients|A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients|Terminated||Phase 2|3|Actual|Health Sciences Centre, Winnipeg, Manitoba||2||Poor recruitment|f||||f||||||||||2018-05-31 21:43:11.697598|2018-05-31 21:43:11.697598
NCT01516541|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13||2016-07-08|2016-11-01|2012-01-24|2012-01-25|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease|A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD).|Completed||Phase 3|2220|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:43:11.880844|2018-05-31 21:43:11.880844
NCT01516528|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-09-18|2012-01-19|2012-01-25|Estimate|||||||2017-09-18|2017-09-20|Actual|November 17, 2011||2011-11-17|September 2017|2017-09-30|June 12, 2015|Actual|2015-06-12|May 1, 2015|Actual|2015-05-01||Observational|ACCESS||Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care|Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care|Completed|||3500|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:43:12.416826|2018-05-31 21:43:12.416826
NCT01516515|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-02-13|2012-01-24|2012-01-25|Estimate|||||||2018-02-13|2018-02-15|Actual|February 2013||2013-02-28|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis|A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Patients With Actinic Keratosis (AK)|Active, not recruiting||Phase 2|86|Actual|G&E Herbal Biotechnology Co., LTD||2|||f||||f||||||||||2018-05-31 21:43:12.767184|2018-05-31 21:43:12.767184
NCT01516502|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2012-01-24|2012-01-24|2012-01-25|Estimate|||||||2012-01-24|2012-01-25|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Efficacy of Low-level Laser on Cervical Myofascial Pain Syndrome|Is Low-level Laser on Traditional Acupoint as Effective as That on Trigger Point in the Management of Cervical Myofascial Pain Syndrome?|Completed||N/A|100|Actual|Chang Gung Memorial Hospital||4|||f||||f||||||||||2018-05-31 21:43:12.856465|2018-05-31 21:43:12.856465
NCT01516489|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-10-23|2012-01-19|2012-01-25|Estimate|||||||2015-10-23|2015-10-26|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|June 2015|Actual|2015-06-30|October 2013|Actual|2013-10-31||Interventional|||Improving Fecal Occult Blood Test Completion Rates Among Veterans|Improving Fecal Occult Blood Test Completion Rates Among Veterans|Completed||Phase 1/Phase 2|1549|Actual|Corporal Michael J. Crescenz VA Medical Center||8|||f||||f||||||||||2018-05-31 21:43:13.059945|2018-05-31 21:43:13.059945
NCT01516476|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12||2016-07-08|2016-11-01|2012-01-19|2012-01-24|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of RO6807952 in Patients With Diabetes Mellitus Type 2|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of RO6807952 in Type 2 Diabetic Patients Inadequately Controlled With Metformin Alone|Terminated||Phase 2|2|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:43:13.153296|2018-05-31 21:43:13.153296
NCT01516463|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-05-15|2012-01-23|2012-01-24|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Using Santyl or Bacitracin on Second Degree Burns|Comparison of Collagenase Santyl® Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns|Withdrawn||Phase 4|0|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 21:43:13.252897|2018-05-31 21:43:13.252897
NCT01516450|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-06-09|2012-01-19|2012-01-24|Estimate|||||||2017-06-09|2017-06-12|Actual|December 26, 2011|Actual|2011-12-26|June 2017|2017-06-30|April 11, 2012|Actual|2012-04-11|April 11, 2012|Actual|2012-04-11||Interventional|||Japanese phase1 Study of Belimumab (IV vs SC)|An Open Label, Randomized, Parallel, Single Dose Study to Investigate Safety and Pharmacokinetics Following Intravenous Administration and Subcutaneous Administration of GSK1550188 in Healthy Japanese Males|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:43:13.348989|2018-05-31 21:43:13.348989
NCT01516437|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2017-01-10||2017-04-12|2012-01-19|2012-01-24|Estimate|2017-01-16|2017-03-07|Actual||||2017-04-12|2017-05-17|Actual|February 1, 2012|Actual|2012-02-01|April 2017|2017-04-30|December 20, 2012|Actual|2012-12-20|June 28, 2012|Actual|2012-06-28||Interventional|||A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD|A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD) Aged Between 45-75 Years|Completed||N/A|73|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 21:43:13.501982|2018-05-31 21:43:13.501982
NCT01516424|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-12-02|2012-01-19|2012-01-24|Estimate|||||||2013-12-02|2013-12-03|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone|A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone|Completed||Phase 3|267|Actual|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:43:14.160852|2018-05-31 21:43:14.160852
NCT01516411|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-12-08|2012-01-19|2012-01-24|Estimate|||||||2015-12-08|2015-12-09|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Promoting Healthy Lifestyles Using Mobile Phones|Promoting Healthy Lifestyles Using Mobile Phones|Completed||N/A|130|Actual|Stanford University||4|||f||||f||||||||||2018-05-31 21:43:14.246616|2018-05-31 21:43:14.246616
NCT01516398|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2018-04-27|2012-01-19|2012-01-24|Estimate|||||||2018-04-27|2018-05-01|Actual|July 2011|Actual|2011-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia|Endothelin-1 (ET-1) Levels as Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia (BPD)|Recruiting|||60|Anticipated|Stanford University|||||f||||f||||||||Yes|Publication|2018-05-31 21:43:14.304829|2018-05-31 21:43:14.304829
NCT01516385|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-01-26|2012-01-19|2012-01-24|Estimate|||||||2012-01-26|2012-01-31|Estimate|January 2012||2012-01-31|January 2012|2012-01-31||||||||Observational|||Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions.||Unknown status|Not yet recruiting||150|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 21:43:14.38335|2018-05-31 21:43:14.38335
NCT01516372|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2013-07-15|2012-01-19|2012-01-24|Estimate|||||||2013-07-15|2013-07-16|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers|A Randomized, Double-blind, Single Dose Crossover Study to Assess the Effect of Gabapentin Enacarbil on Cardiac Conduction as Compared With Placebo and Moxifloxacin in Healthy Volunteers|Completed||Phase 1|52|Actual|XenoPort, Inc.||4|||f||||f||||||||||2018-05-31 21:43:14.436986|2018-05-31 21:43:14.436986
NCT01516359|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-24|Estimate|||||||2012-01-19|2012-01-24|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Observational|||Incidence and Predictive Factors of Intestinal Injury in Patients Undergoing Heart Valve Replacements|Official Title is Required by the WHO and ICMJE|Unknown status|Recruiting||1000|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||t||||||Samples With DNA|"~     Blood samples are retained for the detections of some biomarkers and gene polymorphism.~   "|||2018-05-31 21:43:15.5393|2018-05-31 21:43:15.5393
NCT01514071|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-07-30|2012-01-17|2012-01-20|Estimate|||||||2013-07-30|2013-07-31|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Animated Picture to Improve Provider Adherence to CT Scan for Head Injury Rule||Completed||N/A|746|Anticipated|Children's Hospitals and Clinics of Minnesota||1|||f||||||||||||||2018-05-31 21:43:52.182716|2018-05-31 21:43:52.182716
NCT01516346|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2018-04-03|2012-01-23|2012-01-24|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2012||2012-01-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction|Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction|Completed||Phase 2|54|Anticipated|Corporal Michael J. Crescenz VA Medical Center||3|||f||||f||||||||||2018-05-31 21:43:15.627809|2018-05-31 21:43:15.627809
NCT01516333|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2015-12-17|2012-01-19|2012-01-24|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2007||2007-02-28|December 2015|2015-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Replace Glycemic Load and Satiety Study|Response of Energy Peak Levels After Carbohydrates Are Eaten Glycemic Load and Satiety Study - Phase 1|Completed||Phase 1|26|Actual|Pennington Biomedical Research Center||4|||f||||f||||||||||2018-05-31 21:43:15.739109|2018-05-31 21:43:15.739109
NCT01516320|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-01-30|2012-01-19|2012-01-24|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 13, 2009|Actual|2009-05-13|January 2017|2017-01-31|September 1, 2014|Actual|2014-09-01|September 1, 2014|Actual|2014-09-01||Interventional|LAF26||Mechanisms of Diabetes Relapse After Bariatric Surgery|Mechanisms of Diabetes Relapse After Bariatric Surgery|Completed||N/A|56|Actual|Columbia University||3|||f||||t|f|f||||||No||2018-05-31 21:43:15.826|2018-05-31 21:43:15.826
NCT01516307|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19||2017-03-02|2018-05-15|2012-01-19|2012-01-24|Estimate||||2017-03-02|2017-03-03|Actual|2018-05-15|2018-05-17|Actual|December 2011||2011-12-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2016|Actual|2016-08-31||Interventional|||Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects|A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast Cancer|Active, not recruiting||Phase 2|349|Actual|OBI Pharma, Inc||2|||f||||t|t|f||||||No||2018-05-31 21:43:15.923879|2018-05-31 21:43:15.923879
NCT01516294|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-10-31|2012-01-23|2012-01-24|Estimate|||||||2012-10-31|2012-11-01|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Interventional|||IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD|A Pilot, Single-center, Interventional Clinical Trial in Which Subjects With Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD) Will Receive Low Voltage Stereotactic Radiotherapy (IRay®) Treatment and Lucentis® Treatment as Needed.|Unknown status|Active, not recruiting|N/A|12|Anticipated|Oraya Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 21:43:16.848065|2018-05-31 21:43:16.848065
NCT01516281|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-01-22|2012-01-23|2012-01-24|Estimate|||||||2016-01-22|2016-01-26|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Imaging Biomarkers of Delayed Sequelae in Trauma Brain Injury|Imaging Biomarkers of Delayed Sequelae in Mild to Moderate Traumatic Brain Injury|Completed|||67|Actual|NorthShore University HealthSystem Research Institute|||2||f||||f||||||Samples With DNA|"~     Collect blood and extract and store plasma and DNA from 100 mTBI and 100 mTBI- subjects~     undergoing clinical assessments and DaTscan studies.~   "|||2018-05-31 21:43:16.917292|2018-05-31 21:43:16.917292
NCT01516268|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2013-02-19||2013-02-19|2012-01-23|2012-01-24|Estimate|2013-02-19|2013-03-27|Estimate||||2013-02-19|2013-03-27|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|TAP|25 & 25|The Effect of Adding Sufentanyl to Bupivacaine in Transversus Abdominis Plane Block to Reduce the Narcotic Dosage and Pain After Cesarean Delivery|the Effect of Adding Sufentanyl to Bupivacaine in Transversus Abdominis Plane (TAP) Block Under the Guide of Ultrasound to Reduce the Narcotic Dosage, Side Effects and Pain in the First 24 Hours After Cesarean Delivery|Completed||Phase 4|50|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:43:16.987107|2018-05-31 21:43:16.987107
NCT01516255|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-01-24|2012-01-19|2012-01-24|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2006||2006-07-31|January 2017|2017-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Effect of Liraglutide on Heart Frequency in Healthy Volunteers|A Thorough QTc Evaluation of the Effect of Liraglutide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Two Period Crossover Study Followed by Open-label Moxifloxacin (Positive Control) Administration|Completed||Phase 1|64|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:43:17.199194|2018-05-31 21:43:17.199194
NCT01516242|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-11-04|2012-01-19|2012-01-24|Estimate|||||||2016-11-04|2016-11-07|Estimate|October 2006||2006-10-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Evaluation of Safety and Parameters of Application Technique|Monitoring of Expected Parameters of the Application Technique and Safety of the Therapy|Completed|||4819|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:43:17.299168|2018-05-31 21:43:17.299168
NCT01516229|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-02-23|2012-01-19|2012-01-24|Estimate|||||||2017-02-23|2017-02-27|Actual|May 1, 1997|Actual|1997-05-01|February 2017|2017-02-28|March 31, 2007|Actual|2007-03-31|March 31, 2007|Actual|2007-03-31||Observational|||Special Survey for Long Term Application|Specific Survey of Norditropin® in Achondroplasia: Survey for Long-term Application|Completed|||395|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:43:17.374304|2018-05-31 21:43:17.374304
NCT01516216|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-02-07|2012-01-23|2012-01-24|Estimate|||||||2018-02-07|2018-02-09|Actual|March 2012||2012-03-31|February 2018|2018-02-28||||March 2018|Anticipated|2018-03-31||Interventional|||Study of Vitamin D in Untreated Metastatic Colorectal Cancer|Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|120|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 21:43:17.568815|2018-05-31 21:43:17.568815
NCT01516203|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19||2014-04-16|2016-12-16|2012-01-19|2012-01-24|Estimate||||2014-04-16|2014-05-07|Estimate|2016-12-16|2016-12-19|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Phase 2a EBA Trial of AZD5847|Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis|Completed||Phase 2|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-05-31 21:43:17.705081|2018-05-31 21:43:17.705081
NCT01516190|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-06-01|2012-01-23|2012-01-24|Estimate|||||||2016-06-01|2016-06-02|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|PreHab||The Preoperative Health & Body Study|The Preoperative Health & Body Study|Recruiting||N/A|50|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 21:43:17.855328|2018-05-31 21:43:17.855328
NCT01516177|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-12-16|2012-01-19|2012-01-24|Estimate|||||||2016-12-16|2016-12-20|Estimate|September 2010||2010-09-30|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ARTIST||Associating Renal Transplantation With the ITN Signature of Tolerance|An Observational Study to Assess the Prevalence of a Tolerance Signature in Renal Transplant Recipients (ITN524ST/CTOT-12)|Completed|||250|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Whole blood Isolation PBMC isolated RNA specimens~   "|||2018-05-31 21:43:17.958609|2018-05-31 21:43:17.958609
NCT01516164|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-10-03|2012-01-23|2012-01-24|Estimate|||||||2014-10-03|2014-10-06|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Comparison of the Ease of Tracheal Intubation Using a McGrath MAC Laryngoscope and a Standard MacIntosh Laryngoscope|A Comparison of the Ease of Tracheal Intubation Using a McGrath MAC Laryngoscope and a Standard MacIntosh Laryngoscope|Completed||N/A|158|Actual|NHS Tayside||3|||f||||f||||||||||2018-05-31 21:43:18.079895|2018-05-31 21:43:18.079895
NCT01516151|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-01-07|2012-01-23|2012-01-24|Estimate|||||||2014-01-07|2014-01-08|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|||Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia|A Randomized Open-label Dose-ranging, Multi-center Trial to Assess the Safety and Efficacy of NKPL66(CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia|Completed||Phase 2|289|Actual|Acasti Pharma Inc.||5|||f||||f||||||||||2018-05-31 21:43:18.177917|2018-05-31 21:43:18.177917
NCT01516138|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2014-10-30|2012-01-23|2012-01-24|Estimate|||||||2014-10-30|2014-10-31|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|February 2022|Anticipated|2022-02-28|March 2013|Actual|2013-03-31||Interventional|||Benefits of GIK in Cardiac Surgery Patients|Myocardial Protection of Glucose - Insulin - Potassium in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Active, not recruiting||Phase 2|930|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 21:43:18.360523|2018-05-31 21:43:18.360523
NCT01516125|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2017-11-06|2012-01-18|2012-01-24|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2011||2011-09-30|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Observational|||Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing|Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing|Recruiting|||800|Anticipated|Wake Forest University Health Sciences|||1||f||||t||||||Samples With DNA|"~     A small saliva sample for screening purposes will be collected. If documentation from a~     personal physician of blood glucose and lipid levels are unavailable, we will collect a small~     tube (10-12 ml) of blood to determine these measurements.~   "|No|This is a screening (one visit) to recruit healthy people for genotyping and re-contact for future studies|2018-05-31 21:43:18.477791|2018-05-31 21:43:18.477791
NCT01516112|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-01-19|2012-01-19|2012-01-24|Estimate|||||||2012-01-19|2012-01-24|Estimate|February 2012||2012-02-29|July 2011|2011-07-31||||||||Observational|||Meir Medical Center Home Monitoring Clinic Registry|Meir Medical Center Home Monitoring Clinic Registry|Unknown status|Not yet recruiting||20|Anticipated|Meir Hospital, Kfar Saba, Israel|||||f||||f||||||||||2018-05-31 21:43:18.544171|2018-05-31 21:43:18.544171
NCT01516099|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-08-12|2012-01-23|2012-01-24|Estimate|||||||2013-08-12|2013-08-13|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||A Structural Approach to Implement the Role of 'Physical Activity Counselors' in Sports and Exercise Promotion|Pilot Study: A Structural Approach to Implement the Role of 'Physical Activity Counselors' in Sports and Exercise Promotion in Flanders|Completed||Phase 4|110|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 21:43:18.628059|2018-05-31 21:43:18.628059
NCT01516086|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13||2014-11-24|2014-11-24|2012-01-19|2012-01-24|Estimate||||2014-11-24|2014-12-11|Estimate|2014-11-24|2014-12-11|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A 12-Week Study in Adult Subjects With Asthma|A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects With Partly Controlled and Uncontrolled Asthma|Completed||Phase 2|498|Actual|Dey||6|||f||||f||||||||||2018-05-31 21:43:18.722357|2018-05-31 21:43:18.722357
NCT01516073|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13||2014-11-24|2014-11-24|2012-01-19|2012-01-24|Estimate||||2014-11-24|2014-12-11|Estimate|2014-11-24|2014-12-11|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||12-Week Study in Adult Subjects With Asthma|A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects With Partly Controlled and Uncontrolled Asthma|Completed||Phase 2|629|Actual|Dey||6|||f||||f||||||||||2018-05-31 21:43:18.925247|2018-05-31 21:43:18.925247
NCT01516060|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2013-09-18|2012-01-19|2012-01-24|Estimate|||||||2013-09-18|2013-09-19|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Neurocognitive Sub-study of Encore1|The Neurocognitive Sub Study of Encore1:A Randomised, Double‐Blind, Placebo‐Controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus 2N(t)RTI in Antiretroviral‐naïve HIV‐Infected Individuals Over 96 Weeks A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks|Completed||Phase 3|71|Actual|Kirby Institute||2|||f||||t||||||||||2018-05-31 21:43:19.023092|2018-05-31 21:43:19.023092
NCT01516047|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-06-24|2012-01-19|2012-01-24|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function|An Open-Label Pharmacokinetic Study of Abiraterone Acetate Suspension in Subjects With Severe Hepatic Impairment Compared to Matched Control Subjects With Normal Hepatic Function|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 21:43:19.122698|2018-05-31 21:43:19.122698
NCT01516034|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2012-11-09||2012-11-22|2012-01-19|2012-01-24|Estimate|2012-11-22|2012-12-21|Estimate||||2012-11-22|2012-12-21|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Efficacy of the Cupola Ultrasonic Tattoo Removal Device|The Efficacy of the Cupola Ultrasonic Tattoo Removal Device: A Prospective Single Blinded, Before-After Study Design|Terminated||N/A|8|Actual|Cupola Medical Ltd||1||Sponsor decided that the results were not significant enough to continue.|f||||f||||||||||2018-05-31 21:43:19.234913|2018-05-31 21:43:19.234913
NCT01516021|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-18|2012-01-18|2012-01-24|Estimate|||||||2012-01-18|2012-01-24|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||How Fat Influences the Brain|Fat Intake Modulates Cerebral Blood Flow in Homeostatic and Gustatory Brain Areas in Humans|Completed||N/A|11|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 21:43:19.462445|2018-05-31 21:43:19.462445
NCT01515839|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players|Brain Single Photon Emission Computed Tomography and Quantitative Electroencephalography In Former NFL Players: A Single-Site Exploratory Pilot Study|Completed||N/A|100|Actual|Amen Clinics, Inc.||1|||f||||t||||||||||2018-05-31 21:43:22.900279|2018-05-31 21:43:22.900279
NCT01516008|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2014-01-24||2014-03-28|2012-01-19|2012-01-24|Estimate|2014-03-28|2014-04-28|Estimate||||2014-03-28|2014-04-28|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy; Bridging Study for Korea|Completed||Phase 3|353|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 21:43:19.606187|2018-05-31 21:43:19.606187
NCT01515995|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2016-05-03|2012-01-18|2012-01-24|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation|Nebulized Magnesium Sulfate Versus Normal Saline as a Vehicle for Albuterol in Children With Moderate to Severe Asthma Exacerbation: a Randomized Controlled Trial|Completed||Phase 4|50|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 21:43:20.397372|2018-05-31 21:43:20.397372
NCT01515982|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2014-12-01|2012-01-23|2012-01-24|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Physical Exercise as an Additional Treatment for Alzheimer Disease||Completed||N/A|20|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 21:43:20.490974|2018-05-31 21:43:20.490974
NCT01515969|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-07-11|2012-01-23|2012-01-24|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|February 2013|Actual|2013-02-28||Interventional|||Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase I Study of Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer|Terminated||Phase 1|9|Actual|Stanford University||1||Patient safety - Unacceptable toxicity|f||||t||||||||||2018-05-31 21:43:20.582|2018-05-31 21:43:20.582
NCT01515956|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2017-04-13||2017-07-12|2012-01-23|2012-01-24|Estimate|2017-06-07|2017-07-06|Actual||||2017-07-12|2017-08-10|Actual|October 2011||2011-10-31|July 2017|2017-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)|Completed||Phase 2|15|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||||2018-05-31 21:43:20.720118|2018-05-31 21:43:20.720118
NCT01515943|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2016-05-02||2017-04-11|2012-01-19|2012-01-24|Estimate|2016-06-24|2016-08-05|Estimate||||2017-04-11|2017-04-12|Actual|June 2012||2012-06-30|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Convergence Insufficiency Treatment Study (CITS)|Effectiveness of Home-Based Therapy for Symptomatic Convergence Insufficiency|Completed||N/A|204|Actual|Jaeb Center for Health Research|"Differential loss to follow-up (HB-C 8%, HB-PU 19%, and HB-P 30%).~Did not formally assess whether participants remained masked to their treatment group during the study.~Assessment of compliance was not completely objective."|3|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 21:43:21.325651|2018-05-31 21:43:21.325651
NCT01515930|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-06-01|2012-01-23|2012-01-24|Estimate|||||||2017-06-01|2017-06-02|Actual|April 2011||2011-04-30|June 2017|2017-06-30|September 9, 2014|Actual|2014-09-09|March 3, 2014|Actual|2014-03-03||Interventional|||Computerized Intervention of Parental Involvement in Diabetes Care of Their Child|Computer-Delivered Motivational Intervention to Improve Teen Diabetes Management|Completed||N/A|145|Actual|Wayne State University||3|||f||||t|f|f||||||No||2018-05-31 21:43:21.975185|2018-05-31 21:43:21.975185
NCT01515917|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-01-15|2012-01-23|2012-01-24|Estimate|||||||2015-01-15|2015-01-19|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)|Citicoline and Omega-3 Fatty Acid Effects in Veterans With TBI|Withdrawn||N/A|0|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 21:43:22.062402|2018-05-31 21:43:22.062402
NCT01515904|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-11-13|2012-01-23|2012-01-24|Estimate|||||||2017-11-13|2017-11-17|Actual|April 2011||2011-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|STOMP||Evaluation of the SickKids Team Obesity Management Program|Evaluation of the SickKids Team Obesity Management Program (STOMP)|Recruiting|||400|Anticipated|The Hospital for Sick Children|||2||f||||f||||||||||2018-05-31 21:43:22.149004|2018-05-31 21:43:22.149004
NCT01515891|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2014-12-30||2014-12-30|2012-01-19|2012-01-24|Estimate|2014-12-30|2015-01-09|Estimate||||2014-12-30|2015-01-09|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional|||Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites|An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites Following a Single-dose Oral Administration|Completed||Phase 1|4|Actual|Bial - Portela C S.A.||1|||f||||f||||||||||2018-05-31 21:43:22.242052|2018-05-31 21:43:22.242052
NCT01515878|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-07-04|2012-01-23|2012-01-24|Estimate|||||||2012-07-04|2012-07-06|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|HERACLES||Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS|Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS|Unknown status|Recruiting|Phase 4|396|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 21:43:22.423442|2018-05-31 21:43:22.423442
NCT01515865|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2014-10-16||2014-11-10|2012-01-18|2012-01-24|Estimate|2014-10-16|2014-10-22|Estimate||||2014-11-10|2014-11-21|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||The Enrolled Population consisted of all subjects who participated in Part A baseline procedures starting at Day -1.|Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension|A Phase 4, Randomized-withdrawal, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects With Symptomatic Orthostatic Hypotension|Completed||Phase 4|67|Actual|Shire||2|||f||||t||||||||||2018-05-31 21:43:22.532872|2018-05-31 21:43:22.532872
NCT01515852|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-02-20|2012-01-23|2012-01-24|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|GALAXY||General Anesthesia vs. Local Anesthesia in Stereotaxy|General Anesthesia vs. Local Anesthesia in Stereotaxy|Unknown status|Recruiting|N/A|80|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 21:43:22.812843|2018-05-31 21:43:22.812843
NCT01515826|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-03-24|2012-01-19|2012-01-24|Estimate|||||||2014-03-24|2014-03-26|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery|Evaluation of the Safety and Efficacy of VIGADEXA Ophthalmic Gel Compared to VIGADEXA Ophthalmic Solution in Preventing Inflammation and Infection Following Cataract Surgery|Withdrawn||Phase 3|0|Actual|Alcon Research||2||Management decision|f||||f||||||||||2018-05-31 21:43:22.9689|2018-05-31 21:43:22.9689
NCT01515813|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2016-01-29|2012-01-19|2012-01-24|Estimate|||||||2016-01-29|2016-02-01|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation|A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts|Withdrawn||Phase 2|0|Actual|AIDS Clinical Trials Group||3||On 05/08/12, team working on revising protocol and re-open study under version 2.0|f||||t||||||||||2018-05-31 21:43:23.043922|2018-05-31 21:43:23.043922
NCT01515800|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-21|||2018-03-06|2012-01-21|2012-01-24|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2012||2012-05-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Interventional|||S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer|S1105, Randomized Trial Of Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer|Completed||N/A|724|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 21:43:23.180505|2018-05-31 21:43:23.180505
NCT01515787|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2018-05-04|2012-01-18|2012-01-24|Estimate|||||||2018-05-04|2018-05-08|Actual|January 2012|Actual|2012-01-31|May 2018|2018-05-31||||January 2021|Anticipated|2021-01-31||Interventional|||PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery|A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)|Recruiting||Phase 2/Phase 3|1120|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 21:43:24.125481|2018-05-31 21:43:24.125481
NCT01515774|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-18|2012-01-18|2012-01-24|Estimate|||||||2012-01-18|2012-01-24|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)|An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease|Unknown status|Recruiting|Phase 4|200|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:43:27.548661|2018-05-31 21:43:27.548661
NCT01515761|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|September 2010||2010-09-30|January 2012|2012-01-31||||March 2013|Anticipated|2013-03-31||Interventional|POLAR||POsition of Leads in Advanced heaRt Failure: the POLAR Study|POsition of Leads in Advanced heaRt Failure: the POLAR Study - A 6 Month, Observational, Mult-centered, Blinded, Randomized Study to Determine if Lead Positioning in the Lateral Wall of LV in Patients Meeting Criteria for CRT Plays a Role in Determining Myocardial Function and Affect the Severity of Mitral Regurgitation|Unknown status|Recruiting|N/A|60|Anticipated|Southern Arizona VA Health Care System||2|||f||||t||||||||||2018-05-31 21:43:27.64104|2018-05-31 21:43:27.64104
NCT01515748|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2017-04-12|2012-01-18|2012-01-24|Estimate|||||||2017-04-12|2017-04-13|Actual|January 2012||2012-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PRODIGY||Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer|A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer|Active, not recruiting||Phase 3|640|Anticipated|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 21:43:27.743369|2018-05-31 21:43:27.743369
NCT01515735|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||LOXL1 Polymorphism in Pseudoexfoliation Syndrome|Evaluation of LOXL1 Polymorphism in Pseudoexfoliation Syndrome in the Korean Population|Unknown status|Recruiting||60|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     Peripheral blood sample~   "|||2018-05-31 21:43:27.803148|2018-05-31 21:43:27.803148
NCT01515722|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder|Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder : 6-month, Randomized, Open-label, Multi-center Trial|Unknown status|Recruiting|N/A|692|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:43:27.994844|2018-05-31 21:43:27.994844
NCT01515709|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2017-05-11|2012-01-18|2012-01-24|Estimate|||||||2017-05-11|2017-05-12|Actual|April 2011|Actual|2011-04-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2013|Actual|2013-09-30||Observational|||Is the Short Physical Performance Battery a Useful Outcome Measure in Chronic Obstructive Pulmonary Disease|Is the Short Physical Performance Battery a Useful Outcome Measure in Patients With Chronic Obstructive Pulmonary Disease ?|Active, not recruiting|||445|Actual|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 21:43:28.132145|2018-05-31 21:43:28.132145
NCT01515696|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2013-10-29||2014-06-17|2012-01-23|2012-01-24|Estimate|2014-06-17|2014-07-18|Estimate||||2014-06-17|2014-07-18|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|||Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants|Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants- a Phase 4 Study|Completed||Phase 4|96|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:43:28.227192|2018-05-31 21:43:28.227192
NCT01515683|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-05-05|2012-01-18|2012-01-24|Estimate|||||||2014-05-05|2014-05-06|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|STØB||Behavioral Support Before Anesthesia|Behavioral Support to Cancer Patients Before Anesthesia|Completed||Phase 2|350|Actual|Odense University Hospital||4|||f||||t||||||||||2018-05-31 21:43:28.548716|2018-05-31 21:43:28.548716
NCT01515670|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-07-30|2012-01-23|2012-01-24|Estimate|||||||2017-07-30|2017-08-01|Actual|February 2010||2010-02-28|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|90 Days|Observational [Patient Registry]|||Length of Stay and Complications in High-risk Patients Receiving Fast-track Total Hip (THA) or Knee- Alloplasty (TKA)|Length of Stay and Complications in High-risk Patients Receiving Fast-track Total Hip (THA) or Knee- Alloplasty (TKA).|Recruiting|||30000|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 21:43:28.626172|2018-05-31 21:43:28.626172
NCT01515657|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2015-06-22||2016-02-11|2012-01-18|2012-01-24|Estimate|2015-08-05|2015-09-04|Estimate||||2016-02-11|2016-03-14|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients|A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes|Completed||Phase 3|40|Actual|PLx Pharma||3|||f||||f||||||||||2018-05-31 21:43:28.71514|2018-05-31 21:43:28.71514
NCT01515644|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-04-22|2012-01-18|2012-01-24|Estimate|||||||2013-04-22|2013-04-24|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|STAR-IFFO||Study on the Effect of Inulin in Infant Formula on Gut Health|A Randomized, Double-blind, Controlled Study on the Effect of Inulin on Gut Health of Infants|Completed||Phase 3|164|Actual|PT. Sari Husada||3|||f||||f||||||||||2018-05-31 21:43:28.862504|2018-05-31 21:43:28.862504
NCT01515631|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-10-14|2012-01-23|2012-01-24|Estimate|||||||2016-10-14|2016-10-18|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review|Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record|Recruiting|||25|Anticipated|Stanford University|||1||f||||f||||||||No||2018-05-31 21:43:28.931036|2018-05-31 21:43:28.931036
NCT01515618|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-08-30|2012-01-23|2012-01-24|Estimate|||||||2012-08-30|2012-08-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:43:28.985732|2018-05-31 21:43:28.985732
NCT01515605|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-10-12|2012-01-23|2012-01-24|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|MoMoTxRes||Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation|Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation|Recruiting|||1000|Anticipated|Odense University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood, urine, tissue~   "|No||2018-05-31 21:43:29.019328|2018-05-31 21:43:29.019328
NCT01515592|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-01-24|2012-01-18|2012-01-24|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2006||2006-01-31|January 2017|2017-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers|A Randomised, Double-blind Within Dose Group, Single Centre, Placebo-controlled, Dose Escalation, Multiple s.c. Dose Study to Assess the Safety and Tolerability of Liraglutide 20 ug/kg and 25 ug/kg in Healthy Japanese Male Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:43:29.09103|2018-05-31 21:43:29.09103
NCT01515579|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-01-29|2012-01-18|2012-01-24|Estimate|||||||2015-01-29|2015-01-30|Estimate|April 2006||2006-04-30|January 2015|2015-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Comparison of Two Liraglutide Formulations in Healthy Subjects|A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 2 Formulation of Liraglutide at pH 7.7 (Formulation 3) and the Phase 3 Formulation at pH 8.15 (Formulation 4)|Completed||Phase 1|22|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:43:30.199305|2018-05-31 21:43:30.199305
NCT01515566|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2014-08-07||2014-08-07|2012-01-18|2012-01-24|Estimate|2014-08-07|2014-08-22|Estimate||||2014-08-07|2014-08-22|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Breakthrough Dyspnea Fentanyl Study in Cancer Patients|Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized Controlled Trial|Completed||Phase 1/Phase 2|26|Actual|M.D. Anderson Cancer Center|The small sample size means findings are susceptible to random errors and regression to the mean.|2|||f||||t||||||||||2018-05-31 21:43:30.281355|2018-05-31 21:43:30.281355
NCT01515553|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-01-12|2012-01-23|2012-01-24|Estimate|||||||2015-01-12|2015-01-13|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers|A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 3a Formulation of Liraglutide (Formulation 4) and the Planned Phase 3b Formulation (Final Formulation 4)|Completed||Phase 1|22|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:43:30.527337|2018-05-31 21:43:30.527337
NCT01515540|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2012-10-16||2013-07-23|2012-01-23|2012-01-24|Estimate|2013-07-23|2013-07-30|Estimate||||2013-07-23|2013-07-30|Estimate|January 2004||2004-01-31|July 2013|2013-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Brain Imaging of Lidoderm for Chronic Back Pain|Brain Imaging of Lidoderm for Chronic Back Pain|Completed||Phase 4|38|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:43:30.597658|2018-05-31 21:43:30.597658
NCT01515527|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-02-27|2012-01-18|2012-01-24|Estimate|||||||2018-02-27|2018-03-01|Actual|February 2012|Actual|2012-02-29|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)|Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|160|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:43:30.806472|2018-05-31 21:43:30.806472
NCT01515514|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2013-05-15|2012-01-23|2012-01-24|Estimate|||||||2013-05-15|2013-05-17|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Confocal Endomicroscopy for GI Neoplasia Study|Confocal Endomicroscopy for GI Neoplasia Study|Completed|||40|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 21:43:30.999156|2018-05-31 21:43:30.999156
NCT01515501|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2017-03-22|2012-01-23|2012-01-24|Estimate|||||||2017-03-22|2017-03-24|Actual|October 2007||2007-10-31|March 2017|2017-03-31|July 2021|Anticipated|2021-07-31|January 2020|Anticipated|2020-01-31||Interventional|EDGE||Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)|Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial)|Recruiting||N/A|50|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:43:31.07584|2018-05-31 21:43:31.07584
NCT01515488|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2012-08-14||2012-09-13|2012-01-23|2012-01-24|Estimate|2012-09-13|2012-10-15|Estimate||||2012-09-13|2012-10-15|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Kiosk-Model Self-Triage System in the Pediatric Emergency Department|"Assessing Utility of a Kiosk Model Self-Triage System in the Pediatric Emergency Department of A Tertiary Care Teaching Hospital"|Completed||N/A|400|Actual|Maricopa Integrated Health System||2|||f||||f||||||||||2018-05-31 21:43:31.21345|2018-05-31 21:43:31.21345
NCT01515475|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-05-29|2012-01-18|2012-01-24|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 23, 2012|Actual|2012-02-23|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|HTS1||Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation|Glasses Versus Observation for Moderate Hyperopia in Young Children (HTS1)|Completed||N/A|249|Actual|Jaeb Center for Health Research||2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 21:43:31.550829|2018-05-31 21:43:31.550829
NCT01515462|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2018-01-22|2012-01-18|2012-01-24|Estimate|||||||2018-01-22|2018-01-24|Actual|April 20, 2010|Actual|2010-04-20|January 2018|2018-01-31|September 11, 2023|Anticipated|2023-09-11|September 11, 2018|Anticipated|2018-09-11||Interventional|TIGET-WAS||Gene Therapy for Wiskott-Aldrich Syndrome|A Phase I/II Clinical Trial of Hematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome|Active, not recruiting||Phase 2|8|Anticipated|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 21:43:31.649323|2018-05-31 21:43:31.649323
NCT01515449|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|October 1998||1998-10-31|January 2012|2012-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Predictors of Poor Outcomes in 1038 Sigma Knees|Predictors of Poor Outcomes in 1038 Sigma Knees|Completed|||1038|Actual|NHS Fife|||||f||||f||||||||||2018-05-31 21:43:31.755625|2018-05-31 21:43:31.755625
NCT01515436|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|February 2004||2004-02-29|January 2012|2012-01-31|December 2007|Actual|2007-12-31|May 2004|Actual|2004-05-31||Interventional|||The Effect of Music Periodicity on Interictal Epileptiform Discharges|A Randomized, Single-Blinded Clinical Trial: The Effect of Music Periodicity on Interictal Epileptiform Discharges|Completed||N/A|10|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:43:31.815977|2018-05-31 21:43:31.815977
NCT01515423|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2016-02-01||2016-04-28|2012-01-23|2012-01-24|Estimate|2016-04-28|2016-05-02|Estimate||||2016-04-28|2016-05-02|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional||The safety analysis set included all participants who were randomly assigned to treatment during the Double-blind Phase and received at least 1 dose study drug.|Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia|A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia|Completed||Phase 3|1429|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 21:43:31.992442|2018-05-31 21:43:31.992442
NCT01515410|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2013-11-20||2014-01-27|2012-01-23|2012-01-24|Estimate|2014-01-27|2014-03-10|Estimate||||2014-01-27|2014-03-10|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations|A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations|Completed||Phase 2|34|Actual|Depomed||2|||f||||f||||||||||2018-05-31 21:43:33.29303|2018-05-31 21:43:33.29303
NCT01515397|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2013-11-26|2012-01-18|2012-01-24|Estimate|||||||2013-11-26|2013-11-27|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison of Two Gelatine Solutions|Efficacy and Safety of a Balanced Gelatine Solution in Combination With a Balanced Electrolyte Solution Versus a Standard Gelatine Solution in Combination With a Non-balanced Electrolyte Solution in Patients Scheduled for Abdominal Surgery|Completed||Phase 3|40|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-05-31 21:43:33.496276|2018-05-31 21:43:33.496276
NCT01515384|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2012-11-08|2012-01-18|2012-01-24|Estimate|||||||2012-11-08|2012-11-09|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||A Trial of 18F-AV-133 Positron Emission Tomography (PET)|A Preliminary Evaluation of the Safety and Pancreas Imaging Properties of 18F-AV-133 in Healthy Volunteers and in Patients With Type 1 or Type 2 Diabetes|Suspended||Phase 1|35|Anticipated|Avid Radiopharmaceuticals||3|||f||||f||||||||||2018-05-31 21:43:33.571379|2018-05-31 21:43:33.571379
NCT01515371|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-06-18|2012-01-18|2012-01-24|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-stage Dose-finding Study to Identify a Safe and Effective Dose of NT 201 for Unilateral Injection Into the Soft Palate for Treatment of Habitual Snoring|Terminated||Phase 2|8|Actual|Merz Pharmaceuticals GmbH||2||Due to lack of sufficient eligible subjects, no safety concerns|f||||t||||||||||2018-05-31 21:43:33.638064|2018-05-31 21:43:33.638064
NCT01515358|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-05-30|2012-01-18|2012-01-24|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3000328 in Healthy Subjects|Completed||Phase 1|18|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:43:33.713435|2018-05-31 21:43:33.713435
NCT01515345|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2013-02-03||2017-03-24|2012-01-23|2012-01-24|Estimate|2013-03-19|2013-05-01|Estimate||||2017-03-24|2017-04-25|Actual|July 2011||2011-07-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|IDEAL-PCI||Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry|Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry|Completed||Phase 3|1008|Actual|Kaiser Franz Josef Hospital||2|||f||||f||||||||||2018-05-31 21:43:33.777707|2018-05-31 21:43:33.777707
NCT01515332|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2015-09-08|2012-01-18|2012-01-24|Estimate|||||||2015-09-08|2015-09-10|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|March 2011|Actual|2011-03-31||Observational|||Energy Expenditure Methodology|Energy Expenditure Methodology|Completed|||15|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-05-31 21:43:34.091791|2018-05-31 21:43:34.091791
NCT01512121|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2017-09-08|2012-01-13|2012-01-19|Estimate|||||||2017-09-08|2017-09-11|Actual|September 2011|Actual|2011-09-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Spinal Cord Stimulation and Functional MRI|Investigating the Cortical Correlates of Spinal Cord Stimulation Using Functional Magnetic Resonance Imaging|Completed|||10|Actual|Ohio State University|||1||f||||f||||||||||2018-05-31 21:44:17.234517|2018-05-31 21:44:17.234517
NCT01515319|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-03-27|2012-01-18|2012-01-24|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|Y242-01||Safety and Pharmacokinetic Study of Y242 in Adult Subjects|A Randomised, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Y242 in Adult Subjects|Completed||Phase 1|68|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 21:43:34.150851|2018-05-31 21:43:34.150851
NCT01515306|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2014-05-16|2014-04-25|2017-10-11|2012-01-18|2012-01-24|Estimate|2014-05-16|2014-06-18|Estimate|2014-04-25|2014-05-13|Estimate|2017-10-11|2017-11-13|Actual|July 2012||2012-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|March 2013|Actual|2013-03-31||Interventional||All participants who received at least 1 dose of study drug.|A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors|A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors|Active, not recruiting||Phase 2|40|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:43:34.257291|2018-05-31 21:43:34.257291
NCT01515293|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|September 2009||2009-09-30|May 2011|2011-05-31||||December 2010|Actual|2010-12-31||Interventional|||Single Incision Versus Conventional Laparoscopic Appendectomy|Prospective Randomised Study Comparing Single Incision Transumbilical Versus Conventional Laparoscopic Appendectomy|Completed||Phase 3|184|Actual|Hospital Universitario Virgen de la Arrixaca||2|||f||||f||||||||||2018-05-31 21:43:34.808481|2018-05-31 21:43:34.808481
NCT01515280|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2013-12-11|2012-01-23|2012-01-24|Estimate|||||||2013-12-11|2013-12-12|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Hull Airway Reflux Questionnaire Scores Following Cough Treatment|"Supplementary Study of Hull Airway Reflux Questionnaire Scores Before and After Treatment Study: A Multicentre, Double-Blind, Placebo-Controlled, Pivotal Study of the Efficacy and Safety of Oral Theobromine in the Management of Cough."|Completed|||57|Actual|Hull and East Yorkshire Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 21:43:34.889258|2018-05-31 21:43:34.889258
NCT01515267|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-23|2012-01-23|2012-01-24|Estimate|||||||2012-01-23|2012-01-24|Estimate|November 2011||2011-11-30|January 2012|2012-01-31||||||||Observational|LVivoEF||Automated Left Ventricular Function Evaluation by LVivoEF|Automated Left Ventricular Function Evaluation by LVivoEF|Unknown status|Active, not recruiting||100|Anticipated|Diacardio LTD|||||f||||t||||||||||2018-05-31 21:43:34.971132|2018-05-31 21:43:34.971132
NCT01515254|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2018-01-24|2012-01-23|2012-01-24|Estimate|||||||2018-01-24|2018-01-25|Actual|February 2012||2012-02-29|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|FeeDIn||The Feeding Dynamic Intervention: Self Regulation of Intake in Preschoolers|The Feeding Dynamic Intervention Study|Recruiting||N/A|84|Anticipated|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 21:43:35.021547|2018-05-31 21:43:35.021547
NCT01515241|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18||2014-01-29|2014-01-29|2012-01-23|2012-01-24|Estimate||||2014-01-29|2014-03-03|Estimate|2014-01-29|2014-03-03|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|EXPRESS||Exploratory Study of Plaque Regression|EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia|Completed||Phase 2|10|Actual|Cerenis Therapeutics, SA||1|||f||||f||||||||||2018-05-31 21:43:35.086511|2018-05-31 21:43:35.086511
NCT01515228|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-01-08|2012-01-23|2012-01-24|Estimate|||||||2015-01-08|2015-01-09|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)|Randomized Comparison of Dual Drug-Eluting Cilotax Stent and Everolimus -Eluting Stent Implantation for DE Novo Coronary Artery DisEase in Patients With DIABETES Mellitus|Completed||Phase 4|291|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-05-31 21:43:35.17526|2018-05-31 21:43:35.17526
NCT01515215|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-10-31|2012-01-23|2012-01-24|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder|Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder|Completed||N/A|107|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||No||2018-05-31 21:43:35.275572|2018-05-31 21:43:35.275572
NCT01515202|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-12-04|2012-01-23|2012-01-24|Estimate|||||||2012-12-04|2012-12-05|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Japanese Phase 1 Multiple Ascending Dose Study|A Randomized, Placebo-Controlled, Double-Blinded, Multiple Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-823778 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|40|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 21:43:35.357115|2018-05-31 21:43:35.357115
NCT01515189|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2017-02-03||2018-01-25|2012-01-18|2012-01-24|Estimate|2017-02-03|2017-03-24|Actual||||2018-01-25|2018-02-22|Actual|February 17, 2012|Actual|2012-02-17|January 2018|2018-01-31|August 17, 2017|Actual|2017-08-17|February 6, 2016|Actual|2016-02-06||Interventional||All randomized participants|Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab|A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma|Completed||Phase 4|831|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 21:43:35.504582|2018-05-31 21:43:35.504582
NCT01515176|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2017-08-11||2018-02-15|2012-01-19|2012-01-23|Estimate|2018-02-15|2018-03-15|Actual||||2018-02-15|2018-03-15|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|July 19, 2016|Actual|2016-07-19|March 4, 2015|Actual|2015-03-04||Interventional|||Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia|Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL|Completed||Phase 1/Phase 2|36|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:43:36.77478|2018-05-31 21:43:36.77478
NCT01515163|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-01-12|2012-01-20|2012-01-23|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Exercise and Systemic Lupus Erythematosus||Unknown status|Active, not recruiting|N/A|90|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 21:43:37.35897|2018-05-31 21:43:37.35897
NCT01515150|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-01-23|2012-01-20|2012-01-23|Estimate|||||||2015-01-23|2015-01-26|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Observational|P-VOD||The Out-patient, Non Antibiotic Management of Patients With Acute Uncomplicated Colonic Diverticulitis|Management of Patients With Uncomplicated Diverticulitis as Out-patient and Without Antibiotics|Completed|||161|Actual|Uppsala University|||1||f||||t||||||||||2018-05-31 21:43:37.426673|2018-05-31 21:43:37.426673
NCT01515137|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-01-28|2012-01-20|2012-01-23|Estimate|||||||2016-01-28|2016-01-29|Estimate|November 2005||2005-11-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma|Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac|Completed||Phase 1|47|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:43:37.491882|2018-05-31 21:43:37.491882
NCT01515124|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-02-13|2012-01-18|2012-01-23|Estimate|||||||2017-02-13|2017-02-15|Actual|January 2012||2012-01-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||The Women In Steady Exercise Research (WISER) Survivor Trial|The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and Cost Effectiveness of Alternative Management Strategies|Active, not recruiting||N/A|555|Anticipated|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 21:43:37.576137|2018-05-31 21:43:37.576137
NCT01515111|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-18|2012-01-18|2012-01-23|Estimate|||||||2012-01-18|2012-01-23|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Observational|||Guatemala Internal Medicine Physicians' Knowledge of Non-communicable Disease Clinical Preventive Services|Knowledge and Recommendations on Tobacco Cessation and Other Preventive Interventions Among Internal Medicine Staff in Guatemala Teaching Hospitals|Completed|||394|Actual|Unidad de Cirugía Cardiovascular|||1||f||||f||||||||||2018-05-31 21:43:37.689509|2018-05-31 21:43:37.689509
NCT01515098|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-05-13|2012-01-20|2012-01-23|Estimate|||||||2015-05-13|2015-05-14|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|BERRY||Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline|The Effect of Blueberry Consumption on Cognition and Body Composition in Elderly Who Are Experiencing Mild Cognitive Decline|Completed||Phase 2|123|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 21:43:37.75757|2018-05-31 21:43:37.75757
NCT01515085|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2014-05-20|2012-01-20|2012-01-23|Estimate|||||||2014-05-20|2014-05-22|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|LITT||MRI-Guided Laser Induced Thermal Therapy|MRI-Guided Laser-Induced Thermal Therapy for Cytoreduction of Inoperable Grade III/IV GLiomas Prior to Chemotherapy and Radiation|Terminated|||1|Actual|Rutgers, The State University of New Jersey|||1|PI elected to close study|f||||f||||||||||2018-05-31 21:43:37.814602|2018-05-31 21:43:37.814602
NCT01515072|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2016-04-28||2017-04-06|2012-01-18|2012-01-23|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|July 2011||2011-07-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|July 2014|Actual|2014-07-31||Interventional|RIPNOD|All donors enrolled in both groups were included in the in-between group comparisons of baseline characteristics|Remote Ischemic Preconditioning in Neurological Death Organ Donors|Remote Ischemic Preconditioning in Neurological Death Organ Donors|Completed||N/A|321|Actual|Rutgers, The State University of New Jersey|1) Bias from variation in the intervention between two sites; 2) Lack of blinding; 3) Inadequate data precludes analyses of ejection fraction; 4) Data on some of the other secondary outcomes were not available for all donors.|2|||f||||f||||||||No||2018-05-31 21:43:37.996812|2018-05-31 21:43:37.996812
NCT01515059|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-12-14|2012-01-20|2012-01-23|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ADIPOSE||Analysing Differences in Glycaemic Control Immediately Post Obesity SurgEry (The ADIPOSE Study)|A Prospective Pilot Study Investigating the Effects of Bariatric Surgery on Measures of Glycaemic Control and Incretin Levels|Terminated|||16|Actual|University of Leicester|||1|Slow recruitment and sufficient data available to analyse|f||||f||||||||||2018-05-31 21:43:38.841955|2018-05-31 21:43:38.841955
NCT01515046|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2017-02-10||2017-05-11|2012-01-18|2012-01-23|Estimate|2017-02-10|2017-03-29|Actual||||2017-05-11|2017-06-08|Actual|September 2012||2012-09-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|July 2015|Actual|2015-07-31||Interventional|PACMAN-II||Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer|Pharmacological Ascorbate for the Control of Metastatic and Node-Positive Pancreatic Cancer (PACMAN): A Phase II Trial|Terminated||Phase 2|1|Actual|University of Iowa|There was only one treated participant. Conclusions cannot be drawn from these data due to limited sampling size.|1||Standard of care changed to FOLFIRINOX; poor accrual.|f||||t||||||||No||2018-05-31 21:43:38.922037|2018-05-31 21:43:38.922037
NCT01515033|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-20|2012-01-20|2012-01-23|Estimate|||||||2012-01-20|2012-01-23|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Aerobic Exercise on PETCO2 Response in Coronary Artery Disease Patients|Effect of Continuous and Interval Exercise Training on PETCO2 Response During Graded Exercise Test in Patients With Coronary Artery Disease|Completed||Phase 2|37|Actual|Hospital TotalCor||2|||f||||t||||||||||2018-05-31 21:43:39.154776|2018-05-31 21:43:39.154776
NCT01515020|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2014-08-25|2012-01-20|2012-01-23|Estimate|||||||2014-08-25|2014-08-26|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|June 2013|Actual|2013-06-30||Interventional|DAVASAB||Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia|A Randomized, Multicenter Trial of Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated Methicillin-resistant Staphylococcus Aureus Bacteremia|Terminated||Phase 3|10|Actual|Assistance Publique - Hôpitaux de Paris||2||lack of inclusion|f||||f||||||||||2018-05-31 21:43:39.251957|2018-05-31 21:43:39.251957
NCT01515007|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10||2018-01-08|2018-01-17|2012-01-18|2012-01-23|Estimate||||2018-01-08|2018-01-10|Actual|2018-01-17|2018-01-19|Actual|April 2014||2014-04-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension and Pharmacokinetic Substudy (ORBIT-3)|Completed||Phase 3|278|Actual|Aradigm Corporation||2|||f||||f||||||||||2018-05-31 21:43:39.366172|2018-05-31 21:43:39.366172
NCT01514994|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2016-04-15|2012-01-18|2012-01-23|Estimate|||||||2016-04-15|2016-04-18|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Interventional|||Valvuloplasty Scoring Balloon Catheter First-in-Man Study|Treatment of Critical Aortic Valve Stenosis Using a Novel Valvuloplasty Scoring Balloon Catheter: a First-in-Man Study|Completed||N/A|25|Actual|Spectranetics Corporation||1|||f||||f||||||||||2018-05-31 21:43:39.669062|2018-05-31 21:43:39.669062
NCT01514630|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2015-05-14||2015-06-09|2012-01-17|2012-01-23|Estimate|2015-06-09|2015-06-29|Estimate||||2015-06-09|2015-06-29|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Creatine as a Treatment Option for Depression in Methamphetamine Using Females|Creatine as a Treatment Option for Depression in Methamphetamine Using Females|Completed||Phase 4|14|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 21:43:43.373301|2018-05-31 21:43:43.373301
NCT01514981|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2014-04-16|2012-01-18|2012-01-23|Estimate|||||||2014-04-16|2014-04-21|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||AMG 761 in Adults With Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 761 in Subjects With Asthma|Terminated||Phase 1|7|Actual|Amgen||2||Administrative decision|f||||f||||||||||2018-05-31 21:43:39.734565|2018-05-31 21:43:39.734565
NCT01514968|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2016-11-01|2012-01-18|2012-01-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers|A Drug-Drug Interaction Study Between Danoprevir/Low-dose Ritonavir and Cyclosporine, a Potent Inhibitor of OATP, in Healthy Subjects|Completed||Phase 1|18|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:43:39.799188|2018-05-31 21:43:39.799188
NCT01514955|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-02-24|2012-01-18|2012-01-23|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|IMRT||An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer|An Initial Feasibility Study to Integrate High-precision, Image Guided, Radiotherapy(MRI Based Brachytherapy and CT/MRI Fused Dynamic IMRT Planning) in the Treatment Planning of 10 Patients With Locally Advanced Carcinoma of the Cervix|Withdrawn||Phase 1|0|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-05-31 21:43:39.861963|2018-05-31 21:43:39.861963
NCT01514942|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-18|2012-01-18|2012-01-23|Estimate|||||||2012-01-18|2012-01-23|Estimate||||January 2012|2012-01-31||||||||Interventional|||Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||||||||||||2018-05-31 21:43:39.912145|2018-05-31 21:43:39.912145
NCT01514929|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-05-08|2012-01-18|2012-01-23|Estimate|||||||2012-05-08|2012-05-09|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|||||Interventional|||A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers|A Randomized, Double-Blind, Placebo and Positive-Controlled, Crossover Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers|Completed||Phase 1|64|Actual|Achaogen, Inc.||4|||f||||t||||||||||2018-05-31 21:43:39.995545|2018-05-31 21:43:39.995545
NCT01514916|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-02-08|2012-01-18|2012-01-23|Estimate|||||||2012-02-08|2012-02-09|Estimate||||February 2012|2012-02-29||||||||Interventional|VJ||New Anastomotic Device for End to End Vascular Anastomosis in the Treatment of Peripheral Vascular Disease|Evaluation of a Mechanical System (Vascular Join) Facilitating Arterial Anastomoses During Peripheral Vascular Surgery (Bypass).|Unknown status|Recruiting|N/A|30|Anticipated|Ab Medica Spa|||||f||||t||||||||||2018-05-31 21:43:40.136366|2018-05-31 21:43:40.136366
NCT01514903|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-10-11|2012-01-20|2012-01-23|Estimate|||||||2016-10-11|2016-10-12|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetics of Sildenafil Following Administration of an Chewable Tablet of Sildenafil Relative to Viagra® Conventional Oral Tablet in Healthy Volunteers||Completed||Phase 1|54|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||t||||||||||2018-05-31 21:43:40.219256|2018-05-31 21:43:40.219256
NCT01514890|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-01-23|2012-01-20|2012-01-23|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 2011|Actual|2011-02-28|January 2017|2017-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|CUPIC||French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin|Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) Included in the French Early Access Program for the Use of Protease Inhibitors in Genotype 1 Patients Who Failed to Eradicate HCV With a Previous Standard PEG-IFN and RBV Combination.|Completed|||675|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:43:40.297466|2018-05-31 21:43:40.297466
NCT01514877|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-07-22|2012-01-20|2012-01-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer|Phase II Study of Icotinib Combined With Whole Brain Radiotherapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer|Completed||Phase 2|20|Actual|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 21:43:40.363681|2018-05-31 21:43:40.363681
NCT01514864|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2015-07-23||2015-11-02|2012-01-20|2012-01-23|Estimate|2015-11-02|2015-12-03|Estimate||||2015-11-02|2015-12-03|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All participants who received at least 1 dose of study drug|Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation|Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation|Terminated||Phase 2|19|Actual|Bristol-Myers Squibb|The study was terminated due to lack of efficacy and slow enrollment of patients.|2||Lack of efficacy and slow accrual|f||||f||||||||||2018-05-31 21:43:40.460824|2018-05-31 21:43:40.460824
NCT01514851|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-06-07|2012-01-18|2012-01-23|Estimate|||||||2012-06-07|2012-06-08|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate|Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis|Completed||Phase 3|259|Actual|Bayer||2|||f||||f||||||||||2018-05-31 21:43:41.133197|2018-05-31 21:43:41.133197
NCT01514838|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2016-01-19|2012-01-20|2012-01-23|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus|A Phase III, Double-Blind, Randomized, Active Controlled, Monotherapy Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 3|46|Actual|Astellas Pharma Inc||2||Discontinued due to company's strategic reason|f||||f||||||||Undecided||2018-05-31 21:43:41.262706|2018-05-31 21:43:41.262706
NCT01514825|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-23|2012-01-20|2012-01-23|Estimate|||||||2012-01-23|2012-01-24|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects|YM150 Clinical Pharmacology Study - Repeated Oral Administration to Elderly Subjects|Completed||Phase 1|36|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 21:43:41.361146|2018-05-31 21:43:41.361146
NCT01514812|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-23|2012-01-20|2012-01-23|Estimate|||||||2012-01-23|2012-01-24|Estimate|February 2006||2006-02-28|January 2012|2012-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects|A Double Blind, Randomized, Two Period Crossover Study To Determine The Effect of Multiple Doses of 120 MG Modified Release Formulation of YM150 on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:43:41.435817|2018-05-31 21:43:41.435817
NCT01514799|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2015-03-16|2012-01-20|2012-01-23|Estimate|||||||2015-03-16|2015-03-17|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effects of Long Biliopancreatic Limb vs. Long Alimentary Limb in Superobesity, a Randomized Study|Randomized Study Comparing the Effects of Gastric Bypass Using a Long BP-limb vs. a Long Alimentary Limb in Morbid Obesity|Unknown status|Recruiting|N/A|200|Anticipated|Aleris Obesity||2|||f||||f||||||||||2018-05-31 21:43:41.516947|2018-05-31 21:43:41.516947
NCT01514786|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2017-03-14||2017-09-10|2012-01-20|2012-01-23|Estimate|2017-09-10|2017-09-15|Actual||||2017-09-10|2017-09-15|Actual|May 2012||2012-05-31|September 2017|2017-09-30|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional|DATES||Decision Aid to Technologically Enhance Shared Decision Making|Decision Aid to Technologically Enhance Shared Decision Making|Completed||N/A|570|Actual|University of Michigan||2|||f||||t||||||||Yes|Data is still being analyzed and papers written|2018-05-31 21:43:41.609161|2018-05-31 21:43:41.609161
NCT01514773|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-03-15|2012-01-20|2012-01-23|Estimate|||||||2017-03-15|2017-03-17|Actual|August 2011|Actual|2011-08-31|March 2017|2017-03-31|August 30, 2013|Actual|2013-08-30|August 30, 2013|Actual|2013-08-30||Observational|||Patient and Physician Survey Determinants of Appropriate ICD Utilization|Patient and Physician Knowledge and Attitudes Toward Defibrillator Therapy Survey Study|Completed|||452|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 21:43:41.812616|2018-05-31 21:43:41.812616
NCT01514760|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2014-01-27||2017-09-11|2012-01-20|2012-01-23|Estimate|2016-02-17|2016-02-18|Estimate||||2017-09-11|2017-10-11|Actual|June 2012||2012-06-30|September 2017|2017-09-30|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans|A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans|Completed||N/A|22|Actual|Arkansas Children's Hospital Research Institute|There are no limitations/caveats to report.|1|||f||||t||||||||||2018-05-31 21:43:41.882105|2018-05-31 21:43:41.882105
NCT01514747|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2017-03-10|2012-01-20|2012-01-23|Estimate|||||||2017-03-10|2017-03-13|Actual|October 2011||2011-10-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||A MRI Study of Visual and Motor Pathways in Premature Infants||Active, not recruiting|||40|Anticipated|Arkansas Children's Hospital Research Institute|||1||f||||f||||||||||2018-05-31 21:43:42.066566|2018-05-31 21:43:42.066566
NCT01514734|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|2013-08-15||2013-08-15|2012-01-18|2012-01-23|Estimate|2013-08-15|2013-10-21|Estimate||||2013-08-15|2013-10-21|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Brazil|Terminated||Phase 4|9|Actual|Alcon Research||1||Low recruitment rate|f||||f||||||||||2018-05-31 21:43:42.217371|2018-05-31 21:43:42.217371
NCT01514721|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2014-12-02|2012-01-18|2012-01-23|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy|Assessing the Efficacy and Tolerability of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Prior Prostaglandin Fixed Combination|Terminated||Phase 4|37|Actual|Alcon Research||1||low enrollment|f||||f||||||||||2018-05-31 21:43:42.354693|2018-05-31 21:43:42.354693
NCT01514708|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-12-27|2012-01-18|2012-01-23|Estimate|||||||2012-12-27|2012-12-28|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||The Safety and Immune Response to Influenza Vaccination in Pregnant Women|The Safety and Immune Response to Influenza Vaccination in Pregnant Women|Completed||Phase 4|46|Actual|Adimmune Corporation||1|||f||||f||||||||||2018-05-31 21:43:42.445491|2018-05-31 21:43:42.445491
NCT01514695|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2013-01-28|2012-01-17|2012-01-23|Estimate|||||||2013-01-28|2013-01-30|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FUSE||Fentanyl Use for Sedation in Esophagogastroduodenoscopy|Fentanyl Use for Sedation in Esophagogastroduodenoscopy (FUSE): a Phase 4, Randomized, Double-blind, Placebo-controlled Trial of Fentanyl Added to Midazolam Compared to Midazolam Alone for Sedation in Routine Upper Endoscopy|Completed||Phase 4|139|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 21:43:42.507566|2018-05-31 21:43:42.507566
NCT01514682|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2018-01-04||2018-02-28|2012-01-17|2012-01-23|Estimate|2018-02-28|2018-03-29|Actual||||2018-02-28|2018-03-29|Actual|June 2012|Actual|2012-06-30|May 2017|2017-05-31|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Interventional|||Anti-Inflammatory Treatment of Schizophrenia|Anti-Inflammatory Combination Therapy for the Treatment of Schizophrenia|Completed||N/A|50|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 21:43:42.606099|2018-05-31 21:43:42.606099
NCT01514669|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-01-31|2012-01-17|2012-01-23|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2012||2012-01-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer|Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer|Active, not recruiting|||75|Anticipated|University of Arkansas|||1||f||||f||||||Samples With DNA|"~     Tear Sample collection; serum sample collection~   "|||2018-05-31 21:43:43.154104|2018-05-31 21:43:43.154104
NCT01514656|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-05-02|2012-01-17|2012-01-23|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2011||2011-11-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|July 2015|Actual|2015-07-31||Interventional|||CPR Training: Video Self-Instruction Kit or Video-Only|Hospital-based CPR Training for At-risk Family Members Using a Video-self Instruction Kit or Video-only|Completed||N/A|1870|Actual|University of Pennsylvania||6|||f||||t||||||||No||2018-05-31 21:43:43.20753|2018-05-31 21:43:43.20753
NCT01514643|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-05-26|2012-01-17|2012-01-23|Estimate|||||||2018-05-26|2018-05-30|Actual|October 2011||2011-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PTOA||Inflammatory Response Following Intraarticular Fracture|Inflammatory Response Following Intraarticular Fracture|Recruiting|||60|Anticipated|University of Utah|||1||f||||f||||||Samples Without DNA|"~     Synovial fluid and blood serum~   "|||2018-05-31 21:43:43.289713|2018-05-31 21:43:43.289713
NCT01514617|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2015-12-01|2012-01-17|2012-01-23|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2012||2012-01-31|October 2011|2011-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization|Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization|Unknown status|Active, not recruiting|N/A|100|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 21:43:43.565031|2018-05-31 21:43:43.565031
NCT01514604|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-04-29|2012-01-20|2012-01-23|Estimate|||||||2014-04-29|2014-04-30|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Constructing a Learning Curve in Ultrasound Guided Needling|Constructing a Learning Curve in Ultrasound Guided Needling - an Observational Study Using Cumulative Sum (Cusum) Analysis|Completed|||21|Actual|University of Aberdeen|||3||f||||f||||||||||2018-05-31 21:43:43.639472|2018-05-31 21:43:43.639472
NCT01514591|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2013-06-19|2012-01-17|2012-01-23|Estimate|||||||2013-06-19|2013-06-21|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Thromboelastography in Non-elective Cesarean Delivery|Thromboelastography to Assess Hemostatic Changes in Laboring Patients Undergoing Non-elective (Intrapartum) Cesarean Delivery|Completed|||33|Actual|Stanford University|||1||f||||t||||||Samples With DNA|"~     Blood samples for TEG analysis.~   "|||2018-05-31 21:43:43.755106|2018-05-31 21:43:43.755106
NCT01514578|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-08-23|2012-01-20|2012-01-23|Estimate|||||||2012-08-23|2012-08-24|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males|A Multi-Part, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TRV130A in Healthy Adult Males|Completed||Phase 1|74|Actual|Trevena Inc.||2|||f||||t||||||||||2018-05-31 21:43:43.838882|2018-05-31 21:43:43.838882
NCT01514565|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2015-03-17|2012-01-20|2012-01-23|Estimate|||||||2015-03-17|2015-03-18|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Observational|||Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer|Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer.|Recruiting|||70|Anticipated|Thomas Jefferson University|||||f||||f||||||||||2018-05-31 21:43:43.928412|2018-05-31 21:43:43.928412
NCT01514552|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-04-07|2012-01-20|2012-01-23|Estimate|||||||2017-04-07|2017-04-10|Actual|November 2010||2010-11-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|January 2018|Anticipated|2018-01-31||Interventional|||The Use of Functional Confections in Promoting Oral Health|A Pilot Phase I Study of the Use of Functional Confections in Promoting Oral Health in Men and Women|Active, not recruiting||Phase 1|36|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 21:43:44.064244|2018-05-31 21:43:44.064244
NCT01514539|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-01-07|2012-01-18|2012-01-23|Estimate|||||||2015-01-07|2015-01-09|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Hormonal Regulation of Postpartum Weight and Presence of Gut Peptides in Human Milk|Role of Ghrelin and PYY in Postpartum Body Weight Regulation and Presence in Human Milk|Completed||N/A|44|Actual|University of Wyoming||2|||f||||t||||||||||2018-05-31 21:43:44.148028|2018-05-31 21:43:44.148028
NCT01514526|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-04-24|2012-01-17|2012-01-23|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2012||2012-01-31|April 2016|2016-04-30|November 2016|Actual|2016-11-30|July 2013|Actual|2013-07-31||Interventional|||Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma|Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma|Completed||Phase 2|17|Actual|Spanish Oncology Genito-Urinary Group||1|||f||||f||||||||||2018-05-31 21:43:44.215608|2018-05-31 21:43:44.215608
NCT01514513|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2014-12-03||2014-12-18|2012-01-17|2012-01-23|Estimate|2014-12-18|2015-01-01|Estimate||||2014-12-18|2015-01-01|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Safety of Licefreee Spray Against Nix 1% Permethrin|A Comparative Study to Demonstrate the Efficacy and Safety of Licefreee Spray Against Nix 1% Permethrin in Head Lice Infested Individuals|Completed||N/A|42|Actual|South Florida Family Health and Research Centers||2|||f||||t||||||||||2018-05-31 21:43:44.311818|2018-05-31 21:43:44.311818
NCT01514500|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-05-23|2012-01-20|2012-01-23|Estimate|||||||2018-05-23|2018-05-25|Actual|January 16, 2012|Actual|2012-01-16|May 2018|2018-05-31|March 18, 2013|Actual|2013-03-18|March 18, 2013|Actual|2013-03-18||Interventional|||First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects|First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects|Completed||Phase 1|105|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:43:44.649754|2018-05-31 21:43:44.649754
NCT01514487|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-02-28|2012-01-20|2012-01-23|Estimate|||||||2017-02-28|2017-03-01|Actual|January 13, 2005|Actual|2005-01-13|February 2017|2017-02-28|March 30, 2005|Actual|2005-03-30|March 30, 2005|Actual|2005-03-30||Interventional|||Comparison of Three Liraglutide Formulations in Healthy Volunteers|A Randomised, Double-blind, Single-centre, Three-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Each of the Two New Liraglutide Formulations at pH 7.9 and 8.15 and the Planned Phase 3 Formulation at pH 7.7|Completed||Phase 1|24|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:43:44.720393|2018-05-31 21:43:44.720393
NCT01514461|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2015-05-15||2015-05-15|2012-01-20|2012-01-23|Estimate|2015-05-15|2015-06-03|Estimate||||2015-05-15|2015-06-03|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Full analysis set (FAS) consisted of all randomized patients, except for those who were mis-randomized.|A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome|A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome|Completed||Phase 3|45|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:43:44.81327|2018-05-31 21:43:44.81327
NCT01514448|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2017-03-31||2017-07-17|2012-01-20|2012-01-23|Estimate|2017-07-17|2017-07-19|Actual||||2017-07-17|2017-07-19|Actual|May 21, 2012|Actual|2012-05-21|July 2017|2017-07-31|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Interventional||Demographic and other baseline data (including disease characteristics) were summarized descriptively for all patients for the FAS. The full analysis set (FAS) consisted of all patients who received at least one dose of everolimus.|Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib|An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib|Completed||Phase 4|29|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:43:45.677983|2018-05-31 21:43:45.677983
NCT01514435|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-17|2012-01-17|2012-01-23|Estimate|||||||2012-01-17|2012-01-23|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|May 2009|Actual|2009-05-31||Interventional|||Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)|Clinical Effects of Electroconvulsive Therapy in Severe Depression and Concomitant Changes in Cerebral Glucose Metabolism - an Exploratory Study|Completed||N/A|13|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 21:43:46.243772|2018-05-31 21:43:46.243772
NCT01514422|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2016-09-29||2016-12-06|2012-01-20|2012-01-23|Estimate|2016-12-06|2017-01-30|Estimate||||2016-12-06|2017-01-30|Estimate|May 2011||2011-05-31|December 2016|2016-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Minocycline for Bipolar Depression|Minocycline for Bipolar Disorder|Completed||Phase 4|20|Actual|Icahn School of Medicine at Mount Sinai|Limitations are this is an open label study with no placebo and low number of subjects.|1|||f||||f||||||||||2018-05-31 21:43:47.28145|2018-05-31 21:43:47.28145
NCT01514409|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-20|2012-01-20|2012-01-23|Estimate|||||||2012-01-20|2012-01-23|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Sub-chronic Effects of 5-hydroxytryptophan on Mood and Emotional Processing in Healthy Volunteers|Sub-chronic Effects of 5-hydroxytryptophan on Mood and Emotional Processing in Healthy Volunteers: A Randomised Trial|Completed||N/A|33|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 21:43:47.443009|2018-05-31 21:43:47.443009
NCT01514396|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2014-03-24|2012-01-17|2012-01-23|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|||Skin Incision Adhesive in Pediatrics|Evaluation of Surgiseal as a Topical Emergency Department Skin Incision Adhesive in Pediatrics A Case Series|Unknown status|Recruiting|Phase 4|50|Anticipated|Medline Industries||1|||f||||f||||||||||2018-05-31 21:43:47.530859|2018-05-31 21:43:47.530859
NCT01514383|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-20|2012-01-20|2012-01-23|Estimate|||||||2012-01-20|2012-01-23|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Interventional|||Octylseal Surgical Adhesive in General Surgery|Evaluation of Octylseal as a Topical Surgical Skin Incision Adhesive in General Surgery: A Case Series|Unknown status|Recruiting|Phase 4|50|Anticipated|Medline Industries||1|||f||||f||||||||||2018-05-31 21:43:47.616261|2018-05-31 21:43:47.616261
NCT01514370|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2016-09-02|2012-01-20|2012-01-23|Estimate|||||||2016-09-02|2016-09-05|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CONTAIN||Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a|ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)|Completed||Phase 2|80|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 21:43:47.690004|2018-05-31 21:43:47.690004
NCT01514357|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2017-04-27||2018-03-21|2012-01-20|2012-01-23|Estimate|2017-10-19|2017-10-20|Actual||||2018-03-21|2018-03-23|Actual|April 2012|Actual|2012-04-30|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Nesiritide in Resistant Hypertension|Novel Peptides in Resistant Human Hypertension|Terminated||Phase 1/Phase 2|12|Actual|Mayo Clinic|This study was terminated early because the original principal investigator left the institution, and also due to the lack of funding.|2||Original PI left the institution, and lack of funding.|f||||f|t|f||||||No||2018-05-31 21:43:47.79968|2018-05-31 21:43:47.79968
NCT01514344|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-17|2012-01-17|2012-01-23|Estimate|||||||2012-01-17|2012-01-23|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|IRIS||Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma|Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone|Unknown status|Recruiting|Phase 2|20|Anticipated|IRCCS San Raffaele||1|||f||||f||||||||||2018-05-31 21:43:48.141667|2018-05-31 21:43:48.141667
NCT01514331|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-11-19|2012-01-20|2012-01-23|Estimate|||||||2013-11-19|2013-11-20|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Ventilatory Parameters and Inflammatory Responses of Neonates Ventilated by Different Modes of Ventilation|Determination of Ventilatory Parameters and Inflammatory Responses of Neonates Who Are Ventilated by Volume Guarantee Combined With Synchronized Intermittent Mandatory Ventilation or Pressure Support Ventilation|Completed||N/A|40|Actual|Gazi University||2|||f||||f||||||||||2018-05-31 21:43:48.238862|2018-05-31 21:43:48.238862
NCT01514318|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2012-07-18||2012-10-31|2012-01-20|2012-01-23|Estimate|2012-10-31|2012-11-30|Estimate||||2012-10-31|2012-11-30|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Encore Revelation Hip Stem|A Long-term Follow Up Study of the Revelation™ Hip Stem|Completed|||8|Actual|Encore Medical, L.P.|Small patient population to choose from and difficulty in locating people who have not been seen by the doctor in almost 10 years.||1||f||||f||||||||||2018-05-31 21:43:48.339561|2018-05-31 21:43:48.339561
NCT01514305|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-01-20|2012-01-20|2012-01-23|Estimate|||||||2012-01-20|2012-01-23|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System|Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System|Completed|||21|Actual|DexCom, Inc.|||1||f||||f||||||||||2018-05-31 21:43:48.505523|2018-05-31 21:43:48.505523
NCT01514292|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2014-02-03||2015-09-10|2012-01-17|2012-01-23|Estimate|2015-09-10|2015-10-05|Estimate||||2015-09-10|2015-10-05|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Type 1 Diabetes and Type 2 Diabetes with Insulin treatment.|Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System|PTL-900590 Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System|Completed||N/A|72|Actual|DexCom, Inc.||1|||f||||f||||||||||2018-05-31 21:43:48.579746|2018-05-31 21:43:48.579746
NCT01514279|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-01-26|2012-01-17|2012-01-23|Estimate|||||||2016-01-26|2016-01-27|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|IMPACT||Ideas Moving Parents and Adolescents to Change Together (IMPACT)|Targeting Obesity and Blood Pressure in Urban Youth(Consortium Title: Childhood Obesity Prevention and Treatment Research [COPTR] and Site Project Name IMPACT (Ideas Moving Parents and Adolescents to Change Together).|Unknown status|Enrolling by invitation|N/A|360|Anticipated|Case Western Reserve University||3|||f||||t||||||||Yes|Conducted in conjunction with the Research Coordinating Unit (UNC Chapel Hill) of the COPTR Consortium.|2018-05-31 21:43:48.773293|2018-05-31 21:43:48.773293
NCT01514253|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-20|2012-01-20|2012-01-23|Estimate|||||||2012-01-20|2012-01-23|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|glucose||Reduced Infant Response to a Routine Care Procedure After Glucose 25% Analgesia in Comparison to Materna RTF Stage 1|Reduced Infant Response to a Routine Care Procedure After Glucose 25% Analgesia in Comparison to Materna RTF Stage 1|Unknown status|Not yet recruiting|N/A|180|Anticipated|The Baruch Padeh Medical Center, Poriya||3|||f||||f||||||||||2018-05-31 21:43:48.915705|2018-05-31 21:43:48.915705
NCT01514240|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2015-03-04||2016-09-08|2012-01-20|2012-01-23|Estimate|2016-09-08|2016-10-31|Estimate||||2016-09-08|2016-10-31|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan|A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safety of D9421-C 9 mg Versus Mesalazine 3 g in Patients With Active Crohn's Disease (CD) in Japan|Completed||Phase 3|123|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:43:49.057147|2018-05-31 21:43:49.057147
NCT01514227|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-01-26|2012-01-20|2012-01-23|Estimate|||||||2017-01-26|2017-01-27|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Nobori Dual Antiplatelet Therapy as Appropriate Duration|Nobori Dual Antiplatelet Therapy as Appropriate Duration.|Completed||Phase 4|3773|Actual|Associations for Establishment of Evidence in Interventions||2|||f||||f||||||||No||2018-05-31 21:43:50.161561|2018-05-31 21:43:50.161561
NCT01514214|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2018-04-30|2012-01-20|2012-01-23|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|June 2015|Actual|2015-06-30||Interventional|||Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction|A Randomized Trial Comparing a Winged Perimeter Stent and Traditional Polyethylene Plastic Stent in the Management of Malignant Distal Biliary Strictures|Completed||N/A|58|Actual|University of British Columbia||2|||f||||t|f|f|||f|||No||2018-05-31 21:43:50.254566|2018-05-31 21:43:50.254566
NCT01514201|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2018-03-30|2012-01-16|2012-01-23|Estimate|||||||2018-03-30|2018-04-02|Actual|November 17, 2011|Actual|2011-11-17|March 2018|2018-03-31|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|||Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas|A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)|Completed||Phase 1/Phase 2|66|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 21:43:50.341612|2018-05-31 21:43:50.341612
NCT01514188|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-09-12|2012-01-19|2012-01-23|Estimate|||||||2013-09-12|2013-09-13|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|||Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma|A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma|Unknown status|Active, not recruiting|Phase 2|105|Anticipated|CytRx||2|||f||||t||||||||||2018-05-31 21:43:50.503192|2018-05-31 21:43:50.503192
NCT01514175|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2012-05-15|2012-01-17|2012-01-23|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac|A Pilot Study Comparing the Analgesic Efficacy of IV Ibuprofen and IV Ketorolac|Unknown status|Enrolling by invitation|Phase 4|50|Actual|Culpeper Surgery Center||1|||f||||f||||||||||2018-05-31 21:43:50.617721|2018-05-31 21:43:50.617721
NCT01514162|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2016-10-14||2017-05-02|2012-01-17|2012-01-20|Estimate|2017-05-02|2017-05-31|Actual||||2017-05-02|2017-05-31|Actual|February 2012||2012-02-29|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve|Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve|Completed||N/A|245|Actual|St. Jude Medical||1|||f||||f||||||||No||2018-05-31 21:43:50.698828|2018-05-31 21:43:50.698828
NCT01514149|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2017-05-02||2017-06-21|2012-01-17|2012-01-20|Estimate|2017-06-21|2017-07-19|Actual||||2017-06-21|2017-07-19|Actual|September 2011||2011-09-30|June 2017|2017-06-30|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional||Intent to Treat population|Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy|Terminated||Phase 2|73|Actual|ConjuChem||5||Business decision|f||||f||||||||||2018-05-31 21:43:50.882648|2018-05-31 21:43:50.882648
NCT01514136|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2015-01-19||2015-02-20|2012-01-17|2012-01-20|Estimate|2015-01-19|2015-01-29|Estimate||||2015-02-20|2015-03-11|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||An Investigation of Ostomy Devices|CP216: An Exploratory Investigation of Convex Ostomy Devices|Completed||N/A|32|Actual|Coloplast A/S|This was an exploratory investigation where the participating subjects had to test 8 different test products. A small number of subjects were analysed from two different populations (convex product/flat product users).|1|||f||||f||||||||||2018-05-31 21:43:51.385463|2018-05-31 21:43:51.385463
NCT01514123|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-07-21|2012-01-19|2012-01-20|Estimate|||||||2017-07-21|2017-07-25|Actual|January 2012||2012-01-31|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors|A Phase I, Open Label, Dose Escalation Study of the VEGF-C Human Monoclonal Antibody VGX-100 Administered by Intravenous Infusion Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1|40|Anticipated|Circadian Technologies Ltd.||2|||f||||f||||||||Undecided||2018-05-31 21:43:51.88755|2018-05-31 21:43:51.88755
NCT01514110|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-01-14|2012-01-17|2012-01-20|Estimate|||||||2018-01-14|2018-01-17|Actual|January 2008||2008-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gastric Cancer RAD001 Study|Phase I/II Study of Paclitaxel / Carboplatin / RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach|Active, not recruiting||Phase 1/Phase 2|35|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 21:43:51.974164|2018-05-31 21:43:51.974164
NCT01514097|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2015-07-29|2012-01-17|2012-01-20|Estimate|||||||2015-07-29|2015-07-30|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Adequacy of Pain Management for Upper Extremity Fracture After Discharge From a Pediatric Emergency Depart||Unknown status|Recruiting||300|Anticipated|Children's Hospitals and Clinics of Minnesota|||2||f||||||||||||||2018-05-31 21:43:52.050744|2018-05-31 21:43:52.050744
NCT01514058|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-05-25|2012-01-17|2012-01-20|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2011||2011-11-30|July 2015|2015-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction|A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction|Terminated||N/A|8|Actual|Wake Forest University Health Sciences||2||new clinical strategies have rendered the question posed by this study less relevant|f||||f|f|f||||||||2018-05-31 21:43:52.2518|2018-05-31 21:43:52.2518
NCT01514045|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-03-30|2012-01-17|2012-01-20|Estimate|||||||2018-03-30|2018-04-03|Actual|April 2011||2011-04-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Gastric Cancer Foundation: A Gastric Cancer Registry|The Gastric Cancer Foundation: A Gastric Cancer Registry|Recruiting|||500|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     Blood samples with DNA Paraffin embedded tissue will be stored in the Stanford Tissue Bank~     for 100 years.~   "|||2018-05-31 21:43:52.317221|2018-05-31 21:43:52.317221
NCT01514032|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Extracorporal Shockwave Lithotripsy Versus Retrograde Intrarenal Surgery for the Treatment of Kidney Stones|TOP-Stone: Treatment of Patients With Small Kidney Stones - Randomized Head-to-head Trial Comparing Extracorporal Shockwave Lithotripsy With Retrograde Intrarenal Surgery|Unknown status|Recruiting|N/A|230|Anticipated|University of Zurich||2|||f||||||||||||||2018-05-31 21:43:52.391094|2018-05-31 21:43:52.391094
NCT01514019|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-06-19|2012-01-17|2012-01-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese Volunteers|An Open-label, Single-dose, Two-treatment, Randomized, Cross-over Study to Investigate the Effects of the SLCO2B1 c.1457C>T Polymorphism and Apple Juice on the Pharmacokinetics and Pharmacodynamics of Acebutolol in Healthy Korean and Japanese Volunteers|Completed||Phase 4|16|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:43:52.467657|2018-05-31 21:43:52.467657
NCT01514006|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2015-03-06|2012-01-19|2012-01-20|Estimate|||||||2015-03-06|2015-03-09|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Postoperative Anemia and Functional Outcomes After Fast-track Primary Hip Arthroplasty|Postoperative Anemia and Functional Outcomes After Fast-track Primary Hip Arthroplasty - a Prospective Observational Study|Completed|||125|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 21:43:52.557276|2018-05-31 21:43:52.557276
NCT01513993|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2015-10-27|2012-01-17|2012-01-20|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Remote Monitoring of Chronic Heart Failure in Veneto Region|RENEWING HEALTH - Large Scale Pilot in Veneto Region: Remote Monitoring of Chronic Heart Failure|Completed||N/A|315|Actual|Regione Veneto||2|||f||||t||||||||||2018-05-31 21:43:52.651128|2018-05-31 21:43:52.651128
NCT01513980|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-04-13|2012-01-17|2012-01-20|Estimate|||||||2017-04-13|2017-04-17|Actual|November 2011||2011-11-30|January 2012|2012-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Life-long Monitoring of COPD in Veneto Region|RENEWING HEALTH - Large Scale Pilot in Veneto Region: Life-long Monitoring in COPD|Completed||N/A|750|Actual|Regione Veneto||3|||f||||t||||||||No||2018-05-31 21:43:52.774182|2018-05-31 21:43:52.774182
NCT01513967|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2016-12-05|2012-01-17|2012-01-20|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease|A Randomized Single and Multiple Dose Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease|Completed||Phase 1/Phase 2|36|Actual|Regenera Pharma Ltd||14|||f||||t||||||||||2018-05-31 21:43:52.857145|2018-05-31 21:43:52.857145
NCT01513954|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-17|2012-01-17|2012-01-20|Estimate|||||||2012-01-17|2012-01-20|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Observational|||Examination of Serum Progesterone Levels in an IVF Population Following Two Types of Egg Aspiration|Examination of Serum Progesterone Levels in an IVF Population Following Two Types of Egg Aspiration|Unknown status|Recruiting||450|Anticipated|Red Rock Fertility Center|||2||f||||t||||||||||2018-05-31 21:43:52.975928|2018-05-31 21:43:52.975928
NCT01513941|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2016-05-04|2012-01-19|2012-01-20|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|INSIGHT||An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)|Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects With Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Type 1 (HCV-1/HIV-1) Coinfection|Completed||Phase 3|163|Actual|Janssen-Cilag International NV||1|||f||||f||||||||||2018-05-31 21:43:53.076916|2018-05-31 21:43:53.076916
NCT01513928|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-03-08|2012-01-19|2012-01-20|Estimate|||||||2012-03-08|2012-03-12|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects|A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04937319 In Overweight And Obese Otherwise Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer|||||f||||t||||||||||2018-05-31 21:43:53.300478|2018-05-31 21:43:53.300478
NCT01513915|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2016-04-23|2012-01-19|2012-01-20|Estimate|||||||2016-04-23|2016-04-26|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||A Parent-only Group Cognitive Behavioral Intervention for Children With Anxiety Disorders: a Control Group Study|A Parent-only Group Cognitive Behavioral Intervention for Children With Anxiety Disorders: a Control Waiting List Group Study|Completed||N/A|40|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:43:53.400524|2018-05-31 21:43:53.400524
NCT01513694|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2017-06-01|2012-01-19|2012-01-20|Estimate|||||||2017-06-01|2017-06-02|Actual|January 2010||2010-01-31|May 2017|2017-05-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease|Clinical Trial Phase I / II Prospective, Open, Non-randomized for Treatment of Lumbar Intervertebral Degenerative Disc Disease With Posterolateral Instrumented and Autologous Mesenchymal Stem Cells.|Completed||Phase 1/Phase 2|15|Anticipated|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 21:43:55.162775|2018-05-31 21:43:55.162775
NCT01513902|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|2016-05-24||2016-05-24|2012-01-17|2012-01-20|Estimate|2016-05-24|2016-07-04|Estimate||||2016-05-24|2016-07-04|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||The safety analysis population included all participants who received at least 1 dose of study drug.|Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)|An Open-label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (JIA)|Completed||Phase 1|26|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:43:53.483732|2018-05-31 21:43:53.483732
NCT01513863|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-12-19|2012-01-19|2012-01-20|Estimate|||||||2013-12-19|2013-12-23|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|MTZG||A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multi-Site Clinical Study to Compare the Bioequivalence of Two Metronidazole 1% Topical Gel Formulations in Patients With Moderate to Severe Rosacea|Completed||Phase 1|602|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 21:43:53.935966|2018-05-31 21:43:53.935966
NCT01513850|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2015-05-29|2012-01-19|2012-01-20|Estimate|||||||2015-05-29|2015-06-01|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients|A 52-week, Multi-center, Open Label, Single Arm, Phase 3 Study to Evaluate the Efficacy and Safety of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients|Completed||Phase 3|87|Actual|SK Chemicals Co.,Ltd.||1|||f||||f||||||||||2018-05-31 21:43:54.148507|2018-05-31 21:43:54.148507
NCT01513837|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-09-07|2012-01-19|2012-01-20|Estimate|||||||2012-09-07|2012-09-10|Estimate|March 2011||2011-03-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Observational|IRIS-ASMA||Rinitis y Sinusitis según la Gravedad Del Asma|PREVALENCIA, GRAVEDAD E IMPACTO DE LA RINITIS Y DE LA SINUSITIS SEGÚN EL NIVEL DE GRAVEDAD Y CONTROL DEL ASMA (PROYECTO IRIS-ASMA)|Completed|||450|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||||||||||||2018-05-31 21:43:54.25758|2018-05-31 21:43:54.25758
NCT01513824|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-02-25|2012-01-19|2012-01-20|Estimate|||||||2014-02-25|2014-02-26|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|SongHeart||Stress and Ischemic Heart Disease. The Effect of Bio Feedback Guided Stress Management on Life Quality Including Signs of Depression and Stress|Stress, Ongoing Self Monitoring and Ischemic Heart Disease Rehabilitation, a Randomized Controlled Trial (SongHeart)|Completed||N/A|216|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 21:43:54.315173|2018-05-31 21:43:54.315173
NCT01513811|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-04-17|2012-01-19|2012-01-20|Estimate|||||||2012-04-17|2012-04-19|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Itopride as an Adjuvant for Bowel Preparation in Patients With Chronic Constipation is Effective|High Dose of Itopride: a Valid Adjuvant for Bowel Preparation in Patients With Chronic Constipation|Completed||Phase 2|115|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||||2018-05-31 21:43:54.390571|2018-05-31 21:43:54.390571
NCT01513798|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2015-02-25|2012-01-19|2012-01-20|Estimate|||||||2015-02-25|2015-02-26|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial|Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial|Completed||N/A|40|Actual|Umeå University||2|||f||||||||||||||2018-05-31 21:43:54.489179|2018-05-31 21:43:54.489179
NCT01513785|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study|New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study|Completed||Phase 2|40|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 21:43:54.569693|2018-05-31 21:43:54.569693
NCT01513772|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-08-07|2012-01-19|2012-01-20|Estimate|||||||2012-08-07|2012-08-09|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect of Dexmedetomidine on the Emergence Agitation in Nasal Surgery||Completed||N/A|100|Actual|Severance Hospital||2|||f||||||||||||||2018-05-31 21:43:54.665475|2018-05-31 21:43:54.665475
NCT01513759|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2013-06-11|2012-01-17|2012-01-20|Estimate|||||||2013-06-11|2013-06-13|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|SEATTLE II||A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).|Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy|Completed||Phase 3|150|Actual|EKOS Corporation||1|||f||||f||||||||||2018-05-31 21:43:54.739896|2018-05-31 21:43:54.739896
NCT01513746|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-08-25|2012-01-17|2012-01-20|Estimate|||||||2014-08-25|2014-08-26|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity|Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity|Completed|||83|Actual|Duke University|||||f||||t||||||||||2018-05-31 21:43:54.857494|2018-05-31 21:43:54.857494
NCT01513733|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-08-11|2012-01-17|2012-01-20|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2012||2012-01-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|CATCH||The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer|The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer|Completed||Phase 1|25|Actual|Duke University||3|||f||||t||||||||||2018-05-31 21:43:54.922236|2018-05-31 21:43:54.922236
NCT01513720|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-17|2012-01-17|2012-01-20|Estimate|||||||2012-01-17|2012-01-20|Estimate|December 2002||2002-12-31|October 2002|2002-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition|Single Dose, Two-way, Crossover, Oral Bioequivalence Study of Lamotrigine Tablets 200 mg With Lamictal® Tablets 200 mg in Healthy, Volunteers Under Fasting Condition.|Completed||Phase 1|20|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:43:54.998862|2018-05-31 21:43:54.998862
NCT01513707|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2017-04-25|2012-01-19|2012-01-20|Estimate|||||||2017-04-25|2017-04-27|Actual|December 22, 2011|Actual|2011-12-22|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|PDMP||The Effects of Pre-transplant Dialysis Modality on Post-transplant Events|The Effects of Pre-transplant Dialysis Modality on Post-transplant Events|Recruiting|||1040|Anticipated|Samsung Medical Center|||2||f||||f||||||||Undecided||2018-05-31 21:43:55.080224|2018-05-31 21:43:55.080224
NCT01513512|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-12-26|2012-01-16|2012-01-20|Estimate|||||||2012-12-26|2012-12-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:43:56.771354|2018-05-31 21:43:56.771354
NCT01513681|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-17|2012-01-17|2012-01-20|Estimate|||||||2012-01-17|2012-01-20|Estimate|November 2002||2002-11-30|October 2002|2002-10-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition|Single Dose, Two-way, Crossover, Oral Bioequivalence Study of Lamotrigine Tablets 200 mg With Lamictal® Tablets 200 mg in Healthy, Volunteers Under Fed Condition.|Completed||Phase 1|20|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:43:55.231589|2018-05-31 21:43:55.231589
NCT01513668|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-27|2012-01-19|2012-01-20|Estimate|||||||2012-01-27|2012-01-31|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||A Relative Bioavailability Study of Acetaminophen Extended Release Gel Tabs 650 mg Under Fed Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gel Tabs (Containing Acetaminophen 650 mg) of OHM Laboratories (Subsidiary of Ranbaxy) With Tylenol 8 Hour 650 mg Gel Tabs (Containing Acetaminophen 650 mg) of Mc Neil, Consumer & Speciality Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fed Condition|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:43:55.301054|2018-05-31 21:43:55.301054
NCT01513655|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2015-11-23|2012-01-19|2012-01-20|Estimate|||||||2015-11-23|2015-11-24|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation|Home Non Invasive Ventilation (NIV) Treatment for COPD-patients After a NIV-treated Exacerbation|Recruiting||Phase 4|150|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 21:43:55.365221|2018-05-31 21:43:55.365221
NCT01513642|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|February 2010|Actual|2010-02-28||Interventional|||Respiratory Physiotherapy After Cardiac Surgery|Inspiratory Volume and Muscle Recruitment During Breath-stacking and Incentive Spirometry Techniques in Postoperative Cardiac Patients|Completed||N/A|16|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 21:43:55.450914|2018-05-31 21:43:55.450914
NCT01513629|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Structural Connectivity as Imaging Endophenotypes of Autism Spectrum Disorders||Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 21:43:55.543597|2018-05-31 21:43:55.543597
NCT01513616|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-12-14|2012-01-16|2012-01-20|Estimate|||||||2012-12-14|2012-12-17|Estimate|November 2006||2006-11-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Impact of Pulmonary Rehabilitation on Dyspnea in Chronic Obstructive Pulmonary Disease|Mechanisms of Dyspnea Relief Following Exercise Training in COPD|Completed||N/A|48|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 21:43:55.683532|2018-05-31 21:43:55.683532
NCT01513603|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia|Phase II Trial of CLAG-M in Relapsed ALL|Unknown status|Recruiting|Phase 2|50|Anticipated|New York Medical College||1|||f||||f||||||||||2018-05-31 21:43:55.754001|2018-05-31 21:43:55.754001
NCT01513590|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2015-10-19||2017-02-09|2012-01-19|2012-01-20|Estimate|2015-10-19|2015-11-20|Estimate||||2017-02-09|2017-03-17|Actual|January 2012||2012-01-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|BOOST™||A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes|A 26-week, Randomised, Open-label, Multinational, Treat-to-target Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) Twice Daily (BID) and BIAsp 30 BID Both With Metformin in Insulin naïve Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy or Metformin in Combination With One Additional Oral Antidiabetic Drug (OAD)|Completed||Phase 3|394|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:43:55.863725|2018-05-31 21:43:55.863725
NCT01513577|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2014-09-12|2012-01-19|2012-01-20|Estimate|||||||2014-09-12|2014-09-15|Estimate|January 2003||2003-01-31|September 2014|2014-09-30|June 2006|Actual|2006-06-30|December 2004|Actual|2004-12-31||Interventional|||Percutaneous Minimal Invasive Pedicular Screw and Rod Insertion in Circumferential Lumbar Fusion|Percutaneous Minimal Invasive Pedicular Screw and Rod Insertion Reduces Hospital Stay and Morbidity Compared to Open Midline Approach in Circumferential Lumbar Fusion. A Randomized Study With 2 Years Follow-up|Completed||N/A|16|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:43:56.290921|2018-05-31 21:43:56.290921
NCT01513564|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2015-05-27|2012-01-19|2012-01-20|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2001||2001-01-31|May 2015|2015-05-31|June 2006|Actual|2006-06-30|December 2003|Actual|2003-12-31||Interventional|||Multimodal Perioperative Pain Management|Multimodal Perioperative Pain Management of Circumferential Lumbar Fusion Improves Recovery|Completed||N/A|120|Actual|Northern Orthopaedic Division, Denmark||1|||f||||f||||||||||2018-05-31 21:43:56.363345|2018-05-31 21:43:56.363345
NCT01513551|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2015-02-26|2012-01-16|2012-01-20|Estimate|||||||2015-02-26|2015-02-27|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||A Study to Compare the Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in Healthy Volunteers (V114-002)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older|Completed||Phase 2|692|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 21:43:56.438932|2018-05-31 21:43:56.438932
NCT01513538|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2016-05-25||2017-05-22|2012-01-16|2012-01-20|Estimate|2017-05-22|2017-12-18|Actual||||2017-05-22|2017-12-18|Actual|May 2011|Actual|2011-05-31|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Analysis of the Acceptance and Changes to Parameters Programming Suggested by the TherapyGuide Function|TherapyGuide : Analysis of the Acceptance and Changes to Parameters Programming Suggested by the TherapyGuide Function|Completed|||700|Actual|Medtronic Bakken Research Center|||1||f||||f||||||||||2018-05-31 21:43:56.516815|2018-05-31 21:43:56.516815
NCT01513525|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2017-01-25|2012-01-16|2012-01-20|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2007||2007-02-28|January 2017|2017-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers|A Randomised, Open-label, Single Centre, Three Period Cross-over Trial in Healthy Subjects Comparing the Pharmacokinetic Profiles After Single Dose Administration of Liraglutide at Three Different Injection Sites|Completed||Phase 1|21|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:43:56.696138|2018-05-31 21:43:56.696138
NCT01513499|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-02-15|2012-01-19|2012-01-20|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2012|Actual|2012-01-31|February 2018|2018-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Men and Women|Effect of Intranasal Oxytocin on Appetite and Caloric Intake in Humans|Completed||Early Phase 1|25|Actual|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 21:43:56.804602|2018-05-31 21:43:56.804602
NCT01513486|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2013-05-20|2012-01-16|2012-01-20|Estimate|||||||2013-05-20|2013-05-22|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|ESDIM||Electrical Stimulation During Immobilization|The Effects of Daily Neuromuscular Electrical Stimulation on Muscle Mass During Short-term One-legged Knee Immobilization in Healthy Young Men|Completed||N/A|24|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:43:56.876522|2018-05-31 21:43:56.876522
NCT01513473|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2015-10-12|2013-11-07|2017-01-19|2012-01-19|2012-01-20|Estimate|2015-12-08|2016-01-12|Estimate|2013-11-07|2013-12-02|Estimate|2017-01-19|2017-03-03|Actual|January 2012||2012-01-31|January 2017|2017-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|BEGIN™|Full Analysis set (FAS) included all randomised subjects.|A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus|A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in Children and Adolescents 1 to Less Than 18 Years With Type 1 Diabetes Mellitus on a Basal-bolus Regimen With Insulin Aspart as Bolus Insulin, Followed by a 26-week Extension Investigating Long Term Safety (BEGIN™: Young 1)|Completed||Phase 3|350|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:43:56.991526|2018-05-31 21:43:56.991526
NCT01513460|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2014-12-10||2014-12-23|2012-01-19|2012-01-20|Estimate|2014-12-23|2015-01-05|Estimate||||2014-12-23|2015-01-05|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease|A Multicenter, Randomized, Blinded, Active-controlled, Parallel-group Study to Compare the Efficacy, Tolerability and Safety of NVA237 Compared to Tiotropium Added on to Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|773|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:43:57.654083|2018-05-31 21:43:57.654083
NCT01513447|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2015-01-30||2015-02-23|2012-01-19|2012-01-20|Estimate|2015-02-23|2015-03-02|Estimate||||2015-02-23|2015-03-02|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Laboring women requesting labor analgesia|Intracutaneous Sterile Water Injections|Intracutaneous Sterile Water Injection as an Adjunct to Neuraxial Labor Analgesia: A Randomized Controlled Trial|Terminated||N/A|8|Actual|Northwestern University|Early termination leading to small numbers of subjects analyzed; Subjects recruitment unsuccessful because of low number of subjects that were eligible for study inclusion.|2||low qualified candidate enrollment|f||||f||||||||||2018-05-31 21:43:58.463418|2018-05-31 21:43:58.463418
NCT01513434|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Femoral Tunnel Position on Conventional MRI After Anterior Cruciate Ligament Reconstruction-Transtibial Technique Versus Transportal Technique||Completed||N/A|64|Actual|National Police Hospital||2|||f||||t||||||||||2018-05-31 21:43:58.713991|2018-05-31 21:43:58.713991
NCT01513421|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-20|2012-01-17|2012-01-20|Estimate|||||||2012-01-20|2012-01-23|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Observational|||Active Versus Non Active Drainage for the Treatment of Infected Intra-abdominal Collection|Active Versus Non Active Drainage for the Treatment of Infected Intra-abdominal Collection: a Randomized Prospective Trial|Unknown status|Recruiting||100|Anticipated|Centre Hospitalier Universitaire Vaudois|||2||f||||f||||||||||2018-05-31 21:43:58.7935|2018-05-31 21:43:58.7935
NCT01513408|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-10-17|2012-01-17|2012-01-20|Estimate|||||||2017-10-17|2017-10-18|Actual|May 2012|Actual|2012-05-31|June 2017|2017-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PRIMUNEO||Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy|Prospective Study of the Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as a New imMUne Prognostic Biomarker in Breast Cancer Treated by NEOadjuvant Chemotherapy|Completed||N/A|500|Actual|Centre Georges Francois Leclerc||1|||f||||f||||||||||2018-05-31 21:43:58.948639|2018-05-31 21:43:58.948639
NCT01513395|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-20|2012-01-17|2012-01-20|Estimate|||||||2012-01-20|2012-01-23|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|November 2013|Anticipated|2013-11-30|June 2013|Anticipated|2013-06-30||Interventional|||Focal Myometrial Contractions: Impact on Cervical Assessment and Association With Voiding|Focal Myometrial Contractions: Impact on Cervical Assessment and Association With Voiding. A Randomized Trial|Unknown status|Recruiting|N/A|112|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 21:43:59.02463|2018-05-31 21:43:59.02463
NCT01513382|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2016-07-23|2012-01-19|2012-01-20|Estimate|||||||2016-07-23|2016-07-26|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|BAVUGC-2||Effectiveness of Methylene Blue Guidance in Total Excision of Pilonidal Sinus.|Does Intraoperative Methylene Blue Guidance in Pilonidal Sinus Surgery Really Effective in Total Excision of the Nest ?|Completed||N/A|30|Actual|Bezmialem Vakif University||1|||f||||t||||||||||2018-05-31 21:43:59.12458|2018-05-31 21:43:59.12458
NCT01513369|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2016-12-12|2012-01-16|2012-01-20|Estimate|||||||2016-12-12|2016-12-13|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|CLEVER||Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency|Intravenous Ferric Carboxymaltose for Improvement of Metabolic Parameters and Vascular Function in T2DM-patients With Iron Deficiency|Recruiting||Phase 3|152|Anticipated|GWT-TUD GmbH||2|||f||||f||||||||||2018-05-31 21:43:59.206176|2018-05-31 21:43:59.206176
NCT01513356|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-04-01|2012-01-16|2012-01-20|Estimate|||||||2014-04-01|2014-04-02|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pharmacodynamic Study of BKM120 in Breast Cancer|Evaluation of PI3K/AKT/mTOR Signaling Pathway Using BKM120 in Early Breast Cancer|Completed||Early Phase 1|20|Actual|Grupo Hospital de Madrid||1|||f||||f||||||||||2018-05-31 21:43:59.324901|2018-05-31 21:43:59.324901
NCT01513343|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-12-28|2012-01-19|2012-01-20|Estimate|||||||2017-12-28|2018-01-02|Actual|August 2014||2014-08-31|December 2017|2017-12-31|January 31, 2018|Anticipated|2018-01-31|December 27, 2017|Actual|2017-12-27||Interventional|SEEDs||Promoting The Self-Regulation Of Energy Intake|Promoting The Self-Regulation Of Energy Intake In African American And Latino Preschoolers: A Family Focused Obesity Prevention Program|Active, not recruiting||N/A|330|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 21:43:59.406761|2018-05-31 21:43:59.406761
NCT01513330|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2013-08-06||2013-11-21|2012-01-16|2012-01-20|Estimate|2013-11-21|2014-01-09|Estimate||||2013-11-21|2014-01-09|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Performance Study of Newly Developed Ostomy Products|An Open-labelled, Randomised, Controlled, Crossover Investigation Evaluating Performance of a Newly Developed Ostomy Care Product Compared to Standard Care.|Completed||Phase 4|122|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 21:43:59.518325|2018-05-31 21:43:59.518325
NCT01513317|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2014-09-24|2013-10-04|2014-09-24|2012-01-16|2012-01-20|Estimate|2014-09-24|2014-09-29|Estimate|2013-10-04|2013-10-28|Estimate|2014-09-24|2014-09-29|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome|Terminated||Phase 2|76|Actual|Janssen Research & Development, LLC||2||"The study was stopped after the interim analysis based on lack of sufficient efficacy. There~   were no safety concerns."|f||||t||||||||||2018-05-31 21:43:59.721922|2018-05-31 21:43:59.721922
NCT01513304|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|September 2007||2007-09-30|January 2012|2012-01-31||||May 2011|Actual|2011-05-31||Interventional|||Chiropractic Manual Therapy in Infantile Colic||Completed||N/A|||Anglo-European College of Chiropractic||1|||f||||f||||||||||2018-05-31 21:44:00.158147|2018-05-31 21:44:00.158147
NCT01513291|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2016-06-08||2016-07-28|2012-01-16|2012-01-20|Estimate|2016-06-08|2016-07-20|Estimate||||2016-07-28|2016-09-16|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Baseline characteristics are reported for all randomized participants|A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)|A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Patients With Episodic Migraine|Completed||Phase 2|237|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:44:00.253276|2018-05-31 21:44:00.253276
NCT01513278|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-07-12|2012-01-16|2012-01-20|Estimate|||||||2013-07-12|2013-07-15|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer|Randomized, Double-blind, Split-body, Placebo-controlled Phase Ib Study of APN201 (Liposomal Recombinant Human Cu/Zn-superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer|Completed||Phase 1/Phase 2|20|Actual|Apeiron Biologics||2|||f||||f||||||||||2018-05-31 21:44:00.632158|2018-05-31 21:44:00.632158
NCT01513265|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2014-05-21|2012-01-16|2012-01-20|Estimate|||||||2014-05-21|2014-05-22|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|RASP||Rationalisation of Polypharmacy in the Elderly by the RASP Instrument|Rationalisation of Polypharmacy in the Elderly by the RASP Instrument (Rationalisation of Home Medication by an Adjusted STOPP-list in Older Patients): a Prospective, Clinical Trial.|Completed||N/A|172|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 21:44:00.70214|2018-05-31 21:44:00.70214
NCT01513252|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-05-30|2012-01-16|2012-01-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 2011||2011-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MAPT-PLUS||Long-term Effects of Interventional Strategies to Prevent Cognitive Decline in Elderly.|A 2-years Extension Study of MAPT Trial : Evaluation of the Long Term Effects of Interventional Strategies to Prevent the Decline in Cognitive Functioning in Frail Older Adults|Recruiting||N/A|1150|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 21:44:00.767502|2018-05-31 21:44:00.767502
NCT01513239|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2016-10-24||2018-01-24|2012-01-19|2012-01-20|Estimate|2016-10-24|2016-12-15|Estimate||||2018-01-24|2018-02-21|Estimate|February 2012||2012-02-29|January 2018|2018-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MODIFY II|All Randomized Participants|A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY II)|Completed||Phase 3|1203|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:44:00.889423|2018-05-31 21:44:00.889423
NCT01513226|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|June 2006||2006-06-30|January 2012|2012-01-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|||Cycled Light and Crying of Preterm Infants|Cycled Light Exposure Reduces Fussing and Crying in Very Preterm Infants|Completed||N/A|37|Actual|University Children's Hospital, Zurich||1|||f||||f||||||||||2018-05-31 21:44:04.555194|2018-05-31 21:44:04.555194
NCT01513213|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-01-20|2012-01-16|2012-01-20|Estimate|||||||2017-01-20|2017-01-24|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2014|Actual|2014-05-31||Observational|O2 Fraction||Correlation of PaCO2 to the Inspired and Expired Oxygen Gradient|Correlation of PaCO2 to the Inspired and Expired Oxygen Gradient|Completed|||65|Actual|Swedish Medical Center|||||f||||f||||||||||2018-05-31 21:44:04.666877|2018-05-31 21:44:04.666877
NCT01513200|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-04-17|2012-01-16|2012-01-20|Estimate|||||||2012-04-17|2012-04-19|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia|A Two Part Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers and the Effects of Bendavia™ and Unfractionated Heparin When Administered Concurrently|Completed||Phase 1|12|Actual|Stealth BioTherapeutics Inc.||2|||f||||f||||||||||2018-05-31 21:44:04.820103|2018-05-31 21:44:04.820103
NCT01513187|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2018-04-25|2012-01-16|2012-01-20|Estimate|||||||2018-04-25|2018-04-26|Actual|September 2010||2010-09-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2015|Actual|2015-12-31||Interventional|||Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma|Phase I/II Prospective, Open Label and Multicentric Clinical Trial to Determine the Recommended Dose (Phase I) and Efficacy of Pazopanib in Combination With Interferon Alfa 2-A (Phase II), in Patients With Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|53|Actual|Spanish Oncology Genito-Urinary Group||1|||f||||f||||||||||2018-05-31 21:44:04.903215|2018-05-31 21:44:04.903215
NCT01513174|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2017-04-25|2012-01-16|2012-01-20|Estimate|||||||2017-04-25|2017-04-26|Actual|August 2011||2011-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|GOAL||Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone|Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer|Completed||Phase 1/Phase 2|186|Actual|Spanish Lung Cancer Group||2|||f||||t||||||||||2018-05-31 21:44:04.990791|2018-05-31 21:44:04.990791
NCT01513161|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|TRK-820||Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis|A 14 Day, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose, Phase III Clinical Trial to Assess the Efficacy and Safety of TRK-820 in Treating Conventional-treatment-resistant Pruritus in Patients Receiving Hemodialysis|Completed||Phase 3|104|Actual|SK Chemicals Co.,Ltd.||3|||f||||f||||||||||2018-05-31 21:44:05.0826|2018-05-31 21:44:05.0826
NCT01513148|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2012-06-11||2013-07-10|2012-01-16|2012-01-20|Estimate|2013-05-29|2013-07-04|Estimate||||2013-07-10|2013-07-29|Estimate|June 2006||2006-06-30|July 2013|2013-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effects of Light Emitting Diode Irradiation on the Conduction Parameters of the Superficial Radial Nerve|The Effect of Light Therapy on Superficial Radial Nerve Conduction Using a Clustered Array of Infrared Super Luminous and Red Light Emitting Diodes|Completed||N/A|32|Actual|Shenandoah University|4 subjects were terminated early in the project, two from the light therapy group and two from the sham therapy group. All cases, we were unable to achieve an appropriate baseline temperature of 30 degrees celsius to allow continued participation|2|||f||||f||||||||||2018-05-31 21:44:05.174238|2018-05-31 21:44:05.174238
NCT01513135|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2016-03-03|2012-01-19|2012-01-20|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|ISS T-003||A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers|A Phase Il, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Immunogenicity and Safety of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers|Completed||Phase 2|200|Actual|Istituto Superiore di Sanità||2|||f||||t||||||||||2018-05-31 21:44:05.648301|2018-05-31 21:44:05.648301
NCT01513122|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2013-12-01||2013-12-01|2012-01-19|2012-01-20|Estimate|2013-12-01|2014-01-17|Estimate||||2013-12-01|2014-01-17|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|August 2013|Actual|2013-08-31|September 2012|Actual|2012-09-30||Interventional|||Bone and Body Comp: A Sub Study of the SECOND-LINE Study||Completed||Phase 4|211|Actual|Kirby Institute||2|||f||||t||||||||||2018-05-31 21:44:05.736916|2018-05-31 21:44:05.736916
NCT01513109|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|ASCI||Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia|A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT).|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 21:44:06.152086|2018-05-31 21:44:06.152086
NCT01513096|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-03-30|2012-01-19|2012-01-20|Estimate|||||||2012-03-30|2012-04-03|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PSPEG||Efficacy of Prokinetics With Split Dose of PEG in Morning Colonoscopic Bowel Preparation|Efficacy of Prokinetics With Split Dose of PEG in Morning Colonoscopic Bowel Preparation: A Randomized, Controlled Trial|Completed||Phase 3|152|Actual|Inje University||2|||f||||f||||||||||2018-05-31 21:44:06.259225|2018-05-31 21:44:06.259225
NCT01513083|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2016-11-01|2012-01-16|2012-01-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function|A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function|Completed||Phase 1|28|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:44:06.324929|2018-05-31 21:44:06.324929
NCT01513070|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2014-08-03|2012-01-19|2012-01-20|Estimate|||||||2014-08-03|2014-08-05|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|July 2012|Actual|2012-07-31||Interventional|||A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis|A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis|Completed||Phase 4|120|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 21:44:06.406674|2018-05-31 21:44:06.406674
NCT01513057|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fed Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study in Healthy, Adult,Human, Male Subjects Under Fed Conditions.|Completed||Phase 1|61|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:44:06.486156|2018-05-31 21:44:06.486156
NCT01513044|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule, Under Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study in Healthy, Adult,Human, Male Subjects Under Fasting Conditions.|Completed||Phase 1|68|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:44:06.563624|2018-05-31 21:44:06.563624
NCT01513031|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-06-28|2012-01-19|2012-01-20|Estimate|||||||2012-06-28|2012-07-02|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation|Pilot Project to Determine Rates and Reasons for Non-Adherence in Patients Receiving Chronic Oral Antiarrhythmic Therapy for Atrial Fibrillation in the State of Nebraska|Terminated||Phase 4|9|Actual|Creighton University||1||Low enrollment|f||||f||||||||||2018-05-31 21:44:06.707201|2018-05-31 21:44:06.707201
NCT01513005|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2014-02-04|2012-01-19|2012-01-20|Estimate|||||||2014-02-04|2014-02-05|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|GASTRAMBU||Feasibility of Laparoscopic Sleeve Gastrectomy in Day Case Surgery|Feasibility of Day Case Management by Laparoscopic Sleeve Gastrectomy for Obesity: a Pilot Study|Completed||N/A|30|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 21:44:06.89015|2018-05-31 21:44:06.89015
NCT01512992|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-09-04|2012-01-19|2012-01-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Home Telehealth Follow-up After Hospital Discharge for Chronic Obstructive Pulmonary Disease (COPD) Patients|Renewing Health RCT in Catalonia for the Evaluation of Home Telehealth Follow-up After Hospital Discharge for COPD Patients|Unknown status|Active, not recruiting|N/A|380|Anticipated|Catalan Agency for Health Information, Assessment and Quality||2|||f||||t||||||||||2018-05-31 21:44:06.979046|2018-05-31 21:44:06.979046
NCT01512979|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|2014-04-08||2014-05-12|2012-01-16|2012-01-20|Estimate|2014-04-08|2014-05-09|Estimate||||2014-05-12|2014-05-20|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Patients from Treated Set (TS): All patients treated with at least 1 dose of study drug.|Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes|A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patients|Completed||Phase 4|316|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:44:07.106971|2018-05-31 21:44:07.106971
NCT01512966|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2014-10-08|2012-01-16|2012-01-20|Estimate|||||||2014-10-08|2014-10-09|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|VIVID-Japan||Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)|An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema|Completed||Phase 3|73|Actual|Bayer||1|||f||||t||||||||||2018-05-31 21:44:07.596606|2018-05-31 21:44:07.596606
NCT01512953|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|August 2013|Anticipated|2013-08-31|August 2012|Anticipated|2012-08-31||Interventional|GENIOUS||Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata|Randomized Comparison of PPI Versus no PPI on Top of Standard Dose Clopidogrel Therapy in Patients Stratified Based on CYC2C19 Activity Via a Genetic Point of Care System.|Unknown status|Recruiting|Phase 4|522|Anticipated|Università degli Studi di Ferrara||2|||f||||f||||||||||2018-05-31 21:44:07.689116|2018-05-31 21:44:07.689116
NCT01512940|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2012-03-11|2012-01-15|2012-01-19|Estimate|||||||2012-03-11|2012-03-13|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|October 2014|Anticipated|2014-10-31|October 2012|Anticipated|2012-10-31||Interventional|LGCP||Resolution of Comorbidities, Safety and Efficacy of Greater Curvature Plication in Obese Patients.|Laparoscopic Greater Curvature Plication for Weight Loss and Resolution of Diabetes and Other Comorbidities.|Unknown status|Recruiting|N/A|50|Anticipated|Singh, Kuldeep, M.D., P.A.|||||f||||t||||||||||2018-05-31 21:44:07.763401|2018-05-31 21:44:07.763401
NCT01512927|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Observational|||Electro Stethoscope in Detect Arteriovenous Fistula (AVF) Stenosis|Electronic Stethoscope and Computer-aided Diagnostic System in Detecting Arteriovenous Fistula (AVF) Stenosis|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 21:44:07.823787|2018-05-31 21:44:07.823787
NCT01512914|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Impact of Intraperitonael Nebulization of Local Anesthetic on Postoperative Pain Associated With Laparoscopic Surgery|Impact of Intraperitonael Nebulization of Local Anesthetic on Postoperative Pain Associated With Laparoscopic Surgery|Completed||Phase 3|120|Actual|San Gerardo Hospital||4|||f||||f||||||||||2018-05-31 21:44:07.896428|2018-05-31 21:44:07.896428
NCT01512901|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2014-07-17|2012-01-15|2012-01-19|Estimate|||||||2014-07-17|2014-07-21|Estimate||||July 2014|2014-07-31||||||||Interventional|||Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI)|A Randomized, Sham Controlled, Multicenter, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion|Completed||Phase 2/Phase 3|||Santen Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 21:44:08.104515|2018-05-31 21:44:08.104515
NCT01512888|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-01-18|2012-01-18|2012-01-19|Estimate|||||||2018-01-18|2018-01-23|Actual|August 17, 2016|Actual|2016-08-17|January 2018|2018-01-31|August 2034|Anticipated|2034-08-31|August 2025|Anticipated|2025-08-31||Interventional|LVXSCID-ND||Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants|A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells|Recruiting||Phase 1/Phase 2|28|Anticipated|St. Jude Children's Research Hospital||1|||f||||t|t|t|f|||||||2018-05-31 21:44:08.191176|2018-05-31 21:44:08.191176
NCT01512875|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-11-16|2012-01-18|2012-01-19|Estimate|||||||2015-11-16|2015-11-17|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Observational|||S1119 Peruvian H. Pylori Water Contamination Study|Gastric Cancer and Helicobacter Pylori Infection in Lima, Peru: The Role of Water Contamination|Completed|||107|Actual|Southwest Oncology Group|||1||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-05-31 21:44:08.303468|2018-05-31 21:44:08.303468
NCT01512862|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-04-09|2012-01-18|2012-01-19|Estimate|||||||2012-04-09|2012-04-10|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients|Additive Renoprotective Effects of Oral Calcitriol in Nondiabetic Chronic Kidney Disease Patients|Unknown status|Recruiting|Phase 4|240|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:44:08.377529|2018-05-31 21:44:08.377529
NCT01512849|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2014-03-25||2014-05-13|2012-01-15|2012-01-19|Estimate|2014-05-13|2014-06-11|Estimate||||2014-05-13|2014-06-11|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment|An Open-Label, Randomized, 2 Way Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment|Completed||Phase 1|24|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 21:44:08.490503|2018-05-31 21:44:08.490503
NCT01512836|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2015-03-31|2012-01-18|2012-01-19|Estimate|||||||2015-03-31|2015-04-01|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Randomized Controlled Trial to Determine Outcome and Cost Effectiveness of Case Management of Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized Controlled Trial to Determine Outcome and Cost Effectiveness of Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease (COPD) in a Danish Setting|Completed||N/A|150|Actual|Kronikerenheden Nordjylland||2|||f||||t||||||||||2018-05-31 21:44:08.848289|2018-05-31 21:44:08.848289
NCT01512823|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-02-03|2012-01-13|2012-01-19|Estimate|||||||2012-02-03|2012-02-06|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|March 2011|Actual|2011-03-31|January 2009|Actual|2009-01-31||Interventional|OTEBP||Randomised Trial of Two Educational Intervention for Improving Evidence-based Practice Knowledge, Atttitudes and Practice|Randomised Trial of the Effectiveness of Two Educational Interventions to Improve Evidence-based Practice Knowledge, Attitudes and Behaviour in Occupational Therapists|Completed||N/A|58|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 21:44:08.922028|2018-05-31 21:44:08.922028
NCT01512810|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-10-17|2012-01-18|2012-01-19|Estimate|||||||2017-10-17|2017-10-19|Actual|January 2012||2012-01-31|October 2017|2017-10-31|July 28, 2021|Anticipated|2021-07-28|July 28, 2020|Anticipated|2020-07-28||Interventional|||Treatment of Endometrial Cancer|Treatment of Endometrial Cancer Utilizing Pathology Intraoperative Consultation to Determine Extent of Surgical Staging|Active, not recruiting||Phase 2|200|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 21:44:08.990116|2018-05-31 21:44:08.990116
NCT01512797|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2017-12-01||2018-02-20|2012-01-18|2012-01-19|Estimate|2018-02-20|2018-02-23|Actual||||2018-02-20|2018-02-23|Actual|July 2012||2012-07-31|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|LAF33||Treatment of Diabetes After Gastric Bypass With Sitagliptin|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess Efficacy, Safety and Tolerability of Sitagliptin Phosphate 100 mg as Treatment for Recurrent, Persistent or Newly Diagnosed Type 2 Diabetes After Gastric Bypass|Completed||N/A|37|Actual|Columbia University|Study of short duration, designed as proof of concept. Absorption of sitagliptin may have been variable amongst subjects. The groups were small and the data cannot be extrapolated to a larger group of individuals with wide range of diabetes control.|2|||f||||t||||||||Undecided||2018-05-31 21:44:09.085094|2018-05-31 21:44:09.085094
NCT01512784|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults|Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults vs. Healthy Adolescents and Young Adults: Non-randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 3|100|Anticipated|University of Milan||2|||f||||||||||||||2018-05-31 21:44:09.620936|2018-05-31 21:44:09.620936
NCT01512771|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2014-09-23|2012-01-13|2012-01-19|Estimate|||||||2014-09-23|2014-09-25|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|PTSD||The Effect of Nasal Continuous Positive Airway Pressure Treatment on PTSD Symptoms.|The Effect of Nasal Continuous Positive Airway Pressure (Nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms.|Completed|||18|Actual|Northport Veterans Affairs Medical Center|||||f||||t||||||||||2018-05-31 21:44:09.70164|2018-05-31 21:44:09.70164
NCT01512758|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-10-15|2012-01-13|2012-01-19|Estimate|||||||2015-10-15|2015-10-16|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||A Study of Alisertib (MLN8237) in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas|A Phase 1 Dose Escalation and Pharmacokinetic Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, in Adult East Asian Patients With Advanced Solid Tumors or Lymphomas|Completed||Phase 1|36|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:44:09.795952|2018-05-31 21:44:09.795952
NCT01512745|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2015-08-06||2016-08-30|2012-01-15|2012-01-19|Estimate|2016-05-08|2016-06-15|Estimate||||2016-08-30|2016-10-17|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||5 participants in the apatinib group and 1 in the placebo group withdrew from the study before receiving the assigned treatments.As a result,267 randomly assigned participants were included in Full Analysis Set （FAS），with 176 assigned to the apatinib group and 91 assigned to the placeo group.|Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer|A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer|Completed||Phase 3|267|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:44:09.920173|2018-05-31 21:44:09.920173
NCT01512732|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2012-01-22|2012-01-15|2012-01-19|Estimate|||||||2012-01-22|2012-01-24|Estimate|February 2012||2012-02-29|January 2012|2012-01-31||||||||Observational|||Validation of the Hebrew Version of the Montreal Affective Voices.||Unknown status|Not yet recruiting||120|Anticipated|Hadassah Medical Organization|||3||f||||||||||||||2018-05-31 21:44:10.17615|2018-05-31 21:44:10.17615
NCT01512719|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2016-04-12|2012-01-18|2012-01-19|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|POEM||POEM- Peroral Endoscopic Myotomy for Esophageal Motility Disorders|POEM a Novel Endoscopic Treatment for Achalasia|Unknown status|Recruiting|N/A|25|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-05-31 21:44:10.237129|2018-05-31 21:44:10.237129
NCT01512706|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2012-04-26|2012-01-15|2012-01-19|Estimate|||||||2012-04-26|2012-04-27|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants|A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants|Completed||Phase 2|660|Actual|Chinese Academy of Medical Sciences||15|||f||||t||||||||||2018-05-31 21:44:10.315403|2018-05-31 21:44:10.315403
NCT01512693|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2017-06-12||2017-06-12|2012-01-18|2012-01-19|Estimate|2017-06-12|2017-10-27|Actual||||2017-06-12|2017-10-27|Actual|February 23, 2012|Actual|2012-02-23|June 2017|2017-06-30|April 24, 2012|Actual|2012-04-24|April 24, 2012|Actual|2012-04-24||Interventional|||Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)|Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Hepatic Insufficiency|Completed||Phase 1|17|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 21:44:10.424824|2018-05-31 21:44:10.424824
NCT01512329|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2015-12-16|2012-01-13|2012-01-19|Estimate|||||||2015-12-16|2015-12-17|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Pacing Activity Self-management for Patients With Multiple Sclerosis|Pacing Activity Self-management for Patients With Multiple Sclerosis: Randomized Controlled Clinical Trial|Completed||Phase 2|31|Actual|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 21:44:13.378593|2018-05-31 21:44:13.378593
NCT01512680|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-11-28|2012-01-14|2012-01-19|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Interventional|IFOPI||Evaluation of Functional Insulin Therapy in Type 1 Diabetic Patients|Evaluation of Functional Insulin Therapy on Blood Glucose Control in Type 1 Diabetic Patients Treated by Insulin Pumps|Completed||Phase 2|52|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 21:44:10.641593|2018-05-31 21:44:10.641593
NCT01512667|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2017-06-12||2017-08-17|2012-01-13|2012-01-19|Estimate|2017-08-17|2018-02-26|Actual||||2017-08-17|2018-02-26|Actual|January 17, 2012|Actual|2012-01-17|August 2017|2017-08-31|August 22, 2012|Actual|2012-08-22|August 22, 2012|Actual|2012-08-22||Interventional|||Pharmacokinetic Assessment of Single-Dose Odanacatib (MK-0822) in Subjects With Severe Renal Insufficiency (MK-0822-067)|A Single Dose Study to Investigate the Pharmacokinetics of Odanacatib (MK-0822) in Subjects With Renal Insufficiency|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 21:44:10.708473|2018-05-31 21:44:10.708473
NCT01512654|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-12-02|2012-01-14|2012-01-19|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|June 2012|Actual|2012-06-30|February 2009|Actual|2009-02-28||Interventional|||Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2|Assessment of an Enhanced Version of a Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor-2) for Diabetic Patients Treated by Basal-Bolus Insulin Regimens|Completed||Phase 2|60|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:44:11.033084|2018-05-31 21:44:11.033084
NCT01512641|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-01-31|2012-01-18|2012-01-19|Estimate|||||||2014-01-31|2014-02-03|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Prevalence of Dissociative Disorders in Children|Prevalence of Dissociative Disorders in Children in a Population Supported in the Medico-social and Health Structures in Provence Alpes Cote d'Azur|Completed||N/A|301|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 21:44:11.118878|2018-05-31 21:44:11.118878
NCT01512628|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-01-26|2012-01-14|2012-01-19|Estimate|||||||2014-01-26|2014-01-28|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Rotational Thromboelstometry (ROTEM) change_colloid_total Hip Replacement Arthroplasty|Hemostatic Changes After Colloid Fluid Administration During Total Hip Replacement Arthroplasty|Completed||N/A|75|Actual|Seoul National University Bundang Hospital||3|||f||||f||||||||||2018-05-31 21:44:11.207162|2018-05-31 21:44:11.207162
NCT01512615|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2016-11-28|2012-01-14|2012-01-19|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|May 2017|Anticipated|2017-05-31||Interventional|||CopenHeart IE - Integrated Rehabilitation of Patients Treated for Infective Endocarditis|CopenHeart IE - A Randomized Clinical Trial Investigating the Effect and Meaning of Integrated Rehabilitation Versus Usual Follow-up of Patients Treated for Infective Endocarditis|Recruiting||Phase 2|150|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:44:11.274456|2018-05-31 21:44:11.274456
NCT01512602|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-04-25|2012-01-14|2012-01-19|Estimate|||||||2015-04-25|2015-04-28|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DiaS||Efficacy of Dialectical Behavior Therapy Versus CAMS-informed Supportive Psychotherapy on Self Harming Behavior|Efficacy of Dialectical Behavior Therapy in Patient With Self Harming Behavior and Traits Within the Spectrum of Borderline Personality Disorder.|Completed||N/A|108|Actual|Mental Health Services in the Capital Region, Denmark||2|||f||||f||||||||||2018-05-31 21:44:11.345774|2018-05-31 21:44:11.345774
NCT01512589|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-03-13|2012-01-18|2012-01-19|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2012|Actual|2012-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial|Phase IIB Randomized Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for the Treatment of Esophageal Cancer|Recruiting||Phase 2|180|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 21:44:11.413696|2018-05-31 21:44:11.413696
NCT01512576|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-15|2012-01-15|2012-01-19|Estimate|||||||2012-01-15|2012-01-19|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Does Acupuncture Activate Endogenous Pain Inhibition in Chronic Whiplash?|Does Acupuncture Activate Endogenous Pain Inhibition in Chronic Whiplash Associated Disorders? A Randomized Cross-over Trial|Completed||Phase 2|39|Actual|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 21:44:11.579113|2018-05-31 21:44:11.579113
NCT01512563|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-15|2012-01-15|2012-01-19|Estimate|||||||2012-01-15|2012-01-19|Estimate|February 2007||2007-02-28|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|MIRA-cover||Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent|Clinical Trial Comparing Patency and Safety of the Paclitaxel Eluting Covered Metallic Biliary Stent(Niti-S Mira-Cover Biliary Stent ) to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent)|Completed||Phase 3|106|Actual|Taewoong Medical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:44:11.663854|2018-05-31 21:44:11.663854
NCT01512550|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-09-26|2012-01-15|2012-01-19|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2010||2010-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|December 2011|Actual|2011-12-31||Interventional|||Importance of Restoring Biomechanical Correct Hip Anatomy During Total Hip Arthroplasty|Evaluation of the Importance in Restoring Biomechanical Correct Hip Anatomy During THA. A Prospective, Randomized and Controlled Study Evaluated by RSA, CT and Gait Analysis|Completed||N/A|75|Actual|Region Skane||3|||f||||f||||||||||2018-05-31 21:44:11.7507|2018-05-31 21:44:11.7507
NCT01512537|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-01-15|2012-01-15|2012-01-19|Estimate|||||||2012-01-15|2012-01-19|Estimate|February 2010||2010-02-28|January 2012|2012-01-31|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|||Alternative Treatments of Vitamin D Deficiency|Comparison of UVB and Vitamin D Supplementation in Treatment of Vitamin D Deficiency|Completed||N/A|32|Actual|Lund University||2|||f||||f||||||||||2018-05-31 21:44:11.835603|2018-05-31 21:44:11.835603
NCT01512524|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2014-03-21|2012-01-15|2012-01-19|Estimate|||||||2014-03-21|2014-03-24|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|INSPIRE-TC||Hormonal Deficiency in the Quality of Life of Patients With Traumatic Brain Injury|Long Term Follow-up of Moderate and Severe Traumatic Bain Injury and Assessment of Involvement of Hormonal Deficiency in the Quality of Life|Unknown status|Recruiting|N/A|140|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 21:44:11.917253|2018-05-31 21:44:11.917253
NCT01512511|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-15|2012-01-15|2012-01-19|Estimate|||||||2012-01-15|2012-01-19|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Comparing Nitrous Oxide and Carbon Dioxide for Laparoscopic Cholecystectomy|Prospective Randomized Trial Comparing Nitrous Oxide and Carbon Dioxide for Laparoscopic Cholecystectomy|Completed||N/A|64|Actual|Ahvaz Jundishapur University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:44:11.988196|2018-05-31 21:44:11.988196
NCT01512498|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-02-24|2012-01-18|2012-01-19|Estimate|||||||2018-02-24|2018-02-27|Actual|December 2012||2012-12-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menarche|Vulvovaginal Graft Versus Host Disease in Women Who Underwent Transplantation Before and After Menarche|Recruiting|||50|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||No||2018-05-31 21:44:12.049274|2018-05-31 21:44:12.049274
NCT01512485|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-13|2012-01-13|2012-01-19|Estimate|||||||2012-01-13|2012-01-19|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions|Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fed Conditions|Completed||Phase 1|51|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:44:12.123807|2018-05-31 21:44:12.123807
NCT01512472|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-10-13|2012-01-18|2012-01-19|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|FIT||Firmagon (Degarelix) Intermittent Therapy|Randomized, Multicentre Efficacy and Safety Study Comparing 10 Mons vs 4 Mons Degarelix Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy|Terminated||Phase 4|144|Actual|Canadian Urology Research Consortium||2||acrrual target was not being met|f||||f||||||||||2018-05-31 21:44:12.222834|2018-05-31 21:44:12.222834
NCT01512459|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence Two-period, Single Dose Sprinkled on Apple Sauce, Crossover and Relative Bioavailability Study in Healthy Adult, Human Subjects Under Fed Conditions|Completed||Phase 1|33|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:44:12.334557|2018-05-31 21:44:12.334557
NCT01512446|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2017-07-10|2012-01-14|2012-01-19|Estimate|||||||2017-07-10|2017-07-12|Actual|February 2012|Actual|2012-02-29|July 2017|2017-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|BILANZ||Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy|Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy|Terminated||Phase 3|436|Actual|Evangelisches Krankenhaus Lutherhaus gGmbH||2||low recruitment rate|f||||t||||||||||2018-05-31 21:44:12.413081|2018-05-31 21:44:12.413081
NCT01512433|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2013-03-21|2012-01-18|2012-01-19|Estimate|||||||2013-03-21|2013-03-25|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|March 2012|Actual|2012-03-31||Interventional|||The Clinical Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts|The Clinical Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts: A Randomized Controlled Trial|Completed||N/A|60|Actual|China Medical University, Taiwan||2|||f||||t||||||||||2018-05-31 21:44:12.49704|2018-05-31 21:44:12.49704
NCT01512420|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-11-01|2012-01-13|2012-01-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)|A Multicenter, Prospective, Observational Study to Identify Different Prognostic Factors Related to Survival in Patients With Previously Treated Advanced NSCLC With Wild-type Epidermal Growth Factor Receptor (EGFR) Gene.|Completed|||355|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:44:12.593049|2018-05-31 21:44:12.593049
NCT01512407|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-14|||2015-02-02|2012-01-14|2012-01-19|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|A-TECH||RCT on Adjuvant TACE After Hepatectomy for HCC|Randomised Controlled Trial on Adjuvant Transarterial Chemoembolisation After Curative Hepatectomy for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 3|144|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:44:12.723153|2018-05-31 21:44:12.723153
NCT01512394|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2016-01-27|2012-01-14|2012-01-19|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|December 2013|Anticipated|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pre-op Bowel Prep Before Abdominal Surgery|Effects of Preoperative Bowel Preparation Prior to Elective Bowel Resection or Ostomy Closure in the Pediatric Patient Population|Withdrawn||N/A|0|Actual|Children's Mercy Hospital Kansas City||2||Study was never started.|f||||f||||||||||2018-05-31 21:44:12.818251|2018-05-31 21:44:12.818251
NCT01512381|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-08-10|2012-01-14|2012-01-19|Estimate|||||||2017-08-10|2017-08-11|Actual|December 2010||2010-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|VISTA||Atrioventricular Node Ablation in Patients With Atrial Fibrillation and Moderate Chronic Heart Failure|Variant of Stimulation in Atrioventricular Node Ablation (VISTA) in Patients With Atrial Fibrillation and Moderate Chronic Heart Failure|Recruiting||Phase 4|60|Anticipated|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health||2|||f||||f||||||||||2018-05-31 21:44:12.880691|2018-05-31 21:44:12.880691
NCT01512368|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2012-01-20||2013-01-09|2012-01-13|2012-01-19|Estimate|2012-02-23|2012-03-26|Estimate||||2013-01-09|2013-01-14|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Changes in Serum Fibroblast Growth Factor 21 (FGF21) Levels Correlated With Exercise|Changes in Serum Fibroblast Growth Factor 21 (FGF21) Levels After a Cardiorespiratory Exercise Program|Completed||N/A|82|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|We cannot fully control other potential sources of physical activity. The results may not be applicable to men. We did not register the caloric consumption during the study.|1|||f||||t||||||||||2018-05-31 21:44:12.955755|2018-05-31 21:44:12.955755
NCT01512355|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-07-15|2012-01-13|2012-01-19|Estimate|||||||2015-07-15|2015-07-16|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery||Completed||N/A|88|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:44:13.194588|2018-05-31 21:44:13.194588
NCT01512342|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2015-12-16|2012-01-13|2012-01-19|Estimate|||||||2015-12-16|2015-12-17|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome|Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome: Randomized Controlled Clinical Trial|Completed||Phase 2|33|Actual|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 21:44:13.256305|2018-05-31 21:44:13.256305
NCT01512303|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2018-05-01|2012-01-13|2012-01-19|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2012|Actual|2012-04-30|May 2018|2018-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Complementary and Alternative Interventions for Veterans With Posttraumatic Stress Disorder|Complementary and Alternative Interventions for Veterans With Posttraumatic Stress Disorder: Community Program Evaluation Study|Terminated||N/A|70|Actual|University of Wisconsin, Madison||4||Study terminated due to funding issues|f||||f||||||||||2018-05-31 21:44:13.599042|2018-05-31 21:44:13.599042
NCT01512290|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-09-24|2012-01-13|2012-01-19|Estimate|||||||2014-09-24|2014-09-25|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations|Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations; a Placebo-controlled Trail|Completed||N/A|71|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 21:44:13.671309|2018-05-31 21:44:13.671309
NCT01512277|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-08-26|2012-01-13|2012-01-19|Estimate|||||||2013-08-26|2013-08-27|Estimate|September 1998||1998-09-30|August 2013|2013-08-31|September 1999|Actual|1999-09-30|March 1999|Actual|1999-03-31||Interventional|Bilhvax1a||Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis|Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis|Completed||Phase 1|24|Actual|University Hospital, Lille||3|||f||||f||||||||||2018-05-31 21:44:13.913883|2018-05-31 21:44:13.913883
NCT01512264|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2018-05-10|2012-01-13|2012-01-19|Estimate|||||||2018-05-10|2018-05-11|Actual|January 2012||2012-01-31|May 2018|2018-05-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|PART||Post-Stroke Aphasia and Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Study|Post-Stroke Aphasia and rTMS Treatment Study|Completed||N/A|57|Actual|University of Alabama at Birmingham||5|||f||||t||||||||||2018-05-31 21:44:14.013176|2018-05-31 21:44:14.013176
NCT01512251|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2018-02-23||2018-04-16|2012-01-13|2012-01-19|Estimate|2018-04-16|2018-05-16|Actual||||2018-04-16|2018-05-16|Actual|June 9, 2012|Actual|2012-06-09|April 2018|2018-04-30|March 21, 2017|Actual|2017-03-21|December 13, 2013|Actual|2013-12-13||Interventional|||BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma|A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)|Completed||Phase 1/Phase 2|8|Actual|University of California, San Francisco|Study was terminated early due to dose limiting toxicities.|1|||f||||t||||||||||2018-05-31 21:44:14.132811|2018-05-31 21:44:14.132811
NCT01512238|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-09-30|2012-01-13|2012-01-19|Estimate|||||||2014-09-30|2014-10-01|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|November 2013|Actual|2013-11-30|January 2011|Actual|2011-01-31||Observational|||Improvement of Intentional and Unintentional Non-adherence in the Elderly|Improvement of Intentional and Unintentional Non-adherence in the Elderly. Importance of Pharmaceutical Care, Generic Substitution, Non-prescription Drugs, Herbal Medicine and Dietary Supplements|Completed|||630|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 21:44:14.491946|2018-05-31 21:44:14.491946
NCT01512225|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2016-11-07||2017-03-08|2012-01-13|2012-01-19|Estimate|2017-03-08|2017-04-20|Actual||||2017-03-08|2017-04-20|Actual|May 2012||2012-05-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|EMPOWER||Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates|Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates|Completed||Phase 2|90|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||No||2018-05-31 21:44:14.644526|2018-05-31 21:44:14.644526
NCT01512212|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-13|2012-01-13|2012-01-19|Estimate|||||||2012-01-13|2012-01-19|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|fnab||New Thyroid Fine Needle Aspiration Biopsy Apparatus|New Thyroid Fine Needle Biopsy Apparatus|Unknown status|Recruiting|N/A|40|Anticipated|SB Istanbul Education and Research Hospital||1|||f||||f||||||||||2018-05-31 21:44:15.055442|2018-05-31 21:44:15.055442
NCT01512199|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-10-16|2012-01-13|2012-01-19|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2011|Actual|2011-11-30|October 2017|2017-10-31|January 28, 2015|Actual|2015-01-28|January 28, 2015|Actual|2015-01-28||Interventional|||Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)|Randomized, Placebo Controlled, Double Blind Phase 1b/2 Study of U3-1287 (AMG 888) in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed HER2 Positive Metastatic Breast Cancer (MBC)|Terminated||Phase 1/Phase 2|29|Actual|Daiichi Sankyo, Inc.||3||Improved, different standard of care caused business decision to terminate|f||||t||||||||||2018-05-31 21:44:15.166001|2018-05-31 21:44:15.166001
NCT01512186|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-06-11|2012-01-13|2012-01-19|Estimate|||||||2014-06-11|2014-06-12|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|February 2014|Actual|2014-02-28||Observational|Panther||A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)|A Phase II Study Investigating Upfront Pazopanib In Metastatic Clear Cell Renal Cancer (Panther)|Unknown status|Active, not recruiting||95|Anticipated|Queen Mary University of London|||||f||||t||||||Samples With DNA|"~     Pre-treatment biopsy and post treatment nephrectomy samples will be obtained~   "|||2018-05-31 21:44:15.319637|2018-05-31 21:44:15.319637
NCT01512173|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-10-29|2012-01-13|2012-01-19|Estimate|||||||2014-10-29|2014-10-30|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo|A Randomised, Double Blind, Controlled, Multicentre Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo.|Completed||Phase 2|82|Actual|Pierre Fabre Dermatology||2|||f||||||||||||||2018-05-31 21:44:15.397555|2018-05-31 21:44:15.397555
NCT01512160|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2013-03-14||2013-05-23|2012-01-13|2012-01-19|Estimate|2013-05-23|2013-06-28|Estimate||||2013-05-23|2013-06-28|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy Of Pf-04531083 In Treating Post-Surgical Dental Pain|A Randomized, Double-Blind Third Party Open, Double-Dummy, Parallel Group, Placebo Controlled Study Assessing The Efficacy Of Single Doses Of Pf-04531083 For The Treatment Of Post-Surgical Dental Pain Using Ibuprofen 400 Mg As A Positive Control|Terminated||Phase 2|90|Actual|Pfizer|Study was terminated for futility based on results of interim analysis.|4||See termination reason in detailed description.|f||||t||||||||||2018-05-31 21:44:15.568386|2018-05-31 21:44:15.568386
NCT01512147|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2018-04-03|2012-01-13|2012-01-19|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2011||2011-12-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Dexmedetomidine on Intraoperative Somatosensory and Motor Evoked Potential Monitoring During Neurosurgery in Pediatric Patients|Measuring the Effects of Dexmedetomidine on Somatosensory Evoked and Muscular Evoked Potential During Neurosurgery in Pediatric Patients|Completed||N/A|20|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 21:44:17.023915|2018-05-31 21:44:17.023915
NCT01512108|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2014-04-25||2017-11-08|2012-01-13|2012-01-19|Estimate|2014-04-25|2014-05-28|Estimate||||2017-11-08|2017-12-18|Actual|January 10, 2012|Actual|2012-01-10|November 2017|2017-11-30|April 26, 2013|Actual|2013-04-26|April 26, 2013|Actual|2013-04-26||Interventional|||Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone|A 52-week, Multi-centre, Open-labelled, Randomised (2:1), Parallel-group Trial With an Active Control (Two OADs Combination Therapy) to Evaluate the Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Monotherapy|Completed||Phase 3|363|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:44:17.297185|2018-05-31 21:44:17.297185
NCT01512095|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-09-13|2012-01-13|2012-01-19|Estimate|||||||2013-09-13|2013-09-16|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers|A Trial to Examine the Bioequivalence of Norditropin® Versus Nutropin AQ® in Healthy Adult Volunteers|Withdrawn||Phase 1|0|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:44:17.702617|2018-05-31 21:44:17.702617
NCT01512082|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2015-04-09|2012-01-13|2012-01-19|Estimate|||||||2015-04-09|2015-04-10|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Effect of Reducing Soreness in Marathon Runners|The Effect of Pulsed Electromagnetic Field Therapy in Reducing Delayed Onset Muscle Soreness in Marathon Runners. A Double-blind Randomized Placebo-controlled Study.|Completed||N/A|47|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:44:17.788758|2018-05-31 21:44:17.788758
NCT01512069|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-04-23|2012-01-13|2012-01-19|Estimate|||||||2014-04-23|2014-04-24|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy of a Web-based Tailored Self-management Program|Efficacy of a Web-based Self-management Exercise and Diet Intervention Program With Tailored Motivation and Action Planning for Breast Cancer Survivors: A Randomized Controlled Trial|Completed||N/A|59|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 21:44:17.868948|2018-05-31 21:44:17.868948
NCT01512056|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-01-13|2012-01-13|2012-01-19|Estimate|||||||2012-01-13|2012-01-19|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients|Unknown status|Recruiting|Phase 4|300|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 21:44:19.039761|2018-05-31 21:44:19.039761
NCT01512043|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2014-05-05|2012-01-13|2012-01-19|Estimate|||||||2014-05-05|2014-05-06|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Breathing Control in Patients With Chronic Obstructive Pulmonary Disease (COPD) Intervention With Device-guided Breathing Control in COPD|Completed||N/A|150|Actual|Lovisenberg Diakonale Hospital||3|||f||||t||||||||||2018-05-31 21:44:19.151823|2018-05-31 21:44:19.151823
NCT01512030|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2016-09-06|2012-01-18|2012-01-19|Estimate|||||||2016-09-06|2016-09-07|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Prevalence of Peripheral Neuropathy in Children and Adolescents With Type I Diabetes Mellitus: a Prospective Study|Prospective Study of Peripherla Neuropathy in Diabetic Type I|Completed|||35|Actual|Landeskrankenhaus Feldkirch|||||f||||f||||||||||2018-05-31 21:44:19.248842|2018-05-31 21:44:19.248842
NCT01512017|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-01-24|2012-01-13|2012-01-19|Estimate|||||||2012-01-24|2012-01-25|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Clinical Study on Veloderm for the Treatment of Split-thickness Skin Graft Donor Sites|A Clinical Study to Evaluate the Safety and Efficacy on Veloderm (a Crystalline Cellulose Simple Occlusive Dressing) for the Split-thickness Skin Graft Donor Sites in Burn and Plastic Surgery|Completed||Phase 3|96|Actual|Lee's Pharmaceutical Limited||2|||f||||t||||||||||2018-05-31 21:44:19.3116|2018-05-31 21:44:19.3116
NCT01512004|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2012-01-24|2012-01-13|2012-01-19|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|January 2010|Actual|2010-01-31||Interventional|||Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder|Phase III Study of Propiverine Hydrochloride Extended-Release Capsule in the Treatment of Overactive Bladder (OAB) in Chinese Population With Urgent Micturition, Frequent Micturition and/or Urge Urinary Incontinence|Completed||Phase 3|324|Actual|Lee's Pharmaceutical Limited||2|||f||||t||||||||||2018-05-31 21:44:19.381357|2018-05-31 21:44:19.381357
NCT01511991|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2015-02-20|2012-01-13|2012-01-19|Estimate|||||||2015-02-20|2015-02-24|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Sevoflurane's Effect on Mitral Valve Annular Velocity in Cardiac Surgery|Sevoflurane's Effect on Tissue Doppler Profiles of Lateral Mitral Annulus During Cardiac Surgery|Completed||Early Phase 1|20|Actual|Konkuk University Medical Center||1|||f||||t||||||||||2018-05-31 21:44:19.479175|2018-05-31 21:44:19.479175
NCT01511978|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|2017-06-07||2017-07-07|2012-01-13|2012-01-19|Estimate|2017-07-07|2017-07-11|Actual||||2017-07-07|2017-07-11|Actual|January 2012||2012-01-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|February 2014|Actual|2014-02-28||Interventional|DAPPER||Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome|Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects With Known Lambert-Eaton Myasthenic Syndrome|Completed||Phase 2|32|Actual|Jacobus Pharmaceutical||2|||||||f|t|f||||||Undecided||2018-05-31 21:44:19.696301|2018-05-31 21:44:19.696301
NCT01511965|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2014-01-31|2012-01-13|2012-01-19|Estimate|||||||2014-01-31|2014-02-03|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Viticell||Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo||Completed||Phase 1/Phase 2|23|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 21:44:20.459199|2018-05-31 21:44:20.459199
NCT01511952|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2015-03-19|2012-01-16|2012-01-19|Estimate|||||||2015-03-19|2015-03-24|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Multi-Site Study of Music Therapy Interventions on Vitals, Feeding and Sleep in Premature Infants|A Multi-Site Study of Music Therapy Interventions on Vitals, Feeding and Sleep in Premature Infants|Completed||N/A|272|Actual|Beth Israel Medical Center||3|||f||||t||||||||||2018-05-31 21:44:20.597606|2018-05-31 21:44:20.597606
NCT01511601|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-05-19|2012-01-13|2012-01-18|Estimate|||||||2018-05-19|2018-05-22|Actual|December 20, 2011||2011-12-20|July 28, 2016|2016-07-28|July 28, 2016||2016-07-28|||||Observational|||Apheresis to Obtain Plasma and White Blood Cells in Malies|Apheresis to Obtain Plasma and Leukocytes in Mali for In Vitro Studies|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:44:27.114026|2018-05-31 21:44:27.114026
NCT01511939|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2014-03-26||2014-06-24|2012-01-18|2012-01-19|Estimate|2014-06-24|2014-06-26|Estimate||||2014-06-24|2014-06-26|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|ATCCTCP-1|One subject in the warfarin group and one subject in the dabigatran group were also taking aspirin. For the Outcome measures, these two subjects were also included in the aspirin and/or clopidogrel group.|Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants|Single Center, Open-label Study of Effect of PENNSAID (Diclofenac Sodium Solution Topical) on Coagulation Parameters (PT, PTT, INR and Platelet Function) in Patients With Moderate to Severe Osteoarthritis Pain of the Knee Taking Anticoagulant Medication|Completed||Phase 3|22|Actual|Arthritis Treatment Center, Maryland||3|||f||||f||||||||||2018-05-31 21:44:20.746957|2018-05-31 21:44:20.746957
NCT01511926|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2015-03-09|2012-01-18|2012-01-19|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|CHARACTERIZE||Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns|European Study in Patients With Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis at Gastrointestinal Risk: A Retrospective, Non-interventional Study of Vimovo™ Prescribing Patterns|Completed|||2000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:44:21.210869|2018-05-31 21:44:21.210869
NCT01511913|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2018-05-01|2012-01-18|2012-01-19|Estimate|||||||2018-05-01|2018-05-02|Actual|April 30, 2012|Actual|2012-04-30|May 2018|2018-05-31|November 28, 2020|Anticipated|2020-11-28|May 11, 2020|Anticipated|2020-05-11||Observational|IMAGE||A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma|A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma|Active, not recruiting|||1800|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 21:44:21.54768|2018-05-31 21:44:21.54768
NCT01511900|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2012-06-07|2012-01-13|2012-01-19|Estimate|||||||2012-06-07|2012-06-08|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAT-1004 in Patients With Type 2 Diabetes|Completed||Phase 1|44|Actual|Catabasis Pharmaceuticals||5|||f||||f||||||||||2018-05-31 21:44:22.144529|2018-05-31 21:44:22.144529
NCT01511887|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-19|2012-01-18|2012-01-19|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)|Evaluation of the Safety and Efficacy of Oral Ibuprofen in Term 20-28 Days Old Newborns Referred to Bandar Abbass Children Hospital in 2011|Completed||N/A|40|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:44:22.404561|2018-05-31 21:44:22.404561
NCT01511874|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-09-21|2012-01-18|2012-01-19|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer|Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer|Completed||Phase 4|42|Actual|HanAll BioPharma Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:44:22.657606|2018-05-31 21:44:22.657606
NCT01511861|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2016-11-30|2012-01-18|2012-01-19|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2012|Actual|2012-12-31||Observational|||Assessing the Reliability of Non-invasive Blood Glucose Monitoring Device|Assessing the Reliability of Non-invasive Blood Glucose Monitoring Device|Active, not recruiting|||137|Anticipated|GlucoVista|||||f||||f||||||||||2018-05-31 21:44:22.962953|2018-05-31 21:44:22.962953
NCT01511848|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-02-03|2012-01-18|2012-01-19|Estimate|||||||2012-02-03|2012-02-06|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload|A Prospective Randomized Comparative Study of Efficacy and Safety of Combined Deferiprone (DFP) and Deferasirox Versus DFP and Desferrioxamine (DFO) Therapy in Diseases With Severe Iron Overload|Unknown status|Not yet recruiting|Phase 2/Phase 3|60|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 21:44:23.273292|2018-05-31 21:44:23.273292
NCT01511835|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-01-13|2012-01-13|2012-01-19|Estimate|||||||2012-01-13|2012-01-19|Estimate||||January 2012|2012-01-31||||||||Interventional|||Efficacy of Myo-inositol in Preventing Gestational Diabetes in High-risk Pregnant Women||Unknown status|Recruiting|Phase 4|||AGUNCO Obstetrics and Gynecology Centre||3|||f||||||||||||||2018-05-31 21:44:23.739408|2018-05-31 21:44:23.739408
NCT01511822|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate||||January 2012|2012-01-31||||||||Interventional|||Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||3|||f||||||||||||||2018-05-31 21:44:23.993765|2018-05-31 21:44:23.993765
NCT01511809|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2014-11-07||2016-01-08|2012-01-18|2012-01-19|Estimate|2014-11-17|2014-11-24|Estimate||||2016-01-08|2016-02-05|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression|Efficacy of Atazanavir / Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression. Randomized, Open Label Non Inferiority Trial. A Phase 3 Study.|Completed||Phase 3|117|Actual|Ospedale San Raffaele||2|||f||||t||||||||||2018-05-31 21:44:24.558406|2018-05-31 21:44:24.558406
NCT01511796|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-17|2012-01-17|2012-01-19|Estimate|||||||2012-01-17|2012-01-19|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Examining the Effectiveness of Combined Rehabilitation and Botulinum Toxin Injection on Functional Improvement of the Upper Limb After Stroke|Effectiveness of Botulinum Toxin Combined With Upper Limb Rehabilitation on Arm Function|Unknown status|Enrolling by invitation|Phase 3|38|Anticipated|Toronto Rehabilitation Institute||1|||f||||t||||||||||2018-05-31 21:44:25.228791|2018-05-31 21:44:25.228791
NCT01511783|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2015-11-02|2012-01-18|2012-01-19|Estimate|||||||2015-11-02|2015-11-03|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of E2609 in Healthy Subjects|Completed||Phase 1|50|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 21:44:25.323871|2018-05-31 21:44:25.323871
NCT01511770|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|August 2002||2002-08-31|January 2012|2012-01-31|September 2002|Actual|2002-09-30|August 2002|Actual|2002-08-31||Interventional|||Bioavailability Study of Fluconazole Tablets 200 mg Under Fasting Conditions|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Fluconazole Tablets 200 mg and PFIZER (DIFLUCAN) 200 MG in Healthy Males Under Fasting Condition.|Completed||Phase 1|17|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:44:25.43809|2018-05-31 21:44:25.43809
NCT01511757|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|June 2002||2002-06-30|January 2012|2012-01-31|July 2002|Actual|2002-07-31|June 2002|Actual|2002-06-30||Interventional|||Bioavailability Study of Fluconazole Tablets 200 mg Under Fed Conditions|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Fluconazole Tablets 200 mg and PFIZER (DIFLUCAN) 200 MG in Healthy Males Under Fed Condition.|Completed||Phase 1|15|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:44:25.570937|2018-05-31 21:44:25.570937
NCT01511744|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-08-13|2012-01-18|2012-01-19|Estimate|||||||2012-08-13|2012-08-14|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine|A Randomised, Controlled Phase IV Clinical Trial With an Inactivated Influenza Vaccine(Split Virion)|Completed||Phase 4|6000|Actual|Hualan Biological Engineering, Inc.||2|||f||||t||||||||||2018-05-31 21:44:25.706536|2018-05-31 21:44:25.706536
NCT01511731|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 1998||1998-10-31|January 2012|2012-01-31|October 1998|Actual|1998-10-31|October 1998|Actual|1998-10-31||Interventional|||Bioavailability Study of Famotidine Tablets 40 mg Under Fasting Conditions|Open-label, Randomized, 2-way Crossover Study to Compare the Bioavailability of Reddy Cheminor and Merck &Co, Pepcid Famotidine Tablets 40 mg Under Fasting Conditions.|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:44:25.862762|2018-05-31 21:44:25.862762
NCT01511718|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Ondansetron Hydrochloride Tablets 8 mg With Zofran® (Containing Ondansetron Hydrochloride Dihydrate) Tablets 8 mg in Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:44:25.9678|2018-05-31 21:44:25.9678
NCT01511705|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-01-18|2012-01-18|2012-01-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Ondansetron Hydrochloride Tablets 8 mg With Zofran® (Containing Ondansetron Hydrochloride Dihydrate) Tablets 8 mg in Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:44:26.089463|2018-05-31 21:44:26.089463
NCT01511692|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-01-24|2012-01-18|2012-01-19|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2005||2005-11-30|January 2017|2017-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes|A 4 Week Single Center, Double-dummy, Randomised Double-blind, Balanced Incomplete Latin Square Design Study to Evaluate the Effects of Liraglutide on Appetite in Subjects With Type 2 Diabetes Compared to Glimepiride and Placebo|Completed||Phase 1|43|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:44:26.228162|2018-05-31 21:44:26.228162
NCT01511679|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2013-01-02|2012-01-18|2012-01-19|Estimate|||||||2013-01-02|2013-01-03|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Observational|BANC||Brain-imaging and Adolescent Neuroscience Consortium|Brain-imaging and Adolescent Neuroscience Consortium|Withdrawn|||0|Actual|Boston Children’s Hospital|||3|The project was not funded.|f||||f||||||Samples With DNA|"~     Saliva DNA samples for future analyses.~   "|||2018-05-31 21:44:26.467377|2018-05-31 21:44:26.467377
NCT01511666|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-01-29|2012-01-18|2012-01-19|Estimate|||||||2017-01-29|2017-01-31|Estimate|March 2013|Actual|2013-03-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Hyperinvasive Approach in Cardiac Arrest|"Hyperinvasive Approach to out-of Hospital Cardiac Arrest Using Mechanical Chest Compression Device, Prehospital Intraarrest Cooling, Extracorporeal Life Support and Early Invasive Assessment Compared to Standard of Care. A Randomized Parallel Groups Comparative Study. Prague OHCA Study"|Recruiting||Phase 4|170|Anticipated|Charles University, Czech Republic||2|||f||||t|f|f||||||Undecided||2018-05-31 21:44:26.600737|2018-05-31 21:44:26.600737
NCT01511653|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-11-29|2012-01-12|2012-01-18|Estimate|||||||2017-11-29|2017-11-30|Actual|October 2011|Actual|2011-10-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|GLNE010||Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma|Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma|Recruiting|||13000|Anticipated|University of Michigan|||||f||||f|f|f||||Samples With DNA|"~     Two 10 ml red top (serum) tubes Three 10 ml purple top (EDTA)tubes 25 ml of urine 2 Fecal~     Immunohistochemical Tests (FIT) Stool~   "|||2018-05-31 21:44:26.762554|2018-05-31 21:44:26.762554
NCT01511640|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2018-05-04|2012-01-12|2012-01-18|Estimate|||||||2018-05-04|2018-05-07|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Behavioral Effects of Pregabalin and Cannabis|Behavioral Effects of Drugs (Outpatient)(43)|Recruiting||Early Phase 1|13|Anticipated|University of Kentucky||2|||f||||f|t|f||||||No||2018-05-31 21:44:26.892587|2018-05-31 21:44:26.892587
NCT01511627|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-11-10|2012-01-17|2012-01-18|Estimate|||||||2016-11-10|2016-11-15|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Randomized Controlled Trial Comparing Postoperative Pain Following TAH With GA vs. Combined GA + SAB|A Randomized Controlled Trial Comparing Postoperative Pain Following Total Abdominal Hysterectomy With General Anesthetic vs. Combined General and Spinal Anesthetic|Withdrawn||N/A|0|Actual|University of Saskatchewan||2||Research question was answered by Acta Anaesthesiol Scand 2012; 56: 102-109.|f||||f||||||||||2018-05-31 21:44:26.968373|2018-05-31 21:44:26.968373
NCT01511614|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-05-16|2012-01-13|2012-01-18|Estimate|||||||2018-05-16|2018-05-17|Actual|February 1, 2012||2012-02-01|March 23, 2018|2018-03-23||||||||Observational|||Nicotine Withdrawal Symptoms and Smoking Relapse|Identifying Neurobiological Mechanisms That Underlie Acute Nicotine Withdrawal and Drive Early Relapse in Smokers|Recruiting|||577|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:44:27.044823|2018-05-31 21:44:27.044823
NCT01511575|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2016-05-13|2012-01-13|2012-01-18|Estimate|||||||2016-05-13|2016-05-17|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder|Analysis of MicroRNA Expression in Down Syndrome Acute Myeloid Leukemia and the Transient Myeloproliferative Disorder|Completed|||60|Actual|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:44:27.299581|2018-05-31 21:44:27.299581
NCT01511562|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-05-02|2012-01-13|2012-01-18|Estimate|||||||2017-05-02|2017-05-04|Actual|September 2012||2012-09-30|May 2017|2017-05-31||||October 2026|Anticipated|2026-10-31||Interventional|||Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma|A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma|Active, not recruiting||Phase 2|113|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 21:44:27.481527|2018-05-31 21:44:27.481527
NCT01511549|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-09-28|2012-01-12|2012-01-18|Estimate|||||||2012-09-28|2012-10-01|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee Osteoarthritis|A Randomized, Double-blind, Placebo-controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SAR113945 (IKK Inhibitor) Following Intra-articular Administration in Japanese Patients With Knee Osteoarthritis|Completed||Phase 1|24|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 21:44:27.735482|2018-05-31 21:44:27.735482
NCT01511536|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2015-10-02||2016-06-28|2012-01-12|2012-01-18|Estimate|2015-10-02|2015-11-04|Estimate||||2016-06-28|2016-07-28|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional||All treated/safety population defined as all registered participants exposed to both investigational medicinal product (IMP) components, regardless of the amount of treatment administered.|Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer|A Phase I/II Study of Cabazitaxel Combined With Abiraterone Acetate and Prednisone in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC) Whose Disease Has Progressed After Docetaxel Chemotherapy|Completed||Phase 1/Phase 2|38|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:44:27.95137|2018-05-31 21:44:27.95137
NCT01511523|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2012-03-15|2012-01-17|2012-01-18|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD).|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Biovil Research Group, LLC||2|||f||||f||||||||||2018-05-31 21:44:28.746232|2018-05-31 21:44:28.746232
NCT01511510|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-01-17|2012-01-17|2012-01-18|Estimate|||||||2012-01-17|2012-01-18|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers|A Phase I, Randomized, Subject And Investigator Blind, Sponsor Open, Multiple Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Healthy Adult Volunteers|Completed||Phase 1|39|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:44:28.829952|2018-05-31 21:44:28.829952
NCT01511497|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-02-20|2012-01-12|2012-01-18|Estimate|||||||2013-02-20|2013-02-21|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers|A Randomized, Placebo Controlled, Double-Blind, Third Party Open, Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Female Adult Volunteers|Completed||Phase 1|31|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:44:28.932249|2018-05-31 21:44:28.932249
NCT01511484|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2012-01-12|2012-01-12|2012-01-18|Estimate|||||||2012-01-12|2012-01-18|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||You Are What You Eat: A Randomised Controlled Trial of an Appearance-based Dietary Intervention||Completed||N/A|73|Actual|Perception Lab||3|||f||||f||||||||||2018-05-31 21:44:29.041432|2018-05-31 21:44:29.041432
NCT01511471|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-02-02|2012-01-12|2012-01-18|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis|Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis|Completed||Phase 3|20|Actual|University of Patras||1|||f||||f||||||||||2018-05-31 21:44:29.222765|2018-05-31 21:44:29.222765
NCT01511458|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2014-07-11|2012-01-17|2012-01-18|Estimate|||||||2014-07-11|2014-07-14|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Observational|NEXT||Non-invasive Chromosomal Examination of Trisomy Study|Non-invasive Chromosomal Examination of Trisomy|Completed|||18955|Actual|Roche Sequencing Solutions|||2||f||||t||||||||||2018-05-31 21:44:29.522044|2018-05-31 21:44:29.522044
NCT01511445|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2017-01-26||2017-03-27|2012-01-17|2012-01-18|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|December 2011||2011-12-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|CASCADE||Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome|Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome; a Blinded Randomised Trial of Cancellous Structured Ceramic (CSC) Versus PEEK Cages.|Completed||N/A|100|Actual|Amedica Corporation||2|||f||||t||||||||No||2018-05-31 21:44:29.976146|2018-05-31 21:44:29.976146
NCT01511432|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-07-03|2012-01-17|2012-01-18|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects|A Two-Part, Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of 3 Novel Oral Formulations of Telaprevir Relative to Incivek 375-mg Tablets When Administered as a Single 1125-mg Dose to Healthy Subjects|Completed||Phase 1|64|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 21:44:30.398315|2018-05-31 21:44:30.398315
NCT01511419|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-07-10|2012-01-12|2012-01-18|Estimate|||||||2012-07-10|2012-07-11|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Safety Trial of Live Attenuated Influenza (H7N3) Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Mallard/Netherlands/00/95 (H7N3) Influenza Vaccine|Completed||Phase 1|40|Actual|PATH||2|||f||||t||||||||||2018-05-31 21:44:30.473785|2018-05-31 21:44:30.473785
NCT01511406|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2014-10-22|2012-01-17|2012-01-18|Estimate|||||||2014-10-22|2014-10-23|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Cognitive Behavioral Therapy for Patients With an Early Psychosis|Does Cognitive Behavioral Therapy Improve Depressive Symptoms and Self-Esteem in Patients With a First Episode Psychosis? A Randomized Controlled Study|Completed||Phase 2|60|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 21:44:30.627127|2018-05-31 21:44:30.627127
NCT01511393|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2018-02-26|2012-01-12|2012-01-18|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2012||2012-01-31|February 2018|2018-02-28|December 2035|Anticipated|2035-12-31|December 2035|Anticipated|2035-12-31|15 Years|Observational [Patient Registry]|||An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)|Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry|Enrolling by invitation|||6750|Anticipated|United BioSource Corporation|||1||f||||t||||||||Undecided|Currently this is undecided for this 15 year registry. The Data Monitoring Committee is a group of external interdisciplinary consultants who oversee the registry data to review if there are any signals or safety concerns with patients who have taken any of the long-acting GLP-1 RAs and were diagnosed with medullary thyroid carcinoma.|2018-05-31 21:44:30.732771|2018-05-31 21:44:30.732771
NCT01511380|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-05-03|2012-01-12|2012-01-18|Estimate|||||||2016-05-03|2016-05-04|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth|Targeting HIV Risk Behaviors in Juvenile Drug Court-Involved Youth|Completed||Phase 2|120|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:44:30.883635|2018-05-31 21:44:30.883635
NCT01511367|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2014-02-13|2012-01-12|2012-01-18|Estimate|||||||2014-02-13|2014-02-14|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients|A Double-blind, Double Dummy, Randomised, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Flutiform pMDI With Fluticasone pMDI and With Seretide pMDI in Paediatric Subjects Aged 5 to Less Than 12 Years With Moderate to Severe Persistent Reversible Asthma|Completed||Phase 3|498|Anticipated|Mundipharma Research Limited||3|||f||||||||||||||2018-05-31 21:44:30.994086|2018-05-31 21:44:30.994086
NCT01511354|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-10-10|2012-01-17|2012-01-18|Estimate|||||||2017-10-10|2017-10-11|Actual|February 2008||2008-02-29|October 2017|2017-10-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||New Stable Isotope Method to Determine Protein Requirements in Critically Ill Children|Development of New Stable Isotope Method to Determine Protein Requirements in Critically Ill Children|Completed|||12|Actual|Texas A&M University|||1||f||||f||||||||||2018-05-31 21:44:31.102567|2018-05-31 21:44:31.102567
NCT01511341|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2015-02-03|2012-01-12|2012-01-18|Estimate|||||||2015-02-03|2015-02-04|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Impact of a Telenursing Service on Satisfaction and Health Outcomes of Children With Inflammatory Rheumatic Diseases|Impact of a Telenursing Service on Satisfaction and Health Outcomes of Children With Inflammatory Rheumatic Diseases and Their Family: a Crossover Trial|Completed||N/A|55|Actual|University of Applied Sciences of Western Switzerland||2|||f||||f||||||||||2018-05-31 21:44:31.202107|2018-05-31 21:44:31.202107
NCT01511328|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-03-01|2012-01-12|2012-01-18|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2012||2012-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Randomized Implementation of Primary HPV Testing in the Organized Screening for Cervical Cancer in Stockholm|Randomized Implementation of Primary Human Papillomavirus (HPV) Testing in the Organized Screening for Cervical Cancer in Stockholm|Active, not recruiting||N/A|270000|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:44:31.310967|2018-05-31 21:44:31.310967
NCT01511315|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2015-12-07||2016-01-13|2012-01-17|2012-01-18|Estimate|2016-01-13|2016-02-12|Estimate||||2016-01-13|2016-02-12|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Patients who did not complete the study (n=4) were not included in the baseline analysis.|The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment|A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI)|Completed||Phase 4|36|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 21:44:31.447696|2018-05-31 21:44:31.447696
NCT01511302|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2014-07-24|2012-01-17|2012-01-18|Estimate|||||||2014-07-24|2014-07-28|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma|A Phase I, Single-Blinded, Randomized Study of Nebulized RNS60 in Combination With Budesonide in Adult Subjects With Mild to Moderate Asthma|Completed||Phase 1|65|Actual|Revalesio Corporation||3|||f||||||||||||||2018-05-31 21:44:31.857347|2018-05-31 21:44:31.857347
NCT01511289|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2016-02-22|2012-01-12|2012-01-18|Estimate|||||||2016-02-22|2016-02-24|Estimate|August 2011||2011-08-31|January 2016|2016-01-31||||February 2015|Actual|2015-02-28||Interventional|||Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients|A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase|Completed||Phase 3|242|Actual|Il-Yang Pharm. Co., Ltd.||3|||f||||t||||||||||2018-05-31 21:44:31.965368|2018-05-31 21:44:31.965368
NCT01511276|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-05-02|2012-01-17|2012-01-18|Estimate|||||||2017-05-02|2017-05-05|Actual|February 2012||2012-02-29|May 2017|2017-05-31|October 2014|Actual|2014-10-31|June 2013|Actual|2013-06-30||Interventional|SHAPE-2||The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk (SHAPE-2)|The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk Biomarkers in Postmenopausal Women: the SHAPE-2 Study|Completed||N/A|243|Actual|UMC Utrecht||3|||f||||t||||||||||2018-05-31 21:44:32.196312|2018-05-31 21:44:32.196312
NCT01511263|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2018-03-20|2012-01-17|2012-01-18|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2012|Actual|2012-01-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EpiCardiAL||Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis|A Phase II Open-label Randomized Study of Dietary Supplement With Epigallocatechin Gallate (EGCG) to Improve Cardiac Dysfunction in Patients With AL Amyloidosis Who do Not Require Chemotherapy (EpiCardiAL)|Terminated||Phase 2|86|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 21:44:32.358694|2018-05-31 21:44:32.358694
NCT01511250|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2017-11-20|2016-11-29|2018-02-27|2012-01-17|2012-01-18|Estimate|2018-02-27|2018-03-27|Actual|2016-11-29|2016-11-30|Estimate|2018-02-27|2018-03-27|Actual|November 16, 2011|Actual|2011-11-16|February 2018|2018-02-28|April 15, 2016|Actual|2016-04-15|April 1, 2016|Actual|2016-04-01||Interventional||The full analysis set (FAS) included all randomized participants who received at least one dose of study vaccine or placebo and for whom valid pre-dosing and at least one valid post-dosing blood sample have been received.|Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years|A Double-Blind, Randomized, Placebo-Controlled, Age Descending and Expansion Phase 2 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years|Completed||Phase 2|360|Actual|Takeda||10|||f||||t|t|f||||||||2018-05-31 21:44:32.616593|2018-05-31 21:44:32.616593
NCT01511237|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2016-11-07|2012-01-12|2012-01-18|Estimate|||||||2016-11-07|2016-11-08|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|June 2015|Actual|2015-06-30||Interventional|PHPT-5||Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers|PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy|Active, not recruiting||Phase 3|1837|Anticipated|Institut de Recherche pour le Developpement||1|||f||||t||||||||||2018-05-31 21:44:36.716697|2018-05-31 21:44:36.716697
NCT01511224|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-17|2012-01-17|2012-01-18|Estimate|||||||2012-01-17|2012-01-18|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|ANTI-AB||A Prospective Observational Study of Patients With Drug Resistant Acinetobacter Baumannii Bacteremia|A Prospective Observational Study of Patients With Drug Resistant Acinetobacter Baumannii Bacteremia Treated With Antibiotics Therapy|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||5||f||||f||||||Samples With DNA|"~     Blood sample will be collected on the day of enrollment (Day 0), Day 1, 2, 3 and 7 for PCR~     identification and quantification of Acinetobacter species.~   "|||2018-05-31 21:44:36.837233|2018-05-31 21:44:36.837233
NCT01511211|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-09-11|2012-01-17|2012-01-18|Estimate|||||||2013-09-11|2013-09-12|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Duration of Leg Nerve Blocks With Dexamethasone Added to Local Anesthetic|Effect of Dexamethasone on Duration of Analgesia After Ultrasound-Guided Femoral, Obturator, and Popliteal Blocks With Ropivacaine in Total Knee Arthroplasty|Withdrawn||Phase 4|0|Actual|University of New Mexico||2||Other researchers have published results on a similar trial|f||||||||||||||2018-05-31 21:44:36.917037|2018-05-31 21:44:36.917037
NCT01511198|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-01-25|2012-01-17|2012-01-18|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2001||2001-02-28|January 2017|2017-01-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent|NNC 90-1170 Dose-response, Efficacy and Safety: A 12-week Randomized, Multicenter, Doubleblind, Double-dummy, Parallel-group Study of Metformin and Five Doses of NNC 90-1170 in Previously-treated OHA Monotherapy Obese Subjects With Type 2 Diabetes|Completed||Phase 2|223|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-05-31 21:44:37.020781|2018-05-31 21:44:37.020781
NCT01511185|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-01-25|2012-01-17|2012-01-18|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2001||2001-02-28|January 2017|2017-01-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group|NNC 90-1170 Mechanism of Action: A Double-blind, Randomized, Single-center, Placebo Controlled, Crossover Study to Examine Beta-cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes|Completed||Phase 1|20|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:44:37.136608|2018-05-31 21:44:37.136608
NCT01511172|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-01-24|2012-01-17|2012-01-18|Estimate|||||||2017-01-24|2017-01-25|Estimate|August 2002||2002-08-31|January 2017|2017-01-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes|Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Double-dummy, Randomised, Parallel-group, Dose Titration Study With an Open Labelled OHA Arm|Completed||Phase 2|145|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:44:37.207153|2018-05-31 21:44:37.207153
NCT01511159|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2015-03-25|2012-01-17|2012-01-18|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2001||2001-10-31|March 2015|2015-03-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers|A Single-Centre, Open-Label, Five-Period Crossover Trial In Healthy Male Volunteers Investigating the Relative Bioavailability of NNC 90-1170 By Pulmonary Administration Compared To A Subcutaneous Injection|Completed||Phase 1|32|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:44:37.616423|2018-05-31 21:44:37.616423
NCT01511146|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2012-01-18|2012-01-12|2012-01-18|Estimate|||||||2012-01-18|2012-01-19|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor|Intrahepatic and Systemic Chemotherapy Together With Antibody to Patients With Non-resectable Liver Metastases From Solid Tumors|Unknown status|Recruiting|Phase 2|100|Anticipated|Copenhagen University Hospital at Herlev||1|||f||||t||||||||||2018-05-31 21:44:37.698077|2018-05-31 21:44:37.698077
NCT01511133|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-05-15|2012-01-12|2012-01-18|Estimate|||||||2017-05-15|2017-05-16|Actual|April 2010||2010-04-30|May 2017|2017-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™|Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in the Stool of Infants Aged 6 to 12 Weeks Following Administration of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (444563)|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||Samples With DNA|"~     Serum and stool samples~   "|||2018-05-31 21:44:37.778112|2018-05-31 21:44:37.778112
NCT01511120|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2015-05-11|2012-01-17|2012-01-18|Estimate|||||||2015-05-11|2015-05-12|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect on Fluid Balance After Cardiac Surgery After Use of Two Different Priming Protocols|Ringer`s Acetat Versus Balanced Hydroxyethyl-starch as Primesolution in the Heart-lung Maschine During Cardio-pulmonary-bypass. Postoperatively Fluid Balance and Cardiac Function|Completed||Phase 2|40|Anticipated|Haukeland University Hospital||1|||f||||t||||||||||2018-05-31 21:44:37.843439|2018-05-31 21:44:37.843439
NCT01511107|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2016-09-30||2017-10-05|2012-01-13|2012-01-18|Estimate|2016-12-19|2017-02-10|Actual||||2017-10-05|2017-10-06|Actual|January 2012||2012-01-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional||520 children underwent randomization; 260 were randomized to the amoxicillin-clavulante 10 days group and 260 to the amoxicillin-clavulante 5 days, placebo 5 days group. 3 and 2, respectively, were found ineligible after randomization and were withdrawn by the PI. The remaining 257 and 258 participants, respectively, were the basis for analysis.|Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance|A Phase 2b, Multicenter, Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Short-Course Antimicrobial Therapy for Young Children With Acute Otitis Media (AOM) and Impact on Antimicrobial Resistance|Terminated||Phase 2|520|Actual|University of Pittsburgh||2||The primary objective of the study was met.|f||||t||||||||No||2018-05-31 21:44:37.973309|2018-05-31 21:44:37.973309
NCT01511094|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2012-01-17|2012-01-17|2012-01-18|Estimate|||||||2012-01-17|2012-01-18|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|January 2012|Anticipated|2012-01-31|May 2010|Actual|2010-05-31||Interventional|GC||Goniocurettage as First Choice of Surgical Treatment in Chronic Open-Angle Glaucoma: Outcomes and Complications|Goniocurettage as First Choice of Surgical Treatment in Chronic Open-Angle Glaucoma: Outcomes and Complications|Unknown status|Active, not recruiting|Phase 2/Phase 3|32|Actual|Federal University of Minas Gerais||1|||f||||f||||||||||2018-05-31 21:44:39.582239|2018-05-31 21:44:39.582239
NCT01511081|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2017-10-31||2017-10-31|2012-01-17|2012-01-18|Estimate|2017-10-31|2017-12-07|Actual||||2017-10-31|2017-12-07|Actual|August 2012||2012-08-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)|Randomized Phase II Study Comparing Stereotactic Body Radiotherapy (SBRT) With Stereotactic Body Proton Therapy (SBPT) for Centrally Located Stage I, Selected Stage II and Recurrent Non-Small Cell Lung Cancer|Terminated||Phase 2|21|Actual|M.D. Anderson Cancer Center|Early termination leading to small numbers of subjects to be analyzed none meeting the two year reporting period for analysis.|2||Low Accrual|f||||t||||||||||2018-05-31 21:44:39.660004|2018-05-31 21:44:39.660004
NCT01511068|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2014-06-03|2012-01-12|2012-01-18|Estimate|||||||2014-06-03|2014-06-04|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|FAMPAP||Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)|Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)|Completed||Phase 2|2|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 21:44:39.845229|2018-05-31 21:44:39.845229
NCT01511055|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2015-06-03|2012-01-17|2012-01-18|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand|Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand|Terminated||Phase 2|21|Actual|Mayo Clinic||1||"Accrual temporarily suspended, followed by study closure due to technical problems with~   investigational camera."|f||||t||||||||||2018-05-31 21:44:39.910851|2018-05-31 21:44:39.910851
NCT01511042|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-11-16|2012-01-12|2012-01-18|Estimate|||||||2017-11-16|2017-11-20|Actual|December 1999|Actual|1999-12-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|January 2017|Actual|2017-01-31|20 Years|Observational [Patient Registry]|||Vascular Dysfunction in Diabetes: Genes and Hormones|Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus|Active, not recruiting|||200|Anticipated|Brigham and Women's Hospital|||||f||||t||||||Samples With DNA|"~     Urine, blood, DNA~   "|||2018-05-31 21:44:40.179434|2018-05-31 21:44:40.179434
NCT01511029|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-11-24|2012-01-17|2012-01-18|Estimate|||||||2014-11-24|2014-11-25|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)|A Single-Center, Randomized, Blinded, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Dexpramipexole (BIIB050) on the QTc Interval in Healthy Volunteers|Completed||Phase 1|68|Actual|Knopp Biosciences||3|||f||||f||||||||||2018-05-31 21:44:40.257343|2018-05-31 21:44:40.257343
NCT01511016|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2013-08-13||2015-12-21|2012-01-17|2012-01-18|Estimate|2015-12-21|2016-01-27|Estimate||||2015-12-21|2016-01-27|Estimate|February 2003||2003-02-28|December 2015|2015-12-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome|The Effect of Leptin Therapy on Abnormal Lipid Kinetics in Subjects With HIV Lipodystrophy Syndrome|Completed||N/A|17|Actual|Baylor College of Medicine|"Relatively small sample size.~Early drop-out of 3 subjects (2 in placebo arm, 2 in metreleptin arm).~Possible confounders in phenotypic hetereogeneity of HIV lipodystrophy, and differences in antiretroviral drugs."|2|||f||||f||||||||||2018-05-31 21:44:40.35586|2018-05-31 21:44:40.35586
NCT01511003|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-07-17|2012-01-12|2012-01-18|Estimate|||||||2017-07-17|2017-07-19|Actual|December 5, 2011|Actual|2011-12-05|July 2017|2017-07-31|May 11, 2015|Actual|2015-05-11|May 11, 2015|Actual|2015-05-11||Interventional|TREASURE||A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)|An Open- Label, Single-arm, Phase 4 Study to Assess the Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against DMARDs|Completed||Phase 4|128|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:44:40.656439|2018-05-31 21:44:40.656439
NCT01510990|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2013-01-26|2012-01-17|2012-01-18|Estimate|||||||2013-01-26|2013-01-29|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|November 2015|Anticipated|2015-11-30|June 2013|Anticipated|2013-06-30||Interventional|||First Line Gefitinib by FDG-PET Metabolic Response|First Line Gefitinib Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) by the FDG-PET Metabolic Response|Unknown status|Recruiting|Phase 2|60|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:44:40.747727|2018-05-31 21:44:40.747727
NCT01510977|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-02-11|2012-01-17|2012-01-18|Estimate|||||||2013-02-11|2013-02-13|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Second Bowel Preparation for Colonoscopy Failure|The Outcome of a Second Preparation for Colonoscopy After Preparation Failure in the First Procedure: a Prospective Randomized Controlled Study|Terminated||Phase 4|150|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:44:40.893654|2018-05-31 21:44:40.893654
NCT01510587|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-07|||2015-01-28|2012-01-11|2012-01-16|Estimate|||||||2015-01-28|2015-01-29|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|4-Health||Family Influences to Prevent Childhood Obesity|Family Influences to Prevent Childhood Obesity: An Integrated Research and Outreach Program for Parents of Montana 4-H Youth|Completed||N/A|194|Actual|Montana State University||2|||f||||f||||||||||2018-05-31 21:44:45.951829|2018-05-31 21:44:45.951829
NCT01510964|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-08-09|2012-01-12|2012-01-18|Estimate|||||||2013-08-09|2013-08-13|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|INCA||The Involvement of Breast Cancer Patients During Oncological Consultations|The Involvement of Breast Cancer Patients During Oncological Consultations. A Multi-centre Randomized Controlled Trial. The Study Protocol|Completed||N/A|300|Actual|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||t||||||||||2018-05-31 21:44:41.017746|2018-05-31 21:44:41.017746
NCT01510951|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-03-25|2012-01-12|2012-01-18|Estimate|||||||2013-03-25|2013-03-27|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|9|Actual|Amgen||2|||f||||||||||||||2018-05-31 21:44:41.084549|2018-05-31 21:44:41.084549
NCT01510938|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-12-25|2012-01-17|2012-01-18|Estimate|||||||2013-12-25|2013-12-30|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Probiotics in Respiratory Tract Infections in Children|Role of Probiotics in Prevention of Respiratory Tract Infections in Preschool and Primary School Children|Completed||Phase 2|242|Actual|Lviv National Medical University||2|||f||||t||||||||||2018-05-31 21:44:41.156153|2018-05-31 21:44:41.156153
NCT01510912|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2014-04-08||2014-04-08|2012-01-17|2012-01-18|Estimate|2014-04-08|2014-05-09|Estimate||||2014-04-08|2014-05-09|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The safety population included all subjects who were treated with at least 1 dose of trial drug. Of the 602 subjects who started the study, 601 received at least 1 dose of trial drug.|Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain|A Multicenter, Open-Label, Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip|Completed||Phase 3|602|Actual|Iroko Pharmaceuticals, LLC||1|||f||||f||||||||||2018-05-31 21:44:41.245798|2018-05-31 21:44:41.245798
NCT01510899|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2016-11-01|2012-01-17|2012-01-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838|A Multiple Center, Open-label, Single Dose, Parallel-group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of RO4917838|Completed||Phase 1|12|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:44:41.576861|2018-05-31 21:44:41.576861
NCT01510886|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2014-08-12|2012-01-17|2012-01-18|Estimate|||||||2014-08-12|2014-08-13|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PismaEP||Assessment of MDD Management in Andalusia|Assessment of MDD Management Strategies in Andalusia: A Sub-analysis of the PismaEP Study|Completed|||5309|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:44:41.652294|2018-05-31 21:44:41.652294
NCT01510873|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2014-01-22|2012-01-17|2012-01-18|Estimate|||||||2014-01-22|2014-01-23|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP)|Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP).|Completed|||424|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||3||f||||f||||||||||2018-05-31 21:44:41.740168|2018-05-31 21:44:41.740168
NCT01510860|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-17|2012-01-17|2012-01-18|Estimate|||||||2012-01-17|2012-01-18|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis|Double-blind, Double-dummy, Randomised, Crossover, Multicentre Phase IV Clinical Study Comparing the Effect of Ursofalk 500 mg Tablets od Versus Ursofalk 250 mg Capsules od on Liver Enzymes in the Treatment of Primary Biliary Cirrhosis|Completed||Phase 4|65|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-05-31 21:44:41.846025|2018-05-31 21:44:41.846025
NCT01510847|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-01-05|2012-01-12|2012-01-18|Estimate|||||||2016-01-05|2016-01-06|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|OTEST||The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)|The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes: OTEST|Terminated||Phase 4|19|Actual|Singapore Clinical Research Institute||1||Unable to reach the target recruitment within timeline|f||||t||||||||||2018-05-31 21:44:42.108335|2018-05-31 21:44:42.108335
NCT01510834|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|2013-03-05||2017-11-02|2012-01-13|2012-01-18|Estimate|2013-07-02|2013-07-04|Estimate||||2017-11-02|2017-12-07|Actual|July 2011||2011-07-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|CTI-PTSD||Computerized Tailored Intervention for Behavioral Sequelae of PTSD in Veterans|Computerized Tailored Intervention for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans|Completed||N/A|90|Actual|VA Pacific Islands Health Care System|N.A.|1|||f||||f||||||||No||2018-05-31 21:44:42.207879|2018-05-31 21:44:42.207879
NCT01510821|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2013-09-30|2012-01-14|2012-01-18|Estimate|||||||2013-09-30|2013-10-01|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Investigation of Endothelium in Saphenous Vein Grafts|A Prospective Trial to Investigate Endothelial Dysfunction in Saphenous Vein Grafts Subjected to the Maquet Vasoshield Pressure Limiting Syringe Versus Non-Regulated Vessel Dilation in Patients Undergoing Coronary Artery Bypass Grafting|Completed||N/A|30|Actual|Emory University||2|||f||||t||||||||||2018-05-31 21:44:42.39288|2018-05-31 21:44:42.39288
NCT01510808|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-15|2012-01-15|2012-01-18|Estimate|||||||2012-01-15|2012-01-18|Estimate|January 2012||2012-01-31|January 2012|2012-01-31||||||||Observational|||The Affect of Orthodontic Treatment on the Periodontal Status of Patients With Aggressive Periodontitis||Unknown status|Recruiting||25|Anticipated|Hadassah Medical Organization|||2||f||||f||||||||||2018-05-31 21:44:42.461985|2018-05-31 21:44:42.461985
NCT01510795|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-17|2012-01-17|2012-01-18|Estimate|||||||2012-01-17|2012-01-18|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|June 2013|Anticipated|2013-06-30||Interventional|||Mineralocorticoid Receptor Antagonist and Kidney Allograft Histology|Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft|Unknown status|Enrolling by invitation|Phase 4|40|Anticipated|Clinical Hospital Merkur||2|||f||||f||||||||||2018-05-31 21:44:42.541967|2018-05-31 21:44:42.541967
NCT01510613|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-03-08|2012-01-13|2012-01-16|Estimate|||||||2018-03-08|2018-03-12|Actual|February 2012||2012-02-29|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis|An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis.|Completed||Phase 2|28|Actual|IRCCS Policlinico S. Matteo||1|||f||||t||||||||||2018-05-31 21:44:45.816897|2018-05-31 21:44:45.816897
NCT01510782|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-10-31|2012-01-12|2012-01-16|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.2 mg to 120 mg Administered by Intravenous Infusion and 40 mg to 120 mg Administered by Subcutaneous Injection) of BI 655064 (Buffer Solution for Injection) in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)|Completed||Phase 1|72|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:44:42.674671|2018-05-31 21:44:42.674671
NCT01510769|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2016-01-14|2015-03-23|2016-04-20|2012-01-13|2012-01-16|Estimate|2016-04-20|2016-05-26|Estimate|2015-03-23|2015-04-10|Estimate|2016-04-20|2016-05-26|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CRYSTAL||Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects With Tophaceous Gout|Completed||Phase 3|330|Actual|Ardea Biosciences, Inc.||3|||f||||t||||||||||2018-05-31 21:44:42.792104|2018-05-31 21:44:42.792104
NCT01510756|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2015-08-21||2015-12-16|2012-01-13|2012-01-16|Estimate|2015-08-31|2015-10-05|Estimate||||2015-12-16|2016-01-21|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)|A Phase II Translational Study of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia Patients|Terminated||Phase 2|4|Actual|University of California, San Diego||1||slow enrollment|f||||t||||||||||2018-05-31 21:44:43.624528|2018-05-31 21:44:43.624528
NCT01510743|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2018-04-18|2012-01-13|2012-01-16|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Ultrasound Guided Central Vein Catheterization and Complications|Incidence of Complication Depending on the Cannulation Site in US Guided Central Vein Catheterization|Completed||N/A|1484|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 21:44:43.800806|2018-05-31 21:44:43.800806
NCT01510730|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-03-13|2012-01-13|2012-01-16|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2005||2005-01-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Helicobacter Pylori Eradication After Endoscopic Resection of Gastric Tumors|Effect of Helicobacter Pylori Eradication on the New Tumor Development After Endoscopic Resection of Gastric Tumors|Completed||Phase 3|855|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:44:43.868725|2018-05-31 21:44:43.868725
NCT01510717|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2015-05-08||2015-05-08|2012-01-12|2012-01-16|Estimate|2015-05-08|2015-05-27|Estimate||||2015-05-08|2015-05-27|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||This analysis population includes all participants with successful IOL implantation in at least 1 eye.|Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0]|Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2|Completed||N/A|409|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:44:43.94717|2018-05-31 21:44:43.94717
NCT01510704|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|2013-05-15||2013-05-15|2012-01-12|2012-01-16|Estimate|2013-05-15|2013-07-18|Estimate||||2013-05-15|2013-07-18|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase II Dose-ranging Study of APD421 in PONV|Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study of APD421 for the Prevention of Post-operative Nausea and Vomiting|Completed||Phase 2|215|Actual|Acacia Pharma Ltd||4|||f||||f||||||||||2018-05-31 21:44:44.651326|2018-05-31 21:44:44.651326
NCT01510691|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2015-04-14|2012-01-13|2012-01-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Vitrectomy Retinal Oxygenation|The Influence of Retinal Oxygenation on the Clinical Outcomes in Eyes With Different Vitreoretinal Pathologies After a Successful Vitrectomy|Completed|||7|Anticipated|Medical University of Vienna|||3||f||||||||||||||2018-05-31 21:44:44.899585|2018-05-31 21:44:44.899585
NCT01510678|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2018-04-03|2012-01-11|2012-01-16|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Three Different Dietary Messages on Dietary Intake and Health in Families|The Effect of Three Different Dietary Messages on Dietary Intake and Health in Families|Active, not recruiting||N/A|45|Anticipated|The University of Tennessee, Knoxville||3|||f||||t||||||||||2018-05-31 21:44:44.950256|2018-05-31 21:44:44.950256
NCT01510665|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2013-06-12|2012-01-13|2012-01-16|Estimate|||||||2013-06-12|2013-06-14|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals|Magnesium Supplementation in the Second Trimester of Pregnancy for Overweight Individuals|Completed||N/A|28|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 21:44:45.095219|2018-05-31 21:44:45.095219
NCT01510652|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2015-08-14||2017-10-03|2012-01-11|2012-01-16|Estimate|2015-09-23|2015-10-23|Estimate||||2017-10-03|2017-11-06|Actual|November 2011||2011-11-30|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MORE-CRT||More Options Available With a Quadripolar LV Lead pRovidE In-clinic Solutions to CRT Challenges|More Options Available With a Quadripolar Left Ventricular (LV) Lead pRovidE In-clinic Solutions to Cardiac Resynchronization Therapy (CRT) Challenges|Completed||N/A|1078|Actual|St. Jude Medical|Patients were followed for only 6 months, studies with longer follow-up would add to the body of evidence.|2|||f||||f||||||||||2018-05-31 21:44:45.198282|2018-05-31 21:44:45.198282
NCT01510639|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-04-30|2012-01-11|2012-01-16|Estimate|||||||2014-04-30|2014-05-01|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|July 2013|Actual|2013-07-31||Interventional|PRP||The Influence of Growth Factors (PDGF), Applied as Autologous Thrombocyte Concentrate, on Functional Recovery|Results of Subacromial Surgery; The Influence of Growth Factors (PDGF), Applied as Autologous Thrombocyte Concentrate, on Functional Recovery|Completed||Phase 3|73|Actual|St. Antonius Hospital||4|||f||||f||||||||||2018-05-31 21:44:45.669031|2018-05-31 21:44:45.669031
NCT01510626|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-12-09|2012-01-11|2012-01-16|Estimate|||||||2015-12-09|2015-12-10|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|April 2014|Actual|2014-04-30||Interventional|||Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center|Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center|Completed||Phase 1|35|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 21:44:45.744566|2018-05-31 21:44:45.744566
NCT01510561|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2015-02-12|2012-01-11|2012-01-16|Estimate|||||||2015-02-12|2015-02-16|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.|A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|Immunomedics, Inc.||2|||f||||f||||||||||2018-05-31 21:44:46.110672|2018-05-31 21:44:46.110672
NCT01510548|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2013-10-10|2012-01-13|2012-01-16|Estimate|||||||2013-10-10|2013-10-11|Estimate|March 2007||2007-03-31|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||ADALISKIAS: Adalimumab for Acute Disc Prolapse|Adalimumab (Anti TNF Alfa) in the Management of Acute Lumbar Disc Prolapses - a One Year, Randomized, Placebo Controlled, Double Blind, Single Center Trial|Unknown status|Active, not recruiting|Phase 3|90|Anticipated|Kuopio University Hospital||3|||f||||f||||||||||2018-05-31 21:44:46.20954|2018-05-31 21:44:46.20954
NCT01510535|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2013-01-16|2012-01-11|2012-01-16|Estimate|||||||2013-01-16|2013-01-17|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis|An Double-blind, Active-controlled, Parallel-group, Randomized, Multi-center Study to Compare Efficacy and Safety of LBSA0103 Once Versus Hyruan Plus Injection Once Weekly for 3weeks in the Treatment of Patients With Osteoarthritis of the Knee|Completed||Phase 3|287|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 21:44:46.307386|2018-05-31 21:44:46.307386
NCT01510522|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2014-02-03|2012-01-11|2012-01-16|Estimate|||||||2014-02-03|2014-02-04|Estimate|June 2012||2012-06-30|February 2014|2014-02-28||||June 2012|Actual|2012-06-30||Interventional|||Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets|Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients, Previously Treated With Metformin Tablets|Withdrawn||Phase 4|0|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 21:44:46.36543|2018-05-31 21:44:46.36543
NCT01510509|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-13|2012-01-13|2012-01-16|Estimate|||||||2012-01-13|2012-01-16|Estimate|January 2009||2009-01-31|December 2008|2008-12-31||||||||Interventional|TITANIC-XV||The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients|TITANIC-XV Trial: Prospective, Multicenter and Randomized Trial (Bioactive Bare Metal Titanium Stent Versus Everolimus Drug Eluting Stent)|Unknown status|Active, not recruiting|Phase 4|||Hospital Universitario Infanta Cristina||2|||f||||t||||||||||2018-05-31 21:44:46.438567|2018-05-31 21:44:46.438567
NCT01510496|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2015-12-29|2012-01-11|2012-01-16|Estimate|||||||2015-12-29|2015-12-30|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|December 2012|Actual|2012-12-31||Observational|||Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy: Analysis of Risk Factors and Association With Genetic Polymorphisms|Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy : Analysis of Risk Factors and Association With Genetic Polymorphisms|Completed|||3979|Actual|Fundacion IMIM|||3||f||||f||||||Samples With DNA|"~     Sample collection Five milliliters of venous blood will be extracted from each patient with~     chronic pain; control samples will come from a DNA bank. All patients must have given their~     written consent to testing and storage.~      - Plasma DNA will be extracted with a BioRobot EZ1 Workstation (Qiagen).~   "|||2018-05-31 21:44:46.555557|2018-05-31 21:44:46.555557
NCT01510483|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2018-04-16|2012-01-11|2012-01-16|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2010||2010-01-31|April 2018|2018-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HS||Clinician Promotion of Healthy Diet and Activity to Reduce Obesity Among Adolescents: HEALTHY SMILES|Clinician Promotion of Healthy Diet and Activity to Reduce Obesity Among Adolescents|Completed||N/A|693|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 21:44:46.644114|2018-05-31 21:44:46.644114
NCT01510470|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-01-13|2012-01-13|2012-01-16|Estimate|||||||2012-01-13|2012-01-16|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Clinical and Radiological Outcomes Study on Astra Tech Osseospeed Tx Profile Implant|Clinical and Radiological Outcomes Study on Astra Tech Osseospeed Tx Profile Implant|Unknown status|Enrolling by invitation||15|Anticipated|Hong Kong Brånemark Osseointegration Center|||||f||||t||||||||||2018-05-31 21:44:46.859285|2018-05-31 21:44:46.859285
NCT01510457|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2014-11-05||2015-05-26|2012-01-13|2012-01-16|Estimate|2015-01-20|2015-01-22|Estimate||||2015-05-26|2015-06-22|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|KOA||Milnacipran for Chronic Pain in Knee Osteoarthritis|Milnacipran for the Pain, Sensory Sensitization and Mood Changes in Knee Osteoarthritis|Completed||Phase 4|46|Actual|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 21:44:46.94795|2018-05-31 21:44:46.94795
NCT01510431|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-10-12|2012-01-11|2012-01-16|Estimate|||||||2016-10-12|2016-10-14|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease|An Open-label Compassionate Treatment Protocol to Evaluate the Safety and Treatment Outcomes of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease|Completed||N/A|11|Actual|Mesoblast, Ltd.||1|||f||||f||||||||||2018-05-31 21:44:47.306143|2018-05-31 21:44:47.306143
NCT01510418|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2016-08-01|2012-01-13|2012-01-16|Estimate|||||||2016-08-01|2016-08-03|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|PWBCD||Socialization of Adult Men With Congenital Hemophilia A or B|Socialization of Adult Men With Congenital Hemophilia A or B: A Study to Examine Socialization Measures, the Role of Spouse/Significant Other and Health Related Quality of Life|Completed|||27|Actual|Dana-Farber Cancer Institute|||2||f||||t||||||||||2018-05-31 21:44:47.374454|2018-05-31 21:44:47.374454
NCT01510405|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2016-03-23|2012-01-11|2012-01-16|Estimate|||||||2016-03-23|2016-03-24|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Observational|||Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer|Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting||42|Anticipated|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||||||2018-05-31 21:44:47.448209|2018-05-31 21:44:47.448209
NCT01510392|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-04-10|2012-01-11|2012-01-16|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2012||2012-01-31|April 2018|2018-04-30|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Observational|||CEI Van Outreach Screening Study|Prospective Evaluation of Optical Coherence Tomography Usage in the Screening of Eye Diseases|Completed|||118|Actual|Oregon Health and Science University|||||f||||t||||||||||2018-05-31 21:44:47.516391|2018-05-31 21:44:47.516391
NCT01510379|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2013-11-15||2014-02-24|2012-01-11|2012-01-16|Estimate|2014-02-24|2014-03-05|Estimate||||2014-02-24|2014-03-05|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|Reletex||Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery|Median Nerve Acustimulation Plus Medical Anti-emetic Therapy for Control Post-operative Nausea in Patients Undergoing Foregut Surgery: A Randomized Control Trial|Completed||N/A|100|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 21:44:47.642618|2018-05-31 21:44:47.642618
NCT01510366|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2015-09-13|2012-01-11|2012-01-16|Estimate|||||||2015-09-13|2015-09-15|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|IPV||The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)|The Phase Ⅲ Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|Completed||Phase 3|1200|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:44:47.929584|2018-05-31 21:44:47.929584
NCT01510353|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-07-02|2012-01-11|2012-01-16|Estimate|||||||2014-07-02|2014-07-04|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization|Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization|Completed||Phase 3|505|Actual|North Texas Veterans Healthcare System||2|||f||||||||||||||2018-05-31 21:44:48.022218|2018-05-31 21:44:48.022218
NCT01510340|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-01-23|2012-01-11|2012-01-16|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2012||2012-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|HIVMediconline||Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management||Suspended||Phase 3|234|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2||Changes & upgrades in informatic infrastructure of the web-based intervention.|f||||t||||||||||2018-05-31 21:44:48.112119|2018-05-31 21:44:48.112119
NCT01510327|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2012-01-16||2017-02-02|2012-01-11|2012-01-16|Estimate|2012-03-02|2012-04-05|Estimate||||2017-02-02|2017-03-13|Actual|October 2009||2009-10-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|February 2010|Actual|2010-02-28||Interventional|PLATINUM PK||PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Pharmacokinetics Sub-trial|Completed||Phase 3|22|Actual|Boston Scientific Corporation||1|||f||||t||||||||No|Primary endpoint data uploaded|2018-05-31 21:44:48.240303|2018-05-31 21:44:48.240303
NCT01510314|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2017-04-13|2012-01-13|2012-01-16|Estimate|||||||2017-04-13|2017-04-14|Actual|November 2011|Actual|2011-11-30|April 2017|2017-04-30|July 2014|Actual|2014-07-31|||||Interventional|IMACORS||Inflammatory Markers After COloRectal Surgery)|Comparison of C-reactive Protein and Procalcitonin to Detect Infectious Complications After Elective Colorectal Surgery|Completed||N/A|552|Actual|Centre Hospitalier Universitaire Dijon|||||f||||t||||||||||2018-05-31 21:44:48.783565|2018-05-31 21:44:48.783565
NCT01510301|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2016-09-14|2012-01-13|2012-01-16|Estimate|||||||2016-09-14|2016-09-15|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Mobile Phone in Hypertension Management|Mastery and Autonomy in Management of Hypertension With a Mobile Self-report System|Completed||N/A|51|Actual|Göteborg University||1|||f||||t||||||||||2018-05-31 21:44:48.840423|2018-05-31 21:44:48.840423
NCT01510288|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-10|2012-01-10|2012-01-16|Estimate|||||||2012-01-10|2012-01-16|Estimate|November 2004||2004-11-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|December 2007|Actual|2007-12-31||Interventional|||Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer|A Phase 1 Dose Escalation Trial of Ipilimumab in Combination With CG1940 and CG8711 in Patients With Metastatic Hormone-Refractory Prostate Cancer|Terminated||Phase 1|28|Actual|VU University Medical Center||1||The study was terminated because Cell Genesys stopped all activities for GVAX.|f||||t||||||||||2018-05-31 21:44:48.908541|2018-05-31 21:44:48.908541
NCT01510275|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-10-25|2012-01-13|2012-01-16|Estimate|||||||2012-10-25|2012-10-26|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Combined Use of Respiratory Devices After Thoracic Surgery|Efficacy on Combined Use of Respiratory Devices RESPILIFT® and RESPIVOL® in Adult Cardio-thoracic Surgery Patients. Randomized-controlled Study|Completed||N/A|60|Actual|Villa Pineta Hospital||2|||f||||f||||||||||2018-05-31 21:44:48.971993|2018-05-31 21:44:48.971993
NCT01510262|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-10-25|2012-01-13|2012-01-16|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2012|Actual|2012-04-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Repeat Sexually Transmitted Infection (STI) Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk|Repeat STI Patients: Tailored Socio-Contextual Intervention to Reduce HIV Risk|Completed||N/A|130|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 21:44:49.048189|2018-05-31 21:44:49.048189
NCT01510249|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2012-01-13|2012-01-13|2012-01-16|Estimate|||||||2012-01-13|2012-01-16|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Observational|||A Comparison of the Analgesic Efficacies of Ultrasound and Shock Wave Therapy in the Patients With Calcaneal Spur|A Comparison of the Analgesic Efficacies of Ultrasound and Shock Wave Therapy in the Patients With Calcaneal Spur|Completed|||3|Actual|Medical Universtity of Lodz|||||f||||t||||||||||2018-05-31 21:44:49.13301|2018-05-31 21:44:49.13301
NCT01510236|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2015-05-27|2012-01-10|2012-01-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|May 2018|Anticipated|2018-05-31|July 2015|Anticipated|2015-07-31||Interventional|U-CARE:TeenCan||Self-help Program Via Internet for Adolescents With Cancer|A Randomized Controlled Study of the Clinical Efficacy and Cost-effectiveness of a Self-help Program Via Internet on Psychosocial Function Among Adolescents With Cancer|Withdrawn||Phase 2|0|Actual|Uppsala University||2||a feasibility study showed low recruitment and adherence|f||||||||||||||2018-05-31 21:44:49.183839|2018-05-31 21:44:49.183839
NCT01510223|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-10|2012-01-10|2012-01-16|Estimate|||||||2012-01-10|2012-01-16|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||The Effect of Macronutrients in the Diet on Digestive and Cardiovascular Health|Effect of a 5-day Adaptation and Deadaptation Periods to a High-fat Diet Supplemented With Specific Fatty Acids on Gastrointestinal Transit, Appetite and Substrate Utilisation|Completed||N/A|24|Actual|University of Limerick||3|||f||||f||||||||||2018-05-31 21:44:49.403838|2018-05-31 21:44:49.403838
NCT01509495|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2014-07-03|2012-01-10|2012-01-13|Estimate|||||||2014-07-03|2014-07-04|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SIM-HF||Impedance Measurements in Heart Failure Patients|Impedance Measurements in Heart Failure Patients|Terminated||Phase 1|20|Anticipated|Medtronic BRC||||Enrollment rate too low; rate much under estimation of sponsor and investigators|f||||f||||||||||2018-05-31 21:44:59.022373|2018-05-31 21:44:59.022373
NCT01510210|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2016-05-10|2012-01-13|2012-01-16|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Observational|||Risk Profile for Patients With Atrial Fibrillation|Identification of a Risk Profile to Guide Atrial Fibrillation Therapy|Unknown status|Active, not recruiting||500|Actual|University Medical Center Groningen|||||f||||f||||||Samples With DNA|"~     Serum and plasma stored at -80 degrees Celcius. If informed consent was obtained, DNA~     extraction has been performed.~   "|Undecided||2018-05-31 21:44:49.496826|2018-05-31 21:44:49.496826
NCT01510197|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2015-07-27|2012-01-10|2012-01-16|Estimate|||||||2015-07-27|2015-07-28|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Risk Profile for Atrial Fibrillation|Identification of a Risk Profile in Patients With Atrial Fibrillation|Completed|||503|Actual|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 21:44:49.580456|2018-05-31 21:44:49.580456
NCT01510184|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-10-16|2012-01-12|2012-01-13|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2012||2012-04-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy|A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy|Terminated||Phase 3|81|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||t||||||||||2018-05-31 21:44:49.728855|2018-05-31 21:44:49.728855
NCT01510171|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2014-09-24|2012-01-11|2012-01-13|Estimate|||||||2014-09-24|2014-09-25|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|RAPID||Rapid Activity of Platelet Inhibitor Drugs Study|Rapid Activity of Platelet Inhibitor Drugs Study|Completed||Phase 4|50|Actual|Careggi Hospital||2|||f||||t||||||||||2018-05-31 21:44:49.952408|2018-05-31 21:44:49.952408
NCT01510158|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2016-01-21|2015-04-09|2016-07-11|2012-01-11|2012-01-13|Estimate|2016-07-11|2016-08-18|Estimate|2015-04-30|2015-05-19|Estimate|2016-07-11|2016-08-18|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|CLEAR 1||Combining Lesinurad With Allopurinol in Inadequate Responders|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol.|Completed||Phase 3|607|Actual|Ardea Biosciences, Inc.||3|||f||||t||||||||||2018-05-31 21:44:50.10473|2018-05-31 21:44:50.10473
NCT01510145|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|2014-05-15||2014-05-15|2012-01-11|2012-01-13|Estimate|2014-05-15|2014-06-13|Estimate||||2014-05-15|2014-06-13|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||This analysis population includes all enrolled patients.|Efficacy of Changing to TRAVATAN® From Prior Therapy|Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy|Completed||Phase 4|191|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:44:52.910042|2018-05-31 21:44:52.910042
NCT01510132|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2012-10-16|2012-01-11|2012-01-13|Estimate|||||||2012-10-16|2012-10-18|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Travacom Post Marketing Surveillance Study|Post Marketing Surveillance Study to Evaluate the Safety Profile of Travacom (Travoprost/Timolol Fixed Combination) in Patients With Open-Angle Glaucoma or Ocular Hypertension Across India|Withdrawn||Phase 4|0|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:44:53.059434|2018-05-31 21:44:53.059434
NCT01510119|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2016-12-06|2012-01-11|2012-01-13|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2011||2011-09-30|December 2016|2016-12-31||||July 2016|Actual|2016-07-31||Interventional|||Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma|Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|40|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:44:53.208423|2018-05-31 21:44:53.208423
NCT01510093|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2013-01-28|2012-01-11|2012-01-13|Estimate|||||||2013-01-28|2013-01-29|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)|Interactions Between Exogenous Insulin Aspart, Endogenous Insulin and Plasma Glucose in Type 2 Diabetes Mellitus Patients|Completed||Phase 2|10|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 21:44:53.282436|2018-05-31 21:44:53.282436
NCT01510080|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-01-19|2012-01-10|2012-01-13|Estimate|||||||2015-01-19|2015-01-21|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Acceptance and Efficacy of Live Supervision|Live Supervision Put to Test - Studies of Acceptance and Efficacy of Computer-assisted Live Supervision|Completed||N/A|42|Actual|Goethe University||2|||f||||f||||||||||2018-05-31 21:44:53.363794|2018-05-31 21:44:53.363794
NCT01510067|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2016-10-24|2012-01-12|2012-01-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus|Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus|Recruiting|||400|Anticipated|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     Blood, Skin Tissue Biopsies~   "|No||2018-05-31 21:44:53.449327|2018-05-31 21:44:53.449327
NCT01510054|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-04-02|2012-01-10|2012-01-13|Estimate|||||||2015-04-02|2015-04-03|Estimate|July 2002||2002-07-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA|Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With Gonadotropin Releasing Hormone (GnRH) Antagonists: Focusing on MicroRNA Identification and Expression|Withdrawn|||0|Actual|Johns Hopkins University|||1||f||||t||||||Samples With DNA|"~     endometril tissue~   "|||2018-05-31 21:44:53.51771|2018-05-31 21:44:53.51771
NCT01510041|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-12|2012-01-12|2012-01-13|Estimate|||||||2012-01-12|2012-01-13|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|February 2013|Anticipated|2013-02-28|January 2012|Actual|2012-01-31||Interventional|||Effects of Respiratory Muscle Training and Respiratory Exercise in Exercise Tolerance, Performing Daily Life Activities and Quality of Life of Patients With Chronic Obstructive Pulmonary Disease|Effects of Respiratory Muscle Training and Respiratory Exercise in Exercise Tolerance, Performing Daily Life Activities and Quality of Life of Patients With COPD.|Unknown status|Recruiting|N/A|40|Anticipated|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 21:44:53.575945|2018-05-31 21:44:53.575945
NCT01510028|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-01-31|2012-01-12|2012-01-13|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 2012||2012-08-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|IDEAMLD||Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)|A Phase I/II Multicenter Open-label Dose Escalation Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy|Completed||Phase 1/Phase 2|24|Actual|Shire||4|||f||||t||||||||||2018-05-31 21:44:53.699005|2018-05-31 21:44:53.699005
NCT01510015|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-01-10|2012-01-10|2012-01-13|Estimate|||||||2012-01-10|2012-01-13|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Evaluation of the Effects of Treatment of Psycho-stimulant and Cannabis-dependent Users in Israel|Evaluation of the Effects of Psychological and Pharmacological Treatment of Psycho-stimulant and Cannabis-dependent Users in Kfar Izun in Israel|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 21:44:53.919957|2018-05-31 21:44:53.919957
NCT01510002|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-10|2012-01-10|2012-01-13|Estimate|||||||2012-01-10|2012-01-13|Estimate|January 1993||1993-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Prophylactic Central Neck Dissection for Papillary Thyroid Cancer|Prophylactic Central Neck Dissection for Papillary Thyroid Cancer|Completed||N/A|640|Actual|Jagiellonian University||2|||f||||t||||||||||2018-05-31 21:44:54.068241|2018-05-31 21:44:54.068241
NCT01509989|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2016-07-05|2012-01-10|2012-01-13|Estimate|||||||2016-07-05|2016-07-06|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|Adherence-SLE||International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus|International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus|Completed|||307|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 21:44:54.157068|2018-05-31 21:44:54.157068
NCT01509976|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-12|2012-01-12|2012-01-13|Estimate|||||||2012-01-12|2012-01-13|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Triclosan, Triclocarban, and the Microbiota|Triclosan, Triclocarban, and the Microbiota|Unknown status|Recruiting|N/A|20|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 21:44:54.249345|2018-05-31 21:44:54.249345
NCT01509963|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-08-02|2012-01-10|2012-01-13|Estimate|||||||2013-08-02|2013-08-05|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|NOTEGS||The Memorial Sloan-Kettering Cancer Center (MSKCC|Prospective Evaluation of the Reliability of the Combined Use of Two Models to Predict Non-sentinel Lymph Node Status in Breast Cancer Patients With Metastatic Sentinel Lymph Nodes: the MSKCC Nomogram and the Tenon Score.|Completed|||3194|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:44:54.328703|2018-05-31 21:44:54.328703
NCT01509950|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2016-10-13|2012-01-10|2012-01-13|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Staples Versus Prolene Suture for Skin Closure at Cesarean Delivery|Comparison of Staples Versus Nonabsorbable Subcuticular (Prolene) Suture for Skin Closure in Cesarean Deliveries: A Randomized Study|Recruiting||Phase 1|100|Anticipated|Stanford University||3|||f||||f||||||||No||2018-05-31 21:44:54.519312|2018-05-31 21:44:54.519312
NCT01509937|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-11-22|2012-01-12|2012-01-13|Estimate|||||||2015-11-22|2015-11-24|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BOCOMO||Body Composition Monitor(BCM) Guided Fluid Management in Maintenance Hemodialysis (MHD) Patients|A Randomized Controlled Trial of Long Term Effect of BCM Guided Fluid Management in MHD Patients|Completed||N/A|433|Actual|Peking University First Hospital||2|||f||||t||||||||||2018-05-31 21:44:54.607179|2018-05-31 21:44:54.607179
NCT01509924|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2014-09-15|2012-01-12|2012-01-13|Estimate|||||||2014-09-15|2014-09-16|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|April 2015|Anticipated|2015-04-30||Interventional|||Cognitive and Physical Functions in Patients With Transient Ischemic Attack. A Randomized Controlled Trial of Physical Activity on Prescription up to One Year After the Event|Cognitive and Physical Functions in Patients With TIA. A Randomized Controlled Trial of Physical Activity on Prescription up to One Year After the Event|Unknown status|Active, not recruiting|N/A|100|Anticipated|Tiohundra AB||4|||f||||t||||||||||2018-05-31 21:44:54.700694|2018-05-31 21:44:54.700694
NCT01509911|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2016-02-04|2012-01-12|2012-01-13|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment||Unknown status|Active, not recruiting|Phase 2|99|Actual|Tiltan Pharma Ltd.||2|||f||||||||||||||2018-05-31 21:44:54.783879|2018-05-31 21:44:54.783879
NCT01509898|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2017-09-27|2012-01-12|2012-01-13|Estimate|||||||2017-09-27|2017-09-29|Actual|July 18, 2012|Actual|2012-07-18|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Use of Water Jet for Initial Treatment FOR Peri-Implant Disease|The Use of Water Jet for Initial Treatment FOR Peri-Implant Disease|Recruiting||N/A|40|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 21:44:54.878721|2018-05-31 21:44:54.878721
NCT01509885|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-11-16|2012-01-12|2012-01-13|Estimate|||||||2012-11-16|2012-11-20|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Cyproheptadine and Chlorpromazine Effects on Spasticity|Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury|Completed|||20|Actual|University of Alberta|||2||f||||||||||||||2018-05-31 21:44:55.02576|2018-05-31 21:44:55.02576
NCT01509872|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-10|2012-01-10|2012-01-13|Estimate|||||||2012-01-10|2012-01-13|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|April 2012|Anticipated|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Psychological and Psychosocial Intervention With War-Affected Children|An RCT Comparing Trauma-Focused Cognitive Behavioral Therapy (a Specific Psychological Intervention) and A Child Friendly Space (a Non-trauma Focused Psychosocial Intervention) in Reducing Psychological Distress Among War-affected Children|Unknown status|Active, not recruiting|Phase 2|50|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 21:44:55.110965|2018-05-31 21:44:55.110965
NCT01509859|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-12|2012-01-12|2012-01-13|Estimate|||||||2012-01-12|2012-01-13|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|||Comparing Weight Bearing After Intramedullary Fixation Devices for the Proximal Femur Fracture|Prospective Randomized Trial Comparing the Weight Bearing After Fixation of Proximal Femur Fractures With Two Different Proximal Intramedullary Devices|Unknown status|Recruiting|Phase 4|100|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 21:44:55.204883|2018-05-31 21:44:55.204883
NCT01509846|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-02-04|2012-01-10|2012-01-13|Estimate|||||||2013-02-04|2013-02-05|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults|A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Oral Inactivated Whole Cell Shigella Flexneri 2a Vaccine in Healthy Adult Subjects|Completed||Phase 1|82|Actual|PATH||4|||f||||t||||||||||2018-05-31 21:44:55.294252|2018-05-31 21:44:55.294252
NCT01509833|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-10|2012-01-10|2012-01-13|Estimate|||||||2012-01-10|2012-01-13|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy of Low Dose hCG on Oocyte Maturity in Poor Responder Women Undergoing Intracytoplasmic Sperm Injection|Efficacy of Low Dose hCG on Oocyte Maturity for Ovarian Stimulation in Poor Responder Women Undergoing ICSI: a Prospective Randomized Controlled Trial|Completed||Phase 3|73|Actual|Royan Institute||3|||f||||t||||||||||2018-05-31 21:44:55.385401|2018-05-31 21:44:55.385401
NCT01509807|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-11-30||2014-03-09|2012-01-10|2012-01-13|Estimate|2014-03-09|2014-04-07|Estimate||||2014-03-09|2014-04-07|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|IMPROVE-IR|One patient in Group 1 did not have the planned surgery. Thus, while 16 participants were enrolled in Group 1, 15 participants were in the Safety Analysis Set and had the planned surgery.|A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of BupiVacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal|Completed||Phase 4|33|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 21:44:55.487866|2018-05-31 21:44:55.487866
NCT01509794|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-03-27|2012-01-12|2012-01-13|Estimate|||||||2013-03-27|2013-03-29|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Psychophysiological Indicators of Performance in Computer-Based Simulation|Psychophysiological Indicators of Performance in Computer-Based Simulation|Completed||N/A|17|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:44:55.886515|2018-05-31 21:44:55.886515
NCT01509781|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2015-10-05|2012-01-10|2012-01-13|Estimate|||||||2015-10-05|2015-10-06|Estimate|September 2011||2011-09-30|October 2015|2015-10-31||||January 2016|Anticipated|2016-01-31||Interventional|||Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study|Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study|Unknown status|Recruiting|Phase 3|400|Anticipated|National Institute of Oncology, Hungary||2|||f||||t||||||||||2018-05-31 21:44:55.960531|2018-05-31 21:44:55.960531
NCT01509768|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2014-11-24|2012-01-12|2012-01-13|Estimate|||||||2014-11-24|2014-11-25|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)|An Observational Prospective Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)|Completed|||19|Actual|Shire|||1||f||||f||||||Samples With DNA|"~     blood (plasma and serum), cerebrospinal fluid (CSF), urine~   "|||2018-05-31 21:44:56.040848|2018-05-31 21:44:56.040848
NCT01509755|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-01-23|2012-01-12|2012-01-13|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 2000||2000-10-31|January 2017|2017-01-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes|Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm|Completed||Phase 2|196|Anticipated|Novo Nordisk A/S||7|||f||||f||||||||||2018-05-31 21:44:56.101934|2018-05-31 21:44:56.101934
NCT01509742|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-01-23|2012-01-12|2012-01-13|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2001||2001-04-30|January 2017|2017-01-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes|Effect of NNC 90-1170 on Hypoglycaemic Counterregulation During Stepwise Hypoglycaemic Clamp in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, 2-period Cross-over Trial|Completed||Phase 1|19|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:44:56.200772|2018-05-31 21:44:56.200772
NCT01509729|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-04-09|2012-01-12|2012-01-13|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Topical Lidocaine After Major Arthroscopic Knee Surgery|Topical Lidocaine Patch Does Not Have an Analgesic Effect After Major Arthroscopic Knee Surgery. A Double-blind Place-controlled Randomized Study|Completed||N/A|21|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:44:56.269021|2018-05-31 21:44:56.269021
NCT01509716|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2015-04-14|2012-01-10|2012-01-13|Estimate|||||||2015-04-14|2015-04-15|Estimate||||April 2015|2015-04-30||||||||Observational|||Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients|Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis CKD Patients|Unknown status|Recruiting||400|Anticipated|National University, Singapore|||||f||||f||||||||||2018-05-31 21:44:56.336177|2018-05-31 21:44:56.336177
NCT01509703|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-03-23|2012-01-12|2012-01-13|Estimate|||||||2015-03-23|2015-03-24|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Respiratory Physiology Under High Flow Therapy|Respiratory Physiology Measurements Under Transnasal High Flow Therapy in Patients With Tracheostoma After Long Term Ventilation|Completed||N/A|10|Actual|Institut für Pneumologie Hagen Ambrock eV||1|||f||||f||||||||||2018-05-31 21:44:56.505419|2018-05-31 21:44:56.505419
NCT01509690|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2015-04-14|2012-01-12|2012-01-13|Estimate|||||||2015-04-14|2015-04-15|Estimate||||April 2015|2015-04-30||||||||Interventional|||Impact of a Multidisciplinary Intensive Management Clinic on Outcomes in Multi-Ethnic Asian Incident Hemodialysis Patients|Impact of a Multidisciplinary Intensive Management Clinic on Clinical, Patient-Reported and Economic Outcomes in Multi-Ethnic Asian Incident Hemodialysis Patients|Unknown status|Recruiting|Phase 2/Phase 3|150|Anticipated|National University, Singapore|||||f||||f||||||||||2018-05-31 21:44:56.585017|2018-05-31 21:44:56.585017
NCT01509677|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2016-12-19|2012-01-10|2012-01-13|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease|A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease|Completed||Phase 3|150|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:44:56.670245|2018-05-31 21:44:56.670245
NCT01509664|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|2014-01-10||2014-01-10|2012-01-10|2012-01-13|Estimate|2014-01-10|2014-02-26|Estimate||||2014-01-10|2014-02-26|Estimate|August 2006||2006-08-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Baseline characteristics for participants who completed the study|Encouraging Healthy Food Shopping and Eating Behaviors by Price Reduction: A Community Supermarket Study|Encouraging Healthy Food Shopping and Eating Behaviors by Price Reduction: A Community Supermarket Study|Completed||N/A|137|Actual|New York Obesity and Nutrition Research Center||2|||f||||t||||||||||2018-05-31 21:44:56.782617|2018-05-31 21:44:56.782617
NCT01509651|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2012-04-03|2012-01-10|2012-01-13|Estimate|||||||2012-04-03|2012-04-04|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Sugammadex and Heart Failure|Reversal of Rocuronium-induced Neuromuscular Block With Sugammadex in Heart Failure Patients|Completed||Phase 3|12|Actual|Onze Lieve Vrouw Hospital||1|||f||||t||||||||||2018-05-31 21:44:57.122224|2018-05-31 21:44:57.122224
NCT01509638|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-11-30||2014-01-19|2012-01-12|2012-01-13|Estimate|2014-01-19|2014-03-06|Estimate||||2014-01-19|2014-03-06|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|IMPROVE-IR|23 patients in Group 1 and 25 patients in Group 2 were enrolled. 22 patients from Group 1 and 23 patients from Group 2 were in the Safety Analysis Set (patients who underwent planned surgery).|A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal|Completed||Phase 4|47|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 21:44:57.214534|2018-05-31 21:44:57.214534
NCT01509625|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|2014-06-02||2016-04-25|2012-01-10|2012-01-13|Estimate|2016-04-25|2016-06-01|Estimate||||2016-04-25|2016-06-01|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Observational|EFFICACY||Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)|Assessment of Treatment Response With Faslodex® (500 mg) in Standard Clinical Practice Through a Retrospective Study|Completed|||272|Actual|Hospital Clinico Universitario San Cecilio|||||f||||f||||||||Undecided||2018-05-31 21:44:57.704626|2018-05-31 21:44:57.704626
NCT01509612|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-07|||2017-08-28|2012-01-10|2012-01-13|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2011||2011-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|HIC||Additive Homeopathy in Cancer Patients|"Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Lung Tumors With or Without add-on Homeopathy"|Recruiting||Phase 2/Phase 3|150|Anticipated|Medical University of Vienna||3|||f||||f||||||||No||2018-05-31 21:44:58.078467|2018-05-31 21:44:58.078467
NCT01509599|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2016-04-03|2012-01-12|2012-01-13|Estimate|||||||2016-04-03|2016-04-05|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cooling Lower Leg Skin to Prevent Venous Leg Ulcers in Patients With Poor Vein Circulation|Preventing Venous Leg Ulcers With Cryotherapy: A Randomized Clinical Trial|Completed||Phase 1/Phase 2|197|Actual|Medical University of South Carolina||2|||f||||t||||||||Yes|Data may be requested via the PI and is available through REDCap.|2018-05-31 21:44:58.174532|2018-05-31 21:44:58.174532
NCT01509586|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2016-06-20||2016-06-20|2012-01-10|2012-01-13|Estimate|2016-06-20|2016-08-01|Estimate||||2016-06-20|2016-08-01|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco|A Test of Short and Long Term Naturalistic Outcomes of Smokers Who Sample Smokeless Tobacco|Completed||N/A|1236|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:44:58.285478|2018-05-31 21:44:58.285478
NCT01509573|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-08-25|2012-01-10|2012-01-13|Estimate|||||||2014-08-25|2014-08-27|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pilot Feasibility Trial of the Family Strengthening Intervention in Rwanda (FSI-R)|Family-Based Prevention of Mental Health Problems in HIV/AIDS-Affected Children (R34MH084679-01A1)|Completed||N/A|82|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 21:44:58.592646|2018-05-31 21:44:58.592646
NCT01509560|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-02-20|2012-01-10|2012-01-13|Estimate|||||||2017-02-20|2017-02-23|Actual|November 1, 2011|Actual|2011-11-01|February 2017|2017-02-28|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood|PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood|Completed||Phase 2|21|Actual|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||1|||f||||f||||||||||2018-05-31 21:44:58.68735|2018-05-31 21:44:58.68735
NCT01509547|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2018-01-29|2012-01-10|2012-01-13|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2012||2012-08-31|January 2018|2018-01-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||Varenicline for Adolescent Smoking Cessation|A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation|Completed||Phase 3|158|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:44:58.751586|2018-05-31 21:44:58.751586
NCT01509534|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-07-27|2012-01-12|2012-01-13|Estimate|||||||2015-07-27|2015-07-29|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|SUP2||Guideline-based Pacing Therapy for Reflex Syncope|Guideline-based Pacing Therapy for Reflex Syncope|Completed|||281|Actual|Gruppo Italiano Multidisciplinare per lo Studio della Sincope|||||f||||t||||||||||2018-05-31 21:44:58.814148|2018-05-31 21:44:58.814148
NCT01509521|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2012-08-05|2012-01-12|2012-01-13|Estimate|||||||2012-08-05|2012-08-07|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|OBDUC||The Oxygenation of the Brain During Caesarean Section|The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine|Completed||Phase 4|24|Anticipated|Naestved Hospital||2|||f||||t||||||||||2018-05-31 21:44:58.879992|2018-05-31 21:44:58.879992
NCT01509508|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-07-20|2012-01-10|2012-01-13|Estimate|||||||2016-07-20|2016-07-21|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TasP||Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence|A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.|Completed||N/A|28153|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 21:44:58.943689|2018-05-31 21:44:58.943689
NCT01509482|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-11-23|2012-01-10|2012-01-13|Estimate|||||||2014-11-23|2014-11-25|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Insulin Resistance in Idiopathic Oligospermia and Azoospermia|Insulin Resistance : a New Diagnosis of the Pathogenesis of Idiopathic Oligozoospermia and Non Obstructive Azoospermia|Completed||N/A|100|Actual|The Egyptian IVF-ET Center||2|||f||||t||||||||||2018-05-31 21:44:59.186589|2018-05-31 21:44:59.186589
NCT01509469|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-01-28|2012-01-10|2012-01-13|Estimate|||||||2014-01-28|2014-01-29|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of Different Macronutrients on Ileal Brake Activation|The Effect of Different Macronutrients on Ileal Brake Activation|Completed||N/A|15|Actual|Maastricht University Medical Center||6|||f||||f||||||||||2018-05-31 21:44:59.277594|2018-05-31 21:44:59.277594
NCT01509456|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2017-02-28|2012-01-10|2012-01-13|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2010||2010-02-28|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|NUC||The Effect of Potassium Bicarbonate on Bone and Several Physiological Systems During Immobilisation|The Effect of Potassium Bicarbonate on Bone and the Immune System During 21 Days of 6° Head- Down- Tilt Bedrest (HDT- Bedrest)|Completed||N/A|8|Actual|DLR German Aerospace Center||2|||f||||f||||||||||2018-05-31 21:44:59.38685|2018-05-31 21:44:59.38685
NCT01509443|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2016-02-10|2012-01-10|2012-01-13|Estimate|||||||2016-02-10|2016-02-11|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Breathing & Mild Physical Exercise Therapy for Asthma|Application of Breathing Exercise Program to Improve Asthma in Obese Patients: Effects on Clinico-immunological Parameters|Unknown status|Recruiting|N/A|200|Anticipated|Dasman Diabetes Institute||2|||f||||f||||||||||2018-05-31 21:44:59.495421|2018-05-31 21:44:59.495421
NCT01509430|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2016-11-28|2012-01-12|2012-01-13|Estimate|||||||2016-11-28|2016-11-29|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||DAHANCA 25B: Progressive Resistance Training as Intervention for Regaining Muscle Mass After Radiation Therapy in Patients With HNSCC|Progressive Resistance Training as Intervention for Regaining Muscle Mass After Radiation Therapy in Patients With HNSCC - a Randomized Controlled Trial|Completed||N/A|41|Actual|Danish Head and Neck Cancer Group||2|||f||||t||||||||||2018-05-31 21:44:59.59369|2018-05-31 21:44:59.59369
NCT01509417|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-05-28|2012-01-12|2012-01-13|Estimate|||||||2013-05-28|2013-05-29|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Different Feeding Methods After Pyloromyotomy|Prospective Randomized Trial Evaluating the Feeding Regimen After Pyloromyotomy.|Completed||N/A|150|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 21:44:59.658773|2018-05-31 21:44:59.658773
NCT01509404|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2016-02-12|2012-01-12|2012-01-13|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection|Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection|Completed||Phase 4|40|Actual|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 21:44:59.789023|2018-05-31 21:44:59.789023
NCT01509391|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-10-16|2012-01-12|2012-01-13|Estimate|||||||2012-10-16|2012-10-17|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|IM1||Keyhole Limpet Hemocyanin in Chronic Hepatitis C|Keyhole Limpet Hemocyanin in Chronic Hepatitis C and Compensated Cirrhosis - Pilot Study IM1|Completed||N/A|14|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 21:44:59.874717|2018-05-31 21:44:59.874717
NCT01509378|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2016-06-08|2012-01-12|2012-01-13|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|4P||4P Study: Predictive Quality With Painfree Therapies|4P Study: A Prospective Study on Predictive Quality Preferring PainFree Therapies|Completed|||200|Actual|Medtronic Bakken Research Center|||||f||||t||||||||||2018-05-31 21:44:59.933398|2018-05-31 21:44:59.933398
NCT01509365|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-05-06|2012-01-12|2012-01-13|Estimate|||||||2015-05-06|2015-05-07|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|PLATO-dose||Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27|Evaluation the Effect of the Double Maintenance Dose of Clopidogrel Versus Single Dose in Patients With Coronary Artery Disease With a BMI ≥ 27 kg.m-2|Completed||Phase 4|116|Actual|Les Laboratoires des Médicaments Stériles||3|||f||||t||||||||||2018-05-31 21:45:00.026681|2018-05-31 21:45:00.026681
NCT01509352|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-01-25|2012-01-10|2012-01-13|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2010||2010-02-28|January 2017|2017-01-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication|Prospective Randomized Trial Evaluating the Utility of Esophageal Stitches During Laparoscopic Fundoplication.|Completed||N/A|65|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||No||2018-05-31 21:45:00.165349|2018-05-31 21:45:00.165349
NCT01509339|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-01-25|2012-01-10|2012-01-13|Estimate|||||||2013-01-25|2013-01-29|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis|Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Case Western Reserve University||1|||f||||t||||||||||2018-05-31 21:45:00.247688|2018-05-31 21:45:00.247688
NCT01509326|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-10|2012-01-10|2012-01-13|Estimate|||||||2012-01-10|2012-01-13|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||Chiropractic and Acupressure for Headaches|A Randomized Clinical Trial of Chiropractic Care for Headaches With and Without an Acupressure Device|Unknown status|Recruiting|Phase 2/Phase 3|36|Anticipated|Canadian Memorial Chiropractic College||2|||f||||f||||||||||2018-05-31 21:45:00.326878|2018-05-31 21:45:00.326878
NCT01509313|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-09-13|2012-01-12|2012-01-13|Estimate|||||||2013-09-13|2013-09-16|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MERT||A Trial Comparing Morcellation With Electrical Resection for Removal of Uterine Polyps|A Randomised Controlled Trial Comparing Morcellation With Electrical Resection for Removal of Uterine Polyps|Completed||Phase 3|121|Actual|Birmingham Women's NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:45:00.46209|2018-05-31 21:45:00.46209
NCT01509118|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2012-01-11|2012-01-11|2012-01-12|Estimate|||||||2012-01-11|2012-01-12|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Observational|||Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery|Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery|Unknown status|Recruiting||500|Anticipated|Phramongkutklao College of Medicine and Hospital|||||f||||f||||||||||2018-05-31 21:45:02.973808|2018-05-31 21:45:02.973808
NCT01509300|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-12|2012-01-12|2012-01-13|Estimate|||||||2012-01-12|2012-01-13|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors|HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3 Depletion for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors After Conditioning of TBI, Fludarabine, Cyclophosphamide and Antithymocyte Globulin|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Asan Medical Center||1|||f||||||||||||||2018-05-31 21:45:00.580528|2018-05-31 21:45:00.580528
NCT01509287|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2013-11-07|2012-01-11|2012-01-12|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Metabolic Screening in Patients With Donnai-Barrow Syndrome|Metabolic Screening in Patients With Donnai-Barrow Syndrome|Unknown status|Recruiting||70|Anticipated|Massachusetts General Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood, saliva, urine~   "|||2018-05-31 21:45:00.699046|2018-05-31 21:45:00.699046
NCT01509274|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-16|2012-01-11|2012-01-12|Estimate|||||||2012-01-16|2012-01-18|Estimate|August 2011||2011-08-31|January 2012|2012-01-31||||June 2012|Anticipated|2012-06-30||Interventional|||Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia|Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia - a Prospective, Randomized and Double Blinded Study.|Unknown status|Recruiting|Phase 4|90|Anticipated|Kolding Sygehus||3|||f||||t||||||||||2018-05-31 21:45:00.789258|2018-05-31 21:45:00.789258
NCT01509261|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-10|2012-01-10|2012-01-12|Estimate|||||||2012-01-10|2012-01-12|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy Study of Ilaprazole to Treat Erosive Esophgitis|A Phase Ⅲ Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Ilaprazole (20mg QD) in Adult Patients With Erosive Esophagitis|Completed||Phase 3|292|Actual|Il-Yang Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:45:00.897308|2018-05-31 21:45:00.897308
NCT01509248|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-02-21|2012-01-11|2012-01-12|Estimate|||||||2012-02-21|2012-02-23|Estimate|May 2010||2010-05-31|February 2012|2012-02-29||||||||Observational|||Population Pharmacokinetics and Metabolomics of Theophylline in Preterm Infants|Population Pharmacokinetics and Metabolomic Analysis of Aminopylline/Theophylline Drug Levels in Preterm Infants With Apnea of Prematurity|Unknown status|Enrolling by invitation||110|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 21:45:00.996765|2018-05-31 21:45:00.996765
NCT01509235|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-05-07|2012-01-11|2012-01-12|Estimate|||||||2012-05-07|2012-05-08|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|GYM-MUCO||Self Drainage in Pediatric Cystic Fibrosis Patients|Exercise Coupled to Self Drainage in Pediatric Cystic Fibrosis Patients: an Open Label Cross Over Randomised Clinical Trial|Completed||N/A|34|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:45:01.063384|2018-05-31 21:45:01.063384
NCT01509222|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-04-24|2012-01-09|2012-01-12|Estimate|||||||2013-04-24|2013-04-25|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Changing Dietary Patterns: an Individually Tailored Nutrition Intervention (OKE-study)|Changing Dietary Patterns: an Individually Tailored Nutrition Intervention|Completed||N/A|186|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 21:45:01.124034|2018-05-31 21:45:01.124034
NCT01509209|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2013-05-22|2012-01-10|2012-01-12|Estimate|||||||2013-05-22|2013-05-23|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis|Efficacy and Safety of Cossac L Tablet in Vasomotor Rhinitis Patients : A Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial|Completed||Phase 3|137|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 21:45:01.248466|2018-05-31 21:45:01.248466
NCT01509196|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-03-28|2012-01-10|2012-01-12|Estimate|||||||2012-03-28|2012-03-29|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||A Bioequivalence Study Comparing HIP0901 Capsule With Lipidilsupra Tablet|Open-label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics of Fenofibric Acid Between Lipidilsupra Tablet and HIP0901 Capsule in Healthy Male Subjects|Completed||Phase 1|28|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 21:45:01.335387|2018-05-31 21:45:01.335387
NCT01509183|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2018-01-09||2018-02-09|2012-01-11|2012-01-12|Estimate|2018-02-09|2018-02-13|Actual||||2018-02-09|2018-02-13|Actual|April 2012||2012-04-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|October 2014|Actual|2014-10-31||Interventional|||Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System|Effectiveness of the Propeller Health (Formerly Asthmapolis) Monitoring System|Completed||N/A|495|Actual|Reciprocal Labs||2|||f||||f||||||||||2018-05-31 21:45:01.579586|2018-05-31 21:45:01.579586
NCT01509170|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-01-10|2012-01-10|2012-01-12|Estimate|||||||2012-01-10|2012-01-12|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|January 2017|Anticipated|2017-01-31|January 2015|Anticipated|2015-01-31||Observational|0597-10-HMO||The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia|Observational Cohort Study- The Clinical and Laboratory Characteristics of Recurrent Drug- Related|Unknown status|Not yet recruiting||500|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 21:45:02.308973|2018-05-31 21:45:02.308973
NCT01509157|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2013-07-15|2012-01-11|2012-01-12|Estimate|||||||2013-07-15|2013-07-16|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|MDRS||MDRS for Prevention of Nocturnal Hypoglycemia|Prevention of Nocturnal Hypoglycemia in Children and Young Adults With Type 1 Diabetes Using a Remote Safety and Control Diabetes Management System|Completed||Phase 1|38|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 21:45:02.447448|2018-05-31 21:45:02.447448
NCT01509144|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-05-20|2012-01-09|2012-01-12|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||EuroNeut41: Safety & Immunogenicity of Immunisations With HIV Vaccine|Phase 1, Randomised, Single-centre, Observer-blind Clinical Trial of Safety and Immunogenicity of Nasal-prime and Intramuscular Boost Immunisation With EN41-FPA2 HIV Vaccine in Healthy Female Volunteers|Completed||Phase 1|48|Actual|PX'Therapeutics||5|||f||||t||||||||||2018-05-31 21:45:02.648959|2018-05-31 21:45:02.648959
NCT01509131|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-11|2012-01-11|2012-01-12|Estimate|||||||2012-01-11|2012-01-12|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of a Mixed Bowel Prep (2L PEG + Bisacodyl) Versus PEG With Ascorbate|Low Volume Bowel Preparation for Colonoscopy: a Comparison Between PEG-CS Plus Bisacodyl Versus PEG-ASC|Completed||Phase 4|408|Actual|Promefarm S.r.l.||2|||f||||f||||||||||2018-05-31 21:45:02.819797|2018-05-31 21:45:02.819797
NCT01509105|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2016-12-20||2016-12-20|2012-01-09|2012-01-12|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|September 2011||2011-09-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational||Safety analysis set included all participants who recieved at least 1 dose of Prevenar 13 and had the safety assessment through appropriate follow-up.|Prevenar13 Post Market Surveillance|Post Marketing Surveillance To Observe Safety Of Prevenar 13|Completed|||649|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:45:03.09726|2018-05-31 21:45:03.09726
NCT01509092|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2014-10-06|2012-01-09|2012-01-12|Estimate|||||||2014-10-06|2014-10-07|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Comparative Study Between Early Vitrectomy and Observation for Spontaneous Closure of Traumatic Macular Hole|Traumatic Macular Hole: Six-months Observation Versus Early Surgical Intervention, A Multicenter Clinical Trial|Completed||N/A|44|Actual|Peking University Third Hospital||2|||f||||t||||||||||2018-05-31 21:45:03.653794|2018-05-31 21:45:03.653794
NCT01509079|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2016-08-15||2018-03-09|2012-01-09|2012-01-12|Estimate|2016-11-10|2016-11-29|Estimate||||2018-03-09|2018-04-04|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors|Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors|Completed||Phase 2|116|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 21:45:03.758256|2018-05-31 21:45:03.758256
NCT01509066|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-09-18|2012-01-11|2012-01-12|Estimate|||||||2013-09-18|2013-09-20|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HERHealth||Healthy Eating for Reproductive Health (HERHealth)|Healthy Eating for Reproductive Health (HERHealth)|Completed||Phase 1/Phase 2|18|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 21:45:04.260218|2018-05-31 21:45:04.260218
NCT01509053|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2013-11-26||2015-02-12|2012-01-09|2012-01-12|Estimate|2013-11-26|2014-01-16|Estimate||||2015-02-12|2015-03-04|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ARRIVE- EU|Baseline measures are based on all enrolled participants.|Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole|Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting, Europe, Canada and Asia|Terminated||Phase 3|30|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 21:45:04.41124|2018-05-31 21:45:04.41124
NCT01509040|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2016-06-08||2016-06-08|2012-01-11|2012-01-12|Estimate|2016-06-08|2016-06-09|Estimate||||2016-06-08|2016-06-09|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|||Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest|Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest|Completed||Phase 1/Phase 2|2|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 21:45:04.851219|2018-05-31 21:45:04.851219
NCT01509027|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-05-29|2012-01-11|2012-01-12|Estimate|||||||2012-05-29|2012-05-30|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Study of the Compliance With Phosphorus Restricted Diet and Phosphate Binder Therapy in Hemodialysis Patients|A Randomized Controlled Trial to Evaluate the Impact of Education on the Knowledge About and Compliance With a Phosphorus Restricted Diet and Phosphate Binder Therapy in Maintenance Dialysis Patients|Unknown status|Recruiting|N/A|150|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-05-31 21:45:05.408629|2018-05-31 21:45:05.408629
NCT01509014|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-11|2012-01-11|2012-01-12|Estimate|||||||2012-01-11|2012-01-12|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|January 2012|Anticipated|2012-01-31|November 2011|Actual|2011-11-30||Interventional|CPATCH||Community Pharmacy Assisting in Total Cardiovascular Health||Unknown status|Active, not recruiting|N/A|2250|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 21:45:05.52646|2018-05-31 21:45:05.52646
NCT01509001|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-13|2012-01-11|2012-01-12|Estimate|||||||2012-01-13|2012-01-16|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes Mellitus|Study of Metabolic and Haemodynamic Effects of Metformin and Glimepiride in Patients With Type 2 Diabetes|Completed||Phase 4|20|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:45:05.619677|2018-05-31 21:45:05.619677
NCT01508988|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-06-12|2012-01-11|2012-01-12|Estimate|||||||2012-06-12|2012-06-14|Estimate|January 2012||2012-01-31|June 2012|2012-06-30||||April 2012|Actual|2012-04-30||Interventional|||Single Dose Escalation Study of ONO-9054 in Healthy Volunteers|A Double-masked Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ONO-9054 in Healthy Adult Subjects|Completed||Phase 1|48|Actual|Ono Pharmaceutical Co. Ltd||7|||f||||f||||||||||2018-05-31 21:45:05.769284|2018-05-31 21:45:05.769284
NCT01508975|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-02-13|2012-01-11|2012-01-12|Estimate|||||||2013-02-13|2013-02-15|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Satiety Response of White and Brown Rice Compared to Glucose Control|Satiety Response of White and Brown Rice Compared to Glucose Control|Completed||N/A|20|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 21:45:05.87192|2018-05-31 21:45:05.87192
NCT01508962|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2018-03-15|2012-01-11|2012-01-12|Estimate|||||||2018-03-15|2018-03-16|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Observational|PRESS-ALS||PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis|PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis|Active, not recruiting|||100|Anticipated|University of Miami|||2||f||||t||||||||||2018-05-31 21:45:05.94674|2018-05-31 21:45:05.94674
NCT01508949|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-01-24|2012-01-09|2012-01-12|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 2001||2001-06-30|January 2017|2017-01-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes|NNC 90-1170 Mechanism of Action: A Single-centre, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial Evaluating the Effect of NNC 90-1170 on Weight and Appetite in Obese Subjects With Type 2 Diabetes|Completed||Phase 2|35|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:05.999451|2018-05-31 21:45:05.999451
NCT01508936|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|2016-03-23|2014-05-08|2016-05-26|2012-01-10|2012-01-12|Estimate|2016-05-26|2016-06-27|Estimate|2014-05-08|2014-05-26|Estimate|2016-05-26|2016-06-27|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Randomized, analyzed|Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma|A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) Treatment in Patients With Moderate to Severe Asthma|Completed||Phase 3|511|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 21:45:06.110702|2018-05-31 21:45:06.110702
NCT01508923|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-01-23|2012-01-09|2012-01-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2001||2001-05-31|January 2017|2017-01-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes|Effect of NNC 90-1170 on 24-hour Glucose and Hormonal Profiles, Gastric Emptying, and Fasting Gluconeogenesis in Type 2 Diabetic Subjects. A Double-blind, Placebo-controlled, Randomised, Cross-over Trial|Completed||Phase 2|17|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:07.086542|2018-05-31 21:45:07.086542
NCT01508910|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2016-12-22||2017-10-19|2012-01-11|2012-01-12|Estimate|2016-12-22|2017-02-15|Actual||||2017-10-19|2017-10-23|Actual|April 2012||2012-04-30|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|RENEW|Arms for baseline characteristics based on the Safety population as randomized i.e. randomized participants prior to treatment.|Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina|A Prospective, Randomized, Double-blinded, Active-control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of Autologous CD34+ Cells (Auto-CD34+ Cells) for Increasing Exercise Capacity During Standardized Exercise Testing in Subjects With Refractory Angina Pectoris and Chronic Myocardial Ischemia|Completed||Phase 3|291|Actual|Shire|Study terminated early due to business considerations. Participants in Treatment or Active Control arms who did not have injection of target cells/placebo assigned to Not Injected Arm. Not included in efficacy analysis but in safety follow-up.|3|||f||||t||||||||||2018-05-31 21:45:07.193402|2018-05-31 21:45:07.193402
NCT01508897|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-02-28|2012-01-09|2012-01-12|Estimate|||||||2017-02-28|2017-03-01|Actual|May 28, 2004|Actual|2004-05-28|February 2017|2017-02-28|June 30, 2004|Actual|2004-06-30|June 30, 2004|Actual|2004-06-30||Interventional|||Comparison of Two Liraglutide Formulations in Healthy Volunteers|A Randomized, Single-blind, Single-centre, Two-period, Cross-over Trial Investigating the Bioequivalence Between Completed Phase 2 and Planned Phase 3 Formulations of Liraglutide in Healthy Subjects|Completed||Phase 1|22|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:09.642553|2018-05-31 21:45:09.642553
NCT01508884|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-12-08|2012-01-11|2012-01-12|Estimate|||||||2013-12-08|2013-12-10|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intradermal Trivalent Influenza Vaccine With Imiquimod|Efficacy and Effectiveness of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod, a Double Blind Randomized Controlled Trial|Completed||N/A|93|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 21:45:09.990797|2018-05-31 21:45:09.990797
NCT01508871|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-09|2012-01-09|2012-01-12|Estimate|||||||2012-01-09|2012-01-12|Estimate|January 2011||2011-01-31|August 2011|2011-08-31||||||||Observational|||Electrical Interactions in Heart Disease||Unknown status|Recruiting||100|Anticipated|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 21:45:10.19841|2018-05-31 21:45:10.19841
NCT01508858|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-01-23|2012-01-09|2012-01-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2006||2006-11-30|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women|A Double-blind, Two Period Cross-over, Single Centre Trial in Healthy Subjects Investigating the Influence on the Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Drug After Multiple Dose Administration of Liraglutide|Completed||Phase 1|21|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:10.284258|2018-05-31 21:45:10.284258
NCT01508845|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-07-18|2012-01-09|2012-01-12|Estimate|||||||2014-07-18|2014-07-21|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MUFA/PUFA||A Pilot Study of the Effect of Dietary Fat Type and Amount on Vitamin D3 Absorption|A Pilot Study of the Effect of Dietary Fat Type and Amount on Vitamin D3 Absorption|Completed||N/A|61|Actual|Tufts University||4|||f||||f||||||||||2018-05-31 21:45:10.440246|2018-05-31 21:45:10.440246
NCT01508832|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2013-05-23||2014-07-01|2012-01-11|2012-01-12|Estimate|2013-08-16|2013-08-19|Estimate||||2014-07-01|2014-07-15|Estimate|January 2012||2012-01-31|July 2014|2014-07-31||||March 2013|Actual|2013-03-31||Interventional|||Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers|Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers|Suspended||Phase 4|12|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:45:10.729419|2018-05-31 21:45:10.729419
NCT01508819|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2016-10-17|2012-01-09|2012-01-12|Estimate|||||||2016-10-17|2016-10-18|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|ICECUBII||Impact on Mid-term Mortality of Guidelines for ICU Admission of Elderly Patients Arriving in Emergency Departments|Impact on Mid-term Mortality of Guidelines for ICU Admission of Elderly Patients Arriving in Emergency Departments: a Cluster Randomized Controlled Trial|Completed|||3036|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 21:45:11.118203|2018-05-31 21:45:11.118203
NCT01508806|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-01-23|2012-01-09|2012-01-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2005||2005-08-31|January 2017|2017-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function|A Single-centre, Open-label, Trial Investigating the Pharmacokinetics and the Tolerability of Liraglutide in Subjects With Normal Renal Function and in Subjects With Impaired Renal Function|Completed||Phase 1|30|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-05-31 21:45:11.226139|2018-05-31 21:45:11.226139
NCT01508793|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2016-12-02|2012-01-09|2012-01-12|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||Enhancing Sleep Duration: Effects on Children's Eating and Activity Behaviors||Completed||N/A|103|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 21:45:11.511253|2018-05-31 21:45:11.511253
NCT01508780|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2014-02-11|2012-01-09|2012-01-12|Estimate|||||||2014-02-11|2014-02-13|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan|Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||1||Due to complex study protocol, no patients have been enrolled in the study.|f||||||||||||||2018-05-31 21:45:11.687268|2018-05-31 21:45:11.687268
NCT01508767|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-08-16|2012-01-09|2012-01-12|Estimate|||||||2013-08-16|2013-08-19|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Early Post-operative Removal of Urethral Catheter in Patients Undergoing Colorectal Surgery With Epidural Analgesia|Prospective Randomized Controlled Trial of Early Post-operative Removal of Urethral Catheter in Patients Undergoing Colorectal Surgery With Epidural Analgesia|Completed||N/A|41|Actual|University College Hospital Galway||2|||f||||f||||||||||2018-05-31 21:45:11.80858|2018-05-31 21:45:11.80858
NCT01508754|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2014-09-12|2012-01-09|2012-01-12|Estimate|||||||2014-09-12|2014-09-15|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy of CPAP Treatment on Blood Pressure of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome|Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).|Completed||Phase 4|125|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 21:45:11.916621|2018-05-31 21:45:11.916621
NCT01508741|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-03-18|2012-01-09|2012-01-12|Estimate|||||||2013-03-18|2013-03-20|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Use Of The Dietary Supplement 5-ALA And Its Relationship With Sleep And Mood|Supplement 5-ALA And Sleep And Mood Study|Completed||N/A|85|Actual|University of Hawaii||2|||f||||t||||||||||2018-05-31 21:45:12.078389|2018-05-31 21:45:12.078389
NCT01508728|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2014-09-24|2012-01-09|2012-01-12|Estimate|||||||2014-09-24|2014-09-25|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ORTHOSENS||Efficacy Study of a Sensory Feedback Knee Orthosis in Patients Suffering From Unoperated Severe Knee Sprain||Terminated||Phase 2|104|Anticipated|Thuasne||2|||f||||||||||||||2018-05-31 21:45:12.178305|2018-05-31 21:45:12.178305
NCT01508715|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-04-15|2012-01-09|2012-01-12|Estimate|||||||2014-04-15|2014-04-17|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Comparison of Exercise Interventions in Adults With Subacromial Impingement Syndrome|Comparison of an Eccentric Exercise Intervention to a Concentric Exercise Intervention in Adults With Subacromial Impingement Syndrome|Completed||N/A|36|Actual|Texas Woman's University||2|||f||||f||||||||||2018-05-31 21:45:12.284031|2018-05-31 21:45:12.284031
NCT01508702|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|2016-01-14|2014-04-28|2016-01-14|2012-01-11|2012-01-12|Estimate|2016-01-14|2016-02-12|Estimate|2014-05-13|2014-05-28|Estimate|2016-01-14|2016-02-12|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|LIGHT||Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor|Completed||Phase 3|214|Actual|Ardea Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 21:45:12.496608|2018-05-31 21:45:12.496608
NCT01508689|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-02-17|2012-01-09|2012-01-12|Estimate|||||||2015-02-17|2015-02-19|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Calcium-fortified Cereal Bars on Dietary Calcium Intake in Women|Effect of Calcium-fortified Cereal Bars on Dietary Calcium Intake in Women|Completed||N/A|36|Actual|Texas Woman's University||2|||f||||f||||||||||2018-05-31 21:45:13.339206|2018-05-31 21:45:13.339206
NCT01508676|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2016-09-23||2016-12-13|2012-01-11|2012-01-12|Estimate|2016-12-13|2017-02-06|Estimate||||2016-12-13|2017-02-06|Estimate|November 2011||2011-11-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|March 2013|Actual|2013-03-31||Interventional|||Effects of Pennsaid on Clinical Neuropathic Pain|Effects of Pennsaid on Clinical Neuropathic Pain|Completed||N/A|35|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:45:13.49623|2018-05-31 21:45:13.49623
NCT01508663|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-09|2012-01-09|2012-01-12|Estimate|||||||2012-01-09|2012-01-12|Estimate|August 2010||2010-08-31|January 2012|2012-01-31||||February 2014|Anticipated|2014-02-28||Interventional|BRAVE||The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease|The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study|Unknown status|Recruiting|Phase 4|1600|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 21:45:14.039364|2018-05-31 21:45:14.039364
NCT01508650|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-01-16|2012-01-11|2012-01-12|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2011||2011-10-31|January 2017|2017-01-31|September 7, 2012|Actual|2012-09-07|June 8, 2012|Actual|2012-06-08||Interventional|REHAB-HF||Rehabilitation and Exercise Training After Hospitalization|Rehabilitation and Exercise Training After Hospitalization: Assessing Benefit in Acute Heart Failure (REHAB-HF) Pilot Study|Completed||N/A|27|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 21:45:14.306512|2018-05-31 21:45:14.306512
NCT01508637|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2015-07-30|2012-01-11|2012-01-12|Estimate|||||||2015-07-30|2015-08-03|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|CVDTRAP4||Diesel Exhaust and Vascular Function|Effect of Diesel Exhaust Exposures on Vascular Function in Humans: The Role of Sympathetic Activation|Unknown status|Recruiting|N/A|24|Anticipated|University of Washington||4|||f||||f||||||||||2018-05-31 21:45:14.473586|2018-05-31 21:45:14.473586
NCT01508624|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2014-05-20|2012-01-09|2012-01-12|Estimate|||||||2014-05-20|2014-05-21|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Evaluation of Interventions to Improve Pain Relief, Perceived Anxiety and Recovery in Participants Receiving Office Based Surgery|Evaluation of an Intervention to Increase Pain Relief, Perceived Anxiety and Recovery in Participants Receiving Office Based Surgery|Completed||N/A|404|Actual|University of Surrey||5|||f||||t||||||||||2018-05-31 21:45:14.631853|2018-05-31 21:45:14.631853
NCT01508611|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-03-20|2012-01-09|2012-01-12|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2015||2015-02-28|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Cost-efficacy of Silver Diammine Fluoride in Erupting Molars|Cost-efficacy of Silver Diammine Fluoride to Control Caries Lesions in Erupting Permanent First Molars - Randomized Clinical Trial.|Active, not recruiting||N/A|192|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:45:14.840589|2018-05-31 21:45:14.840589
NCT01508598|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-01-30|2012-01-09|2012-01-12|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2012|Actual|2012-02-29|January 2018|2018-01-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Observational|||Validation of Circulating Endothelial Cells and Microparticles in Youth|Validation of Circulating Endothelial Cells and Microparticles in Youth|Completed|||390|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f|f|f||||Samples Without DNA|"~     10 mL of blood serum and 5 mL of blood plasma will be frozen in long-term storage for future~     study analyses and use. 8 mL of urine will be frozen in long-term storage for future study~     analyses and use.~   "|||2018-05-31 21:45:15.024631|2018-05-31 21:45:15.024631
NCT01508585|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-07-14|2012-01-09|2012-01-12|Estimate|||||||2015-07-14|2015-07-16|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Telephone-based Cognitive Behavioral Therapy for Bariatric Surgery Patients: A Pilot Study|Telephone-based Cognitive Behavioral Therapy for Bariatric Surgery Patients: A Pilot Study|Completed||N/A|47|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:45:15.529123|2018-05-31 21:45:15.529123
NCT01508572|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-10-25|2012-01-09|2012-01-12|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2011||2011-10-31|October 2017|2017-10-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer|Validation of Uptake of a VEGF-targeted Optical Fluorescent Imaging Tracer in Surgical Specimens of Breast Cancer and Application of Pre- and Intra-operative Human Molecular Fluorescence Imaging Techniques. A Multicenter Feasibility Study|Completed||Phase 1|20|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 21:45:15.815904|2018-05-31 21:45:15.815904
NCT01508559|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2014-04-10|2012-01-11|2012-01-12|Estimate|||||||2014-04-10|2014-04-11|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|MSM Neurocog||Men Who Have Sex With Men (MSM) Neurocog 1&2 Study|Neurocognitive Function in a Central London Cohort of HIV Infected and Uninfected Men Who Have Sex With Men|Completed|||237|Actual|St Stephens Aids Trust|||2||f||||f||||||||||2018-05-31 21:45:15.904419|2018-05-31 21:45:15.904419
NCT01508546|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-01-09|2012-01-09|2012-01-12|Estimate|||||||2012-01-09|2012-01-12|Estimate|May 1998||1998-05-31|January 2012|2012-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer||Completed||Phase 3|565|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 21:45:16.058328|2018-05-31 21:45:16.058328
NCT01508533|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-09|2012-01-09|2012-01-12|Estimate|||||||2012-01-09|2012-01-12|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Observational|||Epidemiology of Rotavirus Infection in North India Community|Disease Burden Study and Site Preparation for Planning and Implementation of the Phase III Trials for the Oral Rotavirus Vaccine 116E|Completed|||200|Actual|Society for Applied Studies|||2||f||||f||||||||||2018-05-31 21:45:16.409038|2018-05-31 21:45:16.409038
NCT01508520|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2012-01-11|2012-01-11|2012-01-12|Estimate|||||||2012-01-11|2012-01-12|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions|a Prospective Study on the Efficacy of Magnifying Endoscopy With Narrow-band Imaging in Diagnosing Gastric Lesions|Completed|||146|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     Samples after biopsy or resection are to be retained.~   "|||2018-05-31 21:45:16.575515|2018-05-31 21:45:16.575515
NCT01508507|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-06-04|2012-01-09|2012-01-12|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Observational|||Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine|Effectiveness of a Bivalent, Killed Whole-cell Based Oral Cholera Vaccine(Shanchol®) Delivered Through Community-based Mass Vaccination Campaign in a High-risk Population in India: Matched Case-control Studies|Unknown status|Recruiting||240|Anticipated|International Vaccine Institute|||2||f||||f||||||Samples Without DNA|"~     Rectal swabs will be collected from all cases that fulfills inclusion criteria. It will be~     plated directly into TCBS agar as well as after enrichment in APW for 6 to 20 hours (pH 8.6,~     37 degree centrigrade). After this overnight incubation, suspected colonies from TCBS will be~     tested biochemically and agglutinated with polyvalent, Ogawa and Inaba antisera. Biotyping of~     O1 isolates will be done with chicken erythrocyte agglunitation tests and determination of~     polymyxin sensitivity. Non - agglunating strains will be tested with antiserum to V cholarae~     O139 strain. V cholarae isolates will be tested for susceptibility to the following~     antimicrobials: tetracycline, erythromycin, furazolidin, trimithprim - sulfame thoxale,~     ciprofloxacin and norfloxacin.~   "|||2018-05-31 21:45:16.654915|2018-05-31 21:45:16.654915
NCT01508494|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2016-12-06|2012-01-11|2012-01-12|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|COGICRehab||Cognitive Rehabilitation and Galantamine for Post Stroke Cognitive Impairment|Evaluation de l'efficacité de la Galantamine Versus Placebo associée à Une Revalidation Neuropsychologique Chez Des Patients présentant un Trouble Cognitif après un Premier Infarctus cérébral : étude en Neuroimagerie Fonctionnelle|Unknown status|Recruiting|Phase 2|30|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 21:45:16.866762|2018-05-31 21:45:16.866762
NCT01508481|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-10-05|2012-01-11|2012-01-12|Estimate|||||||2012-10-05|2012-10-10|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Vitamin D Inadequacy is Associated With Incidence of Type 2 Diabetes|Vitamin D Inadequacy is Associated With Incidence of Type 2 Diabetes|Completed|||1500|Actual|Seoul National University Bundang Hospital|||1||f||||f||||||None Retained|"~     Blood sample was collected at the baseline.~   "|||2018-05-31 21:45:17.116502|2018-05-31 21:45:17.116502
NCT01508468|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2016-08-23|2012-01-11|2012-01-12|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|January 2015|Actual|2015-01-31||Interventional|GEMRITUX||Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy|Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)|Active, not recruiting||Phase 3|80|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:45:17.212431|2018-05-31 21:45:17.212431
NCT01508455|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2013-08-02||2017-08-10|2012-01-11|2012-01-12|Estimate|2013-10-18|2013-12-11|Estimate||||2017-08-10|2017-08-23|Actual|March 2012||2012-03-31|September 2015|2015-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||All subjects that received study drug.|Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age|A Phase II/III, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age|Completed||Phase 2/Phase 3|6|Actual|Hospira, now a wholly owned subsidiary of Pfizer||1|||f||||t||||||||||2018-05-31 21:45:17.420921|2018-05-31 21:45:17.420921
NCT01508429|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2016-07-06|2012-01-09|2012-01-12|Estimate|||||||2016-07-06|2016-07-11|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Misoprostol for Treatment of Postpartum Haemorrhage (PPH) in Home Births|Misoprostol for the Treatment of Postpartum Haemorrhage (PPH) Following Self- Administration of Misoprostol Prophylaxis in Home Deliveries.|Completed||N/A|70|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 21:45:17.868547|2018-05-31 21:45:17.868547
NCT01508416|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2015-07-27|2012-01-09|2012-01-12|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|METRO||Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma|Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma: a Multicentric Study|Completed|||71|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     whole blood and serum~   "|||2018-05-31 21:45:17.959921|2018-05-31 21:45:17.959921
NCT01508403|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-05-13|2012-01-11|2012-01-12|Estimate|||||||2013-05-13|2013-05-14|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|RSCMI-I||A Registry Study on Shuxuetong (a Chinese Medicine Injection) Used in Twenty Hospitals|A Registry Study on Shuxuetong (a Chinese Medicine Injection) Used in Twenty Hospitals|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||1||f||||t||||||||||2018-05-31 21:45:18.176245|2018-05-31 21:45:18.176245
NCT01508390|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2017-11-30|2012-01-11|2012-01-12|Estimate|||||||2017-11-30|2017-12-04|Actual|June 2011||2011-06-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate|Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer|Recruiting||N/A|30|Anticipated|Boston Medical Center||1|||f||||t|f|t|f||t|||No||2018-05-31 21:45:18.338457|2018-05-31 21:45:18.338457
NCT01508377|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2016-01-30|2012-01-11|2012-01-12|Estimate|||||||2016-01-30|2016-02-02|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of an Internet-based Intervention for Posttraumatic Stress Disorder|Additive Effect of Cognitive Restructuring in a Web-based Treatment for Traumatized Arab People|Completed||N/A|293|Actual|Berlin Center for the Treatment of Torture Victims||2|||f||||f||||||||||2018-05-31 21:45:18.517665|2018-05-31 21:45:18.517665
NCT01508364|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-01-19|2012-01-09|2012-01-12|Estimate|||||||2015-01-19|2015-01-21|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|NEXTAR||Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma|NEXTAR - NEXavar® as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma|Completed|||20|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:45:18.608161|2018-05-31 21:45:18.608161
NCT01508351|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-04-28|2012-01-10|2012-01-11|Estimate|||||||2015-04-28|2015-04-29|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The Hypotensive Effect of Propofol: an Observational Study|The Hypotensive Effect of Propofol: an Observational Study of Hypotension With Anesthetic Induction by Propofol in the General Population Under Standard of Care Anesthesia|Completed|||100|Actual|Milton S. Hershey Medical Center|||1||f||||f||||||||||2018-05-31 21:45:18.787821|2018-05-31 21:45:18.787821
NCT01508338|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-07-28|2012-01-09|2012-01-11|Estimate|||||||2017-07-28|2017-08-01|Actual|January 2012||2012-01-31|July 2017|2017-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes|The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes|Completed||N/A|44|Actual|Metabolic Technologies Inc.||4|||f||||f||||||||||2018-05-31 21:45:18.902533|2018-05-31 21:45:18.902533
NCT01508325|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2015-04-28||2015-04-28|2012-01-09|2012-01-11|Estimate|2015-04-28|2015-05-13|Estimate||||2015-04-28|2015-05-13|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CREATIVE|Intention-to-treat (ITT) analysis population included all randomized subjects.|Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients|Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients (CREATIVE Study)|Completed||Phase 4|186|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 21:45:19.373555|2018-05-31 21:45:19.373555
NCT01508312|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2017-11-29|2012-01-09|2012-01-11|Estimate|||||||2017-11-29|2017-12-02|Actual|January 5, 2012||2012-01-05|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma|Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma|Active, not recruiting||Phase 2|46|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:45:20.244289|2018-05-31 21:45:20.244289
NCT01508299|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-10-06|2012-01-10|2012-01-11|Estimate|||||||2015-10-06|2015-10-07|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Skin Prick Test for the Diagnosis of Food Allergy- a Comparison of Different Commercial Extracts and Raw Food|Skin Prick Test for the Diagnosis of Food Allergy- a Comparison of Different Commercial Extracts and Raw Food|Completed||N/A|200|Anticipated|Meir Medical Center||1|||f||||t||||||||||2018-05-31 21:45:20.350955|2018-05-31 21:45:20.350955
NCT01508286|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-07-22|2012-01-09|2012-01-11|Estimate|||||||2015-07-22|2015-07-24|Estimate||||July 2015|2015-07-31||||||||Expanded Access|||Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects|Multicenter, Open-label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis|No longer available|||||Janssen-Cilag International NV|||||f||||f||||||||||2018-05-31 21:45:20.508673|2018-05-31 21:45:20.508673
NCT01508273|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-12-01|2012-01-09|2012-01-11|Estimate|||||||2016-12-01|2016-12-02|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Lifestyle Intervention for High Risk Cancer Survivors|Development of an Aerobic and Resistance Training Feasibility Study for a Racially and Ethnically Diverse Sample of Breast Cancer Survivors|Completed||N/A|1150|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 21:45:20.89737|2018-05-31 21:45:20.89737
NCT01508260|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-04-04|2012-01-09|2012-01-11|Estimate|||||||2013-04-04|2013-04-05|Estimate|March 2013||2013-03-31|April 2013|2013-04-30||||March 2018|Anticipated|2018-03-31||Interventional|||Ultrafiltration (Aquapheresis) in Patients With Leukemia and Severe Fluid Overload|Ultrafiltration (Aquapheresis) in the Management of Patients With Leukemia and Severe Fluid Overload|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-05-31 21:45:21.225749|2018-05-31 21:45:21.225749
NCT01508247|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-03-27|2012-01-10|2012-01-11|Estimate|||||||2013-03-27|2013-03-29|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months|A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months|Completed||Phase 3|10245|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 21:45:21.324177|2018-05-31 21:45:21.324177
NCT01508221|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2016-07-30|2012-01-08|2012-01-11|Estimate|||||||2016-07-30|2016-08-02|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis|A Phase II Trial to Evaluate the Use of Trental and Vitamin E for Prophylaxis of Radiation Necrosis|Recruiting||Phase 2|50|Anticipated|University of Cincinnati||1|||f||||f||||||||||2018-05-31 21:45:21.544775|2018-05-31 21:45:21.544775
NCT01508208|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2018-01-02|2012-01-10|2012-01-11|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2012||2012-03-31|January 2018|2018-01-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Comparison of Urine Protein/Creatinine Ratio With 24-hour Urine Protein Excretion in Woman With Hypertensive Disorders|A Comparison of Spot Test (Urine Protein/Creatinine Ratio) With 24 - Hour Urine Protein Excretion in Woman With Hypertensive Disorders of Pregnancy|Completed||N/A|420|Actual|Saint Thomas Hospital, Panama||1|||f||||f||||||||||2018-05-31 21:45:21.625129|2018-05-31 21:45:21.625129
NCT01508195|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-01-30|2012-01-09|2012-01-11|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (50 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 500 mg) in Healthy Fed Subjects|Completed||Phase 1|64|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 21:45:21.711968|2018-05-31 21:45:21.711968
NCT01508182|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2013-01-15|2012-01-10|2012-01-11|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (150 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1x300 mg) and Metformin IR Tablets (2x500 mg) in Healthy Fed Subjects|Completed||Phase 1|64|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 21:45:22.081245|2018-05-31 21:45:22.081245
NCT01508169|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2012-02-02||2012-03-09|2012-01-10|2012-01-11|Estimate|2012-03-09|2012-04-06|Estimate||||2012-03-09|2012-04-06|Estimate|April 2011||2011-04-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Foot Orthoses and Elderly Women With Osteoporosis|The Effect of Foot Orthoses on the Balance of Elderly Women With Osteoporosis|Completed||N/A|94|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 21:45:22.284509|2018-05-31 21:45:22.284509
NCT01508156|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-04-24|2012-01-09|2012-01-11|Estimate|||||||2015-04-24|2015-04-27|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001)|A Phase I/IIa Study Assessing Single and Multiple Doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-Infected Subjects|Completed||Phase 1/Phase 2|130|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:45:22.867566|2018-05-31 21:45:22.867566
NCT01508143|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-09-30|2012-01-09|2012-01-11|Estimate|||||||2012-09-30|2012-10-02|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparitive Study of Two Misoprostol Regimen in Early Pregnancy Termination|A Comparative Study of Vaginal Misoprostol Two Dosing Regimen for First Trimester Pregnancy Termination in Patients Admitted at Bandarabbas in Shariati Hospital in 2009|Completed||N/A|41|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:45:23.066219|2018-05-31 21:45:23.066219
NCT01508130|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2015-10-19||2017-03-10|2012-01-09|2012-01-11|Estimate|2016-01-25|2016-02-22|Estimate||||2017-03-10|2017-04-10|Actual|January 31, 2012|Actual|2012-01-31|March 2017|2017-03-31|March 31, 2014|Actual|2014-03-31|March 31, 2014|Actual|2014-03-31||Observational|||An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1|Non-Interventional, Prospective Cohort Study of the Effectiveness, Safety and Utilization of Two Approved Pegylated Interferon-Based Direct Acting Antiviral Triple Therapies in the Management of Genotype 1 Chronic Hepatitis C in Routine Clinical Practice in the USA|Completed|||672|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:45:23.364425|2018-05-31 21:45:23.364425
NCT01508117|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2017-08-18||2017-08-18|2012-01-10|2012-01-11|Estimate|2017-08-18|2017-09-19|Actual||||2017-08-18|2017-09-19|Actual|August 2011||2011-08-31|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients|A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)|Terminated||Phase 2|1|Actual|University of Cincinnati|Early termination due to lack of accrual.|1||transferred study sponsor|f||||t||||||||||2018-05-31 21:45:25.007918|2018-05-31 21:45:25.007918
NCT01508104|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-08-21|2012-01-06|2012-01-11|Estimate|||||||2017-08-21|2017-08-23|Actual|January 2012||2012-01-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors|A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies|Terminated||Phase 1|19|Actual|University of Cincinnati||1||funding|f||||t||||||||||2018-05-31 21:45:25.348221|2018-05-31 21:45:25.348221
NCT01508091|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-10-20|2012-01-10|2012-01-11|Estimate|||||||2012-10-20|2012-10-23|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Calorie Restriction Retards the Aging Process|Calorie Restriction Retards the Aging Process by Inducing Sirtuins and Uncoupling Protein 3, Thereby Reducing the Production of Reactive Oxygen Species.|Unknown status|Recruiting|N/A|48|Anticipated|University of Chile||1|||f||||f||||||||||2018-05-31 21:45:25.604198|2018-05-31 21:45:25.604198
NCT01508078|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2018-04-10|2012-01-10|2012-01-11|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2010||2010-05-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|CASA||Characterization of Adult Subjects for Asthmatic Research Studies|Characterization of Adult Subjects for Asthmatic Research Studies|Recruiting|||2000|Anticipated|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     Samples of induced sputum and blood for DNA and RNA extraction, plasma, and serum will be~     banked in the UCSF Airway Tissue Bank.~   "|||2018-05-31 21:45:25.772599|2018-05-31 21:45:25.772599
NCT01508065|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-08-24|2012-01-10|2012-01-11|Estimate|||||||2016-08-24|2016-08-25|Estimate|September 2012||2012-09-30|August 2016|2016-08-31||||July 2014|Actual|2014-07-31||Observational|||Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device|Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device|Active, not recruiting|||20|Anticipated|GlucoVista|||1||f||||f||||||||||2018-05-31 21:45:25.888762|2018-05-31 21:45:25.888762
NCT01508052|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2014-02-24||2014-04-03|2012-01-09|2012-01-11|Estimate|2014-04-03|2014-05-05|Estimate||||2014-04-03|2014-05-05|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Sequential Compression Device on Body Temperature|The Effects of Sequential Compression Device on Body Temperature During Propofol Anaesthesia: A Comparison With Elastic Stockings|Completed||N/A|40|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 21:45:25.959957|2018-05-31 21:45:25.959957
NCT01508039|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-01-25|2012-01-10|2012-01-11|Estimate|||||||2012-01-25|2012-01-26|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|INCA||Immunological Effects From Intranasal Chitin Micro-Particles|A Randomised, Double-blind,Single-dose,Placebo and Single-blind Active Controlled Cross-over Study in Healthy Volunteers to Access in Effects of Intranasal Chitin Micro-particles on the Release of Cytokines From Nasal Mucosa|Completed||N/A|14|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 21:45:26.475381|2018-05-31 21:45:26.475381
NCT01508026|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09||2014-03-28|2014-03-28|2012-01-09|2012-01-11|Estimate||||2014-03-28|2014-04-25|Estimate|2014-03-28|2014-04-25|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension|A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension|Completed||Phase 3|4161|Actual|Forest Laboratories||8|||f||||f||||||||||2018-05-31 21:45:26.648246|2018-05-31 21:45:26.648246
NCT01508013|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2016-01-21||2016-04-26|2012-01-09|2012-01-11|Estimate|2016-04-26|2016-06-02|Estimate||||2016-04-26|2016-06-02|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|iSTART|Adolescent females aged 12-18 years old who expressed interest in future indoor tanning.|An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk|An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk|Completed||N/A|443|Actual|East Tennessee State University|None noted|2|||f||||t||||||||Yes|The proposed research will include data from high school teenage women who indoor tan. The final dataset will include self-reported demographic, attitudinal, cognitive and behavioral data from surveys about private personal behaviors. The final dataset will be stripped of identifiers prior to release for sharing. We will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and to not attempting to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 21:45:28.580114|2018-05-31 21:45:28.580114
NCT01508000|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-10-11|2012-01-10|2012-01-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|BOS2||Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases|Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS/NRAS Colorectal Cancer|Terminated||Phase 2|44|Actual|European Organisation for Research and Treatment of Cancer - EORTC||3||Low or poor accrual|f||||||||||||||2018-05-31 21:45:29.175796|2018-05-31 21:45:29.175796
NCT01507987|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2018-04-13|2012-01-10|2012-01-11|Estimate|||||||2018-04-13|2018-04-17|Actual|March 2013||2013-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Observational|CLAS||St.Jude Medical Cardiac Lead Assessment Study|St.Jude Medical Cardiac Lead Assessment Study|Active, not recruiting|||2215|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 21:45:29.441391|2018-05-31 21:45:29.441391
NCT01507974|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-10-30|2012-01-08|2012-01-11|Estimate|||||||2016-10-30|2016-11-01|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections|The Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections|Recruiting||N/A|100|Anticipated|HaEmek Medical Center, Israel||3|||f||||t||||||||||2018-05-31 21:45:29.556941|2018-05-31 21:45:29.556941
NCT01507961|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-08|||2012-01-10|2012-01-10|2012-01-11|Estimate|||||||2012-01-10|2012-01-11|Estimate|February 2012||2012-02-29|December 2011|2011-12-31||||||||Observational|||Comparison of Soft and Hard Tissue Thickness in the Anterior Regions of the Upper and Lower Jaws Taken From CBCT Versus Clinical Measurements||Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 21:45:29.798285|2018-05-31 21:45:29.798285
NCT01507948|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-01-19|2012-01-06|2012-01-11|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD)|The Neurobiology of Psychotherapy: Emotional Reactivity and Regulation in PTSD|Completed||N/A|94|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 21:45:29.866049|2018-05-31 21:45:29.866049
NCT01507935|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-09-04|2012-01-08|2012-01-11|Estimate|||||||2012-09-04|2012-09-05|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|ColoR||Colonisation Resistance Study|Randomised, Controlled, Double-blind Exploratory Study to Investigate the Effect of Specific Prebiotic Oligosaccharides on Gut Microbiota Composition in Healthy Infants|Withdrawn||Phase 2|0|Actual|Danone Asia Pacific Holdings Pte, Ltd.||4||The study was withdrawn due to change of the study product formulation.|f||||f||||||||||2018-05-31 21:45:30.009945|2018-05-31 21:45:30.009945
NCT01507922|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2014-12-17|2012-01-08|2012-01-11|Estimate|||||||2014-12-17|2014-12-18|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|FEN-401||Comparative Efficacy and Safety of Fenoverine|Comparative Efficacy and Safety of Fenoverine and Trimebutine Maleate in Irritable Bowel Syndrome; A Randomized Double-blind Parallel Multi-center Phase IV Trial|Completed||Phase 4|186|Anticipated|Bukwang Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:45:30.256915|2018-05-31 21:45:30.256915
NCT01507909|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-07-25|2012-01-10|2012-01-11|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Observational|||Quantitative EEG Assessment of Cue-Induced Changes in Brain Activity in Alcohol Use Disorders|Quantitative EEG Assessment of Cue-Induced Changes in Brain Activity in Alcohol Use Disorders|Terminated|||11|Actual|Boston University||||Equipment Failure|f||||f||||||||||2018-05-31 21:45:30.408095|2018-05-31 21:45:30.408095
NCT01507896|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2016-07-27|2015-05-07|2017-10-19|2012-01-09|2012-01-11|Estimate|2016-12-22|2017-02-15|Actual|2015-05-07|2015-05-25|Estimate|2017-10-19|2017-10-23|Actual|December 2011||2011-12-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Note there were 30 unique participants with a total of 40 planned surgeries, as participants may have > 1 surgery. Baseline data reflects number of planned surgeries.|BAX 326 Surgery Study in Hemophilia B Patients|BAX 326 (Recombinant Factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B Undergoing Surgical or Other Invasive Procedures|Completed||Phase 3|30|Actual|Shire|Data provided for surgical procedures, treatments with BAX326 etc. and for unique participants (one unique participant could undergo more than one surgical procedure).|1|||f||||t||||||||||2018-05-31 21:45:30.621639|2018-05-31 21:45:30.621639
NCT01507883|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-01-10|2012-01-10|2012-01-11|Estimate|||||||2012-01-10|2012-01-11|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|January 2012|Anticipated|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Time-lapse Evaluation of Human Embryo Development in Single Versus Sequential Culture Media - a Sibling Oocyte Study|Time-lapse Evaluation of Human Embryo Development in Single Versus Sequential Culture Media - a Sibling Oocyte Study|Unknown status|Recruiting||50|Anticipated|Bahceci Health Group|||1||f||||f||||||Samples With DNA|"~     Human embryos~   "|||2018-05-31 21:45:31.888387|2018-05-31 21:45:31.888387
NCT01507870|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2015-07-01|2012-01-10|2012-01-11|Estimate|||||||2015-07-01|2015-07-02|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Randomized Controlled Prospective Multicenter Study Primary Onlay- Mesh After Elective Median Laparotomy in Patients With BMI ≥ 27||Terminated||N/A|300|Anticipated|Austrian Hernia Study Group||2|||f||||||||||||||2018-05-31 21:45:32.040191|2018-05-31 21:45:32.040191
NCT01507857|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2013-11-27|2012-01-06|2012-01-11|Estimate|||||||2013-11-27|2013-11-28|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine|A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines|Completed||Phase 3|10077|Actual|Sinovac Biotech Co., Ltd||2|||f||||t||||||||||2018-05-31 21:45:32.186827|2018-05-31 21:45:32.186827
NCT01507844|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2012-01-08|2012-01-08|2012-01-11|Estimate|||||||2012-01-08|2012-01-11|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|CPAP||Continuous Positive Airway Pressure Effect on Air Trapping in Chronic Obstructive Pulmonary Disease Patients|Continuous Positive Airway Pressure Effect on Air Trapping, Endurance Time in Chronic Obstructive Pulmonary Disease Patients|Completed||N/A|24|Actual|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 21:45:32.371101|2018-05-31 21:45:32.371101
NCT01507831|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2015-11-18||2015-11-18|2012-01-10|2012-01-11|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)|Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 3|2341|Actual|Sanofi|"Manual reclassification was done by the Sponsor for the other reasons of non-completion of study as specified in the electronic case report (eCRF) form."|2|||f||||t||||||||||2018-05-31 21:45:32.739152|2018-05-31 21:45:32.739152
NCT01507818|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2012-07-06|2012-01-10|2012-01-11|Estimate|||||||2012-07-06|2012-07-09|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Effectiveness of the Ivivi Torino II, Pulsed Radio Frequency Device, on Narcotic Use, Pain and Quality of Life Following Shoulder Arthroscopic Rotator Cuff Repair.|Impact of Non-thermal Pulsed Radio Frequency (PRF)on Narcotic Use, Pain, and Health-related Quality of Life Following Shoulder Arthroscopic Rotator Cuff Repair: A Double-Blind, Randomized Sham-Controlled Trial|Terminated||N/A|37|Actual|Amp Orthopedics, Inc.||2||Sponsor decision|f||||f||||||||||2018-05-31 21:45:36.0488|2018-05-31 21:45:36.0488
NCT01507805|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-01-08|2012-01-08|2012-01-11|Estimate|||||||2012-01-08|2012-01-11|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|January 2013|Anticipated|2013-01-31|June 2012|Anticipated|2012-06-30||Interventional|||Electroacupuncture Preconditioning on Geriatric Noncardiac Surgery|Effects of Electroacupuncture Preconditioning on Outcomes of the Geriatric Patients With Coronary Heart Disease Undergoing Non-cardiac Surgery|Unknown status|Recruiting|N/A|300|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 21:45:36.173685|2018-05-31 21:45:36.173685
NCT01507792|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2012-01-08|2012-01-08|2012-01-11|Estimate|||||||2012-01-08|2012-01-11|Estimate|January 2002||2002-01-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|CID||Iron Repletion in Chronic Cough and Iron Deficiency|Effect of Iron Repletion in Women With Chronic Cough and Iron Deficiency|Completed||N/A|22|Actual|University of Turin, Italy|||||f||||f||||||||||2018-05-31 21:45:36.383468|2018-05-31 21:45:36.383468
NCT01507779|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2013-09-19|2012-01-10|2012-01-11|Estimate|||||||2013-09-19|2013-09-23|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine|Evaluation of The Safety and Immunogenicity of an Influenza A/H1N1 Vaccine (IVACFLU), Produced by IVAC, in Healthy Adults in Vietnam|Completed||Phase 1|48|Actual|PATH||2|||f||||f||||||||||2018-05-31 21:45:36.536173|2018-05-31 21:45:36.536173
NCT01507766|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-11-15|2012-01-10|2012-01-11|Estimate|||||||2012-11-15|2012-11-16|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis|The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis|Completed||Phase 4|60|Actual|Nanjing University School of Medicine||2|||f||||t||||||||||2018-05-31 21:45:36.630841|2018-05-31 21:45:36.630841
NCT01507753|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2016-03-04|2012-01-07|2012-01-11|Estimate|||||||2016-03-04|2016-03-08|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|OATS||Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified|Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Bipolar Disorder- Not Otherwise Specified|Completed||Phase 1|23|Actual|Ohio State University||4|||f||||t||||||||||2018-05-31 21:45:36.727396|2018-05-31 21:45:36.727396
NCT01507558|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-01-04|2012-01-10|2012-01-11|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2010||2010-12-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|DANCE||Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization|Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization|Completed||N/A|22|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:45:40.231414|2018-05-31 21:45:40.231414
NCT01507740|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2015-04-28|2012-01-08|2012-01-11|Estimate|||||||2015-04-28|2015-04-29|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|December 2012|Actual|2012-12-31||Observational|||Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients|Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients|Terminated|||60|Actual|Medical University Innsbruck|||2|"Study was stopped 04.10.2014 prematurly after recruitment of HCC and RCC patients. NSCLC (2 of~   10 patients planned) and CRC patients recruitment was stopped"|f||||t||||||Samples With DNA|"~     Consecutive serum and blood probes will be taken and will be examined and correlated with~     functional imaging and the clinical course. Following parameters have been selected: soluble~     markers in the plasma (VEGF, bFGF, ICAM, sVGFR-2 IL-8, SDF1 and Dickkopf 3) and cellular~     parameters like circulating endothelial cells (CEC) and circulating endothelial progenitor~     cells (CEPs).~   "|||2018-05-31 21:45:36.883615|2018-05-31 21:45:36.883615
NCT01507727|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-08|2012-01-08|2012-01-11|Estimate|||||||2012-01-08|2012-01-11|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia|A Multicenter, Randomized, Double-blind, Placebo-controlled (Standard Therapy + Placebo) Study to Evaluate the Efficacy and Safety of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia|Unknown status|Recruiting|Phase 2/Phase 3|240|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:45:37.076977|2018-05-31 21:45:37.076977
NCT01507714|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-08|2012-01-08|2012-01-11|Estimate|||||||2012-01-08|2012-01-11|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Anterior Vaginal Wall Repair With Mesh in Combination With TVT-O to Reduce Urinary Stress Incontinence|Anterior Vaginal Wall Repair With Mesh in Combination With TVT-O to Reduce Urinary Stress Incontinence|Unknown status|Not yet recruiting|N/A|100|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 21:45:37.257322|2018-05-31 21:45:37.257322
NCT01507701|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-01-12|2012-01-10|2012-01-11|Estimate|||||||2012-01-12|2012-01-13|Estimate|January 2010||2010-01-31|January 2012|2012-01-31||||March 2010|Actual|2010-03-31||Interventional|||Pilot Study for the NorCAPITAL Trial|Pilot Study for the NorCAPITAL Trial|Completed||N/A|5|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 21:45:37.480812|2018-05-31 21:45:37.480812
NCT01507688|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-12-19|2012-01-06|2012-01-11|Estimate|||||||2017-12-19|2017-12-21|Actual|January 7, 2013|Actual|2013-01-07|December 2017|2017-12-31|December 31, 2017|Anticipated|2017-12-31|March 31, 2017|Actual|2017-03-31||Interventional|||Stroke Self-Management|Stroke Self-Management: Effect on Function and Stroke Quality of Life|Active, not recruiting||N/A|263|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 21:45:37.629399|2018-05-31 21:45:37.629399
NCT01507675|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-03-21|2012-01-06|2012-01-11|Estimate|||||||2014-03-21|2014-03-26|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Burden, Belonging, and Response to Pain in Veterans|Burden, Belonging, and Response to Pain in Veterans|Withdrawn|||0|Actual|VA Eastern Colorado Health Care System|||1|Study should not have been listed on ClinicalTrials|f||||t||||||||||2018-05-31 21:45:37.812632|2018-05-31 21:45:37.812632
NCT01507662|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2017-02-24||2017-02-24|2012-01-10|2012-01-11|Estimate|2017-02-24|2017-04-11|Actual||||2017-02-24|2017-04-11|Actual|February 2012||2012-02-29|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PAADRN||Patient Activation After DXA Result Notification|Patient Activation After DXA Result Notification|Completed||N/A|7749|Actual|University of Iowa||2|||f||||t|f|f||||||Undecided||2018-05-31 21:45:37.987857|2018-05-31 21:45:37.987857
NCT01507649|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-12-01|2012-01-06|2012-01-11|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of a Telephone-based Intervention on Postnatal Depression|The Effect of a Telephone-based Cognitive-behavioral Intervention on Postnatal Depression: a Randomized Controlled Trial|Completed||N/A|397|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:45:38.747449|2018-05-31 21:45:38.747449
NCT01507636|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-05-14|2012-01-10|2012-01-11|Estimate|||||||2013-05-14|2013-05-15|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Occupational Therapy in Patients With Multiple Sclerosis|Apraxia-specific Occupational Therapy in Patients With Multiple Sclerosis|Completed||N/A|40|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 21:45:38.90561|2018-05-31 21:45:38.90561
NCT01507623|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2012-01-10|2012-01-10|2012-01-11|Estimate|||||||2012-01-10|2012-01-11|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Value of Capnography During Nurse Administered Propofol Sedation (NAPS)|The Role of Capnography in Endoscopy Patients Undergoing Nurse Administered Propofol Sedation (NAPS): A Randomized Study|Completed||N/A|591|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 21:45:39.040078|2018-05-31 21:45:39.040078
NCT01507610|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-02-28|2012-01-10|2012-01-11|Estimate|||||||2012-02-28|2012-02-29|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects|An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX® (Sumatriptan) Nasal Spray, 100 mg IMITREX® (Sumatriptan) Oral Tablet and 6 mg IMITREX® (Sumatriptan) Subcutaneous Injection in Healthy Subjects|Completed||Phase 1|20|Actual|Optinose US Inc.||4|||f||||f||||||||||2018-05-31 21:45:39.212722|2018-05-31 21:45:39.212722
NCT01507597|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-12-09|2012-01-10|2012-01-11|Estimate|||||||2013-12-09|2013-12-10|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of GLP-1 on the Inhibition of Glucagon Secretion||Completed||N/A|30|Actual|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-05-31 21:45:39.521316|2018-05-31 21:45:39.521316
NCT01507584|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2012-01-06|2012-01-06|2012-01-11|Estimate|||||||2012-01-06|2012-01-11|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||The Effects of the Water Drinking Test on Intraocular Pressure|The Effects of the Water Drinking Test on Intraocular Pressure of Glaucoma Patients Undergoing 24 Hour Continuous Monitoring With the SENSIMED Triggerfish|Unknown status|Enrolling by invitation|Phase 3|40|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:45:39.611854|2018-05-31 21:45:39.611854
NCT01507571|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2012-01-10|2012-01-10|2012-01-11|Estimate|||||||2012-01-10|2012-01-11|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|DignityDK||Implementation and Evaluation of Dignity Therapy in Denmark|Implementation and Evaluation of Dignity Therapy in Denmark|Completed||Phase 2|80|Actual|Bispebjerg Hospital||1|||f||||f||||||||||2018-05-31 21:45:39.738498|2018-05-31 21:45:39.738498
NCT01507545|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05||2015-06-25|2015-09-04|2012-01-10|2012-01-11|Estimate||||2015-06-25|2015-07-20|Estimate|2015-09-04|2015-09-21|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)|A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer|Completed||Phase 2|126|Actual|Morphotek||2|||f||||t||||||||||2018-05-31 21:45:40.386315|2018-05-31 21:45:40.386315
NCT01507532|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-03-17|2012-01-10|2012-01-11|Estimate|||||||2018-03-17|2018-03-20|Actual|January 2012||2012-01-31|March 2018|2018-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients|Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients|Withdrawn||Phase 4|0|Actual|Midwestern University||1||did not enroll a patient|f||||f||||||||||2018-05-31 21:45:40.756396|2018-05-31 21:45:40.756396
NCT01507519|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2018-04-03|2012-01-10|2012-01-11|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2009|Actual|2009-04-30|April 2018|2018-04-30|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|meriT-1||Study Safety and Performance of the Biomime Stent in Patients With Single, De Novo, Non-Complex Coronary Lesions|The First-In-Man Safety and Performance Evaluation of the Biomime Sirolimus Eluting Stent System for the Treatment of Patients With Single, De Novo, Non-Complex Coronary Lesions-The Biomime Pilot FiM Trial.|Completed||N/A|30|Actual|Meril Life Sciences Pvt. Ltd.||1|||f||||f||||||||||2018-05-31 21:45:40.894617|2018-05-31 21:45:40.894617
NCT01507506|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-03-01|2012-01-10|2012-01-11|Estimate|||||||2018-03-01|2018-03-02|Actual|March 15, 2011|Actual|2011-03-15|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2020|Anticipated|2020-03-31||Interventional|SPECTRO GLIO||Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma|Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost Guided by Magnetic Resonance Spectroscopic Imaging|Recruiting||Phase 3|220|Anticipated|Institut Claudius Regaud||2|||f||||f||||||||||2018-05-31 21:45:41.024122|2018-05-31 21:45:41.024122
NCT01507493|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|2013-05-30||2014-08-31|2012-01-06|2012-01-11|Estimate|2014-08-31|2014-09-03|Estimate||||2014-08-31|2014-09-03|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population|The Impact of SCN9A Gene Polymorphism on Individual Pain Perception in the General Population|Completed|||200|Actual|Huazhong University of Science and Technology|||2||f||||t||||||Samples With DNA|"~     Heparin anti-coagulated blood (2 ml) was collected from the central venous during the~     operation and all blood samples were stored at -80℃. Genomic DNA was extracted from the blood~     samples using a guanidinium isothiocyanate method.~   "|||2018-05-31 21:45:41.440169|2018-05-31 21:45:41.440169
NCT01507480|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-05-13|2012-01-06|2012-01-11|Estimate|||||||2013-05-13|2013-05-14|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ELLIPSE||The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia|The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.|Completed||Phase 1|42|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 21:45:42.228717|2018-05-31 21:45:42.228717
NCT01507467|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-14|||2016-11-22|2012-01-10|2012-01-11|Estimate|||||||2016-11-22|2016-11-25|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2014|Actual|2014-05-31||Interventional|IAEA-HypoX||IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck|IAEA-HypoX. A Randomized Multicenter Study of Accelerated Fractionated Radiotherapy With or Without the Hypoxic Radiosensitizer Nimorazole in the Treatment of Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 3|104|Actual|Danish Head and Neck Cancer Group||2||Insufficient recruitment|f||||t||||||||||2018-05-31 21:45:42.321644|2018-05-31 21:45:42.321644
NCT01507454|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-02-06|2012-01-09|2012-01-11|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2006||2006-04-30|February 2017|2017-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency|Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency|Completed|||1613|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:45:42.524395|2018-05-31 21:45:42.524395
NCT01507441|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2016-05-17|2012-01-06|2012-01-10|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2012||2012-02-29|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial|Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia|Completed|||10|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:45:42.799314|2018-05-31 21:45:42.799314
NCT01507428|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2018-04-02|2012-01-05|2012-01-10|Estimate|||||||2018-04-02|2018-04-03|Actual|February 22, 2012|Actual|2012-02-22|March 2018|2018-03-31||||June 8, 2019|Anticipated|2019-06-08||Interventional|||Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer|Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|138|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:45:43.005481|2018-05-31 21:45:43.005481
NCT01507415|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-11-04|2012-01-06|2012-01-10|Estimate|||||||2014-11-04|2014-11-05|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Observational|||Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?|Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?|Completed|||226|Actual|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma and serum.~   "|||2018-05-31 21:45:43.403286|2018-05-31 21:45:43.403286
NCT01507402|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-11-12|2012-01-09|2012-01-10|Estimate|||||||2012-11-12|2012-11-14|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)||Completed||Phase 1|76|Actual|Regeneron Pharmaceuticals||9|||f||||t||||||||||2018-05-31 21:45:43.55301|2018-05-31 21:45:43.55301
NCT01507038|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2015-02-16|2012-01-05|2012-01-10|Estimate|||||||2015-02-16|2015-02-18|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy of YH14617 in Diabetes Mellitus|Phase II Clinical Trial to Investigate the Efficacy, Safety and Pharmacokinetics of YH14617 After Once Weekly or Biweekly Administration in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|84|Actual|Yuhan Corporation||4|||f||||t||||||||||2018-05-31 21:45:56.460654|2018-05-31 21:45:56.460654
NCT01507389|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-12-08|2012-01-06|2012-01-10|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2006||2006-03-31|December 2014|2014-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function|A Single-centre, Open-label Trial Investigating the Pharmacokinetics and the Safety Profile After a Single Dose of Liraglutide in Subjects With Hepatic Impairment and in Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:45:43.734916|2018-05-31 21:45:43.734916
NCT01507376|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-04-24|2012-01-05|2012-01-10|Estimate|||||||2014-04-24|2014-04-25|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|||Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity|Comparing the Efficacy of Urinary and Recombinant hCG on Oocyte Maturity for Ovulation Induction in Assisted Reproductive Techniques: a Randomized Clinical Trial|Completed||Phase 3|180|Actual|Royan Institute||3|||f||||t||||||||||2018-05-31 21:45:43.874532|2018-05-31 21:45:43.874532
NCT01507363|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-04-10|2012-01-06|2012-01-10|Estimate|||||||2014-04-10|2014-04-11|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Analgesic Effect of Gabapentin in Total Knee Arthroplasty (TKA)|Analgesic Effect of Perioperative Gabapentin in Total Knee Arthroplasty: A Randomized, Double-blind, Placebo-controlled, Dose-response Study|Completed||Phase 4|300|Actual|Hvidovre University Hospital||3|||f||||t||||||||||2018-05-31 21:45:44.02012|2018-05-31 21:45:44.02012
NCT01507350|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-08-09|2012-01-09|2012-01-10|Estimate|||||||2017-08-09|2017-08-11|Actual|June 2011||2011-06-30|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|June 1, 2017|Actual|2017-06-01||Observational|||Effects of Obesity Surgery on Renal Function|Effects of Obesity Surgery on Renal Function|Completed|||45|Actual|Imperial College London|||3||f||||t||||||||No||2018-05-31 21:45:44.180834|2018-05-31 21:45:44.180834
NCT01507337|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-01-23|2012-01-06|2012-01-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2004||2004-04-30|January 2017|2017-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers|An Open Label, Single Dose Trial With Two Groups Comparing the Pharmacokinetics of Liraglutide in Young Versus Elderly Healthy Subjects of Both Sexes|Completed||Phase 1|32|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:44.369137|2018-05-31 21:45:44.369137
NCT01507311|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2017-01-23|2012-01-06|2012-01-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|September 1999||1999-09-30|January 2017|2017-01-31|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes|Effect of NNC90-1170 on Pulsatile Insulin Secretion in Type 2 Diabetic Patients. A Double-blind, Placebo-controlled, Randomised, Single-dose, Cross-over Trial|Completed||Phase 1|11|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:44.500266|2018-05-31 21:45:44.500266
NCT01507298|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2014-12-11|2012-01-09|2012-01-10|Estimate|||||||2014-12-11|2014-12-12|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Physical Activity and Gastrointestinal Investigations|An Observational Study to Compare the Outcomes of Ambulatory Gastrointestinal Investigations With Physical Activity Using Accelerometry.|Completed|||30|Actual|Imperial College London|||2||f||||f||||||||||2018-05-31 21:45:44.640836|2018-05-31 21:45:44.640836
NCT01507285|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-01-23|2012-01-06|2012-01-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 1999||1999-08-31|January 2017|2017-01-31|November 1999|Actual|1999-11-30|November 1999|Actual|1999-11-30||Interventional|||Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Dose-escalation, Parallel-group, Single and Multiple Dosing Trial of NN90-1170 in Healthy Volunteers and Patients With Type 2 Diabetes to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:44.766827|2018-05-31 21:45:44.766827
NCT01507272|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-01-23|2012-01-06|2012-01-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 1999||1999-03-31|January 2017|2017-01-31|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||Safety and Tolerability of Liraglutide in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Doses of NNC90-1170 to Assess Tolerability, Pharmacokinetics, Pharmacodynamics and Absolute Bioavailability in Healthy Male Subjects|Completed||Phase 1|34|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:45:45.058014|2018-05-31 21:45:45.058014
NCT01507259|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-07-26|2012-01-09|2012-01-10|Estimate|||||||2012-07-26|2012-07-27|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|February 2012|Actual|2012-02-29|||||Observational|||Chocolate's Effect on the Cerebral Vasculature|A Randomised Trial of Effect of Chocolate Upon Cerebrovascular Reactivity in Healthy Adult Volunteers|Completed|||24|Actual|NHS Greater Glasgow and Clyde|||1||f||||f||||||||||2018-05-31 21:45:45.337608|2018-05-31 21:45:45.337608
NCT01507246|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|2013-02-26||2013-05-06|2012-01-05|2012-01-10|Estimate|2013-05-06|2013-05-08|Estimate||||2013-05-06|2013-05-08|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|IMPROVE-Open||Adult Patients Undergoing Open Colectomy MA402S23B303|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy|Completed||Phase 4|42|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 21:45:45.421619|2018-05-31 21:45:45.421619
NCT01507233|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-11-30||2014-01-19|2012-01-05|2012-01-10|Estimate|2014-01-19|2014-03-06|Estimate||||2014-01-19|2014-03-06|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|IMPROVE-Open||A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy|Terminated||Phase 4|5|Actual|Pacira Pharmaceuticals, Inc||2||Slow enrollment.|f||||f||||||||||2018-05-31 21:45:46.122153|2018-05-31 21:45:46.122153
NCT01507220|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-11-29||2014-01-19|2012-01-05|2012-01-10|Estimate|2014-01-19|2014-03-06|Estimate||||2014-01-19|2014-03-06|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|IMPROVE-Open||A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy|Terminated||Phase 4|2|Actual|Pacira Pharmaceuticals, Inc||2||Slow enrollment|f||||f||||||||||2018-05-31 21:45:46.719009|2018-05-31 21:45:46.719009
NCT01507207|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-09-18|2012-01-05|2012-01-10|Estimate|||||||2017-09-18|2017-09-20|Actual|January 2012||2012-01-31|September 2017|2017-09-30|May 15, 2015|Actual|2015-05-15|May 15, 2015|Actual|2015-05-15||Interventional|||Pediatric Dysphagia Outcomes After Injection Laryngoplasty for Type I Laryngeal Cleft|Pediatric Dysphagia Outcomes After Injection Laryngoplasty for Type I Laryngeal Cleft|Completed||Phase 4|50|Actual|Oregon Health and Science University|||||f||||f||||||||||2018-05-31 21:45:47.171695|2018-05-31 21:45:47.171695
NCT01507194|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-09-30|2012-01-05|2012-01-10|Estimate|||||||2012-09-30|2012-10-02|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)|A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 mg) Dose of the Neurokinin-1 Receptor Antagonist, Vestipitant (GW597599), Compared With a Single 4 mg Intravenous Ondansetron Hydrochloride Dose for the Treatment of Breakthrough Post-Operative Nausea and Vomiting After Failed Prophylaxis With an Ondansetron-Containing Regimen in Patients Undergoing Non-Emergency Surgical Procedures|Completed||Phase 2|131|Actual|Accenture||6|||f||||||||||||||2018-05-31 21:45:47.398433|2018-05-31 21:45:47.398433
NCT01507181|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2016-04-18||2016-12-16|2012-01-09|2012-01-10|Estimate|2016-12-16|2017-02-08|Estimate||||2016-12-16|2017-02-08|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Ketamine For Suicidal Ideation|Investigating Rapid Anti-Suicidal Ideation Effects of Intravenous (IV) Ketamine in Hospitalized Patients|Completed||Phase 4|24|Actual|Icahn School of Medicine at Mount Sinai|Sample size is small, increasing the likelihood of a false negative finding due to limited power. Unknown if the lack of significant separation between the treatment and control conditions at 24 h represents a true null finding or a false negative.|2|||f||||t||||||||||2018-05-31 21:45:47.566653|2018-05-31 21:45:47.566653
NCT01507168|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2016-11-01|2012-01-06|2012-01-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma|A Randomised, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients With Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)|Completed||Phase 2|186|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:45:48.906012|2018-05-31 21:45:48.906012
NCT01507155|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2015-09-29||2016-05-05|2012-01-09|2012-01-10|Estimate|2016-03-29|2016-05-02|Estimate||||2016-05-05|2016-06-08|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|COM-1||An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay|An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay|Completed||N/A|685|Actual|Genomind, LLC||2|||f||||f||||||||||2018-05-31 21:45:49.359425|2018-05-31 21:45:49.359425
NCT01507142|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2018-02-13|2012-01-06|2012-01-10|Estimate|||||||2018-02-13|2018-02-15|Actual|October 2011|Actual|2011-10-31|February 2018|2018-02-28|October 2013|Actual|2013-10-31|September 2012|Actual|2012-09-30||Observational|||Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients|Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients|Completed|||100|Actual|Gaia Medical Institute|||4||f||||f||||||Samples Without DNA|"~     Saliva~   "|||2018-05-31 21:45:51.049715|2018-05-31 21:45:51.049715
NCT01507129|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-08-14|2012-01-06|2012-01-10|Estimate|||||||2012-08-14|2012-08-15|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Biomarkers for Noninvasive Assessment of Human Hydration|Biomarkers for Noninvasive Assessment of Human Hydration|Completed|||15|Actual|Gaia Medical Institute|||||f||||t||||||Samples With DNA|"~     Plasma, Serum, Urine, Saliva~   "|||2018-05-31 21:45:51.131774|2018-05-31 21:45:51.131774
NCT01507116|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-01-18|2012-01-05|2012-01-10|Estimate|||||||2017-01-18|2017-01-19|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|DAWN2||Diabetes Attitudes Wishes and Needs|Diabetes Attitudes Wishes and Needs (DAWN) 2 Study: A Multinational, Multi-stakeholder Survey Study of Psychosocial Issues in Diabetes and Patient-centred Diabetes Care|Completed|||8985|Actual|Novo Nordisk A/S|||3||f||||f||||||||||2018-05-31 21:45:51.214423|2018-05-31 21:45:51.214423
NCT01507103|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2015-09-21||2017-01-12|2012-01-06|2012-01-10|Estimate|2016-04-26|2016-06-02|Estimate||||2017-01-12|2017-01-13|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SPRINT|Safety analysis set included all subjects who received at least one dose of study treatment (tecemotide [L-BLP25] or CPA).|Tecemotide (L-BLP25) in Rectal Cancer|A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy|Completed||Phase 2|124|Actual|Merck KGaA|Not all efficacy data were analyzed as no acceptable ELISpot assay is available. The Sponsor decided to discontinue the development of tecemotide (L-BLP25) in September 2014|3|||f||||f||||||||||2018-05-31 21:45:51.370688|2018-05-31 21:45:51.370688
NCT01507090|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2014-07-22||2015-02-06|2012-01-09|2012-01-10|Estimate|2015-02-06|2015-02-10|Estimate||||2015-02-06|2015-02-10|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Observational|TAPE||Validation of the Mercy TAPE|Taking the Guesswork Out of Pediatric Weight Estimation (TAPE): Validation of the Mercy TAPE|Completed|||642|Actual|Children's Mercy Hospital Kansas City|||1||f||||f||||||||||2018-05-31 21:45:52.291822|2018-05-31 21:45:52.291822
NCT01507077|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-07-17|2012-01-09|2012-01-10|Estimate|||||||2012-07-17|2012-07-18|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity|ZGN-440 (Beloranib for Subcutaneous Injection), A Novel Methionine Aminopeptidase 2 Inhibitor for Treatment of Obesity: A Randomized Double-Blind Placebo Controlled Dose Escalation Phase 1b Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Initial Weight Loss|Completed||Phase 1|25|Actual|Zafgen, Inc.||2|||f||||t||||||||||2018-05-31 21:45:53.731747|2018-05-31 21:45:53.731747
NCT01507064|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-03-04|2012-01-06|2012-01-10|Estimate|||||||2017-03-04|2017-03-07|Actual|January 2012||2012-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|LANEX||Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma|Randomized Controlled Phase II Trial Of Neoadjuvant Sorafenib Therapy Prior to Thermal Ablation for Hepatocellular Carcinoma More Than 4 cm in Size|Completed||Phase 2|40|Actual|Cardarelli Hospital||2|||f||||f||||||||||2018-05-31 21:45:53.936431|2018-05-31 21:45:53.936431
NCT01507051|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2012-01-30||2015-01-26|2012-01-06|2012-01-10|Estimate|2012-03-29|2012-04-26|Estimate||||2015-01-26|2015-02-09|Estimate|November 2008||2008-11-30|January 2015|2015-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Switching Study From Warfarin to Rivaroxaban|Randomized, Placebo-controlled, Parallel-group Study in Healthy Male Subjects to Investigate the Pharmacodynamics During the Switching Procedure From Warfarin to Rivaroxaban|Completed||Phase 1|96|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:45:54.184841|2018-05-31 21:45:54.184841
NCT01506700|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2018-02-06|2012-01-09|2012-01-10|Estimate|||||||2018-02-06|2018-02-07|Actual|May 2012||2012-05-31|February 2018|2018-02-28|February 2019||2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Real Time Optical Coherence Tomography (OCT) of Human Tissue|Real Time Optical Coherence Tomography (OCT) of Human Tissue|Suspended|||20|Anticipated|Diagnostic Photonics, Inc.|||||f||||f||||||||||2018-05-31 21:46:09.782733|2018-05-31 21:46:09.782733
NCT01507025|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2014-02-12|2012-01-09|2012-01-10|Estimate|||||||2014-02-12|2014-02-13|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis|The Effect of Hinge Location on Corneal Sensation and Dry Eye After LASIK: A Systematic Review and Meta-analysis|Completed|||400|Anticipated|Wenzhou Medical University|||2||f||||||||||||||2018-05-31 21:45:56.576816|2018-05-31 21:45:56.576816
NCT01507012|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||The Effect Of Berry Polyphenols On Human Behaviour|A Double Blind, Placebo Controlled Study Measuring The Effect Of Berry Polyphenols On Mood And Cognition In Healthy Adults|Completed||N/A|36|Actual|Northumbria University||3|||f||||f||||||||||2018-05-31 21:45:56.656294|2018-05-31 21:45:56.656294
NCT01506999|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-05|2012-01-05|2012-01-10|Estimate|||||||2012-01-05|2012-01-10|Estimate|July 2006||2006-07-31|January 2012|2012-01-31|July 2012||2012-07-31|||||Observational|GENOCOR||Genetic Mapping for Cardiac Risk Assessment|GENOCOR Project-Laboratory of Genetic Mapping for Assessment of Cardiovascular Risk(GENOCOR LAB)|Unknown status|Recruiting||2000|Anticipated|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"|||3||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:45:56.779414|2018-05-31 21:45:56.779414
NCT01506986|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-11-29|2012-01-05|2012-01-10|Estimate|||||||2017-11-29|2017-11-30|Actual|March 2012||2012-03-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|October 31, 2017|Actual|2017-10-31||Interventional|HEAT||Helicobacter Eradication Aspirin Trial|Helicobacter Eradication to Prevent Ulcer Bleeding in Aspirin Users: a Large Simple Randomised Controlled Trial|Active, not recruiting||Phase 4|30024|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 21:45:56.935539|2018-05-31 21:45:56.935539
NCT01506973|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-02-01|2012-01-09|2012-01-10|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2011||2011-12-31|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Interventional|||A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer|A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:45:57.307919|2018-05-31 21:45:57.307919
NCT01506960|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|2013-05-16||2013-10-23|2012-01-09|2012-01-10|Estimate|2013-08-08|2013-10-18|Estimate||||2013-10-23|2013-11-18|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||47 subjects did not meet angiographic criteria for participation.|Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque|Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque|Terminated||Phase 4|64|Actual|Massachusetts General Hospital||1||It was felt that a sufficient number of subjects were enrolled.|f||||f||||||||||2018-05-31 21:45:58.517386|2018-05-31 21:45:58.517386
NCT01506947|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|2017-04-06||2017-04-06|2012-01-06|2012-01-10|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|May 10, 2012|Actual|2012-05-10|April 2017|2017-04-30|April 7, 2016|Actual|2016-04-07|April 7, 2016|Actual|2016-04-07||Interventional||The per-protocol analysis set which included participants who completed the study according to the protocol. One patient was enrolled into the study under protocol version 1.0 and was not included in the per-protocol analysis set due to subsequent major changes to the protocol.|A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients|A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients|Completed||Phase 4|65|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:45:59.782339|2018-05-31 21:45:59.782339
NCT01506934|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2012-08-24|2012-01-06|2012-01-10|Estimate|||||||2012-08-24|2012-08-28|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1, Open Label, Randomized, Adaptive, Cross-Over Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors|Terminated||Phase 1|14|Actual|Abbott||1||Sponsor decision|f||||f||||||||||2018-05-31 21:46:01.415684|2018-05-31 21:46:01.415684
NCT01506921|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2012-02-20|2012-01-05|2012-01-10|Estimate|||||||2012-02-20|2012-02-22|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Racemic Ketamine Versus S-ketamine With Arterial Spin Labeling (ASL)-MRI in Healthy Volunteers|A Prospective Randomised, Double-blinded Cross-over Study to Investigate the Effects of Racemic and S-ketamine on Cerebral Blood Flow on Healthy Volunteers With MRI-ASL|Completed||N/A|14|Anticipated|Lund University||2|||f||||t||||||||||2018-05-31 21:46:02.215738|2018-05-31 21:46:02.215738
NCT01506908|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2013-12-12||2014-02-06|2012-01-05|2012-01-10|Estimate|2013-12-12|2014-01-30|Estimate||||2014-02-06|2014-03-12|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Provoked Craving Assessment|Evaluation of the Nicotine Mini Lozenge in Relief of Provoked Acute Craving|Completed||Phase 2|323|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:46:02.56846|2018-05-31 21:46:02.56846
NCT01506895|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2016-11-18|2012-01-05|2012-01-10|Estimate|||||||2016-11-18|2016-11-21|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema|A Phase 2, Multi-national, Multi-centre, Double Masked, Randomised, Placebo Controlled, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Darapladib Administered for 3 Months to Adult Subjects With Diabetic Macular Edema With Centre Involvement|Completed||Phase 2|54|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:46:03.725447|2018-05-31 21:46:03.725447
NCT01506882|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2014-10-07||2015-11-24|2012-01-09|2012-01-10|Estimate|2014-10-07|2014-10-13|Estimate||||2015-11-24|2015-12-31|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|October 2013|Actual|2013-10-31||Interventional||Baseline Characteristics refer to the Safety Set (SS). SS consists of all subjects in the Enrolled Set, who received at least 1 dose of the Investigational Medicinal Product (IMP).|An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy|An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16 Years With Partial Seizures|Completed||Phase 3|71|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:46:04.363895|2018-05-31 21:46:04.363895
NCT01506869|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Observational|REACTION||Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal Study|A Prospective Cohort Study on the Associations of Diabetes With Cancer Risk in Chinese Men and Women|Unknown status|Recruiting||200000|Anticipated|Shanghai Jiao Tong University School of Medicine|||3||f||||t||||||Samples With DNA|"~     Blood and urine samples were collected and retained for biomarker analysis~   "|||2018-05-31 21:46:06.398106|2018-05-31 21:46:06.398106
NCT01506856|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-07-31|2012-01-05|2012-01-10|Estimate|||||||2017-07-31|2017-08-02|Actual|May 2010||2010-05-31|July 2017|2017-07-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|iPocc||Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial|A Randomized Phase II/III Trial of Intravenous (IV) Paclitaxel Weekly Plus IV Carboplatin Once Every 3 Weeks Versus IV Paclitaxel Weekly Plus Intraperitoneal (IP) Carboplatin Once Every 3 Weeks in Women With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 2/Phase 3|654|Anticipated|Gynecologic Oncology Trial & Investigation Consortium||2|||f||||t||||||||||2018-05-31 21:46:06.712709|2018-05-31 21:46:06.712709
NCT01506843|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|October 2008||2008-10-31|August 2007|2007-08-31|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|SLIT||Sublingual Immunotherapy in Children With Allergic Rhinitis|Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-allergic Children in a Randomized Double-blind, Placebo-controlled Study in Brazil|Completed||N/A|122|Actual|Federal University of Uberlandia||3|||f||||t||||||||||2018-05-31 21:46:06.959336|2018-05-31 21:46:06.959336
NCT01506830|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2016-02-23|2012-01-09|2012-01-10|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Cervical Restorations Placed Under Two Isolation Methods|Influence of Operatory Field Isolation Techniques on the Clinical Performance of Class V Restorations|Completed||Phase 2/Phase 3|30|Actual|Federal University of Pelotas||2|||f||||f||||||||||2018-05-31 21:46:07.136846|2018-05-31 21:46:07.136846
NCT01506817|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-05|2012-01-05|2012-01-10|Estimate|||||||2012-01-05|2012-01-10|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Dynamic Contrast Enhanced (DCE)-MRI in Fibromyalgia|Dynamic Contrast Enhanced MRI of the Hands in Patients With Fibromyalgia. A Pilot Study|Unknown status|Enrolling by invitation||20|Anticipated|Frederiksberg University Hospital|||2||f||||||||||||||2018-05-31 21:46:07.313107|2018-05-31 21:46:07.313107
NCT01506804|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-08-09|2012-01-05|2012-01-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Exercise Therapy and Ultrasound Guided Injections in Painful Shoulder|The Efficacy of Exercise Therapy Followed by Ultrasound Guided Injection in Patients With a Painful Shoulder - a Randomised Controlled Study With Blinded Observer|Completed||N/A|99|Actual|Frederiksberg University Hospital||2|||f||||f||||||||||2018-05-31 21:46:07.452275|2018-05-31 21:46:07.452275
NCT01506791|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-01-05|2012-01-05|2012-01-10|Estimate|||||||2012-01-05|2012-01-10|Estimate|April 2006||2006-04-30|June 2006|2006-06-30|April 2006|Actual|2006-04-30|||||Interventional|||Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D® 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fed Conditions|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:46:07.664561|2018-05-31 21:46:07.664561
NCT01506778|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Tenaculum||Tenaculum in Endometrial Sampling Procedure|Using a Tenaculum Which is Actually Necessary for Endometrial Sampling Procedure by Pipelle.|Completed||N/A|115|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 21:46:07.736519|2018-05-31 21:46:07.736519
NCT01506765|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-17|2012-01-05|2012-01-10|Estimate|||||||2012-01-17|2012-01-18|Estimate|August 2003||2003-08-31|January 2012|2012-01-31|September 2006|Actual|2006-09-30|December 2004|Actual|2004-12-31||Interventional|||Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia|Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia: Double-blind and Crossover Study|Completed||Phase 1|13|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 21:46:07.906286|2018-05-31 21:46:07.906286
NCT01506752|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-06-25|2012-01-09|2012-01-10|Estimate|||||||2012-06-25|2012-06-27|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males|A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males|Completed||Phase 1|20|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 21:46:08.172419|2018-05-31 21:46:08.172419
NCT01506739|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males|A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males|Completed||Phase 1|12|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 21:46:08.425409|2018-05-31 21:46:08.425409
NCT01506726|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2015-10-26||2016-08-31|2012-01-09|2012-01-10|Estimate|2015-10-26|2015-11-26|Estimate||||2016-08-31|2016-10-18|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia|A Randomized, Double-Blind, Placebo Controlled Pilot Trial of Oral Salsalate in the Treatment of the Subset of Unexplained Anemia in Elderly Patients With Elevated Interleukin-6|Terminated||Phase 2|11|Actual|Duke University||2||Study drug expiration and supply shortage|f||||t||||||||||2018-05-31 21:46:08.608802|2018-05-31 21:46:08.608802
NCT01506713|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions|Randomized, Open-label, 2-Way Crossover, Bioequivalence Study of Clopidogrel 75 mg Tablet With Plavix® 75 mg In Healthy Subjects Under Fasting Conditions|Completed||Phase 1|53|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:46:09.671695|2018-05-31 21:46:09.671695
NCT01506687|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-12-02|2012-01-09|2012-01-10|Estimate|||||||2013-12-02|2013-12-03|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Increasing Colorectal Cancer Screening Uptake With a Patient Navigator|Increasing Colorectal Cancer Screening Uptake With a Patient Navigator - Phase III Trial|Completed||Phase 3|750|Anticipated|Cancer Care Ontario||2|||f||||f||||||||||2018-05-31 21:46:10.008396|2018-05-31 21:46:10.008396
NCT01506674|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2018-02-26|2012-01-09|2012-01-10|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2015||2015-01-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Metabolomic in Critical Ill Patients||Recruiting|||||Università Vita-Salute San Raffaele|||1||f||||||||||||||2018-05-31 21:46:10.175491|2018-05-31 21:46:10.175491
NCT01506661|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-09-15|2012-01-09|2012-01-10|Estimate|||||||2017-09-15|2017-09-18|Actual|January 2012||2012-01-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|||Zostavax in Rheumatoid Arthritis|Immune Response to Varicella Zoster Vaccination (ZOSTAVAX) in Subjects With Rheumatoid Arthritis|Active, not recruiting||Phase 1|20|Actual|Oklahoma Medical Research Foundation||2|||f||||t||||||||Undecided||2018-05-31 21:46:10.519984|2018-05-31 21:46:10.519984
NCT01506648|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2016-11-25|2012-01-09|2012-01-10|Estimate|||||||2016-11-25|2016-11-28|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Observational|||Assessment of Zinc Absorption From a Phytic Acid Rich Complementary Food|Assessment of Zinc Absorption From a Phytic Acid Rich Complementary Food, Consumed by Young Children Immediately After the Addition of the Enzyme Phytase. A Randomized Single Blind Study|Completed|||40|Actual|Swiss Federal Institute of Technology|||||f||||||||||||||2018-05-31 21:46:10.676264|2018-05-31 21:46:10.676264
NCT01506635|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|March 2010||2010-03-31|October 2009|2009-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After LASIK: a Randomized Clinical Trial|Effect of Timolol on Refractive Outcomes in Eyes With Myopic Regression After Laser in Situ Keratomileusis: A Randomized Clinical Trial|Completed||N/A|45|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:46:10.84348|2018-05-31 21:46:10.84348
NCT01506622|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2015-07-14|2012-01-09|2012-01-10|Estimate|||||||2015-07-14|2015-07-16|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison Between Propofol and Fentanyl for Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia||Completed||N/A|222|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 21:46:11.227961|2018-05-31 21:46:11.227961
NCT01506609|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2018-02-12|2012-01-09|2012-01-10|Estimate|||||||2018-02-12|2018-02-14|Actual|January 23, 2012|Actual|2012-01-23|February 2018|2018-02-28|August 10, 2018|Anticipated|2018-08-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer|A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer|Active, not recruiting||Phase 2|294|Actual|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 21:46:11.498601|2018-05-31 21:46:11.498601
NCT01506596|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|2016-04-18||2016-12-29|2012-01-09|2012-01-10|Estimate|2016-04-18|2016-05-25|Estimate||||2016-12-29|2017-02-15|Actual|March 2012||2012-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|October 2014|Actual|2014-10-31||Interventional|||Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma|A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma|Completed||Phase 2|42|Actual|Vector Oncology||1|||f||||f||||||||No||2018-05-31 21:46:12.06873|2018-05-31 21:46:12.06873
NCT01506583|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-06|||2012-01-09|2012-01-09|2012-01-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Observational|QFlu||Clinical Evaluation of QFlu Combo Test|Clinical Evaluation of QFlu Combo Test|Unknown status|Recruiting||1000|Anticipated|Cellex, Inc.|||3||f||||f||||||Samples Without DNA|"~     Samples were retained in case that the testing needs to be repeated. They are to be discarded~     12 months after the study is completed.~   "|||2018-05-31 21:46:12.65202|2018-05-31 21:46:12.65202
NCT01506570|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2015-08-19|2012-01-09|2012-01-10|Estimate|||||||2015-08-19|2015-08-20|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-experienced Adult Subjects|Completed||Phase 1|58|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 21:46:12.725895|2018-05-31 21:46:12.725895
NCT01506557|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-07-22|2012-01-09|2012-01-10|Estimate|||||||2013-07-22|2013-07-23|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|MAVID||Vitamin D Supplementation of Lactating Mothers|Effect of Vitamin D Supplementation During Lactation on Vitamin D Status, Bone Mineralisation and Body Composition of Mother and Their Exclusively Breastfed Infants.|Completed||Phase 4|174|Actual|Children's Memorial Health Institute, Poland||2|||f||||f||||||||||2018-05-31 21:46:12.820425|2018-05-31 21:46:12.820425
NCT01506544|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2014-12-10|2012-01-05|2012-01-10|Estimate|||||||2014-12-10|2014-12-12|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|HU||Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia|Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients With Sickle Cell Anemia|Completed||Phase 1|39|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-05-31 21:46:12.900398|2018-05-31 21:46:12.900398
NCT01506531|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2017-01-06|2012-01-09|2012-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Silo Versus Primary Closure for Gastroschisis|Bedside Silo Versus Attempted Operative Closure for Gastroschisis|Recruiting||N/A|100|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||No||2018-05-31 21:46:12.982249|2018-05-31 21:46:12.982249
NCT01506518|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-01-16|2012-01-05|2012-01-10|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2012||2012-01-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular Dystrophy|Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy|Recruiting|||60|Anticipated|University of North Carolina, Chapel Hill|||4||f||||f||||||||||2018-05-31 21:46:13.066214|2018-05-31 21:46:13.066214
NCT01506505|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-08-12|2012-01-05|2012-01-10|Estimate|||||||2013-08-12|2013-08-13|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TEMPUS||The Evening Versus Morning Polypill Utilization Study|A Randomised Controlled Cross-over Trial to Evaluate Evening Versus Morning Administration of a Cardiovascular Polypill|Completed||N/A|78|Actual|UMC Utrecht||3|||f||||t||||||||||2018-05-31 21:46:13.149025|2018-05-31 21:46:13.149025
NCT01506492|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-11-10|2012-01-05|2012-01-10|Estimate|||||||2016-11-10|2016-11-15|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|CALM||Managing Cancer and Living Meaningfully (CALM): A Study to Evaluate the Effectiveness of a Psychological Intervention for Cancer Patients|Managing Cancer and Living Meaningfully (CALM): A Randomized Controlled Trial of a Psychotherapeutic Intervention for Patients With Metastatic Cancer|Completed||Phase 3|305|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 21:46:13.221858|2018-05-31 21:46:13.221858
NCT01506479|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2017-06-23||2017-09-12|2012-01-05|2012-01-10|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|May 2012|Actual|2012-05-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SPARX||Study in Parkinson's Disease of Exercise|Exploratory Study of Different Doses of Endurance Exercise in People With Parkinson Disease|Completed||N/A|128|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 21:46:13.312331|2018-05-31 21:46:13.312331
NCT01506466|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-07-23|2012-01-05|2012-01-10|Estimate|||||||2015-07-23|2015-07-24|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|||Weight Variation During Chemotherapy in Breast Cancer Patients|Weight Variation and Mechanisms Involved, During Chemotherapy in Breast Cancer Patients|Completed||N/A|52|Actual|Centre Jean Perrin||1|||f||||f||||||||||2018-05-31 21:46:15.054316|2018-05-31 21:46:15.054316
NCT01506453|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2018-01-08|2012-01-05|2012-01-10|Estimate|||||||2018-01-08|2018-01-09|Actual|January 24, 2012|Actual|2012-01-24|January 2018|2018-01-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|TINALL||Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)|Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol|Completed||Phase 2|51|Actual|St. Jude Children's Research Hospital||2|||f||||f|t|f||||||||2018-05-31 21:46:15.481505|2018-05-31 21:46:15.481505
NCT01506440|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-05-25|2012-01-09|2012-01-10|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2011|Actual|2011-10-31|February 2017|2017-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy|Feasibility Study of a Cognitive Assessment Tool During Systemic Chemotherapy for Cancer Patients|Completed|||29|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 21:46:15.88455|2018-05-31 21:46:15.88455
NCT01506427|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2012-12-12|2012-01-09|2012-01-10|Estimate|||||||2012-12-12|2012-12-17|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|||A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients|A Phase I/II, Open Label, Nonrandomized, Multi-Center Study of [F-18]HX4 Positron Emission Tomography (PET) in Head and Neck Cancer Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Siemens Molecular Imaging||1|||f||||f||||||||||2018-05-31 21:46:16.092555|2018-05-31 21:46:16.092555
NCT01506414|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-04-18|2012-01-09|2012-01-10|Estimate|||||||2016-04-18|2016-04-20|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)|A Multicentre Investigation of Recombinant Human Thrombopoietin (Rh-TPO) Combine With Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)|Completed||Phase 3|91|Actual|Shandong University||1|||f||||t||||||||||2018-05-31 21:46:16.279037|2018-05-31 21:46:16.279037
NCT01506401|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-08-05|2012-01-09|2012-01-10|Estimate|||||||2015-08-05|2015-08-06|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|OSCILLATE||The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial|The Oscillation for ARDS Treated Early (OSCILLATE) Trial|Terminated||Phase 3|548|Actual|Canadian Critical Care Trials Group||2||Enrolment halted by Steering Committee on advice from Data Monitoring Committee.|f||||t||||||||||2018-05-31 21:46:16.516633|2018-05-31 21:46:16.516633
NCT01506388|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-01-19|2012-01-05|2012-01-10|Estimate|||||||2014-01-19|2014-01-22|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||A Novel Protocol for Labour Induction|Foley Catheter Plus Vaginal Isosorbide Mononitrate Versus Vaginal Misoprostol for Induction of Labour:a Randomised Controlled Trial|Completed||Phase 3|400|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 21:46:17.00493|2018-05-31 21:46:17.00493
NCT01506375|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2014-05-23|2012-01-05|2012-01-10|Estimate|||||||2014-05-23|2014-05-26|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant|Safety, Clinical Tolerability and Immunogenicity of gpASIT+TM Administered Subcutaneously to Hay Fever Patients Either Alone or in Presence of DnaK Immunoregulating Adjuvant|Completed||Phase 2|24|Actual|BioTech Tools S.A.||2|||f||||f||||||||||2018-05-31 21:46:17.451241|2018-05-31 21:46:17.451241
NCT01506362|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|2014-03-31||2014-07-01|2012-01-09|2012-01-10|Estimate|2014-03-31|2014-05-01|Estimate||||2014-07-01|2014-07-15|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis|An Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis|Completed||Phase 2|22|Actual|BioLineRx, Ltd.||1|||f||||f||||||||||2018-05-31 21:46:17.865573|2018-05-31 21:46:17.865573
NCT01506349|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-03-16|2012-01-09|2012-01-10|Estimate|||||||2018-03-16|2018-03-20|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|October 2017|Actual|2017-10-31||Interventional|||Assessing Neurocognitive Effects of Gluten Exposure|An Assessment of Neurocognitive Symptoms After Gluten Exposure in Adult Patients With Celiac Disease - a Pilot Study|Terminated||N/A|2|Actual|Beth Israel Deaconess Medical Center||2||enrollment|f||||f||||||||||2018-05-31 21:46:18.271159|2018-05-31 21:46:18.271159
NCT01506336|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-09-25|2012-01-05|2012-01-10|Estimate|||||||2012-09-25|2012-09-26|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|September 2011|Actual|2011-09-30||Interventional|||A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib|A Prospective, Multicenter, Randomized, Open-label, Active Controlled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of Masitinib at 12 mg/kg/Day to Sunitinib at 50 mg/Day in Treatment of Patients With Gastro-intestinal Stromal Tumor Resistant to Imatinib|Unknown status|Active, not recruiting|Phase 2|44|Actual|AB Science||2|||f||||t||||||||||2018-05-31 21:46:18.396854|2018-05-31 21:46:18.396854
NCT01506323|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2015-07-08||2015-08-26|2012-01-09|2012-01-10|Estimate|2015-08-26|2015-09-02|Estimate||||2015-08-26|2015-09-02|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|March 2014|Actual|2014-03-31||Interventional|||Mantram Repetition Meditation for Veterans With PTSD|Portable Mantram Meditation for Veterans With Military Related PTSD|Completed||Phase 3|181|Actual|VA Office of Research and Development|"Study was to provide interventions for both conditions (MRP and PCT) in group format. Due to poor recruitment and after approval from Data Monitoring Committee, the study protocol was changed to provide both interventions in individual format."|2|||f||||t||||||||||2018-05-31 21:46:18.561365|2018-05-31 21:46:18.561365
NCT01506310|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2013-01-22|2012-01-09|2012-01-10|Estimate|||||||2013-01-22|2013-01-23|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Efficacy of Behavioral Therapy and Exercise in Gestational Diabetes Mellitus (GDM)|Randomized Comparative Trial on the Efficacy of Behavioral Therapy, Exercise and Their Combination in Gestational Diabetes Mellitus (GDM).|Completed||Phase 3|200|Actual|University of Turin, Italy||4|||f||||f||||||||||2018-05-31 21:46:19.874196|2018-05-31 21:46:19.874196
NCT01506297|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-09-20|2012-01-04|2012-01-09|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2012|Actual|2012-07-31|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Biologic Assessment of Satiety|Biologic Assessment of Satiety|Completed|||31|Actual|USDA Grand Forks Human Nutrition Research Center|||||f||||t||||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 21:46:19.97721|2018-05-31 21:46:19.97721
NCT01506284|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-12-08|2012-01-04|2012-01-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|November 2012|Actual|2012-11-30|March 2012|Actual|2012-03-31||Observational|||Assessment of Airways Mechanical Properties by FOT and LIR During Anesthesia|Assessment of Airways Mechanical Properties by Forced Oscillatory Technique (FOT) and Laser Interferometry (LIR) During Anesthesia.|Completed|||14|Actual|Uppsala University Hospital|||1||f||||f||||||||||2018-05-31 21:46:20.147018|2018-05-31 21:46:20.147018
NCT01506271|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2016-11-03|2012-01-06|2012-01-09|Estimate|||||||2016-11-03|2016-11-04|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)|A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Intra-Abdominal Infection [cIAI]|Completed||Phase 2|351|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 21:46:20.361584|2018-05-31 21:46:20.361584
NCT01506258|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-18|2012-01-05|2012-01-09|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Interventional|||Autologous Stem Cells in Newborns With Oxygen Deprivation|Effects of the Infusion of Autologous Non-cryopreserved CD34+ Cells in Newborns With Asphyxia|Unknown status|Recruiting|N/A|20|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t||||||||||2018-05-31 21:46:20.485264|2018-05-31 21:46:20.485264
NCT01506245|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-31|||2012-01-04|2012-01-04|2012-01-09|Estimate|||||||2012-01-04|2012-01-09|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Exercise and Behavioral Therapy in Obese Children|Exercise Training and Family-based Behavioural Treatment in Pre-pubertal Obese Children and Their Mother|Unknown status|Enrolling by invitation|N/A|75|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 21:46:20.596301|2018-05-31 21:46:20.596301
NCT01506232|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-10-24|2012-01-05|2012-01-09|Estimate|||||||2013-10-24|2013-10-25|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study|Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study|Terminated|||1|Actual|Massachusetts General Hospital|||4|Due to slow enrollment and lack of funding the study was terminated prior to completion.|f||||f||||||||||2018-05-31 21:46:21.72015|2018-05-31 21:46:21.72015
NCT01506219|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2018-01-18|2012-01-06|2012-01-09|Estimate|||||||2018-01-18|2018-01-23|Actual|January 17, 2012|Actual|2012-01-17|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|May 29, 2015|Actual|2015-05-29||Interventional|GCGCCRU||Geriatrician-performed Comprehensive Geriatric Care in an Outpatient Community Rehabilitation Unit|Geriatrician-performed Comprehensive Geriatric Care in Older Adults Referred to an Outpatient Community Rehabilitation Unit|Completed||N/A|368|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 21:46:21.827217|2018-05-31 21:46:21.827217
NCT01506206|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2017-01-13|2012-01-06|2012-01-09|Estimate|||||||2017-01-13|2017-01-16|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||ON/OFF Stimulation and Impulsivity in Patients With Deep Brain Stimulators|ON/OFF Stimulation and Impulsivity in Patients With Deep Brain Stimulators|Recruiting|||60|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 21:46:21.983704|2018-05-31 21:46:21.983704
NCT01506193|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2016-11-08|2014-05-29|2017-06-01|2012-01-05|2012-01-09|Estimate|2016-11-08|2017-01-09|Estimate|2014-05-29|2014-06-02|Estimate|2017-06-01|2017-06-28|Actual|February 6, 2012|Actual|2012-02-06|June 2017|2017-06-30|March 31, 2014|Actual|2014-03-31|February 17, 2014|Actual|2014-02-17||Interventional|||Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children|Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children|Completed||Phase 3|716|Actual|GlaxoSmithKline||3|||f|||||f|f||||||||2018-05-31 21:46:22.129527|2018-05-31 21:46:22.129527
NCT01506180|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-01-06|2012-01-06|2012-01-09|Estimate|||||||2012-01-06|2012-01-09|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||In-Hospital Comprehensive Geriatric Assessment in Aged Acute Medical Patients||Completed|||3877|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 21:46:23.521517|2018-05-31 21:46:23.521517
NCT01506167|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2018-05-08|2012-01-05|2012-01-09|Estimate|||||||2018-05-08|2018-05-14|Actual|July 6, 2012|Actual|2012-07-06|May 2018|2018-05-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)|An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma|Completed|||719|Actual|Hoffmann-La Roche|||7||f|||||f|||||||||2018-05-31 21:46:23.634759|2018-05-31 21:46:23.634759
NCT01506154|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2018-01-12|2012-01-05|2012-01-09|Estimate|||||||2018-01-12|2018-01-16|Actual|December 2011||2011-12-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Topical Patch in the Treatment of Pain Due to Recent Onset Supraspinatous and/or Subacromial Tendonitis/Bursitis and/or Subdeltoid Bursitis of Shoulder|Completed||Phase 3|210|Actual|MEDRx USA, Inc.||2|||f||||f||||||||||2018-05-31 21:46:23.932327|2018-05-31 21:46:23.932327
NCT01506141|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-02-14|2012-01-06|2012-01-09|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2010||2010-08-31|February 2017|2017-02-28|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Extension of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase (IT)in Conjunction With Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment|An Open Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Shire||1|||f||||f||||||||||2018-05-31 21:46:24.067455|2018-05-31 21:46:24.067455
NCT01506128|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2013-03-04|2012-01-04|2012-01-09|Estimate|||||||2013-03-04|2013-03-05|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Human Papillomavirus in Menstrual Blood|Exploration of Optimal Experimental Settings to Detect Human Papillomavirus From Menstrual Blood in Women With High-grade Squamous Intraepithelial Lesion or High-risk Human Papillomavirus Infection|Completed|||19|Actual|Seoul National University Hospital|||1||f||||f||||||Samples With DNA|"~     Menstrual blood in pad~   "|||2018-05-31 21:46:24.258534|2018-05-31 21:46:24.258534
NCT01506115|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2015-11-17|2012-01-06|2012-01-09|Estimate|||||||2015-11-17|2015-11-20|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma|Observational Study for Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma|Completed||N/A|11|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 21:46:24.583878|2018-05-31 21:46:24.583878
NCT01506102|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-06|2012-01-06|2012-01-09|Estimate|||||||2012-01-06|2012-01-09|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Thromboelastography During and After Delivery|Determination of Thromboelastography Values in Pregnancy and After Delivery|Unknown status|Recruiting|N/A|120|Anticipated|Città di Roma Hospital|||||f||||f||||||||||2018-05-31 21:46:24.756828|2018-05-31 21:46:24.756828
NCT01506089|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-03-25|2012-01-06|2012-01-09|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Optimizing the Temperature for Embryo Culture in In Vitro Fertilization|Optimizing the Temperature for Embryo Culture in In Vitro Fertilization: A Randomized Controlled Trial|Completed||N/A|55|Actual|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 21:46:25.040343|2018-05-31 21:46:25.040343
NCT01506076|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-06|2012-01-06|2012-01-09|Estimate|||||||2012-01-06|2012-01-09|Estimate|December 2007||2007-12-31|January 2012|2012-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|29|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:46:25.170299|2018-05-31 21:46:25.170299
NCT01506063|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-10|2012-01-06|2012-01-09|Estimate|||||||2012-01-10|2012-01-11|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fed Conditions|Completed||Phase 1|31|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:46:25.396625|2018-05-31 21:46:25.396625
NCT01506050|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-06|2012-01-06|2012-01-09|Estimate|||||||2012-01-06|2012-01-09|Estimate|January 2006||2006-01-31|May 2006|2006-05-31|February 2006|Actual|2006-02-28|||||Interventional|||Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition|Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fasting Conditions|Completed||Phase 1|35|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:46:26.320557|2018-05-31 21:46:26.320557
NCT01506037|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-10|2012-01-06|2012-01-09|Estimate|||||||2012-01-10|2012-01-11|Estimate|January 2006||2006-01-31|May 2006|2006-05-31|February 2006|Actual|2006-02-28|||||Interventional|||Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition|Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fed Conditions|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:46:27.925943|2018-05-31 21:46:27.925943
NCT01506024|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2017-11-07|2012-01-04|2012-01-09|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2011|Actual|2011-09-30|November 2017|2017-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term Results|Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Short- and Long Term Results|Completed||N/A|60|Actual|Norwegian University of Science and Technology||3|||f||||f|f|f||||||Undecided||2018-05-31 21:46:28.518647|2018-05-31 21:46:28.518647
NCT01506011|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-05|2012-01-05|2012-01-09|Estimate|||||||2012-01-05|2012-01-09|Estimate|March 2007||2007-03-31|January 2012|2012-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fasting Conditions|An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fasting Conditions.|Completed||Phase 1|50|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:46:28.642294|2018-05-31 21:46:28.642294
NCT01505998|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-06|2012-01-06|2012-01-09|Estimate|||||||2012-01-06|2012-01-09|Estimate|March 2007||2007-03-31|January 2012|2012-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Bioequivalence Study of Amlodipine Besylate/Benazepril HCl 10 mg/40 mg Capsules of Dr. Reddy's Under Fed Conditions|An Open-label Randomized, Single Dose, Two Way Crossover Oral Bioequivalence Study of Amlodipine Besylate/Benazepril HCl Capsules of Dr. Reddy's With Lotrel® Capsules of Novartis in Human Subjects Under Fed Conditions|Completed||Phase 1|49|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:46:28.806127|2018-05-31 21:46:28.806127
NCT01505985|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-11-22|2012-01-06|2012-01-09|Estimate|||||||2013-11-22|2013-11-25|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|HIATUS||Hip Fracture Surgery and Oral Nutritional Supplements|Effect of a Nutritional Intervention on Hip Fracture Surgery Recovery|Terminated||Phase 3|24|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 21:46:28.980343|2018-05-31 21:46:28.980343
NCT01505972|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2012-01-06|2012-01-04|2012-01-09|Estimate|||||||2012-01-06|2012-01-10|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Time Schedules for Sending Invitations to Colonoscopy Screening||Completed||N/A|1600|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 21:46:29.151132|2018-05-31 21:46:29.151132
NCT01505959|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2014-09-04|2012-01-06|2012-01-09|Estimate|||||||2014-09-04|2014-09-05|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Blood Pressure Reduction Induced by CPAP in Sleep Apnea Patients at High Cardiovascular Risk : OPTISAS 2 Study|Blood Pressure Reduction Induced by Continuous Positive Airway Pressure (CPAP) in Sleep Apnea Patients at High Cardiovascular Risk : A Randomized Controlled Trial Comparing Usual CPAP Care Versus a Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform|Unknown status|Recruiting|Phase 4|936|Anticipated|Fédération Française de Pneumologie||2|||f||||t||||||||||2018-05-31 21:46:29.428947|2018-05-31 21:46:29.428947
NCT01505946|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-06-14|2012-01-06|2012-01-09|Estimate|||||||2013-06-14|2013-06-17|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|PredicTGA||Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors|Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic Effectiveness of Factor VIII (FVIII) Concentrates in Patients Affected by Inherited Haemophilia A With FVIII Inhibitors High and Low Anamnestic Response.|Unknown status|Recruiting||25|Anticipated|Grifols Italia S.p.A|||2||f||||t||||||Samples Without DNA|"~     plasma samples~   "|||2018-05-31 21:46:29.818186|2018-05-31 21:46:29.818186
NCT01505933|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-02-14|2012-01-04|2012-01-09|Estimate|||||||2017-02-14|2017-02-16|Actual|February 2012|Actual|2012-02-29|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Airway Dimension Study in Children Undergoing MRI Sedated With Propofol and Dexmedetomidine|Comparison of Changes in Upper Airway Dimensions With Dexmedetomidine and Propofol in Children Undergoing MRI|Recruiting||N/A|40|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||No||2018-05-31 21:46:30.16393|2018-05-31 21:46:30.16393
NCT01505920|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-01-13|2012-01-06|2012-01-09|Estimate|||||||2013-01-13|2013-01-15|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial|Lidocaine Spray Compared With Submucosal Injection in Reducing Pain During Loop Electrosurgical Excision Procedure: a Randomized Controlled Trial|Completed||Phase 3|101|Actual|Chiang Mai University||2|||f||||f||||||||||2018-05-31 21:46:30.441586|2018-05-31 21:46:30.441586
NCT01505907|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2012-01-06|2012-01-06|2012-01-09|Estimate|||||||2012-01-06|2012-01-09|Estimate|December 2012||2012-12-31|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Pharmacokinetic Study of CXB909 in Healthy Male Subjects|Phase I, Randomized, Double-Blind, Placebo Controlled, Dose Escalation,Single Dose, Safety, Tolerance, and Pharmacokinetic Study of CXB909 in Healthy Male Volunteers|Unknown status|Not yet recruiting|Phase 1/Phase 2|40|Anticipated|CeNeRx BioPharma Inc.||5|||f||||t||||||||||2018-05-31 21:46:30.572331|2018-05-31 21:46:30.572331
NCT01505894|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|||2013-10-31|2012-01-05|2012-01-09|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses|Safety, Tolerability Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 409306 Film-coated Tablets Given Orally q.d. or Bid for 14 Days in Young Healthy and Elderly Healthy Male/Female Volunteers (Randomised, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)|Completed||Phase 1|83|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:46:30.777095|2018-05-31 21:46:30.777095
NCT01505881|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-05|2014-06-06||2014-07-10|2012-01-05|2012-01-09|Estimate|2014-07-10|2014-07-11|Estimate||||2014-07-10|2014-07-11|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Treated set (TRT): The TRT comprised all patients who were documented to have taken at least 1 dose of study drug|Follow on Study From RE-ALIGN|Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve|Terminated||Phase 2|158|Actual|Boehringer Ingelheim|This study was terminated prematurely due to safety concerns arising during conduct of the trial.|2|||f||||||||||||||2018-05-31 21:46:30.954442|2018-05-31 21:46:30.954442
NCT01505868|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-04-17|2012-01-04|2012-01-09|Estimate|||||||2018-04-17|2018-04-19|Actual|July 2012|Actual|2012-07-31|April 2018|2018-04-30|July 2030|Anticipated|2030-07-31|July 2029|Anticipated|2029-07-31||Interventional|||Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer|An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|178|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:46:31.557617|2018-05-31 21:46:31.557617
NCT01505855|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2014-10-14|2012-01-04|2012-01-09|Estimate|||||||2014-10-14|2014-10-16|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy Study of Pneumococcal Vaccination in Crohn's Disease|Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study|Completed||Phase 4|197|Actual|Kyunghee University Medical Center||4|||f||||t||||||||||2018-05-31 21:46:31.739946|2018-05-31 21:46:31.739946
NCT01505842|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2015-08-05|2012-01-04|2012-01-09|Estimate|||||||2015-08-05|2015-08-06|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|February 2017|Anticipated|2017-02-28|June 2016|Anticipated|2016-06-30||Interventional|||Chromoendoscopy for Dysplasia Detection in Chronic Inflammatory Bowel Disease|Randomized Controlled Trial (RCT) to Compare Dysplasia Detection Rate in Colonoscopy Without Chromoendoscopy Versus Colonoscopy With Chromoendoscopy in Detecting Dysplasia in Ulcerative Colitis and Crohn's Colitis Patients.|Unknown status|Recruiting|N/A|300|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 21:46:32.019863|2018-05-31 21:46:32.019863
NCT01505829|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-09-14|2012-01-04|2012-01-09|Estimate|||||||2017-09-14|2017-09-15|Actual|August 2012|Actual|2012-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|DISCOVAR||Diffusion-weighted Imaging Study in Cancer of the Ovary|Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging.|Active, not recruiting|||134|Actual|Institute of Cancer Research, United Kingdom|||2||f||||f||||||Samples With DNA|"~     Tumour samples taken at surgery for histological analysis~   "|||2018-05-31 21:46:32.183258|2018-05-31 21:46:32.183258
NCT01505816|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-06|2012-01-06|2012-01-09|Estimate|||||||2012-01-06|2012-01-09|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Visual Outcomes After Implantation of a New Multifocal Intraocular Lens|Visual Outcomes After Implantation of a New Refractive Toric Multifocal Intraocular Lens|Completed||Phase 4|40|Actual|Hospital Oftalmologico de Brasilia||1|||f||||t||||||||||2018-05-31 21:46:32.325907|2018-05-31 21:46:32.325907
NCT01505803|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-01-05|2012-01-05|2012-01-09|Estimate|||||||2012-01-05|2012-01-09|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effect of a Nutritional Supplement in Individuals With Type 2 Diabetes Mellitus: a Pilot Study|The Effect of a Nutritional Supplement on Cardiometabolic, Inflammatory, and Oxidative Stress Markers in Individuals With Type 2 Diabetes Mellitus: a Pilot Study|Completed||Phase 1|48|Actual|University of Sydney||4|||f||||f||||||||||2018-05-31 21:46:32.485351|2018-05-31 21:46:32.485351
NCT01505790|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2012-05-22|2012-01-06|2012-01-09|Estimate|||||||2012-05-22|2012-05-23|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention|Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention|Completed||Phase 3|187|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 21:46:32.70802|2018-05-31 21:46:32.70802
NCT01505777|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2013-04-04|2012-01-04|2012-01-09|Estimate|||||||2013-04-04|2013-04-05|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea|Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea: Double Blinded, Randomized, Placebo Drug Controlled, Parallel Designed, Multi-centered, Phase 2 Study|Completed||Phase 2|280|Anticipated|Hanmi Pharmaceutical Company Limited||5|||f||||f||||||||||2018-05-31 21:46:32.943655|2018-05-31 21:46:32.943655
NCT01505764|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|2017-01-05||2017-01-05|2012-01-04|2012-01-09|Estimate|2017-01-05|2017-02-24|Actual||||2017-01-05|2017-02-24|Actual|June 2012||2012-06-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||The Role of Ghrelin in Cancer Cachexia|The Role of Ghrelin in Cancer Cachexia|Terminated||Phase 2|10|Actual|VA Office of Research and Development||2||poor recruitment|f||||f||||||||No||2018-05-31 21:46:33.293914|2018-05-31 21:46:33.293914
NCT01505751|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2016-09-04|2012-01-06|2012-01-09|Estimate|||||||2016-09-04|2016-09-07|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||The Association of G9a Protein and the Outcome of Patients With Cervical Cancer||Completed|||69|Actual|Far Eastern Memorial Hospital|||1||f||||||||||Samples With DNA|"~     Residual pathology block after pathological exam~   "|||2018-05-31 21:46:33.781121|2018-05-31 21:46:33.781121
NCT01505738|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-12-13|2012-01-05|2012-01-06|Estimate|||||||2012-12-13|2012-12-17|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|||Bacterial Growth in Vascular Surgery Wounds|The Effect of Bacterial Growth in Vascular Surgery Wounds to the Incidence of Postoperative Wound Infections|Completed|||100|Actual|North Karelia Central Hospital|||1||f||||f||||||||||2018-05-31 21:46:33.839777|2018-05-31 21:46:33.839777
NCT01505725|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2018-04-04|2012-01-04|2012-01-06|Estimate|||||||2018-04-04|2018-04-05|Actual|March 16, 2010||2010-03-16|November 29, 2013|2013-11-29|November 29, 2013||2013-11-29|||||Observational|||Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms|Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms|Completed|||92|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:46:33.923895|2018-05-31 21:46:33.923895
NCT01505712|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-05-17|2012-01-04|2012-01-06|Estimate|||||||2017-05-17|2017-05-18|Actual|December 15, 2011|Actual|2011-12-15|May 2017|2017-05-31|November 19, 2012|Actual|2012-11-19|November 19, 2012|Actual|2012-11-19||Observational|||Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial|Outcome Prediction in Hodgkin Lymphoma by Low-Density Gene Expression Profiling of Formalin Fixed Paraffin Embedded Tissues: A Correlative Study of Inter-Group Trial E2496|Completed|||393|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:46:34.046523|2018-05-31 21:46:34.046523
NCT01505699|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-05-16|2012-01-04|2012-01-06|Estimate|||||||2017-05-16|2017-05-17|Actual|January 6, 2012|Actual|2012-01-06|May 2017|2017-05-31|February 6, 2012|Actual|2012-02-06|February 6, 2012|Actual|2012-02-06||Observational|||Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia|Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities|Completed|||186|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:46:34.114882|2018-05-31 21:46:34.114882
NCT01505686|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-06-25|2012-01-05|2012-01-06|Estimate|||||||2014-06-25|2014-06-26|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||MRI Findings in Inguinal Hernia|MRI Findings in Inguinal Hernia|Completed||N/A|22|Actual|North Karelia Central Hospital||1|||f||||f||||||||||2018-05-31 21:46:34.184084|2018-05-31 21:46:34.184084
NCT01505673|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2017-08-01||2017-12-15|2012-01-05|2012-01-06|Estimate|2017-11-14|2017-12-15|Actual||||2017-12-15|2018-01-16|Actual|January 2012||2012-01-31|December 2017|2017-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Adding Liraglutide to High Dose Insulin: Breaking the Cycle|Adding Liraglutide to High Dose Insulin: Breaking the Cycle|Completed||Phase 4|71|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 21:46:34.404845|2018-05-31 21:46:34.404845
NCT01505660|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2015-04-11|2012-01-05|2012-01-06|Estimate|||||||2015-04-11|2015-04-14|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Randomized Controlled Trial Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care|Randomized Controlled Trial Using Patient Reported Outcomes and Care Managers to Improve HIV Medication Adherence in Routine Clinical Care|Unknown status|Active, not recruiting|N/A|270|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 21:46:35.650436|2018-05-31 21:46:35.650436
NCT01505647|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2013-04-10||2017-03-14|2012-01-04|2012-01-06|Estimate|2013-07-01|2013-07-03|Estimate||||2017-03-14|2017-04-12|Actual|April 2012||2012-04-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)|A Phase III Double-Blinded, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Made With an Alternative Manufacturing Process (AMP)|Completed||Phase 3|498|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:46:35.881625|2018-05-31 21:46:35.881625
NCT01505634|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-08-10|2012-01-05|2012-01-06|Estimate|||||||2017-08-10|2017-08-14|Actual|May 16, 2012|Actual|2012-05-16|August 2017|2017-08-31|July 28, 2015|Actual|2015-07-28|July 28, 2015|Actual|2015-07-28||Interventional|||Study of the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for the Treatment of Complicated Urinary Tract Infection (cUTI) (MK-7655-003)|A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)|Completed||Phase 2|302|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 21:46:36.520569|2018-05-31 21:46:36.520569
NCT01505621|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-04-09|2012-01-04|2012-01-06|Estimate|||||||2014-04-09|2014-04-10|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Novel Methodology to Measure Protein Accumulation|Novel Methodology to Measure Protein Accumulation|Completed|||24|Actual|Mayo Clinic|||2||f||||t||||||Samples With DNA|"~     On day one of the study (day of the study drink administration): blood samples and skeletal~     muscle biopsy (vastus lateralis). Muscle biopsy tissue will be frozen subsequent to~     collection.~      Week 2 and 3 of the study: blood sample collection Week 4 of the study: blood sample and~     skeletal muscle (vastus lateralis) biopsy. Muscle biopsy tissue will be frozen subsequent to~     collection.~   "|||2018-05-31 21:46:36.677282|2018-05-31 21:46:36.677282
NCT01505608|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2016-05-10||2016-09-09|2012-01-05|2012-01-06|Estimate|2016-09-09|2016-10-28|Estimate||||2016-09-09|2016-10-28|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma|A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma|Terminated||Phase 1/Phase 2|14|Actual|Spectrum Health Hospitals||2||Lack of Enrollment|f||||t||||||||||2018-05-31 21:46:36.839633|2018-05-31 21:46:36.839633
NCT01505595|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-12-04|2012-01-05|2012-01-06|Estimate|||||||2013-12-04|2013-12-05|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|||Proprioceptive Training and Low Back Pain||Unknown status|Recruiting|N/A|40|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 21:46:37.783653|2018-05-31 21:46:37.783653
NCT01505582|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-12-10|2012-01-05|2012-01-06|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Inspiratory Muscle Training and Low Back Pain||Completed||N/A|28|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 21:46:37.909059|2018-05-31 21:46:37.909059
NCT01505569|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2018-04-24|2012-01-04|2012-01-06|Estimate|||||||2018-04-24|2018-04-26|Actual|October 20, 2011|Actual|2011-10-20|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Auto Transplant for High Risk or Relapsed Solid or CNS Tumors|Alkylator-Intense Conditioning Followed by Autologous Transplantation for Patients With High Risk or Relapsed Solid or CNS Tumors|Recruiting||N/A|20|Anticipated|Masonic Cancer Center, University of Minnesota||5|||f||||f|f|f||||||||2018-05-31 21:46:38.106926|2018-05-31 21:46:38.106926
NCT01505556|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-12-04|2012-01-05|2012-01-06|Estimate|||||||2013-12-04|2013-12-05|Estimate|January 2014||2014-01-31|January 2012|2012-01-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Observational|||Proprioceptive Postural Control and Diaphragm Paresis||Unknown status|Not yet recruiting||20|Anticipated|Katholieke Universiteit Leuven|||2||f||||t||||||||||2018-05-31 21:46:38.446254|2018-05-31 21:46:38.446254
NCT01505543|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-12-04|2012-01-05|2012-01-06|Estimate|||||||2013-12-04|2013-12-05|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|||Proprioceptive Postural Control and Chronic Obstructive Pulmonary Disease (COPD)||Completed|||40|Anticipated|Katholieke Universiteit Leuven|||2||f||||t||||||||||2018-05-31 21:46:38.576122|2018-05-31 21:46:38.576122
NCT01505530|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04||2015-01-16|2016-02-10|2012-01-04|2012-01-06|Estimate||||2015-01-16|2015-01-29|Estimate|2016-02-10|2016-03-11|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|October 2014|Actual|2014-10-31||Interventional|||A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer|A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy|Completed||Phase 2|125|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:46:38.71324|2018-05-31 21:46:38.71324
NCT01505517|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-12-04|2012-01-05|2012-01-06|Estimate|||||||2013-12-04|2013-12-05|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|||Inspiratory Resistive Loading and Diaphragm Fatigue|Inspiratory Resistive Loading and Diaphragm Fatigue in Healthy Individuals and Individuals With Recurrent Low Back Pain|Completed|||20|Actual|Katholieke Universiteit Leuven|||2||f||||t||||||||||2018-05-31 21:46:38.928573|2018-05-31 21:46:38.928573
NCT01505504|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-05|2012-01-05|2012-01-06|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2004||2004-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Mirtazapine in Alzheimer-associated Weight Loss|Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study|Completed|||22|Actual|Brugmann University Hospital|||||f||||f||||||||||2018-05-31 21:46:39.091488|2018-05-31 21:46:39.091488
NCT01505491|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-12-12|2012-01-04|2012-01-06|Estimate|||||||2012-12-12|2012-12-13|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects|Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Open-label, Single Dose, Parallel Arm, Active Comparator Clinical Phase I Study|Completed||Phase 1|193|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:46:39.233084|2018-05-31 21:46:39.233084
NCT01505478|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-04-04|2012-01-05|2012-01-06|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2012||2012-07-31|January 2012|2012-01-31||||||||Observational|||Comparing an Automated to a Conventional Sepsis Clinical Prediction Rule|Comparing an Automated to a Conventional Sepsis Clinical Prediction Rule|Withdrawn|||0|Actual|Beth Israel Deaconess Medical Center|||1||f||||f||||||||||2018-05-31 21:46:39.454039|2018-05-31 21:46:39.454039
NCT01505465|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2017-03-23||2017-07-28|2012-01-04|2012-01-06|Estimate|2017-07-28|2017-08-31|Actual||||2017-07-28|2017-08-31|Actual|February 2012||2012-02-29|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery|Effects of Perioperative Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery|Completed||N/A|50|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 21:46:39.671646|2018-05-31 21:46:39.671646
NCT01504919|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-09-12|2012-01-05|2012-01-06|Estimate|||||||2017-09-12|2017-09-14|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Reducing Cancer Disparities Among Latinos in Texas|Reducing Cancer Disparities Among Latinos in Texas|Active, not recruiting||N/A|500|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 21:46:53.29784|2018-05-31 21:46:53.29784
NCT01505452|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-12-16|2012-01-05|2012-01-06|Estimate|||||||2017-12-16|2017-12-19|Actual|November 2011||2011-11-30|December 2017|2017-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Study of Surgical Technique With Use of Single-radius Prosthesis in Total Knee Replacement|Translational Error in Flexion-extension Gap Balancing With Singe Radius Total Knee Arthroplasty|Completed|||43|Actual|Athens Orthopedic Clinic, P.A.|||||f||||f||||||||||2018-05-31 21:46:40.522547|2018-05-31 21:46:40.522547
NCT01505439|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-06-13|2012-01-04|2012-01-06|Estimate|||||||2016-06-13|2016-06-15|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Estimate the Efficacy and Safety of Solifenacin in Female With Stress Urinary Incontinence and Urgency Urinary Incontinence|A Prospective, Open Label, Single Arm, Multicenter Study to Estimate the Efficacy and Safety of Solifenacin in Female With Clinically Significant Stress Urinary Incontinence and Urgency Urinary Incontinence|Completed||Phase 4|311|Actual|Korea University Anam Hospital||1|||f||||f||||||||||2018-05-31 21:46:40.612695|2018-05-31 21:46:40.612695
NCT01505426|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-01-19|2012-01-04|2012-01-06|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients|A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|Completed||Phase 3|171|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 21:46:40.805555|2018-05-31 21:46:40.805555
NCT01505413|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2014-04-02|2012-01-05|2012-01-06|Estimate|||||||2014-04-02|2014-04-03|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|GEMOX-T||Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer|Phase 2 Study of GEMOX-T in Previously Untreated Patients With Advanced Pancreatic Cancer|Completed||Phase 2|33|Actual|Soonchunhyang University Hospital||1|||f||||t||||||||||2018-05-31 21:46:41.057939|2018-05-31 21:46:41.057939
NCT01505400|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2018-02-26|2012-01-05|2012-01-06|Estimate|||||||2018-02-26|2018-02-28|Actual|February 2012||2012-02-29|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|IMPACT||Integrated Molecular Profiling in Advanced Cancers Trial|Integrated Molecular Profiling in Advanced Cancers Trial|Active, not recruiting|||3026|Actual|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Archival tumor tissue~      1 tube of whole blood~   "|||2018-05-31 21:46:41.203292|2018-05-31 21:46:41.203292
NCT01505387|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2015-03-24||2015-05-13|2012-01-05|2012-01-06|Estimate|2015-03-24|2015-04-03|Estimate||||2015-05-13|2015-06-01|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Litramine in Weight Maintenance|Double-blind, Randomized, Placebo-controlled Clinical Investigation to Evaluate the Safety and Efficacy of Litramine in Maintaining Body Weight Loss in Overweight and Obese Subjects|Completed||Phase 4|50|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 21:46:41.310272|2018-05-31 21:46:41.310272
NCT01505374|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2014-02-25||2017-03-21|2012-01-04|2012-01-06|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|March 2012||2012-03-31|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty|Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty: A Comparative Effectiveness Study in Bilateral Total Knee Arthroplasty Patients|Completed||N/A|60|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 21:46:41.659778|2018-05-31 21:46:41.659778
NCT01505361|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-11|2012-01-05|2012-01-06|Estimate|||||||2012-01-11|2012-01-12|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|PROBIOPREG||Study of a Probiotic Strain to Prevent Mastitis and to Eradicate GBS Colonization|Oral Administration of a Probiotic Strain to Pregnant Women: Effects on the Prevention of Lactational Mastitis and on the Eradication of GBS Colonization|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Universidad Complutense de Madrid||2|||f||||f||||||||||2018-05-31 21:46:42.096702|2018-05-31 21:46:42.096702
NCT01505348|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-04|2012-01-04|2012-01-06|Estimate|||||||2012-01-04|2012-01-06|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Fasting Versus Feeding on the Bone Metabolic Response to Running|Effect of Fasting Versus Feeding on the Bone Metabolic Response to Running|Completed||N/A|10|Actual|QinetiQ Ltd||2|||f||||f||||||||||2018-05-31 21:46:42.27844|2018-05-31 21:46:42.27844
NCT01505335|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-05|2012-01-05|2012-01-06|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Observational|||The Use of Novel us Device (Jetguide) to Measure the Distance to the Roof of the IAC (Inferior Alveolar Canal)|The Use of Novel us Device (Jetguide) to Measure the Distance to the Roof of the IAC (Inferior Alveolar Canal)|Unknown status|Not yet recruiting||25|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 21:46:42.407299|2018-05-31 21:46:42.407299
NCT01505322|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-05|2012-01-05|2012-01-06|Estimate|||||||2012-01-05|2012-01-06|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||Persistent Pain to Impair Daily Activities Following Thoracic Surgery|Persistent Pain to Impair Daily Activities Following Thoracic Surgery|Completed|||396|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 21:46:42.527026|2018-05-31 21:46:42.527026
NCT01505309|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-12-30|2012-01-05|2012-01-06|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Endovascular Aortic Repair for Aortic Dissection|Endovascular Aortic Repair for Aortic Dissection------XiJing Registry|Recruiting||N/A|500|Anticipated|Xijing Hospital||1|||f||||t||||||||||2018-05-31 21:46:42.67881|2018-05-31 21:46:42.67881
NCT01505296|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2014-12-13|2012-01-03|2012-01-06|Estimate|||||||2014-12-13|2014-12-16|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CABAL||Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation|Randomized Comparison of Catheter Ablation Versus Anti-arrhythmic Drug Therapy in Patients With Recently Diagnosed Paroxysmal Atrial Fibrillation as Assessed by a Continuous Implantable Monitor|Withdrawn||Phase 4|0|Actual|Valley Health System||2||Never initiated|f||||f||||||||||2018-05-31 21:46:42.852683|2018-05-31 21:46:42.852683
NCT01505283|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2016-11-02|2012-01-05|2012-01-06|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|APD-ANI||Effect of Epidural Analgesia on the Parameter ANI During Childbirth|Effect of Epidural Analgesia on the Parameter ANI During Childbirth|Terminated||N/A|42|Actual|Hopital Foch||3||recruitment difficulties|f||||f||||||||||2018-05-31 21:46:42.991733|2018-05-31 21:46:42.991733
NCT01505270|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-05|2012-01-05|2012-01-06|Estimate|||||||2012-01-05|2012-01-06|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||The Prevalence of Psychological and Medical Comorbidities Among Children Suffering From Autistic Spectrum Disorder and the Differences Between Ethnic Groups in Israel||Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 21:46:43.193788|2018-05-31 21:46:43.193788
NCT01505257|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-10-25|2012-01-05|2012-01-06|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2010||2010-04-30|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|END-DSD||Early Nurse Detection and Management of Delirium|Early Nurse Detection of Delirium Superimposed on Dementia|Completed||N/A|391|Actual|Penn State University||2|||f||||t||||||||||2018-05-31 21:46:43.379652|2018-05-31 21:46:43.379652
NCT01505244|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2014-12-01|2012-01-03|2012-01-06|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Before-School Physical Activity Intervention in Elementary School Children|Before-School Physical Activity Intervention in Elementary School Children: A Pilot Study|Completed||N/A|39|Actual|University of Vermont||1|||f||||f||||||||||2018-05-31 21:46:43.544938|2018-05-31 21:46:43.544938
NCT01505231|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2013-02-11|2012-01-05|2012-01-06|Estimate|||||||2013-02-11|2013-02-12|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|May 2013|Anticipated|2013-05-31|February 2013|Anticipated|2013-02-28||Interventional|VaNCS||Vasopressin Versus Norepinephrine for the Management of Shock After Cardiac Surgery||Unknown status|Recruiting|Phase 3|300|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:46:43.65426|2018-05-31 21:46:43.65426
NCT01505218|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2015-12-01|2012-01-05|2012-01-06|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PER-projekt||Propofol Patient-controlled Sedation for Endoscopic Retrograde Cholangiopancreatography|Patient-controlled Propofol Sedation for Endoscopic Retrograde Cholangiopancreatography|Completed||N/A|281|Actual|University Hospital, Linkoeping||3|||f||||f||||||||||2018-05-31 21:46:43.83724|2018-05-31 21:46:43.83724
NCT01505205|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-05|2012-01-05|2012-01-06|Estimate|||||||2012-01-05|2012-01-06|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Observational|||Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors||Completed|||60|Actual|Guangxi Medical University|||||f||||t||||||||||2018-05-31 21:46:44.059377|2018-05-31 21:46:44.059377
NCT01505192|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2012-01-05|2012-01-05|2012-01-06|Estimate|||||||2012-01-05|2012-01-06|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Interventional|||Noninvasive Continuous Measurement of SpHb After Spontaneous Vaginal Delivery|Determination of the Physiological Reference Values of Trend of Hemoglobin in the Post-partum Period After Spontaneous Vaginal Delivery. A Sequential Pilot Study Using the Noninvasive Continuous Technology of SpHb|Unknown status|Recruiting|N/A|120|Anticipated|Città di Roma Hospital|||||f||||f||||||||||2018-05-31 21:46:44.121076|2018-05-31 21:46:44.121076
NCT01505179|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-01-11|2012-01-05|2012-01-06|Estimate|||||||2013-01-11|2013-01-15|Estimate|February 2011||2011-02-28|January 2013|2013-01-31||||December 2015|Anticipated|2015-12-31||Interventional|RAZE||The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction|The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction|Unknown status|Enrolling by invitation|N/A|40|Anticipated|University of California, San Diego||2|||f||||||||||||||2018-05-31 21:46:44.289399|2018-05-31 21:46:44.289399
NCT01505166|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2018-02-15||2018-03-29|2012-01-05|2012-01-06|Estimate|2018-03-29|2018-05-01|Actual||||2018-03-29|2018-05-01|Actual|March 2012||2012-03-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|FANG-CLM||Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases|Randomized Phase II Trial of Post-operative Adjuvant Chemotherapy ± FANG™ Autologous Tumor Cell Vaccine in Colorectal Carcinoma With Liver Metastases|Completed||Phase 2|3|Actual|Gradalis, Inc.||3|||f||||t||||||||||2018-05-31 21:46:44.439479|2018-05-31 21:46:44.439479
NCT01505153|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2018-02-16|2012-01-05|2012-01-06|Estimate|||||||2018-02-16|2018-02-22|Actual|February 2012|Actual|2012-02-29|February 2018|2018-02-28|April 13, 2017|Actual|2017-04-13|March 2017|Actual|2017-03-31||Interventional|STMN1-LP||Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer|Phase I Trial of Intratumoral Bi-functional shRNA Stathmin 1-knockdown Lipoplex in Patients With Advanced and/or Metastatic Cancer|Completed||Phase 1|20|Actual|Gradalis, Inc.||1|||f||||t||||||||||2018-05-31 21:46:45.058947|2018-05-31 21:46:45.058947
NCT01505140|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-31|||2016-11-23|2012-01-03|2012-01-06|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Benefits of Walnuts for Male Reproductive Health|Benefits of Walnuts for Male Reproductive Health|Completed||Phase 2|120|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 21:46:45.219628|2018-05-31 21:46:45.219628
NCT01505127|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2013-11-02|2012-01-03|2012-01-06|Estimate|||||||2013-11-02|2013-11-05|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori|A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the First Line Eradication of H.Pylori|Completed||Phase 3|650|Actual|Takeda||2|||f||||f||||||||||2018-05-31 21:46:45.375283|2018-05-31 21:46:45.375283
NCT01505114|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2017-05-16||2017-06-20|2012-01-04|2012-01-06|Estimate|2017-06-20|2017-07-18|Actual||||2017-06-20|2017-07-18|Actual|June 2012||2012-06-30|June 2017|2017-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women|A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women|Completed||Phase 2|594|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 21:46:45.846702|2018-05-31 21:46:45.846702
NCT01505101|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2014-08-04|2012-01-05|2012-01-06|Estimate|||||||2014-08-04|2014-08-06|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy|Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy: Exploration of Cognitive, Affective, and Physiological Mechanisms|Completed||Phase 1|115|Actual|Florida State University||2|||f||||t||||||||||2018-05-31 21:46:48.368073|2018-05-31 21:46:48.368073
NCT01505088|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-03-28|2012-01-05|2012-01-06|Estimate|||||||2013-03-28|2013-03-29|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis|A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis|Completed||Phase 3|193|Actual|Eyegate Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:46:48.576443|2018-05-31 21:46:48.576443
NCT01505075|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-04-26|2012-01-05|2012-01-06|Estimate|||||||2017-04-26|2017-04-27|Actual|September 2011||2011-09-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2013|Actual|2013-01-31||Interventional|pHART8||Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer|Phase II Study of Dose-escalated, Hypofractionated Radiotherapy and Androgen Deprivation Therapy for High-Risk Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 21:46:48.853003|2018-05-31 21:46:48.853003
NCT01505062|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-10-18|2012-01-05|2012-01-06|Estimate|||||||2017-10-18|2017-10-19|Actual|March 20, 2012|Actual|2012-03-20|October 2017|2017-10-31|February 24, 2020|Anticipated|2020-02-24|February 24, 2020|Anticipated|2020-02-24||Interventional|||Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B|A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected UshStat®, Administered to Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B|Recruiting||Phase 1/Phase 2|18|Anticipated|Sanofi||5|||f||||t||||||||||2018-05-31 21:46:48.96851|2018-05-31 21:46:48.96851
NCT01505049|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2015-07-20|2012-01-05|2012-01-06|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|IMAP-1||Immune Memory After Papillomavirus Vaccination|Immune Memory After Papillomavirus Vaccination (IMAP-I) Study . DMID 10-0014|Completed|||203|Actual|Emory University|||3||f||||t||||||Samples With DNA|"~     we will retain lymphocyte samples for testing immune function~   "|||2018-05-31 21:46:49.072911|2018-05-31 21:46:49.072911
NCT01505036|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-02-05|2012-01-03|2012-01-06|Estimate|||||||2013-02-05|2013-02-06|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SMARTCARE_DM||Study to Evaluate the Effect of the Smart Care-diabetes Management System on Subjects With Diabetes|Randomized, Multi-center, Open-label, Parallel Group Study to Evaluate the Effect of the Smart Care-diabetes Management System on Subjects With Diabetes|Completed||N/A|554|Actual|SK Telecom Consortium||2|||f||||f||||||||||2018-05-31 21:46:49.147689|2018-05-31 21:46:49.147689
NCT01505023|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-04|2012-01-04|2012-01-06|Estimate|||||||2012-01-04|2012-01-06|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|February 2007|Actual|2007-02-28|November 2006|Actual|2006-11-30||Interventional|||Partial Meal Replacement and Inulin in Obese Women|Evaluation of the Effectiveness of a Partial Meal Replacement With Inulin on Obesity and Dyslipidemias in Women.|Completed||Phase 2|179|Actual|Cindetec||4|||f||||f||||||||||2018-05-31 21:46:49.211333|2018-05-31 21:46:49.211333
NCT01505010|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-02-17|2012-01-04|2012-01-06|Estimate|||||||2015-02-17|2015-02-18|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|INSPiRED||Renal Denervation for Management of Drug-Resistant Hypertension|Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension|Unknown status|Recruiting|Phase 2|240|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 21:46:50.28494|2018-05-31 21:46:50.28494
NCT01504997|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|2016-04-18||2016-10-12|2012-01-05|2012-01-06|Estimate|2016-04-18|2016-05-25|Estimate||||2016-10-12|2016-11-29|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2012|Actual|2012-12-31||Interventional|RADGphaseII||Phase II Study for Robot Assisted Distal Gastrectomy|A Phase II Study of Robot Assisted Distal Gastrectomy With Nodal Dissection for Clinical Stage Ia Gastric Cancer|Active, not recruiting||Phase 2|23|Actual|Shizuoka Cancer Center||1|||f||||t||||||||||2018-05-31 21:46:50.541346|2018-05-31 21:46:50.541346
NCT01504984|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-06-10|2012-01-05|2012-01-06|Estimate|||||||2012-06-10|2012-06-12|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers|An Open-label, Randomized, Single Dose, Crossover Phase I Clinical Trial to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab., 4T (400mg) in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||t||||||||||2018-05-31 21:46:50.906041|2018-05-31 21:46:50.906041
NCT01504971|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2015-08-04||2015-08-04|2012-01-04|2012-01-06|Estimate|2015-08-04|2015-09-02|Estimate||||2015-08-04|2015-09-02|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|June 2012|Actual|2012-06-30||Observational|||Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease|Diagnostic Value of Narrow-band Imaging, Autofluorescence Imaging & White-light Imaging on Gastroesophageal Reflux Disease|Unknown status|Active, not recruiting||95|Actual|Chinese PLA General Hospital|||1||f||||t||||||||||2018-05-31 21:46:51.181006|2018-05-31 21:46:51.181006
NCT01504958|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2017-01-13||2017-06-05|2012-01-04|2012-01-06|Estimate|2017-04-28|2017-06-05|Actual||||2017-06-05|2017-07-02|Actual|December 2010||2010-12-31|June 2017|2017-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Total number analyzed: 21 (1 enrolled was excluded from analysis) Real/Real: 10 Real/Sham: 5 Sham/Sham: 6|Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients|Effects of a Combined TMS and Cognitive Training in Alzheimer Patients: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study|Completed||N/A|22|Actual|Beth Israel Deaconess Medical Center||3|||f||||f||||||||||2018-05-31 21:46:51.786191|2018-05-31 21:46:51.786191
NCT01504945|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2018-02-21|2012-01-05|2012-01-06|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2010||2010-02-28|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)|Red Blood Cell Transfusion in Patients With Acute and Chronic Coronary Syndrome|Terminated||Phase 1/Phase 2|60|Anticipated|Beth Israel Deaconess Medical Center||2||Recruitment difficulty|f||||t||||||||||2018-05-31 21:46:52.769618|2018-05-31 21:46:52.769618
NCT01504932|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-03-04|2012-01-03|2012-01-06|Estimate|||||||2018-03-04|2018-03-06|Actual|February 23, 2007|Actual|2007-02-23|March 2018|2018-03-31|April 22, 2015|Actual|2015-04-22|April 22, 2015|Actual|2015-04-22||Interventional|||Freeze-Dried Black Raspberries in Preventing Oral Cancer Recurrence in High-Risk Appalachian Patients Previously Treated With Surgery For Oral Cancer|Pilot Long-Term Oral Dose of Freeze-Dried Black Raspberries in Post-Surgical Appalachian Oral Cancer|Completed||N/A|44|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||f||||||||2018-05-31 21:46:52.996651|2018-05-31 21:46:52.996651
NCT01504906|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-12-11|2012-01-05|2012-01-06|Estimate|||||||2012-12-11|2012-12-12|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor|A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine|Completed||Phase 1|20|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:46:53.466286|2018-05-31 21:46:53.466286
NCT01504893|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-03-25|2012-01-05|2012-01-06|Estimate|||||||2018-03-25|2018-03-27|Actual|September 2013|Actual|2013-09-30|March 2018|2018-03-31|September 2017|Actual|2017-09-30|August 2016|Actual|2016-08-31||Interventional|U-PROVE||Protective Ventilation With Low Tidal Volume Versus an Ultraprotective Ventilatory Strategy for One-lung Ventilation in Patients Undergoing Thoracic Anesthesia.|Multicenter Randomized Trial on Protective Ventilation Versus Conventional Ventilation During OLV in Patients Undergoing Thoracic Surgery|Completed||N/A|1100|Actual|Azienda Ospedaliera S. Maria della Misericordia||2|||f||||t||||||||||2018-05-31 21:46:53.690977|2018-05-31 21:46:53.690977
NCT01504880|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-03-07|2012-01-05|2012-01-06|Estimate|||||||2018-03-07|2018-03-09|Actual|June 2010||2010-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Atrioventricular Valve Regurgitation Vena Contracta; Echo Versus MRI|Evaluation of Mitral and Tricuspid Regurgitation: Cardiovascular Magnetic Resonance Imaging Versus Echocardiographic Doppler Color Flow Mapping of the Vena Contracta|Active, not recruiting|||3|Actual|Medical College of Wisconsin|||||f||||f|f|f||||||Yes||2018-05-31 21:46:53.882191|2018-05-31 21:46:53.882191
NCT01504867|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|2016-08-17||2017-01-23|2012-01-05|2012-01-06|Estimate|2016-08-17|2016-10-13|Estimate||||2017-01-23|2017-03-06|Actual|January 2012|Actual|2012-01-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||400 subjects were randomized, and 10 subjects were excluded, leaving 390 in the final modified intention-to-treat analysis cohort.|LIPS-A: Lung Injury Prevention Study With Aspirin|LIPS-A: Lung Injury Prevention Study With Aspirin|Completed||Phase 2|400|Actual|Mayo Clinic||2|||f||||t||||||||Undecided||2018-05-31 21:46:54.086822|2018-05-31 21:46:54.086822
NCT01504854|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|2016-01-28||2016-05-06|2012-01-03|2012-01-06|Estimate|2016-05-06|2016-06-14|Estimate||||2016-05-06|2016-06-14|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Resveratrol for Alzheimer's Disease|Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|119|Actual|Alzheimer's Disease Cooperative Study (ADCS)|This phase 2 study has limitations. A larger study is required to determine whether resveratrol may be beneficial. More potent and bioavailable SIRT1 activators are also in development.|2|||f||||t||||||||||2018-05-31 21:46:54.824107|2018-05-31 21:46:54.824107
NCT01504841|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-05-24|2012-01-03|2012-01-05|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2012|Actual|2012-03-31|May 2018|2018-05-31|October 31, 2021|Anticipated|2021-10-31|July 30, 2018|Anticipated|2018-07-30||Interventional|||Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children|A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 21:46:55.662832|2018-05-31 21:46:55.662832
NCT01504828|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-03-29|2012-01-03|2012-01-05|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cardiac Energetics and Function in Normal Human Ageing|Cardiac Energetics and Function in Normal Human Ageing|Completed||N/A|135|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 21:46:55.82371|2018-05-31 21:46:55.82371
NCT01504815|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-09-26|2012-01-03|2012-01-05|Estimate|||||||2017-09-26|2017-09-28|Actual|March 2012||2012-03-31|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|April 2019|Anticipated|2019-04-30||Interventional|ARTFORCE||Adaptive Radiation Treatment for Head and Neck Cancer|Phase III Randomized Study With Cisplatinum and Conventional or Adaptive High Dose Radiotherapy for Advanced Head and Neck Cancer|Recruiting||Phase 3|268|Anticipated|The Netherlands Cancer Institute||2|||f||||f|f|f||||||||2018-05-31 21:46:55.977186|2018-05-31 21:46:55.977186
NCT01504802|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-09-30|2012-01-03|2012-01-05|Estimate|||||||2014-09-30|2014-10-02|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|March 2013|Actual|2013-03-31||Observational|||Pharmacodynamics of CNP During Growth Hormone Treatment|Pharmacodynamics of C-Type Natriuretic Peptide During Growth Hormone Treatment in Children: A Potential Biomarker of Efficacy|Completed|||22|Actual|Nemours Children's Clinic|||2||f||||f||||||Samples Without DNA|"~     Serum, plasma, and urine will be saved for potential future studies.~   "|||2018-05-31 21:46:56.168178|2018-05-31 21:46:56.168178
NCT01504789|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2017-09-28|2012-01-03|2012-01-05|Estimate|||||||2017-09-28|2017-09-29|Actual|February 2012|Actual|2012-02-29|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Part II: Exercise in Hispanic Breast Cancer Survivors|Part II: Exercise in Hispanic Breast Cancer Survivors|Active, not recruiting||N/A|180|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 21:46:56.285182|2018-05-31 21:46:56.285182
NCT01504776|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2014-09-18|2012-01-04|2012-01-05|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|BUS48T||Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)|A Phase I Study of Panobinostat in Combination With Bortezomib in the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma|Completed||Phase 1|3|Actual|Augusta University||1|||f||||t||||||||||2018-05-31 21:46:56.456136|2018-05-31 21:46:56.456136
NCT01504763|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2012-02-07|2012-01-03|2012-01-05|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Measuring the Effect of Chair Massage on Stress Related Symptoms for Nurses|Measuring the Effect of Chair Massage on Stress Related Symptoms for Nurses: A Pilot Study|Completed||N/A|40|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:46:56.580394|2018-05-31 21:46:56.580394
NCT01504750|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-01-05|2012-01-03|2012-01-05|Estimate|||||||2012-01-05|2012-01-06|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Healing Patient Rooms|Healing Patient Rooms; The Effect of Lighting on Recovery and Well-being of Patients|Completed||N/A|196|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 21:46:56.696594|2018-05-31 21:46:56.696594
NCT01499784|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-10-26|2011-12-22|2011-12-26|Estimate|||||||2015-10-26|2015-10-27|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Urinary Incontinence in an Inpatient Rehab Unit|Can Urinary Incontinence be Treated in an In-patient Rehabilitation Setting?|Completed||N/A|5|Actual|Shirley Ryan AbilityLab||1|||f||||f||||||||||2018-05-31 21:48:09.391331|2018-05-31 21:48:09.391331
NCT01504737|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2017-10-16|2012-01-03|2012-01-05|Estimate|||||||2017-10-16|2017-10-17|Actual|September 2011||2011-09-30|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|RASP||Rehabilitation in Aortic Stenosis Patients|Rehabilitation in the Form of Exercise Training in Aortic Stenosis Patients (RASP)|Terminated||N/A|12|Actual|Linkoeping University||2||Slow inclusion rate, failure to recruit a priori determined no of patients.|f||||f||||||||||2018-05-31 21:46:56.858593|2018-05-31 21:46:56.858593
NCT01504724|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2013-12-24|2012-01-03|2012-01-05|Estimate|||||||2013-12-24|2013-12-25|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|IVB||Effect of the Adjunctive IVB Before PRP|Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness|Completed||Phase 4|30|Actual|Kyungpook National University||2|||f||||t||||||||||2018-05-31 21:46:57.00432|2018-05-31 21:46:57.00432
NCT01504711|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-04-15|2012-01-03|2012-01-05|Estimate|||||||2018-04-15|2018-04-17|Actual|June 2012||2012-06-30|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy|Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in Gastrointestinal Cancer Patients|Active, not recruiting||N/A|42|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 21:46:57.124197|2018-05-31 21:46:57.124197
NCT01504698|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-05-18|2012-01-04|2012-01-05|Estimate|||||||2015-05-18|2015-05-19|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Manipulative Treatment of Children With Neck and Back Pain|Manipulative Treatment of Children With Neck and Back Pain. A Randomised Controlled Trial of 1200 Children From 3rd to 7th Grade|Completed||N/A|237|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 21:46:57.24399|2018-05-31 21:46:57.24399
NCT01504685|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-25|2012-01-04|2012-01-05|Estimate|||||||2012-01-25|2012-01-26|Estimate|May 2003||2003-05-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|March 2005|Actual|2005-03-31||Interventional|||Long-Term Results of a Randomized Trial Comparing Banded-versus-Standard Laparoscopic Roux-en-Y Gastric Bypass|Long-Term Results of a Randomized Trial Comparing Banded-versus-Standard Laparoscopic Roux-en-Y Gastric Bypass|Completed||N/A|60|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||||2018-05-31 21:46:57.319785|2018-05-31 21:46:57.319785
NCT01504672|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-11-30|2012-01-04|2012-01-05|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia|A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia|Completed||N/A|460|Actual|Umeå University||2|||f||||||||||||||2018-05-31 21:46:57.464019|2018-05-31 21:46:57.464019
NCT01504659|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-03-14|2012-01-04|2012-01-05|Estimate|||||||2017-03-14|2017-03-16|Actual|July 2012||2012-07-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|IKBP||Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder|Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder|Terminated||Phase 2/Phase 3|5|Actual|Juvenile Bipolar Research Foundation||2||Administrative issues|f||||t||||||||||2018-05-31 21:46:57.553392|2018-05-31 21:46:57.553392
NCT01504646|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2013-04-02|2012-01-04|2012-01-05|Estimate|||||||2013-04-02|2013-04-04|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Randomized Controlled Trial of Marine Lipid Fraction PCSO-524™ on Airway Inflammation and Hyperpnea-Induced Bronchoconstriction in Asthma|Completed||N/A|20|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 21:46:57.725508|2018-05-31 21:46:57.725508
NCT01504633|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-31|||2014-02-25|2012-01-03|2012-01-05|Estimate|||||||2014-02-25|2014-02-26|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|NUPICO||Nutrigenomics, PUFA, Iron and Cognition Amongst Under-two-year-old Indonesian Children|Can NUtrigenomics / Nutrigenetics Help Explain the Mixed Results on Effect of LCPUFA (DHA) and Iron on Child COgnition?|Unknown status|Active, not recruiting|N/A|240|Anticipated|Indonesia University||4|||f||||f||||||||||2018-05-31 21:46:57.886377|2018-05-31 21:46:57.886377
NCT01504620|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-01-03|2012-01-03|2012-01-05|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|Polaris||Performance Evaluation of Blood Glucose Monitoring Systems|Performance Evaluation of BGStar and iBGStar in Terms of Accuracy (Polaris), Intra-assay Precision, and Hematocrit Interference (Helios Substudy) Following ISO15197 and TNO Guidelines|Completed||Phase 4|106|Actual|IKFE Institute for Clinical Research and Development||2|||f||||f||||||||||2018-05-31 21:46:58.042089|2018-05-31 21:46:58.042089
NCT01504607|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-01-03|2012-01-03|2012-01-05|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Corneal Endothelial Changes Following Pediatric Cataract Surgery With IOL Implantation|Corneal Endothelial Morphologic Assessment in Pediatric Cataract Surgery With IOL Implantation: Comparison of Preoperative and Early Postoperative Specular Microscopy|Completed|||106|Actual|Iladevi Cataract and IOL Research Center|||1||f||||t||||||||||2018-05-31 21:46:58.161628|2018-05-31 21:46:58.161628
NCT01504594|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-08-06|2012-01-04|2012-01-05|Estimate|||||||2013-08-06|2013-08-09|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|August 2013|Anticipated|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy|Safeness and Effectiveness of Autologous Hematopoietic Cell Infusion Through Catheterization in Pediatric Patients With Dilated Cardiomyopathy|Suspended||Phase 1|10|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||1||Suspended because the lack of patients among the time this clinical trial was running.|f||||t||||||||||2018-05-31 21:46:58.284833|2018-05-31 21:46:58.284833
NCT01504581|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2014-02-06|2012-01-03|2012-01-05|Estimate|||||||2014-02-06|2014-02-07|Estimate|March 2011||2011-03-31|February 2014|2014-02-28||||September 2011|Actual|2011-09-30||Interventional|||Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo- And Active-Controlled Study Of The Pharmacokinetics, Pharmacodynamics And Safety Of Single Ascending Doses Of HM10660A (LAPS-INTERFERON ALPHA-2B) In Healthy Male Subjects|Completed||Phase 1|48|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 21:46:58.48493|2018-05-31 21:46:58.48493
NCT01504568|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-11-08|2012-01-04|2012-01-05|Estimate|||||||2012-11-08|2012-11-09|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Use of Prophylactic Antibiotics in Isolated Blowout Fractures|The Use of Prophylactic Antibiotics in Isolated Blowout Fractures|Withdrawn||N/A|0|Actual|University of Arkansas||2||No subjects enrolled|f||||f||||||||||2018-05-31 21:46:58.676878|2018-05-31 21:46:58.676878
NCT01504555|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-09-23|2012-01-03|2012-01-05|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|DXM||Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?|Evaluation of the Diagnostic Utility of Serum Dexamethasone Measurements in the Overnight 1mg Dexamethasone Suppression Test in Patients Investigated for Cushing's Syndrome and Incidentalomas|Recruiting|||300|Anticipated|Haukeland University Hospital|||1||f||||f||||||Samples Without DNA|"~     Blood, saliva, urine~   "|||2018-05-31 21:46:58.828732|2018-05-31 21:46:58.828732
NCT01504542|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-11-20|2012-01-04|2012-01-05|Estimate|||||||2013-11-20|2013-11-21|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer|A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|Heat Biologics||3||Lack of enrollment|f||||t||||||||||2018-05-31 21:46:59.046476|2018-05-31 21:46:59.046476
NCT01504529|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2013-04-12|2012-01-04|2012-01-05|Estimate|||||||2013-04-12|2013-04-15|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|RETO-PD||Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine|Non-Interventional, Retrospective, Multi-center Study to Evaluate Non-Motor Symptoms in Advanced PD Patients Already Treated With Rotigotine|Completed|||391|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 21:46:59.272807|2018-05-31 21:46:59.272807
NCT01504516|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-05|2012-01-04|2012-01-05|Estimate|||||||2012-01-05|2012-01-06|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10mg in Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|25|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:46:59.458363|2018-05-31 21:46:59.458363
NCT01504503|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-05|2012-01-04|2012-01-05|Estimate|||||||2012-01-05|2012-01-06|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg With ARICEPT® (Containing Donepezil Hydrochloride) Tablets 10 mg in Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:46:59.643598|2018-05-31 21:46:59.643598
NCT01504490|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-02-13|2012-01-03|2012-01-05|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2011||2011-12-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase I Study of CS-7017 and Bexarotene|A Phase I Study of a Combination of the Proteosome Proliferator-Activated Receptor Gamma Agonist, CS-7017 and the Retinoid X Receptor Agonist, Bexarotene|Terminated||Phase 1|9|Actual|Georgetown University||1||Drug no longer available|f||||t||||||||||2018-05-31 21:46:59.817639|2018-05-31 21:46:59.817639
NCT01504477|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-07-09|2012-01-03|2012-01-05|Estimate|||||||2017-07-09|2017-07-12|Actual|December 2011||2011-12-31|July 2017|2017-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer|A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer|Terminated||Phase 1/Phase 2|6|Actual|Georgetown University||1||Low accrual--unable to meet accrual goals|f||||t||||||||No|There is no plan for this|2018-05-31 21:46:59.974555|2018-05-31 21:46:59.974555
NCT01504464|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2016-05-15|2012-01-04|2012-01-05|Estimate|||||||2016-05-15|2016-05-17|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis|Evaluation the Effects of Intra-articular Injection of Mesenchymal Stem Cells in Patients With Knee Joint Osteoarthritis, Triple Blind Randomized Clinical Trial|Completed||Phase 2|40|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 21:47:00.172266|2018-05-31 21:47:00.172266
NCT01504451|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2014-06-25|2012-01-03|2012-01-05|Estimate|||||||2014-06-25|2014-06-26|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|LAAPITUP 2||Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study: The LAAPITUP 2 Study|Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2|Unknown status|Active, not recruiting|Phase 4|75|Anticipated|Eastbourne General Hospital||3|||f||||t||||||||||2018-05-31 21:47:00.28699|2018-05-31 21:47:00.28699
NCT01504438|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2018-01-08|2012-01-03|2012-01-05|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2011||2011-10-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement|Prospective Randomized Evaluation Of A Two And Three Piece Total Ankle Replacement|Active, not recruiting||N/A|100|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 21:47:00.46596|2018-05-31 21:47:00.46596
NCT01504425|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2014-04-06|2012-01-04|2012-01-05|Estimate|||||||2014-04-06|2014-04-08|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Observational|||Difficult Colon Polypectomies|An Observational Study of Difficult Colonic Polypectomies|Completed|||91|Actual|Clinical Hospital Colentina|||||f||||||||||||||2018-05-31 21:47:00.584841|2018-05-31 21:47:00.584841
NCT01504412|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2013-12-11|2012-01-04|2012-01-05|Estimate|||||||2013-12-11|2013-12-12|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuorpathy|An Asian, Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Pregabalin-controlled, Dose-finding Study of DS-5565 in Patients With Pain Associated With Diabetic Peripheral Neuropathy|Completed||Phase 2|450|Actual|Daiichi Sankyo, Inc.||5|||f||||||||||||||2018-05-31 21:47:00.725055|2018-05-31 21:47:00.725055
NCT01504399|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2016-10-10|2012-01-03|2012-01-05|Estimate|||||||2016-10-10|2016-10-12|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Rhinological Outcomes in Endonasal Pituitary Surgery|Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study|Active, not recruiting|||200|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix|||2||f||||f||||||||||2018-05-31 21:47:00.897455|2018-05-31 21:47:00.897455
NCT01504386|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2013-08-21|2012-01-03|2012-01-05|Estimate|||||||2013-08-21|2013-08-22|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|TAP-block||Transversus Abdominis Plane Block After Robot-assisted Laparocopic Hysterectomy|Effekt of Transversus Abdominis Plane (TAP) Block After Robot-assisted Laparocopic Hysterectomy|Terminated||Phase 4|70|Actual|Copenhagen University Hospital at Herlev||2||Due to local restructering, further recruting was not possible|f||||t||||||||||2018-05-31 21:47:01.027812|2018-05-31 21:47:01.027812
NCT01504373|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2018-03-27|2012-01-03|2012-01-05|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2011||2011-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation|Regional Distribution Differences Between Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation|Recruiting||N/A|25|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 21:47:01.178194|2018-05-31 21:47:01.178194
NCT01504360|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2017-06-09|2012-01-04|2012-01-05|Estimate|||||||2017-06-09|2017-06-12|Actual|December 2011||2011-12-31|April 2016|2016-04-30|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|SARI||Predictive Study of Radiation Induced Sarcoma|Predictive Study of Radiation Induced Sarcoma From the GSF-GETO Data Base.|Completed||N/A|360|Actual|Centre Georges Francois Leclerc||2|||f||||f||||||||||2018-05-31 21:47:01.311388|2018-05-31 21:47:01.311388
NCT01504347|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-10-19|2012-01-03|2012-01-05|Estimate|||||||2017-10-19|2017-10-23|Actual|March 2011||2011-03-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|August 2011|Actual|2011-08-31||Interventional|||Phase 1/2 Lyme Vaccine Study|Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years|Completed||Phase 1/Phase 2|1630|Actual|Shire||3|||f||||t||||||||||2018-05-31 21:47:01.487896|2018-05-31 21:47:01.487896
NCT01504334|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2012-02-05|2012-01-03|2012-01-05|Estimate|||||||2012-02-05|2012-02-07|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|March 2013|Anticipated|2013-03-31|November 2012|Anticipated|2012-11-30||Interventional|||Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for the Safety and Efficacy of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)|Unknown status|Recruiting|Phase 2|80|Anticipated|Beijing Kawin Technology Share-Holding Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:47:01.690211|2018-05-31 21:47:01.690211
NCT01504321|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2016-01-11|2012-01-03|2012-01-05|Estimate|||||||2016-01-11|2016-01-13|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Polycystic Ovary Syndrome - Improving Outcomes|Polycystic Ovary Syndrome - Targeting the Sympathetic Nervous System to Improve Outcomes|Completed||Phase 4|42|Actual|Baker IDI Heart and Diabetes Institute||2|||f||||||||||||||2018-05-31 21:47:01.848762|2018-05-31 21:47:01.848762
NCT01504308|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-04-03|2012-01-03|2012-01-05|Estimate|||||||2017-04-03|2017-04-05|Actual|May 2012||2012-05-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SOFIA||Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids|Philips Pivotal Clinical Trial for MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Terminated||Phase 2/Phase 3|49|Actual|Philips Healthcare||2||It was not possible to enroll patients into the study in a realistic timeframe.|f||||t|f|t|t|||||||2018-05-31 21:47:01.962444|2018-05-31 21:47:01.962444
NCT01504295|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2015-07-20|2012-01-04|2012-01-05|Estimate|||||||2015-07-20|2015-07-22|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease|A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease|Completed||Phase 2|38|Actual|Brown University||2|||f||||t||||||||||2018-05-31 21:47:02.14809|2018-05-31 21:47:02.14809
NCT01504282|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-04|2012-01-04|2012-01-05|Estimate|||||||2012-01-04|2012-01-05|Estimate||||June 2010|2010-06-30||||||||Interventional|||Mitomycin-c Application for PRK|Mitomycin-c Application for Photorefractive Keratectomy|Completed||N/A|90||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 21:47:02.368786|2018-05-31 21:47:02.368786
NCT01504256|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-01-19|2012-01-04|2012-01-05|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2011||2011-10-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|CatuNeo||Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas|Explorative Trial to Investigate Catumaxomab (Anti-EpCAM x Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas Prior to Gastrectomy|Completed||Phase 2|42|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 21:47:02.519502|2018-05-31 21:47:02.519502
NCT01504243|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2012-01-04|2012-01-04|2012-01-05|Estimate|||||||2012-01-04|2012-01-05|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|||Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population|Association Between cd163 Gene Polymorphisms and Sepsis Among Chinese Han Population|Unknown status|Recruiting||400|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||||||2018-05-31 21:47:02.64318|2018-05-31 21:47:02.64318
NCT01504230|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2016-12-15|2012-01-04|2012-01-05|Estimate|||||||2016-12-15|2016-12-16|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Multi-joint Coordination Underlies Upright Balance Control in Elderly With Osteoporosis|Multi-joint Coordination Underlies Upright Balance Control in Elderly With Osteoporosis|Completed|||50|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 21:47:02.758754|2018-05-31 21:47:02.758754
NCT01504217|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2015-07-07|2012-01-04|2012-01-05|Estimate|||||||2015-07-07|2015-07-08|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Control of Center of Mass to Predict Balance Ability and Fall Risks in Elderly|Analysis of Muscle Strength and Control of Center of Mass Acceleration Mechanism to Predict Balance Ability and Fall Risks in Elderly|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 21:47:02.824741|2018-05-31 21:47:02.824741
NCT01504204|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|2017-10-31||2017-12-26|2012-01-02|2012-01-05|Estimate|2017-12-26|2018-01-23|Actual||||2017-12-26|2018-01-23|Actual|December 2011||2011-12-31|November 2017|2017-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Samples on Acne Treatment With Epiduo® Gel|Effect of Sample Medication Use and Application Instructions on Adherence to and Efficacy of Treatment of Patients With Mild to Moderate Acne With Epiduo(R) Gel|Completed||Phase 4|20|Actual|Wake Forest University Health Sciences|This small pilot study subgroup analyses was limited.|2|||f||||f|t|f||||||No||2018-05-31 21:47:02.904462|2018-05-31 21:47:02.904462
NCT01502436|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2016-01-22|2011-12-29|2011-12-30|Estimate|||||||2016-01-22|2016-01-25|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|November 2014|Actual|2014-11-30|December 2010|Actual|2010-12-31||Observational|||An Exploration of the Relationship Between Chronic Pain and Suicide Attempt Among Veterans|An Exploration of the Relationship Between Chronic Pain and Suicide Attempt Among Veterans|Completed|||230|Actual|VA Eastern Colorado Health Care System|||||f||||f||||||||||2018-05-31 21:47:34.674475|2018-05-31 21:47:34.674475
NCT01504191|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2017-03-02|2012-01-04|2012-01-05|Estimate|||||||2017-03-02|2017-03-03|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|U-CARE: Heart||Internet-based Cognitive Behavior Therapy After Myocardial Infarction|A Randomized Controlled Study of the Effects of Internet-based Cognitive Behavior Therapy on Depression and Anxiety in Patients With a Previous Myocardial Infarction|Active, not recruiting||Phase 3|239|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 21:47:03.473796|2018-05-31 21:47:03.473796
NCT01504178|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2017-02-21|2012-01-02|2012-01-05|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2011||2011-05-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DOULOX||Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease|Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease|Completed||Phase 3|28|Actual|University Hospital, Toulouse||3|||f||||f||||||||Undecided||2018-05-31 21:47:03.722157|2018-05-31 21:47:03.722157
NCT01504165|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2014-02-03|2012-01-04|2012-01-05|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Pharmacokinetics in Subjects With Renal Impairment|A Phase I, Open-label, Parallel-group, Mono-center Trial to Investigate the Pharmacokinetics of a Single Intravenous Dose of Cilengitide in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|Merck KGaA||5|||f||||f||||||||||2018-05-31 21:47:04.11752|2018-05-31 21:47:04.11752
NCT01504152|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2013-07-11|2012-01-04|2012-01-05|Estimate|||||||2013-07-11|2013-07-12|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center|Survey to Assess International Travel Patterns and Health Preparations of Hematopoietic Stem Cell Transplant Recipients at Memorial Sloan-Kettering Cancer Center|Completed|||519|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:47:04.359356|2018-05-31 21:47:04.359356
NCT01504139|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2015-03-09|2012-01-04|2012-01-05|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||The Luteal Phase After GnRHa Trigger - a Proof of Concept Study|The Luteal Phase After GnRHa Trigger - a Proof of Concept Study|Completed||Phase 4|93|Actual|Regionshospitalet Viborg, Skive||4|||f||||t||||||||||2018-05-31 21:47:04.484689|2018-05-31 21:47:04.484689
NCT01504126|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-12-13|2012-01-04|2012-01-05|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2012|Actual|2012-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients|Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients|Active, not recruiting||N/A|25|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:47:04.629448|2018-05-31 21:47:04.629448
NCT01504113|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2012-01-02|2012-01-02|2012-01-05|Estimate|||||||2012-01-02|2012-01-05|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis|The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||3||f||||||||||Samples Without DNA|"~     Serum and skin scales~   "|||2018-05-31 21:47:04.749678|2018-05-31 21:47:04.749678
NCT01504100|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2013-10-29|2012-01-04|2012-01-05|Estimate|||||||2013-10-29|2013-10-31|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Efficiency of Patellar Taping in Treatment of Patellofemoral Pain Syndrome|The Effects of Distal Femoral Rotation on Patellofemoral Pain Syndrome Treated With Patella Taping|Completed|||39|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 21:47:04.872385|2018-05-31 21:47:04.872385
NCT01504087|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-01-04|2012-01-04|2012-01-05|Estimate|||||||2012-01-04|2012-01-05|Estimate|May 2011||2011-05-31|July 2011|2011-07-31||||||||Observational|||ICU Venous Thromboembolism Incidence Study in a Chinese Population|Using Inflammatory Markers to Predict the Development and Outcome of Venous Thromboembolism in an Intensive Care Unit|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-05-31 21:47:05.071664|2018-05-31 21:47:05.071664
NCT01504074|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2015-09-23|2012-01-04|2012-01-05|Estimate|||||||2015-09-23|2015-09-24|Estimate|November 2011||2011-11-30|September 2015|2015-09-30||||July 2014|Actual|2014-07-31||Observational|||Morphological and Functional Evaluation of Irvine-Gass Syndrome||Completed|||50|Actual|Medical University of Vienna|||1||f||||||||||||||2018-05-31 21:47:05.23892|2018-05-31 21:47:05.23892
NCT01504061|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-10-23|2012-01-02|2012-01-05|Estimate|||||||2013-10-23|2013-10-24|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Mederma to Reduce Appearance of Post Surgical Scars|The Comparison of Mederma® N&I to Mederma® Ultra Gel to Reduce the Appearance of Post Surgical Scars|Completed||N/A|20|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 21:47:05.330492|2018-05-31 21:47:05.330492
NCT01504048|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2015-08-05|2012-01-04|2012-01-05|Estimate|||||||2015-08-05|2015-08-06|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Usefulness of Chromoendoscopy in Diagnosing Microscopic Colitis|Prospective Study on the Usefulness of Chromoendoscopy in Detecting Microscopic Colitis in Patients Undergoing Colonoscopy Due to Chronic Watery Diarrhoea|Unknown status|Recruiting|N/A|150|Anticipated|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 21:47:05.503237|2018-05-31 21:47:05.503237
NCT01504035|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-02-08|2012-01-03|2012-01-04|Estimate|||||||2012-02-08|2012-02-09|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|||Analgetic Effectiveness of a Lidocaine Loaded Hemostatic, Bioresorbable Putty|Effectiveness of the Addition of Lidocaine to a Hemostatic, Bioresorbable Putty in the Treatment of Iliac Crest Donor Site Pain|Completed||Phase 2/Phase 3|14|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 21:47:05.678455|2018-05-31 21:47:05.678455
NCT01504022|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2012-01-02|2012-01-02|2012-01-04|Estimate|||||||2012-01-02|2012-01-04|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|WISH||Web Based Interactive Treatment and Self-monitoring in Hypertension|Role of Self Monitoring in Combination With Proactive Web-based Management in the Treatment of Hypertension: a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|300|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-05-31 21:47:05.835604|2018-05-31 21:47:05.835604
NCT01501019|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-02-17|2011-12-26|2011-12-29|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2011||2011-10-31|February 2016|2016-02-29||||July 2016|Anticipated|2016-07-31||Interventional|||Exercise in Sjogren, Myositis and Takayasu's Arteritis|Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:47:48.869871|2018-05-31 21:47:48.869871
NCT01504009|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2016-06-13|2012-01-03|2012-01-04|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2011||2011-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2012|Actual|2012-12-31||Interventional|ALS-project||Muscle Training of Patients With Amyotrophic Lateral Sclerosis (ALS)|Investigating the Effect of Muscle Training in Patients With Amyotrophic Lateral Sclerosis and Looking Into the Mechanisms Behind Development of Muscle Atrophy|Completed||N/A|6|Actual|University of Southern Denmark||1|||f||||t||||||||Undecided|Data has been and will be published. Individual participant data may not be available.|2018-05-31 21:47:06.033941|2018-05-31 21:47:06.033941
NCT01503996|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2015-11-26|2012-01-02|2012-01-04|Estimate|||||||2015-11-26|2015-11-30|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Drinking Habits of Glaucoma Patients and Age Matched Controls|Clinical Study to Evaluate the Drinking Habits of Glaucoma Patients and Age Matched Controls|Completed|||600|Actual|Technische Universität Dresden|||2||f||||f||||||||||2018-05-31 21:47:06.175018|2018-05-31 21:47:06.175018
NCT01503983|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2015-08-26|2012-01-03|2012-01-04|Estimate|||||||2015-08-26|2015-08-27|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|May 2015|Actual|2015-05-31|December 2013|Actual|2013-12-31||Interventional|HerXO||Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive|Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive.|Completed||Phase 2|45|Actual|Fundación para el Progreso de la Oncología en Cantabria||1|||f||||t||||||||||2018-05-31 21:47:06.24737|2018-05-31 21:47:06.24737
NCT01503970|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-04-11|2012-01-02|2012-01-04|Estimate|||||||2017-04-11|2017-04-12|Actual|December 2008||2008-12-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Autologous Chondrocyte Transplantation For Articular Cartilage Regeneration|Autologous Chondrocyte Transplantation For Articular Cartilage Regeneration. Pilot Study|Completed||Phase 1/Phase 2|10|Actual|Instituto Nacional de Rehabilitacion||1|||f||||t||||||||||2018-05-31 21:47:06.368126|2018-05-31 21:47:06.368126
NCT01503957|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-10-25|2012-01-02|2012-01-04|Estimate|||||||2012-10-25|2012-10-26|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Nasya in Allergic Rhinitis|Double-blind, Randomized, Placebo-controlled, Crossover Clinical Investigation to Evaluate Safety and Efficacy of Nasya in Reducing Symptoms of Allergic Rhinitis When Applied Before Allergen Challenge|Completed||Phase 3|20|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 21:47:06.784592|2018-05-31 21:47:06.784592
NCT01503944|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14||2012-08-03|2012-08-03|2012-01-02|2012-01-04|Estimate||||2012-08-03|2012-08-14|Estimate|2012-08-03|2012-08-14|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)|Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers|Completed||Phase 1/Phase 2|30|Actual|Avid Radiopharmaceuticals||4|||f||||f||||||||||2018-05-31 21:47:07.158965|2018-05-31 21:47:07.158965
NCT01503931|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2016-01-27|2012-01-02|2012-01-04|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|NGFN PLUS TP13||Endophenotyping With Functional Magnetic Resonance Imaging (fMRI)|Endophenotyping With fMRI: Genetic Modulation and Treatment Response|Completed|||480|Actual|Charite University, Berlin, Germany|||2||f||||t||||||Samples With DNA|"~     whole blood (EDTA)~   "|||2018-05-31 21:47:07.374231|2018-05-31 21:47:07.374231
NCT01503918|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2015-01-09|2011-12-31|2012-01-04|Estimate|||||||2015-01-09|2015-01-12|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|CCCC||Cytomegalovirus Control in Critical Care|Anti-viral Prophylaxis for Prevention of Cytomegalovirus (CMV) Reactivation in Immunocompetent Patients in Critical Care|Completed||Phase 2|124|Actual|University Hospital Birmingham NHS Foundation Trust||3|||f||||t||||||||||2018-05-31 21:47:07.635289|2018-05-31 21:47:07.635289
NCT01503905|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2016-05-23|2012-01-03|2012-01-04|Estimate|||||||2016-05-23|2016-05-24|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|December 2021|Anticipated|2021-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients|Comparison of the Effectiveness of Neoadjuvant Chemotherapy and the Outcomes Associated With Chemo-induced Amenorrhea Between Docetaxel Plus Epirubicin, and Docetaxel Plus Epirubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients.|Recruiting||N/A|600|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 21:47:07.846223|2018-05-31 21:47:07.846223
NCT01503892|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2012-07-16|2011-12-31|2012-01-04|Estimate|||||||2012-07-16|2012-07-17|Estimate|December 2011||2011-12-31|July 2012|2012-07-31||||October 2013|Anticipated|2013-10-31||Interventional|SLHN2011-18||Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics|Metanx Effects on Nerve Fiber Density in Neuropathic Diabetics|Unknown status|Recruiting|N/A|100|Anticipated|St. Luke's Hospital and Health Network, Pennsylvania||2|||f||||t||||||||||2018-05-31 21:47:08.094183|2018-05-31 21:47:08.094183
NCT01503879|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-31|||2012-08-28|2012-01-03|2012-01-04|Estimate|||||||2012-08-28|2012-08-29|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|||||Observational|||Evaluation of Gas Exchange by the Measurement of Lung Diffusion for Carbon Monoxide During General Anaesthesia|Effects of General Anaesthesia and Invasive Mechanical Ventilation on Alveolo-capillary Membrane: Evaluation of Gas Exchange by the Measurement of Lung Diffusion for Carbon Monoxide (DLCO) and Plasma Dosage of Surfactant Protein-B (SPB).|Unknown status|Recruiting||20|Anticipated|San Gerardo Hospital|||||f||||f||||||Samples Without DNA|"~     surfactant protein B~   "|||2018-05-31 21:47:08.461551|2018-05-31 21:47:08.461551
NCT01503866|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2011-12-31|2011-12-31|2012-01-04|Estimate|||||||2011-12-31|2012-01-04|Estimate|December 2011||2011-12-31|December 2011|2011-12-31||||December 2011|Actual|2011-12-31||Interventional|||A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Bardoxolone Methyl Following a Single Oral Dose Administration in Healthy Male Subjects|Completed||Phase 1|6|Actual|Reata Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:47:08.844515|2018-05-31 21:47:08.844515
NCT01503853|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-31|||2018-04-04|2011-12-31|2012-01-04|Estimate|||||||2018-04-04|2018-04-05|Actual|April 16, 2011||2011-04-16|September 16, 2016|2016-09-16|September 16, 2016||2016-09-16|||||Observational|||Discussing Costs in the Doctor-Patient Encounter|Discussing Costs in the Doctor-Patient Encounter|Completed|||211|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:47:09.106607|2018-05-31 21:47:09.106607
NCT01501006|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2018-03-16|2011-12-26|2011-12-29|Estimate|||||||2018-03-16|2018-03-20|Actual|October 2010||2010-10-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|SBI||Social and Behavioral Influence (SBI)|Social and Behavioral Influences on Clinical Care|Completed|||96|Actual|University of Rochester|||1||f||||t||||||||||2018-05-31 21:47:48.9999|2018-05-31 21:47:48.9999
NCT01503840|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2014-04-20|2011-12-31|2012-01-04|Estimate|||||||2014-04-20|2014-04-22|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis|Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis|Completed||N/A|20|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||||||||||||2018-05-31 21:47:09.420507|2018-05-31 21:47:09.420507
NCT01503827|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-03-07|2012-01-02|2012-01-04|Estimate|||||||2018-03-07|2018-03-09|Actual|October 2007||2007-10-31|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|September 2017|Actual|2017-09-30||Interventional|WBRTMel||Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma|Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma - A Randomised Phase III Trial|Active, not recruiting||N/A|220|Anticipated|Australia and New Zealand Melanoma Trials Group||2|||f||||t|f|f||||||No||2018-05-31 21:47:09.708852|2018-05-31 21:47:09.708852
NCT01503814|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2017-05-15|2012-01-03|2012-01-04|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2012||2012-01-31|August 2014|2014-08-31|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional|SimCard||Simplified Cardiovascular Management Study|Simplified Cardiovascular Management Study: A Cluster-Randomized Trial to Evaluate the Effects of a Simplified Cardiovascular Management Program in Tibet, China and Haryana, India|Completed||N/A|2086|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||f||||||||||2018-05-31 21:47:10.100475|2018-05-31 21:47:10.100475
NCT01503801|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-01-24|2012-01-03|2012-01-04|Estimate|||||||2013-01-24|2013-01-28|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|NO-BPD||Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia|Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia in Preterm Infants|Completed||Phase 2/Phase 3|400|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 21:47:10.350616|2018-05-31 21:47:10.350616
NCT01503788|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Bedside Sedation for the Prevention of Post Dural Puncture Headache|Periprocedural Sedation for the Prevention of Post Dural Puncture Headache|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 21:47:10.648902|2018-05-31 21:47:10.648902
NCT01503775|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2017-06-19|2011-12-31|2012-01-04|Estimate|||||||2017-06-19|2017-06-20|Actual|December 1, 2011|Actual|2011-12-01|June 2017|2017-06-30|August 1, 2014|Actual|2014-08-01|August 1, 2014|Actual|2014-08-01||Observational|TRULINE||TRUfill®'s Line in Intracranial aNeurysm Embolisation|A Prospective, Multicentric Observational Study Evaluating the Long Term Efficacy and Safety of the CODMAN TRUFILL®'s Line of Coils in the Endovascular Treatment of Intracranial Aneurysms|Completed|||171|Actual|Codman & Shurtleff|||1||f||||t||||||||||2018-05-31 21:47:10.974658|2018-05-31 21:47:10.974658
NCT01503762|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2012-02-27|2012-01-03|2012-01-04|Estimate|||||||2012-02-27|2012-02-28|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Mirror Therapy and Hand Rehabilitation|Mirror Therapy in Patients With Hand Orthopedic Disorders|Completed||N/A|23|Actual|Ahvaz Jundishapur University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:47:11.040967|2018-05-31 21:47:11.040967
NCT01503749|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|2014-11-27||2014-12-17|2012-01-03|2012-01-04|Estimate|2014-12-17|2014-12-19|Estimate||||2014-12-17|2014-12-19|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis|The Role of Peripheral Mononuclear Cells for Treatment of Advanced Liver Cirrhosis|Completed||Phase 1|9|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 21:47:11.108749|2018-05-31 21:47:11.108749
NCT01503736|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2013-12-23|2012-01-03|2012-01-04|Estimate|||||||2013-12-23|2013-12-24|Estimate|June 2010||2010-06-30|December 2013|2013-12-31||||June 2012|Actual|2012-06-30||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease|Completed||Phase 3|183|Actual|Panion & BF Biotech Inc.||3|||f||||t||||||||||2018-05-31 21:47:11.439221|2018-05-31 21:47:11.439221
NCT01503723|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|August 2011||2011-08-31|September 2011|2011-09-30||||||||Observational|||Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors|Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     Exhaled breath condensate~   "|||2018-05-31 21:47:11.674057|2018-05-31 21:47:11.674057
NCT01503710|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|June 2011||2011-06-30|July 2011|2011-07-31|July 2012|Anticipated|2012-07-31|August 2011|Actual|2011-08-31||Observational|NSARF||Early Diagnosis of Postoperative Acute Renal Failure-using Biomarker to Predict Outcome of Cardiac Surgery Associated Acute Kidney Injury|Early Diagnosis of Postoperative Acute Renal Failure - Using Biomarker to Predict the Outcome of Cardiac Surgery Associated Acute Kidney Injury|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     Blood samples are drawn before the first dialysis session after postcardiac sugary associated~     severe AKI ( initializing RRT). Blood is drawn into Vacutainer tubes containing EDTA, and~     immediately placed on ice and centrifuged within 1 h. All the samples are stored at -70°C~     until analysis.~   "|||2018-05-31 21:47:12.045192|2018-05-31 21:47:12.045192
NCT01503697|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|January 2012||2012-01-31|January 2012|2012-01-31||||||||Observational|||The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer|The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer|Unknown status|Not yet recruiting||75|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 21:47:12.295119|2018-05-31 21:47:12.295119
NCT01503684|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|August 2011||2011-08-31|September 2011|2011-09-30||||||||Observational|||Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome|Biomarkers in Exhaled Breath Condensates of Septic Patients to Predict Development of Multi-organ Dysfunction Syndrome|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     Exhaled breath condensate~   "|||2018-05-31 21:47:12.631759|2018-05-31 21:47:12.631759
NCT01499030|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-01-11|2011-12-21|2011-12-26|Estimate|||||||2018-01-11|2018-01-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:48:24.203818|2018-05-31 21:48:24.203818
NCT01503671|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2015-08-09|2012-01-03|2012-01-04|Estimate|||||||2015-08-09|2015-08-11|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|ALEVENT||Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients|Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT)|Unknown status|Recruiting|Phase 4|36|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 21:47:12.854082|2018-05-31 21:47:12.854082
NCT01503658|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2012-06-18|2012-01-03|2012-01-04|Estimate|||||||2012-06-18|2012-06-19|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Clinical Trial to Evaluate the Influence of Genotype on the Pharmacokinetics/Pharmacodynamics of Clopidogrel|Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions on the Pharmacokinetics/Pharmacodynamics of Clopidogrel in Healthy Volunteers|Completed||Phase 4|18|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 21:47:13.111725|2018-05-31 21:47:13.111725
NCT01503645|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-11-12|2012-01-03|2012-01-04|Estimate|||||||2012-11-12|2012-11-14|Estimate|May 2006||2006-05-31|January 2012|2012-01-31||||||||Observational|||Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism|Epidemiology of Chinese Herb Nephropathy and Its Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-05-31 21:47:13.402677|2018-05-31 21:47:13.402677
NCT01503632|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-09-27|2012-01-03|2012-01-04|Estimate|||||||2017-09-27|2017-09-28|Actual|February 2012||2012-02-29|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission|A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL|Recruiting||Phase 3|608|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 21:47:13.652109|2018-05-31 21:47:13.652109
NCT01503619|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2017-06-26|2012-01-03|2012-01-04|Estimate|||||||2017-06-26|2017-06-27|Actual|January 2012||2012-01-31|June 2017|2017-06-30||||January 2100|Anticipated|2100-01-31||Observational|||Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202|Genomics of Small Cell Lung Carcinoma|Active, not recruiting|||23|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue, blood~   "|||2018-05-31 21:47:15.311237|2018-05-31 21:47:15.311237
NCT01503606|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2015-11-24|2012-01-01|2012-01-04|Estimate|||||||2015-11-24|2015-11-26|Estimate|October 2011||2011-10-31|November 2015|2015-11-30||||August 2016|Anticipated|2016-08-31||Interventional|||Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane|Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane, Phase III Study.|Unknown status|Recruiting|Phase 3|206|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 21:47:15.452594|2018-05-31 21:47:15.452594
NCT01503593|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2012-05-28|2012-01-03|2012-01-04|Estimate|||||||2012-05-28|2012-05-30|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Using Combination of Synthetic Bone Substitutes During Extractions|Phase 3 Study of Using Combination of Bi Phasic Calcium Phosphate and Bu Phasic Calcium Sulphate During Extractions|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 21:47:15.726855|2018-05-31 21:47:15.726855
NCT01503580|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2013-10-30|2012-01-03|2012-01-04|Estimate|||||||2013-10-30|2013-10-31|Estimate|August 2008||2008-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2010|Actual|2010-07-31||Interventional|||Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome|Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome|Completed||N/A|155|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 21:47:15.958733|2018-05-31 21:47:15.958733
NCT01503567|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2017-01-17|2012-01-02|2012-01-04|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|HAEMOcare||Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries|Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries|Completed|||282|Actual|Novo Nordisk A/S|||4||f||||f||||||||||2018-05-31 21:47:16.140759|2018-05-31 21:47:16.140759
NCT01503554|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2013-05-30|2011-12-30|2012-01-04|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Combined Social Worker and Pharmacist Transitional Care Program|Multidisciplinary Care Transition Intervention - Cardinal Health Grant|Completed||N/A|100|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 21:47:16.396575|2018-05-31 21:47:16.396575
NCT01503541|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2015-03-05|2012-01-01|2012-01-04|Estimate|||||||2015-03-05|2015-03-06|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin|The Development of Predictive Biomarker Models for Patients Receiving Standard Induction Chemotherapy With and Without Gemtuzumab Ozogamicin|Completed|||365|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-05-31 21:47:16.561921|2018-05-31 21:47:16.561921
NCT01503528|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2017-11-28|2012-01-03|2012-01-04|Estimate|||||||2017-11-28|2017-11-30|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Motor Sparing Block vs. Peri-Articular Catheters|Outcomes After Total Knee Joint Arthroplasty: A Comparative Study Using 3 Different Analgesic Techniques|Recruiting||Phase 4|70|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||||2018-05-31 21:47:16.698748|2018-05-31 21:47:16.698748
NCT01503515|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2018-01-24|2012-01-01|2012-01-04|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31||||September 2018|Anticipated|2018-09-30||Interventional|||Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant|A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)|Active, not recruiting||Phase 3|292|Actual|Children's Oncology Group||2|||f||||t|f|f||||||||2018-05-31 21:47:17.105242|2018-05-31 21:47:17.105242
NCT01502800|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2018-05-09|2011-12-29|2012-01-02|Estimate|||||||2018-05-09|2018-05-15|Actual|December 29, 2011|Actual|2011-12-29|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Trial of ARQ 761 in Advanced Solid Tumors|A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|27|Actual|University of Texas Southwestern Medical Center||4|||f||||t||||||||No||2018-05-31 21:47:31.371212|2018-05-31 21:47:31.371212
NCT01503502|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2013-04-09|2012-01-01|2012-01-04|Estimate|||||||2013-04-09|2013-04-10|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|June 2012|Actual|2012-06-30||Interventional|||A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia|Phase II Study of Flumatinib Versus Imatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Unknown status|Active, not recruiting|Phase 2|150|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||t||||||||||2018-05-31 21:47:17.497368|2018-05-31 21:47:17.497368
NCT01503489|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|October 2005||2005-10-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|January 2010|Actual|2010-01-31||Observational|||Risk Factors for AD-Associated Switch to Mania|Risk for Antidepressant-associated Switch From Depression to Hypomania, Mania, or Mixed Episode During the 8 Weeks After the Introduction of an Antidepressant or After Increasing the Dosage of Baseline Antidepressant.|Completed|||221|Actual|Hospital Clinic of Barcelona|||1||f||||t||||||||||2018-05-31 21:47:17.736753|2018-05-31 21:47:17.736753
NCT01503476|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2015-07-15|2012-01-03|2012-01-04|Estimate|||||||2015-07-15|2015-07-16|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance|RD-40 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance|Unknown status|Active, not recruiting|Phase 4|170|Anticipated|Given Imaging Ltd.||2|||f||||f||||||||||2018-05-31 21:47:18.119189|2018-05-31 21:47:18.119189
NCT01503463|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2015-03-19|2012-01-03|2012-01-04|Estimate|||||||2015-03-19|2015-03-20|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|RHCluster7GR||Remote Monitoring of Patients With CHF in Central Greece|Renewing Health RCT for the Evaluation of Remote Monitoring of Patients With Congestive Heart Failure (CHF) in Central Greece|Completed||N/A|60|Actual|Regional Health Authority of Sterea & Thessaly||2|||f||||t||||||||||2018-05-31 21:47:18.304745|2018-05-31 21:47:18.304745
NCT01503450|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-04|2012-01-03|2012-01-04|Estimate|||||||2012-01-04|2012-01-05|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fed Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:47:18.642631|2018-05-31 21:47:18.642631
NCT01503437|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-04|2012-01-03|2012-01-04|Estimate|||||||2012-01-04|2012-01-05|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Bioequivalence Study of Olanzapine 5 mg OD Tablets With Zyprexa Zydis 5 mg Tablets in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|22|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:47:18.808511|2018-05-31 21:47:18.808511
NCT01503424|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-04|2012-01-03|2012-01-04|Estimate|||||||2012-01-04|2012-01-05|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Olanzapine Tablets 5 mg With Zyprexa® Tablets 5 mg in Healthy Subjects Under Fed Conditions|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:47:18.970046|2018-05-31 21:47:18.970046
NCT01503411|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2014-04-08|2011-12-30|2012-01-04|Estimate|||||||2014-04-08|2014-04-09|Estimate|January 2012||2012-01-31|April 2014|2014-04-30||||March 2014|Actual|2014-03-31||Observational|||High Resolution Optical Imaging of Barrett's Esophagus Using Nvision Volumetric Laser Endomicroscopy (VLE)|High Resolution Optical Imaging of Barrett's Esophagus Using Nvision Volumetric Laser Endomicroscopy (VLE)|Completed|||120|Actual|NinePoint Medical|||||f||||f||||||||||2018-05-31 21:47:19.306706|2018-05-31 21:47:19.306706
NCT01503398|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-01-04|2012-01-03|2012-01-04|Estimate|||||||2012-01-04|2012-01-05|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Olanzapine Tablets 5 mg With Zyprexa® Tablets 5 mg in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:47:19.511025|2018-05-31 21:47:19.511025
NCT01503385|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 21:47:19.78048|2018-05-31 21:47:19.78048
NCT01503372|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-01-10|2012-01-01|2012-01-04|Estimate|||||||2012-01-10|2012-01-11|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|PaFLO||FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer|Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie|Unknown status|Recruiting|Phase 2|75|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 21:47:20.013935|2018-05-31 21:47:20.013935
NCT01503359|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2016-09-15|2012-01-03|2012-01-04|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|February 2015|Actual|2015-02-28||Interventional|PULSAR||Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia|Effect of Sarcosine on Symptomatology, Quality of Life, Cognitive and Sexual Functioning, Blood Levels of Sarcosine, Glycine, BDNF and MMP-9, Oculomotor, Brain Metabolism and Oxidative Stress Parameters in Schizophrenia.|Completed||Phase 2|70|Anticipated|Medical Universtity of Lodz||2|||f||||f||||||||||2018-05-31 21:47:20.819719|2018-05-31 21:47:20.819719
NCT01499979|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-01-25|2011-12-23|2011-12-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Hypothermic Perfusion During Hemihepatectomy|In Situ Hypothermic Perfusion During Right Hemihepatectomy|Completed||N/A|22|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||Undecided||2018-05-31 21:48:06.662386|2018-05-31 21:48:06.662386
NCT01503346|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2012-01-03|2012-01-03|2012-01-04|Estimate|||||||2012-01-03|2012-01-04|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|March 2012|Anticipated|2012-03-31|September 2011|Actual|2011-09-30||Interventional|TCM||DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients|Taking Herbal Formula：DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients in Late-stage：A Clinical Control Trial Study|Unknown status|Recruiting|Phase 2|30|Anticipated|Changhua Christian Hospital||1|||f||||f||||||||||2018-05-31 21:47:21.319412|2018-05-31 21:47:21.319412
NCT01503333|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2016-05-02|2012-01-03|2012-01-04|Estimate|||||||2016-05-02|2016-05-03|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Girls on the Move Intervention to Increase Physical Activity Among Middle School Girls|Girls on the Move Intervention|Completed||Phase 3|1543|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 21:47:21.803551|2018-05-31 21:47:21.803551
NCT01503320|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2015-06-03|2012-01-03|2012-01-04|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy of Enteral Glutamine Supplementation in Patients With Predicted Severe Acute Pancreatitis- A Double-Blinded Randomized Controlled Trial||Completed||N/A|60|Actual|Asian Institute of Gastroenterology, India||2|||f||||t||||||||||2018-05-31 21:47:22.082435|2018-05-31 21:47:22.082435
NCT01503307|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2015-08-19|2011-12-30|2012-01-04|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Parenting After Infant Congenital Heart Defect Diagnosis|Parenting After Infant Congenital Heart Defect Diagnosis|Active, not recruiting|||16|Anticipated|Medical College of Wisconsin|||1||f||||f||||||||||2018-05-31 21:47:22.628213|2018-05-31 21:47:22.628213
NCT01503294|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2014-06-27|2012-01-03|2012-01-04|Estimate|||||||2014-06-27|2014-06-30|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||Comparison of Temporal to Pulmonary Artery Temperature Measurement in Patients With Fever|Comparison of Temporal to Pulmonary Artery Temperature Measurement in Patients With Fever|Completed|||60|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 21:47:23.05524|2018-05-31 21:47:23.05524
NCT01503281|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-01-11|2012-01-03|2012-01-04|Estimate|||||||2012-01-11|2012-01-12|Estimate||||January 2011|2011-01-31||||||||Interventional|||Effects of Group Vs. Home-Based Combined Exercise-Diet Program In Childhood Obesity: A Randomised Controlled Trial|Effects of Group Vs. Home-Based Combined Exercise-Diet Program In Childhood Obesity: A Randomised Controlled Trial|Completed||N/A|110|Actual|Cardenal Herrera University||3|||f||||f||||||||||2018-05-31 21:47:23.144331|2018-05-31 21:47:23.144331
NCT01503268|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2013-06-19|2012-01-03|2012-01-04|Estimate|||||||2013-06-19|2013-06-21|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|ACTUAL||Atrial Fibrillation After Catheter Versus Thoracoscopic Ablation Using Patient Activated Implantable Loop Recorders: The ACTUAL Study|Atrial Fibrillation After Catheter Versus Thoracoscopic Ablation Using Patient Activated Implantable Loop Recorders|Withdrawn||Phase 4|0|Actual|Eastbourne General Hospital||3||Study methodology redesigned|f||||t||||||||||2018-05-31 21:47:23.274449|2018-05-31 21:47:23.274449
NCT01503255|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-07-13|2011-12-30|2012-01-04|Estimate|||||||2017-07-13|2017-07-14|Actual|July 2012||2012-07-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|RAFIKI||A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention|A Stage 2 Cognitive-behavioral Trial: Reduce Alcohol First in Kenya Intervention|Completed||Phase 1|614|Actual|Brown University||2|||f||||t||||||||||2018-05-31 21:47:23.518308|2018-05-31 21:47:23.518308
NCT01503242|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2017-09-20|2011-12-30|2012-01-02|Estimate|||||||2017-09-20|2017-09-25|Actual|January 9, 2012|Actual|2012-01-09|September 2017|2017-09-30|December 6, 2019|Anticipated|2019-12-06|June 6, 2017|Actual|2017-06-06||Interventional|||90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma|Active, not recruiting||Phase 1|15|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 21:47:23.853351|2018-05-31 21:47:23.853351
NCT01503229|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2018-01-17|2011-12-30|2012-01-02|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2012|Actual|2012-12-31|January 2018|2018-01-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer|Completed||Phase 2|28|Actual|University of Washington||1|||f||||||||||||||2018-05-31 21:47:24.051501|2018-05-31 21:47:24.051501
NCT01503216|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-10-07|2011-12-30|2012-01-02|Estimate|||||||2012-10-07|2012-10-10|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Bioefficacy of Vitamin D2 and Vitamin D3|Safety and Bioefficacy of Vitamin D2 and Vitamin D3: Randomized Trial With Human Volunteers|Completed||N/A|120|Actual|Martin-Luther-Universität Halle-Wittenberg||3|||f||||t||||||||||2018-05-31 21:47:24.36682|2018-05-31 21:47:24.36682
NCT01503203|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2011-12-29|2011-12-29|2012-01-02|Estimate|||||||2011-12-29|2012-01-02|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|August 2012|Anticipated|2012-08-31|April 2012|Anticipated|2012-04-30||Interventional|||Physical Virtual Training for Older Women|Physical Virtual Training Effectiveness on Nonspecific Chronic Low Back Pain, Body Balance, Functional Autonomy and Mood of Older Women|Unknown status|Recruiting|N/A|39|Anticipated|Universidade Gama Filho||2|||f||||f||||||||||2018-05-31 21:47:24.686651|2018-05-31 21:47:24.686651
NCT01503190|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2018-01-17|2011-12-30|2012-01-02|Estimate|||||||2018-01-17|2018-01-19|Actual|July 21, 2009|Actual|2009-07-21|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Observational|||The Immune System's Response to Young Women's Breast Cancer|A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction|Recruiting|||800|Anticipated|University of Colorado, Denver|||||f||||f|f|f||||Samples With DNA|"~     Tissue, Blood and urine may be collected from subjects who were recently diagnosed. Subjects~     who were diagnosed after treatment begins or has ended will only be eligible for tissue~     donation section of study~   "|No||2018-05-31 21:47:24.789528|2018-05-31 21:47:24.789528
NCT01503177|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-08-28|2011-12-30|2012-01-02|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2011|Actual|2011-11-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma|A Phase 1 Trial of Oncolytic Measles Virotherapy in Mesothelioma|Recruiting||Phase 1|36|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:47:24.948501|2018-05-31 21:47:24.948501
NCT01503164|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|2017-08-10||2017-10-18|2011-12-30|2012-01-02|Estimate|2017-10-18|2017-10-19|Actual||||2017-10-18|2017-10-19|Actual|September 2011|Actual|2011-09-30|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SOMNOS|55 randomized to PAP (2 dropout); 56 randomized to lifestyle (1 dropout)|Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism|Sleep, Obesity, and Metabolism in Normal and Overweight Subjects: Effects of CPAP on Glucose Metabolism|Completed||N/A|111|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:47:25.119726|2018-05-31 21:47:25.119726
NCT01503151|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2014-12-01|2011-12-30|2012-01-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CBMSP||Cognitive Biases Modification Treatment for Social Anxiety|Cognitive Biases Modification Treatment for Social Anxiety|Completed||Phase 2|95|Actual|Tel Aviv University||4|||f||||f||||||||||2018-05-31 21:47:25.653637|2018-05-31 21:47:25.653637
NCT01503138|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2014-12-02|2011-12-30|2012-01-02|Estimate|||||||2014-12-02|2014-12-03|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Intervention for Abused Chinese Immigrant Women|The Effect of a Purpose-built Intervention on Mental Health in Mainland Chinese Immigrant Women Survivors of Intimate Partner Violence: A Randomized Controlled Trial|Completed||N/A|250|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:47:25.732994|2018-05-31 21:47:25.732994
NCT01503125|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-01-26|2011-12-30|2012-01-02|Estimate|||||||2017-01-26|2017-01-27|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Observational|||Giant Axonal Neuropathy Natural History Study|Clinical Study of Giant Axonal Neuropathy|Terminated|||13|Actual|Columbia University||||PI left the institution|f||||f|f|f||||Samples With DNA|"~     Skin Tissue, Blood, Cerebrospinal fluid (CSF)~   "|Undecided||2018-05-31 21:47:25.826089|2018-05-31 21:47:25.826089
NCT01503112|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-04-17|2011-12-30|2012-01-02|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2011||2011-05-31|April 2018|2018-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|PRIBA||Predicting Response to Incretin Based Agents in Type 2 Diabetes|Does Urinary C-peptide Creatinine Ratio Predict Response to Incretin Based Agents in Type 2 Diabetes|Completed|||957|Actual|Royal Devon and Exeter NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Extracted DNA, stored serum/plasma~   "|||2018-05-31 21:47:25.901214|2018-05-31 21:47:25.901214
NCT01503099|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2011-12-30|2011-12-30|2012-01-02|Estimate|||||||2011-12-30|2012-01-02|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease|Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease in Populations of High vs. Low Tuberculosis Endemicity|Unknown status|Recruiting||550|Anticipated|Lovisenberg Diakonale Hospital|||6||f||||f||||||Samples With DNA|"~     Stool samples frozen at -20'C. Blood serum samples frozen at -20'C. Saliva samples stored at~     room temperature. Paraffin embedded intestinal biopsies.~   "|||2018-05-31 21:47:26.021476|2018-05-31 21:47:26.021476
NCT01503086|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2017-07-10|2011-12-30|2012-01-02|Estimate|||||||2017-07-10|2017-07-12|Actual|November 2013||2013-11-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy|Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study|Recruiting||N/A|71|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 21:47:26.15241|2018-05-31 21:47:26.15241
NCT01503073|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2018-05-02|2011-12-30|2012-01-02|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2008|Actual|2008-01-31|May 2018|2018-05-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31||Interventional|NIBSstroke||Noninvasive Brain Stimulation for Stroke|Noninvasive Brain Stimulation for Stroke Improvement|Recruiting||N/A|200|Anticipated|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 21:47:26.316852|2018-05-31 21:47:26.316852
NCT01503060|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2015-11-09|2011-12-29|2012-01-02|Estimate|||||||2015-11-09|2015-11-10|Estimate|December 2011||2011-12-31|November 2015|2015-11-30||||April 2016|Anticipated|2016-04-30||Interventional|||Effectiveness of Parent-Led Interventions in Reducing Infant Hypersensitivity to Pain|Effectiveness of Parent-Led Interventions in Reducing Infant Hypersensitivity to Pain: A Longitudinal Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|352|Anticipated|The Hospital for Sick Children||4|||f||||f||||||||||2018-05-31 21:47:26.411148|2018-05-31 21:47:26.411148
NCT01503047|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2012-01-02|2011-12-30|2012-01-02|Estimate|||||||2012-01-02|2012-01-05|Estimate|March 2008||2008-03-31|January 2012|2012-01-31||||March 2010|Actual|2010-03-31||Interventional|CLA||Conjugated Linoleic Acid (1:1 Isomer Mixture) Intake in Overweight People|Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tonalin(R)Intake in Overweight People|Completed||Phase 4|50|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||2|||f||||||||||||||2018-05-31 21:47:26.535587|2018-05-31 21:47:26.535587
NCT01503034|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-30|||2018-03-30|2011-12-30|2012-01-02|Estimate|||||||2018-03-30|2018-04-03|Actual|December 14, 2010|Actual|2010-12-14|March 2018|2018-03-31|September 28, 2015|Actual|2015-09-28|September 28, 2015|Actual|2015-09-28||Observational|||Pregnant Women With a Breast Cancer Diagnosed Between 2000 and 2014|Study of Tumor Characteristics, Patient Care and Prognosis of Women With Breast Cancer During a Pregnancy Diagnosed Between 2000 and 2014|Completed|||394|Actual|Centre Oscar Lambret|||2||f||||f||||||||||2018-05-31 21:47:26.604288|2018-05-31 21:47:26.604288
NCT01503021|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|2015-04-03||2016-09-14|2011-12-30|2012-01-02|Estimate|2015-04-03|2015-04-21|Estimate||||2016-09-14|2016-10-25|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||All participants who received at least one dose of study drug.|Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis|A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Multicenter Phase III Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in Chronic Kidney Disease Patients Receiving Chronic Hemodialysis|Completed||Phase 3|718|Actual|Rockwell Medical Technologies, Inc.||2|||f||||f||||||||||2018-05-31 21:47:26.741809|2018-05-31 21:47:26.741809
NCT01503008|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2013-03-01|2011-12-30|2012-01-02|Estimate|||||||2013-03-01|2013-03-05|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Proteus Sustained Behavior Change Study|Proteus Sustained Behavior Change Study|Withdrawn||N/A|0|Actual|Proteus Digital Health, Inc.||2|||f||||f||||||||||2018-05-31 21:47:28.293312|2018-05-31 21:47:28.293312
NCT01502995|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-30|2011-12-30|2012-01-02|Estimate|||||||2011-12-30|2012-01-02|Estimate|June 2003||2003-06-30|December 2011|2011-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease|Laser Light Visual Cueing for Freezing of Gait in Parkinson's Disease|Completed||Phase 3|22|Actual|Parkinson's Disease Research, Education, and Clinical Center, Philadelphia||2|||f||||f||||||||||2018-05-31 21:47:28.380602|2018-05-31 21:47:28.380602
NCT01502982|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-09-27|2011-12-30|2012-01-02|Estimate|||||||2014-09-27|2014-09-30|Estimate|November 2004||2004-11-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|CRY-04||Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)|CHOEP-14 + Rituximab With CNS Prophylaxis in Patients Less Than 65 Years With Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade III, Stage II-IV With Risk Factors (Age Adjusted IPI) ≥ 2. A Phase II Study|Completed||Phase 2|160|Actual|Nordic Lymphoma Group||1|||f||||f||||||||||2018-05-31 21:47:28.458132|2018-05-31 21:47:28.458132
NCT01502969|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-29|||2011-12-30|2011-12-30|2012-01-02|Estimate|||||||2011-12-30|2012-01-02|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|Rotavin-M1||Safety and Immunogenicity Assessment of Rotavin-M1 in Vietnamese Children|A Phase 2b Study of Rotavin-M1 Vaccine in Vietnamese Children|Completed||Phase 2/Phase 3|799|Actual|National Institute of Hygiene and Epidemiology, Vietnam||2|||f||||t||||||||||2018-05-31 21:47:28.562089|2018-05-31 21:47:28.562089
NCT01502956|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|2017-10-03||2018-04-30|2011-12-29|2012-01-02|Estimate|2018-02-06|2018-03-08|Actual||||2018-04-30|2018-05-02|Actual|February 2012||2012-02-29|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ROSETTA|All eligible participants who provided at least 1 post-baseline diary assessment.|Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)|Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)|Completed||Phase 3|386|Actual|NICHD Pelvic Floor Disorders Network||2|||f||||t||||||||No||2018-05-31 21:47:28.706942|2018-05-31 21:47:28.706942
NCT01502943|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-30|2011-12-30|2012-01-02|Estimate|||||||2011-12-30|2012-01-02|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index|Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index With Stable Angina Pectoris of Coronary Heart Disease as an Example|Completed||Phase 4|480|Actual|Liaoning University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 21:47:30.244664|2018-05-31 21:47:30.244664
NCT01502930|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-05-15|2011-12-30|2012-01-02|Estimate|||||||2014-05-15|2014-05-16|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|MARI||Treatment of Nightmares Via the Internet|MARI - Treatment of Nightmares Via the Internet - a Randomized Controlled Trial|Completed||Phase 3|175|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 21:47:30.414297|2018-05-31 21:47:30.414297
NCT01502917|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-09-21|2011-12-30|2012-01-02|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2011||2011-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy|A Phase I Study of Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy|Recruiting||Phase 1|64|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:47:30.508714|2018-05-31 21:47:30.508714
NCT01502904|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2016-07-25|2011-12-29|2012-01-02|Estimate|||||||2016-07-25|2016-07-27|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents||Completed||Phase 4|120|Actual|Yonsei University||6|||f||||f||||||||||2018-05-31 21:47:30.618147|2018-05-31 21:47:30.618147
NCT01502891|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2015-12-30|2011-12-30|2012-01-02|Estimate|||||||2015-12-30|2015-12-31|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|iADAPT||Making Decisions About Depression Medications|Translation of Comparative Effectiveness of Depression Medications Into Practice|Completed||N/A|301|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:47:30.735853|2018-05-31 21:47:30.735853
NCT01502878|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2016-09-12|2011-12-30|2012-01-02|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Nut Allergy Study: Double-blind Challenge and Oral Desensitization|Nut Allergy Study: Improving Diagnosis And Treatment Of Nut Allergy|Completed||N/A|102|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 21:47:30.820528|2018-05-31 21:47:30.820528
NCT01502865|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-10-18|2011-12-30|2012-01-02|Estimate|||||||2017-10-18|2017-10-20|Actual|December 2010|Actual|2010-12-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|CASSI||Clinician Access to Soldier Suicide Information (CASSI)|Clinician Access to Soldier Suicide Information (CASSI)|Withdrawn|||0|Actual|VA Eastern Colorado Health Care System||||Should not have been listed on ClinicalTrials|f||||f||||||||||2018-05-31 21:47:30.898675|2018-05-31 21:47:30.898675
NCT01502852|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2014-11-24|2011-12-29|2012-01-02|Estimate|||||||2014-11-24|2014-11-25|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Identifying the Needs of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans and Their Families: TBI and Co-Occurring Behavioral Health Issues|Identifying the Needs of OEF/OIF Veterans and Their Families: TBI and Co-Occurring Behavioral Health Issues|Completed|||44|Actual|VA Eastern Colorado Health Care System|||3||f||||f||||||||||2018-05-31 21:47:30.950756|2018-05-31 21:47:30.950756
NCT01502839|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2017-05-12|2011-12-30|2012-01-02|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2011||2011-03-31|December 2012|2012-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Role of NSI in Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions|Differentiating Between Mild Traumatic Brain Injury And Behavioral Health Conditions: The Role of The Neurobehavioral Symptom Inventory|Terminated|||887|Actual|VA Eastern Colorado Health Care System|||1|Unable to complete the data collection for this study.|f||||t||||||||||2018-05-31 21:47:31.008913|2018-05-31 21:47:31.008913
NCT01502826|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2012-01-18|2011-12-29|2012-01-02|Estimate|||||||2012-01-18|2012-01-19|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|December 2013|Anticipated|2013-12-31|||||Observational|||Mechanisms of Atherogenesis During Post-prandial Time in Childhood Obesity|Candidate Mechanisms of Atherogenesis During the Post-prandial Period in the Obese Child/Adolescent|Unknown status|Not yet recruiting||40|Anticipated|Universita di Verona|||2||f||||t||||||Samples With DNA|"~     Whole blood Serum Plasma Urine~   "|||2018-05-31 21:47:31.069383|2018-05-31 21:47:31.069383
NCT01502813|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-05-24|2011-12-29|2012-01-02|Estimate|||||||2017-05-24|2017-05-30|Actual|February 2012||2012-02-29|May 2017|2017-05-31|October 30, 2017|Anticipated|2017-10-30|October 30, 2017|Anticipated|2017-10-30||Interventional|||Citicoline, Creatine, and Omega-3 Effects in Middle Age Women||Active, not recruiting||N/A|25|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 21:47:31.142586|2018-05-31 21:47:31.142586
NCT01502787|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2014-12-02||2014-12-29|2011-12-29|2012-01-02|Estimate|2014-12-29|2014-12-31|Estimate||||2014-12-29|2014-12-31|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients|Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients|Completed||Phase 4|46|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 21:47:31.457709|2018-05-31 21:47:31.457709
NCT01502774|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2018-02-23|2011-12-29|2012-01-02|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2011||2011-04-30|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|CIRCUS||Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients|Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients|Completed||Phase 3|970|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 21:47:31.724406|2018-05-31 21:47:31.724406
NCT01502761|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2017-06-30||2017-07-26|2011-12-29|2012-01-02|Estimate|2017-07-26|2017-08-28|Actual||||2017-07-26|2017-08-28|Actual|March 2012||2012-03-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||4 patients were enrolled (regional intra-arterial Magnesium 0.75g) before the study was stopped (not due to safety concerns). They were all enrolled in the first group|Intra-arterial Magnesium Administration for Acute Stroke|Intra-arterial Magnesium Therapy: A Novel Platorm for Neuroprotectant Delivery in Acute Stroke|Terminated||Phase 1/Phase 2|4|Actual|University of Southern California|The trial was terminated early (with enrollment only in the first arm) by the investigators due to low enrollment (given results of relevant studies at the time) . There were no safety concerns with the trial or the agent.|4||No safety issues. Low enrollment secondary to negative stroke studies 2013|f||||t||||||||||2018-05-31 21:47:31.921653|2018-05-31 21:47:31.921653
NCT01502748|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2017-07-27|2011-12-30|2012-01-02|Estimate|||||||2017-07-27|2017-08-01|Actual|March 2012||2012-03-31|July 2017|2017-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Endovascular Magnesium Sampling in Acute Stroke|Magnesium Therapy: a Novel Platform for Neuroprotectant Sampling in Acute Stroke|Terminated||N/A|2|Actual|University of Southern California||1||FAST-Mag study finished|f||||f|f|f||||||No||2018-05-31 21:47:32.307477|2018-05-31 21:47:32.307477
NCT01502735|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2015-04-21|2011-12-29|2012-01-02|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|DENV-1 PIV||Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease|A Phase 1 Trial of the Walter Reed Army Institute of Research (WRAIR) Dengue Virus Serotype-1 Purified Inactivated Vaccine (DENV-1 PIV) in Flavivirus Antibody Naïve Adults|Completed||Phase 1|20|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-05-31 21:47:32.385267|2018-05-31 21:47:32.385267
NCT01502722|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2013-01-15|2011-12-29|2012-01-02|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Effect of Ingestion of Sugary Drinks on Thirst Sensation|Effect of Ingestion of Sugary Drinks on Thirst Sensation|Completed||N/A|24|Actual|Universidade do Porto||3|||f||||t||||||||||2018-05-31 21:47:32.476253|2018-05-31 21:47:32.476253
NCT01502709|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2013-08-02||2016-04-25|2011-12-30|2012-01-02|Estimate|2016-04-25|2016-04-26|Estimate||||2016-04-25|2016-04-26|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|CVS||Neurostimulation in Temporomandibular Disorders (TMD) Patients|Randomized Blinded Placebo-Controlled Clinical Trial of Caloric Vestibular Neurostimulation in Patients With Chronic TMD|Terminated||N/A|5|Actual|University of North Carolina, Chapel Hill||2||recruiting difficulties|f||||f||||||||No||2018-05-31 21:47:32.589912|2018-05-31 21:47:32.589912
NCT01502696|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-02-28|2011-12-29|2012-01-02|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2012||2012-10-31|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Adjuvant PEG Intron in Ulcerated Melanoma|Adjuvant Pegylated-Interferon-alpha2b (SylatronTM) for 2 Years Versus Observation in Patients With an Ulcerated Primary Cutaneous Melanoma With T(2-4)bN0M0: a Randomized Phase III Trial of the EORTC Melanoma Group.|Active, not recruiting||Phase 3|1200|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 21:47:32.854508|2018-05-31 21:47:32.854508
NCT01502683|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2017-01-20|2011-12-29|2012-01-02|Estimate|||||||2017-01-20|2017-01-24|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Stroke Study: Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery|Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery|Completed||N/A|193|Actual|Emory University||4|||f||||t||||||||||2018-05-31 21:47:33.028352|2018-05-31 21:47:33.028352
NCT01502670|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2013-11-18|2011-12-30|2012-01-02|Estimate|||||||2013-11-18|2013-11-19|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|SPN||Amino Acid Tracer (FACBC) Positron Emission Tomography for Lung Nodule|A Pilot Study of the Utility of the Novel Amino Acid Radiotracer Anti-[18 F]FACBC for the Noninvasive Imaging of Lung Nodules|Completed||Phase 1|10|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:47:33.104443|2018-05-31 21:47:33.104443
NCT01502657|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-12-30|2011-12-30|2012-01-02|Estimate|||||||2011-12-30|2012-01-02|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Ultrasound Guided Percutaneous Tracheostomy|Ultrasound Guided Percutaneous Tracheostomy in the ICU|Completed||N/A|40|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||f||||||||||2018-05-31 21:47:33.17023|2018-05-31 21:47:33.17023
NCT01502644|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|2017-04-07||2017-06-14|2011-12-29|2012-01-02|Estimate|2017-06-07|2017-06-08|Actual||||2017-06-14|2017-07-11|Actual|February 2009|Actual|2009-02-28|June 2017|2017-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Modified Intent-to-Treat Population, all participants who completed at least 50% of the opioid treatment period (at least 10 weeks of treatment).|Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms|Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms|Completed||Phase 4|81|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 21:47:33.244137|2018-05-31 21:47:33.244137
NCT01502631|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27||2016-08-23|2016-08-23|2011-12-29|2012-01-02|Estimate||||2016-08-23|2016-08-25|Estimate|2016-08-23|2016-08-25|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury|Completed||Phase 2|62|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||||2018-05-31 21:47:33.464003|2018-05-31 21:47:33.464003
NCT01502618|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-02-27|2011-12-27|2011-12-30|Estimate|||||||2017-02-27|2017-02-28|Actual|August 2010||2010-08-31|May 2016|2016-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Intervention for HIV-Positive Black Young Men Who Have Sex With Men (YMSM)|Development of a Secondary Prevention Intervention Targeting HIV-Positive Black Young Men Who Have Sex With Men|Completed||N/A|18|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 21:47:33.589246|2018-05-31 21:47:33.589246
NCT01502605|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-01-03|2011-12-29|2011-12-30|Estimate|||||||2017-01-03|2017-01-05|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31||Interventional|||Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas|Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas|Terminated||Phase 1|6|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||PI leaving institution|f||||t||||||||||2018-05-31 21:47:33.642354|2018-05-31 21:47:33.642354
NCT01502592|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2016-01-04|2011-12-29|2011-12-30|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer|A Pilot Study of Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer|Completed||Phase 1|19|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 21:47:33.840211|2018-05-31 21:47:33.840211
NCT01502579|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2013-08-27|2011-12-29|2011-12-30|Estimate|||||||2013-08-27|2013-08-28|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data|An Observational Study of the Relationship Between Pathological Variants and Clinical Data at Presentation and Follow-up in IgA Nephropathy|Completed|||603|Actual|Guangdong General Hospital|||||f||||t||||||||||2018-05-31 21:47:33.91132|2018-05-31 21:47:33.91132
NCT01502566|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2013-07-19|2011-12-29|2011-12-30|Estimate|||||||2013-07-19|2013-07-22|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|||Educational Intervention in Preventing Early Childhood Caries|A Cluster-randomized Trial of the Effectiveness of an Educational Intervention in Preventing Early Childhood Caries|Completed||Phase 3|500|Actual|Federal University of Pelotas||2|||f||||f||||||||||2018-05-31 21:47:33.965148|2018-05-31 21:47:33.965148
NCT01502553|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-29|2011-12-29|2011-12-30|Estimate|||||||2011-12-29|2011-12-30|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|BPM_S||Clinical Study of Blood Pressure Monitor in Conformance With the ANSI/AAMI SP10|Verify the Functions of BPM LS-802 to Comply With ANSI/AAMI SP10|Completed||N/A|95|Actual|BTS International||1|||f||||f||||||||||2018-05-31 21:47:34.026083|2018-05-31 21:47:34.026083
NCT01502540|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2013-01-13|2011-12-29|2011-12-30|Estimate|||||||2013-01-13|2013-01-15|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Pain Prevalence After Major Craniotomy|Pain Prevalence After Major Craniotomy in Siriraj Hospital|Completed|||302|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 21:47:34.096363|2018-05-31 21:47:34.096363
NCT01502527|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-03-16|2011-12-29|2011-12-30|Estimate|||||||2017-03-16|2017-03-20|Actual|January 2011||2011-01-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy|An Open Labeled Prospective Study to Investigate the Effect of Femarelle® on Vulvo-vaginal Atrophy Symptoms|Completed||N/A|12|Actual|Dr. Lila Nachtigall Rapid Medical Research, New York||1|||f||||f||||||||||2018-05-31 21:47:34.145009|2018-05-31 21:47:34.145009
NCT01502514|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2017-07-19|2011-12-29|2011-12-30|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2011||2011-05-31|July 2017|2017-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Ischemic Congestive Heart Failure Patients|Withdrawn||Phase 1|0|Actual|Ageless Regenerative Institute||||no participants enrolled|f||||f||||||||||2018-05-31 21:47:34.207864|2018-05-31 21:47:34.207864
NCT01502501|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2017-07-19|2011-12-29|2011-12-30|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2011||2011-05-31|July 2017|2017-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Intramyocardial and Intravenous Implantation of Autologous Adipose-Derived Stem Cells in Non-Ischemic Congestive Heart Failure Patients|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||||no participants enrolled|f||||f||||||||||2018-05-31 21:47:34.330854|2018-05-31 21:47:34.330854
NCT01502488|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2017-07-19|2011-12-29|2011-12-30|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2016||2016-10-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Adipose Derived Stem Cell Therapy for Autism|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Autism|Withdrawn||Phase 1/Phase 2|0|Actual|Ageless Regenerative Institute|||||f||||f||||||||Undecided||2018-05-31 21:47:34.399935|2018-05-31 21:47:34.399935
NCT01502475|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2014-11-25|2011-12-28|2011-12-30|Estimate|||||||2014-11-25|2014-12-02|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|CACMAS||A Survey of Complementary and Conventional Medicine Use Patterns in the Veteran Population|A Survey of Complementary and Conventional Medicine Use Patterns in the Veteran Population|Completed|||97|Actual|VA Eastern Colorado Health Care System|||1||f||||f||||||||||2018-05-31 21:47:34.469244|2018-05-31 21:47:34.469244
NCT01502462|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2018-01-09|2011-12-29|2011-12-30|Estimate|||||||2018-01-09|2018-01-10|Actual|February 2012||2012-02-29|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Prospective Registry of Patients With Isolated Severe Tricuspid Regurgitation||Recruiting|||200|Anticipated|Asan Medical Center|||||f||||f||||||||||2018-05-31 21:47:34.530101|2018-05-31 21:47:34.530101
NCT01502449|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2012-01-11|2011-12-29|2011-12-30|Estimate|||||||2012-01-11|2012-01-12|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|DESTRESS-T||Delivery of Self Training and Education for Stressful Situations-Telephone Version|Randomized Trial of Telephonic Psychotherapy and Case Management for Combat-Related Posttraumatic Stress Disorder|Unknown status|Not yet recruiting|N/A|91|Anticipated|Uniformed Services University of the Health Sciences||2|||f||||t||||||||||2018-05-31 21:47:34.588118|2018-05-31 21:47:34.588118
NCT01502423|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2013-11-07||2014-01-23|2011-12-29|2011-12-30|Estimate|2014-01-23|2014-02-20|Estimate||||2014-01-23|2014-02-20|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||All analyses were based on the cITT population, which included all subjects who were randomized and completed both periods and received study drug in both periods of the study (N = 60).|A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab|A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis|Completed||Phase 2|61|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 21:47:34.76991|2018-05-31 21:47:34.76991
NCT01502410|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|2015-04-14||2015-05-14|2011-12-29|2011-12-30|Estimate|2015-05-14|2015-05-15|Estimate||||2015-05-14|2015-05-15|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer|A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma|Completed||Phase 2|20|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-05-31 21:47:35.189902|2018-05-31 21:47:35.189902
NCT01502397|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2014-12-29|2011-12-28|2011-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|||Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study||Unknown status|Enrolling by invitation||70|Anticipated|The University of Hong Kong|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma for hepatitis B virus genotypic, virologic and serologic testing~   "|||2018-05-31 21:47:35.808342|2018-05-31 21:47:35.808342
NCT01502384|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2011-12-29|2011-12-29|2011-12-30|Estimate|||||||2011-12-29|2011-12-30|Estimate|January 2012||2012-01-31|December 2011|2011-12-31||||June 2015|Anticipated|2015-06-30||Observational|||A Longitudinal Study in 1st Degree Relatives of Parkinson's Disease (PD) Patients||Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 21:47:35.86857|2018-05-31 21:47:35.86857
NCT01502371|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|2015-09-01||2017-03-09|2011-12-28|2011-12-30|Estimate|2015-09-01|2015-10-06|Estimate||||2017-03-09|2017-04-07|Actual|January 2012||2012-01-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||The Baseline Analysis Population consisted of all randomized participants who received at least one dose of randomized study drug.|A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)|A 12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma (Phase 2; Protocol No. P04223AM3)|Completed||Phase 2|583|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:47:35.978234|2018-05-31 21:47:35.978234
NCT01502358|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-11-03|2011-12-28|2011-12-30|Estimate|||||||2016-11-03|2016-11-04|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|TVDV||Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease|A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin®|Completed||Phase 1|40|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||t||||||||||2018-05-31 21:47:36.395455|2018-05-31 21:47:36.395455
NCT01502345|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2013-01-30|2011-12-29|2011-12-30|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|HTNV/PUUV||Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines|Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines, pWRG/HTN-M(x) and pWRG/PUU-M(s2), for Prevention of Hemorrhagic Fever With Renal Syndrome Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device|Completed||Phase 1|31|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-05-31 21:47:36.465625|2018-05-31 21:47:36.465625
NCT01502332|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2016-07-21||2016-10-01|2011-12-28|2011-12-30|Estimate|2016-10-01|2016-11-23|Estimate||||2016-10-01|2016-11-23|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Intensive Alveolar Recruitment Protocol After Cardiac Surgery|Comparison of Two Protective Mechanical Ventilation Strategies After Cardiac Surgery: Aggressive Versus Moderate Alveolar Recruitment Strategies|Completed||N/A|320|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 21:47:36.536152|2018-05-31 21:47:36.536152
NCT01502319|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2017-10-18|2011-12-29|2011-12-30|Estimate|||||||2017-10-18|2017-10-20|Actual|September 2010|Actual|2010-09-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|MSRC||Military Suicide Research Consortium|Military Suicide Research Consortium|Completed|||5400|Actual|VA Eastern Colorado Health Care System|||1||f||||t||||||||||2018-05-31 21:47:36.912325|2018-05-31 21:47:36.912325
NCT01502306|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2017-11-07|2011-12-28|2011-12-30|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2012|Actual|2012-06-30|November 2017|2017-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline|A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline|Completed||Phase 3|3819|Actual|University of California, San Diego||3|||f||||f||||||||No||2018-05-31 21:47:36.988106|2018-05-31 21:47:36.988106
NCT01502293|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-02-24|2011-12-28|2011-12-30|Estimate|||||||2017-02-24|2017-02-28|Actual|December 2011||2011-12-31|December 2016|2016-12-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|IL-12MEL||Trial of pIL-12 Electroporation Malignant Melanoma|A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma|Completed||Phase 2|51|Actual|OncoSec Medical Incorporated||2|||f||||t||||||||||2018-05-31 21:47:37.074299|2018-05-31 21:47:37.074299
NCT01502280|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-01-04|2011-12-29|2011-12-30|Estimate|||||||2017-01-04|2017-01-06|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|BALANCE||Fluorescence-guided Surgery for Low- and High-grade Gliomas|Barrow 5-ALA Intraoperative Confocal Evaluation Trial|Recruiting||Phase 3|192|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||||2018-05-31 21:47:37.172698|2018-05-31 21:47:37.172698
NCT01502267|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|||2012-01-05|2011-12-29|2011-12-30|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|January 2016|Anticipated|2016-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant|Phase 2 Study of Desensitization Protocol for Highly Sensitized Wait Listed Patients|Unknown status|Enrolling by invitation|Phase 2|2|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:47:37.277391|2018-05-31 21:47:37.277391
NCT01502254|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-02-11|2011-12-29|2011-12-30|Estimate|||||||2014-02-11|2014-02-12|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Patients' Knowledge and Understanding of Cancer Clinical Trials - a Study of Audio Recorded Information|Patients' Knowledge and Understanding of Cancer Clinical Trials - a Randomised Study of Audio Recorded Information|Completed||N/A|130|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 21:47:37.345244|2018-05-31 21:47:37.345244
NCT01502241|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|||2011-12-29|2011-12-29|2011-12-30|Estimate|||||||2011-12-29|2011-12-30|Estimate|January 2005||2005-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|Methusalem||Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly|Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)|Completed||Phase 3|412|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 21:47:37.480661|2018-05-31 21:47:37.480661
NCT01502228|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|2016-11-23||2017-03-01|2011-12-29|2011-12-30|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|October 2011||2011-10-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma|PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma|Terminated||N/A|14|Actual|Indiana University||1||No further funding|f||||t||||||||No||2018-05-31 21:47:37.614545|2018-05-31 21:47:37.614545
NCT01502215|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2012-12-04|2011-12-29|2011-12-30|Estimate|||||||2012-12-04|2012-12-05|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|TRISOP||Transfusion Requirements in Surgical Oncologic Patient||Completed||Phase 3|198|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 21:47:37.885208|2018-05-31 21:47:37.885208
NCT01502202|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-06-19|2011-12-29|2011-12-30|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|February 2015|Anticipated|2015-02-28|August 2014|Anticipated|2014-08-31||Interventional|||Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers|A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers|Unknown status|Recruiting|Phase 2|162|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 21:47:37.962289|2018-05-31 21:47:37.962289
NCT01502189|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-12-01|2011-12-29|2011-12-30|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||Information to Parents of Children With Cancer. An Exploratory Study|Information to Parents of Children With Cancer. An Exploratory Study|Completed||N/A|8|Actual|Umeå University||1|||f||||f||||||||||2018-05-31 21:47:38.086271|2018-05-31 21:47:38.086271
NCT01502176|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2011-12-29|2011-12-29|2011-12-30|Estimate|||||||2011-12-29|2011-12-30|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010|A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010|Unknown status|Recruiting||1600|Anticipated|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 21:47:38.183496|2018-05-31 21:47:38.183496
NCT01502163|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2012-03-07|2011-12-29|2011-12-30|Estimate|||||||2012-03-07|2012-03-08|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy of a Convective Prewarming System in Prevention of Perioperative Hypothermia|Efficacy of a Convective Prewarming System in Prevention of Perioperative Hypothermia|Completed||N/A|90|Actual|University of Göttingen||3|||f||||f||||||||||2018-05-31 21:47:38.261101|2018-05-31 21:47:38.261101
NCT01502150|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-03-13|2011-12-28|2011-12-30|Estimate|||||||2018-03-13|2018-03-15|Actual|June 16, 2005|Actual|2005-06-16|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Observational|||Data Collection of Normal Tissue Toxicity for Proton Therapy for Pediatrics|Data Collection of Normal Tissue Toxicity for Proton Therapy for Pediatrics|Active, not recruiting|||798|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 21:47:38.345177|2018-05-31 21:47:38.345177
NCT01502137|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-01-23|2011-12-29|2011-12-30|Estimate|||||||2017-01-23|2017-01-24|Estimate|June 2005||2005-06-30|January 2017|2017-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis|An Open, Non-randomized, Single-centre, Parallel Group Trial Investigating the Steady-state Blood Concentration Profile and Effects of Once Daily Subcutaneously Injected Recombinant Human Growth Hormone (Norditropin® SimpleXx®) in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis and in Matched Healthy Subjects|Completed||Phase 1|21|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:47:38.429213|2018-05-31 21:47:38.429213
NCT01502124|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2017-02-27|2011-12-29|2011-12-30|Estimate|||||||2017-02-27|2017-02-28|Actual|May 8, 2001|Actual|2001-05-08|February 2017|2017-02-28|March 5, 2003|Actual|2003-03-05|March 5, 2003|Actual|2003-03-05||Interventional|||Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency|Norditropin® and Norditropin® Cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children With Growth Hormone Deficiency|Completed||Phase 3|78|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:47:38.537294|2018-05-31 21:47:38.537294
NCT01502111|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-05-07|2011-12-29|2011-12-30|Estimate|||||||2013-05-07|2013-05-08|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|AIRPORT||Airway Management Study in Physician Manned Helicopter Emergency Medical Services|Improved Knowledge Through Better Data, Implementing and Evaluating a Novel Consensus-based Template for Uniform Reporting of Data From Pre-hospital Airway Management - a Prospective Multicentre Observational Study|Completed|||2333|Actual|Norwegian Air Ambulance Foundation|||1||f||||f||||||||||2018-05-31 21:47:38.64224|2018-05-31 21:47:38.64224
NCT01502098|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|||2012-01-09|2011-12-29|2011-12-30|Estimate|||||||2012-01-09|2012-01-10|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Effect of Postoperative Immobilization on Healing After Rotator Cuff Arthroscopic Repair|Effect of Postoperative Immobilization on Healing After Rotator Cuff Arthroscopic Repair With Double Row Technique in Small or Medium Ruptures. Prospective, Comparative and Randomized.|Unknown status|Recruiting|N/A|114|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||||2018-05-31 21:47:38.724446|2018-05-31 21:47:38.724446
NCT01497353|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-10-17|2011-12-20|2011-12-22|Estimate|||||||2012-10-17|2012-10-19|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Placental Transfusion and Cord Clamping|Is the Placental Transfusion Volume Influenced by the Position of the New Born at Birth?|Completed||N/A|400|Actual|Fundacion para la Salud Materno Infantil||2|||f||||t||||||||||2018-05-31 21:48:45.15922|2018-05-31 21:48:45.15922
NCT01502085|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2015-08-21|2011-12-28|2011-12-30|Estimate|||||||2015-08-21|2015-08-24|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|RZD||Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens|A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens|Unknown status|Active, not recruiting|Phase 1/Phase 2|92|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 21:47:38.794391|2018-05-31 21:47:38.794391
NCT01502072|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-09-05|2011-12-29|2011-12-30|Estimate|||||||2017-09-05|2017-09-08|Actual|December 2011|Actual|2011-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Respiratory Syncytial Virus - RSV Protocol|An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant|Active, not recruiting||Phase 2|96|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 21:47:38.873686|2018-05-31 21:47:38.873686
NCT01502059|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2011-12-29|2011-12-29|2011-12-30|Estimate|||||||2011-12-29|2011-12-30|Estimate|June 2008||2008-06-30|December 2011|2011-12-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|PTLBP||Pilates to Treat Low Back Pain|The Effectiveness of Pilates to Treat Low Back Pain: A Randomized Controlled Trial|Completed||Phase 3|60|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:47:38.942624|2018-05-31 21:47:38.942624
NCT01502046|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-29|||2013-01-31|2011-12-29|2011-12-30|Estimate|||||||2013-01-31|2013-02-01|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Neuroprotection by Cannabinoids in Huntington's Disease|A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease|Completed||Phase 2|25|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f||||||||||2018-05-31 21:47:39.003571|2018-05-31 21:47:39.003571
NCT01502033|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|2015-08-06||2016-04-20|2011-12-28|2011-12-30|Estimate|2016-01-20|2016-02-17|Estimate||||2016-04-20|2016-04-22|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Depressed Teens|An Open-Label Eight-Week Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents: Mechanisms of Response|Completed||N/A|10|Actual|Mayo Clinic|Please note that clinical results must be interpreted with caution due to small sample size and study design.|1|||f||||t||||||||No||2018-05-31 21:47:39.078132|2018-05-31 21:47:39.078132
NCT01502020|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2011-12-29|2011-12-29|2011-12-30|Estimate|||||||2011-12-29|2011-12-30|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses|Completed||N/A|410|Actual|Actavis Mid-Atlantic LLC||3|||f||||f||||||||||2018-05-31 21:47:39.282016|2018-05-31 21:47:39.282016
NCT01502007|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-06-05|2011-12-29|2011-12-30|Estimate|||||||2014-06-05|2014-06-06|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Activity Monitoring and Counseling in a Geriatric Population|Activity Monitoring and Counseling in a Geriatric Population: a Randomized Trial|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:47:39.380247|2018-05-31 21:47:39.380247
NCT01501994|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-06-05|2011-12-29|2011-12-30|Estimate|||||||2014-06-05|2014-06-06|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Personalized Approach for Promoting Physical Activity in Mayo Clinic Physicians|Personalized Approach for Promoting Physical Activity in Mayo Clinic Physicians|Completed||N/A|17|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:47:39.574287|2018-05-31 21:47:39.574287
NCT01501981|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-07-22|2011-12-29|2011-12-30|Estimate|||||||2017-07-22|2017-07-25|Actual|February 2011||2011-02-28|July 2017|2017-07-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|MOLITOR||Impact of Therapy Optimization on the Level of Biomarkers in Patients With Decompensated Heart Failure|Impact of Therapy Optimization on the Level of Biomarkers in Patients With Acute Decompensated and Decompensated Chronic Heart Failure|Completed|||150|Actual|Charite University, Berlin, Germany|||||f||||t||||||||||2018-05-31 21:47:39.667321|2018-05-31 21:47:39.667321
NCT01501968|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|||2011-12-29|2011-12-29|2011-12-30|Estimate|||||||2011-12-29|2011-12-30|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity|Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity|Unknown status|Not yet recruiting|Phase 3|54|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 21:47:39.726301|2018-05-31 21:47:39.726301
NCT01501955|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2017-02-21|2011-12-29|2011-12-30|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2012||2012-10-31|June 2014|2014-06-30|December 2023|Anticipated|2023-12-31|January 2016|Actual|2016-01-31||Interventional|||The Metaphyseal Hip Prosthesis - Total Hip|Evaluation of the Safety and Efficiency of the Metaphyseal Hip Prosthesis - Total Hip Arthroplasty|Terminated||N/A|20|Actual|Zimmer Biomet||2||First safety criterium not met.|f||||t||||||||Undecided||2018-05-31 21:47:39.823909|2018-05-31 21:47:39.823909
NCT01501942|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2014-02-12|2011-12-29|2011-12-30|Estimate|||||||2014-02-12|2014-02-14|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma|A Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma|Completed||Phase 2|11|Actual|AIM Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 21:47:39.911829|2018-05-31 21:47:39.911829
NCT01501929|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-12-01|2011-12-29|2011-12-30|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients|Effects of Nebivolol on Microvascular Perfusion in the Skeletal Muscles During Exercise in Hypertensive Patients|Completed||Phase 4|32|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 21:47:39.995521|2018-05-31 21:47:39.995521
NCT01499797|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-06-06|2011-12-22|2011-12-26|Estimate|||||||2013-06-06|2013-06-07|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|CareWell||The CareWell-programme for Community-dwelling Frail Elderly Persons.|Towards a CARE AND WELFARE STANDARD for Community-dwelling Frail Elderly People With Complex Health Problems|Completed||N/A|536|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:48:09.284454|2018-05-31 21:48:09.284454
NCT01501916|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2013-01-08|2011-12-27|2011-12-30|Estimate|||||||2013-01-08|2013-01-10|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|April 2013|Anticipated|2013-04-30||Interventional|||Effect of Vitamin D3 on Cardiovascular Risk Factors|Effect of Vitamin D3 on Cardiovascular Risk Factors: a Randomized Trial in Human|Suspended||N/A|250|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2||technical problems|f||||t||||||||||2018-05-31 21:47:40.11067|2018-05-31 21:47:40.11067
NCT01501903|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-02-01|2011-12-29|2011-12-30|Estimate|||||||2012-02-01|2012-02-02|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Standard Versus Fanning Techniques for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA)|Randomized Trial Comparing the Standard and Fanning Techniques for Fine Needle Aspiration of Pancreatic Mass Lesions at Endoscopic Ultrasound|Completed||N/A|52|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 21:47:40.178285|2018-05-31 21:47:40.178285
NCT01501890|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2016-10-24|2011-12-27|2011-12-30|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|September 2014|Anticipated|2014-09-30|December 2013|Anticipated|2013-12-31||Interventional|||Progesterone for First Trimester Vaginal Bleeding|The Impact of Progesterone Treatment on Obstetrical Outcome Among Women With First Trimester Vaginal Bleeding|Withdrawn||N/A|0|Actual|Soroka University Medical Center||2||never started|f||||f||||||||||2018-05-31 21:47:40.24787|2018-05-31 21:47:40.24787
NCT01501877|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-04-10|2011-12-27|2011-12-30|Estimate|||||||2017-04-10|2017-04-12|Actual|December 2011||2011-12-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|SSTOP||Smoking Cessation Intervention for Diabetic Patients|Smoking Cessation Intervention for Diabetic Patients|Completed||N/A|20|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 21:47:40.31908|2018-05-31 21:47:40.31908
NCT01501864|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-09-22|2011-12-29|2011-12-30|Estimate|||||||2017-09-22|2017-09-26|Actual|July 2011|Actual|2011-07-31|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||School Support as Structural HIV Prevention for Adolescent Orphans in Kenya|School Support as Structural HIV Prevention for Adolescent Orphans in Kenya|Completed||Phase 2|835|Actual|Pacific Institute for Research and Evaluation||2|||f||||f||||||||||2018-05-31 21:47:40.383373|2018-05-31 21:47:40.383373
NCT01501851|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Observational|||Prediction of Low Birth Weight Infants Using Ultrasound Measurement of Placental Diameter and Thickness|Prediction of Low Birth Weight Infants Using Ultrasound Measurement of Placental Diameter and Thickness|Unknown status|Recruiting||265|Anticipated|Ain Shams Maternity Hospital|||||f||||t||||||||||2018-05-31 21:47:40.453051|2018-05-31 21:47:40.453051
NCT01501838|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-03-08|2011-12-26|2011-12-29|Estimate|||||||2018-03-08|2018-03-12|Actual|December 2010||2010-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|RIHP||Pulmonary Hypertension Institutional Registry|Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires|Suspended|||100000|Anticipated|Hospital Italiano de Buenos Aires||||By the moment nvestigators are not recuiting because logistics issues|f||||f||||||||||2018-05-31 21:47:40.501022|2018-05-31 21:47:40.501022
NCT01501825|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-07-03|2011-12-28|2011-12-29|Estimate|||||||2012-07-03|2012-07-04|Estimate|August 2012||2012-08-31|December 2011|2011-12-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||A Prospective, Comparative Study to Explore the Efficacy and Safety of the Five Channels Multiway Deep Transcranial Magnetic Stimulation (TMS) Device in Subjects With Major Depression Disorder (MDD)||Unknown status|Not yet recruiting|N/A|60|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 21:47:40.552649|2018-05-31 21:47:40.552649
NCT01501812|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2011-12-27|2011-12-27|2011-12-29|Estimate|||||||2011-12-27|2011-12-29|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|||Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders|Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders (Schizophrenia, Affective Spectrum and Anxiety Disorders) - an Open, Single Center, Longitudinal Study|Unknown status|Recruiting||180|Anticipated|Shalvata Mental Health Center|||6||f||||t||||||||||2018-05-31 21:47:41.645414|2018-05-31 21:47:41.645414
NCT01501799|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris|A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) and Both Active Treatments to Topical Gel Placebo (Actavis Mid-Atlantic Llc) in the Treatment of Mild to Severe Acne Vulgaris|Completed||N/A|885|Actual|Actavis Mid-Atlantic LLC||3|||f||||f||||||||||2018-05-31 21:47:41.748611|2018-05-31 21:47:41.748611
NCT01501786|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-10|||2013-07-28|2011-12-26|2011-12-29|Estimate|||||||2013-07-28|2013-07-30|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions|The Effect of Small-dose Ketamine on Depression of Respiratory and Cardiac Functions Caused by Propofol in Pediatric Cardiac Catheterization|Completed||N/A|150|Actual|Ibaraki Children's Hospital||3|||f||||f||||||||||2018-05-31 21:47:41.866902|2018-05-31 21:47:41.866902
NCT01501773|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2011-12-26|2011-12-26|2011-12-29|Estimate|||||||2011-12-26|2011-12-29|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke|Phase II Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke|Completed||Phase 2|120|Actual|Manipal Acunova Ltd.||2|||f||||t||||||||||2018-05-31 21:47:41.958343|2018-05-31 21:47:41.958343
NCT01501760|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2015-04-01|2011-12-28|2011-12-29|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|BECONNEC||Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea|Effect of Bevacizumab Subconjunctival Injections on Corneal Newvessels|Unknown status|Recruiting|Phase 3|48|Anticipated|University Hospital, Limoges||2|||f||||t||||||||||2018-05-31 21:47:42.039015|2018-05-31 21:47:42.039015
NCT01501747|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2013-04-08|2011-12-28|2011-12-29|Estimate|||||||2013-04-08|2013-04-09|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Placebo Effect May Involve Modulating Drug Bioavailability|The Placebo Effect May Involve Modulating Drug Bioavailability|Completed||N/A|162|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||f||||||||||2018-05-31 21:47:42.12619|2018-05-31 21:47:42.12619
NCT01501734|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2015-04-12|2011-12-28|2011-12-29|Estimate|||||||2015-04-12|2015-04-14|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Bilevel Positive Pressure Ventilation (BIPAP)in Patients With Sleep Disorders Breathing (SDB)and Congestive Heart Failure (CHF):Comparison of Two Diagnostic Methods||Unknown status|Recruiting|Phase 3|200|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 21:47:43.039939|2018-05-31 21:47:43.039939
NCT01501721|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Anthropometric Changes Associated With Home-based Exercise Among School Cooks|Anthropometric and Metabolic Changes Associated With a Low-volume Home-based Exercise Program|Completed||Phase 4|95|Actual|Rio de Janeiro State University||2|||f||||t||||||||||2018-05-31 21:47:43.113073|2018-05-31 21:47:43.113073
NCT01501708|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2016-05-09|2011-12-26|2011-12-29|Estimate|||||||2016-05-09|2016-05-10|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection|Phase II Study of Caspofungin Based Combined Anti-fungal Therapy for Patients With Proven or Probable Invasive Fungal Infection After Allogeneic Stem Cell Transplantation From HLA-matched Unrelated or HLA-mismatched Related Donors|Unknown status|Recruiting|Phase 2|55|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 21:47:43.248683|2018-05-31 21:47:43.248683
NCT01501695|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2012-12-10|2011-12-26|2011-12-29|Estimate|||||||2012-12-10|2012-12-12|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Interventional|5LGr||Phase III Study of 5LGr to Treat Tic Disorder|A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder|Completed||Phase 3|603|Actual|Tasly Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 21:47:43.393288|2018-05-31 21:47:43.393288
NCT01501682|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Long Term Complaints After Elective Repair for Small Umbilical or Epigastric Hernias|Long Term Complaints After Elective Repair for Small Umbilical or Epigastric Hernias|Unknown status|Recruiting||150|Anticipated|Zealand University Hospital|||3||f||||f||||||||||2018-05-31 21:47:43.522475|2018-05-31 21:47:43.522475
NCT01501669|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-07-17|2011-12-28|2011-12-29|Estimate|||||||2012-07-17|2012-07-18|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|PROCEED||Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer|Phase III Multicenter Randomized Open-label Study of Irinotecan Plus Capecitabine Versus Capecitabine in Patients Previously Treated With Anthracycline and Taxane for HER2 Negative Metastatic Breast Cancer[PROCEED]|Unknown status|Recruiting|Phase 3|222|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 21:47:43.615342|2018-05-31 21:47:43.615342
NCT01501656|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2016-05-31|2011-12-28|2011-12-29|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Epigenetic Testing for Breast Cancer Risk Stratification|Epigenetic Testing for Breast Cancer Risk Stratification|Completed|||158|Actual|University of Texas Southwestern Medical Center|||||f||||t||||||Samples With DNA|"~     benign samples from unselected healthy control populations~   "|No||2018-05-31 21:47:43.711433|2018-05-31 21:47:43.711433
NCT01501643|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2015-04-09|2011-12-28|2011-12-29|Estimate|||||||2015-04-09|2015-04-10|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|VPACS||Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease|Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease With Vaso-occlusive Crisis and Morphinic Treatment|Terminated||N/A|6|Actual|Assistance Publique - Hôpitaux de Paris||2||decision of the promoter|f||||f||||||||||2018-05-31 21:47:43.87512|2018-05-31 21:47:43.87512
NCT01501630|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2015-10-13|2011-12-26|2011-12-29|Estimate|||||||2015-10-13|2015-10-14|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|FLUPROSTIC||Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer|Role of PET/CT With Fluorine-18 Tracers and of Diffusion Weighted Whole-body MRI in the Early Detection of Bone Metastases in Prostate Cancer|Completed|||112|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:47:43.962419|2018-05-31 21:47:43.962419
NCT01501617|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-01-13|2011-12-27|2011-12-29|Estimate|||||||2012-01-13|2012-01-18|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|HSC Phase I/II||Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia|The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial|Unknown status|Active, not recruiting|Phase 1/Phase 2|56|Actual|Histogen||2|||f||||t||||||||||2018-05-31 21:47:44.050379|2018-05-31 21:47:44.050379
NCT01501604|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2015-09-16|2011-12-28|2011-12-29|Estimate|||||||2015-09-16|2015-09-17|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||BKM120 in Cancers With PIK3CA Activating Mutations|An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||||The study has been closed due to lack of accrual|f||||t||||||||||2018-05-31 21:47:44.139432|2018-05-31 21:47:44.139432
NCT01501591|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2017-03-01|2011-12-28|2011-12-29|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2012||2012-11-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size|Interaction Between Drug and Placebo Effect:Randomized Placebo Controlled Trials May Not be Accurate in Determining Drug Effect Size|Completed||N/A|480|Actual|King Faisal Specialist Hospital & Research Center||3|||f||||f||||||||||2018-05-31 21:47:44.205617|2018-05-31 21:47:44.205617
NCT01501578|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-02-19|2011-12-27|2011-12-29|Estimate|||||||2018-02-19|2018-02-20|Actual|December 2011||2011-12-31|February 2018|2018-02-28|December 2015|Actual|2015-12-31|June 2012|Actual|2012-06-30||Observational|||Pulmonary Fibrosis and Telomerase Mutation Study|Phenotype of Pulmonary Fibrosis Associated With a Mutation of Telomerase|Completed|||81|Actual|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|||2||f||||f||||||Samples With DNA|"~     one blood sample is collected for genetic analysis of telomerase mutation~   "|Yes|Under analysis, publication in preparation|2018-05-31 21:47:44.284241|2018-05-31 21:47:44.284241
NCT01497015|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-04-11|2011-12-19|2011-12-22|Estimate|||||||2017-04-11|2017-04-13|Actual|September 2008||2008-09-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Memory Training Intervention for Breast Cancer Survivors|Memory Training Intervention for Breast Cancer Survivors|Completed||N/A|88|Actual|Indiana University||3|||f||||f||||||||||2018-05-31 21:48:49.28757|2018-05-31 21:48:49.28757
NCT01501565|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-11-15|2011-12-27|2011-12-29|Estimate|||||||2012-11-15|2012-11-16|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Analgesic Efficacy of Ultrasound-guided Transverse-abdominal Plain Blockade in Urological Surgery|Ultrasound-guided Analgesic Transverse Abdominal Plain Blockade in the Multimodal Pain Management for Laparoscopic Urological Surgery. Analgesic Efficacy Assessment.|Completed||Phase 4|141|Actual|Fundacio Puigvert||2|||f||||t||||||||||2018-05-31 21:47:44.358501|2018-05-31 21:47:44.358501
NCT01501552|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-09-05|2011-12-27|2011-12-29|Estimate|||||||2016-09-05|2016-09-07|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|ODHIN_RCT||Trial Testing the Effect of Strategies on Performance of Brief Intervention Programmes for Harmful Alcohol Consumption|Randomised Controlled Trial Testing the Incremental Effect of Strategies That Raise Awareness, Acceptance and Performance of Identification and Brief Intervention Programmes for Harmful Alcohol Consumption in Primary Health Care|Completed||N/A|120|Actual|Fundacion Clinic per a la Recerca Biomédica||8|||f||||f||||||||||2018-05-31 21:47:44.446357|2018-05-31 21:47:44.446357
NCT01501539|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-02-06|2011-12-27|2011-12-29|Estimate|||||||2018-02-06|2018-02-08|Actual|December 2010||2010-12-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement|Prevention of Hypergranulation Tissue After Gastrostomy Tube Placement: A Randomized Controlled Trial of Hydrocolloid Dressings|Completed||N/A|171|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||3|||f||||f||||||||No||2018-05-31 21:47:44.56233|2018-05-31 21:47:44.56233
NCT01501526|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-25|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|||||Observational|||Unusual Clinical Findings of Herpes Esophagitis||Unknown status|Recruiting||1|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 21:47:44.66211|2018-05-31 21:47:44.66211
NCT01501513|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22||2014-07-11|2014-07-11|2011-12-27|2011-12-29|Estimate||||2014-07-11|2014-07-15|Estimate|2014-07-11|2014-07-15|Estimate|December 2011||2011-12-31|July 2014|2014-07-31||||April 2013|Actual|2013-04-30||Interventional|||A Safety Study of 3 Different Bowel Cleansing Preparations|A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel Cleansing Preparations in Adult Subjects, Including the Elderly and Subjects With Hepatic or Renal Insufficiency|Completed||Phase 3|540|Anticipated|Braintree Laboratories||3|||f||||f||||||||||2018-05-31 21:47:44.73401|2018-05-31 21:47:44.73401
NCT01501500|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2013-09-05|2011-12-28|2011-12-29|Estimate|||||||2013-09-05|2013-09-06|Estimate|August 2010||2010-08-31|March 2010|2010-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact Insole|Therapeutic Effect of Botulinum Toxin Type A in Addition to Total Contact Insole in Treating Painful Hallux valgus-a Pilot Study|Completed||Phase 4|25|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:47:44.818125|2018-05-31 21:47:44.818125
NCT01501487|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-01-23|2011-12-27|2011-12-29|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|February 2016|Actual|2016-02-29||Interventional|MINT||MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I|MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I|Active, not recruiting||Phase 4|226|Actual|Agendia||2|||f||||f||||||||||2018-05-31 21:47:44.957521|2018-05-31 21:47:44.957521
NCT01501474|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2014-07-01|2011-12-28|2011-12-29|Estimate|||||||2014-07-01|2014-07-03|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures|Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures|Terminated|||5|Actual|King Chulalongkorn Memorial Hospital|||1|No suitable case available and many techinical error|f||||f||||||Samples Without DNA|"~     Brush cytology and FISH test~   "|||2018-05-31 21:47:45.216998|2018-05-31 21:47:45.216998
NCT01501461|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-04-17|2011-12-27|2011-12-29|Estimate|||||||2018-04-17|2018-04-19|Actual|May 1, 2011||2011-05-01|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|May 30, 2017|Actual|2017-05-30||Interventional|||Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Intra-venous Implantation of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||||Company dissolved|f||||f||||||||||2018-05-31 21:47:45.341108|2018-05-31 21:47:45.341108
NCT01501448|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2016-03-20|2011-12-28|2011-12-29|Estimate|||||||2016-03-20|2016-03-22|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional|||Oral Estradiol Valerate Versus Oral Contraceptive Pill in Invitro Fertilization Patients||Completed||Phase 4|118|Actual|IVI Madrid||2|||f||||||||||||||2018-05-31 21:47:45.462682|2018-05-31 21:47:45.462682
NCT01501435|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|||2016-12-29|2011-12-28|2011-12-29|Estimate|||||||2016-12-29|2017-01-02|Estimate|December 2011||2011-12-31|December 2016|2016-12-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra|A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study to Compare the Pharmacokinetics of CJ-30039 and Lipidil Supra and to Investigate Food-effect on Pharmacokinetics of CJ-30039|Completed||Phase 1|48|Actual|CJ HealthCare Corporation||2|||f||||f||||||||No||2018-05-31 21:47:45.565567|2018-05-31 21:47:45.565567
NCT01501422|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-12-26|2011-12-24|2011-12-29|Estimate|||||||2012-12-26|2012-12-28|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women|Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women at Menopause Clinic, King Chulalongkorn Memorial Hospital, Double- Blind, Randomized, Placebo-controlled Trial|Completed||Phase 3|40|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 21:47:45.718027|2018-05-31 21:47:45.718027
NCT01501409|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis|Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis : a Randomised Clinical Trial|Completed||N/A|90|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 21:47:45.848777|2018-05-31 21:47:45.848777
NCT01501396|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-01-31|2011-12-28|2011-12-29|Estimate|||||||2014-01-31|2014-02-03|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite|Treatment of Cancer Anorexia-cachexia Syndrome (CACS) With Mirtazapine and Megestrol Acetate|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 21:47:45.936755|2018-05-31 21:47:45.936755
NCT01501383|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-01-15|2011-12-23|2011-12-29|Estimate|||||||2014-01-15|2014-01-16|Estimate|December 2011||2011-12-31|October 2012|2012-10-31||||August 2013|Actual|2013-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy With a 24-Week Open-Label Extension|Terminated||Phase 2|55|Actual|Vertex Pharmaceuticals Incorporated||6||Terminated by Sponsor|f||||t||||||||||2018-05-31 21:47:46.042796|2018-05-31 21:47:46.042796
NCT01501370|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-05-09|2011-12-28|2011-12-29|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ZLd_Ld||Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy|A Phase II, Multi-center, Open-label, Randomized Study of Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy|Withdrawn||Phase 2|0|Actual|University of Turin, Italy||2|||f||||t||||||||||2018-05-31 21:47:46.184012|2018-05-31 21:47:46.184012
NCT01501357|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-03-20|2011-12-23|2011-12-29|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2011||2011-07-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|toothbrushing||Effectiveness of Toothbrushing Techniques in Plaque Removal and Caries Lesion Control|Effectiveness of Toothbrushing Techniques in Plaque Removal and Caries Lesion Control in Erupting Primary Permanent Molars - Randomized Clinical Trial Abbreviated Over 24 Months|Completed||N/A|220|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:47:46.281004|2018-05-31 21:47:46.281004
NCT01501344|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2012-01-05|2011-12-28|2011-12-29|Estimate|||||||2012-01-05|2012-01-09|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|YogA||Open-label Study to Evaluate the Effect of MBP-80 on Bone Remodelling|A 12-week, Open-label Study to Evaluate the Effect of MBP-80 (200g of Yogurt With Fortified Calcium Content and MBP 80 mg) on Bone Remodelling as Assessed by Bone Turnover Markers in Early Postmenopausal Women|Completed||N/A|50|Actual|Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.|||||f||||f||||||||||2018-05-31 21:47:46.364051|2018-05-31 21:47:46.364051
NCT01501331|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-11-16|2011-12-28|2011-12-29|Estimate|||||||2014-11-16|2014-11-18|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|MULTITUDE-HF||Multiparametric Heart Failure Evaluation in Internal Cardioverter Defibrillators (ICD) Patients|Multiparametric Evaluation of Heart Failure in Device-implanted Patients.|Completed|||180|Anticipated|University of Rome Tor Vergata|||1||f||||f||||||||||2018-05-31 21:47:46.455494|2018-05-31 21:47:46.455494
NCT01501318|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2016-09-29|2011-12-23|2011-12-29|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Impact of Personalized Feedback Alone on Substance Use Behaviors|Brief Education to Reduce Health Care Consumers' Risky Substance Use Behaviors: How Brief is Brief?|Completed||N/A|40|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 21:47:46.52045|2018-05-31 21:47:46.52045
NCT01501305|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Interventional|||Influence of Carob and Probiotics on Acute Diarrhea in Children||Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 21:47:46.594075|2018-05-31 21:47:46.594075
NCT01501292|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-26|2011-12-26|2011-12-29|Estimate|||||||2011-12-26|2011-12-29|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Changes in the Distribution of Mitochondria During Oocyte Maturation||Unknown status|Not yet recruiting||20|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 21:47:46.664014|2018-05-31 21:47:46.664014
NCT01501279|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-06-10|2011-12-26|2011-12-29|Estimate|||||||2016-06-10|2016-06-13|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Ultrasound Guided Pudendal Block in Transurethral Prostatectomies|Ultrasound Guided Pudendal Block in Transurethral Prostatectomies|Completed||N/A|40|Actual|Diskapi Teaching and Research Hospital||2|||f||||t||||||||||2018-05-31 21:47:46.724283|2018-05-31 21:47:46.724283
NCT01501266|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2016-05-09|2011-12-28|2011-12-29|Estimate|||||||2016-05-09|2016-05-10|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Faslodex Specific Clinical Experience Investigation|Faslodex Specific Clinical Experience Investigation for Long-term Use|Completed|||660|Anticipated|AstraZeneca|||1||f||||||||||||||2018-05-31 21:47:46.802542|2018-05-31 21:47:46.802542
NCT01501253|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2012-11-12|2011-12-26|2011-12-29|Estimate|||||||2012-11-12|2012-11-14|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||CKD-828 S-Amlodipine Non-Responder Trial|Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) vs. S-Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by S-Amlodipine Monotherapy.|Completed||Phase 3|187|Actual|Chong Kun Dang Pharmaceutical||3|||f||||f||||||||||2018-05-31 21:47:46.988947|2018-05-31 21:47:46.988947
NCT01501240|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-26|||2014-01-26|2011-12-26|2011-12-29|Estimate|||||||2014-01-26|2014-01-28|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|August 2013|Anticipated|2013-08-31|December 2012|Anticipated|2012-12-31||Observational|PriMPa||Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver|Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver: Prospective Pathologic Correlation With Explanted Liver|Withdrawn|||0|Actual|Asan Medical Center|||1||f||||f||||||||||2018-05-31 21:47:47.079294|2018-05-31 21:47:47.079294
NCT01501227|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|February 2012||2012-02-29|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||Ventilator Associated Pneumonia in Taper Guard Versus Normal Tube in ICU Patients|Comparison of the Incidence of Ventilator Associated Pneumonia in Patients Intubated With the Taper Guard Endotracheal Tube Versus a Normal Endotracheal Tube|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Malaya||2|||f||||t||||||||||2018-05-31 21:47:47.167582|2018-05-31 21:47:47.167582
NCT01501214|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-01-06|2011-12-28|2011-12-29|Estimate|||||||2014-01-06|2014-01-07|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Use of Atosiban in in Vitro Fertilization (IVF) Treatment|A Randomized Double Blind Comparison of Atosiban in Patients Undergoing in Vitro Fertilization Treatment|Completed||Phase 4|800|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:47:47.28899|2018-05-31 21:47:47.28899
NCT01501201|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-05-17|2011-12-23|2011-12-29|Estimate|||||||2017-05-17|2017-05-19|Actual|August 8, 2011|Actual|2011-08-08|May 2017|2017-05-31|September 2027|Anticipated|2027-09-30|September 2018|Anticipated|2018-09-30||Interventional|DIABSURG||Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients|Comparison of Gastric By-Pass and Optimized Medical Treatment in Obese Diabetic Patients in Terms of Mortality, Glycemic Control, and Cost Effectiveness - Prospective, Multicenter, Randomized Study|Recruiting||Phase 4|490|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||No||2018-05-31 21:47:47.393375|2018-05-31 21:47:47.393375
NCT01501188|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-05-28|2011-12-28|2011-12-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy Study of Kinesio Taping to Treat Muscular and Joint Problems in Chronic Venous Insufficiency|Study on the Effect of Kinesio Taping on Bioelectrical Activity of Gastrocnemius Muscles and Range of Ankle Motion in Post-menopausal Women With Chronic Venous Insufficiency|Completed||Phase 1|259|Actual|Universidad de Granada||2|||f||||f||||||||||2018-05-31 21:47:47.508385|2018-05-31 21:47:47.508385
NCT01501175|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2013-02-12|2011-12-28|2011-12-29|Estimate|||||||2013-02-12|2013-02-13|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|STEPH||Incidence of Superficial Vein Thrombosis|Evaluation of Annual Incidence of Superficial Vein Thrombosis in the Legs|Completed|||848|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 21:47:47.588702|2018-05-31 21:47:47.588702
NCT01501162|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|2014-12-31||2015-03-24|2011-12-28|2011-12-29|Estimate|2015-01-23|2015-01-27|Estimate||||2015-03-24|2015-04-14|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|EPALD||Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease|Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease|Completed||Phase 4|130|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 21:47:47.691429|2018-05-31 21:47:47.691429
NCT01501149|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-07-15|2011-12-25|2011-12-29|Estimate|||||||2015-07-15|2015-07-17|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|May 2019|Anticipated|2019-05-31|December 2015|Anticipated|2015-12-31||Interventional|CTTNKTL-Ⅲ/Ⅳ||Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ|A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)|Recruiting||Phase 4|80|Anticipated|Zhengzhou University||2|||f||||t||||||||||2018-05-31 21:47:47.937033|2018-05-31 21:47:47.937033
NCT01501136|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2015-07-15|2011-12-25|2011-12-29|Estimate|||||||2015-07-15|2015-07-17|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|May 2019|Anticipated|2019-05-31|December 2015|Anticipated|2015-12-31||Interventional|CTTNKTL-I/II||Treatment of Natural Killer/T Cell Lymphoma-I/II|A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)|Recruiting||Phase 4|200|Anticipated|Zhengzhou University||5|||f||||t||||||||||2018-05-31 21:47:48.045649|2018-05-31 21:47:48.045649
NCT01501123|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|PHASR||Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient|Re-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient|Unknown status|Recruiting|N/A|162|Anticipated|Catholic Health East||2|||f||||f||||||||||2018-05-31 21:47:48.143099|2018-05-31 21:47:48.143099
NCT01501110|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|2014-12-03||2015-03-30|2011-12-28|2011-12-29|Estimate|2015-03-30|2015-03-31|Estimate||||2015-03-30|2015-03-31|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Effects of N-acetylcysteine on Low T3 Syndrome|Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome|Completed||Phase 4|83|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 21:47:48.230319|2018-05-31 21:47:48.230319
NCT01501097|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2011-12-28|2011-12-25|2011-12-29|Estimate|||||||2011-12-28|2011-12-30|Estimate|December 2011||2011-12-31|December 2011|2011-12-31||||December 2013|Anticipated|2013-12-31||Interventional|CRRT||The Impact of Continuous Renal Replacement Therapy on the Outcomes of Burn Patients With Early Phase of Sepsis|A Randomized Controlled Trial on the Impact of Early Application of CRRT on the Outcomes of Burn Patients With Early Phase of Sepsis|Unknown status|Active, not recruiting|N/A|60|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 21:47:48.465371|2018-05-31 21:47:48.465371
NCT01501084|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-11-03|2011-12-28|2011-12-29|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2011||2011-12-31|November 2017|2017-11-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women|Effects of the GLP-1 Exenatide on Intrinsic Brain Activity in Lean and Obese Women|Completed||Phase 1|34|Actual|University of California, Los Angeles||2|||f||||f||||||||Yes||2018-05-31 21:47:48.52751|2018-05-31 21:47:48.52751
NCT01501071|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2011-12-28|2011-12-28|2011-12-29|Estimate|||||||2011-12-28|2011-12-29|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Esophageal Calibration During Laparoscopic Fundoplication Reduces Dysphagia|Esophageal Calibration With Soft Orogastric Tube During Laparoscopic Fundoplication Reduces Postoperative Transient Dysphagia|Completed||N/A|50|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||||2018-05-31 21:47:48.596818|2018-05-31 21:47:48.596818
NCT01501058|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-05-27|2011-12-25|2011-12-29|Estimate|||||||2013-05-27|2013-05-29|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|September 2013|Anticipated|2013-09-30|June 2012|Actual|2012-06-30||Interventional|||Parent-supported Social Skills Training for Teens With Autism Spectrum Disorders (PEERS-K)|Parent-Assisted Social Skill Training Program in the Adolescents With Autism Spectrum Disorder|Unknown status|Active, not recruiting|N/A|40|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:47:48.676221|2018-05-31 21:47:48.676221
NCT01501045|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-10-01|2011-12-28|2011-12-29|Estimate|||||||2017-10-01|2017-10-03|Actual|January 2011|Actual|2011-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Transmagnetic Stimulation on Conditioned Pain Modulation (CPM)|The Effect of Transmagnetic Stimulation on Descending Pain Modulation|Recruiting||N/A|200|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 21:47:48.732995|2018-05-31 21:47:48.732995
NCT01501032|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-03-18|2011-12-25|2011-12-29|Estimate|||||||2015-03-18|2015-03-19|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MD-Logic- Cont||Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients With Type 1 Diabetes|Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients|Withdrawn||Phase 1|0|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 21:47:48.805315|2018-05-31 21:47:48.805315
NCT01500993|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-26|2011-12-26|2011-12-29|Estimate|||||||2011-12-26|2011-12-29|Estimate|March 2002||2002-03-31|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|Rektum-III||Capecitabine in the Perioperative Treatment of Rectal Cancer|5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial|Completed||Phase 3|401|Actual|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 21:47:49.055015|2018-05-31 21:47:49.055015
NCT01500980|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2012-12-11|2011-12-23|2011-12-29|Estimate|||||||2012-12-11|2012-12-13|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|ITV||Malaria Challenge in Healthy Volunteers|Infection-Treatment-Vaccination for Plasmodium Falciparum|Completed||Phase 1|36|Actual|Seattle Biomedical Research Institute||5|||f||||t||||||||||2018-05-31 21:47:49.229873|2018-05-31 21:47:49.229873
NCT01500967|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2012-01-24|2011-12-26|2011-12-29|Estimate|||||||2012-01-24|2012-01-25|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|May 2014|Anticipated|2014-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Shi-style Cervical Manipulations for Cervical Radiculopathy|Shi-style Cervical Manipulations for Cervical Radiculopathy-A Randomized Single Blinded Controlled Trial|Unknown status|Recruiting|N/A|648|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 21:47:49.327097|2018-05-31 21:47:49.327097
NCT01500954|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2012-10-15|2011-12-28|2011-12-29|Estimate|||||||2012-10-15|2012-10-16|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma|Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma|Completed|||7|Actual|Ruhr University of Bochum|||2||f||||f||||||Samples With DNA|"~     cutaneous squamous cell carcinoma (SCC) non.lesional skin~   "|||2018-05-31 21:47:49.419404|2018-05-31 21:47:49.419404
NCT01500941|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2012-01-03|2011-12-28|2011-12-29|Estimate|||||||2012-01-03|2012-01-05|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Probiotics in Adults: do They Improve Atopic Dermatitis?|Evaluation of the Effects of a Combination of Probiotics in the Treatment of Adult Atopic Dermatitis: Randomized Phase III, Double-blind Placebo-controlled|Completed||Phase 3|48|Actual|ASST Fatebenefratelli Sacco||2|||f||||f||||||||||2018-05-31 21:47:49.495184|2018-05-31 21:47:49.495184
NCT01500928|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2011-12-25|2011-12-25|2011-12-29|Estimate|||||||2011-12-25|2011-12-29|Estimate|July 2011||2011-07-31|December 2011|2011-12-31||||July 2012|Anticipated|2012-07-31||Interventional|||Performance Study of the SOLO 2.0 Insulin Pump||Unknown status|Recruiting|N/A|40|Anticipated|Medingo Ltd|||||f||||f||||||||||2018-05-31 21:47:49.573493|2018-05-31 21:47:49.573493
NCT01500915|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-03-23|2011-12-25|2011-12-29|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|FUSION||FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration|FUSION Regimen: A Disease Activity Guided Treatment Algorithm With Ranibizumab in naïve Subjects With Exudative Age-related Macular Degeneration|Completed||Phase 4|17|Actual|Institut de la Macula y la Retina||1|||f||||f||||||||||2018-05-31 21:47:49.669361|2018-05-31 21:47:49.669361
NCT01500902|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-09-22|2011-12-28|2011-12-29|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome|The Assessment of Novel Functional Risk Factors for the Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome|Completed||N/A|101|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:47:49.756993|2018-05-31 21:47:49.756993
NCT01500889|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-23|2011-12-23|2011-12-29|Estimate|||||||2011-12-23|2011-12-29|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|CAF||Conventional Lateral Internal Sphincterotomy, V-Y Anoplasty and Tailored Lateral Internal Sphincterotomy With V-YF in Treatment of Chronic Anal Fissure(CAF)|Comparative Study of Conventional Lateral Internal Sphincterotomy, V-Y Anoplasty and Tailored Lateral Internal Sphincterotomy With V-Y Anoplasty in Treatment of Chronic Anal Fissure|Completed||N/A|150|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 21:47:49.844122|2018-05-31 21:47:49.844122
NCT01500876|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2018-01-03|2011-12-28|2011-12-29|Estimate|||||||2018-01-03|2018-01-05|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer|A Feasibility Study Using Four-Dimensional CT Imaging to Evaluate Lung Strain in Patients Treated With External Beam Radiation Therapy for Primary Lung Cancer|Active, not recruiting||N/A|35|Actual|University of Louisville||1|||f||||t||||||||||2018-05-31 21:47:49.939849|2018-05-31 21:47:49.939849
NCT01500863|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-10-25|2011-12-28|2011-12-29|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2011||2011-11-30|October 2016|2016-10-31||||May 2012|Actual|2012-05-31||Interventional|ERAMAD||Endometrial Receptivity After GnRH Agonist Triggering|Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation|Completed||Phase 4|35|Actual|IVI Madrid||6|||f||||f||||||||No||2018-05-31 21:47:50.016997|2018-05-31 21:47:50.016997
NCT01500850|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-23|2011-12-23|2011-12-29|Estimate|||||||2011-12-23|2011-12-29|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use|Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use.|Unknown status|Recruiting|Phase 4|60|Anticipated|ikfe-CRO GmbH||4|||f||||f||||||||||2018-05-31 21:47:50.144|2018-05-31 21:47:50.144
NCT01500837|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2013-09-17|2011-12-28|2011-12-29|Estimate|||||||2013-09-17|2013-09-18|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CLINDOS||Treatment of Methicillin-sensitive Staphylococcus Aureus (MSSA)|Treatment of Methicillin-sensitive Staphylococcus Aureus Orthopaedic Infections With Clindamycin in Combination With Rifampin or Levofloxacin: a Randomized Pharmacological and Clinical Study (the CLINDOS Trial)|Completed||N/A|23|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:47:50.325639|2018-05-31 21:47:50.325639
NCT01500824|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-02-22|2011-12-22|2011-12-28|Estimate|||||||2013-02-22|2013-02-25|Estimate|May 2014||2014-05-31|February 2013|2013-02-28|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer|Phase 2 Open-label Single Arm Study Of The Efficacy And Safety Of Crizotinib In East Asian Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus|Withdrawn||Phase 2|0|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 21:47:50.474549|2018-05-31 21:47:50.474549
NCT01500811|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-04-24|2011-12-22|2011-12-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Autologous Chondrocyte Intra-articular Implantation in Patients With Severe Hip Osteoarthritis|Evaluation the Side Effects of Autologous Chondrocyte Intra-articular Implantation in Patients With Severe Hip Osteoarthritis|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 21:47:50.561372|2018-05-31 21:47:50.561372
NCT01500798|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-10-27|2011-12-22|2011-12-28|Estimate|||||||2014-10-27|2014-10-29|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|||A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes|A Pharmacodynamic Study of Measured Glomerular Filtration Rate Assessed by Tc99m-DTPA in Patients With Chronic Kidney Disease and Type 2 Diabetes|Terminated||Phase 1|18|Actual|Reata Pharmaceuticals, Inc.||2||IDMC recommendation for safety concerns|f||||||||||||||2018-05-31 21:47:50.635874|2018-05-31 21:47:50.635874
NCT01500785|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-04-07|2011-12-22|2011-12-28|Estimate|||||||2014-04-07|2014-04-08|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Intracoronary Administration of Levosimendan in Cardiac Surgery Patients|Intracoronary Administration of Levosimendan in Cardiac Surgery Patients|Unknown status|Recruiting|Phase 4|50|Anticipated|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 21:47:50.696649|2018-05-31 21:47:50.696649
NCT01500772|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|2016-05-19||2016-06-30|2011-12-27|2011-12-28|Estimate|2016-05-19|2016-06-27|Estimate||||2016-06-30|2016-08-01|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||All enrolled patients|Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C|A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease Inhibitor Treatment Failure Patients With Chronic Hepatitis C Genotype 1|Terminated||Phase 3|6|Actual|Debiopharm International SA|Due to early termination of the study, none of the planned outcome measures could be evaluated.|1|||f||||||||||||||2018-05-31 21:47:50.791804|2018-05-31 21:47:50.791804
NCT01500759|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2015-08-04|2011-12-23|2011-12-28|Estimate|||||||2015-08-04|2015-08-05|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31|4 Weeks|Observational [Patient Registry]|SchlaHF||Sleep-Disordered Breathing in Heart Failure - The SchlaHF-Registry|Prevalence, Clinical Characteristics and Type of Sleep-disordered Breathing in Patients With Chronic, Symptomatic, Systolic Heart Failure|Completed|||10775|Actual|ResMed|||||f||||f||||||||||2018-05-31 21:47:51.064741|2018-05-31 21:47:51.064741
NCT01500746|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|2014-01-20||2014-03-10|2011-12-23|2011-12-28|Estimate|2014-03-10|2014-04-14|Estimate||||2014-03-10|2014-04-14|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|PLI2||Evaluation of the Effectiveness of Daily Pulse Lavage Therapy in Chronic Wounds|Bedside Pulse Lavage Irrigation Project|Completed||N/A|8|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:47:51.500423|2018-05-31 21:47:51.500423
NCT01500733|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-03-01|2011-12-23|2011-12-28|Estimate|||||||2018-03-01|2018-03-02|Actual|November 28, 2011||2011-11-28|February 1, 2018|2018-02-01|May 1, 2018|Anticipated|2018-05-01|June 20, 2014|Actual|2014-06-20||Interventional|||PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion|Active, not recruiting||Phase 2|86|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:47:51.818784|2018-05-31 21:47:51.818784
NCT01500720|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2015-03-30||2015-03-30|2011-12-27|2011-12-28|Estimate|2015-03-30|2015-04-13|Estimate||||2015-03-30|2015-04-13|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Randomized population included all randomized participants, and was analyzed according to the randomized treatment.|Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer|Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy|Completed||Phase 2|179|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:47:51.984719|2018-05-31 21:47:51.984719
NCT01500707|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-01-07|2011-12-22|2011-12-28|Estimate|||||||2015-01-07|2015-01-08|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)|A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease|Withdrawn||Phase 1|0|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 21:47:52.812617|2018-05-31 21:47:52.812617
NCT01500694|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2016-07-22||2017-05-30|2011-12-27|2011-12-28|Estimate|2017-04-10|2017-05-18|Actual||||2017-05-30|2017-06-23|Actual|March 2012||2012-03-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional||Safety analysis set included all enrolled participants who took at least 1 dose of SPD503.|Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe|A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended-release for European Subjects With Attention-deficit/Hyperactivity Disorder (ADHD) Who Participated in Study SPD503-315 or SPD503-316|Completed||Phase 3|215|Actual|Shire||1|||f||||t||||||||No||2018-05-31 21:47:52.915276|2018-05-31 21:47:52.915276
NCT01500681|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2017-03-21|2011-12-23|2011-12-28|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2012||2012-06-30|March 2017|2017-03-31||||August 2017|Anticipated|2017-08-31||Observational|MultiPLEX||Maintenance Plasma Exchange for Neuromyelitis Optica|A Prospective Observational Study of Maintenance Plasma Exchange (PLEX) for Neuromyelitis Optica Spectrum Disorders (MultiPLEX Study)|Active, not recruiting|||14|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 21:47:53.39988|2018-05-31 21:47:53.39988
NCT01500668|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-01-03|2011-12-27|2011-12-28|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis|Botulinum Toxin for Treatment of Catocholamine Induced Finger Necrosis - a Double Blind Randomized Control Prospective Study.|Unknown status|Recruiting|Phase 4|20|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:47:53.464428|2018-05-31 21:47:53.464428
NCT01500655|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2016-12-05|2011-12-27|2011-12-28|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2008||2008-04-30|December 2016|2016-12-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients|Evaluation of Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients for Reconstructive Surgical Procedures|Completed||N/A|19|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 21:47:53.537291|2018-05-31 21:47:53.537291
NCT01500642|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-01-04|2011-12-27|2011-12-28|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy|Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy in Patients With Ragweed Pollinosis: a Phase III Randomized and Controlled Clinical Study|Completed||Phase 3|45|Actual|ASST Fatebenefratelli Sacco||3|||f||||f||||||||||2018-05-31 21:47:53.593506|2018-05-31 21:47:53.593506
NCT01500629|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2013-12-15||2017-01-11|2011-12-22|2011-12-28|Estimate|2014-04-09|2014-05-09|Estimate||||2017-01-11|2017-02-27|Actual|January 2012||2012-01-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever|A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of a Topical Nasal Spray in the the Relief of Signs and Symptoms of an Acute Response to a Nasal Allergen Challenge|Completed||Early Phase 1|21|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 21:47:54.959923|2018-05-31 21:47:54.959923
NCT01500616|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2016-08-16|2011-12-27|2011-12-28|Estimate|||||||2016-08-16|2016-08-18|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Telaprevir Open-Label Study in Co-Infected Patients|Multicenter, Open-Label, Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis or Compensated Cirrhosis|Completed||Phase 3|122|Actual|Janssen-Cilag International NV||1|||f||||f||||||||||2018-05-31 21:47:56.204646|2018-05-31 21:47:56.204646
NCT01500603|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2014-10-07|2011-12-27|2011-12-28|Estimate|||||||2014-10-07|2014-10-08|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|BALLANCE||Periurethral Pro-ACTTM Balloons vs Retrourethral AdvanceXP(TM) Male Sling for Post-prostatectomy Incontinence|Prospective, Randomized, Multicentric, Comparative Trial of Two Devices in Surgical Treatment of Post-radical Prostatectomy Stress Urinary Incontinence: Periurethral Pro-ACTTM Balloons and AdvanceXP(TM) Retrourethral Male Sling|Terminated||N/A|6|Actual|Assistance Publique - Hôpitaux de Paris||2||lack of inclusion in the study|f||||f||||||||||2018-05-31 21:47:56.318092|2018-05-31 21:47:56.318092
NCT01500590|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2016-09-02|2011-12-27|2011-12-28|Estimate|||||||2016-09-02|2016-09-05|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|eGFR||Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria|Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial|Active, not recruiting||Phase 4|1400|Actual|Hospital Authority, Hong Kong||2|||f||||f||||||||Undecided||2018-05-31 21:47:56.427414|2018-05-31 21:47:56.427414
NCT01500577|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2014-06-17|2011-12-27|2011-12-28|Estimate|||||||2014-06-17|2014-06-18|Estimate|April 2005||2005-04-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|November 2012|Actual|2012-11-30||Interventional|||A Prevention Trial in Subjects at High Risk for Breast Cancer|A Randomized Phase II Prevention Trial in Subjects at High Risk for Hormone Non-responsive Breast Cancer|Completed||Phase 2|150|Actual|European Institute of Oncology||3|||f||||f||||||||||2018-05-31 21:47:56.500486|2018-05-31 21:47:56.500486
NCT01500564|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-01-30|2011-12-27|2011-12-28|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2, 2012|Actual|2012-01-02|January 2018|2018-01-31|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Interventional|ReSTIM||Functional Interest of Non Invasive Brain Stimulation During Physiotherapy at a Subacute Phase Post Stroke (Anodal Protocol): ReSTIM|Functional Interest of Non Invasive Brain Stimulation During Physiotherapy at a Subacute Phase Post Stroke (Anodal Protocol).|Completed||N/A|10|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 21:47:56.572651|2018-05-31 21:47:56.572651
NCT01500551|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-05-03|2011-12-27|2011-12-28|Estimate|||||||2018-05-03|2018-05-04|Actual|March 18, 2013|Actual|2013-03-18|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Long-Term Safety Study Of Tofacinib In Patients With Juvenile Idiopathic Arthritis|A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia)|Recruiting||Phase 3|340|Anticipated|Pfizer||1|||f||||t||||||||||2018-05-31 21:47:56.672849|2018-05-31 21:47:56.672849
NCT01500538|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2016-02-12|2011-12-22|2011-12-28|Estimate|||||||2016-02-12|2016-02-15|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|VEIL||A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)|A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)|Terminated||Phase 2|1|Actual|Peter MacCallum Cancer Centre, Australia||1||Poor recruitment rate|f||||t||||||||||2018-05-31 21:47:56.990144|2018-05-31 21:47:56.990144
NCT01500525|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2013-02-25|2011-12-27|2011-12-28|Estimate|||||||2013-02-25|2013-02-26|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Bronchodilator Response in 4-12 Years Chinese Controller Naive Asthmatic Children|A Prospective Observational Study in a Tertiary Pediatric Hospital in Beijing to Understand the Accuracy of Bronchodilator Response (BDR) in Chinese Controller Naive Asthmatic Children Between the Age of 4~12 Years Old|Unknown status|Recruiting||600|Anticipated|Capital Institute of Pediatrics, China|||2||f||||t||||||||||2018-05-31 21:47:57.061522|2018-05-31 21:47:57.061522
NCT01500512|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|||2017-08-23|2011-12-24|2011-12-28|Estimate|||||||2017-08-23|2017-08-24|Actual|January 3, 2012|Actual|2012-01-03|August 2017|2017-08-31||||July 1, 2015|Actual|2015-07-01||Observational|GROINSS-V||Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection|GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) II: An Observational Study|Active, not recruiting|||148|Actual|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 21:47:57.142546|2018-05-31 21:47:57.142546
NCT01500499|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-24|||2016-05-17|2011-12-24|2011-12-28|Estimate|||||||2016-05-17|2016-05-18|Estimate|December 2011||2011-12-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia|The Role of AF1q in Progression of Leukemia|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:47:57.275719|2018-05-31 21:47:57.275719
NCT01500486|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2016-11-16|2011-12-22|2011-12-28|Estimate|||||||2016-11-16|2016-11-17|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™|Observational Study to Assess Ease of Use, Acceptability and Preference of Norditropin NordiFlex® With NordiFlex PenMate™ in Subjects on Prescribed Growth Hormone Therapy|Completed|||84|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:47:57.343625|2018-05-31 21:47:57.343625
NCT01500473|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-02-13|2011-12-22|2011-12-28|Estimate|||||||2012-02-13|2012-02-14|Estimate|February 2012||2012-02-29|February 2012|2012-02-29||||December 2012|Anticipated|2012-12-31||Interventional|||Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome|Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome|Unknown status|Not yet recruiting|N/A|8|Anticipated|Children's Hospital Los Angeles||1|||f||||t||||||||||2018-05-31 21:47:57.423005|2018-05-31 21:47:57.423005
NCT01500447|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-05-08|2011-12-22|2011-12-28|Estimate|||||||2018-05-08|2018-05-09|Actual|December 20, 2011||2011-12-20|May 3, 2018|2018-05-03||||||||Observational|||Inherited Reproductive Disorders|The Molecular Basis of Inherited Reproductive Disorders|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:47:57.525132|2018-05-31 21:47:57.525132
NCT01500434|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2012-01-11||2017-02-02|2011-12-22|2011-12-28|Estimate|2012-01-11|2012-02-14|Estimate||||2017-02-02|2017-03-13|Actual|February 2009||2009-02-28|February 2017|2017-02-28|May 2015|Actual|2015-05-31|March 2011|Actual|2011-03-31||Interventional|PLATINUM LL||The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Long Lesion Sub-trial|Completed||Phase 3|102|Actual|Boston Scientific Corporation||1|||f||||t||||||||No|Primary endpoint data uploaded.|2018-05-31 21:47:57.670062|2018-05-31 21:47:57.670062
NCT01500421|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2011-12-27|2011-12-27|2011-12-28|Estimate|||||||2011-12-27|2011-12-28|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)|The Øresund Copenhagen-Malmø Acute Stroke Cooling Trial|Completed||Phase 2|31|Actual|Bispebjerg Hospital||4|||f||||t||||||||||2018-05-31 21:47:58.53253|2018-05-31 21:47:58.53253
NCT01500408|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-11-16|2011-12-27|2011-12-28|Estimate|||||||2012-11-16|2012-11-19|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers|A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of Interferon Beta-1a Manufactured by Two Different Processes|Completed||Phase 1|110|Actual|Biogen||2|||f||||f||||||||||2018-05-31 21:47:58.630618|2018-05-31 21:47:58.630618
NCT01500395|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-12-30|2011-12-22|2011-12-28|Estimate|||||||2015-12-30|2016-01-01|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31|3 Years|Observational [Patient Registry]|||Hybrid Operation in Thoracic Aortic Dissection|Hybrid Operation in Thoracic Aortic Dissection---Registry of China|Recruiting|||50|Anticipated|Xijing Hospital|||1||f||||t||||||||||2018-05-31 21:47:58.715254|2018-05-31 21:47:58.715254
NCT01500382|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2016-08-02||2016-08-02|2011-12-22|2011-12-28|Estimate|2016-08-02|2016-09-26|Estimate||||2016-08-02|2016-09-26|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)|A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder|Terminated||Phase 1|4|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to insufficient recruitment. Only four participants in total participated in the study with three completing and one discontinuation.|4||This study was terminated early due to insufficient recruitment.|f||||f||||||||||2018-05-31 21:47:58.826338|2018-05-31 21:47:58.826338
NCT01500369|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-07-02|2011-12-27|2011-12-28|Estimate|||||||2013-07-02|2013-07-03|Estimate|December 2010||2010-12-31|July 2013|2013-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery|Effect of Remote Ischemic Preconditioning on Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|410|Anticipated|Baystate Medical Center||2|||f||||t||||||||||2018-05-31 21:47:59.237172|2018-05-31 21:47:59.237172
NCT01500356|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-07-24|2011-12-22|2011-12-28|Estimate|||||||2017-07-24|2017-07-25|Actual|December 13, 2011|Actual|2011-12-13|July 2017|2017-07-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|Heart Health||Effect of Exercise and Weight Loss on Cardiovascular Health|Effect of Exercise and Weight Loss on Cardiovascular Health|Completed||N/A|383|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:47:59.340507|2018-05-31 21:47:59.340507
NCT01500343|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2011-12-27|2011-12-27|2011-12-28|Estimate|||||||2011-12-27|2011-12-28|Estimate|November 2008||2008-11-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|PROICA||A Pilot Study of Probiotic Saccharomyces Boulardii Use in Chronic Heart Failure Patients. Estudo PROICA|A Pilot Study of Probiotic Saccharomyces Boulardii Use in Chronic Heart Failure Patients|Completed||Phase 2|20|Actual|Universidade Federal Fluminense||2|||f||||t||||||||||2018-05-31 21:47:59.421247|2018-05-31 21:47:59.421247
NCT01500330|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2013-10-08|2011-12-22|2011-12-28|Estimate|||||||2013-10-08|2013-10-09|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|NaSK||Home Use of Cupping Massage in Chronic Neck Pain|Randomised Controlled Study on the Effectiveness of Cupping Massage for Home Use in Chronic Neck Pain [Randomisierte Kontrollierte Studie Zur Wirksamkeit Der Schröpfkopfmassage Als Heimanwendung Bei Chronischen Nackenschmerzen]|Completed||N/A|84|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 21:47:59.602589|2018-05-31 21:47:59.602589
NCT01500317|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2012-11-08||2012-12-13|2011-12-22|2011-12-28|Estimate|2012-12-13|2012-12-17|Estimate||||2012-12-13|2012-12-17|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|tap-oxy||Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans|Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans|Completed||Phase 4|38|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 21:47:59.70983|2018-05-31 21:47:59.70983
NCT01500304|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-03-21|2011-12-22|2011-12-28|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2012||2012-06-30|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SAFE-MILND||Minimally Invasive Groin Dissection for Melanoma|Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma|Completed||N/A|88|Actual|Mayo Clinic||1|||f||||t||||||||No|no plan to share data|2018-05-31 21:48:00.016543|2018-05-31 21:48:00.016543
NCT01500291|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2016-03-14|2011-12-27|2011-12-28|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|October 2015|Actual|2015-10-31||Observational|stress||A Study Survey of Stress in Anesthesia Personnel|Principal Investigator|Unknown status|Enrolling by invitation||639|Anticipated|Mahidol University|||2||f||||f||||||||||2018-05-31 21:48:00.116951|2018-05-31 21:48:00.116951
NCT01500278|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2016-11-22||2017-07-07|2011-12-27|2011-12-28|Estimate|2017-02-10|2017-03-31|Actual||||2017-07-07|2017-08-08|Actual|December 2011||2011-12-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional||Baseline Characteristics refer to the Randomized Treatment Group (RTG) that consisted of all subjects randomized into the study.|Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate|A Multicenter, Single-blind, Randomized Parallel-group Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis Responding Inadequately to Methotrexate|Completed||Phase 4|915|Actual|UCB Pharma||4|||f||||f||||||||||2018-05-31 21:48:00.240558|2018-05-31 21:48:00.240558
NCT01500265|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2016-02-23|2011-12-27|2011-12-28|Estimate|||||||2016-02-23|2016-02-24|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Observational|HBVSECURE||Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus|Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus.|Completed|||216|Actual|University Hospital, Limoges|||3||f||||f||||||Samples With DNA|"~     Plasma and urine samples for determination of TMPi / GFR and FEUA A sample of genomic DNA~     will be collected after informed consent of the patient from a saliva sample (Saliva~     autocollection kits) in order to investigate genetic polymorphism in transporters responsible~     for the renal elimination of TDF and ETV.~   "|||2018-05-31 21:48:01.299704|2018-05-31 21:48:01.299704
NCT01500252|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2012-01-03||2012-04-05|2011-12-27|2011-12-28|Estimate|2012-04-05|2012-05-01|Estimate||||2012-04-05|2012-05-01|Estimate|September 1996||1996-09-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|June 2004|Actual|2004-06-30||Interventional|PROFIX||Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty - A Randomized Clinical Trial|A Randomized Clinical Trial Comparing Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty Using the PROFIX* Total Knee System|Completed||Phase 4|38|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:48:01.423332|2018-05-31 21:48:01.423332
NCT01500226|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2015-10-02||2016-02-02|2011-12-27|2011-12-28|Estimate|2015-10-02|2015-11-04|Estimate||||2016-02-02|2016-03-02|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||"684 subjects were randomized to Rolapitant and 685 were randomized to control;~670 of those randomized to Rolapitant received study drug in C1; 674 of those who were randomized to control received study drug in C1.~4 Rolapitant subject and 8 control subject were from GCP-non-compliant sites.~MITT = 666 Rolapitant and 666 control"|Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy|Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy|Completed||Phase 3|1369|Actual|Tesaro, Inc.||2|||f||||f||||||||||2018-05-31 21:48:01.838405|2018-05-31 21:48:01.838405
NCT01500213|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|2015-10-02||2016-02-02|2011-12-27|2011-12-28|Estimate|2015-10-02|2015-11-04|Estimate||||2016-02-02|2016-03-02|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|HEC|MITT population: 278 subjects were randomized to Rolapitant and 277 were randomized to control, 272 of those randomized to Rolapitant received study drug in C1; 274 of those who were randomized to control received study drug in C1, 1 Rolapitant subject and 1 control subject were from GCP-non-compliant sites.|Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy|A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy|Completed||Phase 3|555|Actual|Tesaro, Inc.||2|||f||||f||||||||||2018-05-31 21:48:02.506288|2018-05-31 21:48:02.506288
NCT01500200|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22||2013-11-08|2016-11-21|2011-12-27|2011-12-28|Estimate||||2013-11-08|2013-12-03|Estimate|2016-11-21|2016-11-22|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Therapy|Completed||Phase 2|142|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 21:48:03.175718|2018-05-31 21:48:03.175718
NCT01500187|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-01-15|2011-12-27|2011-12-28|Estimate|||||||2015-01-15|2015-01-19|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Fluoride Varnish for Treatment of White Spot Lesions|Fluoride Varnish Application for Treatment of White Spot Lesion After Fixed Orthodontic Treatment. A Pilot Study.|Completed||N/A|30|Anticipated|3M||2|||f||||f||||||||||2018-05-31 21:48:03.312535|2018-05-31 21:48:03.312535
NCT01500174|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-09-04|2011-12-21|2011-12-28|Estimate|||||||2012-09-04|2012-09-05|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Ultraviolet-C Effectiveness in the Management of Pressure Ulcers in People With Spinal Cord Injury|Ultraviolet-C Irradiation in the Management of Pressure Ulcers in People With Spinal Cord Injury: A Randomized, Stratified, Placebo-controlled Trial|Completed||N/A|43|Actual|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-05-31 21:48:03.394939|2018-05-31 21:48:03.394939
NCT01500161|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-11-21|2011-12-27|2011-12-28|Estimate|||||||2013-11-21|2013-11-25|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match|A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood (UCB) Transplant For Patients With Hematologic Malignancies Needing Allogeneic Stem Cell Transplant But Do Not Have A Related HLA-Matched Donor|Terminated||Phase 2|1|Actual|Texas Oncology Cancer Center||1||Insufficient accruals|f||||t||||||||||2018-05-31 21:48:03.485212|2018-05-31 21:48:03.485212
NCT01500148|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-01-20|2011-12-27|2011-12-28|Estimate|||||||2014-01-20|2014-01-22|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|SJM PMVr||St. Jude Medical Percutaneous Mitral Valve Repair Study|Clinical Assessment of the St. Jude Medical (SJM) Percutaneous Mitral Valve Repair (PMVr) Device Concept|Completed||Phase 1|2|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 21:48:03.579839|2018-05-31 21:48:03.579839
NCT01496495|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-12-27|2011-12-20|2011-12-21|Estimate|||||||2014-12-27|2014-12-30|Estimate|January 2012||2012-01-31|December 2014|2014-12-31||||December 2014|Actual|2014-12-31||Interventional|||A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes||Completed||Phase 1|71|Actual|Array BioPharma||1|||f||||||||||||||2018-05-31 21:48:54.554189|2018-05-31 21:48:54.554189
NCT01500135|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2016-12-15|2016-08-19|2016-12-15|2011-12-23|2011-12-26|Estimate|2016-12-15|2017-02-08|Estimate|2016-08-19|2016-08-23|Estimate|2016-12-15|2017-02-08|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|VASUS|Full Analysis Set included all randomized participants.|Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery|A Randomized, Open Label, Parallel-group, Multi-center Trial to Compare Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery|Completed||Phase 3|150|Actual|Takeda||2|||f||||t||||||||||2018-05-31 21:48:03.664033|2018-05-31 21:48:03.664033
NCT01500122|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-06-20|2011-12-23|2011-12-26|Estimate|||||||2012-06-20|2012-06-21|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Study Evaluating the Pharmacokinetic Profile of Novel Formulations of RHUDEX®|An Open-label, Non Randomized Monocentric Phase I Study Evaluation the Pharmacokinetic Profile of Novel Formulations of RHUDEX®|Completed||Phase 1|12|Anticipated|MediGene|||||f||||f||||||||||2018-05-31 21:48:04.35093|2018-05-31 21:48:04.35093
NCT01500109|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2015-03-23||2017-10-23|2011-12-23|2011-12-26|Estimate|2015-03-23|2015-04-01|Estimate||||2017-10-23|2017-11-28|Actual|November 2011||2011-11-30|October 2017|2017-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair|Analgesic Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair; a Randomized, Double, Blinded, Placebo Controlled Study|Completed||N/A|45|Actual|Loma Linda University||3|||f||||f||||||||||2018-05-31 21:48:04.484541|2018-05-31 21:48:04.484541
NCT01500096|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14||2017-08-15|2017-09-05|2011-12-23|2011-12-26|Estimate||||2017-09-05|2017-09-11|Actual|2017-09-05|2017-09-11|Actual|February 2013||2013-02-28|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial|American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Multiple-Dose Escalation Clinical Trial|Completed||Phase 2|96|Actual|Johns Hopkins University||4|||f||||t||||||||||2018-05-31 21:48:04.715596|2018-05-31 21:48:04.715596
NCT01500083|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2014-10-10||2017-06-29|2011-12-23|2011-12-26|Estimate|2014-10-10|2014-10-16|Estimate||||2017-06-29|2017-08-14|Actual|March 2012||2012-03-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|BENDACT|all-patients-treated set (APTS): all enrolled patients who took at least one dose of investigational medicinal product (IMP)|Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia|An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 3|90|Actual|Lundbeck Canada Inc.||2|||f||||f||||||||||2018-05-31 21:48:04.825506|2018-05-31 21:48:04.825506
NCT01500070|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-08-10|2011-12-23|2011-12-26|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PREVENT||PREVENT: Promus BTK|PREVENT: a Prospective, Multi-center, Monitored Trial Investigating the Implant of the Promus Everolimus-Eluting Stent System in Critically Ischemic Lesions BTK|Completed||Phase 2|70|Anticipated|Flanders Medical Research Program||1|||f||||t||||||||||2018-05-31 21:48:05.401876|2018-05-31 21:48:05.401876
NCT01500057|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2018-04-13||2018-04-13|2011-12-23|2011-12-26|Estimate|2018-04-13|2018-05-14|Actual||||2018-04-13|2018-05-14|Actual|December 2011||2011-12-31|April 2018|2018-04-30|October 10, 2016|Actual|2016-10-10|October 10, 2016|Actual|2016-10-10||Interventional|||Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia|An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia|Completed||Phase 4|66|Actual|Brooklyn Urology Research Group||2|||f||||f||||||||||2018-05-31 21:48:05.507377|2018-05-31 21:48:05.507377
NCT01500044|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-07-02|2011-12-21|2011-12-26|Estimate|||||||2013-07-02|2013-07-03|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Mobilizations and Exercises Targeting the Opening of Intervertebral Foramens Following Cervical Radiculopathy|Cervical Radiculopathy: A Randomized Clinical Trial Evaluating the Effect of Mobilizations and Exercises Targeting the Opening of Intervertebral Foramens|Completed||N/A|36|Actual|Laval University||2|||f||||f||||||||||2018-05-31 21:48:05.732492|2018-05-31 21:48:05.732492
NCT01500031|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2014-01-06||2014-03-10|2011-12-23|2011-12-26|Estimate|2014-03-10|2014-04-15|Estimate||||2014-03-10|2014-04-15|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|Re-ROUTE||Boston Scientific OffRoad™ Re-entry Catheter System for Subintimal Recanalization of Chronic Total Occlusions in Femoropopliteal Arteries|Boston Scientific OffRoad™ Re-entry Catheter System for Subintimal Recanalization of Chronic Total Occlusions in Femoropopliteal Arteries|Completed||Phase 4|92|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 21:48:05.823675|2018-05-31 21:48:05.823675
NCT01500018|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-03-21|2011-12-23|2011-12-26|Estimate|||||||2012-03-21|2012-03-22|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|TC-5214||Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214|A Single-center, Single-dose, Double-blind, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of TC-5214 in Healthy Recreational Polydrug Users|Withdrawn||Phase 1|0|Actual|AstraZeneca||14||Sponsor decision to withdraw.|f||||||||||||||2018-05-31 21:48:06.365712|2018-05-31 21:48:06.365712
NCT01500005|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2011-12-23|2011-12-23|2011-12-26|Estimate|||||||2011-12-23|2011-12-26|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||The Effect of Vitamin D Supplementation on Arterial Stiffness in Diabetic Patients|The Effect of Vitamin D Supplementation on Arterial Stiffness, Blood Pressure, Oxidative Stress and Inflammation in Diabetic Patients|Completed||N/A|74|Actual|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 21:48:06.515009|2018-05-31 21:48:06.515009
NCT01499992|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2014-03-18|2011-12-23|2011-12-26|Estimate|||||||2014-03-18|2014-03-19|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Rehabilitation of Reconstructed Shoulder Rotator Cuff|Rehabilitation of Reconstructed Shoulder Rotator Cuff : Optimizing Physical Therapy Dosage and Effect of Aquatic Physical Therapy - A Randomized, Factorial Study|Completed||N/A|14|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:48:06.59594|2018-05-31 21:48:06.59594
NCT01499966|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-12-23|2011-12-23|2011-12-26|Estimate|||||||2011-12-23|2011-12-26|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|POPTuLAS||Comparison of Plaster of Paris Against Tubigrip for the Treatment of Lateral Ankle Sprains|Assessment of Tubigrip Versus Plaster of Paris in the Treatment of Grade 1 and 2 Lateral Ankle Sprains|Completed||N/A|200|Actual|Liaquat National Hospital & Medical College||2|||f||||f||||||||||2018-05-31 21:48:06.735317|2018-05-31 21:48:06.735317
NCT01499953|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-09-12|2011-12-21|2011-12-26|Estimate|||||||2016-09-12|2016-09-13|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux|Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux|Completed||Phase 3|472|Actual|GWT-TUD GmbH||2|||f||||t||||||||||2018-05-31 21:48:06.813328|2018-05-31 21:48:06.813328
NCT01499940|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-11-02|2011-12-22|2011-12-26|Estimate|||||||2016-11-02|2016-11-04|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway|Phase II Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through the Vitamin D Pathway|Terminated||Phase 2|9|Actual|West Virginia University||1||Research cancelled - no funding identified.|f||||t||||||||||2018-05-31 21:48:06.92514|2018-05-31 21:48:06.92514
NCT01499927|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2013-12-18|2011-12-22|2011-12-26|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AIR||"Early Reassessment of Intravenous Antiinfective Therapy Due to Antiinfective Reminders (AIR Study)"|"Early Reassessment of Intravenous Antiinfective Therapy Due to Antiinfective Reminders (AIR Study)"|Completed||N/A|74766|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 21:48:07.002282|2018-05-31 21:48:07.002282
NCT01499914|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-08-25|2011-12-21|2011-12-26|Estimate|||||||2014-08-25|2014-08-26|Estimate|November 2009||2009-11-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|January 2011|Actual|2011-01-31||Interventional|MUCOFLU||Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination|Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination in Patients With Cystic Fibrosis and, Where Applicable, the Clinical Expression of Influenza A (H1N1)|Completed||Phase 4|439|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 21:48:07.070773|2018-05-31 21:48:07.070773
NCT01499901|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-11-16|2011-12-21|2011-12-26|Estimate|||||||2012-11-16|2012-11-19|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|Cochleo||Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children|Interest of the Bilateral Cochlear Implantation in the Deep Deaf Children Respect to the Unilateral Implantation - a Randomized Test|Withdrawn||Phase 3|0|Actual|Assistance Publique - Hôpitaux de Paris||2||Recommendations of HAS have changed, the study is now useless|f||||t||||||||||2018-05-31 21:48:07.133935|2018-05-31 21:48:07.133935
NCT01499888|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-04-19|2011-12-22|2011-12-26|Estimate|||||||2017-04-19|2017-04-20|Actual|November 11, 2011|Actual|2011-11-11|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)|Phase I/II Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (SCD)|Recruiting||Phase 1/Phase 2|15|Anticipated|University of Illinois at Chicago||1|||f||||t|t|f|||f|||||2018-05-31 21:48:07.194336|2018-05-31 21:48:07.194336
NCT01499875|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2014-09-30|2011-12-22|2011-12-26|Estimate|||||||2014-09-30|2014-10-01|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of Phenoxymethylpenicillin for Children|A Pharmacokinetic and Pharmacodynamic Study of Phenoxymethylpenicillin for Children|Completed||Phase 1|80|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 21:48:07.273737|2018-05-31 21:48:07.273737
NCT01499862|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2012-06-18||2013-06-30|2011-12-22|2011-12-26|Estimate|2013-06-30|2013-08-02|Estimate||||2013-06-30|2013-08-02|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Mobility Training Using a Bionic Knee Orthosis in Patients Chronic Post-Stroke: A Case Series|Discriminatory Neurosensory Stimulation Neurological H5394-11417-15|Completed||Phase 4|3|Actual|Tibion Bionics, Inc.|These results are from a small group (n of 3) of patients and should not be assumed to be consistent across all populations. Furthermore, the inherent subjective variability of patient response in physical therapy interventions should be considered.|1|||f||||f||||||||||2018-05-31 21:48:07.3464|2018-05-31 21:48:07.3464
NCT01499849|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2015-10-02||2016-04-19|2011-12-22|2011-12-26|Estimate|2015-10-02|2015-11-04|Estimate||||2016-04-19|2016-05-19|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||"Overall Number of Baseline Participants only included the Modified Intent to Treat (MITT) population:~266 subjects were randomized to Rolapitant and 266 were randomized to control;~264 of those randomized to Rolapitant received study drug in Cycle 1; 262 of those who were randomized to control received study drug in Cycle 1."|Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy|Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety & Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)|Completed||Phase 3|532|Actual|Tesaro, Inc.||2|||f||||f||||||||||2018-05-31 21:48:07.644476|2018-05-31 21:48:07.644476
NCT01499836|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-10|||2014-01-14|2011-12-22|2011-12-26|Estimate|||||||2014-01-14|2014-01-16|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|PQSAT||Quality Study of Anesthetic Technique on Breast Cancer Surgery|Effect of Anesthetic Technique on Pain、 Recovery and Satisfaction in Women Undergoing Breast Surgery|Completed||Phase 4|101|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 21:48:08.198645|2018-05-31 21:48:08.198645
NCT01499823|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-12-27|2011-12-22|2011-12-26|Estimate|||||||2013-12-27|2013-12-30|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2011|Actual|2011-12-31||Observational|||Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma|Permeability Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma|Unknown status|Enrolling by invitation||74|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 21:48:08.260516|2018-05-31 21:48:08.260516
NCT01499810|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2014-09-04||2016-01-26|2011-12-22|2011-12-26|Estimate|2014-09-16|2014-09-17|Estimate||||2016-01-26|2016-02-26|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension|Study of Efficacy and Safety of Radiofrequency Sympathetic Renal Denervation for Treatment of Drug Resistant Hypertension|Completed||Phase 2/Phase 3|53|Actual|Federal State Budgetary Scientific Institution, Research Institute of Cardiology||1|||f||||f||||||||Undecided||2018-05-31 21:48:08.441225|2018-05-31 21:48:08.441225
NCT01499771|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-07-08|2011-12-22|2011-12-26|Estimate|||||||2012-07-08|2012-07-10|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions|A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fed Conditions.|Completed||Phase 1|80|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:48:09.478259|2018-05-31 21:48:09.478259
NCT01499758|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-07-08|2011-12-22|2011-12-26|Estimate|||||||2012-07-08|2012-07-10|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.|A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.|Completed||Phase 1|80|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:48:09.550817|2018-05-31 21:48:09.550817
NCT01499745|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2011-12-22|2011-12-22|2011-12-26|Estimate|||||||2011-12-22|2011-12-26|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients|Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients|Unknown status|Not yet recruiting|N/A|40|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 21:48:09.615673|2018-05-31 21:48:09.615673
NCT01499732|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-05-06|2011-12-22|2011-12-26|Estimate|||||||2013-05-06|2013-05-08|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects|An Exploratory Trial to Evaluate Premature Endothelial Dysfunction, as Measured by Positron Emission Tomography (PET) Scan With Cold Pressor Test (CPT), in Patients With Early Rheumatoid Arthritis (RA) Compared to Patients With Established RA, and Normal Subjects. Additionally, the Relationship Between the PET Scan Findings and the Inflammatory, Cardiovascular Risk, and Endothelial Dysfunction Biomarkers Will be Analyzed|Completed|||15|Actual|Orrin M Troum, M.D. and Medical Associates|||3||f||||f||||||||||2018-05-31 21:48:09.700318|2018-05-31 21:48:09.700318
NCT01499719|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2016-03-28|2011-12-22|2011-12-26|Estimate|||||||2016-03-28|2016-03-29|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery|Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery|Completed|||100|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 21:48:09.766047|2018-05-31 21:48:09.766047
NCT01499706|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-22|2011-12-22|2011-12-26|Estimate|||||||2011-12-22|2011-12-26|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|MI||Telephone-delivered Behavioral Interventions to Reduce Risky Sexual Behavior in HIV-positive Late Middle-age and Older Adults|Phase I Clinical Trial of Telephone-delivered Motivational Interviewing to Reduce Sexual Risk Behavior in HIV-positive Persons 45-plus Years of Age|Completed||Phase 1|100|Actual|Ohio University College of Osteopathic Medicine||3|||f||||t||||||||||2018-05-31 21:48:09.831063|2018-05-31 21:48:09.831063
NCT01499693|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2012-09-14|2011-12-23|2011-12-26|Estimate|||||||2012-09-14|2012-09-17|Estimate||||September 2012|2012-09-30||||||||Interventional|||Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition|Phase IIIb, Randomized, Triple-blinded and Crossover Study to Evaluate the Effect of Magnesium Pantoprazole 20mg Bid Versus Magnesium Pantoprazole 40mg qd on Intragastric Acid Inhibition Assessed by pHmetry, in Healthy Volunteers|Withdrawn||Phase 3|0|Actual|Takeda||2|||f||||t||||||||||2018-05-31 21:48:09.911794|2018-05-31 21:48:09.911794
NCT01499680|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2014-07-14|2011-12-22|2011-12-26|Estimate|||||||2014-07-14|2014-07-15|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|NV in XLIF®||Multimodality Neuromonitoring in XLIF|Multimodality Neuromonitoring In eXtreme Lateral Interbody Fusion (XLIF®)|Completed|||323|Actual|NuVasive|||1||f||||f||||||||||2018-05-31 21:48:10.000533|2018-05-31 21:48:10.000533
NCT01499667|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|2013-11-25||2014-08-06|2011-12-22|2011-12-26|Estimate|2014-02-25|2014-04-04|Estimate||||2014-08-06|2014-08-08|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TOFIINGO|Randomized set includes all subjects who receive a randomization number, regardless of whether or not they receive study medication.|Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod|A 32-week, Patient- and Rater-blinded, Randomized, Multi-center, Parallel-group Study to Evaluate Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis Transferred From Previous Treatment With Natalizumab to Fingolimod (FTY720)|Terminated||Phase 3|142|Actual|Novartis|Study was terminated due to new data on nataluzimab washout prior to treatment with other disease modifying treatments. The power to detect statistically significant differences between the washout groups based on the (-)binomial is estimated 30-40%.|3||"Based on recent publications, determination of natalizumub washout period was no longer~   relevant."|f||||f||||||||||2018-05-31 21:48:10.12417|2018-05-31 21:48:10.12417
NCT01499654|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2015-12-18||2016-01-27|2011-12-22|2011-12-26|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|REGA-1102||Half-Dose Radiopharmaceutical in Wide Beam Reconstruction|Feasibility of Half-Dose Radiopharmaceutical Administration Utilizing Wide-Beam Reconstruction|Terminated||N/A|64|Actual|Northwestern University|Early termination of study lead to a small numbers of subjects analyzed. Technical problems in WBR processing settings including acquisition matrix sizes and/or number of iterations.|1||Low enrollment|f||||f||||||||||2018-05-31 21:48:10.579611|2018-05-31 21:48:10.579611
NCT01499641|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-09-12|2011-12-22|2011-12-26|Estimate|||||||2014-09-12|2014-09-15|Estimate|May 2001||2001-05-31|September 2014|2014-09-30|December 2005|Actual|2005-12-31|August 2003|Actual|2003-08-31||Interventional|||Epidural Steroid Following Discectomy for Herniated Disc Reduces Morbidity|Epidural Steroid Following Discectomy for Herniated Lumbar Disc Reduces Neurological Impairment and Enhances Recovery. A Randomized Study With Two-year Follow-up|Completed||N/A|200|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:48:11.131302|2018-05-31 21:48:11.131302
NCT01499628|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-09-29|2011-12-22|2011-12-26|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2011||2011-04-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|EFFECT||EFFECT:Eccentric Fixation From Enhanced Clinical Training|Eccentric Fixation From Enhanced Clinical Training (EFFECT): A Randomised Clinical Trial for Patients With AMD|Active, not recruiting||N/A|200|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||4|||f||||f||||||||||2018-05-31 21:48:11.193445|2018-05-31 21:48:11.193445
NCT01499615|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-04-07|2011-12-22|2011-12-26|Estimate|||||||2015-04-07|2015-04-09|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||A Prospective Study of a New Non-Invasive Cardiac Output Monitor in Children Undergoing General Anesthesia|A Prospective Study of a New Non-Invasive Cardiac Output Monitor in Children Undergoing General Anesthesia|Completed|||402|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:48:11.264313|2018-05-31 21:48:11.264313
NCT01499602|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2011-12-22|2011-12-22|2011-12-26|Estimate|||||||2011-12-22|2011-12-26|Estimate|May 2009||2009-05-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women|LNG-IUS or Norethisterone Acetate for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women|Completed||N/A|120|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 21:48:11.31805|2018-05-31 21:48:11.31805
NCT01499589|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2011-12-22|2011-12-22|2011-12-26|Estimate|||||||2011-12-22|2011-12-26|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Observational|||Can the Usage of Regional Block Room Save the Time of Anesthesia Team|Can the Usage of Regional Block Room Save the Time of Anesthesia Team in the Main Orthopedic Operating Room?|Unknown status|Recruiting||800|Anticipated|Mahidol University|||2||f||||t||||||||||2018-05-31 21:48:11.384123|2018-05-31 21:48:11.384123
NCT01499576|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2014-05-19||2014-09-20|2011-12-22|2011-12-26|Estimate|2014-09-20|2014-09-26|Estimate||||2014-09-20|2014-09-26|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|IM||Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia|Acetic Acid Chromoendoscopy for Judging Extent of Gastric Intestinal Metaplasia|Completed||N/A|126|Actual|Konyang University Hospital|Concomitant comparison with methylene blue chromoendoscopy was not performed.|1|||f||||t||||||||||2018-05-31 21:48:12.494108|2018-05-31 21:48:12.494108
NCT01499563|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16||2014-09-03|2017-03-09|2011-12-22|2011-12-26|Estimate||||2014-09-03|2014-09-10|Estimate|2017-03-09|2017-03-10|Actual|December 2011||2011-12-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Study of a Novel Antipsychotic ITI-007 in Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia|Completed||Phase 2|335|Actual|Intra-Cellular Therapies, Inc.||4|||f||||f||||||||||2018-05-31 21:48:12.68131|2018-05-31 21:48:12.68131
NCT01499550|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-09-24|2011-12-22|2011-12-26|Estimate|||||||2012-09-24|2012-09-25|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Nocturnal Transnasal Insufflation (nTNI)|Nocturnal Transnasal Insufflation in Patients With COPD and Hypercapnia|Completed||N/A|31|Actual|Institut für Pneumologie Hagen Ambrock eV||2|||f||||f||||||||||2018-05-31 21:48:12.752578|2018-05-31 21:48:12.752578
NCT01499537|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2016-05-18|2011-12-22|2011-12-26|Estimate|||||||2016-05-18|2016-05-19|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct|Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct in Patients With Malignant or Post-operative Jaundice After Failure or Impossibility to Perform Endoscopic Retrograde Cholangiography|Completed||N/A|65|Actual|Institut Paoli-Calmettes||2|||f||||f||||||||||2018-05-31 21:48:12.819546|2018-05-31 21:48:12.819546
NCT01499524|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2017-01-09|2011-12-22|2011-12-26|Estimate|||||||2017-01-09|2017-01-10|Estimate|November 2011||2011-11-30|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus|A Longitudinal Study of Alterations in Metabolic Markers and Gut Hormones in Pregnant and Non-pregnant Patients With Intrahepatic Cholestasis of Pregnancy, Gestational Diabetes Mellitus and Normal Pregnant and Non-pregnant Controls|Recruiting|||160|Anticipated|Imperial College London|||||f||||f||||||Samples Without DNA|"~     Serum, whole blood, plasma.~   "|No|Any results and findings will be disseminated in research publications.|2018-05-31 21:48:12.980427|2018-05-31 21:48:12.980427
NCT01499511|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-12-22|2011-12-22|2011-12-26|Estimate|||||||2011-12-22|2011-12-26|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Observational|ASCOT-10||Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study|Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study|Unknown status|Not yet recruiting||5450|Anticipated|Imperial College London|||1||f||||f||||||Samples Without DNA|"~     Plasma to be stored for future measurement of biochemical markers of cardiovascular disease~   "|||2018-05-31 21:48:13.268347|2018-05-31 21:48:13.268347
NCT01499498|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2014-10-09||2016-10-26|2011-12-22|2011-12-26|Estimate|2014-11-06|2014-11-07|Estimate||||2016-10-26|2016-12-08|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|April 2013|Actual|2013-04-30||Interventional|||The Boceprevir and Sildenafil Pharmacokinetics Study|A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Boceprevir and Sildenafil When Dosed Separately and Together in Healthy Male Volunteers|Completed||Phase 1|13|Actual|Imperial College London||1|||f||||f||||||||Yes||2018-05-31 21:48:14.260569|2018-05-31 21:48:14.260569
NCT01499485|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-03-16|2011-12-22|2011-12-26|Estimate|||||||2015-03-16|2015-03-17|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TRAMA||Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.|Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial.|Completed||Phase 3|140|Actual|Hospital Son Llatzer||2|||f||||f||||||||||2018-05-31 21:48:14.474694|2018-05-31 21:48:14.474694
NCT01499472|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2011-12-22|2011-12-22|2011-12-26|Estimate|||||||2011-12-22|2011-12-26|Estimate|January 2012||2012-01-31|August 2011|2011-08-31|January 2015|Anticipated|2015-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Comparing the Expected Benefit of Extra-corporeal-shockwave Therapy (ESWT) Treatment to Standard Care in Treating Diabetic Foot Ulcers|ESWT Treatment of Diabetic Foot VS. Standard Care Trial|Unknown status|Not yet recruiting|N/A|300|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 21:48:14.557227|2018-05-31 21:48:14.557227
NCT01499459|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-03-20|2011-12-22|2011-12-26|Estimate|||||||2012-03-20|2012-03-22|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis|Efficacy of Exvivo Expanded Autologous Mesenchymal Stem Cell Transplantation Via Peripheral Vein in Patients With Liver Cirrhosis|Unknown status|Active, not recruiting|N/A|25|Anticipated|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||1|||f||||t||||||||||2018-05-31 21:48:14.613982|2018-05-31 21:48:14.613982
NCT01496482|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-03|||2011-12-21|2011-12-16|2011-12-21|Estimate|||||||2011-12-21|2011-12-22|Estimate|September 2008||2008-09-30|December 2011|2011-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Comparison of Evaporimetry With the Established Methods of Tear Film Measurement|Comparison of Evaporimetry With the Established Methods of Tear Film Measurement|Completed|||90|Actual|University of Zagreb|||2||f||||f||||||||||2018-05-31 21:48:54.625063|2018-05-31 21:48:54.625063
NCT01499446|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-09-13|2011-12-21|2011-12-26|Estimate|||||||2016-09-13|2016-09-15|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.|A Randomised, Double-blind, Double Dummy, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening All Administered by Inhalation Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.|Completed||Phase 2|669|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:48:14.712792|2018-05-31 21:48:14.712792
NCT01499433|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2014-01-22|2011-12-22|2011-12-26|Estimate|||||||2014-01-22|2014-01-23|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|November 2014|Anticipated|2014-11-30|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease|Prospective, Open-label Study of the Efficacy and Safety of Caspofungin for the Treatment of Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|Phase 4|40|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||1|||f||||t||||||||||2018-05-31 21:48:15.025784|2018-05-31 21:48:15.025784
NCT01499420|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19||2014-01-08|2014-01-08|2011-12-22|2011-12-26|Estimate||||2014-01-08|2014-02-06|Estimate|2014-01-08|2014-02-06|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients|A Phase 2a, Multi-center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of CSL112 in Patients With Stable Atherothrombotic Disease|Completed||Phase 2|45|Actual|CSL Limited||2|||f||||||||||||||2018-05-31 21:48:15.126495|2018-05-31 21:48:15.126495
NCT01499407|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2012-01-02|2011-12-22|2011-12-26|Estimate|||||||2012-01-02|2012-01-05|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|COCTAIL II||Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction|A Randomized Trial to Compare Four Different Intracoronary Modalities to Reduce Thrombus Burden and Improve Microcirculatory Function in Patients With ST-elevation Myocardial Infarction: Rationale and Design of the COCTAIL II Study|Unknown status|Recruiting|Phase 4|128|Anticipated|CLI Foundation||4|||f||||f||||||||||2018-05-31 21:48:15.225306|2018-05-31 21:48:15.225306
NCT01499394|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-06-07|2011-12-22|2011-12-26|Estimate|||||||2016-06-07|2016-06-09|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|November 2025|Anticipated|2025-11-30|November 2020|Anticipated|2020-11-30||Observational|||Caris Biorepository Research Protocol|The Caris Biorepository Research Protocol|Active, not recruiting|||100000|Anticipated|Caris Science, Inc.|||2||f||||f||||||Samples With DNA|"~     Currently plasma with an opportunity to collect other biospecimens~   "|||2018-05-31 21:48:15.313009|2018-05-31 21:48:15.313009
NCT01499381|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-06-07|2011-12-23|2011-12-26|Estimate|||||||2016-06-07|2016-06-09|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||EMBRACE1: Prostate Biorepository|Evaluation of a Novel Circulating Microvesicle-Based Multi-analyte Assay for the Detection of Prostate Cancer in Men With Elevated Risk for Prostate Cancer; the EMBRACE1 Study|Completed|||1290|Actual|Caris Science, Inc.|||1||f||||f||||||Samples With DNA|"~     Plasma~   "|||2018-05-31 21:48:15.402236|2018-05-31 21:48:15.402236
NCT01499368|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2013-01-23|2011-12-22|2011-12-26|Estimate|||||||2013-01-23|2013-01-24|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients|Completed||Phase 3|495|Actual|Boryung Pharmaceutical Co., Ltd||3|||f||||t||||||||||2018-05-31 21:48:15.464064|2018-05-31 21:48:15.464064
NCT01499355|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2016-11-22||2016-11-22|2011-12-22|2011-12-26|Estimate|2016-11-22|2017-01-18|Estimate||||2016-11-22|2017-01-18|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ATLAS||BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis|Terminated||Phase 2|276|Actual|Biogen|Study was terminated based on the review of results following the prespecified, blinded futility analysis, which did not demonstrate sufficient efficacy to warrant continuation of the study. Study was not terminated based on safety considerations.|3||"Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant~   continuation of the study."|f||||t||||||||||2018-05-31 21:48:15.588556|2018-05-31 21:48:15.588556
NCT01499342|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-05-13|2011-12-22|2011-12-26|Estimate|||||||2014-05-13|2014-05-14|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|BOSS||Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent in the Superficial Femoral Artery|Belgian Prospective Multicentre Registry to Evaluate Safety and Performance of the Optimed Stent to Treat Atherosclerotic Lesions in the Superficial Femoral Artery|Completed|||500|Anticipated|be Medical|||1||f||||f||||||||||2018-05-31 21:48:16.599274|2018-05-31 21:48:16.599274
NCT01499329|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-07-15|2011-12-22|2011-12-26|Estimate|||||||2015-07-15|2015-07-16|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|EAZY||Safety and Performance of the Zeus CC Stent for the Treatment of Iliac Occlusive Disease|Endovascular Treatment of Iliac Artery Occlusions or Stenoses Using the Zeus CC Stent System|Unknown status|Recruiting||200|Anticipated|be Medical|||1||f||||f||||||||||2018-05-31 21:48:16.660605|2018-05-31 21:48:16.660605
NCT01499316|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-03-06|2011-12-22|2011-12-26|Estimate|||||||2014-03-06|2014-03-10|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Investigating the Effects of Hyperoxia on Fractional Flow Reserve|Investigating the Effects of Hyperoxia on Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease|Unknown status|Not yet recruiting|N/A|18|Anticipated|Bayside Health||2|||f||||f||||||||||2018-05-31 21:48:16.717013|2018-05-31 21:48:16.717013
NCT01499303|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2014-06-17||2014-08-08|2011-12-22|2011-12-26|Estimate|2014-08-08|2014-08-22|Estimate||||2014-08-08|2014-08-22|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Most patients were male (69.1%). The mean age (± standard deviation) was 63.6 ± 12.6 years.|Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer|Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(DLBCL)|Completed||Phase 2|101|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 21:48:16.801278|2018-05-31 21:48:16.801278
NCT01499290|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2015-11-06||2017-08-31|2011-12-22|2011-12-26|Estimate|2016-01-29|2016-03-01|Estimate||||2017-08-31|2017-09-06|Actual|March 2012||2012-03-31|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||The MITT analysis set includes all patients who met the disease definition for cIAI and received at least 1 dose of study drug. 15 patients excluded received at least one dose of study drug but failed the minimum disease criteria.|Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections|A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults|Completed||Phase 3|493|Actual|Pfizer|This summary describes data collected from two identical CSPs (D4280C00001 and D4280C00005). With agreement from the EMA and the FDA the data have been combined into a single study database.|2|||f||||||||||||||2018-05-31 21:48:17.202934|2018-05-31 21:48:17.202934
NCT01499277|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2015-06-23||2017-09-01|2011-12-22|2011-12-26|Estimate|2015-10-07|2015-11-09|Estimate||||2017-09-01|2017-09-06|Actual|May 2012||2012-05-31|September 2017|2017-09-30|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional||761 randomized patients who received any amount of study therapy. there are 11 patients who are randomized , but didn't receive any study therapy.|Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections|A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities|Completed||Phase 3|802|Actual|Pfizer||2|||f||||||||||||||2018-05-31 21:48:18.318092|2018-05-31 21:48:18.318092
NCT01499264|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-01-10|2011-12-22|2011-12-26|Estimate|||||||2014-01-10|2014-01-13|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial|Efficacy of MySkin Patch for the Healing of Burn Wounds: a Randomised Controlled Trial|Unknown status|Recruiting|Phase 3|120|Anticipated|Associazione Infermieristica per lo studio delle Lesioni Cutanee||2|||f||||t||||||||||2018-05-31 21:48:19.100748|2018-05-31 21:48:19.100748
NCT01499251|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-05-04|2011-12-22|2011-12-26|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma|A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide|Terminated||Phase 1|75|Anticipated|Actelion||1||Results did not clearly support continuing development in recurrent GBM|f||||f||||||||||2018-05-31 21:48:19.177992|2018-05-31 21:48:19.177992
NCT01499238|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-21|2011-12-21|2011-12-26|Estimate|||||||2011-12-21|2011-12-26|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Interventional|||Comparison of Nasal CPAP and Nasal SIMV in Transient Tachypnea of Newborn|Comparison of Nasal CPAP and Nasal SIMV in Transient Tachypnea of Newborn|Unknown status|Recruiting|Phase 4|40|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 21:48:19.262955|2018-05-31 21:48:19.262955
NCT01499225|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-07-30|2011-12-21|2011-12-26|Estimate|||||||2014-07-30|2014-07-31|Estimate|December 2011||2011-12-31|July 2014|2014-07-31||||July 2013|Actual|2013-07-31||Interventional|YH14642||A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease|A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH14642 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease|Completed||Phase 2|162|Anticipated|Yuhan Corporation||6|||f||||f||||||||||2018-05-31 21:48:19.352859|2018-05-31 21:48:19.352859
NCT01499212|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2011-12-21|2011-12-21|2011-12-26|Estimate|||||||2011-12-21|2011-12-26|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Effects of Different I:E Ratio on Intrapulmonary Shunt Fraction and Oxygenation During One Lung Ventilation in the Lateral Decubitus Position|Effects of Different Inspiratory to Expiratory Ratios on Intrapulmonary Shunt Fraction and Oxygenation During One Lung Ventilation in the Lateral Decubitus Position|Completed||N/A|58|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 21:48:19.423638|2018-05-31 21:48:19.423638
NCT01499199|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2013-08-15||2015-01-15|2011-12-21|2011-12-26|Estimate|2013-09-19|2013-11-25|Estimate||||2015-01-15|2015-02-25|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|October 2012|Actual|2012-10-31||Interventional|||A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects|A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination With the Abacavir/Lamivudine Fixed Dose Combination Tablet Over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects|Completed||Phase 3|13|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 21:48:19.515185|2018-05-31 21:48:19.515185
NCT01499186|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2014-03-17|2011-12-21|2011-12-26|Estimate|||||||2014-03-17|2014-03-18|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effect of 6 Months of Local Vibration Training in Institutionalized Elderly|The Effect of 6 Months of Local Vibration Training of the Thigh and Hip on Muscle Strength, Muscle Mass, Bone Density, Bone Structure and Functionality in Institutionalized Elderly.|Completed||N/A|50|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 21:48:19.980714|2018-05-31 21:48:19.980714
NCT01499173|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2016-12-15||2017-08-04|2011-12-21|2011-12-26|Estimate|2017-08-04|2017-09-29|Actual||||2017-08-04|2017-09-29|Actual|December 2014||2014-12-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|August 2015|Actual|2015-08-31||Interventional|||A Community Partnership to Treat Stroke|A Community Partnership to Treat Stroke|Completed||N/A|101|Actual|University of Michigan|Because this was a pre-post design, it cannot be the basis for a conclusion that Stroke Ready caused an increase in stroke preparedness and psychological variables|1|||f||||f|f|f||||||No||2018-05-31 21:48:20.079916|2018-05-31 21:48:20.079916
NCT01499160|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2016-03-15||2018-02-05|2011-12-21|2011-12-26|Estimate|2018-02-05|2018-03-06|Actual||||2018-02-05|2018-03-06|Actual|May 2012||2012-05-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|November 2014|Actual|2014-11-30||Interventional|||Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer|GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer|Terminated||Phase 2|7|Actual|University of Maryland|The trial was terminated due to low accrual.|1||low accrual|f||||t|t|f|||f|||No||2018-05-31 21:48:20.373666|2018-05-31 21:48:20.373666
NCT01499147|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2015-06-19||2017-10-25|2011-12-21|2011-12-26|Estimate|2017-05-17|2017-06-14|Actual||||2017-10-25|2017-12-02|Actual|February 2000||2000-02-29|May 2017|2017-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies|Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies|Completed||N/A|100|Actual|University of Illinois at Chicago||2|||f||||t||||||||Yes||2018-05-31 21:48:20.57758|2018-05-31 21:48:20.57758
NCT01499134|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2014-07-29||2014-12-02|2011-12-21|2011-12-26|Estimate|2014-11-21|2014-12-03|Estimate||||2014-12-02|2014-12-17|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|ENCOMPASS|Original sample size for pilot study was fixed at 40 subjects. Lagging enrollment necessitated completion at 17 subjects.|Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure|Effect of Nebivolol Compared With Metoprolol in Hypertensive Patients With Peripheral Arterial Disease|Completed||Phase 3|17|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 21:48:21.003212|2018-05-31 21:48:21.003212
NCT01499121|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-03-02|2011-12-21|2011-12-26|Estimate|||||||2018-03-02|2018-03-06|Actual|May 2012||2012-05-31|March 2018|2018-03-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule|A Phase II, Multi-Centre, Study of the Efficacy and Safety of Sunitinib Given on an Individualized Schedule as First-Line Therapy for Metastatic Renal Cell Cancer|Completed||Phase 2|117|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 21:48:21.431301|2018-05-31 21:48:21.431301
NCT01499108|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-01-30|2011-12-21|2011-12-26|Estimate|||||||2015-01-30|2015-02-02|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|Liratime||Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes|Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes|Completed||Phase 4|32|Actual|Steno Diabetes Center||1|||f||||t||||||||||2018-05-31 21:48:21.538447|2018-05-31 21:48:21.538447
NCT01499095|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2015-03-24|2014-04-08|2016-09-27|2011-12-21|2011-12-26|Estimate|2015-04-22|2015-04-23|Estimate|2014-04-08|2014-05-02|Estimate|2016-09-27|2016-11-02|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|EDITION II|Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy|6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension Period|Completed||Phase 3|811|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 21:48:21.664094|2018-05-31 21:48:21.664094
NCT01499082|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2015-03-24|2014-02-13|2016-09-27|2011-12-21|2011-12-26|Estimate|2015-04-22|2015-04-23|Estimate|2014-02-13|2014-03-14|Estimate|2016-09-27|2016-11-02|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|EDITION I|Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin|6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both Plus Mealtime Insulin in Patients With Type 2 Diabetes Mellitus With a 6-month Safety Extension Period|Completed||Phase 3|807|Actual|Sanofi||2|||f||||||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 21:48:22.675813|2018-05-31 21:48:22.675813
NCT01499069|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-02-12|2011-12-21|2011-12-26|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients|Urinary NGF, PGE2 and ATP: Potential Biomarkers for Diagnosis and Prediction of Treatment Efficacy in Overactive Bladder Patients|Unknown status|Recruiting|N/A|197|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 21:48:23.976949|2018-05-31 21:48:23.976949
NCT01499056|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|||2011-12-21|2011-12-21|2011-12-26|Estimate|||||||2011-12-21|2011-12-26|Estimate|June 2010||2010-06-30|January 2010|2010-01-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Mesenchymal Stem Cell Transplantation in Osteoarthritis of Hip Joint|Evaluation the Side Effect of Bone Marrow Derived Mesenchymal Stem Cell in Patients With Osteoarthritis of Hip Joint|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 21:48:24.070415|2018-05-31 21:48:24.070415
NCT01499043|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20||2015-03-23|2015-03-23|2011-12-21|2011-12-26|Estimate||||2015-03-23|2015-04-14|Estimate|2015-03-23|2015-04-14|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)|A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC)Counts|Completed||Phase 2|6|Actual|Plexxikon||1|||f||||f||||||||||2018-05-31 21:48:24.141732|2018-05-31 21:48:24.141732
NCT01499017|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-01-27|2011-12-21|2011-12-26|Estimate|||||||2012-01-27|2012-01-31|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Single Dose Study Of PF-06291874 In Healthy Adult Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single Dose Escalating Study To Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of PF-06291874 After Administration Under Fasted And Fed Conditions In Healthy Adult Subjects|Terminated||Phase 1|9|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 21:48:24.238448|2018-05-31 21:48:24.238448
NCT01499004|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2012-01-11|2011-12-21|2011-12-26|Estimate|||||||2012-01-11|2012-01-12|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers|A Phase 1, Randomized, Open Label, Partial Crossover Study To Evaluate The Pharmacokinetics (PK) And Safety Of Three Modified Release (MR) And One Immediate Release (IR) Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers|Completed||Phase 1|30|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 21:48:24.308364|2018-05-31 21:48:24.308364
NCT01498991|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-11-23|2011-12-21|2011-12-26|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|AMES||Spinal Cord Injury Leg Rehabilitation|Rehabilitation of the Lower Extremity With AMES Following Incomplete Spinal Cord Injury (SCI)|Completed||Phase 1/Phase 2|17|Actual|Oregon Health and Science University||1|||f||||t||||||||No||2018-05-31 21:48:24.382523|2018-05-31 21:48:24.382523
NCT01498978|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2018-01-22||2018-05-15|2011-12-21|2011-12-26|Estimate|2018-05-15|2018-05-18|Actual||||2018-05-15|2018-05-18|Actual|February 6, 2012|Actual|2012-02-06|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|February 28, 2017|Actual|2017-02-28||Interventional||10 subjects received combination therapy.|Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase II Study of CTLA Blockade by Ipilimumab Plus Androgen Suppression Therapy in Patients With an Incomplete Response to AST Alone for Metastatic Prostate Cancer|Active, not recruiting||Phase 2|10|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 21:48:24.470489|2018-05-31 21:48:24.470489
NCT01498965|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-01-20|2011-12-21|2011-12-26|Estimate|||||||2015-01-20|2015-01-21|Estimate|August 2008||2008-08-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Observational|BASELINE||The Cork BASELINE Birth Cohort Study|BASELINE: Babies After Scope: Evaluating the Longitudinal Impact Using Neurological and Nutritional Endpoints|Unknown status|Active, not recruiting||2185|Actual|National Children's Research Centre, Ireland|||||f||||t||||||Samples With DNA|"~     MAternal DNA, plasma, serum and urine Umbilical serum, plasma, DNA, RNA At 2 years and 5~     years: serum, and DNA~   "|||2018-05-31 21:48:24.819639|2018-05-31 21:48:24.819639
NCT01498952|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2013-11-26|2011-12-21|2011-12-26|Estimate|||||||2013-11-26|2013-11-27|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MEDI-573-1028||MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.|A Phase 1b/2, Open-label, Randomized Study of MEDI-573 in Combination With Sorafenib Verses Sorafenib Alone in Adult Subjects With Unresectable or Metastatic Hepatocellular Carcinoma|Completed||Phase 1|6|Actual|MedImmune LLC||3|||f||||f||||||||||2018-05-31 21:48:24.892411|2018-05-31 21:48:24.892411
NCT01498939|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2016-10-27|2011-12-21|2011-12-26|Estimate|||||||2016-10-27|2016-10-28|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects|A Single Centre, Randomised, Double-blind, Three-period Cross-over Trial to Investigate the 24-hour Pharmacokinetics After Single Dose of Insulin Detemir in Healthy Chinese Male Subjects|Completed||Phase 1|20|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:48:24.968485|2018-05-31 21:48:24.968485
NCT01498926|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-01-13|2011-12-21|2011-12-26|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2005||2005-11-30|January 2015|2015-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Comparison of Two Insulin Detemir Formulations in Healthy Volunteers|A Randomised, Single Centre, Two-period, Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Two Insulin Detemir Formulations Containing Mannitol and Glycerol as Isotonic Agents Respectively, in Healthy Subjects|Completed||Phase 1|34|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:48:25.02796|2018-05-31 21:48:25.02796
NCT01498913|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-02-17|2011-12-21|2011-12-26|Estimate|||||||2017-02-17|2017-02-20|Actual|August 30, 2001|Actual|2001-08-30|February 2017|2017-02-28|March 25, 2005|Actual|2005-03-25|March 25, 2005|Actual|2005-03-25||Observational|||Observational Study of NovoNorm® in Subjects With Diabetes|NovoNorm Post Marketing Surveillance Study|Completed|||5841|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:48:26.093813|2018-05-31 21:48:26.093813
NCT01498900|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2016-10-26|2011-12-21|2011-12-26|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 2004||2004-08-31|October 2016|2016-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoNorm® in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice|Completed|||30554|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:48:26.168235|2018-05-31 21:48:26.168235
NCT01498887|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2017-05-03|2011-12-22|2011-12-26|Estimate|||||||2017-05-03|2017-05-05|Actual|December 21, 2011|Actual|2011-12-21|May 2017|2017-05-31|December 23, 2015|Actual|2015-12-23|December 23, 2015|Actual|2015-12-23||Interventional|EARLiMS||Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy|A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.|Completed||Phase 4|349|Actual|Novartis||1|||f|||||f|f||||||No||2018-05-31 21:48:26.24793|2018-05-31 21:48:26.24793
NCT01498874|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-03-03|2011-12-21|2011-12-26|Estimate|||||||2014-03-03|2014-03-04|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Gevokizumab in Subjects With Moderate to Severe Acne Vulgaris|Completed||Phase 2|127|Actual|XOMA (US) LLC||3|||f||||f||||||||||2018-05-31 21:48:26.394687|2018-05-31 21:48:26.394687
NCT01490333|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-11-19|2011-12-08|2011-12-12|Estimate|||||||2014-11-19|2014-11-20|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Sunweavers: Supporting Native American Women's Vitamin D Research|Sunweavers: Supporting Native American Women's Vitamin D Research|Completed||Phase 2|99|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 21:50:55.603907|2018-05-31 21:50:55.603907
NCT01498861|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2012-05-17|2011-12-21|2011-12-26|Estimate|||||||2012-05-17|2012-05-21|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol|A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol When Co-administered With Dolutegravir in Healthy Adult Female Subjects|Completed||Phase 1|16|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 21:48:26.578794|2018-05-31 21:48:26.578794
NCT01498848|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2013-06-18|2011-12-21|2011-12-23|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Cooking Oils on Whole Blood and Saliva Fatty Acids in Children in Bogota, Colombia|Effect of Cooking Oils on Whole Blood and Saliva Fatty Acids in Children in Bogota, Colombia|Completed||N/A|60|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:48:26.668882|2018-05-31 21:48:26.668882
NCT01498835|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-08-25|2011-12-22|2011-12-23|Estimate|||||||2017-08-25|2017-08-28|Actual|February 2012||2012-02-29|August 2017|2017-08-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|SunRaSe||Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma|Phase 1 Trial of Concurrent Sunitinib and Radiation Therapy as Preoperative Treatment for Locally Advanced or Recurrent Soft Tissue Sarcoma.|Completed||Phase 1|9|Actual|Heidelberg University||1|||f||||t||||||||||2018-05-31 21:48:26.73935|2018-05-31 21:48:26.73935
NCT01498822|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2015-06-25||2015-07-24|2011-12-21|2011-12-23|Estimate|2015-07-24|2015-08-20|Estimate||||2015-07-24|2015-08-20|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|OPTIMAL|Baseline Characteristics refer to the Randomized Set, consisting of all subjects who were randomized in this study.|Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy|A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy|Completed||Phase 4|353|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:48:26.854614|2018-05-31 21:48:26.854614
NCT01498809|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-03-14|2011-12-22|2011-12-23|Estimate|||||||2014-03-14|2014-03-17|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Blood Pressure and Brain Blood Flow Regulation After Midodrine Administration in Those With Spinal Cord Injury|Neural and Mechanical Baroreflex Sensitivity and Cerebral Blood Flow|Completed|||22|Actual|University of British Columbia|||||f||||t||||||||||2018-05-31 21:48:27.301012|2018-05-31 21:48:27.301012
NCT01498796|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-22|2011-12-22|2011-12-23|Estimate|||||||2011-12-22|2011-12-23|Estimate||||December 2011|2011-12-31||||||||Interventional|KITS||KITS Study -Ketorolac In Tonsillectomy Surgery: a Double Blinded, Randomized Clinical Trial|KITS Study -Ketorolac In Tonsillectomy Surgery: a Double Blinded, Randomized Clinical Trial|Unknown status|Recruiting|N/A|||University of Alberta||2|||f||||f||||||||||2018-05-31 21:48:27.361096|2018-05-31 21:48:27.361096
NCT01498783|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2016-02-01|2011-12-22|2011-12-23|Estimate|||||||2016-02-01|2016-02-02|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SJREFU||Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma|Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma|Completed||Phase 1|26|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-05-31 21:48:27.440082|2018-05-31 21:48:27.440082
NCT01498770|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-02-28|2011-12-21|2011-12-23|Estimate|||||||2018-02-28|2018-03-01|Actual|April 1, 2013|Actual|2013-04-01|February 2018|2018-02-28|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Observational|||An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)|An Observational Drug Utilization Study of SYCREST^® (Asenapine) in the United Kingdom|Completed|||42|Actual|Merck Sharp & Dohme Corp.|||13||f||||f||||||||||2018-05-31 21:48:27.549048|2018-05-31 21:48:27.549048
NCT01498757|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-12-28|2011-12-21|2011-12-23|Estimate|||||||2015-12-28|2015-12-29|Estimate|January 2012||2012-01-31|December 2015|2015-12-31||||June 2012|Actual|2012-06-30||Observational|||Genome-wide Association Study|Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma|Withdrawn|||0|Actual|Samsung Medical Center|||1|Registration poor|f||||f||||||||||2018-05-31 21:48:27.672768|2018-05-31 21:48:27.672768
NCT01498744|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2015-11-11||2016-01-27|2011-12-21|2011-12-23|Estimate|2016-01-27|2016-02-25|Estimate||||2016-01-27|2016-02-25|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess|Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Skin and Soft Tissue Abscess Undergoing Incision and Drainage|Terminated||N/A|53|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|Inadequate enrollment numbers leading to early termination of study.|2||The study was closed due to poor enrollment and lack of interest.|f||||f||||||||No||2018-05-31 21:48:27.831333|2018-05-31 21:48:27.831333
NCT01498731|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2013-06-04|2011-12-21|2011-12-23|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|BiC-8||Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS)|The Effect of Integrating the Biomarker Copeptin Into the Process of Managing Patients With Suspected ACS|Completed||N/A|902|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:48:28.163077|2018-05-31 21:48:28.163077
NCT01498718|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2016-03-23|2011-12-21|2011-12-23|Estimate|||||||2016-03-23|2016-03-24|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone|Double-Blind, Randomized Phase 1b Study of 2011/12 Influenza Investigational DNA Vaccine, VRC-FLUDNA061-00-VP, Followed by 2012/13 Trivalent Inactivated Vaccine (TIV) Compared to 2012/13 TIV Alone in Healthy Adults|Completed||Phase 1|131|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 21:48:28.3179|2018-05-31 21:48:28.3179
NCT01498705|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-01-31|2011-12-21|2011-12-23|Estimate|||||||2014-01-31|2014-02-04|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Observational|||The Natural History of Procalcitonin in Hemorrhagic Stroke|The Natural History of Procalcitonin in Hemorrhagic Stroke|Withdrawn|||0|Actual|CAMC Health System|||1|Anticipated grant was withdrawn and additional funding was unable to be obtained|f||||f||||||Samples Without DNA|"~     3 mL of blood will be obtained for each PCT sample and will be sent to the Virology lab at~     CAMC Memorial hospital where the serum will be frozen until all samples are collected. After~     all samples from each of the 30 patients are obtained, the specimens will be analyzed for the~     PCT value and then discarded.~   "|||2018-05-31 21:48:28.440186|2018-05-31 21:48:28.440186
NCT01498692|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2012-01-10||2017-02-02|2011-12-21|2011-12-23|Estimate|2012-01-10|2012-02-13|Estimate||||2017-02-02|2017-03-13|Actual|February 2009||2009-02-28|February 2017|2017-02-28|May 2015|Actual|2015-05-31|December 2010|Actual|2010-12-31||Interventional|PLATINUM SV||The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Small Vessel Sub-trial|Completed||N/A|94|Actual|Boston Scientific Corporation||1|||f||||t||||||||No|Primary endpoints uploaded|2018-05-31 21:48:28.608194|2018-05-31 21:48:28.608194
NCT01498679|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2014-02-13||2017-01-25|2011-12-21|2011-12-23|Estimate|2014-02-13|2014-04-01|Estimate||||2017-01-25|2017-03-08|Actual|January 2012||2012-01-31|January 2017|2017-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily for 12 Weeks in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With Low to Mid-strength Inhaled Corticosteroid or Low-strength Combination Therapy.|Completed||Phase 3|311|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:48:29.280548|2018-05-31 21:48:29.280548
NCT01498666|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-12-02|2011-12-21|2011-12-23|Estimate|||||||2013-12-02|2013-12-03|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|LactoFAP||Efficacy of Lactobacillus Reuteri Protectis on Functional Abdominal Pain (FAP) in Children 8-14 Years Old|Efficacy of Lactobacillus Reuteri Protectis on Functional Abdominal Pain (FAP) in Children 8-14 Years Old|Terminated||Phase 4|9|Actual|BioGaia AB||2||The recruitment rate was too slow according to study protocol and agreement.|f||||f||||||||||2018-05-31 21:48:29.687833|2018-05-31 21:48:29.687833
NCT01498653|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2013-09-19||2016-11-18|2011-12-21|2011-12-23|Estimate|2013-10-31|2013-12-20|Estimate||||2016-11-18|2017-01-09|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry|A Randomised, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily Compared to Fluticasone Propionate Delivered Twice Daily in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With High-strength Inhaled Corticosteroids or Mid-strength ICS/LABA Combination Therapy.|Completed||Phase 3|313|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:48:29.778178|2018-05-31 21:48:29.778178
NCT01498640|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|2015-02-04||2017-09-07|2011-12-21|2011-12-23|Estimate|2015-02-04|2015-02-20|Estimate||||2017-09-07|2017-10-05|Actual|March 2012||2012-03-31|September 2017|2017-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Retreatment of Recurrent Dupuytren's Contractures|Retreatment of Recurrent Contractures in Joints Effectively Treated With AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX®/XIAPEX®]) in an Auxilium-sponsored Phase 3 Study in the United States, Australia, and Europe|Completed||Phase 4|52|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:48:30.228173|2018-05-31 21:48:30.228173
NCT01498627|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-04-02|2011-12-21|2011-12-23|Estimate|||||||2015-04-02|2015-04-06|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PGRx||Cervarix Long-term Safety Surveillance|Cervarix Long-term Safety Surveillance Using the PGRx Information System (PGRx Study)|Completed|||2945|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 21:48:30.619911|2018-05-31 21:48:30.619911
NCT01498614|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-22|2011-12-22|2011-12-23|Estimate|||||||2011-12-22|2011-12-23|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Psychological Impact in Diabetes: Intervention With Affect School and Basal Body Awareness|Psychological Impact, Metabolic Control, and Biological Stress Markers in Diabetes: Intervention Study With Affect School and Basal Body Awareness|Unknown status|Active, not recruiting|N/A|321|Actual|Lund University||2|||f||||f||||||||||2018-05-31 21:48:30.69503|2018-05-31 21:48:30.69503
NCT01498601|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2015-03-30||2015-08-19|2011-12-22|2011-12-23|Estimate|2015-08-19|2015-09-22|Estimate||||2015-08-19|2015-09-22|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Improving Oral Care to Reduce Hospital-Acquired Pneumonia (HAP) in the Acute Neurologically Impaired Adult|Improving Oral Care to Reduce Hospital Acquired Pneumonia (HAP) in the Acute, Non-Intubated, Care Dependent, Neurologically Impaired Adult Patient Population|Completed||N/A|32|Actual|Fraser Health|This study was supported by the Fraser Health Point of Care Research Challenge.|2|||f||||f||||||||||2018-05-31 21:48:30.775484|2018-05-31 21:48:30.775484
NCT01498588|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2016-06-21||2016-09-28|2011-12-21|2011-12-23|Estimate|2016-09-28|2016-10-03|Estimate||||2016-09-28|2016-10-03|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer|Phase II Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer|Terminated||Phase 2|7|Actual|Emory University|Study accrual was low at 7 patients.|1||Slow accrual|f||||t||||||||||2018-05-31 21:48:30.979789|2018-05-31 21:48:30.979789
NCT01498575|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2015-01-22||2015-03-03|2011-12-21|2011-12-23|Estimate|2015-03-03|2015-03-17|Estimate||||2015-03-03|2015-03-17|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||An Evaluation of a Web-based Intervention Program for Parents and Teens to Promote Safe Driving|An Evaluation of a Web-based Intervention Program for Parents and Teens to Promote Safe Driving|Completed||N/A|1024|Actual|Children's Hospital of Philadelphia|Moderate attrition (although no evidence of selective attrition); limited generalizability of results; and eight teenagers were not administered the highway module and were censored from analysis.|2|||f||||f||||||||||2018-05-31 21:48:31.203656|2018-05-31 21:48:31.203656
NCT01498562|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-11-26|2011-12-22|2011-12-23|Estimate|||||||2014-11-26|2014-12-02|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DATE||Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer|Randomized Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Patients With Advanced Non-small Cell Lung Cancer: Dual-agent Molecular Targeting of EGFR (DATE)|Completed||Phase 2|160|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:48:31.489037|2018-05-31 21:48:31.489037
NCT01498549|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2017-02-08||2017-06-08|2011-12-22|2011-12-23|Estimate|2017-05-04|2017-06-08|Actual||||2017-06-08|2017-07-11|Actual|December 2011||2011-12-31|June 2017|2017-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||The total number of people enrolled in the study before randomization to crossover assignment.|Cognitive Effects of Atomoxetine in Humans: Genetic Moderators|Cognitive Effects of Atomoxetine in Humans: Genetic Moderators|Completed||N/A|35|Actual|Yale University||2|||f||||t||||||||No||2018-05-31 21:48:31.579622|2018-05-31 21:48:31.579622
NCT01498536|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-10-29|2011-12-22|2011-12-23|Estimate|||||||2013-10-29|2013-10-30|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|F4F tri neg||Effect of Diet and Exercise in Breast Cancer Survivors|Fit for the Fight: Effect of a Multidisciplinary Diet and Exercise Program on Body Weight, Quality of Life and Inflammation in Survivors of Triple-negative Breast Cancer|Completed||N/A|28|Actual|West Virginia University|||||f||||f||||||||||2018-05-31 21:48:31.778819|2018-05-31 21:48:31.778819
NCT01498523|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-02-03|2011-12-20|2011-12-23|Estimate|||||||2012-02-03|2012-02-06|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|GLUCAM||The Glycaemic and Insulinaemic Responses of Camel Milk|An Explorative Study to Characterize the Glycaemic and Insulinaemic Responses of Regular Camel Milk and Camel Milk Powder|Completed||N/A|20|Actual|Wageningen University||4|||f||||f||||||||||2018-05-31 21:48:31.824406|2018-05-31 21:48:31.824406
NCT01498510|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-05-23|2011-12-22|2011-12-23|Estimate|||||||2017-05-23|2017-05-25|Actual|February 2012||2012-02-29|May 2017|2017-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|WebCBTPain||Web-based Cognitive-behavior Therapy (CBT) for Opioid-treated, Chronic Pain Patients With Aberrant Behavior|Web-based CBT for Opioid-treated, Chronic Pain Patients With Aberrant Behavior|Completed||N/A|110|Actual|National Development and Research Institutes, Inc.||2|||f||||f||||||||Undecided||2018-05-31 21:48:31.894228|2018-05-31 21:48:31.894228
NCT01498497|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-02-08|2011-12-21|2011-12-23|Estimate|||||||2017-02-08|2017-02-09|Estimate|January 2012||2012-01-31|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021|Six Month Safety Follow-up Study for PR-021 [Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Eosinophilic Esophagitis Subjects]|Completed|||14|Actual|Forest Laboratories|||1||f||||f||||||||||2018-05-31 21:48:32.051445|2018-05-31 21:48:32.051445
NCT01498484|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-02-26|2011-12-22|2011-12-23|Estimate|||||||2018-02-26|2018-02-28|Actual|December 2011|Actual|2011-12-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies|A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies|Active, not recruiting||Phase 2|112|Anticipated|Atara Biotherapeutics||1|||t||||||||||||||2018-05-31 21:48:32.131143|2018-05-31 21:48:32.131143
NCT01498471|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2011-12-22|2011-12-22|2011-12-23|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|February 2014|Anticipated|2014-02-28|February 2013|Anticipated|2013-02-28||Observational|||NICE Guideline 'Red Flags' to Predict Serious Outcome After Transient Loss of Consciousness|NICE Guideline 'Red Flags' to Predict Serious Outcome After Transient Loss of Consciousness: Prospective Validation Study in the Emergency Department.|Unknown status|Not yet recruiting||490|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-05-31 21:48:32.211152|2018-05-31 21:48:32.211152
NCT01498458|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2014-07-04||2014-09-17|2011-12-22|2011-12-23|Estimate|2014-09-17|2014-09-18|Estimate||||2014-09-17|2014-09-18|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|December 2011|Actual|2011-12-31||Interventional|PazoX||Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer|Phase I Study to Assess the Optimal Dose for Pazopanib in Combination With Capecitabine in Patients With HER2-negative, Metastatic Breast Cancer (PazoX)|Completed||Phase 1|9|Actual|German Breast Group||1|||f||||t||||||||||2018-05-31 21:48:32.283906|2018-05-31 21:48:32.283906
NCT01498445|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-01-23|2011-12-21|2011-12-23|Estimate|||||||2018-01-23|2018-01-25|Actual|June 12, 2012|Actual|2012-06-12|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)|An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)|Active, not recruiting||Phase 1/Phase 2|33|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:48:32.599805|2018-05-31 21:48:32.599805
NCT01498432|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2011-12-22|2011-12-22|2011-12-23|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Interventional|||Physiological Response to Heliox21 and Air O2|Phase 4, Single Centre, Single Blinded,Prospective Randomised Cross Over Comparison on the Physiological Response of Post Extubation Intensive Care Patients to Non-invasive Ventilation Using Either Air O2 or Heliox21|Unknown status|Not yet recruiting|Phase 4|38|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 21:48:32.721539|2018-05-31 21:48:32.721539
NCT01498419|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2016-07-12||2017-03-15|2011-12-22|2011-12-23|Estimate|2016-10-19|2016-12-12|Estimate||||2017-03-15|2017-04-12|Actual|March 2012||2012-03-31|January 2017|2017-01-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional||The ages of four participants in the Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg) group and one participant in the Drug Sensitive: Rifafour group were missing and so were not included in the demographics.|Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)|A Phase II Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 8 Weeks of Treatment in Adult Patients With Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear-Positive Pulmonary Tuberculosis|Completed||Phase 2|207|Actual|Global Alliance for TB Drug Development||4|||f||||t||||||||||2018-05-31 21:48:32.824804|2018-05-31 21:48:32.824804
NCT01498406|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2013-11-18|2011-12-22|2011-12-23|Estimate|||||||2013-11-18|2013-11-20|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus|Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus|Terminated||Phase 2|3|Actual|Emory University||2||secondary to funding issues and low enrollment|f||||t||||||||||2018-05-31 21:48:33.545777|2018-05-31 21:48:33.545777
NCT01498393|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-02-08|2011-12-22|2011-12-23|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2011||2011-12-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis|A Randomized, Placebo-Controlled Study of the 1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis|Completed||Phase 1|10|Actual|University of California, Irvine||1|||f||||t||||||||||2018-05-31 21:48:33.616629|2018-05-31 21:48:33.616629
NCT01498380|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-06-30|2011-12-22|2011-12-23|Estimate|||||||2017-06-30|2017-07-05|Actual|January 2012||2012-01-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|DexMED||The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children|The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children|Completed||N/A|21|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 21:48:33.686945|2018-05-31 21:48:33.686945
NCT01498367|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-02-16|2011-12-22|2011-12-23|Estimate|||||||2015-02-16|2015-02-18|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|RHCluster2GR||Life-long Tele-monitoring of Patients With Type 2 Diabetes Mellitus in Central Greece|Renewing Health RCT for the Evaluation of Life-long Tele-monitoring of Patients With Diabetes Mellitus Type 2 in Central Greece|Completed||N/A|154|Actual|Regional Health Authority of Sterea & Thessaly||2|||f||||t||||||||||2018-05-31 21:48:33.75413|2018-05-31 21:48:33.75413
NCT01498354|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2015-09-09|2011-12-21|2011-12-23|Estimate|||||||2015-09-09|2015-09-10|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|February 2012|Actual|2012-02-29|October 2010|Actual|2010-10-31||Interventional|||Efficiency of Two Dimensional High Definition Versus Three Dimensional Endoscopic Systems in Transanal Endoscopic Surgery|Comparing the Efficiency of Two Dimensional High Definition (TEO) Versus Three Dimensional (TEM) Endoscopic Systems in Transanal Endoscopic Surgery; a Prospective Control Trial|Completed||Phase 3|36|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 21:48:33.830985|2018-05-31 21:48:33.830985
NCT01498341|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-06-30|2011-12-22|2011-12-23|Estimate|||||||2014-06-30|2014-07-01|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|HypoPT||Hypoparathyroidism in Denmark|Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism in Denmark - Epidemiology, Causes, Symptoms and Prognoses|Completed|||1000|Actual|University of Aarhus|||||f||||f||||||None Retained|"~     2 designs: Case-finding; Case-control~   "|||2018-05-31 21:48:33.898505|2018-05-31 21:48:33.898505
NCT01498328|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21||2017-04-06|2017-04-06|2011-12-22|2011-12-23|Estimate||||2017-04-06|2017-04-07|Actual|2017-04-06|2017-04-07|Actual|December 2011||2011-12-31|April 2017|2017-04-30|May 17, 2016|Actual|2016-05-17|April 2015|Actual|2015-04-30||Interventional|ReACT||A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma|A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma|Completed||Phase 2|127|Actual|Celldex Therapeutics||3|||t||||f||||||||||2018-05-31 21:48:33.962236|2018-05-31 21:48:33.962236
NCT01498315|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-05-15|2011-12-22|2011-12-23|Estimate|||||||2014-05-15|2014-05-16|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Observational|Hematoma||The Incidence of Pelvic Hematoma Following Hysterectomy|The Incidence of Pelvic Hematoma Following Hysterectomy|Completed|||39|Actual|Carmel Medical Center|||1||f||||f||||||||||2018-05-31 21:48:34.081761|2018-05-31 21:48:34.081761
NCT01498302|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2016-07-07|2011-12-22|2011-12-23|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2012||2012-02-29|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia|Interlaboratory Comparability Study of Residual Disease in Acute Myelogenous Leukemia|Completed|||10|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Bone marrow and/or peripheral blood~   "|||2018-05-31 21:48:34.138004|2018-05-31 21:48:34.138004
NCT01498289|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2018-04-09|2011-12-22|2011-12-23|Estimate|||||||2018-04-09|2018-04-10|Actual|February 2012||2012-02-29|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2018|Actual|2018-03-31||Interventional|||S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer|A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer|Active, not recruiting||Phase 2|213|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 21:48:34.26373|2018-05-31 21:48:34.26373
NCT01498276|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-05-26|2011-12-21|2011-12-23|Estimate|||||||2018-05-26|2018-05-30|Actual|December 6, 2011||2011-12-06|May 22, 2018|2018-05-22||||||||Observational|||Family Genetics Health Education and Healthy Behaviors|The Role of the Family Genetics Health Educator in Influencing Health Promoting Behaviors|Recruiting|||335|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:48:35.245046|2018-05-31 21:48:35.245046
NCT01498263|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-05-26|2011-12-21|2011-12-23|Estimate|||||||2018-05-26|2018-05-30|Actual|December 6, 2011||2011-12-06|May 22, 2018|2018-05-22||||||||Observational|||Inherited Diseases, Caregiving, and Social Networks|Inherited Diseases, Caregiving, and Social Networks|Recruiting|||3100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:48:35.309676|2018-05-31 21:48:35.309676
NCT01498250|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-10-15|2011-12-22|2011-12-23|Estimate|||||||2012-10-15|2012-10-16|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Microarray Analysis of microRNA Expression in Basal Cell Carcinoma|Microarray Analysis of microRNA Expression in Basal Cell Carcinoma|Completed|||7|Actual|Ruhr University of Bochum|||2||f||||t||||||Samples With DNA|"~     basal cell carcinoma and non-lesional skin~   "|||2018-05-31 21:48:35.37427|2018-05-31 21:48:35.37427
NCT01498237|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-07-09|2011-12-22|2011-12-23|Estimate|||||||2013-07-09|2013-07-11|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Photoacoustic Endoscopy in Endometrial Cancer|A Pilot Study of Photoacoustic Endoscopy in Endometrial Cancer|Withdrawn||Early Phase 1|0|Actual|Washington University School of Medicine||1||Need to obtain IDE prior to commencement of study|f||||t||||||||||2018-05-31 21:48:35.502704|2018-05-31 21:48:35.502704
NCT01498224|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2016-12-08|2011-12-22|2011-12-23|Estimate|||||||2016-12-08|2016-12-12|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||ReSure Sealant Pivotal Study|ReSure Sealant Pivotal Study|Completed||Phase 3|488|Actual|Ocular Therapeutix, Inc.||2|||f||||f||||||||No|Data is available on FDA website for approved PMA P130004|2018-05-31 21:48:35.596291|2018-05-31 21:48:35.596291
NCT01498211|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2012-07-04|2011-12-20|2011-12-23|Estimate|||||||2012-07-04|2012-07-06|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Normative Data of Intra-epidermal Nerve Fiber Density|Establishement of Normative Intra-epidermal Nerve Fiber Density Using Skin|Unknown status|Active, not recruiting|N/A|300|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 21:48:35.678388|2018-05-31 21:48:35.678388
NCT01498198|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2011-12-22|2011-12-22|2011-12-23|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2012||2012-01-31|December 2011|2011-12-31||||January 2014|Anticipated|2014-01-31||Interventional|||Workers Compensation Board: Rotator Cuff Tear Management|A Randomized Study of Non-Operative Management Versus Expedited Surgery Among WCB Patients With Small Rotator Cuff Tears: Affect Upon Time to Claim Closure in 2 Prairie Provinces|Unknown status|Not yet recruiting|N/A|144|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:48:35.770983|2018-05-31 21:48:35.770983
NCT01498185|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|2016-10-07||2016-12-20|2011-12-21|2011-12-23|Estimate|2016-12-20|2017-02-10|Actual||||2016-12-20|2017-02-10|Actual|February 2012||2012-02-29|December 2016|2016-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||All randomized participants who received at least 1 dose of study medication|BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes|A Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Explore the Safety, Pharmacokinetics and Pharmacodynamics of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 2|171|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 21:48:35.88892|2018-05-31 21:48:35.88892
NCT01498172|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2015-02-03|2011-12-22|2011-12-23|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2012||2012-01-31|February 2015|2015-02-28||||February 2015|Actual|2015-02-28||Interventional|||BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients|BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Patients With Non Muscle Invasive Bladder Cancer|Completed||Phase 1|23|Actual|University of Lausanne Hospitals||3|||f||||t||||||||||2018-05-31 21:48:36.600319|2018-05-31 21:48:36.600319
NCT01498159|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-04-30|2011-12-20|2011-12-23|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2011||2011-12-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|April 2016|Actual|2016-04-30||Interventional|||Health Promoters and Pharmacists in Diabetes Team Management|Health Promoters and Pharmacists in Diabetes Team Management|Completed||N/A|244|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 21:48:36.67454|2018-05-31 21:48:36.67454
NCT01498146|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2014-07-15|2011-12-22|2011-12-23|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2013|Actual|2013-10-31||Observational|SURPRISE||Finding Atrial Fibrillation in Patients With Unexplained Stroke Using Longterm Cardiac Monitoring|Stroke Prior to Diagnosis of Atrial Fibrillation Using Longterm Observation With Implantable Cardiac Monitoring Apparatus Reveal(SURPRISE) -the SURPRISE Study|Unknown status|Active, not recruiting||100|Anticipated|Bispebjerg Hospital|||||f||||f||||||||||2018-05-31 21:48:36.747832|2018-05-31 21:48:36.747832
NCT01498133|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-12-20|2011-12-20|2011-12-23|Estimate|||||||2011-12-20|2011-12-23|Estimate|May 2008||2008-05-31|December 2011|2011-12-31||||November 2010|Actual|2010-11-30||Interventional|||Skin-to-skin Contact to Promote Bacterial Decolonization in Preterm Infants|Does Skin-to-skin Contact Promote Bacterial Decolonization in Preterm Infants in Neonatal Intensive Care Unit? A Randomized, Single-blinded Controlled Trial|Unknown status|Active, not recruiting|Phase 2|102|Actual|Universidade Federal do Maranhão||2|||f||||t||||||||||2018-05-31 21:48:36.802289|2018-05-31 21:48:36.802289
NCT01498120|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2016-08-01||2017-07-06|2011-12-20|2011-12-23|Estimate|2016-08-01|2016-09-21|Estimate||||2017-07-06|2017-08-01|Actual|December 2011||2011-12-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All enrolled subjects who received at least 1 dose of study medication were included in the SS.|Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome|An Open-Label, Long-Term, Follow-Up Study To Determine The Safety, Tolerability, and Efficacy of Rotigotine Transdermal System As Monotherapy in Adolescents With Restless Legs Syndrome|Completed||Phase 2|14|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 21:48:37.019953|2018-05-31 21:48:37.019953
NCT01498107|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2014-01-07|2011-12-20|2011-12-23|Estimate|||||||2014-01-07|2014-01-08|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Technology-enhanced Therapy: the SilverCloud Study|A Pilot Study Evaluating Engagement With a Platform Supporting Online Interventions for Common Mental Health Problems|Completed||N/A|30|Anticipated|University of Cambridge|||||f||||f||||||||||2018-05-31 21:48:37.28347|2018-05-31 21:48:37.28347
NCT01498094|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2015-05-08|2011-12-22|2011-12-23|Estimate|||||||2015-05-08|2015-05-12|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|Hi-Flo||Study of High-flow Oxygen Therapy Against Standard Therapy in Bronchiolitis|A Prospective Open Randomized Clinical Trial Comparing High Flow Nasal Cannula Oxygen Therapy Against Standard Therapy for Children Hospitalized With Bronchiolitis|Completed||N/A|79|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 21:48:37.347344|2018-05-31 21:48:37.347344
NCT01498081|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2012-10-25|2011-12-21|2011-12-23|Estimate|||||||2012-10-25|2012-10-26|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients|A Randomised, Double-blind, Placebo and Active Controlled, Multi-centre, 6 Way Cross-over, Single-dose Phase IIa Study to Investigate the Local and Systemic Effects of 3 Different Doses of Inhaled AZD2115 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|39|Actual|AstraZeneca||6|||f||||||||||||||2018-05-31 21:48:37.446247|2018-05-31 21:48:37.446247
NCT01498068|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2013-09-11||2015-01-29|2011-12-20|2011-12-23|Estimate|2013-11-08|2013-12-30|Estimate||||2015-01-29|2015-01-30|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|April 2012|Actual|2012-04-30||Interventional|||Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C|Open-Label, Bridging Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Treatment- Naïve and Treatment-Experienced Russian Subjects With Genotype 1 Chronic Hepatitis C|Completed||Phase 3|36|Actual|Janssen-Cilag International NV||2|||f||||f||||||||||2018-05-31 21:48:37.55465|2018-05-31 21:48:37.55465
NCT01498055|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2012-03-21|2011-12-22|2011-12-23|Estimate|||||||2012-03-21|2012-03-22|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|CIK||Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study|A Randomized Controlled Trail on the Efficacy and Safety of Autologous Cytokine-induced Killer (CIK) Cells Infusion Treatment in Advanced Primary Lung Cancer|Unknown status|Recruiting||120|Anticipated|Third Military Medical University|||2||f||||f||||||Samples With DNA|"~     The one-time folic acid sodium anticoagulation vacuum picks bag, through the venous blood~     sampling 60 ml. When blood alcohol on parts of the need blood disinfects processing. After~     the department shows will seal in a sterile bag, 16-21 degrees Celsius save, and transported~     to a cell biological treatment as soon as possible a follow-up operation center GMP~     laboratory.~   "|||2018-05-31 21:48:37.97608|2018-05-31 21:48:37.97608
NCT01498042|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-12-20|2011-12-20|2011-12-23|Estimate|||||||2011-12-20|2011-12-23|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Predictors of Outcome in t-PA Treated Stroke.|Ischemic Stroke Treated With iv Thrombolysis Within 4.5 Hours: Predictors of Outcome in a Cohort With a Large Proportion of Patients Above 80 Years|Completed|||162|Actual|Sorlandet Hospital HF|||1||f||||f||||||||||2018-05-31 21:48:38.060988|2018-05-31 21:48:38.060988
NCT01498029|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-03-20|2011-12-22|2011-12-23|Estimate|||||||2012-03-20|2012-03-21|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|CAIS||Knee Articular Cartilage Repair: Cartilage Autograft Implantation System Versus Conventional Microfracture|A Randomised Clinical Trial Comparing a Novel Single-stage Autologous Cartilage Implantation System to Conventional Microfracture for Repair of Articular Cartilage Defects in the Knee|Unknown status|Recruiting|Phase 3|36|Anticipated|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 21:48:38.136805|2018-05-31 21:48:38.136805
NCT01498016|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-05-09|2011-12-20|2011-12-23|Estimate|||||||2016-05-09|2016-05-10|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia|Pharmacokinetic Study of Intravenous Busulfan as Conditioning Regimen for Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia|Unknown status|Recruiting|Phase 2|60|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 21:48:38.241084|2018-05-31 21:48:38.241084
NCT01498003|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2015-07-13|2011-12-20|2011-12-23|Estimate|||||||2015-07-13|2015-07-14|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PETITION||Tirofiban in Stenting for Long Coronary Lesion|Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent|Completed||Phase 4|748|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 21:48:38.322276|2018-05-31 21:48:38.322276
NCT01497990|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-11-02|2011-12-22|2011-12-23|Estimate|||||||2012-11-02|2012-11-05|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pharmacokinetics Ertapenem Burns|Pharmacokinetics of Ertapenem When Used in Empiric Treatment in Burn Patients. Prospective Open Label Study.|Completed||Phase 4|8|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 21:48:38.400272|2018-05-31 21:48:38.400272
NCT01497977|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-27|2011-12-22|2011-12-23|Estimate|||||||2011-12-27|2011-12-29|Estimate|September 2008||2008-09-30|December 2011|2011-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phytoestrogen Supplementation in Postmenopausal Women|Impact of Phytoestrogens on Serum Lipids in Postmenopausal Women|Completed||Phase 4|74|Actual|American Medical Academy, Serbia||3|||f||||t||||||||||2018-05-31 21:48:38.470411|2018-05-31 21:48:38.470411
NCT01497964|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-11-07|2011-12-22|2011-12-23|Estimate|||||||2014-11-07|2014-11-10|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|GASTANA||Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy|A Phase 2, Multicenter Study of Cabazitaxel Single Agent Administered as a 1-Hour Intravenous Infusion Every 3 Weeks to Evaluate the Safety, Tolerability and Anti-tumor Activity of Cabazitaxel in Patients With Advanced Gastric Adenocarcinoma Who Have Failed Prior Chemotherapy Regimens|Completed||Phase 1/Phase 2|16|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:48:38.541997|2018-05-31 21:48:38.541997
NCT01497951|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2017-05-16|2011-12-22|2011-12-23|Estimate|||||||2017-05-16|2017-05-17|Actual|May 2011||2011-05-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|PDT||Photodynamic Therapy for Oral Precursor Lesions|A Randomized Controlled Trial: Photodynamic Treatment for the Therapy of Premalignant Mucosal Oral Lesions.|Completed||Phase 3|28|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:48:38.609483|2018-05-31 21:48:38.609483
NCT01497938|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|2013-10-24||2014-01-31|2011-12-22|2011-12-23|Estimate|2014-01-31|2014-03-17|Estimate||||2014-01-31|2014-03-17|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ASPIRE||Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature|ASPIRE (Automation to Simulate Pancreatic Insulin Response): Pivotal In Home Study to Determine Safety and Efficacy of the LGS Feature in Sensor-augmented Pumps|Completed||Phase 3|247|Actual|Medtronic Diabetes||2|||f||||t||||||||||2018-05-31 21:48:38.699542|2018-05-31 21:48:38.699542
NCT01497925|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-05-18|2011-12-20|2011-12-23|Estimate|||||||2018-05-18|2018-05-21|Actual|September 6, 2011|Actual|2011-09-06|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|March 23, 2016|Actual|2016-03-23||Interventional|||Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer|Phase 1 Trial of ADI PEG 20 Plus Docetaxel in Advanced Solid Tumors With Emphasis on Castration Resistant Prostate Cancer (CRPC) and Advanced Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|39|Anticipated|Polaris Group||1|||f||||f||||||||||2018-05-31 21:48:39.016734|2018-05-31 21:48:39.016734
NCT01497912|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2011-12-22|2011-12-22|2011-12-23|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|||Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes||Completed||Phase 4|20|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 21:48:39.08925|2018-05-31 21:48:39.08925
NCT01497899|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2015-12-04|2013-10-21|2017-08-22|2011-12-22|2011-12-23|Estimate|2015-12-04|2016-01-08|Estimate|2013-10-21|2013-11-11|Estimate|2017-08-22|2017-09-20|Actual|December 28, 2011|Actual|2011-12-28|August 2017|2017-08-31|August 22, 2016|Actual|2016-08-22|October 17, 2012|Actual|2012-10-17||Interventional||"E/C/F/TAF and E/C/F/TDF arms: participants who were randomized to the Double-Blind Phase and received at least 1 dose of study drug.~D/C/F/TAF to E/C/F/TAF and DRV+COBI+TVD to E/C/F/TAF arms: participants who enrolled from Gilead-sponsored Study GS-US-299-0102 in the Open-Label Extension Phase and received at least 1 dose of open-label E/C/F/TAF"|Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Completed||Phase 2|279|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|3|||f||||t|t|f||||||||2018-05-31 21:48:39.182536|2018-05-31 21:48:39.182536
NCT01497886|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2018-01-25|2011-12-22|2011-12-23|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2011|Actual|2011-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Intervention to Improve Stroke Recognition|Randomized Controlled Trial Effect of Novel Intervention to Improve Stroke Symptom Recognition|Active, not recruiting||N/A|4614|Actual|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 21:48:40.011832|2018-05-31 21:48:40.011832
NCT01497873|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2015-09-15|2011-12-22|2011-12-23|Estimate|||||||2015-09-15|2015-09-16|Estimate|September 2010||2010-09-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients|A Phase IIb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Relapsed Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|176|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-05-31 21:48:40.095806|2018-05-31 21:48:40.095806
NCT01497860|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-07-10|2011-12-22|2011-12-23|Estimate|||||||2017-07-10|2017-07-12|Actual|July 2011||2011-07-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31||Interventional|||Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas|Phase 2 Study of Weekly Vinorelbine in Children With Progressive or Recurrent Low-Grade Gliomas|Completed||Phase 2|13|Actual|Children's Research Institute||1|||f||||t||||||||||2018-05-31 21:48:40.277059|2018-05-31 21:48:40.277059
NCT01497847|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2013-04-25|2011-12-22|2011-12-23|Estimate|||||||2013-04-25|2013-04-26|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|PI-IBS||Post-Infectious Irritable Bowel Syndrome (PI-IBS)|Post-Infectious Irritable Bowel Syndrome (PI-IBS)|Completed|||131|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||Samples With DNA|"~     whole blood, blood plasma, feces, rectal biopsy~   "|||2018-05-31 21:48:40.352474|2018-05-31 21:48:40.352474
NCT01497834|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02||2015-09-23|2015-09-23|2011-12-20|2011-12-23|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients|A Phase 3 Japanese Study of BMS-790052 Plus BMS-650032 Combination Therapy in Chronic Hepatitis C Genotype 1b Infected Subjects Who Are Non Response to Interferon Plus Ribavirin and Interferon Based Therapy Ineligible Naive/Intolerant|Completed||Phase 3|224|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 21:48:40.415095|2018-05-31 21:48:40.415095
NCT01497821|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-03-23|2011-12-20|2011-12-23|Estimate|||||||2016-03-23|2016-03-25|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||AMG 172 First in Human Study in Patients With Kidney Cancer|A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects With Relapsed / Refractory Renal Cell Carcinoma|Completed||Phase 1|37|Actual|Amgen||2|||f||||||||||||||2018-05-31 21:48:40.547533|2018-05-31 21:48:40.547533
NCT01497808|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2016-09-12|2011-12-22|2011-12-23|Estimate|||||||2016-09-12|2016-09-14|Estimate|December 2011||2011-12-31|August 2016|2016-08-31||||October 2015|Actual|2015-10-31||Interventional|||RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA|RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA|Active, not recruiting||Phase 1/Phase 2|23|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:48:40.652505|2018-05-31 21:48:40.652505
NCT01497782|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2011-12-21|2011-12-21|2011-12-22|Estimate|||||||2011-12-21|2011-12-22|Estimate|April 2011||2011-04-30|December 2011|2011-12-31|January 2012|Anticipated|2012-01-31|October 2011|Actual|2011-10-31||Interventional|Feedback||The FEEDBACK Trial, a Randomized Controlled Trial|Impact of Instructor Feedback on Performance in a Virtual Reality Simulator: A Randomized, Controlled Trial|Unknown status|Enrolling by invitation|N/A|99|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 21:48:40.74425|2018-05-31 21:48:40.74425
NCT01497769|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-07-01|2011-12-20|2011-12-22|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|||Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route|A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intradermal Route in Healthy BCG-vaccinated Adult Subjects|Completed||Phase 1|24|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:48:40.818845|2018-05-31 21:48:40.818845
NCT01497756|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2012-07-02||2012-08-17|2011-12-21|2011-12-22|Estimate|2012-08-17|2012-09-17|Estimate||||2012-08-17|2012-09-17|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Feasibility Trial of the Circumferential Abdominal Pelvic Pressure Device (CAPP)|Feasibility Trial of the Circumferential Abdominal Pelvic Pressure Device (CAPP)|Completed||N/A|10|Actual|University of New Mexico||1|||f||||f||||||||||2018-05-31 21:48:40.900262|2018-05-31 21:48:40.900262
NCT01497743|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-12-20|2011-12-20|2011-12-22|Estimate|||||||2016-12-20|2016-12-22|Estimate|February 2012||2012-02-29|December 2016|2016-12-31||||February 2013|Anticipated|2013-02-28||Interventional|PRISS||Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis|Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis|Withdrawn||Phase 4|0|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:48:41.079631|2018-05-31 21:48:41.079631
NCT01497730|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-11-02|2011-12-21|2011-12-22|Estimate|||||||2017-11-02|2017-11-06|Actual|October 1, 2011|Actual|2011-10-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|10003||Multi-center, Non-comparative Study of Primary Total Knee Arthroplasty (TKA) Functional Performance|Multi-center, Non-comparative Study of Primary Total Knee Arthroplasty (TKA) Functional Performance|Active, not recruiting||N/A|840|Anticipated|DePuy Orthopaedics||1|||f||||f||||||||||2018-05-31 21:48:41.16814|2018-05-31 21:48:41.16814
NCT01497717|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-10-25|2011-12-21|2011-12-22|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy of Humira in Behcet Patients With Arthritis|Efficacy of Humira in Behcet Patients With Arthritis|Completed||Phase 3|9|Actual|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 21:48:41.285774|2018-05-31 21:48:41.285774
NCT01497704|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18||2017-03-15|2017-09-26|2011-12-20|2011-12-22|Estimate||||2017-03-15|2017-03-16|Actual|2017-09-26|2017-10-02|Actual|April 2012||2012-04-30|September 2017|2017-09-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Dose-Escalation and Safety Trial of YN968D1|Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors|Completed||Phase 1/Phase 2|55|Actual|LSK BioPartners Inc.||1|||f||||f||||||||Undecided||2018-05-31 21:48:41.36295|2018-05-31 21:48:41.36295
NCT01497691|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-08-22|2011-12-21|2011-12-22|Estimate|||||||2017-08-22|2017-08-24|Actual|January 2013|Anticipated|2013-01-31|August 2017|2017-08-31|November 19, 2013|Actual|2013-11-19|November 19, 2013|Actual|2013-11-19||Interventional|RCT BiPAP||Noninvasive Positive Airway Pressure in the Pediatric Emergency Department for the Treatment of Acute Asthma Exacerbations|A Randomized Controlled Trial of Noninvasive Positive Airway Pressure in the Pediatric Emergency Department for the Treatment of Acute Asthma Exacerbations|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||3||unable to recruit participants|f||||t||||||||||2018-05-31 21:48:41.447252|2018-05-31 21:48:41.447252
NCT01497678|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2016-10-19|2011-12-21|2011-12-22|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|MTURR||Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) Coordinating Center|Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury (Coordinating Center Protocol)|Withdrawn||N/A|0|Actual|University of Pittsburgh||1||Funding issues. 0 subjects enrolled|f||||t||||||||||2018-05-31 21:48:41.534834|2018-05-31 21:48:41.534834
NCT01497665|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2015-05-12||2016-03-08|2011-12-20|2011-12-22|Estimate|2015-11-10|2015-12-14|Estimate||||2016-03-08|2016-04-06|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|GRABM-L|"Safety population (all patients): 16~Efficacy population (defined as the number of patients who had ≥1 intracranial lesions followed as target or non-target lesions, and who were evaluated by Overall RECIST v.1.1):10"|GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)|A Phase II, Multi-center, Open-label Study Evaluating the Efficacy and Safety of GRN1005 in Non-Small Cell Lung Cancer Patients With Brain Metastases|Terminated||Phase 2|16|Actual|Angiochem Inc||1||Slow recruitment|f||||t||||||||||2018-05-31 21:48:41.632156|2018-05-31 21:48:41.632156
NCT01497652|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-12-15|2011-12-21|2011-12-22|Estimate|||||||2015-12-15|2015-12-16|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|RECOGNIZE||A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy|A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy|Completed||Phase 4|34|Actual|Georgetown University||2|||f||||f||||||||||2018-05-31 21:48:41.905795|2018-05-31 21:48:41.905795
NCT01497639|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2016-10-30|2011-12-21|2011-12-22|Estimate|||||||2016-10-30|2016-11-01|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of the Efficacy of Double Monopolar Versus Interleaving Stimulation Modes for Pallidal Deep Brain Stimulation|Comparison of the Efficacy of Double Monopolar Versus Interleaving Stimulation Modes for the Deep Brain Stimulation Treatment of Primary Generalized or Segmental Dystonia|Recruiting||Phase 4|20|Anticipated|University of Pecs||2|||f||||t||||||||||2018-05-31 21:48:41.998675|2018-05-31 21:48:41.998675
NCT01497626|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2016-02-15|2011-12-20|2011-12-22|Estimate|||||||2016-02-15|2016-02-17|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Lapatinib and Bortezomib in Patients With Advanced Malignancies|A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies|Terminated||Phase 1|15|Actual|Georgetown University||1||Drug support withdrawn|f||||t||||||||||2018-05-31 21:48:42.081988|2018-05-31 21:48:42.081988
NCT01497613|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2017-03-27||2017-07-10|2011-12-21|2011-12-22|Estimate|2017-07-10|2018-01-29|Actual||||2017-07-10|2018-01-29|Actual|February 2011||2011-02-28|July 2017|2017-07-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|PRISM||A Personalized Reminder Information and Social Management System||Completed||N/A|300|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 21:48:42.150405|2018-05-31 21:48:42.150405
NCT01497600|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-01-26|2011-12-20|2011-12-22|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2004||2004-02-29|January 2017|2017-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Six-period, Cross-over, Dose-response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects of Blacks or African American, Whites of Hispanic or Latino Origin and Whites Not of Hispanic or Latino Origin With Type 2 Diabetes|Completed||Phase 1|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:48:42.6614|2018-05-31 21:48:42.6614
NCT01497587|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-01-30|2011-12-20|2011-12-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2005||2005-08-31|January 2017|2017-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan|A Single Centre, Open-labelled Trial to Investigate the Pharmacokinetics of Insulin Detemir in Healthy Taiwanese Subjects|Completed||Phase 1|20|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:48:42.753004|2018-05-31 21:48:42.753004
NCT01497574|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-01-27|2011-12-20|2011-12-22|Estimate|||||||2017-01-27|2017-01-30|Estimate|May 2005||2005-05-31|January 2017|2017-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes|A Single-centre, Randomised, Double-blind, Cross-over Trial Comparing the Within-subject Variability of the Pharmacokinetic Profiles of Insulin Detemir and Insulin Glargine in Children and Adolescents With Type 1 Diabetes|Completed||Phase 1|32|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:48:42.817954|2018-05-31 21:48:42.817954
NCT01497561|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-01-26|2011-12-20|2011-12-22|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2003||2003-03-31|January 2017|2017-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Four-period, Cross-over, Dose Response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 2 Diabetes|Completed||Phase 1|15|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:48:42.886442|2018-05-31 21:48:42.886442
NCT01497548|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-12-21|2011-12-21|2011-12-22|Estimate|||||||2011-12-21|2011-12-22|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients|A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care|Unknown status|Recruiting|Phase 3|120|Anticipated|University of Malaya||2|||f||||f||||||||||2018-05-31 21:48:42.960042|2018-05-31 21:48:42.960042
NCT01497535|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-02-22|2011-12-20|2011-12-22|Estimate|||||||2017-02-22|2017-02-24|Actual|May 27, 2004|Actual|2004-05-27|February 2017|2017-02-28|October 31, 2004|Actual|2004-10-31|October 31, 2004|Actual|2004-10-31||Interventional|||Within-subject Variability of Insulin Detemir in Healthy Volunteers|A Single-centre, Parallel-group, Randomised, Double Blind Trial in Healthy Japanese Subjects Comparing the Within-subject Variability of Insulin Detemir and Insulin Glargine With Respect to Pharmacodynamic and Pharmacokinetic Properties|Completed||Phase 1|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:48:43.061022|2018-05-31 21:48:43.061022
NCT01488240|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-10-25|2011-12-07|2011-12-08|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2012||2012-11-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars|The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars|Recruiting||N/A|12|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:51:40.065498|2018-05-31 21:51:40.065498
NCT01497522|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2017-02-23|2011-12-20|2011-12-22|Estimate|||||||2017-02-23|2017-02-27|Actual|December 2011||2011-12-31|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With LAF237 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy|Completed||Phase 3|183|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:48:43.190427|2018-05-31 21:48:43.190427
NCT01497509|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2012-04-28|2011-12-21|2011-12-22|Estimate|||||||2012-04-28|2012-05-01|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Intrapartum Epidural Fentanyl and Breastfeeding in the Immediate Postpartum Period: a Randomized, Controlled, Double-blinded Study|Effect of Intrapartum Epidural Fentanyl Upon Breastfeeding in the Immediate Postpartum Period: a Randomized, Controlled, Double-blinded Study|Unknown status|Not yet recruiting|N/A|450|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 21:48:43.326032|2018-05-31 21:48:43.326032
NCT01497496|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-05-10|2011-12-20|2011-12-22|Estimate|||||||2018-05-10|2018-05-11|Actual|January 20, 2012||2012-01-20|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial|Active, not recruiting||Phase 2|29|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 21:48:43.430582|2018-05-31 21:48:43.430582
NCT01497483|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2015-01-14|2011-12-19|2011-12-22|Estimate|||||||2015-01-14|2015-01-16|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Drug-Drug Interaction Study With Pravastatin and Cyclosporine|The Pharmacokinetic Interaction Between Pravastatin and Cyclosporine in Healthy Volunteers|Completed||Phase 1|21|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:48:43.529659|2018-05-31 21:48:43.529659
NCT01497470|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2016-10-07|2011-12-19|2011-12-22|Estimate|||||||2016-10-07|2016-10-10|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen|An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel|Completed||Phase 1|36|Actual|Achieve Life Sciences||1|||f||||||||||||||2018-05-31 21:48:43.625003|2018-05-31 21:48:43.625003
NCT01497457|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-05-19|2011-12-19|2011-12-22|Estimate|||||||2015-05-19|2015-05-20|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Interest of Saline MR Peritoneography for Pre-operative Assessment of Rectal Cancer|Interest of Saline MR Peritoneography for Pre-operative Assessment of Rectal Cancer|Completed||N/A|17|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 21:48:43.70614|2018-05-31 21:48:43.70614
NCT01497444|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-02-23|2011-12-20|2011-12-22|Estimate|||||||2018-02-23|2018-02-27|Actual|May 2012||2012-05-31|February 2018|2018-02-28||||January 2016|Actual|2016-01-31||Interventional|||Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery|Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC|Active, not recruiting||Phase 1|24|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 21:48:43.788812|2018-05-31 21:48:43.788812
NCT01497431|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-11-25|2011-12-20|2011-12-22|Estimate|||||||2014-11-25|2014-11-26|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants|Phase I Multiple Dose Study of 12-Week Treatment by Se-Methyl-L-Cysteine(MSC) and L SeMet in Adult Males|Completed||Phase 1|66|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-05-31 21:48:43.879447|2018-05-31 21:48:43.879447
NCT01497418|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2014-09-18|2011-12-19|2011-12-22|Estimate|||||||2014-09-18|2014-09-19|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|July 2012|Actual|2012-07-31||Observational|||Long Term Follow-up of the 23mm Portico™ Aortic Valve Implant and the St. Jude Medical Transfemoral Delivery System|Long Term Follow-up of the 23mm Portico™ Aortic Valve Implant and the SJM Transfemoral Delivery System|Completed|||2|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 21:48:43.971557|2018-05-31 21:48:43.971557
NCT01497405|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-09-18|2011-12-19|2011-12-22|Estimate|||||||2017-09-18|2017-09-20|Actual|May 2012||2012-05-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||WHC+ (Women's Health CoOp PLUS)|Combination Prevention for Vulnerable Women in South Africa|Completed||Phase 1|641|Actual|RTI International||2|||f||||t||||||||||2018-05-31 21:48:44.029094|2018-05-31 21:48:44.029094
NCT01497392|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2017-02-14|2011-12-19|2011-12-22|Estimate|||||||2017-02-14|2017-02-15|Actual|March 29, 2012|Actual|2012-03-29|February 2017|2017-02-28|February 7, 2017|Actual|2017-02-07|August 31, 2015|Actual|2015-08-31||Interventional|||Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers|Phase I Study of Dovitinib (TKI258) in Combination With Gemcitabine and Capecitabine in Advanced Solid Tumors, Pancreatic Cancer and Biliary Cancers|Completed||Phase 1|26|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 21:48:44.112883|2018-05-31 21:48:44.112883
NCT01497379|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-03-28|2011-12-19|2011-12-22|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2011||2011-10-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients|Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Mono- & Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Degenerative Retinal Disease Patients.|Completed||N/A|2|Actual|Retina Implant AG||2|||f||||t||||||||||2018-05-31 21:48:44.200027|2018-05-31 21:48:44.200027
NCT01497366|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2014-01-15|2013-11-20|2014-03-04|2011-12-21|2011-12-22|Estimate|2014-03-04|2014-04-02|Estimate|2013-11-20|2013-12-06|Estimate|2014-03-04|2014-04-02|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|FISSION|Safety Analysis Set|Phase 3 Study of Sofosbuvir and Ribavirin|A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients With Chronic Genotype 2 or 3 HCV Infection|Completed||Phase 3|527|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:48:44.335278|2018-05-31 21:48:44.335278
NCT01497340|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2011-12-21|2011-12-21|2011-12-22|Estimate|||||||2011-12-21|2011-12-22|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Position at Birth,Placental Transfusion Volume and Cord Clamping|Is the Placental Transfusion Volume Influenced by the Position of the New Born at Birth? a Pilot Study|Terminated||N/A|27|Actual|Fundacion para la Salud Materno Infantil||2||difficulties with the center|f||||||||||||||2018-05-31 21:48:45.250641|2018-05-31 21:48:45.250641
NCT01497327|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-06-07|2011-12-21|2011-12-22|Estimate|||||||2012-06-07|2012-06-08|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Open-Label Hepatic Impairment Study|An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment|Completed||Phase 1|24|Actual|Gilead Sciences||6|||f||||f||||||||||2018-05-31 21:48:45.321667|2018-05-31 21:48:45.321667
NCT01497314|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-05-14|2011-12-19|2011-12-22|Estimate|||||||2013-05-14|2013-05-15|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Growth and Safety of a Low Lactose Milk-Based Infant Formula|An Open Label Clinical Study to Evaluate Growth and Safety of a Low Lactose Milk-Based Infant Formula in Healthy Term Infants|Completed||N/A|85|Actual|Perrigo Nutritionals||1|||f||||f||||||||||2018-05-31 21:48:45.395973|2018-05-31 21:48:45.395973
NCT01497301|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2011-12-21|2011-12-21|2011-12-22|Estimate|||||||2011-12-21|2011-12-22|Estimate|February 2012||2012-02-29|December 2011|2011-12-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Efficacy Study of Diabetes Group Visits|Initiating Diabetic Group Visits in Newly Diagnosed Diabetics in an Urban Academic Medical Practice|Unknown status|Not yet recruiting|N/A|20|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 21:48:45.465672|2018-05-31 21:48:45.465672
NCT01497288|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2012-09-28|2011-12-21|2011-12-22|Estimate|||||||2012-09-28|2012-10-02|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PK400 INFS||A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects|An Open Label, Randomised, Single-centre, Two Sequence, Cross-over Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects Using a Population PK Approach|Completed||Phase 1|20|Anticipated|Takeda||2|||f||||||||||||||2018-05-31 21:48:45.53455|2018-05-31 21:48:45.53455
NCT01497275|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2015-05-20||2015-06-18|2011-12-20|2011-12-22|Estimate|2015-05-20|2015-06-04|Estimate||||2015-06-18|2015-07-15|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma|A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma|Terminated||Phase 2|5|Actual|Duke University|The study was closed to enrollment due to the approval of new drugs for use in Mantle Cell Lymphoma. We were not able to enroll enough subjects to answer our study questions.|1||Low accrual due to the approval of new drugs for use in Mantle cell lymphoma.|f||||t||||||||||2018-05-31 21:48:45.59228|2018-05-31 21:48:45.59228
NCT01497262|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2015-02-26||2015-03-17|2011-12-19|2011-12-22|Estimate|2015-03-17|2015-03-19|Estimate||||2015-03-17|2015-03-19|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||The Enrolled Set (ENR) included all patients who signed the informed consent and enrolled in study|Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis|A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 3|162|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:48:45.778428|2018-05-31 21:48:45.778428
NCT01497249|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-03-15|2011-12-21|2011-12-22|Estimate|||||||2018-03-15|2018-03-16|Actual|December 1, 2011|Actual|2011-12-01|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|FCHO||Assessing Fermentability of a Dietary Fiber|Assessing Fermentability of a Dietary Fiber (FCHO) in Healthy Non-obese Men and Women|Active, not recruiting||N/A|29|Actual|Institute for Food Safety and Health, United States||2|||f||||f||||||||Undecided||2018-05-31 21:48:46.970173|2018-05-31 21:48:46.970173
NCT01497236|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-06-29|2011-12-21|2011-12-22|Estimate|||||||2015-06-29|2015-06-30|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|MSF-nutcon03||Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection in Karamoja, Uganda|Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Kaabong, Karamoja, Uganda|Completed||N/A|2202|Actual|Medecins Sans Frontieres, Spain||3|||f||||t||||||||||2018-05-31 21:48:47.065933|2018-05-31 21:48:47.065933
NCT01497223|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-04-02|2011-12-21|2011-12-22|Estimate|||||||2013-04-02|2013-04-04|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis|Completed||Phase 2|220|Actual|MethylGene Inc.||2|||f||||f||||||||||2018-05-31 21:48:47.158354|2018-05-31 21:48:47.158354
NCT01497210|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-04-24|2011-12-21|2011-12-22|Estimate|||||||2012-04-24|2012-04-25|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||EASH Dressing on Chronic Venous Leg Ulcers|A Prospective, Multi-centre, Non-comparative Study to Evaluate the Safety and Preliminary Performance of the EASH Dressing on Chronic Venous Leg Ulcers|Completed||Phase 2|40|Actual|ConvaTec Inc.||1|||f||||f||||||||||2018-05-31 21:48:47.258491|2018-05-31 21:48:47.258491
NCT01497197|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2015-06-15||2015-10-12|2011-12-21|2011-12-22|Estimate|2015-10-12|2015-11-09|Estimate||||2015-10-12|2015-11-09|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Baseline analysis population included all the subjects randomized in the study.|A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique|A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART)|Terminated||Phase 3|174|Actual|Merck KGaA|Study was terminated as per sponsor's decision.|2||Study was terminated as per sponsor's decision|f||||f||||||||||2018-05-31 21:48:47.376449|2018-05-31 21:48:47.376449
NCT01497184|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-01-09|2011-12-20|2011-12-22|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2011|Actual|2011-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood|CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 1|140|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 21:48:47.86374|2018-05-31 21:48:47.86374
NCT01497171|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|2014-08-06||2014-08-06|2011-12-21|2011-12-22|Estimate|2014-08-06|2014-08-21|Estimate||||2014-08-06|2014-08-21|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||5 women were enrolled at the German site (St. Hedwig's). No subjects were enrolled at the US sites.|The ELEGANT Trial: Elevate Transvaginal Mesh vs. Anterior Colporrhaphy|Safety and Efficacy of Transvaginal Mesh Colposuspension for Anterior Vaginal Prolapse: the Elevate vs. Anterior Colporrhaphy Trial|Terminated||Phase 4|5|Actual|Mayo Clinic|Early termination of study due to changes in funding.|2||Early termination of study due to changes in funding.|f||||f||||||||||2018-05-31 21:48:47.996785|2018-05-31 21:48:47.996785
NCT01497158|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-08-21|2011-12-21|2011-12-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|June 2007||2007-06-30|August 2014|2014-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Promoting Home Smoking Restrictions: Biomarker Feedback to Smoking and Non-Smoking Adults|Promoting Home Smoking Restrictions: Biomarker Feedback to Cohabitating Smoking and Non-Smoking Adults|Completed||N/A|122|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 21:48:48.25214|2018-05-31 21:48:48.25214
NCT01497145|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-03-02|2011-12-21|2011-12-22|Estimate|||||||2015-03-02|2015-03-04|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome|A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Response Study to Evaluate the Efficacy and Safety of KRN321 in Adult Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndrome|Completed||Phase 2|45|Anticipated|Kyowa Hakko Kirin Co., Ltd|||||f||||f||||||||||2018-05-31 21:48:48.323969|2018-05-31 21:48:48.323969
NCT01497132|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-09-09|2011-12-21|2011-12-22|Estimate|||||||2014-09-09|2014-09-10|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|EVIDENS||Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2|Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS|Completed||Phase 4|44|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:48:48.382328|2018-05-31 21:48:48.382328
NCT01497119|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2015-11-30|2011-12-20|2011-12-22|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-39758979 in Adult Japanese Subjects With Moderate Atopic Dermatitis|Terminated||Phase 2|88|Actual|Janssen Pharmaceutical K.K.||3||This study was terminated prematurely due to 2 cases of agranulocytosis.|f||||f||||||||||2018-05-31 21:48:48.45938|2018-05-31 21:48:48.45938
NCT01497106|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2014-11-25|2011-12-21|2011-12-22|Estimate|||||||2014-11-25|2014-11-26|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults|Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults|Completed||N/A|29|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:48:48.548491|2018-05-31 21:48:48.548491
NCT01497093|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-04-09|2011-12-21|2011-12-22|Estimate|||||||2018-04-09|2018-04-10|Actual|February 15, 2012|Actual|2012-02-15|April 2018|2018-04-30|September 12, 2019|Anticipated|2019-09-12|April 2, 2015|Actual|2015-04-02||Interventional|||Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)|Active, not recruiting||Phase 1|34|Actual|Celgene||1|||f||||f||||||||||2018-05-31 21:48:48.776445|2018-05-31 21:48:48.776445
NCT01497080|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2014-03-18|2011-12-21|2011-12-22|Estimate|||||||2014-03-18|2014-03-19|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Distal Radius Fracture Prospective Database 50-80 Years Old|"Distal Radius Fracture Prospective Database 50-80 Years Old Overview: Identification of Risk of Adverse Activity Transition Following a Distal Radius Fracture."|Completed|||195|Anticipated|Lawson Health Research Institute|||3||f||||f||||||||||2018-05-31 21:48:48.852265|2018-05-31 21:48:48.852265
NCT01497067|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2018-03-28|2011-12-20|2011-12-22|Estimate|||||||2018-03-28|2018-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:48:48.992328|2018-05-31 21:48:48.992328
NCT01497054|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-07-02|2011-12-21|2011-12-22|Estimate|||||||2013-07-02|2013-07-04|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Do Elevated BNP Levels Predict Hemodynamically Significant PDAs|Diagnostic Prediction Value of B Type Natriuretic Peptide (BNP) Levels in Hemodynamically Significant Patent Ductus Arteriosus (hsPDA) in Premature Infants.|Completed|||109|Actual|Albany Medical College|||||f||||f||||||||||2018-05-31 21:48:49.028196|2018-05-31 21:48:49.028196
NCT01497041|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-19|2011-12-19|2011-12-22|Estimate|||||||2011-12-19|2011-12-22|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment|A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment|Unknown status|Recruiting|Phase 2|35|Anticipated|Korean South West Oncology Group|||||f||||f||||||||||2018-05-31 21:48:49.092475|2018-05-31 21:48:49.092475
NCT01497028|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-04-02|2011-12-21|2011-12-22|Estimate|||||||2015-04-02|2015-04-03|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Plicated Laparoscopic Adjustable Gastric Banding (Lap Band)|Prospective Randomized Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding|Terminated|||||Jacksonville Surgical Associates|||2||f||||t||||||||||2018-05-31 21:48:49.198809|2018-05-31 21:48:49.198809
NCT01497002|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2011-12-22|2011-12-21|2011-12-22|Estimate|||||||2011-12-22|2011-12-23|Estimate|April 2005||2005-04-30|March 2011|2011-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|AML 2004||Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a|Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm. Efficacy of Allogeneic Stem Cell Transplantation in Comparison to a Second Consolidation Chemotherapy in Elderly Patients With Newly Diagnosed AML in the Age Over 60 Years|Unknown status|Recruiting|Phase 3|730|Anticipated|University of Leipzig||3|||f||||t||||||||||2018-05-31 21:48:49.392787|2018-05-31 21:48:49.392787
NCT01496989|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-08-30|2011-12-21|2011-12-22|Estimate|||||||2013-08-30|2013-09-02|Estimate|December 2011||2011-12-31|August 2013|2013-08-31||||March 2013|Actual|2013-03-31||Interventional|||Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers|A Phase 1 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Safety and Immunogenicity of a Multiantigen HIV (HIV-MAG) pDNA Vaccine With or Without Human IL-12 pDNA GENEVAX® IL-12) and Ad35-GRIN/ENV Vaccine in HIV-Uninfected, Healthy Volunteers|Completed||Phase 1|75|Anticipated|International AIDS Vaccine Initiative||5|||f||||t||||||||||2018-05-31 21:48:49.490904|2018-05-31 21:48:49.490904
NCT01496976|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2018-01-09|2011-12-21|2011-12-22|Estimate|||||||2018-01-09|2018-01-11|Actual|January 20, 2012|Actual|2012-01-20|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL|Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial|Active, not recruiting||Phase 2|45|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t|t|f||||||||2018-05-31 21:48:49.597193|2018-05-31 21:48:49.597193
NCT01496963|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-08-03|2011-12-21|2011-12-22|Estimate|||||||2015-08-03|2015-08-05|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|PAH2010||Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia|Observational Multicenter Study Lasting 12 Months to Determine the Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia Major and Intermedia and Verify the Suitability of Common Diagnostic Criteria in This Population|Unknown status|Active, not recruiting||1500|Anticipated|Ente Ospedaliero Ospedali Galliera|||3||f||||f||||||||||2018-05-31 21:48:49.698566|2018-05-31 21:48:49.698566
NCT01496950|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2018-04-04|2011-12-19|2011-12-21|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2008||2008-10-31|April 2018|2018-04-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|TMS-CHROMIG||Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine|Double-blind Randomized Clinical Trial to Evaluate Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in the Preventive Treatment of Chronic Migraine|Completed||Phase 1|18|Actual|Hospital Israelita Albert Einstein||2|||f||||f||||||||||2018-05-31 21:48:49.788544|2018-05-31 21:48:49.788544
NCT01496937|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2012-04-18|2011-12-19|2011-12-21|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||First-in-Human Exploratory Single Ascending Dose of GLPG0974|Exploratory Double-blind Placebo-controlled Study for the Assessment of Pharmacokinetics (PK), Safety, Tolerability, and Pharmacodynamics (PD) of Single Ascending Oral Doses of GLPG0974 in Healthy Subjects|Completed||Phase 1|32|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 21:48:49.917534|2018-05-31 21:48:49.917534
NCT01496924|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-12-19|2011-12-19|2011-12-21|Estimate|||||||2011-12-19|2011-12-21|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|||Swallowing Rehabilitation of Dysphagic Tracheostomized Patients Under Mechanical Ventilation at ICU|Swallowing Rehabilitation of Dysphagic Tracheostomized Patients Under Mechanical Ventilation at Intensive Care Unit|Unknown status|Recruiting|Phase 2|30|Anticipated|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 21:48:49.994164|2018-05-31 21:48:49.994164
NCT01496911|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-11-05|2011-12-19|2011-12-21|Estimate|||||||2013-11-05|2013-11-06|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving|Study to Investigate the Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving at 2 Bar and 4 Bar in Professional Navy Divers|Completed||Phase 4|24|Actual|Utrecht Institute for Pharmaceutical Sciences||3|||f||||t||||||||||2018-05-31 21:48:50.101372|2018-05-31 21:48:50.101372
NCT01496898|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2016-01-11|2011-12-15|2011-12-21|Estimate|||||||2016-01-11|2016-01-13|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|July 2013|Actual|2013-07-31|December 2011|Actual|2011-12-31||Observational|||Changes in Vaginal, Cervical and Uterine Microflora With Levonorgestrel Intrauterine Device Placement|Vaginal Microflora and Inflammatory Markers Before and After Levonorgestrel Device Insertion|Completed|||13|Actual|University of Utah|||||f||||t||||||Samples With DNA|"~     A total of 648 samples will be collected from 12 participants for bacterial species and human~     cytokine analysis in 9 collection visits. Specimens will be collected up to one week prior to~     IUD insertion and two months after IUD insertion. Vaginal and cervical specimens will be~     collected using FLOQSwabs® (Copan) to maximize bacterial DNA sample collection. Uterine~     samples will be collected by uterine irrigation with sterile saline using an embryo~     replacement catheter.~   "|||2018-05-31 21:48:50.179133|2018-05-31 21:48:50.179133
NCT01496885|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2015-10-19|2011-12-20|2011-12-21|Estimate|||||||2015-10-19|2015-10-20|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke|A Multicenter Observational Study to Evaluate the Simplified STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Obtained Between 24 and 48 Hours of a Nonhemorrhagic Ischemic Stroke|Completed|||120|Actual|Daiichi Sankyo, Inc.|||1||f||||f||||||||||2018-05-31 21:48:50.275513|2018-05-31 21:48:50.275513
NCT01496872|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2014-08-11|2011-12-19|2011-12-21|Estimate|||||||2014-08-11|2014-08-13|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Newborn Cranial Somatic Dysfunction - An Observational Study|Newborn Cranial Somatic Dysfunction - An Observational Study|Completed|||100|Actual|A.T. Still University of Health Sciences|||||f||||f||||||||||2018-05-31 21:48:50.353397|2018-05-31 21:48:50.353397
NCT01496859|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2012-03-23|2011-12-20|2011-12-21|Estimate|||||||2012-03-23|2012-03-26|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Observational Study of Baska Mask, a New Supraglottic Airway Device|Observational Study of Baska Mask, a New Supraglottic Airway Device|Completed||Phase 2|30|Actual|University College Hospital Galway||1|||f||||f||||||||||2018-05-31 21:48:50.432131|2018-05-31 21:48:50.432131
NCT01496846|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2017-07-11||2017-09-27|2011-12-20|2011-12-21|Estimate|2017-08-09|2017-09-13|Actual||||2017-09-27|2017-10-31|Actual|September 2011||2011-09-30|September 2017|2017-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ARTIC|Overall number of participants include all enrolled subjects that received the initial IANB anesthesia.|Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars|Articaine Versus Lidocaine Supplemental Infiltration Efficacy in Irreversible Pulpitis Mandibular Molars After Failed Inferior Alveolar Nerve Block|Completed||Phase 4|201|Actual|University of Michigan||3|||f||||f||||||||Undecided||2018-05-31 21:48:50.55785|2018-05-31 21:48:50.55785
NCT01496833|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2015-12-30|2011-12-18|2011-12-21|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Total Endovascular Aortic Arch Re-construction Study(TEARS)|Total Endovascular Aortic Arch Re-construction Study(TEARS)------China's Registry|Recruiting||N/A|50|Anticipated|Xijing Hospital||1|||f||||t||||||||||2018-05-31 21:48:51.031114|2018-05-31 21:48:51.031114
NCT01496820|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2013-07-15|2011-12-20|2011-12-21|Estimate|||||||2013-07-15|2013-07-17|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||A Randomized Trial to Assess the Efficacy and Safety of GO2KA1(Chitosan Oligosaccharide)on Blood Glucose Control|Effect of GO2KA1(Chitosan Oligosaccharide) on Postprandial Blood Glucose in Korean Adults: a Clinical Randomized Trial|Completed||Phase 2/Phase 3|60|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:48:51.165879|2018-05-31 21:48:51.165879
NCT01496807|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2017-01-31||2017-03-20|2011-12-19|2011-12-21|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|February 17, 2012||2012-02-17|January 2017|2017-01-31|August 29, 2016|Actual|2016-08-29|March 16, 2016|Actual|2016-03-16||Interventional||All evaluable participants will be those who completed treatment per study criteria.|Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma|A Phase Ib Study of Yervoy With Sylatron for Patients With Unresectable Stages IIIB/C/IV Melanoma|Completed||Phase 1|31|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 21:48:51.293551|2018-05-31 21:48:51.293551
NCT01496794|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2017-02-20|2011-12-19|2011-12-21|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2011||2011-10-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|PROSPER||Endophthalmitis Cultures|Prospective Surveillance of Patients With Endophthalmitis for Multi-antibiotic Resistance (PROSPER) Study|Terminated|||3|Actual|Vanderbilt University Medical Center|||1|poor enrollment|f||||f||||||||||2018-05-31 21:48:51.93275|2018-05-31 21:48:51.93275
NCT01496781|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2012-04-14|2011-12-19|2011-12-21|Estimate|||||||2012-04-14|2012-04-17|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|EMR||EndoClot for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection|EndoClotTM Absorbable Polysaccharide Hemostat in Comparison With Metallic Hemoclip for Hemostasis and Preventing Post-procedure Bleeding After Endoscopic Mucosal Resection: a Prospective, Randomized Trial|Completed||N/A|164|Actual|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||||2018-05-31 21:48:52.05317|2018-05-31 21:48:52.05317
NCT01496768|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-02-22|2011-12-19|2011-12-21|Estimate|||||||2013-02-22|2013-02-25|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|February 2013|Anticipated|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effects of Chronic Leucine Supplemetion on Glucose Homeostasis, Body Compositin, Muscle Mass and Strength of Healthy and Young Subjects|Effects of Chronic Leucine Supplemetion on Glucose Homeostasis, Body Compositin, Muscle Mass and Strength of Healthy and Young Subjects: a Randomized, Double-blind, and Placebo Controlled Trial|Suspended||N/A|24|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:48:52.203796|2018-05-31 21:48:52.203796
NCT01496755|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-11-01|2011-12-19|2011-12-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of RG7667 in Healthy Volunteers|A Phase I Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Doses of RG7667 in Healthy Adult Volunteers|Completed||Phase 1|170|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 21:48:52.318466|2018-05-31 21:48:52.318466
NCT01496742|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-09-21|2011-12-19|2011-12-21|Estimate|||||||2016-09-21|2016-09-23|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC|Completed||Phase 2|259|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 21:48:52.408467|2018-05-31 21:48:52.408467
NCT01496729|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-10-08|2011-12-19|2011-12-21|Estimate|||||||2013-10-08|2013-10-10|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|||Transversus Abdominis Plane (TAP) Block After Kidney Transplantation|Single Shot Transversus Abdominis Plane (TAP) Block Versus Sham Block for Analgesia in Donors and Recipients Following Kidney Transplantation|Withdrawn||N/A|0|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:48:52.703156|2018-05-31 21:48:52.703156
NCT01496716|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-08-12|2011-12-20|2011-12-21|Estimate|||||||2013-08-12|2013-08-13|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Obesity's Impact on the Effect of Hip Arthroplasty|Obesity's Impact on the Clinical Efficacy and Quality of Life 1 Year After Primary Total Hip Arthroplasty|Completed|||102|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 21:48:52.831663|2018-05-31 21:48:52.831663
NCT01496703|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|||2011-12-20|2011-12-20|2011-12-21|Estimate|||||||2011-12-20|2011-12-21|Estimate|January 1996||1996-01-31|December 2011|2011-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients|Reasons for Dose Reduction of Mycophenolate Mofetil During the First Post-transplant Year in Renal Transplant Recipients and Its Impact on Graft Outcome: a Single-center Retrospective Analysis|Completed|||749|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 21:48:52.936251|2018-05-31 21:48:52.936251
NCT01496690|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2017-01-06|2011-12-19|2011-12-21|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PACS||Pregablin for Anxiety-comorbidity in Patients With Schizophrenia|Pregablin for Anxiety-comorbidity in Patients With Schizophrenia - a Double-blinded Randomized Placebo Controlled Study|Completed||Phase 4|54|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:48:53.048608|2018-05-31 21:48:53.048608
NCT01496677|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2017-10-04|2011-12-20|2011-12-21|Estimate|||||||2017-10-04|2017-10-06|Actual|January 17, 2012|Actual|2012-01-17|October 2017|2017-10-31|February 28, 2012|Actual|2012-02-28|February 28, 2012|Actual|2012-02-28||Interventional|||Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects|A Phase 1 Open-Label Study With Oral TR-701 Free Acid to Assess Pharmacokinetics, Safety, and Tolerability in Elderly Subjects|Completed||Phase 1|28|Actual|Trius Therapeutics LLC||2|||f||||f||||||||||2018-05-31 21:48:53.148034|2018-05-31 21:48:53.148034
NCT01496664|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2017-03-20|2011-12-19|2011-12-21|Estimate|||||||2017-03-20|2017-03-22|Actual|September 2010||2010-09-30|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Coronary Hybrid Revascularisation Study|Coronary Hybrid Revascularisation Study Registry on Treatment of Significant Coronary Artery Disease by Combined Bypass Operation (CABG) and Catheter Based Treatment (PCI)|Active, not recruiting||Phase 4|2000|Anticipated|Aarhus University Hospital Skejby||1|||f||||t||||||||||2018-05-31 21:48:53.347249|2018-05-31 21:48:53.347249
NCT01496651|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2015-01-30|2011-12-19|2011-12-21|Estimate|||||||2015-01-30|2015-02-02|Estimate|November 2008||2008-11-30|January 2015|2015-01-31|December 2018|Anticipated|2018-12-31|January 2015|Actual|2015-01-31||Interventional|LeftMain/NOBLE||Coronary Artery Bypass Grafting Vs Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis|Nordic-Baltic-British Left Main Revascularization Study (NOBLE)|Active, not recruiting||Phase 4|1200|Anticipated|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 21:48:53.462506|2018-05-31 21:48:53.462506
NCT01496638|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-09-22|2011-12-19|2011-12-21|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2012|Actual|2012-12-31||Interventional|BIF IV||The Nordic-Baltic Bifurcation Study IV|How Should Coronary Artery Stenoses With Significant Side Branch be Stented? A Strategy of Stenting Both Main Vessel and Side Branch Compared to a Strategy of Stenting the Main Vessel and Only Stenting the Side Branch if Necessary.|Active, not recruiting||Phase 4|450|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 21:48:53.545315|2018-05-31 21:48:53.545315
NCT01496625|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|||2018-04-03|2011-12-17|2011-12-21|Estimate|||||||2018-04-03|2018-04-04|Estimate|December 1, 2011||2011-12-01|March 20, 2018|2018-03-20||||||||Observational|||National Eye Institute Biorepository for Retinal Diseases|NEI Intramural Biorepository for Retinal Diseases|Recruiting|||2300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:48:53.623722|2018-05-31 21:48:53.623722
NCT01496612|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|||2018-05-24|2011-12-17|2011-12-21|Estimate|||||||2018-05-24|2018-05-25|Actual|November 22, 2011||2011-11-22|April 19, 2016|2016-04-19|April 19, 2016|Actual|2016-04-19|April 19, 2016|Actual|2016-04-19||Interventional|||Buspirone Therapy for Localized Epilepsy|A Phase Two Clinical Trial of Buspirone Therapy in Localization-Related Epilepsy|Terminated||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:48:53.703051|2018-05-31 21:48:53.703051
NCT01496599|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|||2018-03-27|2011-12-17|2011-12-21|Estimate|||||||2018-03-27|2018-03-29|Actual|November 23, 2011||2011-11-23|March 19, 2018|2018-03-19||||||||Observational|||Imaging Biomarkers in Parkinson s Disease|Imaging Biomarkers in Parkinson Disease|Recruiting|||95|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:48:53.845351|2018-05-31 21:48:53.845351
NCT01496586|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|||2018-05-16|2011-12-17|2011-12-21|Estimate|||||||2018-05-16|2018-05-17|Actual|December 1, 2011||2011-12-01|August 3, 2015|2015-08-03|August 3, 2015||2015-08-03|||||Observational|||Service Member Fatigue and Lack of Motivation Following Concussion|Fatigue and Amotivation Following Mild Traumatic Brain Injury and Their Influence on Service Member Community Reintegration|Completed|||45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:48:54.031726|2018-05-31 21:48:54.031726
NCT01496573|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-05-17|2011-12-17|2011-12-21|Estimate|||||||2016-05-17|2016-05-19|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma|Observational - CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)|Completed|||77|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tumor tissue~   "|||2018-05-31 21:48:54.09269|2018-05-31 21:48:54.09269
NCT01496560|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2015-11-16|2011-12-20|2011-12-21|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30|1 Day|Observational [Patient Registry]|||Open Prospective Study for Determination of Predictive Measures for Pain During Colonoscopy|Comparison of Procedural Sequence in Same Day Consecutive Bidirectional Endoscopy Using Moderate Sedation: A Prospective Randomized Study|Withdrawn|||0|Actual|Sheba Medical Center||||study terminated due toTechnical issue pre -recruiting|f||||f||||||||||2018-05-31 21:48:54.158036|2018-05-31 21:48:54.158036
NCT01496547|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-05-09|2011-12-19|2011-12-21|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML|Sequential Intensive Chemotherapy Followed by Allogeneic Stem Cell Transplantation With Reduce-intensity Conditioning for Refractory and Relapse Acute Myeloid Leukemia in Adult Patients|Recruiting||Phase 2|42|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 21:48:54.238582|2018-05-31 21:48:54.238582
NCT01496534|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-11-26|2011-12-17|2011-12-21|Estimate|||||||2013-11-26|2013-11-27|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors|Phase Ib Study of Dovitinib in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Plus Carboplatin in Patients With Advanced Solid Tumors|Terminated||Phase 1|14|Actual|Icahn School of Medicine at Mount Sinai||2||toxicity of combination of medications|f||||f||||||||||2018-05-31 21:48:54.321601|2018-05-31 21:48:54.321601
NCT01496521|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-17|2011-12-17|2011-12-21|Estimate|||||||2011-12-17|2011-12-21|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|January 2013|Anticipated|2013-01-31|June 2012|Anticipated|2012-06-30||Interventional|CREAT||Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols|Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial.|Unknown status|Not yet recruiting|Phase 3|600|Anticipated|Beijing Friendship Hospital||3|||f||||t||||||||||2018-05-31 21:48:54.405091|2018-05-31 21:48:54.405091
NCT01496508|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-20|2011-12-20|2011-12-21|Estimate|||||||2011-12-20|2011-12-21|Estimate|June 2007||2007-06-30|December 2011|2011-12-31|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|||High-frequency Oscillatory Ventilation (HFOV) in Preterm Infants With Severe Respiratory Distress Syndrome (RDS)|Principal Investigator|Completed||Phase 2|360|Actual|Zhengzhou Children's Hospital, China||2|||f||||t||||||||||2018-05-31 21:48:54.482376|2018-05-31 21:48:54.482376
NCT01496469|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|2015-07-31||2015-07-31|2011-12-18|2011-12-21|Estimate|2015-07-31|2015-08-31|Estimate||||2015-07-31|2015-08-31|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.|Effect of Febuxostat on Blood Pressure|A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension|Completed||Phase 2|121|Actual|Takeda||2|||f||||t||||||||||2018-05-31 21:48:54.716447|2018-05-31 21:48:54.716447
NCT01496456|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2016-02-17||2017-07-09|2011-12-20|2011-12-21|Estimate|2016-07-12|2016-07-14|Estimate||||2017-07-09|2017-08-08|Actual|May 2010||2010-05-31|July 2017|2017-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ICON|Enrolled: 17 patients; 1 patient was not treated according to protocol. Baseline: 16 patients with 22 tooth pairs.|Radiographic Progression of Infiltrated Caries Lesions In-vivo|Radiographic Progression of Infiltrated Caries Lesions In-vivo|Completed||N/A|17|Actual|University of Michigan|Small number of subjects analyzed.|2|||f||||f||||||||No||2018-05-31 21:48:55.333757|2018-05-31 21:48:55.333757
NCT01496443|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2012-09-12|2011-12-20|2011-12-21|Estimate|||||||2012-09-12|2012-09-13|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||TAK-875 Glimepiride Drug-Interaction Study|A Phase 1, Single-Blind, Placebo Controlled, Sequential Design Study to Evaluate the Drug Interaction Potential Between Glimepiride and TAK-875 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|28|Actual|Takeda||1|||f||||f||||||||||2018-05-31 21:48:55.56448|2018-05-31 21:48:55.56448
NCT01496430|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|2014-05-14||2015-04-20|2011-12-20|2011-12-21|Estimate|2015-04-20|2015-05-06|Estimate||||2015-04-20|2015-05-06|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Randomized Set includes all enrolled participants who were randomized via the Interactive Voice/Web Response System.|Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes|A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes|Terminated||Phase 3|105|Actual|Takeda|Because of low enrollment in the study, the sample sizes in the results data do not allow for significant interpretation of the results.|3||Business Decision; No Safety Or Efficacy Concerns. (See below)|f||||f||||||||||2018-05-31 21:48:55.669445|2018-05-31 21:48:55.669445
NCT01496417|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-08-16|2011-12-20|2011-12-21|Estimate|||||||2017-08-16|2017-08-21|Actual|March 2012||2012-03-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores|A 12 Month, Single-center, Non-randomized, Open-label Study of Outcomes of Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores in de Novo Renal Transplant Recipients|Active, not recruiting||N/A|20|Actual|University of Maryland||1|||f||||t||||||||||2018-05-31 21:48:57.150102|2018-05-31 21:48:57.150102
NCT01496404|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2014-07-19|2011-12-20|2011-12-21|Estimate|||||||2014-07-19|2014-07-22|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Electrocautery Versus Scalpel for Skin Incisions|A Randomized Controlled Trial Comparing the Cosmetic Outcome of Electrocautery Versus Scalpel for Surgical Skin Incisions|Completed||N/A|66|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 21:48:57.235257|2018-05-31 21:48:57.235257
NCT01496391|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2014-04-08|2011-12-20|2011-12-21|Estimate|||||||2014-04-08|2014-04-09|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Observational|||A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function|A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function|Completed|||6|Actual|Centre for Probe Development and Commercialization|||3||f||||t||||||None Retained|"~     Whole blood (chemistry, hematology) and kidney function (eGRF, eRPF)~   "|||2018-05-31 21:48:57.320581|2018-05-31 21:48:57.320581
NCT01496378|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2015-05-26|2011-12-20|2011-12-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Problem Solving Skills Training For Parent Caregivers of Youth With Chronic Pain|Problem Solving Skills Training For Parent Caregivers of Youth With Chronic Pain|Completed||Phase 1|122|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 21:48:57.388728|2018-05-31 21:48:57.388728
NCT01496365|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19||2014-02-07|2014-03-10|2011-12-20|2011-12-21|Estimate||||2014-02-07|2014-03-11|Estimate|2014-03-10|2014-04-07|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|Completed||Phase 2|452|Actual|Daiichi Sankyo, Inc.||6|||f||||t||||||||||2018-05-31 21:48:57.525941|2018-05-31 21:48:57.525941
NCT01496352|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2014-08-15||2014-08-15|2011-12-19|2011-12-21|Estimate|2014-08-15|2014-09-01|Estimate||||2014-08-15|2014-09-01|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||DFA-02 in Patients Undergoing Colorectal Surgery|A Randomized, Double-blind, Placebo Controlled, Safety, Tolerability, and Pharmacokinetic Dose Escalation Study of DFA-02 in Patients Undergoing Colorectal Surgery|Completed||Phase 1/Phase 2|30|Actual|Dr. Reddy's Laboratories Limited|Protocol specified cohorts of 10, 20, 30 or 40 mL to be placed after closure of the fascia and prior to skin closure. Experience with 20 and 30 mL dose levels showed that even largest patients would not accommodate 40 mL so that arm was not done.|2|||f||||t||||||||||2018-05-31 21:48:57.71651|2018-05-31 21:48:57.71651
NCT01496339|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2012-06-06|2011-12-18|2011-12-21|Estimate|||||||2012-06-06|2012-06-07|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation in Treating Type 1 Diabetic Patients|Phase 1/2 Clinical Study of MenSCs Infusion in Type 1 Diabetes|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|S-Evans Biosciences Co.,Ltd.||2|||f||||t||||||||||2018-05-31 21:48:58.035341|2018-05-31 21:48:58.035341
NCT01496326|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-19|2011-12-19|2011-12-21|Estimate|||||||2011-12-19|2011-12-21|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ANTIPAIN||Osteoarthritis Topical Treatment|A Pilot Study to Compare the Efficacy and Safety of a Novel 10% Ibuprofen Formulation Versus Placebo Alone Applied to the Knee in Patients With Painful Osteoarthritis of the Knee|Completed||Phase 2|75|Actual|BioChemics, Inc.||2|||f||||t||||||||||2018-05-31 21:48:58.135277|2018-05-31 21:48:58.135277
NCT01496313|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|2015-04-01||2016-10-11|2011-12-19|2011-12-21|Estimate|2015-10-27|2015-11-27|Estimate||||2016-10-11|2016-11-14|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|April 2014|Actual|2014-04-30||Interventional|||To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer|An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease|Active, not recruiting||Phase 4|81|Actual|Sanofi||2|||f||||||||||||||2018-05-31 21:48:58.214495|2018-05-31 21:48:58.214495
NCT01496300|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-09-02|2011-12-19|2011-12-21|Estimate|||||||2014-09-02|2014-09-03|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|BONARTH||Benefit of Orthopedic Navigation in the ARThroplasty of the Hip|Randomised Controlled Double-blind Monocenter Therapy Study Validating the Benefit From Information Provided by Image Free Navigation System on the Precision of the Placement of Acetabular Component in Patients Undergoing Primary THA|Completed||Phase 4|89|Actual|Aesculap AG||2|||f||||f||||||||||2018-05-31 21:48:59.87259|2018-05-31 21:48:59.87259
NCT01496287|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2014-06-26||2014-11-04|2011-12-19|2011-12-21|Estimate|2014-06-26|2014-07-24|Estimate||||2014-11-04|2014-11-06|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Inova||Tympanostomy Tube Placement in Children in the Office (Inova Study)|Tympanostomy Tube Placement in Children in the Office (Inova Study)|Completed||N/A|70|Actual|Acclarent||1|||f||||f||||||||||2018-05-31 21:48:59.983311|2018-05-31 21:48:59.983311
NCT01496274|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|2016-04-03|2015-09-29|2016-04-03|2011-12-19|2011-12-21|Estimate|2016-04-03|2016-05-09|Estimate|2015-09-29|2015-10-19|Estimate|2016-04-03|2016-05-09|Estimate|February 2012||2012-02-29|April 2016|2016-04-30||||July 2014|Actual|2014-07-31||Interventional||Safety Population|A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B|A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B|Completed||Phase 2/Phase 3|63|Actual|CSL Behring||2|||f||||t||||||||||2018-05-31 21:49:00.196519|2018-05-31 21:49:00.196519
NCT01496261|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2011-12-20|2011-12-20|2011-12-21|Estimate|||||||2011-12-20|2011-12-21|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial|Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:49:00.825839|2018-05-31 21:49:00.825839
NCT01496248|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|2014-09-24||2014-10-06|2011-12-20|2011-12-21|Estimate|2014-10-06|2014-10-10|Estimate||||2014-10-06|2014-10-10|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy Study of Korean Red Ginseng to Treat Depression|The Effect of Korean Red Ginseng as Adjuvant Treatment for the Residual Symptoms of Depression|Completed||N/A|35|Actual|Korea University||1|||f||||f||||||||||2018-05-31 21:49:00.928666|2018-05-31 21:49:00.928666
NCT01496235|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-12-16|2011-12-16|2011-12-21|Estimate|||||||2011-12-16|2011-12-21|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Cocoa Consumption in Cardiovascular and Immune Parameters|Randomized Clinical Trial of the Effect of Cocoa Consumption in Cardiovascular and Immune Parameters in Colombian Patients With Newly Diagnosed Stage 1 Arterial Hypertension|Terminated||N/A|69|Actual|Universidad de Antioquia||2||Difficulties with the patient recruitment|f||||t||||||||||2018-05-31 21:49:01.173777|2018-05-31 21:49:01.173777
NCT01496222|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-03-14|2011-12-18|2011-12-21|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|October 2015|Actual|2015-10-31||Observational|MoCA||The Montreal Cognitive Assessment as a Screening Tool for Preoperative Mild Cognitive Impairment in Geriatric Patients|The Montreal Cognitive Assessment as a Screening Tool for Preoperative Mild Cognitive|Unknown status|Enrolling by invitation||582|Anticipated|Mahidol University|||||f||||t||||||||||2018-05-31 21:49:01.253159|2018-05-31 21:49:01.253159
NCT01496209|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2014-02-10|2011-12-20|2011-12-21|Estimate|||||||2014-02-10|2014-02-12|Estimate|July 2015||2015-07-31|February 2014|2014-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|RECONSTRUCT||REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts||Withdrawn||Phase 1|0|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 21:49:01.305203|2018-05-31 21:49:01.305203
NCT01496196|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-18|||2015-04-12|2011-12-20|2011-12-21|Estimate|||||||2015-04-12|2015-04-14|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis||Unknown status|Recruiting|Phase 3|100|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 21:49:01.367056|2018-05-31 21:49:01.367056
NCT01496183|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2014-11-24||2014-11-24|2011-12-20|2011-12-21|Estimate|2014-11-24|2014-12-01|Estimate||||2014-11-24|2014-12-01|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Metabolic Effects of Olanzapine in Healthy Males|Metabolic Effects of Olanzapine in Healthy Males|Completed||N/A|24|Actual|State University of New York at Buffalo|The small sample size, the exclusion of obese subjects, and the short olanzapine exposure in the current study may limit the interpretation and generalizability of our findings.|2|||f||||f||||||||||2018-05-31 21:49:01.446705|2018-05-31 21:49:01.446705
NCT01496170|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2015-10-22|2011-12-16|2011-12-21|Estimate|||||||2015-10-22|2015-10-23|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])|A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)]|Completed||Phase 1|32|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 21:49:01.625413|2018-05-31 21:49:01.625413
NCT01496157|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-06-16|2011-12-20|2011-12-21|Estimate|||||||2014-06-16|2014-06-18|Estimate|December 2011||2011-12-31|June 2014|2014-06-30||||January 2015|Anticipated|2015-01-31||Interventional|||Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer|Evaluation of PSMA-based PET as an Imaging Biomarker of Primary Prostate Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||t||||||||||2018-05-31 21:49:01.77696|2018-05-31 21:49:01.77696
NCT01495624|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2016-01-26|2011-12-16|2011-12-20|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine||Terminated||N/A|16|Actual|The Cleveland Clinic||2||Accrual insufficient to complete study in a feasible time frame|f||||f||||||||||2018-05-31 21:49:11.006779|2018-05-31 21:49:11.006779
NCT01496144|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2011-12-20|2011-12-20|2011-12-21|Estimate|||||||2011-12-20|2011-12-21|Estimate|December 2005||2005-12-31|December 2011|2011-12-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Manual Therapy on the Improvement of Functional Disability in Patients With Chronic Non Specific Low Back Pain|Manual Therapy Followed by Specific Active Exercises Versus a Placebo Followed by Specific Active Exercises on the Improvement of Functional Disability in Patients With Chronic Non Specific Low Back Pain: a Randomized Controlled Trial|Completed||N/A|42|Actual|University of Applied Sciences of Western Switzerland||2|||f||||f||||||||||2018-05-31 21:49:01.903063|2018-05-31 21:49:01.903063
NCT01496131|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2018-02-09||2018-02-09|2011-12-20|2011-12-21|Estimate|2018-02-09|2018-03-09|Actual||||2018-02-09|2018-03-09|Actual|October 24, 2011|Actual|2011-10-24|February 2018|2018-02-28|November 25, 2016|Actual|2016-11-25|November 25, 2016|Actual|2016-11-25||Interventional||Baseline population included all randomized subjects.|Tecemotide (L-BLP25) in Prostate Cancer|A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients|Completed||Phase 2|28|Actual|EMD Serono|For primary outcome measure, antigen specific data was provided with updated technique. Enzyme-Linked ImmunoSpot technique was not done, but intracellular cytokine antigen specific responses was evaluated, which is now the lab technique used.|2|||f||||f||||||||||2018-05-31 21:49:02.072023|2018-05-31 21:49:02.072023
NCT01496118|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-11-08|2011-12-20|2011-12-21|Estimate|||||||2017-11-08|2017-11-13|Actual|December 2011||2011-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma|Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|80|Anticipated|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 21:49:02.614582|2018-05-31 21:49:02.614582
NCT01496105|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-20|2011-12-20|2011-12-21|Estimate|||||||2011-12-20|2011-12-21|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Interventional|||Efficacy Study of Topical Application of Lidacaine Spray Prior to IUD Insertion||Unknown status|Recruiting|Phase 4|200|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 21:49:02.778626|2018-05-31 21:49:02.778626
NCT01496092|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2014-02-19|2011-12-16|2011-12-21|Estimate|||||||2014-02-19|2014-02-21|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of Keto Acid (KA) on Insulin Resistance in Peritoneal Dialysis (PD) Patients|Effects of Regular Protein Diet Supplemented With Keto Acid on Insulin Resistance In Peritoneal Dialysis Patients|Completed||Phase 3|100|Actual|Peking University First Hospital||2|||f||||f||||||||||2018-05-31 21:49:02.862965|2018-05-31 21:49:02.862965
NCT01496079|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-04-12|2011-12-17|2011-12-21|Estimate|||||||2017-04-12|2017-04-14|Actual|December 2011||2011-12-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MI GIFT||Maternal Immunization: Giving Immunity For Tomorrow|The Role of Immunizing Pregnant Women In Protecting Young Infants Against Influenza|Completed|||166|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 21:49:02.954488|2018-05-31 21:49:02.954488
NCT01496066|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2017-12-29||2018-02-01|2011-12-20|2011-12-21|Estimate|2018-02-01|2018-03-05|Actual||||2018-02-01|2018-03-05|Actual|December 2011||2011-12-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism|A Prospective Randomized Controlled Multi-Center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism|Completed||N/A|600|Actual|Calhoun Vision, Inc.||2|||f||||f||||||||No||2018-05-31 21:49:03.061719|2018-05-31 21:49:03.061719
NCT01496053|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2015-04-13|2011-12-20|2011-12-21|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)|Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 21:49:03.723775|2018-05-31 21:49:03.723775
NCT01496040|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-10-06|2011-12-16|2011-12-21|Estimate|||||||2015-10-06|2015-10-07|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|RPE65||Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65|Prospective Monocentric Open Label Non Randomized Uncontrolled Phase I/II Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65|Completed||Phase 1/Phase 2|9|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 21:49:03.821436|2018-05-31 21:49:03.821436
NCT01496027|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-10|||2013-09-09|2011-12-20|2011-12-21|Estimate|||||||2013-09-09|2013-09-10|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Observational|||Cerebral Tissue Oxygenation Values in Newborns Measured Using Laser and LED NIRS Oximeters|A Comparison of Cerebral Tissue Oxygenation Values in Newborns Measured Simultaneously Using Laser and LED NIRS Oximeters|Completed|||30|Actual|Poznan University of Medical Sciences|||2||f||||f||||||||||2018-05-31 21:49:03.903907|2018-05-31 21:49:03.903907
NCT01496014|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2016-12-22|2011-12-20|2011-12-21|Estimate|||||||2016-12-22|2016-12-23|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|September 2016|Actual|2016-09-30||Observational|Bioburden||Assessment of Severe Extremity Wound Bioburden at the Time of Definitive Wound Closure or Coverage|Assessment of Severe Extremity Wound Bioburden at the Time of Definitive Wound Closure or Coverage: Correlation With Subsequent Post-Closure Deep Wound Infection: Bioburden Study|Unknown status|Active, not recruiting||600|Anticipated|Major Extremity Trauma Research Consortium|||1||f||||t||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 21:49:04.107105|2018-05-31 21:49:04.107105
NCT01496001|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-10-05|2011-12-20|2011-12-21|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Cosmetic and Functional Outcomes After Breast Conserving Surgery|The Effect of Tumor - Breast Volume Ratio on Cosmetic and Functional Outcomes in Breast Conserving Surgery Patients; a Prospective Cohort Study|Completed||N/A|300|Actual|National Institute of Oncology, Hungary||1|||f||||t||||||||||2018-05-31 21:49:04.271961|2018-05-31 21:49:04.271961
NCT01495988|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2017-05-30||2017-09-22|2011-12-16|2011-12-21|Estimate|2017-05-30|2017-06-23|Actual||||2017-09-22|2017-10-24|Actual|August 2013||2013-08-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma|Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma|Terminated||Phase 2|10|Actual|Melanoma Research Foundation Breakthrough Consortium|The study was terminated prematurely on June 13, 2016. No further accrual to the study will occur.|4||Slow accrual; toxicity; change in priorities|f||||t||||||||||2018-05-31 21:49:04.411588|2018-05-31 21:49:04.411588
NCT01495975|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2015-04-06||2016-09-12|2011-12-16|2011-12-20|Estimate|2015-04-06|2015-04-16|Estimate||||2016-09-12|2016-10-25|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|DTTK||Impact of a Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control|Impact of a Web-based Diabetes Transitions Tool Kit on Post-Hospitalization Glycemic Control|Completed||N/A|29|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:49:05.684866|2018-05-31 21:49:05.684866
NCT01495962|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-04-25|2011-12-16|2011-12-20|Estimate|||||||2016-04-25|2016-04-27|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|||The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy|The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy: A Pilot Study|Completed||Phase 1|46|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:49:05.969929|2018-05-31 21:49:05.969929
NCT01495949|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-05-21|2011-12-16|2011-12-20|Estimate|||||||2014-05-21|2014-05-23|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Cortisol Levels During Cardiac Surgery. The Comparison Between Etomidate and Thiopentone|The Changes in Cortisol Levels and Stress Responses During Cardiac Surgery. The Comparison Between Two Induction Agents: Etomidate and Thiopentone.|Completed||Phase 4|92|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 21:49:06.053906|2018-05-31 21:49:06.053906
NCT01495936|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-11-01|2011-12-19|2011-12-20|Estimate|||||||2017-11-01|2017-11-06|Actual|October 17, 2011|Actual|2011-10-17|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Two Airway Interventions, During One Lung Ventilation, on Blood Oxygen Content|The Influence Of Continuous Positive Airway Pressure and Positive End-Expiratory Pressure, With A Recruitment Maneuver, On Oxygenation During One Lung Ventilation Employing A Lung Protective Ventilation Strategy.|Recruiting||N/A|40|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:49:06.136243|2018-05-31 21:49:06.136243
NCT01495923|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2016-08-10||2017-02-28|2011-12-16|2011-12-20|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|December 2011||2011-12-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Steroids Versus Gabapentin|Randomized, Double-blind, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Gabapentin in Patients With Lumbosacral Radiculopathy|Completed||N/A|145|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:49:06.29079|2018-05-31 21:49:06.29079
NCT01495910|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2014-02-27|2011-12-16|2011-12-20|Estimate|||||||2014-02-27|2014-02-28|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency|An Open-Label, Multiple-Dose, Dose-Finding Study of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency|Completed||Phase 1|6|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||t||||||||||2018-05-31 21:49:06.777107|2018-05-31 21:49:06.777107
NCT01495897|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-02-23|2011-12-16|2011-12-20|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|MOUVADOC||Abnormal Movements, Cerebellum and Sensorimotor : Oculomotor Study|Adaptation Sensorimotrice, Cervelet et Mouvements Anormaux: Projet d'étude Oculomotrice|Completed||N/A|14|Actual|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||f||||||||||2018-05-31 21:49:06.862653|2018-05-31 21:49:06.862653
NCT01495884|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2015-10-23|2011-12-19|2011-12-20|Estimate|||||||2015-10-23|2015-10-26|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Myocet/Lapatinib Study. ICORG 10-03, V5|A Phase I/II Study of Lapatinib Plus Myocet TM in Patients With HER2+ve Metastatic Breast Cancer Following Disease Progression During, or After, Treatment With Trastuzumab and Taxanes|Terminated||Phase 1/Phase 2|11|Actual|Cancer Trials Ireland||1||Slower than anticipated accrual|f||||f||||||||||2018-05-31 21:49:06.981312|2018-05-31 21:49:06.981312
NCT01495871|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2015-02-10|2011-12-19|2011-12-20|Estimate|||||||2015-02-10|2015-02-11|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TBIS||Amino Acid Supplementation in Recovery From Traumatic Brain Injury|Amino Acid Supplementation in Recovery From Traumatic Brain Injury|Withdrawn||N/A|0|Actual|The University of Texas Medical Branch, Galveston||3||PI decided not to pursue this study.|f||||f||||||||||2018-05-31 21:49:07.051242|2018-05-31 21:49:07.051242
NCT01495858|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2014-01-24|2012-05-30|2015-05-13|2011-12-19|2011-12-20|Estimate|2014-05-16|2014-06-17|Estimate|2012-05-30|2012-06-05|Estimate|2015-05-13|2015-06-08|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Morpheus/DPH||Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain|A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep|Completed||Phase 3|267|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:49:07.141476|2018-05-31 21:49:07.141476
NCT01495845|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2012-06-07|2011-12-19|2011-12-20|Estimate|||||||2012-06-07|2012-06-08|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy|Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy|Completed||Phase 1|48|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 21:49:08.284316|2018-05-31 21:49:08.284316
NCT01495832|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2014-09-24|2011-12-19|2011-12-20|Estimate|||||||2014-09-24|2014-09-25|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PULSA-2011||Impact of Pulse-enriched Foods on Cognitive Function and Cardiometabolic Health in Obese Adults|Impact of Pulse-enriched Foods on Cognitive Function and Cardiometabolic Health in Obese Adults|Completed||N/A|150|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:49:08.374068|2018-05-31 21:49:08.374068
NCT01495819|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2018-01-26|2011-12-15|2011-12-20|Estimate|||||||2018-01-26|2018-01-30|Actual|January 4, 2017|Actual|2017-01-04|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Nicotine Reinforcement and Aversion in Young Adult Light Smokers|Nicotine Reinforcement and Aversion in Young Adult Light Smokers|Recruiting||N/A|64|Anticipated|Yale University||2|||f||||t||||||||Undecided||2018-05-31 21:49:08.480316|2018-05-31 21:49:08.480316
NCT01495806|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2013-06-11|2011-12-19|2011-12-20|Estimate|||||||2013-06-11|2013-06-13|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood|Glucomannn for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood Randomized Double Blind Placebo Controlled Trial|Completed||Phase 4|90|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 21:49:08.561739|2018-05-31 21:49:08.561739
NCT01495793|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2015-04-29||2018-03-08|2011-12-16|2011-12-20|Estimate|2015-06-17|2015-07-14|Estimate||||2018-03-08|2018-04-04|Actual|December 2011||2011-12-31|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Baseline Characteristics refers to the 24 treated subjects (Safety Set).|Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome|A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome|Completed||Phase 2|42|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 21:49:08.659249|2018-05-31 21:49:08.659249
NCT01495780|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2013-06-28|2011-12-16|2011-12-20|Estimate|||||||2013-06-28|2013-07-02|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||eRT Remote Health Monitoring|Feasibility and Cost Effectiveness of Physiological Monitoring at Home in COPD Patients|Unknown status|Recruiting|N/A|75|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 21:49:08.970783|2018-05-31 21:49:08.970783
NCT01495767|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2011-12-22|2011-12-19|2011-12-20|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|July 2009|Actual|2009-07-31|||||Observational|||Quality of Life in Juvenile Patients With Uveitis|The Impact of Uveitis on Health-related Quality of Life in Adolescents|Completed|||37|Actual|Hospital Hietzing|||1||f||||f||||||||||2018-05-31 21:49:09.079904|2018-05-31 21:49:09.079904
NCT01495754|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2011-12-19|2011-12-19|2011-12-20|Estimate|||||||2011-12-19|2011-12-20|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Different Coffee Amounts on Energy Intake, Appetite, Glucose Metabolism and Inflammatory Markers|The Effect of Different Amounts of Coffee on Dietary Intake, Appetite-related Feeling, Appetite Hormones, Glucose Metabolism and Inflammatory Markers of Normal Weight and Overweight/Obese Individuals|Completed||N/A|33|Actual|Harokopio University||3|||f||||f||||||||||2018-05-31 21:49:09.14886|2018-05-31 21:49:09.14886
NCT01495741|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2018-02-28|2011-12-16|2011-12-20|Estimate|||||||2018-02-28|2018-03-01|Actual|July 1, 2013|Actual|2013-07-01|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Observational|||Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)|An Observational Post-Authorization Safety Surveillance (PASS) Study of Sycrest® (Asenapine) Among Patients Aged 18 and Older Diagnosed With Bipolar Disorder|Completed|||42|Actual|Merck Sharp & Dohme Corp.|||3||f||||f||||||||||2018-05-31 21:49:09.251071|2018-05-31 21:49:09.251071
NCT01495728|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2011-12-19|2011-12-19|2011-12-20|Estimate|||||||2011-12-19|2011-12-20|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Thoracic Manipulation in Patients With Cervical Radiculopathy|Immediate and Short Term Effects of Thoracic Manipulation in Patients With Cervical Radiculopathy|Unknown status|Recruiting|N/A|50|Anticipated|Spine and Sport, Georgia||2|||f||||f||||||||||2018-05-31 21:49:09.309646|2018-05-31 21:49:09.309646
NCT01495715|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2014-08-21|2011-12-19|2011-12-20|Estimate|||||||2014-08-21|2014-08-22|Estimate||||August 2014|2014-08-31||||||||Interventional|||Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)||Withdrawn||Phase 3|0|Actual|Santhera Pharmaceuticals||2|||f||||||||||||||2018-05-31 21:49:09.387794|2018-05-31 21:49:09.387794
NCT01495702|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2014-12-31|2014-08-25|2015-12-01|2011-12-16|2011-12-20|Estimate|2015-01-22|2015-01-26|Estimate|2014-08-25|2014-08-27|Estimate|2015-12-01|2016-01-07|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study drug|Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients|A Phase 3b Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients|Completed||Phase 3|439|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||f||||||||||2018-05-31 21:49:09.488591|2018-05-31 21:49:09.488591
NCT01495689|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2017-03-23||2017-03-23|2011-12-19|2011-12-20|Estimate|2017-03-23|2017-05-05|Actual||||2017-03-23|2017-05-05|Actual|November 2011||2011-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|Quit&Win||Smoking Cessation With the Ottawa Model and SmartCard in Out-patient Respirology Clinic Setting|A Pilot Randomized Control Trial of Smoking Cessation Using The Ottawa Model With the SmartCard in Out-patient Respirology Clinic Setting|Completed||N/A|50|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 21:49:10.458844|2018-05-31 21:49:10.458844
NCT01495676|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-08-10|2011-12-16|2011-12-20|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2011||2011-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|GETUGV04||A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer|A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer|Recruiting||Phase 2|108|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||t||||||||||2018-05-31 21:49:10.701664|2018-05-31 21:49:10.701664
NCT01495663|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2015-02-25|2011-12-16|2011-12-20|Estimate|||||||2015-02-25|2015-02-26|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned|A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapsed or Refractory Advanced Solid Malignancies|Completed||Phase 1|12|Actual|Cellectar Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 21:49:10.777556|2018-05-31 21:49:10.777556
NCT01495650|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-08-16|2011-12-19|2011-12-20|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2010||2010-12-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|APAD||Effect of a Tailored Program of Physical Activity and Nutritional Counseling on Fatigue Reduction in Breast Cancer Patients Receiving an Adjuvant Treatment|A Randomized Controlled Trial to Evaluate the Effect of a Tailored Program of Physical Activity and Nutritional Counseling on Fatigue Reduction in Breast Cancer Patients Receiving Adjuvant Treatment.|Completed||Phase 3|240|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f||||||||||2018-05-31 21:49:10.843641|2018-05-31 21:49:10.843641
NCT01495637|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2017-07-24|2011-12-16|2011-12-20|Estimate|||||||2017-07-24|2017-07-26|Actual|December 2011||2011-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|GIFT||GM-CSF for Immunomodulation Following Trauma (GIFT) Study|GM-CSF for Immunomodulation Following Trauma (GIFT) Study|Recruiting||Phase 4|200|Anticipated|Nationwide Children's Hospital||1|||f||||t||||||||Yes|A public use data set will be made available on the website of the NICHD's Collaborative Pediatric Critical Care Research Network.|2018-05-31 21:49:10.916395|2018-05-31 21:49:10.916395
NCT01495611|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-01-30|2011-12-16|2011-12-20|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2010|Actual|2010-11-30|January 2017|2017-01-31|April 30, 2017||2017-04-30|January 2016|Actual|2016-01-31||Observational|||Multicenter Perioperative Opioid Pharmacogenetic Study|Predicting Perioperative Opioid Adverse Effects and Personalizing Analgesia in Children: A Multicenter Pharmacogenetic Study|Completed|||1000|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||Samples With DNA|"~     A database/ repository will be constructed for future research, analysis, and recruitment.~     De-identified study subjects' genetic information and their responses to pain and pain~     medications, side-effects will be included in the database. Blood specimens will be included~     in the repository for exploring potentially important SNPs and biomarkers in future. No~     patient identifiers will be included in the repository and there will be a confidential~     (access limited to investigators only) code or link between the repository/database and other~     information about the participant.~   "|||2018-05-31 21:49:11.090982|2018-05-31 21:49:11.090982
NCT01495598|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2018-05-23|2011-12-16|2011-12-20|Estimate|||||||2018-05-23|2018-05-24|Actual|December 13, 2011||2011-12-13|April 23, 2018|2018-04-23|December 31, 2020|Anticipated|2020-12-31|December 1, 2020|Anticipated|2020-12-01||Interventional|||Pomalidomide for Kaposi Sarcoma in People With or Without HIV|A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV|Active, not recruiting||Phase 1/Phase 2|28|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:49:11.216637|2018-05-31 21:49:11.216637
NCT01495585|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2016-04-28||2016-07-18|2011-12-16|2011-12-20|Estimate|2016-07-18|2016-08-31|Estimate||||2016-07-18|2016-08-31|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||"Enrolled patients were sequentially assigned into one of two dosing groups which consisted of lonafarnib 100mg in group 1 and lonafarnib 200mg in group 2, with placebo controls in each group.~Group1 placebo patients received open-label lonafarnib as group 2 participants."|Lonafarnib for Chronic Hepatitis D|Treatment of Chronic Delta Hepatitis With Lonafarnib|Completed||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||Yes|De-identified data with outside collaborators|2018-05-31 21:49:11.340429|2018-05-31 21:49:11.340429
NCT01495572|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|2014-05-08||2015-10-13|2011-12-16|2011-12-20|Estimate|2014-05-08|2014-06-10|Estimate||||2015-10-13|2015-10-15|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells|Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin|Terminated||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|Due to slow accrual, the investigator decided to close the study.|2||Due to slow accrual, the investigator decided to close the study.|f||||t||||||||||2018-05-31 21:49:11.895054|2018-05-31 21:49:11.895054
NCT01495546|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2012-09-13|2011-12-19|2011-12-20|Estimate|||||||2012-09-13|2012-09-17|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|Latearly||Total Hip Arthroplasty (THA): Early Load Versus Load Late|Randomized Comparison of Quality of Life and Functional Patients Undergoing Total Hip Replacement Uncemented. Load Early X Load Late|Unknown status|Recruiting|N/A|45|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:49:12.429229|2018-05-31 21:49:12.429229
NCT01495533|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-05-05|2011-12-15|2011-12-20|Estimate|||||||2014-05-05|2014-05-06|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Paclitaxel-coated or Uncoated AngioSculpt Scoring Balloon Catheter|Treatment of Coronary In-stent Restenosis by a Paclitaxel Coated AngioSculpt Scoring Balloon - a First-in-man Pilot Study|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|University Hospital, Saarland||2|||f||||t||||||||||2018-05-31 21:49:12.579281|2018-05-31 21:49:12.579281
NCT01495520|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-03-06|2011-12-19|2011-12-20|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|RYPPLE||Ranolazine for Improving Symptoms of Palpitations|Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:49:12.669857|2018-05-31 21:49:12.669857
NCT01495507|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2016-07-16|2011-12-19|2011-12-20|Estimate|||||||2016-07-16|2016-07-19|Estimate|November 2011||2011-11-30|July 2016|2016-07-31||||January 2017|Anticipated|2017-01-31||Observational|||Validation of Kujala German|Cross-cultural Adaptation and Validation of the German Version of the Kujala Score in Patients With Patellofemoral Instability - a Prospective Multi-centric Study|Recruiting|||45|Anticipated|Medical University Innsbruck|||1||f||||||||||||||2018-05-31 21:49:12.750216|2018-05-31 21:49:12.750216
NCT01495494|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2014-11-20|2011-12-16|2011-12-20|Estimate|||||||2014-11-20|2014-11-24|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Multiple Use Tolerability Study of a Breathe Right Nasal Strip Prototype|A Multiple Use Tolerability Study of a Breathe Right Nasal Strip Prototype|Completed||Phase 1|80|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:49:12.830146|2018-05-31 21:49:12.830146
NCT01495481|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2016-02-18||2017-02-07|2011-12-19|2011-12-20|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|January 2012||2012-01-31|February 2017|2017-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Dexmedetomidine and Adenosine: Therapeutic Use for SVT|Dexmedetomidine Versus Adenosine: Electrophysiologic Effects and Therapeutic Use for Terminating Supraventricular Tachycardia|Completed||N/A|22|Actual|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 21:49:12.897269|2018-05-31 21:49:12.897269
NCT01495468|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-07-27|2011-12-16|2011-12-20|Estimate|||||||2017-07-27|2017-07-31|Actual|March 2007||2007-03-31|December 2011|2011-12-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Phase III Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children|Pegylated Somatropin in the Treatment of Children With Growth Hormone Deficient：A Multicenter, Randomized, Open-label, Controlled Phase Ⅲ Clinical Trial|Completed||Phase 3|343|Actual|GeneScience Pharmaceuticals Co., Ltd.|||||f||||t||||||||||2018-05-31 21:49:13.119368|2018-05-31 21:49:13.119368
NCT01495455|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2013-01-29|2011-12-15|2011-12-20|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Nottingham Osteoarthritis Biomarker Study 2011|Nottingham Osteoarthritis Biomarker Study 2011|Completed|||140|Actual|University of Nottingham|||2||f||||f||||||Samples With DNA|"~     Serum, urine and synovial fluid.~   "|||2018-05-31 21:49:13.287337|2018-05-31 21:49:13.287337
NCT01495442|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-01-20|2011-12-15|2011-12-20|Estimate|||||||2017-01-20|2017-01-24|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|DPI||Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques|Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques|Completed||N/A|6|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||||2018-05-31 21:49:13.429702|2018-05-31 21:49:13.429702
NCT01495429|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2015-08-03|2011-12-19|2011-12-20|Estimate|||||||2015-08-03|2015-08-04|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PICNIC||Peripherally Inserted Versus Centrally Inserted Central Venous Catheters in the Neurological Intensive Care|A Phase III Study of Peripherally Inserted Versus Centrally Inserted Central Venous Catheters in the Neurological Intensive Care Unit|Completed||Phase 3|80|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:49:13.532737|2018-05-31 21:49:13.532737
NCT01495403|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2015-07-29|2011-12-19|2011-12-20|Estimate|||||||2015-07-29|2015-07-30|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Treatment of Muscle Cramps in Patients With Liver Cirrhosis|A Pilot Study of Hydroxychloroquine for the Treatment of Muscle Cramps in Patients With Cirrhosis|Completed||Early Phase 1|3|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:49:13.630814|2018-05-31 21:49:13.630814
NCT01495390|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2017-05-24|2011-12-19|2011-12-20|Estimate|||||||2017-05-24|2017-05-30|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers|A Multicenter Study for the Discovery and Validation of ALS Biomarkers|Completed|||139|Actual|Massachusetts General Hospital|||||f||||t||||||Samples With DNA|"~     Biological samples will be collected from participants with ALS over time. These biological~     samples include blood (plasma, serum, and RNA) and cerebrospinal fluid (CSF). DNA will be~     collected at one time point.~   "|Undecided||2018-05-31 21:49:13.72459|2018-05-31 21:49:13.72459
NCT01495377|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2012-08-21|2011-12-19|2011-12-20|Estimate|||||||2012-08-21|2012-08-22|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Opioid Induced Swallowing Difficulties and Risk for Pulmonary Aspiration|Does Opioid Induced Swallowing Difficulty Lead to Elevated Risk for Pulmonary Aspiration?|Completed||Phase 4|25|Actual|Region Örebro County||4|||f||||t||||||||||2018-05-31 21:49:13.789642|2018-05-31 21:49:13.789642
NCT01495364|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2016-04-26|2011-12-16|2011-12-20|Estimate|||||||2016-04-26|2016-04-28|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|June 2014|Actual|2014-06-30||Interventional|PreSERVE-AMI||NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction|A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction.|Completed||Phase 2|195|Actual|Caladrius Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 21:49:13.989312|2018-05-31 21:49:13.989312
NCT01495351|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2017-09-21|2011-12-16|2011-12-20|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2011|Actual|2011-10-31|September 2017|2017-09-30|February 10, 2015|Actual|2015-02-10|February 2015|Actual|2015-02-28||Interventional|||Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma|Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma|Completed||Phase 1|19|Actual|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-05-31 21:49:14.15359|2018-05-31 21:49:14.15359
NCT01495338|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-09-13|2011-12-16|2011-12-20|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2011||2011-12-31|September 2017|2017-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Comparison of the Safety and Comfort of AC-170||Completed||Phase 1|60|Actual|Aciex Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 21:49:14.247608|2018-05-31 21:49:14.247608
NCT01495325|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-01-23|2011-12-15|2011-12-20|Estimate|||||||2013-01-23|2013-01-24|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|FIREWOOD||Effect of Woodsmoke on Vascular Function|Effect of Woodsmoke on Vascular Function in Healthy Firefighters|Unknown status|Recruiting|N/A|20|Anticipated|University of Edinburgh||2|||f||||t||||||||||2018-05-31 21:49:14.339471|2018-05-31 21:49:14.339471
NCT01495312|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2011-12-19|2011-12-19|2011-12-20|Estimate|||||||2011-12-19|2011-12-20|Estimate|December 2011||2011-12-31|December 2011|2011-12-31||||August 2012|Anticipated|2012-08-31||Interventional|||24-hr Intraocular Pressure (IOP) Patterns of Glaucoma Patients After Selective Laser Trabeculoplasty (SLT)||Unknown status|Recruiting|N/A|20|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 21:49:14.540371|2018-05-31 21:49:14.540371
NCT01495299|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2011-12-19|2011-12-19|2011-12-20|Estimate|||||||2011-12-19|2011-12-20|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|||24-hour IOP Fluctuation Profile Recorded With SENSIMED Triggerfish in Primary Open-angle Glaucoma (POAG) Patients After Cataract Surgery||Unknown status|Recruiting||20|Anticipated|University of California, San Diego|||1||f||||f||||||||||2018-05-31 21:49:14.656249|2018-05-31 21:49:14.656249
NCT01495286|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2012-09-17||2012-10-18|2011-12-15|2011-12-20|Estimate|2012-10-18|2012-11-19|Estimate||||2012-10-18|2012-11-19|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety of Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) in Infants|Is the Use of Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) During a Routine Heelstick Safe in Infants?|Completed||N/A|30|Actual|University of Arkansas|This was a small pilot study to determine safety of a TENS unit to deliver NESAP to newborn infants during routine heel sticks. The purpose was not to determine efficacy of NESAP to relieve pain during heel sticks. A large clinical trial will follow.||||f||||t||||||||||2018-05-31 21:49:14.754993|2018-05-31 21:49:14.754993
NCT01495273|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2016-10-24|2011-12-15|2011-12-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2017||2017-05-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Electrically Guided Needle Insertion: Transtracheal Injection|Adaptation of Nerve Stimulation Technology to Aid Transtracheal Needle Insertion and Injection|Not yet recruiting||N/A|30|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 21:49:14.976631|2018-05-31 21:49:14.976631
NCT01495260|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2016-09-16|2011-12-16|2011-12-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants|A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E|Completed||Phase 2|13|Actual|Onofre, Aurora Pujol, M.D.||1|||f||||f||||||||||2018-05-31 21:49:15.063717|2018-05-31 21:49:15.063717
NCT01495247|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2014-07-22|2011-12-15|2011-12-19|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer|A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|18|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:49:15.142682|2018-05-31 21:49:15.142682
NCT01495234|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-15|2011-12-19|Estimate|||||||2013-08-01|2013-08-02|Estimate|October 1996||1996-10-31|December 2011|2011-12-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Pilot Study of rhBMP-2/BCP in Patients With Spinal Degeneration With Instability Requiring Surgical Fusion|A Pilot Investigation of Recombinant Human Bone Morphogenetic Protein- 2/Biphasic Calcium Phosphate in Patients With Spinal Degeneration With Instability Requiring Surgical Fusion|Completed||N/A|15|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-05-31 21:49:15.257139|2018-05-31 21:49:15.257139
NCT01495221|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2015-12-30|2011-12-16|2011-12-19|Estimate|||||||2015-12-30|2015-12-31|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||To Evaluate tHe rOle of Intravitreal Aflibercept Injection (2.0 mg) in the Management of previousLy Treated Patients With Exudative AMD|To Evaluate tHe rOle of Intravitreal Aflibercept Injection (2.0 mg) in the Management of previousLy Treated Patients With Exudative AMD|Completed||Phase 4|9|Actual|Vitreous -Retina- Macula Consultants of New York||1|||f||||f||||||||||2018-05-31 21:49:15.355311|2018-05-31 21:49:15.355311
NCT01495208|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-08-01|2011-12-16|2011-12-19|Estimate|||||||2013-08-01|2013-08-02|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment|This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg|Completed||Phase 4|6|Actual|Vitreous -Retina- Macula Consultants of New York||1|||f||||f||||||||||2018-05-31 21:49:15.491578|2018-05-31 21:49:15.491578
NCT01495195|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-12-17|2011-12-16|2011-12-19|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SDC||Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior||Completed||Phase 2|12|Actual|Midwest Biomedical Research Foundation||4|||f||||t||||||||||2018-05-31 21:49:15.627059|2018-05-31 21:49:15.627059
NCT01495182|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2016-04-20|2011-12-15|2011-12-19|Estimate|||||||2016-04-20|2016-04-21|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Dietary Fiber on Gastrointestinal Function|A Double-blind, Randomized, Crossover Trial to Assess the Gastrointestinal Tolerability of a Dietary Fiber Ingredient in Healthy Men and Women|Completed||N/A|26|Actual|Ingredion Incorporated||3|||f||||f||||||||||2018-05-31 21:49:15.780662|2018-05-31 21:49:15.780662
NCT01495169|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-06-10|2011-12-15|2011-12-19|Estimate|||||||2016-06-10|2016-06-13|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients|A Multicenter, Open-label, Sequential Cohort, Dose-escalation, 14-day Study to Explore the Tolerability and Pharmacokinetics of Iloperidone 12 to 24 mg/Day Followed by 26 Weeks of Flexible Dosing (6 to 24 mg/Day) in Adolescent Patients (Aged 12 to 17 Years)|Completed||Phase 1|33|Actual|Vanda Pharmaceuticals||1|||f||||||||||||||2018-05-31 21:49:15.892026|2018-05-31 21:49:15.892026
NCT01495156|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-01-21|2011-12-15|2011-12-19|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania|A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Adjunctive Lithium for the Treatment of Psychotic Mania Followed by an Open Label Long-term Safety Period.|Withdrawn||Phase 4|0|Actual|Northwell Health||2|||f||||f||||||||||2018-05-31 21:49:15.973759|2018-05-31 21:49:15.973759
NCT01495143|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2014-09-12|2011-12-15|2011-12-19|Estimate|||||||2014-09-12|2014-09-15|Estimate|January 2007||2007-01-31|September 2014|2014-09-30|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Surgical Stress Measured by Microdialysis|Microdialysis of Paraspinal Muscle in Healthy Volunteers and Patients Underwent Posterior Lumbar Fusion Surgery|Completed||N/A|16|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:49:16.033026|2018-05-31 21:49:16.033026
NCT01495130|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-01-27|2011-12-16|2011-12-19|Estimate|||||||2014-01-27|2014-01-29|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery|Mechanically-Manipulated Transrectal Ultrasound (TRUS) During Robotic-Assisted Laparoscopic Prostatectomy (RALP)|Completed||N/A|11|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 21:49:16.08874|2018-05-31 21:49:16.08874
NCT01495117|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-12-19|2011-12-15|2011-12-19|Estimate|||||||2016-12-19|2016-12-21|Estimate|October 2011||2011-10-31|December 2016|2016-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CHG||Study of Chlorhexidine Gluconate as a Preoperative Antisepsis|Comparison of Chlorhexidine Gluconate and Povidone Iodine as a Preoperative Antisepsis in Clean-contaminated Abdominal Surgery : a Randomized Prospective Trial|Completed||Phase 3|534|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 21:49:16.153998|2018-05-31 21:49:16.153998
NCT01495104|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-11-01|2011-12-16|2011-12-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers|A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE VALPROATE ON THE PHARMACOKINETICS OF RO4917838 AND VICE VERSA IN HEALTHY MALE VOLUNTEERS|Completed||Phase 1|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:49:16.250775|2018-05-31 21:49:16.250775
NCT01495091|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2012-09-11|2011-12-16|2011-12-19|Estimate|||||||2012-09-11|2012-09-12|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|December 2040|Anticipated|2040-12-31|December 2014|Anticipated|2014-12-31||Observational|CADENCE||Markers of Coronary Artery Disease During Exercise Testing|Markers of Coronary Artery Disease During Exercise Testing|Recruiting|||600|Anticipated|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood, serum.~   "|||2018-05-31 21:49:16.318968|2018-05-31 21:49:16.318968
NCT01495078|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-02-13|2011-12-15|2011-12-19|Estimate|||||||2016-02-13|2016-02-17|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|June 2013|Actual|2013-06-30||Interventional|ICOR||Telemonitoring and Teleintervention of Heart Failure and Decrease of Non-fatal Events.|Telemonitoring and Teleintervention of Heart Failure and Decrease of Non-fatal Events.|Completed||N/A|178|Actual|Parc de Salut Mar||2|||f||||f||||||||No||2018-05-31 21:49:16.501683|2018-05-31 21:49:16.501683
NCT01495065|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-06-13|2011-12-15|2011-12-19|Estimate|||||||2017-06-13|2017-06-15|Actual|December 19, 2011|Actual|2011-12-19|June 2017|2017-06-30|February 17, 2012|Actual|2012-02-17|February 17, 2012|Actual|2012-02-17||Interventional|||A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers|A Two Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK2251052 After Single Ascending Dosesand Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and a Repeat Dose Study to Evaluatesupratherapeutic Doses of IV GSK2251052 in Healthy Volunteers|Terminated||Phase 1|8|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:49:16.62926|2018-05-31 21:49:16.62926
NCT01495052|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2011-12-15|2011-12-15|2011-12-19|Estimate|||||||2011-12-15|2011-12-19|Estimate|August 2011||2011-08-31|December 2011|2011-12-31||||November 2011|Actual|2011-11-30||Interventional|||Effect of Organic Naked Oat With Whole Germ on Type 2 Diabetes Mellitus||Completed||N/A|445|Actual|Peking University||4|||f||||f||||||||||2018-05-31 21:49:16.852937|2018-05-31 21:49:16.852937
NCT01495039|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-04-03|2011-12-16|2011-12-19|Estimate|||||||2017-04-03|2017-04-05|Actual|November 2008||2008-11-30|April 2017|2017-04-30|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients|The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients|Completed||Phase 4|99|Actual|Policlinico Hospital||2|||f||||t||||||||||2018-05-31 21:49:16.929674|2018-05-31 21:49:16.929674
NCT01495026|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-05-17|2011-12-15|2011-12-19|Estimate|||||||2018-05-17|2018-05-18|Actual|November 6, 2011|Actual|2011-11-06|May 2018|2018-05-31|April 3, 2012|Actual|2012-04-03|April 3, 2012|Actual|2012-04-03||Interventional|||A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia|An Open-label, Randomized, Single Dose, Multi-stage, Cross-over Study to Determine the Relative Bioavailability of Fixed Dose Combination Products Containing a 3-oblong Dutasteride Soft Gel Capsule and Tamsulosin (0.5 mg Dutasteride /0.2 mg Tamsulosin HCl) Pellets Having a Range of Tamsulosin Release Rates Produced by Different Mixtures of Enteric Coated and Uncoated Pellets Relative to Harnal-D Tablets, in Healthy Male Subjects of North East Asian Ancestry.|Completed||Phase 1|63|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:49:17.022061|2018-05-31 21:49:17.022061
NCT01495013|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15||2014-03-06|2016-11-18|2011-12-15|2011-12-19|Estimate||||2014-03-06|2014-04-03|Estimate|2016-11-18|2016-11-21|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus|Study ATG115317, a Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|427|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:49:17.15698|2018-05-31 21:49:17.15698
NCT01495000|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2013-09-12||2014-01-09|2011-12-15|2011-12-19|Estimate|2013-11-27|2013-12-25|Estimate||||2014-01-09|2014-02-07|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab|A Six-Month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Indian Postmenopausal Women With Osteoporosis|Completed||Phase 3|250|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:49:18.377116|2018-05-31 21:49:18.377116
NCT01494987|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2014-08-21|2013-12-12|2014-11-05|2011-12-16|2011-12-19|Estimate|2014-08-21|2014-09-01|Estimate|2013-12-12|2014-01-14|Estimate|2014-11-05|2014-11-18|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Baseline characteristics are reported for the Safety Analysis Set following randomization. The Safety Analysis Set includes randomized participants who received at least one dose of study treatment.|Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|431|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:49:19.259104|2018-05-31 21:49:19.259104
NCT01494974|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-04-06|2011-12-16|2011-12-19|Estimate|||||||2014-04-06|2014-04-08|Estimate|December 2011||2011-12-31|April 2014|2014-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma|Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial.|Unknown status|Recruiting|Phase 4|40|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:49:20.221898|2018-05-31 21:49:20.221898
NCT01494961|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-16|2011-12-16|2011-12-19|Estimate|||||||2011-12-16|2011-12-19|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|Prenahtest||Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries|The Public Health Impact of Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries|Completed||N/A|1943|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||f||||||||||2018-05-31 21:49:20.326448|2018-05-31 21:49:20.326448
NCT01494948|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-01-07|2011-12-15|2011-12-19|Estimate|||||||2014-01-07|2014-01-08|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Innate Immunity and the Allergic Response|Innate Immunity and the Allergic Response|Completed||N/A|36|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 21:49:20.404837|2018-05-31 21:49:20.404837
NCT01494935|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-08-31|2011-12-15|2011-12-19|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2011||2011-04-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||"Effect of High Fat and High Glycemic Diets"|Effect of High Fat and High Glycemic Diets on Muscle Protein Synthesis in Somali Immigrants and Americans of Northern European Descent|Recruiting||N/A|24|Anticipated|Mayo Clinic||2|||f||||||||||||||2018-05-31 21:49:20.617667|2018-05-31 21:49:20.617667
NCT01494922|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15||2014-10-15|2014-11-06|2011-12-16|2011-12-19|Estimate||||2014-11-06|2014-11-20|Estimate|2014-11-06|2014-11-20|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001|A Phase 2, Open-label Study to Provide Revision of Scars Resulting From Surgery in Prior Studies of EXC 001 (Currently Called PF-06473871)|Completed||Phase 2|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:49:20.758853|2018-05-31 21:49:20.758853
NCT01494909|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-04-24|2011-12-16|2011-12-19|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2011||2011-01-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|July 2012|Actual|2012-07-31||Interventional|||Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function|Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function|Active, not recruiting||N/A|31|Anticipated|Texas A&M University||1|||f||||f||||||||||2018-05-31 21:49:20.855619|2018-05-31 21:49:20.855619
NCT01494896|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2015-05-06|2011-12-16|2011-12-19|Estimate|||||||2015-05-06|2015-05-07|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching|An Open-Label Study to Explore the Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching When Used for Treatment of Group 1 Pulmonary Arterial Hypertension in Patients With Concomitant Chronic Obstructive Pulmonary Disease (COPD)|Terminated|||9|Actual|University of Florida||||due to slow enrollment. United Therapeutics and Dr. Bajwa MD decided to terminate study|f||||f||||||||||2018-05-31 21:49:20.927566|2018-05-31 21:49:20.927566
NCT01494883|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-09-09|2011-12-15|2011-12-19|Estimate|||||||2015-09-09|2015-09-11|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Mindfulness for Lung Cancer Patients and Partners|Mindfulness Based Stress Reduction (MBSR) for Patients With Lung Cancer and Their Partners: a Randomized Controlled Trial.|Completed||N/A|107|Actual|Radboud University||2|||f||||||||||||||2018-05-31 21:49:20.996245|2018-05-31 21:49:20.996245
NCT01494870|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-01-07|2011-12-16|2011-12-19|Estimate|||||||2012-01-07|2012-01-10|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|November 2013|Anticipated|2013-11-30|June 2013|Anticipated|2013-06-30||Interventional|||Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block||Unknown status|Not yet recruiting|N/A|300|Anticipated|Samara Regional Cardiology Dispensary|||||f||||f||||||||||2018-05-31 21:49:21.088346|2018-05-31 21:49:21.088346
NCT01494857|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-10-28|2011-12-16|2011-12-19|Estimate|||||||2012-10-28|2012-10-30|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis|Open-Label, Non-Randomized, Single Patient Group, Multi-Center Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Moderately to Severely Active Ulcerative Colitis|Unknown status|Recruiting|Phase 3|200|Anticipated|Clalit Health Services||1|||f||||f||||||||||2018-05-31 21:49:21.190788|2018-05-31 21:49:21.190788
NCT01494844|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-08-07|2011-12-15|2011-12-19|Estimate|||||||2013-08-07|2013-08-09|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces|Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces|Completed||Early Phase 1|30|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 21:49:21.343087|2018-05-31 21:49:21.343087
NCT01494831|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-01-17|2011-12-16|2011-12-19|Estimate|||||||2012-01-17|2012-01-18|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Randomized Control Trial of Group Intervention With Former War-affected Boys in the Democratic Republic of Congo|Evaluation of a Group-based, Cognitive-behavioural Intervention With Former Child Soldiers and Other War-affected Children in the Democratic Republic of Congo: A Randomised Controlled Trial.|Completed||Phase 2|58|Actual|Queen's University, Belfast||2|||f||||t||||||||||2018-05-31 21:49:21.694363|2018-05-31 21:49:21.694363
NCT01494818|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2013-07-30||2013-07-30|2011-12-16|2011-12-19|Estimate|2013-07-30|2013-09-27|Estimate||||2013-07-30|2013-09-27|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||This reporting group includes all enrolled and dispensed participants who completed the study.|Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues|Evaluation of the Effects of Clear Care/AOSEPT Plus Hydrogen Peroxide Solution on the Eyelid Tissues - Part II: Comparative Evaluation With RENU MPS Over 3 Months of Wear|Completed||N/A|79|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:49:21.834298|2018-05-31 21:49:21.834298
NCT01494805|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-08-30|2011-12-15|2011-12-19|Estimate|||||||2017-08-30|2017-09-01|Actual|December 2011|Actual|2011-12-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|AMD||Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration|A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)|Completed||Phase 1/Phase 2|40|Actual|Lions Eye Institute, Perth, Western Australia||3|||f||||t||||||||||2018-05-31 21:49:22.316211|2018-05-31 21:49:22.316211
NCT01494792|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-10-05|2011-12-16|2011-12-19|Estimate|||||||2012-10-05|2012-10-10|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Sofia Strep A FIA Field Study|Sofia Strep A FIA Field Study|Terminated|||2090|Actual|Quidel Corporation||||Performance did not meet sponsor requirements.|f||||f||||||||||2018-05-31 21:49:22.47287|2018-05-31 21:49:22.47287
NCT01494779|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-09-21|2011-12-16|2011-12-19|Estimate|||||||2012-09-21|2012-09-25|Estimate|March 2013||2013-03-31|September 2012|2012-09-30|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A.||Unknown status|Not yet recruiting|Phase 1|32|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 21:49:22.560958|2018-05-31 21:49:22.560958
NCT01494766|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-04-25|2011-12-16|2011-12-19|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2012||2012-01-31|April 2017|2017-04-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|||Efficacy of Tyrosine in Restless Legs Syndrome|Pilot Study of the Efficacy of Tyrosine in Restless Legs Syndrome|Completed||N/A|5|Actual|Seton Healthcare Family||1|||f||||f||||||||||2018-05-31 21:49:22.800053|2018-05-31 21:49:22.800053
NCT01494753|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2014-11-12||2014-12-22|2011-12-15|2011-12-19|Estimate|2014-12-22|2015-01-06|Estimate||||2014-12-22|2015-01-06|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension||Completed||Phase 2|30|Actual|Laboratoires Thea||2|||f||||||||||||||2018-05-31 21:49:22.869882|2018-05-31 21:49:22.869882
NCT01494740|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-16|2011-12-16|2011-12-19|Estimate|||||||2011-12-16|2011-12-19|Estimate|December 2009||2009-12-31|October 2009|2009-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants|Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants|Completed||Phase 2|312|Actual|Shanghai Institute Of Biological Products||3|||f||||t||||||||||2018-05-31 21:49:23.070674|2018-05-31 21:49:23.070674
NCT01494727|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-04-29|2011-12-16|2011-12-19|Estimate|||||||2012-04-29|2012-05-01|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|48|Anticipated|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 21:49:23.138063|2018-05-31 21:49:23.138063
NCT01494714|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-10-30|2011-12-15|2011-12-19|Estimate|||||||2012-10-30|2012-10-31|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants|A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Subjects|Completed||Phase 1|30|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 21:49:23.227183|2018-05-31 21:49:23.227183
NCT01494701|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2017-04-05|2011-12-15|2011-12-19|Estimate|||||||2017-04-05|2017-04-06|Actual|November 30, 2011|Actual|2011-11-30|April 2017|2017-04-30|January 31, 2013|Actual|2013-01-31|January 31, 2013|Actual|2013-01-31||Interventional|SMNRx||An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)|An Open-label, Escalating Dose Study to Assess the Safety, Tolerability and Dose-range Finding of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy|Completed||Phase 1|28|Actual|Biogen||4|||t||||t||||||||||2018-05-31 21:49:23.400219|2018-05-31 21:49:23.400219
NCT01494688|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2018-03-14|2011-12-15|2011-12-19|Estimate|||||||2018-03-14|2018-03-16|Actual|December 20, 2011|Actual|2011-12-20|March 2018|2018-03-31|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors|Open-Label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|217|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:49:23.559758|2018-05-31 21:49:23.559758
NCT01494675|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-15|2011-12-15|2011-12-19|Estimate|||||||2011-12-15|2011-12-19|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU|Clinical Impact of Procalcitonin to Shorten Antimicrobial Therapy in Septic Patients With Proven Bacterial Infection in an Intensive Care Setting|Completed||N/A|81|Actual|Hospital Israelita Albert Einstein|||||f||||t||||||||||2018-05-31 21:49:23.69178|2018-05-31 21:49:23.69178
NCT01494662|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2018-01-24|2011-12-15|2011-12-19|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2012||2012-02-29|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||HKI-272 for HER2-Positive Breast Cancer and Brain Metastases|A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases|Active, not recruiting||Phase 2|96|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||Undecided||2018-05-31 21:49:23.762918|2018-05-31 21:49:23.762918
NCT01494649|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2013-03-21||2013-03-21|2011-12-15|2011-12-19|Estimate|2013-03-21|2013-05-08|Estimate||||2013-03-21|2013-05-08|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity|A Pilot Clinical Study Investigating the Efficacy of a Toothpaste in Providing Immediate and Short Term Relief From Dentinal Hypersensitivity|Completed||N/A|118|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:49:23.965124|2018-05-31 21:49:23.965124
NCT01494636|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-06-19|2011-12-15|2011-12-19|Estimate|||||||2017-06-19|2017-06-20|Actual|October 17, 2011|Actual|2011-10-17|June 2017|2017-06-30|March 15, 2012|Actual|2012-03-15|March 15, 2012|Actual|2012-03-15||Interventional|FTIH||The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects|A Two Part Study to Investigate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2339345 in Healthy Subjects. Part A: an Open Label, Dose Escalating, Rinse, Gargle and Spit Study. Part B: a Randomised, Double-blind, Placebo Controlled, Inhaled Dose Escalating Study Using Nebulised Lidocaine for Blinding Purposes.|Completed||Phase 1|31|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:49:24.43574|2018-05-31 21:49:24.43574
NCT01494623|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-06-10|2011-12-16|2011-12-19|Estimate|||||||2013-06-10|2013-06-11|Estimate|May 2006||2006-05-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory|Treating Working Memory Deficits in Patients With Schizophrenia Using Repetitive Transcranial Magnetic Stimulation (rTMS)|Completed||N/A|122|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 21:49:24.574638|2018-05-31 21:49:24.574638
NCT01494610|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2012-02-16||2017-07-14|2011-12-15|2011-12-19|Estimate|2012-04-19|2012-05-23|Estimate||||2017-07-14|2017-08-21|Actual|October 25, 2010|Actual|2010-10-25|July 2017|2017-07-31|June 8, 2011|Actual|2011-06-08|June 8, 2011|Actual|2011-06-08||Interventional|||Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry Powder Inhaler, in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.|Completed||Phase 2|60|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:49:24.744221|2018-05-31 21:49:24.744221
NCT01494597|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-16|2011-12-16|2011-12-19|Estimate|||||||2011-12-16|2011-12-19|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Drug Interaction Study of Isavuconazole and Cyclosporine|Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Cyclosporine: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:49:26.575949|2018-05-31 21:49:26.575949
NCT01494584|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2014-07-10||2017-04-25|2011-12-15|2011-12-19|Estimate|2014-08-21|2014-09-04|Estimate||||2017-04-25|2017-05-25|Actual|July 25, 2012|Actual|2012-07-25|April 2017|2017-04-30|April 29, 2013|Actual|2013-04-29|April 29, 2013|Actual|2013-04-29||Interventional|||Study in Pediatric Subjects With Epilepsy|Open-label, Multiple Dose Study to Evaluate the Parmacokinetics, Safety and Tolerability of Ezogabine/Retigabine as Adjunctive Treatment in Subjects Aged From 12 Years to Less Than 18 Years With Partial Onset Seizures or Lennox-Gastaut Syndrome|Terminated||Phase 2|5|Actual|GlaxoSmithKline||1||Terminated after placing the study on hold at the request of the FDA|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:49:26.706016|2018-05-31 21:49:26.706016
NCT01494571|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-03-06|2011-12-15|2011-12-19|Estimate|||||||2013-03-06|2013-03-07|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|PharmaJet||Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System|Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System|Completed|||101|Actual|University of Colorado, Denver|||7||f||||f||||||||||2018-05-31 21:49:28.293456|2018-05-31 21:49:28.293456
NCT01494558|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-16|2011-12-16|2011-12-19|Estimate|||||||2011-12-16|2011-12-19|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|October 2010|Actual|2010-10-31||Interventional|||Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer|Phase 3 Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy in Patients With Unresectable Locally Advanced, Stage III Non-Small Cell Lung Cancer|Completed||Phase 2/Phase 3|200|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:49:28.401935|2018-05-31 21:49:28.401935
NCT01494545|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2013-05-01||2013-07-12|2011-12-15|2011-12-19|Estimate|2013-05-01|2013-06-25|Estimate||||2013-07-12|2013-07-19|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||This reporting group includes all enrolled participants who were dispensed study product.|Performance Evaluation of DAILIES® TOTAL1™ in First Time Contact Lens Wearers|Performance Evaluation of DAILIES® TOTAL1™ in First Time Contact Lens Wearers|Completed||N/A|102|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:49:28.750873|2018-05-31 21:49:28.750873
NCT01494532|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2015-07-13||2017-06-10|2011-12-15|2011-12-19|Estimate|2015-11-02|2015-12-03|Estimate||||2017-06-10|2017-07-11|Actual|April 2, 2012|Actual|2012-04-02|June 2017|2017-06-30|November 18, 2014|Actual|2014-11-18|November 18, 2014|Actual|2014-11-18||Interventional|TANDEM-569||A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease|A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease|Completed||Phase 4|352|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:49:29.57|2018-05-31 21:49:29.57
NCT01494519|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2017-04-20|2011-12-15|2011-12-19|Estimate|||||||2017-04-20|2017-04-21|Actual|July 2011||2011-07-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|FIXIT||Assessment of Fixation Strategies for Severe Open Tibia Fractures|A Prospective Randomized Trial to Assess Fixation Strategies for Severe Open Tibia Fractures:Modern Ring External Fixators Versus Internal Fixation|Recruiting||Phase 3|624|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t||||||||||2018-05-31 21:49:31.785003|2018-05-31 21:49:31.785003
NCT01494506|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2015-11-25|2014-12-23|2016-06-16|2011-12-15|2011-12-19|Estimate|2016-02-11|2016-02-12|Estimate|2014-12-23|2015-01-12|Estimate|2016-06-16|2016-06-17|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|February 2014|Actual|2014-02-28||Interventional|NAPOLI-1|All randomized patients.|Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer|A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy|Completed||Phase 3|417|Actual|Merrimack Pharmaceuticals||3|||f||||t||||||||||2018-05-31 21:49:31.979427|2018-05-31 21:49:31.979427
NCT01494493|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-15|2011-12-19|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2000||2000-09-30|December 2011|2011-12-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|Terminated||N/A|85|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-05-31 21:49:33.711583|2018-05-31 21:49:33.711583
NCT01494480|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-06-18|2011-12-15|2011-12-19|Estimate|||||||2012-06-18|2012-06-20|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|April 2015|Anticipated|2015-04-30|January 2013|Anticipated|2013-01-31||Interventional|||The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis|The Clinical Study on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis|Unknown status|Enrolling by invitation|Phase 2|30|Anticipated|General Hospital of Chinese Armed Police Forces||1|||f||||t||||||||||2018-05-31 21:49:33.798303|2018-05-31 21:49:33.798303
NCT01494467|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2015-01-08|2014-01-27|2015-01-15|2011-12-15|2011-12-19|Estimate|2015-01-15|2015-01-16|Estimate|2014-01-27|2014-02-28|Estimate|2015-01-15|2015-01-16|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||ITT population|Phase 3 Papulopustular Rosacea Study|A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.|Completed||Phase 3|688|Actual|Galderma||2|||f||||t||||||||||2018-05-31 21:49:33.915379|2018-05-31 21:49:33.915379
NCT01494454|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-15|2011-12-19|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 1999||1999-08-31|December 2011|2011-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Clinical Study of rhBMP-2/BCP With the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease|A Clinical Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With Either the TSRH® Spinal System or the CD Horizon® Spinal System for Posterolateral Lumbar Fusion in Patients With DDD|Completed||N/A|197|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-05-31 21:49:34.814281|2018-05-31 21:49:34.814281
NCT01493583|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-03-06|2011-12-14|2011-12-16|Estimate|||||||2013-03-06|2013-03-07|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Central Nervous Processing of Visual Food Stimuli in Severely Obese Subjects|Central Nervous Processing of Visual Food Stimuli in Severely Obese Subjects and After Roux-en Y Gastric Bypass Surgery - a fMRI Study|Completed|||38|Actual|Cantonal Hospital of St. Gallen|||3||f||||f||||||||||2018-05-31 21:49:46.510809|2018-05-31 21:49:46.510809
NCT01494441|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-15|2011-12-19|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 1999||1999-05-31|December 2011|2011-12-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease|A Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease|Completed||N/A|27|Actual|Medtronic Spinal and Biologics||3|||f||||f||||||||||2018-05-31 21:49:34.929242|2018-05-31 21:49:34.929242
NCT01494428|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-15|2011-12-19|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 1998||1998-04-30|December 2011|2011-12-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||A Pilot Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|Completed||N/A|46|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-05-31 21:49:35.05009|2018-05-31 21:49:35.05009
NCT01494415|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-12-13|2011-12-15|2011-12-19|Estimate|||||||2015-12-13|2015-12-15|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|July 2016|Anticipated|2016-07-31||Interventional|||Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer|A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer|Unknown status|Recruiting|Phase 2|21|Anticipated|First People's Hospital of Hangzhou||1|||f||||t||||||||||2018-05-31 21:49:35.120183|2018-05-31 21:49:35.120183
NCT01494402|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-04-06|2011-12-16|2011-12-19|Estimate|||||||2012-04-06|2012-04-09|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects|A Phase I, Open Label, Randomized, Single Center, 2 Way Crossover Bioequivalence Study Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic Acid 81 mg) With a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects|Completed||Phase 1|77|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:49:35.201241|2018-05-31 21:49:35.201241
NCT01494389|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2011-12-16|2011-12-16|2011-12-19|Estimate|||||||2011-12-16|2011-12-19|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||The Changes of CD4+T Lymphocyte Subsets in Septic Patients|The Role of CD4+T Lymphocyte Subsets in Cell Immunity in Patients With Sepsis|Unknown status|Active, not recruiting||||Chinese PLA General Hospital|||3||f||||t||||||||||2018-05-31 21:49:35.267694|2018-05-31 21:49:35.267694
NCT01494376|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-03-08|2011-12-15|2011-12-19|Estimate|||||||2012-03-08|2012-03-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:49:35.321284|2018-05-31 21:49:35.321284
NCT01494363|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-14|2011-12-14|2011-12-19|Estimate|||||||2011-12-14|2011-12-19|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer|Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer|Unknown status|Recruiting|Phase 2|53|Anticipated|Soon Chun Hyang University|||||f||||f||||||||||2018-05-31 21:49:35.420293|2018-05-31 21:49:35.420293
NCT01494350|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2014-12-09||2014-12-18|2011-12-15|2011-12-19|Estimate|2014-12-18|2014-12-19|Estimate||||2014-12-18|2014-12-19|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||modified intent to treat (mITT)/safety subjects|WR 279,396 Open Label Treatment Protocol in Tunisia|Open-label Treatment of Non-complicated, Non-severe, Cutaneous Leishmaniasis in Tunisia With WR 279,396 (Paromomycin + Gentamicin Topical Cream) )|Terminated||Phase 2|50|Actual|U.S. Army Medical Research and Materiel Command|This study was closed prematurely due study team and travel restrictions but not due to any safety issues with the study subjects. Only a total of 50 of the 110 planned subjects were enrolled in the study.|1||This study was closed prematurely due study team travel restrictions.|f||||f||||||||||2018-05-31 21:49:35.510739|2018-05-31 21:49:35.510739
NCT01494337|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-08-25|2011-12-16|2011-12-19|Estimate|||||||2014-08-25|2014-08-26|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP)|Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH|Completed||Phase 4|108|Actual|Royal Victoria Hospital, Canada||2|||f||||f||||||||||2018-05-31 21:49:35.736281|2018-05-31 21:49:35.736281
NCT01494324|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-01-22|2011-12-14|2011-12-19|Estimate|||||||2018-01-22|2018-01-23|Actual|October 27, 2009||2009-10-27|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome|Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome|Recruiting||N/A|160|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:49:35.811842|2018-05-31 21:49:35.811842
NCT01494311|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-03-15|2011-12-15|2011-12-16|Estimate|||||||2013-03-15|2013-03-18|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Rapydan Topical Anaesthesia for Arterial Cannulation|Lidocaine/Tetracaine Patch (Rapydan) for Topical Anaesthesia Before Arterial Access: A Double-blind, Randomized Trial|Completed||Phase 4|90|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:49:35.936058|2018-05-31 21:49:35.936058
NCT01494298|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2013-06-19||2013-10-23|2011-12-15|2011-12-16|Estimate|2013-10-23|2013-12-13|Estimate||||2013-10-23|2013-12-13|Estimate|December 2011||2011-12-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|LAAD|The primary objective of this project was to determine the difference in Apo B levels in African-American men with and without diabetes.To achieve a power of 80%, 48 subjects in each group were needed to detect 15 mg/dL difference in ApoB levels, assuming a standard deviation of 26 mg/dL if alpha was set at 0.05.|Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes|Preliminary Analysis of Lipoprotein Subclasses, Apoprotein Levels, and Genetic Architecture of African-American Males With Type 2 Diabetes. Lipids in African Americans With Type 2 Diabetes|Completed|||111|Actual|Mercer University|||2||f||||f||||||Samples With DNA|"~     We will retain a sample of serum, plasma and whole blood.~   "|||2018-05-31 21:49:36.036992|2018-05-31 21:49:36.036992
NCT01494285|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-12-01|2011-12-15|2011-12-16|Estimate|||||||2013-12-01|2013-12-03|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients|Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group, Ambulatory Safety and Efficacy Study of ARK-E021 Topical Foam of 5% and 10% in Subjects With Mild to Moderate Acne Vulgaris.|Completed||Phase 1/Phase 2|157|Actual|M. Arkin 1999 Ltd.||3|||f||||f||||||||||2018-05-31 21:49:36.335217|2018-05-31 21:49:36.335217
NCT01494272|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2015-11-23|2011-12-15|2011-12-16|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|April 2014|Actual|2014-04-30||Observational|||Analgesia in Children Using Caudal Epidural Ropivacaine|Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine: A Prospective, Randomized, Double-blinded, Controlled Study|Completed|||90|Actual|Loma Linda University|||3||f||||f||||||||||2018-05-31 21:49:36.405323|2018-05-31 21:49:36.405323
NCT01494259|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2015-10-09|2011-12-15|2011-12-16|Estimate|||||||2015-10-09|2015-10-14|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|||Bupivacaine Pain Pumps to Decrease Mastectomy Post-Operative Pain|Use of Percutaneously-Placed Continuous Flow Bupivacaine Pain Pumps to Decrease Post-operative Pain Following Mastectomy With Immediate Reconstruction: A Prospective, Randomized, Double-Blind Clinical Trial|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:49:36.514941|2018-05-31 21:49:36.514941
NCT01494246|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-06-18|2011-12-15|2011-12-16|Estimate|||||||2014-06-18|2014-06-19|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|September 2013|Actual|2013-09-30||Interventional|TABATIC||Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption|Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption (TABATIC). A Randomized Controlled Multicentric Trial|Unknown status|Active, not recruiting|Phase 4|1064|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 21:49:36.672509|2018-05-31 21:49:36.672509
NCT01494233|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13||2015-03-03|2015-03-03|2011-12-14|2011-12-16|Estimate||||2015-03-03|2015-03-23|Estimate|2015-03-03|2015-03-23|Estimate|February 2012||2012-02-29|March 2015|2015-03-31||||September 2013|Actual|2013-09-30||Interventional|||A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|Completed||Phase 2|373|Actual|Lexicon Pharmaceuticals||4|||f||||f||||||||||2018-05-31 21:49:36.764679|2018-05-31 21:49:36.764679
NCT01494220|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-04-03|2011-12-14|2011-12-16|Estimate|||||||2012-04-03|2012-04-04|Estimate|June 2007||2007-06-30|April 2012|2012-04-30|February 2011|Actual|2011-02-28|March 2010|Actual|2010-03-31||Observational|||Validation of the Bispectral Index Monitor During Living Donor Liver Transplantation|Validation of the Bispectral Index Monitor During Living Donor Liver Transplantation|Completed|||42|Actual|Mansoura University|||1||f||||t||||||||||2018-05-31 21:49:37.157238|2018-05-31 21:49:37.157238
NCT01494207|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-02-24|2011-12-15|2011-12-16|Estimate|||||||2012-02-24|2012-02-27|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|May 2011|Actual|2011-05-31||Interventional|WOW||Working on Wellness (WOW) Intervention|Working on Wellness (WOW): A Worksite Health Promotion Intervention Programme|Unknown status|Active, not recruiting|N/A|800|Actual|University of Cape Town||1|||f||||f||||||||||2018-05-31 21:49:37.229199|2018-05-31 21:49:37.229199
NCT01494194|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-06-05|2011-12-14|2011-12-16|Estimate|||||||2015-06-05|2015-06-08|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study to Evaluate the Potential of Air Structuring Protein to Elicit Allergic Reactions in Mold Sensitized People|Evaluation of the Potential of Air Structuring Protein, a Novel Protein Preparation Derived From Trichoderma Reesei, to Elicit Allergic Reactions in Mold Sensitized People|Completed||N/A|252|Actual|Unilever SEAC||3|||f||||f||||||||||2018-05-31 21:49:37.323765|2018-05-31 21:49:37.323765
NCT01494181|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-01-25|2011-12-14|2011-12-16|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2011||2011-07-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|OSA||Unrecognised Obstructive Sleep Apnea Study|Postoperative Vascular Events in Unrecognised Obstructive Sleep Apnea|Completed|||1200|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 21:49:37.388107|2018-05-31 21:49:37.388107
NCT01494168|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2016-11-30|2011-12-15|2011-12-16|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|January 2015|Actual|2015-01-31||Observational|BASTOD||Bariatric Surgery, Arterial Stiffness and Target Organ Damage Study (BASTOD)|Longitudinal Assessment of the Effect of Bariatric Surgery on Arterial Function and Blood Pressure Target Organs Damage|Completed|||90|Actual|University Hospital, Montpellier|||||f||||t||||||||||2018-05-31 21:49:37.463869|2018-05-31 21:49:37.463869
NCT01494155|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2018-04-05|2011-12-14|2011-12-16|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2011||2011-12-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|March 2019|Anticipated|2019-03-31||Interventional|||Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton or Photon RT Plus Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer|Active, not recruiting||Phase 2|50|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:49:37.532288|2018-05-31 21:49:37.532288
NCT01494142|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2018-02-28|2011-12-14|2011-12-16|Estimate|||||||2018-02-28|2018-03-02|Actual|August 2011||2011-08-31|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Observational|||Registry for the Atopic Dermatitis Research Network|Registry for the Atopic Dermatitis Research Network (ADRN-02)|Completed|||3386|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||5||f||||f||||||Samples With DNA|"~     Whole blood DNA, whole blood RNA,blood cards, blood clots, serum, skin swabs, and skin swab~     isolates will be retained.~   "|||2018-05-31 21:49:37.671022|2018-05-31 21:49:37.671022
NCT01494116|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-02-26|2011-12-14|2011-12-16|Estimate|||||||2012-02-26|2012-02-28|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Pediatric Fast Fluid Randomized Controlled Trial|Factors Affecting Pediatric Isotonic Fluid Resuscitation Efficiency: Impact of Syringe Size|Completed||N/A|48|Actual|McMaster Children's Hospital||4|||f||||f||||||||||2018-05-31 21:49:37.841389|2018-05-31 21:49:37.841389
NCT01494103|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-10-02|2011-12-15|2011-12-16|Estimate|||||||2017-10-02|2017-10-04|Actual|November 2011||2011-11-30|October 2017|2017-10-31|May 2029|Anticipated|2029-05-31|May 2029|Anticipated|2029-05-31||Interventional|DOTTI||Administration of Donor T Cells With the Caspase-9 Suicide Gene|Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene|Active, not recruiting||Phase 1|15|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-05-31 21:49:38.155179|2018-05-31 21:49:38.155179
NCT01494090|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-09-19|2011-12-15|2011-12-16|Estimate|||||||2012-09-19|2012-09-20|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|STAFF||Statin in Hip Fracture|Efficacy and Safety of Rosuvastatin in the Prevention of Arterial and Venous Vascular Events and Mortality After Hip Fracture: A Multicenter Randomised, Double-blinded, Placebo Controlled Trial.|Terminated||Phase 3|36|Actual|University Hospital, Brest||2||Decision of the Steering Committee. Recruitment more difficult and slower than expected.|f||||t||||||||||2018-05-31 21:49:38.258997|2018-05-31 21:49:38.258997
NCT01494077|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2014-12-10|2011-12-14|2011-12-16|Estimate|||||||2014-12-10|2014-12-12|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for Carcinoembryonic Antigen (CEA) Measurement|Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for CEA Measurement|Completed|||32|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 21:49:38.365165|2018-05-31 21:49:38.365165
NCT01494064|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2015-12-21|2011-12-14|2011-12-16|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Observational|STANDAREA||Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care|Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care Unit : Standardization of Critical Care Nursing|Completed|||224|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 21:49:38.45458|2018-05-31 21:49:38.45458
NCT01494051|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-15|2011-12-15|2011-12-16|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders|Fatty Acid Oxidation and Body Weight Regulation in Long-chain Fatty Acid Oxidation Disorders.|Completed||Phase 1/Phase 2|13|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 21:49:38.517949|2018-05-31 21:49:38.517949
NCT01494038|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-09-19|2011-12-14|2011-12-16|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2014|Actual|2014-04-30|September 2017|2017-09-30|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women|A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Settings|Completed||Phase 4|956|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 21:49:38.58812|2018-05-31 21:49:38.58812
NCT01494025|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-08-27|2011-12-15|2011-12-16|Estimate|||||||2012-08-27|2012-08-28|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|FL-68||Identification of Muscle-specific Biomarkers of Fatty Acid Beta-oxidation|Identification of Muscle-specific Biomarkers of Fatty Acid Beta-oxidation|Completed||N/A|13|Actual|USDA, Western Human Nutrition Research Center||1|||f||||f||||||||||2018-05-31 21:49:38.715217|2018-05-31 21:49:38.715217
NCT01494012|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2017-04-26|2011-12-14|2011-12-16|Estimate|||||||2017-04-26|2017-04-28|Actual|April 2012||2012-04-30|April 2017|2017-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer|A Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer|Terminated||Phase 1|1|Actual|Stanford University||1||low accrual|f||||t||||||||||2018-05-31 21:49:38.792013|2018-05-31 21:49:38.792013
NCT01493999|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2014-10-06|2011-12-15|2011-12-16|Estimate|||||||2014-10-06|2014-10-08|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|TREAT-HPR||Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity|Prasugrel Versus Adjusted High-dose Clopidogrel to TREAT High On-clopidogrel Platelet Reactivity in Acute Coronary Syndrome Patients After PCI|Completed||Phase 4|147|Actual|University of Pecs||2|||f||||t||||||||||2018-05-31 21:49:38.89813|2018-05-31 21:49:38.89813
NCT01493986|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-09-09|2011-12-15|2011-12-16|Estimate|||||||2012-09-09|2012-09-11|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Minimum Effective Volume of Ropivacaine 7.5 mg/ml for the Lateral and Sagittal Infraclavicular Brachial Plexus Block|Minimum Effective Volume of Ropivacaine 7.5 mg/ml for the Lateral and Sagittal Infraclavicular Brachial Plexus Block When Using Guidance by Both Ultrasound and Nerve Stimulation.|Completed||Phase 4|25|Anticipated|University Hospital of North Norway|||||f||||f||||||||||2018-05-31 21:49:38.985118|2018-05-31 21:49:38.985118
NCT01493973|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2015-08-10|2011-12-15|2011-12-16|Estimate|||||||2015-08-10|2015-08-11|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|FRIEMAX||Efficacy Study of Epoetin Alfa in Friedreich Ataxia|A Double-blind, Randomized, Placebo-controlled, Clinical Trial to Test the Efficacy of Epoetin Alfa on Physical Performance of Friedreich Ataxia Patients.|Completed||Phase 2|56|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 21:49:39.051598|2018-05-31 21:49:39.051598
NCT01493960|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2016-09-30||2017-06-05|2011-12-14|2011-12-16|Estimate|2017-06-05|2018-01-24|Actual||||2017-06-05|2018-01-24|Actual|December 2011||2011-12-31|June 2017|2017-06-30|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Interventional|COLLECT|FAS|The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients|A Placebo-controlled, Double-blind, Randomised Study to Assess the Efficacy and Safety of Cobitolimod as an add-on to Current Practice in Chronic Active Treatment Refractory Ulcerative Colitis Patients|Completed||Phase 3|131|Actual|InDex Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 21:49:39.193633|2018-05-31 21:49:39.193633
NCT01493947|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|2015-06-29||2015-09-22|2011-12-15|2011-12-16|Estimate|2015-09-22|2015-10-28|Estimate||||2015-09-22|2015-10-28|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ATTRACT||CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study|Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.|Completed||Phase 3|962|Actual|Galderma R&D||2|||f||||t||||||||||2018-05-31 21:49:41.411071|2018-05-31 21:49:41.411071
NCT01493934|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-02-23|2011-12-14|2011-12-16|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|GLUCIMAG||Development of a Fast Measurement Technique of Insulin Resistance in Human|Development of a Fast Measurement Technique of Insulin Resistance in Human, With 123-6-deoxy-6 Iodo-D-glucose, a New Tracer of Glucose Transport|Completed||Phase 1/Phase 2|12|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 21:49:42.185643|2018-05-31 21:49:42.185643
NCT01493921|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-02-17|2011-12-15|2011-12-16|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy Study & Safety Evaluation of SR-T100 Gel in Actinic Keratosis Treatment|A Randomized, Double-Blind, Parallel, Vehicle-Controlled Phase III Trial to Assess the Efficacy and Safety of Topical SR-T100 Gel in the Treatment of Patients With Actinic Keratosis|Completed||Phase 3|113|Actual|G&E Herbal Biotechnology Co., LTD||2|||f||||f||||||||||2018-05-31 21:49:42.278043|2018-05-31 21:49:42.278043
NCT01493908|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-15|2011-12-15|2011-12-16|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||The Effect of Marketing Variable on Effect of Active Drugs|The Effect of Price and Marketing Variable on the Pain Controlling Effect of Active Drugs in a Clinical Trial.|Unknown status|Not yet recruiting|N/A|220|Anticipated|Hadassah Medical Organization||5|||f||||f||||||||||2018-05-31 21:49:42.388556|2018-05-31 21:49:42.388556
NCT01493895|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-03-21|2011-12-15|2011-12-16|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31||||||||Interventional|||Study Assessing Safety and Efficacy of B-cure Laser Treating Diabetic Chronic Wounds||Unknown status|Not yet recruiting|Phase 1/Phase 2|||Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:49:42.484701|2018-05-31 21:49:42.484701
NCT01493882|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2012-05-10|2011-12-15|2011-12-16|Estimate|||||||2012-05-10|2012-05-14|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, 2-Part Study of JNJ-39758979 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma|Withdrawn||Phase 2|0|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4||"Study was withdrawn due to 2 cases of agranulocytosis in a different clinical trial with this~   same drug."|f||||t||||||||||2018-05-31 21:49:42.568382|2018-05-31 21:49:42.568382
NCT01493869|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2014-09-19|2011-12-14|2011-12-16|Estimate|||||||2014-09-19|2014-09-22|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects|A Phase I, Open-Label, Parallel-Group, Single-Dose Study to Assess the Pharmacokinetics of XL184 (Cabozantinib) Capsules in Hepatic Impaired Adult Subjects|Completed||Phase 1|26|Actual|Exelixis||4|||f||||f||||||||||2018-05-31 21:49:42.654165|2018-05-31 21:49:42.654165
NCT01493856|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2012-04-02|2011-12-14|2011-12-16|Estimate|||||||2012-04-02|2012-04-04|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276|A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers|Completed||Phase 1|58|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||||2018-05-31 21:49:42.734472|2018-05-31 21:49:42.734472
NCT01493843|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-04-21|2011-12-15|2011-12-16|Estimate|||||||2017-04-21|2017-04-25|Actual|January 20, 2012|Actual|2012-01-20|April 2017|2017-04-30|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|||Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer|A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer|Completed||Phase 2|501|Actual|Genentech, Inc.||6|||f|||||t|f||||||||2018-05-31 21:49:42.842426|2018-05-31 21:49:42.842426
NCT01493830|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-07-07|2011-12-15|2011-12-16|Estimate|||||||2016-07-07|2016-07-11|Estimate|December 2011||2011-12-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma|Proposed Studies on the Role of Growth Factor Receptor Trafficking in Neuroblastoma Pathogenesis|Completed|||5|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tumor samples~   "|||2018-05-31 21:49:43.068769|2018-05-31 21:49:43.068769
NCT01493817|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2016-05-17|2011-12-15|2011-12-16|Estimate|||||||2016-05-17|2016-05-19|Estimate|December 2011||2011-12-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Samples From Younger Patients With Wilms Tumor|Observational - Relationships Between Tumor-Associated Macrophages and Clinicopathological Factors in Wilms Tumor|Completed|||30|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 21:49:43.25402|2018-05-31 21:49:43.25402
NCT01493804|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-09-02|2011-12-15|2011-12-16|Estimate|||||||2017-09-02|2017-09-06|Actual|November 8, 2011||2011-11-08|September 1, 2017|2017-09-01|September 1, 2017||2017-09-01|||||Observational|||Noninvasive Study of Brain Connectivity With EEG and NIRS|Non-Invasive Study of Brain Connectivity Using Combined EEG and NIRS|Completed|||5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:49:43.320142|2018-05-31 21:49:43.320142
NCT01493791|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-05-23|2011-12-15|2011-12-16|Estimate|||||||2018-05-23|2018-05-24|Actual|November 8, 2011||2011-11-08|July 24, 2013|2013-07-24|July 24, 2013|Actual|2013-07-24|July 24, 2013|Actual|2013-07-24||Interventional|||CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women|Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Reduce Bleeding in Premenopausal Women With Abnormal Uterine Bleeding: A Pilot Study|Withdrawn||Early Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:49:43.388775|2018-05-31 21:49:43.388775
NCT01493778|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2018-05-16|2011-12-15|2011-12-16|Estimate|||||||2018-05-16|2018-05-17|Actual|September 17, 2012|Actual|2012-09-17|May 2018|2018-05-31|December 10, 2018|Anticipated|2018-12-10|August 16, 2017|Actual|2017-08-16||Interventional|guardian™4||Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A|Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A|Active, not recruiting||Phase 3|60|Anticipated|Novo Nordisk A/S||1|||f||||f|t|f||||||||2018-05-31 21:49:43.462423|2018-05-31 21:49:43.462423
NCT01493765|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2017-01-30|2011-12-14|2011-12-16|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Observational|||Virtual Temporal Bone Surgery: Defining and Translating Metrics|Virtual Temporal Bone Surgery: Defining and Translating Metrics|Completed|||96|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 21:49:43.606948|2018-05-31 21:49:43.606948
NCT01493258|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2016-09-01|2011-12-13|2011-12-15|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|iADAPT||Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination|Comprehensive Informatics Framework for Comparative Effectiveness Research (CER) Dissemination|Active, not recruiting||N/A|360|Anticipated|Johns Hopkins University||2|||f||||f||||||||No|The data contain sensitive information|2018-05-31 21:49:54.066049|2018-05-31 21:49:54.066049
NCT01493752|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-04-08|2011-12-15|2011-12-16|Estimate|||||||2014-04-08|2014-04-09|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function and Platelet Reactivity in Hypercholesterolemics.|Investigation of the Effect of Dietary Nitrate Treatment on Endothelial Function, Platelet Reactivity in Hypercholesterolemics Without Known Cardiovascular Disease or Atherosclerosis.|Completed||Phase 1|69|Actual|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 21:49:43.672255|2018-05-31 21:49:43.672255
NCT01493739|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-12-15|2011-12-15|2011-12-16|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy|EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy|Unknown status|Recruiting||100|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-05-31 21:49:43.728441|2018-05-31 21:49:43.728441
NCT01493726|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2016-11-16|2011-12-14|2011-12-16|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072 in Subjects With Chronic Stable Schizophrenia|Completed||Phase 1|88|Actual|Alkermes, Inc.||4|||f||||f||||||||||2018-05-31 21:49:43.786847|2018-05-31 21:49:43.786847
NCT01493713|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-02-14|2011-12-14|2011-12-16|Estimate|||||||2018-02-14|2018-02-16|Estimate|November 16, 2011|Actual|2011-11-16|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 8, 2014|Actual|2014-12-08||Interventional|AVAMET||Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer|Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX|Completed||Phase 4|83|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f||||||||No||2018-05-31 21:49:43.858698|2018-05-31 21:49:43.858698
NCT01493700|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-06-26|2011-12-14|2011-12-16|Estimate|||||||2013-06-26|2013-06-27|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Changes of Body Temperature During Shoulder Arthroscopy|Effect of Heated Humidifier on the Body Temperature During Shouler Arthroscopy|Completed||N/A|50|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 21:49:43.941096|2018-05-31 21:49:43.941096
NCT01493687|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2015-01-08|2014-01-27|2015-01-15|2011-12-15|2011-12-16|Estimate|2015-01-15|2015-01-16|Estimate|2014-01-27|2014-02-28|Estimate|2015-01-15|2015-01-16|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional||ITT population|Phase 3 Papulopustular Rosacea Study|A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.|Completed||Phase 3|683|Actual|Galderma||2|||f||||t||||||||||2018-05-31 21:49:45.036998|2018-05-31 21:49:45.036998
NCT01493674|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-14|2011-12-14|2011-12-16|Estimate|||||||2011-12-14|2011-12-16|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Folic Acid Supplementation in Eating Disorder|Folic Acid Supplementation for Improving Homocysteine Levels, Cognitive and Depressive Status in Eating Disorders|Completed||Phase 4|24|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||2|||f||||t||||||||||2018-05-31 21:49:45.833215|2018-05-31 21:49:45.833215
NCT01493661|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2016-02-02|2011-12-15|2011-12-16|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|CSR||Chronic Sleep Restriction|Chronic Sleep Restriction: Neurobehavioral and Physiological Responses|Completed|||20|Actual|Federal University of São Paulo|||3||f||||t||||||||||2018-05-31 21:49:45.996518|2018-05-31 21:49:45.996518
NCT01493648|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-01-26|2011-12-14|2011-12-16|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation|Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation|Completed||N/A|78|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 21:49:46.087666|2018-05-31 21:49:46.087666
NCT01493635|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2017-05-16|2011-12-15|2011-12-16|Estimate|||||||2017-05-16|2017-05-17|Actual|November 2012||2012-11-30|December 2015|2015-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|TVT||Two Step Versus the Standard Three Step Approach of the WHO Analgesic Ladder for Cancer Pain Relief.|An International, Multicentre, Open Randomised Parallel Group Trial Comparing a Two Step Approach for Cancer Pain Relief With the Standard Three Step Approach of the WHO Analgesic Ladder in Patients With Cancer Pain Requiring Step 2 Analgesia.|Completed||N/A|152|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 21:49:46.171103|2018-05-31 21:49:46.171103
NCT01493622|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2011-12-14|2011-12-14|2011-12-16|Estimate|||||||2011-12-14|2011-12-16|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia|A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia|Completed||Phase 4|78|Actual|Central South University||2|||f||||t||||||||||2018-05-31 21:49:46.257442|2018-05-31 21:49:46.257442
NCT01493609|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2013-11-21|2011-12-15|2011-12-16|Estimate|||||||2013-11-21|2013-11-25|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Click-East||A Clinical Trial of a New Computer Based Intervention for Children With Autism.|Computer Learning in Children - the Edinburgh Autism Social-attention Trial.|Completed||Early Phase 1|54|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 21:49:46.342306|2018-05-31 21:49:46.342306
NCT01493596|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-05-10|2011-12-14|2011-12-16|Estimate|||||||2012-05-10|2012-05-14|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||A Safety, Tolerability and Pharmacokinetic Study of CPP-115|A Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of CPP-115 Solution Administered Orally to Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|48|Anticipated|Catalyst Pharmaceuticals, Inc.||6|||f||||t||||||||||2018-05-31 21:49:46.41913|2018-05-31 21:49:46.41913
NCT01493245|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2014-03-21|2011-12-13|2011-12-15|Estimate|||||||2014-03-21|2014-03-24|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of JNS020QD in Patients With Chronic Pain|A Phase 3 Study of JNS020QD in Patients With Chronic Pain|Completed||Phase 3|77|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 21:49:54.287249|2018-05-31 21:49:54.287249
NCT01493570|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-10-31|2011-12-14|2011-12-16|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2011||2011-12-31|October 2013|2013-10-31||||February 2012|Actual|2012-02-29||Interventional|||Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers|Randomised, Double-blind, Placebo-controlled Parallel-group Proof of Mechanism Study to Assess the Pharmacokinetics and to Evaluate the Pharmacodynamic Effect of Different Single Oral Doses of BI 409306 in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:49:46.572668|2018-05-31 21:49:46.572668
NCT01493557|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2015-07-06||2015-09-02|2011-12-14|2011-12-16|Estimate|2015-09-02|2015-10-05|Estimate||||2015-09-02|2015-10-05|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Entered Set (ES): This patient set included all patients entered in the study. For those patients who were randomized to management strategies, their data prior to randomization was included in the entered set. All data from patients who were never randomized are in the entered set.|A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation|A Prospective, Open Label Study Evaluating the Efficacy of Two Management Strategies (Pantoprazole 40 mg q.a.m. and Taking Pradaxa® With Food (Within 30 Minutes After a Meal) on Gastrointestinal Symptoms (GIS) in Patients Newly on Treatment With Pradaxa® 150 mg b.i.d., 110 mg b.i.d. or 75 mg b.i.d. for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation (NVAF)|Completed||Phase 4|1067|Actual|Boehringer Ingelheim|The modest sample size,non-specific nature of symptoms,&reliance on patient self-reporting of their symptoms may contributed some bias to the final result.An open-label design may lead to patient/investigator bias in reporting symptoms.|3|||f||||||||||||||2018-05-31 21:49:46.721035|2018-05-31 21:49:46.721035
NCT01493544|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-04-25|2011-12-15|2011-12-16|Estimate|||||||2013-04-25|2013-04-26|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|PUMA PROJECT||Prevalence Study and Regular Practice Among General Practitioners in Populations at Risk of Chronic Obstructive Pulmonary Disease (COPD) in Latin America|Prevalence Study and Regular Practice (Diagnosis and Treatment) Among General Practitioners in Populations at Risk of COPD in Latin America|Completed|||1907|Actual|AstraZeneca|||||f||||||||||||||2018-05-31 21:49:47.955029|2018-05-31 21:49:47.955029
NCT01493531|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2016-01-14|2015-03-23|2016-04-20|2011-12-15|2011-12-16|Estimate|2016-04-20|2016-05-26|Estimate|2015-03-23|2015-04-10|Estimate|2016-04-20|2016-05-26|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|CLEAR 2||Combining Lesinurad With Allopurinol in Inadequate Responders|A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol|Completed||Phase 3|610|Actual|Ardea Biosciences, Inc.||3|||f||||t||||||||||2018-05-31 21:49:48.102289|2018-05-31 21:49:48.102289
NCT01493518|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2013-11-15|2011-12-14|2011-12-16|Estimate|||||||2013-11-15|2013-11-19|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Subjects With Moderate to Severe Psoriasis|Terminated||Phase 1|6|Actual|Amgen||2||Sponsor decision|f||||||||||||||2018-05-31 21:49:49.10372|2018-05-31 21:49:49.10372
NCT01493505|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29||2016-11-14|2017-02-22|2011-12-15|2011-12-16|Estimate||||2016-11-14|2016-11-15|Estimate|2017-02-22|2017-02-23|Actual|January 2012||2012-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers|Terminated||Phase 3|1015|Actual|Amgen||2||Amgen Administrative Decision - termination of LTFU|f||||||||||||||2018-05-31 21:49:49.227151|2018-05-31 21:49:49.227151
NCT01493492|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-15|2011-12-15|2011-12-16|Estimate|||||||2011-12-15|2011-12-16|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Urinary Proteomics Analysis for Sepsis and Prognosis|Urinary Proteomics Analysis for Sepsis Identification and Its Prognosis in Sepsis Patient With iTRAQ Labeling and and LC-MS/MS|Unknown status|Recruiting||60|Anticipated|Chinese PLA General Hospital|||3||f||||t||||||||||2018-05-31 21:49:49.827381|2018-05-31 21:49:49.827381
NCT01493479|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-15|2011-12-15|2011-12-16|Estimate|||||||2011-12-15|2011-12-16|Estimate|June 2007||2007-06-30|December 2011|2011-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|FIZZ||Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma|Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin)|Unknown status|Active, not recruiting|Phase 2|76|Actual|The Christie NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 21:49:49.894648|2018-05-31 21:49:49.894648
NCT01493466|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2011-12-15|2011-12-15|2011-12-16|Estimate|||||||2011-12-15|2011-12-16|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||Serum Proteomics Analysis for Sepsis|Serum Proteomics Analysis for Dynamic Changes of Differential Proteins in Sepsis Patient With iTRAQ Labeling and LC-MS/MS|Unknown status|Recruiting||100|Anticipated|Chinese PLA General Hospital|||5||f||||t||||||||||2018-05-31 21:49:49.971221|2018-05-31 21:49:49.971221
NCT01493453|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2013-11-25|2011-12-15|2011-12-16|Estimate|||||||2013-11-25|2013-11-27|Estimate|March 2008||2008-03-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|May 2014|Anticipated|2014-05-31||Interventional|CD19||A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy|A Phase I Study of Adoptive Transfer of Autologous Tumour Antigen-Specific T Cells With Pre-conditioning Chemotherapy and Intravenous IL2 in Patients With CD19 Positive Malignancy|Unknown status|Recruiting|Phase 1|24|Anticipated|The Christie NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 21:49:50.033712|2018-05-31 21:49:50.033712
NCT01493440|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2011-12-16|2011-12-15|2011-12-16|Estimate|||||||2011-12-16|2011-12-20|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure|Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure|Completed||N/A|71|Actual|An Sinh Hospital||1|||f||||f||||||||||2018-05-31 21:49:50.107012|2018-05-31 21:49:50.107012
NCT01493427|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|2014-02-17||2014-05-09|2011-12-14|2011-12-16|Estimate|2014-04-10|2014-05-09|Estimate||||2014-05-09|2014-05-19|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||This reporting group includes all subjects who instilled at least one dose of the test article|Efficacy of Changing to TRAVATAN® From Prior Therapy|Multi-Center Study Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (0.004% Travoprost) in Patients Previously on Latanoprost 0.005% or Bimatoprost 0.01% Ophthalmic Solution Monotherapy|Completed||Phase 4|202|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:49:50.179809|2018-05-31 21:49:50.179809
NCT01493414|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2017-12-19|2011-12-14|2011-12-16|Estimate|||||||2017-12-19|2017-12-21|Actual|August 16, 2011|Actual|2011-08-16|December 2017|2017-12-31|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional|JUMP||INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.|An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).|Completed||Phase 3|2232|Actual|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 21:49:50.462782|2018-05-31 21:49:50.462782
NCT01493401|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-02-12|2011-12-14|2011-12-16|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Urinary Urinary Nerve Growth Factor (NGF) as a Biomarker for Mixed Urinary Incontinence|Exploration of the Potential of Urinary Nerve Growth Factor (NGF) as a Biomarker for Diagnosis and Prognosis of Mixed Urinary Incontinence After Midurethral Slings|Unknown status|Recruiting|N/A|121|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 21:49:50.96373|2018-05-31 21:49:50.96373
NCT01493388|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-01-18|2011-12-14|2011-12-16|Estimate|||||||2017-01-18|2017-01-19|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1|Observational, Cross-sectional and Retrospective Study on Diabetes Mellitus Type 1 in Tunisian Children and Adolescents Under 15 Years|Completed|||402|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:49:51.173242|2018-05-31 21:49:51.173242
NCT01493375|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2015-05-27|2011-12-14|2011-12-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2010||2010-06-30|May 2015|2015-05-31||||December 2010|Actual|2010-12-31||Observational|||Surgical Field Bacterial Contamination in Primary Total Hip (THA) and Knee (TKA) Arthroplasty|Surgical Field Bacterial Contamination in Primary Hip and Knee Replacement Surgery|Suspended|||60|Actual|Northern Orthopaedic Division, Denmark||||Study principal investigator left the organization|f||||t||||||||||2018-05-31 21:49:51.305462|2018-05-31 21:49:51.305462
NCT01493362|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2014-08-14|2011-12-14|2011-12-16|Estimate|||||||2014-08-14|2014-08-15|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Imaging the Dopamine Systems in Bulimia Nervosa|Imaging the Dopamine Systems in Bulimia Nervosa|Completed|||33|Actual|New York State Psychiatric Institute|||2||f||||f||||||||||2018-05-31 21:49:51.386819|2018-05-31 21:49:51.386819
NCT01493349|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2012-01-04|2011-12-14|2011-12-16|Estimate|||||||2012-01-04|2012-01-05|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Observational|||Pathophysiology of Diverticular Disease|The Role of Intestinal Microbiota Composition and Intestinal Permeability in the Development of (Complicated) Diverticular Disease.|Unknown status|Not yet recruiting||210|Anticipated|Maastricht University Medical Center|||4||f||||f||||||Samples Without DNA|"~     -  1 bloodsample (14.5mL)~        -  9 Colonic mucosal biopsies~        -  1 Intestinal washing sample (at least 15mL)~        -  1 Fecal sample~   "|||2018-05-31 21:49:51.487194|2018-05-31 21:49:51.487194
NCT01493336|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2016-11-01|2011-12-14|2011-12-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours|A Randomized, Open-label, Single Dose, Two-way Cross-Over Study to Investigate the Relative Bioavailability of Capecitabine in Rapid Disintegrating Tablets (RDT) Versus the Commercial Xeloda® Tablets Following Oral Administrations in Adult Patients With Solid Tumours|Completed||Phase 1|37|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:49:51.583029|2018-05-31 21:49:51.583029
NCT01493323|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-12-03|2011-12-13|2011-12-15|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Functional Imaging of Psychic Pain|Neuro Anatomic Basis of Psychic Pain in Depression and Suicidal Behaviour|Terminated||N/A|123|Actual|University Hospital, Montpellier||2||difficult to patient inclusion|f||||f||||||||||2018-05-31 21:49:51.703201|2018-05-31 21:49:51.703201
NCT01493310|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-09-08|2011-12-14|2011-12-15|Estimate|||||||2017-09-08|2017-09-12|Actual|November 2011||2011-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer|A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer|Active, not recruiting||Phase 1|32|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 21:49:51.863819|2018-05-31 21:49:51.863819
NCT01493297|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-01-22|2011-12-13|2011-12-15|Estimate|||||||2014-01-22|2014-01-23|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|||Effects of Vitamin A and Carotenoids on Iron Absorption|Effects of Vitamin A and Carotenoids on Iron Absorption|Completed||N/A|25|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 21:49:52.024139|2018-05-31 21:49:52.024139
NCT01493284|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2017-03-15||2018-04-18|2011-12-13|2011-12-15|Estimate|2018-04-18|2018-04-23|Actual||||2018-04-18|2018-04-23|Actual|December 2011||2011-12-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Interventional|||Portico TAVI Implant With Transfemoral Delivery System|Assessment Of The St. Jude Medical Portico™ Transcatheter Aortic Valve Implant (TAVI) And The SJM TAVI Transfemoral Delivery System (Portico TF EU)|Completed||N/A|222|Actual|St. Jude Medical||1|||f||||t||||||||No||2018-05-31 21:49:52.215204|2018-05-31 21:49:52.215204
NCT01493271|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14||2016-07-07|2016-11-01|2011-12-14|2011-12-15|Estimate||||2016-07-07|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma|An Adaptive, Multi-center, Randomized, Investigator-masked, Subject-masked, Multiple-dose, Placebo-controlled, Parallel Study to Investigate Efficacy, Safety, Tolerability and Pharmacokinetics of RO5093151 for up to 28 Days in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.|Completed||Phase 2|31|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:49:52.829085|2018-05-31 21:49:52.829085
NCT01493232|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2011-12-17|2011-12-14|2011-12-15|Estimate|||||||2011-12-17|2011-12-20|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Interventional|||Comparing Patient Satisfaction & Stress Distribution on Mandibular Ridge by Three Posterior Occlusal Scheme in Complete Denture|Comparing Patient Satisfaction & Stress Distribution on Mandibular Ridge by Three Posterior Occlusal Scheme in Complete Denture|Unknown status|Recruiting|N/A|15|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:49:54.466979|2018-05-31 21:49:54.466979
NCT01493219|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-01-29|2011-12-14|2011-12-15|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2011||2011-09-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Biomarkers for Prognosis of Glioblastoma (GBM)|MMP-2, MMP-9 and NGAL as Biomarkers for Glioblastoma (GBM) Biomarkers for the Prognosis of Glioblastoma|Completed|||19|Actual|University of Nebraska|||2||f||||f||||||Samples Without DNA|"~     Whole Blood, Urine, and Tissue.~   "|Undecided|not available|2018-05-31 21:49:54.595629|2018-05-31 21:49:54.595629
NCT01493206|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-14|2011-12-13|2011-12-15|Estimate|||||||2011-12-14|2011-12-16|Estimate|July 2004||2004-07-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer|A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer|Completed||Phase 2|32|Actual|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 21:49:54.80221|2018-05-31 21:49:54.80221
NCT01493193|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-07-31|2011-12-13|2011-12-15|Estimate|||||||2013-07-31|2013-08-01|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Different Endurance Training Protocols in Cardiac Rehabilitation|Effects of Different Endurance Training Protocols on Physical Performance in Cardiac Patients|Completed||Phase 4|60|Actual|Paracelsus Medical University||3|||f||||f||||||||||2018-05-31 21:49:54.858479|2018-05-31 21:49:54.858479
NCT01493180|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2014-01-17||2015-02-19|2011-12-13|2011-12-15|Estimate|2014-01-17|2014-03-03|Estimate||||2015-02-19|2015-03-10|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Exploratory Study of OPC-12759 Ophthalmic Suspension|Exploratory Study of OPC-12759 Ophthalmic Suspension in Patients With Keratoconjunctiva Epithelial Disorder|Completed||Phase 2|102|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:49:54.940647|2018-05-31 21:49:54.940647
NCT01493167|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2016-03-30||2017-06-13|2011-12-14|2011-12-15|Estimate|2016-09-26|2016-11-15|Estimate||||2017-06-13|2017-07-05|Actual|December 2011||2011-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|WOODCAST||Study on Wood-plastic Composite for Circumferential Casting|Study on Circumferential Casting Techniques With WOODCAST|Completed||N/A|97|Actual|Onbone Oy||1|||f||||f||||||||No||2018-05-31 21:49:55.319874|2018-05-31 21:49:55.319874
NCT01493154|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2016-10-12|2011-12-13|2011-12-15|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients|A Phase I Clinical Trial Assessing the Safety and Feasibility of Administration of pNGVL4a-CRT/E7(Detox) DNA Vaccine Using the Intramuscular TriGridTM Delivery System in Combination With Cyclophosphamide in HPV-16 Associated Head and Neck Cancer Patients|Terminated||Phase 1|2|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4||Study Funding Terminated|f||||t||||||||||2018-05-31 21:49:55.482572|2018-05-31 21:49:55.482572
NCT01493141|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-12-14|2011-12-13|2011-12-15|Estimate|||||||2012-12-14|2012-12-17|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|Metal Ions||Systemic Effects of Chronic Metal Ion Exposure From Metal-on Metal Hip Resurfacing|Systemic Effects of Chronic Metal Ion Exposure From Metal-on Metal Hip Resurfacing|Completed|||46|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||2||f||||f||||||Samples With DNA|"~     The following markers will be measured using the blood samples:~        1. Serum, erythrocyte, and whole blood cobalt, chromium, and nickel~        2. Serum iron stores:~           Iron, ferritin, transferrin, and total iron binding capacity.~        3. Serum biochemical markers of bone turnover:~           Osteoblast activity markers (including PINP, OC, BALP) Osteoclast activity markers~          (including NTX-I, CTX-I, ICTP)~        4. Hypothalamo-pituitary axis hormones (in the following order of priority):~           Prolactin LH/FSH + testosterone/oestradiol Growth hormone + IGF-I TSH + Free T3 ACTH +~          cortisol~        5. Renal function:~           Urea, electrolytes, and creatinine~        6. Hepatic function Liver function tests Clotting screen~        7. Serum lipid profile, full blood count~   "|||2018-05-31 21:49:55.697692|2018-05-31 21:49:55.697692
NCT01493128|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2017-03-10|2011-12-14|2011-12-15|Estimate|||||||2017-03-10|2017-03-13|Actual|April 2010|Actual|2010-04-30|March 2017|2017-03-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Observational|||Ultrastructure of Atrial Myocytes in Patients in Sinus Rhythm and With Atrial Fibrillation|Ultrastructure of Sarcolemma, Immunofluorescence of Calcium Handling Proteins and Mitochondrial Function in Atrial Myocytes of Patients in Sinus Rhythm and With Atrial Fibrillation|Completed|||45|Actual|Norwegian University of Science and Technology|||3||f||||f|f|f||||Samples Without DNA|"~     Myocardial tissue from the right and left atrial appendage.~   "|||2018-05-31 21:49:55.766537|2018-05-31 21:49:55.766537
NCT01493115|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2012-04-30|2011-12-13|2011-12-15|Estimate|||||||2012-04-30|2012-05-01|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus|A Randomized, Double-blind, 3-sequence, 3-period Cross-over, Single-dose Study of a New Formulation of Insulin Glargine Compared to the Marketed Lantus® in Japanese Patients With Type 1 Diabetes Mellitus Using the Euglycemic Clamp Technique|Completed||Phase 1|18|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:49:55.840415|2018-05-31 21:49:55.840415
NCT01493102|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-01-28|2011-12-14|2011-12-15|Estimate|||||||2015-01-28|2015-01-30|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DOVSS||Discontinuation Order of Vasopressors in Septic Shock|Incidence of Hypotension Based on the Discontinuation Order of Vasopressors in the Management of Septic Shock|Terminated||N/A|78|Actual|Samsung Medical Center||2||Futility by interim analysis|f||||f||||||||||2018-05-31 21:49:55.912981|2018-05-31 21:49:55.912981
NCT01493089|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2012-12-07||2013-08-12|2011-12-14|2011-12-15|Estimate|2013-08-12|2013-08-13|Estimate||||2013-08-12|2013-08-13|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease|A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated With GERD as on Demand Therapy|Completed||Phase 3|239|Actual|Norgine||2|||f||||f||||||||||2018-05-31 21:49:55.996539|2018-05-31 21:49:55.996539
NCT01493076|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2011-12-14|2011-12-14|2011-12-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|June 2000||2000-06-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Safety and Efficacy of a Newly Developed Baby-sphincterotome for Bile Duct Cannulation|Safety and Efficacy of a New Baby-sphincterotome for Cannulation and Pre-cut in Failed Selective Wire-guided Bile Duct Access|Completed|||1886|Actual|Ruhr University of Bochum|||1||f||||f||||||||||2018-05-31 21:49:56.838073|2018-05-31 21:49:56.838073
NCT01493063|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-03-19|2011-12-14|2011-12-15|Estimate|||||||2018-03-19|2018-03-20|Actual|October 25, 2011|Actual|2011-10-25|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|April 2018|Anticipated|2018-04-30||Observational|||LACTACOL 01 - Impact of Breast Milk on the Neurodevelopment of Preterm Newborns|"BRD/11/02-Y LACTACOL 01 - Impact of Breast Milk on the Neurodevelopment of Preterm Newborns."|Active, not recruiting|||160|Actual|Nantes University Hospital|||||f||||f|f|f||||Samples With DNA|"~     Breastmilk samples et infant serum samples~   "|||2018-05-31 21:49:57.0264|2018-05-31 21:49:57.0264
NCT01493050|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-04-08|2011-12-14|2011-12-15|Estimate|||||||2014-04-08|2014-04-09|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of Sevelamer Carbonate on Diabetic Nephropathy|Multi-Center Study of the Effect of Sevelamer Carbonate (Renvela®) on Metabolic/Inflammatory/ROS in Diabetics With Nephropathy|Completed||Phase 2|117|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:49:57.181057|2018-05-31 21:49:57.181057
NCT01493037|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-07-15|2011-12-14|2011-12-15|Estimate|||||||2014-07-15|2014-07-16|Estimate|December 2011||2011-12-31|July 2014|2014-07-31||||March 2014|Actual|2014-03-31||Interventional|pRAMSES||PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention|Pressure Controlled Intermittent Coronary Sinus Occlusion in Patients With ST Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: Safety and Feasibility Study|Completed||N/A|30|Actual|Miracor Medical Systems||1|||f||||t||||||||||2018-05-31 21:49:57.398393|2018-05-31 21:49:57.398393
NCT01493024|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12||2013-06-05|2016-06-02|2011-12-13|2011-12-15|Estimate||||2013-06-05|2013-06-13|Estimate|2016-06-02|2016-06-07|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia|Multicenter, Prospective, Randomized, Placebo-Controlled, Double-blind Dose Escalating Study of Safety, Tolerability and Pharmacodynamics of Zirconium Silicate in Chronic Kidney Disease and Moderate Kidney Dysfunction With Mild Hyperkalemia|Completed||Phase 2|90|Actual|ZS Pharma, Inc.||2|||f||||t||||||||||2018-05-31 21:49:57.582618|2018-05-31 21:49:57.582618
NCT01493011|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-05-13|2011-12-13|2011-12-15|Estimate|||||||2012-05-13|2012-05-15|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|December 2015|Anticipated|2015-12-31|December 2012|Anticipated|2012-12-31||Interventional|WBH&NSCLC||Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer|A Randomized Contrasted Polycentric Clinical Study About Chemotherapy Combined With Whole-body Hyperthermia(WBH)to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|N/A|120|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 21:49:57.720906|2018-05-31 21:49:57.720906
NCT01492998|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2011-12-14|2011-12-14|2011-12-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|January 2010||2010-01-31|September 2010|2010-09-30||||March 2010|Actual|2010-03-31||Interventional|GGST||Role of FXR in Hepatitis C Virus Replication|Study of the Role of the Biliary Salts Nuclear Receptor FXR in Hepatitis C Virus Replication|Terminated||N/A|15|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 21:49:57.852682|2018-05-31 21:49:57.852682
NCT01492985|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2018-02-09|2011-12-13|2011-12-15|Estimate|||||||2018-02-09|2018-02-12|Actual|July 2013|Actual|2013-07-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|October 2016|Actual|2016-10-31||Interventional|||Lipopeptide Immunisation With GTU-multiHIV Trial|Evaluation of a Therapeutic Immunization Strategy Associating a DNA Vaccine (GTU-MultiHIV B) Followed by a Lipopeptide Vaccine (LIPO-5) in the Control of Viral Replication Following Antiretroviral Treatment Interruption in HIV-1 Infected Patients With a CD4 Cell Count ≥ 600/mm3|Active, not recruiting||Phase 2|103|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 21:49:57.966266|2018-05-31 21:49:57.966266
NCT01492972|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2018-01-16|2011-12-13|2011-12-15|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2012||2012-01-31|January 2018|2018-01-31||||December 2021|Anticipated|2021-12-31||Interventional|||Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer|Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate|Recruiting||Phase 3|192|Anticipated|Proton Collaborative Group||2|||f||||t||||||||||2018-05-31 21:49:58.061791|2018-05-31 21:49:58.061791
NCT01492959|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2017-02-27|2011-12-13|2011-12-15|Estimate|||||||2017-02-27|2017-02-28|Actual|March 23, 2004|Actual|2004-03-23|February 2017|2017-02-28|March 23, 2005|Actual|2005-03-23|March 23, 2005|Actual|2005-03-23||Observational|||Observational Study With InnoLet® in Daily Clinical Practice|A Prospective, Open, Uncontrolled, Observational Study With Innolet in Daily Clinical Situations According to the Product Labelling, Without Any Study Specific Investigations|Completed|||1030|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:49:58.221478|2018-05-31 21:49:58.221478
NCT01492946|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2017-01-20|2011-12-14|2011-12-15|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2010||2010-05-31|January 2017|2017-01-31|July 2012|Actual|2012-07-31|November 2010|Actual|2010-11-30||Observational|PreopBIA||Impaired Preoperative Nutritional Status as a Risk Factor for Postoperative Clinical Outcome|Impaired Preoperative Nutritional Status as a Risk Factor for Postoperative Clinical Outcome (PreopBIA)|Completed|||400|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 21:49:58.31255|2018-05-31 21:49:58.31255
NCT01492933|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2018-05-19|2011-12-14|2011-12-15|Estimate|||||||2018-05-19|2018-05-22|Actual|November 22, 2011||2011-11-22|February 24, 2015|2015-02-24|February 24, 2015||2015-02-24|||||Observational|||Measuring Effects of Alcohol on Brain Chemistry|Measuring Effects of Acute Ethanol on Human Brain Metabolites Using Magnetic Resonance Spectroscopy|Terminated|||34|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:49:58.364567|2018-05-31 21:49:58.364567
NCT01492920|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2014-12-29|2011-12-14|2011-12-15|Estimate|||||||2014-12-29|2014-12-31|Estimate|April 2012||2012-04-30|December 2014|2014-12-31||||May 2015|Anticipated|2015-05-31||Interventional|||Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy|A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Withdrawn||Phase 3|0|Actual|Gynecologic Oncology Group||2||Withdrawn|f||||||||||||||2018-05-31 21:49:58.425452|2018-05-31 21:49:58.425452
NCT01492907|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-08-21|2011-12-14|2011-12-15|Estimate|||||||2014-08-21|2014-08-22|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer|Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer|Completed||Phase 1|8|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 21:49:58.506559|2018-05-31 21:49:58.506559
NCT01492894|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2016-12-08|2011-12-13|2011-12-15|Estimate|||||||2016-12-08|2016-12-09|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|KADWORC||Kidney Allograft Dysfunction Without Reversible Causes|A Randomized Controlled Trial of Reducing Calcineruin Inhibitor Target Level by 50% Versus Converting to Rapamycin in Chronic Kidney Dysfunction Without Reversible Causes|Withdrawn||Phase 4|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||study terminated due to low enrollment|f||||f||||||||||2018-05-31 21:49:58.57127|2018-05-31 21:49:58.57127
NCT01492881|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2012-05-09|2011-12-13|2011-12-15|Estimate|||||||2012-05-09|2012-05-11|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|January 2017|Anticipated|2017-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma|A Multi-Center, Single-Arm, Phase II Study of Vorinostat (V) in Combination With Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) Followed by VB Maintenance in Patients With Relapsed and Relapsed/Refractory Multiple Myeloma|Withdrawn||Phase 2|0|Actual|UNC Lineberger Comprehensive Cancer Center||1||Doxil is currently unavailable|f||||t||||||||||2018-05-31 21:49:58.633496|2018-05-31 21:49:58.633496
NCT01492868|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-05-02|2011-12-14|2011-12-15|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2012||2012-01-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Sinusitis in Children and the Nasopharyngeal Microbiome|My Nose Study: Sinusitis in Children and How Virus Infections Promote Secondary Bacterial Infections|Completed|||323|Actual|University of Wisconsin, Madison|||||f||||f||||||Samples Without DNA|"~     Nasopharyngeal microbiome samples~   "|||2018-05-31 21:49:58.701309|2018-05-31 21:49:58.701309
NCT01492855|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2014-09-12|2011-12-13|2011-12-15|Estimate|||||||2014-09-12|2014-09-15|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Evaluation of MRI Diagnosed Meniscal Lesions|The Value of MRI in the Evaluation of Knees Suspected for Meniscal Lesions|Completed||N/A|324|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:49:58.833226|2018-05-31 21:49:58.833226
NCT01492842|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2017-02-27|2011-12-13|2011-12-15|Estimate|||||||2017-02-27|2017-02-28|Actual|September 2011||2011-09-30|March 2016|2016-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV|Behavioral, Immunologic and Virologic Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV-Infection|Completed|||272|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 21:49:58.904391|2018-05-31 21:49:58.904391
NCT01492829|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-02-15|2011-12-14|2011-12-15|Estimate|||||||2013-02-15|2013-02-20|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|FASY||A Community-health Worker Delivered HIV/STI Prevention Intervention for Internally Displaced Women in Leogane, Haiti|Development and Evaluation of a Community Health Worker Delivered HIV/STI Prevention Intervention for Women Living in Internally Displaced Persons Camps in Leogane, Haiti|Completed||Phase 1|200|Actual|Women's College Hospital|||||f||||f||||||||||2018-05-31 21:49:58.980181|2018-05-31 21:49:58.980181
NCT01492816|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-02-27|2011-12-13|2011-12-15|Estimate|||||||2017-02-27|2017-02-28|Actual|August 2011||2011-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Enhancement of Connect to Protect® (C2P)|Enhancement of Connect to Protect® (C2P) to Increase Structural Change and Reduce HIV Risk: Phase IV|Completed||N/A|927|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 21:49:59.049198|2018-05-31 21:49:59.049198
NCT01492803|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-02-27|2011-12-14|2011-12-15|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2011||2011-12-31|February 2016|2016-02-29|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Trial of Probiotics to Lower Microbial Translocation and Immune Activation in HIV-Infected Adolescents|A Randomized Placebo-Controlled Trial of Probiotics to Lower Microbial Translocation and Immune Activation in HIV-Infected Adolescents|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:49:59.137542|2018-05-31 21:49:59.137542
NCT01492790|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-08-12|2011-12-14|2011-12-15|Estimate|||||||2013-08-12|2013-08-13|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|CCK first||Cholecystectomy First vs Sequential Common Bile Duct Imaging + Cholecystectomy|An Open Randomized Study Comparing Emergency Cholecystectomy First Versus Sequential Common Bile Duct Imaging/Cholecystectomy for the Management of Gallstone Migration|Completed||N/A|100|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 21:49:59.206661|2018-05-31 21:49:59.206661
NCT01492777|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-06-20|2011-12-13|2011-12-15|Estimate|||||||2013-06-20|2013-06-21|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|||Pharmacogenetics of Acenocoumarol|Stabilization of Anticoagulation by Acenocoumarol: Role of Genetic Vulnerability and Risk of Drug Interactions|Completed|||115|Actual|University Hospital, Geneva|||||f||||f||||||Samples With DNA|"~     Whole blood samples~   "|||2018-05-31 21:49:59.293697|2018-05-31 21:49:59.293697
NCT01492764|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-12-11|2011-12-14|2011-12-15|Estimate|||||||2013-12-11|2013-12-12|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|VTFIRM||Ablation of Sources for Rapid Heart Rhythms|Ventricular Tachyarrhythmia Focal Impulse and Rotor Modulation Trial|Unknown status|Recruiting||40|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-05-31 21:49:59.368376|2018-05-31 21:49:59.368376
NCT01492751|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2018-05-07|2011-12-14|2011-12-15|Estimate|||||||2018-05-07|2018-05-11|Actual|April 2003||2003-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2015|Actual|2015-05-31||Observational|E-PROSTCaT||Effectiveness of Localized Prostate Cancer Treatments|Effectiveness of Three Primary Treatments for Localized Prostate Cancer: Radical Prostatectomy, External-beam Radiotherapy, and Prostate Brachytherapy|Active, not recruiting|||500|Anticipated|Fundacion IMIM|||1||f||||f||||||||Undecided||2018-05-31 21:49:59.455677|2018-05-31 21:49:59.455677
NCT01492738|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2015-04-14|2011-12-13|2011-12-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effect of Acupuncture on Anxiety and Working Memory|The Effect of Acupuncture on Anxiety and Working Memory|Completed||N/A|90|Actual|National University of Health Sciences||2|||f||||t||||||||||2018-05-31 21:49:59.536464|2018-05-31 21:49:59.536464
NCT01492725|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2015-04-20|2011-12-14|2011-12-15|Estimate|||||||2015-04-20|2015-04-21|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|EXTEND-IA||Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial|A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection.|Terminated||Phase 2|70|Actual|Neuroscience Trials Australia||2||On DSMB advice, trial recruitment has been halted for efficacy. F/U continues|f||||t||||||||||2018-05-31 21:49:59.593328|2018-05-31 21:49:59.593328
NCT01492712|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-08-11|2011-12-13|2011-12-15|Estimate|||||||2017-08-11|2017-08-14|Actual|January 2011|Actual|2011-01-31|August 2017|2017-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|VaSCoM||Validation Study of Covariates Model (VaSCoM) for Propofol|Validation Study of Covariates Model (VaSCoM) for Propofol|Completed||N/A|40|Actual|Golden Jubilee National Hospital||2|||f||||f||||||||||2018-05-31 21:49:59.682157|2018-05-31 21:49:59.682157
NCT01492699|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-09-24|2011-12-13|2011-12-15|Estimate|||||||2014-09-24|2014-09-25|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder|Single Site, Open Label Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder.|Completed||N/A|7|Actual|Ology Bioservices||1|||f||||f||||||||||2018-05-31 21:50:00.967464|2018-05-31 21:50:00.967464
NCT01492686|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2015-06-18|2011-12-14|2011-12-15|Estimate|||||||2015-06-18|2015-06-19|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis|Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2|Completed||Phase 3|137|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||t||||||||||2018-05-31 21:50:01.063975|2018-05-31 21:50:01.063975
NCT01492673|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-04-17|2011-12-13|2011-12-15|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2011|Actual|2011-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma|A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma|Active, not recruiting||Phase 2|9|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:50:01.276408|2018-05-31 21:50:01.276408
NCT01492660|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-04-19|2011-12-13|2011-12-15|Estimate|||||||2013-04-19|2013-04-23|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Echostim1||Echogenic Versus Stimulating Needle and Catheter for Sciatic Blocks|Comparison of Visibility of Echogenic and Standard Non-echogenic Block Needles During Ultrasound Guided Sciatic Blocks. A Randomized Prospective Study|Completed||Phase 3|70|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:50:01.443362|2018-05-31 21:50:01.443362
NCT01492647|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-02-18|2011-12-14|2011-12-15|Estimate|||||||2013-02-18|2013-02-20|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris|A Randomized, Double Blinded, Single Topical Dose Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Subjects With Acne Vulgaris|Completed||Phase 1|18|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 21:50:01.567759|2018-05-31 21:50:01.567759
NCT01492634|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2014-02-27|2011-12-13|2011-12-15|Estimate|||||||2014-02-27|2014-02-28|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Optimizing Fluid Status|Clinical Investigation Plan Optimizing Fluid Status|Completed||N/A|56|Actual|Hospital Clinic of Barcelona|||||f||||f||||||||||2018-05-31 21:50:01.694748|2018-05-31 21:50:01.694748
NCT01492621|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2011-12-14|2011-12-14|2011-12-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Interventional|||Effect of Antidepressants on White Matter Structure|White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal|||||f||||f||||||||||2018-05-31 21:50:01.778159|2018-05-31 21:50:01.778159
NCT01492608|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2017-09-25|2011-12-14|2011-12-15|Estimate|||||||2017-09-25|2017-09-26|Actual|December 2011|Actual|2011-12-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|December 2017|Anticipated|2017-12-31||Interventional|MASP||Magnesium Sulphate for Preterm Birth (MASP Study)|Administration of Antenatal Magnesium Sulphate for Prevention of Cerebral Palsy in Preterm Infants (MASP-STUDY)|Recruiting||Phase 3|560|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||Undecided||2018-05-31 21:50:01.964203|2018-05-31 21:50:01.964203
NCT01492595|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-02-29|2011-12-13|2011-12-15|Estimate|||||||2016-02-29|2016-03-02|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|TBcontact||Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda|Screening of Children in Household Contact With Adult TB Patients in Mbarara Hospital, Uganda: An Open Cohort of Children <5 Years in Contact With Newly Diagnosed Adult TB Cases in Mbarara Hospital|Completed|||281|Actual|Epicentre|||||f||||f||||||||No||2018-05-31 21:50:02.150795|2018-05-31 21:50:02.150795
NCT01492582|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-10-13|2011-12-13|2011-12-15|Estimate|||||||2017-10-13|2017-10-16|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors|Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial|Recruiting||Phase 2|1268|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 21:50:02.313673|2018-05-31 21:50:02.313673
NCT01492569|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2013-06-11|2011-12-14|2011-12-15|Estimate|||||||2013-06-11|2013-06-12|Estimate|May 2012||2012-05-31|June 2013|2013-06-30||||July 2013|Anticipated|2013-07-31||Interventional|||Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting|Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting|Withdrawn||N/A|0|Actual|Stanford University||2||low accrual|f||||t||||||||||2018-05-31 21:50:02.448225|2018-05-31 21:50:02.448225
NCT01492556|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-03-14|2011-12-13|2011-12-15|Estimate|||||||2013-03-14|2013-03-15|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer|A Phase II, Single-arm, Multicenter Study of Etoposide Monotherapy in Treating Patients With Recurrent or Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:50:02.555102|2018-05-31 21:50:02.555102
NCT01492543|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-03-14|2011-12-13|2011-12-15|Estimate|||||||2013-03-14|2013-03-15|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Interventional|||Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer|An Open-label, Single-arm, Multicenter, Phase II Study to Assess the Efficacy and Safety of Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule) as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:50:02.790526|2018-05-31 21:50:02.790526
NCT01492530|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-06-10|2011-12-14|2011-12-15|Estimate|||||||2014-06-10|2014-06-11|Estimate|August 2007||2007-08-31|June 2014|2014-06-30|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|MAALES||Men of African American Legacy Empowering Self|Reducing HIV Risk Behaviors and Psychosocial Stressors Among Bisexual African American Men|Completed||Phase 2|437|Actual|Charles Drew University of Medicine and Science||2|||f||||t||||||||||2018-05-31 21:50:02.920626|2018-05-31 21:50:02.920626
NCT01492517|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2016-01-15|2011-12-14|2011-12-15|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|May 2015|Actual|2015-05-31|June 2013|Actual|2013-06-30||Interventional|Lamarck||Epigenetic Effects of Diesel Exhaust and Ozone Exposure|Epigenetic Effects of Diesel Exhaust and Ozone Exposure|Completed||N/A|42|Actual|Environmental Protection Agency (EPA)||4|||f||||f||||||||||2018-05-31 21:50:03.000808|2018-05-31 21:50:03.000808
NCT01492504|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-12-06|2011-12-13|2011-12-15|Estimate|||||||2017-12-06|2017-12-07|Actual|February 7, 2012|Actual|2012-02-07|December 2017|2017-12-31|February 16, 2021|Anticipated|2021-02-16|February 15, 2021|Anticipated|2021-02-15||Observational|||Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial|A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C|Active, not recruiting|||1850|Anticipated|Bristol-Myers Squibb|||1||f||||f|t|f||||||||2018-05-31 21:50:03.160233|2018-05-31 21:50:03.160233
NCT01492491|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-10|||2016-06-13|2011-12-14|2011-12-15|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|SALATO||Collaborative Research on HFR High Flux|Collaborative Study on Outcome of Antioxidant Vitamines, Microinflammation Parameters and Middle-high Toxins in ESRD Patients Treated With Online HDF, HFR and SUPRA-HFR|Completed||Phase 3|50|Actual|Azienda Sanitaria Locale di Cagliari||2|||f||||t||||||||||2018-05-31 21:50:03.643504|2018-05-31 21:50:03.643504
NCT01492478|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-14|2011-12-14|2011-12-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Observational|||Psychobiological Characterization of Depression in Hepatitis C|Psychobiological Characterization of Depression in Hepatitis C|Unknown status|Not yet recruiting||200|Anticipated|Centro Hospitalar Lisboa Norte|||||f||||f||||||||||2018-05-31 21:50:03.807462|2018-05-31 21:50:03.807462
NCT01492465|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2013-02-13|2011-12-14|2011-12-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Single Ascending Dose Trial in Patients With Type 2 Diabetes|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes|Terminated||Phase 1|47|Actual|Amgen||2||Decision by Sponsor|f||||||||||||||2018-05-31 21:50:03.914371|2018-05-31 21:50:03.914371
NCT01492452|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-14|2011-12-14|2011-12-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|December 2010||2010-12-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Anxiety of Parents of Children Undergoing Cardiac Surgery|Standard Guidelines Impact of Nursing Anxiety of Parents of Children Undergoing Cardiac Surgery: Randomized Clinical Trial|Completed||N/A|44|Actual|Instituto de Cardiologia do Rio Grande do Sul||1|||f||||f||||||||||2018-05-31 21:50:04.007131|2018-05-31 21:50:04.007131
NCT01492439|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2014-01-22||2014-06-10|2011-12-14|2011-12-15|Estimate|2014-06-10|2014-06-11|Estimate||||2014-06-10|2014-06-11|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness of Cognitive Remediation in a Supported Education Setting|Examining the Effectiveness of Cognitive Remediation in a Supported Education Setting|Completed||N/A|37|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 21:50:04.143207|2018-05-31 21:50:04.143207
NCT01492426|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2015-08-17||2016-04-28|2011-12-14|2011-12-15|Estimate|2016-04-28|2016-06-03|Estimate||||2016-04-28|2016-06-03|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|COMMAND-3||Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection|A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C|Completed||Phase 3|605|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 21:50:05.48271|2018-05-31 21:50:05.48271
NCT01492413|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2011-12-14|2011-12-14|2011-12-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Impact of an Online Behavioral Weight Loss Program|Impact of an Online Behavioral Weight Loss Program Provided With or Without a Fortified Diet Beverage|Completed||N/A|572|Actual|Baylor College of Medicine||4|||f||||f||||||||||2018-05-31 21:50:06.998762|2018-05-31 21:50:06.998762
NCT01492400|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|2015-01-21||2015-01-21|2011-12-13|2011-12-15|Estimate|2015-01-21|2015-01-29|Estimate||||2015-01-21|2015-01-29|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema||Completed||Phase 2|363|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:50:07.206988|2018-05-31 21:50:07.206988
NCT01492387|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2013-12-31|2011-12-14|2011-12-15|Estimate|||||||2013-12-31|2014-01-03|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|DURATION||Duration of Antibiotic Therapy in Community - Acquired Pneumonia|Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial.|Unknown status|Recruiting|Phase 4|892|Anticipated|University of Milan||2|||f||||t||||||||||2018-05-31 21:50:07.872696|2018-05-31 21:50:07.872696
NCT01492374|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-07-23|2011-12-13|2011-12-15|Estimate|||||||2014-07-23|2014-07-24|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease|Completed||Phase 1|40|Actual|Bristol-Myers Squibb||4|||f||||t||||||||||2018-05-31 21:50:08.111554|2018-05-31 21:50:08.111554
NCT01492361|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-03-30|2011-12-13|2011-12-15|Estimate|||||||2018-03-30|2018-04-02|Actual|November 2011||2011-11-30|March 2018|2018-03-31||||July 2018|Anticipated|2018-07-31||Interventional|REDUCE-IT||A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.|Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)|Active, not recruiting||Phase 3|8000|Anticipated|Amarin Pharma Inc.||2|||f||||t||||||||Undecided||2018-05-31 21:50:08.281386|2018-05-31 21:50:08.281386
NCT01492348|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-03-10|2011-12-12|2011-12-14|Estimate|||||||2017-03-10|2017-03-14|Actual|January 2012||2012-01-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|October 2014|Actual|2014-10-31||Interventional|STEPS UP||Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial|Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial|Completed||N/A|666|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t|f|f||||||No||2018-05-31 21:50:09.310071|2018-05-31 21:50:09.310071
NCT01492335|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2016-01-13|2011-12-13|2011-12-14|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|||Cognitive Assessment of Elderly Primary Care Patients|Cognitive Assessment of Elderly Primary Care Patients|Completed||N/A|524|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:50:09.503035|2018-05-31 21:50:09.503035
NCT01492322|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-10-07|2011-12-12|2011-12-14|Estimate|||||||2015-10-07|2015-10-12|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|October 2014|Actual|2014-10-31|July 2013|Actual|2013-07-31||Observational|DDAT||SPECT Imaging of DAT Genotype|Use of SPECT (Single-photon Emission Computed Tomography) to Examine the Role of DAT (Dopamine Transporter) Genotype in Motivated Smoking Behavior|Terminated|||14|Actual|University of Pennsylvania|||1|UPenn suspended production of the ligand necessary to produce the tracer TRODAT.|f||||f||||||||||2018-05-31 21:50:09.600995|2018-05-31 21:50:09.600995
NCT01492309|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-03|2017-09-21||2018-03-14|2011-12-12|2011-12-14|Estimate|2018-03-14|2018-04-10|Actual||||2018-03-14|2018-04-10|Actual|November 2011||2011-11-30|March 2018|2018-03-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|TMS||Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) in Pregnant Women With Depressive Disorder|Completed||N/A|22|Actual|University of Pennsylvania||2|||f||||t||t|f|f||||||2018-05-31 21:50:09.731045|2018-05-31 21:50:09.731045
NCT01492296|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-12|2011-12-12|2011-12-14|Estimate|||||||2011-12-12|2011-12-14|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|safendoscopy||Endoscopy With Short Fasting|Safety, Quality and Comfort of Upper Gastrointestinal Endoscopy With Conscious Sedation After Fasting for Two Hours|Completed||N/A|115|Actual|Universidade de Passo Fundo||2|||f||||f||||||||||2018-05-31 21:50:10.380788|2018-05-31 21:50:10.380788
NCT01492283|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-07-09|2011-12-13|2011-12-14|Estimate|||||||2014-07-09|2014-07-10|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2013|Actual|2013-05-31||Observational|||Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes|Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without Diabetes|Completed|||48|Actual|University Hospital, Gentofte, Copenhagen|||5||f||||t||||||Samples With DNA|"~     DNA (whole blood) will be kept for 15 years~   "|||2018-05-31 21:50:10.629848|2018-05-31 21:50:10.629848
NCT01492270|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-28|2011-12-12|2011-12-14|Estimate|||||||2011-12-28|2011-12-30|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|PICTURE||Imaging for Significant Prostate Cancer Risk Evaluation|PICTURE - Prostate Imaging (Multi-parametric MRI and Prostate HistoScanning™) Compared to Transperineal Ultrasound Guided Biopsy for Significant Prostate Cancer Risk Evaluation.|Unknown status|Recruiting|N/A|126|Anticipated|University College London Hospitals|||||f||||f||||||||||2018-05-31 21:50:10.899217|2018-05-31 21:50:10.899217
NCT01492257|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-12-12|2011-12-12|2011-12-14|Estimate|||||||2012-12-12|2012-12-13|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|SDM||Shared Decision Making in Patients With Osteoarthritis of the Hip and Knee|Shared Decision Making in Patients With Osteoarthritis of the Hip and Knee|Completed||N/A|120|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:50:11.001799|2018-05-31 21:50:11.001799
NCT01492244|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-03-26|2011-12-12|2011-12-14|Estimate|||||||2012-03-26|2012-03-27|Estimate|December 2011||2011-12-31|March 2012|2012-03-31||||||||Observational|||Validation of an Online Knee Pain Map and Questionnaire: A Probabilistic Diagnostic Tool|Alidation of an Online Knee Pain Map and Questionnaire: A Probabilistic Diagnostic Tool|Terminated|||1000|Anticipated|University of California, Los Angeles|||1||f||||t||||||||||2018-05-31 21:50:11.099834|2018-05-31 21:50:11.099834
NCT01492231|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2014-12-10|2011-12-12|2011-12-14|Estimate|||||||2014-12-10|2014-12-12|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Clinical Impact and Outcomes of Interventional Endoscopy Procedures|The Clinical Impact and Outcomes of Interventional Endoscopy Procedures|Enrolling by invitation|||3500|Anticipated|University of California, Irvine|||1||f||||t||||||||||2018-05-31 21:50:11.166255|2018-05-31 21:50:11.166255
NCT01492218|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-02-24|2011-12-12|2011-12-14|Estimate|||||||2017-02-24|2017-02-28|Actual|March 15, 2004|Actual|2004-03-15|February 2017|2017-02-28|August 30, 2004|Actual|2004-08-30|August 30, 2004|Actual|2004-08-30||Observational|||Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction|A Prospective, Open-labelled, Non-controlled Observational Study to Assess Patient Satisfaction, Physician Acceptability and Safety of Mixtard® 30 NovoLet® for the Treatment of Diabetes Mellitus|Completed|||1330|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:50:11.226078|2018-05-31 21:50:11.226078
NCT01492205|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2016-10-13|2011-12-12|2011-12-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||NovoLet® Acceptance Study Within the Hospital Practise in Indonesia|A Doctor and Nurse Survey on Using NovoLet® Within the Hospital Practice in Indonesia|Completed|||203|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:50:11.302601|2018-05-31 21:50:11.302601
NCT01492192|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-10-30|2011-12-12|2011-12-14|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2013||2013-05-31|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||RGD-PET-CT in Cancer Angiogenesis|Prospective Study of 18F-RGD PET-CT in Assessment of Response to Antiangiogenic Treatment in Patients With Cancer and Comparison With Perfusion CT|Terminated||Phase 2|10|Actual|Oxford University Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 21:50:11.379356|2018-05-31 21:50:11.379356
NCT01492179|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2014-05-25|2011-12-13|2011-12-14|Estimate|||||||2014-05-25|2014-05-28|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PoPuLAR||Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management.|A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study.|Completed||Phase 4|60|Anticipated|Örebro University, Sweden||3|||f||||t||||||||||2018-05-31 21:50:11.452185|2018-05-31 21:50:11.452185
NCT01492166|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2016-12-12|2011-12-12|2011-12-14|Estimate|||||||2016-12-12|2016-12-13|Estimate|November 2006||2006-11-30|December 2016|2016-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Mixtard® 30 NovoLet® as Monotherapy, or in Combination With Oral Hypoglycaemic Agent ( OHA ), in Treatment of Subjects With Type 2 Diabetes in Routine Clinical Practice|Completed|||1935|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:50:11.607498|2018-05-31 21:50:11.607498
NCT01492153|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-02-24|2011-12-12|2011-12-14|Estimate|||||||2017-02-24|2017-02-28|Actual|February 11, 2003|Actual|2003-02-11|February 2017|2017-02-28|September 5, 2006|Actual|2006-09-05|September 5, 2006|Actual|2006-09-05||Observational|||NovoLet® Surveillance Study on Using Human Insulin System in Indonesia|A Post Marketing Surveillance on the Use of NovoLet® Human Insulin System in Indonesia|Completed|||1981|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:50:11.729128|2018-05-31 21:50:11.729128
NCT01492140|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2011-12-12|2011-12-12|2011-12-14|Estimate|||||||2011-12-12|2011-12-14|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers|A Randomized, Evaluator-Blind, Bilateral Comparison of an Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers in Patients Seeking Aesthetic Correction of the Nasolabial Folds|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|TKL Research, Inc.|||||f||||f||||||||||2018-05-31 21:50:11.815665|2018-05-31 21:50:11.815665
NCT01492127|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-04-22|2011-12-13|2011-12-14|Estimate|||||||2015-04-22|2015-04-23|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|March 2016|Anticipated|2016-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment|Evolution of Plasma Proteasome Levels Following Curative Treatment of Hepatocellular Carcinoma in Cirrhotic Patients|Unknown status|Active, not recruiting|N/A|64|Actual|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 21:50:12.053825|2018-05-31 21:50:12.053825
NCT01492114|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2012-07-06|2011-12-13|2011-12-14|Estimate|||||||2012-07-06|2012-07-10|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.|Double-blind Cross-over Randomised Controlled Trial on the Anti-inflammatory and Antioxidant Effects of Resveratrol on Healthy Adults.|Completed||Phase 3|40|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 21:50:12.174556|2018-05-31 21:50:12.174556
NCT01492101|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2016-08-02|2011-12-12|2011-12-14|Estimate|||||||2016-08-02|2016-08-04|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|BEACON||The BEACON Study (Breast Cancer Outcomes With NKTR-102)|The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine|Completed||Phase 3|852|Actual|Nektar Therapeutics||2|||f||||t||||||||||2018-05-31 21:50:12.314363|2018-05-31 21:50:12.314363
NCT01492088|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2017-04-05|2017-02-08|2018-04-26|2011-12-12|2011-12-14|Estimate|2017-04-05|2017-05-15|Actual|2017-02-08|2017-02-09|Estimate|2018-04-26|2018-04-30|Actual|April 16, 2012|Actual|2012-04-16|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|October 12, 2016|Actual|2016-10-12||Interventional||Safety population is defined as participants who received at least 1 dose of study drug.|Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma|A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma|Completed||Phase 1/Phase 2|36|Actual|Takeda||2|||f||||f|t|f||||||||2018-05-31 21:50:12.954649|2018-05-31 21:50:12.954649
NCT01492075|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2015-09-26|2011-12-13|2011-12-14|Estimate|||||||2015-09-26|2015-09-29|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PoPuLAR||A Comparison Between Continuous and Intermittent Intraabdominal Analgesia Using Local Anaesthetics|Phase IV Study of Postoperative Pain Management|Completed||Phase 4|40|Actual|Örebro University, Sweden||2|||f||||t||||||||||2018-05-31 21:50:16.786298|2018-05-31 21:50:16.786298
NCT01492062|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2015-03-31|2011-12-12|2011-12-14|Estimate|||||||2015-03-31|2015-04-02|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery|A Study to Evaluate a Multiple Model Probabilistic Predictive Controller (MMPPC) for Closed Loop Insulin Delivery|Withdrawn||N/A|0|Actual|Stanford University||1||Study halted prior to enrollment of first participant.|f||||t||||||||||2018-05-31 21:50:16.912076|2018-05-31 21:50:16.912076
NCT01492049|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-05-03|2011-12-13|2011-12-14|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2012|Actual|2012-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||R-21 Colorectal Cancer Screening (CRCS) Pilot Trial|Pilot Trial - Promoting Health Literacy for Colorectal Cancer Screening|Active, not recruiting||N/A|180|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 21:50:17.429762|2018-05-31 21:50:17.429762
NCT01492036|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-06-15|2011-12-12|2011-12-14|Estimate|||||||2017-06-15|2017-06-16|Actual|December 2011|Actual|2011-12-31|June 2017|2017-06-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Long-Term Follow-Up of Recipient of Gene Transfer Research|Long-Term Follow-Up Study of Recipients of Gene Transfer Research Protocols|Recruiting|||130|Anticipated|M.D. Anderson Cancer Center|||1||f||||t||||||Samples With DNA|"~     Study visits once a year during Years 1-5. Blood (about 2-4 tablespoons each time) drawn for~     routine tests. If retroviral gene transfer therapy received, blood (up to 4 tablespoons each~     time) drawn every 3 months for first year after gene transfer therapy and once a year after~     that. If joining study more than a year after gene transfer therapy, RCR test performed once~     a year for all 15 years of the study.~   "|||2018-05-31 21:50:17.615319|2018-05-31 21:50:17.615319
NCT01492023|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2013-03-08|2011-12-12|2011-12-14|Estimate|||||||2013-03-08|2013-03-11|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Observational|MSattention||The Effects of Attention Retraining in MS|The Effects of Attention Retraining on Cognitive Performance, QoL and Perceived Cognitive Impairment in MS - a Single Blind, Randomized, Controlled Study|Completed|||97|Actual|Finnish MS Society|||2||f||||f||||||None Retained|"~     A randomised, controlled, single-blind study~   "|||2018-05-31 21:50:17.731147|2018-05-31 21:50:17.731147
NCT01492010|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2011-12-12|2011-12-12|2011-12-14|Estimate|||||||2011-12-12|2011-12-14|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Role of Leucine in the Regulation of Human Myofibrillar Protein Synthesis at Rest and Following Resistance Exercise|Role of Leucine in the Regulation of Human Myofibrillar Protein Synthesis at Rest and Following Resistance Exercise|Completed||N/A|24|Actual|McMaster University||3|||f||||f||||||||||2018-05-31 21:50:17.836088|2018-05-31 21:50:17.836088
NCT01491997|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2017-09-26|2011-12-12|2011-12-14|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2011||2011-08-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mind-Body Medicine and Ulcerative Colitis|Mind-Body Medicine and Ulcerative Colitis|Active, not recruiting||N/A|100|Anticipated|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 21:50:17.940663|2018-05-31 21:50:17.940663
NCT01491984|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2013-05-22||2015-02-24|2011-12-12|2011-12-14|Estimate|2015-02-24|2015-03-10|Estimate||||2015-02-24|2015-03-10|Estimate|July 2009||2009-07-31|February 2015|2015-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effectiveness and Safety of the Levitan Scope for Laryngoscopy and Tracheal Intubation With a Simulated Difficult Airway|Effectiveness and Safety of the Levitan FPS Scope for Laryngoscopy and Tracheal Intubation With a Simulated Difficult Airway in Surgical Subjects Under General Anesthesia|Completed||Phase 4|105|Actual|IWK Health Centre||2|||f||||t||||||||||2018-05-31 21:50:18.020755|2018-05-31 21:50:18.020755
NCT01491971|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22||2013-11-18|2013-11-18|2011-12-12|2011-12-14|Estimate||||2013-11-18|2013-12-12|Estimate|2013-11-18|2013-12-12|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|IM1||Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer|Open-label, Multi-centre, Parallel Group Dose-Escalation Trial Assessing the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer|Completed||Phase 2|76|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-05-31 21:50:18.550012|2018-05-31 21:50:18.550012
NCT01491958|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2017-05-23||2018-01-16|2011-12-13|2011-12-14|Estimate|2018-01-16|2018-01-23|Actual||||2018-01-16|2018-01-23|Actual|December 10, 2011|Actual|2011-12-10|January 2018|2018-01-31|June 27, 2016|Actual|2016-06-27|January 1, 2014|Actual|2014-01-01||Interventional|||Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation|Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Versus Host Disease(GVHD) in Patients With Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)|Completed||Phase 2|40|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:50:19.053863|2018-05-31 21:50:19.053863
NCT01491945|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2015-08-20|2011-12-12|2011-12-14|Estimate|||||||2015-08-20|2015-08-24|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|April 2018|Anticipated|2018-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Safety and Effectiveness Trial of the Ventana Fenestrated Stent Graft System|Prospective, Multicenter, Single Arm Safety and Effectiveness Trial of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms|Unknown status|Active, not recruiting|Phase 2|122|Anticipated|Endologix||1|||f||||t||||||||||2018-05-31 21:50:19.726601|2018-05-31 21:50:19.726601
NCT01491932|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-03-20|2011-12-12|2011-12-14|Estimate|||||||2017-03-20|2017-03-22|Actual|March 2012||2012-03-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|Completed||Phase 2|129|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:50:19.870573|2018-05-31 21:50:19.870573
NCT01491919|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2015-04-27||2015-06-15|2011-12-12|2011-12-14|Estimate|2015-06-15|2015-07-08|Estimate||||2015-06-15|2015-07-08|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PTN_LISINO||Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant|Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients|Completed||Phase 1|26|Actual|Duke University||3|||f||||t||||||||||2018-05-31 21:50:20.068545|2018-05-31 21:50:20.068545
NCT01491906|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-07-28|2011-12-12|2011-12-14|Estimate|||||||2014-07-28|2014-07-29|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|February 2012|Actual|2012-02-29||Interventional|||Weight Loss Among Adults in Beijing, China|Weight Loss Among Adults in Beijing, China|Completed||N/A|123|Actual|Duke University||2|||f||||f||||||||||2018-05-31 21:50:20.954228|2018-05-31 21:50:20.954228
NCT01491893|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2018-02-26|2011-12-12|2011-12-14|Estimate|||||||2018-02-26|2018-02-28|Actual|April 25, 2012|Actual|2012-04-25|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 27, 2017|Actual|2017-06-27||Interventional|PVSRIPO||PVSRIPO for Recurrent Glioblastoma (GBM)|Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant Glioma|Active, not recruiting||Phase 1|61|Actual|Duke University||1|||f||||t|t|f||||||No||2018-05-31 21:50:21.033821|2018-05-31 21:50:21.033821
NCT01491880|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2012-01-17|2011-12-13|2011-12-14|Estimate|||||||2012-01-17|2012-01-18|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Treatment Study for Rural Latino Youth With Anxiety|Feasible Delivery of CBT for Rural Latino Youth With Anxiety|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:50:21.170116|2018-05-31 21:50:21.170116
NCT01491867|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-03-20|2011-12-13|2011-12-14|Estimate|||||||2013-03-20|2013-03-22|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect|Evaluation of Continuous IOP Measurement and the Influence of Drug Induced IOP Decrease on the Measurement|Completed||N/A|9|Actual|Semmelweis University||1|||f||||f||||||||||2018-05-31 21:50:21.469607|2018-05-31 21:50:21.469607
NCT01491854|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-06-08|2011-12-13|2011-12-14|Estimate|||||||2017-06-08|2017-06-09|Actual|July 2009||2009-07-31|June 2017|2017-06-30|July 2031|Anticipated|2031-07-31|July 2031|Anticipated|2031-07-31||Interventional|SGA||Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational Age|Long-term Safety Follow-up After Growth Hormone Treatment (rhGH) of Short Children Born Small for Gestational Age (SGA)|Recruiting||N/A|200|Anticipated|Sandoz||1|||f||||f||||||||||2018-05-31 21:50:21.820989|2018-05-31 21:50:21.820989
NCT01491841|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2016-09-30|2011-12-12|2011-12-14|Estimate|||||||2016-09-30|2016-10-03|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|November 2021|Anticipated|2021-11-30|November 2016|Anticipated|2016-11-30||Interventional|BRP||IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma|Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|33|Actual|Duke University||1|||f||||f||||||||||2018-05-31 21:50:22.166908|2018-05-31 21:50:22.166908
NCT01491828|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-10|||2012-03-19|2011-12-13|2011-12-14|Estimate|||||||2012-03-19|2012-03-20|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study to Determine Results of Vibratory Stimulus on Subject's Neck|Study to Determine Results of Vibratory Stimulus on Subject's Neck|Completed||Phase 1|100|Anticipated|Kai Medical, Inc.|||||f||||f||||||||||2018-05-31 21:50:22.607789|2018-05-31 21:50:22.607789
NCT01491815|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-12-01|2011-12-12|2011-12-14|Estimate|||||||2017-12-01|2017-12-04|Actual|December 2012||2012-12-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction|A Multicenter, Randomized, Open-label, Blinded-assessor, Phase 4 Study in Patients With Early Rheumatoid Arthritis to Compare Active Conventional Therapy Versus Three Biologic Treatments, and Two De-escalation Strategies in Patients Who Respond to Treatment|Recruiting||Phase 4|800|Anticipated|Karolinska Institutet||4|||f||||t||||||||No||2018-05-31 21:50:22.838682|2018-05-31 21:50:22.838682
NCT01491802|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2016-12-13||2017-05-02|2011-12-13|2011-12-14|Estimate|2017-05-02|2017-08-15|Actual||||2017-05-02|2017-08-15|Actual|January 2012||2012-01-31|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD|A 4-week Randomized, Double-blind, Crossover Study to Assess the Effect of a New LABA/LAMA Combination Versus LAMA Alone on Exertional Dyspnea, Exercise Endurance and Neuromechanical Coupling in Patients With GOLD Stage II COPD|Completed||Phase 3|17|Actual|Queen's University||2|||f||||t||||||||||2018-05-31 21:50:23.056341|2018-05-31 21:50:23.056341
NCT01491789|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2018-02-19|2011-12-12|2011-12-14|Estimate|||||||2018-02-19|2018-02-20|Actual|May 2011||2011-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VSail||Virtual Sailing Simulator in Individuals With Spinal Cord Injury|Virtual Sailing Simulator in Individuals With Spinal Cord Injury|Recruiting||Phase 1/Phase 2|20|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t||||||||||2018-05-31 21:50:23.782259|2018-05-31 21:50:23.782259
NCT01491776|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2012-03-07|2011-12-12|2011-12-14|Estimate|||||||2012-03-07|2012-03-08|Estimate|December 2011||2011-12-31|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Observational|||Evaluation of the IND One Step Strep A Rapid Test vs. Culture|Evaluation of the IND One Step Strep A Rapid Test Versus Culture Using Clinical Throat Swab Samples From Patients With Suspected Strep A Infections, CLIA Waiver Study|Unknown status|Recruiting||315|Anticipated|IND Diagnostic Inc.|||||f||||f||||||||||2018-05-31 21:50:24.348363|2018-05-31 21:50:24.348363
NCT01491763|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-03-19|2011-12-13|2011-12-14|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2008|Actual|2008-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE||Recruiting||Phase 4|70|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-05-31 21:50:25.173266|2018-05-31 21:50:25.173266
NCT01491750|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-01-02|2011-12-12|2011-12-14|Estimate|||||||2014-01-02|2014-01-06|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Guided Imagery Response in Total Knee Replacement|Factors Affecting Guided Imagery Response in Total Knee Replacement|Completed||Phase 2|82|Anticipated|Kent State University||2|||f||||t||||||||||2018-05-31 21:50:25.603905|2018-05-31 21:50:25.603905
NCT01491737|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2017-05-11||2018-05-04|2011-12-12|2011-12-14|Estimate|2017-05-11|2017-06-07|Actual||||2018-05-04|2018-05-08|Actual|February 17, 2012|Actual|2012-02-17|May 2018|2018-05-31|October 26, 2019|Anticipated|2019-10-26|March 17, 2016|Actual|2016-03-17||Interventional|PERTAIN|Intent to treat (ITT) included all randomized participants.|A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer|A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-Positive and Hormone Receptor-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer|Active, not recruiting||Phase 2|258|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 21:50:25.918579|2018-05-31 21:50:25.918579
NCT01491724|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-14|2011-12-12|2011-12-14|Estimate|||||||2011-12-14|2011-12-15|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|January 2012|Anticipated|2012-01-31||Observational|||The Learning Curve of Probe-based Confocal Laser Endomicroscopy (pCLE) Images Interpretation in Gastric Intestinal Metaplasia (GIM)|The Learning Curve of Probe-based Confocal Laser Endomicroscopy (pCLE) Images Interpretation in Gastric Intestinal Metaplasia(GIM)|Unknown status|Recruiting||5|Anticipated|King Chulalongkorn Memorial Hospital|||1||f||||f||||||||||2018-05-31 21:50:26.858949|2018-05-31 21:50:26.858949
NCT01491711|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-01-30|2011-12-12|2011-12-14|Estimate|||||||2014-01-30|2014-01-31|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate|Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate|Unknown status|Recruiting|Phase 4|162|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:50:26.970733|2018-05-31 21:50:26.970733
NCT01491698|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2013-08-14|2011-12-12|2011-12-14|Estimate|||||||2013-08-14|2013-08-15|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma|A Pilot Randomized Controlled Trial Examining the Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Health-Related Quality of Life in Patients Undergoing Total Gastrectomy for Adenocarcinoma|Completed||Phase 3|12|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:50:27.923287|2018-05-31 21:50:27.923287
NCT01491685|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-01-18|2011-12-12|2011-12-14|Estimate|||||||2012-01-18|2012-01-19|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Parturient Microcirculation|An Observational Assessment of the Sublingual Microcirculation of Pregnant and Non-pregnant Women (Parturient Microcirculation - Phase 1)|Completed|||36|Actual|IWK Health Centre|||2||f||||||||||||||2018-05-31 21:50:29.667501|2018-05-31 21:50:29.667501
NCT01491672|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2016-04-26||2016-06-02|2011-12-13|2011-12-14|Estimate|2016-04-26|2016-06-02|Estimate||||2016-06-02|2016-06-06|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RECORD-4||Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma|An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|134|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:50:29.990374|2018-05-31 21:50:29.990374
NCT01491659|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2013-09-23|2011-12-13|2011-12-14|Estimate|||||||2013-09-23|2013-09-24|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||A Study to Evaluate the Effect and Safety of Idoform Plus on Bowel Side Effects in Healthy Subjects Treated With Amoxicillin/ Clavulanate|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect and Safety of Idoform Plus on Bowel Side Effects in Healthy Subjects Treated With Amoxicillin/ Clavulanate|Withdrawn||Phase 4|0|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:50:30.667244|2018-05-31 21:50:30.667244
NCT01491646|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-04-14|2011-12-13|2011-12-14|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension|Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension|Completed|||25|Actual|National Jewish Health|||2||f||||f||||||Samples Without DNA|"~     plasma, serum~   "|||2018-05-31 21:50:30.730315|2018-05-31 21:50:30.730315
NCT01491633|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2014-05-14||2014-06-14|2011-12-12|2011-12-14|Estimate|2014-06-14|2014-07-15|Estimate||||2014-06-14|2014-07-15|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Dasatinib in Advanced Squamous Cell Lung Cancer|Phase II Trial of Dasatinib in Advanced (Stage IIIB/IV) Squamous Cell Lung Cancer|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|Due to the toxicity of the study agent no subjects were evaluable for response|1||Safety issues/concerns per DF/HCC PI|f||||t||||||||||2018-05-31 21:50:30.80288|2018-05-31 21:50:30.80288
NCT01491620|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2013-08-05|2011-12-13|2011-12-14|Estimate|||||||2013-08-05|2013-08-07|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte|A Single-Center Prospective, Open-Label Study of the Excel V 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte|Completed||N/A|24|Actual|Cutera Inc.||1|||f||||f||||||||||2018-05-31 21:50:30.970076|2018-05-31 21:50:30.970076
NCT01491607|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2013-07-11||2013-09-25|2011-12-13|2011-12-14|Estimate|2013-09-25|2013-11-28|Estimate||||2013-09-25|2013-11-28|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Participants 18 to 65 years of age who received all three doses of BioThrax within the allowable time window and had a blood sample collected for immunogenicity testing on Day 63 ± 2 days. Subjects with key protocol deviations that may have impacted assessment of immune response or sample testing (as determined by Sponsor) on Day 63 were excluded.|Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults|Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults|Completed||Phase 3|200|Actual|Emergent BioSolutions||1|||f||||f||||||||||2018-05-31 21:50:31.151355|2018-05-31 21:50:31.151355
NCT01491594|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2014-04-01|2011-12-13|2011-12-14|Estimate|||||||2014-04-01|2014-04-02|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia|A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy|Terminated||Phase 1|1|Actual|Duke University||||Unable to accrue subjects to the study.|f||||f||||||||||2018-05-31 21:50:33.572433|2018-05-31 21:50:33.572433
NCT01491581|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-11-20|2011-12-12|2011-12-14|Estimate|||||||2012-11-20|2012-11-21|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy of a Milk-based Nutrient-rich Bar on Nutritional Status and Cognitive Performance of School Children in Vietnam|Efficacy of a Milk-based Nutrient-rich Bar on Nutritional Status and Cognitive Performance of School Children in Vietnam|Completed||N/A|415|Actual|Institut de Recherche pour le Developpement||2|||f||||f||||||||||2018-05-31 21:50:33.647896|2018-05-31 21:50:33.647896
NCT01491568|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2005||2005-07-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|May 2009|Actual|2009-05-31||Interventional|||rhBMP-2/CRM/CD HORIZON® Spinal System Pilot Study (2-Level)|Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic DDD at Two Adjacent Vertebral Levels|Completed||Phase 1|29|Actual|Medtronic Spinal and Biologics||1|||f||||t||||||||||2018-05-31 21:50:34.801344|2018-05-31 21:50:34.801344
NCT01491555|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-03-23|2011-12-13|2011-12-14|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|QED||Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy|Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular Dystrophy|Completed|||73|Actual|Boston Children’s Hospital|||2||f||||f||||||||Undecided||2018-05-31 21:50:34.878198|2018-05-31 21:50:34.878198
NCT01491542|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2003||2003-04-30|December 2011|2011-12-31|March 2007|Actual|2007-03-31|November 2006|Actual|2006-11-30||Interventional|||INFUSE® Bone Graft and MASTERGRAFT® Granules With CD HORIZON® for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease - Pilot Study|A Pilot Prospective Randomized Clinical Investigation of INFUSE® Bone Graft and MASTERGRAFT® Granules With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease|Completed||N/A|46|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-05-31 21:50:34.959028|2018-05-31 21:50:34.959028
NCT01491529|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12||2016-03-28|2016-03-28|2011-12-12|2011-12-14|Estimate||||2016-03-28|2016-05-02|Estimate|2016-03-28|2016-05-02|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease|Completed||Phase 2|154|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:50:35.054295|2018-05-31 21:50:35.054295
NCT01490528|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2011-12-12|2011-12-09|2011-12-13|Estimate|||||||2011-12-12|2011-12-14|Estimate|January 2012||2012-01-31|December 2011|2011-12-31||||||||Observational|||Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience||Unknown status|Not yet recruiting||200|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 21:50:52.986444|2018-05-31 21:50:52.986444
NCT01491516|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2003||2003-07-31|December 2011|2011-12-31|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||TELAMON P™ Implant/INFUSE® Bone Graft/CD HORIZON® Spinal System Pilot Study|A Pilot, Prospective, Non-Randomized Clinical Investigation of TELAMON P™ Implant With INFUSE® Bone Graft and the CD HORIZON® Spinal System for Posterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|Completed||Phase 1|30|Actual|Medtronic Spinal and Biologics||1|||f||||t||||||||||2018-05-31 21:50:35.268656|2018-05-31 21:50:35.268656
NCT01491503|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2013-04-04|2011-12-13|2011-12-14|Estimate|||||||2013-04-04|2013-04-05|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|MOLZ||A Drug Interaction Study of Montelukast and Levocetirizine|Open Label, Randomized, 6-sequence Crossover Study to Evaluate the Drug-drug Interaction Between Montelukast Sodium and Levocetirizine Dihydrochloride in Health Male Volunteers|Completed||Phase 1|30|Anticipated|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 21:50:35.442826|2018-05-31 21:50:35.442826
NCT01491490|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2013-08-28||2014-09-09|2011-12-13|2011-12-14|Estimate|2013-08-28|2013-11-01|Estimate||||2014-09-09|2014-09-18|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|GWMD09126|Only two subjects of a planned 60 were randomised due to early termination of the study due to problems with recruitment.|Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine|A Randomised, Doubleblind,Placebo Controlled, Parallel Group, Pilot Study of 40:1 Ratio of Formulated GW42003 :GW42004 in the Treatment of Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine Treatment in Subjects With Functional Psychosis|Terminated||Phase 2|2|Actual|GW Research Ltd|Early termination due to low subject recruitment meant only two subjects were randomised; one to active and the other to placebo. Only safety data of these two subjects has been reported.|2||"The Chief Investigator and the Sponsor have concluded that it will not be possible to complete~   the enrolment in any meaningful timeframe."|f||||f||||||||||2018-05-31 21:50:35.556304|2018-05-31 21:50:35.556304
NCT01491477|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2002||2002-04-30|December 2011|2011-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||INFUSE ® Bone Graft/CORNERSTONE-SR® Allograft Ring/ATLANTIS® Anterior Cervical Plate System Pivotal Trial|Study of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the Cornerstone-SR™ Allograft Ring and the ATLANTIS™ Anterior Cervical Plate System in Treatment of Patients With Degenerative Cervical Disc Disease|Terminated||N/A|3|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-05-31 21:50:35.875414|2018-05-31 21:50:35.875414
NCT01491464|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|March 1999||1999-03-31|December 2011|2011-12-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||A Pivotal Study of rhBMP-2/ACS/INTER FIX™ Device for Posterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the INTER FIX™ Device for Posterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|Terminated||N/A|67|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-05-31 21:50:35.953208|2018-05-31 21:50:35.953208
NCT01491451|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 1999||1999-02-28|December 2011|2011-12-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||A Pilot Study of rhBMP-2/ACS With the INTERFIX™ Device for the AnteriorLumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Pilot Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the INTERFIX™ Device for the Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|Completed||N/A|45|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-05-31 21:50:36.038102|2018-05-31 21:50:36.038102
NCT01491438|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2013-02-06|2011-12-13|2011-12-14|Estimate|||||||2013-02-06|2013-02-07|Estimate|November 2013||2013-11-30|December 2011|2011-12-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Plasma Rich Growth Factors in Venous Ulcers|Randomized Clinical Trial to Determinate the Effectiveness and Safety of Plasma Rich Growth Factors (PRGF) in Venous Ulcers Treatment|Unknown status|Not yet recruiting|N/A|214|Anticipated|Basque Health Service||2|||f||||||||||||||2018-05-31 21:50:36.108275|2018-05-31 21:50:36.108275
NCT01491425|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 1998||1998-11-30|December 2011|2011-12-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||A Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|Completed||N/A|134|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-05-31 21:50:36.186875|2018-05-31 21:50:36.186875
NCT01491412|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2012-11-29|2011-12-13|2011-12-14|Estimate|||||||2012-11-29|2012-11-30|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|||||Observational|||Non-interventional Study: Real-life Use of Atypical Antipsychotics in Acute Inpatient Management of Schizophrenia|RECONNECT-S GAMMA : A Non-interventional Study to Observe Real-life Usage of Atypical Antipsychotics in the Acute Inpatient Management of Schizophrenia|Completed|||503|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:50:36.259962|2018-05-31 21:50:36.259962
NCT01491399|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 1999||1999-09-30|December 2011|2011-12-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||INFUSE™ BONE GRAFT/CORNERSTONE-SR™ Allograft Ring/ATLANTIS™ Anterior Cervical Plate- Pilot Study|Study of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the CORNERSTONE-SR™Allograft Ring and ATLANTIS™ Anterior Cervical Plate System in Treatment of Patients With Degenerative Cervical Disc Disease|Completed||N/A|33|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-05-31 21:50:36.346279|2018-05-31 21:50:36.346279
NCT01491386|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-13|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 1998||1998-08-31|December 2011|2011-12-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|A Clinical Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease|Completed||N/A|279|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-05-31 21:50:36.410045|2018-05-31 21:50:36.410045
NCT01491373|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-08-01|2011-12-12|2011-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 1997||1997-01-31|December 2011|2011-12-31|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Pilot Study of rhBMP-2/ACS/LT-CAGE® for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|A Feasibility Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease|Completed||N/A|14|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-05-31 21:50:36.474449|2018-05-31 21:50:36.474449
NCT01491360|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-04-25|2011-12-13|2011-12-14|Estimate|||||||2014-04-25|2014-04-29|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||LaserACE® Procedure Restore Visual Function and Range of Accommodation LaserACE® Procedure|Evaluation of the Safety & Efficacy of the LaserACE® Procedure to Restore Visual Function and Range of Accommodation|Unknown status|Enrolling by invitation|Phase 3|146|Anticipated|ACE Vision Group, Inc.||1|||f||||f||||||||||2018-05-31 21:50:36.576513|2018-05-31 21:50:36.576513
NCT01491347|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-01-30|2011-12-13|2011-12-14|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal|Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months Following After Alcohol Withdrawal in Alcohol-dependent Subjects in Relation to Abstinence|Completed|||389|Actual|Centre Hospitalier Esquirol|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:50:36.72449|2018-05-31 21:50:36.72449
NCT01491334|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2014-02-24|2011-12-13|2011-12-14|Estimate|||||||2014-02-24|2014-02-25|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Observational|VTI-03||Validation of Transvaginal Tactile Imaging|A Clinical Validation Study With Transvaginal Tactile Imaging|Completed|||158|Actual|Artann Laboratories|||2||f||||f||||||||||2018-05-31 21:50:36.846197|2018-05-31 21:50:36.846197
NCT01491321|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-03-20|2011-12-12|2011-12-14|Estimate|||||||2012-03-20|2012-03-21|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Bee Venom Acupuncture for the Treatment of Chronic Low Back Pain|Clinical Trial to Evaluate the Efficacy of Bee Venom Acupuncture on Chronic Low Back Pain|Unknown status|Recruiting|Phase 2|54|Anticipated|Kyunghee University Medical Center||2|||f||||||||||||||2018-05-31 21:50:36.918669|2018-05-31 21:50:36.918669
NCT01491308|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2011-12-12|2011-12-12|2011-12-13|Estimate|||||||2011-12-12|2011-12-13|Estimate|January 2012||2012-01-31|December 2011|2011-12-31||||January 2013|Anticipated|2013-01-31||Interventional|||Restrictive Versus Liberal Red Cell Transfusion Strategy in Orthopedic-Oncology Patients Undergoing Surgery - a Randomized Controlled Study||Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 21:50:37.009148|2018-05-31 21:50:37.009148
NCT01491295|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2016-03-31|2011-12-11|2011-12-13|Estimate|||||||2016-03-31|2016-04-01|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients|Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment|Recruiting||Phase 4|160|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 21:50:37.084592|2018-05-31 21:50:37.084592
NCT01491282|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2011-12-11|2011-12-11|2011-12-13|Estimate|||||||2011-12-11|2011-12-13|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Observational|||Study of the Effect of Vagus Nerve Stimulation on Human Brown Adipose Tissue Activity|Brown Adipose Tissue After Vagus Nerve Stimulation|Unknown status|Recruiting||5|Anticipated|Maastricht University|||1||f||||f||||||||||2018-05-31 21:50:37.213325|2018-05-31 21:50:37.213325
NCT01491269|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2011-12-11|2011-12-11|2011-12-13|Estimate|||||||2011-12-11|2011-12-13|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Guided Internet-delivered Cognitive-behavioral Therapy for Former Chronic Pain Patients|Guided Internet-delivered Cognitive-behavioral Therapy for Former Chronic Pain Patients: Randomised Controlled Trial|Completed||N/A|72|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 21:50:37.376856|2018-05-31 21:50:37.376856
NCT01491256|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2011-12-11|2011-12-11|2011-12-13|Estimate|||||||2011-12-11|2011-12-13|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|February 2012|Anticipated|2012-02-29|November 2011|Actual|2011-11-30||Interventional|RESIST-ACS||Index of Microcirculatory Resistance After Drug-Eluting Stent Implantation With High Dose Atorvastatin Loading|Randomized Comparison Multicenter Trial of High Dose Atorvastatin Pre-treatment on Microcirculatory Dysfunction After Drug-ElutIng Stent Implantation in Patients With Acute Coronary Syndrome|Unknown status|Recruiting|N/A|100|Anticipated|The Korean Society of Circulation||2|||f||||t||||||||||2018-05-31 21:50:37.493683|2018-05-31 21:50:37.493683
NCT01491243|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2013-03-06|2011-12-11|2011-12-13|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|NEW-MOON||N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy|Neutrophil gElatinase-associated Lipocalin alloWs Intensive treatMent Of cOntrast Induced Nephropathy in Patients With Urgent/Emergency Percutaneous Coronary Intervention|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:50:37.719345|2018-05-31 21:50:37.719345
NCT01491230|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2011-12-12|2011-12-12|2011-12-13|Estimate|||||||2011-12-12|2011-12-13|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|NETs post HSCT||Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation|Neutrophil Extracellular Traps (NETs) Formation Post-hematopoietic Stem Cell Transplantation (HSCT) and Its Relation to Chemotaxis and Creation of Reactive Oxygen Species|Unknown status|Recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     10cc of peripheral venous blood will be collected from each patient at several time points:~     Before transplant, at neutrophil engraftment, 6 weeks, 3 months, 4 months, 6 months, 9~     months, 1 year, 1.5 years, 2 years, and 3 years post-transplant, or until normalization of~     NETs formation in 2 consecutive examinations.~   "|||2018-05-31 21:50:37.800341|2018-05-31 21:50:37.800341
NCT01491217|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-11|2011-12-11|2011-12-13|Estimate|||||||2011-12-11|2011-12-13|Estimate|May 2009||2009-05-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|March 2012|Anticipated|2012-03-31||Interventional|||A Study of Oraxol® in Gastric Cancer Patients|A Phase I-II Clinical Trial to Determine Recommended Dose and to Assess the Efficacy, Safety and Pharmacokinetic Profile of Oral Paclitaxel(Oraxol®) in Patients With Advanced/Metastatic or Recurrent Gastric Cancer|Unknown status|Recruiting|Phase 1/Phase 2|53|Anticipated|Hanmi Pharmaceutical Company Limited|||||f||||f||||||||||2018-05-31 21:50:37.924412|2018-05-31 21:50:37.924412
NCT01491204|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-11|2011-12-11|2011-12-13|Estimate|||||||2011-12-11|2011-12-13|Estimate|August 2006||2006-08-31|December 2011|2011-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer|Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer|Completed||Phase 1|25|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 21:50:38.031265|2018-05-31 21:50:38.031265
NCT01491191|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2011-12-12|2011-12-12|2011-12-13|Estimate|||||||2011-12-12|2011-12-13|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|PEAforCPSP||Palmitoylethanolamide for Post-operative Pain Prevention|Perioperative Use of Palmitoylethanolamide for Prevention of Chronic Postsurgical Pain in Patients Undergoing Elective Surgery.|Unknown status|Not yet recruiting|N/A|300|Anticipated|University of Modena and Reggio Emilia||2|||f||||f||||||||||2018-05-31 21:50:38.099605|2018-05-31 21:50:38.099605
NCT01491178|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|2017-07-26||2017-07-26|2011-12-12|2011-12-13|Estimate|2017-07-26|2018-01-30|Actual||||2017-07-26|2018-01-30|Actual|December 12, 2011|Actual|2011-12-12|July 2017|2017-07-31|August 2, 2016|Actual|2016-08-02|August 2, 2016|Actual|2016-08-02||Observational||Safety set: This patient set includes all patients who received treatment of Prazaxa® Capsules except those who were found not following registration rule, no actual visit, previous treatment experience with Prazaxa.|Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation|Post-Marketing Surveillance on the Long-Term Use of Prazaxa® Capsules in Patients With Nonvalvular Atrial Fibrillation|Completed|||6772|Actual|Boehringer Ingelheim|The study was conducted in an unblinded manner and without controls. The explanatory power of the study results was limited and the study results should be interpreted with the necessary caution.||1||f||||||||||||||2018-05-31 21:50:38.405374|2018-05-31 21:50:38.405374
NCT01491165|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2012-10-25|2011-12-11|2011-12-13|Estimate|||||||2012-10-25|2012-10-26|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis|Safety and Efficacy of Umbilical Cord Mesenchyma Stem Cell Transplantation in Liver Cirrhosis Patients|Unknown status|Recruiting|Phase 2/Phase 3|75|Anticipated|General Hospital of Chinese Armed Police Forces||1|||f||||t||||||||||2018-05-31 21:50:41.045174|2018-05-31 21:50:41.045174
NCT01491152|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-03-06|2011-12-12|2011-12-13|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pilot Study of Whole Body Vibration for Children With Cerebral Palsy (CP) From 12 Months of Age|Side-alternating Whole Body Vibration in Children With Cerebral Palsy (CP) From 12 Months of Age - Pilot Study|Completed||N/A|24|Actual|University of Cologne||2|||f||||t||||||||||2018-05-31 21:50:41.136809|2018-05-31 21:50:41.136809
NCT01491139|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2012-05-29|2011-12-12|2011-12-13|Estimate|||||||2012-05-29|2012-05-30|Estimate||||May 2012|2012-05-31||||||||Interventional|ORCA||Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Study of Olaparib in Addition to Cisplatin Based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)|Withdrawn||Phase 1|0|Actual|University College, London||1||Study stopped due to issues surrounding development and formulation of olaparib|f||||t||||||||||2018-05-31 21:50:41.239737|2018-05-31 21:50:41.239737
NCT01491126|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2014-02-24|2011-12-12|2011-12-13|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Observational|||Single Center Open Prospective Study for the Comparison of Procedural Sequence in Same Day Consecutive Bidirectional Endoscopy||Unknown status|Not yet recruiting||170|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 21:50:41.347599|2018-05-31 21:50:41.347599
NCT01491113|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2013-11-21||2014-01-13|2011-12-09|2011-12-13|Estimate|2013-11-21|2014-01-10|Estimate||||2014-01-13|2014-02-10|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||The Baseline Analysis Population refers to the Pharmacokinetic Per Protocol Set (PK-PPS) which consists of all subjects included in the Safety Set (SS), who also had a sufficient number of bioanalytical assessments (plasma or urine) to calculate reliable estimates for the PK parameters.|Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients|Single-Dose Pharmacokinetics of Orally Administered Levetiracetam (LEV) in Japanese Subjects With Normal Renal Function and Various Degrees of Renal Impairment Using a Dosing Regimen Adjusted to Renal Function (250 mg or 500 mg)|Completed||Phase 4|30|Actual|UCB Pharma||5|||f||||f||||||||||2018-05-31 21:50:41.46965|2018-05-31 21:50:41.46965
NCT01491100|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-04-04|2011-12-12|2011-12-13|Estimate|||||||2018-04-04|2018-04-05|Actual|April 30, 2012|Actual|2012-04-30|April 2018|2018-04-30|April 5, 2017|Actual|2017-04-05|December 22, 2016|Actual|2016-12-22||Observational|CogniPlus||Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis|Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon®|Completed|||1085|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:50:42.513226|2018-05-31 21:50:42.513226
NCT01491087|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2013-03-28|2011-12-09|2011-12-13|Estimate|||||||2013-03-28|2013-03-29|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China|Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China|Completed||Phase 4|900|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:50:42.610372|2018-05-31 21:50:42.610372
NCT01491074|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-05-16|2011-12-12|2011-12-13|Estimate|||||||2014-05-16|2014-05-19|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction|Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction - a Randomized, Double Blind, Placebo Controlled Study.|Completed||Phase 2|120|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 21:50:42.684501|2018-05-31 21:50:42.684501
NCT01491061|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-03-06|2011-12-09|2011-12-13|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|TWILIGHT||Ranolazine Loading to Prevent PCI-induced Myocardial Injury|TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:50:42.751749|2018-05-31 21:50:42.751749
NCT01491048|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2011-12-09|2011-12-09|2011-12-13|Estimate|||||||2011-12-09|2011-12-13|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Artrhosis||Evaluation of Functional Rehabilitation in Patients Undergoing Physiotherapy After Total Hip Arthroplasty|Evaluation of Functional Rehabilitation Therapy in Patients Undergoing Physiotherapy After Total Hip Arthroplasty|Completed||N/A|104|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 21:50:42.825132|2018-05-31 21:50:42.825132
NCT01491035|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2015-12-10||2017-02-08|2011-12-09|2011-12-13|Estimate|2015-12-10|2016-01-15|Estimate||||2017-02-08|2017-03-16|Actual|April 2012||2012-04-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder|An Open-label Study Evaluating the Pharmacokinetics and Tolerability of [Vortioxetine] Lu AA21004 in Connection With Multiple Oral Dosing of [Vortioxetine] Lu AA21004 in Child and Adolescent Patients With a DSM-IV Diagnosis of Depressive or Anxiety Disorder|Completed||Phase 2|48|Actual|H. Lundbeck A/S||8|||f||||t||||||||||2018-05-31 21:50:42.918955|2018-05-31 21:50:42.918955
NCT01491022|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2016-03-02||2017-12-05|2011-12-12|2011-12-13|Estimate|2017-03-01|2017-04-13|Actual||||2017-12-05|2018-01-02|Actual|July 2012||2012-07-31|December 2017|2017-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease|A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease|Completed||Phase 1/Phase 2|22|Actual|University of Miami||2|||f||||t||||||||Yes||2018-05-31 21:50:45.014097|2018-05-31 21:50:45.014097
NCT01491009|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-12|2011-12-12|2011-12-13|Estimate|||||||2011-12-12|2011-12-13|Estimate|May 2006||2006-05-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|February 2007|Actual|2007-02-28||Interventional|||Comparison of Remifentanil With Dexmedetomidine or Midazolam in Regards of Sedation Effectivity and Postoperative Cognitive Functions in Cystoscopies||Completed||N/A|40|Actual|Gazi University|||||f||||||||||||||2018-05-31 21:50:45.364088|2018-05-31 21:50:45.364088
NCT01490996|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2017-05-23|2011-12-09|2011-12-13|Estimate|||||||2017-05-23|2017-05-24|Actual|February 2012||2012-02-29|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CUFOX||Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer|A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.|Active, not recruiting||Phase 1/Phase 2|51|Anticipated|University of Leicester||2|||f||||t||||||||||2018-05-31 21:50:45.435964|2018-05-31 21:50:45.435964
NCT01490983|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-04-07|2011-12-12|2011-12-13|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Telemonitoring Study - for Chronic Myeloid Leukemia (CML)|Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy|Completed||N/A|14|Actual|Rex Cancer Center, Raleigh, NC||2|||f||||f||||||||||2018-05-31 21:50:45.522998|2018-05-31 21:50:45.522998
NCT01490970|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2016-01-04|2011-12-11|2011-12-13|Estimate|||||||2016-01-04|2016-01-05|Estimate|April 2008||2008-04-30|January 2016|2016-01-31||||April 2018|Anticipated|2018-04-30||Observational|||Sarcoma Database at KFSH&RC|Sarcoma Database at KFSH&RC.|Unknown status|Recruiting||44|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 21:50:45.607648|2018-05-31 21:50:45.607648
NCT01490957|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2011-12-11|2011-12-11|2011-12-13|Estimate|||||||2011-12-11|2011-12-13|Estimate|March 2008||2008-03-31|December 2011|2011-12-31||||||||Observational|FACT-BMT||Functional Assessment of Cancer Therapy - Bone Marrow Transplant|Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT)|Unknown status|Recruiting||113|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 21:50:45.716614|2018-05-31 21:50:45.716614
NCT01490944|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2012-02-25|2011-12-11|2011-12-13|Estimate|||||||2012-02-25|2012-02-28|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2013|Anticipated|2013-01-31|November 2012|Anticipated|2012-11-30||Interventional|||Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls|Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls|Unknown status|Recruiting|Phase 2|360|Anticipated|Indian Council of Medical Research||2|||f||||t||||||||||2018-05-31 21:50:45.898067|2018-05-31 21:50:45.898067
NCT01490931|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|2014-02-24||2014-04-11|2011-12-11|2011-12-13|Estimate|2014-04-11|2014-05-09|Estimate||||2014-04-11|2014-05-09|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Pilot Study. No power analysis performed.|Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients|Single-dose and Multi-dose Open-label Pilot Trial of the Analgesic Efficacy and Tolerability of Intranasal Ketorolac Tromethamine (SPRIX®) in Dental Implant Surgery Patients With Postoperative Pain.|Completed||Phase 4|28|Actual|Hersh, Elliot V., DMD, MS, PhD|The major weakness of this study was its open-label design and lack of a placebo control and an active comparator drug. The study was also not powered to determine differences between the sites of implant placement and the number of implants placed.|1|||f||||t||||||||||2018-05-31 21:50:46.158497|2018-05-31 21:50:46.158497
NCT01490918|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-09-11|2011-12-11|2011-12-13|Estimate|||||||2014-09-11|2014-09-15|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients|A Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Acarbose Added on Top of Metformin and Sitagliptin Combination Treatment in Type 2 Diabetes Mellitus Patients|Completed||Phase 3|165|Anticipated|The Catholic University of Korea||3|||f||||t||||||||||2018-05-31 21:50:46.742824|2018-05-31 21:50:46.742824
NCT01490905|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-12-09|2011-12-09|2011-12-13|Estimate|||||||2011-12-09|2011-12-13|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain|A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain|Completed||Phase 4|127|Actual|Targeted Medical Pharma||3|||f||||t||||||||||2018-05-31 21:50:47.008089|2018-05-31 21:50:47.008089
NCT01490892|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2018-05-01|2011-12-09|2011-12-13|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2011||2011-11-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Quantitative Subharmonic Breast Imaging|Quantitative Subharmonic Breast Imaging|Active, not recruiting||Phase 4|236|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 21:50:47.140329|2018-05-31 21:50:47.140329
NCT01490879|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-11|||2014-04-29|2011-12-11|2011-12-13|Estimate|||||||2014-04-29|2014-05-01|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|DUNE||A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)|A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-ranging, Multi-center Study to Assess the Safety and Clinical Effect of Nexagon® in the Treatment of Subjects With a Diabetic Foot Ulcer|Completed||Phase 2|168|Actual|CoDa Therapeutics Inc.||4|||f||||t||||||||||2018-05-31 21:50:47.235201|2018-05-31 21:50:47.235201
NCT01490866|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2016-09-21||2016-11-15|2011-12-12|2011-12-13|Estimate|2016-11-15|2017-01-12|Estimate||||2016-11-15|2017-01-12|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)|A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)|Completed||Phase 2|70|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 21:50:47.372425|2018-05-31 21:50:47.372425
NCT01490853|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2014-12-02|2011-12-10|2011-12-13|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|January 2012|Actual|2012-01-31||Observational|||Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy|Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Remission With Interferon Based Therapy|Completed|||116|Actual|Università degli Studi di Brescia|||1||f||||t||||||||||2018-05-31 21:50:47.931734|2018-05-31 21:50:47.931734
NCT01490840|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2015-07-10||2016-04-07|2011-12-12|2011-12-13|Estimate|2016-04-07|2016-05-12|Estimate||||2016-04-07|2016-05-12|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PACE||Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis|A 6-month, Multicenter, Randomized, Controlled Parallel Group Study to Evaluate the Effect of Physical Training on Fatigue in Patients With Relapsing-remitting Multiple Sclerosis Treated With Fingolimod, Followed by a 6 Month Optional Extension Phase|Terminated||Phase 4|178|Actual|Novartis||2||The study stopped due to slow enrollment and low participant compliance.|f||||||||||||||2018-05-31 21:50:48.071703|2018-05-31 21:50:48.071703
NCT01490827|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-10-06|2011-12-12|2011-12-13|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2011|Actual|2011-11-30|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|December 2018|Anticipated|2018-12-31||Observational|||Argus® II Retinal Prosthesis System Post-Market Surveillance Study|Argus® II Retinal Prosthesis System Post-Market Surveillance Study|Recruiting|||45|Anticipated|Second Sight Medical Products|||1||f||||f||||||||||2018-05-31 21:50:48.576058|2018-05-31 21:50:48.576058
NCT01490814|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-05-09|2011-12-09|2011-12-13|Estimate|||||||2016-05-09|2016-05-10|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation|A Controlled, Prospective, Non-Inferiority, Parallel-Group, Randomised, Interventional, Open, Blinded Outcome Assessment (PROBE-Design), Multi-centre Trial, Comparing Efficacy and Safety of Isolation of the PVs With a Cryoballoon Catheter vs a Radiofrequency Ablation With a ThermoCool Catheter in Patients With PAF|Completed||N/A|769|Actual|Medtronic International Trading Sarl||2|||f||||t||||||||||2018-05-31 21:50:48.677802|2018-05-31 21:50:48.677802
NCT01490801|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2016-05-13|2011-12-09|2011-12-13|Estimate|||||||2016-05-13|2016-05-17|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma|Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma|Completed|||50|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Blood and Tissue~   "|||2018-05-31 21:50:48.792726|2018-05-31 21:50:48.792726
NCT01490788|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2014-09-24|2011-12-09|2011-12-13|Estimate|||||||2014-09-24|2014-09-26|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Comparative Bioavailability of TNX-102 and Cyclobenzaprine and Effect of Food on the Pharmacokinetics of TNX-102 in Healthy Adults|A Single-Dose, Open-Label, Randomized, Three-Way Crossover Study of the Comparative Bioavailability of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets and of the Effect of Food on the Pharmacokinetics of TNX-102 in Healthy Adults.|Completed||Phase 1|30|Actual|Tonix Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 21:50:48.885973|2018-05-31 21:50:48.885973
NCT01490775|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2017-04-10|2011-12-12|2011-12-13|Estimate|||||||2017-04-10|2017-04-11|Actual|April 2009||2009-04-30|April 2017|2017-04-30|June 1, 2017|Anticipated|2017-06-01|February 12, 2015|Actual|2015-02-12||Interventional|||Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy|Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib)Therapy|Active, not recruiting||N/A|48|Anticipated|Rex Cancer Center, Raleigh, NC||2|||f||||f||||||||||2018-05-31 21:50:48.957948|2018-05-31 21:50:48.957948
NCT01490762|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-09-05|2011-12-09|2011-12-13|Estimate|||||||2012-09-05|2012-09-07|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler|A Phase 1, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Effect Following Inhalation of Technosphere® Insulin Inhalation Powder at Multiple Doses Using the Gen2C Inhaler|Completed||Phase 1|35|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-05-31 21:50:49.024163|2018-05-31 21:50:49.024163
NCT01490749|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-03-10|2011-12-12|2011-12-13|Estimate|||||||2018-03-10|2018-03-13|Actual|February 2012|Actual|2012-02-29|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer|Phase I/IIB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy and Dose Escalation of RAD001 in Patients With Esophageal Cancer|Active, not recruiting||Phase 1|17|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:50:49.08532|2018-05-31 21:50:49.08532
NCT01490736|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2013-07-23|2011-12-09|2011-12-13|Estimate|||||||2013-07-23|2013-07-25|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Phase 1/2 Sequentially Staged Safety Study in Healthy Subjects and Subjects With Mild Acne|Phase 1/2 Study of Photodynamic Therapy (PDT) With Lemuteporfin Topical Solution (LTS) in Healthy Volunteers and in Subjects With Mild Acne|Completed||Phase 1/Phase 2|129|Actual|Dermira, Inc.||1|||f||||f||||||||||2018-05-31 21:50:49.153379|2018-05-31 21:50:49.153379
NCT01490723|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2017-11-07|2011-12-12|2011-12-13|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2013|Actual|2013-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)|Dose-Intense Yttrium-90 Ibritumomab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies|Active, not recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:50:49.212706|2018-05-31 21:50:49.212706
NCT01490710|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2013-09-02|2011-12-12|2011-12-13|Estimate|||||||2013-09-02|2013-09-04|Estimate|November 2011||2011-11-30|September 2013|2013-09-30||||||||Interventional|||NAVADYN11 : Hemodynamic Impact of a New Ventilatory Support Mode With Diaphragmatic Synchronization|NAVADYN11 : Hemodynamic Impact of a New Ventilatory Support Mode With Diaphragmatic Synchronization|Terminated||N/A|9|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 21:50:49.39094|2018-05-31 21:50:49.39094
NCT01490697|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2017-04-06||2017-05-26|2011-12-12|2011-12-13|Estimate|2017-05-26|2017-06-29|Actual||||2017-05-26|2017-06-29|Actual|March 2009|Actual|2009-03-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All randomized participants included in the analysis. 3 participants did not meet PTSD diagnostic criteria and are excluded.|Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments|Developing Memory Reconsolidation Blockers as Novel PTSD Treatments|Completed||Phase 4|34|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:50:49.464174|2018-05-31 21:50:49.464174
NCT01490684|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2012-08-13|2011-12-10|2011-12-13|Estimate|||||||2012-08-13|2012-08-15|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|January 2014|Anticipated|2014-01-31|July 2013|Anticipated|2013-07-31||Observational|ICIP-SA||Invasive Candidiasis in ICU|Invasive Candidiasis in Critically Ill Patients in Saudi Arabia: A Prospective Cohort Study|Unknown status|Recruiting||170|Anticipated|King Abdulaziz Medical City|||||f||||f||||||||||2018-05-31 21:50:49.740779|2018-05-31 21:50:49.740779
NCT01490671|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-05-01|2011-12-09|2011-12-13|Estimate|||||||2015-05-01|2015-05-04|Estimate||||May 2015|2015-05-31||||August 2015|Anticipated|2015-08-31||Interventional|||Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women|Phase 2 Expanded Safety Study of Tenofovir Gel in Pregnancy|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-05-31 21:50:49.856471|2018-05-31 21:50:49.856471
NCT01490658|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-02-09|2011-12-09|2011-12-13|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2006||2006-06-30|February 2017|2017-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers|A Randomized, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Volunteers|Completed||Phase 1|93|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:50:49.947095|2018-05-31 21:50:49.947095
NCT01490645|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-09-04|2011-12-12|2011-12-13|Estimate|||||||2014-09-04|2014-09-05|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|ProAcor||A NIS Registry of the Prospective Structured Care In Acute Coronary Syndrome|ProAcor: Prospective Structured Care In Acute Coronary Syndrome Registry|Completed|||1006|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:50:50.048429|2018-05-31 21:50:50.048429
NCT01490632|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|2017-03-10|2013-01-11|2017-06-19|2011-12-09|2011-12-13|Estimate|2017-06-19|2017-07-18|Actual|2013-01-25|2013-01-29|Estimate|2017-06-19|2017-07-18|Actual|December 2011||2011-12-31|June 2017|2017-06-30|August 2014|Actual|2014-08-31|December 2012|Actual|2012-12-31||Interventional||All randomized participants who received at least one dose of study drug.|A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 2|271|Actual|Eli Lilly and Company||5|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 21:50:50.257777|2018-05-31 21:50:50.257777
NCT01490619|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2017-07-20|2011-12-09|2011-12-13|Estimate|||||||2017-07-20|2017-07-24|Actual|October 2011||2011-10-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2016|Actual|2016-09-30||Interventional|||Resilience Promotion in Teens With Type 1 Diabetes: Preventing Negative Outcomes|Resilience Promotion in Teens With Type 1 Diabetes: Preventing Negative Outcomes|Active, not recruiting||N/A|280|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 21:50:52.27914|2018-05-31 21:50:52.27914
NCT01490606|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2012-03-02|2011-12-10|2011-12-13|Estimate|||||||2012-03-02|2012-03-05|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|OA||Knee Osteoarthritis (OA) Project Treatment Versus Conventional Physical Therapy in the Treatment of Knee OA Patients|A Comparative, Non Randomized Trial of Knee Osteoarthritis (OA) Project Treatment Versus Conventional Physical Therapy in the Treatment of Knee OA Patients|Unknown status|Recruiting|N/A|60|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 21:50:52.362314|2018-05-31 21:50:52.362314
NCT01490593|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-11-01|2011-12-09|2011-12-13|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2, 2011|Actual|2011-03-02|November 2017|2017-11-30|January 31, 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|CEIR||Canadian Eye Injury Registry|Canadian Eye Injury Registry|Completed|||104|Actual|Lawson Health Research Institute|||1||f||||t||||||||||2018-05-31 21:50:52.520107|2018-05-31 21:50:52.520107
NCT01490580|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2018-01-23|2011-12-09|2011-12-13|Estimate|||||||2018-01-23|2018-01-24|Actual|May 2012||2012-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2016|Actual|2016-08-31||Interventional|PRETTINEO||Premedication Trial for Tracheal Intubation of the NEOnate|"Double Blind Randomized Controlled Trial Comparing Atropine+Propofol Versus Atropine+Atracurium+Sufentanil as a Premedication Prior to Semi-urgent or Elective Endotracheal Intubation of Term and Preterm Newborns"|Active, not recruiting||Phase 2/Phase 3|173|Actual|Centre Hospitalier Intercommunal Creteil||2|||f||||t||||||||Undecided||2018-05-31 21:50:52.599329|2018-05-31 21:50:52.599329
NCT01490567|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-12-09|2011-12-09|2011-12-13|Estimate|||||||2011-12-09|2011-12-13|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia|Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia|Unknown status|Recruiting|Phase 4|80|Anticipated|Central South University||2|||f||||t||||||||||2018-05-31 21:50:52.719984|2018-05-31 21:50:52.719984
NCT01490554|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2012-07-23|2011-12-12|2011-12-13|Estimate|||||||2012-07-23|2012-07-24|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|March 2011|Actual|2011-03-31||Interventional|||Autologous Fibroblast Grafts in Facial Skin Regeneration|Effectiveness of Autologous Fibroblast Grafts in the Regeneration of Facial Ectoderm|Unknown status|Active, not recruiting|N/A|20|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 21:50:52.809642|2018-05-31 21:50:52.809642
NCT01490541|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-06-22|2011-12-09|2011-12-13|Estimate|||||||2012-06-22|2012-06-25|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|October 2017|Anticipated|2017-10-31|December 2012|Anticipated|2012-12-31||Observational|||The Predictive Scores for Gastric Cancer in Gastric Intestinal Metaplasia (GIM) Patient: a Recommendation for Thai Population||Unknown status|Recruiting||280|Anticipated|King Chulalongkorn Memorial Hospital|||1||f||||f||||||||||2018-05-31 21:50:52.888048|2018-05-31 21:50:52.888048
NCT01490515|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2013-12-13|2011-12-12|2011-12-13|Estimate|||||||2013-12-13|2013-12-16|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Embryo Selection Using Non-invasive Metabolomic Analysis Versus Morphology|Embryo Selection Using Non-invasive Metabolomic Analysis Indicates Improvement in Implantation Rates With Fetal Cardiac Activity|Completed||Phase 4|125|Actual|Eugonia||2|||f||||f||||||||||2018-05-31 21:50:53.058964|2018-05-31 21:50:53.058964
NCT01490502|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2017-09-27|2011-12-12|2011-12-13|Estimate|||||||2017-09-27|2017-09-29|Actual|March 2012||2012-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Vitamin D Supplementation in Multiple Sclerosis|A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis|Recruiting||Phase 3|172|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:50:53.161232|2018-05-31 21:50:53.161232
NCT01490489|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-02-05|2011-12-09|2011-12-13|Estimate|||||||2015-02-05|2015-02-06|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|EGEVE||EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction|EG-VEGF (Endocrine Gland-derived Vascular Endothelial Growth Factor) in Normal and Pathological Pregnancies: Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction|Unknown status|Recruiting|N/A|500|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 21:50:53.338052|2018-05-31 21:50:53.338052
NCT01490476|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-05-22|2011-12-09|2011-12-13|Estimate|||||||2017-05-22|2017-05-23|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|April 2016|Actual|2016-04-30||Interventional|AFINF2||Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients|A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma|Completed||Phase 2|10|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 21:50:53.516554|2018-05-31 21:50:53.516554
NCT01490463|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-01-28|2011-12-12|2011-12-13|Estimate|||||||2013-01-28|2013-01-30|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|LESUIA||Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms|Brain Lesions Following Endovascular and Surgical Treatment of Unruptured Intracranial Aneurysms: Incidence and Influence on Clinical Outcome in a Prospective Study.|Completed|||||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-05-31 21:50:53.85634|2018-05-31 21:50:53.85634
NCT01490450|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14||2015-07-24|2017-09-13|2011-12-09|2011-12-13|Estimate||||2015-07-24|2015-08-13|Estimate|2017-09-13|2017-09-19|Actual|December 2011||2011-12-31|September 2017|2017-09-30|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|||Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults With Active Psoriatic Arthritis|Completed||Phase 2|165|Actual|Vitaeris INC||4|||f||||t||||||||||2018-05-31 21:50:53.921254|2018-05-31 21:50:53.921254
NCT01490437|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-09-22|2011-12-09|2011-12-13|Estimate|||||||2014-09-22|2014-09-25|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PECULIAR||Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma|A Prospective Phase 2 Study of PEmetrexed in Combination With Cisplatin in Patients With Advanced UrotheLIal CAnceR|Completed||Phase 2|42|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:50:54.197971|2018-05-31 21:50:54.197971
NCT01490424|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2011-12-12|2011-12-12|2011-12-13|Estimate|||||||2011-12-12|2011-12-13|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||TREM-1 Gene Polymorphisms|Association Between TREM-1 Gene Polymorphisms and Prognosis in Sepsis Patient|Completed|||160|Actual|Chinese PLA General Hospital|||2||f||||f||||||||||2018-05-31 21:50:54.321646|2018-05-31 21:50:54.321646
NCT01490411|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2014-01-23|2011-12-09|2011-12-13|Estimate|||||||2014-01-23|2014-01-24|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With rBet v1-FV Compared to Placebo in Birch Pollen-Allergic Patients With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis|Completed||Phase 2|37|Actual|Allergopharma GmbH & Co. KG||5|||f||||t||||||||||2018-05-31 21:50:54.402129|2018-05-31 21:50:54.402129
NCT01490398|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2014-05-08|2011-12-12|2011-12-13|Estimate|||||||2014-05-08|2014-05-09|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|RESERVE||Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve|Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients|Completed||Phase 4|56|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:50:54.684503|2018-05-31 21:50:54.684503
NCT01490385|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2013-12-15|2011-12-12|2011-12-13|Estimate|||||||2013-12-15|2013-12-17|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of Light Emitting Diode Phototherapy on the Rate of Orthodontic Tooth Movement - A Clinical Study|The Effect of Light Emitting Diode Phototherapy on the Rate of Orthodontic Tooth Movement - A Clinical Study|Completed||N/A|11|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 21:50:54.77597|2018-05-31 21:50:54.77597
NCT01490372|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2018-05-02|2011-12-12|2011-12-13|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2011||2011-08-31|May 2018|2018-05-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Observational|DG3||Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring|Is Gestational Diabetes Mellitus (GDM) an Independent Risk Factor for Cardiometabolic Syndrome in Offspring?|Completed|||41|Actual|Université de Sherbrooke|||2||f||||f||||||||||2018-05-31 21:50:54.839082|2018-05-31 21:50:54.839082
NCT01490359|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|2015-09-23||2017-11-18|2011-12-08|2011-12-13|Estimate|2017-11-18|2017-12-19|Actual||||2017-11-18|2017-12-19|Actual|November 2007||2007-11-30|November 2017|2017-11-30|April 2011|Actual|2011-04-30|December 2009|Actual|2009-12-31||Interventional|||Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men|South African Men Health Promotion Project|Completed||N/A|1181|Actual|University of Pennsylvania|A limitation of the study is the reliance on self-reports of behavior. In addition, the results may not generalize to all South African men.|2|||f||||f||||||||||2018-05-31 21:50:54.937092|2018-05-31 21:50:54.937092
NCT01490346|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2015-06-01|2011-12-08|2011-12-13|Estimate|||||||2015-06-01|2015-06-03|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Tissue Drug Levels of HIV Medications|A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution|Completed|||22|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||Samples Without DNA|"~     Blood & lymphatic tissue.~   "|||2018-05-31 21:50:55.522091|2018-05-31 21:50:55.522091
NCT01490320|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2011-12-08|2011-12-08|2011-12-12|Estimate|||||||2011-12-08|2011-12-12|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Primary Care Interventions on Children's Media Viewing Habits and Exposure to Violence|The Effect of Primary Care Interventions on Children's Media Viewing Habits and Exposure to Violence|Completed||N/A|336|Actual|Vanderbilt University||3|||f||||f||||||||||2018-05-31 21:50:55.722737|2018-05-31 21:50:55.722737
NCT01490307|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-12-08|2011-12-08|2011-12-12|Estimate|||||||2011-12-08|2011-12-12|Estimate|February 2006||2006-02-28|December 2011|2011-12-31|March 2011|Actual|2011-03-31|January 2010|Actual|2010-01-31||Interventional|PAL-2||A Family Intervention for Adolescent Problem Behavior (AKA Project Alliance 2)|A Family Intervention for Adolescent Problem Behavior|Completed||N/A|593|Actual|University of Oregon||2|||f||||t||||||||||2018-05-31 21:50:55.828976|2018-05-31 21:50:55.828976
NCT01490294|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2011-12-23||2014-05-20|2011-12-08|2011-12-12|Estimate|2012-05-24|2012-06-28|Estimate||||2014-05-20|2014-05-22|Estimate|March 2004||2004-03-31|May 2014|2014-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Myocardial Perfusion MRI|Multicenter, Double Blind, Randomized Dose Finding Study in Myocardial Perfusion MRI With Gadavist®1.0|Completed||Phase 2|232|Actual|Bayer|Study designed for perfusion imaging, not optimized for delayed enhancement. Routine SPECT selected as standard of reference (SoR) despite known quality limitations.|4|||f||||f||||||||||2018-05-31 21:50:56.042919|2018-05-31 21:50:56.042919
NCT01490281|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-01-07|2011-12-09|2011-12-12|Estimate|||||||2015-01-07|2015-01-08|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Exercise in Women With Fibromyalgia|Land- and Water-Based Exercise Intervention in Women With Fibromyalgia: The Al-Andalus Physical Activity Randomised Control Trial|Completed||Phase 2|180|Actual|Universidad de Granada||3|||f||||t||||||||||2018-05-31 21:50:58.37316|2018-05-31 21:50:58.37316
NCT01490268|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-12-05|2011-12-08|2011-12-12|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PKPDHM-001||Pain Therapy After Elective Cardiac Surgery|Pharmacokinetic-pharmacodynamic Modeling of the Postoperative Pain Sensation During Patient-controlled Analgesia With Target-controlled Infusion of Hydromorphone, Taking Into Account the Interaction With Intraoperatively Administered Sufentanil for Elective Cardiac Surgery|Completed||Phase 4|50|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 21:50:58.441809|2018-05-31 21:50:58.441809
NCT01490255|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2014-03-23|2011-12-09|2011-12-12|Estimate|||||||2014-03-23|2014-03-26|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|ROMAN||Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity|Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:50:58.502844|2018-05-31 21:50:58.502844
NCT01490229|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-03-06|2011-12-09|2011-12-12|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|ECLIPSE||Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients|Randomized Trial of Ezetimibe Versus nutraCeuticals in Statin-intoLerant patIents Treated With PercutaneouS Coronary Intervention|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:50:58.58347|2018-05-31 21:50:58.58347
NCT01490216|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-11-12|2011-12-09|2011-12-12|Estimate|||||||2013-11-12|2013-11-13|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence|Open-Label Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence|Completed||Phase 1/Phase 2|5|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 21:50:58.649178|2018-05-31 21:50:58.649178
NCT01490203|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2018-03-22|2011-12-08|2011-12-12|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2011||2011-12-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|February 2014|Actual|2014-02-28||Observational|LiFE||Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma|Pre-Surgical Treatment or Radio Frequency Ablation (RFA) Evaluation of Future Remnant Liver Function Using Gd-EOB-DTPA Enhanced MRI in Patients Undergoing Hepatic Resection /RFA for Hepatocellular Carcinoma|Completed|||71|Actual|Seoul National University Hospital|||2||f||||t||||||||No||2018-05-31 21:50:58.726678|2018-05-31 21:50:58.726678
NCT01490190|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2013-11-25||2017-05-17|2011-12-08|2011-12-12|Estimate|2013-11-25|2014-01-14|Estimate||||2017-05-17|2017-06-14|Actual|December 26, 2011|Actual|2011-12-26|May 2017|2017-05-31|December 5, 2012|Actual|2012-12-05|December 5, 2012|Actual|2012-12-05||Interventional|||Study of the Use of a Contraceptive Vaginal Ring (NuvaRing) in Normal Daily Practice in Indian Women (P07733)|Contraceptive Vaginal Ring Releasing Etonogestrel and Ethinylestradiol (NuvaRing): Cycle Control, Acceptability and Tolerability Study in Indian Women|Completed||Phase 4|252|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:50:58.840473|2018-05-31 21:50:58.840473
NCT01490177|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-11-24|2011-12-08|2011-12-12|Estimate|||||||2015-11-24|2015-11-26|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Single Center Food Allergy Oral Immunotherapy Study|Single Center, Phase I Food Allergy Oral Immunotherapy Study|Completed||Phase 1|50|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 21:51:00.40597|2018-05-31 21:51:00.40597
NCT01490164|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-11-12|2011-12-09|2011-12-12|Estimate|||||||2013-11-12|2013-11-13|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Observational|||Transfusion Requirements During Spinal Surgery for Severe Scoliosis|An Observational Prospective Study of Transfusion Requirements During Spinal Surgery for Severe Scoliosis|Completed|||50|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||||||2018-05-31 21:51:00.465801|2018-05-31 21:51:00.465801
NCT01490151|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2017-01-05||2017-08-31|2011-12-09|2011-12-12|Estimate|2017-08-31|2017-09-29|Actual||||2017-08-31|2017-09-29|Actual|December 2011||2011-12-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Subjects with Type 1 Diabetes|Medtronic Treat to Range (TTR) Closed-Loop Control|Medtronic Treat to Range (TTR) Closed-Loop Control: Tuning a Treat-to-Range Controller for the Effects of High and Low Glycemic Index Meals|Completed||N/A|22|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 21:51:00.620123|2018-05-31 21:51:00.620123
NCT01476462|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-05-23|2011-11-17|2011-11-22|Estimate|||||||2012-05-23|2012-05-24|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Observational|PdL-SMN1||Second Malignant Neoplasms After Childhood ALL Therapy|Second Malignant Neoplasms After Childhood ALL Therapy; An International Ponte di Legno Study|Completed|||642|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 21:54:55.514156|2018-05-31 21:54:55.514156
NCT01490138|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2011-12-09|2011-12-09|2011-12-12|Estimate|||||||2011-12-09|2011-12-12|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Observational|||Investigation of Clinical Relevance of β-D-Glucan Tests in Patients With Invasive Fungal Infection (IFI)|Investigation of the Clinical Relevance of Serial Concentrations of β-D-Glucan Tests in the Patients With Invasive Fungal Infection|Unknown status|Enrolling by invitation||50|Anticipated|Ruijin Hospital|||||f||||t||||||||||2018-05-31 21:51:00.799743|2018-05-31 21:51:00.799743
NCT01490125|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2013-08-09||2013-11-05|2011-12-08|2011-12-12|Estimate|2013-11-05|2013-12-24|Estimate||||2013-11-05|2013-12-24|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|BLAZE|One misrandomized participant did not receive study treatment, was discontinued and not included in the full analysis set used for demographics.|The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Multicenter, Randomized, Blinded, Double-dummy, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control|Completed||Phase 3|247|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:51:00.907719|2018-05-31 21:51:00.907719
NCT01490112|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-10-26|2011-12-08|2011-12-12|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Surveillance Study of NovoRapid® for New Drug Re-examination|Regulatory Post Marketing Surveillance Study of NovoRapid for New Drug Re-examination|Completed|||1239|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:51:01.494498|2018-05-31 21:51:01.494498
NCT01490099|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-02-05|2011-12-08|2011-12-12|Estimate|||||||2016-02-05|2016-02-08|Estimate|August 2006||2006-08-31|February 2016|2016-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Cross-over Glucose Clamp Trial to Demonstrate Bioequivalence Between Insulin Detemir Produced by the NN729 Process and Insulin Detemir Produced by the Current Process in Healthy Subjects|Completed||Phase 1|37|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:51:01.565511|2018-05-31 21:51:01.565511
NCT01490086|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|2015-01-12||2015-01-20|2011-12-09|2011-12-12|Estimate|2015-01-20|2015-01-26|Estimate||||2015-01-20|2015-01-26|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|REFRESH|The Baseline Analysis Population is the Safety Population (Total 233), which comprises all enrolled subjects (Total 234) who received at least one dose of study treatment. One Placebo subject was enrolled in the study but did not receive any study treatment.|RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder|REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder|Completed||Phase 2|234|Actual|Reviva Pharmaceuticals||5|||f||||t||||||||||2018-05-31 21:51:01.673809|2018-05-31 21:51:01.673809
NCT01490073|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-02-04|2011-12-09|2011-12-12|Estimate|||||||2013-02-04|2013-02-06|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women|The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study|Unknown status|Recruiting|N/A|24|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 21:51:02.949808|2018-05-31 21:51:02.949808
NCT01490060|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2015-03-20||2016-03-11|2011-12-08|2011-12-12|Estimate|2015-05-15|2015-06-03|Estimate||||2016-03-11|2016-04-11|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Fosaprepitant in Patients Receiving Ifosfamide-based Regimen|Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen|Completed||N/A|47|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 21:51:03.081948|2018-05-31 21:51:03.081948
NCT01490047|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-06-15|2011-12-09|2011-12-12|Estimate|||||||2015-06-15|2015-06-16|Estimate|January 2013||2013-01-31|June 2015|2015-06-30||||||||Interventional|||Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas|Phase I Trial of Intravenous Recombinant Human TNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas|Withdrawn||Phase 1|0|Actual|Ludwig Institute for Cancer Research||7|||f||||t||||||||||2018-05-31 21:51:03.53098|2018-05-31 21:51:03.53098
NCT01490034|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-10-14|2011-12-09|2011-12-12|Estimate|||||||2015-10-14|2015-10-15|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|September 2013|Actual|2013-09-30||Interventional|||Effects of Learning and Food Form on Intake in Humans|Effects of Learning and Food Form on Intake in Humans|Completed||N/A|120|Anticipated|Purdue University||4|||f||||f||||||||||2018-05-31 21:51:03.646272|2018-05-31 21:51:03.646272
NCT01490021|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2013-05-14|2011-12-09|2011-12-12|Estimate|||||||2013-05-14|2013-05-15|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Influence of Repetitive Transcranial Magnetic Stimulation (rTMS) Challenge on Cognitive and Functional Magnetic Resonance Imaging Markers in Healthy Subjects|Influence of Repetitive Transcranial Magnetic Stimulation (rTMS) Challenge on Cognitive and Functional Magnetic Resonance Imaging Markers in Healthy Subjects|Terminated||N/A|14|Actual|Qualissima||2||"Study stopped for scientific reasons. Another study with a new design is in course of~   authorization and implementation"|f||||f||||||||||2018-05-31 21:51:03.722115|2018-05-31 21:51:03.722115
NCT01490008|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2012-04-18|2011-12-08|2011-12-12|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers|An Open-label, Single-center Triqal to Evaluate Systemic Exposure of Catechins From Commercially Available, Topically Applied Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers|Completed||Phase 1|30|Actual|MediGene||2|||f||||f||||||||||2018-05-31 21:51:03.794424|2018-05-31 21:51:03.794424
NCT01489995|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-12-17|2011-12-08|2011-12-12|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Migalastat Food Effect Study|A Randomized, Open-Label, 5-Period Crossover Study to Evaluate the Effect of Meal Type and Timing on the Pharmacokinetics of Migalastat Hydrochloride in Healthy Volunteers.|Completed||Phase 1|20|Actual|Amicus Therapeutics||5|||f||||f||||||||||2018-05-31 21:51:03.853846|2018-05-31 21:51:03.853846
NCT01489982|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-04-15|2011-12-09|2011-12-12|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Treatments for Insomnia in Patients With Parkinson's Disease|Treatments for Insomnia in Patients With Parkinson's Disease: A Pilot Study|Completed||Early Phase 1|20|Actual|McGill University Health Center||4|||f||||||||||||||2018-05-31 21:51:03.97759|2018-05-31 21:51:03.97759
NCT01489969|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-07-15|2011-12-09|2011-12-12|Estimate|||||||2013-07-15|2013-07-16|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Interventional|||Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients|A Double-blind, Parallel Group, Randomized, Placebo Controlled Sleep Laboratory Study of Efficacy and Safety of Neu-P11 in Insomnia Patients Aged 18-80|Completed||Phase 2|137|Actual|Neurim Pharmaceuticals Ltd.||3|||f||||f||||||||||2018-05-31 21:51:04.09791|2018-05-31 21:51:04.09791
NCT01489956|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2015-12-24||2016-03-11|2011-12-09|2011-12-12|Estimate|2016-03-11|2016-04-12|Estimate||||2016-03-11|2016-04-12|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Enrolled Sample|A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)|Pilot Study to Determine the Immunogenicity of Immucothel® and Oral Tolerance Induction With Biosyn Native KLH in Healthy Subjects (ITN047AI)|Terminated||Early Phase 1|19|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Data from 4 of the 5 evaluable subjects in Part B was negative for tolerance to KLH as defined by a stimulation index <3 on day 42 after booster immunization. The study was terminated. Data were not collected and no analyses were performed.|3||Due to futility, identified after 5 subjects completed treatment in Part B|f||||t||||||||||2018-05-31 21:51:04.21004|2018-05-31 21:51:04.21004
NCT01489943|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-07-24|2011-12-08|2011-12-12|Estimate|||||||2017-07-24|2017-07-25|Actual|September 19, 2011|Actual|2011-09-19|July 2017|2017-07-31|November 10, 2011|Actual|2011-11-10|November 10, 2011|Actual|2011-11-10||Interventional|||A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects|A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 21:51:04.847725|2018-05-31 21:51:04.847725
NCT01489930|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2011-12-09|2011-12-09|2011-12-12|Estimate|||||||2011-12-09|2011-12-12|Estimate|May 2008||2008-05-31|December 2011|2011-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults|Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults|Completed||N/A|67|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 21:51:04.928543|2018-05-31 21:51:04.928543
NCT01489917|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-05-07|2011-12-09|2011-12-12|Estimate|||||||2012-05-07|2012-05-08|Estimate|May 2009||2009-05-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PHARAOH||A-priori Versus Provisional Heparin on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis|Comparison of A-priori Versus Provisional Heparin Therapy on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis|Completed||N/A|428|Actual|Laval University||2|||f||||f||||||||||2018-05-31 21:51:05.008042|2018-05-31 21:51:05.008042
NCT01489904|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2012-10-28|2011-12-08|2011-12-12|Estimate|||||||2012-10-28|2012-10-30|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy|Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial.|Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Anticipated|Hospital Vall d'Hebron||2|||f||||t||||||||||2018-05-31 21:51:05.075565|2018-05-31 21:51:05.075565
NCT01489891|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-03|2012-10-29||2013-03-07|2011-12-08|2011-12-12|Estimate|2013-03-07|2013-03-08|Estimate||||2013-03-07|2013-03-08|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol|Usefulness of Applying Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopies Performed Under Sedation With Propofol- a Randomized Controlled Trial|Completed||Phase 4|120|Actual|Hospital Universitario Infanta Cristina|Unicenter study|2|||f||||t||||||||||2018-05-31 21:51:05.161154|2018-05-31 21:51:05.161154
NCT01489878|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2013-01-23|2011-12-08|2011-12-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|StaphMRG||Antibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients|Impact of Ambulatory Antibiotics Use on Nasal Carriage of Methicillin-resistant Staphylococci in Community Patients : the StaphMRG Study|Completed|||571|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||Samples Without DNA|"~     Three samples of nasal flora should be obtained for each included patient: (i) the first one~     before antibiotic exposure (at inclusion, by the patient's GP) (ii) the second and third ones~     at the GP's office at the end and 23 to 45 days after the termination of antibiotherapy,~     respectively.~   "|||2018-05-31 21:51:05.496523|2018-05-31 21:51:05.496523
NCT01489865|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-12-27|2011-12-08|2011-12-12|Estimate|||||||2017-12-27|2017-12-29|Actual|February 2011||2011-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer|A Phase I/II Study of ABT-888 in Combination With 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients With Metastatic Pancreatic Cancer|Recruiting||Phase 1/Phase 2|79|Anticipated|Georgetown University||1|||f||||t||||||||No||2018-05-31 21:51:05.571386|2018-05-31 21:51:05.571386
NCT01489852|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2011-12-09|2011-12-09|2011-12-12|Estimate|||||||2011-12-09|2011-12-12|Estimate|December 2006||2006-12-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|July 2010|Actual|2010-07-31||Interventional|||Estrogen Pretreatment Prior to GnRH Antagonist Protocol|Interest of a Steroid Pre-treatment Prior to IVF Protocol With Ovarian Stimulation by Recombinant FSH and With LH Surge Blockage by Daily GnRH Antagonist|Completed||Phase 4|472|Actual|Gemer||2|||f||||f||||||||||2018-05-31 21:51:05.664103|2018-05-31 21:51:05.664103
NCT01489683|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-07-13|2011-12-09|2011-12-12|Estimate|||||||2012-07-13|2012-07-16|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Intubating Conditions During Propofol-remifentanil Anesthesia With Topical Lidocaine|Effect of Tracheal Lidocaine on Intubating Conditions During Propofol-remifentanil TCI Without Neuromuscular Blockade|Completed||N/A|50|Actual|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 21:51:08.881402|2018-05-31 21:51:08.881402
NCT01489839|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2018-02-06|2011-12-08|2011-12-12|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2012||2012-01-31|June 2016|2016-06-30|May 2017|Actual|2017-05-31|June 2016|Actual|2016-06-30||Observational|||Biomarkers of Periodontal Disease Progression|Biomarkers of Periodontal Disease Progression|Completed|||157|Actual|The Forsyth Institute|||2||f||||t||||||Samples With DNA|"~     The biological samples listed below will be obtained at baseline, each 2-month assessment~     visit for 12 months, and the 6-month post-therapy visit.~      Blood. Ten mL of blood will be obtained by venipuncture from the antecubital fossa. Subjects~     consenting to have a blood sample drawn for future DNA analysis will have an additional 7 mL~     of blood drawn at the baseline visit.~      Saliva. Each subject will provide a timed sample of whole saliva by expectorating into a~     sterile graduated cylinder.~      Gingival crevicular fluid. A GCF sample will be collected from the mesial and distal aspect~     of each posterior tooth (excluding third molars) using filter strips (Periopaper®) gently~     inserted 1 to 2 mm subgingivally. A total of up to 32 samples will be obtained.~      Subgingival plaque samples. Two plaque samples will be taken from the mesial and distal~     aspects of each posterior tooth (excluding third molars) for up to 64 samples.~   "|||2018-05-31 21:51:05.735558|2018-05-31 21:51:05.735558
NCT01489826|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|2016-06-10||2016-12-16|2011-12-08|2011-12-12|Estimate|2016-08-22|2016-10-18|Estimate||||2016-12-16|2017-02-09|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours|A Phase 1, Pharmacokinetically-Guided, Dose Escalation Study to Assess the Safety and Tolerability of Dexanabinol in Patients With Advanced Solid Tumours|Completed||Phase 1|40|Actual|e-Therapeutics PLC||9|||f||||t||||||||||2018-05-31 21:51:05.864494|2018-05-31 21:51:05.864494
NCT01489813|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-10-25|2011-12-09|2011-12-12|Estimate|||||||2017-10-25|2017-10-26|Actual|May 19, 2017|Actual|2017-05-19|October 2017|2017-10-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment|Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy|Recruiting||Phase 2|88|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided||2018-05-31 21:51:07.737919|2018-05-31 21:51:07.737919
NCT01489800|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-07-02|2011-12-09|2011-12-12|Estimate|||||||2015-07-02|2015-07-03|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer|The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer|Unknown status|Enrolling by invitation|Phase 3|164|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 21:51:07.911016|2018-05-31 21:51:07.911016
NCT01489787|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2018-01-26|2011-12-09|2011-12-12|Estimate|||||||2018-01-26|2018-01-29|Actual|March 2010|Actual|2010-03-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|HIFU||Study to Evaluate a High Intensity Focused Ultrasound (HIFU) Procedure in Patient With Liver Metastases|A Phase I-II Study to Evaluate, in Patients Operated for a Hepatic Resection of Colorectal Liver Metastases, a High Intensity Focused Ultrasound (HIFU) Procedure: Feasibility, Safety and Accuracy.|Recruiting||N/A|38|Anticipated|Centre Leon Berard||3|||f||||f||||||||||2018-05-31 21:51:08.013528|2018-05-31 21:51:08.013528
NCT01489774|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-08-01|2011-12-08|2011-12-12|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dose, Dose-escalation Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of CJ-12406 After Oral Administration in Healthy Male Subjects, Phase I Study|Completed||Phase 1|86|Actual|CJ HealthCare Corporation||2|||f||||t||||||||||2018-05-31 21:51:08.248847|2018-05-31 21:51:08.248847
NCT01489761|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-02-23|2011-12-09|2011-12-12|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2012|Actual|2012-01-31|February 2017|2017-02-28|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|||LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)|Percutaneous Treatment of Very LONG Native Coronary Lesions With Drug-Eluting Stent-VI: Everolimus-eluting Versus Zotarolimus-Eluting Stents|Terminated||Phase 4|302|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 21:51:08.370302|2018-05-31 21:51:08.370302
NCT01489748|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2015-02-18|2011-12-08|2011-12-12|Estimate|||||||2015-02-18|2015-02-20|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|CAPPS||Canadian Avonex PEN Productivity Study|An Open-Label, Observational, Multicenter Study to Evaluate the Impact of AVONEX PEN Autoinjector Therapy on Work Capacity of Multiple Sclerosis Patients in Canada|Completed|||111|Actual|Biogen|||||f||||f||||||||||2018-05-31 21:51:08.495436|2018-05-31 21:51:08.495436
NCT01489735|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-01-25|2011-12-09|2011-12-12|Estimate|||||||2013-01-25|2013-01-28|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|GERDq||The Use of International GerdQ Questionnaire|Observational Non-interventional Study on the Use of International GerdQ Questionnaire for the Diagnosis of Gastroesophageal Reflux Disease in the Russian Practice|Completed|||150|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:51:08.577676|2018-05-31 21:51:08.577676
NCT01489722|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-08-10|2011-12-08|2011-12-12|Estimate|||||||2015-08-10|2015-08-11|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients|A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML)|Terminated||Phase 1|55|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 21:51:08.648558|2018-05-31 21:51:08.648558
NCT01489709|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2014-09-04|2011-12-08|2011-12-12|Estimate|||||||2014-09-04|2014-09-05|Estimate|June 2010||2010-06-30|September 2014|2014-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|SET-Q||Post Marketing Survey of Vesicare in Japan|Specified Drug Use Results Survey of Vesicare Tablets|Completed|||1160|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 21:51:08.725095|2018-05-31 21:51:08.725095
NCT01489696|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-12-06|2011-12-08|2011-12-12|Estimate|||||||2013-12-06|2013-12-09|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin|A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin|Completed||Phase 1|48|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:51:08.803095|2018-05-31 21:51:08.803095
NCT01489657|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-06-07|2011-12-08|2011-12-09|Estimate|||||||2016-06-07|2016-06-08|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2012|Actual|2012-12-31||Observational|||The Metabolite Profiling of Obese Subjects Before and After Sleeve Gastrectomy|The Impact of Sleeve Gastrectomy Surgery in Obese Subjects on Metabolite Profiling|Withdrawn|||0|Actual|Wolfson Medical Center||||The results were not significant, therfore the study ended prematurily|f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:51:09.245789|2018-05-31 21:51:09.245789
NCT01489644|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-02-09|2011-12-08|2011-12-09|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2006||2006-06-30|February 2017|2017-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers|A Randomized, Single-Blind, Four-Period Crossover Study Examining the Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet Dosing (NN4440) in Fasting and Fed Healthy Volunteers|Completed||Phase 1|62|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:51:09.305005|2018-05-31 21:51:09.305005
NCT01489631|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-06-04|2011-12-08|2011-12-09|Estimate|||||||2015-06-04|2015-06-08|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Analgesia After Total Knee Replacement Surgery|Comparison of Intra-articular Infiltration and Gabapentin With Epidural Analgesia After Total Knee Replacement Surgery|Completed||N/A|81|Actual|St. Antonius Hospital||3|||f||||f||||||||||2018-05-31 21:51:09.414964|2018-05-31 21:51:09.414964
NCT01489618|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-02-23|2011-12-08|2011-12-09|Estimate|||||||2016-02-23|2016-02-24|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EVAD||"Prime Boost Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency"|"Randomised, Multicentric, Phase ii Study of the Immunogenicity of a Prime Boost Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency"|Terminated||Phase 2|45|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2||End of production|f||||t||||||||||2018-05-31 21:51:09.512627|2018-05-31 21:51:09.512627
NCT01489605|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2016-09-07|2011-12-08|2011-12-09|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2017||2017-07-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||GlideScope Groove vs. Standard GlideScope: A Non-inferiority Study|Comparison of GlideScope Groove to Standard GlideScope for Orotracheal Intubation: A Non-inferiority Study|Not yet recruiting||N/A|130|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:51:09.61141|2018-05-31 21:51:09.61141
NCT01489592|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-04-10|2011-12-08|2011-12-09|Estimate|||||||2013-04-10|2013-04-11|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|CURHEP||Effect of Curcumin on Iron Metabolism in Healthy Volunteer|Effect of Curcumin on Iron Metabolism in Healthy Volunteer|Completed||Phase 2|18|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 21:51:09.706849|2018-05-31 21:51:09.706849
NCT01489579|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-07-20|2011-12-08|2011-12-09|Estimate|||||||2015-07-20|2015-07-21|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Telephone Counseling for Tobacco Cessation|Evaluation of Brief, Structured, Telephone Counseling for Tobacco Cessation as Part of a Cardiovascular Risk Reduction Service|Completed||N/A|192|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 21:51:09.776227|2018-05-31 21:51:09.776227
NCT01489566|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2011-12-13|2011-12-08|2011-12-09|Estimate|||||||2011-12-13|2011-12-14|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|August 2013|Anticipated|2013-08-31|March 2013|Anticipated|2013-03-31||Interventional|||Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients|A Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Phase III Clinical Trial to Evaluate the Safety and Efficacy of Injectable Tyroserleutide to Treat Hepatocellular Carcinoma|Unknown status|Enrolling by invitation|Phase 3|300|Anticipated|Shenzhen Kangzhe Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:51:09.864838|2018-05-31 21:51:09.864838
NCT01489553|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2013-10-21|2011-12-08|2011-12-09|Estimate|||||||2013-10-21|2013-10-22|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Egg Oral Immunotherapy|Egg Oral Immunotherapy|Completed|||9|Actual|Children's Hospital of Philadelphia|||||f||||t||||||Samples Without DNA|"~     Immunocap testing (bloodwork) will be performed prior to and upon completion of the~     desensitization protocol. This testing is considered standard of care in the management of~     food allergies.~   "|||2018-05-31 21:51:09.962727|2018-05-31 21:51:09.962727
NCT01489540|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2013-09-18|2011-12-08|2011-12-09|Estimate|||||||2013-09-18|2013-09-19|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Cost-effectiveness of Laser Doppler Imaging in Burn Care|Cost-effectiveness of Laser Doppler Imaging in Burn Care in the Netherlands|Completed||N/A|200|Anticipated|Association of Dutch Burn Centres||2|||f||||f||||||||||2018-05-31 21:51:10.018735|2018-05-31 21:51:10.018735
NCT01489527|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2015-01-05||2015-01-21|2011-12-08|2011-12-09|Estimate|2015-01-05|2015-01-12|Estimate||||2015-01-21|2015-02-06|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional||All treated participants|Preparedness Study - HPV Vaccine|Preparedness Study: Efficacy of HPV Vaccine to Reduce HIV Infection|Completed||N/A|406|Actual|H. Lee Moffitt Cancer Center and Research Institute|The EVRI Trial had a short duration with limited follow-up time; therefore, clinical efficacy in reducing HIV acquisition cannot be assessed.|2|||f||||t||||||||||2018-05-31 21:51:10.248145|2018-05-31 21:51:10.248145
NCT01489514|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2015-05-26|2011-12-08|2011-12-09|Estimate|||||||2015-05-26|2015-05-27|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2013|Actual|2013-01-31||Observational|peanut||Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects|Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects.|Completed|||22|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     Venipuncture for 30mL of blood taken for measurement of peanut IgE.~   "|||2018-05-31 21:51:10.635727|2018-05-31 21:51:10.635727
NCT01489501|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-03-24|2011-12-08|2011-12-09|Estimate|||||||2015-03-24|2015-03-25|Estimate||||March 2015|2015-03-31||||||||Interventional|||Multicenter Study of CAOMECS Transplantation to Patients With Total Limbal Stem Cell Deficiency|Multicenter Study of Cultured Autologous Oral Mucosal Epithelial Cell-Sheet (CAOMECS) Transplantation to Patients With Total Limbal Stem Cell Deficiency|Withdrawn||Phase 3|0|Actual|CellSeed France S.A.R.L.||1||Change of strategic priorities in the sponsor's clinical development sector.|f||||f||||||||||2018-05-31 21:51:10.693691|2018-05-31 21:51:10.693691
NCT01489488|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-06-29|2011-12-08|2011-12-09|Estimate|||||||2015-06-29|2015-07-01|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Relative Bioavailability and Food Effect Study|Relative Bioavailability and Food Effect Study of Two Oral Liquid Formulations in Comparison to a 1 mg Tablet of Riociguat to Characterize Its Pharmacokinetic Properties in Healthy Male and Female Adult Subjects in a Randomized, Open Label, 5-fold Crossover Design|Completed||Phase 1|32|Actual|Bayer||5|||f||||f||||||||||2018-05-31 21:51:10.764745|2018-05-31 21:51:10.764745
NCT01489475|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-02-24|2011-12-07|2011-12-09|Estimate|||||||2015-02-24|2015-02-26|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass|Plasma Angiopoietin Levels in Children Undergoing Modified Ultrafiltration Following Cardiopulmonary Bypass|Completed|||31|Actual|Yale University|||||f||||f||||||Samples With DNA|"~     1. Modified ultrafiltration fluid~        2. Whole blood which will be spun down to plasma (cells to be discarded)~   "|||2018-05-31 21:51:10.863396|2018-05-31 21:51:10.863396
NCT01489462|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-11-02|2011-12-08|2011-12-09|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2012||2012-03-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|START||Strength Training for ARthritis Trial|Strength Training for ARthritis Trial|Completed||N/A|375|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||||2018-05-31 21:51:11.036762|2018-05-31 21:51:11.036762
NCT01489449|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2016-05-11|2011-12-07|2011-12-09|Estimate|||||||2016-05-11|2016-05-12|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|September 2017|Anticipated|2017-09-30||Interventional|PEPCADNSTEMI||Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction|Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction|Recruiting||Phase 4|1000|Anticipated|University Hospital, Saarland||2|||f||||t||||||||||2018-05-31 21:51:11.136476|2018-05-31 21:51:11.136476
NCT01489436|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2014-03-19|2011-12-07|2011-12-09|Estimate|||||||2014-03-19|2014-03-21|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CENoMIP||A Comparison of Single Port and Four Port Laparoscopic Gallbladder Removal|Comparative Effectiveness of Novel Minimally Invasive Procedures|Completed||N/A|118|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:51:11.247271|2018-05-31 21:51:11.247271
NCT01489423|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-05-16|2011-12-08|2011-12-09|Estimate|||||||2017-05-16|2017-05-17|Actual|April 26, 2013|Actual|2013-04-26|May 2017|2017-05-31|May 26, 2013|Actual|2013-05-26|May 26, 2013|Actual|2013-05-26||Observational|||Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim|Correlative Analyses of Specimens From Eastern Cooperative Group Study E1608|Completed|||270|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:51:11.345462|2018-05-31 21:51:11.345462
NCT01489410|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2017-08-30|2011-12-07|2011-12-09|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2012||2012-10-31|August 2017|2017-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma|Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Insufficient staff|f||||f||||||||||2018-05-31 21:51:11.463866|2018-05-31 21:51:11.463866
NCT01489397|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-06-09|2011-12-08|2011-12-09|Estimate|||||||2014-06-09|2014-06-11|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Magnified Intelligence Chromoendoscopy Plus Probe-based Confocal Laser Endomicroscopy for Gastric Intestinal Metaplasia Diagnosis||Completed||N/A|45|Actual|King Chulalongkorn Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:51:11.64987|2018-05-31 21:51:11.64987
NCT01489384|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2017-04-12|2011-12-08|2011-12-09|Estimate|||||||2017-04-12|2017-04-13|Actual|December 2011||2011-12-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|August 27, 2018|Anticipated|2018-08-27||Observational|||Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)|A Canadian Randomized Controlled Trial of DMARD Withdrawal in RA Patients Achieving Therapeutic Response With Cimzia + DMARD Combination Treatment.|Active, not recruiting|||125|Actual|Pope Research Corporation|||4||f||||f||||||||||2018-05-31 21:51:11.758717|2018-05-31 21:51:11.758717
NCT01489371|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2017-08-23|2011-12-08|2011-12-09|Estimate|||||||2017-08-23|2017-08-24|Actual|July 9, 2012|Actual|2012-07-09|August 2017|2017-08-31||||July 21, 2015|Actual|2015-07-21||Interventional|||EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase I Study of Intraperitoneal Egen-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC# 712227 or Lipodox (NSC#673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 1|16|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-05-31 21:51:11.910563|2018-05-31 21:51:11.910563
NCT01489358|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|2016-03-11||2016-06-09|2011-12-08|2011-12-09|Estimate|2016-03-11|2016-04-12|Estimate||||2016-06-09|2016-07-25|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||All enrolled participants|Chikungunya Virus Vaccine Trial in Healthy Adults|VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults|Completed||Phase 1|25|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 21:51:12.064314|2018-05-31 21:51:12.064314
NCT01489345|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-07-31|2011-12-08|2011-12-09|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2011||2011-12-31|July 2012|2012-07-31||||April 2012|Actual|2012-04-30||Interventional|||Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects|Completed||Phase 1|36|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 21:51:13.004282|2018-05-31 21:51:13.004282
NCT01489332|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2011-12-07|2011-12-07|2011-12-09|Estimate|||||||2011-12-07|2011-12-09|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|April 2018|Anticipated|2018-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Induction Chemotherapy,Radiochemotherapy, Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer|Induction Chemotherapy, Preoperative Radiochemotherapy, Consolidation Chemotherapy, Operation and Adjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer- OIGIT 5-01 Phase II Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Institute of Oncology Ljubljana|||||f||||f||||||||||2018-05-31 21:51:13.096977|2018-05-31 21:51:13.096977
NCT01489319|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2017-02-08|2011-12-08|2011-12-09|Estimate|||||||2017-02-08|2017-02-10|Actual|February 2012||2012-02-29|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ELI-ROAS||Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)|Evaluation of the Ovarian Dynamic Response and the Inflammatory Response to Oral Lipid Challenge in Relation to Body Composition in Polycystic Ovary Syndrome|Terminated||Phase 1|47|Actual|Indiana University||6||"The PI left Indiana University. The findings served as preliminary data for a recently awarded~   NIH R01 grant."|f||||f|t|||||||||2018-05-31 21:51:13.330243|2018-05-31 21:51:13.330243
NCT01489306|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-04-10|2011-12-08|2011-12-09|Estimate|||||||2012-04-10|2012-04-12|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 Administered to Healthy Volunteers for 10 Days|Completed||Phase 1|36|Anticipated|MicroDose Therapeutx, Inc||2|||f||||||||||||||2018-05-31 21:51:13.428303|2018-05-31 21:51:13.428303
NCT01489293|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2018-03-21|2011-12-07|2011-12-09|Estimate|||||||2018-03-21|2018-03-22|Actual|May 1, 2012|Actual|2012-05-01|March 2018|2018-03-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Observational|||Inhibitory Receptors in Eosinophils of Atopic Subjects|Characterization of the Expression and Activity of Inhibitory Receptors Such as CLM-1 in Eosinophils of Atopic Subjects|Completed|||40|Actual|Meir Medical Center|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:51:13.50245|2018-05-31 21:51:13.50245
NCT01489280|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2012-09-09|2011-12-08|2011-12-09|Estimate|||||||2012-09-09|2012-09-11|Estimate|May 2012||2012-05-31|September 2012|2012-09-30||||February 2014|Anticipated|2014-02-28||Observational|TTP||Temple Touch Pro (TTP) Non Invasive Continuous Temperature Measurement System|Temple Touch Pro (TTP) Non Invasive Continuous Temperature Measurement System.|Unknown status|Recruiting||800|Anticipated|Medisim Ltd|||||f||||f||||||||||2018-05-31 21:51:13.576249|2018-05-31 21:51:13.576249
NCT01489267|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2012-06-18|2011-12-08|2011-12-09|Estimate|||||||2012-06-18|2012-06-20|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|SCA||A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation|The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Transplantation in Hereditary Cerebellar Ataxia Patients|Unknown status|Enrolling by invitation|Phase 2|20|Anticipated|General Hospital of Chinese Armed Police Forces||2|||f||||t||||||||||2018-05-31 21:51:13.718764|2018-05-31 21:51:13.718764
NCT01489254|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2016-04-18||2016-11-10|2011-12-08|2011-12-09|Estimate|2016-09-13|2016-10-31|Estimate||||2016-11-10|2016-12-29|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|GATE||Efficacy and Safety of GTR in Comparison to Copaxone®|Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects|Completed||Phase 3|794|Actual|Synthon BV||3|||f||||t||||||||Yes||2018-05-31 21:51:13.846131|2018-05-31 21:51:13.846131
NCT01489241|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2015-02-21|2011-12-07|2011-12-09|Estimate|||||||2015-02-21|2015-02-24|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|RHCluster4GR||Short-term Telehealth Follow up After Hospital Discharge for Chronic Obstructive Pulmonary Disease Exacerbation|Renewing Health RCT in Central Greece for the Evaluation of Short-term Telehealth Follow up After Hospital Discharge for COPD Exacerbation|Completed||N/A|155|Actual|Regional Health Authority of Sterea & Thessaly||2|||f||||t||||||||||2018-05-31 21:51:15.74314|2018-05-31 21:51:15.74314
NCT01489228|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-12-19|2011-12-07|2011-12-09|Estimate|||||||2011-12-19|2011-12-21|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease|Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease|Unknown status|Recruiting|Phase 2|230|Anticipated|Drugs for Neglected Diseases||5|||f||||t||||||||||2018-05-31 21:51:15.880711|2018-05-31 21:51:15.880711
NCT01489215|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2011-12-08|2011-12-08|2011-12-09|Estimate|||||||2011-12-08|2011-12-09|Estimate|February 2012||2012-02-29|December 2011|2011-12-31||||February 2015|Anticipated|2015-02-28||Interventional|||Interventions for Sleep Problems in Early Childhood|Interventions for Sleep Problems in Early Childhood:The Role of Child, Parental and Intervention Factors|Unknown status|Not yet recruiting|N/A|180|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||||||||||||2018-05-31 21:51:16.136036|2018-05-31 21:51:16.136036
NCT01489202|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-03-06|2011-12-08|2011-12-09|Estimate|||||||2013-03-06|2013-03-07|Estimate|September 2014||2014-09-30|March 2013|2013-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|PLATFORM||Effects of DES Platforms on Markers of Endothelial Damage and Inflammation|Randomized Comparison of the Effects of PLatinum Chromium Everolimus-eluting Stent vs. cobAlT Chromium Everolimus-eluting Stent on inFlammatOry maRkers and Endothelial daMage - The PLATFORM Trial|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:51:16.271248|2018-05-31 21:51:16.271248
NCT01489189|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2016-02-12||2018-02-27|2011-12-07|2011-12-09|Estimate|2016-04-25|2016-06-01|Estimate||||2018-02-27|2018-03-29|Actual|March 2012||2012-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|January 2015|Actual|2015-01-31||Interventional|Protocol S|Units in Eyes|Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Active, not recruiting||Phase 3|305|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 21:51:16.575856|2018-05-31 21:51:16.575856
NCT01489176|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2012-09-25|2011-12-07|2011-12-09|Estimate|||||||2012-09-25|2012-09-26|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Regadenoson Real Time Perfusion Imaging Trial-Optison|Regadenoson Real Time Perfusion Imaging Trial-Optison|Unknown status|Recruiting|N/A|50|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 21:51:19.717599|2018-05-31 21:51:19.717599
NCT01489163|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2017-07-31|2011-12-08|2011-12-09|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2011|Actual|2011-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2015|Actual|2015-10-31||Interventional|APPLES||Lifestyle Intervention Program for Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance|Translational Diabetes Prevention in GDM|Active, not recruiting||N/A|350|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 21:51:19.922581|2018-05-31 21:51:19.922581
NCT01489150|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-05-15|2011-12-07|2011-12-09|Estimate|||||||2013-05-15|2013-05-16|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Observational|||Use of EtCO2 as a PaCO2 Predictor Under Non Invasive Ventilation (NIV) in Cases of Acute Hypercapnic Respiratory Failure|Use of EtCO2 and Prolonged Expiratory Maneuvers as a PaCO2 Predictor in Cases of Acute Hypercapnic Respiratory Failure|Completed|||11|Actual|University of Lausanne Hospitals|||||f||||f||||||||||2018-05-31 21:51:20.020085|2018-05-31 21:51:20.020085
NCT01489137|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-08-15|2011-12-07|2011-12-09|Estimate|||||||2012-08-15|2012-08-17|Estimate|November 2011||2011-11-30|August 2012|2012-08-31||||February 2012|Actual|2012-02-29||Interventional|||The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation|The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation in the Patients Undergoing Neurosurgery|Completed||N/A|50|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 21:51:20.135567|2018-05-31 21:51:20.135567
NCT01489124|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-12-08|2011-12-08|2011-12-09|Estimate|||||||2011-12-08|2011-12-09|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia|The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia|Completed||Phase 4|9|Actual|Prince of Songkla University||3|||f||||f||||||||||2018-05-31 21:51:20.358453|2018-05-31 21:51:20.358453
NCT01489111|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-05-16|2011-12-07|2011-12-09|Estimate|||||||2018-05-16|2018-05-17|Actual|August 3, 2012|Actual|2012-08-03|May 2018|2018-05-31|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|pathfinder™3||Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.|Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A|Recruiting||Phase 3|49|Anticipated|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:51:20.545754|2018-05-31 21:51:20.545754
NCT01489098|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-03-17|2011-12-08|2011-12-09|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Effect of the Level of Dietary Protein on Body Composition|Effect of the Level of Dietary Protein on Infant Growth and Body Composition in the First Year of Life - Three and Five Year Growth and Body Composition Follow-up|Completed|||178|Actual|Nestlé|||3||f||||f||||||||||2018-05-31 21:51:20.919577|2018-05-31 21:51:20.919577
NCT01489085|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-07-21|2011-12-08|2011-12-09|Estimate|||||||2014-07-21|2014-07-22|Estimate|January 2013||2013-01-31|November 2010|2010-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|intellivent||Observational Study Evaluating the Use of Intellivent® for Patients With Respiratory Distress Syndrome|Etude Clinique Observationnelle, Prospective, Ouverte, Monocentrique Sur l'Utilisation d'un Mode Ventilatoire entièrement automatisé Chez Les Patients de réanimation de l'Intubation Jusqu'au Sevrage.|Completed|||100|Actual|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|||||f||||t||||||||||2018-05-31 21:51:20.995533|2018-05-31 21:51:20.995533
NCT01489072|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-10-25|2011-12-08|2011-12-09|Estimate|||||||2012-10-25|2012-10-29|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy of Two Bolus Doses of Remifentanil on the Incidence of Coughing During Emergence of Anesthesia|Comparison of the Efficacy of Two Bolus Doses of Remifentanil on the Incidence of Coughing During Emergence of Anesthesia.|Completed||N/A|180|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 21:51:21.183914|2018-05-31 21:51:21.183914
NCT01489059|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2014-08-28|2011-12-07|2011-12-09|Estimate|||||||2014-08-28|2014-08-29|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma|A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma|Completed||Phase 1|42|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 21:51:21.378017|2018-05-31 21:51:21.378017
NCT01489046|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07||2016-03-17|2016-03-17|2011-12-08|2011-12-09|Estimate||||2016-03-17|2016-04-15|Estimate|2016-03-17|2016-04-15|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|July 2014|Actual|2014-07-31|March 2013|Actual|2013-03-31||Interventional|||Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive|A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose|Terminated||Phase 2|297|Actual|Bristol-Myers Squibb||4|||f||||t||||||||||2018-05-31 21:51:21.664053|2018-05-31 21:51:21.664053
NCT01489033|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2017-04-28|2011-12-08|2011-12-09|Estimate|||||||2017-04-28|2017-05-01|Actual|January 2010||2010-01-31|April 2017|2017-04-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense|Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Phleum Pratense.|Completed||Phase 1|42|Actual|Roxall Medicina España S.A||6|||f||||f||||||||||2018-05-31 21:51:21.88177|2018-05-31 21:51:21.88177
NCT01489020|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-04-28|2011-12-07|2011-12-09|Estimate|||||||2017-04-28|2017-05-01|Actual|January 2011||2011-01-31|April 2017|2017-04-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)|Multicentre Phase I Randomized Double Blind Placebo Controlled Study of Subcutaneous Immunotherapy in Subjects With Allergic Rhinoconjunctivitis ± Asthma Sensitised to Dermatophagoides Pteronyssinus.|Completed||Phase 1|48|Actual|Roxall Medicina España S.A||6|||f||||f||||||||||2018-05-31 21:51:22.183595|2018-05-31 21:51:22.183595
NCT01489007|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2015-03-25|2011-12-08|2011-12-09|Estimate|||||||2015-03-25|2015-03-27|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||Iron Absorption in Vegetarian Children|Evaluation of Iron Absorption in Healthy Vegetarian Children 4 to 10 Years of Age|Unknown status|Active, not recruiting||36|Anticipated|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 21:51:22.344261|2018-05-31 21:51:22.344261
NCT01488994|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2016-03-24|2014-05-29|2017-10-19|2011-12-07|2011-12-09|Estimate|2016-07-21|2016-09-01|Estimate|2014-05-29|2014-06-02|Estimate|2017-10-19|2017-10-23|Actual|December 2011||2011-12-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||BAX 326 Pediatric Study|BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B|Completed||Phase 2/Phase 3|23|Actual|Shire||2|||f||||t||||||||||2018-05-31 21:51:22.57312|2018-05-31 21:51:22.57312
NCT01488825|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-07|2011-12-07|2011-12-08|Estimate|||||||2011-12-07|2011-12-08|Estimate|January 2005||2005-01-31|December 2011|2011-12-31|June 2006|Actual|2006-06-30|February 2006|Actual|2006-02-28||Interventional|||Yoga Intervention Study on Episodic Tension Type Headache|Effect of Yoga Intervention on Episodic Tension Type Headache: A Randomized Controlled Trial|Completed||Phase 2|77|Actual|NMP Medical Research Institute||2|||f||||t||||||||||2018-05-31 21:51:26.745515|2018-05-31 21:51:26.745515
NCT01488981|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2013-12-18|2011-12-07|2011-12-09|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Feasibility of the Radio-Frequency Microstimulator System to Improve Arm Function Following Traumatic Brain Injury|A Feasibility Study to Assess the Safety and Efficacy of the Radio-Frequency Microstimulator System to Improve Function of the Arm Following Traumatic Brain Injury|Terminated||Phase 1|1|Actual|The Alfred E. Mann Foundation for Scientific Research||||low enrollment|f||||f||||||||||2018-05-31 21:51:24.527873|2018-05-31 21:51:24.527873
NCT01488968|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-01-23|2011-12-07|2011-12-09|Estimate|||||||2017-01-23|2017-01-25|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|January 2018|Anticipated|2018-01-31||Interventional|CHIRP||Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients|A Phase II Randomized Control Trial of Conventional Versus Hypofractionated Radiation Regimen in Single Phase Using IMRT Technique and Long Term Androgen Suppression Therapy in High-risk Prostate Cancer Patients.|Recruiting||N/A|134|Anticipated|AHS Cancer Control Alberta||2|||f||||t||||||||||2018-05-31 21:51:24.765028|2018-05-31 21:51:24.765028
NCT01488955|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2014-08-07|2011-12-07|2011-12-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|||Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI|Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - a Comparative Effectiveness Study in General Practice (ICUTI)|Completed||Phase 4|494|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||f||||||||||2018-05-31 21:51:25.074682|2018-05-31 21:51:25.074682
NCT01488942|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2017-11-01|2011-12-06|2011-12-08|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2012||2012-12-31|November 2017|2017-11-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|Incentives-2||Use of Incentives to Retain Drug Users in HIV Therapy|A Randomized Clinical Trial Evaluating the Role of Contingent Reinforcement in the Engagement of and Retention of Drug Users in HAART Programs|Active, not recruiting||N/A|139|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 21:51:25.187271|2018-05-31 21:51:25.187271
NCT01488929|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06||2015-05-11|2015-05-11|2011-12-06|2011-12-08|Estimate||||2015-05-11|2015-06-03|Estimate|2015-05-11|2015-06-03|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia|A Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia|Completed||Phase 2|603|Actual|Targacept Inc.||3|||f||||f||||||||||2018-05-31 21:51:25.314221|2018-05-31 21:51:25.314221
NCT01488916|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-12|2011-12-07|2011-12-08|Estimate|||||||2011-12-12|2011-12-14|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Observational|||Vitamin D Inadequacy on Postprandial Glucose in Type 2 Diabetes Mellitus|Impacts of Vitamin D Inadequacy on Postprandial Glucose Excursion in Patients With Type 2 Diabetes|Unknown status|Recruiting||45|Anticipated|Taipei Veterans General Hospital, Taiwan|||3||f||||f||||||Samples Without DNA|"~     Serum samples after meal challenge~   "|||2018-05-31 21:51:25.501406|2018-05-31 21:51:25.501406
NCT01488903|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-12|2011-12-06|2011-12-08|Estimate|||||||2011-12-12|2011-12-14|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Observational|CROWN||A Cohort Research of Genetic Susceptibility for Common Obesity in Women|A Cohort Research of Genetic Susceptibility for Common Obesity in Women (CROWN Study)|Unknown status|Recruiting||1200|Anticipated|Taipei Veterans General Hospital, Taiwan|||2||f||||f||||||Samples With DNA|"~     DNA, fasting blood samples~   "|||2018-05-31 21:51:25.621763|2018-05-31 21:51:25.621763
NCT01488890|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06||2014-04-08|2014-05-01|2011-12-07|2011-12-08|Estimate||||2014-04-08|2014-05-02|Estimate|2014-05-01|2014-05-19|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|||Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine|Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults.|Completed||Phase 2|390|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 21:51:25.731905|2018-05-31 21:51:25.731905
NCT01488877|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2013-07-18||2013-09-24|2011-12-06|2011-12-08|Estimate|2013-07-18|2013-09-23|Estimate||||2013-09-24|2013-10-29|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy|A 2-week, Phase 1b, Randomized, Double-Blind, Placebo- Controlled, Multi-Dose, Dose-Escalating Study With PF-03882845 And One Dose Of Spironolactone To Evaluate Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Subjects With Type 2 Diabetes Mellitus And Albuminuria|Terminated||Phase 1|6|Actual|Pfizer|Study was terminated prematurely; this was based on a strategic decision by the sponsor to terminate further development of this compound for proposed indication. The study was not terminated for safety or lack of efficacy reasons.|3||See termination reason in detailed description.|f||||f||||||||||2018-05-31 21:51:26.042688|2018-05-31 21:51:26.042688
NCT01488864|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-05-10|2011-12-07|2011-12-08|Estimate|||||||2012-05-10|2012-05-11|Estimate|March 2007||2007-03-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Applied Relaxation for Vasomotor Symptoms|Applied Relaxation for Vasomotor Symptoms in Postmenopausal Women - a Randomized, Controlled Trial|Terminated||N/A|60|Actual|Ostergotland County Council, Sweden||2||Low drop-out rate and slow recruitment rate|f||||f||||||||||2018-05-31 21:51:26.504039|2018-05-31 21:51:26.504039
NCT01488851|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2016-01-04|2011-12-07|2011-12-08|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Observational|||Study to Assess Incidence of ONJ in Pts With Bone Mets Starting Zoledronic Acid Treatment|Prospective Observational Multi Central Cohort Study to Assess the Incidence of Osteo Necrosis of Jaw in Patients With Bone Metastasis Starting Zoledronic Acid Treatment|Completed|||100|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 21:51:26.601117|2018-05-31 21:51:26.601117
NCT01488838|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2016-02-24|2011-12-07|2011-12-08|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors||Completed||Phase 2|120|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||||||||||||2018-05-31 21:51:26.658866|2018-05-31 21:51:26.658866
NCT01488799|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2015-12-28|2011-12-07|2011-12-08|Estimate|||||||2015-12-28|2015-12-29|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Motivational Interviewing and Cognitive Behavioural Therapy for Generalized Anxiety Disorder|Adding Motivational Interviewing to Cognitive Behavioural Therapy for Severe Generalized Anxiety Disorder|Completed||N/A|85|Actual|York University||2|||f||||t||||||||||2018-05-31 21:51:27.056449|2018-05-31 21:51:27.056449
NCT01488786|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-08-06|2011-12-07|2011-12-08|Estimate|||||||2013-08-06|2013-08-09|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind|A Study to Evaluate the Safety and Efficacy of the BrainPort® Vision Device in Subjects Who Are Blind|Completed||N/A|75|Actual|Wicab||1|||f||||t||||||||||2018-05-31 21:51:27.151691|2018-05-31 21:51:27.151691
NCT01488773|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-01-10|2011-12-07|2011-12-08|Estimate|||||||2012-01-10|2012-01-12|Estimate|April 1995||1995-04-30|January 2012|2012-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Comparison of Two Treatment Regimens in Asthmatic Patients|A Four Year Observational Study Comparing Two Treatment Regimens: Inhaled Glucocorticosteroid + Salmeterol and Inhaled Glucocorticosteroid + Montelukast.|Completed|||132|Actual|Medical Universtity of Lodz|||2||f||||f||||||||||2018-05-31 21:51:27.300518|2018-05-31 21:51:27.300518
NCT01488760|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-06|2011-12-06|2011-12-08|Estimate|||||||2011-12-06|2011-12-08|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Abdominal Wall Evaluation in Low Back Pain|Deep Abdominal Wall Muscle Dysfunction During Calm Respiration in Chronic Low Back Pain Patients|Completed|||39|Actual|University of Sao Paulo General Hospital|||2||f||||f||||||||||2018-05-31 21:51:27.404103|2018-05-31 21:51:27.404103
NCT01488747|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-04-21|2011-12-07|2011-12-08|Estimate|||||||2016-04-21|2016-04-22|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|October 2012|Actual|2012-10-31||Interventional|||Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride|Bioavailability of Fish Oils: Emulsified vs. Capsular Triglyceride|Completed||N/A|19|Actual|USDA Grand Forks Human Nutrition Research Center||4|||f||||t||||||||No||2018-05-31 21:51:27.679239|2018-05-31 21:51:27.679239
NCT01488734|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2017-04-12|2011-12-07|2011-12-08|Estimate|||||||2017-04-12|2017-04-14|Actual|November 2011||2011-11-30|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom|Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom|Completed||N/A|47|Actual|Icahn School of Medicine at Mount Sinai||4|||f||||f|f|f||||||||2018-05-31 21:51:28.102016|2018-05-31 21:51:28.102016
NCT01488721|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-08-16|2011-12-07|2011-12-08|Estimate|||||||2012-08-16|2012-08-17|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Observational|||Clinical Evaluation of NeoPlex4 Assay and NeoPlex System|Clinical Evaluation of the xMAP® NeoPlex4™ Assay for Detection of T4, TSH, 17-OHP and IRT Using the NeoPlex System|Completed|||7462|Actual|Luminex Molecular Diagnostics|||2||f||||f||||||||||2018-05-31 21:51:28.203166|2018-05-31 21:51:28.203166
NCT01488708|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2018-03-24|2016-03-10|2018-05-16|2011-12-06|2011-12-08|Estimate|2018-05-16|2018-05-17|Actual|2016-03-10|2016-03-24|Estimate|2018-05-16|2018-05-17|Actual|January 2012||2012-01-31|May 2018|2018-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Illuminate-X||On Open-Label Study in Participants With Systemic Lupus Erythematosus|A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)|Terminated||Phase 3|1518|Actual|Eli Lilly and Company|Study terminated early due to lack of efficacy in parent studies.|2||Lack of efficacy|f||||t||||||||||2018-05-31 21:51:28.326576|2018-05-31 21:51:28.326576
NCT01488695|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-09-07|2011-12-07|2011-12-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2017||2017-07-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||GlideScope Groove Versus Macintosh Blade for Double-Lumen Endotracheal Tube Intubation|Comparison of GlideScope Groove to Macintosh Blade for Orotracheal Intubation With Double-Lumen Endotracheal Tube: a Randomised Controlled Trial|Not yet recruiting||N/A|80|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:51:30.721811|2018-05-31 21:51:30.721811
NCT01488682|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-06|2011-12-06|2011-12-08|Estimate|||||||2011-12-06|2011-12-08|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||The Safety and Efficacy of the Harmonic Scalpel in Neck Dissection|The Safety and Efficacy of the Harmonic Scalpel in Neck Dissection : A Prospective Randomized Study|Unknown status|Recruiting|N/A|59|Anticipated|Yonsei University||2|||f||||||||||||||2018-05-31 21:51:30.804367|2018-05-31 21:51:30.804367
NCT01488669|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-06|2011-12-06|2011-12-08|Estimate|||||||2011-12-06|2011-12-08|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|September 2013|Anticipated|2013-09-30|September 2011|Actual|2011-09-30||Interventional|||Robot Assisted Supraomohyoid Neck Dissection Via Retroauricular Approach||Unknown status|Recruiting|N/A|26|Anticipated|Yonsei University||2|||f||||||||||||||2018-05-31 21:51:30.892322|2018-05-31 21:51:30.892322
NCT01488656|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-08-14|2011-12-07|2011-12-08|Estimate|||||||2012-08-14|2012-08-15|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Effects of Dietary Supplements on Response to Air Pollution|Effect of an Antioxidant and Anti-inflammatory Dietary Supplement Pack on the Adverse Physiological Actions Associated With Acute PM2.5 Exposure|Completed||N/A|66|Actual|Utah State University||2|||f||||f||||||||||2018-05-31 21:51:30.987491|2018-05-31 21:51:30.987491
NCT01488643|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-07|2011-12-07|2011-12-08|Estimate|||||||2011-12-07|2011-12-08|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Observational|||Observational Study on Obese Patients During General Anesthesia|Bronchospasm During General Anesthesia in Obese Patients|Unknown status|Recruiting||50|Anticipated|Larissa University Hospital|||2||f||||f||||||||||2018-05-31 21:51:31.15409|2018-05-31 21:51:31.15409
NCT01488630|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2015-09-15|2011-12-06|2011-12-08|Estimate|||||||2015-09-15|2015-09-17|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|STaRS||Substance Treatment and HIV Testing and Referral System|Substance Treatment Referral System|Completed||Phase 2|60|Actual|Polaris Health Directions||2|||f||||f||||||||||2018-05-31 21:51:31.246751|2018-05-31 21:51:31.246751
NCT01488617|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-10-30|2011-12-07|2011-12-08|Estimate|||||||2013-10-30|2013-10-31|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Observational|MOPS||Mainz Outcome Predictor Studies: An Observational Clinical Trial Investigating Predictors for Postoperative Outcome|Mainz Outcome Predictor Studies: An Observational Clinical Trial Investigating Physiological and Psychological Data as Predictors for Postoperative Outcome.|Completed|||616|Actual|Johannes Gutenberg University Mainz|||||f||||t||||||||||2018-05-31 21:51:31.375815|2018-05-31 21:51:31.375815
NCT01488604|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-05-08|2011-12-07|2011-12-08|Estimate|||||||2012-05-08|2012-05-09|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold|Efficacy and Safety of an Antiviral Polymeric Nasal Spray: A Randomized, Parallel Group, Double-blind, Placebo-controlled Study in Subjects With Early Symptoms of Common Cold|Completed||N/A|163|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 21:51:31.480631|2018-05-31 21:51:31.480631
NCT01488591|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-05-30|2011-12-07|2011-12-08|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2009||2009-04-30|May 2013|2013-05-31||||||||Observational|||Biomarker Research for Personalized Medicine|Biomarker Research for Personalized Medicine in Blood Cancer Patient|Unknown status|Recruiting||1000|Anticipated|Inje University|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:51:31.76112|2018-05-31 21:51:31.76112
NCT01488578|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2012-03-08||2012-05-11|2011-12-06|2011-12-08|Estimate|2012-05-11|2012-06-14|Estimate||||2012-05-11|2012-06-14|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|POTTOR||Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)|Postmarketing Observational Study of Tolterodine Treatment on Overactive Bladder in Real Life Setting|Completed|||11157|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:51:31.841209|2018-05-31 21:51:31.841209
NCT01488565|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-02-12|2011-12-06|2011-12-08|Estimate|||||||2016-02-12|2016-02-15|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|Aza-E||A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia|A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndrome / Acute Myeloid Leukaemia, With Eltrombopag Support for Thrombocytopenia.|Completed||Phase 2|25|Actual|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 21:51:33.385085|2018-05-31 21:51:33.385085
NCT01488552|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2016-08-17|2011-12-06|2011-12-08|Estimate|||||||2016-08-17|2016-08-18|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer|A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|60|Actual|Pancreatic Cancer Research Team||1|||f||||f||||||||||2018-05-31 21:51:33.601812|2018-05-31 21:51:33.601812
NCT01488539|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2016-05-26|2011-12-07|2011-12-08|Estimate|||||||2016-05-26|2016-05-30|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2016|Actual|2016-04-30||Interventional|||Implementation of an Evidence Based Post-Traumatic Stress Disorder (PTSD) Treatment in Public Sector Settings|Implementation of an Evidence Based PTSD Treatment in Public Sector Settings|Unknown status|Active, not recruiting|Phase 2/Phase 3|352|Anticipated|Palo Alto Veterans Institute for Research||2|||f||||t||||||||||2018-05-31 21:51:33.929816|2018-05-31 21:51:33.929816
NCT01488526|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-06-14|2011-12-06|2011-12-08|Estimate|||||||2017-06-14|2017-06-16|Actual|March 1, 2012|Actual|2012-03-01|June 2017|2017-06-30|October 28, 2017|Anticipated|2017-10-28|April 28, 2014|Actual|2014-04-28||Interventional|||Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus|Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers|Active, not recruiting||Phase 4|200|Actual|New Discovery LLC||2|||f||||t||||||||||2018-05-31 21:51:34.481711|2018-05-31 21:51:34.481711
NCT01488513|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-08-19|2011-12-07|2011-12-08|Estimate|||||||2015-08-19|2015-08-20|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|ABC-101||ABC294640 in Treating Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients With Advanced Solid Tumors|Completed||Phase 1|22|Actual|RedHill Biopharma Limited||1|||f||||t||||||||||2018-05-31 21:51:34.620943|2018-05-31 21:51:34.620943
NCT01488500|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-08-03|2011-12-07|2011-12-08|Estimate|||||||2012-08-03|2012-08-06|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Woodsmoke Exposure and Cardiovascular Function|Cardiovascular Effects of Experimental Exposure to Woodsmoke in Man|Completed||N/A|20|Anticipated|University of Edinburgh||3|||f||||f||||||||||2018-05-31 21:51:34.839659|2018-05-31 21:51:34.839659
NCT01488487|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2015-12-18||2016-03-08|2011-12-07|2011-12-08|Estimate|2016-03-08|2016-04-07|Estimate||||2016-03-08|2016-04-07|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Patients assigned to treatment|Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma|Phase II Single Arm Study of Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)|Completed||Phase 2|24|Actual|UNC Lineberger Comprehensive Cancer Center|Unplanned interim analysis due to negative results from another trial found conditional probability of rejecting null hypothesis based on events in the 24 patients enrolled was 0.08. Accrual goals had been met and study was complete per protocol.|1|||f||||t||||||||No||2018-05-31 21:51:34.961121|2018-05-31 21:51:34.961121
NCT01488474|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-01-29|2011-12-06|2011-12-08|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Peripheral Nerve Stimulation in Diabetic Patients|Influence of Diabetic Neuropathy on Current Settings During Peripheral Nerve Stimulation in Regional Anesthesia|Completed|||124|Actual|Medical University of Graz|||2||f||||f||||||Samples With DNA|"~     -  blood samples~        -  any material from surgical resections~   "|||2018-05-31 21:51:35.794324|2018-05-31 21:51:35.794324
NCT01488461|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2015-06-12|2011-12-06|2011-12-08|Estimate|||||||2015-06-12|2015-06-15|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|ATAXIC||Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias|Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias|Completed|||165|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 21:51:35.879781|2018-05-31 21:51:35.879781
NCT01488448|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|2014-08-07||2017-01-31|2011-12-06|2011-12-08|Estimate|2014-08-07|2014-08-22|Estimate||||2017-01-31|2017-02-02|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||A Study of Hypertonic Saline for Infants Hospitalized With Bronchiolitis|A Double-Blind, Controlled, Randomized Clinical Trial of Nebulized Hypertonic Saline for Hospitalized Infants With Viral Bronchiolitis|Completed||N/A|227|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 21:51:35.979546|2018-05-31 21:51:35.979546
NCT01488435|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-12-05|2011-12-06|2011-12-08|Estimate|||||||2012-12-05|2012-12-06|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age||Completed||N/A|310|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 21:51:36.641008|2018-05-31 21:51:36.641008
NCT01488409|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|2016-01-04||2016-02-02|2011-12-06|2011-12-08|Estimate|2016-01-04|2016-02-03|Estimate||||2016-02-02|2016-03-01|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Acipimox on Mitochondrial Function in Obesity|The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity|Completed||Phase 2|39|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:51:37.096445|2018-05-31 21:51:37.096445
NCT01488396|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-12-06|2011-12-06|2011-12-08|Estimate|||||||2011-12-06|2011-12-08|Estimate|February 2007||2007-02-28|December 2011|2011-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye|Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye|Completed||Phase 4|31|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 21:51:37.704857|2018-05-31 21:51:37.704857
NCT01488383|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2015-09-07|2011-12-07|2011-12-08|Estimate|||||||2015-09-07|2015-09-09|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Effect of Stevioside in Postpandrial Glucose in Healthy Adults|Comparison of the Effect on Postpandrial Capillary Blood Glucose Between Oral Stevioside Versus Saccharin in Healthy Adults.|Withdrawn||N/A|0|Actual|Basque Health Service||2||not i|f||||f||||||||||2018-05-31 21:51:37.840214|2018-05-31 21:51:37.840214
NCT01488370|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2016-12-08||2017-04-14|2011-12-06|2011-12-08|Estimate|2017-04-14|2017-05-18|Actual||||2017-04-14|2017-05-18|Actual|November 2011||2011-11-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of 2 Laryngoscopes for Endotracheal Intubation in Children Younger Than 2 Years Old|A Comparison of the Glidescope® Video Laryngoscope and the Storz DCI® Video Laryngoscope for Endotracheal Intubation in Children Younger Than Two Years of Age|Completed||N/A|65|Actual|Loma Linda University|Trainees reported more prior intubation experience using DL than the other laryngoscopes, so we were unable to equalize prior clinical experience between DL & other laryngoscopes. Assessment of learning effect limited by intubation types within study|3|||f||||f||||||||No||2018-05-31 21:51:38.0127|2018-05-31 21:51:38.0127
NCT01488357|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-04-25|2011-12-06|2011-12-08|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2012||2012-06-30|April 2017|2017-04-30|June 30, 2016|Actual|2016-06-30|February 27, 2014|Actual|2014-02-27||Observational|||Patient Preferences for Breast Reconstruction After Mastectomy|Patient Preferences for Breast Reconstruction After Mastectomy|Completed|||145|Actual|UNC Lineberger Comprehensive Cancer Center|||1||f||||f||||||||||2018-05-31 21:51:38.46819|2018-05-31 21:51:38.46819
NCT01488344|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2013-12-10|2011-12-06|2011-12-08|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2012||2012-03-31|December 2013|2013-12-31||||November 2014|Anticipated|2014-11-30||Interventional|||Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)|A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy|Unknown status|Active, not recruiting|Phase 1/Phase 2|140|Anticipated|University Hospital Muenster||1|||f||||t||||||||||2018-05-31 21:51:38.536279|2018-05-31 21:51:38.536279
NCT01488331|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-11-01|2011-12-07|2011-12-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer|A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months|Completed|||217|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:51:38.6461|2018-05-31 21:51:38.6461
NCT01488318|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2017-11-08||2017-12-07|2011-12-06|2011-12-08|Estimate|2017-12-07|2018-01-05|Actual||||2017-12-07|2018-01-05|Actual|September 2011|Actual|2011-09-30|December 2017|2017-12-31|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma|Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6|Terminated||Phase 2|21|Actual|University of Pittsburgh||1||PI leaving the institution|f||||t||||||||No||2018-05-31 21:51:38.826341|2018-05-31 21:51:38.826341
NCT01488305|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-07|2011-12-07|2011-12-08|Estimate|||||||2011-12-07|2011-12-08|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Interventional|MNP||Action Against Malnutrition Through Agriculture (AAMA) Plus MNP Study|Impact of Micronutrient Powders (MNP)With Homestead Food Production and an Intensive Community Level IYCF-BCC Intervention on Reducing Anemia and Improving Growth in Young Children, Nepal|Unknown status|Active, not recruiting|N/A|334|Actual|Helen Keller International||3|||f||||t||||||||||2018-05-31 21:51:39.057981|2018-05-31 21:51:39.057981
NCT01488292|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2015-06-04|2011-12-06|2011-12-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||RECAP Multi-Component Intervention Program|Multi-Component Mental Health & Academic Intervention for Student Reintegration|Completed||Phase 2|150|Actual|Vanderbilt University||2|||f||||||||||||||2018-05-31 21:51:39.145597|2018-05-31 21:51:39.145597
NCT01488279|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2016-07-05||2018-02-13|2011-12-06|2011-12-08|Estimate|2018-01-22|2018-02-09|Actual||||2018-02-13|2018-03-12|Actual|September 2012||2012-09-30|February 2018|2018-02-28|December 2015|Actual|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy|Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy|Completed||N/A|10|Actual|University of Vermont|Sample size or length of study drug may have been too small|2|||f||||f||||||||Undecided||2018-05-31 21:51:39.39021|2018-05-31 21:51:39.39021
NCT01488266|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2011-12-06|2011-12-06|2011-12-08|Estimate|||||||2011-12-06|2011-12-08|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|||Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder|Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study|Unknown status|Active, not recruiting|N/A|90|Anticipated|Korea University||2|||f||||f||||||||||2018-05-31 21:51:39.849545|2018-05-31 21:51:39.849545
NCT01488253|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2015-03-31|2011-12-06|2011-12-08|Estimate|||||||2015-03-31|2015-04-03|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants|Multicenter Trials to Evaluate the Efficacy and Toxicity of Sirolimus/Tacrolimus Combination as a GVHD Prophylaxis After HLA Matched Related PBSCT|Terminated||Phase 2|3|Actual|The Korean Society of Blood and Marrow Transplantation||1||"We could not receive the support from the national medical insurance owing to the changed~   policy of the government for clincal trials."|f||||t||||||||||2018-05-31 21:51:39.94959|2018-05-31 21:51:39.94959
NCT01488227|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2013-02-22|2011-12-06|2011-12-08|Estimate|||||||2013-02-22|2013-02-25|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Prospective Trial on the Effects of Vitamin D Supplementation in Collegiate Swimmers and Divers|A Prospective Trial on the Effects of Vitamin D Supplementation on 25(OH)D, Body Composition and Injury in Collegiate Swimmers and Divers|Completed||Phase 3|45|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 21:51:40.151721|2018-05-31 21:51:40.151721
NCT01488214|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2017-11-08|2011-12-07|2011-12-08|Estimate|||||||2017-11-08|2017-11-09|Actual|February 16, 2011|Actual|2011-02-16|November 2017|2017-11-30|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Interventional|NeuroScS||Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis|Assessment of Neuropsychiatric Involvement in Systemic Sclerosis.|Completed||N/A|108|Actual|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 21:51:40.235751|2018-05-31 21:51:40.235751
NCT01488201|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-11-01|2011-12-06|2011-12-08|Estimate|||||||2012-11-01|2012-11-02|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis|A Randomized, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KHK4827 in Healthy Volunteers and Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|48|Anticipated|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||||2018-05-31 21:51:40.435343|2018-05-31 21:51:40.435343
NCT01488188|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|2013-07-31||2013-11-05|2011-12-06|2011-12-08|Estimate|2013-11-05|2013-12-23|Estimate||||2013-11-05|2013-12-23|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route|A Controlled Study to Determine the Immunogenicity and Safety of Cold-adaptive Live Attenuated Influenza Vaccine (Flumist) Administered by the Nasal and Sublingual Route in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-05-31 21:51:40.583476|2018-05-31 21:51:40.583476
NCT01488175|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-03-17|2011-12-06|2011-12-08|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Clinical and Stereoradiological Comparison of the Results After Primary Cemented Total Knee Arthroplasty Inserted With or Without the Use of a Tourniquet|Clinical and Stereoradiological Comparison of the Results After Primary TKA Inserted With or Without the Use of a Tourniquet|Withdrawn||Phase 4|0|Actual|Hvidovre University Hospital||2||Funding problems|f||||t||||||||||2018-05-31 21:51:41.46759|2018-05-31 21:51:41.46759
NCT01488162|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-03-21|2011-12-06|2011-12-08|Estimate|||||||2017-03-21|2017-03-22|Actual|April 4, 2011|Actual|2011-04-04|March 2017|2017-03-31|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Observational|||An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia|Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera|Completed|||327|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:51:41.888172|2018-05-31 21:51:41.888172
NCT01488149|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-05-29|2011-12-06|2011-12-08|Estimate|||||||2012-05-29|2012-05-30|Estimate|February 2012||2012-02-29|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Intrapartum Epidural Fentanyl and Breast-feeding in the Immediate Postpartum Period: a Prospective Cohort Study|Intrapartum Epidural Fentanyl and Breast-feeding in the Immediate Postpartum Period: a Prospective Cohort Study|Unknown status|Recruiting||500|Anticipated|University Hospitals Cleveland Medical Center|||2||f||||t||||||||||2018-05-31 21:51:42.192242|2018-05-31 21:51:42.192242
NCT01488136|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2012-06-05|2011-12-07|2011-12-08|Estimate|||||||2012-06-05|2012-06-06|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Use of Diazoxide in Acute Hypoglycaemia|Use of Diazoxide in Acute Hypoglycaemia|Unknown status|Recruiting|Phase 4|12|Anticipated|University of Dundee||2|||f||||t||||||||||2018-05-31 21:51:42.273236|2018-05-31 21:51:42.273236
NCT01488123|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-10-24|2011-12-06|2011-12-08|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Interventional|IACS||Integrative Approaches for Cancer Survivorship|A Whole Systems Approach to the Study of Ayurveda for Cancer Survivorship, Project II|Completed||N/A|32|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 21:51:42.435476|2018-05-31 21:51:42.435476
NCT01488110|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-06-17|2011-12-06|2011-12-08|Estimate|||||||2013-06-17|2013-06-18|Estimate|January 2012||2012-01-31|June 2013|2013-06-30||||||||Interventional|||Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine|Undersökning av ny Behandlingsmetod Vid migränanfall (Evaluation of a New Treatment for Migraine Attacks)|Terminated||N/A|40|Anticipated|Karolinska University Hospital||2||"Too slow recruitment rate. The study has been terminated and will be re-started with an~   improved and more suitable study design."|f||||f||||||||||2018-05-31 21:51:42.553362|2018-05-31 21:51:42.553362
NCT01488097|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|2016-01-14||2017-01-23|2011-12-06|2011-12-08|Estimate|2016-04-05|2016-05-09|Estimate||||2017-01-23|2017-03-06|Actual|November 2011||2011-11-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|March 2014|Actual|2014-03-31||Interventional|||Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency|An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01|Active, not recruiting||Phase 2|8|Actual|Alexion Pharmaceuticals||3|||f||||t||||||||||2018-05-31 21:51:42.66101|2018-05-31 21:51:42.66101
NCT01488084|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2012-12-11|2011-12-07|2011-12-08|Estimate|||||||2012-12-11|2012-12-12|Estimate|June 2010||2010-06-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Assessing Vein Graft Properties Between Conventional & No-Touch Harvesting Technique - (PATENT SVG)|Comparative Evaluation of Vasomotor Function in Saphenous Veins Harvested Using Pedicled vs Conventional Technique|Completed||Phase 1|15|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:51:43.396623|2018-05-31 21:51:43.396623
NCT01487902|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-07|2011-12-07|2011-12-08|Estimate|||||||2011-12-07|2011-12-08|Estimate|July 2010||2010-07-31|December 2011|2011-12-31||||October 2013|Anticipated|2013-10-31||Interventional|||The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer|Randomized Phase II Screening Trial of Docetaxel Plus Prednisolone With or Without Androgen Deprivation Treatment in Castrate-Resistant Prostatic Cancer|Unknown status|Recruiting|Phase 2|90|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:51:48.755168|2018-05-31 21:51:48.755168
NCT01488071|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2013-12-19||2014-02-11|2011-12-06|2011-12-08|Estimate|2014-02-11|2014-03-26|Estimate||||2014-02-11|2014-03-26|Estimate|January 2012||2012-01-31|February 2014|2014-02-28||||December 2012|Actual|2012-12-31||Interventional|REVIVE|"Age and Gender: All-patients-treated set (APTS) – all patients in the APRS who took at least one dose of investigational medicinal product (IMP).~Study Specific Characteristics: Full-analysis set (FAS) - all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the MADRS total score."|A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication|A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Evaluating the Effects of [Vortioxetine] Lu AA21004 Versus Agomelatine in Adult Patients Suffering From Major Depressive Disorder With Inadequate Response to Antidepressant Treatment|Completed||Phase 3|495|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 21:51:43.570685|2018-05-31 21:51:43.570685
NCT01488058|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-09-18|2011-12-06|2011-12-08|Estimate|||||||2012-09-18|2012-09-20|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Cognitive Bias Modification (CBM) and Internet Cognitive Behavioural Therapy (iCBT) for Depression- A Randomised Controlled Trial|A Randomised Controlled Trial Comparing Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder Plus a Cognitive Bias Modification Intervention (OxIGen) vs. Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder vs. a Waitlist Control on Symptoms of Depression and Negative Interpretation Bias.|Completed||N/A|69|Actual|St Vincent's Hospital, Sydney||2|||f||||t||||||||||2018-05-31 21:51:44.39292|2018-05-31 21:51:44.39292
NCT01488045|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2014-12-19|2011-12-06|2011-12-08|Estimate|||||||2014-12-19|2014-12-23|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Compare Propofol to Fentanyl and Midazolam for Colonoscopy|Randomized Trial to Compare Propofol to Fentanyl and Midazolam for Colonoscopy.|Unknown status|Active, not recruiting|N/A|290|Anticipated|Saint Joseph Mercy Health System||2|||f||||f||||||||||2018-05-31 21:51:44.533195|2018-05-31 21:51:44.533195
NCT01488032|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2011-12-08|2011-12-07|2011-12-08|Estimate|||||||2011-12-08|2011-12-09|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Differences in Nerve Fiber Layer Between Patients With Normal- and High-Pressure-Glaucoma|Differences in Nerve Fiber Layer Between Patients With Normal- and High-Pressure-Glaucoma With Similar Structural Optic Nerve Damage|Completed|||44|Actual|Technische Universität Dresden|||2||f||||f||||||||||2018-05-31 21:51:44.692556|2018-05-31 21:51:44.692556
NCT01488019|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2017-03-21||2017-05-11|2011-12-07|2011-12-08|Estimate|2017-05-11|2017-06-12|Actual||||2017-05-11|2017-06-12|Actual|March 2012||2012-03-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Safety Set|Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|1071|Actual|Dey||2|||f||||f||||||||No||2018-05-31 21:51:44.79048|2018-05-31 21:51:44.79048
NCT01488006|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-07-07|2011-12-07|2011-12-08|Estimate|||||||2015-07-07|2015-07-09|Estimate|April 2001||2001-04-30|July 2015|2015-07-31|November 2012|Actual|2012-11-30|October 2009|Actual|2009-10-31||Observational|CSS||Columbia Shoulder Study (CSS)|5- Year Follow-up in Total Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis: A Prospective Multicenter Study|Completed|||207|Actual|Columbia University|||1||f||||f||||||||||2018-05-31 21:51:47.391642|2018-05-31 21:51:47.391642
NCT01487993|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2017-04-26|2011-12-06|2011-12-08|Estimate|||||||2017-04-26|2017-04-27|Actual|August 2011||2011-08-31|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|August 2015|Actual|2015-08-31||Interventional|MetVoorMin||Metformin in Obese Children and Adolescents|An Efficacy, Safety and Pharmacokinetic Study on the Short-term and Long-term Use of Metformin in Obese Children and Adolescents|Completed||Phase 3|62|Actual|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 21:51:47.489237|2018-05-31 21:51:47.489237
NCT01487980|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-12-15|2011-12-06|2011-12-08|Estimate|||||||2012-12-15|2012-12-18|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Delayed Cord Clamping on Haematological Status in Low Birth Weight Infants|The Effect of Delayed Cord Clamping on Haematological Status in Low Birth Weight Infants: a Randomised Controlled Trial in South Africa.|Completed||N/A|102|Anticipated|Stanger Hospital||2|||f||||f||||||||||2018-05-31 21:51:47.723447|2018-05-31 21:51:47.723447
NCT01487967|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-07-19|2011-12-06|2011-12-08|Estimate|||||||2016-07-19|2016-07-21|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Preference and Goal Directed Attention Deficit Hyperactivity Disorder Care- Pilot Study|Preference and Goal-Directed Primary Care to Minimize Disparities and Improve Outcomes in ADHD|Completed||N/A|120|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 21:51:47.797084|2018-05-31 21:51:47.797084
NCT01487954|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2015-06-01||2015-06-01|2011-12-06|2011-12-08|Estimate|2015-06-01|2015-06-18|Estimate||||2015-06-01|2015-06-18|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy|Alkaline Water Consumption to Reduce Skin Radiation Toxicity in Women With Breast Cancer|Completed||Phase 2|45|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:51:47.887839|2018-05-31 21:51:47.887839
NCT01487941|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-11-19|2011-12-06|2011-12-08|Estimate|||||||2014-11-19|2014-11-20|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|February 2013|Actual|2013-02-28||Observational|||Setrox JS Master Study|Efficacy and Safety of the Setrox JS Lead (J=J-shaped, S=Screw)|Completed|||66|Actual|Biotronik SE & Co. KG|||||f||||f||||||||||2018-05-31 21:51:48.329263|2018-05-31 21:51:48.329263
NCT01487928|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-06-15|2011-12-06|2011-12-08|Estimate|||||||2015-06-15|2015-06-16|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Human Milk Cream as a Caloric Supplement in Pre-Term Infants|A Randomized Study of the Use of Human Milk Cream as a Caloric Supplement in a Subset of Very Low Birth Weight Pre-Term Infants|Completed||N/A|78|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 21:51:48.426815|2018-05-31 21:51:48.426815
NCT01487915|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-09-22|2011-12-06|2011-12-08|Estimate|||||||2014-09-22|2014-09-25|Estimate|October 2010||2010-10-31|September 2014|2014-09-30||||June 2015|Anticipated|2015-06-30||Interventional|COACH||Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma|Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin Un-fit Advanced Urothelial Carcinoma: Randomized Phase II Study|Unknown status|Recruiting|Phase 2|80|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:51:48.542117|2018-05-31 21:51:48.542117
NCT01487889|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-11-05|2011-12-06|2011-12-08|Estimate|||||||2014-11-05|2014-11-06|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PINGU||Polyunsaturated Fatty Acids in Child Nutrition|Polyunsaturated Fatty Acids in Child Nutrition - A German Multimodal Optimisation Study|Completed||N/A|214|Actual|Research Institute of Child Nutrition, Dortmund||3|||f||||f||||||||||2018-05-31 21:51:48.969859|2018-05-31 21:51:48.969859
NCT01487876|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-12-07|2011-12-07|2011-12-08|Estimate|||||||2011-12-07|2011-12-08|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients|A Randomized Controlled Trial of Dual-plasmid HBV DNA Vaccine Mediated by in Vivo Electroporation in Chronic Hepatitis B Patients Under Lamivudine Chemotherapy|Unknown status|Recruiting|Phase 2|240|Anticipated|The 458 Hospital of Chinese PLA||2|||f||||t||||||||||2018-05-31 21:51:49.067318|2018-05-31 21:51:49.067318
NCT01487863|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2017-03-27||2017-05-11|2011-12-07|2011-12-08|Estimate|2017-05-11|2017-06-12|Actual||||2017-05-11|2017-06-12|Actual|December 2011||2011-12-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer|A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)|Completed||Phase 2|69|Actual|Dendreon||2|||f||||f||||||||Undecided||2018-05-31 21:51:49.247402|2018-05-31 21:51:49.247402
NCT01487850|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-08|2011-12-07|2011-12-08|Estimate|||||||2011-12-08|2011-12-09|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Wind Instruments' Fungal Contamination|Study of Wind Reed Instruments' Fungal Contamination and Its Immunological and Clinical Consequences for Musicians.|Completed||N/A|||Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 21:51:50.095157|2018-05-31 21:51:50.095157
NCT01487837|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-10-24|2011-12-05|2011-12-07|Estimate|||||||2014-10-24|2014-10-27|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study.|A Phase IV, Randomized, Single Center, Parallel Group Trial of Human Fibrinogen Concentrate (Haemocomplettan) in the Treatment of Dilutional Coagulopathy During Major Pediatric Surgery|Completed||Phase 4|57|Actual|University Children's Hospital, Zurich||2|||f||||t||||||||||2018-05-31 21:51:50.209662|2018-05-31 21:51:50.209662
NCT01487824|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-12-02|2011-12-05|2011-12-07|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|EVS||What is the Impact of Early Life Exposures on the Cardiovascular System in Young Adulthood?|What is the Impact of Early Life Exposures on the Cardiovascular System in Young Adulthood? A 25-Year Follow-up Study of Preterm-born Individuals|Unknown status|Recruiting||250|Anticipated|University of Oxford|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, immortalised cell lines~   "|||2018-05-31 21:51:50.328675|2018-05-31 21:51:50.328675
NCT01487811|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-01-05|2011-12-06|2011-12-07|Estimate|||||||2017-01-05|2017-01-06|Estimate|May 2005||2005-05-31|January 2017|2017-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers|Bioequivalence of Two Biphasic Insulin Aspart 30 (NovoLog® Mix 70/30) Formulations (Current and New Formulation With Glycerol): A Randomized, Double-Blind, Two-Period Crossover Study in Healthy Volunteers|Completed||Phase 1|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:51:50.413244|2018-05-31 21:51:50.413244
NCT01487798|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-01-05|2011-12-06|2011-12-07|Estimate|||||||2017-01-05|2017-01-06|Estimate|June 2002||2002-06-30|January 2017|2017-01-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|REACH||Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes|A Double-blind, Randomised, Crossover Study to Investigate the Difference in Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 Compared to Biphasic Human Insulin 30 in Patients With Well-controlled Type 2 Diabetes|Completed||Phase 4|170|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:51:50.510842|2018-05-31 21:51:50.510842
NCT01487785|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-01-24|2011-12-06|2011-12-07|Estimate|||||||2016-01-24|2016-01-26|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients|A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 1|18|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:51:50.708944|2018-05-31 21:51:50.708944
NCT01487772|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-09-18|2011-12-06|2011-12-07|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|Q-HIP||Improving Quality of Care for Hip-Fracture Patients: Studies on Fast-track Surgery|Improving Quality of Care for Hip-Fracture Patients: Studies on Fast-track Surgery|Completed|||1307|Actual|Danderyd Hospital|||1||f||||f||||||||||2018-05-31 21:51:51.011682|2018-05-31 21:51:51.011682
NCT01487759|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2011-12-09|2011-12-06|2011-12-07|Estimate|||||||2011-12-09|2011-12-12|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|July 2009||2009-07-31|||||Interventional|||Prebiotic Effect on Metabolites in Crohn's Disease|Metabolite Profiling of the Impact of Oligofructose Enriched Inulin in Crohn's Disease Patients|Completed||N/A|67|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 21:51:51.273659|2018-05-31 21:51:51.273659
NCT01487746|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-06|2011-12-06|2011-12-07|Estimate|||||||2011-12-06|2011-12-07|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|September 2012|Anticipated|2012-09-30|March 2012|Anticipated|2012-03-31||Observational|||Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls|Presence of Minor Anti Phospholipid Antibodies in Blood Samples of Ischemic Stroke Patients and Healthy Controls.|Unknown status|Not yet recruiting||207|Anticipated|Meir Medical Center|||2||f||||f||||||Samples Without DNA|"~     Serum samples of Stroke patients withdrawned within 36 hrs since stroke evoked. Healthy~     controls~   "|||2018-05-31 21:51:51.531322|2018-05-31 21:51:51.531322
NCT01487733|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2017-05-16|2011-12-06|2011-12-07|Estimate|||||||2017-05-16|2017-05-17|Actual|December 22, 2011|Actual|2011-12-22|May 2017|2017-05-31|January 22, 2012|Actual|2012-01-22|January 22, 2012|Actual|2012-01-22||Observational|||Biomarkers in Tissue Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on ECOG-E1395 and ECOG-E3301|Analysis of HPV and Other Biomarkers in Specimens From ECOG Studies in Recurrent or Metastatic Head and Neck Cancer (E1395 and E3301)|Completed|||155|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:51:51.891249|2018-05-31 21:51:51.891249
NCT01487720|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-11-30|2011-12-06|2011-12-07|Estimate|||||||2013-11-30|2013-12-03|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer|A Prosepctive Phase II Study of Gemcitabine and Oxaliplatin in Combination With Prednisolone for the Treatment of Hormone Refracotry Metastatic Prostate Cancer Previously Treated With Docetaxel Regimen|Completed||Phase 2|33|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:51:52.136854|2018-05-31 21:51:52.136854
NCT01487707|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2017-07-12|2011-12-06|2011-12-07|Estimate|||||||2017-07-12|2017-07-14|Actual|December 2011||2011-12-31|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Community Based Strategies to Reduce Maternal Mortality in Northern Nigeria|Strengthening the Midwife Service Scheme With Community Focused Interventions: Evidence From a Randomized Controlled Field Trial in Nigeria|Completed||N/A|7200|Actual|Abdul Latif Jameel Poverty Action Lab||3|||f||||f||||||||||2018-05-31 21:51:52.320519|2018-05-31 21:51:52.320519
NCT01487694|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-24|2011-12-05|2011-12-07|Estimate|||||||2011-12-24|2011-12-29|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Black Cohosh Extract for the Management of Moderate to Severe Menopausal Symptoms in Thai Women|Cimicifuga Racemosa Rhizome and Root Extract for the Management of Moderate to Severe Menopausal Symptoms in Thai Women: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|54|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 21:51:52.472589|2018-05-31 21:51:52.472589
NCT01487681|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2011-12-06|2011-12-06|2011-12-07|Estimate|||||||2011-12-06|2011-12-07|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Observational|||Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China|Prevaccination Distribution of Cervical Human Papillomavirus (HPV) Types and Their Associations With Invasive Cervical Cancer and Its Precursors in Yangtze River Delta Area, China|Unknown status|Recruiting||4000|Anticipated|Zhejiang University|||3||f||||f||||||Samples With DNA|"~     The biospecimens are remainder tissue and exfoliated cervical cells of standard diagnosis and~     surgery.~   "|||2018-05-31 21:51:52.565174|2018-05-31 21:51:52.565174
NCT01487668|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|2015-11-10||2015-12-15|2011-12-05|2011-12-07|Estimate|2015-12-15|2016-01-22|Estimate||||2015-12-15|2016-01-22|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders|Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders|Completed||N/A|304|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 21:51:52.65962|2018-05-31 21:51:52.65962
NCT01487655|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2013-02-05|2011-12-05|2011-12-07|Estimate|||||||2013-02-05|2013-02-06|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Glaucoma Patients|Waveform Analysis of the Doppler Curve of Ophthalmic Arteries in Primary Open-angle and Normal Tension Glaucoma Patients|Completed|||150|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 21:51:53.095853|2018-05-31 21:51:53.095853
NCT01487642|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-12-19|2011-12-05|2011-12-07|Estimate|||||||2011-12-19|2011-12-20|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|Fristart||Comparison of Four Different Smoking Cessation Programmes|Study of the Effect of Two Different Types of Telephone Counselling Respectively and a Web-based Smoking Cessation Programme Among Adult Daily Cigarette Smokers.|Unknown status|Active, not recruiting|N/A|1600|Anticipated|University of Southern Denmark||4|||f||||t||||||||||2018-05-31 21:51:53.316812|2018-05-31 21:51:53.316812
NCT01487629|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2011-12-09|2011-12-05|2011-12-07|Estimate|||||||2011-12-09|2011-12-13|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|IBERA-DME||Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema|Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema|Unknown status|Active, not recruiting|Phase 2|53|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:51:53.437013|2018-05-31 21:51:53.437013
NCT01487616|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-02-17|2011-12-05|2011-12-07|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|PUMA||Prevalence of Congenital Uterine Malformations|Prevalence of Congenital Uterine Malformations in Women With a History of Preterm Delivery or Miscarriage|Unknown status|Recruiting||246|Anticipated|University of Nottingham|||3||f||||f||||||||No||2018-05-31 21:51:53.689167|2018-05-31 21:51:53.689167
NCT01487603|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2018-02-22|2011-12-06|2011-12-07|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2011||2011-10-31|February 2018|2018-02-28||||October 2020|Anticipated|2020-10-31||Observational|||Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer|Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer|Recruiting|||400|Anticipated|University Health Network, Toronto|||1||f||||f|||||||"~     Tissue.~   "|||2018-05-31 21:51:53.859246|2018-05-31 21:51:53.859246
NCT01487590|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-01-16|2011-12-05|2011-12-07|Estimate|||||||2012-01-16|2012-01-18|Estimate|October 2006||2006-10-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ACUVERSE||Cephalic Version by Acupuncture-Moxibustion for Breech Presentation|A Simple Blind Controlled Randomized Trial: Cephalic Version by Acupuncture-moxibustion vs Placebo for Breech Presentation|Completed||N/A|328|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 21:51:53.951072|2018-05-31 21:51:53.951072
NCT01487577|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2016-02-24||2016-05-13|2011-12-05|2011-12-07|Estimate|2016-05-13|2016-06-21|Estimate||||2016-05-13|2016-06-21|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional||Pediatric hematopoietic stem cell recipients undergoing myeloablative conditioning therapy|Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention|A Pilot Study of Pharmacokinetics-based Mycophenolate Mofetil Dosing for Graft-Versus-Host-Disease Prophylaxis in Pediatric Blood and Marrow Transplantation|Completed||Phase 2|19|Actual|University of Pittsburgh|Our study is limited by small sample size and heterogeneity in stem cell sources. Besides targeted MMF dosing, other factors that might have affected clinical outcomes include duration of MMF and use of ATG in unrelated-donor transplants.|1|||f||||t||||||||||2018-05-31 21:51:54.17741|2018-05-31 21:51:54.17741
NCT01487564|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2013-03-01|2011-12-05|2011-12-07|Estimate|||||||2013-03-01|2013-03-04|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene|A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetic Profile of OROS Hydromorphone in Healthy Adult Taiwanese Subjects Having Different Genotypes for the UGT2B7 Gene|Completed||Phase 1|29|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:51:54.701445|2018-05-31 21:51:54.701445
NCT01487551|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2014-08-26|2011-12-06|2011-12-07|Estimate|||||||2014-08-26|2014-08-27|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)|An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)|Completed||Phase 2|9|Actual|Active Biotech AB||1|||f||||f||||||||||2018-05-31 21:51:54.814398|2018-05-31 21:51:54.814398
NCT01487538|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-02-05|2011-12-05|2011-12-07|Estimate|||||||2014-02-05|2014-02-07|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Weight Maintenance Through Physical Activity and Social Support in Rural Middle-Aged Women|Weight Maintenance Through Physical Activity and Social Support in Rural Middle-Aged Women|Completed||N/A|52|Actual|University of Nebraska||2|||f||||t||||||||||2018-05-31 21:51:54.979281|2018-05-31 21:51:54.979281
NCT01487525|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2015-06-11||2016-01-05|2011-12-05|2011-12-07|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|PBFR3|Control BFR p-value Age (years) 56.1±7.7 58.4±8.7 0.377|Assessment of Efficacy of Low Intensity Resistance Training in Men at Risk for Symptomatic Knee Osteoarthritis|Assessment of Efficacy of Low Intensity Resistance Training in Men at Risk for Symptomatic Knee Osteoarthritis|Completed||N/A|44|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 21:51:55.114314|2018-05-31 21:51:55.114314
NCT01487512|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-11-15|2011-12-06|2011-12-07|Estimate|||||||2012-11-15|2012-11-16|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Dose on the Pharmacokinetics of OROS Hydromorphone Under Fasted Conditions in Healthy Taiwanese Participants|A Single-Dose, Open-Label, Randomized, Crossover Dose Proportionality Study to Evaluate the Effect of Dose on the Pharmacokinetics of 8, 16, 32 and 64 mg OROS Hydromorphone Under Fasted Conditions in Healthy Adult Taiwanese Subjects|Completed||Phase 1|29|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-05-31 21:51:55.542002|2018-05-31 21:51:55.542002
NCT01487499|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2015-03-16||2015-05-15|2011-12-05|2011-12-07|Estimate|2015-03-16|2015-03-25|Estimate||||2015-05-15|2015-06-11|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SCLC||Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)|Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer|Terminated||Phase 3|4|Actual|University of Florida||2||Unable to enroll adequate number of participants|f||||t||||||||||2018-05-31 21:51:55.69293|2018-05-31 21:51:55.69293
NCT01487486|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-12-05|2011-12-05|2011-12-07|Estimate|||||||2011-12-05|2011-12-07|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Observational|||Proteomics & Glyco-Proteomic Analysis of Follicular Fluid|Proteomics & Glyco-Proteomic Analysis of Follicular Fluid Derived From Health Patient/Donors and Polycystic Ovary Syndrome Patients|Unknown status|Not yet recruiting||30|Anticipated|University of Cincinnati|||3||f||||f||||||Samples Without DNA|"~     Follicular Fluid~   "|||2018-05-31 21:51:55.947338|2018-05-31 21:51:55.947338
NCT01487473|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-02-12|2011-12-05|2011-12-07|Estimate|||||||2014-02-12|2014-02-13|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effects of Mindfulness-Based Stress Reduction on Attention and Pain-related Symptoms in Chronic Pain Patients|The Effects of Mindfulness-Based Stress Reduction on Attention and Pain-related Symptoms in Chronic Pain Patients: A Randomized Controlled Trial|Completed||N/A|49|Actual|York University||2|||f||||f||||||||||2018-05-31 21:51:56.123698|2018-05-31 21:51:56.123698
NCT01487460|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2016-04-15|2011-12-05|2011-12-07|Estimate|||||||2016-04-15|2016-04-19|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients|A First-in-human Randomized, Double-blind, Placebo-controlled, 4-part Study to Assess Safety, Tolerability, Pharmacokinetics (Including Open Label Study of Food Effect and Interaction With Simvastatin) and Pharmacodynamics of Interwoven Single- and Multiple-ascending Doses of TAP311 in Healthy Subjects and Dyslipidemic Patients.|Completed||Phase 1|137|Actual|Novartis||4|||f||||||||||||||2018-05-31 21:51:56.300632|2018-05-31 21:51:56.300632
NCT01487447|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-07-03|2011-12-05|2011-12-07|Estimate|||||||2013-07-03|2013-07-04|Estimate|January 2010||2010-01-31|July 2013|2013-07-31||||July 2014|Anticipated|2014-07-31||Interventional|||Customized Acoustic Stimulation for the Treatment of Tinnitus||Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Anticipated|University of California, Irvine||2|||f||||||||||||||2018-05-31 21:51:56.38805|2018-05-31 21:51:56.38805
NCT01487434|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2016-03-23|2011-12-05|2011-12-07|Estimate|||||||2016-03-23|2016-03-24|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||A Randomized Study to Abate Truancy and Violence in Grades 3-9 in Chicago Public Schools|Preventing Truancy in Urban Schools Through Provision of Social Services by Truancy Officers|Unknown status|Active, not recruiting|N/A|600|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 21:51:56.506976|2018-05-31 21:51:56.506976
NCT01487421|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2014-06-23|2011-12-05|2011-12-07|Estimate|||||||2014-06-23|2014-06-24|Estimate|July 2003||2003-07-31|June 2014|2014-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime|The Physiological Therapy of Type 2 Diabetes - NovoRapid® FlexPen® Before Meals, Additionally Levemir® FlexPen® in the Evening or at Bedtime if Needed|Completed|||2134|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:51:56.593829|2018-05-31 21:51:56.593829
NCT01487408|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-03-03|2011-12-05|2011-12-07|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2002||2002-04-30|March 2016|2016-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Special Survey for Type 1 or Type 2 Diabetic Patients|Special Survey for Type 1 or Type 2 Diabetic Patients|Completed|||1463|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:51:56.699552|2018-05-31 21:51:56.699552
NCT01487395|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-04-08|2011-12-06|2011-12-07|Estimate|||||||2015-04-08|2015-04-09|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|PharmacogWP3||Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development|Effect of a 15-day Donepezil Treatment on Biomarkers of AD in Healthy Volunteers|Completed||Phase 1|30|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 21:51:56.774612|2018-05-31 21:51:56.774612
NCT01487382|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-03-03|2011-12-05|2011-12-07|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2002||2002-04-30|March 2016|2016-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Special Survey for Paediatric Subjects|Special Survey for Paediatric Subjects|Completed|||241|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:51:56.885876|2018-05-31 21:51:56.885876
NCT01487356|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-12-05|2011-12-05|2011-12-07|Estimate|||||||2011-12-05|2011-12-07|Estimate|May 2008||2008-05-31|December 2011|2011-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Factors Associated With Short Withdrawal Time and Polyp Detection Rate During Colonoscopy|Factors Associated With Short Withdrawal Time and Polyp Detection Rate During Colonoscopy|Completed|||802|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 21:51:57.047572|2018-05-31 21:51:57.047572
NCT01487343|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2016-11-07|2011-12-05|2011-12-07|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Patient Factors Impacting Adherence to Oral Chemotherapy|A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy|Completed|||79|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:51:57.122267|2018-05-31 21:51:57.122267
NCT01487330|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2014-08-05|2011-12-05|2011-12-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|SJM TAVI FIH||First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System|First In Human Experience and Assessment of the 23mm SJM Transcatheter Aortic Valve Implant and the SJM TAVI Transfemoral Delivery System (SJM TAVI FIH)|Completed||N/A|10|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 21:51:57.310459|2018-05-31 21:51:57.310459
NCT01487317|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-07-19|2011-12-06|2011-12-07|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|confuriv||Rivastigmine in the Management of Delirium|A Randomized, Double-blind, Placebo-controlled Study of an Acetylcholinesterase Inhibitor in the Management of Delirium in Hospitalized Patients Aged 75 Years and Over|Completed||Phase 3|23|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:51:57.506806|2018-05-31 21:51:57.506806
NCT01487304|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-10-14|2011-12-06|2011-12-07|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2005||2005-04-30|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy|"Impact of Professional Societies Recommendations on Practical Use of Hormone Replacement Therapy - Project WOMAN 2005"|Completed|||3760|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:51:57.839809|2018-05-31 21:51:57.839809
NCT01487291|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-12-15|2011-12-06|2011-12-07|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Prevalence of Clinical and Laboratory Markers of Hypofibrinolysis in Psychotic Patients|Prevalence of Clinical and Laboratory Markers of Hypofibrinolysis in Psychotic Patients|Completed|||176|Actual|Universidade Federal do Rio de Janeiro|||1||f||||t||||||||||2018-05-31 21:51:57.936095|2018-05-31 21:51:57.936095
NCT01487278|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-01-08|2011-12-06|2011-12-07|Estimate|||||||2014-01-08|2014-01-09|Estimate||||January 2014|2014-01-31||||||||Interventional|||Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali|Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin in UnijectTM in Mali|Withdrawn||N/A|0|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 21:51:58.054072|2018-05-31 21:51:58.054072
NCT01487265|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2017-08-17||2017-11-14|2011-12-05|2011-12-07|Estimate|2017-11-14|2017-12-13|Actual||||2017-11-14|2017-12-13|Actual|March 2014||2014-03-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|May 31, 2016|Actual|2016-05-31||Interventional||Patients that have received at least one dose of study treatment|Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib|Phase II Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib|Active, not recruiting||Phase 2|37|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 21:51:58.298583|2018-05-31 21:51:58.298583
NCT01487252|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-04-10|2011-12-06|2011-12-07|Estimate|||||||2017-04-10|2017-04-12|Actual|December 2011||2011-12-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Circadian Phase Assessments at Home||Completed||N/A|73|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 21:51:58.884966|2018-05-31 21:51:58.884966
NCT01487239|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-11-01|2011-12-05|2011-12-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects|Completed||Phase 1|4|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 21:51:59.026137|2018-05-31 21:51:59.026137
NCT01487226|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2011-12-06|2011-12-06|2011-12-07|Estimate|||||||2011-12-06|2011-12-07|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer|A Phase II Trial of Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in FIGO Stage IA2-IIA Cervical Cancer|Unknown status|Recruiting|Phase 2|69|Anticipated|Korean Gynecologic Oncology Group|||||f||||f||||||||||2018-05-31 21:51:59.163517|2018-05-31 21:51:59.163517
NCT01487213|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-08-06|2011-12-06|2011-12-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Routine Follow-up Versus Self-assessment in Medical Abortion|Routine Follow-up Versus Self-assessment of Complete Abortion Following Medical Abortion, Effect on Its Success and Acceptability: a Randomized Controlled Trial|Completed||N/A|929|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 21:51:59.32951|2018-05-31 21:51:59.32951
NCT01487200|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-11-16|2011-12-06|2011-12-07|Estimate|||||||2012-11-16|2012-11-19|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Active Comparator Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects (HPA Axis) of FX006 in Patients With Osteoarthritis of the Knee|Completed||Phase 2|24|Actual|Flexion Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 21:51:59.574289|2018-05-31 21:51:59.574289
NCT01487187|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-03-07|2011-12-05|2011-12-07|Estimate|||||||2017-03-07|2017-03-09|Actual|November 2011||2011-11-30|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Cord Milking on Hemodynamic Status of Preterm Infants|The Effect of Umbilical Cord Milking on Hemodynamic Status of Preterm Infants: a Randomized Controlled Trial|Active, not recruiting||N/A|73|Actual|IWK Health Centre||2|||f||||t||||||||Yes||2018-05-31 21:51:59.719872|2018-05-31 21:51:59.719872
NCT01487174|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02||2014-07-21|2014-07-21|2011-12-05|2011-12-07|Estimate||||2014-07-21|2014-07-24|Estimate|2014-07-21|2014-07-24|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy|A Multi-Center, Phase 3, Double-Blind, Randomized, and Controlled Trial of KD019 vs Erlotinib in Subjects With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Progressed After First- or Second-Line Chemotherapy|Terminated||Phase 3|8|Actual|Kadmon Corporation, LLC||2||"Kadmon has made a business decision to terminate the study due to slow enrollment. Note the~   decision to terminate the study was not related to safety issues"|f||||||||||||||2018-05-31 21:51:59.860508|2018-05-31 21:51:59.860508
NCT01487161|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2017-11-02|2015-03-16|2018-01-16|2011-12-05|2011-12-07|Estimate|2017-12-13|2018-01-12|Actual|2015-03-16|2015-04-03|Estimate|2018-01-16|2018-01-18|Actual|June 2012||2012-06-30|January 2018|2018-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||A total of 229 patients were randomized to treatment in this study. 228 of 229 randomized patients received treatment and were included in the Safety Population; 1 patient randomized to the TCA IR group withdrew consent before receiving study treatment and was excluded.|Study of FX006 in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee|Completed||Phase 2|229|Actual|Flexion Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 21:51:59.96774|2018-05-31 21:51:59.96774
NCT01487148|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2011-12-06|2011-12-06|2011-12-07|Estimate|||||||2011-12-06|2011-12-07|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||POCARED Diagnostics, LTD, Field Study Protocol|POCARED Diagnostics, LTD, Field Study Protocol|Unknown status|Not yet recruiting||40000|Anticipated|Pocared Diagnostics|||||f||||f||||||None Retained|"~     Samples are de-identified leftover samples.~   "|||2018-05-31 21:52:00.821666|2018-05-31 21:52:00.821666
NCT01487135|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-10-09|2011-12-06|2011-12-07|Estimate|||||||2014-10-09|2014-10-10|Estimate|December 2011||2011-12-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|TQT||Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects|A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.|Completed||Phase 1|60|Actual|FORUM Pharmaceuticals Inc||3|||f||||f||||||||||2018-05-31 21:52:00.921842|2018-05-31 21:52:00.921842
NCT01487122|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2011-12-06|2011-12-06|2011-12-07|Estimate|||||||2011-12-06|2011-12-07|Estimate|September 2008||2008-09-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|MOFIS||Microwave Diathermy for Treating Nonspecific Chronic Neck Pain|Microwave Diathermy for Treating Nonspecific Chronic Neck Pain. A Randomised Controlled Trial|Completed||N/A|145|Actual|Health Service of Andalucia||3|||f||||f||||||||||2018-05-31 21:52:01.100389|2018-05-31 21:52:01.100389
NCT01487109|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-03-12|2011-12-06|2011-12-07|Estimate|||||||2015-03-12|2015-03-17|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients|A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy|Completed||Phase 2|170|Actual|Concert Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:52:01.809025|2018-05-31 21:52:01.809025
NCT01487096|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-10-03|2011-12-05|2011-12-07|Estimate|||||||2012-10-03|2012-10-04|Estimate|April 2001||2001-04-30|October 2012|2012-10-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses|A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses|Completed||Phase 2|179|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 21:52:02.774437|2018-05-31 21:52:02.774437
NCT01487083|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30||2013-01-11|2013-01-11|2011-12-06|2011-12-07|Estimate||||2013-01-11|2013-01-21|Estimate|2013-01-11|2013-01-21|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Long-Term Study in Schizophrenia|Long-Term Open-Label Safety Study of Pomaglumetad Methionil in Patients With Schizophrenia|Terminated||Phase 3|282|Anticipated|Eli Lilly and Company||1||"The decision to stop the trial was based on efficacy results in the overall schizophrenia~   participant population."|f||||f||||||||||2018-05-31 21:52:03.322687|2018-05-31 21:52:03.322687
NCT01487070|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-05|2011-12-05|2011-12-07|Estimate|||||||2011-12-05|2011-12-07|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy|A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy|Completed||Phase 1|5|Actual|Retina Institute of Hawaii||1|||f||||||||||||||2018-05-31 21:52:03.636324|2018-05-31 21:52:03.636324
NCT01487057|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2012-12-26|2011-12-06|2011-12-07|Estimate|||||||2012-12-26|2012-12-27|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Observational|LITCA||Lipid Metabolic Status in Thyroid Carcinoma|"Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution"|Completed|||52|Actual|Prof. Dr. I. Chiricuta Institute of Oncology|||2||f||||f||||||||||2018-05-31 21:52:04.121539|2018-05-31 21:52:04.121539
NCT01487044|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2011-12-05|2011-12-05|2011-12-07|Estimate|||||||2011-12-05|2011-12-07|Estimate||||December 2011|2011-12-31||||||||Expanded Access|GUARDIAN||A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema|A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema|Available|||||Retina Institute of Hawaii|||||||||||||||||||2018-05-31 21:52:04.519727|2018-05-31 21:52:04.519727
NCT01487031|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2013-07-31|2011-12-06|2011-12-07|Estimate|||||||2013-07-31|2013-08-02|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Music Therapy on Nausea and Pain for Autologous Stem Cell|Assessment of the Use of Music Therapy on Nausea and Pain During Hospitalization for Autologous Stem Cell Transplantation|Completed||N/A|108|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:52:04.809211|2018-05-31 21:52:04.809211
NCT01486693|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|September 2012|Anticipated|2012-09-30|December 2011|Anticipated|2011-12-31||Observational|||Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis|Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 21:52:12.024418|2018-05-31 21:52:12.024418
NCT01487018|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-10-20|2011-12-05|2011-12-07|Estimate|||||||2015-10-20|2015-10-21|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of Navigation Assisted Reconstruction of Posttraumatic Zygomatic Deformity|Evaluation of the Application of Point-to-Point Computer-Assisted Navigation for Mirroring-Reconstructing of Unilateral Posttraumatic Zygomatic Deformity: A Randomized Controlled Trial|Completed||Phase 3|103|Actual|Peking University||2|||f||||t||||||||||2018-05-31 21:52:05.194153|2018-05-31 21:52:05.194153
NCT01487005|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-06-08|2011-12-05|2011-12-07|Estimate|||||||2012-06-08|2012-06-11|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|MOSES||Cardiovascular Effects of Exposure to Ozone|Multicenter Ozone Study in Elderly Subjects|Unknown status|Recruiting||90|Anticipated|Health Effects Institute|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:52:05.386433|2018-05-31 21:52:05.386433
NCT01486992|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-01-11|2011-12-05|2011-12-07|Estimate|||||||2012-01-11|2012-01-12|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus||Unknown status|Recruiting|Phase 2|40|Anticipated|Peking University||1|||f||||f||||||||||2018-05-31 21:52:05.597504|2018-05-31 21:52:05.597504
NCT01486979|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-02-06|2011-12-06|2011-12-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2007||2007-01-31|February 2017|2017-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis|A Pharmacokinetic Randomized Study With a Parallel Group Design to Assess the Extent of Systemic Absorption of Estradiol During Treatment With a 10 µg or 25 µg Estradiol Vaginal Tablet Administered Once Daily for 2 Weeks Followed by 10 Weeks of Twice-Weekly Maintenance Therapy in Postmenopausal Women With Atrophic Vaginitis|Completed||Phase 1|58|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:52:05.760917|2018-05-31 21:52:05.760917
NCT01486966|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|2013-04-22||2017-02-09|2011-12-06|2011-12-07|Estimate|2013-04-22|2013-06-17|Estimate||||2017-02-09|2017-03-17|Actual|November 2011||2011-11-30|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes|A 2-week, Randomised, Controlled, Open-label, Two-group Parallel, Multi-centre Trial Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin Both in a Basal Bolus Regimen With or Without Metformin in Chinese Inpatients With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment|Terminated||Phase 4|58|Actual|Novo Nordisk A/S|The size of population analysed in study was smaller than that planned in the protocol. Therefore, the superiority of experimental products to comparator could not be concluded with sufficient statistical power.|2||Trial terminated prematurely due to slow recruitment.|f||||f||||||||||2018-05-31 21:52:05.913848|2018-05-31 21:52:05.913848
NCT01486953|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2013-07-22|2011-12-05|2011-12-07|Estimate|||||||2013-07-22|2013-07-23|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum|Phase 4 Study of Desflurane and Sevoflurane That Affect Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum|Unknown status|Recruiting|Phase 4|70|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 21:52:07.325859|2018-05-31 21:52:07.325859
NCT01486940|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-01-26|2011-12-05|2011-12-07|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2002||2002-03-31|January 2017|2017-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes|A Multi-centre, Multinational, Open-labelled, Randomised, Parallel-Group Comparison of Insulin Detemir Plus Insulin Aspart With NPH Insulin Plus Human Soluble Insulin in Subjects With Type 1 Diabetes on a Basal-Bolus Regimen|Completed||Phase 3|598|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:52:07.517194|2018-05-31 21:52:07.517194
NCT01486927|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|2016-06-24|2015-12-11|2016-06-24|2011-12-05|2011-12-07|Estimate|2016-06-24|2016-08-09|Estimate|2015-12-11|2016-01-13|Estimate|2016-06-24|2016-08-09|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A|A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study|Completed||Phase 2/Phase 3|175|Actual|CSL Behring||1|||f||||||||||||||2018-05-31 21:52:07.856597|2018-05-31 21:52:07.856597
NCT01486914|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-02-28|2011-12-05|2011-12-07|Estimate|||||||2017-02-28|2017-03-01|Actual|January 19, 2003|Actual|2003-01-19|February 2017|2017-02-28|February 24, 2003|Actual|2003-02-24|February 24, 2003|Actual|2003-02-24||Interventional|||Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process|A Single Centre, Randomized, Balanced Double Blind, Cross-Over Trial Investigating the Bioequivalence of NovoRapid® Produced by the Current Process and Insulin Aspart With the Same Formulation as NovoRapid®, Produced by the NN2000 Process|Completed||Phase 1|28|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:52:09.718063|2018-05-31 21:52:09.718063
NCT01486901|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-04-27|2011-12-05|2011-12-07|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence of Two Insulatard® Formulations in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Insulatard® (600 Nmol/ml) and Insulatard® (1998 Nmol/ml) in Healthy Subjects|Completed||Phase 1|44|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:52:09.89501|2018-05-31 21:52:09.89501
NCT01486888|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-03-17|2011-12-05|2011-12-07|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2006||2006-05-31|March 2015|2015-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Cross-over, Glucose Clamp Trial to Test for Bioequivalence Between Insulin Mixtard® 30 (600 Nmol/ml) and Insulin Mixtard® 30 (1998 Nmol/ml) in Healthy Subjects|Completed||Phase 1|45|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:52:09.997718|2018-05-31 21:52:09.997718
NCT01486875|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-01-05|2011-12-05|2011-12-07|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2006||2006-01-31|January 2017|2017-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|Start||Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes|NovoMix® Start - A Multicentre, Open Label, Non-randomised, Non-interventional, Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix 30® Treatment|Completed|||1155|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:52:10.127629|2018-05-31 21:52:10.127629
NCT01486862|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2014-11-13|2011-12-05|2011-12-07|Estimate|||||||2014-11-13|2014-11-14|Estimate|October 2005||2005-10-31|November 2014|2014-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs|NovoMix® 30 (Biphasic Insulin Aspart 70/30) Titrate-to-target: An Observational Study of the Efficacy of NovoMix® 30 in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs|Completed||Phase 4|26|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:52:10.229299|2018-05-31 21:52:10.229299
NCT01486849|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-09-16|2011-12-05|2011-12-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|28|Actual|Cytokinetics||2|||f||||f||||||||||2018-05-31 21:52:10.364202|2018-05-31 21:52:10.364202
NCT01486836|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2013-09-11|2011-12-05|2011-12-07|Estimate|||||||2013-09-11|2013-09-12|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Lumax DX / Linox DX Evaluation|Evaluation of the Lumax DX ICD and the Linox DX Lead (ICD=Implantable Cardioverter Defibrillator, DX=Extended Diagnostics)|Completed|||38|Anticipated|Biotronik SE & Co. KG|||1||f||||f||||||||||2018-05-31 21:52:10.470371|2018-05-31 21:52:10.470371
NCT01486823|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-12-10|2011-12-06|2011-12-07|Estimate|||||||2012-12-10|2012-12-11|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects|An Open-label, Single-dose Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects|Completed||Phase 1|22|Actual|BioInvent International AB||2|||f||||t||||||||||2018-05-31 21:52:10.631576|2018-05-31 21:52:10.631576
NCT01486810|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2016-10-25|2011-12-05|2011-12-07|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Vyvance||Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence|Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence|Completed||Phase 1/Phase 2|17|Actual|New York State Psychiatric Institute||1|||f||||t||||||||No||2018-05-31 21:52:10.750588|2018-05-31 21:52:10.750588
NCT01486797|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-05-19|2011-12-05|2011-12-07|Estimate|||||||2017-05-19|2017-05-22|Actual|March 2012||2012-03-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|November 2014|Actual|2014-11-30||Interventional|||NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)|A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bendamustine and Rituximab (BR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|28|Actual|NOXXON Pharma AG||1|||f||||t||||||||||2018-05-31 21:52:10.846505|2018-05-31 21:52:10.846505
NCT01486784|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2017-07-28|2011-12-06|2011-12-07|Estimate|||||||2017-07-28|2017-07-31|Actual|November 2011||2011-11-30|July 2017|2017-07-31||||November 2014|Actual|2014-11-30||Interventional|||A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia|A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 1/Phase 2|37|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:52:10.966109|2018-05-31 21:52:10.966109
NCT01486771|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|||Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)|A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase|Unknown status|Active, not recruiting|Phase 4|30|Actual|Valley Retina Institute||3|||f||||f||||||||||2018-05-31 21:52:11.078607|2018-05-31 21:52:11.078607
NCT01486758|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2016-04-12||2017-05-15|2011-12-04|2011-12-06|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|December 2011||2011-12-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|APW-RSV||Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis|Pilot Study: Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis|Completed||Phase 2|40|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:52:11.237258|2018-05-31 21:52:11.237258
NCT01486745|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-03|||2016-05-12|2011-12-03|2011-12-06|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2008||2008-04-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Urine Metabolomics and Colorectal Cancer Screening|Is There a Role for Using NMR Urine Metabolomics as a New Method of Screening for Colorectal Cancer?|Recruiting|||1800|Anticipated|University of Alberta|||4||f||||f||||||Samples Without DNA|"~     Urine sample~   "|||2018-05-31 21:52:11.682543|2018-05-31 21:52:11.682543
NCT01486732|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2013-11-17|2011-12-05|2011-12-06|Estimate|||||||2013-11-17|2013-11-19|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|July 2014|Anticipated|2014-07-31|April 2014|Anticipated|2014-04-30||Interventional|||FLT-PET Activity Change After Allogeneic Umbilical Cord Blood (UCB) Therapy in Cerebral Palsy|FLT(3'-Deoxy-3'-[F-18]Fluorothymidine)-PET Activity Change After Allogeneic Umbilical Cord Blood Cell Therapy in Cerebral Palsy|Withdrawn||Phase 2|0|Actual|Bundang CHA Hospital||2||Difficulty in obtaining specific isotope tracer|f||||f||||||||||2018-05-31 21:52:11.770474|2018-05-31 21:52:11.770474
NCT01486719|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|February 2008||2008-02-29|December 2011|2011-12-31|March 2011|Actual|2011-03-31|May 2009|Actual|2009-05-31||Interventional|||Sensory Reconstruction of Finger Pulp Defect Using a Dorsal Digital Island Flap|Sensory Reconstruction of Finger Pulp Defect Using a Dorsal Digital Island Flap|Completed||N/A|12|Actual|The Second Hospital of Tangshan|||||f||||t||||||||||2018-05-31 21:52:11.874901|2018-05-31 21:52:11.874901
NCT01486706|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2016-12-29|2011-12-05|2011-12-06|Estimate|||||||2016-12-29|2017-01-02|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|OAB||Efficacy and Safety of Gabapentin in Treating Overactive Bladder|Efficacy and Safety of Gabapentin in Treating Overactive Bladder|Completed||Phase 2/Phase 3|94|Actual|St. Luke's Medical Center, Philippines||3|||f||||t||||||||||2018-05-31 21:52:11.944694|2018-05-31 21:52:11.944694
NCT01486680|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2015-04-27|2011-12-04|2011-12-06|Estimate|||||||2015-04-27|2015-04-28|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|October 2019|Anticipated|2019-10-31|October 2014|Actual|2014-10-31||Interventional|||Silastic Ring Gastric Bypass Versus Sleeve Gastrectomy for Type 2 Diabetes Mellitus in Obese Patients|Prospective Randomised Controlled Trial Comparing the Efficacy of Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy for the Management of Type 2 Diabetes Mellitus in Obese Patients|Active, not recruiting||N/A|106|Anticipated|North Shore Hospital, New Zealand||2|||f||||f||||||||||2018-05-31 21:52:12.098568|2018-05-31 21:52:12.098568
NCT01486667|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-03|||2011-12-06|2011-12-05|2011-12-06|Estimate|||||||2011-12-06|2011-12-08|Estimate|October 2011||2011-10-31|December 2011|2011-12-31||||October 2013|Anticipated|2013-10-31||Interventional|||Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP|Effect of Thyroxin Treatment in Sub Clinical Hypothyroidism Patients, on the Apnea Hypopnea Index Score, Lipid Profiles and Highly Sensitive CRP : A Randomized Double Blind Controlled Trial|Unknown status|Recruiting|Phase 3|200|Anticipated|King Saud University||2|||f||||t||||||||||2018-05-31 21:52:12.293279|2018-05-31 21:52:12.293279
NCT01486654|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-05-12|2011-12-05|2011-12-06|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2010||2010-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Transcranial Direct Current Stimulation and Aphasia Language Therapy|Transcranial Direct Current Stimulation and Aphasia Language Therapy|Completed||Phase 1|12|Anticipated|Shirley Ryan AbilityLab||3|||f||||f||||||||||2018-05-31 21:52:12.406761|2018-05-31 21:52:12.406761
NCT01486641|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-07-31|2011-12-05|2011-12-06|Estimate|||||||2017-07-31|2017-08-02|Actual|February 2012||2012-02-29|April 2014|2014-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|APAF||Anterolateral Versus Posterolateral Approach to the Fractured Hip Arthroplasty|Anterolateral Versus Posterolateral Approach to the Fractured Hip Arthroplasty - a Change in Approach at Sundsvall Hospital.|Completed||N/A|160|Anticipated|Sundsvall Hospital||2|||f||||t||||||||Yes|Publication in an international peer-review journal.|2018-05-31 21:52:12.503133|2018-05-31 21:52:12.503133
NCT01486628|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2016-03-31|2011-12-05|2011-12-06|Estimate|||||||2016-03-31|2016-04-01|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers|A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers|Completed||Phase 1|36|Actual|NeuroDerm Ltd.||2|||f||||t||||||||||2018-05-31 21:52:12.602759|2018-05-31 21:52:12.602759
NCT01486615|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2012-05-20||2012-09-06|2011-12-04|2011-12-06|Estimate|2012-09-06|2012-10-05|Estimate||||2012-09-06|2012-10-05|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone|Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone: a Randomized, Double Blind Placebo Controlled Study|Completed||Phase 4|80|Actual|B.P. Koirala Institute of Health Sciences|The study was not designed to measure drug plasma concentrations. We did not perform a battery of tests to evaluate psychomotor and amnesic performances. We only did an orientation score and assessed delayed visual episodic memory.|4|||f||||f||||||||||2018-05-31 21:52:12.765958|2018-05-31 21:52:12.765958
NCT01486602|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2018-01-17|2011-12-02|2011-12-06|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|January 2017|Actual|2017-01-31||Interventional|||Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer|Completed||Phase 1|22|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 21:52:14.006801|2018-05-31 21:52:14.006801
NCT01486589|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2014-02-05|2011-12-05|2011-12-06|Estimate|||||||2014-02-05|2014-02-06|Estimate|October 2010||2010-10-31|February 2014|2014-02-28||||June 2013|Actual|2013-06-30||Observational|PREDICT-ER||Cardiac Autonomic Function For Risk Stratification in the Emergency Room|Risk Stratification in the Emergency Room by Cardiac Autonomic Function|Completed|||6521|Actual|Thebiosignals.com|||||f||||f||||||||||2018-05-31 21:52:14.131935|2018-05-31 21:52:14.131935
NCT01486576|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2013-05-28|2011-12-04|2011-12-06|Estimate|||||||2013-05-28|2013-05-29|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|VOHO||Hydroxyethyl Starch and Renal Function After Hip Replacement Surgery|Effect of Hydroxyethyl Starch on Renal Handling of Sodium and Water, Vasoactive Hormones,Biomarkers and the Circulatory System in Patients Undergoing Hip Replacement Surgery|Completed||Phase 4|42|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 21:52:14.210733|2018-05-31 21:52:14.210733
NCT01486563|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2013-09-16|2011-12-04|2011-12-06|Estimate|||||||2013-09-16|2013-09-17|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|VORA||Hydroxyethyl Starch and Renal Function After Radical Prostatectomy|Effect of Hydroxyethyl Starch on Renal Handling of Sodium and Water, Vasoactive Hormones,Biomarkers and the Circulatory System in Patients Undergoing Radical Prostatectomy|Completed||Phase 4|40|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 21:52:14.292983|2018-05-31 21:52:14.292983
NCT01486550|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2014-10-08|2011-12-05|2011-12-06|Estimate|||||||2014-10-08|2014-10-09|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|VONE||Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy|Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery|Terminated||Phase 4|14|Actual|Regional Hospital Holstebro||2||Lack of patient enrollment|f||||t||||||||||2018-05-31 21:52:14.386236|2018-05-31 21:52:14.386236
NCT01486537|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-03|||2018-02-20|2011-12-05|2011-12-06|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 2011||2011-12-31|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Observational|||Acidity Level of Blood From Primary Molar's Pulp While Undergoing Pulpotomy or Pulpectomy Procedure|Characterization of Blood Drawn From the Pulp of Primary Molar Undergoing Pulpotomy or Pulpectomy.|Recruiting|||50|Anticipated|Hadassah Medical Organization|||2||f||||t||||||None Retained|"~     blood specimens which are undergoing Astrop test (acidity level .po2 pco2)~   "|||2018-05-31 21:52:14.51723|2018-05-31 21:52:14.51723
NCT01486212|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-12-11|2011-12-02|2011-12-06|Estimate|||||||2012-12-11|2012-12-12|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|IROX-NH||Ischemia-reperfusion Injury Model on Healthy Volunteers and Measurement of Oxidative and Inflammatory Markers|Ischemia-reperfusion Injury Model on Healthy Volunteers and Measurement of Oxidative and Inflammatory Markers|Completed|||10|Actual|Herlev Hospital|||1||f||||f||||||||||2018-05-31 21:52:19.019665|2018-05-31 21:52:19.019665
NCT01486524|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis|A Multicenter Pharmacogenomic Biomarker Study in Matched Patients With Severe Sepsis Treated With or Without Recombinant Human Activated Protein C [Xigris®, Drotrecogin Alfa (Activated)]|Unknown status|Active, not recruiting||3000|Anticipated|Sirius Genomics Inc.|||2||f||||f||||||Samples With DNA|"~     Minimum 700 ng DNA required, extracted from blood samples. Two Improved Response~     Polymorphisms (IRPs) will be tested in this study. IRP A is comprised of two single~     nucleotide polymorphisms (SNPs), RYR2 (ryanodine receptor 2 gene) rs684923 and ACIN1~     (apoptotic chromatin condensation inducer 1 gene)rs3751501. IRP B is comprised of two SNPs,~     SPATA7 (spermatogenesis associated 7 gene) rs3179969 and FLI1 (Friend leukemia virus~     integration 1 gene) rs640098. An individual patient will be considered to be biomarker~     positive if they have the responsive genotype for either of the SNPs or for both of the SNPs~     in the IRP.~   "|||2018-05-31 21:52:14.626832|2018-05-31 21:52:14.626832
NCT01486511|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Pulmonary Embolism After Liver Resection|Pulmonary Embolism After Liver Resection: A Prospective Analysis of Risk Factors|Unknown status|Enrolling by invitation||500|Anticipated|Beaujon Hospital|||1||f||||t||||||||||2018-05-31 21:52:14.701629|2018-05-31 21:52:14.701629
NCT01486498|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-03|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|November 2005||2005-11-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2009|Actual|2009-11-30||Observational|SABAL||Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy|Health Economic Analyses of Treatment Strategies for Allergic Respiratory Diseases|Completed|||571|Actual|Aalborg University|||||f||||f||||||||||2018-05-31 21:52:14.799061|2018-05-31 21:52:14.799061
NCT01486485|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-02-18|2011-12-05|2011-12-06|Estimate|||||||2013-02-18|2013-02-20|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Nafamostat Efficacy and Safety in Critically Ill Patients(NICE)|Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming|Unknown status|Recruiting|Phase 3|160|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:52:14.84095|2018-05-31 21:52:14.84095
NCT01486472|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2011-12-06|2011-12-05|2011-12-06|Estimate|||||||2011-12-06|2011-12-07|Estimate|November 2010||2010-11-30|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|||S-1-induced Lacrimal Drainage Obstruction|Lacrimal Drainage Obstruction in Gastric Cancer Patients Receiving Adjuvant S-1 Chemotherapy: A Prospective Study|Unknown status|Recruiting||200|Anticipated|Seoul National University Bundang Hospital|||1||f||||f||||||Samples Without DNA|"~     Plasma Tears~   "|||2018-05-31 21:52:15.049931|2018-05-31 21:52:15.049931
NCT01486459|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2015-03-16|2011-12-04|2011-12-06|Estimate|||||||2015-03-16|2015-03-18|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|TULIP||A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer|A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer|Terminated||N/A|7|Actual|Barwon Health||2||Insufficient recruits|f||||f||||||||||2018-05-31 21:52:15.152209|2018-05-31 21:52:15.152209
NCT01486446|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|2014-01-21||2014-03-10|2011-12-02|2011-12-06|Estimate|2014-03-10|2014-04-14|Estimate||||2014-03-10|2014-04-14|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia|Phase 2a, Exploratory, Double-blind, Placebo-controlled Two-part Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Topically Applied XPF-002 (XEN402 8% w/w Ointment) in Patients With Primary/Inherited Erythromelalgia|Completed||Phase 1/Phase 2|8|Actual|Xenon Pharmaceuticals Inc.|"This was a small trial with many exploratory efficacy measures. There was no primary outcome measure, all measures are other: pre-specified.~Only 8 subjects were enrolled (1 placebo), the actual number of Adverse Events is used, not incidence."|2|||f||||f||||||||||2018-05-31 21:52:15.258455|2018-05-31 21:52:15.258455
NCT01486433|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-04-29|2011-12-02|2011-12-06|Estimate|||||||2015-04-29|2015-04-30|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects|An Open-Label, Randomized, 2-Way Crossover Study to Evaluate the Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects|Completed||Phase 1|52|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:52:15.841866|2018-05-31 21:52:15.841866
NCT01486420|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2015-10-27|2011-12-03|2011-12-06|Estimate|||||||2015-10-27|2015-10-28|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Open Surgery Versus Corticosteroid Injections in Treatment of Trigger Finger|Open Surgery Versus Ultrasound Guided Local Corticosteroid Injections in Treatment of Trigger Finger - a Randomized Controlled Trial.|Completed||N/A|166|Actual|Regionshospitalet Silkeborg||2|||f||||f||||||||||2018-05-31 21:52:16.050385|2018-05-31 21:52:16.050385
NCT01486407|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-01-31|2011-12-05|2011-12-06|Estimate|||||||2013-01-31|2013-02-01|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Observational Study of Rapid Sequence Intubation (RSI) Drug Delivery Using Intraosseous (IO) and Intravenous (IV) Access.|An Observational Study of Intubating Conditions Comparing Intraosseous Vascular Access With Peripheral Intravenous Access for Drug Delivery in Rapid Sequence Intubation|Terminated|||2|Actual|Vidacare Corporation|||2|For poor enrollment|f||||f||||||||||2018-05-31 21:52:16.234206|2018-05-31 21:52:16.234206
NCT01486394|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2013-08-02|2011-12-02|2011-12-06|Estimate|||||||2013-08-02|2013-08-05|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Sonography in an Unselected Population of Acute Admitted Patients With Respiratory Symptoms|Focused Sonographic Examination of the Heart, Lungs and Deep Veins in an Unselected Population of Acute Admitted Patients With Respiratory Symptoms: a Randomised Clinical Trial|Completed||N/A|315|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 21:52:16.320108|2018-05-31 21:52:16.320108
NCT01486199|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2017-04-05||2017-07-24|2011-12-05|2011-12-06|Estimate|2017-07-24|2017-09-25|Actual||||2017-07-24|2017-09-25|Actual|October 2011||2011-10-31|July 2017|2017-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Imaging Airway Liquid Absorption in Cystic Fibrosis|Imaging Airway Liquid Absorption in Cystic Fibrosis|Completed||N/A|20|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:52:19.243429|2018-05-31 21:52:19.243429
NCT01486381|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-02-22|2011-12-02|2011-12-06|Estimate|||||||2017-02-22|2017-02-24|Actual|March 20, 2002|Actual|2002-03-20|February 2017|2017-02-28|May 30, 2003|Actual|2003-05-30|May 30, 2003|Actual|2003-05-30||Interventional|||Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes|A Multi-national, Multi-centre, Open-labelled Extension Study Assessing the Long-term Safety of Biphasic Insulin Aspart 30 (BIAsp 30) in Young Diabetic Subjects With Type 1 Diabetes Mellitus Previously Treated in BIAsp-1240|Completed||Phase 3|22|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:52:16.413929|2018-05-31 21:52:16.413929
NCT01486368|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2016-09-16|2011-12-02|2011-12-06|Estimate|||||||2016-09-16|2016-09-19|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|||A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma|A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma|Completed||Phase 2|17|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-05-31 21:52:16.553049|2018-05-31 21:52:16.553049
NCT01486355|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-11-14|2011-12-05|2011-12-06|Estimate|||||||2013-11-14|2013-11-15|Estimate|August 2011||2011-08-31|November 2013|2013-11-30||||July 2016|Anticipated|2016-07-31||Interventional|||Additional Measles Vaccine at 4 Months of Age|A Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality and to Explore the Role of Maternal Measles Antibodies for the Beneficial Non-specific Effects of Measles Vaccine|Unknown status|Recruiting|Phase 4|||Bandim Health Project||2|||f||||f||||||||||2018-05-31 21:52:16.650415|2018-05-31 21:52:16.650415
NCT01486342|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-01-03|2011-12-02|2011-12-06|Estimate|||||||2013-01-03|2013-01-04|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|PET-ALI||PET Imaging in Patients at Risk for Acute Lung Injury|Positron Emission Tomography With [18F]Fluorodeoxyglucose in Patients at Risk for Acute Lung Injury|Completed|||5|Actual|Washington University School of Medicine|||1||f||||t||||||||||2018-05-31 21:52:16.807497|2018-05-31 21:52:16.807497
NCT01486329|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-06-05|2011-12-05|2011-12-06|Estimate|||||||2015-06-05|2015-06-08|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer|VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01|Completed||Phase 1|72|Actual|Vaximm GmbH||2|||f||||t||||||||||2018-05-31 21:52:16.969321|2018-05-31 21:52:16.969321
NCT01486316|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2013-11-08|2011-12-02|2011-12-06|Estimate|||||||2013-11-08|2013-11-11|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|IDENTIFY-HF||Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure|Integrated Diagnostic Evaluation in Non-Therapy DevIces For the studY of Heart Failure|Unknown status|Recruiting|N/A|100|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-05-31 21:52:17.155711|2018-05-31 21:52:17.155711
NCT01486303|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-12-05|2011-12-02|2011-12-06|Estimate|||||||2011-12-05|2011-12-07|Estimate|August 2011||2011-08-31|December 2011|2011-12-31||||December 2011|Anticipated|2011-12-31||Interventional|||Facial Cosmetic Acupuncture on Skin Rejuvenation|Efficacy and Safety of Facial Cosmetic Acupuncture on Skin Rejuvenation|Unknown status|Active, not recruiting|N/A|28|Actual|Kyunghee University||1|||f||||t||||||||||2018-05-31 21:52:17.335111|2018-05-31 21:52:17.335111
NCT01486290|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2014-03-26|2011-12-02|2011-12-06|Estimate|||||||2014-03-26|2014-03-28|Estimate|July 2007||2007-07-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DISCO||Identifying and Overcoming Barriers to Diabetes Management in the Elderly: A Cost-effective Intervention Study|Identifying and Overcoming Barriers to Diabetes Management in the Elderly: A Cost-effective Intervention Study|Completed||N/A|52|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-05-31 21:52:17.493602|2018-05-31 21:52:17.493602
NCT01486277|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29||2015-11-04|2016-11-02|2011-12-02|2011-12-06|Estimate||||2015-11-04|2015-12-01|Estimate|2016-11-02|2016-11-03|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|November 2014|Actual|2014-11-30||Interventional|||A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma|A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma|Completed||Phase 2|26|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:52:17.641689|2018-05-31 21:52:17.641689
NCT01486264|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02||2017-04-26|2017-04-26|2011-12-05|2011-12-06|Estimate||||2017-04-26|2017-04-27|Actual|2017-04-26|2017-04-27|Actual|December 1, 2011|Actual|2011-12-01|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|March 2016|Actual|2016-03-31||Interventional|||Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex|An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment|Completed||Phase 4|286|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 21:52:17.820972|2018-05-31 21:52:17.820972
NCT01486251|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-02-09|2011-12-02|2011-12-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|April 2013|Actual|2013-04-30||Interventional|AXUS||Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer|Assessment of the Tumor Vascular Effects of the Pan-vegfr Tyrosine Kinase Inhibitor Axitinib Using Dynamic Contrast-enhanced Ultrasonography (Dce-us) in Patients With Refractory Metastatic Colorectal Cancer|Completed||N/A|27|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 21:52:17.993592|2018-05-31 21:52:17.993592
NCT01486238|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|2013-04-02||2013-06-12|2011-12-05|2011-12-06|Estimate|2013-06-12|2013-07-16|Estimate||||2013-06-12|2013-07-16|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|PRESERVE|"In the IVMac q6 Arm, 23 subjects started the study. Two (2) subjects withdrew early. For this reason data from the 21 remaining subjects was used.~In the IVMac q4 Arm, 49 subjects started the study. 6 subjects were lost in this arm - 2 died, 1 withdrew, & 3 were lost to follow-up. For this reason data from the 43 remaining subjects was used."|Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study|Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study|Completed||Phase 4|72|Actual|Valley Retina Institute||2|||f||||f||||||||||2018-05-31 21:52:18.202098|2018-05-31 21:52:18.202098
NCT01486225|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2014-08-07|2011-12-05|2011-12-06|Estimate|||||||2014-08-07|2014-08-08|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Tolerance Study of the Silicone Bands on Medical Compression Stockings|Exploratory Comparative Single-blind Study Evaluating Tolerability of the Silicone Bands on Medical Compression Stockings|Terminated||Phase 4|3|Actual|Laboratoires Innothera||2|||f||||f||||||||||2018-05-31 21:52:18.889736|2018-05-31 21:52:18.889736
NCT01486186|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-12-02|2011-12-02|2011-12-06|Estimate|||||||2011-12-02|2011-12-06|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Traditional Chinese Medicine on Outcomes in Patients With Mild/Moderate Chronic Obstructive Pulmonary Disease|Detection and Intervention on Mild/Moderate Chronic Obstructive Pulmonary Disease by Traditional Chinese Medicine Treatment and Application|Unknown status|Not yet recruiting|Phase 2|504|Anticipated|Henan University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 21:52:19.58535|2018-05-31 21:52:19.58535
NCT01486173|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-04-16|2011-12-05|2011-12-06|Estimate|||||||2013-04-16|2013-04-17|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|EPINUTRI||Early Nutrition and Neurological Development of Very Preterm Infants|Early Nutrition and Neurological Development of Very Preterm Infants|Unknown status|Active, not recruiting||260|Anticipated|Lapillonne, Alexandre, M.D.|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:52:19.724792|2018-05-31 21:52:19.724792
NCT01486160|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-11-28|2011-12-05|2011-12-06|Estimate|||||||2012-11-28|2012-11-30|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Observational|||Respiratory Viral Infection in Nursing Home Slovenia|Etiology, Frequency and Epidemiology of Respiratory Viral Infection in Nursing Home Residents|Completed|||132|Actual|University Maribor|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:52:19.802694|2018-05-31 21:52:19.802694
NCT01486147|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of a Visual Nutrient Profiling System on Recall of Nutrition Information||Completed||N/A|63|Actual|University of Illinois at Urbana-Champaign||2|||f||||||||||||||2018-05-31 21:52:19.896498|2018-05-31 21:52:19.896498
NCT01486134|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-08-28|2011-12-05|2011-12-06|Estimate|||||||2017-08-28|2017-08-29|Actual|June 20, 2012|Actual|2012-06-20|August 2017|2017-08-31|June 20, 2019|Anticipated|2019-06-20|January 6, 2016|Actual|2016-01-06||Interventional|ARMTICH||Major RF Ablations of Hepatomas Under MR Thermometry Monitoring|Pilot Study of Real Time MR Temperature Monitoring of Multipolar Radiofrequency Ablation of Large Hepatocellular Carcinomas (≥ 5 CM)-ARMTICH STUDY|Active, not recruiting||N/A|15|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 21:52:19.971108|2018-05-31 21:52:19.971108
NCT01486121|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2015-12-01|2011-12-02|2011-12-06|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Sedation Optimisation Strategy (S.O.S.) Ventilation|S.O.S. Ventilation - Sedation Optimisation Strategy For Mechanical Ventilation In Intensive Care Unit Patients|Completed||Phase 3|140|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:52:20.066372|2018-05-31 21:52:20.066372
NCT01486108|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-12-02|2011-12-02|2011-12-06|Estimate|||||||2011-12-02|2011-12-06|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Burst Spinal Cord Stimulation for Neuropathic Pain|Burst, Tonic and Sham Spinal Cord Stimulation. A Verification of the Best Treatment Protocol|Completed||N/A|15|Actual|University Hospital, Antwerp||3|||f||||f||||||||||2018-05-31 21:52:20.187635|2018-05-31 21:52:20.187635
NCT01486095|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-05-08|2011-12-05|2011-12-06|Estimate|||||||2017-05-08|2017-05-09|Actual|November 29, 2011||2011-11-29|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2013|Actual|2013-12-31||Interventional|COBRA||COmplex BifuRcation Lesions: a Comparison Between the AXXESS Device and Culotte Stenting: an Optical Coherence Tomography (OCT) Study|Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With a Dedicated Bifurcation Device (Axxess™ Drug Eluting Coronary Bifurcation Stent System + Biomatrix™ Drug Eluting Coronary Stent System Stents in the Distal Branches) Versus the Culotte Technique Using Xience Prime Everolimus-eluting Stents : an Optical Coherence Tomography (OCT) Analysis|Active, not recruiting||N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 21:52:20.266987|2018-05-31 21:52:20.266987
NCT01486082|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|||2011-12-11|2011-12-02|2011-12-06|Estimate|||||||2011-12-11|2011-12-13|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|November 2011|Actual|2011-11-30||Observational|||Antimicrobial Susceptibility for Helicobacter Pylori Eradication|Usefulness of Antimicrobial Susceptibility in the Eradication of Helicobacter Pylori|Unknown status|Recruiting||1|Anticipated|Hospital Donostia|||2||f||||f||||||||||2018-05-31 21:52:20.362321|2018-05-31 21:52:20.362321
NCT01486069|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2013-06-12|2011-12-05|2011-12-06|Estimate|||||||2013-06-12|2013-06-14|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|||Mandibular Stability and Dentofacial Deformity|Evaluation of the Perioperative Mandibular Positional Stability in Subjects With Dentofacial Deformity|Completed|||30|Actual|University of Sao Paulo|||1||f||||t||||||||||2018-05-31 21:52:20.480927|2018-05-31 21:52:20.480927
NCT01486056|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-08-20|2011-12-02|2011-12-06|Estimate|||||||2012-08-20|2012-08-21|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||ECG Vector Determination|ECG Vector Determination for Model 106 Generator Implant Site Selection|Completed|||29|Actual|Cyberonics, Inc.|||1||f||||f||||||||||2018-05-31 21:52:20.564727|2018-05-31 21:52:20.564727
NCT01486043|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2015-01-13||2015-01-20|2011-12-02|2011-12-06|Estimate|2015-01-20|2015-01-30|Estimate||||2015-01-20|2015-01-30|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Metformin and Transient Hyperglycemia|Metformin as an Adjunctive Therapy For Transient Hyperglycemia in Patients With Acute Lymphoblastic Leukemia During Induction Chemotherapy|Terminated||N/A|4|Actual|Children's Hospital Los Angeles|Early termination leading to small numbers of subjects analyzed.|1||"The research project was terminated due to lower than projected patient recruitment within the~   period of time allowed for the study."|f||||t||||||||||2018-05-31 21:52:20.647776|2018-05-31 21:52:20.647776
NCT01486030|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2018-02-21|2011-12-02|2011-12-06|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2011||2011-09-30|February 2018|2018-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|EXERCISE||Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test|Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD Diagnostic Test (Age, Sex, Gene Expression Score ASGES).|Completed|||20|Actual|CardioDx|||||f||||f||||||Samples With DNA|"~     RNA PAXgene~   "|||2018-05-31 21:52:20.849457|2018-05-31 21:52:20.849457
NCT01486017|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2011-12-02|2011-12-02|2011-12-06|Estimate|||||||2011-12-02|2011-12-06|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K|A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Across Three Strengths of a New ASP015K Tablet Formulation in Healthy Volunteers|Completed||Phase 1|30|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:52:20.924074|2018-05-31 21:52:20.924074
NCT01486004|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2013-01-30|2011-12-02|2011-12-06|Estimate|||||||2013-01-30|2013-01-31|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen|A Phase-I, Open-label Trial in Healthy Female Subjects to Investigate the Effect of TMC435 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone|Completed||Phase 1|18|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||f||||||||||2018-05-31 21:52:21.010925|2018-05-31 21:52:21.010925
NCT01485991|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|2015-03-27||2016-03-24|2011-12-02|2011-12-06|Estimate|2015-04-09|2015-04-10|Estimate||||2016-03-24|2016-04-26|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ATTAIN|Intent-to-treat (ITT) population included all randomized participants who took at least 1 dose of study medication.|TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy|Phase III in Partial and Null Responders|Completed||Phase 3|771|Actual|Janssen R&D Ireland||2|||f||||t||||||||||2018-05-31 21:52:21.144642|2018-05-31 21:52:21.144642
NCT01485978|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-10-24|2011-12-05|2011-12-06|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2012||2012-03-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome|Early Prospective Therapy Trial to Delay Renal Failure in Children With Alport Syndrome|Active, not recruiting||Phase 3|66|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||3|||f||||t||||||||||2018-05-31 21:52:21.960692|2018-05-31 21:52:21.960692
NCT01485965|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2013-03-19|2011-12-05|2011-12-06|Estimate|||||||2013-03-19|2013-03-20|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease|A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196|Completed||Phase 1|26|Actual|Siena Biotech S.p.A.||2|||f||||f||||||||||2018-05-31 21:52:22.076069|2018-05-31 21:52:22.076069
NCT01485952|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-11-24|2011-12-02|2011-12-06|Estimate|||||||2015-11-24|2015-11-25|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|PADDINGTON||An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196|An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196.|Completed||Phase 1|55|Actual|Siena Biotech S.p.A.||3|||f||||f||||||||||2018-05-31 21:52:22.212673|2018-05-31 21:52:22.212673
NCT01485939|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Interventional|||Lidocaine Patch for Postoperative Analgesia After Laparoscopic Cholecystectomy||Unknown status|Recruiting|Phase 4|80|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:52:22.358323|2018-05-31 21:52:22.358323
NCT01485926|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-05-30|2011-12-05|2011-12-06|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2010||2010-10-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|September 2014|Actual|2014-09-30||Interventional|TCHL Phase II||A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.|A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.|Active, not recruiting||Phase 2|120|Anticipated|Cancer Trials Ireland||2|||f||||f||||||||||2018-05-31 21:52:22.514064|2018-05-31 21:52:22.514064
NCT01485913|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-04-26|2011-12-02|2011-12-06|Estimate|||||||2017-04-26|2017-04-28|Actual|July 1, 2011|Actual|2011-07-01|April 2017|2017-04-30|June 30, 2013|Actual|2013-06-30|December 31, 2012|Actual|2012-12-31||Interventional|||A Randomized Trial of an Intensive Education Intervention Using a Network of Involved Diabetic Patients (Peer Educators) to Improve Glycemic Control of Type 2 Diabetic Patients|A Randomized Trial of an Intensive Education Intervention Using a Network of Involved Diabetic Patients (Peer Educators) to Improve Glycemic Control of Type 2 Diabetic Patients|Completed||N/A|151|Actual|Sante Diabete Mali||2|||f||||t||||||||||2018-05-31 21:52:22.640562|2018-05-31 21:52:22.640562
NCT01485900|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2012-08-22|2011-12-05|2011-12-06|Estimate|||||||2012-08-22|2012-08-23|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Hemodynamics of Ascending Repeated Oral Doses of SAR407899A in Patients With Moderate Chronic Kidney Disease on Stable Angiotensin Converting Enzyme-inhibitor (ACE-I) Treatment|Completed||Phase 1|20|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:52:22.776024|2018-05-31 21:52:22.776024
NCT01485887|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2015-01-09||2015-09-30|2011-12-02|2011-12-06|Estimate|2015-05-13|2015-05-15|Estimate||||2015-09-30|2015-10-20|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)|A Open-label Long-term Extension Study To Evaluate The Safety And Efficacy Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|50|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:52:22.976541|2018-05-31 21:52:22.976541
NCT01485874|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2016-08-04|2011-12-05|2011-12-06|Estimate|||||||2016-08-04|2016-08-08|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer|A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149|Terminated||Phase 1|11|Actual|Hoosier Cancer Research Network||1||Funding withdrawn due to drug unavailability|f||||t||||||||||2018-05-31 21:52:23.582218|2018-05-31 21:52:23.582218
NCT01485861|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2018-03-19|2011-12-02|2011-12-06|Estimate|||||||2018-03-19|2018-03-20|Actual|January 11, 2012|Actual|2012-01-11|March 2018|2018-03-31|June 29, 2018|Anticipated|2018-06-29|September 1, 2015|Actual|2015-09-01||Interventional|||Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy|A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|Active, not recruiting||Phase 1/Phase 2|273|Actual|Genentech, Inc.||5|||f||||||||||||||2018-05-31 21:52:23.693584|2018-05-31 21:52:23.693584
NCT01485848|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2014-06-09|2011-12-05|2011-12-06|Estimate|||||||2014-06-09|2014-06-10|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ESP2011-002||EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer|EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial|Completed||Phase 2|49|Actual|Esperance Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 21:52:23.965768|2018-05-31 21:52:23.965768
NCT01485835|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-10-08|2011-12-02|2011-12-06|Estimate|||||||2015-10-08|2015-10-12|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma|Completed||Phase 1|8|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:52:24.125196|2018-05-31 21:52:24.125196
NCT01485822|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2013-05-13|2011-12-02|2011-12-06|Estimate|||||||2013-05-13|2013-05-14|Estimate|July 2004||2004-07-31|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution|A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution|Terminated|||88|Actual|Alcon Research|||2|Study objectives met|f||||f||||||||||2018-05-31 21:52:24.32804|2018-05-31 21:52:24.32804
NCT01485809|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-12-05|2011-12-05|2011-12-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|February 2014|Anticipated|2014-02-28|October 2011|Actual|2011-10-31||Interventional|SIIS||Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy|A Phase II Trial of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy|Unknown status|Recruiting|Phase 2|56|Anticipated|Seoul Veterans Hospital||1|||f||||t||||||||||2018-05-31 21:52:24.50624|2018-05-31 21:52:24.50624
NCT01485796|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|2017-03-10|2014-09-08|2018-01-23|2011-12-05|2011-12-06|Estimate|2017-03-10|2017-04-24|Actual|2014-09-15|2014-09-29|Estimate|2018-01-23|2018-02-21|Estimate|December 29, 2011|Actual|2011-12-29|January 2018|2018-01-31|January 1, 2013|Actual|2013-01-01|January 1, 2013|Actual|2013-01-01||Interventional|||Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD|Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)|Completed||Phase 2/Phase 3|54|Actual|Shire|Treatment with rHuPH20 was stopped as of August 2012 following discussion with the FDA. 26 subjects still active in Study Epoch 2 went into a safety follow-up period and were treated with IGI, 10% (GAMMAGARD LIQUID) intravenously or subcutaneously.|1|||f||||f||||||||||2018-05-31 21:52:24.668694|2018-05-31 21:52:24.668694
NCT01485783|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2015-09-08|2011-12-05|2011-12-06|Estimate|||||||2015-09-08|2015-09-10|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|July 2013|Actual|2013-07-31||Observational|||Improving Outcomes for Hypertensive Children|Improving Outcomes for Hypertensive Children|Completed|||112|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||None Retained|"~     none collected~   "|||2018-05-31 21:52:26.268666|2018-05-31 21:52:26.268666
NCT01485770|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02||2013-03-08|2016-04-05|2011-12-02|2011-12-06|Estimate||||2013-03-08|2013-03-18|Estimate|2016-04-05|2016-05-04|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness|A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness|Completed||Phase 2|33|Actual|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:52:26.336777|2018-05-31 21:52:26.336777
NCT01485757|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2017-01-09|2011-12-02|2011-12-05|Estimate|||||||2017-01-09|2017-01-10|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Prospective L-arginine Study|Effect of Chronic Oral L-arginine Supplementation on Peripheral Endothelial Function and Exercise Tolerance in a Population of Young Heart Transplant Patients.|Terminated||Phase 1|3|Actual|University of Michigan||1||Technical difficulty with Endo-PAT machine|f||||t||||||||||2018-05-31 21:52:26.426399|2018-05-31 21:52:26.426399
NCT01485744|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2018-03-20|2011-12-02|2011-12-05|Estimate|||||||2018-03-20|2018-03-21|Actual|December 2011||2011-12-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer|A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose|Active, not recruiting||Phase 1|39|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:52:26.499717|2018-05-31 21:52:26.499717
NCT01485731|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-06-01|2011-12-01|2011-12-05|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer|Phase 1 Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)|Completed||Phase 1|8|Actual|University of Miami||1|||f||||t||||||||||2018-05-31 21:52:26.685198|2018-05-31 21:52:26.685198
NCT01485718|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2011-12-09|2011-12-02|2011-12-05|Estimate|||||||2011-12-09|2011-12-13|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Effect of Daily Glucomannan in Overweight Patients|Effect of Daily Glucomannan in Overweight Patients|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|ProMedica Health System||2|||f||||f||||||||||2018-05-31 21:52:26.82345|2018-05-31 21:52:26.82345
NCT01485705|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-07-01|2011-12-01|2011-12-05|Estimate|||||||2014-07-01|2014-07-02|Estimate|August 2009||2009-08-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Diabact||Retrospective Examination of Initial Care of Severe Bacterial Infections of the Child|Frequency, Consequences and Determinants of Sub-optimal Care in the Initial Care of Severe Bacterial Infections of the Child|Completed||N/A|270|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 21:52:26.933088|2018-05-31 21:52:26.933088
NCT01485692|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2011-12-01|2011-12-01|2011-12-05|Estimate|||||||2011-12-01|2011-12-05|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation|Safety and Efficacy of Four Intramuscular Interventions for the Management of Acute Psychomotor Agitation|Completed||N/A|120|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 21:52:27.01632|2018-05-31 21:52:27.01632
NCT01485679|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2016-05-17|2011-12-01|2011-12-05|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas|Evaluation of 18 Fluoro-deoxy-glucose Positrons Emission Tomography Combined With Computed Tomography (18-FDG TEP-CT ) in the Diagnosis of the Degeneration of Intraductal Papillary Mucinous Tumor of the Pancreas|Completed||N/A|126|Actual|Nantes University Hospital||1|||f||||||||||||||2018-05-31 21:52:27.152225|2018-05-31 21:52:27.152225
NCT01485666|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2016-04-08|2011-12-02|2011-12-05|Estimate|||||||2016-04-08|2016-04-11|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|RESIST||Thoratec's Reduce Driveline Trauma Through Stabilization and Exit Site Management Study|Reduce Driveline Trauma Through Stabilization and Exit Site Management (RESIST) Pilot Study Protocol|Completed|||50|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 21:52:27.265634|2018-05-31 21:52:27.265634
NCT01485653|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-12-07|2011-12-02|2011-12-05|Estimate|||||||2011-12-07|2011-12-08|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Dosage of Mepivacaine in Ultrasound Axillary Block|Effective Low Dosage of Mepivacaine in Ultrasound Guided Axillary Block in Patients Undergoing Distal Upper Extremity Surgery|Completed||N/A|64|Actual|Wayne State University||1|||f||||f||||||||||2018-05-31 21:52:27.360581|2018-05-31 21:52:27.360581
NCT01485640|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2015-02-26||2016-09-29|2011-12-02|2011-12-05|Estimate|2015-02-26|2015-03-11|Estimate||||2016-09-29|2016-11-04|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Lurasidone Extended Use Study|A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study|Completed||Phase 3|162|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 21:52:27.480253|2018-05-31 21:52:27.480253
NCT01485627|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2018-04-24|2011-12-02|2011-12-05|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2011|Actual|2011-04-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|VOICE||VOICE: Values and Options in Cancer Care|Randomized Controlled Trial(RCT)of Patient, Caregiver and Physician Communication Coaching in Advanced Cancer|Completed||N/A|406|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 21:52:27.809659|2018-05-31 21:52:27.809659
NCT01485614|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2018-05-23|2011-12-01|2011-12-05|Estimate|||||||2018-05-23|2018-05-25|Actual|February 10, 2012|Actual|2012-02-10|May 2018|2018-05-31|January 23, 2020|Anticipated|2020-01-23|January 23, 2020|Anticipated|2020-01-23||Interventional|||Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)|A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control|Recruiting||Phase 3|170|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 21:52:27.927786|2018-05-31 21:52:27.927786
NCT01485601|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-09-19|2011-12-02|2011-12-05|Estimate|||||||2012-09-19|2012-09-20|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines|A Randomised, Double-blind, Multi-centre, Phase II, Optimal Dose-finding Study to Determine the Safety and Efficacy of MT10109 (Clostridium Botulinum Toxin Type A) in Subjects With Moderate to Severe Glabellar Lines in Comparison to BOTOX®|Completed||Phase 2|121|Actual|Medy-Tox||2|||f||||t||||||||||2018-05-31 21:52:28.264855|2018-05-31 21:52:28.264855
NCT01485588|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01||2015-02-04|2015-02-04|2011-12-02|2011-12-05|Estimate||||2015-02-04|2015-02-24|Estimate|2015-02-04|2015-02-24|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Tolerability Study for Age-Related Macular Degeneration|A Phase 1 / 2 Trial to Investigate The Safety and Tolerability of Single and Repeated Doses of hI-CON1™ Following Administration by Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD)|Completed||Phase 1/Phase 2|18|Actual|Iconic Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 21:52:28.329019|2018-05-31 21:52:28.329019
NCT01485575|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2018-04-27|2011-12-01|2011-12-05|Estimate|||||||2018-04-27|2018-04-30|Actual|November 2011||2011-11-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Observational|||Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy|Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy|Recruiting|||50|Anticipated|University Hospital, Basel, Switzerland|||1||f||||f||||||Samples Without DNA|"~     Internal limiting membrane as removed during routine surgery.~   "|Undecided||2018-05-31 21:52:28.411633|2018-05-31 21:52:28.411633
NCT01485562|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2016-03-09|2011-12-02|2011-12-05|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Treatment of Postpartum Haemorrhage (PPH) Using Misoprostol in Home Births|Treatment of Postpartum Haemorrhage (PPH) Using Misoprostol in Home Births|Completed||N/A|84|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 21:52:28.508878|2018-05-31 21:52:28.508878
NCT01485549|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2017-11-09|2011-12-01|2011-12-05|Estimate|||||||2017-11-09|2017-11-13|Actual|November 26, 2012|Actual|2012-11-26|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|BIOAMS||Oligomeric Alpha-synuclein in Multiple System Atrophy|Oligomeric Alpha-synuclein Levels as a Biomarker for Multiple System Atrophy|Recruiting|||40|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||Samples With DNA|"~     -  cerebrospinal fluid (CSF)~        -  whole blood~        -  plasma~        -  blood serum~        -  urine~   "|||2018-05-31 21:52:28.624221|2018-05-31 21:52:28.624221
NCT01485536|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2016-11-28||2016-11-28|2011-12-02|2011-12-05|Estimate|2016-11-28|2017-01-23|Estimate||||2016-11-28|2017-01-23|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of the HSP90 Inhibitor AUY922|A Phase II Study of the HSP90 Inhibitor AUY922 in Patients With Relapsed and Refractory Lymphoma|Terminated||Phase 2|21|Actual|M.D. Anderson Cancer Center|Although the study surpassed the first futility endpoint for DLBCL cohort, it was terminated early due to limited responses and significant toxicities witnessed in the entire cohort of the study.|1||Study halted early due to limited response.|f||||f||||||||||2018-05-31 21:52:28.730842|2018-05-31 21:52:28.730842
NCT01485523|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2013-03-12|2011-12-02|2011-12-05|Estimate|||||||2013-03-12|2013-03-13|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites|Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites|Completed|||120|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 21:52:29.023694|2018-05-31 21:52:29.023694
NCT01485510|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-06-10|2011-12-01|2011-12-05|Estimate|||||||2014-06-10|2014-06-11|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|BEST?||Evaluation of the New Orleans Intervention for Infant Mental Health|Evaluation of the New Orleans Intervention for Infant Mental Health in Glasgow|Recruiting||Phase 2|100|Anticipated|University of Glasgow||2|||f||||f||||||||||2018-05-31 21:52:29.091846|2018-05-31 21:52:29.091846
NCT01485497|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-02-08|2011-12-01|2011-12-05|Estimate|||||||2017-02-08|2017-02-10|Actual|May 2011||2011-05-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Obstructive Sleep Apnea With Long Range 3D Endoscopic Fourier Domain Optical Coherence Tomography (FDOCT)|Evaluation of Obstructive Sleep Apnea With Long Range 3D Endoscopic Fourier Domain Optical Coherence Tomography (FDOCT)|Withdrawn||Phase 1|0|Actual|University of California, Irvine||1||no participants enrolled|f||||t||||||||||2018-05-31 21:52:29.170962|2018-05-31 21:52:29.170962
NCT01485484|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2018-02-12|2011-12-01|2011-12-05|Estimate|||||||2018-02-12|2018-02-14|Actual|September 2011||2011-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Development and Validation of a NIRS-based Sinusitis Screening|Development and Validation of a NIRS-based Sinusitis Screening|Suspended|||170|Anticipated|University of California, Irvine|||1|Awaiting IRB renewal|f||||f||||||||||2018-05-31 21:52:29.245535|2018-05-31 21:52:29.245535
NCT01485471|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-02-08|2011-12-01|2011-12-05|Estimate|||||||2017-02-08|2017-02-10|Actual|June 2011||2011-06-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Spectroscopic Evaluation of Middle Ear Infection|Spectroscopic Evaluation of Middle Ear Infection|Withdrawn|||0|Actual|University of California, Irvine|||1|No paticipants enrolled|f||||f||||||||||2018-05-31 21:52:29.30522|2018-05-31 21:52:29.30522
NCT01485458|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-04-25|2011-12-02|2011-12-05|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2011||2011-12-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|OSCIS||Optimal Treatment for Spinal Cord Injury Associated With Cervical Canal Stenosis (OSCIS) Study|Randomized Trial of Early Versus Delayed Surgery for Acute Traumatic Cervical Spinal Cord Injury Without Bone Injury in Patients With Cervical Canal Stenosis|Recruiting||N/A|100|Anticipated|Tokyo University||2|||f||||t||||||||||2018-05-31 21:52:29.361504|2018-05-31 21:52:29.361504
NCT01485445|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-06-09|2011-12-01|2011-12-05|Estimate|||||||2017-06-09|2017-06-12|Actual|December 21, 2011|Actual|2011-12-21|June 2017|2017-06-30|March 12, 2012|Actual|2012-03-12|March 12, 2012|Actual|2012-03-12||Interventional|||Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination|An Open-label, Randomised, Replicate, Six-way Crossover, Single Dose Study to Determine the Bioequivalence of Fluticasone Furoate (FF) Inhalation Powder (Single Strip Configuration) Compared With FF Inhalation Powder (Two Strip Configuration) and Compared With FF / Vilanterol (VI) Inhalation Powder Administered Via the Novel Dry Powder Inhaler.|Completed||Phase 1|30|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:52:29.443086|2018-05-31 21:52:29.443086
NCT01485432|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2013-01-16|2011-12-01|2011-12-05|Estimate|||||||2013-01-16|2013-01-17|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|October 2015|Anticipated|2015-10-31|||||Observational|IROR||Goal Directed Hemodynamic Management and Renal Outcome After Renal Transplant Surgery|Can Goal Directed Hemodynamic Management Improve Renal Outcome After Renal Transplant Surgery?|Unknown status|Recruiting||98|Anticipated|Technische Universität München|||2||f||||t||||||||||2018-05-31 21:52:29.527695|2018-05-31 21:52:29.527695
NCT01485419|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-03-28|2011-12-02|2011-12-05|Estimate|||||||2017-03-28|2017-03-29|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|||Characterization of the Early Sex Hormone Milieu Post Injury and Relationship With Resuscitation Requirements and Coagulopathy|Characterization of the Early Sex Hormone Milieu Post Injury and Relationship With Resuscitation Requirements and Coagulopathy|Completed|||292|Actual|University of Pittsburgh|||||f||||f||||||||||2018-05-31 21:52:29.705761|2018-05-31 21:52:29.705761
NCT01485406|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-05-12|2011-12-01|2011-12-05|Estimate|||||||2017-05-12|2017-05-15|Actual|December 12, 2011|Actual|2011-12-12|May 2017|2017-05-31|March 15, 2012|Actual|2012-03-15|March 15, 2012|Actual|2012-03-15||Interventional|||Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers|Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months|Completed||Phase 1|61|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:52:29.789479|2018-05-31 21:52:29.789479
NCT01485393|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-12-12|2011-12-01|2011-12-05|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2015||2015-01-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep|Pilot Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:52:29.914683|2018-05-31 21:52:29.914683
NCT01485380|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2014-09-24||2016-06-20|2011-12-02|2011-12-05|Estimate|2014-10-08|2014-10-10|Estimate||||2016-06-20|2016-06-21|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep|Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep|Completed||N/A|20|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:52:29.992845|2018-05-31 21:52:29.992845
NCT01485367|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-04-19|2011-12-01|2011-12-05|Estimate|||||||2012-04-19|2012-04-23|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura|Phase II Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in The Prevention and Treatment of Senile Purpura|Unknown status|Recruiting|Phase 2|20|Anticipated|Multispecialty Aesthetic Clinical Research Organization||2|||f||||t||||||||||2018-05-31 21:52:30.16585|2018-05-31 21:52:30.16585
NCT01485354|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2017-04-05||2017-06-12|2011-12-01|2011-12-05|Estimate|2017-06-12|2017-07-12|Actual||||2017-06-12|2017-07-12|Actual|December 2008|Actual|2008-12-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|October 2015|Actual|2015-10-31||Interventional|||Upper Arm Training With Armeo Spring for Stroke|The Effect of Repetitive Upper Arm Training in a Virtual Environment on Upper Extremity Motor Recovery in Chronic-stroke Survivors|Terminated||N/A|17|Actual|Spaulding Rehabilitation Hospital||1||Lack of funding|f||||f|f|t|f|f|f|||No||2018-05-31 21:52:30.28018|2018-05-31 21:52:30.28018
NCT01484821|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-01-12|2011-11-30|2011-12-02|Estimate|||||||2015-01-12|2015-01-13|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|CAPARFI||Assessment of in Vivo Skeletal Muscle Viscoelasticity (ARFI Imaging) With Aging and Cancer||Completed||N/A|65|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 21:52:43.932651|2018-05-31 21:52:43.932651
NCT01485341|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2016-04-12|2011-12-01|2011-12-05|Estimate|||||||2016-04-12|2016-04-13|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|GS||Gluten Sensitivity in Non-Celiac Patients|Double Blind Randomized Placebo Controlled Multicenter Trial (Gluten vs Placebo) in Gluten Sensitive Subjects|Completed||Phase 3|108|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||||2018-05-31 21:52:30.564096|2018-05-31 21:52:30.564096
NCT01485328|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-12-05|2011-12-02|2011-12-05|Estimate|||||||2011-12-05|2011-12-06|Estimate|December 2008||2008-12-31|December 2011|2011-12-31|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|AMARGOL||Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics|Phase III - Efficacy Study of AMARGOL - Phytomedicine on Therapeutics|Completed||Phase 3|60|Actual|Laboratorio Saude Ltda.||2|||f||||t||||||||||2018-05-31 21:52:30.644449|2018-05-31 21:52:30.644449
NCT01485315|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-10-02|2011-12-02|2011-12-05|Estimate|||||||2014-10-02|2014-10-03|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|TRISS||Transfusion-requirements in Septic Shock Trial|Effects of Red Blood Cell Transfusion on Mortality and Morbidity in Patients With Septic Shock|Completed||Phase 3|1005|Actual|Scandinavian Critical Care Trials Group||2|||f||||t||||||||||2018-05-31 21:52:30.74019|2018-05-31 21:52:30.74019
NCT01485302|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2015-03-24|2011-12-01|2011-12-05|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients|A Multi-center, Parallel-group, Double-blind, Placebo-controlled Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability and the Pharmacokinetic Properties of SAR228810 Given as IV Infusion or as SC Injection in Patients With Mild to Moderate Alzheimer's Disease.|Completed||Phase 1|48|Actual|Sanofi||6|||f||||f||||||||||2018-05-31 21:52:30.899048|2018-05-31 21:52:30.899048
NCT01485289|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2016-10-03|2011-12-01|2011-12-05|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Stabilimax Investigational Device Exemption (IDE) Clinical Investigation Patient Followup Study|Stabilimax Study Participants Collection of Additional Follow-up Data Clinical Investigation Plan R-001|Completed|||43|Actual|Rachiotek LLC|||2||f||||f||||||||||2018-05-31 21:52:31.009943|2018-05-31 21:52:31.009943
NCT01485276|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2018-05-18|2011-12-02|2011-12-05|Estimate|||||||2018-05-18|2018-05-21|Actual|November 8, 2011||2011-11-08|July 30, 2014|2014-07-30|July 30, 2014|Actual|2014-07-30|||||Interventional|||Combined Deep Brain Stimulation for Parkinson's Disease|Pilot Study of Bilateral Pedunculo-Pontine Nucleus (PPN) Deep Brain Stimulation for Patients With Parkinson Disease (PD) Who Have Persistent Gait Disturbance, Despite Bilateral Subthalamic Nucleus (STN) Deep Brain Stimulation|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:52:31.094349|2018-05-31 21:52:31.094349
NCT01485263|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-02|||2017-07-07|2011-12-02|2011-12-05|Estimate|||||||2017-07-07|2017-07-11|Actual|May 26, 2011||2011-05-26|July 6, 2017|2017-07-06|July 6, 2017||2017-07-06|||||Observational|||Analysis of Visual-Motor Task Electrophysiological Activity During Deep Brain Stimulation for Treatment-Resistant Movement Disorders|Analysis of Visual-Motor Task Electrophysiological Activity During Deep Brain Stimulation for Treatment-Resistant Movement Disorders|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:52:31.199009|2018-05-31 21:52:31.199009
NCT01485250|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2018-04-04|2011-11-30|2011-12-05|Estimate|||||||2018-04-04|2018-04-05|Actual|February 19, 2010||2010-02-19|August 23, 2017|2017-08-23||||||||Observational|||A Cross-Cultural Assessment of the Motivations of Healthy Participants in Phase I Research|A Cross-Cultural Assessment of the Motivations of Healthy Participants in Phase I Research|Completed|||1278|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:52:31.290305|2018-05-31 21:52:31.290305
NCT01485237|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2015-12-01|2011-12-02|2011-12-05|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Observational|||Severe Pandemic H1N1 Infection in ICU: Comparative Resource Utilization|Severe Pandemic H1N1 Infection in ICU: Comparative Resource Utilization|Completed|||400|Actual|University of Manitoba|||2||f||||f||||||||||2018-05-31 21:52:31.383674|2018-05-31 21:52:31.383674
NCT01485224|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-08-28|2011-12-01|2011-12-05|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2011||2011-11-30|August 2017|2017-08-31|October 11, 2016|Actual|2016-10-11|October 2014|Actual|2014-10-31||Interventional|THALI-HHT||Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia|Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|Completed||Phase 2|31|Actual|IRCCS Policlinico S. Matteo||1|||f||||t||||||||No||2018-05-31 21:52:31.465289|2018-05-31 21:52:31.465289
NCT01485211|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-12-02|2011-12-02|2011-12-05|Estimate|||||||2011-12-02|2011-12-05|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin|Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Hypo-osmolar Riboflavin Solution in Thin Corneas|Completed||Phase 4|18|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-05-31 21:52:31.564595|2018-05-31 21:52:31.564595
NCT01485198|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2016-02-29|2011-12-02|2011-12-05|Estimate|||||||2016-02-29|2016-03-01|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|||Autologous Stem Cells in Osteoarthritis|Clinical Effects of Autologous Bone Marrow Mononuclear Cell Infusion in Knee Osteoarthritis.|Completed||Phase 1|61|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t||||||||||2018-05-31 21:52:31.642062|2018-05-31 21:52:31.642062
NCT01485185|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-06-09|2011-12-01|2011-12-05|Estimate|||||||2017-06-09|2017-06-12|Actual|October 11, 2011|Actual|2011-10-11|June 2017|2017-06-30|July 3, 2012|Actual|2012-07-03|July 3, 2012|Actual|2012-07-03||Interventional|||Gabapentin and Donepezil Combination on Experimental Human Pain Models|A Randomized, Double Blind, Placebo Controlled Study to Investigate the Effect of Donepezil and Gabapentin Combination on an Experimental Pain Model in Healthy Subjects|Completed||Phase 1|48|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:52:31.736354|2018-05-31 21:52:31.736354
NCT01485172|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2014-12-18||2017-06-10|2011-12-01|2011-12-05|Estimate|2015-01-29|2015-02-02|Estimate||||2017-06-10|2017-07-11|Actual|January 31, 2012|Actual|2012-01-31|June 2017|2017-06-30|April 30, 2014|Actual|2014-04-30|April 30, 2014|Actual|2014-04-30||Interventional|TANDEM-662||A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease|A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease|Completed||Phase 4|186|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:52:31.855096|2018-05-31 21:52:31.855096
NCT01485159|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-02-20|2011-12-01|2011-12-05|Estimate|||||||2014-02-20|2014-02-24|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|ALICE||Airflow Limitation in Cardiac Diseases in Europe|Airflow Limitation in Cardiac Diseases in Europe|Completed|||3000|Actual|GlaxoSmithKline|||1||f||||f||||||Samples With DNA|"~     In patients that specifically consent, blood samples will be taken for future analysis of the~     genetic links between COPD and cardiovascular disease~   "|||2018-05-31 21:52:35.71527|2018-05-31 21:52:35.71527
NCT01485146|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-04-12|2011-12-01|2011-12-05|Estimate|||||||2012-04-12|2012-04-13|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects|A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ETC-1002 at Doses Above 120 mg/Day in Healthy Subjects|Completed||Phase 1|32|Anticipated|Esperion Therapeutics||4|||f||||f||||||||||2018-05-31 21:52:36.057494|2018-05-31 21:52:36.057494
NCT01485133|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-11-06|2011-12-01|2011-12-05|Estimate|||||||2012-11-06|2012-11-07|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Observational|||Water Method Colonoscopy in Patients With Prior Surgery|Water Colonoscopy Versus Air Colonoscopy for Unsedated Patients With Prior Abdominal or Pelvic Surgery: a Prospective Randomized, Controlled Trial|Completed|||110|Actual|Fourth Military Medical University|||2||f||||t||||||||||2018-05-31 21:52:36.310043|2018-05-31 21:52:36.310043
NCT01485120|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2012-02-28|2011-12-02|2011-12-05|Estimate|||||||2012-02-28|2012-02-29|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Accuracy Study of a Non-Invasive Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood Pressure|Accuracy Study of a Non-Invasive Forearm Blood Pressure Cuff in Comparison to an Invasive Radial Arterial Blood Pressure|Completed||N/A|34|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 21:52:36.497054|2018-05-31 21:52:36.497054
NCT01485107|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-11-22|2011-12-02|2011-12-05|Estimate|||||||2017-11-22|2017-11-24|Actual|June 2011||2011-06-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||Feasibility Study: Evaluation of the Ulthera® System for Treatment of the Décolleté|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Décolleté|Completed||N/A|24|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 21:52:36.832604|2018-05-31 21:52:36.832604
NCT01485094|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2014-09-16||2014-09-30|2011-12-01|2011-12-05|Estimate|2014-09-30|2014-10-02|Estimate||||2014-09-30|2014-10-02|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Intention-to-treat|A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain|Evaluation of the Efficacy, Tolerability, and Safety of 7 Days of Treatment With GRT6010 or Pregabalin in Comparison to Placebo in Subjects With Peripheral Neuropathic Pain.|Terminated||Phase 2|114|Actual|Grünenthal GmbH||3||"The trial was early terminated after it was concluded that there was no added benefit from~   exposing further participants after an unblinded interim analysis."|f||||f||||||||||2018-05-31 21:52:37.286169|2018-05-31 21:52:37.286169
NCT01485081|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-04-07|2011-12-02|2011-12-05|Estimate|||||||2015-04-07|2015-04-08|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|DEBSIDE||Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in Side Branches of de Novo Bifurcation Lesions (DEBSIDE)|Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of Side Branches of de Novo Bifurcation Lesions in Native Coronary Arteries.|Completed||N/A|52|Actual|MINVASYS||1|||f||||t||||||||||2018-05-31 21:52:39.532455|2018-05-31 21:52:39.532455
NCT01485068|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-04-07|2011-12-02|2011-12-05|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|DEBREST||Safety and Efficacy Study of the DANUBIO Paclitaxel Eluting Balloon in In-Stent Restenosis Lesions (DEBREST)|Assessment of the Safety and Efficacy of the Danubio Paclitaxel-Eluting Balloon for the Treatment of In-Stent Restenosis Lesions in Native Coronary Arteries.|Completed||N/A|44|Actual|MINVASYS||1|||f||||t||||||||||2018-05-31 21:52:39.720357|2018-05-31 21:52:39.720357
NCT01485055|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-02-28|2011-12-02|2011-12-05|Estimate|||||||2017-02-28|2017-03-03|Actual|December 2011||2011-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease|Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease|Active, not recruiting||Phase 2|10|Actual|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 21:52:39.871952|2018-05-31 21:52:39.871952
NCT01485042|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-08-31|2011-12-02|2011-12-05|Estimate|||||||2017-08-31|2017-09-01|Actual|December 2011||2011-12-31|August 2017|2017-08-31|March 2014|Actual|2014-03-31|February 2013|Actual|2013-02-28||Interventional|PATH||Dose Escalation Study of Pazopanib Plus TH-302|Phase I Dose Escalation of Pazopanib Plus TH-302 in Advanced Solid Tumors|Completed||Phase 1|50|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 21:52:40.08511|2018-05-31 21:52:40.08511
NCT01485029|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2012-12-17|2011-12-02|2011-12-05|Estimate|||||||2012-12-17|2012-12-18|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|January 2013|Anticipated|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||Streptococcus Pneumoniae Nasopharyngeal Carriage|Streptococcus Pneumoniae Nasopharyngeal Carriage Among Children Attending Day-care Centres in the Alpes Maritimes. Substudy: Enterobacterial Intestinal Carriage and Susceptibility to 3rd Generation Cephalosporins|Unknown status|Recruiting|N/A|500|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 21:52:40.225604|2018-05-31 21:52:40.225604
NCT01485016|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-08-20|2011-12-01|2011-12-05|Estimate|||||||2012-08-20|2012-08-21|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|||Physiological and Biomechanical Data Collection Study in Epilepsy Subjects|Observational Study Collecting Physiological and Biomechanical Data in Ambulatory Subjects With Epilepsy|Completed|||20|Actual|Cyberonics, Inc.|||1||f||||f||||||||||2018-05-31 21:52:40.348076|2018-05-31 21:52:40.348076
NCT01485003|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-10-16|2011-12-02|2011-12-05|Estimate|||||||2017-10-16|2017-10-17|Actual|February 29, 2012|Actual|2012-02-29|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|STRIVE||Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants|A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients|Active, not recruiting|||231|Actual|Biogen|||||f||||||||||||||2018-05-31 21:52:40.446681|2018-05-31 21:52:40.446681
NCT01484639|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2013-02-20|2011-11-30|2011-12-02|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TRICSII||Transfusion Requirements in Cardiac Surgery|Transfusion Requirements in Cardiac Surgery (TRICS II): A Randomized Controlled Trial|Completed||N/A|208|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 21:52:45.940314|2018-05-31 21:52:45.940314
NCT01484990|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-11-17|2011-12-02|2011-12-05|Estimate|||||||2017-11-17|2017-11-21|Actual|April 2010||2010-04-30|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease|A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease|Completed||Phase 1|19|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:52:40.640536|2018-05-31 21:52:40.640536
NCT01484977|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2014-11-20||2017-07-07|2011-12-02|2011-12-05|Estimate|2014-11-20|2014-11-26|Estimate||||2017-07-07|2017-08-08|Actual|December 2011||2011-12-31|July 2017|2017-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|VERVE|The Baseline characteristics consist of subjects in the Safety Set (SS). The SS is all subjects who received at least 1 dose of lacosamide.|eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam|Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With Uncontrolled Partial-onset Seizures|Completed||Phase 3|120|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 21:52:40.756744|2018-05-31 21:52:40.756744
NCT01484964|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2011-12-01|2011-12-01|2011-12-05|Estimate|||||||2011-12-01|2011-12-05|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation|A Phase I, Single-Dose, Open-Label, Three-Period, Randomized, Crossover Study to Compare the Relative Bioavailability Between Two Tablet Formulations of ASP015K and to Assess the Food Effect on a New Formulation in Healthy Volunteers|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:52:41.085869|2018-05-31 21:52:41.085869
NCT01484951|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2013-03-12||2013-04-25|2011-12-01|2011-12-05|Estimate|2013-03-12|2013-04-26|Estimate||||2013-04-25|2013-05-01|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure|Assessing the Safety and Efficacy of Switching to AZARGA® (Brinzolamide/Timolol Fixed Combination) as Replacement Therapy in Patients With Uncontrolled Intraocular Pressure in Taiwan|Completed||Phase 4|74|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:52:41.17374|2018-05-31 21:52:41.17374
NCT01484938|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2012-09-06||2012-10-05|2011-12-01|2011-12-05|Estimate|2012-09-06|2012-10-08|Estimate||||2012-10-05|2012-10-10|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers|Lens Wearing Experience and Biocompatibility of a Marketed Multi-Purpose Disinfecting Solution in Silicone Hydrogel and Soft Contact Lens Wearers|Completed||N/A|175|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:52:41.563921|2018-05-31 21:52:41.563921
NCT01484925|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-01-24|2011-12-02|2011-12-05|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2011||2011-11-30|January 2017|2017-01-31||||November 2017|Anticipated|2017-11-30||Observational|||BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus|Notch Signaling and Novel Biomarkers for Barretts Esophagus|Recruiting|||60|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 21:52:41.73644|2018-05-31 21:52:41.73644
NCT01484912|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|2010-11-11||2011-12-01|2011-10-28|2011-12-02|Estimate|2011-10-28|2011-12-02|Estimate||||2011-12-01|2011-12-06|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Phase II Study of STA-2 in Patients With Chronic Stable Angina|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of STA-2 in Patients With Chronic Stable Angina|Completed||Phase 2|79|Actual|Sinphar Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 21:52:41.88494|2018-05-31 21:52:41.88494
NCT01484899|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2013-07-04|2011-11-30|2011-12-02|Estimate|||||||2013-07-04|2013-07-08|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|DACH||Smoking: a Risk Factor for Pulmonary Arterial Hypertension?|Smoking: a Risk Factor for Pulmonary Arterial Hypertension? A D-A-CH Pulmonary Hypertension Study (Germany- Austria - Switzerland)|Completed|||500|Actual|University of Zurich|||3||f||||f||||||||||2018-05-31 21:52:42.2468|2018-05-31 21:52:42.2468
NCT01484886|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-12|||2014-09-04|2011-11-30|2011-12-02|Estimate|||||||2014-09-04|2014-09-05|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Restrictive Versus Liberal Transfusion Protocol in Infants Undergoing Cardiac Surgery|Prospective Randomized Controlled Clinical Trial Comparing a Restrictive Versus Liberal Transfusion Strategy in Neonates and Infants Undergoing Surgery for Congenital Heart Disease|Completed||N/A|162|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 21:52:42.394049|2018-05-31 21:52:42.394049
NCT01484873|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2016-02-09||2017-01-17|2011-12-01|2011-12-02|Estimate|2016-06-29|2016-08-11|Estimate||||2017-01-17|2017-03-03|Actual|June 2012||2012-06-30|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor|Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity|Completed||Phase 2|10|Actual|Vanderbilt University Medical Center||1|||f||||t||||||||No||2018-05-31 21:52:42.573901|2018-05-31 21:52:42.573901
NCT01484860|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-07-03|2011-11-30|2011-12-02|Estimate|||||||2014-07-03|2014-07-04|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy|A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy|Terminated||Phase 2|15|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 21:52:42.968061|2018-05-31 21:52:42.968061
NCT01484847|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2015-07-09|2011-11-30|2011-12-02|Estimate|||||||2015-07-09|2015-07-10|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|March 2013|Actual|2013-03-31||Interventional|||A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma|Pharmacokinetic Assessment of PF-00299804 in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Following Administration Through a Gastrojejunostomy Feeding Tube|Completed||N/A|6|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 21:52:43.125064|2018-05-31 21:52:43.125064
NCT01484834|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2015-12-04||2017-05-02|2011-11-30|2011-12-02|Estimate|2017-05-02|2017-08-15|Actual||||2017-05-02|2017-08-15|Actual|August 2011||2011-08-31|May 2017|2017-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Comparison of Interventions to Promote Health in Workers|Comparison of Interventions to Promote Health in Workers: A Cluster Randomized Controled Trial|Completed||N/A|190|Actual|Universidade Metodista de Piracicaba||4|||f||||t||||||||Yes|Data are available when required|2018-05-31 21:52:43.278025|2018-05-31 21:52:43.278025
NCT01484808|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2011-12-01|2011-12-01|2011-12-02|Estimate|||||||2011-12-01|2011-12-02|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Observational|PSADv||The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage|Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage|Unknown status|Not yet recruiting||6600|Anticipated|University Urological Associates Inc.|||||f||||f||||||||||2018-05-31 21:52:44.101366|2018-05-31 21:52:44.101366
NCT01484795|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2011-12-01|2011-12-01|2011-12-02|Estimate|||||||2011-12-01|2011-12-02|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Noninvasive Ventilation in Acute Myocardial Infarction|Non Invasive Ventilation in Acute Myocardial Infarction|Completed||Phase 1|10|Actual|Centro Universitário Augusto Motta||2|||f||||t||||||||||2018-05-31 21:52:44.205805|2018-05-31 21:52:44.205805
NCT01484782|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2015-04-24|2011-12-01|2011-12-02|Estimate|||||||2015-04-24|2015-04-28|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Developing Accessible Telehealth Programs for Hypertensive Patients in Latin America|Developing Accessible Telehealth Programs for Hypertensive Patients in Latin America|Completed||N/A|200|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:52:44.365968|2018-05-31 21:52:44.365968
NCT01484769|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-04-07|2011-12-01|2011-12-02|Estimate|||||||2017-04-07|2017-04-10|Actual|July 2005||2005-07-31|April 2017|2017-04-30|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Observational|H&N||Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells|Method Development and Assessment of the Effects of Tobacco Products on Oral Cavity Cells|Withdrawn|||0|Actual|University of Louisville|||||f||||f||||||Samples With DNA|"~     Tissue samples from patients undergoing elective neck dissection will be collected. Primary~     tumors and adjacent normal tissue from unaffected areas will be collected at the time of~     surgery. All tissue dissection and removal are part of the standard of care for this type of~     surgical procedure. Remaining resected tissue will be used for research.~   "|||2018-05-31 21:52:44.524114|2018-05-31 21:52:44.524114
NCT01484756|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-12-05|2011-11-30|2011-12-02|Estimate|||||||2011-12-05|2011-12-06|Estimate|August 2008||2008-08-31|December 2011|2011-12-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Combined Vitamins and Minerals Decrease Incidence of Upper Respiratory Tract Infections in Older Persons|Combined Vitamins and Minerals Decrease Incidence of Upper Respiratory Tract Infections in Older Persons|Completed||Phase 3|270|Actual|Trisakti University||2|||f||||t||||||||||2018-05-31 21:52:44.657778|2018-05-31 21:52:44.657778
NCT01484743|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2011-12-01|2011-12-01|2011-12-02|Estimate|||||||2011-12-01|2011-12-02|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Observational|PAHEREP||Risk Factors for Morbidity After Parastomal Hernia Repair|Nationwide Prospective Study of Surgical Risk Factors for Poor Outcome After Parastomal Hernia Repair|Completed|||199|Actual|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 21:52:44.802779|2018-05-31 21:52:44.802779
NCT01484730|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2017-09-15|2011-12-01|2011-12-02|Estimate|||||||2017-09-15|2017-09-19|Actual|November 2011||2011-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||A Pilot Study to Evaluate Multi-Spectral Imaging and Laser Speckle Imaging During Vascular Occlusion|A Pilot Study to Evaluate Multi-Spectral Imaging and Laser Speckle Imaging During Vascular Occlusion|Withdrawn|||0|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 21:52:44.864367|2018-05-31 21:52:44.864367
NCT01484717|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-02-16|2011-12-01|2011-12-02|Estimate|||||||2017-02-16|2017-02-20|Actual|January 2012||2012-01-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Interactive Voice Response Technology to Mobilize Contingency Management for Smoking Cessation|Interactive Voice Response Technology to Mobilize Contingency Management for Smoking Cessation|Completed||Phase 2|90|Actual|UConn Health||2|||f||||t|f|f||||||||2018-05-31 21:52:44.923272|2018-05-31 21:52:44.923272
NCT01484704|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2011-12-01|2011-12-01|2011-12-02|Estimate|||||||2011-12-01|2011-12-02|Estimate|February 2011||2011-02-28|November 2011|2011-11-30||||||||Observational|||The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer||Unknown status|Recruiting||100|Anticipated|Turku University Hospital|||2||f||||||||||||||2018-05-31 21:52:45.124398|2018-05-31 21:52:45.124398
NCT01484691|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2018-05-01|2011-11-30|2011-12-02|Estimate|||||||2018-05-01|2018-05-04|Actual|October 2011||2011-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|RITA||Role of microRNAs in T Cell-Driven Inflammation in Asthma|Role of miRNAs in Th2-driven Inflammation in Asthma|Active, not recruiting||N/A|50|Anticipated|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 21:52:45.259025|2018-05-31 21:52:45.259025
NCT01484678|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2018-04-04|2011-11-30|2011-12-02|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2010||2010-05-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy|Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy; The Relationship Between Genomic Variants And MRI/MRS Markers In DMD|Recruiting|||200|Anticipated|University of Florida|||2||f||||f|f|f||||Samples With DNA|"~     Blood and Skin Samples Collected~   "|||2018-05-31 21:52:45.36917|2018-05-31 21:52:45.36917
NCT01484665|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-08-21|2011-11-30|2011-12-02|Estimate|||||||2014-08-21|2014-08-22|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening|Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening|Completed||N/A|72|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 21:52:45.515043|2018-05-31 21:52:45.515043
NCT01484652|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2014-04-11||2016-09-08|2011-11-30|2011-12-02|Estimate|2014-06-30|2014-07-02|Estimate||||2016-09-08|2016-10-21|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional||The analysis population for baseline characteristics includes all 329 subjects who received at least one dose of study treatment. The subjects were assigned 2 cohort classifications. Cohort 1 included 26 subjects enrolled under the original protocol and amendment 1. Cohort 2 is the remainder of the 303 subjects enrolled after amendment 1.|Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension|Completed||Phase 3|329|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 21:52:45.611931|2018-05-31 21:52:45.611931
NCT01484626|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-10-29|2011-11-30|2011-12-02|Estimate|||||||2012-10-29|2012-10-31|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|BVRD||Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma|An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|76|Anticipated|Loyola University||1|||f||||t||||||||||2018-05-31 21:52:46.086013|2018-05-31 21:52:46.086013
NCT01484613|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-11-21|2011-12-01|2011-12-02|Estimate|||||||2014-11-21|2014-11-24|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|EffaceQ||Selected Site Pacing to Avoid Phrenic Nerve Stimulation in Cardiac Resynchronization Patients With Quadripolar Left Ventricular Leads|Effectiveness and Reliability of Selected Site Pacing for Avoidance of Phrenic Nerve Stimulation in CRT Patients With Quadripolar LV Leads|Completed|||337|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 21:52:46.207054|2018-05-31 21:52:46.207054
NCT01484600|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-03-12|2011-12-01|2011-12-02|Estimate|||||||2012-03-12|2012-03-14|Estimate|December 2011||2011-12-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers||Completed||Phase 1|36|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 21:52:46.340983|2018-05-31 21:52:46.340983
NCT01484587|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2017-09-01|2011-11-30|2011-12-02|Estimate|||||||2017-09-01|2017-09-05|Actual|August 22, 2011|Actual|2011-08-22|September 2017|2017-09-30|April 11, 2013|Actual|2013-04-11|April 11, 2013|Actual|2013-04-11||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single Subcutaneous Administration in Japanese Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 1|24|Actual|Janssen Pharmaceutical K.K.||2|||f||||t||f||||||||2018-05-31 21:52:46.426052|2018-05-31 21:52:46.426052
NCT01484574|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2016-09-12|2011-12-01|2011-12-02|Estimate|||||||2016-09-12|2016-09-13|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|February 2014|Actual|2014-02-28||Interventional|||A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease|A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease|Completed||Phase 2|90|Actual|Stempeutics Research Pvt Ltd||3|||f||||t||||||||||2018-05-31 21:52:46.517275|2018-05-31 21:52:46.517275
NCT01484561|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2014-01-11||2014-03-04|2011-11-30|2011-12-02|Estimate|2014-03-04|2014-04-02|Estimate||||2014-03-04|2014-04-02|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis|A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis|Completed||Phase 1|148|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:52:46.692057|2018-05-31 21:52:46.692057
NCT01484548|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-02-24|2011-11-30|2011-12-02|Estimate|||||||2014-02-24|2014-02-26|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|August 2012|Actual|2012-08-31||Interventional|||Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Randomized Clinical Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of The LEISH-F3 + GLA-SE Vaccine Compared To The LEISH-F3 Protein Alone In Healthy Adult Subjects|Completed||Phase 1|36|Actual|IDRI||3|||f||||t||||||||||2018-05-31 21:52:47.828338|2018-05-31 21:52:47.828338
NCT01484535|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2015-07-16|2011-12-01|2011-12-02|Estimate|||||||2015-07-16|2015-07-17|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|February 2014|Actual|2014-02-28||Interventional|||Aspiration for Pain Relief Following Ankle Fracture|Aspiration for Pain Relief Following Ankle Fracture: A Prospective Double-Blind Randomized Controlled Trial|Completed||N/A|130|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:52:47.888582|2018-05-31 21:52:47.888582
NCT01484522|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-11-30|2011-11-30|2011-12-02|Estimate|||||||2011-11-30|2011-12-02|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|September 2010|Actual|2010-09-30|January 2010|Actual|2010-01-31||Observational|||Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth|A Laboratory Study to Assess the Immunogenicity of Three Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-1 Perinatally Infected Children and Youth|Completed|||149|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||3||f||||t||||||||||2018-05-31 21:52:47.951231|2018-05-31 21:52:47.951231
NCT01484509|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2012-05-14|2011-12-01|2011-12-02|Estimate|||||||2012-05-14|2012-05-15|Estimate|June 2011||2011-06-30|November 2011|2011-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Subjective and Objective Methods of Assessing Walking Limitation Due to Claudication|The Estimation of Ambulation Capacity by History Questionnaire (EACH-Q): An Assessment of Its Validity and Inter-day Reproducibility in Patients With Vascular-type Claudication|Completed|||37|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 21:52:48.187327|2018-05-31 21:52:48.187327
NCT01484496|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2017-01-30|2015-06-11|2018-05-24|2011-11-30|2011-12-02|Estimate|2017-07-23|2017-07-25|Actual|2015-06-11|2015-07-09|Estimate|2018-05-24|2018-05-30|Actual|November 16, 2011||2011-11-16|May 2018|2018-05-31|October 1, 2015|Actual|2015-10-01|February 13, 2015|Actual|2015-02-13||Interventional|BLISS-SC||A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 3|839|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:52:48.366404|2018-05-31 21:52:48.366404
NCT01484483|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2018-05-16|2011-11-30|2011-12-02|Estimate|||||||2018-05-16|2018-05-17|Actual|August 8, 2011|Actual|2011-08-08|May 2018|2018-05-31|October 19, 2020|Anticipated|2020-10-19|October 19, 2020|Anticipated|2020-10-19||Observational|||An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya|Breast Cancer Care (BRECC) Registry - Development of a Breast Cancer Registry to Determine the Magnitude of Breast Cancer and Current Clinical Care Patterns in Kenya|Active, not recruiting|||367|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:52:50.175761|2018-05-31 21:52:50.175761
NCT01484470|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-12-14|2011-12-01|2011-12-02|Estimate|||||||2017-12-14|2017-12-18|Actual|January 2010||2010-01-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|January 14, 2014|Actual|2014-01-14||Interventional|||Umbilical Cord Transplantation for the Elderly Population|An Open Label,Double Arm,Single Center Pilot Study to Evaluate the Safety and Efficacy of Transplantation of Either StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded ex Vivo, or an Unmanipulated Cord Blood Unit in the Elderly Population With Hematologic Malignancies Using Reduced Intensity Regimen|Active, not recruiting||Phase 2|18|Actual|Loyola University||2|||f||||t||||||||||2018-05-31 21:52:50.247194|2018-05-31 21:52:50.247194
NCT01484457|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2012-06-05|2011-11-30|2011-12-02|Estimate|||||||2012-06-05|2012-06-07|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Controlled Insulin Delivery: Combining Technology With Treatment|Controlled Insulin Delivery: Combining Technology With Treatment|Completed||Early Phase 1|19|Actual|Sansum Diabetes Research Institute||1|||f||||t||||||||||2018-05-31 21:52:50.319502|2018-05-31 21:52:50.319502
NCT01484444|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-12-04|2011-11-30|2011-12-02|Estimate|||||||2011-12-04|2011-12-06|Estimate|September 2011||2011-09-30|December 2011|2011-12-31||||August 2013|Anticipated|2013-08-31||Observational|||Biomarker Analysis of Gastrointestinal Cancer|Biomarker Analysis of Gastrointestinal Cancer|Unknown status|Recruiting||500|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 21:52:50.514065|2018-05-31 21:52:50.514065
NCT01484431|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-08-16|2011-11-30|2011-12-02|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2012||2012-07-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|April 2017|Actual|2017-04-30||Interventional|||A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension|A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 21:52:50.593932|2018-05-31 21:52:50.593932
NCT01484418|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-09-01|2011-12-01|2011-12-02|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2011||2011-08-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2015|Actual|2015-08-31||Interventional|ETABP||Exposure-based Treatment for Avoidant Back Pain Patients|Exposure Therapy in Chronic Low Back Pain Patients|Completed||N/A|68|Actual|Philipps University Marburg Medical Center||3|||f||||f||||||||||2018-05-31 21:52:50.714897|2018-05-31 21:52:50.714897
NCT01484405|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-11-10|2011-12-01|2011-12-02|Estimate|||||||2014-11-10|2014-11-11|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|THA||Anterolateral Versus Posterior Approach for Total Hip Arthroplasty After Displaced Femoral Neck Fracture|Anterolateral Versus Posterior Approach for Total Hip Arthroplasty After Displaced Femoral Neck Fracture|Terminated||N/A|16|Actual|Florida Orthopaedic Institute||2||Low enrollment.|f||||f||||||||||2018-05-31 21:52:50.812258|2018-05-31 21:52:50.812258
NCT01484392|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2016-03-07|2011-12-01|2011-12-02|Estimate|||||||2016-03-07|2016-03-09|Estimate|August 2006||2006-08-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Determinants of Compliance With Glaucoma Therapy|Determinants of Compliance With Glaucoma Therapy|Completed|||60|Actual|Legacy Health System|||||f||||f||||||||||2018-05-31 21:52:50.897221|2018-05-31 21:52:50.897221
NCT01484379|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2017-08-24|2011-12-01|2011-12-02|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2011||2011-12-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Surgical Approach for Primary Hyperparathyroidism in the Elderly|Surgical Approach for Primary Hyperparathyroidism in the Elderly - a Prospective Study|Withdrawn||N/A|0|Actual|Rambam Health Care Campus||1||difficulties in Recruiting patients|f||||f||||||||||2018-05-31 21:52:50.952242|2018-05-31 21:52:50.952242
NCT01484366|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-11-10|2011-11-30|2011-12-02|Estimate|||||||2014-11-10|2014-11-11|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Forearm Shaft Fractures: Plating of Radius and Ulna Versus Plating of Radius and Nailing of Ulna|Prospective Randomized Trial for Forearm Shaft Fractures: Plating of Radius and Ulna vs. Plating of Radius and Nailing of Ulna|Terminated||N/A|13|Actual|Florida Orthopaedic Institute||2||Low enrollment. Treament no longer used by researchers.|f||||f||||||||||2018-05-31 21:52:51.052899|2018-05-31 21:52:51.052899
NCT01484353|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2015-03-10|2011-12-01|2011-12-02|Estimate|||||||2015-03-10|2015-03-11|Estimate||||March 2015|2015-03-31||||||||Interventional|KPTLCP||Intensive Lifestyle Intervention for Type 2 Diabetics: The KP TLC Pilot|Intensive Lifestyle Intervention for Type 2 Diabetics: The Kaiser Permanente TLC Pilot|Withdrawn||N/A|0|Actual|Kaiser Permanente||1||This study was cancelled.|f||||f||||||||||2018-05-31 21:52:51.125388|2018-05-31 21:52:51.125388
NCT01484340|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-12-21|2011-11-30|2011-12-02|Estimate|||||||2017-12-21|2017-12-26|Actual|March 28, 2014|Actual|2014-03-28|December 2017|2017-12-31|June 30, 2017|Actual|2017-06-30|June 30, 2016|Actual|2016-06-30||Interventional|JHU||A Smoking Cessation Trial in HIV-infected Patients in South Africa|A Smoking Cessation Trial in HIV-infected Patients in South Africa|Completed||N/A|561|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:52:51.19865|2018-05-31 21:52:51.19865
NCT01484327|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2012-08-30|2011-11-30|2011-12-02|Estimate|||||||2012-08-30|2012-08-31|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|CARVEDIA||Carvedilol Vascular Efficacy Trial|Multicentre, Open-label, Non-interventional Observational Clinical Study Lasting 48 Weeks in Patients With Heart Failure or Reduced Left Ventricular Ejection Fraction Following Acute Myocardial Infarction Who Are Treated With Carvedilol|Completed|||415|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 21:52:51.278915|2018-05-31 21:52:51.278915
NCT01484314|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2016-09-23||2017-02-01|2011-11-30|2011-12-02|Estimate|2016-11-16|2016-11-17|Estimate||||2017-02-01|2017-03-15|Actual|April 2012|Actual|2012-04-30|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma|A Phase II Study of Eltrombopag for the Treatment of Thrombocytopenia in Patients Undergoing Therapy for Relapsed Multiple Myeloma|Terminated||Phase 2|1|Actual|Dana-Farber Cancer Institute|The study is limited because it terminated early with only 1 patient enrolled.|1||Low accrual.|f||||t|t|f||||||No||2018-05-31 21:52:51.360418|2018-05-31 21:52:51.360418
NCT01484301|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2013-03-19|2011-12-01|2011-12-02|Estimate|||||||2013-03-19|2013-03-20|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Impact of Tolerability Issues on Chronic Pain|The Impact of Opioid Tolerability Outcomes on the Management of Chronic Pain|Completed|||165|Actual|Janssen-Ortho Inc., Canada|||||f||||f||||||||||2018-05-31 21:52:51.531363|2018-05-31 21:52:51.531363
NCT01484288|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-12-23|2011-12-01|2011-12-02|Estimate|||||||2015-12-23|2015-12-28|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|July 2013|Actual|2013-07-31||Interventional|||Baroreflex Activation Therapy in Heart Failure|Baroreflex Activation Therapy in Heart Failure|Completed||N/A|12|Actual|CVRx, Inc.||1|||f||||t||||||||||2018-05-31 21:52:51.581595|2018-05-31 21:52:51.581595
NCT01484275|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2018-02-01|2011-12-01|2011-12-02|Estimate|||||||2018-02-01|2018-02-05|Actual|March 1, 2012|Actual|2012-03-01|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma|A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma|Active, not recruiting||Phase 2|87|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 21:52:52.841773|2018-05-31 21:52:52.841773
NCT01484262|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2016-11-16|2011-11-30|2011-12-02|Estimate|||||||2016-11-16|2016-11-17|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2|Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2|Completed|||1344|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 21:52:53.008169|2018-05-31 21:52:53.008169
NCT01484249|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-12-02|2011-11-30|2011-12-02|Estimate|||||||2011-12-02|2011-12-05|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Carotid Filtration During Endovascular Aortic Valve Implantation|Carotid Filtration During Endovascular Aortic Valve Implantation|Completed||N/A|38|Actual|Claret Medical|||||f||||t||||||||||2018-05-31 21:52:53.113447|2018-05-31 21:52:53.113447
NCT01484236|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2017-02-22|2011-12-01|2011-12-02|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2012||2012-01-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|RE-LAM-CE||National Lymphangioleiomyomatosis Registry, France|National Lymphangioleiomyomatosis Registry, France|Recruiting|||200|Anticipated|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|||||f||||f||||||||||2018-05-31 21:52:53.234875|2018-05-31 21:52:53.234875
NCT01484223|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-10-10|2011-12-01|2011-12-02|Estimate|||||||2012-10-10|2012-10-11|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Effectiveness of Cognitive Behavioral Intervention in Patients With Symptoms Somatization in Primary Care|Efectiveness of a Cognitive Behavioral Intervention in Patients With Symptoms Somatization, as Measure Quality of Life, Front the Clinical Practice Usual Action in Primary Health Care. A Controlled Clinical Trial With Parallel Groups|Completed||N/A|242|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 21:52:53.346663|2018-05-31 21:52:53.346663
NCT01484210|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2012-08-30|2011-12-01|2011-12-02|Estimate|||||||2012-08-30|2012-08-31|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®|Phase III Therapeutic Evaluation Study Comparing the Efficacy and Safety of the Fluticasone/Salmeterol (500/50 μg) Combination Administered With Elpenhaler® (Rolenium®) Versus the Innovative One (Seretide Diskus®) in Patients With Asthma.|Completed||Phase 3|28|Actual|Elpen Pharmaceutical Co. Inc.||1|||f||||f||||||||||2018-05-31 21:52:53.488782|2018-05-31 21:52:53.488782
NCT01484197|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2013-05-17||2015-03-18|2011-12-01|2011-12-02|Estimate|2013-10-10|2013-12-06|Estimate||||2015-03-18|2015-04-01|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device|A Multi-centre, Randomized, Double-blind, Double-dummy, Multiple-dose, Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered as Either PulmoSphere or Lactose-blend Powder Via the Concept1 Device in Adult Patients With Persistent Asthma|Completed||Phase 2|36|Actual|Novartis||4|||f||||f||||||||||2018-05-31 21:52:53.798264|2018-05-31 21:52:53.798264
NCT01484184|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2015-08-19|2011-11-30|2011-12-02|Estimate|||||||2015-08-19|2015-08-20|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury|Tri-therapy (SPINALON)-Elicited Spinal Locomotor Network Activation: Phase I-IIa Clinical Trial in Patients With Chronic Spinal Cord Injury|Completed||Phase 1/Phase 2|50|Actual|Nordic Life Science Pipeline Inc.||2|||f||||t||||||||||2018-05-31 21:52:55.594777|2018-05-31 21:52:55.594777
NCT01484171|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2016-07-12|2011-12-01|2011-12-02|Estimate|||||||2016-07-12|2016-07-13|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia|HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia|Recruiting||Phase 3|50|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||f||||||||||2018-05-31 21:52:55.791824|2018-05-31 21:52:55.791824
NCT01484158|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2015-01-20|2011-12-01|2011-12-02|Estimate|||||||2015-01-20|2015-01-22|Estimate|October 2001||2001-10-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Gait Speed for Predicting Cardiovascular Events After Myocardial Infarction|Gait Speed for Predicting Cardiovascular Events After Myocardial Infarction|Completed|||450|Actual|Yokohama City University Medical Center|||1||f||||f||||||Samples Without DNA|"~     We retain only blood sample only in this study.~   "|||2018-05-31 21:52:55.967772|2018-05-31 21:52:55.967772
NCT01484145|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-10-18|2011-11-30|2011-12-02|Estimate|||||||2012-10-18|2012-10-19|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Deposition of Terbinafine After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail|An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail|Completed||Phase 2|25|Actual|Nitric BioTherapeutics, Inc||5|||f||||f||||||||||2018-05-31 21:52:56.026405|2018-05-31 21:52:56.026405
NCT01484132|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2015-05-15||2015-07-06|2011-12-01|2011-12-02|Estimate|2015-07-06|2015-07-10|Estimate||||2015-07-06|2015-07-10|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CUBS|98 of 101 subjects who had the pre-treatment urine sample completed the baseline interview. Therefore, 98 subjects were included in the baseline analysis.|Composites and Urinary Bisphenol-A Study|Health Effects of Dental Composites in Children|Completed||N/A|113|Actual|New England Research Institutes||1|||f||||f||||||||||2018-05-31 21:52:56.123682|2018-05-31 21:52:56.123682
NCT01484119|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29||2013-03-27|2013-03-27|2011-12-01|2011-12-02|Estimate||||2013-03-27|2013-04-04|Estimate|2013-03-27|2013-04-04|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|SAR||Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis|Multi-center, Double-blind, Double-dummy, Randomized, Placebo-controlled, Active-reference, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-129968 in Adolescent, Adult & Elderly Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|630|Actual|Actelion||3|||f||||f||||||||||2018-05-31 21:52:56.410753|2018-05-31 21:52:56.410753
NCT01484106|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2016-02-16|2011-11-30|2011-12-02|Estimate|||||||2016-02-16|2016-02-17|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|COMMIT||Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis|Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis|Completed||N/A|65|Actual|Cheetah Medical Inc.||2|||f||||f||||||||||2018-05-31 21:52:56.50737|2018-05-31 21:52:56.50737
NCT01484093|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2017-09-07|2011-11-30|2011-12-02|Estimate|||||||2017-09-07|2017-09-08|Actual|November 2011||2011-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma|Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma: A Phase I/II Trial|Active, not recruiting||Phase 1/Phase 2|96|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:52:56.597213|2018-05-31 21:52:56.597213
NCT01484080|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-04-15|2011-11-30|2011-12-02|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates|Phase I/II Randomized Clinical Trial of Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates|Completed||Phase 1/Phase 2|140|Actual|Centro Nacional de Investigaciones Oncologicas CARLOS III||2|||f||||t||||||||||2018-05-31 21:52:56.698265|2018-05-31 21:52:56.698265
NCT01484067|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2012-09-27|2011-12-01|2011-12-02|Estimate|||||||2012-09-27|2012-10-01|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of a Cold Sore Patch for the Treatment of Herpes Labialis|A Randomized, Clinician-Blind, Clinical Study to Examine the Safety and Performance of Compeed© Total Care™ Cold Sore Patch With Zinc Sulfate for the Treatment of Herpes Labialis|Completed||N/A|472|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 21:52:56.781006|2018-05-31 21:52:56.781006
NCT01484054|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2013-08-30||2015-05-05|2011-12-01|2011-12-02|Estimate|2013-12-04|2014-01-20|Estimate||||2015-05-05|2015-05-21|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Baseline summary was conducted on all enrolled subjects who received study lenses.|Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens|Dispensing Evaluation of Lens Comfort and Subjective Vision of an Etafilcon A With Print and PVP Lens for Dark Eyes|Completed||N/A|103|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 21:52:56.894734|2018-05-31 21:52:56.894734
NCT01484041|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2016-03-10||2018-01-15|2011-12-01|2011-12-02|Estimate|2016-08-01|2016-09-20|Estimate||||2018-01-15|2018-02-09|Actual|April 2012||2012-04-30|November 2015|2015-11-30|December 2017|Actual|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer|A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|12|Actual|Georgetown University||1||Decision by company to cease development of dovitinib|f||||t||||||||No|Will not be reporting outcome data as study closed by sponsor prior to completing accrual. Will be reporting aggregate findings for correlative science project|2018-05-31 21:52:57.240787|2018-05-31 21:52:57.240787
NCT01484028|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2013-08-30||2015-05-05|2011-11-30|2011-12-02|Estimate|2013-08-30|2013-11-15|Estimate||||2015-05-05|2015-05-21|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Baseline summary was conducted on all randomized subjects who worn at least one pair of study lenses.|Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens|Clinical Validation of Etafilcon A With Print and PVP Contact Lenses for Dark Eyes and Light Eyes|Completed||N/A|275|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||f||||||||||2018-05-31 21:52:57.524111|2018-05-31 21:52:57.524111
NCT01484015|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-05-25|2011-11-30|2011-12-02|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2011||2011-02-28|July 2013|2013-07-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia|Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study|Completed||Phase 1|70|Actual|Wake Forest University Health Sciences||2|||f||||f|t|f||||||||2018-05-31 21:52:57.848161|2018-05-31 21:52:57.848161
NCT01484002|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-01-23|2011-11-30|2011-12-02|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Analysis of Crosslinked and Conventional Polyethylene Explants|Collaborative Analysis of UHMWPE Explants: Conventional UHMWPE With No Radiation and Marathon|Enrolling by invitation|||60|Anticipated|Anderson Orthopaedic Research Institute|||2||f||||f||||||||||2018-05-31 21:52:57.962639|2018-05-31 21:52:57.962639
NCT01483989|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-11-17|2011-11-30|2011-12-02|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||In Vivo Measurement of Corneal Epithelial Changes in Dry Eye Patients|In Vivo Measurement of Corneal Epithelial Changes in Dry Eye(DE) Patients|Completed||N/A|19|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:52:58.093564|2018-05-31 21:52:58.093564
NCT01483976|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-01-30|2011-11-30|2011-12-02|Estimate|||||||2013-01-30|2013-01-31|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Comparison of Medical Nutritional Supplements|Comparison of Medical Nutritional Supplements With or Without AN777 in Elderly Men|Completed||Phase 3|27|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 21:52:58.176245|2018-05-31 21:52:58.176245
NCT01483963|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2017-04-18|2015-03-17|2017-09-07|2011-12-01|2011-12-02|Estimate|2017-04-18|2017-05-25|Actual|2015-03-17|2015-04-03|Estimate|2017-09-07|2017-10-05|Actual|November 2011||2011-11-30|September 2017|2017-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder|A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder|Completed||Phase 2|50|Actual|Endo Pharmaceuticals||5|||f||||f||||||||||2018-05-31 21:52:58.320371|2018-05-31 21:52:58.320371
NCT01483950|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2013-02-04|2011-12-01|2011-12-02|Estimate|||||||2013-02-04|2013-02-05|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values|Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors in Bosnia and Herzegovina|Completed|||800|Actual|AstraZeneca|||1||f||||t||||||||||2018-05-31 21:52:59.608593|2018-05-31 21:52:59.608593
NCT01483937|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2013-08-19||2014-06-26|2011-11-30|2011-12-02|Estimate|2014-06-26|2014-06-27|Estimate||||2014-06-26|2014-06-27|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|SEMD|4 withdrew from Conventional care physical therapy 3 withdrew from Conventional care physical therapy plus SEMD|Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium|Clinical Trial Evaluation of a Sensory Enrichment Multimodal Device (SEMD) on Physical Therapy Patients With Disequilibrium|Completed||N/A|32|Actual|BalanceSense LLC|Small number of subjects recruited because of lengthy study commitment.|2|||f||||f||||||||||2018-05-31 21:52:59.695254|2018-05-31 21:52:59.695254
NCT01483924|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2015-01-20||2015-02-09|2011-11-30|2011-12-02|Estimate|2015-02-09|2015-02-20|Estimate||||2015-02-09|2015-02-20|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional||A total of 60 patients were enrolled. No formal sample size calculation for this study was done, as this study was an exploratory study with main objective to assess the safety and tolerability of Apo805K1.|Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|60|Actual|ApoPharma||4|||f||||t||||||||||2018-05-31 21:53:00.451432|2018-05-31 21:53:00.451432
NCT01483911|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2013-02-26|2011-11-30|2011-12-02|Estimate|||||||2013-02-26|2013-02-27|Estimate|December 2011||2011-12-31|October 2012|2012-10-31||||May 2012|Actual|2012-05-31||Interventional|||ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers|Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Ablynx||2|||f||||t||||||||||2018-05-31 21:53:01.592113|2018-05-31 21:53:01.592113
NCT01483898|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30||2016-06-23|2017-05-31|2011-12-01|2011-12-02|Estimate||||2016-06-27|2016-06-29|Estimate|2017-05-31|2017-06-06|Actual|February 2012||2012-02-29|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|REVIVE||An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization|Completed||Phase 3|41|Actual|Vericel Corporation||2|||f||||t||||||||No||2018-05-31 21:53:01.713296|2018-05-31 21:53:01.713296
NCT01483885|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-11-29|2011-11-29|2011-12-02|Estimate|||||||2011-11-29|2011-12-02|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of the Analgesic Effects of Acupuncture and Modulated Electroanalgesia in Cold Induced Pain|Comparison of the Analgesic Effects of Acupuncture and Modulated Electroanalgesia in Cold Induced Pain.|Completed||Phase 1/Phase 2|82|Actual|Universidade Federal do Piauí||7|||f||||t||||||||||2018-05-31 21:53:01.948907|2018-05-31 21:53:01.948907
NCT01483872|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2015-10-06|2011-11-29|2011-12-02|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections|Phase II Trial of a Novel Catheter Lock Solution For Adjunctive Treatment of Hemodialysis Catheter-Associated Bacteremia.|Terminated||Phase 3|9|Actual|University of California, San Diego||2||The study was stopped due to poor enrollment.|f||||t||||||||||2018-05-31 21:53:02.067498|2018-05-31 21:53:02.067498
NCT01483859|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-07-14|2011-11-29|2011-12-01|Estimate|||||||2015-07-14|2015-07-16|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Prediction of Intraoperative Blood Loss and Postoperative Recovery by Liver Stiffness Measurement (Fibroscan®) in Right Hepatectomy|Prediction of Intraoperative Blood Loss and Postoperative Recovery by Liver Stiffness Measurement (Fibroscan®) in Right Hepatectomy|Completed||N/A|45|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 21:53:02.135151|2018-05-31 21:53:02.135151
NCT01483846|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-12-18|2011-11-29|2011-12-01|Estimate|||||||2012-12-18|2012-12-20|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers|A Phase 1b, Single-Site, Randomized, Double-Blind,Placebo-Controlled, Dose-Escalation Study: Safety, Pharmacokinetics, and Antihyperalgesic Activity of Multiple Doses of AV-101 on Capsaicin-Induced Pain in Healthy Volunteers|Completed||Phase 1|50|Actual|VistaGen Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 21:53:02.202998|2018-05-31 21:53:02.202998
NCT01483833|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2013-08-19|2011-11-29|2011-12-01|Estimate|||||||2013-08-19|2013-08-21|Estimate|September 2001||2001-09-30|November 2011|2011-11-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Efficacy Study of Iferanserin to Treat Hemorrhoids|Protocol for the Study of the Effects of S-MPEC (Iferanserin) in Patients With Hemorrhoids|Completed||Phase 2|121|Actual|Ventrus Biosciences, Inc||2|||f||||f||||||||||2018-05-31 21:53:02.366975|2018-05-31 21:53:02.366975
NCT01483820|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2016-05-10||2016-09-09|2011-11-29|2011-12-01|Estimate|2016-09-09|2016-10-28|Estimate||||2016-09-09|2016-10-28|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma|A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma|Terminated||Phase 1/Phase 2|8|Actual|Spectrum Health Hospitals||1||Lack of enrollment|f||||t||||||||||2018-05-31 21:53:02.610414|2018-05-31 21:53:02.610414
NCT01483807|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2018-02-01|2011-11-29|2011-12-01|Estimate|||||||2018-02-01|2018-02-05|Actual|August 1, 2011|Actual|2011-08-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|January 31, 2017|Actual|2017-01-31||Interventional|Apraxia||Treatments of Acquired Apraxia of Speech|Treatments of Acquired Apraxia of Speech|Active, not recruiting||N/A|24|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 21:53:02.893527|2018-05-31 21:53:02.893527
NCT01483794|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-11-30|2011-11-30|2011-12-01|Estimate|||||||2011-11-30|2011-12-01|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Observational|||Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile|Genital Warts: Studies for Establishing Epidemiological Profile, Psychosocial Consequences and Costs of Disease in Attendants to the Sexual Health Clinic of the Public Health Service of Valparaiso and San Antonio, Chile.|Unknown status|Not yet recruiting||60|Anticipated|Universidad de Valparaiso|||2||f||||f||||||||||2018-05-31 21:53:02.987648|2018-05-31 21:53:02.987648
NCT01483781|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2014-08-19|2011-11-30|2011-12-01|Estimate|||||||2014-08-19|2014-08-20|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Groups Study to Investigate the Effects of JNJ-28431754 (Canagliflozin) on Plasma Volume and Renal Function in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|36|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 21:53:03.076341|2018-05-31 21:53:03.076341
NCT01483768|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2018-04-03|2011-11-30|2011-12-01|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 25, 2012|Actual|2012-09-25|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|FORBES||Study of Sleeve Gastrectomy on Iron Intestinal Absorption in Morbidly Obese Patients|Evaluation of the Impact of Bariatric Surgery by Sleeve Gastrectomy on Iron Intestinal Absorption in Morbidly Obese Patients|Completed||N/A|88|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||Undecided||2018-05-31 21:53:03.151801|2018-05-31 21:53:03.151801
NCT01483755|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2013-07-26|2011-11-30|2011-12-01|Estimate|||||||2013-07-26|2013-07-29|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PRIME||Delayed Postconditioning|Delayed Angioplasty Postconditioning in STEMI Patients|Completed||Phase 2|72|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:53:03.273763|2018-05-31 21:53:03.273763
NCT01483742|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30||2016-07-20|2016-07-28|2011-11-30|2011-12-01|Estimate||||2016-07-20|2016-07-22|Estimate|2016-07-28|2016-08-01|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis|A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR and RO5024048 in Different Combinations in Null Responder or Treatment Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis|Completed||Phase 2|43|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:53:03.35402|2018-05-31 21:53:03.35402
NCT01483729|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2016-11-01|2011-11-30|2011-12-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers||Completed||Phase 1|36|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 21:53:03.475646|2018-05-31 21:53:03.475646
NCT01483716|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2015-08-16|2011-11-30|2011-12-01|Estimate|||||||2015-08-16|2015-08-18|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||A Trial of Rehabilitation in Obesity Hypoventilation Syndrome (OHS)||Completed||N/A|37|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||||||||||||2018-05-31 21:53:03.562267|2018-05-31 21:53:03.562267
NCT01483703|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2017-02-08|2011-11-29|2011-12-01|Estimate|||||||2017-02-08|2017-02-10|Actual|May 2010||2010-05-31|February 2017|2017-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Noninvasive Optical Measurement of Critical Care Neonates|Noninvasive Optical Measurement of Critical Care Neonates|Completed|||6|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 21:53:03.625994|2018-05-31 21:53:03.625994
NCT01483690|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-11-20|2011-11-30|2011-12-01|Estimate|||||||2015-11-20|2015-11-24|Estimate|December 2011||2011-12-31|September 2015|2015-09-30||||June 2015|Actual|2015-06-30||Interventional|||A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL|A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL|Terminated||Phase 1/Phase 2|23|Actual|Therapeutic Advances in Childhood Leukemia Consortium||||Toxicity|f||||t||||||||||2018-05-31 21:53:03.692846|2018-05-31 21:53:03.692846
NCT01483677|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2011-11-30|2011-11-30|2011-12-01|Estimate|||||||2011-11-30|2011-12-01|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Comparison Study of the Nintendo Wii Versus Playstation2 in Enhancing Laparoscopic Skills|Is Nintendo Wii a More Suitable Video Game Platform Than Playstation 2 for Enhancing Laparoscopic Skills?|Completed||Early Phase 1|42|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 21:53:03.811387|2018-05-31 21:53:03.811387
NCT01483664|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2017-10-03|2011-11-30|2011-12-01|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2011||2011-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Communication Skills Intervention to Promote Transition Into Survivorship|Communication Skills Intervention to Promote Transition Into Survivorship|Active, not recruiting|||314|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||t||||||||||2018-05-31 21:53:03.90907|2018-05-31 21:53:03.90907
NCT01483651|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2014-09-08||2016-03-01|2011-11-30|2011-12-01|Estimate|2014-09-17|2014-09-22|Estimate||||2016-03-01|2016-03-29|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Physiologic Response to Glucagon at Varying Insulin Levels|The Hepatic Glucose Response to Glucagon at Varying Insulin Levels: Implications for Closed Loop Glycemic Control.|Completed||N/A|11|Actual|Legacy Health System||6|||f||||t||||||||||2018-05-31 21:53:04.050336|2018-05-31 21:53:04.050336
NCT01483638|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-05-11|2011-11-30|2011-12-01|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|TTD-11-01||Axitinib as Maintenance Treatment in Patients With Metastatic CRC|A Phase II Study of Axitinib as Maintenance Treatment for Patients With Metastatic Colorectal Carcinoma|Terminated||Phase 2|84|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2||The trial was prematurely closed due to lack of accrual|f||||f||||||||||2018-05-31 21:53:04.341484|2018-05-31 21:53:04.341484
NCT01483625|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|2013-12-23||2014-06-03|2011-11-30|2011-12-01|Estimate|2014-03-05|2014-04-10|Estimate||||2014-06-03|2014-06-09|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection|A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Patients With Newly Diagnosed and/or Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection (TICARI 1: Tiotropium In COPD Patients With an Acute Respiratory Infection 1)|Completed||Phase 4|140|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:53:04.452697|2018-05-31 21:53:04.452697
NCT01483612|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2016-10-24|2011-11-29|2011-12-01|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|OF||Evaluation of Clinical Outcomes and Costs of a Lifestyle Intervention in Obese Infertile Women|"Evaluation of Clinical Outcomes and Costs of a Transferable Interdisciplinary Lifestyle Intervention Pre- and Per-pregnancy in Obese Infertile Women"|Active, not recruiting||N/A|130|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 21:53:04.876874|2018-05-31 21:53:04.876874
NCT01483599|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2017-07-05|2013-10-16|2017-07-05|2011-11-29|2011-12-01|Estimate|2017-07-05|2017-08-02|Actual|2013-11-14|2013-12-06|Estimate|2017-07-05|2017-08-02|Actual|November 10, 2011|Actual|2011-11-10|July 2017|2017-07-31|August 5, 2013|Actual|2013-08-05|November 27, 2012|Actual|2012-11-27||Interventional|X-PLORE|Population analyzed included all participants who were randomized.|A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis|A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)|Completed||Phase 2|293|Actual|Janssen Inc.||7|||f||||t||f||||||||2018-05-31 21:53:04.99091|2018-05-31 21:53:04.99091
NCT01483586|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-04-11|2011-11-29|2011-12-01|Estimate|||||||2014-04-11|2014-04-14|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer|Efficacy and Safety of Oral Kanglaite (KLTc)in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy|Terminated||Phase 2|90|Actual|KangLaiTe USA||2||Sponsor decision|f||||t||||||||||2018-05-31 21:53:06.494901|2018-05-31 21:53:06.494901
NCT01483573|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2016-03-21|2011-11-30|2011-12-01|Estimate|||||||2016-03-21|2016-03-22|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Hamstring Stretching and Neural Mobilization on Range of Motion and Low Back Pain|Effect of Hamstring Stretching and Neural Mobilization on Range of Motion and Low Back Pain|Terminated||N/A|25|Actual|Rutgers, The State University of New Jersey||2||Insufficient recruitment over time|f||||f||||||||||2018-05-31 21:53:06.599213|2018-05-31 21:53:06.599213
NCT01483560|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-04-25|2011-11-30|2011-12-01|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2011||2011-12-31|April 2017|2017-04-30|April 18, 2017|Actual|2017-04-18|March 19, 2017|Actual|2017-03-19||Interventional|REMOVAL||REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)|Phase 3 Study of Metformin in Adults With Type 1 Diabetes|Completed||Phase 3|502|Actual|University of Glasgow||2|||f||||t||||||||Yes|Site specific participant data will be made available to the site PIs later in 2017, after the main publications.|2018-05-31 21:53:06.719092|2018-05-31 21:53:06.719092
NCT01483547|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2013-02-15|2011-11-29|2011-12-01|Estimate|||||||2013-02-15|2013-02-18|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Reliability of BIS Monitoring in Neurosurgical Patients|Reliability of Bispectral Index for Depth of Anesthesia Monitoring in Neurosurgical Patients|Completed|||405|Actual|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|||2||f||||t||||||||||2018-05-31 21:53:06.881162|2018-05-31 21:53:06.881162
NCT01483534|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-09-22|2011-11-30|2011-12-01|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2013|Actual|2013-11-30||Interventional|IPS-I||Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation|Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study|Completed||Phase 1|22|Actual|Nuvaira, Inc.||1|||f||||t||||||||||2018-05-31 21:53:06.976024|2018-05-31 21:53:06.976024
NCT01483521|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-11-30|2011-11-30|2011-12-01|Estimate|||||||2011-11-30|2011-12-01|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Infant Psychiatry Home Visitation Program|Externalizing Behavior in Early Childhood: A Randomized Control Evaluation of a Home Visitation Program|Completed||N/A|40|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 21:53:07.068192|2018-05-31 21:53:07.068192
NCT01483508|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-10-23|2011-11-29|2011-12-01|Estimate|||||||2012-10-23|2012-10-25|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Absorption and Metabolism of Dietary Cocoa Procyanidins in Humans|Contribution of Dietary Cocoa Procyanidins to the Systemic Presence of Flavanols Metabolites in Humans|Completed||N/A|12|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 21:53:07.157976|2018-05-31 21:53:07.157976
NCT01483495|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-02-08|2011-11-30|2011-12-01|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2011||2011-12-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|DOSI||Assessing Cerebrovascular Reactivity Based on Cerebral Oximetry: a Pilot Study|Assessing Cerebrovascular Reactivity Based on Cerebral Oximetry|Completed|||78|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 21:53:07.243386|2018-05-31 21:53:07.243386
NCT01483482|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-03-15|2011-11-30|2011-12-01|Estimate|||||||2016-03-15|2016-03-17|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Treatment of Displaced, Midshaft Clavicle Fractures. Sling or Plate?|Treatment of Displaced, Midshaft Clavicle Fractures. Sling or Plate?|Unknown status|Active, not recruiting|N/A|120|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 21:53:07.308296|2018-05-31 21:53:07.308296
NCT01483469|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-11-01|2011-11-29|2011-12-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers|Human Proof of Concept Positron Emission Tomography Study to Investigate [11C]-RO5011232 as a Radiotracer for Brain mGlu5 Receptor Occupancy and to Investigate the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-state.|Completed||Phase 1|56|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:53:07.37775|2018-05-31 21:53:07.37775
NCT01483456|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-09-16|2011-11-30|2011-12-01|Estimate|||||||2014-09-16|2014-09-17|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|IPR||Impact of Multidisciplinary Program on Falls in Elderly Inpatients|"A Multidisciplinary Program for Preventing Falls Identify, Prevent and Get up: Impact on Falls in Elderly Inpatients"|Unknown status|Active, not recruiting|N/A|1852|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 21:53:07.4478|2018-05-31 21:53:07.4478
NCT01483443|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-08-28|2011-11-30|2011-12-01|Estimate|||||||2015-08-28|2015-09-01|Estimate|August 2008||2008-08-31|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|||Oophorectomy Followed by Chemotherapy Versus Chemotherapy Alone in Colorectal Cancer Patients|Prophylactic Oophorectomy Followed by Chemotherapy Versus Chemotherapy Alone in Colorectal Patients With or Without Ovarian Metastasis|Completed||Phase 3|140|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 21:53:07.5321|2018-05-31 21:53:07.5321
NCT01483092|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-06-06|2011-11-29|2011-12-01|Estimate|||||||2013-06-06|2013-06-07|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Effect of Inulin on Iron Absorption in Humans|Inulin Modifies Gut Microbiota, Fecal Lactate Concentration and Fecal pH But Does Not Influence Iron Absorption in Women With Low Iron Status|Completed||N/A|32|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 21:53:17.863931|2018-05-31 21:53:17.863931
NCT01483430|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2011-11-30|2011-11-29|2011-12-01|Estimate|||||||2011-11-30|2011-12-02|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Effect of Ginseol Kg1 on Blood Pressure Lowering|Effect of Ginseol Kg1 on Blood Pressure Lowering in Prehypertensive or Stage I Hypertensive Patients: Multicenter, Randomized, Placebo-controlled, Double-blind Study|Unknown status|Recruiting|Phase 3|90|Anticipated|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 21:53:07.611635|2018-05-31 21:53:07.611635
NCT01483417|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2012-02-20|2011-11-29|2011-12-01|Estimate|||||||2012-02-20|2012-02-22|Estimate|December 2011||2011-12-31|November 2011|2011-11-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy|Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis|Unknown status|Recruiting|Phase 3|240|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:53:07.690093|2018-05-31 21:53:07.690093
NCT01483404|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2012-11-09|2011-11-29|2011-12-01|Estimate|||||||2012-11-09|2012-11-12|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Observational|MicroFemNeck||Identification of the Microcirculation of the Caput Femoris After Fracture of the Femoral Neck|Identification of Microcirculation in Fracture of the Femural Neck: How Does the Intracapsular Hematoma Affect the Capillary Bloodflow in the Caput Femoris?|Withdrawn|||0|Actual|RWTH Aachen University|||1||f||||t||||||||||2018-05-31 21:53:07.890756|2018-05-31 21:53:07.890756
NCT01483391|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2016-04-19|2011-11-30|2011-12-01|Estimate|||||||2016-04-19|2016-04-21|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Early Intervention for Youth at Risk for Bipolar Disorder|Early Intervention for Youth at Risk for Bipolar Disorder|Unknown status|Recruiting|Phase 2/Phase 3|150|Anticipated|University of California, Los Angeles||2|||f||||t||||||||Yes|Upon completing the study we will submit a CD-ROM to the NIH Freedom of Information Act Coordinator containing all raw data, variable coding information, and copies of measures. Prior to archiving the data, we will remove all personal identifiers and other protected information. The youth's and parents' consent forms will make clear that the data, minus any identifying information, will be made available to other researchers at the end of the study.|2018-05-31 21:53:07.955049|2018-05-31 21:53:07.955049
NCT01483378|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2013-02-19||2013-08-07|2011-11-30|2011-12-01|Estimate|2013-08-07|2013-08-09|Estimate||||2013-08-07|2013-08-09|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||170 patients were enrolled in the study, however 2 met FDA contraindications for herpes zoster vaccination and 2 already received the vaccine, so only 166 were included in the analysis.|Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital|Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital|Completed||N/A|170|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 21:53:08.077417|2018-05-31 21:53:08.077417
NCT01483365|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-06-15|2011-11-30|2011-12-01|Estimate|||||||2014-06-15|2014-06-17|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Need for Luteal Support in NC-FET|The Use of Luteal Support After NC-FET|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Wolfson Medical Center|||||f||||t||||||||||2018-05-31 21:53:08.217371|2018-05-31 21:53:08.217371
NCT01483352|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2015-04-24||2016-03-16|2011-11-30|2011-12-01|Estimate|2016-02-04|2016-03-03|Estimate||||2016-03-16|2016-04-15|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All participants who received the implant were included in analysis.|Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes|Evaluation of Accu-Chek DiaPort, a Port System for Continuous Intraperitoneal Insulin Infusion, in Patients With Type I Diabetes|Completed||N/A|12|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:53:08.353056|2018-05-31 21:53:08.353056
NCT01483339|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2017-10-05|2011-11-30|2011-12-01|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2011||2011-11-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Metacognitive Therapy for Patients With Obsessive-Compulsive Disorder|Metacognitive Therapy Versus Exposition With Response Prevention for Patients With Obsessive-Compulsive Disorder|Completed||N/A|37|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-05-31 21:53:10.261475|2018-05-31 21:53:10.261475
NCT01483326|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-05-10|2011-11-30|2011-12-01|Estimate|||||||2018-05-10|2018-05-11|Actual|December 31, 2010|Actual|2010-12-31|May 2018|2018-05-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Observational|||An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)|FAct: A Non-interventional Multi-center Study to Follow Patients Starting With RoActemra Assessing the Long Term Efficacy, Effectiveness and Safety of RoActemra|Completed|||215|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:53:10.385002|2018-05-31 21:53:10.385002
NCT01483313|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-02-09|2011-11-29|2011-12-01|Estimate|||||||2014-02-09|2014-02-11|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Observational|||Intelligence Changes Following Minor Surgery|Intelligence Performance in Adolescence After Early Exposure to Anesthesia and Minor Surgery|Withdrawn|||0|Actual|RenJi Hospital||||No patients enrolled.|f||||t||||||||||2018-05-31 21:53:10.563959|2018-05-31 21:53:10.563959
NCT01483300|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2012-01-22|2011-11-29|2011-12-01|Estimate|||||||2012-01-22|2012-01-24|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|November 2014|Anticipated|2014-11-30|August 2014|Anticipated|2014-08-31||Interventional|||Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer||Unknown status|Recruiting|Phase 2|80|Anticipated|Harbin Medical University||2|||f||||t||||||||||2018-05-31 21:53:10.761196|2018-05-31 21:53:10.761196
NCT01483287|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-11-17|2011-11-29|2011-12-01|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in Irritable Bowel Syndrome (IBS)|The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in IBS|Completed||Early Phase 1|20|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||||||||||||2018-05-31 21:53:11.081645|2018-05-31 21:53:11.081645
NCT01483274|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-05-08|2011-11-30|2011-12-01|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2015||2015-03-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AML||Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation|Pharmacologic Upregulation of Cancer Testis Antigens Followed by Vaccine Therapy for Patients With Relapsed Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation|Withdrawn||Phase 1|0|Actual|University of Louisville||2||Adult patient population barriers.|f||||t||||||||||2018-05-31 21:53:11.326277|2018-05-31 21:53:11.326277
NCT01483261|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2011-12-01|2011-11-29|2011-12-01|Estimate|||||||2011-12-01|2011-12-02|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||An RCT of Trauma Focused-Cognitive Behavioral Therapy With Sexually Exploited, War-affected Girls in the DRC|Is Trauma-Focused Cognitive Behavioral Therapy Effective in Reducing Post-traumatic Stress and Psychosocial Distress Among Sexually Exploited, War-affected Girls in the Democratic Republic of Congo.|Completed||Phase 2|60|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 21:53:11.716756|2018-05-31 21:53:11.716756
NCT01483248|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2012-06-06|2011-11-29|2011-12-01|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|October 2015|Anticipated|2015-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis|Phase 1/2 Study of Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation for the Evaluation of the Efficacy and Safety in Patients With Liver Cirrhosis|Unknown status|Enrolling by invitation|Phase 1/Phase 2|50|Anticipated|S-Evans Biosciences Co.,Ltd.||2|||f||||t||||||||||2018-05-31 21:53:11.856466|2018-05-31 21:53:11.856466
NCT01483235|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2011-12-01|2011-11-30|2011-12-01|Estimate|||||||2011-12-01|2011-12-02|Estimate|September 2006||2006-09-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|rCRP||Reduced Cardiac Rehabilitation Program|Design, Implementation and Evaluation of a Reduced Cardiac Rehabilitation Program|Completed||N/A|118|Actual|Simon Fraser University||2|||f||||f||||||||||2018-05-31 21:53:11.991719|2018-05-31 21:53:11.991719
NCT01483222|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2014-10-14|2011-11-29|2011-12-01|Estimate|||||||2014-10-14|2014-10-15|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Inelastic and Elastic Lumbosacral Orthoses on Low Back Pain Prevention in Hospital Nurses|Comparison of Inelastic and Elastic Lumbosacral Orthoses on Low Back Pain Prevention in Hospital Nurses|Completed||N/A|300|Actual|Central South University||3|||f||||t||||||||||2018-05-31 21:53:12.129781|2018-05-31 21:53:12.129781
NCT01483209|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2015-02-16||2015-02-16|2011-11-30|2011-12-01|Estimate|2015-02-16|2015-03-02|Estimate||||2015-02-16|2015-03-02|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A|Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A|Terminated||N/A|2|Actual|Duke University|Due to low accrual for this study we were unable to perform any data analysis.|1||Low accrual|f||||t||||||||||2018-05-31 21:53:12.373994|2018-05-31 21:53:12.373994
NCT01483196|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-05-25|2011-11-29|2011-12-01|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2012|Actual|2012-01-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery|Feasibility Study of Vascular and Cognitive Assessments During Adjuvant Chemotherapy for Breast Cancer (VASCOG)|Completed||N/A|30|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 21:53:12.634382|2018-05-31 21:53:12.634382
NCT01483183|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2016-10-04||2017-02-24|2011-11-30|2011-12-01|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|November 2011||2011-11-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CADENCE 215||Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation|A Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects With Paroxysmal and Persistent Atrial Fibrillation|Terminated||Phase 1|40|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The trial was terminated after Part 1 enrollment completed. It did not progress due to many factors including slow enrollment, limited site activity in pre-screening, absence of reproducible efficacy signal and increased costs.|4||Enrollment Difficulty|f||||f||||||||||2018-05-31 21:53:12.862391|2018-05-31 21:53:12.862391
NCT01483170|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2017-03-29|2011-11-30|2011-12-01|Estimate|||||||2017-03-29|2017-03-31|Actual|September 2011||2011-09-30|March 2017|2017-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food|Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers.|Terminated||Phase 1|30|Actual|Drugs for Neglected Diseases||2||poor tolerability at highest dose|f||||||||||||Undecided||2018-05-31 21:53:14.532716|2018-05-31 21:53:14.532716
NCT01483157|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-02-27|2011-11-30|2011-12-01|Estimate|||||||2014-02-27|2014-02-28|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Vascular Occlusion and Rheumatoid Arthritis|Effects of Strength Training With Vascular Occlusion in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|30|Anticipated|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 21:53:14.849354|2018-05-31 21:53:14.849354
NCT01483144|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2017-08-01|2011-11-30|2011-12-01|Estimate|||||||2017-08-01|2017-08-03|Actual|October 2013||2013-10-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)|Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis|Active, not recruiting||Phase 3|171|Actual|Cancer Prevention Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 21:53:15.162566|2018-05-31 21:53:15.162566
NCT01483131|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-02-27|2011-11-30|2011-12-01|Estimate|||||||2014-02-27|2014-02-28|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|November 2013|Actual|2013-11-30||Interventional|||Vascular Occlusion in Patients With Osteoarthritis|Effects of Strength Training Associated With Vascular Occlusion in Patients With Knee Osteoarthritis|Unknown status|Recruiting|N/A|45|Anticipated|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 21:53:15.584996|2018-05-31 21:53:15.584996
NCT01483118|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2016-05-26||2017-09-05|2011-11-30|2011-12-01|Estimate|2017-07-07|2017-08-02|Actual||||2017-09-05|2017-10-03|Actual|March 2011||2011-03-31|June 2017|2017-06-30|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|||Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)|The Effects of Oral Cinnamon Extract on Menstrual Cyclicity in PolyCystic Ovary Syndrome|Completed||Phase 3|45|Actual|Columbia University|High percentage of patients lost to follow up|2|||f||||t||||||||Undecided||2018-05-31 21:53:15.946837|2018-05-31 21:53:15.946837
NCT01483105|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-05-02|2011-11-29|2011-12-01|Estimate|||||||2017-05-02|2017-05-04|Actual|October 2011||2011-10-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|VCUG||DVD-Based Training Program in Self-Hypnosis for Children|DVD-Based Training Program in Self-Hypnosis for Children: A Randomized Clinical Trial|Recruiting||N/A|56|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 21:53:17.472199|2018-05-31 21:53:17.472199
NCT01483079|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-05-14|2011-11-29|2011-12-01|Estimate|||||||2018-05-14|2018-05-15|Actual|December 2011||2011-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|NICU||Post-Discharge Growth of Infants Who Received Donor Human Milk Products in the Neonatal Intensive Care Unit (NICU)|Evaluation of Post-Discharge Growth and Development of Infants Who Received Donor Human Milk Products in the NICU|Enrolling by invitation|||80|Anticipated|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 21:53:18.133973|2018-05-31 21:53:18.133973
NCT01483066|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2017-10-27|2011-11-29|2011-12-01|Estimate|||||||2017-10-27|2017-10-31|Actual|June 2012||2012-06-30|October 2017|2017-10-31|June 26, 2015|Actual|2015-06-26|June 26, 2015|Actual|2015-06-26||Interventional|||Clinical Outcomes and Cost-effectiveness Analysis of ShapeMatch Technology|A Prospective, Randomized, Post-market, Multi-center Study and Cost-effectiveness Analysis of ShapeMatch Technology A Prospective, Randomized, Post-market, Multi-center Study and Cost-effectiveness Analysis of ShapeMatch Technology|Terminated||Phase 4|38|Actual|University of Alberta||2||"FDA recall - Canadian system did voluntary suspension of study; Investigators subsequently~   decided to terminate the study"|f||||f||||||||||2018-05-31 21:53:18.389896|2018-05-31 21:53:18.389896
NCT01483053|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2013-12-16|2011-11-29|2011-12-01|Estimate|||||||2013-12-16|2013-12-18|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)|A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder.|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Baker IDI Heart and Diabetes Institute||2|||f||||f||||||||||2018-05-31 21:53:18.688605|2018-05-31 21:53:18.688605
NCT01483040|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-11-07|2011-11-29|2011-12-01|Estimate|||||||2012-11-07|2012-11-08|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||PeerScope B System™ Clinical Protocol|a Prospective Clinical Study to Establish the Usability of the PeerScope B System™ When Used During Standard Colonoscopy Procedure|Completed||N/A|50|Actual|PeerMedical Ltd.|||||f||||t||||||||||2018-05-31 21:53:19.01015|2018-05-31 21:53:19.01015
NCT01483027|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2018-03-02|2011-11-29|2011-12-01|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2012||2012-01-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|EPOCH||Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer|A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy|Recruiting||Phase 3|420|Anticipated|BTG International Inc.||2|||f||||t||||||||||2018-05-31 21:53:19.114556|2018-05-31 21:53:19.114556
NCT01483014|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-11-16|2011-11-30|2011-12-01|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|CONVERT||Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)|Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)|Completed||Phase 2|30|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:53:19.662533|2018-05-31 21:53:19.662533
NCT01483001|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2015-01-13|2011-11-30|2011-12-01|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional|STELLA||Feasibility Study on Stem Cells Sensitivity Assay|STELLA: a Feasibility Study on Stem Cells Sensitivity Assay|Completed||Phase 2|23|Actual|Associazione Oncologia Traslazionale||1|||f||||f||||||||||2018-05-31 21:53:19.787115|2018-05-31 21:53:19.787115
NCT01482988|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2011-11-30|2011-11-30|2011-12-01|Estimate|||||||2011-11-30|2011-12-01|Estimate|December 2011||2011-12-31|November 2011|2011-11-30||||||||Observational|Dectin-1||Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients|Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients|Unknown status|Not yet recruiting||600|Anticipated|Cardiff and Vale University Health Board|||1||f||||f||||||||||2018-05-31 21:53:19.88116|2018-05-31 21:53:19.88116
NCT01482975|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-05-10|2011-11-29|2011-12-01|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Project BEST||Tailored Interventions to Prevent Substance Abuse|Tailored Interventions to Prevent Substance Abuse|Completed||N/A|4158|Actual|University of Rhode Island||2|||f||||f||||||||No||2018-05-31 21:53:19.949707|2018-05-31 21:53:19.949707
NCT01482962|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2018-04-24|2011-11-30|2011-12-01|Estimate|||||||2018-04-24|2018-04-26|Actual|June 11, 2012|Actual|2012-06-11|April 2018|2018-04-30|December 18, 2017|Actual|2017-12-18|June 30, 2015|Actual|2015-06-30||Interventional|||Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma|A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma|Completed||Phase 3|271|Actual|Takeda||2|||f||||t|t|f||||||||2018-05-31 21:53:20.077316|2018-05-31 21:53:20.077316
NCT01482949|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-01-23|2011-11-29|2011-12-01|Estimate|||||||2017-01-23|2017-01-24|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Rollover Protocol for Subjects Previously Treated With AGS-003|A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects With Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006|Active, not recruiting||Phase 2|2|Actual|Argos Therapeutics||1|||f||||f||||||||No||2018-05-31 21:53:20.397145|2018-05-31 21:53:20.397145
NCT01482936|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-08-10|2011-11-29|2011-12-01|Estimate|||||||2015-08-10|2015-08-11|Estimate|May 2010||2010-05-31|August 2015|2015-08-31||||April 2011|Actual|2011-04-30||Interventional|||Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient|A Single Dose PK Study of Oxycodone Hydrochloride Injection 2.5, 5, and 10mg in Chinese Patients With Cancer Pain or Post-operation Patients|Completed||Phase 1|44|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||1|||f||||f||||||||||2018-05-31 21:53:20.480679|2018-05-31 21:53:20.480679
NCT01482923|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2018-02-06|2011-11-30|2011-12-01|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2011|Actual|2011-11-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations|Feasibility of Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations|Active, not recruiting|||60|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 21:53:20.555652|2018-05-31 21:53:20.555652
NCT01482910|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2015-03-01||2016-09-28|2011-11-29|2011-12-01|Estimate|2015-03-01|2015-03-13|Estimate||||2016-09-28|2016-11-04|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|||VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)|A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 3|304|Actual|Bayer||2|||f||||t||||||||||2018-05-31 21:53:20.662353|2018-05-31 21:53:20.662353
NCT01482897|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-12-01|2011-11-30|2011-12-01|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Hiatus||Efficacy of corticoïd Infiltration Via Sacro-coccygien Hiatus in Discal Sciatica|Open Randomized Study on the Efficacy of corticoïd Infiltration Versus Physiological Solution Infiltration Versus Feigning of Infiltration Via Sacro-coccygien Hiatus Versus Natural Evolution in Discal Sciatica|Terminated||Phase 3|13|Actual|Nantes University Hospital||4||"Enrolment stopped on December 01, 2014 since after 3 years, only 13 patients were included~   (instead of 274) (Date of last visit last patient : October 3, 2013)."|f||||f||||||||||2018-05-31 21:53:21.060509|2018-05-31 21:53:21.060509
NCT01482884|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|2015-01-20|2015-01-12|2016-03-07|2011-11-30|2011-12-01|Estimate|2016-03-07|2016-04-05|Estimate|2015-01-12|2015-01-21|Estimate|2016-03-07|2016-04-05|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional||All randomised participants.|Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis|A Phase IIa, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of Tralokinumab (CAT-354), a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), as add-on Therapy, on Clinical Response in Patients With Active, Moderate-to-severe, Ulcerative Colitis|Completed||Phase 2|147|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:53:21.296046|2018-05-31 21:53:21.296046
NCT01482871|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-12-06|2011-11-29|2011-12-01|Estimate|||||||2012-12-06|2012-12-07|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of ALG- 1001 to Treat Diabetic Macular Edema|Safety Study of ALG 1001 to Treat Diabetic Macular Edema|Withdrawn||Phase 1/Phase 2|0|Actual|Allegro Ophthalmics, LLC||4|||f||||t||||||||||2018-05-31 21:53:22.306347|2018-05-31 21:53:22.306347
NCT01482858|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2011-11-30|2011-11-30|2011-12-01|Estimate|||||||2011-11-30|2011-12-01|Estimate|December 2011||2011-12-31|November 2011|2011-11-30|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures|A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Amorphical Ltd.||2|||f||||f||||||||||2018-05-31 21:53:22.402022|2018-05-31 21:53:22.402022
NCT01482845|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-05-01|2011-11-29|2011-12-01|Estimate|||||||2012-05-01|2012-05-02|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|Completed||Phase 1|20|Actual|Abbott||2|||f||||f||||||||||2018-05-31 21:53:22.524648|2018-05-31 21:53:22.524648
NCT01482832|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2018-05-09|2011-11-30|2011-12-01|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2011|Actual|2011-12-31|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|December 2017|Actual|2017-12-31||Interventional|REACH 2||Interpersonal Therapy-Based Treatment to Prevent Postpartum Depression in Adolescent Mothers|Preventing Postpartum Depression in Adolescent Mothers|Active, not recruiting||N/A|250|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t|f|f||||||No|Not at this point.|2018-05-31 21:53:22.634015|2018-05-31 21:53:22.634015
NCT01482819|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2015-01-08||2017-08-21|2011-11-28|2011-12-01|Estimate|2015-04-28|2015-04-30|Estimate||||2017-08-21|2017-09-19|Actual|October 1, 2011|Actual|2011-10-01|August 2017|2017-08-31|December 1, 2011|Actual|2011-12-01|December 1, 2011|Actual|2011-12-01||Interventional||Subjects who were screened, gave consent, enrolled, and were randomized in the study.|Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses||Completed||N/A|21|Actual|Johnson & Johnson Vision Care, Inc.||10|||f||||f||||||||||2018-05-31 21:53:22.766618|2018-05-31 21:53:22.766618
NCT01482806|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-07-21|2011-11-28|2011-12-01|Estimate|||||||2017-07-21|2017-07-24|Actual|February 2012||2012-02-29|July 2017|2017-07-31|May 30, 2017|Actual|2017-05-30|December 2015|Actual|2015-12-31||Interventional|||Online Treatments for Mood and Anxiety Disorders in Primary Care|Online Treatments for Mood and Anxiety Disorders in Primary Care|Completed||Phase 2/Phase 3|700|Anticipated|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:53:23.058745|2018-05-31 21:53:23.058745
NCT01482793|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2015-07-10|2011-11-30|2011-12-01|Estimate|||||||2015-07-10|2015-07-13|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures|A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures.|Completed||N/A|120|Actual|Optimus Clinical Research||2|||f||||t||||||||||2018-05-31 21:53:23.136813|2018-05-31 21:53:23.136813
NCT01482780|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-04-06|2011-11-29|2011-12-01|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery|EASY-TRIAL: Evaluation of a Local Preconditioning Effect in Patients Undergoing Cardiac Surgery|Terminated||N/A|5|Actual|Medical University of Vienna||2||Logistic reasons, lack of funding|f||||f||||||||||2018-05-31 21:53:23.214306|2018-05-31 21:53:23.214306
NCT01482767|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2016-04-05||2016-06-01|2011-11-28|2011-12-01|Estimate|2016-04-05|2016-05-10|Estimate||||2016-06-01|2016-06-03|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All eligible participants enrolled (Group B participants who were found ineligible after enrollment, n=5, were excluded).|Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection|A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects|Completed||Phase 3|262|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 21:53:23.335565|2018-05-31 21:53:23.335565
NCT01482754|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2013-12-08|2011-11-30|2011-12-01|Estimate|||||||2013-12-08|2013-12-10|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma|Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma|Completed||N/A|30|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 21:53:24.337775|2018-05-31 21:53:24.337775
NCT01482741|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2015-06-24|2011-11-28|2011-12-01|Estimate|||||||2015-06-24|2015-06-25|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging|Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging|Completed|||30|Actual|Memorial Sloan Kettering Cancer Center|||6||f||||||||||||||2018-05-31 21:53:24.410479|2018-05-31 21:53:24.410479
NCT01482728|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2016-05-11|2011-11-29|2011-11-30|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer|A Phase 0 Pharmacodynamic Study of Dasatinib in Women With Newly Diagnosed Endometrial Cancer|Completed||Early Phase 1|12|Actual|University of Virginia|||||f||||t||||||||||2018-05-31 21:53:24.492026|2018-05-31 21:53:24.492026
NCT01482715|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-05-08|2011-11-29|2011-11-30|Estimate|||||||2018-05-08|2018-05-14|Actual|November 2011||2011-11-30|May 2018|2018-05-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)|A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor|Active, not recruiting||Phase 1/Phase 2|136|Actual|Clovis Oncology, Inc.||1|||f||||f||||||||||2018-05-31 21:53:24.565428|2018-05-31 21:53:24.565428
NCT01482702|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-01-14|2011-11-28|2011-11-30|Estimate|||||||2013-01-14|2013-01-15|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|VCC0910||Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors|Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors|Completed||N/A|72|Actual|University of Vermont||3|||f||||f||||||||||2018-05-31 21:53:24.677681|2018-05-31 21:53:24.677681
NCT01482689|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-11-28|2011-11-28|2011-11-30|Estimate|||||||2011-11-28|2011-11-30|Estimate|February 2005||2005-02-28|November 2011|2011-11-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Bioavailability of Vitamin D in Cod Liver Oil and Multivitamin Tablets in Healthy Subjects in Norway|Bioavailability of Vitamin D in Cod Liver Oil and Multivitamin Tablets in Healthy Subjects in Norway|Completed||N/A|74|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 21:53:24.811235|2018-05-31 21:53:24.811235
NCT01482676|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-06-01|2011-11-29|2011-11-30|Estimate|||||||2015-06-01|2015-06-03|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction|Investigating the Role of microRNAs in the Regulation of Gene Expression and Organ Remodeling During Lower Urinary Tract Dysfunction, Including Bladder Pain Syndrome/Interstitial Cystitis (BPS), and Overactive Bladder Syndrome (OAB)|Completed|||103|Actual|University Hospital Inselspital, Berne|||4||f||||f||||||Samples With DNA|"~     Frozen cold-cut bladder biopsies preserved in RNAlater buffer or in SDS-PAGE sample buffer;~     PFA-fixed tissue, primary cultures of urothelium and smooth muscle~   "|||2018-05-31 21:53:24.898297|2018-05-31 21:53:24.898297
NCT01482663|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2014-12-02|2011-11-28|2011-11-30|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Chronic Hand Eczema - Self-management and Prognosis|Chronic Hand Eczema - Self-management and Prognosis|Completed||N/A|306|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 21:53:25.008241|2018-05-31 21:53:25.008241
NCT01482650|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2012-06-18|2011-11-28|2011-11-30|Estimate|||||||2012-06-18|2012-06-19|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparison of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients|Comparison of the Effectiveness of the BASKA Airway, a Novel Supraglottic Device, to the LMA Airway in Low Risk Female Patients|Completed||Phase 2|92|Actual|University College Hospital Galway||2|||f||||f||||||||||2018-05-31 21:53:25.118434|2018-05-31 21:53:25.118434
NCT01482637|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-07-10|2011-11-29|2011-11-30|Estimate|||||||2014-07-10|2014-07-14|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CAS||Development of Coercion Assessment Scale|Improving Ethics in Research: Development of the Coercion Assessment Scale|Completed|||228|Actual|Treatment Research Institute|||1||f||||t||||||||||2018-05-31 21:53:25.250628|2018-05-31 21:53:25.250628
NCT01482624|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2013-08-27|2011-11-29|2011-11-30|Estimate|||||||2013-08-27|2013-08-28|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Intra-articular Hyaluronan After Arthroscopic Meniscal Surgery|Intra-articular Hyaluronan After Arthroscopic Meniscal Surgery.|Completed||N/A|64|Actual|TRB Chemedica AG||2|||f||||f||||||||||2018-05-31 21:53:25.34213|2018-05-31 21:53:25.34213
NCT01482611|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-02-18|2011-11-28|2011-11-30|Estimate|||||||2013-02-18|2013-02-20|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382|Phase I, First-in-human, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Increasing Single Oral Doses of JNJ-47910382 in Healthy Caucasian and Japanese Volunteers|Completed||Phase 1|35|Actual|Janssen R&D Ireland||4|||f||||f||||||||||2018-05-31 21:53:25.472586|2018-05-31 21:53:25.472586
NCT01482598|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2016-03-03|2011-11-28|2011-11-30|Estimate|||||||2016-03-03|2016-03-04|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|August 2018|Anticipated|2018-08-31|August 2016|Anticipated|2016-08-31||Interventional|COR-HF||Clinical Benefits in Optimized Remote HF Patient Management|COR HF - Clinical Benefits in Optimized Remote HF Patient Management|Active, not recruiting||Phase 4|438|Anticipated|St. Jude Medical||2|||f||||t||||||||||2018-05-31 21:53:25.586474|2018-05-31 21:53:25.586474
NCT01482585|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2011-11-29|2011-11-29|2011-11-30|Estimate|||||||2011-11-29|2011-11-30|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Observational|||Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy|Prospective Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy|Unknown status|Recruiting||200|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     lung tissue, serum~   "|||2018-05-31 21:53:25.71993|2018-05-31 21:53:25.71993
NCT01482572|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2015-11-17|2011-11-29|2011-11-30|Estimate|||||||2015-11-17|2015-11-20|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Feasibility of Mutational Analysis of Non-Small Cell Lung Cancer (NSCLC) Using Low-volume Lung Aspirates|Feasibility of Gene Expression Profiling Using Low-volume Lung Aspirate|Withdrawn|||0|Actual|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     lung tissue~   "|||2018-05-31 21:53:25.857966|2018-05-31 21:53:25.857966
NCT01482559|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2015-01-27|2011-11-29|2011-11-30|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|HIP||Management of Hypotension In the Preterm Infant|Management of Hypotension In Preterm Infants: The HIP Trial Protocol for a Randomized Controlled Trial of Hypotension Management in the Extremely Low Gestational Age Newborn|Unknown status|Recruiting|Phase 3|830|Anticipated|University College Cork||2|||f||||t||||||||||2018-05-31 21:53:25.962192|2018-05-31 21:53:25.962192
NCT01482546|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2017-06-26|2011-11-29|2011-11-30|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2012|Actual|2012-05-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Comparing Clinical Performance of Novice Trainee Endoscopists Using Conventional Air Insufflation Versus Warm Water Infusion Colonoscopy|Randomized Cross-Over Comparing Clinical Performance of Novice Trainee Endoscopists Using Conventional Air Insufflation Versus Warm Water Infusion Colonoscopy|Completed|||6|Actual|University of California, Davis|||2||f||||t||||||||||2018-05-31 21:53:26.132192|2018-05-31 21:53:26.132192
NCT01482533|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2011-11-29|2011-11-29|2011-11-30|Estimate|||||||2011-11-29|2011-11-30|Estimate||||November 2011|2011-11-30||||||||Observational|||Tissue Culture Versus Swab Culture in Prosthetic Joint Infections||Unknown status|Not yet recruiting||||Rothman Institute Orthopaedics|||2||f||||f||||||||||2018-05-31 21:53:26.211205|2018-05-31 21:53:26.211205
NCT01482520|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-05-12|2011-11-29|2011-11-30|Estimate|||||||2014-05-12|2014-05-14|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma|Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma|Completed|||200|Anticipated|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 21:53:26.28463|2018-05-31 21:53:26.28463
NCT01482507|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2018-04-04|2011-11-29|2011-11-30|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2011|Actual|2011-08-31|November 2011|2011-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis|Examination of the Effectiveness of Diffusion Weighted Magnetic Resonance Imaging for Identifying Poor Prognosis in Patients With Rheumatoid Arthritis|Completed|||10|Actual|Optimus Clinical Research|||||f||||f||||||||||2018-05-31 21:53:26.382869|2018-05-31 21:53:26.382869
NCT01482494|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2011-11-30|2011-11-29|2011-11-30|Estimate|||||||2011-11-30|2011-12-01|Estimate|December 2011||2011-12-31|November 2011|2011-11-30||||December 2012|Anticipated|2012-12-31||Observational|||Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia|Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia|Unknown status|Not yet recruiting||50|Anticipated|Hospital Vall d'Hebron|||1||f||||f||||||||||2018-05-31 21:53:26.547332|2018-05-31 21:53:26.547332
NCT01482481|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2011-11-29|2011-11-29|2011-11-30|Estimate|||||||2011-11-29|2011-11-30|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|December 2009|Actual|2009-12-31||Observational|||Effectiveness of Nursing Care Plans Based in Nursing Diagnoses in Metabolic Control of Type 2 Diabetes Mellitus|Effectiveness of Implementing Nursing Care Plans Based on Scientific Methodology in Improving Metabolic and Blood Pressure Control of Type 2 Diabetes Mellitus Patients.|Completed|||23488|Actual|Hospital Carlos III, Madrid|||||f||||f||||||||||2018-05-31 21:53:26.600746|2018-05-31 21:53:26.600746
NCT01482468|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-03-21|2011-11-29|2011-11-30|Estimate|||||||2012-03-21|2012-03-23|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting|Effect of Continuous Infusion of Palonosetron Following Single Prophylactic Injection of Palonosetron for Preventing Postoperative Nausea and Vomiting|Unknown status|Recruiting|N/A|132|Anticipated|Incheon St.Mary's Hospital||2|||f||||t||||||||||2018-05-31 21:53:26.663915|2018-05-31 21:53:26.663915
NCT01482455|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2012-09-07|2011-11-29|2011-11-30|Estimate|||||||2012-09-07|2012-09-10|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|FATRAIN||Fat and Transcapillary Insulin Transport|Lipid-induced Insulin Resistance is Not Mediated by Impaired Transcapillary Transport of Insulin and Glucose in Humans|Completed||N/A|8|Actual|German Diabetes Center||4|||f||||f||||||||||2018-05-31 21:53:26.73452|2018-05-31 21:53:26.73452
NCT01482442|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-01-13|2011-11-29|2011-11-30|Estimate|||||||2017-01-13|2017-01-16|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SARAH||SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma|A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 3|496|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:53:26.812522|2018-05-31 21:53:26.812522
NCT01482429|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|2013-01-12||2013-01-27|2011-11-29|2011-11-30|Estimate|2013-01-27|2013-03-04|Estimate||||2013-01-27|2013-03-04|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of a Systematic Approach to Weaning From Mechanical Ventilation|Implantation of a Multidisciplinary Ventilator-weaning Protocol in a Intensive Care Unit of Teaching Hospital of Federal University of Uberlandia|Completed||N/A|235|Actual|Federal University of Uberlandia|The lack of sedation protocol in the intensive care unit.|2|||f||||t||||||||||2018-05-31 21:53:26.928135|2018-05-31 21:53:26.928135
NCT01482416|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2014-08-13|2011-11-29|2011-11-30|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|EDILA||Vascular Effect of Estrogens Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery|Flow-mediated Evaluation of the Brachial Artery of Climacteric Women Using Estradiol and Placebo. Randomized, Double Blinded, Placebo Controlled Study.|Completed||N/A|60|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 21:53:27.239791|2018-05-31 21:53:27.239791
NCT01482403|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28||2016-07-08|2016-08-03|2011-11-28|2011-11-30|Estimate||||2016-07-08|2016-07-12|Estimate|2016-08-03|2016-08-05|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C|A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination With Boceprevir and Pegasys®/Copegus® in Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders to Treatment With Pegylated Interferon/Ribavirin|Completed||Phase 2|58|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:53:27.333427|2018-05-31 21:53:27.333427
NCT01482390|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28||2016-08-09|2017-04-21|2011-11-28|2011-11-30|Estimate||||2016-08-09|2016-08-11|Estimate|2017-04-21|2017-04-24|Actual|November 30, 2011|Actual|2011-11-30|April 2017|2017-04-30|January 31, 2014|Actual|2014-01-31|January 31, 2014|Actual|2014-01-31||Interventional|||A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C|A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination With Telaprevir and Pegasys®/Copegus® in Patients With Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders to Treatment With Pegylated Interferon/Ribavirin|Completed||Phase 2|80|Actual|Hoffmann-La Roche||4|||f|||||t|f||||||||2018-05-31 21:53:27.506759|2018-05-31 21:53:27.506759
NCT01482377|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-01-26|2011-11-28|2011-11-30|Estimate|||||||2017-01-26|2017-01-27|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin|Phase Ia/Ib, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, A Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotinib (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-Positive Solid Tumors of Epithelial Cell Origin|Completed||Phase 1|145|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:53:27.699741|2018-05-31 21:53:27.699741
NCT01482364|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2015-03-23|2011-11-29|2011-11-30|Estimate|||||||2015-03-23|2015-03-24|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|BEAUTY||BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem|BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem|Completed||Phase 3|183|Actual|Hemo Sapiens, Inc.||2|||f||||f||||||||||2018-05-31 21:53:27.878054|2018-05-31 21:53:27.878054
NCT01482351|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2015-03-10|2011-11-28|2011-11-30|Estimate|||||||2015-03-10|2015-03-17|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MEMORIES||Mild Cognitive Impairment and Obstructive Sleep Apnea|Mild Cognitive Impairment and Obstructive Sleep Apnea|Completed||Phase 3|86|Actual|George Mason University||1|||f||||t||||||||||2018-05-31 21:53:27.976621|2018-05-31 21:53:27.976621
NCT01482338|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-27|||2012-03-13|2011-11-29|2011-11-30|Estimate|||||||2012-03-13|2012-03-14|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone|A Comparative Efficacy of Low-dose Combine Oral Contraceptives Containing Desogestrel 150 mg and Drospirenone 3 mg on Premenstrual Symptoms|Completed||Phase 4|90|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 21:53:28.08568|2018-05-31 21:53:28.08568
NCT01482325|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2015-07-06||2016-08-08|2011-11-28|2011-11-30|Estimate|2016-08-08|2016-09-30|Estimate||||2016-08-08|2016-09-30|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SNIPE|No analysis was performed, study prematurely terminated.|SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement|SNIPE:SuperSTAT 2.0 Noninvasive Blood Pressure Algorithm Enhancement|Terminated||N/A|31|Actual|GE Healthcare||1||The business decided not to pursue the study at this time.|f||||f||||||||||2018-05-31 21:53:28.170842|2018-05-31 21:53:28.170842
NCT01482312|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2012-05-22||2012-06-26|2011-11-28|2011-11-30|Estimate|2012-06-26|2012-07-27|Estimate||||2012-06-26|2012-07-27|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effect of Contact Lenses on Tear Osmolarity in a Controlled Low Humidity Chamber||Completed||N/A|29|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 21:53:28.292319|2018-05-31 21:53:28.292319
NCT01482299|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-01-11|2011-11-27|2011-11-30|Estimate|||||||2015-01-11|2015-01-13|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression|A Phase II Trial of RAD001 (Everolimus) for 2nd Line Treatment After Failure of Fluoropyrimidine Plus Platinum Chemotherapy in Patients With Metastatic or Recurrent Gastric Cancer With pS6 Ser 240/4 Expression|Completed||Phase 2|45|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:53:28.623777|2018-05-31 21:53:28.623777
NCT01482286|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2017-01-27|2011-11-28|2011-11-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|PULSE||Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS|Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS|Completed||Phase 3|32|Actual|Pennington Biomedical Research Center||4|||f||||t||||||||||2018-05-31 21:53:28.737388|2018-05-31 21:53:28.737388
NCT01482273|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2015-07-16|2011-11-29|2011-11-30|Estimate|||||||2015-07-16|2015-07-17|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|BERNUTIFUL||Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis|The BERN Ultrasound-enhanced Thrombolysis for Ilio-Femoral Deep Vein Thrombosis versUs Standard Catheter Directed thromboLysis Trial (BERNUTIFUL-Trial)|Completed||N/A|48|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 21:53:28.871735|2018-05-31 21:53:28.871735
NCT01482260|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2012-11-05|2011-11-29|2011-11-30|Estimate|||||||2012-11-05|2012-11-06|Estimate|December 2011||2011-12-31|November 2012|2012-11-30||||January 2012|Actual|2012-01-31||Observational|||Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma|Comparative Microarray Analysis of microRNA Expression Profiles in Primary Cutaneous Malignant Melanoma, Cutaneous Malignant Melanoma Metastases and Benign Melanocytic Naevi|Completed|||21|Actual|Ruhr University of Bochum|||3||f||||t||||||Samples With DNA|"~     skin biopsy~   "|||2018-05-31 21:53:29.135324|2018-05-31 21:53:29.135324
NCT01482247|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2016-07-27|2011-11-28|2011-11-30|Estimate|||||||2016-07-27|2016-07-28|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||L-Arginine, Vascular Response and Mechanisms|L-Arginine, Vascular Response and Mechanisms|Completed||Phase 2|25|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:53:29.284638|2018-05-31 21:53:29.284638
NCT01482234|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2016-01-18|2011-11-29|2011-11-30|Estimate|||||||2016-01-18|2016-01-20|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Text Messages and Physical Activity Among Teens|TXT Me: Texting Motivational Messages Encouraging Adolescent Physical Activity|Completed||N/A|160|Actual|Baylor College of Medicine||4|||f||||f||||||||||2018-05-31 21:53:29.410438|2018-05-31 21:53:29.410438
NCT01482221|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2014-10-13||2017-04-10|2011-11-29|2011-11-30|Estimate|2017-04-10|2017-04-11|Actual||||2017-04-10|2017-04-11|Actual|December 16, 2011|Actual|2011-12-16|April 2017|2017-04-30|August 26, 2013|Actual|2013-08-26|August 26, 2013|Actual|2013-08-26||Interventional|||A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients With Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants|Completed||Phase 2|542|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:53:29.600217|2018-05-31 21:53:29.600217
NCT01482208|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-03-28|2011-11-29|2011-11-30|Estimate|||||||2014-03-28|2014-03-31|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|IHM-01||Clinical Evaluation of Ultrasonic Hydration Monitor for Infants|Study of Ultrasonic Hydration Monitor for Neonatology and Pediatric Children and Infants and/or Children up to Age 3 Years Old With Diarrhea|Completed|||42|Actual|Artann Laboratories|||||f||||f||||||||||2018-05-31 21:53:30.727161|2018-05-31 21:53:30.727161
NCT01482195|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-11-29|2011-11-29|2011-11-30|Estimate|||||||2011-11-29|2011-11-30|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|August 2023|Anticipated|2023-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations|Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations|Recruiting||Phase 1|6|Anticipated|King Khaled Eye Specialist Hospital||1|||f||||t||||||||||2018-05-31 21:53:30.796559|2018-05-31 21:53:30.796559
NCT01482182|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-11-17|2011-11-28|2011-11-30|Estimate|||||||2015-11-17|2015-11-20|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Observational|||Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy|Prediction of Chemotherapy Response and Patient Prognosis in Non-small Cell Lung Cancer: Dynamic Contrast-enhanced MRI and Diffusion-weighted Imaging Versus Volume-based Parameter of 18F-FDG PET|Completed|||35|Actual|Samsung Medical Center|||||f||||t||||||||||2018-05-31 21:53:31.969657|2018-05-31 21:53:31.969657
NCT01482169|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2017-04-26||2018-05-09|2011-11-28|2011-11-30|Estimate|2018-05-09|2018-05-10|Estimate||||2018-05-09|2018-05-10|Estimate|March 2012||2012-03-31|May 2018|2018-05-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)|Efficacy of Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve Measurements|Completed||N/A|48|Actual|Ochsner Health System||2|||f||||t||||||||No||2018-05-31 21:53:32.061937|2018-05-31 21:53:32.061937
NCT01482156|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2015-11-18|2011-11-29|2011-11-30|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors|An Open-label, Multi-center Phase I Dose-finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors|Completed||Phase 1|46|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:53:32.28413|2018-05-31 21:53:32.28413
NCT01482143|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-09-29|2011-11-29|2011-11-30|Estimate|||||||2014-09-29|2014-09-30|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)|Sequential, Two-period Study to Assess the Pharmacokinetics, Safety & Tolerability of Single and Multiple Oral Doses of AFQ056 in Patients With FXS (Fragile X Syndrome) Aged 5-11 Years (Cohort 1) and 3-4 Years (Cohort 2)|Completed||Phase 1|21|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:53:32.395019|2018-05-31 21:53:32.395019
NCT01482130|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-07-29|2011-11-28|2011-11-30|Estimate|||||||2016-07-29|2016-08-01|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||High Intensity Strength Training & Bone Mineral Density in Young Women|Preventing Osteoporosis: The Effect of High Intensity Strength Training on Bone Mineral Density in Young and Healthy Women|Completed||N/A|30|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 21:53:32.478032|2018-05-31 21:53:32.478032
NCT01482117|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-26|||2013-05-31|2011-11-26|2011-11-30|Estimate|||||||2013-05-31|2013-06-03|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers|Randomized, Open-label, Crossover Study to Evaluate the Effect of Genetic Polymorphism on Pharmacokinetic & Pharmacodynamic Interactions of Clopidogrel and Cilostazol in Korean Healthy Adult Volunteers|Completed||N/A|28|Actual|Inje University||3|||f||||f||||||||||2018-05-31 21:53:32.573671|2018-05-31 21:53:32.573671
NCT01482104|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-10-26|2011-11-29|2011-11-30|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2012|Actual|2012-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)|A Randomized Controlled Blinded Multi-centre Study of Photodynamic Therapy With Methyl-aminolevulinate Comparing a Simplified Regime With the Approved Regime in Patients With Clinical Low-risk Superficial and Nodular Basal Cell Carcinoma.|Completed||N/A|277|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 21:53:32.750098|2018-05-31 21:53:32.750098
NCT01482091|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2016-03-30||2016-07-11|2011-11-29|2011-11-30|Estimate|2016-07-11|2016-08-19|Estimate||||2016-07-11|2016-08-19|Estimate|December 2011||2011-12-31|July 2016|2016-07-31||||February 2015|Actual|2015-02-28||Interventional|||Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis|Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial|Completed||Phase 4|124|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 21:53:32.890689|2018-05-31 21:53:32.890689
NCT01482078|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2018-04-06|2011-11-29|2011-11-30|Estimate|||||||2018-04-06|2018-04-10|Actual|January 26, 2012|Actual|2012-01-26|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|MnMs||Magnesium for Neonatal Neuroprotection and Mothers|Prospective Observational Study, Maternal Effects of Magnesium Sulphate for Neonatal Neuroprotection in Women Having Cesarean Section Under Neuraxial Anesthesia|Recruiting|||50|Anticipated|University of British Columbia|||2||f||||f||||||||||2018-05-31 21:53:33.578441|2018-05-31 21:53:33.578441
NCT01482065|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2016-11-01||2016-11-01|2011-11-29|2011-11-30|Estimate|2016-11-01|2017-01-04|Estimate||||2016-11-01|2017-01-04|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|SLEEP||The Sleep, Liver Evaluation and Effective Pressure Study|The Sleep, Liver Evaluation and Effective Pressure Study (SLEEP)|Completed||Phase 2|40|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 21:53:33.691105|2018-05-31 21:53:33.691105
NCT01482052|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-01-11|2011-11-28|2011-11-30|Estimate|||||||2013-01-11|2013-01-14|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis|A Double-Blind, Randomized, Controlled, Two Arm Phase 1 Clinical Trial of the Safety and Immunogenicity of Group A, C, Y & W-135 Meningococcal Polysaccharide DT Conjugate Vaccine: NmVac4-A/C/Y/W-135-DT™|Completed||Phase 1|60|Actual|JN-International Medical Corporation||2|||f||||t||||||||||2018-05-31 21:53:33.930621|2018-05-31 21:53:33.930621
NCT01482039|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2011-11-28|2011-11-28|2011-11-30|Estimate|||||||2011-11-28|2011-11-30|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|TVUS||Patient Attitudes Toward Ultrasound Measurement of Cervical Length|Patient Attitudes Regarding Abdominal Versus Transvaginal Ultrasonography for Assessment of the Cervical Length in Low Risk Patients: a Randomized Trial|Unknown status|Recruiting|N/A|210|Anticipated|Intermountain Women and Children's Research||3|||f||||f||||||||||2018-05-31 21:53:34.011429|2018-05-31 21:53:34.011429
NCT01482026|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2016-01-20|2011-11-29|2011-11-30|Estimate|||||||2016-01-20|2016-01-21|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Attention-Deficit Hyperactivity Disorder (ADHD) Rating Scale and Epilepsy|Sensitivity of ADHD-IV Rating Scale in the Evaluation of the Evolution of Attention Disorders Associated With Childhood Epilepsy : a Validation Study|Completed||N/A|173|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:53:34.114812|2018-05-31 21:53:34.114812
NCT01482013|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2012-08-29|2011-11-28|2011-11-30|Estimate|||||||2012-08-29|2012-08-30|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease|A Double-blind, Randomized, Placebo-controlled, Phase I , Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease|Terminated||Phase 1|7|Actual|High Point Pharmaceuticals, LLC.||2|||f||||f||||||||||2018-05-31 21:53:34.293609|2018-05-31 21:53:34.293609
NCT01482000|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2011-11-29|2011-11-29|2011-11-30|Estimate|||||||2011-11-29|2011-11-30|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Does Pulmonary Daoyin of China Give Additional Benefit Over Usual Therapy in Management of Stable Chronic Obstructive Pulmonary Disease?|Detection and Intervention on Mild/Moderate Chronic Obstructive Pulmonary Disease by Traditional Chinese Medicine Treatment and Application|Unknown status|Not yet recruiting|Phase 3|464|Anticipated|Henan University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 21:53:34.371902|2018-05-31 21:53:34.371902
NCT01481987|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-11-29|2011-11-29|2011-11-30|Estimate|||||||2011-11-29|2011-11-30|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Microperimetry and Optical Coherence Tomography (OCT) in Idiopathic Epiretinal Membrane|Retinal Sensitivity and Optical Coherence Tomography Findings in Eyes With Idiopathic Epiretinal Membrane|Completed||N/A|76|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 21:53:34.442926|2018-05-31 21:53:34.442926
NCT01481974|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2018-02-11|2011-11-27|2011-11-30|Estimate|||||||2018-02-11|2018-02-13|Actual|December 2012||2012-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Treprostinil in Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplantation|An Evaluation of the Safety and Preliminary Efficacy of Perioperative Treprostinil in Preventing Ischemia and Reperfusion Injury in Adult Orthotopic Liver Transplant Recipients|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 21:53:34.509866|2018-05-31 21:53:34.509866
NCT01481961|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2015-02-27|2011-11-29|2011-11-30|Estimate|||||||2015-02-27|2015-03-03|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|ALSTIMAG||Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease|Feasibility Study: Cognitive Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)on add-on in Patients With Early Alzheimer's Disease|Completed||N/A|15|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 21:53:34.623334|2018-05-31 21:53:34.623334
NCT01481948|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2016-01-18|2011-11-28|2011-11-30|Estimate|||||||2016-01-18|2016-01-20|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|FFFIPG||Food, Fun, & Fitness Internet Program for Girls: Outcome Evaluation|Using Technology to Prevent Obesity Among African American Girls|Completed||N/A|342|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 21:53:34.747654|2018-05-31 21:53:34.747654
NCT01481935|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|2012-09-19||2012-10-25|2011-11-29|2011-11-30|Estimate|2012-09-19|2012-10-19|Estimate||||2012-10-25|2012-10-31|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria|Use of an Enhanced Room Cleaning Protocol in the Intensive Care Unit to Reduce Contamination of Disposable Isolation Gowns and Gloves With Methicillin-resistant Staphylococcus Aureus and Multi-drug Resistant Acinetobacter Baumannii|Completed||N/A|190|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 21:53:34.848846|2018-05-31 21:53:34.848846
NCT01481922|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-03-19|2011-11-29|2011-11-30|Estimate|||||||2016-03-19|2016-03-22|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||What Needle Diameter Should Physician Use When They Perform Lumbar Puncture ? A Randomized Controlled Trial|Should Physicians Use a 24 Gauge Spinal Needle Instead of a 22 Gauge When Performing a Lumbar Puncture ? A Randomized Controlled Trial.|Completed||Phase 4|62|Actual|McGill University||2|||f||||f||||||||||2018-05-31 21:53:35.151751|2018-05-31 21:53:35.151751
NCT01481909|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2016-11-02|2011-11-28|2011-11-30|Estimate|||||||2016-11-02|2016-11-03|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|SMART||Study on Mastocytosis for Rupatadine Treatment|Study on Mastocytosis for Rupatadine Treatment An Exploratory Phase IV, Randomised, Double-blind, Placebo Controlled Crossover Study to Assess the Efficacy of 20 mg Rupatadine on the Treatment of|Completed||Phase 2/Phase 3|30|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 21:53:35.277385|2018-05-31 21:53:35.277385
NCT01481727|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2015-05-22|2011-11-28|2011-11-29|Estimate|||||||2015-05-22|2015-05-25|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation|Exacerbation's Prevention in Patients With COPD in GOLD IV Stage (Very Severe) With Non Invasive Mechanical Ventilation|Unknown status|Active, not recruiting|Phase 4|20|Actual|National Institute of Respiratory Diseases, Mexico||2|||f||||f||||||||||2018-05-31 21:53:38.239896|2018-05-31 21:53:38.239896
NCT01481896|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2012-06-30||2013-08-01|2011-11-29|2011-11-30|Estimate|2013-08-01|2013-10-09|Estimate||||2013-08-01|2013-10-09|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational||The Overall Number of Baseline Participants is defined as the number of hips included in the study population instead of the number of participants since 5 participants had both hips replaced and objective of this study was to evaluated the outcome of each hip.|A Five-Year Metal-on-Metal Retrospective Clinical Study|A Five-Year Metal-on-Metal Retrospective Clinical Study|Completed|||126|Actual|Anderson Orthopaedic Research Institute|||1||f||||f||||||||||2018-05-31 21:53:35.381939|2018-05-31 21:53:35.381939
NCT01481883|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2018-01-09|2011-11-28|2011-11-30|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?|A Randomised Controlled Trial of Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?|Recruiting||Phase 4|180|Anticipated|The Alfred||2|||f||||t||||||||||2018-05-31 21:53:35.707158|2018-05-31 21:53:35.707158
NCT01481870|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2013-02-21|2011-11-25|2011-11-30|Estimate|||||||2013-02-21|2013-02-25|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|July 2013|Anticipated|2013-07-31||Interventional|CROSS-J-RCC||Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma|Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|Yamagata University||2|||f||||t||||||||||2018-05-31 21:53:35.813755|2018-05-31 21:53:35.813755
NCT01481857|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-11-25|2011-11-25|2011-11-30|Estimate|||||||2011-11-25|2011-11-30|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Influence of Thoracolumbar Proprioceptive Support in the Segmental Stabilization Training|Influence of Thoracolumbar Proprioceptive Support in the Segmental Stabilization Training|Completed||Phase 1/Phase 2|24|Actual|Universidade Federal do Piauí||2|||f||||t||||||||||2018-05-31 21:53:35.909309|2018-05-31 21:53:35.909309
NCT01481844|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2015-07-05|2011-11-27|2011-11-30|Estimate|||||||2015-07-05|2015-07-08|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Sequential Therapy Versus Quadruple Therapy as Second Line Treatment After Failure of the Standard Triple Therapy for H Pylori Infection||Completed||Phase 3|101|Actual|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 21:53:35.96302|2018-05-31 21:53:35.96302
NCT01481831|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2012-12-28|2011-11-27|2011-11-30|Estimate|||||||2012-12-28|2012-12-31|Estimate|July 2011||2011-07-31|December 2012|2012-12-31||||August 2012|Actual|2012-08-31||Interventional|ESPNV||Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting|A Multi-center, Stratified Randomized, Controlled Study to Evaluate the Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in China|Completed||Phase 4|599|Actual|Shanghai Changzheng Hospital||4|||f||||||||||||||2018-05-31 21:53:36.034456|2018-05-31 21:53:36.034456
NCT01481818|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-03-13|2011-11-27|2011-11-30|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2011||2011-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis|Phase Ⅰ,ⅡStudy of Topically Applied Green Tea Extract for Prevention and Treatment of Radio Dermatitis and Radiation Mucositis|Enrolling by invitation||Phase 1/Phase 2|15|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||f||||||||||2018-05-31 21:53:36.216248|2018-05-31 21:53:36.216248
NCT01481805|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2017-04-24|2011-11-27|2011-11-30|Estimate|||||||2017-04-24|2017-04-26|Actual|January 14, 2010|Actual|2010-01-14|April 2017|2017-04-30|August 13, 2014|Actual|2014-08-13|January 13, 2014|Actual|2014-01-13||Observational|||Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients|Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients|Completed|||100|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 21:53:36.288466|2018-05-31 21:53:36.288466
NCT01481792|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2016-05-10|2011-11-29|2011-11-30|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Observational|||Efficacy and Safety of ReLEx Smile for Laser Correction of Myopia|Use of the VisuMax Femtosecond Laser for the Correction of Myopia With Small Incision Lenticular Extraction|Completed|||125|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 21:53:36.357997|2018-05-31 21:53:36.357997
NCT01481779|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2018-03-16|2014-04-25|2018-03-16|2011-11-28|2011-11-30|Estimate|2018-03-16|2018-04-17|Actual|2014-04-25|2014-05-13|Estimate|2018-03-16|2018-04-17|Actual|January 2012||2012-01-31|March 2018|2018-03-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|IMAGINE 1|All randomized participants.|A Study in Participants With Type 1 Diabetes Mellitus|The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: An Open-Label, Randomized, 78-Week Study - The IMAGINE 1 Study|Completed||Phase 3|455|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 21:53:36.490637|2018-05-31 21:53:36.490637
NCT01481766|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-05-02|2011-11-25|2011-11-30|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2012||2012-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|OptEC||Iron Treatment for Young Children With Non-anemic Iron Deficiency|Optimizing Early Child Development in the Primary Care Practice Setting: Pragmatic Randomized Trial of Iron Treatment for Young Children With Non-anemic Iron Deficiency (OptEC)|Recruiting||Phase 4|230|Anticipated|The Hospital for Sick Children||4|||f||||f||||||||||2018-05-31 21:53:37.766444|2018-05-31 21:53:37.766444
NCT01481753|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-03-02|2011-11-29|2011-11-30|Estimate|||||||2017-03-02|2017-03-06|Actual|December 2009||2009-12-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pancreaticoduodenectomy With or Without Braun Enteroenterostomy: Comparison of Postoperative Pancreatic Fistula and Delayed Gastric Emptying||Terminated||N/A|341|Actual|Johns Hopkins University||2||"last patient recruited Feb 2015,completion of data review; study data do not meet statistical~   significance to answer proposed study question"|f||||t||||||||||2018-05-31 21:53:37.889178|2018-05-31 21:53:37.889178
NCT01481740|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|2016-09-14||2018-03-22|2011-11-25|2011-11-30|Estimate|2016-09-14|2016-11-02|Estimate||||2018-03-22|2018-04-23|Actual|November 2010||2010-11-30|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)|A Double Blind Randomized Controlled Trial of Phenylephrine for the Prevention of Spinal Induced Hypotension in Obese Parturients|Completed||Phase 4|178|Actual|IWK Health Centre||2|||f||||t||||||||||2018-05-31 21:53:37.959689|2018-05-31 21:53:37.959689
NCT01480349|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-12-21|2011-11-23|2011-11-28|Estimate|||||||2017-12-21|2017-12-26|Actual|January 10, 2011|Actual|2011-01-10|December 2017|2017-12-31|May 10, 2016|Actual|2016-05-10|May 10, 2016|Actual|2016-05-10||Observational|SOPHH||Shunt Outcomes of Post-Hemorrhagic Hydrocephalus|Shunt Outcomes of Post-Hemorrhagic Hydrocephalus: A Network Pilot Study|Completed|||146|Actual|University of Utah|||||f||||f||||||||||2018-05-31 21:53:54.600371|2018-05-31 21:53:54.600371
NCT01481714|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|||Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies|Phase IV, Prospective, Randomized Study Comparing Preparation the Day Before and Split-dose Regimen With Sodium Picosulphate/Magnesium Citrate for Morning Colonoscopies|Unknown status|Recruiting|Phase 4|300|Anticipated|Infante, Javier Molina, M.D.||2|||f||||t||||||||||2018-05-31 21:53:38.429851|2018-05-31 21:53:38.429851
NCT01481701|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2014-10-14|2011-11-25|2011-11-29|Estimate|||||||2014-10-14|2014-10-15|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma|A Non Randomized Stratified Phase II Trial Evaluating Efficacy and Safety of Oxaliplatin in Combination With 5-Fluorouracil in Patients With Platinum-sensitive and Platinum-resistant Recurrent Ovarian Carcinoma|Completed||Phase 2|90|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 21:53:38.558329|2018-05-31 21:53:38.558329
NCT01481688|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise|Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial.|Unknown status|Recruiting|Phase 4|14|Anticipated|Bangor University||3|||f||||f||||||||||2018-05-31 21:53:38.67536|2018-05-31 21:53:38.67536
NCT01481675|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-11-29|2011-11-24|2011-11-29|Estimate|||||||2011-11-29|2011-11-30|Estimate|May 2007||2007-05-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Diabetes Resolution and Hormone Changes After BPDLL and LSG|Resolution of Diabetes and Hormonal Changes Following Biliopancreatic Diversion Long Limbs and Laparoscopic Sleeve Gastrectomy. A Comparative Prospective Study.|Completed|||24|Actual|University of Patras|||2||f||||f||||||||||2018-05-31 21:53:38.790999|2018-05-31 21:53:38.790999
NCT01481662|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-12-20|2011-11-25|2011-11-29|Estimate|||||||2017-12-20|2017-12-21|Actual|November 2011||2011-11-30|June 2017|2017-06-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|CARESS||Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome|Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome (RETINOCOCHLEOCEREBRAL Vasculopathy)|Recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     -  serum sample~        -  cerebrospinal fluid sample~        -  DNA sample~        -  RNA sample~        -  Peripheral Blood Mononuclear Cell sample~   "|Undecided||2018-05-31 21:53:38.871711|2018-05-31 21:53:38.871711
NCT01481649|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2016-04-13|2011-11-28|2011-11-29|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Observational|||Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure|Risk of Hepatitis B Reactivation After Hematopoietic Stem Cell Transplantation in Donors and Recipients With Prior HBV Exposure|Completed|||69|Actual|The University of Hong Kong|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma for hepatitis B virus genotypic, virologic and serologic testing~   "|||2018-05-31 21:53:38.975752|2018-05-31 21:53:38.975752
NCT01481636|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2014-06-16|2011-11-24|2011-11-29|Estimate|||||||2014-06-16|2014-06-17|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|OSA||Assessing the Symptoms of Obstructive Sleep Apnea|Association of Health Outcomes With Severity of OSA Symptomatology- a Correlation Study.|Completed|||66|Actual|Bangor University|||1||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-05-31 21:53:39.046547|2018-05-31 21:53:39.046547
NCT01481623|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2015-06-01|2011-11-25|2011-11-29|Estimate|||||||2015-06-01|2015-06-03|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|DIAGENE||Identification and Characterization of Monogenic Diabetes|Identification and Genetic, Clinical and Metabolic Characterization of Monogenic Forms of Insulin-dependent Diabetes|Unknown status|Recruiting|N/A|1000|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 21:53:39.151049|2018-05-31 21:53:39.151049
NCT01481610|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-02-11|2011-11-25|2011-11-29|Estimate|||||||2013-02-11|2013-02-13|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia|Comparison of the Effects on Renal Function of Lumiracoxib and Diclofenac in Patients With Chronic Kidney Failure K/DOQI Stage III at the HCSAE PEMEX|Terminated||Phase 2|28|Actual|Hospital Central Sur de Pemex||2||Interim analysis shows harma to one of the study arms.|f||||f||||||||||2018-05-31 21:53:39.243672|2018-05-31 21:53:39.243672
NCT01481597|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-05-14|2011-11-25|2011-11-29|Estimate|||||||2012-05-14|2012-05-16|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Deuteporfin Tolerance and Pharmacokinetics in Healthy Volunteers|Tolerance and Pharmacokinetics of Single-dose Intravenous Deuteporfin in Healthy Volunteers|Completed||Phase 1|32|Actual|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||5|||f||||f||||||||||2018-05-31 21:53:39.33321|2018-05-31 21:53:39.33321
NCT01481584|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-03-04|2011-11-24|2011-11-29|Estimate|||||||2015-03-04|2015-03-05|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|July 2010|Actual|2010-07-31||Interventional|||Nutritional Evaluation of Canola Protein in Comparison With Soy Protein|Comparison of the Bioavailability the of a Single Administration of Two Canola Proteins (Hydrolyzate, Isolate) and Soy Protein in Healthy Men.|Completed||N/A|28|Actual|University of Jena||4|||f||||t||||||||||2018-05-31 21:53:39.410299|2018-05-31 21:53:39.410299
NCT01481571|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18||2013-12-27|2014-02-24|2011-11-28|2011-11-29|Estimate||||2014-02-24|2014-03-24|Estimate|2014-02-24|2014-03-24|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Performance Study of New Media for Vitrification of Human Oocytes|Performance Study of New Media for Vitrification of Human Oocytes|Completed||N/A|17|Actual|Vitrolife||1|||f||||f||||||||||2018-05-31 21:53:39.51598|2018-05-31 21:53:39.51598
NCT01481558|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|2013-03-20||2013-12-09|2011-11-28|2011-11-29|Estimate|2013-12-09|2014-01-09|Estimate||||2013-12-09|2014-01-09|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's Disease|Effects of Transcranial Direct Current Stimulation on the Apathy of Alzheimer's: a Randomized, Sham-controlled Clinical Trial|Completed||Phase 2|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:53:39.593439|2018-05-31 21:53:39.593439
NCT01478815|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-01-15|2011-11-22|2011-11-23|Estimate|||||||2013-01-15|2013-01-16|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Contingency Management for Persons With Severe Mental Illness|Contingency Management for Persons With Severe Mental Illness|Completed||Phase 2|19|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 21:54:24.059792|2018-05-31 21:54:24.059792
NCT01481545|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2017-09-13|2011-11-25|2011-11-29|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2006||2006-12-31|November 2015|2015-11-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|BRANCH||Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer|Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer: the BRANCH Trial|Active, not recruiting||Phase 2|46|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 21:53:39.836149|2018-05-31 21:53:39.836149
NCT01481532|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-01-31|2011-11-28|2011-11-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Open Label Clinical Trial of Intravenous Crotoxin|Open Label Phase I Clinical Trial of Crotoxin in Patients With Advanced Cancer Using an Intravenous Route of Administration|Recruiting||Phase 1|18|Anticipated|Celtic Biotech Ltd||1|||f||||t|t|f|||t|||||2018-05-31 21:53:39.913223|2018-05-31 21:53:39.913223
NCT01481519|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2014-12-02|2011-11-28|2011-11-29|Estimate|||||||2014-12-02|2014-12-04|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis|A Randomized, Double-Masked Trial of Topical Dexamethasone 0.1%/Povidone-iodine 0.4% Versus Artificial Tears for Treatment of Viral Conjunctivitis|Completed||Phase 3|100|Anticipated|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 21:53:39.997968|2018-05-31 21:53:39.997968
NCT01481506|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|SweetAge||Multiparametric Telemonitoring In Elderly People With Chronic Obstructive Pulmonary Disease|Efficacy Of Multiparametric Telemonitoring On Respiratory Outcomes In Elderly People With Chronic Obstructive Pulmonary Disease.|Completed||N/A|100|Actual|Campus Bio-Medico University||2|||f||||t||||||||||2018-05-31 21:53:40.102809|2018-05-31 21:53:40.102809
NCT01481493|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2015-02-19|2011-11-25|2011-11-29|Estimate|||||||2015-02-19|2015-02-20|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)|A Multi-center, Double-blind, Randomized, Placebo-controlled, Dose-finding Study in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable MTX Doses to Investigate Efficacy and Safety of SC BT061|Completed||Phase 2|127|Actual|Biotest||2|||f||||t||||||||||2018-05-31 21:53:40.183034|2018-05-31 21:53:40.183034
NCT01481480|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2017-11-23|2011-11-24|2011-11-29|Estimate|||||||2017-11-23|2017-11-27|Actual|August 2012||2012-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Latissimus Dorsi Tendon Transfer or Partial Arthroscopic Repair of Massive Rotator Cuff Tears|A Multicenter, Randomized Controlled Trial Comparing Functional Outcomes After Latissimus Dorsi Tendon Transfer or Partial Arthroscopic Repair of Massive Rotator Cuff Tears|Recruiting||N/A|108|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:53:40.386764|2018-05-31 21:53:40.386764
NCT01481467|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-12-19|2011-11-23|2011-11-29|Estimate|||||||2011-12-19|2011-12-20|Estimate|April 2009||2009-04-30|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Evaluation of an Influenza Vaccination Implementation Strategy for Hospital Health Care Workers|Evaluation of a Multi-faceted Influenza Vaccination Implementation Strategy for Health Care Workers in Hospitals|Unknown status|Recruiting|N/A|6|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 21:53:40.483979|2018-05-31 21:53:40.483979
NCT01481454|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-03-28|2011-11-25|2011-11-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults|Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Child/Adolescent and Adult Subjects|Completed||Phase 3|1701|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 21:53:40.585933|2018-05-31 21:53:40.585933
NCT01481441|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2016-07-04|2011-11-28|2011-11-29|Estimate|||||||2016-07-04|2016-07-06|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|AMC_2011_190||Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer|Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer|Terminated||N/A|208|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1||New study protocol started including targeted biopsies|f||||f||||||||||2018-05-31 21:53:40.69899|2018-05-31 21:53:40.69899
NCT01481428|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-01-06|2011-11-28|2011-11-29|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Reducing High Risk Behavior in Treatment Court|Delivering HIV Risk Reduction Services in Treatment Court|Completed||Phase 1|371|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-05-31 21:53:40.770926|2018-05-31 21:53:40.770926
NCT01481415|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2011-12-03|2011-11-28|2011-11-29|Estimate|||||||2011-12-03|2011-12-06|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|November 2011|Actual|2011-11-30||Observational|||Left Atrial Volume and Function in Children Assessed by Echo 3DRT: Reference Values for Normal Children|Left Atrial Volume and Function in Healthy Children Assessed by Three Dimensional Echocardiography|Unknown status|Recruiting||145|Anticipated|Hospital Israelita Albert Einstein|||||f||||t||||||||||2018-05-31 21:53:40.852529|2018-05-31 21:53:40.852529
NCT01481402|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2014-02-25|2011-11-28|2011-11-29|Estimate|||||||2014-02-25|2014-02-26|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|LIHFA||Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)|Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Heart Function, Body Composition and Metabolic Status|Completed||N/A|21|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 21:53:40.980203|2018-05-31 21:53:40.980203
NCT01481389|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-09-17|2011-11-28|2011-11-29|Estimate|||||||2012-09-17|2012-09-18|Estimate|December 2010||2010-12-31|September 2012|2012-09-30||||January 2011|Actual|2011-01-31||Interventional|||The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects|The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects|Completed||N/A|152|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 21:53:41.06656|2018-05-31 21:53:41.06656
NCT01481376|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-12-06||2015-12-08|2011-11-23|2011-11-29|Estimate|2014-01-29|2014-03-17|Estimate||||2015-12-08|2016-01-07|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|April 2013|Actual|2013-04-30|October 2011|Actual|2011-10-31||Observational|||TAPP Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh|Laparoscopic Transabdominal Preperitoneal (TAPP) Inguinal Hernia Repair With Self-fixating Parietex™ ProGrip™ Mesh: A Retrospective Study With 12 Month Follow-up|Completed|||200|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 21:53:41.159702|2018-05-31 21:53:41.159702
NCT01481363|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-07-18|2011-11-28|2011-11-29|Estimate|||||||2014-07-18|2014-07-21|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||The Talking Sense Communication Programme for Dementia Carers|A Feasibility Study of a Psychosocial Intervention - The Talking Sense Communication Programme for Dementia Family Carers|Completed||Phase 1/Phase 2|55|Actual|University of Portsmouth||2|||f||||t||||||||||2018-05-31 21:53:41.349578|2018-05-31 21:53:41.349578
NCT01481350|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2014-12-06|2011-11-28|2011-11-29|Estimate|||||||2014-12-06|2014-12-09|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|SiPaHCS||Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery|Phase 2 Use of Sildenafil for the Treatment of Post-capillary Hypertension in Patients Undergoing Cardiac Surgery|Completed||Phase 2|20|Actual|University of Turin, Italy||1|||f||||f||||||||||2018-05-31 21:53:41.438056|2018-05-31 21:53:41.438056
NCT01481337|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-04-22|2011-11-28|2011-11-29|Estimate|||||||2014-04-22|2014-04-23|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|OPERA||Endoscopic Mucosal Colonic Resection and Polypectomy Under Aspirin|"Prospective Observatory of Endoscopic Mucosal Colonic Resection and Polypectomy Under Aspirin : the OPERA Study"|Completed|||317|Actual|Société Française d'Endoscopie Digestive|||1||f||||f||||||||||2018-05-31 21:53:41.529407|2018-05-31 21:53:41.529407
NCT01481324|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2014-05-13||2014-11-17|2011-11-23|2011-11-29|Estimate|2014-11-17|2014-11-24|Estimate||||2014-11-17|2014-11-24|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Observational||Number analyzed in each group|Outcomes of Compliance With Brace Wear in Clubfoot|Measurement of Compliance in Clubfoot Bracing Via a Novel Pressure Sensor|Completed|||67|Actual|Shriners Hospitals for Children|As shown in the monthly completion numbers, most families complied during the first month of treatment. After the first month, not only did the wear rates drop significantly, but also the number of subjects reporting sensor and diary data.||3||f||||f||||||||||2018-05-31 21:53:41.634099|2018-05-31 21:53:41.634099
NCT01481311|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2012-10-02|2011-11-23|2011-11-29|Estimate|||||||2012-10-02|2012-10-03|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)|Detection of Patients With Abnormal Water Distribution Based on Bioelectrical Impedance Analysis (BIA)|Completed|||62|Actual|Seca GmbH & Co. Kg.|||2||f||||t||||||||||2018-05-31 21:53:41.95921|2018-05-31 21:53:41.95921
NCT01481298|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|December 2004||2004-12-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Observational|||Value of Cardiac Magnetic Resonance (CMR) Derived Parameters for Diagnosing Left Ventricular Non-compaction Cardiomyopathy|Value of Different Myocardial Parameters to Differentiate Left Ventricular Noncompaction Cardiomyopathy From Other Cardiomyopathies and Healthy Controls by Cardiac Magnetic Resonance|Completed|||57|Actual|University of Leipzig|||4||f||||f||||||||||2018-05-31 21:53:42.048757|2018-05-31 21:53:42.048757
NCT01481285|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-10-02|2011-11-23|2011-11-29|Estimate|||||||2012-10-02|2012-10-04|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Generation of Normal Ranges to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)|Generation of Normal Ranges to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)|Completed|||992|Actual|Seca GmbH & Co. Kg.|||1||f||||t||||||||||2018-05-31 21:53:42.117371|2018-05-31 21:53:42.117371
NCT01481272|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-07-12|2011-11-28|2011-11-29|Estimate|||||||2017-07-12|2017-07-17|Actual|November 2011||2011-11-30|July 2017|2017-07-31||||July 2017|Actual|2017-07-31||Interventional|PLRG8||Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients|A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant|Completed||Phase 2|77|Actual|Polish Lymphoma Research Group||1|||f||||t||||||||No||2018-05-31 21:53:42.212212|2018-05-31 21:53:42.212212
NCT01481259|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-07-02|2011-11-23|2011-11-29|Estimate|||||||2012-07-02|2012-07-03|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Interventional|||Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer|Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Stage IIIb/IV Nonsquamous Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|People's Hospital of Guangxi||2|||f||||t||||||||||2018-05-31 21:53:42.333337|2018-05-31 21:53:42.333337
NCT01481246|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2018-05-01|2011-11-28|2011-11-29|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2009||2009-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|NEUROAGE||Neurocognitive Study for the Aging|The Neurocognitive Study for the Aging|Recruiting|||400|Anticipated|University of Cyprus|||1||f||||t||||||Samples With DNA|"~     APOE phenotyping~   "|||2018-05-31 21:53:42.412237|2018-05-31 21:53:42.412237
NCT01481233|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2013-09-26|2011-11-23|2011-11-29|Estimate|||||||2013-09-26|2013-09-27|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Oral Colchicine in Men With Castrate Resistant Prostate Cancer|Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy|Withdrawn||Phase 2|0|Actual|Milton S. Hershey Medical Center||1||Due to funding|f||||t||||||||||2018-05-31 21:53:42.508406|2018-05-31 21:53:42.508406
NCT01481220|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2013-05-02|2011-11-28|2011-11-29|Estimate|||||||2013-05-02|2013-05-03|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|NMDSG10A||Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)|A Pilot Phase I Dose Finding Safety Study of a Thrombopoietin-receptor Agonist, Eltrombopag, in Patients With Myelodysplastic Syndrome Treated With Azacitidine|Completed||Phase 1|12|Actual|Nordic MDS Group||1|||f||||t||||||||||2018-05-31 21:53:42.602706|2018-05-31 21:53:42.602706
NCT01481207|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2018-05-16|2011-11-24|2011-11-29|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2011||2011-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy|Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy|Recruiting|||60|Anticipated|University Children's Hospital, Zurich|||1||f||||f||||||||No||2018-05-31 21:53:42.71255|2018-05-31 21:53:42.71255
NCT01481194|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2018-02-08|2011-11-24|2011-11-29|Estimate|||||||2018-02-08|2018-02-09|Actual|November 2011||2011-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|May 2014|Actual|2014-05-31||Interventional|ACVDL||ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma|An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination With Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|35|Anticipated|Vejle Hospital||1|||f||||t||||||||||2018-05-31 21:53:42.808356|2018-05-31 21:53:42.808356
NCT01481181|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2014-02-27|2011-11-28|2011-11-29|Estimate|||||||2014-02-27|2014-02-28|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||An Efficacy Trial of a Gravity Fed Household Water Treatment Device as a Delivery System for Zinc|An Efficacy Trial of a Gravity Fed Household Water Treatment Device as a Delivery System for Zinc in Zinc Deficient Children and Women From Low Income Settings|Completed||N/A|270|Actual|Wageningen University||3|||f||||f||||||||||2018-05-31 21:53:42.900415|2018-05-31 21:53:42.900415
NCT01481168|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-11-17|2011-11-28|2011-11-29|Estimate|||||||2017-11-17|2017-11-20|Actual|April 12, 2012|Actual|2012-04-12|November 2017|2017-11-30|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Interventional|ADEPT-ILR||Adenosine Testing to DEtermine the Need for Pacing Therapy|Adenosine Testing to DEtermine the Need for Pacing Therapy With the Additional Use of an Implantable Loop Recorder (ADEPT-ILR Study). The Efficacy of Permanent Pacing in Patients With Syncope and a Positive Intravenous Adenosine Test: a Randomised, Double-blind, Placebo-controlled, Cross-over Trial.|Completed||N/A|52|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||3|||f||||t||||||||||2018-05-31 21:53:42.99837|2018-05-31 21:53:42.99837
NCT01481155|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-12-07|2011-11-24|2011-11-29|Estimate|||||||2011-12-07|2011-12-08|Estimate|March 2011||2011-03-31|December 2011|2011-12-31||||December 2011|Anticipated|2011-12-31||Interventional|||Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses|Prospective, Single-center, Investigator-blinded, Randomized, Half-side, Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses|Unknown status|Active, not recruiting|N/A|21|Actual|Ruhr University of Bochum|||||f||||||||||||||2018-05-31 21:53:43.103867|2018-05-31 21:53:43.103867
NCT01481142|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-10-16|2011-11-24|2011-11-29|Estimate|||||||2015-10-16|2015-10-19|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|ART||Adacolumn in Refractory UC Patients Trial|Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies|Completed||Phase 4|100|Actual|Otsuka Pharmaceutical Europe Ltd||1|||f||||f||||||||||2018-05-31 21:53:43.157429|2018-05-31 21:53:43.157429
NCT01481129|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|2016-12-02||2017-08-30|2011-11-24|2011-11-29|Estimate|2017-02-23|2017-04-07|Actual||||2017-08-30|2017-09-28|Actual|December 2011|Actual|2011-12-31|August 2017|2017-08-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 21:53:43.223147|2018-05-31 21:53:43.223147
NCT01481116|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|2015-07-24||2016-04-24|2011-11-25|2011-11-29|Estimate|2016-04-24|2016-06-01|Estimate||||2016-04-24|2016-06-01|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional||The randomized set included all participants who were randomized.|Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination With Metformin in Subjects With Type 2 Diabetes|Terminated||Phase 3|2454|Actual|Takeda||3||Due to potential concerns about liver safety (See Detailed Description)|f||||t||||||||||2018-05-31 21:53:43.62895|2018-05-31 21:53:43.62895
NCT01481103|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2013-04-02|2011-11-23|2011-11-29|Estimate|||||||2013-04-02|2013-04-04|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Integrating Acupuncture Into the Management of Migraines|Integrating Acupuncture Into the Management of Migraines: A Randomized, Comparative Trial|Terminated||N/A|9|Actual|National University of Health Sciences||2||PI cited personal reasons|f||||t||||||||||2018-05-31 21:53:45.919494|2018-05-31 21:53:45.919494
NCT01481090|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-04-14|2011-11-23|2011-11-29|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Electro-acupuncture and Assisted Reproductive Technology|Electro-acupuncture and Assisted Reproductive Technology: Impact of EA on Endometrium During Medicated Frozen Embryo Transfer Uterine Preparation|Terminated||N/A|16|Actual|National University of Health Sciences||2||IRB violations|f||||t||||||||||2018-05-31 21:53:46.260391|2018-05-31 21:53:46.260391
NCT01481077|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25||2013-09-16|2013-09-19|2011-11-28|2011-11-29|Estimate||||2013-09-16|2013-09-19|Estimate|2013-09-19|2013-09-26|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma|PPL GLAU 13: A Randomized Phase 2 Study of the Effect of Plug Placement on Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)|Completed||Phase 2|77|Actual|Mati Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 21:53:46.35317|2018-05-31 21:53:46.35317
NCT01481064|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-07-22|2011-11-24|2011-11-29|Estimate|||||||2013-07-22|2013-07-23|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Interventional|||Effect and Cost Evaluation of a Multifaceted Approach With a Patient-centredness Questionnaire in Fertility Care|Effect and Cost Evaluation of a Multifaceted Approach Including Audit and Feedback With a Patient-centredness Questionnaire in Fertility Care.|Unknown status|Active, not recruiting|N/A|870|Anticipated|University Medical Center Nijmegen||2|||f||||f||||||||||2018-05-31 21:53:46.454841|2018-05-31 21:53:46.454841
NCT01481051|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25||2013-09-16|2013-09-19|2011-11-25|2011-11-29|Estimate||||2013-09-16|2013-09-19|Estimate|2013-09-19|2013-09-26|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma|PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)|Completed||Phase 2|57|Actual|Mati Therapeutics Inc.|||||f||||f||||||||||2018-05-31 21:53:46.518099|2018-05-31 21:53:46.518099
NCT01481038|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-05-02|2011-11-28|2011-11-29|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Observational|||Anticipative Diagnosis of Central Venous Catheter Related Bloodstream Infections|Anticipative Diagnosis of Central Venous Catheter Related Bloodstream Infections Using Biphasic PNA FISH and Gram Stain/AOLC Tests|Completed|||150|Actual|Medical University of Graz|||2||f||||f||||||Samples With DNA|"~     Serum samples~   "|||2018-05-31 21:53:46.595042|2018-05-31 21:53:46.595042
NCT01481025|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|CH||Efficacy and Safety for Cimicifuga/Hypericum Product|Phase 3 Study - Efficacy and Tolerance for the Mixture of Dry Extracts Black Cohosh and Saint John's Worth Versus Isolated Black Cohosh Extract for the Climacteric Symptoms' Control|Unknown status|Not yet recruiting|Phase 3|210|Anticipated|Phytopharm Consulting Brazil||3|||f||||t||||||||||2018-05-31 21:53:46.650094|2018-05-31 21:53:46.650094
NCT01481012|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-23|2011-11-23|2011-11-29|Estimate|||||||2011-11-23|2011-11-29|Estimate|January 2006||2006-01-31|November 2011|2011-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices|The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices|Terminated|||94|Actual|Icahn School of Medicine at Mount Sinai|||4|Slow enrollment - terminated for futility.|f||||t||||||Samples Without DNA|"~     Blood for the following markers of thrombin generation and platelet function will be drawn,~     spun, aliquoted and stored for later batched analysis: - Thrombo-antithrombin complex (TAT);~     - Prothrombin Fragment 1+2 (F1.2); - Thromboelastrograph (TEG) (performed at the clinical~     site when available); - Additional markers of coagulation and platelet activation (for future~     consideration) - 4ml of plasma frozen in 1ml aliquots.~   "|||2018-05-31 21:53:46.736334|2018-05-31 21:53:46.736334
NCT01480999|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-05-10|2011-11-24|2011-11-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|July 2015|Actual|2015-07-31||Observational|GOC2||Comparing Robotics and Laparoscopy With Laparotomy/Open Surgery for Endometrial Cancer|A Prospective Study Evaluating Surgical and Quality of Life Outcomes in Robotics and Laparoscopy Compared to Laparotomy in Early Stage Endometrial Cancer|Unknown status|Active, not recruiting||550|Actual|University Health Network, Toronto|||3||f||||t||||||||||2018-05-31 21:53:47.908744|2018-05-31 21:53:47.908744
NCT01480986|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2015-05-17|2011-11-25|2011-11-29|Estimate|||||||2015-05-17|2015-05-19|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional|||IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC|a Prospective Study on the Efficacy and Safety Using Sequential Therapy of Irinotecan Combined With Cisplatin (IP)and Octretide Lar in the First Line Treatment of Metastatic or Inoperable Gastrointestinal Poorly Differentiated Neuroendocrine Carcinoma: the IPO-NEC Trial|Completed||Phase 2|40|Actual|Peking University||1|||f||||f||||||||||2018-05-31 21:53:47.995215|2018-05-31 21:53:47.995215
NCT01480973|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-09-19|2011-11-28|2011-11-29|Estimate|||||||2017-09-19|2017-09-20|Actual|June 2011||2011-06-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|||Stereotactic Body Radiotherapy (RT) for Non-Small Cell Lung Cancer|MRI Assessment of Post-Radiation Change Following Stereotactic Body RT for Non-Small Cell Lung Cancer: A Pilot Study|Active, not recruiting||N/A|30|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-05-31 21:53:48.0785|2018-05-31 21:53:48.0785
NCT01480960|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2016-02-23|2011-11-24|2011-11-29|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of a Whole Body Vibration Training in Patients After Lung Transplantation|Effects of a Whole Body Vibration Training on the Exercise Performance in Patients After Lung Transplantation|Completed||N/A|140|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 21:53:48.152907|2018-05-31 21:53:48.152907
NCT01480947|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Bio-three||The Treatment Effect of Bio-Three on Children With Enteritis|The Treatment Effect of Bio-Three on Children With Enteritis Due to Salmonella or Rotavirus or Any Unknown Reason|Completed||Phase 4|80|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 21:53:48.241238|2018-05-31 21:53:48.241238
NCT01480934|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|June 2005||2005-06-30|November 2011|2011-11-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Observational|DM & PCO||Evaluation of Posterior Capsule Opacification in Eyes With Diabetes Mellitus|A Prospective Evaluation of Posterior Capsule Opacification in Eyes With Diabetes Mellitus -A Case Control Study|Completed|||150|Actual|Iladevi Cataract and IOL Research Center|||2||f||||t||||||||||2018-05-31 21:53:48.324211|2018-05-31 21:53:48.324211
NCT01480921|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-23|2011-11-23|2011-11-29|Estimate|||||||2011-11-23|2011-11-29|Estimate|July 2003||2003-07-31|November 2011|2011-11-30|November 2007|Actual|2007-11-30|June 2006|Actual|2006-06-30||Interventional|PEAK-HF||Hospital Versus Home Based Exercise in Patients With Chronic Stable Heart Failure|The Effect of Hospital Versus Home-based Exercise on Psychosocial and Physical Outcomes in Patients With Chronic Stable Heart Failure|Completed||N/A|62|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 21:53:48.478405|2018-05-31 21:53:48.478405
NCT01480908|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2014-12-02|2011-11-24|2011-11-29|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Right Bundle Branch Block After Surgical Closure of Ventricular Septal Defect|Postoperative Right Bundle Branch Block - Long-term Effect on the Right Ventricle in Children Operated for Ventricular Septal Defect|Completed||N/A|60|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 21:53:48.562797|2018-05-31 21:53:48.562797
NCT01480895|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|March 2007||2007-03-31|November 2011|2011-11-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|GDM||Prevention of Diabetes Mellitus Type 2 in Women Post Gestational Diabetes Mellitus Diagnosis|Identification of Risk Factors for DM Type 2 in Women Post GDM Diagnosis and Its Prevention by Changing Life Style|Completed||N/A|180|Actual|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 21:53:48.678738|2018-05-31 21:53:48.678738
NCT01480882|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2012-12-04|2011-11-24|2011-11-29|Estimate|||||||2012-12-04|2012-12-06|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|LEGA||Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage|"A Prospective, Cross-over Randomized Trial to Assess the Efficacy and Safety of Mechanical Percussor LEGA Compared With Conventional Chest Physiotherapy in Adults With Chronic Bronchiectasis or Chronic Obstructive Pulmonary Disease (COPD"|Completed||Phase 2/Phase 3|20|Actual|Penang Hospital, Malaysia||2|||f||||t||||||||||2018-05-31 21:53:48.766047|2018-05-31 21:53:48.766047
NCT01480869|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-07-29|2011-11-28|2011-11-29|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|VITACAL||Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients|Randomized Phase III Trial Comparing Conventional Vitamin D Supplementation vs. Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients Treated by Neoadjuvant or Adjuvant Chemotherapy.|Completed||Phase 3|264|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f||||||||||2018-05-31 21:53:48.891913|2018-05-31 21:53:48.891913
NCT01480856|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2014-10-14|2011-11-28|2011-11-29|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|February 2014|Actual|2014-02-28|January 2012|Actual|2012-01-31||Interventional|Cobedding||Cobedding in Daily Weight Gain of Neonate Twins|Evaluation of the Efficacy of Cobedding in Daily Weight Gain of Neonate Twins|Completed||N/A|64|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 21:53:48.995763|2018-05-31 21:53:48.995763
NCT01480843|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|2017-04-25||2017-10-09|2011-11-23|2011-11-29|Estimate|2017-10-09|2017-11-08|Actual||||2017-10-09|2017-11-08|Actual|June 2011||2011-06-30|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SIMPLE||Simplified Insulin Protocol Using Lantus in Elderly|Simplification of Diabetes Regimen in Elderly Patients Using Glargine|Completed||Phase 4|65|Actual|Joslin Diabetes Center||1|||f||||t||||||||Undecided||2018-05-31 21:53:49.124154|2018-05-31 21:53:49.124154
NCT01480830|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2013-12-01|2011-11-28|2011-11-29|Estimate|||||||2013-12-01|2013-12-03|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|SCOPE GUIDE||The Use of Magnetic Endoscopic Imaging for Improving Quality Indicators in Outpatient Colonoscopy|The Use of Magnetic Endoscopic Imaging for Improving Quality Indicators in Outpatient Colonoscopy|Completed||N/A|633|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 21:53:49.342678|2018-05-31 21:53:49.342678
NCT01480817|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2016-04-28|2011-11-24|2011-11-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Sorafenib VS TACE in HCC Patients With Portal Vein Invasion|An Open Label, Phase 2 Trial Comparing Sorafenib And TACE in Advanced Hepatocellular Carcinoma With Portal Vein Invasion|Terminated||Phase 2|2|Actual|Seoul National University Hospital||2||Difficulty of participant enrollment.|f||||f||||||||||2018-05-31 21:53:49.407606|2018-05-31 21:53:49.407606
NCT01480804|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2014-03-26|2011-11-23|2011-11-29|Estimate|||||||2014-03-26|2014-03-28|Estimate|November 2006||2006-11-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DISCO||Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study|Identifying and Overcoming Barriers to Diabetes Management in the Elderly: An Intervention Study|Completed||N/A|48|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-05-31 21:53:49.485736|2018-05-31 21:53:49.485736
NCT01480791|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2015-05-18|2011-11-24|2011-11-29|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries|A Double-Blind, Randomized, Parallel Design Study of Aliskiren Versus Hydrochlorothiazide in Mild-to Moderate Hypertensive Type II Diabetes Mellitus Patients on Remodeling of Resistance Arteries|Withdrawn||Phase 2|0|Actual|Sir Mortimer B. Davis - Jewish General Hospital||3||Because of results of Altitude trial, this trial was cancelled.|f||||f||||||||||2018-05-31 21:53:49.580396|2018-05-31 21:53:49.580396
NCT01480778|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2016-03-02|2011-11-28|2011-11-29|Estimate|||||||2016-03-02|2016-03-03|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.|Pharmacodynamic Assessment to Drug Ciclo 21 (Levonorgestrel + Ethinyl Estradiol) Market by União Química Farmacêutica Nacional S/A Compared to Drug Nordette of Wieth Indústria Farmacêutica Ltda.|Completed||Phase 3|62|Actual|Azidus Brasil||2|||f||||t||||||||Yes|The study data will be maked available after journal's approbation. The manuscript contained all of data it has been submitted.|2018-05-31 21:53:49.749449|2018-05-31 21:53:49.749449
NCT01480765|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2012-11-11|2011-11-24|2011-11-29|Estimate|||||||2012-11-11|2012-11-14|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Preventing Pain After Heart Surgery|Prospective, Double-blinded, Randomised, Placebo Controlled Trial of Pre-emptive Analgesia to Prevent Pain Following Sternotomy for Cardiac Surgery.|Unknown status|Recruiting|Phase 4|150|Anticipated|Barts & The London NHS Trust||3|||f||||t||||||||||2018-05-31 21:53:49.842005|2018-05-31 21:53:49.842005
NCT01480752|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2013-01-11|2011-11-24|2011-11-29|Estimate|||||||2013-01-11|2013-01-14|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Reduction of Post-operative Endodontic Pain|the Effect of Intraligamentary Injection of Lornoxicam on the Intensity of Post-operative Endodontic Pain in the Tooth With Symptomatic Irreversible Pulpitis|Completed||Phase 2|60|Actual|Islamic Azad University, Tehran||3|||f||||t||||||||||2018-05-31 21:53:49.942453|2018-05-31 21:53:49.942453
NCT01480739|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-06-24|2011-11-24|2011-11-29|Estimate|||||||2015-06-24|2015-06-25|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||AZD5069 Neutrophil Function Study|A Randomised, Double-blind, Placebo-Controlled, Two-way Cross-over, Single Centre Study in Healthy Subjects to Assess the Effect of Oral Dosing of AZD5069 on Neutrophil Number and Function in Peripheral Blood and the Ability to Recruit Neutrophils Into the Circulation After Exercise and Subcutaneous|Completed||Phase 1|30|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:53:50.088882|2018-05-31 21:53:50.088882
NCT01480726|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-04-13|2011-11-28|2011-11-29|Estimate|||||||2015-04-13|2015-04-14|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|January 2015|Actual|2015-01-31|December 2013|Actual|2013-12-31||Observational|||Long-term Results Following Endoscopic Vein Harvesting in Coronary Artery Bypass Surgery|Endoscopic Versus Open Vein Harvest in Coronary Artery Bypass Grafting. Clinical and CT-angiographic Long-term Result From a Randomized Study.|Completed|||132|Actual|Aalborg Universitetshospital|||2||f||||f||||||||||2018-05-31 21:53:50.174183|2018-05-31 21:53:50.174183
NCT01480713|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-06-27|2011-11-28|2011-11-29|Estimate|||||||2014-06-27|2014-06-30|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors|Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors. A 24-week Open-label, Proof-of-concept Pilot Clinical Trial.|Completed||Phase 3|41|Actual|IrsiCaixa||1|||f||||f||||||||||2018-05-31 21:53:50.250407|2018-05-31 21:53:50.250407
NCT01480700|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2013-08-02|2011-11-28|2011-11-29|Estimate|||||||2013-08-02|2013-08-05|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ALGOVUE||Consumption of Eggs Rich in Lutein and Omega-3 Fatty Acids on the Macular Pigment|Effect of Consumption of Eggs Rich in Xanthophyll Carotenoids and Omega-3 Fatty Acids on the Macular Pigment in Healthy People|Completed||N/A|99|Actual|Institut Pasteur de Lille||2|||f||||t||||||||||2018-05-31 21:53:50.33822|2018-05-31 21:53:50.33822
NCT01480687|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-11-23|2011-11-23|2011-11-29|Estimate|||||||2011-11-23|2011-11-29|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia|Effects of Fish Oil Supplementation on Vascular Structure and Function in Hypertensive Patients With Hypertriglyceridemia|Unknown status|Recruiting|Phase 4|52|Anticipated|Hospital Universitario Pedro Ernesto||2|||f||||t||||||||||2018-05-31 21:53:50.41537|2018-05-31 21:53:50.41537
NCT01480674|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|2016-01-27||2017-07-07|2011-11-28|2011-11-29|Estimate|2016-01-27|2016-02-24|Estimate||||2017-07-07|2017-08-16|Actual|March 28, 2011|Actual|2011-03-28|June 2017|2017-06-30|November 16, 2012|Actual|2012-11-16|November 16, 2012|Actual|2012-11-16||Observational||Analyzed set population included all enrolled participants without any protocol deviation used as a primary analysis population for all efficacy outcome measures.|An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years|A Retrospective Study to Characterize Patients With HER2-positive Metastatic or Locally Advanced Breast Cancer, Treated by Herceptin® as 1st Line-therapy and Without Progression for at Least 3 Years Followed by a 1-year Prospective Study for Patients Still Alive|Completed|||160|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:53:50.546046|2018-05-31 21:53:50.546046
NCT01480661|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-09-18|2011-11-28|2011-11-29|Estimate|||||||2013-09-18|2013-09-19|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients|Analysis of Airway Responses in Severe COPD Patients to Daxas®, Using CT Based Functional Respiratory Imaging|Completed||Phase 4|41|Actual|FLUIDDA nv||2|||f||||f||||||||||2018-05-31 21:53:51.00465|2018-05-31 21:53:51.00465
NCT01480648|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-10-31|2011-11-24|2011-11-29|Estimate|||||||2013-10-31|2013-11-01|Estimate|November 2011||2011-11-30|October 2013|2013-10-31||||February 2012|Actual|2012-02-29||Interventional|||Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 144807 Powder in Bottle (1 to 1200 mg) in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Trial|Completed||Phase 1|74|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:53:51.086199|2018-05-31 21:53:51.086199
NCT01480635|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Observational|PCCE||PillCam Colon 2 Capsule Endoscopy (PCCE) After Incomplete Colonoscopy|Evaluation of the PillCam Colon Capsule Endoscopy (PCCE) After Incomplete Colonoscopy|Unknown status|Recruiting||74|Anticipated|Bethesda Krankenhaus|||1||f||||t||||||||||2018-05-31 21:53:51.149435|2018-05-31 21:53:51.149435
NCT01480622|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-06-13|2011-11-23|2011-11-29|Estimate|||||||2017-06-13|2017-06-14|Actual|December 5, 2011|Actual|2011-12-05|June 2017|2017-06-30|December 30, 2011|Actual|2011-12-30|December 30, 2011|Actual|2011-12-30||Interventional|PK of TDF||Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects|An Open-label Single and Repeat Dose Study to Investigate the Pharmacokinetic Profiles of Tenofovir Disoproxil Fumarate 300 mg in Healthy Chinese Subjects|Completed||Phase 1|14|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:53:51.229718|2018-05-31 21:53:51.229718
NCT01480609|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2018-05-17|2011-11-23|2011-11-29|Estimate|||||||2018-05-17|2018-05-18|Actual|November 30, 2011|Actual|2011-11-30|May 2018|2018-05-31|April 24, 2012|Actual|2012-04-24|April 24, 2012|Actual|2012-04-24||Interventional|||Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite|An Open Label, Single-dose, Fixed Sequence, Two Treatment Period Study to Assess the Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR).|Completed||Phase 1|8|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:53:51.399776|2018-05-31 21:53:51.399776
NCT01480596|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2016-03-24||2016-12-15|2011-11-23|2011-11-29|Estimate|2016-03-24|2016-04-27|Estimate||||2016-12-15|2017-02-09|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||The Evaluation of Belimumab in Myasthenia Gravis (MG)|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects With Generalized Myasthenia Gravis (MG)|Completed||Phase 2|40|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:53:51.549542|2018-05-31 21:53:51.549542
NCT01480583|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16||2016-07-11|2016-07-11|2011-11-23|2011-11-29|Estimate||||2016-07-11|2016-07-13|Estimate|2016-07-11|2016-07-13|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|GRABM-B||GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases|A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases|Completed||Phase 2|85|Actual|Angiochem Inc||2|||f||||f||||||||||2018-05-31 21:53:52.397458|2018-05-31 21:53:52.397458
NCT01480570|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2015-02-09|2011-11-28|2011-11-29|Estimate|||||||2015-02-09|2015-02-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:53:52.512046|2018-05-31 21:53:52.512046
NCT01480557|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-01-14|2011-11-28|2011-11-29|Estimate|||||||2017-01-14|2017-01-18|Estimate|April 2011||2011-04-30|January 2017|2017-01-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Aqualase Versus Torsional ip. A Study on Endothelial Cells, Corneal Edema and Corneal Sensitivity|Liquefaction Versus Torsional ip. A Comparative Study on Endothelial Cells, Corneal Edema and Corneal Sensitivity|Completed||N/A|75|Actual|Democritus University of Thrace||2|||f||||f||||||||||2018-05-31 21:53:52.550059|2018-05-31 21:53:52.550059
NCT01480544|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2015-12-14|2011-11-28|2011-11-29|Estimate|||||||2015-12-14|2015-12-16|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Interventional|IMATCHINE||Improving Maternal and Child Health in India: Evaluating Demand and Supply Side Strategies (IMATCHINE)|Improving Maternal and Child Health in India: Evaluating Demand and Supply Side Strategies|Completed||N/A|14990|Anticipated|Duke University||4|||f||||f||||||||||2018-05-31 21:53:52.648212|2018-05-31 21:53:52.648212
NCT01480531|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2013-02-07|2011-11-23|2011-11-29|Estimate|||||||2013-02-07|2013-02-11|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|Clevidipine||Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection|Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection.|Withdrawn||N/A|0|Actual|Duke University||||We elected to stop this study due to our inability to recruit suitable subjects.|f||||f||||||||||2018-05-31 21:53:52.747321|2018-05-31 21:53:52.747321
NCT01480518|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-05-08|2011-11-28|2011-11-29|Estimate|||||||2015-05-08|2015-05-12|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Biomarkers in Tissue Samples From Patients With Ewing Sarcoma|Analysis of GGAA-Microsatellites in Ewing Sarcoma|Completed|||166|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 21:53:52.832546|2018-05-31 21:53:52.832546
NCT01480505|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|October 1999||1999-10-31|November 2011|2011-11-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Observational|||Primary Vitrectomy for the Treatment of Retinal Detachment in Highly Myopic||Completed|||840|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||f||||||||||2018-05-31 21:53:52.898758|2018-05-31 21:53:52.898758
NCT01480492|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-28|2011-11-28|2011-11-29|Estimate|||||||2011-11-28|2011-11-29|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection|Study the Effect of Nucleoside on Host Immune in Patients With CHB|Completed||N/A|56|Actual|Changhai Hospital||1|||f||||t||||||||||2018-05-31 21:53:52.972637|2018-05-31 21:53:52.972637
NCT01480479|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21||2017-04-06|2018-01-11|2011-11-28|2011-11-29|Estimate||||2017-04-06|2017-04-07|Actual|2018-01-11|2018-01-16|Actual|November 2011||2011-11-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ACT IV||Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma|An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma|Completed||Phase 3|745|Actual|Celldex Therapeutics||2|||f||||t||||||||||2018-05-31 21:53:53.120183|2018-05-31 21:53:53.120183
NCT01480466|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-04-28|2011-11-28|2011-11-29|Estimate|||||||2014-04-28|2014-04-29|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Use of Electronic Health Records for Addressing Overweight and Obesity in Primary Care|Use of Electronic Health Records for Addressing Overweight and Obesity in Primary Care|Completed||N/A|65278|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:53:53.56945|2018-05-31 21:53:53.56945
NCT01480453|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-02-06|2011-11-25|2011-11-28|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2011||2011-01-31|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Observational|||Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty|Retrospective and Prospective Post Market Clinical Follow-up Study of the Zimmer Trabecular Metal Humeral Stem|Recruiting|||120|Anticipated|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-05-31 21:53:53.657794|2018-05-31 21:53:53.657794
NCT01480440|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-02-13|2011-11-25|2011-11-28|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2011||2011-01-31|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty|Prospective Post Market Clinical Follow-up Study of the Zimmer Trabecular Metal Reverse Should System|Active, not recruiting|||200|Anticipated|Zimmer Biomet|||1||f||||f||||||||||2018-05-31 21:53:53.758007|2018-05-31 21:53:53.758007
NCT01480427|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2011-11-25|2011-11-25|2011-11-28|Estimate|||||||2011-11-25|2011-11-28|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Assessment of Quality of Life in Food Allergic Children|Assessment of Quality of Life in Food Allergic Children|Completed|||60|Actual|University of Lausanne Hospitals|||||f||||||||||||||2018-05-31 21:53:53.865092|2018-05-31 21:53:53.865092
NCT01480414|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2012-12-25|2011-11-25|2011-11-28|Estimate|||||||2012-12-25|2012-12-27|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Side Effects of 4 Times Bone Marrow Mono Nuclear Transplantation in Patients With Ischemic Lower Limb|Evaluation the Side Effects of Repeated Bone Marrow Derived Mono Nuclear Stem Cells Transplantation in Patients With Lower Limb Ischemic Ulcer|Completed||Phase 1/Phase 2|20|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 21:53:53.931537|2018-05-31 21:53:53.931537
NCT01480401|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2014-12-17|2011-11-25|2011-11-28|Estimate|||||||2014-12-17|2014-12-19|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SODIUM-HF||Study of Dietary Intervention Under 100 MMOL in Heart Failure|The Long Term Effects of Dietary Sodium Restriction on Clinical Outcomes in Patients With Heart Failure|Completed||N/A|38|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 21:53:54.055071|2018-05-31 21:53:54.055071
NCT01480388|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2016-11-30|2011-11-25|2011-11-28|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate|A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy|Withdrawn||Phase 2|0|Actual|Janssen Research & Development, LLC||5||"Study was terminated prematurely due to 2 cases of agranulocytosis in a different clinical~   trial with this same drug."|f||||t||||||||||2018-05-31 21:53:54.261046|2018-05-31 21:53:54.261046
NCT01480375|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-05-01|2011-11-25|2011-11-28|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2011||2011-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|NaSBxP01||A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy|A 3D Navigation Technology for Improved TRUS Prostate Biopsy|Recruiting||N/A|600|Anticipated|UC Care, Ltd.||2|||f||||f||||||||||2018-05-31 21:53:54.35456|2018-05-31 21:53:54.35456
NCT01480362|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-08-18|2011-11-25|2011-11-28|Estimate|||||||2017-08-18|2017-08-22|Actual|November 2011||2011-11-30|August 2017|2017-08-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|DiaFu||Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds|Randomized, Controlled Clinical Trial Evaluating the Efficacy and Clinical Effectiveness of Negative Pressure Wound Therapy for the Treatment of Diabetic Foot Wounds When Compared to Standard Wound Therapy|Completed||N/A|360|Actual|University of Witten/Herdecke||2|||f||||t||||||||||2018-05-31 21:53:54.454179|2018-05-31 21:53:54.454179
NCT01480336|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-03-18|2011-11-23|2011-11-28|Estimate|||||||2013-03-18|2013-03-19|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot|The Pharmacokinetics and Electrocardiographic Implications of Adjunctive Amiodarone and Ranolazine Therapy in Patients on Implantable Cardioverter Defibrillators: The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot|Completed||N/A|19|Actual|Hartford Hospital||2|||f||||f||||||||||2018-05-31 21:53:54.674027|2018-05-31 21:53:54.674027
NCT01480323|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2015-07-17|2011-11-25|2011-11-28|Estimate|||||||2015-07-17|2015-07-21|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|||A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2|A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 in Pretreated Patients With Stage IV Melanoma|Completed||Phase 2|15|Actual|University Hospital Tuebingen||1|||f||||t||||||||||2018-05-31 21:53:54.742574|2018-05-31 21:53:54.742574
NCT01480310|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2016-11-01|2011-11-23|2011-11-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers|A Phase Ia, Single-Center, Randomized, Placebo-Controlled, Double-Blind, Single Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers|Completed||Phase 1|23|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 21:53:54.825505|2018-05-31 21:53:54.825505
NCT01480297|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2014-12-02||2015-04-23|2011-11-25|2011-11-28|Estimate|2015-04-23|2015-04-24|Estimate||||2015-04-23|2015-04-24|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|April 2012|Actual|2012-04-30||Interventional|SALP|adults with type 1 diabetes and painful peripheral neuropathy|Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy|A Pilot Study to Determine the Effects of 12 Weeks of Treatment With Salsalate on Measures of Peripheral Neuropathy in Type 1 Diabetes|Completed||Phase 2|8|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 21:53:54.898498|2018-05-31 21:53:54.898498
NCT01480284|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2013-08-22||2016-07-07|2011-11-23|2011-11-28|Estimate|2013-08-22|2013-10-29|Estimate||||2016-07-07|2016-08-10|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|November 2014|Actual|2014-11-30|January 2013|Actual|2013-01-31||Interventional|||Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue|A Multi-center, Randomized, Active Controlled, Double-blind, Parallel Group Comparison Study and Subsequent Open-label Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue|Completed||Phase 3|166|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:53:55.116812|2018-05-31 21:53:55.116812
NCT01480271|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-06-27|2011-11-23|2011-11-28|Estimate|||||||2017-06-27|2017-06-28|Actual|May 30, 2011|Actual|2011-05-30|June 2017|2017-06-30|September 30, 2011|Actual|2011-09-30|September 30, 2011|Actual|2011-09-30||Interventional|||An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.|A Randomized, Double-blind, Placebo-controlled First Time Into Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intranasal Dosing With GSK2245035, a TLR7 Agonist, in Healthy Volunteers and Allergic Rhinitics|Completed||Phase 1|61|Actual|GlaxoSmithKline||16|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:53:55.697082|2018-05-31 21:53:55.697082
NCT01480258|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-02-27|2011-11-23|2011-11-28|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2011||2011-11-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)|A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months|Completed||Phase 3|1315|Actual|MCM Vaccines B.V.||2|||f||||f||||||||||2018-05-31 21:53:55.928344|2018-05-31 21:53:55.928344
NCT01480245|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-03-21|2011-11-23|2011-11-28|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2011||2011-09-30|March 2017|2017-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 3|233|Actual|GlaxoSmithKline||3||"The study was formally terminated given that GSK is not submitting an application for~   regulatory approval for drisapersen in Duchenne Muscular Dystrophy."|f||||f||||||||||2018-05-31 21:53:56.088467|2018-05-31 21:53:56.088467
NCT01480232|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2016-12-15||2017-02-21|2011-11-23|2011-11-28|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|December 2011||2011-12-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence|Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence|Terminated||Phase 2|345|Actual|Massachusetts General Hospital||4||Study has been put on clinical hold by FDA|f||||t||||||||||2018-05-31 21:53:56.358442|2018-05-31 21:53:56.358442
NCT01480219|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2013-02-04||2013-02-04|2011-11-25|2011-11-28|Estimate|2013-02-04|2013-03-11|Estimate||||2013-02-04|2013-03-11|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g|Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009|Completed|||467|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 21:53:57.120906|2018-05-31 21:53:57.120906
NCT01480206|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-05-30|2011-11-25|2011-11-28|Estimate|||||||2017-05-30|2017-05-31|Actual|November 2011||2011-11-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Overlay of 3D Scans on Live Fluoroscopy for Endovascular Procedures in the Hybrid OR|3D Interventional Tools for Endovascular Procedures in the OR|Enrolling by invitation|||140|Anticipated|Philips Healthcare|||||f||||f||||||||||2018-05-31 21:53:57.324144|2018-05-31 21:53:57.324144
NCT01480193|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-05-30|2011-11-25|2011-11-28|Estimate|||||||2017-05-30|2017-05-31|Actual|September 2011||2011-09-30|November 2011|2011-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||New Therapy for Patients With Severe Tinnitus|Preliminary Clinical Trial of an Integrative Therapy With Severe Tinnitus|Completed||N/A|40|Actual|Duke University||2|||f||||f||||||||||2018-05-31 21:53:57.38541|2018-05-31 21:53:57.38541
NCT01480180|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-11-07|2011-11-23|2011-11-28|Estimate|||||||2017-11-07|2017-11-08|Actual|January 30, 2012|Actual|2012-01-30|November 2017|2017-11-30|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|pathfinder™2||Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A|A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A|Active, not recruiting||Phase 3|186|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:53:57.4775|2018-05-31 21:53:57.4775
NCT01480167|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-01-18|2011-11-25|2011-11-28|Estimate|||||||2017-01-18|2017-01-20|Estimate|November 2011|Actual|2011-11-30|January 2017|2017-01-31||||December 2012|Actual|2012-12-31||Interventional|PRIORi-T||The PRIORi-T Trial--Prospective Randomized Investigation of Radiofrequency Targeted Vertebral Augmentation|Prospective Randomized Investigation of Radiofrequency Targeted Vertebral Augmentation (The PRIORi-T Trial)|Withdrawn||Phase 4|0|Actual|Merit Medical Systems, Inc.||2||Lack of enrollment|f||||f||||||||||2018-05-31 21:53:57.670748|2018-05-31 21:53:57.670748
NCT01480154|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-05-15|2011-11-23|2011-11-28|Estimate|||||||2018-05-15|2018-05-16|Actual|November 23, 2011|Actual|2011-11-23|May 2018|2018-05-31||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer|A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis|Active, not recruiting||Phase 1|62|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:53:57.755369|2018-05-31 21:53:57.755369
NCT01480141|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-03-25|2011-11-25|2011-11-28|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)|A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC|Withdrawn||Phase 2|0|Actual|Medical University of South Carolina||1||PI left MUSC, no patient enrollments|f||||t||||||||||2018-05-31 21:53:57.832005|2018-05-31 21:53:57.832005
NCT01480128|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2015-10-05|2011-11-25|2011-11-28|Estimate|||||||2015-10-05|2015-10-06|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|SIMPLE||Multicenter Single-port Colectomy RCT|A Multicenter Prospective Randomized Clinical Trail on the Efficacy of the Single Port Laparoscopic Surgery Compared With Multiport Laparoscopic Surgery|Unknown status|Enrolling by invitation|Phase 3|388|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 21:53:57.912576|2018-05-31 21:53:57.912576
NCT01480115|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2013-03-10|2011-11-25|2011-11-28|Estimate|||||||2013-03-10|2013-03-12|Estimate|April 2013||2013-04-30|November 2011|2011-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||A New Tool for Automatic Ovarian Follicle Count and it Abilities to Evaluate Ovarian Reserve|A New Tool for Automatic Ovarian Follicle Count and it Abilities to Evaluate Ovarian Reserve|Unknown status|Not yet recruiting||50|Anticipated|Meir Medical Center|||||f||||t||||||Samples With DNA|"~     Whole blood and serum for FSH, LH, E2, AMH, Prolactin, TSH, Testosterone, Progesterone,~     17-OHP, DHEA-S.~   "|||2018-05-31 21:53:57.985479|2018-05-31 21:53:57.985479
NCT01480102|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2017-03-28|2011-11-23|2011-11-28|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2011||2011-08-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|PRONE||Paravertebral Block for Percutaneous Nephrolithotomy|Paravertebral Block for Percutaneous Nephrolithotomy (PRONE)|Recruiting||N/A|82|Anticipated|Loyola University||2|||f||||f||||||||Undecided||2018-05-31 21:53:59.136122|2018-05-31 21:53:59.136122
NCT01480089|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2016-06-16||2016-06-16|2011-11-25|2011-11-28|Estimate|2016-06-16|2016-07-27|Estimate||||2016-06-16|2016-07-27|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|SPRAY|All women randomized to treatment were included in the baseline analysis population.|Surgical Pain Control With Ropivacaine by Atomized Delivery|Surgical Pain Control With Ropivacaine by Atomized Delivery|Completed||Phase 4|56|Actual|Loyola University|There are no caveats to report.|2|||f||||f||||||||No|There is no plan to make individual participant data (IPD) available|2018-05-31 21:53:59.26257|2018-05-31 21:53:59.26257
NCT01480076|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|2016-07-11||2017-02-14|2011-11-25|2011-11-28|Estimate|2016-09-14|2016-11-04|Estimate||||2017-02-14|2017-03-21|Actual|February 2012||2012-02-29|February 2017|2017-02-28|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|ENABLE|Intent-to-treat population: all participants who received at least 1 dose of study treatment and who provided at least 1 efficacy assessment at Baseline and the 3-month visit.|Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis|An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects With Multiple Sclerosis|Completed||Phase 4|901|Actual|Biogen||1|||f||||||||||||||2018-05-31 21:54:00.278198|2018-05-31 21:54:00.278198
NCT01480063|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-03-23|2011-11-25|2011-11-28|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 16, 2012|Actual|2012-04-16|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|LIBERATE||An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice|A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE)|Active, not recruiting|||4734|Actual|Biogen|||1||f||||||||||||||2018-05-31 21:54:05.516388|2018-05-31 21:54:05.516388
NCT01480050|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2016-10-12|2011-11-23|2011-11-28|Estimate|||||||2016-10-12|2016-10-14|Estimate|April 2012||2012-04-30|October 2016|2016-10-31||||August 2015|Actual|2015-08-31||Interventional|||Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma|A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment|Completed||Phase 1|28|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-05-31 21:54:05.849751|2018-05-31 21:54:05.849751
NCT01480037|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2015-01-13|2011-11-25|2011-11-28|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|February 2013|Actual|2013-02-28|June 2011|Actual|2011-06-30||Observational|||Genetic and Physiological Aspects of Oxidative Profile in Sleep and Well-succeed Aging|Genetic and Physiological Aspects of Oxidative Profile in Sleep and Well-succeed Aging|Completed|||38|Actual|Associação Fundo de Incentivo à Pesquisa|||3||f||||t||||||Samples With DNA|"~     Blood samples collected for DNA and RNA extraction, as well as for laboratory examinations~   "|||2018-05-31 21:54:06.063495|2018-05-31 21:54:06.063495
NCT01480024|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-23|||2018-02-12|2011-11-25|2011-11-28|Estimate|||||||2018-02-12|2018-02-13|Actual|April 2011||2011-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Effect of Body Composition and Metabolism on Oocyte Gene Expression|Effect of Body Composition and Metabolism on Oocyte Gene Expression|Active, not recruiting|||70|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f||||||Samples With DNA|"~     oocytes and follicular fluid~   "|||2018-05-31 21:54:06.13026|2018-05-31 21:54:06.13026
NCT01480011|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2013-02-19|2011-11-25|2011-11-28|Estimate|||||||2013-02-19|2013-02-20|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation|A Pilot Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation|Completed||Phase 2|31|Actual|All India Institute of Medical Sciences, New Delhi||1|||f||||f||||||||||2018-05-31 21:54:06.238288|2018-05-31 21:54:06.238288
NCT01479998|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2014-01-10|2011-11-22|2011-11-28|Estimate|||||||2014-01-10|2014-01-13|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes|Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes|Terminated||Phase 1|8|Actual|Yale University||2||Reevaluating recruitment strategies|f||||t||||||||||2018-05-31 21:54:06.307362|2018-05-31 21:54:06.307362
NCT01479985|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-12-14|2011-11-25|2011-11-28|Estimate|||||||2015-12-14|2015-12-15|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|CDM RCT||Computerized Decision Aid|Randomized Clinical Trial of a Computerized Contraceptive Decision Aid|Completed||N/A|201|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 21:54:06.377341|2018-05-31 21:54:06.377341
NCT01479972|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-10-28|2011-11-22|2011-11-28|Estimate|||||||2013-10-28|2013-10-29|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa|Phase II Open Label, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-unexposed, BCG Naive Newborn Infants in South Africa|Completed||Phase 2|48|Actual|Vakzine Projekt Management GmbH||2|||f||||t||||||||||2018-05-31 21:54:06.452408|2018-05-31 21:54:06.452408
NCT01479959|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2011-11-22|2011-11-22|2011-11-28|Estimate|||||||2011-11-22|2011-11-28|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|OptiPEP||Impact of Patient Controlled Positive End-expiratory Pressure on Speech in Tracheostomized Ventilated Patients|Determination of Optimal PEEP Level Under Patient Control in Tracheostomized Ventilated Patients|Completed||N/A|14|Actual|University of Versailles||3|||f||||f||||||||||2018-05-31 21:54:06.518746|2018-05-31 21:54:06.518746
NCT01479946|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-12-08|2011-11-25|2011-11-28|Estimate|||||||2014-12-08|2014-12-09|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin|An International Randomized Phase II Study Comparing Early Electrochemotherapy to Delayed or No Electrochemotherapy in Patients With Cutaneous Breast Cancer Metastases|Withdrawn||Phase 2|0|Actual|Uppsala University Hospital||2||ECT equipment not available at study center|f||||f||||||||||2018-05-31 21:54:06.593462|2018-05-31 21:54:06.593462
NCT01479933|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2013-03-03|2011-11-22|2011-11-28|Estimate|||||||2013-03-03|2013-03-05|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|VitDmet||Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes|Randomized Controlled Trial of Vitamin D Supplementation on Glucose Metabolism in Subjects With Components of the Metabolic Syndrome|Completed||N/A|73|Actual|University of Eastern Finland||3|||f||||f||||||||||2018-05-31 21:54:06.735265|2018-05-31 21:54:06.735265
NCT01479920|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2015-12-04|2011-11-22|2011-11-28|Estimate|||||||2015-12-04|2015-12-07|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture|The Identification of Central Neural Network for Antidepressant Effects of Dense Cranial Electroacupuncture Stimulation - a Positron Emission Topographic (PET) Study|Completed||N/A|36|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:54:06.830558|2018-05-31 21:54:06.830558
NCT01479907|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-05-11|2011-11-25|2011-11-28|Estimate|||||||2016-05-11|2016-05-13|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|March 2012|Actual|2012-03-31||Interventional|||Synbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer|Synbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer|Completed||N/A|100|Actual|University of Athens||2|||f||||f||||||||No||2018-05-31 21:54:06.943391|2018-05-31 21:54:06.943391
NCT01479894|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-02-18|2011-11-22|2011-11-28|Estimate|||||||2015-02-18|2015-02-19|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer||Completed|||44|Actual|University of Arkansas|||1||f||||f||||||Samples With DNA|"~     The Oncotype DX Colon Cancer Assay will be utilized to define the gene expression profile of~     the tumor tissue.~   "|||2018-05-31 21:54:07.049904|2018-05-31 21:54:07.049904
NCT01479881|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-10-31|2011-11-22|2011-11-28|Estimate|||||||2012-10-31|2012-11-01|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus|A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Effect of TMC435 at Steady-state on the Pharmacokinetics of the Immunosuppressants Cyclosporine and Tacrolimus|Completed||Phase 1|29|Actual|Tibotec Pharmaceuticals, Ireland||4|||f||||f||||||||||2018-05-31 21:54:07.120392|2018-05-31 21:54:07.120392
NCT01479868|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|2014-08-26||2014-10-28|2011-11-22|2011-11-28|Estimate|2014-10-28|2014-10-29|Estimate||||2014-10-28|2014-10-29|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Analysis population included all participants who received at least 1 dose of study drug.|A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1|A Phase III Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of TMC435 Plus PegIFNα-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Subjects Who Are Co-infected With Human Immunodeficiency Virus Type 1 (HIV-1)|Completed||Phase 3|109|Actual|Janssen R&D Ireland||1|||f||||f||||||||||2018-05-31 21:54:07.245211|2018-05-31 21:54:07.245211
NCT01479855|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2013-11-26|2011-11-22|2011-11-28|Estimate|||||||2013-11-26|2013-11-27|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|ALZ-vit||Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type|Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type|Unknown status|Recruiting||180|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, urine, cerebrospinal fluid~   "|||2018-05-31 21:54:07.750551|2018-05-31 21:54:07.750551
NCT01479842|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2017-11-07|2011-11-22|2011-11-28|Estimate|||||||2017-11-07|2017-11-09|Actual|December 7, 2011|Actual|2011-12-07|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|March 2014|Actual|2014-03-31||Interventional|||Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma|A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|48|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 21:54:07.823935|2018-05-31 21:54:07.823935
NCT01479829|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2018-01-30|2011-11-22|2011-11-24|Estimate|||||||2018-01-30|2018-02-01|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bipolar Depression and Inflammation|Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers|Active, not recruiting||Phase 4|80|Anticipated|Loyola University||2|||f||||t||||||||||2018-05-31 21:54:08.046506|2018-05-31 21:54:08.046506
NCT01479816|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2016-07-19|2011-11-22|2011-11-24|Estimate|||||||2016-07-19|2016-07-21|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|||Urinary Continence Index for Prediction of Urinary Incontinence in Older Women|Urinary Continence Index for Prediction of Urinary Incontinence in Older Women|Completed|||702|Actual|William Beaumont Hospitals|||||f||||f||||||||No||2018-05-31 21:54:08.118167|2018-05-31 21:54:08.118167
NCT01479803|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-04-22|2011-11-22|2011-11-24|Estimate|||||||2014-04-22|2014-04-23|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PICORE||Comparison of Two Needles (ProCore vs EchoTip) for the Diagnosis of Pancreatic Solid Mass Under EUS|"COMPARATIVE STUDY OF DIAGNOSTIC VALUE FOR THE ECHOTIP® PROCORE™ 22 Gauge NEEDLE VERSUS ECHOTIP® 22 Gauge IN THE DIAGNOSIS OF PANCREATIC SOLID TUMORS UNDER ENDOSCOPIC ULTRASONOGRAPHY : THE PICORE STUDY"|Completed||Phase 3|80|Actual|Société Française d'Endoscopie Digestive||2|||f||||t||||||||||2018-05-31 21:54:08.196893|2018-05-31 21:54:08.196893
NCT01479790|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2013-02-20|2011-11-22|2011-11-24|Estimate|||||||2013-02-20|2013-02-21|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Repeatability and Agreement of Anterior Segment Optical Coherence Tomography (AS-OCT) and Thermography|Repeatability and Agreement of Visante and Cirrus Anterior Segment Optical Coherence Tomography and Functional Infrared Thermography|Completed||N/A|40|Actual|Singapore National Eye Centre||2|||f||||f||||||||||2018-05-31 21:54:08.262165|2018-05-31 21:54:08.262165
NCT01479777|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2013-08-01||2014-09-09|2011-11-22|2011-11-24|Estimate|2014-09-09|2014-09-15|Estimate||||2014-09-09|2014-09-15|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Functional Electrical Stimulation (FES) Driven Stepping in Individuals With Spinal Cord Injury|FES Driven Stepping in Individuals With Spinal Cord Injury|Completed||Phase 1/Phase 2|12|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t||||||||||2018-05-31 21:54:08.399299|2018-05-31 21:54:08.399299
NCT01479764|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2013-08-26||2017-05-08|2011-11-22|2011-11-24|Estimate|2013-11-11|2013-12-31|Estimate||||2017-05-08|2017-06-06|Actual|December 2, 2011|Actual|2011-12-02|May 2017|2017-05-31|November 5, 2012|Actual|2012-11-05|October 26, 2012|Actual|2012-10-26||Interventional|||Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)|Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry|Completed||Phase 3|154|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:54:08.642569|2018-05-31 21:54:08.642569
NCT01479751|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-08-24|2011-11-23|2011-11-24|Estimate|||||||2012-08-24|2012-08-27|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Comparison of Methods to Facilitate Rapid Sequence Intubation|Comparison of Mg, Ketamine, Large Dose Rocuronium, and Priming on Intubating Condition in Rapid Sequence Intubation|Completed||N/A|110|Actual|Seoul National University Bundang Hospital||5|||f||||t||||||||||2018-05-31 21:54:08.99351|2018-05-31 21:54:08.99351
NCT01479738|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|||2011-11-24|2011-11-22|2011-11-24|Estimate|||||||2011-11-24|2011-11-28|Estimate|January 2005||2005-01-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|PIPPC||Proximal Interphalangeal Joint Arthroplasty Using a Graft From the Capitate|The Second Hospital of Qinhuangdao, Qinhuangdao, Hebei, 066600, China|Completed||N/A|18|Actual|The Second Hospital of Qinhuangdao||1|||f||||t||||||||||2018-05-31 21:54:09.097173|2018-05-31 21:54:09.097173
NCT01479725|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2016-11-13||2017-01-12|2011-11-23|2011-11-24|Estimate|2017-01-12|2017-03-03|Actual||||2017-01-12|2017-03-03|Actual|March 2011||2011-03-31|January 2017|2017-01-31|May 2013|Actual|2013-05-31|August 2012|Actual|2012-08-31||Interventional|||Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis|A Prospective Trial Comparing the Response to Hyperbaric Oxygen Treatment in Patients With Ulcerative and Non-Ulcerative Interstitial Cystitis|Completed||Phase 2|8|Actual|William Beaumont Hospitals|A small number of patients were enrolled and treated (n=8), with only 5 patients completing the entire study. Three patients withdrew within the year following HBOT and were considered non-responders.|2|||f||||f||||||||No||2018-05-31 21:54:09.193224|2018-05-31 21:54:09.193224
NCT01479712|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-22|2011-11-22|2011-11-24|Estimate|||||||2011-11-22|2011-11-24|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Intra-abdominal at Cesarean Section: A Randomized Controlled Trial|Intra-abdominal at Cesarean Section: A Randomized Controlled Trial|Completed||N/A|263|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 21:54:09.4918|2018-05-31 21:54:09.4918
NCT01479699|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-22|2011-11-22|2011-11-24|Estimate|||||||2011-11-22|2011-11-24|Estimate|June 2011||2011-06-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations|Absorption and Metabolism of Olive Leaf Extract and Its Effect on Vascular Reactivity and Cytokine Concentrations|Completed||N/A|18|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 21:54:09.593327|2018-05-31 21:54:09.593327
NCT01479686|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|||2015-03-21|2011-11-23|2011-11-24|Estimate|||||||2015-03-21|2015-03-24|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|July 2021|Anticipated|2021-07-31|December 2015|Anticipated|2015-12-31||Interventional|||iMRI Guided Resection in Cerebral Glioma Surgery|3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial|Recruiting||Phase 3|303|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 21:54:09.688185|2018-05-31 21:54:09.688185
NCT01479673|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2013-11-21|2011-11-23|2011-11-24|Estimate|||||||2013-11-21|2013-11-25|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|P2 -RMCS||TICACOS International|Tight Caloric Balance in ICU Patients: a Multicenter, Prospective, Randomized, Controlled Study.|Unknown status|Recruiting|N/A|560|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 21:54:09.798642|2018-05-31 21:54:09.798642
NCT01479660|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Role of Healthy Bacteria in Ulcerative Colitis|Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 21:54:09.886556|2018-05-31 21:54:09.886556
NCT01479647|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-02-25|2011-11-22|2011-11-24|Estimate|||||||2012-02-25|2012-02-28|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study To Investigate The Effect Of Food On The Pharmacokinetics Of PH-797804|A Phase 1, Randomized, Open-Label, Single Dose, 2-Cohort Crossover Study To Determine The Effect Of Food On The Pharmacokinetics Of Orally Administered PH-797804 In Healthy Volunteers|Completed||Phase 1|28|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:54:09.968879|2018-05-31 21:54:09.968879
NCT01479634|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2016-03-03|2011-11-22|2011-11-24|Estimate|||||||2016-03-03|2016-03-04|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EARLI||Early HIV Therapy in Patients With High CD4 Cell Counts|Early Antiretroviral Therapy in Resource Limited Settings in Patients With High CD4+ Cell Counts (EARLI)|Completed||N/A|279|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:54:10.038962|2018-05-31 21:54:10.038962
NCT01479621|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2017-02-28|2015-03-19|2017-05-02|2011-11-23|2011-11-24|Estimate|2017-02-28|2017-04-12|Actual|2015-03-19|2015-04-09|Estimate|2017-05-02|2017-06-05|Actual|January 2012||2012-01-31|May 2017|2017-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Intent-to-Treat Analysis set|A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids|A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fluticasone Propionate DPI Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Persistent Asthma Uncontrolled on Non-steroidal Therapy|Completed||Phase 2|909|Actual|Teva Pharmaceutical Industries||6|||f||||f||||||||||2018-05-31 21:54:10.173017|2018-05-31 21:54:10.173017
NCT01479608|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-05-24|2011-11-23|2011-11-24|Estimate|||||||2017-05-24|2017-05-30|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 2027|Anticipated|2027-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Liver Transplantation and Colorectal Cancer|A Randomized Controlled Clinical Trial to Evaluate the Benefit and Efficacy of Liver Transplantation as Treatment for Selected Patients With Liver Metastases From ColoRectal Carcinoma|Recruiting||Phase 3|25|Anticipated|Oslo University Hospital||3|||f||||f||||||||||2018-05-31 21:54:11.998997|2018-05-31 21:54:11.998997
NCT01479595|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2016-02-23||2016-06-20|2011-11-23|2011-11-24|Estimate|2016-06-20|2016-08-01|Estimate||||2016-06-20|2016-08-01|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma|A Randomized Double-blind Multiple-dose Placebo-controlled Trial to Establish the Efficacy of QBX258 (Combination of VAK694 and QAX576) in Asthma That is Inadequately Controlled With Inhaled Corticosteroids and Long Acting Beta Agonists|Completed||Phase 2|65|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:54:12.098639|2018-05-31 21:54:12.098639
NCT01479582|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-06-30|2011-11-22|2011-11-24|Estimate|||||||2017-06-30|2017-07-02|Actual|October 27, 2011||2011-10-27|November 26, 2012|2012-11-26|November 26, 2012|Actual|2012-11-26|November 26, 2012|Actual|2012-11-26||Interventional|||Providing Access to Cord Blood Units for Transplants|A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:54:12.446922|2018-05-31 21:54:12.446922
NCT01479569|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-02-13|2011-11-22|2011-11-24|Estimate|||||||2018-02-13|2018-02-14|Actual|November 8, 2011||2011-11-08|February 17, 2017|2017-02-17|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Interventional|||Pericardiocentesis With Magnetic Resonance Imaging|Real-time MRI Pericardiocentesis Using Passive Needles|Terminated||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:54:12.698552|2018-05-31 21:54:12.698552
NCT01479556|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2011-11-22|2011-11-22|2011-11-24|Estimate|||||||2011-11-22|2011-11-24|Estimate|December 2011||2011-12-31|November 2011|2011-11-30|October 2014|Anticipated|2014-10-31|May 2014|Anticipated|2014-05-31||Interventional|||Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain|Assessment of Pregabalin Efficacy for the Treatment and Prevention of At-level Non-evoked and Evoked Spinal Cord Injury Neuropathic Pain|Unknown status|Not yet recruiting|Phase 4|82|Anticipated|Hospital Nacional de Parapléjicos de Toledo||2|||f||||f||||||||||2018-05-31 21:54:12.796692|2018-05-31 21:54:12.796692
NCT01479543|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2014-08-19||2014-09-04|2011-11-23|2011-11-24|Estimate|2014-09-04|2014-09-05|Estimate||||2014-09-04|2014-09-05|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|SETOPROB|The average age was 28 years in all groups. Gender male/female in Probiotic groups 37/43 and placebo groups 9/11. Región of enrollment were Granada, Murcia and Valencia cities placed in southeast of Spain.|Effects of Probiotics in Immune System of Healthy Adults|Colonization, Safety, Tolerance, and Effects of Three Probiotic Strains on the Immune System of Healthy Adults|Completed||N/A|103|Actual|Hero Institute for Infant Nutrition||5|||f||||t||||||||||2018-05-31 21:54:12.86521|2018-05-31 21:54:12.86521
NCT01479530|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2014-05-23||2014-05-23|2011-11-22|2011-11-24|Estimate|2014-05-23|2014-06-26|Estimate||||2014-05-23|2014-06-26|Estimate|December 2011||2011-12-31|May 2014|2014-05-31||||June 2013|Actual|2013-06-30||Interventional|CHORAL||Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China|Completed||Phase 3|321|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 21:54:13.419536|2018-05-31 21:54:13.419536
NCT01479517|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2016-11-02|2015-05-15|2016-11-02|2011-11-23|2011-11-24|Estimate|2016-11-02|2016-12-29|Estimate|2015-05-15|2015-06-08|Estimate|2016-11-02|2016-12-29|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Open-Label Study of Efficacy and Recommended Dose of Kovacaine Mist for Anesthetizing Maxillary Teeth|A Phase II, Single-Site, Open-Label Clinical Trial To Evaluate The Efficacy And Recommended Dosing Regimen Of Kovacaine Mist Administered Unilaterally For Anesthetizing Maxillary Teeth In Healthy Dental Patients|Completed||Phase 2|30|Actual|St. Renatus, LLC||3|||f||||f||||||||Undecided||2018-05-31 21:54:13.774615|2018-05-31 21:54:13.774615
NCT01479504|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-24|2011-11-22|2011-11-24|Estimate|||||||2011-11-24|2011-11-28|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|December 2017|Anticipated|2017-12-31|November 2012|Anticipated|2012-11-30||Interventional|||A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 3|2|Anticipated|Guangxi Medical University||4|||f||||t||||||||||2018-05-31 21:54:14.249784|2018-05-31 21:54:14.249784
NCT01479491|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-10-18|2011-11-23|2011-11-24|Estimate|||||||2012-10-18|2012-10-22|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Study on the Incidence of Intussusception (IS) in Children Aged < 12 Months in Japan|Observational Database Study on the Incidence of Intussusception in Children Aged < 12 Months in Japan|Completed|||54|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:54:14.33656|2018-05-31 21:54:14.33656
NCT01479478|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-04-17|2011-11-23|2011-11-24|Estimate|||||||2018-04-17|2018-04-19|Actual|November 2011||2011-11-30|April 2018|2018-04-30|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy|Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.|Completed||N/A|251|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 21:54:14.393411|2018-05-31 21:54:14.393411
NCT01479465|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09||2015-03-10|2015-03-10|2011-11-22|2011-11-24|Estimate||||2015-03-10|2015-03-30|Estimate|2015-03-10|2015-03-30|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.|Completed||Phase 2|266|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 21:54:14.48787|2018-05-31 21:54:14.48787
NCT01479452|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|January 1987||1987-01-31|November 2011|2011-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|SOS||Effects of Bariatric Surgery in Swedish Obese Subjects|Effects of Bariatric Surgery in Swedish Obese Subjects|Completed||N/A|4047|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 21:54:15.790045|2018-05-31 21:54:15.790045
NCT01479439|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2017-10-04|2011-11-22|2011-11-24|Estimate|||||||2017-10-04|2017-10-06|Actual|February 2012||2012-02-29|October 2017|2017-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Losartan to Reverse Sickle Nephropathy|A Phase II Trial of Losartan to Reverse Sickle Nephropathy|Completed||Phase 2|36|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 21:54:15.900434|2018-05-31 21:54:15.900434
NCT01479426|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|||A Trial to Evaluate the Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Sexual Function in Men With Erectile Dysfunction|Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Erectile Dysfunction|Unknown status|Enrolling by invitation|Phase 2/Phase 3|80|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:54:15.995641|2018-05-31 21:54:15.995641
NCT01479413|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-10|||2013-09-10|2011-11-22|2011-11-24|Estimate|||||||2013-09-10|2013-09-11|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Observational|||Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs|Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs|Completed|||77|Actual|Chang Gung Memorial Hospital|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:54:16.185531|2018-05-31 21:54:16.185531
NCT01479400|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-22|2011-11-22|2011-11-24|Estimate|||||||2011-11-22|2011-11-24|Estimate|October 2007||2007-10-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Observational|||Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective Study|Safety Study for Infants Who Exposed to Antipsychotics as Fetus|Completed|||152|Actual|Central South University|||2||f||||t||||||||||2018-05-31 21:54:16.273105|2018-05-31 21:54:16.273105
NCT01479387|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-11-22|2011-11-22|2011-11-24|Estimate|||||||2011-11-22|2011-11-24|Estimate|August 2008||2008-08-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|||||Observational|ZEVALIN-SDUI||Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan|Special Drug Use Investigation of Zevalin|Completed|||72|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:54:16.351981|2018-05-31 21:54:16.351981
NCT01479374|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2013-03-28||2013-05-28|2011-11-22|2011-11-24|Estimate|2013-03-28|2013-05-23|Estimate||||2013-05-28|2013-06-04|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model|A Multi-Center, Randomized, Double-Masked, Vehicle and Active Controlled, Parallel-Group Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model|Completed||Phase 3|397|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 21:54:16.448523|2018-05-31 21:54:16.448523
NCT01479361|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-06-30|2011-11-22|2011-11-24|Estimate|||||||2017-06-30|2017-07-02|Actual|October 31, 2011||2011-10-31|June 1, 2016|2016-06-01|February 20, 2014|Actual|2014-02-20|February 20, 2014|Actual|2014-02-20||Interventional|||Antiretroviral Drug Interaction Study in Volunteers With HIV|The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers|Completed||Phase 1|36|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:54:16.880751|2018-05-31 21:54:16.880751
NCT01479348|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-02-24|2011-11-22|2011-11-24|Estimate|||||||2018-02-24|2018-02-27|Actual|November 1, 2011||2011-11-01|February 13, 2018|2018-02-13|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||Imaging Study for FdCyd and THU Cancer Treatment|Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine|Completed||Early Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:54:16.963732|2018-05-31 21:54:16.963732
NCT01479322|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-31|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|January 2007||2007-01-31|November 2011|2011-11-30|July 2007|Actual|2007-07-31|||||Observational|||Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome|Correlation Between Hyperghrelinemia and Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome|Completed|||51|Actual|Samsung Medical Center|||||f||||t||||||||||2018-05-31 21:54:17.053493|2018-05-31 21:54:17.053493
NCT01479309|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|September 2006||2006-09-30|November 2011|2011-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study to Evaluate Sodium Stibogluconate With Interferon Alpha-2b|A Phase IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Pharmaceutical sponsor terminated study.|f||||f||||||||||2018-05-31 21:54:17.099949|2018-05-31 21:54:17.099949
NCT01479296|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-05-29|2011-11-22|2011-11-24|Estimate|||||||2018-05-29|2018-05-30|Actual|December 2011||2011-12-31|May 2018|2018-05-31|November 27, 2017|Actual|2017-11-27|May 2013|Actual|2013-05-31||Interventional|||Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults|A Phase 1b Randomized Double-Blind Clinical Trial to Examine Whether Polytopic Administration of VRC rAd5 Gag-pol/Env A/B/C Vaccine Enhances HIV-Specific Cellular Immune Responses in Humans|Completed||Phase 1|90|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 21:54:17.192725|2018-05-31 21:54:17.192725
NCT01479283|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-05-23|2011-11-23|2011-11-24|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PARITY||Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)|Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements|Recruiting||Phase 3|600|Anticipated|McMaster University||2|||f||||t||||||||Undecided||2018-05-31 21:54:17.318919|2018-05-31 21:54:17.318919
NCT01479270|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-10-23|2011-11-22|2011-11-24|Estimate|||||||2012-10-23|2012-10-24|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|TAP||Transversus Abdominal Plane Block at Total Laparoscopic Hysterectomy: Effect on Quality of Recovery|Randomized Trial of Transversus Abdominal Plane (TAP) Block at Total Laparoscopic Hysterectomy: Effect of Regional Analgesia on Quality of Recovery|Completed||N/A|58|Actual|MetroHealth Medical Center||2|||f||||f||||||||||2018-05-31 21:54:17.687275|2018-05-31 21:54:17.687275
NCT01479257|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-10-23|2011-11-23|2011-11-24|Estimate|||||||2017-10-23|2017-10-25|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Determinants of Multiple Health Risk Behaviors Among Latinos|Determinants of Multiple Health Risk Behaviors Among Latinos|Active, not recruiting|||225|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 21:54:17.767528|2018-05-31 21:54:17.767528
NCT01479244|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2017-02-23|2011-11-22|2011-11-24|Estimate|||||||2017-02-23|2017-02-27|Actual|November 2011||2011-11-30|February 2017|2017-02-28|September 21, 2016|Actual|2016-09-21|September 21, 2016|Actual|2016-09-21||Interventional|PRESENT||Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence|PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment|Completed||Phase 3|758|Actual|Galena Biopharma, Inc.||2|||f||||t||||||||||2018-05-31 21:54:17.912697|2018-05-31 21:54:17.912697
NCT01479231|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2012-04-18|2011-11-23|2011-11-24|Estimate|||||||2012-04-18|2012-04-19|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis|Predictors of PPI Response in Eosinophilic Esophagitis|Withdrawn||Phase 1/Phase 2|0|Actual|Mayo Clinic||1||Souces of funding have been terminated|f||||t||||||||||2018-05-31 21:54:18.32452|2018-05-31 21:54:18.32452
NCT01479218|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2014-10-15|2011-11-23|2011-11-24|Estimate|||||||2014-10-15|2014-10-16|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus|Phase 1 Study for Safety and Effectiveness of the New Occlutech PDA Occluder, for Non Surgical Closure of Patent Ductus Arteriosus|Completed||Phase 1|50|Actual|Occlutech International AB||1|||f||||f||||||||||2018-05-31 21:54:18.405004|2018-05-31 21:54:18.405004
NCT01479205|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Observational|ITASIT||Induction of Allergen Specific Bronchial Immunotolerance After Specific Immunotherapy|Security of the Bronchial Allergen Provocation With Mite and Aspergillus and Predictors for a Positive Reaction.|Completed|||42|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:54:18.47638|2018-05-31 21:54:18.47638
NCT01479192|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2016-01-21|2011-11-23|2011-11-24|Estimate|||||||2016-01-21|2016-01-22|Estimate|December 2009||2009-12-31|December 2015|2015-12-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Fenretinide in Healthy Young Women at Genetic and Familial Risk|Breast Cancer Prevention With Fenretinide in Young Women at Genetic and Familil Risk. A Phase III Randomized Clinical Trial|Terminated||Phase 3|20|Actual|European Institute of Oncology||2||very low rate of patient accrual|f||||f||||||||||2018-05-31 21:54:18.539689|2018-05-31 21:54:18.539689
NCT01479179|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2016-10-25|2011-11-23|2011-11-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2012||2012-11-30|October 2016|2016-10-31||||November 2015|Anticipated|2015-11-30||Interventional|||Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab|Phase I/II Study of Trastuzumab in Combination With AMG 479, A Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R), in Patients With HER-2 Overexpressing Metastatic Breast Cancer Progressing on Trastuzumab-Based or Lapatinib-based Therapy|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Drug sponsor decision to discontinue study.|f||||f||||||||||2018-05-31 21:54:18.69981|2018-05-31 21:54:18.69981
NCT01479166|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-10-28|2011-11-23|2011-11-24|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|FRA-MUKO||Bronchial Inflammation of Small Airways in Patients With Cystic Fibrosis|Bronchial Inflammation of Small Airways in Patients With Cystic Fibrosis|Completed|||20|Actual|Johann Wolfgang Goethe University Hospital|||3||f||||f||||||Samples With DNA|"~     whole blood, serum and Sputum~   "|||2018-05-31 21:54:18.820941|2018-05-31 21:54:18.820941
NCT01479153|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2016-08-22|2011-11-23|2011-11-24|Estimate|||||||2016-08-22|2016-08-23|Estimate|October 2011||2011-10-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|3SITES||Venous Site for Central Catheterization|Comparison of Subclavian, Femoral and Internal Jugular Venous Catheterization in Term of Complications in the Intensive Care Unit: a Randomized Controlled Trial|Completed||N/A|3471|Actual|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 21:54:18.900603|2018-05-31 21:54:18.900603
NCT01479140|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2015-09-24|2011-11-23|2011-11-24|Estimate|||||||2015-09-24|2015-09-28|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|PRYME||Prevalence and Long-term Impact of Non-atherosclerotic CAD|Prospective Registry of Young Women With MI: Evaluating the Prevalence and Long-term Impact of Non-atherosclerotic CAD (PRYME)|Recruiting|||200|Anticipated|Cardiology Research UBC|||||f||||f||||||||||2018-05-31 21:54:18.98071|2018-05-31 21:54:18.98071
NCT01479127|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2016-02-15||2016-03-23|2011-11-22|2011-11-24|Estimate|2016-02-15|2016-03-15|Estimate||||2016-03-23|2016-04-21|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||full safety sample|Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease|An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease|Completed||Phase 2|8|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:54:19.135553|2018-05-31 21:54:19.135553
NCT01479114|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-11-24|2011-11-22|2011-11-24|Estimate|||||||2011-11-24|2011-11-28|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates|In Vivo Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on Neutrophilic Expression of CD11b in Septic Neonates|Completed||Phase 4|90|Actual|Ain Shams University||3|||f||||f||||||||||2018-05-31 21:54:20.074586|2018-05-31 21:54:20.074586
NCT01479101|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2016-11-01|2011-11-22|2011-11-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|January 2015|Actual|2015-01-31||Observational|NBRST||NBRST: Prospective Neo-adjuvant REGISTRY Trial|"Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST) (Pronounced in Breast)"|Active, not recruiting|||1142|Actual|Agendia|||1||f||||f||||||Samples With DNA|"~     As part of routine breast cancer treatment, the doctor will conduct a core needle biopsy and~     provide tissue from the tumor to Agendia for testing. After the diagnostic test(s) from the~     Agendia Breast Cancer Suite have been performed on the tumor specimen, there might be some~     remaining tissue left.~   "|||2018-05-31 21:54:20.149334|2018-05-31 21:54:20.149334
NCT01479088|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)|Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension.|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|Istituto Giannina Gaslini||1|||f||||t||||||||||2018-05-31 21:54:20.398619|2018-05-31 21:54:20.398619
NCT01479075|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2017-05-30|2011-11-23|2011-11-24|Estimate|||||||2017-05-30|2017-05-31|Actual|August 2011||2011-08-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|Centrin||The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism|The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism|Active, not recruiting||Phase 4|30|Anticipated|German Diabetes Center||6|||f||||f||||||||||2018-05-31 21:54:20.564051|2018-05-31 21:54:20.564051
NCT01479062|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2018-01-16|2011-11-23|2011-11-24|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2014||2014-02-28|July 2016|2016-07-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics|Multi-Channel Automated Diet and Physical Activity Intervention for Pre-Diabetics (ALIVE-PD)|Completed||N/A|339|Actual|Berkeley Analytics, Inc.||2|||f||||f||||||||||2018-05-31 21:54:20.661649|2018-05-31 21:54:20.661649
NCT01479049|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2011-11-23|2011-11-23|2011-11-24|Estimate|||||||2011-11-23|2011-11-24|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|||The Myocardial Protective Effects of a Moderate-potassium Blood Cardioplegia in Pediatric Cardiac Surgery|The Myocardial Protective Effects of a Moderate-potassium Blood Cardioplegia in Pediatric Cardiac Surgery：a Randomized Controlled Trial|Completed||N/A|100|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 21:54:20.759629|2018-05-31 21:54:20.759629
NCT01479036|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2011-11-21|2011-11-21|2011-11-24|Estimate|||||||2011-11-21|2011-11-24|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|CBCRT01||Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer|Phase Ⅲ Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy in Patients With Breast Cancer|Unknown status|Recruiting|Phase 3|800|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 21:54:20.861642|2018-05-31 21:54:20.861642
NCT01479023|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2013-12-19|2011-11-21|2011-11-24|Estimate|||||||2013-12-19|2013-12-20|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors|A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287|Terminated||Phase 1|12|Actual|Washington University School of Medicine||7||treatment was not working|f||||f||||||||||2018-05-31 21:54:20.967752|2018-05-31 21:54:20.967752
NCT01479010|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-05-20||2017-10-09|2011-11-21|2011-11-24|Estimate|2015-05-20|2015-06-08|Estimate||||2017-10-09|2017-11-13|Actual|November 2011||2011-11-30|October 2017|2017-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Due to the small number of participants, results are not included to protect the privacy of individual participants.|Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension|Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension|Terminated||Phase 1/Phase 2|2|Actual|Virginia Commonwealth University||1||recruitment issues, critical investigators left institution|f||||t||||||||||2018-05-31 21:54:21.067488|2018-05-31 21:54:21.067488
NCT01466049|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-08-04|2011-11-04|2011-11-07|Estimate|||||||2014-08-04|2014-08-05|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||New Biomarkers Evaluating Ovarian Cancer|Evaluation of New Biomarker Assays in Ovarian Cancer Patients Presenting to a Generalist With an Adnexal Mass|Completed|||280|Actual|Fujirebio Diagnostics, Inc.|||||f||||t||||||||||2018-05-31 21:59:02.290112|2018-05-31 21:59:02.290112
NCT01478997|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-05-15|2011-11-23|2011-11-24|Estimate|||||||2012-05-15|2012-05-16|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Flexsure||A Study for Moderate Osteoarthritis of the Knee|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Centric Study to Determine Whether Flexsure is Safe, Tolerable and Effective in Relieving Symptoms of Moderate Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|76|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 21:54:21.291662|2018-05-31 21:54:21.291662
NCT01478984|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2011-11-21|2011-11-21|2011-11-24|Estimate|||||||2011-11-21|2011-11-24|Estimate|October 2011||2011-10-31|November 2011|2011-11-30||||October 2011|Actual|2011-10-31||Interventional|SMILE||Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction (NSTEMI) Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention (PCI)|Impact of One Stage Compared With Multistaged PCI Complete Revascularization on Clinical Outcome in Multivessel NSTEMI Patients. Smile Trial|Unknown status|Recruiting|Phase 3|247|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:54:21.426729|2018-05-31 21:54:21.426729
NCT01478971|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|2014-02-06||2016-09-16|2011-11-23|2011-11-24|Estimate|2014-04-29|2014-05-26|Estimate||||2016-09-16|2016-09-20|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|DIAMOND||Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis|A Phase 3b Single-Arm, Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis|Completed||Phase 3|184|Actual|Takeda||1|||f||||f||||||||||2018-05-31 21:54:21.566569|2018-05-31 21:54:21.566569
NCT01478958|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2014-05-13||2014-06-12|2011-11-21|2011-11-23|Estimate|2014-06-12|2014-07-15|Estimate||||2014-06-12|2014-07-15|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|DIVAS||Dietary Intervention and Vascular Function|The Effects of the Substitution of Dietary SFA With n-6 PUFA or MUFA on Vascular Function|Completed||N/A|202|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 21:54:22.633858|2018-05-31 21:54:22.633858
NCT01478945|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2013-08-22|2011-11-21|2011-11-23|Estimate|||||||2013-08-22|2013-08-23|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional|HI-Light||HI-Light Pilot Trial for Vitiligo: Hand Held NB-UVB for Early or Focal Vitiligo at Home|Pilot Randomised Controlled Trial of Hand Held NB-UVB for the Treatment of Focal or Early Vitiligo at Home|Completed||N/A|29|Actual|University of Nottingham||3|||f||||f||||||||||2018-05-31 21:54:23.081009|2018-05-31 21:54:23.081009
NCT01478932|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2014-01-07|2011-11-22|2011-11-23|Estimate|||||||2014-01-07|2014-01-08|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Diaphragmatic Breathing Retraining in Heart Failure Patients: Health-Behavior Related Outcomes|Diaphragmatic Breathing Retraining in Heart Failure Patients: Health-Behavior Related Outcomes|Unknown status|Recruiting|N/A|50|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 21:54:23.167112|2018-05-31 21:54:23.167112
NCT01478919|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-09-19|2011-11-22|2011-11-23|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Observational|||Risk Factors for Residual Neoplasia After Endoscopic Mucosal Resection|Risk Factors for Local Residual Neoplasia After Convetional Endoscopic Mucosal Resection of Laterally Spreading Tumors|Completed|||127|Actual|Vitkovice Hospital|||||f||||f||||||||||2018-05-31 21:54:23.231682|2018-05-31 21:54:23.231682
NCT01478906|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-05-13|2011-11-22|2011-11-23|Estimate|||||||2012-05-13|2012-05-15|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Observational|||Difference of Plasma Orexin A Levels Between Elderly and Young Patients at Emergence|To Investigate Difference of Plasma Orexin A Levels Between Elderly and Youth Patients at Emergence From Sevoflurane-fentanyl Anesthesia Undergoing Elective Lumbar Surgery|Unknown status|Recruiting||40|Anticipated|Xijing Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 21:54:23.366883|2018-05-31 21:54:23.366883
NCT01478893|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2016-01-05|2011-11-21|2011-11-23|Estimate|||||||2016-01-05|2016-01-07|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacodynamics of Increasing Subcutaneous Doses of SEL-068 in Healthy Non-Smoker and Smoker Adults|Completed||Phase 1|82|Actual|Selecta Biosciences, Inc.||2|||f||||||||||||||2018-05-31 21:54:23.433965|2018-05-31 21:54:23.433965
NCT01478880|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-07-13|2011-11-21|2011-11-23|Estimate|||||||2013-07-13|2013-07-16|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TBS-H||Efficacy and Safety of Bilateral Theta Burst Stimulation for the Treatment of Auditory Hallucinations|Efficacy and Safety of Bilateral Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation) for the Treatment of Auditory Hallucinations|Completed||Phase 2|16|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 21:54:23.530221|2018-05-31 21:54:23.530221
NCT01478867|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-11-23|2011-11-22|2011-11-23|Estimate|||||||2011-11-23|2011-11-24|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|||||Observational|CELIQK2||Detection of Immunotoxic Gluten Peptides in Feces|Phase 0 Monitoring of Gluten-free Diet Compliance in Celiac Patients by Assessment of Gliadin 33-mer Equivalent Epitopes in Feces|Completed|||53|Actual|University of Seville|||1||f||||f||||||Samples Without DNA|"~     Fecal samples~   "|||2018-05-31 21:54:23.606254|2018-05-31 21:54:23.606254
NCT01478854|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2018-04-04|2011-11-21|2011-11-23|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2011||2011-05-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide|A Prospective Trial of Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Glioblastoma Multiforme|Active, not recruiting||N/A|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 21:54:23.696295|2018-05-31 21:54:23.696295
NCT01478841|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-02-10|2011-11-22|2011-11-23|Estimate|||||||2012-02-10|2012-02-13|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|July 2010|Actual|2010-07-31||Interventional|POLYOXRESIST||Polyphenols and Insulin Resistance|INFLUENCE OF POLYPHENOLS ON OXIDATIVE STRESS IN HEALTHY INDIVIDUALS WITH HIGH METABOLISM RISK: RELATIONSHIP WITH THE MECHANISMS OF INSULIN RESISTANCE|Completed||N/A|44|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 21:54:23.777922|2018-05-31 21:54:23.777922
NCT01478828|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2015-01-13||2015-10-13|2011-11-21|2011-11-23|Estimate|2015-10-13|2015-11-09|Estimate||||2015-10-13|2015-11-09|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|April 2013|Actual|2013-04-30||Interventional|||Pre-Prostatectomy Lovastatin on Prostate Cancer|Pharmacodynamic Trial of Pre-Prostatectomy Lovastatin on MYC (V-myc Myelocytomatosis Viral Oncogene Homolog) Down-Regulation in Localized Prostate Cancer|Suspended||N/A|2|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||The study was stopped due to an unanticipated serious adverse event.|f||||t||||||||||2018-05-31 21:54:23.879478|2018-05-31 21:54:23.879478
NCT01478802|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2015-04-26|2011-11-22|2011-11-23|Estimate|||||||2015-04-26|2015-04-28|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||High Frequency Oscillatory Ventilation for Acute Respiratory Distress Syndrome (ARDS)|Effect of Intermittent High Frequency Oscillatory Ventilation on the Pathophysiology and Survival of Patients With the Acute Respiratory Distress Syndrome.|Terminated||Phase 2/Phase 3|42|Actual|University of Athens||2||Low rate of enrollment, in conjunction with inability of continuation of funding|f||||t||||||||||2018-05-31 21:54:24.130242|2018-05-31 21:54:24.130242
NCT01478789|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2011-12-20|2011-11-21|2011-11-23|Estimate|||||||2011-12-20|2011-12-21|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|February 2011|Actual|2011-02-28||Interventional|||Efficacy of Plant Sterol-Fortified Dairy Product on Plasma Lipid and Plant Sterol Concentrations in Humans|Naturalis Clinical Trial for a Novel Phytosterol Formulation|Completed||N/A|47|Actual|University of Manitoba||3|||f||||t||||||||||2018-05-31 21:54:24.228489|2018-05-31 21:54:24.228489
NCT01478776|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-11-30|2011-11-22|2011-11-23|Estimate|||||||2012-11-30|2012-12-03|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Interventional|||The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics|The Impact of Omega-3 Supplementation on Acylation Stimulating Protein(ASP), Retinol-binding Protein 4 (RBP4) and Lipocalin-2 (LCN2) Gene Expression of ASP Receptor (C5L2) in WBC of Patient With Diabetes Type 2|Unknown status|Enrolling by invitation|Phase 4|20|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:54:24.306208|2018-05-31 21:54:24.306208
NCT01478763|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-09-24|2011-11-22|2011-11-23|Estimate|||||||2014-09-24|2014-09-25|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Vitrous Analysis in Proliferative Diabetic Retinopathy|Analysis of Vitreous Proteins in Patients Undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy|Completed|||200|Actual|St. Erik Eye Hospital|||||f||||f||||||Samples With DNA|"~     Vitreous samples~   "|||2018-05-31 21:54:24.401366|2018-05-31 21:54:24.401366
NCT01478750|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-10-24|2011-11-21|2011-11-23|Estimate|||||||2012-10-24|2012-10-25|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Oro-gastro-intestinal Digestion of Emulsified Fat|Oro-gastro-intestinal Digestion of Emulsified Fat and How This Digestion Relates to Colloidal Stability and Physiological Responses|Completed||N/A|15|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 21:54:24.45824|2018-05-31 21:54:24.45824
NCT01478737|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-09-24|2011-11-22|2011-11-23|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy|A Prospective, Randomized Study on Intravitreal Ozurdex for Preventing Recurrent Vitreous Hemorrhage Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy|Unknown status|Recruiting|Phase 2|100|Anticipated|St. Erik Eye Hospital||2|||f||||f||||||||||2018-05-31 21:54:24.541727|2018-05-31 21:54:24.541727
NCT01478724|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2015-05-22|2011-11-21|2011-11-23|Estimate|||||||2015-05-22|2015-05-25|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention|Effects of Proteins Fraction Derived From Milk on Bone Mineral Density and Bone Metabolism in Healthy Postmenopausal Women|Completed||Phase 1|291|Actual|Soredab||3|||f||||t||||||||||2018-05-31 21:54:24.629013|2018-05-31 21:54:24.629013
NCT01478711|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-02-25|2011-11-22|2011-11-23|Estimate|||||||2013-02-25|2013-02-26|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PreemieCDS||Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants|Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants|Completed||N/A|1517|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 21:54:24.691073|2018-05-31 21:54:24.691073
NCT01478698|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2017-10-09|2011-11-22|2011-11-23|Estimate|||||||2017-10-09|2017-10-10|Actual|January 2016||2016-01-31|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|||The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients|A Phase 1, Open Label, Non Randomised Safety Trial of Intraperitoneal tPA and DNase in Peritoneal Dialysis Patients With Peritonitis|Active, not recruiting||Phase 1|20|Anticipated|Sir Charles Gairdner Hospital||4|||f||||t||||||||||2018-05-31 21:54:24.754957|2018-05-31 21:54:24.754957
NCT01478685|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2016-03-23|2011-11-22|2011-11-23|Estimate|||||||2016-03-23|2016-03-25|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors|A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors|Completed||Phase 1|169|Actual|Celgene Corporation||3|||f||||f||||||||||2018-05-31 21:54:24.830954|2018-05-31 21:54:24.830954
NCT01478672|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2011-11-21|2011-11-21|2011-11-23|Estimate|||||||2011-11-21|2011-11-23|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Medium Term Health Coaching and Life-long Monitoring in Cardiovascular Disease in Norrbotten|Medium Term Health Coaching and Life-long Monitoring in Cardiovascular Disease in Norrbotten|Completed||N/A|741|Actual|Luleå Tekniska Universitet||2|||f||||t||||||||||2018-05-31 21:54:24.932123|2018-05-31 21:54:24.932123
NCT01478659|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-12-12|2011-11-21|2011-11-23|Estimate|||||||2012-12-12|2012-12-13|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|FIB||The Effect of Fiber Snack Foods on Dietary Intake in Healthy Adults|The Effect of Fiber Snack Foods on Dietary Intake in Healthy Adults|Completed||N/A|97|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 21:54:25.00148|2018-05-31 21:54:25.00148
NCT01478646|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) III-IV|The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy on Dyspnoea and Activity in Patients With COPD III-IV|Completed||N/A|24|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 21:54:25.065259|2018-05-31 21:54:25.065259
NCT01478633|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-03-24|2011-11-21|2011-11-23|Estimate|||||||2014-03-24|2014-03-26|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil|Evaluation of Efficacy and Safety of Galantamine in Subjects With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil|Completed||Phase 4|102|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 21:54:25.1327|2018-05-31 21:54:25.1327
NCT01478620|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|2014-08-27||2014-10-10|2011-11-21|2011-11-23|Estimate|2014-10-10|2014-10-13|Estimate||||2014-10-10|2014-10-13|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)|An Open-label, Non-randomized, Multicenter, Interventional Study to Investigate the Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)|Completed||Phase 3|125|Actual|Bionorica SE||1|||f||||||||||||||2018-05-31 21:54:25.215509|2018-05-31 21:54:25.215509
NCT01478607|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2015-10-12|2011-11-21|2011-11-23|Estimate|||||||2015-10-12|2015-10-14|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PACE||A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients|A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZATM Plus Standard of Care Versus Standard of Care Alone in Subjects With Painful Diabetic Peripheral Neuropathy|Completed||Phase 3|468|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:54:25.481274|2018-05-31 21:54:25.481274
NCT01478594|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|2015-02-19||2015-06-09|2011-11-21|2011-11-23|Estimate|2015-04-02|2015-04-03|Estimate||||2015-06-09|2015-07-08|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|September 2013|Actual|2013-09-30||Interventional|||A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy|A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination With mFOLFOX6 to Bevacizumab in Combination With mFOLFOX6, In Stage IV Metastatic Colorectal Cancer (mCRC) Subjects|Completed||Phase 2|265|Actual|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:54:25.683018|2018-05-31 21:54:25.683018
NCT01478581|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-11-01|2011-11-21|2011-11-23|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2012|Actual|2012-03-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|January 2017|Actual|2017-01-31||Interventional|||Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma|A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 2|92|Actual|Pharmacyclics LLC.||4|||f||||f||||||||||2018-05-31 21:54:28.073995|2018-05-31 21:54:28.073995
NCT01478568|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-04-08|2011-11-21|2011-11-23|Estimate|||||||2014-04-08|2014-04-10|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together|An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects|Completed||Phase 1|28|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:54:28.161448|2018-05-31 21:54:28.161448
NCT01478555|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-08-28|2011-11-21|2011-11-23|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|ISV-101||A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease|A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite® Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers|Withdrawn||Phase 2|0|Actual|InSite Vision||5||Project postponed|f||||f|t|f||||||||2018-05-31 21:54:28.236688|2018-05-31 21:54:28.236688
NCT01478542|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-10-02|2011-11-22|2011-11-23|Estimate|||||||2017-10-02|2017-10-04|Actual|November 2011||2011-11-30|October 2015|2015-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|OPTIMAL>60||OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine|Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution|Recruiting||Phase 3|1152|Anticipated|University Hospital, Saarland||6|||f||||t||||||||||2018-05-31 21:54:28.313727|2018-05-31 21:54:28.313727
NCT01478529|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-06-25|2011-11-21|2011-11-23|Estimate|||||||2013-06-25|2013-06-27|Estimate|February 2006||2006-02-28|June 2013|2013-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation|A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation|Completed||Phase 1|12|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:54:28.522685|2018-05-31 21:54:28.522685
NCT01478516|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2011-12-01|2011-11-21|2011-11-23|Estimate|||||||2011-12-01|2011-12-02|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy|Autologous Intravitreal Plasmin and Fibrinolytic System of Vitreous in Patient With Macular Edema|Unknown status|Recruiting|N/A|40|Anticipated|Hallym University Medical Center||1|||f||||t||||||||||2018-05-31 21:54:28.601368|2018-05-31 21:54:28.601368
NCT01478503|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-07-01|2011-11-21|2011-11-23|Estimate|||||||2013-07-01|2013-07-02|Estimate|May 2005||2005-05-31|July 2013|2013-07-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females|Double-blind, Randomized, Placebo-controlled, Dose-escalating, Exploratory Study to Investigate the Pharmacokinetics, Safety and Tolerability of Multiple Doses of YM178 OCAS-M in Healthy Young Male and Female Subjects and Healthy Elderly Male and Female Subjects|Completed||Phase 1|96|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:54:28.666609|2018-05-31 21:54:28.666609
NCT01478490|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2014-04-08|2011-11-21|2011-11-23|Estimate|||||||2014-04-08|2014-04-10|Estimate|September 2002||2002-09-30|November 2011|2011-11-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol|An Open Label, One-sequence, Parallel Study to Compare the Single Dose Pharmacokinetics of YM178 in Healthy Poor or Extensive Metabolisers for CYP2D6 and to Assess the Effect of Multiple Doses of YM178 on the Metabolism of the Model Substrate Metoprolol|Completed||Phase 1|28|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:54:28.765174|2018-05-31 21:54:28.765174
NCT01478152|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2011-11-21|2011-11-21|2011-11-23|Estimate|||||||2011-11-21|2011-11-23|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|February 2010|Actual|2010-02-28|||||Interventional|||Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma|A Single Center, Dose Finding, Safety, and Feasibility Study to Investigate the Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma|Completed||Phase 2|18|Actual|Bitop AG||1|||f||||f||||||||||2018-05-31 21:54:33.386664|2018-05-31 21:54:33.386664
NCT01478477|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-08-07|2011-11-21|2011-11-23|Estimate|||||||2017-08-07|2017-08-08|Actual|October 4, 2011|Actual|2011-10-04|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|January 9, 2014|Actual|2014-01-09||Interventional|||Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole|Prevention of Aromatase Inhibitor-Induced Joint Symptoms With Omega 3 Fatty Acid Supplementation: a Randomized Placebo Controlled Pilot Study|Active, not recruiting||N/A|40|Anticipated|Ohio State University Comprehensive Cancer Center||6|||f||||t||||||||||2018-05-31 21:54:29.928502|2018-05-31 21:54:29.928502
NCT01478464|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-06-27|2011-11-21|2011-11-23|Estimate|||||||2013-06-27|2013-06-28|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|IRMA||Effect of Massage on Hamstring Muscle Soreness|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|Completed||N/A|22|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 21:54:30.065688|2018-05-31 21:54:30.065688
NCT01478451|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2012-02-27|2011-11-21|2011-11-23|Estimate|||||||2012-02-27|2012-02-28|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Acute Effect of Massage and Exercise on Muscle Tenderness|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|Completed||N/A|20|Actual|National Research Centre for the Working Environment, Denmark||3|||f||||f||||||||||2018-05-31 21:54:30.139944|2018-05-31 21:54:30.139944
NCT01478438|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-09-12|2011-11-22|2011-11-23|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2012||2012-04-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2015|Actual|2015-12-31||Interventional|||"A Multicenter Ablate and Resect Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers"|"A Multicenter Ablate and Resect Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers"|Active, not recruiting||N/A|60|Anticipated|Novian Health Inc.||1|||f||||||||||||||2018-05-31 21:54:30.219448|2018-05-31 21:54:30.219448
NCT01478425|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-11-28|2011-11-22|2011-11-23|Estimate|||||||2011-11-28|2011-11-29|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Efficacy and Tolerability of a Topical Microemulsion in Patients With Allergic Rhinitis Due to Sensitization to Pollen|Study on the Efficacy and Tolerability of a Topical Microemulsion in Patients With Intermittent or Persistent Allergic Rhinitis Due to Sensitization to Birch, Olive Tree or Grass Pollen|Completed||Phase 4|110|Actual|Reig Jofre Group||2|||f||||t||||||||||2018-05-31 21:54:30.321643|2018-05-31 21:54:30.321643
NCT01478412|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-12-06|2011-11-22|2011-11-23|Estimate|||||||2011-12-06|2011-12-07|Estimate|December 2011||2011-12-31|December 2011|2011-12-31||||||||Observational|Clarity||An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer|A Prospective Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer|Unknown status|Recruiting||20|Anticipated|ProCure Proton Therapy Center|||1||f||||f||||||||||2018-05-31 21:54:30.43356|2018-05-31 21:54:30.43356
NCT01478399|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-04-12|2011-11-22|2011-11-23|Estimate|||||||2013-04-12|2013-04-15|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function|Phase 1 Open-Label Pharmacokinetic, Safety and Tolerability Study of a Single Subcutaneous Dose of Glymera (PB1023) Injection in Subjects With Normal Renal Function and Subjects With Impaired Renal Function|Completed||Phase 1|16|Actual|PhaseBio Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 21:54:30.522836|2018-05-31 21:54:30.522836
NCT01478386|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2013-07-22|2011-11-22|2011-11-23|Estimate|||||||2013-07-22|2013-07-23|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis|Randomized Trail to Assess the Effectiveness of an Off-Loading Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis|Terminated||N/A|11|Actual|OAD Orthopaedics||3||The study was terminated due to poor enrollment|f||||f||||||||||2018-05-31 21:54:30.713077|2018-05-31 21:54:30.713077
NCT01478373|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2015-07-14||2016-04-26|2011-11-21|2011-11-23|Estimate|2015-07-14|2015-08-10|Estimate||||2016-04-26|2016-04-27|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Full Analysis Set - All subjects with histologically confirmed diagnosis of GIST who received at least one dose of study drug.|Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib|DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib|Completed||Phase 2|39|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:54:30.83227|2018-05-31 21:54:30.83227
NCT01478360|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2015-10-20||2015-10-20|2011-11-22|2011-11-23|Estimate|2015-10-20|2015-11-20|Estimate||||2015-10-20|2015-11-20|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma|A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Administration of Secukinumab (AIN457) in Patients With Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting Beta-agonists.|Terminated||Phase 2|46|Actual|Novartis||2||"Further investigations would require changes in study design; the use of different endpoints, a~   different IL-17 antibody or a different patient population."|f||||||||||||||2018-05-31 21:54:31.276489|2018-05-31 21:54:31.276489
NCT01478347|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|2015-02-20||2015-03-06|2011-11-22|2011-11-23|Estimate|2015-02-20|2015-03-06|Estimate||||2015-03-06|2015-03-27|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Interventional||Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures, were administered two injections of rMenB + OMV NZ vaccine, 2 months apart in part I (Visit 1-Visit 3). In part II (Visit 4-Visit 7), subjects were re-enrolled for optional blood draws and safety follow-up.|A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults|A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults|Completed||Phase 3|18|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:54:31.612651|2018-05-31 21:54:31.612651
NCT01478334|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2015-05-28|2011-11-21|2011-11-23|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||Exercise-induced Improvements of Inflammatory Status in Patients With Rheumatoid Arthritis|Exercise-induced Improvements of Inflammatory Status in Patients With Rheumatoid Arthritis - Improvements of Cardiovascular Risk Factors and Quality of Life|Completed||N/A|18|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 21:54:31.802414|2018-05-31 21:54:31.802414
NCT01478321|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2018-04-11|2011-11-21|2011-11-23|Estimate|||||||2018-04-11|2018-04-12|Actual|November 2011||2011-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas|A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas|Active, not recruiting||Phase 2|63|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 21:54:31.927845|2018-05-31 21:54:31.927845
NCT01478308|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2013-03-05|2011-11-21|2011-11-23|Estimate|||||||2013-03-05|2013-03-06|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer|Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|New Mexico Cancer Care Alliance||||No accrual in initial period, PI decided to close study.|f||||t||||||||||2018-05-31 21:54:32.104396|2018-05-31 21:54:32.104396
NCT01478295|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-02-10|2011-11-21|2011-11-23|Estimate|||||||2016-02-10|2016-02-11|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CuidaCare||Effectiveness of Nursing Intervention on Caregivers|Effectiveness of Nursing Intervention on Quality of Life of Older Caregivers: Clinical Trial Randomised by Clusters|Completed||N/A|266|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 21:54:32.185711|2018-05-31 21:54:32.185711
NCT01478282|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2012-03-09|2011-11-21|2011-11-23|Estimate|||||||2012-03-09|2012-03-12|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|REVANT||Reversal of the Antithrombotic Action of New Oral Anticoagulants|Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers|Unknown status|Recruiting|Phase 4|10|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 21:54:32.288638|2018-05-31 21:54:32.288638
NCT01478269|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|ProDLBCL||Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen|Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)|Completed|||1927|Actual|Fondazione Italiana Linfomi ONLUS|||1||f||||f||||||||||2018-05-31 21:54:32.411395|2018-05-31 21:54:32.411395
NCT01478256|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|2013-04-09||2013-11-20|2011-11-22|2011-11-23|Estimate|2013-09-17|2013-11-20|Estimate||||2013-11-20|2013-12-19|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis|A Comparative Study in the Clinical and Microbial Efficacy of Topical Besifloxocin Ophthalmic Suspension 0.6% With Erythromycin Ophthalmic Ointment 0.5% BID for the Management of Acute Blepharitis|Completed||Phase 4|30|Actual|John, George, M.D.||2|||f||||f||||||||||2018-05-31 21:54:32.559976|2018-05-31 21:54:32.559976
NCT01478243|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2016-10-17|2011-11-22|2011-11-23|Estimate|||||||2016-10-17|2016-10-18|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Study of Psycho-Social Impact of Keloid|Study of Psycho-Social Impact of Keloid|Terminated|||1000|Anticipated|Tirgan, Michael H., M.D.||||Lack of institutional support and IRB related issues.|f||||f||||||||||2018-05-31 21:54:32.80538|2018-05-31 21:54:32.80538
NCT01478230|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-07-06|2011-11-21|2011-11-23|Estimate|||||||2012-07-06|2012-07-10|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Exploratory Study Comparing Two Nicotine Inhalers|A Proof of Concept With a New Nicotine Inhaler in Comparison With Nicotine Inhaler 10 mg|Completed||Early Phase 1|36|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 21:54:32.862941|2018-05-31 21:54:32.862941
NCT01478217|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||PEEP Recruitment-comparison Between Ultrasonographic Assessment and LIP Assessment|Positive End-expiratory Pressure Induced Lung Recruitment -Comparison Between Ultrasonographic Assessment and Lower Inflection Point Assessment on the Pressure -Volume Loop|Completed|||17|Actual|Sisters of Mercy University Hospital|||||f||||f||||||||||2018-05-31 21:54:32.967482|2018-05-31 21:54:32.967482
NCT01478204|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-10-30|2011-11-21|2011-11-23|Estimate|||||||2012-10-30|2012-10-31|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||A Study to Evaluate Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease|An Observational Epidemiological Study on Evaluation of Sleep Quality in Patients With Mild to Moderate Alzheimer's Disease in Clinical Practice|Completed|||925|Actual|Janssen-Cilag, S.A.|||||f||||f||||||||||2018-05-31 21:54:33.040318|2018-05-31 21:54:33.040318
NCT01478191|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2013-03-05|2011-11-22|2011-11-23|Estimate|||||||2013-03-05|2013-03-06|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|||||Observational|IIL-ProHLRec||Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT|Prognosis of Patients With Relapsed/Refractory Hl Treated With Combination of Ifosfamide, Gemcitabine and Vinorelbine(IGEV) Induction Therapy Before High-dose Chemotherapy (HDCT) With Autologous Hematopoietic Stem Cells Transplantation (AHSCT)|Completed|||495|Anticipated|Fondazione Italiana Linfomi ONLUS|||||f||||f||||||||||2018-05-31 21:54:33.104204|2018-05-31 21:54:33.104204
NCT01478178|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14||2017-01-10|2017-01-19|2011-11-22|2011-11-23|Estimate||||2017-01-10|2017-01-11|Estimate|2017-01-19|2017-01-20|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma|Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of VAL-083 in Patients With Recurrent Malignant Glioma|Completed||Phase 1/Phase 2|55|Actual|DelMar Pharmaceuticals, Inc.||1|||f||||f||||||||No|The Clinical Study Report for this trial will be prepared and provided to U.S. F.D.A. as required by applicable regulatory requirement(s). Each participating trial investigator has been provided a copy their patient data captured in the electronic data base for this trial.|2018-05-31 21:54:33.223122|2018-05-31 21:54:33.223122
NCT01478165|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting|Comparative Study of TIVA(Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing PONV(Postoperative Nausea and Vomiting)|Completed||N/A|100|Actual|Incheon St.Mary's Hospital||2|||f||||t||||||||||2018-05-31 21:54:33.313991|2018-05-31 21:54:33.313991
NCT01478139|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2013-11-26|2011-11-22|2011-11-23|Estimate|||||||2013-11-26|2013-11-28|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|LIFT-plug||Ligation of Intersphincteric Fistula Tract (LIFT) Versus LIFT-plug Procedure for Anal Fistula Repair|Ligation of Intersphincteric Fistula Tract (LIFT) Versus LIFT-plug Procedure for Anal Fistula Repair: a Multicenter, Randomized, Open-label, Parallel Controlled Trial|Unknown status|Recruiting|Phase 3|240|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 21:54:33.454251|2018-05-31 21:54:33.454251
NCT01478126|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2013-10-30|2011-11-21|2011-11-23|Estimate|||||||2013-10-30|2013-11-01|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|||Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass|Prospective Randomized Study of Glutamin Protective Properties in Cardiac Surgery.|Completed||Phase 3|24|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 21:54:33.561465|2018-05-31 21:54:33.561465
NCT01478113|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2017-01-17||2017-03-16|2011-11-21|2011-11-23|Estimate|2017-03-16|2017-04-26|Actual||||2017-03-16|2017-04-26|Actual|February 2012||2012-02-29|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|||Stimulant Enhancement of Well-Being Therapy for Depression|Stimulant Enhancement of Well-Being Therapy for Depression|Terminated||N/A|5|Actual|Massachusetts General Hospital|This study was shut down due to original PI leaving the institution and due to lack of continued funding. As such, we were not able to enroll a sufficient number of patients to analyze data/answer study hypothesis/achieve study aims.|2||PI left the institution and was no funding to continue study.|f||||f||||||||No|No plan to make IPD available.|2018-05-31 21:54:33.647817|2018-05-31 21:54:33.647817
NCT01478100|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Virtual Coronary Intervention and Non-invasive Fractional Flow Reserve (FFR)||Completed|||20|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 21:54:34.05102|2018-05-31 21:54:34.05102
NCT01478087|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2013-01-08||2013-02-12|2011-11-22|2011-11-23|Estimate|2013-01-08|2013-02-11|Estimate||||2013-02-12|2013-02-15|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)|Pilot Study of Immunoadsorption Therapy for Patients With Chronic Non-Ischemic Dilated Cardiomyopathy|Terminated||N/A|2|Actual|Asahi Kasei Medical Co., Ltd.||1||Sponsor terminated due to business reasons|f||||t||||||||||2018-05-31 21:54:34.120972|2018-05-31 21:54:34.120972
NCT01478074|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-01-02|2011-11-22|2011-11-23|Estimate|||||||2014-01-02|2014-01-03|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia|A Single-center Open-label Phase I Study of ALT-801 for ex Vivo Maturation and in Vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Withdrawn||Phase 1|0|Actual|Altor BioScience||1||"The treatment planned was determined to be of low feasibility as no subject was found eligible~   and able to enroll after screening over 30 subjects"|f||||||||||||||2018-05-31 21:54:34.314569|2018-05-31 21:54:34.314569
NCT01478061|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2015-07-20|2011-11-21|2011-11-23|Estimate|||||||2015-07-20|2015-07-22|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|January 2013|Actual|2013-01-31||Interventional|||Multi-center Assessment of Grafts in Coronaries: Long-term Evaluation of the C-Port Device|Multi-center Assessment of Grafts in Coronaries: Long-term Evaluation of the C-Port Device|Completed||Phase 4|115|Actual|Cardica, Inc||1|||f||||f||||||||||2018-05-31 21:54:34.423282|2018-05-31 21:54:34.423282
NCT01478048|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2015-12-17|2015-09-23|2018-04-20|2011-11-22|2011-11-23|Estimate|2015-12-17|2016-01-26|Estimate|2015-12-02|2015-12-03|Estimate|2018-04-20|2018-05-21|Actual|November 30, 2011|Actual|2011-11-30|April 2018|2018-04-30|April 21, 2017|Actual|2017-04-21|May 30, 2014|Actual|2014-05-30||Interventional||All enrolled participants who were randomized to a treatment arm were summarized.|Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma|A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|185|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 21:54:34.631925|2018-05-31 21:54:34.631925
NCT01478035|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2012-12-19|2011-11-22|2011-11-23|Estimate|||||||2012-12-19|2012-12-20|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.|Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial|Unknown status|Recruiting|Phase 4|122|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 21:54:36.213855|2018-05-31 21:54:36.213855
NCT01478022|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|ISOFEN1||To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20|Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses|Unknown status|Recruiting|Phase 1|12|Anticipated|Parent Project, Italy||3|||f||||t||||||||||2018-05-31 21:54:36.377765|2018-05-31 21:54:36.377765
NCT01478009|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2012-07-02||2012-11-26|2011-11-22|2011-11-23|Estimate|2012-11-26|2012-12-25|Estimate||||2012-11-26|2012-12-25|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy of an Extract of Concentrated Korean Red Ginseng for Preventing Upper Respiratory Tract Infections|A Placebo-Controlled Trial of Korean Red Ginseng Extract to Prevent Acute Respiratory Illness in Healthy Subjects|Completed||Phase 2/Phase 3|100|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:54:36.645751|2018-05-31 21:54:36.645751
NCT01477996|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2016-01-24|2011-11-22|2011-11-23|Estimate|||||||2016-01-24|2016-01-26|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pain After Intravitreal Therapy||Completed||N/A|200|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||||2018-05-31 21:54:37.053693|2018-05-31 21:54:37.053693
NCT01477983|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-12|||2017-08-15|2011-11-20|2011-11-23|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2011||2011-11-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|KPAF||Kansai Plus Atrial Fibrillation Trial|Kansai Plus Atrial Fibrillation Trial; UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate Trial; Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation Trial|Completed||Phase 4|2113|Actual|Kyoto University, Graduate School of Medicine||4|||f||||t||||||||||2018-05-31 21:54:37.148288|2018-05-31 21:54:37.148288
NCT01477957|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2017-09-13|2011-11-22|2011-11-23|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2012||2012-09-30|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|Bariatrix||The Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism|Assessment of the Effect of Bariatric Surgery on Insulin Sensitivity and Energy Metabolism|Recruiting||N/A|250|Anticipated|German Diabetes Center||1|||f||||f||||||||||2018-05-31 21:54:37.476185|2018-05-31 21:54:37.476185
NCT01477944|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2012-02-20|2011-11-22|2011-11-23|Estimate|||||||2012-02-20|2012-02-22|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Pattern of Statins Use in Catalonia|Pattern of Statins Use in Catalonia|Completed|||180723|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 21:54:37.578146|2018-05-31 21:54:37.578146
NCT01477931|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|WellbutrinXL||Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features|An Open-Label, 8-week Trial of Bupropion Hydrochloride Extended Release (Wellbutrin XL®) In Patients With Major Depressive Disorder (MDD) With Atypical Features.|Completed||Phase 4|50|Actual|The Catholic University of Korea||1|||f||||f||||||||||2018-05-31 21:54:37.642324|2018-05-31 21:54:37.642324
NCT01477918|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-20|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|December 2011||2011-12-31|November 2011|2011-11-30||||||||Observational|||Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea||Unknown status|Not yet recruiting||1000|Anticipated|Asan Medical Center|||||f||||f||||||||||2018-05-31 21:54:37.747103|2018-05-31 21:54:37.747103
NCT01477905|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-22|2011-11-22|2011-11-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Impact of Priming the Infusion System on the Performance of Target-controlled Infusion of Remifentanil|Study of Proper Operation of the Syringe Pump Used in Priming of the Syringe|Completed||N/A|48|Actual|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 21:54:37.840522|2018-05-31 21:54:37.840522
NCT01477892|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2013-04-12||2013-09-11|2011-11-22|2011-11-23|Estimate|2013-09-11|2013-09-13|Estimate||||2013-09-11|2013-09-13|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluation of Safety and Efficacy of Remifentanil in Pediatric Population|Evaluation of Safety and Efficacy of Remifentanil in Preterm Infant|Completed||Phase 1/Phase 2|14|Actual|Seoul National University Hospital|relatively small numbers of subjects|2|||f||||t||||||||||2018-05-31 21:54:37.94908|2018-05-31 21:54:37.94908
NCT01477879|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-19|2011-11-19|2011-11-23|Estimate|||||||2011-11-19|2011-11-23|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Hsv 1 and 2 Gowey Protocol Versus Placebo|Phase II Clinical Trial of Versabase/Sarracenia Purpurea Versus Placebo|Completed||Phase 1/Phase 2|33|Actual|Naturopaths International||2|||f||||f||||||||||2018-05-31 21:54:38.222693|2018-05-31 21:54:38.222693
NCT01477866|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-12-09|2011-11-22|2011-11-23|Estimate|||||||2017-12-09|2017-12-12|Actual||||December 2017|2017-12-31||||||||Interventional|CITOGENEX PA||Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer|Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer|Suspended||N/A|250|Anticipated|University of Palermo||2||the study has never started|f||||f||||||||||2018-05-31 21:54:38.317058|2018-05-31 21:54:38.317058
NCT01477853|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|2016-06-21||2017-05-25|2011-11-19|2011-11-23|Estimate|2016-08-11|2016-10-05|Estimate||||2017-05-25|2017-06-19|Actual|October 24, 2011|Actual|2011-10-24|May 2017|2017-05-31|December 4, 2012|Actual|2012-12-04|December 4, 2012|Actual|2012-12-04||Interventional|||A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-administration of Sitagliptin and Atorvastatin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy|Terminated||Phase 3|166|Actual|Merck Sharp & Dohme Corp.|The study was terminated early by the Sponsor for business reasons. Due to the small number of participants included in the FAS, the results for Phase A and for the overall study should be interpreted with caution.|3||The study was terminated early by the Sponsor for business reasons.|f||||f||||||||||2018-05-31 21:54:38.411763|2018-05-31 21:54:38.411763
NCT01477840|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-12-12|2011-11-19|2011-11-23|Estimate|||||||2011-12-12|2011-12-13|Estimate|August 2012||2012-08-31|December 2011|2011-12-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Comparative of Effects of Sublingual Misoprostol and Infusion Oxytocin in Reduction of Bleeding at Cesarean|Phase 2-3 Study of Comparative of Effects of Sublingual Misoprostol and Infusion Oxytocin in Reduction of Blood Loss at Cesarean Deliveries|Unknown status|Not yet recruiting|Phase 2/Phase 3|180|Anticipated|Kermanshah University of Medical Sciences||1|||f||||t||||||||||2018-05-31 21:54:38.964101|2018-05-31 21:54:38.964101
NCT01477827|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-01-14|2011-11-18|2011-11-23|Estimate|||||||2013-01-14|2013-01-16|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Sunlight Exposure and Vitamin D in Children|Sunlight Exposure and Vitamin D Status of Children in the UK|Completed|||125|Actual|University of Manchester|||1||f||||f||||||||||2018-05-31 21:54:39.085893|2018-05-31 21:54:39.085893
NCT01477814|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-04-20|2011-11-18|2011-11-23|Estimate|||||||2017-04-20|2017-04-24|Actual|July 2008||2008-07-31|April 2017|2017-04-30|July 16, 2015|Actual|2015-07-16|April 27, 2010|Actual|2010-04-27||Interventional|||Interventions to Improve Colon Cancer Screening in Poor Rural Iowa Counties|Randomized Clinical Trial to Improve Colon Cancer Screening in Poor Rural Iowa Counties|Completed||N/A|743|Actual|University of Iowa||3|||f||||f||||||||Yes|Written request from an appropriate researcher to the PI|2018-05-31 21:54:39.185628|2018-05-31 21:54:39.185628
NCT01477801|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2011-11-18|2011-11-18|2011-11-23|Estimate|||||||2011-11-18|2011-11-23|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|ECSPLOIT -D||Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels|Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels. A Phase 2 Randomized Double Blind Study|Unknown status|Recruiting|Phase 2/Phase 3|34|Anticipated|Azienda Unita' Sanitaria Locale Di Modena||2|||f||||f||||||||||2018-05-31 21:54:39.330433|2018-05-31 21:54:39.330433
NCT01477788|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2015-06-17|2011-11-19|2011-11-23|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass|Prediction of Ovarian Malignancy, in the Presence of Sonographic Pelvic Mass Using Patient History, Sonographic Parameters and Serum Markers|Withdrawn|||0|Actual|HaEmek Medical Center, Israel|||1|The researcher Left the organization|f||||f||||||||||2018-05-31 21:54:39.418494|2018-05-31 21:54:39.418494
NCT01477775|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2014-09-01|2011-11-19|2011-11-23|Estimate|||||||2014-09-01|2014-09-03|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|PRU-MATRIX||Customized Choice of Oral P2Y12 Receptor Blocker|Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing|Unknown status|Recruiting|Phase 4|4000|Anticipated|Italian Society of Invasive Cardiology||2|||f||||t||||||||||2018-05-31 21:54:39.485921|2018-05-31 21:54:39.485921
NCT01477762|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2016-08-25||2017-03-07|2011-11-21|2011-11-23|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|November 2011||2011-11-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CSS|A total of 63 participants completed all study visits of which data were analyzed.|Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)|Effects of Cortisol Suppression on Fear-Potentiated Startle in Traumatized Individuals With and Without PTSD|Completed||N/A|165|Actual|Emory University||2|||f||||t||||||||||2018-05-31 21:54:39.597279|2018-05-31 21:54:39.597279
NCT01477749|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|2015-06-10||2015-11-04|2011-11-19|2011-11-23|Estimate|2015-11-04|2015-12-09|Estimate||||2015-11-04|2015-12-09|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Sipuleucel-T Manufacturing Demonstration Study|An Open-Label Study Study of Sipuleucel-T in European Men With Metastatic, Castrate Resistant Prostate Cancer|Completed||Phase 2|47|Actual|Dendreon||1|||f||||f||||||||||2018-05-31 21:54:40.029639|2018-05-31 21:54:40.029639
NCT01477736|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|||2011-11-19|2011-11-19|2011-11-22|Estimate|||||||2011-11-19|2011-11-22|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity|A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity|Completed||N/A|68|Actual|Centro de Reabilitação e Readaptação Dr. Henrique Santillo||2|||f||||t||||||||||2018-05-31 21:54:40.336394|2018-05-31 21:54:40.336394
NCT01477723|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-19|||2013-02-14|2011-11-21|2011-11-22|Estimate|||||||2013-02-14|2013-02-15|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of an Oral Nutritional Supplement in Older Hospitalized Patients|Evaluation of an Oral Nutritional Supplement Containing AN 777 in Older Hospitalized Patients|Terminated||Phase 3|17|Actual|Abbott Nutrition||2||Low enrollment|f||||t||||||||||2018-05-31 21:54:40.410032|2018-05-31 21:54:40.410032
NCT01477710|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2013-01-23||2013-03-11|2011-11-18|2011-11-22|Estimate|2013-03-11|2013-03-12|Estimate||||2013-03-11|2013-03-12|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Ability of Caregivers to Provide Ventilation With the SAVe Resuscitator in a Model|Ability of Caregivers to Provide Ventilation With the SAVe Resuscitator in a Model|Completed||N/A|30|Actual|University of Cincinnati||3|||f||||f||||||||||2018-05-31 21:54:40.480812|2018-05-31 21:54:40.480812
NCT01477697|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-02-22|2011-11-18|2011-11-22|Estimate|||||||2013-02-22|2013-02-25|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients|Effects of Omega-3 Fatty Acid Supplementation on Inflammatory Response in Multisystem Trauma Patients|Terminated||Phase 1/Phase 2|12|Actual|University of Cincinnati||2||"Terminated due to slow enrollment and interim analysis showing no difference between treatment~   arms."|f||||f||||||||||2018-05-31 21:54:40.788733|2018-05-31 21:54:40.788733
NCT01477684|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2012-10-15|2011-11-18|2011-11-22|Estimate|||||||2012-10-15|2012-10-16|Estimate|October 2011||2011-10-31|October 2012|2012-10-31||||November 2011|Actual|2011-11-30||Observational|||Documentation of In-flight Medical Emergencies With Medical Incident Report Forms.||Completed|||10|Actual|Ruhr University of Bochum|||||f||||t||||||||||2018-05-31 21:54:40.878459|2018-05-31 21:54:40.878459
NCT01477671|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2018-01-09|2011-11-18|2011-11-22|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2011||2011-09-30|January 2018|2018-01-31|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Observational|||Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children|Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children in India|Completed|||667|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 21:54:40.960657|2018-05-31 21:54:40.960657
NCT01477658|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-05-04|2011-11-21|2011-11-22|Estimate|||||||2013-05-04|2013-05-07|Estimate|November 2007||2007-11-30|May 2013|2013-05-31|November 2013|Anticipated|2013-11-30|November 2012|Actual|2012-11-30||Observational|||Effects of Chronic Right Ventricular Pacing in Children With Advanced Atrioventricular Block|Effects of Chronic Right Ventricular Pacing in Children With Advanced Atrioventricular Block|Unknown status|Enrolling by invitation||140|Actual|University of Sao Paulo|||2||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 21:54:41.074823|2018-05-31 21:54:41.074823
NCT01477645|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-10-13|2011-11-21|2011-11-22|Estimate|||||||2013-10-13|2013-10-16|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|||Health Effects Following Use of Lead Free Ammunition Used With HK416|In Norwegian: Helseffekter av Stoff Som Avgis Ved Skyting Med HK416|Completed|||55|Actual|Oslo University Hospital|||3||f||||f||||||Samples Without DNA|"~     Sputum and serum~   "|||2018-05-31 21:54:41.164173|2018-05-31 21:54:41.164173
NCT01477632|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2016-01-14|2011-11-18|2011-11-22|Estimate|||||||2016-01-14|2016-01-15|Estimate|March 2005||2005-03-31|January 2016|2016-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women|Single Dose, Three-way, Cross-over, Relative Bioavailability Study With 3 Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women: 0.5 mg Estradiol + 0.1 mg Norethisterone Acetate, 0.5 mg Estradiol + 0.25 mg Norethisterone Acetate, and 1.0 mg Estradiol + 0.5 mg Norethisterone Acetate|Completed||Phase 1|24|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:54:41.253026|2018-05-31 21:54:41.253026
NCT01477619|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-02-14|2011-11-21|2011-11-22|Estimate|||||||2014-02-14|2014-02-17|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects|An Open-label, Single Dose, Parallel Group Study to Assess the Effects of Smoking Status, Age and Body Size on the Pharmacokinetics, Safety, and Tolerability of Tasimelteon in Healthy Volunteers|Completed||Phase 1|60|Actual|Vanda Pharmaceuticals||3|||f||||f||||||||||2018-05-31 21:54:41.358201|2018-05-31 21:54:41.358201
NCT01477606|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2018-02-27|2011-11-21|2011-11-22|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2012||2012-05-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Protocol in Acute Myeloid Leukemia With FLT3-ITD|Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication|Active, not recruiting||Phase 2|440|Anticipated|University of Ulm||1|||f||||t||||||||||2018-05-31 21:54:41.476412|2018-05-31 21:54:41.476412
NCT01477580|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2015-12-16|2011-11-18|2011-11-22|Estimate|||||||2015-12-16|2015-12-17|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)|A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults|Completed||Phase 1|98|Actual|Merck Sharp & Dohme Corp.||13|||f||||t||||||||||2018-05-31 21:54:41.764253|2018-05-31 21:54:41.764253
NCT01477567|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2014-06-13||2014-10-02|2011-11-18|2011-11-22|Estimate|2014-10-02|2014-10-06|Estimate||||2014-10-02|2014-10-06|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||All enrolled participants.|A First-in-Human Study of LY3009385 in Healthy Participants|A Single Ascending Dose (SAD) Study of LY3009385 in Healthy Volunteers|Completed||Phase 1|40|Actual|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 21:54:41.921427|2018-05-31 21:54:41.921427
NCT01477554|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2018-03-01|2011-11-18|2011-11-22|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2009||2009-09-30|March 2018|2018-03-31|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Interventional|PRONTO||PRONTO: Obstetric and Neonatal Emergency Training Program: A Cluster-Randomized Trial to Measure Impact|PRONTO: Obstetric and Neonatal Emergency Training Program: A Cluster-Randomized Trial to Measure Impact|Completed||N/A|24|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||f||||||||||2018-05-31 21:54:42.90313|2018-05-31 21:54:42.90313
NCT01477541|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|November 2007||2007-11-30|November 2011|2011-11-30||||March 2010|Actual|2010-03-31||Interventional|||Cluster-randomized Trial Measuring Integration of Professional Midwives and Obstetric Nurses in Rural Clinics in Mexico|Incorporation of Alternative Providers for Care During Pregnancy, Delivery and Postpartum in Rural Public Health Clinics.|Completed||N/A|27|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||||||||||||2018-05-31 21:54:42.999576|2018-05-31 21:54:42.999576
NCT01477528|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2016-04-18|2011-11-21|2011-11-22|Estimate|||||||2016-04-18|2016-04-19|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|TRACE||Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)|Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II LVAS (TRACE)|Completed|||201|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 21:54:43.062715|2018-05-31 21:54:43.062715
NCT01477515|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2012-08-21|2011-11-21|2011-11-22|Estimate|||||||2012-08-21|2012-08-23|Estimate|February 2012||2012-02-29|August 2012|2012-08-31||||||||Observational|||Endocannabinoids in End Stage Renal Disease||Completed|||30|Actual|Indiana University|||2||f||||f||||||||||2018-05-31 21:54:43.177047|2018-05-31 21:54:43.177047
NCT01477502|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2016-10-12|2011-11-21|2011-11-22|Estimate|||||||2016-10-12|2016-10-13|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Clinical Value of Homeopathic Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury|Clinical Value of Homeopathic Assessment and Treatment for Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury|Completed||N/A|46|Actual|Swiss Paraplegic Centre Nottwil||2|||f||||f||||||||||2018-05-31 21:54:43.228288|2018-05-31 21:54:43.228288
NCT01477489|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-12-13|2011-11-21|2011-11-22|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2012||2012-01-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2014|Actual|2014-10-31||Interventional|||Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer|A Phase 1 Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer|Completed||Phase 1|33|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:54:43.289589|2018-05-31 21:54:43.289589
NCT01477476|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-06-28|2011-11-21|2011-11-22|Estimate|||||||2017-06-28|2017-07-02|Actual|March 2012||2012-03-31|June 2017|2017-06-30|April 22, 2016|Actual|2016-04-22|March 2016|Actual|2016-03-31||Interventional|||Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes|Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes.|Terminated||Phase 2|1|Actual|University of Colorado, Denver||2||funding loss and only one subject enrolled|f||||t||||||||||2018-05-31 21:54:43.358701|2018-05-31 21:54:43.358701
NCT01477463|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2016-06-30||2016-10-31|2011-11-17|2011-11-22|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers|Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers|Completed||N/A|24|Actual|Stanford University||2|||f||||t||||||||Yes|Results will be submitted to scientific journal for publication.|2018-05-31 21:54:43.44455|2018-05-31 21:54:43.44455
NCT01477450|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2014-01-01||2014-09-24|2011-11-18|2011-11-22|Estimate|2014-09-24|2014-09-26|Estimate||||2014-09-24|2014-09-26|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Comparison of Oxygen Delivery Devices for Reversal of Altitude-Induced Hypoxemia in Normal Subjects|Comparison of Oxygen Delivery Devices for Reversal of Altitude-Induced Hypoxemia in Normal Subjects|Completed||N/A|30|Actual|University of Cincinnati||3|||f||||f||||||||||2018-05-31 21:54:43.655993|2018-05-31 21:54:43.655993
NCT01477437|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-12-29|2011-11-21|2011-11-22|Estimate|||||||2017-12-29|2018-01-03|Actual|November 2011||2011-11-30|December 2017|2017-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia|Development and Evaluation of an Internet-based Educational Program to Promote Self- Management for Teens With Hemophilia|Completed||N/A|29|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 21:54:44.898897|2018-05-31 21:54:44.898897
NCT01477424|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-02-14|2011-11-18|2011-11-22|Estimate|||||||2012-02-14|2012-02-16|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Drug-Drug Interaction Study of Warfarin and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Warfarin in Healthy Male and Female Adults|Completed||Phase 1|45|Actual|Vifor Inc.||3|||f||||f||||||||||2018-05-31 21:54:44.966273|2018-05-31 21:54:44.966273
NCT01477411|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-01-17|2011-11-18|2011-11-22|Estimate|||||||2012-01-17|2012-01-18|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Drug-Drug Interaction Study of Digoxin and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Digoxin in Healthy Male and Female Adults|Completed||Phase 1|42|Actual|Vifor Inc.||3|||f||||f||||||||||2018-05-31 21:54:45.037642|2018-05-31 21:54:45.037642
NCT01477398|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2016-08-18|2011-11-18|2011-11-22|Estimate|||||||2016-08-18|2016-08-22|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Improved Patient Recovery After Anesthesia|Improved Patient Recovery of Spontaneous Respiration After Anesthesia With Hypercapnic Hyperpnoea|Completed||Early Phase 1|31|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 21:54:45.118108|2018-05-31 21:54:45.118108
NCT01477385|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-05-03|2011-11-18|2011-11-22|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Treatment of Initial Caries Lesions on Proximal Surfaces of Primary and Permanent Posterior Teeth|Treatment of Initial Caries Lesions on Proximal Surfaces of Primary and Permanent Posterior Teeth: a Randomized Placebo-controlled Study.|Recruiting||N/A|183|Anticipated|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 21:54:45.209843|2018-05-31 21:54:45.209843
NCT01477372|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2012-04-10|2011-11-18|2011-11-22|Estimate|||||||2012-04-10|2012-04-11|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effect of Physical Exercise Program During Pregnancy on Excessive Weight Gain and Its Consequences|Effect of Physical Exercise Program During Pregnancy on Excessive Weight Gain and Its Consequences|Completed||N/A|320|Actual|Universidad Politecnica de Madrid||2|||f||||f||||||||||2018-05-31 21:54:45.33676|2018-05-31 21:54:45.33676
NCT01477359|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-11-20|2011-11-18|2011-11-22|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2012||2012-08-31|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|CHASM-CS||Cardiac Sarcoidosis Multi-Center Prospective Cohort|Cardiac Sarcoidosis Multi-Center Prospective Cohort Study|Recruiting|||1500|Anticipated|Ottawa Heart Institute Research Corporation|||1||f||||f||||||Samples With DNA|"~     Frozen plasma, serum and buffy coat.~   "|||2018-05-31 21:54:45.439919|2018-05-31 21:54:45.439919
NCT01477346|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-01-04|2011-11-18|2011-11-22|Estimate|||||||2017-01-04|2017-01-05|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Arthritis Research UK Gout Treatment Trial - Phase 2|Arthritis Research UK Gout Treatment Trial. Phase 2: Two Year Randomised Controlled Trial of a Nurse Led Package of Care|Completed||N/A|517|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 21:54:45.695551|2018-05-31 21:54:45.695551
NCT01477333|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2016-08-01||2017-01-11|2011-11-18|2011-11-22|Estimate|2017-01-11|2017-03-06|Actual||||2017-01-11|2017-03-06|Actual|October 2011||2011-10-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®|An Evaluation of the Safety and Efficacy of the Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®|Completed||Phase 2|18|Actual|United Therapeutics||1|||f||||f||||||||||2018-05-31 21:54:45.803387|2018-05-31 21:54:45.803387
NCT01477320|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2017-08-17||2017-12-14|2011-11-18|2011-11-22|Estimate|2017-12-14|2018-01-16|Actual||||2017-12-14|2018-01-16|Actual|September 2013||2013-09-30|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.|Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. Prospective, Double-blind, Randomized, Placebo-controlled Study.|Completed||N/A|124|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 21:54:46.255242|2018-05-31 21:54:46.255242
NCT01477307|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-10-24|2011-11-18|2011-11-22|Estimate|||||||2017-10-24|2017-10-26|Actual|July 1, 2013|Actual|2013-07-01|October 2017|2017-10-31|September 15, 2016|Actual|2016-09-15|August 31, 2016|Actual|2016-08-31||Observational|||Dietary Intervention and Intestinal Microbiota in Non-alcoholic Fatty Liver|Effect of Dietary Intervention on Intestinal Microbiota in Patients With Non-alcoholic Fatty Liver Disease|Completed|||20|Actual|University Hospital, Geneva|||1||f||||t||||||||||2018-05-31 21:54:46.460454|2018-05-31 21:54:46.460454
NCT01477294|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effects of Caffeine in Hydration and Energy Metabolism|Effects of Caffeine Ingestion in Total-body Water, Extra and Intracellular Water Distribution, and Energy Metabolism|Completed||N/A|30|Actual|Technical University of Lisbon||2|||f||||f||||||||||2018-05-31 21:54:46.573555|2018-05-31 21:54:46.573555
NCT01477281|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|February 2012||2012-02-29|November 2011|2011-11-30|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon|A Clinical Multicenter, Phase III, Prospective, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon|Unknown status|Not yet recruiting|Phase 3|82|Anticipated|Laboratório Teuto Brasileiro S/A||2|||f||||t||||||||||2018-05-31 21:54:46.687975|2018-05-31 21:54:46.687975
NCT01477268|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|June 2007||2007-06-30|May 2011|2011-05-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Cognitive Correlates of Antidepressant Treatment Response in Elders|Determining the Impact of Dementia and Executive Impairment on Antidepressant Treatment Response in Older Persons|Completed||Phase 4|30|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 21:54:46.770697|2018-05-31 21:54:46.770697
NCT01477255|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-04-06|2011-11-18|2011-11-22|Estimate|||||||2016-04-06|2016-04-08|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|DIARY1||The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population|The Feasibility Of a Daily Diary Methodology With a Pediatric Cancer Population: A Pilot Study|Completed|||154|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||||||2018-05-31 21:54:46.941974|2018-05-31 21:54:46.941974
NCT01477242|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2012-01-19|2011-11-18|2011-11-22|Estimate|||||||2012-01-19|2012-01-20|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department|The Effect of Oral Ondansetron During Intramuscular Ketamine Use in Children|Unknown status|Recruiting|N/A|266|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:54:47.021578|2018-05-31 21:54:47.021578
NCT01477229|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-10-12|2011-11-18|2011-11-22|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|September 2020|Anticipated|2020-09-30|September 2015|Actual|2015-09-30||Observational|QoLiRECT||Quality of Life in RECTal Cancer - a Prospective Multicenter Cohort Study|Quality of Life in RECTal Cancer - A Study Within the Scandinavian Surgical Outcomes Research Group|Active, not recruiting|||1500|Anticipated|Sahlgrenska University Hospital, Sweden|||4||f||||f||||||||||2018-05-31 21:54:47.118878|2018-05-31 21:54:47.118878
NCT01477216|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|January 2003||2003-01-31|November 2011|2011-11-30|December 2013|Anticipated|2013-12-31|December 2008|Actual|2008-12-31||Interventional|ELSA||Determination of Glycemic and Insulinemic Indices|The Glycemic and Insulinemic Responses of the Finnish Foods: Measurement and Modification|Unknown status|Active, not recruiting|N/A|142|Actual|National Institute for Health and Welfare, Finland||9|||f||||f||||||||||2018-05-31 21:54:47.222942|2018-05-31 21:54:47.222942
NCT01477203|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-09-13|2011-11-18|2011-11-22|Estimate|||||||2016-09-13|2016-09-14|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MAN-BIOPSY||Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders|Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders|Completed||Phase 4|289|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 21:54:47.305223|2018-05-31 21:54:47.305223
NCT01477190|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-24|2011-11-18|2011-11-22|Estimate|||||||2011-11-24|2011-11-28|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program|Spinal Analgesia for Colonic Resection Using an Enhanced Recovery After Surgery (ERAS) Program|Completed||Phase 1/Phase 2|40|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 21:54:47.405724|2018-05-31 21:54:47.405724
NCT01477177|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-04-08|2011-11-18|2011-11-22|Estimate|||||||2014-04-08|2014-04-10|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Polar Wand Carbon Dioxide Cryotherapy for Barrett's Esophagus|Pilot Study of Polar Wand Carbon Dioxide Cryotherapy for Barrett's Esophagus With Low Grade and High Grade Dysplasia|Terminated||N/A|4|Actual|Mayo Clinic||1||enrollment much slower than anticipated, and, funding issues|f||||||||||||||2018-05-31 21:54:47.495718|2018-05-31 21:54:47.495718
NCT01477164|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-08-07|2011-11-18|2011-11-22|Estimate|||||||2017-08-07|2017-08-08|Actual|November 2011||2011-11-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults|Effects of Aerobic and Resistance Training on Accumulation of Old, Modified Proteins in Young and Older Adults|Completed||N/A|72|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 21:54:47.573827|2018-05-31 21:54:47.573827
NCT01477151|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2015-06-03|2011-11-18|2011-11-22|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|RISCCS||Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery|Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial.|Completed||Phase 4|464|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 21:54:47.703726|2018-05-31 21:54:47.703726
NCT01477138|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|VOTE||RV Septal Versus Minimized RV Pacing in Sick Sinus Syndrome|Comparison of Right Ventricular Septal Pacing to Minimized Right Ventricular Septal Stimulation in Patients With Sick Sinus Syndrome|Unknown status|Recruiting||126|Anticipated|Klinikum Nürnberg|||2||f||||t||||||||||2018-05-31 21:54:47.794423|2018-05-31 21:54:47.794423
NCT01477125|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2015-09-29|2011-11-18|2011-11-22|Estimate|||||||2015-09-29|2015-10-01|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Working Memory Training in Adults With ADHD|Computerised Working Memory Training in Adults With ADHD: A Randomised Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:54:47.892317|2018-05-31 21:54:47.892317
NCT01477112|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Low Dose β-carotene Supplementation Diminishes Oxidative Stress in Type 2 Diabetics and Healthy Individuals|Effect of the Supplementation With β-carotene to Type 2 Diabetic Patients and Healthy Controls on the Iron Status and Antioxidant Capacity of Plasma|Completed||N/A|117|Actual|Instituto Venezolano de Investigaciones Cientificas||4|||f||||t||||||||||2018-05-31 21:54:48.035372|2018-05-31 21:54:48.035372
NCT01477099|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Toothbrushing and Ventilator-associated Pneumonia|Efficacy of Toothbrushing for the Prevention of Ventilator-associated Pneumonia|Completed||Phase 4|436|Actual|Hospital Universitario de Canarias||2|||f||||t||||||||||2018-05-31 21:54:48.173801|2018-05-31 21:54:48.173801
NCT01477086|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-02-04|2011-11-18|2011-11-22|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PREFISSARC||Prevalence and Pathophysiology of Sarcopenia in the Elderly Patient With Hip Fracture|Prevalence and Pathophysiology of Sarcopenia in the Elderly Patient With Hip Fracture. Prospective, Observational Study on Consecutive Series|Completed|||198|Actual|Hospital Viamed Valvanera, Spain|||1||f||||f||||||||||2018-05-31 21:54:48.269347|2018-05-31 21:54:48.269347
NCT01477073|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-01-02|2011-11-18|2011-11-22|Estimate|||||||2013-01-02|2013-01-03|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Multiple Dose FSH-GEX(TM) in Healthy Volunteers|A Phase I, Mono-center, Placebo and Comparator Controlled, Single-blind, Randomized, Parallel Group, Clinical Study to Determine Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FSH-GEX(TM) Administered Subcutaneously in Healthy Pituitary-suppressed Female Volunteers|Completed||Phase 1|57|Actual|Glycotope GmbH||4|||f||||f||||||||||2018-05-31 21:54:48.34448|2018-05-31 21:54:48.34448
NCT01477060|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2014-02-19|2011-11-18|2011-11-22|Estimate|||||||2014-02-19|2014-02-20|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer|Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With HER2-negative, ER and/or PgR Positive Metastatic Brest Cancer With Progressive Disease After First-line Therapy|Terminated||Phase 2|32|Actual|Fondazione Michelangelo||3||The study was stopped due to insufficient accrual|f||||f||||||||||2018-05-31 21:54:48.426941|2018-05-31 21:54:48.426941
NCT01477047|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-02-24|2011-11-18|2011-11-22|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2012|Actual|2012-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Identification of Risk Factors of Prolonged Wound Healing Following Primary Arthroplasty|Identification of Risk Factors of Prolonged Wound Healing Following Total Hip and Knee Arthroplasty|Recruiting|||3000|Anticipated|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 21:54:48.514074|2018-05-31 21:54:48.514074
NCT01477034|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-04-02|2011-11-18|2011-11-22|Estimate|||||||2014-04-02|2014-04-04|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Vitamin D and Adipose Tissue Inflammation|Vitamin D and Adipose Tissue Inflammation|Completed||N/A|18|Actual|Fred Hutchinson Cancer Research Center||4|||f||||f||||||||||2018-05-31 21:54:48.579084|2018-05-31 21:54:48.579084
NCT01477021|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-12-09|2011-11-18|2011-11-22|Estimate|||||||2014-12-09|2014-12-11|Estimate|January 2012||2012-01-31|December 2014|2014-12-31||||September 2013|Actual|2013-09-30||Interventional|||Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery|A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma.|Completed||Phase 1|6|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 21:54:48.693385|2018-05-31 21:54:48.693385
NCT01477008|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2018-04-10|2011-11-18|2011-11-22|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2011||2011-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||BiPhasic Cartilage Repair Implant (BiCRI) IDE Clinical Trial - Taiwan|A Prospective, Multi-Center, Randomized Clinical Trial Comparing the Biphasic Cartilage Repair Implant to Marrow Stimulation in the Treatment of Focal Chondral and Osteochondral Lesions of the Knee|Recruiting||N/A|92|Anticipated|BioGend Therapeutics Co.Ltd||2|||f||||t||||||||||2018-05-31 21:54:48.863232|2018-05-31 21:54:48.863232
NCT01476995|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|GBMC||Prognostic Indicators as Provided by the EPIC ClearView|Prognostic Indicators as Provided by the EPIC ClearView|Completed|||353|Actual|Epic Research & Diagnostics, Inc.|||2||f||||f||||||||||2018-05-31 21:54:49.000813|2018-05-31 21:54:49.000813
NCT01476982|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2013-03-18|2011-11-18|2011-11-22|Estimate|||||||2013-03-18|2013-03-20|Estimate|May 2012||2012-05-31|March 2013|2013-03-31||||June 2013|Anticipated|2013-06-30||Observational|EPIC-ER||Evaluation of Patients in Chest Pain in the Emergency Room|Evaluation of Patients in Chest Pain in the Emergency Room|Unknown status|Active, not recruiting||200|Anticipated|Epic Research & Diagnostics, Inc.|||1||f||||f||||||||||2018-05-31 21:54:49.123148|2018-05-31 21:54:49.123148
NCT01476969|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-08-11|2011-11-18|2011-11-22|Estimate|||||||2012-08-11|2012-08-14|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Effect of Remote Ischemic Perconditioning on Acute Kidney Injury in Adult Valve Replace|Effect of Remote Ischemic Perconditioning on Acute Kidney Injury in Adult Valve Replace|Unknown status|Recruiting|N/A|90|Anticipated|Central South University||1|||f||||t||||||||||2018-05-31 21:54:49.200493|2018-05-31 21:54:49.200493
NCT01476956|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2016-11-16|2011-11-18|2011-11-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography|Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis|Active, not recruiting|||600|Anticipated|Canadian Research & Education in Arthritis|||1||f||||f||||||Samples Without DNA|"~     -  whole blood/serum~        -  urine~   "|||2018-05-31 21:54:49.304545|2018-05-31 21:54:49.304545
NCT01476943|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-05-03|2011-11-18|2011-11-22|Estimate|||||||2018-05-03|2018-05-04|Actual|March 31, 2012|Actual|2012-03-31|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Observational|CTS||Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study|Belatacept in Renal Transplantation: Patterns of Use Analysis Using the Collaborative Transplant Study (CTS)|Completed|||72392|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 21:54:49.434433|2018-05-31 21:54:49.434433
NCT01476930|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-11-20|2011-11-18|2011-11-22|Estimate|||||||2014-11-20|2014-11-24|Estimate|June 2008||2008-06-30|November 2014|2014-11-30|October 2011|Actual|2011-10-31|September 2009|Actual|2009-09-30||Interventional|||Cupping and Serkangabin Versus Conventional Migraine Treatment|Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial|Completed||Phase 4|391|Actual|Birjand University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:54:49.516238|2018-05-31 21:54:49.516238
NCT01476917|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-11-05|2011-11-18|2011-11-22|Estimate|||||||2012-11-05|2012-11-07|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||The ATLAST Long-Term Study|The ATLAST Long-Term Study. A Multicenter, Prospective, Long-Term Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)|Completed||Phase 2/Phase 3|39|Actual|ApniCure, Inc.||1|||f||||f||||||||||2018-05-31 21:54:49.623863|2018-05-31 21:54:49.623863
NCT01476904|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15||2016-02-11|2017-02-10|2011-11-18|2011-11-22|Estimate||||2016-02-11|2016-03-11|Estimate|2017-02-10|2017-02-13|Actual|November 2011||2011-11-30|February 2017|2017-02-28|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Safety Study in Adolescent and Adult Patients With Asthma|A 3-month Safety Evaluation Extension to the 12-week E004-C Study in Asthma Patients (A Double Blinded, Placebo-controlled, Parallel, 3-month Safety Study in Adolescent and Adult Patients With Asthma)|Completed||Phase 3|208|Actual|Amphastar Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 21:54:49.707073|2018-05-31 21:54:49.707073
NCT01476891|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2013-01-17|2011-11-18|2011-11-22|Estimate|||||||2013-01-17|2013-01-18|Estimate|January 2011||2011-01-31|January 2013|2013-01-31||||August 2014|Anticipated|2014-08-31||Interventional|eCALM||The eCALM Study - An Online Mindfulness-Based Stress Reduction Program for Individuals Living With Cancer in Alberta|The eCALM Study - eTherapy for Cancer Applying Mindfulness: Online Mindfulness-Based Stress Reduction Program for Underserved Cancer Patients in Alberta: A Randomized Wait-list Controlled Trial.|Unknown status|Active, not recruiting|N/A|64|Anticipated|AHS Cancer Control Alberta||2|||f||||t||||||||||2018-05-31 21:54:49.829057|2018-05-31 21:54:49.829057
NCT01476878|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Frameless Stereotactic Radiosurgery for Brain Metastases|Frameless Stereotactic Radiosurgery for Brain Metastases|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-05-31 21:54:49.920562|2018-05-31 21:54:49.920562
NCT01476865|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2011-11-18|2011-11-18|2011-11-22|Estimate|||||||2011-11-18|2011-11-22|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Articular Sonography: Healthy Subjects Versus Rheumatoid Arthritis Patients|Articular Sonography: Findings in Healthy Subjects Compared With Rheumatoid Arthritis Patients|Completed|||190|Actual|Federal University of São Paulo|||2||f||||f||||||Samples With DNA|"~     serum~   "|||2018-05-31 21:54:50.037517|2018-05-31 21:54:50.037517
NCT01476839|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2018-05-07|2011-11-18|2011-11-22|Estimate|||||||2018-05-07|2018-05-09|Actual|November 9, 2012||2012-11-09|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma|"Phase I Study of Yttrium-90 Labeled Anti-CD25 (a-Tac) Monoclonal Antibody Plus BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma, the a-Tac BEAM Regimen"|Recruiting||Phase 1|22|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 21:54:50.312362|2018-05-31 21:54:50.312362
NCT01476813|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2017-03-14|2011-11-18|2011-11-22|Estimate|||||||2017-03-14|2017-03-16|Actual|March 2012||2012-03-31|March 2017|2017-03-31|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Interventional|||Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate|A Randomized, Double-blind, Active-controlled, Cross-over Study to Assess Efficacy and Safety of 3 Free Doses of Glycopyrrolate With Beclomethasone/Formoterol pMDI for the Treatment of COPD Patients|Completed||Phase 2|281|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-05-31 21:54:50.875409|2018-05-31 21:54:50.875409
NCT01476800|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2015-08-31|2011-11-18|2011-11-22|Estimate|||||||2015-08-31|2015-09-01|Estimate|July 2006||2006-07-31|August 2015|2015-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers|A Phase 1, Open-Label, Two-Period, One-Sequence Crossover Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Male and Female Adult Volunteers|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:54:51.029238|2018-05-31 21:54:51.029238
NCT01476787|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2018-03-22|2011-11-18|2011-11-22|Estimate|||||||2018-03-22|2018-03-23|Actual|December 29, 2011|Actual|2011-12-29|March 2018|2018-03-31|June 1, 2024|Anticipated|2024-06-01|June 1, 2024|Anticipated|2024-06-01||Interventional|RELEVANCE||Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma|A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma|Active, not recruiting||Phase 3|255|Actual|Celgene||2|||f||||t||||||||||2018-05-31 21:54:51.211259|2018-05-31 21:54:51.211259
NCT01476774|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-07-07|2011-11-17|2011-11-22|Estimate|||||||2015-07-07|2015-07-08|Estimate|August 2009||2009-08-31|July 2015|2015-07-31||||June 2010|Actual|2010-06-30||Interventional|||NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain|NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain|Completed||Phase 3|280|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 21:54:51.447423|2018-05-31 21:54:51.447423
NCT01476761|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-08-07|2011-11-18|2011-11-22|Estimate|||||||2013-08-07|2013-08-09|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|MET1||MicroCutter in Surgical Stapling - European Trial I|The Cardica MicroCutter in Surgical Stapling: A Prospective, Open-label, Multi-center Study|Completed||Phase 4|160|Actual|Cardica, Inc||1|||f||||t||||||||||2018-05-31 21:54:51.549017|2018-05-31 21:54:51.549017
NCT01476748|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2013-08-23||2014-09-08|2011-11-21|2011-11-22|Estimate|2014-08-19|2014-08-29|Estimate||||2014-09-08|2014-09-17|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Intraoperative Trocar Slippage Study|A Pilot Study to Determine the Extent of Intraoperative Laparoscopic Trocar Slippage.|Completed||Phase 3|15|Actual|Brigham and Women's Hospital|There were no adverse events encountered during this study|3|||f||||f||||||||||2018-05-31 21:54:51.614789|2018-05-31 21:54:51.614789
NCT01476735|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2018-04-05|2011-11-21|2011-11-22|Estimate|||||||2018-04-05|2018-04-06|Actual|August 2011||2011-08-31|November 2011|2011-11-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Individual Approach for Bowel Preparation Before Colonoscopy|A Prospective, Randomized, Single-blind Study Evaluating Individual Approach on Bowel Preparation Quality for Colonoscopy|Completed||N/A|266|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 21:54:51.994452|2018-05-31 21:54:51.994452
NCT01476722|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|2012-10-19||2012-11-16|2011-11-21|2011-11-22|Estimate|2012-11-16|2012-11-19|Estimate||||2012-11-16|2012-11-19|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Lens Wearing Experience and Biocompatibility of a Multi-Purpose Disinfecting Solution (MPDS)|Lens Wearing Experience and Biocompatibility With OPTI-FREE® PureMoist® Multi-Purpose Disinfecting Solution (OFP MPDS) in Silicone Hydrogel and Soft Contact Lens Wearers (US)|Completed||N/A|125|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:54:52.083762|2018-05-31 21:54:52.083762
NCT01476709|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-04-05|2011-11-21|2011-11-22|Estimate|||||||2012-04-05|2012-04-06|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|PhotonicNeedle||Photonic Needle and Sleeve Study|Photonic Needle and Intraforaminal Epidural Injection (Sleeve) - Observational Study in Humans|Completed|||30|Actual|Maastricht University Medical Center|||||f||||f||||||||||2018-05-31 21:54:52.301516|2018-05-31 21:54:52.301516
NCT01476696|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2013-10-18||2014-01-17|2011-11-17|2011-11-22|Estimate|2013-10-18|2013-12-11|Estimate||||2014-01-17|2014-02-13|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Crescent|All enrolled participants.|A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease|An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease|Completed||Phase 2|33|Actual|Eli Lilly and Company|Data for the Primary Outcome Measures 1 and 2 were collected for presentation of results in a scatter plot and were not intended to be summarized due to the limited number of participants per treatment.|2|||f||||f||||||||||2018-05-31 21:54:52.412382|2018-05-31 21:54:52.412382
NCT01476683|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-07-06|2011-11-17|2011-11-22|Estimate|||||||2012-07-06|2012-07-10|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study to Compare the Pharmacokinetics Profiles of Four Racecadotril Products|An Open-Label, Fasting, Crossover, Single-Dose Pharmacokinetic Study of Four Formulations of Racecadotril|Completed||Phase 1|24|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||||2018-05-31 21:54:53.175483|2018-05-31 21:54:53.175483
NCT01476670|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2011-11-21|2011-11-21|2011-11-22|Estimate|||||||2011-11-21|2011-11-22|Estimate|July 2012||2012-07-31|November 2011|2011-11-30||||||||Observational|||Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor|Cerebral Autoregulation and Carbon Dioxide Reactivity in Patients With Posterior Fossa Tumor|Unknown status|Not yet recruiting||20|Anticipated|All India Institute of Medical Sciences, New Delhi|||1||f||||f||||||||||2018-05-31 21:54:53.296104|2018-05-31 21:54:53.296104
NCT01476657|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2018-05-02|2011-11-17|2011-11-22|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2011||2011-10-31|May 2018|2018-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies|A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies|Terminated||Phase 1|210|Actual|Verastem, Inc.||1||"The scope of the program has been reduced to focus resources on studies which can potentially~   enable the registration of duvelisib."|f||||f||||||||Undecided||2018-05-31 21:54:53.375561|2018-05-31 21:54:53.375561
NCT01476449|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2016-10-03|2011-11-17|2011-11-22|Estimate|||||||2016-10-03|2016-10-05|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema|Monthly Ranibizumab Versus Treat and Extend Ranibizumab for Diabetic Macular Edema|Completed||Phase 2|20|Actual|Retina Vitreous Associates of Florida||2|||f||||t||||||||||2018-05-31 21:54:55.603115|2018-05-31 21:54:55.603115
NCT01476644|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-07-26|2011-11-21|2011-11-22|Estimate|||||||2016-07-26|2016-07-27|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||How Has Glaucoma Affected Your Quality of Life?|A Prospective, Longitudinal, Observational Cohort Study Examining How Glaucoma Affects Quality of Life and Visual Function Over a 4-Year Period|Completed|||163|Actual|Wills Eye|||||f||||f||||||||Yes|Results section will include analysis from published manuscripts. References will be provided as soon as the manuscripts are accepted.|2018-05-31 21:54:53.457826|2018-05-31 21:54:53.457826
NCT01476631|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-08-02|2011-11-17|2011-11-22|Estimate|||||||2013-08-02|2013-08-05|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Step Down Colon Cancer Risk|Step Down Colon Cancer Risk: A Pilot Intervention for Colon Cancer Risk Reduction|Terminated||N/A|17|Actual|Washington University School of Medicine||2||not enough patients consented during the funding period|f||||f||||||||||2018-05-31 21:54:53.531169|2018-05-31 21:54:53.531169
NCT01476618|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-06-08|2011-11-17|2011-11-22|Estimate|||||||2015-06-08|2015-06-09|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|July 2012|Actual|2012-07-31||Observational|||Providing Mental Health Services to Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans|Providing Mental Health Services to Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans: Provider Perspectives|Completed|||13|Actual|VA Eastern Colorado Health Care System|||1||f||||t||||||||||2018-05-31 21:54:53.598355|2018-05-31 21:54:53.598355
NCT01476605|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-10-09|2011-11-17|2011-11-22|Estimate|||||||2015-10-09|2015-10-12|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|November 2011|Actual|2011-11-30||Interventional|||Efficacy of Injection Therapy for Lateral Epicondylosis|The Efficacy of Prolotherapy and Platelet Rich Plasma Injections for Lateral Epicondylosis: a Pilot Study|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|University of Wisconsin, Madison||4|||f||||t||||||||||2018-05-31 21:54:53.701674|2018-05-31 21:54:53.701674
NCT01476592|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-03-05|2011-11-17|2011-11-22|Estimate|||||||2018-03-05|2018-03-07|Actual|December 2011||2011-12-31|March 2018|2018-03-31|November 15, 2018|Anticipated|2018-11-15|October 2013|Actual|2013-10-31||Interventional|||A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors|A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors|Active, not recruiting||N/A|7|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 21:54:53.811522|2018-05-31 21:54:53.811522
NCT01476579|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-06-16|2011-11-17|2011-11-22|Estimate|||||||2016-06-16|2016-06-17|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|January 2022|Anticipated|2022-01-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Low-radiation Dose CT Angiography With Invasive Coronary Angiography in Stable Coronary Disease|Diagnostic Accuracy of New Generation Low-dose CT Coronary Angiography|Active, not recruiting||Phase 4|769|Actual|University Hospital of North Norway||1|||f||||f||||||||||2018-05-31 21:54:54.030639|2018-05-31 21:54:54.030639
NCT01476566|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|January 2013||2013-01-31|November 2011|2011-11-30|January 2016|Anticipated|2016-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Can Diagnostics and Pharmacological Prescriptions in Patients With Heart Failure be Improved in General Practice?|Can Diagnostics and Pharmacological Prescriptions in Patients With Heart Failure be Improved? A Cluster Randomised Educational Intervention in General Practice. A Study Protocol.|Unknown status|Not yet recruiting|Phase 1/Phase 2|1940|Anticipated|University of Oslo||2|||f||||f||||||||||2018-05-31 21:54:54.110389|2018-05-31 21:54:54.110389
NCT01476553|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2017-05-01|2011-11-17|2011-11-22|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2011||2011-02-28|May 2017|2017-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EIPL||Elimination of Peritoneal Tumor Cells With Extensive Peritoneal Lavage During Surgery in Patients With Gastric Cancer|"Elimination of Peritoneal Tumor Cells With Extensive Intraperitoneal Lavage (EIPL) During Surgical Treatment of Gastric Adenocarcinoma"|Terminated||N/A|30|Actual|Universitätsmedizin Mannheim||1||Prematurely halted after interim data analysis|f||||f||||||||||2018-05-31 21:54:54.187861|2018-05-31 21:54:54.187861
NCT01476540|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|July 2011||2011-07-31|November 2011|2011-11-30||||March 2013|Anticipated|2013-03-31||Interventional|||Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa|Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa|Unknown status|Recruiting|Phase 1|12|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 21:54:54.286944|2018-05-31 21:54:54.286944
NCT01476527|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|May 2011||2011-05-31|November 2011|2011-11-30||||March 2013|Anticipated|2013-03-31||Interventional|||Deep Brain Stimulation for the Treatment of Refractory Bipolar Disorder||Unknown status|Recruiting|Phase 1|6|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 21:54:54.346022|2018-05-31 21:54:54.346022
NCT01476514|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2014-09-03|2011-11-17|2011-11-22|Estimate|||||||2014-09-03|2014-09-04|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing|Effects of Mutations of the Glycine Gene Associated With Hyperekplexia on Central Pain Processing|Terminated||N/A|9|Actual|University Hospital Inselspital, Berne||1||Recruitment problems|f||||f||||||||||2018-05-31 21:54:54.402665|2018-05-31 21:54:54.402665
NCT01476501|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2015-05-26|2011-11-17|2011-11-22|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Vitamin D Supplementation in Diabetic Nephropathy|Vitamin D Supplementation and Bone Health in Adults With Diabetic Nephropathy|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|University of Alberta||2|||f||||t||||||||||2018-05-31 21:54:54.473366|2018-05-31 21:54:54.473366
NCT01476488|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2015-05-24|2011-11-17|2011-11-22|Estimate|||||||2015-05-24|2015-05-27|Estimate|July 2011||2011-07-31|May 2015|2015-05-31||||March 2013|Actual|2013-03-31||Interventional|||Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients|Conversion of Twice-a-day Tacrolimus to Once-Daily Tacrolimus Extended-Release Formulation in Stable Pediatric Kidney Transplant Recipients|Completed||Phase 2/Phase 3|||Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 21:54:54.601083|2018-05-31 21:54:54.601083
NCT01476475|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2016-12-16|2013-12-19|2016-12-16|2011-11-17|2011-11-22|Estimate|2016-12-16|2017-02-10|Actual|2013-12-19|2014-01-27|Estimate|2016-12-16|2017-02-10|Actual|November 2011||2011-11-30|December 2016|2016-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients|A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients|Completed||Phase 2|323|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 21:54:54.691776|2018-05-31 21:54:54.691776
NCT01476436|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2012-04-10|2011-11-17|2011-11-22|Estimate|||||||2012-04-10|2012-04-11|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers|Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers|Unknown status|Recruiting|N/A|22|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 21:54:55.793185|2018-05-31 21:54:55.793185
NCT01476423|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2014-12-19|2011-11-17|2011-11-22|Estimate|||||||2014-12-19|2014-12-23|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Observational Registry of the Treatment of Glanzmann's Thrombasthenia|Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry|Completed|||218|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:54:55.965183|2018-05-31 21:54:55.965183
NCT01476410|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2018-02-01|2011-11-17|2011-11-22|Estimate|||||||2018-02-01|2018-02-05|Actual|November 2011||2011-11-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma|A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma|Active, not recruiting||Phase 2|48|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 21:54:56.08433|2018-05-31 21:54:56.08433
NCT01476397|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-11-03|2011-11-17|2011-11-22|Estimate|||||||2014-11-03|2014-11-04|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Probiotic Formula and Infant Growth|ASSESSMENT OF GROWTH OF INFANTS FED FORMULA WITH PROBIOTICS|Completed||N/A|||Nestlé||2|||f||||f||||||||||2018-05-31 21:54:56.268437|2018-05-31 21:54:56.268437
NCT01476384|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-04-10|2011-11-17|2011-11-22|Estimate|||||||2014-04-10|2014-04-11|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Orthogonal Polarisation Study in Young, Elderly and Type 2 Diabetics|Postprandial Insulin Release and the Impact on Muscle Perfusion|Completed||N/A|45|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:54:56.378896|2018-05-31 21:54:56.378896
NCT01476371|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2014-09-25|2011-11-17|2011-11-22|Estimate|||||||2014-09-25|2014-09-26|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|June 2012|Actual|2012-06-30||Interventional|||Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety|Mindfulness-based Group Treatment of Patients With Depression and Anxiety: Effects on Symptoms and Inflammatory Markers in a Randomized Controlled Multicenter Study in Primary Care|Completed||N/A|215|Actual|Lund University||2|||f||||f||||||||||2018-05-31 21:54:56.463224|2018-05-31 21:54:56.463224
NCT01476358|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-11-12|2011-11-17|2011-11-22|Estimate|||||||2012-11-12|2012-11-14|Estimate|November 2011||2011-11-30|November 2012|2012-11-30||||June 2013|Anticipated|2013-06-30||Interventional|NNVAS||Effect of Vitamin A Supplementation on Immune Responses in Human Neonates|A Randomized Controlled Trial in Human Neonates to Determine the Effect of Vitamin A Supplementation on Immune Responses|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 21:54:56.530416|2018-05-31 21:54:56.530416
NCT01476345|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2014-10-03||2014-10-03|2011-11-17|2011-11-22|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All randomized participants.|A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants|Bioequivalence Study Comparing the Pharmacokinetics and Pharmacodynamics of LY2963016 With Insulin Glargine in Healthy Volunteers|Completed||Phase 1|80|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:54:56.64332|2018-05-31 21:54:56.64332
NCT01476332|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2012-05-15|2011-11-17|2011-11-22|Estimate|||||||2012-05-15|2012-05-17|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)|A Single Dose (Part 1) and Multiple Dose (Part 2) Phase I, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers|Completed||Phase 1|37|Actual|Laurantis Pharma, Ltd.||3|||f||||f||||||||||2018-05-31 21:54:56.976878|2018-05-31 21:54:56.976878
NCT01476319|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2017-04-05|2011-11-17|2011-11-22|Estimate|||||||2017-04-05|2017-04-07|Actual|November 9, 2009|Actual|2009-11-09|April 2017|2017-04-30|September 9, 2014|Actual|2014-09-09|September 9, 2014|Actual|2014-09-09||Interventional|||Improving Informed Consent Process for Percutaneous Cholecystostomy in the Emergency Department||Completed||N/A|22|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||||||||||||2018-05-31 21:54:57.057901|2018-05-31 21:54:57.057901
NCT01476306|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-12-07|2011-11-17|2011-11-22|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2011|Actual|2011-11-30|December 2017|2017-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|TELEMED-PD||Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study|Providing Specialty Care to Individuals With Parkinsonism Directly in Their Homes Via Web-based Video Conferencing— A Comparative Effectiveness Study|Completed||N/A|20|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:54:57.127961|2018-05-31 21:54:57.127961
NCT01476293|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-02-17|2011-11-17|2011-11-22|Estimate|||||||2012-02-17|2012-02-20|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Monitoring the Peripheral Intravenous Infusion Site for Infiltration and Extravasation|Non-invasive Optical Medical Device for Monitoring and Detecting Peripheral Intravenous Infusion Sites for Infiltration and Extravasation in Subjects Receiving Continuous Fluids|Completed|||139|Actual|ivWatch, LLC|||||f||||t||||||||||2018-05-31 21:54:57.205669|2018-05-31 21:54:57.205669
NCT01476280|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting|A Randomized Double Blind Study to Evaluate Efficacy of Ramosetron and Palonosetron for Prevention of Postoperative Nausea and Vomiting After Gynaecological Laparoscopic Surgery|Completed||N/A|100|Actual|Incheon St.Mary's Hospital||2|||f||||t||||||||||2018-05-31 21:54:57.285701|2018-05-31 21:54:57.285701
NCT01476267|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2016-11-01|2011-11-17|2011-11-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers|An Open Label, Single Centre Study to Investigate the Metabolic Profile of Dalcetrapib After a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:54:57.35628|2018-05-31 21:54:57.35628
NCT01476241|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|September 2005||2005-09-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Observational|||Percutaneous Endoscopic Gastrostomy Tube Placement by Otorhinolaryngologist|Percutaneous Endoscopic Gastrostomy Tube Placement by Otorhinolaryngologist: a Single Institution Experience|Completed|||292|Actual|Helsinki University|||2||f||||f||||||||||2018-05-31 21:54:57.536566|2018-05-31 21:54:57.536566
NCT01476228|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|November 2011||2011-11-30|August 2011|2011-08-31|December 2015|Anticipated|2015-12-31|November 2013|Anticipated|2013-11-30||Interventional|||EEG Objectification in Neuropsychiatry|EEG Objectification in Neuropsychiatry|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 21:54:57.620222|2018-05-31 21:54:57.620222
NCT01476215|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-11-20|2011-11-17|2011-11-22|Estimate|||||||2014-11-20|2014-11-24|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions|A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions|Completed||Phase 1|18|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:54:57.710104|2018-05-31 21:54:57.710104
NCT01476202|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2013-07-30||2013-07-30|2011-11-17|2011-11-22|Estimate|2013-07-30|2013-09-30|Estimate||||2013-07-30|2013-09-30|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|NRT||Provoked Craving Relief Study by NRT|A Pilot Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Strip, Nicorette ® Nicotine Lozenge and Gum|Completed||Phase 2|120|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:54:57.782752|2018-05-31 21:54:57.782752
NCT01476189|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-11-20|2011-11-17|2011-11-22|Estimate|||||||2014-11-20|2014-11-24|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations|A Repeat Dose PK Study Investigating the Extent of Paracetamol Absorption From Two Sustained Release Paracetamol Formulations|Completed||Phase 1|28|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:54:58.067591|2018-05-31 21:54:58.067591
NCT01476176|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-11-20|2011-11-17|2011-11-22|Estimate|||||||2014-11-20|2014-11-24|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Pharmacokinetic Study of an Experimental Paracetamol Formulation|A Pivotal Pharmacokinetic Study Investigating the Extent of Absorptions of Paracetamol and Caffeine for Two Different Paracetomol Formulations Containing Caffeine|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:54:59.271389|2018-05-31 21:54:59.271389
NCT01476163|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2018-05-02|2011-11-17|2011-11-22|Estimate|||||||2018-05-02|2018-05-03|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease|Physician Initiated Expanded Access Request for Treatment Use of Migalastat Hydrochloride (AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (AT1001-188)|Available|||||Amicus Therapeutics|||||f||||||||||||||2018-05-31 21:54:59.342777|2018-05-31 21:54:59.342777
NCT01476150|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2011-11-22|2011-11-21|2011-11-22|Estimate|||||||2011-11-22|2011-11-23|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Observational|||Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population|Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population|Unknown status|Not yet recruiting||10000|Anticipated|China-Japan Friendship Hospital|||8||f||||t||||||Samples Without DNA|"~     complete blood~   "|||2018-05-31 21:54:59.428343|2018-05-31 21:54:59.428343
NCT01476137|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-11-08|2011-11-17|2011-11-22|Estimate|||||||2017-11-08|2017-11-13|Actual|October 26, 2011|Actual|2011-10-26|November 2017|2017-11-30|March 12, 2013|Actual|2013-03-12|March 12, 2013|Actual|2013-03-12||Interventional|||A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers|An Open-Label, Two Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With the AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Multiple Myeloma|Completed||Phase 1|335|Actual|GlaxoSmithKline||10|||f||||t||||||||||2018-05-31 21:54:59.525667|2018-05-31 21:54:59.525667
NCT01476124|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2013-07-15|2011-11-17|2011-11-22|Estimate|||||||2013-07-15|2013-07-16|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine|A Double-Blind, 3-Part Crossover Study to Assess the Pharmacokinetics and Tolerability of Single Doses of Gabapentin Enacarbil and Morphine Administered Alone and in Combination in Healthy Subjects|Completed||Phase 1|18|Actual|XenoPort, Inc.||3|||f||||f||||||||||2018-05-31 21:54:59.623477|2018-05-31 21:54:59.623477
NCT01476111|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2015-03-06|2011-11-17|2011-11-22|Estimate|||||||2015-03-06|2015-03-09|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer|A Prospective, Exploratory Observational Study Evaluating Specific Biomarkers in Primary Invasive Breast Cancer and Their Modulation by Standard Neoadjuvant Therapy|Terminated|||117|Actual|GlaxoSmithKline|||1|"Study termination due to negative Phase III of another study product from same technology~   platform."|f||||||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 21:54:59.712673|2018-05-31 21:54:59.712673
NCT01476098|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2016-11-30|2011-11-17|2011-11-22|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Investigate the Effect of SB-705498 on Chronic Cough|Two Part Study to Investigate Pharmacokinetics (PK) & Pharamcodynamics (PD) of SB-705498 in Cough. Part A:Open Label Study in Healthy Subjects to Determine Exposure to SB-705498. Part B:Double-blind, Placebo Controlled, Cross Over Study to Investigate Effect of SB-705498 on Capsaicin Induced Cough and 24 Hour Cough Counts in Cough Patients|Completed||Phase 2|21|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:54:59.927132|2018-05-31 21:54:59.927132
NCT01476085|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-06-27|2011-11-17|2011-11-22|Estimate|||||||2013-06-27|2013-07-01|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)|An Open-label Study to Evaluate the Utility of the Apoptosis Imaging Biomarker 18F]ML10 to Assess the Response to Chemotherapy in Patients With Non-Hodgkin's Lymphoma(NHL).|Terminated||Phase 1|1|Actual|GlaxoSmithKline||1||"Study terminated as ongoing analysis suggested objectives not practical to achieve with study~   as implemented"|f||||f||||||||||2018-05-31 21:55:00.105075|2018-05-31 21:55:00.105075
NCT01476059|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-06-26|2011-11-17|2011-11-22|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2004||2004-05-31|June 2017|2017-06-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|ADERE (Ped)||Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT|Prospective, Parallel-group, Randomized Study to Evaluate the Compliance to the Treatment of Children Aged Between 6 and 14 Years Old With Persistent Moderate or Severe Asthma, Receiving the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose Twice a Day. ADERE PROJECT|Completed||Phase 4|472|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:55:00.282492|2018-05-31 21:55:00.282492
NCT01476046|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2017-06-09|2011-11-17|2011-11-22|Estimate|||||||2017-06-09|2017-06-12|Actual|March 8, 2011|Actual|2011-03-08|June 2017|2017-06-30|June 17, 2012|Actual|2012-06-17|June 17, 2012|Actual|2012-06-17||Interventional|||Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.|A Two-part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamicsof Single and Repeat Doses of Intravenously Infused GSK1995057 in Healthy Subjects.|Completed||Phase 1|56|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:55:00.370505|2018-05-31 21:55:00.370505
NCT01476033|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2013-04-09|2011-11-17|2011-11-22|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Strong Women Study|Impact of Encapsulated Fruit, Berry and Vegetable Juice Powder Concentrate on Oxidative Stress, Inflammation and Blood Flow Before and Post Exercise in Overweight, Middle-aged, Women.|Completed||N/A|44|Actual|Green Beat||2|||f||||t||||||||||2018-05-31 21:55:00.494489|2018-05-31 21:55:00.494489
NCT01476020|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|July 2015|Anticipated|2015-07-31|July 2012|Anticipated|2012-07-31||Observational|ITALICplus||Is There A LIfe for Drug Eluting Stent (DES) After Discontinuation of Clopidogrel|Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial|Unknown status|Not yet recruiting||1240|Anticipated|Gilard, Martine|||2||f||||t||||||||||2018-05-31 21:55:00.583936|2018-05-31 21:55:00.583936
NCT01476007|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-11-28|2011-11-21|2011-11-22|Estimate|||||||2017-11-28|2017-11-29|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|OB12||Oral/Intramuscular B12 to Treat Cobalamin Deficiency|Oral Versus Intramuscular Cobalamin to Treat Cobalamin Deficiency: Noninferiority Randomised Controlled Trial Pragmatic and Multi-center in the Primary Healthcare Setting (OB12 Project)|Completed||N/A|284|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 21:55:00.678705|2018-05-31 21:55:00.678705
NCT01475994|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2012-04-04|2011-11-17|2011-11-22|Estimate|||||||2012-04-04|2012-04-05|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|Neurop||Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic Dermatitis|Pilot Study to Assess the Effect of Pollen Challenges in an Environmental Challenge Chamber on Dermal Symptoms in Patients With Atopic Dermatitis|Completed||N/A|18|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine||2|||f||||f||||||||||2018-05-31 21:55:00.765392|2018-05-31 21:55:00.765392
NCT01475981|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects|Randomized,Double-blind,Placebo-controlled,Ascending Dose Part Evaluating Safety,Tolerability and Pharmacokinetics (PK) of JTK-853 (Fasted/Fed) and Randomized,Open-label,Crossover Part Evaluating Food Effect on PK in Healthy Male Subjects|Completed||Phase 1|70|Actual|Akros Pharma Inc.||11|||f||||f||||||||||2018-05-31 21:55:00.88299|2018-05-31 21:55:00.88299
NCT01475968|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2013-11-05|2011-11-17|2011-11-22|Estimate|||||||2013-11-05|2013-11-07|Estimate|December 2004||2004-12-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|June 2011|Actual|2011-06-30||Interventional|XCON||Physiological Changes in Adults With Metabolic Syndrome Exposed to Ultrafine Air Particles|Physiological Changes in Adults With Metabolic Syndrome Exposed to Concentrated Ultrafine Chapel Hill Air Particles|Completed||N/A|48|Actual|Environmental Protection Agency (EPA)||2|||f||||f||||||||||2018-05-31 21:55:00.974801|2018-05-31 21:55:00.974801
NCT01475955|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2013-09-20||2016-09-23|2011-11-17|2011-11-22|Estimate|2013-11-26|2013-12-24|Estimate||||2016-09-23|2016-10-28|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)|A Phase II Study of Photodynamic Therapy With LEVULAN® Topical Solution + Blue Light Versus LEVULAN® Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face or Scalp|Completed||Phase 2|235|Actual|DUSA Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-05-31 21:55:01.34421|2018-05-31 21:55:01.34421
NCT01475942|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-01-26|2011-11-17|2011-11-22|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Probiotic Intervention With Elderly Subjects|Randomized Placebo Controlled Study to Assess the Effect of a Probiotic Supplement on the Subclinical Levels of Intestinal C. Difficile Among Elderly|Completed||Phase 2|104|Actual|Danisco||2|||f||||f||||||||No||2018-05-31 21:55:05.341908|2018-05-31 21:55:05.341908
NCT01475929|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2015-08-11|2011-11-17|2011-11-22|Estimate|||||||2015-08-11|2015-08-13|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|IBS2||Effect of Probiotic Supplement on Bowel Function|Effect of Probiotic Supplement on Bowel Function|Terminated||Phase 2|149|Actual|Danisco||3||Protocol violations|f||||f||||||||||2018-05-31 21:55:05.410677|2018-05-31 21:55:05.410677
NCT01475916|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|December 2011||2011-12-31|November 2011|2011-11-30|October 2012|Anticipated|2012-10-31|April 2012|Anticipated|2012-04-30||Interventional|||Quality of Life in Asthmatic Children at School Age|Quality of Life in Asthmatic Children at School Age : Influence of Therapeutic Education|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||f||||||||||2018-05-31 21:55:05.48184|2018-05-31 21:55:05.48184
NCT01475903|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-11-17|2011-11-17|2011-11-22|Estimate|||||||2011-11-17|2011-11-22|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|May 2015|Anticipated|2015-05-31|November 2014|Anticipated|2014-11-30||Observational|ERNEST||Assessment of Nutritional Consequences of Sleeve Gastrectomy|Assessment of Nutritional Consequences of Sleeve Gastrectomy|Unknown status|Not yet recruiting||60|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 21:55:05.531836|2018-05-31 21:55:05.531836
NCT01475877|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2016-05-01|2011-11-16|2011-11-21|Estimate|||||||2016-05-01|2016-05-03|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy|Bromday (Bromfenac Ophthalmic Solution)0.09% QD vs Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Control of Pain and Epithelial Healing Post (PRK)|Completed|||20|Actual|Virdi Eye Clinic|||1||f||||f||||||||No|In the observational study conducted, there was no significant difference in pain levels or epithelial healing of post-photorefractive keratectomy patients who were treated with bromfenac 0.09% or nepafenac 0.1%|2018-05-31 21:55:05.828353|2018-05-31 21:55:05.828353
NCT01475864|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2013-06-26|2011-11-18|2011-11-21|Estimate|||||||2013-06-26|2013-06-27|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Prospective Evaluation of the Covered Self-expandable Metal Stents (CSEMS) for Incomplete Biliary Stone Clearance|Prospective Evaluation of the Clinical Utility of Endoscopically-placed Self Expandable Stents|Withdrawn|||0|Actual|University of Florida|||1|no subjects were found who met criteria|f||||f||||||||||2018-05-31 21:55:05.906409|2018-05-31 21:55:05.906409
NCT01475851|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2013-08-22||2015-06-18|2011-11-17|2011-11-21|Estimate|2013-08-22|2013-11-04|Estimate||||2015-06-18|2015-06-22|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|June 2013|Actual|2013-06-30||Interventional|||Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs|A Multi-center, Open-label Study of GSK548470 (Tenofovir Disoproxil Fumarate) in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs|Completed||Phase 3|34|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:55:06.012302|2018-05-31 21:55:06.012302
NCT01475838|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2015-01-08|2014-08-25|2016-05-06|2011-11-18|2011-11-21|Estimate|2015-01-22|2015-01-26|Estimate|2014-08-25|2014-08-27|Estimate|2016-05-06|2016-06-08|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study medication.|Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients|A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients|Completed||Phase 3|438|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||f||||||||||2018-05-31 21:55:06.672624|2018-05-31 21:55:06.672624
NCT01475825|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2016-08-01|2011-11-17|2011-11-21|Estimate|||||||2016-08-01|2016-08-03|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|FOCUS FH||A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol|Completed||Phase 3|310|Actual|Kastle Therapeutics, LLC||6|||f||||t||||||||||2018-05-31 21:55:07.882729|2018-05-31 21:55:07.882729
NCT01475812|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2011-11-18|2011-11-18|2011-11-21|Estimate|||||||2011-11-18|2011-11-21|Estimate|March 2007||2007-03-31|November 2011|2011-11-30||||||||Observational|Hyperinflation||Daily Activities Are Sufficient to Induce Dynamic Pulmonary Hyperinflation and Dyspnea in Chronic Obstructive Pulmonary Disease Patients||Completed|||19|Actual|Federal University of São Paulo|||1||f||||f||||||||||2018-05-31 21:55:08.273078|2018-05-31 21:55:08.273078
NCT01475799|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2016-10-31|2011-11-17|2011-11-21|Estimate|||||||2016-10-31|2016-11-01|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|July 2019|Anticipated|2019-07-31|July 2014|Actual|2014-07-31||Interventional|||Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis|Active, not recruiting||N/A|112|Actual|Direct Flow Medical, Inc.||1|||f||||t||||||||||2018-05-31 21:55:08.339525|2018-05-31 21:55:08.339525
NCT01475786|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15||2015-12-07|2016-09-20|2011-11-16|2011-11-21|Estimate||||2015-12-07|2016-01-08|Estimate|2016-09-20|2016-09-23|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy|Completed||Phase 2|104|Actual|ViroMed Co., Ltd.||3|||f||||t||||||||||2018-05-31 21:55:08.423918|2018-05-31 21:55:08.423918
NCT01475773|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-18|2011-11-18|2011-11-21|Estimate|||||||2011-11-18|2011-11-21|Estimate|November 2011||2011-11-30|October 2011|2011-10-31||||November 2012|Anticipated|2012-11-30||Observational|||Psychological Assessment of Adults Seeking Orthodontic Treatment|Impact of Personality Characteristics and Self-esteem on the Relationship Between Orthodontic Treatment Need and Oral-health Related Quality of Life in Adults.|Unknown status|Not yet recruiting||100|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 21:55:08.533611|2018-05-31 21:55:08.533611
NCT01475760|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-08-01|2011-11-18|2011-11-21|Estimate|||||||2012-08-01|2012-08-02|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease|A Multi-Center, Open Label Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease|Completed||N/A|167|Actual|Denver Nephrologists, P.C.||3|||f||||f||||||||||2018-05-31 21:55:08.592663|2018-05-31 21:55:08.592663
NCT01475747|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2018-05-10|2011-11-18|2011-11-21|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2011||2011-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SPRINTFAST||Systolic Pressure Intervention Trial Factors Affecting Factors Affecting Atherosclerosis Study|Systolic Pressure Intervention Trial (SPRINT)-Factors Affecting Factors Affecting Atherosclerosis Study (FAST)|Active, not recruiting|||595|Actual|University of Utah|||1||f||||t||||||Samples Without DNA|"~     Urine, plasma and serum samples.~   "|||2018-05-31 21:55:08.667855|2018-05-31 21:55:08.667855
NCT01475578|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-16|2011-11-16|2011-11-21|Estimate|||||||2011-11-16|2011-11-21|Estimate|March 2002||2002-03-31|November 2011|2011-11-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)|A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel, Comparative, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)|Completed||Phase 2|240|Actual|Sinphar Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 21:55:16.790832|2018-05-31 21:55:16.790832
NCT01475734|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2014-04-17|2012-11-21|2016-11-20|2011-11-17|2011-11-21|Estimate|2014-04-17|2014-05-16|Estimate|2012-11-21|2012-11-27|Estimate|2016-11-20|2017-01-11|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes|A Single-site, Randomized, Double-blind, Placebo-controlled, Parallel-group, Stepped Glucose Clamp Study to Assess the Effects of Albiglutide on Counter-regulatory Hormone Responses and Recovery From Hypoglycemia in Subjects With Type 2 Diabetes Mellitus.|Completed||Phase 2|44|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:55:08.758922|2018-05-31 21:55:08.758922
NCT01475721|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|2015-12-03||2018-02-08|2011-11-17|2011-11-21|Estimate|2015-12-10|2016-01-14|Estimate||||2018-02-08|2018-02-09|Actual|November 18, 2011|Actual|2011-11-18|February 2018|2018-02-28|June 23, 2015|Actual|2015-06-23|June 23, 2015|Actual|2015-06-23||Interventional|AUSTRI||SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.|SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma|Completed||Phase 4|11751|Actual|GlaxoSmithKline||6|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:55:09.711529|2018-05-31 21:55:09.711529
NCT01475708|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-03-23|2011-11-16|2011-11-21|Estimate|||||||2016-03-23|2016-03-24|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||Doxycycline in Therapy of Erythema Migrans|Doxycycline in Therapy of Erythema Migrans - do the Accompanying Symptoms Influence the Outcome?|Completed|||400|Actual|University Medical Centre Ljubljana|||3||f||||f||||||Samples Without DNA|"~     whole blood, serum, cerebrospinal fluid, skin tissue~   "|Undecided||2018-05-31 21:55:11.759863|2018-05-31 21:55:11.759863
NCT01475695|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-06-27|2011-11-17|2011-11-21|Estimate|||||||2017-06-27|2017-06-28|Actual|April 21, 2011|Actual|2011-04-21|June 2017|2017-06-30|May 19, 2011|Actual|2011-05-19|May 19, 2011|Actual|2011-05-19||Interventional|||GSK2251052 Mass Balance in Healthy Adult Subjects|An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2251052 Administered as a Single Intravenous Dose to Healthy Adult Subjects|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:55:11.837005|2018-05-31 21:55:11.837005
NCT01475682|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2014-07-16|2011-11-18|2011-11-21|Estimate|||||||2014-07-16|2014-07-17|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea|Long Term Cardiovascular Complications in Men With Obstructive Sleep Apnea - Prospective 9 Years Follow-up Study|Unknown status|Recruiting||167|Anticipated|The University of Hong Kong|||1||f||||t||||||||||2018-05-31 21:55:12.91177|2018-05-31 21:55:12.91177
NCT01475669|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2014-09-17|2011-11-17|2011-11-21|Estimate|||||||2014-09-17|2014-09-18|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|REPLACE||Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery|REPLACE (Randomized Evaluation of Fibrinogen Versus Placebo in Complex Cardiovascular Surgery): a Prospective, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study for the Use of Fibrinogen Concentrate (Human) (FCH) in Complex Cardiovascular Surgery|Completed||Phase 3|152|Actual|CSL Behring||2|||f||||t||||||||||2018-05-31 21:55:13.160084|2018-05-31 21:55:13.160084
NCT01475656|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2013-04-17|2011-11-18|2011-11-21|Estimate|||||||2013-04-17|2013-04-19|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Efficacy of Keppra for Neonatal Seizures|Safety, Tolerability, and Efficacy of Levetiracetam for Neonatal Seizures|Terminated|||2|Actual|Children's Hospital Medical Center, Cincinnati|||2|difficulty with recruitment|f||||t||||||||||2018-05-31 21:55:13.552141|2018-05-31 21:55:13.552141
NCT01475643|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2017-04-25|2011-11-17|2011-11-21|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.|Safety and Efficacy of Topical Loteprednol Etabonate 0.5%, Versus Prednisolone Acetate 1%, for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract|Active, not recruiting||Phase 3|170|Anticipated|Bausch & Lomb Incorporated||2|||f||||f||||||||Yes||2018-05-31 21:55:13.84655|2018-05-31 21:55:13.84655
NCT01475630|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2011-11-21|2011-11-18|2011-11-21|Estimate|||||||2011-11-21|2011-11-22|Estimate|June 2003||2003-06-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Physical Therapy for Temporomandibular Joint (TMJ) Closed Lock|Randomised Controlled Trial on Physical Therapy PT) for TMJ Closed Lock|Completed||N/A|49|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 21:55:14.245261|2018-05-31 21:55:14.245261
NCT01475617|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-01-20|2011-11-16|2011-11-21|Estimate|||||||2015-01-20|2015-01-22|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Efficacy of a Novel Multivitamin-Mineral Supplement in Preventing Vitamin Deficiency in Postoperative Bariatric Patients|Efficacy of a Novel Multivitamin-Mineral Supplement in Preventing Vitamin Deficiency in Postoperative Bariatric Patients|Completed||Phase 2/Phase 3|61|Actual|Yasoo Health||2|||f||||f||||||||||2018-05-31 21:55:16.316232|2018-05-31 21:55:16.316232
NCT01475604|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-07-06|2011-11-17|2011-11-21|Estimate|||||||2012-07-06|2012-07-10|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty|Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty: A Double-Blind, Randomized, Sham-controlled Trial|Terminated||Phase 4|23|Actual|Amp Orthopedics, Inc.||2||Sponsor decision|f||||f||||||||||2018-05-31 21:55:16.640878|2018-05-31 21:55:16.640878
NCT01475591|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2016-09-22|2011-11-16|2011-11-21|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||Individually Tailored Web-based Multimodal Pain Rehabilitation in Primary Health Care|Individually Tailored Web-based Multimodal Pain Rehabilitation in Primary Health Care|Completed||N/A|109|Actual|Luleå Tekniska Universitet||1|||f||||f||||||||||2018-05-31 21:55:16.720902|2018-05-31 21:55:16.720902
NCT01475565|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2015-12-10|2011-11-16|2011-11-21|Estimate|||||||2015-12-10|2015-12-14|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Insulin Resistance Before and During Pregnancy in Women With Polycystic Ovary Syndrome|Insulin Resistance Before and During Pregnancy in Women With PCOS|Terminated|||2|Actual|Virginia Commonwealth University|||2|Only 2 participants were enrolled|f||||f||||||Samples With DNA|"~     -  blood sample~        -  blood sample sample for DNA~        -  fasting plasma for insulin, glucose, sex steroids (testosterone, androstenedione,~          DHEA-sulfate, estradiol, estrone, progesterone), sex hormone-binding globulin and~          estrogen metabolites~        -  blood sample for oral glucose tolerance test~        -  urine for estrogen metabolites~   "|||2018-05-31 21:55:16.895306|2018-05-31 21:55:16.895306
NCT01475552|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-12-12|2011-11-18|2011-11-21|Estimate|||||||2012-12-12|2012-12-13|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus|The Effect of Point-of-care Platelet Function Assay Guided Antiplatelet Therapy on the Periprocedural Increase of Cardiac Enzymes.|Completed||Phase 4|130|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 21:55:17.256775|2018-05-31 21:55:17.256775
NCT01475539|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-01-09|2011-11-16|2011-11-21|Estimate|||||||2015-01-09|2015-01-12|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine|Immunogenicity and Safety of Different Sequential Schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) Followed by Oral Poliomyelitis Vaccine in Healthy Infants in China Versus Oral Poliomyelitis Vaccine Alone.|Completed||Phase 4|456|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:55:17.354758|2018-05-31 21:55:17.354758
NCT01475526|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-11-16|2011-11-18|2011-11-21|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||The Value of Our Health|El Valor de Nuestra Salud (The Value of Our Health)|Completed||N/A|370|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 21:55:17.533238|2018-05-31 21:55:17.533238
NCT01475513|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-02-12|2011-11-16|2011-11-21|Estimate|||||||2018-02-12|2018-02-14|Actual|November 2011||2011-11-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women|Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women|Active, not recruiting||Phase 4|47|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 21:55:17.633464|2018-05-31 21:55:17.633464
NCT01475500|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2018-04-30|2011-11-16|2011-11-21|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2011||2011-04-30|April 2018|2018-04-30|November 30, 2022|Anticipated|2022-11-30|July 30, 2022|Anticipated|2022-07-30||Observational|||Nashville Early Diagnosis Lung Cancer Project|Nashville Early Diagnosis Lung Cancer Project|Recruiting|||410|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||Samples With DNA|"~     Sputum, Blood, Urine, Nasal brushings, Buccal cells, Bronchical washings, Bronchioalveolar~     lavage brushings, Endobronchial biopsies~   "|||2018-05-31 21:55:17.764108|2018-05-31 21:55:17.764108
NCT01475487|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2015-06-24||2015-06-24|2011-11-16|2011-11-21|Estimate|2015-06-24|2015-06-25|Estimate||||2015-06-24|2015-06-25|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2011|Actual|2011-09-30||Interventional||Characteristics of participants and human cadavers|Ultrasound Guided Versus Palpation Guided Cricothyrotomy With Poorly Defined Anatomical Landmarks|A Comparison of Ultrasound Versus Digital Palpation Guided Cricothyrotomy in Subjects With Poorly Defined Anatomical Landmarks|Completed||N/A|47|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 21:55:17.905529|2018-05-31 21:55:17.905529
NCT01475474|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2013-07-02||2013-09-27|2011-11-16|2011-11-21|Estimate|2013-09-27|2013-11-28|Estimate||||2013-09-27|2013-11-28|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|REST||A Study to Evaluate the Safety, Tolerability and Effectiveness of the Renew Insert in Treating Accidental Bowel Leakage|A Multi-Center, Prospective, Non-Randomized Study of the Renew Insert Efficacy, Safety and Tolerability For the Management of Accidental Bowel Leakage Due to Bowel Incontinence|Completed||N/A|97|Actual|Renew Medical|||||f||||f||||||||||2018-05-31 21:55:18.327972|2018-05-31 21:55:18.327972
NCT01475461|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2016-12-06|2014-04-21|2016-12-06|2011-11-16|2011-11-21|Estimate|2016-12-06|2017-01-31|Estimate|2014-04-21|2014-05-09|Estimate|2016-12-06|2017-01-31|Estimate|November 2011||2011-11-30|December 2016|2016-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Baseline analysis population included all randomized participants who received at least 1 dose of study treatment.|Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes|A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety And Efficacy Of Pf-04937319 And Sitagliptin On Glycemic Control In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Completed||Phase 2|345|Actual|Pfizer||6|||f||||t||||||||||2018-05-31 21:55:18.68538|2018-05-31 21:55:18.68538
NCT01475448|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-05-02|2011-11-16|2011-11-21|Estimate|||||||2015-05-02|2015-05-05|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Long Distance Running Training by Older Adults|Effects of Long Distance Running Training on the Posture and Movement Control of Sedentary Older Adults|Completed||N/A|34|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:55:20.861113|2018-05-31 21:55:20.861113
NCT01475435|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-11-16|2011-11-16|2011-11-21|Estimate|||||||2011-11-16|2011-11-21|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2013|Anticipated|2013-08-31|December 2011|Anticipated|2011-12-31||Interventional|||Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients|Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients With Generalized Chronic Periodontitis and Healthy Periodontium|Unknown status|Recruiting|Early Phase 1|200|Anticipated|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 21:55:20.928165|2018-05-31 21:55:20.928165
NCT01475422|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-11-16|2011-11-16|2011-11-21|Estimate|||||||2011-11-16|2011-11-21|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Effectiveness of the Self Monitoring of Capillary Blood Glucose at Home|Effectiveness of the Self Monitoring of Capillary Blood Glucose at Home in Metabolic Control of People With Diabetes Mellitus|Unknown status|Recruiting|N/A|91|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:55:21.151521|2018-05-31 21:55:21.151521
NCT01446653|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2016-10-24|2011-10-04|2011-10-05|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2007||2007-02-28|October 2016|2016-10-31|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|EARLY RCT||Reducing Alcohol Exposed Pregnancy Risk: EARLY Randomized Controlled Trial|Reducing Alcohol Exposed Pregnancy Risk|Completed||N/A|232|Actual|University of Virginia||3|||f||||f||||||||||2018-05-31 22:06:17.315966|2018-05-31 22:06:17.315966
NCT01475409|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-11-16|2011-11-16|2011-11-21|Estimate|||||||2011-11-16|2011-11-21|Estimate|July 2008||2008-07-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study on Changes in IFN-gamma Levels Following Anti-TNF Treatment in Patients Undergoing Serial QuantiFERON-TB Gold In-Tube|Dynamic Changes in IFN-gamma Plasma Levels Following Anti-TNF Treatment in Patients With Inflammatory Rheumatic Diseases Undergoing Serial QuantiFERON-TB Gold In-Tube Testing: a Prospective Study in a Low Tuberculosis Burden Country|Completed||N/A|119|Actual|University of Roma La Sapienza||1|||f||||f||||||||||2018-05-31 21:55:21.380713|2018-05-31 21:55:21.380713
NCT01475396|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2012-06-18|2011-11-16|2011-11-21|Estimate|||||||2012-06-18|2012-06-19|Estimate|March 2006||2006-03-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Physical Activity on the Brain|Clinical Study on the Effect of Physical Activity on Cognition and Memory in the Elderly|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|University Hospital Muenster||3|||f||||f||||||||||2018-05-31 21:55:21.566274|2018-05-31 21:55:21.566274
NCT01475383|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-07-30|2011-11-16|2011-11-21|Estimate|||||||2012-07-30|2012-08-01|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Of The Safety And Efficacy Of PF-03654746 In Adults With Tourette's Syndrome|Terminated||Phase 2|1|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 21:55:21.829683|2018-05-31 21:55:21.829683
NCT01475370|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-12-22|2011-11-16|2011-11-21|Estimate|||||||2017-12-22|2017-12-26|Actual|January 24, 2012|Actual|2012-01-24|December 2017|2017-12-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)||Completed||Phase 1|18|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:55:22.098703|2018-05-31 21:55:22.098703
NCT01475357|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2014-10-14|2011-11-16|2011-11-21|Estimate|||||||2014-10-14|2014-10-15|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Intestinal Function in Neonates With Complex Congenital Heart Disease|Intestinal Function in Neonates With Complex Congenital Heart Disease|Completed||N/A|27|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 21:55:22.214009|2018-05-31 21:55:22.214009
NCT01475344|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2015-12-07|2011-11-18|2011-11-21|Estimate|||||||2015-12-07|2015-12-08|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)|A Multicenter Double-blind, Placebo Controlled, Randomized, Pilot Trial to Assess the Efficacy of Pre-hospital Administration of Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)|Completed||Phase 1/Phase 2|67|Actual|Medical University Innsbruck||2|||f||||t||||||||||2018-05-31 21:55:22.358266|2018-05-31 21:55:22.358266
NCT01475331|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2018-01-05||2018-02-20|2011-11-16|2011-11-21|Estimate|2018-02-20|2018-03-20|Actual||||2018-02-20|2018-03-20|Actual|November 2011||2011-11-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts||Completed||Phase 2|46|Actual|Milton S. Hershey Medical Center|Because of small number of participants this single-center trial is still weakly powered to show these differences with high levels of scientific certainty.Study was limited to one ablation only.|2|||f||||t||||||||||2018-05-31 21:55:22.512933|2018-05-31 21:55:22.512933
NCT01475318|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-11-16|2011-11-16|2011-11-21|Estimate|||||||2011-11-16|2011-11-21|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy|A Pilot Study on the Combined Use of Letrozole, Miferpristone and Misoprostol in Termination of First Trimester Pregnancy up to 63 Days Gestation|Unknown status|Recruiting|N/A|50|Anticipated|The University of Hong Kong||1|||f||||||||||||||2018-05-31 21:55:22.90328|2018-05-31 21:55:22.90328
NCT01475305|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2017-04-05||2017-07-20|2011-11-16|2011-11-21|Estimate|2017-07-20|2017-07-21|Actual||||2017-07-20|2017-07-21|Actual|October 20, 2011|Actual|2011-10-20|July 2017|2017-07-31|December 13, 2012|Actual|2012-12-13|December 3, 2011|Actual|2011-12-03||Interventional||The Intent-to-treat (ITT) population included all participants who were randomized into the study.|Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)|A Phase 1 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of MEDI-557 in Healthy Adults Intranasally Challenged With Respiratory Syncytial Virus (RSV)|Terminated||Phase 1|7|Actual|MedImmune LLC|The study was terminated before an adequate number of subjects were enrolled.|2||"The study was terminated as it was determined to not be feasible to complete enrollment and the~   study within the required timeline and budget."|f||||f||||||||||2018-05-31 21:55:23.037038|2018-05-31 21:55:23.037038
NCT01475292|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-05-02|2011-11-18|2011-11-21|Estimate|||||||2012-05-02|2012-05-03|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Treatment With Repeat Doses of Inhaled RV568 in Patients With COPD|Completed||Phase 2|30|Actual|Respivert Ltd||3|||f||||f||||||||||2018-05-31 21:55:23.837797|2018-05-31 21:55:23.837797
NCT01475279|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-11-07|2011-11-18|2011-11-21|Estimate|||||||2012-11-07|2012-11-08|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin|An Open-Label, Multiple-Dose, Single-Center, Sequential, Inpatient Study to Determine the Effect of T89 on Steady-State Pharmacodynamics of Warfarin in Healthy Subjects|Completed||Phase 1|24|Actual|Tasly Pharmaceuticals, Inc.|||||f||||t||||||||||2018-05-31 21:55:23.958533|2018-05-31 21:55:23.958533
NCT01475266|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2017-03-27|2011-11-18|2011-11-21|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2011||2011-11-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)|Randomized, Placebo-controlled, Double-blinded Study of Single Immediate Instillation of EO9 After TURBT in Patients With NMIBC|Terminated||Phase 2/Phase 3|51|Actual|Nippon Kayaku Co.,Ltd.||2||Sponsor's decision|f||||t||||||||||2018-05-31 21:55:24.022624|2018-05-31 21:55:24.022624
NCT01475097|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2014-03-11||2014-06-03|2011-11-16|2011-11-21|Estimate|2014-03-11|2014-04-15|Estimate||||2014-06-03|2014-06-11|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography|A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography|Completed||Phase 4|255|Actual|GE Healthcare||2|||f||||t||||||||||2018-05-31 21:55:27.194076|2018-05-31 21:55:27.194076
NCT01475253|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2014-08-05||2015-08-19|2011-11-16|2011-11-21|Estimate|2015-08-19|2015-09-21|Estimate||||2015-08-19|2015-09-21|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis|A Phase 2a Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® in Women With Interstitial Cystitis Followed by an Open Label Extension|Terminated||Phase 2|104|Actual|Allergan|As per protocol, efficacy analyses were not performed for the Sham Cytoscopic Procedure-Randomized Study Arm/Group. Only safety analyses were completed.|3||This study was not enrolled completely and was terminated.|f||||t||||||||||2018-05-31 21:55:24.13531|2018-05-31 21:55:24.13531
NCT01475240|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2014-04-10|2011-11-16|2011-11-21|Estimate|||||||2014-04-10|2014-04-11|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|SSAT044||The Effect of Hyperbilirubinemia on CV Disease, Neurocog Function and Renal Function|A Cross-sectional Controlled Study to Evaluate the Impact of Hyperbilirubinemia on Markers of Cardiovascular Disease, Neurocognitive Function and Renal Markers in HIV-1 Infected Subjects on Protease Inhibitors|Completed|||101|Actual|St Stephens Aids Trust|||2||f||||f||||||||||2018-05-31 21:55:25.124437|2018-05-31 21:55:25.124437
NCT01475227|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2012-03-21|2011-11-18|2011-11-21|Estimate|||||||2012-03-21|2012-03-22|Estimate|December 2011||2011-12-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|SSAT043||Atazanavir/Ritonavir and Zinc Pharmacokinetic Study|A Randomized Crossover Study of the Effects of Zinc Sulphate Supplementation on Atazanavir/Ritonavir-associated Hyperbilirubinemia|Completed||Phase 4|16|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-05-31 21:55:25.258262|2018-05-31 21:55:25.258262
NCT01475214|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2015-06-10||2015-09-18|2011-11-18|2011-11-21|Estimate|2015-09-18|2015-10-19|Estimate||||2015-09-18|2015-10-19|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Musculoskeletal Effects of Bicarbonate|Musculoskeletal Benefits of Bicarbonate in Older Adults - A Dose-Finding Trial|Completed||Phase 2|244|Actual|Tufts University||3|||f||||f||||||||||2018-05-31 21:55:25.375801|2018-05-31 21:55:25.375801
NCT01475201|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2017-03-21|2011-11-18|2011-11-21|Estimate|||||||2017-03-21|2017-03-23|Actual|February 2012||2012-02-29|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SMARTER||Step Monitoring to Improve ARTERial Health|Step Monitoring to Improve ARTERial Health|Completed||N/A|347|Actual|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 21:55:26.005803|2018-05-31 21:55:26.005803
NCT01475188|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-18|2011-11-18|2011-11-21|Estimate|||||||2011-11-18|2011-11-21|Estimate|March 2007||2007-03-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy|Regulatory Lymphocytes (Treg) in the Modulation of Allergic Inflammation in Patients Treated With Specific Immunotherapy.|Completed||Phase 4|41|Actual|Ministry of Science and Higher Education, Poland||2|||f||||f||||||||||2018-05-31 21:55:26.11299|2018-05-31 21:55:26.11299
NCT01475175|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2012-09-12||2012-09-12|2011-11-18|2011-11-21|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Adaptive Cardiac Resynchronization Therapy Optimization at Rest and During Exercise (AdOPT CRT)|Adaptive Cardiac Resynchronization Therapy Optimization at Rest and During Exercise (AdOPT CRT)|Terminated||N/A|12|Actual|Medtronic Cardiac Rhythm and Heart Failure|A pre-planned interim evaluation of the sample size calculation assumptions was conducted. The variability of the outcome measures was higher than assumed. The study was stopped since the planned sample size would unlikely be sufficient.|1||"Decision was made to stop the study based on a pre-planned interim analysis that the sample~   size would unlikely be sufficient to satisfy the primary objective."|f||||||||||||||2018-05-31 21:55:26.222806|2018-05-31 21:55:26.222806
NCT01475162|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2018-04-09|2011-11-18|2011-11-21|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2011||2011-08-31|April 2018|2018-04-30|December 27, 2017|Actual|2017-12-27|February 17, 2016|Actual|2016-02-17||Interventional|||Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease|Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease|Terminated||Phase 1/Phase 2|13|Actual|Medical College of Wisconsin||1||The DSMB felt the risks of the study now outweighed the potential benefits.|f||||t||||||||||2018-05-31 21:55:26.492954|2018-05-31 21:55:26.492954
NCT01475149|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-03-23|2011-11-16|2011-11-21|Estimate|||||||2017-03-23|2017-03-27|Actual|September 2010||2010-09-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|September 2013|Actual|2013-09-30||Observational|||Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)|Effect of Hydroxychloroquine on the Annexin A5 Resistance Assay in Antiphospholipid Antibody-Positive Patients With and Without Systemic Lupus Erythematosus|Completed|||33|Actual|Hospital for Special Surgery, New York|||6||f||||f||||||Samples Without DNA|"~     serum, plasma~   "|No||2018-05-31 21:55:26.613612|2018-05-31 21:55:26.613612
NCT01475136|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2013-01-10|2011-11-16|2011-11-21|Estimate|||||||2013-01-10|2013-01-11|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of LY2140023 in Hepatic Impaired Participants|A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:55:26.725564|2018-05-31 21:55:26.725564
NCT01475123|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2017-03-02|2011-11-18|2011-11-21|Estimate|||||||2017-03-02|2017-03-06|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2011|Actual|2011-06-30||Interventional|||Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil|Effects of Nicorandil on Cardiovascular Events in Patients With Coronary Artery Disease Receiving Hemodialysis|Active, not recruiting||Phase 4|268|Actual|Kumamoto University||2|||f||||t||||||||Undecided||2018-05-31 21:55:26.79522|2018-05-31 21:55:26.79522
NCT01475110|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2018-03-21|2011-11-18|2011-11-21|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2012||2012-02-29|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|CML0609||Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib|Observational Study in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia (CML) Treated With Nilotinib: Follow-up of the Italian Patients. GIMEMA Study CML0609|Recruiting|||100|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 21:55:26.934604|2018-05-31 21:55:26.934604
NCT01475084|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2015-09-08|2011-11-18|2011-11-21|Estimate|||||||2015-09-08|2015-09-10|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Cryobiopsy or Forceps Biopsy During Semirigid Thoracoscopy: a Comparative Study|Cryobiopsy or Forceps Biopsy During Semirigid Thoracoscopy: a Comparative Study|Completed||Phase 2/Phase 3|40|Actual|The University Clinic of Pulmonary and Allergic Diseases Golnik||1|||f||||t||||||||||2018-05-31 21:55:27.607802|2018-05-31 21:55:27.607802
NCT01475071|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2013-08-29||2016-03-17|2011-11-16|2011-11-21|Estimate|2016-03-17|2016-04-18|Estimate||||2016-03-17|2016-04-18|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|CoMet||Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses|Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses.|Completed||Phase 3|100|Actual|Galderma||2|||f||||f||||||||||2018-05-31 21:55:27.685568|2018-05-31 21:55:27.685568
NCT01475058|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10||2017-01-31|2017-02-14|2011-11-16|2011-11-21|Estimate||||2017-02-14|2017-02-15|Actual|2017-02-14|2017-02-15|Actual|April 2012||2012-04-30|February 2017|2017-02-28|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant|A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant|Completed||Phase 1/Phase 2|1|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 21:55:27.939016|2018-05-31 21:55:27.939016
NCT01475045|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-11-18|2011-11-18|2011-11-21|Estimate|||||||2011-11-18|2011-11-21|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Observational|ANASA||ANASA (Patients' Satisfaction With Pulmonary Diseases' Treatment)|Multicenter, Prospective, Non Interventional Observational Study in Treatments of Asthma and Chronic Obstructive Pulmonary Disease (COPD)|Completed|||1160|Actual|Elpen Pharmaceutical Co. Inc.|||3||f||||f||||||||||2018-05-31 21:55:28.011716|2018-05-31 21:55:28.011716
NCT01475032|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2017-03-28|2011-11-18|2011-11-21|Estimate|||||||2017-03-28|2017-03-29|Actual|September 2011||2011-09-30|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PAED2/FRESH||"Efficacy Study of the Product CHF 1535 Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children"|A Phase III, 12-week, Multicentre, Multinational, Randomised, Double-blind, Double-dummy, 3 Arm-parallel Group Study to Test the Efficacy of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate (BDP) Plus Formoterol Fumarate (FF)) Versus a Free Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate and Versus a Monotherapy of Beclomethasone Dipropionate in Partly Controlled Asthmatic Children|Completed||Phase 3|638|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||t||||||||||2018-05-31 21:55:28.108582|2018-05-31 21:55:28.108582
NCT01475019|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-18|2011-11-18|2011-11-21|Estimate|||||||2011-11-18|2011-11-21|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|January 2010|Actual|2010-01-31||Interventional|||The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)|The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome|Unknown status|Active, not recruiting|Phase 4|200|Anticipated|Aristotle University Of Thessaloniki||4|||f||||t||||||||||2018-05-31 21:55:28.271485|2018-05-31 21:55:28.271485
NCT01475006|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2016-04-14|2011-11-18|2011-11-21|Estimate|||||||2016-04-14|2016-04-15|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||AMG 595 First-in-Human in Recurrent Gliomas|A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)|Completed||Phase 1|32|Actual|Amgen||2|||f||||f||||||||||2018-05-31 21:55:28.359324|2018-05-31 21:55:28.359324
NCT01474993|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2014-11-04||2018-03-15|2011-11-17|2011-11-18|Estimate|2014-11-19|2014-11-24|Estimate||||2018-03-15|2018-04-12|Actual|December 2011||2011-12-31|March 2018|2018-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Sulforaphane-rich Broccoli Sprout Extract for Autism|Sulforaphane-rich Broccoli Sprout Extract for Autism|Completed||Phase 2|44|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 21:55:28.515367|2018-05-31 21:55:28.515367
NCT01474980|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-17|2011-11-17|2011-11-18|Estimate|||||||2011-11-17|2011-11-18|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|January 2011|Actual|2011-01-31||Observational|POCoMS||Pregnancy Outcomes in Congenital Myasthenie Syndrome|Retrospective Study :Describe the Changes of the Disease in Many Cases Likely to Aggravate.|Completed|||25|Actual|Institut de Myologie, France|||||f||||t||||||||||2018-05-31 21:55:30.011684|2018-05-31 21:55:30.011684
NCT01474967|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2011-11-18|2011-11-17|2011-11-18|Estimate|||||||2011-11-18|2011-11-21|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Effect of Dosage of Metformin on Menstruation and Lipid Profile in Women With Polycystic Ovary Syndrome|Effect of Dosage of Metformin on Menstruation and Lipid Profile in Women With Polycystic Ovary Syndrome|Completed||N/A|50|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:55:30.146316|2018-05-31 21:55:30.146316
NCT01474954|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2015-05-08|2011-11-17|2011-11-18|Estimate|||||||2015-05-08|2015-05-12|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors|A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus|Terminated|||5|Actual|University of California, San Francisco||||Low enrollment|f||||t||||||||||2018-05-31 21:55:30.229689|2018-05-31 21:55:30.229689
NCT01474941|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2012-01-25|2011-11-15|2011-11-18|Estimate|||||||2012-01-25|2012-01-26|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects|A Phase 1, Randomized, Double-Blind, Parallel, Placebo-Controlled, Multiple-Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of A Modified-Release Formulation Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects|Completed||Phase 1|27|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:55:30.294471|2018-05-31 21:55:30.294471
NCT01474928|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-11-26|2011-11-17|2011-11-18|Estimate|||||||2017-11-26|2017-11-28|Actual|August 2009||2009-08-31|November 2017|2017-11-30|July 2014|Actual|2014-07-31|October 2013|Actual|2013-10-31||Interventional|||Asthma and Health Literacy in Newcomer Communities in the Greater Vancouver Area|Asthma and Health Literacy in Newcomer Communities in the Greater Vancouver Area (GVA): A Population-based Qualitative Study|Completed||N/A|92|Actual|University of British Columbia||4|||f||||t||||||||||2018-05-31 21:55:30.415371|2018-05-31 21:55:30.415371
NCT01474915|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2013-04-30||2013-11-08|2011-11-15|2011-11-18|Estimate|2013-11-08|2013-12-03|Estimate||||2013-11-08|2013-12-03|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting|Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting|Completed||Phase 4|122|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 21:55:30.53061|2018-05-31 21:55:30.53061
NCT01474902|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2013-08-25|2011-11-17|2011-11-18|Estimate|||||||2013-08-25|2013-08-27|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery|A Randomized Controlled Trial of Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery|Withdrawn||Phase 3|0|Actual|The Hospital for Sick Children||2||Poor enrollment|f||||t||||||||||2018-05-31 21:55:31.07749|2018-05-31 21:55:31.07749
NCT01474889|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2018-05-01|2011-11-15|2011-11-18|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2011||2011-10-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Glucose Counterregulation in Long Standing Type 1 Diabetes|Effect of Real-Time Continuous Glucose Monitoring on Glucose Counterregulation in Long Standing Type 1 Diabetes|Recruiting||N/A|36|Anticipated|University of Pennsylvania||1|||f||||t||||||||Undecided||2018-05-31 21:55:31.16557|2018-05-31 21:55:31.16557
NCT01474876|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2015-05-18||2015-06-15|2011-11-16|2011-11-18|Estimate|2015-06-15|2015-07-08|Estimate||||2015-06-15|2015-07-08|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||Participants who received adalimumab treatment|Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis|Multicountry Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis and Psoriatic Arthritis|Completed|||566|Actual|AbbVie|||2||f||||f||||||||||2018-05-31 21:55:31.350239|2018-05-31 21:55:31.350239
NCT01474863|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|2017-03-22||2017-06-02|2011-11-17|2011-11-18|Estimate|2017-06-02|2017-06-05|Actual||||2017-06-02|2017-06-05|Actual|August 2012||2012-08-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Citrulline in Severe Sepsis|Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous Citrulline to Prevent or Mitigate Acute Lung Injury in Patients With Severe Sepsis|Completed||Phase 2|72|Actual|Vanderbilt University Medical Center||3|||f||||f||||||||||2018-05-31 21:55:32.23511|2018-05-31 21:55:32.23511
NCT01474850|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-12-05|2011-11-15|2011-11-18|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Thoraco-abdominal Volume Variations During Anesthesia Studied by OEP.|Thoraco-abdominal Volume Variation During Recovery From Total Intravenous Anesthesia Studied by Opto-electronic Plethysmography (OEP).|Completed||N/A|18|Actual|Uppsala University Hospital||2|||f||||f||||||||||2018-05-31 21:55:32.633449|2018-05-31 21:55:32.633449
NCT01474837|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2014-01-16|2011-11-15|2011-11-18|Estimate|||||||2014-01-16|2014-01-17|Estimate|October 2011||2011-10-31|January 2014|2014-01-31||||November 2013|Actual|2013-11-30||Interventional|HEALTH||Exercise for Depression in Young People|The H.E.A.L.T.H. Project: Help Enabling Active Lifestyles Toward Health in Young People With Depression.|Completed||N/A|86|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 21:55:32.74884|2018-05-31 21:55:32.74884
NCT01474824|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2014-12-03|2011-11-15|2011-11-18|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Validation of Nexfin Cardiac Output in Elderly Patients With Hip Fracture|Validation of the Nexfin Non-invasive Cardiac Output Monitor in Patients Undergoing Hip Fracture Repair|Terminated|||6|Actual|University of Nottingham||||Unable to recruit sufficient participants|f||||f||||||||||2018-05-31 21:55:32.829785|2018-05-31 21:55:32.829785
NCT01474811|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-05-01|2011-11-15|2011-11-18|Estimate|||||||2017-05-01|2017-05-04|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network|HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.|Recruiting|||4500|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     All patients will be invited to participate in the HCV-TARGET Biorepository Specimen Bank~     (BSB).~      The following will be collected: Blood (Serum and DNA).~      All samples will be collected on a voluntary basis and participation in this project will not~     affect participation in the main study.~      Samples collected will be stored at the University of Florida for up to 15 years after the~     end of the study (database closure) at which time they will be destroyed. The implementation~     and use of the BSB specimens is governed by the University of Florida Biospecimen Repository~     policy to ensure the appropriate use of the deposited samples.~   "|||2018-05-31 21:55:32.926857|2018-05-31 21:55:32.926857
NCT01474798|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15||2014-06-05|2014-06-05|2011-11-15|2011-11-18|Estimate||||2014-06-05|2014-06-18|Estimate|2014-06-05|2014-06-18|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris|A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-Inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Acne Vulgaris|Completed||Phase 2|11|Actual|XBiotech, Inc.||1|||f||||f||||||||||2018-05-31 21:55:33.313344|2018-05-31 21:55:33.313344
NCT01474785|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2018-05-18|2011-11-15|2011-11-18|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2012||2012-01-31|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||RYGB and the Gastric Adipose Axis|RYGB Improves Metabolism by Interrupting the Gastric Adipose Tissue Axis|Completed||Phase 1|49|Actual|Vanderbilt University Medical Center||3|||f||||t||||||||||2018-05-31 21:55:33.406585|2018-05-31 21:55:33.406585
NCT01474772|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2014-05-21||2014-11-17|2011-11-15|2011-11-18|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-17|2014-11-18|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)|A Phase 3b Multicenter, Double-blind, Randomized, Placebo-controlled Cross-over Efficacy And Safety Study Of Pregabalin In The Treatment Of Patients With Painful Diabetic Peripheral Neuropathy And Pain On Walking|Completed||Phase 3|217|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:55:33.517479|2018-05-31 21:55:33.517479
NCT01474759|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2015-05-14|2011-11-17|2011-11-18|Estimate|||||||2015-05-14|2015-05-15|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Portion Size Strategies for Management of Body Weight||Completed||N/A|186|Actual|Penn State University||3|||f||||t||||||||||2018-05-31 21:55:34.266947|2018-05-31 21:55:34.266947
NCT01474746|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2017-03-27||2017-08-25|2011-11-17|2011-11-18|Estimate|2017-08-25|2017-09-25|Actual||||2017-08-25|2017-09-25|Actual|January 2012||2012-01-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Trial of Sertraline to Treat Children With Fragile X Syndrome|A Controlled Trial of Sertraline in Young Children With Fragile X Syndrome|Completed||Phase 2|57|Actual|University of California, Davis|Several secondary analyses. Subject non-compliance with eye tracking led to unreliable/uninterpretable data. Subjects and caregivers were unblinded at the time they completed the study. Limited number of girls in the study (total 9 girls).|2|||f||||t||||||||Undecided||2018-05-31 21:55:34.349611|2018-05-31 21:55:34.349611
NCT01474733|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2015-10-14|2011-11-17|2011-11-18|Estimate|||||||2015-10-14|2015-10-16|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effects of a Longitudinal Health Literacy Training Program on Family Medicine Residents|Effects of a Longitudinal Health Literacy Training Program on Family Medicine Residents|Completed||N/A|12|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 21:55:36.044226|2018-05-31 21:55:36.044226
NCT01474720|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2013-09-16|2011-11-17|2011-11-18|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Zostavax in Systemic Lupus Erythematosus|Immunologic Response to Varicella Zoster Vaccination With Zostavax in Patients With Systemic Lupus Erythematosus|Completed||Phase 1|20|Actual|Oklahoma Medical Research Foundation||2|||f||||t||||||||||2018-05-31 21:55:36.118024|2018-05-31 21:55:36.118024
NCT01474707|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-11-26|2011-11-17|2011-11-18|Estimate|||||||2017-11-26|2017-11-28|Actual|January 2011||2011-01-31|November 2017|2017-11-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|COPD||Educational Interventions for Chronic Obstructive Pulmonary Disease (COPD) Self-management in Ethno-cultural Communities|Assessing Chronic Obstructive Pulmonary Disease (COPD) Knowledge, Beliefs, and Health Literacy in Chinese Immigrant Adults With a Diagnosis of COPD|Completed||N/A|120|Actual|University of British Columbia||4|||f||||t||||||||||2018-05-31 21:55:36.18671|2018-05-31 21:55:36.18671
NCT01474694|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2015-11-25|2011-11-17|2011-11-18|Estimate|||||||2015-11-25|2015-11-26|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CALS||Accuracy Assessment for Computer-assisted Surgical Interventions of the Liver|Accuracy Assessment for Computer-assisted Surgical Interventions of the Liver: A Prospective, Non Randomized Study|Completed|||14|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-05-31 21:55:36.274893|2018-05-31 21:55:36.274893
NCT01474681|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2017-04-03||2017-04-03|2011-11-17|2011-11-18|Estimate|2017-04-03|2017-05-12|Actual||||2017-04-03|2017-05-12|Actual|January 9, 2012|Actual|2012-01-09|March 2017|2017-03-31|October 3, 2016|Actual|2016-10-03|October 3, 2016|Actual|2016-10-03||Interventional|||Safety and Tolerability of HSC835 in Patients With Hematological Malignancies|A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies|Completed||Phase 1/Phase 2|27|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:55:36.405917|2018-05-31 21:55:36.405917
NCT01474668|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-11-01|2011-11-16|2011-11-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14c]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects|Completed||Phase 1|5|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 21:55:37.89508|2018-05-31 21:55:37.89508
NCT01474655|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2011-11-15|2011-11-15|2011-11-18|Estimate|||||||2011-11-15|2011-11-18|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal|Assessment of Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal|Completed||N/A|52|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 21:55:38.036696|2018-05-31 21:55:38.036696
NCT01474642|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2015-12-28|2011-11-15|2011-11-18|Estimate|||||||2015-12-28|2015-12-29|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional|||Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma|A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Genexol (XG) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma|Completed||Phase 2|64|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:55:38.128434|2018-05-31 21:55:38.128434
NCT01474629|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2013-04-09|2011-11-17|2011-11-18|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Probiotic Sport Study|Impact of Supplementation With Probiotics on Exercise-induced Oxidative Stress and Endotoxemia in Trained Men|Completed||N/A|24|Actual|Green Beat||2|||f||||t||||||||||2018-05-31 21:55:38.219374|2018-05-31 21:55:38.219374
NCT01474616|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-01-25|2011-11-17|2011-11-18|Estimate|||||||2017-01-25|2017-01-26|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|MOVE||Mobility of Vulnerable Elders (MOVE): Translating Knowledge to Health Care Aides in Long-term Care Facilities|Mobility of Vulnerable Elders (MOVE): Translating Knowledge to Health Care Aides in Long-term Care Facilities|Completed||N/A|113|Actual|University of Alberta||1|||f||||f||||||||||2018-05-31 21:55:38.288012|2018-05-31 21:55:38.288012
NCT01474603|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-03-14|2011-11-17|2011-11-18|Estimate|||||||2016-03-14|2016-03-16|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Observational|IMPEDE-DM2||Impact of n-3 Polyunsaturated Fatty Acids in a Protein-enriched Diet With Low GI in Type 2 Diabetes Patients|IMpact of n-3 Polyunsaturated Fatty Acids With a Protein-Enriched DiEt With Low Glycemic Index on Metabolic and Inflammatory Parameters in Type 2 Diabetic and Obese Patients: an Observational Pilot Study|Completed|||30|Actual|Medical University of Vienna|||1||f||||f||||||Samples Without DNA|"~     serum and plasma samples for biochemical analyses~   "|||2018-05-31 21:55:38.552504|2018-05-31 21:55:38.552504
NCT01474590|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2017-01-17||2017-08-25|2011-11-17|2011-11-18|Estimate|2017-08-25|2017-08-28|Actual||||2017-08-25|2017-08-28|Actual|November 2011||2011-11-30|August 2017|2017-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|POWER||Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne|Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With 200 mg Doxycycline Capsules Versus Vehicle Gel Associated With Isotretinoin Capsules in the Treatment of Severe Acne|Completed||Phase 3|266|Actual|Galderma||2|||f||||f||||||||||2018-05-31 21:55:38.674449|2018-05-31 21:55:38.674449
NCT01474577|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2018-04-06|2011-11-17|2011-11-18|Estimate|||||||2018-04-06|2018-04-09|Actual|November 8, 2011|Actual|2011-11-08|November 2016|2016-11-30|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Observational|||Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging||Completed|||57|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:55:38.947672|2018-05-31 21:55:38.947672
NCT01474564|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-10-03|2011-11-15|2011-11-18|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2011||2011-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma|Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma|Recruiting|||60|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:55:39.034846|2018-05-31 21:55:39.034846
NCT01474551|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2015-04-15||2015-10-20|2011-11-17|2011-11-18|Estimate|2015-04-15|2015-04-30|Estimate||||2015-10-20|2015-11-18|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation|A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation|Terminated||Phase 2|2|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 21:55:39.163674|2018-05-31 21:55:39.163674
NCT01474538|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2014-02-04||2014-02-04|2011-11-15|2011-11-18|Estimate|2014-02-04|2014-03-20|Estimate||||2014-02-04|2014-03-20|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All randomized participants who received at least 1 dose of study drug.|Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy|A Randomized, Double-Blind, Crossover Trial Comparing the Safety and Efficacy of Insulin Lispro With the Safety and Efficacy of Insulin Aspart in Subjects With Type 2 Diabetes on CSII Therapy|Completed||Phase 3|122|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:55:39.377611|2018-05-31 21:55:39.377611
NCT01474525|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-11-17|2011-11-15|2011-11-18|Estimate|||||||2011-11-17|2011-11-21|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Managing Diabetes During Pregnancy in the Wireless Age|Managing Diabetes During Pregnancy in the Wireless Age: a RCT of Glucose Telemonitoring|Unknown status|Recruiting|N/A|100|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 21:55:40.292193|2018-05-31 21:55:40.292193
NCT01474512|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2016-04-20|2014-09-29|2017-12-06|2011-11-17|2011-11-18|Estimate|2016-04-20|2016-05-27|Estimate|2014-09-29|2014-10-08|Estimate|2017-12-06|2017-12-29|Actual|November 2011||2011-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|June 2014|Actual|2014-06-30||Interventional|UNCOVER-1|All randomized participants who received at least 1 dose of study drug.|A Phase 3 Study in Participants With Moderate to Severe Psoriasis|A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis|Active, not recruiting||Phase 3|1296|Actual|Eli Lilly and Company||4|||f||||t||||||||||2018-05-31 21:55:40.591798|2018-05-31 21:55:40.591798
NCT01474499|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2012-09-24|2011-11-16|2011-11-18|Estimate|||||||2012-09-24|2012-09-25|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation|A Multi-center, Randomized, Single-blind Clinical Study of the Comparative Safety and Efficacy of Docusate Sodium and Sorbitol Rectal Solution and Glycerine Enemas in Patients With Constipation|Completed||Phase 3|300|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:55:44.157376|2018-05-31 21:55:44.157376
NCT01474486|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-02-21|2011-11-17|2011-11-18|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2010||2010-04-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure|Feasibility and Effectiveness of a Multi-Micronutrient Intervention as a Palliative Care Therapy in Patients With Congestive Heart Failure(CHF)|Completed||N/A|20|Actual|Phoenix VA Health Care System||1|||f||||t||||||||No||2018-05-31 21:55:44.268096|2018-05-31 21:55:44.268096
NCT01474473|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2014-04-08|2011-11-15|2011-11-18|Estimate|||||||2014-04-08|2014-04-09|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|DIAPLIQ||Efficacy Of CACIPLIQ20 On Diabetic Ulcers In Patients Wearing An Nonremovable, Windowed, Fiberglass Cast Boot|A Pilot Placebo-Controlled, Randomized and Double Blind Monocenter Study Evaluating CACIPLIQ20 Efficacy On Neuropathic Perforating Foot Ulcer Healing In Diabetic Patients Wearing An Irremovable Windowed Resin Cast|Completed||N/A|20|Actual|Organ, Tissue, Regeneration, Repair and Replacement||2|||f||||f||||||||||2018-05-31 21:55:44.377396|2018-05-31 21:55:44.377396
NCT01474460|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-03-07|2011-11-17|2011-11-18|Estimate|||||||2017-03-07|2017-03-09|Actual|September 2011||2011-09-30|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy|Use of Phytonadione to Reduce INR Variability in Patients on Long-term Warfarin Therapy|Completed||N/A|370|Actual|James A. Haley Veterans Administration Hospital||2|||f||||t||||||||No||2018-05-31 21:55:44.507524|2018-05-31 21:55:44.507524
NCT01474447|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2013-02-28|2011-11-17|2011-11-18|Estimate|||||||2013-02-28|2013-03-01|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Effect of Grinberg Method (GM) Intervention on Low-back Pain (LBP) and Improving the Quality of Life|The Research Protocol: The Effect of Grinberg Method (GM) Intervention on Low-back Pain (LBP) and Improving the Quality of Life|Unknown status|Recruiting|N/A|140|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||||2018-05-31 21:55:44.591335|2018-05-31 21:55:44.591335
NCT01474434|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|2015-06-04||2016-03-16|2011-11-15|2011-11-18|Estimate|2016-03-16|2016-04-14|Estimate||||2016-03-16|2016-04-14|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||The safety analysis set included all patients who received at least one dose of study drug.|Efficacy of LCQ908 on Cardiovascular Risk|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of LCQ908 on Cardiovascular Risk|Terminated||Phase 2|41|Actual|Novartis|The study was terminated based on the interim analysis on Part A, Cohort 1 after patients completed Part A. Part B was not conducted. Not all the planned assessments were completed due to the termination|2||The study was terminated based on interim analysis. See detailed description.|f||||||||||||||2018-05-31 21:55:44.777393|2018-05-31 21:55:44.777393
NCT01474421|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-05-02|2011-11-15|2011-11-18|Estimate|||||||2017-05-02|2017-05-05|Actual|September 15, 2011|Actual|2011-09-15|May 2017|2017-05-31|February 21, 2013|Actual|2013-02-21|February 21, 2013|Actual|2013-02-21||Interventional|||Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias|Completed||Phase 2|71|Actual|Novartis||3|||f|||||t|f||||||||2018-05-31 21:55:45.453246|2018-05-31 21:55:45.453246
NCT01474408|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-02-13|2011-11-15|2011-11-18|Estimate|||||||2017-02-13|2017-02-14|Actual|November 2011||2011-11-30|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Venous Function in Cardiovascular Disease Patients|Venous Function in Cardiovascular Disease Patients; The Neglected Part of Circulatory Regulation|Completed||N/A|10|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 21:55:45.661071|2018-05-31 21:55:45.661071
NCT01474395|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2012-10-24|2011-11-15|2011-11-18|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2012||2012-03-31|July 2011|2011-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia|NMDA and Cognitive Remediation in Schizophrenia|Unknown status|Recruiting|Phase 2|16|Anticipated|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-05-31 21:55:45.750768|2018-05-31 21:55:45.750768
NCT01474382|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2014-08-28|2011-11-16|2011-11-18|Estimate|||||||2014-08-28|2014-08-29|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients|A Phase 4, Multicenter, Randomized, Double-Blinded, Controlled Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients Undergoing Mandibular and Maxillary Procedures|Completed||Phase 4|150|Actual|Novocol Pharmaceutical of Canada, Inc.||2|||f||||t||||||||||2018-05-31 21:55:45.940174|2018-05-31 21:55:45.940174
NCT01474369|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-07-02|2011-11-15|2011-11-18|Estimate|||||||2013-07-02|2013-07-03|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease|A Phase 3, Randomized, Double Blind, Placebo Control, Multicenter Study to Evaluate the Efficacy and Safety of TAK- 438 (10 and 20 mg Once-Daily) in Patients With Non-Erosive Gastroesophageal Reflux Disease.|Completed||Phase 3|827|Actual|Takeda||3|||f||||f||||||||||2018-05-31 21:55:46.053127|2018-05-31 21:55:46.053127
NCT01474356|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-11-15|2011-11-15|2011-11-18|Estimate|||||||2011-11-15|2011-11-18|Estimate|November 2006||2006-11-30|November 2011|2011-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Hyperthermia Combined Brachytherapy in CCU|HDR Brachytherapy Combined With Interstitial Hyperthermia 500 kHz in Locally Advanced Cervical Cancer Patients. A Prospective Clinical Trial|Completed||Phase 3|224|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 21:55:46.28546|2018-05-31 21:55:46.28546
NCT01474343|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-05-05|2011-11-15|2011-11-18|Estimate|||||||2014-05-05|2014-05-06|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Intracerebral Gene Therapy for Sanfilippo Type A Syndrome|An Open-label, Single Arm, Monocentric, Phase I/II Clinical Study of Intracerebral Administration of Adeno-associated Viral Vector Serotype 10 Carrying the Human SGSH and SUMF1 cDNAs for the Treatment of Sanfilippo Type A Syndrome.|Completed||Phase 1/Phase 2|4|Actual|LYSOGENE||1|||f||||t||||||||||2018-05-31 21:55:46.367277|2018-05-31 21:55:46.367277
NCT01474330|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|||2016-03-25|2011-11-17|2011-11-18|Estimate|||||||2016-03-25|2016-03-28|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects|A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) Following Multiple Daily Doses in Healthy Male Subjects|Completed||Phase 1|33|Actual|Celgene Corporation||3|||f||||f||||||||||2018-05-31 21:55:46.466778|2018-05-31 21:55:46.466778
NCT01474317|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-16|2012-11-30||2016-01-29|2011-11-16|2011-11-18|Estimate|2012-11-30|2013-01-03|Estimate||||2016-01-29|2016-02-29|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study of an Investigational Glucose Meter System|Performance of the G3 Blood Glucose Monitoring System With TATSU Strip|Completed||N/A|226|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 21:55:46.57851|2018-05-31 21:55:46.57851
NCT01474304|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-09-27|2011-11-15|2011-11-18|Estimate|||||||2016-09-27|2016-09-29|Estimate|November 2011||2011-11-30|September 2016|2016-09-30||||June 2017|Anticipated|2017-06-30||Interventional|IVAC||Intravenous Acetaminophen for Craniotomy Patients|Intravenous Acetaminophen for Craniotomy Patients: A Single-blinded, Randomized Controlled Trial to Evaluate the Effect of Intravenous Acetaminophen Administered at Induction and Emergence From Craniotomy|Recruiting||Phase 2|80|Anticipated|Swedish Medical Center||2|||f||||f||||||||||2018-05-31 21:55:46.789501|2018-05-31 21:55:46.789501
NCT01474291|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2016-09-08||2016-09-08|2011-11-15|2011-11-18|Estimate|2016-09-08|2016-10-28|Estimate||||2016-09-08|2016-10-28|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|ACT SOLO|Efficacy population, defined as all participants who received at least one infusion of tocilizumab and who met all inclusion and exclusion criteria.|An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice|Evaluation of Factors Influencing Use of RoActemra® as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO|Completed|||608|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:55:47.329956|2018-05-31 21:55:47.329956
NCT01474278|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-11-01|2011-11-15|2011-11-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of RO5028442 in Adult Male High-Functioning Autistic Patients|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients|Completed||Phase 1|19|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:55:48.832067|2018-05-31 21:55:48.832067
NCT01474265|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-10-24|2011-11-15|2011-11-18|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2011||2011-11-30|October 2017|2017-10-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Sympathovagal Balance in Smoking Cessation|Alterations in the Autonomic Nervous System During Smoking Quit Attempts- Possible Effects of Pharmacological Interventions|Completed||Phase 4|85|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||5|||f||||f||||||||||2018-05-31 21:55:49.028446|2018-05-31 21:55:49.028446
NCT01474252|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-06-01|2011-11-17|2011-11-18|Estimate|||||||2016-06-01|2016-06-02|Estimate|July 2008||2008-07-31|June 2016|2016-06-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Intubation Duration Between Rapid Sequence Intubation (RSI) Technique and Non-RSI Technique|Comparison of Intubation Duration Between Rapid Sequence Intubation Technique and Non- Rapid Sequence Intubation Technique in Siriraj Hospital by Emergency Medicine Residences|Completed||Phase 4|224|Actual|Siriraj Hospital||2|||f||||t||||||||||2018-05-31 21:55:49.103388|2018-05-31 21:55:49.103388
NCT01474239|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2015-07-09||2016-02-16|2011-11-15|2011-11-18|Estimate|2015-07-09|2015-08-07|Estimate||||2016-02-16|2016-03-15|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Safety population included all randomized participants with at least one administration of the study drug and at least one safety assessment.|A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma|Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma|Completed||Phase 2|91|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:55:49.226068|2018-05-31 21:55:49.226068
NCT01474226|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2013-07-26|2011-11-17|2011-11-18|Estimate|||||||2013-07-26|2013-07-29|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Metabolic Availability of Lysine From Rice|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From Cooked Rice Protein in Adult Men|Completed||Phase 1|5|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 21:55:51.498625|2018-05-31 21:55:51.498625
NCT01474213|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2012-06-06||2012-10-22|2011-11-15|2011-11-18|Estimate|2012-10-22|2012-11-21|Estimate||||2012-10-22|2012-11-21|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Sedation Effect of Dexmedetomidine Versus Remifentanil to Fibreoptic Intubation|Dexmedetomidine Versus Remifentanil Target Controlled Infusion for Sedation During Awake Fibreoptic Nasotracheal Intubation|Completed||Phase 4|42|Actual|Shanghai 9th People's Hospital|The sample number is relatively small|2|||f||||t||||||||||2018-05-31 21:55:51.642667|2018-05-31 21:55:51.642667
NCT01474200|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|2015-07-23||2017-04-04|2011-11-15|2011-11-18|Estimate|2015-09-11|2015-10-12|Estimate||||2017-04-04|2017-05-10|Actual|January 2012||2012-01-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|AVOID-HF|3 patients in the IV Loop Diuretics (LD) arm were randomized, but withdrawn from the study prior to beginning study treatment. These patients are excluded from the number of baseline participants (analysis population).|Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment|Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure (AVOID-HF)|Terminated||N/A|224|Actual|Baxter Healthcare Corporation|Due to patient recruitment challenges, the study was terminated early. At that time, no interim analyses of the data had been completed; therefore the decision to close the study was not related to any underlying concerns about safety or futility.|2||"Closed due to patient recruitment challenges. No interim analyses were completed; study closure~   was not related to any concerns about safety or futility."|f||||t||||||||||2018-05-31 21:55:52.135856|2018-05-31 21:55:52.135856
NCT01474187|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2011-11-15|2011-11-15|2011-11-18|Estimate|||||||2011-11-15|2011-11-18|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer|Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer|Unknown status|Recruiting|Phase 1|60|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 21:55:53.310692|2018-05-31 21:55:53.310692
NCT01474174|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-07-28|2011-11-15|2011-11-18|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2011|Actual|2011-09-30|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors|A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors|Completed|||38|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 21:55:53.425914|2018-05-31 21:55:53.425914
NCT01474161|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2012-11-23|2011-11-17|2011-11-18|Estimate|||||||2012-11-23|2012-11-27|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505|Comparative Bioavailability Study of a New GFT505 Formulation With the Existing One After 120 mg Single Oral GFT505 Administration and Assessment of the Gender Effect in Young Healthy Male and Female Volunteers Followed by a Single and Multiple Ascending Dose Safety, Tolerability and Pharmacokinetic Study of GFT505 in Overweight or Obese Subjects and in Diabetic Patients|Completed||Phase 1|96|Actual|Genfit||3|||f||||f||||||||||2018-05-31 21:55:53.609197|2018-05-31 21:55:53.609197
NCT01474148|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-03-28|2011-11-15|2011-11-18|Estimate|||||||2018-03-28|2018-03-29|Actual|July 1, 2011|Actual|2011-07-01|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|Trunk Protocol||A Neuroprosthesis for Seated Posture and Balance|A Neuroprosthesis for Seated Posture and Balance|Recruiting||N/A|10|Anticipated|VA Office of Research and Development||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 21:55:53.699615|2018-05-31 21:55:53.699615
NCT01474135|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11||2014-02-17|2016-09-12|2011-11-17|2011-11-18|Estimate||||2014-03-25|2014-04-21|Estimate|2016-09-12|2016-09-23|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure|A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of Two AR 12286/Travoprost Fixed-dose Combination Products Compared to Travatan® Z in Patients With Elevated Intraocular Pressure|Completed||Phase 2|93|Actual|Aerie Pharmaceuticals||3|||f||||f||||||||||2018-05-31 21:55:53.808712|2018-05-31 21:55:53.808712
NCT01474122|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2015-01-19||2016-11-22|2011-11-15|2011-11-18|Estimate|2015-01-19|2015-01-28|Estimate||||2016-11-22|2017-01-23|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|DUAL-2|Full analysis set|Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis|Terminated||Phase 3|265|Actual|Actelion||3||company decision|f||||t||||||||||2018-05-31 21:55:53.945848|2018-05-31 21:55:53.945848
NCT01474109|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2014-12-03||2015-01-02|2011-11-15|2011-11-18|Estimate|2015-01-02|2015-01-06|Estimate||||2015-01-02|2015-01-06|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|DUAL-1|Full analysis set|Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis|Completed||Phase 3|289|Actual|Actelion||3|||f||||t||||||||||2018-05-31 21:55:55.951045|2018-05-31 21:55:55.951045
NCT01474096|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2015-04-08|2011-11-17|2011-11-18|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Implementation Strategy for a Breastfeeding Guideline in Primary Care|Effectiveness of Implementation Strategy for a Breastfeeding Guideline in Primary Care: Cluster Randomised Trial|Completed||N/A|208|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 21:55:57.382879|2018-05-31 21:55:57.382879
NCT01474083|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15||2012-10-03|2013-09-03|2011-11-15|2011-11-18|Estimate||||2012-10-03|2012-10-05|Estimate|2013-09-03|2013-09-13|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GK1-399 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|248|Actual|vTv Therapeutics||4|||f||||t||||||||||2018-05-31 21:55:57.469678|2018-05-31 21:55:57.469678
NCT01474070|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2016-10-17|2011-11-14|2011-11-17|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||GAT-DCT-Discordance Due to Corneal Properties|Influence of Discordant Intraocular Eye Pressure Readings Taken by Dynamic Contour Tonometry and Goldmann Applanation Tonometry|Completed|||112|Actual|University of Zurich|||||f||||f||||||||No||2018-05-31 21:55:57.559572|2018-05-31 21:55:57.559572
NCT01474057|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2012-01-11|2011-11-14|2011-11-17|Estimate|||||||2012-01-11|2012-01-12|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DESTRESS-PC||DElivery of Self Training and Education for Stressful Situations-Primary Care Version|"Online Early Resilience Intervention for Combat-Related PTSD in Military Primary Healthcare Settings: A Randomized Trial of DESTRESS-PC"|Completed||Phase 2|133|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t||||||||||2018-05-31 21:55:57.623917|2018-05-31 21:55:57.623917
NCT01474044|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2013-07-06|2011-11-14|2011-11-17|Estimate|||||||2013-07-06|2013-07-09|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||To Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis (CAG)|A Phase IV Study to Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis|Completed||Phase 4|851|Actual|Xinjiang Biochemical Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:55:57.77738|2018-05-31 21:55:57.77738
NCT01474031|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-14|2011-11-14|2011-11-17|Estimate|||||||2011-11-14|2011-11-17|Estimate|October 2011||2011-10-31|August 2011|2011-08-31||||||||Observational|||Prospective Study Deltamotion - DAA THA Study|Prospective Study Deltamotion - DAA THA Study|Unknown status|Recruiting||40|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 21:55:58.267815|2018-05-31 21:55:58.267815
NCT01474018|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2014-05-20|2011-11-14|2011-11-17|Estimate|||||||2014-05-20|2014-05-22|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes|QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes|Completed||Phase 4|15|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 21:55:58.612009|2018-05-31 21:55:58.612009
NCT01474005|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-06-28|2011-11-14|2011-11-17|Estimate|||||||2012-06-28|2012-07-02|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|LA||Establishment of an Artificial Larynx After Total Laryngectomy|Establishment of an Artificial Larynx After Total Laryngectomy|Unknown status|Recruiting|N/A|5|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 21:55:58.933859|2018-05-31 21:55:58.933859
NCT01473992|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2014-05-06||2014-11-20|2011-11-14|2011-11-17|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-20|2014-11-26|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Comparative Outcomes Assessment of the C-Leg With a New Knee Prosthesis|Comparative Outcomes Assessment of the C-Leg With a New Knee Prosthesis|Completed||N/A|25|Actual|University of South Florida||3|||f||||t||||||||||2018-05-31 21:55:59.243358|2018-05-31 21:55:59.243358
NCT01473979|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2012-01-24|2011-11-14|2011-11-17|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|July 2014|Anticipated|2014-07-31|January 2014|Anticipated|2014-01-31||Interventional|||Delayed Primary Versus Late Secondary Wound Closure in Sternum Infections|Delayed Primary Versus Late Secondary Wound Closure in the Treatment of Postsurgical Sternum Osteomyelitis|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 21:56:00.969315|2018-05-31 21:56:00.969315
NCT01473966|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-11-14|2011-11-14|2011-11-17|Estimate|||||||2011-11-14|2011-11-17|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Coffee Against Obstipation in Intensive Care Treatment|Coffee Against Obstipation in Intensive Care Treatment|Unknown status|Enrolling by invitation|N/A|120|Anticipated|University Hospital Heidelberg||3|||f||||f||||||||||2018-05-31 21:56:01.58696|2018-05-31 21:56:01.58696
NCT01473953|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2013-06-20||2017-03-22|2011-11-14|2011-11-17|Estimate|2013-06-20|2013-09-04|Estimate||||2017-03-22|2017-03-23|Actual|October 2011||2011-10-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects|Completed||Phase 1|31|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-05-31 21:56:02.119594|2018-05-31 21:56:02.119594
NCT01473940|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2017-04-11|2011-11-14|2011-11-17|Estimate|||||||2017-04-11|2017-04-12|Actual|April 2012||2012-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery|Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study|Active, not recruiting||Phase 1|21|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 21:56:04.752245|2018-05-31 21:56:04.752245
NCT01473927|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-03-11|2011-11-14|2011-11-17|Estimate|||||||2014-03-11|2014-03-12|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|||Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease|Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease|Completed|||136|Actual|University of Bern|||2||f||||f||||||Samples With DNA|"~     Serum Stool~   "|||2018-05-31 21:56:04.934013|2018-05-31 21:56:04.934013
NCT01473914|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2016-12-14|2011-11-14|2011-11-17|Estimate|||||||2016-12-14|2016-12-16|Estimate|November 2012||2012-11-30|December 2016|2016-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Trace Element Replenishment Study in Hemodialysis Patients|Trace Element Replenishment Study in Hemodialysis Patients|Completed||Phase 3|150|Actual|University of Alberta||3|||f||||f||||||||No||2018-05-31 21:56:05.064224|2018-05-31 21:56:05.064224
NCT01473901|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2017-09-12|2011-11-14|2011-11-17|Estimate|||||||2017-09-12|2017-09-13|Actual|December 30, 2011|Actual|2011-12-30|September 2017|2017-09-30|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|Completed||Phase 1|38|Actual|Novartis||2|||f||||f|t|f||||||No||2018-05-31 21:56:05.266985|2018-05-31 21:56:05.266985
NCT01473888|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2012-11-07|2011-11-14|2011-11-17|Estimate|||||||2012-11-07|2012-11-08|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|||A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes|An Open-label, One-sequence, Two Periods, Crossover Trial Study to Evaluate the Effect of T89 on the Pharmacokinetics of Five CYP450 Substrates Cocktail in Healthy Subjects|Completed||Phase 1|24|Actual|Tasly Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 21:56:05.43206|2018-05-31 21:56:05.43206
NCT01473875|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10||2017-02-17|2017-02-17|2011-11-14|2011-11-17|Estimate||||2017-02-17|2017-02-20|Actual|2017-02-17|2017-02-20|Actual|November 2011||2011-11-30|February 2017|2017-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102|An Open Label Multicenter Extension Study to Evaluate the Long-term Efficacy and Safety of SBC-102 in Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102|Terminated||Phase 2/Phase 3|10|Actual|Alexion Pharmaceuticals||1||Study has been merged with NCT01371825|f||||f||||||||Undecided||2018-05-31 21:56:05.582596|2018-05-31 21:56:05.582596
NCT01473862|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2016-08-11|2011-11-14|2011-11-17|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|December 2013|Actual|2013-12-31||Observational|ALOSS||Adolescent Loss: The Impact of Loss on Adolescent Oncology Patients|Adolescent Loss: The Impact of Loss on Adolescent Oncology Patients|Completed|||153|Actual|St. Jude Children's Research Hospital|||||f||||f||||||||||2018-05-31 21:56:05.786381|2018-05-31 21:56:05.786381
NCT01473849|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2012-12-19|2011-11-16|2011-11-17|Estimate|||||||2012-12-19|2012-12-20|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Observational|VHENUS||Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients|Non-interventional, Prospective Study to Evaluate the Impact of CMV Replication Over Hepatitis C Recurrence in Liver Transplant Recipients|Unknown status|Active, not recruiting||179|Anticipated|Sociedad Española de Trasplante Hepático|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:56:05.912879|2018-05-31 21:56:05.912879
NCT01473836|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2013-10-10||2013-12-18|2011-11-14|2011-11-17|Estimate|2013-10-10|2013-12-10|Estimate||||2013-12-18|2014-01-24|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection|A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone|Completed||Phase 3|38|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:56:06.317529|2018-05-31 21:56:06.317529
NCT01473823|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-03-02|2011-11-14|2011-11-17|Estimate|||||||2012-03-02|2012-03-05|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31||Interventional|Omega-Treat||Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood|Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood|Enrolling by invitation||N/A|160|Anticipated|Ostergotland County Council, Sweden||2|||f||||f||||||||||2018-05-31 21:56:06.768571|2018-05-31 21:56:06.768571
NCT01473810|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-06-19|2011-11-14|2011-11-17|Estimate|||||||2012-06-19|2012-06-20|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant|Immunotherapy of HIV-infected Patients: A Single-blinded, Randomized, Immunogenicity, Pilot Study of Intranasal Administration of Vacc-4x With Endocine as Adjuvant|Completed||Phase 1/Phase 2|24|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-05-31 21:56:06.88236|2018-05-31 21:56:06.88236
NCT01473797|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2017-12-07|2011-11-16|2011-11-17|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2011||2011-11-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ECLA||Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis|Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function|Active, not recruiting||Phase 2|10|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 21:56:06.984662|2018-05-31 21:56:06.984662
NCT01473784|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-04-03|2011-11-14|2011-11-17|Estimate|||||||2017-04-03|2017-04-05|Actual|December 3, 2007|Actual|2007-12-03|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck|A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System|Recruiting||N/A|360|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:56:07.065355|2018-05-31 21:56:07.065355
NCT01473771|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-09-12|2011-11-16|2011-11-17|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2011||2011-11-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Caring Letters for Military Suicide Prevention|Caring Letters for Military Suicide Prevention: A Randomized Controlled Trial|Active, not recruiting||N/A|4730|Anticipated|National Center for Telehealth and Technology||2|||f||||f||||||||||2018-05-31 21:56:07.194832|2018-05-31 21:56:07.194832
NCT01473758|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2015-07-23|2015-02-20|2016-12-22|2011-11-14|2011-11-17|Estimate|2016-08-31|2016-10-24|Estimate|2015-02-20|2015-03-11|Estimate|2016-12-22|2017-02-14|Actual|February 2012||2012-02-29|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|TREAT|Full Analysis set consisted of all randomized patients who received at least 1 dose of investigational medicinal product (IMP)|Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Effect of Roflumilast 500 μg Tablets Once Daily at Acute COPD Exacerbations Treated With Standard Therapy of Oral Steroids and Antibiotics. A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial|Terminated||Phase 2|81|Actual|AstraZeneca||2||Company decision: No Safety or Efficacy Concerns|f||||f||||||||||2018-05-31 21:56:07.354561|2018-05-31 21:56:07.354561
NCT01473745|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2014-08-06||2014-10-28|2011-11-16|2011-11-17|Estimate|2014-08-26|2014-09-08|Estimate||||2014-10-28|2014-11-04|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional||Taiwanese Class III patients|The Nasal Changes Affected by Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy|The Nasal Changes Affected by 2 Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy--A Randomized Controlled Trial|Completed||Phase 2/Phase 3|48|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:56:10.607187|2018-05-31 21:56:10.607187
NCT01473225|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2015-05-19|2011-11-16|2011-11-17|Estimate|||||||2015-05-19|2015-05-21|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|September 2014||2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Can Calorie Labels Increase Caloric Intake|Can Calorie Labels Increase Caloric Intake? A Test of Possible Perverse Effects of Calorie Labels|Withdrawn||N/A|0|Actual|Carnegie Mellon University||2||Funding was pulled after unsuccessful pilot study|f||||||||||||||2018-05-31 21:56:23.42458|2018-05-31 21:56:23.42458
NCT01473732|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-16|2011-11-16|2011-11-17|Estimate|||||||2011-11-16|2011-11-17|Estimate|November 2011||2011-11-30|November 2011|2011-11-30||||December 2013|Anticipated|2013-12-31||Interventional|||Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity|Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity|Unknown status|Active, not recruiting|N/A|30|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 21:56:11.271841|2018-05-31 21:56:11.271841
NCT01473719|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-09-15|2011-11-15|2011-11-17|Estimate|||||||2017-09-15|2017-09-18|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|HEAT||Emerging Adults Who Use Alcohol and Marijuana|Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana|Completed||Phase 3|566|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 21:56:11.380048|2018-05-31 21:56:11.380048
NCT01473706|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2013-07-16|2011-11-14|2011-11-17|Estimate|||||||2013-07-16|2013-07-17|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Observational|||Validation of a Nutrition Screening Tool|Mini Nutritional Assessment: Consumer Validation|Completed|||463|Actual|Nestlé|||2||f||||f||||||||||2018-05-31 21:56:11.505211|2018-05-31 21:56:11.505211
NCT01473693|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-01-14|2011-11-14|2011-11-17|Estimate|||||||2014-01-14|2014-01-16|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging|Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging|Terminated|||1|Actual|Memorial Sloan Kettering Cancer Center|||2|Lack of Accrual|f||||||||||||||2018-05-31 21:56:11.604184|2018-05-31 21:56:11.604184
NCT01473680|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2012-09-12|2011-11-14|2011-11-17|Estimate|||||||2012-09-12|2012-09-13|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients|Pilot Study of Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients|Terminated|||2|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-05-31 21:56:11.707013|2018-05-31 21:56:11.707013
NCT01473667|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-11-05|2011-11-16|2011-11-17|Estimate|||||||2015-11-05|2015-11-06|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|March 2015|Actual|2015-03-31||Interventional|||Superficial Cervical Plexus Block for Pacemaker Insertion|Superficial Cervical Plexus Block for Pacemaker Insertion|Terminated||N/A|30|Actual|Mayo Clinic||2||change in practice occured|f||||f||||||||||2018-05-31 21:56:11.790269|2018-05-31 21:56:11.790269
NCT01473654|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2014-08-11|2011-11-16|2011-11-17|Estimate|||||||2014-08-11|2014-08-12|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|ADAPT||The Avoiding Diabetes Thru Action Plan Targeting Pilot Randomized Control Trial|Avoiding Diabetes Thru Action Plan Targeting (ADAPT): A Pilot Randomized Control Trial of an Electronic Medical Record Embedded Prediabetes Shared Goal Setting Tool in Primary Care|Completed||N/A|60|Actual|Boston University||2|||f||||f||||||||||2018-05-31 21:56:11.84936|2018-05-31 21:56:11.84936
NCT01473641|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-05-17|2011-11-16|2011-11-17|Estimate|||||||2017-05-17|2017-05-18|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|NORA||Nexplanon Observational Risk Assessment Study (NORA)|Nexplanon Observational Risk Assessment Study (NORA)|Active, not recruiting|||7384|Actual|Center for Epidemiology and Health Research, Germany|||1||f||||t||||||||||2018-05-31 21:56:11.920452|2018-05-31 21:56:11.920452
NCT01473628|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2018-05-02|2011-11-14|2011-11-17|Estimate|||||||2018-05-02|2018-05-07|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|May 2028|Anticipated|2028-05-31|May 2027|Anticipated|2027-05-31||Interventional|||Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II|Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II|Recruiting||Phase 1/Phase 2|130|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:56:11.991354|2018-05-31 21:56:11.991354
NCT01473615|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-05-06|2011-11-14|2011-11-17|Estimate|||||||2013-05-06|2013-05-07|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression|Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression|Unknown status|Active, not recruiting|N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:56:12.081733|2018-05-31 21:56:12.081733
NCT01473602|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2014-11-10||2015-04-10|2011-11-14|2011-11-17|Estimate|2014-11-10|2014-11-17|Estimate||||2015-04-10|2015-04-16|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Full Analysis Set: All randomized participants who received at least 1 dose of study drug.|Second Study of the Effect of Teriparatide on Hip Fracture Healing|Second Study of the Effect of Teriparatide on Femoral Neck Fracture Healing|Completed||Phase 3|39|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 21:56:12.298859|2018-05-31 21:56:12.298859
NCT01473589|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2014-11-10||2015-04-10|2011-11-14|2011-11-17|Estimate|2014-11-10|2014-11-17|Estimate||||2015-04-10|2015-04-16|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug.|Effect of Teriparatide on Hip Fracture Healing|Effect of Teriparatide on Femoral Neck Fracture Healing|Completed||Phase 3|122|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 21:56:15.150992|2018-05-31 21:56:15.150992
NCT01473576|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2016-04-14|2011-11-14|2011-11-17|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional|PRO-Nitrate||Impact of Nitrate Ingestion on Protein Synthesis|The Impact of Dietary Nitrate Ingestion on Muscle Protein Synthesis in Elderly Type II Diabetics|Completed||N/A|25|Actual|Maastricht University Medical Center||2|||f||||f||||||||No||2018-05-31 21:56:16.890633|2018-05-31 21:56:16.890633
NCT01473407|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02||2015-02-23|2015-05-01|2011-11-16|2011-11-17|Estimate||||2015-02-23|2015-03-11|Estimate|2015-05-01|2015-05-20|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|AiME - 01||A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin|A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|Completed||Phase 3|612|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-05-31 21:56:20.189372|2018-05-31 21:56:20.189372
NCT01473563|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2014-06-12||2014-10-03|2011-11-14|2011-11-17|Estimate|2014-10-03|2014-10-06|Estimate||||2014-10-03|2014-10-06|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Safety Population: Participants who received at least 1 dose of study drug.|A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)|Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed After Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study|Completed||Phase 2|52|Actual|Eli Lilly and Company|A thorough literature search revealed that no specific validated questionnaire was available to assess participant and physician satisfaction with home care or resource utilization, therefore specific questions were created by the sponsor for use.|1|||f||||f||||||||||2018-05-31 21:56:17.008926|2018-05-31 21:56:17.008926
NCT01473550|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2016-03-04|2011-11-14|2011-11-17|Estimate|||||||2016-03-04|2016-03-07|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MHEN||Mental Health Engagement Network (MHEN)|Mental Health Engagement Network (MHEN): Connecting Clients With Their Health Team|Completed||N/A|400|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:56:17.794897|2018-05-31 21:56:17.794897
NCT01473537|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-09-21|2011-11-14|2011-11-17|Estimate|||||||2012-09-21|2012-09-25|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|Fluor-Ca||Optimised Fluoride Prevention by Double Rinse With Fluoride and Calcium|A Double Blind, Randomized, Cross Over Designed Trial of Fluoride Prevention by Double Rinse With Calcium and Fluoride|Completed||Phase 1|9|Actual|Karolinska Institutet||3|||f||||t||||||||||2018-05-31 21:56:17.896155|2018-05-31 21:56:17.896155
NCT01473524|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2016-12-20||2018-03-09|2011-11-16|2011-11-17|Estimate|2016-12-20|2017-02-13|Actual||||2018-03-09|2018-04-03|Actual|January 2012||2012-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 2013|Actual|2013-12-31||Interventional|POISE|71 subjects were randomized in the OCA 5-10 mg group, however 1 subject never received treatment. Therefore, the Baseline Analysis Population of 70 subjects is the Intent-to-Treat Population|Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis|A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis|Active, not recruiting||Phase 3|217|Actual|Intercept Pharmaceuticals||3|||f||||t||||||||||2018-05-31 21:56:18.023808|2018-05-31 21:56:18.023808
NCT01473511|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2016-09-01|2011-11-14|2011-11-17|Estimate|||||||2016-09-01|2016-09-02|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|SF-ON||Strongest Families Ontario (Formerly the Family Help Program)|Delivering Intervention for Pediatric Behaviour Problems at a Distance: a Randomized Trial of Strongest Families Ontario|Completed||Phase 3|172|Actual|IWK Health Centre||2|||f||||t||||||||No|Aggregate summary data would be made available but not individual data.|2018-05-31 21:56:19.225062|2018-05-31 21:56:19.225062
NCT01473498|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-05-09|2011-11-14|2011-11-17|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|DORESEP||Personalized Mean Arterial Pressure Management on Renal Function During Septic Shock|Personalized Haemodynamic Management of Septic Shock: Influence of Mean Arterial Pressure Level on Renal Function: Randomized Controlled Trial|Completed||N/A|27|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:56:19.296214|2018-05-31 21:56:19.296214
NCT01473485|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2018-03-26|2011-11-14|2011-11-17|Estimate|||||||2018-03-26|2018-03-27|Actual|April 2011||2011-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors|A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors|Recruiting||N/A|10|Anticipated|InSightec||1|||f||||f||||||||||2018-05-31 21:56:19.39503|2018-05-31 21:56:19.39503
NCT01473472|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2017-05-10|2011-11-14|2011-11-17|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2012||2012-01-31|May 2017|2017-05-31|December 15, 2016|Actual|2016-12-15|June 30, 2016|Actual|2016-06-30||Interventional|IPERGAY||On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men|On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men|Completed||Phase 3|400|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||No||2018-05-31 21:56:19.606916|2018-05-31 21:56:19.606916
NCT01473459|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-04-25|2011-11-16|2011-11-17|Estimate|||||||2012-04-25|2012-04-26|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients|Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 21:56:19.700408|2018-05-31 21:56:19.700408
NCT01473446|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-03-27|2011-11-16|2011-11-17|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2012||2012-01-31|March 2013|2013-03-31||||December 2013|Actual|2013-12-31||Interventional|||Traditional Versus Goal Directed Perioperative Fluid Therapy in High Risk Patients|Traditional Versus Goal Directed Perioperative Fluid Therapy in High Risk Patients. A Randomized, Assessor-blinded Study|Terminated||N/A|30|Actual|Haukeland University Hospital||2||High exclusion rate|f||||f||||||||||2018-05-31 21:56:19.796094|2018-05-31 21:56:19.796094
NCT01473433|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-07-23|2011-11-16|2011-11-17|Estimate|||||||2015-07-23|2015-07-24|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|adiFLAP||Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial)|Randomized Trial to Evaluate the Safety and Efficacy of a New Surgical Approach to Cardiac Regeneration: Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial)|Completed||Phase 1/Phase 2|10|Actual|Germans Trias i Pujol Hospital||2|||f||||||||||||||2018-05-31 21:56:19.890403|2018-05-31 21:56:19.890403
NCT01473420|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02||2015-02-23|2015-05-01|2011-11-16|2011-11-17|Estimate||||2015-02-23|2015-03-11|Estimate|2015-05-01|2015-05-20|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|AiME - 13||A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin|A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|Completed||Phase 3|320|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-05-31 21:56:20.035829|2018-05-31 21:56:20.035829
NCT01473394|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2014-02-21||2014-02-21|2011-11-16|2011-11-17|Estimate|2014-02-21|2014-04-03|Estimate||||2014-02-21|2014-04-03|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Safety population: All randomized participants who received at least 1 dose of double-blind investigational product.|Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder|A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder|Completed||Phase 4|518|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 21:56:20.35746|2018-05-31 21:56:20.35746
NCT01473381|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2014-06-13||2014-08-06|2011-11-16|2011-11-17|Estimate|2014-08-06|2014-08-08|Estimate||||2014-08-06|2014-08-08|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|VLZ-MD-01|Safety population: All randomized participants who received at least 1 dose of double-blind investigational product (placebo, vilazodone, or citalopram).|Safety and Efficacy of Vilazodone in Major Depressive Disorder|A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder|Completed||Phase 4|1162|Actual|Forest Laboratories||4|||f||||f||||||||||2018-05-31 21:56:20.871542|2018-05-31 21:56:20.871542
NCT01473368|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|2016-03-30||2017-03-03|2011-11-16|2011-11-17|Estimate|2016-09-06|2016-09-09|Estimate||||2017-03-03|2017-04-04|Actual|April 2012||2012-04-30|March 2017|2017-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota|Open Label, Randomized Pilot Study to Examine The Effects of the Probiotic Saccharomyces Boulardii, the Antibiotic Amoxicillin/Clavulanate and the Combination on the Gut Microbiota of Healthy Volunteers|Completed||N/A|53|Actual|Beth Israel Deaconess Medical Center||4|||f||||f||||||||||2018-05-31 21:56:21.844047|2018-05-31 21:56:21.844047
NCT01473355|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-08-21|2011-11-15|2011-11-17|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2011||2011-10-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|September 2014|Actual|2014-09-30||Interventional|||Study on OsseoSpeed™ TX Narrow Implants in the Lower Jaw in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate OsseoSpeed™ TX Single Implant 3 mm Diameter in the Anterior Mandible. A 3-years Follow-up Study.|Completed||N/A|45|Actual|Dentsply Sirona Implants||1|||f||||||||||||||2018-05-31 21:56:22.426792|2018-05-31 21:56:22.426792
NCT01473342|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-10-23|2011-11-16|2011-11-17|Estimate|||||||2014-10-23|2014-10-24|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|September 2013|Actual|2013-09-30||Interventional|||Mila Blooms Intervention Study|Mila Blooms Intervention Study: An App for Promoting Physical Activity and Health Diet Among Adolescent Survivors of Childhood Cancer|Completed||N/A|21|Actual|Duke University||1|||f||||t||||||||||2018-05-31 21:56:22.508448|2018-05-31 21:56:22.508448
NCT01473329|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-18|2011-11-14|2011-11-17|Estimate|||||||2011-11-18|2011-11-21|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Structured Diabetes Self-Management Education in Primary Care and Metabolic Control|Structured Diabetes Self-Management Education in Primary Care and Metabolic Control: a Randomized Clinical Trial.|Completed||N/A|138|Actual|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-05-31 21:56:22.582421|2018-05-31 21:56:22.582421
NCT01473316|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-11-01|2011-11-14|2011-11-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980|An Open-Label, Fixed-Sequence, 2-Period Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980|Completed||Phase 1|22|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 21:56:22.633452|2018-05-31 21:56:22.633452
NCT01473303|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-06-27|2011-11-15|2011-11-17|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2012||2012-08-31|June 2016|2016-06-30||||August 2012|Actual|2012-08-31||Interventional|||Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer|Phase IB/Randomized Phase II Study of Folfirinox Plus AMG-479 (Ganitumab) or Placebo in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Alliance for Clinical Trials in Oncology||2||"CALGB 81003 closed about a week after it was activated because of withdrawal of support. No~   patients were registered on this study."|f||||||||||||||2018-05-31 21:56:22.70861|2018-05-31 21:56:22.70861
NCT01473290|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2016-07-01|2011-11-15|2011-11-17|Estimate|||||||2016-07-01|2016-07-06|Estimate||||July 2016|2016-07-31||||||||Interventional|||Probiotic Therapy in Preventing Gastrointestinal Complications in Patients Undergoing Chemotherapy and Pelvic Radiation Therapy|A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy|Withdrawn||Phase 3|0|Actual|Alliance for Clinical Trials in Oncology||2||The study was not activated.|f||||||||||||||2018-05-31 21:56:22.813572|2018-05-31 21:56:22.813572
NCT01473277|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-14|2011-11-14|2011-11-17|Estimate|||||||2011-11-14|2011-11-17|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|January 2013|Anticipated|2013-01-31|June 2012|Anticipated|2012-06-30||Interventional|||Botulinum Toxin Type A (BT-A) in Hemiplegic Shoulder Pain Versus Steroid|Intra-articular Injection of Botulinum Toxin Type A in Hemiplegic Shoulder Pain: a Multicentric, Double Blind Randomised, Versus Steroid Study|Unknown status|Not yet recruiting|Phase 2|52|Anticipated|The Foundation Institute San Raffaele G. Giglio of Cefalù||2|||f||||t||||||||||2018-05-31 21:56:22.981454|2018-05-31 21:56:22.981454
NCT01473264|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-16|2011-11-16|2011-11-17|Estimate|||||||2011-11-16|2011-11-17|Estimate|January 2000||2000-01-31|November 2011|2011-11-30|December 2003|Actual|2003-12-31|June 2002|Actual|2002-06-30||Interventional|||Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)|Safety and Tolerability of Recombinant Human Clara Cell 10kDa Protein (rhCC10) Delivered Intratracheally to Premature Neonates With Respiratory Distress Syndrome|Completed||Phase 1/Phase 2|22|Actual|Clarassance, Inc.||3|||f||||t||||||||||2018-05-31 21:56:23.091364|2018-05-31 21:56:23.091364
NCT01473251|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-12-16|2011-11-14|2011-11-17|Estimate|||||||2014-12-16|2014-12-17|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration|Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration|Completed||N/A|16|Actual|Vitreo-Retinal Associates, Michigan||3|||f||||f||||||||||2018-05-31 21:56:23.19616|2018-05-31 21:56:23.19616
NCT01473238|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2013-08-22|2011-11-16|2011-11-17|Estimate|||||||2013-08-22|2013-08-23|Estimate|January 2014||2014-01-31|August 2013|2013-08-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Desktop Versus Mobile Data Collection in Clinical Trial|Desktop vs. Mobile Data Collection in a Prospective Multicenter Clinical Trial|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 21:56:23.263172|2018-05-31 21:56:23.263172
NCT01473186|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2015-05-29|2011-11-16|2011-11-17|Estimate|||||||2015-05-29|2015-06-02|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Study of Menstrual Irregularities and Endometrial Pathology in Women Undergoing Bariatric Surgery|Prevalence of Menstrual Irregularities and Endometrial Pathology in Women Who Are Candidates for Bariatric Surgery: Correlation With Perceived Risk, Biomarkers, and Weight Loss|Completed|||100|Anticipated|University of Virginia|||||f||||t||||||Samples With DNA|"~     blood, omentum, endometrium, adipose tissue~   "|||2018-05-31 21:56:23.63805|2018-05-31 21:56:23.63805
NCT01473173|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2013-04-09|2011-11-14|2011-11-17|Estimate|||||||2013-04-09|2013-04-10|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study, to Investigate the Safety, Tolerability, PK and PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects|Completed||Phase 1|59|Actual|CJ HealthCare Corporation||7|||f||||f||||||||||2018-05-31 21:56:23.722975|2018-05-31 21:56:23.722975
NCT01473160|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2012-11-19||2013-04-16|2011-11-14|2011-11-17|Estimate|2013-01-14|2013-01-16|Estimate||||2013-04-16|2013-04-17|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Daily Disposable Contact Lens Tear Film Study|DAILIES TOTAL1 Pre-Lens Tear Film Performance - Pilot Trial|Completed||N/A|9|Actual|Alcon Research|Pilot study. Small number of participants analyzed.|2|||f||||f||||||||||2018-05-31 21:56:23.827953|2018-05-31 21:56:23.827953
NCT01473147|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2013-07-28|2011-11-14|2011-11-17|Estimate|||||||2013-07-28|2013-07-30|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|AGAC2||Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients|Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients|Completed||N/A|51|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:56:24.17127|2018-05-31 21:56:24.17127
NCT01473134|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-08-31|2011-11-14|2011-11-17|Estimate|||||||2017-08-31|2017-09-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:56:24.256132|2018-05-31 21:56:24.256132
NCT01473121|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2018-05-04|2011-11-14|2011-11-17|Estimate|||||||2018-05-04|2018-05-07|Actual|August 13, 2012|Actual|2012-08-13|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|June 30, 2017|Actual|2017-06-30||Observational|||Hepatocellular Carcinoma Registry for Turkey (3K Trial)|Profile of the Hepatocellular Carcinoma Patients in Turkey|Active, not recruiting|||600|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 21:56:24.309374|2018-05-31 21:56:24.309374
NCT01473108|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-12-01|2011-11-14|2011-11-17|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862|Study to Investigate the Effectiveness of Different Single Oral Doses of BAY94-8862 on Natriuresis After Administration of 0.5 mg Fludrocortisone (Astonin H®) With 50 mg Eplerenone (Inspra®) as Active Control in Healthy Male Subjects in a Randomized, Single-blind, Placebo-controlled, Combined 3-fold Crossover and Parallel-group Design|Completed||Phase 1|68|Actual|Bayer||5|||f||||f||||||||||2018-05-31 21:56:24.398494|2018-05-31 21:56:24.398494
NCT01473095|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-10-19|2011-11-14|2011-11-17|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2011||2011-11-30|October 2017|2017-10-31|August 7, 2017|Actual|2017-08-07|July 6, 2017|Actual|2017-07-06||Interventional|||Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma|A Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma|Completed||Phase 1|120|Actual|ArQule|||||f||||f||||||||||2018-05-31 21:56:24.502613|2018-05-31 21:56:24.502613
NCT01473082|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-02-12|2011-11-14|2011-11-17|Estimate|||||||2016-02-12|2016-02-15|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Proximal Femoral Nail Antirotation (PFNA) Versus PFNA Augmentation|Comparison of Proximal Femoral Nail Antirotation (PFNA) Versus PFNA Augmentation for the Treatment of Closed Unstable Trochanteric Fractures - A Randomized-controlled Trial|Completed||Phase 4|251|Actual|AO Clinical Investigation and Documentation||2|||f||||t||||||||||2018-05-31 21:56:24.585719|2018-05-31 21:56:24.585719
NCT01473069|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-11-17|2011-11-14|2011-11-17|Estimate|||||||2011-11-17|2011-11-21|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of JTK-853 Administered for Two Weeks in Healthy Subjects|Terminated||Phase 1|41|Actual|Akros Pharma Inc.||5|||f||||f||||||||||2018-05-31 21:56:24.698203|2018-05-31 21:56:24.698203
NCT01473056|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-11-17|2011-11-14|2011-11-17|Estimate|||||||2011-11-17|2011-11-21|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|October 2010|Actual|2010-10-31||Interventional|||Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects|Phase I,Randomized,Double-blind,Placebo-controlled,Multiple Dose Study Evaluating Safety,Tolerability,Pharmacokinetics and Antiviral Activity of JTK-853 in HCV Genotype 1 Infected Subjects,Followed by a Genotypic Resistance Monitoring Study|Completed||Phase 1|29|Actual|Akros Pharma Inc.||5|||f||||f||||||||||2018-05-31 21:56:24.771765|2018-05-31 21:56:24.771765
NCT01473043|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2014-05-28|2011-11-14|2011-11-17|Estimate|||||||2014-05-28|2014-05-30|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Expanded Access|||Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment|Clinical Study With Axitinib (AG 013736) In Patients With Metastatic Renal Cell Carcinoma After Failure Of One Prior Systemic First-Line Therapy|No longer available|||||Pfizer|||||||||f||||||||||2018-05-31 21:56:24.872708|2018-05-31 21:56:24.872708
NCT01473030|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-11-01|2011-11-16|2011-11-17|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2011||2011-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue|Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue|Active, not recruiting|||80|Actual|University of Illinois at Chicago|||2||f||||f|||||||"~     Biopsy tissue (Year 2 and Year 4) already collected in REDUCE trial~   "|||2018-05-31 21:56:24.939657|2018-05-31 21:56:24.939657
NCT01473017|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-11-14|2011-11-14|2011-11-17|Estimate|||||||2011-11-14|2011-11-17|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Improving Mental Health in Diabetes: A Guided Self-Help Study|Improving Mental Health in Diabetes: A Guided Self-Help Study|Unknown status|Not yet recruiting|N/A|120|Anticipated|University of Edinburgh||2|||f||||t||||||||||2018-05-31 21:56:25.010162|2018-05-31 21:56:25.010162
NCT01473004|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-11-08|2011-11-14|2011-11-17|Estimate|||||||2017-11-08|2017-11-13|Actual|October 31, 2011|Actual|2011-10-31|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver|An Open-Label, Single Institution, Phase II Study Using Radioactive Yttrium90 Microsphere (SIR-Sphere®) in Uveal Melanoma Patients With Hepatic Metastasis|Active, not recruiting||Phase 2|48|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 21:56:25.094649|2018-05-31 21:56:25.094649
NCT01472991|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14||2013-04-22|2013-04-22|2011-11-16|2011-11-17|Estimate||||2013-04-22|2013-04-30|Estimate|2013-04-22|2013-04-30|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Inattentive-Predominant Attention Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|250|Actual|Targacept Inc.||3|||f||||f||||||||||2018-05-31 21:56:25.168509|2018-05-31 21:56:25.168509
NCT01472978|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-06-11|2011-11-16|2011-11-17|Estimate|||||||2012-06-11|2012-06-12|Estimate|December 2011||2011-12-31|June 2012|2012-06-30||||December 2014|Anticipated|2014-12-31||Interventional|c diff||Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy|Prospective Study of Clostridium Difficile in Children Undergoing Colonoscopy|Unknown status|Recruiting|N/A|50|Anticipated|State University of New York at Buffalo||2|||f||||f||||||||||2018-05-31 21:56:25.281106|2018-05-31 21:56:25.281106
NCT01472965|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2017-08-18||2017-10-12|2011-11-16|2011-11-17|Estimate|2017-10-12|2017-11-13|Actual||||2017-10-12|2017-11-13|Actual|December 29, 2011|Actual|2011-12-29|August 2017|2017-08-31|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|||Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection|A Double-Blind, Randomized, Placebo-Controlled, Trial of Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line Associated Bloodstream Infection (CLABSI) in Children and Adolescents|Completed||Phase 3|95|Actual|St. Jude Children's Research Hospital||2|||f||||f|t|f||||||||2018-05-31 21:56:25.380765|2018-05-31 21:56:25.380765
NCT01472952|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-10-20|2011-11-16|2011-11-17|Estimate|||||||2014-10-20|2014-10-21|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|||System-level Monitoring of Immune Activation Concerning Susceptibility to Sepsis in Trauma Patients||Withdrawn|||0|Actual|Universitätsmedizin Mannheim|||||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 21:56:25.934051|2018-05-31 21:56:25.934051
NCT01472939|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2014-03-04||2014-04-25|2011-11-16|2011-11-17|Estimate|2014-03-04|2014-04-15|Estimate||||2014-04-25|2014-05-12|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Safety Analysis Set was used which consisted of all randomized subjects who took at least 1 dose of investigational product. Three subjects did not receive investigational product, therefore n=477.|Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)|A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) With Persistent Regurgitation With or Without Heartburn|Completed||Phase 2|480|Actual|Shire||4|||f||||t||||||||||2018-05-31 21:56:26.030146|2018-05-31 21:56:26.030146
NCT01472926|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2012-08-09|2011-11-16|2011-11-17|Estimate|||||||2012-08-09|2012-08-10|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|January 2014|Anticipated|2014-01-31|September 2013|Anticipated|2013-09-30||Interventional|ATTEST||Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)|Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis - Pilot Phase (ATTEST)|Unknown status|Recruiting|Phase 2|104|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t||||||||||2018-05-31 21:56:26.873382|2018-05-31 21:56:26.873382
NCT01472913|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-04-20|2011-11-16|2011-11-17|Estimate|||||||2015-04-20|2015-04-22|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Fibrin Sealant in Bilateral Simultaneous Total Knee Arthroplasty With Focus on Blood Loss, Pain, Swelling and Strength|Fibrin Sealant in Bilateral Simultaneous Total Knee Arthroplasty. A Prospective Randomised Double-blinded Study Focus in on: Blood Loss, Pain, ROM, Swelling and Strength|Completed||Phase 4|48|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 21:56:26.956374|2018-05-31 21:56:26.956374
NCT01472900|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-12|||2012-06-17|2011-11-16|2011-11-17|Estimate|||||||2012-06-17|2012-06-19|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne|A Randomized Split-Face Controlled Trial Comparing Efficacy of 2940 Nanometer Er:YAG Laser to 2.5% BP Gel for the Treatment of Inflammatory Acne|Completed||N/A|25|Anticipated|Chulalongkorn University||2|||f||||||||||||||2018-05-31 21:56:27.058279|2018-05-31 21:56:27.058279
NCT01472887|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14||2018-01-18|2018-01-18|2011-11-14|2011-11-17|Estimate||||2018-01-18|2018-01-25|Actual|2018-01-18|2018-01-25|Actual|January 2012||2012-01-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|STARLYTE||SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients|An Open Label Non-Randomized Phase 2 Study Evaluating SAR3419, an Anti-CD19 Antibody - Maytansine Conjugate, Administered as Single Agent by Intravenous Infusion to Patients With Relapsed or Refractory CD19+ Diffuse Large B-Cell Lymphoma|Completed||Phase 2|61|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:56:27.149062|2018-05-31 21:56:27.149062
NCT01472874|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|2014-04-21||2014-05-19|2011-11-16|2011-11-17|Estimate|2014-04-21|2014-05-19|Estimate||||2014-05-19|2014-05-22|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease|Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease|Completed||N/A|8|Actual|Yale University||1|||f||||f||||||||||2018-05-31 21:56:28.339833|2018-05-31 21:56:28.339833
NCT01472861|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2015-06-10|2011-11-16|2011-11-17|Estimate|||||||2015-06-10|2015-06-12|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|AECCT||Autologous Endometrial Coculture (AECCT)|A Randomized Controlled Trial Evaluating Autologous Endometrial Coculture (AECC) As An Effective Tool For Young Patients With Poor Ovarian Reserve|Terminated||N/A|20|Actual|Weill Medical College of Cornell University||2||poor recruitment|f||||f||||||||||2018-05-31 21:56:28.697458|2018-05-31 21:56:28.697458
NCT01472848|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-11-11|2011-11-11|2011-11-17|Estimate|||||||2011-11-11|2011-11-17|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|||A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects|A Randomized, Double-Blind, Outpatient, Placebo-Controlled, Dose Titration Study Of Gastrointestinal Tolerability Of Pf 05212389 (Oap-189) In Obese Subjects|Withdrawn||Phase 1|0|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 21:56:28.77143|2018-05-31 21:56:28.77143
NCT01472835|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2014-03-19||2016-10-31|2011-11-16|2011-11-17|Estimate|2014-05-19|2014-06-16|Estimate||||2016-10-31|2016-12-15|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of Sedation on Diagnostic Injections|Randomized, Cross-over Study Evaluating the Effect of Sedation on Pain Relief After Diagnostic Injections|Completed||N/A|73|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:56:28.882385|2018-05-31 21:56:28.882385
NCT01472822|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|2012-07-26||2012-12-27|2011-11-16|2011-11-17|Estimate|2012-12-27|2013-02-04|Estimate||||2012-12-27|2013-02-04|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Efficacy of Omija (Schisandra Chinensis) Extract in Subjects With Knee Osteoarthritis|Efficacy and Safety of Omija Extract on Gonarthritis|Completed||Phase 2/Phase 3|60|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:56:30.019465|2018-05-31 21:56:30.019465
NCT01472809|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2015-11-20|2011-11-16|2011-11-17|Estimate|||||||2015-11-20|2015-11-24|Estimate|December 2011||2011-12-31|November 2015|2015-11-30||||December 2012|Actual|2012-12-31||Interventional|||A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers|A Randomized, Double Blind Placebo Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYGK1, a Novel Glucokinase Activator, Following Oral Administration in Healthy Volunteers|Suspended||Phase 1|96|Anticipated|Cadila Healthcare Limited||2||Not achieved the objective till 4 mg single dose|f||||t||||||||||2018-05-31 21:56:30.517828|2018-05-31 21:56:30.517828
NCT01472796|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2011-11-11|2011-11-11|2011-11-16|Estimate|||||||2011-11-11|2011-11-16|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|March 2014|Anticipated|2014-03-31|July 2013|Anticipated|2013-07-31||Interventional|VDATH||Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension|Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH)|Unknown status|Recruiting|Phase 4|92|Anticipated|Wayne State University||2|||f||||t||||||||||2018-05-31 21:56:30.639553|2018-05-31 21:56:30.639553
NCT01472783|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2016-11-15|2011-11-11|2011-11-16|Estimate|||||||2016-11-15|2016-11-16|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|Veli-BRCA||Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation|Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer|Completed||Phase 1/Phase 2|49|Actual|Vejle Hospital||1|||f||||t||||||||||2018-05-31 21:56:30.799695|2018-05-31 21:56:30.799695
NCT01472770|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-12-03|2011-11-11|2011-11-16|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|GemCaP||A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer|A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer|Completed||Phase 2|49|Actual|Vejle Hospital|||||f||||t||||||||||2018-05-31 21:56:31.046924|2018-05-31 21:56:31.046924
NCT01472757|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11||2014-05-09|2014-05-09|2011-11-11|2011-11-16|Estimate||||2014-05-09|2014-05-26|Estimate|2014-05-09|2014-05-26|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma|Completed||Phase 2/Phase 3|374|Actual|Vectura Limited||4|||f||||||||||||||2018-05-31 21:56:31.18647|2018-05-31 21:56:31.18647
NCT01472744|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2017-02-21|2011-11-11|2011-11-16|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2011||2011-08-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|FAST||Fit & Active Seniors Trial|Influence of Fitness on Brain and Cognition II|Completed||N/A|247|Actual|University of Illinois at Urbana-Champaign||4|||f||||t||||||||No||2018-05-31 21:56:31.519104|2018-05-31 21:56:31.519104
NCT01472731|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-11-13|2011-11-11|2011-11-16|Estimate|||||||2012-11-13|2012-11-14|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Imaging Study of GC1008 in Glioma|Guiding GC1008 Treatment of Primary Brain Tumors by 89Zr-GC1008 PET Imaging.|Completed||Phase 2|12|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 21:56:31.670601|2018-05-31 21:56:31.670601
NCT01472718|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2012-05-24|2011-11-15|2011-11-16|Estimate|||||||2012-05-24|2012-05-25|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention (PCI)|Efficacy of Thromboaspiration in Patients With High Thrombotic Burden Undergoing Primary Percutaneous Coronary Intervention|Completed||Phase 4|208|Actual|University of Pisa||2|||f||||f||||||||||2018-05-31 21:56:31.821555|2018-05-31 21:56:31.821555
NCT01472705|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2015-12-01|2011-11-13|2011-11-16|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Observational|EverBio||Everolimus- Versus Biolimus-Eluting Stents in All-Comers|Long-Term Comparison of Everolimus-Eluting and Biolimus-Eluting Stents in All-Comer Patients|Completed|||814|Actual|University of Freiburg|||2||f||||f||||||||||2018-05-31 21:56:31.900439|2018-05-31 21:56:31.900439
NCT01472692|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2014-03-31|2011-11-15|2011-11-16|Estimate|||||||2014-03-31|2014-04-02|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure|Treatment of Uric Acid With the Xanthine Oxidase Inhibitor Febuxostat: Effects on Blood Pressure, Metabolic Markers, and Aortic Stiffness in Prehypertensive|Completed||Phase 4|47|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:56:32.011547|2018-05-31 21:56:32.011547
NCT01472679|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2018-05-02|2011-11-11|2011-11-16|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2018|Actual|2018-05-31||Observational|||Body Composition: a Predictor of Mortality in Subjects Over 65 Years|Body Composition: a Predictor of Mortality in Subjects Over 65 Years|Active, not recruiting|||4500|Anticipated|University Hospital, Geneva|||||f||||f||||||||No||2018-05-31 21:56:32.095965|2018-05-31 21:56:32.095965
NCT01472666|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2016-02-29|2011-11-15|2011-11-16|Estimate|||||||2016-02-29|2016-03-01|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||"Dairy Lipids, Proteins, and the Metabolic Syndrome - DairyHealth"|"Dairy Lipids, Proteins, and the Metabolic Syndrome - DairyHealth"|Completed||N/A|63|Actual|University of Aarhus||4|||f||||f||||||||No|No plan to share data|2018-05-31 21:56:32.151526|2018-05-31 21:56:32.151526
NCT01472653|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2011-12-11|2011-11-13|2011-11-16|Estimate|||||||2011-12-11|2011-12-13|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2016|Anticipated|2016-12-31|March 2014|Anticipated|2014-03-31||Interventional|||Treatment Selection According to Skin Reaction to Cetuximab|Skin Reaction to Cetuximab as Criteria for Treatment Selection in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase 2 Study|Unknown status|Recruiting|Phase 2|120|Anticipated|Institute of Oncology Ljubljana|||||f||||f||||||||||2018-05-31 21:56:32.275049|2018-05-31 21:56:32.275049
NCT01472640|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2015-10-09|2011-11-15|2011-11-16|Estimate|||||||2015-10-09|2015-10-12|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus|A Randomised, Double-blind, Placebo-controlled Study of the Effect of LIraglutide on Left VEntricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes (The LIVE-study)|Completed||N/A|240|Actual|Flyvbjerg, Allan, DMSc||2|||f||||f||||||||||2018-05-31 21:56:32.507202|2018-05-31 21:56:32.507202
NCT01472627|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2018-01-09|2011-11-11|2011-11-16|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2010||2010-10-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro|Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro|Completed|||11|Actual|Dana-Farber Cancer Institute|||1||f||||t||||||Samples Without DNA|"~     Peripheral blood samples, bone marrow~   "|||2018-05-31 21:56:32.606212|2018-05-31 21:56:32.606212
NCT01472614|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2013-05-24|2011-11-11|2011-11-16|Estimate|||||||2013-05-24|2013-05-27|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus|Effect of Add-on Therapy With DLBS3233 on Glycemic Control, Lipid Profile, and Adiponectin in Patients With Type-2 Diabetes Mellitus|Completed||Phase 3|54|Actual|Dexa Medica Group||1|||f||||t||||||||||2018-05-31 21:56:32.71706|2018-05-31 21:56:32.71706
NCT01472601|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2017-04-25|2011-11-13|2011-11-16|Estimate|||||||2017-04-25|2017-04-26|Actual|May 24, 2011|Actual|2011-05-24|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile|A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile in Patients Receiving Adjuvant Therapy With FOLFOX-6 After Curative Resection of Colon Cancer|Recruiting|||2660|Anticipated|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 21:56:32.839917|2018-05-31 21:56:32.839917
NCT01472588|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2014-09-30|2011-11-14|2011-11-16|Estimate|||||||2014-09-30|2014-10-01|Estimate|September 2007||2007-09-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Translating the Diabetes Prevention Program (DPP) Lifestyle Intervention to Rural African-American Communities (HEALTHY Ways)|Translating the DPP Lifestyle Intervention to Rural African-American Communities|Completed||Phase 2|277|Actual|University of Arkansas||3|||f||||||||||||||2018-05-31 21:56:32.962095|2018-05-31 21:56:32.962095
NCT01472575|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-11-15|2011-11-15|2011-11-16|Estimate|||||||2011-11-15|2011-11-16|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Impact of Rotavirus Vaccine Introduction for South Australian Children|An Observational, Cross-sectional, Cohort Study to Assess the Impact of the Rotavirus Vaccine Introduction on Severe Gastroenteritis in South Australian Children|Unknown status|Active, not recruiting||1200|Anticipated|Women's and Children's Hospital, Australia|||2||f||||f||||||||||2018-05-31 21:56:33.07148|2018-05-31 21:56:33.07148
NCT01472562|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2017-02-22||2018-02-27|2011-11-10|2011-11-16|Estimate|2017-02-23|2017-04-07|Actual||||2018-02-27|2018-03-27|Actual|June 2011||2011-06-30|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|April 2014|Actual|2014-04-30||Interventional|||Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma|Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma|Active, not recruiting||Phase 2|38|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 21:56:33.225451|2018-05-31 21:56:33.225451
NCT01472549|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-12-04|2011-11-10|2011-11-16|Estimate|||||||2016-12-04|2016-12-06|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Skin Prep Study|Antiseptic Skin Preparation for Preventing Surgical Site Infection at Cesarean Delivery: a Randomized Comparative Effectiveness Trial|Completed||N/A|1147|Actual|Washington University School of Medicine||2|||f||||t||||||||No||2018-05-31 21:56:33.542562|2018-05-31 21:56:33.542562
NCT01472536|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2016-01-24|2011-11-15|2011-11-16|Estimate|||||||2016-01-24|2016-01-26|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|eX-FLU||A Study of Exclusion Criteria in a University Population|A Randomized Study of Exclusion Criteria in a University Population|Completed||N/A|1400|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:56:33.647337|2018-05-31 21:56:33.647337
NCT01472523|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-01-17|2011-11-15|2011-11-16|Estimate|||||||2018-01-17|2018-01-18|Actual|April 2007||2007-04-30|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|IONA||A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood|A Safer Pre-Natal Diagnosis Using Free DNA in Maternal Blood|Recruiting|||600|Anticipated|Premaitha Health|||2||f||||t||||||Samples With DNA|"~     Maternal peripheral blood samples taken in EDTA with that required for existing analysis.~      Approx 1ml of fluid from amniocentesis/chorionic villus sampling is taken additional.~     Patients will be followed up for 1 year after sample taken.~   "|||2018-05-31 21:56:33.717119|2018-05-31 21:56:33.717119
NCT01472510|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-03-13|2011-11-10|2011-11-16|Estimate|||||||2014-03-13|2014-03-14|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy|Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy|Completed||Phase 2|20|Actual|Vitreo-Retinal Associates, PC||2|||f||||t||||||||||2018-05-31 21:56:33.802478|2018-05-31 21:56:33.802478
NCT01472497|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-06-03|2011-11-15|2011-11-16|Estimate|||||||2012-06-03|2012-06-05|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Pioglitazone in Hypertensive Patients|Effects of Pioglitazone and Glimepiride in Hypertensive Patients - Relationship With AGE, Inflammatory Cytokines and Cardiac Markers -|Completed||Phase 4|16|Actual|Tottori University Hospital||1|||f||||f||||||||||2018-05-31 21:56:33.884943|2018-05-31 21:56:33.884943
NCT01472484|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-06-18|2011-11-15|2011-11-16|Estimate|||||||2012-06-18|2012-06-19|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Impact of Bean Polyphenols and Phytic Acid on Iron Absorption|A Stable Iron Isotope Study to Investigate the Impact of Phytic Acid and Polyphenols on Iron Absorption From Beans in Humans|Completed||N/A|20|Actual|Swiss Federal Institute of Technology||4|||f||||f||||||||||2018-05-31 21:56:33.954533|2018-05-31 21:56:33.954533
NCT01472471|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2013-06-05|2011-11-15|2011-11-16|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Urinary 8-isoprostane is Elevated in Acute Childhood Asthma|Urinary 8-isoprostane is Elevated in Acute Childhood Asthma|Completed|||52|Actual|Stony Brook University|||2||f||||f||||||Samples Without DNA|"~     urine~   "|||2018-05-31 21:56:34.070641|2018-05-31 21:56:34.070641
NCT01472458|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-02-03|2011-11-15|2011-11-16|Estimate|||||||2017-02-03|2017-02-06|Estimate|November 2011||2011-11-30|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PremaTOR||Premature Termination of Resuscitation in Survivors of Cardiac Arrest|Premature Termination of Resuscitation in Survivors of Cardiac Arrest|Completed||N/A|905|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:56:34.131535|2018-05-31 21:56:34.131535
NCT01472445|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2014-12-17|2011-11-15|2011-11-16|Estimate|||||||2014-12-17|2014-12-19|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Vitamin D and Breast Cancer: Does Weight Make a Difference?|Vitamin D and Breast Cancer: Does Weight Make a Difference?|Terminated||N/A|41|Actual|Stanford University||2||Slow accrual|f||||t||||||||||2018-05-31 21:56:34.191074|2018-05-31 21:56:34.191074
NCT01472432|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-05-19||2016-08-27|2011-11-15|2011-11-16|Estimate|2015-05-19|2015-06-04|Estimate||||2016-08-27|2016-10-11|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes|Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes|Completed||Phase 4|106|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||Undecided||2018-05-31 21:56:34.282845|2018-05-31 21:56:34.282845
NCT01472419|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2013-04-07|2011-11-15|2011-11-16|Estimate|||||||2013-04-07|2013-04-09|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|||Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma|Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients|Completed|||239|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 21:56:34.668038|2018-05-31 21:56:34.668038
NCT01472406|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2013-05-22|2011-11-11|2011-11-16|Estimate|||||||2013-05-22|2013-05-24|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)|Artificial Pancreas Device Feasibility Study for Type 1 Diabetes Patients Using Model-predictive Control and Health Monitoring System Algorithms With an Approved Subcutaneous Insulin Delivery Pump and Subcutaneous Continuous Glucose Monitor|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Sansum Diabetes Research Institute||1|||f||||t||||||||||2018-05-31 21:56:34.729013|2018-05-31 21:56:34.729013
NCT01472393|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2015-01-29|2011-11-15|2011-11-16|Estimate|||||||2015-01-29|2015-01-30|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Creatine on Bone Mass in Postmenopausal Women|A Randomized Controlled Trial: Effects of Creatine Supplementation on Bone Mass and Turnover and Muscle Function in Healthy Postmenopausal Women|Unknown status|Recruiting|N/A|200|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:56:34.874858|2018-05-31 21:56:34.874858
NCT01472380|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|2012-06-15||2012-07-30|2011-11-11|2011-11-16|Estimate|2012-06-15|2012-07-23|Estimate||||2012-07-30|2012-08-01|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz|An Open-label, Drug Interaction Study to Investigate the Effects of Steady-State Fenofibric Acid on the Single-Dose Pharmacokinetics of Efavirenz in Healthy Subjects|Completed||Phase 1|30|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-05-31 21:56:34.976377|2018-05-31 21:56:34.976377
NCT01472367|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2018-05-08|2011-11-11|2011-11-16|Estimate|||||||2018-05-08|2018-05-09|Actual|December 7, 2011|Actual|2011-12-07|May 2018|2018-05-31|January 23, 2020|Anticipated|2020-01-23|January 23, 2020|Anticipated|2020-01-23||Interventional|||A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)|A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)|Recruiting||Phase 3|140|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 21:56:35.29947|2018-05-31 21:56:35.29947
NCT01472354|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-05-29|2011-11-10|2011-11-16|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|LEAP-C||Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults|Feasibility of a HCV Decision-Making Intervention Among HIV-infected Adults|Completed||N/A|50|Anticipated|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 21:56:35.45665|2018-05-31 21:56:35.45665
NCT01472341|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|2015-02-04||2017-01-30|2011-11-15|2011-11-16|Estimate|2015-02-04|2015-02-20|Estimate||||2017-01-30|2017-03-10|Actual|November 2008||2008-11-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|BETADECLINE||Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)|Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes|Completed|||507|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 21:56:35.54383|2018-05-31 21:56:35.54383
NCT01472328|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2011-11-20|2011-11-15|2011-11-16|Estimate|||||||2011-11-20|2011-11-22|Estimate|March 2012||2012-03-31|November 2011|2011-11-30|August 2015|Anticipated|2015-08-31|March 2015|Anticipated|2015-03-31||Interventional|||Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes|Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes|Unknown status|Not yet recruiting|N/A|30|Anticipated|German Diabetes Center||2|||f||||f||||||||||2018-05-31 21:56:35.714774|2018-05-31 21:56:35.714774
NCT01472315|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2013-03-08|2011-11-10|2011-11-16|Estimate|||||||2013-03-08|2013-03-11|Estimate|January 2000||2000-01-31|March 2013|2013-03-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities|Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities|Completed||Phase 2/Phase 3|34|Actual|Turku University Hospital||2|||f||||||||||||||2018-05-31 21:56:35.833909|2018-05-31 21:56:35.833909
NCT01472302|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2014-03-05|2011-11-15|2011-11-16|Estimate|||||||2014-03-05|2014-03-06|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Closed Loop Ventilation Strategy in Intensive Care Unit (ICU) Patients|Effect of a Closed Loop Ventilation Strategy on Reducing the Total Duration of Mechanical Ventilation of Intubated Intensive Care Unit Patients: A Randomized Controlled Trial|Completed||Phase 4|229|Actual|Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital||2|||f||||f||||||||||2018-05-31 21:56:35.926837|2018-05-31 21:56:35.926837
NCT01472120|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-11-15|2011-11-15|2011-11-16|Estimate|||||||2011-11-15|2011-11-16|Estimate|December 2011||2011-12-31|August 2011|2011-08-31|January 2013|Anticipated|2013-01-31|September 2012|Anticipated|2012-09-30||Observational|||Adiponectin and Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease (NAFLD)|The Relationship of Adiponectin With Circulating Macrophage Phenotypes in Non-alcoholic Fatty Liver Disease|Unknown status|Not yet recruiting||160|Anticipated|Gulhane School of Medicine|||1||f||||f||||||||||2018-05-31 21:56:38.958401|2018-05-31 21:56:38.958401
NCT01472289|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2015-07-17||2015-10-16|2011-11-15|2011-11-16|Estimate|2015-10-16|2015-11-18|Estimate||||2015-10-16|2015-11-18|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional||A total of 17 subjects who met the eligibility criteria were enrolled in this study.|Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia|To Study and Demonstrate the Safety and Efficacy of RES-Q Prepared Bone Marrow Mononuclear Cells Injected Into Ischemic Tissue of Patients With Non-Reconstructable Critical Limb Ischemia (CLI).|Completed||Phase 1/Phase 2|17|Actual|TotipotentSC Scientific Product Pvt. Ltd.||1|||f||||t||||||||||2018-05-31 21:56:36.051371|2018-05-31 21:56:36.051371
NCT01472276|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-03-11|2011-11-11|2011-11-16|Estimate|||||||2013-03-11|2013-03-12|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect of a Unique Web-based Behaviour Change Program on Weight Loss and Cardiovascular Risk Factors|Effect of a Unique Web-based Behaviour Change Program for Physical Activity and Weight Management on Weight Loss and Cardiovascular Risk Factors in Overweight or Obese Adults at High Risk of Cardiovascular Disease|Completed||Phase 2|65|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 21:56:36.325391|2018-05-31 21:56:36.325391
NCT01472263|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2015-03-17|2011-11-15|2011-11-16|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Pentox||Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases|Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response.|Completed||Phase 3|48|Actual|Hospital Universitário Professor Edgard Santos||2|||f||||t||||||||||2018-05-31 21:56:36.397244|2018-05-31 21:56:36.397244
NCT01472250|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2017-05-07|2011-11-11|2011-11-16|Estimate|||||||2017-05-07|2017-05-09|Actual|November 2011||2011-11-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China|A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China|Completed|||498|Actual|Peking University|||1||f||||f||||||Samples With DNA|"~     the tumor tissue samples were collected to do gene mutation analysis~   "|||2018-05-31 21:56:36.49445|2018-05-31 21:56:36.49445
NCT01472237|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2015-09-18|2011-11-11|2011-11-16|Estimate|||||||2015-09-18|2015-09-22|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PICNIC||Nutritional Intervention Program in Malnourished Patients Admitted for Heart Failure|Randomized Cotrolled Trial of Nutritional Intervention Program in Malnourished (Mini Nutritional Assessment < 17) Patients Admitted for Heart Failure|Terminated||Phase 3|120|Actual|Hospital San Juan de la Cruz||2||"Randomization was stopped early because a significant beneficial effect of nutritional~   intervention was found in the interim analysis"|f||||||||||||||2018-05-31 21:56:36.551977|2018-05-31 21:56:36.551977
NCT01472224|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2013-07-22|2011-11-15|2011-11-16|Estimate|||||||2013-07-22|2013-07-24|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Volume Measurement and Progression Surveillance of Intracerebral Haemorrhage Using Transcranial Ultrasound|Volume Measurement and Progression Surveillance of Intracerebral Haemorrhage Using Transcranial Ultrasound|Completed|||30|Anticipated|Bispebjerg Hospital|||||f||||f||||||||||2018-05-31 21:56:36.618639|2018-05-31 21:56:36.618639
NCT01472211|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-06-17|2011-11-15|2011-11-16|Estimate|||||||2013-06-17|2013-06-18|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Water-based Zinc Intervention Trial in Zinc Deficient Children|An Efficacy Trial of a Gravity-fed Household Water Treatment Device as a Delivery System for Zinc in Zinc Deficient Preschool Children and Pregnant Women From Rural Settings With Poor Access to Potable Water in Benin.|Terminated||Early Phase 1|317|Actual|Swiss Federal Institute of Technology||3||"Zn released from vehicle led to fortification levels higher than planned. New filter will be~   developed."|f||||t||||||||||2018-05-31 21:56:36.682757|2018-05-31 21:56:36.682757
NCT01472198|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10||2014-08-06|2015-02-19|2011-11-15|2011-11-16|Estimate||||2014-08-06|2014-08-08|Estimate|2015-02-19|2015-03-10|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|October 2013|Actual|2013-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma|A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|250|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 21:56:36.956358|2018-05-31 21:56:36.956358
NCT01472185|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|2014-10-08|2013-12-12|2014-10-15|2011-11-11|2011-11-16|Estimate|2014-10-08|2014-10-15|Estimate|2013-12-12|2014-01-14|Estimate|2014-10-15|2014-10-24|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Baseline characteristics are reported for the Safety Analysis Set following randomization. The Safety Analysis Set includes randomized participants who received at least one dose of study treatment, analyzed based on actual treatment received.|Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|465|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:56:37.323477|2018-05-31 21:56:37.323477
NCT01472172|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-12-03|2011-11-15|2011-11-16|Estimate|||||||2013-12-03|2013-12-05|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Pleural Cryobiopsies During Semirigid Thoracoscopy: A New Technique|Pleural Cryobiopsies During Semirigid Thoracoscopy: A New Technique|Completed||Early Phase 1|15|Actual|The University Clinic of Pulmonary and Allergic Diseases Golnik||1|||f||||t||||||||||2018-05-31 21:56:38.613023|2018-05-31 21:56:38.613023
NCT01472159|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-04-20|2011-11-11|2011-11-16|Estimate|||||||2018-04-20|2018-04-23|Actual|October 2011||2011-10-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|May 2014|Actual|2014-05-31||Interventional|||Can Glucose Monitoring Improve (CGMi Study)|Optimizing CGM Use and Metabolic Outcomes in Youth With Type 1 Diabetes|Completed||N/A|130|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-05-31 21:56:38.703269|2018-05-31 21:56:38.703269
NCT01472146|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-05-04|2011-11-11|2011-11-16|Estimate|||||||2017-05-04|2017-05-09|Actual|October 2011|Actual|2011-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|July 2016|Actual|2016-07-31||Interventional|||ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer|Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer|Completed||Phase 2|58|Actual|Instituto Nacional de Cancer, Brazil||1|||f||||t||||||||No|I don`t plan to share IPD|2018-05-31 21:56:38.791536|2018-05-31 21:56:38.791536
NCT01472107|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-11|||2018-03-21|2011-11-15|2011-11-16|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2012||2012-02-29|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|APL0511||Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy|Observational Study on Number and Outcome of Pregnancy in Childbearing Age Female Patients Treated With Chemotherapy for APL (Studies AIDA 0493, AIDA 2000)|Recruiting|||100|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 21:56:39.033138|2018-05-31 21:56:39.033138
NCT01472094|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2018-05-04|2011-11-15|2011-11-16|Estimate|||||||2018-05-04|2018-05-08|Actual|September 9, 2011||2011-09-09|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults|Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults|Active, not recruiting|||700|Anticipated|City of Hope Medical Center|||1||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 21:56:39.254095|2018-05-31 21:56:39.254095
NCT01472081|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2017-04-17|2011-11-11|2011-11-16|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2012||2012-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|February 2016|Actual|2016-02-29||Interventional|||Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)|A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 1|175|Anticipated|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 21:56:39.343429|2018-05-31 21:56:39.343429
NCT01472068|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-02-02|2011-11-11|2011-11-16|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||A Pilot Study to Evaluate Safety and Performance of Neuromuscular Electrical Stimulation With the Inko RS Device for the Treatment of Stress Urinary Incontinence|A Pilot Study to Evaluate the Safety and Performance of Neuromuscular Electrical Stimulation (NMES) With the Inko RS Device for the Treatment of Stress Urinary Incontinence|Completed||Phase 1|21|Actual|Bio-Medical Research, Ltd.||1|||f||||f||||||||||2018-05-31 21:56:39.455989|2018-05-31 21:56:39.455989
NCT01472055|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-06|||2014-08-18|2011-11-15|2011-11-16|Estimate|||||||2014-08-18|2014-08-20|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation|Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|46|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 21:56:39.510135|2018-05-31 21:56:39.510135
NCT01472042|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-07-18|2011-11-11|2011-11-16|Estimate|||||||2016-07-18|2016-07-20|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|GATOR||A Evaluation Of Biomarkers Associated With Sports Induced Concussions In College Student Athletes|A Prospective Evaluation Of Biomarkers Associated With Sports Induced Concussions In College Student Athletes|Completed|||265|Actual|Banyan Biomarkers, Inc|||3||f||||f||||||Samples Without DNA|"~     Serum Whole Blood and Plasma~   "|||2018-05-31 21:56:39.588476|2018-05-31 21:56:39.588476
NCT01472029|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-06-16|2011-11-11|2011-11-16|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2011||2011-12-31|June 2017|2017-06-30|September 12, 2016|Actual|2016-09-12|August 25, 2014|Actual|2014-08-25||Interventional|HerFLOT||Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach|Multicenter, Explorative Phase II Study of Perioperative 5-FU, Leucovorin, Docetaxel, and Oxaliplatin (FLOT) in Combination With Trastuzumab in Patients With HER2-positive, Locally Advanced, Resectable Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT)|Completed||Phase 2|53|Actual|AIO-Studien-gGmbH||1|||f||||t||||||||||2018-05-31 21:56:39.653417|2018-05-31 21:56:39.653417
NCT01472016|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2017-11-17|2011-11-15|2011-11-16|Estimate|||||||2017-11-17|2017-11-21|Actual|October 6, 2011|Actual|2011-10-06|June 2017|2017-06-30|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||Study of ABT-700 in Subjects With Advanced Solid Tumors|A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors|Completed||Phase 1|74|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 21:56:39.846061|2018-05-31 21:56:39.846061
NCT01472003|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2013-01-10|2011-11-11|2011-11-16|Estimate|||||||2013-01-10|2013-01-14|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types|An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR)|Completed||Phase 1|18|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 21:56:40.118131|2018-05-31 21:56:40.118131
NCT01471990|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-08-28|2011-11-10|2011-11-16|Estimate|||||||2012-08-28|2012-08-29|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance|The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner|Completed||N/A|24|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 21:56:40.532312|2018-05-31 21:56:40.532312
NCT01471977|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-15|2011-11-15|2011-11-16|Estimate|||||||2011-11-15|2011-11-16|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|February 2010|Actual|2010-02-28|December 2007|Actual|2007-12-31||Interventional|TBAD||Treatment Adherence of Tuberculosis Medicines|Interventions to Promote Adherence to Tuberculosis Treatment Among Patients Attending Basic Medical Unit of Taluka Gambat, Pakistan|Completed||N/A|1280|Actual|Gambat Institute of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:56:40.695718|2018-05-31 21:56:40.695718
NCT01471964|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2018-05-14|2011-11-10|2011-11-16|Estimate|||||||2018-05-14|2018-05-17|Actual|October 20, 2011|Actual|2011-10-20|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|February 7, 2017|Actual|2017-02-07||Interventional|||Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer|A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|22|Actual|Fox Chase Cancer Center||1||Phase I portion completed. Phase II will open pending amendment approval.|f||||t||||||||||2018-05-31 21:56:40.884355|2018-05-31 21:56:40.884355
NCT01471951|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-11-15|2011-11-15|2011-11-16|Estimate|||||||2011-11-15|2011-11-16|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|SET||Single Human Embryo Transfer in Assisted Reproduction Programs|Single Human Embryo Transfer: Comparison of Morphologic and Morphometric Parameters for Day 2 Embryo Selection Before Transference.|Unknown status|Recruiting|Early Phase 1|154|Anticipated|Fundacion Para La Investigacion Hospital La Fe||1|||f||||t||||||||||2018-05-31 21:56:41.061552|2018-05-31 21:56:41.061552
NCT01471938|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2012-02-08|2011-11-10|2011-11-16|Estimate|||||||2012-02-08|2012-02-09|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Application and Adaption of Device Specific Body Composition Formulas to Various Ethnic Groups|Application and Adaption of Device Specific Body Composition Formulas to Various Ethnic Groups|Completed|||130|Actual|Seca GmbH & Co. Kg.|||4||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 21:56:41.390527|2018-05-31 21:56:41.390527
NCT01471925|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2015-07-24|2011-11-10|2011-11-16|Estimate|||||||2015-07-24|2015-07-27|Estimate||||November 2011|2011-11-30||||||||Interventional|||Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC|A Phase III, Randomized, Open-label, Superiority Study Comparing the Incremental Product Esomeprazole Associated With Sodium Bicarbonate Made by Eurofarma and Nexium® in the Treatment of Gastroesophageal Reflux Disease|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||2||Change company strategy|f||||f||||||||||2018-05-31 21:56:41.576704|2018-05-31 21:56:41.576704
NCT01471912|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-06|||2011-11-16|2011-11-10|2011-11-16|Estimate|||||||2011-11-16|2011-11-17|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Elongation of Foveal Tissue After Macular Hole Surgery|Asymmetric Elongation of Foveal Tissue After Macular Hole Surgery and Its Impact on Metamorphopsia|Completed||N/A|31|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 21:56:41.702259|2018-05-31 21:56:41.702259
NCT01471899|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-09-24|2011-11-15|2011-11-16|Estimate|||||||2013-09-24|2013-09-25|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment|Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment|Unknown status|Not yet recruiting|Phase 3|78|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 21:56:41.788668|2018-05-31 21:56:41.788668
NCT01471886|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-09-23|2011-11-15|2011-11-16|Estimate|||||||2013-09-23|2013-09-25|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment|Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment|Unknown status|Recruiting|Phase 3|78|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 21:56:41.89047|2018-05-31 21:56:41.89047
NCT01471873|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-01-14|2011-11-10|2011-11-16|Estimate|||||||2017-01-14|2017-01-18|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Observational|||Variability of Pentacam-derived Back Elevation Measurements in Keratoconus and Cross-linked Corneas|Variability of Pentacam-derived Back Elevation Measurements in Keratoconus and Cross-linked Corneas|Completed|||67|Actual|Democritus University of Thrace|||2||f||||f||||||||||2018-05-31 21:56:42.086322|2018-05-31 21:56:42.086322
NCT01471860|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-02-26|2011-11-10|2011-11-16|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2011|Actual|2011-08-31|February 2018|2018-02-28|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Barostim Neo System in the Treatment of Heart Failure|Neo Randomized Heart Failure Study|Completed||N/A|94|Actual|CVRx, Inc.||2|||f||||t||||||||||2018-05-31 21:56:42.242241|2018-05-31 21:56:42.242241
NCT01471847|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2018-02-27|2011-11-10|2011-11-16|Estimate|||||||2018-02-27|2018-03-01|Actual|February 2012||2012-02-29|February 2018|2018-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab|A Phase Ib/Randomized Phase II Study of BEZ235 and Trastuzumab Versus Lapatinib and Capecitabine in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Failed Prior to Trastuzumab|Completed||Phase 1|5|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:56:42.52771|2018-05-31 21:56:42.52771
NCT01471834|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-02-26|2011-11-10|2011-11-16|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2011||2011-06-30|February 2018|2018-02-28|August 2026|Anticipated|2026-08-31|May 2012|Actual|2012-05-31||Interventional|||Barostim Neo System in the Treatment of Resistant Hypertension|Neo Non-Randomized Hypertension Study|Active, not recruiting||N/A|40|Actual|CVRx, Inc.||1|||f||||t||||||||||2018-05-31 21:56:42.75148|2018-05-31 21:56:42.75148
NCT01471821|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2014-07-28|2011-11-15|2011-11-16|Estimate|||||||2014-07-28|2014-07-29|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|OLE||Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression|Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up|Completed||Phase 4|250|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 21:56:42.959643|2018-05-31 21:56:42.959643
NCT01471808|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2013-04-08|2011-11-15|2011-11-16|Estimate|||||||2013-04-08|2013-04-09|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Different Early Intensive Therapies on Long-term β-cell Function|Effects of Oral Hypoglycemic Agents Combined With Short-term CSII on Glycemic Control in Newly-diagnosed Type 2 Diabetic Patients|Enrolling by invitation||Phase 4|336|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 21:56:43.096846|2018-05-31 21:56:43.096846
NCT01471795|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-15|2011-11-15|2011-11-16|Estimate|||||||2011-11-15|2011-11-16|Estimate|January 2006||2006-01-31|November 2011|2011-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||The Epidemiology of Ventricular Assist Device-Related Infections|The Epidemiology of Ventricular Assist Device-Related Infections|Completed|||150|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||t||||||||||2018-05-31 21:56:43.223287|2018-05-31 21:56:43.223287
NCT01471782|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2016-09-23|2015-07-23|2016-12-16|2011-11-10|2011-11-16|Estimate|2016-12-16|2017-02-08|Estimate|2015-07-23|2015-08-13|Estimate|2016-12-16|2017-02-08|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|August 2014|Actual|2014-08-31||Interventional|||Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|A Single-Arm Multicenter Phase II Study Preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 1/Phase 2|93|Actual|Amgen Research (Munich) GmbH||1|||f||||t||||||||||2018-05-31 21:56:43.433465|2018-05-31 21:56:43.433465
NCT01471769|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-12-17|2011-11-10|2011-11-16|Estimate|||||||2012-12-17|2012-12-19|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Video Education Intervention in the Emergency Department|Video Education Intervention in the Emergency Department|Completed||N/A|100|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 21:56:47.137313|2018-05-31 21:56:47.137313
NCT01471756|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-09-05|2011-11-15|2011-11-16|Estimate|||||||2014-09-05|2014-09-08|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia|Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps|Completed||Phase 4|66|Actual|Mayo Clinic||4|||f||||t||||||||||2018-05-31 21:56:47.222681|2018-05-31 21:56:47.222681
NCT01471743|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-02-22|2011-11-10|2011-11-16|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||GI Surgery Pre-Operative Nutrition|"The Effect of Pre-Operative Immunonutrition With Impact Advanced Recovery (R) on Patients Undergoing Major GI Cancer Surgery"|Completed||N/A|108|Actual|James A. Haley Veterans Administration Hospital||2|||f||||t||||||||||2018-05-31 21:56:47.387868|2018-05-31 21:56:47.387868
NCT01471730|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-03-29|2011-11-15|2011-11-16|Estimate|||||||2015-03-29|2015-03-31|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ZEPLAST||The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery|The ZEroPLASmaTrial (ZEPLAST): a Randomized, Controlled Trial on Transfusion Avoidance in High Transfusion-risk Cardiac Surgery Patients|Completed||Phase 3|119|Actual|IRCCS Policlinico S. Donato||3|||f||||f||||||||||2018-05-31 21:56:47.480641|2018-05-31 21:56:47.480641
NCT01471717|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-06-21|2011-11-10|2011-11-16|Estimate|||||||2012-06-21|2012-06-22|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|INX-189-004||Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects|A Phase Ib, Single-Center, Randomized, Two-Sequence, Placebocontrolled, Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects|Completed||Phase 1/Phase 2|32|Actual|Bristol-Myers Squibb||6|||f||||t||||||||||2018-05-31 21:56:47.588226|2018-05-31 21:56:47.588226
NCT01471704|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-06-21|2011-11-10|2011-11-16|Estimate|||||||2012-06-21|2012-06-22|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|INX-189-005||Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers|A Phase 1b, Drug-Drug Interaction Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers|Completed||Phase 1/Phase 2|24|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-05-31 21:56:47.719703|2018-05-31 21:56:47.719703
NCT01471691|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|2015-03-17||2015-04-10|2011-11-10|2011-11-16|Estimate|2015-04-10|2015-04-29|Estimate||||2015-04-10|2015-04-29|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|RAVEN||Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab|Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)|Completed||Phase 1/Phase 2|14|Actual|Hanscom, Thomas, M.D.||2|||f||||f||||||||||2018-05-31 21:56:47.843002|2018-05-31 21:56:47.843002
NCT01471678|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2018-05-17|2011-11-10|2011-11-16|Estimate|||||||2018-05-17|2018-05-18|Actual|June 30, 2011|Actual|2011-06-30|May 2018|2018-05-31|September 7, 2011|Actual|2011-09-07|September 7, 2011|Actual|2011-09-07||Interventional|ARI115707||Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.|An Open-label, Randomized, Single Dose, Four-Period Crossover Study to Compare the Bioavailability of Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) With 10% and 15% of Enteric Coated Pellets With Harnal-D Tablets and Harnal Capsules Co-administered With Dutasteride (0.5 mg) Soft Gel Capsules in Healthy Male Subjects of North East Asian Ancestry|Completed||Phase 1|27|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:56:48.13136|2018-05-31 21:56:48.13136
NCT01471665|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-11-20|2011-11-10|2011-11-16|Estimate|||||||2016-11-20|2016-11-22|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||GSK2190915 Neutrophilic Asthma Study|A Randomised, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effect of Treatment With Repeat Dose GSK2190915 as an add-on to Current Therapy on the Percentage of Neutrophils in Induced Sputum in Asthmatic Patients With Elevated Sputum Neutrophils|Completed||Phase 2|14|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:56:48.269522|2018-05-31 21:56:48.269522
NCT01471587|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-12-01|2011-11-14|2011-11-16|Estimate|||||||2011-12-01|2011-12-02|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||Fibre Specific Signalling in the Locomotor Myopathy of Chronic Obstructive Pulmonary Disease|Fibre Specific Signalling in the Locomotor Myopathy of COPD|Unknown status|Recruiting||80|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     muscle and blood~   "|||2018-05-31 21:56:48.379574|2018-05-31 21:56:48.379574
NCT01471561|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-02-02|2011-11-10|2011-11-16|Estimate|||||||2016-02-02|2016-02-04|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Analysis of Cataract Surgery Induced Dry Eye|Retrospective Analysis of Cataract Surgery-induced Dry Eye Using Tear Osmolarity Testing|Completed|||61|Actual|TearLab Corporation|||||f||||f||||||||No|No data will be shared.|2018-05-31 21:56:48.445436|2018-05-31 21:56:48.445436
NCT01471548|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-04-20|2011-11-10|2011-11-16|Estimate|||||||2016-04-20|2016-04-21|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Phase I Dose Escalating Study of TKI258|A Phase I Dose Escalating Study to Evaluate TKI258 Administered Orally on a 5 Days on/2days Off Schedule in Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|31|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:56:48.627104|2018-05-31 21:56:48.627104
NCT01471431|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-06-03|2011-11-10|2011-11-16|Estimate|||||||2016-06-03|2016-06-07|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Extubation Readiness Study in Very Low Birthweight Infants|A Randomized Trial of the Spontaneous Breathing Trial to Extubate Very Low Birthweight Infants|Terminated||N/A|81|Actual|University of Pennsylvania||2||Futility analysis by DSMC recommended termination.|f||||t||||||||||2018-05-31 21:56:48.702178|2018-05-31 21:56:48.702178
NCT01470404|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-01-15|2011-11-10|2011-11-11|Estimate|||||||2018-01-15|2018-01-17|Actual|July 10, 2008|Actual|2008-07-10|January 2018|2018-01-31|July 10, 2013|Actual|2013-07-10|May 10, 2013|Actual|2013-05-10||Observational|||Pharmacogenomic Study (Adjuvant Chemotherapy)|Pharmacogenomic Study to Predict Toxicity and Response in Gastric Cancer Patients Treated With Adjuvant Chemotherapy|Completed|||792|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 21:57:09.490204|2018-05-31 21:57:09.490204
NCT01471418|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2015-07-06|2011-11-14|2011-11-16|Estimate|||||||2015-07-06|2015-07-08|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||The Use of PET/CT to Evaluate Synovitis in the Temporomandibular Joint (TMJ)|Investigation of the Use of Positron Emission Tomography With 18F-FDG PET/CT for the Diagnosis of Synovitis in the Temporomandibular Joint|Withdrawn||Phase 2|0|Actual|University of Pennsylvania||1||29-Apr-14 UPENN IRB granted approval to close study due to lack of funding|f||||f||||||||||2018-05-31 21:56:48.779047|2018-05-31 21:56:48.779047
NCT01471379|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2013-07-03||2017-03-15|2011-11-14|2011-11-16|Estimate|2013-11-05|2013-12-24|Estimate||||2017-03-15|2017-04-13|Actual|April 2012||2012-04-30|March 2017|2017-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||The study was terminated early resulting in a small number of subjects enrolled leaving the ability to analyze only certain categories.|Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Milnacipran in the Treatment of Irritable Bowel Syndrome|Terminated||Phase 2|2|Actual|University of North Carolina, Chapel Hill||3||Due to recruitment difficulties the study is terminated.|f||||f||||||||||2018-05-31 21:56:48.860429|2018-05-31 21:56:48.860429
NCT01471366|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-07-25|2011-11-10|2011-11-16|Estimate|||||||2014-07-25|2014-07-28|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Method of Fish Oil Administration on Patient Compliance|What is the Best Way to Take Fish Oil?|Completed||N/A|60|Actual|University of Mississippi, Oxford||4|||f||||f||||||||||2018-05-31 21:56:49.351692|2018-05-31 21:56:49.351692
NCT01471353|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2016-11-15||2018-04-04|2011-11-15|2011-11-16|Estimate|2017-02-09|2017-03-30|Actual||||2018-04-04|2018-05-07|Actual|November 2011||2011-11-30|April 2018|2018-04-30|May 2017|Actual|2017-05-31|October 2015|Actual|2015-10-31||Interventional|SorCape|Adults with metastatic colorectal cancer who had previously received two or more lines of systemic therapy.|Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer|Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer|Completed||Phase 2|43|Actual|University of Florida||1|||f||||t||||||||||2018-05-31 21:56:49.530379|2018-05-31 21:56:49.530379
NCT01471340|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2017-11-07||2018-01-04|2011-11-14|2011-11-16|Estimate|2018-01-04|2018-01-05|Actual||||2018-01-04|2018-01-05|Actual|January 9, 2012|Actual|2012-01-09|January 2018|2018-01-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|SPIRO|These are all participants who were randomized and treated with at least one dose of study medication|A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)|A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)|Completed||Phase 4|11744|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 21:56:49.956922|2018-05-31 21:56:49.956922
NCT01471652|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2015-04-09|2011-11-10|2011-11-15|Estimate|||||||2015-04-09|2015-04-13|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CFS:M||Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder|Chronic Fatigue Syndrome: Correction of Mitochondrial Dysfunction by Conditioning Exercise and Nutraceutical Therapy.|Withdrawn||Phase 2|0|Actual|Columbia University||2||PI left the institution|f||||t||||||||||2018-05-31 21:56:50.902311|2018-05-31 21:56:50.902311
NCT01471639|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2017-04-17||2017-08-16|2011-11-14|2011-11-15|Estimate|2017-08-16|2017-09-12|Actual||||2017-08-16|2017-09-12|Actual|November 2011||2011-11-30|August 2017|2017-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Sprix||An Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain|A Prospective, Open-label, Nonrandomized Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain|Completed||N/A|37|Actual|The Cleveland Clinic||1|||f||||f||||||||Undecided||2018-05-31 21:56:51.155978|2018-05-31 21:56:51.155978
NCT01471626|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2012-05-29||2012-09-06|2011-11-10|2011-11-15|Estimate|2012-09-06|2012-10-05|Estimate||||2012-09-06|2012-10-05|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|sleepbox||Real-time Attended Home-polysomnography Through Telematic Data Transmission|Real-time Attended Home-polysomnography Through Telematic Data Transmission|Completed||N/A|21|Actual|Centre Hospitalier Universitaire Saint Pierre|-technical problems with the Skype® connection|1|||f||||f||||||||||2018-05-31 21:56:51.508343|2018-05-31 21:56:51.508343
NCT01471613|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2014-01-27|2011-11-10|2011-11-15|Estimate|||||||2014-01-27|2014-01-28|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury|Safety and Effect of Lithium, Umbilical Cord Blood Cells and the Combination in the Treatment of Acute and Sub-acute Spinal Cord Injury : a Randomized, Double-Blinded Placebo-Controlled Clinical Trial|Completed||Phase 1/Phase 2|16|Actual|China Spinal Cord Injury Network||4|||f||||||||||||||2018-05-31 21:56:51.759615|2018-05-31 21:56:51.759615
NCT01471600|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-02-26|2011-11-10|2011-11-15|Estimate|||||||2013-02-26|2013-02-27|Estimate|May 2008||2008-05-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|ENDOGLUcide||Safety and Efficacy of Carbohydrate Drink Ingested Two Hours Before Upper Endoscopy Under General Anaesthesia|Randomized Control Study : Safety and Efficacy of Carbohydrate Drink Ingested Two Hours Before Upper Endoscopy Under General Anaesthesia|Completed||N/A|119|Actual|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 21:56:51.858661|2018-05-31 21:56:51.858661
NCT01471574|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2015-08-18||2015-12-22|2011-11-10|2011-11-15|Estimate|2015-11-16|2015-12-17|Estimate||||2015-12-22|2016-01-29|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional||All participants who received at least 1 dose of study therapy.|Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus|A Phase 3, Open Label Study of Safety and Efficacy With BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected With Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV)|Completed||Phase 3|549|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 21:56:51.982273|2018-05-31 21:56:51.982273
NCT01471535|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2015-03-08|2011-11-10|2011-11-15|Estimate|||||||2015-03-08|2015-03-10|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated|HBsAg Loss/Seroconversion in Inactive Chronic Hepatitis B Carriers Treated With Peginterferon Alpha-2a|Completed||N/A|20|Actual|Beijing Ditan Hospital||1|||f||||t||||||||||2018-05-31 21:56:52.994679|2018-05-31 21:56:52.994679
NCT01471522|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2018-03-15|2011-11-14|2011-11-15|Estimate|||||||2018-03-15|2018-03-19|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ISCHEMIA||International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)|International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)|Active, not recruiting||N/A|5179|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 21:56:53.190008|2018-05-31 21:56:53.190008
NCT01471509|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-11-06|2011-11-14|2011-11-15|Estimate|||||||2017-11-06|2017-11-08|Actual|August 1982||1982-08-31|November 2017|2017-11-30|November 6, 2017|Anticipated|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||Protein, Amino Acids & Insulin & Glucagon Secretion in Humans|The Effect of Ingestion of Foods on the Plasma Glucose and Insulin Response in Subjects With Type 2 Diabetes: Protein, Amino Acids & Insulin & Glucagon Secretion in Humans|Suspended||N/A|300|Anticipated|Minneapolis Veterans Affairs Medical Center||4||Lack of funding|f||||f||||||||||2018-05-31 21:56:53.877406|2018-05-31 21:56:53.877406
NCT01471496|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-10|2011-11-10|2011-11-15|Estimate|||||||2011-11-10|2011-11-15|Estimate|January 2003||2003-01-31|November 2011|2011-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Prophylactic Injection Therapy Reduces Recurrent Bleeding In Forrest Type IIb Duodenal Ulcers|Prophylactic Injection Therapy Reduces Recurrent Bleeding Rate In Forrest Type IIb Duodenal Ulcer Bleeding|Completed||N/A|80|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital||2|||f||||t||||||||||2018-05-31 21:56:53.997402|2018-05-31 21:56:53.997402
NCT01471483|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-10-03|2011-11-14|2011-11-15|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2011||2011-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer|Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer|Active, not recruiting|||50|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 21:56:54.195627|2018-05-31 21:56:54.195627
NCT01471470|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2018-01-10|2011-11-10|2011-11-15|Estimate|||||||2018-01-10|2018-01-11|Actual|July 2010|Actual|2010-07-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer|A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer|Active, not recruiting||Phase 2|31|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 21:56:54.317471|2018-05-31 21:56:54.317471
NCT01471457|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-05-16|2011-11-14|2011-11-15|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|TBVAP||Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis|The Use of Trimo-San Gel for the Prevention of Pessary-associated Bacterial Vaginosis|Completed||Phase 2/Phase 3|184|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 21:56:54.402049|2018-05-31 21:56:54.402049
NCT01471444|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2018-01-29|2011-11-14|2011-11-15|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2, 2011|Actual|2011-11-02|January 2018|2018-01-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 3|250|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:56:54.493862|2018-05-31 21:56:54.493862
NCT01471405|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-03-27|2011-11-14|2011-11-15|Estimate|||||||2014-03-27|2014-03-28|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|||One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma|Retrospective Non-interventional Study Evaluating Treatment Adaption During a One Year Follow-up After Completion of the 2-79-52030-207 Study in a Group of Acromegalic Patients With Macroadenoma Who Received 12 Injections of Lanreotide Autogel® 120 mg|Completed|||54|Actual|Ipsen|||||f||||f||||||||||2018-05-31 21:56:54.608233|2018-05-31 21:56:54.608233
NCT01471392|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2013-05-31|2011-11-14|2011-11-15|Estimate|||||||2013-05-31|2013-06-03|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Identigene STD Test Collection Kit Validation Study|Identigene STD Test Collection Kit Validation Study|Unknown status|Recruiting|Phase 3|3000|Anticipated|Identigene||1|||f||||f||||||||||2018-05-31 21:56:54.679577|2018-05-31 21:56:54.679577
NCT01471327|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-06-19|2011-11-10|2011-11-15|Estimate|||||||2017-06-19|2017-06-20|Actual|August 9, 2011|Actual|2011-08-09|June 2017|2017-06-30|April 27, 2012|Actual|2012-04-27|April 27, 2012|Actual|2012-04-27||Interventional|||Japanese Phase 1 Study of Mepolizumab|A Single Blind, Placebo Controlled, Parallel Group, Single Ascending Intravenous Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-240563 (Mepolizumab) in Healthy Japanese Male Subjects.|Completed||Phase 1|35|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:56:54.75843|2018-05-31 21:56:54.75843
NCT01471314|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2012-08-28|2011-11-14|2011-11-15|Estimate|||||||2012-08-28|2012-08-29|Estimate||||August 2012|2012-08-31||||||||Observational|||MRA/fMRI Study of Spontaneous Migraine|Functional MRI and MR Angiography Used in Spontaneous Migraine|Unknown status|Recruiting||||Glostrup University Hospital, Copenhagen|||1||f||||t||||||||||2018-05-31 21:56:54.87106|2018-05-31 21:56:54.87106
NCT01471301|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-11-14|2011-11-14|2011-11-15|Estimate|||||||2011-11-14|2011-11-15|Estimate|June 2011||2011-06-30|November 2011|2011-11-30||||November 2011|Anticipated|2011-11-30||Observational|||Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus|Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus|Unknown status|Recruiting||120|Anticipated|Federal University of São Paulo|||||f||||f||||||Samples With DNA|"~     serum~   "|||2018-05-31 21:56:54.937908|2018-05-31 21:56:54.937908
NCT01471288|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-11-14|2011-11-14|2011-11-15|Estimate|||||||2011-11-14|2011-11-15|Estimate|May 2011||2011-05-31|October 2011|2011-10-31||||December 2011|Anticipated|2011-12-31||Interventional|||Effect of Carum Carvi on Thyroid Hormones and TSH Level|Evaluation of the Effect of Carum Carvi on Levels of Plasma Thyroid Hormones and TSH Level in Patients on Thyroid Hormone Therapy and Normal Controls.|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Mashhad University of Medical Sciences||4|||f||||t||||||||||2018-05-31 21:56:54.997174|2018-05-31 21:56:54.997174
NCT01470209|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-03-15|2011-11-09|2011-11-11|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2012|Actual|2012-01-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies|A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies|Completed||Phase 1|43|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:57:12.864256|2018-05-31 21:57:12.864256
NCT01471275|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2011-12-05|2011-11-14|2011-11-15|Estimate|||||||2011-12-05|2011-12-06|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Chinese Medicine Treatment of Obesity With Type 2 Diabetes, Dyslipidemia|The Study of TCM in Prevention and Promote of Community-based Diabetes|Unknown status|Recruiting|N/A|450|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 21:56:55.231116|2018-05-31 21:56:55.231116
NCT01471262|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-11-21|2011-11-14|2011-11-15|Estimate|||||||2011-11-21|2011-11-22|Estimate|January 2006||2006-01-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Right Hepatectomy in Patients Beyond 70 Years Old|Right and Extended Right Hepatectomy in Patients Beyond 70 Years of Age - Liver Function and Outcome|Unknown status|Enrolling by invitation||90|Anticipated|Centre Hospitalier Universitaire Vaudois|||2||f||||t||||||||||2018-05-31 21:56:55.50763|2018-05-31 21:56:55.50763
NCT01471249|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-08-31|2011-11-14|2011-11-15|Estimate|||||||2017-08-31|2017-09-01|Actual|June 2011||2011-06-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|||Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer|Quality of Life and Dysphagia Following Palliative Stenting in Esophageal Cancer (CT0023)|Suspended|||100|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 21:56:55.647024|2018-05-31 21:56:55.647024
NCT01471236|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-02-28|2011-11-14|2011-11-15|Estimate|||||||2017-02-28|2017-03-01|Actual|June 2011||2011-06-30|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Agili-C Biphasic Implant in the Knee Joint|Evaluation of the Agili-C Bi-phasic Implant Performances in the Repair of Cartilage and Osteochondral Defects|Active, not recruiting||N/A|65|Actual|Cartiheal (2009) Ltd||1|||f||||f||||||||||2018-05-31 21:56:55.790786|2018-05-31 21:56:55.790786
NCT01471223|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-09-18|2011-11-14|2011-11-15|Estimate|||||||2017-09-18|2017-09-19|Actual|March 31, 2012|Actual|2012-03-31|September 2017|2017-09-30|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Observational|CTS||Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study|Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study (CTS)|Completed|||89|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 21:56:55.933309|2018-05-31 21:56:55.933309
NCT01471210|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2017-04-17|2011-11-14|2011-11-15|Estimate|||||||2017-04-17|2017-04-19|Actual|February 2012||2012-02-29|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)|Completed||Phase 1|124|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 21:56:56.059416|2018-05-31 21:56:56.059416
NCT01471197|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2014-03-06||2014-04-14|2011-11-14|2011-11-15|Estimate|2014-04-14|2014-05-12|Estimate||||2014-04-14|2014-05-12|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Randomized participants who received at least one dose of either study medication.|Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer|A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy|Terminated||Phase 2|9|Actual|Bristol-Myers Squibb|At the time of the early termination of this study, most participants only had only one on-study tumor assessment performed. Therefore, the tumor response-related endpoints were too immature to report.|2||Administrative reasons|f||||f||||||||||2018-05-31 21:56:56.370866|2018-05-31 21:56:56.370866
NCT01471184|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2011-11-18|2011-11-14|2011-11-15|Estimate|||||||2011-11-18|2011-11-21|Estimate|September 2009||2009-09-30|November 2011|2011-11-30||||March 2010|Actual|2010-03-31||Interventional|PPL-003||The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo|A Double-Blind, Randomized, Cross-Over Study of The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo, in Patients With Allergic Rhinitis and Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model|Completed||Phase 1|46|Actual|Bitop AG||2|||f||||f||||||||||2018-05-31 21:56:57.092746|2018-05-31 21:56:57.092746
NCT01471171|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|2013-05-21||2016-11-16|2011-11-14|2011-11-15|Estimate|2013-07-25|2013-07-30|Estimate||||2016-11-16|2017-01-04|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose, Randomised, Double-blind, Placebo Controlled, 2 Period Crossover Clinical Trial to Assess the Effect of Aclidinium Bromide 400 μg BID on Exercise Endurance in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|112|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:56:57.194222|2018-05-31 21:56:57.194222
NCT01471158|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-11-18|2011-11-14|2011-11-15|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma|Patient Preference Comparison of AZARGA Versus COSOPT After Single Doses in Patients With Open-Angled Glaucoma or Ocular Hypertension|Completed||Phase 4|120|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:56:57.509505|2018-05-31 21:56:57.509505
NCT01471145|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2014-10-10|2011-11-10|2011-11-15|Estimate|||||||2014-10-10|2014-10-13|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|XRNT||Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT|Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients|Completed||Phase 4|40|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 21:56:57.622132|2018-05-31 21:56:57.622132
NCT01471132|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-12-06|2011-11-10|2011-11-11|Estimate|||||||2012-12-06|2012-12-07|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|September 2015|Anticipated|2015-09-30|September 2013|Anticipated|2013-09-30||Interventional|SHOP-G01||Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis|Phase 2 Study of Sequential Hyperthermic Intraperitoneal Chemotherapy of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis or Positive Free Cancer Cells in Abdomen|Unknown status|Recruiting|Phase 2|20|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 21:56:57.716105|2018-05-31 21:56:57.716105
NCT01471119|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2015-08-11|2011-11-09|2011-11-11|Estimate|||||||2015-08-11|2015-08-13|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Sublingual Immunotherapy in Patients With Atopic Dermatitis|Usefulness and Safety of Sublingual Dermatophagoides Farinae Drops in Patients With Atopic Dermatitis:A Randomized,Double-blind,Placebo-controlled Study.|Completed||Phase 2|240|Anticipated|Zhejiang University||4|||f||||f||||||||||2018-05-31 21:56:57.807705|2018-05-31 21:56:57.807705
NCT01471106|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-10-20|2011-11-10|2011-11-11|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer|Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer|Recruiting||Phase 2|66|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 21:56:58.028067|2018-05-31 21:56:58.028067
NCT01471093|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-02-23|2011-11-09|2011-11-11|Estimate|||||||2012-02-23|2012-02-27|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Safety Study of OPC-12759 Ophthalmic Solution|Safety Study of OPC-12759 Ophthalmic Solution in Healthy Subjects|Completed||Phase 1|100|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:56:58.215188|2018-05-31 21:56:58.215188
NCT01471080|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-07-01|2011-11-10|2011-11-11|Estimate|||||||2014-07-01|2014-07-02|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver|A Prospective Controlled Study on Treatment of Giant Cavernous Hemangiomas of the Liver：RFA Versus Laparoscopic Hepatectomy.|Completed||N/A|140|Anticipated|Southwest Hospital, China||2|||f||||f||||||||||2018-05-31 21:56:58.310365|2018-05-31 21:56:58.310365
NCT01471067|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-04-27|2011-11-09|2011-11-11|Estimate|||||||2017-04-27|2017-04-28|Actual|July 13, 2012|Actual|2012-07-13|April 2017|2017-04-30|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies|Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies|Completed||Phase 1|33|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 21:56:58.394548|2018-05-31 21:56:58.394548
NCT01471054|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2016-12-09|2011-11-10|2011-11-11|Estimate|||||||2016-12-09|2016-12-12|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma|Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma|Terminated||Phase 2|6|Actual|Wills Eye||2||Could not enroll enough patients.|f||||f||||||||Undecided||2018-05-31 21:56:58.518772|2018-05-31 21:56:58.518772
NCT01471041|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2016-04-26||2016-04-26|2011-11-09|2011-11-11|Estimate|2016-04-26|2016-06-03|Estimate||||2016-04-26|2016-06-03|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|SAVE|ESRD patients treated with HD having a deep, uncanulatable AVF|Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae|Vital Access Venous Window Needle Guide for Salvage of AV FistulaE (SAVE) Trial|Completed||Phase 2/Phase 3|54|Actual|Vital Access Corp.||1|||f||||t||||||||||2018-05-31 21:56:58.620318|2018-05-31 21:56:58.620318
NCT01471028|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-09-22|2011-11-10|2011-11-11|Estimate|||||||2015-09-22|2015-09-24|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure|A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)|Completed||Phase 3|203|Actual|Vital Therapies, Inc.||2|||f||||t||||||||||2018-05-31 21:56:58.83991|2018-05-31 21:56:58.83991
NCT01471015|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2015-05-06||2015-05-06|2011-11-09|2011-11-11|Estimate|2015-05-06|2015-05-22|Estimate||||2015-05-06|2015-05-22|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|DANCE||Darbe Administration in Newborns Undergoing Cooling for Encephalopathy|Darbe Administration in Newborns Undergoing Cooling for Encephalopathy|Completed||Phase 1/Phase 2|30|Actual|University of Utah|Due to the small number of participants, infrequent adverse events may not have been detected. There is a lack of long-term follow up to assess for long-term safety concerns.|3|||f||||t||||||||||2018-05-31 21:56:59.111435|2018-05-31 21:56:59.111435
NCT01471002|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2016-04-07|2011-11-09|2011-11-11|Estimate|||||||2016-04-07|2016-04-08|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|CRYOREIN||Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours < 4cm in Patients Who Are Not Candidates for Partial Nephrectomy|Prospective Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours < 4cm in Patients Who Are Not Candidates for Partial Nephrectomy|Completed||N/A|100|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 21:56:59.47556|2018-05-31 21:56:59.47556
NCT01470989|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-02-21|2011-11-09|2011-11-11|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2011||2011-11-30|February 2017|2017-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|β-RELIEVED||β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)|An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective|Completed||Phase 3|135|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:56:59.544574|2018-05-31 21:56:59.544574
NCT01470976|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2016-02-03|2011-11-10|2011-11-11|Estimate|||||||2016-02-03|2016-02-04|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|GRICS||Goal-directed Resuscitation in High-risk Patients Undergoing Cardiac Surgery|Randomized Controlled Trial of Goal-directed Resuscitation in High-risk Patients Undergoing Cardiac Surgery|Completed||Phase 3|126|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:56:59.769627|2018-05-31 21:56:59.769627
NCT01470963|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2014-07-10|2011-11-10|2011-11-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Practical Health Co-operation - The Impact of a Referral Template on Quality of Health Care|Practical Health Co-operation - a Randomised Controlled Intervention Study. The Impact of a Referral Template on Quality of Care and Health Care Co-operation Between Primary and Secondary Care|Completed||N/A|500|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 21:56:59.855765|2018-05-31 21:56:59.855765
NCT01470950|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-02-04|2011-11-09|2011-11-11|Estimate|||||||2015-02-04|2015-02-05|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy|Characterization of the Changes in the Signalling Pathways During Spinal Cord Injury-induced Skeletal Muscle Atrophy|Unknown status|Active, not recruiting|N/A|28|Anticipated|Clinique Romande de Readaptation||1|||f||||||||||||||2018-05-31 21:56:59.945265|2018-05-31 21:56:59.945265
NCT01470937|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|February 1998||1998-02-28|November 2011|2011-11-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|EDIP||Early Diabetes Intervention Program|Early Diabetes Intervention Program|Completed||Phase 4|219|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 21:57:00.04264|2018-05-31 21:57:00.04264
NCT01470924|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|January 2003||2003-01-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|||||Observational|||Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007|High Curability Via Intensive Reinduction Chemotherapy and Stem Cell Transplantation in Young Adults With Relapsed Acute Lymphoblastic Leukemia in Sweden 2003-2007|Completed|||76|Actual|Region Örebro County|||||f||||||||||||||2018-05-31 21:57:00.145424|2018-05-31 21:57:00.145424
NCT01470911|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2012-11-21|2011-11-09|2011-11-11|Estimate|||||||2012-11-21|2012-11-22|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Orally Inhaled DNAzyme Solution for Nebulisation in Healthy Male Subjects|Phase-I Study in Healthy Male Subjects to Investigate Safety, Tolerability and Pharmacokinetics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation.|Completed||Phase 1|46|Actual|Sterna Biologicals GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 21:57:00.251138|2018-05-31 21:57:00.251138
NCT01470898|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2012-07-09|2011-11-09|2011-11-11|Estimate|||||||2012-07-09|2012-07-10|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|February 2013|Anticipated|2013-02-28|July 2011|Actual|2011-07-31||Interventional|||Bispectral Index (BIS) Monitoring in Abdominal Surgery|Effect of Bispectral Index (BIS) Monitoring on Faster Recovery Time and Analgesic Consumption in Abdominal Surgery Patients|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|University Hospital Dubrava||2|||f||||f||||||||||2018-05-31 21:57:00.36439|2018-05-31 21:57:00.36439
NCT01470885|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-05-02|2011-11-10|2011-11-11|Estimate|||||||2014-05-02|2014-05-05|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|ROGAAP||Relation of Glucose and Acute Pancreatitis|the Influence of Glucose to the Prognosis of Patients of Acute Pancreatitis|Completed|||350|Actual|Huashan Hospital|||1||f||||t||||||||||2018-05-31 21:57:00.461172|2018-05-31 21:57:00.461172
NCT01470859|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|2015-06-23||2015-09-21|2011-11-10|2011-11-11|Estimate|2015-09-21|2015-10-21|Estimate||||2015-09-21|2015-10-21|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease|a Pilot Follow-up Study of Investigating the Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Chinese Patients With Early Parkinson's Disease|Completed||N/A|30|Actual|Huashan Hospital|In the further study, a larger sample size and strict enrollment of early PD patients may enhance the accuracy of clinical trial conclusions.|2|||f||||t||||||||||2018-05-31 21:57:00.553699|2018-05-31 21:57:00.553699
NCT01470846|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-08-13|2011-11-10|2011-11-11|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|PERIDIGE||Postoperative Analgesia in Abdominal Surgery: a Medico-economic Study|Epidural Analgesia vs. Morphine Patient-controlled Analgesia in Abdominal Surgery Under Laparotomy : a Medico-economic Study|Terminated||Phase 4|35|Actual|University Hospital, Limoges||2||Lack of patients eligible for the study|f||||f||||||||||2018-05-31 21:57:00.92238|2018-05-31 21:57:00.92238
NCT01470833|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-08-17|2011-11-10|2011-11-11|Estimate|||||||2013-08-17|2013-08-20|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Non-operative Treatment of Acute Achilles Tendon Rupture Using Dynamic Rehabilitation. Influence of Early Weight-bearing Compared With Non-weight-bearing|Non-operative Treatment of Acute Achilles Tendon Rupture Using Dynamic Rehabilitation. The Influence of Early Weight-bearing Compared With Non-weight-bearing|Completed||N/A|60|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 21:57:00.989462|2018-05-31 21:57:00.989462
NCT01470820|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||"Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a Saturation Point"|"Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a Saturation Point?"|Completed||N/A|151|Actual|University of Aarhus||4|||f||||f||||||||||2018-05-31 21:57:01.055041|2018-05-31 21:57:01.055041
NCT01470807|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-11-28|2011-11-10|2011-11-11|Estimate|||||||2012-11-28|2012-11-29|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing|Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes|Completed||N/A|5|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 21:57:01.129387|2018-05-31 21:57:01.129387
NCT01470794|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2018-05-16|2011-11-09|2011-11-11|Estimate|||||||2018-05-16|2018-05-21|Actual|February 2012|Actual|2012-02-29|May 2018|2018-05-31|April 12, 2016|Actual|2016-04-12|April 12, 2016|Actual|2016-04-12||Interventional|||Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor|A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC|Completed||Phase 1|58|Actual|Tocagen Inc.||1|||f||||t||||||||||2018-05-31 21:57:01.199062|2018-05-31 21:57:01.199062
NCT01470781|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-03-22|2011-11-09|2011-11-11|Estimate|||||||2017-03-22|2017-03-24|Actual|June 2011||2011-06-30|March 2017|2017-03-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|TREC-BD||Treatment to Enhance Cognition in Bipolar Disorder|Efficacy of a Cognitive Remediation Treatment Program for Bipolar Disorder|Completed||N/A|84|Actual|Mclean Hospital||2|||f||||f||||||||||2018-05-31 21:57:01.302576|2018-05-31 21:57:01.302576
NCT01470768|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2012-03-20|2011-11-10|2011-11-11|Estimate|||||||2012-03-20|2012-03-22|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based (AA) Formulas|Evaluation of Fatty Acid Levels and Growth in Infants Fed Amino Acid Based Formulas|Withdrawn||N/A|0|Actual|Mead Johnson Nutrition||2||Sponsor cancelled study|f||||f||||||||||2018-05-31 21:57:01.381108|2018-05-31 21:57:01.381108
NCT01470755|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-05-22|2011-11-10|2011-11-11|Estimate|||||||2014-05-22|2014-05-23|Estimate|January 2012||2012-01-31|July 2011|2011-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|DORESI||Study of Dose-response to Bronchodilator and Dose-finding in Child 2.5 to 6 Years - Study Golden|Study on Dose-response to Bronchodilator Then Bronchodilator Dose-finding Using the Flow Interruption Technique in Children Aged 2.5 TO 6 Years|Completed||Phase 2|90|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-05-31 21:57:01.591856|2018-05-31 21:57:01.591856
NCT01470742|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-04-30|2011-11-09|2011-11-11|Estimate|||||||2015-04-30|2015-05-01|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer|A Randomized, Phase III, Multicenter Clinical Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:57:01.732833|2018-05-31 21:57:01.732833
NCT01470729|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2015-12-15|2011-11-09|2011-11-11|Estimate|||||||2015-12-15|2015-12-16|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|BIOSCA||Biomarkers in Autosomal Dominant Cerebellar Ataxia|Identification of Biomarkers in Patients With Autosomal Dominant Cerebellar Ataxia|Completed|||102|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 21:57:01.823473|2018-05-31 21:57:01.823473
NCT01470716|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-08-24|2011-11-10|2011-11-11|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2012||2012-01-31|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations|A Phase II Study of Neo-adjuvant Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lunc Cancer With Epidermal Growth Factor Receptor Activation Mutations|Recruiting||Phase 2|26|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 21:57:01.908637|2018-05-31 21:57:01.908637
NCT01470703|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-01-11|2011-11-10|2011-11-11|Estimate|||||||2018-01-11|2018-01-12|Actual|December 8, 2011|Actual|2011-12-08|September 2017|2017-09-30|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|EOLIA||Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome|Extracorporeal Membrane Oxygenation(ECMO) for Severe Acute Respiratory Distress Syndrome (ARDS)|Completed||N/A|249|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:57:02.019584|2018-05-31 21:57:02.019584
NCT01470690|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-11-26|2011-11-09|2011-11-11|Estimate|||||||2012-11-26|2012-11-27|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|PROMO||Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)|Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)|Completed||Phase 1|24|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 21:57:02.168291|2018-05-31 21:57:02.168291
NCT01470677|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-01-19|2011-11-09|2011-11-11|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Tachosil for the Prevention of Symptomatic Lymph Cysts|A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial|Completed||Phase 3|220|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 21:57:02.262512|2018-05-31 21:57:02.262512
NCT01470664|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09||2015-09-03|2015-09-22|2011-11-10|2011-11-11|Estimate||||2015-09-03|2015-09-18|Estimate|2015-09-22|2015-10-08|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||FST-100 in the Treatment of Acute Adenoviral Conjunctivitis|A Proof-of-Concept, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Adenoviral Conjunctivitis|Completed||Phase 2|176|Actual|Shire||3|||f||||f||||||||||2018-05-31 21:57:02.345494|2018-05-31 21:57:02.345494
NCT01470651|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2016-10-25||2016-12-19|2011-11-10|2011-11-11|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|October 2011||2011-10-31|October 2016|2016-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Armodafinil for Patients Starting Hepatitis C Virus Treatment|Armodafinil for Patients Starting Hepatitis C Treatment|Terminated||Phase 4|26|Actual|Research Foundation for Mental Hygiene, Inc.|It is difficult to attribute side effects to Armodafinil or placebo given patients were undergoing Hepatitis C Treatment throughout the trial.|2||European Medicines Agency issued a drug/drug interaction: sofosbuvir/modafinil|f||||t||||||||No||2018-05-31 21:57:02.434679|2018-05-31 21:57:02.434679
NCT01470638|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-07-03|2011-11-10|2011-11-11|Estimate|||||||2017-07-03|2017-07-05|Actual|June 2009||2009-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Study of Flt3-Ligand Levels in Sjögrens Syndrome|Analyzes of Cerebrospinal Fluid in Autoimmune Systemic Diseases|Recruiting|||50|Anticipated|Göteborg University|||||f||||f||||||Samples Without DNA|"~     Serum, cerebrospinal fluid~   "|||2018-05-31 21:57:02.810376|2018-05-31 21:57:02.810376
NCT01470625|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2013-01-11|2011-11-09|2011-11-11|Estimate|||||||2013-01-11|2013-01-14|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Improving Quality of Care for the Dying Patient in Hospice: A Quasi Experimental Trial in Liguria Region||Completed||Phase 2|282|Actual|Regional Palliative Care Network||1|||f||||f||||||||||2018-05-31 21:57:02.888125|2018-05-31 21:57:02.888125
NCT01470612|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2018-05-17|2011-11-09|2011-11-11|Estimate|||||||2018-05-17|2018-05-18|Actual|October 1, 2012|Actual|2012-10-01|May 2018|2018-05-31|July 27, 2018|Anticipated|2018-07-27|July 27, 2018|Anticipated|2018-07-27||Interventional|OCTAVE||Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis|A Multi-center, Open-label Study Of Cp-690,550 In Subjects With Moderate To Severe Ulcerative Colitis|Active, not recruiting||Phase 3|946|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:57:02.979736|2018-05-31 21:57:02.979736
NCT01470599|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2017-06-20||2017-09-12|2011-11-09|2011-11-11|Estimate|2017-09-12|2017-10-16|Actual||||2017-09-12|2017-10-16|Actual|April 2012|Actual|2012-04-30|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||The safety analysis set (SAS) consisted of all participants enrolled in this open label (OL) extension study who received at least 1 dose of study medication.|A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease|A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn's Disease|Completed||Phase 2|150|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:57:04.707581|2018-05-31 21:57:04.707581
NCT01470586|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Interventional|||Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer|Surgical Resection Lowers Oxidative Stress Markers in Patients With Colorectal Cancer|Completed||N/A|60|Actual|G. Hatzikosta General Hospital||2|||f||||t||||||||||2018-05-31 21:57:07.087071|2018-05-31 21:57:07.087071
NCT01470573|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-12-07|2011-11-10|2011-11-11|Estimate|||||||2012-12-07|2012-12-10|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MeRSO09||Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Cells of Sclerocorneal Limbus Amplified ex Vivo|Regenerative Medicine in Ocular Surface: Application of Cell Therapy for Ocular Surface Repair Using Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo|Completed||Phase 2|10|Actual|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 21:57:07.286589|2018-05-31 21:57:07.286589
NCT01470560|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-12-10|2011-11-09|2011-11-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional|MBSR-Yoga||Mindfulness-Based Stress Reduction Techniques and Yoga for Treatment of Urinary Urge Incontinence (MBSR-Yoga)|Mindfulness-Based Stress Reduction Techniques and Yoga for Treatment of Urinary Urge Incontinence (MBSR-Yoga)|Completed||N/A|||University of Utah||2|||f||||f||||||||||2018-05-31 21:57:07.398753|2018-05-31 21:57:07.398753
NCT01470547|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-03-13|2011-11-10|2011-11-11|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2012||2012-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|April 2017|Actual|2017-04-30||Observational|PRO-LIVER||Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry|Portal Vein Thrombosis Relevance On Liver Cirrhosis: Italian Venous Thrombotic Events Registry|Completed|||753|Actual|University of Roma La Sapienza|||||f||||t||||||Samples Without DNA|"~     Plasma and serum samples (in ancillary study)~   "|No||2018-05-31 21:57:07.46865|2018-05-31 21:57:07.46865
NCT01470534|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-10-04|2011-11-10|2011-11-11|Estimate|||||||2012-10-04|2012-10-05|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Mechanisms Underlying Postoperative Insulin Resistance and Inflammation|Investigating Whether the Magnitude of Postoperative Inflammatory and Insulin Resistant Responses is Related to Body Composition and Physiological Function of Skeletal Muscle & Adipose Tissue|Unknown status|Recruiting|Phase 4|32|Anticipated|University of Nottingham||4|||f||||t||||||||||2018-05-31 21:57:07.538957|2018-05-31 21:57:07.538957
NCT01470521|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-01-28|2011-11-09|2011-11-11|Estimate|||||||2016-01-28|2016-01-29|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|WIRMS||Worms for Immune Regulation of Multiple Sclerosis|Worms for Immune Regulation of Multiple Sclerosis (WIRMS)|Completed||Phase 2|72|Actual|University of Nottingham||2|||f||||t||||||||No||2018-05-31 21:57:07.659212|2018-05-31 21:57:07.659212
NCT01470508|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-05-16|2011-11-09|2011-11-11|Estimate|||||||2016-05-16|2016-05-18|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PAS||Engaging Latino Families in Eating Disorders Treatment|Engaging Latino Families in Eating Disorders Treatment|Completed||N/A|25|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:57:07.862092|2018-05-31 21:57:07.862092
NCT01470495|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-03-27|2011-11-10|2011-11-11|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|REPEAT||Combined Treatment of RFA and Sorafenib on Recurrent HCC|Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy|Recruiting||N/A|430|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 21:57:07.963867|2018-05-31 21:57:07.963867
NCT01470482|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-06-08|2011-11-10|2011-11-11|Estimate|||||||2015-06-08|2015-06-09|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Does Tourniquet Use in Total Knee Replacement Improve Fixation|Does Tourniquet Use in Total Knee Replacement Improve Fixation|Completed||Phase 3|50|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 21:57:08.091384|2018-05-31 21:57:08.091384
NCT01470469|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|2014-04-24||2014-04-24|2011-11-09|2011-11-11|Estimate|2014-04-24|2014-05-23|Estimate||||2014-04-24|2014-05-23|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).|Completed||Phase 2|83|Actual|Shire|Efficacy endpoints were exploratory. No statistical testing was performed because the study was not powered.|2|||f||||||||||||||2018-05-31 21:57:08.279259|2018-05-31 21:57:08.279259
NCT01470456|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-11-12|2011-11-10|2011-11-11|Estimate|||||||2014-11-12|2014-11-13|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Interventional|||Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma|An Open Label, Multicenter Phase II Study of Intravenous SAR3419, an Anti-CD19 Antibody-Maytansine Conjugate, in Combination With Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphomas|Completed||Phase 2|50|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:57:08.740726|2018-05-31 21:57:08.740726
NCT01470443|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-02-15|2011-11-10|2011-11-11|Estimate|||||||2017-02-15|2017-02-17|Actual|December 28, 2011|Actual|2011-12-28|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma|A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma|Recruiting||Phase 3|240|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:57:08.825154|2018-05-31 21:57:08.825154
NCT01470430|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-01-26|2011-11-09|2011-11-11|Estimate|||||||2014-01-26|2014-01-28|Estimate|March 2012||2012-03-31|January 2014|2014-01-31||||March 2014|Anticipated|2014-03-31||Observational|||VEGF In Systemic Circulation Of ROP-infants|Study to Measure Systemic VEGF Levels in ROP Infants Following Intravitreal Anti-VEGF Therapy or Retinal Laser Treatment|Withdrawn|||0|Actual|University Hospital Freiburg|||2||f||||f||||||||||2018-05-31 21:57:08.916407|2018-05-31 21:57:08.916407
NCT01470417|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|2015-01-08||2018-04-12|2011-11-10|2011-11-11|Estimate|2015-01-27|2015-02-09|Estimate||||2018-04-12|2018-04-17|Actual|October 2011||2011-10-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2014|Actual|2014-01-31||Interventional|GAIN-1|Adults with pathologically confirmed resectable or borderline resectable pancreatic adenocarcinoma|Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma|GAIN-1 Study: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|10|Actual|University of Florida||2|||f||||t|t|f||||||||2018-05-31 21:57:09.022669|2018-05-31 21:57:09.022669
NCT01470391|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2012-12-17|2011-11-09|2011-11-11|Estimate|||||||2012-12-17|2012-12-18|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength, Pain and Mobilization After Total Knee Replacement|"A Comparison of the Efficacy of the Adductor-Canal-Blockade Versus the Femoral Nerve Block on Muscle Strength, Pain and Mobilization After Total Knee Arthroplasty: a Randomized Study"|Completed||N/A|54|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 21:57:09.554437|2018-05-31 21:57:09.554437
NCT01470378|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2013-08-07|2011-11-10|2011-11-11|Estimate|||||||2013-08-07|2013-08-09|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|November 2013|Anticipated|2013-11-30|November 2012|Actual|2012-11-30||Interventional|Thight_lift||Manual Lymphatic Drainage in Women Undergone to Thigh Lifting|Manual Lymphatic Drainage in Women Undergone to Thigh Lifting After Bariatric Surgery|Unknown status|Recruiting|Phase 1|20|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:57:09.637809|2018-05-31 21:57:09.637809
NCT01470365|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2018-02-06|2011-11-09|2011-11-11|Estimate|||||||2018-02-06|2018-02-07|Actual|November 3, 2011|Actual|2011-11-03|February 2018|2018-02-28|September 9, 2018|Anticipated|2018-09-09|August 31, 2015|Actual|2015-08-31||Interventional|||3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors|Phase I Study of Pulsed Low Dose Rate Reirradiation Delivered With 3DCRT/IMRT for Palliation of Recurrent Tumors|Active, not recruiting||Phase 1|24|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 21:57:09.739393|2018-05-31 21:57:09.739393
NCT01470352|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-09-26|2011-11-10|2011-11-11|Estimate|||||||2017-09-26|2017-09-27|Actual|December 2011||2011-12-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|||Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention||Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 21:57:09.828757|2018-05-31 21:57:09.828757
NCT01470339|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2015-09-16|2011-11-10|2011-11-11|Estimate|||||||2015-09-16|2015-09-17|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Improvement the Anti-migraine Treatment Efficacy by Tailoring the Drug to Individual's Pain Modulation Profile||Completed||N/A|200|Actual|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 21:57:09.901157|2018-05-31 21:57:09.901157
NCT01470326|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-10-18|2011-11-09|2011-11-11|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|VIOLINE||Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)|Viviant®20mg Special Investigation (Regulatory Post Marketing Commitment Plan)|Completed|||3185|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:57:10.073384|2018-05-31 21:57:10.073384
NCT01470313|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2014-01-27|2011-11-09|2011-11-11|Estimate|||||||2014-01-27|2014-01-29|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus|A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE)|Terminated||Phase 1|28|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 21:57:10.482259|2018-05-31 21:57:10.482259
NCT01470300|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Reducing Energy Density by Different Methods to Decrease Energy Intake|Reducing Energy Density by Different Methods to Decrease Energy Intake|Completed||N/A|62|Actual|Penn State University||4|||f||||f||||||||||2018-05-31 21:57:10.75095|2018-05-31 21:57:10.75095
NCT01470287|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-05-17|2011-11-10|2011-11-11|Estimate|||||||2017-05-17|2017-05-19|Actual|December 2011||2011-12-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age|A Phase-III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine (DTwP-Hib-HepB Vaccine) When Administered to Indian Infants at 6, 10, and 14 Weeks of Age|Completed||Phase 3|175|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:57:10.827194|2018-05-31 21:57:10.827194
NCT01470274|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-07-28|2011-11-10|2011-11-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Observational|||Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients|Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients|Completed|||18|Actual|Norwegian University of Science and Technology|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 21:57:11.383549|2018-05-31 21:57:11.383549
NCT01470261|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2016-09-20|2011-11-10|2011-11-11|Estimate|||||||2016-09-20|2016-09-21|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Observational|ADDUCE||Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects|Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects|Completed|||1398|Actual|NHS Tayside|||3||f||||t||||||||||2018-05-31 21:57:11.647463|2018-05-31 21:57:11.647463
NCT01470248|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2017-01-18||2017-03-08|2011-11-10|2011-11-11|Estimate|2017-01-18|2017-03-08|Actual||||2017-03-08|2017-04-05|Actual|August 2011||2011-08-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study of Arsenic Trioxide in Small Cell Lung Cancer|A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer|Completed||Phase 2|20|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:57:11.987746|2018-05-31 21:57:11.987746
NCT01470235|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2013-10-31|2011-11-09|2011-11-11|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|August 2015|Anticipated|2015-08-31|September 2014|Anticipated|2014-09-30||Observational|||Hypodontia and Ovarian Cancer|Hypodontia and Ovarian Cancer - the Connection Between Dental Agenesis and Epithelial Cancers, Especially Ovarian Cancer.|Unknown status|Recruiting||200|Anticipated|University of Aarhus|||3||f||||t||||||Samples With DNA|"~     5ml EDTA full blood for DNA analysis.~      1 PAX-tube for RNA analysis. Biopsi from removed tumor-tissue for DNA analysis. Both~     preserved in Danish Cancer Biobank for later analysis.~   "|||2018-05-31 21:57:12.504673|2018-05-31 21:57:12.504673
NCT01470222|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|March 2011|Actual|2011-03-31||Interventional|HWL||The Healthy Weight for Life Program|The Healthy Weight for Life Program|Completed||N/A|175|Actual|Tufts University||2|||f||||f||||||||||2018-05-31 21:57:12.679183|2018-05-31 21:57:12.679183
NCT01470196|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2017-03-20||2017-05-01|2011-11-09|2011-11-11|Estimate|2017-03-20|2017-05-01|Actual||||2017-05-01|2017-06-09|Actual|October 2011||2011-10-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CaRD||Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia|Carfilzomib, Rituximab, and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia|Completed||Phase 2|31|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||Undecided||2018-05-31 21:57:13.096986|2018-05-31 21:57:13.096986
NCT01470183|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-02-05|2011-11-09|2011-11-11|Estimate|||||||2014-02-05|2014-02-07|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients|Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients|Completed|||46|Actual|Columbia University|||2||f||||f||||||||||2018-05-31 21:57:13.767515|2018-05-31 21:57:13.767515
NCT01470170|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2015-03-17||2015-08-07|2011-11-09|2011-11-11|Estimate|2015-08-07|2015-08-13|Estimate||||2015-08-07|2015-08-13|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy|The Optimal Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy：a Prospective Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 4|173|Actual|Chang Gung Memorial Hospital||5|||f||||f||||||||||2018-05-31 21:57:13.924262|2018-05-31 21:57:13.924262
NCT01470157|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-11-09|2011-11-09|2011-11-11|Estimate|||||||2011-11-09|2011-11-11|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|||A Clinical Trial of Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair|A Randomized, Clinical Trial of Oral Midazolam Plus Placebo Versus Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair|Unknown status|Recruiting|Phase 4|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 21:57:15.848683|2018-05-31 21:57:15.848683
NCT01470144|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2016-10-18||2017-06-01|2011-11-09|2011-11-11|Estimate|2016-10-18|2016-12-09|Estimate||||2017-06-01|2017-06-26|Actual|June 1, 2011|Actual|2011-06-01|June 2017|2017-06-30|July 1, 2015|Actual|2015-07-01|June 1, 2015|Actual|2015-06-01||Interventional|Epitome2ext||Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension|An Open-label Extension of Study AC-066A301 Investigating the Safety and Tolerability of ACT-385781A in Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 3|41|Actual|Actelion||1|||f||||f||||||||||2018-05-31 21:57:16.11185|2018-05-31 21:57:16.11185
NCT01470131|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-12-12|2011-11-09|2011-11-11|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|April 2013|Anticipated|2013-04-30||Interventional|||A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma|A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase 3 Study to Compare Efficacy and Safety of Masitinib 6 mg/kg/Day in Combination With Bortezomib and Dexamethasone to Placebo in Combination With Bortezomib and Dexamethasone in the Treatment of Patients With Relapsing Multiple Myeloma Who Received One Previous Therapy|Unknown status|Recruiting|Phase 3|300|Anticipated|AB Science||2|||f||||t||||||||||2018-05-31 21:57:16.554357|2018-05-31 21:57:16.554357
NCT01470118|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|2012-12-13||2013-01-18|2011-11-10|2011-11-11|Estimate|2013-01-18|2013-02-21|Estimate||||2013-01-18|2013-02-21|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis||Completed||Phase 4|127|Actual|Allergan||3|||f||||f||||||||||2018-05-31 21:57:16.817296|2018-05-31 21:57:16.817296
NCT01470105|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2018-04-24|2011-11-09|2011-11-11|Estimate|||||||2018-04-24|2018-04-25|Actual|November 2011||2011-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases|Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases|Active, not recruiting|||230|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 21:57:17.903639|2018-05-31 21:57:17.903639
NCT01470092|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2017-08-07|2011-11-10|2011-11-11|Estimate|||||||2017-08-07|2017-08-09|Actual|July 2012||2012-07-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal Depression|Double-Blind Randomised Investigation of Tibolone Alone or in Adjunct to Standard Antidepressant Treatment for Depression in Menopausal Women|Recruiting||Phase 4|120|Anticipated|The Alfred||2|||f||||t||||||||No||2018-05-31 21:57:18.147482|2018-05-31 21:57:18.147482
NCT01470079|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:57:18.395946|2018-05-31 21:57:18.395946
NCT01470066|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-10|2011-11-10|2011-11-11|Estimate|||||||2011-11-10|2011-11-11|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|May 2012|Anticipated|2012-05-31|May 2010|Actual|2010-05-31||Observational|||Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas||Unknown status|Recruiting||80|Anticipated|Chonnam National University Hospital|||||f||||t||||||||||2018-05-31 21:57:18.442648|2018-05-31 21:57:18.442648
NCT01470053|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2013-08-26|2011-11-10|2011-11-11|Estimate|||||||2013-08-26|2013-08-27|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis|A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Mometasone Furoate/Azelastine Hydrochloride Combination Group and Mometasone Furoate and Azelastine Hydrochloride Group 4 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Perennial Allergic Rhinitis Patient.|Completed||Phase 3|347|Actual|Hanlim Pharm. Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:57:18.590008|2018-05-31 21:57:18.590008
NCT01470040|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2012-01-17|2011-11-10|2011-11-11|Estimate|||||||2012-01-17|2012-01-18|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?|Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma?|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:57:18.864234|2018-05-31 21:57:18.864234
NCT01469845|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-09|||2015-03-24|2011-11-09|2011-11-10|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|SABRE||The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis|Hypertonic Saline in Acute Bronchiolitis: Randomised Controlled Trial and Economic Evaluation|Completed||Phase 3|300|Actual|Sheffield Children's NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:57:23.547644|2018-05-31 21:57:23.547644
NCT01470027|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2017-11-06||2018-03-19|2011-11-09|2011-11-10|Estimate|2018-03-19|2018-04-18|Actual||||2018-03-19|2018-04-18|Actual|January 2012||2012-01-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|NAC for PD||N-Acetylcysteine for Neuroprotection in Parkinson's Disease|N-Acetylcysteine for Neuroprotection in Parkinson's Disease|Completed||Phase 1/Phase 2|50|Actual|Weill Medical College of Cornell University|This study was limited by recruitment challenges related to identifying sufficient numbers of patients with PD who met all the eligibility criteria, especially with respect to medication status, and were willing to enter into the 4-week trial.|3|||f||||f||||||||||2018-05-31 21:57:19.071166|2018-05-31 21:57:19.071166
NCT01470014|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2015-12-09|2011-11-09|2011-11-10|Estimate|||||||2015-12-09|2015-12-10|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Cardiac Computed Tomography: Characteristics of Isolated Left Ventricular Non-compaction||Completed|||39|Actual|University of Zurich|||2||f||||||||||||||2018-05-31 21:57:20.856181|2018-05-31 21:57:20.856181
NCT01470001|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2016-09-28||2017-07-24|2011-11-08|2011-11-10|Estimate|2017-07-24|2017-08-23|Actual||||2017-07-24|2017-08-23|Actual|November 2011||2011-11-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Effect of Solifenacin on Post Void Dribbling in Women|The Effect of Solifenacin on Post Void Dribbling in Women: A Randomized Controlled Multicenter Trial|Completed||N/A|118|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 21:57:20.982134|2018-05-31 21:57:20.982134
NCT01469988|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2018-01-18|2011-11-09|2011-11-10|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2012||2012-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|VITA-HF||The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial|The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial|Terminated||Phase 2|318|Anticipated|University of Alberta||2||Feasibility|f||||t||||||||||2018-05-31 21:57:21.880495|2018-05-31 21:57:21.880495
NCT01469975|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-05-16|2011-11-08|2011-11-10|Estimate|||||||2017-05-16|2017-05-17|Actual|December 2011||2011-12-31|May 2017|2017-05-31|June 30, 2015|Actual|2015-06-30|February 3, 2015|Actual|2015-02-03||Interventional|SYNFRIZZ||First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10|First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas|Terminated||Phase 1|20|Actual|Centre Leon Berard||3||Too slow accrual.|f||||t||||||||||2018-05-31 21:57:21.990951|2018-05-31 21:57:21.990951
NCT01469962|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2014-06-18|2011-11-09|2011-11-10|Estimate|||||||2014-06-18|2014-06-19|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Observational|FIBROTEST||Evaluation of Liver Fibrosis Following Surgical-induced Weight Loss|Evolution of Fibrosis Scores During Weight Loss in a Population of Patients Operated on for Morbid Obesity|Completed|||255|Actual|University Hospital, Rouen|||1||f||||t||||||||||2018-05-31 21:57:22.125764|2018-05-31 21:57:22.125764
NCT01469949|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-09|2011-11-09|2011-11-10|Estimate|||||||2011-11-09|2011-11-10|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|MI||Mental Imagery Enhances Proprioception in Patients With Low Back Pain|Effect of Mental Imagery in Improvement of the Repositioning Accuracy and Proprioception in Patients With Low Back Pain|Completed|||55|Actual|Lebanese University|||3||f||||t||||||||||2018-05-31 21:57:22.213674|2018-05-31 21:57:22.213674
NCT01469936|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2016-09-06|2011-11-08|2011-11-10|Estimate|||||||2016-09-06|2016-09-07|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|February 2016|Actual|2016-02-29||Interventional|L2009-03||Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia|Study of the Effect of the Food Supplement PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia (a Pilot, Double-blind, Randomized, Placebo-controlled Study)|Active, not recruiting||N/A|40|Actual|Lescuyer Laboratory||2|||f||||f||||||||||2018-05-31 21:57:22.298777|2018-05-31 21:57:22.298777
NCT01469923|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2012-07-23|2011-11-08|2011-11-10|Estimate|||||||2012-07-23|2012-07-24|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses|A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 After Administration of Multiple Ascending Doses|Terminated||Phase 1|18|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:57:22.377958|2018-05-31 21:57:22.377958
NCT01469910|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2012-07-09|2011-11-08|2011-11-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects|Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects|Completed||Phase 1|63|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:57:22.513554|2018-05-31 21:57:22.513554
NCT01469897|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2018-01-12|2011-11-08|2011-11-10|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2012||2012-01-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|December 2014|Actual|2014-12-31||Observational|||Cost of Care for Juvenile Idiopathic Arthritis|Cost of Care for Juvenile Idiopathic Arthritis|Completed|||165|Actual|The Cleveland Clinic|||||f||||f|f|f||||||||2018-05-31 21:57:22.696547|2018-05-31 21:57:22.696547
NCT01469884|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2015-04-01|2011-11-08|2011-11-10|Estimate|||||||2015-04-01|2015-04-03|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CONCERVIC||Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients|A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients.|Completed||Phase 4|30|Actual|Irmandade Santa Casa de Misericórdia de Porto Alegre||2|||f||||f||||||||||2018-05-31 21:57:22.7953|2018-05-31 21:57:22.7953
NCT01469871|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-09|2011-11-09|2011-11-10|Estimate|||||||2011-11-09|2011-11-10|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of Three Types of Dressings After Hip Surgery|Reduction of Tape Blisters After Hip Surgery. A Prospective Evaluation of Three Types of Dressings.|Completed||Phase 4|150|Actual|Hopital de l'Enfant-Jesus||3|||f||||f||||||||||2018-05-31 21:57:23.058756|2018-05-31 21:57:23.058756
NCT01469858|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-08|2011-11-08|2011-11-10|Estimate|||||||2011-11-08|2011-11-10|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|November 2015|Anticipated|2015-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Perception and Multisensory Integration in Neurological Patients Using fMRI|Perception and Multisensory Integration in Neurological Patients Using fMRI|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 21:57:23.258418|2018-05-31 21:57:23.258418
NCT01469832|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08||2016-09-16|2017-02-20|2011-11-09|2011-11-10|Estimate||||2016-09-16|2016-09-23|Estimate|2017-02-20|2017-02-23|Actual|November 2011||2011-11-30|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)|A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)|Completed||Phase 1/Phase 2|12|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 21:57:23.674578|2018-05-31 21:57:23.674578
NCT01469819|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2016-05-09||2017-05-05|2011-11-08|2011-11-10|Estimate|2016-06-17|2016-08-01|Estimate||||2017-05-05|2017-06-09|Actual|June 2012||2012-06-30|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation|The Effect of Lubiprostone on Transit Times Within the Alimentary Tract, Measured by Novel Smartpill Methodology in Patients With Chronic Constipation|Completed||Phase 2/Phase 3|37|Actual|Texas Tech University Health Sciences Center, El Paso||1|||f||||f||||||||No||2018-05-31 21:57:23.957462|2018-05-31 21:57:23.957462
NCT01469806|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-09-26|2011-11-09|2011-11-10|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Observational|PFJPMCF||Patello-Femoral Joint Post Market Clinical Follow-up Within the Knee Registry|Zimmer(R) Gender Solutions(TM) Patello-Femoral Joint Prothesis Used Within the Knee Registry Protocol|Withdrawn|||0|Actual|Zimmer Biomet|||1|"Suspended pending internal review/direction of the company's focus. No sites ever engaged or~   collected data."|f||||f||||||||No||2018-05-31 21:57:24.462727|2018-05-31 21:57:24.462727
NCT01469793|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-01-06|2011-11-08|2011-11-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer|A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer|Completed||Phase 1|71|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 21:57:24.55713|2018-05-31 21:57:24.55713
NCT01469780|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2012-03-07|2011-11-09|2011-11-10|Estimate|||||||2012-03-07|2012-03-08|Estimate|April 1999||1999-04-30|March 2012|2012-03-31|February 2005|Actual|2005-02-28|August 2003|Actual|2003-08-31||Observational|||Assessing Pain as a Mediator of Behavior Change in Post-coronary Angioplasty Patients|Assessing Pain as a Mediator of Behavior Change in Post-coronary Angioplasty Patients|Completed|||660|Actual|Weill Medical College of Cornell University|||||f||||f||||||||||2018-05-31 21:57:24.678564|2018-05-31 21:57:24.678564
NCT01469767|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2017-01-27||2017-11-01|2011-11-09|2011-11-10|Estimate|2017-04-27|2017-05-01|Actual||||2017-11-01|2017-12-07|Actual|February 1, 2012|Actual|2012-02-01|November 2017|2017-11-30|August 17, 2013|Actual|2013-08-17|August 17, 2013|Actual|2013-08-17||Interventional|||Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis|Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis|Completed||N/A|10|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-05-31 21:57:24.819003|2018-05-31 21:57:24.819003
NCT01469754|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-05-01|2011-11-08|2011-11-10|Estimate|||||||2014-05-01|2014-05-05|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|CLEAR Stress||Longitudinal Survey Analysis in Lymphoma Survivors|Coping With Lymphoma to Enhance Adjustment and Reduce Stress in Lymphoma Survivors|Completed|||97|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-05-31 21:57:25.210021|2018-05-31 21:57:25.210021
NCT01469741|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2015-06-01|2011-11-09|2011-11-10|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|REMI-PD||Rehabilitation of Everyday Memory Impairment in Parkinson Disease: A Pilot Study|Rehabilitation of Everyday Memory Impairment in Parkinson Disease: A Pilot Study|Completed||N/A|74|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 21:57:25.290371|2018-05-31 21:57:25.290371
NCT01469728|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-11-08|2011-11-08|2011-11-10|Estimate|||||||2011-11-08|2011-11-10|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Comparison of Thoracoscopic Talc Pleurodesis by Thoracic Epidural or General Anesthesia|Randomized Study of Thoracoscopic Talc Pleurodesis Performed by Thoracic Epidural or General Anesthesia|Completed||Phase 2|40|Actual|University of Rome Tor Vergata||2|||f||||f||||||||||2018-05-31 21:57:25.524631|2018-05-31 21:57:25.524631
NCT01469715|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-07-03||2015-07-03|2011-11-08|2011-11-10|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SMA002||A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)|A Clinical Study of the Warm-Up, Accuracy, and Lag Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)|Completed||Phase 2|16|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 21:57:25.785649|2018-05-31 21:57:25.785649
NCT01469702|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-11-10|2011-11-09|2011-11-10|Estimate|||||||2011-11-10|2011-11-11|Estimate|December 2011||2011-12-31|November 2011|2011-11-30||||August 2012|Anticipated|2012-08-31||Interventional|||The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease|Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease|Unknown status|Not yet recruiting|Phase 4|10|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 21:57:26.01636|2018-05-31 21:57:26.01636
NCT01469689|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-05-29|2011-11-09|2011-11-10|Estimate|||||||2014-05-29|2014-05-30|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Raising Awareness of Online Therapies for Depression: Pilot Study|Raising Awareness of Online Therapies for Depression: Pilot Study|Completed||Phase 1|8231|Actual|University of Plymouth||4|||f||||f||||||||||2018-05-31 21:57:26.275495|2018-05-31 21:57:26.275495
NCT01469676|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-11-09|2011-11-09|2011-11-10|Estimate|||||||2011-11-09|2011-11-10|Estimate|February 2007||2007-02-28|November 2011|2011-11-30|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Interventional|PulmFunction||Effects of Cardiopulmonary Bypass (CPB)-Leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function|Effects of CPB-leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function.|Completed||N/A|22|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:57:26.700839|2018-05-31 21:57:26.700839
NCT01469663|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2011-11-09|2011-11-09|2011-11-10|Estimate|||||||2011-11-09|2011-11-10|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Event Related Potentials in Borderline Personality Disorder and Major Depression|Event Related Potentials in Borderline Personality Disorder and Major Depression|Unknown status|Recruiting||40|Anticipated|State University of New York - Upstate Medical University|||4||f||||f||||||||||2018-05-31 21:57:27.235706|2018-05-31 21:57:27.235706
NCT01469650|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2017-09-13|2011-11-09|2011-11-10|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants|Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants|Completed||N/A|32|Actual|University of Nebraska||2|||f||||f||||||||||2018-05-31 21:57:27.751759|2018-05-31 21:57:27.751759
NCT01469637|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2012-09-26||2012-09-26|2011-11-08|2011-11-10|Estimate|2012-09-26|2012-10-25|Estimate||||2012-09-26|2012-10-25|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects|Completed||Phase 1|44|Actual|Shire||2|||f||||||||||||||2018-05-31 21:57:27.994585|2018-05-31 21:57:27.994585
NCT01469624|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2011-11-08|2011-11-08|2011-11-10|Estimate|||||||2011-11-08|2011-11-10|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Evaluating the Protective Effect of Pentoxifylline on Contrast Induced Nephropathy|Evaluating the Protective Effect of Pentoxifylline on Contrast Induced Nephropathy|Unknown status|Recruiting|N/A|||Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:57:28.477597|2018-05-31 21:57:28.477597
NCT01469611|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-02-15|2011-11-09|2011-11-10|Estimate|||||||2017-02-15|2017-02-17|Actual|July 2010|Actual|2010-07-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|October 2012|Actual|2012-10-31||Interventional|||A Trial of JX-594 in Refractory Colorectal Carcinoma|A Phase 1b Dose Escalation Study of JX-594 (Thymidine Kinase-Inactivated Vaccinia Virus Plus GM-CSF) Administered by Biweekly (Every Two Weeks) Intravenous Infusion in Patients With Metastatic, Refractory Colorectal Carcinoma|Completed||Phase 1|15|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 21:57:28.693872|2018-05-31 21:57:28.693872
NCT01469598|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-12-28|2011-11-09|2011-11-10|Estimate|||||||2015-12-28|2015-12-29|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|||Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer|Phase II Study of Docetaxel and Gemcitabine in Previously Treated Metastatic Esophageal Squamous Cell Cancer|Completed||Phase 2|24|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 21:57:28.997427|2018-05-31 21:57:28.997427
NCT01469585|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-08-18|2011-11-08|2011-11-10|Estimate|||||||2014-08-18|2014-08-19|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|June 2012|Actual|2012-06-30||Interventional|||Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial MMPs|Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial MMPs|Unknown status|Active, not recruiting|N/A|14|Anticipated|University of Hawaii||2|||f||||f||||||||||2018-05-31 21:57:29.297198|2018-05-31 21:57:29.297198
NCT01469572|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-11-20|2011-11-08|2011-11-10|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2011||2011-12-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases|Phase IB/II Study of Pasireotide, Everolimus and Selective Internal Radioembolization Therapy (SIRT) for Unresectable Neuroendocrine Hepatic Metastases|Active, not recruiting||Phase 1|13|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:57:29.533165|2018-05-31 21:57:29.533165
NCT01469559|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2012-08-09|2011-11-09|2011-11-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|IIDPN||Safety Study of Intranasal Insulin in Type 1 Diabetes and Diabetic Peripheral Neuropathy|A Phase IIa Dose Escalation Pilot Study to Investigate the Safety and Tolerability of Intranasal Insulin in Subjects With Diabetic Polyneuropathy.|Completed||Phase 2|12|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 21:57:29.721482|2018-05-31 21:57:29.721482
NCT01469546|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2015-11-03||2016-07-26|2011-11-09|2011-11-10|Estimate|2015-11-03|2015-12-09|Estimate||||2016-07-26|2016-08-29|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Interventional||42 patients were enrolled. 12 patients did not complete the first cycle or undergo repeat tumor imaging (due to adverse event, disease progression, non-compliance or physician discretion). Only 30 patients were analyzed.|Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer|Phase II Trial Evaluating Axitinib (AG-013736) In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer|Completed||Phase 2|42|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:57:29.902641|2018-05-31 21:57:29.902641
NCT01469533|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-08|2011-11-08|2011-11-10|Estimate|||||||2011-11-08|2011-11-10|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pressure Pain Thresholds and Basal Electromyographic Activities Following Spinal Mechanical Manipulation|Changes in Pressure Pain Thresholds and Basal Electromyographic Activities Following Spinal Mechanical Manipulation in Asymptomatic Subjects|Completed||N/A|30|Actual|RenJi Hospital||2|||f||||t||||||||||2018-05-31 21:57:30.392704|2018-05-31 21:57:30.392704
NCT01469520|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-08|2011-11-08|2011-11-10|Estimate|||||||2011-11-08|2011-11-10|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Bioequivalence Study of Pediatric Formulations to Treat HIV Infection|Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers|Unknown status|Active, not recruiting|Phase 1|24|Actual|Elim Pediatric Pharmaceuticals Inc.||3|||f||||t||||||||||2018-05-31 21:57:30.594637|2018-05-31 21:57:30.594637
NCT01469507|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2013-02-20|2011-11-08|2011-11-10|Estimate|||||||2013-02-20|2013-02-21|Estimate||||February 2013|2013-02-28||||||||Interventional|VESTA||Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis|Comparative Study of Efficacy and Safety of Three Intra Articular Injections of V0220 Versus Hyalgan® in Patients Suffering From Symptomatic Knee Osteoarthritis. A Multinational Multicentric, Randomised, Double-blind, Parallel-group Study|Withdrawn||N/A|0|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-05-31 21:57:30.791638|2018-05-31 21:57:30.791638
NCT01469494|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2015-03-19|2011-11-09|2011-11-10|Estimate|||||||2015-03-19|2015-03-24|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Breast and Abdominal Related Morbidity of DIEP and SIEA Flaps|A Randomized Clinical Trial Comparing Breast and Abdominal Related Morbidity of DIEP and SIEA Flaps|Unknown status|Active, not recruiting|N/A|91|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 21:57:30.947132|2018-05-31 21:57:30.947132
NCT01469117|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2014-08-06|2011-11-08|2011-11-10|Estimate|||||||2014-08-06|2014-08-07|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Feeding Trial in Pediatric Patients|Enteral Formula Tolerance In Pediatric Patients With Developmental Disabilities|Completed|||16|Actual|Nestlé|||1||f||||f||||||||||2018-05-31 21:57:39.619865|2018-05-31 21:57:39.619865
NCT01469481|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2012-01-27|2011-11-08|2011-11-10|Estimate|||||||2012-01-27|2012-01-31|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532|An Open Label, Single-Period, Phase 1 Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance And Metabolism Of [14c]-PF-04991532 In Healthy Adult Male Subjects|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:57:31.073746|2018-05-31 21:57:31.073746
NCT01469468|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-29|||2011-12-27|2011-11-08|2011-11-10|Estimate|||||||2011-12-27|2011-12-30|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects|A Phase 1, Open-Label, Fixed-Sequence Study To Estimate The Effect Of Repeated Dosing Of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:57:31.260445|2018-05-31 21:57:31.260445
NCT01469455|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-06-16|2011-11-09|2011-11-10|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|DRIIM||DNA Repair Inhibitor & Irradiation on Melanoma|An Open Label, Non-randomized, First-in-human, Multi-centre Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Locally Administered DT01 in Combination With Radiotherapy and Concomitant Dose of Chloroquine in Patients With Local Metastatic Melanoma With Relapsed Cutaneous/Subcutaneous Tumors Including Melanoma-in-transit|Completed||Phase 1|27|Actual|DNA Therapeutics||1|||f||||t||||||||||2018-05-31 21:57:31.373532|2018-05-31 21:57:31.373532
NCT01469442|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2018-01-03|2011-11-07|2011-11-10|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2009||2009-05-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Postoperative Biliary Fistula Prevention After Hepatectomy|Postoperative Biliary Fistula Prevention After Hepatectomy by External Biliary Duct Stent:Prospective Multicenter Randomized Trial|Completed||N/A|304|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 21:57:31.562294|2018-05-31 21:57:31.562294
NCT01469429|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2018-03-05|2011-11-09|2011-11-10|Estimate|||||||2018-03-05|2018-03-07|Actual|September 4, 2007|Actual|2007-09-04|March 2018|2018-03-31|September 17, 2014|Actual|2014-09-17|September 17, 2014|Actual|2014-09-17||Interventional|||Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.|Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer|Completed||Phase 1/Phase 2|70|Actual|Ohio State University Comprehensive Cancer Center||4|||f||||t||f||||||||2018-05-31 21:57:31.966326|2018-05-31 21:57:31.966326
NCT01469416|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2014-07-16|2011-11-07|2011-11-10|Estimate|||||||2014-07-16|2014-07-18|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Drug Interaction Study of Clopidogrel and Rosuvastatin|The Effects of Administering Clopidogrel on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers|Completed||Phase 1|10|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:57:32.247199|2018-05-31 21:57:32.247199
NCT01469403|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2015-03-16|2011-11-07|2011-11-10|Estimate|||||||2015-03-16|2015-03-17|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Weight Loss Intervention Before Total Knee Replacement|Weight Loss Intervention Before Total Knee Replacement, a Randomized Controlled Trial|Completed||N/A|76|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:57:32.366732|2018-05-31 21:57:32.366732
NCT01469377|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2018-03-29||2018-03-29|2011-11-09|2011-11-10|Estimate|2018-03-29|2018-05-01|Actual||||2018-03-29|2018-05-01|Actual|December 15, 2011|Actual|2011-12-15|March 2018|2018-03-31|December 12, 2013|Actual|2013-12-12|December 12, 2013|Actual|2013-12-12||Interventional||The Safety Population consisted of all subjects in the Randomized Population who received at least 1 dose of double-blind investigational product.|Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder|A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder|Completed||Phase 2|819|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 21:57:32.581336|2018-05-31 21:57:32.581336
NCT01469364|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2015-10-23||2015-12-22|2011-11-09|2011-11-10|Estimate|2015-10-23|2015-11-26|Estimate||||2015-12-22|2016-01-29|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|AZLI||Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)|Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation|Completed||Phase 4|30|Actual|Duke University||1|||f||||f||||||||||2018-05-31 21:57:33.624063|2018-05-31 21:57:33.624063
NCT01469351|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2013-04-18|2011-11-07|2011-11-10|Estimate|||||||2013-04-18|2013-04-19|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Identifying Potential Effects of Liraglutide on Degenerative Changes|Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes|Completed||N/A|34|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:57:34.201345|2018-05-31 21:57:34.201345
NCT01469338|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-11-21|2011-11-09|2011-11-10|Estimate|||||||2014-11-21|2014-11-24|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel|A Phase II Clinical Trial of Cabazitaxel Plus Prednisone With Octreotide in the Treatment of Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel|Terminated||Phase 2|9|Actual|University of Southern California||1||lack of funding|f||||t||||||||||2018-05-31 21:57:34.500705|2018-05-31 21:57:34.500705
NCT01469325|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2011-11-20|2011-11-07|2011-11-10|Estimate|||||||2011-11-20|2011-11-22|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Sequential Left Prefrontal Repetitive Transcranial Magnetic Stimulation, With High Frequency, for Treatment-Resistant Depression|Effectiveness of of Sequential Left Prefrontal Repetitive Transcranial Magnetic Stimulation, With High Frequency, for Treatment-Resistant Depression, in TMS Unit, Neurcognitive Lab, Iranian National Center for Addiction Studies (INCAS), in 2011. A Randomized, Controlled Trial.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:57:34.719801|2018-05-31 21:57:34.719801
NCT01469312|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-09|2011-11-08|2011-11-10|Estimate|||||||2011-11-09|2011-11-11|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Pasta on Blood Glucose Response in Normal Subjects|Effect of Pasta on Blood Glucose Response in Normal Subjects|Completed||N/A|20|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 21:57:34.906658|2018-05-31 21:57:34.906658
NCT01469299|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2017-01-09|2011-11-09|2011-11-10|Estimate|||||||2017-01-09|2017-01-11|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Prospective Study Measuring Clinical Outcomes of Knee Arthroplasty Using the VERASENSE™ Knee System|Prospective Study Measuring Clinical Outcomes of Knee Arthroplasty Using the VERASENSE™ Knee System|Completed|||285|Actual|Orthosensor, Inc.|||||f||||f||||||||||2018-05-31 21:57:35.107296|2018-05-31 21:57:35.107296
NCT01469286|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2017-04-27|2011-11-08|2011-11-10|Estimate|||||||2017-04-27|2017-05-01|Actual|March 2010||2010-03-31|April 2017|2017-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|TEA||Transcutaneous Electroacupuncture for Gastroparesis|Transcutaneous Electroacupuncture for Gastroparesis|Completed||Phase 1|26|Actual|Transtimulation Research, Inc||2|||f||||t||||||||||2018-05-31 21:57:35.346068|2018-05-31 21:57:35.346068
NCT01469273|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2011-11-09|2011-11-09|2011-11-10|Estimate|||||||2011-11-09|2011-11-10|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Interventional|PIURA||Prophylaxis of Gastrointestinal Infections With EcN|Prophylaxis of Gastrointestinal Infections in Newborn and Infants With a Suspension Containing the Probiotic Escherichia Coli Strain Nissle|Unknown status|Not yet recruiting|Phase 4|198|Anticipated|Hospital San Bartolome||3|||f||||f||||||||||2018-05-31 21:57:35.558279|2018-05-31 21:57:35.558279
NCT01469260|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2011-11-08|2011-11-08|2011-11-10|Estimate|||||||2011-11-08|2011-11-10|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Pedometer Use to Prevent Excessive Pregnancy Weight Gain in Overweight Women|Effective Pedometer Use to Prevent Excessive Gestational Weight Gain in Overweight/Obese Women|Unknown status|Not yet recruiting|N/A|480|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 21:57:35.840972|2018-05-31 21:57:35.840972
NCT01469247|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2018-01-19|2011-11-09|2011-11-10|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2011|Actual|2011-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)|Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma|Active, not recruiting||Phase 1/Phase 2|12|Actual|M.D. Anderson Cancer Center||1|||f||||t|f|f||||||||2018-05-31 21:57:36.085567|2018-05-31 21:57:36.085567
NCT01469234|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2013-02-12||2015-02-20|2011-11-08|2011-11-10|Estimate|2013-02-12|2013-03-22|Estimate||||2015-02-20|2015-03-11|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)|A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber|Completed||Phase 4|255|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:57:36.241449|2018-05-31 21:57:36.241449
NCT01469221|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2017-10-17||2017-12-13|2011-11-09|2011-11-10|Estimate|2017-12-13|2017-12-15|Actual||||2017-12-13|2017-12-15|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)|A Phase 3 International, Double-Bind Trial Evaluating Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)|Terminated||Phase 3|47|Actual|Spectrum Pharmaceuticals, Inc||2||Business reason|f||||t||||||||||2018-05-31 21:57:37.27414|2018-05-31 21:57:37.27414
NCT01469208|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2013-07-31|2011-11-09|2011-11-10|Estimate|||||||2013-07-31|2013-08-02|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|MAGIC||Music Therapy: An Adjunct To Gastroschisis Infants' Care|The Effect of Music Therapy On Infants Born With Gastroschisis|Unknown status|Recruiting||30|Anticipated|Children's Hospitals and Clinics of Minnesota|||||f||||f||||||||||2018-05-31 21:57:37.696837|2018-05-31 21:57:37.696837
NCT01469195|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-11-07|2011-11-07|2011-11-10|Estimate|||||||2011-11-07|2011-11-10|Estimate|December 2011||2011-12-31|November 2011|2011-11-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||A Lead Rectangle to Lower the Operator's Radiation Exposure|A Lead Rectangle to Lower the Radiation Exposure for Operators Who Uses Radial Approach in Coronary Procedures.|Unknown status|Not yet recruiting||50|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||f||||||||||2018-05-31 21:57:37.763086|2018-05-31 21:57:37.763086
NCT01469182|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2014-04-25||2017-01-18|2011-11-09|2011-11-10|Estimate|2014-06-03|2014-06-05|Estimate||||2017-01-18|2017-03-03|Actual|November 2011||2011-11-30|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)|A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)|Completed||Phase 3|914|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-05-31 21:57:37.846644|2018-05-31 21:57:37.846644
NCT01469169|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2017-12-06|2011-11-08|2011-11-10|Estimate|||||||2017-12-06|2017-12-07|Actual|June 19, 2012|Actual|2012-06-19|December 2017|2017-12-31|December 14, 2016|Actual|2016-12-14|December 26, 2014|Actual|2014-12-26||Interventional|IBUKI||Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study|A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of BAY q 6256 (Iloprost) Inhalation in Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 3|27|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 21:57:38.217978|2018-05-31 21:57:38.217978
NCT01469156|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-02-19|2011-11-09|2011-11-10|Estimate|||||||2014-02-19|2014-02-20|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy|Treatment of Polypoidal Choroidal Vasculopathy With High Dose Ranibizumab (Lucentis): A Phase I Safety Study.|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Southeast Retina Center, Georgia||2|||f||||f||||||||||2018-05-31 21:57:38.32502|2018-05-31 21:57:38.32502
NCT01469143|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2015-02-20|2011-11-08|2011-11-10|Estimate|||||||2015-02-20|2015-02-23|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes|Completed||Phase 1|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:57:38.401419|2018-05-31 21:57:38.401419
NCT01469130|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-03-20|2011-11-09|2011-11-10|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2011||2011-11-30|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|April 2014|Actual|2014-04-30||Interventional|||A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors|A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|21|Actual|Array BioPharma||1|||f||||||||||||||2018-05-31 21:57:38.476381|2018-05-31 21:57:38.476381
NCT01469104|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2011-11-09|2011-11-09|2011-11-10|Estimate|||||||2011-11-09|2011-11-10|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|CHO-free diet||Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes|Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes|Completed||N/A|7|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 21:57:39.695846|2018-05-31 21:57:39.695846
NCT01469091|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2015-03-12|2011-11-09|2011-11-10|Estimate|||||||2015-03-12|2015-03-17|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|August 2014|Actual|2014-08-31|September 2012|Actual|2012-09-30||Interventional|ROC||Tobacco's Impact on Postoperative Complications in Acute Surgery|Tobacco's Impact on Postoperative Complications in Acute Vascular Surgery. A Randomized Clinical Trial|Terminated||N/A|160|Anticipated|Rigshospitalet, Denmark||2||Lack of patient inclusion|f||||f||||||||||2018-05-31 21:57:39.788501|2018-05-31 21:57:39.788501
NCT01469078|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-11-07|2011-11-07|2011-11-10|Estimate|||||||2012-11-07|2012-11-08|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|||Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered as Single Bolus Injections in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D) (PK-CKD-05)|Completed||Phase 1|18|Actual|Pharmacosmos A/S||3|||f||||t||||||||||2018-05-31 21:57:39.854399|2018-05-31 21:57:39.854399
NCT01469065|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2013-06-12||2013-09-26|2011-11-07|2011-11-10|Estimate|2013-06-12|2013-08-29|Estimate||||2013-09-26|2013-10-30|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes|A 2-week, Phase 1, Placebo-Controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Oral Doses Of PF-04991532 Given As Monotherapy To Adult Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|82|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:57:39.992983|2018-05-31 21:57:39.992983
NCT01469052|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2012-02-25||2012-02-25|2011-11-07|2011-11-10|Estimate|2012-02-25|2012-03-26|Estimate||||2012-02-25|2012-03-26|Estimate|November 2002||2002-11-30|February 2012|2012-02-29|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors|Phase I, Open-Label, Multicenter, Dose-Escalation Study Of The Tyrosine Kinase Inhibitor Of VEGFR-2, AG013736, In Patients With Advanced Solid Tumors|Completed||Phase 1|36|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 21:57:41.818606|2018-05-31 21:57:41.818606
NCT01469039|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2015-11-04|2014-04-14|2016-11-21|2011-11-08|2011-11-10|Estimate|2015-12-16|2016-01-22|Estimate|2014-04-14|2014-05-06|Estimate|2016-11-21|2017-01-11|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional||Randomized Population|A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia|Completed||Phase 3|623|Actual|Alkermes, Inc.||2|||f||||t||||||||||2018-05-31 21:57:42.785505|2018-05-31 21:57:42.785505
NCT01469026|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-11-09|2011-11-09|2011-11-10|Estimate|||||||2011-11-09|2011-11-10|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||CUP Project PET/CT|The Value of Early PET/CT in Patients With Metastasising Cancer of Unknown Primary|Unknown status|Not yet recruiting|Phase 4|220|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 21:57:43.572798|2018-05-31 21:57:43.572798
NCT01469013|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08||2013-01-11|2014-01-24|2011-11-08|2011-11-10|Estimate||||2013-01-11|2013-01-21|Estimate|2014-01-24|2014-02-24|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Interventional|||Oral JAK1/JAK2 Selective Inhibitor Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of LY3009104 in Japanese Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy|Completed||Phase 2|144|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 21:57:43.664943|2018-05-31 21:57:43.664943
NCT01469000|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2016-03-28||2018-01-16|2011-11-08|2011-11-10|Estimate|2016-03-28|2016-04-28|Estimate||||2018-01-16|2018-02-13|Actual|February 2012||2012-02-29|January 2018|2018-01-31|November 2017|Actual|2017-11-30|April 2015|Actual|2015-04-30||Interventional||All participants who received at least 1 dose of study drug.|A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)|A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations|Completed||Phase 2|195|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:57:43.856754|2018-05-31 21:57:43.856754
NCT01468987|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2018-03-16|2013-09-27|2018-03-16|2011-11-08|2011-11-10|Estimate|2018-03-16|2018-04-17|Actual|2013-09-27|2013-10-28|Estimate|2018-03-16|2018-04-17|Actual|December 2011||2011-12-31|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|IMAGINE 4|All participants.|A Study in Participants With Type 2 Diabetes Mellitus|The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin With Insulin Lispro: a Double-Blind, Randomized, 26-week Study - The IMAGINE 4 Study|Completed||Phase 3|1369|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 21:57:45.279035|2018-05-31 21:57:45.279035
NCT01468974|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2016-01-28|2011-11-08|2011-11-10|Estimate|||||||2016-01-28|2016-02-01|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System|A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System for the Treatment of Subjects With Symptomatic Claudication From Occlusive Vascular Disease of the Superficial Femoral (SFA) or Common or External Iliac Arteries.|Completed||N/A|35|Actual|Abbott Vascular||1|||f||||t||||||||||2018-05-31 21:57:46.997081|2018-05-31 21:57:46.997081
NCT01468961|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2017-08-17|2011-11-09|2011-11-10|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2011||2011-11-30|August 2017|2017-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pilot Study of Internet-based Cognitive Behavior Therapy for Fibromyalgia|Pilot Study of Internet-based Cognitive Behavior Therapy for Fibromyalgia|Completed||N/A|41|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 21:57:47.21062|2018-05-31 21:57:47.21062
NCT01468948|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-05-18|2011-11-08|2011-11-10|Estimate|||||||2018-05-18|2018-05-21|Actual|October 28, 2011||2011-10-28|July 18, 2012|2012-07-18|July 18, 2012|Actual|2012-07-18|July 18, 2012|Actual|2012-07-18||Interventional|||Octanoic Acid for Essential Tremor|Dose Escalation Study of Oral Octanoic Acid in Patients With Essential Tremor|Completed||Phase 1|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:57:47.300735|2018-05-31 21:57:47.300735
NCT01468935|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-05-15|2011-11-08|2011-11-10|Estimate|||||||2018-05-15|2018-05-16|Actual|October 31, 2011||2011-10-31|September 21, 2017|2017-09-21|September 21, 2017||2017-09-21|||||Observational|||Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning|Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning|Completed|||79|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:57:47.363581|2018-05-31 21:57:47.363581
NCT01468922|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-05-30|2011-11-08|2011-11-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 25, 2011||2011-10-25|December 7, 2017|2017-12-07|February 11, 2016|Actual|2016-02-11|September 30, 2014|Actual|2014-09-30||Interventional|||Pazopanib and ARQ 197 for Advanced Solid Tumors|Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors|Completed||Phase 1|32|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:57:47.426486|2018-05-31 21:57:47.426486
NCT01468909|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2018-05-23|2011-11-08|2011-11-10|Estimate|||||||2018-05-23|2018-05-24|Actual|December 12, 2011|Actual|2011-12-12|May 2018|2018-05-31||||July 31, 2019|Anticipated|2019-07-31||Interventional|||Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|A Randomized Phase IIB Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Active, not recruiting||Phase 2|110|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 21:57:47.517993|2018-05-31 21:57:47.517993
NCT01468896|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2017-07-31||2017-09-28|2011-11-08|2011-11-10|Estimate|2017-07-31|2017-08-31|Actual||||2017-09-28|2017-10-27|Actual|November 4, 2011|Actual|2011-11-04|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|July 12, 2013|Actual|2013-07-12||Interventional|||Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery|A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 1/Phase 2|23|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:57:47.822742|2018-05-31 21:57:47.822742
NCT01468883|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-01|||2018-05-23|2011-11-09|2011-11-10|Estimate|||||||2018-05-23|2018-05-24|Actual|September 13, 1979||1979-09-13|October 27, 2017|2017-10-27|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|||The Treatment of Stage I and II Breast Cancer With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Radiotherapy|The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection vs. Excisional Biopsy, Axillary Dissection, and Definitive Irradiation|Completed||Phase 3|256|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:57:48.486442|2018-05-31 21:57:48.486442
NCT01468857|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-05-22|2011-11-09|2011-11-10|Estimate|||||||2018-05-22|2018-05-23|Actual|September 26, 2011||2011-09-26|September 28, 2017|2017-09-28|September 28, 2017||2017-09-28|||||Observational|||Physical and Emotional Health of Caregivers for People Who Have Had Stem Cell Transplants|A Pilot Study to Examine Physiological and Clinical Markers of Chronic Stress in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:57:48.558467|2018-05-31 21:57:48.558467
NCT01468844|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-08|||2018-03-27|2011-11-09|2011-11-10|Estimate|||||||2018-03-27|2018-03-29|Actual|September 27, 2011||2011-09-27|March 5, 2018|2018-03-05|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Minocycline to Treat Central Retinal Vein Occlusion|A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions|Recruiting||Phase 1/Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:57:48.625254|2018-05-31 21:57:48.625254
NCT01468831|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-08|||2018-03-27|2011-11-09|2011-11-10|Estimate|||||||2018-03-27|2018-03-29|Actual|September 21, 2011||2011-09-21|March 5, 2018|2018-03-05|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Minocycline to Treat Branch Retinal Vein Occlusion|A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions|Recruiting||Phase 1/Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:57:48.737994|2018-05-31 21:57:48.737994
NCT01468818|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2016-05-19||2016-05-19|2011-11-09|2011-11-10|Estimate|2016-05-19|2016-06-27|Estimate||||2016-05-19|2016-06-27|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma|A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma|Terminated||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)|Study was closed prematurely due to slow and insufficient accrual.|1||Study was closed prematurely due to slow and insufficient accrual.|f||||f||||||||No||2018-05-31 21:57:48.861411|2018-05-31 21:57:48.861411
NCT01468805|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2018-05-23|2011-11-09|2011-11-10|Estimate|||||||2018-05-23|2018-05-24|Actual|September 4, 2011||2011-09-04|November 15, 2013|2013-11-15|November 15, 2013|Actual|2013-11-15|November 15, 2013|Actual|2013-11-15||Interventional|||Childhood Asthma Reduction Study|Childhood Asthma Reduction Study|Withdrawn||N/A|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:57:49.103993|2018-05-31 21:57:49.103993
NCT01468792|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-02-18|2011-11-07|2011-11-09|Estimate|||||||2014-02-18|2014-02-19|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Hemodynamic Changes in Connective Tissue Disease|Hemodynamic Changes in Connective Tissue Disease|Completed|||85|Actual|Medical University of Graz|||||f||||f||||||||||2018-05-31 21:57:49.162091|2018-05-31 21:57:49.162091
NCT01468779|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-03-01|2011-11-07|2011-11-09|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2010||2010-02-28|March 2017|2017-03-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Effect of Probiotics in Patients Undergoing Surgery for Periampullary Neoplasms|Effect of the Probiotics Use in Patients Undergoing Surgery for Periampullary Neoplasia - A Randomized Clinical Trial|Completed||Phase 3|58|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 21:57:49.220903|2018-05-31 21:57:49.220903
NCT01468766|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-04-18|2011-11-07|2011-11-09|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|BEST||Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy|Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy - A Randomised Controlled Intervention Trial|Completed||N/A|160|Actual|German Cancer Research Center||2|||f||||||||||||||2018-05-31 21:57:49.295985|2018-05-31 21:57:49.295985
NCT01468753|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-05-13|2011-11-08|2011-11-09|Estimate|||||||2015-05-13|2015-05-15|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pilot Study: Acceptability, Feasibility and Efficacy of Vaginal Insemination in HIV Discordant Couples (Female Positive, Male Negative) Desiring Conception in Kisumu, Kenya|Pilot Study: Acceptability, Feasibility and Efficacy of Vaginal Insemination in HIV Discordant Couples (Female Positive, Male Negative) Desiring Conception in Kisumu, Kenya|Completed||N/A|40|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 21:57:49.389869|2018-05-31 21:57:49.389869
NCT01468740|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-07|2011-11-07|2011-11-09|Estimate|||||||2011-11-07|2011-11-09|Estimate|March 2004||2004-03-31|November 2011|2011-11-30|July 2012|Anticipated|2012-07-31|February 2012|Anticipated|2012-02-29||Interventional|||Prospective Study on HIV-related Hodgkin Lymphoma|A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma|Unknown status|Recruiting|Phase 2|130|Anticipated|Harlachinger Krebshilfe e.V.|||||f||||||||||||||2018-05-31 21:57:49.471442|2018-05-31 21:57:49.471442
NCT01468727|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-14|2011-11-08|2011-11-09|Estimate|||||||2011-11-14|2011-11-16|Estimate|January 2007||2007-01-31|November 2011|2011-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|WIPE||Study on Use of Xylitol-wipes to Prevent Dental Caries|Effectiveness of Xylitol Wipes on Infants in Reducing Bacterial Transmission and Colonization From Mother to Child|Completed||N/A|88|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:57:49.595829|2018-05-31 21:57:49.595829
NCT01468714|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-11-11|2011-11-06|2011-11-09|Estimate|||||||2011-11-11|2011-11-16|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Pf-04937319 In Healthy Subjects|A Phase I, Open-Label, Fixed Sequence Study To Estimate The Steady-State Effect Of Ketoconazole On The Single-Dose Pharmacokinetics Of PF-04937319 In Healthy Adult Subjects|Completed||Phase 1|10|Actual|Pfizer|||||f||||f||||||||||2018-05-31 21:57:49.661251|2018-05-31 21:57:49.661251
NCT01468701|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2018-03-28|2011-11-07|2011-11-09|Estimate|||||||2018-03-28|2018-03-29|Actual|November 7, 2011|Actual|2011-11-07|March 2018|2018-03-31|January 14, 2020|Anticipated|2020-01-14|January 14, 2020|Anticipated|2020-01-14||Observational|||GLORIA-AF Registry Program - Second and Third Phases|GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)|Active, not recruiting|||19000|Anticipated|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 21:57:49.803855|2018-05-31 21:57:49.803855
NCT01468688|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-06|||2017-07-05|2011-11-08|2011-11-09|Estimate|||||||2017-07-05|2017-07-07|Actual|April 20, 2012|Actual|2012-04-20|July 2017|2017-07-31|July 29, 2016|Actual|2016-07-29|July 29, 2016|Actual|2016-07-29||Interventional|||A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients|A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib|Completed||Phase 1|60|Actual|Novartis||3|||f||||f|t|f||||||No||2018-05-31 21:57:51.037863|2018-05-31 21:57:51.037863
NCT01468675|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2016-12-21||2017-03-20|2011-11-07|2011-11-09|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|February 2013||2013-02-28|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care|Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care|Completed||N/A|6075|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 21:57:51.173636|2018-05-31 21:57:51.173636
NCT01468662|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-10-27|2011-11-08|2011-11-09|Estimate|||||||2014-10-27|2014-10-28|Estimate|November 2011||2011-11-30|October 2014|2014-10-31||||April 2013|Actual|2013-04-30||Observational|||CMR Repeatability in STEMI|Cardiovascular Magnetic Resonance Scan Repeatability in ST Segment Elevation Myocardial Infarction|Completed|||40|Actual|University of Bristol|||1||f||||f||||||||||2018-05-31 21:57:51.501434|2018-05-31 21:57:51.501434
NCT01468649|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-03-03|2011-11-08|2011-11-09|Estimate|||||||2017-03-03|2017-03-07|Actual|June 2011||2011-06-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer|Phase II Real-Time NIR-Guided Sentinel Lymph Node Mapping in Breast Cancer|Completed||Early Phase 1|50|Actual|Beth Israel Deaconess Medical Center||1|||f||||f|f|f||||||||2018-05-31 21:57:51.581213|2018-05-31 21:57:51.581213
NCT01468636|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2016-10-31|2011-11-08|2011-11-09|Estimate|||||||2016-10-31|2016-11-02|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts|A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts|Terminated||Phase 4|50|Actual|University of British Columbia||2||There was no clear benefit but numerous side effects.|f||||f||||||||||2018-05-31 21:57:51.680221|2018-05-31 21:57:51.680221
NCT01468623|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2013-01-29|2011-11-07|2011-11-09|Estimate|||||||2013-01-29|2013-01-31|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|PROFUSE||Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6|A Prospective, Randomized, Open-label Trial Comparing OnDose® AUC Optimized 5-FU Based Administration Versus Standard Body Surface Area (BSA) Dosing in Metastatic Colorectal Cancer Patients (mCRC) Treated With mFOLFOX6|Terminated||Phase 4|51|Actual|Myriad Genetic Laboratories, Inc.||2||Study terminated due to slow enrollment.|f||||t||||||||||2018-05-31 21:57:51.864581|2018-05-31 21:57:51.864581
NCT01468610|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2015-04-08|2011-11-08|2011-11-09|Estimate|||||||2015-04-08|2015-04-10|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Neurocognition and Work Productivity in Major Depressive Disorder (MDD)|Neurocognition and Work Productivity in Major Depressive Disorder|Completed||N/A|47|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 21:57:52.057163|2018-05-31 21:57:52.057163
NCT01468597|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-01-26|2011-11-07|2011-11-09|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery|Does Platelet Inhibition Predict Surgery Related Bleeding in Patients Undergoing Emergent Cardiac Surgery During Dual Antiplatelet Therapy - a Pilot Study|Completed|||161|Actual|Medical University of Graz|||1||f||||f||||||||||2018-05-31 21:57:52.141855|2018-05-31 21:57:52.141855
NCT01468415|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-06|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|June 2011||2011-06-30|May 2011|2011-05-31||||June 2013|Anticipated|2013-06-30||Interventional|||Efficiency Comparison Between Methylprednisolone and Phenol 8% Treatment Using a Trans Sacral Approach - on Lower Back Pain and Limbs|Efficiency Comparison Between Methylprednisolone and Phenol 8% Treatment Using a Trans Sacral Approach - on Lower Back Pain and Limbs|Unknown status|Recruiting|Phase 1|60|Anticipated|Assaf-Harofeh Medical Center|||||f||||t||||||||||2018-05-31 21:57:56.070943|2018-05-31 21:57:56.070943
NCT01468584|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2014-10-29||2014-10-29|2011-11-07|2011-11-09|Estimate|2014-10-29|2014-11-03|Estimate||||2014-10-29|2014-11-03|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Subjects With Genotype 2 Hepatitis C, Who Did Not Respond to Previous Treatment|Completed||Phase 3|10|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 21:57:52.212757|2018-05-31 21:57:52.212757
NCT01468571|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-05-06|2011-11-07|2011-11-09|Estimate|||||||2015-05-06|2015-05-08|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension|Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension|Unknown status|Recruiting|Phase 4|50|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 21:57:52.369492|2018-05-31 21:57:52.369492
NCT01468558|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2013-08-19||2013-12-09|2011-11-07|2011-11-09|Estimate|2013-08-19|2013-10-22|Estimate||||2013-12-09|2014-01-09|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole|A Phase I Evaluation of the Effect of Ketoconazole on the Pharmacokinetics and Safety of Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004) in Healthy Volunteers Compared to DHE Delivered Intravenously (DHE 45®)|Completed||Phase 1|24|Actual|Allergan||1|||f||||f||||||||||2018-05-31 21:57:52.462732|2018-05-31 21:57:52.462732
NCT01468545|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-08-28|2011-11-07|2011-11-09|Estimate|||||||2014-08-28|2014-08-29|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|January 2013|Actual|2013-01-31||Observational|Inventa||Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System|Prospective, Non-interventional, Multi-centre Study. The Observation Period for Each Subject Covers 1 Year of Treatment. One Initial Visit and 4 Follow-up Visits Every 3 Months and One Extra Educational Reinforcement at Baseline and at 6 Months Will be Given to a Group of Patients.|Completed|||38|Actual|Bayer|||2||f||||f||||||||||2018-05-31 21:57:52.782375|2018-05-31 21:57:52.782375
NCT01468532|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2016-12-02|2011-11-08|2011-11-09|Estimate|||||||2016-12-02|2016-12-06|Estimate|October 2011||2011-10-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Phase I/II Trial to Establish the Safety and Preliminary Efficacy of the Combination of Docetaxel, Prednisone, and SOM 230 (Pasireotide) in Metastatic Castrate Resistant Prostate Cancer (CRPC).|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||f||||||||||2018-05-31 21:57:53.984614|2018-05-31 21:57:53.984614
NCT01468519|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-02|||2014-12-10|2011-11-08|2011-11-09|Estimate|||||||2014-12-10|2014-12-11|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|ECSIITED||Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients|Effects of Continuous Subcutaneous Insulin Infusion (CSII) on Erectile Dysfunction in T2DM Patients: A Prospective, Exploratory, Controlled Trial|Completed||Phase 4|20|Actual|Jothydev's Diabetes and Research Centre||2|||f||||t||||||||||2018-05-31 21:57:54.117453|2018-05-31 21:57:54.117453
NCT01468506|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-09-23|2011-11-08|2011-11-09|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|UPSAC||Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)|Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)|Withdrawn|||0|Actual|Baptist Health South Florida|||1||f||||f||||||||||2018-05-31 21:57:54.203348|2018-05-31 21:57:54.203348
NCT01468493|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-29|||2017-04-20|2011-11-08|2011-11-09|Estimate|||||||2017-04-20|2017-04-24|Actual|January 2011||2011-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|SuparSDRF||A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients|A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis|Recruiting|||90|Anticipated|Guangdong General Hospital|||3||f||||t||||||||||2018-05-31 21:57:54.321131|2018-05-31 21:57:54.321131
NCT01468480|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Human Pulpal Response After Pulp Capping With Four Different Agents|Comparison of Human Pulpal Response After Pulpal Exposure to Common Treatments and Single-visit MTA|Completed||Phase 2/Phase 3|32|Actual|Islamic Azad University, Tehran||4|||f||||t||||||||||2018-05-31 21:57:54.40964|2018-05-31 21:57:54.40964
NCT01468467|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2016-11-30|2011-11-07|2011-11-09|Estimate|||||||2016-11-30|2016-12-02|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)|A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant|Completed||Phase 1|13|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 21:57:54.592567|2018-05-31 21:57:54.592567
NCT01468454|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18||2013-08-07|2018-02-15|2011-11-06|2011-11-09|Estimate||||2013-08-07|2013-08-12|Estimate|2018-02-15|2018-02-19|Actual|January 2009||2009-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|June 2014|Actual|2014-06-30||Interventional|F-DOPA PET||Phase II Safety and Efficacy Study of F-DOPA PET/CT in Children With Hyperinsulinemic Hypoglycemia|A Phase II Safety and Efficacy Study of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Children With Hyperinsulinemic Hypoglycemia|Completed||Phase 2|128|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-05-31 21:57:54.718613|2018-05-31 21:57:54.718613
NCT01468441|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2012-07-12|2011-11-08|2011-11-09|Estimate|||||||2012-07-12|2012-07-13|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Gonapeptyl||Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days|Effect of Ovarian Stimulation Using Recombinant FSH and GHRH Antagonist in Alternate Days on ICSI Outcomes|Completed||N/A|96|Actual|Fertility - Assisted Fertilization Center||2|||f||||f||||||||||2018-05-31 21:57:55.943534|2018-05-31 21:57:55.943534
NCT01468428|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-10|2011-11-07|2011-11-09|Estimate|||||||2011-11-10|2011-11-11|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Small Intestinal Function in Patients With Cystic Fibrosis|Small Intestinal Function in Patients With Cystic Fibrosis|Unknown status|Enrolling by invitation||15|Actual|University of Aarhus|||||f||||t||||||||||2018-05-31 21:57:56.01782|2018-05-31 21:57:56.01782
NCT01468402|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Observational|||Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma|Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma|Completed|||50|Actual|Hospital Israelita Albert Einstein|||1||f||||f||||||||||2018-05-31 21:57:56.142223|2018-05-31 21:57:56.142223
NCT01468389|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-08|2011-11-06|2011-11-09|Estimate|||||||2011-11-08|2011-11-10|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|||Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction|A Randomized Multicenter Phase III Study:Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone vs.Taxanes or Platinum Combined With Capecitabine in Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction.|Unknown status|Recruiting|Phase 3|300|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 21:57:56.24773|2018-05-31 21:57:56.24773
NCT01468376|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2012-01-26|2011-11-08|2011-11-09|Estimate|||||||2012-01-26|2012-01-31|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||GLU-xx Formulations in Individuals With Impaired Glucose Tolerance|An Open-label, Dose-finding Pilot Study of Various Formulations of Glucose-lowering Products in Otherwise Healthy Individuals With Impaired Glucose Tolerance|Terminated||Phase 1|17|Actual|Afexa Life Sciences Inc||6||Sponsor company was acquired and new owner chose not to proceed with clinical study|f||||f||||||||||2018-05-31 21:57:56.362227|2018-05-31 21:57:56.362227
NCT01468363|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2011-11-09|2011-11-08|2011-11-09|Estimate|||||||2011-11-09|2011-11-10|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Hypervolemia in ESRD Patients in Zonguldak (Prospective Study)|Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study)|Unknown status|Recruiting|Phase 4|550|Anticipated|Zonguldak Karaelmas University||2|||f||||f||||||||||2018-05-31 21:57:56.462394|2018-05-31 21:57:56.462394
NCT01468350|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2014-03-24||2014-05-22|2011-11-08|2011-11-09|Estimate|2014-05-22|2014-06-24|Estimate||||2014-05-22|2014-06-24|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional||Safety Population (Took at least one dose)|Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy|A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER|Completed||Phase 1|35|Actual|Acorda Therapeutics||4|||f||||f||||||||||2018-05-31 21:57:56.718931|2018-05-31 21:57:56.718931
NCT01468337|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|2014-11-12||2014-11-12|2011-11-05|2011-11-09|Estimate|2014-11-12|2014-11-19|Estimate||||2014-11-12|2014-11-19|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Topical Interferon Gamma-1b for Central Serous Chorioretinopathy|Pilot Phase I/II Study of the Treatment of Classic Central Serous Chorioretinopathy With Topical Interferon Gamma-1b|Completed||Phase 1/Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|After study completion, a participant presented with a cataract on 4/12/13 (last study dose:10/3/12 and TOTAL study dosage received: 2758 µg). Although age (58) was consistent with the possibility of cataract, relatedness to drug cannot be ruled out.|1|||f||||f||||||||||2018-05-31 21:57:57.268342|2018-05-31 21:57:57.268342
NCT01468324|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2018-05-15|2011-11-05|2011-11-09|Estimate|||||||2018-05-15|2018-05-16|Actual|October 5, 2011||2011-10-05|April 22, 2014|2014-04-22|April 23, 2014|Actual|2014-04-23|April 23, 2014|Actual|2014-04-23||Interventional|||AZD7451 for Recurrent Gliomas|Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)|Completed||Phase 1|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:57:57.548082|2018-05-31 21:57:57.548082
NCT01468311|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|2017-04-17||2018-04-26|2011-11-05|2011-11-09|Estimate|2017-04-17|2017-05-25|Actual||||2018-04-26|2018-05-25|Actual|October 11, 2011|Actual|2011-10-11|April 2018|2018-04-30|September 1, 2021|Anticipated|2021-09-01|November 16, 2014|Actual|2014-11-16||Interventional|||Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma|Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin s Lymphoma|Active, not recruiting||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-05-31 21:57:57.629974|2018-05-31 21:57:57.629974
NCT01468298|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2011-11-07|2011-11-07|2011-11-09|Estimate|||||||2011-11-07|2011-11-09|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Global Posture Reeducation (GPR) Compared To Isostretching in Chronic Low Back Pain Patients|Comparing the Global Posture Reeducation With Isostretching in Chronic Low Back Pain Patients|Unknown status|Active, not recruiting|Early Phase 1|40|Anticipated|Centro Universitario de Maringa||2|||f||||f||||||||||2018-05-31 21:57:58.099131|2018-05-31 21:57:58.099131
NCT01468285|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-10-25|2011-11-08|2011-11-09|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2012||2012-02-29|October 2017|2017-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CBF||The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow|A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Effect of Betahistine on Cerebral Blood Flow and Gait in Subjects at Risk of Falling|Completed||Phase 4|27|Actual|Abbott||2|||f||||f||||||||||2018-05-31 21:57:58.223295|2018-05-31 21:57:58.223295
NCT01468272|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2017-03-28|2011-11-07|2011-11-09|Estimate|||||||2017-03-28|2017-03-29|Actual|November 2011||2011-11-30|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PAED4||Clinical Pharmacology of CHF 1535 50/6 ug Next DPI in Children 5-11 Years Old|A Single-dose,Open-label,Randomized,2-way Cross-over,Clinical Pharmacology Study of CHF1535 50/6 NEXT DPI® Fixed Combination of Beclomethasone Dipropionate 50µg Plus Formoterol Fumarate 6µg)Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Children|Completed||Phase 2|26|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 21:57:58.3339|2018-05-31 21:57:58.3339
NCT01468259|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2013-03-27|2011-11-08|2011-11-09|Estimate|||||||2013-03-27|2013-03-29|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Multi-Center, Open-Label Study|A Phase I, Multi-Center, Open-Label Study to Examine the Pharmacokinetics of a Single Dose of Droxidopa in Subjects With Renal Impairment Compared to Healthy Volunteers|Withdrawn||Phase 1|0|Actual|Chelsea Therapeutics||5|||f||||f||||||||||2018-05-31 21:57:58.465532|2018-05-31 21:57:58.465532
NCT01468246|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2018-02-08|2011-11-08|2011-11-09|Estimate|||||||2018-02-08|2018-02-12|Actual|November 2006||2006-11-30|February 2018|2018-02-28|January 2026|Anticipated|2026-01-31|November 2025|Anticipated|2025-11-30||Observational|HOHO||The Young Women's Breast Cancer Study|Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study|Active, not recruiting|||1302|Actual|Dana-Farber Cancer Institute|||1||f||||f||||||Samples With DNA|"~     The investigators are collecting blood and tumor specimens.~   "|||2018-05-31 21:57:58.588734|2018-05-31 21:57:58.588734
NCT01468233|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-09-16|2015-04-28|2015-10-15|2011-11-07|2011-11-09|Estimate|2015-10-15|2015-10-28|Estimate|2015-04-28|2015-05-15|Estimate|2015-10-15|2015-10-28|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PIONEER II||Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa|A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II|Completed||Phase 3|326|Actual|AbbVie||6|||f||||t||||||||||2018-05-31 21:57:58.748653|2018-05-31 21:57:58.748653
NCT01468220|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-08-16|2011-11-07|2011-11-09|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2012||2012-01-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|July 2017|Actual|2017-07-31||Interventional|||Normobaric Hypoxic Training and Metabolic Syndrome|Normobaric Hypoxic Training Compared to Ambient Training on the Course of the Metabolic Syndrome|Active, not recruiting||N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 21:57:59.627099|2018-05-31 21:57:59.627099
NCT01468207|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-09-16|2015-01-22|2015-10-15|2011-11-07|2011-11-09|Estimate|2015-10-15|2015-10-28|Estimate|2015-01-22|2015-01-29|Estimate|2015-10-15|2015-10-28|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PIONEER I||Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa|A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I|Completed||Phase 3|307|Actual|AbbVie||6|||f||||t||||||||||2018-05-31 21:57:59.814707|2018-05-31 21:57:59.814707
NCT01468194|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Change in Peripheral Oxygen Saturation by Using Different Breathing Procedures in High Altitude||Completed||N/A|30|Anticipated|University of Giessen||3|||f||||f||||||||||2018-05-31 21:58:01.210113|2018-05-31 21:58:01.210113
NCT01468181|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2014-12-08|2014-04-14|2015-01-16|2011-11-07|2011-11-09|Estimate|2014-12-08|2014-12-16|Estimate|2014-04-14|2014-05-07|Estimate|2015-01-16|2015-01-29|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All enrolled participants|A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus|A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|394|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 21:58:01.422606|2018-05-31 21:58:01.422606
NCT01468168|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2012-12-14|2011-11-08|2011-11-09|Estimate|||||||2012-12-14|2012-12-17|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients|A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease|Completed||Phase 2|183|Actual|Santen Inc.||3|||f||||||||||||||2018-05-31 21:58:03.532524|2018-05-31 21:58:03.532524
NCT01468155|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-11-02|2011-11-08|2011-11-09|Estimate|||||||2017-11-02|2017-11-06|Actual|July 13, 2011|Actual|2011-07-13|November 2017|2017-11-30|June 7, 2017|Actual|2017-06-07|January 2017|Actual|2017-01-31||Interventional|DAPPARAF||DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation|Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation|Completed||Phase 4|50|Actual|Lawson Health Research Institute||1|||f||||t||||||||||2018-05-31 21:58:03.611277|2018-05-31 21:58:03.611277
NCT01468142|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2016-12-19|2011-11-08|2011-11-09|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Pulmonary Pathophysiology and Inflammatory Response in Patients Treated With Ecmo for Severe Respiratory Failure|Pulmonary Pathophysiology and Inflammatory Response in Patients Treated With Ecmo for Severe Respiratory Failure|Completed|||6|Actual|Karolinska University Hospital|||||f||||f||||||||||2018-05-31 21:58:03.695343|2018-05-31 21:58:03.695343
NCT01468129|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|December 2012||2012-12-31|December 2012||2012-12-31||Interventional|||Cell Saver Use in Bilateral Total Hip Arthroplasty (THA)|A Prospective, Randomized Controlled Trial to Evaluate the Efficacy of Cell Saver to Redue Blood Loss in One-stage Bilateral Total Hip Arthroplasty (THA)|Unknown status|Recruiting|N/A|||Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-05-31 21:58:03.750673|2018-05-31 21:58:03.750673
NCT01468116|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-07|2011-11-07|2011-11-09|Estimate|||||||2011-11-07|2011-11-09|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Observational|||The Effect of Roux-en-Y Gastric Bypass on Mitochondrial Function in Type 2 Diabetes||Unknown status|Recruiting||30|Anticipated|Hvidovre University Hospital|||3||f||||f||||||Samples Without DNA|"~     serum, plasma~   "|||2018-05-31 21:58:03.813346|2018-05-31 21:58:03.813346
NCT01468103|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-06|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Laser Iridotomy Versus Surgical Iridectomy in Early Angle Closure|Laser Peripheral Iridotomy Versus Surgical Peripheral Iridectomy in Early Angle Closure:a Randomized Clinical Trial|Unknown status|Recruiting|N/A|120|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 21:58:03.892003|2018-05-31 21:58:03.892003
NCT01468090|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-09-15|2011-11-08|2011-11-09|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Disease Course in an IBD Cohort in the Era of Biological Treatment|Risk of Surgery Among Patients Wih Ulcerative Colitis and Croh'ns Disease After Seven Years of Follow-up in the Era of Biological Treatment.|Completed|||192|Actual|Hvidovre University Hospital|||1||f||||f||||||Samples With DNA|"~     Whole blood and faeces will be retained for biobank~   "|||2018-05-31 21:58:03.984308|2018-05-31 21:58:03.984308
NCT01467908|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2013-02-12|2011-11-08|2011-11-09|Estimate|||||||2013-02-12|2013-02-15|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|February 2012|Actual|2012-02-29||Interventional|C-fMRI-NBS||Navigated Brain Stimulation in Diagnosis of Minimally Conscious State|Navigated Brain Stimulation in Diagnosis of Minimally Conscious State|Completed||N/A|6|Actual|Clinical Institute of the Brain, Russia||1|||f||||t||||||||||2018-05-31 21:58:08.440003|2018-05-31 21:58:08.440003
NCT01468077|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-06-23||2015-07-20|2011-11-07|2011-11-09|Estimate|2015-07-20|2015-08-17|Estimate||||2015-07-20|2015-08-17|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Intent-to-treat (ITT) Population: All participants enrolled in the study who had been randomly assigned to one of the two study treatments.|A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment|Multicenter, Randomized, Parallel Group Study to Compare the Incidence of Tocilizumab Related Infusion Reactions in Patients With Moderate to Severe Active RA, When Infusion is Given Over 31 Minutes Compared to 1 Hour|Completed||Phase 2|47|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:58:04.077745|2018-05-31 21:58:04.077745
NCT01468064|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2015-11-12|2011-11-06|2011-11-09|Estimate|||||||2015-11-12|2015-11-13|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|AMETIS||Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke|Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Patients With Ischemic Stroke: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Southern Medical University, China||3|||f||||f||||||||||2018-05-31 21:58:05.057877|2018-05-31 21:58:05.057877
NCT01468051|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Two Schedules of Hepatitis B Vaccination in Predialysis Chronic Renal Failure Patients|A Randomized Controlled Trial of Two Schedules of Hepatitis B Vaccination in Predialysis Chronic Renal Failure Patients|Completed||N/A|51|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:58:05.165424|2018-05-31 21:58:05.165424
NCT01468038|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||A Double-blind Placebo Controlled Trial of Sentra PM, a Medical Food|Sentra PM (a Medical Food) and Trazadone in the Management of Sleep Disorders|Completed||Phase 3|111|Actual|Targeted Medical Pharma||4|||f||||t||||||||||2018-05-31 21:58:05.312851|2018-05-31 21:58:05.312851
NCT01468025|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2011-11-05|2011-11-05|2011-11-09|Estimate|||||||2011-11-05|2011-11-09|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effectiveness of Theramine on Chronic Back Pain|A Randomized Double-blind Placebo Study to Determine the Effectiveness of Theramine and a Low Dose Naproxen on the Management of Chronic Back Pain|Completed||Phase 3|127|Actual|Targeted Medical Pharma||3|||f||||f||||||||||2018-05-31 21:58:05.395092|2018-05-31 21:58:05.395092
NCT01468012|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2016-10-25||2018-05-17|2011-11-08|2011-11-09|Estimate|2016-10-25|2016-12-16|Estimate||||2018-05-17|2018-05-22|Actual|July 2014||2014-07-31|May 2018|2018-05-31|December 2015|Actual|2015-12-31|July 2014|Actual|2014-07-31||Interventional|COST||Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence|Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence|Completed||Phase 2/Phase 3|23|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 21:58:05.774295|2018-05-31 21:58:05.774295
NCT01467999|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-04-03|2011-11-08|2011-11-09|Estimate|||||||2017-04-03|2017-04-05|Actual|February 2012||2012-02-29|March 2017|2017-03-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|GUAN||Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence|Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence|Completed||Phase 1|22|Actual|New York State Psychiatric Institute||1|||f||||t|t|f||||||No||2018-05-31 21:58:06.477572|2018-05-31 21:58:06.477572
NCT01467986|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2016-12-29|2011-11-04|2011-11-09|Estimate|||||||2016-12-29|2016-12-30|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|RIST-rNB-2011||Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma|Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma|Recruiting||Phase 2|114|Anticipated|University of Regensburg||2|||f||||t||||||||||2018-05-31 21:58:06.612522|2018-05-31 21:58:06.612522
NCT01467973|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2014-04-20|2011-11-07|2011-11-09|Estimate|||||||2014-04-20|2014-04-22|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Observational|GulfCARE||Gulf Acute Heart Failure Registry|Gulf aCute heArt failuRe rEgistry (Gulf CARE)|Completed|||5005|Actual|Gulf Heart Association|||||f||||t||||||||||2018-05-31 21:58:06.771618|2018-05-31 21:58:06.771618
NCT01467960|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|2013-06-11||2013-09-23|2011-11-08|2011-11-09|Estimate|2013-06-11|2013-08-16|Estimate||||2013-09-23|2013-10-30|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|June 2013|Actual|2013-06-30||Observational|ApoD||Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease|Detection of Apolipoprotein D (ApoD) in Human Serum as Marker of Parkinson's Disease|Unknown status|Enrolling by invitation||180|Actual|Privatklinik Villa Melitta|||6||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-05-31 21:58:06.884662|2018-05-31 21:58:06.884662
NCT01467947|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-10-16||2016-12-12|2011-11-08|2011-11-09|Estimate|2015-10-16|2015-11-16|Estimate||||2016-12-12|2017-02-06|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert|Prospective Open-label Uncontrolled Multi-center Post-marketing Study to Assess Inhibitory Antibody Formation in Subjects With Congenital C1-INH Deficiency and Acute Hereditary Angioedema (HAE) Attacks Treated With Berinert® , a C1-esterase Inhibitor|Completed||Phase 4|46|Actual|CSL Behring||1|||f||||||||||||||2018-05-31 21:58:07.780861|2018-05-31 21:58:07.780861
NCT01467934|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2014-06-22||2014-07-19|2011-11-08|2011-11-09|Estimate|2014-07-19|2014-07-21|Estimate||||2014-07-19|2014-07-21|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|||FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging|FeverText: Assessing Fever Rates After Influenza and Pneumococcal Vaccination During the 2011-12 Influenza Season Using Text Messaging|Completed|||530|Actual|Columbia University|||3||f||||f||||||||||2018-05-31 21:58:08.049498|2018-05-31 21:58:08.049498
NCT01467921|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-06|||2011-11-14|2011-11-08|2011-11-09|Estimate|||||||2011-11-14|2011-11-16|Estimate|December 2010||2010-12-31|November 2011|2011-11-30||||February 2012|Anticipated|2012-02-29||Interventional|||Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma|A Randomized Phase II Study of Leucovorin, 5-fluorouracil With or Without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma.|Unknown status|Recruiting|Phase 2|68|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:58:08.366503|2018-05-31 21:58:08.366503
NCT01467882|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|2015-06-25|2014-08-19|2017-07-27|2011-11-08|2011-11-09|Estimate|2015-08-05|2015-09-04|Estimate|2014-08-19|2014-08-21|Estimate|2017-07-27|2017-07-28|Actual|April 2012||2012-04-30|July 2017|2017-07-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional||Intention to treat, defined as all participants enrolled|Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty|An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty|Completed||Phase 3|44|Actual|Debiopharm International SA||1|||f||||f||||||||||2018-05-31 21:58:08.55687|2018-05-31 21:58:08.55687
NCT01467869|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-11-10|2011-11-08|2011-11-09|Estimate|||||||2017-11-10|2017-11-14|Actual|January 1991||1991-01-31|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2021|Anticipated|2021-12-31||Observational|MFP||Male Fertility Program|The Miami Project Male Fertility Program|Recruiting|||100|Anticipated|University of Miami|||||f||||t||||||||||2018-05-31 21:58:09.288027|2018-05-31 21:58:09.288027
NCT01467856|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-02-15|2011-11-08|2011-11-09|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2010||2010-10-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|SDB||Sleep Disordered Breathing|Sleep Disordered Breathing (SDB) in Persons With Chronic Tetraplegia: Characterization and Treatment|Completed|||304|Actual|University of Miami|||1||f||||t||||||Samples Without DNA|"~     Insulin Sensitivity (SI) and Lipid/Inflammation panels: (30 minutes, Taken at Baseline, 1~     month, and 3 month time points) SI will be calculated using the Quantitative Insulin~     Sensitivity Check Index (QUICKI) method177 that requires single fasting blood glucose and~     insulin values. The same blood sample will be used to assay for a lipid panel containing~     total cholesterol, LDL, HDL, and triglycerides and an inflammatory panel testing hs-CRP and~     IL-6.~   "|||2018-05-31 21:58:09.402262|2018-05-31 21:58:09.402262
NCT01467843|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-10-11|2011-11-08|2011-11-09|Estimate|||||||2017-10-11|2017-10-13|Actual|June 2012||2012-06-30|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain|Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain|Completed||Phase 3|342|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-05-31 21:58:09.52969|2018-05-31 21:58:09.52969
NCT01467830|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2014-07-03|2011-11-08|2011-11-09|Estimate|||||||2014-07-03|2014-07-04|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|Withdrawn||N/A|0|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 21:58:09.704653|2018-05-31 21:58:09.704653
NCT01467817|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-11-29|2011-11-08|2011-11-09|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI)|Obesity/Overweight in Persons With Early and Chronic SCI: A Randomized Multi-Center Controlled Lifestyle Intervention|Completed||N/A|29|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 21:58:09.846161|2018-05-31 21:58:09.846161
NCT01467804|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2011-11-09|2011-11-08|2011-11-09|Estimate|||||||2011-11-09|2011-11-10|Estimate|November 2011||2011-11-30|January 2010|2010-01-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||"Randomized Double Blinding Controlled Study on Jia Wei Xiao Yao Jiaonang Treating Mild to Moderate Major Depressive Disorder"|"Randomized Double Blinding Controlled Study on Jia Wei Xiao Yao Jiaonang Treating Mild to Moderate Major Depressive Disorder"|Unknown status|Not yet recruiting|N/A|180|Anticipated|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 21:58:09.967037|2018-05-31 21:58:09.967037
NCT01467791|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2015-12-04|2011-11-08|2011-11-09|Estimate|||||||2015-12-04|2015-12-08|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|RESAPH||Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)|Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)|Unknown status|Recruiting||300|Anticipated|University of Cincinnati|||1||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 21:58:10.133959|2018-05-31 21:58:10.133959
NCT01467778|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-11-07|2011-11-07|2011-11-09|Estimate|||||||2011-11-07|2011-11-09|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Safety Study of Three Formulations of the Dermal Implant ELAPR|A Phase I Study to Assess the Safety of Three Formulations of the Dermal Implant ELAPR in Healthy Subjects|Completed||Phase 1|14|Actual|Elastagen Pty Ltd||4|||f||||f||||||||||2018-05-31 21:58:10.265517|2018-05-31 21:58:10.265517
NCT01467765|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2012-08-07|2011-11-05|2011-11-09|Estimate|||||||2012-08-07|2012-08-09|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Elental||The Effect of Elemental Diet on Gastric Emptying|The Comparative Study of Elemental Diet and Regular Liquid Diet on Gastric Emptying in Patients With Percutaneous Endoscopic Gastrostomy|Completed||N/A|20|Anticipated|Showa Inan General Hospital||2|||f||||f||||||||||2018-05-31 21:58:10.36005|2018-05-31 21:58:10.36005
NCT01467752|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|January 2005||2005-01-31|November 2011|2011-11-30|December 2009|Actual|2009-12-31|January 2005|Actual|2005-01-31||Interventional|MJRUVCBG||Metacarpophalangeal Joint Reconstruction Using a Vascularized Cartilage and Bone Graft|Phase 1 Study for Reconstruction of Metacarpophalangeal Joint Using a Vascularized Cartilage and Bone Graft From the Third Metacarpal|Completed||Phase 1|15|Actual|The Second Hospital of Qinhuangdao||1|||f||||t||||||||||2018-05-31 21:58:10.502256|2018-05-31 21:58:10.502256
NCT01467739|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|||2013-12-13|2011-11-08|2011-11-09|Estimate|||||||2013-12-13|2013-12-16|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Evaluation of the Ambu ® aScope® for Tracheal Intubation in Difficult Airways|Evaluation of the Ambu ® aScope® for Tracheal Intubation During Cervical Spine Immobilization With a Cervical Collar, in Comparison With a Conventional Reusable Fiberscope.|Completed||N/A|100|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 21:58:10.597839|2018-05-31 21:58:10.597839
NCT01467726|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2014-12-01|2011-11-04|2011-11-09|Estimate|||||||2014-12-01|2014-12-03|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects|A Phase 1, Randomized, Placebo−Controlled, Double−Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects|Completed||Phase 1|40|Actual|Theravance Biopharma R & D, Inc.||3|||f||||f||||||||||2018-05-31 21:58:10.665283|2018-05-31 21:58:10.665283
NCT01467713|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2016-04-08||2016-04-08|2011-11-04|2011-11-09|Estimate|2016-04-08|2016-05-16|Estimate||||2016-04-08|2016-05-16|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||All randomized participants.|Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients|Terminated||Phase 3|642|Actual|Takeda||4||Business Decision; No Safety Concerns.|f||||f||||||||||2018-05-31 21:58:10.789502|2018-05-31 21:58:10.789502
NCT01467700|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2016-04-08||2016-04-08|2011-11-08|2011-11-09|Estimate|2016-04-08|2016-05-16|Estimate||||2016-04-08|2016-05-16|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||All randomized participants.|Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) in the Treatment of Acute Depressive Episodes Associated With Bipolar I Disorder in Adult Patients Who Are on Lithium and/or Valproate|Terminated||Phase 3|490|Actual|Takeda||4||Business Decision; No Safety Concerns|f||||f||||||||||2018-05-31 21:58:13.420925|2018-05-31 21:58:13.420925
NCT01467687|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|July 2007||2007-07-31|November 2011|2011-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Synerx Pharma and Verelan PM 300 mg Verapamil HCl Extended Release Capsules Controlled-Onset in Healthy Aduly Volunteers Under Fed Conditions|Completed||Phase 1|58|Actual|Synerx Pharma, LLC||2|||f||||t||||||||||2018-05-31 21:58:16.484912|2018-05-31 21:58:16.484912
NCT01467674|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||The Effect Of Glycemic Control On Malondialdehyde, Glutathione Peroxidase, Glutathione And Paraoxonase|Malondialdehyde And Antioxidant Levels In Chronic Periodontitis Patients With Type 2 Diabetes Mellitus Under Different Stages Of Metabolic Control|Completed|||84|Actual|Suleyman Demirel University|||4||f||||f||||||||||2018-05-31 21:58:16.654296|2018-05-31 21:58:16.654296
NCT01467661|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2016-05-02||2016-06-22|2011-11-04|2011-11-09|Estimate|2016-05-02|2016-06-08|Estimate||||2016-06-22|2016-07-21|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Safety analysis set included all enrolled participants who had taken at least 1 dose of SPD422 since enrolment into Study SPD422-308 (NCT01214915).|Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia|A Phase 3, Multi-centre, Open-label, Extension Study to Investigate the Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia|Completed||Phase 3|41|Actual|Shire||1|||f||||f||||||||||2018-05-31 21:58:16.97985|2018-05-31 21:58:16.97985
NCT01467648|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-11-08|2011-11-08|2011-11-09|Estimate|||||||2011-11-08|2011-11-09|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia|The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia|Completed||Phase 4|12|Actual|Prince of Songkla University||2|||f||||f||||||||||2018-05-31 21:58:19.171453|2018-05-31 21:58:19.171453
NCT01467635|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2016-07-12|2011-11-07|2011-11-09|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|July 2016|Anticipated|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||EBUS-TBNA Versus EBUS-TBNB|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Endobronchial Ultrasound Transbronchial Needle Biopsy (EBUS-TBNB) in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial|Withdrawn||N/A|0|Actual|Royal Brompton & Harefield NHS Foundation Trust||2||Manufacturer did not develop and deliver the necessary biopsy forceps needles in time|f||||f||||||||||2018-05-31 21:58:19.783031|2018-05-31 21:58:19.783031
NCT01467622|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2013-05-06|2011-11-04|2011-11-09|Estimate|||||||2013-05-06|2013-05-07|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|August 2009|Actual|2009-08-31||Observational|||Effects of Local Protocols on Duration of Chest Tube Therapy Following Thoracic Surgery|Prospective, Non Randomized Investigator Initiated Multi-centre Trial on the Effects of Local Treatment Protocols on the Duration of Chest Tube Therapy Following Thoracic Surgery in Germany|Completed|||80|Actual|Schillerhoehe Hospital|||1||f||||f||||||||||2018-05-31 21:58:20.246781|2018-05-31 21:58:20.246781
NCT01467609|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-11-04|2011-11-04|2011-11-08|Estimate|||||||2011-11-04|2011-11-08|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Observational|||PillCam Colon Capsule Endoscopy for Ulcerative Colitis|PillCam Colon Capsule Endoscopy Versus Conventional Colonoscopy for the Detection of the Severity and Extent of Ulcerative Colitis|Completed|||20|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     regular biopsy was taken during conventional colonoscopy according to the activity and~     position of ulcerative colitis involved.~   "|||2018-05-31 21:58:20.695842|2018-05-31 21:58:20.695842
NCT01467596|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2012-11-14|2011-11-07|2011-11-08|Estimate|||||||2012-11-14|2012-11-15|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|US-SCB||Ultrasound-guided Supraclavicular Brachial Plexus Block in Elderly|Effects of Age on Minimum Effective Volume of Local Anesthetic for Ultrasound-guided Supraclavicular Brachial Plexus Block (US-SCB)|Completed||N/A|44|Actual|Šarić, Jadranka Pavičić, M.D.||2|||f||||f||||||||||2018-05-31 21:58:21.413348|2018-05-31 21:58:21.413348
NCT01467583|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2015-03-17||2015-06-18|2011-11-07|2011-11-08|Estimate|2015-06-18|2015-06-19|Estimate||||2015-06-18|2015-06-19|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Fondaparinux in Critically Ill Patients With Renal Failure|Use of Fondaparinux in Critically Ill Patients With Renal Failure|Completed||Phase 4|32|Actual|Wayne State University||3|||f||||f||||||||||2018-05-31 21:58:21.863302|2018-05-31 21:58:21.863302
NCT01467570|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2013-11-20||2014-02-14|2011-11-03|2011-11-08|Estimate|2014-02-14|2014-04-01|Estimate||||2014-02-14|2014-04-01|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis|Efficacy and Safety of a New Oral Rehydration Solution (Hipp ORS 200 Apple) in Children With Acute Gastroenteritis: Randomized, Double-Blind Controlled Trial|Completed||Phase 4|147|Actual|Medical University of Warsaw|Potential limitations included lack of perfect blinding. Because of technological reasons, it was not feasible to produce study products that were identical in colour, smell and taste.|2|||f||||t||||||||||2018-05-31 21:58:23.321247|2018-05-31 21:58:23.321247
NCT01467557|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2015-07-01||2015-10-22|2011-11-03|2011-11-08|Estimate|2015-08-12|2015-09-15|Estimate||||2015-10-22|2015-11-20|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|TEMPO||Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY|1•DAY ACUVUE® TruEye™ Brand Contact Lenses & 1•DAY ACUVUE® MOIST® Brand Contact Lenses With LACREON® TECHNOLOGY Daily Disposable Performance Overview Registry -TEMPO Study|Completed|||1171|Actual|Johnson & Johnson Vision Care, Inc.|||2||f||||f||||||||||2018-05-31 21:58:24.548057|2018-05-31 21:58:24.548057
NCT01467544|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2013-05-17|2011-11-03|2011-11-08|Estimate|||||||2013-05-17|2013-05-21|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Reduce Cardiovascular Risk in Women Through Tai Chi Intervention|Exploring the Effects of Tai Chi on Cardiometabolic Risk in Women|Completed||N/A|96|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 21:58:25.329638|2018-05-31 21:58:25.329638
NCT01467531|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-10-11|2011-11-03|2011-11-08|Estimate|||||||2012-10-11|2012-10-15|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects|A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects|Completed||Phase 1|28|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 21:58:25.496085|2018-05-31 21:58:25.496085
NCT01467518|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-04-05|2011-11-03|2011-11-08|Estimate|||||||2012-04-05|2012-04-09|Estimate|December 2011||2011-12-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.|A Phase 1, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD With Dolutegravir (GSK1349572) 50 mg Twice Daily in Opiate-Dependent, HIV Seronegative Adult Subjects.|Completed||Phase 1|11|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 21:58:25.720819|2018-05-31 21:58:25.720819
NCT01467505|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2015-05-02||2015-06-01|2011-11-03|2011-11-08|Estimate|2015-06-01|2015-06-18|Estimate||||2015-06-01|2015-06-18|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Full analysis set included all participants who received at least 1 dose of study drug.|An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients|A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation|Terminated||Phase 2|61|Actual|Vertex Pharmaceuticals Incorporated|It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.|2||"The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify~   the drug development plan."|f||||f||||||||||2018-05-31 21:58:25.947525|2018-05-31 21:58:25.947525
NCT01467492|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2015-06-01||2015-07-13|2011-11-03|2011-11-08|Estimate|2015-06-01|2015-06-16|Estimate||||2015-07-13|2015-08-03|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Full Analysis (FA) Set included all enrolled participants who received at least 1 dose of any study drug.|Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C|An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Interferon-Based Therapy|Terminated||Phase 4|121|Actual|Vertex Pharmaceuticals Incorporated|It was decided by Sponsor on 13 January 2014 to terminate the study early as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.|2||"It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy~   endpoint as part of a decision to modify drug development plan."|f||||f||||||||||2018-05-31 21:58:27.935495|2018-05-31 21:58:27.935495
NCT01467479|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2015-03-03||2015-03-03|2011-11-07|2011-11-08|Estimate|2015-03-03|2015-03-17|Estimate||||2015-03-03|2015-03-17|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||The Full Analysis Set (FAS), included all randomized participants who received at least 1 dose of study drug.|A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)|An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1)|Terminated||Phase 3|185|Actual|Vertex Pharmaceuticals Incorporated|It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination.|3||"It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy~   endpoint as part of a decision to modify drug development plan."|f||||t||||||||||2018-05-31 21:58:29.651201|2018-05-31 21:58:29.651201
NCT01467466|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2018-01-22|2011-11-03|2011-11-08|Estimate|||||||2018-01-22|2018-01-24|Actual|February 7, 2013|Actual|2013-02-07|January 2018|2018-01-31|October 17, 2017|Actual|2017-10-17|September 29, 2017|Actual|2017-09-29||Interventional|PRESERVE||Prevention of Serious Adverse Events Following Angiography|CSP #578 - Prevention of Serious Adverse Events Following Angiography (PRESERVE)|Completed||Phase 3|5183|Actual|VA Office of Research and Development||4|||f||||t|t|f|||f|||Undecided||2018-05-31 21:58:31.302025|2018-05-31 21:58:31.302025
NCT01467453|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-14|2011-11-07|2011-11-08|Estimate|||||||2011-11-14|2011-11-16|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|December 2012||2012-12-31|||||Observational|||Clinical Application of Sensimed Triggerfish Sensor (TS) With Wireless Signal Transmission for Continuous Intraocular Pressure Measurement||Unknown status|Enrolling by invitation||30|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 21:58:31.570815|2018-05-31 21:58:31.570815
NCT01467440|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-01-05|2011-11-07|2011-11-08|Estimate|||||||2015-01-05|2015-01-06|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Efficacy of Selective Laser Trabeculoplasty in Patients Under Treatment With Topical Prostaglandines||Unknown status|Enrolling by invitation||200|Anticipated|University of Zurich|||2||f||||||||||||||2018-05-31 21:58:31.646415|2018-05-31 21:58:31.646415
NCT01467427|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2017-06-21|2016-09-26|2018-04-10|2011-11-04|2011-11-08|Estimate|2017-06-21|2017-11-17|Actual|2016-09-26|2016-09-27|Estimate|2018-04-10|2018-04-11|Actual|May 16, 2012|Actual|2012-05-16|April 2018|2018-04-30|November 30, 2023|Anticipated|2023-11-30|March 30, 2014|Actual|2014-03-30||Interventional|paradigm™5||Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.|Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B|Active, not recruiting||Phase 3|25|Actual|Novo Nordisk A/S||1|||f||||f|t|f||||||Yes|According to the Novo Nordiskdisclosure commitment on novonordisk-trials.com|2018-05-31 21:58:31.759687|2018-05-31 21:58:31.759687
NCT01467414|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-11-26|2011-11-04|2011-11-08|Estimate|||||||2013-11-26|2013-11-27|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 2 Diabetes|Terminated||Phase 1|1|Actual|Novo Nordisk A/S||1||This trial was terminated due to low recruitment|f||||f||||||||||2018-05-31 21:58:32.31493|2018-05-31 21:58:32.31493
NCT01467401|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-02-22|2011-11-04|2011-11-08|Estimate|||||||2017-02-22|2017-02-24|Actual|August 19, 2002|Actual|2002-08-19|February 2017|2017-02-28|May 15, 2003|Actual|2003-05-15|May 15, 2003|Actual|2003-05-15||Interventional|||Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes|A Multi-National, Multi-Centre, Randomised, Open-Labelled, Parallel Trial Comparing Efficacy and Safety of NovoMix® 30 FlexPen® and Mixtard® 30 Twice Daily Injections in Subjects With Type 2 Diabetes|Completed||Phase 4|292|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:58:32.425865|2018-05-31 21:58:32.425865
NCT01467388|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-01-05|2011-11-07|2011-11-08|Estimate|||||||2015-01-05|2015-01-06|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Efficacy of Selective Laser Trabeculoplasty in Pseudophakic Patients||Unknown status|Enrolling by invitation||200|Anticipated|University of Zurich|||2||f||||||||||||||2018-05-31 21:58:32.607141|2018-05-31 21:58:32.607141
NCT01467375|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-02-22|2011-11-04|2011-11-08|Estimate|||||||2017-02-22|2017-02-24|Actual|January 8, 2001|Actual|2001-01-08|February 2017|2017-02-28|October 22, 2004|Actual|2004-10-22|October 22, 2004|Actual|2004-10-22||Interventional|||Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes|An Open Label, Non Comparative, Multicentre Extension Trial to Assess the Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Who Have Completed BIAsp-1234|Completed||Phase 3|89|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:58:32.69615|2018-05-31 21:58:32.69615
NCT01467362|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-02-20|2011-11-04|2011-11-08|Estimate|||||||2013-02-20|2013-02-21|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy Emollient on Xerosis in Children With Atopic Dermatitis|Efficacy of the V0034CR01B Emollient on Xerosis in Children With Atopic Dermatitis. Randomised, Vehicle-controlled, Parallel-groups, Double-blind Study With an Open Label Extension.|Completed||Phase 3|251|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-05-31 21:58:32.785209|2018-05-31 21:58:32.785209
NCT01467349|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2013-02-08|2011-11-07|2011-11-08|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|Real-Life||Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan|Efficacy of Raltegravir in a Large Urban HIV Clinic Population in Milan (Efficacy of Raltegravir in a Large Urban HIV Clinic Setting)|Completed|||400|Actual|Università Vita-Salute San Raffaele|||1||f||||f||||||||||2018-05-31 21:58:33.021919|2018-05-31 21:58:33.021919
NCT01467336|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-02-08|2011-11-03|2011-11-08|Estimate|||||||2012-02-08|2012-02-09|Estimate|December 2011||2011-12-31|February 2012|2012-02-29|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Supra-spinatus Rehabilitation Program Comparison|Prospective Randomized Study Comparing 3 Post-operative Rehabilitation Programs After Arthroscopic Supra-spinatus Tendon Repair|Unknown status|Recruiting|N/A|294|Anticipated|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-05-31 21:58:33.135387|2018-05-31 21:58:33.135387
NCT01467323|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-01-03|2011-11-04|2011-11-08|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 1998||1998-04-30|January 2017|2017-01-31|September 1998|Actual|1998-09-30|September 1998|Actual|1998-09-30||Interventional|||Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes|An Open-labelled, Randomised, Parallel Group, Multicentre, Multinational Efficacy and Safety Comparison of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30/70 as Meal Related Insulin in a Twice Daily Regimen in Type 1 and Type 2 Diabetic Subjects|Completed||Phase 3|303|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:58:33.33931|2018-05-31 21:58:33.33931
NCT01467310|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-03-09|2011-11-03|2011-11-08|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2012||2012-01-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212|Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212|Completed||Early Phase 1|15|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 21:58:33.50538|2018-05-31 21:58:33.50538
NCT01467297|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2012-06-02|2011-11-03|2011-11-08|Estimate|||||||2012-06-02|2012-06-05|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB)|Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB). Multi-centre, Open-label, Randomised, Pilot Study to Evaluate the Effects of the Treatment on Serum Inflammatory Biomarkers|Completed||Phase 4|40|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 21:58:33.63544|2018-05-31 21:58:33.63544
NCT01467284|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2014-07-17|2011-11-03|2011-11-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||School Worksite Weight Gain Prevention Intervention Study|School Worksite Weight Gain Prevention Intervention Study|Completed||Phase 2/Phase 3|844|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 21:58:33.743834|2018-05-31 21:58:33.743834
NCT01467271|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2018-03-02|2011-11-04|2011-11-08|Estimate|||||||2018-03-02|2018-03-05|Actual|April 2011||2011-04-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|NSsaFe||Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration|Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM Administration|Completed|||540|Actual|Guerbet|||||f||||f||||||||||2018-05-31 21:58:33.890635|2018-05-31 21:58:33.890635
NCT01467258|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-07-26|2011-11-03|2011-11-08|Estimate|||||||2013-07-26|2013-07-29|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers|Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers|Completed||N/A|20|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 21:58:33.994622|2018-05-31 21:58:33.994622
NCT01467245|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2012-06-08|2011-11-07|2011-11-08|Estimate|||||||2012-06-08|2012-06-11|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|The CO2||Open or Keyhole Surgery Through the Chest for Newborn Babies: Effect on Blood Gases|Hypercapnia During Thoracoscopy or Open Surgery for Repair of Oesophageal Atresia With Tracheo-oesophageal Fistula or Congenital Diaphragmatic Hernia in Neonates: Pilot Randomised Controlled Trial|Unknown status|Recruiting|N/A|30|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||||||||||||2018-05-31 21:58:34.070816|2018-05-31 21:58:34.070816
NCT01467232|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2015-11-30|2011-11-07|2011-11-08|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Interventional|IMPACT-CABG||IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting|Implantation of Autologous CD133+ Stem Cells in Patients Undergoing CABG|Completed||Phase 2|20|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 21:58:34.186534|2018-05-31 21:58:34.186534
NCT01467219|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2015-06-19|2011-11-03|2011-11-08|Estimate|||||||2015-06-19|2015-06-23|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pilot Study Using a PET Gamma Probe to Evaluate Lymph Nodes in Endometrial Cancer|Intra-operative Lymph Node Evaluation Using a Hand Held PET Gamma Probe in Endometrial Cancer Surgery - A Pilot Study|Completed||N/A|12|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 21:58:34.288564|2018-05-31 21:58:34.288564
NCT01467206|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-12-30|2011-11-04|2011-11-08|Estimate|||||||2017-12-30|2018-01-03|Actual|November 2011|Actual|2011-11-30|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|LAST||Life After STroke - the LAST Study|Life After STroke - the LAST Study. A Norwegian Multi Centre Randomized Controlled Trial|Completed||N/A|380|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 21:58:34.366668|2018-05-31 21:58:34.366668
NCT01467193|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-09-08|2011-11-03|2011-11-08|Estimate|||||||2014-09-08|2014-09-09|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.|The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.|Unknown status|Recruiting||30|Anticipated|University Hospital Inselspital, Berne|||3||f||||f||||||||||2018-05-31 21:58:34.490323|2018-05-31 21:58:34.490323
NCT01467180|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-04-04|2011-11-04|2011-11-08|Estimate|||||||2017-04-04|2017-04-05|Actual|November 2011||2011-11-30|April 2017|2017-04-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|HicoRhabdo||Myoglobin Removal by High Cut-off CVVHD|Myoglobin Reduction by High Cut-off (HCO) Continuous Veno- Venous Hemodialysis (CVVHD) in Patients With Rhabdomyolysis and an Increased Risk for Acute Kidney Injury|Completed||N/A|16|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 21:58:34.595041|2018-05-31 21:58:34.595041
NCT01467167|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2016-10-24|2011-11-03|2011-11-08|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||Utility of the Smart Pilot View in Clinical Practice: A Two Center Prospective Observational Study|Utility of the Smart Pilot View in Clinical Practice: A Two Center Prospective Observational Study|Recruiting|||400|Anticipated|University Medical Center Groningen|||2||f||||f||||||||||2018-05-31 21:58:34.684196|2018-05-31 21:58:34.684196
NCT01467154|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-08|2011-11-07|2011-11-08|Estimate|||||||2011-11-08|2011-11-09|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Observational|||Evaluation of Intravenous N-acetylcysteine to Prevent Contrast Media Induced Nephrotoxicity in an Emergency Center|Does Ultra-High Dose i.v. N-acetylcysteine Prevent Contrast Nephropathy in Patients With Chronic Kidney Disease Undergoing Emergency Contrast Tomography.|Completed|||124|Actual|University Hospital, Geneva|||2||f||||f||||||||||2018-05-31 21:58:34.754102|2018-05-31 21:58:34.754102
NCT01467141|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-02-22|2011-11-04|2011-11-08|Estimate|||||||2017-02-22|2017-02-23|Actual|June 19, 2002|Actual|2002-06-19|February 2017|2017-02-28|October 15, 2003|Actual|2003-10-15|October 15, 2003|Actual|2003-10-15||Interventional|||Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes|Meal-related Insulin Aspart Therapy Versus Meal-related Human Insulin Therapy in Children 2-6 Years of Age With Type 1 Diabetes Mellitus: A Multi-centre Randomised, Open-labelled, Cross-over, Safety and Efficacy Trial|Completed||Phase 4|26|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:58:34.819868|2018-05-31 21:58:34.819868
NCT01467128|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2012-06-05|2011-11-03|2011-11-08|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Adverse Drug Event Prevention Using Structured Pharmacist Review|Title of Study: Adverse Drug Event (ADE) Incidence in Older Patients Following Hospital Admission and Pharmacist Review to Older Persons' Prescriptions and Its' Effect on ADE Reduction in Hospital: a Randomised Controlled Trial|Completed||Phase 4|720|Actual|University College Cork||2|||f||||f||||||||||2018-05-31 21:58:34.928505|2018-05-31 21:58:34.928505
NCT01467115|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2017-05-08|2011-11-04|2011-11-08|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2010||2010-03-31|May 2017|2017-05-31|October 7, 2014|Actual|2014-10-07|June 2014|Actual|2014-06-30||Interventional|DREXNECK||Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer|Induction Chemotherapy With Taxotere, Cisplatin and 5-Fluorouracil Followed by Concomitant Cetuximab and Radiation for Locoregionally Advanced Squamous Cell Cancer of the Head and Neck: A Phase II Trial|Completed||Phase 2|1|Actual|Drexel University||1|||f||||t||||||||No||2018-05-31 21:58:35.029545|2018-05-31 21:58:35.029545
NCT01467102|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2014-07-16|2011-11-07|2011-11-08|Estimate|||||||2014-07-16|2014-07-17|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|PAIN-OUT||euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT Study|euCPSP: European Observational Study on Chronic Post Surgical Pain,PAIN-OUT|Completed|||3618|Actual|European Society of Anaesthesiology|||1||f||||f||||||||||2018-05-31 21:58:35.155651|2018-05-31 21:58:35.155651
NCT01467089|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-09-19|2011-11-04|2011-11-08|Estimate|||||||2016-09-19|2016-09-21|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||The Assessment of Movement Disorders Utilizing Live Two-Way Video|The Assessment of Movement Disorders Utilizing Live Two-Way Video|Completed|||37|Actual|Northwell Health|||1||f||||f||||||||||2018-05-31 21:58:35.279684|2018-05-31 21:58:35.279684
NCT01466907|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2014-01-22|2011-11-04|2011-11-08|Estimate|||||||2014-01-22|2014-01-23|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Secondary Prevention and Health Promotion After Stroke|Secondary Prevention and Health Promotion After Stroke A Nurse-led Randomized Controlled Open Trial|Completed||N/A|597|Actual|Skane University Hospital||2|||f||||f||||||||||2018-05-31 21:58:37.228765|2018-05-31 21:58:37.228765
NCT01467076|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2016-11-03||2016-11-03|2011-11-07|2011-11-08|Estimate|2016-11-03|2016-12-30|Estimate||||2016-11-03|2016-12-30|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional||"Infants randomized to the Control group were given the placebo dose.~Infants randomized to the Low Dose IPGE1 were given the lower dose.~Infants randomized to the High Dose IPGE1 were given the higher dose."|Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)|Pilot Randomized Clinical Trial of Inhaled PGE1 in Neonates With Sub-Optimal Response to Inhaled Nitric Oxide|Terminated||Phase 2|7|Actual|NICHD Neonatal Research Network||3||"The study was halted due to futility concerns based on the unmet benchmarks as specified in the~   pilot study protocol."|f||||t||||||||||2018-05-31 21:58:35.39128|2018-05-31 21:58:35.39128
NCT01467063|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2013-05-02|2011-11-04|2011-11-08|Estimate|||||||2013-05-02|2013-05-03|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Glutamine and Insulin Sensitivity in Type I Diabetes|Dietary Amino Acids and Insulin Sensitivity in Children With Type 1 Diabetes|Unknown status|Active, not recruiting|N/A|20|Anticipated|Nemours Children's Clinic||2|||f||||f||||||||||2018-05-31 21:58:35.734054|2018-05-31 21:58:35.734054
NCT01467050|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-06-05|2011-11-03|2011-11-08|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients|Prevention of Adverse Drug Events (ADEs) in Hospitalised Older Patients Using STOPP/START Criteria|Completed||Phase 4|732|Actual|University College Cork||2|||f||||f||||||||||2018-05-31 21:58:35.81144|2018-05-31 21:58:35.81144
NCT01467037|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2015-11-16||2016-03-17|2011-11-07|2011-11-08|Estimate|2015-12-18|2016-01-29|Estimate||||2016-03-17|2016-04-19|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||Among all active surveillance eligible patients, patients were included if parent/legal guardian had provided informed consent, and if an adequate stool specimen was provided within 7 days of hospital presentation. Patients needed to be aged <15 months at RV1 program implementation (November 1, 2011), AND aged ≥16 weeks at symptom onset.|Vaccine Effectiveness of RV1 in a Naïve Population|Vaccine Effectiveness of RV1 in a Naïve Population|Completed|||374|Actual|McGill University Health Center|||2||f||||f||||||Samples Without DNA|"~     stool sample~   "|||2018-05-31 21:58:35.901935|2018-05-31 21:58:35.901935
NCT01467024|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-11-07|2011-11-07|2011-11-08|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Observational|||Evaluation of the MP Diagnostics HTLV Blot 2.4|Evaluation of the MP Diagnostics HTLV Blot 2.4|Unknown status|Enrolling by invitation||600|Anticipated|MP Biomedicals, LLC|||3||f||||t||||||||||2018-05-31 21:58:36.316447|2018-05-31 21:58:36.316447
NCT01467011|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2018-05-11|2011-11-07|2011-11-08|Estimate|||||||2018-05-11|2018-05-16|Actual|December 2010||2010-12-31|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation|An Open-label Study of the Pharmacokinetics of Mycophenolic Acid as Myfortic (Enteric-coated Mycophenolate Sodium) When Used in Combination With Prograf (Tacrolimus) and Corticosteroids in Patients Undergoing de Novo Liver Transplantation|Completed|||25|Actual|The Methodist Hospital System|||1||f||||f|t|f|||f|Samples Without DNA|"~     Serum will be retained and frozen for MPA levels~   "|Undecided|Plan to share data to be determined.|2018-05-31 21:58:36.405168|2018-05-31 21:58:36.405168
NCT01466998|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-05-05|2011-11-03|2011-11-08|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|MaTURE||Menopausal Treatment Using Relaxation Exercises (MaTURE)|Menopausal Treatment Using Relaxation Exercises (MaTURE)|Completed||N/A|123|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:58:36.494655|2018-05-31 21:58:36.494655
NCT01466985|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2015-10-01|2011-11-04|2011-11-08|Estimate|||||||2015-10-01|2015-10-02|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-1439 in HIV-1 Infected Patients|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 21:58:36.644635|2018-05-31 21:58:36.644635
NCT01466972|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-05-30|2011-11-03|2011-11-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2012||2012-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib|Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib|Active, not recruiting||Phase 2|30|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:58:36.710197|2018-05-31 21:58:36.710197
NCT01466959|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-03-23|2011-11-07|2011-11-08|Estimate|||||||2013-03-23|2013-03-26|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Effect of Citrasate Dialysate on Heparin Dose in Hemodialysis|The Effect of Citrasate Dialysate on Heparin Dose: A Randomized Cross Over Trial in Hemodialysis Patients.|Completed||N/A|20|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 21:58:36.795106|2018-05-31 21:58:36.795106
NCT01466946|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2016-02-10|2011-11-04|2011-11-08|Estimate|||||||2016-02-10|2016-02-11|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients|Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients|Completed|||25|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:58:36.881521|2018-05-31 21:58:36.881521
NCT01466933|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2013-07-16|2011-11-04|2011-11-08|Estimate|||||||2013-07-16|2013-07-18|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Responsive Parenting Program for Infants in Rural Bangladesh|Design, Implementation and Evaluation of a Parent Support/Counselling Program With a Focus on Responsive Stimulation for Infants and Young Children in Rural Bangladesh|Completed||N/A|474|Actual|McGill University||3|||f||||f||||||||||2018-05-31 21:58:37.039575|2018-05-31 21:58:37.039575
NCT01466920|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-04-07|2011-11-03|2011-11-08|Estimate|||||||2015-04-07|2015-04-09|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|August 2013|Actual|2013-08-31||Observational|||Why Are so Many Patients Dissatisfied With Knee Replacement Surgery? Exploring Variations of the Patient Experience|Why Are so Many Patients Dissatisfied With Knee Replacement Surgery? Exploring Variations of the Patient Experience|Unknown status|Active, not recruiting||515|Actual|University of British Columbia|||||f||||||||||||||2018-05-31 21:58:37.140271|2018-05-31 21:58:37.140271
NCT01466400|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2015-07-21|2011-11-07|2011-11-08|Estimate|||||||2015-07-21|2015-07-23|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|August 2013|Actual|2013-08-31|November 2012|Actual|2012-11-30||Observational|||Fermentation Rate of Infant Formula||Completed|||13|Actual|Father Flanagan’s Boys’ Home|||1||f||||f||||||||||2018-05-31 21:58:49.051598|2018-05-31 21:58:49.051598
NCT01466894|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-12-04|2011-11-07|2011-11-08|Estimate|||||||2012-12-04|2012-12-06|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis|A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis|Withdrawn||Phase 2|0|Actual|Immuron Ltd.||3||Sponsor administrative decision|f||||f||||||||||2018-05-31 21:58:37.331788|2018-05-31 21:58:37.331788
NCT01466881|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2016-02-09||2016-02-09|2011-11-03|2011-11-08|Estimate|2016-02-09|2016-03-10|Estimate||||2016-02-09|2016-03-10|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional||Only eligible patients were included in the analysis.|Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma|Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma|Completed||Phase 2|42|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 21:58:37.544911|2018-05-31 21:58:37.544911
NCT01466868|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2014-07-09|2011-11-04|2011-11-08|Estimate|||||||2014-07-09|2014-07-10|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|AKTIL||Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma|A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma|Terminated||Phase 2|22|Actual|Centre Leon Berard||1||Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions|f||||t||||||||||2018-05-31 21:58:38.209448|2018-05-31 21:58:38.209448
NCT01466855|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2017-02-28|2011-11-04|2011-11-08|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2011||2011-10-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|IARB1||A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma|A Pilot Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma|Terminated||N/A|36|Actual|Children's Hospital Medical Center, Cincinnati||1||Competing studies|f||||t||||||||||2018-05-31 21:58:38.309773|2018-05-31 21:58:38.309773
NCT01466842|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-07|2011-11-07|2011-11-08|Estimate|||||||2011-11-07|2011-11-08|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|January 2016|Anticipated|2016-01-31|January 2013|Anticipated|2013-01-31||Interventional|AFLIT-PAF||Ablation as First Line Treatment in Paroxysmal Atrial Fibrillation|Ablation as First Line Treatment in Paroxysmal Atrial Fibrillation|Unknown status|Not yet recruiting|N/A|160|Anticipated|Maastricht University Medical Center||2|||f||||||||||||||2018-05-31 21:58:38.38482|2018-05-31 21:58:38.38482
NCT01466829|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-05-30|2011-11-07|2011-11-08|Estimate|||||||2014-05-30|2014-06-02|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PAATH||Treatment With PTH After Sternotomy in Cardiac Surgery Patients|Clinical Effects of Parathyroid Hormone as Adjuvant Therapy for Bone Healing After Sternotomy.|Completed||Phase 3|20|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:58:38.453923|2018-05-31 21:58:38.453923
NCT01466816|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-11-03|2011-11-03|2011-11-08|Estimate|||||||2011-11-03|2011-11-08|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Lipids and Insulin Sensitivity|Skeletal Muscle Lipid Metabolism and Insulin Sensitivity: Can Dietary Fatty Acid Composition Modulate Muscle Lipid Storage?|Completed||N/A|10|Actual|Maastricht University Medical Center||3|||f||||||||||||||2018-05-31 21:58:38.525063|2018-05-31 21:58:38.525063
NCT01466803|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2013-04-27|2011-11-07|2011-11-08|Estimate|||||||2013-04-27|2013-04-30|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects|Effects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy Subjects|Completed||Phase 1|12|Actual|Turku University Hospital||2|||f||||||||||||||2018-05-31 21:58:38.704025|2018-05-31 21:58:38.704025
NCT01466790|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2014-10-17||2015-01-26|2011-11-03|2011-11-08|Estimate|2014-10-17|2014-10-22|Estimate||||2015-01-26|2015-02-09|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|COSMOS||A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients|An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects|Completed||Phase 2|168|Actual|Janssen R&D Ireland||4|||f||||t||||||||||2018-05-31 21:58:38.83425|2018-05-31 21:58:38.83425
NCT01466777|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-03-23|2011-11-03|2011-11-08|Estimate|||||||2016-03-23|2016-03-24|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy|Robotic-assisted vs. Traditional Laparoscopic Surgery in Treatment of Endometrial Cancer Patients|Unknown status|Active, not recruiting|N/A|100|Anticipated|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 21:58:39.742124|2018-05-31 21:58:39.742124
NCT01466764|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2017-06-06||2017-07-10|2011-11-07|2011-11-08|Estimate|2017-06-06|2017-07-06|Actual||||2017-07-10|2017-08-09|Actual|October 2011||2011-10-31|July 2017|2017-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain|Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain|Terminated||N/A|13|Actual|Stanford University|The trial terminated early. We did not expect to see an effect in such a small number of subjects.|2||Due to inability to demonstrate benefit in this patient population.|f||||t||||||||No||2018-05-31 21:58:39.805988|2018-05-31 21:58:39.805988
NCT01466751|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-11-17|2011-11-07|2011-11-08|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits|Neurobehavioral Intervention as a Novel Treatment Approach for Emotion-Regulatory Deficits|Completed||N/A|58|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 21:58:40.084939|2018-05-31 21:58:40.084939
NCT01466738|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2012-02-20|2011-11-04|2011-11-08|Estimate|||||||2012-02-20|2012-02-22|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers|Clinical Characterization of a Human Rhinovirus Type 16 Challenge Pool Following Intranasal Administration to Healthy Adult Subjects|Completed||Phase 1|52|Actual|Centocor Ortho Biotech Services, L.L.C.||2|||f||||||||||||||2018-05-31 21:58:40.166401|2018-05-31 21:58:40.166401
NCT01466725|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04||2013-08-16|2016-05-02|2011-11-04|2011-11-08|Estimate||||2013-08-16|2013-08-26|Estimate|2016-05-02|2016-05-30|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus|A Phase 2, Pilot, Multicenter, Randomized, Placebo-Controlled Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Activity of CC-930 in Subjects With Recalcitrant Discoid Lupus Erythematosus (DLE)|Terminated||Phase 2|5|Actual|Celgene Corporation||4||The benefit/risk profile does not support continuation of this study.|f||||t||||||||||2018-05-31 21:58:40.235405|2018-05-31 21:58:40.235405
NCT01466712|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2013-07-29|2011-11-04|2011-11-08|Estimate|||||||2013-07-29|2013-07-30|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function|Randomized Double-blind Placebo-controlled Crossover Study to Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function in COPD Patients.|Unknown status|Enrolling by invitation|Phase 4|20|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 21:58:41.457708|2018-05-31 21:58:41.457708
NCT01466699|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2011-11-07|2011-11-04|2011-11-08|Estimate|||||||2011-11-07|2011-11-09|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|||The Study of Blood Pressure Variability to Impact Arterial Stiffness and Carotid Atherosclerosis|The Relationship of Blood Pressure Variability, Arterial Stiffness and Carotid Atherosclerosis in Beijing Residents|Unknown status|Enrolling by invitation||1235|Anticipated|Capital Medical University|||||f||||t||||||||||2018-05-31 21:58:41.550146|2018-05-31 21:58:41.550146
NCT01466686|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-10-05|2011-11-07|2011-11-08|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2012||2012-09-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Low Dose Radiation Therapy for Glioblastoma Multiforme|A Phase II Trial of Low Dose Fractionated Radiation Therapy as a Chemo-Potentiator of Salvage Temozolomide for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme|Recruiting||Phase 2|49|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 21:58:41.610024|2018-05-31 21:58:41.610024
NCT01466673|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-02-22||2013-06-14|2011-11-03|2011-11-08|Estimate|2013-06-14|2013-06-19|Estimate||||2013-06-14|2013-06-19|Estimate|December 2008||2008-12-31|June 2013|2013-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||An Efficacy and Safety Study Comparing Oral Contraceptive Containing Norgestimate or Desogestrel for Acne Treatment|Comparative Study of the Effect on Acne With Norgestimate Containing Triphasic Oral Contraceptive and Biphasic Preparation Containing Desogestrel|Completed||Phase 4|201|Actual|Janssen-Cilag Ltd.,Thailand||2|||f||||f||||||||||2018-05-31 21:58:41.747229|2018-05-31 21:58:41.747229
NCT01466660|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|2017-04-04||2018-04-12|2011-11-04|2011-11-08|Estimate|2017-04-04|2017-06-19|Actual||||2018-04-12|2018-04-13|Actual|December 13, 2011|Actual|2011-12-13|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|April 8, 2016|Actual|2016-04-08||Interventional||Randomised set which included all patients randomised to receive treatment, whether treated or not.|LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung|LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung|Active, not recruiting||Phase 2|319|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:58:43.246677|2018-05-31 21:58:43.246677
NCT01466647|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2012-11-09|2011-11-04|2011-11-08|Estimate|||||||2012-11-09|2012-11-12|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)|A Phase I Pilot Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Squamous Non-small-cell Lung Cancer|Completed||Phase 1|12|Actual|Axelar AB||1|||f||||t||||||||||2018-05-31 21:58:44.427141|2018-05-31 21:58:44.427141
NCT01466634|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-11-04|2011-11-04|2011-11-08|Estimate|||||||2011-11-04|2011-11-08|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis|Bioabsorbable Versus Permanent Polymer Bare Metal Stents in Saphenous Vein Graft Disease: Insights From a Meta-analysis of 6221 Patients|Completed|||6221|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita|||2||f||||f||||||||||2018-05-31 21:58:44.59075|2018-05-31 21:58:44.59075
NCT01466621|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2016-02-23|2011-11-07|2011-11-08|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Response to Cardiac Resynchronization Therapy of Previously Right Ventricular Paced Heart Failure Patients|Response to Cardiac Resynchronization Therapy of Previously Right Ventricular Paced Heart Failure Patients|Completed|||743|Actual|Allina Health System|||2||f||||f||||||||||2018-05-31 21:58:44.680084|2018-05-31 21:58:44.680084
NCT01466608|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2014-05-15|2011-11-03|2011-11-08|Estimate|||||||2014-05-15|2014-05-16|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional|||Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients|Lipid Lowering Effect, and Lipidomic Profiles by Genotype of OATP1B1 and BCRP After Administration of Rosuvastatin in Patients With Hyperlipidemia|Completed||Phase 4|21|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 21:58:44.746789|2018-05-31 21:58:44.746789
NCT01466595|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2013-09-03||2013-11-08|2011-11-04|2011-11-08|Estimate|2013-09-03|2013-11-07|Estimate||||2013-11-08|2013-12-04|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Rifaximin as a Modulator of Microbial Translocation and Immune Activation|A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy|Completed||Phase 2|73|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 21:58:44.943817|2018-05-31 21:58:44.943817
NCT01466582|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2018-02-27|2011-11-04|2011-11-08|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2010||2010-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|agehIV||Comorbidity and Aging With HIV|Comorbidity and Aging With HIV, the agehIV Cohort Study|Active, not recruiting|||1148|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||Samples With DNA|"~     whole blood, serum (EDTA/heparin/citrate), PBMCs, urine~   "|||2018-05-31 21:58:46.918721|2018-05-31 21:58:46.918721
NCT01466569|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2015-06-22|2011-11-04|2011-11-08|Estimate|||||||2015-06-22|2015-06-23|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors|A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors|Completed||Phase 1|13|Actual|AbGenomics B.V Taiwan Branch||5|||f||||f||||||||||2018-05-31 21:58:47.106881|2018-05-31 21:58:47.106881
NCT01466556|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-07|2011-11-07|2011-11-08|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||The Incidence of Metabolic Syndrome Among Obese Children in Our Region||Unknown status|Recruiting||70|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 21:58:47.337029|2018-05-31 21:58:47.337029
NCT01466543|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2011-11-07|2011-11-07|2011-11-08|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|November 2012|Anticipated|2012-11-30|March 2012|Anticipated|2012-03-31||Interventional|SMCZN01||Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity|Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:58:47.504726|2018-05-31 21:58:47.504726
NCT01466530|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2011-11-06|2011-11-06|2011-11-08|Estimate|||||||2011-11-06|2011-11-08|Estimate|January 2006||2006-01-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Sublingual Misoprostol & Isoflurane During Caesarean Section|Effects of Preoperative Sublingual Misoprostol on Uterine Tone During Isoflurane Anaesthesia for Caesarean Section|Completed||Phase 2|366|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 21:58:47.65896|2018-05-31 21:58:47.65896
NCT01466517|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-02-07|2011-11-03|2011-11-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|B4371005||A Relative BioavailabilityStudy Of Ibuprofen 40mg/ml (laboratórios Pfizer Ltda) In The Oral Suspension Form.|A Phase IV, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Relative Bioavailability Of Ibupirac 40 mg/ml (Laboratorios Pfizer LTDA) Oral Suspension Form Versus Alivium® 50mg/ml (Mantecorp Industria Quimicae Farmaceutica LTDA.) Oral Suspension Form, Under Fasted Conditions In Healthy Volunteers.|Completed||Phase 4|70|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:58:47.765718|2018-05-31 21:58:47.765718
NCT01466504|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-04-11|2011-11-07|2011-11-08|Estimate|||||||2013-04-11|2013-04-15|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin|A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin|Terminated|||4|Actual|Dartmouth-Hitchcock Medical Center||||"Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study.~   The goal of 30 subjects was not attainable."|f||||t||||||Samples Without DNA|"~     skin biopsies will be performed using a 4mm biopsy punch. Participants will undero 2 skin~     biopsies - one prior to starting sorafenib or regorafenib, the other once rash develops. If a~     rash does not develop within 84 days a biopsy of normal skin will be done.~   "|||2018-05-31 21:58:47.84637|2018-05-31 21:58:47.84637
NCT01466491|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2017-06-26||2017-06-26|2011-11-03|2011-11-08|Estimate|2017-06-26|2017-07-25|Actual||||2017-06-26|2017-07-25|Actual|October 2011||2011-10-31|June 2017|2017-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Refining Paracervical Block Techniques for Pain Control in First Trimester Surgical Abortion|Refining Paracervical Block Techniques for Pain Control in First Trimester Surgical Abortion|Completed||Phase 4|282|Actual|Oregon Health and Science University||4|||f||||f||||||||||2018-05-31 21:58:47.948611|2018-05-31 21:58:47.948611
NCT01466478|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-10-24|2011-11-07|2011-11-08|Estimate|||||||2013-10-24|2013-10-25|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris|A Phase I Exploratory Study Evaluating 3 Formulations of LEO 29102 Plus Calcipotriol, Ointment, LEO 29102 Ointment, Calcipotriol Ointment, Daivonex® Ointment and Diprosone® Ointment in the Treatment of Psoriasis|Completed||Phase 1|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 21:58:48.475544|2018-05-31 21:58:48.475544
NCT01466465|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2015-06-24|2011-11-07|2011-11-08|Estimate|||||||2015-06-24|2015-06-25|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Vitamin D and Grass Pollen Specific Immunotherapy||Completed||Phase 2|35|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:58:48.610643|2018-05-31 21:58:48.610643
NCT01466452|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-11-07|2011-11-07|2011-11-08|Estimate|||||||2011-11-07|2011-11-08|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|ASABYVALV||Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery||Unknown status|Recruiting|Phase 2|99|Anticipated|Centro Cardiologico Monzino||3|||f||||f||||||||||2018-05-31 21:58:48.689176|2018-05-31 21:58:48.689176
NCT01466439|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2013-06-07|2011-11-07|2011-11-08|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|rTMS-P50||Repetitive Transcranial Magnetic Stimulation (rTMS) and P50 Evoked Potential Component|Evaluation of Effect of Low and High-frequencies of Repetitive Transcranial Magnetic Stimulation (rTMS) by the Suppression of P50 Evoked Potential Component (rTMS-P50)|Completed||Phase 2|30|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 21:58:48.783951|2018-05-31 21:58:48.783951
NCT01466426|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-10-26|2011-11-07|2011-11-08|Estimate|||||||2014-10-26|2014-10-28|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|PETVET||The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders (The PETVET Study)|The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders|Completed|||40|Actual|Odense University Hospital|||4||f||||f||||||||||2018-05-31 21:58:48.857747|2018-05-31 21:58:48.857747
NCT01466413|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2012-10-11|2011-11-06|2011-11-08|Estimate|||||||2012-10-11|2012-10-15|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Two Formulations of ELAPR Compared to Restylane® Vital Light Following Repeat Implants in the Upper Arm Dermis|A Phase 1B Study to Assess the Safety and Efficacy of Two Formulations of ELAPR Compared to Restylane® Vital Light Following Repeat Implants in the Upper Arm Dermis|Completed||Phase 1|16|Actual|Elastagen Pty Ltd||1|||f||||f||||||||||2018-05-31 21:58:48.933716|2018-05-31 21:58:48.933716
NCT01466387|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2013-08-21|2012-11-28|2014-02-07|2011-11-07|2011-11-08|Estimate|2014-02-07|2014-03-11|Estimate|2012-12-06|2012-12-10|Estimate|2014-02-07|2014-03-11|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults|A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults|Completed||Phase 3|552|Actual|Novartis||6|||f||||t||||||||||2018-05-31 21:58:49.153472|2018-05-31 21:58:49.153472
NCT01466374|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03||2015-09-23|2015-09-23|2011-11-07|2011-11-08|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease|A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Crohn's Disease|Completed||Phase 2|121|Actual|Bristol-Myers Squibb||7|||f||||t||||||||||2018-05-31 21:58:50.200658|2018-05-31 21:58:50.200658
NCT01466361|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2012-08-23||2012-11-08|2011-11-06|2011-11-07|Estimate|2012-11-08|2012-12-04|Estimate||||2012-11-08|2012-12-04|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving|Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving|Completed||Phase 2|187|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:58:50.433449|2018-05-31 21:58:50.433449
NCT01466348|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|2013-06-27||2013-09-25|2011-11-03|2011-11-07|Estimate|2013-09-25|2013-11-25|Estimate||||2013-09-25|2013-11-25|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effects of a Common Cold Treatment on Cognitive Function|Effects of a Common Cold Treatment on Cognitive Function|Completed||Phase 4|72|Actual|GlaxoSmithKline|Apparent carryover effect from the paracetamol/ caffeine treatment taken in Period 1 into the baseline assessment of Period 2 was observed, hence the statistical analysis was amended after unblinding the statistician.|2|||f||||f||||||||||2018-05-31 21:58:51.009651|2018-05-31 21:58:51.009651
NCT01466335|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2017-06-19|2011-11-03|2011-11-07|Estimate|||||||2017-06-19|2017-06-20|Actual|October 27, 2011|Actual|2011-10-27|June 2017|2017-06-30|March 5, 2012|Actual|2012-03-05|March 5, 2012|Actual|2012-03-05||Interventional|||An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers|A Randomized, Double Blind, Parallel Group, Single Center, Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist) for Durations Not to Exceed 28 Days, Versusplacebo in Healthy Human Volunteers.|Completed||Phase 1|39|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 21:58:51.529616|2018-05-31 21:58:51.529616
NCT01466322|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2017-07-05|2011-11-03|2011-11-07|Estimate|||||||2017-07-05|2017-07-07|Actual|December 22, 2010|Actual|2010-12-22|July 2017|2017-07-31|February 15, 2011|Actual|2011-02-15|February 15, 2011|Actual|2011-02-15||Interventional|P1A114919||A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.|An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:58:51.627787|2018-05-31 21:58:51.627787
NCT01466309|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-06|2011-11-06|2011-11-07|Estimate|||||||2011-11-06|2011-11-07|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|ThaiSomnoguard||Efficacy of Adjustable Thermoplastic Oral Appliances in Patient With OSA|The Efficacy of Adjustable Thermoplastic Oral Appliances in Thai Patient With OSA|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Mahidol University||1|||f||||f||||||||||2018-05-31 21:58:51.954413|2018-05-31 21:58:51.954413
NCT01466296|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2011-11-03|2011-11-03|2011-11-07|Estimate|||||||2011-11-03|2011-11-07|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|April 2012|Anticipated|2012-04-30|April 2011|Actual|2011-04-30||Interventional|MESF||"The Middle East Stepping Forward Project (MESF)"|Improving Treatment of People With Movement Disorders in the Middle East|Unknown status|Recruiting|Phase 2|120|Anticipated|Assaf-Harofeh Medical Center||3|||f||||t||||||||||2018-05-31 21:58:52.314334|2018-05-31 21:58:52.314334
NCT01466283|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2016-05-17|2011-11-02|2011-11-07|Estimate|||||||2016-05-17|2016-05-19|Estimate|October 2011||2011-10-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Patients With Rhabdomyosarcoma|Integrative Epigenomic Approach to Gene Discovery in Rhabdomyosarcoma (RMS)|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:58:52.560071|2018-05-31 21:58:52.560071
NCT01466270|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2014-12-31||2017-07-28|2011-11-02|2011-11-07|Estimate|2014-12-31|2015-01-09|Estimate||||2017-07-28|2017-08-28|Actual|April 2012||2012-04-30|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All randomized patients.|Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction|A Feasibility Study of Donepezil in Female Breast Cancer Survivors With Self-Reported Cognitive Dysfunction Following Chemotherapy|Completed||Phase 2|62|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f|||f|||No||2018-05-31 21:58:52.789785|2018-05-31 21:58:52.789785
NCT01466257|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2017-05-17|2011-11-02|2011-11-07|Estimate|||||||2017-05-17|2017-05-19|Actual|November 21, 2011|Actual|2011-11-21|May 2017|2017-05-31|January 1, 2012|Actual|2012-01-01|January 1, 2012|Actual|2012-01-01||Observational|||Biomarkers in Patients With Head and Neck Cancer|Detection of DNA Mutations in Head and Neck Squamous Cell Carcinoma|Completed|||70|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:58:53.590936|2018-05-31 21:58:53.590936
NCT01466244|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2017-05-16|2011-11-02|2011-11-07|Estimate|||||||2017-05-16|2017-05-17|Actual|November 11, 2011|Actual|2011-11-11|May 2017|2017-05-31|January 11, 2012|Actual|2012-01-11|January 11, 2012|Actual|2012-01-11||Observational|||Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397|PTEN Determination in Squamous Cell Cancer of The Head and Neck Treated on E5397, A Randomized Phase III Trial of Cisplatin Plus Placebo Versus Cisplatin Plus C225 (Cetuximab) in Metastatic/Recurrent Head and Neck Cancer|Completed|||42|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:58:53.694278|2018-05-31 21:58:53.694278
NCT01466231|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-01-11|2011-11-04|2011-11-07|Estimate|||||||2016-01-11|2016-01-12|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Everolimus in Refractory Testicular Germ Cell Cancer|Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.|Completed||Phase 2|15|Actual|National Cancer Institute, Slovakia||1|||f||||t||||||||||2018-05-31 21:58:53.921103|2018-05-31 21:58:53.921103
NCT01466218|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2014-06-27|2011-11-04|2011-11-07|Estimate|||||||2014-06-27|2014-07-01|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||World Trade Center (WTC) CHEST|Pulmonary Abnormalities, Diastolic Dysfunction, and World Trade Center Exposure: Implications for Diagnosis and Treatment|Completed|||1012|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||t||||||||||2018-05-31 21:58:54.107985|2018-05-31 21:58:54.107985
NCT01466205|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-07-19|2011-11-02|2011-11-07|Estimate|||||||2012-07-19|2012-07-20|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|SPD||Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder|Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder|Unknown status|Recruiting|Phase 2|20|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:58:54.311581|2018-05-31 21:58:54.311581
NCT01466192|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2014-10-29||2014-10-29|2011-11-04|2011-11-07|Estimate|2014-10-29|2014-11-03|Estimate||||2014-10-29|2014-11-03|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 2 Hepatitis C, Who Relapsed After Previous Treatment|Completed||Phase 3|108|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 21:58:54.481581|2018-05-31 21:58:54.481581
NCT01466179|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2014-12-21||2017-07-18|2011-11-04|2011-11-07|Estimate|2015-01-20|2015-01-22|Estimate||||2017-07-18|2017-08-18|Actual|December 2011||2011-12-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|October 2013|Actual|2013-10-31||Interventional||Primary Analysis Set|Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2|225|Actual|Amgen Research (Munich) GmbH||1|||f||||t||||||||||2018-05-31 21:58:55.02546|2018-05-31 21:58:55.02546
NCT01466166|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2017-07-17|2011-11-04|2011-11-07|Estimate|||||||2017-07-17|2017-07-19|Actual|November 15, 2011|Actual|2011-11-15|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|EyesOnGOUT||Observational Study of the Use of KRYSTEXXA® in Refractory Chronic Gout|Observational Study of the Use of KRYSTEXXA® (Pegloticase)in Adult Hyperuricemic Patients With Gout Refractory to Conventional Therapy|Completed|||187|Actual|Horizon Pharma Rheumatology LLC|||1||f||||f||||||Samples Without DNA|"~     Serum samples~   "|No||2018-05-31 21:58:56.496439|2018-05-31 21:58:56.496439
NCT01466153|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2017-04-20||2017-04-20|2011-11-04|2011-11-07|Estimate|2017-04-20|2017-05-31|Actual||||2017-04-20|2017-05-31|Actual|February 7, 2012||2012-02-07|April 2017|2017-04-30|January 8, 2016|Actual|2016-01-08|January 8, 2016|Actual|2016-01-08||Interventional||Intent-to-treat (ITT) Population includes all participants who were randomized into the study.|A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL|Completed||Phase 2|183|Actual|MedImmune LLC||3|||f||||t||||||||||2018-05-31 21:58:56.889099|2018-05-31 21:58:56.889099
NCT01466140|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2011-11-04|2011-11-04|2011-11-07|Estimate|||||||2011-11-04|2011-11-07|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Writing Down the Request for Help on Patient Satisfaction in General Practices|Effects of Writing Down the Request for Help With Regard to Patient Satisfaction in General Practices|Completed||N/A|209|Actual|Medical Research Foundation, The Netherlands||2|||f||||f||||||||||2018-05-31 21:58:58.60705|2018-05-31 21:58:58.60705
NCT01466127|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2016-11-04||2017-03-03|2011-11-04|2011-11-07|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|October 2011||2011-10-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Although 60 participants were enrolled, only 30 participants had usable physiological data from recording electrodes, and therefore, the only data analyzed were from these 30 participants (16 placebo and 14 oxytocin).|The Effect of Oxytocin on Fear Memory Consolidation Novel Intervention to Prevent Posttraumatic Stress Disorder (PTSD)|The Effect of Oxytocin on Fear Memory Consolidation: A Novel Intervention to Prevent PTSD|Completed||N/A|60|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:58:58.789087|2018-05-31 21:58:58.789087
NCT01466114|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-04-19|2011-11-02|2011-11-07|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2011||2011-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition|A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.|Recruiting||Phase 2|64|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 21:58:59.363358|2018-05-31 21:58:59.363358
NCT01466101|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-02-17|2011-11-01|2011-11-07|Estimate|||||||2012-02-17|2012-02-20|Estimate|January 2011||2011-01-31|February 2012|2012-02-29||||||||Interventional|||Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy|Analgesic Effect of Pregabalin in Patients Undergoing Total Abdominal Hysterectomy|Withdrawn||N/A|0|Actual|Northwestern University||2||PI left the institution. No subjects screened or enrolled.|f||||f||||||||||2018-05-31 21:58:59.609615|2018-05-31 21:58:59.609615
NCT01466088|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02||2015-05-11|2015-05-11|2011-11-04|2011-11-07|Estimate||||2015-05-11|2015-06-03|Estimate|2015-05-11|2015-06-03|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)|Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type|Completed||Phase 2|386|Actual|Targacept Inc.||2|||f||||f||||||||||2018-05-31 21:58:59.79316|2018-05-31 21:58:59.79316
NCT01466075|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2012-12-21||2016-01-29|2011-11-03|2011-11-07|Estimate|2012-12-21|2013-01-30|Estimate||||2016-01-29|2016-02-29|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of an Investigational Glucose Meter System|Clinical Study of the Apollo Evolution BGMS With Tatsu Blood Glucose Test Strips|Completed||N/A|207|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 21:59:00.010069|2018-05-31 21:59:00.010069
NCT01466062|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2013-04-25||2013-06-13|2011-11-04|2011-11-07|Estimate|2013-06-13|2013-06-17|Estimate||||2013-06-13|2013-06-17|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions|Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions|Completed||Phase 3|28|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:59:00.371763|2018-05-31 21:59:00.371763
NCT01466036|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2018-04-04|2011-11-04|2011-11-07|Estimate|||||||2018-04-04|2018-04-06|Actual|July 2012||2012-07-31|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors|An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors|Active, not recruiting||Phase 2|62|Actual|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 21:59:02.840707|2018-05-31 21:59:02.840707
NCT01466023|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2017-05-02|2011-11-04|2011-11-07|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2011|Actual|2011-10-31|July 2011|2011-07-31|April 2016|Actual|2016-04-30|April 2014|Actual|2014-04-30||Observational|||The Reduced Thyroid Function of the Premature Newborn: Relation With Molecular Changes in the Placenta and Maternal Thyroid Hormone Status and Neurodevelopmental Implications|The Reduced Thyroid Function of the Premature Newborn: Relation With Molecular Changes in the Placenta and Maternal Thyroid Hormone Status and Neurodevelopmental Implications|Completed|||319|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples With DNA|"~     Placenta and blood samples~   "|||2018-05-31 21:59:03.162209|2018-05-31 21:59:03.162209
NCT01466010|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2011-11-04|2011-11-04|2011-11-07|Estimate|||||||2011-11-04|2011-11-07|Estimate|January 1998||1998-01-31|September 2011|2011-09-30|January 2010|Actual|2010-01-31|||||Observational|||Treatment Outcome After Surgical Treatment of Osteoid Osteoma|Treatment Outcome After Surgical Treatment of Osteoid Osteoma, a Retrospective Study|Completed|||150|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 21:59:03.372865|2018-05-31 21:59:03.372865
NCT01465997|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2017-06-27||2017-09-07|2011-11-04|2011-11-07|Estimate|2017-07-07|2017-08-02|Actual||||2017-09-07|2017-10-09|Actual|May 2012||2012-05-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional||The analysis group for Baseline Characteristics is the Safety Set (SS). The SS consists of all subjects in the Enrolled Set who have received at least 1 dose of study medication.|Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older|A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.|Completed||Phase 3|551|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:59:03.58814|2018-05-31 21:59:03.58814
NCT01465984|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-12-06|2011-11-04|2011-11-07|Estimate|||||||2012-12-06|2012-12-10|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy of Intravenous (IV) Paracetamol for Treatment of Acute Pain|Comparison of IV Paracetamol With Intravenous Morphine Sulfate in Treatment of Acute Pain Due to Limb Trauma|Completed||Phase 4|60|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:59:04.627328|2018-05-31 21:59:04.627328
NCT01465971|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2012-04-04|2011-11-02|2011-11-07|Estimate|||||||2012-04-04|2012-04-06|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|PerOxySleep||Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude|Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During the Sleep in High Altitude|Completed|||6|Actual|Goethe University|||2||f||||f||||||||||2018-05-31 21:59:04.757319|2018-05-31 21:59:04.757319
NCT01465958|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2015-01-19||2015-02-23|2011-11-02|2011-11-07|Estimate|2015-01-19|2015-01-28|Estimate||||2015-02-23|2015-03-13|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|KIDS|All 12 enrolled subjects who were infused with any amount of study drug (GAMUNEX-C) were included in the safety population. The demographic data of the safety population are provided.|Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency|An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency|Completed||Phase 4|12|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-05-31 21:59:05.063087|2018-05-31 21:59:05.063087
NCT01465945|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2014-07-19|2011-11-02|2011-11-07|Estimate|||||||2014-07-19|2014-07-22|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of Unsutured Versus Sutured Closure of Rectal Defects After Rectal Lesion Excisions Using Transanal Endoscopic Microsurgery|A Randomized Clinical Trial of Open Versus Suture Closure in Patients With Rectal Lesions Excised Using Transanal Endoscopic Microsurgery|Completed||N/A|50|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 21:59:05.469433|2018-05-31 21:59:05.469433
NCT01465932|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2011-11-04|2011-11-04|2011-11-07|Estimate|||||||2011-11-04|2011-11-07|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Effectiveness of Physical Therapy Program to Treat Rotator Cuff Disorders Among Nursing Professionals|Evaluation of the Effectiveness of Physical Therapy Program to Treat Rotator Cuff Disorders Among Nursing Professionals According to Indicators of Quality of Life and Job Satisfaction|Completed||N/A|16|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:59:05.582055|2018-05-31 21:59:05.582055
NCT01465919|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2018-04-23|2011-11-02|2011-11-07|Estimate|||||||2018-04-23|2018-04-24|Actual|August 2011|Actual|2011-08-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C|Phase 4 Open-labeled Study to Compare the Anti-depressive Efficacy Between Mirtazapine and Psychotherapy for Patients With Interferon-related Depression During Antiviral Therapy for Hepatitis C|Terminated||Phase 4|5|Actual|Seoul National University Boramae Hospital||2||Due to the recent change in standard of care for hepatitis C.|f||||f||||||||Undecided||2018-05-31 21:59:05.687835|2018-05-31 21:59:05.687835
NCT01465906|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-11-08|2011-11-02|2011-11-07|Estimate|||||||2011-11-08|2011-11-09|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease||Unknown status|Active, not recruiting|Phase 4|160|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 21:59:05.784597|2018-05-31 21:59:05.784597
NCT01465893|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-11-21|2011-11-04|2011-11-07|Estimate|||||||2011-11-21|2011-11-22|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography|The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography|Unknown status|Recruiting|Phase 2|60|Anticipated|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 21:59:05.873658|2018-05-31 21:59:05.873658
NCT01465880|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-12-20|2011-11-04|2011-11-07|Estimate|||||||2011-12-20|2011-12-21|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Smoking Research Study|A Single-centre, Dose Titration Study in Healthy Volunteers (Smokers and Non-smokers) to Evaluate the Capacity of 2-cyanoethylmercapturic Acid (CEMA) to Detect Low Level of Cigarette Smoking Exposure|Completed||N/A|88|Actual|Philip Morris Products S.A.||2|||f||||f||||||||||2018-05-31 21:59:05.962962|2018-05-31 21:59:05.962962
NCT01465867|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2018-01-27|2011-11-04|2011-11-07|Estimate|||||||2018-01-27|2018-01-30|Actual|April 2012||2012-04-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|June 2017|Actual|2017-06-30||Interventional|Serena||Selenium Supplementation in Pregnancy|Selenium Supplementation Treatment in Euthyroid Pregnant Women With Autoimmune Thyroid Disease: Effects on Obstetrical Complications|Completed||N/A|56|Actual|University of Roma La Sapienza||4|||f||||t||||||||||2018-05-31 21:59:06.060092|2018-05-31 21:59:06.060092
NCT01465854|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2017-09-28|2011-11-04|2011-11-07|Estimate|||||||2017-09-28|2017-10-02|Actual|November 2011||2011-11-30|September 2017|2017-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|BioCAST||French Biological Observatory on Lung Cancer in Never Smokers|French Biological Observatory on Lung Cancer in Never Smokers|Completed|||422|Actual|Intergroupe Francophone de Cancerologie Thoracique|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, plama, white cells~   "|||2018-05-31 21:59:06.21966|2018-05-31 21:59:06.21966
NCT01465841|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2016-09-26|2011-11-03|2011-11-07|Estimate|||||||2016-09-26|2016-09-28|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|ACE||Study of the Penumbra Coil 400 System to Treat Aneurysm|ACE: An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System|Active, not recruiting||Phase 4|2000|Anticipated|Penumbra Inc.||1|||f||||f||||||||||2018-05-31 21:59:06.403721|2018-05-31 21:59:06.403721
NCT01465828|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2012-03-24|2011-11-04|2011-11-07|Estimate|||||||2012-03-24|2012-03-27|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|RESET GENE||Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial|PhaRmacodynamic Effects of Switching thErapy in paTients With High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose Versus Prasugrel RESET GENE Trial|Completed||Phase 3|30|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:59:06.474317|2018-05-31 21:59:06.474317
NCT01465815|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2014-11-17|2011-11-02|2011-11-07|Estimate|||||||2014-11-17|2014-11-19|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)|Phase I/II Study of Postoperative Adjuvant Chemoradiation for cSCCHN|Withdrawn||Phase 1/Phase 2|0|Actual|OHSU Knight Cancer Institute||3||"Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and~   OSI-906 in other oncology studies was determined to be unfavorable."|f||||t||||||||||2018-05-31 21:59:06.65718|2018-05-31 21:59:06.65718
NCT01465802|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2016-04-15|2015-12-14|2016-07-07|2011-11-02|2011-11-07|Estimate|2016-07-07|2016-08-17|Estimate|2015-12-14|2016-01-14|Estimate|2016-07-07|2016-08-17|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ARCHER 1042|As Treated Population - included all participants who received at least 1 dose of study treatment assigned at enrollment.|Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO|Archer 1042: A Phase 2 Study Of Dacomitinib In Advanced Non-Small Cell Lung Cancer (Post-Chemotherapy Or Select First Line Patients) To Evaluate Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes|Completed||Phase 2|236|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:59:06.908988|2018-05-31 21:59:06.908988
NCT01465789|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-08-05|2011-11-04|2011-11-07|Estimate|||||||2013-08-05|2013-08-07|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|||Noninvasive Biomarkers for Monitoring Cardiometabolic Risk in Children|Noninvasive Biomarkers for Monitoring Cardiometabolic Risk in Children|Terminated|||33|Actual|West Virginia School of Osteopathic Medicine||||Loss of participants to follow-up|f||||f||||||Samples Without DNA|"~     saliva~   "|||2018-05-31 21:59:09.609501|2018-05-31 21:59:09.609501
NCT01465776|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2018-03-04|2011-11-02|2011-11-07|Estimate|||||||2018-03-04|2018-03-06|Actual|January 10, 2005|Actual|2005-01-10|March 2018|2018-03-31|February 16, 2010|Actual|2010-02-16|February 16, 2010|Actual|2010-02-16||Interventional|||Freeze-Dried Black Raspberries in Treating Patients With Oral Squamous Cell Cancer Undergoing Surgery|A Phase 1b Pilot Study Evaluating Oral Administration of Freeze-Dried Black Raspberries in Pre-Surgical Patients With Oral Squamous Cell Carcinoma|Completed||N/A|38|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||f||||||||2018-05-31 21:59:09.762043|2018-05-31 21:59:09.762043
NCT01465763|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2016-05-01||2016-05-01|2011-11-02|2011-11-07|Estimate|2016-05-01|2016-06-07|Estimate||||2016-05-01|2016-06-07|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|OCTAVE|The safety analysis set consists of all randomized participants who received at least 1 dose of study medication.|A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis|Completed||Phase 3|614|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:59:09.939761|2018-05-31 21:59:09.939761
NCT01465750|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2011-11-02|2011-11-02|2011-11-07|Estimate|||||||2011-11-02|2011-11-07|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|April 2014|Anticipated|2014-04-30|April 2012|Anticipated|2012-04-30||Observational|||Epidemiology of Ovarian Cancer in Taiwan|Epidemiology of Ovarian Cancer in Taiwan|Unknown status|Recruiting||10000|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 21:59:11.187909|2018-05-31 21:59:11.187909
NCT01465737|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2011-11-02|2011-11-02|2011-11-07|Estimate|||||||2011-11-02|2011-11-07|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Observational|||Epidemiology of Uterine Cancer in Taiwan|Importance of Cohort and Histologic Type for Secular Trends in Rising Incidence and Different Survival of Uterine Cancer -a Taiwan Population-based Registry From 1979 to 2008|Unknown status|Recruiting||10000|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 21:59:11.343338|2018-05-31 21:59:11.343338
NCT01465724|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2014-12-28|2011-11-04|2011-11-07|Estimate|||||||2014-12-28|2014-12-30|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|DREAMS||Denervation of the REnal Artery in Metabolic Syndrome|Sympathetic Denervation of the Renal Artery for the Treatment of Obesity-related Hypertension and Insulin Resistance|Completed||Phase 3|29|Actual|UMC Utrecht||1|||f||||f||||||||||2018-05-31 21:59:11.504602|2018-05-31 21:59:11.504602
NCT01465711|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2014-12-02|2011-11-04|2011-11-07|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2007||2007-07-31|November 2011|2011-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Value of PSP in Predicting Outcome in ICU Surgical Peritonitis Patients|Diagnostic Accuracy of Pancreatic Stone Protein in Predicting Severe Outcome in Patients With Peritonitis at the Intensive Care Unit|Completed|||137|Actual|University of Magdeburg|||2||f||||t||||||Samples Without DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 21:59:11.646258|2018-05-31 21:59:11.646258
NCT01465698|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2016-01-21|2011-11-04|2011-11-07|Estimate|||||||2016-01-21|2016-01-22|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|NURSE-RCT||Prevention of Chronic Low Back Pain in Female Nurses|Effectiveness and Financial Feasibility of Neuromuscular Exercise and Counselling Interventions on Pain, Movement Dysfunction, and Fear-avoidance Behaviour in Female Nurses With Non-specific Low Back Pain|Completed||N/A|219|Actual|UKK Institute||4|||f||||f||||||||No||2018-05-31 21:59:11.766106|2018-05-31 21:59:11.766106
NCT01465685|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2016-01-20|2011-11-02|2011-11-07|Estimate|||||||2016-01-20|2016-01-21|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Emotional Effects of Methylphenidate and MDMA in Healthy Subjects|Emotional Effects of Methylphenidate and MDMA in Healthy Subjects|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 21:59:11.996749|2018-05-31 21:59:11.996749
NCT01465672|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2014-05-19|2011-11-04|2011-11-07|Estimate|||||||2014-05-19|2014-05-20|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis|Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis|Completed|||125|Actual|University Hospital, Basel, Switzerland|||1||f||||t||||||||||2018-05-31 21:59:12.128247|2018-05-31 21:59:12.128247
NCT01465659|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-10-25|2011-11-04|2011-11-07|Estimate|||||||2017-10-25|2017-10-26|Actual|November 2011||2011-11-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery|A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)|Recruiting||Phase 1/Phase 2|39|Anticipated|Northwestern University||5|||f||||t||||||||||2018-05-31 21:59:12.267426|2018-05-31 21:59:12.267426
NCT01465646|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2011-11-04|2011-11-04|2011-11-07|Estimate|||||||2011-11-04|2011-11-07|Estimate|June 2003||2003-06-30|November 2011|2011-11-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 100 μg/ 75 μg Tablets||Completed||Phase 1|24|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 21:59:12.528974|2018-05-31 21:59:12.528974
NCT01465633|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2011-11-04|2011-11-04|2011-11-07|Estimate|||||||2011-11-04|2011-11-07|Estimate|August 2003||2003-08-31|November 2011|2011-11-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets|Bioavailability Investigations of Thyronajod Mite Tablets of Dosage Strengths 50 μg Levothyrox-ine/75 μg Iodine, and 100 μg Levothyroxine/75 μg Iodine vs. a Levothyroxine Drinking-Solution: A Randomised Cross Over Study in Healthy Male Individuals. Currently: 50 μg/ 75 μg Tablets|Completed||Phase 1|24|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 21:59:12.874486|2018-05-31 21:59:12.874486
NCT01465620|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-02-18|2011-11-02|2011-11-07|Estimate|||||||2016-02-18|2016-02-19|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study|Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study|Unknown status|Recruiting|N/A|40|Anticipated|Henri Mondor University Hospital||2|||f||||f||||||||||2018-05-31 21:59:13.000463|2018-05-31 21:59:13.000463
NCT01465607|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2015-05-26|2011-11-04|2011-11-07|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Implementation of an Efficacious Intervention for High Risk Women in Mexico|Implementation of an Efficacious Intervention for High Risk Women in Mexico|Completed||N/A|1228|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:59:13.370651|2018-05-31 21:59:13.370651
NCT01465594|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2015-05-19|2011-11-04|2011-11-07|Estimate|||||||2015-05-19|2015-05-20|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study Comparing Urinary Diversion (Transurethral/Suprapubic) After Radical Prostatectomy|Randomized Study Comparing Urinary Diversion by Suprapubic Catheter With Transurethral Catheter in Patients After Radical Prostatectomy|Completed||N/A|106|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 21:59:13.515022|2018-05-31 21:59:13.515022
NCT01465581|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2015-04-16|2011-11-02|2011-11-07|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|NICNOC||Treatment of Neurogenic Incontinence by Surgery to Cut the Filum Terminale|A Prospective Trial of Division of the Filum Terminale for Neurogenic Bladder Dysfunction With a Normal Conus|Terminated|||5|Actual|Nemours Children's Clinic|||1|Insufficient patient accrual.|f||||f||||||||||2018-05-31 21:59:13.604897|2018-05-31 21:59:13.604897
NCT01465568|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2015-05-11|2011-11-04|2011-11-07|Estimate|||||||2015-05-11|2015-05-12|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis|Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial|Completed||Phase 4|40|Actual|Tuen Mun Hospital||2|||f||||t||||||||||2018-05-31 21:59:13.694042|2018-05-31 21:59:13.694042
NCT01465555|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-04-15|2011-11-04|2011-11-07|Estimate|||||||2014-04-15|2014-04-17|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of Web-Based Recovery Monitoring With Clinical Alerts|Evaluation of Web-Based Recovery Monitoring With Clinical Alerts|Completed||Phase 1/Phase 2|389|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-05-31 21:59:13.811752|2018-05-31 21:59:13.811752
NCT01465542|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-09-07|2011-11-02|2011-11-04|Estimate|||||||2017-09-07|2017-09-11|Actual|June 2011||2011-06-30|September 2017|2017-09-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Observational|||Treatment of APAP Toxicity With IV and Oral NAC 2008-2011|Treatment of Acetaminophen Toxicity With Intravenous vs. Oral N-acetylcysteine: A Retrospective Review|Completed|||47|Actual|Akron Children's Hospital|||2||f||||f||||||||||2018-05-31 21:59:13.949221|2018-05-31 21:59:13.949221
NCT01465529|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2015-01-13|2011-11-02|2011-11-04|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|OligoG||A Cross-over Study of OligoG in Subjects With Cystic Fibrosis. Fibrosis|A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa|Completed||Phase 1/Phase 2|26|Actual|AlgiPharma AS||2|||f||||t||||||||||2018-05-31 21:59:14.062844|2018-05-31 21:59:14.062844
NCT01465516|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2015-06-27|2011-11-03|2011-11-04|Estimate|||||||2015-06-27|2015-06-30|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir|Response Guided Therapy (RGT) for Boceprevir Combined With Peginterferon Alpha-2b Plus Ribavirin in Naïve Hispanic Patients With Genotype 1 Hepatitis C Infection|Terminated|||105|Actual|Arrowhead Regional Medical Center|||1|"The study was terminated and recruitment was capped because of the new changes in hepatitis C~   market"|f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:59:14.173504|2018-05-31 21:59:14.173504
NCT01465503|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-04-06|2011-11-03|2011-11-04|Estimate|||||||2014-04-06|2014-04-08|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|NAPLESIII||Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients|Bivalirudin in Patient at High Risk of Bleeding Undergoing Percutaneous Coronary Interventions.|Completed||Phase 3|837|Actual|Clinica Mediterranea||2|||f||||t||||||||||2018-05-31 21:59:14.283423|2018-05-31 21:59:14.283423
NCT01465490|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-01|2011-11-01|2011-11-04|Estimate|||||||2011-11-01|2011-11-04|Estimate|September 2007||2007-09-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Monitoring and Feedback in Substance Abuse Treatment|Monitoring and Feedback in Substance Abuse Treatment|Completed||Phase 1/Phase 2|327|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-05-31 21:59:14.391826|2018-05-31 21:59:14.391826
NCT01465477|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-11-01|2011-11-01|2011-11-04|Estimate|||||||2011-11-01|2011-11-04|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|November 2012|Anticipated|2012-11-30|June 2012|Anticipated|2012-06-30||Interventional|||Influenza Vaccination in Fibromyalgia Patients|Influenza Vaccination in Patients Suffering From Fibromyalgia|Unknown status|Not yet recruiting|N/A|80|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 21:59:14.539537|2018-05-31 21:59:14.539537
NCT01465464|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2017-02-03|2011-11-03|2011-11-04|Estimate|||||||2017-02-03|2017-02-06|Estimate|December 2010||2010-12-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|ORIENTAL||Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma|A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma|Terminated||Phase 3|888|Actual|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 21:59:14.667966|2018-05-31 21:59:14.667966
NCT01465451|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2016-08-10|2011-11-03|2011-11-04|Estimate|||||||2016-08-10|2016-08-11|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|IOCCRC||Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety|A Prospective,Single-center,Randomized,Controlled Phase III Clinical Study Comparing Efficacy and Safety of Intraoperative Chemotherapy With 5-Fluorouracil Plus Curative Resection Versus Surgery Alone for Patients With Colorectal Cancer|Active, not recruiting||Phase 3|695|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:59:14.785776|2018-05-31 21:59:14.785776
NCT01465438|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-11-03|2011-11-03|2011-11-04|Estimate|||||||2011-11-03|2011-11-04|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|HUPSA||HUmira in Psoriatic Arthritis|Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Psoriatic Arthritis Patients Receiving Adalimumab?|Completed||Phase 4|42|Actual|Glostrup University Hospital, Copenhagen||1|||f||||t||||||||||2018-05-31 21:59:14.894287|2018-05-31 21:59:14.894287
NCT01465425|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-03-16|2011-11-03|2011-11-04|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2011||2011-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ACRIN7151||Extracolonic Findings on Computed Tomography (CT) Colonography|"Incidence and Significance of Extracolonic Findings on CT Colonography: Retrospective Analysis of National CT Colonography Trial Data"|Enrolling by invitation|||520|Anticipated|American College of Radiology Imaging Network|||3||f||||t||||||||No||2018-05-31 21:59:15.021132|2018-05-31 21:59:15.021132
NCT01465412|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2016-03-08||2016-03-08|2011-11-01|2011-11-04|Estimate|2016-03-08|2016-04-06|Estimate||||2016-03-08|2016-04-06|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Randomized participants|A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)|An Open-label, Single Dose, Oral Administration, Sequential Two Parts Study to Compare the Pharmacokinetics of SCH 420814 / MK-3814 in Subjects With Mild and Moderate Chronic Hepatic Impairment With Their Respectively Matching Healthy Volunteers|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 21:59:15.148995|2018-05-31 21:59:15.148995
NCT01465399|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-12-24|2011-11-02|2011-11-04|Estimate|||||||2012-12-24|2012-12-27|Estimate|June 2011||2011-06-30|December 2012|2012-12-31||||||||Interventional|||Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-Extraction Sockets|Randomized Clinical Trial, Controlled With Conventional Treatment, of Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) in the Regeneration of Post-extraction Sockets in Simple Extractions of Molars in the Mandible|Completed||N/A|||Fundación Eduardo Anitua||2|||f||||||||||||||2018-05-31 21:59:16.0506|2018-05-31 21:59:16.0506
NCT01465386|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2017-02-17||2017-02-17|2011-11-02|2011-11-04|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|November 2011||2011-11-30|February 2017|2017-02-28|March 2, 2015|Actual|2015-03-02|January 28, 2014|Actual|2014-01-28||Interventional|||Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission|A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission|Terminated||Phase 2|6|Actual|Fred Hutchinson Cancer Research Center|Difficulty finding patients willing or available to come in to clinic for weekly injections for the duration of the study. Study was ultimately closed because of slow enrollment.|1||Closed early due to slow enrollment|f||||f||||||||||2018-05-31 21:59:16.160798|2018-05-31 21:59:16.160798
NCT01465022|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2015-05-29||2016-04-14|2011-11-01|2011-11-04|Estimate|2015-12-02|2016-01-15|Estimate||||2016-04-14|2016-05-20|Estimate|January 2005||2005-01-31|February 2016|2016-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial|Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial|Completed||N/A|197|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 21:59:22.695694|2018-05-31 21:59:22.695694
NCT01465373|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2011-11-02|2011-11-02|2011-11-04|Estimate|||||||2011-11-02|2011-11-04|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs|Comparison of the Effectiveness of Micronized Vaginal Progesterone (Endometrin, Ferring) Vs. Progesterone in Oil for Luteal Phase Support in Donor Egg Recipient IVF Cycles Utilizing Previously Vitrified Donor Oocytes|Completed||Phase 4|10|Actual|Fertility Centers of Illinois||2|||f||||f||||||||||2018-05-31 21:59:16.342967|2018-05-31 21:59:16.342967
NCT01465360|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2012-07-04|2011-11-02|2011-11-04|Estimate|||||||2012-07-04|2012-07-06|Estimate|November 2011||2011-11-30|July 2012|2012-07-31||||||||Observational|||Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center|Performance of AclarusDx™, A Blood-Based Transcriptomic Test for Alzheimer's Disease, in US-based Patients Suffering From Memory Impairment and Newly Referred to A Reference Memory Center, for AD Diagnostic Workup—A Pilot Descriptive Study|Completed|||160|Actual|Exonhit|||1||f||||f||||||Samples With DNA|"~     Whole blood samples collected in PAXgene® blood RNA tubes~   "|||2018-05-31 21:59:16.505685|2018-05-31 21:59:16.505685
NCT01465347|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|2016-10-04||2017-06-16|2011-11-02|2011-11-04|Estimate|2017-06-16|2017-07-14|Actual||||2017-06-16|2017-07-14|Actual|February 2012||2012-02-29|June 2017|2017-06-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional||The baseline analysis population was the 56 patients in phase 2 given the comparison to historical control (Stupp 2005) wherein patients were treated for 6 weeks.|Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma|Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy|Completed||Phase 1/Phase 2|59|Actual|Diffusion Pharmaceuticals Inc||1|||f||||t||||||||No||2018-05-31 21:59:16.707631|2018-05-31 21:59:16.707631
NCT01465334|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-05-25|2011-11-02|2011-11-04|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL|A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL|Active, not recruiting||Phase 2|30|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 21:59:17.212449|2018-05-31 21:59:17.212449
NCT01465308|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2014-10-07|2011-11-02|2011-11-04|Estimate|||||||2014-10-07|2014-10-08|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|AC-H||The Effect of Honey on Xerostomia and Oral Mucositis|A Randomized Control Trial for the Effect of Honey on Radiotherapy Induced Xerostomia and Oral Mucositis in Patients With Head and Neck Cancers|Completed||Phase 2|72|Actual|Cyprus University of Technology||2|||f||||f||||||||||2018-05-31 21:59:17.426316|2018-05-31 21:59:17.426316
NCT01465295|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2018-02-02|2011-11-03|2011-11-04|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2011||2011-08-31|February 2018|2018-02-28|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis|Prospective Trial to Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis|Completed||N/A|6|Actual|SpineForm LLC||1|||f||||t||||||||||2018-05-31 21:59:17.566954|2018-05-31 21:59:17.566954
NCT01465282|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2013-03-07|2011-11-02|2011-11-04|Estimate|||||||2013-03-07|2013-03-08|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris|A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris|Completed||Phase 2|160|Actual|Creabilis SA||4|||f||||f||||||||||2018-05-31 21:59:17.799618|2018-05-31 21:59:17.799618
NCT01465269|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2015-07-27|2011-11-02|2011-11-04|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Treatment of Social Competence After Traumatic Brain Injury|Treatment of Social Competence in Military Veterans, Service Members, and Civilians With Traumatic Brain Injury|Completed||N/A|231|Actual|Craig Hospital||2|||f||||f||||||||||2018-05-31 21:59:17.989461|2018-05-31 21:59:17.989461
NCT01465256|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-03-25|2011-11-03|2011-11-04|Estimate|||||||2014-03-25|2014-03-26|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Postpolypectomy Bleeding in Patients With Antiplatelet Therapy|Postpolypectomy Bleeding in Patients Undergoing Colonoscopy on Antiplatelet Therapy. - Multicenter, Prospective Observational Study -|Unknown status|Recruiting|N/A|500|Anticipated|Soonchunhyang University Hospital||2|||f||||t||||||||||2018-05-31 21:59:18.465918|2018-05-31 21:59:18.465918
NCT01465243|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-02-13|2011-11-03|2011-11-04|Estimate|||||||2014-02-13|2014-02-17|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|||Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose|An Open , Single-Center, Single Arm Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After Routine Icotinib Therapy|Completed||Phase 4|32|Actual|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 21:59:18.621692|2018-05-31 21:59:18.621692
NCT01465230|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2014-08-26||2014-10-22|2011-11-01|2011-11-04|Estimate|2014-10-22|2014-10-23|Estimate||||2014-10-22|2014-10-23|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia|Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia|Terminated||Phase 2|2|Actual|Yale University||1||"This study was unsuccessful in enrolling the target number of subjects during the funding~   period."|f||||t||||||||||2018-05-31 21:59:18.782256|2018-05-31 21:59:18.782256
NCT01465217|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2014-12-15|2011-11-03|2011-11-04|Estimate|||||||2014-12-15|2014-12-16|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Text Messaging to Improve Hypertension Medication Adherence in African Americans|Text Messaging to Improve Hypertension Medication Adherence in African Americans|Completed||N/A|58|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 21:59:19.260002|2018-05-31 21:59:19.260002
NCT01465204|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-03|2011-11-03|2011-11-04|Estimate|||||||2011-11-03|2011-11-04|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|July 2012|Anticipated|2012-07-31|December 2010|Actual|2010-12-31||Interventional|||Impact Evaluation of Large-Scale Sanitation and Hygiene Interventions|Impact Evaluation of Large-Scale Sanitation and Hygiene Interventions in Peru, Tanzania, Senegal, Vietnam, Indonesia, and India|Unknown status|Active, not recruiting|N/A|21878|Actual|Water and Sanitation Program, World Bank||4|||f||||||||||||||2018-05-31 21:59:19.402729|2018-05-31 21:59:19.402729
NCT01465191|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2015-01-15|2011-11-02|2011-11-04|Estimate|||||||2015-01-15|2015-01-19|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section|Effect of OPRM1 Genotype on the Dose Response to Spinal Morphine for Post-Cesarean Analgesia|Unknown status|Recruiting|Phase 4|300|Anticipated|Columbia University||3|||f||||f||||||||||2018-05-31 21:59:19.625244|2018-05-31 21:59:19.625244
NCT01465178|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2016-08-03||2016-10-04|2011-11-01|2011-11-04|Estimate|2016-10-04|2016-11-25|Estimate||||2016-10-04|2016-11-25|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Postmenopausal women with 25(OH)D 10 - 29 ng/ml.|Improving the Understanding of the Response to Vitamin D Supplementation|Improving the Understanding of the Response to Vitamin D Supplementation|Completed||Phase 3|62|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 21:59:19.946227|2018-05-31 21:59:19.946227
NCT01465165|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2017-05-18|2011-11-03|2011-11-04|Estimate|||||||2017-05-18|2017-05-19|Actual|May 15, 2011|Actual|2011-05-15|May 2017|2017-05-31|June 24, 2012|Actual|2012-06-24|June 24, 2012|Actual|2012-06-24||Observational|||Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression|Comparison of Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and Magnetic Resonance Spectroscopy (MRS) as Bioenergetic Imaging Modalities in Healthy Human Brain and Major Depressive Disorder|Terminated|||12|Actual|University of Utah|||3|Study procedures were not feasible.|f||||f|f|f|||f|||Yes|De-identified scanning images may be individually examined after the study is completed if new analysis methods become available to collaborators.|2018-05-31 21:59:20.398597|2018-05-31 21:59:20.398597
NCT01465152|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-02-17|2011-11-03|2011-11-04|Estimate|||||||2017-02-17|2017-02-20|Actual|March 6, 2002|Actual|2002-03-06|February 2017|2017-02-28|October 21, 2004|Actual|2004-10-21|October 21, 2004|Actual|2004-10-21||Interventional|||Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes|Multicentre, Randomised, Comparative, Open, Three Armed Parallel Group Study on the Use of Metformin, Repaglinide or the Combination of Both in Type 2 Diabetic Patients After Failure of Dietary Measures|Completed||Phase 4|182|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:59:20.570409|2018-05-31 21:59:20.570409
NCT01465139|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-06-26|2011-11-02|2011-11-04|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2011||2011-10-31|June 2017|2017-06-30|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers|A Phase 1 Safety, Pharmacokinetic, and Immunologic Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers|Completed||Phase 1|30|Actual|Celldex Therapeutics||1|||f||||f||||||||||2018-05-31 21:59:20.757976|2018-05-31 21:59:20.757976
NCT01465126|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2011-11-01|2011-11-01|2011-11-04|Estimate|||||||2011-11-01|2011-11-04|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Enalapril in Collagen Type 4 Nephropathy|Collagen Type 4-related Nephropathies: From Alport to Thin Membrane Nephropathy. A Series of Cases Treated With Angiotensin Converting Enzyme Inhibitor|Completed|||19|Actual|University of Sao Paulo|||||f||||f||||||||||2018-05-31 21:59:20.847761|2018-05-31 21:59:20.847761
NCT01465113|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2016-03-09|2011-11-02|2011-11-04|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus|Effect of Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus|Completed||Early Phase 1|26|Actual|Case Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 21:59:20.956923|2018-05-31 21:59:20.956923
NCT01465100|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2018-01-17|2011-11-01|2011-11-04|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2011||2011-12-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Liver Cell Transplant for Phenylketonuria|Hepatocyte Transplantation for Phenylketonuria|Suspended||Phase 1/Phase 2|10|Anticipated|University of Pittsburgh||1||seeking additional funding|f||||t||||||||Undecided||2018-05-31 21:59:21.144388|2018-05-31 21:59:21.144388
NCT01465087|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-06-26|2011-11-03|2011-11-04|Estimate|||||||2016-06-26|2016-06-28|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|||Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples|Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis, In Comparison to Other Autoimmune and Neurological Diseases by Exhalation Samples|Completed||N/A|314|Actual|Carmel Medical Center||1|||f||||t||||||||||2018-05-31 21:59:21.390703|2018-05-31 21:59:21.390703
NCT01465074|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2013-08-09|2011-11-02|2011-11-04|Estimate|||||||2013-08-09|2013-08-13|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|NIC-PAS||Effects of Acute Nicotine Treatment on Neuroplasticity and Memory in Patients With Schizophrenia|Effects of Acute Nicotine on Long-term Potentiation in the Dorsolateral Prefrontal Cortex of Patients With Schizophrenia and Healthy Controls|Terminated||N/A|20|Actual|Centre for Addiction and Mental Health||2||Limited staff and operating resources|f||||f||||||||||2018-05-31 21:59:21.555215|2018-05-31 21:59:21.555215
NCT01465061|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2011-11-01|2011-11-01|2011-11-04|Estimate|||||||2011-11-01|2011-11-04|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Observational|||A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis|A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis|Completed|||124|Actual|University of the Philippines|||1||f||||f||||||||||2018-05-31 21:59:21.788738|2018-05-31 21:59:21.788738
NCT01465048|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2013-04-08||2013-06-18|2011-11-01|2011-11-04|Estimate|2013-04-08|2013-05-28|Estimate||||2013-06-18|2013-06-24|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Interventional|||Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe|A Pilot Study to Optimise Controlled Human Malaria Infections Using Plasmodium Falciparum Sporozoites Administered by Needle and Syringe|Completed||N/A|18|Actual|University of Oxford||3|||f||||t||||||||||2018-05-31 21:59:22.075018|2018-05-31 21:59:22.075018
NCT01465035|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2012-11-28|2011-11-01|2011-11-04|Estimate|||||||2012-11-28|2012-11-29|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine|A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine|Completed||Phase 1|24|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:59:22.552654|2018-05-31 21:59:22.552654
NCT01465009|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2014-12-10|2011-11-02|2011-11-04|Estimate|||||||2014-12-10|2014-12-11|Estimate|November 2003||2003-11-30|November 2011|2011-11-30|March 2005|Actual|2005-03-31|||||Interventional|||Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold|Double-blind, Randomized, Placebo-controlled, Single Dose, Parallel Group Study Evaluating Efficacy and Safety of 1000 mg Acetylsalicylic Acid and 1000 mg Paracetamol in Adult Patients With Sore Throat Associated With a Common Cold|Completed||Phase 4|508|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:59:23.307419|2018-05-31 21:59:23.307419
NCT01464996|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2015-06-19||2015-07-24|2011-11-01|2011-11-04|Estimate|2015-07-24|2015-07-27|Estimate||||2015-07-24|2015-07-27|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|XTR|There were 24 participants in the study. The 24 participants received 83 restorations. As per protocol, participants received restorations from both arms, hence total number of study participants should not be the sum of the number of participants for each arm.|Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive|Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive (OptiBond XTR)|Completed||N/A|24|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:59:23.412042|2018-05-31 21:59:23.412042
NCT01464983|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2014-12-23|2011-11-02|2011-11-04|Estimate|||||||2014-12-23|2014-12-25|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Placebo and Active Controlled, Double Dummy Study to Compare Efficacy of Aspirin and Ibuprofen in Treatment of Episodic Tension-type Headache|A Multicentre Randomised Parallel-groups Double-blind Double-dummy Single-dose Study to Compare Acetylsalicylic Acid 500 mg and 1,000 mg With Ibuprofen 200 mg and 400 mg and Placebo for Tolerability and Efficacy in the Treatment of Episodic Tension-type Headache|Completed||Phase 4|1115|Actual|Bayer||5|||f||||f||||||||||2018-05-31 21:59:25.112921|2018-05-31 21:59:25.112921
NCT01464970|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2012-05-11|2011-11-03|2011-11-04|Estimate|||||||2012-05-11|2012-05-14|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Influence of the Superficial Inferior Epigastric System in Deep Inferior Epigastric Perforator (DIEP) Flaps|The Potential Role of the Superficial Inferior Epigastric Vascular System in the Perfusion of Zone IV of Deep Inferior Epigastric Perforator (DIEP) Flaps|Unknown status|Enrolling by invitation|N/A|12|Anticipated|NHS Greater Glasgow and Clyde||4|||f||||f||||||||||2018-05-31 21:59:25.390345|2018-05-31 21:59:25.390345
NCT01464957|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-14|||2013-01-23|2011-11-01|2011-11-04|Estimate|||||||2013-01-23|2013-01-25|Estimate|November 2003||2003-11-30|January 2013|2013-01-31|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Interventional|||Skin Cancer Prevention in a Pediatric Population|Skin Cancer Prevention in a Pediatric Population|Completed||Phase 2|867|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 21:59:25.675331|2018-05-31 21:59:25.675331
NCT01464944|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-11-07|2011-11-02|2011-11-04|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2003||2003-11-30|November 2011|2011-11-30|April 2004|Actual|2004-04-30|||||Interventional|||Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin|A Randomized, Double-blind, Double-dummy, Single-dose, Parallel Group, Multicenter Study to Compare the Antipyretic Efficacy of Acetylsalicy-lic Acid 500 mg and 1,000 mg (2 x 500 mg) and Paracetamol 500 mg and 1,000 mg (2 x 500 mg) With Placebo in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin.|Completed||Phase 4|392|Actual|Bayer||5|||f||||f||||||||||2018-05-31 21:59:25.925567|2018-05-31 21:59:25.925567
NCT01464931|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2015-12-14||2016-01-22|2011-11-03|2011-11-04|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis|An Open-label Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg Administered Subcutaneously in Subjects With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis|Completed||Phase 1|32|Actual|Amgen||1|||f||||f||||||||||2018-05-31 21:59:26.197211|2018-05-31 21:59:26.197211
NCT01464918|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2011-11-01|2011-11-01|2011-11-04|Estimate|||||||2011-11-01|2011-11-04|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy of Using MASTER to Perform Endoscopic Submucosal Dissection in Human|Safety and Efficacy of Using MASTER, a Novel Robotics Enhanced Endosurgical System to Perform Endoscopic Submucosal Dissection in Human|Unknown status|Not yet recruiting|N/A|7|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 21:59:27.465185|2018-05-31 21:59:27.465185
NCT01464905|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-09-20|2011-11-02|2011-11-04|Estimate|||||||2013-09-20|2013-09-23|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|Nuron Biotech Inc.||3|||f||||f||||||||||2018-05-31 21:59:27.679017|2018-05-31 21:59:27.679017
NCT01464892|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-12-18|2011-11-03|2011-11-04|Estimate|||||||2015-12-18|2015-12-21|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||Imagery Rescripting in the Treatment of Post Traumatic Stress Disorder (PTSD) Following Early Chronic Interpersonal Trauma|Rescripting With vs. Without Prior Stabilization in PTSD Following Early Chronic Interpersonal Trauma|Unknown status|Active, not recruiting|Phase 2|61|Actual|VU University of Amsterdam||3|||f||||t||||||||||2018-05-31 21:59:27.835289|2018-05-31 21:59:27.835289
NCT01464879|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2017-06-29|2013-05-13|2017-08-15|2011-11-03|2011-11-04|Estimate|2017-06-29|2017-07-28|Actual|2013-05-13|2013-05-21|Estimate|2017-08-15|2017-09-13|Actual|December 2011||2011-12-31|August 2017|2017-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||The data are presented for Intent-to-treat (ITT) population, which comprised of all subjects who received at least one dose of the Investigational Medicinal Product (IMP).|A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator|A Phase 2, Open-Label, Sequential Dose Escalation Study in Adult Hypogonadal Males to Evaluate the Pharmacokinetics of Three Volumes of FE 999303 (Testosterone Gel), Applied to the Shoulder/Upper Arm, Using an Applicator Compared With Hand Application|Completed||Phase 2|20|Actual|Ferring Pharmaceuticals||4|||f||||f||||||||||2018-05-31 21:59:28.055507|2018-05-31 21:59:28.055507
NCT01464866|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-09-04|2011-11-02|2011-11-04|Estimate|||||||2012-09-04|2012-09-06|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Effect of Nutritional Supplementation on Pediatric Burn Patients|Effect of Nutritional Supplementation on Pediatric Burn Patients|Completed||Phase 3|116|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 21:59:29.209149|2018-05-31 21:59:29.209149
NCT01464853|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2011-11-02|2011-11-02|2011-11-04|Estimate|||||||2011-11-02|2011-11-04|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Effect of Enteral Nutrition Support for Critically Ill Patients|Effect of Enteral Nutrition Support for Critically Ill Patients|Terminated||Phase 3|84|Actual|Abbott Nutrition||2||"Interim analysis indicated significant additional subjects needed to demonsate statistical~   difference in primary outcome."|f||||f||||||||||2018-05-31 21:59:29.388965|2018-05-31 21:59:29.388965
NCT01464840|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2013-11-02||2017-04-04|2011-11-01|2011-11-04|Estimate|2013-11-18|2014-01-09|Estimate||||2017-04-04|2017-05-11|Actual|November 2011||2011-11-30|April 2017|2017-04-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|PKAZ||The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery|The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery|Completed|||30|Actual|University of Alabama at Birmingham|||3||f||||f||||||Samples Without DNA|"~     Maternal blood, maternal adipose tissue, maternal myometrium, maternal breast milk, amniotic~     fluid, and fetal cord blood.~   "|||2018-05-31 21:59:29.501685|2018-05-31 21:59:29.501685
NCT01464827|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2014-12-23|2014-03-25|2015-04-02|2011-11-03|2011-11-04|Estimate|2014-12-23|2015-01-06|Estimate|2014-03-25|2014-04-21|Estimate|2015-04-02|2015-04-22|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional||Safety population (participants who received at least 1 dose of direct-acting antiviral agent)|ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients|A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects With Genotype 1 Chronic Hepatitis C Virus Infection|Completed||Phase 2|580|Actual|AbbVie||14|||f||||t||||||||||2018-05-31 21:59:29.994161|2018-05-31 21:59:29.994161
NCT01464814|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-11-11|2011-11-02|2011-11-04|Estimate|||||||2011-11-11|2011-11-16|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|Probiomega||Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules|A Double Blind Placebo Controlled Crossover Clinical Trial Evaluating The Viability Of KE-99 With Fish Oil In Healthy Adults|Unknown status|Recruiting|N/A|15|Anticipated|Nutrition 21, Inc.||2|||f||||f||||||||||2018-05-31 21:59:31.772492|2018-05-31 21:59:31.772492
NCT01464801|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-06-12|2011-11-01|2011-11-04|Estimate|||||||2015-06-12|2015-06-15|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|LIRMOI3||Resveratrol in Patients With Non-alcoholic Fatty Liver Disease|Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds, Study 3|Completed||N/A|28|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:59:31.919547|2018-05-31 21:59:31.919547
NCT01464788|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2017-01-26||2017-03-31|2011-11-01|2011-11-04|Estimate|2017-03-31|2017-05-11|Actual||||2017-03-31|2017-05-11|Actual|October 2011||2011-10-31|March 2017|2017-03-31|June 11, 2015|Actual|2015-06-11|June 11, 2015|Actual|2015-06-11||Interventional|ARTSS-2||Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke|ARTSS-2: A Pilot, Phase 2b, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke|Terminated||Phase 2|90|Actual|The University of Texas Health Science Center, Houston|Study limitations include the open-label design that was necessary due to prohibitive costs of placebo manufacture and sham aPTT tests. Given that vessel imaging was not mandatory, a meaningful analysis of early recanalization rates was not possible.|3||"The study was halted prematurely at 90 of 105 planned patients due to the beneficial results of~   embolectomy clinical trials."|f||||t||||||||||2018-05-31 21:59:32.035146|2018-05-31 21:59:32.035146
NCT01464775|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-01-21|2011-11-02|2011-11-04|Estimate|||||||2015-01-21|2015-01-22|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||A Comparison of Narrow Band Imaging (NBI) and Standard White Light Laporoscopy to Detect Endometriosis|Diagnostic Yield of Narrow Band Imaging (NBI) and Standard Visible White Light Laparoscopy for the Detection of Endometriosis|Completed||N/A|156|Actual|Mercy Medical Center||2|||f||||t||||||||||2018-05-31 21:59:32.672514|2018-05-31 21:59:32.672514
NCT01464762|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-11-23|2011-10-31|2011-11-04|Estimate|||||||2017-11-23|2017-11-27|Actual||||November 2017|2017-11-30||||||||Expanded Access|||Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis|Early Access of TMC207 in Combination With Other Anti-Tuberculosis (TB) Drugs in Subjects With Extensively Drug Resistant (XDR) or Pre-XDR Pulmonary Tuberculosis|Approved for marketing|||||Janssen Infectious Diseases BVBA|||||||||||||||||||2018-05-31 21:59:32.776561|2018-05-31 21:59:32.776561
NCT01464749|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2014-04-09|2011-11-02|2011-11-03|Estimate|||||||2014-04-09|2014-04-10|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|May 2012|Actual|2012-05-31||Interventional|||Task-oriented Circuit Class Training in Multiple Sclerosis Subjects||Completed||N/A|24|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 21:59:32.880194|2018-05-31 21:59:32.880194
NCT01464736|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2011-10-31|2011-10-31|2011-11-03|Estimate|||||||2011-10-31|2011-11-03|Estimate|January 2006||2006-01-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|kmarrara||Noninvasive Ventilation on Chronic Obstructive Pulmonary Disease (COPD) Patient Functionality|Impact of Aerobic Physical Training Associated With Noninvasive Ventilation on COPD Patient Functionality - A Controlled Randomized Study|Completed||N/A|23|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 21:59:32.976635|2018-05-31 21:59:32.976635
NCT01464723|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-01-22|2011-10-31|2011-11-03|Estimate|||||||2013-01-22|2013-01-24|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional|SEAGUL2||Study EvAluating Genotypes While Using Lucentis 2|VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis|Completed||Phase 4|66|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 21:59:33.117001|2018-05-31 21:59:33.117001
NCT01464710|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-02-18|2011-10-31|2011-11-03|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|GALLEY2||Genetic Assessment of Early to Late Macular Degeneration Study|Genetic Assessment of Early to Late macuLar dEgeneration studY 2|Completed|||170|Actual|University of California, San Diego|||||f||||t||||||Samples With DNA|"~     Specimen collected for genotype analysis.~   "|No|Data not available.|2018-05-31 21:59:33.205156|2018-05-31 21:59:33.205156
NCT01464697|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-05-08|2011-11-02|2011-11-03|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2011||2011-10-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms|Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms|Active, not recruiting||Phase 3|249|Actual|University of British Columbia||2|||f||||t||||||||No||2018-05-31 21:59:33.334484|2018-05-31 21:59:33.334484
NCT01464684|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-04-18|2011-10-31|2011-11-03|Estimate|||||||2017-04-18|2017-04-20|Actual|October 2011||2011-10-31|April 2017|2017-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Body Composition of Infants: Follow-up to Placenta and Cord Blood Analyses|Body Composition of Infants: Follow-up to Placenta and Cord Blood Analyses|Withdrawn|||0|Actual|University of Arkansas||||"determined not enough participants would be able to be enrolled and not enough data collected~   for good analyses"|f||||||||||Samples With DNA|"~     Blood, urine, and a cheek swab may be collected from study participants~   "|||2018-05-31 21:59:33.435051|2018-05-31 21:59:33.435051
NCT01464671|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2014-11-19|2011-11-02|2011-11-03|Estimate|||||||2014-11-19|2014-11-20|Estimate|July 2009||2009-07-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|STATUS PCI||Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention|STATUS-PCI: Stable Angina Therapy With Angiomax® or Unfractionated Heparin for patientS Undergoing Percutaneous Coronary Intervention|Terminated||Phase 4|260|Actual|Stony Brook University||2||DSMB halted the study early due to futility. There were no safety concerns.|f||||t||||||||||2018-05-31 21:59:33.494953|2018-05-31 21:59:33.494953
NCT01464658|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-11-01|2011-11-02|2011-11-03|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2009||2009-03-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Prospective Study of Functional and Quality of Life Outcomes in Panniculectomy Patients|Prospective Study of Functional and Quality of Life Outcomes in Panniculectomy Patients|Terminated||N/A|2|Actual|Wake Forest University Health Sciences||1||Due to complexity and cost of study (no outside funding)|f||||f||||||||||2018-05-31 21:59:33.629921|2018-05-31 21:59:33.629921
NCT01464645|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2017-02-06|2011-11-02|2011-11-03|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 2012||2012-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|MRHS||Post-Market Study of the Modular Revision Hip System|Prospective Multicenter Open Label Study Examining the Short-term Safety and Efficacy of the Modular Revision Hip System (MRHS)|Terminated|||16|Actual|Encore Medical, L.P.|||1||f||||f||||||||||2018-05-31 21:59:33.708742|2018-05-31 21:59:33.708742
NCT01464632|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-05-14|2011-11-02|2011-11-03|Estimate|||||||2012-05-14|2012-05-16|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|EPIK||Post-Market Study of the EPIK Knee System|Prospective, Open Label Study of the Short-and Midterm Safety and Efficacy of the EPIK Uni-Compartmental Knee System in Community Practice|Withdrawn|||0|Actual|Encore Medical, L.P.|||1|Unable to enroll any study participants.|f||||f||||||||||2018-05-31 21:59:33.897144|2018-05-31 21:59:33.897144
NCT01464619|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2015-02-03||2016-03-11|2011-11-01|2011-11-03|Estimate|2015-02-23|2015-03-06|Estimate||||2016-03-11|2016-04-11|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|EPDC||Enhancing Parenting for Depressed Caregivers|Enhancing Parenting for Depressed Caregivers|Completed||N/A|61|Actual|Children's Hospital of Philadelphia|Outcomes are assessed by maternal report measures only. Incentives were given for completing the adapted IY group. There was poor attendance at IY sessions. The study was conducted in only one geographic area .|2|||f||||f||||||||||2018-05-31 21:59:33.998692|2018-05-31 21:59:33.998692
NCT01464606|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-12-19|2011-11-01|2011-11-03|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2011||2011-09-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry|International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Protocol|Recruiting||N/A|125|Anticipated|Children's Hospitals and Clinics of Minnesota||2|||f||||f||||||||||2018-05-31 21:59:34.557803|2018-05-31 21:59:34.557803
NCT01464593|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2016-03-04|2011-11-02|2011-11-03|Estimate|||||||2016-03-04|2016-03-07|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|ABLATE||Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)|Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions|Terminated||Phase 2|3|Actual|Celsion||1||trial design contingent on RFA optimization|f||||t||||||||||2018-05-31 21:59:34.735288|2018-05-31 21:59:34.735288
NCT01464580|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2016-10-11|2011-10-31|2011-11-03|Estimate|||||||2016-10-11|2016-10-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:59:34.892749|2018-05-31 21:59:34.892749
NCT01464567|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-11-23|2011-11-02|2011-11-03|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Spontaneous Breathing Trials Using Pressure-Support or T-Tube in Chronic Obstructive Pulmonary Disease Patients Weaning Mechanical Ventilation|"Comparison Between Spontaneous Breathing Trials Through Pressure-Support Ventilation or T Tube in the Weaning of Mechanical Ventilation in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial"|Completed||Phase 4|190|Actual|Hospital Nossa Senhora da Conceicao||2|||f||||t||||||||||2018-05-31 21:59:34.939582|2018-05-31 21:59:34.939582
NCT01464554|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-05-06|2011-11-02|2011-11-03|Estimate|||||||2015-05-06|2015-05-08|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|November 2011|Actual|2011-11-30||Interventional|||Brief Substance Use Intervention for Youth in Teen Court|Brief Substance Use Intervention for Youth in Teen Court|Completed||Phase 1/Phase 2|193|Actual|RAND||2|||f||||f||||||||||2018-05-31 21:59:35.061254|2018-05-31 21:59:35.061254
NCT01464541|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-09-07|2011-11-02|2011-11-03|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Orbital Fractures Measurement: Intraoperative Versus Computed Tomography (CT) Scan||Recruiting||N/A|20|Anticipated|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-05-31 21:59:35.229084|2018-05-31 21:59:35.229084
NCT01464528|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-11-02|2011-11-02|2011-11-03|Estimate|||||||2011-11-02|2011-11-03|Estimate|November 2011||2011-11-30|July 2011|2011-07-31|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Interventional|||Safety Study of Use of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery|Use Of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery|Unknown status|Not yet recruiting|Early Phase 1|10|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 21:59:35.46503|2018-05-31 21:59:35.46503
NCT01464515|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-01-24|2011-11-02|2011-11-03|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2019|Anticipated|2019-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Efficiency of Deep Transcranial Magnetic Stimulation on Patients With Mild Cognitive Impairment|Feasibility Study in Order to Test the Efficiency of Deep TMS on Patient With MCI|Not yet recruiting||Phase 1|30|Anticipated|Brainsway||2|||f||||f|f|f||||||||2018-05-31 21:59:35.621198|2018-05-31 21:59:35.621198
NCT01464502|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2017-04-03|2011-11-01|2011-11-03|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2012||2012-09-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pressure Wire Guided Cardiac Resynchronisation Therapy|A Prospective Randomised Controlled Trial of Cardiac Resynchronisation Therapy Guided by Invasive dP/dT: Radi-CRT Study|Recruiting||Phase 2/Phase 3|282|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:59:35.940547|2018-05-31 21:59:35.940547
NCT01464489|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-11-01|2011-11-01|2011-11-03|Estimate|||||||2011-11-01|2011-11-03|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Intubation Time With Low Dose Rocuronium|Study of Intubation Time Required for Excellent Tracheal Intubation With Low Dose Rocuronium During Propofol Anaesthesia in Children With and Without Atropine|Completed||N/A|44|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 21:59:36.112849|2018-05-31 21:59:36.112849
NCT01464476|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2013-05-02|2011-11-02|2011-11-03|Estimate|||||||2013-05-02|2013-05-06|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|SHIELD-2||Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)|Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator|Terminated||Phase 3|240|Actual|Forest Laboratories||2|||f||||t||||||||||2018-05-31 21:59:36.31296|2018-05-31 21:59:36.31296
NCT01464463|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-06-09|2011-11-02|2011-11-03|Estimate|||||||2016-06-09|2016-06-10|Estimate|August 2011||2011-08-31|June 2016|2016-06-30||||April 2016|Actual|2016-04-30||Interventional|||The Impact of Psychological Interventions on Psychometric and Immunological Measures in Patients With Major Depression|The Impact of Psychological Interventions (With and Without Exercise) on Psychometric and Immunological Measures in Patients With Major Depression|Completed||Phase 3|200|Anticipated|Philipps University Marburg Medical Center||4|||f||||f||||||||||2018-05-31 21:59:36.680111|2018-05-31 21:59:36.680111
NCT01464450|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2017-01-23|2011-11-01|2011-11-03|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants|PK Study of Oral Rivaroxaban in Healthy Subjects|Completed||Phase 1|55|Actual|Janssen Scientific Affairs, LLC||6|||f||||f||||||||||2018-05-31 21:59:36.87052|2018-05-31 21:59:36.87052
NCT01464437|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14||2013-11-06|2014-04-24|2011-11-01|2011-11-03|Estimate||||2013-11-06|2013-11-28|Estimate|2014-04-24|2014-05-13|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||AMG 151 Amgen Protocol Number 20100761|A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|236|Actual|Amgen||7|||f||||t||||||||||2018-05-31 21:59:37.381099|2018-05-31 21:59:37.381099
NCT01464424|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2013-06-26||2013-09-05|2011-11-02|2011-11-03|Estimate|2013-06-26|2013-09-04|Estimate||||2013-09-05|2013-09-13|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||This reporting group includes all enrolled subjects.|Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)|Assessment of Late Day IOP Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)|Completed||Phase 4|84|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:59:37.661918|2018-05-31 21:59:37.661918
NCT01464411|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2011-11-02|2011-11-02|2011-11-03|Estimate|||||||2011-11-02|2011-11-03|Estimate|July 2011||2011-07-31|November 2011|2011-11-30||||||||Observational|D-First||Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan|Phase II Clinical Trial of Dasatinib First Line Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase|Unknown status|Recruiting||40|Anticipated|Kanto CML Study Group|||||f||||t||||||Samples With DNA|"~     Copy numbers of bcr-abl mRNA in patients with dasatinib treatment will be measured by~     real-time RT-PCR to evaluate the efficiency of dasatinib.~      For patients resistant to dasatinib therapy, DNA mutation analysis of the bcr-abl gene~     associated with drug-resistancy will be performed.~   "|||2018-05-31 21:59:38.034414|2018-05-31 21:59:38.034414
NCT01464398|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2015-05-13|2011-11-02|2011-11-03|Estimate|||||||2015-05-13|2015-05-14|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS)|Stress Reduction for PCOS and Non-PCOS Women|Completed||N/A|86|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 21:59:38.18145|2018-05-31 21:59:38.18145
NCT01464385|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-04-30|2011-11-02|2011-11-03|Estimate|||||||2012-04-30|2012-05-01|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Nutrition Beverage Tolerance Study|Nutrition Beverage Tolerance Study|Completed||Phase 2|121|Actual|Abbott Nutrition||3|||f||||t||||||||||2018-05-31 21:59:38.435748|2018-05-31 21:59:38.435748
NCT01464372|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-01-30|2011-11-01|2011-11-03|Estimate|||||||2013-01-30|2013-01-31|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|ELEC STIM||Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder|Electrical Field Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder - Version: 3.0 Dated 16 APR 2012.|Terminated||Phase 3|130|Actual|EMKinetics, Inc||2|||f||||f||||||||||2018-05-31 21:59:38.527374|2018-05-31 21:59:38.527374
NCT01464359|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2015-04-29||2017-12-03|2011-11-02|2011-11-03|Estimate|2015-04-29|2015-05-15|Estimate||||2017-12-03|2017-12-28|Actual|October 2011||2011-10-31|December 2017|2017-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||T-Cell Depleted Double UCB for Refractory AML|T-Cell Depleted Double UCB With Post Transplant IL-2 for Refractory Myeloid Leukemia|Terminated||Phase 2|3|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||f||||||||||2018-05-31 21:59:38.657453|2018-05-31 21:59:38.657453
NCT01464346|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2013-10-23||2018-05-29|2011-11-02|2011-11-03|Estimate|2018-05-29|2018-05-30|Actual||||2018-05-29|2018-05-30|Actual|November 2011||2011-11-30|May 2018|2018-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use|A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use|Completed||N/A|90|Actual|Medtronic Diabetes||3|||f||||t|f|t|t|||||No||2018-05-31 21:59:38.976026|2018-05-31 21:59:38.976026
NCT01464333|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2018-04-12|2011-11-01|2011-11-03|Estimate|||||||2018-04-12|2018-04-17|Actual|December 16, 2011|Actual|2011-12-16|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|||Special Investigation on Long-term Treatment in Patients With Crohn's Disease|Special Investigation (Long-term Investigation) in Patients With Crohn's Disease|Completed|||521|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 21:59:39.520998|2018-05-31 21:59:39.520998
NCT01464320|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2012-08-21|2011-11-01|2011-11-03|Estimate|||||||2012-08-21|2012-08-22|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.|A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single-Dose of ABT-614 and the Effect of ABT-614 on Glomerular Filtration Rate in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Albuminuria|Completed||Phase 1|16|Actual|Abbott||2|||f||||f||||||||||2018-05-31 21:59:39.823084|2018-05-31 21:59:39.823084
NCT01464307|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|2016-07-26|2015-07-31|2016-11-04|2011-11-01|2011-11-03|Estimate|2016-11-04|2016-11-07|Estimate|2015-07-31|2015-08-21|Estimate|2016-11-04|2016-11-07|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|August 2014|Actual|2014-08-31||Interventional|PLUS|The Safety Evaluation Set (SES) is the subset of all subjects who were exposed to Investigational product (IP) in the main period at least once.|Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Lower Limb|Completed||Phase 3|290|Actual|Merz Pharmaceuticals GmbH||2|||f||||t||||||||||2018-05-31 21:59:39.937191|2018-05-31 21:59:39.937191
NCT01464294|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2015-01-26|2011-11-02|2011-11-03|Estimate|||||||2015-01-26|2015-01-27|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Clinical Evaluation of Chairside CAD/CAM Nano-ceramic Restorations|Clinical Evaluation of Chairside CAD/CAM Nano-ceramic Restorations|Terminated|||120|Actual|3M|||2|not a required sutudy to be posted|f||||f||||||||||2018-05-31 21:59:40.787301|2018-05-31 21:59:40.787301
NCT01464281|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-11-01|2011-11-01|2011-11-03|Estimate|||||||2011-11-01|2011-11-03|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|New Switch||A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml|A Randomized, Multicenter Study Evaluating HBsAg Clearance in CHB Patients Achieving HBeAg Loss and HBV DNA <200copies/ml on Treatment With Nucleotide Analogues and Switched to Peginterferon Alfa-2a|Unknown status|Active, not recruiting|N/A|300|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 21:59:40.953075|2018-05-31 21:59:40.953075
NCT01464268|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2018-01-05|2011-11-01|2011-11-03|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2011||2011-11-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia|Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia|Active, not recruiting||Phase 3|160|Anticipated|Cornea and Laser Eye Institute||2|||f||||f||||||||||2018-05-31 21:59:41.091822|2018-05-31 21:59:41.091822
NCT01464255|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2014-04-03||2014-08-15|2011-11-01|2011-11-03|Estimate|2014-08-15|2014-08-19|Estimate||||2014-08-15|2014-08-19|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional||1 subject being disqualified after 1 week of wear|Comparative Study of Two Marketed 1-day Soft Contact Lenses|Clinical Performance of Ocufilcon D With a Wetting Agent to Ocufilcon B|Completed||N/A|71|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 21:59:41.278641|2018-05-31 21:59:41.278641
NCT01464242|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-08-22|2011-11-01|2011-11-03|Estimate|||||||2016-08-22|2016-08-23|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|GT||Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis|Therapeutic Gain of Adding the Immunomodulator Pentoxifylline to the Treatment of Cutaneous Leishmaniasis|Completed||Phase 2/Phase 3|75|Actual|Centro Internacional de Entrenamiento e Investigaciones Médicas||2|||f||||t||||||||||2018-05-31 21:59:42.36829|2018-05-31 21:59:42.36829
NCT01464229|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2016-10-25||2017-02-28|2011-11-02|2011-11-03|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|April 2012||2012-04-30|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability|A Placebo-Controlled Crossover Study of Iloperidone Augmentation of SSRIs for Residual Anger and Irritability in Major Depressive Disorder|Completed||Phase 4|20|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:59:42.793479|2018-05-31 21:59:42.793479
NCT01464216|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-12-08|2011-11-02|2011-11-03|Estimate|||||||2016-12-08|2016-12-09|Estimate|October 2011||2011-10-31|December 2016|2016-12-31|December 2030|Anticipated|2030-12-31|December 2016|Anticipated|2016-12-31||Observational|FuncProst||MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness|MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness|Recruiting|||180|Anticipated|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     Blood, bone marrow, lymph nodes, prostate tissue, urine~   "|||2018-05-31 21:59:43.377704|2018-05-31 21:59:43.377704
NCT01464203|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2011-10-31|2011-10-31|2011-11-03|Estimate|||||||2011-10-31|2011-11-03|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|RADICAL||Role of Cardiac CT in Rapid Access Chest Pain Clinics (RADICAL)|Randomized Controlled Trial to Evaluate the Cost and Clinical Effectiveness of CT Coronary Angiography in Patients With Stable Angina Pectoris (RADICAL Trial)|Unknown status|Recruiting|N/A|600|Anticipated|Wellington Hospital||2|||f||||t||||||||||2018-05-31 21:59:43.515202|2018-05-31 21:59:43.515202
NCT01464190|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2013-12-20|2013-08-08|2014-03-03|2011-10-31|2011-11-03|Estimate|2013-12-20|2014-02-17|Estimate|2013-08-08|2013-08-20|Estimate|2014-03-03|2014-04-01|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional||For baseline characteristics, data from All Randomised patients was used.|A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients|An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A (NCT01324128)|Completed||Phase 3|659|Actual|Vifor Inc.||2|||f||||t||||||||||2018-05-31 21:59:43.776476|2018-05-31 21:59:43.776476
NCT01464177|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-05-10|2011-10-31|2011-11-03|Estimate|||||||2018-05-10|2018-05-11|Actual|October 2011|Actual|2011-10-31|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|GBM Hypo RT||Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme|Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme|Recruiting||Phase 2|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:59:45.030458|2018-05-31 21:59:45.030458
NCT01464164|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2018-01-22|2011-11-02|2011-11-03|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2012|Actual|2012-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ACE-011-DBA||Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia|Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia|Recruiting||Phase 1/Phase 2|20|Anticipated|Northwell Health||2|||f||||t||||||||No||2018-05-31 21:59:45.241383|2018-05-31 21:59:45.241383
NCT01464151|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-10-25|2011-10-31|2011-11-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study|Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study|Recruiting|||700|Anticipated|UMC Utrecht|||1||f||||f||||||Samples With DNA|"~     biopsies, blood, stool~   "|||2018-05-31 21:59:45.473852|2018-05-31 21:59:45.473852
NCT01464138|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-11-02|2011-11-02|2011-11-03|Estimate|||||||2011-11-02|2011-11-03|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children|Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children|Completed||Phase 2|52|Actual|Jomaa Pharma GmbH||1|||f||||t||||||||||2018-05-31 21:59:45.679501|2018-05-31 21:59:45.679501
NCT01464125|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-10-31|2011-10-31|2011-11-03|Estimate|||||||2011-10-31|2011-11-03|Estimate|November 2008||2008-11-30|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|October 2009|Actual|2009-10-31||Interventional|JP011||Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults|Evaluation of Fosmidomycin and Azithromycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria|Unknown status|Active, not recruiting|Phase 2|43|Actual|Jomaa Pharma GmbH||1|||f||||f||||||||||2018-05-31 21:59:45.860859|2018-05-31 21:59:45.860859
NCT01464112|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2016-12-30|2011-10-31|2011-11-03|Estimate|||||||2016-12-30|2017-01-02|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma|A Phase 1b Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Subjects With Relapsed Multiple Myeloma|Completed||Phase 1|18|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:59:46.074353|2018-05-31 21:59:46.074353
NCT01464099|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-10-26|2011-11-02|2011-11-03|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes|A Single Center, Randomized, Double-blind, Balanced Two-period Cross-over Trial to Test for Bioequivalence Between a Marketed NovoLog® Formulation Containing 100 U/mL Versus a New NovoLog® Formulation Containing 200 U/mL in a Combined Regimen of a Continuous Subcutaneous Infusion and a Meal-time Bolus in Subjects With Type 1 Diabetes|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:59:46.25894|2018-05-31 21:59:46.25894
NCT01464086|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2016-02-09|2011-11-02|2011-11-03|Estimate|||||||2016-02-09|2016-02-10|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|LIFSCREEN||LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)||Unknown status|Recruiting|Phase 3|110|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 21:59:46.435374|2018-05-31 21:59:46.435374
NCT01464073|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-07-28|2011-10-31|2011-11-03|Estimate|||||||2015-07-28|2015-07-29|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|LIPOXmax-RUN||Effectiveness of Individualized Exercise Program, Combined With a Balanced Diet on the Evolution of Body Fat|Evaluation of the Effectiveness of Individualized Exercise Program, Combined With a Balanced Diet Rich in Fruits and Vegetables, on the Evolution of Body Fat in Overweight or Obese Women, as Part of Type 2 Diabetes Prevention in Reunion Island.|Completed||N/A|137|Actual|Centre Hospitalier Universitaire de la Réunion||3|||f||||t||||||||||2018-05-31 21:59:46.592164|2018-05-31 21:59:46.592164
NCT01464060|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-12-27|2011-10-31|2011-11-03|Estimate|||||||2012-12-27|2012-12-31|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication|"Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"|Unknown status|Recruiting|Phase 4|400|Anticipated|Infante, Javier Molina, M.D.||2|||f||||t||||||||||2018-05-31 21:59:46.761302|2018-05-31 21:59:46.761302
NCT01464047|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-04-25|2011-10-31|2011-11-03|Estimate|||||||2016-04-25|2016-04-27|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Korean Post-marketing Surveillance for Sprycel®|Korean Post-marketing Surveillance for Sprycel®|Completed|||670|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 21:59:46.966724|2018-05-31 21:59:46.966724
NCT01464034|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2017-10-16|2011-11-02|2011-11-03|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2011||2011-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|117|Anticipated|Criterium, Inc.||1|||f||||f||||||||||2018-05-31 21:59:47.062561|2018-05-31 21:59:47.062561
NCT01463865|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2015-03-19|2011-11-01|2011-11-02|Estimate|||||||2015-03-19|2015-03-20|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Selective Block of the Axillary Nerve in Postoperative Pain Management|Selective Block of the Axillary Nerve in Postoperative Pain Management, a Randomised, Blinded, Placebo-controlled Trial|Completed||N/A|60|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-05-31 21:59:54.260436|2018-05-31 21:59:54.260436
NCT01464021|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2013-12-11||2014-02-03|2011-10-31|2011-11-03|Estimate|2013-12-11|2014-01-30|Estimate||||2014-02-03|2014-03-06|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China|A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China|Terminated|||26|Actual|AbbVie|The study was terminated early due to low enrollment and high drop-out rate. Only serious adverse events and events leading to discontinuation were collected.||1|This study was prematurely terminated due to low enrollment|f||||f||||||Samples Without DNA|"~     Whole blood, serum~   "|||2018-05-31 21:59:47.258169|2018-05-31 21:59:47.258169
NCT01464008|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2016-09-24|2011-11-01|2011-11-02|Estimate|||||||2016-09-24|2016-09-27|Estimate|January 2004||2004-01-31|September 2016|2016-09-30|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Observational|||The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C|The Predictive Values of Rapid Virus Response and Complete Early Virus Response for Sustained Virus Response in Chronic Hepatitis C Treated With Individual Therapeutic Programme|Completed|||297|Actual|Beijing Ditan Hospital|||1||f||||t||||||||||2018-05-31 21:59:47.612505|2018-05-31 21:59:47.612505
NCT01463995|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2018-02-01|2011-11-01|2011-11-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 2012||2012-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|proNICU||Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort)|Prognosis in Neurological Intensive Care Unit Patients (proNICU Cohort)|Recruiting|||200|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||Samples With DNA|"~     Blood samples (serum, plasma), cerebrovascular fluid~   "|||2018-05-31 21:59:47.912929|2018-05-31 21:59:47.912929
NCT01463982|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|2015-04-08||2015-04-08|2011-10-31|2011-11-02|Estimate|2015-04-08|2015-04-23|Estimate||||2015-04-08|2015-04-23|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|April 2012|Actual|2012-04-30||Interventional|||Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies|A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Cancer|Completed||Phase 1|21|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 21:59:48.102037|2018-05-31 21:59:48.102037
NCT01463969|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2011-11-01|2011-11-01|2011-11-02|Estimate|||||||2011-11-01|2011-11-02|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|||||Observational|||High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome (PCOS)|High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome|Completed|||80|Actual|Gulhane School of Medicine|||2||f||||f||||||||||2018-05-31 21:59:49.970359|2018-05-31 21:59:49.970359
NCT01463956|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2017-01-23|2011-10-31|2011-11-02|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 6, 2012||2012-01-06|January 2017|2017-01-31|January 22, 2015|Actual|2015-01-22|June 2014|Actual|2014-06-30||Interventional|||Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation|Pilot Study on the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT)|Completed||Phase 2|58|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 21:59:50.135204|2018-05-31 21:59:50.135204
NCT01463943|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2015-07-24|2011-11-01|2011-11-02|Estimate|||||||2015-07-24|2015-07-27|Estimate|February 2012||2012-02-29|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|ACROSS||Non-Inferiority Trial Comparing Eurofarma's Experimental Product Saccharomyces Boulardii Versus Floratil® in the Prevention of Antibiotic-Associated Diarrhea|"An Open-Label, Non-Inferiority, Phase III Trial Comparing Eurofarma's Experimental Product Saccharomyces Boulardii Versus Floratil® (S. Boulardii - Merck) in the Prevention of Antibiotic-Associated Diarrhea."|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||3||Change company strategy|f||||||||||||||2018-05-31 21:59:50.35255|2018-05-31 21:59:50.35255
NCT01463930|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2016-02-18|2011-10-31|2011-11-02|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||Audiovisual Videodisc Education and Modification of Expectations With Total Knee Replacement (TKR)|Effects of an Educational Audiovisual Videodisc on Patients' Pre-operative Expectations With Total Knee Replacement: a Randomized Study|Completed||N/A|92|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 21:59:50.487549|2018-05-31 21:59:50.487549
NCT01463917|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-31|2011-10-31|2011-11-02|Estimate|||||||2011-10-31|2011-11-02|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Interventional|||Hypertonic Solution in Off Pump Coronary Artery Bypass Graft Surgery|Use of Hypertonic Versus Isotonic Solutions in Off Pump Coronary Artery Bypass Graft Surgery Targeting the Left Marginal Branch|Unknown status|Recruiting|Phase 4|20|Anticipated|Hospital Pitangueiras||2|||f||||t||||||||||2018-05-31 21:59:50.592195|2018-05-31 21:59:50.592195
NCT01463904|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2011-11-01|2011-11-01|2011-11-02|Estimate|||||||2011-11-01|2011-11-02|Estimate|April 2007||2007-04-30|October 2011|2011-10-31|April 2015|Anticipated|2015-04-30|July 2009|Actual|2009-07-31||Observational|SADI-S 250||Single-Anastomosis Duodeno-Ileal Bypass With Sleeve Gastrectomy (SADI-S) for the Treatment of Morbid Obesity and Its Metabolic Complications|Single-Anastomosis Duodeno-Ileal Bypass With Sleeve Gastrectomy (SADI-S) for the Treatment of Morbid Obesity and Its Metabolic Complications|Unknown status|Recruiting||250|Anticipated|Hospital San Carlos, Madrid|||1||f||||f||||||Samples With DNA|"~     Samples of subcutaneous and visceral fat, and samples of liver tissue.~   "|||2018-05-31 21:59:50.904036|2018-05-31 21:59:50.904036
NCT01463891|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2016-12-30|2011-10-31|2011-11-02|Estimate|||||||2016-12-30|2017-01-04|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Observational|||Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)|Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer|Completed|||963|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 21:59:51.116722|2018-05-31 21:59:51.116722
NCT01463878|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2012-06-22||2012-10-03|2011-11-01|2011-11-02|Estimate|2012-08-28|2012-09-28|Estimate||||2012-10-03|2012-10-05|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ANUS1014||Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study|Enteral Nutrition and Glycemic Variability NICU Study|Terminated||Phase 4|14|Actual|Eastern Virginia Medical School||2||Unlikely to show statistical significance and slow recruitment.|f||||f||||||||||2018-05-31 21:59:52.859863|2018-05-31 21:59:52.859863
NCT01463852|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2015-05-08|2011-11-01|2011-11-02|Estimate|||||||2015-05-08|2015-05-12|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)|A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation Status in Patients With Chronic Lymphocytic Leukemia (CLL)|Terminated||Early Phase 1|11|Actual|Dartmouth-Hitchcock Medical Center||1||Enrollment underperformance.|f||||t||||||||||2018-05-31 21:59:54.561185|2018-05-31 21:59:54.561185
NCT01463839|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-11-01|2011-11-01|2011-11-02|Estimate|||||||2011-11-01|2011-11-02|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Observational|SOHab||Sleep Disorder and Oral Habits in Children|Association Between Quality of Sleep and Harmful Oral Habits Among Children|Completed|||50|Actual|University of Nove de Julho|||1||f||||f||||||||||2018-05-31 21:59:54.703171|2018-05-31 21:59:54.703171
NCT01463826|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-11-01|2011-11-01|2011-11-02|Estimate|||||||2011-11-01|2011-11-02|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Observational|RPCB||Respiratory Problems and Caries in Children With Bruxism|Association Between Respiratory Problem and Dental Caries in Children With Bruxism|Completed|||90|Actual|University of Nove de Julho|||2||f||||f||||||||||2018-05-31 21:59:54.866455|2018-05-31 21:59:54.866455
NCT01463813|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-11-07|2011-11-01|2011-11-02|Estimate|||||||2017-11-07|2017-11-08|Actual|September 2012||2012-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|FIND||Finnish Vitamin D Trial (FIND)|Finnish Vitamin D Trial (FIND)|Active, not recruiting||N/A|2495|Actual|University of Eastern Finland||3|||f||||t||||||||||2018-05-31 21:59:55.018315|2018-05-31 21:59:55.018315
NCT01463800|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2017-09-28|2011-11-01|2011-11-02|Estimate|||||||2017-09-28|2017-10-02|Actual|May 2011||2011-05-31|September 2017|2017-09-30|January 1, 2017|Actual|2017-01-01|May 2016|Actual|2016-05-31||Interventional|CARE-GUCH||Rehabilitation in Patients With Congenital Heart Disease|Cardiac Rehabilitation in Patients With Complex Congenital Heart Disease: Improvement of Exercise Intolerance|Terminated||N/A|28|Actual|University Hospital, Basel, Switzerland||2||low inclusion rate|f||||f||||||||||2018-05-31 21:59:55.241527|2018-05-31 21:59:55.241527
NCT01463787|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-04-08|2011-11-01|2011-11-02|Estimate|||||||2013-04-08|2013-04-10|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Outcomes of Two Approaches in Microsurgical Varicocelectomy in Chinese Infertile Males: A Prospective Randomized, Controlled Trial||Completed||Phase 4|120|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 21:59:55.40173|2018-05-31 21:59:55.40173
NCT01463774|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2012-11-20|2011-11-01|2011-11-02|Estimate|||||||2012-11-20|2012-11-21|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers|Pivotal BE CANA/MET IR FDC - Low Strength|Completed||Phase 1|74|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 21:59:55.595213|2018-05-31 21:59:55.595213
NCT01463761|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-03-05|2011-11-01|2011-11-02|Estimate|||||||2013-03-05|2013-03-06|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Autonomic Nervous System, Fatigue and Intolerance to Physical Training, and Overtraining in High-Level Athletes|Autonomic Nervous System, Fatigue and Intolerance to Physical Training, and Overtraining in High-Level Athletes. A Multicentre Study|Completed|||131|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 21:59:55.827255|2018-05-31 21:59:55.827255
NCT01463748|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-31|||2013-07-02|2011-10-31|2011-11-02|Estimate|||||||2013-07-02|2013-07-03|Estimate|July 2011||2011-07-31|July 2013|2013-07-31||||April 2013|Actual|2013-04-30||Interventional|||Effects of Graptopetalum Paraguayense E. Walther on the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome||Completed||Phase 2/Phase 3|54|Actual|Chung Shan Medical University||2|||f||||t||||||||||2018-05-31 21:59:56.006441|2018-05-31 21:59:56.006441
NCT01463735|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2014-03-17|2011-11-01|2011-11-02|Estimate|||||||2014-03-17|2014-03-18|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Vitamin E Supplement in Patients With Cirrhosis and Acanthocytosis||Completed||Phase 2|27|Anticipated|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 21:59:56.182424|2018-05-31 21:59:56.182424
NCT01463722|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2011-11-01|2011-11-01|2011-11-02|Estimate|||||||2011-11-01|2011-11-02|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Accuracy of Amniotic Fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity|Study of Accuracy of Amniotic Fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity|Completed||Phase 2|128|Actual|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 21:59:56.326506|2018-05-31 21:59:56.326506
NCT01463709|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-02-19|2011-10-31|2011-11-02|Estimate|||||||2013-02-19|2013-02-21|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|NPEF||Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer|Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer|Completed||Phase 1|4|Actual|Children's Hospital & Research Center Oakland||1|||f||||f||||||||||2018-05-31 21:59:56.487727|2018-05-31 21:59:56.487727
NCT01463696|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2016-03-23||2017-05-24|2011-10-28|2011-11-02|Estimate|2016-05-06|2016-05-23|Estimate||||2017-05-24|2017-05-25|Actual|December 21, 2011|Actual|2011-12-21|May 2017|2017-05-31|October 15, 2015|Actual|2015-10-15|September 15, 2014|Actual|2014-09-15||Interventional|||Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)|A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors|Terminated||Phase 1|48|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 21:59:56.874591|2018-05-31 21:59:56.874591
NCT01463683|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2013-10-09||2017-03-16|2011-11-01|2011-11-02|Estimate|2013-12-23|2014-02-17|Estimate||||2017-03-16|2017-04-13|Actual|November 2011||2011-11-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)|A Study in Healthy Japanese Young Adults to Assess the Safety, Tolerability, and Immunogenicity of HEPTAVAX-II Manufactured Using a Modified Process|Completed||Phase 3|722|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:59:59.097466|2018-05-31 21:59:59.097466
NCT01462825|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2012-12-17|2011-10-27|2011-10-31|Estimate|||||||2012-12-17|2012-12-18|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||The Effect of Tomato Ketchup on Inflammation|The Protective Effect of Tomato Ketchup Consumption on Inflammation Induced Ex-vivo in Human Blood|Completed||N/A|6|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:00:17.406596|2018-05-31 22:00:17.406596
NCT01463670|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2018-04-17|2011-10-28|2011-11-02|Estimate|||||||2018-04-17|2018-04-18|Actual|October 2011|Actual|2011-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance|A Phase II Clinical Trial of Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance|Active, not recruiting||Phase 2|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:00:00.341614|2018-05-31 22:00:00.341614
NCT01463657|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2013-01-22|2011-10-30|2011-11-02|Estimate|||||||2013-01-22|2013-01-24|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Split-face Comparison Study to Assess ELAPR Compared to Juvéderm® for the Treatment of Nasolabial Folds|A Phase 2 Bilateral (Split-face) Comparison Study to Assess Two Formulations of ELAPR Compared to Juvéderm® Ultra Plus for the Treatment of Moderate to Severe Nasolabial Folds|Completed||Phase 1/Phase 2|30|Anticipated|Elastagen Pty Ltd||2|||f||||f||||||||||2018-05-31 22:00:00.494605|2018-05-31 22:00:00.494605
NCT01463644|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2015-09-21|2011-11-01|2011-11-02|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis|Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial|Completed||Phase 3|19|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:00:00.710882|2018-05-31 22:00:00.710882
NCT01463631|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2014-01-15|2011-10-28|2011-11-02|Estimate|||||||2014-01-15|2014-01-16|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of LY3007113 in Participants With Advanced Cancer|A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer|Completed||Phase 1|36|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:00:00.947111|2018-05-31 22:00:00.947111
NCT01463618|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2017-07-10|2011-10-30|2011-11-02|Estimate|||||||2017-07-10|2017-07-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:00:01.21631|2018-05-31 22:00:01.21631
NCT01463605|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2011-11-01|2011-11-01|2011-11-02|Estimate|||||||2011-11-01|2011-11-02|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial|Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Phase II Clinical Trial|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:00:01.3116|2018-05-31 22:00:01.3116
NCT01463592|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2011-11-21|2011-11-01|2011-11-02|Estimate|||||||2011-11-21|2011-11-22|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||To Study the Efficacy and Safety of Renessans in Chronic HCV Patients|An Open Labelled, Active Controlled, Three Arm, Parallel- Group Study of the Safety and Efficacy of Renessans Administered Alone and in Combination With Standard Interferon Therapy in Patients Chronic HCV Hepatitis|Unknown status|Active, not recruiting|Phase 3|90|Actual|MTI Medical Private Limited, Pakistan||3|||f||||t||||||||||2018-05-31 22:00:01.533296|2018-05-31 22:00:01.533296
NCT01463579|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-12-11|2011-11-01|2011-11-02|Estimate|||||||2015-12-11|2015-12-14|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|REVIVE||Exercise After Intensive Care Unit: a Randomised Controlled Trial|Effectiveness of a Programme of Exercise on Physical Function in Survivors of Critical Illness Following Discharge From the Intensive Care Unit (ICU): a Randomised Controlled Trial|Completed||Phase 2|60|Actual|University of Ulster||2|||f||||t||||||||||2018-05-31 22:00:01.808535|2018-05-31 22:00:01.808535
NCT01463566|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-10-03|2011-11-01|2011-11-02|Estimate|||||||2017-10-03|2017-10-06|Actual|January 2012||2012-01-31|October 2017|2017-10-31|January 2025|Anticipated|2025-01-31|July 2024|Anticipated|2024-07-31||Observational|||Gender Solutions Natural Knee Post-Market Study|Prospective Multicenter Post-market Study of the Zimmer Gender Solutions Natural Knee Flex System|Suspended|||300|Anticipated|Zimmer Biomet|||1|Suspended pending internal review/direction of the company's focus.|f||||f||||||||||2018-05-31 22:00:02.356569|2018-05-31 22:00:02.356569
NCT01463553|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2013-11-10|2011-11-01|2011-11-02|Estimate|||||||2013-11-10|2013-11-13|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Improving Primary Spontaneous Pneumothorax (PSP) Treatment Techniques in VATS||Unknown status|Recruiting|Phase 4|320|Anticipated|Beijing Haidian Hospital||2|||f||||t||||||||||2018-05-31 22:00:02.611379|2018-05-31 22:00:02.611379
NCT01463540|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-30|||2015-08-17|2011-11-01|2011-11-02|Estimate|||||||2015-08-17|2015-08-19|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|||Gastrostomy Tube Placed After Gastropexy Versus Gastrostomy Tube Placed Using the Traditional Push/Pull Techniques|A Multicentric, Randomised Clinical Trial Comparing Short and Long Time Outcome of Gastrostomy Tube Placed After Gastropexy, Versus Gastrostomy Tube Placed Using the Traditional Push/Pull Techniques|Completed||Phase 4|206|Actual|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||f||||||||||2018-05-31 22:00:02.84431|2018-05-31 22:00:02.84431
NCT01463527|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2014-01-14||2017-12-13|2011-11-01|2011-11-02|Estimate|2014-07-08|2014-08-04|Estimate||||2017-12-13|2018-01-11|Actual|September 2011||2011-09-30|December 2017|2017-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Using Capnography to Reduce Hypoxia During Pediatric Sedation|Using Capnography to Reduce the Incidence of Hypoxia in Children During Moderate Sedation in the Pediatric Emergency Department: A Randomized Controlled Trial|Completed||N/A|167|Actual|Yale University|No serious adverse events were recorded. Since these events are rare and this study was not powered to detect them, we are unable to predict how capnography may have impacted staff behavior and patient outcomes for these less frequent events.|2|||f||||f||||||||||2018-05-31 22:00:03.105209|2018-05-31 22:00:03.105209
NCT01463514|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2015-11-13|2011-11-01|2011-11-02|Estimate|||||||2015-11-13|2015-11-16|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension|Noninvasive Determination Of Cerebral Tissue Oxygenation And Cerebral Blood Flow With Near-Infrared Spectroscopy In Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization|Completed||N/A|20|Anticipated|University of Zurich||4|||f||||f||||||||||2018-05-31 22:00:04.232568|2018-05-31 22:00:04.232568
NCT01461642|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2011-10-27|2011-10-27|2011-10-28|Estimate|||||||2011-10-27|2011-10-28|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|E-ASTHMA||E-support for Healthcare Processes - ASTHMA|E-support for Healthcare Processes - ASTHMA|Unknown status|Recruiting|N/A|120|Anticipated|The University Clinic of Pulmonary and Allergic Diseases Golnik||2|||f||||f||||||||||2018-05-31 22:00:54.198716|2018-05-31 22:00:54.198716
NCT01463501|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2013-05-11|2011-10-29|2011-11-02|Estimate|||||||2013-05-11|2013-05-14|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|December 2016|Anticipated|2016-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer|Prospective Randomized Phase Ⅱ Trial Comparing Preoperative Chemoradiotherapy (Paclitaxel and Carboplatin) Followed by Surgery to Surgery Followed by Postoperative Chemoradiotherapy (Paclitaxel and Carboplatin) for Esophageal Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 22:00:04.35896|2018-05-31 22:00:04.35896
NCT01463488|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-29|||2012-08-22|2011-10-29|2011-11-02|Estimate|||||||2012-08-22|2012-08-23|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part I|A Two Part Protocol to Assess, Using Double Blind Placebo Control, the Safety, Tolerability, and Pharmacokinetics of Ascending Single Doses of a New Intra-articular Administration Formulation of SAR113945 (IKK Inhibitor) Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose in Patients With Knee Osteoarthritis|Completed||Phase 1|24|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 22:00:04.833424|2018-05-31 22:00:04.833424
NCT01463475|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2014-12-02|2011-10-28|2011-11-02|Estimate|||||||2014-12-02|2014-12-04|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol|University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol|Completed||N/A|3|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 22:00:05.128166|2018-05-31 22:00:05.128166
NCT01463462|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-05-26|2011-10-28|2011-11-02|Estimate|||||||2016-05-26|2016-05-27|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Electronic Catheter Stethoscope|Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery|Completed|||75|Actual|University of South Florida|||1||f||||t||||||||||2018-05-31 22:00:05.291965|2018-05-31 22:00:05.291965
NCT01463449|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2014-08-12|2011-10-28|2011-11-01|Estimate|||||||2014-08-12|2014-08-13|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Observational|sCD163||"Can Soluble-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"|"Influence of Obesity, Weight Loss, and Diet on Low Grade Inflammation With Particular Focus on the Macrophage Marker, Soluble-CD163 - a New Predictor of Diabetes.Can s-CD163 Discriminate Between Healthy and Unhealthy Obese Individuals?"|Completed|||31|Actual|University of Aarhus|||1||f||||t||||||Samples With DNA|"~     Blood, adipose tissue~   "|||2018-05-31 22:00:05.405483|2018-05-31 22:00:05.405483
NCT01463436|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2011-11-01|2011-10-31|2011-11-01|Estimate|||||||2011-11-01|2011-11-02|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|March 2010|Actual|2010-03-31||Interventional|||The Effect of Soy Isoflavone Supplementation on Endothelial Function|Study of Soy Isoflavone 100 mg/Day in Postmenopausal Women to Elaborate the Effect of Soy Isoflavone in Endothelial Function and to Reduce Oxidative Stress|Completed||Phase 3|200|Actual|Trisakti University||2|||f||||f||||||||||2018-05-31 22:00:05.563381|2018-05-31 22:00:05.563381
NCT01463423|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-10-03|2011-10-28|2011-11-01|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2011||2011-10-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)|Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)|Recruiting||Phase 2|250|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 22:00:05.814377|2018-05-31 22:00:05.814377
NCT01463410|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2013-05-27|2011-10-31|2011-11-01|Estimate|||||||2013-05-27|2013-05-29|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|||Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler|Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler|Terminated|||264|Actual|Skyline Diagnostics BV||||"The required number of banked samples could not be met due to limited availability. There is no~   realistic possibility to complete the study succesfully."|f||||f||||||Samples With DNA|"~     RNA from bone marrow samples will be retained.~   "|||2018-05-31 22:00:06.001092|2018-05-31 22:00:06.001092
NCT01463397|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28||2016-01-28|2016-01-28|2011-10-31|2011-11-01|Estimate||||2016-01-28|2016-02-26|Estimate|2016-01-28|2016-02-26|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Alchemilla||Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain|Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain|Completed||Phase 2|191|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 22:00:06.240699|2018-05-31 22:00:06.240699
NCT01463384|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2012-10-25||2014-09-23|2011-10-28|2011-11-01|Estimate|2014-09-23|2014-09-25|Estimate||||2014-09-23|2014-09-25|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Minocycline in Patients With Alzheimer's Disease|MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy|Completed||Phase 2|13|Actual|Huntington Medical Research Institutes||1|||f||||f||||||||||2018-05-31 22:00:06.580871|2018-05-31 22:00:06.580871
NCT01463371|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-10-31|2011-10-31|2011-11-01|Estimate|||||||2011-10-31|2011-11-01|Estimate|October 2006||2006-10-31|October 2011|2011-10-31|September 2007|Actual|2007-09-30|April 2007|Actual|2007-04-30||Interventional|||Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis|Effects of Long-Term Azithromycin Treatment on Airway Oxidative Stress Markers in Patients With Stable Non-Cystic Fibrosis Bronchiectasis|Completed||N/A|30|Actual|Instituto de Investigacion Sanitaria La Fe||2|||f||||t||||||||||2018-05-31 22:00:07.128079|2018-05-31 22:00:07.128079
NCT01463358|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-01-05|2011-10-28|2011-11-01|Estimate|||||||2016-01-05|2016-01-06|Estimate|March 2005||2005-03-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|PRESS||Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block|Prevention of Syncope by Cardiac Pacing in Patients With Bifascicular Block|Completed||N/A|101|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 22:00:07.2379|2018-05-31 22:00:07.2379
NCT01463345|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2014-02-02|2011-10-31|2011-11-01|Estimate|||||||2014-02-02|2014-02-04|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Blood Conservation in Cardiac Surgery|Blood Conservation in Cardiac Surgery|Terminated||N/A|900|Anticipated|Hackensack University Medical Center||2||PI left and closed study at Hackensack went to RUTGERS - Robert Wood Johnson Medical Center|f||||t||||||||||2018-05-31 22:00:07.367829|2018-05-31 22:00:07.367829
NCT01463332|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2011-10-31|2011-10-31|2011-11-01|Estimate|||||||2011-10-31|2011-11-01|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Effect of Dexmedetomidine on Pain Due to Propofol Injection|Effect of Dexmedetomidine on Pain Due to Propofol Injection:A Randomised, Double-blind, Controlled Clinical Trial|Unknown status|Active, not recruiting|N/A|150|Anticipated|KVG Medical College and Hospital||3|||f||||t||||||||||2018-05-31 22:00:07.485803|2018-05-31 22:00:07.485803
NCT01463319|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2013-02-07|2011-10-28|2011-11-01|Estimate|||||||2013-02-07|2013-02-08|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|WW||Warm Water and Unsedated Colonoscopy|Warm Water Colonoscopy: a Novel Method for Unsedated Colonoscopy|Completed||Early Phase 1|818|Actual|Presidio Ospedaliero Santa Barbara||2|||f||||f||||||||||2018-05-31 22:00:07.617707|2018-05-31 22:00:07.617707
NCT01463306|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2018-05-30|2011-10-28|2011-11-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 21, 2012|Actual|2012-02-21|May 2018|2018-05-31|July 8, 2020|Anticipated|2020-07-08|July 7, 2020|Anticipated|2020-07-07||Interventional|||A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures|A 12-month Open-label Study To Evaluate The Safety And Tolerability Of Pregabalin As Adjunctive Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-clonic Seizures|Recruiting||Phase 3|400|Anticipated|Pfizer||1|||f||||f|t|f||||||||2018-05-31 22:00:07.765347|2018-05-31 22:00:07.765347
NCT01463293|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2014-06-26||2014-06-26|2011-10-31|2011-11-01|Estimate|2014-06-26|2014-07-24|Estimate||||2014-06-26|2014-07-24|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|CTT||B. Lactis HN019 for Functional Constipation|Effects of 4-week Bifidobacterium Lactis HN019 Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults With Constipation: A Double-blind, Randomized, Placebo-controlled Dose-ranging Trial|Completed||Phase 3|224|Actual|Fonterra Research Centre|A substantial number of protocol violations occurred for the primary end-point. Only 39 out of 224 subjects consumed sufficent radio-opaque markers for baseline and post-intervention transit time.Therefore, the study failed to yield evaluable data.|3|||f||||f||||||||||2018-05-31 22:00:08.597376|2018-05-31 22:00:08.597376
NCT01463280|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-02-23|2011-10-31|2011-11-01|Estimate|||||||2014-02-23|2014-02-25|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Tumescent Lidocaine on Platelet Function|Tumescent Lidocaine Effects on Platelet Function Following Liposuction Surgical Trauma: a Prospective Controlled Dosage-response Phase I Clinical Trial|Completed||Phase 1|129|Actual|Klein, Jeffrey A., M.D.||1|||f||||f||||||||||2018-05-31 22:00:09.492752|2018-05-31 22:00:09.492752
NCT01463267|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2011-10-28|2011-10-28|2011-11-01|Estimate|||||||2011-10-28|2011-11-01|Estimate|November 2010||2010-11-30|October 2011|2011-10-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|Heart iRx||Study of Reminding to Improve Medication Adherence in Heart Failure|Heart iRx This Short Non-descriptive Title is the Real Title|Unknown status|Recruiting|N/A|60|Anticipated|Kent State University||4|||f||||f||||||||||2018-05-31 22:00:09.674251|2018-05-31 22:00:09.674251
NCT01463254|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2013-07-11|2011-10-31|2011-11-01|Estimate|||||||2013-07-11|2013-07-15|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||A Prospective Observational Study of the Clinical Performance of Femplant in Pakistan|A Prospective Observational Study of the Clinical Performance of Femplant in Pakistan|Completed|||724|Actual|FHI 360|||2||f||||f||||||||||2018-05-31 22:00:09.845197|2018-05-31 22:00:09.845197
NCT01463241|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2015-04-15|2011-10-28|2011-11-01|Estimate|||||||2015-04-15|2015-04-16|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|BASIC||Behavioral and Affective Skills in Coping (BASIC) Open Trial|Behavioral and Affective Skills in Coping: Practice-Adapted Child Psychotherapy|Completed||N/A|24|Actual|Judge Baker Children's Center||1|||f||||f||||||||||2018-05-31 22:00:10.031726|2018-05-31 22:00:10.031726
NCT01463228|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2012-08-21|2011-10-28|2011-11-01|Estimate|||||||2012-08-21|2012-08-22|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of FDC Tablets of Canagliflozin and Metformin IR (2x150 mg/1000 mg) With Respect to the Individual Components of Canagliflozin (1x300 mg) and Metformin IR (2x1000 mg) Tablets in Healthy Fed Subjects|Completed||Phase 1|83|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 22:00:10.143317|2018-05-31 22:00:10.143317
NCT01463215|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2013-02-12|2011-10-31|2011-11-01|Estimate|||||||2013-02-12|2013-02-15|Estimate|December 2012||2012-12-31|February 2012|2012-02-29|August 2015|Anticipated|2015-08-31|December 2014|Anticipated|2014-12-31||Interventional|||Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease|An Open-Label, Dose Escalation With 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Type I Gaucher Disease|Suspended||Phase 1/Phase 2|20|Anticipated|Exsar Corporation||1|||f||||f||||||||||2018-05-31 22:00:10.274555|2018-05-31 22:00:10.274555
NCT01463202|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2018-02-14||2018-02-14|2011-10-31|2011-11-01|Estimate|2018-02-14|2018-03-13|Actual||||2018-02-14|2018-03-13|Actual|November 2011||2011-11-30|February 2018|2018-02-28|October 16, 2017|Actual|2017-10-16|February 13, 2017|Actual|2017-02-13||Interventional|DEPO-ABCD||Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression|Effect of Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding Continuation, Contraceptive Continuation, and Postpartum Depression: a Randomized Trial|Completed||Phase 4|184|Actual|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-05-31 22:00:10.415591|2018-05-31 22:00:10.415591
NCT01463189|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-12-07|2011-10-28|2011-11-01|Estimate|||||||2012-12-07|2012-12-10|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Web-based Support to Manage Arthritis Pain|Web-based Support to Manage Arthritis Pain|Completed||Phase 2|228|Actual|Inflexxion, Inc.||2|||f||||t||||||||||2018-05-31 22:00:10.870692|2018-05-31 22:00:10.870692
NCT01463176|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2015-08-10|2011-10-28|2011-11-01|Estimate|||||||2015-08-10|2015-08-11|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Music Therapy as Procedural Support for Young Children Undergoing Immunizations|Music Therapy as Procedural Support for Young Children Undergoing Immunizations: A Randomized Controlled Study|Completed||N/A|150|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 22:00:10.950424|2018-05-31 22:00:10.950424
NCT01463163|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-04-09|2011-10-31|2011-11-01|Estimate|||||||2012-04-09|2012-04-10|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|Completed||Phase 4|50|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 22:00:11.05039|2018-05-31 22:00:11.05039
NCT01463150|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-07-10|2011-10-31|2011-11-01|Estimate|||||||2012-07-10|2012-07-11|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)|Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)|Completed||Phase 4|27|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 22:00:11.152049|2018-05-31 22:00:11.152049
NCT01463137|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2016-10-29|2011-10-31|2011-11-01|Estimate|||||||2016-10-29|2016-11-01|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|SOFIE-11||Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder|Computerized Attention Bias Modification Training in Social Phobia/Social Anxiety Disorder|Completed||N/A|129|Actual|Umeå University||6|||f||||f||||||||||2018-05-31 22:00:11.248618|2018-05-31 22:00:11.248618
NCT01463124|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-03-12|2011-10-27|2011-11-01|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||School Nurse Intervention and After School Exercise Program for Overweight Teens|School Nurse Intervention and After School Exercise Program for Overweight Teens|Completed||Phase 2|126|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 22:00:11.5928|2018-05-31 22:00:11.5928
NCT01463111|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2017-03-21||2017-05-02|2011-10-28|2011-11-01|Estimate|2017-05-02|2017-05-31|Actual||||2017-05-02|2017-05-31|Actual|May 2011||2011-05-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Decision-Making in Bipolar Disorder|Decision-Making in Bipolar Disorder|Completed||N/A|37|Actual|Emory University||1|||f||||t||||||||||2018-05-31 22:00:11.724359|2018-05-31 22:00:11.724359
NCT01463098|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-05-20|2011-10-31|2011-11-01|Estimate|||||||2013-05-20|2013-05-22|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006|A 2-Part, Randomized, Double-blind, Placebo- and Active- Controlled, Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Subjects and Otherwise Healthy Subjects With Primary Insomnia|Completed||Phase 1|122|Actual|Eisai Inc.||11|||f||||||||||||||2018-05-31 22:00:12.082718|2018-05-31 22:00:12.082718
NCT01463085|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-05-23|2011-10-28|2011-11-01|Estimate|||||||2012-05-23|2012-05-24|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Clinical Trial to Assess the Effects of Low-fat Dairy on Systolic Blood Pressure|A Randomized, Controlled, Trial to Assess the Effects of Low-fat Dairy Intake on Endothelial Function and Blood Pressure in Subjects With Pre-hypertension or Stage 1 Hypertension|Unknown status|Active, not recruiting|N/A|65|Anticipated|Dairy Research Institute||2|||f||||f||||||||||2018-05-31 22:00:12.22785|2018-05-31 22:00:12.22785
NCT01463072|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-03-05|2011-10-31|2011-11-01|Estimate|||||||2018-03-05|2018-03-06|Actual|June 19, 2012||2012-06-19|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer|Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older With Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 2|40|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 22:00:12.335748|2018-05-31 22:00:12.335748
NCT01463059|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27||2013-03-19|2013-03-19|2011-10-27|2011-11-01|Estimate||||2013-03-19|2013-03-25|Estimate|2013-03-19|2013-03-25|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy|A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy|Completed||Phase 2|119|Actual|UCB Pharma||6|||f||||f||||||||||2018-05-31 22:00:12.56084|2018-05-31 22:00:12.56084
NCT01463046|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2018-04-23|2011-10-27|2011-11-01|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2012||2012-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 14, 2015|Actual|2015-11-14||Interventional|||Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome|A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome|Active, not recruiting||Phase 1|29|Actual|University of California, San Francisco||1|||f||||t|t|f||||||||2018-05-31 22:00:12.731551|2018-05-31 22:00:12.731551
NCT01463033|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|2014-11-11||2015-12-11|2011-10-28|2011-11-01|Estimate|2015-10-01|2015-11-02|Estimate||||2015-12-11|2016-01-13|Estimate|April 2005||2005-04-30|December 2015|2015-12-31|February 2010|Actual|2010-02-28|June 2008|Actual|2008-06-30||Interventional|||Levetiracetam to Prevent Post-Traumatic Epilepsy|Pilot: Levetiracetam to Prevent Post-Traumatic Epilepsy|Completed||Phase 2|126|Actual|Children's Research Institute||2|||f||||t||||||||||2018-05-31 22:00:12.90496|2018-05-31 22:00:12.90496
NCT01463020|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2013-06-18|2011-10-31|2011-11-01|Estimate|||||||2013-06-18|2013-06-19|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Behavioural Activation-Based Treatment Administered Through Smartphone|Behavioural Activation-Based Guided Self-Help Treatment Administered Through a Smartphone Application|Completed||N/A|81|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 22:00:13.32529|2018-05-31 22:00:13.32529
NCT01463007|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2015-06-24||2017-05-11|2011-10-31|2011-11-01|Estimate|2015-07-28|2015-08-21|Estimate||||2017-05-11|2017-06-09|Actual|August 2011||2011-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2013|Actual|2013-09-30||Interventional|||Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer|ACCELERATED PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (ACCUBOOST) FOR EARLY STAGE BREAST CANCERS: A TOXICITY ASSESSMENT|Active, not recruiting||N/A|40|Actual|Brown University||2|||f||||t||||||||||2018-05-31 22:00:13.43845|2018-05-31 22:00:13.43845
NCT01462994|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2016-03-16|2011-10-27|2011-11-01|Estimate|||||||2016-03-16|2016-03-17|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)|Prospective, Explorative Trial for the Detection of Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)Harboring Activating Mutations of CKIT or PDGFRA Pre/Post Surgery or Pre/Under Treatment With a Tyrosine Kinase Inhibitor or Progressive Disease Irrespective of Current or Planned Treatment. An Open-label, Non-randomized, Multicenter Phase IIIb Clinical Trial|Completed||Phase 3|25|Actual|Technische Universität München||1|||f||||f||||||||||2018-05-31 22:00:13.72142|2018-05-31 22:00:13.72142
NCT01462981|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2011-11-01|2011-10-28|2011-11-01|Estimate|||||||2011-11-01|2011-11-02|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|July 2012|Anticipated|2012-07-31|||||Observational|COBRA||Cohort of Hepatitis B Research of Amsterdam|Cohort of Hepatitis B Research of Amsterdam|Unknown status|Recruiting||172|Anticipated|Public Health Service of Amsterdam|||||f||||f||||||Samples With DNA|"~     Serum, White cells~   "|||2018-05-31 22:00:13.846775|2018-05-31 22:00:13.846775
NCT01462968|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2015-06-25|2011-10-31|2011-11-01|Estimate|||||||2015-06-25|2015-06-26|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Interruptions in the Coagulationsystem in Relation With Cardiac Surgery - A Study Comparing Two Heparinization Strategies During On-pump Cardiac Surgery|Interruptions in the Coagulationsystem in Relation With Cardiac Surgery -A Randomized Study Comparing Two Heparinization Strategies During On-pump Cardiac Surgery|Withdrawn||N/A|0|Actual|Aalborg Universitetshospital||2||The study never started due to problems with Laboratory facilities in collaborating center|f||||f||||||||||2018-05-31 22:00:13.926932|2018-05-31 22:00:13.926932
NCT01462955|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-11-05|2011-10-28|2011-11-01|Estimate|||||||2012-11-05|2012-11-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:00:14.011236|2018-05-31 22:00:14.011236
NCT01462942|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2016-09-14||2016-12-22|2011-10-31|2011-11-01|Estimate|2016-12-22|2017-02-15|Actual||||2016-12-22|2017-02-15|Actual|October 2011||2011-10-31|December 2016|2016-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination|Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.|Completed||Phase 3|2443|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 22:00:14.103692|2018-05-31 22:00:14.103692
NCT01462929|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2013-03-27||2016-11-16|2011-10-31|2011-11-01|Estimate|2013-03-27|2013-05-22|Estimate||||2016-11-16|2017-01-04|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose, Double-blind, Double-dummy, Placebo Controlled, Parallel Clinical Trial to Assess the Efficacy and Safety of Twice Daily Inhaled Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|414|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:00:15.622257|2018-05-31 22:00:15.622257
NCT01462916|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2018-01-08|2011-10-31|2011-11-01|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Honey in Chronic Immune Thrombocytopenia|Effect of Honey Bee Honey Intake on Children With Chronic Immune Thrombocytopenia|Terminated|||30|Actual|Ain Shams University|||1|problem with the candidate (investigator)|f||||t||||||||||2018-05-31 22:00:16.197645|2018-05-31 22:00:16.197645
NCT01462903|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-11-21|2011-10-27|2011-11-01|Estimate|||||||2014-11-21|2014-11-24|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors|A Phase I Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors|Unknown status|Recruiting|Phase 1|20|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 22:00:16.312611|2018-05-31 22:00:16.312611
NCT01462890|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-07-14|2011-10-28|2011-11-01|Estimate|||||||2017-07-14|2017-07-18|Actual|November 2011||2011-11-30|July 2017|2017-07-31|November 2021|Anticipated|2021-11-30|November 2018|Anticipated|2018-11-30||Interventional|BOOST||Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer|A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer|Active, not recruiting||Phase 3|800|Anticipated|AGO Study Group||2|||f||||t||||||||No||2018-05-31 22:00:16.485523|2018-05-31 22:00:16.485523
NCT01462877|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|2015-02-06||2015-02-25|2011-10-28|2011-11-01|Estimate|2015-02-06|2015-02-23|Estimate||||2015-02-25|2015-03-17|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional||Full Analysis Set|A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic|An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Statin-fenofibrate Combination Therapy in Dyslipidemic Chinese Patients|Completed||Phase 4|506|Actual|Abbott||1|||f||||f||||||||||2018-05-31 22:00:16.85445|2018-05-31 22:00:16.85445
NCT01462864|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-05-25|2011-10-31|2011-11-01|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2011||2011-09-30|October 2011|2011-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SUCCESS||Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome|StructUred eduCation Programme to Improve Cardiovascular Risk in womEn With polycyStic Ovary Syndrome; SUCCESS Study|Completed||N/A|162|Actual|University of Leicester||2|||f||||f|f|f||||||No||2018-05-31 22:00:17.145206|2018-05-31 22:00:17.145206
NCT01462851|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-03-12|2011-10-27|2011-10-31|Estimate|||||||2012-03-12|2012-03-13|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults|A Phase 1, Randomized Investigator-And-Subject-Blind, Sponsor Open, Placebo Controlled Two-Part Study To Characterize The Pharmacokinetics And Pharmacodynamics Of Single Doses Of Pf-05297909 In Healthy Adult Subjects|Completed||Phase 1|51|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:00:17.23476|2018-05-31 22:00:17.23476
NCT01462838|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-06-22|2011-10-27|2011-10-31|Estimate|||||||2015-06-22|2015-06-23|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Immune Therapy of HPV-induced Cancers|Phase I/IIa Study of Immunization With a p16INK4a Peptide Combined With MONTANIDE ISA-51 VG in Patients With Advanced HPV-associated Cancers|Completed||Phase 1/Phase 2|26|Actual|Oryx GmbH & Co. KG||1|||f||||t||||||||||2018-05-31 22:00:17.322796|2018-05-31 22:00:17.322796
NCT01462812|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2015-04-20||2015-04-20|2011-10-27|2011-10-31|Estimate|2015-04-20|2015-05-06|Estimate||||2015-04-20|2015-05-06|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura|Completed||Phase 3|223|Actual|Optinose US Inc.||2|||f||||f||||||||||2018-05-31 22:00:17.659077|2018-05-31 22:00:17.659077
NCT01462799|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-27|2011-10-27|2011-10-31|Estimate|||||||2011-10-27|2011-10-31|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|March 2019|Anticipated|2019-03-31|March 2015|Anticipated|2015-03-31||Interventional|CORPRIM||COR-PRIM: Problem-based Learning (PBL) After Coronary Heart Disease (CHD) - Long-term Evaluation in Primary Care of Self-care|COR-PRIM: Problem-based Learning in Patient Education After an Event of Coronary Heart Disease. A Randomised Study in Primary Care of Long-term Effects on Self-care|Recruiting||N/A|150|Anticipated|Linkoeping University||2|||f||||f||||||||||2018-05-31 22:00:17.948216|2018-05-31 22:00:17.948216
NCT01462786|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2016-05-05|2011-10-27|2011-10-31|Estimate|||||||2016-05-05|2016-05-06|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101|Phase 1, Open-Label, Crossover, Safety and Pharmacokinetic Study of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Injections in the Submental and Abdominal Areas|Completed||Phase 1|5|Actual|Kythera Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 22:00:18.085053|2018-05-31 22:00:18.085053
NCT01462773|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2014-12-10||2014-12-30|2011-10-28|2011-10-31|Estimate|2014-12-29|2014-12-30|Estimate||||2014-12-30|2015-01-13|Estimate|January 2006||2006-01-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|October 2010|Actual|2010-10-31||Interventional|||Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma|A Phase I Study of PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma.|Completed||Phase 1|16|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:00:18.179433|2018-05-31 22:00:18.179433
NCT01462760|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-27|2011-10-27|2011-10-31|Estimate|||||||2011-10-27|2011-10-31|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|August 2012|Anticipated|2012-08-31|May 2012|Anticipated|2012-05-31||Interventional|BIOVAL||Contribution of Actigraphy for the Evaluation of Elbow Range of Motion in the Joint Assessment in Gerontology|Contribution of Actigraphy for the Evaluation of Elbow Range of Motion in the Joint Assessment in Gerontology|Unknown status|Recruiting|N/A|85|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 22:00:18.41742|2018-05-31 22:00:18.41742
NCT01462747|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2013-02-12|2011-10-27|2011-10-31|Estimate|||||||2013-02-12|2013-02-13|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Safety Study of a Medical Device (KULIST)to Treat Perianal Fistulas|An Open Prospective Study Evaluating the Efficacy and Safety of a Medical Device,KULIST, for the Treatment of Chronic, Non-complicated Perianal Fistulas|Completed||Phase 2|28|Actual|Nordic Drugs AB||1|||f||||f||||||||||2018-05-31 22:00:18.511634|2018-05-31 22:00:18.511634
NCT01462734|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2015-03-31|2011-10-27|2011-10-31|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2011||2011-10-31|March 2015|2015-03-31||||December 2014|Actual|2014-12-31||Observational|||MicroRNA Expression in Human Blood Serum and Vitreous Body|MicroRNA Expression in Human Blood Serum and Vitreous Body|Completed|||8|Actual|Kyorin University|||1||f||||f||||||Samples With DNA|"~     3ml of blood serum and 1ml of vitreous~   "|||2018-05-31 22:00:18.588897|2018-05-31 22:00:18.588897
NCT01462721|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2014-02-27|2011-10-27|2011-10-31|Estimate|||||||2014-02-27|2014-02-28|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The eSVS® Mesh Randomized Post-Market Study|Post-market Study to Evaluate Post-implant Patency Rates of the External Saphenous Vein Support (eSVS®) Mesh in the Treatment of Saphenous Vein Grafts (SVGs) During Coronary Artery Bypass Grafting (CABG) Versus SVGs Without the eSVS Mesh.|Terminated||N/A|12|Actual|Kips Bay Medical, Inc.||1|||f||||t||||||||||2018-05-31 22:00:18.658538|2018-05-31 22:00:18.658538
NCT01462708|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-11-08|2011-10-26|2011-10-31|Estimate|||||||2013-11-08|2013-11-11|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MK9470||Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects|Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls|Completed||Phase 1|16|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-05-31 22:00:18.734633|2018-05-31 22:00:18.734633
NCT01462695|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2015-02-05||2015-08-18|2011-10-27|2011-10-31|Estimate|2015-03-11|2015-03-23|Estimate||||2015-08-18|2015-08-27|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma|A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:00:18.836557|2018-05-31 22:00:18.836557
NCT01462682|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-06-20|2011-10-28|2011-10-31|Estimate|||||||2012-06-20|2012-06-21|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Perception of Fatigue Among Surgeons During Night Shifts|Perception of Fatigue Among Surgeons During Night Shifts, a Focus Group Study.|Completed|||13|Actual|Herlev Hospital|||||f||||f||||||||||2018-05-31 22:00:20.546373|2018-05-31 22:00:20.546373
NCT01462669|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2018-05-17|2011-10-27|2011-10-31|Estimate|||||||2018-05-17|2018-05-21|Actual|April 10, 2012|Actual|2012-04-10|May 2018|2018-05-31|June 27, 2012|Actual|2012-06-27|June 27, 2012|Actual|2012-06-27||Interventional|||Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects|An Open-label, Randomized, Single Centre, 4-way Crossover Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ezogabine/Retigabine in Healthy Adult Taiwanese Subjects|Completed||Phase 1|1|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:00:20.609509|2018-05-31 22:00:20.609509
NCT01462656|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2016-11-23|2011-10-27|2011-10-31|Estimate|||||||2016-11-23|2016-11-25|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Risk of Urinary Retention With Retigabine|A Post Marketing Surveillance Study to Monitor the Risk of Urinary Retention in Retigabine Users|Terminated|||1|Anticipated|GlaxoSmithKline|||1|"This study was halted as the preliminary analysis revealed that the numbers were too low to~   warrant continuing the project"|f||||f||||||||||2018-05-31 22:00:20.756785|2018-05-31 22:00:20.756785
NCT01462643|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-28|2011-10-28|2011-10-31|Estimate|||||||2011-10-28|2011-10-31|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PPT4||Efficacy and Tolerability of LAS41004 Formulations in a Non-occlusive Psoriasis Plaque Test|A 22 Day Controlled, Randomized Clinical Study (PPT) Investigating the Anti-psoriatic Efficacy and the Tolerability of an Ointment Containing a Retinoid and a Steroid in Different Concentrations|Completed||Phase 2|22|Actual|Almirall, S.A.||7|||f||||f||||||||||2018-05-31 22:00:20.949246|2018-05-31 22:00:20.949246
NCT01462630|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2018-02-23|2011-10-28|2011-10-31|Estimate|||||||2018-02-23|2018-02-26|Actual|November 3, 2011|Actual|2011-11-03|February 2018|2018-02-28|December 15, 2020|Anticipated|2020-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma|Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma|Recruiting||Phase 2|30|Anticipated|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 22:00:21.099946|2018-05-31 22:00:21.099946
NCT01462617|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2017-07-24|2011-10-27|2011-10-31|Estimate|||||||2017-07-24|2017-07-25|Actual|July 24, 2011|Actual|2011-07-24|July 2017|2017-07-31|March 26, 2012|Actual|2012-03-26|March 26, 2012|Actual|2012-03-26||Interventional|||Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557|A Single-centre. Double-blind, Placebo Controlled Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Repeat Doses of Nebulised GSK2269557 in Healthy Male Subjects|Completed||Phase 1|61|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:00:21.247025|2018-05-31 22:00:21.247025
NCT01462604|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2018-05-17|2011-10-27|2011-10-31|Estimate|||||||2018-05-17|2018-05-21|Actual|November 23, 2011||2011-11-23|May 2018|2018-05-31|January 24, 2013|Actual|2013-01-24|January 1, 2013|Actual|2013-01-01||Observational|||Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer|PROACTYVE Pilot:Pilot Study of Patient's Adherence to TYKERB™/TYVERB™+Capecitabine in Metastatic Breast Cancer-Observation of Patient Adherence and Evaluation of Predictive Factors for Patient Adherence After Providing Educational Programme|Completed|||27|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:00:21.373722|2018-05-31 22:00:21.373722
NCT01462591|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2014-08-04|2011-10-28|2011-10-31|Estimate|||||||2014-08-04|2014-08-05|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||L-citrulline Supplementation & Cold Exposure|The Effects L-citrulline Supplementation on Arterial Stiffness, Wave Reflection, and Cardiac Autonomic Responses to Cold Exposure With Isometric Exercise|Completed||Phase 1/Phase 2|16|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 22:00:21.514453|2018-05-31 22:00:21.514453
NCT01462578|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-09-13|2011-10-28|2011-10-31|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2011||2011-09-30|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|RELAZA2||Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)|Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)|Recruiting||Phase 2|93|Anticipated|Technische Universität Dresden||1|||f||||f||||||||||2018-05-31 22:00:21.608871|2018-05-31 22:00:21.608871
NCT01462565|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2017-05-22|2012-10-04|2017-09-13|2011-10-27|2011-10-31|Estimate|2017-09-13|2017-10-16|Actual|2012-10-04|2012-10-08|Estimate|2017-09-13|2017-10-16|Actual|November 1, 2011||2011-11-01|May 2017|2017-05-31|November 8, 2012|Actual|2012-11-08|May 16, 2012|Actual|2012-05-16||Interventional|||Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)|A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.)|Completed||Phase 4|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:00:21.852542|2018-05-31 22:00:21.852542
NCT01462552|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-04-14|2011-10-27|2011-10-31|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Physician Liver Function Test (LFT) Monitoring for Tykerb Pts|Assessment of Physician Compliance to Recommended Liver Function Test Monitoring for Tykerb Patients|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:00:22.270752|2018-05-31 22:00:22.270752
NCT01462539|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-11-29|2011-10-28|2011-10-31|Estimate|||||||2012-11-29|2012-11-30|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Observational|||Adenotonsillectomy and Obstructive Sleep Apnea Study|Factors That Increase Length of Stay After Outpatient Surgery of 3-6 Year Olds With OSAS Symptoms Versus Without OSAS Symptoms After Adenotonsillectomy|Completed|||200|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 22:00:22.45297|2018-05-31 22:00:22.45297
NCT01462526|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2017-10-10|2011-10-28|2011-10-31|Estimate|||||||2017-10-10|2017-10-12|Actual|March 2011||2011-03-31|October 2017|2017-10-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Observational|RAPiD||The Detection of Glaucoma Using Pupillography|The Detection of Glaucoma Using Pupillography|Completed|||798|Actual|Johns Hopkins University|||2||f||||f||||||||||2018-05-31 22:00:22.53895|2018-05-31 22:00:22.53895
NCT01462513|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2018-02-12|2011-10-27|2011-10-31|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2011||2011-08-31|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Interventional|LICC||L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases|LICC: L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases - a Randomized, Placebo-controlled, Multicenter, Multinational, Double Blinded Phase II Trial|Completed||Phase 2|122|Actual|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 22:00:22.624721|2018-05-31 22:00:22.624721
NCT01462500|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2016-08-18|2011-10-27|2011-10-31|Estimate|||||||2016-08-18|2016-08-22|Estimate|October 2011||2011-10-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|May 2014|Actual|2014-05-31||Interventional|PK||Pharmacokinetics of Miltefosine in Children and Adults|Pharmacokinetics of Miltefosine in Children and Adults: Implications for the Treatment of Cutaneous Leishmaniasis in Colombia.|Completed||Phase 4|60|Actual|Centro Internacional de Entrenamiento e Investigaciones Médicas||1|||f||||f||||||||||2018-05-31 22:00:22.778619|2018-05-31 22:00:22.778619
NCT01462487|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-04-17|2011-10-27|2011-10-31|Estimate|||||||2014-04-17|2014-04-21|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Safety of Inhaled Zanamivir in Pregnancy|Assessing the Safety of Inhaled Zanamivir Exposure in Pregnant Women|Completed|||1|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 22:00:22.882268|2018-05-31 22:00:22.882268
NCT01461629|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2016-04-06|2011-10-27|2011-10-28|Estimate|||||||2016-04-06|2016-04-07|Estimate|June 2010||2010-06-30|April 2016|2016-04-30||||April 2015|Actual|2015-04-30||Observational|Heart ABC||Self-management and Cognitive Function in Adults With Heart Failure|Cognitive Impairment and Self-management in Adults With Heart Failure|Completed|||372|Actual|Kent State University|||1||f||||||||||Samples Without DNA|"~     Urinary sodium~   "|||2018-05-31 22:00:54.449364|2018-05-31 22:00:54.449364
NCT01462474|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2018-04-16|2011-10-27|2011-10-31|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2011||2011-10-31|November 2011|2011-11-30|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|FMTN-I-LNPC||Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma|Phase I Study of Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma|Completed||Phase 1|20|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:00:22.975312|2018-05-31 22:00:22.975312
NCT01462461|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-10-14|2011-10-27|2011-10-31|Estimate|||||||2015-10-14|2015-10-16|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|VIE||Virtual Integrated Environment in Decreasing Phantom Limb Pain|Pilot Study of the Efficacy of a Virtual Integrated Environment in Decreasing Phantom Limb Pain|Completed|||14|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine|||||f||||f||||||||||2018-05-31 22:00:23.122146|2018-05-31 22:00:23.122146
NCT01462448|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-10-05|2011-10-27|2011-10-31|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2012||2012-03-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|April 2014|Actual|2014-04-30||Observational|||Study to Identify the Genetic Variations Associated With Phantom Limb Pain|Study to Identify the Genetic Variations Associated With Phantom Limb Pain|Active, not recruiting|||41|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 22:00:23.216976|2018-05-31 22:00:23.216976
NCT01462435|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2013-02-20||2014-01-02|2011-10-27|2011-10-31|Estimate|2013-11-21|2013-12-19|Estimate||||2014-01-02|2014-02-04|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Study of Diclofenac Capsules to Treat Pain Following Bunionectomy|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy|Completed||Phase 3|428|Actual|Iroko Pharmaceuticals, LLC||4|||f||||f||||||||||2018-05-31 22:00:23.376837|2018-05-31 22:00:23.376837
NCT01462422|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2014-06-13|2011-10-28|2011-10-31|Estimate|||||||2014-06-13|2014-06-16|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India|Two Community Strategies Comparing Use of Misoprostol for Secondary Prevention to Primary Prevention for Postpartum Hemorrhage: A Randomized Cluster Non-Inferiority Study in Bijapur District, Karnataka, India|Completed||N/A|3032|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 22:00:24.044595|2018-05-31 22:00:24.044595
NCT01462409|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-09-17|2011-10-27|2011-10-31|Estimate|||||||2012-09-17|2012-09-18|Estimate|March 2011||2011-03-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Humidity Under Continuous Positive Airway Pressure|Luftfeuchtigkeit Unter CPAP Mit Temperatur- Und Feuchtigkeitskontrolle|Completed||N/A|19|Actual|Institut für Pneumologie Hagen Ambrock eV||3|||f||||f||||||||||2018-05-31 22:00:24.151067|2018-05-31 22:00:24.151067
NCT01462396|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-02-04|2011-10-27|2011-10-31|Estimate|||||||2015-02-04|2015-02-05|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|STALLO||Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors|Phase I Study of Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using Major Histocompatibility Complex (MHC) Mismatched Related Donors and Sub-Myeloablative Regimen|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Children's Mercy Hospital Kansas City|||||f||||t||||||||||2018-05-31 22:00:24.220563|2018-05-31 22:00:24.220563
NCT01462383|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2011-12-09|2011-10-28|2011-10-31|Estimate|||||||2011-12-09|2011-12-12|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||The Role of the EKG in Anticancer Drug Development|The Role of the EKG in Anticancer Phase I Drug Development|Completed|||525|Actual|M.D. Anderson Cancer Center|||||f||||t||||||||||2018-05-31 22:00:24.277683|2018-05-31 22:00:24.277683
NCT01462370|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2013-05-21||2015-10-08|2011-10-27|2011-10-31|Estimate|2013-05-21|2013-07-10|Estimate||||2015-10-08|2015-10-09|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)|A Phase III, Randomized, Active-Comparator-Controlled, 2-period, Crossover, Double-Blind Study in China to Assess the Safety and Efficacy of Etoricoxib 120 mg Versus Ibuprofen up to 2400 mg (600 mg Q6h) in the Treatment of Patients With Primary Dysmenorrhea|Completed||Phase 3|139|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:00:24.355945|2018-05-31 22:00:24.355945
NCT01462357|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2014-08-11||2017-03-02|2011-10-27|2011-10-31|Estimate|2016-02-25|2016-03-28|Estimate||||2017-03-02|2017-03-31|Actual|November 2011||2011-11-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil® Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females|Completed||Phase 3|1079|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:00:25.023491|2018-05-31 22:00:25.023491
NCT01462344|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2016-05-02||2018-02-08|2011-10-27|2011-10-31|Estimate|2016-08-11|2016-10-05|Estimate||||2018-02-08|2018-02-09|Actual|November 17, 2011||2011-11-17|February 2018|2018-02-28|November 3, 2015|Actual|2015-11-03|November 1, 2015|Actual|2015-11-01||Interventional|VESTRI||6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old|A 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma|Completed||Phase 4|6250|Actual|GlaxoSmithKline||4|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:00:27.001095|2018-05-31 22:00:27.001095
NCT01462331|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-07-24|2011-10-28|2011-10-31|Estimate|||||||2012-07-24|2012-07-26|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||the Dietary Effects of VitaSugar/VitaFiber-IMO in Healthy Adults|Double-blind, Randomized, Placebo Controlled Study to Investigate the Dietary Effects of VitaSugar/VitaFiber-IMO in Healthy Adults|Completed||Phase 1|60|Actual|BioNeutra Inc.||3|||f||||f||||||||||2018-05-31 22:00:29.390679|2018-05-31 22:00:29.390679
NCT01461265|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-07-13|2011-10-26|2011-10-28|Estimate|||||||2015-07-13|2015-07-15|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases|Cryoablation for the Palliation of Painful Bone Metastases|Completed||Phase 1|29|Actual|Galil Medical||1|||f||||f||||||||||2018-05-31 22:01:04.456816|2018-05-31 22:01:04.456816
NCT01462318|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2017-01-23|2014-10-13|2017-01-23|2011-10-28|2011-10-31|Estimate|2017-01-23|2017-03-14|Actual|2014-10-13|2014-10-22|Estimate|2017-01-23|2017-03-14|Actual|November 2011||2011-11-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|OBSERVE||An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis|A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|133|Actual|Biogen||1|||f||||t||||||||||2018-05-31 22:00:29.649431|2018-05-31 22:00:29.649431
NCT01462305|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2012-08-06|2011-10-28|2011-10-31|Estimate|||||||2012-08-06|2012-08-07|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|SAD||30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder|30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder|Terminated||N/A|36|Actual|Philips Respironics||2||enrollment targets having been met|f||||f||||||||||2018-05-31 22:00:30.865848|2018-05-31 22:00:30.865848
NCT01462292|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|2017-08-03|2015-04-27|2017-09-13|2011-10-27|2011-10-31|Estimate|2017-09-13|2017-10-16|Actual|2015-04-27|2015-05-14|Estimate|2017-09-13|2017-10-16|Actual|October 26, 2011|Actual|2011-10-26|August 2017|2017-08-31|November 4, 2013|Actual|2013-11-04|May 21, 2013|Actual|2013-05-21||Interventional|DMD114876||A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)|An Exploratory Study to Assess Two Doses of GSK2402968 in the Treatment of Ambulant Boys With Duchenne Muscular Dystrophy|Completed||Phase 2|51|Actual|GlaxoSmithKline||4|||f||||t||||||||||2018-05-31 22:00:31.190605|2018-05-31 22:00:31.190605
NCT01462279|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2016-10-07||2017-12-11|2011-10-27|2011-10-31|Estimate|2016-10-07|2016-11-30|Estimate||||2017-12-11|2018-01-16|Actual|September 2011||2011-09-30|December 2017|2017-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|VO2||Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness|The Effect of Thiamine on VO2 Levels in Critically Ill Patients|Completed||N/A|20|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-05-31 22:00:33.235449|2018-05-31 22:00:33.235449
NCT01462266|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2014-01-08||2017-03-24|2011-10-28|2011-10-31|Estimate|2014-03-07|2014-04-08|Estimate||||2017-03-24|2017-04-24|Actual|January 13, 2012|Actual|2012-01-13|March 2017|2017-03-31|June 7, 2013|Actual|2013-06-07|June 6, 2013|Actual|2013-06-06||Interventional||One participant in both the Sitagliptin group and Placebo group was randomized in error and did not receive study medication.|Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin|Completed||Phase 3|660|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:00:33.465764|2018-05-31 22:00:33.465764
NCT01462253|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-10-09|2011-10-27|2011-10-31|Estimate|||||||2017-10-09|2017-10-10|Actual|October 2012||2012-10-31|October 2017|2017-10-31|March 11, 2017|Actual|2017-03-11|March 11, 2017|Actual|2017-03-11||Interventional|LAL1610||Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults|"A Phase II Study With a Sequential Clofarabine-cyclophosphamide Combination Schedule as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) in Adult Patients"|Completed||Phase 2|35|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-05-31 22:00:34.306118|2018-05-31 22:00:34.306118
NCT01462240|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-08-31|2011-10-28|2011-10-31|Estimate|||||||2017-08-31|2017-09-05|Actual|May 20, 2008|Actual|2008-05-20|August 2017|2017-08-31|December 2024|Anticipated|2024-12-31|June 2024|Anticipated|2024-06-30||Observational|||LPS Flex Porous Femoral Components|Prospective Multicenter Post-market Study of the Zimmer NexGen LPS-Flex Porous Femoral Components|Active, not recruiting|||150|Anticipated|Zimmer Biomet|||1||f||||f||||||||||2018-05-31 22:00:34.707202|2018-05-31 22:00:34.707202
NCT01462227|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2016-01-20||2016-02-17|2011-10-28|2011-10-31|Estimate|2016-02-17|2016-02-18|Estimate||||2016-02-17|2016-02-18|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Baseline population includes subjects that completed study|Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia|The Effect of Opiate Blockade With Naltrexone on Counterregulatory Mechanisms in Hypoglycemia|Completed||N/A|17|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:00:34.844948|2018-05-31 22:00:34.844948
NCT01462214|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2017-05-09|2011-10-26|2011-10-31|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2011||2011-10-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer|Phase 1-2 Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer.|Completed||Phase 1/Phase 2|96|Anticipated|VU University Medical Center|||||f||||f||||||||||2018-05-31 22:00:35.51176|2018-05-31 22:00:35.51176
NCT01462201|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2013-11-10|2011-10-28|2011-10-31|Estimate|||||||2013-11-10|2013-11-13|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Multicenter,2-Arm,Randomized,Controlled Study Evaluate the Effectiveness of the UltraShape® Contour I VER 3.1 System for Non-Invasive Reduction in Abdominal Circumference|A Multicenter,Two-Arm,Randomized,Controlled Study for the Evaluation of the Treatment of Adipose Tissue Using a Focused Ultrasound Device|Completed||N/A|156|Actual|UltraShape||2|||f||||t||||||||||2018-05-31 22:00:35.664576|2018-05-31 22:00:35.664576
NCT01462188|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-28|2011-10-28|2011-10-31|Estimate|||||||2011-10-28|2011-10-31|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2015|Anticipated|2015-10-31|October 2012|Anticipated|2012-10-31||Interventional|OPTIMASTRATEGY||Optimizing Infarct Size by Transforming Emergent Stenting Into an Elective Procedure Study|Immediate Versus Delayed Stenting in Patients With ST-Elevation Myocardial Infarction Undergoing Mechanical Intervention|Unknown status|Recruiting|Phase 4|100|Anticipated|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-05-31 22:00:35.735686|2018-05-31 22:00:35.735686
NCT01462175|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2016-11-01|2011-10-27|2011-10-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia|A Multi-center, Open Label, First in Human Phase I Dose Escalation Study of Single Agent RO5503781, a Small Molecule MDM2 Antagonist, Administered Orally in Patients With Advanced Malignancies, Except Leukemia|Completed||Phase 1|99|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:00:35.852535|2018-05-31 22:00:35.852535
NCT01438580|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2012-05-18|2011-09-21|2011-09-22|Estimate|||||||2012-05-18|2012-05-21|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation||Completed||Phase 4|260|Actual|Nanjing Medical University||3|||f||||t||||||||||2018-05-31 22:08:31.58975|2018-05-31 22:08:31.58975
NCT01462162|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|2015-12-01||2016-09-08|2011-10-27|2011-10-31|Estimate|2016-09-08|2016-10-31|Estimate||||2016-09-08|2016-10-31|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational||All participants who satisfied inclusion and exclusion criteria of the study were included in the analysis.|A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis|A Prospective Observational Study to Evaluate and Correlate the Impact of Treatment With Tocilizumab (RoActemra®) on Fatigue and Different Factors Influencing Fatigue in Participants With Rheumatoid Arthritis in Routine Clinical Practice|Completed|||122|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:00:36.005507|2018-05-31 22:00:36.005507
NCT01462149|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-05-27|2011-10-27|2011-10-31|Estimate|||||||2017-05-27|2017-05-31|Actual|October 2011||2011-10-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer|Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer|Completed||Phase 2|43|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:00:38.996014|2018-05-31 22:00:38.996014
NCT01462136|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2012-08-21|2011-10-27|2011-10-31|Estimate|||||||2012-08-21|2012-08-23|Estimate|September 2011||2011-09-30|August 2012|2012-08-31||||||||Interventional|||PK Study of ACHN-490 Injection in Renally Impaired Subjects|A Phase 1 Study To Assess The Pharmacokinetics, Safety, And Tolerability of Intravenous ACHN-490 Injection in Volunteers With Varying Degrees of Renal Dysfunction Compared to Healthy Volunteers|Completed||Phase 1|24|Actual|Achaogen, Inc.||1|||f||||f||||||||||2018-05-31 22:00:39.61349|2018-05-31 22:00:39.61349
NCT01462123|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-27|||2011-10-28|2011-10-28|2011-10-31|Estimate|||||||2011-10-28|2011-10-31|Estimate|February 2011||2011-02-28|October 2011|2011-10-31||||||||Observational|||Resect and Discard Strategy in Clinical Practice||Completed|||286|Actual|Valduce Hospital|||1||f||||||||||||||2018-05-31 22:00:39.79093|2018-05-31 22:00:39.79093
NCT01462110|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2011-12-20|2011-10-26|2011-10-31|Estimate|||||||2011-12-20|2011-12-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:00:39.913662|2018-05-31 22:00:39.913662
NCT01462097|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2018-01-22|2011-10-26|2011-10-28|Estimate|||||||2018-01-22|2018-01-24|Actual|March 2012||2012-03-31|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|October 31, 2017|Actual|2017-10-31||Interventional|AWARD||Exercise Trial in Chronic Kidney Disease|Randomized Trial of Aerobic Exercise Training on Cognitive and Physical Function in Chronic Kidney Disease|Active, not recruiting||N/A|99|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 22:00:39.990796|2018-05-31 22:00:39.990796
NCT01462084|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2016-10-19||2017-04-13|2011-10-27|2011-10-28|Estimate|2017-04-13|2017-04-17|Actual||||2017-04-13|2017-04-17|Actual|September 2011||2011-09-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional||A total of 60 patients were screened, 21 met the inclusion criteria, 1 dropped out, 2 patients were not titrated according to protocol and were excluded, leaving data from 18 patients available for inclusion in the analysis.|Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use|Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use|Completed||N/A|21|Actual|ResMed||2|||f||||f|f|t|f||f|||No|There is no plan to share IPD with other researchers|2018-05-31 22:00:40.270807|2018-05-31 22:00:40.270807
NCT01462071|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2016-02-22|2011-10-26|2011-10-28|Estimate|||||||2016-02-22|2016-02-24|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|RBC||Red Blood Cell Lifespan|Red Blood Cell Lifespan and Inflammation in Dialysis Patients|Terminated|||58|Actual|Renal Research Institute|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 22:00:40.691124|2018-05-31 22:00:40.691124
NCT01462058|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2012-03-28|2011-10-27|2011-10-28|Estimate|||||||2012-03-28|2012-03-29|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|D3-vit-SAD||The Role of Vitamin D Supplementation on Well Being and Symptoms of Depression During the Winter Season in Health Service Staff||Completed||Phase 4|50|Actual|Region Syddanmark||2|||f||||t||||||||||2018-05-31 22:00:40.77654|2018-05-31 22:00:40.77654
NCT01462045|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|2013-06-05||2014-12-15|2011-10-27|2011-10-28|Estimate|2014-12-10|2014-12-15|Estimate||||2014-12-15|2015-01-06|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy Study of Mindfulness-Based Exercise for Posttraumatic Stress Disorder (PTSD)|The Efficacy of Mindfulness-Based Stretching and Breathing Exercise as a Complementary Therapy for Posttraumatic Stress Disorder: A Prospective Randomized Study|Completed||N/A|29|Actual|University of New Mexico||3|||f||||f||||||||||2018-05-31 22:00:40.911708|2018-05-31 22:00:40.911708
NCT01462032|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-06-03|2011-10-26|2011-10-28|Estimate|||||||2014-06-03|2014-06-04|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|NIPA||Non-pharmacological Interventions for Preschoolers With Attention Deficit Hyperactivity Disorder (ADHD)|Training Executive, Attention, and Motor Skills (TEAMS): Preliminary Studies|Completed||Phase 2|52|Actual|Queens College, The City University of New York||2|||f||||f||||||||||2018-05-31 22:00:41.406421|2018-05-31 22:00:41.406421
NCT01462019|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2011-10-26|2011-10-26|2011-10-28|Estimate|||||||2011-10-26|2011-10-28|Estimate|February 2006||2006-02-28|October 2011|2011-10-31|November 2006|Actual|2006-11-30|August 2006|Actual|2006-08-31||Interventional|||Photobiomodulation as a New Approach for the Treatment of Nipple Traumas||Completed||Phase 1/Phase 2|||Pontifícia Universidade Católica de Minas Gerais||2|||f||||||||||||||2018-05-31 22:00:41.528668|2018-05-31 22:00:41.528668
NCT01462006|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2017-05-09|2011-10-27|2011-10-28|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2015|Actual|2015-10-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)|Double-blind Placebo-controlled Pilot Study of Sirolimus in IPF|Active, not recruiting||N/A|32|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 22:00:41.620576|2018-05-31 22:00:41.620576
NCT01461993|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2014-11-21|2014-07-25|2014-11-21|2011-10-26|2011-10-28|Estimate|2014-11-21|2014-11-26|Estimate|2014-07-25|2014-07-30|Estimate|2014-11-21|2014-11-26|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17|A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Gardasil (Registered) (Hpv) Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged >=11 To <18 Years|Completed||Phase 2|2499|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:00:41.780996|2018-05-31 22:00:41.780996
NCT01437228|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2011-11-16|2011-09-19|2011-09-20|Estimate|||||||2011-11-16|2011-11-17|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Does Preoperative Vaginal Preparation With Povidone-iodine Before Cesarean Delivery Reduce the Risk of Endometritis?||Completed||Phase 4|668|Actual|Erzincan Military Hospital||2|||f||||||||||||||2018-05-31 22:09:03.43194|2018-05-31 22:09:03.43194
NCT01461980|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2015-05-07||2015-05-07|2011-10-26|2011-10-28|Estimate|2015-05-07|2015-05-25|Estimate||||2015-05-07|2015-05-25|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Intent-to-treat (ITT) population included all participants who were randomized.|A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age|A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Mcv4, Tdap Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged > = 10 To <13 Years|Completed||Phase 2|2648|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:00:43.420954|2018-05-31 22:00:43.420954
NCT01461967|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-11-01|2011-10-26|2011-10-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers|A Single-Center, Randomized, Double-Blind, Single and Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food) and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects.|Completed||Phase 1|49|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:00:45.177383|2018-05-31 22:00:45.177383
NCT01461954|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24||2015-03-25|2015-09-14|2011-10-26|2011-10-28|Estimate||||2015-03-25|2015-04-15|Estimate|2015-09-14|2015-09-30|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||FST-100 in the Treatment of Acute Viral Conjunctivitis|A Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Viral Conjunctivitis|Completed||Phase 2|132|Actual|Shire||2|||f||||f||||||||||2018-05-31 22:00:45.335055|2018-05-31 22:00:45.335055
NCT01461941|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2018-02-28|2011-10-27|2011-10-28|Estimate|||||||2018-02-28|2018-03-01|Actual|December 2011||2011-12-31|February 2018|2018-02-28|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||A Phase 2 Study of E6005 in Patients With Atopic Dermatitis|A Phase 2 Study of E6005 in Patients With Atopic Dermatitis|Completed||Phase 2|78|Actual|Dermavant Sciences GmbH||2|||f||||||||||||||2018-05-31 22:00:45.487763|2018-05-31 22:00:45.487763
NCT01461928|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-04-10|2011-10-26|2011-10-28|Estimate|||||||2018-04-10|2018-04-11|Actual|December 20, 2011|Actual|2011-12-20|April 2018|2018-04-30|May 8, 2018|Anticipated|2018-05-08|May 8, 2018|Anticipated|2018-05-08||Interventional|MabCute||A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab|A Randomized Study Comparing Maintenance Therapy With Subcutaneous Rituximab Continued Until Progression With Observation Only in Patients With Relapsed or Refractory, Indolent Non-Hodgkin's Lymphoma Who Completed and Responded to Rituximab-based Immunochemotherapy Induction and Initial 2-year Rituximab Maintenance Therapy Administered Subcutaneously|Active, not recruiting||Phase 3|694|Actual|Hoffmann-La Roche||2|||f|||||t|f|||t|||||2018-05-31 22:00:45.810386|2018-05-31 22:00:45.810386
NCT01461915|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13||2016-08-24|2016-08-25|2011-10-26|2011-10-28|Estimate||||2016-08-24|2016-08-26|Estimate|2016-08-25|2016-08-29|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|December 2012|Actual|2012-12-31||Interventional|PGPC1||Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane|A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer|Completed||Phase 2|61|Actual|Cantex Pharmaceuticals||3|||f||||||||||||||2018-05-31 22:00:46.325077|2018-05-31 22:00:46.325077
NCT01461902|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2015-01-30|2011-10-27|2011-10-28|Estimate|||||||2015-01-30|2015-02-02|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|PTBI||Vasospasm in Pediatric Traumatic Brain Injury|Measuring Vasospasm, Biomarkers, and Neurocognitive Outcomes in Pediatric Traumatic Brain Injury|Completed|||6|Actual|Duke University|||1||f||||t||||||||||2018-05-31 22:00:47.017139|2018-05-31 22:00:47.017139
NCT01461889|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2017-03-23|2011-10-27|2011-10-28|Estimate|||||||2017-03-23|2017-03-27|Actual|July 2011||2011-07-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|I-TRIGER||INR-Triggered Transfusion In GI Bleeders From ER|Transfusion-related Acute Lung Injury in Patients With Liver Disease|Terminated||Phase 3|50|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 22:00:47.94096|2018-05-31 22:00:47.94096
NCT01461876|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2015-10-11|2011-10-26|2011-10-28|Estimate|||||||2015-10-11|2015-10-14|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Obesity in HIV After Antiretroviral Therapy|Changes in Overweight/Obesity Status, hsCRP, and D-dimer in HIV-infected Patients After 12 Months of Initial Antiretroviral Treatment|Completed|||200|Actual|Duke University|||2||f||||f||||||Samples Without DNA|"~     These samples represent residual plasma retained after clinical testing (HIV RNA PCR) has~     been completed. Since the samples were obtained as part of routine clinical care, they are~     part of the HIV samples repository at Duke University Medical Center.~   "|||2018-05-31 22:00:48.548822|2018-05-31 22:00:48.548822
NCT01461863|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-09-26|2011-10-26|2011-10-28|Estimate|||||||2014-09-26|2014-09-29|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DarDar2B||DarDar Nutrition Study in HIV Breastfeeding Women|Effects of Protein-calorie Supplementation on HIV Disease in Breastfeeding Women|Completed||Phase 2/Phase 3|96|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 22:00:48.682675|2018-05-31 22:00:48.682675
NCT01461850|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-02-16|2011-10-26|2011-10-28|Estimate|||||||2018-02-16|2018-02-20|Estimate|September 2011|Actual|2011-09-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|February 2018|Actual|2018-02-28||Interventional|SCORPION||Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm|Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm|Active, not recruiting||Phase 3|171|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 22:00:48.770636|2018-05-31 22:00:48.770636
NCT01461837|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2017-12-14|2011-10-26|2011-10-28|Estimate|||||||2017-12-14|2017-12-18|Actual|January 2012||2012-01-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|HaploSCD||Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease|Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)|Recruiting||Phase 2|20|Anticipated|New York Medical College||1|||f||||t||||||||||2018-05-31 22:00:48.894121|2018-05-31 22:00:48.894121
NCT01455259|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-02-16|2011-10-17|2011-10-19|Estimate|||||||2016-02-16|2016-02-17|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors|Phase I/IIa AdCD40L Immunogene Therapy for Patients With Advanced Malignant Disease.|Completed||Phase 1/Phase 2|30|Actual|Uppsala University||1|||f||||f||||||||||2018-05-31 22:03:23.065827|2018-05-31 22:03:23.065827
NCT01461824|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2017-10-11||2018-03-23|2011-10-27|2011-10-28|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|September 2011||2011-09-30|March 2018|2018-03-31|July 2016|Actual|2016-07-31|April 2015|Actual|2015-04-30||Interventional|||Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects|Relationship Between Drug Exposure and DNA Markers With Depot Medroxyprogesterone Acetate-associated Side Effects in Adolescents|Completed||Phase 3|34|Actual|Nationwide Children's Hospital||3|||f||||t||||||||No||2018-05-31 22:00:49.085642|2018-05-31 22:00:49.085642
NCT01461811|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2013-08-09||2013-08-09|2011-10-27|2011-10-28|Estimate|2013-08-09|2013-10-17|Estimate||||2013-08-09|2013-10-17|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||This reporting group includes all enrolled and dispensed participants.|Prospective Study of an Investigational Toric Soft Contact Lens|ARES Registration Trial|Completed||N/A|154|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:00:49.670519|2018-05-31 22:00:49.670519
NCT01461798|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-10-26|2011-10-26|2011-10-28|Estimate|||||||2011-10-26|2011-10-28|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|Ben2011||Assessment of the Efficacy of Plant Stanol Esters in Reducing Cholesterol, Medellin 2011|Assessment of the Efficacy of Plant Stanol Esters in Reducing Cholesterol, Medellin 2011|Unknown status|Not yet recruiting|N/A|40|Anticipated|CES University||2|||f||||t||||||||||2018-05-31 22:00:50.311234|2018-05-31 22:00:50.311234
NCT01461785|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-22|||2017-10-13|2011-10-26|2011-10-28|Estimate|||||||2017-10-13|2017-10-17|Actual|April 2012|Actual|2012-04-30|July 2012|2012-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Use of Activated Platelet Rich Plasma (PRP) in Human Autologous Fat Transfer|The Use of Activated Platelet Rich Plasma (PRP) in Human Autologous Fat Transfer|Completed||Phase 2/Phase 3|25|Actual|Bergman Clinics||2|||f||||f||||||||||2018-05-31 22:00:50.473077|2018-05-31 22:00:50.473077
NCT01461772|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2017-05-27|2011-10-27|2011-10-28|Estimate|||||||2017-05-27|2017-05-31|Actual|December 2009||2009-12-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer|Comparison of Concurrent Chemoradiation Therapy With Weekly Cisplatin and Concurrent Chemoradiation Therapy With Weekly Carboplatin in Locally Advanced Cervical Cancer: Phase III Multicenter Prospective Randomized Controlled Trial|Terminated||Phase 3|21|Actual|Asan Medical Center||2||Because of very slow rate of enrollement|f||||f||||||||||2018-05-31 22:00:50.616787|2018-05-31 22:00:50.616787
NCT01461759|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-05-27|2011-10-27|2011-10-28|Estimate|||||||2017-05-27|2017-05-31|Actual|October 2011||2011-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer|A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer|Recruiting||Phase 2|59|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:00:50.759474|2018-05-31 22:00:50.759474
NCT01461746|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-05-27|2011-10-27|2011-10-28|Estimate|||||||2017-05-27|2017-05-31|Actual|October 2011||2011-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer|A Phase II Trial of Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients, With High-risk Endometrial Carcinoma After Staging Surgery|Recruiting||Phase 2|67|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:00:50.887922|2018-05-31 22:00:50.887922
NCT01461733|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2014-09-09||2014-09-09|2011-10-27|2011-10-28|Estimate|2014-09-09|2014-09-15|Estimate||||2014-09-09|2014-09-15|Estimate|July 2007||2007-07-31|September 2014|2014-09-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|AFIB||Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit|Atrial Fibrillation WITHOUT Hemodynamic Stability|Completed||Phase 4|25|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 22:00:51.000241|2018-05-31 22:00:51.000241
NCT01461720|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-03-30|2011-10-26|2011-10-28|Estimate|||||||2015-03-30|2015-04-01|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct|An Open Lable, Phase II Exploratory Study Assessing the Efficacy of Intravenous Autologous Mesenchymal Stem Cells in Patients With Middle Cerebral Artery Infarct|Unknown status|Recruiting|Phase 2|50|Anticipated|National University of Malaysia||2|||f||||f||||||||||2018-05-31 22:00:51.295821|2018-05-31 22:00:51.295821
NCT01461707|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2017-03-24||2017-10-24|2011-10-27|2011-10-28|Estimate|2017-03-24|2017-05-05|Actual||||2017-10-24|2017-11-30|Actual|October 2012||2012-10-31|October 2017|2017-10-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||The MOTHER (Mobile Technologies to Help Enhancing Regular Physical Activity) Trial for Pregnant Women|A Pilot Study of a Mobile Phone-Based Physical Activity Program in Pregnant Women|Completed||N/A|30|Actual|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 22:00:51.457907|2018-05-31 22:00:51.457907
NCT01461694|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-05-11|2011-10-26|2011-10-28|Estimate|||||||2012-05-11|2012-05-14|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Facial Hair Reduction Using Intense Pulsed Light (IPL) & Alexandrite Laser|Comparison of Intense Pulsed Light System 650 Advance Hand-Piece and Alexandrite Laser for Female Facial Hair Reduction|Unknown status|Enrolling by invitation|Phase 2/Phase 3|35|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 22:00:52.647067|2018-05-31 22:00:52.647067
NCT01461681|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2014-05-13|2011-10-27|2011-10-28|Estimate|||||||2014-05-13|2014-05-14|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Improving Care of Patients With Heart Failure|A Randomized Controlled Trial for Patients With Heart Failure|Completed||N/A|30|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:00:52.758247|2018-05-31 22:00:52.758247
NCT01461668|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2018-01-13||2018-03-29|2011-10-27|2011-10-28|Estimate|2018-03-29|2018-04-02|Actual||||2018-03-29|2018-04-02|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional||Number of participant totals reflect total subjects included in analysis.|Retapamulin for Reducing MRSA Nasal Carriage|Retapamulin for Reducing MRSA Nasal Carriage|Completed||Phase 4|53|Actual|University of California, Irvine|Recruitment challenges from low yield of mupirocin-resistant MRSA. Trial suspended when funding concluded. Extensive efforts to acquire new sites and new funding to extend trial requirement were unsuccessful. Trial was closed and analysis completed.|2|||f||||t||||||||||2018-05-31 22:00:53.095831|2018-05-31 22:00:53.095831
NCT01461655|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2013-04-17||2016-12-30|2011-10-26|2011-10-28|Estimate|2013-10-07|2013-12-04|Estimate||||2016-12-30|2017-02-15|Actual|November 2011||2011-11-30|December 2016|2016-12-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris|Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model|Completed||Phase 2|40|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 22:00:53.72441|2018-05-31 22:00:53.72441
NCT01461616|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-12-03|2011-10-26|2011-10-28|Estimate|||||||2012-12-03|2012-12-04|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis|Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on IGFBP-1 Production and Serum IGF-I in Subjects With Type 1 Diabetes Mellitus: An Open-label, Randomised, Triple Cross-over Trial|Completed||Phase 3|19|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 22:00:54.534683|2018-05-31 22:00:54.534683
NCT01461603|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-03-02|2011-10-26|2011-10-28|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|February 2013|Actual|2013-02-28||Interventional|||Local Effects of Amino Acids and 3-hydroxybutyrate in the Bilaterally Perfused Human Leg|Local Effects of Amino Acids and 3-hydroxybutyrate in the Bilaterally Perfused Human Leg|Unknown status|Active, not recruiting|N/A|10|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:00:54.792875|2018-05-31 22:00:54.792875
NCT01461590|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2015-03-31|2011-10-26|2011-10-28|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|Tx30||Study of Safe Blood Transfusion Volumes to Correct Acute Severe Anaemia|Phase II Trial of Transfusion Volumes in Children With Acute Severe Anaemia|Completed||Phase 2|160|Actual|KEMRI-Wellcome Trust Collaborative Research Program||2|||f||||f||||||||||2018-05-31 22:00:54.943491|2018-05-31 22:00:54.943491
NCT01461577|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-01-29|2011-10-27|2011-10-28|Estimate|||||||2013-01-29|2013-01-30|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GAUDI||Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure|A Multicenter, Open-label, Single-arm, 24 Week Phase IV Study Evaluating the Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure|Completed||Phase 4|89|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:00:55.330264|2018-05-31 22:00:55.330264
NCT01461564|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2014-06-15|2011-10-27|2011-10-28|Estimate|||||||2014-06-15|2014-06-17|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Carbon Dioxide During Screening Unsedated Colonoscopy|Randomized Clinical Trial to Compare Air Versus Carbon Dioxide in Screening Unsedated Colonoscopy.|Completed||Phase 4|200|Actual|Jagiellonian University||2|||f||||f||||||||||2018-05-31 22:00:55.461751|2018-05-31 22:00:55.461751
NCT01461551|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2014-11-05||2015-05-06|2011-10-26|2011-10-28|Estimate|2014-11-12|2014-11-20|Estimate||||2015-05-06|2015-05-22|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|February 2012|Actual|2012-02-29||Interventional|OPCAB||Anesthesia and Lymphocytes Apoptosis|Different Effects of Sevoflurane, Propofol and Combine of Sevoflurane and Propofol Maintained Anesthesia on Peripheral Blood Lymphocytes During Off-pump Coronary Artery Bypass Graft Surgery|Completed||N/A|105|Actual|Ruijin Hospital||3|||f||||t||||||||||2018-05-31 22:00:55.57958|2018-05-31 22:00:55.57958
NCT01461538|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2015-12-18||2016-02-05|2011-10-27|2011-10-28|Estimate|2016-02-05|2016-03-04|Estimate||||2016-02-05|2016-03-04|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All participants who received treatment. One additional patient enrolled, but withdrew prior to treatment group assignment.|Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies|A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies|Completed||Phase 2|84|Actual|Seattle Genetics, Inc.||3|||f||||f||||||||||2018-05-31 22:00:56.325822|2018-05-31 22:00:56.325822
NCT01461525|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2016-10-04|2011-10-27|2011-10-28|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|ASPIRE||Comparison of Sphincter Preservation Surgery and Abdominoperineal Resection (APR): Prospective Clinical Trial|Comparison of Sphincter Preservation Surgery Versus Abdominoperineal Resection for Low Rectal Cancer: Prospective Clinical Trial|Active, not recruiting||N/A|342|Actual|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 22:00:58.016834|2018-05-31 22:00:58.016834
NCT01461512|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-10-26|2011-10-26|2011-10-28|Estimate|||||||2011-10-26|2011-10-28|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Heme Arginate in Functional Magnetic Resonance Imaging (fMRI)|The Effects of Intravenous Heme Arginate on Functional Magnetic Resonance Imaging During Ischemia|Unknown status|Active, not recruiting|Phase 2|16|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 22:00:58.32149|2018-05-31 22:00:58.32149
NCT01461499|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2016-11-11||2017-08-15|2011-10-27|2011-10-28|Estimate|2017-08-15|2018-02-19|Actual||||2017-08-15|2018-02-19|Actual|October 2011||2011-10-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Shiga Microalbuminuria Reduction Trial-2|Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2|Completed||Phase 4|237|Actual|Shiga University||2|||f||||t||||||||||2018-05-31 22:00:58.834336|2018-05-31 22:00:58.834336
NCT01461486|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2013-01-23|2011-10-27|2011-10-28|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|OSAS||Continuous Positive Airway Pressure and Oral Appliances Treatments in Mild Obstructive Sleep Apnea|Effectiveness of Continuous Positive Airway Pressure and Oral Appliances in Mild Obstructive Sleep Apnea: a Randomized, Parallel, Single Blind and Controlled Study|Unknown status|Recruiting|N/A|90|Anticipated|Associação Fundo de Incentivo à Pesquisa||3|||f||||t||||||||||2018-05-31 22:00:59.259456|2018-05-31 22:00:59.259456
NCT01461473|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2016-12-08||2017-04-14|2011-10-26|2011-10-28|Estimate|2017-04-14|2017-05-17|Actual||||2017-04-14|2017-05-17|Actual|December 2011||2011-12-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|COMET||Comparative Outcomes Management With Electronic Data Technology (COMET) Study|R01: Comparative Outcomes Management With Electronic Data Technology (COMET) Study|Completed||N/A|131|Actual|Stanford University||2|||f||||t||||||||No||2018-05-31 22:00:59.486242|2018-05-31 22:00:59.486242
NCT01461460|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2016-05-02|2011-10-27|2011-10-28|Estimate|||||||2016-05-02|2016-05-03|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects|A Phase 1 Blinded, Placebo-controlled Crossover Study to Evaluate the Effects of Oral TR 701 Free Acid on the Electrocardiogram|Completed||Phase 1|48|Actual|Trius Therapeutics LLC||4|||f||||f||||||||||2018-05-31 22:01:00.372694|2018-05-31 22:01:00.372694
NCT01461252|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2014-03-31|2011-10-26|2011-10-28|Estimate|||||||2014-03-31|2014-04-01|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases|Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases|Withdrawn||Phase 1|0|Actual|Galil Medical||1||No patients were treated due to enrollment challenges.|f||||f||||||||||2018-05-31 22:01:04.563579|2018-05-31 22:01:04.563579
NCT01461447|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-05-23|2011-10-26|2011-10-28|Estimate|||||||2012-05-23|2012-05-24|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|HIVIS06||Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines|Safety and Immunogenicity Following Further Boosting With HIV-1 MVA-CMDR Vaccine to HIVIS03 Volunteers Who Were Primed With HIV-1 DNA Low Dose Intradermally or 'Standard' Dose Intramuscularly and Boosted With MVA-CMDR Vaccine|Completed||Phase 1/Phase 2|20|Actual|Muhimbili University of Health and Allied Sciences||1|||f||||t||||||||||2018-05-31 22:01:00.520666|2018-05-31 22:01:00.520666
NCT01461434|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2015-12-20|2011-10-27|2011-10-28|Estimate|||||||2015-12-20|2015-12-22|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|May 2015|Actual|2015-05-31||Interventional|GRAF||Graz Study on the Risk of Atrial Fibrillation|Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients|Unknown status|Active, not recruiting|Phase 4|82|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 22:01:00.605555|2018-05-31 22:01:00.605555
NCT01461421|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-04-06|2011-10-26|2011-10-28|Estimate|||||||2017-04-06|2017-04-07|Actual|July 2011||2011-07-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Acceptance Based Behavioral Intervention for Weight Loss: A Randomized Trial|Acceptance Based Behavioral Intervention for Weight Loss: A Randomized Trial|Completed||N/A|160|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 22:01:00.725211|2018-05-31 22:01:00.725211
NCT01461408|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2013-10-09|2011-10-27|2011-10-28|Estimate|||||||2013-10-09|2013-10-10|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Promoting Human Papillomavirus (HPV) Vaccination Through African American Beauty Salons|Promoting HPV Vaccination Through African American Beauty Salons: a Pilot Test of a Culturally-Competent Education and Empowerment Strategy|Completed||N/A|240|Actual|MEE Productions, Inc.||16|||f||||t||||||||||2018-05-31 22:01:00.832167|2018-05-31 22:01:00.832167
NCT01461395|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2012-08-23|2011-10-27|2011-10-28|Estimate|||||||2012-08-23|2012-08-24|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Polscope Sperm: A Non-invasive Method to Assess DNA Damage in Individual Sperm|A Non-invasive Method to Assess DNA Damage in Individual Sperm|Completed|||84|Actual|University of South Florida|||||f||||t||||||Samples With DNA|"~     sperm~   "|||2018-05-31 22:01:00.983741|2018-05-31 22:01:00.983741
NCT01461382|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-27|2011-10-27|2011-10-28|Estimate|||||||2011-10-27|2011-10-28|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss|Workplace Intervention: Activity Monitoring as a Tool for Corporate Wellness and Weight Loss|Completed||N/A|36|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:01:01.118607|2018-05-31 22:01:01.118607
NCT01461369|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2014-03-12||2014-04-29|2011-10-26|2011-10-28|Estimate|2014-04-29|2014-05-26|Estimate||||2014-04-29|2014-05-26|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Study of Diclofenac Capsules to Treat Osteoarthritis Pain|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy and Safety Study of Diclofenac [Test] Capsules in Subjects With Osteoarthritis of the Knee or Hip|Completed||Phase 3|305|Actual|Iroko Pharmaceuticals, LLC||3|||f||||f||||||||||2018-05-31 22:01:02.430811|2018-05-31 22:01:02.430811
NCT01461356|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-10-27|2011-10-27|2011-10-28|Estimate|||||||2011-10-27|2011-10-28|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Minimally Invasive Surgical Approaches In Total Knee Arthroplasty|Prospective, Randomized, Controlled, Blinded Functional Outcomes Of Two Contemporary Surgical Approaches In Total Knee Arthroplasty|Completed||N/A|40|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:01:03.460876|2018-05-31 22:01:03.460876
NCT01461343|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-03-21|2011-10-26|2011-10-28|Estimate|||||||2018-03-21|2018-03-23|Actual|February 2013||2013-02-28|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|November 21, 2017|Actual|2017-11-21||Interventional|||Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging|Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Arterial Hypertension Using Functional Positron Emission Tomography Imaging|Completed||N/A|16|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:01:03.662349|2018-05-31 22:01:03.662349
NCT01461330|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-01-25|2011-10-27|2011-10-28|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2011|Actual|2011-02-28|January 2017|2017-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Lifestyle Changes in Patients With Type 2 Diabetes Mellitus and Hypertension|Lifestyle Changes in Patients With Type 2 DM and Hypertension: DASH Diet and Exercise Effects|Terminated||N/A|40|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 22:01:03.745398|2018-05-31 22:01:03.745398
NCT01461317|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-03-14|2011-10-27|2011-10-28|Estimate|||||||2017-03-14|2017-03-15|Actual|November 30, 2011|Actual|2011-11-30|March 2017|2017-03-31|August 8, 2016|Actual|2016-08-08|August 8, 2016|Actual|2016-08-08||Interventional|||Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis|A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis|Completed||Phase 2|121|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:01:03.838917|2018-05-31 22:01:03.838917
NCT01461304|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-05-02|2011-10-27|2011-10-28|Estimate|||||||2018-05-02|2018-05-03|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism|Dietary Therapy for Inherited Disorders of Energy Metabolism|Available|||||University of Pittsburgh|||||||||||||||||||2018-05-31 22:01:04.013465|2018-05-31 22:01:04.013465
NCT01461291|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-03-29|2011-10-26|2011-10-28|Estimate|||||||2018-03-29|2018-04-02|Actual|November 30, 2011|Actual|2011-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 4, 2017|Actual|2017-08-04||Interventional|||Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery|A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery|Active, not recruiting||Phase 2/Phase 3|1200|Anticipated|Glaukos Corporation||2|||f||||t||||||||||2018-05-31 22:01:04.151102|2018-05-31 22:01:04.151102
NCT01461278|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-12-14|2011-10-26|2011-10-28|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2011||2011-10-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery|A Prospective, Randomized, Single-Masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery|Active, not recruiting||Phase 3|1200|Anticipated|Glaukos Corporation||2|||f||||t||||||||||2018-05-31 22:01:04.336482|2018-05-31 22:01:04.336482
NCT01461239|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2017-04-05|2011-10-26|2011-10-28|Estimate|||||||2017-04-05|2017-04-06|Actual|July 2009||2009-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Comparison of Endodontically Treated Teeth Restored With Fiber Posts or Cast Metal Posts|Randomized Clinical Comparison of Endodontically Treated Teeth Restored With Fiber Posts or Cast Metal Posts|Recruiting||Phase 3|200|Anticipated|Federal University of Pelotas||3|||f||||f||||||||||2018-05-31 22:01:04.723192|2018-05-31 22:01:04.723192
NCT01461226|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-28|2011-10-25|2011-10-28|Estimate|||||||2011-10-28|2011-10-31|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|EDOC||Endothelial Dysfunction in Obese Children|Adolescent Obesity: What Determines Vascular Endothelial Dysfunction And Is The Process Reversible?|Unknown status|Recruiting|Phase 3|60|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||||2018-05-31 22:01:04.895592|2018-05-31 22:01:04.895592
NCT01461213|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-11-16|2011-10-27|2011-10-28|Estimate|||||||2017-11-16|2017-11-17|Actual|October 2011||2011-10-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Gene Therapy for Blindness Caused by Choroideremia|An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)|Completed||Phase 1/Phase 2|14|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 22:01:05.005669|2018-05-31 22:01:05.005669
NCT01461200|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-03-26|2011-10-27|2011-10-28|Estimate|||||||2014-03-26|2014-03-27|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Observational|||Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome|A Parallel Group Observational Study of the Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome|Completed|||40|Actual|University of Chicago|||2||f||||f||||||||||2018-05-31 22:01:05.11867|2018-05-31 22:01:05.11867
NCT01461187|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-26|2011-10-26|2011-10-27|Estimate|||||||2011-10-26|2011-10-27|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Effects in Type of Birth of Physical Exercise During Pregnancy|Effects in Type of Birth of Physical Exercise During Pregnancy|Completed||N/A|66|Actual|Hospital do Servidor Publico Estadual||2|||f||||t||||||||||2018-05-31 22:01:05.215513|2018-05-31 22:01:05.215513
NCT01461174|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2015-02-03|2011-10-25|2011-10-27|Estimate|||||||2015-02-03|2015-02-04|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers|Effects of 15-day Donepezil and Memantine on Cognitive Functions After a 24 Hours Sleep Deprivation Challenge in Healthy Volunteers: a Double-blind, Placebo-controlled, Randomised, Cross-over Study, With Modafinil as Positive Control|Completed||Phase 1|36|Actual|Qualissima||3|||f||||t||||||||||2018-05-31 22:01:05.331007|2018-05-31 22:01:05.331007
NCT01461161|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-03-30|2011-10-25|2011-10-27|Estimate|||||||2012-03-30|2012-04-02|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl|A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl|Completed||Phase 1|32|Actual|Reata Pharmaceuticals, Inc.||3|||f||||||||||||||2018-05-31 22:01:05.515661|2018-05-31 22:01:05.515661
NCT01461148|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-06-22|2011-10-26|2011-10-27|Estimate|||||||2015-06-22|2015-06-23|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Vaccination Against MSI Colorectal Cancer|Phase I/IIa Study of Immunization With Frameshift Peptides Administered With Montanide® ISA-51 VG in Patients With Advanced MSI-H Colorectal Cancer|Completed||Phase 1/Phase 2|22|Actual|Oryx GmbH & Co. KG||1|||f||||t||||||||||2018-05-31 22:01:05.629934|2018-05-31 22:01:05.629934
NCT01461109|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2014-06-02|2011-10-25|2011-10-27|Estimate|||||||2014-06-02|2014-06-04|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|September 2012|Actual|2012-09-30||Interventional|||Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls|Evaluation of [18F] CFPyPB PET as a Marker of Glycine Transporter-1 (GlyT1) Receptor in Subjects With Parkinson Disease, Alzheimer Disease and Healthy Subjects|Completed||Phase 1|4|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-05-31 22:01:05.75547|2018-05-31 22:01:05.75547
NCT01461096|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2016-12-14||2017-02-10|2011-10-26|2011-10-27|Estimate|2016-12-14|2017-02-07|Estimate||||2017-02-10|2017-03-21|Actual|March 2012||2012-03-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional||All participants randomized who had results for the respective baseline measure available. The numbers of participants for each measure are shown below.|Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women|A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men and Women|Completed||Phase 3|575|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 22:01:05.96647|2018-05-31 22:01:05.96647
NCT01461083|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2014-06-02|2011-10-25|2011-10-27|Estimate|||||||2014-06-02|2014-06-04|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|November 2012|Actual|2012-11-30||Interventional|MPPF||Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a|Phase I Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a in Subjects With Parkinson Disease and Healthy Subjects|Completed||Phase 1|19|Actual|Institute for Neurodegenerative Disorders||1|||f||||t||||||||||2018-05-31 22:01:07.310134|2018-05-31 22:01:07.310134
NCT01461070|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-04-04|2011-10-26|2011-10-27|Estimate|||||||2018-04-04|2018-04-05|Actual|August 10, 2011||2011-08-10|July 12, 2017|2017-07-12||||||||Observational|||Intestine Bacteria and Breast Cancer Risk|BRANCH:Fecal Microbiota Among Participants in a Pre-paid Health Plan|Completed|||175|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:01:07.43303|2018-05-31 22:01:07.43303
NCT01461057|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|2016-05-19||2018-04-04|2011-10-26|2011-10-27|Estimate|2016-05-19|2016-06-27|Estimate||||2018-04-04|2018-04-05|Actual|December 6, 2011||2011-12-06|April 2018|2018-04-30|October 31, 2017|Actual|2017-10-31|March 1, 2015|Actual|2015-03-01||Interventional|||A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer|An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer|Completed||Phase 2|30|Actual|Hoffmann-La Roche||2|||f||||f||||||||||2018-05-31 22:01:09.150073|2018-05-31 22:01:09.150073
NCT01460875|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2016-05-17|2011-10-25|2011-10-27|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2008||2008-04-30|May 2016|2016-05-31||||January 2014|Actual|2014-01-31||Interventional|||Recombinant Interferon Alfa-2b in Treating Patients With Melanoma|Pilot Study of IFN-alpha-2b Dose Reduction With Dose Optimization|Unknown status|Active, not recruiting|N/A|35|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:01:14.015529|2018-05-31 22:01:14.015529
NCT01461044|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2015-10-22||2015-12-18|2011-10-26|2011-10-27|Estimate|2015-12-18|2016-01-26|Estimate||||2015-12-18|2016-01-26|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational||Efficacy population included all participants who did not violate any inclusion or exclusion.|An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer|An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin® (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.|Completed|||228|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:01:10.327675|2018-05-31 22:01:10.327675
NCT01461031|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2012-07-04|2011-10-26|2011-10-27|Estimate|||||||2012-07-04|2012-07-06|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Effect of Nefopam on Acute Postoperative Pain in Patients Undergoing Orthognathic Surgery|Effect of Nefopam on Acute Postoperative Pain in Patients Undergoing Orthognathic Surgery|Unknown status|Recruiting|N/A|40|Anticipated|The Catholic University of Korea|||||f||||t||||||||||2018-05-31 22:01:12.027583|2018-05-31 22:01:12.027583
NCT01461018|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-11-25|2011-10-26|2011-10-27|Estimate|||||||2014-11-25|2014-12-02|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)|A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects With Primary Immunodeficiency|Completed||Phase 3|22|Actual|CSL Behring||1|||f||||||||||||||2018-05-31 22:01:12.193918|2018-05-31 22:01:12.193918
NCT01461005|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-10-06|2011-10-26|2011-10-27|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|DSS||A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)|A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS)|Completed||N/A|1|Actual|Paradigm Spine||1|||f||||f||||||||||2018-05-31 22:01:12.427972|2018-05-31 22:01:12.427972
NCT01460992|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-11-27|2011-10-26|2011-10-27|Estimate|||||||2013-11-27|2013-11-28|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|ProMRIAFFIRM||ProMRI AFFIRM Study of the EVIA/ENTOVIS Pacemaker With Safio S Pacemaker Leads|Master Study for the MRI Compatibility of the EVIA/ENTOVIS Pacemaker in Combination With Safio S Pacemaker Lead|Completed|||121|Actual|Biotronik SE & Co. KG|||1||f||||t||||||||||2018-05-31 22:01:12.564947|2018-05-31 22:01:12.564947
NCT01460979|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2016-02-26|2011-10-26|2011-10-27|Estimate|||||||2016-02-26|2016-02-29|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma|Activity, Tolerability, Safety of Temsirolimus in Women With Ovarian Cancer Who Progressed During Previous Platinum Chemotherapy or Within 6 Months After Therapy or Advanced Endometrial Carcinoma|Completed||Phase 2|47|Actual|AGO Study Group||1|||f||||f||||||||||2018-05-31 22:01:12.791806|2018-05-31 22:01:12.791806
NCT01460966|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2017-04-19|2011-10-25|2011-10-27|Estimate|||||||2017-04-19|2017-04-20|Actual|July 2012||2012-07-31|April 2017|2017-04-30|January 31, 2017|Actual|2017-01-31|December 23, 2015|Actual|2015-12-23||Interventional|VAMPIRE3||Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)|Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)|Completed||N/A|200|Actual|Yokohama City University Medical Center||2|||f||||t||||||||||2018-05-31 22:01:12.962545|2018-05-31 22:01:12.962545
NCT01460953|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-10-14|2011-10-26|2011-10-27|Estimate|||||||2015-10-14|2015-10-16|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Use of a Training Video to Teach Medical Students About Health Literacy|Use of a Training Video to Teach Medical Students About Health Literacy|Completed||N/A|110|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 22:01:13.073808|2018-05-31 22:01:13.073808
NCT01460940|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2017-01-24||2017-11-09|2011-10-26|2011-10-27|Estimate|2017-01-24|2017-03-14|Actual||||2017-11-09|2017-11-14|Actual|October 13, 2011||2011-10-13|November 2017|2017-11-30|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|||A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma|Completed||Phase 2|24|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:01:13.187825|2018-05-31 22:01:13.187825
NCT01460927|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-09-06||2014-06-04|2011-10-25|2011-10-27|Estimate|2014-06-04|2014-07-04|Estimate||||2014-06-04|2014-07-04|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides|Clinical Study to Evaluate the Performance of TriActive+ RF for the Non-invasive Treatment of Wrinkles & Rhytides|Completed||N/A|25|Actual|Deka Medical, Inc.||1|||f||||t||||||||||2018-05-31 22:01:13.564578|2018-05-31 22:01:13.564578
NCT01460914|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-04-13|2011-10-26|2011-10-27|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2011||2011-10-31|April 2018|2018-04-30|October 2050|Anticipated|2050-10-31|September 2050|Anticipated|2050-09-30||Observational|||Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment|Outcomes of Cutaneous T-Cell Lymphoma and Chronic Graft-Versus-Host Disease in Patients Treated With Extracorporeal Photopheresis|Active, not recruiting|||100|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-05-31 22:01:13.727844|2018-05-31 22:01:13.727844
NCT01460901|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-02-04|2011-10-26|2011-10-27|Estimate|||||||2015-02-04|2015-02-06|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|STALLONe||Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma|Phase I Study of Donor Derived,Gene Modified, Multi-virus-specific, Cytotoxic T-Lymphocytes Redirected to the Tumor Marker GD2 for Relapsed/Refractory Neuroblastoma Post-allogeneic Stem Cell Transplantation With a Submyeloblative Conditioning Regimen|Completed||Phase 1|5|Actual|Children's Mercy Hospital Kansas City|||||f||||t||||||||||2018-05-31 22:01:13.791619|2018-05-31 22:01:13.791619
NCT01460888|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2013-08-16|2011-10-26|2011-10-27|Estimate|||||||2013-08-16|2013-08-19|Estimate|July 2013||2013-07-31|December 2011|2011-12-31|August 2018|Anticipated|2018-08-31|July 2015|Anticipated|2015-07-31||Interventional|ROCOCO||Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus|Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.|Recruiting||Phase 1|36|Anticipated|The Christie NHS Foundation Trust||5|||f||||t||||||||||2018-05-31 22:01:13.871669|2018-05-31 22:01:13.871669
NCT01460862|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-11-15|2011-10-25|2011-10-27|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2011||2011-05-31|November 2017|2017-11-30||||||||Observational|||Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations|Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations Among Patients With Uncontrolled Asthma Receiving High Dose Inhaled Corticosteroids|Active, not recruiting|||||Novartis|||1||f||||||||||||||2018-05-31 22:01:14.123549|2018-05-31 22:01:14.123549
NCT01460849|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-11-15|2011-10-25|2011-10-27|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2011||2011-03-31|November 2017|2017-11-30||||||||Observational|||Assess Increased Mortality Risk With Each Year of Delayed Tobramycin Solution (TIS) Initiation, and Effect of TIS on Mortality Across Study Centers|Assess the Increased Mortality Risk With Each Year of Delayed TIS Initiation, and the Effect of TIS on Mortality Across Study Centers|Active, not recruiting|||||Novartis|||||f||||||||||||||2018-05-31 22:01:14.18565|2018-05-31 22:01:14.18565
NCT01460836|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2011-10-26|2011-10-26|2011-10-27|Estimate|||||||2011-10-26|2011-10-27|Estimate|April 2010||2010-04-30|October 2011|2011-10-31||||October 2010|Actual|2010-10-31||Observational|||Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis|Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis|Completed|||||Novartis|||2||f||||||||||||||2018-05-31 22:01:14.259011|2018-05-31 22:01:14.259011
NCT01460823|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-12-15|2011-10-26|2011-10-27|Estimate|||||||2014-12-15|2014-12-16|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|October 2012|Actual|2012-10-31||Interventional|PCI-I||Percutaneous Cochlear Implantation: Implementation of Technique|Percutaneous Cochlear Implantation: Implementation of Technique|Terminated||N/A|5|Actual|Vanderbilt University||1||Currently in the process of submitting IDE to the FDA|f||||t||||||||||2018-05-31 22:01:14.338828|2018-05-31 22:01:14.338828
NCT01460810|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-08-29|2011-10-26|2011-10-27|Estimate|||||||2017-08-29|2017-08-31|Actual|July 2011||2011-07-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma|A Prospective Pilot Study of Surgical Radiation Shielding With Vitrectomy & Silicone Oil Tamponade for the Protection of Radiation-induced Ocular Injury in the Treatment of Choroidal Melanoma With Radioactive Iodine-125 Plaque Brachytherapy|Recruiting||N/A|20|Anticipated|University of Colorado, Denver||1|||f||||f||||||||No|Data will be released in publications, but no information will be used that could disclose the subjects' identity.|2018-05-31 22:01:14.551107|2018-05-31 22:01:14.551107
NCT01460797|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2011-10-25|2011-10-25|2011-10-27|Estimate|||||||2011-10-25|2011-10-27|Estimate|October 2004||2004-10-31|October 2011|2011-10-31|October 2006|Actual|2006-10-31|June 2005|Actual|2005-06-30||Interventional|||Metabolic Effects of a Caloric Restriction High/Low Glycemic Index Diet Plus Metformin in Overweight/Obese Subjects|Effects of a Caloric Restriction High/Low-glycemic Index Diets and in Combination With Metformin on Glucose Metabolism, Lipid Profile and Body Composition in Overweight/Obese Subjects|Completed||N/A|41|Actual|University of Brasilia||3|||f||||t||||||||||2018-05-31 22:01:14.692171|2018-05-31 22:01:14.692171
NCT01460784|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-12-01|2011-10-26|2011-10-27|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|STAGES||STAGES Trial: Study of Adiposity, Growth and Endocrine Stages|Changes in Adipokines and Adiposity During Puberty and Young Adulthood|Completed|||575|Actual|University of Utah|||3||f||||t||||||Samples With DNA|"~     Buffy coat in -80F long-term storage~   "|||2018-05-31 22:01:14.785328|2018-05-31 22:01:14.785328
NCT01460771|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2014-05-20|2011-10-26|2011-10-27|Estimate|||||||2014-05-20|2014-05-22|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Transcranial Direct-Current Stimulation in Childhood Dystonia|Pilot Open-label and Blinded Clinical Trial of Transcranial Direct-current Stimulation in Childhood Dystonia|Unknown status|Recruiting|Phase 2|100|Anticipated|University of Southern California||2|||f||||f||||||||||2018-05-31 22:01:14.862862|2018-05-31 22:01:14.862862
NCT01460758|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2014-04-25|2011-10-26|2011-10-27|Estimate|||||||2014-04-25|2014-04-28|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|ACDC||Effectiveness of rTMS With Double-Cone-Coil in Patients With Major Depression|Effectiveness of Medial Frontal Repetitive Transcranial Magnetic Stimulation With Double-Cone-Coil in Patients With Major Depression|Completed||N/A|45|Actual|University of Regensburg||3|||f||||f||||||||||2018-05-31 22:01:14.999667|2018-05-31 22:01:14.999667
NCT01460745|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2014-02-03|2011-10-25|2011-10-27|Estimate|||||||2014-02-03|2014-02-04|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|RESECT||A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice|A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice|Completed|||60|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 22:01:15.147837|2018-05-31 22:01:15.147837
NCT01460732|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2012-02-05||2012-07-08|2011-10-26|2011-10-27|Estimate|2012-05-01|2012-06-12|Estimate||||2012-07-08|2012-07-10|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Home Versus Ambulatory Monitoring, Diurnal Blood Pressure Profile, Detection of Non-Dippers|Home Versus Ambulatory Monitoring in the Assessment of the Diurnal Blood Pressure Profile and the Detection of Non-Dippers|Completed||N/A|81|Actual|University of Athens||1|||f||||f||||||||||2018-05-31 22:01:15.256864|2018-05-31 22:01:15.256864
NCT01460719|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-04-17|2011-10-25|2011-10-27|Estimate|||||||2017-04-17|2017-04-18|Actual|January 24, 2012|Actual|2012-01-24|April 2017|2017-04-30|September 25, 2012|Actual|2012-09-25|September 25, 2012|Actual|2012-09-25||Interventional|||A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With HM Receiving Treatment With Anti-CD20 Monoclonal Antibodies (V212-013)|A Phase I, Open-Label, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies Receiving Treatment With Anti-CD20 Monoclonal Antibodies|Completed||Phase 1|80|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 22:01:16.218869|2018-05-31 22:01:16.218869
NCT01460706|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2013-12-11|2011-10-26|2011-10-27|Estimate|||||||2013-12-11|2013-12-12|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DOTAGLI||Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT|PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC|Completed||Phase 2/Phase 3|30|Actual|Turku University Hospital||1|||f||||t||||||||||2018-05-31 22:01:16.550218|2018-05-31 22:01:16.550218
NCT01460693|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2018-04-20|2011-10-26|2011-10-27|Estimate|||||||2018-04-20|2018-04-24|Actual|August 2008||2008-08-31|April 2018|2018-04-30|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|SPIRIT2||Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia|A Phase III, Prospective Randomised Comparison of Imatinib (STI571, Glivec/Gleevec) 400mg Daily Versus Dasatinib 100mg in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia|Completed||Phase 3|814|Actual|Newcastle University||2|||f||||t||||||||||2018-05-31 22:01:16.888206|2018-05-31 22:01:16.888206
NCT01460680|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-25|2011-10-25|2011-10-27|Estimate|||||||2011-10-25|2011-10-27|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|June 2013|Anticipated|2013-06-30|October 2012|Anticipated|2012-10-31||Observational|||Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE)|Association of Membrane Polyunsaturated Fatty Acid Content and Intracellular Magnesium Concentration With Mental and Physical Symptoms in Fibromyalgia and SLE: a Case-control Study|Unknown status|Not yet recruiting||300|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 22:01:17.353141|2018-05-31 22:01:17.353141
NCT01460667|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-26|2011-10-26|2011-10-27|Estimate|||||||2011-10-26|2011-10-27|Estimate|October 2011||2011-10-31|October 2011|2011-10-31||||October 2012|Anticipated|2012-10-31||Interventional|IV APAP||Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients|A Randomized, Double-Blind, Placebo-Controlled, Single Center Study of IV Acetaminophen for the Treatment of Post-Operative Pain After Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP)|Unknown status|Recruiting|N/A|85|Anticipated|McLaren Regional Medical Center||2|||f||||t||||||||||2018-05-31 22:01:17.471979|2018-05-31 22:01:17.471979
NCT01460654|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2018-02-22|2011-10-25|2011-10-27|Estimate|||||||2018-02-22|2018-02-26|Actual|October 2011||2011-10-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Testosterone and Alendronate in Hypogonadal Men|Testosterone and Alendronate in Hypogonadal Men|Suspended||Phase 2|100|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 22:01:17.77938|2018-05-31 22:01:17.77938
NCT01460641|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2016-09-21|2011-10-25|2011-10-27|Estimate|||||||2016-09-21|2016-09-23|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Observational|||Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer|Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer|Active, not recruiting|||21|Actual|Stanford University|||1||f||||t||||||Samples With DNA|"~     If the patient undergoes surgery to remove the lesion in the rectum, the surgical specimen~     will be examined by the pathologist, who will perform a variety of tests to detect evidence~     of new blood vessel growth. The sample will be stored per routine protocol of the Stanford~     Department of Pathology.~   "|||2018-05-31 22:01:18.181015|2018-05-31 22:01:18.181015
NCT01460628|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|2016-07-12||2017-01-25|2011-10-26|2011-10-27|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|October 2011||2011-10-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Nuvigil on Fatigue|The Effect of Armodafinil (Nuvigil) on Fatigue and Quality of Life in Peri- and Postmenopausal Women|Completed||Phase 4|25|Actual|Massachusetts General Hospital||1|||f||||||||||||||2018-05-31 22:01:18.521374|2018-05-31 22:01:18.521374
NCT01460615|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-07-01|2011-10-26|2011-10-27|Estimate|||||||2015-07-01|2015-07-02|Estimate|February 2011||2011-02-28|October 2011|2011-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Cortisone Treatment for the Prevention of Postoperative Pancreatitis and Pancreatitis-induced Complications After Pancreaticoduodenectomy (Whipple Operation)||Completed||Phase 2|||Tampere University Hospital|||||f||||||||||||||2018-05-31 22:01:19.07338|2018-05-31 22:01:19.07338
NCT01460602|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2011-10-25|2011-10-25|2011-10-27|Estimate|||||||2011-10-25|2011-10-27|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma|Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma|Terminated||Phase 1/Phase 2|30|Anticipated|Louisiana State University Health Sciences Center Shreveport||2||Investigator has relocated to MD Anderson|f||||f||||||||||2018-05-31 22:01:19.205278|2018-05-31 22:01:19.205278
NCT01460589|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-01-23|2011-10-26|2011-10-27|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2011||2011-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|ECTX||Early Commencement of Adjuvant Chemotherapy for Colon Cancer|Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Trial|Recruiting||Phase 3|440|Anticipated|Kyungpook National University||2|||f||||t||||||||||2018-05-31 22:01:19.312063|2018-05-31 22:01:19.312063
NCT01460576|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-05-02|2011-10-26|2011-10-27|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2011||2011-09-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|IMPROV||Improving Prematurity-Related Respiratory Outcomes at Vanderbilt|Improving Prematurity-Related Respiratory Outcomes at Vanderbilt: The Prematurity and Respiratory Outcomes Program (PROP)|Completed|||253|Actual|Vanderbilt University Medical Center|||||f||||t||||||Samples With DNA|"~     saliva for DNA, plasma, red blood cells, urine and tracheal aspirates~   "|Undecided||2018-05-31 22:01:19.42188|2018-05-31 22:01:19.42188
NCT01460563|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-12-26|2011-10-26|2011-10-27|Estimate|||||||2011-12-26|2011-12-29|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia|Effects of Valproic Acid and Magnesium Sulphate on Rocuronium Requirement and Postoperative Analgesia in Patients Undergoing Craniotomy for Cerebrovascular Surgery|Unknown status|Recruiting|N/A|60|Anticipated|Seoul National University Bundang Hospital||3|||f||||f||||||||||2018-05-31 22:01:19.511775|2018-05-31 22:01:19.511775
NCT01460550|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-03-31|2011-10-25|2011-10-27|Estimate|||||||2015-03-31|2015-04-01|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction|Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial|Unknown status|Recruiting|Phase 3|240|Anticipated|Kobe University||1|||f||||t||||||||||2018-05-31 22:01:19.609366|2018-05-31 22:01:19.609366
NCT01460355|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2011-10-25|2011-10-25|2011-10-26|Estimate|||||||2011-10-25|2011-10-26|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone|Surgery Associated to Intraoperative Botulinum Toxin A for Large Angle Horizontal Strabismus: a Pilot Study|Completed||Phase 4|23|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 22:01:22.296464|2018-05-31 22:01:22.296464
NCT01460537|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-10-02|2011-10-26|2011-10-27|Estimate|||||||2017-10-02|2017-10-04|Actual|November 18, 2011|Actual|2011-11-18|October 2017|2017-10-31|December 18, 2015|Actual|2015-12-18|July 20, 2015|Actual|2015-07-20||Interventional|||Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer|A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy|Completed||Phase 1|50|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:01:19.74685|2018-05-31 22:01:19.74685
NCT01460524|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2015-06-23|2011-10-26|2011-10-27|Estimate|||||||2015-06-23|2015-06-24|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Nebulized Hypertonic Saline for Bronchiolitis|Observational Study on the Use of Hypertonic Saline for the Treatment of Bronchiolitis|Completed|||2580|Actual|Hôpital Armand Trousseau|||||f||||f||||||||||2018-05-31 22:01:19.873484|2018-05-31 22:01:19.873484
NCT01460511|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-07-11|2011-10-25|2011-10-27|Estimate|||||||2012-07-11|2012-07-12|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Evaluation of Efficacy and Safety of E004 in Children With Asthma|Phase III Study of Epinephrine Inhalation Aerosol for Evaluation of Efficacy and Safety of E004 in Children With Asthma|Completed||Phase 3|70|Actual|Amphastar Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 22:01:20.004106|2018-05-31 22:01:20.004106
NCT01460498|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-10-19|2011-10-26|2011-10-27|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2012|Actual|2012-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)|Phase I-II Study of Low-Dose Azacitidine (Vidaza) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors (VZ-CML-PI-0236)|Active, not recruiting||Phase 1/Phase 2|48|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 22:01:20.27154|2018-05-31 22:01:20.27154
NCT01460472|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2016-07-28|2011-10-24|2011-10-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Immunotherapy With Racotumomab in Advanced Lung Cancer|A Prospective, Randomized, Multicenter, Open Label Phase III Study of Active Specific Immunotherapy With Racotumomab Plus Best Support Treatment Versus Best Support Treatment in Patients With Advanced Non-small Cell Lung Camcer.|Active, not recruiting||Phase 3|1082|Anticipated|Recombio SL||2|||f||||t||||||||||2018-05-31 22:01:20.480191|2018-05-31 22:01:20.480191
NCT01460459|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-24|2011-10-24|2011-10-26|Estimate|||||||2011-10-24|2011-10-26|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Self-monitoring of Blood Glucose in Insulin-treated Patients With Type 2 Diabetes|Self-monitoring of Blood Glucose in Insulin-treated Patients With Type 2 Diabetes: a 9-month Randomised Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|Medical Research Foundation, The Netherlands||3|||f||||f||||||||||2018-05-31 22:01:20.691991|2018-05-31 22:01:20.691991
NCT01460446|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2013-11-14||2014-01-07|2011-10-25|2011-10-26|Estimate|2014-01-07|2014-02-06|Estimate||||2014-01-07|2014-02-06|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ABACUS|Intent-to-treat population: All randomized participants.|ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?|A Prospective, Multi-centre Study With Diabetic Patients Randomized to 24 Weeks Treatment Supported by Either Accu-Chek® Aviva Expert Blood Glucose Meter With an Integrated Bolus Advisor or MDI Standard Therapy With Accu-Chek® Aviva Nano Meter (Without Bolus Advisor)|Completed||N/A|218|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:01:20.810867|2018-05-31 22:01:20.810867
NCT01460433|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-09-04|2011-10-24|2011-10-26|Estimate|||||||2014-09-04|2014-09-05|Estimate|September 2008||2008-09-30|September 2014|2014-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Problems With Immune Recovery in the Gut Tissue|A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution (C)|Completed|||21|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples Without DNA|"~     Blood, lymphatic tissues and anogenital swabs.~   "|||2018-05-31 22:01:21.346672|2018-05-31 22:01:21.346672
NCT01460420|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2017-07-05|2011-10-25|2011-10-26|Estimate|||||||2017-07-05|2017-07-06|Actual|November 2011||2011-11-30|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|June 2017|Actual|2017-06-30||Interventional|EMN-alloRIC||Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation|European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients|Completed||Phase 1/Phase 2|49|Actual|European Myeloma Network||1|||f||||t||||||||||2018-05-31 22:01:21.453934|2018-05-31 22:01:21.453934
NCT01460407|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-04-24|2011-10-24|2011-10-26|Estimate|||||||2012-04-24|2012-04-25|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Effect of Clarithromycin on LY2216684|Effect of Clarithromycin on the Pharmacokinetics of LY2216684 in Healthy Subjects|Completed||Phase 1|16|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:01:21.672422|2018-05-31 22:01:21.672422
NCT01460394|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2016-03-31|2011-10-25|2011-10-26|Estimate|||||||2016-03-31|2016-04-01|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Normative Data of Brain Network Activation in Adolescents and Young Adults|Establishment of Normative Data of Brain Network Activation (BNA) Using Evoked Response Potentials in Adolescents and Young Adults|Completed|||71|Actual|ElMindA Ltd|||1||f||||f||||||||Yes||2018-05-31 22:01:21.829916|2018-05-31 22:01:21.829916
NCT01460381|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-11-01|2011-10-24|2011-10-26|Estimate|||||||2012-11-01|2012-11-02|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Evaluate the Effect of Genotype on LY2216684|A Study to Investigate the Effect of CYP2C19 Phenotype on the Pharmacokinetics of LY2216684 in Healthy Subjects|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:01:21.973409|2018-05-31 22:01:21.973409
NCT01460368|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2012-03-09|2011-10-24|2011-10-26|Estimate|||||||2012-03-09|2012-03-12|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart|A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Supratherapeutic Dose of LY2409021 in Healthy Subjects|Completed||Phase 1|68|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:01:22.129937|2018-05-31 22:01:22.129937
NCT01459328|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|September 2009||2009-09-30|October 2011|2011-10-31||||September 2013|Anticipated|2013-09-30||Interventional|||Resource-Sparing Curative Treatment for Rectal Cancer|Resource-Sparing Curative Treatment for Rectal Cancer|Unknown status|Recruiting|Phase 3|350|Anticipated|International Atomic Energy Agency||2|||f||||t||||||||||2018-05-31 22:01:51.311445|2018-05-31 22:01:51.311445
NCT01460342|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-07-23||2013-07-23|2011-10-24|2011-10-26|Estimate|2013-07-23|2013-09-25|Estimate||||2013-07-23|2013-09-25|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||All randomized participants.|Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|610|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:01:22.471189|2018-05-31 22:01:22.471189
NCT01460329|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-05-03|2011-10-24|2011-10-26|Estimate|||||||2013-05-03|2013-05-06|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Comparing Cardiac Output Measurements in Critically Ill Children Using USCOM and Transthoracic ECHO|Comparing Cardiac Output Measurements in Critically Ill Children Using Ultrasonic Cardiac Output Monitor and Transthoracic Echocardiography.|Completed|||22|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 22:01:23.970671|2018-05-31 22:01:23.970671
NCT01460316|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2016-01-26|2011-10-25|2011-10-26|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2011||2011-10-31|January 2016|2016-01-31||||May 2015|Actual|2015-05-31||Observational|CCOMET||Conotruncal Cardiac Defects and Nutrigenetic Etiopathogeny|Conotruncal Cardiac Defects and Metabolism, Nutrigenetic Factors of Etiopathogeny of Conotruncal Cardiac Defects|Completed|||400|Actual|Central Hospital, Nancy, France|||2||f||||t||||||||||2018-05-31 22:01:24.055328|2018-05-31 22:01:24.055328
NCT01460303|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2017-05-01||2018-05-02|2011-10-24|2011-10-26|Estimate|2017-08-02|2017-09-05|Actual||||2018-05-02|2018-05-04|Actual|January 2011||2011-01-31|May 2018|2018-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Patient-operated Valved Catheter Versus Indwelling Transurethral Catheter|Clinical Trial of Patient Operated Valved Catheter Compared With Standard Indwelling Transurethral Catheter for Postoperative Bladder Management|Completed||N/A|49|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 22:01:24.179831|2018-05-31 22:01:24.179831
NCT01460290|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2014-03-12||2014-12-08|2011-10-24|2011-10-26|Estimate|2014-07-07|2014-08-05|Estimate||||2014-12-08|2014-12-30|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Asenapine in the Treatment of Older Adults With Bipolar Disorder|Asenapine in the Treatment of Older Adults With Bipolar Disorder|Completed||Phase 4|15|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-05-31 22:01:24.684271|2018-05-31 22:01:24.684271
NCT01460277|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-22|||2016-10-24|2011-10-25|2011-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|hydro||Τhe Effectiveness of Hydrotherapy Exercises on the Rehabilitation of Hemiplegic Patients||Completed||Phase 4|60|Actual|University of Ioannina||2|||f||||||||||||||2018-05-31 22:01:25.299646|2018-05-31 22:01:25.299646
NCT01460264|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-05-22|2011-10-25|2011-10-26|Estimate|||||||2018-05-22|2018-05-23|Actual|October 16, 2013|Actual|2013-10-16|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|BIG3||An Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study|BIG3 - An Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study|Enrolling by invitation|||10000|Anticipated|Region Skane|||2||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 22:01:25.411668|2018-05-31 22:01:25.411668
NCT01460251|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2015-03-18|2011-10-25|2011-10-26|Estimate|||||||2015-03-18|2015-03-19|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277|OPen Label Study to Evaluate Long Term Treatment Effect of DiaPep277 in Patients Who Have Completed Study 901 and Study 910 (Extension to 901 Phase III Study|Terminated||Phase 3|11|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 22:01:25.483873|2018-05-31 22:01:25.483873
NCT01460238|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2018-04-13|2011-10-25|2011-10-26|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2011||2011-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia|Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia|Active, not recruiting|||30|Anticipated|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||Samples With DNA|"~     10 cc of peripheral blood and Archived lymph node tissue or bone marrow samples~   "|||2018-05-31 22:01:25.605584|2018-05-31 22:01:25.605584
NCT01460225|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-02-24|2011-10-25|2011-10-26|Estimate|||||||2012-02-24|2012-02-27|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation|Effects of Lubiprostone on Gastric Sensory and Motor Function in Patients With Chronic Idiopathic Constipation|Completed||Phase 4|19|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-05-31 22:01:25.680346|2018-05-31 22:01:25.680346
NCT01460212|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-09-24|2011-10-25|2011-10-26|Estimate|||||||2014-09-24|2014-09-25|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|October 2015|Anticipated|2015-10-31|December 2014|Anticipated|2014-12-31||Interventional|||Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder|Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder|Unknown status|Recruiting|Phase 4|80|Anticipated|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 22:01:25.795214|2018-05-31 22:01:25.795214
NCT01460199|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-05-23|2011-10-25|2011-10-26|Estimate|||||||2013-05-23|2013-05-24|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease|A Multi Center, Double-Blind, Two-Arm,Placebo Controlled, Randomized Safety and Tolerability Study of CTP-499 in Non-Dialysis Patients With Stage 3 Chronic Kidney Disease|Completed||Phase 1|33|Actual|Concert Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:01:25.878056|2018-05-31 22:01:25.878056
NCT01460186|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-02-27|2011-10-24|2011-10-26|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2011|Actual|2011-12-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|StoRM||Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer|Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer : a Multicenter Non-randomized Prospective Cohort Study|Active, not recruiting||N/A|1000|Anticipated|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 22:01:27.116007|2018-05-31 22:01:27.116007
NCT01460173|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-09-24|2011-10-25|2011-10-26|Estimate|||||||2012-09-24|2012-09-25|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|DASS||Divided Attention Steering Simulator Alertness Test|Aufmerksamkeitstest Mittels Fahrsimulation Bei Normalpersonen Und Patienten Mit Obstruktivem Schlafapnoesyndrom|Completed||N/A|200|Actual|Institut für Pneumologie Hagen Ambrock eV||2|||f||||f||||||||||2018-05-31 22:01:27.376773|2018-05-31 22:01:27.376773
NCT01460160|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-04-23|2011-10-25|2011-10-26|Estimate|||||||2018-04-23|2018-04-24|Actual|January 30, 2012|Actual|2012-01-30|April 2018|2018-04-30|May 28, 2021|Anticipated|2021-05-28|May 28, 2017|Actual|2017-05-28||Interventional|||Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia|A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|109|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-05-31 22:01:27.589953|2018-05-31 22:01:27.589953
NCT01460147|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2017-10-19|2011-10-25|2011-10-26|Estimate|||||||2017-10-19|2017-10-23|Actual|October 2011||2011-10-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Osteoporosis and MRI Study in Hemophilia|Bone and Joint Health in an Adult Hemophilia Population|Terminated||N/A|3|Actual|Shire||1|||f||||f||||||||||2018-05-31 22:01:28.483812|2018-05-31 22:01:28.483812
NCT01460134|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2018-01-29|2011-10-25|2011-10-26|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2011||2011-10-31|August 2017|2017-08-31|October 16, 2017|Actual|2017-10-16|December 2015|Actual|2015-12-31||Interventional|||A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers|A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors|Completed||Phase 1|90|Actual|Celldex Therapeutics||4|||f||||f||||||||||2018-05-31 22:01:29.006006|2018-05-31 22:01:29.006006
NCT01460121|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2018-05-09|2011-10-25|2011-10-26|Estimate|||||||2018-05-09|2018-05-15|Actual|February 2012||2012-02-29|May 2018|2018-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness|A Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SpotOn Specs™ for the Treatment of Chronic Dizziness|Completed||N/A|40|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 22:01:29.510638|2018-05-31 22:01:29.510638
NCT01460108|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2011-10-26|2011-10-25|2011-10-26|Estimate|||||||2011-10-26|2011-10-27|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|CV+||AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation|Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System|Unknown status|Recruiting|Phase 4|10|Anticipated|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology||1|||f||||f||||||||||2018-05-31 22:01:29.734984|2018-05-31 22:01:29.734984
NCT01460095|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2016-04-16|2011-10-24|2011-10-26|Estimate|||||||2016-04-16|2016-04-19|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|IA3||Improving Access to HbA1c in Sub Saharan Africa|Improving Access to HbA1c Measurement in Sub-Saharan Africa|Completed||N/A|1349|Actual|Yaounde Central Hospital||1|||f||||t||||||||||2018-05-31 22:01:30.112855|2018-05-31 22:01:30.112855
NCT01460082|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2014-03-10|2011-10-25|2011-10-26|Estimate|||||||2014-03-10|2014-03-12|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|EDAECOPD||Endothelial Dysfunction in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|Endothelial Dysfunction and Systemic Inflammation in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Completed|||29|Actual|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|||1||f||||f||||||Samples Without DNA|"~     Serum, Plasma~   "|||2018-05-31 22:01:30.408165|2018-05-31 22:01:30.408165
NCT01460069|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-06-19|2011-10-24|2011-10-26|Estimate|||||||2013-06-19|2013-06-21|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis|The Effect of GLP-1 in Psoriasis|Completed||N/A|20|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 22:01:30.5376|2018-05-31 22:01:30.5376
NCT01460056|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-01-31|2011-10-25|2011-10-26|Estimate|||||||2013-01-31|2013-02-01|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|e-STEPS||e-STEPS: Endotoxin-Associated Sterile Peritonitis Observational Study|e-STEPS: Endotoxin-Associated Sterile Peritonitis Observational Study|Completed|||127|Actual|Baxter Healthcare Corporation|||1||f||||t||||||||||2018-05-31 22:01:30.78662|2018-05-31 22:01:30.78662
NCT01460043|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-11-09|2011-10-25|2011-10-26|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Trial of Homeopathy on Management of Menorrhagia|Pilot Study of Homeopathy in Dysfunctional Uterine Bleeding Presenting as Menorrhagia|Completed||N/A|25|Actual|NMP Medical Research Institute||2|||f||||t||||||||||2018-05-31 22:01:31.03078|2018-05-31 22:01:31.03078
NCT01460030|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2017-02-28|2011-10-25|2011-10-26|Estimate|||||||2017-02-28|2017-03-03|Actual|November 2011||2011-11-30|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism|An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism|Completed||Phase 3|||Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-05-31 22:01:31.264021|2018-05-31 22:01:31.264021
NCT01460017|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2011-10-25|2011-10-25|2011-10-26|Estimate|||||||2011-10-25|2011-10-26|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Comparison Between Deep Sclerectomy and Traditional Trabeculotomy & Trabeculectomy in Congenital Glaucoma|Comparison Between The Outcome of Deep Sclerectomy and Traditional Trabeculotomy and Trabeculectomy Surgeries in Congenital Glaucoma|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|King Saud University||2|||f||||f||||||||||2018-05-31 22:01:31.562069|2018-05-31 22:01:31.562069
NCT01460004|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2015-07-16|2011-10-24|2011-10-26|Estimate|||||||2015-07-16|2015-07-17|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Infrapatellar Strap Treatment on Pain Extent and Athletic Measures in Young Athletes|The Effect of Infra Patellar Strap Treatment on the Extent of Pain and Performance in Young Athletes With Patellar Tendinopathy|Completed||N/A|16|Actual|Wingate Institute||1|||f||||f||||||||||2018-05-31 22:01:31.754368|2018-05-31 22:01:31.754368
NCT01459991|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-26|2011-10-25|2011-10-26|Estimate|||||||2011-10-26|2011-10-28|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||The Mediterranean Diet and Lactation Study: A Diet Study in Lactating Women|The Mediterranean Diet and Lactation Study: A Diet Study in Lactating Women|Completed||N/A|138|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 22:01:31.966393|2018-05-31 22:01:31.966393
NCT01458990|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2017-11-29||2018-03-14|2011-10-24|2011-10-25|Estimate|2018-03-14|2018-03-19|Actual||||2018-03-14|2018-03-19|Actual|October 2011||2011-10-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Proton Pump Inhibitors and Dysbiosis in Cirrhosis||Completed||N/A|60|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||2|||f||||f||||||||Undecided||2018-05-31 22:01:58.400566|2018-05-31 22:01:58.400566
NCT01459978|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2018-03-01|2011-10-25|2011-10-26|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2012|Actual|2012-09-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|MATICUS||Impact of Monitoring Quality Indicators in Maternity Departments on Mother and Infant Health|Impact of Using Cumulative SUM (CUSUM) Control Chart in Maternity Department on Mother and Infant Health: a Cluster Randomized Trial|Completed|||60000|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 22:01:32.136435|2018-05-31 22:01:32.136435
NCT01459965|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2011-10-25|2011-10-25|2011-10-26|Estimate|||||||2011-10-25|2011-10-26|Estimate|July 1993||1993-07-31|October 2011|2011-10-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Stenting Malignant Jaundice for Quality of Life|Endoscopic Palliation of Malignant Biliary Tract Obstruction: Emphasis on Improvement in Quality of Life|Completed||N/A|164|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 22:01:32.289493|2018-05-31 22:01:32.289493
NCT01459952|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-25|||2012-06-05|2011-10-25|2011-10-26|Estimate|||||||2012-06-05|2012-06-06|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold|A Double-blind, Randomised, Parallel Group, Phase III Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold|Completed||Phase 3|120|Actual|Hyben Vital ApS||2|||f||||f||||||||||2018-05-31 22:01:32.514566|2018-05-31 22:01:32.514566
NCT01459939|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-06-05|2011-10-25|2011-10-26|Estimate|||||||2012-06-05|2012-06-06|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip|A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip|Completed||Phase 3|120|Actual|Hyben Vital ApS||2|||f||||f||||||||||2018-05-31 22:01:32.664537|2018-05-31 22:01:32.664537
NCT01459926|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24||2013-06-05|2015-06-04|2011-10-25|2011-10-26|Estimate||||2013-06-05|2013-06-13|Estimate|2015-06-04|2015-07-02|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation|Completed||Phase 2|217|Actual|Theravance Biopharma R & D, Inc.||4|||f||||f||||||||||2018-05-31 22:01:32.769369|2018-05-31 22:01:32.769369
NCT01459913|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2015-01-26||2015-05-14|2011-10-24|2011-10-26|Estimate|2015-01-26|2015-02-11|Estimate||||2015-05-14|2015-06-10|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CONCISE|Full Analysis (FA) Set included all subjects who received at least 1 dose of study drug and fulfilled all relevant inclusion criteria. One subject from “Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)” was excluded from the FA Set due to having HCV Genotype 6.|Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype|A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype|Terminated||Phase 3|239|Actual|Vertex Pharmaceuticals Incorporated|The study was terminated early at the primary efficacy endpoint (SVR12), by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.|4||"The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify~   the drug development plan."|f||||f||||||||||2018-05-31 22:01:33.015521|2018-05-31 22:01:33.015521
NCT01459900|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-09-19|2011-10-25|2011-10-26|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ReSET||Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial|Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial|Completed||N/A|69|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 22:01:35.845829|2018-05-31 22:01:35.845829
NCT01459887|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-25|2011-10-25|2011-10-26|Estimate|||||||2011-10-25|2011-10-26|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma|An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL|Completed||Phase 3|278|Actual|Shanghai CP Guojian Pharmaceutical Co.,Ltd.||2|||f||||t||||||||||2018-05-31 22:01:36.435124|2018-05-31 22:01:36.435124
NCT01459874|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-03-26|2011-10-25|2011-10-26|Estimate|||||||2013-03-26|2013-03-28|Estimate|March 2008||2008-03-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Evaluation of an Organizational Model for Remote Monitoring of Pacemaker and Implantable Cardioverter Defibrillator Recipients|Prospective Registry for the Evaluation of an Organizational Model for Remote Monitoring of Pacemaker and Implantable Cardioverter Defibrillator (ICD) Recipients in the Clinical Practice|Completed|||1650|Actual|San Filippo Neri General Hospital|||1||f||||t||||||||||2018-05-31 22:01:36.590157|2018-05-31 22:01:36.590157
NCT01459861|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-03-04|2011-10-24|2011-10-26|Estimate|||||||2013-03-04|2013-03-06|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Early Ambulation After Adductor Canal Block for Total Knee Arthroplasty|Assessment of Early Ambulation in Patients Receiving Continuous Adductor Canal Block With Ultrasound Guided Posterior Capsular Knee Injection vs. Femoral Nerve Block With Tibial Nerve Block Following Total Knee Replacement|Terminated||N/A|11|Actual|Saint Francis Care||2||Administratively closed early|f||||f||||||||||2018-05-31 22:01:36.974318|2018-05-31 22:01:36.974318
NCT01459848|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-03-24|2011-10-24|2011-10-26|Estimate|||||||2014-03-24|2014-03-26|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Baby Dvd Effects on Cortisol|A Randomized Controlled Trial of Block Play vs Dvd Viewing|Completed||N/A|50|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 22:01:37.084797|2018-05-31 22:01:37.084797
NCT01459835|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2014-03-24|2011-10-25|2011-10-26|Estimate|||||||2014-03-24|2014-03-26|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Media Impact on Preschool Behavior||Completed||N/A|600|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 22:01:37.213461|2018-05-31 22:01:37.213461
NCT01459822|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-25|2011-10-25|2011-10-26|Estimate|||||||2011-10-25|2011-10-26|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Observational|METPSDS||MiRNAs Evaluate the Prognosis of Sepsis by Dynamic Study|MiRNAhs in the Evaluation of the Value of Sepsis Prognosis Dynamics Observational Research|Unknown status|Recruiting||70|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||Samples Without DNA|"~     human serum~   "|||2018-05-31 22:01:37.326123|2018-05-31 22:01:37.326123
NCT01459809|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2015-01-19|2011-10-24|2011-10-26|Estimate|||||||2015-01-19|2015-01-21|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|RECOMMEND||Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients|A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes|Completed||Phase 3|538|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 22:01:37.430476|2018-05-31 22:01:37.430476
NCT01459796|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|2017-04-23|2013-09-27|2017-06-19|2011-10-24|2011-10-26|Estimate|2017-06-19|2017-07-18|Actual|2013-09-27|2013-10-28|Estimate|2017-06-19|2017-07-18|Actual|November 2011||2011-11-30|June 2017|2017-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|UPSURGE|Baseline population included full analysis set (FAS) comprising of all randomized participants who received any study medication and was based on treatment allocated by Interactive web response system (IWRS) at randomization (as randomized).|Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares|Terminated||Phase 3|220|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:01:37.694206|2018-05-31 22:01:37.694206
NCT01459783|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2015-02-25||2015-05-06|2011-10-25|2011-10-26|Estimate|2015-05-06|2015-05-22|Estimate||||2015-05-06|2015-05-22|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Comparative Effectiveness of Dementia Care Strategies in Underserved Communities|Comparative Effectiveness of Dementia Care Strategies in Underserved Communities|Completed||N/A|144|Actual|RAND||2|||f||||t||||||||||2018-05-31 22:01:38.955372|2018-05-31 22:01:38.955372
NCT01459770|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-04-04|2011-10-24|2011-10-26|Estimate|||||||2017-04-04|2017-04-06|Actual|November 2011||2011-11-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|CKD/ESRD-MIT||Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD|Medication Intervention in Transitional Care to Optimize Outcomes & Costs in CKD & ESRD|Completed||N/A|120|Actual|Providence Medical Research Center||2|||f||||t||||||||No||2018-05-31 22:01:39.549072|2018-05-31 22:01:39.549072
NCT01459757|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-06-17|2011-10-25|2011-10-26|Estimate|||||||2013-06-17|2013-06-19|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib|A Non-Interventional Retrospective Correlation Of Tumor Mutation Status To Clinical Benefit From The SU011248, A6181036 Treatment Protocol Titled: A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate|Completed|||322|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:01:39.74343|2018-05-31 22:01:39.74343
NCT01459744|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2016-10-05|2011-10-24|2011-10-26|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|WISDOM||An Intervention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations|An Intervention to Improve ICD Deactivation Conversations (WISDOM - Working to Improve discuSsions About DefibrillatOr Management)|Completed||N/A|562|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 22:01:39.941146|2018-05-31 22:01:39.941146
NCT01459731|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2012-05-01|2011-10-24|2011-10-26|Estimate|||||||2012-05-01|2012-05-02|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Optical Coherence Tomography (OCT) Data Collection Study|Optical Coherence Tomography Data Collection Study|Completed|||400|Anticipated|Optovue|||6||f||||f||||||||||2018-05-31 22:01:40.17319|2018-05-31 22:01:40.17319
NCT01459718|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-02-09|2011-10-24|2011-10-26|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MACS1097||Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload|A Multicenter Open Label Phase II Study to Evaluate the Safety and Efficacy of Deferasirox in Combination With Deferoxamine Followed by Transitioning to Deferasirox Monotherapy in β-thalassemia Patients With Severe Cardiac Iron Overload|Completed||Phase 2|32|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:01:40.31084|2018-05-31 22:01:40.31084
NCT01459705|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2015-10-09||2015-11-09|2011-10-25|2011-10-26|Estimate|2015-11-09|2015-12-14|Estimate||||2015-11-09|2015-12-14|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|VRPE Extension|All participants randomized to a treatment arm included in baseline data analysis|Comparing Virtual Reality Exposure Therapy to Prolonged Exposure|Comparing Virtual Reality Exposure Therapy to Prolonged Exposure in the Treatment of Soldiers With Post Traumatic Stress Disorder (PTSD)|Completed||N/A|162|Actual|National Center for Telehealth and Technology||3|||f||||t||||||||||2018-05-31 22:01:40.494477|2018-05-31 22:01:40.494477
NCT01459692|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2018-05-02|2011-10-25|2011-10-26|Estimate|||||||2018-05-02|2018-05-07|Actual|February 2005||2005-02-28|May 2018|2018-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological Handicaps|Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological Handicaps|Completed||N/A|40|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 22:01:41.320148|2018-05-31 22:01:41.320148
NCT01459679|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-06-20|2011-10-24|2011-10-26|Estimate|||||||2017-06-20|2017-06-21|Actual|July 2012||2012-07-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery|A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery|Terminated||Phase 3|1719|Actual|American-European Congress of Ophthalmic Surgery||3|||f||||f||||||||||2018-05-31 22:01:41.397238|2018-05-31 22:01:41.397238
NCT01459666|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2018-05-17|2011-10-25|2011-10-26|Estimate|||||||2018-05-17|2018-05-21|Actual|September 2011||2011-09-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer|A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer|Recruiting||Phase 4|50|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 22:01:41.816836|2018-05-31 22:01:41.816836
NCT01459653|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2015-03-26||2015-12-09|2011-10-24|2011-10-25|Estimate|2015-06-09|2015-07-07|Estimate||||2015-12-09|2016-01-11|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|Monitor-GCSF|Baseline characteristics are based on the evaluable sample, e.g. all patients who received at least one dose of the study medication, had no major protocol violation and have a minimum of enrollment cycle and either one follow-up cycle or study end data with valid outcome data (i.e., ANC or completed CIN/FN data).|Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor|International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.|Completed|||1496|Actual|Sandoz|||1||f||||f||||||||||2018-05-31 22:01:42.128641|2018-05-31 22:01:42.128641
NCT01459640|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis|Phase 2 Study Assessing the Efficacy of Intra-Articular Autologous Mesenchymal Stem Cells in Patients With Mild to Moderate Osteoarthritis|Unknown status|Recruiting|Phase 2|50|Anticipated|National University of Malaysia||2|||f||||f||||||||||2018-05-31 22:01:46.231993|2018-05-31 22:01:46.231993
NCT01459627|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-09-06|2011-10-24|2011-10-25|Estimate|||||||2017-09-06|2017-09-07|Actual|December 2011||2011-12-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|DAPT-STEMI||Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI|Prospective, Randomized, Open Label Trial of 6 Months vs. 12 Months Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation Myocardial Infarction|Completed||Phase 4|1100|Anticipated|Maasstad Hospital||2|||f||||t||||||||No||2018-05-31 22:01:46.549028|2018-05-31 22:01:46.549028
NCT01459614|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-05-02|2011-10-24|2011-10-25|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2011||2011-11-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2015|Actual|2015-11-30||Interventional|||Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer|Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|43|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-05-31 22:01:46.778858|2018-05-31 22:01:46.778858
NCT01459601|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|January 2012||2012-01-31|October 2011|2011-10-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Cabergoline Effect on Blood Sugar in Type 2 Diabetics|Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics|Unknown status|Not yet recruiting|N/A|10|Anticipated|Mashhad University of Medical Sciences|||||f||||f||||||||||2018-05-31 22:01:46.894706|2018-05-31 22:01:46.894706
NCT01459588|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|2013-02-11||2013-02-11|2011-10-24|2011-10-25|Estimate|2013-02-11|2013-03-14|Estimate||||2013-02-11|2013-03-14|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease||Completed||Phase 3|315|Actual|Allergan||4|||f||||f||||||||||2018-05-31 22:01:47.000314|2018-05-31 22:01:47.000314
NCT01459575|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|July 2005||2005-07-31|October 2011|2011-10-31|December 2006|Actual|2006-12-31|December 2005|Actual|2005-12-31||Observational|||Unboosted Atazanavir as Initial ART Therapy in China||Completed|||||National Center for AIDS/STD Control and Prevention, China CDC|||||f||||f||||||||||2018-05-31 22:01:47.588491|2018-05-31 22:01:47.588491
NCT01459562|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2014-02-17|2011-10-24|2011-10-25|Estimate|||||||2014-02-17|2014-02-19|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy Volunteers|A Randomized Double-blinded Placebo Controlled Single Center Phase I Study of Escalating Single Intravenous Doses of NI-0501 in Healthy Volunteers|Completed||Phase 1|||NovImmune SA||2|||f||||f||||||||||2018-05-31 22:01:47.780186|2018-05-31 22:01:47.780186
NCT01459549|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-01-25|2011-10-24|2011-10-25|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Randomized Controlled Trial of Treating Hepatolithiasis (Accompanied With SOL) With Choledochojejunostomy|Randomized Controlled Trial of Treating Hepatolithiasis(Accompanied With Sphincter of Oddi Laxity) With Roux-en-Y Choledochojejunostomy|Recruiting||N/A|100|Anticipated|Zhejiang University||2|||f||||||||||||||2018-05-31 22:01:47.859976|2018-05-31 22:01:47.859976
NCT01459536|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-11-03|2011-10-24|2011-10-25|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|ARC||Assessment of Muscle Function and Size in Older Adults With Rotator Cuff Tear|Rotator Cuff Function and Muscle Morphology in Older Adults With Rotator Cuff Tear|Completed|||25|Actual|Wake Forest University Health Sciences|||3||f||||||||||||||2018-05-31 22:01:48.003105|2018-05-31 22:01:48.003105
NCT01459523|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-11-21|2011-10-21|2011-10-25|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2011||2011-10-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Optimizing Catheter Insertion Technique for Ultrasound-guided Continuous Peripheral Nerve Blocks|Optimizing Catheter Insertion Technique for Ultrasound-guided Continuous Peripheral Nerve Blocks|Active, not recruiting||N/A|200|Anticipated|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 22:01:48.097019|2018-05-31 22:01:48.097019
NCT01459510|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-10-21|2011-10-21|2011-10-25|Estimate|||||||2011-10-21|2011-10-25|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Brief Multimedia Program Affects Parents' Attitudes Toward Physical Punishment|A Brief Multimedia Program Affects Parents' Attitudes Toward Physical Punishment|Completed||Phase 1|260|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 22:01:48.264268|2018-05-31 22:01:48.264268
NCT01437046|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2015-07-20|2011-09-19|2011-09-20|Estimate|||||||2015-07-20|2015-07-22|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|August 2013|Actual|2013-08-31||Interventional|||Doxazosin an a1 Antagonist for Alcohol Dependence|Doxazosin an a1 Antagonist for Alcohol Dependence|Completed||Phase 2|48|Actual|Brown University||2|||f||||||||||||||2018-05-31 22:09:06.098817|2018-05-31 22:09:06.098817
NCT01459497|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-04-13|2011-10-21|2011-10-25|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2012||2012-10-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer|Phase III Randomized Study of Standard Versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status|Recruiting||Phase 3|226|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 22:01:48.5823|2018-05-31 22:01:48.5823
NCT01459484|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-04-09|2011-10-24|2011-10-25|Estimate|||||||2018-04-09|2018-04-11|Actual|July 2011||2011-07-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|ISG/OS-2||ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma|ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)|Recruiting||Phase 2/Phase 3|225|Anticipated|Italian Sarcoma Group||2|||f||||t||||||||||2018-05-31 22:01:48.812749|2018-05-31 22:01:48.812749
NCT01459471|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-21|2011-10-21|2011-10-25|Estimate|||||||2011-10-21|2011-10-25|Estimate|April 2010||2010-04-30|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Staple-line Reinforcement During Laparoscopic Sleeve Gastrectomy Using Three Different Techniques: a Randomized Trial|Staple-line Reinforcement During Laparoscopic Sleeve Gastrectomy Using Three Different Techniques: a Randomized Trial|Completed||N/A|120|Actual|University of Rome Tor Vergata||1|||f||||t||||||||||2018-05-31 22:01:49.0665|2018-05-31 22:01:49.0665
NCT01459458|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2015-11-30|2011-10-21|2011-10-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|February 2014|Actual|2014-02-28||Interventional|||Family Planning-based Partner Abuse Intervention to Reduce Unintended Pregnancy|Family Planning-based Partner Abuse Intervention to Reduce Unintended Pregnancy|Completed||Phase 3|3687|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:01:49.158231|2018-05-31 22:01:49.158231
NCT01459445|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-23|2011-10-23|2011-10-25|Estimate|||||||2011-10-23|2011-10-25|Estimate|February 2011||2011-02-28|October 2011|2011-10-31|January 2012|Anticipated|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||Metformin+ Drospirenone/ethinylestradiol30µg and Flow-mediated Dilation in Polycystic Ovary Syndrome|Metformin Plus EE30µg-drospirenone and Weight Loss- Impact on Endothelial Function and hsCRP Levels in PCOS|Unknown status|Active, not recruiting|N/A|26|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||1|||f||||t||||||||||2018-05-31 22:01:49.270237|2018-05-31 22:01:49.270237
NCT01459432|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-11-06|2011-10-24|2011-10-25|Estimate|||||||2015-11-06|2015-11-09|Estimate|November 2011||2011-11-30|November 2015|2015-11-30||||April 2012|Actual|2012-04-30||Observational|||Understanding Immunity Persistence After Adolescent MenC Vaccination|A Study to Evaluate the Persistence of Antibody Seven Years After a Booster Dose of Either a Glycoconjugate or a Polysaccharide Vaccine Against Serogroup C Neisseria Meningitidis Given to Adolescents|Completed|||134|Actual|University of Oxford|||1||f||||||||||||||2018-05-31 22:01:49.434166|2018-05-31 22:01:49.434166
NCT01459419|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2011-10-23|2011-10-23|2011-10-25|Estimate|||||||2011-10-23|2011-10-25|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|May 2013|Anticipated|2013-05-31||Interventional|||Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects|A Phase IIa Safety Study of Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects, a Single-blind, Randomized, Controlled Multi-center Study.|Unknown status|Not yet recruiting|Phase 2|36|Anticipated|Inspira Medical AB||2|||f||||f||||||||||2018-05-31 22:01:49.542764|2018-05-31 22:01:49.542764
NCT01459406|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2012-12-18|2011-10-24|2011-10-25|Estimate|||||||2012-12-18|2012-12-19|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FODMAPs||Effects of FODMAPs on Small Bowel Water Content: an MRI Study|Effects of FODMAPs (Fermentable Oligo-, Di-, and Mono-saccharides, And Polyols) on Small Bowel Water Content: an MRI Study|Completed||N/A|17|Actual|University of Nottingham||4|||f||||f||||||||||2018-05-31 22:01:49.731158|2018-05-31 22:01:49.731158
NCT01459393|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-06-27|2011-10-23|2011-10-25|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2010||2010-11-30|February 2014|2014-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment|Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis|Completed||Phase 3|137|Actual|Barretos Cancer Hospital||2|||f||||t||||||||||2018-05-31 22:01:49.956914|2018-05-31 22:01:49.956914
NCT01459380|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2017-07-24|2011-10-24|2011-10-25|Estimate|||||||2017-07-24|2017-07-25|Actual|October 11, 2011|Actual|2011-10-11|July 2017|2017-07-31|February 11, 2017|Actual|2017-02-11|June 8, 2016|Actual|2016-06-08||Interventional|||Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer|Completed||Phase 1|41|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 22:01:50.191101|2018-05-31 22:01:50.191101
NCT01459367|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-08-22|2011-10-24|2011-10-25|Estimate|||||||2013-08-22|2013-08-23|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis|A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to AG-1749 (15 mg Once-Daily) in a 24-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE).|Completed||Phase 3|607|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:01:50.535507|2018-05-31 22:01:50.535507
NCT01459354|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|August 2011||2011-08-31|October 2011|2011-10-31||||||||Observational|||The Effects of Bimanual Laryngoscopy on Post-Operative Sore Throat in Adults||Unknown status|Recruiting||490|Anticipated|China Medical University Hospital|||1||f||||||||||||||2018-05-31 22:01:50.789166|2018-05-31 22:01:50.789166
NCT01459341|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-12-05|2011-10-23|2011-10-25|Estimate|||||||2012-12-05|2012-12-06|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Observational|NIRS||Near Infrared Spectroscopy and Transcutaneous Oxygen Pressure in Critical Limb Ischemia Before and After Treatment|Comparison of Near Infrared Spectroscopy (NIRS) and Transcutaneous Oxygen Pressure (TCPO2) Measurements in Critical Limb Ischemia (CLI) Patients After Invasive Treatment (Endovascular or Surgery)|Completed|||15|Actual|Carmel Medical Center|||||f||||t||||||||||2018-05-31 22:01:51.174387|2018-05-31 22:01:51.174387
NCT01459315|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2013-07-03|2011-10-21|2011-10-25|Estimate|||||||2013-07-03|2013-07-04|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects|Phase I, Open-Label Study in Healthy Male Subjects Describing GSK1349572 Exposure in Blood Plasma, Seminal Fluid and Rectal Mucosal Tissue Following Single and Multiple Dosing|Completed||Phase 1|14|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 22:01:51.63129|2018-05-31 22:01:51.63129
NCT01459302|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-08-30|2011-10-24|2011-10-25|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2009||2009-01-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders|Family Studies in Neuromuscular Disorders|Recruiting|||6000|Anticipated|University of Massachusetts, Worcester|||1||f||||f||||||Samples With DNA|"~     DNA(plus Serum, frozen cells when available) will be obtained from the initial blood or~     saliva sample for genetic study. RNA, skin cells or lymphoblast cells may be obtained and~     stored.~   "|||2018-05-31 22:01:51.920294|2018-05-31 22:01:51.920294
NCT01459289|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2011-10-21|2011-10-21|2011-10-25|Estimate|||||||2011-10-21|2011-10-25|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Psychosocial Effect of HPV Positivity|The Psychosocial Effect of Testing Positive for HPV on Hong Kong Chinese Women With Normal Cervical Cytology|Unknown status|Recruiting|N/A|200|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:01:52.229634|2018-05-31 22:01:52.229634
NCT01459276|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2012-05-18|2011-10-21|2011-10-25|Estimate|||||||2012-05-18|2012-05-21|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects|A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccine Containing 6μgHA of Seasonal A/H1N1, A/H3N2 and B Influenza Antigens in Non-elderly Adult and Elderly Subjects|Completed||N/A|1206|Actual|Fluart Innovative Vaccine Ltd, Hungary||2|||f||||f||||||||||2018-05-31 22:01:52.388368|2018-05-31 22:01:52.388368
NCT01459263|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2018-04-25|2011-10-24|2011-10-25|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2010||2010-11-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|ClariVein-2||Early Outcome of Mechanochemical Endovenous Ablation|Mechanochemical Endovenous Ablation of Great Saphenous Vein Incompetence Using the ClariVeinTM Device: a Prospective Study|Completed|||124|Actual|Rijnstate Hospital|||1||f||||f||||||||||2018-05-31 22:01:52.619464|2018-05-31 22:01:52.619464
NCT01459250|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2011-10-21|2011-10-21|2011-10-25|Estimate|||||||2011-10-21|2011-10-25|Estimate|March 2011||2011-03-31|October 2011|2011-10-31||||August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects|An Open Label, Non-randomised, Parallel Group Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of a Single Dose of AGO178C in Subjects With Mild, Moderate, Severe Renal Impairment and End-stage Renal Disease With That in Healthy Matched Control Subjects|Completed||Phase 1|32|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:01:52.840453|2018-05-31 22:01:52.840453
NCT01459237|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2018-05-10|2011-10-21|2011-10-25|Estimate|||||||2018-05-10|2018-05-11|Actual|October 11, 2011||2011-10-11|January 30, 2018|2018-01-30|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Effects of Hormone Stimulation on Brain Scans for Cushing s Disease|Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease|Completed||Early Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:01:53.076215|2018-05-31 22:01:53.076215
NCT01459224|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2015-12-01|2011-10-21|2011-10-25|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|September 2014|Actual|2014-09-30||Observational|MELT||MELT - MRI Evaluation of Lymphoma Treatment|Whole Body Functional and Anatomical MRI: Accuracy in Staging and Treatment Response Monitoring in Adolescent Hodgkin's Lymphoma Compared to Conventional Multimodality Imaging|Completed|||58|Actual|University College, London|||||f||||t||||||||||2018-05-31 22:01:53.229033|2018-05-31 22:01:53.229033
NCT01459211|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-11-07|2011-10-21|2011-10-25|Estimate|||||||2016-11-07|2016-11-08|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|LenD||Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)|A Pilot Study to Establish the Safety & Efficacy of a Combination of Dexamethasone & Lenalidomide in Patients With Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)|Completed||Phase 2|12|Actual|University College, London||1|||f||||t||||||||Undecided||2018-05-31 22:01:53.353118|2018-05-31 22:01:53.353118
NCT01459198|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-12-14|2011-10-21|2011-10-25|Estimate|||||||2015-12-14|2015-12-15|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV MEDI ΔM2-2 Lot RSV#002A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, RSV-Seropositive Children 12 to 59 Months of Age, and RSV-Seronegative Infants and Children 6 to 24 Months of Age|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||t||||||||||2018-05-31 22:01:53.545662|2018-05-31 22:01:53.545662
NCT01459185|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2014-09-23|2011-10-24|2011-10-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|June 2005||2005-06-30|September 2014|2014-09-30|March 2012|Actual|2012-03-31|May 2008|Actual|2008-05-31||Interventional|||A Feasibility Study of Oral Adjuvant Chemotherapy With S-1|A Feasibility Study of Adjuvant Chemotherapy With Oral Fluoropyrimidine S-1 for Non-small Cell Lung Cancer|Completed||Phase 2|55|Anticipated|Nagasaki University||1|||f||||f||||||||||2018-05-31 22:01:53.709385|2018-05-31 22:01:53.709385
NCT01459172|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2016-04-19|2011-10-21|2011-10-25|Estimate|||||||2016-04-19|2016-04-21|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Human Breast Tissue Bioavailability of Topically Applied Limonene|Human Breast Tissue Bioavailability of Topically Applied Limonene|Completed||Phase 1|103|Actual|University of Arizona||1|||f||||f||||||||||2018-05-31 22:01:53.837298|2018-05-31 22:01:53.837298
NCT01458821|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2014-05-07|2011-10-24|2011-10-25|Estimate|||||||2014-05-07|2014-05-09|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|FEMAICT||Cognitive Training for Firefighters With Tinnitus|Investigating the Impact of Cognitive Training for Firefighters With Tinnitus|Completed||Phase 3|60|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 22:02:02.899027|2018-05-31 22:02:02.899027
NCT01459159|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-11-20|2011-10-21|2011-10-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome|Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome|Terminated||Phase 2|162|Anticipated|Telik||||Study TLK199.2108 was terminated for business reasons.|f||||f||||||||||2018-05-31 22:01:53.925099|2018-05-31 22:01:53.925099
NCT01459146|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2011-10-22|2011-10-22|2011-10-25|Estimate|||||||2011-10-22|2011-10-25|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|November 2012|Anticipated|2012-11-30|October 2011|Anticipated|2011-10-31||Interventional|ACTIPT||Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana|The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana|Unknown status|Recruiting|Phase 4|345|Anticipated|Navrongo Health Research Centre, Ghana||3|||f||||t||||||||||2018-05-31 22:01:54.165314|2018-05-31 22:01:54.165314
NCT01459133|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-03-10|2011-10-24|2011-10-25|Estimate|||||||2015-03-10|2015-03-17|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System|Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere|Withdrawn||N/A|0|Actual|South Orange County Endocrinology||1||"Unable to register Treatment IND with the US Food And Drug Administration's new process of~   establishing TLS encryption for email correspondence."|f||||f||||||||||2018-05-31 22:01:54.352057|2018-05-31 22:01:54.352057
NCT01459120|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-02-08|2011-10-21|2011-10-25|Estimate|||||||2012-02-08|2012-02-09|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|DoDoPi||Comparison of Door-to-door Versus Community Gathering to Provide HIV Counseling and Testing Services in Rural Lesotho|Comparing Door-to-door Versus Community Gathering in Providing HIV Counseling and Testing Within an Integrated Primary Health Care Package: a Cluster Randomized Trial in Rural Lesotho|Completed||N/A|1800|Anticipated|SolidarMed||3|||f||||f||||||||||2018-05-31 22:01:54.422673|2018-05-31 22:01:54.422673
NCT01459107|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-10-04|2011-10-24|2011-10-25|Estimate|||||||2017-10-04|2017-10-06|Actual|July 2011|Actual|2011-07-31|October 2017|2017-10-31|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30||Interventional|||Human Upper Extremity Allotransplantation|Human Upper Extremity Allotransplantation|Recruiting||Phase 2|30|Anticipated|Johns Hopkins University||1|||f||||t||f||||||No|Pooled patient data will be shared.|2018-05-31 22:01:54.569815|2018-05-31 22:01:54.569815
NCT01459094|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2013-02-18|2011-10-21|2011-10-25|Estimate|||||||2013-02-18|2013-02-20|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers|Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Subjects|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 22:01:54.706074|2018-05-31 22:01:54.706074
NCT01459081|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2013-01-15|2011-10-24|2011-10-25|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China|Randomised, Double-blind, Placebo-controlled Trial of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China|Completed||Phase 3|298|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:01:54.805513|2018-05-31 22:01:54.805513
NCT01459068|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2014-04-16||2014-05-19|2011-10-21|2011-10-25|Estimate|2014-05-19|2014-06-06|Estimate||||2014-05-19|2014-06-06|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|MHAP|We estimated 150 participants in each arm using the test for paired means, based on a moderate effect size (0.50), 80% power, two-tailed 5% significance level, design effect of 1.5, and up to a 50% expected drop-out rate (due to frequent cross-border movement).|Mental Health Assessment Project on the Thailand-Burma Border|Study of Effectiveness of Mental Health Interventions Among Torture Survivors on the Thailand-Burma Border|Completed||N/A|347|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 22:01:55.097528|2018-05-31 22:01:55.097528
NCT01459055|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2016-05-02|2011-10-21|2011-10-25|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2020|Anticipated|2020-08-31|January 2017|Anticipated|2017-01-31||Observational|||Long-term Follow-up in Patients Affected With Acrofacial Vitiligo|Long-term Ten Years Follow-up in Patients Affected With Acrofacial Vitiligo|Not yet recruiting|||100|Anticipated|Irmandade da Santa Casa de Misericordia de Curitiba|||||f||||f||||||||||2018-05-31 22:01:56.821388|2018-05-31 22:01:56.821388
NCT01459042|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|January 2010||2010-01-31|October 2011|2011-10-31||||October 2011|Actual|2011-10-31||Observational|||Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China|Prevalence of Primary Aldosteronism and Status of Renin-Angiotensin System in Resistant Hypertension:An Observational Study in China|Completed|||2000|Anticipated|Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||Samples With DNA|"~     blood samples,including serum, plasma and whole blood.~   "|||2018-05-31 22:01:56.924154|2018-05-31 22:01:56.924154
NCT01459029|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Interventional|SATROS||High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia|High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia : A Randomized, Double-Blind, Placebo-Controlled Study|Unknown status|Not yet recruiting|Phase 2|54|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 22:01:57.029635|2018-05-31 22:01:57.029635
NCT01459016|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|2016-12-21||2016-12-21|2011-10-24|2011-10-25|Estimate|2016-12-21|2017-02-13|Actual||||2016-12-21|2017-02-13|Actual|December 2011||2011-12-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All participants who enrolled in the study.|A Non-drug Methods Study in Participants With Alzheimer's Disease|An Exploratory Study of Brain Imaging Biomarkers in Patients With Alzheimer's Pathology Receiving Standard of Care|Completed||Phase 1|56|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:01:57.285268|2018-05-31 22:01:57.285268
NCT01459003|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2014-05-05|2011-10-24|2011-10-25|Estimate|||||||2014-05-05|2014-05-06|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|BEAUTY||Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer|Evaluation of Beauty Care Before Chemotherapy in Women With Breast Cancer|Completed||Phase 3|400|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||||||||||||2018-05-31 22:01:58.285752|2018-05-31 22:01:58.285752
NCT01458977|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2014-06-18|2011-10-24|2011-10-25|Estimate|||||||2014-06-18|2014-06-19|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors|Prospective, Randomised, Crossover, Double-Blind, Placebo-Controlled Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors|Completed||Phase 4|48|Actual|Fundacio Lluita Contra la SIDA||2|||f||||f||||||||||2018-05-31 22:01:59.424059|2018-05-31 22:01:59.424059
NCT01458964|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2014-07-08|2011-10-24|2011-10-25|Estimate|||||||2014-07-08|2014-07-09|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Quetiapine Compared With Placebo in the Management of Fibromyalgia|Quetiapine Compared With Placebo in the Management of Fibromyalgia|Completed||Phase 4|42|Actual|East Tennessee State University||2|||f||||f||||||||||2018-05-31 22:01:59.585752|2018-05-31 22:01:59.585752
NCT01458951|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2016-04-26||2016-04-26|2011-10-24|2011-10-25|Estimate|2016-04-26|2016-06-01|Estimate||||2016-04-26|2016-06-01|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|OCTAVE|The safety analysis set consists of all randomized participants who received at least 1 dose of study medication.|A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis.|Completed||Phase 3|547|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:02:00.095989|2018-05-31 22:02:00.095989
NCT01458938|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2017-01-30|2011-10-24|2011-10-25|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2009||2009-07-31|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|Substance P||This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.|Substance P Neuropeptide Levels in Saliva, Serum and Cerebrospinal Fluid in Patients With Spinal Disease: A Pilot Study|Terminated|||53|Actual|Carolina Neurosurgery & Spine Associates|||4|Study will need to be redesigned for improved efficacy.|f||||t||||||Samples Without DNA|"~     Blood, saliva and cerebrospinal fluid~   "|||2018-05-31 22:02:01.339634|2018-05-31 22:02:01.339634
NCT01458925|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2016-05-04|2011-10-24|2011-10-25|Estimate|||||||2016-05-04|2016-05-05|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Feasibility of Check-Cap's P1 Capsule System Screening|Feasibility, Multi-center Prospective Study of Check-Cap's P1 Capsule System in Patients Eligible for ColoRectal Cancer [CRC] Screening|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Ceck Cap Ltd.||1|||f||||t||||||||No||2018-05-31 22:02:01.509489|2018-05-31 22:02:01.509489
NCT01458912|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-11-21|2011-10-24|2011-10-25|Estimate|||||||2011-11-21|2011-11-23|Estimate|November 2011||2011-11-30|November 2011|2011-11-30||||May 2013|Anticipated|2013-05-31||Interventional|||Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids|A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of a 12-week Treatment With BI 54903 at Doses of 181.8 Mcg b.i.d. and 363.6 Mcg q.d. (p.m. Dosing) Administered Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy|Withdrawn||Phase 2|0|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:02:01.682529|2018-05-31 22:02:01.682529
NCT01458899|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2012-01-10|2011-10-24|2011-10-25|Estimate|||||||2012-01-10|2012-01-11|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|TC-5214||Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214|Phase I, Open-label, Randomized, Single-dose, Two Treatment (Fed Versus Fasted) Crossover Study to Assess the Effects of Food on the Pharmacokinetics of TC-5214 (S-Mecamylamine) in Healthy Subjects|Completed||Phase 1|18|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:02:01.984423|2018-05-31 22:02:01.984423
NCT01458886|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-10-30|2011-10-24|2011-10-25|Estimate|||||||2013-10-30|2013-10-31|Estimate|November 2011||2011-11-30|October 2013|2013-10-31||||May 2013|Anticipated|2013-05-31||Interventional|||Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study Assessing Efficacy and Safety of a 12 Week Treatment With BI 54903 Administered at 90.9 Mcg b.i.d. and 181.8 Mcg q.d. (p.m.Dosing) Via Respimat® Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone|Withdrawn||Phase 2|0|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:02:02.120777|2018-05-31 22:02:02.120777
NCT01458873|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2011-10-30|2011-10-21|2011-10-25|Estimate|||||||2011-10-30|2011-11-01|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Spontaneously Breathing Adult Volunteers|Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Spontaneously Breathing Adult Volunteers|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 22:02:02.373739|2018-05-31 22:02:02.373739
NCT01458860|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2011-10-31|2011-10-24|2011-10-25|Estimate|||||||2011-10-31|2011-11-01|Estimate|February 2012||2012-02-29|October 2011|2011-10-31|February 2014|Anticipated|2014-02-28|February 2012|Anticipated|2012-02-29||Observational|||Aortic Calcification - is it a Marker for Carotid Artery Stenosis?|Aortic Calcification - is it a Marker for Carotid Artery Stenosis?|Unknown status|Not yet recruiting||200|Anticipated|Ziv Hospital|||2||f||||f||||||||||2018-05-31 22:02:02.555305|2018-05-31 22:02:02.555305
NCT01458847|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2012-11-09|2011-10-21|2011-10-25|Estimate|||||||2012-11-09|2012-11-12|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer|A Single Dose, Dose-escalating, Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Intravesical Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer|Completed||Phase 1|12|Actual|BioCis Pharma Ltd||3|||f||||t||||||||||2018-05-31 22:02:02.625265|2018-05-31 22:02:02.625265
NCT01458834|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-22|||2011-10-22|2011-10-22|2011-10-25|Estimate|||||||2011-10-22|2011-10-25|Estimate|September 2011||2011-09-30|October 2011|2011-10-31||||July 2012|Anticipated|2012-07-31||Interventional|||Attentional Training for Smoking Cessation Via Handheld Device or Personal Computer|Attentional Training for Smoking Cessation Via Handheld Device or Personal Computer|Unknown status|Recruiting|N/A|60|Anticipated|Boston University||2|||f||||f||||||||||2018-05-31 22:02:02.770731|2018-05-31 22:02:02.770731
NCT01458808|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|April 2007||2007-04-30|October 2011|2011-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Dietary and Dialysate Sodium Reduction on Body Fluid Volume and Inflammatory State in Hemodialysis Patients|Effects of Dietary and Dialysate Sodium Reduction on Body Fluid Volume and Inflammatory State in Hemodialysis Patients. A Prospective Randomized Controlled Study|Completed||Phase 4|59|Actual|UPECLIN HC FM Botucatu Unesp||3|||f||||t||||||||||2018-05-31 22:02:03.051568|2018-05-31 22:02:03.051568
NCT01458795|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-11-02|2011-10-24|2011-10-25|Estimate|||||||2011-11-02|2011-11-03|Estimate||||November 2011|2011-11-30||||||||Interventional|||The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins|The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins|Completed||Phase 4|60|Anticipated|Baskent University|||||f||||t||||||||||2018-05-31 22:02:03.183657|2018-05-31 22:02:03.183657
NCT01458782|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2016-10-27|2011-10-24|2011-10-25|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|October 2024|Anticipated|2024-10-31|October 2014|Actual|2014-10-31||Interventional|||ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee|A Randomized Trial Comparing Autologous Chondrocyte Implantation Using Collagen Membrane (ACI-C) Versus (Autologous Matrix Induced Chondrogenesis) AMIC for Repair of Cartilage Defects in the Knee|Active, not recruiting||Phase 2/Phase 3|80|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 22:02:03.274314|2018-05-31 22:02:03.274314
NCT01458769|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-05-23|2011-10-24|2011-10-25|Estimate|||||||2013-05-23|2013-05-24|Estimate|December 2010||2010-12-31|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacokinetics, Safety & Tolerability of Isotopologs of Atazanavir (ATV), With Pharmacokinetic Comparison to Reyataz|Open-labeled, Randomized, Crossover, Single-dose Study in Healthy Male Subjects to Evaluate the Pharmacokinetics, Safety & Tolerability of Stable Isotopologs of Atazanavir (ATV), Administered as Single Agents or as Combinations of Two Isotopologs, With a Pharmacokinetic Comparison to Reyataz®.|Completed||Phase 1|47|Actual|Concert Pharmaceuticals||7|||f||||t||||||||||2018-05-31 22:02:03.398696|2018-05-31 22:02:03.398696
NCT01458756|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-10-24|2011-10-24|2011-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|GHEPA||Study of Psychological Defense Mechanisms Used by Liver Transplant Patients|Evaluation of Psychological Defense Mechanisms Used by Liver Transplant Patients on Their Somatic Psychological and Social Outcome. Research for Protective or Vulnerability Factors.|Completed|||81|Actual|University Hospital, Lille|||1||f||||f||||||||||2018-05-31 22:02:03.561835|2018-05-31 22:02:03.561835
NCT01458743|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-09-01|2011-10-24|2011-10-25|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2011||2011-10-31|September 2017|2017-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|CeftarolineChi||Ceftaroline China Pharmacokinetics Study|A Phase I, Single Center, Open Label, Two Groups Study to Assess the Safety and Pharmacokinetics of Ceftaroline in Healthy Chinese Volunteers Following Single and Multiple Administration of 600 mg Ceftaroline Fosamil as 60-minute Intravenous Infusion Every 12 Hours and as 120-minute Intravenous Infusion Every 8 Hours|Completed||Phase 1|24|Actual|Pfizer||2|||f||||||||||||||2018-05-31 22:02:03.697418|2018-05-31 22:02:03.697418
NCT01458730|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2012-11-15|2011-10-24|2011-10-25|Estimate|||||||2012-11-15|2012-11-16|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|October 2020|Anticipated|2020-10-31|October 2010|Actual|2010-10-31||Interventional|||Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma|Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomide.|Active, not recruiting||Phase 2|66|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 22:02:03.825155|2018-05-31 22:02:03.825155
NCT01458717|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-04-30|2011-10-24|2011-10-25|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2011||2011-11-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer|Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer|Completed||Phase 2/Phase 3|58|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:02:03.906866|2018-05-31 22:02:03.906866
NCT01458704|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-23|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|August 2011||2011-08-31|October 2011|2011-10-31||||April 2013|Anticipated|2013-04-30||Observational|||Cancer Genome Analysis|Cancer Genome Analysis|Unknown status|Recruiting||100|Anticipated|Seoul National University Hospital|||1||f||||||||||Samples With DNA|"~     fresh frozen tumor tissue~   "|||2018-05-31 22:02:03.985175|2018-05-31 22:02:03.985175
NCT01458691|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-05-21|2011-10-24|2011-10-25|Estimate|||||||2015-05-21|2015-05-25|Estimate|September 2013||2013-09-30|May 2015|2015-05-31||||March 2015|Actual|2015-03-31||Interventional|||Intra-articular Injection of Allogeneic Platelet Rich Plasma (PRP) for Adhesive Capsulitis|Intra-articular Injection of Allogeneic PRP for Adhesive Capsulitis|Completed||N/A|58|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:02:04.060301|2018-05-31 22:02:04.060301
NCT01458678|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2015-09-16|2011-10-24|2011-10-25|Estimate|||||||2015-09-16|2015-09-17|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Non Invasive Methods to Guide Volume Optimization|Evaluation of Non Invasive Methods for Goal Directed Fluid Therapy During Abdominal Surgery|Completed||N/A|150|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 22:02:04.18025|2018-05-31 22:02:04.18025
NCT01458665|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2014-06-16|2011-10-24|2011-10-25|Estimate|||||||2014-06-16|2014-06-18|Estimate|October 2011||2011-10-31|June 2014|2014-06-30||||December 2013|Actual|2013-12-31||Interventional|||Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma (PRP) in Medium to Large Rotator Cuff Tears|Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma (PRP) in Medium to Large Rotator Cuff Tears: A Randomized Controlled Trial|Completed||N/A|74|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:02:04.384082|2018-05-31 22:02:04.384082
NCT01458652|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2014-05-08|2011-10-24|2011-10-25|Estimate|||||||2014-05-08|2014-05-09|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation|Effect of Replacement Volume and AST-120 (Kremezin) on Protein-bound Toxins, Oxidative Stress and MicroInflammation in Patients Receiving Online Hemodiafiltration|Completed||Phase 4|30|Actual|Tungs’ Taichung Metroharbour Hospital||1|||f||||t||||||||||2018-05-31 22:02:04.681122|2018-05-31 22:02:04.681122
NCT01458184|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2013-04-05|2011-10-20|2011-10-24|Estimate|||||||2013-04-05|2013-04-08|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ComplexPt||Study of PhoneCare System to Treat Patients With Chronic Diseases|A Randomized Trial of the PhoneCare System to Improve Ambulatory Care for Patients With Chronic Diseases|Completed||N/A|264|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 22:02:26.479696|2018-05-31 22:02:26.479696
NCT01458639|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2015-07-20||2015-10-13|2011-10-24|2011-10-25|Estimate|2015-10-13|2015-11-10|Estimate||||2015-10-13|2015-11-10|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||All subjects enrolled in the trial.|Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism|A Comparison of Technegas® Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging in Subjects Being Evaluated for Pulmonary Embolism|Terminated||Phase 3|18|Actual|Cyclomedica Australia PTY Limited|PE adjudication by Independent Committee for final clinical diagnosis and blinded readings of Xe-133 and Technegas Ventilation and Tc-99m MAA Perfusion images were not performed due to early trial termination. No efficacy data available.|2||Decision to change trial design.|f||||t||||||||||2018-05-31 22:02:04.914137|2018-05-31 22:02:04.914137
NCT01458626|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-08-30|2011-10-24|2011-10-25|Estimate|||||||2017-08-30|2017-08-31|Actual|November 14, 2012|Actual|2012-11-14|August 2017|2017-08-31|August 24, 2016|Actual|2016-08-24|August 24, 2016|Actual|2016-08-24||Interventional|||Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement|A Double-blind, Active-controlled, Randomized Study Comparing Mirtazapine Combined With Paroxetine or Paroxetine Monotherapy in Patients With Major Depressive Patients Without Early Improvement in the First 2 Weeks|Completed||Phase 4|525|Actual|Capital Medical University||3|||f||||t||||||||||2018-05-31 22:02:05.412278|2018-05-31 22:02:05.412278
NCT01458613|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2018-05-18|2011-10-24|2011-10-25|Estimate|||||||2018-05-18|2018-05-21|Actual|October 2011||2011-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|BioMaroteaux||Biomarker for Maroteaux-Lamy Disease|Biomarker for Maroteaux-Lamy Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||80|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of mass-spectometry 7,5 ml EDTA~     blood, a dry blood spot filter card and a sputum tube are taken. To proof the correct~     Maroteaux-Lamy diagnosis in those patients where up to the enrollment in the study no genetic~     testing has been done, sequencing of Maroteaux-Lamy will be done as routine diagnostic.~      The analyses are done in the~      Albrecht-Kossel-Institute for Neuroregeneration Centre for Mental Health University of~     Rostock Gehlsheimerstrasse 20 D-18147 Rostock Germany~   "|Undecided||2018-05-31 22:02:05.613678|2018-05-31 22:02:05.613678
NCT01458600|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-02-23|2011-10-21|2011-10-25|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2006||2006-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|aGO||Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)|Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)|Completed||Phase 4|65|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 22:02:05.854231|2018-05-31 22:02:05.854231
NCT01458587|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2012-12-21||2013-03-12|2011-10-24|2011-10-25|Estimate|2012-12-21|2013-02-04|Estimate||||2013-03-12|2013-03-14|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)|A Phase II Study of Photodynamic Therapy (PDT)With LEVULAN® Topical Solution + Blue Light Versus LEVULAN® Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities|Completed||Phase 2|70|Actual|DUSA Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 22:02:06.272065|2018-05-31 22:02:06.272065
NCT01458574|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2017-04-07||2017-04-07|2011-10-24|2011-10-25|Estimate|2017-04-07|2017-05-18|Actual||||2017-04-07|2017-05-18|Actual|July 20, 2012|Actual|2012-07-20|April 2017|2017-04-30|May 27, 2016|Actual|2016-05-27|May 27, 2016|Actual|2016-05-27||Interventional|OCTAVE|Full analysis set (FAS) included all randomized participants.|A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis|Completed||Phase 3|593|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:02:10.607241|2018-05-31 22:02:10.607241
NCT01458561|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2013-07-05||2015-04-29|2011-10-21|2011-10-25|Estimate|2015-04-29|2015-05-15|Estimate||||2015-04-29|2015-05-15|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|BARRIER||Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery|An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding By Means of an Adjunctive Application of BioFoam Surgical Matrix in Liver Surgery|Terminated||Phase 3|1|Actual|CryoLife, Inc.|Early termination leading to small number of subjects evaluated (n=1).|2||Sponsor terminated due to signif. difficulty with pilot investigation enrollment|f||||t||||||||||2018-05-31 22:02:12.959451|2018-05-31 22:02:12.959451
NCT01458548|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-24|2011-10-24|2011-10-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|December 2002||2002-12-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|May 2008|Actual|2008-05-31||Interventional|||Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)|Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (Including 1st+2nd Amendment)|Terminated||Phase 2|70|Actual|Charite University, Berlin, Germany||||"This study had an major amendment in 12/2006 introducing risk stratified sequential treatment~   (RSST). The modified protocol is registered with NCT00590447."|f||||f||||||||||2018-05-31 22:02:13.717339|2018-05-31 22:02:13.717339
NCT01458535|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2016-05-31|2014-05-30|2016-05-31|2011-10-21|2011-10-25|Estimate|2016-05-31|2016-07-11|Estimate|2014-05-30|2014-06-17|Estimate|2016-05-31|2016-07-11|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Navigator|All participants who received at least 1 dose of study drug.|A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)|An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-267 With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|61|Actual|AbbVie||6|||f||||f||||||||||2018-05-31 22:02:13.916249|2018-05-31 22:02:13.916249
NCT01458522|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20||2015-08-13|2017-03-17|2011-10-24|2011-10-25|Estimate||||2015-08-13|2015-09-02|Estimate|2017-03-17|2017-03-20|Actual|May 2012||2012-05-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|TRENdS||Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures|Utility of Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures|Completed||Phase 2|74|Actual|Duke University||2|||f||||t||||||||||2018-05-31 22:02:16.075|2018-05-31 22:02:16.075
NCT01456793|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2017-03-06|2011-10-20|2011-10-21|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2011||2011-10-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of the Effectiveness of the Teen Options to Prevent Pregnancy (T.O.P.P.) Program|Evaluation of the Effectiveness of the Teen Options to Prevent Pregnancy (T.O.P.P.) Program|Completed||N/A|598|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 22:02:57.050695|2018-05-31 22:02:57.050695
NCT01458509|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-09-07|2011-10-21|2011-10-25|Estimate|||||||2017-09-07|2017-09-08|Actual|October 2011||2011-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys|A Comparison of the Feasibility and Psychometric Properties of Paper vs. Web vs. Automated Telephone Administration of Patient Reported Outcome Surveys|Active, not recruiting|||328|Anticipated|Memorial Sloan Kettering Cancer Center|||4||f||||||||||||||2018-05-31 22:02:16.302698|2018-05-31 22:02:16.302698
NCT01458496|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-03-14|2011-10-20|2011-10-24|Estimate|||||||2016-03-14|2016-03-16|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HC||Health Coaching to Effect Lifestyle Behaviour Change|Health Coaching to Effect Lifestyle Behaviour Change: A Randomized Trial of Individuals With Pre-disease|Completed||N/A|219|Actual|Memorial University of Newfoundland||2|||f||||t||||||||||2018-05-31 22:02:16.432904|2018-05-31 22:02:16.432904
NCT01458483|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2012-10-29|2011-10-20|2011-10-24|Estimate|||||||2012-10-29|2012-10-30|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ACES II||Acute Carotid Sinus Endovascular Stimulation II Study|Acute Carotid Sinus Endovascular Stimulation II Study|Completed||Phase 1|9|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 22:02:16.519523|2018-05-31 22:02:16.519523
NCT01458470|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-03-17|2011-10-21|2011-10-24|Estimate|||||||2014-03-17|2014-03-18|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|MITIGATE-HD||A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease|A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb Study|Completed||Phase 2|19|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 22:02:16.583866|2018-05-31 22:02:16.583866
NCT01458457|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-02-13|2011-10-21|2011-10-24|Estimate|||||||2015-02-13|2015-02-16|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|BBK||Life Quality and Mental State in Patients With Breast Cancer|Life Quality and Mental State in Patients With Breast Cancer - a Randomized Study|Completed||Phase 4|275|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:02:16.72811|2018-05-31 22:02:16.72811
NCT01458444|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2015-08-30|2011-10-21|2011-10-24|Estimate|||||||2015-08-30|2015-09-01|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|OPTIFLOW||BIPAP Vision Versus OPTIFLOW System Comparison in Acute Respiratory Failure After Cardio Thoracic Surgery|Acute Respiratory Failure After Cardio Thoracic Surgery: Non Invasive Ventilation (VNI) by BIPAP Vision Versus OPTIFLOW System, Comparison.|Completed||N/A|830|Actual|Centre Chirurgical Marie Lannelongue||2|||f||||t||||||||||2018-05-31 22:02:16.969127|2018-05-31 22:02:16.969127
NCT01458431|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2014-12-20|2011-10-20|2011-10-24|Estimate|||||||2014-12-20|2014-12-23|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Levobupivacaine to the Surgical Wound Following Cesarean|Efficacy of Continuous Infusion of Levobupivacaine to the Surgical Wound Following Cesarean|Completed||Phase 3|70|Actual|Complexo Hospitalario Universitario de A Coruña||2|||f||||t||||||||||2018-05-31 22:02:17.136306|2018-05-31 22:02:17.136306
NCT01458418|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2015-02-17|2011-10-20|2011-10-24|Estimate|||||||2015-02-17|2015-02-19|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children|A Trial of Montelukast for Maintenance Therapy of Eosinophilic Esophagitis in Children|Terminated||N/A|4|Actual|Children's Mercy Hospital Kansas City||3||Inability to complete enrollment due to difficulty in finding subjects|f||||f||||||||||2018-05-31 22:02:17.322778|2018-05-31 22:02:17.322778
NCT01458405|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2017-02-01|2011-10-21|2011-10-24|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|September 2021|Anticipated|2021-09-30|September 2017|Anticipated|2017-09-30||Interventional|ALLSTAR||Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration|Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction|Active, not recruiting||Phase 1/Phase 2|134|Anticipated|Capricor Inc.||2|||f||||t||||||||||2018-05-31 22:02:17.566008|2018-05-31 22:02:17.566008
NCT01458392|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2017-04-11||2017-05-23|2011-10-21|2011-10-24|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|October 2011||2011-10-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck|An Open-label Phase 2 Study of Dalantercept in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|46|Actual|Acceleron Pharma, Inc.||1|||f||||t||||||||||2018-05-31 22:02:17.793985|2018-05-31 22:02:17.793985
NCT01458366|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2017-12-04|2011-10-20|2011-10-24|Estimate|||||||2017-12-04|2017-12-06|Actual|November 9, 2011|Actual|2011-11-09|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|April 2020|Anticipated|2020-04-30||Interventional|||Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas|Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas|Recruiting||Phase 1/Phase 2|36|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 22:02:18.799346|2018-05-31 22:02:18.799346
NCT01458353|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-21|2011-10-21|2011-10-24|Estimate|||||||2011-10-21|2011-10-24|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer|Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer: Are There Differences in the Peritoneal Contamination After Performing a Stapled or a Handsewn Anastomosis?|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 22:02:18.96784|2018-05-31 22:02:18.96784
NCT01458340|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2015-03-04|2011-10-21|2011-10-24|Estimate|||||||2015-03-04|2015-03-06|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|285|Actual|Theravance Biopharma R & D, Inc.||3|||f||||f||||||||||2018-05-31 22:02:19.079475|2018-05-31 22:02:19.079475
NCT01457521|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2015-08-11||2015-12-10|2011-10-21|2011-10-24|Estimate|2015-12-10|2016-01-13|Estimate||||2015-12-10|2016-01-13|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Inclusive of participants who provided follow-up data only|Pain Control In First Trimester Medical Abortion: A Randomized Trial|PAIN CONTROL IN FIRST TRIMESTER MEDICAL ABORTION: A Randomized Trial|Completed||Phase 4|250|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 22:02:42.242865|2018-05-31 22:02:42.242865
NCT01458327|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12||2016-08-18|2017-02-13|2011-10-20|2011-10-24|Estimate||||2016-08-18|2016-08-23|Estimate|2017-02-13|2017-02-14|Actual|November 2011||2011-11-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|||Additional MDMA-assisted Psychotherapy for People Who Relapsed After MDMA-assisted Psychotherapy Trial|An Open-Label Proof-of-Principle Study Testing the Use of an Additional MDMA-Assisted Psychotherapy Session in People Who Relapsed After Participating in a Phase 2 Clinical Trial of MDMA-Assisted Psychotherapy to Treat Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)|Completed||Phase 2|3|Actual|Multidisciplinary Association for Psychedelic Studies||1|||f||||f||||||||||2018-05-31 22:02:19.211749|2018-05-31 22:02:19.211749
NCT01458314|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2015-11-12|2011-10-21|2011-10-24|Estimate|||||||2015-11-12|2015-11-13|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Non Invasive Mechanical Ventilation in Chronic Respiratory Insufficiency Patients During Rehabilitation|Evaluation of the Additional Effect of Non Invasive Mechanical Ventilation During a Rehabilitative Program With Cycloergometer in Patients With Chronic Respiratory Insufficiency Using Nocturnal Home Ventilation|Completed||N/A|35|Actual|Fondazione Salvatore Maugeri||2|||f||||t||||||||||2018-05-31 22:02:19.566663|2018-05-31 22:02:19.566663
NCT01458301|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-02-24|2011-10-21|2011-10-24|Estimate|||||||2014-02-24|2014-02-25|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety of TAK-385 in the Treatment of Endometriosis|A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Endometriosis|Completed||Phase 2|487|Actual|Takeda||5|||f||||f||||||||||2018-05-31 22:02:19.714365|2018-05-31 22:02:19.714365
NCT01458288|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2014-12-16||2018-04-27|2011-10-20|2011-10-24|Estimate|2014-12-25|2015-01-08|Estimate||||2018-04-27|2018-05-25|Actual|October 2012||2012-10-31|April 2018|2018-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease||Completed||Phase 2|12|Actual|TaiGen Biotechnology Co., Ltd.||1|||f||||||||||||||2018-05-31 22:02:19.945908|2018-05-31 22:02:19.945908
NCT01458275|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2014-03-10||2014-04-16|2011-10-21|2011-10-24|Estimate|2014-04-16|2014-05-15|Estimate||||2014-04-16|2014-05-15|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)|A 2-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6 to 11 Years With Seasonal Allergic Rhinitis|Completed||Phase 3|847|Actual|Sunovion||3|||f||||f||||||||||2018-05-31 22:02:20.300596|2018-05-31 22:02:20.300596
NCT01458262|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2014-01-27|2011-10-20|2011-10-24|Estimate|||||||2014-01-27|2014-01-29|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Observational|||Observational Study on the Clinical Impact of Desaturation During Liver Surgery|Observational Study on the Clinical Impact of Systemic and Cerebral Desaturation During Liver Transplantation and Hepatectomy|Completed|||100|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 22:02:22.404346|2018-05-31 22:02:22.404346
NCT01458249|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|2016-02-07||2016-03-09|2011-10-21|2011-10-24|Estimate|2016-03-09|2016-03-28|Estimate||||2016-03-09|2016-03-28|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|November 2014|Actual|2014-11-30||Interventional||Full analysis set included all participants who received at least one dose of study drug. Arm 1 included all participants with ADI or LMS. Arm 2 included all participants with OTH.|An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)|An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma|Completed||Phase 2|52|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 22:02:22.504596|2018-05-31 22:02:22.504596
NCT01458236|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-05-10|2011-10-20|2011-10-24|Estimate|||||||2012-05-10|2012-05-14|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor|A Multinational, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor|Withdrawn||Phase 3|0|Actual|Lung Biotechnology PBC||2|||f||||t||||||||||2018-05-31 22:02:24.784651|2018-05-31 22:02:24.784651
NCT01458223|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2017-03-07|2011-10-20|2011-10-24|Estimate|||||||2017-03-07|2017-03-08|Actual|October 2011||2011-10-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PARISS||The Effect of Prolonged Postoperative Antibiotics Administration on Rate of Infection in Patients Undergoing Posterior Spine Surgery Requiring a Hemovac Drain|The Effect of Prolonged Postoperative Antibiotics Administration on Rate of Infection in Patients Undergoing Posterior Spine Surgery Requiring a Hemovac Drain|Recruiting||Phase 4|1066|Anticipated|The London Spine Centre||2|||f||||f||||||||||2018-05-31 22:02:25.331625|2018-05-31 22:02:25.331625
NCT01458210|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2014-10-03||2014-10-03|2011-10-20|2011-10-24|Estimate|2014-10-03|2014-10-08|Estimate||||2014-10-03|2014-10-08|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Participants who received at least 1 dose of study drug.|A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants|Effect of Dulaglutide (LY2189265) on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects|Completed||Phase 1|22|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:02:25.552497|2018-05-31 22:02:25.552497
NCT01458197|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2014-03-11|2011-10-20|2011-10-24|Estimate|||||||2014-03-11|2014-03-12|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.|A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.|Completed||Phase 2|235|Actual|Kwang Dong Pharmaceutical co., ltd.||3|||f||||f||||||||||2018-05-31 22:02:26.30881|2018-05-31 22:02:26.30881
NCT01458171|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|2013-02-27||2013-02-27|2011-10-21|2011-10-24|Estimate|2013-02-27|2013-04-09|Estimate||||2013-02-27|2013-04-09|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)|A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency|Completed||Phase 3|23|Actual|CSL Behring||1|||f||||||||||||||2018-05-31 22:02:26.61847|2018-05-31 22:02:26.61847
NCT01458158|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2015-02-20|2011-10-21|2011-10-24|Estimate|||||||2015-02-20|2015-02-23|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|MMACKD||Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease|The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease|Unknown status|Recruiting||300|Anticipated|Aristotle University Of Thessaloniki|||3||f||||f||||||Samples Without DNA|"~     serum and vessels~   "|||2018-05-31 22:02:27.092998|2018-05-31 22:02:27.092998
NCT01458145|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-01-12|2011-10-20|2011-10-24|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2009|Actual|2009-09-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Minding the Baby Home Visiting: Program Evaluation|Minding the Baby Home Visiting: Program Evaluation|Completed||N/A|151|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:02:27.167176|2018-05-31 22:02:27.167176
NCT01458132|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2017-06-06|2011-10-20|2011-10-24|Estimate|||||||2017-06-06|2017-06-08|Actual|July 29, 2011|Actual|2011-07-29|June 2017|2017-06-30|April 30, 2013|Actual|2013-04-30|April 30, 2013|Actual|2013-04-30||Interventional|||Drug Exposure Registry for GSK2248761, an Investigational NNRTI|Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761|Completed||N/A|1|Actual|ViiV Healthcare||2|||f||||f|f|f||||||||2018-05-31 22:02:27.289983|2018-05-31 22:02:27.289983
NCT01458119|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20||2017-05-23|2018-01-09|2011-10-20|2011-10-24|Estimate||||2017-05-23|2017-05-25|Actual|2018-01-09|2018-01-16|Actual|October 2011||2011-10-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|AT1001-041||Open-Label Phase 3 Long-Term Safety Study of Migalastat|An Open-Label Extension Study to Evaluate the LongTerm Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease|Completed||Phase 3|85|Actual|Amicus Therapeutics||1|||f||||t||||||||||2018-05-31 22:02:27.492741|2018-05-31 22:02:27.492741
NCT01458106|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2014-12-04||2017-02-27|2011-10-21|2011-10-24|Estimate|2014-12-04|2014-12-12|Estimate||||2017-02-27|2017-03-28|Actual|November 2012||2012-11-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Kids ALONG||Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A|An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A|Completed||Phase 3|71|Actual|Bioverativ Therapeutics Inc.||1|||f||||t||||||||||2018-05-31 22:02:27.72146|2018-05-31 22:02:27.72146
NCT01458093|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-20|2011-10-20|2011-10-24|Estimate|||||||2011-10-20|2011-10-24|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Large Overuse of Post-polypectomy Surveillance Colonoscopy|Large Overuse of Post-polypectomy Surveillance Colonoscopy: a Prospective Nation-wide Study|Completed|||7081|Actual|Valduce Hospital|||1||f||||f||||||||||2018-05-31 22:02:28.755924|2018-05-31 22:02:28.755924
NCT01458080|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2013-12-05|2011-10-20|2011-10-24|Estimate|||||||2013-12-05|2013-12-09|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||WEUSKOP5410: Observational Study in ENABLE Clinical Trials|WEUSKOP5410: A Retrospective Observational Non-Interventional Nested Case Control Study to Evaluate the Risk for Thromboembolic Events Associated With Surgery and Eltrombopag Exposure in the ENABLE Studies|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:02:28.997247|2018-05-31 22:02:28.997247
NCT01458067|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-04-27|2011-10-20|2011-10-24|Estimate|||||||2017-04-27|2017-04-28|Actual|November 10, 2011|Actual|2011-11-10|April 2017|2017-04-30|February 25, 2016|Actual|2016-02-25|November 12, 2015|Actual|2015-11-12||Interventional|||A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency|A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency|Completed||Phase 1|30|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 22:02:29.323363|2018-05-31 22:02:29.323363
NCT01458054|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2017-07-18|2011-10-20|2011-10-24|Estimate|||||||2017-07-18|2017-07-21|Actual|September 27, 2011|Actual|2011-09-27|July 2017|2017-07-31|November 28, 2011|Actual|2011-11-28|November 28, 2011|Actual|2011-11-28||Interventional|||Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults|Phase 1, Open Label Study to Evaluate the Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults|Completed||Phase 1|28|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 22:02:29.541733|2018-05-31 22:02:29.541733
NCT01458041|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2015-02-27|2011-10-20|2011-10-24|Estimate|||||||2015-02-27|2015-03-02|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||Iloprost Therapy in Patients With Critical Limb Ischemia|Iloprost Therapy in Patients With Critical Limb Ischemia: Evaluation of Efficacy and Safety|Completed|||126|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:02:29.844084|2018-05-31 22:02:29.844084
NCT01458028|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2014-05-05|2011-10-21|2011-10-24|Estimate|||||||2014-05-05|2014-05-06|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Age and Gender Effects on the Pharmacokinetics of BAY85-3934|A Parallel Group, Double-Blind Study to Evaluate the Effects of Age and Gender on the Single-Dose Pharmacokinetics of BAY85-3934, Tablet Formulation|Completed||Phase 1|48|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:02:29.974599|2018-05-31 22:02:29.974599
NCT01458015|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-03-25|2011-10-20|2011-10-24|Estimate|||||||2014-03-25|2014-03-26|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain|Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain|Terminated||Phase 4|5|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 22:02:30.196242|2018-05-31 22:02:30.196242
NCT01458002|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-05-10|2011-10-20|2011-10-24|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Project RAISE||Online Tailored Interventions & Relational Agents for Exercise and Sun Protection|Online Tailored Interventions & Relational Agents for Exercise and Sun Protection|Completed||N/A|1364|Actual|University of Rhode Island||3|||f||||f||||||||No||2018-05-31 22:02:30.576971|2018-05-31 22:02:30.576971
NCT01457989|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-10-25|2011-10-20|2011-10-24|Estimate|||||||2012-10-25|2012-10-29|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304|Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extensions of Studies VRX-RET-E22-301 and VRX-RET-E22-302)|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:02:30.731342|2018-05-31 22:02:30.731342
NCT01457976|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2016-08-17|2011-10-20|2011-10-24|Estimate|||||||2016-08-17|2016-08-18|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||A Survey on Attitudes on Financial Incentives|A Survey on Attitudes on Personal Responsibility and the Use of Financial Incentives for Health Promotion|Withdrawn|||0|Actual|University of Pennsylvania|||3|protocol never approved by local IRB|f||||f||||||||||2018-05-31 22:02:30.80073|2018-05-31 22:02:30.80073
NCT01457963|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-10-21|2011-10-21|2011-10-24|Estimate|||||||2011-10-21|2011-10-24|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|PEICU||Prevalence of Pulmonary Embolism in ICU|Pulmonary Embolism in Mechanically Ventilated Patients Requiring Computed Tomography: Prevalence, Risk Factors and Outcome|Completed|||176|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 22:02:30.894564|2018-05-31 22:02:30.894564
NCT01457950|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2013-08-22||2014-04-17|2011-10-20|2011-10-24|Estimate|2013-08-22|2013-10-29|Estimate||||2014-04-17|2014-05-07|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab|A Six Month Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study With a Six Month Open-Label Extension to Evaluate the Efficacy and Safety of Denosumab in Korean Postmenopausal Women With Osteoporosis|Completed||Phase 3|135|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 22:02:31.189153|2018-05-31 22:02:31.189153
NCT01457937|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-08|||2012-09-29|2011-10-20|2011-10-24|Estimate|||||||2012-09-29|2012-10-02|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|MEN_BOC||Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)|Boceprevir/Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba) in Difficult-to-Treat Menopausal Women With Chronic Hepatitis C Genotype 1 (Gt 1), Either Deemed Nonresponders to Peginterferon/Ribavirin or Treatment-naives (MEN_BOC)|Unknown status|Recruiting|Phase 3|240|Anticipated|University of Modena and Reggio Emilia||2|||f||||t||||||||||2018-05-31 22:02:33.574083|2018-05-31 22:02:33.574083
NCT01457924|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2017-03-21|2013-11-27|2018-05-24|2011-10-20|2011-10-24|Estimate|2018-02-28|2018-03-01|Actual|2014-01-16|2014-02-12|Estimate|2018-05-24|2018-05-30|Actual|November 1, 2011||2011-11-01|May 2018|2018-05-31|June 10, 2015|Actual|2015-06-10|August 23, 2013|Actual|2013-08-23||Interventional|MIRROR||Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)|Completed||Phase 2|232|Actual|GlaxoSmithKline|The incorrect exclusion of one par. from ITT pop. at Wk 24 was not considered to impact overall interpretation of data: no updates were made to source tables/analyses. This par. had withdrawn early, having never received a dose of active study drug.|8|||f||||t||||||||||2018-05-31 22:02:33.731759|2018-05-31 22:02:33.731759
NCT01457911|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-05-07|2011-10-21|2011-10-24|Estimate|||||||2014-05-07|2014-05-08|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin|A Multicenter, Randomized, Open-label, 2-arm Parallel Group, 20-week Study Comparing the Efficacy and Safety of Fixed-dose Combination of 1 mg Glimepiride and 250 mg Metformin (AMARYL M 1/250 mg) Versus Glimepiride (AMARYL®) in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin.|Completed||Phase 3|244|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:02:34.938048|2018-05-31 22:02:34.938048
NCT01457898|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-21|2011-10-20|2011-10-24|Estimate|||||||2011-10-21|2011-10-25|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Non-invasive Mechanical Ventilation After Cardiac Surgery|Effects of Non-invasive Mechanical Ventilation on Hemodynamics and Gas Exchanges Parameters After Cardiac Surgery in Patients With Relative Hypoxemia|Completed||N/A|42|Actual|Irmandade Santa Casa de Misericórdia de Porto Alegre||1|||f||||f||||||||||2018-05-31 22:02:35.042857|2018-05-31 22:02:35.042857
NCT01457885|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2016-06-14||2017-05-03|2011-10-21|2011-10-24|Estimate|2016-06-14|2016-07-25|Estimate||||2017-05-03|2017-06-02|Actual|November 2011||2011-11-30|May 2017|2017-05-31|June 14, 2016|Actual|2016-06-14|November 2014|Actual|2014-11-30||Interventional|CloBu4|75 patients were enrolled. Only 74 patients were treated. Of the treated patients, 3 were pediatric and were left off of the analysis. 71 adult patients were analyzed.|Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen|Multi-center Single Arm Phase II Study of Myeloablative Allogeneic Stem Cell Transplantation for Non-remission Acute Myeloblastic Leukemia (AML) Using Clofarabine and Busulfan x 4 (CloBu4) Regimen|Completed||Phase 2|75|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 22:02:35.134745|2018-05-31 22:02:35.134745
NCT01457872|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2014-11-24|2011-10-20|2011-10-24|Estimate|||||||2014-11-24|2014-11-25|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MATRIS||Malmö Treatment Referral and Intervention Study|Malmö Treatment Referral and Intervention Study|Completed||N/A|79|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:02:35.482283|2018-05-31 22:02:35.482283
NCT01457859|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2011-10-21|2011-10-21|2011-10-24|Estimate|||||||2011-10-21|2011-10-24|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Effectiveness of Triclosan Coated Sutures in Preventing Leg Wound Infection After Coronary Artery Bypass Surgery|Effectiveness of Triclosan Coated VICRYL\MONOCRYL Sutures in Preventing Leg Wound Infection Compared to POLYSORB\ BIOSYN Sutures in Patients After Coronary Bypass Surgery- a Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|410|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:02:35.56274|2018-05-31 22:02:35.56274
NCT01457508|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2017-06-15|2011-10-20|2011-10-24|Estimate|||||||2017-06-15|2017-06-16|Actual|January 1999||1999-01-31|June 2017|2017-06-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately|Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Vaccine Mixed With Hib Vaccine to Healthy Infants at 3, 5 and 11 Months of Age, Compared to Each Vaccine Administered Separately|Completed||Phase 3|440|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:02:42.45114|2018-05-31 22:02:42.45114
NCT01457846|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2016-02-11||2017-01-16|2011-10-20|2011-10-24|Estimate|2017-01-16|2017-03-07|Actual||||2017-01-16|2017-03-07|Actual|November 2011||2011-11-30|January 2017|2017-01-31|February 2015|Actual|2015-02-28|August 2013|Actual|2013-08-31||Interventional|SHINE||Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer|A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy Versus Paclitaxel in Patients With Advanced Gastric Adenocarcinoma (Inc. Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction)With FGFR2 Polysomy or Gene Amplification.|Terminated||Phase 2|960|Actual|AstraZeneca|Prompted by slow recruitment, AZ and the SRC instigated unscheduled analysis of the efficacy and tolerability. It was concluded that the study was unlikely to meet its primary objective. Enrolment ceased and the study closed.|2|||f||||||||||||||2018-05-31 22:02:35.655804|2018-05-31 22:02:35.655804
NCT01457833|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-21|2011-10-21|2011-10-24|Estimate|||||||2011-10-21|2011-10-24|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Implantation of Endobronchial Valves Versus Intrabronchial Valves in Patients With Severe Heterogeneous Emphysema|Endoscopic Lung Volume Reduction by Implantation of Endobronchial Valves (EBV) vs. Intrabronchial Valves (IBV) in Patients With Severe Heterogeneous Emphysema|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Heidelberg University||2|||f||||||||||||||2018-05-31 22:02:37.154394|2018-05-31 22:02:37.154394
NCT01457820|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2015-05-26|2011-10-20|2011-10-24|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ALLACS||Allopurinol in Acute Coronary Syndrome|Allopurinol as a Possible New Therapy for Acute Coronary Syndromes:The Next Steps|Terminated||Phase 4|26|Actual|University of Dundee||3||slow recruitment: stopped early|f||||f||||||||||2018-05-31 22:02:37.239525|2018-05-31 22:02:37.239525
NCT01457807|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-08-16|2011-10-20|2011-10-24|Estimate|||||||2012-08-16|2012-08-17|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers|A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Different Extended Release Formulations of Tablets of AZD3241 (300 mg) After Administration of Multiple Doses in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 22:02:37.325461|2018-05-31 22:02:37.325461
NCT01457794|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2017-03-03|2011-10-20|2011-10-24|Estimate|||||||2017-03-03|2017-03-06|Actual|May 2011||2011-05-31|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||OPUS School Meal Study|OPUS(Optimal Well-being, Development and Health for Danish Children Through a Healthy New Nordic Diet) School Meal Study|Completed||N/A|834|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 22:02:37.443976|2018-05-31 22:02:37.443976
NCT01457781|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12||2015-01-30|2016-08-02|2011-10-19|2011-10-24|Estimate||||2015-01-30|2015-02-18|Estimate|2016-08-02|2016-08-04|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|October 2014|Actual|2014-10-31||Interventional|PAH||Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)|A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 2|80|Actual|Bellerophon||3|||f||||t||||||||||2018-05-31 22:02:37.618973|2018-05-31 22:02:37.618973
NCT01457768|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2018-05-03|2011-10-20|2011-10-24|Estimate|||||||2018-05-03|2018-05-04|Actual|December 19, 2011|Actual|2011-12-19|May 2018|2018-05-31|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Observational|||A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response|A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection|Completed|||570|Actual|Gilead Sciences|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 22:02:37.858671|2018-05-31 22:02:37.858671
NCT01457755|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-12-08|2011-10-20|2011-10-24|Estimate|||||||2017-12-08|2017-12-12|Actual|April 13, 2012|Actual|2012-04-13|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Gilead Sustained Virologic Response (SVR) Registry|A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection|Completed|||6625|Actual|Gilead Sciences|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 22:02:38.611855|2018-05-31 22:02:38.611855
NCT01457742|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2012-07-06|2011-10-20|2011-10-24|Estimate|||||||2012-07-06|2012-07-10|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effectiveness Study of the Ivivi SofPulse for Pain Amelioration in Adults With Mild to Moderate Knee Osteoarthritis|Non-thermal Pulsed Radio Frequency for Pain Amelioration in Adults With Knee Osteoarthritis: A Double-blind, Randomized, Sham-controlled Trial|Terminated||Phase 4|45|Actual|Amp Orthopedics, Inc.||2||Sponsor decision|f||||f||||||||||2018-05-31 22:02:39.236701|2018-05-31 22:02:39.236701
NCT01457729|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-09-17|2011-10-20|2011-10-24|Estimate|||||||2012-09-17|2012-09-18|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Ergometer Training in Patients With OSA|Telemedizinisches Trainings-Monitoring Von Patienten Mit Obstruktivem Schlafapnoesyndrom|Completed||N/A|24|Actual|Institut für Pneumologie Hagen Ambrock eV||2|||f||||f||||||||||2018-05-31 22:02:39.326711|2018-05-31 22:02:39.326711
NCT01457716|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-02-02|2011-10-20|2011-10-24|Estimate|||||||2012-02-02|2012-02-03|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Pharmacokinetic Pilot Study on Budesonide/Formoterol|Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||N/A|17|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 22:02:39.413242|2018-05-31 22:02:39.413242
NCT01457703|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2014-06-19||2016-11-15|2011-10-20|2011-10-24|Estimate|2015-03-12|2015-03-25|Estimate||||2016-11-15|2017-01-12|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Reproductive Hormonal Alterations in Obesity|Reproductive Hormonal Alterations in Obesity, AIMS #1 & #2|Completed||N/A|62|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:02:39.548643|2018-05-31 22:02:39.548643
NCT01457690|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2015-11-12|2011-10-20|2011-10-24|Estimate|||||||2015-11-12|2015-11-13|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|VEDROP||Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention|Study of the Absorption of Vitamin E Water-soluble Form (Pegylated) in the Familial Hypocholesterolemia With Chylomicron Retention|Completed||Phase 3|14|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 22:02:40.007091|2018-05-31 22:02:40.007091
NCT01457677|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20||2016-07-08|2016-11-01|2011-10-20|2011-10-24|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment|A Multi Center, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder Having Inadequate Response to Ongoing Antidepressant Treatment (ARTDeCo)|Completed||Phase 2|357|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 22:02:40.111552|2018-05-31 22:02:40.111552
NCT01457664|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2016-11-01|2011-10-20|2011-10-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of RO4995819 in Healthy Elderly Volunteers|A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of RO4995819 Following Oral Administration in Healthy Elderly Subjects.|Completed||Phase 1|30|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:02:40.523228|2018-05-31 22:02:40.523228
NCT01457651|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-06-24|2011-10-21|2011-10-24|Estimate|||||||2013-06-24|2013-06-25|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|RECR-CABG||Comparison of Four Different Recruitment Maneuvers in Patients After Coronary Surgery|Comparison of Different Types of Postoperative Pulmonary Recruitment and Predicting Its Efficacy Following Off-pump Coronary Artery Bypass Grafting|Completed||N/A|76|Actual|Northern State Medical University||4|||f||||f||||||||||2018-05-31 22:02:40.755861|2018-05-31 22:02:40.755861
NCT01457638|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2011-10-20|2011-10-20|2011-10-24|Estimate|||||||2011-10-20|2011-10-24|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Inferior Turbinate Surgery in Rhinoseptoplasty: a Randomized Clinical Trial With Quality of Life Outcomes|Inferior Turbinate Surgery in Rhinoseptoplasty: a Randomized Clinical Trial With Quality of Life and Acoustic Rhinometry Outcomes|Unknown status|Recruiting|N/A|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 22:02:40.866979|2018-05-31 22:02:40.866979
NCT01457625|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2011-10-20|2011-10-20|2011-10-24|Estimate|||||||2011-10-20|2011-10-24|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Clinical Study of Serum Fetuin A Level, Insulin Resistance and Hepatic Fat Content in Dialysis Patients|The Association of Serum Fetuin A Level, Insulin Resistance and Hepatic Fat Content and Their Associations With Overall Survival in Maintenance Hemodialysis and Peritoneal Dialysis Patients|Unknown status|Recruiting||300|Anticipated|Far Eastern Memorial Hospital|||1||f||||t||||||||||2018-05-31 22:02:40.9893|2018-05-31 22:02:40.9893
NCT01457612|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-03-15|2011-10-20|2011-10-24|Estimate|||||||2018-03-15|2018-03-16|Actual|October 1, 2011|Actual|2011-10-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)|Effect of 6 Weeks Strawberry Supplementation on Insulin Action and Associated Risk Factors in Insulin Resistant (IR) Subjects (STR2)|Active, not recruiting||N/A|45|Actual|Institute for Food Safety and Health, United States||3|||f||||f||||||||||2018-05-31 22:02:41.114398|2018-05-31 22:02:41.114398
NCT01457599|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-08-15|2011-10-21|2011-10-24|Estimate|||||||2016-08-15|2016-08-16|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Computertomography-guided Wire Marking of the Liver|Computertomography-guided Wire Marking of Colorectal Hepatic Metastases After Complete Response to Neoadjuvant Chemotherapy. A Pilot Study|Completed|||20|Actual|Medical University of Graz|||1||f||||f||||||||Undecided||2018-05-31 22:02:41.252039|2018-05-31 22:02:41.252039
NCT01457586|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-21|2011-10-21|2011-10-24|Estimate|||||||2011-10-21|2011-10-24|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery|Observational Study of Hemoderivative Imputable Complications in Initial Uncomplicated Heart Surgery|Unknown status|Recruiting|Phase 4|200|Anticipated|Hospital Pitangueiras||2|||f||||t||||||||||2018-05-31 22:02:41.318207|2018-05-31 22:02:41.318207
NCT01457573|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|2015-04-23||2018-03-19|2011-10-21|2011-10-24|Estimate|2018-03-19|2018-04-02|Actual||||2018-03-19|2018-04-02|Actual|October 2011|Actual|2011-10-31|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|LUTS||Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms|Urinary Nerve Growth Factor as a Biomarker for Medical Treatment of Male Lower Urinary Tract Symptoms: A Pilot Trial|Completed||Phase 4|10|Actual|The Methodist Hospital System||1|||f||||f|t|f|||f|||Undecided|Plan to share data to be determined.|2018-05-31 22:02:41.456854|2018-05-31 22:02:41.456854
NCT01457560|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2016-08-04|2011-10-20|2011-10-24|Estimate|||||||2016-08-04|2016-08-05|Estimate|February 2000||2000-02-29|August 2016|2016-08-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine|Study to Assess the Immunogenicity and Reactogenicity of DTPa-HBV-IPV Mixed With Hib Vaccine in Healthy Infants, Followed by a Dose of the Same Vaccine Administered Simultaneously With One Dose of Oral Polio Vaccine (OPV)|Completed||Phase 3|80|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:02:41.891518|2018-05-31 22:02:41.891518
NCT01457547|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2016-08-04|2011-10-20|2011-10-24|Estimate|||||||2016-08-04|2016-08-05|Estimate|October 2003||2003-10-31|August 2016|2016-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course|Study to Assess and Compare the Immunogenicity and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA) and Aventis Pasteur MSD's DTPa-HBV-IPV-Hib Vaccine (HEXAVAC™) Given at 3, 5 and 11-12 Months of Age|Completed||Phase 4|494|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:02:41.988488|2018-05-31 22:02:41.988488
NCT01457534|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2013-02-26|2011-10-21|2011-10-24|Estimate|||||||2013-02-26|2013-02-27|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||The Predictors for Continuous Renal Replacement Therapy in Liver Transplant Patient||Completed|||148|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 22:02:42.114985|2018-05-31 22:02:42.114985
NCT01455623|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2014-03-25|2011-10-19|2011-10-20|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|6604||Development and Validation of a Disability Severity Index for CMT|Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease|Completed|||291|Actual|University of Iowa|||2||f||||f||||||||||2018-05-31 22:03:17.428948|2018-05-31 22:03:17.428948
NCT01457495|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-06-15|2011-10-20|2011-10-24|Estimate|||||||2017-06-15|2017-06-16|Actual|September 1998||1998-09-30|June 2017|2017-06-30|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly|Study to Assess Immunogenicity and Reactogenicity of SB Biologicals' DTPa-HBV-IPV/Hib Vaccine Given as Three-dose Primary Vaccination Course Compared to DTPa-IPV/Hib and HBV Administered Concomitantly at Separate Sites|Completed||Phase 2|312|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:02:42.533927|2018-05-31 22:02:42.533927
NCT01457482|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2012-02-13|2011-10-19|2011-10-24|Estimate|||||||2012-02-13|2012-02-14|Estimate|May 2011||2011-05-31|February 2012|2012-02-29||||December 2012|Anticipated|2012-12-31||Interventional|||Art Therapy as Treatment for Fear of Childbirth|Art Therapy as Treatment for Fear of Childbirth:a Randomized Controlled Study|Unknown status|Recruiting|N/A|124|Anticipated|Helsingborgs Hospital||2|||f||||f||||||||||2018-05-31 22:02:42.651932|2018-05-31 22:02:42.651932
NCT01457469|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2017-05-25|2011-10-21|2011-10-24|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2011||2011-01-31|February 2017|2017-02-28|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer|Adapting Smoking Cessation Interventions for the Outpatient Oncology Setting|Completed||Phase 1|6|Actual|Wake Forest University Health Sciences||2|||f||||f|t|f||||||||2018-05-31 22:02:42.746572|2018-05-31 22:02:42.746572
NCT01457456|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2018-05-15|2011-10-21|2011-10-24|Estimate|||||||2018-05-15|2018-05-18|Actual|October 2011||2011-10-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|BioMorquio||Biomarker for Morquio Disease|Biomarker for Morquio Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||250|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml EDTA~     blood,sputum tube and a dry blood spot filter card are taken. To proof the correct Morquio~     diagnosis in those patients where up to the enrollment in the study no genetic testing has~     been done, sequencing of Morquio will be done. The analyses are done in the~     Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20,~     18055 Rostock (Germany)~   "|||2018-05-31 22:02:42.831941|2018-05-31 22:02:42.831941
NCT01457443|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-21|||2018-05-18|2011-10-21|2011-10-24|Estimate|||||||2018-05-18|2018-05-21|Actual|October 2011||2011-10-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|BioPompe||Biomarker for Pompe Disease|Biomarker for Pompe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||80|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml EDTA~     blood,sputum tube and a dry blood spot filter card are taken. To proof the correct Pompe~     diagnosis in those patients where up to the enrollment in the study no genetic testing has~     been done, sequencing of Pompe will be done. The analyses are done in the~     Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20,~     18055 Rostock (Germany)~   "|Undecided||2018-05-31 22:02:42.920083|2018-05-31 22:02:42.920083
NCT01457430|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2016-08-11||2016-10-17|2011-10-20|2011-10-24|Estimate|2016-10-17|2016-10-18|Estimate||||2016-10-17|2016-10-18|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|IHA||Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE|Open Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema (IHA)|Completed||Phase 4|19|Actual|Massachusetts General Hospital|All adverse events were recorded and assessed out of total attacks, not total participants. There were 78 HAE attacks; 4 adverse events were identified.|1|||f||||t||||||||Undecided|The data is under review for publication but individual data will likely not be available|2018-05-31 22:02:43.11909|2018-05-31 22:02:43.11909
NCT01457417|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|2015-01-13||2016-09-26|2011-10-21|2011-10-24|Estimate|2016-09-26|2016-09-28|Estimate||||2016-09-26|2016-09-28|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors|A Two Part Phase 1 Multicenter Open-label Study of DKN-01 Given Intravenously. Part A: Dose-Escalation in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: Expansion Cohort in Patients With Relapsed / Refractory Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|32|Actual|Leap Therapeutics, Inc.||5|||f||||f||||||||||2018-05-31 22:02:43.378898|2018-05-31 22:02:43.378898
NCT01457404|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-10-23|2011-10-21|2011-10-24|Estimate|||||||2015-10-23|2015-10-26|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders|Integrated Cognitive Behavioral Therapy for Co-Occurring PTSD and Substance Use Disorders|Completed||Phase 3|56|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 22:02:44.396526|2018-05-31 22:02:44.396526
NCT01457391|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-02-12|2011-10-21|2011-10-24|Estimate|||||||2015-02-12|2015-02-16|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment|A Stage II Efficacy Study of Cognitive Behavioral Therapy for PTSD in Community Addiction Treatment|Completed||Phase 3|443|Actual|Dartmouth-Hitchcock Medical Center||3|||f||||t||||||||||2018-05-31 22:02:44.485858|2018-05-31 22:02:44.485858
NCT01457378|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-09-19|2011-10-21|2011-10-24|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Observational|||Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome|Assessment of Gastrointestinal Symptoms and Health-related Quality of Life in Healthy People and Patients With Irritable Bowel Syndrome|Completed|||200|Actual|Danone Research|||2||f||||f||||||||||2018-05-31 22:02:44.580847|2018-05-31 22:02:44.580847
NCT01457365|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2011-10-20|2011-10-20|2011-10-21|Estimate|||||||2011-10-20|2011-10-21|Estimate|December 2011||2011-12-31|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|February 2012|Anticipated|2012-02-29||Observational|||Vitamin D Deficiency Epidemiological Research in Sichuan, China|Vitamin D Status and Its Correlation to Bone Density, Bone Turnover Markers and Muscle Function in Community-dwelling People in Sichuan Province , P.R. China|Unknown status|Not yet recruiting||1500|Anticipated|West China Hospital|||1||f||||||||||||||2018-05-31 22:02:44.640545|2018-05-31 22:02:44.640545
NCT01457352|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2018-02-02|2011-10-20|2011-10-21|Estimate|||||||2018-02-02|2018-02-05|Actual|September 2012||2012-09-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|September 22, 2017|Actual|2017-09-22||Interventional|||Efficacy and Safety of SPARC0921 in Subjects With Spasticity||Active, not recruiting||Phase 3|300|Anticipated|Sun Pharma Advanced Research Company Limited||2|||f||||f||||||||||2018-05-31 22:02:44.719093|2018-05-31 22:02:44.719093
NCT01457339|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2012-12-13||2015-03-03|2011-10-19|2011-10-21|Estimate|2012-12-13|2013-01-21|Estimate||||2015-03-03|2015-03-23|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia|A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending, Multiple Oral Doses of SPD489 (Lisdexamfetamine Dimesylate) in Clinically Stable Adults With Schizophrenia|Completed||Phase 1|31|Actual|Shire||2|||f||||f||||||||||2018-05-31 22:02:44.92866|2018-05-31 22:02:44.92866
NCT01457326|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-07-13|2011-10-19|2011-10-21|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Early Standardized Weight Bearing Utilizing Immersion Therapy Following Periarticular Lower Extremity Fractures|Early Standardized Weight Bearing Utilizing Immersion Therapy Following Periarticular Lower Extremity Fractures: Clinical and Radiographic Outcomes|Terminated|||122|Actual|University of Utah|||2|"Loss to follow-up rate too high for publication and data on completed patients does not allow~   for a powered analysis."|f||||f||||||||||2018-05-31 22:02:46.68405|2018-05-31 22:02:46.68405
NCT01457313|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2013-02-04|2011-10-20|2011-10-21|Estimate|||||||2013-02-04|2013-02-06|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Observational|||Pain Compared Between the First and the Second Surgery in Staged BTKA|Comparison of Postoperative Pain in the First and Second Knee in Staged Bilateral Total Knee Arthroplasty: Clinical Evidence That Central Sensitization Increases Systemic Pain Sensitivity|Unknown status|Recruiting||34|Anticipated|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 22:02:46.811715|2018-05-31 22:02:46.811715
NCT01457300|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-24|2011-10-19|2011-10-21|Estimate|||||||2011-10-24|2011-10-25|Estimate|June 2006||2006-06-30|October 2011|2011-10-31|October 2010|Actual|2010-10-31|April 2009|Actual|2009-04-30||Observational|||Outcome of Rehabilitation of Older People in Primary Health Care|Outcome of Multi-Disciplinary, Structured Rehabilitation of Older People in an Inpatient District Rehabilitation Centre Versus Standard Primary Health Care Rehabilitation - An Open Comparative Observational Stdy|Completed|||302|Actual|University of Oslo|||2||f||||t||||||||||2018-05-31 22:02:46.916821|2018-05-31 22:02:46.916821
NCT01457287|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-20|2011-10-20|2011-10-21|Estimate|||||||2011-10-20|2011-10-21|Estimate|October 2003||2003-10-31|October 2011|2011-10-31||||||||Observational|||A Longitudinal Investigation of Cognitive Function in Colorectal Cancer Patients|Cognitive Function and Fatigue in Cancer Patients After Chemotherapy: A Longitudinal Controlled Study in Patients With Colorectal Cancer|Completed|||300|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 22:02:47.039215|2018-05-31 22:02:47.039215
NCT01457274|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-04-23|2011-10-19|2011-10-21|Estimate|||||||2015-04-23|2015-04-27|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||"Light Versus Deep Bispectral Index (BIS) Guided Sedation for Colonoscopy"|"A Randomised Controlled Trial of Light Versus Deep Sedation for Elective Outpatient Colonoscopy: Recall, Procedural Conditions and Recovery"|Completed||N/A|200|Actual|Melbourne Health||2|||f||||f||||||||||2018-05-31 22:02:47.10317|2018-05-31 22:02:47.10317
NCT01457261|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2014-11-04|2011-10-19|2011-10-21|Estimate|||||||2014-11-04|2014-11-05|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|TOPICAL-IPF||IPF Drug Deposition Study|A Study of the Pharmacokinetics and Deposition of Inhaled Salbutamol in Patients With Idiopathic Pulmonary Fibrosis (TOPICAL-IPF)|Completed||Phase 1|10|Actual|Royal Brompton & Harefield NHS Foundation Trust||4|||f||||f||||||||||2018-05-31 22:02:47.212469|2018-05-31 22:02:47.212469
NCT01457248|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2014-07-02|2011-10-20|2011-10-21|Estimate|||||||2014-07-02|2014-07-03|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|TETRIS||Taper-shaped Cuff Endotracheal Tube Against Respiratory Infections|Effect of Endotracheal Tube With Taper-shaped Cuff on Incidence of Postoperative Pneumonia After Aortic Surgery|Completed||N/A|162|Actual|Groupe Hospitalier Pitie-Salpetriere||2|||f||||t||||||||||2018-05-31 22:02:47.313453|2018-05-31 22:02:47.313453
NCT01457235|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2014-01-29|2011-10-19|2011-10-21|Estimate|||||||2014-01-29|2014-01-30|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|REMEDI||The Effects of Cognitive Remediation on Cognitive Function in Remitted Bipolar Disorder - a Proof of Concept Study|The Effects of Cognitive Remediation on Cognitive Function in Remitted Bipolar Disorder - a Proof of Concept Study (REMEDI)|Completed||N/A|46|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 22:02:47.386646|2018-05-31 22:02:47.386646
NCT01457222|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-02-13|2011-10-19|2011-10-21|Estimate|||||||2012-02-13|2012-02-14|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|CHAMPS||Cognition and Health in Adolescents, Mindfulness as Prevention of Stress.|Mindfulness as a Method of Improving Mental Health and Cognitive Results and Decreasing Stress in Secondary School Students; a Prospective Randomised Controlled Single-blinded Pilot Study|Unknown status|Active, not recruiting|N/A|150|Anticipated|Region Skane||3|||f||||f||||||||||2018-05-31 22:02:47.493007|2018-05-31 22:02:47.493007
NCT01457209|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2014-01-20|2011-10-20|2011-10-21|Estimate|||||||2014-01-20|2014-01-22|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PCOS-AcupIR||Acupuncture to Treat Insulin Resistance in Women With and Without Polycystic Ovary Syndrome|Effect of Acupuncture on Insulin Sensitivity in Women With and Without Polycystic Ovary Syndrome|Completed||Phase 1|42|Actual|Göteborg University|||||f||||f||||||||||2018-05-31 22:02:48.034651|2018-05-31 22:02:48.034651
NCT01457196|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-09-26|2011-10-20|2011-10-21|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2011||2011-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions|Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions|Active, not recruiting||N/A|5000|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:02:48.130678|2018-05-31 22:02:48.130678
NCT01457183|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-12-26|2011-10-20|2011-10-21|Estimate|||||||2012-12-26|2012-12-28|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Clinical Evaluation of Bedside Pulse Lavage Irrigation Device|Bedside Pulse Lavage Irrigation Project|Completed||N/A|5|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 22:02:48.228453|2018-05-31 22:02:48.228453
NCT01457170|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-07-12|2011-10-20|2011-10-21|Estimate|||||||2013-07-12|2013-07-15|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Effects of Apelin on the Lung Circulation in Pulmonary Hypertension|Investigating the Acute Pulmonary Vascular Haemodynamic Effects of Apelin in Pulmonary Hypertension|Unknown status|Recruiting|N/A|63|Anticipated|Golden Jubilee National Hospital||2|||f||||t||||||||||2018-05-31 22:02:48.341712|2018-05-31 22:02:48.341712
NCT01457144|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2016-03-15|2011-10-20|2011-10-21|Estimate|||||||2016-03-15|2016-03-16|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|September 2014|Actual|2014-09-30||Interventional|RIBVD||Study of Mantle Cell Lymphoma Treatment by RiBVD|First Line Mantle Cell Lymphoma (MCL) Treatment by RiBVD Schema in Patients Older Than 65 Years or 18 to 65 Years Old Who Cannot or Refuse Receive Conditioning Regimen Followed by Autograft|Completed||Phase 2|76|Actual|French Innovative Leukemia Organisation||1|||f||||t||||||||No||2018-05-31 22:02:48.540567|2018-05-31 22:02:48.540567
NCT01457131|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2018-02-13|2011-10-19|2011-10-21|Estimate|||||||2018-02-13|2018-02-14|Actual|October 6, 2011||2011-10-06|August 2, 2013|2013-08-02|August 7, 2013|Actual|2013-08-07|August 7, 2013|Actual|2013-08-07||Interventional|||Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Gene Engineered Lymphocytes Cotransduced With Genes Encoding IL-12 and Anti-NY ESO-1 TCR|Terminated||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:02:48.646548|2018-05-31 22:02:48.646548
NCT01457118|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2018-04-30|2011-10-20|2011-10-21|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2011|Actual|2011-10-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies|An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies|Completed||Phase 2|27|Actual|Nektar Therapeutics||1|||f||||f||||||||||2018-05-31 22:02:48.794263|2018-05-31 22:02:48.794263
NCT01457105|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-20|2011-10-20|2011-10-21|Estimate|||||||2011-10-20|2011-10-21|Estimate|November 2006||2006-11-30|October 2011|2011-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Covered Self-expandable Metal Stents for Palliation of Malignant Biliary Strictures: Evaluation of a New Type of Stent|"PARTIALLY COVERED NITINOL ComVi STENT FOR PALLIATION OF MALIGNANT NON HILAR BILIARY OBSTRUCTION"|Completed||N/A|70|Actual|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-05-31 22:02:48.86008|2018-05-31 22:02:48.86008
NCT01457092|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2015-11-06|2011-10-20|2011-10-21|Estimate|||||||2015-11-06|2015-11-09|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Self-expandable, Fully Covered Metal Stents in Biliary Strictures Due to Chronic Pancreatitis|Self-expandable, Fully Covered Metal Stents in Biliary Strictures Due to Chronic Pancreatitis Not Responding to Plastic Stenting: a Prospective Study With Two Years Follow-up.|Completed||N/A|17|Actual|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-05-31 22:02:48.923607|2018-05-31 22:02:48.923607
NCT01457079|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-10-17|2011-10-20|2011-10-21|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|||Keloid Radiation Registry|Keloid Radiation Registry|Active, not recruiting|||1000|Anticipated|Tirgan, Michael H., M.D.|||||f||||f||||||||||2018-05-31 22:02:49.012524|2018-05-31 22:02:49.012524
NCT01457066|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2015-05-26|2011-10-20|2011-10-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|PODER||Culturally Sensitive Intervention to Improve Retention in HIV Care for Latino MSM|Culturally Sensitive Intervention to Improve Retention in HIV Care for Latino MSM|Completed||Phase 1/Phase 2|118|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 22:02:49.192604|2018-05-31 22:02:49.192604
NCT01457053|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2014-12-19||2016-10-24|2011-10-20|2011-10-21|Estimate|2015-05-28|2015-06-08|Estimate||||2016-10-24|2016-12-05|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics|A Randomized Controlled Pilot Study for Assessment of Coronary Flow Reserve With Cardiac PET Imaging in Acute Decompensated Heart Failure Patients Treated With Diuretics Versus Ultrafiltration|Terminated||N/A|4|Actual|University of Cincinnati||2||Population not available for enrollment|f||||t||||||||No||2018-05-31 22:02:49.347944|2018-05-31 22:02:49.347944
NCT01457040|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2017-10-11|2011-10-19|2011-10-21|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2011||2011-10-31|October 2015|2015-10-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia|A Prospective Study of Intensified Conditioning Regimen With High-Dose-Etoposide for Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia in China|Completed||Phase 2/Phase 3|200|Actual|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 22:02:49.819455|2018-05-31 22:02:49.819455
NCT01457027|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-02-19|2011-10-20|2011-10-21|Estimate|||||||2013-02-19|2013-02-20|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season|A Phase IV, Open Label Study to Evaluate the Short and Long Term Immune Response and CROSS-protection After Vaccination With viroSOME Adjuvanted Inflexal V in Elderly Subjects|Completed||Phase 4|52|Actual|Crucell Holland BV||1|||f||||f||||||||||2018-05-31 22:02:49.979271|2018-05-31 22:02:49.979271
NCT01457014|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2015-10-29||2016-01-22|2011-10-20|2011-10-21|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional||Number of participants that completed the baseline PSG and were randomized for the study.|Sleep Disordered Breathing and Chronic Pain|BiPAP Adaptive Servo-Ventilation (AutoSV) Therapy in Patients With Chronic Pain and Sleep Disordered Breathing (SDB)|Completed||N/A|88|Actual|Philips Respironics||3|||f||||f||||||||||2018-05-31 22:02:50.168135|2018-05-31 22:02:50.168135
NCT01457001|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2016-11-30|2011-10-20|2011-10-21|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|NUTRIVITA-D001||Clinical Trial on the Use of 25-OH -D Vitamin in Haemodialysis Patients|Controlled Randomised Interventional Trial on the Use of 25-OH D Vitamin in Haemodialysis Patients.|Terminated||Phase 3|284|Actual|Italian Society of Nephrology||2|||f||||t||||||||||2018-05-31 22:02:50.60241|2018-05-31 22:02:50.60241
NCT01456975|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-09-21|2011-10-19|2011-10-21|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|December 2012|Actual|2012-12-31||Interventional|EPSTAAA||Extravalvular Procedure for Surgical Treatment of Ascending Aorta Aneurism|Reimplantation Procedure for Surgical Treatment of Ascending Aorta Aneurism With Concomitant Aortic Valve Insufficiency|Unknown status|Active, not recruiting|N/A|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||1|||f||||f||||||||||2018-05-31 22:02:50.82218|2018-05-31 22:02:50.82218
NCT01456962|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2015-05-18||2017-05-08|2011-10-20|2011-10-21|Estimate|2015-06-08|2015-06-12|Estimate||||2017-05-08|2017-06-09|Actual|October 2011|Actual|2011-10-31|May 2017|2017-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract|Influence of Raltegravir-Containing Antiretroviral Therapy (ART) on Immune Reconstitution and Activation in the Female Genital Tract|Completed|||36|Actual|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     Blood, vaginal fluid samples, cervical biopsies~   "|||2018-05-31 22:02:50.924359|2018-05-31 22:02:50.924359
NCT01456949|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2017-12-19|2011-10-20|2011-10-21|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2012||2012-05-31|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|STOP AF PAS||Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)|Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)|Completed||Phase 4|402|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||t||||||||||2018-05-31 22:02:51.273241|2018-05-31 22:02:51.273241
NCT01456936|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2016-01-12||2016-05-09|2011-10-19|2011-10-21|Estimate|2016-03-29|2016-05-02|Estimate||||2016-05-09|2016-06-10|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|EAGLES|The safety analysis population contained all treated participants i.e. who received at least one partial dose of study medication.|Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders|A Phase 4, Randomized, Double-blind, Active And Placebo-controlled, Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1mg Bid And Bupropion Hydrochloride 150mg Bid For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders|Completed||Phase 4|8144|Actual|Pfizer|After database lock and unblinding, one additional participant in the NRT arm of psychiatric cohort was found who had a primary endpoint event (moderate suicidal ideation) which required hospitalization; this event is not included in any analyses.|4|||f||||t||||||||||2018-05-31 22:02:51.648252|2018-05-31 22:02:51.648252
NCT01456923|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-20|2011-10-20|2011-10-21|Estimate|||||||2011-10-20|2011-10-21|Estimate||||September 2008|2008-09-30||||||||Interventional|||Chemotherapy With DNA Damaging Agents In Colorectal Cancer|Phase 1 Study Of The Efficacy Of Chemotherapy With DNA Damaging Agents Versus Surgery In Colorectal Cancer|Completed||Phase 1|||Centro Hospitalar Nordeste||2|||f||||||||||||||2018-05-31 22:02:56.148266|2018-05-31 22:02:56.148266
NCT01456910|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-10-24|2011-10-20|2011-10-21|Estimate|||||||2011-10-24|2011-10-25|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Resistance Training Program, Labor Inclusion, Intellectual Disability|Evaluation and Effects of a Resistance Training Program and Its Relationship With the Labor Inclusion of the Disabled Intellectual|Completed||N/A|40|Actual|University of Brasilia||2|||f||||f||||||||||2018-05-31 22:02:56.212111|2018-05-31 22:02:56.212111
NCT01456897|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-10-05|2011-10-19|2011-10-21|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2011||2011-10-31|October 2016|2016-10-31||||May 2015|Actual|2015-05-31||Interventional|||A Long-term Trial of OPC-34712 in Patients With Schizophrenia||Completed||Phase 3|306|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 22:02:56.308881|2018-05-31 22:02:56.308881
NCT01456884|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-09-06|2011-10-20|2011-10-21|Estimate|||||||2017-09-06|2017-09-11|Actual|January 2012||2012-01-31|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Music Therapy for Pain Modification in Pediatric Palliative Care|Music Therapy as a Pain Modifying Intervention in Children With Life-limiting Neurological Impairments and Metabolic Conditions|Completed||N/A|13|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:02:56.37516|2018-05-31 22:02:56.37516
NCT01456871|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2013-05-08|2011-10-20|2011-10-21|Estimate|||||||2013-05-08|2013-05-10|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Finger Muscle Reaction After Electrical Stimuli to the Human Finger Pulley System; a Pilot Study|Finger Muscle Reaction After Electrical Stimuli to the Human Finger Pulley System; a Pilot Study|Completed|||6|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 22:02:56.452517|2018-05-31 22:02:56.452517
NCT01456858|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-20|2011-10-20|2011-10-21|Estimate|||||||2011-10-20|2011-10-21|Estimate|December 2003||2003-12-31|November 2003|2003-11-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies|Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies: an Observational Cohort Study in a Refugee Setting in Sierra Leone|Completed||Phase 3|222|Actual|The Mentor Initiative||4|||f||||t||||||||||2018-05-31 22:02:56.517921|2018-05-31 22:02:56.517921
NCT01456845|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-08-30|2011-10-20|2011-10-21|Estimate|||||||2012-08-30|2012-08-31|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity|Estimation of Plasma Free and Total Drug Levels of Rifampicin, Isoniazid and Pyrazinamide in Patients on Antituberculosis Therapy and Its Correlation With Development of Drug Induced Hepatotoxicity|Completed|||110|Actual|All India Institute of Medical Sciences, New Delhi|||1||f||||f||||||||||2018-05-31 22:02:56.60714|2018-05-31 22:02:56.60714
NCT01456832|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-25|2011-10-19|2011-10-21|Estimate|||||||2011-10-25|2011-10-26|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Observational|||Post Operative Hyponatremia in the Renal Transplant Population|Post Operative Hyponatremia in the Renal Transplant Population|Completed|||225|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 22:02:56.783688|2018-05-31 22:02:56.783688
NCT01456819|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-04-09|2011-10-19|2011-10-21|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia|Phase II Efficacy Study of Intramuscular Autologous Bone Marrow Mononuclear Cells Plus Mesenchymal Stem Cell Implantation Versus Autologous Bone Marrow Mononuclear Cells Implantation Only in Patients With Chronic Critical Limb Ischemia|Unknown status|Recruiting|Phase 2|50|Anticipated|National University of Malaysia||2|||f||||f||||||||||2018-05-31 22:02:56.861663|2018-05-31 22:02:56.861663
NCT01456806|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2011-10-20|2011-10-20|2011-10-21|Estimate|||||||2011-10-20|2011-10-21|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|July 2010|Actual|2010-07-31|March 2007|Actual|2007-03-31||Interventional|PRODIACOR||Educative Intervention to Improve Type 2 Diabetes Mellitus Control in Corrientes|Programme of Diabetes Education in the City of Corrientes (PRODIACOR): Clinical, Metabolic and Economic Outcomes of a Prospective-randomized Trial Based on Different Patient-centered Educational Strategies for People With Type 2 Diabetes|Completed||N/A|468|Actual|Centro de Endocrinologia Experimental y Aplicada||4|||f||||t||||||||||2018-05-31 22:02:56.950405|2018-05-31 22:02:56.950405
NCT01456780|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2017-04-06||2017-07-06|2011-10-19|2011-10-21|Estimate|2017-05-19|2017-06-19|Actual||||2017-07-06|2017-08-01|Actual|August 2011|Actual|2011-08-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|March 2013|Actual|2013-03-31||Interventional|ZvL||Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis|Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis|Completed||Phase 4|60|Actual|Massachusetts Eye and Ear Infirmary||3|||f||||f|t|f|||t|||Yes||2018-05-31 22:02:57.346024|2018-05-31 22:02:57.346024
NCT01456767|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-07-18|2011-10-19|2011-10-21|Estimate|||||||2012-07-18|2012-07-19|Estimate|October 2011||2011-10-31|July 2012|2012-07-31||||April 2012|Actual|2012-04-30||Interventional|||Effects of Administration of L.Plantarum WCFS1, L.Plantarum CIP104448, L.Plantarum CIP104450 on Small Intestinal Mucosa|The Effects of Oral Administration of Lactobacillus Plantarum WCFS1, Lactobacillus Plantarum CIP104448, and Lactobacillus Plantarum CIP104450 on Small Intestinal Mucosa and Barrier Function|Completed||N/A|10|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 22:02:57.74388|2018-05-31 22:02:57.74388
NCT01456754|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-12-14|2011-10-19|2011-10-21|Estimate|||||||2011-12-14|2011-12-15|Estimate|December 2010||2010-12-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning in Impaired Glucose Tolerant (IGT) Men|Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning in Impaired Glucose Tolerant (IGT) Men|Completed||N/A|11|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:02:57.828713|2018-05-31 22:02:57.828713
NCT01456741|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-05-19|2011-10-20|2011-10-21|Estimate|||||||2014-05-19|2014-05-20|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Role of Endobronchial Needle Aspiration With Rapid On-site Evaluation in the Diagnosis of Central Malignant Lesions|Endobronchial Needle Aspiration With Rapid On-Site Evaluation in the Diagnosis of Central Malignant Lesions, a Randomized Controlled Trial|Completed||N/A|134|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 22:02:57.925056|2018-05-31 22:02:57.925056
NCT01456728|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2013-09-07|2011-10-20|2011-10-21|Estimate|||||||2013-09-07|2013-09-10|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Interventional|||Lactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects on Proton Pump Inhibitors|Efficacy of Dietary Supplementation With Lactobacillus Reuteri ProGastria in Helicobacter Pylori-infected Adult Subjects Treated Only With Proton Pump Inhibitors|Completed||Phase 3|56|Actual|St Marina University Hospital, Varna, Bulgaria||2|||f||||t||||||||||2018-05-31 22:02:58.013194|2018-05-31 22:02:58.013194
NCT01456715|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2015-09-30|2011-10-20|2011-10-21|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2008||2008-09-30|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.|Immunogenicity and Safety of Gardasil and Twinrix Vaccines Co-administered or Administered a Month Apart, According to the 0, 6 Months Schedule and the Effect of a Third Dose of Gardasil or Cervarix Administered 42 Months Later.|Enrolling by invitation||Phase 3|416|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 22:02:58.136367|2018-05-31 22:02:58.136367
NCT01456702|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2013-12-30|2011-10-20|2011-10-21|Estimate|||||||2013-12-30|2013-12-31|Estimate|October 2014||2014-10-31|December 2013|2013-12-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Risk Stratification and Goal-directed Volume Therapy|Influence of Pre-operative Risk Stratefiction and Intraoperaitve Monitoring on Perioperative Volume Therapy and Postoperative Outcome|Unknown status|Not yet recruiting|N/A|300|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:02:58.225919|2018-05-31 22:02:58.225919
NCT01456689|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-05-29|2011-10-20|2011-10-21|Estimate|||||||2018-05-29|2018-05-30|Actual|April 25, 2012|Actual|2012-04-25|May 2018|2018-05-31|December 27, 2018|Anticipated|2018-12-27|December 2, 2014|Actual|2014-12-02||Interventional|||A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma|A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|79|Actual|Novartis||2|||f|||||t|f||||||No||2018-05-31 22:02:58.443607|2018-05-31 22:02:58.443607
NCT01456676|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-09-01|2011-10-20|2011-10-21|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy|A Single-arm Dose-finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE225 in Combination With Nilotinib in Chronic or Accelerated Phase of Chronic Myeloid Leukemia Patients Who Have Failed Prior Therapy With Other BCR-ABL Tyrosine-kinase Inhibitors|Completed||Phase 1|11|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:02:58.56399|2018-05-31 22:02:58.56399
NCT01456663|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2013-02-04|2011-10-19|2011-10-21|Estimate|||||||2013-02-04|2013-02-05|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects|A Single-dose, Open-label, Parallel Study to Assess the Pharmacokinetics of AFQ056 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects|Completed||Phase 1|118|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:02:58.677697|2018-05-31 22:02:58.677697
NCT01456650|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2014-01-14|2011-10-20|2011-10-21|Estimate|||||||2014-01-14|2014-01-15|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||R230C and C230C Variants of ABCA1 and Glyburide Response|Effect of the R230C Variant of the ATP-binding Cassette Transporter A1 (ABCA1) Gene on the Response to Treatment With Glibenclamide in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|85|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1|||f||||f||||||||||2018-05-31 22:02:58.796178|2018-05-31 22:02:58.796178
NCT01456637|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2013-01-07|2011-10-20|2011-10-21|Estimate|||||||2013-01-07|2013-01-08|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Online Self-Help Intervention for Insomnia: With or Without Feedback|Online Self-Help Intervention for Insomnia: With or Without Feedback|Completed||Phase 3|262|Actual|Utrecht University||2|||f||||t||||||||||2018-05-31 22:02:58.869787|2018-05-31 22:02:58.869787
NCT01456624|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2014-06-23|2011-10-19|2011-10-21|Estimate|||||||2014-06-23|2014-06-25|Estimate|September 2011||2011-09-30|June 2014|2014-06-30||||June 2012|Actual|2012-06-30||Interventional|||Phase 1 Study of Daewon-ES(B) & Megace in Healthy Male Volunteers Under Fasting and Fed Condition|A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of DW-ES(B) and Megace® Under Fasting and Fed Conditions in Healthy Male Volunteers|Completed||Phase 1|56|Actual|Asan Medical Center||4|||f||||f||||||||||2018-05-31 22:02:58.941361|2018-05-31 22:02:58.941361
NCT01456611|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-07-10|2011-10-20|2011-10-21|Estimate|||||||2012-07-10|2012-07-12|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium 1% Gel (Anchen Pharmaceuticals, Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee|Completed||Phase 3|749|Actual|Anchen Pharmaceuticals, Inc||3|||f||||f||||||||||2018-05-31 22:02:59.08118|2018-05-31 22:02:59.08118
NCT01456598|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-06-23|2011-10-19|2011-10-21|Estimate|||||||2015-06-23|2015-06-24|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|KLASS-02-RCT||Efficacy of Laparoscopic Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer|Prospective Multicenter Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 3|1050|Anticipated|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 22:02:59.250915|2018-05-31 22:02:59.250915
NCT01456585|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2014-10-10|2011-10-20|2011-10-21|Estimate|||||||2014-10-10|2014-10-13|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma|Phase 1 Study of Preoperative Gemcitabine Plus CP-870,893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patient With Newly Diagnosed Resectable Pancreatic Carcinoma|Completed||Phase 1|10|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:02:59.370436|2018-05-31 22:02:59.370436
NCT01456572|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-10-18|2011-10-18|2011-10-20|Estimate|||||||2011-10-18|2011-10-20|Estimate|January 2007||2007-01-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People|Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People|Completed||Phase 1|65|Actual|University Hospital, Basel, Switzerland||6|||f||||f||||||||||2018-05-31 22:02:59.450785|2018-05-31 22:02:59.450785
NCT01456559|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2013-01-16|2011-10-19|2011-10-20|Estimate|||||||2013-01-16|2013-01-17|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Detection of Hypovolemia Using Pleth Variability Index (PVI)|Non-invasive Detection of Mild Hypovolemia Using Pleth Variability Index (PVI) During Spontaneous Breathing|Completed|||14|Actual|University Hospital, Linkoeping|||||f||||f||||||||||2018-05-31 22:02:59.581633|2018-05-31 22:02:59.581633
NCT01456546|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-07-02|2011-10-18|2011-10-20|Estimate|||||||2013-07-02|2013-07-03|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel|Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel|Completed||Phase 1|31|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 22:02:59.688316|2018-05-31 22:02:59.688316
NCT01456533|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2015-11-30|2011-10-18|2011-10-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|COMED||Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients|Copeptin in the Differential Diagnosis of Dysnatremia in Hospitalized Patients|Completed|||300|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-05-31 22:02:59.753242|2018-05-31 22:02:59.753242
NCT01456520|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2012-02-07|2011-10-18|2011-10-20|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco|An Open Label, Single Dose, Randomized, Two-Period, Two-Way Crossover Study to Evaluate the Pharmacokinetics and Bioequivalence of Vycavert Tablets Compared to Norco® Tablets in Healthy Subjects|Completed||Phase 1|47|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:02:59.820772|2018-05-31 22:02:59.820772
NCT01456507|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-01-12|2011-10-18|2011-10-20|Estimate|||||||2012-01-12|2012-01-13|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone|An Open-Label, Single-Dose, Randomized, Three-Way Crossover Study in Healthy Volunteers to Estimate the Effects of Food and of Sprinkling ALO-02 Pellets on Applesauce on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Pellets-in-Capsule Formulation of Oxycodone 40 Mg With Sequestered Naltrexone 4.8 Mg|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:02:59.922974|2018-05-31 22:02:59.922974
NCT01456494|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2013-09-04|2011-10-18|2011-10-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|TURI||Teaching Use of Respiratory Inhalers (TURI)|Teaching Use of Respiratory Inhalers (TURI)|Completed||Phase 2|50|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 22:02:59.999645|2018-05-31 22:02:59.999645
NCT01456481|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-08-29|2011-10-19|2011-10-20|Estimate|||||||2016-08-29|2016-08-31|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|POST 4||Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV|Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4)|Recruiting||Phase 4|108|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 22:03:00.107825|2018-05-31 22:03:00.107825
NCT01456468|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-07-12|2011-10-19|2011-10-20|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis|Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis - A Human Pilot Study|Completed||Phase 1|19|Actual|Yale University||1|||f||||f||||||||||2018-05-31 22:03:00.343734|2018-05-31 22:03:00.343734
NCT01456455|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-10-24|2011-10-19|2011-10-20|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31|2 Years|Observational [Patient Registry]|||Gastric Cancer Metastasized to the Central Nervous System (CNS)|Registry of Gastric Cancer and Brain Metastases|Active, not recruiting|||150|Actual|University of Zurich|||||f||||f||||||||No||2018-05-31 22:03:00.419312|2018-05-31 22:03:00.419312
NCT01456442|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-11-13|2011-10-18|2011-10-20|Estimate|||||||2012-11-13|2012-11-14|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Short Protocol Barostat for Assessment of Anorectal Function Versus Standard Protocol Barostat in Healthy Volunteers|Short Protocol Barostat for Assessment of Anorectal Function Versus Standard Protocol Barostat in Healthy Volunteers|Completed||Phase 4|26|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 22:03:00.516632|2018-05-31 22:03:00.516632
NCT01456429|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-10-08|2011-10-19|2011-10-20|Estimate|||||||2013-10-08|2013-10-10|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|April 2014|Anticipated|2014-04-30|October 2013|Actual|2013-10-31||Interventional|ASTER2||Assessment of Invasive Mediastinal Staging in cN1 Lung Cancer.|Assessment of Surgical Mediastinal sTaging Added to Endoscopic Ultrasound in cN1 Lung canceR.|Unknown status|Active, not recruiting|N/A|100|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:03:00.637813|2018-05-31 22:03:00.637813
NCT01456416|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2013-04-02|2011-10-19|2011-10-20|Estimate|||||||2013-04-02|2013-04-04|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities|Pilot Study for Evaluation of Glatiramer Acetate in RRMS Patients With Comorbid Autoimmune Conditions|Completed|||10|Actual|University of Southern California|||1||f||||t||||||||||2018-05-31 22:03:00.832207|2018-05-31 22:03:00.832207
NCT01456403|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-09-06|2011-10-19|2011-10-20|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Histological Validation Of Carotid Plaque Composition In Preoperative Imaging|Histological Validation Of Carotid Plaque Composition In Preoperative Imaging Of Patients Scheduled For Carotid Endarterectomy|Completed|||95|Actual|Lawson Health Research Institute|||1||f||||t||||||Samples Without DNA|"~     Histological sections~   "|No||2018-05-31 22:03:00.929117|2018-05-31 22:03:00.929117
NCT01456390|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-12-14|2011-10-18|2011-10-20|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2011|Actual|2011-09-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|February 2017|Actual|2017-02-28||Interventional|||Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents|A Prospective Evaluation of Open-Angle Glaucoma Subjects With One Prior Trabeculectomy Treated Concurrently With One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin|Active, not recruiting||N/A|80|Anticipated|Glaukos Corporation||1|||f||||f||||||||||2018-05-31 22:03:01.01486|2018-05-31 22:03:01.01486
NCT01456377|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|June 2012|Anticipated|2012-06-30|February 2012|Anticipated|2012-02-29||Interventional|||The Effectiveness of Oral Corticosteroids in the Treatment of Lumbar Stenosis|A Prospective Controlled Study Randomized Double Blind Study, Evaluate the Effectiveness of Oral Corticosteroids in the Treatment of Stenosis of Lumbar Canal In Symptomatic Patients|Unknown status|Recruiting|N/A|60|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:03:01.089204|2018-05-31 22:03:01.089204
NCT01456364|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-10-31|2011-10-18|2011-10-20|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|ISAR ADAPT PF||Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing|Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 4|70|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-05-31 22:03:01.182768|2018-05-31 22:03:01.182768
NCT01456351|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-02-11|2011-10-19|2011-10-20|Estimate|||||||2013-02-11|2013-02-12|Estimate|September 2003||2003-09-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab|Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas|Completed||Phase 3|230|Actual|University of Giessen||2|||f||||f||||||||||2018-05-31 22:03:01.324867|2018-05-31 22:03:01.324867
NCT01456338|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-18|2011-10-18|2011-10-20|Estimate|||||||2011-10-18|2011-10-20|Estimate|June 2007||2007-06-30|October 2011|2011-10-31|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Cognitive Behavioral Therapy for Post Traumatic Stress Disorder in Addiction Treatment|Cognitive Behavioral Therapy for PTSD in Addiction Treatment: A Randomized Pilot Trial|Completed||Phase 2|78|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 22:03:01.402981|2018-05-31 22:03:01.402981
NCT01456325|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-11-01|2011-10-19|2011-10-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)|A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease|Completed||Phase 3|494|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:03:01.625072|2018-05-31 22:03:01.625072
NCT01456312|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2012-10-29|2011-10-19|2011-10-20|Estimate|||||||2012-10-29|2012-10-31|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|August 2016|Anticipated|2016-08-31|February 2016|Anticipated|2016-02-29||Interventional|S-RGT||HBsAg Related Response Guided Therapy|A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B:|Unknown status|Recruiting|Phase 4|200|Anticipated|Gangnam Severance Hospital||3|||f||||f||||||||||2018-05-31 22:03:01.994055|2018-05-31 22:03:01.994055
NCT01456299|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2014-02-23||2014-04-17|2011-10-19|2011-10-20|Estimate|2014-02-23|2014-04-04|Estimate||||2014-04-17|2014-05-15|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||no differences in patient characteristics|Laryngeal Mask Airway (LMA) Insertion With Sevoflurane and Remifentanil|Target-controlled Infusion of Remifentanil for Laryngeal Mask Airway Insertion During Sevoflurane Induction in Adults|Completed||N/A|102|Actual|Gachon University Gil Medical Center||3|||f||||t||||||||||2018-05-31 22:03:02.242296|2018-05-31 22:03:02.242296
NCT01456286|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2013-10-01|2011-10-19|2011-10-20|Estimate|||||||2013-10-01|2013-10-07|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension|Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension|Completed||Phase 2/Phase 3|42|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||t||||||||||2018-05-31 22:03:02.68916|2018-05-31 22:03:02.68916
NCT01456273|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||From the Biomedical to the Biopsychosocial Model, From Theory to Practice|Evaluation of the Efficacy of the Integral Approach (Therapeutic Encounter) Versus the Conventional Medical Approach (Medical Consultation) in Patients With Functional Dyspepsia|Unknown status|Recruiting|N/A|200|Anticipated|Faculdade de Medicina do ABC||4|||f||||f||||||||||2018-05-31 22:03:02.793771|2018-05-31 22:03:02.793771
NCT01456260|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2014-05-07|2011-10-18|2011-10-20|Estimate|||||||2014-05-07|2014-05-08|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|||||Interventional|||Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)|A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)|Completed||Phase 3|406|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:03:02.975057|2018-05-31 22:03:02.975057
NCT01456247|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2014-05-07|2011-10-18|2011-10-20|Estimate|||||||2014-05-07|2014-05-08|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin|A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin|Completed||Phase 3|439|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:03:03.246689|2018-05-31 22:03:03.246689
NCT01456234|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-08-07|2011-10-19|2011-10-20|Estimate|||||||2013-08-07|2013-08-09|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Access||Time to Oseltamivir Access When Prescribed by Pharmacists Versus Physicians (ACCESS)|Comparison of Time From Symptom Onset to Oseltamivir Access When Oseltamivir is Prescribed by Pharmacists vs. Physicians and the Impact on Symptoms, Oseltamivir Resistance, and Patient Safety|Terminated||Phase 4|48|Actual|Trial Management Group Inc.||2||Insufficient recruitment|f||||f||||||||||2018-05-31 22:03:03.609685|2018-05-31 22:03:03.609685
NCT01456221|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-01-30|2011-10-19|2011-10-20|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2012|Actual|2012-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Interventional|O3WLIRADOL||Intervention Study With Omega-3 Fatty Acids for Weight Loss and Insulin Resistance in Adolescents|The Impact of Using omega3 Long-chain Polyunsaturated Fatty Acids in Weight Loss and Insulin Resistance in Obese Adolescents|Completed||N/A|366|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||No||2018-05-31 22:03:03.701452|2018-05-31 22:03:03.701452
NCT01456208|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-11-16|2011-10-19|2011-10-20|Estimate|||||||2017-11-16|2017-11-20|Actual|October 1999||1999-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|January 2017|Actual|2017-01-31|20 Years|Observational [Patient Registry]|||Genetic Mechanisms in Human Hypertension|Vascular Disease and Hbp: Pai-1, Insulin and Genes (Crc): Hypertension Phenotype|Active, not recruiting|||400|Anticipated|Brigham and Women's Hospital|||||f||||t||||||Samples With DNA|"~     urine, blood, DNA~   "|||2018-05-31 22:03:03.790779|2018-05-31 22:03:03.790779
NCT01456195|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|2015-04-08||2016-03-04|2011-10-18|2011-10-20|Estimate|2016-03-04|2016-04-05|Estimate||||2016-03-04|2016-04-05|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared With Placebo in Subjects With Type 2 Diabetes|Completed||Phase 3|421|Actual|Takeda||3|||f||||t||||||||||2018-05-31 22:03:03.934266|2018-05-31 22:03:03.934266
NCT01456182|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-01-23|2011-10-19|2011-10-20|Estimate|||||||2012-01-23|2012-01-25|Estimate|December 2011||2011-12-31|January 2012|2012-01-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|||Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia|Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia|Withdrawn||Phase 1|0|Actual|Afexa Life Sciences Inc||5|||f||||f||||||||||2018-05-31 22:03:04.946963|2018-05-31 22:03:04.946963
NCT01456169|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|2013-12-26||2014-03-21|2011-10-18|2011-10-20|Estimate|2014-03-21|2014-04-23|Estimate||||2014-03-21|2014-04-23|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional||Participants who were randomized into the double-blind treatment period. Baseline was defined as the last observed value while on monotherapy study drug and before the first dose of double-blind study drug.|A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone|A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg Monotherapy|Completed||Phase 3|507|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:03:05.129476|2018-05-31 22:03:05.129476
NCT01456156|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-07-02|2011-10-18|2011-10-20|Estimate|||||||2017-07-02|2017-07-05|Actual|January 2008|Actual|2008-01-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of Postoperative 3D-CRT/IMRT in Hepatocellular Carcinoma|Phase 2 Study of Postoperative Three-dimensional Conformal Radiation Therapy/Intensive Modulated Radiation Therapy in Hepatocellular Carcinoma: a Single Center Prospective Study|Completed||N/A|76|Actual|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 22:03:06.702063|2018-05-31 22:03:06.702063
NCT01456143|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2016-02-29||2018-01-08|2011-10-18|2011-10-20|Estimate|2016-05-06|2016-06-14|Estimate||||2018-01-08|2018-02-01|Actual|December 2011||2011-12-31|January 2018|2018-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Optical Imaging of Head and Neck Cancer|In Vivo Multimodal Imaging of Upper Aerodigestive Epithelia|Terminated||N/A|33|Actual|Anandasabapathy, Sharmila, M.D.||1||PI left, study to be re-open with new PI, no planned data analysis|f||||f||||||||Yes||2018-05-31 22:03:07.052644|2018-05-31 22:03:07.052644
NCT01456130|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2014-03-17||2014-03-17|2011-10-19|2011-10-20|Estimate|2014-03-17|2014-04-21|Estimate||||2014-03-17|2014-04-21|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes|A Long-Term, Open-Label Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Rapid-Acting Insulin Secretagogues in Subjects With Type 2 Diabetes in Japan|Completed||Phase 3|67|Actual|Takeda||1|||f||||||||||||||2018-05-31 22:03:07.758539|2018-05-31 22:03:07.758539
NCT01456117|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-08-06|2011-10-19|2011-10-20|Estimate|||||||2012-08-06|2012-08-08|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants|A Phase 1, Multiple-Dose, Single-Blind Parallel Design, Single-Center, Dose-Ranging Study to Assess the Effects of Daily Administration of Pioglitazone for 14 Days on the Brain Hemodynamics of Healthy Elderly Subjects|Completed||Phase 1|61|Actual|Takeda||4|||f||||f||||||||||2018-05-31 22:03:08.418082|2018-05-31 22:03:08.418082
NCT01456104|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-11-01|2011-10-19|2011-10-20|Estimate|||||||2017-11-01|2017-11-06|Actual|October 17, 2011|Actual|2011-10-17|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma|Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma|Active, not recruiting||Phase 1|9|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:03:08.4947|2018-05-31 22:03:08.4947
NCT01456091|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-03-21|2011-10-19|2011-10-20|Estimate|||||||2016-03-21|2016-03-22|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of the Efficacy of the AIM (Adult Identity Mentoring) 4 Teen Moms Program|Evaluation of the Efficacy of the AIM (Adult Identity Mentoring) 4 Teen Moms Program|Completed||N/A|954|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 22:03:08.606025|2018-05-31 22:03:08.606025
NCT01456078|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2018-03-09|2011-10-18|2011-10-20|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2011||2011-10-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|ILUMINET||A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors|A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors|Recruiting||Phase 2|60|Anticipated|Lund University Hospital||1|||f||||f||||||||||2018-05-31 22:03:08.686038|2018-05-31 22:03:08.686038
NCT01456065|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-02-28|2011-10-18|2011-10-20|Estimate|||||||2013-02-28|2013-03-01|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Safety of Active Immunotherapy in Subjects With Ovarian Cancer|A Phase I, Open, Randomized, Study to Investigate the Safety of Active Immunotherapy With Fully Mature, TERT-mRNA and Survivin - Peptide Double Loaded Dendritic Cells (DCs) in Subjects With Advanced Epithelial Ovarian Cancer, Enrolled in the Study Within Twelve Weeks After Completing Primary Therapy|Unknown status|Active, not recruiting|Phase 1|15|Actual|Life Research Technologies GmbH||2|||f||||t||||||||||2018-05-31 22:03:08.757037|2018-05-31 22:03:08.757037
NCT01456052|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2014-10-15||2017-07-12|2011-10-18|2011-10-20|Estimate|2015-03-10|2015-03-11|Estimate||||2017-07-12|2017-08-10|Actual|January 30, 2012|Actual|2012-01-30|July 2017|2017-07-31|September 3, 2013|Actual|2013-09-03|September 3, 2013|Actual|2013-09-03||Interventional||The baseline analysis population is the safety population. One subject was excluded from the safety population as they did not receive any doses of study drug.|A Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis|Phase 2 Assessment of the Relationship Between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Preliminary Efficacy of Orally Administered LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis|Completed||Phase 2|59|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 22:03:09.98737|2018-05-31 22:03:09.98737
NCT01456039|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|2016-07-11||2018-03-05|2011-10-19|2011-10-20|Estimate|2016-07-11|2016-08-19|Estimate||||2018-03-05|2018-03-30|Actual|December 1, 2011|Actual|2011-12-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|July 28, 2015|Actual|2015-07-28||Interventional||Intent to Treat (ITT) includes all participants who received at least one dose of romidepsin.|A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)|A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|51|Actual|Celgene||1|||f||||f||||||||||2018-05-31 22:03:10.64765|2018-05-31 22:03:10.64765
NCT01456026|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-10-18|2011-10-18|2011-10-20|Estimate|||||||2011-10-18|2011-10-20|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effects of Food Advanced Glycation Endproducts on Vascular Function in Diabetes|Acute Effects of Food Advanced Glycation Endproducts on Macrovascular Function in Subjects With Type 2 Diabetes Mellitus|Completed||N/A|19|Actual|Profil Institut für Stoffwechselforschung GmbH||2|||f||||f||||||||||2018-05-31 22:03:12.402212|2018-05-31 22:03:12.402212
NCT01456013|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2018-04-03|2011-10-18|2011-10-20|Estimate|||||||2018-04-03|2018-04-04|Actual|January 2012||2012-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|CIN-RG||Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients|A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory|Active, not recruiting||Phase 3|326|Actual|PLC Medical Systems, Inc.||2|||f||||t||||||||||2018-05-31 22:03:12.483655|2018-05-31 22:03:12.483655
NCT01456000|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2016-04-18|2015-05-27|2016-07-25|2011-10-18|2011-10-20|Estimate|2016-07-25|2016-09-08|Estimate|2015-07-30|2015-08-20|Estimate|2016-07-25|2016-09-08|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|HeartLight|Average Age|HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)|Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) or HEARTLIGHT for the Treatment of Symptomatic Atrial Fibrillation|Completed||Phase 3|405|Actual|CardioFocus||2|||f||||t||||||||No||2018-05-31 22:03:12.674355|2018-05-31 22:03:12.674355
NCT01455987|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|KYSOCD||Osteochondritis Dissecans of the Knee|Outcome of the Knee Osteochonditis Dissecans Patiets in Kuopio University Hospital (1990-2009): A Retropective Analysis|Unknown status|Enrolling by invitation||265|Anticipated|Kuopio University Hospital|||||f||||||||||||||2018-05-31 22:03:13.003831|2018-05-31 22:03:13.003831
NCT01455974|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Interventional|||The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients||Completed||N/A|16|Actual|Capital Medical University||1|||f||||||||||||||2018-05-31 22:03:13.077252|2018-05-31 22:03:13.077252
NCT01455961|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2014-08-20|2011-10-19|2011-10-20|Estimate|||||||2014-08-20|2014-08-21|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|REED||An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder|An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder Treated With Quetiapine XR and/or Quetiapine IR|Completed|||16000|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:03:13.152144|2018-05-31 22:03:13.152144
NCT01455948|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-09-01|2011-10-19|2011-10-20|Estimate|||||||2015-09-01|2015-09-02|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CHEC||Canadian Health Economics, Outcome, and Effectiveness Comparison of Treatment in Patients With Chronic Rhinosinusitis|Canadian Health Economics, Health Outcome, and Effectiveness Comparison of Treatment of the Frontal Sinus Ostium and Recess and Other Sinuses With Functional Endoscopic Sinus Surgery (FESS) or Balloon Sinuplasty in Patients With Chronic Sinusitis (CRS)|Terminated||Phase 4|25|Actual|Johnson & Johnson Medical Companies||2|||f||||f||||||||||2018-05-31 22:03:13.211612|2018-05-31 22:03:13.211612
NCT01455935|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2012-03-29|2011-10-18|2011-10-20|Estimate|||||||2012-03-29|2012-03-30|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|WASSABI||Wake up Symptomatic Stroke - Benefit of Intravenous Clot Busters or Endovascular Intervention|Wake up Symptomatic Stroke in Acute Brain Ischemia (WASSABI) Trial|Unknown status|Recruiting|Phase 2|90|Anticipated|Jacobs Neurological Institute||3|||f||||t||||||||||2018-05-31 22:03:13.29501|2018-05-31 22:03:13.29501
NCT01455922|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-12-21|2011-10-19|2011-10-20|Estimate|||||||2012-12-21|2012-12-25|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes|Withdrawn||Phase 3|0|Actual|Intarcia Therapeutics||2|||f||||||||||||||2018-05-31 22:03:13.401369|2018-05-31 22:03:13.401369
NCT01455909|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-12-21|2011-10-19|2011-10-20|Estimate|||||||2012-12-21|2012-12-25|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes|Withdrawn||Phase 3|0|Actual|Intarcia Therapeutics||2|||f||||||||||||||2018-05-31 22:03:13.471462|2018-05-31 22:03:13.471462
NCT01455896|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18||2016-06-03|2017-01-26|2011-10-19|2011-10-20|Estimate||||2016-06-03|2016-06-07|Estimate|2017-01-26|2017-01-27|Estimate|March 2013|Actual|2013-03-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650|A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes|Completed||Phase 3|4156|Actual|Intarcia Therapeutics||2|||f||||t||||||||||2018-05-31 22:03:13.553237|2018-05-31 22:03:13.553237
NCT01455883|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2012-12-21|2011-10-19|2011-10-20|Estimate|||||||2012-12-21|2012-12-25|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes|Withdrawn||Phase 3|0|Actual|Intarcia Therapeutics||2|||f||||||||||||||2018-05-31 22:03:13.686232|2018-05-31 22:03:13.686232
NCT01455870|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18||2016-05-13|2016-05-13|2011-10-19|2011-10-20|Estimate||||2016-05-13|2016-06-02|Estimate|2016-05-13|2016-06-02|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes|A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes|Completed||Phase 3|535|Actual|Intarcia Therapeutics||2|||f||||t||||||||||2018-05-31 22:03:13.757462|2018-05-31 22:03:13.757462
NCT01455857|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18||2015-07-28|2015-07-28|2011-10-18|2011-10-20|Estimate||||2015-07-28|2015-08-18|Estimate|2015-07-28|2015-08-18|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes|Completed||Phase 3|460|Actual|Intarcia Therapeutics||3|||f||||t||||||||||2018-05-31 22:03:14.053988|2018-05-31 22:03:14.053988
NCT01455844|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2014-08-21|2011-10-18|2011-10-20|Estimate|||||||2014-08-21|2014-08-22|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|TRIFECTA||TRIal For Efficacy of Capre on hyperTriglyceridemiA|A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia|Completed||Phase 2|387|Actual|Acasti Pharma Inc.||3|||f||||f||||||||||2018-05-31 22:03:14.384398|2018-05-31 22:03:14.384398
NCT01455831|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2018-05-08|2011-10-19|2011-10-20|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2011||2011-09-30|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Interventional|PERIOP-01||Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer|A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer|Recruiting||Phase 3|1075|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 22:03:14.533897|2018-05-31 22:03:14.533897
NCT01455818|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-09-13|2011-10-19|2011-10-20|Estimate|||||||2016-09-13|2016-09-15|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|SSPE||A Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound|A Multicenter Prospective Cohort Management Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound|Recruiting|||300|Anticipated|Ottawa Hospital Research Institute|||||f||||t||||||||||2018-05-31 22:03:14.713955|2018-05-31 22:03:14.713955
NCT01455805|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2016-04-13|2011-10-18|2011-10-20|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Minuteman Spinal Fusion Implant Versus Surgical Decompression for Lumbar Spinal Stenosis|Efficacy and Quality of Life Following Treatment of Lumbar Spinal Stenosis, Spondylolisthesis or Degenerative Disc Disease With the Minuteman Interspinous Interlaminar Fusion Implant Versus Surgical Decompression|Recruiting||Phase 4|50|Anticipated|Spinal Simplicity LLC||2|||f||||t||||||||||2018-05-31 22:03:14.831527|2018-05-31 22:03:14.831527
NCT01455792|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-12-27|2011-10-18|2011-10-20|Estimate|||||||2013-12-27|2013-12-30|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Biopsy Study Comparing MRI and Ultrasound Soft Image Fusion Guided Biopsies and Gold Standard Prostate Biopsies.|MRI and Ultrasound Soft Image Fusion Guided Biopsies Compared to Gold Standard Prostate Biopsies|Completed||N/A|200|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 22:03:14.936714|2018-05-31 22:03:14.936714
NCT01455779|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-12-08|2011-10-18|2011-10-20|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|ROSE||Lyrette: Renewing Continence Objective and Subjective Efficacy Study|Lyrette: Renewing Continence Objective and Subjective Efficacy Study|Unknown status|Active, not recruiting|N/A|54|Actual|Verathon||1|||f||||f||||||||||2018-05-31 22:03:15.028632|2018-05-31 22:03:15.028632
NCT01455766|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2012-09-04|2011-10-19|2011-10-20|Estimate|||||||2012-09-04|2012-09-05|Estimate|June 2005||2005-06-30|September 2012|2012-09-30|November 2011|Actual|2011-11-30|February 2008|Actual|2008-02-29||Observational|EVLW-PNEUMO||Volumetric Monitoring in Major Lung Surgery|Pulmonary Edema Following Major Thoracic Resections: a Value of Perioperative Volumetric Monitoring|Completed|||50|Anticipated|Northern State Medical University|||||f||||f||||||Samples Without DNA|"~     Blood plasma for non-specified additional retrospective tests.~   "|||2018-05-31 22:03:15.152419|2018-05-31 22:03:15.152419
NCT01455753|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-12-14|2011-10-19|2011-10-20|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2011||2011-10-31|December 2017|2017-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||The Effect of Proximity on Flu-Shot Participation|The Effect of Proximity on Flu-Shot Participation|Completed|||1801|Actual|National Bureau of Economic Research, Inc.|||1||f||||f||||||||||2018-05-31 22:03:15.229832|2018-05-31 22:03:15.229832
NCT01455740|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-12-14|2011-10-19|2011-10-20|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2011||2011-10-31|December 2017|2017-12-31|October 2014|Actual|2014-10-31|June 2013|Actual|2013-06-30||Interventional|||A Commitment Device for Medication Adherence Among HIV Patients|A Commitment Device for Medication Adherence Among HIV Patients|Completed||N/A|110|Actual|National Bureau of Economic Research, Inc.||3|||f||||f||||||||||2018-05-31 22:03:15.335618|2018-05-31 22:03:15.335618
NCT01455727|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2012-09-13|2011-10-18|2011-10-20|Estimate|||||||2012-09-13|2012-09-17|Estimate|August 2011||2011-08-31|September 2012|2012-09-30||||August 2012|Actual|2012-08-31||Interventional|||Pharmaceutical Care of Ambulatory Elderly Diabetes Patients||Completed||N/A|100|Actual|Nantou Hospital||2|||f||||||||||||||2018-05-31 22:03:15.406116|2018-05-31 22:03:15.406116
NCT01455714|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|September 2012||2012-09-30|October 2011|2011-10-31|September 2014|Anticipated|2014-09-30|December 2013|Anticipated|2013-12-31||Observational|dysh||Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension|Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension|Unknown status|Not yet recruiting||120|Anticipated|Medical Universtity of Lodz|||1||f||||t||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 22:03:15.47125|2018-05-31 22:03:15.47125
NCT01455701|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-12-07|2011-10-18|2011-10-20|Estimate|||||||2017-12-07|2017-12-08|Actual|October 26, 2012|Actual|2012-10-26|December 2017|2017-12-31|July 13, 2017|Actual|2017-07-13|July 28, 2016|Actual|2016-07-28||Interventional|||A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)|A Phase I Pharmacokinetic and Safety Study of Tocilizumab (TCZ) in Patients Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)|Completed||Phase 1|11|Actual|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 22:03:15.541528|2018-05-31 22:03:15.541528
NCT01455688|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2018-04-10|2011-10-18|2011-10-20|Estimate|||||||2018-04-10|2018-04-12|Actual|January 1, 2012|Actual|2012-01-01|April 2018|2018-04-30|June 30, 2016|Actual|2016-06-30|December 31, 2015|Actual|2015-12-31||Interventional|||Early Antiviral Therapy for Critically Ill HIV Infected Patients|Early Antiretroviral Therapy for Critically Ill HIV Infected Patients|Completed||Phase 4|115|Actual|Hospital Nossa Senhora da Conceicao||2|||f||||f||||||||||2018-05-31 22:03:15.721177|2018-05-31 22:03:15.721177
NCT01455675|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2017-07-03|2011-10-19|2011-10-20|Estimate|||||||2017-07-03|2017-07-06|Actual|October 2011||2011-10-31|July 2017|2017-07-31|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|PsAer-IgY||Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients|Phase III Study to Evaluate Clinical Efficacy and Safety of Avian Polyclonal Anti-Pseudomonas Antibodies (IgY) in Prevention of Recurrence of Pseudomonas Aeruginosa Infection in Cystic Fibrosis Patients|Completed||Phase 3|164|Actual|Mukoviszidose Institut gGmbH||2|||f||||t||||||||Undecided||2018-05-31 22:03:16.777098|2018-05-31 22:03:16.777098
NCT01455662|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-11-02|2011-10-19|2011-10-20|Estimate|||||||2011-11-02|2011-11-03|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Relationship Between Tissue Markes in Patients With Post Cardio Respiratory Syndrome|Relationship Between Lactate and Venous Oxygen Saturation Gradient of Carbon Dioxide in Patients With Post Cardio Respiratory Syndrome|Unknown status|Recruiting||100|Anticipated|Hospital Nossa Senhora da Conceicao|||1||f||||t||||||||||2018-05-31 22:03:16.974774|2018-05-31 22:03:16.974774
NCT01455649|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults|A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium Compared to Patients Who Will Maintain the Use of Calcineurin Inhibitor|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Hospital Federal de Bonsucesso||2|||f||||f||||||||||2018-05-31 22:03:17.072227|2018-05-31 22:03:17.072227
NCT01455636|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2015-06-30|2011-10-19|2011-10-20|Estimate|||||||2015-06-30|2015-07-02|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Preventing Linear Growth Faltering Among Low Birth Weight Infants in Bangladesh|Preventing Linear Growth Faltering and Reversal of Stunting Among Low Birth Weight Infants in Bangladesh: a Community-based Cluster Randomized Control Trial|Completed||Phase 3|467|Actual|The Hospital for Sick Children||4|||f||||f||||||||||2018-05-31 22:03:17.228283|2018-05-31 22:03:17.228283
NCT01455610|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|||Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study|Preoperative Evaluation of Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study|Unknown status|Not yet recruiting||140|Anticipated|Shanghai Zhongshan Hospital|||||f||||t||||||||||2018-05-31 22:03:17.528863|2018-05-31 22:03:17.528863
NCT01455597|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17||2014-02-14|2015-02-24|2011-10-19|2011-10-20|Estimate||||2014-02-14|2014-03-14|Estimate|2015-02-24|2015-03-17|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluate Long-Term Safety and Efficacy WC3011|A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of WC3011 in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women|Completed||Phase 3|309|Actual|Warner Chilcott||1|||f||||f||||||||||2018-05-31 22:03:17.632759|2018-05-31 22:03:17.632759
NCT01455584|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-05-22|2011-10-19|2011-10-20|Estimate|||||||2013-05-22|2013-05-23|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors|Phase Ⅰ Study to Determine the Maximum Tolerated Dose of HM781-36B Continuously Given in Patients With Advanced Solid Tumors and to Assess the Food Effect on Pharmacokinetic Profile|Completed||Phase 1|20|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 22:03:17.84092|2018-05-31 22:03:17.84092
NCT01455571|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2014-02-24|2011-10-19|2011-10-20|Estimate|||||||2014-02-24|2014-02-26|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors|Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B|Completed||Phase 1|55|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 22:03:17.931479|2018-05-31 22:03:17.931479
NCT01455558|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-10-18|2011-10-18|2011-10-20|Estimate|||||||2011-10-18|2011-10-20|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Safety and Pharmacokinetic Comparison of Cilostazol SR and IR Formulations in Healthy Korean Volunteers||Completed||Phase 1|92|Actual|Severance Hospital||1|||f||||||||||||||2018-05-31 22:03:18.009755|2018-05-31 22:03:18.009755
NCT01455545|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2012-08-17||2013-06-04|2011-10-18|2011-10-20|Estimate|2013-06-04|2013-08-28|Estimate||||2013-06-04|2013-08-28|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Observational|||Impact of Adherence to Treatment in Asthma Control|Impact of Adherence to Treatment in Asthma Control Using ASK-20 Questionnaire and Prescription Account.|Completed|||100|Actual|Sociedad Española de Neumología y Cirugía Torácica|This is an observational (cross-sectional )study, with the limitations and biases associated. Patients have not been randomized.||||f||||t||||||||||2018-05-31 22:03:18.158944|2018-05-31 22:03:18.158944
NCT01455532|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2014-10-21|2011-10-19|2011-10-20|Estimate|||||||2014-10-21|2014-10-22|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|||A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors|A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors|Completed||Phase 1|59|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 22:03:18.617606|2018-05-31 22:03:18.617606
NCT01455519|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2015-05-26||2017-10-18|2011-10-19|2011-10-20|Estimate|2015-07-09|2015-07-13|Estimate||||2017-10-18|2017-10-24|Actual|October 2011||2011-10-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Covidien||True Functional Restoration and Analgesia in Non-Radicular Low Back Pain|True Functional Restoration and Analgesia in Non-Radicular Low Back Pain: a Prospective Double Blind, Placebo-controlled Study of Hydromorphone ER|Completed||Phase 4|51|Actual|Shirley Ryan AbilityLab||2|||f||||t||||||||||2018-05-31 22:03:18.808865|2018-05-31 22:03:18.808865
NCT01455506|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-02-01|2011-10-18|2011-10-20|Estimate|||||||2014-02-01|2014-02-04|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||PRO#0118: Decitabine Plus Mini Flu-Bu|PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies|Completed||Phase 1|20|Actual|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 22:03:19.325553|2018-05-31 22:03:19.325553
NCT01455493|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18||2016-08-09|2016-08-09|2011-10-18|2011-10-20|Estimate||||2016-08-09|2016-08-11|Estimate|2016-08-09|2016-08-11|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|||A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma|A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for The Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|56|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:03:19.48216|2018-05-31 22:03:19.48216
NCT01455480|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2016-12-05|2011-10-19|2011-10-20|Estimate|||||||2016-12-05|2016-12-06|Estimate|December 2011||2011-12-31|December 2016|2016-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn|Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn|Withdrawn||Phase 1/Phase 2|0|Actual|Regenera Pharma Ltd||1|||f||||f||||||||||2018-05-31 22:03:19.588127|2018-05-31 22:03:19.588127
NCT01455467|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2018-03-07|2011-10-18|2011-10-20|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2011||2011-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery|A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery|Active, not recruiting||N/A|80|Anticipated|Glaukos Corporation||2|||f||||f||||||||||2018-05-31 22:03:19.676729|2018-05-31 22:03:19.676729
NCT01455454|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-19|2011-10-19|2011-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Heparin's Influence on ROTEM® Analysis|Evaluation of the Feasibility of Rotational Thromboelastrometry During Cardiopulmonary Bypass Using a Heparinase Modified ROTEM® Assay|Completed|||20|Actual|University of Lausanne Hospitals|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 22:03:19.901688|2018-05-31 22:03:19.901688
NCT01455272|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2015-04-05|2011-10-17|2011-10-19|Estimate|||||||2015-04-05|2015-04-07|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||New Therapy for Advanced Stage Leukemia After Stem Cell Transplantation|Clinical Study of Granulocyte Colony-stimulating Factor (G-CSF)-Primed, Peripheral-blood Progenitor Cells for the Prevention of Relapse Advanced Stage Leukemia|Completed||N/A|100|Anticipated|Peking University People's Hospital||1|||f||||t||||||||||2018-05-31 22:03:22.983288|2018-05-31 22:03:22.983288
NCT01455441|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2015-05-28|2011-10-19|2011-10-20|Estimate|||||||2015-05-28|2015-05-29|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes|Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?|Completed||Phase 4|40|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 22:03:20.009561|2018-05-31 22:03:20.009561
NCT01455428|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2015-01-08||2015-05-20|2011-10-17|2011-10-20|Estimate|2015-05-20|2015-05-22|Estimate||||2015-05-20|2015-05-22|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||All randomized and treated participants were included in the baseline characteristics summarization.|Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)|An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn )|Completed||Phase 4|223|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:03:20.166732|2018-05-31 22:03:20.166732
NCT01455415|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2014-10-30||2015-04-22|2011-10-17|2011-10-20|Estimate|2015-04-22|2015-04-23|Estimate||||2015-04-22|2015-04-23|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional||Intent-to-Treat Population (ITT) included all randomized participants with at least one dose of study drug. The ITT population was analyzed according to what the randomization schedule intended for the participants to take in each period.|Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain|A Study Of Pregabalin In The Treatment Of Subjects With Painful Diabetic Peripheral Neuropathy With Background Treatment Of Nsaid For Other Pain Conditions|Completed||Phase 3|306|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:03:21.35659|2018-05-31 22:03:21.35659
NCT01455402|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2014-07-08|2011-10-19|2011-10-20|Estimate|||||||2014-07-08|2014-07-09|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|CD-1089||An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF|An Observational Study to Assess Respiratory Syncytial Virus (RSV)-Associated Illness in Adults With Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF)|Completed|||476|Actual|MedImmune LLC|||||f||||f||||||Samples Without DNA|"~     serum, whole blood, plasma, nasal swab, sputum~   "|||2018-05-31 22:03:22.116126|2018-05-31 22:03:22.116126
NCT01455389|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2017-03-14|2011-10-17|2011-10-20|Estimate|||||||2017-03-14|2017-03-16|Actual|February 2014||2014-02-28|March 2017|2017-03-31||||March 2018|Anticipated|2018-03-31||Interventional|||FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer|Phase I/II Clinical Trial Combining FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer|Recruiting||Phase 1/Phase 2|57|Anticipated|Genprex, Inc.||1|||f||||f||||||||||2018-05-31 22:03:22.322198|2018-05-31 22:03:22.322198
NCT01455376|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2011-10-20|2011-10-17|2011-10-19|Estimate|||||||2011-10-20|2011-10-21|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Exogenous Lactate on Neurocognitive in Brain Trauma|Effect of Exogenous Lactate Infusion on Neurocognitive Function of Patients With Mild Traumatic Brain Injury|Completed||N/A|60|Actual|Universitas Padjadjaran||2|||f||||t||||||||||2018-05-31 22:03:22.416568|2018-05-31 22:03:22.416568
NCT01455363|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-04-03|2011-10-17|2011-10-19|Estimate|||||||2012-04-03|2012-04-04|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|HPOB||Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma|Etude peropératoire de la Perfusion Sanguine Des Carcinomes Basocellulaires Par Imageur Laser Doppler, au Cours de la Manipulation de l'Influx artériel Tumoral - Recherche d'un phénomène d'hyperémie Tumorale Post-occlusive|Completed||N/A|12|Actual|Institut Curie|||||f||||f||||||||||2018-05-31 22:03:22.483978|2018-05-31 22:03:22.483978
NCT01455350|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2016-11-03|2011-10-17|2011-10-19|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy of a Physiotherapy Treatment in Women Suffering From Provoked Vestibulodynia|Efficacy of Treatments for Provoked Vestivulodynia : a Randomised Clinical Trial Comparing Multimodal Physiotherapy Treatments to Topical Lidocaine|Completed||N/A|212|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 22:03:22.538878|2018-05-31 22:03:22.538878
NCT01455337|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline|Principal Investigator|Unknown status|Enrolling by invitation|Phase 3|126|Anticipated|Inje University||2|||f||||f||||||||||2018-05-31 22:03:22.622462|2018-05-31 22:03:22.622462
NCT01455324|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2012-03-01|2011-10-17|2011-10-19|Estimate|||||||2012-03-01|2012-03-05|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Evaluation of the Development of an Advanced, Conformable Prosthetic Socket, Study II||Completed|||1|Actual|Infoscitex Corporation|||1||f||||f||||||||||2018-05-31 22:03:22.696543|2018-05-31 22:03:22.696543
NCT01455311|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2013-02-12|2011-10-17|2011-10-19|Estimate|||||||2013-02-12|2013-02-15|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors|Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in the Diagnosis of Cystic Pancreatic Tumors|Terminated|||21|Actual|H. Lee Moffitt Cancer Center and Research Institute|||1|funding unavailable|f||||f||||||Samples With DNA|"~     Cataloguing the proteins that are expressed in pancreatic cyst fluid will provide preliminary~     data that will be used for identification of candidate biomarkers to predict malignant~     transformation.~   "|||2018-05-31 22:03:22.763635|2018-05-31 22:03:22.763635
NCT01455298|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2012-10-30|2011-10-18|2011-10-19|Estimate|||||||2012-10-30|2012-10-31|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|LIDIA-A1AT||Liver Disease in Adults With Alpha-1 AT Deficiency|Research of Infra Clinical Liver Injuries in Adult Patients Presented With Alpha-1 AT Deficiency|Completed||N/A|33|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 22:03:22.847983|2018-05-31 22:03:22.847983
NCT01455285|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate||||May 2011|2011-05-31||||||||Interventional|||Effectiveness of the Transcutaneous Electrical Nerve Stimulation in Dysmenorrhea|Investigation of the Effectiveness of Different Modulations of Pulse Frequency Transcutaneous Electrical Nerve Stimulation in Dysmenorrhea|Completed||N/A|||Universidade Federal do Piauí|||||f||||t||||||||||2018-05-31 22:03:22.92852|2018-05-31 22:03:22.92852
NCT01455246|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-10-11|2011-10-17|2011-10-19|Estimate|||||||2014-10-11|2014-10-15|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis|Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial|Terminated||Phase 2/Phase 3|32|Actual|University of Padova||2||"Decision of independent monitoring committee after interim analysis: Risk of failure~   significantly higher in ceftazidime group."|f||||f||||||||||2018-05-31 22:03:24.290213|2018-05-31 22:03:24.290213
NCT01455233|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|STB-01||2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery|Phase IV Study: A Prospective Two-Site Study to Evaluate the Safety and Tolerance of Besivance Versus Vigamox Prophylactically Pre and Post Operatively in Subjects Undergoing Routine Cataract Surgery|Completed||Phase 4|60|Actual|Ophthalmology Consultants, Ltd.||2|||f||||t||||||||||2018-05-31 22:03:24.376245|2018-05-31 22:03:24.376245
NCT01455220|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2016-05-10||2017-02-14|2011-10-17|2011-10-19|Estimate|2017-02-14|2017-03-31|Actual||||2017-02-14|2017-03-31|Actual|January 2011||2011-01-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Tysex||The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis|The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis|Completed||N/A|45|Actual|University of South Florida|||||f||||f||||||||No||2018-05-31 22:03:24.481858|2018-05-31 22:03:24.481858
NCT01455207|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2014-04-08|2011-10-18|2011-10-19|Estimate|||||||2014-04-08|2014-04-09|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|ALCOBRAIN||From Uncomplicated Alcoholism to Korsakoff's Syndrome|From Uncomplicated Alcoholism to Korsakoff's Syndrome: Clinical, Genetic, Neuropsychological and Brain Examinations|Unknown status|Recruiting|N/A|220|Anticipated|University Hospital, Caen||3|||f||||t||||||||||2018-05-31 22:03:24.650338|2018-05-31 22:03:24.650338
NCT01455194|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2016-04-24||2016-12-21|2011-10-17|2011-10-19|Estimate|2016-08-29|2016-10-25|Estimate||||2016-12-21|2017-02-10|Actual|November 2011||2011-11-30|December 2016|2016-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CONTRAST|The full analysis set (FAS) was defined as all randomized participants who took at least 1 dose of double-blind study medication.Baseline data was summarized only for those participants who entered treatment period which was the core period of the trial.|Effect of High Dose Ciclesonide on Asthma Control|Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.|Completed||Phase 3|520|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:03:24.797754|2018-05-31 22:03:24.797754
NCT01455181|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2015-02-20||2015-11-10|2011-10-17|2011-10-19|Estimate|2015-02-20|2015-03-06|Estimate||||2015-11-10|2015-12-08|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|REPEAT||A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary|A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study|Completed||Phase 3|24|Actual|Shire||1|||f||||f||||||||||2018-05-31 22:03:26.191991|2018-05-31 22:03:26.191991
NCT01455168|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2011-10-19|2011-10-17|2011-10-19|Estimate|||||||2011-10-19|2011-10-20|Estimate|September 2004||2004-09-30|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|May 2006|Actual|2006-05-31||Observational|Effect of CTR||Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome|Prospective Study to Examine the Efficacy of a Capsular Tension Ring (CTR) in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome (XFS) With no Zonular Weakness|Unknown status|Active, not recruiting||30|Anticipated|University of Occupational and Environmental Health|||3||f||||f||||||||||2018-05-31 22:03:26.556107|2018-05-31 22:03:26.556107
NCT01455155|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2011-10-15|2011-10-15|2011-10-19|Estimate|||||||2011-10-15|2011-10-19|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|May 2014|Anticipated|2014-05-31|October 2013|Anticipated|2013-10-31||Interventional|||Creative Therapy to Affect Stroke Outcomes|Efficacy of Creative Therapy for Stroke Patients|Unknown status|Not yet recruiting|Phase 4|204|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 22:03:26.625906|2018-05-31 22:03:26.625906
NCT01455142|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2015-02-19|2011-10-18|2011-10-19|Estimate|||||||2015-02-19|2015-02-23|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes|A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes|Completed||Phase 1|32|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:03:26.728143|2018-05-31 22:03:26.728143
NCT01455129|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2016-08-10|2011-10-15|2011-10-19|Estimate|||||||2016-08-10|2016-08-11|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Tie-COPD||Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China|Early Intervention With Tiotropium （Spiriva） in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel, Multicentre Trial|Completed||Phase 4|841|Actual|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f||||||||||2018-05-31 22:03:26.865076|2018-05-31 22:03:26.865076
NCT01455116|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2016-11-21|2011-10-18|2011-10-19|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|CASS||The Cooling And Surviving Septic Shock Study (CASS)|Randomized Trial to Determine Whether Mild Induced Hypothermia Can Reduce Mortality in Adult Patients With Septic Shock|Terminated||Phase 2/Phase 3|433|Actual|Danish Procalcitonin Study Group||2||Futility|f||||t||||||||Undecided|The Steering Committee will share data after reviewing study propositions - this to assure quality|2018-05-31 22:03:27.037834|2018-05-31 22:03:27.037834
NCT01455103|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-12-12|2011-10-18|2011-10-19|Estimate|||||||2011-12-12|2011-12-13|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|PD-L1||Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma|A Phase I Study of the Biologic Effects of BMS-936559 Treatment in Subjects With Unresectable Stage III or IV Melanoma|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 22:03:27.152426|2018-05-31 22:03:27.152426
NCT01454934|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2017-01-11||2017-08-03|2011-10-17|2011-10-19|Estimate|2017-01-11|2017-03-01|Actual||||2017-08-03|2017-09-01|Actual|September 2011||2011-09-30|August 2017|2017-08-31|May 2, 2016|Actual|2016-05-02|July 2015|Actual|2015-07-31||Interventional||Full analysis set included all randomized participants.|A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer||Completed||Phase 3|540|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 22:03:29.676419|2018-05-31 22:03:29.676419
NCT01455090|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18||2015-09-23|2017-04-26|2011-10-18|2011-10-19|Estimate||||2015-09-23|2015-10-09|Estimate|2017-04-26|2017-04-27|Actual|November 30, 2011|Actual|2011-11-30|April 2017|2017-04-30|July 31, 2015|Actual|2015-07-31|March 31, 2014|Actual|2014-03-31||Interventional|||Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications|Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With Hepatitis C Virus Genotype 1|Completed||Phase 2|320|Actual|Bristol-Myers Squibb||13|||f||||f||||||||||2018-05-31 22:03:27.248282|2018-05-31 22:03:27.248282
NCT01455077|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|January 2012|Anticipated|2012-01-31|July 2011|Actual|2011-07-31||Observational|||Portable Monitoring Device for the Diagnosis of Sleep Apnea in Obese Patients|Validation of a Portable Monitoring System for the Diagnosis of Obstructive Sleep Apnea Syndrome in Patients With Level II and III Obesity|Unknown status|Recruiting||40|Anticipated|Associacao Fundo de Incentivo a Psicofarmcologia|||1||f||||f||||||||||2018-05-31 22:03:27.438601|2018-05-31 22:03:27.438601
NCT01455064|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|2013-02-07||2013-05-13|2011-10-15|2011-10-19|Estimate|2013-05-13|2013-07-22|Estimate||||2013-05-13|2013-07-22|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Navigator II Continuous Glucose Monitor Home Use Study|FreeStyle Navigator II Continuous Glucose Monitor Home Use Evaluation (FSNv2)|Completed|||31|Actual|Abbott Diabetes Care|||1||f||||f||||||||||2018-05-31 22:03:27.517232|2018-05-31 22:03:27.517232
NCT01455051|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2012-01-10|2011-10-18|2011-10-19|Estimate|||||||2012-01-10|2012-01-11|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|October 2017|Anticipated|2017-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation|Ofatumumab as Part of the Reduced Intensity Conditioning Regimen for Patients With High Risk Chronic Lymphocytic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a Pilot Study by GETH and GELLC|Unknown status|Recruiting|Phase 2|25|Anticipated|Grupo Espanol de trasplantes hematopoyeticos y terapia celular||1|||f||||f||||||||||2018-05-31 22:03:27.674742|2018-05-31 22:03:27.674742
NCT01455038|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Heart Rate Variability of Patients With Bipolar Disorder in Subsyndromal Depressive Phase|Heart Rate Variability of Patients With Bipolar Disorder in Subsyndromal Depressive Phase|Completed|||92|Actual|Asan Medical Center|||2||f||||||||||||||2018-05-31 22:03:27.843457|2018-05-31 22:03:27.843457
NCT01455025|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2016-03-15|2011-10-17|2011-10-19|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|PRIMAL||Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia|A Phase 1, Dose Escalation Study of Plerixafor in Combination With Induction and Consolidation Chemotherapy in Patients With Relapsed Acute Myeloid Leukemia|Terminated||Phase 1|11|Actual|French Innovative Leukemia Organisation||1||no recruitment on time|f||||t||||||||||2018-05-31 22:03:27.906578|2018-05-31 22:03:27.906578
NCT01455012|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2013-05-14||2013-07-19|2011-10-17|2011-10-19|Estimate|2013-05-14|2013-07-18|Estimate||||2013-07-19|2013-07-26|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|ENCORE|Baseline Characteristics refer to the Full Analysis Set (FAS). FAS includes all randomized subjects having both a Baseline and a post-Baseline measurement for the primary efficacy variable.|Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome|Multicenter, Double-Blind, Placebo-Controlled, Two-Arm, Randomized, Parallel, Treatment Intervention, Sleep Lab Phase 4 Study to Assess the Effect of Rotigotine on Nocturnal Blood Pressure in Patients With Idiopathic Restless Legs Syndrome|Completed||Phase 4|81|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 22:03:28.105144|2018-05-31 22:03:28.105144
NCT01454999|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-03-15|2011-10-14|2011-10-19|Estimate|||||||2016-03-15|2016-03-17|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|TXT||Cell Phone-Based Expert Systems for Smoking Cessation|Cell Phone-Based Expert Systems for Smoking Cessation|Completed||Phase 1|446|Actual|VA Pacific Islands Health Care System||2|||f||||f||||||||No||2018-05-31 22:03:28.70062|2018-05-31 22:03:28.70062
NCT01454986|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2017-02-02|2011-10-18|2011-10-19|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2011||2011-11-30|February 2017|2017-02-28|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects|A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of ALXN1007 in Healthy Subjects|Completed||Phase 1|64|Actual|Alexion Pharmaceuticals||7|||f||||t||||||||||2018-05-31 22:03:28.782166|2018-05-31 22:03:28.782166
NCT01454973|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2012-08-09|2011-10-18|2011-10-19|Estimate|||||||2012-08-09|2012-08-10|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects|Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects|Completed|||25|Actual|Foundation for the National Institutes of Health|||1||f||||f||||||||||2018-05-31 22:03:28.866338|2018-05-31 22:03:28.866338
NCT01454960|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2017-03-31|2011-10-18|2011-10-19|Estimate|||||||2017-03-31|2017-04-04|Actual|July 2011||2011-07-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|February 2013|Actual|2013-02-28||Interventional|BEARI||Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Pilot Study)|Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Pilot Study)|Completed||N/A|28|Actual|University of Southern California||8|||f||||t||||||||||2018-05-31 22:03:28.977236|2018-05-31 22:03:28.977236
NCT01454947|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|2015-07-20||2017-03-30|2011-10-14|2011-10-19|Estimate|2017-03-30|2017-06-20|Actual||||2017-03-30|2017-06-20|Actual|August 2011||2011-08-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|BEARI|Enrolled Clinicians|Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)|Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)|Completed||N/A|248|Actual|University of Southern California||8|||f||||t||||||||||2018-05-31 22:03:29.128994|2018-05-31 22:03:29.128994
NCT01437033|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2018-04-04|2011-09-16|2011-09-20|Estimate|||||||2018-04-04|2018-04-05|Actual|August 29, 2011||2011-08-29|September 23, 2016|2016-09-23|September 23, 2016||2016-09-23|||||Observational|||Breath Test for Chemicals (Volatile Organic Compounds)|A Pilot Study of a Breath Test for Assessment of Volatile Organic Compounds|Completed|||5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:09:06.172018|2018-05-31 22:09:06.172018
NCT01454921|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-02-27|2011-10-17|2011-10-19|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2010||2010-02-28|March 2016|2016-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Development of an Empowerment Intervention for Young Women Living With HIV|A Secondary Prevention Empowerment Intervention for Young Women Living With HIV|Completed||Phase 2|43|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:03:30.608434|2018-05-31 22:03:30.608434
NCT01454908|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|April 2006||2006-04-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Oxford Partial Knee Kinematics Gait Analysis Study|Investigation of Unicompartmental Knee Arthroplasty and Functional, Daily Activities: A Quantitative Assessment of Gait, Sit-to-Stand, and Stair Climbing|Unknown status|Active, not recruiting|N/A|18|Actual|The CORE Institute||1|||f||||f||||||||||2018-05-31 22:03:30.92755|2018-05-31 22:03:30.92755
NCT01454895|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2015-10-01|2011-10-18|2011-10-19|Estimate|||||||2015-10-01|2015-10-05|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Test of a Web-based Intervention to Promote Hearing Protector Use|Test of a Web-based Intervention to Promote Hearing Protector Use|Completed||N/A|498|Actual|University of Michigan||6|||f||||f||||||||||2018-05-31 22:03:31.101206|2018-05-31 22:03:31.101206
NCT01454882|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-01-07|2011-10-14|2011-10-19|Estimate|||||||2016-01-07|2016-01-11|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Observational|||Measuring Free-living Energy Expenditure Using Direct Calorimetry|Measuring Free-living Energy Expenditure Using Direct Calorimetry|Completed|||39|Actual|University of Colorado, Denver|||3||f||||t||||||||||2018-05-31 22:03:31.211732|2018-05-31 22:03:31.211732
NCT01454869|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2012-12-14|2011-10-18|2011-10-19|Estimate|||||||2012-12-14|2012-12-17|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|June 2014|Anticipated|2014-06-30|June 2012|Anticipated|2012-06-30||Interventional|||The Effect of Heparin on Inhalation Injury|Efficacy of Heparin Nebulization on Lung Injury Score in Inhalation Burn Injury|Withdrawn||Phase 3|0|Actual|Tehran University of Medical Sciences||2||Due to insufficient funds|f||||t||||||||||2018-05-31 22:03:31.610926|2018-05-31 22:03:31.610926
NCT01454856|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-03-23|2011-10-14|2011-10-19|Estimate|||||||2017-03-23|2017-03-24|Actual|October 2011||2011-10-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Perioperative Evaluation of Immuno-inflammatory Parameters|Perioperative Evaluation of Immuno-inflammatory Parameters|Terminated|||20|Actual|Université Catholique de Louvain|||4||f||||t||||||Samples Without DNA|"~     Plasma and cells (PBMCs) frozen in cryotubes~   "|||2018-05-31 22:03:31.892791|2018-05-31 22:03:31.892791
NCT01454843|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-04-22|2011-10-16|2011-10-19|Estimate|||||||2018-04-22|2018-04-24|Actual|June 2011||2011-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|LASIK||LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser vs AMO Visx Wavefront-Guided Excimer Laser|A Prospective Eye to Eye Comparison of LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser Versus AMO Visx Wavefront-Guided Excimer Laser|Active, not recruiting||Phase 4|60|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 22:03:31.998352|2018-05-31 22:03:31.998352
NCT01454830|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|2016-08-05||2016-09-30|2011-10-17|2011-10-19|Estimate|2016-09-30|2016-11-23|Estimate||||2016-09-30|2016-11-23|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|SCIP-PA||Tailored Intervention to Promote Positive Airway Pressure Adherence|Phase I Double-blind Randomized Controlled Trial: Sociocultural and Cognitive Perception Intervention to Promote Positive Airway Pressure Adherence|Completed||Phase 1|118|Actual|Milton S. Hershey Medical Center|Sampling bias with convenience sampling leading to relatively few PAP users meeting definition of non-adherence (threshold definition </= 4hrs/night PAP use); Modest intervention fidelity (i.e., delivery) for telephone-delivered exposure period|2|||f||||f||||||||||2018-05-31 22:03:32.113604|2018-05-31 22:03:32.113604
NCT01454817|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-10-07|2011-10-17|2011-10-19|Estimate|||||||2016-10-07|2016-10-10|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study of Symptoms and Quality of Life in Patients With Implantable Cardiac Defibrillators (ICDs) and Their Caregivers|A Study of Symptoms and Quality of Life in Patients With ICDs and Their Caregivers|Completed||N/A|562|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 22:03:32.851389|2018-05-31 22:03:32.851389
NCT01454804|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2016-04-11|2011-10-17|2011-10-19|Estimate|||||||2016-04-11|2016-04-13|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors|Phase I Study of Pazopanib in Combination With Lapatinib or Trastuzumab in Subjects With Solid Tumors|Completed||Phase 1|43|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 22:03:32.967226|2018-05-31 22:03:32.967226
NCT01454791|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2014-07-22||2015-02-12|2011-10-18|2011-10-19|Estimate|2015-01-28|2015-02-13|Estimate||||2015-02-12|2015-03-05|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate|Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate: A Randomized Controlled Double- Blind Crossover Trial|Completed||Phase 4|40|Actual|Brown, Theodore R., M.D., MPH||2|||f||||f||||||||||2018-05-31 22:03:33.124107|2018-05-31 22:03:33.124107
NCT01454778|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2015-08-12||2016-04-15|2011-10-16|2011-10-19|Estimate|2016-04-15|2016-05-24|Estimate||||2016-04-15|2016-05-24|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|Pac1||Effects of Paclitaxel on Intimal Hyperplasia|Effects of Paclitaxel on Intimal Hyperplasia Status Post Lower Extremity Revascularization|Completed||N/A|50|Actual|Sanford Health||1|||f||||t||||||||||2018-05-31 22:03:33.443395|2018-05-31 22:03:33.443395
NCT01454765|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-16|||2013-12-10|2011-10-18|2011-10-19|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|August 2015|Anticipated|2015-08-31|December 2014|Anticipated|2014-12-31||Observational|||Generation of Haploid Stem Cells From Human Germ Cells|Generation of Haploid Stem Cells From Human Germ Cells|Unknown status|Recruiting||10|Anticipated|Rambam Health Care Campus|||1||f||||f||||||Samples With DNA|"~     Germ cells and Stem cells~   "|||2018-05-31 22:03:33.735286|2018-05-31 22:03:33.735286
NCT01454752|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2012-04-18|2011-10-17|2011-10-19|Estimate|||||||2012-04-18|2012-04-19|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition|Intermittent Parasite Clearance (IPC) in Schools: a Randomised Double-blind Placebo-controlled Trial of the Impact of IPC on Malaria, Anaemia and Cognition Amongst School Children in Kedougou, Senegal|Completed||N/A|860|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 22:03:33.810086|2018-05-31 22:03:33.810086
NCT01454739|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-12-22|2011-10-17|2011-10-19|Estimate|||||||2017-12-22|2017-12-26|Actual|December 2011||2011-12-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|ASPIRE||Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A|An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A|Completed||Phase 3|240|Actual|Bioverativ Therapeutics Inc.||2|||f||||t||||||||||2018-05-31 22:03:33.89044|2018-05-31 22:03:33.89044
NCT01454726|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2012-01-03||2012-11-23|2011-10-17|2011-10-19|Estimate|2012-11-23|2012-12-24|Estimate||||2012-11-23|2012-12-24|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|TCDMD||Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease|A Random Controlled Clinical Trial:l Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease|Completed||Phase 3|27|Actual|Beijing Administration of Traditional Chinese Medicine Bureau|Our study focused only on the effect of Diaoshi Jifa on Meniere's disease after one-time treatment. There still possibilities that after several days' treatment, both experimental and control groups have similar improvement in their DHI scores.|2|||f||||t||||||||||2018-05-31 22:03:34.086658|2018-05-31 22:03:34.086658
NCT01454713|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2017-04-04|2011-10-17|2011-10-19|Estimate|||||||2017-04-04|2017-04-05|Actual|October 2010||2010-10-31|April 2017|2017-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|RAVE||Retrospective Analysis of Veritas in Breast Reconstruction|Retrospective Analysis of Veritas in Breast Reconstruction (RAVE)|Completed|||54|Actual|Baxter Healthcare Corporation|||1||f||||f||||||||||2018-05-31 22:03:34.373227|2018-05-31 22:03:34.373227
NCT01454700|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2015-01-13|2011-10-18|2011-10-19|Estimate|||||||2015-01-13|2015-01-14|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of CSII and CGM on Progression of Late Diabetic Complications|The Effect of Sensor-Augmented Continuous Subcutaneous Insulin Infusion Compared to Multiple Daily Insulin Injections in Prevention of Increasing Urinary Albumin Excretion Rate in Type 1 Diabetes Mellitus|Completed||Phase 4|60|Actual|Steno Diabetes Center||2|||f||||f||||||||||2018-05-31 22:03:34.44666|2018-05-31 22:03:34.44666
NCT01454687|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-04-10|2011-10-17|2011-10-19|Estimate|||||||2014-04-10|2014-04-11|Estimate|October 2011||2011-10-31|April 2014|2014-04-30||||April 2014|Actual|2014-04-30||Interventional|||Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes|Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes|Withdrawn||N/A|0|Actual|Stanford University|||||f||||f||||||||||2018-05-31 22:03:34.579921|2018-05-31 22:03:34.579921
NCT01454674|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|June 2010|Actual|2010-06-30||Interventional|||The Vegetable Dose Response Study: Effects of Consumption on Inflammation and Oxidative Stress|The Vegetable Dose Response Study: Effects of Consumption on Inflammation and Oxidative Stress|Completed||N/A|75|Actual|University of Arizona|||||f||||f||||||||||2018-05-31 22:03:34.645606|2018-05-31 22:03:34.645606
NCT01454661|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2018-04-18|2011-10-14|2011-10-19|Estimate|||||||2018-04-18|2018-04-19|Actual|April 2014||2014-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ProPre||Probiotics and Early Microbial Contact in Preterm Neonates|Probiotic Modulation of Early Microbial Contact in Premature Infants|Recruiting||N/A|100|Anticipated|Turku University Hospital||5|||f||||f||||||||||2018-05-31 22:03:34.721332|2018-05-31 22:03:34.721332
NCT01454648|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2016-01-15|2011-10-18|2011-10-19|Estimate|||||||2016-01-15|2016-01-18|Estimate|January 2005||2005-01-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Prehospital Traumatic Brain Injury|Severe Traumatic Brain Injury - Comparison of Outcome in Paramedic Versus Physician Staffed Emergency Medical Services|Completed|||458|Actual|Tampere University Hospital|||2||f||||f||||||||||2018-05-31 22:03:34.82863|2018-05-31 22:03:34.82863
NCT01454635|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2011-10-27|2011-10-17|2011-10-19|Estimate|||||||2011-10-27|2011-10-31|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|AFADTRMDD||Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder|Treatment Response Study of Sertraline to Treat Japanese Major Depressive Disorder|Completed||N/A|96|Actual|Showa University||1|||f||||f||||||||||2018-05-31 22:03:34.940277|2018-05-31 22:03:34.940277
NCT01454622|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2013-05-03|2011-10-17|2011-10-19|Estimate|||||||2013-05-03|2013-05-06|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Fed Subjects|Completed||Phase 1|64|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 22:03:35.026853|2018-05-31 22:03:35.026853
NCT01454609|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-08|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Bilateral Superficial Cervical Plexus Block in Thyroidectomy|Safety and Efficacy of Bilateral Superficial Cervical Plexus Block in Thyroidectomy - a Double Blind Randomized Controlled Trial|Completed||Phase 2|60|Actual|Jawaharlal Institute of Postgraduate Medical Education & Research||3|||f||||t||||||||||2018-05-31 22:03:35.112646|2018-05-31 22:03:35.112646
NCT01454596|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-05-23|2011-10-15|2011-10-19|Estimate|||||||2018-05-23|2018-05-24|Actual|September 29, 2011||2011-09-29|February 23, 2018|2018-02-23|December 28, 2029|Anticipated|2029-12-28|December 29, 2028|Anticipated|2028-12-29||Interventional|||CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII|A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII|Recruiting||Phase 1/Phase 2|107|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:03:35.406787|2018-05-31 22:03:35.406787
NCT01454583|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2013-08-15||2016-06-20|2011-10-14|2011-10-19|Estimate|2014-08-05|2014-08-22|Estimate||||2016-06-20|2016-07-21|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|July 2012|Actual|2012-07-31|October 2009|Actual|2009-10-31||Observational|3A||Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany|3A-Register Zur Ambulanten Therapie Mit RAS-Inhibitoren in Patienten Mit Arterieller Hypertonie in Deutschland|Completed|||15337|Actual|Stiftung Institut fuer Herzinfarktforschung|||3||f||||f||||||||No||2018-05-31 22:03:35.809877|2018-05-31 22:03:35.809877
NCT01454570|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-04-08|2011-10-18|2011-10-19|Estimate|||||||2015-04-08|2015-04-10|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|November 2015|Anticipated|2015-11-30|April 2015|Anticipated|2015-04-30||Observational|VA_ReWalk||The ReWalk Exoskeletal Walking System for Persons With Paraplegia|The ReWalk Exoskeletal Walking System for Persons With Paraplegia|Unknown status|Recruiting||40|Anticipated|James J. Peters Veterans Affairs Medical Center|||||f||||f||||||||||2018-05-31 22:03:39.79151|2018-05-31 22:03:39.79151
NCT01454557|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-31|2011-10-17|2011-10-19|Estimate|||||||2011-10-31|2011-11-01|Estimate|November 2011||2011-11-30|October 2011|2011-10-31||||November 2012|Anticipated|2012-11-30||Interventional|||The Effect of Auditory Stimuli on Heart Rate Variability (HRV) Among Patients With Acquired Brain Injury (ABI)|The Effect of Auditory Stimuli on Heart Rate Variability (HRV) During Resting and During Physical Activity Among Patients With Acquired Brain Injury (ABI)|Unknown status|Not yet recruiting|N/A|80|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 22:03:39.88902|2018-05-31 22:03:39.88902
NCT01454544|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-01-27|2011-10-17|2011-10-19|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MT-06||A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet||Completed||Phase 3|992|Actual|ALK-Abelló A/S||3|||f||||f||||||||||2018-05-31 22:03:40.068587|2018-05-31 22:03:40.068587
NCT01454531|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2014-12-03||2015-02-23|2011-10-17|2011-10-19|Estimate|2015-02-23|2015-03-06|Estimate||||2015-02-23|2015-03-06|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional||Subjects treated|An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy|Completed||Phase 2/Phase 3|199|Actual|ALK-Abelló A/S||1|||f||||f||||||||||2018-05-31 22:03:40.263585|2018-05-31 22:03:40.263585
NCT01454518|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-03-08|2011-10-18|2011-10-19|Estimate|||||||2013-03-08|2013-03-11|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||Local Infiltration Analgesia for Hip Arthroscopy|Effectiveness of Ultrasound Guided Hip Infiltration With Local Anesthetic Solution for Pain Control After Hip Arthroscopy|Completed||N/A|36|Actual|Saint Francis Care||2|||f||||f||||||||||2018-05-31 22:03:40.548867|2018-05-31 22:03:40.548867
NCT01454505|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|2013-03-29||2013-03-29|2011-10-18|2011-10-19|Estimate|2013-03-29|2013-05-20|Estimate||||2013-03-29|2013-05-20|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy of AL-53817 Nasal Spray Solution|Safety and Efficacy of AL-53817 Nasal Spray Solution in Ragweed Sensitive Subjects in an Environmental Exposure Chamber (EEC)|Completed||Phase 1|110|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:03:40.656739|2018-05-31 22:03:40.656739
NCT01454492|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|September 2012|Anticipated|2012-09-30|March 2012|Anticipated|2012-03-31||Observational|AR-GT||The Relationship Between Allergic Rhinitis and Geographic Tongue||Unknown status|Recruiting||300|Anticipated|China Medical University Hospital|||2||f||||t||||||||||2018-05-31 22:03:42.334273|2018-05-31 22:03:42.334273
NCT01454479|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|||A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma|A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma|Unknown status|Enrolling by invitation|Phase 1|24|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 22:03:42.417497|2018-05-31 22:03:42.417497
NCT01454466|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|November 2009||2009-11-30|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Partial Posterior Hyaloidectomy in Macular Surgery|Partial Posterior Hyaloidectomy in Macular Surgery : A Modified Procedure of Vitrectomy to Prevent Retinal Break Related to Induction of a Posterior Vitreous Detachment|Completed||Phase 1|50|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 22:03:42.484576|2018-05-31 22:03:42.484576
NCT01454453|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-04-18|2011-10-17|2011-10-19|Estimate|||||||2017-04-18|2017-04-19|Actual|May 2012||2012-05-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Optimisation of Antipsychotic Drug Use in Older People|Rationalisation of Antipsychotic Drug Use in Older People, Using [18F]-Fallypride PET|Terminated||Phase 4|64|Actual|Institute of Psychiatry, London||1||Failure to recruit people with very late onset schizophrenia like psychosis|f||||f||||||||No|Not available|2018-05-31 22:03:42.544495|2018-05-31 22:03:42.544495
NCT01454440|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|INSTANT||The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)|A RANDOMIZED TRIAL COMPARING EPTIFIBATIDE AND PLACEBO IN PATIENTS WITH DIFFUSE CORONARY DISEASE UNDERGOING DRUG-ELUTING STENTING|Terminated||Phase 4|91|Actual|University of Turin, Italy||2||The study was stopped prematurely due to slow enrolment without code breaking.|f||||t||||||||||2018-05-31 22:03:42.622984|2018-05-31 22:03:42.622984
NCT01454427|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Influence of Anesthesia Drugs on Impedance Aggregometry|The Influence of Drugs Routinely Used in Cardiac Anesthesia on Impedance Aggregometry.|Completed|||20|Actual|University of Lausanne Hospitals|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 22:03:42.69303|2018-05-31 22:03:42.69303
NCT01454414|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2014-04-25||2014-05-29|2011-10-15|2011-10-19|Estimate|2014-05-29|2014-06-30|Estimate||||2014-05-29|2014-06-30|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|TICS||Tick-borne Illness and Clothing Study|Preventing Exposure to Ticks and Tick-borne Illness in Outdoor Workers|Completed||N/A|159|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:03:42.767346|2018-05-31 22:03:42.767346
NCT01454401|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2016-05-17||2016-08-15|2011-10-18|2011-10-19|Estimate|2016-08-15|2016-10-06|Estimate||||2016-08-15|2016-10-06|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers|LeucoPatch™ Study. A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers|Completed||Phase 4|60|Actual|Reapplix||1|||f||||t||||||||No||2018-05-31 22:03:43.336494|2018-05-31 22:03:43.336494
NCT01454388|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2015-12-16|2011-10-18|2011-10-19|Estimate|||||||2015-12-16|2015-12-17|Estimate|January 2010||2010-01-31|December 2015|2015-12-31||||May 2012|Actual|2012-05-31||Interventional|||A Trial Comparing Breakfast Versus no Breakfast Prior to Colonoscopy|A Randomized Controlled Trial Comparing Breakfast Versus no Breakfast|Completed||Phase 4|496|Actual|Queen's University||4|||f||||t||||||||||2018-05-31 22:03:43.660856|2018-05-31 22:03:43.660856
NCT01454375|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2014-10-02|2011-10-18|2011-10-19|Estimate|||||||2014-10-02|2014-10-03|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Emergency Department Smoking Cessation Study|Emergency Department Tobacco Cessation Counseling: Implementation and Evaluation of a Community-Based Program|Completed||N/A|1301|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:03:43.735702|2018-05-31 22:03:43.735702
NCT01454362|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2013-04-21|2011-10-14|2011-10-19|Estimate|||||||2013-04-21|2013-04-23|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ECIG24||Effect of the Electronic Cigarette on Withdrawal Symptoms|Phase 4 Study to Compare of the Effects of the Electronic Cigarette and Nicotine Inhalator on Tobacco Withdrawal Symptoms Over 24 Hours of Abstinence|Completed||N/A|60|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 22:03:43.812483|2018-05-31 22:03:43.812483
NCT01454349|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-08-19|2011-10-14|2011-10-19|Estimate|||||||2013-08-19|2013-08-21|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|||Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)|A Randomized Dose-Escalation, Multicenter Safety and Efficacy Study of a Single Transrectal Intraprostatic Treatment of PRX302 for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)|Completed||Phase 1/Phase 2|40|Actual|Sophiris Bio Corp||2|||f||||t||||||||||2018-05-31 22:03:43.899941|2018-05-31 22:03:43.899941
NCT01454336|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2014-05-10|2011-10-18|2011-10-19|Estimate|||||||2014-05-10|2014-05-13|Estimate|June 2010||2010-06-30|February 2010|2010-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone|Phase 1 Trial of Combined Pioglitazone Plus Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients With Compensated Cirrhosis|Completed||Phase 1|3|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 22:03:43.980568|2018-05-31 22:03:43.980568
NCT01454323|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2015-06-29|2011-10-18|2011-10-19|Estimate|||||||2015-06-29|2015-06-30|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Intracoronary Infusion of Bone Marrow Mononuclear Cells in Patients With Previous Myocardial Infarction.|Phase II Clinical Trial on the Effect of Intracoronary Infusion of Bone Marrow Mononuclear Cells on Functional Recovery in Patients With Myocardial Chronic Back and Severely Depressed Left Ventricular Function.|Completed||Phase 2|20|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||1|||f||||t||||||||||2018-05-31 22:03:44.045093|2018-05-31 22:03:44.045093
NCT01454310|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-15|||2011-10-18|2011-10-18|2011-10-19|Estimate|||||||2011-10-18|2011-10-19|Estimate|November 2010||2010-11-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||An Acellular Epithelial Skin Substitute in Deep Partial-thickness Burns|A Prospective Noninferiority Trial to Compare an Acellular Epithelial Skin Substitute With Autologous Split-thickness Skin Grafts in Deep Partial-thickness Burns|Completed||Phase 4|18|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 22:03:44.212091|2018-05-31 22:03:44.212091
NCT01454297|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2016-09-26|2011-10-14|2011-10-19|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Observational|CoMMpass||Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile|A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles|Active, not recruiting|||1154|Actual|Multiple Myeloma Research Foundation|||1||f||||f||||||Samples With DNA|"~     Bone marrow, Peripheral Blood~   "|Yes|Interim Analysis data will be released every 6 months|2018-05-31 22:03:44.305504|2018-05-31 22:03:44.305504
NCT01454284|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2018-03-16|2014-04-14|2018-03-16|2011-10-14|2011-10-18|Estimate|2018-03-16|2018-04-17|Actual|2014-04-14|2014-05-06|Estimate|2018-03-16|2018-04-17|Actual|January 2012||2012-01-31|March 2018|2018-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|IMAGINE 3|All participants.|A Study in Participants With Type I Diabetes Mellitus|The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study|Completed||Phase 3|1114|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 22:03:44.540772|2018-05-31 22:03:44.540772
NCT01454271|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2016-09-13|2011-10-14|2011-10-18|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate|Follow up Study of Patients Undergoing Total Hip Arthroplasty CERAFIT® Grafted With Poly Sodium Styrene Sulfonate|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Laboratoire Ceraver-Osteal||1|||f||||f||||||||||2018-05-31 22:03:45.985568|2018-05-31 22:03:45.985568
NCT01454258|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2015-04-02||2017-08-15|2011-10-14|2011-10-18|Estimate|2015-11-05|2015-12-07|Estimate||||2017-08-15|2017-09-14|Actual|October 2011||2011-10-31|August 2017|2017-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|INDIZ_IV_I||Indication for Intraoperative Volume Therapy|Indication for Intraoperative Volume Therapy|Completed|||10100|Actual|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-05-31 22:03:46.064265|2018-05-31 22:03:46.064265
NCT01454245|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-01-30|2011-10-14|2011-10-18|Estimate|||||||2013-01-30|2013-01-31|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers|An Open-Label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of JNJ-39439335 Capsule Formulations Administered as a Single Oral Dose in Healthy Male Adult Subjects|Completed||Phase 1|43|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 22:03:46.17364|2018-05-31 22:03:46.17364
NCT01454232|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2018-01-10|2011-10-14|2011-10-18|Estimate|||||||2018-01-10|2018-01-11|Actual|June 7, 2011|Actual|2011-06-07|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|microbaria||Adaptation of Human Gut Microbiota to Energetic Restriction|Modification of Human Gut Microbiota in Massive Obesity After Bariatric Surgery: the Role of Energetic Restriction|Active, not recruiting||N/A|140|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:03:46.356679|2018-05-31 22:03:46.356679
NCT01454219|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2012-02-14|2011-10-14|2011-10-18|Estimate|||||||2012-02-14|2012-02-15|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|GIFA||Measurement of Glycaemic Responses of Bakery and Confectionery Products|Measurement of Glycaemic Responses of Bakery and Confectionery Products|Completed||N/A|14|Actual|Clinical Life Sciences Ltd.|||||f||||||||||||||2018-05-31 22:03:46.449971|2018-05-31 22:03:46.449971
NCT01454206|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2016-10-06|2011-10-14|2011-10-18|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Integration of (iSBIRT) for Teen Drug Use Into a Pediatric Network|Integration of Internet-facilitated Screening, Brief Intervention, Referral to Treatment (iSBIRT) for Teen Drug Use Into a Pediatric Network|Withdrawn||Phase 2/Phase 3|0|Actual|Boston Children’s Hospital||2||The project was not funded|f||||t||||||||||2018-05-31 22:03:46.52135|2018-05-31 22:03:46.52135
NCT01454193|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-18|2011-10-17|2011-10-18|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2001||2001-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Are we Loading Our Patients With Sodium During Hemodialysis Treatments?||Completed|||10000|Actual|Renal Research Institute|||||f||||f||||||||||2018-05-31 22:03:46.606197|2018-05-31 22:03:46.606197
NCT01454180|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-10-08|2011-10-17|2011-10-18|Estimate|||||||2015-10-08|2015-10-09|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|October 2011|Actual|2011-10-31||Interventional|||Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets|Ensayo Fase II de selección Individualizada Del Tratamiento de Quimioterapia en Pacientes Con Carcinoma de páncreas Avanzado en función de la determinación de Dianas terapéuticas en el Tejido Tumoral|Completed||Phase 2|31|Actual|Centro Nacional de Investigaciones Oncologicas CARLOS III||2|||f||||t||||||||||2018-05-31 22:03:46.675234|2018-05-31 22:03:46.675234
NCT01454167|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2015-05-25|2011-10-17|2011-10-18|Estimate|||||||2015-05-25|2015-05-27|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Acid Base and Electrolytes Patterns in Drains Operational Wounds and Its Relation to Complications|Acid Base and Electrolytes Patterns in Drains of Different Operational Wounds and Its Relation to Specific Infections and Seroma Formation|Unknown status|Recruiting||200|Anticipated|Carmel Medical Center|||||f||||t||||||||||2018-05-31 22:03:46.752143|2018-05-31 22:03:46.752143
NCT01454154|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-05-05|2011-10-17|2011-10-18|Estimate|||||||2015-05-05|2015-05-06|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Glyburide (RP-1127) for Traumatic Brain Injury (TBI)|A Randomized Clinical Trial of Glyburide (RP-1127) for TBI|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Remedy Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 22:03:46.821102|2018-05-31 22:03:46.821102
NCT01454141|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-14|2011-10-14|2011-10-18|Estimate|||||||2011-10-14|2011-10-18|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Cognitive Control Training for Depression||Completed||N/A|56|Actual|Boston University||2|||f||||f||||||||||2018-05-31 22:03:46.91192|2018-05-31 22:03:46.91192
NCT01454128|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-10-17|2011-10-17|2011-10-18|Estimate|||||||2011-10-17|2011-10-18|Estimate|April 2011||2011-04-30|September 2010|2010-09-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||The Role of Exercise-Periodic-Breathing (EPB) in Impaired Ventilation Regulation Dysfunction in Heart Failure Patients|The Role of Exercise-Periodic-Breathing in Impaired Ventilation Regulation Dysfunction in Patients With Heart Failure|Unknown status|Recruiting|N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:03:46.981701|2018-05-31 22:03:46.981701
NCT01454115|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2011-11-18|2011-10-17|2011-10-18|Estimate|||||||2011-11-18|2011-11-21|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Subjects and a Comparison to Elderly Male and Female Subjects|Completed||Phase 1|116|Actual|Bristol-Myers Squibb||14|||f||||f||||||||||2018-05-31 22:03:47.106777|2018-05-31 22:03:47.106777
NCT01454102|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2017-11-03|2011-10-17|2011-10-18|Estimate|||||||2017-11-03|2017-11-07|Actual|December 9, 2011|Actual|2011-12-09|November 2017|2017-11-30|December 29, 2018|Anticipated|2018-12-29|July 20, 2016|Actual|2016-07-20||Interventional|||Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)|A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|472|Actual|Bristol-Myers Squibb||19|||f||||f|t|f||||||||2018-05-31 22:03:47.207867|2018-05-31 22:03:47.207867
NCT01454089|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05||2015-10-22|2016-10-06|2011-10-13|2011-10-18|Estimate||||2015-10-22|2015-11-16|Estimate|2016-10-06|2016-10-07|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer|A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma|Completed||Phase 2|183|Actual|Achieve Life Sciences||3|||f||||f||||||||||2018-05-31 22:03:47.348357|2018-05-31 22:03:47.348357
NCT01454076|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2017-06-16||2017-06-16|2011-10-17|2011-10-18|Estimate|2017-06-16|2017-11-01|Actual||||2017-06-16|2017-11-01|Actual|November 10, 2011|Actual|2011-11-10|June 2017|2017-06-30|June 16, 2016|Actual|2016-06-16|April 1, 2015|Actual|2015-04-01||Interventional||The safety population included all participants who received at least one dose of any study drug.|Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma|A Phase 1 Study of Oral IXAZOMIB (MLN9708) to Assess Relative Bioavailability, Food Effect, Drug-Drug Interaction With Ketoconazole, Clarithromycin or Rifampin; and Safety and Tolerability in Patients With Advanced Nonhematologic Malignancies or Lymphoma|Completed||Phase 1|112|Actual|Takeda||5|||f||||f|t|f||||||||2018-05-31 22:03:47.644111|2018-05-31 22:03:47.644111
NCT01454063|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2014-07-02|2013-07-10|2014-08-05|2011-10-13|2011-10-18|Estimate|2014-08-05|2014-08-21|Estimate|2013-07-10|2013-07-12|Estimate|2014-08-05|2014-08-21|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|OMS302-ILR-003||Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification|Completed||Phase 3|405|Actual|Omeros Corporation||2|||f||||f||||||||||2018-05-31 22:03:49.552559|2018-05-31 22:03:49.552559
NCT01454050|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2012-11-27|2011-10-17|2011-10-18|Estimate|||||||2012-11-27|2012-11-28|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|Lumax 740||Lumax 740 Master Study|PME/Master Study of the Lumax 740 ICD Family|Completed|||189|Actual|Biotronik SE & Co. KG|||||f||||f||||||||||2018-05-31 22:03:49.979972|2018-05-31 22:03:49.979972
NCT01454037|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-11-12|2011-10-17|2011-10-18|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|October 2015|Anticipated|2015-10-31|October 2013|Anticipated|2013-10-31||Observational|||Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy|Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy|Unknown status|Recruiting||160|Anticipated|National Taiwan University Hospital|||3||f||||||||||||||2018-05-31 22:03:50.155944|2018-05-31 22:03:50.155944
NCT01454024|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2015-06-11|2011-10-17|2011-10-18|Estimate|||||||2015-06-11|2015-06-12|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice|A Study Evaluating the Safety of NovoPen®3 and FlexPen® in Subjects With Type 1 and Type 2 Diabetes. A 24-week, Prospective, Multi-centre, Open-labelled, Non-interventional Study|Completed|||1031|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:03:50.307172|2018-05-31 22:03:50.307172
NCT01454011|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-14|2011-10-14|2011-10-18|Estimate|||||||2011-10-14|2011-10-18|Estimate|September 2008||2008-09-30|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups|Phase 4 Study That Compares the High Density Lipoprotein Cholesterol (HDL) Cholesterol Subgroups of the Patients With Congenital Hypogonadotrophic Hypogonadism With That of the Healthy Control Subjects, and Investigates the Effect of Testosterone Treatment on HDL Subgroups.|Completed||Phase 4|140|Actual|Gulhane School of Medicine||2|||f||||f||||||||||2018-05-31 22:03:50.449402|2018-05-31 22:03:50.449402
NCT01453998|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2014-05-01|2012-11-16|2014-07-24|2011-10-14|2011-10-18|Estimate|2014-07-24|2014-07-28|Estimate|2012-11-16|2012-11-21|Estimate|2014-07-24|2014-07-28|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)|Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)|Completed||Phase 2|657|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 22:03:50.572006|2018-05-31 22:03:50.572006
NCT01453985|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-14|2011-10-14|2011-10-18|Estimate|||||||2011-10-14|2011-10-18|Estimate||||October 2011|2011-10-31||||||||Interventional|||Full-Thickness-Gastroplication For The Treatment Of Gastroesophageal Reflux Disease GERD||Unknown status|Recruiting|N/A|||General Public Hospital Zell am See||1|||f||||||||||||||2018-05-31 22:03:51.674656|2018-05-31 22:03:51.674656
NCT01453972|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-08-01|2011-10-13|2011-10-18|Estimate|||||||2016-08-01|2016-08-02|Estimate|October 2011||2011-10-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|TRENO||Effects of Exercise-intensity on Physiological Adaptations in Overweight and Obese|Effects of Exercise-intensity on Physiological Adaptations in Overweight and Obese|Completed||N/A|30|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 22:03:51.749643|2018-05-31 22:03:51.749643
NCT01453959|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-10-20|2011-10-14|2011-10-18|Estimate|||||||2011-10-20|2011-10-21|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|June 2013|Anticipated|2013-06-30|September 2012|Anticipated|2012-09-30||Interventional|||Fludrocortisone's Test in Salt Sensitivity|Fludrocortisone's Test in the Identification of Salt Sensitivity|Unknown status|Recruiting|Phase 4|40|Anticipated|Fundação de Amparo à Pesquisa do Estado de São Paulo||2|||f||||t||||||||||2018-05-31 22:03:51.840099|2018-05-31 22:03:51.840099
NCT01453946|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|2015-02-11||2016-11-16|2011-10-17|2011-10-18|Estimate|2015-06-03|2015-06-19|Estimate||||2016-11-16|2017-01-04|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Maintenance Study of Entocort for Children With Crohn's Disease|A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC as a Maintenance Treatment for Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive|Completed||Phase 3|55|Actual|Perrigo Company||1|||f||||||||||||||2018-05-31 22:03:52.064465|2018-05-31 22:03:52.064465
NCT01453933|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2013-12-17|2011-10-13|2011-10-18|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|RASSTER||RAltegravir Switch STudy: Effects on Endothelial Recovery|Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication <50 Copies/ml|Unknown status|Recruiting|Phase 4|24|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 22:03:52.428942|2018-05-31 22:03:52.428942
NCT01453920|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-08-27|2011-10-13|2011-10-18|Estimate|||||||2012-08-27|2012-08-28|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing|Choroidal Neovascular Membrane Recurrence Rate in Wet AMD Patients Stable on Three Month Ranibizumab Dosing|Completed||Phase 4|44|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 22:03:52.548002|2018-05-31 22:03:52.548002
NCT01453907|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2017-11-09|2011-10-17|2011-10-18|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2011||2011-10-31|October 2011|2011-10-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects|Completed||Phase 1|108|Actual|Elusys Therapeutics||2|||f||||t||||||||||2018-05-31 22:03:52.653193|2018-05-31 22:03:52.653193
NCT01453894|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2014-07-24||2014-07-24|2011-10-17|2011-10-18|Estimate|2014-07-24|2014-08-15|Estimate||||2014-07-24|2014-08-15|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Improving Rates of Repeat Colorectal Cancer Screening|Center for Advancing Equity in Clinical Preventive Services Project 1: Improving Rates of Repeat Colorectal Cancer Screening|Completed||N/A|450|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 22:03:52.783992|2018-05-31 22:03:52.783992
NCT01453881|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2015-03-29|2011-10-17|2011-10-18|Estimate|||||||2015-03-29|2015-03-31|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|EFFECT-EV||Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation|Randomized Clinical Trials to Compare Asthma Control Efficacy of the Fine-particle Combination Formoterol/Beclomethasone by pMDI Administered With and Without Spacer.|Completed||Phase 3|45|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 22:03:53.207262|2018-05-31 22:03:53.207262
NCT01453868|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-17|2011-10-17|2011-10-18|Estimate|||||||2011-10-17|2011-10-18|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|NIA||The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis|The Effects of Neuromuscular Training on Balance in Patients With Multiple Sclerosis|Unknown status|Recruiting|Early Phase 1|60|Anticipated|Nelson Mandela Metropolitan University||2|||f||||t||||||||||2018-05-31 22:03:53.299266|2018-05-31 22:03:53.299266
NCT01453855|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2013-08-13||2013-08-13|2011-10-17|2011-10-18|Estimate|2013-08-13|2013-10-18|Estimate||||2013-08-13|2013-10-18|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||This reporting group includes subjects exposed to the study medication. Note: One subject in the TRAVATAN arm was randomized but discontinued prior to exposure to study medication and is not included in this reporting group.|Travoprost 3-Month Safety and Efficacy Study|A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|1099|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:03:53.413112|2018-05-31 22:03:53.413112
NCT01453842|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-12-01|2011-10-17|2011-10-18|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Diet Oil Induced Stimulation of GLP-1|Diet Oil Induced Stimulation of GLP-1|Completed||Early Phase 1|12|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 22:03:53.737153|2018-05-31 22:03:53.737153
NCT01453829|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2017-07-19|2011-10-17|2011-10-18|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2014||2014-10-31|July 2017|2017-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Internal Carotid Artery and Intravenously in Patients After Stroke|Withdrawn||Phase 1/Phase 2|0|Actual|Ageless Regenerative Institute||||no enrolled participants|f||||f||||||||||2018-05-31 22:03:53.863489|2018-05-31 22:03:53.863489
NCT01453816|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2017-07-19|2011-10-17|2011-10-18|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2011||2011-05-31|July 2017|2017-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Renal Artery and Intravenously in Patients With Renal Failure|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||||No participants and no longer working with off shore center|f||||f||||||||||2018-05-31 22:03:53.939372|2018-05-31 22:03:53.939372
NCT01453803|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2017-11-21|2011-10-17|2011-10-18|Estimate|||||||2017-11-21|2017-11-24|Actual|May 2014||2014-05-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously and Intranasally in Patients With Parkinson's Disease|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||1||company dissolved|f||||f||||||||Undecided||2018-05-31 22:03:54.044088|2018-05-31 22:03:54.044088
NCT01453790|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2017-05-24|2011-10-13|2011-10-18|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2011||2011-04-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Parent Specific Depression Education and Motivation|Effectiveness of Parent Specific Depression Education and Motivation on Intent to Seek Follow-Up Care for Potential Depression Symptoms|Completed||N/A|104|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 22:03:54.302438|2018-05-31 22:03:54.302438
NCT01453777|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2017-07-19|2011-10-17|2011-10-18|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2011||2011-05-31|March 2017|2017-03-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Via Catheter Into the Internal Carotid Artery and Intravenously in Patients With Diffuse Lesions in the Brain|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||||No participants enrolled|f||||f||||||||||2018-05-31 22:03:54.396047|2018-05-31 22:03:54.396047
NCT01453764|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2017-08-31|2011-10-17|2011-10-18|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2016||2016-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||1||company dissolved|f||||f||||||||Undecided||2018-05-31 22:03:54.464867|2018-05-31 22:03:54.464867
NCT01453751|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2017-11-21|2011-10-17|2011-10-18|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2014||2014-03-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Type II Diabetes|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||1||company dissolved|f||||f||||||||Undecided||2018-05-31 22:03:54.561296|2018-05-31 22:03:54.561296
NCT01453738|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2016-05-11|2011-10-17|2011-10-18|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Allogeneic Mesenchymal Stem Cells in Osteoarthritis|A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee|Completed||Phase 2|60|Actual|Stempeutics Research Pvt Ltd||2|||f||||t||||||||||2018-05-31 22:03:54.644037|2018-05-31 22:03:54.644037
NCT01453725|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2014-12-10||2017-03-10|2011-10-17|2011-10-18|Estimate|2014-12-10|2014-12-18|Estimate||||2017-03-10|2017-04-10|Actual|February 2012||2012-02-29|March 2017|2017-03-31|January 2015|Actual|2015-01-31|March 2014|Actual|2014-03-31||Interventional|GO-AHEAD|The Baseline Analysis Population consisted of all randomized participants.|Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02).|Completed||Phase 3|198|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:03:54.779295|2018-05-31 22:03:54.779295
NCT01453062|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-07-03|2011-10-13|2011-10-17|Estimate|||||||2014-07-03|2014-07-08|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Phase IV Observational Study in Chronic Lymphocytic Leukemia|Phase IV Observational Study in Chronic Lymphocytic Leukemia Patients Receiving Ofatumumab in the European Union|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:04:11.067473|2018-05-31 22:04:11.067473
NCT01453712|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2011-10-17|2011-10-17|2011-10-18|Estimate|||||||2011-10-17|2011-10-18|Estimate|October 2011||2011-10-31|October 2011|2011-10-31||||December 2012|Anticipated|2012-12-31||Interventional|PROTECTION-V||Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study -|Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study -|Unknown status|Recruiting|Phase 4|400|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-05-31 22:03:55.293763|2018-05-31 22:03:55.293763
NCT01453699|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2014-08-11|2011-10-14|2011-10-18|Estimate|||||||2014-08-11|2014-08-12|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Long-term Consequences of Bereavement in Children, Adolescents and Young Adults|Bereavement in Children, Adolescents and Young Adults. - A Study of Health and Psychosocial Well-being in Adults Who Have Experienced Early Parental Death|Completed|||1225660|Actual|Danish Cancer Society|||||f||||f||||||||||2018-05-31 22:03:55.413062|2018-05-31 22:03:55.413062
NCT01453686|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2013-12-06|2011-10-17|2011-10-18|Estimate|||||||2013-12-06|2013-12-09|Estimate|August 2002||2002-08-31|December 2013|2013-12-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata|A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata|Completed||Phase 3|41|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 22:03:55.505269|2018-05-31 22:03:55.505269
NCT01453673|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-13|2011-10-13|2011-10-18|Estimate|||||||2011-10-13|2011-10-18|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|May 2013|Anticipated|2013-05-31|||||Observational|||Results of Knee Arthroscopic Surgery for Treatment of Cruciate Ligament and Meniscus|Results of Knee Arthroscopic Surgery for Treatment of Cruciate Ligament and Meniscus|Unknown status|Active, not recruiting||210|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:03:55.594299|2018-05-31 22:03:55.594299
NCT01453660|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2018-02-26|2011-10-13|2011-10-18|Estimate|||||||2018-02-26|2018-02-27|Actual|October 11, 2011|Actual|2011-10-11|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls|A Pilot Study Measuring Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls|Active, not recruiting|||44|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples Without DNA|"~     Blood, urine~   "|||2018-05-31 22:03:55.750283|2018-05-31 22:03:55.750283
NCT01453647|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-10-13|2011-10-13|2011-10-18|Estimate|||||||2011-10-13|2011-10-18|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Explore the Relationships Among Immunity and Stress and the Symptoms of Fatigue, Pain, and Mood Following Guided Imagery in Women With Fibromyalgia|Self-Efficacy, Stress, Immunity and Symptoms of Fibromyalgia|Completed||N/A|72|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 22:03:55.829031|2018-05-31 22:03:55.829031
NCT01453634|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-09-19|2011-10-14|2011-10-18|Estimate|||||||2014-09-19|2014-09-22|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|2007||Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)|A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis|Withdrawn||Phase 2|0|Actual|OPKO Health, Inc.||2||The company is no longer pursuing this study.|f||||f||||||||||2018-05-31 22:03:55.896642|2018-05-31 22:03:55.896642
NCT01453621|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-04-15|2011-10-17|2011-10-18|Estimate|||||||2015-04-15|2015-04-16|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TBI-KT||Traumatic Brain Injury - Knowledge Translation|Implementation of the Pediatric Emergency Care Applied Research Network (PECARN) Traumatic Brain Injury Prediction Rules Using Computerized Clinical Decision Support: An Interrupted Time Series Trial|Completed||Phase 3|28669|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 22:03:55.960206|2018-05-31 22:03:55.960206
NCT01453608|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2015-03-17|2011-10-17|2011-10-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|CONFIRM-HF||A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency|A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency|Completed||Phase 4|304|Actual|Vifor Inc.||2|||f||||t||||||||||2018-05-31 22:03:56.028216|2018-05-31 22:03:56.028216
NCT01453595|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2015-12-14||2016-02-01|2011-10-17|2011-10-18|Estimate|2016-02-01|2016-02-29|Estimate||||2016-02-01|2016-02-29|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)|A Phase 1b/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)|Terminated||Phase 1/Phase 2|10|Actual|Memorial Sloan Kettering Cancer Center|Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.|1||"Given the number of toxicities seen and the difficulty with patient retention in the dose~   escalation portion, the sponsor decided to close the trial."|f||||t||||||||||2018-05-31 22:03:56.115455|2018-05-31 22:03:56.115455
NCT01453582|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2018-02-06|2011-10-17|2011-10-18|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2011||2011-12-31|December 2017|2017-12-31|September 2015|Actual|2015-09-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety Study of Total Flavonoids of Propolis Dropping Pill to Treat Angina Pectoris|Phase III Study of Total Flavonoids of Propolis Dropping Pill in Angina Pectoris: A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Clinical Trial on Efficacy and Safety.|Completed||Phase 3|478|Actual|Shanghai Greenvalley Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:03:56.487977|2018-05-31 22:03:56.487977
NCT01453569|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2014-11-13||2015-01-25|2011-10-13|2011-10-18|Estimate|2015-01-25|2015-01-27|Estimate||||2015-01-25|2015-01-27|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All the treated subjects were evaluated for safety. 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.|Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease|Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease|Completed||Phase 2|255|Actual|Shanghai Greenvalley Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 22:03:56.62254|2018-05-31 22:03:56.62254
NCT01453556|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-20|2011-10-17|2011-10-18|Estimate|||||||2011-10-20|2011-10-21|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Intracorporeal Versus Extracorporeal Mechanical Anastomosis in Laparoscopic Right Colectomy|Intracorporeal Versus Extracorporeal Mechanical Anastomosis in Laparoscopic Right Colectomy. A Prospective Randomized Controlled Clinical Trial|Unknown status|Recruiting|N/A|158|Anticipated|Scientific Institute San Raffaele||2|||f||||t||||||||||2018-05-31 22:03:57.147178|2018-05-31 22:03:57.147178
NCT01453543|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-11-07|2011-10-17|2011-10-18|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|Friction||The Effect of Deep Friction Massage on the Achilles Tendon Blood Flow|The Effect of Deep Friction Massage on the Achilles Tendon Blood Flow|Completed||N/A|62|Actual|University Ghent||1|||f||||f||||||||||2018-05-31 22:03:57.233876|2018-05-31 22:03:57.233876
NCT01453530|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-17|2011-10-17|2011-10-18|Estimate|||||||2011-10-17|2011-10-18|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|SFINX||Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Blockade|Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Rest Blockade With Sugammadex|Unknown status|Recruiting|Phase 4|30|Anticipated|Radboud University||3|||f||||t||||||||||2018-05-31 22:03:57.308655|2018-05-31 22:03:57.308655
NCT01453517|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2011-10-13|2011-10-13|2011-10-18|Estimate|||||||2011-10-13|2011-10-18|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Psychological and Behavioral Intervention for Post-Bariatric Patients|Dialectical Behavior Therapy (DBT) for Post-Bariatric Patients Experiencing Weight Regain|Completed||N/A|26|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:03:57.499439|2018-05-31 22:03:57.499439
NCT01453504|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2017-11-07|2011-10-17|2011-10-18|Estimate|||||||2017-11-07|2017-11-08|Actual|August 2012||2012-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|HD-R3i||Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma|A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)|Recruiting||Phase 1/Phase 2|125|Anticipated|University of Cologne||2|||f||||||||||||||2018-05-31 22:03:57.598649|2018-05-31 22:03:57.598649
NCT01453491|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-05-31|2011-10-13|2011-10-18|Estimate|||||||2017-05-31|2017-06-01|Actual|February 13, 2012|Actual|2012-02-13|May 2017|2017-05-31|March 18, 2013|Actual|2013-03-18|March 18, 2013|Actual|2013-03-18||Interventional|||A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis|A Phase 1b, Exploratory Study to Assess the Safety, Tolerability, Colonic Tissue Exposure, and Anti-Inflammatory Effects of Two Different Doses of SRT2104 in Subjects With Mild to Moderate Ulcerative Colitis|Completed||Phase 1|17|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:03:57.690525|2018-05-31 22:03:57.690525
NCT01453478|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-06-09|2011-10-13|2011-10-18|Estimate|||||||2017-06-09|2017-06-12|Actual|October 12, 2011|Actual|2011-10-12|June 2017|2017-06-30|December 19, 2011|Actual|2011-12-19|December 19, 2011|Actual|2011-12-19||Interventional|||A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced|A Single Centre, 5-Period, Randomized Study To Evaluate The Relative Bioavailability Of An Immediate Release Tablet Formulation And Prototype Bioenhanced Formulations Of GSK1325756 In Healthy Elderly Subjects During Suppression Of Gastric Acid Secretion|Completed||Phase 1|20|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:03:57.830006|2018-05-31 22:03:57.830006
NCT01453465|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-01|||2016-02-19|2011-10-14|2011-10-17|Estimate|||||||2016-02-19|2016-02-23|Estimate|September 2011||2011-09-30|February 2016|2016-02-29||||January 2100|Anticipated|2100-01-31||Observational|||Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor|Gene Expression (GE) and MicroRNA (MIRNA) Expression Profiles of Malignant Rhabdoid Tumors (MRT) of the Kidney (RTK) and Atypical Teratoid Rhabdoid Tumor (ATRT|Withdrawn|||0|Actual|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:03:58.037033|2018-05-31 22:03:58.037033
NCT01453452|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-14|||2017-12-06|2011-10-14|2011-10-17|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2012||2012-03-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|August 2015|Actual|2015-08-31||Interventional|||S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors|S1008: Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention In Breast and Colorectal Cancer Survivors, Phase II|Completed||Phase 2|50|Anticipated|Southwest Oncology Group||1|||f||||t||||||||||2018-05-31 22:03:58.098952|2018-05-31 22:03:58.098952
NCT01453439|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2016-03-15|2011-10-14|2011-10-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder|CBT Versus Supportive Psychotherapy for Body Dysmorphic Disorder|Unknown status|Recruiting|N/A|120|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:03:58.363488|2018-05-31 22:03:58.363488
NCT01453426|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2013-09-12|2011-10-13|2011-10-17|Estimate|||||||2013-09-12|2013-09-16|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|109HV108||Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers|An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers|Completed||Phase 1|71|Actual|Biogen||6|||f||||f||||||||||2018-05-31 22:03:59.327948|2018-05-31 22:03:59.327948
NCT01453413|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2012-11-12||2013-02-21|2011-10-13|2011-10-17|Estimate|2012-11-12|2012-12-17|Estimate||||2013-02-21|2013-02-25|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Blood Glucose Testing and You|Blood Glucose Testing and You|Completed||N/A|297|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 22:03:59.823781|2018-05-31 22:03:59.823781
NCT01453400|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2014-07-07|2011-10-13|2011-10-17|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Tarot||Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain|Onset of Action of a Fast Release Aspirin Tablet and Acetaminophen Caplet in Sore Throat Pain|Completed||Phase 3|177|Actual|Bayer||3|||f||||f||||||||||2018-05-31 22:04:00.051079|2018-05-31 22:04:00.051079
NCT01453387|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2016-04-08||2017-03-27|2011-10-12|2011-10-17|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|September 2011||2011-09-30|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Safety analysis set included all subjects who received at least one administration of the trial medication.|MSC2015103B in Solid Tumors|A Phase I Dose-Escalation First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral MEK Inhibitor MSC2015103B Administered With Two Different Treatment Schedules in Subjects With Advanced Solid Tumors|Terminated||Phase 1|28|Actual|EMD Serono|The study was terminated early during Part 1 of the trial due to administrative reason. Pharmacodynamics evaluations were not performed due to early termination.|2||Due to an administrative reason|f||||f||||||||||2018-05-31 22:04:00.178229|2018-05-31 22:04:00.178229
NCT01453374|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2015-05-21||2015-06-19|2011-10-13|2011-10-17|Estimate|2015-06-19|2015-07-13|Estimate||||2015-06-19|2015-07-13|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||All subjects who received at least 1 injection of VIVITROL|A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration|A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration|Completed||Phase 4|27|Actual|Alkermes, Inc.|The outcome measure of opioid dependence was not analyzed.|1|||f||||f||||||||||2018-05-31 22:04:02.534896|2018-05-31 22:04:02.534896
NCT01453361|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2018-02-15||2018-05-21|2011-10-14|2011-10-17|Estimate|2018-05-08|2018-05-10|Estimate||||2018-05-21|2018-05-24|Actual|October 2011||2011-10-31|May 2018|2018-05-31|March 22, 2016|Actual|2016-03-22|March 22, 2016|Actual|2016-03-22||Interventional|||Phase II FANG™ in Advanced Melanoma|Phase II Trial of FANG™ Autologous Tumor Cell Vaccine in Advanced Melanoma|Terminated||Phase 2|18|Actual|Gradalis, Inc.||1||Business Decision to pursue other indications|f||||t||||||||||2018-05-31 22:04:03.010363|2018-05-31 22:04:03.010363
NCT01453348|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|2013-10-22|2012-11-20|2017-05-08|2011-10-12|2011-10-17|Estimate|2014-02-06|2014-03-10|Estimate|2012-11-20|2012-11-22|Estimate|2017-05-08|2017-06-08|Actual|October 2011||2011-10-31|May 2017|2017-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine|A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults|Completed||Phase 3|252|Actual|Novartis||3|||f||||f||||||||||2018-05-31 22:04:03.269101|2018-05-31 22:04:03.269101
NCT01453335|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-12-21|2011-10-13|2011-10-17|Estimate|||||||2011-12-21|2011-12-23|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Observational|||Percentage Venous Options in Pediatrics & Adults|Utilizing a Near Infrared Vein Visualization Device To Increase Peripheral Intravenous Access Targets in Pediatric & Adult Patients (% Venous Options)|Completed|||300|Actual|Christie Medical Holdings, Inc.|||||f||||f||||||||||2018-05-31 22:04:03.756608|2018-05-31 22:04:03.756608
NCT01453322|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-17|2011-10-13|2011-10-17|Estimate|||||||2011-10-17|2011-10-18|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Video Documentation of Localized Complications|Video Documentation of Localized Complications in IV Cannulation Using Near-Infrared Technology|Completed|||10|Actual|Christie Medical Holdings, Inc.|||||f||||f||||||||||2018-05-31 22:04:03.826236|2018-05-31 22:04:03.826236
NCT01453309|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-14|2011-10-14|2011-10-17|Estimate|||||||2011-10-14|2011-10-17|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions|Cost Effectiveness and Clinical Utility of Cell Saver Use for Two to Three Level Lumbar Fusions|Unknown status|Not yet recruiting|N/A|240|Anticipated|Norton Leatherman Spine Center||2|||f||||f||||||||||2018-05-31 22:04:03.923637|2018-05-31 22:04:03.923637
NCT01453296|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2013-06-06|2012-07-26|2016-11-29|2011-10-13|2011-10-17|Estimate|2013-08-15|2013-08-19|Estimate|2012-07-26|2012-08-03|Estimate|2016-11-29|2017-01-13|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects|A Randomized, Double-blind, Placebo-controlled, Two-way Crossover 7-day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25 μg (Micrograms) in Children Aged 5-11 Years With Persistent Asthma.|Completed||Phase 2|28|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:04:04.119211|2018-05-31 22:04:04.119211
NCT01453283|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-01|||2017-06-30|2011-10-12|2011-10-17|Estimate|||||||2017-06-30|2017-07-02|Actual|December 20, 2006||2006-12-20|April 4, 2012|2012-04-04|October 11, 2011|Actual|2011-10-11|October 11, 2011|Actual|2011-10-11||Interventional|||Tabectedin to Treat Children and Adolescents With Cancer|A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS [R], ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors|Completed||Phase 1|12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:04:05.183356|2018-05-31 22:04:05.183356
NCT01453270|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2014-09-23|2011-10-12|2011-10-17|Estimate|||||||2014-09-23|2014-09-25|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|AGONIST||Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial|Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial|Completed||N/A|122|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 22:04:05.295972|2018-05-31 22:04:05.295972
NCT01453257|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-18|2011-10-14|2011-10-17|Estimate|||||||2011-10-18|2011-10-19|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|TT||Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients|A Phase 2 Study of Target-Guided Personalized Chemotherapy in Metastatic Colorectal Cancer Patients|Completed||Phase 2|72|Actual|Grupo Hospital de Madrid||1|||f||||f||||||||||2018-05-31 22:04:05.385961|2018-05-31 22:04:05.385961
NCT01453244|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2013-05-30|2011-10-14|2011-10-17|Estimate|||||||2013-05-30|2013-06-03|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Pharmacogenomic Research in Korean Patients With Hepatitis C|Pharmacogenomic Research for Prediction of Drug Response in Korean Patients With Hepatitis C|Completed|||373|Actual|Inje University|||2||f||||f||||||Samples With DNA|"~     DNA extracted from blood~   "|||2018-05-31 22:04:05.537799|2018-05-31 22:04:05.537799
NCT01453231|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2013-05-27|2011-10-14|2011-10-17|Estimate|||||||2013-05-27|2013-05-29|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Quality of Life and Body Image in Women Underwent Thighplasty|Quality of Life and Body Image in Women Underwent Thighplasty|Completed||Phase 1|30|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:04:05.75707|2018-05-31 22:04:05.75707
NCT01453218|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-02-06|2011-10-13|2011-10-17|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2011|Actual|2011-10-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ATG_HVH||Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction|Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction|Recruiting||Phase 3|30|Anticipated|Hospital Vall d'Hebron||2|||f||||f||||||||||2018-05-31 22:04:06.717234|2018-05-31 22:04:06.717234
NCT01453205|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|2017-12-05|2017-06-29|2018-02-08|2011-10-14|2011-10-17|Estimate|2018-02-08|2018-03-12|Actual|2017-06-29|2017-07-05|Actual|2018-02-08|2018-03-12|Actual|February 27, 2012|Actual|2012-02-27|February 2018|2018-02-28|July 11, 2016|Actual|2016-07-11|July 11, 2016|Actual|2016-07-11||Interventional||Intent-To-Treat population included all participants who were randomized into the study.|A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL|Completed||Phase 2|187|Actual|MedImmune LLC||3|||f||||t|t|f||||||||2018-05-31 22:04:06.946717|2018-05-31 22:04:06.946717
NCT01453192|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2016-07-11|2011-10-13|2011-10-17|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ANRS153TREVE||Renal Transplantation and Raltegravir in HIV-Infected Patients|National, Multicenter, Phase III Prospective Trial About Clinical and Immunological Follow-up After Renal Transplantation in HIV-1 Infected Patients With End Stage Chronic Renal Insufficiency|Completed||Phase 3|27|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 22:04:09.20661|2018-05-31 22:04:09.20661
NCT01453179|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-04-13|2011-10-12|2011-10-17|Estimate|||||||2017-04-13|2017-04-14|Actual|October 2011||2011-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|LEIDA 2||Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)|Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma|Completed||Phase 4|221|Actual|MEDA Pharma GmbH & Co. KG||2|||f||||f||||||||||2018-05-31 22:04:09.356108|2018-05-31 22:04:09.356108
NCT01453166|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2012-03-15||2012-07-16|2011-10-13|2011-10-17|Estimate|2012-06-13|2012-07-17|Estimate||||2012-07-16|2012-07-19|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Brazilian Heart-Prevent Meal - A Pilot Randomized Clinical Trial|The Effect of Brazilian Heart Prevent Meal Program Accessible for the Population to Prevent New Cardiovascular Events: A Pilot Randomized Clinical Trial|Completed||N/A|122|Actual|Hospital do Coracao|Small numbers of subjects analyzed, We did not evaluate the patient’s adherence to food intake, The high purchasing power of patients, Randomization with opaque envelope technique, Low statistical power.|3|||f||||t||||||||||2018-05-31 22:04:09.520417|2018-05-31 22:04:09.520417
NCT01453153|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13||2018-02-22|2018-02-23|2011-10-14|2011-10-17|Estimate||||2018-02-23|2018-02-26|Actual|2018-02-23|2018-02-26|Actual|September 2011||2011-09-30|February 2018|2018-02-28|May 2015|Actual|2015-05-31|February 2014|Actual|2014-02-28||Interventional|||Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer|A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer|Completed||Phase 1/Phase 2|28|Actual|Halozyme Therapeutics||2|||f||||f||||||||||2018-05-31 22:04:10.102361|2018-05-31 22:04:10.102361
NCT01453140|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2013-07-17|2011-10-14|2011-10-17|Estimate|||||||2013-07-17|2013-07-18|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|T-REG||In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease|Phase I- II Study of in Vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for the Treatment of Steroid-refractory Acute Graft-versus-host Disease|Completed||Phase 1/Phase 2|3|Actual|Hackensack University Medical Center||3|||f||||t||||||||||2018-05-31 22:04:10.251999|2018-05-31 22:04:10.251999
NCT01453127|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2018-04-12|2011-10-12|2011-10-17|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2011||2011-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DaTSCAN Imaging in Aging and Neurodegenerative Disease|DaTSCAN Imaging in Aging and Neurodegenerative Disease|Enrolling by invitation||Phase 4|130|Anticipated|Mayo Clinic||8|||f||||f||||||||||2018-05-31 22:04:10.420803|2018-05-31 22:04:10.420803
NCT01453114|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2015-04-06|2011-10-14|2011-10-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Cognitive-Behavioral Therapy (CBT) in Women Discontinuing Antidepressant for Pregnancy|Cognitive-Behavioral Therapy in Women Discontinuing Antidepressant for Pregnancy|Completed||N/A|15|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:04:10.512615|2018-05-31 22:04:10.512615
NCT01453101|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2017-06-14|2011-10-14|2011-10-17|Estimate|||||||2017-06-14|2017-06-15|Actual|June 9, 2010|Actual|2010-06-09|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|Flu-Mel-Vel||Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma|A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib|Active, not recruiting||Phase 2|55|Actual|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 22:04:10.592811|2018-05-31 22:04:10.592811
NCT01453088|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-08-08|2011-10-13|2011-10-17|Estimate|||||||2017-08-08|2017-08-09|Actual|June 24, 2010|Actual|2010-06-24|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older|(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older|Recruiting||Phase 2|208|Anticipated|Hackensack University Medical Center||2|||f||||t||||||||||2018-05-31 22:04:10.714787|2018-05-31 22:04:10.714787
NCT01453075|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|2016-06-13||2016-09-30|2011-10-13|2011-10-17|Estimate|2016-09-30|2016-11-22|Estimate||||2016-09-30|2016-11-22|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)|Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and Herpes Simplex Virus 2 (HSV-2) Infection (Phase I)|Completed||Phase 1|31|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 22:04:10.845403|2018-05-31 22:04:10.845403
NCT01453049|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|2011-10-27||2012-03-22|2011-10-13|2011-10-17|Estimate|2011-12-08|2012-01-13|Estimate||||2012-03-22|2012-03-27|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients|A Multi-center, Randomized, Double-blind, Parallel-group Study to Compare the Efficacy and Safety of Fixed-dose Rosiglitazone/Glimepiride Combination Therapy With Glimepiride Monotherapy for 24 Weeks in Drug Naive Subjects With Type 2 Diabetes|Terminated||Phase 3|86|Actual|GlaxoSmithKline||2||US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic|f||||f||||||||||2018-05-31 22:04:11.214133|2018-05-31 22:04:11.214133
NCT01453036|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2012-06-07||2013-07-31|2011-10-13|2011-10-17|Estimate|2013-07-31|2013-09-27|Estimate||||2013-07-31|2013-09-27|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Clarithromycin Resistant Tailored Therapy|Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance|Completed||Phase 4|924|Actual|The Catholic University of Korea||3|||f||||t||||||||||2018-05-31 22:04:12.162|2018-05-31 22:04:12.162
NCT01453023|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2013-06-06||2016-11-20|2011-10-13|2011-10-17|Estimate|2013-06-06|2013-08-09|Estimate||||2016-11-20|2017-01-11|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study|A Randomized, Double-blind, Repeat Dose, Two Period Crossover Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Inhaled Fluticasone Furoate/Vilanterol 100/25 Micrograms in Children Aged 5 to 11 Years With Persistent Asthma|Completed||Phase 2|26|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:04:12.528334|2018-05-31 22:04:12.528334
NCT01453010|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2011-10-13|2011-10-13|2011-10-17|Estimate|||||||2011-10-13|2011-10-17|Estimate|May 2011||2011-05-31|October 2011|2011-10-31||||May 2012|Anticipated|2012-05-31||Interventional|SaeboFlex||Self-directed Upper Limb Training Using a SaeboFlex in Acute Stroke|Self-directed Upper Limb Training Using a SaeboFlex With Acute Stroke Patients: 8 Single Case Reviews|Unknown status|Recruiting|Early Phase 1|8|Anticipated|Colchester Hospital University NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 22:04:13.53538|2018-05-31 22:04:13.53538
NCT01452997|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2015-03-30|2011-10-14|2011-10-17|Estimate|||||||2015-03-30|2015-03-31|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of Anti-inflammatories in the Reduction of Bite Reactions|Evaluation of Topical Ibuprofen and Steroid in the Reduction of Local Reactions and Symptoms From an Aedes Aegypti Mosquito Bite|Completed||Phase 4|40|Actual|London School of Hygiene and Tropical Medicine||4|||f||||f||||||||||2018-05-31 22:04:13.637874|2018-05-31 22:04:13.637874
NCT01452984|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2015-03-18|2011-10-14|2011-10-17|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project|Experience of Patients With Non-Melanoma Skin Cancer of the Head and Neck Undergoing Mohs Surgery|Completed|||16|Actual|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 22:04:13.725937|2018-05-31 22:04:13.725937
NCT01452971|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2011-10-14|2011-10-14|2011-10-17|Estimate|||||||2011-10-14|2011-10-17|Estimate|October 2011||2011-10-31|October 2011|2011-10-31||||||||Observational|||A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer|A Study of the Interaction Between Tumor Susceptibility Gene GNMT and Lung Cancer|Unknown status|Not yet recruiting||200|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 22:04:13.791809|2018-05-31 22:04:13.791809
NCT01452958|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2013-01-29|2011-10-13|2011-10-17|Estimate|||||||2013-01-29|2013-01-30|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on Central Nervous System (CNS) Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?|Endotoxin & Cytokines. Do Protein Loss and Metabolic Effects Depend on CNS Activation of Stress Hormones or on Local Mechanisms in Muscle and Fat?|Completed||N/A|24|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 22:04:13.835655|2018-05-31 22:04:13.835655
NCT01452945|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2015-05-19|2011-10-14|2011-10-17|Estimate|||||||2015-05-19|2015-05-21|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing|Prospective Observational Study Evaluating the Use of Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department With Wheezing|Completed|||30|Actual|Children's Research Institute|||||f||||f||||||||||2018-05-31 22:04:13.908573|2018-05-31 22:04:13.908573
NCT01452932|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-06-22|2011-10-14|2011-10-17|Estimate|||||||2012-06-22|2012-06-26|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Muscle Training Effectiveness in the Degree of Dyspnea and Aerobic Capacity in COPD|Muscle Training Effectiveness in the Degree of Dyspnea and Aerobic Capacity in COPD in an Institution Health Service Provider in the Department of Antioquia|Unknown status|Active, not recruiting|Phase 1/Phase 2|44|Actual|CES University||2|||f||||f||||||||||2018-05-31 22:04:13.996725|2018-05-31 22:04:13.996725
NCT01452919|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12||2013-01-11|2013-01-11|2011-10-12|2011-10-17|Estimate||||2013-01-11|2013-01-21|Estimate|2013-01-11|2013-01-21|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Physical Dependence Study in Schizophrenia|A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia|Completed||Phase 3|150|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:04:14.057429|2018-05-31 22:04:14.057429
NCT01452906|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-12-08|2011-10-12|2011-10-17|Estimate|||||||2011-12-08|2011-12-12|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Drug-Drug Interaction Study of Omeprazole and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Omeprazole in Healthy Male and Female Adults|Completed||Phase 1|45|Actual|Vifor Inc.||3|||f||||f||||||||||2018-05-31 22:04:14.136428|2018-05-31 22:04:14.136428
NCT01452893|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-01-03|2011-10-12|2011-10-17|Estimate|||||||2014-01-03|2014-01-06|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|May 2012|Actual|2012-05-31||Observational|CANDI||Counterregulatory Hormone Production in Adrenal Insufficiency and Diabetes Type I|Counterregulatory Hormone Production and Cognitive Function in Patients With Adrenal Insufficiency and Diabetes Mellitus Type I|Completed|||40|Actual|University of Wuerzburg|||4||f||||f||||||Samples Without DNA|"~     blood samples for hormonal analysis~   "|||2018-05-31 22:04:14.358386|2018-05-31 22:04:14.358386
NCT01452880|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-12|2011-10-12|2011-10-17|Estimate|||||||2011-10-12|2011-10-17|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ESWL||Remifentanil in Extracorporeal Shock Wave Lithotripsy|Total Intravenous Anaesthesia Using Remifentanil In Extracorporeal Shock Wave Lithotripsy (ESWL). Comparison of Two Dosages.|Completed||Phase 4|228|Actual|University of Roma La Sapienza|||||f||||t||||||||||2018-05-31 22:04:14.466906|2018-05-31 22:04:14.466906
NCT01452867|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-14|2011-10-14|2011-10-17|Estimate|||||||2011-10-14|2011-10-17|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Ventilation With Bag-Valve-Mask, Laryngeal Tube S-D and Laryngeal Mask Airway Supreme|Comparison of Ventilation With Bag-Valve-Mask, Laryngeal Tube S-D and Laryngeal Mask Airway Supreme|Completed||N/A|150|Anticipated|Krankenhaus Bruneck||3|||f||||t||||||||||2018-05-31 22:04:14.546562|2018-05-31 22:04:14.546562
NCT01452854|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|2014-06-10||2014-08-13|2011-10-12|2011-10-17|Estimate|2014-08-13|2014-08-28|Estimate||||2014-08-13|2014-08-28|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|OVA-LGG|Low recruitment necessitated the closing of the study. No results available.|Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide|Ovarian Aging in Women Newly Diagnosed With Low Grade Glioma Treated With Temozolomide (Temodar®)|Terminated|||2|Actual|University of California, San Francisco|||1|Low recruitment, sponsor withdrew funding.|f||||t||||||||||2018-05-31 22:04:14.63135|2018-05-31 22:04:14.63135
NCT01452841|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-10-14|2011-10-14|2011-10-17|Estimate|||||||2011-10-14|2011-10-17|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Grapefruit Feeding Trial in Healthy, Overweight Adults|Efficiency of Daily Grapefruit Exposure in Reducing Body Weight and Inflammatory Markers|Completed||N/A|85|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 22:04:14.792595|2018-05-31 22:04:14.792595
NCT01452828|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2016-05-02|2011-10-12|2011-10-17|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Pharmacokinetics and Safety Study in Subjects With Renal Impairment|A Phase I Open-Label Study With 200 mg Intravenous TR-701 Free Acid to Assess Safety and Pharmacokinetics in Advanced Renal Impairment Subjects|Completed||Phase 1|24|Actual|Trius Therapeutics LLC||3|||f||||f||||||||||2018-05-31 22:04:14.862344|2018-05-31 22:04:14.862344
NCT01452815|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2013-04-24|2011-10-12|2011-10-17|Estimate|||||||2013-04-24|2013-04-25|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP-102 for the Treatment of Symptoms Associated With Diabetic Gastroparesis|Completed||Phase 2|201|Actual|Tranzyme, Inc.||3|||f||||f||||||||||2018-05-31 22:04:14.965595|2018-05-31 22:04:14.965595
NCT01452802|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2016-06-10|2011-10-14|2011-10-17|Estimate|||||||2016-06-10|2016-06-13|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Observational|ROADMAP||Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management|Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients|Completed|||200|Actual|St. Jude Medical|||2||f||||f||||||||||2018-05-31 22:04:15.238698|2018-05-31 22:04:15.238698
NCT01452789|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-02-03|2011-10-14|2011-10-17|Estimate|||||||2017-02-03|2017-02-07|Estimate|November 2011||2011-11-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome|A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome|Completed||Phase 3|62|Actual|Thomas Jefferson University||2|||f||||t||||||||Yes||2018-05-31 22:04:15.4126|2018-05-31 22:04:15.4126
NCT01452776|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2013-11-02|2011-10-14|2011-10-17|Estimate|||||||2013-11-02|2013-11-05|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis|A Phase 3, Randomized, Single-Blind, Multicenter Study to Evaluate the Safety of TAK-438 (10 and 20 mg Once-daily) in a 52-week Maintenance Treatment in Patients With Healed Erosive Esophagitis (EE)|Completed||Phase 3|305|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:04:15.556278|2018-05-31 22:04:15.556278
NCT01452763|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2014-01-17|2011-10-14|2011-10-17|Estimate|||||||2014-01-17|2014-01-20|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin|A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin|Completed||Phase 3|621|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:04:15.67723|2018-05-31 22:04:15.67723
NCT01452750|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2014-02-04|2011-10-14|2011-10-17|Estimate|||||||2014-02-04|2014-02-05|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)|A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Non-steroidal Anti-inflammatory Drug (NSAID).|Completed||Phase 3|642|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:04:16.083321|2018-05-31 22:04:16.083321
NCT01452737|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2013-09-17|2011-10-12|2011-10-17|Estimate|||||||2013-09-17|2013-09-19|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Comparing 4L Golytely to 2L Golytely With 15mg Bisacodyl Regimens for Inpatient Colonic Preparation|2L Golytely and Oral Bisacodyl 15 mg Versus 4L Golytely Regimen for Inpatient Colonoscopy Bowel Preparation: A Randomized, Non-Inferiority Open Trial|Withdrawn||N/A|0|Actual|University of British Columbia||2|||f||||||||||||||2018-05-31 22:04:16.367034|2018-05-31 22:04:16.367034
NCT01452724|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2013-08-19|2011-10-14|2011-10-17|Estimate|||||||2013-08-19|2013-08-20|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer|A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Duodenal Ulcer|Completed||Phase 3|372|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:04:16.688844|2018-05-31 22:04:16.688844
NCT01452711|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2013-06-19|2011-10-14|2011-10-17|Estimate|||||||2013-06-19|2013-06-21|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer|A Phase 3, Randomized, Double Blind, Double-Dummy, Multicenter, Parallel Group Comparison Study to on Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Comparing With AG-1749 in Patients With Gastric Ulcer.|Completed||Phase 3|482|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:04:16.996013|2018-05-31 22:04:16.996013
NCT01452698|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2012-11-07|2011-10-14|2011-10-17|Estimate|||||||2012-11-07|2012-11-09|Estimate||||November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis|A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to AG-1749 (30mg Once-Daily) in Patients With Erosive Esophagitis|Completed||Phase 3|409|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:04:17.232157|2018-05-31 22:04:17.232157
NCT01452685|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-05-07|2011-10-12|2011-10-17|Estimate|||||||2014-05-07|2014-05-08|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis|A Phase II, Multicenter, Long-term Extension Study to Compare the Safety and Efficacy of TAK-385 (10, 20, and 40 mg) Following Oral Administration for 12 Weeks or More in the Treatment of Endometriosis|Completed||Phase 2|397|Actual|Takeda||5|||f||||f||||||||||2018-05-31 22:04:17.365503|2018-05-31 22:04:17.365503
NCT01452672|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-14|2011-10-14|2011-10-17|Estimate|||||||2011-10-14|2011-10-17|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer|Resource-sparing Radiotherapy for Breast Cancer|Unknown status|Recruiting|Phase 3|600|Anticipated|International Atomic Energy Agency||2|||f||||t||||||||||2018-05-31 22:04:17.560653|2018-05-31 22:04:17.560653
NCT01452659|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2013-01-17|2011-10-12|2011-10-17|Estimate|||||||2013-01-17|2013-01-21|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids|A Phase II, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of TAK-385 10, 20, and 40 mg (p.o.) in the Treatment of Uterine Fibroids|Completed||Phase 2|216|Actual|Takeda||4|||f||||f||||||||||2018-05-31 22:04:17.762911|2018-05-31 22:04:17.762911
NCT01452646|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2017-10-10|2011-10-14|2011-10-17|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|AML1310||Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia|Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia. GIMEMA Protocol AML1310. EudraCT Number 2010-023809-36|Active, not recruiting||Phase 2|515|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 22:04:17.874525|2018-05-31 22:04:17.874525
NCT01452633|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2013-06-06|2011-10-14|2011-10-17|Estimate|||||||2013-06-06|2013-06-10|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy|Effect of Preincisional Local Analgesia on Post-Operative Pain in 10-12mm Lateral Port Sites|Unknown status|Recruiting|N/A|100|Anticipated|Stony Brook University||4|||f||||f||||||||||2018-05-31 22:04:18.1669|2018-05-31 22:04:18.1669
NCT01452620|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2011-10-14|2011-10-14|2011-10-17|Estimate|||||||2011-10-14|2011-10-17|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|EVAR||Endovascular Abdominal Aortic Aneurysm Repair by Interventional Cardiologists||Completed|||170|Actual|St. Joseph Mercy Oakland Hospital|||1||f||||||||||||||2018-05-31 22:04:18.26283|2018-05-31 22:04:18.26283
NCT01452607|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-06-27|2011-10-14|2011-10-17|Estimate|||||||2016-06-27|2016-06-29|Estimate|May 2006||2006-05-31|June 2016|2016-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of SPI-1005|A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects|Completed||Phase 1|32|Actual|Sound Pharmaceuticals, Incorporated||5|||f||||t||||||||Undecided||2018-05-31 22:04:18.331535|2018-05-31 22:04:18.331535
NCT01452594|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2013-09-04|2011-10-14|2011-10-17|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Analysis of Diphenylcyclopropenone (DPCP) in Normals|Analysis of Immune Reactions Occurring in Normal Volunteers Upon Administration of the Topical Immunomodulator Diphenylcyclopropenone|Completed|||30|Anticipated|Rockefeller University|||1||f||||f||||||Samples With DNA|"~     Skin Biopsy~   "|||2018-05-31 22:04:18.418357|2018-05-31 22:04:18.418357
NCT01452581|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2015-03-05|2011-10-14|2011-10-17|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty|Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip Arthroplasty|Terminated||N/A|5|Actual|Rigshospitalet, Denmark||2||Lack of enrollment|f||||f||||||||||2018-05-31 22:04:18.483853|2018-05-31 22:04:18.483853
NCT01452568|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2014-08-04|2011-10-14|2011-10-17|Estimate|||||||2014-08-04|2014-08-05|Estimate|June 2005||2005-06-30|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin|Early Anticoagulation Therapy After Bioprosthetic Aortic Valve Implantation: Comparing Warfarin Versus Aspirin|Completed||Phase 4|370|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 22:04:18.553408|2018-05-31 22:04:18.553408
NCT01452555|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-12|2011-10-12|2011-10-17|Estimate|||||||2011-10-12|2011-10-17|Estimate|August 2011||2011-08-31|August 2011|2011-08-31||||||||Interventional|||Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos|Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos|Unknown status|Recruiting|Phase 3|200|Anticipated|Rhode Island Hospital||2|||f||||||||||||||2018-05-31 22:04:18.623732|2018-05-31 22:04:18.623732
NCT01452542|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2015-03-19|2011-10-12|2011-10-17|Estimate|||||||2015-03-19|2015-03-23|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects|A Pilot, Phase 1, Single-site, Single-dose, Randomized, Open-label, Two-treatment, Two-sequence, Four-period Replicated Crossover Study Evaluating the Within-subject Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects.|Completed||Phase 1|22|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:04:18.807119|2018-05-31 22:04:18.807119
NCT01452529|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|2014-12-01||2018-02-27|2011-10-12|2011-10-17|Estimate|2014-12-01|2014-12-04|Estimate||||2018-02-27|2018-03-29|Actual|October 2011||2011-10-31|February 2018|2018-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain|A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Low Back Pain|Completed||Phase 3|905|Actual|Purdue Pharma LP||2|||f||||t||||||||||2018-05-31 22:04:18.951785|2018-05-31 22:04:18.951785
NCT01452516|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02||2014-10-28|2016-11-07|2011-10-14|2011-10-17|Estimate||||2014-10-28|2014-11-04|Estimate|2016-11-07|2016-12-07|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions|A Prospective, Multi-Center, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages With Autograft in Conjunction With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive|Terminated||N/A|28|Actual|Pioneer Surgical Technology, Inc.||1||Study was terminated due to slow accrual rate.|f||||f||||||||No||2018-05-31 22:04:19.750794|2018-05-31 22:04:19.750794
NCT01452503|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2016-05-23|2011-10-14|2011-10-17|Estimate|||||||2016-05-23|2016-05-25|Estimate|May 2007||2007-05-31|May 2016|2016-05-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Assessing Preference for 3 Female Condoms: A Comparative Evaluation of the PATH Woman's Condom, FC2 and the Reddy 6|Assessing Preference for 3 Female Condoms: A Comparative Evaluation of the PATH Woman's Condom, FC2 and the Reddy 6|Completed||N/A|170|Actual|FHI 360||3|||f||||f||||||||No||2018-05-31 22:04:19.855769|2018-05-31 22:04:19.855769
NCT01452490|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2014-03-25|2011-10-12|2011-10-14|Estimate|||||||2014-03-25|2014-03-26|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Diode Laser Treatment of Onychomycosis|Study of the V-Raser Diode Laser System in the Treatment of Onychomycosis|Completed||N/A|50|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 22:04:19.943949|2018-05-31 22:04:19.943949
NCT01452477|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-09-03|2011-10-12|2011-10-14|Estimate|||||||2013-09-03|2013-09-04|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|||Tanshinone in Polycystic Ovary Syndrome|Effect of Tanshinone on Hormonal and Metabolic Features in Women With Polycystic Ovary Syndrome (PCOS)|Unknown status|Recruiting|N/A|100|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||t||||||||||2018-05-31 22:04:20.042574|2018-05-31 22:04:20.042574
NCT01452464|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-02-25|2011-10-13|2011-10-14|Estimate|||||||2015-02-25|2015-02-26|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Safety of MenACWY-CRM Vaccination in Adolescents|A Phase IV Study to Assess the Safety of Menveo Vaccine Being Used by HMO Subjects Aged 11-21 Years of Age|Completed|||55397|Actual|Novartis|||1||f||||||||||||||2018-05-31 22:04:20.164085|2018-05-31 22:04:20.164085
NCT01452451|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04||2016-08-08|2016-08-08|2011-10-13|2011-10-14|Estimate||||2016-08-08|2016-08-09|Estimate|2016-08-08|2016-08-09|Estimate|December 2011||2011-12-31|August 2016|2016-08-31||||June 2013|Actual|2013-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus|A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy|Completed||Phase 2|72|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||t||||||||||2018-05-31 22:04:20.552731|2018-05-31 22:04:20.552731
NCT01452438|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-08-05|2011-10-11|2011-10-14|Estimate|||||||2015-08-05|2015-08-06|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Safety Surveillance of MenACWY-CRM Vaccine in Children|Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (Menveo) Vaccination in Children 2 Through 10 Years of Age|Completed|||393|Actual|Novartis|||1||f||||||||||||||2018-05-31 22:04:20.677768|2018-05-31 22:04:20.677768
NCT01452425|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2014-12-01||2014-12-15|2011-10-13|2011-10-14|Estimate|2014-12-15|2014-12-22|Estimate||||2014-12-15|2014-12-22|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome|In Vivo Optical Spectroscopy Monitoring in a New Model of Muscular Compartment Syndrome.|Completed||Phase 1|10|Actual|Université Catholique de Louvain||1|||f||||t||||||||||2018-05-31 22:04:20.761447|2018-05-31 22:04:20.761447
NCT01452412|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2018-04-19|2011-10-12|2011-10-14|Estimate|||||||2018-04-19|2018-04-23|Actual|October 2011||2011-10-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Alkali Therapy in Chronic Kidney Disease|Placebo-controlled Randomized Clinical Trial of Alkali Therapy in Patients With Chronic Kidney Disease|Completed||Phase 2/Phase 3|149|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 22:04:20.912584|2018-05-31 22:04:20.912584
NCT01452399|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-10-16|2011-10-11|2011-10-14|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2011||2011-10-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|August 2014|Actual|2014-08-31||Interventional|||A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients|A Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients|Active, not recruiting||N/A|251|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:04:21.018911|2018-05-31 22:04:21.018911
NCT01452386|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-11-06|2011-10-11|2011-10-14|Estimate|||||||2016-11-06|2016-11-08|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Modified Functional Magnetic Stimulation Treatment for Constipation Improvement|Modified Functional Magnetic Stimulation Treatment for Constipation Improvement|Withdrawn|||0|Actual|Taipei Medical University WanFang Hospital|||2|no sufficient subjects|f||||f||||||||||2018-05-31 22:04:21.126221|2018-05-31 22:04:21.126221
NCT01452373|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2013-12-10|2011-10-13|2011-10-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women|DHEA + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women (Placebo Controlled, Double Blind and Randomized Phase III Study to Evaluate the Effects of 12-Week Treatment With DHEA (Prasterone) and Acolbifene on Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women)|Completed||Phase 3|238|Actual|EndoCeutics Inc.||2|||f||||f||||||||||2018-05-31 22:04:21.189592|2018-05-31 22:04:21.189592
NCT01452191|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-10-04|2011-10-13|2011-10-14|Estimate|||||||2012-10-04|2012-10-05|Estimate|June 2011||2011-06-30|October 2012|2012-10-31||||March 2013|Anticipated|2013-03-31||Interventional|||Helping Children's Centres to Enhance Home Safety|Keeping Children Safe at Home: Cluster Randomised Controlled Trial of the Implementation of an Injury Prevention Briefing in Children's Centres for the Prevention of Fire-related Injuries|Unknown status|Recruiting|N/A|1080|Anticipated|University of Nottingham||3|||f||||t||||||||||2018-05-31 22:04:27.441183|2018-05-31 22:04:27.441183
NCT01452360|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-11|2011-10-11|2011-10-14|Estimate|||||||2011-10-11|2011-10-14|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|May 2014|Anticipated|2014-05-31|||||Observational|||A Research Proposal to Set up an Integrated National Data Bank and Monitoring System and to Establish the Indicators and Risk Factors for Chronic Kidney Disease|A Research Proposal to Set up an Integrated National Data Bank and Monitoring System and to Establish the Indicators and Risk Factors for Chronic Kidney Disease|Unknown status|Active, not recruiting||700|Anticipated|Taipei Medical University WanFang Hospital|||3||f||||f||||||||||2018-05-31 22:04:21.286295|2018-05-31 22:04:21.286295
NCT01452347|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2014-05-23||2014-07-11|2011-10-13|2011-10-14|Estimate|2014-07-11|2014-08-06|Estimate||||2014-07-11|2014-08-06|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|RE-ALIGN|Treated Set (TRT): The set of patients who received at least 1 dose of study medication|Dabigatran Etexilate in Patients With Mechanical Heart Valves|A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt|Terminated||Phase 2|328|Actual|Boehringer Ingelheim|This study was terminated prematurely due to safety concerns arising during conduct of the trial.|2|||f||||||||||||||2018-05-31 22:04:21.380159|2018-05-31 22:04:21.380159
NCT01452334|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2012-02-22|2011-10-11|2011-10-14|Estimate|||||||2012-02-22|2012-02-23|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy|A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-Ligand 1 (PD-L1) Antibody (BMS-936559) in Subjects With Relapsed or Refractory Hematologic Malignancy|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 22:04:23.013019|2018-05-31 22:04:23.013019
NCT01452321|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-10-10|2011-10-10|2011-10-14|Estimate|||||||2011-10-10|2011-10-14|Estimate|August 2007||2007-08-31|October 2011|2011-10-31|September 2009|Actual|2009-09-30|July 2008|Actual|2008-07-31||Interventional|rTMSPPD||Repetitive Transcranial Magnetic Stimulation in Postpartum Depression|Repetitive Transcranial Magnetic Stimulation Effects on Clinical, Cognitive and Social Performance in Postpartum Depression|Completed||Phase 2|14|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 22:04:23.171985|2018-05-31 22:04:23.171985
NCT01452308|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11||2013-11-27|2014-01-02|2011-10-11|2011-10-14|Estimate||||2013-11-27|2013-12-24|Estimate|2014-01-02|2014-02-03|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional|||Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis|A Phase 2a, Pilot, Open-Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624 in Subjects With Fibrosis of the Liver|Completed||Phase 2|20|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 22:04:23.339036|2018-05-31 22:04:23.339036
NCT01452295|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-12-03|2011-10-13|2011-10-14|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion|Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817)|Withdrawn||Phase 2/Phase 3|0|Actual|Vital Therapies, Inc.||2||"Subjects from lead-in study VTI-206 - NCT00973817 lost to follow-up before enrollment in~   VTI-207 (NCT1452295)"|f||||f||||||||||2018-05-31 22:04:23.654312|2018-05-31 22:04:23.654312
NCT01452282|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-08|||2013-11-09|2011-10-13|2011-10-14|Estimate|||||||2013-11-09|2013-11-13|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|ABRACOS||Ankle-Brachial Index Estimating Cardiac Complications After Surgery|Ankle-Brachial Index Estimating Cardiac Complications After Non-Cardiac Surgery|Completed|||196|Actual|University of Sao Paulo|||1||f||||f||||||Samples Without DNA|"~     Whole blood samples will be retained for future exams.~   "|||2018-05-31 22:04:24.031028|2018-05-31 22:04:24.031028
NCT01452269|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2015-06-16||2015-06-16|2011-10-10|2011-10-14|Estimate|2015-06-16|2015-07-09|Estimate||||2015-06-16|2015-07-09|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DWW||Study of a Healthy Lifestyle Intervention for Deaf Adults Who Are Overweight or Obese|Deaf Weight Wise: A Healthy Lifestyle Intervention for Deaf Adults|Completed||N/A|104|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 22:04:25.899147|2018-05-31 22:04:25.899147
NCT01452256|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-02-16|2011-10-13|2011-10-14|Estimate|||||||2016-02-16|2016-02-17|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery|Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery|Completed||Phase 4|460|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 22:04:26.85732|2018-05-31 22:04:26.85732
NCT01452243|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2011-10-11|2011-10-11|2011-10-14|Estimate|||||||2011-10-11|2011-10-14|Estimate|November 2008||2008-11-30|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|November 2011|Anticipated|2011-11-30||Interventional|ANVITAD||Prevention of Falls and Fractures in Old People by Administration of Calcium and Vitamin D. Randomized Clinical Trial|Prevention of Falls and Fractures in Old People by Administration of Calcium and Vitamin D. Randomized Clinical Trial (ANVITAD)|Unknown status|Active, not recruiting|Phase 3|704|Anticipated|Gerencia de Atención Primaria, Albacete||1|||f||||f||||||||||2018-05-31 22:04:26.943513|2018-05-31 22:04:26.943513
NCT01452230|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2017-10-24|2011-10-11|2011-10-14|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2011||2011-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2015|Actual|2015-06-30||Interventional|||Prebariatric Surgery Physical Activity Program|Effectiveness and Efficacity of Presurgery Supervised Physical Activity Training on Health of Obese Individuals Waiting for Bariatric Surgery|Active, not recruiting||N/A|50|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 22:04:27.106168|2018-05-31 22:04:27.106168
NCT01452217|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-13|2011-10-13|2011-10-14|Estimate|||||||2011-10-13|2011-10-14|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers|The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers|Completed||Phase 1|12|Actual|University of Nottingham||1|||f||||f||||||||||2018-05-31 22:04:27.208243|2018-05-31 22:04:27.208243
NCT01452204|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-03-25|2011-10-13|2011-10-14|Estimate|||||||2017-03-25|2017-03-28|Actual|July 2009|Actual|2009-07-31|October 2011|2011-10-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|PEMF||Pulsed Electromagnetic Field (PEMF) in Impingement Shoulder|Pulsed Electromagnetic Field in Patients With Impingement Shoulder: A Randomized, Placebo-Controlled Clinical Trial|Completed||N/A|60|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||f||||||||||2018-05-31 22:04:27.313836|2018-05-31 22:04:27.313836
NCT01452178|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-11|2011-10-11|2011-10-14|Estimate|||||||2011-10-11|2011-10-14|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|VaMIS||Vastmanland Myocardial Infarction Study (VaMIS)|Observational Study on Peripheral Vascular Disease, Glucometabolic Status, and Type D Personality in Patients With Acute Myocardial Infarction.|Completed|||1008|Actual|Uppsala University|||||f||||t||||||Samples With DNA|"~     Whole blood and serum.~   "|||2018-05-31 22:04:27.543259|2018-05-31 22:04:27.543259
NCT01452165|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-11|2011-10-11|2011-10-14|Estimate|||||||2011-10-11|2011-10-14|Estimate|May 2006||2006-05-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|PADVa||Peripheral Artery Disease in Vastmanland|Observational Study on Cardiac Morphology and Function in Patients With Peripheral Artery Disease in Vastmanland County, Sweden(PADVa).|Completed|||457|Actual|Uppsala University|||||f||||t||||||Samples With DNA|"~     Whole blood and serum.~   "|||2018-05-31 22:04:27.626455|2018-05-31 22:04:27.626455
NCT01452152|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2016-02-18||2018-02-01|2011-10-13|2011-10-14|Estimate|2016-05-19|2016-06-28|Estimate||||2018-02-01|2018-03-05|Actual|February 2012||2012-02-29|February 2018|2018-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PAPI-2||Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study|Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study: A Prospective, Multicenter, Randomized Trial of Genotype-directed (G-D)Versus Standard of Care (SOC)Anti-platelet Therapy|Terminated||Phase 4|9|Actual|University of Maryland|The study was terminated early by the sponsor due to low enrollment.|3||Terminated by study sponsor.|f||||t||||||||||2018-05-31 22:04:27.722733|2018-05-31 22:04:27.722733
NCT01452139|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-04-23|2011-10-11|2011-10-14|Estimate|||||||2013-04-23|2013-04-25|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|RAPID STEMI||Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)|ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction|Completed||Phase 2/Phase 3|102|Actual|Ottawa Heart Institute Research Corporation||3|||f||||t||||||||||2018-05-31 22:04:28.376899|2018-05-31 22:04:28.376899
NCT01452126|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2016-10-25||2016-10-25|2011-10-11|2011-10-14|Estimate|2016-10-25|2016-12-19|Estimate||||2016-10-25|2016-12-19|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|MEAC||Minimum Effective Concentration of Ropivacaine for Brachial Plexus Block Via the Supraclavicular and Infraclavicular Approach, Femoral Nerve Block, Sciatic Nerve Block Via the Popliteal and Parasacral Approach|Minimum Effective Anesthetic Concentration of Supraclavicular Block, Infraclavicular Block, Femoral Nerve Block and Sciatic Nerve Block Via the Popliteal and Parasacral Approach|Terminated||Phase 2|49|Actual|University of New Mexico|Early termination leading to small numbers of subjects analyzed. Confidence intervals for primary outcome are not reliable and therefore not reported.|1||Departure of principal investigator|f||||t||||||||||2018-05-31 22:04:28.482349|2018-05-31 22:04:28.482349
NCT01452113|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2014-03-11|2011-10-13|2011-10-14|Estimate|||||||2014-03-11|2014-03-12|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|DPPNAC||Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy|Effect of a DPP-IV Inhibitor Treatment on the Secretion of Glucagon in Patients Presenting With Type 1 Diabetes Mellitus With or Without Autonomic Neuropathy|Completed||Phase 2|21|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 22:04:28.773773|2018-05-31 22:04:28.773773
NCT01452100|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2016-05-06|2011-10-13|2011-10-14|Estimate|||||||2016-05-06|2016-05-09|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|MECCORT||Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)|Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)|Terminated||Phase 2|39|Actual|University Hospital, Toulouse||2||Inclusion default|f||||t||||||||No||2018-05-31 22:04:28.860295|2018-05-31 22:04:28.860295
NCT01452087|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2014-11-20|2011-10-13|2011-10-14|Estimate|||||||2014-11-20|2014-11-24|Estimate|May 2009||2009-05-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Health Benefits of Chronic vs. Acute Exercise in Overweight Adults||Completed||N/A|43|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 22:04:28.950082|2018-05-31 22:04:28.950082
NCT01452074|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-04-30|2011-10-11|2011-10-14|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2011||2011-07-31|April 2018|2018-04-30|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Progressive Metabolic Adaptations to Low Intensity Exercise Training and Weight Loss||Active, not recruiting||N/A|16|Anticipated|University of Michigan||1|||f||||f||||||||||2018-05-31 22:04:29.024483|2018-05-31 22:04:29.024483
NCT01452061|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2014-01-27|2011-10-11|2011-10-14|Estimate|||||||2014-01-27|2014-01-29|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder|Understanding Genetic Differences Associated With Autism Spectrum and Attention Deficit/Hyperactivity Disorder|Completed|||456|Actual|The Cleveland Clinic|||4||f||||f||||||Samples With DNA|"~     Genetic material via a cheek swab will be collected.~   "|||2018-05-31 22:04:29.138986|2018-05-31 22:04:29.138986
NCT01452048|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2017-06-21|2011-10-11|2011-10-14|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2011||2011-09-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Relationship Between Systemic Fatty Acid Availability and Insulin Sensitivity||Recruiting|||30|Anticipated|University of Michigan|||1||f||||f||||||Samples With DNA|"~     frozen tissue, plasma~   "|||2018-05-31 22:04:29.398814|2018-05-31 22:04:29.398814
NCT01452035|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-11-07|2011-10-13|2011-10-14|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Exercise Dose Response for Improving Insulin Sensitivity|Comparing the Effects Exercise Intensity and Energy Expended During a Single Exercise Session on Insulin Sensitivity and Fatty Acid Partitioning Within Skeletal Muscle the Next Day in Obese Adults.|Completed||N/A|13|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:04:29.478141|2018-05-31 22:04:29.478141
NCT01452022|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-04-04|2011-10-12|2011-10-14|Estimate|||||||2017-04-04|2017-04-05|Actual|October 2011||2011-10-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|APOLLO||Performance of Inductigraft in Spinal Fusion|A Prospective Open-label Non-randomdised Multi-centre Clinical Study to Evaluate the Performance of Inductigraft in Posterolateral Fusion|Completed||N/A|125|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-05-31 22:04:29.644808|2018-05-31 22:04:29.644808
NCT01452009|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-12|||2012-02-09|2011-10-13|2011-10-14|Estimate|||||||2012-02-09|2012-02-10|Estimate|November 2011||2011-11-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%|Three Month Safety and Efficacy Study of TRAVATAN® vs Travoprost Ophthalmic Solution, 0.004%|Withdrawn||Phase 3|0|Actual|Alcon Research||2||Management Decision|f||||f||||||||||2018-05-31 22:04:29.749689|2018-05-31 22:04:29.749689
NCT01451996|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2018-01-18||2018-03-09|2011-10-13|2011-10-14|Estimate|2018-03-09|2018-03-13|Actual||||2018-03-09|2018-03-13|Actual|October 2011||2011-10-31|March 2018|2018-03-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional||The sample was stratified into subjects with (Allergy+) and without (Allergy-) a positive skin test and block-randomized each subpopulation to the two advertisement conditions (Claritin ads and Zyrtec ads)|The Efficacy of Claritin in Healthy Subjects|The Efficacy of Claritin in Healthy Subjects|Completed||Phase 4|340|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 22:04:29.833029|2018-05-31 22:04:29.833029
NCT01451983|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2014-12-12||2015-01-07|2011-10-13|2011-10-14|Estimate|2015-01-07|2015-01-14|Estimate||||2015-01-07|2015-01-14|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Genetics, Brain Structure and Thinking Skills in Autism|Genetic, Biochemical, Behavioral and Neuroimaging Phenotypes of Autism Spectrum Disorders (ASDs)|Completed|||138|Actual|The Cleveland Clinic|Modest PTEN-ASD sample size and difficulty in closely matching each PTEN patient to one or more patients from each comparison group; Lack of comprehensively characterized PHTS patients without ASD is also a limitation.||4||f||||t||||||Samples With DNA|"~     About 6 tubes of blood or up to 50 ml (3-4 tablespoons) and 30 mL of urine will be collected.~   "|||2018-05-31 22:04:30.179413|2018-05-31 22:04:30.179413
NCT01451970|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-03-12|2011-10-13|2011-10-14|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2007||2007-08-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|February 2012|Actual|2012-02-29||Interventional|||Dietary Fatty Acid Composition and Obesity-related Metabolic Abnormalities|Assessing the Effects of Two Diets Enriched in Either Saturated or Unsaturated Fatty Acids to Determine the Cellular and Molecular Mechanisms in Insulin Sensitivity|Active, not recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 22:04:30.417422|2018-05-31 22:04:30.417422
NCT01451957|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-11-22|2011-10-13|2011-10-14|Estimate|||||||2016-11-22|2016-11-23|Estimate|August 2003||2003-08-31|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity|Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity|Completed||N/A|7|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:04:30.486422|2018-05-31 22:04:30.486422
NCT01451944|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-12-01|2011-10-13|2011-10-14|Estimate|||||||2014-12-01|2014-12-02|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Home Health Case Management on Asthma Morbidity|Effect of Home Health Nurse Case Management on Asthma Morbidity|Withdrawn||N/A|0|Actual|University of Louisville||1||no one enrolled|f||||f||||||||||2018-05-31 22:04:30.563271|2018-05-31 22:04:30.563271
NCT01451931|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2014-10-30||2014-12-02|2011-10-13|2011-10-14|Estimate|2014-12-02|2014-12-03|Estimate||||2014-12-02|2014-12-03|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|STONE||Study of Tomography of Nephrolithiasis Evaluation|Randomized Controlled Trial of Ultrasound Versus CT (Computed Tomography) for Patients in the Emergency Department With Suspected Renal Colic|Completed||Phase 4|2776|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 22:04:30.649769|2018-05-31 22:04:30.649769
NCT01451918|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2014-05-05|2011-10-13|2011-10-14|Estimate|||||||2014-05-05|2014-05-06|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol|Regulation of Intestinal (and Hepatic) Lipoprotein Secretion by Resveratrol|Completed||Phase 2|8|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:04:31.298969|2018-05-31 22:04:31.298969
NCT01451905|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2012-06-20|2011-10-11|2011-10-14|Estimate|||||||2012-06-20|2012-06-21|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis||Unknown status|Recruiting|N/A|12|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||||||||||||2018-05-31 22:04:31.438795|2018-05-31 22:04:31.438795
NCT01451892|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2014-12-12|2011-10-11|2011-10-14|Estimate|||||||2014-12-12|2014-12-16|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Dance Therapy and Obesity|The Effect of Dance Therapy on the Functional Capacity of Patients With Advanced Obesity|Completed||N/A|60|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 22:04:31.579355|2018-05-31 22:04:31.579355
NCT01451879|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-12-06|2011-10-11|2011-10-14|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2008|Actual|2008-10-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies|Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy|Completed|||11|Actual|University of Florida|||1||f||||f||||||Samples With DNA|"~     Residual blood specimens from GAA Ab testing~   "|||2018-05-31 22:04:31.697455|2018-05-31 22:04:31.697455
NCT01451866|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-11-24|2011-10-11|2011-10-14|Estimate|||||||2014-11-24|2014-11-25|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|dlp||Comparison Between Classic Leg-press Training and Complex Leg-press Training on a Dynamic Leg-press|Comparison of a Classic Leg-press Training Compared to a Complex Training on a Dynamic Leg-press With Visual Feed-back. Pilot-study|Completed||Phase 2/Phase 3|34|Actual|University of Applied Sciences of Western Switzerland||2|||f||||f||||||||||2018-05-31 22:04:31.800207|2018-05-31 22:04:31.800207
NCT01451853|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2017-09-21|2011-10-13|2011-10-14|Estimate|||||||2017-09-21|2017-09-25|Actual|January 15, 2018|Anticipated|2018-01-15|September 2017|2017-09-30|September 23, 2019|Anticipated|2019-09-23|June 26, 2019|Anticipated|2019-06-26||Interventional|||SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss|Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss|Not yet recruiting||Phase 2|80|Anticipated|Sound Pharmaceuticals, Incorporated||4|||||||t|t|f||||||||2018-05-31 22:04:31.920863|2018-05-31 22:04:31.920863
NCT01451840|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2012-10-25|2011-10-13|2011-10-14|Estimate|||||||2012-10-25|2012-10-29|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy of Alkalinized Lidocaine Compared to Remifentanil on the Incidence of Coughing During Emergence of Anesthesia|Efficacy of Alkalinized Lidocaine in the Endotracheal Tube Cuff Compared to a Bolus Dose of Intravenous Remifentanil on the Incidence of Coughing During Emergence of Anesthesia|Completed||N/A|85|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 22:04:32.059867|2018-05-31 22:04:32.059867
NCT01451671|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-07-14|2011-10-13|2011-10-14|Estimate|||||||2016-07-14|2016-07-18|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Development of a Prenatal Test for Fetal Aneuploidy Detection|Prenatal Test for Fetal Aneuploidy Detection|Recruiting|||1500|Anticipated|Roche Sequencing Solutions|||||f||||f||||||||||2018-05-31 22:04:34.556927|2018-05-31 22:04:34.556927
NCT01451827|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11||2014-06-12|2014-06-12|2011-10-13|2011-10-14|Estimate||||2014-06-12|2014-06-19|Estimate|2014-06-12|2014-06-19|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|NOCTURNE||8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Placebo-masked, Parallel-group Pilot Trial to Compare the Efficacy, Tolerability, and Safety of Tolvaptan Modified-release and Immediate-release Formulations in Subjects With Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 2|178|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||f||||||||||2018-05-31 22:04:32.187169|2018-05-31 22:04:32.187169
NCT01451814|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2015-02-23||2015-03-06|2011-10-13|2011-10-14|Estimate|2015-03-06|2015-03-18|Estimate||||2015-03-06|2015-03-18|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Participants fully eligible and attending the first session of counseling|Development of Positive Psychotherapy for Smoking Cessation|Development of Positive Psychotherapy for Smoking Cessation|Completed||Phase 2|66|Actual|Brown University||2|||f||||f||||||||||2018-05-31 22:04:32.344557|2018-05-31 22:04:32.344557
NCT01451801|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-10-25|2011-10-13|2011-10-14|Estimate|||||||2012-10-25|2012-10-26|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders|Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders|Unknown status|Active, not recruiting|Phase 4|400|Anticipated|University of Aarhus||1|||f||||t||||||||||2018-05-31 22:04:32.700461|2018-05-31 22:04:32.700461
NCT01451788|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2014-11-14|2011-10-13|2011-10-14|Estimate|||||||2014-11-14|2014-11-17|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Human Thrombin With Gelatin Matrix on Perioperative Blood Loss in Scoliosis Surgery|Effectiveness Of Gelatin Matrix With Human Derived Thrombin On Blood Loss, Surgical Time, Hospital Stay And Complications In Adolescents Undergoing Spine Surgery For Adolescent Idiopathic Scoliosis: A Randomized Clinical Trial.|Unknown status|Recruiting|Phase 4|60|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 22:04:32.772928|2018-05-31 22:04:32.772928
NCT01451775|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2014-05-16||2014-06-26|2011-10-11|2011-10-14|Estimate|2014-06-26|2014-06-27|Estimate||||2014-06-26|2014-06-27|Estimate|October 2011||2011-10-31|June 2014|2014-06-30||||November 2011|Actual|2011-11-30||Interventional|||Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.|Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet and Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets in an Open, Randomised, Single Dose, Three-period Cross-over Study in Healthy Male and Female Subjects|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:04:32.883098|2018-05-31 22:04:32.883098
NCT01451762|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2013-10-28||2014-02-14|2011-10-11|2011-10-14|Estimate|2014-02-14|2014-03-14|Estimate||||2014-02-14|2014-03-14|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery|A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery|Completed||N/A|90|Actual|Northwestern University|We did not obtain preoperative quality of recovery scores of patients therefore we could not examine whether the effect of diphenhydramine was dependent upon patient's baseline characteristics.|3|||f||||f||||||||||2018-05-31 22:04:33.160425|2018-05-31 22:04:33.160425
NCT01451749|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2013-11-24||2014-10-09|2011-10-13|2011-10-14|Estimate|2014-10-09|2014-10-10|Estimate||||2014-10-09|2014-10-10|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional||216 in Shenwu capusle, and 108 in the Donepezil group was enrolled at baseline, 1 subjects in both group did not meet the inclusion criteria ,and 215 in Shenwu Capsule, and 107 in Donepezil were used to baseline analysis|Efficacy and Safety Study of Shenwu Capsule|Phase III Study of Shenwu Capsule in Treating Amnestic Mild Cognitive Impairment|Completed||Phase 3|324|Actual|North China Pharmaceutical Group Corporation|First, there was no placebo group. As all subjects knew that they were being treated with one of two drugs, and all of the individuals who assessed the patients knew this as well, the results may have been influenced by a positive response bias.|2|||f||||t||||||||||2018-05-31 22:04:33.464976|2018-05-31 22:04:33.464976
NCT01451736|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-02-18|2011-10-11|2011-10-14|Estimate|||||||2018-02-18|2018-02-20|Estimate|October 2011||2011-10-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia|Clinical and Cognitive Effects of Paliperidone Palmitate vs. Oral Risperidone in First-Episode Schizophrenia|Recruiting||Phase 4|170|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:04:33.816675|2018-05-31 22:04:33.816675
NCT01451723|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2013-12-10||2014-01-30|2011-10-13|2011-10-14|Estimate|2014-01-30|2014-03-14|Estimate||||2014-01-30|2014-03-14|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|POEMS||Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II|Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS|Terminated||Phase 2|11|Actual|Louisiana State University Health Sciences Center in New Orleans|The study was halted prematurely because of the high incidence of liver function abnormalities|2||Unusual high frequency of elevated liver function tests.|f||||t||||||||||2018-05-31 22:04:33.904299|2018-05-31 22:04:33.904299
NCT01451710|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2012-07-09|2011-10-11|2011-10-14|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy|The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy|Completed||N/A|30|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-05-31 22:04:34.207656|2018-05-31 22:04:34.207656
NCT01451697|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-11|2011-10-11|2011-10-14|Estimate|||||||2011-10-11|2011-10-14|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|||Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding|Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Hartford Hospital||2|||f||||f||||||||||2018-05-31 22:04:34.283712|2018-05-31 22:04:34.283712
NCT01451684|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-07-14|2011-10-13|2011-10-14|Estimate|||||||2016-07-14|2016-07-18|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Development of a Non-invasive Prenatal Test|Development of a Non-invasive Prenatal Test|Recruiting|||10000|Anticipated|Roche Sequencing Solutions|||||f||||f||||||||||2018-05-31 22:04:34.489336|2018-05-31 22:04:34.489336
NCT01451658|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-13|2011-10-13|2011-10-14|Estimate|||||||2011-10-13|2011-10-14|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|October 2012|Anticipated|2012-10-31|December 2009|Actual|2009-12-31||Interventional|||Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma||Unknown status|Recruiting|Phase 4|100|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 22:04:34.64048|2018-05-31 22:04:34.64048
NCT01451645|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2013-09-24||2014-04-07|2011-10-13|2011-10-14|Estimate|2014-04-07|2014-05-12|Estimate||||2014-04-07|2014-05-12|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional||The study population consisted of adults who met the criteria of the ARA for acute arthritis of primary gout or had monosodium urate monohydrate microcrystals identified in joint fluid, had tophi present in joints or a history of polyarticular gout attacks, a history of ≥2 gout flares in the past year, and were initiating therapy with allopurinol.|Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol||Completed||Phase 4|82|Actual|Regeneron Pharmaceuticals|This clinical trial was not directly related to the development of an investigational/medicinal product.|2|||f||||f||||||||||2018-05-31 22:04:34.742031|2018-05-31 22:04:34.742031
NCT01451632|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|2016-07-12||2016-09-06|2011-10-11|2011-10-13|Estimate|2016-09-06|2016-09-08|Estimate||||2016-09-06|2016-09-08|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|||A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers|A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers|Completed||Phase 1|48|Actual|Merrimack Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 22:04:35.127287|2018-05-31 22:04:35.127287
NCT01451619|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-03-24|2011-10-11|2011-10-13|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)|A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Assess the Pharmacodynamics of MK-0524 in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea. (Protocol No. 155)|Completed||Phase 1|60|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:04:36.044176|2018-05-31 22:04:36.044176
NCT01451606|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2017-12-01||2017-12-21|2011-10-11|2011-10-13|Estimate|2017-12-21|2018-01-23|Actual||||2017-12-21|2018-01-23|Actual|July 11, 2011|Actual|2011-07-11|December 2017|2017-12-31|November 4, 2015|Actual|2015-11-04|November 4, 2015|Actual|2015-11-04||Interventional|||Duloxetine for the Treatment of Chronic Pelvic Pain|Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain|Terminated||Phase 4|34|Actual|University of Maryland||2||Adequate recruitment was not achieved in the time frame allowed.|f||||t||||||||No||2018-05-31 22:04:36.128154|2018-05-31 22:04:36.128154
NCT01451593|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2015-09-08|2011-10-11|2011-10-13|Estimate|||||||2015-09-08|2015-09-09|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Neuroprotection With Phenytoin in Optic Neuritis|A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis|Completed||Phase 2|92|Actual|University College, London||2|||f||||t||||||||||2018-05-31 22:04:36.539917|2018-05-31 22:04:36.539917
NCT01451580|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-12|2011-10-12|2011-10-13|Estimate|||||||2011-10-12|2011-10-13|Estimate|September 2005||2005-09-30|October 2011|2011-10-31||||||||Interventional|||Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer|A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|47|Anticipated|TTY Biopharm|||||f||||||||||||||2018-05-31 22:04:36.624189|2018-05-31 22:04:36.624189
NCT01451567|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-15|2011-10-12|2011-10-13|Estimate|||||||2011-10-15|2011-10-18|Estimate|June 2005||2005-06-30|May 2005|2005-05-31|March 2006|Actual|2006-03-31|October 2005|Actual|2005-10-31||Interventional|||The Effect of a Structured Personalised Ergonomic Intervention for Hospital Nurses With Musculoskeletal Complains|Study That Examined the Effect of a Structured Personalised Ergonomic Intervention Program for Hospital Nurses With Musculoskeletal Complains.|Completed||N/A|31|Actual|Tel Aviv University|||||f||||t||||||||||2018-05-31 22:04:36.697435|2018-05-31 22:04:36.697435
NCT01451554|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2011-10-19||2011-10-19|2011-10-12|2011-10-13|Estimate|2011-10-19|2011-11-28|Estimate||||2011-10-19|2011-11-28|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Portion Control Treatment for Obesity|Portion Control for the Treatment of Obesity in the Primary Care Setting|Completed||Phase 2/Phase 3|65|Actual|Mayo Clinic|small sample size and inability to blind staff/study subject to the intervenion|2|||f||||f||||||||||2018-05-31 22:04:36.77133|2018-05-31 22:04:36.77133
NCT01451541|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2013-12-19||2014-04-04|2011-10-11|2011-10-13|Estimate|2014-04-04|2014-05-06|Estimate||||2014-04-04|2014-05-06|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).|A 12-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis|Completed||Phase 3|848|Actual|Sunovion||3|||f||||f||||||||||2018-05-31 22:04:37.069864|2018-05-31 22:04:37.069864
NCT01451528|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2014-04-02|2011-10-11|2011-10-13|Estimate|||||||2014-04-02|2014-04-03|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Allogeneic Umbilical Cord Blood Therapy for Chronic TBI|The Efficacy and Safety of Allogeneic Umbilical Cord Blood Therapy for Chronic Traumatic Brain Injury Patients|Withdrawn||N/A|0|Actual|Bundang CHA Hospital||1||The research fund, which is yet to be raised and expected to take for a while|f||||f||||||||||2018-05-31 22:04:38.07456|2018-05-31 22:04:38.07456
NCT01451515|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-01-02|2011-10-11|2011-10-13|Estimate|||||||2018-01-02|2018-01-03|Actual|May 25, 2012|Actual|2012-05-25|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma|NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma|Active, not recruiting||Phase 2|23|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 22:04:38.17859|2018-05-31 22:04:38.17859
NCT01451502|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2018-01-03|2011-10-12|2011-10-13|Estimate|||||||2018-01-03|2018-01-05|Actual|October 20, 2011|Actual|2011-10-20|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units|Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units|Recruiting||N/A|250|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 22:04:38.382353|2018-05-31 22:04:38.382353
NCT01451489|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-03-22|2011-10-11|2011-10-13|Estimate|||||||2017-03-22|2017-03-27|Actual|October 13, 2011|Actual|2011-10-13|March 2017|2017-03-31|October 29, 2016|Actual|2016-10-29|March 23, 2016|Actual|2016-03-23||Interventional|FSGS||The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis|A Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental Glomerulosclerosis|Terminated||N/A|70|Actual|Nanjing University School of Medicine||2||The recruitment of subject is very difficult|f||||t||||||||||2018-05-31 22:04:38.484984|2018-05-31 22:04:38.484984
NCT01451476|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-04-18|2011-10-12|2011-10-13|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Observational|GEP||Human Skin Aging: Clinical Parameters and Gene Expression Profiling|Human Skin Aging: Clinical Parameters and Gene Expression Profiling|Completed|||122|Actual|Stanford University|||1||f||||f||||||Samples With DNA|"~     Blood and skin samples~   "|||2018-05-31 22:04:38.591693|2018-05-31 22:04:38.591693
NCT01451463|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2016-04-23||2017-10-22|2011-10-12|2011-10-13|Estimate|2017-10-17|2017-10-19|Actual||||2017-10-22|2017-11-24|Actual|April 2010||2010-04-30|October 2017|2017-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease|Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease|Completed|||11|Actual|Ohio State University|||||f||||f||||||||No||2018-05-31 22:04:38.710075|2018-05-31 22:04:38.710075
NCT01451450|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2012-07-20|2011-10-12|2011-10-13|Estimate|||||||2012-07-20|2012-07-23|Estimate||||July 2012|2012-07-31||||||||Interventional|||Efficacy and Safety of 4 Doses of QGE031 in Patients 18-50 Years of Age With Peanut Allergy|A Phase II, Randomized, Double Blind, Placebo-controlled, Parallel Design, Dose Ranging, Multi-center Trial of Four Levels of Exposure of QGE031 s.c. for 16 Weeks in Subjects Aged 18-50 Years of Age With Peanut Allergy|Withdrawn||Phase 2|0|Actual|Novartis||8|||f||||||||||||||2018-05-31 22:04:39.015945|2018-05-31 22:04:39.015945
NCT01451437|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2016-02-05||2017-05-18|2011-10-11|2011-10-13|Estimate|2016-02-05|2016-03-04|Estimate||||2017-05-18|2017-06-14|Actual|November 18, 2011|Actual|2011-11-18|May 2017|2017-05-31|September 5, 2014|Actual|2014-09-05|September 5, 2014|Actual|2014-09-05||Interventional|||Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)|A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination With Chemotherapy in Subjects With Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 (005))|Terminated||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||9||The study was terminated early due to business reasons.|f||||f||||||||||2018-05-31 22:04:39.218926|2018-05-31 22:04:39.218926
NCT01451424|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|2014-06-25||2014-08-08|2011-10-11|2011-10-13|Estimate|2014-08-08|2014-08-29|Estimate||||2014-08-08|2014-08-29|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional||Safety population|Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids|A Phase 2, 3 Arm, Randomized, Double-Blind Study to Evaluate the Safety, PK and Efficacy of Proellex® Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids|Completed||Phase 2|40|Actual|Repros Therapeutics Inc.||5|||f||||f||||||||||2018-05-31 22:04:41.801736|2018-05-31 22:04:41.801736
NCT01451411|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2015-12-18||2016-02-01|2011-10-11|2011-10-13|Estimate|2016-02-01|2016-03-01|Estimate||||2016-02-01|2016-03-01|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia|Terminated||Phase 3|4|Actual|Cumberland Pharmaceuticals||2||Enrollment goals were not met.|f||||t||||||||||2018-05-31 22:04:42.260284|2018-05-31 22:04:42.260284
NCT01451398|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|2014-07-22|2013-08-19|2014-10-09|2011-10-12|2011-10-13|Estimate|2014-10-09|2014-10-17|Estimate|2013-08-19|2013-08-27|Estimate|2014-10-09|2014-10-17|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional||Safety population|Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus|A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Technosphere Inhalation Powder in Insulin Naïve Subjects With Type 2 Diabetes Mellitus Poorly Controlled With Oral Antidiabetic Agents Over a 24 Week Treatment Period|Completed||Phase 3|353|Actual|Mannkind Corporation||2|||f||||t||||||||||2018-05-31 22:04:43.901051|2018-05-31 22:04:43.901051
NCT01451385|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29||2017-05-18|2017-05-18|2011-10-12|2011-10-13|Estimate||||2017-05-18|2017-05-23|Actual|2017-05-18|2017-05-23|Actual|September 2011||2011-09-30|May 2017|2017-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain|An Open Label Safety Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain|Completed||Phase 3|376|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 22:04:45.003962|2018-05-31 22:04:45.003962
NCT01451372|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-11-06|2011-10-10|2011-10-13|Estimate|||||||2012-11-06|2012-11-07|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study|Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study|Completed|||69|Actual|Medtronic|||||f||||t||||||||||2018-05-31 22:04:45.16179|2018-05-31 22:04:45.16179
NCT01451359|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2013-10-08|2011-10-12|2011-10-13|Estimate|||||||2013-10-08|2013-10-10|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Endobronchial Valves in Persistent Air Leak|Efficacy of Endobronchial Valves in Persistent Air Leak After Anatomical Pulmonary Resection for Cancer.|Completed||N/A|10|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:04:45.242717|2018-05-31 22:04:45.242717
NCT01451346|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-12|2011-10-12|2011-10-13|Estimate|||||||2011-10-12|2011-10-13|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|April 2008|Actual|2008-04-30||Interventional|AH-PSR-01||Study in Patients With Mild to Moderate Psoriasis|B.Infantis 35624 in Patients With Mild to Moderate Chronic Plaque Psoriasis -a Pilot Study|Completed||Phase 1/Phase 2|47|Actual|Alimentary Health Ltd||2|||f||||t||||||||||2018-05-31 22:04:45.328123|2018-05-31 22:04:45.328123
NCT01451333|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-05-10|2011-10-12|2011-10-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|ENCORE1-CNS||The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1|The EFV Central Nervous System Exposure Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks|Completed||Phase 3|32|Actual|Kirby Institute||2|||f||||t||||||||||2018-05-31 22:04:45.542204|2018-05-31 22:04:45.542204
NCT01451320|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-10-11|2011-10-11|2011-10-13|Estimate|||||||2011-10-11|2011-10-13|Estimate|January 1993||1993-01-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|TROIA||Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis|Comparison of Different TRansesophageal Echocardiography Guided thrOmbolytic Regimens for prosthetIc vAlve Thrombosis|Completed||N/A|182|Actual|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital||5|||f||||f||||||||||2018-05-31 22:04:45.811589|2018-05-31 22:04:45.811589
NCT01451307|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2013-09-04|2011-10-11|2011-10-13|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|FraMal||Follow-up of Children With Gastrointestinal Malformations and Postnatal Surgery|Follow-up Study of Children Aged 2 Years With Gastrointestinal Malformations and Postnatal Surgery|Completed|||80|Actual|Goethe University|||2||f||||t||||||||||2018-05-31 22:04:45.894177|2018-05-31 22:04:45.894177
NCT01451294|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-10-12|2011-10-12|2011-10-13|Estimate|||||||2011-10-12|2011-10-13|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Effect of Blood Pressure on rSO2 in Carotid Endarterectomy (CEA)|The Effect of Phenylephrine Versus Ephedrine on Cerebral Perfusion During Carotid Endarterectomy|Unknown status|Not yet recruiting|N/A|40|Anticipated|UMC Utrecht||2|||f||||||||||||||2018-05-31 22:04:45.962051|2018-05-31 22:04:45.962051
NCT01451281|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-08|||2018-03-27|2011-10-08|2011-10-13|Estimate|||||||2018-03-27|2018-03-29|Actual|September 15, 2011||2011-09-15|February 12, 2018|2018-02-12||||||||Observational|||Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular Dystrophy|Evaluation of Skeletal Muscle, Cardiac, and Diaphragm Imaging Biomarkers for GSK2402968 Effects in Ambulatory Boys With Duchenne Muscular Dystrophy|Completed|||35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:04:46.055147|2018-05-31 22:04:46.055147
NCT01451268|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-03-19|2011-10-11|2011-10-13|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2011|Actual|2011-01-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PANOBEST||Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)|Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk MDS or AML (PANOBEST)|Active, not recruiting||Phase 1/Phase 2|62|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 22:04:46.173312|2018-05-31 22:04:46.173312
NCT01451255|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-08|||2016-03-15|2011-10-12|2011-10-13|Estimate|||||||2016-03-15|2016-03-17|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging|Early Detection of Pulmonary Arterial Hypertension Using Cardiac Magnetic Resonance Imaging|Completed|||90|Actual|Mayo Clinic|||||f||||||||||||||2018-05-31 22:04:46.368548|2018-05-31 22:04:46.368548
NCT01451242|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-12|2011-10-12|2011-10-13|Estimate|||||||2011-10-12|2011-10-13|Estimate|October 2011||2011-10-31|October 2011|2011-10-31||||||||Observational|||The Reliability of Heart Rate Variability Among Patients With Brain Injury as Measured by POLAR RC810XE Compared to HOLTER|The Reliability of Heart Rate Variability Measurements Among Patients With Acquired Brain Injury as Measured During Physical Activity by POLAR RC810XE Compared to HOLTER EKG|Unknown status|Not yet recruiting||30|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 22:04:46.43398|2018-05-31 22:04:46.43398
NCT01451229|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2011-10-12|2011-10-12|2011-10-13|Estimate|||||||2011-10-12|2011-10-13|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects|An Open-Label, Single-dose Administration Study of the Pharmacokinetics and Pharmacodynamics of Higenamine, Administered Intravenously Injection to Healthy Chinese Subjects|Completed||Phase 1|10|Actual|Peking Union Medical College Hospital|||||f||||t||||||||||2018-05-31 22:04:46.966127|2018-05-31 22:04:46.966127
NCT01451216|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2011-10-17|2011-10-12|2011-10-13|Estimate|||||||2011-10-17|2011-10-18|Estimate|November 2011||2011-11-30|October 2011|2011-10-31||||||||Observational|||The Evaluation of Balance Control by Quantification of Temporospatial Measures While Forward and Side Reaching|The Evaluation of Balance Control by Quantification of the Temporospatial Measures of Functional Reach Test|Unknown status|Not yet recruiting||40|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 22:04:47.073353|2018-05-31 22:04:47.073353
NCT01451203|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|2015-10-18||2017-06-28|2011-10-11|2011-10-13|Estimate|2015-10-18|2015-11-20|Estimate||||2017-06-28|2017-08-03|Actual|October 11, 2011|Actual|2011-10-11|June 2017|2017-06-30|October 20, 2014|Actual|2014-10-20|August 28, 2013|Actual|2013-08-28||Interventional||The Full Analysis Set (FAS), which consisted of all participants who had received at least 1 study drug administration and provided efficacy data after the administration of the study drug.|Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of CDP870 in Patients With Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors|Completed||Phase 3|319|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 22:04:47.35635|2018-05-31 22:04:47.35635
NCT01451190|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-07-09|2011-10-12|2011-10-13|Estimate|||||||2013-07-09|2013-07-11|Estimate|July 2011||2011-07-31|July 2013|2013-07-31||||March 2013|Actual|2013-03-31||Interventional|||A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)|A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects|Completed||Phase 2|88|Actual|Aderans Research Institute||1|||f||||f||||||||||2018-05-31 22:04:48.576751|2018-05-31 22:04:48.576751
NCT01451177|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-07-09|2011-10-12|2011-10-13|Estimate|||||||2013-07-09|2013-07-11|Estimate|May 2010||2010-05-31|July 2013|2013-07-31||||January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects.|Completed||Phase 2|43|Actual|Aderans Research Institute||1|||f||||f||||||||||2018-05-31 22:04:48.855568|2018-05-31 22:04:48.855568
NCT01451151|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-07-09|2011-10-12|2011-10-13|Estimate|||||||2013-07-09|2013-07-11|Estimate|December 2010||2010-12-31|July 2013|2013-07-31||||June 2012|Actual|2012-06-30||Interventional|||A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects|Completed||Phase 2|33|Actual|Aderans Research Institute||1|||f||||f||||||||||2018-05-31 22:04:49.076742|2018-05-31 22:04:49.076742
NCT01451138|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-07-09|2011-10-12|2011-10-13|Estimate|||||||2013-07-09|2013-07-11|Estimate|November 2010||2010-11-30|July 2013|2013-07-31||||October 2012|Actual|2012-10-31||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects|Completed||Phase 2|40|Actual|Aderans Research Institute||1|||f||||f||||||||||2018-05-31 22:04:49.181525|2018-05-31 22:04:49.181525
NCT01451125|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-07-09|2011-10-12|2011-10-13|Estimate|||||||2013-07-09|2013-07-11|Estimate|May 2010||2010-05-31|July 2013|2013-07-31||||March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil|Completed||Phase 2|43|Actual|Aderans Research Institute||1|||f||||f||||||||||2018-05-31 22:04:49.250743|2018-05-31 22:04:49.250743
NCT01451112|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-07-09|2011-10-12|2011-10-13|Estimate|||||||2013-07-09|2013-07-11|Estimate|August 2009||2009-08-31|July 2013|2013-07-31||||August 2012|Actual|2012-08-31||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)|A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects|Completed||Phase 2|30|Actual|Aderans Research Institute||1|||f||||f||||||||||2018-05-31 22:04:49.352694|2018-05-31 22:04:49.352694
NCT01451099|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2012-02-28|2011-10-12|2011-10-13|Estimate|||||||2012-02-28|2012-02-29|Estimate|June 2009||2009-06-30|February 2012|2012-02-29||||September 2010|Actual|2010-09-30||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss|Completed||Phase 2|21|Actual|Aderans Research Institute|||||f||||f||||||||||2018-05-31 22:04:49.446337|2018-05-31 22:04:49.446337
NCT01451086|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-03-14|2011-10-12|2011-10-13|Estimate|||||||2013-03-14|2013-03-15|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China|Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China|Completed||Phase 3|1200|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 22:04:49.54799|2018-05-31 22:04:49.54799
NCT01451073|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2012-02-28|2011-10-12|2011-10-13|Estimate|||||||2012-02-28|2012-02-29|Estimate|January 2009||2009-01-31|February 2012|2012-02-29||||August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss|Completed||Phase 2|33|Actual|Aderans Research Institute|||||f||||f||||||||||2018-05-31 22:04:49.60783|2018-05-31 22:04:49.60783
NCT01451060|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-09-06|2011-10-12|2011-10-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|Vasopressors||Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean|Maternal and Neonatal Outcomes After the Use of Vasopressors to Correct Hypotension During Cesarean Section Under Spinal Anesthesia in Pregnant Women With Severe Preeclampsia: Randomized Clinical Trial|Withdrawn||Phase 3|0|Actual|Instituto Materno Infantil Prof. Fernando Figueira||||We didn't have enough financial support|f||||t||||||||Yes|We don't have data to share|2018-05-31 22:04:49.846428|2018-05-31 22:04:49.846428
NCT01451047|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2012-02-28|2011-10-12|2011-10-13|Estimate|||||||2012-02-28|2012-02-29|Estimate|July 2009||2009-07-31|February 2012|2012-02-29||||April 2011|Actual|2011-04-30||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss|Completed||Phase 2|31|Actual|Aderans Research Institute|||||f||||f||||||||||2018-05-31 22:04:50.10105|2018-05-31 22:04:50.10105
NCT01451034|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-10-12|2011-10-12|2011-10-13|Estimate|||||||2011-10-12|2011-10-13|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion|Clinical Outcomes of Endoscopic Resection for Treating Extremely Well Differentiated Intestinal-type Adenocarcinoma (WHYX Lesion)|Completed||Phase 4|872|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 22:04:50.208466|2018-05-31 22:04:50.208466
NCT01451021|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2012-02-28|2011-10-11|2011-10-13|Estimate|||||||2012-02-28|2012-02-29|Estimate|October 2008||2008-10-31|February 2012|2012-02-29||||June 2010|Actual|2010-06-30||Interventional|||A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss|A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss|Completed||Phase 2|21|Actual|Aderans Research Institute|||||f||||f||||||||||2018-05-31 22:04:50.281077|2018-05-31 22:04:50.281077
NCT01451008|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2013-07-05|2011-10-10|2011-10-13|Estimate|||||||2013-07-05|2013-07-08|Estimate|June 2009||2009-06-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Compression Anastomosis Using the Compression Anastomotic Ring-locking Procedure (CARP)|Safety Study of Compression Anastomotic Ring-locking Procedure (CARP) in Patients Undergoing Colonic Resection|Completed||Phase 1|25|Actual|Region Skane|||||f||||t||||||||||2018-05-31 22:04:50.421837|2018-05-31 22:04:50.421837
NCT01450995|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-10-10|2011-10-10|2011-10-13|Estimate|||||||2011-10-10|2011-10-13|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex|Open-label, 6 Month Crossover Study Evaluating Migraine Patient Satisfaction Comparing Treximet to 2 Aleve and 100mg Imitrex Taken Concomitantly|Completed||Phase 4|50|Actual|Wesley Headache Clinic||2|||f||||t||||||||||2018-05-31 22:04:50.538015|2018-05-31 22:04:50.538015
NCT01450982|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2013-05-03|2011-10-11|2011-10-13|Estimate|||||||2013-05-03|2013-05-06|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|||||Interventional|||A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants|A Study to Investigate the Effects of JNJ-38518168 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Participants on a Stable Methotrexate Dose|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 22:04:50.620005|2018-05-31 22:04:50.620005
NCT01450969|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2014-09-23|2011-10-12|2011-10-13|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|PREFER||New Fabric Attenuation Device in Endovascular Interventional Radiology (PREFER)|Prospective Randomized Evaluation of a New Fabric Attenuation Device in Endovascular Interventional Radiology (PREFER)|Completed|||60|Actual|Baptist Health South Florida|||1||f||||f||||||||||2018-05-31 22:04:50.699247|2018-05-31 22:04:50.699247
NCT01450956|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2011-11-24|2011-10-12|2011-10-13|Estimate|||||||2011-11-24|2011-11-28|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||The Protective Effects of Sevoflurane in Pediatric Cardiac Surgery|The Protective Effects of Sevoflurane Application During CPB on Pediatric Patients Underwent Cardiac Surgery: a Randomized, Controlled, Blinded Clinical Trial|Unknown status|Recruiting|N/A|100|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 22:04:50.785072|2018-05-31 22:04:50.785072
NCT01450943|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2018-05-10|2011-10-12|2011-10-13|Estimate|||||||2018-05-10|2018-05-16|Actual|October 1, 2011|Actual|2011-10-01|May 2018|2018-05-31|April 4, 2018|Actual|2018-04-04|December 14, 2017|Actual|2017-12-14||Interventional|DOLCE||VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic|A Comparative Efficacy Study: Treatments of Non-Healing Diabetic Foot Ulcers|Completed||Phase 2|169|Actual|VA Office of Research and Development||3|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 22:04:50.946796|2018-05-31 22:04:50.946796
NCT01450930|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-07-31|2011-10-12|2011-10-13|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PHYSCA||Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency|Pharmacokinetics of Hydrocortisone After Subcutaneous Administration Compared With Intramuscular Injection in Chronic Adrenal Insufficiency|Completed||Phase 2|12|Actual|University of Wuerzburg||2|||f||||t||||||||||2018-05-31 22:04:51.108908|2018-05-31 22:04:51.108908
NCT01450917|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2011-10-10|2011-10-10|2011-10-12|Estimate|||||||2011-10-10|2011-10-12|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Diaphragmatic Height Index: the New Diagnostic Test for Phrenic Nerve Dysfunction|Diaphragmatic Height Index: the New Diagnostic Test for Phrenic Nerve Dysfunction|Completed|||245|Actual|Mahidol University|||3||f||||f||||||||||2018-05-31 22:04:51.201072|2018-05-31 22:04:51.201072
NCT01450904|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-10|2011-10-10|2011-10-12|Estimate|||||||2011-10-10|2011-10-12|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Recovery Time of Quadriceps Strength After Total Knee Arthroplasty (TKA): The Effect of Quadriceps Incision Length|The Recovery Time of Quadriceps Strength After Total Knee Arthroplasty: The Effect of Quadriceps Incision Length|Completed||N/A|60|Actual|Mahidol University||3|||f||||f||||||||||2018-05-31 22:04:51.264403|2018-05-31 22:04:51.264403
NCT01450891|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2015-05-27|2011-10-10|2011-10-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease|Novel Diagnostic Approaches for the Diagnosis of Alzheimer's Disease: Technology Assessment and Clinical Effectiveness|Completed|||304|Actual|Maastricht University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Cerebrospinal fluid~   "|||2018-05-31 22:04:51.373492|2018-05-31 22:04:51.373492
NCT01450878|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-09-02|2011-10-11|2011-10-12|Estimate|||||||2016-09-02|2016-09-05|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|FRETEP||Renal Graft Function After Treatment With Erythropoietin (EPO)|Interest of a High Dose of Erythropoietin Administered During Graft Processing for Early Graft Outcome in Kidney Transplant Recipients.|Terminated||Phase 3|6|Actual|University Hospital, Limoges||2||Lack of patients eligible for the study.|f||||f||||||||||2018-05-31 22:04:51.525817|2018-05-31 22:04:51.525817
NCT01450865|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2015-01-12|2011-10-10|2011-10-12|Estimate|||||||2015-01-12|2015-01-13|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo|Evaluation of the Effect of the K+-Channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo: a Randomised Controlled Trial|Completed||Phase 1|20|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 22:04:51.67614|2018-05-31 22:04:51.67614
NCT01450852|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-10|2011-10-10|2011-10-12|Estimate|||||||2011-10-10|2011-10-12|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Strength Training Induced Alterations in Markers of Immune Function|Strength Training Induced Alterations in Markers of Immune Function|Completed||N/A|42|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f||||||||||2018-05-31 22:04:51.809997|2018-05-31 22:04:51.809997
NCT01450839|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2012-05-30|2011-10-11|2011-10-12|Estimate|||||||2012-05-30|2012-06-01|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||E2022 Patch Formulation Multiple Dose Study|E2022 Patch Formulation Multiple Dose Phase I Study|Completed||Phase 1|16|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:04:51.991583|2018-05-31 22:04:51.991583
NCT01450826|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2018-02-12|2011-10-11|2011-10-12|Estimate|||||||2018-02-12|2018-02-14|Actual|June 24, 2014|Actual|2014-06-24|February 2018|2018-02-28|April 21, 2017|Actual|2017-04-21|April 13, 2017|Actual|2017-04-13||Interventional|||Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide|A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen|Completed||Phase 2|136|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 22:04:52.09367|2018-05-31 22:04:52.09367
NCT01450813|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2016-03-10||2017-04-04|2011-10-11|2011-10-12|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|June 2009||2009-06-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy|The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy|Completed||N/A|80|Actual|Medtronic - MITG|Sample size for this study calculation was based upon the assumption that that the expected mean of CVI would be 60 with a variance of 30 and that the variance of 30 would be equal for each group.|4|||f||||t||||||||No|Data collected was for device algorithm development|2018-05-31 22:04:52.2491|2018-05-31 22:04:52.2491
NCT01450800|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2013-09-30||2016-12-23|2011-10-11|2011-10-12|Estimate|2014-03-31|2014-05-01|Estimate||||2016-12-23|2017-02-13|Actual|August 2011||2011-08-31|December 2016|2016-12-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|STOPP UTI|163 participants were randomized, 82 to nitrofurantoin and 81 to placebo. Four randomized participants were excluded from the final analysis. One in the placebo group was excluded, as she had previously been included in the study during a prior surgery. Three participants in the nitrofurantoin group were excluded due to protocol deviations.|Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)|Antibiotic Prophylaxis for Urinary Tract Infection in Patients Requiring Catheterization After Urogynecologic Surgery|Completed||Phase 4|163|Actual|Duke University|Limitations of our study include recall bias and selection bias. Our findings have limited applicability to elderly patients undergoing pelvic reconstructive surgery.|2|||f||||t||||||||||2018-05-31 22:04:52.587452|2018-05-31 22:04:52.587452
NCT01450787|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2013-03-09||2013-08-08|2011-10-11|2011-10-12|Estimate|2013-08-08|2013-09-30|Estimate||||2013-08-08|2013-09-30|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics|Prevalence of Dry Eyes in Diabetics Compared to Non Diabetics|Terminated|||63|Actual|COA Research Foundation, INC|||2|Principle investigator changed practice location and discontinued study|f||||f||||||||||2018-05-31 22:04:52.892813|2018-05-31 22:04:52.892813
NCT01450774|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2017-03-28|2011-10-10|2011-10-12|Estimate|||||||2017-03-28|2017-03-29|Actual|September 2011||2011-09-30|March 2017|2017-03-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children|A Single Centre, Randomised, Double-blind, Double-dummy, 2-way Cross Over Study to Compare Safety Assessed by Knemometry and Urinary Cortisol Measurements of CHF1535 50/6 Pmdi (Fixed Combination of Beclomethasone Dipropionate and Formoterol Fumarate) and the Free Combination of Licensed Beclomethasone Dipropionate and Formoterol Fumarate in Asthmatic Children Already Treated With Inhaled Corticosteroids|Completed||Phase 3|72|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 22:04:53.32492|2018-05-31 22:04:53.32492
NCT01450761|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2016-03-07||2017-06-14|2011-10-11|2011-10-12|Estimate|2016-06-07|2016-07-18|Estimate||||2017-06-14|2017-07-11|Actual|December 2011|Actual|2011-12-31|June 2016|2016-06-30|May 17, 2017|Actual|2017-05-17|March 2015|Actual|2015-03-31||Interventional||All randomized participants who received at least one dose of blinded study therapy|Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone|Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)|Completed||Phase 3|1414|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 22:04:53.545057|2018-05-31 22:04:53.545057
NCT01450748|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2015-06-03|2011-10-11|2011-10-12|Estimate|||||||2015-06-03|2015-06-08|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Alginos Oral Suspension (Sodium Alginate 50 mg/ml) for the Treatment of Patients With Laryngopharyngeal Reflux (LPR)|Completed||Phase 3|80|Actual|TTY Biopharm||2|||f||||t||||||||||2018-05-31 22:04:55.051229|2018-05-31 22:04:55.051229
NCT01450735|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-01-13|2011-10-07|2011-10-12|Estimate|||||||2013-01-13|2013-01-15|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of the MANOS Carpal Tunnel Release System in Patients With Carpal Tunnel Syndrome||Terminated||N/A|100|Anticipated|Thayer Intellectual Property, Inc.||||"Enrollment did not reach our intended sample size due to availability of CTR with MANOS outside~   of the study."|f||||t||||||||||2018-05-31 22:04:55.120296|2018-05-31 22:04:55.120296
NCT01450722|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2018-03-15|2011-10-11|2011-10-12|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2011||2011-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|finnptx||Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery|Paclitaxel Eluting Stent in Long Superficial Femoral Artery Obstruction: a Prospective, Randomized Comparison With Bypass Surgery Using PTFE Graft in a Finnish Multicenter Study|Recruiting||Phase 3|400|Anticipated|Kuopio University Hospital||2|||f||||t||||||||||2018-05-31 22:04:55.177275|2018-05-31 22:04:55.177275
NCT01450709|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-05-02|2011-10-10|2011-10-12|Estimate|||||||2012-05-02|2012-05-03|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Observational|||Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis|Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment|Unknown status|Recruiting||30|Anticipated|Kibow Biotech Inc.|||1||f||||t||||||Samples With DNA|"~     Blood serum, plasma and lymphocytes.~   "|||2018-05-31 22:04:55.254184|2018-05-31 22:04:55.254184
NCT01450696|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2016-10-05||2016-10-05|2011-10-10|2011-10-12|Estimate|2016-10-05|2016-11-28|Estimate||||2016-10-05|2016-11-28|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|HELOISE|The Full Analysis Set (FAS) population included all participants who were randomized in this study.|A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer|A Randomized, Open Label, Multicenter Phase IIIb Study Comparing Two Trastuzumab Dosing Regimens, Each in Combination With Cisplatin/Capecitabine Chemotherapy, as First-Line Therapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Adenocarcinoma Who Have Not Received Prior Treatment for Metastatic Disease|Terminated||Phase 3|296|Actual|Hoffmann-La Roche|Trial was stopped for futility based on pre-planned interim analysis results.|2||futility following planned interim analysis|f||||||||||||||2018-05-31 22:04:55.35235|2018-05-31 22:04:55.35235
NCT01450683|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2014-08-29||2017-03-13|2011-10-07|2011-10-12|Estimate|2014-08-29|2014-09-08|Estimate||||2017-03-13|2017-04-11|Actual|September 2010||2010-09-30|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Castrate-resistant Prostate Cancer Patients|Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy|A Phase 2 Study of Itraconazole in Castrate-resistant Prostate Cancer Post-chemotherapy|Terminated||Phase 2|4|Actual|Stanford University||1||Low accrual|f||||t||||||||||2018-05-31 22:04:56.238371|2018-05-31 22:04:56.238371
NCT01450670|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-05-02|2011-10-10|2011-10-12|Estimate|||||||2012-05-02|2012-05-03|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Observational|||Observational Study of Kibow Biotics in Dialysis Patients|Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Dialysis Patients, in Conjunction With Standardized Care of Treatment|Unknown status|Recruiting||30|Anticipated|Kibow Biotech Inc.|||1||f||||t||||||Samples With DNA|"~     Blood serum and plasma.~   "|||2018-05-31 22:04:56.430631|2018-05-31 22:04:56.430631
NCT01450657|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2017-08-15|2011-10-10|2011-10-12|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2011||2011-07-31|August 2017|2017-08-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Observational Study of Kibow Biotics in Chronic Kidney Failure Patients|Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Chronic Kidney Failure Patients, in Conjunction With Standardized Care of Treatment|Completed|||31|Actual|Kibow Biotech Inc.|||1||f||||t||||||Samples With DNA|"~     Blood plasma and serum~   "|||2018-05-31 22:04:56.53638|2018-05-31 22:04:56.53638
NCT01450644|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2011-12-07|2011-10-11|2011-10-12|Estimate|||||||2011-12-07|2011-12-08|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|H2H-ILD||Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease|A Fast-track Randomised Controlled Trial to Evaluate a Hospital2Home Palliative Care Service for Patients With Advanced Progressive Idiopathic Fibrotic Interstitial Lung Disease|Unknown status|Recruiting|Phase 2|52|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:04:56.640123|2018-05-31 22:04:56.640123
NCT01450631|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2014-07-03||2017-06-15|2011-10-11|2011-10-12|Estimate|2014-07-03|2014-08-01|Estimate||||2017-06-15|2017-07-12|Actual|February 2012||2012-02-29|June 2017|2017-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions|A Prospective, Randomized, Evaluation of the Prevena™ Incision Management System on Closed Incisions in Obese Subjects Undergoing Cesarean Section Surgery|Completed||N/A|92|Actual|KCI USA, Inc.||2|||f||||f||||||||||2018-05-31 22:04:56.865481|2018-05-31 22:04:56.865481
NCT01450618|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2012-12-04|2011-10-11|2011-10-12|Estimate|||||||2012-12-04|2012-12-05|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Observational|||Comparative Tolerability of Protease Inhibitors|Comparative Tolerability of Protease Inhibitors and the Associated Impact on Persistence, Healthcare Utilization, and Healthcare Costs|Completed|||26000|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 22:04:57.276051|2018-05-31 22:04:57.276051
NCT01450605|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-04-20|2011-10-10|2011-10-12|Estimate|||||||2016-04-20|2016-04-21|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Korean Post-marketing Surveillance for Reyataz®|Korean Post-marketing Surveillance for Reyataz®|Completed|||601|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 22:04:57.330727|2018-05-31 22:04:57.330727
NCT01450592|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2013-12-26|2011-10-10|2011-10-12|Estimate|||||||2013-12-26|2013-12-30|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|STARCH||Study To Assess the Dietary Carbohydrate Content of Indian Diabetic Population|Epidemiological Study to Evaluate the Dietary Composition of Indian Type-2 Diabetic Patients Compared to Non-diabetic Population|Completed|||796|Actual|Bayer|||2||f||||f||||||||||2018-05-31 22:04:57.394279|2018-05-31 22:04:57.394279
NCT01450579|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2017-09-27|2011-10-11|2011-10-12|Estimate|||||||2017-09-27|2017-09-29|Actual|July 2011||2011-07-31|September 2017|2017-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers|Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults|Completed||Phase 2|180|Actual|UMN Pharma Inc.||4|||f||||f||||||||||2018-05-31 22:04:57.462108|2018-05-31 22:04:57.462108
NCT01450566|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-11-05|2011-10-11|2011-10-12|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Intraureteral Lidocaine for Post-Ureteroscopy Pain|Intraureteral of Alkalinized Lidocaine as Novel Approach to Post-Ureteroscopy Pain: Double-blind Prospective Randomized Controlled Trial|Unknown status|Recruiting|N/A|48|Anticipated|Queen's University||2|||f||||f||||||||||2018-05-31 22:04:57.52837|2018-05-31 22:04:57.52837
NCT01450553|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2012-01-09|2011-10-07|2011-10-12|Estimate|||||||2012-01-09|2012-01-11|Estimate|October 2011||2011-10-31|January 2012|2012-01-31||||||||Observational|||Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease|Research and Development Study: Tissue Collection From Patients Who Are Undergoing Surgery for Non-Small Cell Lung Cancer|Unknown status|Recruiting||450|Anticipated|Precision Therapeutics|||||f||||f||||||Samples With DNA|"~     Human tumor tissues will be collected and preserved in three different tissue formats:~        -  Fresh Frozen~        -  FFPE~        -  RNAlater~   "|||2018-05-31 22:04:57.628743|2018-05-31 22:04:57.628743
NCT01450540|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2018-01-11|2011-10-11|2011-10-12|Estimate|||||||2018-01-11|2018-01-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:04:57.771915|2018-05-31 22:04:57.771915
NCT01450527|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2013-01-12|2011-10-11|2011-10-12|Estimate|||||||2013-01-12|2013-01-15|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Etiology and Outcomes of Tropical Acute Respiratory Distress Syndrome|Etiology and Outcomes of Acute Respiratory Distress Syndrome in Medical ICU in AIIMS|Completed|||64|Actual|All India Institute of Medical Sciences, New Delhi|||1||f||||f||||||||||2018-05-31 22:04:57.809689|2018-05-31 22:04:57.809689
NCT01450514|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2014-11-18|2011-10-11|2011-10-12|Estimate|||||||2014-11-18|2014-11-19|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia|POC Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks|Completed||Phase 2|7|Actual|PharmaNeuroBoost N.V.||2|||f||||f||||||||||2018-05-31 22:04:57.874342|2018-05-31 22:04:57.874342
NCT01450501|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-07-22|2011-10-10|2011-10-12|Estimate|||||||2013-07-22|2013-07-23|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|QAAD||Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)|Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)|Unknown status|Active, not recruiting||999|Anticipated|Jeroen Bosch Ziekenhuis|||1||f||||f||||||Samples With DNA|"~     Blood and tissue will be investigated using Polymerase Chain Reaction. Serology for~     C.burnetii will be investigated in blood using Immunofluorecense assay (focus diagnostics).~   "|||2018-05-31 22:04:57.950455|2018-05-31 22:04:57.950455
NCT01450488|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-10|2011-10-10|2011-10-12|Estimate|||||||2011-10-10|2011-10-12|Estimate|June 2005||2005-06-30|October 2011|2011-10-31|January 2010|Actual|2010-01-31|July 2007|Actual|2007-07-31||Interventional|||Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS)|A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis|Completed||Phase 2|35|Actual|AB Science||2|||f||||f||||||||||2018-05-31 22:04:58.028121|2018-05-31 22:04:58.028121
NCT01450475|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2013-07-22|2011-10-11|2011-10-12|Estimate|||||||2013-07-22|2013-07-24|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study of Remote Ischemic Postconditioning|A Randomized Control Trial of Effect of Remote Ischemic Postconditioning on Children Undergoing Cardiac Surgery|Completed||Phase 1|65|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 22:04:58.085711|2018-05-31 22:04:58.085711
NCT01450462|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2013-12-03|2011-10-11|2011-10-12|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|DASH||Vitamin D and Sexual Health|Vitamin D and Sexual Health (the DASH Study)|Completed||N/A|118|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 22:04:58.146875|2018-05-31 22:04:58.146875
NCT01450449|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2015-03-23|2011-10-10|2011-10-12|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional|||Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme|A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 3|115|Actual|International Atomic Energy Agency||2|||f||||t||||||||||2018-05-31 22:04:58.212673|2018-05-31 22:04:58.212673
NCT01450436|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-11-16|2011-10-11|2011-10-12|Estimate|||||||2012-11-16|2012-11-19|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Observational|EPIPOD||Impact of Preterm Body Composition at Discharge on 2 Years Neurological Development (ASQ Evaluation)|Impact of Preterm Body Composition at Discharge on 2 Years Neurological Development (ASQ Evaluation)|Unknown status|Recruiting||189|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 22:04:58.434964|2018-05-31 22:04:58.434964
NCT01450423|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2011-10-09|2011-10-09|2011-10-12|Estimate|||||||2011-10-09|2011-10-12|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|EFA||Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy|Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Aged 15-50: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Southern Denmark||2|||f||||||||||||||2018-05-31 22:04:58.551273|2018-05-31 22:04:58.551273
NCT01450410|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2013-01-28|2011-10-11|2011-10-12|Estimate|||||||2013-01-28|2013-01-29|Estimate|July 2012||2012-07-31|November 2011|2011-11-30|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|11MSP011||Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL|Efecto Del ácido nicotínico Sobre la composición de Las lipoproteínas de Alta Densidad (HDL) y la función Del Endotelio Arterial en Los Pacientes Con cardiopatía isquémica Prematura y Concentraciones Elevadas de Colesterol-HDL|Terminated||Phase 4|12|Actual|Hospital Universitari de Bellvitge||2||Study terminated (halted prematurely) as recomended by the drug supplier and medical agencies|f||||t||||||||||2018-05-31 22:04:58.678618|2018-05-31 22:04:58.678618
NCT01450397|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|2013-10-29||2017-03-20|2011-10-11|2011-10-12|Estimate|2014-04-14|2014-05-15|Estimate||||2017-03-20|2017-04-17|Actual|March 2011||2011-03-31|March 2017|2017-03-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex|MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex|Completed||Phase 4|5|Actual|Hospital for Special Surgery, New York||1|||f||||f||||||||||2018-05-31 22:04:58.771328|2018-05-31 22:04:58.771328
NCT01450384|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2016-02-19|2011-10-11|2011-10-12|Estimate|||||||2016-02-19|2016-02-23|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors|Phase I Study of Pemetrexed and Sorafenib in Advanced Malignancy|Completed||Phase 1|37|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 22:04:58.927765|2018-05-31 22:04:58.927765
NCT01450371|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2013-01-23|2011-10-10|2011-10-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|InterM||Interferential Electrical Stimulation and Vasodilatation in Healthy Individuals|Interferential Electrical Stimulation Improves Peripheral Vasodilatation in Healthy Individuals: A Randomized Crossover Study|Completed|||11|Actual|Hospital de Clinicas de Porto Alegre|||2||f||||f||||||||||2018-05-31 22:04:59.026338|2018-05-31 22:04:59.026338
NCT01450358|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-10|||2016-06-07|2011-10-10|2011-10-12|Estimate|||||||2016-06-07|2016-06-09|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture.|Evaluation of Antimicrobial Use and Time of Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction (PCR) in Real Time Multiplex to the Conventional Blood Culture for Etiologic Agents Identification. Randomized Clinical Trial.|Completed||Phase 4|200|Actual|Instituto do Coracao||2|||f||||f||||||||||2018-05-31 22:04:59.110455|2018-05-31 22:04:59.110455
NCT01450345|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2011-10-11|2011-10-11|2011-10-12|Estimate|||||||2011-10-11|2011-10-12|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Efficacy of Pre-operative Oral Pregabalin in Ambulatory Inguinal Hernia Repair for Post Operative Pain|Efficacy of Pre-operative Oral Pregabalin in Ambulatory Inguinal Hernia Repair for Post Operative Pain|Unknown status|Recruiting|Phase 3|72|Anticipated|University of Malaya||1|||f||||f||||||||||2018-05-31 22:04:59.189334|2018-05-31 22:04:59.189334
NCT01450332|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2011-10-11|2011-10-11|2011-10-12|Estimate|||||||2011-10-11|2011-10-12|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Safety and Efficacy of the Knee-T-nol Anterior Cruciate Ligament (ACL) Prosthesis|A Single Arm, Prospective, Single Center, Study To Evaluate The Safety And Efficacy Of Tavor ACL Prosthesis In Patient With ACL Rupture|Unknown status|Recruiting|N/A|20|Anticipated|Tavor Ltd.||1|||f||||t||||||||||2018-05-31 22:04:59.289372|2018-05-31 22:04:59.289372
NCT01450319|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|2016-05-10||2016-10-07|2011-10-07|2011-10-12|Estimate|2016-05-10|2016-06-15|Estimate||||2016-10-07|2016-11-28|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MUTEX|MITT analysis set included all the subjects who received study drug treatment.|Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype|Phase II Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favourable FcγR IIa (CD32) Genotype|Completed||Phase 2|73|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 22:04:59.380238|2018-05-31 22:04:59.380238
NCT01450306|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2012-05-24||2016-03-25|2011-10-11|2011-10-12|Estimate|2016-03-25|2016-04-21|Estimate||||2016-03-25|2016-04-21|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics|Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics|Completed||N/A|20|Actual|Hartford Hospital||2|||f||||t||||||||Yes|De-identified data will be made available upon request|2018-05-31 22:04:59.779381|2018-05-31 22:04:59.779381
NCT01450293|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2013-12-11|2011-10-11|2011-10-12|Estimate|||||||2013-12-11|2013-12-12|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area|Safety and Immunogenicity of Heterologous Prime-boost Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Infants in a Malaria- Endemic Area|Completed||Phase 1|72|Actual|University of Oxford||6|||f||||t||||||||||2018-05-31 22:05:00.114595|2018-05-31 22:05:00.114595
NCT01450280|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-11-28|2011-10-07|2011-10-12|Estimate|||||||2012-11-28|2012-11-29|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS|A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and With MVA CS|Completed||Phase 1|24|Actual|University of Oxford||4|||f||||t||||||||||2018-05-31 22:05:00.192924|2018-05-31 22:05:00.192924
NCT01450267|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2011-10-12|2011-10-09|2011-10-12|Estimate|||||||2011-10-12|2011-10-13|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|May 2012|Anticipated|2012-05-31||Interventional|||Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis|Randomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cystic Fibrosis|Unknown status|Recruiting|Phase 3|150|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||||2018-05-31 22:05:00.269371|2018-05-31 22:05:00.269371
NCT01450254|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-07-06|2011-10-10|2011-10-12|Estimate|||||||2015-07-06|2015-07-07|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Foot Center of Pressure Manipulation on Hip Osteoarthritis Patients During Gait|Effects of Foot Center of Pressure Manipulation on Hip Biomechanics, Muscle Activation Patterns, and Energy Consumption During Gait in Hip Osteoarthritis Patients|Completed||N/A|14|Actual|HaEmek Medical Center, Israel||2|||f||||||||||||||2018-05-31 22:05:00.430282|2018-05-31 22:05:00.430282
NCT01450241|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2013-06-06|2011-10-09|2011-10-12|Estimate|||||||2013-06-06|2013-06-07|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia|Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia: Randomized-controlled Trial|Withdrawn||N/A|0|Actual|Rabin Medical Center||2||slow recruitment, no funding|f||||t||||||||||2018-05-31 22:05:00.530285|2018-05-31 22:05:00.530285
NCT01450228|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2012-04-23|2011-10-11|2011-10-12|Estimate|||||||2012-04-23|2012-04-24|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients|A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Phase III Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in ≥ 55 Years Old Insomnia Patients|Completed||Phase 3|170|Actual|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:05:00.630818|2018-05-31 22:05:00.630818
NCT01450215|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-03-24|2011-10-09|2011-10-12|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 2011||2011-03-31|March 2016|2016-03-31||||January 2016|Actual|2016-01-31||Interventional|||Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma||Completed||Phase 2|62|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 22:05:00.719606|2018-05-31 22:05:00.719606
NCT01450202|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2012-06-24|2011-10-11|2011-10-12|Estimate|||||||2012-06-24|2012-06-26|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|COCE||Safety and Efficacy of Carbon Dioxide Insufflation During Colonoscopy With Consecutive Esophagogastroduodenoscopy in Reduction of Abdominal Pain in Sedated Outpatients|Carbon Dioxide Insufflation During Colonoscopy With Consecutive EGD is Safe and Decreases Abdominal Pain in Sedated Outpatients: a Randomized, Double-blind, Controlled Trial|Completed||Phase 3|100|Actual|Inje University||2|||f||||f||||||||||2018-05-31 22:05:00.799507|2018-05-31 22:05:00.799507
NCT01450189|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|2016-01-13||2018-04-17|2011-10-07|2011-10-12|Estimate|2016-05-10|2016-05-12|Estimate||||2018-04-17|2018-04-19|Actual|October 2011||2011-10-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MP3||A Key Link for Transmission Prevention|Acute HIV Infection - A Key Link for Transmission Prevention: A Randomized Pilot Study|Completed||N/A|46|Actual|University of North Carolina, Chapel Hill|Please note that this trial was a pilot study.|3|||f||||t||||||||||2018-05-31 22:05:00.91659|2018-05-31 22:05:00.91659
NCT01450176|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2014-01-08|2011-10-11|2011-10-12|Estimate|||||||2014-01-08|2014-01-09|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Comparing Patient Satisfaction With Pataday or Bepreve|Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID|Completed||N/A|30|Actual|McCabe Vision Center||2|||f||||f||||||||||2018-05-31 22:05:01.872611|2018-05-31 22:05:01.872611
NCT01449292|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-11-13|2011-10-07|2011-10-10|Estimate|||||||2013-11-13|2013-11-14|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ASPIRE||Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)|Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)|Terminated||Phase 3|300|Anticipated|Aeris Therapeutics||2|||f||||t||||||||||2018-05-31 22:05:39.182921|2018-05-31 22:05:39.182921
NCT01450163|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2017-05-08|2011-10-11|2011-10-12|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2011|Actual|2011-08-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|PreOx||Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy|PHASE III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin in Prevention and Reduction of Oxaliplatin-induced Painful Neuropathy|Completed||Phase 3|200|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:05:02.018414|2018-05-31 22:05:02.018414
NCT01450150|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2016-01-19|2011-10-11|2011-10-12|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression|Transcranial Direct Current Stimulation (tDCS) as an Augmenting Intervention for Treatment-Resistant Major Depression: A Randomized, Double-Blind and Sham-Controlled Trial|Not yet recruiting||Phase 2/Phase 3|30|Anticipated|Douglas Mental Health University Institute||2|||f||||f||||||||||2018-05-31 22:05:02.240374|2018-05-31 22:05:02.240374
NCT01450137|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-09-23|2011-10-11|2011-10-12|Estimate|||||||2015-09-23|2015-09-24|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Interventional|||Tocilizumab for Patients With Giant Cell Arteritis|A Phase II, Randomized, Double-blind, Placebo Controlled Study of Tocilizumab in Patients With Giant Cell Arteritis|Completed||Phase 2|30|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 22:05:02.345083|2018-05-31 22:05:02.345083
NCT01450124|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2015-03-16|2011-10-07|2011-10-12|Estimate|||||||2015-03-16|2015-03-17|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SABA||Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)|Safety, Tolerability And Mechanism Of Action Of Boswellic Acids In Multiple Sclerosis and Clinically Isolated Syndrome: A MRI-Controlled, Multicenter, Baseline-To-Treatment, 32-Weeks, Open-Label, Phase IIa Trial|Completed||Phase 2|29|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||t||||||||||2018-05-31 22:05:02.456566|2018-05-31 22:05:02.456566
NCT01450111|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2011-10-13|2011-10-07|2011-10-12|Estimate|||||||2011-10-13|2011-10-14|Estimate|November 2008||2008-11-30|October 2011|2011-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects|Single-site, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single/Repeated Dose Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects|Completed||Phase 1|51|Actual|UCB Pharma||6|||f||||f||||||||||2018-05-31 22:05:02.562159|2018-05-31 22:05:02.562159
NCT01450098|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2012-01-12|2011-10-07|2011-10-12|Estimate|||||||2012-01-12|2012-01-16|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of LY2484595 in Healthy Subjects|Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects|Completed||Phase 1|45|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:05:02.674563|2018-05-31 22:05:02.674563
NCT01450085|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2017-08-15|2011-10-11|2011-10-12|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2012||2012-09-30|August 2017|2017-08-31|December 30, 2016|Actual|2016-12-30|December 2016|Actual|2016-12-31||Interventional|||Chepetsa TB - Reducing TB Among HIV-Infected Malawians|Impact of a New Molecular Tuberculosis (TB) Test on TB/HIV Outcomes Among HIV-|Completed||N/A|1200|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 22:05:02.785324|2018-05-31 22:05:02.785324
NCT01450072|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2016-05-10|2011-10-07|2011-10-12|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|PREMiSE||Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE|Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE|Completed||Phase 2|20|Actual|University at Buffalo Neurosurgery||2|||f||||t||||||||||2018-05-31 22:05:02.874053|2018-05-31 22:05:02.874053
NCT01450059|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2016-02-19|2011-10-11|2011-10-12|Estimate|||||||2016-02-19|2016-02-22|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|April 2014|Actual|2014-04-30||Observational|||Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section|Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section|Completed|||54|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     Umbilical Cord blood Blood from peripheral vene~   "|||2018-05-31 22:05:02.963296|2018-05-31 22:05:02.963296
NCT01450046|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2016-07-05|2011-10-11|2011-10-12|Estimate|||||||2016-07-05|2016-07-07|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2013|Actual|2013-03-31||Interventional|||Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects|A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Multiple Dose Administration in Healthy Subjects|Completed||Phase 1|18|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 22:05:03.075878|2018-05-31 22:05:03.075878
NCT01450033|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-05-11|2011-10-07|2011-10-12|Estimate|||||||2018-05-11|2018-05-16|Actual|September 2011||2011-09-30|May 2018|2018-05-31|March 29, 2017|Actual|2017-03-29|January 2017|Actual|2017-01-31||Interventional|Peers4PATH||Peers for Promoting Adolescent Transplant Health|A Peer Mentoring Intervention to Improve Adherence and Quality of Life in Adolescents With Solid Organ Transplants|Completed||N/A|74|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 22:05:03.167063|2018-05-31 22:05:03.167063
NCT01450020|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-03-06|2011-10-11|2011-10-12|Estimate|||||||2018-03-06|2018-03-07|Actual|June 1, 2012||2012-06-01|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors|Sister Survivor: Improving the Survivorship Care of African-American Women With Breast Cancer|Active, not recruiting||N/A|145|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 22:05:03.248487|2018-05-31 22:05:03.248487
NCT01450007|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|2016-04-11||2016-05-16|2011-10-07|2011-10-10|Estimate|2016-04-11|2016-05-17|Estimate||||2016-05-16|2016-06-17|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery|Perineural Versus Systemic Dexamethasone as an Analgesic Adjunct to Ultrasound-Guided Ropivacaine Interscalene Blockade in Arthroscopic Rotator Cuff Repair|Completed||Phase 4|130|Actual|Mayo Clinic|Although it was designed to have 80% power at 120 patients, double this number would be required to detect very small differences (<10%) in the systemic and perineural groups.|3|||f||||f||||||||No||2018-05-31 22:05:03.360597|2018-05-31 22:05:03.360597
NCT01449994|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-02-07|2011-10-07|2011-10-10|Estimate|||||||2012-02-07|2012-02-08|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Efficacy of Instrumental Chiropractic Treatment Using Activator Methods for Pain and Dysfunction in Juvenile Athletes|Efficacy of Instrumental Chiropractic Treatment Using Activator Methods for Pain and Dysfunction.A Randomized Placebo-controlled Clinical Study on Juvenile Athletes With Leg Pain|Completed||N/A|26|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 22:05:03.798276|2018-05-31 22:05:03.798276
NCT01449981|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2016-09-12|2011-10-07|2011-10-10|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Interventional|||Development and Testing of Adolescent Twelve-Step Facilitation|Development and Testing of Adolescent Twelve-Step Facilitation|Completed||N/A|59|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:05:03.886042|2018-05-31 22:05:03.886042
NCT01449968|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-04-25|2011-10-07|2011-10-10|Estimate|||||||2014-04-25|2014-04-28|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Observational|UMG||Provision of a Mobile Geriatric Team Extra-Community Hospital|Provision of a Mobile Geriatric Team Extra-Community Hospital in Assessing and Regulating the Hospitalization of Frail Elderly Patients With Complex Medical and Social Situation|Completed|||334|Actual|University Hospital, Grenoble|||2||f||||f||||||||||2018-05-31 22:05:04.034083|2018-05-31 22:05:04.034083
NCT01449955|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2013-06-18||2014-03-01|2011-10-06|2011-10-10|Estimate|2013-12-11|2014-01-30|Estimate||||2014-03-01|2014-03-28|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||Male Veterans with PTSD|Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory|mTOR Kinase as a Therapeutic Target in Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory|Completed||N/A|54|Actual|University of Texas Southwestern Medical Center|Timing of medication administration may not have been optimal and relatively small sample size|2|||f||||t||||||||||2018-05-31 22:05:04.164997|2018-05-31 22:05:04.164997
NCT01449942|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-06|2011-10-06|2011-10-10|Estimate|||||||2011-10-06|2011-10-10|Estimate|May 2009||2009-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|NPC-DZ||Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma|Phase I/II Study of EBV-LMP1 Targeted DNAzyme in Nasopharyngeal Carcinoma|Completed||Phase 1/Phase 2|40|Actual|Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 22:05:04.471208|2018-05-31 22:05:04.471208
NCT01449929|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2013-12-12||2017-12-14|2011-10-06|2011-10-10|Estimate|2014-02-27|2014-03-27|Estimate||||2017-12-14|2018-01-16|Actual|October 31, 2011|Actual|2011-10-31|October 2017|2017-10-31|December 26, 2016|Actual|2016-12-26|April 22, 2013|Actual|2013-04-22||Interventional|FLAMINGO||Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects|A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naïve Adult Subjects|Completed||Phase 3|488|Actual|ViiV Healthcare||2|||f||||f|t|||||||||2018-05-31 22:05:04.801222|2018-05-31 22:05:04.801222
NCT01449916|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2012-06-06|2011-10-06|2011-10-10|Estimate|||||||2012-06-06|2012-06-07|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|SSSP||Simplified Severe Sepsis Protocol in Zambia|Improving Sepsis Diagnosis and Treatment: Simplified Severe Sepsis Protocol (SSSP)|Unknown status|Recruiting|N/A|348|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-05-31 22:05:09.141879|2018-05-31 22:05:09.141879
NCT01449903|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2017-10-30|2011-10-06|2011-10-10|Estimate|||||||2017-10-30|2017-11-01|Actual|January 2012||2012-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Survival of Different Core Build-up Materials|Core Build-up Materials: a Randomized Clinical Study|Recruiting|||300|Anticipated|Heidelberg University|||3||f||||f||||||||||2018-05-31 22:05:09.288265|2018-05-31 22:05:09.288265
NCT01449890|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2015-06-03|2011-10-07|2011-10-10|Estimate|||||||2015-06-03|2015-06-04|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Randomized Trial of Depression Follow-up Care by Email|Randomized Trial of E-mail Follow-up Care After Cognitive Behavioural Treatment for Depression|Completed||N/A|92|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 22:05:09.36639|2018-05-31 22:05:09.36639
NCT01449877|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2016-07-10|2011-10-07|2011-10-10|Estimate|||||||2016-07-10|2016-07-12|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ISROT||Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis|Influence of Trimethoprim-sulfamethoxazole for the Recurrence of Retinochoroiditis Toxoplasma Gondii|Completed||Phase 3|141|Actual|University of Campinas, Brazil||2|||f||||t||||||||Undecided||2018-05-31 22:05:09.519734|2018-05-31 22:05:09.519734
NCT01449864|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2016-09-23|2011-10-07|2011-10-10|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2011||2011-08-31|September 2016|2016-09-30||||June 2013|Actual|2013-06-30||Interventional|||Proton Radiotherapy for Upper Gastrointestinal Malignancies|A Feasibility and Registration Study of Proton Radiotherapy for Upper Gastrointestinal Malignancies|Active, not recruiting||N/A|22|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:05:09.61533|2018-05-31 22:05:09.61533
NCT01449838|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-07-18|2011-10-06|2011-10-10|Estimate|||||||2017-07-18|2017-07-21|Actual|October 23, 2010|Actual|2010-10-23|July 2017|2017-07-31|December 9, 2010|Actual|2010-12-09|December 9, 2010|Actual|2010-12-09||Interventional|||Phase I Study of Colistin Methanesulfonate Sodium|Phase I Study of Colistin Methanesulfonate Sodium (CMS-Na) -A Randomized, Double Blind, Placebo Controlled, Single and Repeat Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CMS-Na in Healthy Japanese Male Subjects -|Completed||Phase 1|22|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:05:09.685438|2018-05-31 22:05:09.685438
NCT01449825|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2014-04-17|2011-10-06|2011-10-10|Estimate|||||||2014-04-17|2014-04-21|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Hepatic Monitoring for Pazopanib|Postmarketing Hepatic Monitoring for Pazopanib Using Observational Databases|Completed|||1|Actual|GlaxoSmithKline|||4||f||||f||||||||||2018-05-31 22:05:09.771906|2018-05-31 22:05:09.771906
NCT01449812|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2017-02-28|2012-07-24|2017-04-13|2011-10-06|2011-10-10|Estimate|2017-04-12|2017-04-13|Actual|2012-07-24|2012-08-01|Estimate|2017-04-13|2017-04-14|Actual|October 1, 2011||2011-10-01|April 2017|2017-04-30|January 16, 2012|Actual|2012-01-16|January 16, 2012|Actual|2012-01-16||Interventional|||Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine|Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) in Healthy Chinese Toddlers|Completed||Phase 3|831|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 22:05:09.902633|2018-05-31 22:05:09.902633
NCT01449799|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2017-07-26|2011-10-06|2011-10-10|Estimate|||||||2017-07-26|2017-07-28|Actual|July 13, 2011|Actual|2011-07-13|July 2017|2017-07-31|September 21, 2011|Actual|2011-09-21|September 21, 2011|Actual|2011-09-21||Interventional|||An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers|A Randomised, Double-blind, Double-dummy, Single Dose, Four Way Cross-over Study to Compare the Pharmacokinetics and Pharmacodynamics of GSK961081 and Fluticasone Propionate When Administered Alone, Concurrently and as a Combination Blend in Healthy Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:05:12.393013|2018-05-31 22:05:12.393013
NCT01449786|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-04-12|2011-10-07|2011-10-10|Estimate|||||||2017-04-12|2017-04-13|Actual|March 14, 2012|Actual|2012-03-14|April 2017|2017-04-30|December 20, 2016|Actual|2016-12-20|February 28, 2014|Actual|2014-02-28||Interventional|||Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy|Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy|Completed||Phase 2|60|Actual|Medical University of Vienna||3|||f||||t|f|f||||||No||2018-05-31 22:05:12.631134|2018-05-31 22:05:12.631134
NCT01449773|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-02-28|2011-10-07|2011-10-10|Estimate|||||||2013-02-28|2013-03-04|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|October 2009|Actual|2009-10-31||Interventional|DBB48||Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes|Effects of N-3 Polyunsaturated Fatty Acids On Chylomicron Secretion And Expression Of Genes That Regulate Intestinal Lipid Metabolism In Men With Type 2 Diabetes|Completed||N/A|12|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:05:12.746714|2018-05-31 22:05:12.746714
NCT01449760|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2014-12-08|2011-10-07|2011-10-10|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Interventional|||Ankle Sprain Rehabilitation With the Wii Balance Board||Unknown status|Active, not recruiting|N/A|90|Actual|University Hospital, Geneva||3|||f||||t||||||||||2018-05-31 22:05:12.83982|2018-05-31 22:05:12.83982
NCT01449747|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2015-08-23||2015-11-10|2011-10-07|2011-10-10|Estimate|2015-11-10|2015-12-14|Estimate||||2015-11-10|2015-12-14|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus|Mechanism of Reduced Response to DPP-4 Inhibitor in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|24|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 22:05:12.983383|2018-05-31 22:05:12.983383
NCT01449734|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2013-02-26||2013-09-04|2011-10-07|2011-10-10|Estimate|2013-09-04|2013-11-11|Estimate||||2013-09-04|2013-11-11|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|November 2012|Actual|2012-11-30|February 2012|Actual|2012-02-29||Observational||Visiting family members|Family Satisfaction (FS) in the Intensive Care Unit|Observational Study of Family Satisfaction in the Intensive Care Unit Using the German-language FS-ICU|Completed|||217|Actual|Center for Sepsis Control and Care, Germany|||||f||||f||||||||||2018-05-31 22:05:13.523369|2018-05-31 22:05:13.523369
NCT01449721|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2016-11-30||2017-10-02|2011-10-07|2011-10-10|Estimate|2017-10-02|2017-10-04|Actual||||2017-10-02|2017-10-04|Actual|September 2011||2011-09-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|||Preemptive Resuscitation for Eradication of Septic Shock|Preemptive Empiric Resuscitation Protocol for the Prevention of Disease Progression in the Treatment of Sepsis|Completed||N/A|142|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-05-31 22:05:13.733416|2018-05-31 22:05:13.733416
NCT01449708|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2015-02-27||2016-02-19|2011-10-07|2011-10-10|Estimate|2016-02-19|2016-03-21|Estimate||||2016-02-19|2016-03-21|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting in Bariatric Surgery|Effect of Intraoperative Anesthetic Management on Postoperative Nausea and Vomiting (PONV) in Bariatric Surgery|Completed||Phase 4|124|Actual|Coastal Anesthesiology Consultants||2|||f||||t||||||||No||2018-05-31 22:05:14.150207|2018-05-31 22:05:14.150207
NCT01449695|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-04-04|2011-10-06|2011-10-10|Estimate|||||||2017-04-04|2017-04-05|Actual|November 2011||2011-11-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Intervention to Improve Medication Adherence in Cardiovascular Patients|Nurse- and Web Based Intervention to Improve Medication Adherence in High Risk Cardiovascular Patients.|Completed||N/A|420|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 22:05:14.577544|2018-05-31 22:05:14.577544
NCT01449682|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2017-04-26||2017-04-26|2011-10-06|2011-10-10|Estimate|2017-04-26|2017-05-31|Actual||||2017-04-26|2017-05-31|Actual|October 2011||2011-10-31|April 2017|2017-04-30|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Interventional|||Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.|Efficacy of an Intravitreal Dexamethasone Implant on Macular Function in Retinal Vein Occlusion Following Treatment With Intravitreal Anti-VEGF Injections.|Completed||Phase 3|10|Actual|Retina Macula Institute||2|||f||||f||||||||||2018-05-31 22:05:14.652253|2018-05-31 22:05:14.652253
NCT01449669|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-02-07|2011-10-06|2011-10-10|Estimate|||||||2014-02-07|2014-02-10|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|April 2013|Actual|2013-04-30||Observational|SSI||Surgical Site Infection Study|Skeletal Muscle and Plasma Concentrations of Cefazolin During Pediatric Cardiac Surgery Utilizing Cardiopulmonary Bypass, Deep Hypothermic Cardiac Arrest, and Modified Ultrafiltration|Completed|||14|Actual|Children's Hospital of Philadelphia|||||f||||t||||||||||2018-05-31 22:05:15.048299|2018-05-31 22:05:15.048299
NCT01449656|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-12-09|2011-10-06|2011-10-10|Estimate|||||||2011-12-09|2011-12-12|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||A Comparison of the Laryngeal Mask Airway (LMA) Proseal and LMA Supreme in Children|A Randomized Trial Comparing the Laryngeal Mask Airway-SupremeTM With the Laryngeal Mask Airway-ProsealTM in Children|Completed|||60|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-05-31 22:05:15.114689|2018-05-31 22:05:15.114689
NCT01449643|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-28|2011-10-07|2011-10-10|Estimate|||||||2011-10-28|2011-10-31|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Influence of Inspiratory Muscular Training (IMT) on Diaphragmatic Mobility in Morbidly Obese|The Influence of Inspiratory Muscular Training on Diaphragmatic Mobility, Lung Function and Quality of Life in Obese Individuals|Completed||N/A|14|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 22:05:15.21688|2018-05-31 22:05:15.21688
NCT01449630|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2012-04-13|2011-10-05|2011-10-10|Estimate|||||||2012-04-13|2012-04-17|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of LY3031207 in Healthy Subjects|A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3031207 in Healthy Subjects|Completed||Phase 1|42|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 22:05:15.321631|2018-05-31 22:05:15.321631
NCT01449617|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-07-16|2011-10-07|2011-10-10|Estimate|||||||2014-07-16|2014-07-17|Estimate|August 2010||2010-08-31|July 2014|2014-07-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Observational|ARS||Residual Platelet Reactivity in Patients on Antiplatelet Therapy After Carotid Angioplasty With Stenting|Observational Study on Predictive Value for Vascular Events of Residual Platelet Aggregation in Patients on Antiplatelet Therapy After Carotid Angioplasty With Stenting|Unknown status|Recruiting||272|Anticipated|Azienda Ospedaliera di Perugia|||1||f||||f||||||Samples Without DNA|"~     Whole blood samples, plasma samples, serum samples, urines.~   "|||2018-05-31 22:05:15.427224|2018-05-31 22:05:15.427224
NCT01449604|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2011-10-06|2011-10-06|2011-10-10|Estimate|||||||2011-10-06|2011-10-10|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Stereotactic Radiation in Vestibular Schwannoma|Randomized Comparison of Steretotactic Radiosurgery and Hypofractionated Steretotactic Radiotherapy in the Treatment of Vestibular Schwannoma|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Ramathibodi Hospital||2|||f||||f||||||||||2018-05-31 22:05:15.598126|2018-05-31 22:05:15.598126
NCT01449591|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-03-24|2011-10-06|2011-10-10|Estimate|||||||2017-03-24|2017-03-28|Actual|September 2011||2011-09-30|March 2017|2017-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients|A Proof of Concept (PoC) Study to Evaluate the Safety, Tolerability, and Efficacy of 12 Week Administration of BFH772 Ointment in Rosacea Patients|Completed||Phase 2|36|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:05:15.707034|2018-05-31 22:05:15.707034
NCT01449578|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2014-11-24|2011-10-07|2011-10-10|Estimate|||||||2014-11-24|2014-11-25|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Dexpramipexole SAD/MAD Study|A Randomized, Blinded, Placebo-Controlled Ascending Dose Study of the Safety and Pharmacokinetics of Dexpramipexole in Healthy Volunteers|Completed||Phase 1|63|Actual|Knopp Biosciences||10|||f||||f||||||||||2018-05-31 22:05:15.830019|2018-05-31 22:05:15.830019
NCT01449565|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2016-04-11|2011-10-06|2011-10-10|Estimate|||||||2016-04-11|2016-04-13|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|TREX||Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)|Extended-Release Naltrexone (XR-NTX, VIVITROL) for the Treatment of Actively-Using Methamphetamine-Dependent Men Who Have Sex With Men|Completed||Phase 2|100|Actual|San Francisco Department of Public Health||2|||f||||t||||||||||2018-05-31 22:05:15.928675|2018-05-31 22:05:15.928675
NCT01449552|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2011-11-04|2011-10-07|2011-10-10|Estimate|||||||2011-11-04|2011-11-07|Estimate|June 2008||2008-06-30|November 2011|2011-11-30|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT|Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.|Completed||N/A|240|Actual|Mahidol University||4|||f||||f||||||||||2018-05-31 22:05:16.111554|2018-05-31 22:05:16.111554
NCT01449539|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2014-11-21||2015-02-20|2011-10-06|2011-10-10|Estimate|2015-02-20|2015-02-23|Estimate||||2015-02-20|2015-02-23|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization|Pilot Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization|Terminated||N/A|8|Actual|University of Arkansas|Study was terminated early because the site that administered the hyperbaric oxygen treatment closed and an alternative site could not be identified. Only four subjects completed the trial.|||"Study was terminated early because the site that administered the hyperbaric oxygen treatment~   closed and an alternative site could not be identified."|f||||t||||||||||2018-05-31 22:05:16.20722|2018-05-31 22:05:16.20722
NCT01449526|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2014-03-28||2015-02-13|2011-10-06|2011-10-10|Estimate|2015-02-13|2015-02-18|Estimate||||2015-02-13|2015-02-18|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional||All Eligible, Dispensed Subjects|A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design|A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design|Completed||N/A|166|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:05:16.379611|2018-05-31 22:05:16.379611
NCT01449513|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2013-10-08||2016-04-04|2011-10-07|2011-10-10|Estimate|2015-05-06|2015-05-27|Estimate||||2016-04-04|2016-05-09|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy|A Phase 1, Two-stage, Single-centre, Open Label, Within- and Between-subject Comparison Trial to Explore the Biological Effects of PEP005 (Ingenol Mebutate) Gel, 0.05%, Applied Once Daily for 2 Consecutive Days in Subjects With Actinic Keratosis on the Upper Extrem-ity. A Single-arm First Stage Followed by a Two-arm, Parallel Group, Randomized, Placebo (Vehicle) -Controlled Second Stage|Completed||Phase 1|24|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 22:05:16.680241|2018-05-31 22:05:16.680241
NCT01449500|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-07|2011-10-07|2011-10-10|Estimate|||||||2011-10-07|2011-10-10|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Supplementation With L. Reuteri in H. Pylori Infected Adults|Effect of Dietary Supplementation With L. Reuteri ProGastria in H. Pylori-infected Adult Subjects Treated Only With Proton Pump Inhibitors|Unknown status|Not yet recruiting|N/A|56|Anticipated|Lama Medical Care s.r.o.||2|||f||||f||||||||||2018-05-31 22:05:17.294694|2018-05-31 22:05:17.294694
NCT01449487|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2014-05-20|2011-10-06|2011-10-10|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid|A Randomized, Double-blind, Cross-over Trial in Patients With Irritable Bowel Syndrome Investigating the Efficacy and Safety of PPC-5650 on Sensation and Pain During Standardized Stimulation of the Rectosigmoid|Completed||Phase 1|25|Actual|Aros Pharma ApS||2|||f||||t||||||||||2018-05-31 22:05:17.370568|2018-05-31 22:05:17.370568
NCT01449474|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2013-02-21|2011-10-07|2011-10-10|Estimate|||||||2013-02-21|2013-02-22|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Accuracy of MRI-based Patients Matched Instruments vs Jig-based Instruments in Total Knee Arthroplasty (TKA)|Accuracy of MRI-based Patients Matched Instruments and Jig-based Instruments in Total Knee Arthroplasty|Completed||N/A|80|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 22:05:17.442898|2018-05-31 22:05:17.442898
NCT01448928|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2015-10-30|2011-10-06|2011-10-07|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|ZEVALIN-DUI||Zevalin Post-marketing Surveillance in Japan|Drug Use Investigation of Zevalin|Unknown status|Recruiting||400|Anticipated|Spectrum Pharmaceuticals, Inc|||1||f||||f||||||||||2018-05-31 22:05:43.306499|2018-05-31 22:05:43.306499
NCT01449461|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2017-05-26||2017-09-05|2011-10-06|2011-10-10|Estimate|2017-05-26|2017-06-21|Actual||||2017-09-05|2017-10-03|Actual|September 20, 2011|Actual|2011-09-20|September 2017|2017-09-30|July 8, 2019|Anticipated|2019-07-08|November 16, 2015|Actual|2015-11-16||Interventional||Safety population included all enrolled participants who received at least one dose of study drug.|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)|A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113|Active, not recruiting||Phase 1/Phase 2|137|Actual|Ariad Pharmaceuticals||6|||f||||f|t|f||||||||2018-05-31 22:05:17.595435|2018-05-31 22:05:17.595435
NCT01449448|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2016-11-02|2011-10-07|2011-10-10|Estimate|||||||2016-11-02|2016-11-04|Estimate|September 2000||2000-09-30|November 2016|2016-11-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|NSAID||Subacromial Injection With Corticosteroid Versus Nonsteroidal Anti-inflammatory Drugs (NSAID) in Shoulder Impingement Syndrome|A Double-blind Randomized Controlled Trial Comparing the Effects of Subacromial Injection With Corticosteroid Versus NSAID in Patients With Shoulder Impingement Syndrome|Withdrawn||N/A|0|Actual|Madigan Army Medical Center||2||PI didn't have time to finish approval process|f||||t||||||||||2018-05-31 22:05:22.981756|2018-05-31 22:05:22.981756
NCT01449435|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2013-04-24|2011-10-07|2011-10-10|Estimate|||||||2013-04-24|2013-04-25|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Predictors of Asthma Exacerbations in Children|Asthma Exacerbations in Young Children With Moderate Asthma - Prospective Evaluation of Predictors|Completed|||75|Actual|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-05-31 22:05:23.099221|2018-05-31 22:05:23.099221
NCT01449422|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2013-03-28|2011-10-06|2011-10-10|Estimate|||||||2013-03-28|2013-03-29|Estimate|May 2011||2011-05-31|March 2013|2013-03-31||||January 2013|Actual|2013-01-31||Interventional|||Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.|Evaluation Of The Efficacy, Tolerance And Acceptability Of URGO Dressing 310 3082 Versus A Hydrofibre Dressing In The Local Management Of Venous Or Predominantly Venous Mixed Leg Ulcers|Completed||Phase 4|159|Actual|Laboratoires URGO||2|||f||||f||||||||||2018-05-31 22:05:23.169281|2018-05-31 22:05:23.169281
NCT01449409|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-03-09|2011-10-06|2011-10-10|Estimate|||||||2018-03-09|2018-03-12|Actual|February 1, 2011|Actual|2011-02-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|RIDUNA||Reduce IDentified UNcontrolled Asthma|Reduce IDentified UNcontrolled Asthma: A Real-time Randomized Administrative Outreach Study to Promote Asthma Guideline Implementation (RIDUNA)|Active, not recruiting||Phase 4|3000|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 22:05:23.256989|2018-05-31 22:05:23.256989
NCT01449396|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2018-03-06|2011-10-07|2011-10-10|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2011|Actual|2011-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|October 2015|Actual|2015-10-31||Interventional|||Acupuncture, Chinese Traditional Medicine, in Embryo Transfer|Chinese Traditional Medicine Contribution to Improve In-vitro Fertilization (IVF) Results: Acupuncture in Embryo Transfer|Completed||N/A|286|Actual|Instituto de Investigacion Sanitaria La Fe||3|||f||||t||||||||||2018-05-31 22:05:23.332408|2018-05-31 22:05:23.332408
NCT01449383|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2012-08-13|2011-10-07|2011-10-10|Estimate|||||||2012-08-13|2012-08-14|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|TORNADO||Effect of Diet on Intestinal Microbiota and Obesity Markers in Adults|Molecular Targets Open for Regulation by the Gut Flora - New Avenues for Improved Diet to Optimize European Health (TORANDO): WP2 Individual Intervention Studies- Effect of Diet on Intestinal Microbiota and Obesity Markers in Adults|Completed||N/A|20|Actual|German Institute of Human Nutrition||2|||f||||f||||||||||2018-05-31 22:05:23.411144|2018-05-31 22:05:23.411144
NCT01449370|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2017-01-13||2017-01-13|2011-10-07|2011-10-10|Estimate|2017-01-13|2017-03-09|Actual||||2017-01-13|2017-03-09|Actual|October 2011||2011-10-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional||The all subjects as treated (ASaT) population included all enrolled participants who received at least 1 dose of TAK-117.|Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer|A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease|Completed||Phase 1|125|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:05:23.895211|2018-05-31 22:05:23.895211
NCT01449357|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-10-07|2011-10-07|2011-10-10|Estimate|||||||2011-10-07|2011-10-10|Estimate||||October 2011|2011-10-31||||||||Interventional|||Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors|A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients With Non-Small Cell Lung Cancer Who Have Progressive Disease After Treatment With Tyrosine Kinase Inhibitors|Withdrawn||Phase 2|0|Actual|Genmab||1||Trial never initiated|f||||f||||||||||2018-05-31 22:05:38.438857|2018-05-31 22:05:38.438857
NCT01449344|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-03-06|2011-10-07|2011-10-10|Estimate|||||||2017-03-06|2017-03-07|Actual|May 9, 2009|Actual|2009-05-09|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|(R-HAD)||Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL|Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma|Active, not recruiting||Phase 3|128|Actual|European Mantle Cell Lymphoma Network||2|||f||||f||||||||||2018-05-31 22:05:38.516089|2018-05-31 22:05:38.516089
NCT01449331|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2016-04-15|2011-10-07|2011-10-10|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|OVNI||The Use of Palliative Non Invasive Ventilation in Acute Respiratory Failure. OVNI Study.|Qualitative Outcomes After Palliative Noninvasive Mechanical Ventilation : OVNI Study|Completed|||1450|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 22:05:38.663946|2018-05-31 22:05:38.663946
NCT01449318|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2014-05-15|2011-10-07|2011-10-10|Estimate|||||||2014-05-15|2014-05-16|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Predictors of Postoperative Pain|Predictors of Postoperative Pain Following Abdominal Hysterectomy|Completed||N/A|60|Actual|American University of Beirut Medical Center||1|||f||||f||||||||||2018-05-31 22:05:38.72613|2018-05-31 22:05:38.72613
NCT01449305|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2012-12-28||2013-02-01|2011-10-07|2011-10-10|Estimate|2012-12-28|2013-02-01|Estimate||||2013-02-01|2013-02-04|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea|Research on Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea|Completed||N/A|44|Actual|Chen Yi Enterprise, Co., Ltd.||1|||f||||||||||||||2018-05-31 22:05:38.803288|2018-05-31 22:05:38.803288
NCT01449279|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2017-01-20||2018-04-17|2011-10-07|2011-10-10|Estimate|2017-01-20|2017-03-10|Actual||||2018-04-17|2018-05-17|Actual|October 2011|Actual|2011-10-31|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 2015|Actual|2015-12-31||Interventional|||Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy|A Pilot Study of Ipilimumab in Subjects With Stage IV Melanoma Receiving Palliative Radiation Therapy|Active, not recruiting||Phase 2|22|Actual|Stanford University|This study was intended to be exploratory and had a limited sample size. Our results are based on a small sample size and further research should be done to really draw firm conclusions.|1|||f||||t|t|f||||||No||2018-05-31 22:05:39.311306|2018-05-31 22:05:39.311306
NCT01449266|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|2015-02-19||2015-06-09|2011-10-06|2011-10-10|Estimate|2015-05-21|2015-06-08|Estimate||||2015-06-09|2015-07-08|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional||No statistical calculation of sample size was done. According to the literature, a sample of 10 patients was judged sufficient to evaluate the dialysability of Dotarem®.|Safety and Dialysability of Dotarem® in Dialysed Patients|Safety and Dialysability of Dotarem® in Dialysed Patients - Phase 1 Clinical Study|Completed||Phase 1|10|Actual|Guerbet||1|||f||||t||||||||||2018-05-31 22:05:39.532444|2018-05-31 22:05:39.532444
NCT01449253|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2013-01-28|2011-10-07|2011-10-10|Estimate|||||||2013-01-28|2013-01-29|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia|Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia|Unknown status|Recruiting|Phase 4|60|Anticipated|All India Institute of Medical Sciences, New Delhi||3|||f||||f||||||||||2018-05-31 22:05:39.827164|2018-05-31 22:05:39.827164
NCT01449240|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2014-12-01||2015-10-06|2011-10-07|2011-10-10|Estimate|2014-12-01|2014-12-05|Estimate||||2015-10-06|2015-10-28|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Observational||Safety Population: All patients who had undergone a procedure for CSF sample collection. This included a patient who underwent unsuccessful CSF sample collection. It did not include a patient who provided a retrospective CSF sample.|Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome|A Cerebrospinal Fluid Collection Study in Pediatric and Adult Patients With Hunter Syndrome|Completed|||10|Actual|Shire|||1||f||||f||||||Samples Without DNA|"~     CSF and urine samples will be retained and analyzed for glycosaminoglycans (GAGs), including~     sulfated DS/HS oligosaccharides, GAG-degradation products, and other biomarkers of CNS or~     lysosomal function.~   "|||2018-05-31 22:05:39.955536|2018-05-31 22:05:39.955536
NCT01449227|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-10|2011-10-07|2011-10-10|Estimate|||||||2011-10-10|2011-10-12|Estimate|September 2011||2011-09-30|October 2011|2011-10-31||||||||Observational|||Natural Course of Adhesive Capsulitis of Hip|Natural Course of Adhesive Capsulitis of Hip|Unknown status|Recruiting||50|Anticipated|Seoul National University Hospital|||||f||||||||||||||2018-05-31 22:05:40.163517|2018-05-31 22:05:40.163517
NCT01449214|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2016-04-29|2011-10-07|2011-10-10|Estimate|||||||2016-04-29|2016-05-02|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Ultrasound-Guided Technique for Thoracic Epidural Insertion|Ultrasound-Guided Technique for Thoracic Epidural Insertion: A Randomized Controlled Trial|Completed||N/A|60|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 22:05:40.237466|2018-05-31 22:05:40.237466
NCT01449201|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-09-28|2011-10-06|2011-10-10|Estimate|||||||2014-09-28|2014-09-30|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma|Phase II Trial of PF-00299804 in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy|Completed||Phase 2|49|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 22:05:40.311713|2018-05-31 22:05:40.311713
NCT01449188|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-11-08|2011-10-06|2011-10-10|Estimate|||||||2017-11-08|2017-11-13|Actual|August 16, 2011|Actual|2011-08-16|November 2017|2017-11-30|December 19, 2011|Actual|2011-12-19|December 19, 2011|Actual|2011-12-19||Interventional|||To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects|A Randomized, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous Ondansetron, a 5-HT3 Antagonist, on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects|Completed||Phase 1|60|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 22:05:40.38968|2018-05-31 22:05:40.38968
NCT01449175|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2013-11-13|2011-10-07|2011-10-10|Estimate|||||||2013-11-13|2013-11-14|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema|A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema|Terminated|||54|Anticipated|Aeris Therapeutics|||||f||||f||||||||||2018-05-31 22:05:40.471866|2018-05-31 22:05:40.471866
NCT01449162|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2012-09-25|2011-10-07|2011-10-10|Estimate|||||||2012-09-25|2012-09-26|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids|A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and the Safety of Masitinib at 6 mg/kg/Day Versus Placebo in the Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids|Unknown status|Recruiting|Phase 3|300|Anticipated|AB Science||2|||f||||t||||||||||2018-05-31 22:05:40.542179|2018-05-31 22:05:40.542179
NCT01449149|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-12-07|2011-10-06|2011-10-10|Estimate|||||||2015-12-07|2015-12-08|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Proton Radiation for Chordomas and Chondrosarcomas|Proton Radiation For Chordomas and Chondrosarcomas|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:05:40.606506|2018-05-31 22:05:40.606506
NCT01449136|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2011-10-05|2011-10-05|2011-10-10|Estimate|||||||2011-10-05|2011-10-10|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|AC||Use of Antibacterial Cement in Infected Dentin|Phase 1 Study of Clinical and Radiographic Success of Antibacterial Cement in Infected Dentin of Deciduous Teeth|Completed||N/A|45|Actual|University of Pernambuco||1|||f||||t||||||||||2018-05-31 22:05:40.672335|2018-05-31 22:05:40.672335
NCT01449123|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-08-08|2011-10-07|2011-10-10|Estimate|||||||2012-08-08|2012-08-09|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations|An Open-label Single Site Single Dose Pilot Study Using Mannitol Challenge Test With the Purpose to Explore Treatment With Fixed Dose Combinations in Adult Subjects With Asthma in Primary Care in Sweden|Completed||Phase 4|97|Actual|Mundipharma AB||1|||f||||f||||||||||2018-05-31 22:05:40.739564|2018-05-31 22:05:40.739564
NCT01449110|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-11-15|2011-10-06|2011-10-07|Estimate|||||||2011-11-15|2011-11-16|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|FUNGRAPE||Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Prevention of Cardiovascular Disease|A Randomized, 12 Months Follow-up, Dose-response, Placebo-Controlled, Double-Blind, 6-Arms Parallel Trial to Evaluate the Safety and Efficacy of a Resveratrol-enriched Grape Extract (Stilvid) in Primary and Secondary Patients of Cardiovascular Disease|Completed||Phase 2|150|Actual|National Research Council, Spain||6|||f||||f||||||||||2018-05-31 22:05:41.034722|2018-05-31 22:05:41.034722
NCT01449097|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-12-21|2011-10-06|2011-10-07|Estimate|||||||2011-12-21|2011-12-22|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Adductor-Canal-Blockade Versus the Femoral Nerve Block Effect on Muscle Strength and Mobilization in Healthy Volunteers|Comparison of the Efficacy of the Adductor-Canal-Blockade Versus the Femoral Nerve Block on Muscle Strength and Mobilization in Healthy Volunteers: a Randomized Study|Completed||Phase 4|12|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 22:05:41.153222|2018-05-31 22:05:41.153222
NCT01449084|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-10|2011-10-06|2011-10-07|Estimate|||||||2011-10-10|2011-10-12|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Early Pancreatic Duct Stent Removal in Preventing Post-endoscopic Pancreatitis|Immediate Pancreatic Duct Stent Removal Does Not Prevent Pancreatitis After Accidental Pancreatic Duct Cannulation - A Prospective Randomized Trial|Completed||N/A|40|Actual|Nuovo Ospedale Civile S.Agostino Estense||2|||f||||f||||||||||2018-05-31 22:05:41.224545|2018-05-31 22:05:41.224545
NCT01449071|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03||2014-01-16|2014-01-16|2011-10-06|2011-10-07|Estimate||||2014-01-16|2014-02-12|Estimate|2014-01-16|2014-02-12|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)|A Phase1/2, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Pharmacokinetics of One 12 Week Treatment Cycle of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects With Moderate to Severe Disease|Completed||Phase 1/Phase 2|20|Actual|UCB Pharma||5|||f||||f||||||||||2018-05-31 22:05:41.298042|2018-05-31 22:05:41.298042
NCT01449058|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2017-09-29|2011-10-06|2011-10-07|Estimate|||||||2017-09-29|2017-10-02|Actual|March 2012||2012-03-31|September 2017|2017-09-30|August 15, 2017|Actual|2017-08-15|August 31, 2016|Actual|2016-08-31||Interventional|||A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors|A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors|Completed||Phase 1|139|Actual|Array BioPharma||1|||f||||||||||||||2018-05-31 22:05:41.377818|2018-05-31 22:05:41.377818
NCT01449045|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|||2012-04-25|2011-10-06|2011-10-07|Estimate|||||||2012-04-25|2012-04-26|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Trial of Malaria Seasonal IPTc Combined With Community Case Management|Cluster Randomized Trial of Malaria Seasonal IPTc Combined With Community Case Management in Saraya District, SE Senegal|Completed||Phase 3|4554|Actual|Cheikh Anta Diop University, Senegal||2|||f||||t||||||||||2018-05-31 22:05:41.457994|2018-05-31 22:05:41.457994
NCT01449032|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2014-06-07|2011-10-06|2011-10-07|Estimate|||||||2014-06-07|2014-06-10|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|MyStromalCell||MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)|MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia (MyStromalCell Trial)|Completed||Phase 2|60|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 22:05:41.529138|2018-05-31 22:05:41.529138
NCT01449019|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2011-10-05|2011-10-05|2011-10-07|Estimate|||||||2011-10-05|2011-10-07|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|July 2010|Actual|2010-07-31|August 2007|Actual|2007-08-31||Interventional|DFG_5||The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)|The Contribution of Glucagon-like Peptide 1 (GLP-1) to the Entero-insulinar Axis in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1|24|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 22:05:41.59287|2018-05-31 22:05:41.59287
NCT01449006|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2016-02-09||2016-04-13|2011-10-06|2011-10-07|Estimate|2016-04-13|2016-05-20|Estimate||||2016-04-13|2016-05-20|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|HANDmac|Data presented reflect baseline demographic and clinical characteristics for participants included in the primary analysis.|A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)|A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Maraviroc in HIV Virally Suppressed Patients With Cognitive Impairment|Completed||Phase 4|19|Actual|St Vincent's Hospital, Sydney|"Small pilot sample size (N=17).~Unrepresentative of international HAND populations.~Open-label design may have contributed to loss to follow-up in controls.~Modified intention-to-treat design potentially introduced bias into analyses."|2|||f||||t||||||||||2018-05-31 22:05:41.68097|2018-05-31 22:05:41.68097
NCT01448993|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2015-04-21|2011-10-06|2011-10-07|Estimate|||||||2015-04-21|2015-04-22|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Azithromycin on Oesophageal Hypomotility|Effect Of Azithromycin On Oesophageal Function In Patients With Dysphagia Or Gastro-Oesophageal Reflux Associated With Frequent Oesophageal Hypomotility|Completed||Phase 2|26|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 22:05:43.013261|2018-05-31 22:05:43.013261
NCT01448980|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2014-06-05|2011-10-06|2011-10-07|Estimate|||||||2014-06-05|2014-06-06|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Massage in Stroke Spasticity|The Efficacy of Thai Traditional Massage in Decreasing Spasticity for Elderly With Stroke|Completed||Phase 3|396|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 22:05:43.118431|2018-05-31 22:05:43.118431
NCT01448954|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-02-17|2011-10-06|2011-10-07|Estimate|||||||2012-02-17|2012-02-20|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma|A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma|Completed||Phase 2|36|Anticipated|Pulmagen Therapeutics||2|||f||||f||||||||||2018-05-31 22:05:43.180077|2018-05-31 22:05:43.180077
NCT01448941|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-04-29|2011-10-06|2011-10-07|Estimate|||||||2018-04-29|2018-05-01|Actual|October 2011||2011-10-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Arthrodesis Versus Extra-articular Plate Fixation in Lisfranc Injury|Arthrodesis Versus Extra-articular Bridge Plating of the First Tarsometatarsal Joint After Acute Lisfranc Injury|Completed||N/A|48|Actual|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 22:05:43.237158|2018-05-31 22:05:43.237158
NCT01448915|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-08-16|2011-10-06|2011-10-07|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2009||2009-09-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)|Management of Hepatitis C in HIV Infected IDUs|Active, not recruiting|||1000|Anticipated|Johns Hopkins University|||1||f||||f|f|f||||Samples Without DNA|"~     Serum and plasma specimens are collected at regular intervals~   "|Undecided||2018-05-31 22:05:43.37617|2018-05-31 22:05:43.37617
NCT01448902|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis|A Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis|Completed||Phase 2|36|Actual|Oxagen Ltd||2|||f||||f||||||||||2018-05-31 22:05:43.43763|2018-05-31 22:05:43.43763
NCT01448889|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy|Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy.|Unknown status|Recruiting|N/A|180|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 22:05:43.502404|2018-05-31 22:05:43.502404
NCT01448876|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2016-02-15|2011-10-06|2011-10-07|Estimate|||||||2016-02-15|2016-02-17|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|Incure||Incubation Time and Test of Cure of Chlamydia Trachomatis|Time to Cure Chlamydia Trachomatis: Prospective Cohort Study on Detection of Chlamydial RNA and DNA in Anorectal and Cervicovaginal Infections During 8 Weeks After Directly Observed Treatment With Azithromycin|Completed|||52|Actual|Maastricht University Medical Center|||1||f||||f|||||||"~     self-taken cervicovaginal and snorectal swabs~   "|||2018-05-31 22:05:43.677012|2018-05-31 22:05:43.677012
NCT01448863|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2015-03-09|2011-10-06|2011-10-07|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Metabolomic Embryo Profiles of Obese in Vitro Fertilization (IVF) Patients and Their Relationship With Polycystic Ovary Syndrome (PCO)||Completed|||28|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA|||3||f||||f||||||||||2018-05-31 22:05:43.739402|2018-05-31 22:05:43.739402
NCT01448850|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2016-06-28||2016-11-30|2011-10-06|2011-10-07|Estimate|2016-11-30|2017-01-30|Estimate||||2016-11-30|2017-01-30|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|SPRING|Modified intent-to-treat (mITT) population included all participants who were randomized into the study and received any investigational product.|A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease|A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease|Completed||Phase 2|464|Actual|MedImmune LLC||2|||f||||t||||||||||2018-05-31 22:05:43.843518|2018-05-31 22:05:43.843518
NCT01448837|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-05-09|2011-10-06|2011-10-07|Estimate|||||||2014-05-09|2014-05-12|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice|24-Hour Intraocular Pressure Control Obtained With the Bimatoprost/Timolol Fixed Combination Compared With Latanoprost as First Choice Therapy in Subjects With Exfoliation Syndrome, or Exfoliative Glaucoma|Completed||Phase 4|37|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 22:05:44.469307|2018-05-31 22:05:44.469307
NCT01448824|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2012-02-20|2011-10-06|2011-10-07|Estimate|||||||2012-02-20|2012-02-22|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of LY2484595 on Pharmacokinetics in Healthy Subjects|A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:05:44.602143|2018-05-31 22:05:44.602143
NCT01448811|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-07|2011-10-06|2011-10-07|Estimate|||||||2011-10-07|2011-10-12|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Auditory Evoked Potential Monitoring on Bronchoscopy|Impact of Auditory Evoked Potential Index Monitoring on Bronchoscopic Examination in the Mechanical Ventilated Patients - A Prospective, Randomized, Controlled Study|Completed||N/A|37|Actual|Kaohsiung Veterans General Hospital.||2|||f||||||||||||||2018-05-31 22:05:44.680366|2018-05-31 22:05:44.680366
NCT01448798|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|AnPro||Athermal Nerve-sparing During Robotic-assisted Radical Prostatectomy Using a Hemostatic Matrix.|Prospective Randomized Investigation of Athermal Nerve-sparing During Robotic-assisted Laparoscopic Prostatectomy Using a Hemostatic Gelatin-thrombin Matrix|Unknown status|Recruiting|N/A|50|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-05-31 22:05:44.738024|2018-05-31 22:05:44.738024
NCT01448785|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-27|2011-10-05|2011-10-07|Estimate|||||||2011-10-27|2011-10-31|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|January 2015|Anticipated|2015-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Abiliti™ Treatment in Obese Subjects|Abiliti™ Treatment in Obese Subjects: A Randomized Post-Market Surveillance Multicenter Study|Unknown status|Recruiting|N/A|165|Anticipated|IntraPace, Inc||2|||f||||f||||||||||2018-05-31 22:05:44.89827|2018-05-31 22:05:44.89827
NCT01448772|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2012-03-23|2011-10-06|2011-10-07|Estimate|||||||2012-03-23|2012-03-26|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions|A Single-Dose, Replicate Crossover Design Comparative Bioavailability Study of Dronabinol Oral Solution 5 mg Versus Marinol Capsules 5 mg Under Fasted Conditions|Completed||Phase 1|88|Actual|INSYS Therapeutics Inc||2|||f||||f||||||||||2018-05-31 22:05:45.063894|2018-05-31 22:05:45.063894
NCT01448759|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2015-04-23|2011-10-06|2011-10-07|Estimate|||||||2015-04-23|2015-04-24|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ALCOOTAX||Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel|Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion|Completed||N/A|30|Actual|Institut Curie|||||f||||f||||||||||2018-05-31 22:05:45.161699|2018-05-31 22:05:45.161699
NCT01448239|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2013-06-27|2011-10-05|2011-10-07|Estimate|||||||2013-06-27|2013-06-28|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)||Completed||Phase 1|24|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:05:52.692041|2018-05-31 22:05:52.692041
NCT01448746|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-02-03|2011-10-06|2011-10-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2011||2011-10-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|January 2016|Actual|2016-01-31||Interventional|||Optimal Prophylactic Method of Venous Thromboembolism (VTE)|Optimal Prophylactic Method of Venous Thromboembolism for Gastrectomy in Korean Patients|Active, not recruiting||Phase 3|682|Actual|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 22:05:45.226412|2018-05-31 22:05:45.226412
NCT01448733|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris|A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the Treatment of Facial Acne Vulgaris.|Unknown status|Active, not recruiting|Phase 4|20|Actual|Zeichner, Joshua, M.D.||1|||f||||t||||||||||2018-05-31 22:05:45.301434|2018-05-31 22:05:45.301434
NCT01448720|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-09-17|2011-10-06|2011-10-07|Estimate|||||||2014-09-17|2014-09-18|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate|Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate - A Pilot Study|Completed||Phase 3|142|Actual|Janssen-Cilag Farmaceutica Ltda.||1|||f||||f||||||||||2018-05-31 22:05:45.396995|2018-05-31 22:05:45.396995
NCT01448707|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2015-10-30||2017-10-23|2011-10-06|2011-10-07|Estimate|2015-10-30|2015-12-03|Estimate||||2017-10-23|2017-11-27|Actual|March 15, 2012|Actual|2012-03-15|October 2017|2017-10-31|March 18, 2015|Actual|2015-03-18|June 11, 2014|Actual|2014-06-11||Interventional|PROTEA|Baseline characteristics were analyzed for all participants who were treated.|A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment|PROTEAse Inhibitor (DRV/Rtv) in Mono- or Triple Therapy in Suppressed HIV-1 Infected Subjects|Completed||Phase 3|274|Actual|Janssen-Cilag International NV||2|||f||||t||||||||||2018-05-31 22:05:45.522484|2018-05-31 22:05:45.522484
NCT01448694|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2014-12-01|2011-10-06|2011-10-07|Estimate|||||||2014-12-01|2014-12-03|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|October 2013|Actual|2013-10-31||Observational|||Non-invasive Hemodynamic Monitoring During Blood Donation for Developing Models of Early Blood Loss|Non-invasive Hemodynamic Monitoring During Blood Donation for Developing Models of Early Blood Loss.|Completed|||320|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 22:05:46.419802|2018-05-31 22:05:46.419802
NCT01448681|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-12-12|2011-10-05|2011-10-07|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2011||2011-08-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Observational|||A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension|A Continuous, Non-Invasive, Real-time Method for Estimating and Predicting Intracranial Hypertension|Active, not recruiting|||32|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 22:05:46.471872|2018-05-31 22:05:46.471872
NCT01448668|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2013-07-01|2011-10-06|2011-10-07|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|||Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)|Prospective Epidemiological Study to Expand Knowledge on Efficacy and Safety of a Routine Post-operative Supportive Therapy With the Mistletoe Extract Iscador® Qu Within Oncological Treatment of Pancreatic Cancer Stages UICC II-IV|Unknown status|Active, not recruiting||220|Actual|IFAG AG|||2||f||||f||||||||||2018-05-31 22:05:46.544519|2018-05-31 22:05:46.544519
NCT01448655|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2013-07-01|2011-10-06|2011-10-07|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)|Prospective Epidemiological Study to Expand Knowledge on Efficacy and Safety of a Routine Post-operative Supportive Therapy With the Mistletoe Extract Iscador® Qu Within Oncological Treatment of Colorectal Cancer Stages UICC II-IV|Unknown status|Recruiting||300|Anticipated|IFAG AG|||2||f||||f||||||||||2018-05-31 22:05:46.625652|2018-05-31 22:05:46.625652
NCT01448642|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2018-05-24|2011-10-06|2011-10-07|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 2012|Actual|2012-04-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Interventional|SECURE-PCI||Statins Evaluation in Coronary Procedures and Revascularization Trial|A Randomized, Multicenter Clinical Trial to Assess the Effect of Atorvastatin in Patients With Acute Coronary Syndrome and Intended Percutaneous Coronary Intervention|Active, not recruiting||Phase 4|4192|Anticipated|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 22:05:46.767148|2018-05-31 22:05:46.767148
NCT01448629|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-02-06|2011-10-06|2011-10-07|Estimate|||||||2012-02-06|2012-02-07|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Performance of a New 1-piece Ostomy Product Compared to Standard Care Ostomy Products in Subjects Ileostomy|An Open-labelled, Randomised, Controlled, Comparative, Explorative, Cross-over Study Investigating Safety and Performance of a New 1-piece Ostomy Product Compared Standard Care Ostomy Products in Subjects With Ileostomy|Withdrawn||N/A|0|Actual|Coloplast A/S||2||The study was withdrawn because of problems found with the baseplate|f||||f||||||||||2018-05-31 22:05:46.957166|2018-05-31 22:05:46.957166
NCT01448616|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2015-08-05||2015-12-02|2011-10-06|2011-10-07|Estimate|2015-12-02|2016-01-12|Estimate||||2015-12-02|2016-01-12|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Participants were randomized 2:2:1 to one of the 3 treatment arms after completing the lead-in phase|Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding|Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 4|73|Actual|University of Washington|The study was not powered to detect differences in lesion rate; the study was appropriately powered to detect a 50% decrease in viral shedding only, and therefore may have been underpowered to detect significant findings for secondary outcomes.|4|||f||||t||||||||||2018-05-31 22:05:47.152357|2018-05-31 22:05:47.152357
NCT01448603|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2012-05-16|2011-10-06|2011-10-07|Estimate|||||||2012-05-16|2012-05-17|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||ToleroMune Ragweed Follow up Study|An Optional One Year Follow-up Study to Evaluate the Continued Efficacy of ToleroMune Ragweed in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber.|Completed|||109|Actual|Circassia Limited|||5||f||||f||||||||||2018-05-31 22:05:48.504315|2018-05-31 22:05:48.504315
NCT01448590|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2016-10-12|2011-10-06|2011-10-07|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Post Dural Puncture Headache After Accidental Dural Puncture|Systematic Review: Post Dural Puncture Headache After Accidental Dural Puncture: Does Insertion of Spinal Catheter Decrease Incidence of Headaches?|Withdrawn|||0|Actual|Sunnybrook Health Sciences Centre|||2||f||||f||||||||||2018-05-31 22:05:49.305549|2018-05-31 22:05:49.305549
NCT01448577|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|November 2010||2010-11-30|October 2011|2011-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||"Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal Pancreatitis Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies"|"A Clinical Records Review Study of the Frequency and Severity of Acute Abdominal Pancreatitis Episodes Reported From LPLD Subjects Previously Recruited to Clinical Studies PREPARATION-02, CT-AMT-011-01 and CT-AMT-011-02"|Unknown status|Enrolling by invitation||22|Actual|Amsterdam Molecular Therapeutics|||2||f||||f||||||||||2018-05-31 22:05:49.409767|2018-05-31 22:05:49.409767
NCT01448564|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2013-09-03|2011-10-06|2011-10-07|Estimate|||||||2013-09-03|2013-09-04|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|December 2013||2013-12-31|December 2013||2013-12-31||Interventional|LTCOPD||Effects of Laser Therapy on Muscle Function in COPD Patients|Effects of Light-emitting Diodes (LED) on Peripheral Muscle Function, Exercise Tolerance and Cardiorespiratory Response During Exercise in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|27|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 22:05:49.57577|2018-05-31 22:05:49.57577
NCT01448551|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2016-12-20|2011-10-05|2011-10-07|Estimate|||||||2016-12-20|2016-12-21|Estimate|October 2011||2011-10-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||MPOWERed Messages: Tailored Mobile Messages to Enhance Weight Loss for Teens|Novel Individually Tailored Mobile Messages to Enhance Weight Loss for Teens|Completed||N/A|50|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:05:49.765799|2018-05-31 22:05:49.765799
NCT01448538|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-09-11|2011-10-06|2011-10-07|Estimate|||||||2015-09-11|2015-09-14|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany|Non-Persistence/Non-Adherence of German wAMD Patients Related to Their Anti-VEGF Injections: Extent, Explanations and Patients' Preferences|Completed|||480|Actual|Bayer|||1||f||||t||||||||||2018-05-31 22:05:49.854115|2018-05-31 22:05:49.854115
NCT01448525|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|2013-04-05||2013-04-05|2011-10-06|2011-10-07|Estimate|2013-04-05|2013-05-22|Estimate||||2013-04-05|2013-05-22|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence||Completed||Phase 4|88|Actual|Allergan||2|||f||||f||||||||||2018-05-31 22:05:50.04797|2018-05-31 22:05:50.04797
NCT01448512|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-01-20|2011-10-06|2011-10-07|Estimate|||||||2014-01-20|2014-01-22|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Promoting Male Involvement to Improve Prevention of Mother to Child Transmission (PMTCT) Uptake and Reduce Antenatal Infection|University of Miami Developmental Center for AIDs Research Promoting Male Involvement to Improve PMTCT Uptake and Reduce Antenatal Infection|Completed||N/A|478|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 22:05:50.261854|2018-05-31 22:05:50.261854
NCT01448499|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2015-12-08|2011-10-05|2011-10-07|Estimate|||||||2015-12-08|2015-12-09|Estimate|October 2011||2011-10-31|December 2015|2015-12-31||||October 2013|Anticipated|2013-10-31||Interventional|ClozAmi||Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients|Clozapine Versus Amisulpride Versus Their Combination in the Treatment of Drug-resistant Schizophrenia Patients|Withdrawn||N/A|0|Actual|Geha Mental Health Center||3|||f||||f||||||||||2018-05-31 22:05:50.410943|2018-05-31 22:05:50.410943
NCT01448486|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2013-11-13||2016-05-19|2011-10-05|2011-10-07|Estimate|2013-11-13|2014-01-03|Estimate||||2016-05-19|2016-06-27|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|HANDral||A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV|A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Raltegravir in HIV Virally Suppressed Patients With Cognitive Impairment|Terminated||Phase 4|6|Actual|St Vincent's Hospital, Sydney|Early termination leading to incomplete dataset with sample size too small to produce any meaningful statistical analysis.|2||Funding withdrawn based on unacceptably slow recruitment rate.|f||||t||||||||||2018-05-31 22:05:50.504806|2018-05-31 22:05:50.504806
NCT01448473|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2013-03-18|2011-10-05|2011-10-07|Estimate|||||||2013-03-18|2013-03-19|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|4vs2||Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients|Is a Two-Film Skull X-ray Series as Sensitive as a Four-Film Series in the Diagnosis of Skull Fractures in Paediatric Patients With Minor Head Trauma?|Completed||N/A|14|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 22:05:50.764768|2018-05-31 22:05:50.764768
NCT01448460|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2013-01-23|2011-10-06|2011-10-07|Estimate|||||||2013-01-23|2013-01-24|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Oocyte Vitrification for In Vitro Fertilization (IVF) Patients and Women With Fertility Threatening Conditions|Oocyte Vitrification for IVF Patients and Women With Fertility Threatening Conditions|Completed|||8|Actual|University of Louisville|||1||f||||t|||||||"~     oocytes~   "|||2018-05-31 22:05:50.890984|2018-05-31 22:05:50.890984
NCT01448447|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2016-04-14|2011-10-05|2011-10-07|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|Mammosite ML||Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®|Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast|Completed||Phase 4|200|Actual|St. John's Mercy Research Institute, St. Louis||2|||f||||f||||||||||2018-05-31 22:05:50.943153|2018-05-31 22:05:50.943153
NCT01448434|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-05-11|2011-10-05|2011-10-07|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Allogeneic Mesenchymal Stem Cells for Osteoarthritis|A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee|Completed||Phase 2|72|Actual|Stempeutics Research Pvt Ltd||2|||f||||t||||||||||2018-05-31 22:05:51.012593|2018-05-31 22:05:51.012593
NCT01448421|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|January 2012||2012-01-31|September 2011|2011-09-30|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|||SMT Embolic Deflection CE Mark Trial DEFLECT I|A Prospective, Single Arm Feasibility Study to Evaluate the Safety and Performance of the SMT Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)|Unknown status|Not yet recruiting|N/A|36|Anticipated|Keystone Heart||1|||f||||f||||||||||2018-05-31 22:05:51.13244|2018-05-31 22:05:51.13244
NCT01448408|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2011-10-05|2011-10-05|2011-10-07|Estimate|||||||2011-10-05|2011-10-07|Estimate|May 2007||2007-05-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|||||Observational|||Corneal Biomechanical Properties and Anterior Segment Parameters, in Forme Fruste Keratoconus|Evaluation of the Sensitivity, Specificity, and Test Accuracy of Corneal Biomechanical Metrics, Anterior Segment Data and a Combination Model, in Differentiating Forme Fruste Keratoconus (FFK) From Healthy Corneas.|Completed|||||Democritus University of Thrace|||2||f||||f||||||||||2018-05-31 22:05:51.234555|2018-05-31 22:05:51.234555
NCT01448395|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-08-31|2011-10-05|2011-10-07|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2011||2011-10-31|August 2017|2017-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104|An Open Label Single-Dose Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104|Completed||Phase 1|6|Actual|Pfizer||1|||f||||||||||||||2018-05-31 22:05:51.284116|2018-05-31 22:05:51.284116
NCT01448382|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-12-28|2011-10-06|2011-10-07|Estimate|||||||2015-12-28|2015-12-29|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of PillCam With Blood-Sensing Feature: A Feasibility Study|Evaluation of PillCam With Blood-Sensing Feature: A Feasibility Study|Terminated||Phase 1|39|Actual|Given Imaging Ltd.||2|||f||||f||||||||||2018-05-31 22:05:51.348157|2018-05-31 22:05:51.348157
NCT01448369|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-06-09|2011-10-06|2011-10-07|Estimate|||||||2014-06-09|2014-06-10|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Eyelid Warming Technology for Meibomian Gland Dysfunction|Eyelid Warming Technology for Relief of Meibomian Gland Dysfunction in an Asian Population|Completed||N/A|75|Actual|Singapore National Eye Centre||3|||f||||f||||||||||2018-05-31 22:05:51.512588|2018-05-31 22:05:51.512588
NCT01448356|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2012-07-17||2012-11-14|2011-10-06|2011-10-07|Estimate|2012-11-14|2012-12-12|Estimate||||2012-11-14|2012-12-12|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation|Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation|Completed||N/A|10|Actual|Singapore Eye Research Institute||1|||f||||f||||||||||2018-05-31 22:05:51.606437|2018-05-31 22:05:51.606437
NCT01448343|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2013-04-15|2011-10-06|2011-10-07|Estimate|||||||2013-04-15|2013-04-16|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|FMS||Effect of Rapid Transfusion With Fluid Management System 2000® (FMS)|Effect of Rapid Transfusion With FMS(Fluid Management System 2000®) on the Plasma Potassium Concentration in Adult Liver Transplantation Recipients)|Completed||N/A|10|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:05:51.75244|2018-05-31 22:05:51.75244
NCT01448330|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2011-12-28|2011-10-05|2011-10-07|Estimate|||||||2011-12-28|2011-12-30|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin|A Sequence-randomized, Open-label, Single Dose, Crossover Study to Evaluate Pharmacokinetics and Safety After Oral Administration of Clopidogrel and Aspirin in Free Combination and Fixed-dose Combination as HCP0911 in Healthy Male Volunteers|Completed||Phase 1|64|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 22:05:51.821104|2018-05-31 22:05:51.821104
NCT01448317|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2016-09-27|2011-10-05|2011-10-07|Estimate|||||||2016-09-27|2016-09-28|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered SAR236553 in Japanese Healthy Male Subjects|Completed||Phase 1|32|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 22:05:51.935001|2018-05-31 22:05:51.935001
NCT01448304|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2013-06-27|2011-10-05|2011-10-07|Estimate|||||||2013-06-27|2013-06-28|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)||Completed||Phase 1|24|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:05:52.084|2018-05-31 22:05:52.084
NCT01448291|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2012-04-23|2011-10-06|2011-10-07|Estimate|||||||2012-04-23|2012-04-24|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|March 2013|Anticipated|2013-03-31|October 2012|Anticipated|2012-10-31||Interventional|||Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers|The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers|Unknown status|Recruiting|Phase 4|30|Anticipated|Eastern Virginia Medical School||1|||f||||f||||||||||2018-05-31 22:05:52.15153|2018-05-31 22:05:52.15153
NCT01448278|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-02-06|2011-10-06|2011-10-07|Estimate|||||||2015-02-06|2015-02-09|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|||Pain Evaluation After Anterior Cruciate Ligament (ACL) Ligamentoplasty|"Pain Evaluation After ACL Ligamentoplasty: All-inside Versus Classical Technique. A Prospective Randomised Comparative Study"|Completed||Phase 4|46|Actual|Hospital Ambroise Paré Paris||2|||f||||f||||||||||2018-05-31 22:05:52.289512|2018-05-31 22:05:52.289512
NCT01448265|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2013-07-24|2011-10-06|2011-10-07|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|CRYO-MAP||Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter|Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter|Completed||Phase 4|40|Actual|Heidelberg University||1|||f||||f||||||||||2018-05-31 22:05:52.36813|2018-05-31 22:05:52.36813
NCT01448252|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|May 2002||2002-05-31|October 2011|2011-10-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||T Cell Vaccination in Patients With Progressive Multiple Sclerosis|Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis|Completed||Phase 1/Phase 2|30|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 22:05:52.509584|2018-05-31 22:05:52.509584
NCT01448226|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2011-10-06|2011-10-06|2011-10-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|January 2000||2000-01-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Observational|||Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy|Diagnosing Invasive Aspergillosis by PCR Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy|Completed|||221|Actual|Heidelberg University|||2||f||||f||||||Samples With DNA|"~     Aliquots of BAL Samples including fungal DNA~   "|||2018-05-31 22:05:52.872097|2018-05-31 22:05:52.872097
NCT01448213|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2014-08-04||2014-08-22|2011-10-05|2011-10-07|Estimate|2014-08-21|2014-08-25|Estimate||||2014-08-22|2014-09-03|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||"Baseline characteristics data are reported in units of eyes as this presentation is most relevant to the assessments presented in the Outcome Measures module."|Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)|Comparison Of Two Corticosteroid Dosing Regimens For Prevention Of Corneal Transplant Rejection Episodes After Descemet's Membrane Endothelial Keratoplasty|Completed||Phase 2|264|Actual|Price Vision Group||2|||f||||t||||||||||2018-05-31 22:05:52.982313|2018-05-31 22:05:52.982313
NCT01448200|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2012-11-14|2011-10-06|2011-10-07|Estimate|||||||2012-11-14|2012-11-16|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1|A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection|Completed||Phase 1|82|Actual|Presidio Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 22:05:53.331767|2018-05-31 22:05:53.331767
NCT01448187|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-07-01|2011-10-06|2011-10-07|Estimate|||||||2016-07-01|2016-07-04|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|EPIDAURE||Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa|Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa|Completed|||361|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:05:53.422805|2018-05-31 22:05:53.422805
NCT01448174|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2014-10-05|2011-10-06|2011-10-07|Estimate|||||||2014-10-05|2014-10-07|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients|Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients|Completed||Phase 4|310|Actual|Poznan University of Medical Sciences||3|||f||||f||||||||||2018-05-31 22:05:53.507247|2018-05-31 22:05:53.507247
NCT01448161|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-12-19|2011-10-06|2011-10-07|Estimate|||||||2017-12-19|2017-12-21|Actual|December 2011||2011-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Machine Learning Approach to Continuous Vital Sign Data Analysis|A Machine Learning Approach to Continuous Vital Sign Data Analysis|Enrolling by invitation|||1200|Anticipated|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 22:05:53.592831|2018-05-31 22:05:53.592831
NCT01448148|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2016-01-26|2011-10-05|2011-10-07|Estimate|||||||2016-01-26|2016-01-27|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment|Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment|Completed||N/A|145|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||3|||f||||t||||||||||2018-05-31 22:05:53.637787|2018-05-31 22:05:53.637787
NCT01448135|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-06-22|2011-10-05|2011-10-07|Estimate|||||||2015-06-22|2015-06-23|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Tolerance and Efficacy of a Predigested, High Protein, High Omega 3 Fat Enteral Feeding Formula Versus a Standard Formula In Multiple Intensive Care Unit Settings|Pilot Study Evaluating the Efficacy, Tolerance and Safety of VITAL AF (Semi Elemental, High Protein, High Omega 3 Fat Enteral Formula) Versus Osmolite 1.2 (High Protein Enteral Formula) in Multiple ICU Settings (Medical, Surgical, Cardiothoracic)|Completed||N/A|50|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 22:05:53.715707|2018-05-31 22:05:53.715707
NCT01448122|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2013-02-26|2011-10-06|2011-10-07|Estimate|||||||2013-02-26|2013-02-27|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Avene Compact Honey for Prevention of Pigmentation From Visible Light|A Randomized, Single-blind Study of the Ability of Avène Compact Honey to Prevent Pigmentation Induced by Visible Light in Subjects With Skin Phototype III or IV|Completed||N/A|21|Actual|Pierre Fabre Dermo Cosmetique||2|||f||||f||||||||||2018-05-31 22:05:53.798545|2018-05-31 22:05:53.798545
NCT01448109|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-12-10|2011-10-05|2011-10-07|Estimate|||||||2017-12-10|2017-12-12|Actual|June 13, 2012|Actual|2012-06-13|September 2017|2017-09-30|November 20, 2017|Actual|2017-11-20|October 22, 2017|Actual|2017-10-22||Interventional|ADRENAL||ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock|A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock|Completed||Phase 4|3800|Actual|The George Institute||2|||f||||t||||||||||2018-05-31 22:05:53.896157|2018-05-31 22:05:53.896157
NCT01448096|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-08-27|2011-10-06|2011-10-07|Estimate|||||||2017-08-27|2017-08-29|Actual|August 2011||2011-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma|Multi-center Phase II Study of the Combination of R-CHOP (RItuximab Plus Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) and Prophylactic Intrathecal Chemotherapy With Methotrexate in Patients With CD20+ Primary Breast Diffuse Large B-cell Lymphoma|Active, not recruiting||Phase 2|33|Actual|Chonbuk National University Hospital||1|||f||||f||||||||||2018-05-31 22:05:54.052711|2018-05-31 22:05:54.052711
NCT01448083|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-09-16|2011-10-05|2011-10-07|Estimate|||||||2012-09-16|2012-09-18|Estimate|October 2011||2011-10-31|September 2012|2012-09-30||||||||Observational|||Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours||Unknown status|Recruiting||40|Anticipated|Nuclear Medicine Consultants, Inc.|||1||f||||f||||||||||2018-05-31 22:05:54.237873|2018-05-31 22:05:54.237873
NCT01448070|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-02-23|2011-10-05|2011-10-07|Estimate|||||||2017-02-23|2017-02-27|Actual|October 15, 2002|Actual|2002-10-15|February 2017|2017-02-28|December 20, 2002|Actual|2002-12-20|December 20, 2002|Actual|2002-12-20||Interventional|||Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers|A Single Centre, Randomized, Balanced Double Blind, Cross-over Trial Investigating the Bioequivalence of Actrapid® Produced by the Current Process and Human Insulin With the Same Formulation as Actrapid®, Produced by the NN729 Process|Completed||Phase 1|28|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:05:54.330562|2018-05-31 22:05:54.330562
NCT01448057|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2016-08-16||2017-01-18|2011-10-06|2011-10-07|Estimate|2016-11-17|2017-01-13|Estimate||||2017-01-18|2017-03-03|Actual|July 2013||2013-07-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu|A Prospective, Randomized, Investigator-Blind Study to Compare Three Days of Treatment With Paracetamol (500 mg) / Dimethindene Maleate (1 mg) / Phenylephrine Hydrochloride (10 mg) Tablets Versus Paracetamol 500 mg Alone in the Treatment of Nasal Congestion and Other Symptoms Due to Cold and Flu|Completed||Phase 3|341|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:05:54.656746|2018-05-31 22:05:54.656746
NCT01448044|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2015-08-07||2015-09-11|2011-10-06|2011-10-07|Estimate|2015-08-07|2015-09-07|Estimate||||2015-09-11|2015-10-12|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C|A Phase 3 Evaluation of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 4|Completed||Phase 3|152|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 22:05:54.948857|2018-05-31 22:05:54.948857
NCT01448031|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2012-05-09|2011-10-06|2011-10-07|Estimate|||||||2012-05-09|2012-05-10|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Healthy Female and Male Volunteers Aspirin Study|A Phase I, Open-label, Randomized, Two Way Crossover Pharmacokinetic Study Comparing the Bioavailability of Acetylsalicylic Acid (ASA) After 5 Days Repeated Once Daily Administration of a Fixed Dose Combination Capsule of ASA 81 mg/Esomeprazole 20 mg and ASA 80 mg (European Aspirin Reference Product)|Completed||Phase 1|54|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:05:55.504973|2018-05-31 22:05:55.504973
NCT01448018|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-08-12|2011-10-05|2011-10-06|Estimate|||||||2014-08-12|2014-08-13|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|CHIC-3||Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion|Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis|Completed||Phase 4|45|Actual|Centre Hospitalier Intercommunal Creteil||3|||f||||t||||||||||2018-05-31 22:05:55.580195|2018-05-31 22:05:55.580195
NCT01448005|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-12-04|2011-10-05|2011-10-06|Estimate|||||||2017-12-04|2017-12-06|Actual|February 2011||2011-02-28|December 2017|2017-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||LifeVest Post-CABG Registry|Post-market Release Registry of Wearable Defibrillator Use in Patients With Ventricular Dysfunction Following CABG Surgery|Terminated|||69|Actual|Zoll Medical Corporation|||1|Enrollment|f||||f||||||||||2018-05-31 22:05:55.682178|2018-05-31 22:05:55.682178
NCT01447992|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-06-17|2011-10-05|2011-10-06|Estimate|||||||2014-06-17|2014-06-19|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|HomeCTR1_2||Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Padova|Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing|Completed||Early Phase 1|5|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:05:55.795971|2018-05-31 22:05:55.795971
NCT01447979|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-11-28|2011-10-05|2011-10-06|Estimate|||||||2012-11-28|2012-11-29|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|HomeCTR1_1||Feasibility Study of a Portable Artificial Pancreas System in Type 1 Diabetes Mellitus (T1DM) - Montpellier|Pilot Study 1 of Outpatient Control-to-Range - System and Monitoring Testing|Completed||Early Phase 1|5|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:05:55.858368|2018-05-31 22:05:55.858368
NCT01447966|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-03-24|2011-10-05|2011-10-06|Estimate|||||||2014-03-24|2014-03-26|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Interventional|||Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder|Family Based Cognitive-Behavioral Treatment for Preschoolers With Obsessive Compulsive Disorder|Completed||N/A|31|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 22:05:55.923728|2018-05-31 22:05:55.923728
NCT01447953|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-12-14|2011-10-05|2011-10-06|Estimate|||||||2015-12-14|2015-12-15|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|||Activity and Life-role Targeted Pain Rehabilitation in Primary Health Care|Activity and Life-role Targeted Pain Rehabilitation in Primary Health Care: a Randomized Controlled Trial|Terminated||N/A|65|Actual|Uppsala University||2||"Organizational changes in health care made further recruitment to the treatment options~   unpossible."|f||||f||||||||||2018-05-31 22:05:55.98536|2018-05-31 22:05:55.98536
NCT01447940|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2014-12-08|2011-10-05|2011-10-06|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2014|Actual|2014-07-31||Interventional|TELEDIAB-3||Prospective Assessment of Meos Telemedicine E-portal on Ambulatory Care of Type 1 Diabetic Patients|Prospective Assessment of Meos Telemedicine E-portal on Ambulatory Care of Type 1 Diabetic Patients|Unknown status|Active, not recruiting|Phase 3|720|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 22:05:56.053118|2018-05-31 22:05:56.053118
NCT01447927|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|2014-04-02||2014-06-19|2011-10-05|2011-10-06|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|||Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus|Randomized Double Blind Placebo Controlled Trial of Barrett's Esophagus Chemoprevention With Metformin|Completed||Phase 2|93|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 22:05:56.147817|2018-05-31 22:05:56.147817
NCT01447914|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2015-01-26||2015-03-12|2011-10-05|2011-10-06|Estimate|2015-03-12|2015-03-13|Estimate||||2015-03-12|2015-03-13|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma|A Phase II Study of the c-Met Inhibitor ARQ 197 in Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:05:56.52988|2018-05-31 22:05:56.52988
NCT01447901|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2015-03-27|2011-10-05|2011-10-06|Estimate|||||||2015-03-27|2015-03-30|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies|Prospective, Non-interventional, Non-randomised, Open-label, Adult Study to Assess the Long Term Biological Therapeutic Response to Alipogene Tiparvovec in Lipoprotein Lipase Deficiency (LPLD) and Comparing Postprandial Chylomicron Metabolism Following a Radiolabeled Meal in LPLD Subjects Previously Treated With Alipogene Tiparvovec (Studies CT-AMT-011-01 or -02) to Untreated LPLD Subjects (Study PREPARATION-02) and to Healthy Volunteers|Terminated|||19|Anticipated|Amsterdam Molecular Therapeutics|||3|Business reason|f||||f||||||Samples With DNA|"~     whole blood, serum, urine, faeces~   "|||2018-05-31 22:05:56.76387|2018-05-31 22:05:56.76387
NCT01447888|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-10-26|2011-10-05|2011-10-06|Estimate|||||||2011-10-26|2011-10-27|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Interventional|||Perioperative Pain Management In Spine Surgery Patients: Part I|Perioperative Pain Management In Spine Surgery Patients: Part I|Unknown status|Recruiting|N/A|200|Anticipated|Abbott Northwestern Hospital||2|||f||||f||||||||||2018-05-31 22:05:56.828795|2018-05-31 22:05:56.828795
NCT01447875|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2014-01-28|2011-10-05|2011-10-06|Estimate|||||||2014-01-28|2014-01-29|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of Sedative on the Fluid Responsiveness in Critically Ill Patients|The Effects of Propofol and Dexmedetomidine Infusion on the Fluid Responsiveness in Critically Ill Patients|Completed||Phase 1|100|Actual|Southeast University, China|||||f||||t||||||||||2018-05-31 22:05:57.760831|2018-05-31 22:05:57.760831
NCT01447862|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2015-05-12|2011-10-05|2011-10-06|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation|Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation|Completed||Phase 4|101|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 22:05:57.823525|2018-05-31 22:05:57.823525
NCT01447849|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2012-11-09||2017-05-05|2011-10-04|2011-10-06|Estimate|2013-07-31|2013-09-23|Estimate||||2017-05-05|2017-06-09|Actual|August 2011||2011-08-31|November 2015|2015-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Lubiprostone and Mucus Secretion in Patients With Chronic Constipation|The Impact of Lubiprostone on Mucus Secretion in Asymptomatic Volunteers and Patients With Chronic Constipation|Completed||Phase 2/Phase 3|40|Actual|Texas Tech University Health Sciences Center, El Paso||2|||f||||f||||||||No||2018-05-31 22:05:57.898978|2018-05-31 22:05:57.898978
NCT01447836|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|November 2012|Anticipated|2012-11-30|August 2012|Anticipated|2012-08-31||Observational|||Indocyanine Clearance Rate and Septic Liver Injury|Prognostic Value of Indocyanine Clearance Rate for Sepsis Patients in ICU|Unknown status|Recruiting||100|Anticipated|Sun Yat-sen University|||2||f||||t||||||Samples With DNA|"~     Blood for transaminase, hemoglobin, prothrombin time, lactate and oxygen pressure test.~   "|||2018-05-31 22:05:58.208074|2018-05-31 22:05:58.208074
NCT01447823|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2011-10-07|2011-10-05|2011-10-06|Estimate|||||||2011-10-07|2011-10-12|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring|Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring|Unknown status|Recruiting||40|Anticipated|University of Zurich|||||f||||t||||||||||2018-05-31 22:05:58.277678|2018-05-31 22:05:58.277678
NCT01447810|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2015-01-12|2011-10-04|2011-10-06|Estimate|||||||2015-01-12|2015-01-14|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SJCIT||Constraint-Induced Movement Therapy in a Pediatric Oncology Population|Constraint Induced Movement Therapy in a Pediatric Oncology Population (SJCIT): A Pilot Study|Completed||N/A|10|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-05-31 22:05:58.436954|2018-05-31 22:05:58.436954
NCT01447797|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-04-01|2011-10-05|2011-10-06|Estimate|||||||2012-04-01|2012-04-03|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin|Single Dose Open-label Comparative Pharmacokinetic Study to Assess the Pharmacokinetic Characteristics of Irbesartan and Atorvastatin Between Irbesartan/Atorvastatin Combination Tablet and Coadministration of Irbesartan and Atorvastatin Tablets in Healthy Male Subjects|Completed||Phase 1|52|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 22:05:58.522327|2018-05-31 22:05:58.522327
NCT01447784|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2013-07-16|2011-10-05|2011-10-06|Estimate|||||||2013-07-16|2013-07-17|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||ToleroMune House Dust Mites (HDM) Exposure Chamber Study|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber.|Completed||Phase 2|172|Actual|Circassia Limited||4|||f||||f||||||||||2018-05-31 22:05:58.599333|2018-05-31 22:05:58.599333
NCT01447771|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-04-08|2011-10-04|2011-10-06|Estimate|||||||2014-04-08|2014-04-09|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Decision Support for Women With Breast Cancer|Decision Support for Women With Breast Cancer|Terminated||N/A|14|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||Lack of funds to continue and volunteer recruitment member left position|f||||t||||||||||2018-05-31 22:05:58.685486|2018-05-31 22:05:58.685486
NCT01447758|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2013-04-30|2011-10-04|2011-10-06|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.|Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. A Multicentre, Prospective, Randomised Phase Ib Study in Subjects Investigating Safety,Tolerability and Pharmacokinetics of LEO 29102 Cream (2.5 mg/g) When Treating Atopic Dermatitis Lesions Twice Daily for 7 Days (Cohorts I, II and III) and 6 Weeks (Cohort IV)|Terminated||Phase 1|58|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 22:05:58.764625|2018-05-31 22:05:58.764625
NCT01447745|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-11-26|2011-10-04|2011-10-06|Estimate|||||||2015-11-26|2015-11-30|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Abdominal Fat and Imaging Measurements of Heart Disease|Visceral Obesity/Ectopic Fat and Non-invasive Markers of Atherosclerosis: A Cardiometabolic-cardiovascular Imaging Study|Unknown status|Recruiting||500|Anticipated|Laval University|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, white cells~   "|||2018-05-31 22:05:58.837599|2018-05-31 22:05:58.837599
NCT01447732|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2015-03-17|2011-10-05|2011-10-06|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors|Two-Part, Open-Label, Multi-Center Phase 1 Study of Monoclonal Antibody CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors|Completed||Phase 1|71|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||f||||||||||2018-05-31 22:05:58.908843|2018-05-31 22:05:58.908843
NCT01447719|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2012-04-06|2011-11-21|2012-05-17|2011-10-05|2011-10-06|Estimate|2012-04-06|2012-05-07|Estimate|2011-11-21|2011-11-23|Estimate|2012-05-17|2012-05-22|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07|Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07|Completed||Phase 3|110|Actual|Avid Radiopharmaceuticals|||||f||||f||||||||||2018-05-31 22:05:59.01508|2018-05-31 22:05:59.01508
NCT01447706|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|2016-02-17||2016-04-11|2011-10-04|2011-10-06|Estimate|2016-04-11|2016-05-12|Estimate||||2016-04-11|2016-05-12|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|September 2013|Actual|2013-09-30||Interventional|||A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers|A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers|Completed||Phase 2|223|Actual|Merrimack Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:05:59.308318|2018-05-31 22:05:59.308318
NCT01447693|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate||||October 2011|2011-10-31||||||||Interventional|||Treatment of Uremic Pruritus by Olive-omega 3 Ointment||Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-05-31 22:06:00.034688|2018-05-31 22:06:00.034688
NCT01447680|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-09-04|2011-10-05|2011-10-06|Estimate|||||||2015-09-04|2015-09-07|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing|Clinical Trial Comparing Two Types of Blood Samples (Plasma and SMARTplasma) for HIV and HCV Antibody Testing|Completed|||1600|Anticipated|G & W Laboratories Inc.|||3||f||||f||||||Samples Without DNA|"~     Plasma and SMARTplasma (SMARTplasma is plasma sample from whole blood treated with SMARTstim)~   "|||2018-05-31 22:06:00.092178|2018-05-31 22:06:00.092178
NCT01447667|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2017-10-11|2011-10-04|2011-10-06|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2011||2011-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MRE||Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)|Magnetic Resonance Elastography Score Reflecting Hepatic Fibrosis as an Independent Predictor for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation Therapy|Recruiting||N/A|72|Anticipated|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 22:06:00.181234|2018-05-31 22:06:00.181234
NCT01447654|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-07-08|2011-10-05|2011-10-06|Estimate|||||||2014-07-08|2014-07-09|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|INHERIT||Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy|INHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.|Completed||Phase 2|130|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 22:06:00.260253|2018-05-31 22:06:00.260253
NCT01447641|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-04-12|2011-10-05|2011-10-06|Estimate|||||||2017-04-12|2017-04-13|Actual|August 2011||2011-08-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Sleep, Circadian Rhythms and Cluster Headache|Characterisation of Sleep and Circadian Physiology in Individuals With Cluster Headache|Completed|||8|Actual|University of Surrey|||1||f||||f||||||Samples With DNA|"~     Blood hormonal and circulating lymphocyte mRNA assays~   "|||2018-05-31 22:06:00.332774|2018-05-31 22:06:00.332774
NCT01447628|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2018-01-29|2011-10-05|2011-10-06|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2011||2011-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients|What is the Effect of Intravenous Iron Supplementation on Cardiopulmonary Haemodynamics, Exercise Capacity and Quality of Life in Patients With IPAH and Iron Deficiency?|Recruiting||Phase 2|60|Anticipated|Imperial College London||2|||f||||f||||||||Undecided||2018-05-31 22:06:00.403831|2018-05-31 22:06:00.403831
NCT01447615|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-07-19|2011-10-04|2011-10-06|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2012||2012-02-29|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Bridges to the Future: Economic Empowerment for AIDS-Orphaned Children in Uganda|Bridges to the Future: Economic Empowerment for AIDS-Orphaned Children in Uganda|Active, not recruiting||N/A|1440|Anticipated|Columbia University||3|||f||||f||||||||||2018-05-31 22:06:00.505071|2018-05-31 22:06:00.505071
NCT01447602|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2014-09-02|2011-10-04|2011-10-06|Estimate|||||||2014-09-02|2014-09-04|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|IPT-A-CSP||A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior|An Open Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior|Completed||Phase 3|10|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-05-31 22:06:00.58738|2018-05-31 22:06:00.58738
NCT01447589|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-06-22|2011-10-04|2011-10-06|Estimate|||||||2016-06-22|2016-06-23|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|NelfLung||Radical Lung Radiotherapy Plus Nelfinavir|A Phase I Dose Escalation Study of the HIV Protease Inhibitor, Nelfinavir, Given Concomitantly With Radical Radiotherapy (RT) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 1/Phase 2|0|Actual|Oxford University Hospitals NHS Trust||1||failed to recruit, no suitable patients|f||||f||||||||||2018-05-31 22:06:00.650818|2018-05-31 22:06:00.650818
NCT01447576|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2015-08-04|2014-01-03|2015-10-06|2011-10-04|2011-10-06|Estimate|2015-10-06|2015-11-06|Estimate|2014-01-03|2014-02-05|Estimate|2015-10-06|2015-11-06|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder|A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients With Major Depressive Disorder|Completed||Phase 2|1036|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-05-31 22:06:00.744791|2018-05-31 22:06:00.744791
NCT01447563|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Comparative Bioavailability Study of Two Oral Formulations of Clopidogrel|Bioavailability of Two Oral Formulations of Clopidogrel: A Randomized, Open Label, Single Dose, Two-Period, Crossover Comparison in Healthy Mexican Volunteers|Terminated||Phase 1|32|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t||||||||||2018-05-31 22:06:01.095728|2018-05-31 22:06:01.095728
NCT01447550|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2016-08-15|2011-10-05|2011-10-06|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan|Treatment of Thromboangiitis Obliterans (Buerger's Disease) With Bosentan|Completed|||12|Actual|Hospital Universitario Getafe|||1||f||||t||||||||||2018-05-31 22:06:01.171298|2018-05-31 22:06:01.171298
NCT01447537|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2015-12-11|2011-10-05|2011-10-06|Estimate|||||||2015-12-11|2015-12-14|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis||Completed||N/A|30|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 22:06:01.244667|2018-05-31 22:06:01.244667
NCT01447524|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Caloric Restriction and Insulin Secretion|Very Low Calorie Diet: a Quick Therapeutic Tool to Improve Beta Cell Function in Morbidly Obese Patients With Type 2 Diabetes Mellitus|Completed||N/A|14|Actual|University of Rome Tor Vergata|||||f||||t||||||||||2018-05-31 22:06:01.318215|2018-05-31 22:06:01.318215
NCT01447511|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2014-07-30||2016-06-22|2011-10-04|2011-10-06|Estimate|2014-07-30|2014-08-18|Estimate||||2016-06-22|2016-07-22|Estimate|May 2009||2009-05-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pharmacogenetics of Warfarin Induction and Inhibition|Pharmacogenetics of Warfarin Induction and Inhibition|Completed||N/A|39|Actual|University of Minnesota - Clinical and Translational Science Institute||5|||f||||f||||||||||2018-05-31 22:06:01.399831|2018-05-31 22:06:01.399831
NCT01447498|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2015-11-09|2011-10-05|2011-10-06|Estimate|||||||2015-11-09|2015-11-11|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment|Effect of a Systematic Screening for Risk-factors for Ulcer Bleeding Before Post-PCI Anti-thrombotic Treatment|Completed||N/A|2024|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 22:06:01.909197|2018-05-31 22:06:01.909197
NCT01447485|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-05-06|2011-10-05|2011-10-06|Estimate|||||||2012-05-06|2012-05-08|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients|A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age|Completed||Phase 1|12|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:06:01.99321|2018-05-31 22:06:01.99321
NCT01447472|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|May 2003||2003-05-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2009|Actual|2009-05-31||Interventional|||-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms|Human Study of the Metabolic Changes Induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in the Metabolism of Dextromethorphan and Caffeine|Completed||Phase 1|27|Actual|Parc de Salut Mar||1|||f||||f||||||||||2018-05-31 22:06:02.083221|2018-05-31 22:06:02.083221
NCT01447459|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-11-13|2011-10-04|2011-10-06|Estimate|||||||2017-11-13|2017-11-17|Actual|February 2011||2011-02-28|November 2017|2017-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|IHOP||Effects of Educational Intervention on Long-Term Outcomes of Hospitalized Children With Asthma|Effects of Educational Intervention on Long-Term Outcomes of Hospitalized Children With Asthma|Completed||N/A|144|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 22:06:02.171276|2018-05-31 22:06:02.171276
NCT01447446|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2016-09-27||2017-02-10|2011-10-05|2011-10-06|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|September 2011||2011-09-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational||Core population: treatment-naive/experienced participants who were without contraindication to Peg-IFN and RBV, end stage renal disease, major organ transplantation, co-infection with hepatitis B or HIV, acute hepatitis and with positive HCV RNA at baseline, known genotype, 1 of 6 treatment (excluding non-G1 participants receiving triple therapy).|An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C|Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C|Completed|||4442|Actual|Hoffmann-La Roche|||6||f||||||||||||||2018-05-31 22:06:02.41409|2018-05-31 22:06:02.41409
NCT01447433|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2012-01-03||2012-07-26|2011-10-04|2011-10-06|Estimate|2012-02-01|2012-03-06|Estimate||||2012-07-26|2012-08-01|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Effect of Calcium + Vitamin D Supplementation on Weight Management in Very-low Calcium Consumers|A Randomized, Open-label, Parallel Groups-controlled Clinical Trial to Evaluate the Effect of Calcium Plus Vitamin D Supplementation on Weight Management in Overweight and Obese Very-low Calcium Consumers|Completed||Phase 4|53|Actual|Changhai Hospital|The study sample was mostly women.|2|||f||||f||||||||||2018-05-31 22:06:06.024469|2018-05-31 22:06:06.024469
NCT01447420|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2016-05-18||2016-06-24|2011-10-04|2011-10-06|Estimate|2016-05-18|2016-06-24|Estimate||||2016-06-24|2016-07-25|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Safety population included all enrolled participants who received at least one dose of any study medication.|A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)|A Clinical Trial Comparing the Sustained Virological Response in Terms of Expression Profile of IL- 28B in Genotype 1 HCV-Infected Treatment-Naïve Subjects With Chronic Hepatitis C on Pegasys® (Peginterferon Alfa-2A) Plus Copegus® (Ribavirin)|Completed||Phase 4|129|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:06:06.702187|2018-05-31 22:06:06.702187
NCT01447407|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2013-05-28|2011-10-04|2011-10-06|Estimate|||||||2013-05-28|2013-05-29|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Study to Assess the Effect of Adjuvant and Route of Administration on the Safety, Tolerability, and Immunogenicity of NDV-3 Vaccine Against S.Aureus and Candida|Phase 1b Partially-blind,Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of NDV-3, A Recombinant Alum Adjuvanted Vaccine for S. Aureus and Candida Infections, Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults|Completed||Phase 1|160|Actual|NovaDigm Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 22:06:07.140452|2018-05-31 22:06:07.140452
NCT01447394|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2012-02-02|2011-10-05|2011-10-06|Estimate|||||||2012-02-02|2012-02-03|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|August 2014|Anticipated|2014-08-31|March 2014|Anticipated|2014-03-31||Interventional|||Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C|A Double-Blinded Randomized Control Study Evaluating the Efficacy and Safety of Pegylated Lambda Interferon Compared to Pegylated Alfa-2a Interferon, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 or 4 Chronic Hepatitis C Subjects|Withdrawn||Phase 3|0|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 22:06:07.328023|2018-05-31 22:06:07.328023
NCT01447381|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2012-11-01|2011-10-04|2011-10-06|Estimate|||||||2012-11-01|2012-11-05|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||Systemic Therapies for Pediatric Atopic Dermatitis|Systemic Therapies for Pediatric Atopic Dermatitis|Recruiting|||250|Anticipated|Rady Children's Hospital, San Diego|||4||f||||t||||||||||2018-05-31 22:06:07.624265|2018-05-31 22:06:07.624265
NCT01447368|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-01-14|2011-10-04|2011-10-06|Estimate|||||||2017-01-14|2017-01-18|Estimate|May 2010||2010-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients|Comparison of Medical (Oral Cinacalcet) Therapy Versus Surgical Therapy (Total Parathyroidectomy) on Vascular/Valvular Calcification in Chronic Peritoneal Dialysis Patients With Secondary Hyperparathyroidism - A Pilot Study|Recruiting||N/A|70|Anticipated|The University of Hong Kong||2|||f||||f||||||||No||2018-05-31 22:06:07.723396|2018-05-31 22:06:07.723396
NCT01447355|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-10-07|2011-10-04|2011-10-06|Estimate|||||||2014-10-07|2014-10-08|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|||Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation|Pilot Study on the Bioactivity of Vitamin D in the Skin After Oral Supplementation|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:06:07.838036|2018-05-31 22:06:07.838036
NCT01447342|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-03-23|2011-10-04|2011-10-06|Estimate|||||||2015-03-23|2015-03-24|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines||Completed||Phase 2/Phase 3|54|Actual|MyoScience, Inc|||||f||||f||||||||||2018-05-31 22:06:07.903667|2018-05-31 22:06:07.903667
NCT01447329|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-08-09|2011-10-05|2011-10-06|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2011|Actual|2011-12-31|August 2017|2017-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|BFAKnee||Ear Acupuncture for Pain Associated With Ambulatory Arthroscopic Knee Surgery|Ear Acupuncture for Post-operative Pain Associated With Ambulatory Arthroscopic Knee Surgery - A Randomized Controlled Trial|Completed||N/A|60|Actual|Mike O'Callaghan Military Hospital||2|||f||||f||||||||No||2018-05-31 22:06:07.970558|2018-05-31 22:06:07.970558
NCT01447316|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2013-01-16|2011-10-05|2011-10-06|Estimate|||||||2013-01-16|2013-01-17|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Bariatric Surgery on Short Term Weight Loss- Related Changes in Gait|Impact of Bariatric Surgery on Short Term Weight Loss- Related Changes in Gait and Quality of Life|Completed|||36|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 22:06:08.313657|2018-05-31 22:06:08.313657
NCT01447303|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-01-24|2011-10-04|2011-10-06|Estimate|||||||2014-01-24|2014-01-27|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Functional and Quality of Life Outcomes Following Viscosupplementation for Knee Osteoarthritis|Functional and Quality of Life Outcomes Following Hyaluronic Acid (HA) Viscosupplementation for Knee Osteoarthritis|Terminated|||43|Actual|University of Florida|||1|Inability to recruit subjects|f||||f||||||||||2018-05-31 22:06:08.398104|2018-05-31 22:06:08.398104
NCT01447290|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-10-10|2011-10-05|2011-10-06|Estimate|||||||2014-10-10|2014-10-13|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|P:C Ratio||Comparison of Random Spot Urine Protein:Creatinine Ratio to 24-Hour Timed Urine Protein Collection in the Evaluation of Preeclampsia|Comparison of Random Spot Urine Protein:Creatinine Ratio to 24-Hour Timed Urine Protein Collection in the Evaluation of Preeclampsia|Completed|||100|Actual|Mike O'Callaghan Military Hospital|||1||f||||f||||||||||2018-05-31 22:06:08.475775|2018-05-31 22:06:08.475775
NCT01447277|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2013-05-16|2011-10-04|2011-10-06|Estimate|||||||2013-05-16|2013-05-17|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Prospective Evaluation of Femoral Versus Femoral and Sciatic Nerve Block for Ambulatory Anterior Cruciate Ligament (ACL) Reconstruction|The Addition of a Preoperative Sciatic Nerve Block to a Femoral Nerve Block for Ambulatory Arthroscopic ACL Reconstruction|Unknown status|Recruiting|N/A|60|Anticipated|University of California, San Francisco||2|||f||||||||||||||2018-05-31 22:06:08.534029|2018-05-31 22:06:08.534029
NCT01447264|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Effectiveness of Water Exercises on Isokinetic Muscle Strength|Comparison of the Effectiveness Between Land and Water Exercises on Isokinetic Muscle Strength of Lower Limbs in Women With Rheumatoid Arthritis: a Randomized Controlled Trial|Completed||Phase 3|100|Actual|Federal University of São Paulo||3|||f||||f||||||||||2018-05-31 22:06:08.606683|2018-05-31 22:06:08.606683
NCT01447251|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2014-10-10|2011-10-04|2011-10-06|Estimate|||||||2014-10-10|2014-10-13|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|OSA & DM||Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea|Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea|Completed||N/A|70|Actual|Mike O'Callaghan Military Hospital||4|||f||||f||||||||||2018-05-31 22:06:08.684693|2018-05-31 22:06:08.684693
NCT01447238|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-10-04|2011-10-04|2011-10-06|Estimate|||||||2011-10-04|2011-10-06|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound With Fine Needle Aspiration (EUS/FNA), Direct Visualization, and Confocal Laser-induced Endomicroscopy—A Pilot Study|Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound With Fine Needle Aspiration (EUS/FNA), Direct Visualization, and Confocal Laser-induced Endomicroscopy—A Pilot Study|Unknown status|Recruiting||30|Anticipated|University of California, Irvine|||||f||||t||||||||||2018-05-31 22:06:08.767895|2018-05-31 22:06:08.767895
NCT01447225|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|2016-07-12||2016-09-13|2011-10-05|2011-10-06|Estimate|2016-09-13|2016-09-14|Estimate||||2016-09-13|2016-09-14|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors|A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors|Completed||Phase 1|43|Actual|Merrimack Pharmaceuticals||4|||f||||f||||||||||2018-05-31 22:06:09.002397|2018-05-31 22:06:09.002397
NCT01447212|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2016-06-05|2011-10-04|2011-10-06|Estimate|||||||2016-06-05|2016-06-07|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|June 2014|Actual|2014-06-30||Interventional|SALOME||Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)|SALOME: Multi-Centre, Double Blind Randomized Controlled Trial Comparing The Effectiveness Of Diacetylmorphine Vs. Hydromorphone For The Treatment Of Long-Term Injection Opioid Users Who Do Not Benefit From Available Therapies|Completed||Phase 3|202|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 22:06:10.816873|2018-05-31 22:06:10.816873
NCT01446835|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-06-26|2011-10-03|2011-10-05|Estimate|||||||2012-06-26|2012-06-28|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Asian Clinical Evaluation of an Investigational Contact Lens for Cosmetic Effect||Completed||N/A|151|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:06:15.569726|2018-05-31 22:06:15.569726
NCT01447199|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2018-01-12|2011-10-05|2011-10-06|Estimate|||||||2018-01-12|2018-01-17|Actual|September 1994|Actual|1994-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)|The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)|Recruiting|||2000|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||Samples With DNA|"~     Participants will have a single sample (8-10 teaspoons) of blood collected at M. D. Anderson,~     depending upon current health status. In the case of individuals not coming to the clinic, a~     blood drawing kit will be sent to the participant's home, which will include instructions and~     a postage-paid return express mail envelope. If participant unable or unwilling to give a~     blood sample, saliva samples can be collected instead.~   "|||2018-05-31 22:06:11.102805|2018-05-31 22:06:11.102805
NCT01447186|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-03-08|2011-10-04|2011-10-06|Estimate|||||||2018-03-08|2018-03-12|Actual|September 21, 2012|Actual|2012-09-21|March 2018|2018-03-31|January 13, 2015|Actual|2015-01-13|January 13, 2015|Actual|2015-01-13||Observational|||Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men|Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men|Completed|||4|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 22:06:11.295756|2018-05-31 22:06:11.295756
NCT01447173|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-10-22|2011-10-04|2011-10-06|Estimate|||||||2012-10-22|2012-10-23|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vitamin and Asthma Study||Completed||Phase 4|10|Actual|Augusta University||2|||f||||||||||||||2018-05-31 22:06:11.39753|2018-05-31 22:06:11.39753
NCT01447160|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|October 2011||2011-10-31|July 2011|2011-07-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Effectiveness of Facet Joint Infiltration in Low Back Pain|Effectiveness of Facet Joint Infiltration in Low Back Pain|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 22:06:11.482745|2018-05-31 22:06:11.482745
NCT01447147|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2014-12-12|2011-10-04|2011-10-06|Estimate|||||||2014-12-12|2014-12-15|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy|Completed||Phase 2|332|Actual|ChemoCentryx||3|||f||||t||||||||||2018-05-31 22:06:11.625154|2018-05-31 22:06:11.625154
NCT01447134|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-05|2011-10-05|2011-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Observational|||RGD-K5 in Head and Neck Cancer Patients|Phase II Study of [18F]RGD-K5 in Head and Neck Cancer Patients|Unknown status|Enrolling by invitation||100|Anticipated|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-05-31 22:06:12.080854|2018-05-31 22:06:12.080854
NCT01447121|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|2012-09-20||2016-01-29|2011-10-04|2011-10-06|Estimate|2012-09-20|2012-10-22|Estimate||||2016-01-29|2016-02-29|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||User Study of an Investigational Blood Glucose Monitoring System|Tatsu/Tradewind System User Performance Evaluation|Completed||N/A|118|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 22:06:12.188298|2018-05-31 22:06:12.188298
NCT01447108|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2012-12-26|2011-10-02|2011-10-05|Estimate|||||||2012-12-26|2012-12-27|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Surface Acoustic Wave Ultrasound in Trigeminal Neuralgia Pain|Examining the Efficacy of Low Intensity Low Frequency Surface Acoustic Wave Ultrasound(LILF/SAWU) in Trigeminal Neuralgia Pain|Completed||Phase 4|16|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 22:06:12.426045|2018-05-31 22:06:12.426045
NCT01447095|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2014-07-18|2011-10-02|2011-10-05|Estimate|||||||2014-07-18|2014-07-21|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage|Effect of Prostacyclin Infusion on Cerebral Vessels, Cerebral Bloodflow and Cerebral Metabolism in Patients With Subarachnoid Haemorrhage|Completed||Phase 2|90|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 22:06:12.74486|2018-05-31 22:06:12.74486
NCT01447082|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2014-02-06|2011-10-04|2011-10-05|Estimate|||||||2014-02-06|2014-02-07|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|GPRD SeroquelS||General Practice Research Database Seroquel XR Safety Study|Epidemiology Study to Assess the Safety of a New Slow-release Form of Seroquel (Quetiapine) in the Post-marketing Phase in the UK|Completed|||37372|Actual|AstraZeneca|||2||f||||||||||||||2018-05-31 22:06:12.985589|2018-05-31 22:06:12.985589
NCT01447069|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2011-10-02|2011-10-02|2011-10-05|Estimate|||||||2011-10-02|2011-10-05|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Use of Beta-agonists in Stable Severe Congestive Heart Failure||Unknown status|Not yet recruiting|N/A|30|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 22:06:13.140344|2018-05-31 22:06:13.140344
NCT01447056|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2017-11-02|2011-10-04|2011-10-05|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2012||2012-02-29|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|March 2015|Actual|2015-03-31||Interventional|MALTED||Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases|Most Closely HLA-Matched Allogeneic LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Relapsed EBV-Associated Diseases|Active, not recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 22:06:13.504996|2018-05-31 22:06:13.504996
NCT01447043|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2014-01-24|2011-10-04|2011-10-05|Estimate|||||||2014-01-24|2014-01-27|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|August 2011|Actual|2011-08-31||Observational|AURA||Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)|AURA Study: A Retrospective Non-interventional Study (NIS) to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration (wAMD)|Completed|||2609|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:06:13.636731|2018-05-31 22:06:13.636731
NCT01447030|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2014-10-19|2011-10-04|2011-10-05|Estimate|||||||2014-10-19|2014-10-21|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Long Time Follow up After HJ Following Iatrogenic Bile Duct Injuries|Langtidsopfølgning Efter Kirurgisk Behandling af Iatrogene galdevejslæsioner opstået i Forbindelse Med Cholecystektomi|Completed|||139|Actual|Odense University Hospital|||||f||||f||||||||||2018-05-31 22:06:13.726532|2018-05-31 22:06:13.726532
NCT01447017|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2013-10-18||2013-10-18|2011-10-04|2011-10-05|Estimate|2013-10-18|2013-12-10|Estimate||||2013-10-18|2013-12-10|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||A Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis|A Randomised, Parallel-group, Double-blind, Placebo-controlled Study of DPK-060 to Investigate Clinical Safety and Efficacy in Patients With Acute External Otitis|Completed||Phase 2|69|Actual|DermaGen AB||2|||f||||||||||||||2018-05-31 22:06:13.784978|2018-05-31 22:06:13.784978
NCT01447004|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|March 2010||2010-03-31|February 2010|2010-02-28||||||||Observational|||a Case-control Study of the Association Between Heavy Mental and Children With Attention Deficit Hyperactivity Disorder in Korea|a Case-control Study of the Association Between Heavy Mental and Children With Attention Deficit Hyperactivity Disorder in Korea|Unknown status|Recruiting||100|Anticipated|Hallym University Medical Center|||||f||||f||||||||||2018-05-31 22:06:14.023837|2018-05-31 22:06:14.023837
NCT01446991|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2017-08-04|2011-10-04|2011-10-05|Estimate|||||||2017-08-04|2017-08-07|Actual|April 2012||2012-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy|Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy|Active, not recruiting||Phase 2|50|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 22:06:14.103284|2018-05-31 22:06:14.103284
NCT01446978|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-11-17|2011-10-03|2011-10-05|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs|Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate|Unknown status|Active, not recruiting|Phase 2|150|Anticipated|Sormland County Council, Sweden||2|||f||||t||||||||||2018-05-31 22:06:14.252459|2018-05-31 22:06:14.252459
NCT01446965|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2017-11-07|2011-10-04|2011-10-05|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2008||2008-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|VEST||Vest Prevention of Early Sudden Death Trial and VEST Registry|Prevention of Sudden Death After Myocardial Infarction Using a LifeVest Wearable Cardioverter-defibrillator|Active, not recruiting||Phase 3|2300|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:06:14.381019|2018-05-31 22:06:14.381019
NCT01446952|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2016-04-08|2011-10-04|2011-10-05|Estimate|||||||2016-04-08|2016-04-11|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|September 2012|Actual|2012-09-30||Interventional|||Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects|A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Single Dose Administration in Healthy Subjects|Completed||Phase 1|18|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 22:06:14.639423|2018-05-31 22:06:14.639423
NCT01446939|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2012-10-26|2011-10-04|2011-10-05|Estimate|||||||2012-10-26|2012-10-29|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|July 2014|Anticipated|2014-07-31|February 2014|Anticipated|2014-02-28||Observational|||Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor|Role of Diffusion Tensor Imaging and Transcranial Sonography in the Parkinson's Disease and Essential Tremor|Unknown status|Recruiting||150|Anticipated|Hospital Israelita Albert Einstein|||3||f||||t||||||||||2018-05-31 22:06:14.765663|2018-05-31 22:06:14.765663
NCT01446926|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-01-09|2011-10-03|2011-10-05|Estimate|||||||2018-01-09|2018-01-10|Actual|September 2011||2011-09-30|January 2018|2018-01-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants|Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh|Completed||Phase 1|280|Actual|Sanofi||11|||f||||t||||||||||2018-05-31 22:06:14.882627|2018-05-31 22:06:14.882627
NCT01446913|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-07-30|2011-10-04|2011-10-05|Estimate|||||||2015-07-30|2015-07-31|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|Sleep Tight||Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure|Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure|Completed||Phase 2|255|Actual|Yale University||3|||f||||t||||||||||2018-05-31 22:06:15.012601|2018-05-31 22:06:15.012601
NCT01446900|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2018-01-30|2011-10-03|2011-10-05|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2011||2011-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma|Rituximab-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma|Terminated||Phase 2|25|Actual|European Institute of Oncology||1||low rate in patient accrual|f||||f||||||||||2018-05-31 22:06:15.108606|2018-05-31 22:06:15.108606
NCT01446887|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-10-08|2011-10-04|2011-10-05|Estimate|||||||2011-10-08|2011-10-12|Estimate|January 2007||2007-01-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Prophylactic Anticoagulation for Preventing Deep Vein Thrombosis After Total Hip Arthroplasty|Phase II Study of Prophylactic Anticoagulation for Preventing Deep Vein Thrombosis After Total Hip Arthroplasty|Completed||Phase 2/Phase 3|||The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||||2018-05-31 22:06:15.212138|2018-05-31 22:06:15.212138
NCT01446874|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2016-10-31|2011-10-04|2011-10-05|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2011||2011-09-30|October 2016|2016-10-31||||June 2017|Anticipated|2017-06-30||Interventional|POPP||Prevention of Post-operative Pneumonia (POPP)|Prevention of Postoperative Pneumonia (POPP Study: A Study to Evaluate the Use of a Prophylactic Clinical Strategy to Prevent Postoperative Pneumonia in Patients Undergoing Thoracic Surgery|Active, not recruiting||Phase 2/Phase 3|330|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 22:06:15.329766|2018-05-31 22:06:15.329766
NCT01446861|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2016-08-23|2011-10-04|2011-10-05|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Exocrine Pancreatic Function Testing in Cystic Fibrosis|Pancreatic Failure in Patients With Cystic Fibrosis A Multimodal Study of Exocrine Pancreatic Failure in Cystic Fibrosis|Active, not recruiting|||60|Anticipated|Haukeland University Hospital|||2||f||||f||||||Samples With DNA|"~     Duodenal juice Serum, full Blood Saliva~   "|Yes|Data will be published in peer rewieved journals|2018-05-31 22:06:15.432106|2018-05-31 22:06:15.432106
NCT01446848|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2014-08-11|2011-10-04|2011-10-05|Estimate|||||||2014-08-11|2014-08-12|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Oral Iron Supplementation in Pulmonary Hypertension|Oral Iron Supplementation in Pulmonary Hypertension|Completed||N/A|6|Actual|The Cleveland Clinic||1|||f||||f||||||||||2018-05-31 22:06:15.486643|2018-05-31 22:06:15.486643
NCT01446822|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-03-02|2011-10-04|2011-10-05|Estimate|||||||2018-03-02|2018-03-05|Actual|October 2011||2011-10-31|March 2018|2018-03-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors|Transurethral Resection of Bladder Tumors Without Obturator Nerve Block or Relaxation: Extent of Adductor Muscle Contraction With Monopolar Versus Bipolar Resection Technique|Completed||N/A|44|Actual|Cantonal Hospital of St. Gallen||2|||f||||t||||||||||2018-05-31 22:06:15.631352|2018-05-31 22:06:15.631352
NCT01446809|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2016-11-14|2011-10-04|2011-10-05|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2012||2012-04-30|November 2016|2016-11-30||||July 2016|Actual|2016-07-31||Interventional|||Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma|The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging|Active, not recruiting||N/A|21|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 22:06:15.871243|2018-05-31 22:06:15.871243
NCT01446796|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2013-06-21||2015-02-19|2011-10-04|2011-10-05|Estimate|2013-09-05|2013-11-07|Estimate||||2015-02-19|2015-03-10|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional||Study terminated early|Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)|Hemodynamic and Clinical Effects of Continuous Right Ventricular Pacing in the Early Post-operative Period After Left Ventricular Assist Device Implantation|Terminated||Phase 4|3|Actual|Duke University||2||Recruitment futility|f||||t||||||||||2018-05-31 22:06:16.003171|2018-05-31 22:06:16.003171
NCT01446783|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-11-19|2011-10-03|2011-10-05|Estimate|||||||2012-11-19|2012-11-20|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients|IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients|Completed||N/A|15|Actual|Bispebjerg Hospital||4|||f||||f||||||||||2018-05-31 22:06:16.22672|2018-05-31 22:06:16.22672
NCT01446770|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2012-03-12|2011-10-04|2011-10-05|Estimate|||||||2012-03-12|2012-03-13|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181|A Prospective, Randomized, Comparative Feasibility Study Evaluating the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181 Adjunctive to Surgical Scar Revision|Completed||Phase 2|19|Actual|Halscion, Inc.|||||f||||f||||||||||2018-05-31 22:06:16.305516|2018-05-31 22:06:16.305516
NCT01446757|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2014-03-29|2011-10-04|2011-10-05|Estimate|||||||2014-03-29|2014-04-01|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|AGE-FIT||Ambulatory Geriatric Evaluation - Frailty Intervention Trial|Effectiveness of a Comprehensive CGA on Frailty in Community-dwelling Elderly People - A Randomised, Controlled Trial|Completed||N/A|383|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 22:06:16.363978|2018-05-31 22:06:16.363978
NCT01446744|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2018-01-23|2011-10-03|2011-10-05|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2011||2011-11-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|SABR-COMET||Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)|Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial|Active, not recruiting||Phase 2|99|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 22:06:16.461683|2018-05-31 22:06:16.461683
NCT01446731|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-02|||2016-08-15|2011-10-02|2011-10-05|Estimate|||||||2016-08-15|2016-08-16|Estimate|October 2011||2011-10-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer|Dendritic Cell Vaccination in Combination With Docetaxel for Patients With Cancer Prostate - a Randomized Phase II Study|Completed||Phase 2|43|Actual|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 22:06:16.644091|2018-05-31 22:06:16.644091
NCT01446718|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2016-09-05|2011-10-04|2011-10-05|Estimate|||||||2016-09-05|2016-09-07|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Observational|||A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years|A Longitudinal Observational Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 9-14 Years in Kenya|Active, not recruiting|||179|Actual|Kenyatta National Hospital|||1||f||||f||||||None Retained|"~     Plasma for HPV antibody testing there will be no long term sample storage~   "|||2018-05-31 22:06:16.759054|2018-05-31 22:06:16.759054
NCT01446705|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2015-07-31||2016-07-14|2011-10-04|2011-10-05|Estimate|2015-12-22|2016-01-29|Estimate||||2016-07-14|2016-08-15|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Observational|VLER-IHIE|Baseline cohort consists of Veterans who had 2 outpatient, or 1 inpatient visit to the Indianapolis VAMC in the year prior to the index date of 3/1/12.|Evaluation of VLER-Indiana Health Information Exchange Demonstration Project|Evaluation of VLER_Indiana Health Information Exchange Demonstration Project|Completed|||57073|Actual|VA Office of Research and Development|||2||f||||f||||||||No||2018-05-31 22:06:16.850166|2018-05-31 22:06:16.850166
NCT01446692|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-01-11|2011-10-04|2011-10-05|Estimate|||||||2012-01-11|2012-01-12|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|||||Observational|||Badalona Major Depressive Disorder Database Study|Therapeutic Strategies for the Management of Patients With Major Depressive Disorder (MDD) and Suboptimal Response to Antidepressant Drugs in Primary Care: the Badalona Database Study|Completed|||2260|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 22:06:17.078074|2018-05-31 22:06:17.078074
NCT01446679|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2013-02-20|2011-10-03|2011-10-05|Estimate|||||||2013-02-20|2013-02-21|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|ALWAYS||Special Drug Use-Results Survey of Lipitor Tablets|Special Drug Use-Results Survey of Lipitor Tablets|Completed|||24050|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 22:06:17.144226|2018-05-31 22:06:17.144226
NCT01446666|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2015-06-23|2011-10-03|2011-10-05|Estimate|||||||2015-06-23|2015-06-25|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PRIUS||Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients|A Prospective Intra-individual Cohort Study to Compare Gadoxetic Acid (Primovist®)-Enhanced Magnetic Resonance Image and Ultrasonography for the Surveillance of Early Stage Hepatocellular Carcinoma in Patients at High-risk|Completed|||423|Actual|Asan Medical Center|||1||f||||t||||||Samples With DNA|"~     Buffy coat and serum~   "|||2018-05-31 22:06:17.245567|2018-05-31 22:06:17.245567
NCT01446640|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|MSC||Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury|PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Spinal Cord Injury.|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||t||||||||||2018-05-31 22:06:17.409183|2018-05-31 22:06:17.409183
NCT01446627|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2013-05-02|2011-10-04|2011-10-05|Estimate|||||||2013-05-02|2013-05-03|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Observational|||Use of Insorb Absorbable Vicryl Staples in Skin Closure for Cesarean Section|Comparison of Vicryl Absorbable Sutures and Metal Staples Used in Skin Closure Following Cesarean Section|Completed|||300|Actual|The University of Texas Health Science Center, Houston|||2||f||||f||||||||||2018-05-31 22:06:17.482254|2018-05-31 22:06:17.482254
NCT01446614|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-04|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease|PhaseⅠ/ⅡTrial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease.|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||t||||||||||2018-05-31 22:06:17.5474|2018-05-31 22:06:17.5474
NCT01446601|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-04-14|2011-10-04|2011-10-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea|Pivotal Study of the Apnex Medical™ Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea|Terminated||Phase 3|132|Anticipated|Apnex Medical, Inc.||2|||f||||t||||||||||2018-05-31 22:06:17.685308|2018-05-31 22:06:17.685308
NCT01446588|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2014-05-23|2011-10-03|2011-10-05|Estimate|||||||2014-05-23|2014-05-26|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|OHAYS||Ocular Hypertension And Yoga Study|Ocular Hypertension And Yoga Study|Withdrawn||N/A|0|Actual|Johns Hopkins University||1||No Funding was acquired.|f||||f||||||||||2018-05-31 22:06:17.793648|2018-05-31 22:06:17.793648
NCT01446562|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2016-06-15|2011-10-04|2011-10-05|Estimate|||||||2016-06-15|2016-06-17|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ZEVISS||Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma|Phase II Trial of Y90 Ibritumomab Tiuxetan Post Rituximab-Cyclophosphamide, Doxobrubicn, Vincristine and Prednisone (R-CHOP) Chemotherapy for Newly Diagnosed Patients With Advanced Stage Follicular Lymphoma|Completed||Phase 2|34|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 22:06:17.867685|2018-05-31 22:06:17.867685
NCT01446549|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2013-09-22|2011-09-30|2011-10-05|Estimate|||||||2013-09-22|2013-09-24|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Motor Performance in Parkinson's Disease After High Intensive Exercise or Deep Brain Stimulation|Quantitative Modeling of Motor Performance in Parkinson's Disease After High Intensive Antigravity Locomotor Exercise or Deep Brain Stimulation|Completed||N/A|40|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 22:06:17.927792|2018-05-31 22:06:17.927792
NCT01446536|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2012-03-18|2011-10-04|2011-10-05|Estimate|||||||2012-03-18|2012-03-20|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Quality Improvement Tools in Congestive Heart Failure (CHF)|Decreased Readmissions and Improved Quality of Care With Use of Inexpensive Checklist in Heart Failure|Completed||N/A|96|Actual|St. Joseph Mercy Oakland Hospital||2|||f||||||||||||||2018-05-31 22:06:17.979256|2018-05-31 22:06:17.979256
NCT01446523|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|||2012-04-09|2011-10-02|2011-10-05|Estimate|||||||2012-04-09|2012-04-10|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|endtxninHE||S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE|Serum Endotoxins, Inflammatory Mediators and MR Spectroscopy Before and After Treatment in Minimal Hepatic Encephalopathy|Completed||N/A|60|Actual|Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-05-31 22:06:18.057895|2018-05-31 22:06:18.057895
NCT01446510|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-04-17|2011-10-04|2011-10-05|Estimate|||||||2012-04-17|2012-04-19|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Observational|||Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients|Systematic Review and Meta-Analysis of Venous Thromboembolism Risk Assessment Models in Hospitalized Medical Patients|Withdrawn|||0|Actual|Intermountain Health Care, Inc.|||1||f||||f||||||||||2018-05-31 22:06:18.118322|2018-05-31 22:06:18.118322
NCT01446497|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2011-10-03|2011-10-03|2011-10-05|Estimate|||||||2011-10-03|2011-10-05|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|August 2012|Anticipated|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma|Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients|Unknown status|Recruiting|Phase 4|22|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:06:18.182355|2018-05-31 22:06:18.182355
NCT01446484|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-11-17|2011-10-04|2011-10-05|Estimate|||||||2011-11-17|2011-11-18|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection|Phase 1 Pilot Study Using Autologous CD4+CD25+FoxP3+ T Regulatory Cells and Campath-1H to Induce Renal Transplant Tolerance|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Pirogov Russian National Research Medical University||2|||f||||f||||||||||2018-05-31 22:06:18.251439|2018-05-31 22:06:18.251439
NCT01446471|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-11-30|2011-10-03|2011-10-05|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Observational|||REASON 1 Trial: Sonography in Cardiac Arrest|REASON 1 Trial: Sonography in Cardiac Arrest|Completed|||793|Actual|University of Massachusetts, Worcester|||1||f||||f||||||||||2018-05-31 22:06:18.341028|2018-05-31 22:06:18.341028
NCT01446458|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-03-21|2011-10-02|2011-10-05|Estimate|||||||2016-03-21|2016-03-22|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer|Phase I Study of Stereotactic Body Radiation Therapy and 5-Fluorouracil, Oxaliplatin and Irinotecan (FOLFIRINOX) in the Neoadjuvant Therapy of Pancreatic Cancer|Completed||Phase 1|13|Actual|Emory University||1|||f||||t||||||||||2018-05-31 22:06:18.54395|2018-05-31 22:06:18.54395
NCT01446445|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2015-03-25|2011-10-03|2011-10-05|Estimate|||||||2015-03-25|2015-03-27|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.|Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirus(CMV)Infection Using Bayesian Prediction.|Completed||Phase 4|60|Actual|Hospital Universitari de Bellvitge||4|||f||||f||||||||||2018-05-31 22:06:18.617016|2018-05-31 22:06:18.617016
NCT01446432|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-04-01|2011-10-04|2011-10-05|Estimate|||||||2015-04-01|2015-04-03|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Validation of Two New Questionnaires for Dupuytren's Disease|A Prospective Study to Validate Two New Patient Reported Outcome Measures for Dupuytren's Disease in Patients Treated With XIAFLEX|Unknown status|Active, not recruiting||80|Anticipated|Hospital for Special Surgery, New York|||||f||||f||||||||||2018-05-31 22:06:18.695235|2018-05-31 22:06:18.695235
NCT01446419|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|2016-07-12||2016-10-24|2011-10-04|2011-10-05|Estimate|2016-10-24|2016-10-31|Estimate||||2016-10-24|2016-10-31|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|SMART|Intent to Treat Population|SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain|A Prospective Randomized, Double-blind, Controlled Investigation Evaluating the Intracept Intraosseous Nerve Ablation System for the Reduction of Pain in Patients With Chronic Axial Low Back Pain|Completed||N/A|225|Actual|Relievant Medsystems, Inc.||2|||f||||t||||||||||2018-05-31 22:06:18.768789|2018-05-31 22:06:18.768789
NCT01446406|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-03-29|2011-10-04|2011-10-05|Estimate|||||||2016-03-29|2016-03-30|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|MONARCA||The MONARCA Project (MONitoring, treAtment and pRediCtion of bipolAr Disorder Episodes)|Electronic Daily Self-monitoring of Subjective and Objective Symptoms in Bipolar Disorder - The MONARCA Project (MONitoring, treAtment and pRediCtion of bipolAr Disorder Episodes)|Completed||N/A|78|Actual|Psychiatric Centre Rigshospitalet||2|||f||||t||||||||||2018-05-31 22:06:19.225185|2018-05-31 22:06:19.225185
NCT01446393|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-11-14|2011-10-04|2011-10-05|Estimate|||||||2012-11-14|2012-11-15|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Observational|Ca-Art-PXE||Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)|Functional and Structural Characterization of the Peripheral Arteriopathy in Pseudoxanthoma Elasticum (PXE)|Completed|||71|Actual|University Hospital, Angers|||||f||||f||||||Samples With DNA|"~     Blood samples for genetic and serum analysis~   "|||2018-05-31 22:06:19.310136|2018-05-31 22:06:19.310136
NCT01446380|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-10-03|2011-10-03|2011-10-05|Estimate|||||||2011-10-03|2011-10-05|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort|Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort|Recruiting|||350|Anticipated|University Hospital, Angers|||1||f||||f||||||Samples With DNA|"~     Sera,Plasma,DNA,skin biopsy~   "|||2018-05-31 22:06:19.363094|2018-05-31 22:06:19.363094
NCT01446367|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|February 2010||2010-02-28|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Corneal Changes After Retinal Surgery|Corneal Topographic Changes After 20-gauge Pars Plana Vitrectomy Associated With Scleral Buckling for the Treatment of Rhegmatogenous Retinal Detachment|Completed|||25|Actual|Universidade Federal do Paraná|||||f||||f||||||||||2018-05-31 22:06:19.438694|2018-05-31 22:06:19.438694
NCT01446354|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-10-23|2011-10-04|2011-10-05|Estimate|||||||2012-10-23|2012-10-24|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Observational|||Goal-orientated Coagulation Management in Hypothermic Cardiac Arrest Surgery|Does the Intraoperative Thromboelastometry-guided Coagulation Management Reduce the Administration of Allogeneic Blood Products in Cardiac Surgery With the Help of Hypothermic Cardiac Arrest? A Retrospective Data Analysis|Completed|||200|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-05-31 22:06:19.490815|2018-05-31 22:06:19.490815
NCT01446341|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|November 2011||2011-11-30|October 2011|2011-10-31||||May 2012|Anticipated|2012-05-31||Interventional|||Cast Immobilization Versus Functional Therapy for Acute, Severe Lateral Ankle Sprains|A Pilot Study Towards a Randomized Clinical Trial of Cast Immobilization Versus Functional Therapy for Acute, Severe Lateral Ankle Sprains|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:06:19.557342|2018-05-31 22:06:19.557342
NCT01446328|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-01-29|2011-10-04|2011-10-05|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2011||2011-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|BP2||Bergen Psychosis Project 2 - The Best Intro Study|Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study|Completed||Phase 4|151|Actual|Haukeland University Hospital||3|||f||||t||||||||||2018-05-31 22:06:19.624709|2018-05-31 22:06:19.624709
NCT01446315|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|Asthma APGAR||Assessing Decision Maker Tools for Asthma: the Asthma APGAR||Unknown status|Enrolling by invitation|Phase 4|1500|Anticipated|Olmsted Medical Center||2|||f||||f||||||||||2018-05-31 22:06:19.716064|2018-05-31 22:06:19.716064
NCT01446302|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-08-13|2011-10-03|2011-10-05|Estimate|||||||2012-08-13|2012-08-14|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Metabolic and Inflammatory Responses to Hemodialysis and the Effect of a Meal|Metabolic and Inflammatory Responses to Hemodialysis and the Effect of a Meal|Completed||N/A|24|Actual|University of Aarhus||4|||f||||f||||||||||2018-05-31 22:06:19.791541|2018-05-31 22:06:19.791541
NCT01446289|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|2014-06-20||2014-09-05|2011-10-03|2011-10-05|Estimate|2014-09-05|2014-09-08|Estimate||||2014-09-05|2014-09-08|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional||All enrolled population|Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings|A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women|Completed||Phase 2|86|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:06:19.900408|2018-05-31 22:06:19.900408
NCT01446276|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2014-04-25|2011-10-04|2011-10-05|Estimate|||||||2014-04-25|2014-04-28|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease|Long-term Investigation of Resveratrol on Lipid Turnover in Obese Men With Nonalcoholic Fatty Liver Disease. Effects on Liver Fat Content and Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism|Completed||N/A|26|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 22:06:20.616584|2018-05-31 22:06:20.616584
NCT01446263|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2013-10-27|2011-10-04|2011-10-05|Estimate|||||||2013-10-27|2013-10-29|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|RADIAL-CABG||RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention (RADIAL-CABG) Trial|A Randomized Comparison of RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention (RADIAL-CABG) Trial|Completed||Phase 3|128|Actual|North Texas Veterans Healthcare System||2|||f||||t||||||||||2018-05-31 22:06:20.676741|2018-05-31 22:06:20.676741
NCT01446250|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2016-06-10||2016-11-18|2011-10-03|2011-10-05|Estimate|2016-11-18|2017-01-16|Estimate||||2016-11-18|2017-01-16|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All enrolled participants.|Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1|A Randomized, Open Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-INFα2a/RBV) and Boceprevir in Combination With Peg-INFα2a/RBV in African American Treatment-naïve Patients With Chronic Hepatitis C Genotype 1|Terminated||Phase 3|8|Actual|Debiopharm International SA|Due to the early termination of study enrollment and discontinuation of alisporivir treatment, Amendment 1 changed the number of study arms to 2, combining Arms A and B, and none of the planned outcome measures could be evaluated.|2|||f||||||||||||||2018-05-31 22:06:20.889218|2018-05-31 22:06:20.889218
NCT01446237|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2017-03-06||2017-04-21|2011-10-03|2011-10-05|Estimate|2017-03-06|2017-04-18|Actual||||2017-04-21|2017-05-25|Actual|June 1, 2011||2011-06-01|March 2017|2017-03-31|December 15, 2011|Actual|2011-12-15|December 1, 2011|Actual|2011-12-01||Interventional|||U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne|An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne|Completed||N/A|125|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:06:21.225319|2018-05-31 22:06:21.225319
NCT01446224|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-03-26|2011-10-03|2011-10-05|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Cardiovascular and Torsades de Pointes Monitoring for Pazopanib|Postmarketing Cardiovascular Ischemia and Torsades de Pointes Monitoring for Pazopanib Using Observational Databases|Completed|||1|Actual|GlaxoSmithKline|||4||f||||f||||||||||2018-05-31 22:06:21.5034|2018-05-31 22:06:21.5034
NCT01446211|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2015-05-28|2011-10-04|2011-10-05|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|November 2012|Actual|2012-11-30||Interventional|SPARROW||Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis|Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)|Terminated||Phase 3|4|Actual|Nordic Pharma SAS||2||Change of design consideration|f||||t||||||||||2018-05-31 22:06:21.563009|2018-05-31 22:06:21.563009
NCT01446198|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-06-29|2011-10-04|2011-10-05|Estimate|||||||2012-06-29|2012-07-03|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System|Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System|Completed|||11816|Actual|Gen-Probe, Incorporated|||1||f||||f||||||Samples With DNA|"~     Cervical specimens collected in ThinPrep Pap Test vials containing PreservCyt Solution~     (Hologic, In., Marlborough, MA) with commercially available collection device or~     cytobrush/spatula combination may be tested with the HPV Assay either pre- or post-Pap~     processing.~   "|||2018-05-31 22:06:21.667799|2018-05-31 22:06:21.667799
NCT01446185|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2013-04-17|2011-10-03|2011-10-05|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|SWITCH||Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients|Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients|Completed||N/A|100|Actual|Genomic Health®, Inc.||1|||f||||f||||||||||2018-05-31 22:06:21.720872|2018-05-31 22:06:21.720872
NCT01446172|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2012-04-20|2011-10-04|2011-10-05|Estimate|||||||2012-04-20|2012-04-23|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia|Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Panic Disroder and Agoraphobia|Completed|||132|Anticipated|Modum Bad|||1||f||||t||||||||||2018-05-31 22:06:21.780061|2018-05-31 22:06:21.780061
NCT01446159|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2018-05-18|2011-10-04|2011-10-05|Estimate|||||||2018-05-18|2018-05-21|Actual|June 13, 2011|Actual|2011-06-13|May 2018|2018-05-31|June 8, 2018|Anticipated|2018-06-08|May 31, 2017|Actual|2017-05-31||Interventional|||Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer|A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)|Active, not recruiting||Phase 2|188|Actual|MedImmune LLC||5|||f||||t||||||||||2018-05-31 22:06:21.827463|2018-05-31 22:06:21.827463
NCT01446146|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2013-07-22|2011-10-03|2011-10-05|Estimate|||||||2013-07-22|2013-07-24|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Increasing Engagement in PTSD Treatment Through Patient Education and Patient Choice||Completed||N/A|27|Actual|Michael Debakey Veterans Affairs Medical Center||2|||f||||||||||||||2018-05-31 22:06:23.071877|2018-05-31 22:06:23.071877
NCT01446133|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2018-02-08|2011-10-04|2011-10-05|Estimate|||||||2018-02-08|2018-02-12|Actual|December 12, 2011|Actual|2011-12-12|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 1, 2019|Anticipated|2019-12-01||Interventional|||Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)|Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy|Active, not recruiting||Phase 2|120|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 22:06:23.14523|2018-05-31 22:06:23.14523
NCT01446120|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate||||October 2011|2011-10-31||||||||Interventional|||Insulin Loaded Orally Dissolved Films (Insulin-ODF)||Unknown status|Not yet recruiting|Phase 1|7|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 22:06:23.227993|2018-05-31 22:06:23.227993
NCT01433029|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-01-27|2011-09-12|2011-09-13|Estimate|||||||2017-01-27|2017-01-30|Estimate|September 1, 2011|Actual|2011-09-01|January 2017|2017-01-31|January 22, 2017|Actual|2017-01-22|January 22, 2017|Actual|2017-01-22||Observational|||Objective Assessment of Technical Skills in Cardiothoracic Surgery|Objective Assessment of Technical Skills in Cardiothoracic Surgery|Completed|||8|Actual|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-05-31 22:10:08.336172|2018-05-31 22:10:08.336172
NCT01446107|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2011-10-04|2011-10-04|2011-10-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|December 2007||2007-12-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effectiveness of Fissure Sealant and Topical Fluoride Application in Preventing Dental Caries|A Randomized Controlled Trial on the Effectiveness of Fissure Sealant and Topical Fluoride Application in Preventing Dental Caries|Completed||Phase 2/Phase 3|502|Actual|The University of Hong Kong||4|||f||||f||||||||||2018-05-31 22:06:23.292463|2018-05-31 22:06:23.292463
NCT01446094|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-09-29|2011-09-30|2011-10-04|Estimate|||||||2017-09-29|2017-10-03|Actual|August 2011||2011-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease|Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease|Recruiting||Phase 4|50|Anticipated|The Methodist Hospital System||1|||f||||f|t|f|||f|||Undecided|Plan to share data to be determined.|2018-05-31 22:06:23.369232|2018-05-31 22:06:23.369232
NCT01446081|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2014-05-23|2011-09-30|2011-10-04|Estimate|||||||2014-05-23|2014-05-26|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy|A Phase II Exercise RCT for AML Patients Undergoing Induction Chemotherapy|Completed||Phase 2|83|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:06:23.574126|2018-05-31 22:06:23.574126
NCT01446068|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2013-06-19|2011-10-03|2011-10-04|Estimate|||||||2013-06-19|2013-06-20|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|||Comparison of Postprandial Inflammation in Lean and Obese Subjects||Completed||Early Phase 1|36|Actual|Agroscope Liebefeld-Posieux Research Station ALP||2|||f||||t||||||||||2018-05-31 22:06:23.671758|2018-05-31 22:06:23.671758
NCT01446055|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2011-10-08|2011-10-02|2011-10-04|Estimate|||||||2011-10-08|2011-10-12|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia|Transplantation of Autologous BM-MNC Processed by ResQ Separator and Conventional Manual Method for Patients With Chronic Limb Ischemia: a Multi-center Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|50|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t||||||||||2018-05-31 22:06:23.764182|2018-05-31 22:06:23.764182
NCT01446042|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2012-06-13|2011-09-30|2011-10-04|Estimate|||||||2012-06-13|2012-06-14|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism|A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days|Unknown status|Active, not recruiting|Phase 3|280|Anticipated|Acerus Pharmaceuticals Corporation||2|||f||||t||||||||||2018-05-31 22:06:23.875662|2018-05-31 22:06:23.875662
NCT01446029|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2014-08-01|2011-09-30|2011-10-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)|Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease|Completed||Phase 3|601|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||t||||||||||2018-05-31 22:06:24.06029|2018-05-31 22:06:24.06029
NCT01446016|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2016-09-12|2011-09-30|2011-10-04|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|CAT||Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)|Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy.|Recruiting||Phase 2|47|Anticipated|The Methodist Hospital System||2|||f||||f||||||||Undecided|to be determined|2018-05-31 22:06:24.172196|2018-05-31 22:06:24.172196
NCT01446003|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2017-03-20||2017-06-01|2011-10-03|2011-10-04|Estimate|2017-03-20|2017-05-02|Actual||||2017-06-01|2017-07-02|Actual|October 25, 2011|Actual|2011-10-25|May 2017|2017-05-31|March 3, 2012|Actual|2012-03-03|February 18, 2012|Actual|2012-02-18||Interventional||All participants that received treatment with either MK-8457 or Placebo in the study.|A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)|A Multiple-Dose Clinical Trial to Study the Effect of MK-8457 on Ambulatory Blood Pressure in Hypertensive Patients|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 22:06:24.30661|2018-05-31 22:06:24.30661
NCT01445990|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2011-10-05|2011-10-03|2011-10-04|Estimate|||||||2011-10-05|2011-10-06|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy Study of Free Flap Monitoring Using Capillary Lactate and Glucose Measurements|Evaluation of Free Tissue Flaps Viability With Capillary Glucose and Lactate Measurements Compared With Clinical Examination|Completed||N/A|31|Actual|Centre Hospitalier Universitaire Dijon|||||f||||t||||||||||2018-05-31 22:06:24.608718|2018-05-31 22:06:24.608718
NCT01445977|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2013-08-01|2011-09-30|2011-10-04|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||SoundBite Hearing System Long Term Multi Site Patient Use Study|SoundBite Hearing System Long Term Multi Site Patient Use Study|Unknown status|Active, not recruiting||150|Anticipated|Sonitus Medical Inc|||||f||||||||||||||2018-05-31 22:06:24.673564|2018-05-31 22:06:24.673564
NCT01445964|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2012-01-20|2011-09-30|2011-10-04|Estimate|||||||2012-01-20|2012-01-23|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean|An Open-label, Single-dose, Three-treatment, Three-period Study to Investigate the Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean|Completed||Phase 4|12|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:06:24.840336|2018-05-31 22:06:24.840336
NCT01445951|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2014-07-22|2013-08-19|2014-10-20|2011-10-03|2011-10-04|Estimate|2014-10-20|2014-10-22|Estimate|2013-08-19|2013-08-27|Estimate|2014-10-20|2014-10-22|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional||Full analysis set|Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period|A Phase 3, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With a Basal Insulin Versus Insulin Aspart in Combination With a Basal Insulin in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period|Completed||Phase 3|518|Actual|Mannkind Corporation||3|||f||||t||||||||||2018-05-31 22:06:24.9752|2018-05-31 22:06:24.9752
NCT01445938|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-12-12|2011-09-30|2011-10-04|Estimate|||||||2012-12-12|2012-12-13|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria|An Open-label, Randomized Multicenter Study to Investigate the Anti-parasitic Activity, Pharmacokinetic and Safety of IM SAR97276A With Oral ACTs as Positive Control in Children Presenting With Symptomatic Plasmodium Falciparum Uncomplicated Malaria|Terminated||Phase 2|20|Actual|Sanofi||6||Data Monitoring Committee recommendation|f||||t||||||||||2018-05-31 22:06:25.960039|2018-05-31 22:06:25.960039
NCT01445925|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2013-08-21|2011-10-03|2011-10-04|Estimate|||||||2013-08-21|2013-08-22|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|SMAAN-PAF||Substrate Ablation and Remodelling in Non-paroxysmal Atrial Fibrillation (AF)|Substrate Modification With Ablation and Antiarrhythmic Drugs in Non-Paroxysmal Atrial Fibrillation|Unknown status|Active, not recruiting|N/A|130|Anticipated|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:06:26.034278|2018-05-31 22:06:26.034278
NCT01445899|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30||2015-01-16|2015-02-03|2011-10-03|2011-10-04|Estimate||||2015-01-16|2015-01-29|Estimate|2015-02-03|2015-02-23|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|MATISSE||PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)|An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination With Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE STUDY)|Completed||Phase 2|258|Actual|Quark Pharmaceuticals||4|||f||||t||||||||||2018-05-31 22:06:26.104532|2018-05-31 22:06:26.104532
NCT01445886|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2014-03-10|2011-10-01|2011-10-04|Estimate|||||||2014-03-10|2014-03-11|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|||Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis|Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract and Calcipotriol Solution in Patients With Nail Psoriasis|Completed||Phase 2/Phase 3|33|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:06:26.312357|2018-05-31 22:06:26.312357
NCT01445873|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2012-02-14||2012-05-09|2011-09-30|2011-10-04|Estimate|2012-05-09|2012-06-08|Estimate||||2012-05-09|2012-06-08|Estimate|December 2009||2009-12-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)|Non-Interventional (NI) Drug Study Protocol: Three-Country Pilot Study For Retrospective Chart Review Of Effectiveness Of Thelin® (Sitaxsentan) In Patients With Pulmonary Arterial Hypertension (PAH)|Completed|||36|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:06:26.433292|2018-05-31 22:06:26.433292
NCT01445860|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-09-30|2011-09-30|2011-10-04|Estimate|||||||2011-09-30|2011-10-04|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics|A Phase 1, Open-Label, Fixed-Sequence Study To Estimate The Effect Of Repeated Dosing Of PF-03882845 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:06:26.821807|2018-05-31 22:06:26.821807
NCT01445847|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2012-06-11||2017-04-09|2011-10-03|2011-10-04|Estimate|2012-06-11|2012-07-12|Estimate||||2017-04-09|2017-05-22|Actual|January 2012||2012-01-31|April 2017|2017-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Effect of Intravenous Lidocaine on Post-extubation Laryngospasm|Effect of Intravenous Lidocaine on the Incidence of Post-extubation Laryngospasm: A Randomised Controlled Trial|Terminated||N/A|134|Actual|King Saud University|"Early termination of the trial led to small numbers of subjects that received allocated intervention, (i.e., 99 total participants).~Additionally, protocol violation led to reduce the analyze subjects to 36 for each group."|2||Patient Safety Concerns|f||||t||||||||||2018-05-31 22:06:26.902182|2018-05-31 22:06:26.902182
NCT01445834|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2015-12-01|2011-09-30|2011-10-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2011||2011-06-30|December 2015|2015-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Observational|||Age-stratified Outcome of Pelvic Floor Muscle Exercise for Urinary Incontinence|Retrospective Study About the Age-stratified Outcome of Pelvic Floor Muscle Exercise for Stress (SUI), Mixed (MUI) and Urgency Urinary Incontinence (UUI) 2003-2008|Completed|||150|Actual|University of Zurich|||1||f||||f||||||||||2018-05-31 22:06:27.146101|2018-05-31 22:06:27.146101
NCT01445821|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2018-03-27|2011-09-30|2011-10-04|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2011||2011-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|DIScl2011||Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial|Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb)|Recruiting||Phase 3|160|Anticipated|Northwestern University||2|||f||||t|t|f|||f|||No||2018-05-31 22:06:27.208755|2018-05-31 22:06:27.208755
NCT01445808|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2016-02-25|2011-09-30|2011-10-04|Estimate|||||||2016-02-25|2016-02-26|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|PMT||Psychodynamic Motivation and Training Program|Psychodynamic Motivation and Training Program (PMT) as Secondary Prevention in Patients With Stable Coronary Heart Disease|Completed||N/A|90|Actual|Johannes Gutenberg University Mainz||3|||f||||f||||||||||2018-05-31 22:06:27.317511|2018-05-31 22:06:27.317511
NCT01445795|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27||2015-09-23|2016-06-23|2011-09-30|2011-10-04|Estimate||||2015-09-23|2015-10-09|Estimate|2016-06-23|2016-06-27|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|INH-189-006||Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects|A Multi-center, Placebo-controlled, Multiple Dose, Study of the Safety and Pharmacokinetics and Pharmacodynamics of INX-08189 Dosed Either QD, BID or Adjunctively With Ribavirin, and a Study of the Food Effect, in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects|Completed||Phase 1/Phase 2|50|Actual|Bristol-Myers Squibb||8|||f||||||||||||||2018-05-31 22:06:27.397032|2018-05-31 22:06:27.397032
NCT01445782|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-10-05|2011-10-03|2011-10-04|Estimate|||||||2012-10-05|2012-10-08|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||AZD2115 Multiple Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects|Completed||Phase 1|32|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:06:27.478604|2018-05-31 22:06:27.478604
NCT01445769|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2014-03-31||2014-09-16|2011-10-03|2011-10-04|Estimate|2014-09-16|2014-09-19|Estimate||||2014-09-16|2014-09-19|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional||Intent-to-treat population: All enrolled participants. Note that this was a pilot study which was not sufficiently powered.|Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis|An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis|Completed||Phase 2|45|Actual|Incyte Corporation|This was a single arm pilot study. The patient population differed from Phase III studies of ruxolitinib in myelofibrosis and therefore comparisons to standard dosing cannot be made from this study.|1|||f||||f||||||||||2018-05-31 22:06:27.56718|2018-05-31 22:06:27.56718
NCT01445756|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2014-08-25|2011-10-03|2011-10-04|Estimate|||||||2014-08-25|2014-08-26|Estimate|July 2010||2010-07-31|August 2014|2014-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Topical Lidocaine for Pain Control With Intrauterine Device (IUD) Insertion|Topical Lidocaine for Pain Control With IUD Insertion: A Randomized Controlled Trial|Completed||Early Phase 1|40|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 22:06:28.009782|2018-05-31 22:06:28.009782
NCT01445743|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2014-02-12|2011-09-30|2011-10-04|Estimate|||||||2014-02-12|2014-02-14|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|August 2012|Actual|2012-08-31||Interventional|||Immunogenicity and Safety of an Acellular DPT Vaccine During Pregnancy|Immunogenicity and Safety of an Acellular DPT Vaccine in Pregnant Women in Nuevo Leon, Mexico|Completed||Phase 2|204|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t||||||||||2018-05-31 22:06:28.144629|2018-05-31 22:06:28.144629
NCT01445730|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-08-08|2011-09-30|2011-10-04|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2011||2011-08-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Fructose Consumption and Metabolic Dysregulation|Fructose Consumption Aggravates Dysregulation of Postprandial Lipid Metabolism in Obese Hypertriglyceridemic Men With High Cardiometabolic Risk Profile and Associates With Liver Fat Deposition|Completed||N/A|82|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 22:06:28.203803|2018-05-31 22:06:28.203803
NCT01445717|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2013-05-02|2011-10-03|2011-10-04|Estimate|||||||2013-05-02|2013-05-03|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|GBS||Rapid Diagnostic Test for Detection of Group B Streptococcus in Pregnancy|Use of a New Rapid Method, BioNanoPore, for Growth and Detection of Group B Streptococcus in Pregnant Patients|Completed|||358|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||Samples Without DNA|"~     Specimens are to be retained for one month, frozen in LIM broth, and will be held for use if~     reprocessing specimens is required.~   "|||2018-05-31 22:06:28.268649|2018-05-31 22:06:28.268649
NCT01445704|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-04-08|2011-09-30|2011-10-04|Estimate|||||||2014-04-08|2014-04-09|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Probiotics||Use of Probiotics to Aid in Weight Loss|Use of Probiotics to Aid in Weight Loss|Completed||N/A|151|Actual|Greenville Health System||2|||f||||f||||||||||2018-05-31 22:06:28.401933|2018-05-31 22:06:28.401933
NCT01445691|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2016-05-13|2011-09-30|2011-10-04|Estimate|||||||2016-05-13|2016-05-17|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery|A Multicenter Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas|Withdrawn||Phase 2|0|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 22:06:28.49681|2018-05-31 22:06:28.49681
NCT01445678|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2015-01-09||2017-03-28|2011-10-03|2011-10-04|Estimate|2015-01-09|2015-01-15|Estimate||||2017-03-28|2017-04-28|Actual|December 1, 2011|Actual|2011-12-01|March 2017|2017-03-31|October 1, 2013|Actual|2013-10-01|October 1, 2013|Actual|2013-10-01||Interventional|||Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections|Completed||Phase 3|494|Actual|Cubist Pharmaceuticals LLC|Two identical P3 protocols were initiated (NCT01445678 and NCT01445665) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.|2|||f||||f||||||||||2018-05-31 22:06:28.651871|2018-05-31 22:06:28.651871
NCT01445652|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2013-06-28||2013-09-11|2011-09-30|2011-10-04|Estimate|2013-06-28|2013-09-09|Estimate||||2013-09-11|2013-09-19|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||This reporting group includes all enrolled and randomized participants.|A Lifestyle Investigation With Spectacles and Daily Disposable Contact Lenses in Young Patients|A Lifestyle Investigation With Spectacles and Daily Disposable Contact Lenses in Young Patients|Completed||N/A|113|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:06:29.333925|2018-05-31 22:06:29.333925
NCT01445639|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2014-01-25|2011-09-30|2011-10-04|Estimate|||||||2014-01-25|2014-01-28|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Dexmedetomidine in Patients After Intracranial Surgery|Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients After Intracranial Surgery (Prophylactic Analgesia and Sedation Trial, PASTrial)|Completed||Phase 4|192|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 22:06:29.565198|2018-05-31 22:06:29.565198
NCT01445626|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2013-01-14||2013-01-14|2011-10-03|2011-10-04|Estimate|2013-01-14|2013-02-18|Estimate||||2013-01-14|2013-02-18|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)||Completed|||87|Actual|Allergan|||1||f||||f||||||||||2018-05-31 22:06:29.703871|2018-05-31 22:06:29.703871
NCT01445613|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2015-12-03||2016-07-13|2011-10-03|2011-10-04|Estimate|2016-03-14|2016-04-12|Estimate||||2016-07-13|2016-08-12|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|December 2014|Actual|2014-12-31||Interventional|CANOPY||Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy|CANOPY: Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy|Completed||N/A|1203|Actual|Abbott Vascular||1|||f||||f||||||||No||2018-05-31 22:06:29.951181|2018-05-31 22:06:29.951181
NCT01445600|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-09-21|2011-09-29|2011-10-04|Estimate|||||||2015-09-21|2015-09-23|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|ALTARGOPMS||ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information|Completed|||3612|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:06:30.90513|2018-05-31 22:06:30.90513
NCT01445587|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2012-03-22|2011-09-29|2011-10-04|Estimate|||||||2012-03-22|2012-03-26|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|November 2011|Anticipated|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma|An Open-Label, Single Arm, Phase Ib/II Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||"Based on the clinical activity, not safety data, of the AKT inhibitor, GSK has decided at this~   time to suspend further development of GSK2110183 as monotherapy."|f||||f||||||||||2018-05-31 22:06:30.974931|2018-05-31 22:06:30.974931
NCT01445561|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-16|2011-09-30|2011-10-03|Estimate|||||||2018-05-16|2018-05-17|Actual|September 28, 2011||2011-09-28|April 27, 2018|2018-04-27|July 15, 2013|Actual|2013-07-15|July 15, 2013|Actual|2013-07-15||Interventional|||Ultra Low Dose Interleukin-2 in Healthy Volunteers|The Safety and the Tolerability of Ultra Low Dose Interleukin-2 in Healthy Volunteers|Completed||Phase 1|22|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:06:31.091187|2018-05-31 22:06:31.091187
NCT01445548|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|2014-04-07||2014-05-15|2011-09-30|2011-10-03|Estimate|2014-04-07|2014-05-09|Estimate||||2014-05-15|2014-05-26|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|April 2013|Actual|2013-04-30||Interventional|SIRGA2||Sirolimus for Advanced Age-Related Macular Degeneration|Pilot Study of the Evaluation of Intravitreal Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration|Completed||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-05-31 22:06:31.266466|2018-05-31 22:06:31.266466
NCT01445535|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-17|2011-09-30|2011-10-03|Estimate|||||||2018-05-17|2018-05-18|Actual|January 13, 2009||2009-01-13|February 23, 2018|2018-02-23|October 1, 2019|Anticipated|2019-10-01|April 1, 2011|Actual|2011-04-01||Interventional|||Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas|Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas|Active, not recruiting||Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:06:31.698515|2018-05-31 22:06:31.698515
NCT01445522|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-19|2011-09-30|2011-10-03|Estimate|||||||2018-05-19|2018-05-22|Actual|December 3, 2008||2008-12-03|June 29, 2012|2012-06-29|July 3, 2012|Actual|2012-07-03|July 3, 2012|Actual|2012-07-03||Interventional|||ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer|A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas|Completed||Phase 1|35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:31.842279|2018-05-31 22:06:31.842279
NCT01445509|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-10-26|2011-09-30|2011-10-03|Estimate|||||||2017-10-26|2017-10-27|Actual|October 30, 2008||2008-10-30|October 12, 2017|2017-10-12|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors|A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors|Active, not recruiting||Phase 1|50|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:06:31.911124|2018-05-31 22:06:31.911124
NCT01445483|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-04-03|2011-09-30|2011-10-03|Estimate|||||||2018-04-03|2018-04-04|Actual|September 15, 2008||2008-09-15|March 29, 2018|2018-03-29||||||||Observational|||Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain Metastases|A Pilot Study to Evaluate Neuropsychological Outcome Measures and Their Relationship With Prognosis in Patients Receiving Radiation Therapy for Brain Metastases|Recruiting|||60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:32.006628|2018-05-31 22:06:32.006628
NCT01445444|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2016-03-09|2011-09-30|2011-10-03|Estimate|||||||2016-03-09|2016-03-10|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Habit Reversal Training for Children and Adolescents With Trichotillomania|Habit Reversal Training for Children and Adolescents With Trichotillomania: A Controlled Trial|Completed||N/A|50|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 22:06:32.086433|2018-05-31 22:06:32.086433
NCT01445431|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-29|2011-09-29|2011-10-03|Estimate|||||||2011-09-29|2011-10-03|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Trial on the Efficacy and Safety of Virgin Coconut Oil Compared to Mineral Oil in the Treatment of Uremic Xerosis|A Randomized Controlled Trial on the Efficacy and Safety of Virgin Coconut Oil Compared to Mineral Oil in the Treatment of Uremic Xerosis|Completed||Phase 3|45|Actual|University of the Philippines||2|||f||||t||||||||||2018-05-31 22:06:32.168628|2018-05-31 22:06:32.168628
NCT01445418|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-02-13|2011-09-30|2011-10-03|Estimate|||||||2018-02-13|2018-02-14|Actual|March 13, 2008||2008-03-13|December 7, 2017|2017-12-07|December 7, 2017|Actual|2017-12-07|September 2, 2014|Actual|2014-09-02||Interventional|||AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer|A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers (Familial Breast and Ovarian Cancer) and Sporadic Triple Negative Breast Cancer and Ovarian Cancer|Completed||Phase 1|103|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:06:32.237294|2018-05-31 22:06:32.237294
NCT01445405|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-11|2011-09-30|2011-10-03|Estimate|||||||2018-05-11|2018-05-14|Actual|February 5, 2008||2008-02-05|February 8, 2013|2013-02-08|August 27, 2010|Actual|2010-08-27|August 27, 2010|Actual|2010-08-27||Interventional|||Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer|Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer|Completed||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:32.327301|2018-05-31 22:06:32.327301
NCT01445392|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-02-14|2011-09-30|2011-10-03|Estimate|||||||2018-02-14|2018-02-15|Actual|November 14, 2007||2007-11-14|February 13, 2018|2018-02-13|October 3, 2016|Actual|2016-10-03|January 31, 2014|Actual|2014-01-31||Interventional|||SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma|A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma|Completed||Phase 1|24|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:06:32.390936|2018-05-31 22:06:32.390936
NCT01445379|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-17|2011-09-30|2011-10-03|Estimate|||||||2018-05-17|2018-05-18|Actual|October 1, 2007||2007-10-01|November 13, 2015|2015-11-13|November 13, 2015|Actual|2015-11-13|April 18, 2014|Actual|2014-04-18||Interventional|||Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer|A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer|Completed||Phase 1|33|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:06:32.486765|2018-05-31 22:06:32.486765
NCT01445366|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2014-12-04|2011-09-29|2011-10-03|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Solute Removal With High Volume Hemodiafiltration Versus Long High Flux Hemodialysis|Solute Removal With High Volume Hemodiafiltration Versus Long High Flux Hemodialysis|Unknown status|Recruiting|N/A|10|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:06:32.565125|2018-05-31 22:06:32.565125
NCT01445340|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-19|2011-09-30|2011-10-03|Estimate|||||||2018-05-19|2018-05-22|Actual|April 21, 2007||2007-04-21|June 29, 2012|2012-06-29|June 29, 2012|Actual|2012-06-29|||||Interventional|||Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma|Phase I Study of Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma|Terminated||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:32.644231|2018-05-31 22:06:32.644231
NCT01445327|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-10-05|2011-09-30|2011-10-03|Estimate|||||||2017-10-05|2017-10-06|Actual|February 20, 2007||2007-02-20|January 20, 2015|2015-01-20|January 20, 2015||2015-01-20|||||Observational|||Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers|A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies|Terminated|||9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:32.708107|2018-05-31 22:06:32.708107
NCT01445314|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-04-19|2011-09-30|2011-10-03|Estimate|||||||2018-04-19|2018-04-20|Actual|February 22, 2007||2007-02-22|April 18, 2018|2018-04-18||||||||Observational|||Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments|Analysis of Stored Data Collected From Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols|Enrolling by invitation|||497|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:32.784525|2018-05-31 22:06:32.784525
NCT01445301|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2017-04-11||2018-04-24|2011-09-29|2011-10-03|Estimate|2018-04-24|2018-04-27|Actual||||2018-04-24|2018-04-27|Actual|September 27, 2011|Actual|2011-09-27|September 2017|2017-09-30|August 2, 2012|Actual|2012-08-02|August 2, 2012|Actual|2012-08-02||Interventional||Intent-to-treat (ITT) population comprised all randomized participants who received at least one application of investigational product. One participant excluded was randomized but was not administered study drug. 799 participant were included in the ITT population.|Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects|Study STF115287, a Clinical Confirmation Study of GSK2585823 (Clindamycin 1%-Benzoyl Peroxide 3% Gel) in the Treatment of Acne Vulgaris in Japanese Subjects. - A Multicenter, Randomized, Single-blind, Active-controlled, Parallel-group Study -|Completed||Phase 3|800|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||||2018-05-31 22:06:33.132676|2018-05-31 22:06:33.132676
NCT01445288|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-10-18|2011-09-30|2011-10-03|Estimate|||||||2017-10-18|2017-10-19|Actual|August 1, 2006||2006-08-01|August 2, 2017|2017-08-02||||||||Observational|||Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors|An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:35.323837|2018-05-31 22:06:35.323837
NCT01445275|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2015-05-27|2011-09-30|2011-10-03|Estimate|||||||2015-05-27|2015-05-29|Estimate|January 2100||2100-01-31|May 2015|2015-05-31||||January 2100|Anticipated|2100-01-31||Observational|||Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199|A Comparative Effectiveness Study of Cancer Risk Management for Women at Elevated Genetic Risk of Ovarian Cancer|Not yet recruiting|||2605|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 22:06:35.922615|2018-05-31 22:06:35.922615
NCT01445262|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-08-10|2011-09-29|2011-10-03|Estimate|||||||2015-08-10|2015-08-13|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Drug Use Investigation for XYZAL®|Drug Use Investigation for XYZAL|Completed|||10728|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:06:36.076947|2018-05-31 22:06:36.076947
NCT01445249|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2011-09-30|2011-09-30|2011-10-03|Estimate|||||||2011-09-30|2011-10-03|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Medial Forefoot Block for Analgesia After Foot Surgery|A Randomised, Blinded Comparison of a Nerve Stimulator Guided Ankle Block Compared to a Landmark Guided Ankle Block for Pain Relief After Forefoot Surgery.|Completed||N/A|72|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 22:06:36.229477|2018-05-31 22:06:36.229477
NCT01445236|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2013-12-19|2011-09-30|2011-10-03|Estimate|||||||2013-12-19|2013-12-20|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance|Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance|Terminated||N/A|25|Anticipated|Hospital Clinic of Barcelona||1||Insufficient recruitment|f||||t||||||||||2018-05-31 22:06:36.391002|2018-05-31 22:06:36.391002
NCT01445223|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-10-02|2011-09-30|2011-10-03|Estimate|||||||2011-10-02|2011-10-04|Estimate|April 2004||2004-04-30|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)|A Study on ART Naïve Patients On Different Regimens to Treat Hiv (a Phase 4 Study)|Completed||Phase 4|242|Actual|Göteborg University||3|||f||||t||||||||||2018-05-31 22:06:36.957861|2018-05-31 22:06:36.957861
NCT01445210|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-10-18|2011-09-30|2011-10-03|Estimate|||||||2012-10-18|2012-10-19|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Saphenous Nerve Block: Single Shot Versus Continuous Infusion to Supplement a Continuous Sciatic Nerve Block After Major Ankle Surgery|A Randomized Comparison of Single Injection vs. Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block in Postoperative Pain Treatment After Major Ankle Surgery: Clinical Outcome and Cost Analysis|Completed||N/A|50|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:06:37.15357|2018-05-31 22:06:37.15357
NCT01445197|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-10-02|2011-09-30|2011-10-03|Estimate|||||||2017-10-02|2017-10-03|Actual|December 2012||2012-12-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development|A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostate®) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (≤ 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors)|Terminated||Phase 3|1|Actual|CSL Behring||1|||f||||||||||||||2018-05-31 22:06:37.345858|2018-05-31 22:06:37.345858
NCT01445171|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2018-04-04|2011-09-30|2011-10-03|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|TRITON||Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve|Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve|Completed||N/A|295|Actual|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 22:06:37.540471|2018-05-31 22:06:37.540471
NCT01445158|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-23|2011-09-30|2011-10-03|Estimate|||||||2018-05-23|2018-05-24|Actual|January 30, 2007||2007-01-30|September 21, 2017|2017-09-21||||||||Observational|||Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures|Pilot Study of Educational Interventions in Pediatric Hematopoietic Stem Cell Donors to Increase Knowledge of Donation and Transplantation Procedures|Completed|||17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:37.830434|2018-05-31 22:06:37.830434
NCT01445145|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-19|2011-09-30|2011-10-03|Estimate|||||||2018-05-19|2018-05-22|Actual|January 26, 2007||2007-01-26|September 25, 2014|2014-09-25|September 25, 2014||2014-09-25|||||Observational|||An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection|An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection|Completed|||70|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:37.952027|2018-05-31 22:06:37.952027
NCT01445132|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-02-13|2011-09-30|2011-10-03|Estimate|||||||2018-02-13|2018-02-14|Actual|January 11, 2007||2007-01-11|April 24, 2013|2013-04-24|April 24, 2013|Actual|2013-04-24|April 24, 2013|Actual|2013-04-24||Interventional|||Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation|Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes|Completed||Phase 1|11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:38.075936|2018-05-31 22:06:38.075936
NCT01445119|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2013-08-27|2011-09-30|2011-10-03|Estimate|||||||2013-08-27|2013-08-28|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas|A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas|Completed||Phase 1|58|Actual|Eli Lilly and Company|||||f||||||||||||||2018-05-31 22:06:38.160564|2018-05-31 22:06:38.160564
NCT01445106|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-23|2011-09-30|2011-10-03|Estimate|||||||2018-05-23|2018-05-24|Actual|December 11, 2006||2006-12-11|December 2, 2014|2014-12-02|May 9, 2011|Actual|2011-05-09|May 9, 2011|Actual|2011-05-09||Interventional|||A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors|A Phase I Trial of Nelfinavir (Viracept) in Adults With Solid Tumors|Completed||Phase 1|28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:38.295908|2018-05-31 22:06:38.295908
NCT01445080|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2017-08-04|2011-09-30|2011-10-03|Estimate|||||||2017-08-04|2017-08-07|Actual|August 23, 2006||2006-08-23|July 28, 2017|2017-07-28|June 14, 2012|Actual|2012-06-14|June 14, 2012|Actual|2012-06-14||Interventional|||Sorafenib (BAY 43-9006) to Treat Children With Solid Tumors or Leukemias|A Phase I/II Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children With Refractory Solid Tumors or Refractory Leukemias|Completed||Phase 1/Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 22:06:38.419514|2018-05-31 22:06:38.419514
NCT01445067|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-05-23|2011-09-30|2011-10-03|Estimate|||||||2018-05-23|2018-05-24|Actual|November 2011||2011-11-30|May 2018|2018-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Evaluate the PK of BMS-927711 in Patient With Migraine During Acute Migraine and Non-migraine Condition|Phase I, Open-Label, Randomized, Single Sequence Study With Two Dose Groups to Compare the Pharmacokinetics of BMS-927711 in Migraine Subjects During an Acute Migraine Attack and During Non-Migraine Period|Completed||Phase 1|48|Actual|Biohaven Pharmaceutical Holding Company Ltd.||2|||f||||f||||||||||2018-05-31 22:06:38.682919|2018-05-31 22:06:38.682919
NCT01445054|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-30|||2018-04-24|2011-09-30|2011-10-03|Estimate|||||||2018-04-24|2018-04-25|Actual|March 1, 2007||2007-03-01|April 18, 2018|2018-04-18|August 20, 2014|Actual|2014-08-20|August 20, 2014|Actual|2014-08-20||Interventional|||111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer|A Phase 0 Trial of (111)Indium CHX-A DTPA Trastuzumab Imaging in Cancer|Completed||Early Phase 1|13|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:06:38.84925|2018-05-31 22:06:38.84925
NCT01445041|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-03-20|2011-09-29|2011-10-03|Estimate|||||||2017-03-20|2017-03-21|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome|Autologous Cord Blood Cells for Patients With HLHS: Phase I Study of Feasibility and Safety|Suspended||Phase 1|20|Anticipated|Duke University||2||Pending Additional Funding|f||||f||||||||||2018-05-31 22:06:38.92585|2018-05-31 22:06:38.92585
NCT01445028|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2017-03-31||2017-03-31|2011-09-29|2011-10-03|Estimate|2017-03-31|2017-05-11|Actual||||2017-03-31|2017-05-11|Actual|September 2011||2011-09-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2013|Actual|2013-08-31||Interventional|DELIVER||Isotretinoin for Proliferative Vitreoretinopathy|Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy|Completed||Phase 4|109|Actual|Wills Eye||2|||f||||f|t|||||||No||2018-05-31 22:06:39.011814|2018-05-31 22:06:39.011814
NCT01445015|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-09-30|2011-09-30|2011-10-03|Estimate|||||||2011-09-30|2011-10-03|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|June 2012|Anticipated|2012-06-30|February 2012|Anticipated|2012-02-29||Interventional|SIPIICAA||Stress Management Intervention in Inner City Adolescents With Asthma|Pilot Study: Stress Management Intervention as a Tool for Managing Persistent Asthma in Inner City Adolescent Patients.|Unknown status|Recruiting|Phase 2|50|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 22:06:39.526159|2018-05-31 22:06:39.526159
NCT01445002|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2013-01-10|2011-09-30|2011-10-03|Estimate|||||||2013-01-10|2013-01-14|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy|Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis|Completed||Phase 2|79|Actual|Biomay AG||4|||f||||f||||||||||2018-05-31 22:06:39.606498|2018-05-31 22:06:39.606498
NCT01424969|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2014-02-12|2011-08-25|2011-08-29|Estimate|||||||2014-02-12|2014-02-14|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||The Effects of Platelet Rich Plasma on the Integrity of Rotator Cuff Repair|Effects of Platelet-Rich Fibrin Matrix on Repair Integrity of At-Risk Rotator Cuff Tears|Completed|||37|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 22:12:41.369844|2018-05-31 22:12:41.369844
NCT01444989|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-11-01|2011-09-30|2011-10-03|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2011||2011-09-30|January 2017|2017-01-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|AKRQ||Development and Validation of a Quality of Life Instrument for Actinic Keratosis|Development and Validation of a Quality of Life Instrument for Actinic Keratosis|Completed||N/A|150|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 22:06:39.726131|2018-05-31 22:06:39.726131
NCT01444976|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-09-30|2011-09-30|2011-10-03|Estimate|||||||2011-09-30|2011-10-03|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||The Effect of Sedation During Transesophageal Echocardiography on Heart Rate Variability|The Effect of Sedation During Transesophageal Echocardiography on Heart Rate Variability:A Comparison of Hypnotic Sedation With Medical Sedation|Completed||N/A|76|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital||3|||f||||f||||||||||2018-05-31 22:06:39.797535|2018-05-31 22:06:39.797535
NCT01444924|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2014-06-06||2018-03-06|2011-09-29|2011-10-03|Estimate|2014-09-15|2014-09-23|Estimate||||2018-03-06|2018-04-05|Actual|September 2011||2011-09-30|March 2018|2018-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||The treatment group, who received TAP block placement, was younger than the saline injection group, on average (55.2 versus 62.1, P = 0.028).|Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery|Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2|75|Actual|University of Wisconsin, Madison|Unilateral placement of block may decrease overall effectiveness. Sample size was small, from single institution, and encompassed a variety of diagnoses and procedures. Analysis also included intraoperative medications.|2|||f||||t||||||||||2018-05-31 22:06:39.896944|2018-05-31 22:06:39.896944
NCT01444911|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2017-01-24||2017-07-26|2011-09-29|2011-10-03|Estimate|2017-06-28|2017-07-27|Actual||||2017-07-26|2017-08-25|Actual|August 2011||2011-08-31|July 2017|2017-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Evaluation of The Vaginal Renewal™ Program in Gynecologic Cancer Patients Experiencing Sexual Dysfunction|Evaluation of a Multifaceted Vaginal Renewal™ Program Utilizing Vibrating Wands in Gynecologic Cancer Patients Experiencing Sexual Dysfunction: A Randomized Controlled Trial|Terminated||Phase 2|29|Actual|University of Wisconsin, Madison|The study was closed before completion due to a slowing accrual rate.|2||Slow accrual|f||||t||||||||||2018-05-31 22:06:40.223792|2018-05-31 22:06:40.223792
NCT01444898|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|2016-06-14||2016-09-27|2011-09-30|2011-10-03|Estimate|2016-09-27|2016-09-29|Estimate||||2016-09-27|2016-09-29|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome|Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome|Completed||N/A|10|Actual|Children's Hospital Los Angeles|"small sample size~referral bias due to small recruitment area~confounding factors during the study, including variations in eating schedule, psychotropic medications, caretaker supervision and activity"|1|||f||||f||||||||Undecided||2018-05-31 22:06:40.832604|2018-05-31 22:06:40.832604
NCT01444885|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-07-13|2011-09-30|2011-10-03|Estimate|||||||2012-07-13|2012-07-16|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|STELLA||Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of PletaalÒ(Cilostazol) in Subjects With Vasospastic Angina (STELLA)|Completed||Phase 2|50|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 22:06:42.179155|2018-05-31 22:06:42.179155
NCT01444872|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-08-24|2011-09-29|2011-10-03|Estimate|||||||2012-08-24|2012-08-27|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction|A Randomized, Single-Blind, Placebo-Controlled, Adaptive, Ascending Dose Study to Evaluate the Effects of TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Mild to Moderate Renal Dysfunction|Completed||Phase 1|17|Actual|Trevena Inc.||2|||f||||||||||||||2018-05-31 22:06:42.309311|2018-05-31 22:06:42.309311
NCT01444859|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-10-23|2011-09-29|2011-10-03|Estimate|||||||2012-10-23|2012-10-24|Estimate|February 2012||2012-02-29|December 2011|2011-12-31|November 2012|Anticipated|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms|Effect of Trenev Trio®/Healthy Trinity® in Otherwise Healthy Adults With Recurrent Gastrointestinal Symptoms: a Double-blind, Randomized, Placebo-controlled, Parallel Group Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|120|Anticipated|Sprim Advanced Life Sciences||2|||f||||f||||||||||2018-05-31 22:06:42.380815|2018-05-31 22:06:42.380815
NCT01444846|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-08-26|2011-09-30|2011-10-03|Estimate|||||||2014-08-26|2014-08-28|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift|Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift|Completed||Phase 2|83|Actual|Sound Pharmaceuticals, Incorporated||4|||f||||t||||||||||2018-05-31 22:06:42.477321|2018-05-31 22:06:42.477321
NCT01444833|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-09-29|2011-09-29|2011-10-03|Estimate|||||||2011-09-29|2011-10-03|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|March 2009|Actual|2009-03-31||Interventional|ADIRAS||Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker|Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension|Unknown status|Recruiting|N/A|35|Anticipated|Slovak Academy of Sciences|||||f||||f||||||||||2018-05-31 22:06:42.596021|2018-05-31 22:06:42.596021
NCT01444820|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-02-01|2011-09-30|2011-10-03|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2012||2012-01-31|February 2017|2017-02-28|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate|Phase III Study of Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate, Using 3D-CRT or Intensity-Modulated Radiotherapy|Active, not recruiting||Phase 3|329|Actual|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||t||||||||||2018-05-31 22:06:42.801119|2018-05-31 22:06:42.801119
NCT01444807|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-03-20|2011-09-30|2011-10-03|Estimate|||||||2017-03-20|2017-03-22|Actual|December 2011||2011-12-31|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|March 2017|Actual|2017-03-31||Interventional|||Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases|A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma (RCC) After a Radical Resection of the Metastases|Recruiting||Phase 2|132|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||Yes||2018-05-31 22:06:42.914602|2018-05-31 22:06:42.914602
NCT01444794|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-06-19|2011-09-29|2011-10-03|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Observational|VALGAS||Adult Subjects Suffering From Lower Limb Spasticity Following Stroke|A National, Prospective Cohort to Document the Effectiveness of One BoNT-A Injection Cycle Based on Attainment of Individual Person-centred Goals in Adult Subjects Suffering From Lower Limb Spasticity Following Stroke|Completed|||100|Actual|Ipsen|||||f||||||||||||||2018-05-31 22:06:43.046952|2018-05-31 22:06:43.046952
NCT01444781|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2014-06-12||2014-07-14|2011-09-30|2011-10-03|Estimate|2014-07-14|2014-07-16|Estimate||||2014-07-14|2014-07-16|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|||Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants|Evaluation of Antibody Persistence Following a Primary Series at 2, 4, and 6 Months on Trial A3L24 and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ Concomitantly Administered With Prevenar™ at 12 to 24 Months of Age in Healthy Latin American Infants|Completed||Phase 3|1106|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 22:06:43.208542|2018-05-31 22:06:43.208542
NCT01444768|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2017-04-04|2011-09-30|2011-10-03|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2012||2012-03-31|April 2017|2017-04-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|CPOE||Prospective Evaluation of Computerized Physician Order Entry in the Emergency Department|Prospective Evaluation of Computerized Physician Order Entry in the Emergency Department|Withdrawn|||0|Actual|Beth Israel Deaconess Medical Center|||||f||||f||||||||||2018-05-31 22:06:44.254768|2018-05-31 22:06:44.254768
NCT01444755|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-09-29|2011-09-29|2011-10-03|Estimate|||||||2011-09-29|2011-10-03|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|April 2012|Anticipated|2012-04-30|December 2011|Anticipated|2011-12-31||Observational|||The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer|Neoadjuvant Chemotherapy Versus Surgery Alone in Locally Advanced Gastric Cancer: A Randomized Controlled Study|Unknown status|Active, not recruiting||80|Anticipated|Haydarpasa Numune Training and Research Hospital|||2||f||||f||||||None Retained|"~     Resected stomach specimen of the patients.~   "|||2018-05-31 22:06:44.315242|2018-05-31 22:06:44.315242
NCT01444742|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2018-03-13||2018-05-01|2011-09-30|2011-10-03|Estimate|2018-05-01|2018-05-31|Estimate||||2018-05-01|2018-05-31|Estimate|November 16, 2011|Actual|2011-11-16|May 2018|2018-05-31|January 29, 2017|Actual|2017-01-29|January 29, 2017|Actual|2017-01-29||Interventional|||Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)|Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, or Are Refractory to, Hypomethylator Therapy|Completed||Phase 2|81|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:06:44.403407|2018-05-31 22:06:44.403407
NCT01444729|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-10-25|2011-09-30|2011-10-03|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2012||2012-03-31|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Post Approval Commitment Study|A Non-Interventional Post Approval Commitment Study To Evaluate The Outcomes Of The Various Treatment Options For Dupuytren's Contracture|Completed|||305|Actual|Endo Pharmaceuticals|||2||f||||f||||||||||2018-05-31 22:06:44.691174|2018-05-31 22:06:44.691174
NCT01444716|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2018-01-09|2011-09-30|2011-10-03|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2011|Actual|2011-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL)|Phase II Study of Ofatumumab as Front-line Treatment in Elderly, Unfit Patients With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 2|34|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:06:44.769213|2018-05-31 22:06:44.769213
NCT01444703|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2016-07-19|2011-09-29|2011-10-03|Estimate|||||||2016-07-19|2016-07-20|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Comparison of Licorice Versus Sugar-water Gargle for Prevention of Postoperative Sore Throat and Postextubation Coughing|Randomized, Double-blind Comparison of Licorice Versus Sugar-water Gargle for Prevention of Postoperative Sore Throat and Postextubation Coughing|Completed||N/A|236|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 22:06:44.847995|2018-05-31 22:06:44.847995
NCT01444690|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-09-30|2011-09-30|2011-10-03|Estimate|||||||2011-09-30|2011-10-03|Estimate|January 2012||2012-01-31|September 2011|2011-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|DIPANAP||Dimiracetam in Painful Neuropathies Affecting AIDS Patients|Dimiracetam in Painful Neuropathies Affecting AIDS Patients. A Double-blind, Placebo-controlled, Parallel-group, Randomised, Multi-centre Study|Unknown status|Not yet recruiting|Phase 2|244|Anticipated|Neurotune AG||2|||f||||f||||||||||2018-05-31 22:06:44.925055|2018-05-31 22:06:44.925055
NCT01444677|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-12-19|2011-09-30|2011-10-03|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2011||2011-04-30|December 2017|2017-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers|A Dose Block-randomized, Double-blind, Placebo-controlled, Single or Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects|Completed||Phase 1|40|Anticipated|Yungjin Pharm. Co., Ltd.||5|||f||||t||||||||||2018-05-31 22:06:45.003624|2018-05-31 22:06:45.003624
NCT01444664|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2016-03-23|2011-09-29|2011-10-03|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Aneurysm Wall Histology Registry|Aneurysm Wall Histology and Correlation With Cerebrospinal Fluid and Blood Plasma Registry|Completed||Phase 4|24|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 22:06:45.095518|2018-05-31 22:06:45.095518
NCT01444651|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2016-07-11||2016-12-04|2011-09-30|2011-10-03|Estimate|2016-12-04|2017-01-30|Estimate||||2016-12-04|2017-01-30|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Trial of Tadalafil and Glycemic Traits|Phase 3 Randomized Trial of Tadalafil and Glycemic Traits|Completed||Phase 3|73|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:06:45.215246|2018-05-31 22:06:45.215246
NCT01444638|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-01-12|2011-09-30|2011-10-03|Estimate|||||||2013-01-12|2013-01-15|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of Ultrasound (US) Assistance for Anesthesia Trainees for Caesarean Section Spinal Placement|Evaluation of US Assistance for Anesthesia Trainees for Spinal Placement in Parturients Having Caesarean Section: A Randomized Control Trial|Completed||N/A|80|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 22:06:45.553141|2018-05-31 22:06:45.553141
NCT01444625|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2013-05-28|2011-09-30|2011-10-03|Estimate|||||||2013-05-28|2013-05-29|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|CHOCOPO||Flavanols and Skin Photo Protection: a Clinical Trial|Flavanols and Skin Photo Protection: a Double Blind Clinical Trial|Completed||Phase 2|78|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:06:45.638585|2018-05-31 22:06:45.638585
NCT01444612|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-05-15|2011-09-29|2011-10-03|Estimate|||||||2017-05-15|2017-05-16|Actual|February 2010||2010-02-28|May 2017|2017-05-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Observational|||Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery|Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery|Completed|||4068|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:06:45.715029|2018-05-31 22:06:45.715029
NCT01444599|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2015-03-23|2011-09-28|2011-10-03|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||VH-IVUS Plaque Composition Analysis By Fractional Flow Reserve|Virtual Histology (VH)-Intravascular Ultrasound (IVUS) Tissue Characteristics Analysis of the Intermediate Coronary Artery Stenosis Lesion Predicting Physiologic Myocardial Ischemia by Myocardial Fraction Flow Reserve (FFR)|Completed|||100|Actual|Inje University|||2||f||||t||||||||||2018-05-31 22:06:45.824858|2018-05-31 22:06:45.824858
NCT01444586|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-01-19|2011-09-30|2011-10-03|Estimate|||||||2017-01-19|2017-01-23|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Observational|SOPRANO||Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)|Prospective Multicentre Non-interventional Study on Compliance and Patient/Doctor Behavior of VTE Prevention in Major Orthopedic Surgery|Completed|||2293|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:06:45.885158|2018-05-31 22:06:45.885158
NCT01444573|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-09-21|2011-09-29|2011-09-30|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|December 2012|Actual|2012-12-31||Interventional|REVEAL||Rate Ventricular Control Therapy in Patients With Permanent Atrial Fibrillation|Rate Ventricular Control Therapy by Implantable Continuous Monitor in Patients With Permanent Atrial Fibrillation|Unknown status|Recruiting|Phase 3|90|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 22:06:46.013031|2018-05-31 22:06:46.013031
NCT01444560|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2012-10-15|2011-09-29|2011-09-30|Estimate|||||||2012-10-15|2012-10-16|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi|The miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi|Completed|||21|Actual|Ruhr University of Bochum|||3||f||||t||||||Samples With DNA|"~     human skin~   "|||2018-05-31 22:06:46.097593|2018-05-31 22:06:46.097593
NCT01444547|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2014-05-02|2011-09-29|2011-09-30|Estimate|||||||2014-05-02|2014-05-06|Estimate|January 2007||2007-01-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study on Predictive Value of ERCC1 in Esophageal Cancer Patients Treated With Paclitaxel and Cisplatin|A Phase Ⅱ Study on Low-expression and High-expression of ERCC1 in Recurrent or Metastastic Esophageal Cancer Patients Treated With Biweekly Paclitaxel and Cisplatin|Unknown status|Recruiting|Phase 2|92|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:06:46.157593|2018-05-31 22:06:46.157593
NCT01444534|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-10-23|2011-09-29|2011-09-30|Estimate|||||||2012-10-23|2012-10-24|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Mobile Phone Applications and Quality of Life|Influence of a Mobile Phone Application on Quality of Life of Patients With Type 1 Diabetes Mellitus: a Randomized Controlled Trial|Completed||N/A|65|Actual|Medical Research Foundation, The Netherlands||2|||f||||f||||||||||2018-05-31 22:06:46.244471|2018-05-31 22:06:46.244471
NCT01444521|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2014-05-02|2011-09-28|2011-09-30|Estimate|||||||2014-05-02|2014-05-06|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer|Genotype-drive Phase II Study of Novel Irinotecan-Cisplatin Combination as First-line Therapy for Advanced Gastric Cancer|Completed||Phase 2|50|Actual|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:06:46.32474|2018-05-31 22:06:46.32474
NCT01444508|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2013-12-12|2011-09-29|2011-09-30|Estimate|||||||2013-12-12|2013-12-13|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Effect of Colloid Versus Crystalloid on Coagulation|Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery|Unknown status|Recruiting|Phase 4|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 22:06:46.409956|2018-05-31 22:06:46.409956
NCT01444495|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-06-15|2011-09-29|2011-09-30|Estimate|||||||2014-06-15|2014-06-17|Estimate|January 1999||1999-01-31|June 2014|2014-06-30|December 2010|Actual|2010-12-31|June 2008|Actual|2008-06-30||Interventional|||Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer|Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer|Completed||Phase 3|154|Actual|Jagiellonian University||2|||f||||f||||||||||2018-05-31 22:06:46.494459|2018-05-31 22:06:46.494459
NCT01444482|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-09-29|2011-09-29|2011-09-30|Estimate|||||||2011-09-29|2011-09-30|Estimate|May 2011||2011-05-31|September 2011|2011-09-30||||November 2011|Anticipated|2011-11-30||Interventional|||Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers|A Phase I Single Blinded Randomised Exploratory Trial in Elderly Volunteers to Assess and Compare Safety and Immunogenicity of Adjuvanted Seasonal Influenza Vaccine (Investigational Vaccine) to Standard Seasonal Influenza Vaccine.|Unknown status|Active, not recruiting|Phase 1|110|Actual|Isconova AB||2|||f||||f||||||||||2018-05-31 22:06:46.588584|2018-05-31 22:06:46.588584
NCT01444469|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2014-07-22|2011-09-29|2011-09-30|Estimate|||||||2014-07-22|2014-07-23|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|AZALEA||AZithromycin Against pLacebo in Exacerbations of Asthma|A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients With Acute Exacerbations of Asthma|Completed||Phase 4|199|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 22:06:46.662973|2018-05-31 22:06:46.662973
NCT01444456|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2014-07-24||2017-02-07|2011-09-29|2011-09-30|Estimate|2014-07-24|2014-08-15|Estimate||||2017-02-07|2017-03-20|Actual|October 2011||2011-10-31|February 2017|2017-02-28||||August 2013|Actual|2013-08-31||Observational||Full analysis set, defined as enrolled participants who received at least 1 dose of darbepoetin alfa or any other erythropoiesis-stimulating agent (ESA) before the end of study.|Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia|Electronic Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia: An International Prospective Observational Study (eAQUA)|Completed|||1262|Actual|Amgen|||2||f||||f||||||||||2018-05-31 22:06:46.802414|2018-05-31 22:06:46.802414
NCT01444443|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-11-19|2011-09-29|2011-09-30|Estimate|||||||2012-11-19|2012-11-20|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|DiaCon2||DiaCon Overnight Closed-Loop Glucose Control Study|DiaCon Closed-Loop Study|Completed||N/A|12|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 22:06:47.182499|2018-05-31 22:06:47.182499
NCT01444430|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2016-04-08||2016-11-29|2011-09-28|2011-09-30|Estimate|2016-11-29|2016-12-15|Estimate||||2016-11-29|2016-12-15|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents|A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma|Completed||Phase 3|12460|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:06:47.32054|2018-05-31 22:06:47.32054
NCT01444417|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2016-11-17|2016-01-13|2017-02-07|2011-09-29|2011-09-30|Estimate|2016-11-22|2017-01-19|Estimate|2016-01-13|2016-02-05|Estimate|2017-02-07|2017-02-09|Estimate|January 2012||2012-01-31|February 2017|2017-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients|A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)|Completed||Phase 3|62|Actual|Amgen||2|||f||||t||||||||||2018-05-31 22:06:48.873169|2018-05-31 22:06:48.873169
NCT01444404|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2017-11-01|2011-09-29|2011-09-30|Estimate|||||||2017-11-01|2017-11-06|Actual|March 31, 2008|Actual|2008-03-31|November 2017|2017-11-30|February 6, 2014|Actual|2014-02-06|February 6, 2014|Actual|2014-02-06||Interventional|||A Study of AMG 820 in Subjects With Advanced Solid Tumors|A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|25|Actual|Amgen||2|||f||||||||||||||2018-05-31 22:06:49.493081|2018-05-31 22:06:49.493081
NCT01444391|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2014-06-26||2014-09-20|2011-09-29|2011-09-30|Estimate|2014-09-13|2014-09-19|Estimate||||2014-09-20|2014-10-01|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|inVENT-visIOn|All enrolled subjects including the lead-in subjects and the study cohort|inVENT-visIOn Study|A Clinical Study of the Acclarent Tympanostomy Tube Delivery and Iontophoresis Systems In-Office|Completed||N/A|42|Actual|Acclarent||1|||f||||f||||||||||2018-05-31 22:06:49.635572|2018-05-31 22:06:49.635572
NCT01444378|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2016-09-26||2017-04-25|2011-09-29|2011-09-30|Estimate|2017-04-25|2017-06-06|Actual||||2017-04-25|2017-06-06|Actual|October 2011||2011-10-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|MOMENTUM|Intent-to-Treat Population|Absolute Pro® MOMENTUM™|Absolute Pro® Peripheral Self-Expanding Stent System and the Absolute Pro® LL Peripheral Self-Expanding Stent Systems in the Treatment of Subjects With Atherosclerotic De Novo or Restenotic Lesions in the Native Superficial Femoral Artery and/or Native Proximal Popliteal Artery.|Completed||N/A|141|Actual|Abbott Vascular||1|||f||||t||||||||||2018-05-31 22:06:49.907234|2018-05-31 22:06:49.907234
NCT01444365|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28||2013-04-18|2013-05-07|2011-09-28|2011-09-30|Estimate||||2013-04-18|2013-04-26|Estimate|2013-05-07|2013-05-15|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee|A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of ABT-652 as an Add On Therapy in Subjects With Osteoarthritis of the Knee Experiencing Partial Benefit of a Nonsteroidal Anti-Inflammatory Drug|Completed||Phase 2|202|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 22:06:51.200102|2018-05-31 22:06:51.200102
NCT01444352|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2015-03-17|2011-09-29|2011-09-30|Estimate|||||||2015-03-17|2015-03-18|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults||Completed||Phase 1|100|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 22:06:51.392472|2018-05-31 22:06:51.392472
NCT01444339|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-09-29|2011-09-29|2011-09-30|Estimate|||||||2011-09-29|2011-09-30|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of Two Investigational Pneumococcal Vaccines in Healthy Adults||Completed||Phase 1|131|Actual|Sanofi||6|||f||||f||||||||||2018-05-31 22:06:51.483675|2018-05-31 22:06:51.483675
NCT01444326|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2014-04-01|2011-09-29|2011-09-30|Estimate|||||||2014-04-01|2014-04-02|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|February 2012|Actual|2012-02-29||Interventional|PLI||Impact of Dairy Consumption on Inflammation: a Clinical Study (PLI)|Impact of Dairy Consumption on Inflammation: a Clinical Study|Completed||N/A|140|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 22:06:51.575745|2018-05-31 22:06:51.575745
NCT01444313|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2014-10-28|2011-09-27|2011-09-30|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2011||2011-01-31|October 2014|2014-10-31||||March 2013|Actual|2013-03-31||Interventional|||Prospective Study of the Health Benefits of Ultra-Violet Filtering Contact Lenses|Prospective Study of the Health Benefits of Ultra-Violet Filtering Contact Lenses|Completed||N/A|40|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-05-31 22:06:51.651719|2018-05-31 22:06:51.651719
NCT01444300|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2014-01-13||2014-05-16|2011-09-29|2011-09-30|Estimate|2014-05-16|2014-06-16|Estimate||||2014-05-16|2014-06-16|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Dalfampridine for Imbalance in Multiple Sclerosis|Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study|Completed||Phase 2|24|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:06:51.729099|2018-05-31 22:06:51.729099
NCT01444287|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|2014-03-27||2015-05-05|2011-09-27|2011-09-30|Estimate|2014-04-30|2014-05-30|Estimate||||2015-05-05|2015-05-21|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Daytime Corneal Swelling During Wear of Narafilcon B Lenses||Completed||N/A|22|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||f||||||||||2018-05-31 22:06:52.138381|2018-05-31 22:06:52.138381
NCT01444274|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-09-28|2011-09-28|2011-09-30|Estimate|||||||2011-09-28|2011-09-30|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Pilot Study to Evaluate A Novel Gastric Space Occupying Device|A Single-Center 60-day Observational, Non-randomized Study to Evaluate Safety and Preliminary Efficacy of a Novel Gastric Space Occupying Device as an Aid for Weight Loss|Completed|||10|Actual|Obalon Therapeutics, Inc.|||1||f||||f||||||||||2018-05-31 22:06:52.492771|2018-05-31 22:06:52.492771
NCT01444261|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-03-29|2011-09-28|2011-09-30|Estimate|||||||2017-03-29|2017-03-31|Actual|December 2010||2010-12-31|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Prevention of Iron Deficiency in Breastfed Infants|Prevention of Iron Deficiency in Breastfed Infants|Completed||Phase 4|219|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-05-31 22:06:52.563783|2018-05-31 22:06:52.563783
NCT01444248|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2012-08-21|2011-09-29|2011-09-30|Estimate|||||||2012-08-21|2012-08-23|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy|A Multi-center, Open, Randomized, Parallel-group Study to Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy|Completed||Phase 4|168|Actual|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:06:52.668427|2018-05-31 22:06:52.668427
NCT01444235|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2013-05-16|2011-09-29|2011-09-30|Estimate|||||||2013-05-16|2013-05-17|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery|A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N Versus Custodiol|Completed||Phase 2|102|Actual|Dr. F. Köhler Chemie GmbH||2|||f||||t||||||||||2018-05-31 22:06:52.889014|2018-05-31 22:06:52.889014
NCT01444222|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2011-09-30|2011-09-29|2011-09-30|Estimate|||||||2011-09-30|2011-10-03|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|August 2012|Anticipated|2012-08-31|||||Observational|||Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart|Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart|Unknown status|Not yet recruiting||120|Anticipated|Universitaire Ziekenhuizen Leuven|||8||f||||f||||||||||2018-05-31 22:06:53.041121|2018-05-31 22:06:53.041121
NCT01444209|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2018-05-01|2011-09-29|2011-09-30|Estimate|||||||2018-05-01|2018-05-02|Actual|September 30, 2011|Actual|2011-09-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas|Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas|Recruiting||Phase 2|24|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 22:06:53.130254|2018-05-31 22:06:53.130254
NCT01444196|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2011-09-30|2011-09-29|2011-09-30|Estimate|||||||2011-09-30|2011-10-03|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|AECUDATT||Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria|Multi-center, Double Blind, Dose Escalating Study to Compare the Effects of 5 mg, 10mg and 20mg of Desloratadine in Patients With Acquired Cold Urticaria (ACU)|Completed||Phase 4|30|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:06:53.215656|2018-05-31 22:06:53.215656
NCT01444183|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2018-04-17|2011-09-28|2011-09-30|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2012||2012-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SMILE||Stress Management Intervention for Living With Epilepsy (SMILE)|Pre-emptive Treatment in Epilepsy Using Electronic Diaries: Towards a New Frontier in Epilepsy Therapy|Completed||N/A|95|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 22:06:53.307743|2018-05-31 22:06:53.307743
NCT01444170|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2011-09-29|2011-09-29|2011-09-30|Estimate|||||||2011-09-29|2011-09-30|Estimate|July 2006||2006-07-31|September 2011|2011-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Nutritional Supplement, Eccentric Exercise and Recovery|A Single Site Double Blind Placebo Controlled Study of the Effects of a Dietary Supplement on Muscle Recovery Following Exercise-Induced Muscle Damage|Completed||Phase 1/Phase 2|42|Actual|University of Florida||2|||f||||||||||||||2018-05-31 22:06:53.390138|2018-05-31 22:06:53.390138
NCT01444157|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-07-17|2011-09-29|2011-09-30|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|FamCope||Family and Coping Oriented Palliative Homecare Nursing Aimed at Advanced Cancer Patients|Family and Coping Oriented Palliative Homecare Nursing as a Supplement to Standard Homecare Nursing Aimed at Advanced Cancer Patients - a Randomized Intervention Trial|Completed||Phase 3|700|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 22:06:53.497407|2018-05-31 22:06:53.497407
NCT01444144|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2017-09-29|2011-09-28|2011-09-30|Estimate|||||||2017-09-29|2017-10-03|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|April 3, 2011|Actual|2011-04-03|April 3, 2011|Actual|2011-04-03||Observational|||Ankle Fracture Treatment in the Elderly|Ankle Fracture Treatment in the Elderly, at Risk Population|Completed|||118|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 22:06:53.589424|2018-05-31 22:06:53.589424
NCT01444131|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2014-03-25|2011-09-29|2011-09-30|Estimate|||||||2014-03-25|2014-03-26|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation|A 26-Week Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Varenicline in Combination With Nicotine Replacement Therapy for Smoking Cessation|Completed||Phase 2|446|Actual|University of Stellenbosch||2|||f||||t||||||||||2018-05-31 22:06:53.659621|2018-05-31 22:06:53.659621
NCT01444118|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2015-07-20|2011-09-29|2011-09-30|Estimate|||||||2015-07-20|2015-07-22|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NSCLC||A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients|Phase III, Open-label, Multicentre, Randomised Trial to Establish Safety and Efficacy of an EGF Cancer Vaccine in Inoperable, Late Stage (IIIb/IV) NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care.|Terminated||Phase 3|||Bioven Sdn. Bhd.||2||"The early termination is not related to safety/toxicity but to initiate new Phase III with~   biomarker to enrich population & to further strengthen OS benefit"|f||||t||||||||||2018-05-31 22:06:53.742057|2018-05-31 22:06:53.742057
NCT01444105|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2018-03-07|2011-09-28|2011-09-30|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2011||2011-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty|A Prospective, Randomized, Controlled, Parallel Groups Evaluation of Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty|Active, not recruiting||N/A|80|Anticipated|Glaukos Corporation||2|||f||||f||||||||||2018-05-31 22:06:53.808292|2018-05-31 22:06:53.808292
NCT01444092|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2015-05-19||2016-11-16|2011-09-29|2011-09-30|Estimate|2016-06-30|2016-08-11|Estimate||||2016-11-16|2017-01-04|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety Study of Entocort for Children With Crohn's Disease|A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive|Completed||Phase 3|123|Actual|Perrigo Company||1|||f||||||||||||||2018-05-31 22:06:54.016732|2018-05-31 22:06:54.016732
NCT01444079|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2015-01-26|2011-09-28|2011-09-30|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation|Graft Rejection or Tolerance Affected by Serial Change of Anti-donor Lymphocyte Antibody After Liver Transplantation|Completed|||48|Actual|Yonsei University|||1||f||||t||||||None Retained|"~     Whole blood (serum)~   "|||2018-05-31 22:06:54.520051|2018-05-31 22:06:54.520051
NCT01444066|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-11-07|2011-09-28|2011-09-30|Estimate|||||||2011-11-07|2011-11-08|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|December 2015|Anticipated|2015-12-31|November 2014|Anticipated|2014-11-30||Interventional|||The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy|The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy|Unknown status|Enrolling by invitation|N/A|96|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 22:06:54.584465|2018-05-31 22:06:54.584465
NCT01444053|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-06-16|2011-09-28|2011-09-30|Estimate|||||||2017-06-16|2017-06-20|Actual|June 1, 2011|Actual|2011-06-01|June 2017|2017-06-30|December 1, 2011|Actual|2011-12-01|December 1, 2011|Actual|2011-12-01||Observational|||Retrospective Study of the Health Benefits of Ultra-Violet Filtering Contact Lenses||Completed|||41|Actual|Johnson & Johnson Vision Care, Inc.|||2||f||||f|f|t|f|f|t|||||2018-05-31 22:06:54.657203|2018-05-31 22:06:54.657203
NCT01444040|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-12-14|2011-09-29|2011-09-30|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2011||2011-09-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 1, 2017|Actual|2017-05-01||Interventional|||Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost|A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost Ophthalmic Solution 0.004%|Active, not recruiting||Phase 4|200|Anticipated|Glaukos Corporation||2|||f||||f||||||||||2018-05-31 22:06:54.722969|2018-05-31 22:06:54.722969
NCT01444027|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2017-10-19||2017-11-17|2011-09-29|2011-09-30|Estimate|2017-10-19|2017-11-20|Actual||||2017-11-17|2017-12-13|Actual|October 2011||2011-10-31|November 2017|2017-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Hospice Problem Solving Intervention|A Problem Solving Intervention for Hospice Caregivers|Completed||N/A|514|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 22:06:54.850075|2018-05-31 22:06:54.850075
NCT01444014|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2015-05-14|2011-09-28|2011-09-30|Estimate|||||||2015-05-14|2015-05-15|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||YF476 and Type I Gastric Carcinoids (Norway)|A Single Centre, Pilot Trial of YF476 in Patients With Chronic Atrophic Gastritis, Hypergastrinaemia and Type I Gastric Carcinoids|Terminated||Phase 2|8|Actual|Trio Medicines Ltd.||1||Difficulties with recruitment|f||||f||||||||||2018-05-31 22:06:55.394791|2018-05-31 22:06:55.394791
NCT01444001|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-09-29|2011-09-29|2011-09-30|Estimate|||||||2011-09-29|2011-09-30|Estimate|February 2007||2007-02-28|September 2011|2011-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers||Completed||Phase 1|63|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 22:06:55.519423|2018-05-31 22:06:55.519423
NCT01443988|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2017-12-14|2011-09-29|2011-09-30|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2011|Actual|2011-09-30|December 2017|2017-12-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost|A Prospective, Randomized Evaluation of Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent) or Travoprost Ophthalmic Solution 0.004%|Completed||Phase 4|101|Actual|Glaukos Corporation||2|||f||||f||||||||||2018-05-31 22:06:56.633149|2018-05-31 22:06:56.633149
NCT01443975|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2014-03-28|2011-09-29|2011-09-30|Estimate|||||||2014-03-28|2014-03-31|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|X-Pander||Clinical Evaluation on the Use of the X-pander Device|Clinical Evaluation on the Use of the X-pander Device|Completed|||100|Anticipated|Northern Orthopaedic Division, Denmark|||1||f||||f||||||||||2018-05-31 22:06:56.782611|2018-05-31 22:06:56.782611
NCT01443962|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-02-02|2011-09-29|2011-09-30|Estimate|||||||2013-02-02|2013-02-05|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|lapaPEEP||The Effect of Positive End Expiratory Pressure (PEEP) During Laparoscopic Cholecystectomy|The Effect of PEEP on Regional Cerebral Oxygen Saturation During Laparoscopic Cholecystectomy|Completed||N/A|60|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 22:06:56.868576|2018-05-31 22:06:56.868576
NCT01443949|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2018-05-12|2011-09-29|2011-09-30|Estimate|||||||2018-05-12|2018-05-15|Actual|September 11, 2011||2011-09-11|April 4, 2013|2013-04-04|April 4, 2013||2013-04-04|||||Observational|||Teenagers, Drug Addiction, and Reward and Impulse Control|Individual Differences in Reward and Impulse Control Circuitry as Risk Factors for Addiction|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:56.95728|2018-05-31 22:06:56.95728
NCT01443936|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2018-04-25|2011-09-29|2011-09-30|Estimate|||||||2018-04-25|2018-04-26|Actual|September 14, 2011||2011-09-14|April 24, 2018|2018-04-24|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||Experimental AD4-H5-VTN Vaccine in Healthy Volunteers|Phase 1 Study of Safety and Immunogenicity of Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers|Completed||Phase 1|96|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:57.01854|2018-05-31 22:06:57.01854
NCT01443923|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2015-02-25||2015-07-09|2011-09-29|2011-09-30|Estimate|2015-07-09|2015-07-13|Estimate||||2015-07-09|2015-07-13|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV|An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1|Terminated||Phase 4|4|Actual|National Institutes of Health Clinical Center (CC)||2||Unable to complete enrollment due to newly approved treatment options.|f||||||||||||||2018-05-31 22:06:57.114231|2018-05-31 22:06:57.114231
NCT01443910|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2018-04-24|2011-09-29|2011-09-30|Estimate|||||||2018-04-24|2018-04-25|Actual|August 25, 2011||2011-08-25|April 10, 2018|2018-04-10||||||||Observational|||Weight Management Interactions in a Virtual Clinical Environment|Weight Management Interactions in a Virtual Clinical Environment|Completed|||318|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:06:57.600607|2018-05-31 22:06:57.600607
NCT01443897|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-09-28|2011-09-28|2011-09-30|Estimate|||||||2011-09-28|2011-09-30|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||Effect of Consumption of Post-harvest UV-B Treated Mushrooms on Vitamin D Status of Healthy Adults|Effect of Consumption of Post-harvest UV-B Treated Mushrooms on Vitamin D Status of Healthy Adults|Completed||N/A|48|Actual|USDA, Western Human Nutrition Research Center||4|||f||||f||||||||||2018-05-31 22:06:57.684126|2018-05-31 22:06:57.684126
NCT01443884|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-12-08|2011-09-28|2011-09-30|Estimate|||||||2011-12-08|2011-12-12|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Anti-Inflammatory Activities of Grapes in Humans at Risk for Cardiovascular Disease|Anti-Inflammatory Activities of Grapes in Humans at Risk for Cardiovascular Disease|Completed||N/A|24|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:06:57.780378|2018-05-31 22:06:57.780378
NCT01443871|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2015-05-26|2011-09-29|2011-09-30|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Essential Oils in Aromatherapy on Emotional Relaxation|Effect of Essential Oils in Aromatherapy on Emotional Relaxation|Completed||N/A|48|Actual|University of Phayao||2|||f||||t||||||||||2018-05-31 22:06:57.864418|2018-05-31 22:06:57.864418
NCT01443858|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|2014-04-07||2014-07-29|2011-09-29|2011-09-30|Estimate|2014-04-07|2014-05-08|Estimate||||2014-07-29|2014-08-01|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Meclizine as a Potential Smoking Cessation Treatment|Meclizine as a Potential Smoking Cessation Treatment|Completed||Phase 2|146|Actual|Duke University||3|||f||||t||||||||||2018-05-31 22:06:57.981809|2018-05-31 22:06:57.981809
NCT01443845|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2016-11-30||2017-03-16|2011-09-28|2011-09-30|Estimate|2016-11-30|2017-01-25|Estimate||||2017-03-16|2017-04-13|Actual|September 30, 2011|Actual|2011-09-30|March 2017|2017-03-31|January 31, 2016|Actual|2016-01-31|November 30, 2015|Actual|2015-11-30||Interventional||The demographic information provided here is for the safety population. The safety population (numbering 2352 patients) of the trial does not include 2 patients from the enrolled population (numbering 2354 patients), due to a protocol deviation for one patient and an adverse event for a second patient, both in the placebo arm|Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)|Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)|Completed||Phase 4|2354|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:06:58.716368|2018-05-31 22:06:58.716368
NCT01443832|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-10-29|2011-09-29|2011-09-30|Estimate|||||||2011-10-29|2011-11-01|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|||Iron Absorption From Iron-fortified Fonio Porridge: a Stable Isotope Study|Effect of Dephytinisation of Fonio With Intrinsic Wheat Phytase on Iron Absorption in Beninese Women|Completed|||16|Actual|Wageningen University|||1||f||||f||||||Samples Without DNA|"~     2 samples of 8 ml venous blood per subject~   "|||2018-05-31 22:07:00.86722|2018-05-31 22:07:00.86722
NCT01443819|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2015-12-14|2011-09-28|2011-09-30|Estimate|||||||2015-12-14|2015-12-16|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Lumbar Transforaminal Epidural Corticosteroid Injection(s) Versus Defined Physical Therapy|Randomized, Prospective Study of Lumbar Transforaminal Epidural Corticosteroid Injection(s) Versus Defined Physical Therapy for the Treatment of Subacute Lumbar Radicular Pain Due to Disc Protrusion|Terminated||Phase 3|5|Actual|Stanford University||3||recruitment problem|f||||f||||||||||2018-05-31 22:07:00.944643|2018-05-31 22:07:00.944643
NCT01443806|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-06-28|2011-09-29|2011-09-30|Estimate|||||||2012-06-28|2012-07-02|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Characterisation of the Human Carboxylesterase 1 (CES1) Mutations in Thailand|Characterisation of the Human Carboxylesterase 1 (CES1) Mutation(s) Which May be Responsible for Markedly Reduced Conversion of Oseltamivir Phosphate to Oseltamivir Carboxylate|Unknown status|Recruiting|Phase 4|15|Anticipated|University of Oxford||1|||f||||f||||||||||2018-05-31 22:07:01.021095|2018-05-31 22:07:01.021095
NCT01443793|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-10-02|2011-09-28|2011-09-30|Estimate|||||||2011-10-02|2011-10-04|Estimate|September 2011||2011-09-30|October 2011|2011-10-31||||||||Observational|||Longitudinal Pattern of Streptococcus Pneumoniae Nasopharyngeal Carriage and Antimicrobial Susceptibility in Healthy Children Aged Less Then 5 Years, in the Area of Milan and Surroundings, Lombardy, Italy.|Longitudinal Pattern of Streptococcus Pneumoniae Nasopharyngeal Carriage and Antimicrobial Susceptibility in Healthy Children Aged Less Then 5 Years, in the Area of Milan and Surroundings, Lombardy, Italy.|Unknown status|Recruiting||1300|Anticipated|University of Milan|||||f||||f||||||||||2018-05-31 22:07:01.119023|2018-05-31 22:07:01.119023
NCT01443780|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-09-30|2011-09-29|2011-09-30|Estimate|||||||2011-09-30|2011-10-03|Estimate|January 2003||2003-01-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|KiSel-10||Intervention With Selenium and Q10 on Cardiovascular Mortality and Cardiac Function in the Elderly Population in Sweden|Kisel-10- a Prospective Randomized Double-blind Placebo Controlled Study of the Results of Intervention With Selenium and Coenzyme Q10 Combined, Regarding Effect With Emphasis on Cardiovascular Mortality and Morbidity.|Completed||N/A|443|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 22:07:01.190195|2018-05-31 22:07:01.190195
NCT01443767|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-02-12|2011-09-29|2011-09-30|Estimate|||||||2012-02-12|2012-02-14|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Correlation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection|Pilot Study to Examine the Correlation of 'Estimated Continuous Cardias Output' (esCCO) With Pulse Contour Analysis of the Arterial Waveform (Picco) in Partial Liver Resection|Completed|||27|Actual|Heidelberg University|||1||f||||f||||||||||2018-05-31 22:07:01.290384|2018-05-31 22:07:01.290384
NCT01443754|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-09-30|2011-09-29|2011-09-30|Estimate|||||||2016-09-30|2016-10-03|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|HYBRID||Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease|Hybrid Revascularisation by Combined CABG and PCI in Multivessel Coronary Disease. An Observational Study.|Terminated|||50|Actual|Ettore Sansavini Health Science Foundation|||1|Lack of recruitment|f||||f||||||||No||2018-05-31 22:07:01.358245|2018-05-31 22:07:01.358245
NCT01443559|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2015-07-16|2011-09-28|2011-09-29|Estimate|||||||2015-07-16|2015-07-17|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|XKFPC||Xenogenic Keratoplasty From Porcine Cornea|Phase I Study of Xenogenic Keratoplasty From Porcine Cornea in the Treatment of Infectious Corneal Ulcer|Suspended||Phase 1|20|Anticipated|Xiamen University||2||there was not enough patients recruited in this study|f||||t||||||||||2018-05-31 22:07:03.645283|2018-05-31 22:07:03.645283
NCT01443741|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2011-09-28|2011-09-28|2011-09-30|Estimate|||||||2011-09-28|2011-09-30|Estimate|January 2012||2012-01-31|September 2011|2011-09-30|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|DIABFIT||Evaluation of Interests of FIT Therapy on Diabetics Children Insulin-dependent|Evaluation of Interests of the Functional Insulin Therapy (FIT Therapy) on Metabolic Control, Hypoglycemia Prevention and Life Quality of Diabetics Children Insulin-dependent Treated With Insulin Pump.|Unknown status|Not yet recruiting|Phase 2|88|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 22:07:01.425207|2018-05-31 22:07:01.425207
NCT01443728|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27||2016-10-10|2018-03-21|2011-09-28|2011-09-30|Estimate||||2016-10-10|2016-10-12|Estimate|2018-03-21|2018-03-23|Actual|December 2011||2011-12-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|September 2015|Actual|2015-09-30||Interventional|||Vitamin D for Sickle-cell Respiratory Complications|Vitamin D for Sickle-cell Respiratory Complications|Active, not recruiting||Phase 2|130|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 22:07:01.530405|2018-05-31 22:07:01.530405
NCT01443715|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2014-09-02|2011-09-29|2011-09-30|Estimate|||||||2014-09-02|2014-09-04|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|SCIPT-A||A Stepped Care Model of Adolescent Depression Treatment in Primary Care|A Stepped Care Model of Adolescent Depression Treatment in Primary Care|Completed||Phase 2/Phase 3|48|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 22:07:01.709669|2018-05-31 22:07:01.709669
NCT01443702|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2013-11-29|2011-09-29|2011-09-30|Estimate|||||||2013-11-29|2013-12-02|Estimate|January 2011||2011-01-31|November 2013|2013-11-30||||December 2011|Actual|2011-12-31||Interventional|||Use of Lapis Judaicus to Dissolve Kidney Stones||Completed||Phase 1/Phase 2|60|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:07:01.782126|2018-05-31 22:07:01.782126
NCT01443689|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-11-26|2011-09-29|2011-09-30|Estimate|||||||2012-11-26|2012-11-28|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|||Allogenic Stem Cell Therapy in Patients With Acute Burn|A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Acute Burn|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen Beike Bio-Technology Co., Ltd.||3|||f||||t||||||||||2018-05-31 22:07:01.945784|2018-05-31 22:07:01.945784
NCT01443676|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2016-10-31|2011-09-28|2011-09-30|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|ARTE||Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma|Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma|Completed||Phase 2|75|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 22:07:02.442403|2018-05-31 22:07:02.442403
NCT01443663|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2016-02-05|2011-09-28|2011-09-30|Estimate|||||||2016-02-05|2016-02-09|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine|Immunogenicity and Safety Study of a 45 Micrograms Dose of Inactivated, Unadjuvanted H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H5N1 and H7N3 Influenza Vaccines and in H5 and Live Attenuated Vaccine Naïve Individuals|Completed||Phase 1|69|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 22:07:02.680391|2018-05-31 22:07:02.680391
NCT01443650|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2013-06-27|2011-09-28|2011-09-30|Estimate|||||||2013-06-27|2013-06-28|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects|A Randomized Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Different Single-Dose Subcutaneous Treatments of SAR236553/REGN727 in Healthy Subjects|Completed||Phase 1|36|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 22:07:02.841714|2018-05-31 22:07:02.841714
NCT01443637|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2018-01-05|2011-09-29|2011-09-30|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2003|Actual|2003-06-30|January 2018|2018-01-31|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Observational|CONFIRM||COroNary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter Registry (CONFIRM)|COronary CT Angiography Evaluation For Clinical Outcomes: An International Multicenter Registry|Enrolling by invitation|||50000|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||Undecided||2018-05-31 22:07:02.933605|2018-05-31 22:07:02.933605
NCT01443624|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-08-13|2011-09-29|2011-09-30|Estimate|||||||2013-08-13|2013-08-14|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional|SOFI||Evaluation of Oxidative Stress Induced by Iron Injection in Healthy Volunteers and Critical Care Patients|Evaluation of Oxidative Stress Induced by Iron Injection in Healthy Volunteers Versus Critical Care Patients|Completed||N/A|80|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 22:07:03.046584|2018-05-31 22:07:03.046584
NCT01443611|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-08-30|2011-09-29|2011-09-30|Estimate|||||||2015-08-30|2015-09-01|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||The Relevance of Performing Lumbar Puncture in Infants Aged 3 to 12 Months With First Episode of Febrile Convulsion||Completed|||122|Actual|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-05-31 22:07:03.156639|2018-05-31 22:07:03.156639
NCT01443598|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2016-06-06|2011-09-28|2011-09-29|Estimate|||||||2016-06-06|2016-06-08|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2011|Actual|2011-12-31||Observational|HYPID||Pulmonary Hypertension in Interstitial Lung Disease|Observational Study of Patients With Pre Capillary Pulmonary Hypertension|Completed|||224|Actual|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|||||f||||f||||||Samples With DNA|"~     whole blood, serum and plasma~   "|Undecided||2018-05-31 22:07:03.221037|2018-05-31 22:07:03.221037
NCT01443585|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-03-14|2011-09-28|2011-09-29|Estimate|||||||2013-03-14|2013-03-15|Estimate|September 2012||2012-09-30|September 2011|2011-09-30||||November 2013|Anticipated|2013-11-30||Interventional|||Clinical Evaluation of a Progressive Addition Lens (PAL)|Clinical Performance Evaluation of a Progressive Addition Lens Among Presbyopic Patients|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Ziv Hospital|||||f||||t||||||||||2018-05-31 22:07:03.312277|2018-05-31 22:07:03.312277
NCT01443572|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2014-07-20|2011-09-28|2011-09-29|Estimate|||||||2014-07-20|2014-07-22|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Comparison of Desflurane and Sevoflurane on Postoperative Recovery and Hepatic Function of Biliary Atresia Patients During Kasai Operation||Completed||N/A|40|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:07:03.444958|2018-05-31 22:07:03.444958
NCT01443546|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-06-10|2011-09-28|2011-09-29|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|DUALTRIGGER||Study of Dual Trigger Ovulation in Oocyte Donors|A Randomized Prospective Trial of Dual Trigger Ovulation in Oocyte Donors|Unknown status|Recruiting|Phase 4|180|Anticipated|Weill Medical College of Cornell University||3|||f||||t||||||||||2018-05-31 22:07:04.492802|2018-05-31 22:07:04.492802
NCT01443533|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-06-26|2011-09-28|2011-09-29|Estimate|||||||2012-06-26|2012-06-28|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of Birth Control Use After Childbirth|A Randomized Controlled Trial of a Brief Educational Script on Postpartum Contraceptive Uptake|Completed||N/A|800|Actual|WakeMed Health and Hospitals||2|||f||||f||||||||||2018-05-31 22:07:04.736693|2018-05-31 22:07:04.736693
NCT01443520|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-05-21|2011-09-28|2011-09-29|Estimate|||||||2012-05-21|2012-05-22|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Duloxetine and Venlafaxine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol: A Three-phase Randomized Balanced Cross-over Study in Healthy Volunteers||Completed||Phase 4|12|Actual|Turku University Hospital||3|||f||||||||||||||2018-05-31 22:07:04.817673|2018-05-31 22:07:04.817673
NCT01443507|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-12-09|2011-09-27|2011-09-29|Estimate|||||||2014-12-09|2014-12-10|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Exercise With Low Intensity and Longer Duration Versus High Intensity Interval Training|Does Endurance Exercise With Low Intensity and Longer Duration Improve Aerobic Capacity to the Same Extent as High Intensity Interval Training?|Completed||Phase 2|22|Actual|Volda University College||2|||f||||f||||||||||2018-05-31 22:07:04.893128|2018-05-31 22:07:04.893128
NCT01443494|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|2014-02-27||2017-06-13|2011-09-28|2011-09-29|Estimate|2014-06-13|2014-06-16|Estimate||||2017-06-13|2017-07-06|Actual|June 2011||2011-06-30|June 2017|2017-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Detailed enquiry about the target MAP to their next kin was performed in all of the patients.|High MAP in Septic Shock With Hypertension|High Mean Arterial Pressure Target Improves Microcirculation in Septic Shock Patients With Previous Hypertension|Completed||N/A|19|Actual|Southeast University, China|"Firstly, cardiac output was monitored by NICOM system to minimize the invasive operation.~Secondly, the number of patients enrolled in the study was relatively small. Next, immediate changes of the increase in MAP were investigated."|1|||f||||f||||||||||2018-05-31 22:07:04.978187|2018-05-31 22:07:04.978187
NCT01443481|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2017-06-06|2011-09-28|2011-09-29|Estimate|||||||2017-06-06|2017-06-08|Actual|November 2011||2011-11-30|June 2017|2017-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function|A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function|Completed||Phase 1|38|Actual|Novartis||4|||f||||f||||||||||2018-05-31 22:07:05.316004|2018-05-31 22:07:05.316004
NCT01443468|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2018-05-18|2011-09-28|2011-09-29|Estimate|||||||2018-05-18|2018-05-21|Actual|September 8, 2011||2011-09-08|February 26, 2018|2018-02-26||||||||Observational|||Clinical and Genetic Studies of Li-Fraumeni Syndrome|Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||5||f||||||||||||||2018-05-31 22:07:05.49781|2018-05-31 22:07:05.49781
NCT01443455|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-09-27|2011-09-28|2011-09-29|Estimate|||||||2017-09-27|2017-10-02|Actual|January 2010|Actual|2010-01-31|September 2017|2017-09-30|September 30, 2012|Actual|2012-09-30|July 31, 2012|Actual|2012-07-31||Interventional|||Adherence and Health Effects of Video Dance in Postmenopausal Women|Phase 2 Trial of Video Dance Versus Walking in Postmenopausal Sedentary Overweight Women|Completed||N/A|168|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 22:07:05.633223|2018-05-31 22:07:05.633223
NCT01443442|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-01-18|2011-09-28|2011-09-29|Estimate|||||||2013-01-18|2013-01-21|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis|A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis|Completed||Phase 4|23|Actual|Southern California College of Optometry||2|||f||||f||||||||||2018-05-31 22:07:05.726543|2018-05-31 22:07:05.726543
NCT01443429|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2014-03-03|2011-09-27|2011-09-29|Estimate|||||||2014-03-03|2014-03-04|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment|A Pharmacokinetic Study of TRK-100STP -A Single Oral Administration Study in Japanese Patients With Renal Impairment as Compared to Subjects With Normal Renal Function|Completed||Phase 1|24|Actual|Toray Industries, Inc||4|||f||||f||||||||||2018-05-31 22:07:05.826962|2018-05-31 22:07:05.826962
NCT01443416|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-11-06|2011-09-28|2011-09-29|Estimate|||||||2015-11-06|2015-11-09|Estimate|April 2012||2012-04-30|November 2015|2015-11-30||||August 2013|Actual|2013-08-31||Interventional|||An Alternative Booster Vaccine Against Meningitis and Ear Infections|An Alternative Booster Vaccine Against Meningitis and Ear Infections.|Completed||Phase 3|178|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 22:07:05.896587|2018-05-31 22:07:05.896587
NCT01443403|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2017-04-19||2017-05-31|2011-09-27|2011-09-29|Estimate|2017-04-19|2017-05-30|Actual||||2017-05-31|2017-06-26|Actual|August 17, 2011|Actual|2011-08-17|May 2017|2017-05-31|August 22, 2012|Actual|2012-08-22|August 22, 2012|Actual|2012-08-22||Interventional||The modified intention-to-treat (mITT) population included all randomized participants who received study drug and had at least 1 postdose primary efficacy assessment completed. One participant who randomized twice was excluded from the naldemedine 0.4 mg arm for the mITT population.|A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy|Completed||Phase 2|244|Actual|Shionogi Inc.||4|||f||||f||||||||||2018-05-31 22:07:06.070414|2018-05-31 22:07:06.070414
NCT01443390|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2014-05-12|2011-09-28|2011-09-29|Estimate|||||||2014-05-12|2014-05-14|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer|An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advanced Refractory Cancer|Completed|||11|Actual|Scottsdale Healthcare|||||f||||f||||||Samples With DNA|"~     Biopsy of an accessible lesion~   "|||2018-05-31 22:07:08.811596|2018-05-31 22:07:08.811596
NCT01443195|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-08-08|2011-09-28|2011-09-29|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2011||2011-10-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Iron Metabolism in Small Pre Term Newborns|Iron Metabolism in Small Pre Term Newborns|Recruiting||N/A|50|Anticipated|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-05-31 22:07:11.174156|2018-05-31 22:07:11.174156
NCT01443377|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-05-06|2011-09-28|2011-09-29|Estimate|||||||2015-05-06|2015-05-07|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|NEOREC-1||Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer|Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer|Completed||Phase 2|48|Anticipated|National Center for Tumor Diseases, Heidelberg|||||f||||t||||||||||2018-05-31 22:07:08.875727|2018-05-31 22:07:08.875727
NCT01443364|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|2016-01-04||2017-07-06|2011-09-28|2011-09-29|Estimate|2016-02-22|2016-03-23|Estimate||||2017-07-06|2017-08-15|Actual|December 2011||2011-12-31|July 2017|2017-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SPEED|The Baseline Characteristics refer to the Safety Set (SS) which consists of all subjects who received at least one dose of study medication.|Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis|Multicenter, Open Label Study to Evaluate the Predictability of Early Response to Certolizumab Pegol (in Combination With Methotrexate) as Confirmed at Week 52 in Subjects With Moderate-severe Rheumatoid Arthritis (RA)|Completed||Phase 4|132|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 22:07:09.020626|2018-05-31 22:07:09.020626
NCT01443351|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-02-04|2011-09-28|2011-09-29|Estimate|||||||2015-02-04|2015-02-05|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)|Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Primary Immune Thrombocytopenia (ITP)|Recruiting|||50|Anticipated|Zealand University Hospital|||1||f||||f||||||Samples With DNA|"~     Whole blood samples will be collected, seru, plasma and mononuclear cells will be stored in a~     biobank for further research use~   "|||2018-05-31 22:07:10.280158|2018-05-31 22:07:10.280158
NCT01443338|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-28|2011-09-28|2011-09-29|Estimate|||||||2011-09-28|2011-09-29|Estimate|September 2011||2011-09-30|September 2011|2011-09-30||||December 2012|Anticipated|2012-12-31||Interventional|||Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2|A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris|Unknown status|Recruiting|Phase 4|720|Anticipated|Ministry of Health, China||2|||f||||t||||||||||2018-05-31 22:07:10.352917|2018-05-31 22:07:10.352917
NCT01443325|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-06-21|2011-09-28|2011-09-29|Estimate|||||||2012-06-21|2012-06-22|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Lidocaine Patch for Treatment of Persistent Inguinal Postherniorrhaphy Pain||Completed||Phase 3|21|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 22:07:10.430745|2018-05-31 22:07:10.430745
NCT01443312|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-08-30|2011-09-28|2011-09-29|Estimate|||||||2015-08-30|2015-09-01|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia||Completed|||28|Actual|HaEmek Medical Center, Israel|||1||f||||f||||||Samples With DNA|"~     DNA samples will be obtained to analyze the beta and alfa globin genes and the xmn1~     polymorphism.~   "|||2018-05-31 22:07:10.494648|2018-05-31 22:07:10.494648
NCT01443299|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-12-08|2011-09-27|2011-09-29|Estimate|||||||2014-12-08|2014-12-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:07:10.56136|2018-05-31 22:07:10.56136
NCT01443286|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2017-04-18|2011-09-27|2011-09-29|Estimate|||||||2017-04-18|2017-04-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:07:10.593689|2018-05-31 22:07:10.593689
NCT01443273|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-08-08|2011-09-28|2011-09-29|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2011||2011-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010|Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010|Recruiting|||50|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-05-31 22:07:10.691123|2018-05-31 22:07:10.691123
NCT01443260|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2015-03-09|2011-09-27|2011-09-29|Estimate|||||||2015-03-09|2015-03-10|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis|Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis|Completed||Phase 1/Phase 2|9|Actual|Genelux Corporation|||||f||||t||||||||||2018-05-31 22:07:10.769635|2018-05-31 22:07:10.769635
NCT01443247|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2011-09-28|2011-09-28|2011-09-29|Estimate|||||||2011-09-28|2011-09-29|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Role of Andi-d in Dengue Fever: a Pilot Study|Role of Andi-d in Dengue Fever: a Pilot Study|Completed||N/A|30|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 22:07:10.835451|2018-05-31 22:07:10.835451
NCT01443234|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2014-01-08|2011-09-28|2011-09-29|Estimate|||||||2014-01-08|2014-01-09|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|OxIGen||OxIGen: Oxford Imagery Generation: Investigating the Effects of an Internet Based Computer Program in Depression|OxIGen: Oxford Imagery Generation: Investigating the Effects of an Internet Based Computer Program in Depression|Completed||Phase 2|150|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 22:07:10.91054|2018-05-31 22:07:10.91054
NCT01443221|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2011-09-28|2011-09-28|2011-09-29|Estimate|||||||2011-09-28|2011-09-29|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.|Open-label, Randomized, Single-dose, 2-way Crossover Study to Investigate Safety and Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.|Completed||Phase 1|24|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-05-31 22:07:11.006084|2018-05-31 22:07:11.006084
NCT01443208|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2011-12-29|2011-09-27|2011-09-29|Estimate|||||||2011-12-29|2012-01-02|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet|A Phase 1, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, Parallel-Group, Single and Multiple-Dose Study of Desvenlafaxine in Korean Healthy Subjects|Completed||Phase 1|36|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:07:11.095214|2018-05-31 22:07:11.095214
NCT01443182|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-10-31|2011-09-28|2011-09-29|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Treatment of Posttraumatic Stress Disorder (PTSD) in Adult Survivors of Early Chronic Interpersonal Trauma|Treatment of PTSD in Adult Survivors of Early Chronic Interpersonal Trauma|Unknown status|Recruiting|Phase 2|90|Anticipated|VU University of Amsterdam||2|||f||||f||||||||||2018-05-31 22:07:11.258679|2018-05-31 22:07:11.258679
NCT01443169|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-04-17|2011-09-28|2011-09-29|Estimate|||||||2012-04-17|2012-04-19|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted|A Phase 1, Randomized, Open Label, Single Dose, 5-treatment, 5- Period Crossover Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release Pregabalin Tablet Formulations Administered Following an Evening Meal and the Immediate Release Formulation Administered Fasted|Completed||Phase 1|16|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:07:11.340147|2018-05-31 22:07:11.340147
NCT01443156|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-02-14|2011-09-27|2011-09-29|Estimate|||||||2013-02-14|2013-02-18|Estimate|January 2012||2012-01-31|February 2013|2013-02-28||||February 2013|Actual|2013-02-28||Observational|||The Effects of Work Schedule and Sleep Patterns on Caregivers' Health||Completed|||211|Actual|Oregon Health and Science University|||1||f||||||||||Samples With DNA|"~     Mouthwash swish containing buccal cells.~   "|||2018-05-31 22:07:11.436106|2018-05-31 22:07:11.436106
NCT01443143|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-27|2011-09-27|2011-09-29|Estimate|||||||2011-09-27|2011-09-29|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Blood Glucose Stability and Variability on Two Diets|A Comparison of Glycemic Stability and Variability During Consumption of Usual Diet or a Commercially Available Portion-controlled Diet Among Patients With Type 2 Diabetes|Unknown status|Recruiting|N/A|15|Anticipated|Nutrisystem, Inc.||2|||f||||f||||||||||2018-05-31 22:07:11.507905|2018-05-31 22:07:11.507905
NCT01443130|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2015-10-01||2016-11-03|2011-09-27|2011-09-29|Estimate|2015-10-01|2015-10-29|Estimate||||2016-11-03|2016-12-28|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional||All participants enrolled in the study are included in the baseline analysis population, with the exception of the age continuous for all groups, which is limited to the maternal participants.|Chloroquine for Malaria in Pregnancy|A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi|Completed||Phase 3|900|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The observed placental malaria rate was lower than expected causing the study to be under powered. After review of a futility analysis, the Sponsor and DSMB recommended allowing the study to conclude as planned and not to increase the sample size.|3|||f||||||||||||||2018-05-31 22:07:11.627398|2018-05-31 22:07:11.627398
NCT01443117|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2014-05-05|2011-09-27|2011-09-29|Estimate|||||||2014-05-05|2014-05-07|Estimate||||May 2014|2014-05-31||||August 2014|Anticipated|2014-08-31||Interventional|||Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women|Administration of Polysaccharide or Conjugated Pneumococcal Vaccines to HIV-Infected Pregnant Women: Safety and Magnitude, Persistence, and Transplacental Transfer of Vaccine-Serotype Pneumococcal Anti-Capsular Antibodies|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 22:07:12.771471|2018-05-31 22:07:12.771471
NCT01443104|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2018-03-14|2011-09-28|2011-09-29|Estimate|||||||2018-03-14|2018-03-15|Actual|February 2012|Actual|2012-02-29|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|June 2014|Actual|2014-06-30||Interventional|||Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents|A Randomized Comparison of a Sirolimus-eluting Stent With Biodegradable Polymer Versus an Everolimus-eluting Stent With a Durable Polymer for Percutaneous Coronary Revascularization|Active, not recruiting||N/A|2119|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 22:07:12.844898|2018-05-31 22:07:12.844898
NCT01443091|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2017-05-25|2011-09-27|2011-09-29|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2011||2011-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Oropharyngeal Colostrum for Immune Stimulation in Very Low Birth Weight Infants|Oropharyngeal Colostrum for Immune Stimulation in Very Low Birth Weight Infants|Completed||N/A|43|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 22:07:13.048449|2018-05-31 22:07:13.048449
NCT01443078|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2016-06-29||2018-01-22|2011-09-27|2011-09-29|Estimate|2016-06-29|2016-08-09|Estimate||||2018-01-22|2018-02-20|Estimate|October 2011||2011-10-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)|Phase II Trial of Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)|Completed||Phase 2|42|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:07:13.130713|2018-05-31 22:07:13.130713
NCT01443065|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-01-24|2011-09-28|2011-09-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|March 2014|Actual|2014-03-31||Interventional|MEGA||MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma|MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial|Active, not recruiting||Phase 2|162|Actual|UNICANCER||3|||f||||t||||||||||2018-05-31 22:07:13.298304|2018-05-31 22:07:13.298304
NCT01443052|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2014-04-11|2011-09-28|2011-09-29|Estimate|||||||2014-04-11|2014-04-14|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|GAITRITE||Gait Parameters Analysis in Post-stroke Patients and in Elderly Fallers|"Study of the Temporospatial Gait Parameters With the Electronic Carpet GAITRite in Patients With Walking Impairment After Stroke and in Old Faller Subjects"|Unknown status|Recruiting||90|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||||2018-05-31 22:07:13.389136|2018-05-31 22:07:13.389136
NCT01442857|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2014-08-04|2011-09-28|2011-09-29|Estimate|||||||2014-08-04|2014-08-05|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||The Axillary Region in a High Resolution MRI|The Axillary Region in a High Resolution MRI. Imaging Before and After Brachial Plexus Block|Completed||Phase 2|18|Actual|Diakonhjemmet Hospital||1|||f||||f||||||||||2018-05-31 22:07:14.823427|2018-05-31 22:07:14.823427
NCT01443039|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2017-01-03|2011-09-28|2011-09-29|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|SODA||Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass|Phenotypical Approach of the Drug Metabolizing Hormones Activity (CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4 and P-gp) Before and After Roux-en Y-Gastric Bypass. The SODA Protocol: Surgery for Obesity and Drug Availability|Completed||Phase 1|11|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:07:13.461089|2018-05-31 22:07:13.461089
NCT01443026|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|2014-04-17||2017-11-01|2011-09-27|2011-09-29|Estimate|2015-06-02|2015-06-04|Estimate||||2017-11-01|2017-11-06|Actual|February 2006||2006-02-28|November 2017|2017-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||The Effects of Lycopene on High Risk Prostatic Tissue|R01 CA90759: The Effects of Lycopene on High Risk Prostatic Tissue|Completed||Phase 2|66|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 22:07:13.611826|2018-05-31 22:07:13.611826
NCT01443013|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-10-18|2011-09-28|2011-09-29|Estimate|||||||2015-10-18|2015-10-20|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|TUFEV||Analysis of Foxp3 and Vimentin Expression in Renal Transplant Recipient|Predictive Value Analysis of Messenger Ribonucleic Acid (mRNA) Urinary Expression of Foxp3 and Vimentin on Graft Outcome in Renal Transplant Recipient: National Prospective Study|Completed|||266|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||Samples Without DNA|"~     Urine for mRNA extraction and congelation~   "|||2018-05-31 22:07:13.907962|2018-05-31 22:07:13.907962
NCT01443000|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2016-11-03|2011-09-28|2011-09-29|Estimate|||||||2016-11-03|2016-11-04|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|SIOI||Survey of Patients With Idiopathic Orbital Inflammation Syndrome|Survey of Patients With Idiopathic Orbital Inflammation Syndrome (IOIS): Clinical, Morphological and Pathological Features and Treatment Outcomes|Active, not recruiting|||87|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Blood samples will be frozen to form a serum storage and a DNAthèque. These samples will~     achieve further analysis based on the evolution of knowledge on mechanisms contributing to~     the orbital inflammation.~   "|||2018-05-31 22:07:13.977883|2018-05-31 22:07:13.977883
NCT01442987|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2013-08-12|2011-09-28|2011-09-29|Estimate|||||||2013-08-12|2013-08-13|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia|Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia|Completed||Phase 3|230|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||||2018-05-31 22:07:14.049001|2018-05-31 22:07:14.049001
NCT01442974|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2013-03-12|2011-09-28|2011-09-29|Estimate|||||||2013-03-12|2013-03-13|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer|Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer|Completed||N/A|15|Actual|Grupo Hospital de Madrid||1|||f||||t||||||||||2018-05-31 22:07:14.140307|2018-05-31 22:07:14.140307
NCT01442961|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-04-09|2011-09-28|2011-09-29|Estimate|||||||2013-04-09|2013-04-10|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Vaginal Hysterectomy, Laparoscopic Hysterectomy, Postoperative Pain|Postoperative Pain After Vaginal or Laparoscopic Hysterectomy: a Prospective Trial|Completed||N/A|188|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 22:07:14.206196|2018-05-31 22:07:14.206196
NCT01442948|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-09-28|2011-09-28|2011-09-29|Estimate|||||||2011-09-28|2011-09-29|Estimate|May 2007||2007-05-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|August 2009|Actual|2009-08-31||Observational|PHAMOS||CD16+ Monocytes in Coronary Heart Disease (CHD)|CD16+ Monocytes in Patients With Coronary Heart Disease|Completed|||1000|Actual|Martin-Luther-Universität Halle-Wittenberg|||2||f||||f||||||||||2018-05-31 22:07:14.267238|2018-05-31 22:07:14.267238
NCT01442935|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-05-06|2011-09-28|2011-09-29|Estimate|||||||2018-05-06|2018-05-08|Actual|February 2011|Actual|2011-02-28|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2015|Actual|2015-12-31||Interventional|||Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases|Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases|Active, not recruiting||Phase 2|256|Anticipated|UNICANCER||3|||f||||t||||||||||2018-05-31 22:07:14.334372|2018-05-31 22:07:14.334372
NCT01442922|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2013-01-16|2011-09-28|2011-09-29|Estimate|||||||2013-01-16|2013-01-17|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Intervertebral Disc Augmentation With Minimally Invasive Surgical Procedure|Intervertebral Disc Nucleus Augmentation With Allograft Meniscus With Minimally Invasive Surgical Procedure|Completed|||1|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 22:07:14.422707|2018-05-31 22:07:14.422707
NCT01442909|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-25|||2011-09-27|2011-09-27|2011-09-29|Estimate|||||||2011-09-27|2011-09-29|Estimate|March 2008||2008-03-31|September 2011|2011-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pemetrexed Followed by Docetaxel or in Reverse Sequence|Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy|Completed||Phase 4|44|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 22:07:14.568654|2018-05-31 22:07:14.568654
NCT01442896|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-28|2011-09-28|2011-09-29|Estimate|||||||2011-09-28|2011-09-29|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|September 2015|Anticipated|2015-09-30|October 2013|Anticipated|2013-10-31||Observational|STARFISH||STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk (STARFISH)|STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk (STARFISH)|Unknown status|Recruiting||130|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-05-31 22:07:14.630903|2018-05-31 22:07:14.630903
NCT01442883|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2018-01-11|2011-09-28|2011-09-29|Estimate|||||||2018-01-11|2018-01-12|Actual|November 2010||2010-11-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Renal Nerve Ablation in Chronic Kidney Disease Patients|Understanding the Mechanisms of Progressive Decrease in Blood Pressure After Renal Nerve Ablation|Recruiting|||100|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 22:07:14.691627|2018-05-31 22:07:14.691627
NCT01442870|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-05-05|2011-09-28|2011-09-29|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2011||2011-09-30|May 2017|2017-05-31|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy|Prospective Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy|Completed||Phase 1|105|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-05-31 22:07:14.769166|2018-05-31 22:07:14.769166
NCT01442844|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|2014-06-18||2014-06-18|2011-09-28|2011-09-29|Estimate|2014-06-18|2014-07-17|Estimate||||2014-06-18|2014-07-17|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MomelanMohs||Secondary Intention Wound Healing Versus Micrografting in Patients Undergoing Mohs Surgery|Secondary Intention Wound Healing Versus Micrografting in Patients Undergoing Mohs Surgery|Terminated||N/A|3|Actual|Massachusetts General Hospital||2||The study sponsor was acquired by a company that focuses on chronic wounds|f||||f||||||||||2018-05-31 22:07:14.883956|2018-05-31 22:07:14.883956
NCT01442831|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2016-04-27|2011-09-26|2011-09-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects|An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-TR-701 in Healthy Adult Male Subjects|Completed||Phase 1|6|Actual|Trius Therapeutics LLC||1|||f||||f||||||||||2018-05-31 22:07:15.05927|2018-05-31 22:07:15.05927
NCT01442818|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-07-09|2011-09-28|2011-09-29|Estimate|||||||2015-07-09|2015-07-10|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|October 2012|Actual|2012-10-31|September 2011|Actual|2011-09-30||Interventional|||Patient Satisfaction and Pain Control Following Reconstructive Vaginal Surgery|Patient Satisfaction and Pain Control Following Reconstructive Vaginal Surgery: A Randomized Trial Comparing Patient-Controlled Intravenous Analgesia (PCA) to Scheduled Intravenous Analgesia|Completed||N/A|54|Actual|TriHealth Inc.||2|||f||||t||||||||||2018-05-31 22:07:15.114605|2018-05-31 22:07:15.114605
NCT01442805|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-03-13|2011-09-28|2011-09-29|Estimate|||||||2017-03-13|2017-03-15|Actual|October 2008||2008-10-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Use of Virtual Reality in the Treatment of Flying Phobia|Etude contrôlée Des Effets de la réalité Virtuelle Sur Les symptômes et Les paramètres Physiologiques de Certaines Phobies spécifiques|Completed||N/A|36|Actual|Luxembourg Institute of Health||2|||f||||t||||||||No||2018-05-31 22:07:15.203669|2018-05-31 22:07:15.203669
NCT01442792|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2017-01-19|2011-09-28|2011-09-29|Estimate|||||||2017-01-19|2017-01-23|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|X-PLORER||Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention|Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention|Completed||Phase 2|108|Actual|Bayer||4|||f||||t||||||||||2018-05-31 22:07:15.263152|2018-05-31 22:07:15.263152
NCT01442779|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2009-09-23||2012-04-18|2011-08-23|2011-09-29|Estimate|2011-08-23|2011-09-29|Estimate||||2012-04-18|2012-04-20|Estimate|September 2000||2000-09-30|April 2012|2012-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis|Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis|Completed||Phase 2|18|Actual|Texas Tech University Health Sciences Center|||||f||||f||||||||||2018-05-31 22:07:15.339618|2018-05-31 22:07:15.339618
NCT01442766|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-29|2011-09-28|2011-09-29|Estimate|||||||2011-09-29|2011-09-30|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|May 2014|Anticipated|2014-05-31|November 2013|Anticipated|2013-11-30||Interventional|||Donepezil Trial for Motor Recovery in Acute Stroke|A Randomised-controlled Trial of Donepezil for Motor Recovery in Acute Stroke|Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 22:07:15.589901|2018-05-31 22:07:15.589901
NCT01442753|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2015-06-02|2011-09-27|2011-09-29|Estimate|||||||2015-06-02|2015-06-04|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth|Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth: A CBPR RCT|Completed||N/A|800|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 22:07:15.668567|2018-05-31 22:07:15.668567
NCT01442740|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2013-08-28|2011-09-27|2011-09-28|Estimate|||||||2013-08-28|2013-08-30|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|RTP||15-Degree Tilt, Head Up, Feet Down Body Position for Sinus Surgery Patients|15-Degree Reverse Trendelenburg Position for FESS|Completed||N/A|64|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:07:15.739664|2018-05-31 22:07:15.739664
NCT01442727|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-10-06|2011-09-27|2011-09-28|Estimate|||||||2011-10-06|2011-10-07|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|SETAC||Selenium in the Treatment of Arsenic Toxicity and Cancers|Selenite in the Detoxification of Arsenic and the Prevention of Arsenical Melanosis and Cancers Amongst Bangladeshi Arsenicosis Patients: A 48-week, Randomized, Double-blinded, Placebo-controlled Phase III Trial|Completed||Phase 3|819|Actual|Texas Tech University||2|||f||||t||||||||||2018-05-31 22:07:15.81853|2018-05-31 22:07:15.81853
NCT01442714|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2016-10-17||2017-12-04|2011-09-27|2011-09-28|Estimate|2017-12-04|2018-01-03|Actual||||2017-12-04|2018-01-03|Actual|August 2011||2011-08-31|December 2017|2017-12-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS|Azacitidine Plus Lenalidomide Combination in Elderly Patients With Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS) (VIREL2 Trial)|Terminated||Phase 2|33|Actual|Stanford University||1||Lack of efficacy - Inability to meet the primary response endpoint|f||||t||||||||No||2018-05-31 22:07:15.922545|2018-05-31 22:07:15.922545
NCT01442701|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2018-05-13|2011-09-26|2011-09-28|Estimate|||||||2018-05-13|2018-05-17|Actual|November 17, 2011|Actual|2011-11-17|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|STORK||Stanford's Outcomes Research in Kids|Stanford's Outcomes Research in Kids (STORK)|Active, not recruiting|||200|Anticipated|Stanford University|||1||f||||f||||||Samples With DNA|"~     Blood, saliva, skin swabs, stool, urine.~   "|||2018-05-31 22:07:16.17122|2018-05-31 22:07:16.17122
NCT01442688|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2012-08-16||2012-08-16|2011-09-27|2011-09-28|Estimate|2012-08-16|2012-09-14|Estimate||||2012-08-16|2012-09-14|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Amoxicillin Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects|Completed||Phase 1|62|Actual|Shire||2|||f||||||||||||||2018-05-31 22:07:16.232794|2018-05-31 22:07:16.232794
NCT01442675|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2014-11-11|2012-12-03|2014-11-17|2011-09-27|2011-09-28|Estimate|2014-11-17|2014-11-18|Estimate|2012-12-03|2012-12-05|Estimate|2014-11-17|2014-11-18|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine|Safety and Immunogenicity of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine|Completed||Phase 2|834|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:07:16.458945|2018-05-31 22:07:16.458945
NCT01442662|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-03-19|2011-09-27|2011-09-28|Estimate|||||||2015-03-19|2015-03-20|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|LMS03||Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas|Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas|Unknown status|Recruiting|Phase 2|94|Anticipated|UNICANCER||1|||f||||t||||||||||2018-05-31 22:07:17.669759|2018-05-31 22:07:17.669759
NCT01442649|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2017-10-30|2011-09-27|2011-09-28|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2010|Actual|2010-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab|Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab|Active, not recruiting||Phase 2|132|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 22:07:17.81181|2018-05-31 22:07:17.81181
NCT01442636|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-03-06|2011-09-27|2011-09-28|Estimate|||||||2015-03-06|2015-03-09|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|DESTINY 2||Drug Eluting Stents In The Critically Ischemic Lower Leg 2|a Prospective, Multicenter, Controlled Trial Evaluating the Implant of a Drug Eluting Stent (XIENCE PRIME, Abbott Vascular) in the Critically Ischemic Lower Leg|Completed||Phase 2/Phase 3|60|Actual|Flanders Medical Research Program||1|||f||||t||||||||||2018-05-31 22:07:17.904562|2018-05-31 22:07:17.904562
NCT01442623|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-12-11|2011-09-26|2011-09-28|Estimate|||||||2014-12-11|2014-12-12|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Conventional Versus Virtual Reality Based Vestibular Rehabilitation|Conventional Versus Virtual Reality Based Vestibular Rehabilitation; Effect on Dizziness, Gait and Balance|Completed||Phase 2/Phase 3|71|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 22:07:18.728902|2018-05-31 22:07:18.728902
NCT01442610|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2016-01-20|2011-09-27|2011-09-28|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|RaSPar||Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease|Effects of Rasagiline on Sleep Disturbances in PD: A Single Center, Randomized, Double-blind, Placebo run-in, Polysomnographic Clinical Phase IV Trial|Completed||Phase 4|30|Actual|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 22:07:18.810326|2018-05-31 22:07:18.810326
NCT01442597|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2018-02-15|2011-09-27|2011-09-28|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2012||2012-01-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|Man VS Machine||Computer Based Training in Cognitive Behavioral Therapy Web-based|Computer Based Training in Cognitive Behavioral Therapy Web-based|Completed||Phase 1|164|Actual|Yale University||3|||f||||t||||||||||2018-05-31 22:07:18.882765|2018-05-31 22:07:18.882765
NCT01442584|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|ovatrspl||Transplantation of Ovarian Cortex to Restore Fertility|Transplantation of Ovarian Cortex to Restore Fertility|Unknown status|Recruiting|N/A|5|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:07:18.946388|2018-05-31 22:07:18.946388
NCT01442571|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate||||August 2011|2011-08-31||||||||Interventional|||Hyaluronic Acid Injection Post Arthroscopy - Does it Improve Immediate Function? Double Blind Controlled Prospective Study||Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 22:07:19.016236|2018-05-31 22:07:19.016236
NCT01442558|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-01-20|2011-09-27|2011-09-28|Estimate|||||||2015-01-20|2015-01-21|Estimate|December 2011||2011-12-31|September 2011|2011-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Quality of Supraclavicular, Infraclavicular and Axillary Approach of Ultrasound-guided Brachial Plexus Block||Completed||N/A|101|Actual|Hillel Yaffe Medical Center||3|||f||||t||||||||||2018-05-31 22:07:19.076544|2018-05-31 22:07:19.076544
NCT01442545|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2013-03-12|2011-09-27|2011-09-28|Estimate|||||||2013-03-12|2013-03-13|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|||||Interventional|||A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants|A Study to Investigate the Effect of Multiple Doses of JNJ 39758979 on Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients on a Stable Methotrexate Dose|Completed||Phase 1|21|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 22:07:19.145443|2018-05-31 22:07:19.145443
NCT01442532|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-03-01|2011-09-27|2011-09-28|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam|A Double-Blind, Randomized, Single- and Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Healthy Adult Male Subjects and an Open-Label Drug-Drug Interaction Study to Evaluate the Effect of JNJ-38518168 on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate|Completed||Phase 1|94|Actual|Janssen Research & Development, LLC||5|||||||f||||||||||2018-05-31 22:07:19.308196|2018-05-31 22:07:19.308196
NCT01442519|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|January 1994||1994-01-31|September 2011|2011-09-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|BCG/EMDA-MMC||Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer|Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study|Completed||Phase 3|212|Actual|University of Rome Tor Vergata||2|||f||||t||||||||||2018-05-31 22:07:19.389468|2018-05-31 22:07:19.389468
NCT01442506|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Acetic Acid Guided Biopsies Compared With High Definition Endoscopy in the Detection of Barrett`s Esophagus|Acetic Acid Guided Biopsies Compared With High Definition Endoscopy|Unknown status|Recruiting||100|Anticipated|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-05-31 22:07:19.470862|2018-05-31 22:07:19.470862
NCT01442493|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2017-02-01||2017-12-05|2011-09-27|2011-09-28|Estimate|2017-06-29|2017-09-18|Actual||||2017-12-05|2017-12-29|Actual|September 2011||2011-09-30|December 2017|2017-12-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment|Reengineering Methadone Treatment: A Randomized Clinical Trial|Completed||N/A|300|Actual|Friends Research Institute, Inc.||2|||f||||t||||||||No||2018-05-31 22:07:19.571068|2018-05-31 22:07:19.571068
NCT01442480|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|June 2009||2009-06-30|September 2011|2011-09-30||||August 2010|Actual|2010-08-31||Interventional|||Cardioprotective Effects of Omega-3 Fatty Acids Supplementation in Healthy Older Subjects Exposed to Air Pollution Particles||Completed||N/A|29|Actual|Environmental Protection Agency (EPA)||2|||f||||||||||||||2018-05-31 22:07:19.987309|2018-05-31 22:07:19.987309
NCT01442467|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-03-28|2011-09-27|2011-09-28|Estimate|||||||2013-03-28|2013-04-01|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Study of Echocardiogram Accuracy in Patients With Mitral Valve Calcification|Correlation Between Echocardiographic Indices of Diastolic Function (E/E`) and Left Ventricular End Diastolic Pressure (LVEDP) in Patients With Mitral Annular Calcification|Terminated|||4|Actual|Creighton University|||2|Subject accrual too difficult|f||||f||||||||||2018-05-31 22:07:20.065345|2018-05-31 22:07:20.065345
NCT01442454|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-02-29|2011-09-27|2011-09-28|Estimate|||||||2016-02-29|2016-03-01|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis|Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis: A Prospective Correlation With Intraoperative Findings and Surgical Pathology|Terminated|||100|Actual|Indiana University|||1|"The PI left and then the PI who would be taking over has left. No other investigator wanted to~   take the study since not sponsored"|f||||f||||||||||2018-05-31 22:07:20.119541|2018-05-31 22:07:20.119541
NCT01442441|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-09-03|2011-09-27|2011-09-28|Estimate|||||||2014-09-03|2014-09-05|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Correlation of Chronic Pancreatitis Pathology Features With Endoscopic Ultrasound (EUS) Criteria|How Pathologic Features of Chronic Pancreatitis Corelate With Endoscopic Ultrasound (EUS) Criteria for Diagnosing Chronic Pancreatitis|Completed|||400|Anticipated|Indiana University|||1||f||||f||||||||||2018-05-31 22:07:20.172058|2018-05-31 22:07:20.172058
NCT01442428|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2013-11-20|2011-09-27|2011-09-28|Estimate|||||||2013-11-20|2013-11-25|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial|Randomized Controlled Trial for Corticosteroids Versus NSAIDs With or Without Adjunctive Atorvastatin for the Treatment for Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome|Withdrawn||Phase 2/Phase 3|0|Actual|University of Minnesota - Clinical and Translational Science Institute||4||"2011 Thailand flooding led to loss of GMP pharmacy, project delays, and further regulatory~   challenges."|f||||t||||||||||2018-05-31 22:07:20.227182|2018-05-31 22:07:20.227182
NCT01442415|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2012-10-22|2011-09-27|2011-09-28|Estimate|||||||2012-10-22|2012-10-24|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Vikings Fitness Playbook: A Family Based Lifestyle Modification Program for Overweight and Obese Youth|Vikings Fitness Playbook: A Family Based Lifestyle Modification Program for Overweight and Obese Youth|Terminated||N/A|10|Actual|University of Minnesota - Clinical and Translational Science Institute||1||Unable to achieve enrollment goal.|f||||t||||||||||2018-05-31 22:07:20.409927|2018-05-31 22:07:20.409927
NCT01442402|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2013-02-14|2011-09-27|2011-09-28|Estimate|||||||2013-02-14|2013-02-15|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||APOL1 Gene Variants in African American Kidney Transplant Recipients|Impact of APOL1 Gene Variants in African American Kidney Transplant Recipients: A Study of Clinical Outcomes and Molecular Mechanisms|Unknown status|Recruiting||190|Anticipated|Brigham and Women's Hospital|||2||f||||f||||||Samples With DNA|"~     Aims 1 and 2:~      Subjects will collect a saliva specimen in an Oragene®•DNA sample collection kit for~     genotyping. We will also collected any discarded (no longer utilized for clinical purposes)~     tissue from biopsies.~      Aim 3:~      Prior to transplant, subjects will collect saliva in an Oragene®•DNA sample collection kit~     for genotyping and 10cc of blood will be drawn into a Na heparin collection tube for APOL1~     protein analysis. When applicable, plasmapheresis effluent will be collected. We will also~     collected any discarded (no longer utilized for clinical purposes)tissue from biopsies.~   "|||2018-05-31 22:07:20.587822|2018-05-31 22:07:20.587822
NCT01442389|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2012-08-24|2011-09-27|2011-09-28|Estimate|||||||2012-08-24|2012-08-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:07:20.706373|2018-05-31 22:07:20.706373
NCT01442376|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2014-06-27|2013-04-05|2014-08-04|2011-09-27|2011-09-28|Estimate|2014-06-27|2014-07-28|Estimate|2013-04-05|2013-04-12|Estimate|2014-08-04|2014-08-07|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional||Full Analysis Set (FAS) population which included all randomized patients receiving the active study drug and HEC or MEC. Following the intent-to-treat principle, patients were assigned to the study treatment group according to the randomized treatment.|Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients|A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC|Completed||Phase 3|502|Actual|Helsinn Healthcare SA||3|||f||||t||||||||||2018-05-31 22:07:20.792854|2018-05-31 22:07:20.792854
NCT01442363|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2015-01-26|2011-09-27|2011-09-28|Estimate|||||||2015-01-26|2015-01-27|Estimate|November 2011||2011-11-30|January 2015|2015-01-31||||October 2012|Actual|2012-10-31||Interventional|||A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease||Terminated||Phase 2|8|Actual|Braintree Laboratories||3|||f||||f||||||||||2018-05-31 22:07:21.796141|2018-05-31 22:07:21.796141
NCT01442350|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Observational|FAMY||Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers|Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers|Unknown status|Not yet recruiting||120|Anticipated|Hospital Universitario Virgen de la Arrixaca|||||f||||t||||||Samples With DNA|"~     Genotyping of relatives of mutation-known Fabry probands: in order to know which are the~     relatives carrying mutations. (The investigators have already started this task).~   "|||2018-05-31 22:07:21.874094|2018-05-31 22:07:21.874094
NCT01442337|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16||2014-06-17|2014-06-17|2011-09-27|2011-09-28|Estimate||||2014-06-17|2014-06-20|Estimate|2014-06-17|2014-06-20|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients|A Phase 2/3, Double-Blind, Placebo-Controlled, Two-Part Study (Part 1 Open-Label) to Assess the Safety, Efficacy and Pharmacokinetics of Single Intravenous Doses of ASP8597 (Diannexin) in de Novo Kidney Transplant Recipients|Terminated||Phase 2/Phase 3|21|Actual|Astellas Pharma Inc||4||Study was terminated by sponsor decision|f||||t||||||||||2018-05-31 22:07:21.933875|2018-05-31 22:07:21.933875
NCT01442324|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-07-17|2011-09-27|2011-09-28|Estimate|||||||2012-07-17|2012-07-18|Estimate|February 2011||2011-02-28|July 2012|2012-07-31||||September 2012|Anticipated|2012-09-30||Interventional|||Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma|Studio Clinico Pilota Con Uso di Elettroporazione Irreversibile (IRE) Nel Trattamento di Lesioni Neoplastiche Epatiche Con Localizzazione ad accessibilità Limitata o ad Alto Rischio|Unknown status|Recruiting|N/A|5|Anticipated|Azienda Ospedaliera di Padova||1|||f||||t||||||||||2018-05-31 22:07:22.029712|2018-05-31 22:07:22.029712
NCT01442311|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-06-25|2011-09-27|2011-09-28|Estimate|||||||2015-06-25|2015-06-26|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Directly Observed Hepatitis C Treatment in Methadone Clinics|Directly Observed Hepatitis C Treatment in Methadone Clinics|Completed||N/A|80|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 22:07:22.195581|2018-05-31 22:07:22.195581
NCT01442298|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||A Comparison Between an Individual Low Tourniquet Pressure Versus a Standard Pressure During Total Knee Arthroplasty|A Comparison Between an Individual Low Tourniquet Pressure Versus a Standard Pressure During Total Knee Arthroplasty. A Randomized Controlled Study|Completed||N/A|164|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 22:07:22.268701|2018-05-31 22:07:22.268701
NCT01442285|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-16|||2015-04-08|2011-09-27|2011-09-28|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|MHADRO||The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)|The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)|Completed||N/A|1000|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 22:07:22.374529|2018-05-31 22:07:22.374529
NCT01442272|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-05-18|2011-09-27|2011-09-28|Estimate|||||||2012-05-18|2012-05-21|Estimate|January 2012||2012-01-31|September 2011|2011-09-30|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Interventional|NEFROVID2010||Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D|Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D|Unknown status|Recruiting|Phase 4|174|Anticipated|Hospital Universitario de Canarias||3|||f||||t||||||||||2018-05-31 22:07:22.459533|2018-05-31 22:07:22.459533
NCT01442259|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2017-02-28|2011-09-27|2011-09-28|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2011||2011-01-31|February 2017|2017-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects|An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Age, Sex, and Body Weight-matched Healthy Subjects|Completed||Phase 1|48|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:07:22.540625|2018-05-31 22:07:22.540625
NCT01442246|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2018-05-14|2011-09-27|2011-09-28|Estimate|||||||2018-05-14|2018-05-17|Actual|July 2011|Actual|2011-07-31|May 2018|2018-05-31|September 2027|Anticipated|2027-09-30|September 2027|Anticipated|2027-09-30||Interventional|||Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.|Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard® 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.|Active, not recruiting||Phase 3|700|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 22:07:22.615563|2018-05-31 22:07:22.615563
NCT01442233|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2018-01-12|2011-09-27|2011-09-28|Estimate|||||||2018-01-12|2018-01-16|Actual|March 8, 2012|Actual|2012-03-08|January 2018|2018-01-31|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|PLASMASEP||Plasma Exchanges in Multiple Sclerosis (MS) Relapses|Randomized Clinical Trial of Plasma Exchanges Versus Sham Plasma Exchanges in Disabling Multiple Sclerosis Acute Relapses Refractory to Steroid Treatment|Completed||Phase 3|38|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 22:07:22.746059|2018-05-31 22:07:22.746059
NCT01442220|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|July 2014|Anticipated|2014-07-31|June 2013|Anticipated|2013-06-30||Observational|||Genome-wide Association Study of Pituitary Tumors|Genome-wide Association Study of Pituitary Tumors|Unknown status|Recruiting||12500|Anticipated|Huashan Hospital|||||f||||t||||||Samples With DNA|"~     DNA samples~   "|||2018-05-31 22:07:22.838216|2018-05-31 22:07:22.838216
NCT01442207|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-12-17|2011-09-26|2011-09-28|Estimate|||||||2014-12-17|2014-12-19|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Cerclage for Prevention on Preterm Birth in Women With Placenta Previa|Cerclage Placement for the Prevention of Preterm Birth in Women With Placenta Previa - A Multicenter Randomized Controlled Trial|Withdrawn||Phase 3|0|Actual|Mednax Center for Research, Education, Quality and Safety||2||Lack of randomized participants|f||||t||||||||||2018-05-31 22:07:22.908125|2018-05-31 22:07:22.908125
NCT01442194|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2018-04-27|2011-09-26|2011-09-28|Estimate|||||||2018-04-27|2018-04-30|Actual|August 1, 2011|Actual|2011-08-01|April 2018|2018-04-30|November 28, 2022|Anticipated|2022-11-28|November 28, 2022|Anticipated|2022-11-28||Observational|PASSAGE||Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies|Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy|Recruiting|||3620|Anticipated|Novartis|||2||f||||||||||||||2018-05-31 22:07:23.021984|2018-05-31 22:07:23.021984
NCT01442181|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2015-02-24||2015-07-17|2011-09-27|2011-09-28|Estimate|2015-07-17|2015-07-23|Estimate||||2015-07-17|2015-07-23|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation|Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation|Completed||N/A|25|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:07:23.550558|2018-05-31 22:07:23.550558
NCT01442168|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2014-08-18|2011-09-27|2011-09-28|Estimate|||||||2014-08-18|2014-08-19|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria|A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria|Terminated||Phase 1/Phase 2|53|Actual|Modus Therapeutics AB||2|||f||||t||||||||||2018-05-31 22:07:24.21669|2018-05-31 22:07:24.21669
NCT01442155|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2016-05-26||2016-05-26|2011-09-27|2011-09-28|Estimate|2016-05-26|2016-07-07|Estimate||||2016-05-26|2016-07-07|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer|An Open Label Study of the Effect of Adjuvant Treatment With Capecitabine in Combination With Oxaliplatin on Disease-Free Survival in Patients With Stage III Colon Cancer|Completed|||74|Actual|Hoffmann-La Roche|||1||f||||t||||||||||2018-05-31 22:07:24.309922|2018-05-31 22:07:24.309922
NCT01442142|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-09-05|2011-09-26|2011-09-28|Estimate|||||||2017-09-05|2017-09-08|Actual|May 2008||2008-05-31|September 2017|2017-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ROC||A Study to Determine the Effectiveness of a Self-regulation Program to Treat Pediatric Obesity|Self-Regulation Treatment for Pediatric Obesity|Completed||N/A|236|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 22:07:24.516803|2018-05-31 22:07:24.516803
NCT01442129|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2014-10-07||2015-04-10|2011-09-26|2011-09-28|Estimate|2014-10-07|2014-10-13|Estimate||||2015-04-10|2015-05-01|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional||Patients with end-stage heart failure, either ischemic or non-ischemic etiology, who are being evaluated for LVAD implantation as a bridge-to-transplant (BTT) or destination therapy (DT)|The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation|LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function|Completed||Phase 2|30|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 22:07:24.612433|2018-05-31 22:07:24.612433
NCT01442116|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2011-09-28|2011-09-27|2011-09-28|Estimate|||||||2011-09-28|2011-09-29|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential Hypertension|Evaluation of Regional Myocardial Dynamics at Physical Stress in Essential Hypertension|Completed||N/A|60|Actual|Mustafa Kemal University||1|||f||||||||||||||2018-05-31 22:07:25.623399|2018-05-31 22:07:25.623399
NCT01442103|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2013-07-01||2016-03-15|2011-09-26|2011-09-28|Estimate|2013-10-16|2013-11-08|Estimate||||2016-03-15|2016-04-14|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Clinical Utility of a New Silver Gel for Use on Chronic Wounds|Open, Non Comparative, Single Center Investigation Exploring the Clinical Utility of a New Silver Gel for Use on Chronic Wounds|Completed||N/A|10|Actual|Molnlycke Health Care AB|Small study population, 2 patients lost to follow-up.|1|||f||||f||||||||||2018-05-31 22:07:25.835558|2018-05-31 22:07:25.835558
NCT01442090|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26||2016-08-08|2016-08-08|2011-09-27|2011-09-28|Estimate||||2016-08-08|2016-08-10|Estimate|2016-08-08|2016-08-10|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|May 2013|Actual|2013-05-31||Interventional|||Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy|A Phase II, Open-Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy|Completed||Phase 2|85|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:07:26.213257|2018-05-31 22:07:26.213257
NCT01442077|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-01-17|2011-09-26|2011-09-28|Estimate|||||||2012-01-17|2012-01-18|Estimate|November 2011||2011-11-30|January 2012|2012-01-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Low Intensity Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction- 4 Arms|Low Intensity Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction- 4 Arms|Unknown status|Recruiting|Phase 3|200|Anticipated|Rambam Health Care Campus||4|||f||||f||||||||||2018-05-31 22:07:26.383673|2018-05-31 22:07:26.383673
NCT01442064|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2011-12-05||2011-12-05|2011-09-27|2011-09-28|Estimate|2011-12-05|2012-01-10|Estimate||||2011-12-05|2012-01-10|Estimate|July 2008||2008-07-31|December 2011|2011-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)|An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study|Completed||N/A|608|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:07:26.515795|2018-05-31 22:07:26.515795
NCT01442051|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2017-11-06|2011-09-26|2011-09-28|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2011||2011-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer|A Pilot Study of Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer|Recruiting||N/A|56|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:07:29.759411|2018-05-31 22:07:29.759411
NCT01442038|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2016-02-09||2016-06-06|2011-09-27|2011-09-28|Estimate|2016-06-06|2016-07-15|Estimate||||2016-06-06|2016-07-15|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|RIVER-PCI|Safety Analysis Set: participant who were randomized and received at least one dose of study drug|Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization|Completed||Phase 3|2651|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 22:07:29.963001|2018-05-31 22:07:29.963001
NCT01442025|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2015-08-10|2011-09-26|2011-09-28|Estimate|||||||2015-08-10|2015-08-11|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|TAILORIX||Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease|A Randomized Controlled Trial Investigating Tailored Treatment With Infliximab for Active Luminal Crohn's Disease|Completed||Phase 4|121|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||3|||f||||t||||||||||2018-05-31 22:07:32.274271|2018-05-31 22:07:32.274271
NCT01442012|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-10-02|2011-09-27|2011-09-28|Estimate|||||||2012-10-02|2012-10-03|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|PUCTURE-NVPO||Utility of Acupuncture in the Treatment of Postoperative Nausea and Vomiting in Ambulatory Surgery|Randomized Clinical Trial to Evaluate the Utility of Acupuncture in the Treatment of Postoperative Nausea and Vomiting (PONV) in Ambulatory Surgery|Unknown status|Recruiting|N/A|270|Anticipated|Group G-6||2|||f||||f||||||||||2018-05-31 22:07:32.381476|2018-05-31 22:07:32.381476
NCT01441999|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2018-02-13|2011-09-27|2011-09-28|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2011||2011-10-31|February 2018|2018-02-28|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|PJK||Proximal Junctional Kyphosis Following Long Instrumented Spinal Fusion: The Effect of Implant Selection|Proximal Junctional Kyphosis Following Long Instrumented Spinal Fusion: The Effect of Implant Selection|Completed||Phase 4|24|Actual|Globus Medical Inc||2|||f||||f||||||||||2018-05-31 22:07:32.494241|2018-05-31 22:07:32.494241
NCT01441986|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2012-07-11|2011-09-26|2011-09-28|Estimate|||||||2012-07-11|2012-07-12|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|DXM/AMT||Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects|A Phase IIa, Double-blind, Placebo-controlled, Randomised, Fourfold Crossover Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test|Completed||Phase 2|20|Actual|Profil Institut für Stoffwechselforschung GmbH|||||f||||t||||||||||2018-05-31 22:07:32.641817|2018-05-31 22:07:32.641817
NCT01441973|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|2015-12-22|2015-09-23|2017-12-21|2011-09-27|2011-09-28|Estimate|2015-12-23|2016-01-29|Estimate|2015-12-02|2015-12-03|Estimate|2017-12-21|2018-01-23|Actual|December 28, 2011|Actual|2011-12-28|December 2017|2017-12-31|January 17, 2017|Actual|2017-01-17|May 30, 2014|Actual|2014-05-30||Interventional||All participants who received at least 1 dose of study medication|Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma|A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma|Completed||Phase 2|41|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 22:07:32.808531|2018-05-31 22:07:32.808531
NCT01441960|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2015-04-09||2015-06-01|2011-09-26|2011-09-28|Estimate|2015-06-01|2015-06-02|Estimate||||2015-06-01|2015-06-02|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|July 2013|Actual|2013-07-31||Interventional|||Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)|Optimal Control of Muscle Strength for Electroconvulsive Therapy: A Comparison of Succinylcholine Versus Rocuronium-induced Neuromuscular Blockade|Completed||N/A|45|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:07:33.768151|2018-05-31 22:07:33.768151
NCT01441947|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2018-04-05|2011-09-27|2011-09-28|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2011||2011-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer|A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone|Active, not recruiting||Phase 2|68|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 22:07:33.934177|2018-05-31 22:07:33.934177
NCT01441934|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2013-02-01|2011-09-27|2011-09-28|Estimate|||||||2013-02-01|2013-02-04|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|SPHERIC-1||SPHERIC-1. Sildenafil and Pulmonary HypERtension In COPD|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Sildenafil in the Treatment of Patients With Pulmonary Hypertension Associated to Chronic Obstructive Lung Disease|Unknown status|Recruiting|Phase 3|32|Anticipated|Italian Association of Hospital Pneumologists||2|||f||||t||||||||||2018-05-31 22:07:34.005549|2018-05-31 22:07:34.005549
NCT01441921|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-26|2011-09-26|2011-09-28|Estimate|||||||2011-09-26|2011-09-28|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Interventional|EPIRDEM||Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus|Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus|Unknown status|Recruiting|N/A|50|Anticipated|Institut Investigacio Sanitaria Pere Virgili||2|||f||||f||||||||||2018-05-31 22:07:34.090482|2018-05-31 22:07:34.090482
NCT01441908|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2012-04-13|2011-09-26|2011-09-28|Estimate|||||||2012-04-13|2012-04-16|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|April 2012|Anticipated|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Longitudinal Study of Multi-Analyte Profile for Dyslipidemia|Determining Cardiovascular Health Using a Multi-Analyte Profile in a Longitudinal Study of a Statin Intervention for Dyslipidemia|Unknown status|Active, not recruiting|N/A|40|Anticipated|MaiHealth Inc||2|||f||||f||||||||||2018-05-31 22:07:34.267654|2018-05-31 22:07:34.267654
NCT01441895|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2016-04-22|2011-09-27|2011-09-28|Estimate|||||||2016-04-22|2016-04-25|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Corneal Sensation and Incidence of Dry Eye Post Refractive Cataract Extraction With FemtoSecond Laser|A Post Market Pilot Study To Evaluate Corneal Sensation And The Incidence Of Dry Eye In Subjects Undergoing Refractive Cataract Extraction With The Femtosecond Laser For Arcuate Relaxing Incisions|Unknown status|Recruiting||40|Anticipated|Ophthalmic Consultants of Long Island|||||f||||f||||||||||2018-05-31 22:07:34.333732|2018-05-31 22:07:34.333732
NCT01441882|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2017-07-11||2018-01-19|2011-09-27|2011-09-28|Estimate|2018-01-19|2018-02-15|Actual||||2018-01-19|2018-02-15|Actual|October 2011||2011-10-31|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|July 12, 2016|Actual|2016-07-12||Interventional|||Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity|Completed||Phase 2|19|Actual|OHSU Knight Cancer Institute|No limitations or caveats are noted at this time.|1|||f||||t||||||||||2018-05-31 22:07:34.402081|2018-05-31 22:07:34.402081
NCT01441869|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2012-02-07|2011-09-26|2011-09-28|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc|Bioequivalence Study of the Fixed-dose Combination of Saxagliptin/Metformin XR Tablets Relative to Saxagliptin (Onglyza� ) Tablets and Australia-sourced Diabex XR Tablets Coadministered to Healthy Subjects in the Fed State During Steady-state Administration|Completed||Phase 1|28|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 22:07:34.575009|2018-05-31 22:07:34.575009
NCT01441856|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2017-03-21|2011-09-26|2011-09-28|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2013|Actual|2013-10-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The ORANGE II PLUS - Trial: Open Versus Laparoscopic Hemihepatectomy|The ORANGE II PLUS - Trial: an International Multicenter Randomized Controlled Trial of Open Versus Laparoscopic Hemihepatectomies.|Recruiting||N/A|250|Anticipated|Maastricht University Medical Center||3|||f||||t||||||||No||2018-05-31 22:07:34.65071|2018-05-31 22:07:34.65071
NCT01441843|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2013-08-29||2018-02-01|2011-09-27|2011-09-28|Estimate|2014-01-27|2014-03-10|Estimate||||2018-02-01|2018-03-01|Actual|October 2010||2010-10-31|February 2018|2018-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||In retrospect, two patients in the lorazepam group should not have been included due to an administrative error. Data for these two patients were, therefore, excluded from analysis.|Resistance Under the Microscope|Resistance Under the Microscope; a Randomized Placebo Controlled Parallel Group Design|Completed||Phase 4|400|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 22:07:34.776623|2018-05-31 22:07:34.776623
NCT01441830|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-12-17|2011-09-27|2011-09-28|Estimate|||||||2014-12-17|2014-12-18|Estimate|September 2011||2011-09-30|December 2014|2014-12-31||||May 2015|Anticipated|2015-05-31||Interventional|||Radial Extracorporeal Shock Wave Therapy (rESWT) Treatment of Subacromial Shoulder Pain|Treatment of Subacromial Shoulder Pain|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:07:34.988741|2018-05-31 22:07:34.988741
NCT01441817|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|May 2002||2002-05-31|September 2011|2011-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Non--operative Treatment of the Medial Malleolus in bi- and Trimalleolar Ankle Fractures|Non--operative Treatment of the Medial Malleolus in bi- and Trimalleolar Ankle Fractures. A Randomized Controlled Trial|Completed||N/A|100|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 22:07:35.060006|2018-05-31 22:07:35.060006
NCT01441804|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2013-09-28|2011-09-27|2011-09-28|Estimate|||||||2013-09-28|2013-10-01|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31||Interventional|||A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism||Unknown status|Recruiting|Phase 3|200|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 22:07:35.110573|2018-05-31 22:07:35.110573
NCT01441791|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2014-12-07|2011-09-26|2011-09-28|Estimate|||||||2014-12-07|2014-12-09|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|PROVHILO||PROVHILO:Protective Ventilation During General Anesthesia for Open Abdominal Surgery|Protective Ventilation During General Anesthesia for Open Abdominal Surgery - a Randomized Controlled Trial|Completed||N/A|900|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 22:07:35.186155|2018-05-31 22:07:35.186155
NCT01441778|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy of Buffered Hypertonic Saline(BHS)Nasal Irrigation in Allergic Rhinitis (AR) Children|Efficacy of Buffered Hypertonic Saline Nasal Irrigation in Children With Symptomatic Allergic Rhinitis : A Randomized Double-blind Study.|Completed||Phase 2|81|Actual|Thammasat University||2|||f||||f||||||||||2018-05-31 22:07:36.215471|2018-05-31 22:07:36.215471
NCT01441765|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2016-07-28||2016-12-15|2011-09-27|2011-09-28|Estimate|2016-09-22|2016-11-09|Estimate||||2016-12-15|2017-02-08|Estimate|November 2011||2011-11-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine|Phase II Study of PD-1 Blockade Alone or In Conjunction With the Dendritic Cell (DC)/Renal Cell Carcinoma (RCC) Fusion Cell Vaccination|Terminated||Phase 2|11|Actual|Dana-Farber Cancer Institute|Due to lack of funding, the study was terminated early without completing enrollment.|2||Funding|f||||t||||||||||2018-05-31 22:07:36.296392|2018-05-31 22:07:36.296392
NCT01441752|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-06-23|2011-09-27|2011-09-28|Estimate|||||||2016-06-23|2016-06-27|Estimate|November 2011||2011-11-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy Study of Integrated TCM Combined With Chemotherapy in Postoperative NSCLC Patients|State Administration of Traditional Chinese Medicine of Shanghai|Completed||Phase 3|349|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 22:07:36.51987|2018-05-31 22:07:36.51987
NCT01441739|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2013-12-17|2011-09-27|2011-09-28|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2004||2004-09-30|December 2013|2013-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Intestinal Failure in Necrotising Enterocolitis|Intestinal Failure in Necrotising Enterocolitis|Unknown status|Recruiting||300|Anticipated|Maastricht University Medical Center|||3||f||||||||||||||2018-05-31 22:07:36.587931|2018-05-31 22:07:36.587931
NCT01441726|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2015-03-30|2011-09-27|2011-09-28|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Palliative and End-of-life Care in Advanced Dementia: Evaluation of a Program of Organization of Care in Long-term Care|Palliative and End-of-life Care in Advanced Dementia: Evaluation of a Program of Organization of Care in Long-term Care Settings|Completed|||175|Actual|Laval University|||2||f||||f||||||||||2018-05-31 22:07:36.650449|2018-05-31 22:07:36.650449
NCT01441713|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2012-12-04|2011-09-27|2011-09-28|Estimate|||||||2012-12-04|2012-12-05|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer|Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer|Completed|||178|Actual|Copenhagen University Hospital at Herlev|||2||f||||f||||||||||2018-05-31 22:07:36.974515|2018-05-31 22:07:36.974515
NCT01441700|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2011-09-27|2011-09-27|2011-09-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Prone Position Emergence From Anaesthesia in Lumbar Disc Surgery|A Comparative Study of Haemodynamic Changes Between Prone and Supine Emergence From Anaesthesia in Lumbar Disc Surgery|Completed||N/A|50|Actual|KVG Medical College and Hospital||2|||f||||f||||||||||2018-05-31 22:07:37.038925|2018-05-31 22:07:37.038925
NCT01441687|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2018-05-04|2011-09-27|2011-09-28|Estimate|||||||2018-05-04|2018-05-08|Actual|December 4, 2009||2009-12-04|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome|Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome|Active, not recruiting||N/A|260|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 22:07:37.113107|2018-05-31 22:07:37.113107
NCT01441674|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2014-02-13|2011-09-27|2011-09-28|Estimate|||||||2014-02-13|2014-02-14|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|AAT||Animal Assisted Therapy in a Pediatric Setting|The Effectiveness of Animal Assisted Therapy for Children Hospitalized in a Pediatric Setting|Completed||Phase 1/Phase 2|30|Actual|Children's Hospitals and Clinics of Minnesota||2|||f||||f||||||||||2018-05-31 22:07:37.196064|2018-05-31 22:07:37.196064
NCT01441661|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2013-03-15|2011-09-27|2011-09-28|Estimate|||||||2013-03-15|2013-03-18|Estimate|November 2007||2007-11-30|September 2007|2007-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma|Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma: a Multicenter, Non-interventional, Retrospective Survey|Completed|||400|Actual|Cancer Foundation, China|||1||f||||t||||||||||2018-05-31 22:07:37.27407|2018-05-31 22:07:37.27407
NCT01441648|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2014-01-17|2011-09-27|2011-09-28|Estimate|||||||2014-01-17|2014-01-20|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Influence of Cosmetic Color Tinted Contact Lenses on the Ocular Surface|Influence of Cosmetic Color Tinted Contact Lenses on the Ocular Surface|Completed|||14|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||1||f||||f||||||||||2018-05-31 22:07:37.359326|2018-05-31 22:07:37.359326
NCT01441635|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06||2014-11-25|2014-11-25|2011-09-26|2011-09-28|Estimate||||2014-11-25|2014-12-11|Estimate|2014-11-25|2014-12-11|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids|Phase 2a Proof Of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids|Completed||Phase 2|271|Actual|AbbVie||11|||f||||f||||||||||2018-05-31 22:07:37.459422|2018-05-31 22:07:37.459422
NCT01441622|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2014-06-27|2011-09-26|2011-09-27|Estimate|||||||2014-06-27|2014-06-30|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|AL539||Evaluation of a New Medical Device AL539 in Patients With Obstructive Apneas Sleep Syndrome|In-hospital Assessment of the New Medical Device AL539 Developed for the Home Monitoring of Continuous Positive Airway Pressure (CPAP) Treatment in Patients With Obstructive Sleep Apnea Syndrome by Comparison With Respiratory Polygraphy|Completed||N/A|20|Actual|Air Liquide Santé International||1|||f||||f||||||||||2018-05-31 22:07:37.753131|2018-05-31 22:07:37.753131
NCT01441609|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2011-09-27|2011-09-26|2011-09-27|Estimate|||||||2011-09-27|2011-09-28|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Observational|||Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination|Effect of the Expression Level of Th9 Cells and IL-9 In Poor/Non-responsiveness to Hepatitis B Vaccination|Unknown status|Recruiting||94|Anticipated|Beijing Municipal Science & Technology Commission|||4||f||||t||||||||||2018-05-31 22:07:37.832986|2018-05-31 22:07:37.832986
NCT01441596|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2015-02-10||2015-08-25|2011-09-26|2011-09-27|Estimate|2015-02-10|2015-02-25|Estimate||||2015-08-25|2015-09-07|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional||Randomised Set (RS): includes all randomised patients, whether treated or not.|Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases|Lux-Breast 3; Randomised Phase II Study of Afatinib Alone or in Combination With Vinorelbine Versus Investigator's Choice of Treatment in Patients With HER2 Positive Breast Cancer With Progressive Brain Metastases After Trastuzumab and/or Lapatinib Based Therapy|Completed||Phase 2|121|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:07:37.949562|2018-05-31 22:07:37.949562
NCT01441583|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2013-07-16|2011-09-26|2011-09-27|Estimate|||||||2013-07-16|2013-07-17|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional|IVORY||Ingenio Device Algorithm Study|Ingenio Device Algorithm Study|Completed||N/A|139|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 22:07:38.708048|2018-05-31 22:07:38.708048
NCT01441570|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2016-10-31||2017-03-09|2011-09-26|2011-09-27|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|February 2012||2012-02-29|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Impact of Nebivolol Versus Metoprolol on Quality of Life|The Impact of Nebivolol Versus Metoprolol on Quality of Life Measures and Cost-effectiveness in Stable Renal Transplant Recipients|Terminated||N/A|11|Actual|Brigham and Women's Hospital||2||due to slow enrollment|f||||f||||||||||2018-05-31 22:07:38.809651|2018-05-31 22:07:38.809651
NCT01441557|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-04-27|2011-09-26|2011-09-27|Estimate|||||||2016-04-27|2016-04-28|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism|Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism|Completed||Phase 2/Phase 3|3|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 22:07:39.151685|2018-05-31 22:07:39.151685
NCT01441544|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2018-04-03|2011-09-26|2011-09-27|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2011|Actual|2011-09-30|April 2018|2018-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effect of Variety on Physical Activity|The Effect of Variety on Physical Activity|Completed||N/A|32|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-05-31 22:07:39.225759|2018-05-31 22:07:39.225759
NCT01441531|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-03-13|2011-09-26|2011-09-27|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension|Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension During Orif of Tibia Fracture Under General Anesthesia|Withdrawn||Early Phase 1|0|Actual|Baylor College of Medicine||2||Unable to recruit patient due to surgical case type. Not worth continuing study.|f||||f||||||||||2018-05-31 22:07:39.313323|2018-05-31 22:07:39.313323
NCT01441518|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-07-07|2011-09-26|2011-09-27|Estimate|||||||2015-07-07|2015-07-08|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|November 2013|Actual|2013-11-30|January 2013|Actual|2013-01-31||Interventional|||Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia|A Prospective Randomized Trial of Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia|Completed||Phase 2|80|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||||||||||||2018-05-31 22:07:39.395808|2018-05-31 22:07:39.395808
NCT01441505|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2013-02-20|2011-09-25|2011-09-27|Estimate|||||||2013-02-20|2013-02-22|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study of Ketamine as an Antidepressant|A Study of Ketamine as an Antidepressant|Unknown status|Recruiting|Phase 2|42|Anticipated|The University of New South Wales|||||f||||f||||||||||2018-05-31 22:07:39.486447|2018-05-31 22:07:39.486447
NCT01441492|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2017-08-21|2011-09-26|2011-09-27|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2011||2011-09-30|August 2017|2017-08-31|July 25, 2017|Actual|2017-07-25|September 2016|Actual|2016-09-30||Interventional|||Pancreas Resection With and Without Drains|A Randomized Prospective Multicenter Trial of Pancreas Resection With and Without Routine Intraperitoneal Drainage|Completed||N/A|398|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 22:07:39.564518|2018-05-31 22:07:39.564518
NCT01441466|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2013-10-22||2017-01-02|2011-09-26|2011-09-27|Estimate|2015-07-10|2015-07-14|Estimate||||2017-01-02|2017-02-17|Actual|November 2011||2011-11-30|January 2017|2017-01-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|||Cohort Isolation and Cross-infection in Bronchiolitis|Cross-infection in Children Hospitalized for Bronchiolitis: Incidence, Symptoms en Effect of Cohort Isolation|Completed|||48|Actual|Princess Amalia Children's Clinic|||2||f||||f||||||Samples Without DNA|"~     sputum~   "|Undecided||2018-05-31 22:07:39.757487|2018-05-31 22:07:39.757487
NCT01441453|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2011-09-26|2011-09-26|2011-09-27|Estimate|||||||2011-09-26|2011-09-27|Estimate||||September 2011|2011-09-30||||||||Interventional|||Transient Elastography in Hepatectomy for Hepatocellular Carcinoma|Value of Transient Elastography in Predicting Postoperative Liver Failure in Patients Undergoing Liver Resection for Hepatocellular Carcinoma.|Unknown status|Not yet recruiting|N/A|120|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||||2018-05-31 22:07:40.011967|2018-05-31 22:07:40.011967
NCT01441440|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2015-03-02||2015-03-02|2011-09-23|2011-09-27|Estimate|2015-03-02|2015-03-13|Estimate||||2015-03-02|2015-03-13|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)|A Randomized, Double-blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Venlafaxine Er In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|538|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:07:40.124954|2018-05-31 22:07:40.124954
NCT01441427|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2011-09-26|2011-09-26|2011-09-27|Estimate|||||||2011-09-26|2011-09-27|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|||Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial||Completed||Phase 1/Phase 2|93|Actual|Ain Shams University||4|||f||||||||||||||2018-05-31 22:07:40.613143|2018-05-31 22:07:40.613143
NCT01441414|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2015-03-27|2014-04-30|2015-12-11|2011-09-23|2011-09-27|Estimate|2015-12-11|2016-01-18|Estimate|2014-04-30|2014-05-19|Estimate|2015-12-11|2016-01-18|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||The full analysis (FA) set was the primary population for evaluating all safety and efficacy endpoints per the treatment randomization as well as participant characteristics.|PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma|A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (ANG-2) Inhibitor In Combination With AG-013736 (Axitinib) In Patients With Previously Treated Metastatic Renal Cell Carcinoma|Terminated||Phase 2|18|Actual|Pfizer|On 06 Nov 2012, based on Part I safety findings and due to strategic considerations, Pfizer decided not to open enrolment onto Part II of the study and terminated the study. For primary OM, AEs reported in ≥2 participants overall are presented.|2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 22:07:40.777399|2018-05-31 22:07:40.777399
NCT01441401|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2016-08-15||2016-08-15|2011-09-23|2011-09-27|Estimate|2016-08-15|2016-10-06|Estimate||||2016-08-15|2016-10-06|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|||Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Gabapen For Pediatric (Regulatory Post Marketing Commitment Plan)|Completed|||82|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:07:41.864544|2018-05-31 22:07:41.864544
NCT01441388|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2011-12-19|2011-09-26|2011-09-27|Estimate|||||||2011-12-19|2011-12-20|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.|A Phase 1B, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Crizotinib (PF-02341066) Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.|Withdrawn||Phase 1|0|Actual|Pfizer||5||Business/Operational issues|f||||f||||||||||2018-05-31 22:07:42.220764|2018-05-31 22:07:42.220764
NCT01441375|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-10-17|2011-09-23|2011-09-27|Estimate|||||||2012-10-17|2012-10-18|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Sickle Cell Disease: A Retrospective Chart Review|Complications in Patients With Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review|Completed|||261|Actual|Novartis|||3||f||||||||||||||2018-05-31 22:07:42.2932|2018-05-31 22:07:42.2932
NCT01441362|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2012-02-16|2011-09-26|2011-09-27|Estimate|||||||2012-02-16|2012-02-20|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Double-lumen Tube Intubation Technique to Reduce Laryngeal Injuries|A Comparison of Two Methods for Intubation With Double-lumen Endobronchial Tube to Reduce Laryngeal Injuries|Completed||N/A|154|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 22:07:42.345184|2018-05-31 22:07:42.345184
NCT01441349|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-08-24|2011-09-26|2011-09-27|Estimate|||||||2017-08-24|2017-08-25|Actual|August 2011|Actual|2011-08-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer|A Randomized Phase II Study of Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer|Recruiting||Phase 2|192|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 22:07:42.472987|2018-05-31 22:07:42.472987
NCT01441336|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2017-01-06|2011-09-25|2011-09-27|Estimate|||||||2017-01-06|2017-01-09|Estimate|November 2008||2008-11-30|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2012|Actual|2012-07-31||Interventional|||Laparoscopic Gastrectomy for Advanced Gastric Cancer|Laparoscopic Gastrectomy for Advanced Gastric Cancer|Completed||Phase 2|204|Actual|Seoul National University Bundang Hospital||1|||f||||t||||||||No||2018-05-31 22:07:42.554995|2018-05-31 22:07:42.554995
NCT01441323|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2017-03-29|2011-09-26|2011-09-27|Estimate|||||||2017-03-29|2017-03-31|Actual|June 2007||2007-06-30|March 2017|2017-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|STAND||Strength Training and Nutrition Development for African American Youth|USC Center for Transdisciplinary Research on Energetics and Cancer or Obesity-Related Metabolic Disease Risk: Response to Exercise in Minority Youth|Completed||N/A|62|Actual|University of Southern California||3|||f||||t||||||||No||2018-05-31 22:07:42.609454|2018-05-31 22:07:42.609454
NCT01441310|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2017-01-06|2011-09-25|2011-09-27|Estimate|||||||2017-01-06|2017-01-09|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2013|Actual|2013-08-31||Interventional|SNNS||Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer|Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer|Completed||Phase 2|101|Actual|Seoul National University Bundang Hospital||1|||f||||t||||||||No||2018-05-31 22:07:42.682453|2018-05-31 22:07:42.682453
NCT01441297|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2017-08-24|2011-09-26|2011-09-27|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2011|Actual|2011-12-31|August 2017|2017-08-31|March 31, 2016|Actual|2016-03-31|October 31, 2015|Actual|2015-10-31||Interventional|||BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer|A Phase II Study Of BIBF 1120 as Second-line Treatment for Patients With Small Cell Lung Cancer|Completed||Phase 2|24|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 22:07:42.748835|2018-05-31 22:07:42.748835
NCT01441284|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-05-04|2011-09-26|2011-09-27|Estimate|||||||2017-05-04|2017-05-08|Actual|December 2017|Anticipated|2017-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor|Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor: a Double-blind, Cross-over, Placebo-controlled Multicenter Study|Withdrawn||Phase 3|0|Actual|University of Pecs||2||Lack of financial support|f||||f|f|f||||||||2018-05-31 22:07:42.814557|2018-05-31 22:07:42.814557
NCT01441271|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2015-04-29|2011-09-23|2011-09-27|Estimate|||||||2015-04-29|2015-05-01|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|October 2012|Actual|2012-10-31||Interventional|||Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis|Diverting Loop Ileostomy and Colonic Lavage: An Alternative To Total Abdominal Colectomy For The Treatment Of Fulminant Clostridium Difficile Colitis. A Randomized Controlled Trial.|Terminated||N/A|1|Actual|Massachusetts General Hospital||2||Numer of eligible patients markedly decreased since the initiation of the study.|f||||t||||||||||2018-05-31 22:07:42.889387|2018-05-31 22:07:42.889387
NCT01441258|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-04-07|2011-09-26|2011-09-27|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression|Adaptation of Dialectical Behavior Therapy Skills-Groups for Individuals With Suicidal Ideation and Depression|Completed||N/A|26|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:07:42.953105|2018-05-31 22:07:42.953105
NCT01441245|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2015-01-26||2017-12-28|2011-09-23|2011-09-27|Estimate|2016-01-02|2016-02-02|Estimate||||2017-12-28|2018-01-23|Actual|April 2010|Actual|2010-04-30|December 2017|2017-12-31|December 28, 2017|Actual|2017-12-28|June 2016|Actual|2016-06-30||Interventional|diurHF||Loop Diuretics Administration and Acute Heart Failure|Continuous Versus Intermittent Loop Diuretics Infusion Dosing in Acute Heart Failure: Effects on Renal Function, Outcome and BNP Levels|Completed||Phase 4|57|Actual|University of Siena|Our study didn't explain the reasons of renal dysfunction during treatment. Concurrent evaluation of BUN could further clarify the primary defect.The multivariate analysis could be inadequate for small sample; we intend to continue enrollment.|2|||f||||t||||||||No||2018-05-31 22:07:43.035509|2018-05-31 22:07:43.035509
NCT01441232|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2012-01-26|2011-09-26|2011-09-27|Estimate|||||||2012-01-26|2012-01-31|Estimate|October 2011||2011-10-31|January 2012|2012-01-31||||November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics|A Phase 1, Open-label, 3-period, 3-treatment, Single Dose Crossover Study to Evaluate the Pharmacodynamic Effects of LX4211 When Administered Concurrently With JANUVIA® (Sitagliptin) in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|18|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 22:07:43.40566|2018-05-31 22:07:43.40566
NCT01441219|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-03-04|2011-09-26|2011-09-27|Estimate|||||||2013-03-04|2013-03-05|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation the Performance of Given Diagnostic System in Detection of Bleeding Events in the Small Bowel|Evaluation the Performance of Given Diagnostic System in Detection of Bleeding Events in the Small Bowel: a Single-arm Prospective Cohort Study.|Terminated||Phase 2/Phase 3|6|Actual|Chinese University of Hong Kong||1||Results were obtained in another project.|f||||f||||||||||2018-05-31 22:07:43.472748|2018-05-31 22:07:43.472748
NCT01441206|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-09-13|2011-09-26|2011-09-27|Estimate|||||||2012-09-13|2012-09-14|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants|Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants|Terminated||Phase 1|2|Actual|University of North Carolina, Chapel Hill||2||Study to be redesigned.|f||||t||||||||||2018-05-31 22:07:43.66277|2018-05-31 22:07:43.66277
NCT01441193|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2016-03-03|2011-09-26|2011-09-27|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)|A Phase I, Open Label, Safety and Immunogenicity Vaccine Trial Based on the Association of Recombinant HIV-1 Biologically Active Tat and V2-deleted Env Proteins in HIV Uninfected Healthy Adult Volunteers.|Terminated||Phase 1|11|Actual|Istituto Superiore di Sanità||4||"Enrollments were suspended due to delta-V2 Env unavailability, following the~   EMA/CHMP/BWP/534898/2008 guideline, not allowing the use of a retest date"|f||||t||||||||||2018-05-31 22:07:43.742643|2018-05-31 22:07:43.742643
NCT01441180|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|2014-04-23||2014-09-25|2011-09-24|2011-09-27|Estimate|2014-09-25|2014-09-26|Estimate||||2014-09-25|2014-09-26|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|March 2013|Actual|2013-03-31||Interventional|||GS-7977 With Ribavirin for Hepatitis C (SPARE)|A Randomized Controlled Study To Assess Safety, Tolerability And Efficacy Of GS-7977 In Combination With Full or Low Dose RBV In HCV Genotype 1, Monoinfected Treatment Naive Participants|Completed||Phase 1/Phase 2|60|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||||2018-05-31 22:07:43.85463|2018-05-31 22:07:43.85463
NCT01441167|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2018-02-13|2011-09-24|2011-09-27|Estimate|||||||2018-02-13|2018-02-14|Actual|September 14, 2011||2011-09-14|June 5, 2013|2013-06-05|June 5, 2013|Actual|2013-06-05|June 5, 2013|Actual|2013-06-05||Interventional|||Experimental PfSPZ Vaccine in Adults Without Malaria|VRC 312: A Phase 1, Open-Label, Dose-Escalation Clinical Trial With Experimental Challenge to Evaluate Intravenous Administration of the PfSPZ Vaccine in Malaria-Naive Adults|Completed||Phase 1|64|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:07:44.266854|2018-05-31 22:07:44.266854
NCT01441154|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2018-03-27|2011-09-24|2011-09-27|Estimate|||||||2018-03-27|2018-03-29|Actual|September 7, 2011||2011-09-07|November 14, 2017|2017-11-14||||||||Observational|||Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment|Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone|Completed|||16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:07:44.324382|2018-05-31 22:07:44.324382
NCT01441141|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2018-04-03|2011-09-24|2011-09-27|Estimate|||||||2018-04-03|2018-04-04|Actual|September 7, 2011||2011-09-07|March 16, 2018|2018-03-16||||||||Observational|||Genetics and Pain Severity in Sickle Cell Disease|Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease|Completed|||67|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:07:44.438457|2018-05-31 22:07:44.438457
NCT01441128|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2018-05-18|2011-09-24|2011-09-27|Estimate|||||||2018-05-18|2018-05-21|Actual|September 1, 2011||2011-09-01|February 26, 2015|2015-02-26|February 26, 2015|Actual|2015-02-26|February 28, 2014|Actual|2014-02-28||Interventional|||-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer|A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1|20|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:07:44.507859|2018-05-31 22:07:44.507859
NCT01441115|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2018-05-12|2011-09-24|2011-09-27|Estimate|||||||2018-05-12|2018-05-15|Actual|September 6, 2011||2011-09-06|April 24, 2013|2013-04-24|April 24, 2013|Actual|2013-04-24|April 24, 2013|Actual|2013-04-24||Interventional|||ECI301 and Radiation for Advanced or Metastatic Cancer|Phase I Trial of ECI301 in Combination With Radiation in Patients With Advanced or Metastatic Cancer|Terminated||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:07:44.585813|2018-05-31 22:07:44.585813
NCT01441102|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|2015-05-26||2017-01-18|2011-09-24|2011-09-27|Estimate|2015-05-26|2015-06-08|Estimate||||2017-01-18|2017-03-03|Actual|August 2011||2011-08-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Interventional|MiDME2||Dextromethorphan for Diabetic Macular Edema|A Pilot Phase I/II Study for the Evaluation of Dextromethorphan as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema (MiDME2)|Completed||Phase 1/Phase 2|7|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||No||2018-05-31 22:07:44.670097|2018-05-31 22:07:44.670097
NCT01441089|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2017-12-19|2011-09-24|2011-09-27|Estimate|||||||2017-12-19|2017-12-20|Actual|August 25, 2011||2011-08-25|October 6, 2017|2017-10-06||||||||Observational|||Collection of Blood From Cancer Patients for Genetic Analysis|Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:07:44.995716|2018-05-31 22:07:44.995716
NCT01441076|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|2016-04-05||2017-04-03|2011-09-24|2011-09-27|Estimate|2017-04-03|2017-05-12|Actual||||2017-04-03|2017-05-12|Actual|September 2011||2011-09-30|April 2017|2017-04-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Anakinra for Behcet s Disease|A Pilot Study of Anakinra in Behcet's Disease (BD)|Completed||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||No||2018-05-31 22:07:45.102902|2018-05-31 22:07:45.102902
NCT01441063|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2017-12-27|2011-09-24|2011-09-27|Estimate|||||||2017-12-27|2017-12-28|Actual|August 9, 2011||2011-08-09|December 15, 2017|2017-12-15|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Tocilizumab for KSHV-Associated Multicentric Castleman Disease|Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease|Recruiting||Phase 2|17|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:07:45.434921|2018-05-31 22:07:45.434921
NCT01441037|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2017-12-27|2011-09-24|2011-09-27|Estimate|||||||2017-12-27|2017-12-28|Actual|July 19, 2011||2011-07-19|December 18, 2017|2017-12-18|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|||Danazol for Genetic Bone Marrow and Lung Disorders|Male Hormones for Telomere Related Diseases|Completed||Phase 1/Phase 2|27|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:07:45.52128|2018-05-31 22:07:45.52128
NCT01441024|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2018-05-18|2011-09-24|2011-09-27|Estimate|||||||2018-05-18|2018-05-21|Actual|July 14, 2011||2011-07-14|February 27, 2014|2014-02-27|June 30, 2014|Actual|2014-06-30|February 27, 2014|Actual|2014-02-27||Interventional|||DAS181 in Patients With Parainfluenza|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of DAS181 in Patients With Parainfluenza Infection|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:07:45.609915|2018-05-31 22:07:45.609915
NCT01441011|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2016-11-22|2011-09-26|2011-09-27|Estimate|||||||2016-11-22|2016-11-23|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Rural Women Connecting for Better Health|Group Phone-Based Weight Control for Rural Breast Cancer Survivors|Completed||N/A|210|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 22:07:45.787538|2018-05-31 22:07:45.787538
NCT01440998|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-24|||2018-04-04|2011-09-24|2011-09-27|Estimate|||||||2018-04-04|2018-04-05|Actual|September 20, 2011|Actual|2011-09-20|April 2018|2018-04-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer|Pilot and Translational Study of Dasatinib (NSC#732517) Paclitaxel and Carboplatin in Women With Advanced Stage and Recurrent Endometrial Cancer|Completed||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 22:07:45.996765|2018-05-31 22:07:45.996765
NCT01440985|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2012-07-06|2011-09-26|2011-09-27|Estimate|||||||2012-07-06|2012-07-10|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study on the Effects of Two Nicotine Replacement Products on Tooth Staining|An Evaluator-Blinded, Randomized, Parallel Controlled Study of Nicorette® Freshmint Gum Versus Nicorette® Microtab in Healthy Smokers Motivated to Quit Smoking With Visible Staining of Teeth|Completed||N/A|200|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 22:07:46.108233|2018-05-31 22:07:46.108233
NCT01440972|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2015-06-10||2016-10-24|2011-09-23|2011-09-27|Estimate|2015-07-02|2015-07-30|Estimate||||2016-10-24|2016-12-05|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|PBFR2||Assessment of Efficacy of Low Intensity Resistance Training in Women at Risk for Symptomatic Knee Osteoarthritis|Assessment of Efficacy of Low Intensity Resistance Training in Women at Risk for Symptomatic Knee Osteoarthritis|Completed||N/A|45|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 22:07:46.185999|2018-05-31 22:07:46.185999
NCT01440959|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2013-11-12||2014-01-13|2011-09-26|2011-09-27|Estimate|2014-01-13|2014-03-03|Estimate||||2014-01-13|2014-03-03|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST)|A Phase II Trial of TKI258 in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib(CTKI258AKR01T)|Completed||Phase 2|30|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:07:46.58714|2018-05-31 22:07:46.58714
NCT01440946|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2015-06-01||2017-02-27|2011-09-26|2011-09-27|Estimate|2015-06-01|2015-06-18|Estimate||||2017-02-27|2017-03-28|Actual|June 2012||2012-06-30|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Kids B-LONG||Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B|An Open-label, Multicenter Evaluation of Safety, Pharmacokinetics and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B|Completed||Phase 3|30|Actual|Bioverativ Therapeutics Inc.||1|||f||||t||||||||||2018-05-31 22:07:46.972525|2018-05-31 22:07:46.972525
NCT01440933|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-07-06|2011-09-23|2011-09-27|Estimate|||||||2012-07-06|2012-07-10|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MagSug||Efficacy of Sugammadex in Magnesium Pretreated Patients|Efficacy of Sugammadex for the Reversal of Moderate and Deep Rocuronium Induced Neuromuscular Block in Patients Pretreated With Magnesium Sulphate|Completed||Phase 2|32|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 22:07:50.609047|2018-05-31 22:07:50.609047
NCT01440920|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2013-11-10|2011-09-26|2011-09-27|Estimate|||||||2013-11-10|2013-11-13|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients|A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia|Completed||Phase 1|9|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 22:07:51.26003|2018-05-31 22:07:51.26003
NCT01440907|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2017-01-20|2011-09-26|2011-09-27|Estimate|||||||2017-01-20|2017-01-24|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional|||Study of the Impact of a Hospital Discharge Care Coordination Program in an Elderly Population|The Effect of an HIE-Supported Care Coordination Package on Hospital Re-Admission Rates in an Elderly Population|Completed||N/A|201|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||Yes|A fully deidentified data set listing outcomes for the included patients is available by contacting the study PI (Jessica Ancker, jsa7002@med.cornell.edu)|2018-05-31 22:07:51.447658|2018-05-31 22:07:51.447658
NCT01440894|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-25|||2011-09-25|2011-09-25|2011-09-27|Estimate|||||||2011-09-25|2011-09-27|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|GBFA||Clinical Trail of Transtek Glass Body Fat Analyzer|Verify the Functions and Efficiency of Transtek Glass Body Fat Analyzer, GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, GBF-950-D.|Completed|||50|Actual|BTS International|||1||f||||f||||||||||2018-05-31 22:07:51.61786|2018-05-31 22:07:51.61786
NCT01440881|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2014-01-22||2014-05-16|2011-09-26|2011-09-27|Estimate|2014-01-22|2014-03-06|Estimate||||2014-05-16|2014-06-06|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Does Nesiritide Provide Renal Protection|Does Nesiritide Provide Renal Protection By Attenuating the Inflammatory Response|Completed||Phase 2|37|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:07:51.851235|2018-05-31 22:07:51.851235
NCT01440868|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2011-09-26|2011-09-26|2011-09-27|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|SLIS||Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome|SLI STUDY: Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome. A RCT Study|Unknown status|Not yet recruiting|N/A|276|Anticipated|University of Florence||2|||f||||t||||||||||2018-05-31 22:07:52.901768|2018-05-31 22:07:52.901768
NCT01440855|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-09-30|2011-09-23|2011-09-27|Estimate|||||||2011-09-30|2011-10-04|Estimate|February 2005||2005-02-28|September 2011|2011-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting|Efficacy and Feasibility of a Psychosocial Intervention Within CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment (CCOP:Community Clinical Oncology Program)|Completed||N/A|340|Actual|Fox Chase Cancer Center||2|||f||||t||||||||||2018-05-31 22:07:53.097281|2018-05-31 22:07:53.097281
NCT01440842|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2012-12-31|2011-09-26|2011-09-27|Estimate|||||||2012-12-31|2013-01-03|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|CLASSIC||Closed Loop Glucose Control in Intensive Care Unit|An Open-label, Single-centre, Randomised Controlled Trial to Assess the Safety and Efficacy of Automated Closed-loop Blood Glucose Control in Comparison With Standard Care in Adults in Intensive Care Unit|Completed||Phase 2|24|Actual|University of Cambridge||2|||f||||f||||||||||2018-05-31 22:07:53.219661|2018-05-31 22:07:53.219661
NCT01440829|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2012-12-18|2011-09-23|2011-09-27|Estimate|||||||2012-12-18|2012-12-19|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS|The Effectiveness of L-ornithine-L-aspartate on Plasma Ammonia in Cirrhotic Patients After TIPS Procedure: a Prospective, Randomized, Controlled, Open-label Clinical Trial|Completed||Phase 2/Phase 3|40|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 22:07:53.322775|2018-05-31 22:07:53.322775
NCT01440816|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2017-11-14||2017-12-18|2011-09-26|2011-09-27|Estimate|2017-11-14|2017-12-12|Actual||||2017-12-18|2018-01-18|Actual|January 3, 2012|Actual|2012-01-03|December 2017|2017-12-31|April 10, 2015|Actual|2015-04-10|April 10, 2015|Actual|2015-04-10||Interventional|MCC|Safety Analysis Set, all patients who received any amount of the study drug (tavo).|IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer|A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma|Completed||Phase 2|15|Actual|OncoSec Medical Incorporated||2|||f||||t||||||||Undecided||2018-05-31 22:07:53.417873|2018-05-31 22:07:53.417873
NCT01440803|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2018-03-01|2011-09-26|2011-09-27|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2, 2012|Actual|2012-08-02|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|||Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women|Randomized Controlled Trial of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women|Active, not recruiting||Phase 2|41|Actual|Columbia University||2|||f||||t|t|f||||||Undecided||2018-05-31 22:07:53.790348|2018-05-31 22:07:53.790348
NCT01440790|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-03-11|2011-09-23|2011-09-27|Estimate|||||||2013-03-11|2013-03-12|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|AOGI||The Effect of Continuous Sipping of a Glucose Solution on Markers of Oxidation in Men and Women|The Effect of Continuous Sipping of a Glucose Solution on Markers of Oxidation in Men and Women|Completed||N/A|18|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 22:07:53.909745|2018-05-31 22:07:53.909745
NCT01440777|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2014-09-10|2011-09-26|2011-09-27|Estimate|||||||2014-09-10|2014-09-11|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Effectiveness and Adherence to an Online Sleep Program|Effectiveness and Adherence to an Online Sleep Program - A Pilot Study|Completed||N/A|101|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 22:07:53.9983|2018-05-31 22:07:53.9983
NCT01440764|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|2017-04-11||2017-05-18|2011-09-26|2011-09-27|Estimate|2017-05-18|2017-06-14|Actual||||2017-05-18|2017-06-14|Actual|September 2011||2011-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2016|Actual|2016-04-30||Interventional|||Aerosol Inhalation Treatment for Dyspnea|Aerosol Inhalation Treatment for Dyspnea|Completed||Phase 1/Phase 2|24|Actual|Beth Israel Deaconess Medical Center||6|||f||||f||||||||||2018-05-31 22:07:54.078113|2018-05-31 22:07:54.078113
NCT01440751|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-10-30|2011-09-23|2011-09-27|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2011||2011-09-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|MCToCM||Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery|Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery|Completed||Phase 4|99|Actual|Aeon Astron Europe B.V.||2|||f||||t||||||||No||2018-05-31 22:07:55.910537|2018-05-31 22:07:55.910537
NCT01440738|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|September 2012|Anticipated|2012-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Effectiveness of a Group Intervention to Promote Health Through a Clinical Trial|Effectiveness of a Group Intervention to Promote Health Through a Clinical Trial|Unknown status|Recruiting|N/A|376|Anticipated|Jordi Gol i Gurina Foundation||1|||f||||t||||||||||2018-05-31 22:07:56.026046|2018-05-31 22:07:56.026046
NCT01440725|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2013-01-08|2011-09-23|2011-09-26|Estimate|||||||2013-01-08|2013-01-10|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PRP-RICE||Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma|Multicenter Double Blind, With Evaluator Blinding, Parallel, Randomized Clinical Trial, to Assess the Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma|Completed||Phase 3|71|Actual|Institut de Terapia Regenerativa Tissular||2|||f||||f||||||||||2018-05-31 22:07:56.102782|2018-05-31 22:07:56.102782
NCT01440712|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-07-12|2011-09-23|2011-09-26|Estimate|||||||2014-07-12|2014-07-15|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Study of the Effect of Water Soluble Oral Contrast (Gastrografin) on Postoperative Ileus After Colorectal Surgery|Prospective Randomized Double Blind Study of the Effect of Gastrografin on Postoperative Ileus After Colorectal Surgery|Completed||Phase 4|58|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 22:07:56.187609|2018-05-31 22:07:56.187609
NCT01440699|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|ALLO-ASC||Study of Allogenic Adipose-derived Stem Cells in Crohn's Fistula|Phase I Study of Dose Escalation of Human Allogenic Adipose-derived Stem Cells (ALLO-ASC) to Evaluate Safety and Efficacy in Patients With Crohn's Fistula|Unknown status|Recruiting|Phase 1|6|Anticipated|Anterogen Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:07:56.267504|2018-05-31 22:07:56.267504
NCT01440686|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2012-10-15|2011-09-23|2011-09-26|Estimate|||||||2012-10-15|2012-10-16|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|HL-032||Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers|A Dose Block-randomized, Double-blinded, Placebo-controlled, Single-dose, Dose-escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of HL-032 in Healthy Male Volunteers|Completed||Phase 1|40|Anticipated|HanAll BioPharma Co., Ltd.||3|||f||||t||||||||||2018-05-31 22:07:56.346975|2018-05-31 22:07:56.346975
NCT01440673|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy||Completed||N/A|150|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 22:07:56.572867|2018-05-31 22:07:56.572867
NCT01440660|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-10-07|2011-09-23|2011-09-26|Estimate|||||||2015-10-07|2015-10-08|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)|Phenotypes of Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Patients Identified by Optical Coherence Tomography, Colour Fundus Photography, Fluorescein Leakage and Multifocal Electrophysiology (DIAMARKER Project: Genetic Susceptibility for Multi-systemic Complications in Diabetes Type-2: New Biomarkers for Diagnostic and Therapeutic Monitoring).|Completed|||20|Actual|Association for Innovation and Biomedical Research on Light and Image|||2||f||||f||||||||||2018-05-31 22:07:56.681205|2018-05-31 22:07:56.681205
NCT01440647|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2012-12-26||2013-02-07|2011-09-23|2011-09-26|Estimate|2013-02-07|2013-03-12|Estimate||||2013-02-07|2013-03-12|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|||Study of Nasal Ventilation In Preterm Infants To Decrease Time on The Respirator|Nasal Intermittent Positive Pressure Ventilation Allows Early Extubation In Infants Less Than 28 Weeks Gestation: A Pilot Study|Completed||N/A|34|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 22:07:56.784534|2018-05-31 22:07:56.784534
NCT01440634|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2013-03-08||2015-11-30|2011-09-23|2011-09-26|Estimate|2014-02-11|2014-03-28|Estimate||||2015-11-30|2015-12-29|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.|Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.|Completed||N/A|347|Actual|University of Texas Southwestern Medical Center|This study was limited by the lack of patients compliance to follow the schedule for the exercise sessions. Patients did not assisted regularly to the walking sessions, and the schedule was completed in 70 % of the plan.|2|||f||||f||||||||||2018-05-31 22:07:57.175254|2018-05-31 22:07:57.175254
NCT01440621|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2012-03-21|2011-09-22|2011-09-26|Estimate|||||||2012-03-21|2012-03-23|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ModCRF||Modafinil in Cancer Related Fatigue|Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy|Completed||Phase 3|217|Actual|Indira Gandhi Medical College||2|||f||||||||||||||2018-05-31 22:07:57.435497|2018-05-31 22:07:57.435497
NCT01440608|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2012-03-02|2011-09-23|2011-09-26|Estimate|||||||2012-03-02|2012-03-06|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy|Randomized, Double-blind, Placebo-controlled Trial Evaluating the Impact of High-dose Zinc Therapy and Albendazole in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children|Completed||N/A|225|Actual|Washington University School of Medicine||3|||f||||||||||||||2018-05-31 22:07:57.535477|2018-05-31 22:07:57.535477
NCT01440452|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2016-08-29|2011-09-23|2011-09-26|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|FIRST-STIM||CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies|CNS Growth Factors Release and Changes in the Inflammatory Environment in Response to Electrical Stimulation in Subjects With Inflammatory Myelopathies|Active, not recruiting||Phase 2/Phase 3|35|Actual|Johns Hopkins University||4|||f||||f||||||||||2018-05-31 22:08:00.060185|2018-05-31 22:08:00.060185
NCT01440595|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2016-02-03||2017-03-01|2011-09-22|2011-09-26|Estimate|2016-02-03|2016-03-04|Estimate||||2017-03-01|2017-03-30|Actual|November 2011||2011-11-30|March 2017|2017-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Five participants were randomized as indicated in the Participant Flow Module, but only 3 participants were treated. Baseline Characteristics are presented only for treated participants.|Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)|A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection|Terminated||Phase 2|5|Actual|Merck Sharp & Dohme Corp.||4||"Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to~   elevated transaminase levels in treatment with grazoprevir."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:07:57.631132|2018-05-31 22:07:57.631132
NCT01440582|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2018-04-11|2011-09-22|2011-09-26|Estimate|||||||2018-04-11|2018-04-12|Actual|February 18, 2013|Actual|2013-02-18|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients|Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM)|Active, not recruiting||Phase 1|77|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:07:57.909058|2018-05-31 22:07:57.909058
NCT01440569|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2014-10-23|2013-11-17|2016-10-26|2011-09-23|2011-09-26|Estimate|2014-10-23|2014-10-28|Estimate|2013-11-17|2013-12-12|Estimate|2016-10-26|2016-12-14|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|August 2012|Actual|2012-08-31||Interventional||Full Analysis Set: participants who were enrolled into the study and received at least one dose of study drug.|Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults|A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and -Experienced Adults With No Darunavir Resistance-associated Mutations|Completed||Phase 3|314|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 22:07:58.152599|2018-05-31 22:07:58.152599
NCT01440556|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2013-07-10|2011-09-23|2011-09-26|Estimate|||||||2013-07-10|2013-07-11|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|MM2011||Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma|Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: a Study From the Italian Bone Marrow Transplantation Donor Registry|Completed|||196|Actual|Azienda Ospedaliera San Giovanni Battista|||||f||||f||||||||||2018-05-31 22:07:59.035034|2018-05-31 22:07:59.035034
NCT01440543|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2012-12-19||2012-12-20|2011-09-22|2011-09-26|Estimate|2012-12-20|2013-01-28|Estimate||||2012-12-20|2013-01-28|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|Water/CO2||Combination of Water Immersion and Carbon Dioxide Insufflation for Minimal Sedation Colonoscopy|Combination of Water Immersion and Carbon Dioxide Insufflation for Minimal Sedation Colonoscopy - a Prospective, Randomized, Single-center Trial|Completed||N/A|420|Actual|Vitkovice Hospital|There were no procedure- or sedation-related complications recorded in the study.|4|||f||||f||||||||||2018-05-31 22:07:59.094056|2018-05-31 22:07:59.094056
NCT01440530|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TIDES||Technology Intervention for Diabetes Engagement & Self-Care (TIDES)|Technology Intervention for Diabetes Engagement & Self-Care (TIDES):Comparative Effectiveness Randomized Clinical Trial in Primary Care for Type 2 Diabetes to Improve Engagement, Knowledge, and Self-Care|Completed||N/A|170|Actual|Geisinger Clinic||2|||f||||f||||||||||2018-05-31 22:07:59.444099|2018-05-31 22:07:59.444099
NCT01440517|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2013-08-30||2014-01-02|2011-09-23|2011-09-26|Estimate|2014-01-02|2014-02-04|Estimate||||2014-01-02|2014-02-04|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction|An Open-Label, Multicenter, Proof of Concept, Phase 2 Study Evaluating the Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular Ejection Fraction (HFPEF)|Terminated||Phase 2|4|Actual|GE Healthcare||1||Lack of Subject Recruitment|f||||f||||||||||2018-05-31 22:07:59.540637|2018-05-31 22:07:59.540637
NCT01440504|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2013-02-06|2011-09-23|2011-09-26|Estimate|||||||2013-02-06|2013-02-07|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|ABT737 exvivo||Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors|Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors|Completed|||36|Actual|Centre Francois Baclesse|||||f||||t||||||||||2018-05-31 22:07:59.71872|2018-05-31 22:07:59.71872
NCT01440491|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|May 2008||2008-05-31|January 2008|2008-01-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Orientation Booklet for Low Back Pain|Effect of Orientation Through a Booklet of Exercise in Patients With Low Back Pain|Completed||N/A|44|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 22:07:59.849457|2018-05-31 22:07:59.849457
NCT01440478|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-10-07|2011-09-22|2011-09-26|Estimate|||||||2011-10-07|2011-10-12|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects|Impact of Variations in Urinary pH on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects|Completed||Phase 1|30|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 22:07:59.911785|2018-05-31 22:07:59.911785
NCT01440465|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2013-02-07|2011-09-23|2011-09-26|Estimate|||||||2013-02-07|2013-02-08|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Observational|NAVI||Management of Nausea and Vomiting Chemotherapy-induced in Normandy|Management of Nausea and Vomiting Chemotherapy-induced in Normandy|Completed|||300|Actual|Centre Francois Baclesse|||||f||||t||||||||||2018-05-31 22:07:59.982599|2018-05-31 22:07:59.982599
NCT01440439|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-11-07|2011-09-23|2011-09-26|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Comparing Long-acting Insulins During Exercise in Type 1 Diabetes|Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes|Unknown status|Recruiting|Phase 4|30|Anticipated|Buckinghamshire Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 22:08:00.162087|2018-05-31 22:08:00.162087
NCT01440426|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Connective Tissue Graft Versus Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects|Connective Tissue Graft vs Mucograft Collagen Matrix for Coverage of Multiple Gingival Recession Defects Randomized Controlled Clinical Trial Assessing Superiority in Health Related Quality of Life and Non-Inferiority in Root Coverage|Unknown status|Recruiting|Phase 4|280|Anticipated|The European Research Group on Periodontology (ERGOPerio)||2|||f||||f||||||||||2018-05-31 22:08:00.273169|2018-05-31 22:08:00.273169
NCT01440413|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-01-31|2011-09-23|2011-09-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2011|Actual|2011-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BREAST IMMUN||Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer|Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer|Active, not recruiting||N/A|40|Anticipated|Centre Leon Berard|||||f||||f||||||||||2018-05-31 22:08:00.393996|2018-05-31 22:08:00.393996
NCT01440400|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2013-03-11|2011-09-23|2011-09-26|Estimate|||||||2013-03-11|2013-03-12|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Ultrasound Guided Spinal Anesthesia in Non Obese Obstetric Patients|The Use of Ultrasound to Guide Spinal Anesthesia in Obstetrics. Is There an Advantage Over Landmark Technique in Non-obese Patients?|Completed||N/A|150|Actual|Corniche Hospital||2|||f||||t||||||||||2018-05-31 22:08:00.473277|2018-05-31 22:08:00.473277
NCT01440387|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2013-09-05|2012-07-26|2016-09-22|2011-09-22|2011-09-26|Estimate|2013-09-05|2013-11-19|Estimate|2012-07-26|2012-08-03|Estimate|2016-09-22|2016-09-23|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older|A Phase IIIA Study of Immunogenicity and Safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older|Completed||Phase 3|112|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:08:00.561809|2018-05-31 22:08:00.561809
NCT01440374|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2016-03-10||2017-05-02|2011-09-22|2011-09-26|Estimate|2016-05-06|2016-06-14|Estimate||||2017-05-02|2017-06-05|Actual|September 2011||2011-09-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|ASPIRE|Part 3, 59 subjects from Part 2 entered Part 3 (23 of 47 subjects in the placebo group in Part 2 and 36 of 98 subjects in the eltrombopag group in Part 2). All subjects who entered Part 3 received treatment with eltrombopag. SOC was allowed as needed throughout the study. Subjects could receive disease-modifying therapy as needed.|A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia|A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)|Completed||Phase 2|162|Actual|Novartis||4|||f||||t||||||||||2018-05-31 22:08:01.128986|2018-05-31 22:08:01.128986
NCT01440361|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2014-07-24|2011-09-22|2011-09-26|Estimate|||||||2014-07-24|2014-07-28|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.|A Clinical and Mechanistic Proof of Efficacy Study With Belimumab in Chronic Immune Thrombocytopenia (ITP) Patients.|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||This study was Cancelled Before Active|f||||f||||||||||2018-05-31 22:08:03.257089|2018-05-31 22:08:03.257089
NCT01440348|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|May 2011||2011-05-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Simultaneous Multiple Cruciate Ligament Reconstructions Using a Single Achilles Allograft|Simultaneous Multiple Cruciate Ligament Reconstructions Using a Single Achilles Allograft|Completed||Phase 4|51|Actual|National Police Hospital||1|||f||||t||||||||||2018-05-31 22:08:03.329611|2018-05-31 22:08:03.329611
NCT01440335|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2018-04-04|2011-09-23|2011-09-26|Estimate|||||||2018-04-04|2018-04-05|Actual|July 10, 2011||2011-07-10|January 7, 2015|2015-01-07|April 15, 2014|Actual|2014-04-15|April 15, 2014|Actual|2014-04-15||Interventional|||Initial Study of Fenoterol as a Treatment for Heart Failure|A Study of (R, R') and (S,S': R,R')- Fenoterol: Initial Clinical Evaluation for Pharmacokinetics, Pharmacodynamics, and Safety|Completed||Phase 1|29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:08:03.385268|2018-05-31 22:08:03.385268
NCT01440322|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2014-02-18||2014-04-24|2011-09-22|2011-09-26|Estimate|2014-02-18|2014-03-28|Estimate||||2014-04-24|2014-05-08|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||The analysis population includes all enrolled participants.|AIR OPTIX® COLORS Registration Trial||Completed||N/A|150|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:08:03.465397|2018-05-31 22:08:03.465397
NCT01440309|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2012-08-01|2011-09-23|2011-09-26|Estimate|||||||2012-08-01|2012-08-03|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|MSCsTreatPBC||Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis|Phase I Clinical Trial, Randomized, Controlled, to Evaluate the Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells From Bone Marrow for Patients With Refractory Primary Biliary Cirrhosis|Unknown status|Recruiting|Phase 1|20|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:08:03.943856|2018-05-31 22:08:03.943856
NCT01440296|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|March 2010||2010-03-31|September 2011|2011-09-30||||||||Observational|||Magnetic Resonance Imaging (MRI) Characterization of Carotid Plaque and Prediction of End-organ and Clinical Outcomes|Magnetic Resonance Imaging (MRI) Characterization of Carotid Plaque and Prediction of End-organ and Clinical Outcomes|Unknown status|Recruiting||500|Anticipated|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-05-31 22:08:04.179518|2018-05-31 22:08:04.179518
NCT01439620|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-10-27|2011-09-22|2011-09-23|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2009||2009-02-28|April 2016|2016-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging|Pilot Study to Evaluate Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging|Completed||Phase 1|20|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 22:08:14.617899|2018-05-31 22:08:14.617899
NCT01440283|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2015-11-09||2016-02-03|2011-09-22|2011-09-26|Estimate|2016-01-04|2016-02-04|Estimate||||2016-02-03|2016-03-03|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma|A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma|Terminated||Phase 2|14|Actual|St. Jude Children's Research Hospital|The study was closed to accrual in January 2014 due to the principal investigator leaving St. Jude. It was expected to re-open to accrual, however, in September 2015, the decision was made to permanently close the trial to participant enrollment.|1|||f||||f||||||||||2018-05-31 22:08:04.361765|2018-05-31 22:08:04.361765
NCT01440270|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2014-05-12|2011-09-23|2011-09-26|Estimate|||||||2014-05-12|2014-05-13|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|October 2019|Anticipated|2019-10-31|April 2015|Anticipated|2015-04-30||Interventional|||Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer|Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer|Active, not recruiting||Phase 2|145|Actual|Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||||2018-05-31 22:08:04.552976|2018-05-31 22:08:04.552976
NCT01440257|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-01-08|2011-09-23|2011-09-26|Estimate|||||||2015-01-08|2015-01-09|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria|A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|20|Actual|ChemoCentryx||2|||f||||f||||||||||2018-05-31 22:08:04.631326|2018-05-31 22:08:04.631326
NCT01440244|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2018-03-29|2011-09-23|2011-09-26|Estimate|||||||2018-03-29|2018-03-30|Actual|September 2011||2011-09-30|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|CT0030||Cervical Video Assisted Thoracoscopic Surgery (C-VATS)|Cervical Video Assisted Thoracoscopic Surgery (C-VATS)Using a Flexible Endoscope for Thoracoscopy|Recruiting||N/A|10|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 22:08:04.704344|2018-05-31 22:08:04.704344
NCT01440231|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2013-08-20|2011-09-23|2011-09-26|Estimate|||||||2013-08-20|2013-08-21|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|ADDRESS||Atacicept Demonstrating Dose RESponSe|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Dose-Response Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)|Withdrawn||Phase 2|0|Actual|EMD Serono||5|||f||||t||||||||||2018-05-31 22:08:04.7884|2018-05-31 22:08:04.7884
NCT01440218|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2018-03-08|2011-09-22|2011-09-26|Estimate|||||||2018-03-08|2018-03-12|Actual|September 2011||2011-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|IDIOM||Idiopathic Diseases of Man|Idiopathic Diseases of Man (IDIOM)|Enrolling by invitation|||10|Anticipated|Scripps Translational Science Institute|||1||f||||t||||||Samples With DNA|"~     Blood, saliva, or tissue will be obtained after informed consent is completed.~   "|||2018-05-31 22:08:04.860221|2018-05-31 22:08:04.860221
NCT01440205|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2016-09-13|2011-09-23|2011-09-26|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||Licensing Flu Shot Study||Completed||N/A|6098|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 22:08:04.916501|2018-05-31 22:08:04.916501
NCT01440192|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2018-02-27|2011-09-22|2011-09-26|Estimate|||||||2018-02-27|2018-03-01|Actual|September 2011||2011-09-30|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis|A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis|Terminated||Phase 1|4|Actual|Celularity Incorporated||2||Study Terminated by Sponsor|f||||t||||||||||2018-05-31 22:08:04.976505|2018-05-31 22:08:04.976505
NCT01440179|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-08-26|2011-09-22|2011-09-26|Estimate|||||||2014-08-26|2014-08-27|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MYRALL||SAR3419 in Acute Lymphoblastic Leukemia|Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Terminated||Phase 2|100|Actual|Sanofi||1||The study is stopped due to very modest activity compared to competitors|f||||||||||||||2018-05-31 22:08:05.046686|2018-05-31 22:08:05.046686
NCT01440166|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-02-02|2011-09-23|2011-09-26|Estimate|||||||2012-02-02|2012-02-06|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers|A Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers|Completed||Phase 1|52|Actual|Catabasis Pharmaceuticals||9|||f||||f||||||||||2018-05-31 22:08:05.120898|2018-05-31 22:08:05.120898
NCT01440153|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-09-23|2011-09-23|2011-09-26|Estimate|||||||2011-09-23|2011-09-26|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|November 2011|Anticipated|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Additional Exercise Program in Professional Dancers|Influence of an Additional Intervention Targeting Physical Fitness, Endurance and Motor Control, on Physical Condition and Musculoskeletal Injuries in Contemporary Dancers|Unknown status|Active, not recruiting|N/A|44|Anticipated|University College of Antwerp||2|||f||||f||||||||||2018-05-31 22:08:05.371855|2018-05-31 22:08:05.371855
NCT01440140|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2014-01-28|2011-09-22|2011-09-26|Estimate|||||||2014-01-28|2014-01-29|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Closing the Loop in Adults With Type 1 Diabetes in the Home Setting|An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Real-time Continuous Subcutaneous Glucose Monitoring Combined With Overnight Closed-loop Glucose Control in the Home Setting in Comparison With Real-time Continuous Subcutaneous Glucose Monitoring Alone in Adults With Type 1 Diabetes on Subcutaneous Insulin Infusion Pump Therapy|Completed||Phase 2|24|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 22:08:05.448234|2018-05-31 22:08:05.448234
NCT01439815|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-01-25|2011-09-22|2011-09-23|Estimate|||||||2012-01-25|2012-01-26|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo|A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model|Completed||Phase 4|21|Actual|ORA, Inc.||2|||f||||t||||||||||2018-05-31 22:08:12.817726|2018-05-31 22:08:12.817726
NCT01440127|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-03-25|2011-09-23|2011-09-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers|Randomized Clinical Trial Evaluating the Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers|Terminated||Phase 1|9|Actual|Tufts Medical Center||2||"Unable to accrue all planned subjects in a timely fashion, but data collected will still be~   analyzed."|f||||t||||||||||2018-05-31 22:08:05.524613|2018-05-31 22:08:05.524613
NCT01440114|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-09-22|2011-09-22|2011-09-26|Estimate|||||||2011-09-22|2011-09-26|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effect of Intravenous Fentanyl Prior the End of Surgery on Emergence Agitation in Paediatric Patients After General Anesthesia|The Effect of Intravenous Fentanyl Prior the End of Surgery on Emergence Agitation in Paediatric Patients After General Anesthesia|Completed||N/A|144|Actual|Prince of Songkla University||2|||f||||f||||||||||2018-05-31 22:08:05.598693|2018-05-31 22:08:05.598693
NCT01440101|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2014-09-15||2014-10-20|2011-09-22|2011-09-26|Estimate|2014-10-20|2014-10-21|Estimate||||2014-10-20|2014-10-21|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Tysabri Japan|This was a 2-part, multicenter study, each part (open-label, double-blind) comprising discrete cohorts of BG00002-naïve participants.|Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)|Multicenter Study of BG00002 in Japanese Subjects With RRMS, Consisting of a Multiple-Dose, Open-Label Evaluation of Its Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part A) and a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Evaluation of Safety and Efficacy (Part B)|Completed||Phase 2/Phase 3|106|Actual|Biogen||3|||f||||t||||||||||2018-05-31 22:08:05.711741|2018-05-31 22:08:05.711741
NCT01440088|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-06-01|2011-09-23|2011-09-26|Estimate|||||||2016-06-01|2016-06-02|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma|A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma|Completed||Phase 3|640|Actual|Threshold Pharmaceuticals||2|||t||||t||||||||||2018-05-31 22:08:06.493379|2018-05-31 22:08:06.493379
NCT01440075|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-08-18|2011-09-22|2011-09-26|Estimate|||||||2017-08-18|2017-08-22|Actual|October 10, 2011|Actual|2011-10-10|August 2017|2017-08-31|April 13, 2015|Actual|2015-04-13|April 13, 2015|Actual|2015-04-13||Interventional|Kawasaki||Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease|Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease|Completed||N/A|43|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 22:08:06.699913|2018-05-31 22:08:06.699913
NCT01440062|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-12-21|2011-09-23|2011-09-26|Estimate|||||||2017-12-21|2017-12-22|Actual|December 2011||2011-12-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)|Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis|Terminated||Phase 2|80|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:08:06.763482|2018-05-31 22:08:06.763482
NCT01440049|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2012-12-21||2012-12-21|2011-09-22|2011-09-26|Estimate|2012-12-21|2013-01-30|Estimate||||2012-12-21|2013-01-30|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|PERGAME||Patient's Management Receiving Eplerenone Therapy|Assessment Of Follow-Up Methods For Patients Treated In The Long-Term With A Specific Aldosterone Receptor Antagonist|Completed|||160|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:08:06.849037|2018-05-31 22:08:06.849037
NCT01440036|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-12-15|2011-09-22|2011-09-23|Estimate|||||||2011-12-15|2011-12-16|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|October 2014|Anticipated|2014-10-31|October 2012|Anticipated|2012-10-31||Observational|||The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque|The Correlation Between the Enzyme Paraoxigenase 1 (PON1) to Carotid Artery Atheromatous Plaque|Unknown status|Recruiting||100|Anticipated|Ziv Hospital|||1||f||||f||||||Samples Without DNA|"~     Atherosclerotic plaque from carotid arteries Blood sample (5cc)~   "|||2018-05-31 22:08:07.350474|2018-05-31 22:08:07.350474
NCT01440023|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-01-13|2011-09-22|2011-09-23|Estimate|||||||2015-01-13|2015-01-15|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Developing Cognitive Training for Tourette Syndrome|Developing Effective Response Inhibition Training for Symptom Relief in Tourette Syndrome|Completed||Phase 1|20|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 22:08:07.415713|2018-05-31 22:08:07.415713
NCT01440010|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2017-10-25|2011-09-22|2011-09-23|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2011||2011-09-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|TARGIT_BQR||TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry|TARGeted Intraoperative radioTherapy With the INTRABEAM-System as an Advanced Boost in Patients With Breast Cancer - A Quality Control Registry in Germany (TARGIT BQR)|Recruiting|||1000|Anticipated|Universitätsmedizin Mannheim|||1||f||||f||||||||||2018-05-31 22:08:07.493462|2018-05-31 22:08:07.493462
NCT01439997|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-12-04|2011-09-22|2011-09-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study|Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study|Unknown status|Recruiting|Phase 4|50|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:08:07.582011|2018-05-31 22:08:07.582011
NCT01439984|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2012-10-01|2011-09-22|2011-09-23|Estimate|||||||2012-10-01|2012-10-03|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Trial of PED-1 in Male Patients With Premature Ejaculation|A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped, Multi-center Clinical Study to Evaluate the Safety and Efficacy of PED-1 in Male Patients With Premature Ejaculation|Completed||Phase 3|159|Actual|Symyoo||2|||f||||f||||||||||2018-05-31 22:08:07.68707|2018-05-31 22:08:07.68707
NCT01439802|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-22|2011-09-22|2011-09-23|Estimate|||||||2011-09-22|2011-09-23|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Copper Intrauterine Device (IUD) Insertion at Cesarean Delivery|Transcesarean IUD Insertion: A Prospective Cohort Study|Completed||Phase 4|90|Actual|Albert Einstein College of Medicine, Inc.|||||f||||t||||||||||2018-05-31 22:08:12.885294|2018-05-31 22:08:12.885294
NCT01439971|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2016-10-20||2017-04-07|2011-09-22|2011-09-23|Estimate|2017-04-03|2017-04-06|Actual||||2017-04-07|2017-05-12|Actual|December 2011||2011-12-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||The baseline analysis population included all enrolled participants who received the study drug.|Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia|An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics/Pharmacodynamics Of Pf-05280602, A Recombinant Factor Viia Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors|Completed||Phase 1|29|Actual|Catalyst Biosciences|The protocol was amended to a starting dose of 4.5 mcg/kg. The positive anti-PF-05280602 antibody was cross-reactive with NovoSeven and native Factor VII and the weak positive immune response at Day 60 may represent a false-positive test result.|5|||f||||t||||||||No||2018-05-31 22:08:07.876158|2018-05-31 22:08:07.876158
NCT01439958|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-04-13|2011-09-22|2011-09-23|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)|A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy|Terminated||Phase 3|14|Actual|Pari Pharma GmbH||1||Core study 12011.201 was terminated.|f||||f||||||||||2018-05-31 22:08:09.451197|2018-05-31 22:08:09.451197
NCT01439945|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2016-12-08||2017-02-17|2011-09-22|2011-09-23|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|September 2011||2011-09-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes|Completed||Phase 2|289|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-05-31 22:08:09.568543|2018-05-31 22:08:09.568543
NCT01439932|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-02-17|2011-09-22|2011-09-23|Estimate|||||||2013-02-17|2013-02-20|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Effectiveness of Manual Therapy Combined With Standard Treatment in the Management of Plantar Fasciitis|Effectiveness of Manual Therapy Combined With Standard Treatment in the Management of Plantar Fasciitis, a Randomized Control Trial|Completed||N/A|50|Actual|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:08:10.79142|2018-05-31 22:08:10.79142
NCT01439919|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07||2013-03-14|2013-03-14|2011-09-22|2011-09-23|Estimate||||2013-03-14|2013-03-21|Estimate|2013-03-14|2013-03-21|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ACT11705||A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain|Terminated||Phase 2|5|Actual|Sanofi||2||due to strategic reasons|f||||t||||||||||2018-05-31 22:08:10.869506|2018-05-31 22:08:10.869506
NCT01439906|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-04-27|2011-09-22|2011-09-23|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Observational|||Surgical Treatment for Degenerative Scoliosis|Evaluation of Pain Relief and Functional Improvement After the Surgical Treatment for Low Back Pain Due to Degenerative Kyphoscoliosis - Pilot Study|Completed|||31|Actual|Istituto Ortopedico Rizzoli|||1||f||||f||||||||||2018-05-31 22:08:10.951324|2018-05-31 22:08:10.951324
NCT01439893|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-12-19|2011-09-22|2011-09-23|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2011||2011-06-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Efficacy on Cardiac Remodeling of Recombinant Human Neuregulin-1 in Stable Chronic Systolic Heart Failure Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure|Terminated||Phase 3|14|Actual|Zensun Sci. & Tech. Co., Ltd.||2||Sponsor has designed another study with different endpoint to replace the current study|f||||t||||||||||2018-05-31 22:08:11.01552|2018-05-31 22:08:11.01552
NCT01439880|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2017-12-20|2011-09-22|2011-09-23|Estimate|||||||2017-12-20|2017-12-21|Actual|October 7, 2011|Actual|2011-10-07|December 2017|2017-12-31|June 27, 2018|Anticipated|2018-06-27|June 27, 2018|Anticipated|2018-06-27||Interventional|OSLER||Open Label Study of Long Term Evaluation Against LDL-C Trial|A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)|Active, not recruiting||Phase 2|1324|Actual|Amgen||2|||f||||f||||||||||2018-05-31 22:08:11.136599|2018-05-31 22:08:11.136599
NCT01439867|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|2017-07-13|2017-04-25|2017-07-13|2011-09-22|2011-09-23|Estimate|2017-07-13|2017-08-11|Actual|2017-04-25|2017-04-26|Actual|2017-07-13|2017-08-11|Actual|June 22, 2012|Actual|2012-06-22|July 2017|2017-07-31|June 3, 2016|Actual|2016-06-03|June 3, 2016|Actual|2016-06-03||Interventional|||Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism|An Open-label, Single-arm Study to Assess the Safety & Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease & Secondary Hyperparathyroidism Receiving Dialysis|Terminated||Phase 2|18|Actual|Amgen||1||Sponsor decision|f||||f||||||||||2018-05-31 22:08:11.607102|2018-05-31 22:08:11.607102
NCT01439854|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2018-02-19|2011-09-22|2011-09-23|Estimate|||||||2018-02-19|2018-02-20|Actual|March 2011||2011-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DAPA MITO||Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action|Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM|Active, not recruiting||N/A|30|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 22:08:12.540751|2018-05-31 22:08:12.540751
NCT01439841|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2017-09-26|2011-09-21|2011-09-23|Estimate|||||||2017-09-26|2017-09-28|Actual|October 2011||2011-10-31|September 2017|2017-09-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|ProGut||The Effect of Probiotics in HIV-1 Infection|The Effect of Probiotics on Microbial Translocation and Immune Activation in HIV-1 Infection. A Randomised Placebo-controlled Trial|Completed||N/A|32|Actual|Oslo University Hospital||3|||f||||f||||||||||2018-05-31 22:08:12.648053|2018-05-31 22:08:12.648053
NCT01439828|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2012-01-18|2011-09-22|2011-09-23|Estimate|||||||2012-01-18|2012-01-19|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|February 2015|Anticipated|2015-02-28|February 2012|Anticipated|2012-02-29||Interventional|MUCOCRAV||Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal|Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal|Unknown status|Not yet recruiting|Phase 2|150|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:08:12.737274|2018-05-31 22:08:12.737274
NCT01439789|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-12-19|2011-09-22|2011-09-23|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2011||2011-06-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure|Terminated||Phase 3|146|Actual|Zensun Sci. & Tech. Co., Ltd.||2||Sponsor has designed another study with different endpoint to replace the current study|f||||t||||||||||2018-05-31 22:08:12.94938|2018-05-31 22:08:12.94938
NCT01439776|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2011-09-22|2011-09-22|2011-09-23|Estimate|||||||2011-09-22|2011-09-23|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|August 2013|Anticipated|2013-08-31|February 2013|Anticipated|2013-02-28||Interventional|Addwin||Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients|A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin|Unknown status|Not yet recruiting|Phase 4|222|Anticipated|Hanyang University||2|||f||||f||||||||||2018-05-31 22:08:13.059151|2018-05-31 22:08:13.059151
NCT01439763|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-09-14|2011-09-22|2011-09-23|Estimate|||||||2017-09-14|2017-09-18|Actual|September 2011||2011-09-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ABC||Assessment of Bullying in Children|Assessment of Bullying in Children With Psychiatric Symptoms: An Emergency Department Based Evaluation|Recruiting|||80|Anticipated|New York City Health and Hospitals Corporation|||||f||||f||||||||||2018-05-31 22:08:13.19521|2018-05-31 22:08:13.19521
NCT01439750|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-08-04|2011-09-22|2011-09-23|Estimate|||||||2017-08-04|2017-08-07|Actual|May 2012|Actual|2012-05-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)|Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011)|Active, not recruiting||Phase 1|13|Actual|Milton S. Hershey Medical Center||2|||f||||t|t|f|||t|||Undecided|May share data|2018-05-31 22:08:13.270119|2018-05-31 22:08:13.270119
NCT01439737|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-22|2011-09-22|2011-09-23|Estimate|||||||2011-09-22|2011-09-23|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Metabolomic Analysis of Exhaled Breath Condensate in Asthmatics|Metabolomic Analysis of Exhaled Breath Condensate, Plasma and Urine Specimens in Adult Asthmatics|Unknown status|Not yet recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     Exhaled breath condensates, serum, urine~   "|||2018-05-31 22:08:13.363212|2018-05-31 22:08:13.363212
NCT01439724|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2014-03-07||2014-03-07|2011-09-22|2011-09-23|Estimate|2014-03-07|2014-04-11|Estimate||||2014-03-07|2014-04-11|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|June 2008|Actual|2008-06-30||Interventional||The primary end point of the study was the incidence of grade 3–4 OM according to the WHO scale. Assuming an α = 0.05 and a β = 0.20, with the estimates of proportion being 0.40 for placebo (P0) and 0.15 for LLLT (P1) a total of 94 patients were evaluated.|Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients|Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation|Completed||Phase 3|94|Actual|Instituto Nacional de Cancer, Brazil||2|||f||||t||||||||||2018-05-31 22:08:13.442462|2018-05-31 22:08:13.442462
NCT01439711|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2018-02-26||2018-02-26|2011-09-21|2011-09-23|Estimate|2018-02-26|2018-03-27|Actual||||2018-02-26|2018-03-27|Actual|February 2012|Actual|2012-02-29|February 2018|2018-02-28|January 2018|Actual|2018-01-31|August 2016|Actual|2016-08-31||Interventional|||Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ|Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)|Completed||Phase 2|108|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 22:08:13.704621|2018-05-31 22:08:13.704621
NCT01439698|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-02-16|2011-09-22|2011-09-23|Estimate|||||||2017-02-16|2017-02-20|Actual|September 2011||2011-09-30|February 2017|2017-02-28|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01|1 Year|Observational [Patient Registry]|RFA-Registry||Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry|Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry|Recruiting|||200|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD Sharing|2018-05-31 22:08:14.057595|2018-05-31 22:08:14.057595
NCT01439685|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2015-06-01|2011-09-21|2011-09-23|Estimate|||||||2015-06-01|2015-06-03|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|PDT||Comparison of Biliary Stenting Alone vs. Stenting With Photodynamic Therapy (PDT) During ERCP|Comparison of Biliary Stenting Alone vs. Stenting With Photodynamic Therapy During Endoscopic Retrograde Cholangiopancreatography (ERCP): A Retrospective and Prospective Analysis|Withdrawn|||0|Actual|Weill Medical College of Cornell University|||2|A single cohort, alternative trial was started.|f||||f||||||||||2018-05-31 22:08:14.143597|2018-05-31 22:08:14.143597
NCT01439672|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2015-03-30||2016-10-24|2011-09-21|2011-09-23|Estimate|2015-03-30|2015-04-14|Estimate||||2016-10-24|2016-12-06|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|BPK005||Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability|Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability|Completed||N/A|35|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:08:14.216269|2018-05-31 22:08:14.216269
NCT01439659|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2018-03-20|2011-09-21|2011-09-23|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2003|Actual|2003-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer|A Randomized Phase II Study of the Nutritional Supplements Juice Plus + and Juice Plus + Complete in Ovarian Cancer Patients|Active, not recruiting||Phase 2|75|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 22:08:14.337771|2018-05-31 22:08:14.337771
NCT01439646|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-08-11|2011-09-22|2011-09-23|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy|Observational, Retrospective Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy|Completed|||100|Actual|Fortis Hospital, India|||1||f||||f||||||||||2018-05-31 22:08:14.405504|2018-05-31 22:08:14.405504
NCT01439633|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-04-14|2011-09-21|2011-09-23|Estimate|||||||2016-04-14|2016-04-18|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus|Pilot Study to Evaluate OFDI Surveillance and Image Guided Biopsy of the Esophagus|Completed||Phase 1|22|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:08:14.49018|2018-05-31 22:08:14.49018
NCT01439607|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2014-05-22|2011-09-22|2011-09-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|MGMC||Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease|Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells, Macrophages and Plasma Cell Biology in Gaucher Disease.|Completed||N/A|30|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:08:14.691139|2018-05-31 22:08:14.691139
NCT01439594|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-10-27|2011-09-21|2011-09-23|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|OFDI||Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation|Pilot Study to Evaluate Optical Frequency Domain Imaging as a Tool for Assessing the Tissue Response to Radiofrequency Ablation|Completed||Phase 1|17|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 22:08:14.761649|2018-05-31 22:08:14.761649
NCT01439581|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2014-03-04|2011-09-22|2011-09-23|Estimate|||||||2014-03-04|2014-03-05|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Utility of Interface Pressure Mapping||Completed||Phase 2|216|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 22:08:14.832919|2018-05-31 22:08:14.832919
NCT01439568|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21||2014-04-25|2017-01-03|2011-09-21|2011-09-23|Estimate||||2014-04-25|2014-05-13|Estimate|2017-01-03|2017-01-05|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|January 2014|Actual|2014-01-31||Interventional|||A Study of LY2510924 in Patients With Extensive-Stage Small Cell Lung Carcinoma|A Randomized Phase 2 Study of LY2510924 and Carboplatin/Etoposide Versus Carboplatin/Etoposide in Extensive-Stage Small Cell Lung Carcinoma|Completed||Phase 2|92|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:08:14.90687|2018-05-31 22:08:14.90687
NCT01439555|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2018-03-05|2011-09-21|2011-09-23|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2011||2011-11-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Endothelial Facilitation in Alzheimer's Disease|Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.|Completed||Phase 2|10|Actual|University of Massachusetts, Worcester||1|||f||||f||||||||||2018-05-31 22:08:15.010495|2018-05-31 22:08:15.010495
NCT01439542|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-07-22|2011-09-22|2011-09-23|Estimate|||||||2014-07-22|2014-07-24|Estimate|September 2011||2011-09-30|July 2014|2014-07-31||||December 2021|Anticipated|2021-12-31||Interventional|FASTR||FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer|FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer|Terminated||Phase 2|19|Actual|Lawson Health Research Institute||1||Higher then expected Gr3 GU/GI toxicity|f||||t||||||||||2018-05-31 22:08:15.094821|2018-05-31 22:08:15.094821
NCT01439529|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-08-09|2011-09-22|2011-09-23|Estimate|||||||2017-08-09|2017-08-10|Actual|April 2009||2009-04-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2016|Actual|2016-09-30||Interventional|BEST||ECG Optimization of CRT: Evaluation of Mid-term Response|Optimization of Response to Cardiac Resynchronization Therapy by Electrocardiogram: an Assessment of Medium-term Response|Active, not recruiting||Phase 3|180|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 22:08:15.179963|2018-05-31 22:08:15.179963
NCT01439516|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-04-15|2011-09-22|2011-09-23|Estimate|||||||2014-04-15|2014-04-16|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PREPARED||Providing Resources to Enhance African American Patients' Readiness to Make Decisions About Kidney Disease (PREPARED) Study|Information and Financial Interventions for Kidney Donation in African Americans|Completed||N/A|92|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 22:08:15.262656|2018-05-31 22:08:15.262656
NCT01439503|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-10-26|2011-09-21|2011-09-23|Estimate|||||||2017-10-26|2017-10-30|Actual|September 2012||2012-09-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Safer Sex Program for Young African-American Men|A Brief, Clinic-Based, Safer Sex Program for Young African-American Men|Recruiting||Phase 2|620|Anticipated|University of Kentucky||2|||f||||f||||||||||2018-05-31 22:08:15.34173|2018-05-31 22:08:15.34173
NCT01439490|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2014-04-17|2011-09-22|2011-09-23|Estimate|||||||2014-04-17|2014-04-21|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||FES-PET to Determine ER-expression in Epithelial Ovarian Cancer|Feasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer|Completed||Phase 2|15|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 22:08:15.420872|2018-05-31 22:08:15.420872
NCT01439477|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-11-17|2011-09-22|2011-09-23|Estimate|||||||2015-11-17|2015-11-18|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||StrongWomen- Healthy Hearts: A Community Based Program for Midlife and Older Women|StrongWomen- Healthy Hearts: A Community Based Program for Midlife and Older Women|Completed|||763|Actual|Tufts University|||||f||||t||||||||||2018-05-31 22:08:15.501362|2018-05-31 22:08:15.501362
NCT01439464|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2011-09-22|2011-09-22|2011-09-23|Estimate|||||||2011-09-22|2011-09-23|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Interventional|||Study of Bioactive Glass-ceramic Intervertebral Spacer (Bonglass-SS) in Posterior Lumbar Interbody Fusion|Clinical Efficacy and Safety of Bioactive Glass-ceramic Intervertebral Spacer (Bonglass-SS) in Posterior Lumbar Interbody Fusion and, Titanium Cage Controlled, 1-year, Single-Blind, Non-Inferiority Trial|Unknown status|Recruiting|N/A|86|Anticipated|BioAlpha Inc.||2|||f||||f||||||||||2018-05-31 22:08:15.571147|2018-05-31 22:08:15.571147
NCT01439451|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|||2015-08-05|2011-09-22|2011-09-23|Estimate|||||||2015-08-05|2015-08-06|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2013|Actual|2013-08-31||Interventional|BaMPer||Effect of Perturbation Training on Balance Control in Elderly Persons|Effect of Balance Perturbation to Improve Gait and Balance Control and Prevent Falls in Elderly Persons -A Randomized Control Trial|Completed||N/A|48|Actual|Barzilai Medical Center||2|||f||||t||||||||||2018-05-31 22:08:15.652116|2018-05-31 22:08:15.652116
NCT01439438|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-06-27|2011-09-21|2011-09-23|Estimate|||||||2017-06-27|2017-06-28|Actual|July 22, 2011|Actual|2011-07-22|June 2017|2017-06-30|September 11, 2011|Actual|2011-09-11|September 11, 2011|Actual|2011-09-11||Interventional|||Topiramate Bioequivalence Study Brazil - Fast|A Relative Bioavailability Study of Two Formulations of Topiramate 100 mg Coated Tablet in Healthy Male Volunteers, the Test Formulation Produced by Dr. Reddy's Laboratories Ltd. and the Reference Formulation (Topamax®) Marked by Janssen-Cilag Farmacêutica Ltda.|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:08:15.721369|2018-05-31 22:08:15.721369
NCT01439425|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-09-21|2011-09-21|2011-09-23|Estimate|||||||2011-09-21|2011-09-23|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis|Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study|Unknown status|Not yet recruiting|Phase 4|42|Anticipated|Universita di Verona||1|||f||||f||||||||||2018-05-31 22:08:15.791575|2018-05-31 22:08:15.791575
NCT01439412|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-03-23|2011-09-22|2011-09-23|Estimate|||||||2017-03-23|2017-03-27|Actual|March 17, 2014|Actual|2014-03-17|March 2017|2017-03-31|March 17, 2018|Anticipated|2018-03-17|March 17, 2018|Anticipated|2018-03-17||Interventional|Acuback||Acupuncture in Acute Nonspecific Low Back Pain|Acupuncture in Acute Nonspecific Low Back Pain; a Randomized Controlled Multicenter Study in General Practice|Active, not recruiting||N/A|185|Actual|University of Oslo||2|||f||||f|f|f||||||Undecided||2018-05-31 22:08:15.851761|2018-05-31 22:08:15.851761
NCT01439399|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-21|2011-09-21|2011-09-23|Estimate|||||||2011-09-21|2011-09-23|Estimate|December 2005||2005-12-31|September 2011|2011-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Analgesic Efficacy of Intravenous Lidocaine and/or Ketamine|Analgesic Efficacy of Intravenous Perfusion of Lidocaine, Ketamine or a Combination After Laparotomy in a Placebo-controlled, Randomized, Double-blind Prospective Study|Completed||N/A|52|Actual|University of Lausanne Hospitals||4|||f||||f||||||||||2018-05-31 22:08:15.924225|2018-05-31 22:08:15.924225
NCT01439386|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-10-17|2011-09-22|2011-09-23|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2011||2011-09-30|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2013|Actual|2013-07-31||Interventional|APPROVAL||Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter|Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter|Completed||Phase 3|86|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-05-31 22:08:16.001216|2018-05-31 22:08:16.001216
NCT01439373|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2017-09-26|2012-11-15|2017-11-08|2011-09-22|2011-09-23|Estimate|2017-11-08|2017-12-11|Actual|2012-11-15|2012-11-20|Estimate|2017-11-08|2017-12-11|Actual|July 7, 2011|Actual|2011-07-07|November 2017|2017-11-30|December 5, 2011|Actual|2011-12-05|December 5, 2011|Actual|2011-12-05||Interventional|||Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects|Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4|Completed||Phase 2|16|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 22:08:16.102587|2018-05-31 22:08:16.102587
NCT01439360|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2016-12-22|2015-08-06|2017-03-21|2011-09-21|2011-09-23|Estimate|2017-01-16|2017-03-08|Actual|2015-08-06|2015-08-24|Estimate|2017-03-21|2017-04-20|Actual|October 2011||2011-10-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children|An Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine GSK2321138A (FLU D-QIV) When Administered in Children|Completed||Phase 3|12045|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:08:16.948794|2018-05-31 22:08:16.948794
NCT01439347|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-07-20|2011-09-21|2011-09-23|Estimate|||||||2016-07-20|2016-07-22|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL|Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)|Terminated||Phase 3|26|Actual|Spectrum Pharmaceuticals, Inc||2||Sponsor decision|f||||f||||||||||2018-05-31 22:08:20.546062|2018-05-31 22:08:20.546062
NCT01439334|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-09-21|2011-09-21|2011-09-23|Estimate|||||||2011-09-21|2011-09-23|Estimate|December 2009||2009-12-31|September 2011|2011-09-30|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|SBIRT||Multiple Behavior Screening, Brief Intervention and Referral to Treatment (SBIRT) Model of Drug Abuse in Primary Care|Multiple Behavior SBIRT Model of Drug Abuse in Primary Care|Withdrawn||N/A|0|Actual|University of Florida||3||PI left UF|f||||t||||||||||2018-05-31 22:08:21.541822|2018-05-31 22:08:21.541822
NCT01439321|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2012-06-21|2011-09-21|2011-09-23|Estimate|||||||2012-06-21|2012-06-25|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim|Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim|Completed|||280|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:08:21.679733|2018-05-31 22:08:21.679733
NCT01439308|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2016-11-30|2011-09-21|2011-09-23|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Intranasal SB-705498 in Non-allergic Rhinitis Patients|A Randomized, Double Blind, Placebo Controlled Study to Assessthe Effect of Intranasal Single Dose SB-705498 on the Response Tointranasal Capsaicin Challenge in Non-allergic Rhinitis Patients|Completed||Phase 2|40|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:08:21.755419|2018-05-31 22:08:21.755419
NCT01439295|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2015-11-17|2011-09-22|2011-09-23|Estimate|||||||2015-11-17|2015-11-18|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia|Urinary Ascorbyl Peroxide as an Early Biological Marker of Bronchopulmonary Dysplasia in Preterm Infants Less Than 33 Weeks of Gestation|Completed|||51|Actual|St. Justine's Hospital|||1||f||||f||||||Samples With DNA|"~     Urine sample (650 µl) Blood sample (500 µl)~   "|||2018-05-31 22:08:22.009551|2018-05-31 22:08:22.009551
NCT01439282|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2016-05-11||2016-05-11|2011-09-22|2011-09-23|Estimate|2016-05-11|2016-06-20|Estimate||||2016-05-11|2016-06-20|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|November 2012|Actual|2012-11-30||Interventional||Full Analysis Set (FAS) included all participants who received at least one dose of eribulin mesylate plus capecitabine.|Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer|A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer|Completed||Phase 2|77|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 22:08:22.385211|2018-05-31 22:08:22.385211
NCT01439269|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2018-01-09|2011-09-22|2011-09-23|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2008|Actual|2008-06-30|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|July 3, 2012|Actual|2012-07-03||Interventional|||Family Nurture Intervention (FNI) in Neonatal Intensive Care Unit (NICU)|Enhancement of Co-regulation Between Mother and Infant Via Family Nurture Intervention (FNI) in the NICU: Short and Long Term Effects on Development|Completed||N/A|394|Actual|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 22:08:23.276701|2018-05-31 22:08:23.276701
NCT01439256|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-02-14|2011-09-22|2011-09-23|Estimate|||||||2017-02-14|2017-02-15|Actual|September 2011||2011-09-30|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|HTNMedTrack||Telehealth & Remote Measurement Technologies to Improve Medication Adherence in Hypertension|Telehealth & Remote Measurement Technologies to Improve Medication Adherence in Hypertension|Completed||N/A|207|Actual|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 22:08:23.449085|2018-05-31 22:08:23.449085
NCT01439243|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-20|2011-09-20|2011-09-23|Estimate|||||||2011-09-20|2011-09-23|Estimate|June 2007||2007-06-30|September 2011|2011-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Donepezil 10 mg Tablets Under Fed Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Donepezil (Test) 10 mg Tablet and Aricept® (Reference) Following a 10 mg Dose in Healthy Subjects Under Fed Conditions|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 22:08:23.516108|2018-05-31 22:08:23.516108
NCT01439230|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-20|2011-09-20|2011-09-23|Estimate|||||||2011-09-20|2011-09-23|Estimate|June 2007||2007-06-30|September 2011|2011-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Donepezil 10 mg Tablets Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Donepezil 10 mg Tablet and Aricept® (Reference) Following a 10 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 22:08:23.664026|2018-05-31 22:08:23.664026
NCT01439217|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2013-04-15|2011-09-22|2011-09-23|Estimate|||||||2013-04-15|2013-04-17|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Endothelial Function, Arterial Stiffness and Components|Endothelial Function, Arterial Stiffness and Components of Metabolic Syndrome in Acute Lymphoblastic Leukemia (ALL) Survivors|Completed|||32|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-05-31 22:08:23.844185|2018-05-31 22:08:23.844185
NCT01439204|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2013-11-04||2014-02-21|2011-09-22|2011-09-23|Estimate|2013-12-30|2014-02-04|Estimate||||2014-02-21|2014-03-19|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb|A Randomized, Open-label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of Abatacept (BMS-188667) Drug Products Using Active Pharmaceutical Ingredient Manufactured at Devens, MA Site Relative to Active Pharmaceutical Ingredient Manufactured at Lonza, New Hampshire (NH) in Healthy Subjects|Completed||Phase 1|223|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 22:08:23.968719|2018-05-31 22:08:23.968719
NCT01439191|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-21|2011-09-21|2011-09-23|Estimate|||||||2011-09-21|2011-09-23|Estimate|July 2005||2005-07-31|June 2005|2005-06-30|May 2007|Actual|2007-05-31|February 2007|Actual|2007-02-28||Interventional|||Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer|An Open-Label Randomized Phase II Study of Cipterbin® or Cipterbin® in Combination With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer (MBC)|Completed||Phase 2|109|Actual|Shanghai CP Guojian Pharmaceutical Co.,Ltd.||2|||f||||t||||||||||2018-05-31 22:08:24.70734|2018-05-31 22:08:24.70734
NCT01439178|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-09-21|2011-09-21|2011-09-23|Estimate|||||||2011-09-21|2011-09-23|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab|Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab|Unknown status|Recruiting|N/A|28|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 22:08:24.809339|2018-05-31 22:08:24.809339
NCT01439165|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2017-07-28||2017-09-08|2011-09-21|2011-09-23|Estimate|2017-09-08|2017-10-09|Actual||||2017-09-08|2017-10-09|Actual|November 2011||2011-11-30|September 2017|2017-09-30|February 2017|Actual|2017-02-28|December 2015|Actual|2015-12-31||Interventional|||Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose|Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose|Completed||Phase 4|1330|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available at Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 22:08:25.036076|2018-05-31 22:08:25.036076
NCT01439152|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2018-05-25|2011-09-22|2011-09-23|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 7, 2011|Actual|2011-09-07|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.|An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|147|Actual|Bayer||4|||f||||f|t|f||||||||2018-05-31 22:08:25.596404|2018-05-31 22:08:25.596404
NCT01439139|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-03-27|2011-09-22|2011-09-23|Estimate|||||||2014-03-27|2014-03-28|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Bone UltraSonic Scanner (BUSS): Validation Study|Portable Bone Ultrasonometer for Osteoporosis Assessment|Completed|||130|Actual|Artann Laboratories|||||f||||f||||||||||2018-05-31 22:08:25.691016|2018-05-31 22:08:25.691016
NCT01439126|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2013-06-18||2014-10-15|2011-09-20|2011-09-22|Estimate|2014-10-08|2014-10-15|Estimate||||2014-10-15|2014-10-27|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder|A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY™ (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD|Completed||Phase 4|135|Actual|Concordia Pharmaceuticals Inc., Barbados||2|||f||||f||||||||||2018-05-31 22:08:25.785605|2018-05-31 22:08:25.785605
NCT01439113|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2011-09-21|2011-09-21|2011-09-22|Estimate|||||||2011-09-21|2011-09-22|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Single-operator Ultrasound-guided IV Placement by Emergency Nurses|A Randomized Trial of Single-Operator Ultrasound-Guided vs. Standard-of-Care IV Placement by Emergency Nurses|Completed||N/A|50|Actual|Tufts Medical Center||2|||f||||f||||||||||2018-05-31 22:08:26.272102|2018-05-31 22:08:26.272102
NCT01439100|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-02-05|2011-09-21|2011-09-22|Estimate|||||||2014-02-05|2014-02-06|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain||Completed||Phase 3|172|Anticipated|Mundipharma Research GmbH & Co KG||2|||f||||||||||||||2018-05-31 22:08:26.33831|2018-05-31 22:08:26.33831
NCT01439087|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-04-14|2011-09-21|2011-09-22|Estimate|||||||2016-04-14|2016-04-15|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|August 2010|Actual|2010-08-31|October 2009|Actual|2009-10-31||Interventional|||Optical Frequency Domain Imaging for Assessing Colonic Polyps|Pilot Study to Evaluate Optical Frequency Domain Imaging as a Tool for Assessing Colonic Polyps|Completed||Phase 1|15|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:08:26.536731|2018-05-31 22:08:26.536731
NCT01439074|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2014-09-26||2017-11-10|2011-09-21|2011-09-22|Estimate|2014-09-26|2014-10-01|Estimate||||2017-11-10|2017-12-18|Actual|September 2011||2011-09-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||ITT population/Safety population was chosen for the Overall Baseline Participants. ITT includes all Subjects, subject to at least one post-randomisation treatment and that provide some data for the primary endpoint.|Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.|An Open, Randomized, Comparative, Multi-centre Investigation Evaluating the Efficacy and Tolerance of Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.|Completed||N/A|162|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 22:08:26.610119|2018-05-31 22:08:26.610119
NCT01439061|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-12-22|2011-09-21|2011-09-22|Estimate|||||||2017-12-22|2017-12-26|Actual|March 31, 2012|Actual|2012-03-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS ITA||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy|"Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Italy"|Completed|||220|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 22:08:26.894546|2018-05-31 22:08:26.894546
NCT01439048|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-08-27|2011-09-21|2011-09-22|Estimate|||||||2015-08-27|2015-08-28|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Placental and Cord Blood Markers Associated With Premature Birth and Disorders of Premature Birth in Newborn Infants|Study of Environmental Toxicants and Inflammatory Markers in Prematurity and Diseases of Prematurity|Completed|||82|Actual|Medical College of Wisconsin|||2||f||||f||||||Samples With DNA|"~     whole blood, placenta~   "|||2018-05-31 22:08:26.969175|2018-05-31 22:08:26.969175
NCT01439035|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-10-27|2011-09-21|2011-09-22|Estimate|||||||2016-10-27|2016-10-31|Estimate|August 2009||2009-08-31|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluate the Use of Optical Frequency Domain Imaging (OFDI) for Celiac Disease in Children, Adolescents and Young Adults|Pilot Study to Evaluate Use of Optical Frequency Domain Imaging (OFDI) for Duodenal Imaging in Celiac Disease in Children, Adolescents and Young Adults|Completed||Phase 1|6|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 22:08:27.044712|2018-05-31 22:08:27.044712
NCT01439022|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-10-20|2011-09-21|2011-09-22|Estimate|||||||2014-10-20|2014-10-21|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Exercise Interventions in Parkinson's Disease|Longer-term Exercise Interventions in People With Parkinson's Disease|Completed||Phase 2|105|Actual|Oxford Brookes University||2|||f||||f||||||||||2018-05-31 22:08:27.141485|2018-05-31 22:08:27.141485
NCT01439009|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-07-09|2011-09-21|2011-09-22|Estimate|||||||2014-07-09|2014-07-11|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients|A Multi-center,_double-blind,_pararel-group Comparison Trial to Investigate the Effect of Short-term Administration of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients (Phase_4 Study)|Completed||Phase 4|105|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:08:27.26524|2018-05-31 22:08:27.26524
NCT01438996|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2013-12-16||2014-02-04|2011-09-21|2011-09-22|Estimate|2014-02-04|2014-03-24|Estimate||||2014-02-04|2014-03-24|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults|A Phase 2, Open-label, Single-center, Extension Study to Evaluate the Booster Response Induced by Vi-CRM197 After Priming With Either Vi-CRM197 or Typherix Administered in Adult Subjects in H01_04TP Study (NCT01193907)|Completed||Phase 2|51|Actual|Novartis||3|||f||||f||||||||||2018-05-31 22:08:27.41402|2018-05-31 22:08:27.41402
NCT01438983|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2011-09-21|2011-09-21|2011-09-22|Estimate|||||||2011-09-21|2011-09-22|Estimate|July 2009||2009-07-31|September 2011|2011-09-30|June 2010|Actual|2010-06-30|||||Observational|||Oral Candida in Infants and Dietary Type|Evaluation the Effect of Dietary Type on Oral Candida Carriage in Infants|Completed|||90|Actual|Shahid Sadoughi University of Medical Sciences and Health Services|||2||f||||t||||||Samples With DNA|"~     infants with unremarkable health histories, normal weight, free of sign or symptom of oral~     candidiasis or other mucosal disease.their mothers were also healthy and without sign or~     symptom of vagina or mammary candidiasis.~   "|||2018-05-31 22:08:27.86629|2018-05-31 22:08:27.86629
NCT01438970|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-08-10|2011-09-21|2011-09-22|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function|Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function in Patients With Cirrhosis and Recurrent or Refractory Ascites|Active, not recruiting||Phase 2|12|Anticipated|Sequana Medical AG||1|||f||||f||||||||||2018-05-31 22:08:27.932462|2018-05-31 22:08:27.932462
NCT01438957|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-03-20|2011-09-21|2011-09-22|Estimate|||||||2017-03-20|2017-03-22|Actual|June 2011||2011-06-30|November 2015|2015-11-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation|Phase III Randomized Placebo-controlled Double Blind Comparative Study to Investigate the Efficacy and Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation Under Monitored Sedation Care|Completed||Phase 3|120|Actual|Hospira, now a wholly owned subsidiary of Pfizer||5|||f||||f||||||||||2018-05-31 22:08:27.998102|2018-05-31 22:08:27.998102
NCT01438944|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-04-07|2011-09-21|2011-09-22|Estimate|||||||2017-04-07|2017-04-10|Actual|July 2011|Actual|2011-07-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction|Evaluation of Nicotine Receptor Up-regulation Activity Through Metabolic Induction and Changes in Responsiveness Using Surrogate Evaluation Methods|Completed||Phase 1|52|Actual|The Queen Elizabeth Hospital||1|||f||||t||||||||Yes|Available upon request|2018-05-31 22:08:28.086743|2018-05-31 22:08:28.086743
NCT01438931|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2015-07-23|2011-09-21|2011-09-22|Estimate|||||||2015-07-23|2015-07-24|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation|Phase III Randomized Placebo-controlled Double Blind Comparative Study to Investigate the Efficacy and Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation Under Monitored Sedation Care|Completed||Phase 3|162|Actual|Hospira, now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-05-31 22:08:28.171292|2018-05-31 22:08:28.171292
NCT01438918|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2012-01-24|2011-09-20|2011-09-22|Estimate|||||||2012-01-24|2012-01-25|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee|A Long-term, Confirmatory, Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Investigate The Safety And Efficacy Of Orally Administered Sd-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee|Withdrawn||Phase 3|0|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:08:28.297312|2018-05-31 22:08:28.297312
NCT01438905|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2018-02-22|2011-09-21|2011-09-22|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2011||2011-09-30|February 2018|2018-02-28|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Effect of Joint Mobilization in the Treatment of Chronic Ankle Instability|Effect of Joint Mobilization on Muscle Activation and Function in Individuals With Chronic Ankle Instability|Completed||N/A|30|Actual|Creighton University||3|||f||||f||||||||||2018-05-31 22:08:28.362934|2018-05-31 22:08:28.362934
NCT01438892|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-04-04|2011-09-20|2011-09-22|Estimate|||||||2013-04-04|2013-04-08|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Impact Of RA Therapy Compliance On Patient-Reported Outcomes|Impact Of RA Therapy Compliance On Patient-Reported Outcomes|Completed|||396|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 22:08:28.430572|2018-05-31 22:08:28.430572
NCT01438879|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-21|2011-09-21|2011-09-22|Estimate|||||||2011-09-21|2011-09-22|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR)|Molecular Methods in the Etiological Diagnostics of Acute Central Nervous System Infections: Lymphocytic Herpesviruses and PCR|Unknown status|Not yet recruiting||60|Anticipated|PaijatHame Central Hospital|||2||f||||f||||||Samples With DNA|"~     CSF white cells + CSF supernatant, Blood white cells and serum~   "|||2018-05-31 22:08:28.491112|2018-05-31 22:08:28.491112
NCT01438866|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2014-03-16|2011-09-21|2011-09-22|Estimate|||||||2014-03-16|2014-03-18|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Use of Fissure Sealants on Primary Molars|The Effectiveness of Sealants in Prevention of Occlusal Caries on Primary Molars|Completed||Phase 4|148|Actual|Kuwait University||1|||f||||f||||||||||2018-05-31 22:08:28.546423|2018-05-31 22:08:28.546423
NCT01438853|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-21|2011-09-21|2011-09-22|Estimate|||||||2011-09-21|2011-09-22|Estimate|December 2004||2004-12-31|September 2011|2011-09-30|February 2008|Actual|2008-02-29|July 2006|Actual|2006-07-31||Interventional|||Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome|The Safety, Pharmacokinetics, and Pharmacodynamic Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome|Completed||Phase 1|18|Actual|Altor BioScience||2|||f||||t||||||||||2018-05-31 22:08:28.633675|2018-05-31 22:08:28.633675
NCT01438840|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2017-12-05|2015-06-29|2018-01-09|2011-09-21|2011-09-22|Estimate|2017-12-05|2018-01-05|Actual|2015-06-29|2015-07-22|Estimate|2018-01-09|2018-02-05|Actual|February 16, 2012|Actual|2012-02-16|January 2018|2018-01-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenia Purpura)|Completed||Phase 3|49|Actual|Eisai Inc.||3|||f||||t||||||||||2018-05-31 22:08:28.826971|2018-05-31 22:08:28.826971
NCT01438827|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-01-20|2011-09-21|2011-09-22|Estimate|||||||2014-01-20|2014-01-22|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Avanz Phleum Pratense Maintenance Dose|Avanz Phleum Pratense Maintenance Dose|Completed||Phase 2/Phase 3|450|Actual|ALK-Abelló A/S||3|||f||||||||||||||2018-05-31 22:08:29.285595|2018-05-31 22:08:29.285595
NCT01438814|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|2014-02-28||2014-11-13|2011-09-21|2011-09-22|Estimate|2014-05-02|2014-06-03|Estimate||||2014-11-13|2014-11-25|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Treated set (TS): all patients treated with at least 1 dose of randomised study medication|Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control|A Randomised, Double-blind, Double-dummy, Active-comparator Controlled Study Investigating the Efficacy and Safety of Linagliptin Co-administered With Metformin QD at Evening Time Versus Metformin BID Over 14 Weeks in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control|Completed||Phase 4|689|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:08:29.400482|2018-05-31 22:08:29.400482
NCT01438801|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2013-12-19|2011-09-21|2011-09-22|Estimate|||||||2013-12-19|2013-12-20|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)|Predictive Value of Baseline and Stimulated Serum IGF-1 and IGFBP-3 During a Dose-escalation IGF-1 Generation Test for the 1 Year Growth Response to Growth Hormone (GH) Therapy in Short Children With Low IGF-1 and a Normal GH Peak in a Provocation Test|Withdrawn||Phase 4|0|Actual|Ipsen||1||Participant enrollment was not feasible|f||||t||||||||||2018-05-31 22:08:29.969621|2018-05-31 22:08:29.969621
NCT01438788|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2016-10-28|2011-09-21|2011-09-22|Estimate|||||||2016-10-28|2016-10-31|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|LPD||Low Protein Diet in Patients With Collagen VI Related Myopathies|Low Protein Diet to Correct Defective Autophagy in Patients With Collagen VI Related Myopathies|Completed||Phase 2|8|Actual|Istituto Ortopedico Rizzoli||1|||f||||f||||||||||2018-05-31 22:08:30.038364|2018-05-31 22:08:30.038364
NCT01438775|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20||2014-04-01|2014-04-01|2011-09-21|2011-09-22|Estimate||||2014-04-01|2014-04-30|Estimate|2014-04-01|2014-04-30|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)|Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart|Completed||Phase 3|192|Actual|Nymox Corporation||1|||f||||f||||||||||2018-05-31 22:08:30.114613|2018-05-31 22:08:30.114613
NCT01438762|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-03-23|2011-09-21|2011-09-22|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Early Intervention for Adolescents With Patellofemoral Pain Syndrome|Early Intervention for Adolescents With Patellofemoral Pain Syndrome - a Cluster Randomized Trial|Completed||N/A|102|Actual|Northern Orthopaedic Division, Denmark||3|||f||||f||||||||||2018-05-31 22:08:30.21276|2018-05-31 22:08:30.21276
NCT01438749|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2016-11-01|2011-09-21|2011-09-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users|Human Abuse Liability Study in Recreational Drug Users to Investigate the Abuse Liability Potential of RO4917838|Completed||Phase 1|177|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:08:30.288677|2018-05-31 22:08:30.288677
NCT01438736|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-21|2011-09-21|2011-09-22|Estimate|||||||2011-09-21|2011-09-22|Estimate|September 2011||2011-09-30|September 2011|2011-09-30||||November 2012|Anticipated|2012-11-30||Interventional|||Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?|A Randomized Study to Evaluate the Predictive Impact of Using Cerazette Progestin Only Pill Before Nexplanon Insertion Regarding Bleeding Pattern|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|VL-Medi Oy||2|||f||||||||||||||2018-05-31 22:08:30.368509|2018-05-31 22:08:30.368509
NCT01438723|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-07-28|2011-09-21|2011-09-22|Estimate|||||||2014-07-28|2014-07-29|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MetCAB||The Metformin in Coronary Artery Bypass Graft (CABG) (MetCAB) Trial|The Metformin in CABG (MetCAB) Trial|Completed||Phase 4|100|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 22:08:30.440793|2018-05-31 22:08:30.440793
NCT01438710|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2015-03-23||2015-09-15|2011-09-20|2011-09-22|Estimate|2015-05-06|2015-05-08|Estimate||||2015-09-15|2015-10-01|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|August 2012|Actual|2012-08-31||Interventional|STRATO|44 patients started on the initial one-week treatment on Prograf and 41 were switched to the one-week LCP-Tacro treatment. 40 patients completed the one-week treatment on LCP-Tacro and continued into the 24-months extended use period.|Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)|Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)|Completed||Phase 3|44|Actual|Veloxis Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:08:30.532633|2018-05-31 22:08:30.532633
NCT01438697|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-01-11|2011-09-20|2011-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SHUTi||An Interactive Internet Intervention for Adults With Insomnia|An Internet Intervention for Insomnia: Efficacy and Dissemination|Completed||Phase 3|303|Actual|University of Virginia||2|||f||||t||||||||No||2018-05-31 22:08:30.753689|2018-05-31 22:08:30.753689
NCT01438684|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2018-02-04|2011-09-21|2011-09-22|Estimate|||||||2018-02-04|2018-02-06|Actual|September 2012||2012-09-30|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|January 2019|Anticipated|2019-01-31||Interventional|RPh-in-CVS||The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study|Phase 1 Study of RPh201 in Patients With Chronic Vegetative or Minimal Conscious State|Suspended||Phase 1|10|Anticipated|Hadassah Medical Organization||2||due to lack of supply of medication and technical problems with the MRI|f||||||||||||||2018-05-31 22:08:30.836676|2018-05-31 22:08:30.836676
NCT01438671|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-09-29|2011-09-21|2011-09-22|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Wii Fit Balance Training Compared to Traditional Balance Training in Patients With SCI/TBI/CVA|Does Wii Fit Balance Training Significantly Improve Standing Balance Compared to Traditional Balance Training and Is Wii Fit Balance Training Preferred Over Traditional Balance Training by Patients With SCI/TBI/CVA?|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||1||Facility where study was taking place closed.|f||||f||||||||No||2018-05-31 22:08:30.898393|2018-05-31 22:08:30.898393
NCT01438658|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2011-09-27|2011-09-21|2011-09-22|Estimate|||||||2011-09-27|2011-09-28|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2040|Anticipated|2040-12-31|December 2040|Anticipated|2040-12-31||Observational|UM||Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma|Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma|Recruiting|||250|Anticipated|Hadassah Medical Organization|||1||f||||f||||||Samples Without DNA|"~     sera from patients~   "|||2018-05-31 22:08:30.963289|2018-05-31 22:08:30.963289
NCT01438645|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-01-16|2011-09-20|2011-09-22|Estimate|||||||2013-01-16|2013-01-17|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy|ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy for Improved Endoscopic Performance and Enhanced Patient Experience|Completed||N/A|250|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 22:08:31.109849|2018-05-31 22:08:31.109849
NCT01438632|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-03-11|2011-09-21|2011-09-22|Estimate|||||||2013-03-11|2013-03-12|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Pharmacology of Insulin Injected With Jet-injection in Diabetes|Pharmacology of Rapid-acting Insulin Injected by Needle-free Jet-injection in Patients With Diabetes|Completed||Phase 4|24|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 22:08:31.200652|2018-05-31 22:08:31.200652
NCT01438619|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2013-01-21|2011-09-21|2011-09-22|Estimate|||||||2013-01-21|2013-01-23|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Research for the Improvement in Measurement Methods and the Effect of Sodium Intake on Cardiovascular Health|Sodium Intake: Research for the Improvement in Measurement Methods and the Effect of Sodium Intake on Cardiovascular Health|Completed|||620|Actual|DongGuk University|||1||f||||f||||||||||2018-05-31 22:08:31.298866|2018-05-31 22:08:31.298866
NCT01438606|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2016-06-13|2011-09-20|2011-09-22|Estimate|||||||2016-06-13|2016-06-14|Estimate|October 2011||2011-10-31|June 2016|2016-06-30||||January 2013|Actual|2013-01-31||Interventional|||Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of VSV-Indiana HIV Gag Vaccine Given Intramuscularly in Healthy, HIV-1-Uninfected Adult Participants|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||10|||f||||t||||||||||2018-05-31 22:08:31.375443|2018-05-31 22:08:31.375443
NCT01438593|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-07-31|2011-09-21|2011-09-22|Estimate|||||||2012-07-31|2012-08-02|Estimate|January 2013||2013-01-31|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of Purified Umbilical Cord Blood CD34+ Stem Cell on Chronic Ischemic Stroke|An Exploratory Clinical Trial to Assess Treatment of Chronic Ischemic Stroke With Brain Transplants of Purified CD34+ Umbilical Cord Blood Stem Cells|Unknown status|Not yet recruiting|Phase 1|6|Anticipated|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 22:08:31.482687|2018-05-31 22:08:31.482687
NCT01438567|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2014-10-13|2011-09-21|2011-09-22|Estimate|||||||2014-10-13|2014-10-15|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy|A Randomised, Double-blind, Double-dummy, Parallel-group Multicenter Study to Demonstrate Improvement in Symptoms of Constipation and Non-inferiority in Analgesic Efficacy in Subjects With Non-malignant or Malignant Pain That Require Around-the-clock Opioid Therapy Taking 50/25 - 80/40 mg Twice Daily as Oxycodone/Naloxone Prolonged Release (OXN PR) Tablets Compared to Subjects Taking 50 - 80 mg Twice Daily Oxycodone Prolonged Release (OxyPR) Tablets Alone|Completed||Phase 3|270|Actual|Mundipharma Research GmbH & Co KG||2|||f||||||||||||||2018-05-31 22:08:31.688945|2018-05-31 22:08:31.688945
NCT01438554|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2017-04-26|2011-09-21|2011-09-22|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2011|Actual|2011-10-31|April 2017|2017-04-30||||April 2016|Actual|2016-04-30||Interventional|||Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma|Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma|Active, not recruiting||Phase 1|111|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-05-31 22:08:31.776583|2018-05-31 22:08:31.776583
NCT01438541|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2016-05-13||2016-08-22|2011-09-21|2011-09-22|Estimate|2016-08-22|2016-10-14|Estimate||||2016-08-22|2016-10-14|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||A Multi-centre Evaluation of the Performance of Window Dressings on Subjects With High Risk Pressure Ulceration|A Multi-centre, Post CE-mark, Open Study to Evaluate the Performance of Thin Self-adherent Dressing Coated With a Soft Silicone Layer on Subjects With High Risk of Category 2 or Above Pressure Ulceration|Completed||Phase 4|29|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 22:08:31.870667|2018-05-31 22:08:31.870667
NCT01438528|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-12-22|2011-09-21|2011-09-22|Estimate|||||||2017-12-22|2017-12-26|Actual|December 31, 2011|Actual|2011-12-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS CHN||Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone Treatment|"Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using easypodTM Electromechanical Device for Growth Hormone Treatment in China"|Completed|||75|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 22:08:32.05084|2018-05-31 22:08:32.05084
NCT01438515|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2017-08-17|2011-09-21|2011-09-22|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2008||2008-08-31|August 2017|2017-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization|Randomized Controlled Trial of Chlorhexidine Gluconate, Intranasal Mupirocin, Rifampin and Doxycycline Versus Chlorhexidine Gluconate and Intranasal Mupirocin Alone for the Eradication of Methicillin-resistant Staphylococcus Aureus Among an Ambulatory Patient Population|Active, not recruiting||N/A|100|Actual|Horizon Health Network||2|||f||||f||||||||||2018-05-31 22:08:32.128017|2018-05-31 22:08:32.128017
NCT01438502|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-11-23|2011-09-21|2011-09-22|Estimate|||||||2013-11-23|2013-11-26|Estimate||||November 2013|2013-11-30||||||||Observational|||"The Effect of Reduced Fluid Load After Cardiac Surgery"|"The Impact of Hypertonic Saline/ Colloids Infusion During Cardio-pulmonary-bypass in Patients Expected Long CPB-time"|Withdrawn|||0|Actual|Haukeland University Hospital|||1|Changes in staff resulted in logistic difficulties to perform the study|f||||t||||||||||2018-05-31 22:08:32.205514|2018-05-31 22:08:32.205514
NCT01438489|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2016-07-05||2016-08-29|2011-09-21|2011-09-22|Estimate|2016-07-05|2016-08-15|Estimate||||2016-08-29|2016-10-07|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Intent-to-treat (ITT) population included all participants who were randomized into the study.|A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus|A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus|Completed||Phase 2|626|Actual|MedImmune LLC||3|||f||||t||||||||||2018-05-31 22:08:32.334702|2018-05-31 22:08:32.334702
NCT01438476|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-10-31|2011-09-21|2011-09-22|Estimate|||||||2017-10-31|2017-11-06|Actual|January 26, 2012|Actual|2012-01-26|October 2017|2017-10-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|||Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas|Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection|Completed||Phase 3|178|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:08:33.499249|2018-05-31 22:08:33.499249
NCT01438463|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-05-28|2011-09-21|2011-09-22|Estimate|||||||2013-05-28|2013-05-29|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis|Completed||Phase 2|290|Actual|HAL Allergy||5|||f||||t||||||||||2018-05-31 22:08:33.574115|2018-05-31 22:08:33.574115
NCT01438450|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2012-07-12|2011-09-21|2011-09-22|Estimate|||||||2012-07-12|2012-07-13|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|September 2014|Anticipated|2014-09-30|August 2013|Anticipated|2013-08-31||Interventional|OTCHCC||Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma|RCT Of Oral Thalidomide And Capecitabine Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma (BCLC D)|Unknown status|Recruiting|Phase 2/Phase 3|74|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-05-31 22:08:33.673217|2018-05-31 22:08:33.673217
NCT01438437|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2012-07-12|2011-09-21|2011-09-22|Estimate|||||||2012-07-12|2012-07-13|Estimate|March 2001||2001-03-31|July 2012|2012-07-31|September 2015|Anticipated|2015-09-30|August 2014|Anticipated|2014-08-31||Interventional|||Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis||Unknown status|Recruiting|Phase 4|54|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-05-31 22:08:34.634969|2018-05-31 22:08:34.634969
NCT01438424|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2012-06-12||2012-07-19|2011-09-21|2011-09-22|Estimate|2012-07-19|2012-08-23|Estimate||||2012-07-19|2012-08-23|Estimate|January 2001||2001-01-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|December 2009|Actual|2009-12-31||Interventional|||Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials|A Preliminary Assessment of Safety and Antiviral Activity of Open-label Entecavir in Subjects With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials|Completed||Phase 2|1053|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 22:08:34.85149|2018-05-31 22:08:34.85149
NCT01438411|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-08-15|2011-09-21|2011-09-22|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis|An Open Label, Single Center, Nonrandomized Continuation Study of Cholic Acid Capsules to Treat Subjects With Inborn Errors of Bile Acid Synthesis|Completed||Phase 3|53|Actual|Retrophin, Inc.||1|||f||||f||||||||||2018-05-31 22:08:37.772904|2018-05-31 22:08:37.772904
NCT01438398|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2017-05-09|2011-09-20|2011-09-22|Estimate|||||||2017-05-09|2017-05-11|Actual|April 8, 2011|Actual|2011-04-08|May 2017|2017-05-31|October 22, 2015|Actual|2015-10-22|January 6, 2015|Actual|2015-01-06||Interventional|||Efficacy & Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) in the Treatment of Patients With Achalasia|A Prospective, Single Center, Proof of Concept Pilot Study of the Efficacy and Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) Technique in the Treatment of Patients With Achalasia|Completed||N/A|120|Actual|Winthrop University Hospital||1|||f||||t||||||||||2018-05-31 22:08:37.847087|2018-05-31 22:08:37.847087
NCT01438385|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-02-16|2011-09-21|2011-09-22|Estimate|||||||2017-02-16|2017-02-20|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders|Endoscopic Retrograde Cholangiopancreatography, Endoscopic Ultrasound and Interventional Endoscopy in Pancreatico-biliary, Gastrointestinal and Esophageal Disorders|Recruiting|||12000|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD Sharing|2018-05-31 22:08:37.922317|2018-05-31 22:08:37.922317
NCT01438372|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-01-04|2011-09-20|2011-09-22|Estimate|||||||2014-01-04|2014-01-07|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Interventional|||IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD|Intravenous Iron Sucrose Versus Oral Ferrous Sulfate in Treating Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease|Withdrawn||Phase 2|0|Actual|Wayne State University||2||"The study was terminated prior to enrolling patients as we were unable to secure enough funding~   to complete the study."|f||||t||||||||||2018-05-31 22:08:38.003913|2018-05-31 22:08:38.003913
NCT01438359|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2011-09-29|2011-09-21|2011-09-22|Estimate|||||||2011-09-29|2011-09-30|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Drug-Drug Interaction Study of Furosemide and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Furosemide in Healthy Male and Female Adults|Completed||Phase 1|42|Anticipated|Vifor Inc.||3|||f||||f||||||||||2018-05-31 22:08:38.098516|2018-05-31 22:08:38.098516
NCT01438346|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2016-12-01|2011-09-20|2011-09-22|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Behavioral Treatment for Substance Abuse|A Pilot Study of Two Group-based Intervention Programs for Patients With Substance Abuse Problems|Completed||N/A|38|Actual|University of Utah||2|||f||||f||||||||No||2018-05-31 22:08:38.166016|2018-05-31 22:08:38.166016
NCT01438333|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-06-16|2011-09-20|2011-09-22|Estimate|||||||2015-06-16|2015-06-17|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection|Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection: a Randomized, Double Masked, Placebo Controlled Clinical Trial|Completed||N/A|15|Actual|University of L'Aquila||2|||f||||t||||||||||2018-05-31 22:08:38.236873|2018-05-31 22:08:38.236873
NCT01438320|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-03-18|2011-09-20|2011-09-22|Estimate|||||||2015-03-18|2015-03-20|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Q||Q-Trial in Patients With Hepatitis C|A Phase 1 Study of Quercetin in Patients With Hepatitis C|Completed||Phase 1|34|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 22:08:38.387559|2018-05-31 22:08:38.387559
NCT01438307|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2017-03-03||2017-04-24|2011-09-20|2011-09-22|Estimate|2017-04-24|2017-05-24|Actual||||2017-04-24|2017-05-24|Actual|September 2011||2011-09-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer|Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients|Completed||Phase 2|28|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 22:08:38.474508|2018-05-31 22:08:38.474508
NCT01438294|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|2014-07-05||2014-10-05|2011-09-21|2011-09-22|Estimate|2014-10-05|2014-10-10|Estimate||||2014-10-05|2014-10-10|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Exercise Training in Asthma Children|Effects of Exercise Training on Markers of Lung Inflammation and Clinical Crontrol in Asthma Children|Completed||N/A|36|Actual|Hospital Sirio-Libanes||2|||f||||f||||||||||2018-05-31 22:08:38.761747|2018-05-31 22:08:38.761747
NCT01438281|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2012-07-16|2011-09-21|2011-09-22|Estimate|||||||2012-07-16|2012-07-17|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers|Phase I Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers|Completed||Phase 1|30|Actual|Sylentis, S.A.||1|||f||||f||||||||||2018-05-31 22:08:39.024034|2018-05-31 22:08:39.024034
NCT01438268|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-11-15|2011-09-20|2011-09-22|Estimate|||||||2013-11-15|2013-11-19|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|January 2014|Anticipated|2014-01-31|August 2013|Actual|2013-08-31||Observational|TRAM||TRAM Procedure in Ambulatory Surgical Facility: Quality of Recovery Outcomes|Expedited Discharge of Patients Undergoing Pedicled TRAM Flap Breast Reconstruction Procedure in Ambulatory Surgical Facility: Quality of Recovery Outcomes|Unknown status|Active, not recruiting||60|Anticipated|Women's College Hospital|||1||f||||f||||||||||2018-05-31 22:08:39.083659|2018-05-31 22:08:39.083659
NCT01438255|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-08-21|2011-09-20|2011-09-22|Estimate|||||||2012-08-21|2012-08-23|Estimate|July 2010||2010-07-31|August 2012|2012-08-31||||July 2012|Actual|2012-07-31||Observational|||Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice||Completed|||274|Actual|Handok Pharmaceuticals Co., Ltd.|||1||f||||f||||||||||2018-05-31 22:08:39.143882|2018-05-31 22:08:39.143882
NCT01438242|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2015-03-20|2011-09-21|2011-09-22|Estimate|||||||2015-03-20|2015-03-23|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||An Open Label Study of the Genecept™ Assay in Treatment Resistant Depression|An Open Label Study of the Genecept™ Assay to Evaluate Efficacy of Using Assay Guided Treatment in Outpatient Adults With Treatment Resistant Depression|Withdrawn||N/A|0|Actual|Genomind, LLC||2|||f||||f||||||||||2018-05-31 22:08:39.202198|2018-05-31 22:08:39.202198
NCT01438229|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2015-04-17||2015-05-24|2011-09-21|2011-09-22|Estimate|2015-05-05|2015-05-21|Estimate||||2015-05-24|2015-06-19|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|July 2014|Actual|2014-07-31|September 2012|Actual|2012-09-30||Interventional|EnligHTN-I|Subjects completing renal artery ablation procedure|Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients|Ablation-induced Renal Sympathetic Denervation Trial|Completed||N/A|47|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 22:08:39.289995|2018-05-31 22:08:39.289995
NCT01438216|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2011-09-19|2011-09-19|2011-09-22|Estimate|||||||2011-09-19|2011-09-22|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Observational|ANICK||Anidulafungin Pharmacokinetics in Intensive Care Unit Patients|Anidulafungin Population Kinetics in the Intensive Care Population|Unknown status|Recruiting||20|Anticipated|VU University Medical Center|||2||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 22:08:39.923092|2018-05-31 22:08:39.923092
NCT01438203|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-08-31|2011-09-20|2011-09-22|Estimate|||||||2012-08-31|2012-09-05|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Thrust Manipulation Versus Non-Thrust Manipulation|Early Use of Thrust Manipulation Versus Non-Thrust Manipulation: A Randomized Clinical Trial|Completed||Phase 2|149|Actual|Walsh University||2|||f||||f||||||||||2018-05-31 22:08:40.082179|2018-05-31 22:08:40.082179
NCT01438190|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-07-11|2011-09-20|2011-09-22|Estimate|||||||2013-07-11|2013-07-12|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF|A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|University of Modena and Reggio Emilia||2|||f||||f||||||||||2018-05-31 22:08:40.154729|2018-05-31 22:08:40.154729
NCT01438177|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2015-05-14||2018-02-14|2011-09-20|2011-09-21|Estimate|2015-05-14|2015-06-01|Estimate||||2018-02-14|2018-03-13|Actual|October 2011||2011-10-31|February 2018|2018-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma|A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma|Terminated||Phase 2|11|Actual|New York University School of Medicine||1||PI left institution.|f||||t||||||||||2018-05-31 22:08:40.237772|2018-05-31 22:08:40.237772
NCT01438164|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-09-20|2011-09-20|2011-09-21|Estimate|||||||2011-09-20|2011-09-21|Estimate|June 2005||2005-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Observational|||Cost-effectiveness of FDG-PET|Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET|Completed|||500|Actual|University of Sao Paulo|||1||f||||f||||||||||2018-05-31 22:08:40.520216|2018-05-31 22:08:40.520216
NCT01438151|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2014-01-06||2014-03-04|2011-09-20|2011-09-21|Estimate|2014-03-04|2014-04-09|Estimate||||2014-03-04|2014-04-09|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease|Association of Serum Infliximab and Antibodies Toward Infliximab (ATI) to Clinical Outcomes in Crohn's Disease|Terminated||N/A|11|Actual|Icahn School of Medicine at Mount Sinai|Study was terminated without completion due to poor enrollment.|1||terminated due to poor enrollment|f||||f||||||||||2018-05-31 22:08:40.575356|2018-05-31 22:08:40.575356
NCT01438138|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2016-05-16|2011-09-17|2011-09-21|Estimate|||||||2016-05-16|2016-05-18|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia|Validation of a Classifier for the Prediction of Risk of Relapse Using Single Cell Network Profiling (SCNP) Assays for Childhood AML|Completed|||98|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     bone marrow~   "|||2018-05-31 22:08:40.718008|2018-05-31 22:08:40.718008
NCT01438125|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-03-28|2011-09-20|2011-09-21|Estimate|||||||2013-03-28|2013-03-29|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures|A Pilot Study to Evaluate the Safety and Preliminary Efficacy of MF-4181 for the Reduction of Scars Secondary to Abdominoplasty or Laparoscopy/Laparotomy Gynecologic Procedures|Completed||Phase 2|100|Actual|Halscion, Inc.||2|||f||||f||||||||||2018-05-31 22:08:40.788833|2018-05-31 22:08:40.788833
NCT01438112|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2016-07-27|2011-09-20|2011-09-21|Estimate|||||||2016-07-27|2016-07-28|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|BOND||Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer|An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ Disease Who Have Failed BCG|Terminated||Phase 2/Phase 3|22|Actual|Cold Genesys, Inc.||2||Change in study design|f||||t||||||||||2018-05-31 22:08:40.853694|2018-05-31 22:08:40.853694
NCT01438099|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-08-23|2011-09-20|2011-09-21|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Reliability of Ultrasound Assisted Epidural Analgesia in Obese and Normal Weight Parturients|Reliability of Ultrasound Assisted Epidural Analgesia in Obese and Normal Weight Parturients|Completed|||300|Actual|Università degli Studi dell'Insubria|||2||f||||t||||||||||2018-05-31 22:08:40.945363|2018-05-31 22:08:40.945363
NCT01438086|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2017-03-28|2011-09-20|2011-09-21|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2011|Actual|2011-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|RESUS-AMI||Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack|A Randomised Trial Evaluating the Safety and Efficacy of a Single Low Dose of Intracoronary Insulin-like Growth Factor-1 Following Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction (RESUS-AMI)|Completed||Phase 1/Phase 2|47|Actual|University College Cork||3|||f||||t||||||||||2018-05-31 22:08:40.99895|2018-05-31 22:08:40.99895
NCT01438073|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2018-04-18|2011-09-20|2011-09-21|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2011|Actual|2011-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling|Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling|Recruiting||Phase 1|411|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:08:41.093604|2018-05-31 22:08:41.093604
NCT01438060|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2012-02-01||2013-11-07|2011-09-20|2011-09-21|Estimate|2012-02-01|2012-03-05|Estimate||||2013-11-07|2013-12-02|Estimate|August 2000||2000-08-31|November 2013|2013-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type|A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type|Completed||Phase 3|232|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|Limitations of the study, such as early termination leading to small numbers of subjects analyzed and technical problems with measurement leading to unreliable or uninterpretable data|2|||f||||f||||||||||2018-05-31 22:08:41.254688|2018-05-31 22:08:41.254688
NCT01438047|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2014-04-03|2011-09-20|2011-09-21|Estimate|||||||2014-04-03|2014-04-04|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Optical Frequency Domain Imaging (OFDI) in Dermatology|OFDI in Dermatology|Withdrawn|||0|Actual|Massachusetts General Hospital||||"The study was closed due to a shift in research priorities and a lack of resources available~   for the project."|f||||f||||||||||2018-05-31 22:08:43.267316|2018-05-31 22:08:43.267316
NCT01438034|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2018-02-20|2011-09-20|2011-09-21|Estimate|||||||2018-02-20|2018-02-22|Actual|November 2011||2011-11-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Kisspeptin in the Evaluation of Delayed Puberty|Kisspeptin in the Evaluation of Delayed Puberty|Recruiting||Phase 1|100|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:08:43.321223|2018-05-31 22:08:43.321223
NCT01438021|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-11-08|2011-09-19|2011-09-21|Estimate|||||||2012-11-08|2012-11-09|Estimate|September 2012||2012-09-30|November 2012|2012-11-30||||November 2013|Anticipated|2013-11-30||Interventional|||Continuous Intraventricular Methotrexate in Treating Patients With Leptomeningeal Disease|Characterization of the Pharmacokinetics and Efficacy of Intraventricular Methotrexate Continuously Delivered Via a Mini Pump for Treatment of Leptomeningeal Disease|Withdrawn||N/A|0|Actual|City of Hope Medical Center||1||Lack of funding|f||||t||||||||||2018-05-31 22:08:43.385719|2018-05-31 22:08:43.385719
NCT01438008|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2017-08-04|2011-09-20|2011-09-21|Estimate|||||||2017-08-04|2017-08-07|Actual|May 2012|Actual|2012-05-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pilot Study of Sucrose to Reduce Pain in Sick Babies|Be Sweet to Sick Babies: Analgesic Effects of Oral Sucrose and Concomitant Opioid Analgesics; a Pilot Randomized Controlled Trial|Terminated||Phase 4|9|Actual|Children's Hospital of Eastern Ontario||2||Feasibility of study at single site; changes in clinical practice in opioid use|f||||t||||||||||2018-05-31 22:08:43.575018|2018-05-31 22:08:43.575018
NCT01437995|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|2016-10-07||2017-03-14|2011-09-20|2011-09-21|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|March 2012||2012-03-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|LASST||Long-acting Beta Agonist Step Down Study|Long-acting Beta Agonist Step Down Study|Completed||Phase 4|459|Actual|Johns Hopkins University|At the time of this release, this data has not undergone peer-review.|3|||f||||t||||||||||2018-05-31 22:08:43.694977|2018-05-31 22:08:43.694977
NCT01437982|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2017-02-08|2011-09-20|2011-09-21|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2013|Actual|2013-02-28|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%|A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%|Active, not recruiting||Phase 4|140|Anticipated|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:08:44.617827|2018-05-31 22:08:44.617827
NCT01437969|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2012-04-14|2011-09-20|2011-09-21|Estimate|||||||2012-04-14|2012-04-17|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.|Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Chronic Infection naïve to Antiviral Treatment.|Unknown status|Recruiting||500|Anticipated|Casa Sollievo della Sofferenza IRCCS|||||f||||||||||Samples With DNA|"~     DNA from blood sample~   "|||2018-05-31 22:08:44.713031|2018-05-31 22:08:44.713031
NCT01437956|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2011-09-20|2011-09-20|2011-09-21|Estimate|||||||2011-09-20|2011-09-21|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|October 2016|Anticipated|2016-10-31|May 2016|Anticipated|2016-05-31||Observational|||KL-6 Protein as a Biomarker of Lung Injury in Viral Bronchiolitis|Acute Bronchiolitis in Infants: Analysis of a Biomarker of Epithelial Lung Injury - Clinical and Virological Correlation|Unknown status|Not yet recruiting||200|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:08:44.787537|2018-05-31 22:08:44.787537
NCT01437943|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2017-01-15||2017-03-21|2011-09-20|2011-09-21|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|April 2010||2010-04-30|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients|P-MR Spectroscopy Evaluation of the Effect of Short-Term Treatment With Aliskiren on Kidney β-ATP/Pi Level in Kidney Transplant Patients|Terminated||Phase 4|10|Actual|Brigham and Women's Hospital|In December 2011, all studies involving Aliskiren were terminated by Novartis after interim analysis of the ALTITUDE trial.|2||"Novartis has have decided to terminate all clinical investigator-initiated research projects~   involving aliskiren"|f||||f||||||||||2018-05-31 22:08:44.846801|2018-05-31 22:08:44.846801
NCT01437930|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2014-07-28|2011-09-20|2011-09-21|Estimate|||||||2014-07-28|2014-07-29|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients|Influence of Intervention With n-3 PUFA-supplemented Products in Moderate Hypertriglyceridemic Patients on Cardiovascular Risk Factors|Completed||N/A|60|Actual|University of Jena||1|||f||||t||||||||||2018-05-31 22:08:45.100012|2018-05-31 22:08:45.100012
NCT01437917|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2012-05-15|2011-09-20|2011-09-21|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|NOMAC||NOMAC : New Tools for Managing the Fate of Cereal Nutrients in the Gut : Effects of Amylose Content on Glycemic Index.|NOMAC : New Tools for Managing the Fate of Cereal Nutrients in the Gut : Effects of Amylose Content on Glycemic Index.|Completed||N/A|10|Actual|Rennes University Hospital||3|||f||||f||||||||||2018-05-31 22:08:45.205953|2018-05-31 22:08:45.205953
NCT01437904|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2013-11-05|2011-09-20|2011-09-21|Estimate|||||||2013-11-05|2013-11-06|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||A Pilot Study Assessing The Feasibility Of Outpatient Tubeless Percutaneous Nephrolithotomy (PCNL)|A Pilot Study Assessing The Feasibility Of Outpatient Tubeless Percutaneous Nephrolithotomy (PCNL)|Completed||N/A|10|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 22:08:45.315729|2018-05-31 22:08:45.315729
NCT01437891|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2012-02-02|2011-09-20|2011-09-21|Estimate|||||||2012-02-02|2012-02-06|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|GWF001||Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)|An Open-label Clinical Outcomes Study to Determine the Safety and Efficacy of Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder and Gulf War Fibromyalgia|Completed|||30|Actual|Targeted Medical Pharma|||||f||||f||||||||||2018-05-31 22:08:45.436008|2018-05-31 22:08:45.436008
NCT01437878|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|2014-12-12||2015-10-16|2011-09-20|2011-09-21|Estimate|2015-01-02|2015-01-06|Estimate||||2015-10-16|2015-11-20|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Inhaled Iloprost on Endurance Time During Cardiopulmonary Exercise Testing in Patients With Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease|Terminated||Phase 2|2|Actual|Actelion||2||low recruitment|f||||f||||||||||2018-05-31 22:08:45.712854|2018-05-31 22:08:45.712854
NCT01437865|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2012-04-05|2011-09-20|2011-09-21|Estimate|||||||2012-04-05|2012-04-06|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Gadofosveset for Axillary Staging in Breast Cancer Patients|Non-invasive Nodal Staging in Breast Cancer With MRI Lymphography Using Gadofosveset; a Pilot-study|Completed||N/A|10|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 22:08:47.08166|2018-05-31 22:08:47.08166
NCT01437852|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2016-05-23|2011-09-20|2011-09-21|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|October 2014|Actual|2014-10-31|January 2014|Actual|2014-01-31||Interventional|||StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns|An Open-Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety and Efficacy of StrataGraft® Skin Tissue in Promoting the Healing of the Deep Partial-Thickness Component of Complex Skin Defects as an Alternative to Autografting|Completed||Phase 1|30|Actual|Stratatech, a Mallinckrodt Company||1|||f||||t||||||||||2018-05-31 22:08:47.3112|2018-05-31 22:08:47.3112
NCT01437839|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2011-10-21|2011-09-20|2011-09-21|Estimate|||||||2011-10-21|2011-10-25|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Food Effect Study For Apixaban Commercial Image Tablets|An Open Label, Randomized, 2-period Crossover Study Evaluating Single Dose Food Effect On Apixaban Commercial Image Tablets In Healthy Subjects|Completed||Phase 1|22|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:08:47.504616|2018-05-31 22:08:47.504616
NCT01437826|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2011-09-19|2011-09-19|2011-09-21|Estimate|||||||2011-09-19|2011-09-21|Estimate|March 1988||1988-03-31|September 2011|2011-09-30|June 1996|Actual|1996-06-30|June 1996|Actual|1996-06-30||Interventional|||Antioxidant Supplement and Reduction of Metachronous Adenomas of the Large Bowel: a Double Blind Randomized Trial|Evaluation of the Efficacy of a Combination of Micronutrients (Vitamin A, C, E, Selenium and Zinc) in Reducing the Incidence of Colorectal Metachronous Adenomas. A Double Blind, Phase III, Randomized, Placebo-controlled Trial|Terminated||Phase 3|411|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2||50% of eligible patients refused to enter the study|f||||f||||||||||2018-05-31 22:08:47.695405|2018-05-31 22:08:47.695405
NCT01437813|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-09-20|2011-09-20|2011-09-21|Estimate|||||||2011-09-20|2011-09-21|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|GLMT13||BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet Study|Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) After a High Fat Diet, in Healthy Mexican Volunteers|Completed||Phase 1|24|Actual|Laboratorios Silanes S.A. de C.V.|||||f||||t||||||||||2018-05-31 22:08:48.089131|2018-05-31 22:08:48.089131
NCT01437800|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-09-20|2011-09-20|2011-09-21|Estimate|||||||2011-09-20|2011-09-21|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|GLMT12-SIL||BIOAVAILABILITY OF GLI/METXR (4/850 mg)|Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) in Healthy Mexican Volunteers|Completed||Phase 1|24|Actual|Laboratorios Silanes S.A. de C.V.|||||f||||t||||||||||2018-05-31 22:08:48.176854|2018-05-31 22:08:48.176854
NCT01437787|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16||2015-12-08|2015-12-08|2011-09-20|2011-09-21|Estimate||||2015-12-08|2016-01-08|Estimate|2015-12-08|2016-01-08|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|JAKARTA||Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly|Completed||Phase 3|289|Actual|Sanofi||3|||f||||||||||||||2018-05-31 22:08:49.432825|2018-05-31 22:08:49.432825
NCT01437774|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-09-04|2011-09-20|2011-09-21|Estimate|||||||2012-09-04|2012-09-06|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||ReStore Thrombectomy Trial for Flow Restoration in Acute Ischemic Stroke Patients|Prospective Mult-center Randomized Study of the Reverse Medial ReStore Device for Flow Restoration in Arteries of Patients Experiencing Acute Ischemic Stroke|Suspended||N/A|210|Anticipated|Reverse Medical Corporation||2||DSMB recommendation to suspend trial due to control device|f||||t||||||||||2018-05-31 22:08:49.739837|2018-05-31 22:08:49.739837
NCT01437761|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-04-10|2011-09-20|2011-09-21|Estimate|||||||2017-04-10|2017-04-12|Actual|August 2011||2011-08-31|April 2017|2017-04-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Observational|Sorb2||Sorbent Treatment Prescriptions Pilot Study|Hemodialysis With the 2008 Sorbent System: A Pilot Evaluation of Different Treatment Prescriptions|Terminated|||12|Actual|Renal Research Institute|||1|Change of Institutional Affliation & Funding Changes|f||||t|f|||||||No||2018-05-31 22:08:49.864024|2018-05-31 22:08:49.864024
NCT01437748|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2014-10-28|2011-09-20|2011-09-21|Estimate|||||||2014-10-28|2014-10-29|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Closing Volume Interpretation and Bronchodilators Effect|Small Airways Evaluation and Peripherical Effect of Two Bronchodilators in Healthy Subjects and Stable COPD Patients|Completed||Phase 4|40|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 22:08:50.229831|2018-05-31 22:08:50.229831
NCT01437735|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14||2016-03-03|2016-03-03|2011-09-20|2011-09-21|Estimate||||2016-03-03|2016-04-01|Estimate|2016-03-03|2016-04-01|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Dose Finding Study for QAW039 in Asthma|A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.|Completed||Phase 2|1043|Actual|Novartis||15|||f||||f||||||||||2018-05-31 22:08:53.693199|2018-05-31 22:08:53.693199
NCT01437722|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20||2012-10-17|2013-10-27|2011-09-20|2011-09-21|Estimate||||2012-10-19|2012-10-25|Estimate|2013-10-27|2013-11-20|Estimate|August 2011||2011-08-31|October 2013|2013-10-31||||December 2012|Actual|2012-12-31||Interventional|||Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)|A Double-blind, Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel®) Administered Vaginally to Prevent the Recurrence of Bacterial Vaginosis|Completed||Phase 2|205|Actual|Starpharma Pty Ltd||3|||f||||||||||||||2018-05-31 22:08:54.863584|2018-05-31 22:08:54.863584
NCT01437709|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-11-29|2011-09-19|2011-09-21|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2011||2011-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant|Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant|Active, not recruiting||Phase 2|30|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 22:08:54.981466|2018-05-31 22:08:54.981466
NCT01437696|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-09-04|2011-09-19|2011-09-21|Estimate|||||||2014-09-04|2014-09-05|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||How Much Vitamin D is Required to be Protective Against Deficiency During the Winter Months?|How Much Vitamin D is Required to be Protective Against Deficiency During the Winter Months? - An Investigation in Veterans Living at Ste-Anne's Hospital|Completed||Phase 4|77|Actual|McGill University||3|||f||||f||||||||||2018-05-31 22:08:55.071633|2018-05-31 22:08:55.071633
NCT01437683|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2012-10-12|2011-09-20|2011-09-21|Estimate|||||||2012-10-12|2012-10-15|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|June 2012|Actual|2012-06-30|October 2011|Actual|2011-10-31||Observational|PariS-TBI||PariS-TBI Study : Paris Severe Traumatic Brain Injury Study|Four Year Outcome After Severe Traumatic Brain Injury in the Parisian Area|Completed|||252|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||||||2018-05-31 22:08:55.194152|2018-05-31 22:08:55.194152
NCT01437670|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2014-05-28|2011-09-20|2011-09-21|Estimate|||||||2014-05-28|2014-05-30|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Observational|OAB||Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin|A Prospective, Multicenter, Observation Study to Estimate the Dry Mouth in OAB Patients With Solifenacin|Completed|||262|Actual|Asan Medical Center|||1||f||||t||||||||||2018-05-31 22:08:55.295162|2018-05-31 22:08:55.295162
NCT01437657|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20||2016-07-06|2016-11-01|2011-09-20|2011-09-21|Estimate||||2016-07-06|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy|A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment|Completed||Phase 2|319|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:08:55.443468|2018-05-31 22:08:55.443468
NCT01437644|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2015-04-30|2011-09-20|2011-09-21|Estimate|||||||2015-04-30|2015-05-01|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|POPPIES||The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial|Post-operative Pain in Children With Cerebral Palsy Following Major Hip Surgery: a Double Blind Randomised Placebo Controlled Trial of Pre-operative Botulinum Toxin Type A|Completed||Phase 3|54|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:08:55.634221|2018-05-31 22:08:55.634221
NCT01437631|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2016-07-11|2011-09-20|2011-09-21|Estimate|||||||2016-07-11|2016-07-13|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||EFficacy of Prophylactic Clip Application in Decrease of Immediate Postpolypectomy Bleeding and Delayed Postpolypectomy Bleeding After Colonoscopic Removal for a Large Pedunculated Polyps|Does a Prophylactic Clip Application Decrease IPPB(Immediate Postpolypectomy Bleeding) and DPPB(Delayed Postpolypectomy Bleeding) After Colonoscopic Removal for a Large Pedunculated Polyps (>1cm)?|Recruiting||N/A|384|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 22:08:55.830749|2018-05-31 22:08:55.830749
NCT01437618|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-09-20|2011-09-20|2011-09-21|Estimate|||||||2011-09-20|2011-09-21|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|May 2011|Actual|2011-05-31|||||Observational|||First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer|FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation|Completed|||15|Actual|Azienda Ospedaliero, Universitaria Pisana|||1||f||||||||||||||2018-05-31 22:08:55.967351|2018-05-31 22:08:55.967351
NCT01437605|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2018-05-10|2011-09-19|2011-09-21|Estimate|||||||2018-05-10|2018-05-11|Actual|October 11, 2011|Actual|2011-10-11|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC|A Randomized Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC in Patients With Resected MAGE-A3 Positive, Stage IV Melanoma|Active, not recruiting||Phase 2|14|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-05-31 22:08:56.074419|2018-05-31 22:08:56.074419
NCT01437592|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-09-24|2011-09-20|2011-09-21|Estimate|||||||2015-09-24|2015-09-28|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects|A Trial Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 22:08:56.165775|2018-05-31 22:08:56.165775
NCT01437579|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2011-09-20|2011-09-20|2011-09-21|Estimate|||||||2011-09-20|2011-09-21|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions|Randomized Controlled Trial for Efficacy of Botulinum Toxin Type A in Treatment of Patients Suffering Bladder Pain Syndrome/Interstitial Cystitis With Hunners' Lesions|Unknown status|Recruiting|Phase 2|60|Anticipated|Moscow State University of Medicine and Dentistry||2|||f||||f||||||||||2018-05-31 22:08:56.333437|2018-05-31 22:08:56.333437
NCT01437566|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-11-01|2011-09-19|2011-09-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy|A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy|Completed||Phase 2|318|Actual|Genentech, Inc.||5|||f||||||||||||||2018-05-31 22:08:56.457835|2018-05-31 22:08:56.457835
NCT01437553|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2016-06-29|2011-09-20|2011-09-21|Estimate|||||||2016-06-29|2016-07-01|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|iWONDER||Imaging Whole Coronary Artery With Intravascular Ultrasound (Ivus) And Imap For Plaque Tissue Composition In Patients With Acute Myocardial Infarction|Registry Using IVUS and iMAP to Evaluate Atherosclerotic Coronary Plaque in Acute Coronary Syndromes|Completed||N/A|100|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 22:08:56.734976|2018-05-31 22:08:56.734976
NCT01437540|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2016-12-19|2013-04-05|2017-04-03|2011-09-20|2011-09-21|Estimate|2017-04-03|2017-05-11|Actual|2013-04-05|2013-04-11|Estimate|2017-04-03|2017-05-11|Actual|September 19, 2011|Actual|2011-09-19|March 2017|2017-03-31|April 30, 2013|Actual|2013-04-30|March 31, 2013|Actual|2013-03-31||Interventional|||Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|590|Actual|AstraZeneca|The objective of the study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol fixed-dose combination (FDC) Therefore there were were no primary and secondary efficacy assessments|2|||f||||t||||||||||2018-05-31 22:08:56.831224|2018-05-31 22:08:56.831224
NCT01437527|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-20|||2016-02-11|2011-09-20|2011-09-21|Estimate|||||||2016-02-11|2016-02-12|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PIPA||Body Image Therapy in Anorexia Nervosa|Body Image Therapy in Anorexia Nervosa|Completed||N/A|100|Actual|Centre Hospitalier St Anne||2|||f||||f||||||||||2018-05-31 22:08:57.872975|2018-05-31 22:08:57.872975
NCT01437514|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2016-10-08|2011-09-20|2011-09-21|Estimate|||||||2016-10-08|2016-10-11|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|December 2015|Actual|2015-12-31||Interventional|||Effective Study of Preoperative Short-course Radiotherapy for the Advanced Resectable Rectal Cancer|the Effect of the Preoperative Short-course Radiotherapy for the cT3/cN+ Mid-lower Rectal Cancer: a Prospective Randomized Study|Terminated||Phase 2/Phase 3|410|Actual|West China Hospital||4|||f||||t||||||||||2018-05-31 22:08:58.004994|2018-05-31 22:08:58.004994
NCT01437501|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2013-05-02||2018-01-04|2011-09-20|2011-09-21|Estimate|2013-09-19|2013-09-23|Estimate||||2018-01-04|2018-01-30|Actual|October 2011||2011-10-31|January 2018|2018-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Broccoli Sprout Intervention in Qidong, P.R. China|Broccoli Sprout Intervention in Qidong, P.R. China|Completed||Phase 2|291|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 22:08:58.151322|2018-05-31 22:08:58.151322
NCT01437488|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2017-06-05||2017-10-18|2011-09-19|2011-09-21|Estimate|2017-07-11|2017-08-09|Actual||||2017-10-18|2017-11-21|Actual|February 16, 2012|Actual|2012-02-16|October 2017|2017-10-31|March 30, 2017|Actual|2017-03-30|August 4, 2014|Actual|2014-08-04||Interventional|||Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy|A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy|Completed||Phase 2|14|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 22:08:58.562071|2018-05-31 22:08:58.562071
NCT01437475|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-10-05|2011-09-19|2011-09-21|Estimate|||||||2011-10-05|2011-10-06|Estimate|November 2011||2011-11-30|October 2011|2011-10-31|November 2013|Anticipated|2013-11-30|March 2013|Anticipated|2013-03-31||Interventional|||Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients|Efficiency of the Novel Hepatitis B Vaccine Sci-B-Vac in HIV Positive Patients, a Prospective Cohort Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 22:08:58.845091|2018-05-31 22:08:58.845091
NCT01437462|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-04-09|2011-09-19|2011-09-21|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Sevoflurane, Propofol, Postoperative Pain|Postoperative Pain After Propofol Sevoflurane Anaesthesia: a Prospective, Randomized, Single-blinded Trial|Completed||Phase 4|168|Actual|Tampere University Hospital|||||f||||f||||||||||2018-05-31 22:08:58.906935|2018-05-31 22:08:58.906935
NCT01437449|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2018-05-21|2011-09-19|2011-09-20|Estimate|||||||2018-05-21|2018-05-23|Actual|October 2011||2011-10-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With SCCHN|Active, not recruiting||Phase 2|27|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 22:08:58.967099|2018-05-31 22:08:58.967099
NCT01437436|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-09-21|2011-09-19|2011-09-20|Estimate|||||||2011-09-21|2011-09-23|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||The Effect of Obesity on Ventilation Tube Insertion|The Effect of Obesity on Ventilation Tube Insertion|Unknown status|Enrolling by invitation||120|Anticipated|Soonchunhyang University Hospital|||2||f||||f||||||||||2018-05-31 22:08:59.036908|2018-05-31 22:08:59.036908
NCT01437423|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2016-11-06||2016-11-06|2011-09-19|2011-09-20|Estimate|2016-11-06|2017-01-04|Estimate||||2016-11-06|2017-01-04|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Regulatory Post-Marketing Surveillance Study for TETRAXIM™|Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis)|Completed||Phase 4|600|Actual|Sanofi||1|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 22:08:59.094181|2018-05-31 22:08:59.094181
NCT01437410|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2011-09-19|2011-09-19|2011-09-20|Estimate|||||||2011-09-19|2011-09-20|Estimate|January 2009||2009-01-31|September 2011|2011-09-30||||July 2010|Actual|2010-07-31||Observational|||Endoscopic Ultrasound-guided Fine Needle Aspiration of Solid Masses: Histological and Immunohistochemical Evaluation|Endoscopic Ultrasound-guided Fine Needle Aspiration of Solid Masses: Histological and Immunohistochemical Evaluation|Completed|||116|Actual|Samsung Medical Center|||1||f||||||||||Samples Without DNA|"~     cytopathologic result acquired by endoscopic ultrasound-guided fine needle aspiration~     (EUS-FNA).~   "|||2018-05-31 22:08:59.459403|2018-05-31 22:08:59.459403
NCT01436851|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-08-14|2011-09-18|2011-09-20|Estimate|||||||2017-08-14|2017-08-16|Actual|November 24, 2010|Actual|2010-11-24|August 2017|2017-08-31|December 2014|Actual|2014-12-31|September 1, 2011|Actual|2011-09-01||Interventional|NPT||Nasal Provocation Testing in Occupational Rhinitis|Nasal Provocation Testing With Nasal Lavage in Allergic and Non-allergic Occupational Rhinitis|Completed||N/A|17|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 22:09:07.633193|2018-05-31 22:09:07.633193
NCT01437397|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2016-11-16|2013-04-05|2017-02-02|2011-09-19|2011-09-20|Estimate|2017-02-02|2017-03-23|Actual|2013-04-05|2013-04-11|Estimate|2017-02-02|2017-03-23|Actual|September 2011||2011-09-30|January 2017|2017-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Safety population comprising all patients randomized to a treatment group who received at least 1 dose of double-blind investigational treatment.|Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|1692|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 22:08:59.616573|2018-05-31 22:08:59.616573
NCT01437384|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-05-18|2011-09-19|2011-09-20|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2011||2011-09-30|May 2012|2012-05-31||||March 2012|Actual|2012-03-31||Interventional|||Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.|An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects|Completed||Phase 1|36|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 22:09:01.593155|2018-05-31 22:09:01.593155
NCT01437371|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-09-30|2011-09-19|2011-09-20|Estimate|||||||2014-09-30|2014-10-01|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|HF 80||Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?|Is There a Benefit to Optimize HF (Heart Failure) Treatment in Aged Over 80 Year's Old Patients?|Completed||Phase 3|35|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 22:09:01.748703|2018-05-31 22:09:01.748703
NCT01437358|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2012-02-27|2011-09-19|2011-09-20|Estimate|||||||2012-02-27|2012-02-28|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Epidural Analgesia in Intensive Care Unit (APD-REA: Analgesie PeriDurale en REAnimation)|Epidural Analgesia in Intensive Care Unit Patients: an Observational Prospective Multicenter Feasibility and Safety Study|Completed|||80|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 22:09:01.827166|2018-05-31 22:09:01.827166
NCT01437345|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-10-10|2011-09-19|2011-09-20|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2012||2012-07-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|FSHD||A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD|A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset Facioscapulohumeral Muscular Dystrophy|Completed|||53|Actual|Cooperative International Neuromuscular Research Group|||||f||||t||||||Samples With DNA|"~     Blood samples for DNA and RNA analysis are optional.~   "|||2018-05-31 22:09:01.898443|2018-05-31 22:09:01.898443
NCT01437332|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2011-09-19|2011-09-19|2011-09-20|Estimate|||||||2011-09-19|2011-09-20|Estimate|September 2011||2011-09-30|September 2011|2011-09-30||||September 2016|Anticipated|2016-09-30||Observational|||Molecular Mediators of Nerve Injury Signaling|Molecular Mediators of Nerve Injury Signaling|Unknown status|Enrolling by invitation||50|Anticipated|Rambam Health Care Campus|||3||f||||t||||||||||2018-05-31 22:09:01.964919|2018-05-31 22:09:01.964919
NCT01437319|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2015-11-16||2016-01-28|2011-09-19|2011-09-20|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||The analysis population consists of all subjects that entered Phase 1.|Mucin Balls and Corneal Inflammation Events||Completed||Phase 1/Phase 2|289|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-05-31 22:09:02.03057|2018-05-31 22:09:02.03057
NCT01437306|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2018-02-22|2011-09-19|2011-09-20|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2011||2011-10-31|February 2018|2018-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Lofexidine Food Effect Study in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Food Effect Study of Lofexidine 400 μg (2 x 200 μg) Tablets|Completed||Phase 1|13|Actual|US WorldMeds LLC||2|||f||||f||||||||||2018-05-31 22:09:02.214382|2018-05-31 22:09:02.214382
NCT01437293|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2018-05-17|2011-09-19|2011-09-20|Estimate|||||||2018-05-17|2018-05-21|Actual|August 2010||2010-08-31|May 2018|2018-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|COST||Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)|Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)|Completed||Phase 1|15|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 22:09:02.279118|2018-05-31 22:09:02.279118
NCT01437280|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2013-08-12|2011-09-19|2011-09-20|Estimate|||||||2013-08-12|2013-08-14|Estimate||||August 2013|2013-08-31||||||||Interventional|GOAT||GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers|GOAT; Phase I Single-Center Open Label Dose Escalation Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Therapy of Advanced Cancers|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 22:09:02.350173|2018-05-31 22:09:02.350173
NCT01437267|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2014-03-05||2014-03-05|2011-09-19|2011-09-20|Estimate|2014-03-05|2014-04-10|Estimate||||2014-03-05|2014-04-10|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Analysis was done on all enrolled subjects.|Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants|A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants|Completed||Phase 2|120|Actual|Novartis||6|||f||||t||||||||||2018-05-31 22:09:02.44206|2018-05-31 22:09:02.44206
NCT01437254|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-11-10|2011-09-19|2011-09-20|Estimate|||||||2017-11-10|2017-11-14|Actual|October 2011|Actual|2011-10-31|November 2017|2017-11-30|January 2015|Actual|2015-01-31|April 2012|Actual|2012-04-30||Interventional|||To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer|A Phase I Study of Cyclotron-produced Tc-99m Pertechnetate (CPERT) in Patients With Thyroid Cancer|Completed||Phase 1|30|Actual|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-05-31 22:09:03.182267|2018-05-31 22:09:03.182267
NCT01437241|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2011-10-30|2011-09-19|2011-09-20|Estimate|||||||2011-10-30|2011-11-01|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Observational|||Etravirine Plus 2 Analogs in HIV-infected Patients|Virological Efficacy and Safety of Etravirine Plus 2 Active Nucleos(t)Ide Reverse-transcriptase Inhibitors (NRTIs) in HIV-1-infected Patients|Completed|||175|Actual|Hospitales Universitarios Virgen del Rocío|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 22:09:03.341649|2018-05-31 22:09:03.341649
NCT01437215|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2013-06-05|2011-09-19|2011-09-20|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|August 2016|Anticipated|2016-08-31|September 2011|Actual|2011-09-30||Interventional|||Pilot Study of the Endologix Fenestrated Stent Graft System|Prospective, Multicenter, Single Arm Feasibility and Initial Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms|Unknown status|Active, not recruiting|Phase 1|15|Actual|Endologix||1|||f||||f||||||||||2018-05-31 22:09:03.51534|2018-05-31 22:09:03.51534
NCT01437202|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2014-07-08|2011-09-19|2011-09-20|Estimate|||||||2014-07-08|2014-07-09|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|VATIC||Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia|Retrospective Study to Validate Pharmacogenetics Model for Imatinib Metabolism in Patients With Chronic Myeloid Leukemia|Completed|||100|Actual|Asan Medical Center|||3||f||||f||||||Samples With DNA|"~     whole blood 4cc~   "|||2018-05-31 22:09:03.58298|2018-05-31 22:09:03.58298
NCT01437189|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2011-09-19|2011-09-19|2011-09-20|Estimate|||||||2011-09-19|2011-09-20|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|March 2013|Anticipated|2013-03-31|November 2012|Anticipated|2012-11-30||Interventional|PD; PDD||The Effects of Sertraline on Depression in Parkinson's Disease|Clinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's Disease|Unknown status|Recruiting|N/A|35|Anticipated|Zhejiang University|||||f||||f||||||||||2018-05-31 22:09:03.658115|2018-05-31 22:09:03.658115
NCT01437176|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-02-04|2011-09-19|2011-09-20|Estimate|||||||2015-02-04|2015-02-06|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Treatment of Intertrochanteric Fracture With New Type of Intramedullary Nail|Treatment of Intertrochanteric Fracture With New Type of Intramedullary Nail|Unknown status|Recruiting|Phase 4|36|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 22:09:03.732762|2018-05-31 22:09:03.732762
NCT01437163|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2016-07-11|2011-09-19|2011-09-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|LLLT||Treatment of Androgenetic Alopecia in Males and Females|The Growth of Human Scalp Hair Mediated By Visible Red Light Laser and LED Sources.|Completed||N/A|88|Actual|Apira Science, Inc.||2|||f||||f||||||||||2018-05-31 22:09:03.855371|2018-05-31 22:09:03.855371
NCT01437150|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-02-04|2011-09-19|2011-09-20|Estimate|||||||2015-02-04|2015-02-06|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Treatment of Acetabular Posterior Wall Fracture With Anatomical Locking Plate|Treatment of Acetabular Posterior Wall Fracture With Anatomical Locking Plate|Completed||Phase 4|25|Actual|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 22:09:03.931967|2018-05-31 22:09:03.931967
NCT01437137|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-06-01|2011-09-16|2011-09-20|Estimate|||||||2013-06-01|2013-06-04|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Clinical Efficacy of Recently Developed Supraglottic Airway Device, I-gel™, in Neonates and Infants: Comparison With Classic-laryngeal Mask Airway (c-LMA)||Completed||N/A|54|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:09:04.01881|2018-05-31 22:09:04.01881
NCT01437124|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2016-04-27||2016-04-27|2011-09-19|2011-09-20|Estimate|2016-04-27|2016-06-06|Estimate||||2016-04-27|2016-06-06|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31|5 Years|Observational [Patient Registry]|COM||Metal Ions in Ceramic on Metal Total Hip Arthroplasty|Measurement of Metal Ion Levels and Chromosome Abnormalities in Ceramic on Metal Total Hip Arthroplasty in Vivo|Completed|||83|Actual|Wirral University Teaching Hospital NHS Trust|||1||f||||t||||||||||2018-05-31 22:09:04.096396|2018-05-31 22:09:04.096396
NCT01437111|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|2013-12-03||2017-04-05|2011-09-19|2011-09-20|Estimate|2013-12-03|2014-01-22|Estimate||||2017-04-05|2017-05-11|Actual|October 26, 2011|Actual|2011-10-26|April 2017|2017-04-30|December 5, 2012|Actual|2012-12-05|December 5, 2012|Actual|2012-12-05||Interventional||Baseline Analysis was performed on the All Patients as Treated (APaT) population, which included all participants who received treatment. Of 200 participants enrolled in the study, baseline data were not provided for two participants who did not receive treatment.|Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)|A Phase III (Phase IV Program) Open-Label, Multicenter Clinical Trial in Thailand to Study the Effect of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) for 6 Months on 25-Hydroxyvitamin D Levels in the Treatment of Osteoporosis in Postmenopausal Women and Men|Completed||Phase 3|200|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:09:04.236797|2018-05-31 22:09:04.236797
NCT01437098|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2015-10-02||2018-04-27|2011-09-19|2011-09-20|Estimate|2016-04-27|2016-06-06|Estimate||||2018-04-27|2018-05-01|Actual|October 2011||2011-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|April 2013|Actual|2013-04-30||Interventional||As Treated Subjects|Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis|Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis|Active, not recruiting||N/A|55|Actual|Medtronic Cardiovascular||1|||f||||t||||||||||2018-05-31 22:09:04.457969|2018-05-31 22:09:04.457969
NCT01437085|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2017-01-23|2011-09-19|2011-09-20|Estimate|||||||2017-01-23|2017-01-25|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||A Study to Measure Needle Bending and Changes in Prostate Shape During a Prostate Seed Implant|Quantifying Needle Deflection and Tissue Deformation in Transperineal Interstitial Permanent Prostate Brachytherapy: A Basis for Development of Next-Generation Implant Technique|Active, not recruiting|||25|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-05-31 22:09:05.916183|2018-05-31 22:09:05.916183
NCT01437072|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-01-18|2011-09-16|2011-09-20|Estimate|||||||2017-01-18|2017-01-19|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Changing Diabetes® World Tour|Changing Diabetes® World Tour a Study on the Association of Risk Factors and the Presence of Undiagnosed Diabetes in the Middle East, Northern Africa and Europe|Completed|||8304|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:09:05.969553|2018-05-31 22:09:05.969553
NCT01437059|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2012-10-11|2011-09-19|2011-09-20|Estimate|||||||2012-10-11|2012-10-12|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)|A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)|Completed||Phase 1|32|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:09:06.036177|2018-05-31 22:09:06.036177
NCT01437020|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2013-08-26|2011-09-16|2011-09-20|Estimate|||||||2013-08-26|2013-08-28|Estimate||||August 2013|2013-08-31||||||||Interventional|||SCH708980 With and Without AmBisome for Visceral Leishmaniasis|A Phase I/II Clinical Trial To Assess the Safety and Biologic Activity of the Anti-IL-10 Monoclonal Antibody, SCH708980, in Combination With AmBisome(Registered Trademark), Versus That of Placebo in Combination With Ambisome(Registered Trademark), in Subjects With Visceral Leishmaniasis (VL)|Withdrawn||Phase 1/Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1||Drug Product no longer available.|f||||t||||||||||2018-05-31 22:09:06.228409|2018-05-31 22:09:06.228409
NCT01437007|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2017-06-30|2011-09-16|2011-09-20|Estimate|||||||2017-06-30|2017-07-02|Actual|August 26, 2011||2011-08-26|October 9, 2012|2012-10-09|June 21, 2012|Actual|2012-06-21|June 21, 2012|Actual|2012-06-21||Interventional|||TKM 080301 for Primary or Secondary Liver Cancer|A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic|Completed||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:09:06.300756|2018-05-31 22:09:06.300756
NCT01436994|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-09-20|2011-09-16|2011-09-20|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2004||2004-07-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Interventional|||Antithyroid Drug Treatment of Thyrotoxicosis in Young People|A Randomised Study of Two Anti-thyroid Drug Treatment Regimens in Young People|Completed||Phase 3|81|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 22:09:06.411291|2018-05-31 22:09:06.411291
NCT01436981|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-06-03|2011-09-19|2011-09-20|Estimate|||||||2013-06-03|2013-06-04|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Pharmacokinetics of Pavaverine After Intraluminal Administration|Observational Study on Papaverine During Cardiac Surgical Procedures|Completed|||12|Actual|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||||||2018-05-31 22:09:06.580186|2018-05-31 22:09:06.580186
NCT01436968|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2018-04-26|2011-09-19|2011-09-20|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2011||2011-09-30|April 2018|2018-04-30||||December 2020|Anticipated|2020-12-31||Interventional|PrTK03||Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer|A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer|Recruiting||Phase 3|711|Anticipated|Advantagene, Inc.||2|||f||||t||||||||||2018-05-31 22:09:06.667562|2018-05-31 22:09:06.667562
NCT01436955|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-03-02|2011-09-16|2011-09-20|Estimate|||||||2015-03-02|2015-03-03|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of RG1662 in Individuals With Down Syndrome|A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Investigate Safety and Tolerability of RG1662 in Individuals With Down Syndrome|Completed||Phase 1|35|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:09:06.84124|2018-05-31 22:09:06.84124
NCT01436942|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-02-02|2011-09-16|2011-09-20|Estimate|||||||2015-02-02|2015-02-03|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Exercise on Disease Activity and Cardiovascular Risk Factors in Patients With Ankylosing Spondylitis|Effect of Exercise on Disease Activity and Cardiovascular Risk Factors in Patients With AS: A Single Blind Randomized Controlled Trail|Completed||N/A|34|Actual|Diakonhjemmet Hospital||2|||f||||t||||||||||2018-05-31 22:09:06.911231|2018-05-31 22:09:06.911231
NCT01436929|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2012-12-13|2011-09-19|2011-09-20|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|PESOHHERZ||Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs|Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs|Unknown status|Recruiting|N/A|600|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:09:06.969118|2018-05-31 22:09:06.969118
NCT01436916|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-10-23|2011-09-19|2011-09-20|Estimate|||||||2015-10-23|2015-10-26|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Oral Cholecalciferol in Prevention of Type 2 Diabetes Mellitus|Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency|Completed||Phase 4|50|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 22:09:07.042336|2018-05-31 22:09:07.042336
NCT01436903|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2013-03-07|2011-09-18|2011-09-20|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length|Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length, a Questionnaire Investigation on 290 Patients|Completed||Phase 4|290|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 22:09:07.106091|2018-05-31 22:09:07.106091
NCT01436890|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-06-20|2011-09-19|2011-09-20|Estimate|||||||2013-06-20|2013-06-21|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma|A Phase II, 12-week Randomized, Double-blind, Triple Dummy, Parallel Group, Placebo-controlled, Dose Range Finding Study to Evaluate Safety, Tolerability and Efficacy of Revamilast in Patients With Chronic Persistent Asthma|Completed||Phase 2|273|Actual|Glenmark Pharmaceuticals Ltd. India||4|||f||||f||||||||||2018-05-31 22:09:07.176108|2018-05-31 22:09:07.176108
NCT01436877|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2016-09-18|2011-09-18|2011-09-20|Estimate|||||||2016-09-18|2016-09-20|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia|One-arm Feasibility and Prospective Pivotal Study to Assess the Safety and Efficacy of MediTate Temporary Implantable Nitinol Device (TIND) in Subjects Presenting Bladder Outlet Obstruction Secondary to BPH|Completed||Phase 1/Phase 2|6|Actual|Medi-Tate Ltd.||1|||f||||f||||||||||2018-05-31 22:09:07.456308|2018-05-31 22:09:07.456308
NCT01436864|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2014-03-21|2011-09-19|2011-09-20|Estimate|||||||2014-03-21|2014-03-24|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|PHOENIX||A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD|A Phase 3 Clinical Trial of Intravitreal Injections of Human Recombinant Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Completed||Phase 3|125|Actual|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||||||||||||2018-05-31 22:09:07.536668|2018-05-31 22:09:07.536668
NCT01436838|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2016-09-02|2011-09-19|2011-09-20|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|||China Betaferon Adherence, Coping and Nurse Support Study|Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin With Multiple Sclerosis|Completed|||110|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:09:07.706563|2018-05-31 22:09:07.706563
NCT01436825|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-08-07|2011-09-19|2011-09-20|Estimate|||||||2015-08-07|2015-08-10|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2014|Actual|2014-06-30||Observational|OPTIMS||Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients|A Validation Study of the OPTIMS Pharmacokinetic Calculator for Clinician Use in Prophylactic Treatment of Patients With Haemophilia A.|Completed|||69|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:09:07.777676|2018-05-31 22:09:07.777676
NCT01436812|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2013-08-08|2011-09-18|2011-09-20|Estimate|||||||2013-08-08|2013-08-12|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|||Effect of Positive End Expiratory Pressure (PEEP) on Cerebral Oxymetry During Laparoscopy|International Reveiw Board of Gachon Univerity Gil Hospital|Completed||N/A|30|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 22:09:07.910583|2018-05-31 22:09:07.910583
NCT01436799|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2013-02-05||2013-08-25|2011-09-19|2011-09-20|Estimate|2013-08-22|2013-08-26|Estimate||||2013-08-25|2013-09-09|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Desflurane Versus Propofol in the Sitting Position|International Review Board of Gachon University Gil Hospital|Completed||N/A|40|Actual|Gachon University Gil Medical Center|limitations of this study is that the ventilation was adjusted according to ETCO2 value instead of the arterial carbon dioxide tensions (PaCO2).|2|||f||||t||||||||||2018-05-31 22:09:07.995564|2018-05-31 22:09:07.995564
NCT01436786|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-05-14|2011-09-19|2011-09-20|Estimate|||||||2014-05-14|2014-05-16|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effectiveness of Guided Imagery Intervention on Factors Associated With Maternal Stress and Preterm Birth|Guided Imagery Effects on Pregnancy Symptoms and Outcomes|Completed||N/A|73|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 22:09:08.239834|2018-05-31 22:09:08.239834
NCT01436773|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2017-07-20|2011-09-16|2011-09-20|Estimate|||||||2017-07-20|2017-07-24|Actual|May 2009||2009-05-31|July 2017|2017-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events|Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events|Completed|||66|Actual|University of Pittsburgh|||3||f||||t||||||||||2018-05-31 22:09:08.316654|2018-05-31 22:09:08.316654
NCT01436760|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2012-03-23|2011-09-16|2011-09-20|Estimate|||||||2012-03-23|2012-03-26|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Genetic Contribution of Pain and Inflammation in IBS|Genetic Contribution of Pain and Inflammation in Irritable Bowel Syndrome.|Completed|||72|Actual|University of Florida|||||f||||f||||||Samples With DNA|"~     The delinked blood/DNA is stored in the genetics laboratory and they will be analyzed for~     possible polymorphisms~   "|||2018-05-31 22:09:08.37706|2018-05-31 22:09:08.37706
NCT01436747|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-12-22|2011-09-19|2011-09-20|Estimate|||||||2017-12-22|2017-12-27|Actual|July 2012||2012-07-31|December 2017|2017-12-31|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients|Efficacy and Safety of Selective Vitamin D Receptor Activation With Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients: a Randomized Controlled Trial|Completed||Phase 3|168|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 22:09:08.43619|2018-05-31 22:09:08.43619
NCT01436734|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-07-10|2011-09-19|2011-09-20|Estimate|||||||2015-07-10|2015-07-14|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125||Completed||N/A|5|Actual|University Hospital, Gentofte, Copenhagen||1|||f||||t||||||||||2018-05-31 22:09:08.518394|2018-05-31 22:09:08.518394
NCT01436721|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-19|2011-09-19|2011-09-20|Estimate|||||||2011-09-19|2011-09-20|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Use of an Oxidized Regenerated Cellulose After Hepatic Surgery|The Randomized Clinical Trial of Surgicel® Absorbable Haemostat Covering the Raw Cut Surface During the Hepatectomy|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 22:09:08.585529|2018-05-31 22:09:08.585529
NCT01436708|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2016-09-04|2011-09-19|2011-09-20|Estimate|||||||2016-09-04|2016-09-07|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||The Association of Pelvic Organ Prolapse Severity and Urinary Symptoms/Sexual Function||Recruiting|||500|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-05-31 22:09:08.659504|2018-05-31 22:09:08.659504
NCT01436695|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-17|||2011-09-19|2011-09-19|2011-09-20|Estimate|||||||2011-09-19|2011-09-20|Estimate|November 2011||2011-11-30|September 2011|2011-09-30||||June 2012|Anticipated|2012-06-30||Observational|||Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers|Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers|Unknown status|Not yet recruiting||30|Anticipated|Epicall LTD|||1||f||||f||||||||||2018-05-31 22:09:08.717331|2018-05-31 22:09:08.717331
NCT01436682|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-10-24|2011-09-19|2011-09-20|Estimate|||||||2013-10-24|2013-10-25|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Assisted Nerve Blocks||Completed|||13|Actual|McGill University Health Center|||||f||||f||||||||||2018-05-31 22:09:08.796952|2018-05-31 22:09:08.796952
NCT01436669|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2012-10-17|2011-09-19|2011-09-20|Estimate|||||||2012-10-17|2012-10-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:09:08.842449|2018-05-31 22:09:08.842449
NCT01436656|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-08-21|2011-09-19|2011-09-20|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2011||2011-09-30|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|October 2012|Actual|2012-10-31||Interventional|||A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma|A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma|Active, not recruiting||Phase 1|107|Actual|Array BioPharma||2|||f||||f||||||||||2018-05-31 22:09:08.876269|2018-05-31 22:09:08.876269
NCT01436487|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15||2016-07-29|2016-07-29|2011-09-16|2011-09-19|Estimate||||2016-07-29|2016-08-02|Estimate|2016-07-29|2016-08-02|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Study to Examine the Effects of MultiStem in Ischemic Stroke|Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke|Completed||Phase 2|134|Actual|Athersys, Inc||3|||f||||t||||||||No||2018-05-31 22:09:11.28507|2018-05-31 22:09:11.28507
NCT01436643|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2014-09-01||2014-09-24|2011-09-19|2011-09-20|Estimate|2014-09-24|2014-09-25|Estimate||||2014-09-24|2014-09-25|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|REGAIN|The safety set was used for analysis, which consists of 54 patients, of whom 2 patients did not start treatment with any antidepressant|Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression|A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression|Terminated||Phase 4|54|Actual|Novartis||3||Due to slow enrollment the study was terminated early|f||||||||||||||2018-05-31 22:09:08.975138|2018-05-31 22:09:08.975138
NCT01436630|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2011-09-19|2011-09-19|2011-09-20|Estimate|||||||2011-09-19|2011-09-20|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Observational|||Step Test and Six Minute Walk Test in Stroke|Comparação Entre o Teste de Caminhada de Seis Minutos e o Teste do Degrau de Seis Minutos em Pacientes Com Acidente Vascular Encefálico|Completed|||12|Actual|Faculdades Metropolitanas Unidas|||1||f||||f||||||||||2018-05-31 22:09:09.547249|2018-05-31 22:09:09.547249
NCT01436617|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-03-07|2011-09-16|2011-09-19|Estimate|||||||2013-03-07|2013-03-08|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|IgES||Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab|Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab|Completed|||303|Actual|Centre Francois Baclesse|||||f||||t||||||||||2018-05-31 22:09:09.636956|2018-05-31 22:09:09.636956
NCT01436604|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-07-27|2011-09-16|2011-09-19|Estimate|||||||2017-07-27|2017-07-28|Actual|February 2012||2012-02-29|July 2017|2017-07-31|May 2017|Actual|2017-05-31|August 2015|Actual|2015-08-31||Interventional|MRTOX||Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging|Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging|Terminated||Phase 2|19|Actual|Centre Francois Baclesse||2||lack of recruitment|f||||t||||||||||2018-05-31 22:09:09.726989|2018-05-31 22:09:09.726989
NCT01436591|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2012-09-07|2011-09-16|2011-09-19|Estimate|||||||2012-09-07|2012-09-10|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|TEP-Sein||Comparison of Diagnostic Performance of an Algorithm and a High Definition Classical Iterative Algorithm Positron Emission Tomography (PET) to 18Fluoro-deoxy-glucose (18FDG) in the Evaluation of Axillary Lymph Node Invasion of Breast Tumors|Comparison of Diagnostic Performance of an Algorithm and a High Definition Classical Iterative Algorithm Positron Emission Tomography (PET) to 18Fluoro-deoxy-glucose (18FDG) in the Evaluation of Axillary Lymph Node Invasion of Breast Tumors|Terminated|||63|Actual|Centre Francois Baclesse|||||f||||t||||||||||2018-05-31 22:09:09.794246|2018-05-31 22:09:09.794246
NCT01436578|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2015-07-06|2011-09-16|2011-09-19|Estimate|||||||2015-07-06|2015-07-07|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)|Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of NOXAFIL Oral Suspension in Usual Practice|Completed|||273|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:09:09.863443|2018-05-31 22:09:09.863443
NCT01436565|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2014-06-12|2011-09-16|2011-09-19|Estimate|||||||2014-06-12|2014-06-13|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers|A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of SAR245408 Administered in Combination With SAR256212 in Patients With Solid Tumor Cancers|Completed||Phase 1|26|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:09:09.934754|2018-05-31 22:09:09.934754
NCT01436552|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2011-09-16|2011-09-16|2011-09-19|Estimate|||||||2011-09-16|2011-09-19|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2014|Anticipated|2014-02-28|February 2012|Anticipated|2012-02-29||Observational|FPRMCI||Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia|Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia|Unknown status|Recruiting||392|Anticipated|Centre Hospitalier Esquirol|||||f||||t||||||||||2018-05-31 22:09:10.06553|2018-05-31 22:09:10.06553
NCT01436539|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-16|2011-09-16|2011-09-19|Estimate|||||||2011-09-16|2011-09-19|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|||Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients|A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-05-31 22:09:10.129025|2018-05-31 22:09:10.129025
NCT01436526|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2011-11-18||2015-04-02|2011-09-16|2011-09-19|Estimate|2011-11-18|2011-12-22|Estimate||||2015-04-02|2015-04-22|Estimate|August 2009||2009-08-31|April 2015|2015-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban|Single-dose, Open-label, Randomized, 2-way Crossover Pivotal Bioequivalence Study of 2x5 mg Tablets Rivaroxaban Versus 1x10 mg Tablet Rivaroxaban Under Fasted Condition in Healthy Subjects|Completed||Phase 1|28|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:09:10.210115|2018-05-31 22:09:10.210115
NCT01436513|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2012-03-14|2011-09-16|2011-09-19|Estimate|||||||2012-03-14|2012-03-15|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.|Phase 1, Open-Label, Randomized, Single-Dose, Crossover Bioequivalence And Food Effect Study For A New Formulation Of Premarin Compared With A Reference Tablet In Japanese Healthy Postmenopausal Women|Completed||Phase 1|72|Actual|Pfizer||4|||f||||||||||||||2018-05-31 22:09:10.521209|2018-05-31 22:09:10.521209
NCT01436500|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2016-12-22||2017-02-27|2011-09-16|2011-09-19|Estimate|2016-12-22|2017-02-14|Actual||||2017-02-27|2017-03-01|Actual|October 2011||2011-10-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients|A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome|Completed||Phase 2|55|Actual|Cumberland Pharmaceuticals||9|||f||||t||||||||No||2018-05-31 22:09:10.649639|2018-05-31 22:09:10.649639
NCT01436448|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-19|2011-09-16|2011-09-19|Estimate|||||||2011-09-19|2011-09-20|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|May 2013|Anticipated|2013-05-31|November 2012|Anticipated|2012-11-30||Interventional|GRIP||Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy|Effects of Probiotics (Lactobacillus Rhamnosus) In Reducing Glucose Intolerance During and After Pregnancy: A Double Blind Randomized Controlled Trial in Antenatal Clinic of Karachi-Pakistan (GRIP)|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-05-31 22:09:11.486217|2018-05-31 22:09:11.486217
NCT01436435|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2016-07-16||2016-09-03|2011-09-16|2011-09-19|Estimate|2016-07-16|2016-08-26|Estimate||||2016-09-03|2016-10-19|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|JET||The Jetstream (JET) Post-market Registry|Jetstream NAVITUS™ System Endovascular Therapy Post-market Registry (JET)|Completed||Phase 4|241|Actual|Boston Scientific Corporation||1|||f||||f||||||||No||2018-05-31 22:09:11.552549|2018-05-31 22:09:11.552549
NCT01436422|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2015-08-19|2011-09-16|2011-09-19|Estimate|||||||2015-08-19|2015-08-20|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects|Completed||Phase 1|112|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 22:09:11.835218|2018-05-31 22:09:11.835218
NCT01436409|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-11-25|2011-09-16|2011-09-19|Estimate|||||||2011-11-25|2011-11-29|Estimate|December 2005||2005-12-31|July 2011|2011-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|PINKFINGER||Rates of Fetal Extractions Between Only Vaginal Touch Usually Realized and Vaginal Touch + Echography|Comparison of the Rates of Fetal Extractions Between a Systematic Practice of an Echography of Presentation and the Only Vaginal Touch Usually Realized During the Labor|Completed||N/A|1900|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:09:11.92467|2018-05-31 22:09:11.92467
NCT01436396|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2014-04-01|2011-09-16|2011-09-19|Estimate|||||||2014-04-01|2014-04-02|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers|Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru|Completed||Phase 3|792|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:09:11.992618|2018-05-31 22:09:11.992618
NCT01436383|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2011-09-20|2011-09-16|2011-09-19|Estimate|||||||2011-09-20|2011-09-21|Estimate|March 2005||2005-03-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|December 2005|Actual|2005-12-31||Interventional|||Oxidative Stress in Hypobaric Hypoxia|Oxidative Stress in Hypobaric Hypoxia and Influence on Vessel-tone Modifying Mediators|Completed||N/A|36|Actual|University Hospital Inselspital, Berne|||||f||||t||||||||||2018-05-31 22:09:12.097073|2018-05-31 22:09:12.097073
NCT01436370|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-04-17||2014-12-04|2011-09-15|2011-09-19|Estimate|2014-04-17|2014-05-16|Estimate||||2014-12-04|2014-12-24|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional||The baseline analysis population includes all participants who were enrolled and vaccinated.|TIV and High Dose TIV in Subjects With Rheumatoid Arthritis|A Phase II Study in Adults With Rheumatoid Arthritis Receiving TNF-alpha-inhibitor Therapy to Assess the Immunogenicity and Safety of Trivalent Inactivated Vaccine (TIV) and High Dose Trivalent Inactivated Vaccine (High-Dose TIV) Administered at Two Dosage Levels|Completed||Phase 2|102|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 22:09:12.224698|2018-05-31 22:09:12.224698
NCT01436357|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2018-05-03|2011-09-15|2011-09-19|Estimate|||||||2018-05-03|2018-05-04|Actual|March 6, 2012|Actual|2012-03-06|April 5, 2017|2017-04-05|July 28, 2018|Anticipated|2018-07-28|July 28, 2018|Anticipated|2018-07-28||Interventional|||Staged Phase I/II Hepatitis C Prophylactic Vaccine|A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut|Active, not recruiting||Phase 1/Phase 2|548|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 22:09:13.985995|2018-05-31 22:09:13.985995
NCT01436344|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2015-07-22|2011-09-16|2011-09-19|Estimate|||||||2015-07-22|2015-07-23|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|||Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography|Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography|Completed|||50|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 22:09:14.055804|2018-05-31 22:09:14.055804
NCT01436331|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-01-07|2011-09-16|2011-09-19|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|GETUP-PIANO||A Large Pragmatic Cluster Randomized Controlled Trial of a Multi-element Psychosocial Intervention for Early Psychosis|A Pragmatic Cluster Randomized Controlled Trial of a Multi-element Psychosocial Intervention for Early Psychosis in a 10 Million Inhabitant Catchment Area Aimed to Measure the Treatment's Feasibility and Effectiveness: GET UP-PIANO Trial|Completed||N/A|626|Actual|Universita di Verona||2|||f||||f||||||||||2018-05-31 22:09:14.112171|2018-05-31 22:09:14.112171
NCT01436318|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2014-09-22|2011-09-16|2011-09-19|Estimate|||||||2014-09-22|2014-09-23|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|||Respiratory Muscle Strength and Function in Healthy Kids|Respiratory Muscle Strength and Function in Healthy Children|Completed|||7|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 22:09:14.194019|2018-05-31 22:09:14.194019
NCT01436305|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2016-11-10||2017-08-29|2011-09-15|2011-09-19|Estimate|2017-07-28|2017-08-30|Actual||||2017-08-29|2017-09-27|Actual|September 2011||2011-09-30|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Randomized participants|Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation|Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)|Terminated||Phase 2|19|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Enrollment of 210 participants was planned, but study was stopped after 19 participants enrolled due to safety concerns and change in alemtuzumab availability. Enrolled participants continued follow-up after enrollment ended.|3||Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.|f||||t||||||||||2018-05-31 22:09:14.298834|2018-05-31 22:09:14.298834
NCT01436292|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-09-16|2011-09-16|2011-09-19|Estimate|||||||2011-09-16|2011-09-19|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|Halburns||Hypoalbuminemia in Burn Patients|Hypoalbuminemia in Burn Patients: Should we Care? - A Randomized Controlled Clinical Pilot Trial|Unknown status|Not yet recruiting|Phase 4|128|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-05-31 22:09:16.529222|2018-05-31 22:09:16.529222
NCT01436279|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2017-04-11||2017-05-16|2011-09-16|2011-09-19|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|July 2011||2011-07-31|May 2017|2017-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SaMi2||Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks|Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks|Completed||Phase 3|50|Actual|Boston University||2|||f||||t|t|f|||f|||No||2018-05-31 22:09:16.621275|2018-05-31 22:09:16.621275
NCT01436266|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2017-04-18||2017-04-18|2011-09-16|2011-09-19|Estimate|2017-04-18|2017-05-30|Actual||||2017-04-18|2017-05-30|Actual|July 2011|Actual|2011-07-31|April 2017|2017-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PreopMiso||Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion|Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester|Terminated||Phase 3|3|Actual|Boston University|1 of the 3 consented subjects became ineligible due to spontaneous rupture of amniotic membranes prior to the abortion. Early study termination, the PI left the institution, and study records could not be located for secondary data outcomes.|2||Slow enrollment|f||||f|t|f||||||No||2018-05-31 22:09:16.894729|2018-05-31 22:09:16.894729
NCT01436253|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2013-12-03||2015-03-27|2011-09-15|2011-09-19|Estimate|2013-12-03|2014-01-22|Estimate||||2015-03-27|2015-04-16|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)|Non-Interventional Study In Hyperlipidemic Patients Who Do Not Reach Satisfactory Lipid Values With Existing Hypolipemic Therapy|Completed|||2196|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:09:17.110009|2018-05-31 22:09:17.110009
NCT01436240|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-05-22|2011-09-15|2011-09-19|Estimate|||||||2017-05-22|2017-05-23|Actual|September 2011|Actual|2011-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Linguistic Validation of the Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Completed|||112|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 22:09:17.251377|2018-05-31 22:09:17.251377
NCT01436227|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-09-18|2011-09-16|2011-09-19|Estimate|||||||2017-09-18|2017-09-20|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pazopanib in Von Hippel-Lindau (VHL) Syndrome|A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome|Active, not recruiting||Phase 2|32|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:09:17.320743|2018-05-31 22:09:17.320743
NCT01436214|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2015-07-15|2011-09-16|2011-09-19|Estimate|||||||2015-07-15|2015-07-16|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer|Phase 1/2a, Open-Label, Dose-Escalation and Safety Study of APC-100 [Pentamethylchromanol, 2,2,5,7,8-Pentamethyl-6] in Men With Advanced Prostate Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|Adamis Pharmaceuticals Corporation||1|||f||||t||||||||||2018-05-31 22:09:17.387881|2018-05-31 22:09:17.387881
NCT01436201|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-10-03||2014-10-03|2011-09-15|2011-09-19|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants|Effect of Dulaglutide (LY2189265) on the Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|24|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:09:17.454896|2018-05-31 22:09:17.454896
NCT01436188|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-03-15|2011-09-16|2011-09-19|Estimate|||||||2014-03-15|2014-03-18|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|||||Interventional|||A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease|A Biomarker Study to Measure CSF Proteins Upon Application of an Indwelling Lumbar Catheter for 36 Hours in Elderly Healthy Subjects and Subjects With Mild Cognitive Impairment or Alzheimer's Disease|Completed||Early Phase 1|5|Actual|Janssen Research & Development, LLC||5|||f||||||||||||||2018-05-31 22:09:17.881959|2018-05-31 22:09:17.881959
NCT01436175|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2015-02-05||2015-02-05|2011-09-16|2011-09-19|Estimate|2015-02-05|2015-02-23|Estimate||||2015-02-05|2015-02-23|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Safety analysis set included all participants who took at least 1 dose of investigational product and had at least 1 post-Visit 0 (Week 0) safety assessment in this study.|SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study|A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant|Terminated||Phase 3|1570|Actual|Shire|The study was terminated on 11 Feb 2014. SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.|1||"SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination~   was not related to any new safety findings."|f||||||||||||||2018-05-31 22:09:18.071303|2018-05-31 22:09:18.071303
NCT01436162|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-10-31|2014-08-20|2014-11-06|2011-09-16|2011-09-19|Estimate|2014-11-06|2014-11-07|Estimate|2014-08-20|2014-08-22|Estimate|2014-11-06|2014-11-07|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment.|Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder|The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant|Completed||Phase 3|1105|Actual|Shire||2|||f||||||||||||||2018-05-31 22:09:18.924454|2018-05-31 22:09:18.924454
NCT01436006|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2014-05-26||2015-09-03|2011-09-16|2011-09-19|Estimate|2015-07-07|2015-08-04|Estimate||||2015-09-03|2015-09-18|Estimate|February 2011||2011-02-28|September 2015|2015-09-30|June 2012|Actual|2012-06-30|October 2011|Actual|2011-10-31||Observational|MDCTDOSE||Adult and Paediatric Patient Radiation Doses From Multidetector Row Computed Tomography Scans: a National Survey|Adult and Paediatric Patient Radiation Doses From Multidetector CT Scans: a National Survey|Completed|||6700|Actual|University of Palermo|||1||f||||t||||||||||2018-05-31 22:09:22.315066|2018-05-31 22:09:22.315066
NCT01436149|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-11-10|2014-08-20|2015-04-13|2011-09-16|2011-09-19|Estimate|2014-11-10|2014-11-19|Estimate|2014-08-20|2014-08-22|Estimate|2015-04-13|2015-05-05|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment (e.g., coming back for any visit, reporting of an adverse event [AE], or reporting the absence of AEs) after the Augmentation Baseline Visit (Visit 8).|Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder|The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant|Completed||Phase 3|1262|Actual|Shire||2|||f||||||||||||||2018-05-31 22:09:19.728613|2018-05-31 22:09:19.728613
NCT01436136|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-05-10|2011-09-15|2011-09-19|Estimate|||||||2015-05-10|2015-05-12|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CVD||Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months|Effectiveness of Team Intervention Over 12 Months in Reducing Modifiable CVD Risk Factors on Framingham 10yr Risk Scores Outcomes in HIV-1 Subjects on Antiretroviral Therapy|Completed||N/A|92|Actual|Holdsworth House Medical Practice||2|||f||||f||||||||||2018-05-31 22:09:20.369141|2018-05-31 22:09:20.369141
NCT01436123|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-05-17|2011-09-16|2011-09-19|Estimate|||||||2015-05-17|2015-05-19|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|NANOM PCI||Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting|Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis With The Use of Gold Nanoparticles With Iron Oxide-Silica Shells Versus Stenting|Terminated||Phase 1|62|Actual|Ural Medical University||2||"The study was terminated under the political pressure of the Federal Security Service of the~   Russian Federation (FSB) and the Russian Society of Cardiology"|f||||t||||||||||2018-05-31 22:09:20.438389|2018-05-31 22:09:20.438389
NCT01436110|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-08-21|2013-03-14|2016-11-18|2011-09-15|2011-09-19|Estimate|2014-08-21|2014-09-03|Estimate|2013-03-14|2013-03-20|Estimate|2016-11-18|2017-01-09|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma|A Randomised, Double-blind, Double-dummy, Placebo Controlled Multi-centre Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder and Fluticasone Propionate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents Not Currently Treated With Inhaled Corticosteroids|Completed||Phase 3|351|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:09:20.598015|2018-05-31 22:09:20.598015
NCT01436097|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-01-14|2011-09-16|2011-09-19|Estimate|||||||2013-01-14|2013-01-15|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|WTE||Randomized Trial of Healthy Eating Interventions|Financial Incentives for Healthy Eating: A Randomized Pilot Study|Completed||N/A|42|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 22:09:21.06732|2018-05-31 22:09:21.06732
NCT01436084|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2016-05-10||2016-06-14|2011-09-16|2011-09-19|Estimate|2016-05-10|2016-06-15|Estimate||||2016-06-14|2016-07-13|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||SB1518 for Patients With Myelodysplastic Syndrome (MDS)|Phase II Study of SB1518 for Patients With Myelodysplastic Syndrome (MDS)|Terminated||Phase 2|8|Actual|M.D. Anderson Cancer Center||1||Colloborating sponsor decision.|f||||f||||||||||2018-05-31 22:09:21.144365|2018-05-31 22:09:21.144365
NCT01436071|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-08-21|2013-02-28|2016-11-20|2011-09-15|2011-09-19|Estimate|2014-08-21|2014-09-03|Estimate|2013-02-28|2013-03-07|Estimate|2016-11-20|2017-01-11|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma|A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled Corticosteroids|Completed||Phase 3|248|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:09:21.275333|2018-05-31 22:09:21.275333
NCT01436058|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2011-09-16|2011-09-16|2011-09-19|Estimate|||||||2011-09-16|2011-09-19|Estimate|September 2010||2010-09-30|May 2010|2010-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoartritis|Phase 1 Study of Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Patients With Ankle Joint Osteoarteritis|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 22:09:21.768603|2018-05-31 22:09:21.768603
NCT01436045|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|2015-04-09||2015-09-25|2011-09-16|2011-09-19|Estimate|2015-09-25|2015-10-19|Estimate||||2015-09-25|2015-10-19|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.|A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.|Completed||Phase 2|12|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 22:09:21.860581|2018-05-31 22:09:21.860581
NCT01436032|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15||2012-03-12|2012-03-12|2011-09-16|2011-09-19|Estimate||||2012-03-12|2012-03-14|Estimate|2012-03-12|2012-03-14|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of Intravenous N1539 in Subjects After Abdominal Laparoscopic Surgery|Terminated||Phase 3|50|Actual|Alkermes, Inc.||5|||f||||f||||||||||2018-05-31 22:09:22.088095|2018-05-31 22:09:22.088095
NCT01436019|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-16|2011-09-16|2011-09-19|Estimate|||||||2011-09-16|2011-09-19|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Observational|||Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis|Analysis of Anti-infliximab, Anti-adalimumab and Anti-etanercept Antibodies in Children and Young Adolescents With Juvenile Idiopathic Arthritis|Unknown status|Not yet recruiting||100|Anticipated|Blood Transfusion Centre of Slovenia|||1||f||||t||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 22:09:22.221987|2018-05-31 22:09:22.221987
NCT01435993|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2017-06-19|2011-09-15|2011-09-19|Estimate|||||||2017-06-19|2017-06-20|Actual|September 8, 2011|Actual|2011-09-08|June 2017|2017-06-30|January 23, 2012|Actual|2012-01-23|January 23, 2012|Actual|2012-01-23||Interventional|||Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis|A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.|Terminated||Phase 1|3|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:09:22.531524|2018-05-31 22:09:22.531524
NCT01435980|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-03-25|2011-09-15|2011-09-19|Estimate|||||||2015-03-25|2015-03-27|Estimate|February 2008||2008-02-29|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes|Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes|Unknown status|Recruiting|Phase 4|60|Anticipated|Third Military Medical University||3|||f||||t||||||||||2018-05-31 22:09:22.64542|2018-05-31 22:09:22.64542
NCT01435967|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-03-06|2011-09-15|2011-09-19|Estimate|||||||2015-03-06|2015-03-09|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™|Observational, Ecological, Database Study on Epidemiology of Hospitalisations With Rotavirus Gastroenteritis Confirmed in Children Aged ≤5 Years, and Any Impact in the Change From Lyophilised to Liquid Formulation of Rotarix™, in Belgium|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:09:22.755063|2018-05-31 22:09:22.755063
NCT01435954|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-05-15|2011-09-15|2011-09-19|Estimate|||||||2017-05-15|2017-05-16|Actual|August 2010||2010-08-31|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy|Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy|Completed|||13551|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:09:22.846636|2018-05-31 22:09:22.846636
NCT01435941|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-05-15|2011-09-15|2011-09-19|Estimate|||||||2017-05-15|2017-05-16|Actual|September 2009||2009-09-30|May 2017|2017-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine|Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine|Completed|||11249|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:09:22.938505|2018-05-31 22:09:22.938505
NCT01435928|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-07-25||2016-03-10|2011-09-16|2011-09-19|Estimate|2014-09-09|2014-09-25|Estimate||||2016-03-10|2016-04-08|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||PEARL Schizophrenia Maintenance|A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Of Lurasidone For The Maintenance Treatment Of Subjects With Schizophrenia|Completed||Phase 3|676|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 22:09:23.074102|2018-05-31 22:09:23.074102
NCT01435915|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2018-05-17|2011-09-15|2011-09-19|Estimate|||||||2018-05-17|2018-05-18|Actual|June 28, 2010|Actual|2010-06-28|May 2018|2018-05-31|August 5, 2010|Actual|2010-08-05|August 5, 2010|Actual|2010-08-05||Interventional|||Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects|A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 22:09:23.952316|2018-05-31 22:09:23.952316
NCT01435902|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-06-19|2011-09-16|2011-09-19|Estimate|||||||2014-06-19|2014-06-23|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise|A Randomized, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Asthmatic Adolescent and Adult Subjects With Exercise-Induced Bronchoconstriction|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||Study was cancelled prior to enrolling any subjects|f||||f||||||||||2018-05-31 22:09:24.047732|2018-05-31 22:09:24.047732
NCT01435889|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-16|||2015-12-01|2011-09-16|2011-09-19|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2006||2006-06-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Long Term (1 Year) Respiratory Sequelae in Children Surviving an Acute Respiratory Distress Syndrome|Long Term (1 Year) Respiratory Sequelae in Children Surviving Acute Respiratory Distress Syndrome|Completed|||38|Actual|University Hospital, Lille|||||f||||f||||||||||2018-05-31 22:09:24.118484|2018-05-31 22:09:24.118484
NCT01435876|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-15|2011-09-15|2011-09-19|Estimate|||||||2011-09-15|2011-09-19|Estimate|May 2006||2006-05-31|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Surgery and Convergence Insufficiency Intermittent Exotropia|Treatment for Convergence Insufficiency Intermittent Exotropia; A Randomized Trial|Completed||N/A|76|Actual|Sudhalkar Eye Hospital||4|||f||||t||||||||||2018-05-31 22:09:24.183986|2018-05-31 22:09:24.183986
NCT01435863|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-08-11|2011-09-15|2011-09-19|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)|A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)|Completed||Phase 1|17|Actual|Solasia Pharma K.K.||1|||f||||f||||||||||2018-05-31 22:09:24.262064|2018-05-31 22:09:24.262064
NCT01435850|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-04-01|2011-09-15|2011-09-19|Estimate|||||||2015-04-01|2015-04-03|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|October 2012|Actual|2012-10-31||Interventional|SL-PLUS||Safety and Efficacy of the SL PLUS and the SL PLUS MIA Hip Stem|"Enfoncement de la Tige SL-PLUS et de la Tige SL-PLUS MIA:Etude Comparative"|Completed||Phase 4|80|Actual|Smith & Nephew, Inc.||2|||f||||t||||||||||2018-05-31 22:09:24.323388|2018-05-31 22:09:24.323388
NCT01435837|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2013-06-10|2011-09-16|2011-09-19|Estimate|||||||2013-06-10|2013-06-11|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Interaction of Caffeine and Hydration on Voice|Effects of the Interaction of Caffeine and Hydration on Voice Performance|Completed||Early Phase 1|80|Actual|Southern Illinois University Carbondale||2|||f||||f||||||||||2018-05-31 22:09:24.386121|2018-05-31 22:09:24.386121
NCT01435824|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-05-12|2011-09-16|2011-09-19|Estimate|||||||2014-05-12|2014-05-13|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Bioavailability of Amoxicillin Dissolved in Human Milk|Bioavailability of Amoxicillin Dissolved in Human Milk: An Adult Volunteer Study as a First Step Towards Defining Drug Doses for Infants|Completed||Phase 1|16|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 22:09:24.46636|2018-05-31 22:09:24.46636
NCT01435811|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-05-06|2011-09-16|2011-09-19|Estimate|||||||2014-05-06|2014-05-07|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|CIN-002||Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)|Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)|Completed||Phase 1|60|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 22:09:24.5427|2018-05-31 22:09:24.5427
NCT01435798|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2014-06-26||2017-02-15|2011-09-16|2011-09-19|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|April 2003||2003-04-30|February 2017|2017-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial|Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial|Completed||Phase 2|26|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 22:09:24.597664|2018-05-31 22:09:24.597664
NCT01435785|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-03-27|2011-09-16|2011-09-19|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2011|Actual|2011-04-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|TCIGeriatric||Performance Evaluation of Four Pharmacokinetic-Pharmacodynamic(PKPD) Models of Propofol in Elderly Patients|Derivation and Prospective Validation of Four Pharmacokinetic-Pharmacodynamic Models of Propofol in Elderly Patients|Completed|||14|Actual|Universidad del Desarrollo|||||f||||t|f|f||||Samples With DNA|"~     whole blood will be centrifugated, the plasma will be frozen and all the samples where~     analysed wiht HPLC technique~   "|Yes|Open TCI proyect|2018-05-31 22:09:24.785728|2018-05-31 22:09:24.785728
NCT01435772|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2017-09-12||2018-04-23|2011-09-15|2011-09-19|Estimate|2018-04-23|2018-05-22|Actual||||2018-04-23|2018-05-22|Actual|August 15, 2011|Actual|2011-08-15|April 2018|2018-04-30|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Interventional|||Extension Study for Patients Who Have Participated in a BMN 701 Study|A Long-Term Study for Extended BMN 701 Treatment of Patients With Pompe Disease Who Have Participated in a BMN 701 Study|Terminated||Phase 2|21|Actual|BioMarin Pharmaceutical||3||"The study was terminated because BioMarin decided to end the overall development program based~   on competing corporate priorities."|f||||t||||||||||2018-05-31 22:09:24.871676|2018-05-31 22:09:24.871676
NCT01435759|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2015-02-03||2015-02-03|2011-09-16|2011-09-19|Estimate|2015-02-03|2015-02-19|Estimate||||2015-02-03|2015-02-19|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 post-augmentation baseline safety assessment (e.g. coming back for any visit, reporting of an adverse event [AE] or reporting the absence of AEs). Subjects who received only single-blind placebo were not included in this group.|SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder|A Phase 2, Multicenter, Double- Blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant|Completed||Phase 2|1197|Actual|Shire||5|||f||||||||||||||2018-05-31 22:09:28.728919|2018-05-31 22:09:28.728919
NCT01435746|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2011-09-16|2011-09-16|2011-09-19|Estimate|||||||2011-09-16|2011-09-19|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Interventional|TROLL||Transfusion Requirements After Orthotopic Liver Transplantation|A Randomized, Controlled Pilot Trial of Transfusion Requirements After Orthotopic Liver|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|University Medical Center Goettingen||2|||f||||f||||||||||2018-05-31 22:09:30.14745|2018-05-31 22:09:30.14745
NCT01435733|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-08-09|2011-09-16|2011-09-19|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2011||2011-09-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Parenting a Child With Autism Spectrum Disorder and Marital Status|Parenting a Child With Autism Spectrum Disorder and Marital Status|Recruiting|||200|Anticipated|Sheba Medical Center|||1||f||||f||||||||No||2018-05-31 22:09:30.324246|2018-05-31 22:09:30.324246
NCT01435720|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-09-09|2011-09-16|2011-09-19|Estimate|||||||2014-09-09|2014-09-11|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)|Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies|Unknown status|Active, not recruiting|Phase 1/Phase 2|15|Anticipated|Senesco Technologies, Inc.||4|||f||||t||||||||||2018-05-31 22:09:30.395497|2018-05-31 22:09:30.395497
NCT01435707|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2013-12-24|2011-09-16|2011-09-19|Estimate|||||||2013-12-24|2013-12-25|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effect of Epidural Steroid Injections on Glycemic Control in Diabetic Patients According to the Doses of Steroids|The Effect of Epidural Steroid Injections on Glycemic Control in Diabetic Patients According to the Doses of Steroids|Completed||N/A|125|Actual|Samsung Medical Center||4|||f||||f||||||||||2018-05-31 22:09:30.511354|2018-05-31 22:09:30.511354
NCT01435694|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-01-15|2011-09-16|2011-09-19|Estimate|||||||2014-01-15|2014-01-16|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Robot-assisted Gait Training in Multiple Sclerosis Subjects|The Effects of Robot-assisted Gait Training on Locomotor Function and Motor Unit Firing in Multiple Sclerosis Subjects With Severe Gait Impairments. A Randomized Control Trial|Completed||N/A|60|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 22:09:30.634941|2018-05-31 22:09:30.634941
NCT01435681|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2016-09-07|2011-09-16|2011-09-19|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|October 2014|Actual|2014-10-31||Observational|||Can Short Latency Afferent Inhibition Give us Clues to Better DYT 1 Dystonia Treatments?|Can Short Latency Afferent Inhibition Give us Clues to Better Dystonia Treatments?|Completed|||5|Actual|University of Florida|||2||f||||t||||||||Yes||2018-05-31 22:09:30.767026|2018-05-31 22:09:30.767026
NCT01435668|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2014-01-03|2011-09-15|2011-09-16|Estimate|||||||2014-01-03|2014-01-06|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|AURAIA||AURAIA Study : Impact Evaluation at 3 Months Follow-up of a Brief Motivational Intervention in Reducing Alcohol Consumption Among Adolescents Aged 16-24 in Pontchaillou Hospital Emergency Department in Rennes, France|Impact Evaluation at 3 Months Follow-up of a Brief Motivational Intervention in Reducing Alcohol Consumption Versus Simple Written Advice Only Among Adolescents Aged 16-24 in Pontchaillou Hospital Emergency Department in Rennes, France|Completed||N/A|258|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 22:09:30.830495|2018-05-31 22:09:30.830495
NCT01435655|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2015-02-24||2015-08-10|2011-09-15|2011-09-16|Estimate|2015-08-10|2015-09-09|Estimate||||2015-08-10|2015-09-09|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin|The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study|Completed||Phase 3|10|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:09:30.950074|2018-05-31 22:09:30.950074
NCT01435642|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2017-01-19|2011-09-15|2011-09-16|Estimate|||||||2017-01-19|2017-01-20|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Observational|Diabcare||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes|Diabcare Paediatric - A Survey-study on Diabetes Management, Complications and Psychosocial Aspects of Type 1 Childhood Diabetics|Completed|||349|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:09:31.562254|2018-05-31 22:09:31.562254
NCT01435629|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-05-04|2011-09-15|2011-09-16|Estimate|||||||2017-05-04|2017-05-05|Actual|November 22, 2012|Actual|2012-11-22|May 2017|2017-05-31|December 4, 2015|Actual|2015-12-04|December 4, 2015|Actual|2015-12-04||Observational|||A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin|Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]|Completed|||81|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:09:31.666664|2018-05-31 22:09:31.666664
NCT01435616|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2018-03-16|2014-04-14|2018-03-16|2011-09-15|2011-09-16|Estimate|2018-03-16|2018-04-13|Actual|2014-04-14|2014-05-06|Estimate|2018-03-16|2018-04-13|Actual|November 2011||2011-11-30|March 2018|2018-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|IMAGINE 2|All randomized participants.|A Study in Patients With Type 2 Diabetes Mellitus|A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naive Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomized Study|Completed||Phase 3|1538|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 22:09:31.849207|2018-05-31 22:09:31.849207
NCT01435603|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2018-03-27||2018-03-27|2011-09-15|2011-09-16|Estimate|2018-03-27|2018-04-27|Actual||||2018-03-27|2018-04-27|Actual|August 2011||2011-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|I-D-HEALTH||Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study|Community Translation of a Lifestyle Intervention to Improve Health in Diabetes|Completed||N/A|331|Actual|Northwestern University|Over the 1 year measurement period, we experienced significant loss to follow-up in this diverse, predominantly low-income sample. We were only able to measure the primary outcome, body weight, on 257 of 331 participants at the 12 month visit.|2|||f||||t||||||||No||2018-05-31 22:09:33.587378|2018-05-31 22:09:33.587378
NCT01435590|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-05-27|2011-09-15|2011-09-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Endocervical Evaluation With the Curette Versus Cytobrush for the Diagnosis of Dysplasia of the Uterine Cervix||Completed||N/A|180|Anticipated|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 22:09:33.976583|2018-05-31 22:09:33.976583
NCT01435577|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|2013-03-05||2013-06-24|2011-09-15|2011-09-16|Estimate|2013-05-15|2013-06-24|Estimate||||2013-06-24|2013-07-02|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||The summary statistics provided for baseline was based on safety population that included 64 subjects in the tapentadol group and 65 in the placebo group. The safety population includes randomized participants that received at least one dose of study drug.|Intravenous Tapentadol in Post-Bunionectomy Pain|A Randomized, Double-blind, Placebo-controlled Parallel Group, Multicenter Trial to Evaluate the Efficacy and Safety of Multiple Dose Administration of an Intravenous Formulation of Tapentadol in the Treatment of Acute Pain Following Bunionectomy.|Completed||Phase 2|177|Actual|Grünenthal GmbH||2|||f||||f||||||||||2018-05-31 22:09:34.051453|2018-05-31 22:09:34.051453
NCT01435564|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-06-18|2011-09-15|2011-09-16|Estimate|||||||2014-06-18|2014-06-19|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|||Pilot Study: Mobile Phone Based Physical Activity in Sedentary Men and Women|Innovations in Mobile Phone Based Physical Activity- A Pilot of Clinical Trial in Sedentary Men and Women|Withdrawn||N/A|0|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:09:34.777618|2018-05-31 22:09:34.777618
NCT01435551|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2016-02-02|2011-09-15|2011-09-16|Estimate|||||||2016-02-02|2016-02-04|Estimate||||February 2016|2016-02-29||||||||Expanded Access|||Using Hypnotherapy For Dementia & Alzheimer's|Phase 1 a One Year Study of Using Hypnotherapy to Control Beta-amyloid Buildup That Causes Alzheimer's & Dementia CANCELLED|No longer available|||||Families To The Rescue|||||f||||||||||||||2018-05-31 22:09:34.835513|2018-05-31 22:09:34.835513
NCT01435538|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2017-10-12|2011-09-15|2011-09-16|Estimate|||||||2017-10-12|2017-10-13|Actual|May 2009||2009-05-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|June 2014|Actual|2014-06-30||Interventional|EQCP-TEAM||European Quality of Care Pathways Study on the Effect of Care Pathways on Interprofessional Teamwork (EQCP-TEAM)|The Impact of Care Pathways on Interprofessional Teamwork: an International Cluster Randomized Controlled Trial|Completed||N/A|984|Actual|European Pathway Association||2|||f||||t||||||||||2018-05-31 22:09:34.881243|2018-05-31 22:09:34.881243
NCT01435525|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-04-14|2011-09-15|2011-09-16|Estimate|||||||2014-04-14|2014-04-16|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication|Completed|||369|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 22:09:34.949222|2018-05-31 22:09:34.949222
NCT01435512|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-01-11|2011-09-15|2011-09-16|Estimate|||||||2016-01-11|2016-01-13|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Strength At Home: Veterans' Program (PTSD-Focused Therapy for Anger and Relationship Conflict Among OEF/OIF Veterans)|Strength At Home: Veterans' Program (Formerly: Post-Traumatic Stress Disorder (PTSD)-Focused Therapy for Anger and Relationship Conflict Among Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans)|Completed||N/A|135|Actual|Boston VA Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 22:09:35.195568|2018-05-31 22:09:35.195568
NCT01434992|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2012-04-19|2011-09-14|2011-09-15|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Detection of Helicobacter Pylori Infection by High Resolution Endoscopy|Detection of Helicobacter Pylori Infection by Non-magnifying High Resolution Endoscopy is Possible Within the Gastric Corpus|Completed|||585|Actual|Kyunghee University Medical Center|||1||f||||t||||||Samples Without DNA|"~     Gastric mucosa for detecting Helicobacter pylori~   "|||2018-05-31 22:09:41.555302|2018-05-31 22:09:41.555302
NCT01435499|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-05-23|2011-09-14|2011-09-16|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|January 2013|Actual|2013-01-31||Interventional|||Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma|A Feasibility and Toxicity Study of a Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Secreting Allogeneic Melanoma Vaccine Administered Alone or in Combination With Cyclophosphamide in Subjects With Surgically Resected At-Risk Melanoma|Completed||Phase 1|21|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-05-31 22:09:35.282923|2018-05-31 22:09:35.282923
NCT01435486|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-03-31|2011-09-15|2011-09-16|Estimate|||||||2015-03-31|2015-04-01|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants|Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants: A Randomized, Double Blind, Controlled Trial (RCT)|Completed||N/A|90|Actual|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 22:09:35.352867|2018-05-31 22:09:35.352867
NCT01435473|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-01-29|2011-09-15|2011-09-16|Estimate|||||||2016-01-29|2016-02-01|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Observational|CATCH||Clinical Assessment of Thrombosis in Children After Heart Surgery|Clinical Assessment of Thrombosis in Children After Heart Surgery: The CATCH Study|Completed|||400|Actual|The Hospital for Sick Children|||1||f||||t||||||||||2018-05-31 22:09:35.434463|2018-05-31 22:09:35.434463
NCT01435460|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2012-02-17||2012-02-17|2011-09-15|2011-09-16|Estimate|2012-02-17|2012-03-13|Estimate||||2012-02-17|2012-03-13|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)|A Clinical Safety and Efficacy Evaluation of Alrex® (Loteprednol Etabonate Ophthalmic Suspension, 0.2%) Versus Patanol (Olopatadine Hydrochloride Ophthalmic Solution, 0.1%) in the Treatment of Seasonal Allergic Conjunctivitis (SAC)|Completed||Phase 3|300|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:09:35.524969|2018-05-31 22:09:35.524969
NCT01435447|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2016-05-09|2011-09-15|2011-09-16|Estimate|||||||2016-05-09|2016-05-10|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult ALL|Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With ALL Undergoing Allogeienc Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|40|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 22:09:35.745186|2018-05-31 22:09:35.745186
NCT01435434|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2014-03-03|2011-09-15|2011-09-16|Estimate|||||||2014-03-03|2014-03-04|Estimate||||March 2014|2014-03-31||||||||Interventional|||Mononucleotide Autologous Stem Cells and Demineralized Bone Matrix in the Treatment of Non Union/Delayed Fractures||Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:09:35.892674|2018-05-31 22:09:35.892674
NCT01435421|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2011-09-15|2011-09-15|2011-09-16|Estimate|||||||2011-09-15|2011-09-16|Estimate|October 2011||2011-10-31|September 2011|2011-09-30||||December 2012|Anticipated|2012-12-31||Observational|||Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery|Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery|Unknown status|Not yet recruiting||112|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-05-31 22:09:35.951592|2018-05-31 22:09:35.951592
NCT01435408|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2018-05-22|2011-09-15|2011-09-16|Estimate|||||||2018-05-22|2018-05-23|Actual|April 2011||2011-04-30|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2016|Actual|2016-02-29||Interventional|DANAMI-3||DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction|A Randomised Comparison of the Clinical Outcome After Postconditioning or Deferred Stent Implantation Versus Conventional Treatment|Active, not recruiting||N/A|2000|Anticipated|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 22:09:35.994899|2018-05-31 22:09:35.994899
NCT01435395|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2016-04-25|2011-09-15|2011-09-16|Estimate|||||||2016-04-25|2016-04-27|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme|Phase I Trial of Temozolomide, Bevacizumab Plus Bortezomib for Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 1|12|Actual|Emory University||1|||f||||t||||||||||2018-05-31 22:09:36.083103|2018-05-31 22:09:36.083103
NCT01435382|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-03-29|2011-09-15|2011-09-16|Estimate|||||||2012-03-29|2012-03-30|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 in Subjects With Hypercholesterolemia|A Phase 1, Open-Label, Randomized, Single Dose, Parallel Group Study to Assess The Pharmacokinetics and Pharmacodynamics of PF-04950615 Following Subcutaneous and Intravenous Doses in Adult Subjects With Hypercholesterolemia|Completed||Phase 1|49|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:09:36.156037|2018-05-31 22:09:36.156037
NCT01435369|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08||2014-09-11|2015-12-16|2011-09-15|2011-09-16|Estimate||||2014-09-11|2014-09-22|Estimate|2015-12-16|2016-01-21|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma|Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients With Metastatic Melanoma|Completed||Phase 2|103|Actual|Medivation, Inc.||2|||f||||t||||||||||2018-05-31 22:09:36.249917|2018-05-31 22:09:36.249917
NCT01435356|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2017-06-15|2011-09-15|2011-09-16|Estimate|||||||2017-06-15|2017-06-16|Actual|August 2011|Actual|2011-08-31|June 2017|2017-06-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|MAGNOLIA||Safety and Efficacy Study of Cancer Immunotherapeutic MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy|A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy|Terminated||Phase 2|83|Actual|European Association of Urology Research Foundation||2|||f||||t||||||||||2018-05-31 22:09:36.35194|2018-05-31 22:09:36.35194
NCT01435343|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-04-23|2011-09-15|2011-09-16|Estimate|||||||2017-04-23|2017-04-25|Actual|July 2012||2012-07-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia|Multicenter, Prospective, Open-label, Single-arm, Phase I-II Clinical Trial to Analyze Induction Therapy With a Combination of Fludarabine, Idarubicin, Cytarabine, G-CSF and Plerixafor for the Treatment of Young Patients With Relapsed or Refractory AML|Completed||Phase 1/Phase 2|55|Actual|PETHEMA Foundation|||||f||||t||||||||||2018-05-31 22:09:36.494611|2018-05-31 22:09:36.494611
NCT01435330|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-04-23|2011-09-15|2011-09-16|Estimate|||||||2015-04-23|2015-04-24|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Tolerability of BVS857 in Subjects With Insulin Resistance|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Parenterally Administered BVS857 in Healthy Subjects Without and With Insulin Resistance|Completed||Phase 1|43|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:09:36.565089|2018-05-31 22:09:36.565089
NCT01435317|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-07-10|2011-09-15|2011-09-16|Estimate|||||||2014-07-10|2014-07-11|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2013|Actual|2013-06-30||Interventional|RRL||"Acoustic Coordinated Reset (CR®) Neuromodulation for the Treatment of Chronic Tonal Tinnitus (RESET Real Life)"|"Prospective Clinical Study for Confirmation of Efficacy and Safety of Acoustic CR®-Neuromodulation by CE Marked ANM T30 CR®-System in a Real Life Patient Population With Chronic Tonal Tinnitus"|Completed||Phase 4|200|Actual|ANM Adaptive Neuromodulation GmbH||1|||f||||t||||||||||2018-05-31 22:09:36.631717|2018-05-31 22:09:36.631717
NCT01435304|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2018-03-29||2018-03-29|2011-09-15|2011-09-16|Estimate|2018-03-29|2018-05-02|Actual||||2018-03-29|2018-05-02|Actual|September 2011||2011-09-30|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass|The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass|Completed||Phase 4|100|Actual|Maine Medical Center||2|||f||||t||||||||||2018-05-31 22:09:36.730865|2018-05-31 22:09:36.730865
NCT01435291|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-07-28|2011-09-15|2011-09-16|Estimate|||||||2014-07-28|2014-07-29|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|AADAPT||AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation|Prospective Pharmacokinetic and Pharmacogenetic Analysis of Advagraf After Transplantation|Completed||Phase 4|45|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 22:09:37.110106|2018-05-31 22:09:37.110106
NCT01435278|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2012-07-25|2011-09-15|2011-09-16|Estimate|||||||2012-07-25|2012-07-27|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety of Glucosanol in Maintaining Body Weight|Open-label Clinical Investigation to Evaluate the Safety and Efficacy of Glucosanol in Maintaining Body Weight Loss in Overweight and Obese Subjects|Completed||Phase 4|51|Actual|InQpharm Group||1|||f||||f||||||||||2018-05-31 22:09:37.186431|2018-05-31 22:09:37.186431
NCT01435265|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2012-12-19||2017-11-01|2011-09-14|2011-09-16|Estimate|2013-01-28|2013-03-05|Estimate||||2017-11-01|2017-12-06|Actual|January 2010||2010-01-31|November 2017|2017-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab|The Effectiveness of Nurse Education and Its Impact on Treatment Adherence in Subjects With Moderate to Severe Psoriasis Undergoing Treatment With Adalimumab|Completed||N/A|7|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 22:09:37.273071|2018-05-31 22:09:37.273071
NCT01435252|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-11-02|2011-09-15|2011-09-16|Estimate|||||||2017-11-02|2017-11-06|Actual|September 19, 2011|Actual|2011-09-19|November 2017|2017-11-30|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab|A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab|Completed||Phase 2|68|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 22:09:37.631006|2018-05-31 22:09:37.631006
NCT01435239|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-03-04|2011-09-15|2011-09-16|Estimate|||||||2014-03-04|2014-03-06|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Comparison of Two Different Methods of Partial Inflation of Cuff for Facile Insertion of Laryngeal Mask Airway in Pediatric Patients||Completed||N/A|78|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:09:37.70684|2018-05-31 22:09:37.70684
NCT01435226|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13||2013-11-22|2013-11-22|2011-09-15|2011-09-16|Estimate||||2013-11-22|2013-12-17|Estimate|2013-11-22|2013-12-17|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared With GS-5885, GS-9451 With Tegobuvir or RBV in Treatment-Experienced Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection|Completed||Phase 2|170|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 22:09:37.829684|2018-05-31 22:09:37.829684
NCT01435213|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2013-02-15|2011-09-15|2011-09-16|Estimate|||||||2013-02-15|2013-02-18|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|AIMI||Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline|Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline - a PET Study in Healthy Human Subjects|Completed||Phase 1|10|Actual|University of Turku||6|||f||||f||||||||||2018-05-31 22:09:37.983776|2018-05-31 22:09:37.983776
NCT01435200|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-01-31|2011-09-15|2011-09-16|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy|Prevention of Blood Transfusion With Intravenous Iron in Gynecologic Cancer Patients Receiving Platinum Based Chemotherapy|Completed||Phase 3|64|Actual|Chulalongkorn University||2|||f||||f||||||||No||2018-05-31 22:09:38.080861|2018-05-31 22:09:38.080861
NCT01435187|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2016-11-04|2011-09-14|2011-09-16|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Observational|PROP||Prematurity and Respiratory Outcomes Program (PROP)|Prematurity and Respiratory Outcomes Program (PROP) Core Database Protocol|Completed|||835|Actual|University of Pennsylvania|||1||f||||t||||||Samples With DNA|"~     Saliva for DNA, Urine and Tracheal Aspirate~   "|Undecided||2018-05-31 22:09:38.159754|2018-05-31 22:09:38.159754
NCT01435174|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2014-05-21||2017-09-13|2011-09-14|2011-09-16|Estimate|2014-05-21|2014-06-25|Estimate||||2017-09-13|2017-10-16|Actual|October 2011||2011-10-31|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Patients 18 to 74 with chronic kidney disease stage 5 receiving 3 times weekly maintenance hemodialysis for at least 3 months were considered for study inclusion. Patients had to weigh >40 kilograms, be within 50-150% of their ideal body weight, have an eGFR of <10 mL/min, have no evidence of infection, and be able to give informed consent.|Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients|Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients|Completed||Phase 4|17|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 22:09:38.248288|2018-05-31 22:09:38.248288
NCT01435161|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2012-11-15|2011-09-15|2011-09-16|Estimate|||||||2012-11-15|2012-11-16|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF|The Effect of Nifedipine Versus Telmisartan on Prevention of Atrial Fibrillation Recurrence in Hypertensive Patients With Paroxysmal Atrial Fibrillation by Intensive Lower Blood Pressure|Completed||Phase 4|160|Actual|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 22:09:38.399262|2018-05-31 22:09:38.399262
NCT01435148|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-09-14|2011-09-14|2011-09-15|Estimate|||||||2011-09-14|2011-09-15|Estimate|December 2006||2006-12-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Deep Brain Stimulation in Treatment Resistant Depression|A Double Blind Randomised Pilot Study of Deep Brain Stimulation in Patients With Treatment Resistant Unipolar Major Depressive Disorder.|Unknown status|Active, not recruiting|N/A|8|Actual|North Bristol NHS Trust||2|||f||||t||||||||||2018-05-31 22:09:38.474706|2018-05-31 22:09:38.474706
NCT01435135|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2018-05-02|2011-09-14|2011-09-15|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2012||2012-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144|"Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults"|Active, not recruiting||Phase 2|162|Anticipated|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-05-31 22:09:38.550752|2018-05-31 22:09:38.550752
NCT01435122|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2017-03-22||2018-03-19|2011-09-14|2011-09-15|Estimate|2017-04-18|2017-05-25|Actual||||2018-03-19|2018-04-18|Actual|October 25, 2011|Actual|2011-10-25|March 2018|2018-03-31|February 13, 2018|Actual|2018-02-13|January 11, 2017|Actual|2017-01-11||Interventional||All participants.|A Study of Axitinib in Advanced Carcinoid Tumors|A Phase II Study of Axitinib in Advanced Carcinoid Tumors|Completed||Phase 2|30|Actual|H. Lee Moffitt Cancer Center and Research Institute|Results are limited by a relatively high rate of participant withdrawal before progression due to toxicity. Post analysis, 2 participants are still on study at UCSF.|1|||f||||t|t|f||||||||2018-05-31 22:09:38.659286|2018-05-31 22:09:38.659286
NCT01435109|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-06-06|2011-09-14|2011-09-15|Estimate|||||||2016-06-06|2016-06-08|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PRIMO||Patient and Provider Interventions for Managing Osteoarthritis in Primary Care|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care|Completed||N/A|537|Actual|Duke University||4|||f||||f||||||||||2018-05-31 22:09:38.982364|2018-05-31 22:09:38.982364
NCT01435096|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-09-13|2011-09-13|2011-09-15|Estimate|||||||2011-09-13|2011-09-15|Estimate|November 2004||2004-11-30|September 2011|2011-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||BN80927 in Patients With Advanced Malignant Solid Tumors|A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|56|Actual|Ipsen||1|||f||||||||||||||2018-05-31 22:09:39.058116|2018-05-31 22:09:39.058116
NCT01435083|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-12-04|2011-09-14|2011-09-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study|Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study|Completed||Phase 4|50|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:09:39.117144|2018-05-31 22:09:39.117144
NCT01435070|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2011-09-14|2011-09-14|2011-09-15|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Observational|||Functional Outcome Following Fracture of the Distal Radius|A Correlation of Functional Outcome Measures of Fractures of the Distal Radius Following Operative Management|Unknown status|Recruiting||50|Anticipated|University of Warwick|||1||f||||f||||||||||2018-05-31 22:09:39.186737|2018-05-31 22:09:39.186737
NCT01435057|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2015-05-27|2011-09-14|2011-09-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Effects of Different Exercise Training Regimens on Visceral Fat Dynamic and Resting Energy Expenditure in Obese Patients|Monocentric, Randomized, Controlled Study for Reduction on Visceral Fat Dynamic and Resting Energy Expenditure in Obese Patients Via Strength Versus Endurance Training (STEN Study - STrength Versus ENdurance Training)|Unknown status|Recruiting|N/A|200|Anticipated|University of Leipzig||2|||f||||f||||||||||2018-05-31 22:09:39.256788|2018-05-31 22:09:39.256788
NCT01435044|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09||2013-11-20|2014-01-07|2011-09-13|2011-09-15|Estimate||||2013-11-20|2013-12-13|Estimate|2014-01-07|2014-02-06|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|QUANTUM||Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection|QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|239|Actual|Gilead Sciences||7|||f||||f||||||||||2018-05-31 22:09:39.340182|2018-05-31 22:09:39.340182
NCT01435031|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2014-11-14||2018-04-10|2011-09-14|2011-09-15|Estimate|2014-11-14|2014-11-25|Estimate||||2018-04-10|2018-05-09|Actual|September 2011||2011-09-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|February 2014|Actual|2014-02-28||Interventional|EXPERT CTO|ITT subjects (N=222) include all subjects who met the study entry criteria, signed the written informed consent, were enrolled in the trial and whose target lesion was successfully crossed and predilated.|EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions|Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions|Completed||N/A|250|Actual|Abbott Vascular||1|||f||||f||||||||||2018-05-31 22:09:39.716253|2018-05-31 22:09:39.716253
NCT01435018|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-10-17|2011-09-14|2011-09-15|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2013||2013-08-31|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS|A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings|Recruiting||Phase 3|706|Anticipated|AIDS Clinical Trials Group||3|||f||||t||||||||||2018-05-31 22:09:41.26104|2018-05-31 22:09:41.26104
NCT01435005|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-01-27|2011-09-14|2011-09-15|Estimate|||||||2018-01-27|2018-01-30|Actual|March 2010||2010-03-31|January 2018|2018-01-31|June 2014|Actual|2014-06-30|April 2013|Actual|2013-04-30||Interventional|BETA||Breast Cancer and Exercise Trial in Alberta|Breast Cancer and Exercise Trial in Alberta: The BETA Trial|Completed||N/A|400|Actual|AHS Cancer Control Alberta||2|||f||||f||||||||No||2018-05-31 22:09:41.365168|2018-05-31 22:09:41.365168
NCT01434966|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-12-10|2011-09-14|2011-09-15|Estimate|||||||2015-12-10|2015-12-14|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Changes in Quadriceps Function Following Local or Distant Interventions in Individuals With Patellofemoral Pain|Changes in Quadriceps Function Following Local or Distant Interventions in Individuals With Patellofemoral Pain|Completed||N/A|47|Actual|Creighton University||3|||f||||f||||||||||2018-05-31 22:09:41.727076|2018-05-31 22:09:41.727076
NCT01434953|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-07-13|2011-09-14|2011-09-15|Estimate|||||||2017-07-13|2017-07-17|Actual|July 13, 2009|Actual|2009-07-13|July 2017|2017-07-31|July 9, 2012|Actual|2012-07-09|July 9, 2012|Actual|2012-07-09||Interventional|Tanya K23||Prehypertension Labeling|Diagnostic Labeling: Effect on White Coat Hypertension|Terminated||N/A|100|Actual|Columbia University||2||PI left institution|f||||f||||||||||2018-05-31 22:09:41.804413|2018-05-31 22:09:41.804413
NCT01434940|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2017-07-27|2011-09-14|2011-09-15|Estimate|||||||2017-07-27|2017-07-31|Actual|April 2010||2010-04-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|MOMAD||Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression|Early Oculomotor Markers in Alzheimer's Disease: Test of Predictive Value in the Differential Diagnosis Depression/Alzheimer|Recruiting||N/A|288|Anticipated|Centre Hospitalier Universitaire de Besancon||3|||f||||t||||||||||2018-05-31 22:09:41.874336|2018-05-31 22:09:41.874336
NCT01434927|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-09-13|2011-09-13|2011-09-15|Estimate|||||||2011-09-13|2011-09-15|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||The Clinical Acceptability of Unsedated Colonoscopy|Unsedated Colonoscopy: An Option For Some But Not For All|Completed|||964|Actual|Valduce Hospital|||1||f||||f||||||||||2018-05-31 22:09:41.948152|2018-05-31 22:09:41.948152
NCT01434914|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-05-12|2011-09-14|2011-09-15|Estimate|||||||2014-05-12|2014-05-13|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds|Randomized, Double-blind, Single-center, Placebo-controlled Study to Evaluate the Efficacy of Octenisept® in Patients With Chronic Wounds|Terminated||Phase 4|9|Actual|Schülke & Mayr GmbH||2||early termination due to poor recruitment|f||||f||||||||||2018-05-31 22:09:42.01238|2018-05-31 22:09:42.01238
NCT01434901|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-05-07|2011-09-14|2011-09-15|Estimate|||||||2018-05-07|2018-05-08|Actual|August 15, 2011|Actual|2011-08-15|May 2018|2018-05-31|July 7, 2014|Actual|2014-07-07|July 7, 2014|Actual|2014-07-07||Interventional|||The Effects of Bethanechol on Glucose Homeostasis|The Effects of Bethanechol, a Muscarinic Agonist, on Plasma Insulin, Glucagon, and Glucose Levels in Humans With and Without Type 2 Diabetes Mellitus|Completed||Phase 1|50|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 22:09:42.085757|2018-05-31 22:09:42.085757
NCT01434888|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2012-06-07|2011-09-14|2011-09-15|Estimate|||||||2012-06-07|2012-06-08|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops|A Phase I, Randomized, Double-masked, 3-period Cross-over Clinical Study to Compare the Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops to Those of Preservative-free Tafluprost 0.0015% and Timolol 0.5% Eye Drops in Healthy Volunteers|Completed||Phase 1|15|Actual|Santen Oy||3|||f||||f||||||||||2018-05-31 22:09:42.164131|2018-05-31 22:09:42.164131
NCT01434862|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2014-04-30|2011-09-14|2011-09-15|Estimate|||||||2014-04-30|2014-05-01|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ALM002||Pramlintide Combined With Model Predictive Control Algorithm|Pramlintide Combined With Model Predictive Control Algorithm|Terminated||N/A|2|Actual|University of Virginia||3||Modified study; created new study as a result of these modifications|f||||f||||||||||2018-05-31 22:09:42.224967|2018-05-31 22:09:42.224967
NCT01434849|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-11-14|2011-09-14|2011-09-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|TiPPIH||Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)|Phase 1 Study of Topical Beta Blocker to Prevent the Proliferative Stage of Infantile Hemangioma|Terminated||Phase 1|26|Actual|The University of Texas Health Science Center at San Antonio||2||Difficulty with enrolled patients to complete trial.|f||||t||||||||No|Many participants did not complete trial so there is not enough data to share.|2018-05-31 22:09:42.298954|2018-05-31 22:09:42.298954
NCT01434836|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2013-05-30|2011-09-14|2011-09-15|Estimate|||||||2013-05-30|2013-06-03|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Neuro-modulation of the Depressed Brain Using Working Memory Training and Transcranial Direct Current Stimulation (tDCS)|Neuro-modulation of the Depressed Brain Using Working Memory Training and tDCS|Completed||Phase 2|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:09:42.365672|2018-05-31 22:09:42.365672
NCT01434823|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2013-03-01||2017-09-20|2011-09-14|2011-09-15|Estimate|2015-11-30|2016-01-05|Estimate||||2017-09-20|2018-05-28|Estimate|September 2011||2011-09-30|September 2017|2017-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||824 patients were randomized to the intervention group, 4 of which have been excluded from analyses to due incomplete data (n=820), 785 were randomized to the control group, 7 of which have been excluded from analyses due to incomplete data (n=778).|24 Hour Intensivist Coverage in the Medical Intensive Care Unit|The Effects of 24-hour Intensivist Coverage in the Medical ICU|Completed||N/A|1609|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:09:42.432534|2018-05-31 22:09:42.432534
NCT01434810|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2015-06-01|2011-09-14|2011-09-15|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates|Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates|Completed||Phase 1/Phase 2|1273|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 22:09:43.705836|2018-05-31 22:09:43.705836
NCT01434797|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-11-13|2011-09-13|2011-09-15|Estimate|||||||2016-11-13|2016-11-15|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection|Prospective Study on the Usefulness and Diagnostic Value of F-18-FDG PET/CT in the Diagnosis of Permanent Central Venous Catheters Infection|Recruiting|||40|Anticipated|University of Lausanne Hospitals|||3||f||||f||||||||No||2018-05-31 22:09:43.789763|2018-05-31 22:09:43.789763
NCT01434784|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2017-06-08|2011-09-13|2011-09-15|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2011||2011-09-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Update of the EORTC QLQ-LC13 Quality of Life Questionnaire|Update of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) Phases I - III|Completed|||200|Actual|University Hospital Regensburg|||9||f||||f||||||||No||2018-05-31 22:09:43.863184|2018-05-31 22:09:43.863184
NCT01434771|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2013-10-15|2011-09-14|2011-09-15|Estimate|||||||2013-10-15|2013-10-16|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Monitoring Blood Flow and Breathing Using a New Device (RFII) Compared to the Gold Standard Device in Post Operative Cardiac Patients|Simultaneous Hemodynamic and Ventilatory Monitoring Using Radio Frequency Impedance Interrogation (RFII), Thoracic Impedance Cardiography and Invasive Hemodynamic Monitoring Methods in Post Operative Cardiac Patients|Withdrawn|||0|Actual|University of Florida||||Sponsor never funded study.|f||||f||||||||||2018-05-31 22:09:43.932525|2018-05-31 22:09:43.932525
NCT01434758|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2016-11-13|2011-09-14|2011-09-15|Estimate|||||||2016-11-13|2016-11-15|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Observational|||Evaluating Diagnostics for Paediatric Tuberculosis by Blood Culture|Evaluating Diagnostics for Paediatric Tuberculosis by Blood Culture|Completed|||560|Actual|Oxford University Clinical Research Unit, Vietnam|||1||f||||f||||||Samples With DNA|"~     -  sputum~        -  gastric aspirate~        -  blood~        -  urine~        -  cerebrospinal fluid~   "|||2018-05-31 22:09:43.974273|2018-05-31 22:09:43.974273
NCT01434745|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-03-21|2011-09-13|2011-09-15|Estimate|||||||2012-03-21|2012-03-23|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||SLOS: The Effect of Simvastatin in Patients Receiving Cholesterol Supplementation|Smith-Lemli Opitz Syndrome: A Clinical Investigation of the Effect of Simvastatin in Patients Receiving Cholesterol Supplementation|Unknown status|Recruiting|N/A|16|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:09:44.039676|2018-05-31 22:09:44.039676
NCT01434732|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2017-10-06|2011-09-14|2011-09-15|Estimate|||||||2017-10-06|2017-10-09|Actual|April 2011||2011-04-30|October 2017|2017-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Milking the Umbilical Cord on Systemic Blood Flow|A Randomized Controlled Trial of Umbilical Cord Milking Versus Immediate Cord Clamping on Systemic Blood Flow in Premature Infants|Completed||N/A|60|Actual|Sharp HealthCare||2|||f||||t||||||||||2018-05-31 22:09:44.119621|2018-05-31 22:09:44.119621
NCT01434719|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2016-11-13|2011-09-14|2011-09-15|Estimate|||||||2016-11-13|2016-11-15|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Human Suis and Pig Diseases in Northern Vietnam|Spatial and Temporal Associations Between Human Streptococcus Suis Infections and Pig Diseases in Northern Vietnam, 2010|Completed|||273|Actual|Oxford University Clinical Research Unit, Vietnam|||2||f||||f||||||||||2018-05-31 22:09:44.285034|2018-05-31 22:09:44.285034
NCT01434706|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-12-02|2011-09-14|2011-09-15|Estimate|||||||2014-12-02|2014-12-04|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection|NAT: The Early Test Program: Implementation of NAT Screening to Identify Acute and Early HIV Infection at San Diego Public HIV Counseling and Testing Sites|Unknown status|Recruiting|Phase 3|12000|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 22:09:44.366791|2018-05-31 22:09:44.366791
NCT01434693|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2013-02-26||2013-05-17|2011-09-14|2011-09-15|Estimate|2013-05-17|2013-05-20|Estimate||||2013-05-17|2013-05-20|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease|A Sequential Dose-Escalation, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety and Tolerability of Single Doses of 3 Different Doses of Oral CNDO 201 Trichuris Suis Ova Suspension (Tso) in Patients With Crohn's Disease|Completed||Phase 1|36|Actual|Coronado Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 22:09:44.490225|2018-05-31 22:09:44.490225
NCT01434680|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|2013-07-18||2017-03-13|2011-09-14|2011-09-15|Estimate|2014-02-24|2014-03-26|Estimate||||2017-03-13|2017-04-25|Actual|September 2011||2011-09-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers|A Phase 2, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of the New Liquid Formulation of Novartis Meningococcal C Conjugate Vaccine and of the Novartis Lyophilized Meningococcal C Conjugate Vaccine Manufactured at Two Different Sites, in Healthy Toddlers|Completed||Phase 2|992|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:09:44.945825|2018-05-31 22:09:44.945825
NCT01434667|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-07-30|2011-09-14|2011-09-15|Estimate|||||||2013-07-30|2013-08-01|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV|Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV|Unknown status|Active, not recruiting|N/A|360|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:09:45.33454|2018-05-31 22:09:45.33454
NCT01434654|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2016-02-09||2016-07-06|2011-09-13|2011-09-15|Estimate|2016-04-13|2016-05-20|Estimate||||2016-07-06|2016-08-09|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|HANDobs|Data presented reflect baseline demographic and clinical characteristics for participants included in the primary analysis.|Efficacy of Neuro-HAART in Patients With HIV|The Efficacy of Neuro-HAART in HIV Infected Individuals|Terminated|||19|Actual|St Vincent's Hospital, Sydney|Lower than expected participant recruitment rate and early termination led to a small sample size and underpowered statistical analyses||2|Slower than expected recruitment|f||||f||||||Samples Without DNA|"~     Cerbrospinal fluid and bloods~   "|||2018-05-31 22:09:45.45044|2018-05-31 22:09:45.45044
NCT01434641|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2012-10-01||2016-03-10|2011-09-14|2011-09-15|Estimate|2016-03-10|2016-04-11|Estimate||||2016-03-10|2016-04-11|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography|Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial SPECT|Completed||N/A|102|Actual|St. Luke's-Roosevelt Hospital Center||1|||f||||f||||||||||2018-05-31 22:09:45.996319|2018-05-31 22:09:45.996319
NCT01434290|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2017-08-24||2017-10-16|2011-09-13|2011-09-14|Estimate|2017-10-16|2017-11-17|Actual||||2017-10-16|2017-11-17|Actual|September 2011||2011-09-30|October 2017|2017-10-31||||June 2015|Actual|2015-06-30||Interventional||Eligible patients who started protocol treatment|Radiation Therapy in Treating Patients With Prostate Cancer|A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer|Active, not recruiting||Phase 2|255|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 22:09:48.926116|2018-05-31 22:09:48.926116
NCT01434628|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2014-05-22|2011-09-14|2011-09-15|Estimate|||||||2014-05-22|2014-05-23|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by Nurses|One Arm, Open Label, Prospective, Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Non-Surgical Circumcision When Performed by Nurses in Resource Limited Settings for HIV Prevention|Completed||N/A|590|Actual|Ministry of Health, Rwanda||1|||f||||f||||||||||2018-05-31 22:09:46.213976|2018-05-31 22:09:46.213976
NCT01434615|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2017-12-05|2011-09-14|2011-09-15|Estimate|||||||2017-12-05|2017-12-07|Actual|October 2008|Actual|2008-10-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SASHFR||Medtronic South Asian Systolic Heart Failure Registry|SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients.|Completed||Phase 4|502|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-05-31 22:09:46.278268|2018-05-31 22:09:46.278268
NCT01434602|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2018-03-13|2011-09-14|2011-09-15|Estimate|||||||2018-03-13|2018-03-14|Actual|November 5, 2015||2015-11-05|December 16, 2017|2017-12-16|July 1, 2020|Anticipated|2020-07-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas|A Phase I-II Trial of Everolimus and Sorafenib in Patients With Recurrent High-Grade Gliomas|Recruiting||Phase 1/Phase 2|118|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:09:46.364031|2018-05-31 22:09:46.364031
NCT01434589|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-10-10|2011-09-14|2011-09-15|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2012||2012-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|STICA||Effects of a Manualized Short-term Treatment of Internet and Computer Game Addiction|Effects of a Manualized Short-term Treatment of Internet and Computer Game Addiction|Completed||N/A|187|Actual|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 22:09:46.45873|2018-05-31 22:09:46.45873
NCT01434576|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-08-01|2011-09-13|2011-09-15|Estimate|||||||2013-08-01|2013-08-02|Estimate|December 2011||2011-12-31|August 2013|2013-08-31||||December 2012|Anticipated|2012-12-31||Interventional|||Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics and Safety of HGS1025, a Human Monoclonal Anti-CCR5 Antibody, in Subjects With Ulcerative Colitis|Withdrawn||Phase 1|0|Actual|Human Genome Sciences Inc.||3||Sponsor withdrew study for business reasons|f||||f||||||||||2018-05-31 22:09:46.543112|2018-05-31 22:09:46.543112
NCT01434563|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2012-10-22|2011-09-14|2011-09-15|Estimate|||||||2012-10-22|2012-10-24|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|CNS HAND||The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -|The CNS HAND Study: The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort|Completed|||326|Actual|Holdsworth House Medical Practice|||2||f||||f||||||||||2018-05-31 22:09:46.612713|2018-05-31 22:09:46.612713
NCT01434550|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2017-02-21|2011-09-14|2011-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2012||2012-03-31|February 2017|2017-02-28|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer|Phase II Study of First-line Stereotactic Body Radiation Therapy (SBRT) in Patients With Non-Metastatic Unresectable Pancreatic Cancer|Withdrawn||N/A|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||2||research cancelled|f||||t||||||||||2018-05-31 22:09:46.668666|2018-05-31 22:09:46.668666
NCT01434537|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-09-14|2011-09-14|2011-09-15|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Observational|VENSCAN||Evaluation of a Touchless Vein Scanner for Venepuncture and Cannulation in Pediatric Patients|Venepuncture and Vein Cannulation With Support of the AccuVein AV300 Vein Scanner in Paediatric Patients in a Pre-operation Setting|Completed|||238|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 22:09:46.746045|2018-05-31 22:09:46.746045
NCT01434524|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-14|2011-09-14|2011-09-15|Estimate|||||||2011-09-14|2011-09-15|Estimate|April 2007||2007-04-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|October 2008|Actual|2008-10-31||Interventional|||Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids|The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids|Completed||N/A|56|Actual|Kochi University||2|||f||||t||||||||||2018-05-31 22:09:46.803535|2018-05-31 22:09:46.803535
NCT01434511|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2014-12-11||2017-10-19|2011-09-13|2011-09-15|Estimate|2014-12-11|2014-12-17|Estimate||||2017-10-19|2017-11-24|Actual|August 2011||2011-08-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||This study was terminated early and only enrolled one participant. Due to concerns that the participant would be at risk of being re-identified, study results are not posted. The decision to terminate this study was not related to any safety and/or efficacy concern of OBI-1 in the indication described within this study (Congenital Hemophilia A).|Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A|Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients With Congenital Hemophilia A With Factor VIII Inhibitors|Terminated||Phase 3|1|Actual|Shire||1|||f||||t||||||||||2018-05-31 22:09:46.90007|2018-05-31 22:09:46.90007
NCT01434498|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09||2013-11-26|2013-11-26|2011-09-14|2011-09-15|Estimate||||2013-11-26|2013-12-20|Estimate|2013-11-26|2013-12-20|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b HCV Infection (Protocol No. GS US 248 0132)|Completed||Phase 2|163|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 22:09:47.099234|2018-05-31 22:09:47.099234
NCT01434485|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-04-14|2011-09-14|2011-09-15|Estimate|||||||2014-04-14|2014-04-16|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Nexium Capsules Clinical Experience Investigation|Nexium Capsules Clinical Experience Investigation|Completed|||3691|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 22:09:47.331166|2018-05-31 22:09:47.331166
NCT01433939|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2018-04-30|2011-09-13|2011-09-14|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2011||2011-09-30|April 2018|2018-04-30|May 25, 2015|Actual|2015-05-25|May 25, 2015|Actual|2015-05-25||Observational|||Position Changes During Colonoscope Insertion Increases Patient Comfort|Position Changes During Colonoscope Insertion Increases Patient Comfort: a Prospective Trial|Completed|||200|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 22:09:56.877366|2018-05-31 22:09:56.877366
NCT01434472|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-12-04|2011-09-14|2011-09-15|Estimate|||||||2017-12-04|2017-12-06|Actual|November 16, 2011|Actual|2011-11-16|December 2017|2017-12-31||||June 1, 2018|Anticipated|2018-06-01||Interventional|||High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma|A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma|Recruiting||Phase 2|24|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 22:09:47.448714|2018-05-31 22:09:47.448714
NCT01434459|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2015-05-01|2011-09-14|2011-09-15|Estimate|||||||2015-05-01|2015-05-04|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|||Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin|Phase I Trial of Gemcitabine With TheraSphere® (Yttrium-90) in Patients With Hepatic Tumors of Pancreatobiliary Origin|Terminated||Phase 1|9|Actual|Emory University||1||PI moved to different institution|f||||t||||||||||2018-05-31 22:09:47.570375|2018-05-31 22:09:47.570375
NCT01434446|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2012-04-02|2011-09-14|2011-09-15|Estimate|||||||2012-04-02|2012-04-03|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||The Effect of Sound Stimulation on Hearing Ability|The Effect of Sound Stimulation on Hearing Ability|Completed||N/A|21|Actual|Earlogic Korea, Inc.|||||f||||||||||||||2018-05-31 22:09:47.650106|2018-05-31 22:09:47.650106
NCT01434433|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-01-12|2011-09-14|2011-09-15|Estimate|||||||2015-01-12|2015-01-14|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|ABC||Alere Triage fs B-type Natriuretic Peptide (BNP) Method Comparison Evaluation|Alere Triage fs BNP Method Comparison Evaluation|Completed|||360|Actual|Alere San Diego|||||f||||f||||||||||2018-05-31 22:09:47.711641|2018-05-31 22:09:47.711641
NCT01434420|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-12-30|2011-09-13|2011-09-14|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|March 2020|Anticipated|2020-03-31|August 2014|Actual|2014-08-31||Interventional|||Triple Negative Breast Cancer: Study of Molecular and Genetic Factors|Triple Negative Breast Cancer: Study of Molecular and Genetic Factors|Active, not recruiting||N/A|200|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 22:09:47.771995|2018-05-31 22:09:47.771995
NCT01434407|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2012-09-03|2011-09-13|2011-09-14|Estimate|||||||2012-09-03|2012-09-05|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|AGE-1||Effects of Advanced Glycation Endproducts on Satiety and Inflammation|Crossover Meal Study Investigating Effects of Advanced Glycation Endproducts on Satiety and Inflammation|Completed||N/A|19|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 22:09:47.844785|2018-05-31 22:09:47.844785
NCT01434394|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2017-08-16|2011-09-13|2011-09-14|Estimate|||||||2017-08-16|2017-08-21|Actual|August 2011||2011-08-31|May 2014|2014-05-31|February 2017|Actual|2017-02-28|October 2014|Actual|2014-10-31||Interventional|EAGLE||Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer|Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer|Completed||Phase 2/Phase 3|243|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 22:09:47.930223|2018-05-31 22:09:47.930223
NCT01434381|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2014-02-10|2011-09-13|2011-09-14|Estimate|||||||2014-02-10|2014-02-11|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark)|Open Label Phase 1 Study in Malaria Naive Adults of the Safety and Immunogenicity of Pfs25-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 22:09:48.027473|2018-05-31 22:09:48.027473
NCT01434368|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2018-05-18|2011-09-13|2011-09-14|Estimate|||||||2018-05-18|2018-05-21|Actual|September 13, 2011||2011-09-13|April 25, 2018|2018-04-25||||||||Observational|||A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty|A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty|Recruiting|||344|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:09:48.105759|2018-05-31 22:09:48.105759
NCT01434355|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2017-10-05|2011-09-13|2011-09-14|Estimate|||||||2017-10-05|2017-10-09|Actual|November 2011||2011-11-30|October 2017|2017-10-31||||August 2018|Anticipated|2018-08-31||Observational|||DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings|Molecular Epidemiology of Pediatric Germ Cell Tumors|Recruiting|||932|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Saliva and tissue~   "|||2018-05-31 22:09:48.184579|2018-05-31 22:09:48.184579
NCT01434342|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2017-05-08||2017-05-08|2011-09-13|2011-09-14|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|October 2011||2011-10-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional||All randomized participants|Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients|Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study|Completed||N/A|146|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||No||2018-05-31 22:09:48.291497|2018-05-31 22:09:48.291497
NCT01434329|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2016-04-14|2011-09-13|2011-09-14|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia|S8600-S9031-S9333-A, Identification of Differentially Methylated Genomic Regions That Are Prognostically Significant in AML|Completed|||200|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-05-31 22:09:48.686815|2018-05-31 22:09:48.686815
NCT01434316|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2018-05-11|2011-09-13|2011-09-14|Estimate|||||||2018-05-11|2018-05-14|Actual|November 1, 2011|Actual|2011-11-01|May 2018|2018-05-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors|Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|130|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 22:09:48.740915|2018-05-31 22:09:48.740915
NCT01434303|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2018-05-23|2011-09-13|2011-09-14|Estimate|||||||2018-05-23|2018-05-24|Actual|January 10, 2012|Actual|2012-01-10|May 2018|2018-05-31||||March 1, 2012|Actual|2012-03-01||Interventional|||Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only|Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed|Active, not recruiting||Phase 1|37|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:09:48.824963|2018-05-31 22:09:48.824963
NCT01434277|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety Evaluation of a New Preservative in a Lubricating Eye Drop|A Single-Center Study Evaluating the Safety of a New Preservative in an OTC Lubricant Eye Drop Used QID in Healthy Adults and in Subjects Diagnosed With Dry Eye|Completed||N/A|44|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 22:09:49.437531|2018-05-31 22:09:49.437531
NCT01434264|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-03-07|2011-09-13|2011-09-14|Estimate|||||||2014-03-07|2014-03-10|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluating Personalized Effect of an Individualized Intervention|Cross-disciplinary Evaluation of Efficacy and Effectiveness of Individualized Complementary Therapies: Evaluating Personalized Effect of Energy Healing as an Individualized Intervention|Completed||N/A|247|Actual|University of Southern Denmark||4|||f||||t||||||||||2018-05-31 22:09:49.529832|2018-05-31 22:09:49.529832
NCT01434251|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-05-26|2011-09-13|2011-09-14|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|TOHOP||Treatment of Hypotension of Prematurity (TOHOP)|Treatment of Hypotension of Prematurity: a Randomized, Non-blinded Cohort Clinical Trial|Unknown status|Recruiting|N/A|150|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 22:09:49.617859|2018-05-31 22:09:49.617859
NCT01434238|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2011-09-14|2011-09-13|2011-09-14|Estimate|||||||2011-09-14|2011-09-15|Estimate|June 2008||2008-06-30|September 2011|2011-09-30|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of an Infant Feeding Intervention for HIV-exposed Haitian Infants|Evaluation of an Infant Feeding Support Strategy for HIV-exposed Infants 6-12 Months Old in Urban Haiti|Completed||N/A|82|Actual|Cornell University||1|||f||||f||||||||||2018-05-31 22:09:49.733133|2018-05-31 22:09:49.733133
NCT01434225|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-09-11|2011-09-13|2011-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NEMO1||NEMO1:NEonatal Seizure Using Medication Off-patent|NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent|Completed||Phase 1/Phase 2|14|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 22:09:49.852775|2018-05-31 22:09:49.852775
NCT01434212|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2011-10-27|2011-09-13|2011-09-14|Estimate|||||||2011-10-27|2011-10-28|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|sIFN-pred1||Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy|Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort|Unknown status|Active, not recruiting||40|Anticipated|First Hospital of Jilin University|||1||f||||t||||||Samples With DNA|"~     Blood serum,Peripheral blood mononuclear cells (PBMC)~   "|||2018-05-31 22:09:49.950408|2018-05-31 22:09:49.950408
NCT01434199|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|UPD-3||Does Endoscope Position Detecting Unit Facilitate a Complete Colonoscopy Examination|Does Endoscope Position Detecting Unit Facilitate Caecal Intubation? A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|870|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 22:09:50.054705|2018-05-31 22:09:50.054705
NCT01434186|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2017-03-07||2017-03-07|2011-09-13|2011-09-14|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|May 2012||2012-05-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone|Completed||Phase 3|32|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 22:09:50.145293|2018-05-31 22:09:50.145293
NCT01434173|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2014-07-07|2011-09-13|2011-09-14|Estimate|||||||2014-07-07|2014-07-08|Estimate|July 2001||2001-07-31|July 2014|2014-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Risk of Acute Liver Injury in Users of Antimicrobials|Risk of Acute Liver Injury in Users of Antimicrobials in the HealthCore Integrated Research Database Population|Completed|||1299056|Actual|Bayer|||2||f||||f||||||||||2018-05-31 22:09:50.368506|2018-05-31 22:09:50.368506
NCT01434160|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-07-24|2011-09-13|2011-09-14|Estimate|||||||2015-07-24|2015-07-27|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|June 2013|Actual|2013-06-30||Interventional|||LCS12 Adolescent Study|Multi-center, Single-arm Study to Assess the Safety, Efficacy, Discontinuation Rate and Pharmacokinetics of the Low-dose Levonorgestrel Intrauterine Contraceptive System (LCS12) in Post-menarcheal Female Adolescents Under 18 Years of Age for 1 Year, and an Optional 2-year Extension Phase|Completed||Phase 3|304|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:09:50.443862|2018-05-31 22:09:50.443862
NCT01434147|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-03-06|2011-09-13|2011-09-14|Estimate|||||||2014-03-06|2014-03-07|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy|Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin) Followed by Capecitabine (Xeloda) Plus Radiotherapy (RTx)|Completed||Phase 2|25|Actual|Austrian Breast & Colorectal Cancer Study Group||1|||f||||t||||||||||2018-05-31 22:09:50.562552|2018-05-31 22:09:50.562552
NCT01434134|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2014-10-21|2011-09-13|2011-09-14|Estimate|||||||2014-10-21|2014-10-22|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PRADA||Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy|Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol|Completed||Phase 2|130|Actual|University Hospital, Akershus||4|||f||||t||||||||||2018-05-31 22:09:50.669217|2018-05-31 22:09:50.669217
NCT01434121|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2014-03-04||2018-01-08|2011-09-12|2011-09-14|Estimate|2014-05-30|2014-07-01|Estimate||||2018-01-08|2018-02-01|Actual|May 2010||2010-05-31|January 2018|2018-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Ascorbic Acid (Vitamin C) Infusion in Human Sepsis|Ascorbic Acid (Vitamin C) Infusion in Human Sepsis|Completed||Phase 1/Phase 2|24|Actual|Virginia Commonwealth University||3|||f||||t||||||||||2018-05-31 22:09:50.770289|2018-05-31 22:09:50.770289
NCT01434108|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2015-03-19|2011-09-13|2011-09-14|Estimate|||||||2015-03-19|2015-03-24|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding|Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding|Completed||Phase 2/Phase 3|48|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 22:09:51.268183|2018-05-31 22:09:51.268183
NCT01434095|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-14|2011-09-13|2011-09-14|Estimate|||||||2011-09-14|2011-09-15|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy||Completed||N/A|16|Actual|Surugadai Nihon University Hospital||1|||f||||f||||||||||2018-05-31 22:09:51.36814|2018-05-31 22:09:51.36814
NCT01434082|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2011-09-12|2011-09-12|2011-09-14|Estimate|||||||2011-09-12|2011-09-14|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Observational|JIA||Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis|Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis|Unknown status|Recruiting||150|Anticipated|University of Washington|||||f||||t||||||Samples With DNA|"~     Morning urine and saliva~   "|||2018-05-31 22:09:51.488366|2018-05-31 22:09:51.488366
NCT01434069|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-12-22|2011-09-13|2011-09-14|Estimate|||||||2015-12-22|2015-12-24|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase I Trial of Combination of FOLFIRI and SOM 230|Phase I Trial of Combination of FOLFIRI and SOM 230 in Advanced Gastrointestinal Malignancies|Completed||Phase 1|16|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 22:09:51.722786|2018-05-31 22:09:51.722786
NCT01434056|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|February 2015|Anticipated|2015-02-28|November 2014|Anticipated|2014-11-30||Observational|||Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging|Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging|Unknown status|Not yet recruiting||400|Anticipated|Hospital Israelita Albert Einstein|||1||f||||t||||||||||2018-05-31 22:09:51.866042|2018-05-31 22:09:51.866042
NCT01434043|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2018-04-30|2011-09-13|2011-09-14|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2011||2011-09-30|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging|Diagnostic Accuracy of Cardiac CT Perfusion Compared to PET Imaging|Active, not recruiting|||35|Actual|University of Washington|||1||f||||f||||||||||2018-05-31 22:09:52.110719|2018-05-31 22:09:52.110719
NCT01434030|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2014-08-08||2014-08-25|2011-09-13|2011-09-14|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-25|2014-09-04|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Phase1||Development of a Behavioral Observer for Type 1 Diabetes Mellitus|Development of a Behavioral Observer for Type 1 Diabetes Mellitus|Completed||N/A|57|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:09:52.237854|2018-05-31 22:09:52.237854
NCT01434017|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2014-02-26|2011-09-13|2011-09-14|Estimate|||||||2014-02-26|2014-02-27|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting (PONV) in Children|Comparison of Three Different Prophylactic Treatments of PONV in Children|Completed||Phase 4|300|Actual|Centre Hospitalier Universitaire Vaudois||3|||f||||f||||||||||2018-05-31 22:09:52.653482|2018-05-31 22:09:52.653482
NCT01434004|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2015-04-08|2011-09-13|2011-09-14|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2003||2003-01-31|April 2015|2015-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|EASE||Eating, Activity, and Stress Education|A Diet, Physical Activity, and Meditation Intervention in Men With Rising Prostate-specific Antigen|Completed||N/A|58|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 22:09:52.807765|2018-05-31 22:09:52.807765
NCT01433991|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07||2016-04-11|2016-08-11|2011-09-13|2011-09-14|Estimate||||2016-04-11|2016-05-06|Estimate|2016-08-11|2016-08-15|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|March 2015|Actual|2015-03-31||Interventional|||E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)|An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)|Active, not recruiting||Phase 1/Phase 2|30|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:09:52.944959|2018-05-31 22:09:52.944959
NCT01433978|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|2017-12-05|2015-06-29|2018-01-09|2011-09-13|2011-09-14|Estimate|2018-01-09|2018-02-06|Actual|2015-06-29|2015-07-22|Estimate|2018-01-09|2018-02-06|Actual|March 26, 2012|Actual|2012-03-26|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Safety analysis set included all participants who received at least one dose of study treatment and at least one postbaseline safety assessment.|A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)|A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)|Terminated||Phase 3|24|Actual|Eisai Inc.|Study was terminated early (during the Extension Phase) due to significant enrollment changes.|3||Study was terminated early due to significant enrollment challenges.|f||||t|t|||||||||2018-05-31 22:09:54.366222|2018-05-31 22:09:54.366222
NCT01433965|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2018-03-01|2011-09-12|2011-09-14|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2012||2012-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome|Phase I Trial of Maintenance Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Post Allogeneic Bone Marrow Transplantation|Recruiting||Phase 1|24|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 22:09:56.719381|2018-05-31 22:09:56.719381
NCT01433952|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pharmacokinetics of Oral Thiamine|Pharmacokinetics of High Dose Oral Thiamine|Completed||Phase 1|14|Actual|Baystate Medical Center||4|||f||||f||||||||||2018-05-31 22:09:56.812137|2018-05-31 22:09:56.812137
NCT01433926|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Observational|LongHer||Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years|Observational, Cross-sectional Study to Analyze the Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete Remission, Partial Remission or Stabilization of Disease During More Than 3 Years|Completed|||114|Actual|Asociación para el Progreso de la Oncología en Málaga|||||f||||t||||||Samples With DNA|"~     primary tumor, preserved in paraffin~   "|||2018-05-31 22:09:57.048786|2018-05-31 22:09:57.048786
NCT01433913|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2015-04-29||2017-12-12|2011-09-13|2011-09-14|Estimate|2015-04-29|2015-05-15|Estimate||||2017-12-12|2018-01-10|Actual|November 2011||2011-11-30|December 2017|2017-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery|Phase II Study of Metformin in a Pre-prostatectomy Prostate Cancer Cohort|Completed||Phase 2|20|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 22:09:57.260726|2018-05-31 22:09:57.260726
NCT01433900|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-05-15|2011-09-12|2011-09-14|Estimate|||||||2014-05-15|2014-05-16|Estimate|May 2012||2012-05-31|September 2011|2011-09-30|June 2014|Anticipated|2014-06-30|May 2013|Actual|2013-05-31||Interventional|||Switching From Preserved to Preserved-free Treatments for Glaucoma.|The Advantage of Switching From Preserved to Preserved-free Treatments in Glaucoma. A Clinical and Confocal Study.|Unknown status|Recruiting|Phase 3|40|Anticipated|University of Milan||2|||f||||f||||||||||2018-05-31 22:09:57.796491|2018-05-31 22:09:57.796491
NCT01433887|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|||2014-11-14|2011-09-13|2011-09-14|Estimate|||||||2014-11-14|2014-11-18|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6|Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic|Completed||Phase 3|535|Actual|Third Affiliated Hospital, Sun Yat-Sen University||3|||f||||f||||||||||2018-05-31 22:09:57.868842|2018-05-31 22:09:57.868842
NCT01433874|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|February 2011||2011-02-28|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Decreasing Upper and Shoulder Pain After Laparoscopic Surgery|Maneuvers to Decrease Upper and Shoulder Pain After Gynecologic Laparoscopic Surgery|Unknown status|Recruiting|Phase 3|200|Anticipated|Taipei Veterans General Hospital, Taiwan||4|||f||||t||||||||||2018-05-31 22:09:58.010224|2018-05-31 22:09:58.010224
NCT01433861|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2017-01-06|2011-09-13|2011-09-14|Estimate|||||||2017-01-06|2017-01-09|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PRAPT||Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy|Phase III Prospective Randomized Clinical Trial of Laparoscopy-assisted Proximal Gastrectomy (LAPG) and Laparoscopy-assisted Total Gastrectomy (LATG) for Upper Gastric Cancer. (Multicenter Study)|Terminated||Phase 3|7|Actual|Seoul National University Bundang Hospital||2||We planed to study later|f||||t||||||||No||2018-05-31 22:09:58.167838|2018-05-31 22:09:58.167838
NCT01433848|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|June 2011||2011-06-30|September 2011|2011-09-30||||||||Observational|||Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Events|Prospective Analysis Of Cardiac Function In Cirrhotic Patients By Echocardiography And Its Correlation With Adverse Events|Unknown status|Enrolling by invitation||100|Anticipated|Rio de Janeiro State University|||3||f||||f||||||||||2018-05-31 22:09:58.276324|2018-05-31 22:09:58.276324
NCT01433835|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|||2013-08-01|2011-09-12|2011-09-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers|Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers|Completed||Phase 1|48|Actual|Microbiotix, Inc.||2|||f||||f||||||||||2018-05-31 22:09:58.338422|2018-05-31 22:09:58.338422
NCT01433809|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2014-01-20|2011-09-13|2011-09-14|Estimate|||||||2014-01-20|2014-01-22|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm|Biomarkers in Thyroid Cancer|Completed|||1|Actual|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Blood, RNA/DNA from fine needle aspirate biopsies of thyroid nodules, fresh frozen surgical~     tissue, formalin fixed paraffin embedded tissue.~   "|||2018-05-31 22:09:59.359576|2018-05-31 22:09:59.359576
NCT01433796|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|||2016-03-06|2011-09-12|2011-09-14|Estimate|||||||2016-03-06|2016-03-08|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|May 2013|Actual|2013-05-31||Observational|||Screening for Tuberculosis in HIV-infected Patients Eligible for Antiretroviral Treatment|Tuberculosis in HIV-infected Patients Managed in Health Centres in Ethiopia - Identification of a Screening Algorithm for Active Tuberculosis and Determination of Outcome of Combined Antituberculosis and Antiretroviral Treatment|Completed|||812|Actual|Lund University|||1||f||||f||||||Samples Without DNA|"~     Aliquoted plasma samples from consenting participants are stored at -80 C for analysis of~     biomarkers of tuberculosis and for prognostic markers. Stool and urine samples are stored at~     -20 C for analysis of alternative biomarkers of active tuberculosis.~   "|||2018-05-31 22:09:59.451434|2018-05-31 22:09:59.451434
NCT01433770|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-02-17|2011-09-12|2011-09-14|Estimate|||||||2012-02-17|2012-02-22|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Alefacept in Kidney Transplant Recipients|Effects of Alefacept on Donor-Specific Memory in Kidney Transplant Recipients|Withdrawn||N/A|0|Actual|University Hospitals Cleveland Medical Center||1||The drug will no longer be available in the United States.|f||||f||||||||||2018-05-31 22:09:59.524825|2018-05-31 22:09:59.524825
NCT01433757|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-07-03|2011-09-13|2011-09-14|Estimate|||||||2017-07-03|2017-07-05|Actual|September 2011||2011-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Ampicillin for DYT-1 Dystonia Motor Symptoms|A Pilot, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Determine the Safety and Efficacy of Ampicillin in Treating Primary Dystonia Symptoms|Completed||Phase 1|2|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:09:59.601166|2018-05-31 22:09:59.601166
NCT01433744|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Short-term Changes on C-Reactive Protein (CRP) Levels After Non-surgical Periodontal Treatment|Short-term Changes on C-Reactive Protein (CRP) Levels After Non-surgical Periodontal Treatment|Completed||N/A|44|Actual|State University of Maringá||2|||f||||t||||||||||2018-05-31 22:09:59.675659|2018-05-31 22:09:59.675659
NCT01433731|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2015-12-15||2016-02-23|2011-09-12|2011-09-14|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma|Completed||Phase 1|18|Actual|TetraLogic Pharmaceuticals||4|||f||||t||||||||||2018-05-31 22:09:59.754871|2018-05-31 22:09:59.754871
NCT01433718|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2017-04-19|2011-09-13|2011-09-14|Estimate|||||||2017-04-19|2017-04-21|Actual|September 2011||2011-09-30|April 2017|2017-04-30|June 2012|Anticipated|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Decreasing Knee Injury Risk Factors With Neuromuscular Training|The Effectiveness of Neuromuscular Training on Modifiable Anterior Cruciate Ligament Injury Risk Factors|Withdrawn||N/A|0|Actual|Ohio University||1|||f||||f||||||||||2018-05-31 22:10:00.225831|2018-05-31 22:10:00.225831
NCT01433705|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2018-04-25|2011-09-13|2011-09-14|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2011||2011-11-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers|Evaluation of the Normal Distribution of Rubidium-82(Rb-82), Nitrogen-13 (N-13)Ammonia, and Fluorine-18 Fluorodeoxyglucose (F-18FDG) in Normal Volunteers|Active, not recruiting||Phase 1|145|Anticipated|University of Michigan||3|||f||||f|t|f|||f|||No||2018-05-31 22:10:00.304221|2018-05-31 22:10:00.304221
NCT01433692|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2013-01-11|2011-09-13|2011-09-14|Estimate|||||||2013-01-11|2013-01-14|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|July 2014|Anticipated|2014-07-31|March 2014|Anticipated|2014-03-31||Interventional|CANABIC||CANABIC : CANnabis and Adolescents, a Brief Intervention (BI) to Reduce Their Consumption|Does a BI Conducted by General Practitioners Reduce Consumption of Canabis in 15 to 25 Years Old ?|Unknown status|Recruiting|N/A|750|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||f||||||||||2018-05-31 22:10:00.398795|2018-05-31 22:10:00.398795
NCT01433679|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2012-07-12|2011-09-12|2011-09-14|Estimate|||||||2012-07-12|2012-07-16|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of a Web-Based Behavioral Intervention on Physical Activity Levels in Adolescents|The Effect of a Web-Based Behavioral Intervention on Physical Activity Levels in Adolescents|Completed||N/A|448|Actual|HopeLab Foundation||2|||f||||f||||||||||2018-05-31 22:10:00.487016|2018-05-31 22:10:00.487016
NCT01433666|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-09-03|2011-09-13|2011-09-14|Estimate|||||||2013-09-03|2013-09-04|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Interventional|EEGrofl||Roflumilast and Cognition|Effects of Roflumilast on Cognition in Healthy Adults: a Behaviour-EEG Study|Completed||Phase 2|22|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 22:10:00.568286|2018-05-31 22:10:00.568286
NCT01433653|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-06-08|2011-09-13|2011-09-14|Estimate|||||||2015-06-08|2015-06-09|Estimate|May 2005||2005-05-31|June 2015|2015-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|CG-CBT||Cognitive Behavioral Therapy for Complicated Grief|Randomized Controlled Clinical Trial of Cognitive Behavioral Therapy for Complicated Grief|Completed||N/A|51|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 22:10:00.650298|2018-05-31 22:10:00.650298
NCT01433640|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-03-17|2011-09-12|2011-09-14|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Observational|||Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study|Evaluation of Contrast-enhanced Mammography and Contrast-enhanced Breast Tomosynthesis: Comparison to Contrast-enhanced Breast MRI- A Pilot Study|Completed|||30|Actual|Hologic, Inc.|||3||f||||f||||||||||2018-05-31 22:10:00.715811|2018-05-31 22:10:00.715811
NCT01433627|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2015-01-28|2011-09-13|2011-09-14|Estimate|||||||2015-01-28|2015-01-29|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|November 2014|Actual|2014-11-30||Interventional|MATRIX||Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX|Phase IIIb Study Minimizing Adverse Haemmhorragic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)|Unknown status|Active, not recruiting|Phase 3|7200|Anticipated|Italian Society of Invasive Cardiology||6|||f||||t||||||||||2018-05-31 22:10:00.795024|2018-05-31 22:10:00.795024
NCT01433614|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-09-16|2011-09-13|2011-09-14|Estimate|||||||2015-09-16|2015-09-17|Estimate|December 2002||2002-12-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|June 2006|Actual|2006-06-30||Interventional|TEX||Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer|Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study|Completed||Phase 3|304|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 22:10:01.0446|2018-05-31 22:10:01.0446
NCT01433601|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|August 2007||2007-08-31|September 2011|2011-09-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|DotArv||Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure|A Randomised Controlled Trial to Assess Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure|Unknown status|Active, not recruiting|N/A|640|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 22:10:01.157962|2018-05-31 22:10:01.157962
NCT01433588|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2018-02-08|2011-09-13|2011-09-14|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2014||2014-10-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Calmer Project|Calmer: A Novel Approach for Treating Infant Pain|Recruiting||N/A|60|Anticipated|Children's & Women's Health Centre of British Columbia||2|||f||||f||||||||||2018-05-31 22:10:01.233352|2018-05-31 22:10:01.233352
NCT01433575|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-11-01|2011-09-13|2011-09-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers|A Single-center, Open-label, Single Dose, Randomized, Two-way Cross-over Study to Investigate the Pharmacokinetics, Safety, and Tolerability of RO4917838 in Healthy Chinese Volunteers|Completed||Phase 1|16|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:10:01.328965|2018-05-31 22:10:01.328965
NCT01433562|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2013-05-10|2011-09-13|2011-09-14|Estimate|||||||2013-05-10|2013-05-13|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients|Combination of DLBS1425 With Anthracyclin-based Regimen as a Neoadjuvant Therapy in Subjects With Stage II or III Breast Cancer|Completed||Phase 2/Phase 3|40|Actual|Dexa Medica Group||2|||f||||t||||||||||2018-05-31 22:10:01.421303|2018-05-31 22:10:01.421303
NCT01433549|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2013-03-20||2013-04-30|2011-09-12|2011-09-14|Estimate|2013-03-20|2013-04-30|Estimate||||2013-04-30|2013-05-06|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|INVERMERE|This reporting group includes all participants enrolled and dispensed product.|Lens Wear Schedules and End-of-Day Comfort|Effect of Recovery Periods on Ocular Comfort During Daily Lens Wear|Completed||N/A|44|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:10:01.631719|2018-05-31 22:10:01.631719
NCT01433536|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2018-01-23|2011-09-13|2011-09-14|Estimate|||||||2018-01-23|2018-01-24|Actual|December 2010||2010-12-31|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|BMP-9||Evaluation of Circulating Osteogenic Factors in Trauma Patients|Evaluation of Circulating Osteogenic Factors in Trauma Patients (BMP-9)|Terminated|||40|Actual|Centre de recherche du Centre hospitalier universitaire de Sherbrooke|||6|"Guillaume Grenier, principal investigator is no longer working at the lab. The lab is now~   closed."|f||||t||||||Samples Without DNA|"~     blood samples~   "|Undecided||2018-05-31 22:10:01.851334|2018-05-31 22:10:01.851334
NCT01433523|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2017-01-27|2011-09-13|2011-09-14|Estimate|||||||2017-01-27|2017-01-30|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|February 2014|Actual|2014-02-28|April 2013|Actual|2013-04-30||Interventional|MITRA||House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma|Efficacy of ALK House Dust Mite Allergy Immunotherapy Tablet in Subjects With House Dust Mite Induced Asthma. The MITRA Trial|Completed||Phase 3|834|Actual|ALK-Abelló A/S||3|||f||||f||||||||||2018-05-31 22:10:01.925287|2018-05-31 22:10:01.925287
NCT01433510|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2011-09-13|2011-09-13|2011-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|GRAAL||Tolerability of Grazax in Patients With Hayfever in Real Life Settings|Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings|Completed||Phase 4|628|Actual|ALK-Abelló A/S||1|||f||||f||||||||||2018-05-31 22:10:02.012965|2018-05-31 22:10:02.012965
NCT01433497|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2017-04-20|2011-09-13|2011-09-14|Estimate|||||||2017-04-20|2017-04-21|Actual|August 2011||2011-08-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis|A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis|Recruiting||Phase 2/Phase 3|450|Anticipated|AB Science||2|||f||||t||||||||||2018-05-31 22:10:02.098574|2018-05-31 22:10:02.098574
NCT01433484|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-11-16|2011-09-12|2011-09-14|Estimate|||||||2017-11-16|2017-11-20|Actual|September 2011||2011-09-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Heart-Healthy Lenoir Lifestyle Study|Community-Based Lifestyle Intervention to Reduce CVD Risk & Disparities in Risk|Completed||N/A|339|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:10:02.177285|2018-05-31 22:10:02.177285
NCT01433471|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2016-04-26||2016-06-01|2011-09-09|2011-09-14|Estimate|2016-04-26|2016-06-01|Estimate||||2016-06-01|2016-07-01|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MUCUS||Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova|Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova|Completed||N/A|4|Actual|New York University School of Medicine|Because of the small sample size of this study, investigators decided it was not possible to draw meaningful conclusions from the outcome measures and outcome measures were not collected or analyzed as originally planned.|2|||f||||t||||||||||2018-05-31 22:10:02.266632|2018-05-31 22:10:02.266632
NCT01433458|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-01-20|2011-09-12|2011-09-14|Estimate|||||||2013-01-20|2013-01-23|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects|A Single-dose, Open-label Parallel Study to Assess the Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects|Completed||Phase 1|55|Actual|Novartis||4|||f||||||||||||||2018-05-31 22:10:02.503049|2018-05-31 22:10:02.503049
NCT01433445|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-11-09|2011-09-12|2011-09-14|Estimate|||||||2017-11-09|2017-11-14|Actual|November 1, 2011|Actual|2011-11-01|November 2017|2017-11-30|December 12, 2018|Anticipated|2018-12-12|December 12, 2018|Anticipated|2018-12-12||Interventional|||Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis|A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)|Active, not recruiting||Phase 1|61|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 22:10:02.573615|2018-05-31 22:10:02.573615
NCT01433432|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2013-03-05|2011-09-12|2011-09-14|Estimate|||||||2013-03-05|2013-03-07|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|OLE||Open Label Extension Study to Protocol C2/13/DR-6MP-02|Clinical Efficacy and Safety of Delayed Release 6-Mercaptopurine (DR-6MP) for Targeted Ileal Delivery in Patients With Moderately Active Crohn's Disease - Open Label Extension Study|Withdrawn||Phase 2|0|Actual|Teva GTC||2||Sponsor withdrew support for study due to reorganization and project prioritization|f||||f||||||||||2018-05-31 22:10:02.673005|2018-05-31 22:10:02.673005
NCT01433419|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2013-03-21|2011-09-12|2011-09-14|Estimate|||||||2013-03-21|2013-03-22|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Open-label Study of TAK-875||Completed||Phase 3|333|Actual|Takeda||2|||f||||||||||||||2018-05-31 22:10:02.741775|2018-05-31 22:10:02.741775
NCT01433406|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2014-01-24|2011-09-12|2011-09-14|Estimate|||||||2014-01-24|2014-01-27|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Long-term Study of TAK-875||Completed||Phase 3|1222|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:10:02.947082|2018-05-31 22:10:02.947082
NCT01433393|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2012-11-07|2011-09-12|2011-09-14|Estimate|||||||2012-11-07|2012-11-09|Estimate||||November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Double-blind Comparative Study of TAK-875||Completed||Phase 3|192|Actual|Takeda||3|||f||||||||||||||2018-05-31 22:10:03.120823|2018-05-31 22:10:03.120823
NCT01433380|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2012-05-16|2011-09-12|2011-09-13|Estimate|||||||2012-05-16|2012-05-18|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study To Evaluate PF-05175157 In Healthy Volunteers|Phase 1 Study To Evaluate The Effect Of Single Doses Of Pf-05175157 On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers|Completed||Phase 1|22|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:10:03.22686|2018-05-31 22:10:03.22686
NCT01433367|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2015-04-17|2011-09-12|2011-09-13|Estimate|||||||2015-04-17|2015-04-21|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CerPass||A Clinical Trial Evaluating a Total Disc Replacement in Patients With Cervical Disc Disease|A Prospective Observational Study Evaluating the Performance of the CerPass® Total Disc Replacement in Patients With Single-Level Cervical Disc Disease|Terminated|||2|Actual|NuVasive|||1|Marketing of CE marked device has been discontinued.|f||||f||||||||||2018-05-31 22:10:03.298793|2018-05-31 22:10:03.298793
NCT01433354|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2015-09-14||2016-02-24|2011-09-12|2011-09-13|Estimate|2015-09-14|2015-10-12|Estimate||||2016-02-24|2016-03-24|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||All enrolled participants who received at least one dose of the study drug (AFQ056) during the study.|Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)|An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome|Terminated||Phase 2/Phase 3|119|Actual|Novartis|The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).|1||"The study treatment failed to demonstrate efficacy in target population in two other clinical~   studies (CAFQ056B2214 and CAFQ056A2212)."|f||||t||||||||||2018-05-31 22:10:03.38706|2018-05-31 22:10:03.38706
NCT01433341|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2013-11-10|2011-09-12|2011-09-13|Estimate|||||||2013-11-10|2013-11-13|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Evaluation of Postural Control After Exercise in Athletes Using Tetra Axial Posturography (tetrax1)||Completed|||30|Actual|Meir Medical Center|||1||f||||t||||||||||2018-05-31 22:10:03.777552|2018-05-31 22:10:03.777552
NCT01433328|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2012-04-04|2011-09-12|2011-09-13|Estimate|||||||2012-04-04|2012-04-05|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain|Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain|Terminated||Phase 4|4|Actual|Jewish General Hospital||2||Safety considerations|f||||f||||||||||2018-05-31 22:10:03.830837|2018-05-31 22:10:03.830837
NCT01433315|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2018-03-01|2011-09-12|2011-09-13|Estimate|||||||2018-03-01|2018-03-05|Actual|October 2011||2011-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Physiologic Effects of Sleep Restriction|Physiologic Effects of Sleep Restriction|Recruiting||N/A|36|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:10:03.903113|2018-05-31 22:10:03.903113
NCT01433302|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-05-05|2011-09-12|2011-09-13|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass|Determination of the Effect of Lymphatico-venous Bypass Surgery on Inflammatory Responses and Tissue Fibrosis|Completed|||21|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 22:10:03.973531|2018-05-31 22:10:03.973531
NCT01433289|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-02-02|2011-09-12|2011-09-13|Estimate|||||||2015-02-02|2015-02-03|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|July 2015|Anticipated|2015-07-31|August 2014|Actual|2014-08-31||Interventional|||Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals|Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) as Monotherapy for 14 Days in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects|Unknown status|Recruiting|Phase 1|24|Anticipated|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 22:10:04.049678|2018-05-31 22:10:04.049678
NCT01433276|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock|The Clinical Efficacy and Safety of a Proprietary Solution Containing Hypertonic Sodium Lactate (Totilac®) Infusion for Resuscitation of Patients With Hemorrhagic Shock Due to Multiple Injuries|Completed||Phase 3|71|Actual|Innogene Kalbiotech Pte. Ltd||2|||f||||f||||||||||2018-05-31 22:10:04.149197|2018-05-31 22:10:04.149197
NCT01433263|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2015-04-24||2016-02-02|2011-09-09|2011-09-13|Estimate|2015-04-24|2015-05-13|Estimate||||2016-02-02|2016-03-02|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas|A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas|Completed||Phase 2|57|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:10:04.270738|2018-05-31 22:10:04.270738
NCT01433250|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2015-05-28||2016-02-16|2011-09-09|2011-09-13|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis|An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|39|Actual|Novartis|Further development of secukinumab in MS is not being pursued and the extension study , CAIN457B2201E1, further enrollment stopped . Not completing enrollment of this study was not related to the safety or tolerability concerns observed in the study.|2|||f||||f||||||||||2018-05-31 22:10:05.35398|2018-05-31 22:10:05.35398
NCT01433237|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2016-05-17|2011-09-09|2011-09-13|Estimate|||||||2016-05-17|2016-05-19|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma|A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma|Completed|||40|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:10:05.840858|2018-05-31 22:10:05.840858
NCT01433224|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2016-05-17|2011-09-09|2011-09-13|Estimate|||||||2016-05-17|2016-05-18|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression|Genomic Signatures of Malignant Germ Cell Tumor Progression: A Retrospective Study of Banked Specimens|Completed|||90|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:10:05.9082|2018-05-31 22:10:05.9082
NCT01433211|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-11|2011-09-11|2011-09-13|Estimate|||||||2011-09-11|2011-09-13|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Nutrition and Frailty in Older Persons|Relation Between Nutrition and Frailty in Community-dwelling Older Persons|Completed|||206|Actual|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 22:10:05.981679|2018-05-31 22:10:05.981679
NCT01433185|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2015-01-19|2011-09-12|2011-09-13|Estimate|||||||2015-01-19|2015-01-21|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SMS4PMTCT||Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIV|Improving Uptake of Early Infant Diagnosis of HIV for PMTCT: a Randomized Trial of a Text Messaging Intervention|Completed||N/A|388|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 22:10:06.112367|2018-05-31 22:10:06.112367
NCT01433172|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2016-11-01||2017-12-08|2011-09-12|2011-09-13|Estimate|2017-02-20|2017-04-05|Actual||||2017-12-08|2018-01-03|Actual|March 26, 2012|Actual|2012-03-26|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|January 31, 2016|Actual|2016-01-31||Interventional||All participants.|Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer|A Randomized Phase I/II Trial Using a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) Vaccine in Combination With CCL21 for Patients With Stage IV Adenocarcinoma of the Lung|Active, not recruiting||Phase 1/Phase 2|73|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||t||||||||||2018-05-31 22:10:06.226394|2018-05-31 22:10:06.226394
NCT01433159|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2013-10-09||2014-01-10|2011-09-12|2011-09-13|Estimate|2014-01-10|2014-02-10|Estimate||||2014-01-10|2014-02-10|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury|Comparison of HP011-101 to Standard Care in the Management of Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury|Terminated||Phase 2|19|Actual|Healthpoint||2||Business decision|f||||f||||||||||2018-05-31 22:10:06.84829|2018-05-31 22:10:06.84829
NCT01433146|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2012-06-04|2011-09-10|2011-09-13|Estimate|||||||2012-06-04|2012-06-06|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Observational|||Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients. Effetti Del Temperamento, Dell'Ansia e Della Depressione Sulla Sopravvivenza Globale e Sulla Risposta Immunitaria Del Paziente Affetto da Adenocarcinoma Colo-Rettale.|Effect of Temperament, Anxiety and Depression on Immuninity in Colorectal Cancer Patients.|Completed|||120|Anticipated|University of Roma La Sapienza|||||f||||t||||||Samples Without DNA|"~     Blood samples for cell-mediated immunity evaluaion~   "|||2018-05-31 22:10:07.064975|2018-05-31 22:10:07.064975
NCT01433133|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2016-09-12|2011-09-12|2011-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Biological Activity of InfraDure Biopump Secreting Sustained Interferon in HCV Patients|Phase I-II, Open Label, Uncontrolled, Dose Escalation Study of the Safety, Tolerability and Biologic Activity of the INFRADURE Biopump Secreting Sustained Interferon Alpha-2b (IFNα), in Combination With Oral Ribavirin for Genotype 3 Newly Diagnosed Hepatitis C Patients|Terminated||Phase 1/Phase 2|3|Actual|Medgenics Medical Israel Ltd.||1||Company strategic decision|f||||f||||||||No||2018-05-31 22:10:07.124424|2018-05-31 22:10:07.124424
NCT01433120|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2014-06-10|2011-09-10|2011-09-13|Estimate|||||||2014-06-10|2014-06-11|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|August 2013|Actual|2013-08-31|June 2012|Actual|2012-06-30||Interventional|||Targeting the Gut Microbiome to Investigate the Pathways of Progression From Obesity to Metabolic Diseases in an At-risk Population.|Targeting the Gut Microbiome to Investigate the Pathways of Progression From Obesity to Metabolic Diseases in an At-risk Population.|Completed||N/A|58|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 22:10:07.175931|2018-05-31 22:10:07.175931
NCT01433107|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2013-04-08||2013-12-03|2011-09-12|2011-09-13|Estimate|2013-12-03|2013-12-27|Estimate||||2013-12-03|2013-12-27|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis|Completed||Phase 3|290|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:10:07.327859|2018-05-31 22:10:07.327859
NCT01433094|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-20|||2017-09-06|2011-09-10|2011-09-13|Estimate|||||||2017-09-06|2017-09-11|Actual|September 2012|Actual|2012-09-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|SPERA-S||Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia|Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia|Completed||N/A|112|Actual|University of Cagliari||2|||f||||t|f|f||||||Undecided||2018-05-31 22:10:07.517474|2018-05-31 22:10:07.517474
NCT01433081|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2013-11-13||2014-02-19|2011-09-12|2011-09-13|Estimate|2014-02-19|2014-04-02|Estimate||||2014-02-19|2014-04-02|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients|The Effect of Magnesium Sulfate Infusion on the Quality of Recovery of Ambulatory Patients|Completed||N/A|50|Actual|Northwestern University|We only examined subjects with normal kidney function that were at low risk for magnesium toxicity. It is possible that the current intervention regimen could have led to toxic levels in higher risk patients.|2|||f||||f||||||||||2018-05-31 22:10:07.604013|2018-05-31 22:10:07.604013
NCT01433068|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-02-19|2011-09-12|2011-09-13|Estimate|||||||2015-02-19|2015-02-20|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|May 2014|Actual|2014-05-31||Interventional|||NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity|An Open-Label, Single Arm, Feasibility And Safety Phase I Study With Nbtxr3 Intratumor Implantation (By Injection) And Activated By External Beam Radiation Therapy In Patients With Soft Tissue Sarcoma Of The Extremity And Trunk Wall|Completed||Phase 1|22|Actual|Nanobiotix||1|||f||||t||||||||||2018-05-31 22:10:07.801989|2018-05-31 22:10:07.801989
NCT01433055|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2016-05-16||2017-06-07|2011-09-12|2011-09-13|Estimate|2017-06-07|2017-06-09|Actual||||2017-06-07|2017-06-09|Actual|July 2011||2011-07-31|June 2017|2017-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients|Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients|Completed||N/A|52|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 22:10:07.869703|2018-05-31 22:10:07.869703
NCT01433042|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2013-02-12||2013-12-15|2011-09-11|2011-09-13|Estimate|2013-12-15|2014-02-04|Estimate||||2013-12-15|2014-02-04|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||18 years and older patients with history suggestive and /or symptoms suggestive of small bowel disease and whom are eligible and indicated for SB capsule endoscopy and agreed to sign ICF|PillCam SB3 Capsule- Feasibility Study|Assessment the Performance of PillCam SB3 Capsule in Detecting Small Bowel Lesions in Patients|Completed||N/A|225|Actual|Given Imaging Ltd.||1|||f||||f||||||||||2018-05-31 22:10:08.180468|2018-05-31 22:10:08.180468
NCT01433016|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|2014-02-11||2014-04-08|2011-09-12|2011-09-13|Estimate|2014-02-27|2014-04-07|Estimate||||2014-04-08|2014-04-25|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|OBT for HCC|Cirrhotic patients with suspected HCC|Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI|Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement in Patients With Chronic Liver Disease to Differentiate Between Presence and Absence of HCC Determined by MRI|Terminated||Phase 2|20|Actual|Exalenz Bioscience LTD.|Early termination leading to small numbers of subjects analyzed.|1||Due to budgetary issues, the company has decided to focus on other applications at this stage.|f||||f||||||||||2018-05-31 22:10:08.419655|2018-05-31 22:10:08.419655
NCT01433003|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2013-04-16|2011-09-12|2011-09-13|Estimate|||||||2013-04-16|2013-04-17|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|PLEX-RCT||The Plasma Large-Volume Exchange RCT|The Plasma Large-Volume Exchange Randomized Controlled Trial (PLEX-RCT)|Withdrawn||Phase 3|0|Actual|London Health Sciences Centre||2||Funding not obtained|f||||t||||||||||2018-05-31 22:10:08.700238|2018-05-31 22:10:08.700238
NCT01432990|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2012-07-15|2011-09-10|2011-09-13|Estimate|||||||2012-07-15|2012-07-17|Estimate|January 2013||2013-01-31|July 2012|2012-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Robotic Gait Training VS.Conventional Rehabilitation in SCI|Robotic Gait Training VS. Conventional Physical Therapy in Spinal Cord Injury Patients.|Unknown status|Not yet recruiting|Phase 3|16|Anticipated|Prasat Neurological Institute||2|||f||||t||||||||||2018-05-31 22:10:08.771|2018-05-31 22:10:08.771
NCT01432977|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2012-10-30|2011-09-12|2011-09-13|Estimate|||||||2012-10-30|2012-10-31|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PARATRON||Drug Interactions Between Paracetamol and Setrons in Pain Management|Paracetamol and Setrons : Drug Interactions in the Management of Pain After Tonsillectomy in Children|Completed||Phase 3|72|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 22:10:08.852146|2018-05-31 22:10:08.852146
NCT01432964|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|December 2008||2008-12-31|September 2011|2011-09-30|October 2010|Actual|2010-10-31|||||Observational|||Use of a Low Profile Titanium Mesh in Orbital Reconstruction|Low Profile Titanium Mesh in the Use of Orbital Reconstruction|Completed|||27|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 22:10:08.913372|2018-05-31 22:10:08.913372
NCT01432951|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2018-02-01|2011-09-09|2011-09-13|Estimate|||||||2018-02-01|2018-02-05|Actual|November 2011||2011-11-30|February 2018|2018-02-28|January 5, 2018|Actual|2018-01-05|January 11, 2013|Actual|2013-01-11||Interventional|||A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma|Pharmacokinetics of Enzastaurin HCl in Native Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma|Completed||Phase 1|40|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:10:08.9888|2018-05-31 22:10:08.9888
NCT01432938|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2014-10-03||2014-10-03|2011-09-09|2011-09-13|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Participants who received at least 1 dose of study drug (dulaglutide or warfarin).|A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants|The Effect of Dulaglutide (LY2189265) on the Pharmacokinetics and Pharmacodynamics of Single Dose Warfarin in Healthy Subjects|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:10:09.075124|2018-05-31 22:10:09.075124
NCT01432925|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-05-23|2011-09-12|2011-09-13|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2011||2011-09-30|May 2016|2016-05-31||||January 2017|Anticipated|2017-01-31||Interventional|Burulitime||Timing of Surgical Intervention in Buruli Ulcer Patients Treated With Antibiotics|Timing of the Decision on Surgical Intervention for Buruli Ulcer Patients Treated With Rifampicin/Streptomycin|Unknown status|Active, not recruiting|N/A|260|Anticipated|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 22:10:09.44254|2018-05-31 22:10:09.44254
NCT01432912|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-11|||2013-06-18|2011-09-12|2011-09-13|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study Evaluating the Effect of Physician Education on Smoking Cessation Counselling|Pilot Study Evaluating the Influence of Physician Education Regarding the 5A's Smoking Cessation Counselling Strategy, as Evaluated by Patient Interpretation of the Strategy Principles|Completed||N/A|98|Actual|Assuta Hospital Systems||1|||f||||f||||||||||2018-05-31 22:10:09.517345|2018-05-31 22:10:09.517345
NCT01432899|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2018-03-27|2011-09-10|2011-09-13|Estimate|||||||2018-03-27|2018-03-29|Actual|September 10, 2011||2011-09-10|March 6, 2018|2018-03-06||||||||Observational|||Studying Childhood-Onset Hemidystonia|Characteristics and Mechanism of Childhood-Onset Hemidystonia|Completed|||21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:10:09.599464|2018-05-31 22:10:09.599464
NCT01432886|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|2015-03-19||2016-08-29|2011-09-12|2011-09-13|Estimate|2015-03-19|2015-03-30|Estimate||||2016-08-29|2016-10-07|Estimate|October 2011||2011-10-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer|A Phase 1 Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer|Completed||Phase 1|12|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 22:10:09.689291|2018-05-31 22:10:09.689291
NCT01432873|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2012-05-31|2011-09-12|2011-09-13|Estimate|||||||2012-05-31|2012-06-04|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Oral Selenium Therapy for the Prevention of Mucositis|A Randomized Double Blinded Placebo Controlled Oral Selenium Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|76|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:10:10.009272|2018-05-31 22:10:10.009272
NCT01432860|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-07-10|2011-09-12|2011-09-13|Estimate|||||||2016-07-10|2016-07-12|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination|A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination|Completed||N/A|1000|Actual|Northwestern University||4|||f||||t||||||||Yes|publication of results with listing in My NCBI|2018-05-31 22:10:10.098069|2018-05-31 22:10:10.098069
NCT01432847|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2018-03-27|2011-09-12|2011-09-13|Estimate|||||||2018-03-27|2018-03-29|Actual|September 10, 2011||2011-09-10|January 29, 2018|2018-01-29||||||||Observational|||Cell Collection to Study Eye Diseases|Generation of Induced Pluripotent Stem (iPS) Cell Lines From Somatic Cells of Participants With Eye Diseases and From Somatic Cells of Matched Controls|Recruiting|||930|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:10:10.169191|2018-05-31 22:10:10.169191
NCT01432834|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2017-01-14|2011-09-12|2011-09-13|Estimate|||||||2017-01-14|2017-01-18|Estimate|April 2010||2010-04-30|January 2017|2017-01-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Efficacy of the Wavefront Optimized (WFO) Profile in Non-anterior Astigmatisms|Evaluation of the Efficacy of the Allegretto Wave and the Wavefront Optimized Ablation Profile in Non-anterior Astigmatisms|Completed||N/A|74|Actual|Democritus University of Thrace||2|||f||||f||||||||||2018-05-31 22:10:10.243675|2018-05-31 22:10:10.243675
NCT01432821|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2016-11-04|2011-09-12|2011-09-13|Estimate|||||||2016-11-04|2016-11-07|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|BYE BYE DOPA||Blinking and Yawning in Epilepsy: The Role of Dopamine|"Dopaminergic Reactivity In Idiopathic Generalized Epilepsy: A Proof Of Concept Clinical, Pharmacological And Neurophysiological Study"|Completed||N/A|31|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 22:10:10.320545|2018-05-31 22:10:10.320545
NCT01432795|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2013-06-21|2011-09-09|2011-09-13|Estimate|||||||2013-06-21|2013-06-24|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Practicability of Gliding Aids for Medical Compression Stockings|Gliding Aids for Medical Compression Stockings - Practicability in Elderly Patients With Chronic Venous Insufficiency|Completed||Phase 4|40|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 22:10:10.410045|2018-05-31 22:10:10.410045
NCT01432782|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2011-09-09|2011-09-09|2011-09-13|Estimate|||||||2011-09-09|2011-09-13|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|Botox||Botulinum Toxin Injection to Treat Diffuse Esophageal Spasm|Prospective Randomised Double-blind Sham Study on the Use of Botox for the Treatment of Diffuse Esophageal Spasm|Unknown status|Recruiting|N/A|30|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 22:10:10.503228|2018-05-31 22:10:10.503228
NCT01432769|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-09|2011-09-09|2011-09-13|Estimate|||||||2011-09-09|2011-09-13|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Interventional|||Enteral Nutrition After Cardiovascular Surgery|Effect of Enteral Nutrition in the Outcome of Patients With Cardiovascular Surgery|Unknown status|Recruiting|Phase 4|38|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 22:10:10.586625|2018-05-31 22:10:10.586625
NCT01432756|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2015-07-10||2015-08-07|2011-09-12|2011-09-13|Estimate|2015-08-07|2015-09-09|Estimate||||2015-08-07|2015-09-09|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A South African Pilot Worksite Parenting Program to Prevent HIV Among Adolescents|A South African Pilot Worksite Parenting Program to Prevent HIV Among Adolescents|Completed||N/A|132|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 22:10:10.664641|2018-05-31 22:10:10.664641
NCT01432743|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|CAVERN||Cartomerge Versus NavX Fusion in Catheter Ablation of Atrial Fibrillation|Cartomerge Versus NavX Fusion in Catheter Ablation of Atrial Fibrillation|Completed||Phase 2|101|Actual|Barts & The London NHS Trust||2|||f||||f||||||||||2018-05-31 22:10:10.902593|2018-05-31 22:10:10.902593
NCT01432730|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2017-04-14|2011-09-12|2011-09-13|Estimate|||||||2017-04-14|2017-04-18|Actual|August 31, 2011|Actual|2011-08-31|April 2017|2017-04-30|February 28, 2013|Actual|2013-02-28|February 28, 2013|Actual|2013-02-28||Interventional|||A Study to Assess the Efficacy of Gefapixant (AF-219/MK-7264), a P2X3 Receptor Antagonist, in Subjects With Chronic Cough|A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough|Completed||Phase 2|22|Actual|Afferent Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 22:10:10.967235|2018-05-31 22:10:10.967235
NCT01432717|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2012-11-05|2011-09-12|2011-09-13|Estimate|||||||2012-11-05|2012-11-07|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Study of ACE-536 in Healthy Postmenopausal Women|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women|Completed||Phase 1|40|Actual|Acceleron Pharma, Inc.||2|||f||||f||||||||||2018-05-31 22:10:11.034313|2018-05-31 22:10:11.034313
NCT01432704|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|March 2008||2008-03-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|100207MS-H||Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)|Phase IV Study of Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS|Completed||Phase 2/Phase 3|70|Actual|University of Turku||2|||f||||||||||||||2018-05-31 22:10:11.093641|2018-05-31 22:10:11.093641
NCT01432691|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2017-04-17|2011-09-12|2011-09-13|Estimate|||||||2017-04-17|2017-04-18|Actual|June 2010||2010-06-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2011|Actual|2011-06-30||Interventional|THA||Hemi Artificial Hipjoint Versus Total Artificial Hipjoint|Clinical and RSA Comparison of Hemi Versus Total Hip Arthroplasty After Displaced Femoral Neck Fracture. A Randomized Double-Blind Study|Completed||Phase 4|70|Actual|Hvidovre University Hospital||1|||f||||t||||||||||2018-05-31 22:10:11.259909|2018-05-31 22:10:11.259909
NCT01432678|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-10|||2014-09-08|2011-09-10|2011-09-13|Estimate|||||||2014-09-08|2014-09-09|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Vitamin D Status in Pediatric Asthma|Vitamin D Status in Pediatric Asthma|Completed|||120|Anticipated|Mahidol University|||1||f||||t||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 22:10:11.329915|2018-05-31 22:10:11.329915
NCT01432665|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-07-26|2011-09-10|2011-09-13|Estimate|||||||2013-07-26|2013-07-29|Estimate|September 2011||2011-09-30|July 2013|2013-07-31||||May 2013|Actual|2013-05-31||Interventional|||Lybrido for Female Sexual Dysfunction||Completed||Phase 2|196|Actual|Emotional Brain NY Inc.||7|||f||||f||||||||||2018-05-31 22:10:11.405159|2018-05-31 22:10:11.405159
NCT01432652|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2015-07-27|2011-09-12|2011-09-13|Estimate|||||||2015-07-27|2015-07-29|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Observational|||The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery|Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance|Completed|||45|Actual|University of Lausanne Hospitals|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 22:10:11.501057|2018-05-31 22:10:11.501057
NCT01432639|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-06-05|2011-09-09|2011-09-13|Estimate|||||||2013-06-05|2013-06-06|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Exercise Training on Endothelial Function, Inflammation, Arterial Stiffness and Autonomic Function in CAD|Effects of Exercise Training on Endothelial Function, Inflammation, Arterial Stiffness and Autonomic Function in Coronary Artery Disease Patients|Completed||N/A|96|Actual|Universidade do Porto||2|||f||||f||||||||||2018-05-31 22:10:11.551307|2018-05-31 22:10:11.551307
NCT01432626|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2016-03-21||2016-03-21|2011-09-09|2011-09-13|Estimate|2016-03-21|2016-03-22|Estimate||||2016-03-21|2016-03-22|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG|The Evaluation of the Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG Imaging|Completed||N/A|10|Actual|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 22:10:11.654243|2018-05-31 22:10:11.654243
NCT01432613|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2018-03-01|2011-09-12|2011-09-13|Estimate|||||||2018-03-01|2018-03-02|Actual|December 22, 2010|Actual|2010-12-22|February 2018|2018-02-28|November 26, 2016|Actual|2016-11-26|February 11, 2016|Actual|2016-02-11||Interventional|DARWIM||Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies|Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies|Completed||N/A|139|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 22:10:11.847136|2018-05-31 22:10:11.847136
NCT01432600|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2017-03-06||2017-04-18|2011-09-09|2011-09-13|Estimate|2017-04-18|2017-05-23|Actual||||2017-04-18|2017-05-23|Actual|November 2011||2011-11-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||All participants. Arm D (a part of Arm B) started in July 2012 when, per protocol guidelines, 17 participants from Arm B elected to crossover to Arm D. Some measures may include arm D, making the total of participants evaluated higher.|Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide|Evaluation of Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide in Patients With Relapsed and Refractory Myeloma|Completed||Phase 1/Phase 2|80|Actual|H. Lee Moffitt Cancer Center and Research Institute|Phase 2 nature of design may have limited power to detect statistically significant differences in some efficacy outcomes and toxicity measures.|4|||f||||t||||||||||2018-05-31 22:10:11.94531|2018-05-31 22:10:11.94531
NCT01432587|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2015-08-21|2011-09-12|2011-09-13|Estimate|||||||2015-08-21|2015-08-24|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|DFNS01||The Effect of Diflunisal on Familial Transthyretin Amyloidosis|"The Effect of Diflunisal on Familial Transthyretin Amyloidosis: An Open Label Extension Study of the Diflunisal Trial (IND 68092), and an Open Label Observational Study on Previously Untreated Patients With Familial Transthyretin Amyloidosis."|Completed|||55|Actual|Umeå University|||||f||||f||||||Samples Without DNA|"~     Serum Whole blood Urine~   "|||2018-05-31 22:10:13.183171|2018-05-31 22:10:13.183171
NCT01432574|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2015-04-23||2018-04-30|2011-09-09|2011-09-13|Estimate|2015-05-28|2015-06-01|Estimate||||2018-04-30|2018-05-30|Actual|December 7, 2012|Actual|2012-12-07|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|May 23, 2014|Actual|2014-05-23||Interventional||All participants|Study of Gardasil in Mid-Adult Males (MAM)|A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY|Active, not recruiting||Phase 2|150|Actual|H. Lee Moffitt Cancer Center and Research Institute|Participants were followed for just 7 months post-dose one of the vaccine; therefore, investigators were unable to assess the durability of the vaccine response in men vaccinated at an older age.|1|||f||||t|t|f||||||||2018-05-31 22:10:13.254813|2018-05-31 22:10:13.254813
NCT01432561|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2013-07-03||2013-09-23|2011-09-12|2011-09-13|Estimate|2013-09-23|2013-10-09|Estimate||||2013-09-23|2013-10-09|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™|Food-Effect on Bioavailability of Cystagon™ in Normal, Healthy Adults|Completed||N/A|8|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 22:10:13.475765|2018-05-31 22:10:13.475765
NCT01432548|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|IP||Ischemic Preconditioning. Prospective Comparison|Ischemic Preconditioning Versus Intermittent Portal Triad Clamping in Liver Resection. Prospective Randomized Comparison|Unknown status|Recruiting|N/A|60|Anticipated|Hospital General de Agudos “Dr. Cosme Argerich”|||||f||||t||||||||||2018-05-31 22:10:13.655691|2018-05-31 22:10:13.655691
NCT01432535|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2013-07-23||2017-03-09|2011-09-09|2011-09-13|Estimate|2013-07-23|2013-09-25|Estimate||||2017-03-09|2017-04-07|Actual|November 2011||2011-11-30|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)|A Single Dose Study to Assess Pharmacokinetics of SCH 54031 in Patients With Renal Impairment (P05655)|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:10:13.843479|2018-05-31 22:10:13.843479
NCT01432522|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|July 2010||2010-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|Epinephrine||A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine|Comparison of Absorption of Epinephrine Into the Circulation After Epinephrine Intranasal Spray Administration and After Intramuscular Injection|Completed||N/A|12|Anticipated|Siriraj Hospital||1|||f||||f||||||||||2018-05-31 22:10:14.217914|2018-05-31 22:10:14.217914
NCT01432509|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2018-04-05|2011-09-09|2011-09-13|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2011||2011-09-30|April 2018|2018-04-30|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Interventional|DiabeNord||Prospective Follow-up of a Cohort of Pre-diabetics in the North of France (DiabeNord)|DiabeNord: A 5-year Prospective Follow-up Cohort Study in Pre-diabetic Subjects for the Identification of New Biomarkers|Completed||N/A|207|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 22:10:14.305589|2018-05-31 22:10:14.305589
NCT01432496|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2013-02-22|2011-09-12|2011-09-13|Estimate|||||||2013-02-22|2013-02-25|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Peritoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Colectomy|A Multicentric, Randomized, Controlled, Double Blinded, Phase III Clinical Trial; Comparing Peritoneal Nebulization of Ropivacaine 150 mg With Peritoneal Nebulization of Saline|Terminated||Phase 3|130|Anticipated|San Gerardo Hospital||2||There was insuficient recruitment in two centers|f||||f||||||||||2018-05-31 22:10:14.364935|2018-05-31 22:10:14.364935
NCT01432483|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2015-01-22|2011-09-12|2011-09-13|Estimate|||||||2015-01-22|2015-01-26|Estimate||||January 2015|2015-01-31||||||||Expanded Access|||Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)|Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)|No longer available|||||Eisai Inc.|||||||||||||||||||2018-05-31 22:10:14.440792|2018-05-31 22:10:14.440792
NCT01432470|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of Oxytocin to Treat Vaginal Atrophy in Postmenopausal Women|A Double-blind, Placebo Controlled Multi-centre Study to Evaluate the Effects of Topical Oxytocin on Vaginal Atrophy in Postmenopausal Women|Completed||Phase 2|74|Anticipated|PepTonic Medical AB||2|||f||||f||||||||||2018-05-31 22:10:14.581341|2018-05-31 22:10:14.581341
NCT01432457|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2013-06-27||2013-12-17|2011-09-09|2011-09-13|Estimate|2013-12-17|2014-01-20|Estimate||||2013-12-17|2014-01-20|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional||The numbers are correct. Participants flow starts with all randomized subjects while baseline is summarized for safety population defined as randomized AND took at least one dose. Started- (Other Did not take study drug) is the number for baseline summary.|Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)|A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder|Completed||Phase 4|924|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:10:14.698187|2018-05-31 22:10:14.698187
NCT01432444|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2014-12-19||2015-04-20|2011-09-12|2011-09-13|Estimate|2015-03-25|2015-03-27|Estimate||||2015-04-20|2015-05-07|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ARRIVE US||Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole|Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting|Completed||Phase 3|493|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 22:10:15.284094|2018-05-31 22:10:15.284094
NCT01432431|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2013-09-04|2011-09-09|2011-09-13|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff|Archstone Spiritual Care Demonstration Project: Outcomes for Patients, Families, and Staff|Completed||N/A|100|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 22:10:16.023915|2018-05-31 22:10:16.023915
NCT01432418|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-05-06|2011-09-09|2011-09-13|Estimate|||||||2016-05-06|2016-05-09|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effectiveness of a Wheelchair Skills Training Program for Power Mobility Users: A Randomized Controlled Trial|Effectiveness of a Wheelchair Skills Training Program for Power Mobility Users: A Randomized Controlled Trial|Completed||N/A|116|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 22:10:16.09998|2018-05-31 22:10:16.09998
NCT01432405|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2016-02-17||2016-03-14|2011-09-12|2011-09-13|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|June 2009|Actual|2009-06-30|July 2008|Actual|2008-07-31||Interventional|||Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes|Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|24|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 22:10:16.245431|2018-05-31 22:10:16.245431
NCT01432392|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2012-05-09|2011-09-12|2011-09-13|Estimate|||||||2012-05-09|2012-05-10|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease|A Prospective, Observational Study to Describe Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease (GERD)|Completed|||1000|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:10:16.47775|2018-05-31 22:10:16.47775
NCT01432379|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2016-07-26||2016-10-19|2011-09-12|2011-09-13|Estimate|2016-10-19|2016-12-12|Estimate||||2016-10-19|2016-12-12|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational||The Treated Population includes all patients who received at least 1 dose of botulinum toxin Type A and is used for baseline characteristics.|BOTOX® Prophylaxis in Patients With Chronic Migraine||Completed|||1168|Actual|Allergan|||1||f||||f||||||||||2018-05-31 22:10:16.590993|2018-05-31 22:10:16.590993
NCT01432366|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|2015-12-14||2015-12-14|2011-09-08|2011-09-13|Estimate|2015-12-14|2016-01-20|Estimate||||2015-12-14|2016-01-20|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|December 2013|Actual|2013-12-31||Observational|CONTENT|Baseline analysis set (BAS) included all participants who were enrolled in the study and seen at baseline.|Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA)|Subcutaneous Anti-tnf-αlpha In Rheumatoid Arthritis: Analyze The Correlation Between Objective Measures Of Disease Activity And Safety And A Subjective Measure Such As Patient Beliefs About A Medicine|Completed|||460|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:10:16.896438|2018-05-31 22:10:16.896438
NCT01432353|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-11-01|2011-09-08|2011-09-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma|An Open-label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|39|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:10:18.516252|2018-05-31 22:10:18.516252
NCT01432340|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-09|2011-09-09|2011-09-12|Estimate|||||||2011-09-09|2011-09-12|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|March 2013|Anticipated|2013-03-31|||||Observational|||Seasonal Influenza Vaccine Effectiveness Study in Kenya|Seasonal Influenza Vaccine Effectiveness Study in the Kenyan Communities of Kibera and Lwak|Unknown status|Recruiting||10000|Anticipated|Centers for Disease Control and Prevention|||2||f||||f||||||Samples With DNA|"~     Nasopharyngeal and oropharyngeal swabs.Potentially has DNA and RNA retained.~   "|||2018-05-31 22:10:18.682072|2018-05-31 22:10:18.682072
NCT01432327|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2012-02-15||2015-02-23|2011-09-09|2011-09-12|Estimate|2012-03-26|2012-04-18|Estimate||||2015-02-23|2015-03-13|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Impact of Real-time Feedback on Physical Activity Patterns in Flemish Employees|The Impact of Real-time Feedback on Physical Activity Patterns in Flemish Employees: an Intervention Study|Completed||N/A|227|Actual|Katholieke Universiteit Leuven|Malfunction of the SenseWear Armband: 4 out of the 320 baseline measurements|4|||f||||f||||||||||2018-05-31 22:10:18.860662|2018-05-31 22:10:18.860662
NCT01431651|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2012-05-05|2011-09-08|2011-09-09|Estimate|||||||2012-05-05|2012-05-08|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Probiotics Improve Gastrointestinal Symptoms After Roux-en-Y Gastric Bypass: A Prospective Randomized Trial|Asian Pacific Weight Loss and Metabolic Surgery Center|Unknown status|Recruiting|N/A|60|Anticipated|Min-Sheng General Hospital||1|||f||||t||||||||||2018-05-31 22:10:31.864877|2018-05-31 22:10:31.864877
NCT01432314|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2014-06-24|2011-09-09|2011-09-12|Estimate|||||||2014-06-24|2014-06-26|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|RTANDTACE||Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)|A Phase II Trial of Radiation Therapy, Followed by Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Invading 1st or 2nd Order Branch of Portal Vein|Withdrawn||Phase 2|0|Actual|Asan Medical Center||1||Another phase 2 randomized study has been started by other investigators.|f||||t||||||||||2018-05-31 22:10:20.796011|2018-05-31 22:10:20.796011
NCT01432301|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-03-03|2011-09-09|2011-09-12|Estimate|||||||2016-03-03|2016-03-07|Estimate||||March 2016|2016-03-31||||||||Expanded Access|||Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination|An Open-Label Protocol for the Use of Uridine Triacetate as an Antidote to Treat Patients at Excess Risk of 5-Fluorouracil Toxicity Due to Overdosage or Impaired Elimination|Approved for marketing|||||Wellstat Therapeutics|||||||||||||||||||2018-05-31 22:10:20.880351|2018-05-31 22:10:20.880351
NCT01432288|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-08-08|2011-09-09|2011-09-12|Estimate|||||||2017-08-08|2017-08-10|Actual|August 2011||2011-08-31|August 2017|2017-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Touch and Attention MRI Study|Effects of Touch and Attention on Central Nervous System Resting State Network (RSN) Activity|Completed|||10|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-05-31 22:10:21.003701|2018-05-31 22:10:21.003701
NCT01432275|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|2013-07-10||2017-04-27|2011-09-09|2011-09-12|Estimate|2017-04-27|2017-08-04|Actual||||2017-04-27|2017-08-04|Actual|September 2011||2011-09-30|April 2017|2017-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|IHUT||Ease of Use of New Blood Glucose Meter With In-built Insulin Calculator at Home Study|Ease of Use of New Blood Glucose Meter With In-built Insulin Calculator at Home Study|Completed||N/A|179|Actual|Abbott Diabetes Care||2|||f||||f||||||||||2018-05-31 22:10:21.078417|2018-05-31 22:10:21.078417
NCT01432262|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2012-12-04||2013-01-18|2011-09-08|2011-09-12|Estimate|2012-12-04|2013-01-08|Estimate||||2013-01-18|2013-01-25|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico|A Phase 3, Open Label, Single Arm, Multicenter, Trial to Assess The Safety, Tolerability And Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine In Healthy Adults Aged => 50 Years of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine in Mexico.|Completed||Phase 3|324|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:10:21.456459|2018-05-31 22:10:21.456459
NCT01432249|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-11-14|2011-09-08|2011-09-12|Estimate|||||||2013-11-14|2013-11-18|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis|Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis|Withdrawn|||0|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:10:22.612247|2018-05-31 22:10:22.612247
NCT01432236|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2014-05-12||2014-10-21|2011-09-08|2011-09-12|Estimate|2014-10-21|2014-10-22|Estimate||||2014-10-21|2014-10-22|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression|A Phase 3b Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study Of Pregabalin In The Treatment Of Fibromyalgia With Concurrent Antidepressant Therapy For Comorbid Depression (Protocol A0081275)|Completed||Phase 3|197|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:10:23.018036|2018-05-31 22:10:23.018036
NCT01432223|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-04-21|2011-09-09|2011-09-12|Estimate|||||||2015-04-21|2015-04-22|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab|Phase II Study of Primary Chemotherapy With Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients With HER2 Positive Breast Cancer|Completed||Phase 2|46|Actual|Osaka Medical College||1|||f||||t||||||||||2018-05-31 22:10:24.308923|2018-05-31 22:10:24.308923
NCT01432210|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2016-09-28|2011-09-08|2011-09-12|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Provitamin A Absorption and Conversion With Avocados|Enhancing Human Intestinal Absorption of Carotenoids and Bioconversion of Carotene to Vitamin A in the Presence of Hass Avocados|Completed||N/A|24|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 22:10:24.395946|2018-05-31 22:10:24.395946
NCT01432197|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2011-09-09|2011-09-09|2011-09-12|Estimate|||||||2011-09-09|2011-09-12|Estimate|March 2010||2010-03-31|September 2011|2011-09-30||||June 2011|Actual|2011-06-30||Interventional|||Occupational Therapy for Cancer Patients: a Randomised, Controlled Study|Occupational Therapy for Cancer Patients: A Randomised Controlled Study|Completed||Early Phase 1|116|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 22:10:24.642236|2018-05-31 22:10:24.642236
NCT01432184|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-10-16|2011-09-08|2011-09-12|Estimate|||||||2015-10-16|2015-10-20|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|October 2013|Actual|2013-10-31|July 2011|Actual|2011-07-31||Interventional|Tête-à-coeur||Feasibility Trial to Maintain Normal Cerebral Oxygen Saturation in High-Risk Cardiac Surgery|Perioperative Interventions to Optimize Cerebral Oxygen Saturation (rSO2) in High-risk Patients Undergoing Cardiac Surgery Should Have a Beneficial Systemic Effect for Enhancing Global Tissue Perfusion and Improve Outcomes.|Completed||N/A|200|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 22:10:24.727385|2018-05-31 22:10:24.727385
NCT01432171|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-05-24|2011-09-09|2011-09-12|Estimate|||||||2016-05-24|2016-05-26|Estimate|July 2012||2012-07-31|May 2016|2016-05-31||||July 2018|Anticipated|2018-07-31||Interventional|||Lacosamide for Seizure Prophylaxis in High-Grade Gliomas|Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas|Active, not recruiting||N/A|302|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 22:10:24.857575|2018-05-31 22:10:24.857575
NCT01432158|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-11-06|2011-09-09|2011-09-12|Estimate|||||||2015-11-06|2015-11-09|Estimate|January 2012||2012-01-31|November 2015|2015-11-30||||August 2012|Actual|2012-08-31||Interventional|||Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines|A Detailed Kinetics Study to Assess the Antibody and the B Cell Response to Either a 13-valent Conjugate Vaccine or a 23-valent Plain Pneumococcal Polysaccharide Vaccine Administered to Healthy Adults Without Prior Pneumococcal Vaccination|Completed||Phase 3|4|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 22:10:24.990043|2018-05-31 22:10:24.990043
NCT01432145|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-05-27|2011-09-09|2011-09-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|6MP||A Clinical Trial in Patients With BRCA Defective Tumours|Phase II Clinical Trial Of 6-Mercaptopurine (6MP) and Low-Dose Methotrexate In Patients With Known BRCA Defective Tumours|Completed||Phase 2|74|Actual|University of Oxford||1|||f||||f||||||||||2018-05-31 22:10:25.108249|2018-05-31 22:10:25.108249
NCT01432132|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-08-03|2011-09-08|2011-09-12|Estimate|||||||2017-08-03|2017-08-04|Actual|August 24, 2011|Actual|2011-08-24|August 2017|2017-08-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Observational|||Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer|Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer|Completed|||25|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 22:10:25.18456|2018-05-31 22:10:25.18456
NCT01432119|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2013-04-08|2011-09-09|2011-09-12|Estimate|||||||2013-04-08|2013-04-09|Estimate|December 2012||2012-12-31|April 2013|2013-04-30||||December 2019|Anticipated|2019-12-31||Interventional|||Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib|Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 22:10:25.344702|2018-05-31 22:10:25.344702
NCT01432106|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2013-11-14|2011-09-09|2011-09-12|Estimate|||||||2013-11-14|2013-11-18|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SAAVE||The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome|A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome|Withdrawn||Phase 1|0|Actual|University of Michigan||2||"Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the~   ALTITUDE clinical trial found a higher incidence of adverse events."|f||||f||||||||||2018-05-31 22:10:25.441837|2018-05-31 22:10:25.441837
NCT01432093|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-11-11|2011-09-08|2011-09-12|Estimate|||||||2013-11-11|2013-11-13|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Intensive Glycemic Management and Outcomes Following Liver Transplantation|Intensive Glycemic Management and Outcomes Following Liver Transplantation: A Randomized Controlled Trial|Completed||N/A|270|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:10:25.529569|2018-05-31 22:10:25.529569
NCT01432080|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-08-28|2011-09-09|2011-09-12|Estimate|||||||2017-08-28|2017-08-30|Actual|September 2011||2011-09-30|August 2017|2017-08-31|December 30, 2013|Actual|2013-12-30|December 2012|Actual|2012-12-31||Interventional|||Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant|Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study|Terminated||Phase 2|12|Actual|Maisonneuve-Rosemont Hospital||2||Not meeting recruitment targets|f||||f||||||||||2018-05-31 22:10:25.613856|2018-05-31 22:10:25.613856
NCT01432067|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-11-07|2011-09-09|2011-09-12|Estimate|||||||2017-11-07|2017-11-08|Actual|October 4, 2011|Actual|2011-10-04|November 2017|2017-11-30|June 10, 2016|Actual|2016-06-10|June 10, 2016|Actual|2016-06-10||Interventional|CAPADOGE||Physical Activity Advices to Prevent Loss of Autonomy in Cancer Treated Elderly Patients. An Intervention Randomized Study||Completed||N/A|302|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 22:10:25.720563|2018-05-31 22:10:25.720563
NCT01432054|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-06-24|2011-09-09|2011-09-12|Estimate|||||||2015-06-24|2015-06-26|Estimate||||September 2011|2011-09-30||||||||Observational|||Human Tissue Repository for Wound Care|Human Tissue Repository for Wound Care|Withdrawn|||0|Actual|KCI USA, Inc.||||business decision|f||||f||||||Samples With DNA|"~     wound biopsy~   "|||2018-05-31 22:10:25.805448|2018-05-31 22:10:25.805448
NCT01432041|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2011-09-09|2011-09-09|2011-09-12|Estimate|||||||2011-09-09|2011-09-12|Estimate|September 2004||2004-09-30|September 2011|2011-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Brief Child Safety Interventions in Emergency Departments (Safety in Seconds)|Brief Child Safety Interventions in Emergency Departments (Safety in Seconds)|Completed||N/A|901|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||||||2018-05-31 22:10:25.869986|2018-05-31 22:10:25.869986
NCT01432028|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2014-01-23|2011-09-09|2011-09-12|Estimate|||||||2014-01-23|2014-01-27|Estimate|March 2007||2007-03-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women|Polymorphisms in Genes Encoding the Estrogen Metabolism Enzymes and Effects of Hormone Therapy for Oral Low Dose or Not Oral on Variables Related Endothelial Function, Inflammation and Metabolic Profile in Patients in Recent Menopause Study Pharmacogenetic|Completed||N/A|90|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 22:10:25.940734|2018-05-31 22:10:25.940734
NCT01432015|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2015-04-29||2017-02-24|2011-09-08|2011-09-12|Estimate|2015-05-22|2015-05-27|Estimate||||2017-02-24|2017-03-28|Actual|September 2011||2011-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting|A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer|Completed||Phase 4|20|Actual|Gynecologic Oncology Associates||2|||f||||f||||||||No||2018-05-31 22:10:26.024646|2018-05-31 22:10:26.024646
NCT01432002|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2017-05-12|2011-09-08|2011-09-12|Estimate|||||||2017-05-12|2017-05-16|Actual|November 2007||2007-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|May 2013|Actual|2013-05-31||Observational|||FDG-PET/CT for Simulation and Radiation Treatment Planning of Early Breast Cancer|Application of 18F-[FDG] PET/CT to Simulation and Planning of Radiotherapy (RT) for Breast Cancer. Definition of Target Volume for 3-D RT and for Partial Breast Irradiation (PBI) by IMRT Technique|Active, not recruiting|||60|Anticipated|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 22:10:26.266682|2018-05-31 22:10:26.266682
NCT01431989|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2012-01-05||2018-05-17|2011-09-08|2011-09-12|Estimate|2012-01-05|2012-02-07|Estimate||||2018-05-17|2018-05-22|Actual|May 27, 2011|Actual|2011-05-27|May 2018|2018-05-31|June 11, 2011|Actual|2011-06-11|June 11, 2011|Actual|2011-06-11||Interventional|||Amoxicillin Bioequivalence Study Brazil - Fast|Evaluation of Pharmaceutical Bioequivalence of Amoxicillin Trihydrate - Clamoxyl 500mg/5mL (Glaxo Wellcome Production.) in the Form Powder for Oral Suspension Versus Amoxil ® 500mg/5mL (GlaxoSmithKline Mexico SA) in the Form of Powder for Oral Suspension in Healthy Volunteers and Fasting, Using Techniques of Liquid Chromatography|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:10:26.34048|2018-05-31 22:10:26.34048
NCT01431976|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2014-08-14||2017-01-25|2011-09-08|2011-09-12|Estimate|2014-08-14|2014-08-27|Estimate||||2017-01-25|2017-03-08|Actual|September 2011||2011-09-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|February 2014|Actual|2014-02-28||Interventional|||Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents|A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy on Newly Diagnosed Typical Absence Seizures in Children and Adolescents|Completed||Phase 3|20|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:10:26.626672|2018-05-31 22:10:26.626672
NCT01431963|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2013-09-26||2016-09-23|2011-09-08|2011-09-12|Estimate|2013-10-04|2013-12-03|Estimate||||2016-09-23|2016-10-20|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|March 2013|Actual|2013-03-31||Interventional||Baseline data were collected in members of the Safety Population, comprised of all participants who had taken at least one dose of investigational product.|Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy|A Multi-center, Uncontrolled, Open-label, Evaluation of Lamotrigine Monotherapy in Newly Diagnosed Epilepsy or Recurrent Epilepsy (Currently Untreated)|Completed||Phase 3|70|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:10:26.918223|2018-05-31 22:10:26.918223
NCT01431950|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2014-08-21|2013-03-14|2016-11-18|2011-09-08|2011-09-12|Estimate|2014-08-21|2014-09-03|Estimate|2013-03-14|2013-03-20|Estimate|2016-11-18|2017-01-09|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents|A Randomised, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Currently Receiving Mid to High Strength Inhaled Corticosteroids.|Completed||Phase 3|238|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:10:27.268703|2018-05-31 22:10:27.268703
NCT01431937|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-07-05|2011-09-08|2011-09-12|Estimate|||||||2017-07-05|2017-07-07|Actual|October 10, 2010|Actual|2010-10-10|July 2017|2017-07-31|March 29, 2011|Actual|2011-03-29|March 29, 2011|Actual|2011-03-29||Interventional|P1A114347||Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers|A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:10:27.66185|2018-05-31 22:10:27.66185
NCT01431924|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2013-02-21|2011-09-08|2011-09-12|Estimate|||||||2013-02-21|2013-02-25|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients|Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients|Completed|||7779|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:10:27.750145|2018-05-31 22:10:27.750145
NCT01431911|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-05-15|2011-09-08|2011-09-12|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2010||2010-10-31|May 2017|2017-05-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|||Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation|Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation|Completed|||3806|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:10:27.826317|2018-05-31 22:10:27.826317
NCT01431898|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2012-07-23|2011-09-09|2011-09-12|Estimate|||||||2012-07-23|2012-07-25|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection|A Phase 1b, Randomized, Single-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 1|82|Actual|Gilead Sciences||1|||f||||||||||||||2018-05-31 22:10:27.884766|2018-05-31 22:10:27.884766
NCT01431885|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-04-14|2011-09-08|2011-09-12|Estimate|||||||2014-04-14|2014-04-16|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Two Methods of Diagnosing Preterm Labor|Randomized Controlled Trial of Two Methods of Diagnosing Preterm Labor|Unknown status|Recruiting|Phase 3|136|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:10:27.967136|2018-05-31 22:10:27.967136
NCT01431872|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-11-03|2011-09-09|2011-09-12|Estimate|||||||2015-11-03|2015-11-04|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Systemic Dickkopf-related Protein 1 (DKK1)During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors|Systemic DKK1 During Estrogen Level Changes in Post-menopausal Breast Cancer Patients Treated With Aromatase Inhibitors|Completed|||17|Actual|University of Arkansas|||1||f||||f||||||||||2018-05-31 22:10:28.050106|2018-05-31 22:10:28.050106
NCT01431859|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2016-04-05|2011-09-09|2011-09-12|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit?|A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Royal Sussex County Hospital||2|||f||||f||||||||||2018-05-31 22:10:28.110902|2018-05-31 22:10:28.110902
NCT01431846|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2014-11-19||2015-04-06|2011-09-07|2011-09-12|Estimate|2015-01-23|2015-02-10|Estimate||||2015-04-06|2015-04-28|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Transition From Hospital to Home Post Cardiac Condition|Pilot Intervention to Improve the Transition From Hospital to Home|Completed||N/A|19|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-05-31 22:10:28.174518|2018-05-31 22:10:28.174518
NCT01431833|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2016-05-19|2011-09-09|2011-09-12|Estimate|||||||2016-05-19|2016-05-20|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A PK and Safety Study in Subjects With Hepatic Impairment|A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment|Completed||Phase 1|32|Actual|Trius Therapeutics LLC||3|||f||||f||||||||||2018-05-31 22:10:29.316099|2018-05-31 22:10:29.316099
NCT01431820|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08||2015-11-02|2015-11-02|2011-09-09|2011-09-12|Estimate||||2015-11-02|2015-11-30|Estimate|2015-11-02|2015-11-30|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|SOLUTION||Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis|Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study|Completed||Phase 2/Phase 3|334|Actual|Topica Pharmaceuticals||4|||f||||f||||||||||2018-05-31 22:10:29.398329|2018-05-31 22:10:29.398329
NCT01431807|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2016-06-10|2011-09-09|2011-09-12|Estimate|||||||2016-06-10|2016-06-14|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Long-term Study of SYR-472|An Open-label, Multicenter, Long-term Phase 3 Study to Evaluate the Safety and Efficacy of Long-term Treatment With SYR-472 in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Diet and/or Exercise Therapies or Treatment With an Existing Oral Anti-diabetic Drug Added to Diet and/or Exercise Therapies|Completed||Phase 3|680|Actual|Takeda||1|||f||||f||||||||||2018-05-31 22:10:29.512802|2018-05-31 22:10:29.512802
NCT01431794|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2018-04-23|2011-09-08|2011-09-12|Estimate|||||||2018-04-23|2018-04-24|Actual|September 2011||2011-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma|Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma.|Active, not recruiting||Phase 1/Phase 2|52|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-05-31 22:10:29.64609|2018-05-31 22:10:29.64609
NCT01431781|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-25|2011-09-09|2011-09-12|Estimate|||||||2011-09-25|2011-09-27|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||The Prophylactic Effect of Stilamin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis|A Prospective, Multi-center, Investigator Sponsored, Randomized Controlled Trial-- The Prophylactic Effect of Stilamin on Post-ERCP Pancreatitis|Unknown status|Recruiting|N/A|908|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 22:10:30.457751|2018-05-31 22:10:30.457751
NCT01431768|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2014-04-28|2011-09-09|2011-09-12|Estimate|||||||2014-04-28|2014-04-30|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B|Clinical Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B in the Primary Health Setting|Completed||N/A|250|Anticipated|Respirio Pty Ltd|||||f||||f||||||||||2018-05-31 22:10:30.560721|2018-05-31 22:10:30.560721
NCT01431755|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2013-10-16||2014-04-23|2011-09-09|2011-09-12|Estimate|2014-03-20|2014-04-23|Estimate||||2014-04-23|2014-05-09|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride|A Randomised, Subject-blinded Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride 0.3%|Completed||N/A|54|Actual|Q-Med AB||2|||f||||||||||||||2018-05-31 22:10:30.638107|2018-05-31 22:10:30.638107
NCT01431742|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-04-16|2011-09-08|2011-09-12|Estimate|||||||2012-04-16|2012-04-17|Estimate|July 2012||2012-07-31|April 2012|2012-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain|An Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Low Back Pain|Withdrawn||Phase 3|0|Actual|BioDelivery Sciences International||1|||f||||f||||||||||2018-05-31 22:10:30.87861|2018-05-31 22:10:30.87861
NCT01431729|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2011-09-19|2011-09-09|2011-09-12|Estimate|||||||2011-09-19|2011-09-21|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|||Honey and a Mixture of Honey, Beeswax and Olive Oil-propolis Extract in Treatment of Chemotherapy-induced Oral Mucositis|Honey and a Mixture of Honey, Beeswax and Olive Oil-propolis Extract in Treatment of Chemotherapy-induced Oral Mucositis: a Randomized Controlled Pilot Study|Completed|||90|Actual|Ain Shams University|||1||f||||t||||||||||2018-05-31 22:10:30.940435|2018-05-31 22:10:30.940435
NCT01431716|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2015-01-02||2015-01-02|2011-09-09|2011-09-12|Estimate|2015-01-02|2015-01-13|Estimate||||2015-01-02|2015-01-13|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|EPITOME-2|All-treated set (One patient enrolled in the study but withdrew consent prior completing baseline assessment and receiving study drug).|Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension|A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to EFI/ACT-385781A in Patients With Pulmonary Arterial Hypertension|Completed||Phase 3|42|Actual|Actelion||1|||f||||f||||||||||2018-05-31 22:10:31.126145|2018-05-31 22:10:31.126145
NCT01431703|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2016-04-26||2017-01-08|2011-09-08|2011-09-09|Estimate|2017-01-08|2017-03-01|Actual||||2017-01-08|2017-03-01|Actual|May 2010||2010-05-31|January 2017|2017-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||The Learning Curve of NBI With Magnification in the Diagnosis of Colorectal Lesions|The Learning Curve of NBI With Magnification in the Diagnosis of Colorectal Lesions|Completed|||326|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||t||||||Samples Without DNA|"~     if the lesion is neoplastic or sm deeper cancer, we just take biopsy.If the lesion is~     adenomatous or sm1-2 cancer,we do polypectomy, EMR or ESD to get the specimen.~   "|No||2018-05-31 22:10:31.499409|2018-05-31 22:10:31.499409
NCT01431690|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2015-04-23|2011-09-08|2011-09-09|Estimate|||||||2015-04-23|2015-04-24|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals|An Open-label, 2-cohort Study to Evaluate the Effect of Multiple Doses of Epanova® on the Single Dose Pharmacokinetics and Pharmacodynamics of Warfarin and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple-dose Administrations of Epanova® Compared to Lovaza® in Healthy Normal Subjects|Completed||Phase 1|52|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:10:31.652409|2018-05-31 22:10:31.652409
NCT01431677|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2018-05-23|2011-09-08|2011-09-09|Estimate|||||||2018-05-23|2018-05-24|Actual|May 17, 2010||2010-05-17|July 29, 2014|2014-07-29|July 29, 2014|Actual|2014-07-29|June 16, 2014|Actual|2014-06-16||Interventional|||Muscle Biopsies in Healthy Volunteers|Muscle Biopsies in Healthy Volunteers: a Pilot Study|Terminated||N/A|22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:10:31.729722|2018-05-31 22:10:31.729722
NCT01431664|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2014-12-01|2011-09-08|2011-09-09|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia|A Cancer Research UK Phase I/IIa Trial of AT9283 (A Selective Inhibitor of Aurora Kinases) Given Over 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents Aged 6 Months to 18 Years With Relapsed and Refractory Acute Leukemia|Completed||Phase 1|7|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 22:10:31.793242|2018-05-31 22:10:31.793242
NCT01431638|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-11-13|2011-09-08|2011-09-09|Estimate|||||||2017-11-13|2017-11-17|Actual|August 2011||2011-08-31|November 2017|2017-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients|A 36-week Open-label Extension Study of CACZ885H2361 on the Safety and Tolerability of Canakinumab 150 mg s.c. Pre-filled Syringe (PFS) in Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients|Completed||Phase 3|233|Actual|Novartis||1|||f||||t||||||||||2018-05-31 22:10:31.950901|2018-05-31 22:10:31.950901
NCT01431625|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2011-09-08|2011-09-08|2011-09-09|Estimate|||||||2011-09-08|2011-09-09|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype|Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype|Unknown status|Recruiting|Phase 4|30|Anticipated|Hospitales Universitarios Virgen del Rocío||2|||f||||t||||||||||2018-05-31 22:10:32.197834|2018-05-31 22:10:32.197834
NCT01431612|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2011-09-07|2011-09-07|2011-09-09|Estimate|||||||2011-09-07|2011-09-09|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effects of Adrenergic Drugs on the Fluid Balance During Surgery|The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery|Completed||Phase 1/Phase 2|60|Actual|Sodertalje Hospital||3|||f||||f||||||||||2018-05-31 22:10:32.286628|2018-05-31 22:10:32.286628
NCT01431599|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2017-10-08|2011-09-07|2011-09-09|Estimate|||||||2017-10-08|2017-10-10|Actual|September 2011||2011-09-30|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2012|Actual|2012-10-31||Interventional|KROG 11-02||Short-course Preoperative Chemoradiotherapy for Rectal Cancer|Two Week-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Rectal Cancer: Phase II Multicenter Clinical Trial (KROG 11-02)|Recruiting||Phase 2|80|Anticipated|Seoul St. Mary's Hospital||1|||f||||t||||||||||2018-05-31 22:10:32.384592|2018-05-31 22:10:32.384592
NCT01431586|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-05-09|2011-09-08|2011-09-09|Estimate|||||||2012-05-09|2012-05-10|Estimate||||May 2012|2012-05-31||||||||Interventional|||First in Humans Study of JDTic|A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic in Healthy Male Subjects|Terminated||Phase 1|24|Actual|RTI International||1||No further subjects will be enrolled due to adverse events.|f||||t||||||||||2018-05-31 22:10:32.469803|2018-05-31 22:10:32.469803
NCT01431573|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2017-08-14|2011-09-07|2011-09-09|Estimate|||||||2017-08-14|2017-08-17|Actual|July 2011|Actual|2011-07-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Wake Therapy in the Treatment of Depression|Combined Wake Therapy, Light Therapy, and Lithium for Bipolar and Refractory Depression|Recruiting||N/A|25|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||||2018-05-31 22:10:32.56297|2018-05-31 22:10:32.56297
NCT01431560|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-09-08|2011-09-08|2011-09-09|Estimate|||||||2011-09-08|2011-09-09|Estimate|June 2008||2008-06-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|January 2010|Actual|2010-01-31||Interventional|||Outcomes of Operative Treatment of Unstable Ankle Fracture - Comparison Between Metallic and Biodegradable Implants|Outcomes of Operative Treatment of Unstable Ankle Fracture - Comparison Between Metallic and Biodegradable Implants|Completed||Phase 4|109|Actual|National Police Hospital||2|||f||||t||||||||||2018-05-31 22:10:32.673045|2018-05-31 22:10:32.673045
NCT01431547|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-06-16|2011-09-07|2011-09-09|Estimate|||||||2016-06-16|2016-06-17|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)|A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors|Completed||Phase 1|21|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:10:32.750531|2018-05-31 22:10:32.750531
NCT01431534|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2018-02-01|2011-09-07|2011-09-09|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 30, 2012|Actual|2012-01-30|January 2018|2018-01-31|July 9, 2018|Anticipated|2018-07-09|August 20, 2013|Actual|2013-08-20||Interventional|||A Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors (MK-8669-056)|A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|21|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 22:10:32.817725|2018-05-31 22:10:32.817725
NCT01431521|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2016-02-24||2017-07-27|2011-09-07|2011-09-09|Estimate|2016-02-24|2016-03-25|Estimate||||2017-07-27|2017-08-25|Actual|October 26, 2011|Actual|2011-10-26|June 2017|2017-06-30|October 1, 2012|Actual|2012-10-01|September 18, 2012|Actual|2012-09-18||Interventional|||Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)|An Exploratory Study to Evaluate Changes in Hepatic Fat Following Multiple-Dose Administration of MK-4074 and Pioglitazone Hydrochloride|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 22:10:32.9069|2018-05-31 22:10:32.9069
NCT01431508|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2011-10-13||2017-03-31|2011-09-08|2011-09-09|Estimate|2011-10-13|2011-11-22|Estimate||||2017-03-31|2017-05-05|Actual|August 1, 2007|Actual|2007-08-01|March 2017|2017-03-31|June 1, 2009|Actual|2009-06-01|June 1, 2009|Actual|2009-06-01||Interventional|||A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)|An Open-label, Single Arm, Prospective Study to Evaluate the Safety and Anti-hypertensive Efficacy of Losartan 50 mg / Hydrochlorothiazide (HCTZ) 12.5 mg Combination in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 4|15|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:10:33.285964|2018-05-31 22:10:33.285964
NCT01431495|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-09-08|2011-09-08|2011-09-09|Estimate|||||||2011-09-08|2011-09-09|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|(CAPP)||Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)|Clinical Assessment of Pidogrel® Versus Plavix®|Completed||Phase 4|219|Actual|Les Laboratoires des Médicaments Stériles||2|||f||||t||||||||||2018-05-31 22:10:33.457174|2018-05-31 22:10:33.457174
NCT01431482|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-05-01|2011-09-08|2011-09-09|Estimate|||||||2013-05-01|2013-05-03|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Evaluation of the Composition of Human Milk and Health Outcomes in Children|Evaluation of the Composition of Human Milk and Health Outcomes in Children|Completed|||245|Actual|Mead Johnson Nutrition|||||f||||f||||||Samples Without DNA|"~     Human milk samples~   "|||2018-05-31 22:10:33.516647|2018-05-31 22:10:33.516647
NCT01431469|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-12-05|2011-09-08|2011-09-09|Estimate|||||||2012-12-05|2012-12-06|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil||Completed||N/A|250|Anticipated|Mead Johnson Nutrition||2|||f||||||||||||||2018-05-31 22:10:33.562911|2018-05-31 22:10:33.562911
NCT01431456|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-08|2011-09-08|2011-09-09|Estimate|||||||2011-09-08|2011-09-09|Estimate|October 2011||2011-10-31|September 2011|2011-09-30||||October 2014|Anticipated|2014-10-31||Interventional|DARINA||Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery|A Randomized Pilot Study Comparing the Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|Martini Hospital Groningen||3|||f||||t||||||||||2018-05-31 22:10:33.622957|2018-05-31 22:10:33.622957
NCT01431443|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2015-04-08|2011-09-08|2011-09-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CHOCENTA||Consumption of Chocolate in Pregnant Women.|Consumption of Chocolate in Pregnant Women at High Risk for Preeclampsia.|Completed||Phase 2|160|Actual|Laval University||2|||f||||t||||||||||2018-05-31 22:10:33.69869|2018-05-31 22:10:33.69869
NCT01431430|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2017-12-20|2011-09-08|2011-09-09|Estimate|||||||2017-12-20|2017-12-21|Actual|January 6, 2012|Actual|2012-01-06|December 2017|2017-12-31|February 2, 2016|Actual|2016-02-02|February 2, 2016|Actual|2016-02-02||Interventional|VITALE||VITamine D Supplementation in RenAL Transplant Recipients - VITALE|Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients|Completed||Phase 4|538|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 22:10:33.868735|2018-05-31 22:10:33.868735
NCT01431417|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2015-06-02|2011-09-07|2011-09-09|Estimate|||||||2015-06-02|2015-06-04|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Observational|||Validation of a Kinematic Functional Shoulder Score Including Only Essential Movements|Validation of a Kinematic Functional Shoulder Score Including Only Essential Movements|Completed|||108|Actual|Haute Ecole Cantonale Vaudoise de Santé|||5||f||||f||||||||||2018-05-31 22:10:33.945143|2018-05-31 22:10:33.945143
NCT01431404|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2013-07-03|2011-09-08|2011-09-09|Estimate|||||||2013-07-03|2013-07-08|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|March 2012|Actual|2012-03-31||Interventional|||Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects|Randomized,Double-blind,Single-dosing,Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 With Active Comparator|Completed||Phase 1|44|Actual|Hanwha Chemical||2|||f||||f||||||||||2018-05-31 22:10:34.016673|2018-05-31 22:10:34.016673
NCT01431391|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2017-01-05||2017-04-24|2011-09-08|2011-09-09|Estimate|2017-04-24|2017-05-30|Actual||||2017-04-24|2017-05-30|Actual|September 2011||2011-09-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer|A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy|Completed||Phase 2|68|Actual|Dendreon||2|||f||||f||||||||Undecided||2018-05-31 22:10:34.109938|2018-05-31 22:10:34.109938
NCT01431378|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2015-12-10|2011-09-08|2011-09-09|Estimate|||||||2015-12-10|2015-12-11|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|May 2012|Actual|2012-05-31||Observational|MBIR||Pilot Study of Model Based Iterative Reconstruction Using 64-Slice|Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen|Terminated|||92|Actual|GE Healthcare|||4|Feasibility study, sufficient amount of data collected.|f||||f||||||||||2018-05-31 22:10:34.642965|2018-05-31 22:10:34.642965
NCT01431365|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2014-12-12|2011-09-07|2011-09-09|Estimate|||||||2014-12-12|2014-12-16|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of an Acute Bout of Exercise on Smoking Topography|Does an Acute Bout of Exercise Affect Smoking Topography?|Completed||N/A|110|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 22:10:34.718591|2018-05-31 22:10:34.718591
NCT01431352|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2013-11-04|2011-09-08|2011-09-09|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)|The Effects of Chinese Herbal Medicine and Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome:A Double-blind Randomized Controlled Trial|Unknown status|Recruiting|N/A|420|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||f||||||||||2018-05-31 22:10:34.824401|2018-05-31 22:10:34.824401
NCT01431339|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2013-12-27||2013-12-27|2011-09-08|2011-09-09|Estimate|2013-12-27|2014-02-12|Estimate||||2013-12-27|2014-02-12|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 3|739|Actual|Durata Therapeutics Inc., an affiliate of Allergan plc||2|||f||||f||||||||||2018-05-31 22:10:34.978559|2018-05-31 22:10:34.978559
NCT01431326|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-04-02|2011-09-07|2011-09-09|Estimate|||||||2018-04-02|2018-04-04|Actual|November 2011||2011-11-30|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|PTN_POPS||Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care|Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care|Recruiting|||10000|Anticipated|Duke University|||||f||||t|t|f||||Samples With DNA|"~     whole blood~   "|No|Completed study datasets (limited PHI) may be requested from https://pediatrictrials.org/data-sharing-opportunities Study data may be posted to the NICHD Data and Specimen Hub (DASH)|2018-05-31 22:10:35.449673|2018-05-31 22:10:35.449673
NCT01431313|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2018-01-23|2011-09-08|2011-09-09|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2012||2012-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Inhaled Nitrite in Subjects With Pulmonary Hypertension|A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension|Recruiting||Phase 2|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||Undecided||2018-05-31 22:10:35.837326|2018-05-31 22:10:35.837326
NCT01431300|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2013-08-01||2013-10-20|2011-09-08|2011-09-09|Estimate|2013-10-20|2013-12-10|Estimate||||2013-10-20|2013-12-10|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants|Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants|Completed||N/A|30|Actual|Duke University||3|||f||||f||||||||||2018-05-31 22:10:35.927361|2018-05-31 22:10:35.927361
NCT01431287|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2015-06-19|2014-03-28|2015-06-19|2011-09-08|2011-09-09|Estimate|2015-06-19|2015-07-16|Estimate|2014-03-28|2014-04-25|Estimate|2015-06-19|2015-07-16|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Treated set (TS): This patient set included all patients in the randomised set who were dispensed study medication and were documented to have taken any dose of study medication.|Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2]|Completed||Phase 3|2539|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 22:10:36.359068|2018-05-31 22:10:36.359068
NCT01431274|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2015-06-19|2014-03-28|2015-06-19|2011-09-08|2011-09-09|Estimate|2015-06-19|2015-07-16|Estimate|2014-03-28|2014-04-25|Estimate|2015-06-19|2015-07-16|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Treated set (TS): This patient set included all patients in the randomised set who were dispensed study medication and were documented to have taken any dose of study medication.|Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]|Completed||Phase 3|2624|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 22:10:40.959864|2018-05-31 22:10:40.959864
NCT01431261|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2016-10-06|2011-09-08|2011-09-09|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|WADNECXT||Neck Exercises, Training and Pain Management as a Treatment for Whiplash Patients With Chronic Neck Pain|Neck Exercises, Physical and Cognitive Behavioural Graded Activity as a Treatment for Adult Whiplash Patients With Chronic Neck Pain|Completed||N/A|200|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 22:10:46.838831|2018-05-31 22:10:46.838831
NCT01431248|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-01-15|2011-09-08|2011-09-09|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|PEACE||PPROM Erythromycin Versus Azithromycin|Preterm Premature Rupture of Membranes: Erythromycin Versus Azithromycin. A Randomized Trial Comparing Their Efficacy to Prolong Latency|Completed|||7|Actual|University of Oklahoma|||2||f||||f||||||||||2018-05-31 22:10:46.922979|2018-05-31 22:10:46.922979
NCT01431235|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2017-01-13|2011-09-08|2011-09-09|Estimate|||||||2017-01-13|2017-01-16|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders|Investigating the Efficacy of Cognitive Behavioral Therapy in Patients With Substance Use Disorder and Comorbid ADHD. A Randomized Controlled Trial With Cognitive Behavioral Therapy|Completed||N/A|184|Actual|Arkin||2|||f||||f||||||||||2018-05-31 22:10:47.07011|2018-05-31 22:10:47.07011
NCT01431222|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-08|2011-09-08|2011-09-09|Estimate|||||||2011-09-08|2011-09-09|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|ISAR-CLIP||Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery|Interventional Strategy to Abrogate Mitral Regurgitation Using the MitraClip System in High-Risk Patients Considered Unsuitable for Surgery (ISAR-CLIP)|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-05-31 22:10:47.147109|2018-05-31 22:10:47.147109
NCT01431209|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2018-01-13|2011-09-07|2011-09-09|Estimate|||||||2018-01-13|2018-01-17|Actual|August 2011||2011-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant|A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma|Recruiting||Phase 2|90|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 22:10:47.229838|2018-05-31 22:10:47.229838
NCT01431196|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2016-05-18|2011-09-08|2011-09-09|Estimate|||||||2016-05-18|2016-05-19|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer|Phase II Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer|Completed||Phase 2|29|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||Yes|By 2017 scientific data should be communicated|2018-05-31 22:10:47.314683|2018-05-31 22:10:47.314683
NCT01431183|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2011-09-07|2011-09-07|2011-09-09|Estimate|||||||2011-09-07|2011-09-09|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|February 2009|Actual|2009-02-28||Interventional|||Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions|Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions|Completed||N/A|3618|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:10:47.387199|2018-05-31 22:10:47.387199
NCT01431170|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2015-12-23||2016-06-15|2011-09-07|2011-09-09|Estimate|2016-05-02|2016-06-09|Estimate||||2016-06-15|2016-07-14|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children|A Prospective, Double-Blinded, Parallel-Group, Randomized Study to Assess the Safety and Efficacy of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children|Completed||Phase 1|24|Actual|Rutgers, The State University of New Jersey|Limitations include the small sample size which was reduced by participant drop out.We enrolled 24 subjects, completed and collected primary outcome measure data on 20.The recurrence rate was low at 10% (2 subjects), limiting secondary data analysis.|2|||f||||t||||||||||2018-05-31 22:10:47.459058|2018-05-31 22:10:47.459058
NCT01431157|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-12-09|2011-09-08|2011-09-09|Estimate|||||||2013-12-09|2013-12-10|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure|Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure|Terminated||N/A|20|Anticipated|University of Maryland||2||Poor enrollment|f||||f||||||||||2018-05-31 22:10:47.753395|2018-05-31 22:10:47.753395
NCT01431144|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2013-07-07||2016-12-06|2011-09-08|2011-09-09|Estimate|2013-07-07|2013-09-13|Estimate||||2016-12-06|2017-02-01|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Implant Placement With Simultaneous Gum Grafting|The Effect of Implant Placement and Simultaneous Soft Tissue Augmentation in the Esthetic Zone Using Either Connective Tissue Autograft or Acellular Dermal Matrix Allograft on Peri-implant Hard and Soft Tissue Healing|Completed||N/A|27|Actual|University of Louisville|There were no adverse events. There were 2 cases of implant mobility and these was treated as a potential expected complication and handled with routine clinical practice guidelines.|2|||f||||f||||||||||2018-05-31 22:10:47.823846|2018-05-31 22:10:47.823846
NCT01431131|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2013-07-07||2016-12-06|2011-09-08|2011-09-09|Estimate|2016-12-06|2017-01-31|Estimate||||2016-12-06|2017-01-31|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Ridge Preservation Comparing an Intrasocket Graft Alone to an Intrasocket Graft Plus a Facial Overlay Graft|Ridge Preservation Comparing a Socket Allograft Alone to a Socket Allograft Plus a Facial Overlay Xenograft: A Clinical and Histologic Study In Humans|Completed||N/A|24|Actual|University of Louisville|"There were no adverse events.~1 patient in the Intrasocket plus facial overlay graft group was excluded as an outlier. There was a large amount of bone gain and this skewed the data."|2|||f||||f||||||||||2018-05-31 22:10:48.038022|2018-05-31 22:10:48.038022
NCT01431118|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-07-21|2011-09-07|2011-09-09|Estimate|||||||2012-07-21|2012-07-24|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Iron Metabolism in Dragon Boat Athletes|Iron Metabolism in Dragon Boat Athletes - An Analysis of Changes in Blood Count Parameters Under Sport-specific Stress|Completed||N/A|40|Anticipated|University of Giessen||2|||f||||f||||||||||2018-05-31 22:10:48.461138|2018-05-31 22:10:48.461138
NCT01431105|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2018-05-01|2011-09-08|2011-09-09|Estimate|||||||2018-05-01|2018-05-03|Actual|July 2012||2012-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities|Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease|Recruiting||Phase 1/Phase 2|32|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 22:10:48.532808|2018-05-31 22:10:48.532808
NCT01431092|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-06-05|2011-09-07|2011-09-09|Estimate|||||||2014-06-05|2014-06-06|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SMART||Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia|Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial|Completed||Phase 4|86|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 22:10:48.612032|2018-05-31 22:10:48.612032
NCT01431079|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-03|2012-09-30||2013-01-30|2011-09-08|2011-09-09|Estimate|2012-11-12|2012-12-10|Estimate||||2013-01-30|2013-02-04|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men|Designing and Evaluating a Health Belief Model Based Intervention to Increase Intent of HPV Vaccination Among College Men: Use of Qualitative and Quantitative Methodologies|Completed||Phase 4|90|Actual|University of Cincinnati|"Overall limitation of the trial were due to attrition at the one month follow up.~This was due to the end of school year.This meant that students were busy preparing for finals, starting co-ops/internships, moving back home, or lack of interest."|2|||f||||f||||||||||2018-05-31 22:10:48.716139|2018-05-31 22:10:48.716139
NCT01431066|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2014-02-27|2011-09-07|2011-09-09|Estimate|||||||2014-02-27|2014-03-03|Estimate|December 2011||2011-12-31|September 2011|2011-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||ActiPatch Plantar Fasciitis Clinical Trial|Continuous Low Energy Pulsed Radio Frequency Electromagnetic Field Therapy for the Treatment of Plantar Fasciopathy|Completed||Phase 3|28|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:10:49.208621|2018-05-31 22:10:49.208621
NCT01431053|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-03-12|2011-09-08|2011-09-09|Estimate|||||||2013-03-12|2013-03-13|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer|Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer|Unknown status|Recruiting|Phase 2|160|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 22:10:49.287796|2018-05-31 22:10:49.287796
NCT01431040|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-06-13|2011-09-07|2011-09-09|Estimate|||||||2014-06-13|2014-06-16|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|||Patient Experience and Bowel Preparation for Transvaginal Surgical Management of Vaginal Prolapse|Patient Experience and Bowel Preparation for Transvaginal Surgical Management of Vaginal Prolapse|Completed||N/A|150|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 22:10:49.406952|2018-05-31 22:10:49.406952
NCT01431027|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-08-15|2011-09-08|2011-09-09|Estimate|||||||2015-08-15|2015-08-18|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic Function|Left Ventricular Torsional Hysteresis: A Global Parameter for Diastolic Function|Completed|||45|Actual|University of Alabama at Birmingham|||1||f||||t||||||||||2018-05-31 22:10:49.483367|2018-05-31 22:10:49.483367
NCT01431014|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|2014-02-06||2014-02-06|2011-09-08|2011-09-09|Estimate|2014-02-06|2014-03-21|Estimate||||2014-02-06|2014-03-21|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Steroid for the Postoperative Swelling After Orthognathic Surgery|The Effect of Steroid on Reducing Facial Swelling After Orthognathic Surgery|Completed||Phase 4|56|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:10:49.552383|2018-05-31 22:10:49.552383
NCT01431001|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-05-15|2011-09-08|2011-09-09|Estimate|||||||2014-05-15|2014-05-19|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression|Determining Effectiveness of Multi-Coil rTMS for Patients With Major Depressive Disorder: A Pilot Study|Completed||N/A|40|Actual|Cervel Neurotech, Inc.||2|||f||||f||||||||||2018-05-31 22:10:49.867003|2018-05-31 22:10:49.867003
NCT01430988|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-05-02|2011-09-07|2011-09-09|Estimate|||||||2012-05-02|2012-05-03|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Observational Study of the BrainScope® Ahead™ M-100 in UK Emergency Department Patients With Head Injury|An Observational Clinical Study of the BrainScope® Ahead™ M-100 Hand Held Electroencephalogram in Emergency Department Patients With Head Injury (B-AHEAD UK Trial)|Terminated|||318|Actual|BrainScope Company, Inc.|||3|"The trial was terminated prematurely following a suspected data processing concern in the study~   device. The concern did not pose a patient safety issue."|f||||f||||||||||2018-05-31 22:10:49.935855|2018-05-31 22:10:49.935855
NCT01430975|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-04-24|2011-09-08|2011-09-09|Estimate|||||||2012-04-24|2012-04-25|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites|A Prospective Study to Estimate Inadvertent Radiation Exposure From Strontium Isotopes in Patients Who Have Undergone CardioGen-82® PET MPI Scanning at Two Clinical Sites|Completed|||72|Actual|Bracco Diagnostics, Inc|||||f||||f||||||||||2018-05-31 22:10:50.004901|2018-05-31 22:10:50.004901
NCT01430962|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2015-07-22|2011-09-08|2011-09-09|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Observational|EBUS-GA-MS||Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Performed Under General Anesthesia Versus Moderate Sedation|Randomized Controlled Trial Comparing Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Performed Under General Anesthesia Versus Conscious Sedation|Completed|||149|Actual|Baylor College of Medicine|||2||f||||f||||||||||2018-05-31 22:10:50.173135|2018-05-31 22:10:50.173135
NCT01430949|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-09-27|2011-09-08|2011-09-09|Estimate|||||||2013-09-27|2013-09-30|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|GENESIS||GENESIS Feasibility Study of the BARD Over-the-Wire Mesh Ablation System for the Treatment of Paroxysmal Atrial Fibrillation|A Single-Arm Multi-Center Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard Over-the-Wire Ablation System|Completed||Phase 2|42|Actual|C. R. Bard||1|||f||||t||||||||||2018-05-31 22:10:50.256085|2018-05-31 22:10:50.256085
NCT01430936|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-07-09|2011-09-07|2011-09-09|Estimate|||||||2012-07-09|2012-07-10|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|REMOTE-HF-1||Evaluate Heart Failure Patients With Specially Designed Patient Adherence and Monitoring Software on Standard Mobile Devices|Remote Monitoring of Heart Failure Patients (REMOTE-HF-1) Study - to Assess Utility of a Mobile Device for Improved Management of At-risk Patients|Completed|||51|Actual|Aventyn, Inc.|||||f||||f||||||||||2018-05-31 22:10:50.355472|2018-05-31 22:10:50.355472
NCT01430923|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-07-11|2011-09-08|2011-09-09|Estimate|||||||2012-07-11|2012-07-12|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|August 2012|Anticipated|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost|Randomized,Active Comparator-Controlled,Three Months,Open Label Clinical Trial to Compare Efficacy and Safety of Refrigeration-Free Latanoprost (0.005%) and Latanoprost (0.005%) Stored at Refrigeration Temperature in Patients With OAG or OHT|Unknown status|Active, not recruiting|N/A|30|Anticipated|Aurolab||2|||f||||f||||||||||2018-05-31 22:10:50.439839|2018-05-31 22:10:50.439839
NCT01430910|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2017-08-31|2011-09-08|2011-09-09|Estimate|||||||2017-08-31|2017-09-01|Actual|September 2011||2011-09-30|August 2017|2017-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately|A Phase I, 2-Part, Open-Label, Pharmacokinetic and Drug-Drug Interaction Study of CAZ104 (Avibactam and Ceftazidime in Healthy Subjects)|Completed||Phase 1|43|Actual|Pfizer||3|||f||||||||||||||2018-05-31 22:10:50.782623|2018-05-31 22:10:50.782623
NCT01430897|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2011-09-07|2011-09-07|2011-09-08|Estimate|||||||2011-09-07|2011-09-08|Estimate|April 2007||2007-04-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Observational|||Right Ventricular Hypertrophy After Atrial Switch and Cardiovascular Magnetic Resonance (CMR) Findings|Right Ventricular Hypertrophy After Atrial Switch Operation and Its Role in a Systemic RV: Normal Adaptation Process or Risk Factor? A Cardiovascular Magnetic Resonance Study|Completed|||37|Actual|University of Leipzig|||||f||||t||||||||||2018-05-31 22:10:51.015767|2018-05-31 22:10:51.015767
NCT01430884|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-12-02|2011-09-07|2011-09-08|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2004||2004-04-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|March 2015|Anticipated|2015-03-31||Observational|AHCA||Analysis of Human Coronary Aspirate|Human Coronary Aspirate: Characterization of Particular and Soluble Substances and the Impact on Microvascular Obstruction|Unknown status|Recruiting||500|Anticipated|Universität Duisburg-Essen|||1||f||||f||||||Samples With DNA|"~     -  coronary arterial blood distal to the lesion before stent implantation~        -  coronary aspirate blood during stent implantation~   "|||2018-05-31 22:10:51.355661|2018-05-31 22:10:51.355661
NCT01430871|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2012-06-14|2011-09-07|2011-09-08|Estimate|||||||2012-06-14|2012-06-15|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Effects of Serotonin Excess on Bone in Carcinoid Syndrome|Effects of Serotonin Excess on Bone in Carcinoid Syndrome|Completed|||52|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||2||f||||f||||||Samples Without DNA|"~     24 hour urine collections serum samples whole blood samples blood spot on cards~   "|||2018-05-31 22:10:51.671955|2018-05-31 22:10:51.671955
NCT01430858|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-12-14|2011-09-07|2011-09-08|Estimate|||||||2012-12-14|2012-12-17|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Does Vibration Therapy Induce Higher Than Normal Bone Strains and Strain Rates Than Those Experienced During Habitual Daily Activities|Measurement of Induced Strains in the Human Tibia During Vibration Therapy and Habitual Activities|Unknown status|Recruiting|N/A|5|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 22:10:52.058363|2018-05-31 22:10:52.058363
NCT01430845|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-02-22|2011-09-07|2011-09-08|Estimate|||||||2016-02-22|2016-02-23|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay|Predicting Developmental Disability Type and Mental Retardation Level in Children Who Were Diagnosed in General Developmental Delay|Completed|||150|Actual|Sheba Medical Center|||||f||||f||||||||Undecided||2018-05-31 22:10:52.258758|2018-05-31 22:10:52.258758
NCT01430832|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-02-22|2011-09-07|2011-09-08|Estimate|||||||2016-02-22|2016-02-23|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Developmental Outcomes of Extreme Prematurity, 5-15 Years Postpartum|The Long-Term Developmental Outcomes of Extreme Prematurity: Correlations With Maternal Post-Traumatic Symptoms, Parental Stress and Post-Traumatic Growth, 5-15 Years Postpartum|Terminated|||95|Actual|Sheba Medical Center|||2||f||||f||||||||Undecided||2018-05-31 22:10:52.372188|2018-05-31 22:10:52.372188
NCT01430819|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|2013-03-18||2013-05-16|2011-09-07|2011-09-08|Estimate|2013-03-18|2013-05-16|Estimate||||2013-05-16|2013-05-27|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults|Safety and Immunogenicity Among Adults of Fluzone®, Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route)|Completed||Phase 4|300|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:10:52.520422|2018-05-31 22:10:52.520422
NCT01430806|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2011-09-07|2011-09-07|2011-09-08|Estimate|||||||2011-09-07|2011-09-08|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Dronaderone to Prevent Recurrent Implantable Cardioverter Defibrillator (ICD) Shocks|Dronedarone for Patients With Recurrent ICD Shocks Due to Ventricular Arrhythmia Resistant to Their Antiarrhythmic Drug Therapy or Ablation|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 22:10:53.031029|2018-05-31 22:10:53.031029
NCT01430793|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-04-07|2011-09-07|2011-09-08|Estimate|||||||2014-04-07|2014-04-08|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EVIREST-D||Determination of Effective Vitamin D Replacement and Monitoring Strategies in Vitamin D Deficiency State|Vitamin D Dosing and Monitoring Study|Completed||N/A|99|Actual|Aga Khan University||4|||f||||f||||||||||2018-05-31 22:10:53.116205|2018-05-31 22:10:53.116205
NCT01430780|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-03-21|2011-09-06|2011-09-08|Estimate|||||||2013-03-21|2013-03-22|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||A Prospective Study to Evaluate the Effect of Chronic Nitrate Therapy on Vasodilation Function in Coronary Heart Disease|A Prospective Study to Evaluate the Influence of Oxygen Free Radical Injury Induced by Long-term Nitrates Therapy on Vasodilation Function of Patients With Coronary Heart Disease|Unknown status|Recruiting||68|Anticipated|Zhejiang University|||2||f||||t||||||||||2018-05-31 22:10:53.204979|2018-05-31 22:10:53.204979
NCT01430767|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2017-04-18|2011-09-07|2011-09-08|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2011||2011-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder|Measuring Adherence to Standard-of-Care Medication for Depression and ADHD in a College Student Population|Completed|||33|Actual|Wake Forest University Health Sciences|||2||f||||f|f|f||||||||2018-05-31 22:10:53.342562|2018-05-31 22:10:53.342562
NCT01430754|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2014-08-08|2013-05-21|2014-10-08|2011-09-06|2011-09-08|Estimate|2014-10-08|2014-10-10|Estimate|2013-05-21|2013-05-29|Estimate|2014-10-08|2014-10-10|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Run-In - Not Randomized includes the demographics for patients who participated in the run-in phase but who were not randomized.|Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder|A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD|Completed||Phase 3|20|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:10:53.439409|2018-05-31 22:10:53.439409
NCT01430741|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|2016-10-20||2017-05-22|2011-09-06|2011-09-08|Estimate|2017-05-22|2017-05-30|Actual||||2017-05-22|2017-05-30|Actual|October 2012||2012-10-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Interventional||Limited baseline characteristics were collected for the Veteran population who received case management. Only age was collected for Veterans. No baseline characteristics were collected on the staff population.|MISSION-Vet HUD-VASH Implementation Study|MISSION-Vet HUD-VASH Implementation Study|Completed||N/A|227|Actual|VA Office of Research and Development|First peer specialists were not readily available to teams in the IU condition in two of the three sites. Second, HOMES data on case managers reports. Third, we believe the services documented underrepresented the actual amount of services delivered.|4|||f||||f||||||||No||2018-05-31 22:10:53.999817|2018-05-31 22:10:53.999817
NCT01430728|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2016-04-05|2011-09-07|2011-09-08|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Cerebral Tissue Oxygenation in Very Low Birthweight Infants in the First 3 Days of Life|Cerebral Tissue Oxygen Saturation in Preterm Neonates Below 1500g Birth Weight During the First 72 Hours|Recruiting|||200|Anticipated|University of Ulm|||1||f||||f||||||||||2018-05-31 22:10:54.714604|2018-05-31 22:10:54.714604
NCT01430715|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2018-04-03|2011-09-06|2011-09-08|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2011||2011-07-31|April 2018|2018-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Estimating Energy Expenditure in Active Video Gaming Compared to Unstructured, Outdoor Play in Children|Active Video Gaming Compared to Unstructured, Outdoor Play in Children: Measurements of Estimated Energy Expenditure and Measured Percent Time in Moderate-to-Vigorous Physical Activity|Completed||N/A|16|Actual|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-05-31 22:10:54.828362|2018-05-31 22:10:54.828362
NCT01430702|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-01-14|2011-09-07|2011-09-08|Estimate|||||||2013-01-14|2013-01-16|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|EMMA||Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults|Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults That Require Medication Assistance During Transition Form Hospital to Home|Withdrawn||N/A|0|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:10:54.931118|2018-05-31 22:10:54.931118
NCT01430689|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2017-10-18|2011-09-07|2011-09-08|Estimate|||||||2017-10-18|2017-10-20|Actual|September 12, 2011|Actual|2011-09-12|October 2017|2017-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Maternal Flu Vaccine Trial in Bamako, Mali|Prospective, Randomized, Controlled, Observer-Blind Trial to Measure the Efficacy, Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine and the Safety and Immunogenicity of Quadrivalent Meningococcal Polysaccharide Diphtheria Conjugate Vaccine in Pregnant Malian Women and Their Infants up to 6 Months of Age|Completed||Phase 4|4193|Actual|University of Maryland||2|||f||||t||||||||No||2018-05-31 22:10:55.015795|2018-05-31 22:10:55.015795
NCT01430676|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2011-11-30|2011-09-07|2011-09-08|Estimate|||||||2011-11-30|2011-12-01|Estimate|January 2007||2007-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|January 2011|Actual|2011-01-31||Observational|||Risk Factors for Morbidity After Incisional Hernia Repairs|Risk Factors for Morbidity After Incisional Hernia Repairs|Completed|||3460|Actual|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 22:10:55.078957|2018-05-31 22:10:55.078957
NCT01430663|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2016-05-23|2011-09-07|2011-09-08|Estimate|||||||2016-05-23|2016-05-24|Estimate|April 2007||2007-04-30|May 2016|2016-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples|Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples|Completed|||87|Actual|Heidelberg University|||2||f||||f||||||||||2018-05-31 22:10:55.141466|2018-05-31 22:10:55.141466
NCT01430650|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-09-19|2011-09-07|2011-09-08|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2010||2010-07-31|September 2017|2017-09-30|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|||Endometrial Priming for Embryo Transfer|A Randomised Control Trial to Evaluate Efficacy and Safety of Two Different Protocols of Endometrial Priming for Embryo Transfer.|Completed||Phase 4|140|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 22:10:55.250175|2018-05-31 22:10:55.250175
NCT01430637|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-05-17|2011-09-07|2011-09-08|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2011||2011-09-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1|Comprehensive Genome Sequencing of Desmoplastic Small Round Cell Tumors|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:10:55.391474|2018-05-31 22:10:55.391474
NCT01430624|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2015-11-02||2016-03-14|2011-09-07|2011-09-08|Estimate|2016-03-14|2016-04-13|Estimate||||2016-03-14|2016-04-13|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Prevention of Post Sexual Assault Stress|Prevention of Postrape Drug Abuse: Replication Study|Completed||Phase 1/Phase 2|245|Actual|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 22:10:55.466942|2018-05-31 22:10:55.466942
NCT01430611|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2014-02-28||2014-04-09|2011-09-06|2011-09-08|Estimate|2014-04-09|2014-05-08|Estimate||||2014-04-09|2014-05-08|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children|Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China|Completed||Phase 4|666|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:10:56.193397|2018-05-31 22:10:56.193397
NCT01430598|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-09-07|2011-09-07|2011-09-08|Estimate|||||||2011-09-07|2011-09-08|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Study Comparing Patient Function and Satisfaction With Arthroscopic Subacromial Decompression Before and After Repair of Complete Rotator Cuff Tears|Randomized Single Blinded Study Comparing Patient Function and Satisfaction With Arthroscopic Subacromial Decompression Before and After Repair of Complete Rotator Cuff Tears|Unknown status|Recruiting|N/A|100|Anticipated|Genesys Regional Medical Center||2|||f||||f||||||||||2018-05-31 22:10:56.781394|2018-05-31 22:10:56.781394
NCT01430585|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|2014-07-18||2014-07-18|2011-09-06|2011-09-08|Estimate|2014-07-18|2014-08-12|Estimate||||2014-07-18|2014-08-12|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer|An Open-Label, Randomised Phase 1b/2 Study Of PF-04691502 In Combination With Letrozole Compared With Letrozole Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Early Breast Cancer|Terminated||Phase 2|14|Actual|Pfizer|Study was prematurely terminated due to PF-04691502 tolerability findings that prompted Sponsor to re-evaluate strategic goals of program. Unexpected frequency of severe skin toxicity was observed and no participant was enrolled in phase 2 of study.|3||See termination reason in detailed description.|f||||f||||||||||2018-05-31 22:10:56.914661|2018-05-31 22:10:56.914661
NCT01430572|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2018-02-08|2011-09-07|2011-09-08|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2011|Actual|2011-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients|Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients With Advanced Solid Tumors Refractory to Standard Therapy|Active, not recruiting||Phase 1|62|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:10:57.330697|2018-05-31 22:10:57.330697
NCT01430559|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2013-06-24|2011-09-06|2011-09-08|Estimate|||||||2013-06-24|2013-06-25|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee|A Double-Blind Placebo-Controlled Multicentre Parallel Group Study Of The Effect Of Meloxicam In Mainland Chinese Patients With Osteoarthritis Of The Knee|Completed||N/A|353|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:10:57.415525|2018-05-31 22:10:57.415525
NCT01430546|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2016-03-24|2011-09-07|2011-09-08|Estimate|||||||2016-03-24|2016-03-25|Estimate|November 2010||2010-11-30|March 2016|2016-03-31||||January 2016|Actual|2016-01-31||Observational|||Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line|Phase IV Study on QoL in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide|Completed|||133|Actual|Karolinska University Hospital|||||f||||t||||||||||2018-05-31 22:10:57.517663|2018-05-31 22:10:57.517663
NCT01430533|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-02-27|2011-09-07|2011-09-08|Estimate|||||||2014-02-27|2014-02-28|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation|A Randomized, Double-blind, Vehicle Controlled Phase 1 Dermal Safety Study to Evaluate the Sensitizing Potential of Topically Applied Azelaic Acid Pre-foam Formulation in Healthy Subjects Using a Human Repeated Insult Patch Test Design|Completed||Phase 1|240|Actual|Bayer||3|||f||||||||||||||2018-05-31 22:10:57.565934|2018-05-31 22:10:57.565934
NCT01430520|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2013-06-04|2011-09-07|2011-09-08|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Analgesic Effect of Escitalopram in Total Knee Arthroplasty (TKA)|Analgesic Effect of Perioperative Escitalopram for Patients With High Preoperative Level of Pain Catastrophising in Total Knee Arthroplasty|Completed||Phase 4|120|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 22:10:57.634347|2018-05-31 22:10:57.634347
NCT01430507|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-12-27|2011-09-07|2011-09-08|Estimate|||||||2012-12-27|2012-12-28|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TERRA||A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis|A Phase IIb, 12 Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Revamilast in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|Completed||Phase 2|406|Actual|Glenmark Pharmaceuticals Ltd. India||4|||f||||f||||||||||2018-05-31 22:10:57.716222|2018-05-31 22:10:57.716222
NCT01430494|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2015-04-22|2011-09-06|2011-09-08|Estimate|||||||2015-04-22|2015-04-23|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|OVERTURE||Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease|A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression|Completed|||3409|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||1||f||||f||||||||||2018-05-31 22:10:57.875074|2018-05-31 22:10:57.875074
NCT01430481|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2016-08-09|2011-09-07|2011-09-08|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Rosehip Powder for Knee Osteoarthritis|Comparing Different Preparations and Dosages of Rosehip Powder in Patients With Painful Osteoarthritis of the Knee: An Exploratory Randomised Controlled Trial|Completed||Phase 2|150|Actual|Frederiksberg University Hospital||3|||f||||f||||||||||2018-05-31 22:10:58.391278|2018-05-31 22:10:58.391278
NCT01430468|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2017-01-18||2017-01-18|2011-09-07|2011-09-08|Estimate|2017-01-18|2017-03-07|Actual||||2017-01-18|2017-03-07|Actual|September 2010||2010-09-30|January 2017|2017-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|TIOSO - GPS||Patient Specific Instruments Versus Standard Surgical Instruments|Comparison of Glenoid Component Position Using Patient Specific Instruments Versus Standard Surgical Instruments: A Randomized Prospective Clinical Trial|Completed||N/A|34|Actual|The Cleveland Clinic||2|||f||||f||||||||No|There is no plan to share IPD with other researchers.|2018-05-31 22:10:58.470695|2018-05-31 22:10:58.470695
NCT01430455|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2017-09-25||2018-02-15|2011-09-06|2011-09-08|Estimate|2018-02-15|2018-03-15|Actual||||2018-02-15|2018-03-15|Actual|November 2011|Actual|2011-11-30|February 2018|2018-02-28|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||Tranylcypromine Treatment of Bipolar Depression|Tranylcypromine Treatment of Bipolar Depression|Completed||Phase 4|7|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 22:10:59.724158|2018-05-31 22:10:59.724158
NCT01430442|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07||2015-09-23|2018-02-19|2011-09-07|2011-09-08|Estimate||||2015-09-23|2015-10-12|Estimate|2018-02-19|2018-02-21|Estimate|October 2011||2011-10-31|February 2018|2018-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Dose Ranging Study of a Drug for the Treatment of Acute Migraine|Phase IIb: Double-Blind, Randomized, Placebo Controlled, Dose-ranging Trial of BMS-927711 for the Acute Treatment of Migraine|Completed||Phase 2|885|Actual|Biohaven Pharmaceutical Holding Company Ltd.||8|||f||||f||||||||||2018-05-31 22:10:59.935165|2018-05-31 22:10:59.935165
NCT01430429|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2014-04-03|2011-09-07|2011-09-08|Estimate|||||||2014-04-03|2014-04-04|Estimate||||June 2012|2012-06-30||||||||Interventional|PIANO||Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody|An Open Label Single Arm Study to Investigate the Safety and Efficacy of Multiple Administrations of NI-0801, a Fully Human Anti-CXCL10 Monoclonal Antibody in PBC Patients With an Incomplete Response to Ursodeoxycholic Acid|Terminated||Phase 2|||NovImmune SA||1|||f||||f||||||||||2018-05-31 22:11:00.130258|2018-05-31 22:11:00.130258
NCT01430416|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2018-05-30|2011-09-07|2011-09-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 20, 2011|Actual|2011-12-20|May 2018|2018-05-31|October 11, 2018|Anticipated|2018-10-11|October 11, 2018|Anticipated|2018-10-11||Interventional|||Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients|A Phase 1 Study of AEB071, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma|Active, not recruiting||Phase 1|153|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:11:00.213061|2018-05-31 22:11:00.213061
NCT01430403|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2015-08-14||2017-05-25|2011-09-06|2011-09-08|Estimate|2015-08-14|2015-09-16|Estimate||||2017-05-25|2017-05-30|Actual|September 2011||2011-09-30|May 2017|2017-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|PROSE|Intent-to-treat|Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations|Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-20)|Completed||Phase 4|478|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 22:11:00.51871|2018-05-31 22:11:00.51871
NCT01430390|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2018-04-30|2011-09-07|2011-09-08|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2011||2011-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies|A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies|Recruiting||Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:11:01.370749|2018-05-31 22:11:01.370749
NCT01430377|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-03|||2011-09-07|2011-09-07|2011-09-08|Estimate|||||||2011-09-07|2011-09-08|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Interventional|SBPS||Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS)|Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS)|Unknown status|Recruiting|Phase 4|120|Anticipated|Medica Cor Heart Hospital||1|||f||||t||||||||||2018-05-31 22:11:01.44419|2018-05-31 22:11:01.44419
NCT01430364|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-03|||2013-12-24|2011-09-07|2011-09-08|Estimate|||||||2013-12-24|2013-12-25|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|BIOSS LIM||BIfurcation Optimal Treatment Strategy With LYMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study|BIfurcation Optimal Treatment Strategy With LIMus Eluting Dedicated Bifurcation Versus Convention Stent Randomized Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Medica Cor Heart Hospital||1|||f||||t||||||||||2018-05-31 22:11:01.517647|2018-05-31 22:11:01.517647
NCT01430351|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2018-01-09|2011-09-07|2011-09-08|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2011|Actual|2011-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)|A Phase I lead-in to a 2x2x2 Factorial Trial of Dose Dense Temozolomide, Memantine, Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme|Active, not recruiting||Phase 1|144|Anticipated|M.D. Anderson Cancer Center||7|||f||||f|t|f||||||||2018-05-31 22:11:01.621497|2018-05-31 22:11:01.621497
NCT01430338|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2015-03-16|2011-09-07|2011-09-08|Estimate|||||||2015-03-16|2015-03-17|Estimate|December 2010||2010-12-31|September 2011|2011-09-30||||December 2011|Actual|2011-12-31||Observational|||Different Metabolic Characteristics in the Presence of Brown Adipose Tissue in Humans|Different Metabolic Characteristics in the Presence of Brown Adipose Tissue in Humans|Completed|||90|Actual|Korea University|||1||f||||t||||||Samples Without DNA|"~     plasma and serum~   "|||2018-05-31 22:11:01.822352|2018-05-31 22:11:01.822352
NCT01430325|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2013-01-03||2013-02-12|2011-09-07|2011-09-08|Estimate|2013-01-04|2013-02-07|Estimate||||2013-02-12|2013-02-15|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|TOP-DIVER||Test of Chamber Pressure to Divers and Chamber Attendants|"Test of Chamber Pressure to Divers and Chamber Attendants: A Blinded Trial to Investigate if Pressure-familiar Individuals Can Determine Pressure"|Completed||N/A|42|Actual|Intermountain Health Care, Inc.|Smaller sample size; enrollment was stopped at 42 participants when investigators had exhausted the planned recruitment methods. Very few inside attendants enrolled. Pressures in this study were relatively close.|4|||f||||f||||||||||2018-05-31 22:11:01.909335|2018-05-31 22:11:01.909335
NCT01430312|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-02-27|2011-09-07|2011-09-08|Estimate|||||||2014-02-27|2014-02-28|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation|A Randomized, Double-blind, Vehicle-controlled Phase 1 Dermal Safety Study Using a 21 Day Cumulative Irritant Patch Test Design to Evaluate the Local Tolerability of Azelaic Acid Pre-Foam Formulation in Healthy Volunteers|Completed||Phase 1|40|Actual|Bayer||4|||f||||||||||||||2018-05-31 22:11:02.267716|2018-05-31 22:11:02.267716
NCT01430299|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2018-01-04||2018-01-31|2011-09-07|2011-09-08|Estimate|2018-01-31|2018-02-28|Actual||||2018-01-31|2018-02-28|Actual|June 2011||2011-06-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion|Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix Instrumented Posterolateral Lumbar Spine Fusion|Completed||N/A|20|Actual|SeaSpine, Inc.||2|||f||||f||||||||||2018-05-31 22:11:02.367313|2018-05-31 22:11:02.367313
NCT01430286|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2018-03-16|2011-09-07|2011-09-08|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2011||2011-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|DIAPASON||Web-based Psycho-Educational Program to Support Carers of Alzheimer's Patients|Evaluation of a Web-based Psycho-Educational Program for Informal Caregivers of Patients With Alzheimer's Disease (AD).|Completed||N/A|49|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:11:02.627862|2018-05-31 22:11:02.627862
NCT01430273|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2015-04-02|2011-09-06|2011-09-08|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Observational|BLOOD||Assessment of Blood Loss With a Point Of Care Device|Assessment of Blood Loss With a Point Of Care Device During Hip/Knee Surgery Performed On Dual/Single Antiplatelet Therapy|Unknown status|Recruiting||200|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     salivary kit (Oragnèe-DNA approved by FDA) or blood (2 tubes 2.5ml)~   "|||2018-05-31 22:11:02.726582|2018-05-31 22:11:02.726582
NCT01430260|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2012-09-05|2011-09-07|2011-09-08|Estimate|||||||2012-09-05|2012-09-06|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Omnaris Versus Levocetirizine Phase 4 Study|A Multi-center, Open, Randomized, Three-arm, Parallel-group, Phase IV Study to Compare the Efficacy of Ciclesonide Nasal Spray and Levocetirizine, Alone and in Combination for the Patient With Allergic Rhinitis|Completed||Phase 4|349|Actual|Handok Pharmaceuticals Co., Ltd.||3|||f||||t||||||||||2018-05-31 22:11:02.804245|2018-05-31 22:11:02.804245
NCT01430247|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-09-06|2011-09-06|2011-09-08|Estimate|||||||2011-09-06|2011-09-08|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Vision Screening for the Detection of Amblyopia|Vision Screening of the Four Year Old Children for the Detection of Amblyopia in The Town of Zagreb|Unknown status|Enrolling by invitation|N/A|7000|Anticipated|General Hospital Sveti Duh||1|||f||||f||||||||||2018-05-31 22:11:02.888597|2018-05-31 22:11:02.888597
NCT01430234|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-03-10|2011-09-07|2011-09-08|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|SAPES||Enzyme Suppletion in Exocrine Pancreatic Dysfunction|Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen|Completed||Phase 4|10|Actual|Foundation for Liver Research||1|||f||||f||||||||||2018-05-31 22:11:02.993663|2018-05-31 22:11:02.993663
NCT01430221|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2017-02-23|2011-09-07|2011-09-08|Estimate|||||||2017-02-23|2017-02-24|Actual|May 2011||2011-05-31|February 2017|2017-02-28|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|AWARENESS||Mindfulness-based Personalized Health Planning for Reducing Risk of Heart Disease and Diabetes|Mindfulness-based Personalized Health Planning for Reducing Risk of Heart Disease and Diabetes|Completed||N/A|140|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 22:11:03.081486|2018-05-31 22:11:03.081486
NCT01430208|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-09-07|2011-09-07|2011-09-08|Estimate|||||||2011-09-07|2011-09-08|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||A New Alternative to Traditional Hysteroscopy|New Mini-resectoscope as Alternative to Traditional Hysteroscopy in the Treatment of Uterine Lesions|Completed||N/A|401|Actual|Catholic University of the Sacred Heart||3|||f||||f||||||||||2018-05-31 22:11:03.150051|2018-05-31 22:11:03.150051
NCT01430195|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2013-03-21|2011-09-06|2011-09-08|Estimate|||||||2013-03-21|2013-03-22|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|CUV102||Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)|Proof of Concept Study to Compare Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Nonsegmental Vitiligo|Completed||Phase 1|56|Actual|Clinuvel Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 22:11:03.212216|2018-05-31 22:11:03.212216
NCT01430182|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2016-03-03||2016-03-03|2011-09-07|2011-09-08|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Intraoperative Methadone vs Morphine for Postoperative Pain Control in Patients Undergoing Surgery of the Tibia|Intraoperative Methadone Versus Morphine for Postoperative Pain Control in Patients Undergoing Intramedullary Nailing or Open Reduction and Internal Fixation of the Tibia|Terminated||N/A|17|Actual|Baylor College of Medicine|Early termination leading to small numbers of subjects analyzed. Shortages of IV methadone prompted closure of trial.|2||Shortages of study drug, difficulty enrolling patients|f||||f||||||||No||2018-05-31 22:11:03.291706|2018-05-31 22:11:03.291706
NCT01430169|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2015-02-04||2017-09-07|2011-09-07|2011-09-08|Estimate|2015-04-20|2015-05-06|Estimate||||2017-09-07|2017-10-05|Actual|September 2011||2011-09-30|September 2017|2017-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease|A Phase 2, Open-Label Study to Assess the Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease|Completed||Phase 2|20|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:11:03.533656|2018-05-31 22:11:03.533656
NCT01430156|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2015-05-26|2011-09-06|2011-09-07|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|HOT||Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation|A Randomised Placebo-Controlled Trial to Investigate the Effect of Pre-treatment With Haem Arginate (Normosang) on Heme-Oxygenase 1 (HO-1) Upregulation in Recipients of Deceased Donor Kidneys|Completed||Phase 3|40|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 22:11:04.114532|2018-05-31 22:11:04.114532
NCT01430143|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|June 2011|Actual|2011-06-30||Interventional|FINE||Physical Activity for a Long and Healthy Life|Physical Activity for a Long and Healthy Life - Project FINE|Unknown status|Active, not recruiting|N/A|64|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 22:11:04.397983|2018-05-31 22:11:04.397983
NCT01428401|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-02|2011-09-02|2011-09-05|Estimate|||||||2011-09-02|2011-09-05|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke||Completed||Phase 2|80|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 22:11:35.283269|2018-05-31 22:11:35.283269
NCT01430130|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2014-11-10||2014-11-21|2011-09-06|2011-09-07|Estimate|2014-11-21|2014-11-28|Estimate||||2014-11-21|2014-11-28|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|IMPROVE|After meeting all eligibility criteria, 12 patients were enrolled.|Investigation of a Novel Silicone Dressing to Maximize the Outcomes of Scar Revision Procedures (IMPROVE)|Investigation of a Novel Mechanomodulating Polymer to Maximize the Outcomes of Scar Revision Procedures|Completed||N/A|12|Actual|Neodyne Biosciences, Inc.|"The Neodyne Dressing is referred to as the embrace device."|1|||f||||f||||||||||2018-05-31 22:11:04.688925|2018-05-31 22:11:04.688925
NCT01430117|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2012-08-20|2011-09-06|2011-09-07|Estimate|||||||2012-08-20|2012-08-21|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Biological Standardization of Poa Pratensis Allergen Extract|Biological Standardization of Poa Pratensis Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units|Completed||Phase 2|31|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 22:11:05.305971|2018-05-31 22:11:05.305971
NCT01430104|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2012-11-27||2013-01-07|2011-09-06|2011-09-07|Estimate|2012-11-27|2012-12-28|Estimate||||2013-01-07|2013-01-14|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of Teriparatide in Japanese Osteoporosis Patients|A Study to Assess the Effects on Serum Calcium When Teriparatide is Used With Active Vitamin D in Osteoporosis Patients|Completed||Phase 4|30|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:11:05.667906|2018-05-31 22:11:05.667906
NCT01430091|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2012-10-05||2012-10-05|2011-09-06|2011-09-07|Estimate|2012-10-05|2012-11-06|Estimate||||2012-10-05|2012-11-06|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet|Relative Bioavailability of a Prasugrel Paediatric Orally Disintegrating Tablet Formulation Compared to the Tablet in Healthy Adult Subjects|Completed||Phase 1|18|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 22:11:06.881774|2018-05-31 22:11:06.881774
NCT01430078|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study to Assess the Bioavailability of ASP015K|A Phase 1, Open-Label, 4-Way Crossover Regional Drug Absorption Study to Assess the Bioavailability of ASP015K in Healthy Subjects|Completed||Phase 1|12|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 22:11:07.881417|2018-05-31 22:11:07.881417
NCT01430065|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers|A Phase 1, Open Label, Single Sequence, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:11:08.166971|2018-05-31 22:11:08.166971
NCT01430052|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2017-11-19|2011-09-06|2011-09-07|Estimate|||||||2017-11-19|2017-11-21|Actual|April 2009||2009-04-30|April 2015|2015-04-30|September 2015|Actual|2015-09-30|December 2012|Actual|2012-12-31||Interventional|||Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer|Randomized Phase II Study Comparing Gemcitabine/S-1 Combination Chemoradiotherapy With Gemcitabine/S-1 Combination Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer.|Completed||Phase 2|110|Actual|Osaka Medical Center for Cancer and Cardiovascular Diseases||2|||f||||t||||||||||2018-05-31 22:11:08.476561|2018-05-31 22:11:08.476561
NCT01430039|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2015-04-07|2011-09-06|2011-09-07|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|syndecan1||Syndecan-1 a Surrogate Marker for IBD|Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease|Completed|||42|Actual|Meir Medical Center|||2||f||||f||||||None Retained|"~     Venous blood sample for syndecan-1 levels, blood count, CRP levels,serum albumin and total~     protein~   "|||2018-05-31 22:11:08.77469|2018-05-31 22:11:08.77469
NCT01430026|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2015-09-17|2011-09-06|2011-09-07|Estimate|||||||2015-09-17|2015-09-18|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|||Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis|Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis|Completed|||40|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 22:11:09.082638|2018-05-31 22:11:09.082638
NCT01430013|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2015-11-02|2011-09-06|2011-09-07|Estimate|||||||2015-11-02|2015-11-04|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Trial of Endostar Combined With CHOPT for T Cell Lymphoma|Phase II Trial of Endostar Combined With CHOPT for T Cell Lymphoma|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||||2018-05-31 22:11:09.335452|2018-05-31 22:11:09.335452
NCT01430000|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2014-04-16|2011-09-06|2011-09-07|Estimate|||||||2014-04-16|2014-04-17|Estimate||||April 2014|2014-04-30||||||||Interventional|||Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump|Safety and Efficacy of Sustained Interferon Alfa 2b (INF) Therapy of Relapsing Hepatitis C (HCV) Patients Using InfraDure Biopump|Withdrawn||Phase 1/Phase 2|0|Actual|Medgenics Medical Israel Ltd.|||||f||||t||||||||||2018-05-31 22:11:09.591513|2018-05-31 22:11:09.591513
NCT01429987|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|2017-10-25|2016-04-26|2017-10-25|2011-09-06|2011-09-07|Estimate|2017-10-25|2017-11-29|Actual|2016-04-26|2016-05-26|Estimate|2017-10-25|2017-11-29|Actual|October 2011||2011-10-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||The mITT population included all randomized patients who received ≥ 1 dose of study drug and ≥ 1 post-baseline BM assessment. 951 patients were randomized; 3 were not treated and 2 received study drug but did not complete a post-dose assessment, yielding 946 patients in the mITT population.|The Plecanatide Chronic Idiopathic Constipation (CIC) Study|Study SP304-20210: A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Chronic Idiopathic Constipation|Completed||Phase 2/Phase 3|951|Actual|Synergy Pharmaceuticals Inc.||4|||f||||f||||||||||2018-05-31 22:11:09.874029|2018-05-31 22:11:09.874029
NCT01429974|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2017-05-24|2011-09-06|2011-09-07|Estimate|||||||2017-05-24|2017-05-25|Actual|September 2011||2011-09-30|May 2017|2017-05-31|July 7, 2015|Actual|2015-07-07|July 7, 2015|Actual|2015-07-07||Observational|||Detection of Meconium in Amniotic Fluid in Post Term Pregnancies|Detection of Meconium in Amniotic Fluid in Post Term Pregnancies|Terminated|||27|Actual|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 22:11:11.442689|2018-05-31 22:11:11.442689
NCT01429961|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|May 2011||2011-05-31|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma|Phase II Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|38|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:11:11.509833|2018-05-31 22:11:11.509833
NCT01429948|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Observational|ICONS||Identification the Cause of Silent Cerebral infarctiON in Healthy Subjects (ICONS)|Novel Biomarkers for Personalized Therapy in Korean Patients With Ischemic Stroke|Completed|||581|Actual|Samsung Medical Center|||3||f||||t||||||||||2018-05-31 22:11:11.59023|2018-05-31 22:11:11.59023
NCT01429935|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|GPE||Anti Inflammatory and Analgesic Effect of Ginger Powder in Dental Pain Model|Comparison of The Anti Inflammatory and Analgesic Effect of Ginger and Ibuprofen in Post Surgical Pain Model; a Randomized,Placebo-controlled,Double-blind Clinical Trial|Unknown status|Active, not recruiting|Phase 2|60|Actual|Qazvin University Of Medical Sciences||3|||f||||t||||||||||2018-05-31 22:11:11.663796|2018-05-31 22:11:11.663796
NCT01429909|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2016-06-16|2011-09-06|2011-09-07|Estimate|||||||2016-06-16|2016-06-17|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|2010-A01115-34||Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease|Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease: T2* Measurement in the Cortex and the Basal Ganglia|Completed||N/A|19|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:11:11.787793|2018-05-31 22:11:11.787793
NCT01429896|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2015-01-13|2011-09-06|2011-09-07|Estimate|||||||2015-01-13|2015-01-14|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|Ex-Factor||The Effect of Extrinsic Factors on Food Allergy|The Effect of Extrinsic Factors on Food Allergy|Unknown status|Recruiting|Phase 2|100|Anticipated|Cambridge University Hospitals NHS Foundation Trust||6|||f||||t||||||||||2018-05-31 22:11:11.911284|2018-05-31 22:11:11.911284
NCT01429883|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2015-06-02|2011-09-06|2011-09-07|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Extracorporeal Shock Wave Treatment - Can the Pain be Reduced?|Extracorporeal Shock Wave Treatment - Can the Pain be Reduced?|Completed|||36|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 22:11:12.042225|2018-05-31 22:11:12.042225
NCT01429870|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-12-09|2011-09-05|2011-09-07|Estimate|||||||2015-12-09|2015-12-10|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|DIPSO||Steroids Added to Dithranol and Narrow Band UVB(Ultraviolet B) (UVBnb) in Psoriasis|A Phase IV, Randomized, Double Blind, Placebo Controlled, Single-center Study of the Impact of Topical Steroids on Narrow Band UVB (Ultraviolet B) and Dithranol Combination Treatment of Psoriasis (DIPSO)|Suspended||Phase 4|88|Anticipated|University of Zurich||2||Lack of recruitment|f||||f||||||||||2018-05-31 22:11:12.099793|2018-05-31 22:11:12.099793
NCT01429857|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2013-06-13|2011-09-05|2011-09-07|Estimate|||||||2013-06-13|2013-06-14|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Prognostic Relevance of High-sensitivity Troponin in Patients With Acute Decompensated Heart Failure|Prognostic Relevance of High-sensitivity Troponin in Patients With Acute Decompensated Heart Failure|Completed|||304|Actual|University Hospital, Saarland|||||f||||f||||||||||2018-05-31 22:11:12.169308|2018-05-31 22:11:12.169308
NCT01429844|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|January 2001||2001-01-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|October 2007|Actual|2007-10-31||Interventional|EAILTX||Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation|Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients|Completed||Phase 3|274|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 22:11:12.25734|2018-05-31 22:11:12.25734
NCT01429831|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2014-05-19|2011-09-06|2011-09-07|Estimate|||||||2014-05-19|2014-05-21|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Aripiprazole for the Augmentation of Antidepressant Therapy|Aripiprazole for the Augmentation of Antidepressant Therapy: An Observational, Outpatients Study in Inadequate Responders Diagnosed With Major Depressive Disorder|Completed||Phase 4|300|Actual|Taiwan Otsuka Pharm. Co., Ltd||1|||f||||||||||||||2018-05-31 22:11:12.386795|2018-05-31 22:11:12.386795
NCT01429818|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients|Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients. Positron Emission Tomography Assessment(PET)|Completed||Phase 4|16|Actual|Laboratorios Silanes S.A. de C.V.||2|||f||||f||||||||||2018-05-31 22:11:12.451068|2018-05-31 22:11:12.451068
NCT01429805|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2012-06-19|2011-09-06|2011-09-07|Estimate|||||||2012-06-19|2012-06-20|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|BAHA-I||Balloon Assisted Hip Arthroscopy - Clinical Evaluation of a New Tool for Hip Arthroscopy|Balloon Assisted Hip Arthroscopy - Clinical Evaluation of a New Tool for Hip Arthroscopy|Completed||N/A|30|Actual|Pivot Medical Inc.|||||f||||f||||||||||2018-05-31 22:11:12.537947|2018-05-31 22:11:12.537947
NCT01429792|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2016-11-01|2011-09-05|2011-09-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)|A Multi-Center Study Evaluating the Rate of Genotype 1, 2, 3 & 4 Chronic Hepatitis C Patients With Slow Response / Non-rapid Viral Response to Anti-Viral Treatment of Pegasys (Peginterferon Alfa 2a) in Combination With Copegus (Ribavirin)|Completed||Phase 4|940|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:11:12.731829|2018-05-31 22:11:12.731829
NCT01429779|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2014-04-10|2011-09-06|2011-09-07|Estimate|||||||2014-04-10|2014-04-11|Estimate|July 2012||2012-07-31|April 2014|2014-04-30||||October 2014|Anticipated|2014-10-31||Interventional|||The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme|The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial|Unknown status|Recruiting|Phase 4|80|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 22:11:12.882783|2018-05-31 22:11:12.882783
NCT01429766|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||A Prospective Study of Variation in Breath Holding Times at Various Phases of Respiration During the Course of Radiotherapy Including the Effect of Respiratory Training in Lung Cancer Patients|A Prospective Study of Variation in Breath Holding Times at Various Phases of Respiration During the Course of Radiotherapy Including the Effect of Respiratory Training in Lung Cancer Patients|Unknown status|Recruiting|Phase 2|100|Anticipated|Tata Memorial Hospital|||||f||||t||||||||||2018-05-31 22:11:12.98486|2018-05-31 22:11:12.98486
NCT01429753|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||PRISM Cardiac Resynchronisation Therapy (CRT) Randomised Controlled Trial|A Prospective Randomised Study of Advanced Imaging Guided Cardiac Resynchronisation Therapy (CRT) vs Conventional CRT Implantation in Patients With Chronic Heart Failure|Unknown status|Not yet recruiting|Phase 2/Phase 3|270|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:11:13.064537|2018-05-31 22:11:13.064537
NCT01429740|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2012-04-10|2011-09-06|2011-09-07|Estimate|||||||2012-04-10|2012-04-12|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults|A Phase 1, Placebo-Controlled, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-05180999 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects|Completed||Phase 1|29|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:11:13.123281|2018-05-31 22:11:13.123281
NCT01429727|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-04-12|2011-09-06|2011-09-07|Estimate|||||||2018-04-12|2018-04-17|Actual|July 2011||2011-07-31|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|SCAD||"The Virtual Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry"|"The Virtual Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry"|Recruiting|||900|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 22:11:13.21957|2018-05-31 22:11:13.21957
NCT01429714|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2018-04-09|2011-09-06|2011-09-07|Estimate|||||||2018-04-09|2018-04-10|Actual|March 22, 2011||2011-03-22|March 2018|2018-03-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|IDEAL||The Ideal Deep Venous Thrombosis (DVT) Study|Individually Tailored Elastic Compression Therapy After Deep Venous Thrombosis in Relation to the Incidence of Post Thrombotic Syndrome, a Randomized Multicenter Trial|Completed||N/A|865|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:11:13.311344|2018-05-31 22:11:13.311344
NCT01429701|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2013-03-01|2011-09-06|2011-09-07|Estimate|||||||2013-03-01|2013-03-04|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous|Unicentric Comparing Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol to Betamethasone + Gentamicin + Tolnaftate + Clioquinol in Acute and Sub-acute Dermatitis Eczematous|Completed||Phase 3|76|Actual|EMS||2|||f||||t||||||||||2018-05-31 22:11:13.411848|2018-05-31 22:11:13.411848
NCT01429688|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy Volunteers|A Randomized, Single-dose, 2-sequence, 2-period Crossover Study to Investigate the Food-effect Pharmacokinetics of Sarpogrelate HCl Controlled Release Tablet in Healthy Male Subjects|Completed||Phase 1|36|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 22:11:13.520406|2018-05-31 22:11:13.520406
NCT01429675|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2016-10-31|2011-09-05|2011-09-07|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult Volunteers|Randomized, Open-label Crossover Study to Evaluate Comparative Pharmacokinetics of Ibandronate Between DP-R206(150mg Ibandronate / 24,000 IU Vitamin D3 Complex Tablet) and a 150mg Ibandronate Tablet in Healthy Adult Volunteers|Completed||Phase 1|105|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 22:11:13.581587|2018-05-31 22:11:13.581587
NCT01429662|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-03|||2012-05-27|2011-09-06|2011-09-07|Estimate|||||||2012-05-27|2012-05-30|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Modified Relaxation (MR) Technique for Treating Hypertension in Postmenopausal Women|Phase 3 Study of Modified Relaxation (MR) Technique for Treating Hypertension in Postmenopausal Women|Completed||Phase 3|429|Actual|Chiang Mai University||2|||f||||t||||||||||2018-05-31 22:11:13.644974|2018-05-31 22:11:13.644974
NCT01429649|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-03|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|pGGO||Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO)|A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity|Unknown status|Recruiting|Phase 3|100|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||2|||f||||t||||||||||2018-05-31 22:11:13.731665|2018-05-31 22:11:13.731665
NCT01429636|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-12-28|2011-09-06|2011-09-07|Estimate|||||||2011-12-28|2011-12-30|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Applied Relaxation (AR) Technique Versus Its Modified Version for Treating Menopausal Symptoms|Phase 3 Study of Applied Relaxation (AR) Technique That Treating Menopausal Symptoms|Completed||Phase 3|60|Actual|Chiang Mai University||2|||f||||t||||||||||2018-05-31 22:11:13.884702|2018-05-31 22:11:13.884702
NCT01429623|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-03|2017-01-31||2017-06-14|2011-09-06|2011-09-07|Estimate|2017-06-14|2017-06-15|Actual||||2017-06-14|2017-06-15|Actual|February 2012||2012-02-29|June 2017|2017-06-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional||103 were randomized to ladostigil, however 1 subject withdrew consent before first dose.|A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment|A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)|Completed||Phase 2|210|Actual|Avraham Pharmaceuticals Ltd||2|||f||||t||||||||||2018-05-31 22:11:13.999073|2018-05-31 22:11:13.999073
NCT01429610|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-07-18|2011-09-03|2011-09-07|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2011||2011-11-30|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|RADICAL||Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia|Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|78|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:11:15.197851|2018-05-31 22:11:15.197851
NCT01429597|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2017-06-12|2011-09-06|2011-09-07|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2011||2011-08-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Observational|FaCard||Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation|Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation AN INTERNATIONAL,MULTICENTER, EPIDEMIOLOGICAL STUDY|Recruiting|||40|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     The laboratory examinations of the blood samples for measuring the lyso-Gb3-level will be~     done at the Laboratory of the Albrecht-Kossel-Institute, University of Rostock in~     collaboration with associated diagnostic laboratory partners. This laboratory offers an~     existing infrastructure, a highly standardized quality of the workflow, a short examination~     time of the samples and a long period of experiences in the assessment of the biological~     impact of mutations and polymorphism, as evidenced recently in the sifap1-study.~   "|Undecided||2018-05-31 22:11:15.582873|2018-05-31 22:11:15.582873
NCT01429584|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|2012-06-16||2013-12-09|2011-09-06|2011-09-07|Estimate|2013-12-09|2013-12-19|Estimate||||2013-12-09|2013-12-19|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function|Investigation Into the Effect of 0.25% Bupivacaine for Interscalene Peripheral Nerve Block vs 0.125% Bupivacaine on Pulmonary Function|Completed||N/A|30|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 22:11:15.949654|2018-05-31 22:11:15.949654
NCT01429571|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||The Role of Antibiotics After Surgical Treatment of Simple Hand Infections: A Prospective Study||Completed|||90|Actual|BG Trauma Center Tuebingen|||3||f||||||||||||||2018-05-31 22:11:16.827564|2018-05-31 22:11:16.827564
NCT01429558|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2013-04-23|2011-09-06|2011-09-07|Estimate|||||||2013-04-23|2013-04-24|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|||Electrophysiological Recording for Patients Receiving Deep Brain Stimulation Electrode for Treatment-resistant Obsessive-compulsive Disorder||Completed|||2|Actual|University of Arizona|||||f||||f||||||||||2018-05-31 22:11:17.686003|2018-05-31 22:11:17.686003
NCT01429545|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|April 2007||2007-04-30|September 2011|2011-09-30|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||Single Versus Combination Therapy in Acute Tocolysis|Phase 2 Study of Clinical Utility of Combination Tocolysis in Preterm Labor|Completed||Phase 2|110|Actual|Tawam Hospital||2|||f||||t||||||||||2018-05-31 22:11:18.121811|2018-05-31 22:11:18.121811
NCT01429532|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|2012-12-25||2014-06-06|2011-09-06|2011-09-07|Estimate|2014-06-06|2014-07-11|Estimate||||2014-06-06|2014-07-11|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Outcomes of 3 Incision-size-dependent Phacoemulsification Systems|Clinical Evaluation of Three Incision-size-dependent Phacoemulsification Systems|Completed|||120|Actual|Sun Yat-sen University|||3||f||||t||||||||||2018-05-31 22:11:18.6708|2018-05-31 22:11:18.6708
NCT01429519|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2016-12-05|2011-09-06|2011-09-07|Estimate|||||||2016-12-05|2016-12-06|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds|A PRELIMINARY OPEN CLINICAL STUDY, TO ASSESS THE SAFETY AND EFFICACY OF RPh201 APPLIED TOPICALLY FOR THE TREATMENT OF HARD TO HEAL CHRONIC ULCERATED WOUNDS|Terminated||Phase 1/Phase 2|15|Anticipated|Regenera Pharma Ltd||1||Due to slow recruitment|f||||f||||||||||2018-05-31 22:11:19.290218|2018-05-31 22:11:19.290218
NCT01429506|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2015-10-23|2011-09-06|2011-09-07|Estimate|||||||2015-10-23|2015-10-26|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes|Effect of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes|Completed||N/A|30|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 22:11:19.361721|2018-05-31 22:11:19.361721
NCT01429493|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-06-02|2011-09-06|2011-09-07|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases|Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-05-31 22:11:19.576514|2018-05-31 22:11:19.576514
NCT01429480|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|TAP||Comparison of TAP (Transversus Abdominis Plane) and Ilioinguinal/Iliohypogastric Nerve Block for Analgesia of Open Inguinal Herniorrhaphy|Comparison Between Two Ultrasound-guided Blocks (Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve Blocks) for Pain Relief After Open Inguinal Herniorrhaphy|Unknown status|Recruiting|N/A|90|Anticipated|Hillel Yaffe Medical Center||3|||f||||t||||||||||2018-05-31 22:11:19.987993|2018-05-31 22:11:19.987993
NCT01429467|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-05-27|2011-09-06|2011-09-07|Estimate|||||||2016-05-27|2016-05-30|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|February 2014|Actual|2014-02-28||Interventional|INDIGO 2||Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation|Improving Glucose Variability in Type 1 Diabetes and Its Effect on the Underlying Homeostatic Metabolic Pathways of Angiogenesis|Completed||N/A|35|Actual|University of Dundee||1|||f||||t||||||||||2018-05-31 22:11:20.132564|2018-05-31 22:11:20.132564
NCT01429454|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2015-11-30|2011-09-06|2011-09-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||NAPLS Omega-3 Fatty Acid Versus Placebo Study|Randomized Double-Blind Trial of Omega 3 Fatty Acid Versus Placebo in Individuals at Risk for Psychosis|Unknown status|Active, not recruiting|Phase 1|128|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 22:11:20.247002|2018-05-31 22:11:20.247002
NCT01429441|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2015-10-29||2016-02-18|2011-09-06|2011-09-07|Estimate|2015-12-02|2016-01-11|Estimate||||2016-02-18|2016-03-14|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|OASIS|Safety Set: The Safety Set consists of all subjects who received treatment.|Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole|A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole|Completed||Phase 3|220|Actual|ThromboGenics||2|||f||||t||||||||||2018-05-31 22:11:20.351914|2018-05-31 22:11:20.351914
NCT01429428|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2011-09-04|2011-09-04|2011-09-07|Estimate|||||||2011-09-04|2011-09-07|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|November 2011|Anticipated|2011-11-30||Interventional|||Far-IR Emitted by Compression Stockings for Cellulitis Treatment|Randomized and Controlled Study About Efficacy and Safety of Far-Infra Red Radiation Emitted by Compression Stockings for Cellulitis Treatment|Unknown status|Active, not recruiting|N/A|30|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:11:21.808151|2018-05-31 22:11:21.808151
NCT01429415|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2017-11-21|2011-09-06|2011-09-07|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2011||2011-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|MAGNUMPA||Magnesium Nebulization Utilization in Management of Pediatric Asthma|Magnesium Nebulization Utilization in Management of Pediatric Asthma|Recruiting||Phase 2|816|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 22:11:21.898008|2018-05-31 22:11:21.898008
NCT01429402|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-04|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|July 2000||2000-07-31|August 2011|2011-08-31|August 2013|Anticipated|2013-08-31|August 2010|Actual|2010-08-31||Interventional|||Botulinum Toxin to Improve Results in Cleft Lip Repair|Botulinum Toxin to Improve Results in Cleft Lip Repair|Unknown status|Recruiting|Phase 3|120|Anticipated|Chang Gung Memorial Hospital||4|||f||||t||||||||||2018-05-31 22:11:22.088534|2018-05-31 22:11:22.088534
NCT01429389|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2016-10-27|2011-09-06|2011-09-07|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy|Collection of Whole Blood Specimens From Pregnant Women at Increased Risk of Fetal Chromosomal Abnormality for Use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted From Maternal Plasma|Recruiting|||2000|Anticipated|Sequenom, Inc.|||||f||||f||||||Samples With DNA|"~     Whole blood specimens will be collected and processed to plasma. DNA will be extracted from~     the plasma.~   "|No|Samples are used for research and development of a noninvasive prenatal test. However, samples used for publications will have data shared as defined by journal.|2018-05-31 22:11:22.222185|2018-05-31 22:11:22.222185
NCT01429376|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, and Systemic Inflammation in Chronic Heart Failure With or Without COPD|1) Pulmonary Function in CHF; 2) COPD Prevalence, Underdiagnosis and Overdiagnosis in CHF Patients and Its Independent Predictors; 3) Are There Signs of Systemic Inflammation in CHF With or Without COPD?|Completed||N/A|234|Actual|Rijnstate Hospital|||||f||||f||||||||||2018-05-31 22:11:22.436024|2018-05-31 22:11:22.436024
NCT01429363|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2016-12-29|2011-09-06|2011-09-07|Estimate|||||||2016-12-29|2016-12-30|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TDD||Targeted Disc Decompression (TDD) for Contained Herniated Lumbar Discs|Targeted Disc Decompression (TDD) for Contained Herniated Lumbar Discs. A Prospective Clinical Series|Terminated||N/A|9|Actual|Rijnstate Hospital||1|||f||||f||||||||||2018-05-31 22:11:22.526936|2018-05-31 22:11:22.526936
NCT01429350|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2016-11-08|2011-09-06|2011-09-07|Estimate|||||||2016-11-08|2016-11-10|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|October 2016|Actual|2016-10-31||Interventional|THERAPY||Assess the Penumbra System in the Treatment of Acute Stroke|The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke|Active, not recruiting||Phase 4|692|Anticipated|Penumbra Inc.||2|||f||||t||||||||||2018-05-31 22:11:22.631154|2018-05-31 22:11:22.631154
NCT01429337|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-09-11|2011-09-06|2011-09-07|Estimate|||||||2017-09-11|2017-09-12|Actual|March 7, 2011|Actual|2011-03-07|September 2017|2017-09-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function|An Open-label, Multiple Dose, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function|Recruiting||Phase 1|42|Anticipated|Novartis||4|||f||||f|t|f||||||No||2018-05-31 22:11:22.740714|2018-05-31 22:11:22.740714
NCT01429324|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2012-05-18|2011-09-06|2011-09-07|Estimate|||||||2012-05-18|2012-05-21|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Near Infrared Spectroscopy (NIRS)|Validation of Near Infrared Spectroscopy (NIRS) Neuro-monitoring During Deep Hypothermic Circulatory Arrest for Aortic Arch Surgery|Completed|||20|Actual|Nonin Medical, Inc|||1||f||||f||||||||||2018-05-31 22:11:22.837446|2018-05-31 22:11:22.837446
NCT01429311|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-04-26|2011-09-02|2011-09-07|Estimate|||||||2017-04-26|2017-04-28|Actual|April 2011||2011-04-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|ADRN-01||Interferon Responses in Eczema Herpeticum|Investigation of Reduced Interferon Responses in Peripheral Blood Mononuclear Cells of Participants With Atopic Dermatitis and a History of Eczema Herpeticum (ADRN-01)|Completed|||84|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||f||||||Samples With DNA|"~     Blood samples, RNA, serum, protein and cells will be retained.~   "|||2018-05-31 22:11:22.903235|2018-05-31 22:11:22.903235
NCT01429298|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2018-02-09||2018-04-20|2011-09-06|2011-09-07|Estimate|2018-03-20|2018-04-20|Actual||||2018-04-20|2018-05-18|Actual|March 2010||2010-03-31|April 2018|2018-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||The discrepancy between the number of patients who completed the study and the number of patients analyzed is due to: missing primary outcome data (4), enrolled twice (2), and received IV ketorolac prior to enrollment (9). These patients completed the study, but had unusable, duplicate, or unavailable data.|Comparing Intravenous Hydromorphone to Usual Care|Randomized Clinical Trial Comparing Intravenous Hydromorphone to Usual Care|Completed||Phase 4|350|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 22:11:23.037235|2018-05-31 22:11:23.037235
NCT01429285|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2018-02-09||2018-04-20|2011-09-06|2011-09-07|Estimate|2018-03-20|2018-04-19|Actual||||2018-04-20|2018-05-18|Actual|July 2009|Actual|2009-07-31|April 2018|2018-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety and Efficacy of Intravenous Hydromorphone in Elderly Emergency Department Patients With Acute Severe Pain|Safety and Efficacy of Intravenous Hydromorphone Using Incremental Doses of 0.5 mg in Elderly ED Patients With Acute Severe Pain|Completed||Phase 4|350|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 22:11:23.477575|2018-05-31 22:11:23.477575
NCT01429272|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2017-09-07||2017-12-13|2011-09-06|2011-09-07|Estimate|2017-10-09|2017-11-08|Actual||||2017-12-13|2018-01-11|Actual|September 2011||2011-09-30|December 2017|2017-12-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|Minocycline||Minocycline and Aspirin in the Treatment of Bipolar Depression|Minocycline and Aspirin in the Treatment of Bipolar Depression|Completed||Phase 3|99|Actual|Laureate Institute for Brain Research, Inc.||2|||f||||t||||||||||2018-05-31 22:11:24.07373|2018-05-31 22:11:24.07373
NCT01429259|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2015-03-17||2018-02-20|2011-09-06|2011-09-07|Estimate|2015-03-26|2015-03-27|Estimate||||2018-02-20|2018-03-20|Actual|February 2012||2012-02-29|February 2018|2018-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Enrolled participants receiving at least 3 doses of meropenem as a 3 hour prolonged infusion.|Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children|An Open Label Study to Assess the Population Pharmacokinetics, Safety, and Practicality of Administering Meropenem as a Prolonged Infusion to Cystic Fibrosis Children Admitted With an Acute Pulmonary Exacerbation|Completed||Phase 4|30|Actual|Hartford Hospital||1|||f||||f||||||||||2018-05-31 22:11:24.664735|2018-05-31 22:11:24.664735
NCT01429246|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-07-27|2011-09-02|2011-09-07|Estimate|||||||2016-07-27|2016-07-29|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CSSS-Tibet||China Salt Substitute Study in Tibet|China Salt Substitute Study in Tibet: Efficacy of Salt Substitute in Reducing Blood Pressure in Hypertensive Adults|Completed||N/A|282|Actual|The George Institute for Global Health, China||2|||f||||f||||||||||2018-05-31 22:11:24.923699|2018-05-31 22:11:24.923699
NCT01429233|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-09-06|2011-09-06|2011-09-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Observational|XPRES||Real Life Experience of the Use of Isomers as ALENCAL (Levamlodipine) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients|Real Life Experience of the Use of Isomers as ALENCAL(Levoamlodipine) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients|Unknown status|Recruiting||2000|Anticipated|Closter Pharma|||||f||||f||||||||||2018-05-31 22:11:25.016122|2018-05-31 22:11:25.016122
NCT01429220|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2014-09-12|2011-09-06|2011-09-07|Estimate|||||||2014-09-12|2014-09-15|Estimate|August 2011||2011-08-31|September 2014|2014-09-30||||April 2014|Actual|2014-04-30||Observational|||Automated Parkinson's Disease (PD) Motor Symptom Assessment for Deep Brain Stimulation (DBS) Programming||Completed|||9|Actual|Great Lakes NeuroTechnologies Inc.|||||f||||||||||||||2018-05-31 22:11:25.078522|2018-05-31 22:11:25.078522
NCT01429207|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2012-06-28|2011-09-06|2011-09-07|Estimate|||||||2012-06-28|2012-06-29|Estimate|August 2011||2011-08-31|June 2012|2012-06-30||||||||Observational|||Capturing Parkinson's Disease Medication Side Effects During Daily Activities|Phase I Study: Monitoring Levodopa-Induced Dyskinesia Using Accelerometer & Gyroscope-based Motion Detection System|Completed|||15|Actual|Great Lakes NeuroTechnologies Inc.|||||f||||||||||||||2018-05-31 22:11:25.137699|2018-05-31 22:11:25.137699
NCT01429194|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-06-15|2011-09-06|2011-09-07|Estimate|||||||2015-06-15|2015-06-16|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The ACE Follow-up Study|"Continuation of Follow-up for Patients Who Were Previously Enrolled in the Clinical Study: Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity - (Protocol 11-03)."|Completed||N/A|69|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 22:11:25.197627|2018-05-31 22:11:25.197627
NCT01429181|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2017-03-28|2011-09-02|2011-09-05|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2012|Actual|2012-01-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Efficacy & Safety Study of Nonracemic Methadone for the Relief of Chronic Peripheral Neuropathic Pain|Pilot Study to Evaluate Efficacy, Tolerability and Safety Nonracemic Methadone HCl in Patients With Chronic Peripheral Neuropathic Pain: Double-Blind, Placebo-Controlled, Crossover Study Followed by Open-Label, Single-Arm Extension|Completed||Phase 2|37|Actual|MetaPharm, Inc.||2|||f||||f||||||||||2018-05-31 22:11:25.279748|2018-05-31 22:11:25.279748
NCT01429168|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-04-08|2011-09-02|2011-09-05|Estimate|||||||2015-04-08|2015-04-09|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|RESPOND-EUROPE||A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)|The Randomized Etoricoxib Study in Patients With Osteoarthritis Not Responding to Analgesic Drugs - THE RESPOND-EUROPE STUDY|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 22:11:25.355202|2018-05-31 22:11:25.355202
NCT01429155|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2014-09-16|2011-09-02|2011-09-05|Estimate|||||||2014-09-16|2014-09-17|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B|Post Transplant Course of Hepatitis C Patients After Living Donor Liver Transplant in Association With Interleukin 28 B|Completed|||36|Actual|Henry Ford Health System|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 22:11:25.421723|2018-05-31 22:11:25.421723
NCT01429142|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2016-11-12|2011-09-02|2011-09-05|Estimate|||||||2016-11-12|2016-11-15|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|May 2015|Actual|2015-05-31|June 2014|Actual|2014-06-30||Interventional|AIMS||AIMS Study: Improving HIV Treatment Adherence|AIMS Study: Cost-effectiveness of a Nurse-based Intervention to Support HIV-treatment Adherence|Completed||N/A|226|Actual|Wageningen University||2|||f||||f||||||||Yes|Upon request|2018-05-31 22:11:25.50327|2018-05-31 22:11:25.50327
NCT01429129|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-10-14|2011-09-02|2011-09-05|Estimate|||||||2015-10-14|2015-10-16|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers|Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers|Completed||Phase 4|1000|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 22:11:25.57806|2018-05-31 22:11:25.57806
NCT01429116|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2015-04-20|2011-09-02|2011-09-05|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception|An Extension Open-Label Safety Study of a 24-month 20 mg Dose Regimen of Tasimelteon for the Treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception Who Have Enrolled in Other Tasimelteon Clinical Trials|Completed||Phase 3|200|Anticipated|Vanda Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:11:25.663393|2018-05-31 22:11:25.663393
NCT01429103|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2017-02-27|2011-09-02|2011-09-05|Estimate|||||||2017-02-27|2017-03-01|Actual|May 2011||2011-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Hormones and Cognition in the Menopausal Transition|Hormones and Cognition in the Menopausal Transition|Completed|||117|Actual|University of Rochester|||2||f||||f||||||Samples Without DNA|"~     Subjects will have 20 mL of blood drawn by venipuncture by a trained nurse~   "|||2018-05-31 22:11:25.755446|2018-05-31 22:11:25.755446
NCT01429090|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-02|2011-09-02|2011-09-05|Estimate|||||||2011-09-02|2011-09-05|Estimate|October 1999||1999-10-31|September 2011|2011-09-30|January 2000|Actual|2000-01-31|November 1999|Actual|1999-11-30||Interventional|||Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution||Completed||Phase 1|12|Actual|University Medicine Greifswald||2|||f||||||||||||||2018-05-31 22:11:25.815015|2018-05-31 22:11:25.815015
NCT01429077|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2013-06-05||2013-11-27|2011-09-02|2011-09-05|Estimate|2013-09-25|2013-11-28|Estimate||||2013-11-27|2013-12-25|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Augmenting Language Therapy for Aphasia: Levodopa|Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy|Completed||Phase 2/Phase 3|36|Actual|Shirley Ryan AbilityLab|"Dosage and timing of the L-dopa in relation to the behavioral treatment may not have been optimum.~Efficacy of the behavioral treatment in both arms may have overridden the enhancing effect of the l-dopa in one arm"|2|||f||||f||||||||||2018-05-31 22:11:25.986205|2018-05-31 22:11:25.986205
NCT01429064|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2016-10-28||2017-01-03|2011-09-02|2011-09-05|Estimate|2016-10-28|2016-12-22|Estimate||||2017-01-03|2017-02-20|Actual|June 2011||2011-06-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Safety|Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001|Safety and Tolerability of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Extension Study to Study 3104001|Completed||Phase 2|76|Actual|Orion Corporation, Orion Pharma||1|||f||||t||||||||||2018-05-31 22:11:26.252078|2018-05-31 22:11:26.252078
NCT01429051|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2014-01-01||2014-02-20|2011-09-02|2011-09-05|Estimate|2014-02-20|2014-03-26|Estimate||||2014-02-20|2014-03-26|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|NOSE-400|The safety analysis set included all participants who received at least 1 dose of INFS (including the initial test dose).|A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain|A Dose Titrated Clinical Trial With a Placebo-controlled, Double-blind, Randomised, Cross-over Phase to Demonstrate the Efficacy of 400 μg Intranasal Fentanyl (INFS) Dose Strength, and to Evaluate 12 Weeks Safety and Nasal Tolerability of All Dose Strengths Between 50 μg and 400 μg, in Cancer Patients With Breakthrough Pain.|Completed||Phase 3|46|Actual|Takeda||1|||f||||f||||||||||2018-05-31 22:11:27.402443|2018-05-31 22:11:27.402443
NCT01429038|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-01-17|2011-09-02|2011-09-05|Estimate|||||||2013-01-17|2013-01-21|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Interventional|||Mesenchymal Stem Cells After Renal or Liver Transplantation|Infusion of Third-party Mesenchymal Stem Cells After Renal or Liver Transplantation. A Phase I-II, Open-label, Clinical Study|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 22:11:28.088263|2018-05-31 22:11:28.088263
NCT01429025|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2017-08-07|2011-09-02|2011-09-05|Estimate|||||||2017-08-07|2017-08-09|Actual|May 2012|Actual|2012-05-31|August 2017|2017-08-31||||November 2014|Actual|2014-11-30||Interventional|||Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma|A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL|Active, not recruiting||Phase 1|26|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 22:11:28.19162|2018-05-31 22:11:28.19162
NCT01429012|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-01-17|2011-09-02|2011-09-05|Estimate|||||||2013-01-17|2013-01-21|Estimate|October 2013||2013-10-31|January 2013|2013-01-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting|Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting. A Randomized, Double-blind, Controlled Study|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 22:11:28.309938|2018-05-31 22:11:28.309938
NCT01428999|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-09-02|2011-09-02|2011-09-05|Estimate|||||||2011-09-02|2011-09-05|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Effects of Probiotics on Improving the Gastrointestinal Function and Intestinal Bacterial Flora|Effects of Probiotics on Improving the Gastrointestinal Function and Intestinal Bacterial Flora|Unknown status|Not yet recruiting|N/A|48|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 22:11:28.397653|2018-05-31 22:11:28.397653
NCT01428986|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2014-09-24|2011-09-02|2011-09-05|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2009||2009-11-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Observational|MVC-Bone||Safety Study of Maraviroc's Effect on Human Osteoclasts|Safety Study of Maraviroc's Effect on Human Osteoclasts|Completed|||16|Actual|National Center for Global Health and Medicine, Japan|||2||f||||t||||||Samples Without DNA|"~     Blood serum, blood plasma, urine~   "|||2018-05-31 22:11:28.483728|2018-05-31 22:11:28.483728
NCT01428973|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2018-02-09|2011-09-02|2011-09-05|Estimate|||||||2018-02-09|2018-02-12|Actual|September 2011||2011-09-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens|Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donors After Reduced-intensity Conditioning: a Phase II Randomized Study Comparing 2 GVHD Prophylaxis Regimens|Recruiting||Phase 2|200|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 22:11:28.562325|2018-05-31 22:11:28.562325
NCT01428960|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2013-10-30|2011-09-02|2011-09-05|Estimate|||||||2013-10-30|2013-10-31|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Study of Acute Effects of Sn-1 and Sn-3 Palmitic Acid-rich or Stearic Acid-rich Fats on Metabolic Markers|Acute Effects of Sn-1 and Sn-3 Palmitic Acid-rich or Stearic Acid-rich Fats on Postprandial Lipemia, Haemostatic and Inflammatory Markers, Gut Hormone Concentrations, Satiety, and Insulinemic Response in Human Volunteers|Completed||N/A|36|Actual|Malaysia Palm Oil Board||3|||f||||f||||||||||2018-05-31 22:11:28.703113|2018-05-31 22:11:28.703113
NCT01428947|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2016-02-23|2011-09-02|2011-09-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Does Coronary Angiography Cause Cognitive Dysfunction?|Study of Cognitive Function Before and After Coronary Angiography|Completed|||80|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 22:11:28.776205|2018-05-31 22:11:28.776205
NCT01428934|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2018-03-08|2011-09-02|2011-09-05|Estimate|||||||2018-03-08|2018-03-09|Actual|July 2011||2011-07-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|December 2013|Actual|2013-12-31||Observational|MARK||Improving Intermediate Risk Management. MARK Study|Improving Intermediate Risk Management. MARK Study|Completed|||2495|Actual|Jordi Gol i Gurina Foundation|||1||f||||t||||||Samples Without DNA|"~     Blood sample: Cholesterol and triglycerides concentration, HDL cholesterol, LDL cholesterol,~     Glucose concentration, glycated hemoglobin and creatinine Urine sample:urine albumin, to~     calculate the albumin/creatinine index. Postprandial glucose (mg / dl) will be self-measured~     by patients at home 2 hours after meals (breakfast, lunch and dinner) for one day using an~     Accu-chek ® glucometer.~   "|No||2018-05-31 22:11:28.850295|2018-05-31 22:11:28.850295
NCT01428921|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-10-18|2011-09-02|2011-09-05|Estimate|||||||2013-10-18|2013-10-21|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Long Term Efficacy of Education Programme on Continuous Positive Airway Pressure Treatment|Long-term Efficacy of Extended Education Programme on Improving Treatment Adherence to Continuous Positive Airway Pressure in Obstructive Sleep Apnea|Completed||N/A|100|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 22:11:28.920038|2018-05-31 22:11:28.920038
NCT01428908|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2012-04-17|2011-09-02|2011-09-05|Estimate|||||||2012-04-17|2012-04-19|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children|A Phase III Clinical Trial the Immunogenicity and Safety Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children.|Completed||Phase 3|2394|Actual|Jiangsu Province Centers for Disease Control and Prevention||4|||f||||f||||||||||2018-05-31 22:11:28.987572|2018-05-31 22:11:28.987572
NCT01428895|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2018-02-27|2011-09-02|2011-09-05|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2009||2009-03-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Femoral Bone Metastases|A Prospective Cohort Study of the Role of Surgery and/or Radiotherapy for Bone Metastases of the Femur at High Risk of Pathological Fracture|Recruiting||N/A|180|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:11:29.233097|2018-05-31 22:11:29.233097
NCT01428882|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2016-03-17||2016-04-16|2011-09-02|2011-09-05|Estimate|2016-04-16|2016-05-25|Estimate||||2016-04-16|2016-05-25|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|MIDAPROP|Patients were similar at baseline without differences regarding age, gender, body mass index, ASA class or indication for colonoscopy.|Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy|Phase 4, Prospective, Randomized, Double-blinded, Placebo-controlled Study Comparing Propofol vs. Midazolam Plus Propofol for Nonanesthesiologist Targeted Moderate Sedation in Outpatient Colonoscopy|Completed||Phase 4|135|Actual|Infante, Javier Molina, M.D.|Single center study. Small sample size. Fixed and relatively high-dose midazolam (2 mg). Lack of distinction between complications related to either pain stimuli or oversedation.|2|||f||||t||||||||Yes||2018-05-31 22:11:29.322073|2018-05-31 22:11:29.322073
NCT01428869|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2011-09-08|2011-09-01|2011-09-05|Estimate|||||||2011-09-08|2011-09-09|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|||||Observational|||Combination Statin, Acetylsalicylic Acid and Dutasteride Use in Prostate Cancer|The Effect of Combination Statin, Acetylsalicylic Acid and Dutasteride Use on Prostate Cancer - a Sub Analysis of the REDUCE Trial|Completed|||8231|Actual|University Health Network, Toronto|||4||f||||f||||||Samples Without DNA|"~     Specimens were retained as part of the REDUCE protocol, but no biospecimens are required for~     the current protocol.~   "|||2018-05-31 22:11:29.627848|2018-05-31 22:11:29.627848
NCT01428843|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2015-06-21|2011-09-02|2011-09-05|Estimate|||||||2015-06-21|2015-06-23|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|FER||Comparison of Ferrisat vs Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy|A Controlled, Randomised, Double-blind, Multicenter Study, Comparing Ferrisat Versus Placebo in Anemia Associated to Inflammatory Bowel Disease During Anti-TNF Therapy|Terminated||Phase 3|60|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||2||Lack of enrollment|f||||f||||||||||2018-05-31 22:11:29.695705|2018-05-31 22:11:29.695705
NCT01428830|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-01-15|2011-09-02|2011-09-05|Estimate|||||||2015-01-15|2015-01-19|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Non-inferiority of Short-term Catheterization Following Fistula Repair Surgery|Non-inferiority of Short-term Catheterization Following Fistula Repair Surgery|Completed||N/A|524|Actual|EngenderHealth||2|||f||||t||||||||||2018-05-31 22:11:29.785711|2018-05-31 22:11:29.785711
NCT01428817|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2012-03-23|2011-09-02|2011-09-05|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Carbetocin at Elective Cesarean Delivery Part 2|Carbetocin at Elective Cesarean Delivery: A Dose Finding Study (Part 2)|Completed||N/A|120|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||5|||f||||f||||||||||2018-05-31 22:11:29.92919|2018-05-31 22:11:29.92919
NCT01428804|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2016-08-22|2011-09-02|2011-09-05|Estimate|||||||2016-08-22|2016-08-23|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|DEPRESCO||Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression|Pilot Study of Feasibility of the Effect of Treatment With tDCS in Patients Suffering From Resistant Depression|Completed||Phase 2|24|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 22:11:30.003924|2018-05-31 22:11:30.003924
NCT01428791|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-05-12|2011-09-02|2011-09-05|Estimate|||||||2015-05-12|2015-05-13|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|January 2015|Actual|2015-01-31||Interventional|BRIGHTEN-Heart||Reducing Disparities in Late Life Depression and Metabolic Syndrome|BRIGHTEN Heart: Reducing Disparities in Late Life Depression and Metabolic Syndrome|Unknown status|Active, not recruiting|N/A|250|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 22:11:30.068568|2018-05-31 22:11:30.068568
NCT01428778|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-11-07|2011-09-02|2011-09-05|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Berlin Beat of Running Study|Berlin Beat of Running Study - Frequency of Cardiac Arrhythmias & Cerebral Lesions in Marathon Runners|Completed|||110|Actual|Charite University, Berlin, Germany|||||f||||f||||||Samples Without DNA|"~     Whole blood samples~   "|||2018-05-31 22:11:30.173181|2018-05-31 22:11:30.173181
NCT01428765|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2014-01-21||2014-01-21|2011-09-02|2011-09-05|Estimate|2014-01-21|2014-03-05|Estimate||||2014-01-21|2014-03-05|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||GLORIA-AF Registry Program (Phase I)|GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase I)|Completed|||1096|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 22:11:30.257331|2018-05-31 22:11:30.257331
NCT01428752|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2011-09-08|2011-09-02|2011-09-05|Estimate|||||||2011-09-08|2011-09-09|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer|Prevalence of Colorectal Adenoma in 30- to 49-year-old Asymptomatic Subjects With a First Relative History of Colorectal Cancer|Unknown status|Recruiting||1000|Anticipated|Asan Medical Center|||1||f||||t||||||Samples Without DNA|"~     whole blood and serum Colorectal polyp/cancer tissue~   "|||2018-05-31 22:11:30.55595|2018-05-31 22:11:30.55595
NCT01428739|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2017-01-23|2011-09-02|2011-09-05|Estimate|||||||2017-01-23|2017-01-25|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer|Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer|Completed||N/A|8|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-05-31 22:11:30.629668|2018-05-31 22:11:30.629668
NCT01428726|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-03-15|2011-09-02|2011-09-05|Estimate|||||||2014-03-15|2014-03-18|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Phase IIa Study of NT-KO-003 for Multiple Sclerosis|A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis|Completed||Phase 2|99|Anticipated|Neurotec Pharma||3|||f||||f||||||||||2018-05-31 22:11:30.734791|2018-05-31 22:11:30.734791
NCT01428713|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2014-06-09||2016-08-08|2011-09-01|2011-09-05|Estimate|2014-09-16|2014-09-17|Estimate||||2016-08-08|2016-08-10|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||17 post-menarchal girls with menorrhagia or menometrorrhagia without underlying bleeding disorders, pelvic pathology, pelvic infection, thyroid abnormalities or pregnancy.|Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study|Prospective Crossover Trial of Oral Tranexamic Acid and Combined Oral Contraceptive in Adolescents With Menorrhagia - A Pilot Study|Completed||N/A|17|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 22:11:30.832041|2018-05-31 22:11:30.832041
NCT01428700|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-12-02|2011-09-01|2011-09-05|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C|Development of Gene Expression Signatures for the Diagnosis of Liver Allograft Rejection and Recurrent Hepatitis C Disease (CTOT-07)|Completed|||275|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||f||||||Samples With DNA|"~     Liver tissue, whole blood, and serum specimens~   "|||2018-05-31 22:11:31.019598|2018-05-31 22:11:31.019598
NCT01428687|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-08-29|2011-09-02|2011-09-05|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Short Term Effects of Increasing Sleep Duration|Increasing Sleep Duration: A Novel Approach to Weight Control|Completed||Phase 2|60|Actual|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 22:11:31.073742|2018-05-31 22:11:31.073742
NCT01428674|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-03-16|2011-09-02|2011-09-05|Estimate|||||||2017-03-16|2017-03-20|Actual|February 2011||2011-02-28|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Time, Touch, Attention and the Autonomic Nervous System|The Impact of Interpersonal Mindful Compassion on Autonomic Nervous System Function|Completed||N/A|20|Actual|Wake Forest University Health Sciences||4|||f||||t||||||||||2018-05-31 22:11:31.135389|2018-05-31 22:11:31.135389
NCT01428661|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2015-01-06|2013-06-12|2015-06-01|2011-09-02|2011-09-05|Estimate|2015-06-01|2015-06-19|Estimate|2013-06-12|2013-06-21|Estimate|2015-06-01|2015-06-19|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|MAGELLAN||Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder|MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension|Completed||Phase 2/Phase 3|507|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:11:31.212306|2018-05-31 22:11:31.212306
NCT01428648|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2015-03-03|2011-09-02|2011-09-05|Estimate|||||||2015-03-03|2015-03-04|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Impact of Dance Therapy on Parkinson's Disease|Impact of Dance Therapy on Parkinson's Disease|Withdrawn||N/A|0|Actual|University of Arkansas||2||Recruitment slow|f||||f||||||||||2018-05-31 22:11:31.641773|2018-05-31 22:11:31.641773
NCT01428635|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2017-10-27|2011-09-02|2011-09-05|Estimate|||||||2017-10-27|2017-10-31|Actual|January 13, 2012|Actual|2012-01-13|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)|Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)|Active, not recruiting||Phase 2|23|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:11:31.706312|2018-05-31 22:11:31.706312
NCT01428622|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-11-21|2011-08-29|2011-09-05|Estimate|||||||2011-11-21|2011-11-22|Estimate|October 2011||2011-10-31|November 2011|2011-11-30||||||||Interventional|||Olodaterol Bridging Study in Asthma|Single Dose Comparison of 3 Doses of Olodaterol in Double Fixed Dose Combination With BI54903 vs. 3 Doses of Olodaterol Mono in Free Combination|Withdrawn||Phase 2|0|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 22:11:32.033181|2018-05-31 22:11:32.033181
NCT01428609|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2012-03-21|2011-09-02|2011-09-05|Estimate|||||||2012-03-21|2012-03-22|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Blood Mercury Levels Following Retrograde Amalgam Surgeries|Blood Mercury Levels Following Retrograde Amalgam Surgeries|Completed||Phase 4|14|Actual|Isfahan University of Medical Sciences|||||f||||t||||||||||2018-05-31 22:11:32.189852|2018-05-31 22:11:32.189852
NCT01428596|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2017-04-21|2011-09-02|2011-09-05|Estimate|||||||2017-04-21|2017-04-24|Actual|September 2010||2010-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GCHT01||Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects|A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX™) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy|Recruiting||Phase 1|30|Anticipated|GeneCure Biotechnologies||3|||f||||t||||||||No||2018-05-31 22:11:32.273199|2018-05-31 22:11:32.273199
NCT01428583|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|2016-09-28|2013-07-08|2016-09-28|2011-09-02|2011-09-05|Estimate|2016-09-28|2016-11-21|Estimate|2013-07-08|2013-07-11|Estimate|2016-09-28|2016-11-21|Estimate|December 2010||2010-12-31|June 2016|2016-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Safety analysis set included all enrolled participants who had at least 1 dose of oxycodone HCl and naltrexone HCl extended-release capsules.|Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain|A Multicenter, 12-month, Open-label, Single-arm, Safety Study Of Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended-release Capsules In Subjects With Moderate To Severe Chronic Noncancer Pain|Completed||Phase 3|395|Actual|Pfizer|Outcome measure reporting of Participants With Response to Urine Drug Test were based on qualitative point of contact results only.|1|||f||||f||||||||||2018-05-31 22:11:32.426431|2018-05-31 22:11:32.426431
NCT01428570|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-09-02|2011-09-02|2011-09-05|Estimate|||||||2011-09-02|2011-09-05|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|||Comparison of the Pentax AWS® With the Macintosh Laryngoscopic Intubation in Obstructive Sleep Apnea Syndrome Patients|Comparison of the Pentax AWS® With the Macintosh Laryngoscope for Tracheal Intubation in Patients With Obstructive Sleep Apnea Syndrome: a Randomized Comparative Study|Unknown status|Recruiting|Phase 4|50|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 22:11:33.047021|2018-05-31 22:11:33.047021
NCT01428557|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2014-03-05|2011-09-02|2011-09-05|Estimate|||||||2014-03-05|2014-03-06|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|January 2014|Actual|2014-01-31||Observational|BREATHE||BREATHE Registry - I Brazilian Registry of Heart Failure|BREATHE Registry - I Brazilian Registry of Heart Failure|Unknown status|Active, not recruiting||1200|Anticipated|Hospital do Coracao|||1||f||||t||||||||||2018-05-31 22:11:33.112147|2018-05-31 22:11:33.112147
NCT01428544|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-07-13|2011-09-01|2011-09-05|Estimate|||||||2015-07-13|2015-07-15|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)|Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)|Completed|||5|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:11:33.185048|2018-05-31 22:11:33.185048
NCT01428531|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-07-13|2011-09-01|2011-09-05|Estimate|||||||2015-07-13|2015-07-15|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment|Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment|Completed|||200|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:11:33.36831|2018-05-31 22:11:33.36831
NCT01428518|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-04-21|2011-09-01|2011-09-05|Estimate|||||||2016-04-21|2016-04-25|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Special Drug Use Investigation for LAMICTAL Bipolar|Special Drug Use Investigation for LAMICTAL Bipolar|Completed|||1036|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:11:33.818576|2018-05-31 22:11:33.818576
NCT01428505|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-02-04|2011-09-01|2011-09-05|Estimate|||||||2016-02-04|2016-02-08|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||[18F]PBR111 and Microglial Activation in Multiple Sclerosis|A Study to Characterize the Novel TSPO PET Radioligand [18F]PBR111 as an in Vivo Marker of Microglial Activation in Multiple Sclerosis|Terminated||Phase 2|50|Actual|GlaxoSmithKline||1||The Study was terminated because there was insufficient data to complete the study objectives|f||||f||||||||||2018-05-31 22:11:34.328726|2018-05-31 22:11:34.328726
NCT01428492|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2016-03-08|2011-09-01|2011-09-05|Estimate|||||||2016-03-08|2016-03-09|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|PKB115125||Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma|A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|90|Actual|Novartis||3|||f||||f||||||||||2018-05-31 22:11:34.471648|2018-05-31 22:11:34.471648
NCT01428479|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-07-18|2011-09-01|2011-09-05|Estimate|||||||2017-07-18|2017-07-21|Actual|January 7, 2011|Actual|2011-01-07|July 2017|2017-07-31|April 4, 2011|Actual|2011-04-04|April 4, 2011|Actual|2011-04-04||Interventional|||Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males|Phase1 Study of GR121167- A Double Blind, Placebo Controlled, Randomized, Dose Ascending, Single and Multiple Dose Study to Investigate the Safety and Pharmacokinetics Following Intravenous Administration of GR121167 in Healthy Japanese Males-|Completed||Phase 1|18|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:11:34.594751|2018-05-31 22:11:34.594751
NCT01428466|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-08-02|2011-09-01|2011-09-05|Estimate|||||||2017-08-02|2017-08-04|Actual|November 18, 2010|Actual|2010-11-18|August 2017|2017-08-31|February 15, 2011|Actual|2011-02-15|February 15, 2011|Actual|2011-02-15||Interventional|JPN P1||Japanese Phase 1 Study of GSK2585823|Dermal Safety Study of GSK2585823 (Clindamycin 1%-Benzoyl Peroxide 3% Gel) With Healthy Japanese Male and Female Subjects|Completed||Phase 1|20|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:11:34.718438|2018-05-31 22:11:34.718438
NCT01428453|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01||2015-04-27|2015-04-27|2011-09-01|2011-09-05|Estimate||||2015-04-27|2015-05-13|Estimate|2015-04-27|2015-05-13|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease|A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease|Completed||Phase 2|124|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:11:34.820687|2018-05-31 22:11:34.820687
NCT01428440|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2017-01-11|2011-09-01|2011-09-05|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||PET Study to Study Tumour Apoptosis|A Positron Emission Tomography (PET) Study to Evaluate 18FML10 as an Imaging Agent for Tumour Apoptosis|Terminated||Phase 2|7|Actual|GlaxoSmithKline||1||"The study was terminated early as the results did not support study objectives and were not as~   significant as expected."|f||||f||||||||||2018-05-31 22:11:34.965955|2018-05-31 22:11:34.965955
NCT01428427|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-11-08|2011-09-01|2011-09-05|Estimate|||||||2017-11-08|2017-11-13|Actual|August 12, 2009|Actual|2009-08-12|November 2017|2017-11-30|July 18, 2011|Actual|2011-07-18|July 18, 2011|Actual|2011-07-18||Interventional|||Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors|A Phase IB Combination Study of MEK Inhibitor GSK1120212 With Gemcitabine in Subjects With Solid Tumors|Completed||Phase 1|31|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:11:35.053081|2018-05-31 22:11:35.053081
NCT01428414|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2012-08-21|2011-09-02|2011-09-05|Estimate|||||||2012-08-21|2012-08-23|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|February 2015|Anticipated|2015-02-28|August 2014|Anticipated|2014-08-31||Interventional|||Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer|Multicenter, Randomized, Open-label Phase II Study to Compare the Efficacy and Safety of Trastuzumab and Paclitaxel Based Regimen Plus Carboplatin or Epirubicin as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:11:35.179668|2018-05-31 22:11:35.179668
NCT01428388|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2017-10-26|2011-09-02|2011-09-05|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2011||2011-09-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|CRAVE||Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion|Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion|Completed||N/A|150|Anticipated|Barnes Retina Institute||2|||f||||t||||||||||2018-05-31 22:11:36.408682|2018-05-31 22:11:36.408682
NCT01428375|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2013-02-04|2011-09-01|2011-09-05|Estimate|||||||2013-02-04|2013-02-06|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Intravenous Infusion of Paracetamol for Intrapartum Analgesia of Labor|Evaluation of Intravenous Infusion of Paracetamol as Intrapartum Analgesic in the First Stage of Labor: a Double-blind Randomized Trial|Completed||Phase 3|120|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 22:11:36.490809|2018-05-31 22:11:36.490809
NCT01428362|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31||2013-10-23|2013-11-15|2011-08-31|2011-09-05|Estimate||||2013-10-23|2013-11-15|Estimate|2013-11-15|2013-12-11|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|AD-201||VI-1121 for the Treatment Alzheimer's Disease|A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease|Completed||Phase 2|61|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-05-31 22:11:36.575216|2018-05-31 22:11:36.575216
NCT01428349|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2015-05-29|2011-08-31|2011-09-05|Estimate|||||||2015-05-29|2015-06-02|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing Inmates|Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing Inmates|Completed||N/A|180|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 22:11:36.67714|2018-05-31 22:11:36.67714
NCT01428336|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2016-11-30||2017-06-22|2011-09-01|2011-09-02|Estimate|2017-04-09|2017-06-23|Actual||||2017-06-22|2017-07-25|Actual|September 2011||2011-09-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|25CST|Every participant underwent three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test|Value of 25 mcg Cortrosyn Stimulation Test|The Value of 25 mcg Cortrosyn Stimulation Test to Assess Adult HPA Axis|Completed||N/A|22|Actual|The Cleveland Clinic|Small number of participants Cortisol Binding globulin was not measured|2|||f||||t||||||||No||2018-05-31 22:11:36.768491|2018-05-31 22:11:36.768491
NCT01428323|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-01|2011-09-01|2011-09-02|Estimate|||||||2011-09-01|2011-09-02|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Study of the Aerosol Deposition With Vented and Unvented Jet Nebulizer in Healthy Subjets||Unknown status|Recruiting|N/A|7|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-05-31 22:11:37.207556|2018-05-31 22:11:37.207556
NCT01428310|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2015-10-29|2011-09-01|2011-09-02|Estimate|||||||2015-10-29|2015-10-30|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke|A Single Center, Single-Blind, Randomized, Crossover Pilot Study to Evaluate the Safety and Effects of Anatabloc™, a Dietary Supplement, in Reducing the Urge to Smoke in Daily Smokers Followed by an Open-Label Extension|Completed||Phase 1|109|Actual|Rock Creek Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 22:11:37.293357|2018-05-31 22:11:37.293357
NCT01428297|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2015-02-02|2011-09-01|2011-09-02|Estimate|||||||2015-02-02|2015-02-04|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|3||A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome|A First-In-human Study to Evaluate Safety and Tolerability of Topical BPR277 in Healthy Volunteers, and Proof of Concept (PoC) Studies to Evaluate the Safety, Tolerability, and Efficacy of Topical BPR277 in Patients With Atopic Dermatitis and Netherton Syndrome|Completed||Phase 1|12|Actual|Novartis||4|||f||||||||||||||2018-05-31 22:11:37.379228|2018-05-31 22:11:37.379228
NCT01428284|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2012-02-16|2011-09-01|2011-09-02|Estimate|||||||2012-02-16|2012-02-17|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers|An Open-Label, Fixed-Sequence Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects|Completed||Phase 1|14|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 22:11:37.489573|2018-05-31 22:11:37.489573
NCT01428271|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-06-01|2011-09-01|2011-09-02|Estimate|||||||2013-06-01|2013-06-04|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Comparison Between the Expected Site of Sacral Hiatus by Conventional Method and the Real Site by Ultrasonography for Caudal Block in Children||Completed|||80|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 22:11:37.573946|2018-05-31 22:11:37.573946
NCT01428258|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2016-10-11||2017-10-12|2011-09-01|2011-09-02|Estimate|2017-02-28|2017-03-03|Actual||||2017-10-12|2017-11-17|Actual|September 2011||2011-09-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|PKU||Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria|Phase 2 Study of Glycomacropeptide vs. Amino Acid Diet for the Management of PKU|Completed||N/A|32|Actual|University of Wisconsin, Madison|The trial was completed as planned with an adequate number of subjects and there were no limitations.|2|||f||||t||||||||No||2018-05-31 22:11:37.66948|2018-05-31 22:11:37.66948
NCT01428245|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2018-02-20|2011-09-01|2011-09-02|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 27, 2009|Actual|2009-01-27|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|November 2018|Anticipated|2018-11-30||Interventional|JCM026||Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition|Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition in Early Pubertal Girls (JCM026)|Active, not recruiting||N/A|10|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 22:11:38.154908|2018-05-31 22:11:38.154908
NCT01428232|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2017-04-21|2011-09-01|2011-09-02|Estimate|||||||2017-04-21|2017-04-25|Actual|May 2012||2012-05-31|January 2017|2017-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||"Effectiveness of Well-child Clinics as the Community Basis of Step 10 of the Baby Friendly Hospital Initiative"|Comparison of Two Clinic-based Interventions to Promote Early Initiation and Exclusive Breastfeeding Through 6 Months After Birth in Kinshasa, Democratic Republic of Congo|Completed||N/A|992|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 22:11:38.248184|2018-05-31 22:11:38.248184
NCT01428219|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2016-03-29||2017-11-13|2011-09-01|2011-09-02|Estimate|2016-03-29|2016-05-02|Estimate||||2017-11-13|2017-12-12|Actual|February 2012||2012-02-29|November 2017|2017-11-30|September 2015|Actual|2015-09-30|October 2014|Actual|2014-10-31||Interventional|||Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone|A Phase II Trial of Cabozantinib (XL184) in Patients With Castrate-Resistant Prostate Cancer Metastatic to Bone|Terminated||Phase 2|25|Actual|University of Michigan Cancer Center||1||Closed due to slowing enrollment and negative results of a phase III trial using cabozantinib.|f||||t||||||||||2018-05-31 22:11:38.378325|2018-05-31 22:11:38.378325
NCT01428206|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2013-06-13|2011-09-01|2011-09-02|Estimate|||||||2013-06-13|2013-06-14|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Liverpool Care Pathway for the Dying at Residential Care Homes|Liverpool Care Pathway for the Dying at Residential Care Homes|Completed||N/A|260|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 22:11:38.920375|2018-05-31 22:11:38.920375
NCT01428193|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2017-05-30|2011-09-01|2011-09-02|Estimate|||||||2017-05-30|2017-06-01|Actual|September 2006|Actual|2006-09-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone|Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)|Active, not recruiting||N/A|13|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:11:39.020317|2018-05-31 22:11:39.020317
NCT01428180|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-04-05|2011-09-01|2011-09-02|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|October 2012|Actual|2012-10-31||Observational|||Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants|Changes of Cerebral Tissue Oxygen Saturation During Treatment of Patent Ductus Arteriosus in Neonates|Completed|||35|Actual|University of Ulm|||3||f||||f||||||||||2018-05-31 22:11:39.140073|2018-05-31 22:11:39.140073
NCT01428167|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-06-05|2011-09-01|2011-09-02|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|Thyroid Cancer||Hashimotos Thyroiditis and Thyroid Cancer|Is There Any Association Between Thyroid Cancer and Hashimotos Thyroiditis?|Completed|||26|Actual|The University of Texas Medical Branch, Galveston|||1||f||||f||||||Samples Without DNA|"~     Plasma samples with be stored to measure anti inflammatory factors.~   "|||2018-05-31 22:11:39.238289|2018-05-31 22:11:39.238289
NCT01428154|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-06-16|2011-09-01|2011-09-02|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease|An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin Alfa in Paediatric Subjects From Birth to Less Than 1 Year of Age With Anemia Due to Chronic Kidney Disease|Withdrawn||Phase 1|0|Actual|Amgen||1||"Difficulty in recruitment. PDCO in the Day 30 summary report agrred to remove the PK study in~   children <1 year of age."|f||||f||||||||||2018-05-31 22:11:39.328443|2018-05-31 22:11:39.328443
NCT01428141|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2014-02-13|2011-09-01|2011-09-02|Estimate|||||||2014-02-13|2014-02-14|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||A Phase I Study of E7050 in Subjects With Solid Tumors|A Phase I Study of E7050 in Subjects With Solid Tumors|Completed||Phase 1|18|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 22:11:39.41942|2018-05-31 22:11:39.41942
NCT01428128|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2014-06-18||2017-11-13|2011-09-01|2011-09-02|Estimate|2014-06-18|2014-07-18|Estimate||||2017-11-13|2017-12-13|Actual|April 2011||2011-04-30|November 2017|2017-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||"Excluded: screen failures, withdrawals for any cause prior to completion of 2 chemotherapy cycles, or received Neulasta for only one cycle.~Note: The 2 patients who received Neulasta for only one cycle and were not evaluable, were included in the adverse event numbers since they received study drug. Participant number will be 35 for AE module."|Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector|A Phase II Study of Low Dose Arsenic Trioxide in Patients With Malignancies as a Potential Chemotherapy Protector|Completed||Phase 2|50|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 22:11:39.513957|2018-05-31 22:11:39.513957
NCT01428115|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2014-10-02||2014-10-31|2011-09-01|2011-09-02|Estimate|2014-10-31|2014-11-03|Estimate||||2014-10-31|2014-11-03|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|RELAX||Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab|Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab|Completed|||83|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:11:39.812085|2018-05-31 22:11:39.812085
NCT01428102|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-09-13|2011-09-01|2011-09-02|Estimate|||||||2013-09-13|2013-09-16|Estimate|July 2011||2011-07-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|R-TEG MA||RapidTEG MA Validation|Validation of the RapidTEG™ MA Compared to Kaolin in Trauma and Cardiac Patients.|Terminated|||17|Actual|Haemonetics Corporation|||2|Terminiated for trial redesign|f||||f||||||||||2018-05-31 22:11:40.117779|2018-05-31 22:11:40.117779
NCT01428089|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-01-18|2011-09-01|2011-09-02|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2008||2008-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone|Suppression of Daytime and Nighttime LH Frequency by Progesterone in Early Pubertal Girls With and Without Hyperandrogenemia (JCM024)|Recruiting||Phase 1|40|Anticipated|University of Virginia||2|||f||||t|t|f||||||Undecided|We do not have current plans to share IPD|2018-05-31 22:11:40.179275|2018-05-31 22:11:40.179275
NCT01428076|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2014-01-15||2015-02-19|2011-09-01|2011-09-02|Estimate|2014-03-03|2014-03-31|Estimate||||2015-02-19|2015-03-06|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Safety population|Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)|An Open-Label Single-Center Study in Patients With Great Saphenous Vein Incompetence to Investigate the Pharmacokinetic Properties of Polidocanol Endovenous Microfoam (PEM)|Completed||Phase 1|21|Actual|BTG International Inc.||2|||f||||f||||||||||2018-05-31 22:11:40.264755|2018-05-31 22:11:40.264755
NCT01428063|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|2015-08-19||2016-04-21|2011-09-01|2011-09-02|Estimate|2016-04-21|2016-05-27|Estimate||||2016-04-21|2016-05-27|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional||All participants who received at least 1 dose of study drug|Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials|An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C|Completed||Phase 2|276|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 22:11:40.691955|2018-05-31 22:11:40.691955
NCT01428050|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2015-03-17|2011-09-01|2011-09-02|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy|Prospective Randomized Controlled Trial on the Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy|Unknown status|Recruiting|Phase 2|264|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 22:11:41.610193|2018-05-31 22:11:41.610193
NCT01428037|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2013-11-21|2011-09-01|2011-09-02|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Efficacy Study of Vaginal Misoprostol for Cervical Ripening and Induction of Labor|A Randomized,Double-blind,Placebo-controlled, Multicenter Study of the Efficacy and Safety of Vaginal Misoprostol for Cervical Ripening and Induction of Labor|Completed||Phase 3|225|Actual|Regenex Pharmaceutical, China||2|||f||||f||||||||||2018-05-31 22:11:41.68438|2018-05-31 22:11:41.68438
NCT01428024|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-11-22|2011-09-01|2011-09-02|Estimate|||||||2012-11-22|2012-11-27|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||Study to Evaluate Efficacy, Safety and Injection Technique of Restylane Lip Volume and Restylane Lip Refresh|An Open, Multi-center Study Evaluating Efficacy, Safety and Injection Technique of Restylane Lip Products for Lip Enhancement and Lip Rejuvenation|Completed||N/A|60|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 22:11:41.768558|2018-05-31 22:11:41.768558
NCT01428011|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2017-10-16|2011-09-01|2011-09-02|Estimate|||||||2017-10-16|2017-10-18|Actual|March 1, 2014|Actual|2014-03-01|October 2017|2017-10-31|April 22, 2015|Actual|2015-04-22|April 22, 2015|Actual|2015-04-22||Observational|MEDCHAT||Patient-Provider Communication and Medication Adherence|Racial Differences in Patient-Provider Communication and Medication Adherence|Completed|||114|Actual|New York University School of Medicine|||1||f||||t|f|f||||||||2018-05-31 22:11:42.005588|2018-05-31 22:11:42.005588
NCT01427998|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-09-01|2011-09-01|2011-09-02|Estimate|||||||2011-09-01|2011-09-02|Estimate|August 1999||1999-08-31|September 2011|2011-09-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Effect of Olive Leaves as Hypoglycemic Agents in Diabetic Subjects|A Phase Three Clinical Intervention Trial of Olive Leaves and Their Extracts in Human Diabetic Subjects|Completed||Phase 3|79|Actual|Wolfson Medical Center||2|||f||||t||||||||||2018-05-31 22:11:42.119434|2018-05-31 22:11:42.119434
NCT01427985|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-04-05|2011-09-01|2011-09-02|Estimate|||||||2016-04-05|2016-04-06|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Influence of Premedication Protocols for Neonatal Endotracheal Intubation on Cerebral Oxygenation|The Influence of Two Different Premedication Protocols for Endotracheal Intubation in Neonates on Cerebral Oxygenation|Completed||Phase 4|24|Actual|University of Ulm||2|||f||||f||||||||||2018-05-31 22:11:42.240546|2018-05-31 22:11:42.240546
NCT01427972|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31||2013-04-30|2013-04-30|2011-08-31|2011-09-02|Estimate||||2013-04-30|2013-05-08|Estimate|2013-04-30|2013-05-08|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of LY2623091 in Male and Females With Chronic Kidney Disease|Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients|Completed||Phase 2|48|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:11:42.386927|2018-05-31 22:11:42.386927
NCT01427959|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2017-11-27|2011-09-01|2011-09-02|Estimate|||||||2017-11-27|2017-11-28|Actual|November 2010||2010-11-30|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|TheBrainS||Tampere Traumatic Head and Brain Injury Study|Tampere Traumatic Head and Brain Injury Study|Active, not recruiting|||100|Anticipated|Tampere University Hospital|||||f||||f||||||Samples With DNA|"~     1. 10ml whole blood~        2. 10ml EDTA-blood x2~   "|||2018-05-31 22:11:42.532843|2018-05-31 22:11:42.532843
NCT01427946|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-11-12|2011-09-01|2011-09-02|Estimate|||||||2014-11-12|2014-11-13|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer|A Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in Patients With KRAS Mutant NSCLC|Completed||Phase 1/Phase 2|47|Actual|Infinity Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:11:42.639161|2018-05-31 22:11:42.639161
NCT01427933|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2014-07-29|2014-04-25|2016-12-09|2011-09-01|2011-09-02|Estimate|2014-07-29|2014-08-19|Estimate|2014-04-25|2014-05-13|Estimate|2016-12-09|2017-02-06|Estimate|November 2011||2011-11-30|December 2016|2016-12-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional||All randomized participants|A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer|An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy|Completed||Phase 2|141|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 22:11:42.883874|2018-05-31 22:11:42.883874
NCT01427920|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2013-07-03||2017-01-10|2011-09-01|2011-09-02|Estimate|2013-07-03|2013-09-12|Estimate||||2017-01-10|2017-02-24|Actual|September 2011||2011-09-30|January 2017|2017-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SimpleMix™||Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes|A 20 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group Comparison of Twice Daily Subject Driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Versus Twice Daily Investigator-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Both in Combination With Metformin in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin Analogues|Completed||Phase 4|348|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:11:46.598103|2018-05-31 22:11:46.598103
NCT01427907|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2015-03-11||2015-12-11|2011-09-01|2011-09-02|Estimate|2015-12-11|2016-01-14|Estimate||||2015-12-11|2016-01-14|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|COS-002||Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients|Randomized,Multi-center,Phase IV, 2-arm,Open-Label,Cross-over Study to Demonstrate the Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients|Completed||Phase 4|38|Actual|Fresenius Medical Care North America|The Last Patient Last Visit (LPLV) was on 06-July-2012 and last site close out visit was 31 May 2013. Due to inadvertent study deviations, no reliable conclusions can be drawn from the study.|2|||f||||f||||||||||2018-05-31 22:11:47.254061|2018-05-31 22:11:47.254061
NCT01427894|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-03-15|2011-09-01|2011-09-02|Estimate|||||||2016-03-15|2016-03-16|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Maternal Singing During Kangaroo Care in Preterm Infants|The Combined Effects of Maternal Singing During Skin to Skin Contact (Kangaroo Care) in Preterm Infants in the Neonatal Intensive Care Unit Environment.|Completed||N/A|30|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 22:11:47.638409|2018-05-31 22:11:47.638409
NCT01427881|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2017-04-11||2017-05-17|2011-09-01|2011-09-02|Estimate|2017-05-17|2017-05-19|Actual||||2017-05-17|2017-05-19|Actual|September 2011||2011-09-30|May 2017|2017-05-31|July 2015|Actual|2015-07-31|June 2014|Actual|2014-06-30||Interventional|||Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies|A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation|Completed||Phase 2|43|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 22:11:47.803396|2018-05-31 22:11:47.803396
NCT01427868|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-09-01|2011-09-01|2011-09-02|Estimate|||||||2011-09-01|2011-09-02|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Bioequivalence of LB80380 Free Base and Maleate Salt Tablets|An Open-label, Phase I Study in Healthy Male Subjects to Compare the Pharmacokinetics of LB80331 and LB80317, Metabolites of LB80380, After a Single Oral Administration of LB80380 Free Base 150 mg (60 mg + 90 mg) Tablet or LB80380 Maleate Tablet 183 mg (150 mg as a Free Base)|Completed||Phase 1|32|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 22:11:48.24686|2018-05-31 22:11:48.24686
NCT01427855|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2017-10-31|2011-09-01|2011-09-02|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||Dietary Protein Sources and Atherogenic Dyslipidemia|Saturated Fat and Protein Effects on Atherogenic Dyslipidemia|Completed||N/A|113|Actual|Children's Hospital & Research Center Oakland||6|||f||||t||||||||||2018-05-31 22:11:48.423025|2018-05-31 22:11:48.423025
NCT01427842|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-09-01|2011-09-01|2011-09-02|Estimate|||||||2011-09-01|2011-09-02|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|DEVINE||Dose Enhancement of Vancomycin IN Everyday Patients|A Single-centred Randomised Trial of a New Vancomycin Dosing Method Compared to Standard Care in Everyday Patients Receiving Vancomycin|Unknown status|Recruiting|Phase 2|100|Anticipated|The Canberra Hospital||1|||f||||f||||||||||2018-05-31 22:11:48.545166|2018-05-31 22:11:48.545166
NCT01427829|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-09-01|2011-09-01|2011-09-02|Estimate|||||||2011-09-01|2011-09-02|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CaPRA||Computer-assisted Psychosocial Risk Assessment (CaPRA) for Refugee Health and Settlement|Computer-assisted Psychosocial Risk Assessment (CaPRA) for Refugee Health and Settlement - Evaluation Phase|Completed||N/A|50|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 22:11:48.659663|2018-05-31 22:11:48.659663
NCT01427816|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-10-29|2011-09-01|2011-09-02|Estimate|||||||2013-10-29|2013-10-30|Estimate||||October 2013|2013-10-31||||||||Interventional|||A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome|A Randomized, Double Blind, Placebo Controlled, Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome|Completed||Phase 2|180||Kissei Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 22:11:48.778529|2018-05-31 22:11:48.778529
NCT01427803|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2013-02-05||2015-09-24|2011-09-01|2011-09-02|Estimate|2013-04-09|2013-05-20|Estimate||||2015-09-24|2015-10-15|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Kiefer AUT||Actual Use Trial of Naproxen Sodium|An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID|Completed||Phase 3|778|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:11:48.882064|2018-05-31 22:11:48.882064
NCT01427777|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-01|2011-09-01|2011-09-02|Estimate|||||||2011-09-01|2011-09-02|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|June 2012|Anticipated|2012-06-30|||||Observational|||3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China|The Thirty-six-Month Immunogenicity Evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years|Unknown status|Not yet recruiting||300|Anticipated|Guangxi Center for Disease Control and Prevention|||1||f||||f||||||||||2018-05-31 22:11:49.354354|2018-05-31 22:11:49.354354
NCT01427764|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-31|2011-08-31|2011-09-02|Estimate|||||||2011-08-31|2011-09-02|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Dentin Hypersensitivity Following Non-surgical Periodontal Therapy With Hand or Ultrasonic Instruments|Dentin Hypersensitivity Following Non-surgical Periodontal Therapy With Hand or Ultrasonic Instruments|Completed||N/A|14|Actual|Escola Bahiana de Medicina e Saude Publica|||||f||||||||||||||2018-05-31 22:11:49.457331|2018-05-31 22:11:49.457331
NCT01427751|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|2015-11-03||2016-01-19|2011-09-01|2011-09-02|Estimate|2016-01-19|2016-02-15|Estimate||||2016-01-19|2016-02-15|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion||Completed||Phase 4|307|Actual|Allergan||2|||f||||f||||||||||2018-05-31 22:11:49.535803|2018-05-31 22:11:49.535803
NCT01427738|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2015-01-06||2015-02-12|2011-09-01|2011-09-02|Estimate|2015-02-12|2015-02-16|Estimate||||2015-02-12|2015-02-16|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|January 2014|Actual|2014-01-31|September 2012|Actual|2012-09-30||Interventional||All participants who enrolled.|Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis|A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Gentian Violet Oral Solution to That of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings|Completed||Phase 3|221|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 22:11:50.036695|2018-05-31 22:11:50.036695
NCT01427725|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2015-06-09|2011-08-31|2011-09-02|Estimate|||||||2015-06-09|2015-06-10|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency|Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Pancreatectomy and Other Conditions Except Cystic Fibrosis|Completed|||562|Actual|Mylan Inc.|||1||f||||||||||||||2018-05-31 22:11:50.715812|2018-05-31 22:11:50.715812
NCT01427712|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-11-28|2011-08-31|2011-09-02|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Recruiting|||30|Anticipated|Mylan Inc.|||1||f||||f||||||||||2018-05-31 22:11:51.024555|2018-05-31 22:11:51.024555
NCT01427699|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-10-29|2011-08-31|2011-09-01|Estimate|||||||2012-10-29|2012-10-31|Estimate|June 2011||2011-06-30|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|||A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes|A Phase II Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes|Completed||Phase 2|7|Actual|XBiotech, Inc.||1|||f||||f||||||||||2018-05-31 22:11:51.128122|2018-05-31 22:11:51.128122
NCT01427686|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-04-05|2011-08-31|2011-09-01|Estimate|||||||2016-04-05|2016-04-06|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|February 2015|Actual|2015-02-28||Interventional|||Dopamine Versus Dobutamine for Treatment of Arterial Hypotension in Term and Preterm Neonates|Effect of Dobutamine as Compared to Dopamine on Cerebral Oxygenation, Mean Arterial Pressure and Cerebral Hemodynamics in Term and Preterm Neonates With Arterial Hypotension|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|University of Ulm||2|||f||||f||||||||||2018-05-31 22:11:51.187515|2018-05-31 22:11:51.187515
NCT01427673|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-08-31|2011-08-31|2011-09-01|Estimate|||||||2011-08-31|2011-09-01|Estimate|December 2011||2011-12-31|August 2011|2011-08-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|OS||Continuous Positive Airway Pressure Versus Noninvasive Ventilation in Patients With Overlap Syndrome|Phase III Single-blind Randomized Controlled Trial of Bipap Versus CPAP in Overlap Syndrome|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|United States Air Force||2|||f||||f||||||||||2018-05-31 22:11:51.253201|2018-05-31 22:11:51.253201
NCT01427660|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-09-08|2011-08-31|2011-09-01|Estimate|||||||2014-09-08|2014-09-09|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|iDecide||iDecide.Decido: Diabetes Medication Decision Support Study|Technologically Enhanced Community Health Worker (CHW) Delivery of Personalized Diabetes Information|Completed||N/A|190|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:11:51.325645|2018-05-31 22:11:51.325645
NCT01427647|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2016-07-21|2011-08-31|2011-09-01|Estimate|||||||2016-07-21|2016-07-22|Estimate|June 2007||2007-06-30|July 2016|2016-07-31|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|CRC||Inflammatory Response After Colorectal Cancer Surgery|Inflammatory Response Following Colorectal Cancer Surgery Depends on the Type of Anesthesia and Surgery|Completed||N/A|63|Actual|Universidad Complutense de Madrid||3|||f||||t||||||||||2018-05-31 22:11:51.389975|2018-05-31 22:11:51.389975
NCT01427634|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2013-09-05|2011-08-31|2011-09-01|Estimate|||||||2013-09-05|2013-09-06|Estimate|July 2011||2011-07-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Proactive Palliative Care for Patients With Ventricular Assist Devices (VAD) and Their Families|Randomized Controlled Trial of Proactive Palliative Care for Patients With Ventricular Assist Devices and Their Families|Completed||N/A|18|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 22:11:51.462442|2018-05-31 22:11:51.462442
NCT01427621|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2011-08-31|2011-08-31|2011-09-01|Estimate|||||||2011-08-31|2011-09-01|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery|Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery|Completed||Phase 4|54|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:11:51.528121|2018-05-31 22:11:51.528121
NCT01427608|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-04-30|2011-08-31|2011-09-01|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2011||2011-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|STOP-PD||Sustaining Remission of Psychotic Depression|Sustaining Remission of Psychotic Depression|Active, not recruiting||Phase 4|269|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 22:11:51.684054|2018-05-31 22:11:51.684054
NCT01427595|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-01-19|2011-08-31|2011-09-01|Estimate|||||||2018-01-19|2018-01-23|Actual|July 22, 2008|Actual|2008-07-22|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 28, 2018|Anticipated|2018-06-28||Interventional|||Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone|Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)|Active, not recruiting||N/A|11|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:11:51.77537|2018-05-31 22:11:51.77537
NCT01427582|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2011-08-30|2011-08-30|2011-09-01|Estimate|||||||2011-08-30|2011-09-01|Estimate||||August 2011|2011-08-31||||||||Expanded Access|||YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access|YONDELIS(Trabectedin) Single Patient Compassionate Use / Expanded Access in Soft Tissue Sarcoma|No longer available|||||University of Texas Southwestern Medical Center|||||||||||||||||||2018-05-31 22:11:51.876507|2018-05-31 22:11:51.876507
NCT01427569|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2015-12-23|2011-08-31|2011-09-01|Estimate|||||||2015-12-23|2015-12-24|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy Study of IZN-6D4 Gel for the Treatment of Diabetic Foot Ulcers|A Randomized, Placebo-controlled, Double-blind Phase II Study to Evaluate the Efficacy of IZN-6D4 Gel for the Treatment of Diabetic Foot Ulcers|Completed||Phase 2|82|Actual|Izun Pharma Ltd||2|||f||||f||||||||||2018-05-31 22:11:51.945762|2018-05-31 22:11:51.945762
NCT01427556|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2014-08-15|2011-08-30|2011-09-01|Estimate|||||||2014-08-15|2014-08-18|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Observational|FL-74||The Hormonal and Behavioral Impact of Eating Breakfast|CCRC: The Hormonal and Behavioral Impact of Eating Breakfast|Completed|||120|Anticipated|USDA, Western Human Nutrition Research Center|||2||f||||f||||||Samples With DNA|"~     Serum and saliva samples will be retained.~   "|||2018-05-31 22:11:52.034702|2018-05-31 22:11:52.034702
NCT01427543|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2014-05-15|2011-08-31|2011-09-01|Estimate|||||||2014-05-15|2014-05-16|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The HJ MILE HIV Prevention Intervention for Post-incarcerated Men|The HJ MILE HIV Prevention Intervention for Post-incarcerated Bisexual African American Men|Completed||Phase 3|212|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 22:11:52.104061|2018-05-31 22:11:52.104061
NCT01427530|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2013-10-29|2011-08-31|2011-09-01|Estimate|||||||2013-10-29|2013-10-30|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Local Field Potentials Recorded From Deep Brain Stimulating (DBS) Electrodes|Local Field Potentials Recorded From Deep Brain Stimulating Electrodes Implanted for the Treatment of Parkinson's Disease|Completed|||10|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-05-31 22:11:52.186003|2018-05-31 22:11:52.186003
NCT01427517|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2013-05-22||2013-08-02|2011-08-31|2011-09-01|Estimate|2013-05-30|2013-08-02|Estimate||||2013-08-02|2013-08-14|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease|Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease|Completed||Phase 1|9|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 22:11:52.263045|2018-05-31 22:11:52.263045
NCT01426698|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2014-12-03|2011-08-30|2011-08-31|Estimate|||||||2014-12-03|2014-12-05|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|18mo||18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study|18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study|Completed||Phase 2|208|Actual|University of Rhode Island||2|||f||||t||||||||||2018-05-31 22:12:06.607841|2018-05-31 22:12:06.607841
NCT01427504|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2012-11-16||2013-06-04|2011-08-31|2011-09-01|Estimate|2013-06-04|2013-07-09|Estimate||||2013-06-04|2013-07-09|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers|A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/(Hepatitis C Virus) (HCV) Negative Volunteers|Completed||N/A|26|Actual|University of Colorado, Denver|"Healthy volunteer study does not take into account other medications being prescribed to treat the co-infected population.~An interaction at the level of enzyme induction is difficult to rule out since we sampled etravirine over 12 hours."|6|||f||||f||||||||||2018-05-31 22:11:52.588955|2018-05-31 22:11:52.588955
NCT01427491|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2013-07-29|2011-08-31|2011-09-01|Estimate|||||||2013-07-29|2013-07-30|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers|A Prospective, Multi-center, Randomized, Comparative Clinical Study to Compare Aquacel® Ag vs. Mepilex® Border Ag to Manage Bioburden in Leg Ulcers.|Completed||Phase 3|18|Actual|ConvaTec Inc.||2|||f||||f||||||||||2018-05-31 22:11:53.126571|2018-05-31 22:11:53.126571
NCT01427478|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2017-02-22|2011-08-31|2011-09-01|Estimate|||||||2017-02-22|2017-02-23|Actual|September 2011||2011-09-30|February 2017|2017-02-28|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|BIBW2992ORL||Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck|A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02|Recruiting||Phase 3|315|Anticipated|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 22:11:53.226212|2018-05-31 22:11:53.226212
NCT01427465|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-11-21|2011-08-31|2011-09-01|Estimate|||||||2011-11-21|2011-11-22|Estimate|September 2007||2007-09-30|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Brief||Brief Integrative Alcohol Interventions for Adolescents|Brief Integrative Alcohol Interventions for Adolescents|Withdrawn||N/A|0|Actual|University of Florida||4||PI left University of Florida|f||||t||||||||||2018-05-31 22:11:53.419766|2018-05-31 22:11:53.419766
NCT01427452|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-03-18|2011-08-31|2011-09-01|Estimate|||||||2018-03-18|2018-03-20|Actual|August 2011||2011-08-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|KDOC||Kidney Donor Outcomes Cohort (KDOC) Study|Kidney Donor Outcomes Cohort (KDOC) Study|Completed|||720|Anticipated|Beth Israel Deaconess Medical Center|||1||f||||f||||||||||2018-05-31 22:11:53.516828|2018-05-31 22:11:53.516828
NCT01427439|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-07-07|2011-08-31|2011-09-01|Estimate|||||||2015-07-07|2015-07-08|Estimate|February 2011||2011-02-28|July 2015|2015-07-31||||February 2015|Actual|2015-02-28||Observational|PERFORM||A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder|A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder|Completed|||1455|Actual|H. Lundbeck A/S|||1||f||||f||||||||||2018-05-31 22:11:53.589265|2018-05-31 22:11:53.589265
NCT01427426|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-03-14|2011-08-31|2011-09-01|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Does a Nutritional Supplement Increase Vitality, Energy and Perceived Well Being?|Does a Nutritional Supplement Increase Vitality, Energy and Perceived Well Being?|Completed||Phase 4|120|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:11:53.652334|2018-05-31 22:11:53.652334
NCT01427413|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2017-07-20|2011-08-31|2011-09-01|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2011||2011-09-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|||Identification and Standardization of a Method That Would Allow the Study of the Metabolic Profile of Blastocoele Lays the Foundation to Assess Blastocyst Metabolomic Profile and Its Relation With Embryo Morphology and Embryo Implantation|Identification and Standardization of a Method That Would Allow the Study of the Metabolic Profile of Blastocoele Lays the Foundation to Assess Blastocyst Metabolomic Profile and Its Relation With Embryo Morphology and Embryo Implantation|Recruiting|||100|Anticipated|Cervesi Hospital, Cattolica, Italy|||1||f||||t||||||Samples With DNA|"~     blastocoele fluid~   "|||2018-05-31 22:11:53.728143|2018-05-31 22:11:53.728143
NCT01427400|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-07-28|2011-08-30|2011-09-01|Estimate|||||||2016-07-28|2016-07-29|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|Botox||The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction|The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial|Recruiting||Phase 4|128|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:11:53.832876|2018-05-31 22:11:53.832876
NCT01427387|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-09-22|2011-08-31|2011-09-01|Estimate|||||||2011-09-22|2011-09-23|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects|Phase I Study of ASP0456 - A Double-blind, Placebo-controlled, Multiple Ascending Dose Study / Investigational Study for Dose Timing Selection in Non Elderly Healthy Subjects-|Completed||Phase 1|44|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 22:11:54.077756|2018-05-31 22:11:54.077756
NCT01427374|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-04-30|2011-08-30|2011-09-01|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2011|Actual|2011-05-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients|Clinical, Biochemical and Genetic Risk Factors for Coronary Artery Calcification and Left Ventricular Hypertrophy in Hemodialysis Patients (CKDCS/LUCID)|Terminated|||30|Actual|University of Alberta||||low recruitment|f||||f||||||Samples With DNA|"~     Blood and urine will be obtained at baseline, 6 months and annually thereafter. Blood samples~     will be immediately divided into multiple aliquots, from which plasma, DNA, RNA and/or cells~     will be extracted and separately stored. Urine specimens will also be aliquoted to allow~     future measurement of genetic and cellular material. Specimens will be labeled using unique~     study identifiers to maintain confidentiality.~   "|||2018-05-31 22:11:54.176021|2018-05-31 22:11:54.176021
NCT01427361|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2018-03-21|2011-08-31|2011-09-01|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2009||2009-10-31|March 2018|2018-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|BHR||Clinical Outcome of Birmingham Hip Resurfacing (BHR) Using VISIONAIRE Femoral Alignment Guide|Prospective, Multi- Site, Clinical Study of Clinical Outcomes Following Hip Resurfacing Using VISIONAIRE Femoral Alignment Guide|Completed|||25|Actual|Smith & Nephew, Inc.|||||f||||f||||||||||2018-05-31 22:11:54.240281|2018-05-31 22:11:54.240281
NCT01427348|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2012-05-28|2011-08-30|2011-09-01|Estimate|||||||2012-05-28|2012-05-30|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||Maintaining the Head Extension by an Assistant Decreases Dental Contact|Maintaining the Head Extension by an Assistant Decreases Dental Contact Between Laryngoscope Blade and Maxillary Incisors During Direct Laryngoscopy|Completed||N/A|68|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 22:11:54.319343|2018-05-31 22:11:54.319343
NCT01427335|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-07-08|2011-08-31|2011-09-01|Estimate|||||||2014-07-08|2014-07-09|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|OHSS||Calcium for Prevention of Ovarian Hyperstimulation Syndrome|Does Intravenous Calcium Infusion Effectively Prevent OHSS : a Randomised Controlled Trial|Completed||Phase 3|200|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 22:11:54.377076|2018-05-31 22:11:54.377076
NCT01427322|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2015-07-06|2011-08-31|2011-09-01|Estimate|||||||2015-07-06|2015-07-08|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease|A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease|Terminated||Early Phase 1|6|Actual|Virginia Commonwealth University||2||Slow accrual|f||||t||||||||||2018-05-31 22:11:54.456804|2018-05-31 22:11:54.456804
NCT01427309|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2014-07-08||2015-03-30|2011-08-30|2011-09-01|Estimate|2014-08-05|2014-08-06|Estimate||||2015-03-30|2015-04-20|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional||The Full Analysis Set (FAS) as randomized, groups the participants according to the vaccine they were randomized to receive in the study.|A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults|Efficacy Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults|Completed||Phase 4|31989|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:11:55.658255|2018-05-31 22:11:55.658255
NCT01427296|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2017-12-20||2017-12-20|2011-08-30|2011-09-01|Estimate|2017-12-20|2018-01-18|Actual||||2017-12-20|2018-01-18|Actual|September 16, 2011|Actual|2011-09-16|December 2017|2017-12-31|December 9, 2014|Actual|2014-12-09|March 11, 2014|Actual|2014-03-11||Interventional|||Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing|A Phase 4, Randomized, Active Comparator, Open-Label, Multicenter Study to Assess the Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing|Completed||Phase 4|2154|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||t||||||||No||2018-05-31 22:11:59.944665|2018-05-31 22:11:59.944665
NCT01427283|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2015-02-11|2011-08-31|2011-09-01|Estimate|||||||2015-02-11|2015-02-12|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation Who Require Around-the-clock Opioid Therapy|Completed||Phase 3|450|Actual|Purdue Pharma LP||3|||f||||f||||||||||2018-05-31 22:12:00.326788|2018-05-31 22:12:00.326788
NCT01427270|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2014-11-06|2011-08-31|2011-09-01|Estimate|||||||2014-11-06|2014-11-07|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation Who Require Around-the-clock Opioid Therapy|Completed||Phase 3|455|Actual|Purdue Pharma LP||3|||f||||f||||||||||2018-05-31 22:12:00.791409|2018-05-31 22:12:00.791409
NCT01427257|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2012-09-28|2011-08-31|2011-09-01|Estimate|||||||2012-09-28|2012-10-01|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus|Phase 1 Open-Label Two-Way Cross Over Study to Assess the Pharmacokinetic Profile of Two Formulations of PB1023 Injection Following a Single Dose Administered By Subcutaneous Injection in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1|10|Actual|PhaseBio Pharmaceuticals Inc.||3|||f||||t||||||||||2018-05-31 22:12:01.183796|2018-05-31 22:12:01.183796
NCT01427244|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2014-06-12|2011-08-31|2011-09-01|Estimate|||||||2014-06-12|2014-06-16|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease|A Phase II Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease|Withdrawn||Phase 2|0|Actual|Yale University||1|||f||||t||||||||||2018-05-31 22:12:01.276082|2018-05-31 22:12:01.276082
NCT01427231|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2012-03-20|2011-08-31|2011-09-01|Estimate|||||||2012-03-20|2012-03-21|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Short-term Effect of Glucose and Sacharose Ingestion on Cognitive Performance and Mood in Elderly|The Short-term Effect of Glucose and Sacharose Ingestion on Cognitive Performance and Mood in Elderly Subjects|Completed||N/A|43|Actual|Wageningen University||3|||f||||||||||||||2018-05-31 22:12:01.357823|2018-05-31 22:12:01.357823
NCT01427218|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-08-31|2011-08-31|2011-09-01|Estimate|||||||2011-08-31|2011-09-01|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|MUMPS||Monitoring and Adjustment of Medication Therapy for Patients With Heart Disease|A Prospective Evaluation of a Medication Therapy Management Clinic Versus Usual Medical Care in Patients Post Acute Coronary Syndrome: The MUMPS Study|Unknown status|Recruiting|N/A|170|Anticipated|Middle Tennessee Research Institute||2|||f||||f||||||||||2018-05-31 22:12:01.440513|2018-05-31 22:12:01.440513
NCT01426490|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2014-02-17|2011-08-30|2011-08-31|Estimate|||||||2014-02-17|2014-02-19|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Effects of Vitamin B-6 Status on Homocysteine, Oxidative Stress, One-carbon Metabolism and Methylation: Cross-section, Case-control, Intervention and Follow-up Studies in Colorectal Cancer||Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Taichung Veterans General Hospital||4|||f||||t||||||||||2018-05-31 22:12:11.256532|2018-05-31 22:12:11.256532
NCT01427205|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2013-04-04|2011-08-30|2011-09-01|Estimate|||||||2013-04-04|2013-04-05|Estimate|June 2013||2013-06-30|April 2013|2013-04-30||||June 2016|Anticipated|2016-06-30||Interventional|||Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase II Study of Cetuximab With or Without OSI-906, a Dual Insulin-like Growth Factor-1 Receptor and an Insulin Receptor Inhibitor, in Platinum-Refractory, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 22:12:01.530743|2018-05-31 22:12:01.530743
NCT01427192|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-12-11|2011-08-31|2011-09-01|Estimate|||||||2012-12-11|2012-12-12|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CSRPH||Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension|Treatment of Sleep Related Breathing Disorders in Patients With Pulmonary Hypertension (CSRPH)|Completed||Phase 2|23|Actual|University of Zurich||5|||f||||t||||||||||2018-05-31 22:12:01.611313|2018-05-31 22:12:01.611313
NCT01427179|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-02-21|2011-08-30|2011-09-01|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2011||2011-05-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)|Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)|Recruiting|||1000|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     A 30 ml sample of blood from a vein or an existing catheter will be drawn at Mayo Clinic or~     another medical center and returned through the mail in a kit. Alternatively, a saliva sample~     will be collected and returned through the mail in a kit. An additional 10 ml (2 teaspoons)~     of blood, buccal smear, and/or available tissue samples may also be collected.~   "|||2018-05-31 22:12:01.702647|2018-05-31 22:12:01.702647
NCT01427166|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2016-03-14|2011-08-31|2011-09-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Non-Invasive Imaging for Cording in Breast Cancer Patients|Evaluation of Non Invasive Imaging for Assessing the Pathophysiology of Cording in Patients Treated for Breast Cancer|Completed||N/A|5|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:12:01.769537|2018-05-31 22:12:01.769537
NCT01427153|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-07-31|2011-08-31|2011-09-01|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2012|Actual|2012-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|SMART||A Comparison of Manual Physical Therapy and Corticosteroid Injections for Knee Osteoarthritis|Orthopaedic Manual Physical Therapy Versus Corticosteroid Injections for Osteoarthritis of the Knee|Active, not recruiting||N/A|156|Actual|Madigan Army Medical Center||2|||f||||f||||||||Yes|Any data sharing must go through a Data Sharing Agreement approved by the US Defense Health Agency|2018-05-31 22:12:01.833286|2018-05-31 22:12:01.833286
NCT01427140|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-12-08|2011-08-31|2011-09-01|Estimate|||||||2011-12-08|2011-12-09|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|LIPOGAIN||Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN)|Metabolic Consequences of Moderate Weight Gain - Role of Dietary Fat Composition (LIPOGAIN): a Randomized Double-Blind Controlled Study|Completed||N/A|41|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 22:12:01.93812|2018-05-31 22:12:01.93812
NCT01427127|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-30|2011-08-30|2011-09-01|Estimate|||||||2011-08-30|2011-09-01|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Ramosetron on Bowel Motility After Colorectal Resection|Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection|Unknown status|Recruiting|Phase 4|64|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 22:12:02.024755|2018-05-31 22:12:02.024755
NCT01427114|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-08-15|2011-08-30|2011-09-01|Estimate|||||||2017-08-15|2017-08-18|Actual|July 1, 2011|Actual|2011-07-01|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2014|Actual|2014-08-01||Interventional|||R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)|Open-labeled, Multicenter Phase II Study of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients With Non-conjunctival Ocular Adnexal MALT Lymphoma|Active, not recruiting||Phase 2|33|Anticipated|Konkuk University Medical Center||1|||f||||f||||||||||2018-05-31 22:12:02.103255|2018-05-31 22:12:02.103255
NCT01427101|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-08-31|2011-08-31|2011-09-01|Estimate|||||||2011-08-31|2011-09-01|Estimate|September 1993||1993-09-30|August 2011|2011-08-31||||||||Observational|||Results of CRS and Debulking in PMP Patients|Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei|Unknown status|Active, not recruiting||||Uppsala University|||||f||||f|||||||"~     Patients treated from 1993 are included and during these years treatment strategy has~     changed. The different strategies are compared but its juts one cohort of patients. No~     completion date are set due to that reports from other centres show that there are longtime~     survivers in both treatment groups.~   "|||2018-05-31 22:12:02.200592|2018-05-31 22:12:02.200592
NCT01427088|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2015-02-15|2011-08-30|2011-09-01|Estimate|||||||2015-02-15|2015-02-18|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia|Short-Term Response of Serum Brain-Derived Neurotrophic Factor to Repetitive Transcranial Magnetic Stimulation in Patients With Chronic Schizophrenia|Completed||N/A|21|Actual|Jeonbuk Provincial Maeumsarang Hospital||1|||f||||f||||||||||2018-05-31 22:12:02.255563|2018-05-31 22:12:02.255563
NCT01427075|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2012-04-07|2011-08-31|2011-09-01|Estimate|||||||2012-04-07|2012-04-10|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Evaluation Of The Pharynx in Patients Undergoing Lateral Pharyngoplasty|Evaluation of the Pharynx Through MRI in Patients Undergoing Lateral Pharyngoplasty for Treatment of Obstructive Sleep Apnea|Unknown status|Active, not recruiting|N/A|15|Anticipated|Hospital do Servidor Publico Estadual||1|||f||||f||||||||||2018-05-31 22:12:02.332995|2018-05-31 22:12:02.332995
NCT01427062|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2011-08-30|2011-08-30|2011-09-01|Estimate|||||||2011-08-30|2011-09-01|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|||Effects of an Innovative Balance Training Programme in Enhancing Postural Control and Reducing Falls in Patients With Parkinson's Disease||Unknown status|Recruiting|N/A|52|Anticipated|The Hong Kong Polytechnic University||2|||f||||||||||||||2018-05-31 22:12:02.408442|2018-05-31 22:12:02.408442
NCT01427049|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-01-31|2011-08-31|2011-09-01|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||The Effect of Renal Denervation on Biological Variables|The Evaluation of Renal Denervation on Several Biological Variables in Patients With Uncontrolled Hypertension. An Observational Feasibility Study.|Completed|||54|Actual|UMC Utrecht|||1||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:12:02.495069|2018-05-31 22:12:02.495069
NCT01427036|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2018-02-21|2011-08-31|2011-09-01|Estimate|||||||2018-02-21|2018-02-26|Actual|June 2010||2010-06-30|May 2016|2016-05-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|MISSvsPHS||On the Impact of Bleeding on Two Strategies Osteosynthesis of Trochanteric Fractures|Impact Sur le Saignement Per et Post opératoire de 2 stratégies d'ostéosynthèse Des Fractures du Massif trochantérien du Sujet > 65 Ans : Essai randomisé Comparant le système MISS et le système PHS|Completed||N/A|108|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 22:12:02.748502|2018-05-31 22:12:02.748502
NCT01427023|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2014-02-05|2011-08-30|2011-09-01|Estimate|||||||2014-02-05|2014-02-06|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Observational|||Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing|Prospective Collection of Female First-catch Urine, Vaginal Swab, Endocervical Swab, and Cervical Specimens for Testing With the APTIMA Trichomonas Vaginalis Assay|Completed|||532|Actual|Gen-Probe, Incorporated|||||f||||f||||||Samples With DNA|"~     urine specimen, vaginal swab specimen, endocervical swab specimen and PreservCyt specimen~   "|||2018-05-31 22:12:02.826595|2018-05-31 22:12:02.826595
NCT01427010|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2018-04-17|2011-08-31|2011-09-01|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|||A Feasibility Study on Adaptive 18F-FDG-guided Radiotherapy for Recurrent and Second Primary Head and Neck Cancer in the Previously Irradiated Territory.|A Feasibility Study on Adaptive 18F-FDG-guided Radiotherapy for Recurrent and Second Primary Head and Neck Cancer in the Previously Irradiated Territory.|Completed||N/A|10|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:12:02.897577|2018-05-31 22:12:02.897577
NCT01426997|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2016-06-20|2011-08-31|2011-09-01|Estimate|||||||2016-06-20|2016-06-22|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Phenotype Depression Study|Phenotyping Major Depression With Increased Inflammation|Completed|||279|Actual|Emory University|||3||f||||t||||||Samples With DNA|"~     Diurnal plasma samples are collected hourly from 9 am to 9 pm once; Cerebrospinal fluid once;~     mRNA from peripheral blood leuckocytes collected 5 times; DNA for analysis of genetic~     polymorphisms is collected once.~   "|No||2018-05-31 22:12:02.969441|2018-05-31 22:12:02.969441
NCT01426984|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2012-08-22|2011-08-31|2011-09-01|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults|A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With Borderline Personality Disorder (BPD) Compared to Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Healthy Adults|Unknown status|Recruiting|N/A|20|Anticipated|Shalvata Mental Health Center||1|||f||||t||||||||||2018-05-31 22:12:03.044485|2018-05-31 22:12:03.044485
NCT01426971|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2012-11-23|2011-08-31|2011-09-01|Estimate|||||||2012-11-23|2012-11-27|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Ibuprofen Versus Ibuprofen Plus Caffeine in the Treatment of Migraine.|National, Controlled, Randomized, Double-blind, Parallel Study to Investigate the Efficacy of 2 Capsules of Ibuprofen 400mg in Association With Caffeine 100mg in Fixed Dose Combination Compared to Two Capsules of Ibuprofen 400mg in the Treatment of Migraine|Withdrawn||Phase 3|0|Actual|Sanofi||2|||f||||||||||||||2018-05-31 22:12:03.115296|2018-05-31 22:12:03.115296
NCT01426958|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2013-08-08||2014-06-03|2011-08-31|2011-09-01|Estimate|2013-10-29|2013-12-19|Estimate||||2014-06-03|2014-06-09|Estimate|August 2011||2011-08-31|October 2013|2013-10-31||||December 2011|Actual|2011-12-31||Interventional|||Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects|Relative Bioavailability of a Single Oral Dose of 40 mg Afatinib Given Alone Compared to Concomitant and Timed Administration of Multiple Oral Doses of Ritonavir - an Open-label, Randomised, Three-way Crossover Trial in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:12:03.201271|2018-05-31 22:12:03.201271
NCT01426945|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2016-05-17|2011-08-31|2011-09-01|Estimate|||||||2016-05-17|2016-05-18|Estimate|November 2011||2011-11-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Protein Expression in Samples From Young Patients With Rhabdomyosarcoma|Evaluating Candidate Protein Expression in Human Rhabdomyosarcoma (RMS)|Completed|||77|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tumor tissue~   "|||2018-05-31 22:12:03.492193|2018-05-31 22:12:03.492193
NCT01426932|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|||2013-06-27|2011-08-31|2011-09-01|Estimate|||||||2013-06-27|2013-07-01|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Head Impulse Test in the Screening of Vestibular Function|The Head Impulse Test in the Screening of Vestibular Function|Unknown status|Enrolling by invitation||50|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 22:12:03.549391|2018-05-31 22:12:03.549391
NCT01426919|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-08-07|2011-08-31|2011-09-01|Estimate|||||||2017-08-07|2017-08-08|Actual|December 2012||2012-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|ALERT-TBI||Evaluation of Biomarkers of Traumatic Brain Injury|A Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury|Completed|||2011|Actual|Banyan Biomarkers, Inc|||1||f||||f||||||||||2018-05-31 22:12:03.619219|2018-05-31 22:12:03.619219
NCT01426906|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-31|||2011-08-31|2011-08-31|2011-09-01|Estimate|||||||2011-08-31|2011-09-01|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pharmacokinetic Drug Interaction Study in Healthy Male Subjects|A Randomized, Open-Label, Drug-Drug Interaction Study To Evaluate The Effect Of Ketoconazole Or Rifampicin On The Pharmacokinetic Characteristics And Safety Of Lc15-0444 In Healthy Male Volunteers|Completed||Phase 1|24|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 22:12:03.720655|2018-05-31 22:12:03.720655
NCT01426893|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2012-03-28|2011-08-31|2011-09-01|Estimate|||||||2012-03-28|2012-03-29|Estimate|October 2011||2011-10-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct|Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct|Completed|||310|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:12:03.801224|2018-05-31 22:12:03.801224
NCT01426880|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2016-02-12|2011-08-31|2011-09-01|Estimate|||||||2016-02-12|2016-02-15|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|GeparSixto||Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer|A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer|Completed||Phase 2/Phase 3|595|Actual|German Breast Group||2|||f||||t||||||||||2018-05-31 22:12:03.869896|2018-05-31 22:12:03.869896
NCT01426867|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2013-05-17|2012-07-17|2013-05-17|2011-08-30|2011-09-01|Estimate|2013-05-17|2013-07-08|Estimate|2012-07-17|2012-07-25|Estimate|2013-05-17|2013-07-08|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||This reporting group includes all randomized subjects.|A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%|A Descriptive Comfort Study of Brinzolamide 1% / Brimonidine Tartrate 0.2% Fixed Combination Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension and Brimonidine Tartrate 0.2% Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|103|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:12:03.975711|2018-05-31 22:12:03.975711
NCT01426854|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2013-03-27||2013-05-10|2011-08-31|2011-09-01|Estimate|2013-05-10|2013-05-13|Estimate||||2013-05-10|2013-05-13|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Demographics are presented for the 248 participants who received at least one dose of study drug or discontinued before surgery and failed to return the test article bottle or returned the bottle with a broken seal.|Nepafenac Compared to Placebo for Ocular Pain and Inflammation|Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.1% Compared to Placebo for the Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery in Adult Chinese Subjects|Completed||Phase 3|260|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:12:04.214328|2018-05-31 22:12:04.214328
NCT01426841|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-10-01|2011-08-31|2011-09-01|Estimate|||||||2014-10-01|2014-10-02|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer|Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 1|10|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-05-31 22:12:04.469258|2018-05-31 22:12:04.469258
NCT01426828|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30||2018-03-12|2018-03-12|2011-08-31|2011-09-01|Estimate||||2018-03-12|2018-03-14|Actual|2018-03-12|2018-03-14|Actual|August 2011||2011-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Id-KLH Vaccine + T Cells|Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Subjects With Myeloma Undergoing Autologous Transplant|Completed||Phase 2|43|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 22:12:04.569073|2018-05-31 22:12:04.569073
NCT01426815|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2014-12-04|2011-08-30|2011-08-31|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|CRESPA||Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria|Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria|Unknown status|Recruiting|Phase 3|60|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:12:04.674472|2018-05-31 22:12:04.674472
NCT01426802|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2017-02-23|2011-08-30|2011-08-31|Estimate|||||||2017-02-23|2017-02-27|Actual|October 2010||2010-10-31|February 2017|2017-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin|A 12 Week Multi Center, Open Label, Single Arm Study to Assess the Safety and Efficacy of Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin|Completed||Phase 4|150|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:12:04.797139|2018-05-31 22:12:04.797139
NCT01426789|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|2015-02-12||2015-08-06|2011-08-30|2011-08-31|Estimate|2015-02-12|2015-03-02|Estimate||||2015-08-06|2015-08-10|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients|A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension|Completed||Phase 2|100|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:12:04.904173|2018-05-31 22:12:04.904173
NCT01426776|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2012-07-24|2011-08-30|2011-08-31|Estimate|||||||2012-07-24|2012-07-25|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|CSR||Effect of Heart Valve Replacement on Cheyne-Stokes Respiration|Effect of Heart Valve Replacement on Cheyne-Stokes Respiration in Patients With Rheumatic Heart Disease|Completed||N/A|26|Actual|Nanjing Medical University||1|||f||||f||||||||||2018-05-31 22:12:05.420668|2018-05-31 22:12:05.420668
NCT01426763|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2012-11-30||2014-03-19|2011-08-30|2011-08-31|Estimate|2012-11-30|2013-01-04|Estimate||||2014-03-19|2014-04-15|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase|An Open-label Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Hereditary Angioedema|Completed||Phase 2|12|Actual|Shire||2|||f||||f||||||||||2018-05-31 22:12:05.550624|2018-05-31 22:12:05.550624
NCT01426750|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2011-08-29|2011-08-29|2011-08-31|Estimate|||||||2011-08-29|2011-08-31|Estimate|June 2002||2002-06-30|August 2011|2011-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Enteral Nutrition Support in Children and Adolescents With Cancer|Enteral Nutrition Support in Children and Adolescents With Cancer: a Non-randomized Controlled Clinical Trial|Completed||Phase 4|||Grupo de Apoio ao Adolescente e a Crianca com Cancer||1|||f||||t||||||||||2018-05-31 22:12:06.227897|2018-05-31 22:12:06.227897
NCT01426737|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-08-29|2011-08-29|2011-08-31|Estimate|||||||2011-08-29|2011-08-31|Estimate|April 2011||2011-04-30|August 2011|2011-08-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||The Swiss Glucose Variability Study|The Swiss Glucose Variability Study|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Zurich|||||f||||t||||||||||2018-05-31 22:12:06.300242|2018-05-31 22:12:06.300242
NCT01426724|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2014-05-20|2011-08-30|2011-08-31|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease|Effects of Active Form of Vitamin D on Renal Blood Flow, Glomerular Filtration Rate, Proteinuria and Inflammation in Patients With Chronic Kidney Disease and Hyperparathyroidism|Withdrawn||N/A|0|Actual|University of Virginia||||Difficult to enroll eligible subjects.|f||||f||||||||||2018-05-31 22:12:06.389307|2018-05-31 22:12:06.389307
NCT01426711|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2018-04-27|2011-08-30|2011-08-31|Estimate|||||||2018-04-27|2018-04-30|Actual|September 2009||2009-09-30|April 2018|2018-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|CREST||Critical Care Excellence in Sepsis and Trauma|Critical Care Excellence in Sepsis and Trauma|Completed|||26|Actual|Medical University of South Carolina|||||f||||t||||||||||2018-05-31 22:12:06.526809|2018-05-31 22:12:06.526809
NCT01426685|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-12-09|2011-08-30|2011-08-31|Estimate|||||||2015-12-09|2015-12-10|Estimate|August 2007||2007-08-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ARTEMIS||Prognosis of Type 2 Diabetic Patients|Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology|Active, not recruiting|||1880|Actual|University of Oulu|||||f||||f||||||Samples With DNA|"~     Blood samples are stored for analysis of various biomarkers and for extracting DNAs.~   "|||2018-05-31 22:12:06.687107|2018-05-31 22:12:06.687107
NCT01426672|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-30|2011-08-30|2011-08-31|Estimate|||||||2011-08-30|2011-08-31|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Monovision for the Treatment of Diplopia|Monovision for Treatment of Diplopia|Completed||Phase 1|20|Actual|Mount Sinai Hospital, Canada||1|||f||||f||||||||||2018-05-31 22:12:06.825091|2018-05-31 22:12:06.825091
NCT01426659|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2015-06-02|2011-08-30|2011-08-31|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|LAMOPRESCO||Language and Motor Skills of Preterm Infants in Pre-school Age: Diagnosis and Early Intervention|Evaluation of Language and Sensorimotor Constraints of Very Premature Babies at the Age of 3 Years 1 / 2 Without Cerebral Palsy. Randomised Study of Stimulation Training Implicit in Children Vulnerable|Completed||N/A|139|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 22:12:06.976053|2018-05-31 22:12:06.976053
NCT01426646|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-01-03|2011-08-30|2011-08-31|Estimate|||||||2012-01-03|2012-01-05|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|September 2016|Anticipated|2016-09-30|September 2014|Anticipated|2014-09-30||Interventional|||S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer|Randomized Multicenter Phase II Trial of S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy After Curative Resection of Stage II-IV(M0) Gastric Cancer|Unknown status|Recruiting|Phase 2|218|Anticipated|Kyungpook National University||2|||f||||t||||||||||2018-05-31 22:12:07.079004|2018-05-31 22:12:07.079004
NCT01426633|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2014-12-15|2011-08-30|2011-08-31|Estimate|||||||2014-12-15|2014-12-16|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas|Phase I Dose Escalating Trial Evaluating the Combination of Gemcitabine and Trabectedin in Patients With Advanced and/or Metastatic Leiomyosarcoma or Liposarcoma|Completed||Phase 1|5|Actual|Heidelberg University||1|||f||||f||||||||||2018-05-31 22:12:07.254272|2018-05-31 22:12:07.254272
NCT01426620|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|||2018-03-01|2011-08-30|2011-08-31|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2011||2011-06-30|March 2018|2018-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|BIT-2||Standard Chemotherapy With Blueberry Powder in Non-Small Cell Lung Cancer|Salvage Therapy With Docetaxel and Blueberry Powder in Non-Small Cell Lung Cancer|Terminated||Phase 2|4|Actual|University of Louisville||1||slow accrual|f||||t||||||||||2018-05-31 22:12:07.356611|2018-05-31 22:12:07.356611
NCT01426607|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-12-12|2011-08-30|2011-08-31|Estimate|||||||2016-12-12|2016-12-13|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|VASO-AM||VASO-AM :Impact of Oral Appliance Therapy on Endothelial Function in Obstructive Sleep Apnea|VASO-AM :Impact of Oral Appliance Therapy on Endothelial Function in Obstructive Sleep Apnea|Completed||N/A|150|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 22:12:07.965575|2018-05-31 22:12:07.965575
NCT01426594|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-08-30|2011-08-30|2011-08-31|Estimate|||||||2011-08-30|2011-08-31|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Observational|XPERT||Real-life Experience of the Use of Isomers as METPURE XL (S (-) Metoprolol Succinate) for Evaluation of Efficacy, Safety and Tolerability in the Management of Cardiovascular Disease in Colombian Patients||Unknown status|Recruiting||2000|Anticipated|Closter Pharma|||||f||||||||||||||2018-05-31 22:12:08.083512|2018-05-31 22:12:08.083512
NCT01426581|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2013-09-04|2011-08-30|2011-08-31|Estimate|||||||2013-09-04|2013-09-05|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|E-TRaIN||Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)|Effectiveness of Interventions to Teach Respiratory Inhaler techNique (E-TRaIN)|Completed||Phase 2|100|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 22:12:08.476077|2018-05-31 22:12:08.476077
NCT01426568|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2013-08-27|2011-08-30|2011-08-31|Estimate|||||||2013-08-27|2013-08-28|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Trial of Multi-convergent Therapy for Functional Symptoms and Stress in Patients With Inflammatory Bowel Disease|A Randomised Controlled Trial of Multi-convergent Therapy for Inflammatory Bowel Disease Patients With Functional Abdominal Symptoms and High Perceived Stress|Completed||Phase 1/Phase 2|66|Actual|Cardiff and Vale University Health Board||2|||f||||t||||||||||2018-05-31 22:12:08.573259|2018-05-31 22:12:08.573259
NCT01426555|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2016-01-14||2016-03-11|2011-08-30|2011-08-31|Estimate|2016-03-08|2016-03-10|Estimate||||2016-03-11|2016-04-11|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)|FES-Rowing Versus Zoledronic Acid to Improve Bone Health in SCI: A Comparative Clinical Trial|Terminated||Phase 2/Phase 3|70|Actual|Boston VA Research Institute, Inc.|No Data Safety Monitor Board established for this project. Incomplete data set and analysis.|2||Incomplete data set & analysis|f||||f||||||||No|The study has been closed by the VABHS IRB.|2018-05-31 22:12:08.693647|2018-05-31 22:12:08.693647
NCT01426542|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-06-26|2011-08-29|2011-08-31|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2011||2011-03-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Preventing Brain Injury in Infants With Congenital Heart Disease|Pilot Study of Topiramate Prophylaxis in Infants Undergoing Surgery for Congenital Heart Disease|Active, not recruiting||Phase 1|24|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 22:12:09.232355|2018-05-31 22:12:09.232355
NCT01426529|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-03-21|2011-08-30|2011-08-31|Estimate|||||||2017-03-21|2017-03-23|Actual|October 1, 2010|Actual|2010-10-01|March 2017|2017-03-31|October 15, 2017|Anticipated|2017-10-15|October 15, 2017|Anticipated|2017-10-15||Interventional|||Caveolin-1 and Vascular Dysfunction|Caveolin-1 and Vascular Dysfunction|Active, not recruiting||Phase 1|120|Anticipated|Brigham and Women's Hospital|||||f||||t||||||||||2018-05-31 22:12:10.811709|2018-05-31 22:12:10.811709
NCT01426516|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2015-08-25||2015-10-28|2011-08-30|2011-08-31|Estimate|2015-10-28|2015-11-30|Estimate||||2015-10-28|2015-11-30|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PAGE-1_AG1||Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)|A Six-month Study of the Genecept Assay vs. Treatment as Usual to Evaluate Efficacy of Using Assay Guided Treatment in Outpatient Adults With Treatment Resistant Depression|Terminated||N/A|29|Actual|Genomind, LLC||2||Invalid data collection|f||||t||||||||||2018-05-31 22:12:10.919048|2018-05-31 22:12:10.919048
NCT01426464|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|||2011-08-29|2011-08-29|2011-08-31|Estimate|||||||2011-08-29|2011-08-31|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy|Phase 2 Study of Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy|Unknown status|Not yet recruiting|Phase 2|22|Anticipated|Nanduri, Padma, M.D., FACS|||||f||||f||||||||||2018-05-31 22:12:11.487633|2018-05-31 22:12:11.487633
NCT01426451|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2014-03-26|2011-08-29|2011-08-31|Estimate|||||||2014-03-26|2014-03-27|Estimate|November 2011||2011-11-30|March 2014|2014-03-31||||December 2012|Actual|2012-12-31||Interventional|||Assessment of a Drama Workshop Program for Immigrant and Refugee Adolescents|Assessment of a Drama Workshop Program for Immigrant and Refugee Adolescents|Completed||N/A|464|Actual|McGill University Health Center||3|||f||||||||||||||2018-05-31 22:12:11.590329|2018-05-31 22:12:11.590329
NCT01426438|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|2014-10-15||2016-01-04|2011-08-30|2011-08-31|Estimate|2014-10-15|2014-10-21|Estimate||||2016-01-04|2016-02-03|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate|Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate|Completed||Phase 2|99|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 22:12:11.695156|2018-05-31 22:12:11.695156
NCT01426425|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2016-09-22|2016-08-02|2017-02-14|2011-08-29|2011-08-31|Estimate|2017-02-14|2017-03-31|Actual|2016-08-02|2016-08-04|Estimate|2017-02-14|2017-03-31|Actual|May 2012||2012-05-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional||The modified intent-to-treat (mITT) set consists of subjects who signed the ICY-AVNRT consent form and met all Pre-EP and Post-EP study inclusion and no exclusion criteria who had a Freezor Xtra Cardiac Cryoablation Catheter inserted into the vasculature for the purpose of the ICY-AVNRT study.|Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia|ICY-AVNRT (Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia)|Completed||Phase 3|572|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||t||||||||||2018-05-31 22:12:12.692866|2018-05-31 22:12:12.692866
NCT01426412|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2013-08-15|2011-08-29|2011-08-31|Estimate|||||||2013-08-15|2013-08-16|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Subjects With Elevated LDL-C|Completed||Phase 1|68|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 22:12:13.206327|2018-05-31 22:12:13.206327
NCT01426399|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-12-27|2011-08-29|2011-08-31|Estimate|||||||2011-12-27|2011-12-30|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects|Completed||Phase 1|30|Actual|LG Life Sciences||3|||f||||||||||||||2018-05-31 22:12:13.28162|2018-05-31 22:12:13.28162
NCT01426386|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30||2013-04-12|2013-06-17|2011-08-30|2011-08-31|Estimate||||2013-04-12|2013-04-19|Estimate|2013-06-17|2013-06-25|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|April 2012|Actual|2012-04-30||Interventional|||A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multi-national, Multi-centre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Women Undergoing an ART Programme|Completed||Phase 2|265|Actual|Ferring Pharmaceuticals||6|||f||||t||||||||||2018-05-31 22:12:13.337603|2018-05-31 22:12:13.337603
NCT01426373|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2015-12-08|2014-05-30|2015-12-08|2011-08-30|2011-08-31|Estimate|2015-12-08|2016-01-14|Estimate|2014-05-30|2014-06-17|Estimate|2015-12-08|2016-01-14|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area|Multicenter, Open-label Study of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|165|Actual|Kythera Biopharmaceuticals||1|||f||||f||||||||||2018-05-31 22:12:14.489354|2018-05-31 22:12:14.489354
NCT01426360|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2011-10-01||2011-11-14|2011-08-30|2011-08-31|Estimate|2011-11-14|2011-12-19|Estimate||||2011-11-14|2011-12-19|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Instant and Lasting Relief Effects of Strontium Chloride/Potassium Nitrate Dentifrice on Dentin Hypersensitivity|A Randomized, Double-blind Clinical Trial to Assess the Instant and Lasting Relief Effects of a Dentifrice Containing 2% Strontium Chloride and 5% Potassium Nitrate on Dentin Hypersensitivity|Completed||N/A|79|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:12:14.962129|2018-05-31 22:12:14.962129
NCT01426347|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2016-09-14||2017-01-27|2011-08-30|2011-08-31|Estimate|2017-01-27|2017-03-20|Actual||||2017-01-27|2017-03-20|Actual|January 2009||2009-01-31|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis|Vitamin Therapy in Rheumatoid Arthritis|Completed||N/A|139|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:12:16.012768|2018-05-31 22:12:16.012768
NCT01426334|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2014-04-01|2011-08-30|2011-08-31|Estimate|||||||2014-04-01|2014-04-02|Estimate|September 2011||2011-09-30|June 2013|2013-06-30||||June 2012|Actual|2012-06-30||Interventional|||Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate|Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia (ESCAPE1b)|Terminated||Phase 1|4|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:12:16.301698|2018-05-31 22:12:16.301698
NCT01426321|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2018-04-12|2011-08-30|2011-08-31|Estimate|||||||2018-04-12|2018-04-13|Actual|August 2011||2011-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|CRT clinic||Combining Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in CRT Treatment|Individually Tailored Cardiac Resynchronization Therapy - Combing Myocardial Strain and Cardiac CT to Optimize Left Ventricular Lead Placement in Cardiac Resynchronization Therapy|Active, not recruiting||N/A|100|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:12:16.384933|2018-05-31 22:12:16.384933
NCT01426308|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2016-04-26|2011-08-30|2011-08-31|Estimate|||||||2016-04-26|2016-04-28|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test|Method Comparison and Clinical Specificity Study: Evaluation of the Infinium HD Cytogenetic Abnormality Test|Completed|||900|Actual|Illumina, Inc.|||2||f||||f||||||||No||2018-05-31 22:12:16.459113|2018-05-31 22:12:16.459113
NCT01426295|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2016-05-02|2011-08-30|2011-08-31|Estimate|||||||2016-05-02|2016-05-03|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|Caphosol||Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital|Pharmaco-economic Cost-effective Prospective Randomized Trial Evaluating the Open Interest Caphosol ® Mouthwashes in the Prevention and Treatment of Severe Oral Mucositis in Patients Receiving High-dose Chemotherapy in Hematology|Completed||Phase 2|92|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 22:12:16.609524|2018-05-31 22:12:16.609524
NCT01426282|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-29|2011-08-29|2011-08-31|Estimate|||||||2011-08-29|2011-08-31|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Effects of Health Education in Cardiovascular Diseases Prevention and Treatment|The Effects of Health Education Given by Nurse on Out-patient Compliance in Cardiovascular Diseases Prevention and Treatment in China|Completed||N/A|5|Actual|Harbin Medical University||2|||f||||f||||||||||2018-05-31 22:12:16.696279|2018-05-31 22:12:16.696279
NCT01426269|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2013-12-17||2014-07-08|2011-08-29|2011-08-31|Estimate|2014-07-08|2014-08-04|Estimate||||2014-07-08|2014-08-04|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||The safety population included 235 enrolled subjects. However, Baseline demographics were based on the ITT population which included 230 subjects; 5 subjects were excluded from this population due to consent issues.|Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo|Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea|Completed||Phase 4|235|Actual|Galderma Laboratories, L.P.||3|||f||||f||||||||||2018-05-31 22:12:16.811857|2018-05-31 22:12:16.811857
NCT01426256|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2017-07-11|2011-08-30|2011-08-31|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2011||2011-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|DISC||Vitamin D for Enhancing the Immune System in Cystic Fibrosis (DISC Study)|Vitamin D for Enhancing the Immune System in Cystic Fibrosis|Completed||Phase 3|91|Actual|Emory University||2|||f||||t||||||||||2018-05-31 22:12:17.486027|2018-05-31 22:12:17.486027
NCT01426243|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-02-26|2011-08-30|2011-08-31|Estimate|||||||2018-02-26|2018-02-27|Actual|July 2011||2011-07-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|November 2017|Actual|2017-11-30||Interventional|EP46 NOVAA||The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.|The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient|Active, not recruiting||Phase 3|71|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||f||||||||||2018-05-31 22:12:17.579394|2018-05-31 22:12:17.579394
NCT01426230|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2013-01-11||2013-03-18|2011-08-30|2011-08-31|Estimate|2013-03-18|2013-03-21|Estimate||||2013-03-18|2013-03-21|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Observational|||Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia|A Phase 4, Open Label, Study of Safety and Effectiveness of GRALISE™(Gabapentin) Tablets in the Treatment of Patients With Postherpetic Neuralgia in Clinical Practice|Completed|||201|Actual|Depomed|||2||f||||f||||||||||2018-05-31 22:12:17.67573|2018-05-31 22:12:17.67573
NCT01426217|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-12-13|2011-08-30|2011-08-31|Estimate|||||||2011-12-13|2011-12-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:12:18.012682|2018-05-31 22:12:18.012682
NCT01426204|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-08-30|2011-08-30|2011-08-31|Estimate|||||||2011-08-30|2011-08-31|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|August 2013|Anticipated|2013-08-31|June 2012|Anticipated|2012-06-30||Observational|OBSERVER||Efficacy, Safety and Adherence of Patients Infected With Hepatitis C Virus in Retreat With INFERGEN (Interferon Alfacon1)||Unknown status|Not yet recruiting||40|Anticipated|Closter Pharma|||||f||||f||||||||||2018-05-31 22:12:18.060175|2018-05-31 22:12:18.060175
NCT01426191|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2012-09-10|2011-08-30|2011-08-31|Estimate|||||||2012-09-10|2012-09-11|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|November 2013|Anticipated|2013-11-30|August 2013|Anticipated|2013-08-31||Observational|SWSB||Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|A Open Multi-center Clinical Study on Cefotaxime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary Tract Infection|Unknown status|Enrolling by invitation||2000|Anticipated|Xiangbei Welman Pharmaceutical Co., Ltd|||1||f||||t||||||||||2018-05-31 22:12:18.115829|2018-05-31 22:12:18.115829
NCT01426178|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-07-04|2011-08-30|2011-08-31|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Neurally Adjusted Ventilatory Assist (NAVA) in NonInvasive Ventilation (NIV)|Neurally Adjusted Ventilatory Assist (NAVA) in NonInvasive Ventilation (NIV)|Completed||Phase 1|17|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:12:18.196581|2018-05-31 22:12:18.196581
NCT01426165|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-01-31|2011-08-29|2011-08-31|Estimate|||||||2014-01-31|2014-02-04|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients|Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients|Terminated||N/A|5|Actual|CAMC Health System||2||Issues with recruitment. PI decided to terminate study|f||||f||||||||||2018-05-31 22:12:18.270741|2018-05-31 22:12:18.270741
NCT01426152|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2011-08-29|2011-08-29|2011-08-31|Estimate|||||||2011-08-29|2011-08-31|Estimate|January 2006||2006-01-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|ProgBBN||Progesterone on the Day of Ovulation Induction is Associated With Pregnancy Outcome|Association Between Progesterone Levels on the Day of Ovulation Induction and IVF Outcome: Retrospective Study With 2500 Controlled Ovarian Stimulations Cycles|Completed|||2555|Actual|Bollmann Bruckner Noss|||3||f||||t||||||||||2018-05-31 22:12:18.36371|2018-05-31 22:12:18.36371
NCT01426139|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-04-03|2011-08-30|2011-08-31|Estimate|||||||2013-04-03|2013-04-04|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||BIOFLOW-INDIA Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in Single de Novo Coronary Artery Lesions|BIOTRONIK-Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in the Treatment of Patients With Single de Novo Coronary Artery Lesions in an Indian Population|Completed||N/A|120|Actual|Biotronik AG||1|||f||||t||||||||||2018-05-31 22:12:18.433065|2018-05-31 22:12:18.433065
NCT01426126|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-12-06|2011-08-30|2011-08-31|Estimate|||||||2011-12-06|2011-12-07|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|||Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum|Phase II Study of Genexol-PM, a Cremophor-free, Polymeric Micelle Formulation of Paclitaxel for Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum|Completed||Phase 2|37|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:12:18.508858|2018-05-31 22:12:18.508858
NCT01426113|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2015-06-29||2015-09-02|2011-08-29|2011-08-31|Estimate|2015-09-02|2015-10-02|Estimate||||2015-09-02|2015-10-02|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma||Terminated||Phase 3|6|Actual|Allergan||2||Study terminated due to corporate decision.|f||||t||||||||||2018-05-31 22:12:18.597334|2018-05-31 22:12:18.597334
NCT01426100|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2012-09-11|2011-08-30|2011-08-31|Estimate|||||||2012-09-11|2012-09-13|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||CKD-828 Telmisartan Non-Responder Trial|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy|Completed||Phase 3|183|Actual|Chong Kun Dang Pharmaceutical||3|||f||||||||||||||2018-05-31 22:12:18.826648|2018-05-31 22:12:18.826648
NCT01426087|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2011-08-31|2011-08-30|2011-08-31|Estimate|||||||2011-08-31|2011-09-02|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices|Investigator Sponsored Study of Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices|Unknown status|Recruiting|N/A|126|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 22:12:18.941062|2018-05-31 22:12:18.941062
NCT01426074|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2016-09-23|2011-08-30|2011-08-31|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2011||2011-08-31|September 2016|2016-09-30||||August 2014|Actual|2014-08-31||Interventional|||DCE-MRI PET Bevacizumab Study in Rectal Cancer|A Phase II/Pharmacodynamic Study of Preoperative or Definitive FOLFOX Plus Bevacizumab, With the Additional Pharmacodynamic Goal of Assessing Tumor Blood Flow as Measured by Dynamic Contrast-enhanced MRI, and the Induction of Hypoxia and Apoptosis as Measured by PET in Patients With Rectal Cancer|Active, not recruiting||Phase 2|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:12:19.031696|2018-05-31 22:12:19.031696
NCT01426061|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-29|2011-08-29|2011-08-30|Estimate|||||||2011-08-29|2011-08-30|Estimate|May 2006||2006-05-31|August 2011|2011-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Clinical Effect of Reflexology and Homeopathy Added to Conventional Asthma Management|Effect of Reflexology, Homeopathy and Conventional Medical Treatment in Asthma: A Randomised Controlled, Parallel Group Trial.|Completed||N/A|98|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 22:12:19.110406|2018-05-31 22:12:19.110406
NCT01426048|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-01-21|2011-08-29|2011-08-30|Estimate|||||||2013-01-21|2013-01-23|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|||||Observational|||Long-term Outcome of the TVT Procedure Without Preoperative Urodynamic Examination|Long-term Outcome of the TVT Procedure Without Preoperative Urodynamic Examination|Completed|||138|Actual|Turku University Hospital|||1||f||||||||||||||2018-05-31 22:12:19.204945|2018-05-31 22:12:19.204945
NCT01426035|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-03-01|2011-08-29|2011-08-30|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2014||2014-09-30|March 2013|2013-03-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate Cream In The Superficial Varicose Veins Treatment|Phase III of Safety and Efficacy Study of Topic Mucopolysaccharide Polysulfate Cream 5mg/g in the Superficial Varicose Veins Treatment|Suspended||Phase 3|76|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2018-05-31 22:12:19.266213|2018-05-31 22:12:19.266213
NCT01426022|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2012-10-17|2011-08-29|2011-08-30|Estimate|||||||2012-10-17|2012-10-18|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Moderate Alcohol Consumption on Postprandial Mood|The Effect of Moderate Alcohol Consumption With a Meal in Different Ambiances on Postprandial Mood, Evaluated by Subjective and Physiological Responses|Completed||N/A|28|Actual|TNO||2|||f||||f||||||||||2018-05-31 22:12:19.335208|2018-05-31 22:12:19.335208
NCT01426009|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2018-01-02|2013-12-18|2018-05-08|2011-08-29|2011-08-30|Estimate|2018-04-03|2018-05-07|Actual|2013-12-18|2014-01-24|Estimate|2018-05-08|2018-05-09|Actual|August 2011||2011-08-31|May 2018|2018-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||modified Intent to Treat population for analysis set|Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 (SUN101) in Subjects With Moderate to Severe COPD|Completed||Phase 2|140|Actual|Sunovion Respiratory Development Inc.||7|||f||||f||||||||||2018-05-31 22:12:19.463209|2018-05-31 22:12:19.463209
NCT01425996|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2013-04-16|2011-08-29|2011-08-30|Estimate|||||||2013-04-16|2013-04-17|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|||A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma|A Phase I/II, Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Taiwan Liposome Company||1|||f||||t||||||||||2018-05-31 22:12:20.419445|2018-05-31 22:12:20.419445
NCT01425983|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-09-04|2011-08-29|2011-08-30|Estimate|||||||2015-09-04|2015-09-07|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|asn01||Dietary Intervention of Stress-Induced Neurovegetative Disorders With a Specific Amino Acid Composition (asn01)|Dietary Intervention of Stress-Induced Neurovegetative Disorders in Men and Women With a Specific Amino Acid Composition With Micronutrients|Completed||Phase 3|80|Actual|Kyberg Vital GmbH||2|||f||||f||||||||||2018-05-31 22:12:20.511802|2018-05-31 22:12:20.511802
NCT01425632|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|2015-09-17||2015-11-10|2011-08-28|2011-08-30|Estimate|2015-11-10|2015-12-14|Estimate||||2015-11-10|2015-12-14|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis|A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)|Completed||Phase 3|490|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 22:12:28.320456|2018-05-31 22:12:28.320456
NCT01425970|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25||2015-09-23|2015-10-12|2011-08-29|2011-08-30|Estimate||||2015-09-23|2015-10-09|Estimate|2015-10-12|2015-11-04|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin|A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment With Daclatasvir and/or Ribavirin (Copegus®) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects|Terminated||Phase 2|210|Actual|Bristol-Myers Squibb||9||Termination of study was due to safety reasons|f||||t||||||||||2018-05-31 22:12:20.610358|2018-05-31 22:12:20.610358
NCT01425957|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-10-30|2011-08-29|2011-08-30|Estimate|||||||2015-10-30|2015-11-02|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment|Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment: a Two-part Clinical Study. PartA: Multisite MRI Acquisition, Protocol Harmonization. PartB: Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment: a Clinical Study|Completed||N/A|229|Actual|Qualissima||1|||f||||f||||||||||2018-05-31 22:12:20.74716|2018-05-31 22:12:20.74716
NCT01425944|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2017-09-11|2011-08-29|2011-08-30|Estimate|||||||2017-09-11|2017-09-12|Actual|September 2010||2010-09-30|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome|The Brain Vascular Malformations Clinical Research Network: Predictors of Clinical Course, Project 2: Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome|Recruiting|||600|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|||||f||||f||||||Samples With DNA|"~     Aim 1 retains data and samples without DNA. Aim 2 retains data without DNA. Aim 3 retains~     anonymous data with DNA.~   "|||2018-05-31 22:12:20.867073|2018-05-31 22:12:20.867073
NCT01425931|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2014-08-05|2011-08-29|2011-08-30|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Gastrointestinal Microcirculation During Cardiopulmonary Bypass||Completed|||50|Anticipated|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||||||2018-05-31 22:12:20.961485|2018-05-31 22:12:20.961485
NCT01425918|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2018-05-21|2011-08-29|2011-08-30|Estimate|||||||2018-05-21|2018-05-22|Actual|January 2012||2012-01-31|May 2018|2018-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Social Cognitive Development in Young Children With Autism|Effects of Self-Generated Experiences on Social Cognitive Development in Young Children With Autism|Completed||N/A|61|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||||2018-05-31 22:12:21.01896|2018-05-31 22:12:21.01896
NCT01425905|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|||2018-05-23|2011-08-27|2011-08-30|Estimate|||||||2018-05-23|2018-05-24|Actual|August 23, 2011||2011-08-23|January 27, 2016|2016-01-27|August 10, 2015|Actual|2015-08-10|August 10, 2015|Actual|2015-08-10||Interventional|||Mood and Insulin Resistance in Adolescents At-Risk for Diabetes|Mood and Insulin Resistance in Adolescents At-Risk for Diabetes|Completed||Phase 2|174|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:12:21.103298|2018-05-31 22:12:21.103298
NCT01425892|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|||2018-05-23|2011-08-27|2011-08-30|Estimate|||||||2018-05-23|2018-05-24|Actual|August 27, 2011||2011-08-27|May 8, 2018|2018-05-08||||||||Observational|||The Pathogenesis and Natural History of Sjogren s Syndrome|The Pathogenesis and Natural History of Sjogren s Syndrome|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:12:21.182075|2018-05-31 22:12:21.182075
NCT01425879|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|2016-03-15||2016-05-16|2011-08-27|2011-08-30|Estimate|2016-03-15|2016-04-15|Estimate||||2016-05-16|2016-06-17|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery|A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers|Completed||Phase 2|8|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:12:21.268654|2018-05-31 22:12:21.268654
NCT01425866|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2017-09-04|2011-08-29|2011-08-30|Estimate|||||||2017-09-04|2017-09-06|Actual|October 2011|Actual|2011-10-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ERMIES||Two Years Maintenance of Structured Group Self-management Education in Type 2 Diabetes : a Randomized Controlled Trial|Multicenter Randomized Trial of Structured Educational Intervention at the Community Level in Insufficiently Controlled Patients With Type 2 Diabetes in Reunion Island|Completed||N/A|132|Actual|Centre Hospitalier Universitaire de la Réunion||2|||f||||f||||||||||2018-05-31 22:12:21.461688|2018-05-31 22:12:21.461688
NCT01425853|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2015-07-20||2016-01-29|2011-08-29|2011-08-30|Estimate|2016-01-29|2016-02-26|Estimate||||2016-01-29|2016-02-26|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|MOVES|PP population was defined as all randomized patients who met the inclusion criteria, received study medication, had a baseline efficacy measurement and at least one corresponding post-baseline efficacy measurement (for the main efficacy variable) and did not present major violations of the protocol (n=522).|Study on Efficacy and Safety of Chondroitin Sulfate + Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis|Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis|Completed||Phase 4|606|Actual|Bioiberica||2|||f||||t||||||||Undecided||2018-05-31 22:12:21.553258|2018-05-31 22:12:21.553258
NCT01425840|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-27|2011-08-27|2011-08-30|Estimate|||||||2011-08-27|2011-08-30|Estimate|March 2008||2008-03-31|August 2011|2011-08-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Liposomal Lidocaine Gel for Oral Topical Anesthesia|Efficacy of Liposome Lidocaine Gel for Topical Anesthesia in the Palatal Mucosa|Completed||Phase 1|40|Actual|University of Campinas, Brazil||1|||f||||t||||||||||2018-05-31 22:12:22.168328|2018-05-31 22:12:22.168328
NCT01425827|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-27|2011-08-27|2011-08-30|Estimate|||||||2011-08-27|2011-08-30|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Duloxetine for Pain in Older Adults With Knee Osteoarthritis (OA)||Completed||N/A|288|Actual|Faculty of Medicine, University of Alexandria|||||f||||t||||||||||2018-05-31 22:12:22.245453|2018-05-31 22:12:22.245453
NCT01425619|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2015-10-07|2011-08-29|2011-08-30|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests||Completed||N/A|160|Anticipated|Meir Medical Center||4|||f||||f||||||||||2018-05-31 22:12:29.363547|2018-05-31 22:12:29.363547
NCT01425814|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2017-01-03||2017-02-27|2011-08-29|2011-08-30|Estimate|2017-02-27|2017-04-10|Actual||||2017-02-27|2017-04-10|Actual|August 2011||2011-08-31|February 2017|2017-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population|A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|87|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 22:12:22.357943|2018-05-31 22:12:22.357943
NCT01425801|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|2017-02-27||2018-05-07|2011-08-29|2011-08-30|Estimate|2017-06-08|2018-01-26|Actual||||2018-05-07|2018-05-08|Actual|August 1, 2011|Actual|2011-08-01|April 2018|2018-04-30|February 1, 2012|Actual|2012-02-01|February 1, 2012|Actual|2012-02-01||Interventional|||Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.|A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.|Completed||Phase 2|62|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 22:12:23.615856|2018-05-31 22:12:23.615856
NCT01425788|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-06-25|2011-08-29|2011-08-30|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|Osiris||Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense|Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense|Completed||Phase 2|236|Actual|ALK-Abelló A/S||3|||f||||f||||||||||2018-05-31 22:12:25.827004|2018-05-31 22:12:25.827004
NCT01425775|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-27|2011-08-27|2011-08-30|Estimate|||||||2011-08-27|2011-08-30|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|||The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE)||Completed||N/A|248|Actual|Faculty of Medicine, University of Alexandria||2|||f||||t||||||||||2018-05-31 22:12:26.107765|2018-05-31 22:12:26.107765
NCT01425762|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2015-11-10|2011-08-29|2011-08-30|Estimate|||||||2015-11-10|2015-11-13|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Influence of Patient Choice of Intrathecal Morphine on Post-cesarean Delivery Pain.|Influence of Patient Choice of Intrathecal Morphine on Post-cesarean Delivery Pain.|Completed||N/A|120|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 22:12:26.435931|2018-05-31 22:12:26.435931
NCT01425749|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2015-12-13||2016-03-02|2011-08-29|2011-08-30|Estimate|2016-03-02|2016-04-04|Estimate||||2016-03-02|2016-04-04|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|July 2013|Actual|2013-07-31||Interventional|Mel55||Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI|T Cell Activation and Immune Cell Function in Melanoma Patients Treated With recMAGE-A3 + AS15 Immunological Adjuvant System|Completed||Early Phase 1|25|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 22:12:26.564968|2018-05-31 22:12:26.564968
NCT01425736|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2014-06-01|2011-08-29|2011-08-30|Estimate|||||||2014-06-01|2014-06-03|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|January 2011|Actual|2011-01-31||Interventional|||Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma|Phase 2 Study of Nimotuzumab in Combination With TPF for Head and Neck Squamous Cell Carcinoma|Completed||Phase 2|91|Actual|Shanghai 9th People's Hospital||2|||f||||t||||||||||2018-05-31 22:12:27.093472|2018-05-31 22:12:27.093472
NCT01425723|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2017-12-20|2011-08-29|2011-08-30|Estimate|||||||2017-12-20|2017-12-21|Actual|December 8, 2011|Actual|2011-12-08|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|B-YOND||Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B|An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B|Completed||Phase 3|120|Actual|Bioverativ Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 22:12:27.202461|2018-05-31 22:12:27.202461
NCT01425710|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-02-12|2011-08-27|2011-08-30|Estimate|||||||2014-02-12|2014-02-13|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma|Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma|Completed|||15|Actual|Medical University of Vienna|||2||f||||f||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-05-31 22:12:27.355835|2018-05-31 22:12:27.355835
NCT01425697|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2013-06-28|2011-08-28|2011-08-30|Estimate|||||||2013-06-28|2013-07-02|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|ERASE||Eliminate Risk of Cardiac Surgical Site Events|Randomized,Prospective Evaluation of 2% Chlorhexidine Gluconate Cloths to Reduce Surgical Site Infections in Cardiothoracic Surgery Patients|Completed||N/A|739|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 22:12:27.51999|2018-05-31 22:12:27.51999
NCT01425684|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2017-08-03|2011-08-29|2011-08-30|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2011||2011-01-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Brain Circuits in Schizophrenia and Smoking|Brain Circuits in Schizophrenia and Smoking|Recruiting|||800|Anticipated|University of Maryland|||2||f||||f||||||Samples With DNA|"~     -  Whole Blood~        -  Saliva~   "|No||2018-05-31 22:12:27.601108|2018-05-31 22:12:27.601108
NCT01425671|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2018-04-10|2011-08-29|2011-08-30|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2011||2011-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States|Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States|Recruiting|||800|Anticipated|University of Maryland|||2||f||||f||||||Samples With DNA|"~     Blood sample~   "|No||2018-05-31 22:12:27.676537|2018-05-31 22:12:27.676537
NCT01425658|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2012-05-16|2011-08-29|2011-08-30|Estimate|||||||2012-05-16|2012-05-17|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Comparison of Postoperative Analgesic Effect of Intrathecal Clonidine and Fentanyl Added to Bupivacaine in Patients Undergoing Cesarean Section||Completed||Phase 1/Phase 2|90|Actual|Qazvin University Of Medical Sciences||3|||f||||||||||||||2018-05-31 22:12:27.741756|2018-05-31 22:12:27.741756
NCT01425645|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-27|||2017-09-11|2011-08-29|2011-08-30|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2012||2012-01-31|September 2017|2017-09-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|FDD||Families Defeating Diabetes|Families Defeating Diabetes: Canadian Intervention for Family-Centered Diabetes Prevention Following Gestational Diabetes (GDM)|Completed||N/A|180|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 22:12:28.052351|2018-05-31 22:12:28.052351
NCT01425606|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-08-28|2011-08-28|2011-08-30|Estimate|||||||2011-08-28|2011-08-30|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Pseudohyponatremia of Multiple Myeloma is True Hyponatremia|a Study to Evaluate the Electrolyte Changes in Particular Sodium,in Multiple Myeloma and the Effect of the m- Proteins on the Strong Ion Difference|Unknown status|Not yet recruiting||50|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 22:12:29.476556|2018-05-31 22:12:29.476556
NCT01425593|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2012-11-04|2011-08-29|2011-08-30|Estimate|||||||2012-11-04|2012-11-06|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|March 2010|Actual|2010-03-31||Observational|||T Cell Function in Chronic Idiopathic Urticaria|T Cell Function in Chronic Idiopathic Urticaria|Unknown status|Recruiting||40|Anticipated|Meir Medical Center|||||f||||t||||||Samples Without DNA|"~     venous blood sample~   "|||2018-05-31 22:12:29.57914|2018-05-31 22:12:29.57914
NCT01425580|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2016-08-31|2011-08-29|2011-08-30|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Liraglutide and Heart Failure in Type 2 Diabetes|Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin|Completed||Phase 2|62|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:12:29.688853|2018-05-31 22:12:29.688853
NCT01425567|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2018-01-11|2011-08-29|2011-08-30|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2011||2011-08-31|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|Omegaven||Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury|Compassionate Use of an Intravenous Lipid Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Children|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 22:12:29.822529|2018-05-31 22:12:29.822529
NCT01425554|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-28|||2015-02-09|2011-08-29|2011-08-30|Estimate|||||||2015-02-09|2015-02-10|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Doppler Sonography, MR Venography, Plethysmography for the Diagnosis of CCSVI|Doppler Sonography, Magnetic Resonance Venography, Air-plethysmography in the Non-invasive Diagnostics of Chronic Cerebrospinal Venous Insufficiency (CCSVI)|Completed||N/A|126|Actual|Euromedic Specialist Clinics, Poland||1|||f||||t||||||||||2018-05-31 22:12:29.908288|2018-05-31 22:12:29.908288
NCT01425541|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-09-03|2011-08-29|2011-08-30|Estimate|||||||2015-09-03|2015-09-07|Estimate|April 2000||2000-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition|Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition in Normal and Hyperandrogenemic Adolescent Girls (JCM010)|Completed||N/A|60|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:12:29.988836|2018-05-31 22:12:29.988836
NCT01425528|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2014-01-08||2014-03-03|2011-08-26|2011-08-30|Estimate|2014-03-03|2014-04-08|Estimate||||2014-03-03|2014-04-08|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of Kuvan Treatment in Adults With GTPCH Deficiency|Pilot Study to Assess Impact of Kuvan® Supplementation as an Adjunct Treatment in Subjects With Dominantly-inherited GTPCH Deficiency on Mood, Behavioral and Motor Phenotypes|Completed||Phase 1/Phase 2|12|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:12:30.056656|2018-05-31 22:12:30.056656
NCT01425515|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2014-11-17|2011-08-29|2011-08-30|Estimate|||||||2014-11-17|2014-11-19|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Improving Care for Patients With High Blood Pressure|Heart Healthy Lenoir: Improving Care for Patients With High Blood Pressure|Completed||N/A|535|Actual|University of North Carolina, Chapel Hill|||||f||||t||||||||||2018-05-31 22:12:31.097569|2018-05-31 22:12:31.097569
NCT01425502|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2016-01-31|2011-08-29|2011-08-30|Estimate|||||||2016-01-31|2016-02-02|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DQIP||Data-driven Quality Improvement in Primary Care - Trial|Data-driven Quality Improvement in Primary Care: Cluster Randomised Controlled Trial to Test the Effectiveness of a Multifaceted Intervention in Reducing High Risk Prescribing of Non-steroidal Anti-inflammatory Drugs and Antiplatelet Agents|Completed||N/A|33|Actual|University of Dundee||1|||f||||t||||||||Undecided|Follow up data is routinely collected clinical data. The trial team are data processors not data controllers, so cannot make the decision to share, although an application to share can be made to the National Health Service data controllers.|2018-05-31 22:12:31.787234|2018-05-31 22:12:31.787234
NCT01425489|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2018-02-05|2011-08-29|2011-08-30|Estimate|||||||2018-02-05|2018-02-06|Actual|August 2011||2011-08-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|BioKrabbe||Biomarker for Krabbe Disease|Biomarker for Krabbe Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||250|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml EDTA~     blood and a dry blood spot filter card are taken. To proof the correct Krabbe diagnosis in~     those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing of Krabbe will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 22:12:31.96787|2018-05-31 22:12:31.96787
NCT01425476|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2017-08-08|2011-08-29|2011-08-30|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2008||2008-07-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors|Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study)|Completed||Phase 1/Phase 2|45|Actual|Hartford Hospital||3|||f||||f||||||||||2018-05-31 22:12:32.081426|2018-05-31 22:12:32.081426
NCT01425463|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2014-10-30||2015-05-08|2011-08-26|2011-08-30|Estimate|2014-10-30|2014-11-06|Estimate||||2015-05-08|2015-06-01|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional||Baseline Characteristics refer to the Full Analysis Set (FAS). FAS consists of all enrolled subjects who took at least one dose of study medicine and have at least one post-baseline effectiveness measurement (Hemoglobin-value). It also includes subjects with protocol deviance and incomplete data due to withdrawal.|A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects|A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy|Completed||Phase 3|256|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 22:12:32.279201|2018-05-31 22:12:32.279201
NCT01425450|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2011-10-28|2011-08-26|2011-08-30|Estimate|||||||2011-10-28|2011-10-31|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety Study of Four Doses of the Study Drug, HF1020 in Healthy Volunteers|A Randomised, Double-blind Placebo-controlled Study to Assess the Safety of Four Single Ascending Doses of HF1020 in Healthy Male Subjects|Completed||Phase 1|32|Actual|Trident Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 22:12:32.918815|2018-05-31 22:12:32.918815
NCT01425437|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2014-11-14|2011-08-26|2011-08-30|Estimate|||||||2014-11-14|2014-11-18|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Keloid Tissue Bank|Keloid Tissue Bank - Longitudinal Clinical Data Repository; A Genomic and Molecular Research to Identifying Molecular Markers and Signal Transduction Pathways in Keloid; and Correlations With the Natural History of the Disease.|Terminated|||78|Actual|Tirgan, Michael H., M.D.|||1|Poor Enrollment|f||||f||||||Samples With DNA|"~     Sample of keloid tissue and small amount of normal appearing skin from an area that is~     adjacent to the keloid will be collected from each participant. Each patient may undergo one~     or more biopsies during the span of this study. Tissue biopsy may be repeated from the same~     or a different keloid in the same patient. Patients may be re-contacted for additional blood~     or other tissue samples.~   "|||2018-05-31 22:12:32.990375|2018-05-31 22:12:32.990375
NCT01425424|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-12-17|2011-08-29|2011-08-30|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Prediabetes, Prehypertension and Vitamin D Supplementation - A Practice Based Clinical Intervention Pilot Study|Prediabetes, Prehypertension and Vitamin D Supplementation - A Practice Based Clinical Intervention Pilot Study|Terminated||N/A|18|Actual|Pennington Biomedical Research Center||3||The PI was leaving Pennington|f||||f||||||||||2018-05-31 22:12:33.106848|2018-05-31 22:12:33.106848
NCT01425411|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-29|2011-08-29|2011-08-30|Estimate|||||||2011-08-29|2011-08-30|Estimate|November 2006||2006-11-30|August 2011|2011-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy|Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy|Completed||Phase 4|38|Actual|Mustafa Kemal University||1|||f||||||||||||||2018-05-31 22:12:33.223117|2018-05-31 22:12:33.223117
NCT01425398|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2011-08-29|2011-08-29|2011-08-30|Estimate|||||||2011-08-29|2011-08-30|Estimate|November 2011||2011-11-30|August 2011|2011-08-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||A Trial to Evaluate the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery|A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Effect of Rosuvastatin on Inflammation in Patients Undergoing Isolated Cardiac Valve Surgery|Unknown status|Not yet recruiting|Phase 3|170|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:12:33.388866|2018-05-31 22:12:33.388866
NCT01425385|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2017-08-17|2011-08-29|2011-08-30|Estimate|||||||2017-08-17|2017-08-22|Actual|September 2011||2011-09-30|August 2017|2017-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Autoregulation Assessment During Liver Transplantation|Non-Invasive Assessment of Cerebral Blood Flow Autoregulation in Patients Undergoing Liver Transplantation|Completed|||10|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 22:12:33.626402|2018-05-31 22:12:33.626402
NCT01425372|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-07-22|2011-08-29|2011-08-30|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|June 2013|Actual|2013-06-30|May 2012|Actual|2012-05-31||Observational|P13UK||Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months|A Prospective Study to Evaluate the Immune Response of UK Infants Receiving the 13-valent Pneumococcal Conjugate Vaccine as Part of Their Routine Primary Immunisation Schedule at 2 and 4 Months|Completed|||93|Actual|Public Health England|||||f||||t||||||||||2018-05-31 22:12:34.57612|2018-05-31 22:12:34.57612
NCT01425359|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2014-10-20|2013-10-08|2014-10-30|2011-08-26|2011-08-30|Estimate|2014-10-30|2014-11-04|Estimate|2013-10-08|2013-11-01|Estimate|2014-10-30|2014-11-04|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|TERISA|Safety Analysis Set: randomized participants who received at least one dose of study treatment.|Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina|A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus|Completed||Phase 4|949|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 22:12:34.810125|2018-05-31 22:12:34.810125
NCT01425346|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-26|2011-08-26|2011-08-30|Estimate|||||||2011-08-26|2011-08-30|Estimate|June 2011||2011-06-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||ClearPath DS-120 Clinical Study Protocol|Freedom Meditech ClearPath DS-120 Clinical Study Protocol FM2-002-CTP|Completed|||128|Actual|Freedom Meditech|||1||f||||f||||||||||2018-05-31 22:12:35.87951|2018-05-31 22:12:35.87951
NCT01425333|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-26|2011-08-26|2011-08-30|Estimate|||||||2011-08-26|2011-08-30|Estimate|April 2011||2011-04-30|August 2011|2011-08-31|February 2013|Anticipated|2013-02-28|August 2012|Anticipated|2012-08-31||Interventional|||The Impact of Surgical Treatment of Endometriomas on Ovarian Reserve|The Impact of Surgical Treatment of Ovarian Endometriomas on Ovarian Reserve: a Randomised Controlled Trial of Laparoscopic Ovarian Cystectomy Versus Cyst Ablation - a Pilot Study|Unknown status|Recruiting|N/A|20|Anticipated|Derby Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:12:35.958021|2018-05-31 22:12:35.958021
NCT01425320|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2012-11-16|2011-08-26|2011-08-30|Estimate|||||||2012-11-16|2012-11-19|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne||Withdrawn||Phase 1|0|Actual|Allergan||4||"Study was never initiated due to company decision. No study subjects were ever enrolled or~   dosed."|f||||f||||||||||2018-05-31 22:12:36.060232|2018-05-31 22:12:36.060232
NCT01425307|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2016-04-13||2017-05-02|2011-08-26|2011-08-30|Estimate|2017-02-28|2017-04-11|Actual||||2017-05-02|2017-05-31|Actual|August 2011||2011-08-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|TWiTCH||Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea|TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities|Terminated||Phase 3|159|Actual|Children's Hospital Medical Center, Cincinnati|Further analysis is required to verify that the Adverse Events are accurately represented.|2||The study was stopped early due to successfully meeting the primary endpoint|f||||t||||||||No||2018-05-31 22:12:36.208028|2018-05-31 22:12:36.208028
NCT01425294|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2017-12-04|2011-08-26|2011-08-30|Estimate|||||||2017-12-04|2017-12-05|Actual|August 1, 2011|Actual|2011-08-01|December 2017|2017-12-31|January 30, 2016|Actual|2016-01-30|January 30, 2016|Actual|2016-01-30||Observational|||Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment|A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice|Terminated|||231|Actual|AstraZeneca||||"The study has been decided to be early terminated for the FAS 500 mg has launched in 2015. The~   use mothod of 250mg per month in clinical practice is off-label."|f||||t||||||||||2018-05-31 22:12:36.954754|2018-05-31 22:12:36.954754
NCT01425281|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2016-10-27|2011-08-29|2011-08-30|Estimate|||||||2016-10-27|2016-10-31|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Interventional|ABSORB II||ABSORB II Randomized Controlled Trial|ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions|Active, not recruiting||N/A|501|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 22:12:37.088531|2018-05-31 22:12:37.088531
NCT01425268|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2017-02-26||2017-05-23|2011-08-29|2011-08-30|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|October 2011||2011-10-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|XPAND||Patient Controlled Tissue Expansion for Breast Reconstruction|AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction|Completed||N/A|158|Actual|AirXpanders, Inc.|"Device improvements occurred during the study with later subjects completing the study with a revised version of the device.~Results include all subjects treated in the study, regardless of device version."|2|||f||||t||t|f|||||No||2018-05-31 22:12:37.307071|2018-05-31 22:12:37.307071
NCT01425255|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2016-06-18|2011-08-26|2011-08-29|Estimate|||||||2016-06-18|2016-06-21|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||The Impact of Continuous Glucose Monitoring Use on Sleep in Parents of Children With Type 1 Diabetes Mellitus|Prospective Exploratory Study Evaluating Sleep Quality and Sleep-Wake Patterns in Parents of Children With Type 1 Diabetes Before and Several Weeks After Initiating Using RT-CGM of Their Children.|Withdrawn|||0|Actual|Wolfson Medical Center|||1|Enrollment finished and a paper was published.|f||||f||||||||||2018-05-31 22:12:37.670453|2018-05-31 22:12:37.670453
NCT01425242|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2014-12-08|2011-08-26|2011-08-29|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PISA||Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension|An Open-label PET-observer-blinded Pilot Study of the Effect of Aliskiren- Versus Amlodipine-based Antihypertensive Treatment in Patients With Small Abdominal Aortic Aneurysm and Mild to Moderate Hypertension on Aneurysmal FDG-uptake|Terminated||N/A|3|Actual|VU University Medical Center||2||Insufficient number of participants|f||||f||||||||||2018-05-31 22:12:37.729527|2018-05-31 22:12:37.729527
NCT01425229|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2014-07-08||2017-05-03|2011-08-26|2011-08-29|Estimate|2015-07-07|2015-08-04|Estimate||||2017-05-03|2017-05-31|Actual|June 2011||2011-06-30|May 2017|2017-05-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Observational|||Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During Clarithromycin|Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Steady State Bosentan Before and During CYP3A4-inhibition by Clarithromycin|Completed|||16|Actual|Heidelberg University|||1||f||||f||||||||||2018-05-31 22:12:37.885743|2018-05-31 22:12:37.885743
NCT01425216|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2016-10-17|2011-08-26|2011-08-29|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Sorafenib for Patients With Extensive Keloids|Phase II Trial of Sorafenib in Patients With Extensive Keloids|Terminated||Phase 2|60|Anticipated|Tirgan, Michael H., M.D.||1||IND application was not approved by the US FDA - Project was never started|f||||f||||||||||2018-05-31 22:12:38.15379|2018-05-31 22:12:38.15379
NCT01425203|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2014-07-29||2017-03-09|2011-08-26|2011-08-29|Estimate|2014-07-29|2014-08-18|Estimate||||2017-03-09|2017-04-07|Actual|November 2011||2011-11-30|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Baseline Characteristics were reported only for the Full Analysis Set (FAS), which consisted of all randomized participants who received at least 1 dose of any trial medication (PEG, RBV, or BOC) in the Treatment Phase. The Crossover Arm is not included as these participants originally started the study in the PBO + PR Control Arm at Baseline.|The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)|Safety and Efficacy of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Chronic Hepatitis C Genotype 1 in Russia: Previously Untreated Patients and Patients Who Failed Prior Treatment With Pegylated-Interferon Plus Ribavirin|Completed||Phase 3|238|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:12:38.272238|2018-05-31 22:12:38.272238
NCT01425190|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2014-10-03||2017-03-09|2011-08-26|2011-08-29|Estimate|2014-10-03|2014-10-08|Estimate||||2017-03-09|2017-04-07|Actual|January 2012||2012-01-31|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The Baseline Population includes all participants in Cohort 1 that received boceprevir. The trial was terminated prior to enrolling participants in either Cohorts 2 or 3.|Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)|Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (Phase 1b); Protocol No. P07614|Terminated||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3||"The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free~   regimens in pediatric studies of HCV infection."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:12:38.71875|2018-05-31 22:12:38.71875
NCT01425177|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|SIDEROD||Effect of Saline Irrigation to DEcrease Rate Of Residual Common Bile Duct Stones|Effect of Saline Irrigation to Decrease Rate of Residual Common Bile Duct Stones|Unknown status|Recruiting|Phase 3|160|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:12:39.958711|2018-05-31 22:12:39.958711
NCT01425164|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-06-27|2011-08-26|2011-08-29|Estimate|||||||2012-06-27|2012-06-28|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol|Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study|Unknown status|Recruiting|Phase 4|220|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-05-31 22:12:40.05311|2018-05-31 22:12:40.05311
NCT01425151|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2011-09-20|2011-08-26|2011-08-29|Estimate|||||||2011-09-20|2011-09-22|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The i-GelTM. A Randomized, Crossover Study With the Laryngeal Mask Airway ProSealTM in Anesthetized Pediatric Patients||Completed||N/A|60|Anticipated|Schulthess Klinik||2|||f||||f||||||||||2018-05-31 22:12:40.131129|2018-05-31 22:12:40.131129
NCT01425138|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2011-09-28|2011-08-26|2011-08-29|Estimate|||||||2011-09-28|2011-09-29|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Systematic Review And Meta-Analysis Of Psoriasis Treatments.|Biologic And Non-biologic Systemic Treatments For Moderate To Severe Plaque Psoriasis: A Systematic Review & Meta-Analysis|Completed|||0|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 22:12:40.213291|2018-05-31 22:12:40.213291
NCT01425125|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2015-12-09|2011-08-26|2011-08-29|Estimate|||||||2015-12-09|2015-12-10|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Fractional Urate Excretion in Nonedematous Hyponatremia|Study of Nonedematous Hyponatremia and the Utility of Fractional Urate Excretion in Hyponatremia and Suspected Renal Salt Wasting Without Hyponatremia-|Withdrawn||N/A|0|Actual|Winthrop University Hospital||1|||f||||f||||||||||2018-05-31 22:12:40.275475|2018-05-31 22:12:40.275475
NCT01425112|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy|Clinical Trial Comparing Subconjunctival and Topical Bevacizumab as Adjuncts to Trabeculectomy in Improving Outcomes for Primary Open Angle Glaucoma|Completed||N/A|180|Actual|Sudhalkar Eye Hospital||1|||f||||t||||||||||2018-05-31 22:12:40.348287|2018-05-31 22:12:40.348287
NCT01425099|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-11-03|2011-08-26|2011-08-29|Estimate|||||||2011-11-03|2011-11-07|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Drug Interaction Study Between Dolutegravir and Prednisone|An Adaptive, Two Part, Two Period, Single Sequence, Drug Interaction Study Between Dolutegravir 50 mg and Prednisone in Adult Healthy Volunteers|Completed||Phase 1|12|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 22:12:40.405828|2018-05-31 22:12:40.405828
NCT01425086|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2017-10-05|2011-08-26|2011-08-29|Estimate|||||||2017-10-05|2017-10-09|Actual|March 2011||2011-03-31|October 2017|2017-10-31|December 31, 2012|Actual|2012-12-31|December 20, 2012|Actual|2012-12-20||Observational|KBW||Clinical Performance of the Embrace Isothermal Mattress|Clinical Performance of the Embrace Isothermal Mattress in Stabilizing Temperatures of the Preterm Infants During Thermal Weaning|Completed|||36|Actual|Stanford University|||2||f||||t||||||||||2018-05-31 22:12:40.579635|2018-05-31 22:12:40.579635
NCT01425073|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2014-04-09|2011-08-26|2011-08-29|Estimate|||||||2014-04-09|2014-04-11|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya|Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya: a Randomized Trial|Completed||N/A|500|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 22:12:40.675455|2018-05-31 22:12:40.675455
NCT01425060|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2015-03-13|2011-08-26|2011-08-29|Estimate|||||||2015-03-13|2015-03-17|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Improving Effective Contraceptive Use Among Opioid-maintained Women|Improving Effective Contraceptive Use Among Opioid-maintained Women|Completed||Phase 1|31|Actual|University of Vermont||2|||f||||t||||||||||2018-05-31 22:12:40.780344|2018-05-31 22:12:40.780344
NCT01425047|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2011-08-31|2011-08-26|2011-08-29|Estimate|||||||2011-08-31|2011-09-02|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Observational|||Bioavailability of Xanthones From Mangosteen|Bioavailability and Anti-inflammatory Activities of Mangostins: a Pilot Study|Completed|||10|Actual|Ohio State University|||2||f||||t||||||Samples Without DNA|"~     Sera and urine~   "|||2018-05-31 22:12:40.867701|2018-05-31 22:12:40.867701
NCT01425034|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2018-02-17|2011-08-26|2011-08-29|Estimate|||||||2018-02-17|2018-02-20|Actual|September 2011||2011-09-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|LRTI||Postoperative Rehabilitation Following Trapeziectomy and Ligament Reconstruction Tendon Interposition|Postoperative Rehabilitation Following Trapeziectomy and Ligament Reconstruction Tendon Interposition: a Prospective, Randomized Multi-center Study|Active, not recruiting||N/A|229|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 22:12:40.936608|2018-05-31 22:12:40.936608
NCT01425021|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2015-08-17|2011-08-26|2011-08-29|Estimate|||||||2015-08-17|2015-08-19|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery|Retrieval and Analysis of Orthopedic Implants at Revision Arthroplasty Surgery|Completed|||199|Actual|University of Utah|||1||f||||t||||||||||2018-05-31 22:12:41.018659|2018-05-31 22:12:41.018659
NCT01425008|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2018-03-27|2011-08-26|2011-08-29|Estimate|||||||2018-03-27|2018-03-29|Actual|September 15, 2011|Actual|2011-09-15|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|April 11, 2017|Actual|2017-04-11||Interventional|||Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma|An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma|Active, not recruiting||Phase 1|149|Actual|Takeda||1|||f||||f|t|f||||||||2018-05-31 22:12:41.092967|2018-05-31 22:12:41.092967
NCT01424995|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2018-02-17|2011-08-26|2011-08-29|Estimate|||||||2018-02-17|2018-02-20|Actual|December 2010||2010-12-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||The Natural History of Congenital Trigger Thumbs|The Natural History of Congenital Trigger Thumbs|Active, not recruiting|||100|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 22:12:41.187218|2018-05-31 22:12:41.187218
NCT01424982|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2018-04-26|2011-08-26|2011-08-29|Estimate|||||||2018-04-26|2018-04-30|Actual|October 2011|Actual|2011-10-31|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 22:12:41.254971|2018-05-31 22:12:41.254971
NCT01424956|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2013-04-16|2011-08-26|2011-08-29|Estimate|||||||2013-04-16|2013-04-17|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study|To Determine the Impact on Reader Performance, as Defined by the Area Under the Receiver Operating Characteristic Curve, When Automated Breast Ultrasound and a Screening Mammogram Are Combined, Compared to a Screening Mammogram Alone in Asymptomatic Women With >50% Parenchymal Density and a Screening Mammogram Assigned a BI-RADS Assessment Category 1 (Negative) or 2 (Normal With Benign Findings).|Completed|||17|Actual|U-Systems, Inc.|||1||f||||f||||||||||2018-05-31 22:12:41.428632|2018-05-31 22:12:41.428632
NCT01424943|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2014-07-22||2014-12-09|2011-08-26|2011-08-29|Estimate|2014-12-09|2014-12-15|Estimate||||2014-12-09|2014-12-15|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Parents of children with disabilities eligible for IDEA Part C Services and their identified child|Family Networks Project Study One: An Efficacy Study of Stepping Stones Triple P for Children Under Age Two|The Family Networks Project Study One: Supporting Family Confidence, Competence, and Community Connections|Completed||N/A|49|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 22:12:41.516586|2018-05-31 22:12:41.516586
NCT01424930|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|2014-03-28||2014-07-14|2011-08-26|2011-08-29|Estimate|2014-03-28|2014-04-30|Estimate||||2014-07-14|2014-07-25|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer|An Open-Label Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Subjects With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 2|25|Actual|Janssen-Ortho Inc., Canada||2|||f||||t||||||||||2018-05-31 22:12:41.934774|2018-05-31 22:12:41.934774
NCT01424917|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-01-23|2011-08-26|2011-08-29|Estimate|||||||2017-01-23|2017-01-25|Estimate|March 2008||2008-03-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CAV||Noninvasive Predictors of Transplant Vasculopathy|Noninvasive Predictors of Transplant Vasculopathy|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||1|Investigator Left university|f||||f||||||||||2018-05-31 22:12:42.502374|2018-05-31 22:12:42.502374
NCT01424904|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2013-10-17|2011-08-26|2011-08-29|Estimate|||||||2013-10-17|2013-10-18|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||DGB-01 Effects on Endurance Exercise|DGB-01 Effects on Endurance Exercise|Completed||N/A|29|Actual|University of Kentucky||1|||f||||f||||||||||2018-05-31 22:12:42.569371|2018-05-31 22:12:42.569371
NCT01424891|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-08-25|2011-08-25|2011-08-29|Estimate|||||||2011-08-25|2011-08-29|Estimate|April 2004||2004-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|July 2006|Actual|2006-07-31||Interventional|||Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe|Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe|Completed||N/A|31|Actual|Heidelberg University||3|||f||||f||||||||||2018-05-31 22:12:42.639163|2018-05-31 22:12:42.639163
NCT01424878|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2018-04-04|2011-08-26|2011-08-29|Estimate|||||||2018-04-04|2018-04-05|Actual|July 5, 2010||2010-07-05|February 12, 2014|2014-02-12|February 12, 2014||2014-02-12|||||Observational|||Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients|Study of Molecular Pathways in Medullary Thyroid Carcinoma (MTC) and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients|Completed|||150|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:12:42.726105|2018-05-31 22:12:42.726105
NCT01424865|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-05-06|2011-08-26|2011-08-29|Estimate|||||||2015-05-06|2015-05-08|Estimate|November 2011||2011-11-30|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Observational|||Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial|Evaluation of the Co-Expression of the Cancer Stem Cell Marker ALDH1 and of HER2 as a Predictor of Adjuvant Trastuzumab Response in Breast Cancers of Women in NSABP B31|Unknown status|Active, not recruiting||1874|Anticipated|NSABP Foundation Inc|||||f||||f||||||||||2018-05-31 22:12:42.78173|2018-05-31 22:12:42.78173
NCT01424852|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2012-02-21|2011-08-26|2011-08-29|Estimate|||||||2012-02-21|2012-02-22|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Does Administration of Probiotics During Infancy Increase the Caries Risk of a Child|Early Administration of Bifidobacterium Lactis BB-12 and the Caries Occurence of Children a 4 Years of Age|Withdrawn||N/A|0|Actual|University of Turku||2||Too few of the invited subjects wanted to participate|f||||t||||||||||2018-05-31 22:12:42.847708|2018-05-31 22:12:42.847708
NCT01424839|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2015-06-03|2011-08-26|2011-08-29|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SIOPCNSGCTII||Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors|SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors|Recruiting||Phase 4|400|Anticipated|University Hospital Muenster||7|||f||||t||||||||||2018-05-31 22:12:42.920761|2018-05-31 22:12:42.920761
NCT01424826|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2013-10-30|2011-08-26|2011-08-29|Estimate|||||||2013-10-30|2013-10-31|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|RIFRAL||The Effect of Intermittent Rifampicin on Raltegravir|A Single Arm, 3 Phase Study to Determine the Effect of Intermittent Dosing of Rifampicin on the Pharmacokinetics of Raltegravir in Healthy Volunteers|Completed||Phase 1|18|Actual|University of Liverpool|||||f||||t||||||||||2018-05-31 22:12:43.012866|2018-05-31 22:12:43.012866
NCT01424813|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2015-05-01|2014-05-08|2015-05-28|2011-08-25|2011-08-29|Estimate|2015-05-01|2015-05-20|Estimate|2014-05-08|2014-05-26|Estimate|2015-05-28|2015-06-26|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional||Randomized participants|A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma|A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma|Completed||Phase 3|158|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 22:12:43.12271|2018-05-31 22:12:43.12271
NCT01424800|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2012-03-05|2011-08-26|2011-08-29|Estimate|||||||2012-03-05|2012-03-06|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Influence of Variations in Systemic Blood Flow and Blood Pressure on Cerebral Oxygenation Measured by Cerebral Oximetry|Influence of Variations in Systemic Blood Flow and Blood Pressure on Cerebral Oxygenation Measured by Cerebral Oximetry|Completed||N/A|34|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:12:43.918417|2018-05-31 22:12:43.918417
NCT01424787|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2015-03-05|2011-08-26|2011-08-29|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|Steering||Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)|Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)|Completed|||324|Actual|Fresenius Medical Care Deutschland GmbH|||1||f||||f||||||||||2018-05-31 22:12:43.991362|2018-05-31 22:12:43.991362
NCT01424774|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2012-08-13|2011-08-26|2011-08-29|Estimate|||||||2012-08-13|2012-08-15|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning|A Prospective Study to Estimate Inadvertent Radiation Exposure From Strontium Isotopes in Patients Who Have Undergone CardioGen-82® PET MPI Scanning|Completed|||155|Actual|Bracco Diagnostics, Inc|||||f||||f||||||||||2018-05-31 22:12:44.080093|2018-05-31 22:12:44.080093
NCT01424761|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2013-06-10|2011-08-26|2011-08-29|Estimate|||||||2013-06-10|2013-06-12|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Coenzyme Q10 in Relation to the Antioxidative Vitamins, Oxidative Stress and Inflammation in Coronary Artery Disease Patients During Statin Therapy||Completed||Phase 2/Phase 3|51|Actual|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-05-31 22:12:44.136649|2018-05-31 22:12:44.136649
NCT01424748|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate|April 2003||2003-04-30|August 2011|2011-08-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Clinical Trial of Tahitian Noni Juice Safety|A Single Centre, Double-blind, Three Dose Level, Parallel Group, Placebo Controlled Safety Study With Tahitian Noni Juice in Healthy Subjects|Completed||Phase 1|96|Actual|Tahitian Noni International, Inc.||4|||f||||t||||||||||2018-05-31 22:12:44.222501|2018-05-31 22:12:44.222501
NCT01424735|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||TLR-9 Antagonism in Steroid Resistant Optic Neuritis|Outcomes of TLR-9 Antagonism in Steroid Resistant Optic Neuritis; A Pilot Study|Completed||N/A|8|Actual|Sudhalkar Eye Hospital||1|||f||||t||||||||||2018-05-31 22:12:44.289743|2018-05-31 22:12:44.289743
NCT01424722|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2017-08-03|2011-08-26|2011-08-29|Estimate|||||||2017-08-03|2017-08-04|Actual|August 2011|Actual|2011-08-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|AnalyzeST||ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients|ST Monitoring to Detect ACS Events in ICD Patients|Terminated||N/A|2258|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 22:12:44.383385|2018-05-31 22:12:44.383385
NCT01424709|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2014-09-23|2011-08-26|2011-08-29|Estimate|||||||2014-09-23|2014-09-25|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|May 2014|Actual|2014-05-31||Interventional|BRAVO||Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)|Individualized 1st Line Chemotherapy Based on BRCA1 and RRM1 mRNA Expression Levels for Advanced Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|Tongji University||2|||f||||t||||||||||2018-05-31 22:12:44.595456|2018-05-31 22:12:44.595456
NCT01424696|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2015-09-25|2011-08-26|2011-08-29|Estimate|||||||2015-09-25|2015-09-28|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|BONUS||Baby Observational and Nutritional Study|Baby Observational and Nutritional Study (BONUS)|Completed|||231|Actual|Seattle Children's Hospital|||1||f||||t||||||Samples With DNA|"~     -  serum and/or plasma~        -  urine~        -  stool~        -  oropharyngeal swab (OP swab)~        -  saliva~        -  sweat~        -  buccal brushings~   "|||2018-05-31 22:12:44.68731|2018-05-31 22:12:44.68731
NCT01424683|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2013-06-04|2011-08-26|2011-08-29|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Development of a Method for Converting Visual Analogue Scale (VAS) Scores for Pain and Mobility to EQ-5D Answers|Development of a Method for Converting VAS Scores for Pain and Mobility to EQ-5D Answers|Completed|||217|Actual|Aalborg Universitetshospital|||2||f||||t||||||||||2018-05-31 22:12:44.774764|2018-05-31 22:12:44.774764
NCT01424670|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25||2015-03-04|2017-01-30|2011-08-26|2011-08-29|Estimate||||2015-03-04|2015-03-25|Estimate|2017-01-30|2017-01-31|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis|A Phase 3, Multicenter,Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis|Completed||Phase 3|511|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 22:12:44.835951|2018-05-31 22:12:44.835951
NCT01424657|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate|October 1997||1997-10-31|August 2011|2011-08-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Magnetic Resonance Cholangiopancreatography Versus Endoscopic Retrograde Cholangiopancreatography in the Approach to Patients With Suspected Biliary Obstruction||Terminated||Phase 3|378|Actual|McGill University Health Center||2||The study was terminated before reaching the estimated sample size because of trial fatigue.|f||||f||||||||||2018-05-31 22:12:44.923745|2018-05-31 22:12:44.923745
NCT01424644|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2013-11-20||2014-01-21|2011-08-26|2011-08-29|Estimate|2014-01-21|2014-02-14|Estimate||||2014-01-21|2014-02-14|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents|A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine|Completed||Phase 4|801|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:12:45.126391|2018-05-31 22:12:45.126391
NCT01424631|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate||||August 2011|2011-08-31||||||||Interventional|||Single Incision Versus Conventional Laparoscopic Appendectomy||Completed||N/A|2|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 22:12:45.645457|2018-05-31 22:12:45.645457
NCT01424618|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-25|2011-08-25|2011-08-29|Estimate|||||||2011-08-25|2011-08-29|Estimate|January 2006||2006-01-31|August 2011|2011-08-31||||September 2012|Anticipated|2012-09-30||Interventional|||A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs|A Novel Approach to Endometrial Preparation in Recipients of Donor Cycles|Unknown status|Recruiting|N/A|20|Anticipated|Kelly, Maureen, M.D.||2|||f||||t||||||||||2018-05-31 22:12:45.70226|2018-05-31 22:12:45.70226
NCT01424605|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Glidescope||The Comparison of Glidescope® and the Direct Laryngoscopy in the Insertion of the Double Lumen Endotracheal Tube|The Comparison of Glidescope® and the Direct Laryngoscopy in the Insertion of the Double Lumen Endotracheal Tube|Completed||N/A|60|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||t||||||||||2018-05-31 22:12:45.933973|2018-05-31 22:12:45.933973
NCT01424592|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2015-08-31|2011-08-25|2011-08-29|Estimate|||||||2015-08-31|2015-09-01|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|February 2015|Actual|2015-02-28||Observational|||In-Hospital Portable Sleep Monitoring for the Evaluation of Obstructive Sleep Apnea (OSA)|Inpatient Portable Sleep Apnea Testing of Hospitalized Medical Patients for the Evaluation of Obstructive Sleep Apnea Prospectively Compared to Outpatient Laboratory-based Polysomnography|Unknown status|Active, not recruiting||140|Anticipated|John H. Stroger Hospital|||1||f||||f||||||||||2018-05-31 22:12:46.007595|2018-05-31 22:12:46.007595
NCT01424579|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2013-04-03|2011-08-26|2011-08-29|Estimate|||||||2013-04-03|2013-04-05|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Diacutaneous Fibrolysis and Subacromial Syndrome|Effectiveness of Diacutaneous Fibrolysis for the Treatment of Subacromial Impingement Syndrome: a Randomised Controlled Trial|Completed||N/A|120|Actual|Jordi Gol i Gurina Foundation||3|||f||||f||||||||||2018-05-31 22:12:46.217572|2018-05-31 22:12:46.217572
NCT01424566|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2018-03-23|2016-06-24|2018-03-23|2011-08-25|2011-08-29|Estimate|2018-03-23|2018-04-23|Actual|2016-07-04|2016-07-06|Estimate|2018-03-23|2018-04-23|Actual|June 29, 2012|Actual|2012-06-29|March 2018|2018-03-31|December 28, 2015|Actual|2015-12-28|July 10, 2015|Actual|2015-07-10||Interventional||All participants who were randomized and received at least 1 dose of study drug. Two participants who were randomized in the single-blind treatment period did not administer any study drug.|A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer|A Two-part, Placebo-controlled, Study of the Safety and Efficacy of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Have Inadequate Analgesia Even With Optimized Chronic Opioid Therapy.|Completed||Phase 3|406|Actual|GW Pharmaceuticals Ltd.||2|||f||||t||||||||||2018-05-31 22:12:46.341829|2018-05-31 22:12:46.341829
NCT01424553|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2015-04-20|2011-08-26|2011-08-29|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|EPIPAGEADO||Respiratory Outcome at Adolescence of Very Low Birthweight Infants|Respiratory Outcome at Adolescence of Very Low Birthweight Infants : the EPIPAGE Cohort|Completed||N/A|355|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:12:47.034495|2018-05-31 22:12:47.034495
NCT01424540|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2017-07-18|2011-08-25|2011-08-29|Estimate|||||||2017-07-18|2017-07-21|Actual|September 1, 2011|Actual|2011-09-01|July 2017|2017-07-31|October 3, 2011|Actual|2011-10-03|October 3, 2011|Actual|2011-10-03||Interventional|||Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805|A Randomized, Double Blind, Single Dose, Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 in Healthy Adult Volunteers|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:12:47.100798|2018-05-31 22:12:47.100798
NCT01424527|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-05-15|2011-08-25|2011-08-29|Estimate|||||||2017-05-15|2017-05-16|Actual|December 2010||2010-12-31|May 2017|2017-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|CAT||Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation Study|Validation of the New COPD Assessment Test Translated Into Korean in Patients With Chronic Obstructive Pulmonary Disease|Completed|||100|Actual|GlaxoSmithKline|||1||f||||f||||||None Retained|"~     none retained~   "|||2018-05-31 22:12:47.168708|2018-05-31 22:12:47.168708
NCT01424514|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|2017-01-10||2017-07-06|2011-08-25|2011-08-29|Estimate|2017-07-06|2018-01-29|Actual||||2017-07-06|2018-01-29|Actual|December 1, 2010||2010-12-01|April 2017|2017-04-30|April 18, 2011|Actual|2011-04-18|April 1, 2011|Actual|2011-04-01||Interventional|||SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis|A Randomised, Double Blind Placebo Controlled, 2 Way Cross Over Study in Adults With Non-allergic Rhinits to Evaluate the Effect of Once Daily Administration of Intranasal SB-705498 12mg for Two Weeks and the Response to a Chamber Challenge of Cold Dry Air|Completed||Phase 2|40|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:12:47.264032|2018-05-31 22:12:47.264032
NCT01424501|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2016-11-29|2014-05-29|2016-11-29|2011-08-25|2011-08-29|Estimate|2016-11-29|2017-01-24|Estimate|2014-05-29|2014-06-02|Estimate|2016-11-29|2017-01-24|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease|Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease|Terminated||Phase 2|142|Actual|GlaxoSmithKline|Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.|6||"Due to a safety signal found at a planned interim safety review, further conduct of this safety~   study is not recommended hence the study was terminated."|f||||||||||||||2018-05-31 22:12:48.221418|2018-05-31 22:12:48.221418
NCT01424488|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-08-26|2011-08-26|2011-08-29|Estimate|||||||2011-08-26|2011-08-29|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade|Randomized, Parallel-group, Placebo-controlled, Safety-assessor Blinded Trial in Adult Subjects Evaluating the Efficacy and Safety of Sugammadex for Reversal of Pipecuronium-induced Neuromuscular Blockade in Subjects Undergoing Abdominal Surgery Under General Anesthesia|Unknown status|Not yet recruiting|Phase 4|42|Anticipated|Central Clinical Hospital #1 of LLC Russian Railways||2|||f||||f||||||||||2018-05-31 22:12:51.330368|2018-05-31 22:12:51.330368
NCT01424475|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-05-10|2011-08-25|2011-08-29|Estimate|||||||2017-05-10|2017-05-11|Actual|August 11, 2011|Actual|2011-08-11|May 2017|2017-05-31|January 12, 2015|Actual|2015-01-12|January 12, 2015|Actual|2015-01-12||Interventional|||LRRK2 Mutation and Parkinson's Disease|LRRK2 Mutation and Parkinson's Disease: A Functional Neuroimaging and Behavioural Study Characterising the Neurocognitive Phenotype|Terminated||Phase 1|5|Actual|GlaxoSmithKline||2||"Following extensive efforts to increase recruitment, it will not be possible to complete the~   study protocol within a reasonable time"|f||||f||||||||||2018-05-31 22:12:51.712857|2018-05-31 22:12:51.712857
NCT01424293|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2015-08-06|2011-08-25|2011-08-26|Estimate|||||||2015-08-06|2015-08-07|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Fluorescent Evaluation of Colorectal Anastamoses|The Use of Fluorescent Imaging to Evaluate Bowel Anastomotic Perfusion|Unknown status|Active, not recruiting|N/A|120|Anticipated|Maimonides Medical Center||1|||f||||f||||||||||2018-05-31 22:12:57.134671|2018-05-31 22:12:57.134671
NCT01424462|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-06-19|2011-08-25|2011-08-29|Estimate|||||||2017-06-19|2017-06-20|Actual|April 19, 2010|Actual|2010-04-19|June 2017|2017-06-30|July 6, 2010|Actual|2010-07-06|July 6, 2010|Actual|2010-07-06||Interventional|||Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.|An Open Label, Randomised Healthy Volunteer Study to Assess the Single Dose Safety and Pharmacokinetics of Three Modified Release Dosage Forms of Firategrast|Completed||Phase 1|20|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 22:12:52.82132|2018-05-31 22:12:52.82132
NCT01424449|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-12-13|2011-08-25|2011-08-29|Estimate|||||||2012-12-13|2012-12-17|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A PET Study in Healthy Volunteers|A Positron Emission Tomography Study in Healthy Male Subjects to Examine the Test-retest Reliability of the D2/3 Agonist Radiotracer [11C]PHNO|Completed||Phase 1|7|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:12:52.971999|2018-05-31 22:12:52.971999
NCT01424436|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2017-06-13|2011-08-25|2011-08-29|Estimate|||||||2017-06-13|2017-06-14|Actual|May 19, 2010|Actual|2010-05-19|June 2017|2017-06-30|December 8, 2011|Actual|2011-12-08|December 8, 2011|Actual|2011-12-08||Interventional|||Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient|Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment|Completed||Phase 1|19|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:12:53.140114|2018-05-31 22:12:53.140114
NCT01424423|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-09-19|2011-08-25|2011-08-29|Estimate|||||||2017-09-19|2017-09-20|Actual|February 11, 2010|Actual|2010-02-11|September 2017|2017-09-30|August 26, 2010|Actual|2010-08-26|August 26, 2010|Actual|2010-08-26||Interventional|||NOGO-A in Multiple Sclerosis FTIH|A Randomized, Single-blind (Investigator and Subject), Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Subjects With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy|Terminated||Phase 1|3|Actual|GlaxoSmithKline||10|||f||||f||||||||||2018-05-31 22:12:53.421637|2018-05-31 22:12:53.421637
NCT01424410|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-06-12|2011-08-26|2011-08-29|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2012||2012-02-29|June 2017|2017-06-30|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Observational|||Health Benefits of Repeated Treatment in Pediatric Schistosomiasis|Health Benefits of Repeated Treatment in Pediatric Schistosomiasis|Completed|||360|Actual|University of Edinburgh|||||f||||f||||||||||2018-05-31 22:12:55.164026|2018-05-31 22:12:55.164026
NCT01424397|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-11-18|2011-08-25|2011-08-29|Estimate|||||||2016-11-18|2016-11-21|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Intranasal SB-705498 in Allergic Rhinitis (AR) Patients|A Randomized, Double-blind, Placebo Controlled, Incomplete Block, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of SB-705498 When Administered Alone or in Conjunction With Intranasal Fluticasone Propionate on the Symptoms of Rhinitis in the Vienna Allergen Challenge Chamber|Completed||Phase 2|70|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:12:55.383958|2018-05-31 22:12:55.383958
NCT01424384|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2017-07-05|2011-08-25|2011-08-29|Estimate|||||||2017-07-05|2017-07-07|Actual|September 19, 2008|Actual|2008-09-19|July 2017|2017-07-31|April 30, 2009|Actual|2009-04-30|April 30, 2009|Actual|2009-04-30||Interventional|||Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic|Emotional Processing in Healthy Male Volunteers Treated With GSK424887. A Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study|Completed||Phase 1|54|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:12:55.591828|2018-05-31 22:12:55.591828
NCT01424371|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2012-09-28|2011-08-26|2011-08-29|Estimate|||||||2012-09-28|2012-10-01|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Observational|||Adjuvanted Influenza Vaccine Effectiveness in the Elderly (65+Yrs)|A Case-Control Study to Evaluate the Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine in the Elderly Aged ≥65 Years.|Unknown status|Recruiting||1000|Anticipated|Fraser Health|||3||f||||f||||||||||2018-05-31 22:12:55.740294|2018-05-31 22:12:55.740294
NCT01424358|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2015-03-23|2011-08-25|2011-08-29|Estimate|||||||2015-03-23|2015-03-24|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Web-based Education on Oral Cancer for Primary Care Physicians in Ohio|Web-based Education on Oral Cancer for Primary Care Physicians in Ohio|Completed||N/A|10|Actual|Creighton University||1|||f||||f||||||||||2018-05-31 22:12:55.814763|2018-05-31 22:12:55.814763
NCT01424345|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2012-10-04|2011-08-26|2011-08-29|Estimate|||||||2012-10-04|2012-10-05|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient|A Randomized, Controlled Trial Evaluating the Role of ImmuKnow® in the Management of Immunosuppressants Regarding Opportunistic Infections and Acute Rejection in the Renal Transplant Patient|Terminated||Phase 4|40|Anticipated|CAMC Health System||2||The PI is relocating to another State/ another hospital|f||||f||||||||||2018-05-31 22:12:56.046403|2018-05-31 22:12:56.046403
NCT01424332|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-08-25|2011-08-25|2011-08-29|Estimate|||||||2011-08-25|2011-08-29|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||To Evaluate Whether Acetyl Salicylic Acid (Aspirin) and Darexaban (YM150) Interact in Their Effects|A Randomized, Open Label, Three-way Crossover Study to Evaluate the Pharmacodynamic Interactions Between Darexaban (YM150)/Darexaban Glucuronide (YM-222714) and Acetyl Salicylic Acid (ASA) in Healthy Male Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 22:12:56.197609|2018-05-31 22:12:56.197609
NCT01424319|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2017-08-25|2011-08-25|2011-08-29|Estimate|||||||2017-08-25|2017-08-29|Actual|August 2011||2011-08-31|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan|Reducing Residual Albuminuria in Subjects With Diabetes & Nephropathy With Atrasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety & Efficacy in Japanese Subjects|Completed||Phase 2|58|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 22:12:56.288956|2018-05-31 22:12:56.288956
NCT01424306|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2017-04-19||2017-07-06|2011-08-25|2011-08-26|Estimate|2017-07-06|2017-08-14|Actual||||2017-07-06|2017-08-14|Actual|October 2011||2011-10-31|July 2017|2017-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|DASI|Only results of 24 subjects who completed study 'per protocol' are reported here|Diet and Systemic Inflammation|Diet and Systemic Inflammation|Completed||N/A|25|Actual|Fred Hutchinson Cancer Research Center||3|||f||||f||||||||||2018-05-31 22:12:56.452836|2018-05-31 22:12:56.452836
NCT01424280|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-12-01|2011-08-25|2011-08-26|Estimate|||||||2011-12-01|2011-12-02|Estimate|August 2011||2011-08-31|December 2011|2011-12-31||||November 2011|Actual|2011-11-30||Interventional|||Single Dose Study of GSK1440115 in Patients With Asthma|A Phase 1, Randomized, Placebo Controlled, Crossover Study to Evaluate the Efficacy of GSK1440115 After a Single Oral Dose in Patients With Asthma|Completed||Phase 1|12|Actual|Accenture||2|||f||||f||||||||||2018-05-31 22:12:57.214645|2018-05-31 22:12:57.214645
NCT01424267|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2012-10-10|2011-08-25|2011-08-26|Estimate|||||||2012-10-10|2012-10-11|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Zenith® LP Abdominal Aortic Aneurysm (AAA) Post-Market Registry|Zenith® LP AAA Endovascular Graft Post-Market Registry|Terminated|||76|Actual|Cook Group Incorporated|||1|The registry was discontinued due to significant resources required.|f||||||||||||||2018-05-31 22:12:57.439966|2018-05-31 22:12:57.439966
NCT01424254|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|October 2003||2003-10-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||The Effectiveness of Video-capsule Endoscopy in Gastrointestinal Bleeding of Obscure Origin||Completed||Phase 3|79|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:12:57.526659|2018-05-31 22:12:57.526659
NCT01424241|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2012-08-08|2011-08-25|2011-08-26|Estimate|||||||2012-08-08|2012-08-10|Estimate|August 2006||2006-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Effects of Sandostatin LAR® in Acromegaly|Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|Columbia University||1|||f||||f||||||||||2018-05-31 22:12:57.633454|2018-05-31 22:12:57.633454
NCT01424228|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2013-11-11||2014-08-13|2011-08-25|2011-08-26|Estimate|2014-02-19|2014-04-02|Estimate||||2014-08-13|2014-08-18|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SPD555-401|The Safety Population was used for demographics. The Safety Population includes all subjects randomized into the study who took at least 1 dose of investigational product. Three subjects did not receive investigational product and therefore were not included in the Safety Population (n = 361).|Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years|A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Long-term Treatment (24 Weeks) With Prucalopride in Subjects Aged ≥18 Years With Chronic Constipation|Completed||Phase 4|364|Actual|Shire||2|||f||||f||||||||||2018-05-31 22:12:57.737185|2018-05-31 22:12:57.737185
NCT01424215|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-08-12|2011-08-25|2011-08-26|Estimate|||||||2015-08-12|2015-08-13|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Use of Fluorescent Imaging for Intraoperative Cholangiogram During Laparoscopic Cholecystectomy|The Use of Fluorescent Imaging for Intraoperative Cholangiogram During Laparoscopic Cholecystectomy|Completed||N/A|100|Actual|Maimonides Medical Center||2|||f||||t||||||||||2018-05-31 22:12:58.930615|2018-05-31 22:12:58.930615
NCT01424202|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|MIEICU||Effects of Mechanical Insufflation-Exsufflation in Preventing Respiratory Failure After Extubation|Effects of Mechanical Insufflation-Exsufflation in Preventing Respiratory Failure After Extubation|Completed||N/A|92|Actual|Hospital Sao Joao||2|||f||||f||||||||||2018-05-31 22:12:59.023174|2018-05-31 22:12:59.023174
NCT01424189|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2017-01-13||2017-03-06|2011-08-25|2011-08-26|Estimate|2017-01-13|2017-03-06|Actual||||2017-03-06|2017-04-04|Actual|July 2011||2011-07-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||This analysis population includes all participants with successful IOL implantation in at least 1 eye.|Clinical Investigation of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)|Clinical Investigation of AcrySof® IQ ReSTOR® Multifocal Toric Intraocular Lens Models SND1T3/ SND1T4/ SND1T5/ SND1T6|Completed||N/A|677|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:12:59.186133|2018-05-31 22:12:59.186133
NCT01424176|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-11-24|2011-08-25|2011-08-26|Estimate|||||||2014-11-24|2014-11-25|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Dexpramipexole Renal PK Study|A Multicenter, Open-Label, Single-dose, Pharmacokinetic and Safety Study of Dexpramipexole (BIIB050) in Healthy Subjects and Subjects With Renal Impairment|Completed||Phase 1|36|Actual|Knopp Biosciences||2|||f||||f||||||||||2018-05-31 22:12:59.68431|2018-05-31 22:12:59.68431
NCT01424163|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-11-24|2011-08-25|2011-08-26|Estimate|||||||2014-11-24|2014-11-25|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Dexpramipexole Japanese PK Study|A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|56|Actual|Knopp Biosciences||4|||f||||f||||||||||2018-05-31 22:12:59.757833|2018-05-31 22:12:59.757833
NCT01424150|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2018-02-11|2011-08-25|2011-08-26|Estimate|||||||2018-02-11|2018-02-13|Actual|July 2013|Actual|2013-07-31|August 2017|2017-08-31|October 22, 2017|Actual|2017-10-22|September 2017|Actual|2017-09-30||Interventional|RELIEF||REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study|Restrictive Versus Liberal Fluid Therapy in Major Abdominal Surgery|Completed||Phase 4|3000|Actual|Bayside Health||2|||f||||t||||||||No||2018-05-31 22:12:59.854751|2018-05-31 22:12:59.854751
NCT01424137|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2012-02-02|2011-08-25|2011-08-26|Estimate|||||||2012-02-02|2012-02-03|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|SALIF||Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)|Inspiratory Flow Parameters With Placebo Dry Powder Inhalers, Easyhaler and Diskus; an Open, Randomised, Multicentre Study in Patients With Asthma or COPD|Completed||N/A|227|Actual|Orion Corporation, Orion Pharma||3|||f||||f||||||||||2018-05-31 22:12:59.941552|2018-05-31 22:12:59.941552
NCT01424124|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-07-08|2011-08-25|2011-08-26|Estimate|||||||2014-07-08|2014-07-10|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|||Safety and Efficacy of YHD001 in Asthma|Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 Following 8 Weeks Oral Administration of YHD001 in Patients With Partially Controlled Asthma|Completed||Phase 2|56|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 22:13:00.021727|2018-05-31 22:13:00.021727
NCT01424111|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-04-30|2011-08-25|2011-08-26|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2011||2011-08-31|April 2018|2018-04-30|October 14, 2017|Actual|2017-10-14|October 14, 2017|Actual|2017-10-14||Observational|||Exploring Biomarkers for Depression|Exploring Biomarkers for Depression|Completed|||51|Actual|Wyss Institute at Harvard University|||2||f||||f||||||||||2018-05-31 22:13:00.084401|2018-05-31 22:13:00.084401
NCT01424098|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-08-24|2011-08-24|2011-08-26|Estimate|||||||2011-08-24|2011-08-26|Estimate|August 2011||2011-08-31|August 2011|2011-08-31||||September 2012|Anticipated|2012-09-30||Interventional|||Balance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized Controlled Trial of Balance Training in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|46|Anticipated|West Park Healthcare Centre||2|||f||||f||||||||||2018-05-31 22:13:00.156334|2018-05-31 22:13:00.156334
NCT01424085|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2016-07-07|2011-08-25|2011-08-26|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Antibiotic Prophylaxis Before Percutaneous Gastrostomy|Antibiotic Prophylaxis Before Percutaneous Gastrostomy: A Randomized, Controlled Clinical Trial|Completed|||124|Actual|University of Washington|||2||f||||t||||||||No||2018-05-31 22:13:00.242281|2018-05-31 22:13:00.242281
NCT01424072|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2013-01-28||2013-04-22|2011-08-24|2011-08-26|Estimate|2013-04-22|2013-05-31|Estimate||||2013-04-22|2013-05-31|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|||Auriculotherapy as a Coping Strategy in Professional Nursing|Applicability of Auriculotherapy as a Strategy for Stress and Coping in Nursing Professionals|Completed||Phase 1/Phase 2|75|Actual|University of Sao Paulo|Number of the participants(reduced sample)|3|||f||||f||||||||||2018-05-31 22:13:00.467487|2018-05-31 22:13:00.467487
NCT01424059|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-24|2011-08-24|2011-08-26|Estimate|||||||2011-08-24|2011-08-26|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Induction of Women With Fear of Labor|Planned Induction of Women With Fear of Labor and Evaluation of the Experience of Delivery|Unknown status|Recruiting||250|Anticipated|Uppsala University Hospital|||1||f||||f||||||||||2018-05-31 22:13:00.784267|2018-05-31 22:13:00.784267
NCT01424046|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-12-04|2011-08-25|2011-08-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Health Care for Type 1 Diabetes in Developing World|Evaluation of Differing Type 1 Diabetes Regimens in Youth in the Developing World|Completed||N/A|50|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:13:00.852881|2018-05-31 22:13:00.852881
NCT01424033|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2016-01-14||2017-02-22|2011-08-25|2011-08-26|Estimate|2016-01-14|2016-02-12|Estimate||||2017-02-22|2017-04-06|Actual|December 2011||2011-12-31|February 2017|2017-02-28||||February 2013|Actual|2013-02-28||Interventional|||A Clinical Trial for CTD-ILD Treatment|Clinical Trial of Oral Medication for CTD-ILD Treatment|Terminated||Phase 2/Phase 3|5|Actual|University of Michigan|Five subjects were consented. Study was terminated prior to conclusion due to departure of PI.|1||Departure of study team|f||||t||||||||||2018-05-31 22:13:00.933879|2018-05-31 22:13:00.933879
NCT01424020|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2016-12-15|2011-08-24|2011-08-26|Estimate|||||||2016-12-15|2016-12-19|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|WELCH-2||Walking Estimated Limitation Calculated by History - Study 2|Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Les Patients adressés Pour Bilan artériel Des Membres inférieurs|Recruiting||Phase 4|800|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 22:13:01.071629|2018-05-31 22:13:01.071629
NCT01424007|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2016-10-25|2011-08-24|2011-08-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|MENU||Metabolism, Exercise and Nutrition at UCSD (MENU Study)|Diet Composition and Genetics: Effects on Weight, Inflammation and Biomarkers|Completed||N/A|245|Actual|University of California, San Diego||3|||f||||t||||||||||2018-05-31 22:13:01.275867|2018-05-31 22:13:01.275867
NCT01423994|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-08-29|2011-08-25|2011-08-26|Estimate|||||||2016-08-29|2016-08-31|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|Spritely||Syncope: Pacing or Recording in the Later Years|Syncope: Pacing or Recording in the Later Years (SPRITELY)|Active, not recruiting||Phase 4|120|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 22:13:01.352338|2018-05-31 22:13:01.352338
NCT01423981|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2016-10-03|2011-08-24|2011-08-26|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|June 2031|Anticipated|2031-06-30|December 2030|Anticipated|2030-12-31||Observational|||Web Based Investigation of Natural History of Keloid Disorder, an Online Survey|Web Based Investigation of Natural History of Keloid Disorder, an Online Survey|Recruiting|||10000|Anticipated|Tirgan, Michael H., M.D.|||1||f||||f||||||||Yes|All data will be shared and published|2018-05-31 22:13:01.466566|2018-05-31 22:13:01.466566
NCT01423968|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2018-03-23|2011-08-25|2011-08-26|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2011|Actual|2011-07-31|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|LPS||Effect of Lipopolysaccharide on Skeletal Muscle Functions|Impact & Time-Course of Effect of Intravenous Lipopolysaccharide Infusion on Skeletal Muscle Protein Turnover and Insulin Sensitivity in Healthy Human Volunteers|Completed||N/A|6|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 22:13:01.541234|2018-05-31 22:13:01.541234
NCT01423955|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2013-10-24|2011-08-25|2011-08-26|Estimate|||||||2013-10-24|2013-10-25|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|EPRICS||Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery|EPO to Protect Renal Function After Cardiac Surgery. A Phase II Double Blind Randomized Controlled Study.|Completed||Phase 2|75|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:13:01.62398|2018-05-31 22:13:01.62398
NCT01423942|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-05-07|2011-08-24|2011-08-26|Estimate|||||||2015-05-07|2015-05-08|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Maturation of the Autonomic Nervous System in Prematures|Maturation of the Autonomic Nervous System in Prematures|Completed|||300|Actual|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 22:13:01.700447|2018-05-31 22:13:01.700447
NCT01423929|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2016-08-30|2011-08-25|2011-08-26|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SOCCER||Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion|Supplemental Oxygen in Catheterized Coronary Emergency Reperfusion|Completed||Phase 4|100|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:13:01.752872|2018-05-31 22:13:01.752872
NCT01423916|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2015-08-04||2015-09-29|2011-08-25|2011-08-26|Estimate|2015-09-29|2015-10-29|Estimate||||2015-09-29|2015-10-29|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder|A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|218|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||f||||||||||2018-05-31 22:13:01.855264|2018-05-31 22:13:01.855264
NCT01423903|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-01-14|2011-08-24|2011-08-26|Estimate|||||||2014-01-14|2014-01-15|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer|Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once-Daily OPB-51602 in Subjects With Advanced Cancer|Completed||Phase 1|45|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 22:13:02.505576|2018-05-31 22:13:02.505576
NCT01423890|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-03-26|2011-08-24|2011-08-26|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ONCOTYPEDX||A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer|A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer|Completed||N/A|1011|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||f||||||||||2018-05-31 22:13:02.577864|2018-05-31 22:13:02.577864
NCT01423877|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-03-31|2011-08-25|2011-08-26|Estimate|||||||2014-03-31|2014-04-01|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35||Completed|||55|Anticipated|New York University School of Medicine|||||f||||t||||||||||2018-05-31 22:13:02.724225|2018-05-31 22:13:02.724225
NCT01423864|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|June 2005||2005-06-30|August 2011|2011-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|IP steroid||Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome|Retrospective Study of Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome|Completed||Phase 2|29|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 22:13:02.797211|2018-05-31 22:13:02.797211
NCT01423851|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2018-03-27|2011-08-25|2011-08-26|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2011||2011-06-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF|A Phase 1/2, Open-label, Dose-Escalation Multi-center Study to Assess the Safety, Tolerability, PK and PD of Orally Administered NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF|Active, not recruiting||Phase 1/Phase 2|77|Actual|NS Pharma, Inc.||1|||f||||t||||||||||2018-05-31 22:13:02.872352|2018-05-31 22:13:02.872352
NCT01423838|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder|Comparison of Oxybutynin and Solifenacin in the Treatment of Overactive Bladder: a Randomized Controlled Multicenter Trial|Unknown status|Not yet recruiting|Phase 4|500|Anticipated|Adana Numune Training and Research Hospital||2|||f||||t||||||||||2018-05-31 22:13:03.118262|2018-05-31 22:13:03.118262
NCT01423825|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2016-06-01|2011-08-24|2011-08-26|Estimate|||||||2016-06-01|2016-06-02|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)|A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States|Completed||Phase 1|27|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 22:13:03.207529|2018-05-31 22:13:03.207529
NCT01423812|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2015-09-15||2018-01-30|2011-08-25|2011-08-26|Estimate|2018-01-30|2018-02-07|Actual||||2018-01-30|2018-02-07|Actual|January 2012||2012-01-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|DRIVESHAFT||DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects|DRIVESHAFT : Darunavir/Ritonavir In Virologically-suppressed Experienced Subjects Halving an Antiretroviral by Finetuning Therapy - A Phase IV Randomized, Open-Label Study to Evaluate in HIV-1 Infected , Virologically-suppressed Patients on Regimens With Darunavir 600mg/ Ritonavir 100mg Twice-daily Switching to Darunavir 800mg/ Ritonavir 100mg Once-daily Versus Continuing Darunavir 600mg/ Ritonavir 100mg Twice-daily Containing Regimens|Completed||Phase 4|60|Actual|Ruth M. Rothstein CORE Center|The sample size was not adequately powered to evaluate non-inferiority, which might be clinically relevant. As a single-center study, identifying an appropriate number of eligible patients to determine non-inferiority was not feasible.|2|||f||||t||||||||||2018-05-31 22:13:03.311786|2018-05-31 22:13:03.311786
NCT01423799|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2015-11-11|2011-08-25|2011-08-26|Estimate|||||||2015-11-11|2015-11-13|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Neoimmune||Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment|Immunonutrition to Improve Quality of Life of Upper Gastrointestinal Cancer Patients Undergoing Oncological Treatment|Completed||Phase 3|300|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 22:13:03.547182|2018-05-31 22:13:03.547182
NCT01423786|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|August 2011||2011-08-31|August 2011|2011-08-31||||March 2013|Anticipated|2013-03-31||Interventional|||Early Oral Nutrition in Mild Acute Pediatric Pancreatitis|Early Oral Nutrition in Mild Acute Pediatric Pancreatitis|Unknown status|Recruiting|N/A|35|Anticipated|Nationwide Children's Hospital|||||f||||||||||||||2018-05-31 22:13:03.623859|2018-05-31 22:13:03.623859
NCT01423773|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|2012-11-21||2013-06-20|2011-08-25|2011-08-26|Estimate|2012-11-21|2012-12-21|Estimate||||2013-06-20|2013-06-28|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression|Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression|Completed||N/A|20|Actual|Alcon Research|The sample size may be small for establishing relationship between ocular comfort and other measurable variables.|2|||f||||f||||||||||2018-05-31 22:13:03.752454|2018-05-31 22:13:03.752454
NCT01423760|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2016-06-02||2016-08-10|2011-08-25|2011-08-26|Estimate|2016-08-10|2016-10-06|Estimate||||2016-08-10|2016-10-06|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||Screening analysis set included all the subjects included in the trial.|Common Safety Follow-up Trial of Tecemotide (L-BLP25)|An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials|Terminated||N/A|27|Actual|Merck KGaA|The study was terminated prematurely as the sponsor decided to discontinue program with Tecemotide in non-small cell lung cancer (NSCLC).|2||"The study is terminated prematurely as the sponsor decided to discontinue program with~   Tecemotide in NSCLC."|f||||f||||||||||2018-05-31 22:13:03.952902|2018-05-31 22:13:03.952902
NCT01423747|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2015-06-25|2011-08-25|2011-08-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2003||2003-07-31|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|September 2011|Actual|2011-09-30||Interventional|||Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia|Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|St. Anna Kinderkrebsforschung||3|||f||||t||||||||||2018-05-31 22:13:04.461788|2018-05-31 22:13:04.461788
NCT01423734|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2018-05-04|2011-08-25|2011-08-26|Estimate|||||||2018-05-04|2018-05-07|Actual|August 2011||2011-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases|Pilot Study To Assess The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases|Active, not recruiting|||20|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 22:13:04.591729|2018-05-31 22:13:04.591729
NCT01423721|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2013-10-31|2011-08-25|2011-08-26|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2011||2011-08-31|October 2013|2013-10-31||||October 2011|Actual|2011-10-31||Interventional|||Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study)|Relative Bioavailability of Bromhexine for Oral Administration of 16 mg of Bromhexine Hydrochloride Granules Compared to 16 mg of Bromhexine Hydrochloride Syrup in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Replicate Design Phase I Study With Two Treatments in Four Crossover Periods)|Completed||Phase 1|39|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:13:04.664455|2018-05-31 22:13:04.664455
NCT01423708|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2012-07-17|2011-08-25|2011-08-26|Estimate|||||||2012-07-17|2012-07-18|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|EPOCAL||Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study|Terapia Con Everolimus Nel Trapianto de Novo di Fegato: Uno Studio Multicentrico Randomizzato|Unknown status|Recruiting|Phase 2|117|Anticipated|Azienda Ospedaliera di Padova||2|||f||||t||||||||||2018-05-31 22:13:04.73861|2018-05-31 22:13:04.73861
NCT01423695|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-25|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|February 2001||2001-02-28|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer|Weekly Application of Trastuzumab and Paclitaxel in the Treatment of HER2-overexpressing Metastatic Breast Cancer|Completed||Phase 2|121|Actual|WiSP Wissenschaftlicher Service Pharma GmbH||1|||f||||f||||||||||2018-05-31 22:13:04.851308|2018-05-31 22:13:04.851308
NCT01423682|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2014-12-04|2011-08-25|2011-08-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||The Influence of Eccentric Training on the Volume and Vascularisation of the Rotator Cuff in Patients With Rotator Cuff Tendinopathy and Healthy Subjects|The Influence of Eccentric Training on the Volume and Vascularisation of the Rotator Cuff in Patients With Rotator Cuff Tendinopathy and Healthy Subjects|Unknown status|Recruiting|N/A|60|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 22:13:04.905165|2018-05-31 22:13:04.905165
NCT01423669|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Observational|||Epidemiology Study of Psychosis|The Hong Kong Morbidity Survey 2010 Part 3: Epidemiology Study of Psychosis Disorder and Sub-clinical Psychotic Experiences|Unknown status|Recruiting||5000|Anticipated|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 22:13:04.966947|2018-05-31 22:13:04.966947
NCT01423656|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-01-25|2011-08-25|2011-08-26|Estimate|||||||2013-01-25|2013-01-28|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102||Completed||Phase 1|102|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 22:13:05.028162|2018-05-31 22:13:05.028162
NCT01423643|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2016-02-22|2011-08-25|2011-08-26|Estimate|||||||2016-02-22|2016-02-24|Estimate|March 2001||2001-03-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||HCV/HIV Coinfection: Antiviral Therapy and Fibrosis|HCV/HIV Coinfection: Antiviral Therapy and Fibrosis|Completed|||1250|Actual|Johns Hopkins University|||2||f||||f||||||Samples Without DNA|"~     Frozen serum and plasma samples. Liver biopsy fixed slides.~   "|||2018-05-31 22:13:05.268817|2018-05-31 22:13:05.268817
NCT01423630|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2017-10-17|2011-08-25|2011-08-26|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2011|Actual|2011-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver|Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver|Active, not recruiting||N/A|40|Anticipated|Region Skane||1|||f||||f||||||||||2018-05-31 22:13:05.345611|2018-05-31 22:13:05.345611
NCT01423617|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|2015-03-25||2015-04-05|2011-08-25|2011-08-26|Estimate|2015-04-05|2015-04-23|Estimate||||2015-04-05|2015-04-23|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety of Zenoctil in Reducing Body Weight|Double-blind, Randomized, Placebo-controlled, Bicentric Study to Evaluate the Safety and Efficacy of Zenoctil in Reducing Body Weight of Overweight Subjects|Completed||Phase 3|92|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 22:13:05.426341|2018-05-31 22:13:05.426341
NCT01423604|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2016-04-01|2014-04-04|2018-01-15|2011-08-24|2011-08-26|Estimate|2016-07-19|2016-08-29|Estimate|2014-04-04|2014-05-01|Estimate|2018-01-15|2018-02-12|Actual|July 2011||2011-07-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|June 2013|Actual|2013-06-30||Interventional|RECAP||Study of Ruxolitinib in Pancreatic Cancer Patients|A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination With Capecitabine for Subjects With Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP Trial)|Completed||Phase 2|136|Actual|Incyte Corporation||2|||f||||t||||||||||2018-05-31 22:13:05.704952|2018-05-31 22:13:05.704952
NCT01423591|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|June 2007||2007-06-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica|Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica: a Double Blind Placebo Controlled Trial|Unknown status|Active, not recruiting|Phase 3|23|Actual|Hospital Universitario Marqués de Valdecilla||2|||f||||t||||||||||2018-05-31 22:13:07.802065|2018-05-31 22:13:07.802065
NCT01423578|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2017-06-23|2011-08-25|2011-08-26|Estimate|||||||2017-06-23|2017-06-26|Actual|August 21, 2007|Actual|2007-08-21|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|May 2, 2011|Actual|2011-05-02||Interventional|||Effects of Yoga and Cardiovascular Exercise on Smoking Motivation|Effects of Yoga and Cardiovascular Exercise on Smoking Motivation|Completed||N/A|79|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|f|f||||||||2018-05-31 22:13:07.886161|2018-05-31 22:13:07.886161
NCT01423565|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-03-17|2011-08-25|2011-08-26|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Comparison of Constant Current to Constant Voltage Stimulation in Subthalamic Deep Brain Stimulation for Parkinson's Disease|Comparison of Constant Current to Constant Voltage Stimulation in Subthalamic DBS for Parkinson's Disease|Completed||N/A|8|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:13:07.961767|2018-05-31 22:13:07.961767
NCT01423552|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|November 2011||2011-11-30|August 2011|2011-08-31||||||||Observational|||Pharmacology of Immunosuppressants Following Heart Transplantation|Correlation of Immunosuppressant Pharmacokinetics, Pharmacodynamics, Pharmacogenomics and Outcomes Following Heart Transplantation|Unknown status|Not yet recruiting||100|Anticipated|University Hospital Birmingham|||1||f||||f||||||Samples With DNA|"~     Myocardial biopsy, whole blood, peripheral lymphocytes~   "|||2018-05-31 22:13:08.045189|2018-05-31 22:13:08.045189
NCT01423539|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2016-11-01|2011-08-24|2011-08-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)|A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of Bendamustine + Rituximab With or Without Navitoclax in Patients With Relapsed Diffuse Large B-Cell Lymphoma|Withdrawn||Phase 2|0|Actual|Genentech, Inc.||2||The NAVIGATE study has been terminated due to non-safety related reasons.|f||||||||||||||2018-05-31 22:13:08.123631|2018-05-31 22:13:08.123631
NCT01423526|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-02-23|2011-08-25|2011-08-26|Estimate|||||||2014-02-23|2014-02-25|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Single Dose Study of DWP10292 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo Controlled, Single-dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of DWP10292 After Oral Administration in Healthy Male Subjects|Completed||Phase 1|52|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||t||||||||||2018-05-31 22:13:08.21503|2018-05-31 22:13:08.21503
NCT01423513|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-03-03|2011-08-25|2011-08-26|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effects of Ankle Support on Muscle Activation and Function|Effects of Ankle Support on Muscle Activation and Function|Completed||N/A|26|Actual|Creighton University||2|||f||||f||||||||||2018-05-31 22:13:08.375023|2018-05-31 22:13:08.375023
NCT01423500|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-06-25|2011-08-25|2011-08-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2007||2007-01-31|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|September 2011|Actual|2011-09-30||Interventional|ALL-SCT-BFMi||ALL-SCT BFM International- HSCT in Children and Adolescents With ALL|Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia|Unknown status|Active, not recruiting|Phase 3|405|Anticipated|St. Anna Kinderkrebsforschung||3|||f||||t||||||||||2018-05-31 22:13:08.45226|2018-05-31 22:13:08.45226
NCT01423487|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-07-31|2011-08-25|2011-08-26|Estimate|||||||2012-07-31|2012-08-02|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|August 2013|Anticipated|2013-08-31|February 2013|Anticipated|2013-02-28||Interventional|||Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea|Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea:a 24-week, Randomized, Placebo-controlled, Double-blind, Fixed-dose Study|Withdrawn||N/A|0|Actual|Central South University||2||Difficult to obtain informed consent|f||||t||||||||||2018-05-31 22:13:08.590593|2018-05-31 22:13:08.590593
NCT01423474|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2018-02-08|2011-08-24|2011-08-26|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2012||2012-01-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|PATRIOT||Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time|Randomized Phase II Study of 2 Hypofractionated Radiotherapy Schedules for Low- and Intermediate-Risk Prostate Cancer|Active, not recruiting||N/A|152|Actual|CancerCare Manitoba||2|||f||||t||||||||Undecided||2018-05-31 22:13:08.681341|2018-05-31 22:13:08.681341
NCT01423461|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|July 2005||2005-07-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|PACT||Personalized Asthma Care Team|Individualized Health Care for Children With Common Chronic Diseases|Completed|||201|Actual|Brigham and Women's Hospital|||||f||||||||||||||2018-05-31 22:13:08.759032|2018-05-31 22:13:08.759032
NCT01423448|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-01-13|2011-08-25|2011-08-26|Estimate|||||||2015-01-13|2015-01-14|Estimate||||January 2015|2015-01-31||||||||Interventional|ShareIT||Effectiveness of an Online Bulletin Board for Depression: a Longitudinal Randomized Controlled Trial|A Randomized Controlled Trial of an Online Bulletin Board for Depression|Withdrawn||Early Phase 1|0|Actual|Australian National University||2||Recruitment of participants did not commence due to lack of available staff to run the trial.|f||||f||||||||||2018-05-31 22:13:08.81724|2018-05-31 22:13:08.81724
NCT01423435|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-10-02|2011-08-24|2011-08-26|Estimate|||||||2011-10-02|2011-10-04|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males|A Pharmacokinetic Study of TRK-100STP -A Single Oral Administration Study in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males -|Completed||Phase 1|36|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 22:13:08.897065|2018-05-31 22:13:08.897065
NCT01423422|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-25|2011-08-25|2011-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|November 2011||2011-11-30|August 2011|2011-08-31|October 2012|Anticipated|2012-10-31|May 2012|Anticipated|2012-05-31||Observational|||Effects of Low Frequency Magnetic Field on Exercise Induced Angina|Effects of Low Frequency Electromagnetic Field on Patients With Exercise Induced Angina|Unknown status|Not yet recruiting||40|Anticipated|Aerotel Ltd|||1||f||||f||||||||||2018-05-31 22:13:08.991376|2018-05-31 22:13:08.991376
NCT01423409|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2013-07-22|2011-08-24|2011-08-25|Estimate|||||||2013-07-22|2013-07-23|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|EVA_SOURD||Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People|Assessment of an Innovative Visual Analogue Scale of Pain (Pictorial VAS) Versus the Usual VAS (VAS) Among Deaf People|Completed||Phase 2/Phase 3|289|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 22:13:09.07619|2018-05-31 22:13:09.07619
NCT01423396|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2018-04-17|2011-08-23|2011-08-25|Estimate|||||||2018-04-17|2018-04-18|Actual|March 15, 2010|Actual|2010-03-15|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|COVARAD||Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease|Impact of Controlling Vascular Risk Factors on the Progression of Alzheimer's Disease|Recruiting||N/A|406|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||No||2018-05-31 22:13:09.162029|2018-05-31 22:13:09.162029
NCT01423383|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2016-10-17|2011-08-24|2011-08-25|Estimate|||||||2016-10-17|2016-10-18|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|June 2020|Anticipated|2020-06-30||Observational|||Epidemiology Study of Keloid|Epidemiology Study of Keloid|Recruiting|||100000|Anticipated|Tirgan, Michael H., M.D.|||1||f||||f||||||||||2018-05-31 22:13:09.251036|2018-05-31 22:13:09.251036
NCT01423370|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2014-07-30|2011-08-24|2011-08-25|Estimate|||||||2014-07-30|2014-07-31|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Efficacy of YHD1023 in Erectile Dysfunction|Multi-center, Randomized, Double-blind, Placebo/Active-controlled, Phase II Clinical Trial to Assess the Safety and Efficacy of YHD1023 in Patients With Erectile Dysfunction|Completed||Phase 2|104|Anticipated|Yuhan Corporation||5|||f||||t||||||||||2018-05-31 22:13:09.327554|2018-05-31 22:13:09.327554
NCT01423357|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-08-24|2011-08-24|2011-08-25|Estimate|||||||2011-08-24|2011-08-25|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|PLACE||Targeting Interventions at Venues Where Risk of HIV Transmission is High|Targeting Interventions at Venues Where Risk of HIV Transmission is High|Completed||Phase 1|537|Actual|University of Zambia||2|||f||||f||||||||||2018-05-31 22:13:09.409103|2018-05-31 22:13:09.409103
NCT01423344|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-24|2011-08-24|2011-08-25|Estimate|||||||2011-08-24|2011-08-25|Estimate|February 2011||2011-02-28|August 2011|2011-08-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Clinical Evaluation of the Serum Free Light Chain Analysis|Assessment of the Value of the Free Kappa and Free Lambda Light Chain Assay in Clinical Evaluation of Response to Treatment|Unknown status|Recruiting||30|Anticipated|University of Southern Denmark|||||f||||t||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 22:13:09.583587|2018-05-31 22:13:09.583587
NCT01423331|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-24|2011-08-24|2011-08-25|Estimate|||||||2011-08-24|2011-08-25|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||An Evaluation and Factor Analysis for Maternal Mental Health|An Evaluation and Factor Analysis for Maternal Mental Health - The Analytic Study of the Shin Kong Wu Ho-Su Memorial Hospital|Unknown status|Not yet recruiting||200|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital|||||f||||t||||||||||2018-05-31 22:13:09.668898|2018-05-31 22:13:09.668898
NCT01423318|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-11-01|2011-08-23|2011-08-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Doses of Lebrikizumab in Healthy Japanese and Caucasian Volunteers|Completed||Phase 1|60|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:13:09.739457|2018-05-31 22:13:09.739457
NCT01423305|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-10-20|2011-08-24|2011-08-25|Estimate|||||||2011-10-20|2011-10-21|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|BF-BLOCK||Phase I Pharmacokinetic Study (BF-BLOCK)|Effect of Charcoal on Gastrointestinal Absorption of Budesonide and Formoterol|Completed||Phase 1|20|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 22:13:09.813708|2018-05-31 22:13:09.813708
NCT01423292|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-08-02|2011-08-24|2011-08-25|Estimate|||||||2012-08-02|2012-08-06|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection||Completed||Phase 3|56|Actual|National Cancer Center, Korea||2|||f||||||||||||||2018-05-31 22:13:09.881379|2018-05-31 22:13:09.881379
NCT01423279|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2018-03-27|2011-08-24|2011-08-25|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2013||2013-02-28|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||The Effect of a Diabetic- and a Kidney-like Environment on Gene and Protein Expression in Cultured EC and SMC|The Effect of a Diabetic- and a Kidney-like Environment on Gene and Protein Expression in Mono- and Co-cultured Endothelial and Smooth Muscle Cells|Recruiting|||100|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 22:13:09.958014|2018-05-31 22:13:09.958014
NCT01423266|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-05-19|2011-08-23|2011-08-25|Estimate|||||||2016-05-19|2016-05-23|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of a High Protein Diet on Clinical Outcomes in Heart Failure|Examining the Effects of a High Protein Diet on Adiposity and Cardiac Structure in Patients With Heart Failure, Obesity, and Diabetes Mellitus|Completed||N/A|78|Actual|University of California, Irvine||2|||f||||t||||||||Yes|Data management and analysis is in progress.|2018-05-31 22:13:10.036081|2018-05-31 22:13:10.036081
NCT01423253|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2015-09-15|2014-01-23|2016-03-10|2011-08-24|2011-08-25|Estimate|2015-09-15|2015-10-14|Estimate|2014-01-23|2014-02-20|Estimate|2016-03-10|2016-04-08|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|RESOLVE3|Safety population|Major Depressive Disorder With Mixed Features - Extension|A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features|Completed||Phase 3|48|Actual|Sunovion||1|||f||||t||||||||||2018-05-31 22:13:10.154598|2018-05-31 22:13:10.154598
NCT01423240|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2012-12-11|2011-08-24|2011-08-25|Estimate|||||||2012-12-11|2012-12-13|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|RESOLVE2||Major Depressive Disorder With Mixed Features|A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features|Withdrawn||Phase 3|0|Actual|Sunovion||3|||f||||t||||||||||2018-05-31 22:13:10.443974|2018-05-31 22:13:10.443974
NCT01423227|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2012-07-24|2011-08-24|2011-08-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|HomeBase||Benefits and Costs of Home-based Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease|Benefits and Costs of Home-based Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|Phase 3|144|Anticipated|La Trobe University||2|||f||||t||||||||||2018-05-31 22:13:10.58416|2018-05-31 22:13:10.58416
NCT01423214|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-03-09|2011-08-24|2011-08-25|Estimate|||||||2015-03-09|2015-03-11|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|COLRAR||A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer||Recruiting||Phase 3|540|Anticipated|Kyungpook National University||2|||f||||t||||||||||2018-05-31 22:13:10.687338|2018-05-31 22:13:10.687338
NCT01422707|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-01-19|2011-08-23|2011-08-24|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess|Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)|Not yet recruiting||Early Phase 1|20|Anticipated|University of Virginia||1|||f||||f|t|f||||||||2018-05-31 22:13:17.174317|2018-05-31 22:13:17.174317
NCT01423201|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-04-26|2011-08-24|2011-08-25|Estimate|||||||2017-04-26|2017-04-27|Actual|September 2010||2010-09-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk|TIA Triage Trial and Evaluation of Vascular-Specific Inflammatory BiomarkerLp-PLA2 as a Stratification Tool for TIA Triage and Stroke Risk|Active, not recruiting|||262|Actual|Stanford University|||||f||||f||||||Samples Without DNA|"~     First 100 cases:~      2 tiger top or gold top tubes 2 lavender top tubes~        -  Blood specimens should be inverted 10 times before processing.~        -  Centrifuge and separate within four hours of venipuncture.~        -  Transfer 1.0 ml into 2 transfer tubes~      Freeze at -70 C~      Additional 80 cases:~      3 PAXgene tubes (total 16cc) - containing 7.5 cc preservative to stabilize RNA immediately.~      Invert 20 times then sit at room temperature overnight Place into a -70C freezer until~     processed~      2 tiger top or gold top tubes 2 lavender top tubes~        -  Blood specimens should be inverted 10 times before processing.~        -  Centrifuge and separate within four hours of venipuncture.~        -  Transfer 1.0 ml into 2 transfer tubes~      Freeze at -70 C~   "|||2018-05-31 22:13:10.779275|2018-05-31 22:13:10.779275
NCT01423188|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2012-09-19|2011-08-23|2011-08-25|Estimate|||||||2012-09-19|2012-09-20|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|SUSTAIN||The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation|Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial for the Assessment of Lipid Trends and Safety of RVX000222 in Statin Treated Subjects With Low Baseline HDL-C Concentrations|Completed||Phase 2|176|Actual|Resverlogix Corp||2|||f||||t||||||||||2018-05-31 22:13:10.848562|2018-05-31 22:13:10.848562
NCT01423175|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2011-08-26|2011-08-24|2011-08-25|Estimate|||||||2011-08-26|2011-08-29|Estimate|July 2011||2011-07-31|August 2011|2011-08-31||||January 2015|Anticipated|2015-01-31||Interventional|ClAraC-SCT||ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS|Randomized, Multi-centre, Phase II Trial to Compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients With High Risk AML or Advanced MDS Scheduled for Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|60|Anticipated|Hannover Medical School||2|||f||||f||||||||||2018-05-31 22:13:10.9352|2018-05-31 22:13:10.9352
NCT01423162|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2012-08-22||2012-08-22|2011-08-24|2011-08-25|Estimate|2012-08-22|2012-09-21|Estimate||||2012-08-22|2012-09-21|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Iron Bioavailability of Fortified Oat Drink|Iron Bioavailability Study Of Fortified Oat Drink|Completed||Phase 4|21|Actual|PepsiCo Global R&D|One of the isotopes was not detected in blood sample of 1 participant, therefore data from this participant was excluded from final per protocol analysis|2|||f||||f||||||||||2018-05-31 22:13:11.018685|2018-05-31 22:13:11.018685
NCT01423149|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22||2011-10-28|2011-10-28|2011-08-24|2011-08-25|Estimate||||2011-10-28|2011-11-01|Estimate|2011-10-28|2011-11-01|Estimate|March 2005||2005-03-31|October 2011|2011-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia|A Phase II, Dose Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of Combretastatin A4 Phosphate for Treating Subfoveal Choroidal Neovascularization in Subjects With Pathologic Myopia|Completed||Phase 2|23|Actual|Mateon Therapeutics||3|||f||||t||||||||||2018-05-31 22:13:11.20355|2018-05-31 22:13:11.20355
NCT01423136|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-05-30|2011-08-23|2011-08-25|Estimate|||||||2014-05-30|2014-06-02|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Observational|PROSE 3||Remote Electrocardiographic (ECG) ST-Monitoring (PROSE 3)in Post-op Patients|Postop Remote ECG ST-Monitoring (PROSE 3)|Completed|||89|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-05-31 22:13:11.353064|2018-05-31 22:13:11.353064
NCT01423123|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2014-07-07|2011-08-24|2011-08-25|Estimate|||||||2014-07-07|2014-07-08|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|August 2012|Actual|2012-08-31||Interventional|||Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer|A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer|Completed||Phase 1|21|Actual|NSABP Foundation Inc||1|||f||||f||||||||||2018-05-31 22:13:11.422044|2018-05-31 22:13:11.422044
NCT01423110|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2017-02-21|2011-08-23|2011-08-25|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2011||2011-08-31|February 2017|2017-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis|A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis|Completed||Phase 2|14|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:13:11.523151|2018-05-31 22:13:11.523151
NCT01423097|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-24|||2012-10-09|2011-08-24|2011-08-25|Estimate|||||||2012-10-09|2012-10-10|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|MOVES||Magnitude of Osteoarthritis disadVantage on pEoples liveS|Magnitude of Osteoarthritis disadVantage on pEoples liveS|Completed|||1015|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:13:11.618542|2018-05-31 22:13:11.618542
NCT01423084|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2015-02-03||2015-02-03|2011-08-24|2011-08-25|Estimate|2015-02-03|2015-02-20|Estimate||||2015-02-03|2015-02-20|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||adolescents aged 11-17 years|Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years|A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years|Completed||Phase 3|344|Actual|Novartis|None reported|2|||f||||f||||||||||2018-05-31 22:13:11.708712|2018-05-31 22:13:11.708712
NCT01423071|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-06-17|2011-08-23|2011-08-25|Estimate|||||||2015-06-17|2015-06-18|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life|Chronisch Obstruktive Lungenerkrankung Und Pulmonale Hypertonie: Prävalenz Und Lebensqualität|Completed|||220|Actual|Wissenschaftliches Institut Bethanien e.V|||3||f||||f||||||||||2018-05-31 22:13:12.223325|2018-05-31 22:13:12.223325
NCT01422694|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2018-05-26|2011-08-23|2011-08-24|Estimate|||||||2018-05-26|2018-05-30|Actual|August 23, 2011||2011-08-23|May 21, 2018|2018-05-21||||||||Observational|||Natural History and Development of Spondyloarthritis|Studies on the Natural History and Pathogenesis of Spondyloarthritis|Recruiting|||999999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:13:17.25134|2018-05-31 22:13:17.25134
NCT01423058|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07||2015-01-16|2015-01-16|2011-08-24|2011-08-25|Estimate||||2015-01-16|2015-01-28|Estimate|2015-01-16|2015-01-28|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis|A Phase I/II, Open-Label Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis|Completed||Phase 1/Phase 2|61|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 22:13:12.301092|2018-05-31 22:13:12.301092
NCT01423045|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-08-24|2011-08-24|2011-08-25|Estimate|||||||2011-08-24|2011-08-25|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease|Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease|Unknown status|Not yet recruiting||200|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 22:13:12.380094|2018-05-31 22:13:12.380094
NCT01423032|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-24|2011-08-24|2011-08-25|Estimate|||||||2011-08-24|2011-08-25|Estimate|September 2001||2001-09-30|August 2011|2011-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)|Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV|Completed||Phase 2/Phase 3|96|Actual|WiSP Wissenschaftlicher Service Pharma GmbH||2|||f||||f||||||||||2018-05-31 22:13:12.439204|2018-05-31 22:13:12.439204
NCT01423019|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-01-20|2011-08-23|2011-08-25|Estimate|||||||2012-01-20|2012-01-23|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Comparative Effectiveness Study Evaluating the Effects of Thermogenic Supplements on Body Composition|A Comparative Effectiveness Study Evaluating the Effects of Two Thermogenic Supplements on Body Composition Using a Double-Blinded Placebo-Controlled Protocol|Completed||N/A|75|Anticipated|Integrative Health Technologies, Inc.||3|||f||||f||||||||||2018-05-31 22:13:12.518125|2018-05-31 22:13:12.518125
NCT01423006|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2013-11-13|2011-08-24|2011-08-25|Estimate|||||||2013-11-13|2013-11-14|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pilot Study on Focal Prostate Radio-Frequency Ablation|Pilot Study on Focal Prostate Radio-Frequency Ablation for the Treatment of Very-Low Risk Prostate Cancer|Completed||N/A|5|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 22:13:12.605709|2018-05-31 22:13:12.605709
NCT01422993|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2016-12-28|2011-08-24|2011-08-25|Estimate|||||||2016-12-28|2016-12-29|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy|A Pilot Study of a Strength and Balance Training Program for Persons With Oxaliplatin Induced Peripheral Neuropathy|Completed||N/A|4|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 22:13:12.673087|2018-05-31 22:13:12.673087
NCT01422980|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-10-07|2011-08-23|2011-08-25|Estimate|||||||2016-10-07|2016-10-10|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Effect of Consumption of Dairy Product on Upper Gastric Discomfort|Effect of Consumption of Dairy Product on Upper Gastric Discomfort|Completed||N/A|236|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 22:13:12.7417|2018-05-31 22:13:12.7417
NCT01422967|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-24|2011-08-23|2011-08-25|Estimate|||||||2011-08-24|2011-08-26|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Changes Of Sleep on the Sensoriomotor and Cytokine In Patients With Osteoarthritis|Changes of Sleep on the Sensorimotor and Cytokine in Patients With Knee Osteoarthritis|Unknown status|Recruiting|N/A|60|Anticipated|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 22:13:12.795179|2018-05-31 22:13:12.795179
NCT01422954|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2013-04-26|2011-08-23|2011-08-25|Estimate|||||||2013-04-26|2013-04-29|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis|Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis|Completed||N/A|20|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 22:13:12.865468|2018-05-31 22:13:12.865468
NCT01422941|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-07-27|2011-08-23|2011-08-25|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2010||2010-10-31|August 2011|2011-08-31||||June 2011|Actual|2011-06-30||Interventional|||Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study|A PROSPECTIVE, MULTI-CENTER CLINICAL EVALUATION TO ASSESS SAFETY AND PERFORMANCE OF CAVU MEDICAL, INC.'S ATTUNE TUBING WHEN USED WITH NEWLY-IMPLANTED LAPAROSCOPIC ADJUSTABLE GASTRIC BANDS (LAGBs)|Completed||Phase 1|40|Actual|Cavu Medical, Inc.||1|||f||||t||||||||||2018-05-31 22:13:12.938286|2018-05-31 22:13:12.938286
NCT01422928|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2015-05-22|2011-08-23|2011-08-25|Estimate|||||||2015-05-22|2015-05-25|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Acupuncture for the Immune System in Radiation Cancer Patients|Does Radiation Therapy Adversely Affect the Immune System, and Can Acupuncture Ameliorate the Effect? A Pilot Study|Withdrawn||Phase 3|0|Actual|British Columbia Cancer Agency||2||Study was not approved by research ethics board.|f||||f||||||||||2018-05-31 22:13:12.985559|2018-05-31 22:13:12.985559
NCT01422915|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2013-08-20||2017-03-14|2011-08-24|2011-08-25|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|May 2011||2011-05-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|EPP||Sorbent Therapy of the Cutaneous Porphyrias|Sorbent Therapy of the Cutaneous Porphyrias|Completed||Phase 2/Phase 3|4|Actual|Brigham and Women's Hospital|1 subject was removed during Period 1 because of abnormal liver chemistries.|1|||f||||f||||||||||2018-05-31 22:13:13.057444|2018-05-31 22:13:13.057444
NCT01422902|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-02-04|2011-08-24|2011-08-25|Estimate|||||||2016-02-04|2016-02-08|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|e-CAeSAR||Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults|Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults, A Remediation-based Approach|Completed||Phase 2|150|Actual|Posit Science Corporation||2|||f||||f||||||||||2018-05-31 22:13:13.203938|2018-05-31 22:13:13.203938
NCT01422889|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2014-04-23||2016-01-06|2011-08-23|2011-08-25|Estimate|2015-03-09|2015-03-20|Estimate||||2016-01-06|2016-02-04|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|June 2013|Actual|2013-06-30||Observational||Subjects that recevied at least one study stent|ION US Post-Approval Study|A U.S. Post-Approval Study of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System|Completed|||1120|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 22:13:13.286953|2018-05-31 22:13:13.286953
NCT01374282|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2015-10-21|2011-06-14|2011-06-15|Estimate|||||||2015-10-21|2015-10-22|Estimate||||October 2015|2015-10-31||||||||Expanded Access|||Post Marketing Surveillance Study of Cuprimine|Post Marketing Surveillance Study of Cuprimine (MK-0172-001)|No longer available|||||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-05-31 22:30:17.109047|2018-05-31 22:30:17.109047
NCT01422876|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2015-01-15|2014-05-15|2015-04-01|2011-08-23|2011-08-25|Estimate|2015-04-01|2015-04-02|Estimate|2014-05-15|2014-05-28|Estimate|2015-04-01|2015-04-02|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||FAS|Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients|A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control|Completed||Phase 3|1405|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 22:13:14.027723|2018-05-31 22:13:14.027723
NCT01422863|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2017-08-15|2011-08-23|2011-08-24|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2010||2010-10-31|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Lifestyle Interventions for Seniors With Apnea|Effects of Weight Loss Through Diet and Exercise on Sleep Apnea Severity and Cardiovascular Risk in Older Adults|Completed||N/A|18|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 22:13:15.447952|2018-05-31 22:13:15.447952
NCT01422850|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2013-08-05||2014-03-26|2011-08-23|2011-08-24|Estimate|2014-03-26|2014-04-23|Estimate||||2014-03-26|2014-04-23|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|ALECSAT||Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy|A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering Repeated Doses of ALECSAT to Prostate Cancer Patients.|Completed||Phase 1|21|Actual|CytoVac A/S|||||f||||f||||||||||2018-05-31 22:13:15.516347|2018-05-31 22:13:15.516347
NCT01422837|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2014-08-06|2011-08-23|2011-08-24|Estimate|||||||2014-08-06|2014-08-07|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|VICTORY||ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry|VIvitrol's Cost and Treatment Outcomes RegistrY|Completed|||403|Actual|Alkermes, Inc.|||||f||||f||||||||||2018-05-31 22:13:15.795564|2018-05-31 22:13:15.795564
NCT01422824|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|2016-02-26||2016-02-26|2011-08-23|2011-08-24|Estimate|2016-02-26|2016-03-28|Estimate||||2016-02-26|2016-03-28|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational||Safety population included all treated participants.|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis|An Observational. Non-interventional Study to Observe the Safety and Efficacy of MIRCERA in the Treatment of Chronic Renal Anemia in Maintenance ESA Treated Patients on Haemodialysis (STABILE)|Completed|||185|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:13:15.912943|2018-05-31 22:13:15.912943
NCT01422811|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-08-23|2011-08-23|2011-08-24|Estimate|||||||2011-08-23|2011-08-24|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional|||Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation|Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation|Completed||Phase 3|3862|Actual|Azienda Ospedaliero-Universitaria di Parma||2|||f||||f||||||||||2018-05-31 22:13:16.122186|2018-05-31 22:13:16.122186
NCT01422798|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-02-29|2011-08-23|2011-08-24|Estimate|||||||2016-02-29|2016-03-02|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||An Open Cohort of Childhood Tuberculosis in Mbarara National Referral Hospital, Uganda|An Open Cohort of Childhood Tuberculosis in Mbarara National Referral Hospital, Uganda|Completed|||396|Actual|Epicentre|||||f||||f||||||||No||2018-05-31 22:13:16.351519|2018-05-31 22:13:16.351519
NCT01422785|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-08-22|2011-08-22|2011-08-24|Estimate|||||||2011-08-22|2011-08-24|Estimate|July 2011||2011-07-31|August 2011|2011-08-31||||December 2011|Anticipated|2011-12-31||Interventional|||A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne|A Pilot Study to Evaluate the Efficacy of Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Alone Versus Fixed Dose Combination Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel Plus Benzoyl Peroxide 6% Foaming Cloths in the Treatment of Facial Acne Vulgaris|Unknown status|Recruiting|Phase 4|40|Anticipated|Zeichner, Joshua, M.D.||2|||f||||t||||||||||2018-05-31 22:13:16.425148|2018-05-31 22:13:16.425148
NCT01422772|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2015-01-25|2011-08-22|2011-08-24|Estimate|||||||2015-01-25|2015-01-27|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|February 2010|Actual|2010-02-28||Interventional|||Safety Study of Gene Therapy for Ischemic Heart Disease in Korea|Open-label, Dose-escalation, Phase 1 Trial to Evaluate the Safety of VM202RY Gene Medicine Injected Into Myocardial Territory With Incomplete Revascularization During Coronary Artery Bypass Graft in Patients With Ischemic Heart Disease|Completed||Phase 1|9|Actual|ViroMed Co., Ltd.||3|||f||||f||||||||||2018-05-31 22:13:16.537208|2018-05-31 22:13:16.537208
NCT01422759|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2018-01-19|2011-08-23|2011-08-24|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess|Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess (CBS006)|Recruiting||N/A|20|Anticipated|University of Virginia||1|||f||||f||||||||No||2018-05-31 22:13:16.620431|2018-05-31 22:13:16.620431
NCT01422746|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2018-01-19|2011-08-23|2011-08-24|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess|Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess (CBS005)|Recruiting||N/A|20|Anticipated|University of Virginia||1|||f||||t||||||||No||2018-05-31 22:13:16.707486|2018-05-31 22:13:16.707486
NCT01422733|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2018-01-19|2011-08-23|2011-08-24|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction|Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction in Overweight Early Pubertal Girls With Androgen Excess (CBS0004)|Not yet recruiting||Early Phase 1|20|Anticipated|University of Virginia||1|||f||||f|t|f||||||||2018-05-31 22:13:16.787116|2018-05-31 22:13:16.787116
NCT01422720|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2014-05-09||2017-06-29|2011-08-23|2011-08-24|Estimate|2014-07-17|2014-07-18|Estimate||||2017-06-29|2017-08-07|Actual|April 2010||2010-04-30|June 2017|2017-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients|Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients|Completed||Phase 3|72|Actual|Bial - Portela C S.A.||1|||f||||f||||||||||2018-05-31 22:13:16.903575|2018-05-31 22:13:16.903575
NCT01422681|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-01-20|2011-08-23|2011-08-24|Estimate|||||||2014-01-20|2014-01-22|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|DECOPD||Extracorporeal CO2 Removal in COPD Exacerbation|Extracorporeal Carbon Dioxide Removal in Patients With Severe COPD Exacerbation Failing Noninvasive Ventilation|Completed||Phase 2|30|Actual|University of Turin, Italy||1|||f||||f||||||||||2018-05-31 22:13:17.344122|2018-05-31 22:13:17.344122
NCT01422668|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-23|2011-08-23|2011-08-24|Estimate|||||||2011-08-23|2011-08-24|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Coffee Consumption on the Glycemic Index of Khalas Dates Tested in Healthy and Diabetic Subjects|Effect of Coffee Consumption on the Glycemic Index of Khalas Dates Tested in Healthy and Diabetic Subjects|Completed||Phase 3|23|Actual|United Arab Emirates University||2|||f||||t||||||||||2018-05-31 22:13:17.429655|2018-05-31 22:13:17.429655
NCT01422655|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2012-01-22|2011-08-23|2011-08-24|Estimate|||||||2012-01-22|2012-01-24|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Transcutaneous Bilirubinometry in Neonates|Accuracy of Transcutaneous Bilirubin Determinations in Neonates: The Effect of Gestational Age, Time and Site of Measurement|Completed|||255|Actual|University of Patras|||||f||||f||||||||||2018-05-31 22:13:17.50343|2018-05-31 22:13:17.50343
NCT01422642|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-08-29|2011-08-23|2011-08-24|Estimate|||||||2011-08-29|2011-08-30|Estimate|January 2001||2001-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|April 2001|Actual|2001-04-30||Interventional|||Do We Need High-Flexing Total Knee Arthroplasty to Improve the Survivorship and to Decrease the Incidence of Osteolysis?|Do We Need High-Flexing Total Knee Arthroplasty to Improve the Survivorship and to Decrease the Incidence of Osteolysis? A Minimum of Ten Years of Follow-up|Completed||Phase 4|111|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 22:13:17.562435|2018-05-31 22:13:17.562435
NCT01422629|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2014-04-08|2011-08-23|2011-08-24|Estimate|||||||2014-04-08|2014-04-09|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma|High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma: a Feasibility Study. A Multicentric, Open, Uncontrolled Study|Completed||N/A|24|Actual|Theraclion||1|||f||||t||||||||||2018-05-31 22:13:17.638455|2018-05-31 22:13:17.638455
NCT01422616|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2018-04-24|2011-08-23|2011-08-24|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|ENCHANTED||Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)|An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke|Recruiting||Phase 3|4700|Anticipated|The George Institute||4|||f||||t||||||||||2018-05-31 22:13:17.712688|2018-05-31 22:13:17.712688
NCT01422603|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-10-12|2011-08-23|2011-08-24|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2014|Actual|2014-05-31||Interventional|||Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)|A Pilot Study of Clofarabine Pre-conditioning Prior to Full or Reduced Intensity Allogeneic Transplantation in the Treatment of High Risk Acute Myeloid Leukaemia and Myelodysplasia.|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:13:17.806555|2018-05-31 22:13:17.806555
NCT01422590|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-09-06|2011-08-23|2011-08-24|Estimate|||||||2011-09-06|2011-09-07|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin|Pharmacodynamics After Concomitant Administration With Mitiglinide and Sitagliptin Compared to Mitiglinide, Sitagliptin Single Administration in Patients With Type 2 Diabetes|Completed||Phase 1|26|Actual|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 22:13:17.86827|2018-05-31 22:13:17.86827
NCT01422577|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-08-10|2011-08-23|2011-08-24|Estimate|||||||2015-08-10|2015-08-11|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|September 2012|Actual|2012-09-30||Interventional|||Diagnosis of Colonic Adenomas by Bright Narrow Band Imaging (B-NBI)|A Randomized Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in the Diagnosis of Colonic Adenomas in Asymptomatic Subjects Undergoing Screening Colonoscopy|Completed||N/A|1006|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:13:17.93802|2018-05-31 22:13:17.93802
NCT01422564|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2015-05-14|2011-08-23|2011-08-24|Estimate|||||||2015-05-14|2015-05-15|Estimate|January 2007||2007-01-31|March 2014|2014-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MOM||Metal on Metal Versus Metal on Highly Crossed Linked Polyethylene Sytem|A Randomized Multicentre Clinical Trial Comparing The Metal on Metal Hip System Versus The Metal on Highly Crossed Linked Polyethylene System|Terminated||Phase 4|41|Actual|Nova Scotia Health Authority||2||Components were recalled by Depuy|f||||f||||||||||2018-05-31 22:13:18.042041|2018-05-31 22:13:18.042041
NCT01422551|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2011-08-22|2011-08-22|2011-08-24|Estimate|||||||2011-08-22|2011-08-24|Estimate|September 1999||1999-09-30|August 2011|2011-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Facilitating Positive Adaptation to Breast Cancer|Facilitating Positive Adaptation to Breast Cancer|Completed||Phase 2|240|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 22:13:18.104802|2018-05-31 22:13:18.104802
NCT01422538|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2013-06-19||2017-11-16|2011-08-23|2011-08-24|Estimate|2013-06-19|2013-08-27|Estimate||||2017-11-16|2017-12-13|Actual|May 2011||2011-05-31|November 2017|2017-11-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Ultherapy™ Treatment Following Sculptra® Treatment|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Following Sculptra® Treatment|Completed||N/A|30|Actual|Merz North America, Inc.|"Entrance criteria possibly restricted to a population with too little skin laxity to assess a difference.~Group C time from Sculptra to Ultherapy may be too long to discern any added benefit of both treatments."|3|||f||||f||||||||||2018-05-31 22:13:18.177846|2018-05-31 22:13:18.177846
NCT01422525|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2014-12-01|2011-08-22|2011-08-24|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2011||2011-11-30|December 2014|2014-12-31||||February 2012|Actual|2012-02-29||Observational|||Changes of the Peripapillary Retinal Nerve Fiber Layer After Filtration Surgery in Glaucoma Patients|Effect of Trabeculectomy on Peripapillary Retinal Nerve Fiber Layer Thickness Using Spectral Domain Optical Coherence Tomography|Terminated|||12|Actual|University Eye Hospital, Würzburg|||1|short of study staff|f||||f||||||||||2018-05-31 22:13:18.546136|2018-05-31 22:13:18.546136
NCT01422200|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Flu Vaccine Study in Neuromuscular Patients 2011|Comparison of the Immunogenicity of Intramuscular Versus Subcutaneous Administration of Trivalent Inactivated Influenza Vaccine in Individuals With Neuromuscular Diseases|Unknown status|Recruiting|N/A|30|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 22:13:38.274709|2018-05-31 22:13:38.274709
NCT01422512|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2011-10-10|2011-08-23|2011-08-24|Estimate|||||||2011-10-10|2011-10-12|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects|A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture, Formulation 2011/2012, When Administered to Adult and Elderly Subjects|Completed||Phase 3|126|Actual|Novartis||1|||f||||f||||||||||2018-05-31 22:13:18.603663|2018-05-31 22:13:18.603663
NCT01422499|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2018-04-10|2011-08-23|2011-08-24|Estimate|||||||2018-04-10|2018-04-11|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||Vorinostat in Children|Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children With Relapsed Solid Tumor, Lymphoma or Leukemia|Completed||Phase 1/Phase 2|50|Actual|National Center for Tumor Diseases, Heidelberg|||||f||||t||||||||||2018-05-31 22:13:18.687006|2018-05-31 22:13:18.687006
NCT01422486|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2013-11-20|2011-08-22|2011-08-24|Estimate|||||||2013-11-20|2013-11-25|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome|Phase 2 Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Lenalidomide (Revlimid®) Refractory or Resistant, Low to Intermediate-1 Risk, Deletion 5q Myelodysplastic Syndrome|Terminated||Phase 2|2|Actual|Telik||1||Study TLK199.2107 was terminated for business reasons.|f||||f||||||||||2018-05-31 22:13:19.740847|2018-05-31 22:13:19.740847
NCT01422473|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2013-06-04|2011-08-23|2011-08-24|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison Study of Hemorrhoid Surgery Using the Enseal Device to Standard Hemorrhoid Surgical Techniques|Hemorrhoidectomy Using the Enseal Device: A Comparison to Open Hemorrhoidectomy Techniques|Terminated||N/A|9|Actual|Swedish Medical Center||1||Terminated due to poor accrual.|f||||f||||||||||2018-05-31 22:13:19.821866|2018-05-31 22:13:19.821866
NCT01422460|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-14|||2011-08-23|2011-08-23|2011-08-24|Estimate|||||||2011-08-23|2011-08-24|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||The Efficacy of Platelets Rich Plasma Injection With PRGF Method in the Treatment for Osteoarthritis of the Subtalar Joint||Unknown status|Not yet recruiting|N/A|30|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:13:19.881028|2018-05-31 22:13:19.881028
NCT01422447|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-11-24|2011-08-22|2011-08-24|Estimate|||||||2015-11-24|2015-11-25|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RPIMHP||Research of Prevention and Intervention of Mental Health Problems|Prevention and Mental Health Education for Mental Health Problems in Community: A Model of Common Mental Health Problems in Seven Metropolis of China|Completed||N/A|42016|Actual|Shanghai Mental Health Center||2|||f||||f||||||||||2018-05-31 22:13:19.956622|2018-05-31 22:13:19.956622
NCT01422434|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2013-09-24||2015-03-25|2011-08-23|2011-08-24|Estimate|2014-01-24|2014-03-11|Estimate||||2015-03-25|2015-04-14|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||LEO 90105 Ointment in Japanese Subjects With Psoriasis|Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris|Completed||Phase 3|676|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 22:13:20.044528|2018-05-31 22:13:20.044528
NCT01422421|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-23|||2018-03-25|2011-08-23|2011-08-24|Estimate|||||||2018-03-25|2018-03-27|Actual|August 2011||2011-08-31|March 2018|2018-03-31|December 2029|Anticipated|2029-12-31|March 2022|Anticipated|2022-03-31||Interventional|||Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease|Intensive Blood Pressure and LDL Lowering for Better Survival and Cardiovascular Outcome in Diabetic Patients With Coronary Artery Disease: Randomized Controlled Trial|Recruiting||Phase 4|1000|Anticipated|Kyoto University, Graduate School of Medicine||2|||f||||t||||||||||2018-05-31 22:13:20.495763|2018-05-31 22:13:20.495763
NCT01422408|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2017-03-29|2016-10-26|2017-07-07|2011-08-22|2011-08-24|Estimate|2017-07-07|2017-08-09|Actual|2016-10-26|2016-11-28|Estimate|2017-07-07|2017-08-09|Actual|September 2011||2011-09-30|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||An intent-to-treat analysis set will include those who are enrolled in the trial regardless of the number of treatments received. All primary analyses will be conducted using the intent-to-treat analysis set. A safety analysis set will include those who receive at least one treatment.|Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy|Phase II Study of the Effect of the Topical Corticosteroid Fluocinonide in Patients on Endocrine Therapy for Either Breast Cancer or an Increased Risk for Breast Cancer With Symptoms of Vaginal Dryness and Dyspareunia|Completed||Phase 2|34|Actual|OHSU Knight Cancer Institute|Original plan was to use GEE modeling for secondary analysis of primary endpoints. Missing data and small counts caused us to perform this analysis using other statistical methods. Data was categorized and tested using McNemar's Test for results|1|||f||||t||||||||||2018-05-31 22:13:20.744542|2018-05-31 22:13:20.744542
NCT01422395|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2014-06-03|2011-08-23|2011-08-24|Estimate|||||||2014-06-03|2014-06-04|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development|A Study to Compare Vitrified/Warmed Oocytes vs. Fresh Sibling Oocytes Collected Following Controlled Ovarian Stimulation Using Follistim AQ and Ganirelix Acetate on Fertilization Rates, Zygote Quality, Embryo Quality and Embryo Development|Completed||Early Phase 1|40|Actual|Main Line Fertility Center||2|||f||||f||||||||||2018-05-31 22:13:33.22911|2018-05-31 22:13:33.22911
NCT01422382|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2012-01-03||2012-07-05|2011-08-23|2011-08-24|Estimate|2012-04-11|2012-04-12|Estimate||||2012-07-05|2012-07-13|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin|Drug-Drug Interaction Study to Assess the Effects of Steady-State Cardizem LA (Diltiazem Hydrochloride) and Steady-State Pitavastatin on Their Respective Pharmacokinetics in Healthy Adult Volunteers|Completed||Phase 4|28|Actual|Kowa Research Institute, Inc.||1|||f||||f||||||||||2018-05-31 22:13:33.321294|2018-05-31 22:13:33.321294
NCT01422369|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2012-01-03||2012-07-05|2011-08-23|2011-08-24|Estimate|2012-02-13|2012-03-15|Estimate||||2012-07-05|2012-07-13|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin|Drug-Drug Interaction Study to Assess the Effects of Steady-State Darunavir/Ritonavir on Steady-State Pitavastatin in Healthy Adult Volunteers|Completed||Phase 4|28|Actual|Kowa Research Institute, Inc.||1|||f||||f||||||||||2018-05-31 22:13:33.648682|2018-05-31 22:13:33.648682
NCT01422356|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2013-10-27||2013-12-19|2011-08-22|2011-08-24|Estimate|2013-12-19|2014-02-10|Estimate||||2013-12-19|2014-02-10|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|HYPER||Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men|Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men|Completed|||200|Actual|The Alfred|The findings from this study may or may not extend to other populations of teenage MSM.||||f||||f||||||Samples With DNA|"~     Genital samples (genital swabs from anus, penis), oral rinse, and serum.~   "|||2018-05-31 22:13:35.025457|2018-05-31 22:13:35.025457
NCT01422343|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-09-08|2011-08-22|2011-08-23|Estimate|||||||2014-09-08|2014-09-09|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Microparticles and the Risk of Re-stenosis Following Balloon Angioplasty in Patients With Peripheral Arterial Disease|Correlation of Microparticles With Risk of Early Re-stenosis After Percutaneous Transluminal Angioplasty in Patients With Peripheral Arterial Disease|Withdrawn|||0|Actual|University Hospital Inselspital, Berne|||1|Shortage of personnel / main study initiator no longer available|f||||f||||||||||2018-05-31 22:13:35.211348|2018-05-31 22:13:35.211348
NCT01422330|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2014-10-10|2011-08-22|2011-08-23|Estimate|||||||2014-10-10|2014-10-13|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients|An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etravirine (ETR) in Combination With Other Antiretrovirals (ARVs) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects|Completed||Phase 4|211|Actual|Janssen R&D Ireland||1|||f||||f||||||||||2018-05-31 22:13:35.297174|2018-05-31 22:13:35.297174
NCT01422317|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-02-18|2011-08-22|2011-08-23|Estimate|||||||2012-02-18|2012-02-22|Estimate|September 1995||1995-09-30|February 2012|2012-02-29|December 2002|Actual|2002-12-31|December 1997|Actual|1997-12-31||Interventional|OFAMI||Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction|Effects of a High-dose Concentrate of n-3 Fatty Acids or Corn Oil Introduced Early After an Acute Myocardial Infarction on Serum Triacylglycerol and High-density Lipoprotein (HDL)- Cholesterol|Completed||Phase 3|300|Actual|Helse Stavanger HF||2|||f||||t||||||||||2018-05-31 22:13:35.47258|2018-05-31 22:13:35.47258
NCT01422304|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2013-08-19||2017-04-12|2011-08-22|2011-08-23|Estimate|2013-08-19|2013-10-30|Estimate||||2017-04-12|2017-05-23|Actual|October 12, 2011|Actual|2011-10-12|April 2017|2017-04-30|September 26, 2012|Actual|2012-09-26|September 26, 2012|Actual|2012-09-26||Interventional|||Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)|A Randomized, Controlled, Parallel-group, Double-blind Trial of Sugammadex or Usual Care (Neostigmine or Spontaneous Recovery) for Reversal of Rocuronium- or Vecuronium-induced Neuromuscular Blockade in Patients Receiving Thromboprophylaxis and Undergoing Hip Fracture Surgery or Joint (Hip/Knee) Replacement (Protocol No. P07038)|Completed||Phase 3|1198|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 22:13:35.603343|2018-05-31 22:13:35.603343
NCT01422291|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||IV Paracetamol, Dexketoprofen or Morphine for the Treatment of Low Back Pain|Pamukkale University Medical School,Dept. of Emergency Medicine|Completed||Phase 4|120|Actual|Pamukkale University||2|||f||||f||||||||||2018-05-31 22:13:36.224842|2018-05-31 22:13:36.224842
NCT01422278|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Rehabilitation of Conversion Gait Disorder|Patients With Conversion Gait Disorder - Effect on Treatment and Common Gait Patterns. Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|Oslo University Hospital|||||f||||t||||||||||2018-05-31 22:13:36.288585|2018-05-31 22:13:36.288585
NCT01422265|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-11-01|2011-08-22|2011-08-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Patient Reported Symptoms in Ovarian Cancer (PRECISION)|Patient Reported Symptoms in Ovarian Cancer|Completed|||56|Actual|Genentech, Inc.|||1||f||||||||||||||2018-05-31 22:13:36.355116|2018-05-31 22:13:36.355116
NCT01422252|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2015-04-20|2011-08-22|2011-08-23|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|VIGI91||Evaluation of a Fall Detection Device in Isolated Elderly|Evaluation of Falls Occurring at Home in People Over 75 Equipped or Non-equipped With a Precocious Detection Device. Prospective Interventional Study.|Terminated||N/A|33|Actual|Assistance Publique - Hôpitaux de Paris||2||no more inclusions|f||||f||||||||||2018-05-31 22:13:36.51873|2018-05-31 22:13:36.51873
NCT01422239|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2013-03-19||2013-06-06|2011-08-22|2011-08-23|Estimate|2013-05-02|2013-06-07|Estimate||||2013-06-06|2013-06-17|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Smoking Cessation Treatment for Adult Women|A Smoking Cessation Treatment for Adult Women|Completed||Phase 1|28|Actual|Yale University|Small sample size, half to two-thirds of participants dropped out of the active study phase, half to one quarter did not complete the one month follow up. Female participants only results can not be generalized to men.|2|||f||||f||||||||||2018-05-31 22:13:36.610585|2018-05-31 22:13:36.610585
NCT01422226|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2015-02-11||2016-12-08|2011-08-22|2011-08-23|Estimate|2015-02-11|2015-02-26|Estimate||||2016-12-08|2017-02-02|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Intra Uterine Device Insertion in Nulliparous Women|IUD Insertion in Nulliparous Women: A Randomized, Placebo-Controlled Trial of Misoprostol for Cervical Priming|Terminated||N/A|3|Actual|University of Colorado, Denver||2||Unable to recruit participants|f||||f||||||||||2018-05-31 22:13:36.955325|2018-05-31 22:13:36.955325
NCT01422213|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2014-05-14||2014-07-08|2011-08-22|2011-08-23|Estimate|2014-07-08|2014-08-05|Estimate||||2014-07-08|2014-08-05|Estimate|December 2011||2011-12-31|July 2014|2014-07-31||||May 2013|Actual|2013-05-31||Interventional|FOCUS|"Age + Gender: all-patients-treated set (APTS) – all patients in the APRS who took at least one dose of IMP.~Study-specific Measures: full-analysis set (FAS) – all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the DSST, RAVLT (learning [acquisition]), and RAVLT (memory [delayed recall])."|Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose Study on the Efficacy of [Vortioxetine] Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder (MDD)|Completed||Phase 3|598|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 22:13:37.317049|2018-05-31 22:13:37.317049
NCT01422187|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|2015-11-06||2016-04-18|2011-08-22|2011-08-23|Estimate|2015-11-06|2015-12-14|Estimate||||2016-04-18|2016-05-19|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease|A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease|Completed||Phase 3|19|Actual|Protalix||2|||t||||f||||||||||2018-05-31 22:13:38.402573|2018-05-31 22:13:38.402573
NCT01422174|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-03-02|2011-08-22|2011-08-23|Estimate|||||||2015-03-02|2015-03-03|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|ESCAPE-ICD||Clinical Registry on Sudden Death Primary Prevention at Latin America|Clinical Registry on Sudden Death Primary Prevention at Latin America (rEgiStro Clinico en America Latina de Prevencion Primaria en muErte Subita)|Withdrawn|||0|Actual|Biotronik SE & Co. KG|||2|Study stopped due to lost of interest.|f||||f||||||||||2018-05-31 22:13:38.891348|2018-05-31 22:13:38.891348
NCT01422161|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2016-03-31|2011-08-22|2011-08-23|Estimate|||||||2016-03-31|2016-04-04|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Study of Botulinum Toxin and Recovery of Hand Function After Stroke|Botulinum Toxin Type A Therapy as a Plasticity Inducing Agent for Recovery of Hand Function After Stroke|Completed||Phase 3|24|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 22:13:38.958789|2018-05-31 22:13:38.958789
NCT01422148|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2017-07-11|2011-08-22|2011-08-23|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2011||2011-10-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|MINA||Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery|Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery (MINA)|Recruiting||N/A|40|Anticipated|Baystate Medical Center||2|||f||||t||||||||Undecided||2018-05-31 22:13:39.058479|2018-05-31 22:13:39.058479
NCT01422135|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-09-16|2011-08-22|2011-08-23|Estimate|||||||2011-09-16|2011-09-20|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females|A Pharmacokinetic Study of the Agile TCDS AG200-15 Following Weekly Application to Three Anatomical Sites (Abdomen, Buttock and Upper Torso) in Healthy Female Volunteers|Completed||Phase 1|24|Actual|Agile Therapeutics||1|||f||||f||||||||||2018-05-31 22:13:39.131381|2018-05-31 22:13:39.131381
NCT01422122|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2017-04-19|2011-08-22|2011-08-23|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2010||2010-06-30|April 2017|2017-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|VitaminD||Study of Vitamin D Supplementation on Improvement of Gums Health|The Effect of Vitamin D Supplementation on the Periodontal Health and Associated Outcomes in Pregnant Women|Completed||N/A|115|Actual|Aga Khan University||2|||f||||t||||||||No||2018-05-31 22:13:39.197609|2018-05-31 22:13:39.197609
NCT01422109|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-01-05|2011-08-21|2011-08-23|Estimate|||||||2012-01-05|2012-01-09|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|YH14659||Comparative Pharmacokinetics of YH14659|Comparative Pharmacokinetics After Single Oral Administration of YH14659, a Fixed Dose Combination Versus Coadministration of Separate Constituents in Healthy Male Volunteers|Completed||Phase 1|44|Actual|Yuhan Corporation||2|||f||||t||||||||||2018-05-31 22:13:39.349527|2018-05-31 22:13:39.349527
NCT01422096|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-01-19|2011-08-22|2011-08-23|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess|Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)|Not yet recruiting||Early Phase 1|20|Anticipated|University of Virginia||1|||f||||f|t|f||||||No||2018-05-31 22:13:39.423094|2018-05-31 22:13:39.423094
NCT01422083|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2014-12-04|2011-08-22|2011-08-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|GIRD||Glenohumeral Internal Rotation Deficit (GIRD)|Correlation Between Loss of Internal Rotation Range of Motion and Size of the Subacromial Space and the Influence of a Home Stretching Program.|Unknown status|Recruiting|N/A|60|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 22:13:39.506866|2018-05-31 22:13:39.506866
NCT01422070|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2015-02-12||2015-07-31|2011-08-22|2011-08-23|Estimate|2015-02-12|2015-03-02|Estimate||||2015-07-31|2015-08-21|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|ELOISE|337 readmissions, 83 admissions with inconsistencies in dates and 147 patients with unknown vital status at hospital discharge (82 still in hospital at 90 days and 65 with missing vital status) were excluded from the analysis.|European Mortality & Length Of Intensive Care Unit (ICU) Stay Evaluation (ELOISE)|A Multi-centre European Observational Study to Assess Whether Patients Admitted to the ICUs With Availability of Intermediate Care Unit (IMCU) Have Lower Hospital Mortality Than Those Admitted to the ICUs Without Availability of IMCU|Completed|||6433|Actual|Università degli Studi di Ferrara|||1||f||||f||||||||||2018-05-31 22:13:39.573873|2018-05-31 22:13:39.573873
NCT01422057|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-02-05|2011-08-22|2011-08-23|Estimate|||||||2014-02-05|2014-02-06|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|January 2016|Anticipated|2016-01-31|January 2014|Actual|2014-01-31||Observational|||Risk Prediction in Type II Diabetics With Ischemic Heart Disease|Risk Prediction in Type II Diabetics With Ischemic Heart Disease by Cardiac Autonomic Function|Unknown status|Recruiting||500|Anticipated|Thebiosignals.com|||||f||||f||||||||||2018-05-31 22:13:39.78278|2018-05-31 22:13:39.78278
NCT01422044|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-02-05|2011-08-21|2011-08-23|Estimate|||||||2014-02-05|2014-02-06|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|PREDICT-AS||Risk Prediction in Aortic Stenosis|Risk Prediction in Aortic Stenosis by Cardiac Autonomic Function|Completed|||423|Actual|Thebiosignals.com|||||f||||f||||||||||2018-05-31 22:13:39.876286|2018-05-31 22:13:39.876286
NCT01422031|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-01-23|2011-08-22|2011-08-23|Estimate|||||||2015-01-23|2015-01-26|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Study on Primary Care Health Service Utilization in Hong Kong|Utilization Pattern of Primary Health Care Services in Hong Kong - Does Having a Family Doctor Make Any Difference?|Completed|||3148|Actual|The University of Hong Kong|||3||f||||f||||||||||2018-05-31 22:13:39.934653|2018-05-31 22:13:39.934653
NCT01422018|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-09-22|2011-08-22|2011-08-23|Estimate|||||||2011-09-22|2011-09-23|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy||Unknown status|Recruiting|N/A|10|Anticipated|Seoul St. Mary's Hospital||1|||f||||t||||||||||2018-05-31 22:13:40.00621|2018-05-31 22:13:40.00621
NCT01422005|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-01-31|2011-08-22|2011-08-23|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2011||2011-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of the Recovery of Muscle Function in the Arm/Hand After a Stroke|Simultaneous Bimanual Training to Improve Motor Function Post-Stroke|Recruiting||N/A|20|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 22:13:40.078865|2018-05-31 22:13:40.078865
NCT01421992|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Methylphenidate in Myotonic Dystrophy Type 1|Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1|Completed||Phase 2/Phase 3|28|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:13:40.171017|2018-05-31 22:13:40.171017
NCT01421979|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2015-02-04|2011-08-22|2011-08-23|Estimate|||||||2015-02-04|2015-02-05|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Clinical Trial on the Effects of Caffeine and Taurine From Energy Drinks (EDs) to Parameters of the Cardiovascular System in Humans||Completed||N/A|38|Actual|University of Hohenheim||2|||f||||||||||||||2018-05-31 22:13:40.255048|2018-05-31 22:13:40.255048
NCT01421966|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2015-12-03|2011-08-22|2011-08-23|Estimate|||||||2015-12-03|2015-12-07|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes|A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus|Completed||Phase 3|285|Actual|Macrocure Ltd.||2|||f||||t||||||||||2018-05-31 22:13:40.332755|2018-05-31 22:13:40.332755
NCT01421953|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2014-10-22|2011-08-22|2011-08-23|Estimate|||||||2014-10-22|2014-10-23|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PULMOTEP||Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers|Assessment of Four-dimensional (4D) 18F-fluoro-deoxy-glucose (FDG) Positron Emission Tomography and Computed Tomography System (PET-CT) in Radiotherapy for Non Small Cell Lung Cancers (NSCLC)|Completed||N/A|7|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 22:13:40.474431|2018-05-31 22:13:40.474431
NCT01421940|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-03-09|2011-08-21|2011-08-23|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|December 2011|Actual|2011-12-31||Interventional|||The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer||Completed||Phase 4|80|Actual|Kyungpook National University||2|||f||||t||||||||||2018-05-31 22:13:40.544413|2018-05-31 22:13:40.544413
NCT01421927|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2015-07-22|2011-08-22|2011-08-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|REVALLO||Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma|Safety of a Maintenance Therapy With Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Chemosensitive Relapsed Multiple Myeloma|Completed||Phase 1|13|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 22:13:40.604752|2018-05-31 22:13:40.604752
NCT01421914|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2012-11-16|2011-08-22|2011-08-23|Estimate|||||||2012-11-16|2012-11-19|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||Determining the Minimum Effective Volume of Local Anesthetic for Ultrasound-guided Axillary Brachial Plexus Block|Determining the Minimum Effective Volume of Local Anesthetic for Ultrasound-guided Axillary Brachial Plexus Block|Completed||N/A|19|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 22:13:40.67514|2018-05-31 22:13:40.67514
NCT01421901|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2014-06-16|2011-08-20|2011-08-23|Estimate|||||||2014-06-16|2014-06-17|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|ASAA||Antibiotics Versus Surgery in Acute Appendicitis|Antibiotics vs.Surgery in Acute Appendicitis;an Intention to Treat Prospective Randomised Study. The ASAA-study|Unknown status|Recruiting|Phase 4|218|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-05-31 22:13:40.742596|2018-05-31 22:13:40.742596
NCT01421888|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-20|||2018-05-23|2011-08-20|2011-08-23|Estimate|||||||2018-05-23|2018-05-24|Actual|August 8, 2011||2011-08-08|April 17, 2013|2013-04-17|April 17, 2013||2013-04-17|||||Observational|||The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity|The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity|Terminated|||4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:13:40.919191|2018-05-31 22:13:40.919191
NCT01421875|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-20|||2017-05-16|2011-08-20|2011-08-23|Estimate|||||||2017-05-16|2017-05-17|Actual|August 17, 2011|Actual|2011-08-17|May 2017|2017-05-31|October 17, 2011|Actual|2011-10-17|October 17, 2011|Actual|2011-10-17||Observational|||Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia|Genetic and Epigenetic Determinants of Chemotherapy Resistance and Adverse Outcome in Elderly Patients With AML|Completed|||257|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 22:13:40.977223|2018-05-31 22:13:40.977223
NCT01421862|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-20|||2013-07-09|2011-08-20|2011-08-23|Estimate|||||||2013-07-09|2013-07-10|Estimate|September 2011||2011-09-30|August 2011|2011-08-31||||October 2011|Anticipated|2011-10-31||Observational|||Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment|"The Genetics of Non-Response in Adult AML"|Unknown status|Not yet recruiting||400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:13:41.033437|2018-05-31 22:13:41.033437
NCT01421849|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2014-12-04|2011-08-22|2011-08-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mandibular Single Implant Overdenture: a Prospective Clinical Trial|Patient Satisfaction and Clinical Outcomes Following Mandibular Single-implant-retained Overdenture Treatment in Residents of Nursing Homes: a Prospective Clinical Trial|Unknown status|Active, not recruiting|N/A|50|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:13:41.105258|2018-05-31 22:13:41.105258
NCT01421836|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-04-27|2011-08-22|2011-08-23|Estimate|||||||2016-04-27|2016-04-28|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||Prospective Study Comparing EUS vs ERCP Stent Insertion for Malignant Biliary Obstruction|Prospective Study Comparing EUS Guided Biliary Drainage and ERCP With Stent Placement for Malignant Biliary Obstruction|Completed||Phase 2/Phase 3|30|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 22:13:41.178332|2018-05-31 22:13:41.178332
NCT01421823|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-21|||2013-12-11|2011-08-22|2011-08-23|Estimate|||||||2013-12-11|2013-12-12|Estimate|August 2011||2011-08-31|December 2013|2013-12-31||||April 2012|Anticipated|2012-04-30||Interventional|||A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence||Withdrawn||Phase 1/Phase 2|0|Actual|RDD Pharma Ltd||2|||f||||f||||||||||2018-05-31 22:13:41.265767|2018-05-31 22:13:41.265767
NCT01421810|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-01-19|2011-08-19|2011-08-23|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2010||2010-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CBS001||Ovarian Contribution to Androgen Production in Adolescent Girls|Ovarian Contribution to Androgen Production in Adolescent Girls|Recruiting||N/A|80|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 22:13:41.323656|2018-05-31 22:13:41.323656
NCT01421797|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-01-19|2011-08-22|2011-08-23|Estimate|||||||2018-01-19|2018-01-23|Actual|October 10, 2006|Actual|2006-10-10|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 27, 2018|Anticipated|2018-03-27||Interventional|||Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation|Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation (JCM022)|Recruiting||N/A|84|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 22:13:41.39118|2018-05-31 22:13:41.39118
NCT01421784|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-03-19|2011-08-19|2011-08-23|Estimate|||||||2015-03-19|2015-03-20|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Using Rapid Cine-MRI for Monitoring Moving and Deforming Tumors|Investigating the Feasibility of Using Rapid Cine-MRI for Monitoring Moving and Deforming Tumors|Unknown status|Recruiting|N/A|40|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 22:13:41.544673|2018-05-31 22:13:41.544673
NCT01421771|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-01-04|2011-08-19|2011-08-23|Estimate|||||||2017-01-04|2017-01-06|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|BID||Blood Pressure in Dialysis Patients|Blood Pressure in Dialysis Patients (BID Study)|Completed||N/A|126|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 22:13:41.630051|2018-05-31 22:13:41.630051
NCT01421758|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2016-04-15|2011-08-22|2011-08-23|Estimate|||||||2016-04-15|2016-04-19|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|INSHAPE||Testing the Efficacy of an Online Social Network Intervention to Increase Social Support for Physical Activity|Using Facebook to Increase Social Support for Physical Activity: The INSHAPE Study|Completed||N/A|134|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:13:41.744257|2018-05-31 22:13:41.744257
NCT01421745|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2012-05-14|2011-08-19|2011-08-23|Estimate|||||||2012-05-14|2012-05-16|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Construct Validity, Responsiveness, and Demographic Predictors of the IAPCC-SV|Construct Validity, Responsiveness, and Demographic Predictors of the Inventory for Assessing the Process of Cultural Competence Among Healthcare Professionals - Student Version (IAPCC-SV)|Completed||N/A|40|Actual|Texas Woman's University||1|||f||||f||||||||||2018-05-31 22:13:41.803276|2018-05-31 22:13:41.803276
NCT01421732|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-09-29|2011-08-22|2011-08-23|Estimate|||||||2016-09-29|2016-09-30|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Laboratory Diagnosis and Prognosis of Severe Dengue|Laboratory Diagnosis and Prognosis of Severe Dengue|Completed|||8100|Actual|Oxford University Clinical Research Unit, Vietnam|||1||f||||f||||||||||2018-05-31 22:13:41.871797|2018-05-31 22:13:41.871797
NCT01421719|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2011-08-31||2017-01-20|2011-08-22|2011-08-23|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|February 2009||2009-02-28|January 2017|2017-01-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease|Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy|Completed||Phase 4|20|Actual|Stanford University|The limitations of this trial involved the primary disease disorder of Parkinson's Disease and difficulty of communication with subjects; Four patients withdrew from the study prior to the 6-month endpoint because of loss of efficacy.|1|||f||||f||||||||No||2018-05-31 22:13:41.949175|2018-05-31 22:13:41.949175
NCT01421706|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2012-09-16|2011-08-22|2011-08-23|Estimate|||||||2012-09-16|2012-09-18|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|sibu||Effects of Clopidogrel and Clarithromycin on the Oral Disposition of Sibutramine in Healthy Subjects|Effects of Clopidogrel and Clarithromycin on the Disposition of Sibutramine and Its Active Metabolites M1 and M2 in Relation to CYP2B6*6 Polymorphism|Completed||Phase 1|20|Actual|Inje University||2|||f||||f||||||||||2018-05-31 22:13:42.143034|2018-05-31 22:13:42.143034
NCT01421693|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2016-10-02|2011-08-22|2011-08-23|Estimate|||||||2016-10-02|2016-10-04|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever|Randomized, Open-label, Superiority Trial of the Effectiveness of Gatifloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Enteric Fever.|Completed||Phase 4|300|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||t||||||||||2018-05-31 22:13:42.217421|2018-05-31 22:13:42.217421
NCT01421680|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2014-03-12|2011-08-19|2011-08-23|Estimate|||||||2014-03-12|2014-03-14|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients|A Prospective Randomized Controlled Trial Evaluating the Effects of Preoperative and Postoperative Oral Nutritional Supplements (ONS) in Malnourished Post-gastrectomy Patients|Completed||N/A|144|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:13:42.300882|2018-05-31 22:13:42.300882
NCT01421667|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2016-06-21||2016-10-14|2011-08-19|2011-08-23|Estimate|2016-08-19|2016-10-13|Estimate||||2016-10-14|2016-11-28|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||All participants who received treatment.|A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)|Completed||Phase 2|176|Actual|Seattle Genetics, Inc.||2|||f||||f||||||||||2018-05-31 22:13:42.412042|2018-05-31 22:13:42.412042
NCT01421654|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2013-01-31||2013-03-10|2011-08-22|2011-08-23|Estimate|2013-01-31|2013-03-07|Estimate||||2013-03-10|2013-03-12|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy|Evaluation of Positive Airway Pressure (PAP) Feature to Improve Patient Adherence to Therapy|Completed||N/A|20|Actual|ResMed||2|||f||||f||||||||||2018-05-31 22:13:44.00986|2018-05-31 22:13:44.00986
NCT01421641|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2013-11-13||2014-03-18|2011-08-22|2011-08-23|Estimate|2014-03-18|2014-04-21|Estimate||||2014-03-18|2014-04-21|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Tenaculum Pain Control Study|The Effect of Intracervical Lidocaine Injection Versus Topical Lidocaine Gel on the Pain Experienced by Patients Undergoing Tenaculum Application to the Cervix at the Time of an Office Gynecologic Procedure|Completed||Phase 4|74|Actual|Oregon Health and Science University|There are several limitations to this study, including potential selection bias, difficulty with blinding the intervention, timing of the intervention for maximal effect, and the limitations inherent in measuring pain.|2|||f||||f||||||||||2018-05-31 22:13:44.199099|2018-05-31 22:13:44.199099
NCT01421628|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|NLC2010||Enhancement of Physical Fitness in Older Adults|The Effectiveness of a Trainings Program on ADL Performance, Physical Fitness, Wellbeing, and Nocturnal Cramp in Elderly People|Completed||N/A|180|Actual|Hanze University||1|||f||||f||||||||||2018-05-31 22:13:44.387128|2018-05-31 22:13:44.387128
NCT01421615|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|May 2012|Anticipated|2012-05-31|December 2011|Anticipated|2011-12-31||Interventional|BV||Effect of Different Courses of Lactobacilli Treatment on Bacterial Vaginosis and Pregnancy Outcomes|Effect of Different Courses of Lactobacilli Treatment on Bacterial Vaginosis and Related Pregnancy Outcomes|Unknown status|Recruiting|Phase 1|5000|Anticipated|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 22:13:44.442734|2018-05-31 22:13:44.442734
NCT01421602|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2011-09-21|2011-08-22|2011-08-23|Estimate|||||||2011-09-21|2011-09-23|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Observational|||A Prospective Observational Study on the Use of a Self Fixating Lightweight Polyester Mesh in Open Inguinal Hernia|A Prospective Observational Study on the Use of a Self Fixating Lightweight Polyester Mesh in Open Inguinal Hernia|Unknown status|Recruiting||100|Anticipated|De La Salle University Medical Center|||||f||||f||||||||||2018-05-31 22:13:44.572595|2018-05-31 22:13:44.572595
NCT01421589|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2014-03-31||2014-05-29|2011-08-22|2011-08-23|Estimate|2014-05-29|2014-07-01|Estimate||||2014-05-29|2014-07-01|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Obese male subjects with reduced growth hormone secretion|Growth Hormone Treatment on Phosphocreatine Recovery in Obesity|The Effects of Short Term Growth Hormone Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity|Completed||N/A|15|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:13:44.655611|2018-05-31 22:13:44.655611
NCT01421576|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions|A Randomized, Single-dose, 2-sequence, 2-period Crossover Study to Investigate the Food-effect Pharmacokinetics of Sarpogrelate HCl Controlled Release Tablet in Healthy Male Subjects|Completed||Phase 1|24|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 22:13:44.934816|2018-05-31 22:13:44.934816
NCT01421563|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|February 2011||2011-02-28|August 2011|2011-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers|A Randomized, Open-label, Two-Sequence, Two-Period Crossover Study to Assess the Pharmacokinetic Characteristics of Sarpogrelate HCl Controlled Release Tablet Compared With Sarpogrelate HCl Immediate Release Tablet in Healthy Male Subjects|Completed||Phase 1|36|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 22:13:45.013723|2018-05-31 22:13:45.013723
NCT01421550|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|CRUCIAL||Conservative Treatment Versus Elective Repair of Umbilical Hernia in Patients With Ascites and Liver Cirrhosis|Conservative Treatment Versus Elective Repair of the Umbilical Hernia in Patients With Ascites and Liver Cirrhosis, a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|100|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 22:13:45.084853|2018-05-31 22:13:45.084853
NCT01421537|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-22|2011-08-22|2011-08-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Evaluation Of Enoxaparin Pharmacokinetic For Thromboprophylaxis In Burn Care Patients|Evaluation Of Enoxaparin Pharmacokinetic For Thromboprophylaxis In Burn Care Patients|Unknown status|Recruiting||180|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 22:13:45.166526|2018-05-31 22:13:45.166526
NCT01421524|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-04-24|2011-08-22|2011-08-23|Estimate|||||||2018-04-24|2018-04-25|Actual|September 19, 2011|Actual|2011-09-19|April 2018|2018-04-30|October 29, 2018|Anticipated|2018-10-29|October 29, 2018|Anticipated|2018-10-29||Interventional|||Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma|A Phase 1a/1b, Multi-center, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Pleiotropic Pathway Modifier CC-122 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma.|Active, not recruiting||Phase 1|254|Actual|Celgene||4|||f||||t||||||||||2018-05-31 22:13:45.242455|2018-05-31 22:13:45.242455
NCT01421511|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2014-07-15|2014-04-02|2017-03-28|2011-08-19|2011-08-22|Estimate|2014-08-31|2014-09-08|Estimate|2014-04-02|2014-04-30|Estimate|2017-03-28|2017-05-01|Actual|September 15, 2011|Actual|2011-09-15|March 2017|2017-03-31|January 10, 2013|Actual|2013-01-10|January 10, 2013|Actual|2013-01-10||Interventional||All randomized participants|TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of IV to Oral 6-Day TR-701 Free Acid and IV to Oral 10-Day Linezolid for the Treatment of ABSSSI|Completed||Phase 3|666|Actual|Trius Therapeutics LLC|Analyses for this study were conducted using 2 statistical plans, 1 for the US FDA and 1 for the EMA, to address differing guidance on the development of antibacterials. These differences are reflected in the EudraCT and clinicaltrials.gov records.|2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:13:45.425693|2018-05-31 22:13:45.425693
NCT01421498|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|2015-11-09|2013-07-02|2017-01-05|2011-08-19|2011-08-22|Estimate|2017-01-05|2017-02-24|Actual|2013-07-02|2013-07-09|Estimate|2017-01-05|2017-02-24|Actual|August 2011||2011-08-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|OPUS-1|Safety population included all randomized participants who received at least 1 dose of investigational product.|Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE)|A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)|Completed||Phase 3|588|Actual|Shire||2|||f||||f||||||||||2018-05-31 22:13:45.908984|2018-05-31 22:13:45.908984
NCT01421485|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2016-10-03|2011-08-19|2011-08-22|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|April 2015|Actual|2015-04-30||Interventional|ITP||Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth|Integrated Mental Health Treatment & HIV Prevention for Court-Involved Youth|Completed||N/A|170|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 22:13:46.194947|2018-05-31 22:13:46.194947
NCT01421472|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2016-02-14||2016-03-30|2011-08-19|2011-08-22|Estimate|2016-02-14|2016-03-14|Estimate||||2016-03-30|2016-05-03|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer|A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer|Completed||Phase 2|196|Actual|Merrimack Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:13:46.291658|2018-05-31 22:13:46.291658
NCT01421459|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2014-10-03|2013-01-11|2014-12-02|2011-08-19|2011-08-22|Estimate|2014-10-03|2014-10-09|Estimate|2013-01-11|2013-01-21|Estimate|2014-12-02|2014-12-18|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ELEMENT 2|All randomized participants who received at least 1 dose of study drug.|A Study in Adults With Type 2 Diabetes|A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 2 Study|Completed||Phase 3|759|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 22:13:47.211476|2018-05-31 22:13:47.211476
NCT01421446|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2015-03-30|2011-08-19|2011-08-22|Estimate|||||||2015-03-30|2015-04-01|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Study to Validate a Computerized Neuropsychological Test Battery|Reliability and Validity of Umea Computerized Neuropsychological Battery|Terminated|||1|Actual|LifeBridge Health||||Insufficient subject recruitment|f||||f||||||||||2018-05-31 22:13:49.49506|2018-05-31 22:13:49.49506
NCT01421433|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-03-07|2011-08-19|2011-08-22|Estimate|||||||2012-03-07|2012-03-08|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|January 2013|Anticipated|2013-01-31|August 2012|Anticipated|2012-08-31||Interventional|||A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol|Non Inferiority,Phase III,Multicentric,Double Blind,Randomized,Parallel Study,Comparing Dolamin Flex (Lysine Clonixinate+Cyclobenzaprine) and Tandrilax(Caffeine +Carisoprodol+Diclofenac+Paracetamol)in Pain Reduction in Patients With Lumbago|Unknown status|Not yet recruiting|Phase 3|160|Anticipated|Farmoquimica S.A.||2|||f||||f||||||||||2018-05-31 22:13:49.539813|2018-05-31 22:13:49.539813
NCT01421420|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-06-10|2011-08-19|2011-08-22|Estimate|||||||2015-06-10|2015-06-12|Estimate|July 2001||2001-07-31|January 2015|2015-01-31|July 2025|Anticipated|2025-07-31|December 2024|Anticipated|2024-12-31||Observational|ADCC||Alzheimer's Disease Core Center|Arizona Alzheimer's Disease Core Center|Recruiting|||900|Anticipated|University of Arizona|||4||f||||f||||||Samples With DNA|"~     blood, saliva, brain tissue~   "|||2018-05-31 22:13:49.601248|2018-05-31 22:13:49.601248
NCT01421407|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2014-05-05|2011-08-19|2011-08-22|Estimate|||||||2014-05-05|2014-05-06|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism|Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Uncontrolled Secondary Hyperparathyroidism in Chronic Haemodialysis Patients|Withdrawn||N/A|0|Actual|Theraclion||2|||f||||f||||||||||2018-05-31 22:13:49.659692|2018-05-31 22:13:49.659692
NCT01421394|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2014-11-18|2011-08-19|2011-08-22|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2010||2010-11-30|July 2011|2011-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|scissors||Spinal Cord Injury Series of Tampere - Retrospective Study|Spinal Cord Injury Series of Tampere - Retrospective Study|Unknown status|Recruiting||50|Anticipated|Tampere University Hospital|||1||f||||f||||||||||2018-05-31 22:13:49.746263|2018-05-31 22:13:49.746263
NCT01421381|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2013-05-24|2011-08-19|2011-08-22|Estimate|||||||2013-05-24|2013-05-27|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|RHODOS-OFU||RHODOS Follow-up Single-visit Study|A Single Visit, Observational, Follow-up Study of Patients With Leber's Hereditary Optic Neuropathy Following Participation in SNT-II-003 Trial|Completed|||60|Actual|Santhera Pharmaceuticals|||||f||||||||||||||2018-05-31 22:13:49.857139|2018-05-31 22:13:49.857139
NCT01421368|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-04-09|2011-08-19|2011-08-22|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use|Assessing the Effect of Contraception and the Menstrual Cycle on Pharmacokinetics, Pharmacodynamics, and Vaginal Safety in Tenofovir Vaginal Gel Users|Completed||Phase 1|72|Actual|CONRAD||2|||f||||f||||||||||2018-05-31 22:13:49.916433|2018-05-31 22:13:49.916433
NCT01421355|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2014-06-23||2014-06-23|2011-08-19|2011-08-22|Estimate|2014-06-23|2014-07-21|Estimate||||2014-06-23|2014-07-21|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus|A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus|Completed||Phase 1|15|Actual|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 22:13:50.003103|2018-05-31 22:13:50.003103
NCT01421342|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2018-01-29||2018-04-25|2011-08-18|2011-08-22|Estimate|2018-04-25|2018-05-28|Estimate||||2018-04-25|2018-05-28|Estimate|December 2012||2012-12-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional|VAST-D|The ASEX (female) version of the questionnaire was specific to females.The ASEX (male) version of the questionnaire was specific to males. Not all females or males completed the questionnaire, therefore, the number of responders is lower than number of participants due to missing responses.|VA Augmentation and Switching Treatments for Improving Depression Outcomes|CSP #576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)|Completed||Phase 3|1522|Actual|VA Office of Research and Development||3|||f||||t||||||||No||2018-05-31 22:13:50.243266|2018-05-31 22:13:50.243266
NCT01421316|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2015-06-03|2011-08-19|2011-08-22|Estimate|||||||2015-06-03|2015-06-04|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Interventional|||Hair-sparing Whole Brain Radiotherapy|Reducing Hair Loss With Volumetric Arc Therapy in Patients Treated With Whole Brain Radiotherapy: a Phase II Trial|Terminated||Phase 2|29|Anticipated|University Hospital, Ghent||||No reduction in hair loss 1 month after treatment|f||||f||||||||||2018-05-31 22:13:51.371714|2018-05-31 22:13:51.371714
NCT01421303|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2014-12-05||2014-12-05|2011-08-19|2011-08-22|Estimate|2014-12-05|2014-12-12|Estimate||||2014-12-05|2014-12-12|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|AS@WORK|Baseline analysis set (BAS) consisted of all participants enrolled in the study, who were seen at baseline and started the treatment with etanercept (Enbrel).|Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.|Work Productivity In A Cohort Of Employed Ankylosing Spondylitis Patients Treated With Etanercept|Completed|||80|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:13:51.447797|2018-05-31 22:13:51.447797
NCT01420939|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-05-23|2011-08-19|2011-08-22|Estimate|||||||2018-05-23|2018-05-24|Actual|July 21, 2011||2011-07-21|May 21, 2013|2013-05-21|May 21, 2013||2013-05-21|||||Observational|||Developing Therapies for Traumatic Brain Injury|Biomarkers-Driven Development of Experimental Therapeutics for Traumatic Brain Injury|Terminated|||19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:13:56.387448|2018-05-31 22:13:56.387448
NCT01421290|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2015-06-02|2011-08-19|2011-08-22|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Treatment of Cartilage Lesions in Flanders Today|Clinical Outcome After Treating Cartilage Defects in the Knee by Surgical or Conservative Means|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:13:51.988377|2018-05-31 22:13:51.988377
NCT01421277|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2014-09-08||2017-05-26|2011-08-19|2011-08-22|Estimate|2014-09-08|2014-09-15|Estimate||||2017-05-26|2017-06-20|Actual|May 19, 2011|Actual|2011-05-19|May 2017|2017-05-31|March 23, 2012|Actual|2012-03-23|March 23, 2012|Actual|2012-03-23||Observational|MASTER|All eligible particpants. 2 participants did not specify gender in the online questionnaire.|Study of Treatment Used for Migraine Headaches (MK-0974-076)|Migraine Attack Study of Treatment, Efficacy and Resource Use (MASTER) - McKesson Substudy (MK-0974-076)|Terminated|||216|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-05-31 22:13:52.078795|2018-05-31 22:13:52.078795
NCT01421264|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-06-21|2011-08-19|2011-08-22|Estimate|||||||2013-06-21|2013-06-24|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Gabapentin's Effects on Insomnia in Patients With Recent Concussion||Completed||Phase 1|21|Actual|University at Buffalo||1|||f||||f||||||||||2018-05-31 22:13:52.284781|2018-05-31 22:13:52.284781
NCT01421251|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2012-09-11|2011-08-19|2011-08-22|Estimate|||||||2012-09-11|2012-09-12|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||H1N1 Vaccine Safety in Manitoba, Canada|The Safety of GSK Biological's H1N1 Pandemic Vaccine in Manitoba, Canada|Unknown status|Active, not recruiting||800000|Anticipated|International Centre for Infectious Diseases, Canada|||1||f||||f||||||None Retained|"~     None collected~   "|||2018-05-31 22:13:52.35117|2018-05-31 22:13:52.35117
NCT01421238|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2012-11-20|2011-08-19|2011-08-22|Estimate|||||||2012-11-20|2012-11-22|Estimate|May 2006||2006-05-31|November 2012|2012-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Framing and Decision Making in Neonatology|Framing and Perinatal Decision Making at Extremes of Prematurity|Completed||N/A|350|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 22:13:52.413651|2018-05-31 22:13:52.413651
NCT01421225|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-19|2011-08-19|2011-08-22|Estimate|||||||2011-08-19|2011-08-22|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age|Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 22:13:52.475696|2018-05-31 22:13:52.475696
NCT01421212|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-19|2011-08-19|2011-08-22|Estimate|||||||2011-08-19|2011-08-22|Estimate|November 1999||1999-11-30|August 2011|2011-08-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation|Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine|Completed||Phase 1/Phase 2|30|Actual|Biotest Pharmaceuticals Corporation|||||f||||f||||||||||2018-05-31 22:13:52.569491|2018-05-31 22:13:52.569491
NCT01421199|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-19|2011-08-19|2011-08-22|Estimate|||||||2011-08-19|2011-08-22|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Device Study to Evaluate the Detection and Characterization of Middle Ear Fluid in Children|A Prospective, Multi Center, Non-randomized Clinical Trial to Evaluate the Ear Effusion Detection and Characterization System (EEDCS) to Detect and Characterize Middle Ear Fluid in Children|Unknown status|Not yet recruiting|N/A|125|Anticipated|OtoSonics Inc.||1|||f||||f||||||||||2018-05-31 22:13:52.647971|2018-05-31 22:13:52.647971
NCT01421186|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2018-03-27|2011-08-19|2011-08-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2011||2011-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma|A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|121|Actual|MorphoSys AG||2|||f||||t||||||||||2018-05-31 22:13:52.712452|2018-05-31 22:13:52.712452
NCT01421173|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-11-17|2011-08-19|2011-08-22|Estimate|||||||2015-11-17|2015-11-18|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies|Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies|Completed||Phase 1|78|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:13:52.798607|2018-05-31 22:13:52.798607
NCT01421160|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-05-13|2011-08-19|2011-08-22|Estimate|||||||2017-05-13|2017-05-16|Actual|July 2011||2011-07-31|May 2017|2017-05-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Regulating Urine pH Levels to Alleviate Chronic Joint Pain|A Pilot Study to Assess the Effects of Regulating Urine pH Levels for Alleviating Chronic Joint Pain|Withdrawn||Phase 1|0|Actual|Texas Tech University Health Sciences Center, El Paso||||PI left the institution prior to any data being collected|f||||f||||||||||2018-05-31 22:13:52.897764|2018-05-31 22:13:52.897764
NCT01421147|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2014-10-03|2012-09-18|2014-10-03|2011-08-19|2011-08-22|Estimate|2014-10-03|2014-10-09|Estimate|2012-09-18|2012-09-25|Estimate|2014-10-03|2014-10-09|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional|ELEMENT 1|All randomized participants who received at least 1 dose of study drug.|A Study in Adults With Type 1 Diabetes|A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|536|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 22:13:53.138992|2018-05-31 22:13:53.138992
NCT01421134|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|2015-09-10||2016-07-13|2011-08-18|2011-08-22|Estimate|2015-09-10|2015-10-09|Estimate||||2016-07-13|2016-07-15|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|RESOLVE 1|Two subjects were randomized in error and were not treated.|Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose|A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features|Completed||Phase 3|211|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 22:13:54.725042|2018-05-31 22:13:54.725042
NCT01421121|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2012-11-26|2011-08-19|2011-08-22|Estimate|||||||2012-11-26|2012-11-27|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants||Completed||Phase 2|540|Actual|Sinovac Biotech Co., Ltd||5|||f||||t||||||||||2018-05-31 22:13:55.171263|2018-05-31 22:13:55.171263
NCT01421108|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-03-04|2011-08-19|2011-08-22|Estimate|||||||2012-03-04|2012-03-06|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Effectiveness of Gain- Versus Loss-framed Health Messages to Improve Oral Health Among Iranian Adolescents|The Effectiveness of Gain- Versus Loss-framed Health Messages to Improve Oral Health Among Iranian Adolescents:A Randomized Controlled Trial|Completed||Phase 2|372|Actual|Qazvin University Of Medical Sciences||2|||f||||f||||||||||2018-05-31 22:13:55.238145|2018-05-31 22:13:55.238145
NCT01421095|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2017-05-02|2011-08-19|2011-08-22|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2011||2011-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Ovarian Reserve Testing in Female Young Adult Cancer Survivors|Ovarian Reserve Testing in Female Young Adult Cancer Survivors|Recruiting||N/A|34|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 22:13:55.407652|2018-05-31 22:13:55.407652
NCT01421082|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2014-03-11|2011-08-19|2011-08-22|Estimate|||||||2014-03-11|2014-03-12|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema|Evaluation of Physiologic Parameters to Study the Mechanism of Action of the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) in Subjects With Homogeneous Emphysema|Completed||Phase 2/Phase 3|10|Actual|PneumRx, Inc.||1|||f||||f||||||||||2018-05-31 22:13:55.478761|2018-05-31 22:13:55.478761
NCT01421069|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2018-01-23|2011-08-18|2011-08-22|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2011|Actual|2011-10-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|CLIPPER2||Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis|An Open-label Extension Study To Assess The Long-term Safety And Clinical Benefit Of Etanercept In Children And Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Or Psoriatic Arthritis Who Were Previously Enrolled In Protocol 0881a1-3338-ww(b1801014)|Active, not recruiting||Phase 3|109|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 22:13:55.550795|2018-05-31 22:13:55.550795
NCT01421056|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05||2014-01-07|2014-01-07|2011-08-19|2011-08-22|Estimate||||2014-01-07|2014-02-06|Estimate|2014-01-07|2014-02-06|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)|A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment|Completed||Phase 2|74|Actual|Chiesi USA||3|||f||||f||||||||||2018-05-31 22:13:55.66386|2018-05-31 22:13:55.66386
NCT01421043|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-10-21|2011-08-18|2011-08-22|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Triazolam Liquid Oral Drops at a Dose of 0.25 Mg Versus Triazolam 0.25 Mg Tablet in Healthy Subjects|Completed||Phase 1|34|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:13:55.738611|2018-05-31 22:13:55.738611
NCT01421030|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-09-24|2011-08-19|2011-08-22|Estimate|||||||2012-09-24|2012-09-25|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|September 2014|Anticipated|2014-09-30|September 2012|Anticipated|2012-09-30||Interventional|MEQC||Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques|Outcomes in Patients and Their Closest Relatives Treated for Congenital Heart Disease With Catheter Based or Surgical Techniques.|Unknown status|Recruiting|Early Phase 1|40|Anticipated|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 22:13:55.876599|2018-05-31 22:13:55.876599
NCT01421017|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-02-05|2011-08-18|2011-08-22|Estimate|||||||2018-02-05|2018-02-07|Actual|August 2011|Actual|2011-08-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases|Phase I/II Study of TLR7 Agonist Imiquimod, Cyclophosphamide, and Radiotherapy in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases|Active, not recruiting||Phase 1/Phase 2|55|Anticipated|New York University School of Medicine||3|||f||||t|t|f|||t|||||2018-05-31 22:13:55.950971|2018-05-31 22:13:55.950971
NCT01421004|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2015-01-22|2011-08-19|2011-08-22|Estimate|||||||2015-01-22|2015-01-26|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors|A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors|Completed||Phase 1|166|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:13:56.032883|2018-05-31 22:13:56.032883
NCT01420991|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-10-18|2011-08-19|2011-08-22|Estimate|||||||2017-10-18|2017-10-20|Actual|August 2011||2011-08-31|September 2017|2017-09-30|December 2024|Anticipated|2024-12-31|February 2014|Actual|2014-02-28||Observational|BAAS||Brain and Abdominal Aneurysm Study|Brain and Abdominal Aneurysm Study (BAAS)|Active, not recruiting|||81|Anticipated|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:13:56.118356|2018-05-31 22:13:56.118356
NCT01420978|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2013-05-12|2011-08-19|2011-08-22|Estimate|||||||2013-05-12|2013-05-14|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Cerebrospinal Fluid (CSF) Drainage Study|High Volume Cerebrospinal Fluid Diversion in the Management of Aneurysmal Subarachnoid Hemorrhage: A Pilot Study|Completed||N/A|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:13:56.172907|2018-05-31 22:13:56.172907
NCT01420965|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2017-09-15|2011-08-19|2011-08-22|Estimate|||||||2017-09-15|2017-09-18|Actual|September 2012||2012-09-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer|A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge) Administered With or Without Anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men With Advanced Castrate-Resistant Prostate Cancer|Terminated||Phase 2|7|Actual|Augusta University||3||Drug supply issues|f||||t|t|f||||||No||2018-05-31 22:13:56.24955|2018-05-31 22:13:56.24955
NCT01420952|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2018-05-23|2011-08-19|2011-08-22|Estimate|||||||2018-05-23|2018-05-24|Actual|July 29, 2011||2011-07-29|November 27, 2012|2012-11-27|November 27, 2012|Actual|2012-11-27|November 27, 2012|Actual|2012-11-27||Interventional|||Imaging of Brain Receptors Using (11C)mGlu1|PET Imaging of Brain mGlu1 Receptors Using [11]LY2428703|Terminated||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:13:56.335023|2018-05-31 22:13:56.335023
NCT01420926|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2016-08-30||2018-01-15|2011-08-19|2011-08-22|Estimate|2016-08-30|2016-10-24|Estimate||||2018-01-15|2018-02-13|Actual|November 16, 2011|Actual|2011-11-16|November 2017|2017-11-30||||August 30, 2015|Actual|2015-08-30||Interventional||Two (2) participants never received any protocol treatment; per study design these patients were excluded from all analyses.|Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia|A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients &gt;/= 60 Years Old With Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|165|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 22:13:56.494398|2018-05-31 22:13:56.494398
NCT01420913|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2011-08-19|2011-08-19|2011-08-22|Estimate|||||||2011-08-19|2011-08-22|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects|Randomized,Open-label,Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects|Completed||Phase 1|28|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 22:13:57.940142|2018-05-31 22:13:57.940142
NCT01420900|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2017-11-03|2011-08-19|2011-08-22|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2011||2011-09-30|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Interventional|||Ceramic-on-Ceramic Total Hip Arthroplasty and Squeaking: Influence of Component Design|Ceramic-on-Ceramic Total Hip Arthroplasty and Squeaking: A Prospective, Blinded, Randomized Clinical Trial of Influence of Component Design|Completed||N/A|204|Actual|Vejle Hospital||2|||f||||f||||||||||2018-05-31 22:13:57.997984|2018-05-31 22:13:57.997984
NCT01420887|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2018-01-05|2011-08-18|2011-08-22|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CPM||Preservation of Joint Function Using Postoperative Continuous Passive Motion (CPM) A Pilot Study|Preservation of Joint Function Using Postoperative Continuous Passive Motion (CPM) A Pilot Study|Recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:13:58.069745|2018-05-31 22:13:58.069745
NCT01420874|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2017-05-26|2011-08-19|2011-08-22|Estimate|||||||2017-05-26|2017-05-31|Actual|August 2011||2011-08-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)|Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib)|Active, not recruiting||Phase 1|30|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 22:13:58.131336|2018-05-31 22:13:58.131336
NCT01420861|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2014-04-23|2011-08-19|2011-08-22|Estimate|||||||2014-04-23|2014-04-24|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer|Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy|Terminated||Phase 2|8|Actual|GTx||1||FDA Clinical Hold|f||||f||||||||||2018-05-31 22:13:58.197695|2018-05-31 22:13:58.197695
NCT01420848|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|2013-01-30||2013-06-09|2011-08-19|2011-08-22|Estimate|2013-06-09|2013-07-15|Estimate||||2013-06-09|2013-07-15|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Auriculotherapy Effectiveness on Stress and Anxiety in Nursing Student|The Effectiveness of the Auriculotherapy on Reducing Stress and Anxiety in Nursing Student: Randomized Clinical Trial|Completed||Phase 2|71|Actual|University of Sao Paulo|The limitation of the trial was the reduced number of the sample.|3|||f||||f||||||||||2018-05-31 22:13:58.266564|2018-05-31 22:13:58.266564
NCT01420835|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2013-01-17|2011-08-19|2011-08-22|Estimate|||||||2013-01-17|2013-01-21|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||Chinese Auriculotherapy on Stress and Quality of Life in Nursing Professionals: Randomized Clinical Trial|Randomized Clinical Trial: Chinese Auriculotherapy With and Without Protocol on Stress and Quality of Life in Nursing Professionals|Completed||Phase 2|175|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 22:13:58.618613|2018-05-31 22:13:58.618613
NCT01420822|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2015-03-26|2011-08-18|2011-08-22|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Special Drug Use Investigation for ALLERMIST (Long Term)|Special Drug Use Investigation for ALLERMIST (Long Term)|Completed|||500|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:13:58.710903|2018-05-31 22:13:58.710903
NCT01420809|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-05-15|2011-08-18|2011-08-22|Estimate|||||||2017-05-15|2017-05-16|Actual|September 2007||2007-09-30|May 2017|2017-05-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Observational|||Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection|Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection|Completed|||1280|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-05-31 22:13:58.777757|2018-05-31 22:13:58.777757
NCT01420796|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2017-04-25|2011-08-19|2011-08-22|Estimate|||||||2017-04-25|2017-04-27|Actual|November 2013|Actual|2013-11-30|April 2017|2017-04-30|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Swallowing and Breathing Exercises for Dysphagia in Parkinson Disease|Effect of Oral Motor Exercises and Breathing Exercises for Dysphagia in Parkinson Disease: Randomized Clinical Trial|Completed||N/A|38|Actual|Federal University of Bahia||3|||f||||t||||||||||2018-05-31 22:13:58.838966|2018-05-31 22:13:58.838966
NCT01420783|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11||2016-02-17|2016-02-17|2011-08-19|2011-08-22|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|November 2012|Actual|2012-11-30||Interventional|||Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia|A Randomized Phase II, Open-Label Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Who Are Resistant or Intolerant to Hydroxyurea|Completed||Phase 2|81|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 22:13:58.941387|2018-05-31 22:13:58.941387
NCT01420770|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11||2016-02-17|2016-02-17|2011-08-19|2011-08-22|Estimate||||2016-02-17|2016-03-16|Estimate|2016-02-17|2016-03-16|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Phase 2 Study of SAR302503 in Patients With Myelofibrosis|A Phase 2 Randomized, Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly|Completed||Phase 2|30|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 22:13:59.085369|2018-05-31 22:13:59.085369
NCT01420757|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-19|2011-08-19|2011-08-22|Estimate|||||||2011-08-19|2011-08-22|Estimate|May 1999||1999-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|December 2006|Actual|2006-12-31||Interventional|COLIBRI||Laparoscopic Versus Open Incisional Hernia Repair|Laparoscopic Versus Open Incisional Hernia Repair : A Randomized Clinical Trial|Completed||Phase 3|206|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 22:13:59.165346|2018-05-31 22:13:59.165346
NCT01420744|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2015-07-28|2011-08-19|2011-08-22|Estimate|||||||2015-07-28|2015-07-29|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|CIGMA||Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)|Completed||Phase 2|160|Actual|Biotest||2|||f||||t||||||||||2018-05-31 22:13:59.239107|2018-05-31 22:13:59.239107
NCT01420731|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2011-08-19|2011-08-19|2011-08-22|Estimate|||||||2011-08-19|2011-08-22|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Back Pain and Male Sexual Disfunction|Phase 4 Study Back Pain and Male Sexual Disfunction|Unknown status|Not yet recruiting||54|Anticipated|Bezmialem Vakif University|||||f||||f||||||||||2018-05-31 22:13:59.366092|2018-05-31 22:13:59.366092
NCT01420718|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-19|||2012-03-25|2011-08-19|2011-08-22|Estimate|||||||2012-03-25|2012-03-27|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Partial Pulpotomy on Caries Free Human Teeth|Partial Pulpotomy on Caries Free Human Teeth Using iRootBP and White ProRoot MTA: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|24|Actual|Islamic Azad University, Tehran||2|||f||||f||||||||||2018-05-31 22:13:59.431011|2018-05-31 22:13:59.431011
NCT01420705|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-12-27|2011-08-19|2011-08-22|Estimate|||||||2011-12-27|2011-12-29|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Bacille Calmette-Guérin (BCG) Vaccine and Atopy|The Effect of Giving BCG Vaccine at Birth to Low Birth-weight Infants on Development of Allergy and Asthma in Childhood - Follow up of a Randomised Trial in Guinea-Bissau|Completed|||487|Anticipated|Bandim Health Project|||1||f||||f||||||Samples Without DNA|"~     Faecal samples are collected for analyses of parasites and microbes~   "|||2018-05-31 22:13:59.510188|2018-05-31 22:13:59.510188
NCT01420692|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-08-13|2011-08-19|2011-08-22|Estimate|||||||2012-08-13|2012-08-14|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes|The Effects of Insulin Detemir and Gliclazide-MR Treatments in Addition to Life-style Modification and Metformin Therapy on Endothelial Functions in Patients With Type 2 Diabetes : An Open-labelled Randomized Prospective Study|Completed||N/A|64|Actual|Ankara University||2|||f||||t||||||||||2018-05-31 22:13:59.578594|2018-05-31 22:13:59.578594
NCT01420679|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2018-04-30|2011-08-19|2011-08-22|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2011||2011-08-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients|A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy|Terminated||Phase 3|18|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||t||||||||||2018-05-31 22:13:59.6679|2018-05-31 22:13:59.6679
NCT01420666|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2016-01-04|2011-08-19|2011-08-22|Estimate|||||||2016-01-04|2016-01-06|Estimate||||January 2016|2016-01-31||||||||Interventional|||Maxi-Analgesic Osteoarthritis (OA) Study|Maxi-Analgesic OA Study: Multicentre, Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 With Acetaminophen or Ibuprofen on Patients With Pain From Osteoarthritis|Withdrawn||Phase 3|0|Actual|AFT Pharmaceuticals, Ltd.||4||The study was withdrawn for administrative reason|f||||f||||||||||2018-05-31 22:13:59.824576|2018-05-31 22:13:59.824576
NCT01420653|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16||2016-02-15|2016-04-07|2011-08-19|2011-08-22|Estimate||||2016-04-07|2016-05-05|Estimate|2016-04-07|2016-05-05|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Maxigesic 325 Acute Dental Pain Study|Maxigesic 325 Acute Dental Pain Study: A Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 Versus Acetaminophen, Ibuprofen and Placebo in Participants With Acute Dental Pain|Completed||Phase 3|408|Actual|AFT Pharmaceuticals, Ltd.||4|||f||||f||||||||||2018-05-31 22:13:59.893248|2018-05-31 22:13:59.893248
NCT01420640|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-02-09|2011-08-18|2011-08-19|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|FMEx||Tai Chi and Aerobic Exercise for Fibromyalgia (FMEx)|Tai Chi and Aerobic Exercise for Fibromyalgia|Completed||N/A|224|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-05-31 22:13:59.967458|2018-05-31 22:13:59.967458
NCT01420627|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2017-10-27|2011-08-18|2011-08-19|Estimate|||||||2017-10-27|2017-10-31|Actual|December 2013||2013-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|||EZN-2279 in Patients With ADA-SCID|A Study of EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase (ADA)-Deficient Combined Immunodeficiency|Recruiting||Phase 3|6|Anticipated|Leadiant Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 22:14:00.049419|2018-05-31 22:14:00.049419
NCT01420614|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2012-02-05|2011-08-18|2011-08-19|Estimate|||||||2012-02-05|2012-02-07|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|July 2012|Anticipated|2012-07-31|July 2011|Actual|2011-07-31||Interventional|RIFLE-STEACS||RadIal Versus Femoral InvEstigation in ST Elevation Acute Coronary Syndrome|RadIal Versus Femoral Randomized InvEstigation in ST Elevation Acute Coronary Syndrome|Unknown status|Active, not recruiting|N/A|1001|Actual|Policlinico Casilino ASL RMB||2|||f||||f||||||||||2018-05-31 22:14:00.149724|2018-05-31 22:14:00.149724
NCT01420601|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2017-04-02|2011-08-18|2011-08-19|Estimate|||||||2017-04-02|2017-04-04|Actual|September 2011|Actual|2011-09-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)|Torisel 25mg For Intravenous Drip Infusion Special Investigation - Survey On Long-term Use -|Active, not recruiting|||120|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 22:14:00.220158|2018-05-31 22:14:00.220158
NCT01420588|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2017-01-26|2011-08-18|2011-08-19|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 1, 2011|Actual|2011-08-01|January 2017|2017-01-31|December 30, 2017|Anticipated|2017-12-30|December 2015|Actual|2015-12-31||Observational|||Diagnosis of Gastric Lesions With Na-nose|Study of the Exhaled Breath of Patients With Malignant and Benign Lesions With Na-Nose|Recruiting|||960|Anticipated|Anhui Medical University|||4||f||||t||||||None Retained|"~     exhaled breath of volunteers~   "|||2018-05-31 22:14:00.372608|2018-05-31 22:14:00.372608
NCT01420575|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-09-17|2011-08-18|2011-08-19|Estimate|||||||2012-09-17|2012-09-19|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia|Using a Visual Decision Aid (DA) to Facilitate Shared Decision Making (SDM) During Antipsychotic Treatment in Schizophrenia.|Terminated||N/A|8|Actual|VA Nebraska Western Iowa Health Care System||2||Low enrollment rate.|f||||f||||||||||2018-05-31 22:14:00.453119|2018-05-31 22:14:00.453119
NCT01420562|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-01-13|2011-08-18|2011-08-19|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2011||2011-09-30|February 2013|2013-02-28||||March 2015|Anticipated|2015-03-31||Observational|||Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis|Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis|Unknown status|Recruiting||55|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 22:14:00.52574|2018-05-31 22:14:00.52574
NCT01420549|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2016-10-25|2011-08-18|2011-08-19|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|LANCE||Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|Phase III, Multicenter, Randomized, Open-label, Comparative, Parallel Group Study of the Efficacy and Safety of Rosuvastatin + Ezetimibe Versus Simvastatin + Ezetimibe in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|Completed||Phase 3|129|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f||||||||||2018-05-31 22:14:00.596259|2018-05-31 22:14:00.596259
NCT01420536|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Canine Guidance vs Bilateral Balanced Occlusion in Complete Denture|A Cross-over Randomized Clinical Trial of Canine Guidance and Bilateral Balanced Occlusion in Complete Denture Wearers|Completed||N/A|44|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:14:00.668254|2018-05-31 22:14:00.668254
NCT01420523|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-07-23|2011-08-18|2011-08-19|Estimate|||||||2015-07-23|2015-07-24|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ROCnRAL||Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy|Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).|Terminated||Phase 2|48|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 22:14:00.742701|2018-05-31 22:14:00.742701
NCT01420510|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-06-20|2011-08-18|2011-08-19|Estimate|||||||2013-06-20|2013-06-21|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis|Saginil in Vaginal Cannulas vs. Placebo for the Prevention of Vaginitis in Gynecologic Oncologic Patients Receiving Chemotherapy: a Randomized Controlled Trial.|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Università degli Studi dell'Insubria||2|||f||||t||||||||||2018-05-31 22:14:00.809682|2018-05-31 22:14:00.809682
NCT01420497|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|August 2008||2008-08-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|September 2008|Actual|2008-09-30||Interventional|||Systemic Effects of Epidural Methylprednisolone Injection on Glucose Tolerance in Diabetic Patients||Completed||N/A|25|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 22:14:00.879459|2018-05-31 22:14:00.879459
NCT01420484|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2013-12-18|2011-08-18|2011-08-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|||CNAP in Heart Surgery|Noninvasive Blood Pressure Measuring|Completed|||50|Actual|Heidelberg University|||1||f||||f||||||||||2018-05-31 22:14:00.943006|2018-05-31 22:14:00.943006
NCT01420471|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2012-10-26|2011-08-18|2011-08-19|Estimate|||||||2012-10-26|2012-10-30|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|FISHNET||Medicated Punctured-Glove-Finger Spacer Study|Medicated Punctured-Glove-Finger Spacer Study|Completed||Phase 4|50|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:14:01.007272|2018-05-31 22:14:01.007272
NCT01420458|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-11-03|2011-08-18|2011-08-19|Estimate|||||||2011-11-03|2011-11-04|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012|A Randomized, Two-Period Crossover Study in Healthy Volunteers to Establish the Bioequivalence of Two Formulations of BG00012.|Completed||Phase 1|80|Actual|Biogen|||||f||||f||||||||||2018-05-31 22:14:01.070799|2018-05-31 22:14:01.070799
NCT01420445|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-09-25|2011-08-18|2011-08-19|Estimate|||||||2013-09-25|2013-09-26|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis|Randomized, Double-blind, Placebo/Active-controlled, Multi-center, Phase 3 Clinical Trial to Investigate the Safety/Tolerability and Efficacy of YHD001 After Oral Administration in Patients With Acute or Chronic Bronchitis|Completed||Phase 2|118|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 22:14:01.117551|2018-05-31 22:14:01.117551
NCT01420432|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Ankylosing Spondylitis (AS)|Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat AS|Unknown status|Recruiting|Phase 1|10|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 22:14:01.183814|2018-05-31 22:14:01.183814
NCT01420419|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2013-01-14|2011-08-18|2011-08-19|Estimate|||||||2013-01-14|2013-01-16|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|LanP||Evaluating Lanolin for the Treatment of Nipple Pain Among Breastfeeding Women|A Randomized Controlled Trial Evaluating Lanolin for the Treatment of Nipple Pain Among Breastfeeding Women|Completed||Phase 4|186|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 22:14:01.256896|2018-05-31 22:14:01.256896
NCT01420406|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2012-09-11|2011-08-18|2011-08-19|Estimate|||||||2012-09-11|2012-09-12|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|May 2011|Actual|2011-05-31||Interventional|||Vitamin A Bioavailability in Lactating Women With Marginal Vitamin A Status|Impact of Daily Feeding of Food Sources of Cryptoxanthin (CX) and Beta-carotene (BC) on Plasma and Breast Milk Concentrations of CX, BC, and Retinol (VA) in Lactating Women With Marginal Vitamin A Status|Completed||N/A|140|Actual|USDA, Western Human Nutrition Research Center||4|||f||||f||||||||||2018-05-31 22:14:01.320594|2018-05-31 22:14:01.320594
NCT01420393|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-03-21|2011-08-18|2011-08-19|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2011||2011-09-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|RAFT-AF||Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation|A Randomized Ablation-based Atrial Fibrillation Rhythm Control Versus Rate Control Trial in Patients With Heart Failure and High Burden Atrial Fibrillation|Active, not recruiting||N/A|412|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 22:14:02.317965|2018-05-31 22:14:02.317965
NCT01420367|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|November 2011||2011-11-30|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Are Post-operative Antibiotics Indicated in Simple Appendicitis?|Are Post-operative Antibiotics Indicated in Simple Appendicitis? A Prospective Randomized Trial|Unknown status|Not yet recruiting|N/A|300|Anticipated|Monash University||2|||f||||f||||||||||2018-05-31 22:14:02.434047|2018-05-31 22:14:02.434047
NCT01420354|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2017-03-01|2011-08-17|2011-08-19|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2009||2009-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients|Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients|Terminated|||21|Actual|University of British Columbia||||The study was combined with our Urine and Stool Study (NCT01637506).|f||||f||||||Samples Without DNA|"~     Urine collected over 24 hour period~   "|No||2018-05-31 22:14:02.515349|2018-05-31 22:14:02.515349
NCT01420341|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2018-03-06|2011-08-18|2011-08-19|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2011||2011-08-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Co-trimoxazole as Maintenance Therapy for Meliodosis|A Comparison Between 12 vs. 20 Weeks of Co-trimoxazole as Maintenance Therapy for Melioidosis|Recruiting||Phase 4|800|Anticipated|Khon Kaen University||2|||f||||f|f|f||||||No||2018-05-31 22:14:02.576256|2018-05-31 22:14:02.576256
NCT01420328|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2012-12-17|2011-08-18|2011-08-19|Estimate|||||||2012-12-17|2012-12-18|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects|To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects|Unknown status|Active, not recruiting|Phase 3|20|Anticipated|Kaleida Health||2|||f||||f||||||||||2018-05-31 22:14:02.661333|2018-05-31 22:14:02.661333
NCT01420315|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2013-02-15|2011-08-18|2011-08-19|Estimate|||||||2013-02-15|2013-02-18|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|DEVIT-ALZ||The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease|The Prevalence of Vitamin D Deficiency in Patients With Alzheimer's Disease: a Crosssectional Multicenter Study in Turkey|Completed|||502|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi|||||f||||t||||||||||2018-05-31 22:14:02.725158|2018-05-31 22:14:02.725158
NCT01420302|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2012-07-31|2011-08-18|2011-08-19|Estimate|||||||2012-07-31|2012-08-01|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|LOGIC-1||LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness|LOGIC-Insulin Computerized Algorithm-guided Versus Nurse-directed Blood Glucose Control in Critically Ill Patients: the LOGIC-1 Randomized Controlled Trial|Completed||Phase 2/Phase 3|300|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 22:14:03.537973|2018-05-31 22:14:03.537973
NCT01420289|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|2011-08-22||2012-01-06|2011-08-18|2011-08-19|Estimate|2012-01-06|2012-02-09|Estimate||||2012-01-06|2012-02-09|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effect of HPIPC for the Treatment of Ischemic Ulcers in Subjects With PAD|A Randomized, Controlled Trial to Evaluate High Pressure Rapid Sequence, Intermittent Pneumatic Compression (HPIPC) for the Treatment of Intermittent Claudication, Pain and Ulcer Healing in Subjects With PAD|Completed||N/A|44|Actual|Calvary Hospital, Bronx, NY||2|||f||||f||||||||||2018-05-31 22:14:03.636219|2018-05-31 22:14:03.636219
NCT01420276|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Observational|||Female Sexual Function and Back Pain||Unknown status|Not yet recruiting||54|Anticipated|Bezmialem Vakif University|||||f||||||||||||||2018-05-31 22:14:03.868617|2018-05-31 22:14:03.868617
NCT01420263|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-02-07|2011-08-18|2011-08-19|Estimate|||||||2013-02-07|2013-02-11|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Re-feeding Gastric Residuals in Preterm Infants|Re-feeding Residuals Versus Feeding Fresh Formula/Milk for Feeding Intolerance in Premature Infants|Completed||N/A|72|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 22:14:03.918516|2018-05-31 22:14:03.918516
NCT01420250|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2017-10-25|2011-08-17|2011-08-19|Estimate|||||||2017-10-25|2017-10-27|Actual|September 22, 2011|Actual|2011-09-22|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 21, 2015|Actual|2015-07-21||Interventional|||Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer|Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the Prostate|Active, not recruiting||Phase 1|20|Anticipated|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-05-31 22:14:03.986109|2018-05-31 22:14:03.986109
NCT01420237|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2017-06-19|2011-08-17|2011-08-19|Estimate|||||||2017-06-19|2017-06-20|Actual|June 2011||2011-06-30|June 2017|2017-06-30|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30||Interventional|||Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study|Restoration® Anatomic Dual Mobility (ADM) X3® Acetabular System Study With Long Term Data Collection for the Accolade® II Hip Stem|Active, not recruiting||N/A|352|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-05-31 22:14:04.07107|2018-05-31 22:14:04.07107
NCT01420224|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Study of the Effects of Commercial Air Travel on the Lungs|Study of the Effects of Commercial Air Travel on Pulmonary Artery Pressure in Healthy Passengers and in a Patient With Chuvash Polycythaemia|Completed|||9|Actual|University of Oxford|||2||f||||f||||||||||2018-05-31 22:14:04.242207|2018-05-31 22:14:04.242207
NCT01420211|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®|Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® in Healthy Volunteers and in Patients With Liver Disease|Completed||Phase 1/Phase 2|45|Actual|University Medicine Greifswald||1|||f||||f||||||||||2018-05-31 22:14:04.31728|2018-05-31 22:14:04.31728
NCT01420198|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-11-09|2011-08-18|2011-08-19|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MEDIM||Efficiency and Cost-effectiveness of a Culturally Adopted Lifestyle Intervention Program - the MEDIM Study.|A Middle Eastern Immigrant Population At-risk for Diabetes; Contributing Risk Factors and the Efficiency and Cost-effectiveness of a Culturally Adopted Lifestyle Intervention Program - the MEDIM Study.|Completed||N/A|96|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:14:04.391542|2018-05-31 22:14:04.391542
NCT01420185|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2015-05-06|2011-08-18|2011-08-19|Estimate|||||||2015-05-06|2015-05-08|Estimate|October 2011||2011-10-31|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Observational|||Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28|Molecular Predictors of Loco-Regional Recurrence in Node Positive Breast Cancer|Unknown status|Active, not recruiting||1300|Anticipated|NSABP Foundation Inc|||||f||||f||||||||||2018-05-31 22:14:04.474849|2018-05-31 22:14:04.474849
NCT01420172|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-02-24|2011-08-17|2011-08-19|Estimate|||||||2017-02-24|2017-02-27|Actual|August 2011||2011-08-31|October 2015|2015-10-31|July 8, 2016|Actual|2016-07-08|July 8, 2016|Actual|2016-07-08||Observational|||Pulmonary Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation|Pulmonary Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation.|Completed|||200|Actual|Ohio State University|||1||f||||f||||||||||2018-05-31 22:14:04.549151|2018-05-31 22:14:04.549151
NCT01420159|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2012-10-30|2011-08-18|2011-08-19|Estimate|||||||2012-10-30|2012-10-31|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|STOP!||Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma|A Randomised, Double Blind, Multi-centre, Placebo Controlled Study to Evaluate the Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Patients Presenting to an Emergency Department With Minor Trauma|Completed||Phase 3|300|Actual|Medical Developments International Limited||2|||f||||t||||||||||2018-05-31 22:14:04.625332|2018-05-31 22:14:04.625332
NCT01420146|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2017-03-07||2017-03-07|2011-08-18|2011-08-19|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|August 2011||2011-08-31|January 2015|2015-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|IJBMNZrT003||Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients|Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients : Correlation With FDG-PET/CT and Anatomopathological Results|Completed||Phase 1|20|Actual|Jules Bordet Institute||1|||f||||f||||||||Undecided||2018-05-31 22:14:04.734687|2018-05-31 22:14:04.734687
NCT01420133|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-12-21|2011-08-18|2011-08-19|Estimate|||||||2015-12-21|2015-12-22|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Cortisel||Is a Diet Necessary When Corticosteroid Treatment is Prescribed?|Is a Low Salt Diet and Low Sugar Content Necessary When Corticosteroid Treatment is Prescribed?|Completed||N/A|50|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 22:14:04.902603|2018-05-31 22:14:04.902603
NCT01420120|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-07-15|2011-08-18|2011-08-19|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Remedy, Biodegradable Peripheral Stent Registry|A Prospective Multicenter Registry to Evaluate Safety and Performance of REMEDY, Biodegradable Peripheral Stent for the Treatment of Occluded or Stenotic Superficial Femoral Arteries.|Completed|||100|Anticipated|be Medical|||||f||||f||||||||||2018-05-31 22:14:04.96996|2018-05-31 22:14:04.96996
NCT01420107|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-08-18|2011-08-18|2011-08-19|Estimate|||||||2011-08-18|2011-08-19|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|April 2012|Anticipated|2012-04-30|December 2011|Anticipated|2011-12-31||Observational|||Video Recording in the Delivery Room in Very Preterm Infants (Video Apgar Trial)|Video Recording in the Delivery Room in Very Preterm Infants (Video Apgar Trial)|Unknown status|Recruiting||200|Anticipated|University Medicine Greifswald|||||f||||t||||||||||2018-05-31 22:14:05.028503|2018-05-31 22:14:05.028503
NCT01420094|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2016-01-14|2011-08-18|2011-08-19|Estimate|||||||2016-01-14|2016-01-15|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|TAROT compare||Evaluate Onset of Action of a Fast Release Aspirin|Comparative Onset of Action of a Fast Release Aspirin Tablet in a Dental Impaction Pain Model|Completed||Phase 3|510|Actual|Bayer||3|||f||||f||||||||||2018-05-31 22:14:05.089106|2018-05-31 22:14:05.089106
NCT01420081|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|2015-04-30||2017-05-23|2011-08-17|2011-08-19|Estimate|2015-04-30|2015-05-19|Estimate||||2017-05-23|2017-06-21|Actual|January 19, 2012|Actual|2012-01-19|May 2017|2017-05-31|December 25, 2015|Actual|2015-12-25|April 30, 2014|Actual|2014-04-30||Interventional|||A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer|A Randomized Phase 2 Non-comparative Study Of The Efficacy Of Pf-04691502 And Pf-05212384 In Patients With Recurrent Endometrial Cancer|Terminated||Phase 2|67|Actual|Pfizer||3||See termination reason in detailed description.|f||||f||||||||No||2018-05-31 22:14:05.400502|2018-05-31 22:14:05.400502
NCT01420068|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-03-27|2011-08-18|2011-08-19|Estimate|||||||2018-03-27|2018-03-29|Actual|August 19, 2011|Actual|2011-08-19|March 2018|2018-03-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Observational|||52-104 Week Off-therapy Second Extension to Study CSPP100A2365|A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1|Completed|||106|Actual|Novartis|||1||f||||||||||||||2018-05-31 22:14:08.775796|2018-05-31 22:14:08.775796
NCT01420055|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2016-11-16|2011-08-18|2011-08-19|Estimate|||||||2016-11-16|2016-11-18|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|GRACE||Fingolimod -Response According to Coping - Evaluation|A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France|Completed||Phase 4|189|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:14:08.956926|2018-05-31 22:14:08.956926
NCT01420042|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2012-11-20|2011-08-17|2011-08-19|Estimate|||||||2012-11-20|2012-11-22|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration|A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NNZ-2566 in Healthy Subjects, Following Oral Administration|Completed||Phase 1|24|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||||2018-05-31 22:14:09.249435|2018-05-31 22:14:09.249435
NCT01420029|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-09-19|2011-08-18|2011-08-19|Estimate|||||||2013-09-19|2013-09-20|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Hospital-Based Phthalate Exposure in Very Low Birth Weight Neonates|Hospital-Based Phthalate Exposure in Very Low Birth Weight Neonates|Completed|||81|Actual|Icahn School of Medicine at Mount Sinai|||||f||||f||||||Samples With DNA|"~     Urine, whole blood~   "|||2018-05-31 22:14:09.808312|2018-05-31 22:14:09.808312
NCT01420016|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2015-11-25|2011-08-17|2011-08-19|Estimate|||||||2015-11-25|2015-11-26|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|||Prioritized Clinical Decision Support to Reduce Cardiovascular Risk|Prioritized Clinical Decision Support to Reduce Cardiovascular Risk|Completed||N/A|29950|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 22:14:10.075344|2018-05-31 22:14:10.075344
NCT01420003|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2015-03-19|2011-08-18|2011-08-19|Estimate|||||||2015-03-19|2015-03-20|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics|Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics|Completed||N/A|12|Actual|Hamilton Health Sciences Corporation||1|||f||||f||||||||||2018-05-31 22:14:10.342371|2018-05-31 22:14:10.342371
NCT01419990|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2012-08-14|2011-08-17|2011-08-19|Estimate|||||||2012-08-14|2012-08-15|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects|Double-blind Placebo Controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Dosing of GLPG0634 in Healthy Subjects|Completed||Phase 1|16|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 22:14:10.502753|2018-05-31 22:14:10.502753
NCT01419977|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|2015-01-30||2015-01-30|2011-08-18|2011-08-19|Estimate|2015-01-30|2015-02-16|Estimate||||2015-01-30|2015-02-16|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo|Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo|Completed||Phase 2|34|Actual|Duke University|Limitations to our pilot study include the small study sample size, which leads to difficulty in determining significant differences in the outcome measurements.|2|||f||||t||||||||||2018-05-31 22:14:10.678381|2018-05-31 22:14:10.678381
NCT01419964|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2016-03-15|2011-08-18|2011-08-19|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2012||2012-01-31|March 2016|2016-03-31||||December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety of ACH24 in the Treatment of Vitiligo|Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||2||"The Brazilian regulatory agency - ANVISA has requested the cancellation of the phase 3 study~   for conducting a phase 1 study first."|f||||f||||||||||2018-05-31 22:14:12.229951|2018-05-31 22:14:12.229951
NCT01419951|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-10-20|2011-08-17|2011-08-18|Estimate|||||||2014-10-20|2014-10-22|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2011|Actual|2011-10-31||Interventional|||Launch II: A Pilot Randomized Control Trial of a Clinic and Clinic Plus Home Intervention for Preschool Obesity|LAUNCH II: Learning About Activity and Understanding Nutrition for Better Child Health|Completed||Phase 1|60|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||f||||||||||2018-05-31 22:14:12.307504|2018-05-31 22:14:12.307504
NCT01419938|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2013-04-24|2011-08-16|2011-08-18|Estimate|||||||2013-04-24|2013-04-25|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Does Cognitive Behaviour Therapy (CBT) Improve the Effect of Light Therapy|Does CBT Improve the Effect of Light Therapy in Delayed Sleep Phase Syndrome Compared to Only Light Therapy - Short and Long Term Follow up|Completed||N/A|57|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 22:14:12.505701|2018-05-31 22:14:12.505701
NCT01419925|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2014-05-12|2011-08-17|2011-08-18|Estimate|||||||2014-05-12|2014-05-13|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers|A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.|Completed||Phase 2|120|Actual|BiondVax Pharmaceuticals ltd.||4|||f||||f||||||||||2018-05-31 22:14:12.731354|2018-05-31 22:14:12.731354
NCT01419912|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2011-08-29|2011-08-17|2011-08-18|Estimate|||||||2011-08-29|2011-08-30|Estimate||||January 2011|2011-01-31||||||||Interventional|||Comparison of Soy-milk and Cow Milk Consumption on Inflammatory Factors, Cardiovascular Factors ,Renal Factors, Fibrinolytic Indice and Oxidative Stress Among Type-2 Diabetic Patients With Nephropathy Stage 1 and 2||Completed||Phase 3|||Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 22:14:13.079683|2018-05-31 22:14:13.079683
NCT01419899|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-08-05|2011-08-16|2011-08-18|Estimate|||||||2013-08-05|2013-08-07|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|InVITED||Increasing Viral Testing in the Emergency Department|Phase 2/3 Clinical Trial of the Effect of a Brief Intervention on Uptake of Rapid Testing for HIV and Hepatitis C Among Emergency Department Patients|Completed||Phase 2/Phase 3|398|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 22:14:13.154125|2018-05-31 22:14:13.154125
NCT01419886|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2016-05-31|2011-08-17|2011-08-18|Estimate|||||||2016-05-31|2016-06-02|Estimate|October 2010||2010-10-31|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Observational|||Testing of a New Scale Measuring Medical Outcomes of Dysphagia (MOD) in Adult Patients With Swallowing Disorders||Unknown status|Recruiting||500|Anticipated|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 22:14:13.247598|2018-05-31 22:14:13.247598
NCT01419873|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-08-25|2011-08-17|2011-08-18|Estimate|||||||2011-08-25|2011-08-29|Estimate|August 2008||2008-08-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates|Pilot Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates|Completed||Phase 4|30|Actual|Christchurch Women's Hospital|||||f||||f||||||||||2018-05-31 22:14:13.345024|2018-05-31 22:14:13.345024
NCT01419860|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2016-10-31|2011-08-17|2011-08-18|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of Microcirculation in Colon Wall and Bowel Anastomosis by Laser Induced Fluorescence Video Angiography|Evaluation of Microcirculation in Colon Wall and Bowel Anastomosis by Laser Induced Fluorescence Video Angiography of Indocyanine Green|Unknown status|Active, not recruiting|Early Phase 1|4|Anticipated|Ostfold Hospital Trust||1|||f||||t||||||||||2018-05-31 22:14:13.423576|2018-05-31 22:14:13.423576
NCT01419847|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2011-08-17|2011-08-17|2011-08-18|Estimate|||||||2011-08-17|2011-08-18|Estimate|March 2002||2002-03-31|May 2006|2006-05-31|May 2006|Actual|2006-05-31|December 2005|Actual|2005-12-31||Interventional|||Topical Penlac Nail Lacquer for Onychomycosis in Children|A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children|Completed||Phase 4|40|Actual|Rady Children's Hospital, San Diego||2|||f||||f||||||||||2018-05-31 22:14:13.836979|2018-05-31 22:14:13.836979
NCT01419288|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-01-08|2011-08-17|2011-08-18|Estimate|||||||2013-01-08|2013-01-10|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Treadmill Training With Lower Extremity Amputees||Completed||Phase 1|8|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 22:14:19.549744|2018-05-31 22:14:19.549744
NCT01419834|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2017-12-22|2011-08-17|2011-08-18|Estimate|||||||2017-12-22|2017-12-27|Actual|August 2011||2011-08-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors|Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors|Recruiting||Phase 1|74|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 22:14:14.127722|2018-05-31 22:14:14.127722
NCT01419821|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-02-21|2011-08-17|2011-08-18|Estimate|||||||2013-02-21|2013-02-22|Estimate|September 2013||2013-09-30|August 2011|2011-08-31|September 2016|Anticipated|2016-09-30|September 2014|Anticipated|2014-09-30||Interventional|VitD||Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5|Supplemental Vitamin D Administered to One Year Old Vitamin D Deficient Infants Until Age 3 and Its Affect on Growth Rates and Bone Mineral Density Until Age 5|Unknown status|Not yet recruiting|N/A|200|Anticipated|Meir Medical Center||3|||f||||f||||||||||2018-05-31 22:14:14.684138|2018-05-31 22:14:14.684138
NCT01419808|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-17|2011-08-17|2011-08-18|Estimate|||||||2011-08-17|2011-08-18|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Vascularized Versus Non-Vascularized Bone Grafts in Treating Proximal Pole Scaphoid Non Unions|Vascularized vs. Non-vascularized Bone Grafting in the Treatment of Proximal Pole Scaphoid Non Unions: A Prospective Randomized Trial|Unknown status|Recruiting|N/A|40|Anticipated|Hand and Upper Limb Clinic, Canada||2|||f||||f||||||||||2018-05-31 22:14:14.965917|2018-05-31 22:14:14.965917
NCT01419795|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2017-01-31||2017-07-24|2011-08-17|2011-08-18|Estimate|2017-01-31|2017-03-21|Actual||||2017-07-24|2017-07-27|Actual|May 2012||2012-05-31|July 2017|2017-07-31||||September 2013|Actual|2013-09-30||Interventional|||Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant|A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab|Terminated||Phase 2|3|Actual|Fred Hutchinson Cancer Research Center||2||Low accrual|f||||t||||||||||2018-05-31 22:14:15.067398|2018-05-31 22:14:15.067398
NCT01419782|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-05-06|2011-08-17|2011-08-18|Estimate|||||||2013-05-06|2013-05-07|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|WBV-BM||Effects of Unilateral WBV on Muscleactivity of Contralateral Hip Adductor|The Effects Of Femur On The Resting Myoelectrical Activity Of Contralateral Adductor Muscle During Unilateral Lower Extremity Vibration: Bone Myoregulation Reflex|Completed||N/A|20|Actual|Bagcilar Training and Research Hospital||1|||f||||f||||||||||2018-05-31 22:14:15.631261|2018-05-31 22:14:15.631261
NCT01419769|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2014-11-12||2015-09-02|2011-08-17|2011-08-18|Estimate|2014-11-12|2014-11-19|Estimate||||2015-09-02|2015-09-21|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional||Patients between 18 and 75 years of age, suitable for transluminal drainage of symptomatic pancreatic pseudocysts that are greater than or equal to 6 cm in diameter and adherent to the bowel wall are candidates for study treatment.|AXIOS Stent & Delivery System Study|A Prospective, Multi-center, Non-blinded, Single-arm (Nonrandomized) Study of the AXIOS Stent and Delivery System|Completed||N/A|30|Actual|Xlumena, Inc.||1|||f||||t||||||||||2018-05-31 22:14:15.751392|2018-05-31 22:14:15.751392
NCT01419756|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2014-10-03|2011-08-17|2011-08-18|Estimate|||||||2014-10-03|2014-10-06|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|VMS TOF||Assessment of Right Ventricular Volume in Tetralogy of Fallott (TOF) Patients|Assessment of Right Ventricular Volume Using the Ventripoint Medical System in Patients With Tetralogy of Fallott Following Repair; A Comparison Study to cMRI|Completed|||109|Actual|VentriPoint Diagnostics Ltd.|||1||f||||f||||||||||2018-05-31 22:14:16.018336|2018-05-31 22:14:16.018336
NCT01419743|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2014-02-16|2011-08-17|2011-08-18|Estimate|||||||2014-02-16|2014-02-19|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Effect of Vitamin D Supplementation on In-vitro Fertilization (IVF) Outcomes|Randomized Controlled Trial: The Effects of Vitamin D Supplementation on In-vitro Fertilization Outcomes|Terminated|||102|Anticipated|Northwestern University|||6|Low recruitment numbers|f||||f||||||||||2018-05-31 22:14:16.077929|2018-05-31 22:14:16.077929
NCT01419730|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-10-05|2011-08-16|2011-08-18|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2011|Actual|2011-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Vitamin D and Physical Activity on Bone Health|The Effect of High-Dose Vitamin D and Physical Activity on Bone Health in Breast Cancer Patients Receiving Hormonal Therapy|Recruiting||Phase 2|105|Anticipated|University of Rochester||3|||f||||t||||||||||2018-05-31 22:14:16.14043|2018-05-31 22:14:16.14043
NCT01419717|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2018-01-30|2011-08-17|2011-08-18|Estimate|||||||2018-01-30|2018-02-01|Actual|November 22, 2011|Actual|2011-11-22|January 2018|2018-01-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer|Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer|Active, not recruiting||Phase 3|129|Actual|Amgen||1|||f||||f||||||||||2018-05-31 22:14:16.20829|2018-05-31 22:14:16.20829
NCT01419704|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2018-04-19|2011-08-17|2011-08-18|Estimate|||||||2018-04-19|2018-04-20|Actual|May 2011||2011-05-31|April 2018|2018-04-30|May 2030|Anticipated|2030-05-31|May 2025|Anticipated|2025-05-31||Interventional|||Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies|Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies|Suspended||Phase 1/Phase 2|30|Anticipated|University of Louisville||1||Study completed at site, no active participants. IDE open for future enrollment|f||||t|t|f||||||Undecided||2018-05-31 22:14:16.48107|2018-05-31 22:14:16.48107
NCT01419691|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2016-01-15|2011-08-17|2011-08-18|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)|A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL)|Completed||Phase 2|15|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 22:14:16.568573|2018-05-31 22:14:16.568573
NCT01419678|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2014-12-05|2011-08-17|2011-08-18|Estimate|||||||2014-12-05|2014-12-08|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients|Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients|Completed||N/A|20|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:14:16.636534|2018-05-31 22:14:16.636534
NCT01327209|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-06-08|2011-03-31|2011-04-01|Estimate|||||||2011-06-08|2011-06-09|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|||||Observational|BGMS||Blood Glucose Monitoring System Clinical Study|Blood Glucose Monitoring System Clinical Study|Completed|||202|Actual|Intuity Medical, Inc|||1||f||||f||||||||||2018-05-31 22:44:39.310153|2018-05-31 22:44:39.310153
NCT01419665|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-02-12|2011-08-17|2011-08-18|Estimate|||||||2018-02-12|2018-02-13|Actual|December 1, 2011|Actual|2011-12-01|February 2018|2018-02-28|January 22, 2018|Actual|2018-01-22|July 10, 2015|Actual|2015-07-10||Interventional|ASSIST_FL||GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma|A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma|Completed||Phase 3|629|Actual|Sandoz||2|||f||||t||||||||Undecided||2018-05-31 22:14:16.734963|2018-05-31 22:14:16.734963
NCT01419652|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-06-08|2011-08-17|2011-08-18|Estimate|||||||2012-06-08|2012-06-12|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography|Periprocedural Glycemic Control in Patients Undergoing Coronary Angiography With or Without Percutaneous Coronary Intervention|Completed||Phase 4|351|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 22:14:17.048317|2018-05-31 22:14:17.048317
NCT01419639|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|2015-07-08||2017-06-20|2011-08-17|2011-08-18|Estimate|2015-07-08|2015-08-07|Estimate||||2017-06-20|2017-07-18|Actual|October 2011||2011-10-31|June 2017|2017-06-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2|Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2|Completed||Phase 2|10|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 22:14:17.125001|2018-05-31 22:14:17.125001
NCT01419626|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2011-09-15|2011-08-17|2011-08-18|Estimate|||||||2011-09-15|2011-09-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:14:17.326997|2018-05-31 22:14:17.326997
NCT01419613|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2015-06-22|2011-08-17|2011-08-18|Estimate|||||||2015-06-22|2015-06-23|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Promoting a Healthier Lifestyle Among Breast Cancer Survivors|Motivational Interviewing to Promote Physical Activity in Breast Cancer Survivors|Completed||N/A|68|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-05-31 22:14:17.363439|2018-05-31 22:14:17.363439
NCT01419600|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2012-07-02|2011-08-17|2011-08-18|Estimate|||||||2012-07-02|2012-07-03|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD8683 After Single Ascending Doses Administered Via Turbuhaler in Healthy Subjects|Completed||Phase 1|38|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:14:17.44482|2018-05-31 22:14:17.44482
NCT01419587|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2018-01-04|2011-08-16|2011-08-18|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2011||2011-07-31|January 2018|2018-01-31|July 11, 2017|Actual|2017-07-11|June 30, 2017|Actual|2017-06-30||Interventional|||Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)|A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Non-small Cell Lung Cancer|Terminated||N/A|11|Actual|University of Iowa||1||Poor accrual and compliance|f||||t||||||||||2018-05-31 22:14:17.523163|2018-05-31 22:14:17.523163
NCT01419574|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-05-22|2011-08-17|2011-08-18|Estimate|||||||2018-05-22|2018-05-23|Actual|July 29, 2011||2011-07-29|April 27, 2016|2016-04-27|April 27, 2016||2016-04-27|||||Observational|||Ultrasound and Other Images of Artery Blockages|Contrast-Enhanced Ultrasound Imaging of Carotid Plaque Neovascularization|Terminated|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:14:17.587149|2018-05-31 22:14:17.587149
NCT01419561|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2017-11-25|2011-08-17|2011-08-18|Estimate|||||||2017-11-25|2017-11-28|Actual|August 17, 2011||2011-08-17|November 20, 2017|2017-11-20||||||||Observational|||History of the KSHV Inflammatory Cytokine Syndrome (KICS)|Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies|Recruiting|||80|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 22:14:17.640692|2018-05-31 22:14:17.640692
NCT01419548|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2017-06-30|2011-08-17|2011-08-18|Estimate|||||||2017-06-30|2017-07-02|Actual|July 29, 2011||2011-07-29|November 18, 2011|2011-11-18|November 18, 2011|Actual|2011-11-18|November 18, 2011|Actual|2011-11-18||Interventional|||ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems|An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:14:17.704387|2018-05-31 22:14:17.704387
NCT01419535|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-03-27|2011-08-17|2011-08-18|Estimate|||||||2018-03-27|2018-03-29|Actual|August 17, 2011||2011-08-17|November 29, 2017|2017-11-29|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||Mifepristone for Metabolic Syndrome|Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals|Completed||Phase 1/Phase 2|63|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:14:17.760482|2018-05-31 22:14:17.760482
NCT01419522|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-05-23|2011-08-17|2011-08-18|Estimate|||||||2018-05-23|2018-05-24|Actual|July 29, 2011||2011-07-29|January 6, 2014|2014-01-06|January 6, 2014|Actual|2014-01-06|January 6, 2014|Actual|2014-01-06||Interventional|||Treadmill Training at Constant or Different Speeds for People With Traumatic Brain Injury|Effect of Time Varying Walking Velocity in Body-Weight Supported Treadmill Training|Terminated||Phase 3|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:14:17.821113|2018-05-31 22:14:17.821113
NCT01419509|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2016-05-13|2011-08-17|2011-08-18|Estimate|||||||2016-05-13|2016-05-17|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma|DNA Methylation-based Assays for Detecting Disease Spread in Rhabdomyosarcoma|Completed|||170|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tumor, Blood, and Bone Marrow Samples~   "|||2018-05-31 22:14:17.875143|2018-05-31 22:14:17.875143
NCT01419496|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2016-05-17|2011-08-17|2011-08-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2011||2011-09-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia|Identifying Stat3-Dependent Chemotherapy Resistance Pathways in Relapsed AML|Completed|||40|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:14:17.925532|2018-05-31 22:14:17.925532
NCT01419483|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2018-01-04|2011-08-16|2011-08-18|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2011|Actual|2011-07-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|KETOPAN||Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer|A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer.|Terminated||N/A|5|Actual|University of Iowa||1||poor accrual|f||||t||||||||||2018-05-31 22:14:17.974858|2018-05-31 22:14:17.974858
NCT01419470|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2012-07-31|2011-08-17|2011-08-18|Estimate|||||||2012-07-31|2012-08-01|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044|Phase Ⅰ/Ⅱ Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044 After Oral Administration in Premature Ejaculation Patients|Completed||Phase 1/Phase 2|24|Actual|Yuhan Corporation||3|||f||||f||||||||||2018-05-31 22:14:18.042566|2018-05-31 22:14:18.042566
NCT01419457|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-10-20|2011-08-17|2011-08-18|Estimate|||||||2015-10-20|2015-10-22|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment|A Phase I, Open-Label, Parallel-Group, Multiple-Dose Study to Determine the Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment and in Healthy Control Volunteers|Completed||Phase 1|36|Actual|MDVI, LLC||4|||f||||t||||||||||2018-05-31 22:14:18.090823|2018-05-31 22:14:18.090823
NCT01419444|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-12-17|2011-08-17|2011-08-18|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Telemedicine Versus Traditional Treatment of Muscle Tension Dysphonia|Telemedicine Versus Traditional Treatment of Muscle Tension Dysphonia|Completed||Phase 1/Phase 2|14|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 22:14:18.152497|2018-05-31 22:14:18.152497
NCT01419431|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-12-15|2011-08-17|2011-08-18|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Attenuated Inflammatory Response in Laparoscopic Colon Surgery|Increased SOCS 3 mRNA in Monocytes From Patients Subjected to Laparoscopic Colon Surgery|Completed|||20|Anticipated|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 22:14:18.329858|2018-05-31 22:14:18.329858
NCT01419418|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2017-05-22|2011-08-17|2011-08-18|Estimate|||||||2017-05-22|2017-05-23|Actual|January 2011||2011-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Patients' Perspectives of Factors That Support the Management of Peripheral Arterial Disease for Improved Outcomes|A Study of Patients' Perspectives of Factors That Support the Management of Cardiac Care for Improved Outcomes in a Peripheral Arterial Disease Population|Completed|||10|Actual|VA Eastern Colorado Health Care System|||1||f||||f||||||||||2018-05-31 22:14:18.399479|2018-05-31 22:14:18.399479
NCT01419405|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2014-09-11|2011-08-17|2011-08-18|Estimate|||||||2014-09-11|2014-09-12|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pregabalin and Remifentanil - Analgesia and Ventilation|Pregabalin Has Additive Analgesic and Ventilatory Depressive Effects in Combination With Remifentanil|Completed||Phase 4|12|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-05-31 22:14:18.462962|2018-05-31 22:14:18.462962
NCT01419392|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2012-04-14|2011-08-17|2011-08-18|Estimate|||||||2012-04-14|2012-04-17|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages|Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages: a Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 22:14:18.540854|2018-05-31 22:14:18.540854
NCT01419379|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-04-16|2011-08-17|2011-08-18|Estimate|||||||2013-04-16|2013-04-18|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|EPOCH||This is a Multicenter, Prospective and Retrospective and Descriptive Epidemiology Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Korea|Epidemiologic Review and Prospective Observation of COPD and Health in Korea|Completed|||1118|Actual|Takeda|||1||f||||f||||||||||2018-05-31 22:14:18.606595|2018-05-31 22:14:18.606595
NCT01419366|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-08-21|2011-08-17|2011-08-18|Estimate|||||||2013-08-21|2013-08-23|Estimate||||August 2013|2013-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Aricept® (Donepezil Hydrochloride) Tablets 10mg [Reference Formulation, Eisai Inc.), in Healthy Human Volunteers Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:18.67307|2018-05-31 22:14:18.67307
NCT01419353|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-12-23|2011-08-17|2011-08-18|Estimate|||||||2013-12-23|2013-12-24|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol|Programming by Estrogen Treatment in Gonadotropin Releasing Hormone Antagonist Protocol|Completed||Phase 4|63|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 22:14:18.72492|2018-05-31 22:14:18.72492
NCT01419340|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-08-17|2011-08-17|2011-08-18|Estimate|||||||2011-08-17|2011-08-18|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's Donepezil Hydrochloride Tablets Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Donepezil Hydrochloride Tablets 10mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Aricept® (Donepezil Hydrochloride) Tablets 10mg [Reference Formulation, Eisai Inc.), in Healthy Human Volunteers Under Fasting Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:18.854019|2018-05-31 22:14:18.854019
NCT01419327|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2018-05-02|2011-08-17|2011-08-18|Estimate|||||||2018-05-02|2018-05-03|Actual|March 23, 2009|Actual|2009-03-23|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|FOSRENOL-HD||Fosrenol Post-marketing Surveillance for Hemodialysis in Japan|Special Drug Use Investigation of Fosrenol (Long-term Investigation for Patients With Hemodialysis)|Active, not recruiting|||3267|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:14:18.909398|2018-05-31 22:14:18.909398
NCT01419314|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2012-09-13||2012-12-05|2011-08-16|2011-08-18|Estimate|2012-12-05|2013-01-03|Estimate||||2012-12-05|2013-01-03|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy|Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy|Completed||N/A|46|Actual|Texas Woman's University|The contrast between the splinting group and liner group was statistically underpowered. The data was collected and analyzed by the primary investigator. The clinical diagnosis of peripheral neuropathy was not confirmed with EMG or punch skin biopsy.|2|||f||||f||||||||||2018-05-31 22:14:19.003413|2018-05-31 22:14:19.003413
NCT01419301|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2014-11-19|2011-08-16|2011-08-18|Estimate|||||||2014-11-19|2014-11-20|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|April 2013|Actual|2013-04-30||Interventional|||Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)|Mindfulness Based Stress Reduction in MS|Completed||N/A|31|Actual|Stony Brook University|||||f||||f||||||||||2018-05-31 22:14:19.481566|2018-05-31 22:14:19.481566
NCT01419275|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2016-12-21||2017-07-29|2011-08-17|2011-08-18|Estimate|2017-07-29|2017-08-30|Actual||||2017-07-29|2017-08-30|Actual|April 2009||2009-04-30|July 2017|2017-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients|Quantifying Collateral Perfusion in Cerebrovascular Disease-Moyamoya Disease and Stroke Patients|Completed||N/A|126|Actual|Stanford University||4|||f||||||||||||||2018-05-31 22:14:19.626658|2018-05-31 22:14:19.626658
NCT01419262|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-11-16|2011-08-16|2011-08-18|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|DO IT||DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers|DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers|Completed||Phase 3|703|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 22:14:19.754672|2018-05-31 22:14:19.754672
NCT01419249|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2013-11-26||2013-11-26|2011-08-17|2011-08-18|Estimate|2013-11-26|2014-01-16|Estimate||||2013-11-26|2014-01-16|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Full Analysis Set (FAS) population included all the participants who had provided informed consent and had non-missing height at start (defined as within one month prior to treatment start date) and at 1 year (+/- 120 days) of r-hGH treatment and had pharmacogenomics data available.|First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study|First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study|Completed||Phase 4|458|Actual|Merck KGaA|No genetic markers were identified, therefore data for the secondary outcome measures was not analyzed.|1|||f||||f||||||||||2018-05-31 22:14:19.857875|2018-05-31 22:14:19.857875
NCT01419236|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2014-12-12||2014-12-12|2011-08-16|2011-08-18|Estimate|2014-12-12|2014-12-19|Estimate||||2014-12-12|2014-12-19|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All randomized participants.|A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels|A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Explore the Impact of Testosterone Solution 2% on Symptoms of Ejaculatory Dysfunction in Men With Testosterone Deficiency|Completed||Phase 2|76|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:14:20.12702|2018-05-31 22:14:20.12702
NCT01419223|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-10-25|2011-08-16|2011-08-18|Estimate|||||||2013-10-25|2013-10-29|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Patient Participation Beliefs and Post-Traumatic Stress Disorder (PTSD)|Patient Beliefs and Attitudes That Influence Participation in PTSD-TBI Clinical Trials|Completed|||30|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|||2||f||||t||||||||||2018-05-31 22:14:20.794642|2018-05-31 22:14:20.794642
NCT01419210|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-09-23|2011-08-17|2011-08-18|Estimate|||||||2015-09-23|2015-09-24|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Interventional|||Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer|A Pilot Program to Personalize Care by Integrating Traditional and Complementary Medicine for Women With Ovarian Cancer|Completed||N/A|28|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 22:14:20.853608|2018-05-31 22:14:20.853608
NCT01419197|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2014-02-07||2016-08-17|2011-08-16|2011-08-18|Estimate|2014-04-03|2014-05-05|Estimate||||2016-08-17|2016-10-12|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|February 2013|Actual|2013-02-28||Interventional|TH3RESA|Randomized population: All participants who were randomized to the study.|A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy|A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy|Completed||Phase 3|602|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:14:20.979419|2018-05-31 22:14:20.979419
NCT01419184|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2015-04-23||2018-01-07|2011-08-17|2011-08-18|Estimate|2015-06-12|2015-07-08|Estimate||||2018-01-07|2018-01-31|Actual|September 9, 2011|Actual|2011-09-09|January 2018|2018-01-31|October 5, 2012|Actual|2012-10-05|September 1, 2012|Actual|2012-09-01||Interventional|DAPHEOR1006|Baseline analysis population is drawn from the subset of the entire sample of participants that received at least 1 dose of study drug and that had complete data for calculating the primary outcome, infection-related length of stay (IRLOS).|Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA|A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA)|Completed||Phase 4|250|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:14:23.194045|2018-05-31 22:14:23.194045
NCT01419171|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2014-07-24||2014-09-12|2011-08-16|2011-08-18|Estimate|2014-07-24|2014-08-15|Estimate||||2014-09-12|2014-09-25|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||The OMEGA Clinical Trial|OMEGA: A Prospective, Multicenter Single-Arm Trial to Assess the OMEGA™ Coronary Stent System for the Treatment of a Single De Novo Coronary Artery Lesion|Completed||N/A|328|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 22:14:23.651801|2018-05-31 22:14:23.651801
NCT01419158|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-01-18|2011-08-17|2011-08-18|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|PFT||Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)|Targeted Detection of Alpha-1 Antitrypsin Deficiency in Patients Referred for Pulmonary Function Testing|Completed|||3457|Actual|Alpha-1 Foundation|||||f||||f||||||||||2018-05-31 22:14:24.34282|2018-05-31 22:14:24.34282
NCT01419145|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-06-15|2011-08-16|2011-08-17|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2011||2011-10-31|June 2017|2017-06-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study|A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study|Completed||N/A|46|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 22:14:24.414179|2018-05-31 22:14:24.414179
NCT01320644|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-08-10|2011-03-21|2011-03-22|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|ALYTE||A Study of Robotic Assisted Laparoscopic Sacral Colpopexy Using Alyte Mesh||Completed|||150|Actual|Atlantic Health System|||1||f||||f||||||||||2018-05-31 22:46:07.728232|2018-05-31 22:46:07.728232
NCT01419132|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-10-29|2011-08-16|2011-08-17|Estimate|||||||2011-10-29|2011-11-01|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Tra-HSS-Fur||Troponin I Release After High Diuretic Doses|Effects of High Furosemide Doses Alone or With Hypertonic Saline on Troponin I Myocardial Release in Acute Decompensated Heart Failure: a Double Blind Study.|Completed||Phase 4|60|Anticipated|University of Palermo||2|||f||||f||||||||||2018-05-31 22:14:24.511259|2018-05-31 22:14:24.511259
NCT01419119|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-12-10|2011-08-16|2011-08-17|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|VIDI2||Vitamin Deficiency in Immigrants, a Treatment Study|A Study, Four Parallel Arms, Included Two Arms Open Randomisation to Different Doses of Vitamin D, for Assessment of Efficacy of Treatment With Vitamin D at Vitamin D Deficiency, Vitamin D Insufficiency and Suboptimal Levels of Vitamin D|Completed||Phase 4|160|Actual|Umeå University||4|||f||||f||||||||||2018-05-31 22:14:24.592243|2018-05-31 22:14:24.592243
NCT01419106|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2015-06-18|2011-08-16|2011-08-17|Estimate|||||||2015-06-18|2015-06-19|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|SHoC-ED 1||Sonography in Hypotension and Cardiac Arrest in the Emergency Department.|SHoC-ED 1: Sonography in Hypotension and Cardiac Arrest in the Emergency Department.|Unknown status|Recruiting|N/A|400|Anticipated|Horizon Health Network||2|||f||||t||||||||||2018-05-31 22:14:24.675025|2018-05-31 22:14:24.675025
NCT01419093|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-09-16|2011-08-16|2011-08-17|Estimate|||||||2015-09-16|2015-09-18|Estimate|September 2008||2008-09-30|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Communication Intervention Physical Activity|A Communication Intervention for Physical Activity in Underserved Communities|Completed||N/A|325|Actual|University of Rochester||1|||f||||f||||||||||2018-05-31 22:14:24.788243|2018-05-31 22:14:24.788243
NCT01419080|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-11-16|2011-08-16|2011-08-17|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|PORTRAIT||Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)|Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT Registry)|Unknown status|Active, not recruiting||350|Anticipated|Saint Luke's Health System|||1||f||||f||||||||||2018-05-31 22:14:24.855926|2018-05-31 22:14:24.855926
NCT01419067|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-09-28|2011-08-16|2011-08-17|Estimate|||||||2017-09-28|2017-09-29|Actual|August 22, 2011|Actual|2011-08-22|September 2017|2017-09-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection|A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection|Active, not recruiting||Phase 2|112|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|t|f|f||||||2018-05-31 22:14:24.928064|2018-05-31 22:14:24.928064
NCT01419054|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2013-11-21|2011-08-16|2011-08-17|Estimate|||||||2013-11-21|2013-11-25|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|HHFG||Understanding Hand Hygiene Behavior at Unidad Nacional Oncologia Pediatrica|Understanding Hand Hygiene Behavior at Unidad Nacional Oncologia Pediatrica: A Focus Group Approach|Completed|||55|Actual|St. Jude Children's Research Hospital|||||f||||f||||||||||2018-05-31 22:14:25.000118|2018-05-31 22:14:25.000118
NCT01419041|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-09-28|2011-08-16|2011-08-17|Estimate|||||||2012-09-28|2012-10-01|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function|A Phase I, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:14:25.057346|2018-05-31 22:14:25.057346
NCT01419028|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2014-06-11||2014-07-17|2011-08-16|2011-08-17|Estimate|2014-07-17|2014-07-21|Estimate||||2014-07-17|2014-07-21|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Observational||Thirteen participants were alive at the time of data abstraction and were censored in the analysis|A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)|A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)|Completed|||48|Actual|Alexion Pharma GmbH|This was an observational study and, as such, serious and/or other [non-serious] adverse events were not collected/assessed.||1||f||||f||||||||||2018-05-31 22:14:25.157008|2018-05-31 22:14:25.157008
NCT01419015|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-08-24|2011-08-16|2011-08-17|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2011|Actual|2011-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|PREVAIL-20J||PREVAIL-20J - Transfemoral Placement of 20mm Aortic Balloon Expandable Transcatheter Valve Trial|A Clinical Trial of a 20mm Transcatheter Bioprosthetic Valve for Patients With Aortic Stenosis|Active, not recruiting||N/A|15|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 22:14:25.393827|2018-05-31 22:14:25.393827
NCT01419002|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2015-07-27|2011-08-16|2011-08-17|Estimate|||||||2015-07-27|2015-07-29|Estimate|October 2011||2011-10-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Net-Pac||Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer|Neoadjuvant Radiotherapy in Patients With Primary Resectable Adenocarcinoma of the Pancreatic Head Plus Adjuvant Chemotherapy: a Randomized Controlled Phase III Trial|Terminated||Phase 3|5|Actual|CHIR-Net||2||lack of recruitment|f||||f||||||||||2018-05-31 22:14:25.520978|2018-05-31 22:14:25.520978
NCT01418989|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2016-11-01|2011-08-16|2011-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers|An Open-label, Multi-center Study to Compare the Relative Bioavailability of Tocilizumab in Healthy Subjects Following Single Dose Subcutaneous (SC) Administration Via Disposable Auto-Injector (DAI) Device vs Pre-filled Glass Syringe (PFS)|Completed||Phase 1|239|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:14:25.593285|2018-05-31 22:14:25.593285
NCT01418976|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-04-25|2011-08-16|2011-08-17|Estimate|||||||2013-04-25|2013-04-26|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Walking and Balance Post-TBI|IMPROVING WALKING AND BALANCE IN VETERANS WITH TRAUMATIC BRAIN INJURY: A PILOT STUDY EXAMINING FEASIBILITY AND DOSAGE|Completed||N/A|11|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium||1|||f||||t||||||||||2018-05-31 22:14:25.651944|2018-05-31 22:14:25.651944
NCT01318577|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-08-10|2011-03-17|2011-03-18|Estimate|||||||2012-08-10|2012-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:46:35.275275|2018-05-31 22:46:35.275275
NCT01418963|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-11-01|2011-08-16|2011-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of RO5285119 in Healthy Volunteers|A Single- and Multiple Ascending-Dose, Randomized, Double-Blind, Placebo-Controlled Study in Two Single-Center Study Parts to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5285119 Following Oral Administration in Healthy Subjects|Completed||Phase 1|77|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:14:25.722006|2018-05-31 22:14:25.722006
NCT01418950|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-12-16|2011-08-16|2011-08-17|Estimate|||||||2013-12-16|2013-12-18|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Improving Parental Knowledge: Supplementation of Prematurity Counseling With Written Information|Improving Parental Knowledge: Randomized Trial of Supplementation of Prematurity Counseling With Written Information|Completed||N/A|60|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 22:14:25.781017|2018-05-31 22:14:25.781017
NCT01418937|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|2015-07-27||2015-11-19|2011-08-16|2011-08-17|Estimate|2015-07-27|2015-08-21|Estimate||||2015-11-19|2015-12-23|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study|Completed||Phase 3|164|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 22:14:25.843021|2018-05-31 22:14:25.843021
NCT01418924|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-10-19|2011-08-16|2011-08-17|Estimate|||||||2011-10-19|2011-10-20|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|SHSCL||Sex Hormones & Serum Sclerostin Level|Effects Of Sex Hormones On Serum Sclerostin Level During Menstrual Cycle|Completed|||45|Actual|Bagcilar Training and Research Hospital|||||f||||f||||||||||2018-05-31 22:14:25.992094|2018-05-31 22:14:25.992094
NCT01418911|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-04-30|2011-08-16|2011-08-17|Estimate|||||||2012-04-30|2012-05-01|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|||Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control|Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control|Unknown status|Not yet recruiting||300|Anticipated|Assuta Hospital Systems|||1||f||||t||||||||||2018-05-31 22:14:26.047581|2018-05-31 22:14:26.047581
NCT01418898|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|April 2012|Anticipated|2012-04-30|December 2011|Anticipated|2011-12-31||Interventional|||Nutrient Fortified Oat Drink|The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children|Unknown status|Recruiting|Phase 4|80|Anticipated|PepsiCo Global R&D||2|||f||||f||||||||||2018-05-31 22:14:26.107708|2018-05-31 22:14:26.107708
NCT01418885|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Observational|||Cognitive Impairment , Neuroimaging and Inflammatory Markers in Patients With Subcortical Ischemic Vascular Disease|Correlation Exploration Between Cognitive Impairment and Neuroimaging and Inflammatory Markers in Patients With Subcortical Ischemic Vascular Disease|Unknown status|Active, not recruiting||100|Anticipated|Hebei General Hospital|||3||f||||t||||||None Retained|"~     serum~   "|||2018-05-31 22:14:26.186857|2018-05-31 22:14:26.186857
NCT01418872|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2015-01-13|2011-08-16|2011-08-17|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SAVINHEARTS||A Clinical Trial Of Two Educational Strategies In Cardiovascular Health In Child Population|A Cluster-Randomized Clinical Trial Of Two Educational Strategies In Cardiovascular Health (CVH) In Child Population. The Savinghearts Project|Completed||Phase 4|1730|Actual|Agencia Lain Entralgo||2|||f||||f||||||||||2018-05-31 22:14:26.250106|2018-05-31 22:14:26.250106
NCT01418859|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-03-19|2011-08-16|2011-08-17|Estimate|||||||2012-03-19|2012-03-21|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|December 2015|Anticipated|2015-12-31|December 2012|Anticipated|2012-12-31||Observational|||Clinical Study in Post-operation Treatment of Cervical Cancer|Status and the Application of Topotecan at Post-operation Treatment of Cervical Cancer|Unknown status|Recruiting||183|Anticipated|Health Science Center of Xi’an Jiaotong University|||3||f||||t||||||||||2018-05-31 22:14:26.33016|2018-05-31 22:14:26.33016
NCT01418846|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-01-12|2011-08-16|2011-08-17|Estimate|||||||2015-01-12|2015-01-13|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Observational|||Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients|Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients.|Completed|||11|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 22:14:26.403309|2018-05-31 22:14:26.403309
NCT01418833|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2015-02-06|2011-08-16|2011-08-17|Estimate|||||||2015-02-06|2015-02-09|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Preliminary Experience of Routine Voriconazole Therapeutic Drug Monitoring (TDM) in a Tertiary Care Centre|Preliminary Experience of Routine Voriconazole Therapeutic Drug Monitoring (TDM) in a Tertiary Care Centre.|Completed|||160|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 22:14:26.465542|2018-05-31 22:14:26.465542
NCT01418820|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-11-29|2011-08-16|2011-08-17|Estimate|||||||2013-11-29|2013-12-02|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions|Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions|Unknown status|Active, not recruiting|Phase 2/Phase 3|32|Actual|University of Magdeburg||2|||f||||f||||||||||2018-05-31 22:14:26.52601|2018-05-31 22:14:26.52601
NCT01418807|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-02-23|2011-08-16|2011-08-17|Estimate|||||||2012-02-23|2012-02-24|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Transumbilical Versus Transvaginal Specimen Retrieval at Minilaparoscopy||Completed||Phase 2/Phase 3|56|Actual|Università degli Studi dell'Insubria||2|||f||||||||||||||2018-05-31 22:14:26.60186|2018-05-31 22:14:26.60186
NCT01418794|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||November 2011|Anticipated|2011-11-30||Interventional|||Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease||Unknown status|Recruiting|Phase 4|606|Anticipated|Shenyang Northern Hospital||2|||f||||t||||||||||2018-05-31 22:14:26.678551|2018-05-31 22:14:26.678551
NCT01269359|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-03-21|2011-01-03|2011-01-04|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31||||||||Observational|||Robotic Assisted Vertebral Body Augmentation - a Radiation Reduction Tool||Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 23:00:39.113883|2018-05-31 23:00:39.113883
NCT01418781|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-03-14|2011-08-16|2011-08-17|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|March 2010||2010-03-31|March 2010|Actual|2010-03-31||Observational|||CLinical Prediction Rule Score in Veterans|Development of CLinical Prediction Rule Score in Veterans: A Study of Impact of Gout on Health Care Utilization and Costs|Withdrawn|||0|Actual|Minneapolis Veterans Affairs Medical Center|||4|Funding withdrawn by the funding agency; study could not be performed.|f||||f||||||||||2018-05-31 22:14:26.768367|2018-05-31 22:14:26.768367
NCT01418768|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-02-01|2011-08-16|2011-08-17|Estimate|||||||2013-02-01|2013-02-04|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Effects of an Inpatient Rehabilitation for Patients With Chronic Obstructive Pulmonary Disease (COPD) III/IV||Completed||N/A|50|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||1|||f||||f||||||||||2018-05-31 22:14:26.82941|2018-05-31 22:14:26.82941
NCT01418755|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-09-14|2011-08-16|2011-08-17|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|November 2009|Actual|2009-11-30||Interventional|||Study of Platelet-rich Plasma in Treating Patients With Tibiofemoral Cartilage Degeneration|Platelet-rich Plasma in Patients With Tibiofemoral Cartilage Degeneration|Completed||N/A|50|Actual|Hospital Znojmo||1|||f||||t||||||||||2018-05-31 22:14:26.886261|2018-05-31 22:14:26.886261
NCT01418742|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-07-11|2011-08-16|2011-08-17|Estimate|||||||2014-07-11|2014-07-14|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment|SKIP - A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects With Advanced or Metastatic Colorectal Carcinoma Receiving Panitumumab|Terminated||Phase 2|11|Actual|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||2||"Recruitement did not meet expectations. Prev. differentiation of RAS-wild-type and mutated RAS~   are not in accordance with the scientific rank anymore."|f||||f||||||||||2018-05-31 22:14:26.94984|2018-05-31 22:14:26.94984
NCT01418729|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-09-19|2011-08-16|2011-08-17|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2011||2011-09-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|December 2015|Actual|2015-12-31||Interventional|ESTAHEP-2010||Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma|Phase-II, Multicenter, Randomized, Double-Blind, Parallel-Group Trial to Compare the Efficacy and Safety of Sorafenib Plus Pravastatin Against Sorafenib Plus Placebo in Patients With Advanced Hepatocarcinoma|Completed||Phase 2|216|Actual|Hospital Donostia||2|||f||||t||||||||||2018-05-31 22:14:27.044479|2018-05-31 22:14:27.044479
NCT01418716|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-02-15|2011-08-16|2011-08-17|Estimate|||||||2017-02-15|2017-02-17|Actual|April 2011||2011-04-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2013|Actual|2013-10-31||Interventional|TRANSIT||TRANSforming InTerprofessional Cardiovascular Prevention in Primary Care|A Program to TRANSform InTerprofessional Clinical Practices to Improve Cardiovascular Prevention in Primary Care|Completed||N/A|759|Actual|Fonds de la Recherche en Santé du Québec||2|||f||||f||||||||No||2018-05-31 22:14:27.114325|2018-05-31 22:14:27.114325
NCT01418703|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2014-06-24||2014-11-09|2011-08-15|2011-08-17|Estimate|2014-11-09|2014-11-13|Estimate||||2014-11-09|2014-11-13|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MDB003||Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus|Feasibility Study of a Modular Control to Range System in T1DM|Completed||N/A|38|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 22:14:27.250962|2018-05-31 22:14:27.250962
NCT01418690|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2016-11-28|2011-08-16|2011-08-17|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|||Changes in Tissue Oxygenation Following Regional Anesthesia|Changes in Tissue Oxygenation Following Regional Anesthesia|Completed|||29|Actual|Nationwide Children's Hospital|||1||f||||||||||||||2018-05-31 22:14:27.542591|2018-05-31 22:14:27.542591
NCT01418677|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-05-13|2011-08-16|2011-08-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|||An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function|An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function|Completed||Phase 1|19|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 22:14:27.602034|2018-05-31 22:14:27.602034
NCT01418664|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-04-21|2011-08-16|2011-08-17|Estimate|||||||2016-04-21|2016-04-25|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Prevention of Adverse Pregnancy Outcome With Vitamin D Supplementation During Pregnancy|Prevention of Adverse Pregnancy Outcome With Vitamin D Supplementation During Pregnancy|Completed||N/A|172|Actual|Dow University of Health Sciences||2|||f||||t||||||||Yes|Data has been published|2018-05-31 22:14:27.678339|2018-05-31 22:14:27.678339
NCT01418651|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population|Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population: an Open-label Study|Terminated||Phase 3|20|Anticipated|Banner Health||1||Lack of subjects|f||||f||||||||||2018-05-31 22:14:27.743702|2018-05-31 22:14:27.743702
NCT01418638|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-02-19|2011-08-16|2011-08-17|Estimate|||||||2013-02-19|2013-02-20|Estimate|May 2012||2012-05-31|February 2013|2013-02-28||||October 2013|Anticipated|2013-10-31||Observational|||The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder|The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder|Unknown status|Recruiting||30|Anticipated|Ziv Hospital|||1||f||||f||||||||||2018-05-31 22:14:27.803269|2018-05-31 22:14:27.803269
NCT01418625|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test Formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150mg Capsule (Reference Formulation, Wyeth Pharmaceuticals Inc., USA) Administered as the Contents of Capsule Sprinkled Over Apple Sauce in Healthy Volunteers Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:27.863308|2018-05-31 22:14:27.863308
NCT01418287|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-09-10|2011-08-16|2011-08-17|Estimate|||||||2014-09-10|2014-09-11|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Characterization of Influenza-like Illness in Mexico|An Observational Study to Characterize Children and Adults With Influenza Like Illness (ILI) in Mexico|Completed|||5819|Actual|Mexican Emerging Infectious Diseases Clinical Research Network|||2||f||||f||||||Samples With DNA|"~     Plasma, PBMC and Nasopharingeal aspirates~   "|||2018-05-31 22:14:30.093028|2018-05-31 22:14:30.093028
NCT01418612|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's Venlafaxine Hydrochloride ER Capsules Under Fed Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test Formulation, Torrent Pharmaceutical Limited., India) Versus Effexor XR® 150mg Capsule (Reference Formulation, Wyeth Pharmaceuticals Inc., USA) in Healthy Volunteers Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:27.903739|2018-05-31 22:14:27.903739
NCT01418599|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-26|2011-08-16|2011-08-17|Estimate|||||||2011-08-26|2011-08-29|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets vs. Sanofi's Uroxatral ER Tablets in Healthy Human Subjects Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:27.948831|2018-05-31 22:14:27.948831
NCT01418586|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions|An Open Label, Randomised, Two Period, Two Treatment, Two Sequence, Crossover, Single-Dose Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets vs. Sanofi's Uroxatral ER Tablets in Healthy Human Subjects Under Fasted Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:27.994554|2018-05-31 22:14:27.994554
NCT01418573|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-08-12|2011-08-16|2011-08-17|Estimate|||||||2013-08-12|2013-08-13|Estimate|August 2011||2011-08-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Glycemic Response After Palaeolithic-type Meals|Glycemic Response After Two Palaeolithic-type Meals Compared to a Modern-type Meal Composed According to WHO Guidelines|Completed||N/A|24|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 22:14:28.063238|2018-05-31 22:14:28.063238
NCT01418560|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-07-14|2011-08-16|2011-08-17|Estimate|||||||2017-07-14|2017-07-17|Actual|August 2011|Actual|2011-08-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Renal Sympathetic Modification in Patients With Chronic Renal Failure|Renal Sympathetic Modification in Patients With Chronic Renal Failure|Recruiting||N/A|200|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 22:14:28.141308|2018-05-31 22:14:28.141308
NCT01418547|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's Isosorbide Mononitrate 120 mg ER Tablets Under Fed Conditions|An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA in Healthy, Adult, Male, Human Subjects Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:28.223073|2018-05-31 22:14:28.223073
NCT01418534|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's ISMN 120 mg ER Tablets Under Fasting Condition|An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg ER Tablets (Reference) of Kremers Urban, USA in Healthy, Adult, Male, Human Subjects Under Fasting Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:28.276078|2018-05-31 22:14:28.276078
NCT01418521|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|||Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery|Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) Versus Albumin Solution for Volume Replacement in Patients After Cardiac Surgery|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:14:28.332967|2018-05-31 22:14:28.332967
NCT01418508|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|ELPD-CKD||Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease (CKD)- ELPD Study|Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease(CKD)- ELPD Study|Unknown status|Recruiting|N/A|120|Anticipated|Peking Union Medical College Hospital||3|||f||||t||||||||||2018-05-31 22:14:28.411457|2018-05-31 22:14:28.411457
NCT01418495|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2017-08-03|2011-08-16|2011-08-17|Estimate|||||||2017-08-03|2017-08-04|Actual|May 26, 2011|Actual|2011-05-26|August 2017|2017-08-31|November 2, 2012|Actual|2012-11-02|November 2, 2012|Actual|2012-11-02||Observational|||Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma|Pharmacokinetics of the Chimeric Anti-GD2 Antibody, ch14.18, in Children With High-Risk Neuroblastoma|Completed|||12|Actual|National Cancer Institute (NCI)|||1||f||||||||||||||2018-05-31 22:14:28.488434|2018-05-31 22:14:28.488434
NCT01418482|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2016-04-07||2017-05-03|2011-08-16|2011-08-17|Estimate|2017-03-22|2017-05-03|Actual||||2017-05-03|2017-06-05|Actual|January 2011||2011-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||small partial thickness burns|Evaluation of Antimicrobial Soft Silicone, Silver Containing, Foam Dressing, Mepilex Border Ag, in Second Degree Burns|An Open Non-controlled Post-marketing Investigation Evaluating the Experience of Using a Self- Adherent Antimicrobial Soft Silicone, Silver Containing, Foam Dressing, Mepilex Border Ag, in Second Degree Burns|Completed||N/A|15|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 22:14:28.567616|2018-05-31 22:14:28.567616
NCT01418469|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|December 2002||2002-12-31|August 2011|2011-08-31|December 2004|Actual|2004-12-31|December 2003|Actual|2003-12-31||Interventional|||Disturbances in BCAA Metabolism and the Effects of Feeding and Exercise in COPD|The Effects of Exercise on the Metabolic Fate of Branched Chain Amino Acids in Relation to Aging and Chronic Disease.|Completed||N/A|24|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 22:14:28.714247|2018-05-31 22:14:28.714247
NCT01418105|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2016-10-24|2011-08-15|2011-08-16|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|DysphagCerv||Dysphagia and Cervical Spine Disorders in Patients With Brain Lesions|Dysphagia and Cervical Spine Disorders in Patients With Neurologic Deficits Due to Brain Lesions|Completed||Phase 1|70|Actual|University of Ioannina||3|||f||||t||||||||||2018-05-31 22:14:33.418475|2018-05-31 22:14:33.418475
NCT01418456|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|August 2011||2011-08-31|January 2011|2011-01-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|KADFUT||Outcomes of Non-infected Diabetic Foot Ulcers With/Without Antibiotics|A Prospective Single Blind Randomised Controlled Study to Compare the Outcomes of Patients With Diabetes and Clinically Non-infected Neuro-ischaemic and Neuropathic Foot Ulcers Treated With and Without Oral Antibiotics.|Unknown status|Not yet recruiting|Phase 4|166|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 22:14:28.802794|2018-05-31 22:14:28.802794
NCT01418443|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fed Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delayed Release Tablets of Wyeth Pharmaceuticals Inc, in Healthy Human Adult Subjects, Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:28.863807|2018-05-31 22:14:28.863807
NCT01418430|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-08-19|2011-08-16|2011-08-17|Estimate|||||||2011-08-19|2011-08-22|Estimate||||July 2011|2011-07-31||||||||Interventional|||Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)|HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)|Completed||Phase 4|||King's College Hospital NHS Trust||1|||f||||t||||||||||2018-05-31 22:14:28.907154|2018-05-31 22:14:28.907154
NCT01418417|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-15|2011-08-15|2011-08-17|Estimate|||||||2011-08-15|2011-08-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fasting Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delayed Release Tablets of Wyeth Pharmaceuticals Inc, in Healthy Human Adult Subjects, Under Fasting Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 22:14:28.958304|2018-05-31 22:14:28.958304
NCT01418404|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-26|||2015-04-06|2011-08-16|2011-08-17|Estimate|||||||2015-04-06|2015-04-08|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||The Application of Thermal Stimulation on Functional Recovery of Stroke Patients|The Application of Thermal Stimulation on Functional Recovery of Stroke Patients|Completed||N/A|220|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||6|||f||||f||||||||||2018-05-31 22:14:29.004643|2018-05-31 22:14:29.004643
NCT01418391|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2011-08-16|2011-08-16|2011-08-17|Estimate|||||||2011-08-16|2011-08-17|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||the Effect of the Transversus Abdominis Plane (TAP) Block on the Minimal Laparotomy : a Randomized Controlled Trial|the Effect of the Transversus Abdominis Plane (TAP) Block on the Minimal Laparotomy : a Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||t||||||||||2018-05-31 22:14:29.075169|2018-05-31 22:14:29.075169
NCT01418378|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-07-24|2011-08-16|2011-08-17|Estimate|||||||2017-07-24|2017-07-26|Actual|July 1, 2011|Actual|2011-07-01|July 2017|2017-07-31|February 17, 2016|Actual|2016-02-17|February 17, 2016|Actual|2016-02-17||Interventional|||Sigma CR150 Versus Sigma CR Knee RCT|A Double-blinded Randomised Controlled Trial Comparing the Performance of the Sigma® CR150 and Sigma® CR Knee Systems, When Used in Fixed Bearing Primary Cruciate Retaining Total Knee Arthroplasty for the Treatment of Osteoarthritis|Completed||Phase 4|200|Actual|DePuy International||2|||f||||f||||||||||2018-05-31 22:14:29.143274|2018-05-31 22:14:29.143274
NCT01418365|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2012-07-16||2013-08-21|2011-08-16|2011-08-17|Estimate|2012-07-16|2012-08-17|Estimate||||2013-08-21|2013-09-06|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Metronidazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Shire||2|||f||||||||||||||2018-05-31 22:14:29.227726|2018-05-31 22:14:29.227726
NCT01418352|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01||2015-03-25|2015-05-06|2011-08-15|2011-08-17|Estimate||||2015-03-25|2015-04-15|Estimate|2015-05-06|2015-05-25|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|Completed||Phase 3|83|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||t||||||||||2018-05-31 22:14:29.439529|2018-05-31 22:14:29.439529
NCT01418339|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01||2014-10-29|2014-11-04|2011-08-15|2011-08-17|Estimate||||2014-10-29|2014-11-04|Estimate|2014-11-04|2014-11-18|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|Completed||Phase 3|135|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 22:14:29.597601|2018-05-31 22:14:29.597601
NCT01418326|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-05-28|2011-08-16|2011-08-17|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||Cancer Mortality Affected by the Choice of Anesthetic Drugs?|Cancer Mortality Affected by the Choice of Anesthetic Drugs?|Completed|||3284|Actual|Uppsala University|||2||f||||f||||||||||2018-05-31 22:14:29.785044|2018-05-31 22:14:29.785044
NCT01418313|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2018-01-18|2011-08-15|2011-08-17|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2011||2011-09-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Non-Invasive Imaging of Atherosclerosis|In Vivo Molecular Imaging (MRI) of Atherothrombotic Lesions|Recruiting|||159|Anticipated|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||Samples With DNA|"~     Whole Blood, Endarterectomy Specimens~   "|||2018-05-31 22:14:29.877805|2018-05-31 22:14:29.877805
NCT01418300|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2015-04-26|2011-08-16|2011-08-17|Estimate|||||||2015-04-26|2015-04-28|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial||Completed||Phase 4|159|Actual|Jeil Pharmacy Co.||2|||f||||||||||||||2018-05-31 22:14:30.016433|2018-05-31 22:14:30.016433
NCT01418274|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2016-11-01|2011-08-16|2011-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers|A Study to Investigate the Effect of Multiple Doses of Danoprevir/Ritonavir (DNV/RTV) on the Pharmacokinetics (PK) of Escitalopram (ESC) and S-Demethylcitalopram (S-DCT) in Healthy Subjects|Completed||Phase 1|20|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:14:30.177289|2018-05-31 22:14:30.177289
NCT01418261|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15||2014-10-03|2017-04-24|2011-08-16|2011-08-17|Estimate||||2014-10-03|2014-10-13|Estimate|2017-04-24|2017-04-26|Actual|September 2011||2011-09-30|April 2017|2017-04-30|February 17, 2017|Actual|2017-02-17|December 2013|Actual|2013-12-31||Interventional|||SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension|Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)|Completed||N/A|535|Actual|Medtronic Vascular||2|||f||||t||||||||No||2018-05-31 22:14:30.278516|2018-05-31 22:14:30.278516
NCT01418248|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-01-08|2011-08-15|2011-08-17|Estimate|||||||2014-01-08|2014-01-09|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|EXEC||Study of Exercise and Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease|Evaluation of Exercise Intolerance and Right Heart Function in Patients With Heart Failure and Pulmonary Vascular Disease|Completed|||108|Actual|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Serum, plasma~   "|||2018-05-31 22:14:30.48737|2018-05-31 22:14:30.48737
NCT01418235|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2014-10-14|2011-08-15|2011-08-17|Estimate|||||||2014-10-14|2014-10-16|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|October 2013|Actual|2013-10-31||Interventional|||Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults|A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Subtype C gp140 With MF59 Adjuvant in Various Vaccination Schedules in HIV-uninfected Healthy Vaccinia-naïve Adult Participants in South Africa|Unknown status|Active, not recruiting|Phase 1|184|Anticipated|HIV Vaccine Trials Network||4|||f||||t||||||||||2018-05-31 22:14:30.559787|2018-05-31 22:14:30.559787
NCT01418222|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15||2016-08-09|2017-05-25|2011-08-16|2011-08-17|Estimate||||2016-08-09|2016-08-11|Estimate|2017-05-25|2017-05-30|Actual|September 14, 2011|Actual|2011-09-14|May 2017|2017-05-31|March 18, 2013|Actual|2013-03-18|March 18, 2013|Actual|2013-03-18||Interventional|||FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer|Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer|Completed||Phase 2|194|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:14:30.660845|2018-05-31 22:14:30.660845
NCT01418209|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2014-06-18||2014-08-20|2011-08-16|2011-08-17|Estimate|2014-08-01|2014-08-20|Estimate||||2014-08-20|2014-08-27|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Randomized participants per trial arm|MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms|MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and the SNRI Venlafaxine XR for Treatment of Menopausal Symptoms|Completed||N/A|339|Actual|Fred Hutchinson Cancer Research Center|Findings may be specific to the particular dose of each agent used, treatment period, as well as the preparation and oral administration of estrogen therapy.|3|||f||||t||||||||||2018-05-31 22:14:30.803414|2018-05-31 22:14:30.803414
NCT01418196|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2015-03-25|2011-08-15|2011-08-17|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|April 2012|Actual|2012-04-30||Observational|||Relation of Diet to Heart Disease Risk Factors in Children|Relation of Diet to Heart Disease Risk Factors in Children|Completed|||92|Actual|Children's Hospital & Research Center Oakland|||||f||||t||||||||||2018-05-31 22:14:32.466496|2018-05-31 22:14:32.466496
NCT01418183|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-09-04|2011-08-15|2011-08-17|Estimate|||||||2011-09-04|2011-09-07|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|PCOGS||Pain Control After Orthognathic Surgery|Intra-operative Trigeminal Nerve Block For Post-operative Pain Control After Orthognathic Surgery|Unknown status|Recruiting|N/A|40|Anticipated|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 22:14:32.553354|2018-05-31 22:14:32.553354
NCT01418170|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2018-01-23|2011-08-16|2011-08-17|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2011||2011-09-30|August 2011|2011-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Dose Response Effects of Cervical Spinal Manipulative Therapy (SMT) on Pressure Sensitivity of Myofascial Trigger Points|Dose Response Effects of Cervical SMT on Pressure Sensitivity of Myofascial Trigger Points|Completed||Phase 2|26|Actual|Canadian Memorial Chiropractic College||2|||f||||f||||||||||2018-05-31 22:14:32.737348|2018-05-31 22:14:32.737348
NCT01418157|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-06-21|2011-08-15|2011-08-16|Estimate|||||||2013-06-21|2013-06-24|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent|Double Blind, Placebo Controlled Randomised Trial of Acetazolamide Versus Placebo in the Prevention of Acute Mountain Sickness During Rapid Ascent|Completed||Phase 4|380|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||t||||||||||2018-05-31 22:14:32.87318|2018-05-31 22:14:32.87318
NCT01418144|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-08-21|2011-08-15|2011-08-16|Estimate|||||||2013-08-21|2013-08-22|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||Effect of Transversus Abdominis Plane (TAP) Block After Laparoscopic Colon Surgery|Effect of Transversus Abdominis Plane (TAP) Block as Postoperative Pain Management After Laparoscopic Colon Surgery|Completed||Phase 4|80|Actual|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 22:14:32.988213|2018-05-31 22:14:32.988213
NCT01418131|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-12-14|2011-08-15|2011-08-16|Estimate|||||||2016-12-14|2016-12-15|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis|A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis|Completed||Phase 4|21|Actual|The University of Western Australia||2|||f||||t||||||||||2018-05-31 22:14:33.189176|2018-05-31 22:14:33.189176
NCT01418118|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|October 2008||2008-10-31|August 2011|2011-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|Free4Flow||Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery|An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study|Completed||Phase 4|25|Actual|Oxford University Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 22:14:33.3246|2018-05-31 22:14:33.3246
NCT01418092|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15||2012-07-31|2012-07-31|2011-08-15|2011-08-16|Estimate||||2012-07-31|2012-08-07|Estimate|2012-07-31|2012-08-07|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)|A Phase 2b Randomized, Double-blind, Placebo-controlled, 12-week Study to Evaluate the Safety and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation|Completed||Phase 2|91|Actual|Alkermes, Inc.||2|||f||||t||||||||||2018-05-31 22:14:33.50817|2018-05-31 22:14:33.50817
NCT01418079|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-05-21|2011-08-15|2011-08-16|Estimate|||||||2012-05-21|2012-05-23|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Accuracy of the O2 MedTech PMS-3000 Monitor|Accuracy of the O2 MedTech PMS-3000 Monitor for the Non-invasive Measurement of Cerebral and Tissue Oxygenation Using Phase-modulated Infrared Spectroscopy|Completed||Phase 2|42|Actual|O2 MedTech, Inc.||1|||f||||f||||||||||2018-05-31 22:14:33.573349|2018-05-31 22:14:33.573349
NCT01418066|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2012-12-05|2011-08-15|2011-08-16|Estimate|||||||2012-12-05|2012-12-06|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AHIB||Ayurvedic Herbs in Diarrhea Predominant Irritable Bowel Syndrome|Feasibility and Safety of Ayurvedic Herbs in Diarrhoea-predominant Irritable Bowel Syndrome|Completed||N/A|32|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 22:14:33.722465|2018-05-31 22:14:33.722465
NCT01418053|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2018-05-04|2011-08-15|2011-08-16|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 2011||2011-08-31|May 2018|2018-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CarO||The Effect of Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome|Randomised Controlled Study on the Effect of a Kneipp Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome|Completed||N/A|48|Actual|Universität Duisburg-Essen||3|||f||||f||||||||||2018-05-31 22:14:34.913975|2018-05-31 22:14:34.913975
NCT01418040|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2018-01-31|2011-08-15|2011-08-16|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 28, 2012|Actual|2012-11-28|January 2018|2018-01-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Observational|PROCITT||PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)|A Phase 2 Clinical Trial Exploring 3-Dimensional Imaging of Androgen Deprivation Induced Osteoporosis, Radiotherapy Hypofractionation and the Prognostic Significance of Micrometastatic Disease in Men With Prostate Cancer|Completed|||28|Actual|Calvary Mater Newcastle, Australia|||1||f||||t||||||||No|It is not intended that results relating to a specific participant be reported to anyone other than the participant.|2018-05-31 22:14:34.99076|2018-05-31 22:14:34.99076
NCT01418027|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-08-28|2011-08-15|2011-08-16|Estimate|||||||2014-08-28|2014-09-01|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD)|Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease|Completed||Phase 3|220|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||||2018-05-31 22:14:35.05738|2018-05-31 22:14:35.05738
NCT01418014|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2018-01-29|2011-08-15|2011-08-16|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2007||2007-03-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|AMP||Adolescent Master Protocol|Adolescent Master Protocol|Active, not recruiting|||678|Actual|Harvard School of Public Health|||2||f||||f||||||Samples With DNA|"~     Serum, cell pellets, plasma, saliva, and urine~   "|||2018-05-31 22:14:35.145252|2018-05-31 22:14:35.145252
NCT01418001|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2016-01-19||2017-12-11|2011-08-15|2011-08-16|Estimate|2016-01-19|2016-02-17|Estimate||||2017-12-11|2018-01-11|Actual|August 2011||2011-08-31|December 2017|2017-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)|A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)|Terminated||Phase 1/Phase 2|5|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 22:14:35.278407|2018-05-31 22:14:35.278407
NCT01417988|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-02-14|2011-08-15|2011-08-16|Estimate|||||||2014-02-14|2014-02-17|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PrOMPT||Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment|Prevention of Early Mortality by Presumptive TB Treatment in HIV-infected Patients Initiating Antiretroviral Therapy|Terminated||Phase 4|44|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||Study was terminated prematurely due to insufficient enrolment.|f||||t||||||||||2018-05-31 22:14:35.604178|2018-05-31 22:14:35.604178
NCT01417975|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-12-15|2011-08-15|2011-08-16|Estimate|||||||2014-12-15|2014-12-16|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of an Acute Bout of Exercise on Smoking Satisfaction|Does an Acute Bout of Exercise Affect Smoking Satisfaction?|Completed||N/A|43|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 22:14:35.709995|2018-05-31 22:14:35.709995
NCT01417962|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2013-04-19|2011-08-15|2011-08-16|Estimate|||||||2013-04-19|2013-04-22|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|MARIAS||Magnetic Resonance Imaging Autopsy Study|Post Mortem Magnetic Resonance Imaging in the Fetus, Infant and Child: A Comparative Study With Conventional Autopsy|Completed|||400|Anticipated|Thayyil, Sudhin|||2||f||||f||||||||||2018-05-31 22:14:35.863466|2018-05-31 22:14:35.863466
NCT01417949|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2016-11-25|2011-08-15|2011-08-16|Estimate|||||||2016-11-25|2016-11-28|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|IDEAL||Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events|Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study)|Completed||Phase 4|61|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||No||2018-05-31 22:14:35.948073|2018-05-31 22:14:35.948073
NCT01417936|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|2015-12-29||2018-04-06|2011-08-15|2011-08-16|Estimate|2015-12-29|2016-02-02|Estimate||||2018-04-06|2018-04-09|Actual|July 2011||2011-07-31|April 2018|2018-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Full analysis set (FAS) comprised all subjects who had been exposed to trial drug irrespective of their compliance to the planned course of treatment.|Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy|An Open-label, Single Arm, Phase II Trial to Investigate the Safety and Efficacy of Sym004 in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Anti-EGFR Monoclonal Antibody-based Therapy|Completed||Phase 2|26|Actual|Symphogen A/S||1|||f||||t||||||||Undecided||2018-05-31 22:14:36.119558|2018-05-31 22:14:36.119558
NCT01302327|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|March 2011||2011-03-31|February 2011|2011-02-28||||March 2013|Anticipated|2013-03-31||Interventional|||GLP Analogs for Diabetes in Wolfram Syndrome Patients||Unknown status|Not yet recruiting|N/A|10|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:50:52.002582|2018-05-31 22:50:52.002582
NCT01417923|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-11-04|2011-08-14|2011-08-16|Estimate|||||||2012-11-04|2012-11-06|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain|The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain|Unknown status|Recruiting|Phase 4|80|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:14:36.577067|2018-05-31 22:14:36.577067
NCT01417910|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-01-26|2011-08-15|2011-08-16|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Predictors of Post Operative Outcome in Peripheral Vascular Surgical Patients|Prognostic Markers of Outcome in Patients Undergoing Infra-inguinal Revascularisation. A Prospective Observational Study.|Completed|||100|Actual|York Teaching Hospitals NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 22:14:36.823288|2018-05-31 22:14:36.823288
NCT01417897|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2012-03-02|2011-08-15|2011-08-16|Estimate|||||||2012-03-02|2012-03-05|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|HERMES||Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study|Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study|Unknown status|Active, not recruiting|Phase 4|12|Anticipated|ikfe-CRO GmbH||3|||f||||f||||||||||2018-05-31 22:14:36.884525|2018-05-31 22:14:36.884525
NCT01417884|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2018-05-03|2011-08-15|2011-08-16|Estimate|||||||2018-05-03|2018-05-10|Estimate|January 2012||2012-01-31|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|TuePIC||Monocentric Registry to Investigate the Role of Platelet Function, Platelet Genetics, Proteomics and Metabonomics in Heart Disease|Development of a Prospective Cardiovascular Patient Cohort and Biobank and Provision of Genomic Analyses With Focus on Platelet Function and Platelet Mediated Inflammatory Processes|Recruiting|||3000|Anticipated|University Hospital Tuebingen|||2||f||||t||||||Samples With DNA|"~     Blood, salivatory~   "|||2018-05-31 22:14:36.999315|2018-05-31 22:14:36.999315
NCT01417871|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||ABC Program in Patients With Metabolic Syndrome||Completed|||140|Actual|University of Magdeburg|||2||f||||f||||||Samples Without DNA|"~     blood samples for parameter of lipid metabolism~   "|||2018-05-31 22:14:37.145695|2018-05-31 22:14:37.145695
NCT01417858|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Intraocular Pressure Control After Anterior Segment Laser - Comparison Between 2 Drugs|Short-term Intraocular Pressure Control After YAG Iridotomy - Comparison Between Brimonidine 0.1% vs. 0.2%|Unknown status|Recruiting|N/A|50|Anticipated|Universidade Federal do Paraná||2|||f||||t||||||||||2018-05-31 22:14:37.222352|2018-05-31 22:14:37.222352
NCT01417845|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2014-01-31|2011-08-15|2011-08-16|Estimate|||||||2014-01-31|2014-02-03|Estimate|September 2011||2011-09-30|January 2014|2014-01-31||||August 2012|Actual|2012-08-31||Interventional|||The Effect of Exercise Training Intensity in Patients With Type 2 Diabetes|The Effect of Moderate Versus High Intensity Exercise Training on Physical Fitness and Physical Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial|Completed||N/A|21|Actual|University of Central Arkansas||2|||f||||f||||||||||2018-05-31 22:14:37.328243|2018-05-31 22:14:37.328243
NCT01417832|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Radiographic Progression of Sealed and Infiltrated Caries Lesions in Vivo|Radiographic Progression of Sealed and Infiltrated Caries Lesions in Vivo|Completed||Phase 2/Phase 3|37|Actual|Universidad El Bosque, Bogotá||2|||f||||t||||||||||2018-05-31 22:14:37.483177|2018-05-31 22:14:37.483177
NCT01417819|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-08-27|2011-08-15|2011-08-16|Estimate|||||||2011-08-27|2011-08-30|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Mobile Communication on Childhood Cataract Follow-up Adherence|Effect of a Mobile Phone Short Message Service (SMS) on Childhood Cataract Follow-up Adherence in China|Completed||N/A|258|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 22:14:37.696842|2018-05-31 22:14:37.696842
NCT01417806|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer|A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|28|Anticipated|South Florida Veterans Affairs Foundation for Research and Education|||||f||||t||||||||||2018-05-31 22:14:37.781982|2018-05-31 22:14:37.781982
NCT01417793|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-14|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Effects of a Smoking Cessation Program for Prison Inmates|Effects of a Smoking Cessation Program for Prison Inmates-A Case Study of a Prison in Central Taiwan|Unknown status|Recruiting|N/A|500|Anticipated|China Medical University Hospital||1|||f||||f||||||||||2018-05-31 22:14:37.926623|2018-05-31 22:14:37.926623
NCT01417780|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2014-08-14|2011-08-15|2011-08-16|Estimate|||||||2014-08-14|2014-08-15|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients|Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections|Completed||Phase 2|43|Actual|Atox Bio Ltd||3|||f||||t||||||||||2018-05-31 22:14:37.99232|2018-05-31 22:14:37.99232
NCT01417767|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2016-09-08|2011-08-15|2011-08-16|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS|Phase 2/3 Study of Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|Shanghai 6th People's Hospital||2|||f||||f||||||||||2018-05-31 22:14:38.093549|2018-05-31 22:14:38.093549
NCT01417754|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2011-08-22|2011-08-15|2011-08-16|Estimate|||||||2011-08-22|2011-08-23|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||Changes in Breast 3D Ultrasound Measurements Using Toremifene|Volume and Circulation Changes of The Breast in 3D Ultrasound During Toremifene Versus Nonmedicated Menstrual Cycle|Completed||Phase 3|20|Actual|Satakunta Central Hospital||1|||f||||f||||||||||2018-05-31 22:14:38.204714|2018-05-31 22:14:38.204714
NCT01417741|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-04-09|2011-08-15|2011-08-16|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Acupuncture and Nausea/Vomiting in Pediatric Patients|Is Intra-operative Acupuncture at P6 Plus IV Antiemetics More Effective Than IV Antiemetic Therapy Alone in Preventing Postoperative Vomiting in Pediatric Patients Following Tonsillectomy With or Without Adenoidectomy?|Unknown status|Recruiting|N/A|200|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:14:38.265694|2018-05-31 22:14:38.265694
NCT01417728|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2012-11-29|2011-08-15|2011-08-16|Estimate|||||||2012-11-29|2012-11-30|Estimate|May 2011||2011-05-31|November 2012|2012-11-30|August 2013|Anticipated|2013-08-31|April 2013|Anticipated|2013-04-30||Observational|EARLY||Endomicroscopy in IBD Patients|Endomicroscopy for Assessment of Structural and Functional Changes in IBD Patients Treated With Anti-TNFalpha - Insights in the Process in Mucosal Healing|Unknown status|Recruiting||50|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-05-31 22:14:38.352306|2018-05-31 22:14:38.352306
NCT01417715|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-01-23|2011-08-15|2011-08-16|Estimate|||||||2013-01-23|2013-01-24|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31||Observational|||Endomicroscopy for Assessment of Mucosal Healing|Advanced Endoscopic Imaging Using Endomicroscopy for Assessment of Mucosal Healing in IBD|Unknown status|Recruiting||84|Anticipated|University of Erlangen-Nürnberg Medical School|||4||f||||t||||||||||2018-05-31 22:14:38.418224|2018-05-31 22:14:38.418224
NCT01417702|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-01-23|2011-08-15|2011-08-16|Estimate|||||||2013-01-23|2013-01-24|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|November 2014|Anticipated|2014-11-30|May 2014|Anticipated|2014-05-31||Observational|||Endoscopy for Assessment of Mucosal Healing in IBD|Advanced Endoscopic Imaging Using HD+ Endoscopy and i-Scan for Assessment of Mucosal Healing in IBD|Unknown status|Recruiting||232|Anticipated|University of Erlangen-Nürnberg Medical School|||4||f||||t||||||||||2018-05-31 22:14:38.504874|2018-05-31 22:14:38.504874
NCT01417689|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Eyedrop Instillation Technique|Eyedrop Instillation Technique: A Randomizaed Controlled Trial|Unknown status|Recruiting|N/A|230|Anticipated|Oftalmologia Hospital Sotero del Rio||2|||f||||f||||||||||2018-05-31 22:14:38.578941|2018-05-31 22:14:38.578941
NCT01417676|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-01-11|2011-08-15|2011-08-16|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2011||2011-04-30|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|Propel||DAPROCA Pelvic Lymph Node Irradiation to Prostate for High Risk Prostate Cancer: Phase I/II Study|Pelvic Lymph Node Irradiation With Simultaneous Integrated Boost to Prostate for High Risk Prostate Cancer Patients: A Phase I/II Study|Active, not recruiting||Phase 1/Phase 2|80|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-05-31 22:14:38.664366|2018-05-31 22:14:38.664366
NCT01417663|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-09-06|2011-08-15|2011-08-16|Estimate|||||||2013-09-06|2013-09-09|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and Function|Combining Exercise Training With a Drug to Break AGE-crosslinks; Effects on Cardiovascular Structure and Function and Related Mechanisms|Completed||Phase 2/Phase 3|48|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 22:14:38.751164|2018-05-31 22:14:38.751164
NCT01417650|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|January 2011||2011-01-31|June 2010|2010-06-30|January 2012|Anticipated|2012-01-31|October 2011|Anticipated|2011-10-31||Interventional|||The Effect of Low Level Laser Therapy on Improvement of Temporomandibular Joint Osteoarthritis|A Randomized Clinical Trial of the Effect of Low Level Laser Therapy on Improvement of Temporomandibular Joint Osteoarthritis|Unknown status|Active, not recruiting|N/A|20|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:14:38.94908|2018-05-31 22:14:38.94908
NCT01417637|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|November 2011|Anticipated|2011-11-30|September 2011|Anticipated|2011-09-30||Interventional|||The Effect of Low Level Laser Therapy (LLLT) in Myofacial Pain Syndrome|A Randomized Clinical Trial of the Effect of Low Level Laser Therapy in Myofacial Pain Syndrome|Unknown status|Active, not recruiting|N/A|20|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:14:39.026754|2018-05-31 22:14:39.026754
NCT01417624|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Cardiac Magnetic Resonance Imaging Guided Left Ventricular Lead Placement|The Assessment of Cardiac Magnetic Resonance Imaging Guided Left Ventricular Lead Placement During the Implantation of Cardiac Resynchronisation Therapy on Clinical Outcomes in Patients With Chronic Heart Failure|Unknown status|Recruiting|Phase 3|70|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:14:39.102157|2018-05-31 22:14:39.102157
NCT01417611|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||The Usefulness of I-scan in Screening Colonoscopy|The Usefulness of I-scan in Screening Colonoscopy: A Randomized Controlled Trial|Completed||N/A|389|Actual|Konkuk University Hospital||2|||f||||t||||||||||2018-05-31 22:14:39.183293|2018-05-31 22:14:39.183293
NCT01417598|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2015-09-07|2011-08-15|2011-08-16|Estimate|||||||2015-09-07|2015-09-09|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|BETA||BETA Study: Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity|Improving Balance Function in Elderly by Progressive and Specific Training and Physical Activity- a Randomized Controlled Study.|Unknown status|Active, not recruiting|N/A|200|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 22:14:39.257642|2018-05-31 22:14:39.257642
NCT01417585|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2013-04-14|2011-08-15|2011-08-16|Estimate|||||||2013-04-14|2013-04-16|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|LAS-2||A Trial of a Client-centered Intervention Aiming to Improve Functioning in Daily Life After Stroke|A Randomized Controlled Trial of a Client-centered Intervention Aiming to Improve Functioning in Daily Life After Stroke|Completed||N/A|280|Actual|Karolinska Institutet|||||f||||f||||||||||2018-05-31 22:14:39.334976|2018-05-31 22:14:39.334976
NCT01417572|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|September 2011|Anticipated|2011-09-30|August 2010|Actual|2010-08-31||Interventional|||Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia||Unknown status|Recruiting|Phase 4|30|Anticipated|Isfahan University of Medical Sciences||1|||f||||||||||||||2018-05-31 22:14:39.407772|2018-05-31 22:14:39.407772
NCT01417546|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2018-05-08|2011-08-13|2011-08-16|Estimate|||||||2018-05-08|2018-05-09|Actual|August 1, 2011||2011-08-01|May 1, 2018|2018-05-01|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||NHS-IL12 for Solid Tumors|First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid Tumors|Recruiting||Phase 1|83|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:14:39.480811|2018-05-31 22:14:39.480811
NCT01417533|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2018-05-24|2011-08-13|2011-08-16|Estimate|||||||2018-05-24|2018-05-25|Actual|August 13, 2011||2011-08-13|April 12, 2018|2018-04-12||||||||Observational|||A Natural History Study of Patients With GNE Myopathy|A Natural History Study of Patients With GNE Myopathy|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:14:39.559697|2018-05-31 22:14:39.559697
NCT01417520|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2018-05-26|2011-08-13|2011-08-16|Estimate|||||||2018-05-26|2018-05-30|Actual|August 13, 2011||2011-08-13|May 23, 2018|2018-05-23||||||||Observational|||Clinical and Pathophysiological Investigations Into Erdheim Chester Disease|Clinical and Pathophysiological Investigations Into Erdheim-Chester Disease|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:14:39.630873|2018-05-31 22:14:39.630873
NCT01417507|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2015-03-17|2011-08-13|2011-08-16|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery|Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients With Supratentorial Low-Risk Grade II Glioma|Completed|||82|Actual|Radiation Therapy Oncology Group|||1||f||||||||||Samples With DNA|"~     Tissue will be submitted to the RTOG Biospecimen Resource for the purpose of central review~     of pathology (mandatory fo eligibility), tissue banking, and translational research (highly~     recommended). For central review, H&E slide and tumor block must be submitted. For tissue~     banking and translational research, remaining tissue from the central review will be used and~     plasma, whole blood and urine will be collected.~   "|||2018-05-31 22:14:39.716805|2018-05-31 22:14:39.716805
NCT01417494|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2016-05-27|2011-08-13|2011-08-16|Estimate|||||||2016-05-27|2016-05-30|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|September 2014|Actual|2014-09-30||Interventional|||1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer|Evaluation of Bevacizumab Combined With First Line Chemotherapy in Patients Aged 75 and Over Suffering From Metastatic Colorectal Adenocarcinoma. Phase II Randomized - Intergroup Trial: FFCD, FNCLCC, GERICO|Completed||Phase 2|102|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||||2018-05-31 22:14:39.847329|2018-05-31 22:14:39.847329
NCT01417481|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2014-09-09||2014-10-30|2011-08-15|2011-08-16|Estimate|2014-10-21|2014-10-23|Estimate||||2014-10-30|2014-11-05|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||The total number of patiens was fewer than planned mainly because other protocols were running concurrently. The protocolo had to be concluded because some of the researchers finished their participation.|Effect of Glycine in Cystic Fibrosis|Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis|Terminated||Phase 2|13|Actual|Instituto Nacional de Enfermedades Respiratorias||2||Some of the researchers finished their participation in the study.|f||||t||||||||||2018-05-31 22:14:39.950596|2018-05-31 22:14:39.950596
NCT01417468|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-13|||2012-12-15|2011-08-13|2011-08-16|Estimate|||||||2012-12-15|2012-12-18|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|February 2013|Anticipated|2013-02-28||Interventional|CVD||How Well do Patients With Traumatic Brain Injury Learn New Material Using Learning Styles in Online Science Classrooms?|Instructional Design Strategies to Support Adult Patients/Students (Civilian & Military) With Traumatic Brain Injury (TBI).|Unknown status|Active, not recruiting|N/A|30|Anticipated|Center for Vision Development, New Market, Maryland||2|||f||||t||||||||||2018-05-31 22:14:40.392008|2018-05-31 22:14:40.392008
NCT01417455|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2016-01-03||2016-02-29|2011-08-15|2011-08-16|Estimate|2016-02-29|2016-03-21|Estimate||||2016-02-29|2016-03-21|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Observational|||Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis|Differences in Bone Cell Activity Between Rheumatoid Arthritis and Ankylosing Spondylitis|Completed|||101|Actual|Instituto de Medicina Molecular João Lobo Antunes|||3||f||||f||||||Samples With DNA|"~     Blood and bone samples~   "|Undecided||2018-05-31 22:14:40.472092|2018-05-31 22:14:40.472092
NCT01417442|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-08-13|2011-08-13|2011-08-16|Estimate|||||||2011-08-13|2011-08-16|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||BRAF V600E Mutations In Papillary Thyroid Carcinoma|Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma|Unknown status|Recruiting|Early Phase 1|150|Anticipated|Bezmialem Vakif University||1|||f||||f||||||||||2018-05-31 22:14:40.901824|2018-05-31 22:14:40.901824
NCT01417429|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-07-07|2011-08-12|2011-08-16|Estimate|||||||2015-07-07|2015-07-08|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Galantamine Effects on Nicotine Responses in Smokers|Galantamine Effects on Nicotine Responses in Smokers|Completed||Phase 1|12|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:14:40.956136|2018-05-31 22:14:40.956136
NCT01417416|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2011-08-15|2011-08-15|2011-08-16|Estimate|||||||2011-08-15|2011-08-16|Estimate||||February 2009|2009-02-28||||||||Observational|||Changes in the Permeability of the Blood Brain Barrier and Intestinal Barrier in Humans During Conditions of Stress and Immune Activation: in Vivo Studies||Completed|||||National University Hospital, Singapore|||2||f||||||||||||||2018-05-31 22:14:41.016604|2018-05-31 22:14:41.016604
NCT01417403|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-02-01|2011-08-15|2011-08-16|Estimate|||||||2015-02-01|2015-02-03|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases|A Phase 1 Study of Hydroxychloroquine in Patients With Solid Tumors Receiving Radiotherapy for Bone Metastases|Terminated||Phase 1|10|Actual|Virginia Commonwealth University||1||"Recently published data that has shown HCQ to be safe when combined with chemo and or radiation~   at even higher doses than what is used in this study."|f||||t||||||||||2018-05-31 22:14:41.125938|2018-05-31 22:14:41.125938
NCT01417390|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-03-06|2011-08-15|2011-08-16|Estimate|||||||2014-03-06|2014-03-07|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma|Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|80|Anticipated|First People's Hospital of Foshan||2|||f||||t||||||||||2018-05-31 22:14:41.202297|2018-05-31 22:14:41.202297
NCT01417377|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2015-09-24||2017-06-15|2011-08-15|2011-08-16|Estimate|2015-11-04|2015-12-09|Estimate||||2017-06-15|2017-07-13|Actual|May 31, 2010|Actual|2010-05-31|May 2017|2017-05-31|March 31, 2012|Actual|2012-03-31|March 31, 2012|Actual|2012-03-31||Observational||Intent-to-treat (ITT) analysis set included all participants who were enrolled in the study. Age (continuous) data were reported only for treated participants.|An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)|Non-Interventional Study to Document the Efficacy in Routine Clinical Practice of Mircera in Pakistan (NORM)|Completed|||22|Actual|Hoffmann-La Roche|As none of the enrolled participants in the study achieved the endpoint of maintaining Hb level between 11-12 g/dL during the final 2 months of study, therefore efficacy parameters were not analyzed.||1||f||||||||||||||2018-05-31 22:14:41.302881|2018-05-31 22:14:41.302881
NCT01417364|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2015-09-30|2011-08-15|2011-08-16|Estimate|||||||2015-09-30|2015-10-02|Estimate|January 2016||2016-01-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men|The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men|Withdrawn||Phase 4|0|Actual|The University of Texas Medical Branch, Galveston||3||Unable to identify any qualifying subjects willing to enroll into this study.|f||||t||||||||||2018-05-31 22:14:41.464102|2018-05-31 22:14:41.464102
NCT01417351|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2013-07-22|2011-08-15|2011-08-16|Estimate|||||||2013-07-22|2013-07-23|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Vitamin D Supplementation During Pregnancy on Clinical Outcomes and Immune Function|Assessment of Inflammatory Markers and Pregnancy Outcomes in Vitamin D-Supplemented Women at Risk of Vitamin D Deficiency: A Double-Blind, Randomized Controlled Trial|Completed||N/A|60|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:14:41.553121|2018-05-31 22:14:41.553121
NCT01417338|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-06-07|2011-08-15|2011-08-16|Estimate|||||||2017-06-07|2017-06-09|Actual|August 2009||2009-08-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Registry for Pulmonary Hypertension in China|National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China|Recruiting|||3079|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||1||f||||t||||||||||2018-05-31 22:14:41.640112|2018-05-31 22:14:41.640112
NCT01417325|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2018-01-23|2011-08-15|2011-08-16|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2010||2010-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|BJPCI Registry||Beijing Percutaneous Coronary Intervention Registry|A Registry Study of Percutaneous Coronary Intervention Treatment in Beijing Area of P.R. China|Recruiting|||700000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t||||||||||2018-05-31 22:14:41.733175|2018-05-31 22:14:41.733175
NCT01417312|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-12-21|2011-08-15|2011-08-16|Estimate|||||||2017-12-21|2017-12-22|Actual|July 2011||2011-07-31|December 2017|2017-12-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients||Completed||N/A|20|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:14:41.795326|2018-05-31 22:14:41.795326
NCT01417299|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2015-09-20|2011-08-15|2011-08-16|Estimate|||||||2015-09-20|2015-09-22|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|CVS||The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements||Withdrawn||Phase 1/Phase 2|0|Actual|Hadassah Medical Organization||2||This record is an additional copy of the study listed above|f||||f||||||||||2018-05-31 22:14:41.882654|2018-05-31 22:14:41.882654
NCT01417286|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-11-15|2011-08-12|2011-08-16|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2010||2010-12-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer|Accelerated, Hypofractionated Post-Mastectomy Radiation Therapy in Women With Breast Cancer: A Phase II Trial|Active, not recruiting||Phase 2|69|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 22:14:41.945101|2018-05-31 22:14:41.945101
NCT01417273|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2011-08-12|2011-08-12|2011-08-16|Estimate|||||||2011-08-12|2011-08-16|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|August 2013|Anticipated|2013-08-31|February 2013|Anticipated|2013-02-28||Interventional|MS||Impact of Vitamin A on Multiple Sclerosis (MS)|Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:14:42.02345|2018-05-31 22:14:42.02345
NCT01417260|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2015-04-10|2011-08-12|2011-08-16|Estimate|||||||2015-04-10|2015-04-14|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Effects of Breast Feeding on Post-Cesarean and Post-Vaginal Delivery Pain|Effects of Breast Feeding on Post-Cesarean and Post-Vaginal Delivery Pain|Completed|||130|Anticipated|Stanford University|||3||f||||||||||||||2018-05-31 22:14:42.100898|2018-05-31 22:14:42.100898
NCT01417247|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-07-14|2011-08-15|2011-08-16|Estimate|||||||2017-07-14|2017-07-17|Actual|August 2011|Actual|2011-08-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Renal Sympathetic Modification in Patients With Metabolic Syndrome|Renal Sympathetic Modification in Patients With Metabolic Syndrome.|Recruiting||N/A|200|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 22:14:42.173998|2018-05-31 22:14:42.173998
NCT01417234|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-12-11|2011-08-12|2011-08-16|Estimate|||||||2012-12-11|2012-12-12|Estimate|June 2011||2011-06-30|December 2012|2012-12-31||||February 2013|Anticipated|2013-02-28||Observational|||Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds|Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System for Treatment of Acute Trauma and Acute Surgical Excision Wounds|Unknown status|Active, not recruiting||30|Anticipated|Spiracur, Inc.|||1||f||||f||||||||||2018-05-31 22:14:42.251414|2018-05-31 22:14:42.251414
NCT01417221|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-07-13|2011-08-15|2011-08-16|Estimate|||||||2017-07-13|2017-07-17|Actual|August 2011|Actual|2011-08-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Renal Sympathetic Modification in Patients With Essential Hypertension|Renal Sympathetic Modification in Patients With Essential Hypertension|Recruiting||N/A|200|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 22:14:42.308674|2018-05-31 22:14:42.308674
NCT01417208|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-12-11|2011-08-15|2011-08-16|Estimate|||||||2012-12-11|2012-12-12|Estimate|June 2011||2011-06-30|December 2012|2012-12-31||||December 2012|Anticipated|2012-12-31||Observational|||Clinical Evaluation of the SNaP Wound Care System in Promoting Healing in Chronic Wounds|Clinical Evaluation of the SNaP Wound Care System in Promoting Healing in Chronic Wounds|Unknown status|Active, not recruiting||45|Anticipated|Spiracur, Inc.|||1||f||||f||||||||||2018-05-31 22:14:42.385292|2018-05-31 22:14:42.385292
NCT01417195|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2014-03-20|2013-01-08|2014-05-06|2011-08-15|2011-08-16|Estimate|2014-03-20|2014-04-24|Estimate|2013-01-08|2013-01-14|Estimate|2014-05-06|2014-05-16|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|COMBINE||Menopur Mixed Protocol|A Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Combination of Menopur® and Bravelle® With Menopur® Alone in Subjects Undergoing Assisted Reproductive Technology (ART)|Completed||Phase 4|122|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:14:42.461384|2018-05-31 22:14:42.461384
NCT01417182|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-06-16|2011-08-15|2011-08-16|Estimate|||||||2014-06-16|2014-06-18|Estimate|September 2010||2010-09-30|June 2014|2014-06-30||||September 2014|Anticipated|2014-09-30||Interventional|||Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer|Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA Based PET in Patients With Advanced Prostate Cancer|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 22:14:42.94433|2018-05-31 22:14:42.94433
NCT01417169|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-07-11|2011-08-15|2011-08-16|Estimate|||||||2014-07-11|2014-07-14|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Micafungin Prevention Study for Invasive Fungal Disease in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation|Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|112|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:14:43.000436|2018-05-31 22:14:43.000436
NCT01417156|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|2016-10-25||2017-01-13|2011-08-15|2011-08-16|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|September 2011||2011-09-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Treated set (TS): This analysis set included all patients who were given study medication and were documented to have taken at least one dose of the trial medication.|Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)|A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|20|Actual|Boehringer Ingelheim|Annual ROD in FVC results to be interpreted with caution & along with descriptive statistics as inferences used might not be valid as suggested by skewed distribution of data thus Absolute Change from baseline in FVC over time has been defined.|1|||f||||||||||||||2018-05-31 22:14:43.08166|2018-05-31 22:14:43.08166
NCT01417143|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-11-11|2011-08-12|2011-08-16|Estimate|||||||2014-11-11|2014-11-13|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional|||Dovitinib in Adenoid Cystic Carcinoma|Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma|Completed||Phase 2|33|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 22:14:43.268412|2018-05-31 22:14:43.268412
NCT01417130|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-01-05|2011-08-12|2011-08-16|Estimate|||||||2012-01-05|2012-01-09|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|August 2012|Anticipated|2012-08-31|October 2011|Actual|2011-10-31||Observational|ADAPT-FS||Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial|Alzheimer's Disease Anti-Inflammatory Prevention Trial Follow-Up Study|Unknown status|Active, not recruiting||1650|Anticipated|Seattle Institute for Biomedical and Clinical Research|||3||f||||f||||||Samples With DNA|"~     Specimens retained from the ADAPT trial include plasma, serum, urine and cerebrospinal fluid~     (the latter from a smaller sample of volunteers). Additional collection of cerebrospinal~     fluid from prior donors and from a new panel of volunteers is conducted under a different~     sub-study of ADAPT.~   "|||2018-05-31 22:14:43.330329|2018-05-31 22:14:43.330329
NCT01417117|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2017-10-18|2011-08-15|2011-08-16|Estimate|||||||2017-10-18|2017-10-20|Actual|September 2011|Actual|2011-09-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Effect of Ischemic Strokes on Recovery From Intracerebral Hemorrhages|The Effect of Diffusion Weighted Imaging Abnormalities on Outcomes in Patients With Spontaneous Intracerebral Hemorrhage|Completed|||130|Anticipated|Rush University Medical Center|||1||f||||f||||||||No||2018-05-31 22:14:43.406233|2018-05-31 22:14:43.406233
NCT01417104|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2012-10-29||2017-05-09|2011-08-15|2011-08-16|Estimate|2012-11-28|2012-12-31|Estimate||||2017-05-09|2017-05-11|Actual|October 2009||2009-10-31|May 2017|2017-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|ALPINE||Aliskiren Effect on Aortic Plaque Progression|Aliskiren Effect on Plaque Progression In Established Atherosclerosis Using High Resolution 3D MRI (ALPINE): A Double Blind Placebo Controlled Trial|Terminated||Phase 2/Phase 3|71|Actual|Ohio State University||2||Safety concerns with approved medication identified in an unrelated trial|f||||f||||||||||2018-05-31 22:14:43.464547|2018-05-31 22:14:43.464547
NCT01417091|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2015-01-02|2011-08-12|2011-08-16|Estimate|||||||2015-01-02|2015-01-05|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta|A Randomized, Open Label Intra-patient Dose Escalation Study With an Untreated Reference Group to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Infusions of BPS804 in Adults With Moderate Osteogenesis Imperfecta|Completed||Phase 2|10|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:14:43.749008|2018-05-31 22:14:43.749008
NCT01417078|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|2016-12-16|2014-01-27|2017-02-28|2011-08-15|2011-08-16|Estimate|2017-02-28|2017-03-29|Actual|2014-01-27|2014-02-27|Estimate|2017-02-28|2017-03-29|Actual|September 2011||2011-09-30|February 2017|2017-02-28|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||Safety Population Number (N)=31 Pharmacokinetic Population N=30|A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode|An Open-Label Study to Determine the Pharmacokinetics of a Single Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode for Which Acute Treatment With a Benzodiazepine is Clinically Indicated|Completed||Phase 2|31|Actual|Acorda Therapeutics||1|||f||||f||||||||||2018-05-31 22:14:43.857035|2018-05-31 22:14:43.857035
NCT01417065|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2014-06-20|2011-08-12|2011-08-16|Estimate|||||||2014-06-20|2014-06-23|Estimate|August 2010||2010-08-31|June 2014|2014-06-30||||June 2014|Actual|2014-06-30||Interventional|||Temsirolimus In Phase 0|Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets|Completed||Early Phase 1|15|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:14:44.11957|2018-05-31 22:14:44.11957
NCT01417052|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-08-01|2011-08-12|2011-08-16|Estimate|||||||2012-08-01|2012-08-02|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA)|Completed||Phase 1|10|Actual|Lexicon Pharmaceuticals||10|||f||||f||||||||||2018-05-31 22:14:44.210279|2018-05-31 22:14:44.210279
NCT01417026|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2016-09-02||2017-02-10|2011-08-15|2011-08-16|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|September 2011||2011-09-30|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Intranasal Oxytocin and Learning in Autism|Promoting Social Perceptual Learning With Oxytocin in Autism|Completed||Phase 2|36|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 22:14:44.319443|2018-05-31 22:14:44.319443
NCT01417013|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-02-06|2011-08-15|2011-08-16|Estimate|||||||2012-02-06|2012-02-08|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time|A Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time|Withdrawn||N/A|0|Actual|Alcon Research||2||Management Decision|f||||f||||||||||2018-05-31 22:14:44.600692|2018-05-31 22:14:44.600692
NCT01417000|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2018-04-06||2018-04-06|2011-08-12|2011-08-16|Estimate|2018-04-06|2018-05-08|Actual||||2018-04-06|2018-05-08|Actual|September 21, 2011|Actual|2011-09-21|April 2018|2018-04-30|February 10, 2017|Actual|2017-02-10|October 2016|Actual|2016-10-31||Interventional||Baseline analysis provided for the Full Analysis Set (FAS), defined as those randomized study subjects who were administered at least 1 dose of protocol-specified drug. Baseline analysis is provided for subjects on the basis of their original study arm assignments, prior to any rollover from the Cy/GVAX arm to the Cy/GVAX + CRS-207 arm.|Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer|A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|93|Actual|Aduro Biotech, Inc.||2|||f||||t||||||||||2018-05-31 22:14:44.726085|2018-05-31 22:14:44.726085
NCT01416987|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2018-05-22|2011-08-12|2011-08-15|Estimate|||||||2018-05-22|2018-05-23|Actual|August 14, 2011|Actual|2011-08-14|May 2018|2018-05-31|May 10, 2018|Actual|2018-05-10|May 10, 2018|Actual|2018-05-10||Observational|||A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)|A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)|Completed|||600|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 22:14:45.501081|2018-05-31 22:14:45.501081
NCT01416974|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2017-09-05|2011-08-12|2011-08-15|Estimate|||||||2017-09-05|2017-09-06|Actual|November 2011||2011-11-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab|A Phase I Trial of Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab|Active, not recruiting||Phase 1|18|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:14:45.549511|2018-05-31 22:14:45.549511
NCT01416961|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-08-20|2011-08-12|2011-08-15|Estimate|||||||2012-08-20|2012-08-22|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)|Phase I Study of High Linear Energy Transfer (Neutron) Therapy Followed by Concurrent Chemotherapy and Standard Photon Thoracic RT (TRT) in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients|Withdrawn||Phase 1|0|Actual|Barbara Ann Karmanos Cancer Institute||||Neutron therapy has become unavailable|f||||t||||||||||2018-05-31 22:14:45.635129|2018-05-31 22:14:45.635129
NCT01416948|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2013-04-24|2011-08-12|2011-08-15|Estimate|||||||2013-04-24|2013-04-26|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CREATE||Cognitive REmediation After Trauma Exposure Trial = CREATE Trial|Randomized Controlled Trial of Galantamine, Methylphenidate, and Placebo for the Treatment of Cognitive Symptoms in Patients With Traumatic Brain Injury (TBI) and/or Posttraumatic Stress Disorder (PTSD)|Terminated||Phase 2|32|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium||3||"The funding agency, DoD, determined that the study could not meet its enrollment numbers by the~   end of the grant."|f||||t||||||||||2018-05-31 22:14:45.700539|2018-05-31 22:14:45.700539
NCT01416935|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-05-24|2011-08-12|2011-08-15|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|January 2015|Actual|2015-01-31||Interventional|||Necessity of Anti-Arrhythmic Medication After Surgical Ablation for Atrial Fibrillation|Anti-Arrhythmic Medication (Amiodarone) Post Surgical Ablation for Atrial Fibrillation - Is it Necessary?|Unknown status|Active, not recruiting|N/A|186|Anticipated|Inova Health Care Services||2|||f||||f||||||||||2018-05-31 22:14:45.774858|2018-05-31 22:14:45.774858
NCT01416922|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-08-12|2011-08-12|2011-08-15|Estimate|||||||2011-08-12|2011-08-15|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|||||Observational|||oncoFISH Cervical Test for Detection of 3q26 Region Gain|The oncoFISH Cervical Test for Detection of 3q26 Region Gain|Unknown status|Enrolling by invitation||1100|Anticipated|Ikonisys, Inc.|||1||f||||t||||||||||2018-05-31 22:14:45.828275|2018-05-31 22:14:45.828275
NCT01416909|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-02-21|2011-08-12|2011-08-15|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2008||2008-11-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Managing Medication-induced Constipation in Cancer: A Clinical Trial|Managing Medication-induced Constipation in Cancer: A Clinical Trial|Completed||N/A|601|Actual|H. Lee Moffitt Cancer Center and Research Institute||5|||f||||f||||||||||2018-05-31 22:14:45.873853|2018-05-31 22:14:45.873853
NCT01416896|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-12|2011-08-12|2011-08-15|Estimate|||||||2011-08-12|2011-08-15|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|BME-1||New Needle for Two-Needle Hemodialysis|New Needle for Two-Needle Hemodialysis|Unknown status|Recruiting|Phase 2/Phase 3|70|Anticipated|Biomedical Enterprises Inc||2|||f||||t||||||||||2018-05-31 22:14:45.943195|2018-05-31 22:14:45.943195
NCT01416883|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-08-12|2011-08-12|2011-08-15|Estimate|||||||2011-08-12|2011-08-15|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Oral Mucosal Absorption Study of Bicalutamide New Formulation|Oral Mucosal Absorption Study of ICI176,334-1 (Bicalutamide New Formulation) in Japanese Healthy Male Subjects|Terminated||Phase 1|8|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 22:14:46.012847|2018-05-31 22:14:46.012847
NCT01416870|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-01-10|2011-08-12|2011-08-15|Estimate|||||||2012-01-10|2012-01-11|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Bioequivalence of Bicalutamide New Formulation in Japan|Bioequivalence Study of ICI176,334-1 (Bicalutamide New Formulation) in Japanese Healthy Male Subjects - Evaluation of Bioequivalence of ICI176,334-1 and Casodex Tablet (80mg)|Terminated||Phase 1|102|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 22:14:46.063765|2018-05-31 22:14:46.063765
NCT01416857|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2014-07-08|2011-08-12|2011-08-15|Estimate|||||||2014-07-08|2014-07-09|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Emergency Department (ED) Disability Diagnostic Tool|ED Disability Diagnostic Tool: a Health Information Technology Feasibility Study|Completed||N/A|635|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:14:47.106291|2018-05-31 22:14:47.106291
NCT01416844|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2013-03-06|2011-08-12|2011-08-15|Estimate|||||||2013-03-06|2013-03-07|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of Immune Responses in Patients With Metastatic Melanoma|Phase II Exploratory Study of Immune Responses in Patients With Metastatic Melanoma Treated With Mouse Monoclonal Anti-OX40|Withdrawn||Phase 2|0|Actual|Providence Health & Services||||Change in the development plan for the anti-OX40 antibody.|f||||f||||||||||2018-05-31 22:14:47.194862|2018-05-31 22:14:47.194862
NCT01416831|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2018-01-16|2011-08-12|2011-08-15|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2011||2011-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SBRT/IL-2||Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.|Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma|Active, not recruiting||Phase 2|43|Actual|Providence Health & Services||2|||f||||f||||||||No||2018-05-31 22:14:47.25176|2018-05-31 22:14:47.25176
NCT01416818|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-11|2011-08-11|2011-08-15|Estimate|||||||2011-08-11|2011-08-15|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Treatment of Depression in Parkinson's Disease|"A Randomized, Double-Blind, Placebo-Controlled Study of Xiaoyao Pill Treatment of Depression in Patients With Parkinson's Disease"|Unknown status|Recruiting|Phase 2|60|Anticipated|Xuanwu Hospital, Beijing||3|||f||||f||||||||||2018-05-31 22:14:47.325867|2018-05-31 22:14:47.325867
NCT01416805|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-10-25|2011-08-11|2011-08-15|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2011||2011-08-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers|Utilizing Health Information Technology to Improve Health Care Quality: Implementation of a Computerized Cognitive Behavioral Therapy Protocol for Childhood Anxiety|Completed||Phase 3|188|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 22:14:47.409049|2018-05-31 22:14:47.409049
NCT01416792|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-03-29|2011-08-12|2011-08-15|Estimate|||||||2013-03-29|2013-04-01|Estimate|March 2011||2011-03-31|September 2011|2011-09-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Centrifugation vs. Multiple-pass Hemofiltration of the Residual Cardiopulmonary Bypass Volume|Outcomes & Biochemical Parameters Following Cardiac Surgery: Effects of Transfusion of Residual Blood Using Centrifugation and Multiple-Pass Hemofiltration|Completed||N/A|61|Actual|University of Saskatchewan||1|||f||||f||||||||||2018-05-31 22:14:47.483518|2018-05-31 22:14:47.483518
NCT01416779|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2012-07-15|2011-08-12|2011-08-15|Estimate|||||||2012-07-15|2012-07-17|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Finding Balance Writing Intervention for Older Bereaved Caregivers|Finding Balance: The Experience of Hope for Bereaved Caregivers of Palliative Cancer Patients|Completed||N/A|23|Actual|University of Saskatchewan||2|||f||||t||||||||||2018-05-31 22:14:47.639566|2018-05-31 22:14:47.639566
NCT01416766|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-09-15|2011-08-12|2011-08-15|Estimate|||||||2015-09-15|2015-09-16|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|CONDUIT-HID||CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes|CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes|Completed||N/A|196|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 22:14:47.731623|2018-05-31 22:14:47.731623
NCT01416753|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-08-30|2011-08-12|2011-08-15|Estimate|||||||2012-08-30|2012-09-03|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|BVM-Reg||Response Options to Blood Volume Monitoring in Fluid Overloaded Hemodialysis Patients|A Randomized Controlled Clinical Trial Comparing, in Fluid-Overloaded Hemodialysis Patients, Three Strategies of Fluid Removal: Regulation of Ultrafiltration and Dialysate Conductivity, Regulation of Ultrafiltration and Temperature, and Standard Hemodialysis|Completed||N/A|64|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 22:14:47.813487|2018-05-31 22:14:47.813487
NCT01416740|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2014-03-24|2011-08-12|2011-08-15|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation|A Prospective Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||1||difficulty with recruitment, PI left the institution|f||||f||||||||||2018-05-31 22:14:47.894371|2018-05-31 22:14:47.894371
NCT01416727|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-09-06|2011-08-12|2011-08-15|Estimate|||||||2011-09-06|2011-09-07|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|EPIC-OSkER||Simulation Training vs Workplace-Based Supervision in Psychiatry|A Randomised Trial of Simulation Training vs Workplace-Based Supervision for Junior Doctors in Psychiatry|Unknown status|Active, not recruiting|N/A|48|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 22:14:47.991205|2018-05-31 22:14:47.991205
NCT01416714|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2018-02-06|2011-08-12|2011-08-15|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2, 2008|Actual|2008-07-02|February 2018|2018-02-28|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy|Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy|Recruiting|||1000|Anticipated|University of Chicago|||10||f||||t||||||Samples With DNA|"~     blood, tissue, DNA~   "|||2018-05-31 22:14:48.078875|2018-05-31 22:14:48.078875
NCT01416701|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2013-04-08|2011-08-12|2011-08-15|Estimate|||||||2013-04-08|2013-04-09|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Vitamin D and Chronic Obstructive Lung Disease|Vitamin D and COPD. A Randomised, Double-blind, Placebo-controlled Trial of the Effect of Vitamin D on Withdrawal From Pulmonary Rehabilitation and Exercise Endurance|Withdrawn||Phase 4|0|Actual|Hvidovre University Hospital||2||"It was not possible to enroll the planned amount of subjects. Many patients with chronic~   obstructive pulmonary disease already took large doses of vitamin D."|f||||t||||||||||2018-05-31 22:14:48.169707|2018-05-31 22:14:48.169707
NCT01416688|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2017-12-13|2011-08-12|2011-08-15|Estimate|||||||2017-12-13|2017-12-15|Actual|November 2011||2011-11-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride|S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities|Active, not recruiting|||140|Anticipated|Southwest Oncology Group|||1||f||||t||||||||||2018-05-31 22:14:48.284275|2018-05-31 22:14:48.284275
NCT01416675|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2014-06-05|2011-08-12|2011-08-15|Estimate|||||||2014-06-05|2014-06-06|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|DIPI-ICU||Delirium Assessment in the Pediatric Intensive Care Unit|Delirium Assessment in the Pediatric Intensive Care Unit|Completed|||73|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 22:14:48.46999|2018-05-31 22:14:48.46999
NCT01416662|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2016-05-27|2011-08-12|2011-08-15|Estimate|||||||2016-05-27|2016-05-30|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery|Pharmacogenetics of Gemcitabine: Study of the Impact of Genetic Polymorphism of Cytidine Deaminase (CDA) on Toxicity in Resected Pancreatic Adenocarcinomas|Completed||Phase 2|120|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||f||||||||||2018-05-31 22:14:48.605483|2018-05-31 22:14:48.605483
NCT01416649|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2016-09-01|2011-08-11|2011-08-15|Estimate|||||||2016-09-01|2016-09-05|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Impact of Exenatide on Sleep Duration|Impact of Exenatide on Sleep Duration and Quality in Type 2 Diabetes|Recruiting|||12|Anticipated|University of Chicago|||||f||||f||||||||||2018-05-31 22:14:48.680417|2018-05-31 22:14:48.680417
NCT01416636|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2017-10-03|2011-08-12|2011-08-15|Estimate|||||||2017-10-03|2017-10-04|Actual|March 2009||2009-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CTREPH||Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)|A Double Blind Controlled Clinical Study to Investigate the Efficacy and Tolerability of Subcutaneous Treprostinil Sodium in Patients With Severe Non-operable Chronic Thromboembolic Pulmonary Hypertension (CTREPH)|Active, not recruiting||Phase 3|100|Anticipated|SciPharm SàRL||2|||f||||f||||||||||2018-05-31 22:14:48.758816|2018-05-31 22:14:48.758816
NCT01416623|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-12-20|2011-08-12|2011-08-15|Estimate|||||||2012-12-20|2012-12-21|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies|A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies|Terminated||Phase 1|44|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:14:48.844792|2018-05-31 22:14:48.844792
NCT01416610|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|2015-11-04||2017-03-10|2011-08-12|2011-08-15|Estimate|2015-11-04|2015-12-09|Estimate||||2017-03-10|2017-04-10|Actual|April 2010||2010-04-30|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|PEGHOPE||An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy|A Prospective, Observational, Multicenter Non-interventional Trial Examining Efficacy of Combination Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD) Plus COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C, Genotype 2, 3, 1 or 4, Undergoing an Opioid Maintenance-Therapy With Special Focus on Patient Compliance and Quality of Life|Completed|||88|Actual|Hoffmann-La Roche|||1||f||||f||||||||||2018-05-31 22:14:48.944391|2018-05-31 22:14:48.944391
NCT01416597|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2012-12-13|2011-08-12|2011-08-15|Estimate|||||||2012-12-13|2012-12-17|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||A Systematic Review of Studies of the Effect of Influenza Vaccine Against Mismatched Strains|Effect of Influenza Vaccine Against Mismatched Strains: Systematic Review|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:14:49.291771|2018-05-31 22:14:49.291771
NCT01416584|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|2016-09-02||2017-12-01|2011-08-12|2011-08-15|Estimate|2017-08-11|2017-09-29|Actual||||2017-12-01|2017-12-05|Actual|October 2008||2008-10-31|December 2017|2017-12-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment|A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment|Completed||N/A|98|Actual|Johns Hopkins University||3|||f||||f||||||||No||2018-05-31 22:14:49.408089|2018-05-31 22:14:49.408089
NCT01416571|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|2013-12-19|2012-07-26|2016-09-22|2011-08-12|2011-08-15|Estimate|2014-03-20|2014-04-16|Estimate|2012-07-26|2012-08-03|Estimate|2016-09-22|2016-09-23|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|September 2012|Actual|2012-09-30|November 2011|Actual|2011-11-30||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults|Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years|Completed||Phase 2|78|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:14:50.011447|2018-05-31 22:14:50.011447
NCT01416558|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-05-21|2011-08-12|2011-08-15|Estimate|||||||2013-05-21|2013-05-22|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany)|A Multicenter Non-randomized Phase II Study to Evaluate Nab-paclitaxel in Metastatic Brest Cancer Patients Failing a Solvent Based Taxane as (Neo-)Adjuvant Treatment (Tiffany)|Terminated||Phase 2|66|Anticipated|German Breast Group||||Study was terminated because of extrem low recruitment|f||||t||||||||||2018-05-31 22:14:51.022764|2018-05-31 22:14:51.022764
NCT01416545|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-12|2011-08-12|2011-08-15|Estimate|||||||2011-08-12|2011-08-15|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|CETICARP||Children Education and Cardiovascular Risk Reduction in Their Parents|Children Education as Therapeutic Instrument for Cardiovascular Risk Reduction in Their Parents|Completed||N/A|520|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:14:51.097608|2018-05-31 22:14:51.097608
NCT01416532|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-08-17|2011-08-12|2011-08-15|Estimate|||||||2011-08-17|2011-08-18|Estimate|January 2006||2006-01-31|July 2011|2011-07-31|December 2015|Anticipated|2015-12-31|December 2007|Actual|2007-12-31||Observational|ESCORT||Evaluation of Subclinical COronary Atherosclerosis for Risk Stratification Using Coronary Computed Tomography (CT) Angiography|Prognostic Value of Coronary CT Angiography in Relation to Evaluation of Subclinical Coronary Atherosclerosis for Risk Stratification in Asymptomatic Individuals From ESCORT Study|Unknown status|Recruiting||5000|Anticipated|Seoul National University Bundang Hospital|||||f||||t||||||||||2018-05-31 22:14:51.210936|2018-05-31 22:14:51.210936
NCT01416519|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2014-11-17|2011-08-12|2011-08-15|Estimate|||||||2014-11-17|2014-11-19|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation|Incentive Spirometry Decreases Respiratory Complications After Myocardial Revascularization|Completed||N/A|200|Actual|Santa Casa de Votuporanga||2|||f||||t||||||||||2018-05-31 22:14:51.284836|2018-05-31 22:14:51.284836
NCT01416506|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2013-11-04|2011-08-12|2011-08-15|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Observational|||Community-Acquired Pneumonia (CAP) Surveillance|Community-Acquired Pneumonia (CAP) Mycoplasma Surveillance|Completed|||560|Actual|Bayer|||1||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 22:14:51.407827|2018-05-31 22:14:51.407827
NCT01416493|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2015-03-09|2011-08-12|2011-08-15|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ALS-003-2008||Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis|An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase (bIAP), an Inflammation Modulating Moiety, in RA Patients|Completed||Phase 1/Phase 2|6|Actual|Alloksys Life Sciences B.V.||1|||f||||t||||||||||2018-05-31 22:14:51.481571|2018-05-31 22:14:51.481571
NCT01416480|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-12|||2011-08-12|2011-08-12|2011-08-15|Estimate|||||||2011-08-12|2011-08-15|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||"Clinical Trial to Evaluate the Safety and Efficacy of Theobromine Capsule as an Antitussive in Acute Cougher"|"Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Theobromine Capsule 300mg as an Antitussive Agent in Acute Cough Patients."|Completed||Phase 3|332|Actual|Ahn-Gook Pharmaceuticals Co.,Ltd||2|||f||||t||||||||||2018-05-31 22:14:51.557289|2018-05-31 22:14:51.557289
NCT01416467|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-09-18|2011-08-11|2011-08-15|Estimate|||||||2017-09-18|2017-09-19|Actual|February 8, 2012|Actual|2012-02-08|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|CPPGAL||Characterization of the Patient Population With Galactosialidosis|Characterization of the Patient Population With Galactosialidosis|Active, not recruiting|||3|Actual|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     Blood for PPCA gene mutation and AAV2 and AAV8 antibody titer~   "|||2018-05-31 22:14:51.743304|2018-05-31 22:14:51.743304
NCT01416454|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-03-20|2011-08-12|2011-08-15|Estimate|||||||2013-03-20|2013-03-22|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Observational|||Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery|Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Elective Cesarean Delivery.|Completed|||46|Actual|Stanford University|||2||f||||f||||||||||2018-05-31 22:14:51.867458|2018-05-31 22:14:51.867458
NCT01416441|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01||2015-03-25|2015-03-25|2011-08-11|2011-08-15|Estimate||||2015-03-25|2015-04-15|Estimate|2015-03-25|2015-04-15|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|Completed||Phase 3|170|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 22:14:51.949859|2018-05-31 22:14:51.949859
NCT01416428|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2018-05-11|2011-08-12|2011-08-15|Estimate|||||||2018-05-11|2018-05-15|Actual|September 2011||2011-09-30|December 2017|2017-12-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies|Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies|Active, not recruiting||Phase 1/Phase 2|364|Anticipated|Amgen||2|||f||||t||||||||||2018-05-31 22:14:52.151501|2018-05-31 22:14:52.151501
NCT01416415|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2018-04-03|2011-08-12|2011-08-15|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2011||2011-08-31|April 2018|2018-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Glaucoma Eye Drop Instillation: Impact of Education|Glaucoma Eye Drop Instillation: Impact of Education|Terminated||N/A|119|Actual|Northwestern University||2||Not practical to continue due interim results|f||||f||||||||||2018-05-31 22:14:52.224903|2018-05-31 22:14:52.224903
NCT01416402|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11||2015-02-19|2015-03-09|2011-08-12|2011-08-15|Estimate||||2015-03-09|2015-04-03|Estimate|2015-03-09|2015-04-03|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients|A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout|Completed||Phase 2|27|Actual|CymaBay Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 22:14:52.398866|2018-05-31 22:14:52.398866
NCT01416389|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2017-09-27|2014-01-07|2017-10-28|2011-08-11|2011-08-15|Estimate|2017-10-28|2017-12-04|Actual|2014-01-07|2014-02-06|Estimate|2017-10-28|2017-12-04|Actual|August 2011||2011-08-31|October 2017|2017-10-31|September 2013|Actual|2013-09-30|August 2012|Actual|2012-08-31||Interventional||Participants who received at least 1 dose of study medication (LY2523355 or ixabepilone). One participant was mistakenly dosed with 6 mg/m^2/day in Cycle 1 and for 2 doses in Cycle 2. The dose was subsequently corrected and the participant is included in this analysis.|A Study of LY2523355 in Participants With Breast Cancer|A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy|Completed||Phase 2|39|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 22:14:52.526445|2018-05-31 22:14:52.526445
NCT01416376|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-06-13|2011-08-11|2011-08-15|Estimate|||||||2017-06-13|2017-06-15|Actual|August 30, 2011|Actual|2011-08-30|June 2017|2017-06-30|December 12, 2011|Actual|2011-12-12|December 12, 2011|Actual|2011-12-12||Interventional|||Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation|A Double Blind, Placebo Controlled, Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects|Completed||Phase 1|39|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:14:53.197186|2018-05-31 22:14:53.197186
NCT00820040|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2015-07-15|2009-01-08|2009-01-09|Estimate|||||||2015-07-15|2015-07-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:25:18.649791|2018-06-01 01:25:18.649791
NCT01416363|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-07-05|2011-08-11|2011-08-15|Estimate|||||||2017-07-05|2017-07-07|Actual|May 20, 2011|Actual|2011-05-20|July 2017|2017-07-31|September 17, 2011|Actual|2011-09-17|September 17, 2011|Actual|2011-09-17||Interventional|||Healthy Volunteer Study Using 3 Different Formulations of Firategrast|A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers|Completed||Phase 1|38|Actual|GlaxoSmithKline||9|||f||||f||||||||||2018-05-31 22:14:53.311828|2018-05-31 22:14:53.311828
NCT01416350|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-07-18|2011-08-11|2011-08-15|Estimate|||||||2017-07-18|2017-07-21|Actual|March 30, 2011|Actual|2011-03-30|July 2017|2017-07-31|May 12, 2011|Actual|2011-05-12|May 12, 2011|Actual|2011-05-12||Interventional|||A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin|A Single and Repeat Dose Pharmacokinetics/ Pharmacodynamics (PK/PD) Study to Characterise theBiomarker Response in Healthy Subjects Treated With the AntiinflammatoryMacrolide Azithromycin|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:14:53.420198|2018-05-31 22:14:53.420198
NCT01416337|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-11-08|2011-08-11|2011-08-15|Estimate|||||||2017-11-08|2017-11-13|Actual|June 20, 2011|Actual|2011-06-20|November 2017|2017-11-30|December 17, 2011|Actual|2011-12-17|December 17, 2011|Actual|2011-12-17||Interventional|||Absolute Bioavialability of GSK1120212|Determination of the Absolute Bioavailability of GSK1120212 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microdose of GSK1120212 in Subjects With Solid Tumors|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:14:53.507161|2018-05-31 22:14:53.507161
NCT01416324|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-06-19|2011-08-11|2011-08-15|Estimate|||||||2017-06-19|2017-06-20|Actual|June 15, 2011|Actual|2011-06-15|June 2017|2017-06-30|September 9, 2011|Actual|2011-09-09|September 9, 2011|Actual|2011-09-09||Interventional|||First Time in Human Study Using GSK2330672|A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety,Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers|Completed||Phase 1|17|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:14:53.587439|2018-05-31 22:14:53.587439
NCT01416311|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2018-02-20|2011-08-11|2011-08-15|Estimate|||||||2018-02-20|2018-02-22|Actual|December 2010||2010-12-31|February 2018|2018-02-28|October 20, 2020|Anticipated|2020-10-20|October 20, 2020|Anticipated|2020-10-20||Observational|||Drug Use Investigation for REVOLADE (ITP)|Drug Use Investigation for REVOLADE (Chronic Idiopathic Thrombocytopenic Purpura)|Active, not recruiting|||1000|Anticipated|Novartis|||1||f||||f||||||||||2018-05-31 22:14:53.734343|2018-05-31 22:14:53.734343
NCT01416298|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2012-08-01|2011-08-12|2011-08-15|Estimate|||||||2012-08-01|2012-08-02|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI|Use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) to Optimize Fluid Dosing, Continuous Renal Replacement Therapy (CRRT) Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury (AKI)|Unknown status|Recruiting|N/A|100|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-05-31 22:14:53.825719|2018-05-31 22:14:53.825719
NCT01416285|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2016-07-26|2011-08-12|2011-08-15|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2009||2009-06-30|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure|The Impact of Heart Failure Center Program on The Progression of Biomarkers, Changes in Life Quality, Left Ventricular Ejection Fraction, and Cardiac Outcomes in Patients With Congestive Heart Failure|Recruiting|||300|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||Samples Without DNA|"~     At baseline and every 6-month visits, 3 ml of venous blood will be collected. At baseline and~     each 6-month visit, urinary albumin amount will be measured in the core lab in the hospital.~   "|No||2018-05-31 22:14:54.001821|2018-05-31 22:14:54.001821
NCT01416272|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2014-11-18||2014-11-18|2011-08-11|2011-08-15|Estimate|2014-11-18|2014-11-25|Estimate||||2014-11-18|2014-11-25|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses|Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses|Terminated||N/A|12|Actual|Bausch & Lomb Incorporated||1||Study was terminated due to a business decision to cancel the entire project.|f||||f||||||||||2018-05-31 22:14:54.116334|2018-05-31 22:14:54.116334
NCT01416259|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-08-03|2011-08-12|2011-08-15|Estimate|||||||2015-08-03|2015-08-04|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin|A Randomized, Placebo-Controlled, Four-Period Crossover Definitive QT Study Of The Effects of APF530 Exposure, High-Dose IV Granisetron and Moxifloxacin on QTc Prolongation|Completed|||56|Actual|Heron Therapeutics|||1||f||||f||||||||||2018-05-31 22:14:54.247588|2018-05-31 22:14:54.247588
NCT01416246|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2016-04-28|2011-08-11|2011-08-12|Estimate|||||||2016-04-28|2016-04-29|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant|Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant|Completed||N/A|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:14:54.316797|2018-05-31 22:14:54.316797
NCT01416233|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2017-03-08|2011-08-11|2011-08-12|Estimate|||||||2017-03-08|2017-03-09|Actual|September 2010||2010-09-30|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Autologous Fat Augmentation of Orbital Volume Using a Closed Cannula Technique|Autologous Fat Augmentation of Orbital Volume Using a Closed Cannula Technique|Recruiting||N/A|10|Anticipated|Fox, Donald Munro, M.D., P.C.||1|||f||||t||||||||||2018-05-31 22:14:54.39313|2018-05-31 22:14:54.39313
NCT01416220|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2015-02-12|2011-08-11|2011-08-12|Estimate|||||||2015-02-12|2015-02-13|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Lithium Versus Paroxetine in Major Depression|A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide|Completed||Phase 4|2|Actual|Nova Scotia Health Authority||2|||f||||t||||||||||2018-05-31 22:14:54.471173|2018-05-31 22:14:54.471173
NCT01416207|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-11-03|2011-08-11|2011-08-12|Estimate|||||||2011-11-03|2011-11-04|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects|A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects|Completed||Phase 1|24|Actual|Biogen||1|||f||||f||||||||||2018-05-31 22:14:54.54041|2018-05-31 22:14:54.54041
NCT01416194|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2018-03-30|2011-08-11|2011-08-12|Estimate|||||||2018-03-30|2018-04-03|Actual|July 2011|Actual|2011-07-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)|Cohort Study Of Venous Thromboembolism And Other Clinical Endpoints Among Osteoporotic Women Prescribed Bazedoxifene, Bisphosphonates Or Raloxifene In Europe|Active, not recruiting|||1|Actual|Pfizer|||3||f||||f||||||||||2018-05-31 22:14:54.606326|2018-05-31 22:14:54.606326
NCT01416181|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2017-04-13|2016-07-15|2017-08-10|2011-08-11|2011-08-12|Estimate|2017-05-24|2017-06-27|Actual|2016-07-15|2016-07-19|Estimate|2017-08-10|2017-09-11|Actual|September 13, 2011|Actual|2011-09-13|August 2017|2017-08-31|April 13, 2016|Actual|2016-04-13|July 28, 2015|Actual|2015-07-28||Interventional|ASCEND in SPMS|Safety population: all participants who were randomized and received at least 1 infusion of study treatment in Part 1.|A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension|Terminated||Phase 3|889|Actual|Biogen||2||"The ASCEND Study did not achieve statistical significance on the primary or secondary~   endpoints."|f||||t||||||||||2018-05-31 22:14:54.751826|2018-05-31 22:14:54.751826
NCT01416168|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-11-26|2011-08-11|2011-08-12|Estimate|||||||2013-11-26|2013-11-27|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|||Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery|Pilot Study of a Geriatric Intervention After Colorectal and Lung Cancer Surgery|Completed||N/A|15|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 22:14:56.458289|2018-05-31 22:14:56.458289
NCT01416155|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2015-12-10||2015-12-10|2011-08-11|2011-08-12|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis|A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|97|Actual|Biogen||1|||f||||t||||||||||2018-05-31 22:14:56.567589|2018-05-31 22:14:56.567589
NCT01416142|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2013-02-13||2013-11-07|2011-08-11|2011-08-12|Estimate|2013-11-07|2013-12-25|Estimate||||2013-11-07|2013-12-25|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional||All Eligible Baseline Participants|A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens|A Study to Evaluate the Product Performance of the PureVision®2 HD Contact Lens|Completed||N/A|63|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:14:56.86746|2018-05-31 22:14:56.86746
NCT01416129|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2012-10-19||2014-05-06|2011-08-11|2011-08-12|Estimate|2014-05-06|2014-06-02|Estimate||||2014-05-06|2014-06-02|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Southern Bone & Joint Study - Brimless Sockets|Biomechanical Superiority of Brimless Versus Ischial Ramus Containment (IRC) Sub Atmospheric Transfemoral Interfaces|Completed||Phase 3|10|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 22:14:57.15382|2018-05-31 22:14:57.15382
NCT01416116|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2018-04-19|2011-08-11|2011-08-12|Estimate|||||||2018-04-19|2018-04-23|Actual|July 6, 2011|Actual|2011-07-06|April 2018|2018-04-30|April 25, 2012|Actual|2012-04-25|April 25, 2012|Actual|2012-04-25||Interventional|LIFT||Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch|Tolerability of QUTENZATM When Applied After Pre-treatment With Lidocaine or Tramadol in Subjects With Peripheral Neuropathic Pain - A Randomized, Multi-center, Assessor-blinded Study|Completed||Phase 4|122|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 22:14:57.39263|2018-05-31 22:14:57.39263
NCT01416103|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2015-02-18|2011-08-11|2011-08-12|Estimate|||||||2015-02-18|2015-02-19|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Alcohol and Employment|Alcohol and Employment - a Randomized Controlled Trial|Completed||N/A|113|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 22:14:57.525534|2018-05-31 22:14:57.525534
NCT01416090|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-02-17|2011-08-10|2011-08-12|Estimate|||||||2018-02-17|2018-02-20|Actual|July 2004||2004-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Syndactyly Repair: Comparison of Skin Graft and No Skin Graft Techniques|Syndactyly Repair: Comparison of Skin Graft and No Skin Graft Techniques|Active, not recruiting|||30|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 22:14:57.594949|2018-05-31 22:14:57.594949
NCT01416077|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2015-12-01|2011-08-11|2011-08-12|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection|Perioperative Goal Directed Fluid Therapy During Esophageal Resection A Prospective Randomized Controlled Open Multi-centre Trial to Study the Effect on Postoperative Complications|Completed||Phase 4|64|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 22:14:57.658865|2018-05-31 22:14:57.658865
NCT01416064|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08||2013-05-22|2017-04-28|2011-08-11|2011-08-12|Estimate||||2013-05-22|2013-06-05|Estimate|2017-04-28|2017-05-02|Actual|September 2011||2011-09-30|April 2017|2017-04-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Open-Label, Extension Study to 810P202|Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|78|Actual|Supernus Pharmaceuticals, Inc.||1|||f||||f|t|f||||||||2018-05-31 22:14:57.733389|2018-05-31 22:14:57.733389
NCT01416051|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2015-12-17|2011-08-11|2011-08-12|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2005||2005-01-31|December 2015|2015-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy of Olibra: A 12 Week Controlled Trial|Efficacy of Olibra: A 12 Week Randomized Controlled Trial, and Review of Prior Studies|Completed||Phase 1/Phase 2|82|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 22:14:57.838939|2018-05-31 22:14:57.838939
NCT01416038|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-04-20|2011-08-11|2011-08-12|Estimate|||||||2017-04-20|2017-04-21|Actual|December 2011|Actual|2011-12-31|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer|Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer|Completed||Phase 1|19|Actual|ImmunoVaccine Technologies, Inc.||3|||f||||t||||||||No||2018-05-31 22:14:57.915093|2018-05-31 22:14:57.915093
NCT01268462|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2010-12-29|2010-12-29|2010-12-30|Estimate|||||||2010-12-29|2010-12-30|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Use of Heliox Associated With PEEP in Patients With Asthma||Completed||N/A|32|Actual|Universidade Federal de Pernambuco||4|||f||||t||||||||||2018-05-31 23:00:47.625604|2018-05-31 23:00:47.625604
NCT01416025|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2016-04-15||2016-07-18|2011-08-11|2011-08-12|Estimate|2016-04-15|2016-05-23|Estimate||||2016-07-18|2016-08-18|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|VoriTDM||A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing|A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing|Completed||Phase 4|29|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:14:58.010587|2018-05-31 22:14:58.010587
NCT01416012|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2013-04-23|2011-08-11|2011-08-12|Estimate|||||||2013-04-23|2013-04-24|Estimate|October 2011||2011-10-31|June 2011|2011-06-30|September 2013|Anticipated|2013-09-30|October 2011|Actual|2011-10-31||Interventional|||Health Related Quality of Life Effects of Off-the-shelf Computer Gaming in Alzheimer and Related Disorders Populations|Health Related Quality of Life Effects of Off-the-shelf Computer Gaming in Alzheimer and Related Disorders Populations|Unknown status|Recruiting|N/A|180|Anticipated|Centre Hospitalier Universitaire de Nice||4|||f||||f||||||||||2018-05-31 22:14:58.223754|2018-05-31 22:14:58.223754
NCT01415999|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2017-10-24|2011-08-11|2011-08-12|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2011|Actual|2011-08-31|October 2017|2017-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Cardiovascular Function in Adult Survivors of Childhood Malignancies|Novel Imaging and Circulation Biomarkers for Comprehensive Evaluation of Cardiovascular Function in Adult Survivors of Childhood Malignancies|Completed|||142|Actual|The University of Hong Kong|||2||f||||f||||||Samples With DNA|"~     plasma, serum~   "|||2018-05-31 22:14:58.305746|2018-05-31 22:14:58.305746
NCT01415986|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2012-05-11||2012-11-15|2011-08-11|2011-08-12|Estimate|2012-11-15|2012-12-03|Estimate||||2012-11-15|2012-12-03|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers|Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers - PHASE II PILOT STUDY|Terminated||Phase 2|1|Actual|University of Arkansas|Early termination leading to small numbers of subjects analyzed.|1||"The patient was lost to follow-up and the PI left the institution."|f||||f||||||||||2018-05-31 22:14:58.36614|2018-05-31 22:14:58.36614
NCT01415973|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-01-17|2011-08-11|2011-08-12|Estimate|||||||2012-01-17|2012-01-18|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Nutrient Synergy in Beef and Stimulation of Protein Synthesis in Elderly|Nutrient Synergy in Beef and Stimulation of Protein Synthesis in Elderly|Completed||N/A|20|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 22:14:58.501942|2018-05-31 22:14:58.501942
NCT01415960|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2015-07-23||2017-01-19|2011-08-11|2011-08-12|Estimate|2016-11-21|2017-01-18|Estimate||||2017-01-19|2017-03-03|Actual|September 2011||2011-09-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer|Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot Formulation in the Treatment of Prostate Cancer|Completed||Phase 3|163|Actual|GP-Pharm||1|||f||||f||||||||||2018-05-31 22:14:58.575554|2018-05-31 22:14:58.575554
NCT01415947|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2014-12-22|2011-08-11|2011-08-12|Estimate|||||||2014-12-22|2014-12-23|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional|||V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse|V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse|Terminated||Phase 2|5|Actual|Edwards Lifesciences||||Company business decision|f||||||||||||||2018-05-31 22:14:58.797527|2018-05-31 22:14:58.797527
NCT01415934|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2018-04-18|2011-08-11|2011-08-12|Estimate|||||||2018-04-18|2018-04-20|Actual|May 2011||2011-05-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Statin Discontinuation in Advanced Illness|Multisite Randomized Controlled Trial of Continuing vs. Discontinuing Statins|Completed||N/A|380|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 22:14:58.845835|2018-05-31 22:14:58.845835
NCT01415921|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2016-05-20||2017-07-27|2011-08-11|2011-08-12|Estimate|2016-08-31|2016-10-25|Estimate||||2017-07-27|2017-07-31|Actual|October 2011||2011-10-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|APP-HF||Safety Study of Pyridostigmine in Heart Failure|Augmentation of Parasympathetic Signaling With Pyridostigmine in Heart Failure|Completed||Phase 2|33|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 22:14:58.949997|2018-05-31 22:14:58.949997
NCT01415908|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2015-09-25||2016-01-20|2011-08-11|2011-08-12|Estimate|2015-09-25|2015-10-28|Estimate||||2016-01-20|2016-02-18|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|TLIF||INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine|A Prospective, Multi-center, Pivotal Trial for INFUSE® Bone Graft With CAPSTONE® Spinal System and Posterior Supplemental Fixation to Treat 1- or 2-level Advanced Degenerative Disease of the Lumbosacral Spine For a TLIF Approach|Terminated||Phase 3|15|Actual|Medtronic Spinal and Biologics|A total of 534 ± 10 subjects were planned for enrollment. However, this study was terminated early with only 15 enrolled patients, leading to small numbers of subjects analyzed.|2||"Due to study design challenges including DMC enrollment suspension as required by the protocol~   stopping rules and recommended changes to the surgical technique"|f||||t||||||||||2018-05-31 22:14:59.665849|2018-05-31 22:14:59.665849
NCT01415895|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2014-06-24|2011-08-11|2011-08-12|Estimate|||||||2014-06-24|2014-06-25|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy of ATNC05 in Reducing Back Pain Compared With Placebo|ATNC05, A Composition to Reduce Back Pain, A Proof-of-Concept, Randomized, Double-Blind - Placebo Controlled Study|Completed||Phase 2|78|Actual|Allodynic Therapeutics, LLC||2|||f||||t||||||||||2018-05-31 22:15:02.321717|2018-05-31 22:15:02.321717
NCT01415882|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2018-04-12|2011-08-10|2011-08-12|Estimate|||||||2018-04-12|2018-04-13|Actual|February 4, 2016|Actual|2016-02-04|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib|Phase 2 Trial of MLN9708 (Ixazomib) in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib|Recruiting||Phase 2|144|Anticipated|Mayo Clinic||4|||f||||t||||||||||2018-05-31 22:15:02.55251|2018-05-31 22:15:02.55251
NCT01415869|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2014-04-16|2011-08-11|2011-08-12|Estimate|||||||2014-04-16|2014-04-17|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients|Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients|Unknown status|Recruiting||195|Anticipated|Mayo Clinic|||2||f||||f||||||||||2018-05-31 22:15:02.944003|2018-05-31 22:15:02.944003
NCT01414803|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia||Completed||Phase 4|180|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:15:18.723304|2018-05-31 22:15:18.723304
NCT01415856|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-11|2011-08-11|2011-08-12|Estimate|||||||2011-08-11|2011-08-12|Estimate|October 2010||2010-10-31|August 2011|2011-08-31||||May 2012|Anticipated|2012-05-31||Interventional|||Use of Pulsed Electromagnetic Fields for Postoperative Knee Pain|A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Non-Invasive Pulsed Electromagnetic Fields (PEMF) on Postoperative Pain Following Total Knee Arthroplasty|Unknown status|Recruiting|Phase 2|40|Anticipated|Center for Joint Surgery and Sports Medicine, Maryland||2|||f||||t||||||||||2018-05-31 22:15:03.125992|2018-05-31 22:15:03.125992
NCT01415843|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-11|2011-08-11|2011-08-12|Estimate|||||||2011-08-11|2011-08-12|Estimate|January 2010||2010-01-31|July 2009|2009-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Observation of Physiotherapy Treatment Sessions - Exploring What Happens in Physiotherapy for Patients After Stroke.|Do Implicit and Explicit Learning Strategies Applied During Gait Re-education Influence Concurrent Expression of Associated Reactions in Individuals With Hemiplegia? Phase 1a|Completed|||8|Actual|University of Southampton|||||f||||f||||||||||2018-05-31 22:15:03.244418|2018-05-31 22:15:03.244418
NCT01415830|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-02-05|2011-08-11|2011-08-12|Estimate|||||||2013-02-05|2013-02-07|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Compare Two Anti-Scorpion Venom Serum In Children|Randomized Controlled Trial To Evaluate Efficacy And Safety Of The Polyvalent Anti-scorpion Venom Serum Of Birmex Versus Other Commercial Venom Serum In Children Population|Completed||Phase 3|120|Actual|Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.||2|||f||||t||||||||||2018-05-31 22:15:03.302622|2018-05-31 22:15:03.302622
NCT01415817|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-11|2011-08-11|2011-08-12|Estimate|||||||2011-08-11|2011-08-12|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|EQUIP||Endoscopic Quality Improvement Program|"The Effect of an Intensive Endoscopic Quality Improvement Program (EQUIP) on Improved Detection and Classification of Non-polypoid (Flat and Depressed) and Polypoid Colorectal Adenomas. (EQUIP Study)"|Completed||N/A|15|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:15:03.515646|2018-05-31 22:15:03.515646
NCT01415804|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-11|2011-08-11|2011-08-12|Estimate|||||||2011-08-11|2011-08-12|Estimate|February 2002||2002-02-28|March 2011|2011-03-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|INSTEAD||Investigation of Stent-grafts in Aortic Dissection (INSTEAD)|A Randomized Comparison of Strategies for Type B Aortic Dissection - the INvestigation of STEnt-grafts in Aortic Dissection (INSTEAD) Trial|Completed||Phase 2/Phase 3|140|Actual|University of Rostock||2|||f||||t||||||||||2018-05-31 22:15:03.608802|2018-05-31 22:15:03.608802
NCT01415791|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2012-05-29|2011-08-11|2011-08-12|Estimate|||||||2012-05-29|2012-05-30|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Oral Mucosal Absorption of ICI176,334-1|Oral Mucosal Absorption of ICI176,334-1 in Japanese Healthy Male Subjects|Completed||Phase 1|8|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 22:15:03.711194|2018-05-31 22:15:03.711194
NCT01415778|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2012-05-29|2011-08-11|2011-08-12|Estimate|||||||2012-05-29|2012-05-30|Estimate|August 2011||2011-08-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects|Bioequivalence Study of ICI176,334-1 in Japanese Healthy Male Subjects - Evaluation of Bioequivalence of ICI176,334-1 and Casodex 80 mg Tablet -|Completed||Phase 1|48|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 22:15:03.798481|2018-05-31 22:15:03.798481
NCT01415765|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2018-05-19|2011-08-11|2011-08-12|Estimate|||||||2018-05-19|2018-05-22|Actual|July 15, 2011||2011-07-15|January 7, 2014|2014-01-07|January 7, 2014|Actual|2014-01-07|January 7, 2014|Actual|2014-01-07||Interventional|||MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma|Phase I/II Study of MLN4924 Alone Followed by Dose-Adjusted EPOCH-Rituximab + MLN4924 With Gene Expression Profiling and Mutational Analysis in Relapsed/Refractory de Novo Diffuse Large B-Cell Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:15:03.9382|2018-05-31 22:15:03.9382
NCT01415752|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-03-17|2011-08-11|2011-08-12|Estimate|||||||2017-03-17|2017-03-20|Actual|May 2012||2012-05-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma|Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)|Recruiting||Phase 2|332|Anticipated|Eastern Cooperative Oncology Group||8|||f||||t||||||||||2018-05-31 22:15:04.543739|2018-05-31 22:15:04.543739
NCT01415739|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2017-08-07|2011-08-11|2011-08-12|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2011||2011-10-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer|Evaluation of a Novel Molecular NSCLC Classification System|Active, not recruiting|||261|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-05-31 22:15:06.157296|2018-05-31 22:15:06.157296
NCT01415726|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-02-16|2011-08-11|2011-08-12|Estimate|||||||2012-02-16|2012-02-17|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Stem Cell Educator Therapy in Type 2 Diabetes||Completed||Phase 1/Phase 2|25|Actual|University of Illinois at Chicago||2|||f||||||||||||||2018-05-31 22:15:06.307107|2018-05-31 22:15:06.307107
NCT01415713|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-05-03|2011-08-11|2011-08-12|Estimate|||||||2016-05-03|2016-05-04|Estimate|March 2012||2012-03-31|June 2011|2011-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Study of Metastatic Pancreatic Adenocarcinoma|Phase I/II Trial of Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in Metastatic Pancreatic Adenocarcinoma|Completed||Phase 1/Phase 2|73|Actual|National Health Research Institutes, Taiwan||1|||f||||t||||||||Undecided||2018-05-31 22:15:06.414518|2018-05-31 22:15:06.414518
NCT01415700|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2014-07-25|2011-08-11|2011-08-12|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|STEPSTIM||Comparison Between Implanted Functional Electrical Stimulation and Foot Orthosis|Implanted Functional Electrical Stimulation of the Levators of the Ankle Versus Orthosis in the Treatment of Chronic Foot Neurological STEPPAGE-gait by Central Attack|Completed||N/A|27|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 22:15:06.519709|2018-05-31 22:15:06.519709
NCT01414257|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-09-25|2011-08-09|2011-08-11|Estimate|||||||2015-09-25|2015-09-28|Estimate|May 2011||2011-05-31|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)|Rheumatrex High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)|Completed|||2882|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:15:23.61953|2018-05-31 22:15:23.61953
NCT01415687|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2012-05-30|2011-08-11|2011-08-12|Estimate|||||||2012-05-30|2012-05-31|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|BP||Split Dose Pico-Salax + Bisacodyl vs. PEG Split Dose|A Randomized Prospective Trial Comparing Pico-Salax (Magnesium Citrate) Plus Bisacodyl Versus Split Dose Polyethylene Glycol-Based Lavage In Preparation Of Patients For Colonoscopy|Completed||Phase 3|171|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 22:15:06.606988|2018-05-31 22:15:06.606988
NCT01415674|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-08-31|2011-08-11|2011-08-12|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|July 2015|Actual|2015-07-31||Interventional|PREDICTOR||Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients|Multi-centric Randomized Phase II Study of Pre-operative Afatinib (BIBW2992) Aiming at Identifying Predictive and Pharmacodynamic Biomarkers of Biological Activity and Efficacy in Untreated Non-metastatic Head and Neck Squamous Cell Carcinoma Patients|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|UNICANCER||2|||f||||f||||||||||2018-05-31 22:15:06.714384|2018-05-31 22:15:06.714384
NCT01415661|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2012-04-07|2011-08-11|2011-08-12|Estimate|||||||2012-04-07|2012-04-10|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|CP||Efficacy of Cricoid Pressure in Occluding the Esophageal Entrance: A Glidescope ® Study|Efficacy of Cricoid Pressure in Occluding the Esophageal Entrance: A Glidescope ® Study|Completed||N/A|89|Actual|Procare Riaya Hospital||2|||f||||f||||||||||2018-05-31 22:15:06.893905|2018-05-31 22:15:06.893905
NCT01415648|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-08-26|2011-08-11|2011-08-12|Estimate|||||||2016-08-26|2016-08-29|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|EMOCAR||Medico-economic Evaluation of Preoperative Cerebral Oximetry Monitoring During Carotid Endarterectomy|Medico-economic Evaluation of Preoperative Cerebral Oximetry Monitoring During Carotid Endarterectomy.|Terminated||Phase 3|879|Actual|Nantes University Hospital||2||Recruitment time expired.|f||||f||||||||||2018-05-31 22:15:06.984958|2018-05-31 22:15:06.984958
NCT01415635|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-12-12|2011-08-11|2011-08-12|Estimate|||||||2012-12-12|2012-12-13|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|DHH||Fortified Hospital Food as Nutritional Support|Positive Effect of Fortified Hospital Food on Nutritional Intake in Patients at Nutritional Risk. A Randomized Controlled Trial.|Completed||N/A|84|Actual|Copenhagen University Hospital at Herlev||1|||f||||t||||||||||2018-05-31 22:15:07.107555|2018-05-31 22:15:07.107555
NCT01415622|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2012-11-16|2011-08-11|2011-08-12|Estimate|||||||2012-11-16|2012-11-19|Estimate|April 2011||2011-04-30|August 2011|2011-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Feasibility, Efficacy, and Safety of Venous Ulcer Treatment Using a Hand Plasma Generator (PlasmaDerm) Chronisch venöser Ulzerationen (PlasmaDerm)||Completed||N/A|30|Actual|Cinogy GmbH||2|||f||||t||||||||||2018-05-31 22:15:07.192102|2018-05-31 22:15:07.192102
NCT01415609|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-11-07|2011-08-11|2011-08-12|Estimate|||||||2012-11-07|2012-11-09|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|ESD Registry||Endoscopic Submucosal Dissection Registry|Establishment of Registry for Endoscopic Submucosal Dissection for Superficial Gastrointestinal Neoplasia|Completed|||17|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:15:07.294565|2018-05-31 22:15:07.294565
NCT01415596|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2011-08-11|2011-08-11|2011-08-12|Estimate|||||||2011-08-11|2011-08-12|Estimate|August 2011||2011-08-31|March 2011|2011-03-31|August 2013|Anticipated|2013-08-31|August 2012|Anticipated|2012-08-31||Interventional|||The Effect of High Dose Salbutamol on Muscle Performance|The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males|Unknown status|Active, not recruiting|N/A|20|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 22:15:07.361912|2018-05-31 22:15:07.361912
NCT01415583|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2016-12-14||2017-06-12|2011-08-10|2011-08-12|Estimate|2017-06-12|2017-07-12|Actual||||2017-06-12|2017-07-12|Actual|July 2010|Actual|2010-07-31|June 2017|2017-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy|Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy|Completed||N/A|314|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||No||2018-05-31 22:15:07.447806|2018-05-31 22:15:07.447806
NCT01415570|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-05-20|2011-08-11|2011-08-12|Estimate|||||||2015-05-20|2015-05-21|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Observational|MADRAD||Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD)|Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD) - A Prospective Data Collection Study|Unknown status|Recruiting||1050|Anticipated|Los Angeles Biomedical Research Institute|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 22:15:07.627741|2018-05-31 22:15:07.627741
NCT01415557|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2013-11-05|2011-08-11|2011-08-12|Estimate|||||||2013-11-05|2013-11-07|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Effect of Regular Consumption of Micronutrient Fortified Beverage on the Micronutrient Status of Indian Schoolchildren|The Effects of Regular Consumption of a Multiple Micronutrient Fortified Beverage on the Micronutrient Status of Indian Schoolchildren and on Their Mental and Physical Performance|Completed||N/A|227|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-05-31 22:15:07.69873|2018-05-31 22:15:07.69873
NCT01415544|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-02-23|2011-08-10|2011-08-12|Estimate|||||||2012-02-23|2012-02-27|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References|An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References|Unknown status|Active, not recruiting||100|Anticipated|InLight Solutions|||4||f||||f||||||None Retained|"~     capillary glucose measurements~   "|||2018-05-31 22:15:07.86228|2018-05-31 22:15:07.86228
NCT01415531|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2013-03-18||2013-03-18|2011-08-11|2011-08-12|Estimate|2013-03-18|2013-05-16|Estimate||||2013-03-18|2013-05-16|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years) Who Have Stage 1 or 2 Essential Hypertension|Completed||Phase 4|641|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 22:15:07.994457|2018-05-31 22:15:07.994457
NCT01415349|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2012-06-01||2014-06-06|2011-08-10|2011-08-11|Estimate|2012-06-01|2012-07-06|Estimate||||2014-06-06|2014-06-13|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||SSP-002358 Drug Interaction Study With Omeprazole|A Phase 1, Open-label, Randomized, 2-period Crossover Drug Interaction Study in Healthy Adult Subjects to Evaluate the Effect of the Proton Pump Inhibitor Omeprazole on the Pharmacokinetics of SSP-002358|Completed||Phase 1|42|Actual|Shire||2|||f||||||||||||||2018-05-31 22:15:12.705365|2018-05-31 22:15:12.705365
NCT01415518|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2013-11-25||2014-08-11|2011-08-11|2011-08-12|Estimate|2014-08-11|2014-08-26|Estimate||||2014-08-11|2014-08-26|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SECURE2|Two patients in 'Symbicort Turbuhaler + ipratropium + theophylline' group did not receive study treatment and were excluded from the analysis popolation. Thus the number of patients in that group is 290 (= 290 - 2).|Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients|Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.|Completed||Phase 4|581|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:15:08.455202|2018-05-31 22:15:08.455202
NCT01415505|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-05-31|2011-08-11|2011-08-12|Estimate|||||||2013-05-31|2013-06-04|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension|A Multicenter, Open-Label, Single-Arm, Free Tablet Combination, Long-Term Study to Evaluate the Safety of Nebivolol in Combination With Valsartan in Patients With Stage 1 or Stage 2 Essential Hypertension|Completed||Phase 3|812|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 22:15:09.253314|2018-05-31 22:15:09.253314
NCT01415492|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2014-12-30|2011-08-11|2011-08-12|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|HD2||Multiple Risk Behavior Intervention in Health Care Settings|Multiple Risk Behavior Intervention in Health Care Settings|Completed||N/A|2440|Actual|Dana-Farber Cancer Institute||3|||f||||f||||||||||2018-05-31 22:15:09.499228|2018-05-31 22:15:09.499228
NCT01415479|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-04-29|2011-08-11|2011-08-12|Estimate|||||||2013-04-29|2013-04-30|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer Screening|Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer Screening|Completed||N/A|212|Anticipated|Indiana University||4|||f||||f||||||||||2018-05-31 22:15:09.566591|2018-05-31 22:15:09.566591
NCT01415466|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-04-02|2011-08-10|2011-08-12|Estimate|||||||2012-04-02|2012-04-04|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and CS-866 in Healthy Male Volunteers|A Randomized, Open Label, Multiple-Dose, Cross-over Clinical Study to Investigate Pharmacokinetics and Drug-Drug Interaction Between Rosuvastatin and CS-866 in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Daewoong Pharmaceutical Co. LTD.||3|||f||||f||||||||||2018-05-31 22:15:09.698309|2018-05-31 22:15:09.698309
NCT01415453|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2012-06-21||2013-03-01|2011-08-10|2011-08-12|Estimate|2013-03-01|2013-04-05|Estimate||||2013-03-01|2013-04-05|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evoked Retinal Response|Evoked Visual Response Using Pulsed Ultrasound|Terminated||N/A|1|Actual|Columbia University|Difficulty in recruiting appropriate volunteers. Study terminated due to poor enrollment.|1||Poor enrollment.|f||||f||||||||||2018-05-31 22:15:09.788185|2018-05-31 22:15:09.788185
NCT01415440|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-03-30|2011-08-11|2011-08-12|Estimate|||||||2018-03-30|2018-04-02|Actual|July 2011||2011-07-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD|Examining the Effects of Stimulant Medication on Emotional Lability in Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Recruiting||N/A|100|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 22:15:09.928378|2018-05-31 22:15:09.928378
NCT01415427|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2017-04-13||2017-04-13|2011-08-11|2011-08-12|Estimate|2017-04-13|2017-05-19|Actual||||2017-04-13|2017-05-19|Actual|July 2011||2011-07-31|April 2017|2017-04-30|June 16, 2016|Actual|2016-06-16|June 16, 2016|Actual|2016-06-16||Interventional|||Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|Completed||Phase 3|173|Actual|BioMarin Pharmaceutical||2|||f||||t||||||||||2018-05-31 22:15:10.088857|2018-05-31 22:15:10.088857
NCT01415414|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-01-19|2011-08-11|2011-08-12|Estimate|||||||2015-01-19|2015-01-21|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Observational|INDEX||Observational Study of Ultravist in Patients Requiring CECT|The Image Quality and Radiation Dose of CECT With Ultravist® in Patients With Abdominal Pelvic Disease - INDEX|Completed|||11660|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:15:12.211535|2018-05-31 22:15:12.211535
NCT01415401|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2014-05-30||2014-05-30|2011-08-11|2011-08-12|Estimate|2014-05-30|2014-07-01|Estimate||||2014-05-30|2014-07-01|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||This analysis population includes all participants who received study medication.|Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada|Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Canada|Completed||Phase 4|57|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:15:12.276454|2018-05-31 22:15:12.276454
NCT01415388|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-02-20|2011-08-11|2011-08-12|Estimate|||||||2013-02-20|2013-02-21|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Investigate the Effects of Krill Oil on Fasting Serum Triglycerides|A Double-blind, Randomized, Multi-centre, Placebo-controlled Study to Investigate the Effects of Superba(TM) Krill Oil on Fasting Serum Triglycerides|Completed||N/A|300|Actual|Aker Biomarine Antarctic AS|||||f||||t||||||||||2018-05-31 22:15:12.471448|2018-05-31 22:15:12.471448
NCT01415375|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-04-16|2011-08-10|2011-08-11|Estimate|||||||2015-04-16|2015-04-17|Estimate|September 2004||2004-09-30|April 2015|2015-04-30|July 2009|Actual|2009-07-31|July 2007|Actual|2007-07-31||Interventional|||Prostate Cancer Education in African American Men|Prostate Cancer Education in African American Men|Completed||Phase 2/Phase 3|490|Actual|Temple University||2|||f||||t||||||||||2018-05-31 22:15:12.534587|2018-05-31 22:15:12.534587
NCT01415362|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-03-17|2011-08-10|2011-08-11|Estimate|||||||2017-03-17|2017-03-21|Actual|July 2011||2011-07-31|March 2017|2017-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Closed-loop System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy|Development of a Closed-loop Detect-and-treat System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy|Completed||N/A|6|Actual|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 22:15:12.616866|2018-05-31 22:15:12.616866
NCT01249053|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|August 2010||2010-08-31|November 2010|2010-11-30||||||||Observational|||Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma||Unknown status|Recruiting||100|Anticipated|China Medical University Hospital|||||f||||f||||||||||2018-05-31 23:06:47.778464|2018-05-31 23:06:47.778464
NCT01415336|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|March 2010||2010-03-31|August 2011|2011-08-31||||March 2013|Anticipated|2013-03-31||Interventional|||AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer|AX (Doxorubicin, Capecitabine) Versus AC (Doxorubicin, Cyclophosphamide) as Adjuvant Treatment for Node-Negative Breast Cancer|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 22:15:12.918119|2018-05-31 22:15:12.918119
NCT01415323|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-11-21|2011-08-10|2011-08-11|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Agitation in the Acute Psychiatric Department|Agitation in the Acute Psychiatric Department|Completed|||384|Actual|Norwegian University of Science and Technology|||1||f||||t||||||Samples With DNA|"~     Blood samples are collected for storage and analyses both at admittance and discharge from~     the psychiatric acute department.~   "|||2018-05-31 22:15:12.995363|2018-05-31 22:15:12.995363
NCT01415310|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2016-10-03|2011-08-10|2011-08-11|Estimate|||||||2016-10-03|2016-10-04|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|KVALAP||Quality Register for Geriatric Psychiatry|Quality Register for Geriatric Psychiatry in Viken Research Network for Geriatric Psychiatry|Active, not recruiting|||19000|Anticipated|Norwegian Centre for Ageing and Health|||1||f||||f||||||||||2018-05-31 22:15:13.074149|2018-05-31 22:15:13.074149
NCT01415297|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-05-18|2011-08-10|2011-08-11|Estimate|||||||2017-05-18|2017-05-19|Actual|October 2009|Actual|2009-10-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|May 2012|Actual|2012-05-31||Interventional|||Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors|A Phase I Dose Escalation Study of NKP-1339 Administered on Days 1, 8 and 15 of Each 28-Day Cycle in Patients With Advanced Solid Tumors Refractory to Treatment|Completed||Phase 1|46|Actual|Intezyne Technologies, Inc.||1|||f||||f||||||||Undecided||2018-05-31 22:15:13.139629|2018-05-31 22:15:13.139629
NCT01415284|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-02-12|2011-08-10|2011-08-11|Estimate|||||||2013-02-12|2013-02-15|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia|ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia|Unknown status|Recruiting|Phase 4|30|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||||2018-05-31 22:15:13.201549|2018-05-31 22:15:13.201549
NCT01415271|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-08-10|2011-08-10|2011-08-11|Estimate|||||||2015-08-10|2015-08-13|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||3-Month Trial Observation of A1c Change|Assessment of an Internet Blood Glucose Management Program in a Chronic Care Hospital|Terminated||N/A|10|Actual|Endocrine Research Society||1||Preliminary exploration of research concept did not prove to be viable.|f||||f||||||||||2018-05-31 22:15:13.278332|2018-05-31 22:15:13.278332
NCT01415258|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-05-15|2011-08-10|2011-08-11|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Observational|||Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre|Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre|Completed|||209|Actual|Centre Oscar Lambret|||||f||||f||||||||||2018-05-31 22:15:13.347551|2018-05-31 22:15:13.347551
NCT01415245|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2014-05-18|2011-08-10|2011-08-11|Estimate|||||||2014-05-18|2014-05-20|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|VEST||Vein External Support Trial|Vein External Support Trial|Completed||N/A|30|Actual|Vascular Graft Solutions Ltd.||2|||f||||t||||||||||2018-05-31 22:15:13.403846|2018-05-31 22:15:13.403846
NCT01415232|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2013-02-01||2017-09-27|2011-08-10|2011-08-11|Estimate|2013-03-19|2013-05-03|Estimate||||2017-09-27|2017-10-30|Actual|August 2010||2010-08-31|September 2017|2017-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Novel Way to Estimate Epidural Depth in Morbidly Obese Parturient|The Use of Ultrasound With the Epidural Depth Equation (EQ-US) to Estimate Epidural Depth (Est-D) in Morbidly Obese Parturients (BMI>40Kg/m2) Will Have a High Correlation With Actual Epidural Needle Depth (ND)|Completed||N/A|160|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:15:13.477172|2018-05-31 22:15:13.477172
NCT01415219|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2014-12-17|2011-08-10|2011-08-11|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis|Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis|Completed||Phase 2|80|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 22:15:13.634195|2018-05-31 22:15:13.634195
NCT01415206|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-05-05|2011-08-10|2011-08-11|Estimate|||||||2015-05-05|2015-05-07|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|April 2013|Actual|2013-04-30||Interventional|||The Total Health Study|Extended Care Treatment of Multiple Risk Behaviors in Complex Patients|Unknown status|Active, not recruiting|N/A|250|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:15:13.740615|2018-05-31 22:15:13.740615
NCT01415193|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-03-17|2011-08-10|2011-08-11|Estimate|||||||2015-03-17|2015-03-18|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Tibial Nerve Versus Sciatic Nerve Block|Selective Tibial Nerve Block vs Popliteal Sciatic Nerve Block in Patients Having Total Knee Arthroplasty|Completed||N/A|80|Actual|Saint Francis Care||2|||f||||f||||||||||2018-05-31 22:15:13.961724|2018-05-31 22:15:13.961724
NCT01415180|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-05-24|2011-08-10|2011-08-11|Estimate|||||||2013-05-24|2013-05-27|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|LAPSE||Life After Pediatric Sepsis Evaluation|Life After Pediatric Sepsis Evaluation|Withdrawn|||0|Actual|Seattle Children's Hospital|||2|No funding|f||||f||||||||||2018-05-31 22:15:14.020902|2018-05-31 22:15:14.020902
NCT01415167|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-02-10|2011-08-10|2011-08-11|Estimate|||||||2017-02-10|2017-02-14|Actual|August 2011||2011-08-31|February 2017|2017-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy|Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy|Recruiting|||2500|Anticipated|Prometheus Laboratories|||||f||||f||||||||||2018-05-31 22:15:14.12545|2018-05-31 22:15:14.12545
NCT01415154|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-11-11|2011-08-10|2011-08-11|Estimate|||||||2015-11-11|2015-11-13|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|September 2013|Actual|2013-09-30||Interventional|||Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder|A 12-Month Prospective Randomized Dual-Arm Pilot Study of Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients With Major Depressive Disorder|Completed||N/A|67|Actual|Neuronetics||2|||f||||f||||||||||2018-05-31 22:15:14.291937|2018-05-31 22:15:14.291937
NCT01415141|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2017-05-05|2011-08-10|2011-08-11|Estimate|||||||2017-05-05|2017-05-09|Actual|July 2011|Actual|2011-07-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism|A Randomized Trial of Telaprevir, Peginterferon, and Ribavirin Versus Peginterferon and Ribavirin for Treatment of Genotype 1 Hepatitis C Virus With Host Interleukin 28B CC Polymorphism|Withdrawn||Phase 4|0|Actual|University of Vermont||2||Lack of funding|f||||f||||||||||2018-05-31 22:15:14.432357|2018-05-31 22:15:14.432357
NCT01415128|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Compare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects|A PHASE I, SINGLE-CENTER, OPEN-LABEL, CROSSOVER STUDY OF THE EFFECT OF AVANAFIL ON THE PHARMACOKINETICS OF OMEPRAZOLE, DESIPRAMINE AND ROSIGLITAZONE IN HEALTHY MALE SUBJECTS|Completed||Phase 1|60|Actual|VIVUS, Inc.||3|||f||||f||||||||||2018-05-31 22:15:14.547753|2018-05-31 22:15:14.547753
NCT01415115|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|March 2007||2007-03-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|MARC||Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications|A Cross-Sectional Study to Test the Feasibility of Using SCOUT Noninvasive AGE Measurements to Forecast Diabetes Complications|Completed|||250|Actual|VeraLight, Inc.|||2||f||||f||||||None Retained|"~     Blood samples will be drawn for laboratory-based quantification of HbA1c and lipids. Urine~     samples will be collected to determine urine creatinine and microalbumin~   "|||2018-05-31 22:15:14.634195|2018-05-31 22:15:14.634195
NCT01415102|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-08-12|2011-08-10|2011-08-11|Estimate|||||||2011-08-12|2011-08-15|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.|A Double Blind (3rd Party Open), Randomised, Placebo-Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Single Inhaled Doses Of Pf-05212372 In Healthy Subjects|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:15:14.711522|2018-05-31 22:15:14.711522
NCT01415089|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-06-15|2011-08-10|2011-08-11|Estimate|||||||2015-06-15|2015-06-16|Estimate|May 2009||2009-05-31|October 2013|2013-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|FOCUS-WEB||Tailored Web-Based Intervention for Cancer Patients and Family Caregivers|Tailored Web-Based Intervention for Cancer Patients and Family Caregivers|Completed||N/A|63|Actual|University of Michigan|||||f||||t||||||||||2018-05-31 22:15:14.800219|2018-05-31 22:15:14.800219
NCT01415076|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-09-03|2011-08-10|2011-08-11|Estimate|||||||2012-09-03|2012-09-05|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Optimal Timing of Carbon Dioxide Insufflation During Colonoscopy in Unsedated Patients|The Optimal Timing of Carbon Dioxide Insufflation During Colonoscopy in Unsedated Patients|Completed||N/A|200|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 22:15:14.895102|2018-05-31 22:15:14.895102
NCT01415063|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma|Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|120|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:15:14.993292|2018-05-31 22:15:14.993292
NCT01415050|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women|Multicentered, Randomized Study of Safety and Efficacy of Whole-body Vibration as add-on to Standard Pharmacological Treatment of Osteoporosis in Post-menopausal Women|Completed||Phase 2|80|Anticipated|X-pert Med GmbH||2|||f||||t||||||||||2018-05-31 22:15:15.094871|2018-05-31 22:15:15.094871
NCT01415037|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-05-17|2011-08-10|2011-08-11|Estimate|||||||2016-05-17|2016-05-18|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Annular Array Ultrasound in Ophthalmology|High-frequency-ultrasound Annular Arrays for Ophthalmic Imaging|Unknown status|Enrolling by invitation||30|Anticipated|Columbia University|||1||f||||f||||||||||2018-05-31 22:15:15.194281|2018-05-31 22:15:15.194281
NCT01415024|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|May 2011||2011-05-31|August 2011|2011-08-31||||May 2012|Anticipated|2012-05-31||Interventional|CRTICD Dual LV||Resynchronization in Paced Heart Failure Patients With Implantable Cardioverter Defibrillator (ICD) Indication|Resynchronization in Paced Heart Failure Patients With ICD Indication|Unknown status|Recruiting|Phase 4|30|Anticipated|Schuechtermann-Klinik|||||f||||f||||||||||2018-05-31 22:15:15.265573|2018-05-31 22:15:15.265573
NCT01415011|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-05-09|2011-08-10|2011-08-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 2012||2012-12-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|August 2015|Actual|2015-08-31||Interventional|TIMELY||Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients|Trial of Afatinib (BIBW 2992) in Suspected or Confirmed Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy|Active, not recruiting||Phase 2|37|Anticipated|University College, London||1|||f||||t||||||||||2018-05-31 22:15:15.333653|2018-05-31 22:15:15.333653
NCT01414998|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2013-03-19|2011-08-10|2011-08-11|Estimate|||||||2013-03-19|2013-03-20|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SenRep||Sensorimotor Replacement With Electronic and De-nicotinised Cigarettes|The Effect of Non-nicotine Sensorimotor Replacement on Withdrawal and Craving: Studies With Electronic and De-nicotinised Cigarettes|Completed||N/A|120|Anticipated|Queen Mary University of London||4|||f||||f||||||||||2018-05-31 22:15:15.415856|2018-05-31 22:15:15.415856
NCT01414985|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2018-01-08|2011-08-10|2011-08-11|Estimate|||||||2018-01-08|2018-01-09|Actual|April 15, 2010|Actual|2010-04-15|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis|Direct CNS Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human CLN2 cDNA to Children With LINCL With Uncommon Genotypes and/or Moderate to Severe Impairment|Active, not recruiting||Phase 1/Phase 2|8|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||Undecided||2018-05-31 22:15:15.476769|2018-05-31 22:15:15.476769
NCT01184950|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-18|2010-08-18|2010-08-19|Estimate|||||||2010-08-18|2010-08-19|Estimate||||August 2010|2010-08-31||||||||Interventional|||Virtual Reality Laparoscopy Training|Prospective Randomized Trial of Virtual Reality Simulator Training in an Obstetrics and Gynecology Residency|Completed||N/A|||TriHealth Inc.||2|||f||||f||||||||||2018-05-31 23:27:19.785472|2018-05-31 23:27:19.785472
NCT01414972|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|November 2011|Anticipated|2011-11-30|January 2011|Actual|2011-01-31||Interventional|||The Effect of Vitamin A on Atherosclerosis|The Effect of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by T CD4+ Lymphocyte in Atherosclerotic Patients|Unknown status|Enrolling by invitation|Phase 4|45|Actual|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-05-31 22:15:15.560678|2018-05-31 22:15:15.560678
NCT01414959|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2017-08-28|2011-08-10|2011-08-11|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2011||2011-08-31|August 2017|2017-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients|Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients|Completed|||16|Actual|Medical University of Vienna|||||f||||f||||||Samples Without DNA|"~     plasma broncheoalvoeolar lavage microdialysates~   "|||2018-05-31 22:15:15.724455|2018-05-31 22:15:15.724455
NCT01414946|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|November 2009||2009-11-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||The Effect of Intravenous Nutrition in Patients Undergoing Abdominal Surgery|THE PROTEIN SPARING EFFECT OF PERIOPERATIVE NUTRITION: How Important is the Patient's Catabolic State Before Surgery and do we Need Glucose?|Completed||N/A|40|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:15:15.776661|2018-05-31 22:15:15.776661
NCT01414933|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-05-03|2011-08-10|2011-08-11|Estimate|||||||2017-05-03|2017-05-04|Actual|May 2011||2011-05-31|May 2017|2017-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|SAFIR-01||High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents|High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents|Completed|||423|Actual|UNICANCER|||||f||||t||||||Samples With DNA|"~     Metastasis biopsy and DNA from biopsy~   "|||2018-05-31 22:15:15.840917|2018-05-31 22:15:15.840917
NCT01414920|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10||2016-03-04|2016-03-04|2011-08-10|2011-08-11|Estimate||||2016-03-04|2016-04-04|Estimate|2016-03-04|2016-04-04|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Placebo-Controlled, Factorial, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of 25 mg and 50 mg of TAK-875 in Combination With Sitagliptin 100 mg in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|368|Actual|Takeda||6|||f||||f||||||||||2018-05-31 22:15:15.937527|2018-05-31 22:15:15.937527
NCT01414907|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-06-04|2011-08-10|2011-08-11|Estimate|||||||2017-06-04|2017-06-06|Actual|October 2010|Actual|2010-10-31|June 2017|2017-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|VIP||Study of Effectiveness of Adding the Health Promotion and Rehabilitation for Treatment for Alcohol and Drug Abusers|VIP (Very Important Patient) Project on Alcohol and Drug Abusers - RCT of Efficacy of the Adding the Health Promotion and Rehabilitation for Treatment of Alcohol and Drug Abusers|Completed||N/A|214|Actual|Skane University Hospital||2|||f||||f||||||||||2018-05-31 22:15:16.10501|2018-05-31 22:15:16.10501
NCT01414894|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2013-06-18|2011-08-10|2011-08-11|Estimate|||||||2013-06-18|2013-06-20|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|IMPROVES||Intensive Management of Pressure and Volume Expansion in Patients With Subarachnoid Hemorrhage|Intensive Management of Pressure and Volume Expansion in Patients With Subarachnoid Hemorrhage|Completed||Phase 1|20|Actual|University of Washington||4|||f||||f||||||||||2018-05-31 22:15:16.198376|2018-05-31 22:15:16.198376
NCT01414881|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2016-08-01|2011-08-10|2011-08-11|Estimate|||||||2016-08-01|2016-08-03|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects|A Phase 1 Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects|Completed||Phase 1|20|Actual|Kastle Therapeutics, LLC||2|||f||||f||||||||||2018-05-31 22:15:16.257862|2018-05-31 22:15:16.257862
NCT01414868|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-17|2011-08-10|2011-08-11|Estimate|||||||2011-08-17|2011-08-18|Estimate|March 2010||2010-03-31|December 2009|2009-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Leukotriene D4 Bronchial Provocation Test (LTD4-BPT) as an Indicator for the Use of Leukotriene Receptor Antagonist (LTRA)|Could Leukotriene D4 Bronchial Provocation Test be a Clear Indicator for Predicting Therapeutic Outcomes of Leukotriene Receptor Antagonist A Pilot Study|Completed||N/A|32|Actual|Guangzhou Institute of Respiratory Disease|||||f||||f||||||||||2018-05-31 22:15:16.319025|2018-05-31 22:15:16.319025
NCT01414855|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2015-02-05||2018-04-24|2011-08-10|2011-08-11|Estimate|2015-03-17|2015-03-19|Estimate||||2018-04-24|2018-04-25|Actual|August 31, 2011|Actual|2011-08-31|April 2018|2018-04-30|December 23, 2016|Actual|2016-12-23|December 31, 2013|Actual|2013-12-31||Interventional|||A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)|A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy|Completed||Phase 2|100|Actual|Genentech, Inc.||1|||f||||t||||||||||2018-05-31 22:15:16.401461|2018-05-31 22:15:16.401461
NCT01414842|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-26|2011-08-10|2011-08-11|Estimate|||||||2011-08-26|2011-08-29|Estimate|April 2007||2007-04-30|January 2007|2007-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|AIMS||HFR A-equilibrium on Cardiovascular Stability|Randomized Controlled Study on the Effect of the Hemodiafiltration Plasma Sodium Biofeedback System on Cardiovascular Stability in Hemodialysis Patients|Completed||Phase 4|50|Actual|Azienda Ospedaliera di Lecco||2|||f||||f||||||||||2018-05-31 22:15:18.262429|2018-05-31 22:15:18.262429
NCT01414829|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2012-12-02|2011-08-10|2011-08-11|Estimate|||||||2012-12-02|2012-12-04|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|January 2012||2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Efficacy of Gastric Biopsy for Culture and Antibiotic Sensitivity Assessment|Efficacy of Gastric Biopsy for Culture and Antibiotic Sensitivity Assessment and Comparing of Different Methods for Helicobacter Pylori Disclosure|Withdrawn|||0|Actual|The Baruch Padeh Medical Center, Poriya||||difficulty in recruiting parients|f||||f||||||Samples Without DNA|"~     gastric biopsies~   "|||2018-05-31 22:15:18.399699|2018-05-31 22:15:18.399699
NCT01414816|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-08-20|2011-08-10|2011-08-11|Estimate|||||||2014-08-20|2014-08-21|Estimate|April 2008||2008-04-30|August 2014|2014-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Betaferon® Regulatory Post-Marketing Surveillance|Betaferon® Regulatory Post-Marketing Surveillance|Completed|||355|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:15:18.601498|2018-05-31 22:15:18.601498
NCT01266382|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate||||July 2009|2009-07-31||||||||Interventional|||The Effect of AposTherapy on the Level of Pain, Function and Quality of Life in Patients With Neuro-muscular and Neurological Disorders||Unknown status|Recruiting|N/A|||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-05-31 23:01:10.616468|2018-05-31 23:01:10.616468
NCT01414790|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|January 2004||2004-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome|The Use of Human Acellular Dermal Matrix in the Prevention of Infraauricular Depressed Deformities and Frey's Syndrome Following Total Parotidectomy|Completed||Phase 3|70|Actual|West China Hospital||2|||f||||t||||||||||2018-05-31 22:15:18.88062|2018-05-31 22:15:18.88062
NCT01414777|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|November 2009||2009-11-30|August 2011|2011-08-31||||||||Interventional|||Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients|IRB-HSR# 14583: Intravenous Ondansetron to Attenuate the Hypotensive, Bradycardic Response to Spinal Anesthesia in Healthy Parturients|Unknown status|Enrolling by invitation|Phase 2/Phase 3|68|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 22:15:18.98534|2018-05-31 22:15:18.98534
NCT01414764|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-12-07|2011-08-10|2011-08-11|Estimate|||||||2014-12-07|2014-12-09|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Interventional|||Does Autologous Conditioned Plasma Enhance Rotator Cuff Tendon Healing After Surgery?|Does Autologous Conditioned Plasma Enhance Rotator Cuff Tendon Healing After Surgery? A Radomized Control Trial.|Unknown status|Enrolling by invitation|Phase 3|60|Anticipated|The University of Western Australia||2|||f||||t||||||||||2018-05-31 22:15:19.139861|2018-05-31 22:15:19.139861
NCT01414751|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-01-09|2011-08-10|2011-08-11|Estimate|||||||2013-01-09|2013-01-10|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|August 2013|Anticipated|2013-08-31|June 2011|Actual|2011-06-30||Interventional|IMPACT||Influence of Intervention Methodologies on Patient Choice of Therapy|Interventions for Chronic Diseases: Effect of Patient Values and Effectiveness Information on Patients' Choice of Therapy, Adherence to Therapy and Satisfaction With Therapy|Unknown status|Active, not recruiting|N/A|248|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 22:15:19.258931|2018-05-31 22:15:19.258931
NCT01414738|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-01-22|2011-08-10|2011-08-11|Estimate|||||||2018-01-22|2018-01-23|Actual|October 18, 2011|Actual|2011-10-18|January 2018|2018-01-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases|Phase II Trial of Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases|Active, not recruiting||Phase 2|50|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 22:15:19.438927|2018-05-31 22:15:19.438927
NCT01414725|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-03-21|2011-08-10|2011-08-11|Estimate|||||||2014-03-21|2014-03-24|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Core Stability Training in Multiple Sclerosis|Core Stability Training in Ambulant Individuals With Multiple Sclerosis: a Multi-centre Randomised Controlled Trial.|Completed||N/A|100|Actual|University of Plymouth||3|||f||||t||||||||||2018-05-31 22:15:19.535467|2018-05-31 22:15:19.535467
NCT01414712|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2013-03-04|2011-08-10|2011-08-11|Estimate|||||||2013-03-04|2013-03-05|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Circulating Tumor Cells in Prostate Cancer Patients|Circulating Tumor Cells in Patients Undergoing Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer|Terminated|||2|Actual|University of Texas Southwestern Medical Center|||1||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-05-31 22:15:19.647034|2018-05-31 22:15:19.647034
NCT01414699|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-04-03|2011-08-10|2011-08-11|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2011||2011-08-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2011|Actual|2011-12-31||Interventional|||The Influence of Dietary Variety and Course Sequence on Fruit Intake in Preschool-Aged Children|The Influence of Dietary Variety and Course Sequence on Fruit Intake in Preschool-Aged Children|Completed||N/A|16|Actual|The University of Tennessee, Knoxville||4|||f||||f||||||||||2018-05-31 22:15:19.721011|2018-05-31 22:15:19.721011
NCT01414686|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|VEHAB||Virtual Environment Rehabilitation for Chronic Stroke|Commercially-Available Interactive Video Games for Individuals With Chronic Mobility and Balance Deficits Post-Stroke|Completed||Phase 2|30|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 22:15:19.793429|2018-05-31 22:15:19.793429
NCT01414673|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles|Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing Intrauterine Insemination: a Prospective Randomized Study.|Completed||Early Phase 1|300|Actual|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 22:15:19.867331|2018-05-31 22:15:19.867331
NCT01414660|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2017-02-01|2011-08-10|2011-08-11|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2010||2010-06-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|IL-7tran||Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation|Adipocytes, Insulin Resistance and Immunity: Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation|Completed|||49|Actual|University Hospital, Lille|||3||f||||f||||||Samples With DNA|"~     wholeblood and tissue bank~   "|No||2018-05-31 22:15:19.930963|2018-05-31 22:15:19.930963
NCT01414647|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2018-05-12|2011-08-10|2011-08-11|Estimate|||||||2018-05-12|2018-05-17|Actual|January 2006||2006-01-31|May 2018|2018-05-31|March 2010|Actual|2010-03-31|December 2006|Actual|2006-12-31||Interventional|Berry||The Health Effect of Diet Rich in Nordic Berries|The Effect of Diet Rich in Nordic Berries on Gut Microbiota, Glucose and Lipid Metabolism and Metabolism on Fenolic Compounds|Completed||N/A|56|Actual|University of Eastern Finland||3|||f||||t||||||||||2018-05-31 22:15:20.018827|2018-05-31 22:15:20.018827
NCT01414634|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2014-01-24||2015-04-08|2011-08-10|2011-08-11|Estimate|2015-03-24|2015-04-08|Estimate||||2015-04-08|2015-05-04|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ETIMS||Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells|Establish Tolerance in Multiple Sclerosis With Peptide-coupled, Peripheral Blood Mononuclear Cells - A MRI-controlled, Single Center, Phase I Trial in Relapsing-remitting MS Patients|Completed||Phase 1/Phase 2|9|Actual|Universitätsklinikum Hamburg-Eppendorf||8|||f||||t||||||||||2018-05-31 22:15:20.233615|2018-05-31 22:15:20.233615
NCT01414439|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-08-27|2011-08-10|2011-08-11|Estimate|||||||2011-08-27|2011-08-30|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Group Psychotherapy Among Congestive Heart Failure Patients|Group Psychotherapy Among Congestive Heart Failure Patients as a Way to Reduce Psychological Distress and Increase Psycho-social Adjustment|Unknown status|Not yet recruiting||40|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 22:15:22.489611|2018-05-31 22:15:22.489611
NCT01414621|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2016-03-07|2011-08-10|2011-08-11|Estimate|||||||2016-03-07|2016-03-08|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|||Expression of Angiogenic Factors in Myocardial Tissue|IRB #14547: Expression of Angiogenic Factors in Myocardial Tissue in Diabetic and Non-diabetic Patients Undergoing Coronary Bypass Surgery|Completed|||60|Actual|University of Virginia|||1||f||||f||||||Samples With DNA|"~     During the cannulation process before the initiation of CPB(cardiopulmonary bypass) a small~     piece of right atrial tissue is cut in order to insert venous drainage cannula to the right~     atrium. This small piece of tissue is discarded and is not sent for pathology.~   "|No||2018-05-31 22:15:20.616675|2018-05-31 22:15:20.616675
NCT01414608|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2017-08-23|2011-08-10|2011-08-11|Estimate|||||||2017-08-23|2017-08-24|Actual|January 9, 2012|Actual|2012-01-09|August 2017|2017-08-31||||July 9, 2018|Anticipated|2018-07-09||Interventional|||Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer|A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial|Active, not recruiting||Phase 3|900|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 22:15:20.779817|2018-05-31 22:15:20.779817
NCT01414595|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2017-06-26|2011-08-10|2011-08-11|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2012||2012-03-31|June 2017|2017-06-30||||February 2017|Actual|2017-02-28||Observational|||Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer|Molecular Characterization of Lung Cancer: A Collaboration With the Cancer Genome Atlas Project (TGCA)|Completed|||248|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tumor and blood samples~   "|||2018-05-31 22:15:21.383407|2018-05-31 22:15:21.383407
NCT01414582|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2012-06-19|2011-08-10|2011-08-11|Estimate|||||||2012-06-19|2012-06-20|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|tDCS||Transcranial Stimulation and Motor Training in Stroke Rehabilitation|Transcranial Direct Current Stimulation (tDCS) as a Potential Adjunct Intervention in Stroke Rehabilitation|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 22:15:21.479608|2018-05-31 22:15:21.479608
NCT01414569|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-06-03|2011-08-10|2011-08-11|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Dexamethasone for Pain After Shoulder Surgery|High Dose Dexamethasone as Pain Treatment After Arthroscopic Shoulder Surgery: A Randomised, Blinded Clinical Trial|Completed||Phase 4|97|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 22:15:21.586587|2018-05-31 22:15:21.586587
NCT01414556|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-03-31|2011-08-10|2011-08-11|Estimate|||||||2013-03-31|2013-04-02|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|GIP-HYPO-T2DM||GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes|Effects of Glucose-dependent Insulinotropic Polypeptide at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes|Completed||Early Phase 1|12|Actual|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-05-31 22:15:21.671344|2018-05-31 22:15:21.671344
NCT01414543|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2016-05-10|2011-08-10|2011-08-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Psychologists' Lived Experience of Client Violence|Counselling and Clinical Psychologists Lived Experience of Client Violence|Completed||N/A|10|Anticipated|University of East London||4|||f||||t||||||||||2018-05-31 22:15:21.760188|2018-05-31 22:15:21.760188
NCT01414530|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-09-09|2011-08-10|2011-08-11|Estimate|||||||2013-09-09|2013-09-10|Estimate|April 2010||2010-04-30|September 2013|2013-09-30||||June 2014|Anticipated|2014-06-30||Interventional|||Oral Contraceptive During Menopausal Transition|Effects of Oral Contraceptive on Muscle or Joint Ache in Women During Menopausal Transition|Unknown status|Recruiting|N/A|52|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 22:15:21.879536|2018-05-31 22:15:21.879536
NCT01414517|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.|A Double-blind Placebo-controlled Trial of Dietary Supplementation With 15g/Day FOS for Five Weeks in Patients With Endometrial/Cervical Carcinoma or 7.5 Weeks in Patients With Prostate Carcinoma Undergoing Pelvic Radiotherapy.|Unknown status|Recruiting|Phase 3|220|Anticipated|University College London Hospitals||2|||f||||t||||||||||2018-05-31 22:15:21.974463|2018-05-31 22:15:21.974463
NCT01414504|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-09-14|2011-08-10|2011-08-11|Estimate|||||||2012-09-14|2012-09-17|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|PCVFU||Pneumococcal Conjugate Vaccine Followup|Pneumococcal Conjugate Vaccine Followup: Investigation of Serotype-specific Antibody Persistence and B Cell Memory at Age 3-5 Years Following 23valent Pneumococcal Polysaccharide Vaccine at Age 9 Months in PNG Children Previously Primed With 7valent Pneumococcal Conjugate Vaccine|Completed||Phase 2|280|Actual|Papua New Guinea Institute of Medical Research||4|||f||||f||||||||||2018-05-31 22:15:22.074989|2018-05-31 22:15:22.074989
NCT01414491|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-11-03|2011-08-10|2011-08-11|Estimate|||||||2017-11-03|2017-11-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:15:22.17998|2018-05-31 22:15:22.17998
NCT01414478|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-02-01|2011-08-10|2011-08-11|Estimate|||||||2013-02-01|2013-02-04|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||High Protein Intake to Decrease Emesis and Promote Patient Satisfaction in Labor|A Prospective, Randomized Trial to Evaluate the Efficacy of High Protein Intake on the Incidence of Emesis and Promotion of Patient Satisfaction After Epidural Analgesia for Labor|Completed||N/A|150|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:15:22.21753|2018-05-31 22:15:22.21753
NCT01414465|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|||Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females|Orlistat Induced Modulation on the Fatty Acid Composition of the Red Blood Cell Membrane and Plasma Phospholipids, Triglyceride and Cholesteryl Esters in Obese Females|Completed||N/A|17|Actual|University of Campinas, Brazil||3|||f||||f||||||||||2018-05-31 22:15:22.321411|2018-05-31 22:15:22.321411
NCT01414452|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-07-19|2011-08-10|2011-08-11|Estimate|||||||2015-07-19|2015-07-21|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|R²ACE||Role of Adiponectin and Endothelial Progenitor Cells in Reperfusion Injury in Patients With Acute Myocardial Infarction|Reperfusion Injury and Cardiac Remodelling After Myocardial Infarction in Relation to Adiponectin Level, Circulating Endothelial Progenitor Cells and Endothelial Microparticles|Completed|||250|Actual|Universiteit Antwerpen|||1||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 22:15:22.401718|2018-05-31 22:15:22.401718
NCT01414426|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2018-02-06|2011-08-09|2011-08-11|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2012||2012-01-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions|Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck|Active, not recruiting||Phase 2|20|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 22:15:22.57767|2018-05-31 22:15:22.57767
NCT01414413|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2014-02-19||2014-02-19|2011-08-10|2011-08-11|Estimate|2014-02-19|2014-04-07|Estimate||||2014-02-19|2014-04-07|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|CONDA-YAPA|The 14 clusters included in the study had a combined adult population of 16660, with 8194 adults resident in 3213 households in the OHC arm and 8466 adults resident in 3397 households in the FCO arm. Socio-demographic characteristics assessed in the baseline enumeration were well balanced between intervention groups.|Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi|Home Assessment and Initiation of ART: a Cluster-randomised Trial in Blantyre, Malawi|Completed||N/A|16660|Actual|Liverpool School of Tropical Medicine||2|||f||||f||||||||||2018-05-31 22:15:22.681709|2018-05-31 22:15:22.681709
NCT01414400|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-11|2011-08-10|2011-08-11|Estimate|||||||2011-08-11|2011-08-12|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).|Prospective Study of Bacteremia and Infection Rates Following Cholangioscopy With the Spyglass Cholangioscope|Unknown status|Recruiting|N/A|50|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 22:15:22.876947|2018-05-31 22:15:22.876947
NCT01414387|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-07-31|2011-08-10|2011-08-11|Estimate|||||||2017-07-31|2017-08-02|Actual|October 2011|Actual|2011-10-31|July 2017|2017-07-31|February 12, 2016|Actual|2016-02-12|February 12, 2016|Actual|2016-02-12||Interventional|||Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting|Effects of Cerebral Protection With Filters vs. Flow Reversal on Cerebral Embolization After Carotid Artery Stenting|Terminated||N/A|33|Actual|Dallas VA Medical Center||2||"Therapy for carotid disease has recently changed. Carotid stenting is now restricted to high~   risk patients that are not eligible for the study."|f||||f||||||||||2018-05-31 22:15:22.946276|2018-05-31 22:15:22.946276
NCT01414374|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-02-12|2011-08-10|2011-08-11|Estimate|||||||2015-02-12|2015-02-13|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Hibiscus Sabdariffa and Centella Asiatica in the Treatment of Anemia by Iron Deficiency|Prevalence of Genetic Polymorphisms of DMT1 and Ferroportin Enzymes in Adults With Anemia by Iron Deficiency, and Its Influence on the Efficacy of Conventional and Herbal Treatments|Completed||Phase 3|50|Actual|Casa Espirita Terra de Ismael||2|||f||||f||||||||||2018-05-31 22:15:23.005838|2018-05-31 22:15:23.005838
NCT01414361|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Fractional Flow Reserve and Intravascular Ultrasound in Evaluating Intermediate Coronary Lesions|Comparison of Fractional Flow Reserve (FFR) and Minimal Luminal Area (MLA) by Intravascular Ultrasound (IVUS) in Evaluating Intermediate Coronary Artery Stenosis: International Multi-center Study|Unknown status|Recruiting||1000|Anticipated|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 22:15:23.073751|2018-05-31 22:15:23.073751
NCT01414348|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2015-01-26|2011-08-10|2011-08-11|Estimate|||||||2015-01-26|2015-01-27|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Managing Dysexecutive Syndrome (DS): CIHR 2011-2014|Managing the Dysexecutive Syndrome Following Traumatic Brain Injury: An Ecologically Valid Rehabilitation Approach|Completed||N/A|95|Actual|Baycrest||2|||f||||t||||||||||2018-05-31 22:15:23.132557|2018-05-31 22:15:23.132557
NCT01414335|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Interventional|||Amino Acid Composition Reduces Frequency of Common Cold. Results of a Controlled Completely Masked Trial|Amino Acid Composition Reduces Frequency of Common Cold. Results of a Controlled Randomized Completely Masked Trial|Completed||N/A|145|Actual|Kyberg Vital GmbH||2|||f||||f||||||||||2018-05-31 22:15:23.190359|2018-05-31 22:15:23.190359
NCT01414322|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|March 2012|Anticipated|2012-03-31||Observational|||Documentation of Continuous Wheeze and Cough Dynamics in Pediatric ER SOB Patients||Unknown status|Not yet recruiting||45|Anticipated|KarmelSonix Ltd.|||3||f||||f||||||||||2018-05-31 22:15:23.24824|2018-05-31 22:15:23.24824
NCT01414309|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-01-05|2011-08-09|2011-08-11|Estimate|||||||2015-01-05|2015-01-07|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea|Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea|Terminated|||5|Actual|Respicardia, Inc.|||1|Change in company priorities|f||||f||||||||||2018-05-31 22:15:23.388855|2018-05-31 22:15:23.388855
NCT01414296|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-11-12|2011-08-10|2011-08-11|Estimate|||||||2013-11-12|2013-11-14|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer|Extended 39-Week Study of PSMA ADC Following the Initial 12-Week Dose-escalation Study in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer|Completed||Phase 1|10|Actual|Progenics Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:15:23.456152|2018-05-31 22:15:23.456152
NCT01414283|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-10-31|2011-08-10|2011-08-11|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer|A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer|Completed||Phase 1|52|Actual|Progenics Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:15:23.51462|2018-05-31 22:15:23.51462
NCT01414270|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-01-29|2011-08-09|2011-08-11|Estimate|||||||2014-01-29|2014-01-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:15:23.58517|2018-05-31 22:15:23.58517
NCT01413308|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-09|2011-08-09|2011-08-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|March 2012|Anticipated|2012-03-31||Observational|||Pulmonary Functions Test in Patients After Fontan Operation|Long-term Effects on Pulmonary Function in Post- Fontan Operation|Unknown status|Enrolling by invitation||15|Actual|Rambam Health Care Campus|||||f||||t||||||||||2018-05-31 22:15:37.019593|2018-05-31 22:15:37.019593
NCT01414244|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2017-04-10||2017-08-07|2011-08-10|2011-08-11|Estimate|2017-08-07|2017-08-09|Actual||||2017-08-07|2017-08-09|Actual|November 2010||2010-11-30|August 2017|2017-08-31|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional|AT005291||Glutamine for the Treatment of Patients With Irritable Bowel Syndrome|Randomized, Placebo-Controlled Trial of Glutamine for the Treatment of Patients With Irritable Bowel Syndrome|Completed||Phase 2|106|Actual|Tulane University||2|||f||||t||||||||Undecided|Some data will be available through publications, however further plans to make all IPD available is unknown.|2018-05-31 22:15:23.698275|2018-05-31 22:15:23.698275
NCT01414231|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|April 2002||2002-04-30|April 2008|2008-04-30|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|OSHO#061||Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML<60a|Randomised Comparison of OSHO Induction vs. the German AML Intergroup Standard, Randomised Comparison of AraC/Mtx vs. Flu/AraC/Mtx in Pts Without CR After One Induction Cycle and Randomized Comparison of One vs. Two Consolidation Therapies.|Unknown status|Recruiting|Phase 3|850|Anticipated|University of Leipzig||2|||f||||t||||||||||2018-05-31 22:15:23.974937|2018-05-31 22:15:23.974937
NCT01414218|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Impact of a Humor Seminar on General Well Being, Quality of Life and Psychological Distress Among Community Dwelling Elders|Influence of Humor as a Way of Life on Well Being, Quality of Life and Immune Function|Completed||N/A|92|Actual|Happy Nation Society||1|||f||||f||||||||||2018-05-31 22:15:24.08229|2018-05-31 22:15:24.08229
NCT01414205|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|2014-03-21||2017-03-20|2011-08-10|2011-08-11|Estimate|2014-03-21|2014-04-24|Estimate||||2017-03-20|2017-04-17|Actual|October 31, 2011|Actual|2011-10-31|March 2017|2017-03-31|March 31, 2016|Actual|2016-03-31|March 31, 2013|Actual|2013-03-31||Interventional|||A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)|An Open-label, Multicenter, Randomized Phase II Trial Comparing the Efficacy, Safety, and Pharmacokinetics of GA101 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 2|80|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:15:24.19356|2018-05-31 22:15:24.19356
NCT01414192|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2015-09-14||2017-06-05|2011-08-10|2011-08-11|Estimate|2015-12-02|2016-01-08|Estimate||||2017-06-05|2017-07-02|Actual|November 15, 2008|Actual|2008-11-15|June 2017|2017-06-30|September 15, 2014|Actual|2014-09-15|September 15, 2014|Actual|2014-09-15||Observational|MOBS||A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)|Model-Observation Bridging Study (MOBS) for Ezetrol® and Inegy®|Completed|||3215|Actual|Merck Sharp & Dohme Corp.|||4||f||||f||||||||||2018-05-31 22:15:24.896296|2018-05-31 22:15:24.896296
NCT01414179|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2011-08-10|2011-08-10|2011-08-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|October 2010||2010-10-31|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|NESCAV||NESCAV Nutrition Environment and Cardiovascular Health|Nutrition Environnement et Santé Cardio Vasculaire NESCAV|Unknown status|Recruiting||800|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||Samples Without DNA|"~     Blood and urinary biological taking away: glycemia, HbA1C, insulin (specific study analyzes),~     total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apolipoproteines A1 and~     B, numeration of blood picture, creatinin, uric acid, gamma WP, GOT, GPT, CRP; and a urinary~     collection (a micturition) in order to proportion the microalbuminurie. A plasmathèque will~     be made up, in order to measure later on biomarqueurs of the cardiovascular risk (biological~     collection stored with the CIC). A measurement of pollutants and poisons will be carried out~     starting from taking away of hair.~   "|||2018-05-31 22:15:25.36858|2018-05-31 22:15:25.36858
NCT01414166|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2013-11-21||2015-04-27|2011-08-09|2011-08-11|Estimate|2014-01-30|2014-03-14|Estimate||||2015-04-27|2015-05-13|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)|A 16-Week, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Extended Release Niacin/Laropiprant in South and Southeast Asians Not on a Lipid Modulating Agent, With Decreased High-Density Lipoprotein Cholesterol and Low- Density Lipoprotein Cholesterol at or Below NCEP ATP III Goal|Terminated||Phase 3|244|Actual|Merck Sharp & Dohme Corp.|Due to the small number of participants completing the study (n=70), the resulting underpowered nature of any analyses that might be conducted, and the fact that data are not going to be used, no efficacy analyses were performed.|2||"In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a~   significant increase in incidence of some types of non-fatal SAEs"|f||||f||||||||||2018-05-31 22:15:25.500618|2018-05-31 22:15:25.500618
NCT01414153|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2016-06-27||2016-08-22|2011-08-10|2011-08-11|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|Nexus||Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD|Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|Completed||Phase 2|158|Actual|Lpath, Inc.||4|||f||||t||||||||No||2018-05-31 22:15:26.079624|2018-05-31 22:15:26.079624
NCT01414140|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-10|||2014-01-08|2011-08-10|2011-08-11|Estimate|||||||2014-01-08|2014-01-09|Estimate|May 2007||2007-05-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Mirena Post-marketing Surveillance in Japan|Drug Use Investigation of Mirena|Completed|||567|Actual|Bayer|||1||f||||||||||||||2018-05-31 22:15:29.471333|2018-05-31 22:15:29.471333
NCT01414114|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2017-02-27|2015-07-08|2017-02-27|2011-08-10|2011-08-11|Estimate|2017-02-27|2017-04-11|Actual|2015-07-08|2015-07-30|Estimate|2017-02-27|2017-04-11|Actual|December 5, 2011||2011-12-05|February 2017|2017-02-28|May 21, 2012|Actual|2012-05-21|May 21, 2012|Actual|2012-05-21||Interventional|||Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder|A Single-arm, Open-label, Multicenter, Dose Titration Study of KAI-4169 to Treat Secondary Hyperparathyroidism in Hemodialysis Subjects With Chronic Kidney Disease-Mineral and Bone Disorder|Completed||Phase 2|37|Actual|KAI Pharmaceuticals||1|||f||||f|t|f||||||||2018-05-31 22:15:29.588478|2018-05-31 22:15:29.588478
NCT01414101|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-05-16|2011-08-09|2011-08-11|Estimate|||||||2013-05-16|2013-05-17|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis|Completed||Phase 2|51|Actual|Ionis Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 22:15:30.073745|2018-05-31 22:15:30.073745
NCT01414088|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-05-17|2011-08-10|2011-08-11|Estimate|||||||2013-05-17|2013-05-20|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|NARA||The Effects of Isotonic and Hypertonic Saline Infusion on Renal Biomarkers in Healthy Young Subjects|The Effects of Isotonic and Hypertonic Saline Infusion on Renal Biomarkers for the Measurement of Sodium and Water Channel Activity in the Nephron in Healthy Young Subjects|Completed||N/A|23|Actual|Regional Hospital Holstebro||3|||f||||t||||||||||2018-05-31 22:15:30.162141|2018-05-31 22:15:30.162141
NCT01414075|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-04-18|2011-08-09|2011-08-11|Estimate|||||||2014-04-18|2014-04-22|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of FG-4592 to Correct Anemia in New Dialysis Patients||Completed||Phase 2|55|Actual|FibroGen||1|||f||||t||||||||||2018-05-31 22:15:30.232962|2018-05-31 22:15:30.232962
NCT01414062|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2016-05-19|2011-08-10|2011-08-11|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Cocinar Para su Salud! (Cook for Your Life!)|Cocinar Para su Salud! (Cook for Your Life!): Implementing Dietary Change Among Hispanic Breast Cancer Survivors|Unknown status|Active, not recruiting|N/A|82|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 22:15:30.325553|2018-05-31 22:15:30.325553
NCT01414049|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-03-25|2011-08-10|2011-08-11|Estimate|||||||2014-03-25|2014-03-26|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|September 2015|Anticipated|2015-09-30|January 2015|Anticipated|2015-01-31||Interventional|PATENCY||Patency-Coronary Trial|PATency assessmENt of Grafts by Computerized tomographY in CORONARY Patients: the PATENCY-CORONARY Trial|Unknown status|Recruiting|N/A|1200|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 22:15:30.394353|2018-05-31 22:15:30.394353
NCT01414036|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2016-01-26||2016-02-22|2011-08-10|2011-08-11|Estimate|2016-02-22|2016-03-21|Estimate||||2016-02-22|2016-03-21|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pilot Study of Patient Navigation to Promote Smoking Cessation|Primary Care-based Patient Navigation to Promote Smoking Cessation Treatment: a Pilot Randomized Controlled Trial|Completed||N/A|47|Actual|Boston University||2|||f||||f||||||||Yes|"J Ethn Subst Abuse. 2013 ; 12(4): . doi:10.1080/15332640.2013.819311.~http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827692/"|2018-05-31 22:15:30.518492|2018-05-31 22:15:30.518492
NCT01414023|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-07-20|2011-08-10|2011-08-11|Estimate|||||||2015-07-20|2015-07-21|Estimate|July 2011||2011-07-31|July 2015|2015-07-31||||July 2012|Actual|2012-07-31||Interventional|CCT-OC||Assessing the Effects of a Neurobehavioral Intervention on Symptoms of Obsessive Compulsive Disorder||Completed||N/A|48|Actual|Boston University||2|||f||||f||||||||||2018-05-31 22:15:30.880431|2018-05-31 22:15:30.880431
NCT01414010|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2015-12-29||2017-06-25|2011-08-10|2011-08-11|Estimate|2017-06-25|2017-07-24|Actual||||2017-06-25|2017-07-24|Actual|August 2011||2011-08-31|June 2017|2017-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota|Effects of Mushroom Extract, S Boulardii and Amoxicillin on the Human Microbiome|Completed||N/A|32|Actual|Beth Israel Deaconess Medical Center||4|||f||||f||||||||||2018-05-31 22:15:30.958636|2018-05-31 22:15:30.958636
NCT01413997|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-09|2011-08-09|2011-08-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|April 2011||2011-04-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|CTMM1||Connective Tissue Motion Measure|Feasibility Study of Connective Tissue Motion Measure - a Biomarker for Perimuscular Connective Tissue Pathology.|Completed|||39|Actual|Stromatec, Inc.|||2||f||||t||||||||||2018-05-31 22:15:31.498654|2018-05-31 22:15:31.498654
NCT01413984|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-03-17|2011-08-09|2011-08-10|Estimate|||||||2014-03-17|2014-03-18|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Substance Abuse and Trauma in Incarcerated Women|Substance Abuse and Trauma in Incarcerated Women: An Effectiveness Study|Completed||N/A|95|Actual|University of Tulsa||2|||f||||t||||||||||2018-05-31 22:15:31.549218|2018-05-31 22:15:31.549218
NCT01413958|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2012-10-08||2015-02-20|2011-08-09|2011-08-10|Estimate|2012-12-18|2013-01-29|Estimate||||2015-02-20|2015-03-11|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)|A Randomized, Placebo-Controlled Trial to Evaluate the Effects of Phenylephrine HCl 30 mg Extended-Release Tablets on Nasal Congestion in Subjects With Allergic Rhinitis|Completed||Phase 3|575|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:15:31.646217|2018-05-31 22:15:31.646217
NCT01413945|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2018-02-02|2011-08-09|2011-08-10|Estimate|||||||2018-02-02|2018-02-06|Actual|October 2010||2010-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Ileocecal Sphincter Reflex by Cecal Distension During Colonoscopy|Evaluation of the Ileocecal Valve in Patients With and Without Irritable Bowel Syndrome.(IBS)|Suspended|||50|Anticipated|Northwell Health|||2|Waiting to complete some logistics|f||||f||||||||No||2018-05-31 22:15:32.289235|2018-05-31 22:15:32.289235
NCT01413932|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04||2015-11-17|2015-11-17|2011-08-09|2011-08-10|Estimate||||2015-11-17|2015-12-16|Estimate|2015-11-17|2015-12-16|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder|A Two-part Study: Part 1 is a Multiple-dose (7-day), Open-label Evaluation of the Safety, Tolerability, and Pharmacokinetics of HT-2157 in Healthy Subjects. Part 2 is a Randomized, Double-blind, Placebo-controlled, Multiple (21-day) Ascending-dose Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HT-2157 in Patients With Major Depressive Disorder|Completed||Phase 1/Phase 2|26|Actual|Dart NeuroScience, LLC||2|||f||||f||||||||||2018-05-31 22:15:32.374252|2018-05-31 22:15:32.374252
NCT01413906|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2013-05-31|2011-08-09|2011-08-10|Estimate|||||||2013-05-31|2013-06-03|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors|Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors|Completed||Phase 1|12|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 22:15:32.447073|2018-05-31 22:15:32.447073
NCT01413893|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-11-17|2011-08-09|2011-08-10|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2011||2011-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors|An Extension Study of Linifanib in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|35|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 22:15:32.521259|2018-05-31 22:15:32.521259
NCT01413867|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-12-10|2011-08-09|2011-08-10|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EEA/PPH2011||Safety and Short Term Effectiveness of EEA Versus PPH Stapler for III Degree Hemorrhoids|Safety and Short Term Effectiveness of EEA Stapler vs PPH Stapler in the Treatment of III Degree Haemorrhoids. Prospective Randomized Controlled Trial|Completed||Phase 3|120|Actual|Societa Italiana di Chirurgia ColoRettale||2|||f||||f||||||||||2018-05-31 22:15:32.582126|2018-05-31 22:15:32.582126
NCT01413854|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-10|2011-08-09|2011-08-10|Estimate|||||||2011-08-10|2011-08-11|Estimate|August 2011||2011-08-31|August 2011|2011-08-31||||April 2015|Anticipated|2015-04-30||Interventional|||Diclofenac add-on to Treatment as Usual for Suicidal Patients|"Antiinflammatoriska läkemedels Effekt för Att Minska Suicidalitet Hos Deprimerade Patienter Som Nyligen Har Gjort självmordsförsök"|Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|Region Skane||2|||f||||t||||||||||2018-05-31 22:15:32.642544|2018-05-31 22:15:32.642544
NCT01413841|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-08-09|2011-08-09|2011-08-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|OXYPAIN||Effect of Oxygen During Percutaneous Coronary Intervention for Pain Relief|Phase II Randomised Study of Nasal Oxygen Treatment for Pain Relief During Percutaneous Coronary Interventions|Completed||Phase 2|300|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:15:32.701933|2018-05-31 22:15:32.701933
NCT01413828|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2016-08-16|2011-08-09|2011-08-10|Estimate|||||||2016-08-16|2016-08-17|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer|Safety and Efficacy Evaluation of Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer|Completed||Phase 2/Phase 3|201|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||Undecided||2018-05-31 22:15:32.750028|2018-05-31 22:15:32.750028
NCT01413815|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2016-01-13|2011-08-09|2011-08-10|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients|Effect of Oral Supplementation With the Amino Acid L-arginine on Peri- Operative Cardio-vascular Risk in Non-selected Patients - Role of Pre-operative Determination of Plasma ADMA Levels for Therapeutic Stratification.|Completed||N/A|269|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-05-31 22:15:32.816812|2018-05-31 22:15:32.816812
NCT01413802|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-06-02|2011-08-09|2011-08-10|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|CoNeMoTS||Intra Operative Continuous Laryngeal Nerve Monitoring During Thyroid Surgery and Interpretation of the Post-operative Voice Quality in Relation to the Electromyography Data Obtained During Surgery|Intra Operative Continuous Laryngeal Nerve Monitoring During Thyroid Surgery and Interpretation of the Post-operative Voice Quality in Relation to the Electromyography Data Obtained During Surgery|Unknown status|Enrolling by invitation|N/A|100|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:15:32.910587|2018-05-31 22:15:32.910587
NCT01413789|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-04-15|2011-08-09|2011-08-10|Estimate|||||||2013-04-15|2013-04-16|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels and One Gel Cream|Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels: BAP Scar Gel, Dermatix, Kelocote and One Gel- Cream: Alhydran|Completed||N/A|55|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:15:32.976752|2018-05-31 22:15:32.976752
NCT01413776|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-03-14|2011-08-09|2011-08-10|Estimate|||||||2014-03-14|2014-03-17|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of a Fortified Dietary Supplement for Pregnant Women on Maternal and Newborn Outcomes in Kampong Chhnang Province, Cambodia|Effects of a Fortified Dietary Supplement for Pregnant Women on Maternal and Newborn Outcomes in Kampong Chhnang Province, Cambodia|Completed||N/A|547|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:15:33.072485|2018-05-31 22:15:33.072485
NCT01413763|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-10-24|2011-08-09|2011-08-10|Estimate|||||||2012-10-24|2012-10-25|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis|A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Medicis Global Service Corporation||2|||f||||f||||||||||2018-05-31 22:15:33.13344|2018-05-31 22:15:33.13344
NCT01413750|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2015-06-05||2015-07-22|2011-08-09|2011-08-10|Estimate|2015-07-22|2015-08-18|Estimate||||2015-07-22|2015-08-18|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer|Terminated||Phase 1/Phase 2|23|Actual|National Cancer Institute (NCI)|Study was terminated early by NCI due to slow accrual.|2||Slow Accrual|f||||||||||||||2018-05-31 22:15:33.229936|2018-05-31 22:15:33.229936
NCT01413737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2017-03-07|2011-08-09|2011-08-10|Estimate|||||||2017-03-07|2017-03-10|Actual|January 2002|Actual|2002-01-31|March 2017|2017-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days|Postoperative Results of Surgical Treatment of Lung Cancer After 30 Days|Completed|||148|Actual|Norwegian University of Science and Technology|||||f||||||||||||||2018-05-31 22:15:33.852417|2018-05-31 22:15:33.852417
NCT01413724|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2016-08-02|2011-08-09|2011-08-10|Estimate|||||||2016-08-02|2016-08-03|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Survey of Postoperative Pain and Pain Management in Norwegian Hospitals|Survey of Postoperative Pain and Pain Management in Norwegian Hospitals|Completed|||300|Actual|Norwegian University of Science and Technology|||1||f||||f||||||||||2018-05-31 22:15:33.898591|2018-05-31 22:15:33.898591
NCT01413711|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2012-09-12|2011-08-09|2011-08-10|Estimate|||||||2012-09-12|2012-09-13|Estimate|June 2012||2012-06-30|September 2012|2012-09-30||||September 2013|Anticipated|2013-09-30||Interventional|||An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms|An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms|Withdrawn||Phase 4|0|Actual|Lundbeck LLC||1|||f||||f||||||||||2018-05-31 22:15:33.948949|2018-05-31 22:15:33.948949
NCT01413698|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-09|2011-08-09|2011-08-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|January 2012|Anticipated|2012-01-31||Observational|||Cough Count Validation||Unknown status|Not yet recruiting||20|Anticipated|KarmelSonix Ltd.|||1||f||||||||||||||2018-05-31 22:15:34.011861|2018-05-31 22:15:34.011861
NCT01413685|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2014-11-13|2011-08-09|2011-08-10|Estimate|||||||2014-11-13|2014-11-14|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Calcineurin Activity in Renal Recipients|Interest of Calcineurin Activity for the Therapeutic Tacrolimus Monitoring in Renal Recipients|Terminated||Phase 4|23|Actual|Assistance Publique - Hôpitaux de Paris||1||no patient corresponding to criteria|f||||t||||||||||2018-05-31 22:15:34.06914|2018-05-31 22:15:34.06914
NCT01413672|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-06|||2011-12-09|2011-08-09|2011-08-10|Estimate|||||||2011-12-09|2011-12-12|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Preliminary Evaluation of CASTLE Barrier North American Prototype|Peristomal Skin Irritation: A Preliminary Evaluation of CASTLE Barrier North American Prototype|Completed|||30|Actual|Hollister Incorporated|||1||f||||f||||||||||2018-05-31 22:15:34.133768|2018-05-31 22:15:34.133768
NCT01413659|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-24|2011-08-09|2011-08-10|Estimate|||||||2011-08-24|2011-08-25|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of the Effect of Preoperative Symbiotic Bowel Conditioning on Surgical Site Infection After Elective Colorectal Surgery||Unknown status|Not yet recruiting|Early Phase 1|150|Anticipated|Mashhad University of Medical Sciences||1|||f||||||||||||||2018-05-31 22:15:34.197783|2018-05-31 22:15:34.197783
NCT01413646|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-08-09|2011-08-09|2011-08-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|Walnut2||Effects of Walnuts on Endothelial Function in Overweight Adults With at Least One Factor of Metabolic Syndrome|Effects of Walnuts on Endothelial Function in Overweight Adults With at Least One Factor of Metabolic Syndrome: A Randomized, Controlled, Cross-Over Trial|Completed||N/A|40|Actual|Griffin Hospital||2|||f||||f||||||||||2018-05-31 22:15:34.250444|2018-05-31 22:15:34.250444
NCT01413633|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-04-07|2011-08-09|2011-08-10|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic Cholecystectomy|A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic Cholecystectomy|Completed||N/A|34|Actual|Mansoura University||1|||f||||t||||||||||2018-05-31 22:15:34.311853|2018-05-31 22:15:34.311853
NCT01413620|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2016-08-17|2011-08-09|2011-08-10|Estimate|||||||2016-08-17|2016-08-19|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|August 2021|Anticipated|2021-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Vitamin E Supplementation in Burn Patients|Vitamin E Supplementation in Burn Patients|Recruiting||Phase 1|300|Anticipated|Shriners Hospitals for Children||2|||f||||t||||||||No||2018-05-31 22:15:34.369682|2018-05-31 22:15:34.369682
NCT01413607|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-09|2011-08-09|2011-08-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy|The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy|Unknown status|Not yet recruiting|Phase 4|250|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 22:15:34.449712|2018-05-31 22:15:34.449712
NCT01413594|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-09-08|2011-08-09|2011-08-10|Estimate|||||||2011-09-08|2011-09-12|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|HABIT||Bimanual Training in Children With Hemiplegia|Randomized Clinical Trial of Hand Arm Bimanual Intensive Therapy (HABIT)|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 22:15:34.609019|2018-05-31 22:15:34.609019
NCT01413581|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-07-29|2011-08-09|2011-08-10|Estimate|||||||2015-07-29|2015-07-30|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|LAIF||Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants|A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 32 of Gestational Age|Terminated||Phase 3|415|Actual|Swedish Orphan Biovitrum||2||Primary endpoint showed no stat significant difference. FU > M12 terminated.|f||||t||||||||||2018-05-31 22:15:34.719683|2018-05-31 22:15:34.719683
NCT01413568|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2016-02-25|2011-08-08|2011-08-10|Estimate|||||||2016-02-25|2016-02-26|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies|A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies|Completed||Phase 1/Phase 2|38|Actual|Polyphor Ltd.||2|||f||||t||||||||||2018-05-31 22:15:34.90121|2018-05-31 22:15:34.90121
NCT01413555|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-06-02|2011-08-09|2011-08-10|Estimate|||||||2015-06-02|2015-06-04|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Multicenter Blood Culture Quality Improvement|Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department|Completed||N/A|14889|Actual|Vanderbilt University||1|||f||||f||||||||||2018-05-31 22:15:34.981597|2018-05-31 22:15:34.981597
NCT01413542|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2014-11-07||2015-10-05|2011-08-09|2011-08-10|Estimate|2015-10-05|2015-11-04|Estimate||||2015-10-05|2015-11-04|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional||This population represents the 29 participants (12 in Group 1; 17 in Group 2) who passed screening and completed at least one study arm. 1 subject did not complete the 2nd arm in Group 1. 4 subjects did not complete the second arm in Group 2. Results and baseline characteristics are presented inclusive of these patients.|Pharmacogenetics of Ace Inhibitor-Associated Angioedema|Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1|Completed||N/A|44|Actual|Vanderbilt University||4|||f||||t||||||||||2018-05-31 22:15:35.100178|2018-05-31 22:15:35.100178
NCT01413529|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2017-08-21|2011-08-09|2011-08-10|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2011|Actual|2011-09-30|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users|HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users|Completed||Phase 2|35|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 22:15:35.683879|2018-05-31 22:15:35.683879
NCT01413516|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2016-02-25||2017-11-04|2011-08-08|2011-08-10|Estimate|2016-11-04|2016-12-30|Estimate||||2017-11-04|2017-12-08|Actual|August 2011||2011-08-31|November 2017|2017-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|VIP||Varenicline In-Patient Study|A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization|Completed||Phase 2|17|Actual|Stanford University||2|||f||||t||||||||Undecided||2018-05-31 22:15:35.75338|2018-05-31 22:15:35.75338
NCT01413503|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-01-09|2011-08-08|2011-08-10|Estimate|||||||2015-01-09|2015-01-13|Estimate|May 1991||1991-05-31|January 2015|2015-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors|A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors|Completed||Phase 2|50|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 22:15:35.977898|2018-05-31 22:15:35.977898
NCT01413490|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-03-30|2011-08-09|2011-08-10|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|HepRiACT||Hepatitis C Rimantadine and Antiviral Combination Therapy|A Clinical Study to Evaluate the Biological Effects of Administering Rimantadine in Patients With Hepatitis C Virus (HCV) Infection Alongside Standard Combination Therapy With Pegylated Interferon and Ribavirin|Completed|||10|Actual|The Leeds Teaching Hospitals NHS Trust|||||f||||t||||||Samples Without DNA|"~     blood samples of patients undegoing standard combination therpay for hepatits c virus~     infection~   "|||2018-05-31 22:15:36.055783|2018-05-31 22:15:36.055783
NCT01413477|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-08-08|2011-08-08|2011-08-10|Estimate|||||||2011-08-08|2011-08-10|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|February 2012|Anticipated|2012-02-29||Interventional|||Nickel Desensitization Using Topical Therapy|Nickel Desensitization Using Topical Therapy|Unknown status|Not yet recruiting|N/A|24|Anticipated|University of British Columbia||4|||f||||f||||||||||2018-05-31 22:15:36.11906|2018-05-31 22:15:36.11906
NCT01413464|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-07-18|2011-08-09|2011-08-10|Estimate|||||||2013-07-18|2013-07-19|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|REPORT||The Risk of Venous Clotting in Patients After Renal Transplant|The Risk of Thromboembolism in Patients Post Renal Transplantation (REPORT) Study|Unknown status|Active, not recruiting||120|Actual|St. Joseph's Healthcare Hamilton|||||f||||t||||||Samples With DNA|"~     Plasma samples from participants are being banked at various timepoints.~   "|||2018-05-31 22:15:36.210821|2018-05-31 22:15:36.210821
NCT01413451|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2018-05-23|2011-08-09|2011-08-10|Estimate|||||||2018-05-23|2018-05-24|Actual|July 12, 2011||2011-07-12|November 15, 2013|2013-11-15|November 15, 2013|Actual|2013-11-15|November 15, 2013|Actual|2013-11-15||Interventional|||Amatuximab for High Mesothelin Cancers|A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers|Terminated||Early Phase 1|7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:15:36.262037|2018-05-31 22:15:36.262037
NCT01413438|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-06-30|2011-08-09|2011-08-10|Estimate|||||||2017-06-30|2017-07-02|Actual|July 15, 2011||2011-07-15|September 26, 2013|2013-09-26|September 26, 2013|Actual|2013-09-26|September 26, 2013|Actual|2013-09-26||Interventional|||Bevacizumab With or Without Surgery for Adult Glioblastomas|Prospective, Randomized Controlled Trial of Surgical Resection Prior to Bevacizumab Therapy for Recurrent Glioblastoma Multiforme|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:15:36.323958|2018-05-31 22:15:36.323958
NCT01413425|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-06-30|2011-08-09|2011-08-10|Estimate|||||||2017-06-30|2017-07-02|Actual|June 29, 2011||2011-06-29|October 20, 2014|2014-10-20|October 20, 2014||2014-10-20|||||Observational|||A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome|Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:15:36.377102|2018-05-31 22:15:36.377102
NCT01413412|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-09-28|2011-08-09|2011-08-10|Estimate|||||||2015-09-28|2015-09-29|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Full-thickness Skin vs. Synthetic Mesh in the Repair of Large Incisional Hernia|Full-thickness Skin vs. Synthetic Mesh in the Repair of Large Incisional Hernia - a Prospective Randomized Controlled Study|Unknown status|Active, not recruiting|N/A|50|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:15:36.432432|2018-05-31 22:15:36.432432
NCT01413399|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-08-03|2011-08-09|2011-08-10|Estimate|||||||2012-08-03|2012-08-07|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Pilot Study of Intra-arrest Therapeutic Hypothermia in Patients Suffering Non-Traumatic Out of Hospital Cardiac Arrest|A Pilot Study of Intra-arrest Therapeutic Hypothermia in Patients Suffering Non-Traumatic Out of Hospital Cardiac Arrest|Completed||N/A|363|Actual|Carolinas Medical Center||2|||f||||t||||||||||2018-05-31 22:15:36.502499|2018-05-31 22:15:36.502499
NCT01413386|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-07-23|2011-08-09|2011-08-10|Estimate|||||||2017-07-23|2017-07-25|Actual|September 2011||2011-09-30|July 2017|2017-07-31|April 23, 2013|Actual|2013-04-23|April 18, 2013|Actual|2013-04-18||Interventional|MIRAII||Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent|A Randomized Clinical Trial Comparing Patency and Safety of the Paclitaxel Eluting Covered Metallic Biliary Stent (Niti-S Mira-Cover II Biliary Stent) to the Common Covered Metallic Biliary Stent.|Terminated||Phase 3|74|Actual|Taewoong Medical Co., Ltd.||2||Delayed subject enrollment|f||||f||||||||||2018-05-31 22:15:36.563222|2018-05-31 22:15:36.563222
NCT01413373|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-10-15|2011-08-09|2011-08-10|Estimate|||||||2012-10-15|2012-10-16|Estimate|August 2008||2008-08-31|October 2012|2012-10-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|ACRO3D||3D Craniofacial Cephalometric Analysis|Clinical Validation of the Three-dimensional Computer Tomography Based Craniofacial Cephalometric Analysis|Unknown status|Recruiting|N/A|15|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-05-31 22:15:36.627029|2018-05-31 22:15:36.627029
NCT01413360|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2015-05-20||2016-06-06|2011-08-09|2011-08-10|Estimate|2016-06-06|2016-07-15|Estimate||||2016-06-06|2016-07-15|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients|Phase 4 Study of High Dose Vitamin C in Chronic Hepatitis Patients|Completed||Phase 4|10|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:15:36.720609|2018-05-31 22:15:36.720609
NCT01413347|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-12-07|2011-08-09|2011-08-10|Estimate|||||||2011-12-07|2011-12-08|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Method to Reduce Displacement of Double-lumen Tube|The Method to Reduce Displacement of Double-lumen Tube During Patient Positioning|Completed||N/A|100|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 22:15:36.850368|2018-05-31 22:15:36.850368
NCT01413334|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-09|2011-08-09|2011-08-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Observational|||Transluminal Attenuation Gradient Versus CT Fractional Flow Reserve|Noninvasive Diagnosis of Ischemia Causing Coronary Stenosis Using Coronary CT Angiograms (CCTA) : Comparison of Transluminal Attenuation Gradient (TAG) and Fractional Flow Reserve Computed From CCTA (FFR CT)|Unknown status|Recruiting||80|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 22:15:36.905141|2018-05-31 22:15:36.905141
NCT01413321|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-10-04|2011-08-08|2011-08-10|Estimate|||||||2017-10-04|2017-10-05|Actual|December 2011|Actual|2011-12-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Assessing Special Features of Impaired Gait After Acquired Brain Injury With an Instrumented Treadmill|The Reproducibility and Special Features of Hemiparetic Gait in People With Acquired Brain Injury (ABI) Assessed With an Instrumented Treadmill (Zebris)|Completed|||35|Actual|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 22:15:36.960007|2018-05-31 22:15:36.960007
NCT01413295|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2014-11-03|2011-08-09|2011-08-10|Estimate|||||||2014-11-03|2014-11-04|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer|Randomized Phase II Trial in Patients With Progressive Stage IV Colorectal Cancer to Two Lines of Chemotherapy, in Order to Compare the Best Supportive Treatment Versus Treatment With Dendritic Cells Plus the Best Supportive Treatment|Completed||Phase 2|52|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||t||||||||||2018-05-31 22:15:37.058339|2018-05-31 22:15:37.058339
NCT01413282|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2016-08-03|2011-08-09|2011-08-10|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|BEACON||Better Evaluation of Acute Chest Pain With Computed Tomography Angiography|Better Evaluation of Acute Chest Pain With Computed Tomography Angiography - A Randomized Controlled Trial|Completed||N/A|500|Actual|Erasmus Medical Center||2|||f||||t||||||||No||2018-05-31 22:15:37.124685|2018-05-31 22:15:37.124685
NCT01413269|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-07-20|2011-08-09|2011-08-10|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2010||2010-06-30|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2015|Actual|2015-09-30||Interventional|||Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery|Phase 3 Open-labeled Randomized Clinical Study of Comparing Hypofractionated and Conventional Radiotherapy for Breast Cancer Patients After Breast Conservative Surgery|Active, not recruiting||Phase 3|720|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:15:39.218069|2018-05-31 22:15:39.218069
NCT01413256|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2011-08-09|2011-08-09|2011-08-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Allergenic Effect of Ambrosia in Israel||Unknown status|Not yet recruiting||200|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 22:15:39.468627|2018-05-31 22:15:39.468627
NCT01413243|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2016-05-05|2011-08-09|2011-08-10|Estimate|||||||2016-05-05|2016-05-06|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|TRIOMS||Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome|Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial|Terminated||Phase 2|50|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:15:39.627645|2018-05-31 22:15:39.627645
NCT01413230|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-11-23|2011-08-05|2011-08-10|Estimate|||||||2011-11-23|2011-11-24|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|VITALUP||Vitamin D Supplementation in Systemic Lupus Erythematosus|Evaluation of Immunologic Response After Vitamin D Supplementation in Patients With Systemic Lupus Erythematosus|Completed|||20|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     blood with RNA~   "|||2018-05-31 22:15:39.931828|2018-05-31 22:15:39.931828
NCT01413217|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2012-02-07|2011-08-08|2011-08-10|Estimate|||||||2012-02-07|2012-02-09|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Which is a Better Breakfast? Egg or Cereal?|"Which is a Better Breakfast? Egg or Cereal?"|Completed|||20|Actual|Pennington Biomedical Research Center|||2||f||||f||||||||||2018-05-31 22:15:40.058845|2018-05-31 22:15:40.058845
NCT01413204|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|2014-03-26||2014-05-27|2011-08-08|2011-08-10|Estimate|2014-05-27|2014-06-05|Estimate||||2014-05-27|2014-06-05|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TA-7284 as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|272|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 22:15:40.155616|2018-05-31 22:15:40.155616
NCT01413191|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|2015-06-25||2015-06-25|2011-08-09|2011-08-10|Estimate|2015-06-25|2015-07-20|Estimate||||2015-06-25|2015-07-20|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|March 2013|Actual|2013-03-31||Interventional|||Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye|Phase II Study of IMC-A12 in Metastatic Uveal Melanoma|Completed||Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:15:40.833139|2018-05-31 22:15:40.833139
NCT01413178|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2018-04-11|2011-08-08|2011-08-10|Estimate|||||||2018-04-11|2018-04-12|Actual|September 30, 2011|Actual|2011-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma|A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma|Active, not recruiting||Phase 3|205|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:15:41.055852|2018-05-31 22:15:41.055852
NCT01413152|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-12-26|2011-08-09|2011-08-10|Estimate|||||||2012-12-26|2012-12-27|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|EP 49 EVARIST||Residual Risk Assessment Of HIV Transmission|EVALUATION DU RISQUE RESIDUEL DE TRANSMISSION DU VIH CHEZ DES HSH TRAITES AYANT UNE CHARGE VIRALE PLASMATIQUE INDETECTABLE|Completed||N/A|167|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 22:15:41.158034|2018-05-31 22:15:41.158034
NCT01413139|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2013-09-30|2011-08-09|2011-08-10|Estimate|||||||2013-09-30|2013-10-01|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|May 2011|Actual|2011-05-31||Interventional|4-EVER||4-EVER : a Trial Investigating the Safety of 4F Endovascular Treatment of Infra-Inguinal Arterial Stenotic Disease|4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease|Completed||Phase 4|120|Actual|Flanders Medical Research Program||1|||f||||f||||||||||2018-05-31 22:15:41.221033|2018-05-31 22:15:41.221033
NCT01413126|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-08|2011-08-08|2011-08-10|Estimate|||||||2011-08-08|2011-08-10|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||Peanuts Second Meal Glycemic Response|Acute and Second Meal Effects of Peanuts on Glycemic Response and Appetite in Obese Women With High Type 2 Diabetes Risk: a Randomized Crossover Trial|Completed||N/A|15|Actual|Federal University of Vicosa||3|||f||||f||||||||||2018-05-31 22:15:41.377161|2018-05-31 22:15:41.377161
NCT01412593|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|September 2011||2011-09-30|May 2011|2011-05-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Intra-hepatic Artery Bone Marrow Derived Stem Cells Infusion for the Treatment of Advanced Liver Cirrhosis||Unknown status|Not yet recruiting|Phase 1/Phase 2|50|Anticipated|King Saud University||2|||f||||f||||||||||2018-05-31 22:15:53.274414|2018-05-31 22:15:53.274414
NCT01413113|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-11-04|2011-08-08|2011-08-10|Estimate|||||||2015-11-04|2015-11-05|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|November 2013|Actual|2013-11-30||Interventional|||Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery|A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake|Completed||Phase 1|6|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 22:15:41.454055|2018-05-31 22:15:41.454055
NCT01413100|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2018-01-08|2011-08-08|2011-08-10|Estimate|||||||2018-01-08|2018-01-09|Actual|September 15, 2011|Actual|2011-09-15|January 2018|2018-01-31||||September 1, 2019|Anticipated|2019-09-01||Interventional|STAT||Scleroderma Treatment With Autologous Transplant (STAT) Study|A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis|Recruiting||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 22:15:41.555599|2018-05-31 22:15:41.555599
NCT01413087|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2012-08-09|2011-08-09|2011-08-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|September 2015|Anticipated|2015-09-30|September 2013|Anticipated|2013-09-30||Interventional|LAPC-BC-819||Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma|A Multi-Center, Open-Label, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|BioCancell Ltd.||1|||f||||f||||||||||2018-05-31 22:15:41.752245|2018-05-31 22:15:41.752245
NCT01413074|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2016-05-17|2011-08-09|2011-08-10|Estimate|||||||2016-05-17|2016-05-19|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Survival on Peritoneal Dialysis (PD) Versus Hemodialysis (HD) in China|A Prospective, Randomized, Multicenter, Open-Label, Interventional Study Comparing Survival in Subjects Receiving Peritoneal Dialysis vs Hemodialysis in China|Terminated||Phase 4|416|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-05-31 22:15:41.831439|2018-05-31 22:15:41.831439
NCT01413061|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2018-04-11|2011-08-09|2011-08-10|Estimate|||||||2018-04-11|2018-04-13|Actual|June 2010|Actual|2010-06-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|February 2017|Actual|2017-02-28||Interventional|||Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft|Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft|Completed||N/A|140|Actual|AlloSource||2|||f||||f|f|f||||||||2018-05-31 22:15:41.905072|2018-05-31 22:15:41.905072
NCT01413048|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-07|||2011-08-08|2011-08-08|2011-08-10|Estimate|||||||2011-08-08|2011-08-10|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|March 2012|Anticipated|2012-03-31||Interventional|||Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension|Phase III Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 Versus Carvedilol in Patient With Stage 1 to 2 Essential Hypertension|Unknown status|Recruiting|Phase 3|260|Anticipated|Ahn-Gook Pharmaceuticals Co.,Ltd||2|||f||||t||||||||||2018-05-31 22:15:41.989151|2018-05-31 22:15:41.989151
NCT01413035|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|||Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes|Safety/Efficacy Assessed Study on Transplantation Therapy Using Human Umbilical Cord/Placenta-derived Mesenchymal Stem Cells for Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Shandong University||3|||f||||t||||||||||2018-05-31 22:15:42.07752|2018-05-31 22:15:42.07752
NCT01413022|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2016-09-15|2011-08-08|2011-08-09|Estimate|||||||2016-09-15|2016-09-19|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|October 2013|Actual|2013-10-31||Interventional|||FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma|Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma|Completed||Phase 1|44|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 22:15:42.16632|2018-05-31 22:15:42.16632
NCT01413009|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-01-03|2011-08-08|2011-08-09|Estimate|||||||2013-01-03|2013-01-07|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|October 2013|Anticipated|2013-10-31|April 2012|Actual|2012-04-30||Observational|ABCDE||Awakening-Breathing Coordination, Delirium Monitoring/Management & Early Mobility (ABCDE) Protocol|Awakening-Breathing Coordination, Delirium Monitoring/Management & Early Mobility (ABCDE) Protocol|Unknown status|Active, not recruiting||200|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 22:15:42.282441|2018-05-31 22:15:42.282441
NCT01412996|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2012-02-24|2011-08-08|2011-08-09|Estimate|||||||2012-02-24|2012-02-27|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Quality of Life Measures After Single Access Vs Conventional Laparoscopic Cholecystectomy: Prospective Randomized Study.|Single Access Laparoscopic Cholecystectomy|Completed||N/A|250|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 22:15:42.381969|2018-05-31 22:15:42.381969
NCT01412983|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2014-03-27||2014-03-27|2011-08-08|2011-08-09|Estimate|2014-03-27|2014-04-29|Estimate||||2014-03-27|2014-04-29|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional||All participants enrolled in the study|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens|Completed||N/A|100|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:15:42.467457|2018-05-31 22:15:42.467457
NCT01412970|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2015-08-11|2011-08-08|2011-08-09|Estimate|||||||2015-08-11|2015-08-13|Estimate|July 2016||2016-07-31|August 2015|2015-08-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Non-invasive Measurement of Central Hemodynamics by Electrical Impedance Tomography|Non-invasive Measurement of Central Hemodynamics and Heart-lung Interactions by Electrical Impedance Tomography|Unknown status|Not yet recruiting|N/A|30|Anticipated|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-05-31 22:15:42.650122|2018-05-31 22:15:42.650122
NCT01412957|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2016-03-02|2015-07-21|2017-02-07|2011-08-08|2011-08-09|Estimate|2016-04-07|2016-04-08|Estimate|2015-07-21|2015-08-11|Estimate|2017-02-07|2017-03-15|Actual|November 2011||2011-11-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|June 2014|Actual|2014-06-30||Interventional|||Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer|A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer|Completed||Phase 3|377|Actual|Amgen||2|||f||||t||||||||||2018-05-31 22:15:42.861608|2018-05-31 22:15:42.861608
NCT01412944|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2015-01-28||2015-03-17|2011-08-08|2011-08-09|Estimate|2015-03-17|2015-03-18|Estimate||||2015-03-17|2015-03-18|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|STATURE||Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis|A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab|Completed||Phase 3|43|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:15:44.288398|2018-05-31 22:15:44.288398
NCT01412931|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2016-04-22|2011-08-08|2011-08-09|Estimate|||||||2016-04-22|2016-04-26|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Protein and Ultrasound Indicators of Preterm Birth|Protein and Ultrasound Indicators of Preterm Birth|Completed|||3|Actual|University of Colorado, Denver|||3||f||||t||||||Samples With DNA|"~     Cervicovaginal fluid and placental membranes will be retained for study.~   "|||2018-05-31 22:15:47.704164|2018-05-31 22:15:47.704164
NCT01412918|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|2014-06-23||2016-01-29|2011-08-08|2011-08-09|Estimate|2015-12-14|2016-01-18|Estimate||||2016-01-29|2016-02-29|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional||The baseline participants with tinnitus demonstrating the Inhibitor™ Tinnitus Masking Device.|Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression|Clinical Evaluation of the Inhibitor Tinnitus Treatment Masking Device & SCN9 Gene Expression|Terminated||N/A|21|Actual|Medical College of Wisconsin||2||Lack of support to continue|f||||f||||||||No||2018-05-31 22:15:47.776221|2018-05-31 22:15:47.776221
NCT01412905|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|February 2007||2007-02-28|August 2011|2011-08-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Observational|||Telemedicine Retinal Screening Utilizing a Mobile Medical Unit|Telemedicine Retinal Screening Utilizing a Mobile Medical Unit With a Trained Technician Accurately Detects Disease in High Risk Ethnically Diverse Populations: Results of a Project Dulce™ Retinal Screening Study|Completed|||1229|Actual|Scripps Whittier Diabetes Institute|||||f||||||||||||||2018-05-31 22:15:48.086731|2018-05-31 22:15:48.086731
NCT01412892|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2014-11-13|2011-08-08|2011-08-09|Estimate|||||||2014-11-13|2014-11-14|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|NFitor||Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas|A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery|Completed||Phase 2|30|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 22:15:48.165831|2018-05-31 22:15:48.165831
NCT01412879|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-06|2017-02-15||2018-03-12|2011-08-08|2011-08-09|Estimate|2017-05-04|2017-06-07|Actual||||2018-03-12|2018-03-14|Actual|November 2011||2011-11-30|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|February 2016|Actual|2016-02-29||Interventional||All eligible patients who started treatment were included in the analysis|S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma|A Randomized Phase II Trial of R-HCVAD/MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant Vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients ≤ 65 Years of Age With Previously Untreated Mantle Cell Lymphoma|Active, not recruiting||Phase 2|53|Actual|Southwest Oncology Group||2|||f||||f||||||||||2018-05-31 22:15:48.376758|2018-05-31 22:15:48.376758
NCT01412866|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2012-09-26|2011-08-08|2011-08-09|Estimate|||||||2012-09-26|2012-09-28|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Electronic Decision Support Systems for Smokers With Severe Mental Illness||Completed||N/A|142|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 22:15:49.559665|2018-05-31 22:15:49.559665
NCT01412853|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2017-06-20|2011-08-08|2011-08-09|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2008|Actual|2008-02-29|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ERIS||Spectro-IRM and Evaluation Response to Prostatic Radiotherapy|Evaluation of the Response to Irradiation With MR-Spectroscopy for Localised Prostate Cancer Patients (The ERIS Trial)|Completed||N/A|90|Actual|Centre Georges Francois Leclerc||1|||f||||||||||||||2018-05-31 22:15:49.687504|2018-05-31 22:15:49.687504
NCT01412840|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2017-01-22|2011-08-08|2011-08-09|Estimate|||||||2017-01-22|2017-01-24|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Sterile Water Injections for Relieving Ureterolithiasis Pain|Sterile Water Injections as a Complementary Method for Relieving Ureterolithiasis Pain- a Randomized Controlled Trial|Active, not recruiting||N/A|90|Anticipated|University of Skövde||3|||f||||f||||||||||2018-05-31 22:15:49.930777|2018-05-31 22:15:49.930777
NCT01412827|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-07|||2016-02-23|2011-08-08|2011-08-09|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|March 2013|Actual|2013-03-31||Interventional|SPECT-Light||Accuracy of Half of the Usual Radiotracer Dose in SPECT|Diagnostic and Prognostic Accuracy of Stress SPECT Myocardial Perfusion Imaging With Half the Usual Radiotracer Dose|Completed||N/A|18|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 22:15:50.037564|2018-05-31 22:15:50.037564
NCT01412814|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-12-21|2011-08-07|2011-08-09|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2011||2011-07-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Biomechanics of Gait Pattern Adaptation in Patients After Total Knee Arthroplasty|Biomechanics of Gait Pattern Adaptation in Patients After Total Knee Arthroplasty|Completed||N/A|50|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 22:15:50.126217|2018-05-31 22:15:50.126217
NCT01412801|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2014-06-20||2014-09-05|2011-08-08|2011-08-09|Estimate|2014-09-05|2014-09-12|Estimate||||2014-09-05|2014-09-12|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings|A Phase II Open-Label, Multi-Center Study of a Group B Streptococcus Vaccine in HIV Positive and HIV Negative Pregnant Women|Completed||Phase 2|270|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:15:50.2575|2018-05-31 22:15:50.2575
NCT01412788|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-07|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|January 2007||2007-01-31|August 2011|2011-08-31||||January 2013|Anticipated|2013-01-31||Interventional|||Safety and Aesthetic Outcomes of Breast Conserving Surgery With Peri-areolar Incision Approach|Randomized Controlled Trial of Safety and Aesthetic Outcomes of Breast-conserving Surgery With the Peri-areolar Incision Approach|Unknown status|Recruiting|Phase 3|100|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 22:15:51.904|2018-05-31 22:15:51.904
NCT01412775|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-08-29|2011-08-07|2011-08-09|Estimate|||||||2011-08-29|2011-08-30|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Psychological Group Intervention to Reduce Stress and Burnout Among Cardiac Intensive Care Nurses|The Contribution of a Short-term Psychological Group Intervention to Reduce Stress and Burnout Among Cardiac Intensive Care Nurses: A Pilot Study|Unknown status|Not yet recruiting|N/A|24|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:15:51.970579|2018-05-31 22:15:51.970579
NCT01412762|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-11-07|2011-08-08|2011-08-09|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Measuring Patient Expectations for Thyroid Surgery|Measuring Patient Expectations for Thyroid Surgery: Development of a Patient-Reported Outcomes Instrument|Recruiting|||70|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 22:15:52.033737|2018-05-31 22:15:52.033737
NCT01412749|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-06-27|2011-08-08|2011-08-09|Estimate|||||||2013-06-27|2013-06-28|Estimate|April 2011||2011-04-30|June 2013|2013-06-30||||June 2013|Actual|2013-06-30||Observational|TEST||TEST: Registry for Endoscopic Head and Neck Surgery|Transoral Endoscopic Surgery Trial (TEST): A Registry for Endoscopic Head and Neck Surgery (eHNS)|Terminated|||2|Actual|M.D. Anderson Cancer Center|||1|Low Accrual|f||||f||||||||||2018-05-31 22:15:52.09723|2018-05-31 22:15:52.09723
NCT01412736|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-07|||2014-12-21|2011-08-08|2011-08-09|Estimate|||||||2014-12-21|2014-12-23|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|4563-003||A Phase IIa Study of KHK4563|A Phase IIa , Double-blind, Placebo-controlled Dose-ranging Study to Evaluate the Efficacy and Safety of KHK4563 in Adults With Uncontrolled, Suspected Eosinophilic Asthma|Completed||Phase 2|106|Actual|Kyowa Hakko Kirin Co., Ltd||4|||f||||f||||||||||2018-05-31 22:15:52.148065|2018-05-31 22:15:52.148065
NCT01412723|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2012-04-10|2011-08-08|2011-08-09|Estimate|||||||2012-04-10|2012-04-11|Estimate|October 2011||2011-10-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Ferrous Sulfate Versus Iron Amino Acid Chelate|EFICACIA DEL HIERRO AMINOQUELADO COMPARADO CON EL SULFATO FERROSO COMO COMPLEMENTO ALIMENTARIO EN PREESCOLARES CON DEFICIENCIA DE HIERRO.|Completed||Phase 3|64|Actual|CES University||2|||f||||f||||||||||2018-05-31 22:15:52.35264|2018-05-31 22:15:52.35264
NCT01412710|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-07|2017-08-05||2017-11-13|2011-08-08|2011-08-09|Estimate|2017-11-13|2017-12-12|Actual||||2017-11-13|2017-12-12|Actual|July 2011||2011-07-31|October 2017|2017-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Hispanic or Latino and African-Americans, age 30-70 years old, with type 2 diabetes.|Vitamin D Supplementation on Cardiovascular Risk Factors|The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes|Completed||N/A|92|Actual|Florida International University|The study sample was a convenience sample and was not randomly selected from the general adult population. The study lacked a control group.|2|||f||||t||||||||||2018-05-31 22:15:52.440647|2018-05-31 22:15:52.440647
NCT01412697|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2016-02-26|2011-08-08|2011-08-09|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|November 2010|Actual|2010-11-30|June 2009|Actual|2009-06-30||Interventional|||An Intervention Targeting Fruit and Vegetable Intake Among Rural Youth|Fruit and Vegetable Intake Among Rural Youth Following a School-based Randomized Controlled Trial|Completed||N/A|1119|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 22:15:52.684583|2018-05-31 22:15:52.684583
NCT01412684|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2016-08-04|2011-08-08|2011-08-09|Estimate|||||||2016-08-04|2016-08-08|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|September 2011|Actual|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors|Pilot Study of Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors Arising in the Body and Tail of the Pancreas|Withdrawn|||0|Actual|University of Missouri-Columbia||||Never activated|f||||f||||||||||2018-05-31 22:15:52.752486|2018-05-31 22:15:52.752486
NCT01412671|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-07|||2012-04-10|2011-08-07|2011-08-09|Estimate|||||||2012-04-10|2012-04-12|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program|Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma: Early Access Program)|Completed|||117|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:15:52.805897|2018-05-31 22:15:52.805897
NCT01412658|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-07|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|November 2006||2006-11-30|August 2011|2011-08-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||Clinical Safety of a Novel Milk Protein Peptide|Safety Study of Milk Peptide Supplementation in Healthy Volunteers: a Randomized Placebo Controlled Clinical Trial|Completed||Phase 1|73|Actual|Ambryx Biotechnology||2|||f||||t||||||||||2018-05-31 22:15:52.931162|2018-05-31 22:15:52.931162
NCT01412645|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2013-12-12|2011-08-08|2011-08-09|Estimate|||||||2013-12-12|2013-12-13|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|LIRMOI||Long-term Investigation of Resveratrol in Obesity|Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds|Completed||N/A|76|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 22:15:52.995769|2018-05-31 22:15:52.995769
NCT01412632|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2014-09-30|2011-08-08|2011-08-09|Estimate|||||||2014-09-30|2014-10-01|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Comparing Two Types of Sedation to Gynaecological Patients|Deep Sedation in Spontaneously Breathing Patients Combined With Local Anesthesia Versus General Anesthesia in Gynecological Patients at Same Day Surgical at Hospitalsenheden Horsens|Completed||Phase 4|153|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 22:15:53.069797|2018-05-31 22:15:53.069797
NCT01412619|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-12-24|2011-08-08|2011-08-09|Estimate|||||||2011-12-24|2011-12-29|Estimate|December 2008||2008-12-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|CSINVOS||Non-invasive Measurement of Regional Intracerebral Tissue Oxygenation in Elective Cardiac Surgeries|CSINVOS: Non-invasive Measurement of Regional Intracerebral Tissue Oxygenation in Elective Cardiac Surgeries|Completed|||50|Anticipated|RWTH Aachen University|||||f||||f||||||Samples Without DNA|"~     Cytokine IL-6 Cytokine IL-10 Procalcitonin (PCT) S-100-Protein~   "|||2018-05-31 22:15:53.161517|2018-05-31 22:15:53.161517
NCT01412606|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2012-08-28|2011-08-08|2011-08-09|Estimate|||||||2012-08-28|2012-08-30|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|ESUS||Endometrial Scratching in Couples With Unexplained Subfertility|Endometrial Scratching in Couples With Unexplained Subfertility|Completed||Phase 2/Phase 3|105|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 22:15:53.215168|2018-05-31 22:15:53.215168
NCT01110265|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-22|2010-04-22|2010-04-26|Estimate|||||||2010-04-22|2010-04-26|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Attention Training and Its Effects on Body Image Disturbance||Completed||N/A|32|Actual|University of Sydney||2|||f||||f||||||||||2018-05-31 23:51:56.679121|2018-05-31 23:51:56.679121
NCT01412580|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2017-03-23|2011-08-08|2011-08-09|Estimate|||||||2017-03-23|2017-03-27|Actual|April 2002||2002-04-30|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Observational|CDS||In Utero Capacity Formation and Socio-economic Outcomes|The Contribution of Health in Utero to Capacity Formation, Education and Economic Outcomes: Experimental Evidence From Tanzania|Completed|||4000|Actual|Harvard University|||1||f||||f||||||||No||2018-05-31 22:15:53.325247|2018-05-31 22:15:53.325247
NCT01412567|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|October 2005||2005-10-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers|Comparison of Recombinant Hepatitis B Vaccine Plus Hepatitis B Immune Globulin (HBIG) Versus Vaccine Plus Placebo for Prophylaxis of Hepatitis B Infection in Newborns of Hepatitis B Surface Antigen (HBsAg) Positive Mothers|Completed||N/A|259|Actual|Govind Ballabh Pant Hospital||2|||f||||f||||||||||2018-05-31 22:15:53.380353|2018-05-31 22:15:53.380353
NCT01412554|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2016-01-11|2011-08-08|2011-08-09|Estimate|||||||2016-01-11|2016-01-12|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Observational|INFO||Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow up|Impact of INsulin Sensitivity on Cardiovascular Risk Markers During 10-20 Years of FOllow-up|Completed|||103|Actual|Oslo University Hospital|||1||f||||f||||||Samples Without DNA|"~     whole blood, serum, white cells, urine, fat tissue cells~   "|||2018-05-31 22:15:53.443493|2018-05-31 22:15:53.443493
NCT01412541|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2015-07-14||2017-11-09|2011-08-08|2011-08-09|Estimate|2016-03-25|2016-03-29|Estimate||||2017-11-09|2017-12-11|Actual|July 2011||2011-07-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|November 2013|Actual|2013-11-30||Interventional|LEVANT 2||Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries|A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries|Active, not recruiting||N/A|476|Actual|C. R. Bard||2|||f||||t||||||||||2018-05-31 22:15:53.548126|2018-05-31 22:15:53.548126
NCT01412528|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|August 2009||2009-08-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase II Study to Standardize Allergen Extracts: Determination of Biological Activity in HEP Units||Terminated||Phase 2|160|Anticipated|University of Zurich||1||Recruitment problems|f||||||||||||||2018-05-31 22:15:55.083986|2018-05-31 22:15:55.083986
NCT01412515|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2011-12-29|2011-08-08|2011-08-09|Estimate|||||||2011-12-29|2012-01-02|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma|A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma|Terminated||Phase 2|11|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1||results from interim analysis conducted to study interruption|f||||f||||||||||2018-05-31 22:15:55.133225|2018-05-31 22:15:55.133225
NCT01412502|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2018-01-02|2011-08-08|2011-08-09|Estimate|||||||2018-01-02|2018-01-03|Actual|June 15, 2012|Actual|2012-06-15|January 2018|2018-01-31|June 28, 2016|Actual|2016-06-28|June 28, 2016|Actual|2016-06-28||Observational|||Post Traumatic Stress Among Relatives of Brain-dead, Withdrawal of Life Support, and Sudden Death Patients|Evaluation of Post Traumatic Stress Among the Nearest Relatives of Brain-dead, Withdrawal of Life Support, and Sudden Death Patients|Terminated|||119|Actual|Centre Hospitalier Universitaire de Nīmes|||3|no recruitment|f||||f||||||||||2018-05-31 22:15:55.190959|2018-05-31 22:15:55.190959
NCT01412489|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-03-24|2011-08-08|2011-08-09|Estimate|||||||2017-03-24|2017-03-28|Actual|August 2011|Actual|2011-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|HYGEM||Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel|Prevention of Postsurgical Uterine Synechia With HyalobarrierR Gel Endo in Hysteroscopic Myomectomy : a Prospective Multicenter Study|Completed||N/A|189|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:15:55.257346|2018-05-31 22:15:55.257346
NCT01412476|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2012-03-23|2011-08-08|2011-08-09|Estimate|||||||2012-03-23|2012-03-26|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|||||Observational|||Coenzyme Q10 and Vitamin A, C, E in Relation to the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome||Completed|||72|Actual|Chung Shan Medical University|||2||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 22:15:55.315377|2018-05-31 22:15:55.315377
NCT01412463|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2013-09-30|2011-08-08|2011-08-09|Estimate|||||||2013-09-30|2013-10-01|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|DURABILITY+||DURABILITY+ : a Prospective, Multi-center, Controlled Study With the Everflex+ Stent in SFA Lesions|DURABILITY+ : a Prospective, Multi-center, Controlled Study Measuring the Durability in Lesions of the Superficial Femoral Artery of the Protégé Everflex+ Stent|Completed||Phase 4|60|Actual|Flanders Medical Research Program||1|||f||||t||||||||||2018-05-31 22:15:55.359783|2018-05-31 22:15:55.359783
NCT01412450|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2013-09-30|2011-08-08|2011-08-09|Estimate|||||||2013-09-30|2013-10-01|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|DUR-POP||Efficacity Study With the Protégé EverFlex Stent in Popliteal Lesions|DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions|Completed||Phase 4|60|Actual|Flanders Medical Research Program||1|||f||||t||||||||||2018-05-31 22:15:55.416446|2018-05-31 22:15:55.416446
NCT01412437|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2014-12-16|2011-08-08|2011-08-09|Estimate|||||||2014-12-16|2014-12-17|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|PKU||Neuroimaging and Neurocognitive Assessment and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria|Multimodal Neuroimaging and Neurocognitive Assessment of Biomarkers and Response to Sapropterin Dihydrochloride Treatment in Phenylketonuria|Withdrawn||N/A|0|Actual|Children's Research Institute||2||poor recruitment|f||||t||||||||||2018-05-31 22:15:55.605494|2018-05-31 22:15:55.605494
NCT01412424|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2015-10-28||2017-07-14|2011-08-08|2011-08-09|Estimate|2015-10-28|2015-12-01|Estimate||||2017-07-14|2017-08-17|Actual|March 2012||2012-03-31|July 2017|2017-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Safety population: All participants enrolled in the study who received any amount of the study drug.|Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly|Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs|Completed||Phase 3|155|Actual|Chiasma, Inc.||1|||f||||t||||||||||2018-05-31 22:15:55.726054|2018-05-31 22:15:55.726054
NCT01412411|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-08|2011-08-08|2011-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|CFS||Appropriate Complmentary Feeding Strategies in Infants|Appropriate Complementary Feeding Strategies in Infants: An Evaluation of Various Strategies to Assess the Growth and Health of the Infants.|Completed||N/A|470|Actual|Aga Khan University||3|||f||||t||||||||||2018-05-31 22:15:56.357498|2018-05-31 22:15:56.357498
NCT01412398|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2018-01-18|2011-08-08|2011-08-09|Estimate|||||||2018-01-18|2018-01-19|Actual|April 7, 2009|Actual|2009-04-07|January 2018|2018-01-31|September 1, 2016|Actual|2016-09-01|April 8, 2014|Actual|2014-04-08||Observational|FOSRENOL-CAPD||Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan|Special Drug Use Investigation of Fosrenol (Investigation for Patients With Continuous Ambulatory Peritoneal Dialysis)|Completed|||446|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:15:56.43559|2018-05-31 22:15:56.43559
NCT01412385|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2017-10-19|2011-08-08|2011-08-09|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2011||2011-08-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Immune Globulin Subcutaenous (Human), 20%|A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases|Completed||Phase 2/Phase 3|55|Actual|Shire||2|||f||||f||||||||||2018-05-31 22:15:56.508035|2018-05-31 22:15:56.508035
NCT01412372|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2018-01-02|2011-08-05|2011-08-09|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2010||2010-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Mesalamine||The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study|The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study|Recruiting||Phase 3|68|Anticipated|University of Utah||2|||f||||t||||||||||2018-05-31 22:15:56.600454|2018-05-31 22:15:56.600454
NCT01412359|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-03-02|2011-08-05|2011-08-09|Estimate|||||||2018-03-02|2018-03-06|Actual|June 2009||2009-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury|Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury|Enrolling by invitation||Phase 2|90|Anticipated|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 22:15:56.717001|2018-05-31 22:15:56.717001
NCT01412346|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-10-13|2011-08-08|2011-08-09|Estimate|||||||2014-10-13|2014-10-15|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|June 2012|Actual|2012-06-30||Interventional|||Health Effects of a Nordic Diet Rich in Plant-based Foods and Fish|Health Effects of a Nordic Diet Rich in Plant-based Foods and Fish|Completed||N/A|111|Actual|National Institute for Health and Welfare, Finland||2|||f||||f||||||||||2018-05-31 22:15:56.773915|2018-05-31 22:15:56.773915
NCT01412333|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2017-03-30|2016-10-21|2018-05-23|2011-08-08|2011-08-09|Estimate|2017-07-17|2017-07-18|Actual|2016-10-25|2016-10-26|Estimate|2018-05-23|2018-05-25|Actual|September 20, 2011|Actual|2011-09-20|May 2018|2018-05-31|January 16, 2020|Anticipated|2020-01-16|May 12, 2015|Actual|2015-05-12||Interventional||Intent-to-treat (ITT) population included all randomized participants in the study.|A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis|A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis|Active, not recruiting||Phase 3|835|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 22:15:56.873122|2018-05-31 22:15:56.873122
NCT01412320|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-11-12|2011-08-08|2011-08-09|Estimate|||||||2013-11-12|2013-11-13|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cocoa Flavanols in Renal Disease|The Impact of Dietary Flavanols on Cardiovascular Dysfunction in End-stage Renal Disease|Completed||Phase 1/Phase 2|22|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||||2018-05-31 22:15:57.871592|2018-05-31 22:15:57.871592
NCT01412307|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-08-08|2011-08-08|2011-08-09|Estimate|||||||2015-08-08|2015-08-11|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2015|Actual|2015-07-31||Interventional|LEBEN||A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma|A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine (LEBEN) in Relapsed and Primary Refractory Hodgkin Lymphoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|36|Anticipated|Fondazione Giovanni Pascale||1|||f||||t||||||||||2018-05-31 22:15:57.940381|2018-05-31 22:15:57.940381
NCT01412294|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-30|||2017-07-26|2011-08-08|2011-08-09|Estimate|||||||2017-07-26|2017-07-27|Actual|July 2011||2011-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer|Phase II Study to Evaluate Efficacy and Safety of Capecitabine/Cisplatin Combination Therapy in Gastric Cancer Patients Who Relapsed After S-1 Adjuvant Chemotherapy (XParTS)|Active, not recruiting||Phase 2|40|Anticipated|Epidemiological and Clinical Research Information Network||1|||f||||t||||||||||2018-05-31 22:15:58.027074|2018-05-31 22:15:58.027074
NCT01412281|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|2012-10-23||2013-08-29|2011-08-08|2011-08-09|Estimate|2013-02-15|2013-03-22|Estimate||||2013-08-29|2013-09-09|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers|Randomized, Parallel-group, Double-blind, Single-center Phase III Study to Assess the Immunogenicity and Safety of the 2011/2012-season Influenza Vaccine Formulated With HA Antigen From Two Suppliers, in Elderly and Young Adult Subjects Using the Current EMA Regulations as Guideline|Completed||Phase 3|440|Actual|Crucell Holland BV||4|||f||||f||||||||||2018-05-31 22:15:58.102091|2018-05-31 22:15:58.102091
NCT01412268|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2016-07-23|2011-08-08|2011-08-09|Estimate|||||||2016-07-23|2016-07-26|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Observational|||Does Bariatric Surgery Changes Eating Habits and Addiction in Morbid Obesity?|Study of Eating Habits and Addiction Changes in Short and Long Time Follow-up in Morbidly Obese Patients Who Undergo Bariatric Surgery.|Completed|||35|Actual|Bezmialem Vakif University|||||f||||||||||||||2018-05-31 22:15:58.567321|2018-05-31 22:15:58.567321
NCT01412242|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2015-01-22|2011-08-08|2011-08-09|Estimate|||||||2015-01-22|2015-01-26|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|PALLADIO||Simplification of the Diagnosis of Deep Vein Thrombosis|Identification of the Optimal Approach to the Ultrasound Diagnosis of Deep Vein Thrombosis of the Lower Extremities in Symptomatic Patients|Completed||Phase 3|1100|Actual|University of Padova||1|||f||||t||||||||||2018-05-31 22:15:58.654293|2018-05-31 22:15:58.654293
NCT01411306|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2016-10-27|2011-08-05|2011-08-08|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2011||2011-05-31|October 2016|2016-10-31||||November 2015|Actual|2015-11-30||Observational|||Screening for Swallowing Problems in Patients Following Prolonged Intubation: Validation of the Toronto Bedside Swallowing Screening Test (TOR-BSST©)||Completed|||100|Actual|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 22:16:14.28036|2018-05-31 22:16:14.28036
NCT01412229|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2017-03-29||2017-07-05|2011-08-08|2011-08-09|Estimate|2017-06-05|2017-07-02|Actual||||2017-07-05|2017-08-01|Actual|February 2012||2012-02-29|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|June 2015|Actual|2015-06-30||Interventional|||Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 2|40|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:15:58.819991|2018-05-31 22:15:58.819991
NCT01412216|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-11-06|2011-08-08|2011-08-09|Estimate|||||||2013-11-06|2013-11-07|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|Bedrest||The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance|The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance|Terminated||Phase 2|5|Actual|University of California, San Francisco||2||Funding Depleted.|f||||||||||||||2018-05-31 22:16:00.037937|2018-05-31 22:16:00.037937
NCT01412203|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-10-10|2011-08-05|2011-08-09|Estimate|||||||2013-10-10|2013-10-11|Estimate|April 2005||2005-04-30|October 2013|2013-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|AS!BC||Evaluating the Effectiveness of the Dissemination of Action Schools! BC|Evaluating the Effectiveness of the Dissemination of Action Schools! BC: A Socio-ecological Intervention to Increase Physical Activity and Healthy Eating in School Children|Completed||N/A|1529|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:16:00.135929|2018-05-31 22:16:00.135929
NCT01412190|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2012-11-22|2011-08-08|2011-08-09|Estimate|||||||2012-11-22|2012-11-27|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study to Evaluate Restylane Vital Light Using an Injector Device|An Open, Randomized, Single-centre, Intra-individual Controlled, Explorative, Safety and Efficacy Study Comparing Restylane Vital White With no Treatment in the Face, Back of the Hands and décolletage, Using an Injector Device|Completed||N/A|30|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 22:16:00.350951|2018-05-31 22:16:00.350951
NCT01412177|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-31||2015-08-18|2015-08-18|2011-08-08|2011-08-09|Estimate||||2015-08-18|2015-09-03|Estimate|2015-08-18|2015-09-03|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||OTO-104 for the Treatment of Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2b Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease|Completed||Phase 2|154|Actual|Otonomy, Inc.||2|||f||||t||||||||||2018-05-31 22:16:00.547388|2018-05-31 22:16:00.547388
NCT01412164|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2016-02-19||2016-02-19|2011-08-08|2011-08-09|Estimate|2016-02-19|2016-03-17|Estimate||||2016-02-19|2016-03-17|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2013|Actual|2013-02-28||Interventional|||Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)|A Prospective Multicenter Single-Arm Observational Registry Study Assessing the Safety and Efficacy of FIREHAWK Biodegradable Polymer Target-release Rapamycin-eluting Stent for the Treatment of Coronary Artery Disease: TARGET II|Unknown status|Active, not recruiting|N/A|730|Actual|Shanghai MicroPort Medical (Group) Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:16:02.146822|2018-05-31 22:16:02.146822
NCT01412151|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2012-11-28||2018-02-06|2011-08-05|2011-08-09|Estimate|2012-11-28|2012-12-28|Estimate||||2018-02-06|2018-03-09|Actual|April 2005||2005-04-30|February 2018|2018-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|CREST-X||Creatine Safety & Tolerability in Huntington's Disease|Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD|Completed||Phase 2|10|Actual|Massachusetts General Hospital|secondary analyses no completed|1|||f||||f||||||||||2018-05-31 22:16:03.162054|2018-05-31 22:16:03.162054
NCT01412138|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-04-21|2011-08-05|2011-08-09|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Somatic Stem Cells in Endometriosis|"Identification, Characterization and Isolation of Somatic Stem Cells in Human Endometrium of Women With Endometriosis"|Unknown status|Active, not recruiting||30|Anticipated|Igenomix|||1||f||||f||||||Samples With DNA|"~     endometrial biopsy~   "|||2018-05-31 22:16:03.525248|2018-05-31 22:16:03.525248
NCT01412125|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-10-08|2011-08-05|2011-08-09|Estimate|||||||2014-10-08|2014-10-09|Estimate|September 2003||2003-09-30|October 2014|2014-10-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|BIOHD||Study of Biomarkers That Predict the Evolution of Huntington's Disease|Study of Biomarkers That Predict the Evolution of Huntington's Disease|Recruiting|||1800|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||Samples With DNA|"~     -  Blood (for DNA analysis) and plasma sample at inclusion visit~        -  Plasma sample every year~   "|||2018-05-31 22:16:03.590281|2018-05-31 22:16:03.590281
NCT01412112|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2012-02-08|2011-08-08|2011-08-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:16:03.680697|2018-05-31 22:16:03.680697
NCT01412099|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2012-02-02|2011-08-05|2011-08-09|Estimate|||||||2012-02-02|2012-02-06|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Nutrition and Physical Activity Counseling for Nontraditional College Students|Feasibility of a Health Promotion Program for Nontraditional College Students|Completed||N/A|60|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 22:16:03.790114|2018-05-31 22:16:03.790114
NCT01412086|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2012-09-27||2012-09-27|2011-08-08|2011-08-09|Estimate|2012-09-27|2012-10-29|Estimate||||2012-09-27|2012-10-29|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale||Completed|||112|Actual|Allergan|||1||f||||f||||||||||2018-05-31 22:16:03.904325|2018-05-31 22:16:03.904325
NCT01412073|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-10-04|2011-08-05|2011-08-08|Estimate|||||||2014-10-04|2014-10-07|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Control of Blood Loss During Caesarean Section|A Randomized Trial to Determine the Best Strategy for the Control of Blood Loss at Elective Caesarean Section|Completed||Phase 3|600|Actual|Cairo University||3|||f||||t||||||||||2018-05-31 22:16:04.090685|2018-05-31 22:16:04.090685
NCT01412060|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04||2015-09-25|2015-09-25|2011-08-05|2011-08-08|Estimate||||2015-09-25|2015-09-30|Estimate|2015-09-25|2015-09-30|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia|A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study of Cariprazine(RGH-188) in the Prevention of Relapse in Patients With Schizophrenia|Completed||Phase 3|766|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 22:16:04.285383|2018-05-31 22:16:04.285383
NCT01412047|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-10-16|2011-08-05|2011-08-08|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2012||2012-03-31|October 2017|2017-10-31|June 30, 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study|A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria|Completed|||75|Actual|Alexion Pharmaceuticals|||||f||||f|f|f||||||No||2018-05-31 22:16:04.482468|2018-05-31 22:16:04.482468
NCT01412034|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05||2015-07-28|2015-07-28|2011-08-05|2011-08-08|Estimate||||2015-07-28|2015-08-18|Estimate|2015-07-28|2015-08-18|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|October 2013|Actual|2013-10-31||Interventional|MODE||Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects|Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-label Study of the Effects of CER-001 on Plaque Volume in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)|Completed||Phase 2|23|Actual|Cerenis Therapeutics, SA||1|||f||||f||||||||||2018-05-31 22:16:04.606795|2018-05-31 22:16:04.606795
NCT01412021|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2018-05-02|2011-08-05|2011-08-08|Estimate|||||||2018-05-02|2018-05-07|Actual|August 1, 2011|Actual|2011-08-01|May 2018|2018-05-31|April 2, 2018|Actual|2018-04-02|April 2, 2018|Actual|2018-04-02||Observational|||Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis|Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis|Completed|||374|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 22:16:04.743759|2018-05-31 22:16:04.743759
NCT01412008|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2013-09-27|2011-08-04|2011-08-08|Estimate|||||||2013-09-27|2013-10-01|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle|Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion|Completed||N/A|5|Actual|New York Presbyterian Hospital||1|||f||||f||||||||||2018-05-31 22:16:05.02985|2018-05-31 22:16:05.02985
NCT01411995|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2016-01-12||2018-02-09|2011-08-04|2011-08-08|Estimate|2018-02-09|2018-03-09|Actual||||2018-02-09|2018-03-09|Actual|August 2011||2011-08-31|February 2018|2018-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CLIIP|1 participant was excluded for failed IUD placement. The primary outcome could not be assessed.|Cervical Lidocaine for Intrauterine Device Insertion Pain|Randomized Controlled Trial of Cervical Lidocaine for Intrauterine Device Insertion Pain|Completed||N/A|200|Actual|Washington University School of Medicine||2|||f||||t||||||||No||2018-05-31 22:16:05.189027|2018-05-31 22:16:05.189027
NCT01411982|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2015-01-08|2011-08-05|2011-08-08|Estimate|||||||2015-01-08|2015-01-09|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Role of PACAP in Nehprotic Syndrome|Role of PACAP in Increased Platelet Count and Aggregability in Childhood Nephrotic Syndrome|Completed|||29|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples Without DNA|"~     Blood and urine~   "|||2018-05-31 22:16:05.712655|2018-05-31 22:16:05.712655
NCT01411969|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Observational|ARENDS||Impact of External Nasal Dilator on the Rhinogram|Acoustic Rhinometry: Impact of External Nasal Dilator on the Two First Notches of the Rhinogram|Completed|||16|Actual|University of Sao Paulo General Hospital|||1||f||||f||||||||||2018-05-31 22:16:05.76315|2018-05-31 22:16:05.76315
NCT01411956|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effect of a Targeted Video Intervention on Beliefs Regarding Hypertension|The Effect of a Targeted Video Intervention on Beliefs Regarding Hypertension|Completed||N/A|43|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 22:16:05.857806|2018-05-31 22:16:05.857806
NCT01411943|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-12-07|2011-08-05|2011-08-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Observational|||Epigenetics and Psychoneurologic Symptoms in Women With Breast Cancer|Epigenetic Factors Associated With Symptoms and Complications of Chronic Disorders|Completed|||75|Actual|Virginia Commonwealth University|||||f||||f||||||Samples With DNA|"~     This study will be examining cytokine and c-reactive protein levels, DNA methylation, DNA~     repair proteins, telomere length and chromosomal instability.~   "|||2018-05-31 22:16:05.96207|2018-05-31 22:16:05.96207
NCT01411930|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2012-12-19|2011-08-04|2011-08-08|Estimate|||||||2012-12-19|2012-12-20|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|March 2010|Actual|2010-03-31||Interventional|||Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics|Acute Impact of IM Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics|Completed||Phase 4|15|Actual|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-05-31 22:16:06.062969|2018-05-31 22:16:06.062969
NCT01411917|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2017-03-10|2011-08-05|2011-08-08|Estimate|||||||2017-03-10|2017-03-14|Actual|August 2011||2011-08-31|March 2017|2017-03-31|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Interventional|||Transversus Abdominis Plane Blocks for Ileostomy Takedown: A Prospective Study|Transversus Abdominis Plane Blocks for Ileostomy Takedown: A Prospective Study|Terminated||N/A|69|Actual|University of Wisconsin, Madison||2||Recruitment Difficulties due to some factors|f||||f||||||||||2018-05-31 22:16:06.275734|2018-05-31 22:16:06.275734
NCT01411904|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2015-12-10|2011-08-05|2011-08-08|Estimate|||||||2015-12-10|2015-12-11|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia|A Novel Magnetic Needle Using Iron Oxide Nanoparticles for the Detection of Leukemia|Withdrawn||N/A|0|Actual|University of New Mexico||1||"The NPs that we have been buying from a vendor show lot to lot variation. We are making our own~   NPs, need to characterize them before we enroll new patients."|f||||f||||||||||2018-05-31 22:16:06.388658|2018-05-31 22:16:06.388658
NCT01411891|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|2012-04-20||2015-10-01|2011-08-05|2011-08-08|Estimate|2012-05-21|2012-06-25|Estimate||||2015-10-01|2015-10-21|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch|Prospective Randomized Control Trial of Post-Operative Colonization Rates of Femoral Nerve Catheters With the Use of Chlorhexidine-Impregnated Patch|Completed||Phase 4|100|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 22:16:06.463348|2018-05-31 22:16:06.463348
NCT01411878|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2017-04-20|2011-08-05|2011-08-08|Estimate|||||||2017-04-20|2017-04-24|Actual|September 2011||2011-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|March 2014|Actual|2014-03-31||Interventional|CHAMPS||Louisville Teen Pregnancy Prevention Project|Creating Healthy Adolescents Through Meaningful Prevention Services|Completed||N/A|1450|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 22:16:06.746686|2018-05-31 22:16:06.746686
NCT01411865|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-11-21|2011-08-05|2011-08-08|Estimate|||||||2014-11-21|2014-11-24|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Diabetes|Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Diabetes|Completed||N/A|933789|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:16:06.860881|2018-05-31 22:16:06.860881
NCT01411852|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2014-10-03|2014-07-25|2014-12-30|2011-08-04|2011-08-08|Estimate|2014-10-17|2014-10-20|Estimate|2014-08-10|2014-08-12|Estimate|2014-12-30|2015-01-13|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|HypoResus|Demographic, Injury, and Out-of-Hospital Care Characteristics|Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma|Field Trial of Hypotensive Resuscitation Versus Standard Resuscitation in Patients With Hemorrhagic Shock After Trauma: A Pilot Trial|Completed||Phase 2|192|Actual|University of Washington|One patient was determined to have been in police custody at the time of enrollment, which was a protocol violation. This patient was randomized to the controlled resuscitation group but was not included in the primary or secondary outcome analyses.|2|||f||||t||||||||||2018-05-31 22:16:07.015357|2018-05-31 22:16:07.015357
NCT01411839|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2017-11-10||2018-03-15|2011-08-05|2011-08-08|Estimate|2018-03-15|2018-03-19|Actual||||2018-03-15|2018-03-19|Actual|July 2008||2008-07-31|March 2018|2018-03-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|||Depression and ART Adherence in HIV+ Latinos|Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border|Completed||N/A|40|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 22:16:08.750693|2018-05-31 22:16:08.750693
NCT01411826|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2012-11-07|2011-08-05|2011-08-08|Estimate|||||||2012-11-07|2012-11-08|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Online Programs to Promote Colon Cancer Screening|Online Programs to Promote Colon Cancer Screening|Completed||N/A|306|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 22:16:09.031914|2018-05-31 22:16:09.031914
NCT01411813|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2012-11-01|2011-08-05|2011-08-08|Estimate|||||||2012-11-01|2012-11-02|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Alprazolam and Eating Behavior in Anorexia Nervosa|Alprazolam and Eating Behavior in Anorexia Nervosa|Completed|||19|Actual|New York State Psychiatric Institute|||1||f||||t||||||||||2018-05-31 22:16:09.096217|2018-05-31 22:16:09.096217
NCT01411800|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2012-07-19|2011-08-05|2011-08-08|Estimate|||||||2012-07-19|2012-07-20|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects|A Phase 1, Randomized, Open-Label, Two-Way Crossover Study of Two Oral Formulations of LX1033 in Healthy Human Subjects|Completed||Phase 1|28|Actual|Lexicon Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:16:09.157075|2018-05-31 22:16:09.157075
NCT01411787|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-05-09|2011-08-04|2011-08-08|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2009||2009-03-31|May 2018|2018-05-31|April 3, 2018|Actual|2018-04-03|April 3, 2018|Actual|2018-04-03||Interventional|Bootcamp||Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer|"Bootcamp During Neoadjuvant Chemotherapy for Breast Cancer Can we Kick Down Ki-67, Punch Out Insulin Resistance, and Increase Survival?"|Completed||N/A|11|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 22:16:09.224824|2018-05-31 22:16:09.224824
NCT01411774|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2017-11-30||2017-12-22|2011-08-05|2011-08-08|Estimate|2017-12-22|2018-01-23|Actual||||2017-12-22|2018-01-23|Actual|June 2011||2011-06-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)|1/2 D-cycloserine Augmentation of CBT for Pediatric OCD|Completed||Phase 3|142|Actual|University of South Florida|"We did not measure distress ratings within each exposure session, which prohibits examining whether D-cycloserine enhances outcomes when within-session distress reduction is achieved.~The sample was primarily of white race/ethnicity."|2|||f||||t||||||||||2018-05-31 22:16:10.067982|2018-05-31 22:16:10.067982
NCT01411761|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Saccharomyces Boulardii on Indirect Hyperbilirubinemia and Phototherapy Duration in Very Low Birth Weight Infants|Phase 4 Study of Saccharomyces Boulardii on Indirect Hyperbilirubinemia|Unknown status|Recruiting|Phase 4|80|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 22:16:10.357336|2018-05-31 22:16:10.357336
NCT01411748|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Comparison of Saccharomyces Boulardii and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants||Unknown status|Recruiting|Phase 4|140|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 22:16:10.432053|2018-05-31 22:16:10.432053
NCT01411735|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-11-01|2011-08-05|2011-08-08|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2003||2003-07-31|August 2011|2011-08-31|July 2008|Actual|2008-07-31|June 2004|Actual|2004-06-30||Interventional|PIE-I||Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure|Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure|Completed||Phase 3|71|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 22:16:10.500833|2018-05-31 22:16:10.500833
NCT01411722|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-07-31|2011-08-05|2011-08-08|Estimate|||||||2013-07-31|2013-08-01|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Electrical Activity of the Diaphragm During the Weaning Period|Electrical Activity of the Diaphragm in Mechanically Ventilated Patients During the Weaning Period|Completed||Phase 2|50|Actual|University of Turin, Italy||1|||f||||f||||||||||2018-05-31 22:16:10.564767|2018-05-31 22:16:10.564767
NCT01411709|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-03-27|2011-08-05|2011-08-08|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress|A Pilot Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress Assessed Under Laboratory Conditions And In Everyday Life|Completed||Phase 4|80|Actual|University of Surrey||2|||f||||f||||||||||2018-05-31 22:16:10.623279|2018-05-31 22:16:10.623279
NCT01411696|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2013-03-04||2013-03-04|2011-08-05|2011-08-08|Estimate|2013-03-04|2013-04-16|Estimate||||2013-03-04|2013-04-16|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)||Completed|||289|Actual|Allergan|||1||f||||f||||||||||2018-05-31 22:16:10.78128|2018-05-31 22:16:10.78128
NCT01411683|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-04-13|2011-08-05|2011-08-08|Estimate|||||||2017-04-13|2017-04-17|Actual|September 2011||2011-09-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2014|Actual|2014-12-31||Interventional|||Mandibular Overdentures Retained by Conventional or Mini Implants|Mandibular Overdentures Retained by Conventional or Mini Implants: a Randomized Clinical Trial|Completed||N/A|120|Actual|University of Sao Paulo||3|||f||||f||||||||No||2018-05-31 22:16:10.971979|2018-05-31 22:16:10.971979
NCT01411670|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2015-12-01|2011-08-05|2011-08-08|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.|Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock: Effects on Microcirculation and Organ Function.|Completed||Phase 2|60|Actual|University of Roma La Sapienza||3|||f||||f||||||||||2018-05-31 22:16:11.059272|2018-05-31 22:16:11.059272
NCT01411657|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2016-08-01|2011-08-05|2011-08-08|Estimate|||||||2016-08-01|2016-08-02|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|||NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement||Completed||Phase 1|11|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 22:16:11.138422|2018-05-31 22:16:11.138422
NCT01411644|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-05-15|2011-08-05|2011-08-08|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2005||2005-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Pheno- & Genotyping POF (WHO III)|Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives|Recruiting|||650|Anticipated|UMC Utrecht|||||f||||f||||||Samples With DNA|"~     whole blood, serum and litium heparine~   "|||2018-05-31 22:16:11.208596|2018-05-31 22:16:11.208596
NCT01411631|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2014-05-21|2011-08-05|2011-08-08|Estimate|||||||2014-05-21|2014-05-22|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Investigate the Effect of Concord Grape Juice on Cognitive Function in Mums of Preteen Children|A Study to Investigate the Effect of Concord Grape Juice on Cognitive Function in Mums of Preteen Children|Completed||N/A|25|Actual|University of Leeds||2|||f||||f||||||||||2018-05-31 22:16:11.293113|2018-05-31 22:16:11.293113
NCT01411618|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|June 2010||2010-06-30|February 2010|2010-02-28|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Essential Oil Mouthwash With and Without Alcohol: a 3-Day Plaque Accumulation Model|Efficacy of Essential Oil Mouthwash With and Without Alcohol: a 3-Day Plaque Accumulation Model|Completed||N/A|30|Actual|University of L'Aquila||2|||f||||t||||||||||2018-05-31 22:16:11.366298|2018-05-31 22:16:11.366298
NCT01411605|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2012-06-26|2011-08-04|2011-08-08|Estimate|||||||2012-06-26|2012-06-28|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|VENTILOBE||Influence of Cardio-ventilatory Factors on Exercise Intolerance in Obese Adolescents: Effects of Exercise Training|Influence of Cardio-ventilatory Factors on Exercise Intolerance in Obese Adolescents: Effects of Exercise Training|Completed||N/A|40|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 22:16:11.434267|2018-05-31 22:16:11.434267
NCT01411592|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2014-09-04||2014-09-04|2011-08-05|2011-08-08|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-04|2014-09-11|Estimate|October 2006||2006-10-31|September 2014|2014-09-30|April 2018|Anticipated|2018-04-30|April 2008|Actual|2008-04-30||Interventional|||Single Retainer All-Ceramic Resin-bonded Fixed Dental Protheses|Randomized Clinical Trial on Single Retainer All-Ceramic Resin-bonded Fixed Dental Protheses: Impact of the Bonding System|Unknown status|Active, not recruiting|N/A|30|Actual|University of Kiel||2|||f||||t||||||||||2018-05-31 22:16:11.50099|2018-05-31 22:16:11.50099
NCT01411579|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-12-09|2011-08-05|2011-08-08|Estimate|||||||2014-12-09|2014-12-10|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Observational|||Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma|Assessment of Diffusion-weighted Magnetic Resonance (MR) Imaging to Predict Chemotherapy Outcome in Liver Metastases and Hepatocellular Carcinoma (HCC)|Completed|||57|Actual|University of Florence|||2||f||||t||||||||||2018-05-31 22:16:11.67395|2018-05-31 22:16:11.67395
NCT01411566|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|KLIPS||Clinical Intervention Psychosis and Addiction|Evaluation of an Integrative Therapeutic Concept for Schizophrenic Patients With Comorbid Substance Use Disorder|Unknown status|Recruiting|Early Phase 1|122|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 22:16:11.736498|2018-05-31 22:16:11.736498
NCT01411553|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2016-02-21|2011-08-05|2011-08-08|Estimate|||||||2016-02-21|2016-02-23|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|ECG-LW||ECG Leadwires: Disposable Versus Cleaned, Reusable|ECG Leadwires: Do Disposable Leadwires Reduce the Incidence of Bacterial Infections in ICU Patients and Provide Adequate Signaling in Stepdown/Telemetry Environment Compared to Cleaned Reusable ECG Leadwires?|Completed||N/A|4056|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 22:16:11.818222|2018-05-31 22:16:11.818222
NCT01411540|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2017-01-06|2011-08-05|2011-08-08|Estimate|||||||2017-01-06|2017-01-10|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of a Wholegrain Diet on Body Composition and Energy Balance|Effects of Diet on Body Composition|Completed||N/A|35|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 22:16:11.885824|2018-05-31 22:16:11.885824
NCT01411527|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-12-06|2011-08-05|2011-08-08|Estimate|||||||2013-12-06|2013-12-09|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||The COPENHAGEN Puberty Study Providing Normative Data of Healthy Danish Children and Adolescents|The COPENHAGEN Puberty Study|Unknown status|Active, not recruiting||2020|Actual|Rigshospitalet, Denmark|||2||f||||f||||||Samples With DNA|"~     serum, white cells, urine~   "|||2018-05-31 22:16:12.047773|2018-05-31 22:16:12.047773
NCT01411514|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2015-12-17|2011-08-05|2011-08-08|Estimate|||||||2015-12-17|2015-12-18|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis|Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort|Terminated||Phase 4|27|Actual|Ospedale Civico, Lugano||2||Difficulties to recruit patients|f||||f||||||||||2018-05-31 22:16:12.130727|2018-05-31 22:16:12.130727
NCT01411293|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2014-01-03|2011-08-05|2011-08-08|Estimate|||||||2014-01-03|2014-01-06|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome|Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome|Completed||N/A|21|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 22:16:14.349296|2018-05-31 22:16:14.349296
NCT01411501|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2015-09-25||2015-11-08|2011-08-05|2011-08-08|Estimate|2015-11-08|2015-12-11|Estimate||||2015-11-08|2015-12-11|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety of Acupuncture for Functional Constipation|Efficacy and Safety of Acupuncture for Functional Constipation: a Multi-center Randomized Controlled Trial|Completed||Phase 3|684|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Unblinding of participants in the acupuncture and mosapride groups;an insufficient duration to assess the long term effect or risks;a missing assessment of electrocardiograms for possible cardiovascular harm of mosapride|4|||f||||t||||||||||2018-05-31 22:16:12.25619|2018-05-31 22:16:12.25619
NCT01411488|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2017-04-18||2017-08-16|2011-08-05|2011-08-08|Estimate|2017-08-16|2017-09-14|Actual||||2017-08-16|2017-09-14|Actual|January 2011||2011-01-31|April 2017|2017-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Comparative Study Between Two Fecal Management Systems||Completed||N/A|79|Actual|The Cleveland Clinic|Single center Small sample size restricted to medical intensive care and other adults requiring rectal tube placement|2|||f||||f||||||||No||2018-05-31 22:16:12.984733|2018-05-31 22:16:12.984733
NCT01411475|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Observational|LATINA||Prognostic Assessment of Different Pattern of Bifurcation Restenosis|Classification of Bifurcation Restenosis: a Prognostic Assessment|Unknown status|Recruiting||100|Anticipated|Ospedale Santa Maria Goretti|||1||f||||f||||||||||2018-05-31 22:16:13.191161|2018-05-31 22:16:13.191161
NCT01411462|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-09-09|2011-08-05|2011-08-08|Estimate|||||||2011-09-09|2011-09-12|Estimate|August 2011||2011-08-31|August 2011|2011-08-31||||||||Observational|VIBER||VIBE-assisted DEB Registry|Vascular Imaging Balloon Catheter-assisted Drug-eluting Balloon Angioplasty Prospective Registry|Unknown status|Recruiting||25|Anticipated|Ospedale Santa Maria Goretti|||1||f||||f||||||||||2018-05-31 22:16:13.270528|2018-05-31 22:16:13.270528
NCT01411449|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-03-16|2011-08-05|2011-08-08|Estimate|||||||2017-03-16|2017-03-17|Actual|March 11, 2008|Actual|2008-03-11|March 2017|2017-03-31|February 18, 2015|Actual|2015-02-18|December 14, 2010|Actual|2010-12-14||Observational|PRIMOVIST||Primovist Post-marketing Surveillance in Japan|Drug Use Investigation of EOB-Primovist Inj. Syringe|Completed|||2030|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:16:13.327178|2018-05-31 22:16:13.327178
NCT01411436|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2015-03-03|2011-08-05|2011-08-08|Estimate|||||||2015-03-03|2015-03-04|Estimate|May 2009||2009-05-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|March 2014|Actual|2014-03-31||Observational|||Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan|Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma)|Completed|||1637|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:16:13.398132|2018-05-31 22:16:13.398132
NCT01411423|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2014-06-20|2011-08-05|2011-08-08|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2008||2008-04-30|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan|Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma)|Completed|||3305|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:16:13.466542|2018-05-31 22:16:13.466542
NCT01411410|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2017-10-10|2011-08-05|2011-08-08|Estimate|||||||2017-10-10|2017-10-11|Actual|August 24, 2011|Actual|2011-08-24|October 2017|2017-10-31|June 29, 2015|Actual|2015-06-29|October 22, 2014|Actual|2014-10-22||Interventional|||Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer|A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3΄-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy|Completed||Phase 1|55|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:16:13.551854|2018-05-31 22:16:13.551854
NCT01411397|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Mesh Hernioplasty Of Strangulated Hernias With Intestinal Resection|Mesh Hernioplasty Of Strangulated Hernias With Intestinal Resection|Completed||N/A|163|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 22:16:13.635081|2018-05-31 22:16:13.635081
NCT01411384|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-02-21|2011-08-05|2011-08-08|Estimate|||||||2012-02-21|2012-02-22|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||Evaluation of Corneal Hysteresis and Corneal Resistance Factor After Corneal Cross-linking for Keratoconus|Evaluation of Corneal Hysteresis and Corneal Resistance Factor After Corneal Cross-linking for Keratoconus|Completed||N/A|80|Actual|Democritus University of Thrace|||||f||||f||||||||||2018-05-31 22:16:13.711449|2018-05-31 22:16:13.711449
NCT01411371|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2011-08-05|2011-08-05|2011-08-08|Estimate|||||||2011-08-05|2011-08-08|Estimate|March 2005||2005-03-31|May 2010|2010-05-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|CAMTAF||Catheter Ablation Versus Medical Treatment of AF in Heart Failure|Catheter Ablation Versus Medical Treatment of AF in Heart Failure|Unknown status|Recruiting|N/A|60|Anticipated|Barts & The London NHS Trust||2|||f||||f||||||||||2018-05-31 22:16:13.858305|2018-05-31 22:16:13.858305
NCT01411358|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2012-07-10|2011-08-05|2011-08-08|Estimate|||||||2012-07-10|2012-07-12|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2011-2012, in Non-Elderly Adult and Elderly Subjects|Completed||N/A|128|Actual|Adimmune Corporation||1|||f||||f||||||||||2018-05-31 22:16:13.94918|2018-05-31 22:16:13.94918
NCT01411345|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2017-12-20|2011-08-05|2011-08-08|Estimate|||||||2017-12-20|2017-12-22|Actual|July 12, 2012||2012-07-12|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|MAPS||A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial|A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial|Suspended||N/A|80|Anticipated|University of Miami||2||Temporarily closed pending IRB approval of amendment|f||||t|f|t|f|||||||2018-05-31 22:16:14.023207|2018-05-31 22:16:14.023207
NCT01411332|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-12-18|2011-08-05|2011-08-08|Estimate|||||||2017-12-18|2017-12-20|Actual|October 31, 2011|Actual|2011-10-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|HEIGHT||Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial|A Phase III Trial of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial|Active, not recruiting||N/A|19|Actual|University of Miami||2|||f||||t||||||||Yes|Some data after completion of the trial and publication of the primary endpoint. Additional data after publication of the secondary endpoints.|2018-05-31 22:16:14.117062|2018-05-31 22:16:14.117062
NCT01411319|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-11-13|2011-08-05|2011-08-08|Estimate|||||||2017-11-13|2017-11-17|Actual|December 27, 2011|Actual|2011-12-27|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|LEAD||MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer|A Phase I Trial of MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer|Active, not recruiting||N/A|25|Anticipated|University of Miami||1|||f||||t||||||||||2018-05-31 22:16:14.201239|2018-05-31 22:16:14.201239
NCT01411280|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2015-04-29|2011-08-05|2011-08-08|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2006||2006-06-30|August 2011|2011-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)|Ameliorating Attention Problems in Children With SCD|Completed||Phase 3|34|Actual|Temple University||2|||f||||||||||||||2018-05-31 22:16:14.442488|2018-05-31 22:16:14.442488
NCT01411267|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-05-17|2011-08-05|2011-08-08|Estimate|||||||2013-05-17|2013-05-21|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia|A Phase I Study of AC220 for Children With Relapsed or Refractory ALL or AML|Completed||Phase 1|24|Actual|Therapeutic Advances in Childhood Leukemia Consortium|||||f||||t||||||||||2018-05-31 22:16:14.517211|2018-05-31 22:16:14.517211
NCT01411254|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2014-07-17|2011-08-05|2011-08-08|Estimate|||||||2014-07-17|2014-07-21|Estimate||||July 2014|2014-07-31||||||||Interventional|||Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)|A Randomized, Multicenter, Sham Controlled, Double-Masked, Phase 2/3 Study Assessing Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema|Completed||Phase 2/Phase 3|||Santen Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 22:16:14.634415|2018-05-31 22:16:14.634415
NCT01411241|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-01-09|2011-08-04|2011-08-08|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers|Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico|Completed||Phase 3|720|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:16:14.710063|2018-05-31 22:16:14.710063
NCT01411228|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|2015-11-06||2016-06-20|2011-08-04|2011-08-08|Estimate|2015-12-11|2016-01-18|Estimate||||2016-06-20|2016-07-21|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease|A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease|Completed||Phase 3|15|Actual|Protalix||2|||t||||t||||||||||2018-05-31 22:16:14.835737|2018-05-31 22:16:14.835737
NCT01411215|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2014-01-23||2014-01-23|2011-08-04|2011-08-08|Estimate|2014-01-23|2014-03-06|Estimate||||2014-01-23|2014-03-06|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|ENBREL NIS CN|Baseline participants were all enrolled participants who received at least 1 dose of etanercept.|A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department|A Non-Interventional Study of the Treatment With Etanercept in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) Subjects in Rheumatology Department|Terminated|||160|Actual|Pfizer|||1|See termination reason in detailed description.|f||||f||||||||||2018-05-31 22:16:15.440268|2018-05-31 22:16:15.440268
NCT01411202|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-04-26|2011-08-04|2011-08-08|Estimate|||||||2017-04-26|2017-04-27|Actual|June 2011||2011-06-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|OPUS||Effectiveness of Doxycycline for Treating Pleural Effusions Related to Cancer in an Outpatient Population|Outpatient Pleurodesis Using Sclerosants(OPUS):Comparing Doxycycline Pleurodesis to Continued Drainage With the Pleurx Catheter System in the Treatment of Malignant Pleural Effusions in the Outpatient Setting|Recruiting||Phase 2|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 22:16:16.184755|2018-05-31 22:16:16.184755
NCT01411189|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2012-06-27|2011-08-05|2011-08-08|Estimate|||||||2012-06-27|2012-06-29|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy|Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy|Completed||Phase 3|33|Actual|Nihon Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 22:16:16.26278|2018-05-31 22:16:16.26278
NCT01411176|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-06-27|2011-08-05|2011-08-08|Estimate|||||||2012-06-27|2012-06-29|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy|Phase III Placebo-controlled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy (Randomized, Double-blind, Parallel-assignment, Placebo-controlled Study)|Completed||Phase 3|85|Actual|Nihon Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 22:16:16.328269|2018-05-31 22:16:16.328269
NCT01411163|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04||2014-01-10|2014-01-10|2011-08-04|2011-08-08|Estimate||||2014-01-10|2014-02-10|Estimate|2014-01-10|2014-02-10|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Pre-CREST-2X||Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability|Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability|Completed||Phase 2|24|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:16:16.396207|2018-05-31 22:16:16.396207
NCT01411150|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04||2014-01-10|2014-01-10|2011-08-04|2011-08-08|Estimate||||2014-01-10|2014-02-10|Estimate|2014-01-10|2014-02-10|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Pre-CREST-X||Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study|Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study|Completed||Phase 2|38|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:16:16.48573|2018-05-31 22:16:16.48573
NCT01411137|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|2016-03-03|2013-09-27|2017-04-18|2011-08-05|2011-08-08|Estimate|2017-03-06|2017-04-18|Actual|2013-09-27|2013-10-28|Estimate|2017-04-18|2017-05-22|Actual|August 2011||2011-08-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study|An Open Label Conversion Study of Carbidopa-Levodopa (CD-LD) Extended-Release Taken Alone or in Combination With CD-LD Immediate Release to IPX066 Followed by an Open-Label Extension Safety Study of IPX066 in Advanced PD|Completed||Phase 3|43|Actual|IMPAX Laboratories, Inc.||1|||f||||f||||||||No||2018-05-31 22:16:16.605737|2018-05-31 22:16:16.605737
NCT01411124|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-07-15|2011-08-04|2011-08-08|Estimate|||||||2013-07-15|2013-07-16|Estimate|June 2011||2011-06-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects|A Randomized, Double-Blind, Active- and Placebo-Controlled, Crossover Study Assessing the Effect of 600 mg Gabapentin Enacarbil on Simulated Driving in Healthy Subjects|Completed||Phase 1|36|Actual|XenoPort, Inc.||3|||f||||f||||||||||2018-05-31 22:16:16.949362|2018-05-31 22:16:16.949362
NCT01410773|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2012-07-31||2016-01-29|2011-08-04|2011-08-05|Estimate|2012-07-31|2012-08-31|Estimate||||2016-01-29|2016-02-29|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||User Performance Evaluation of an Investigational Blood Glucose Monitoring System|Ninja 2 User Performance Evaluation|Completed||N/A|110|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 22:16:19.253495|2018-05-31 22:16:19.253495
NCT01411111|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-07-24|2011-08-04|2011-08-08|Estimate|||||||2017-07-24|2017-07-25|Actual|January 6, 2011|Actual|2011-01-06|July 2017|2017-07-31|February 23, 2011|Actual|2011-02-23|February 23, 2011|Actual|2011-02-23||Interventional|||A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin|An Open Label, Sequential, Single Cohort, Repeat Dose Study to Investigate the Potential Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects.|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:16:17.029048|2018-05-31 22:16:17.029048
NCT01411098|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2015-11-03|2011-08-04|2011-08-08|Estimate|||||||2015-11-03|2015-11-04|Estimate|October 2011||2011-10-31|November 2015|2015-11-30||||March 2015|Actual|2015-03-31||Interventional|||Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase I Dose-Intensification Study Using Radiation Therapy and Concurrent Cisplatin and Etoposide for Patients With Inoperable Non-small Cell Lung Cancer|Terminated||Phase 1|6|Actual|University of Washington||1||Low accrual|f||||f||||||||||2018-05-31 22:16:17.118532|2018-05-31 22:16:17.118532
NCT01411085|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2017-02-22||2018-03-21|2011-08-04|2011-08-08|Estimate|2018-03-21|2018-03-23|Actual||||2018-03-21|2018-03-23|Actual|December 2011||2011-12-31|March 2018|2018-03-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|RADIAUS|7 completers in the risperidone + desipramine group were analyzed. 3 study subjects in the risperidone + desipramine group did not have sufficient days in study for analysis.|Risperidone and Desipramine in Alcohol Use and Schizophrenia|Alcoholism and Schizophrenia: A Translational Approach to Treatment|Completed||Phase 2|12|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 22:16:17.201197|2018-05-31 22:16:17.201197
NCT01411072|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2014-10-02|2011-08-05|2011-08-08|Estimate|||||||2014-10-02|2014-10-03|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer|Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer|Unknown status|Recruiting|N/A|20|Anticipated|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-05-31 22:16:17.417747|2018-05-31 22:16:17.417747
NCT01411059|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2016-11-14|2011-08-04|2011-08-05|Estimate|||||||2016-11-14|2016-11-16|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|YESS||Yoga Empowers Seniors Study|Safe and Effective Yoga Prescription of Seniors: Biomechanical Considerations|Completed||N/A|27|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 22:16:17.505073|2018-05-31 22:16:17.505073
NCT01411046|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-04-26|2011-08-04|2011-08-05|Estimate|||||||2017-04-26|2017-04-28|Actual|April 2011||2011-04-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Difference in GC-induced Adrenal Insufficiency in RA Related to Polymorphisms in the Glucocorticoid Receptor Gene|Observational Cohort Study on Difference in Glucocorticoid-induced Adrenal Insufficiency in Patients With Rheumatoid Arthritis Related to Different Sensitivity Polymorphisms in the Glucocorticoid Receptor Gene|Recruiting|||106|Anticipated|Rigshospitalet, Denmark|||1||f||||t||||||Samples With DNA|"~     blood samples and DNA from gene analyses~   "|Undecided||2018-05-31 22:16:17.576575|2018-05-31 22:16:17.576575
NCT01411033|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2014-09-10|2011-08-04|2011-08-05|Estimate|||||||2014-09-10|2014-09-11|Estimate|January 1994||1994-01-31|September 2014|2014-09-30||||||||Observational|PoProStu||Poznan Prospective Study of Type 1 Diabetic Patients|Poznan Prospective Study of Type 1 Diabetic Patients Treated With Intensive Insulin Therapy From the Onset of the Disease.|Unknown status|Active, not recruiting||100|Anticipated|Poznan University of Medical Sciences|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:16:17.670709|2018-05-31 22:16:17.670709
NCT01411020|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-05-14|2011-08-04|2011-08-05|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Target-controlled Infusion of Propofol for Induction of Pediatric Anesthesia|Target-controlled Infusion (TCI) of Propofol for Induction in Children 3 to 11 Years|Completed||Phase 4|60|Actual|Pontificia Universidad Catolica de Chile||10|||f||||||||||||||2018-05-31 22:16:17.729491|2018-05-31 22:16:17.729491
NCT01411007|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2016-07-14|2011-08-04|2011-08-05|Estimate|||||||2016-07-14|2016-07-15|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|RTSmoking||The Impact of Real-time Functional Magnetic Resonance Imaging (fMRI) Feedback on Response to Nicotine Cues|The Impact of Real-time fMRI Feedback on Response to Nicotine Cues|Terminated|||44|Anticipated|Medical University of South Carolina|||2||f||||t||||||||||2018-05-31 22:16:17.797196|2018-05-31 22:16:17.797196
NCT01410994|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2015-08-26|2011-08-04|2011-08-05|Estimate|||||||2015-08-26|2015-08-28|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Bariatric Surgery and the Kidney|Study of Renal Parameters After Bariatric Surgical Weight Loss|Completed|||200|Actual|Indiana University|||||f||||f||||||Samples Without DNA|"~     serum, urine~   "|||2018-05-31 22:16:17.864348|2018-05-31 22:16:17.864348
NCT01410981|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2018-04-03|2011-08-04|2011-08-05|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2011|Actual|2011-08-31|April 2018|2018-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma|Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma|Completed|||73|Actual|Medical University of South Carolina|||1||f||||t||||||Samples With DNA|"~     The patients will not have bone marrow biopsy or aspirate solely for this study. When the~     patients undergo routine bone marrow aspirate and biopsy for the purpose of initial~     diagnosis, followup or restaging, they will be asked and consented for participation in the~     study. The patient will then be treated with standard chemotherapy including~     Bortezomib-based, Revlimid-based, Thalidomide-based chemoregimen. The bone marrow aspirate~     from patients who consent to be in the study will be stained for CXCR4, CD47, pS6, in~     addition to standard study flow cytometry panel for multiple myeloma. The staining and flow~     cytometry analysis will be performed at the Clinical Flow Cytometry Facility (Director: Dr.~     Sally Self) according to the standard flow cytometry procedure. Sphingolipid gene expression~     levels will be measured. A small aliquot may be sent to collaborators in Genentech Corp for~     measurement of pS6 and Pim kinase expression. The sample information will be de-identified.~   "|||2018-05-31 22:16:17.910333|2018-05-31 22:16:17.910333
NCT01410760|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2012-06-19|2011-08-04|2011-08-05|Estimate|||||||2012-06-19|2012-06-20|Estimate|April 2011||2011-04-30|June 2012|2012-06-30||||April 2013|Anticipated|2013-04-30||Interventional|PERFORM||PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases|Perfusion Computed Tomography Pilot Study in the NCRN FOXFIRE Clinical Trial to Determine Blood Flow to Liver Metastases|Unknown status|Recruiting|Early Phase 1|40|Anticipated|University of Oxford|||||f||||f||||||||||2018-05-31 22:16:19.383307|2018-05-31 22:16:19.383307
NCT01410968|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2016-12-08|2011-08-04|2011-08-05|Estimate|||||||2016-12-08|2016-12-09|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|November 2013|Actual|2013-11-30||Interventional|||A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma|Completed||Phase 1|12|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 22:16:17.968831|2018-05-31 22:16:17.968831
NCT01410955|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2014-01-22|2011-08-04|2011-08-05|Estimate|||||||2014-01-22|2014-01-23|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Prevention of Irinotecan Induced Diarrhea by Probiotics|Prevention of Irinotecan Induced Diarrhea by Probiotics. A Phase III Study|Completed||Phase 3|46|Actual|Monsea Ltd.||2|||f||||f||||||||||2018-05-31 22:16:18.061189|2018-05-31 22:16:18.061189
NCT01410942|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2018-01-31|2011-08-04|2011-08-05|Estimate|||||||2018-01-31|2018-02-02|Estimate|February 2012|Actual|2012-02-29|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy|Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy|Active, not recruiting||Phase 2|175|Anticipated|M.D. Anderson Cancer Center||8|||f||||t|t|f||||||||2018-05-31 22:16:18.223408|2018-05-31 22:16:18.223408
NCT01410929|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2017-01-18|2011-08-04|2011-08-05|Estimate|||||||2017-01-18|2017-01-20|Estimate|May 2011||2011-05-31|January 2017|2017-01-31||||||||Interventional|MM||Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma|Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma|Withdrawn||Phase 4|0|Actual|Merit Medical Systems, Inc.|||||f||||f||||||||||2018-05-31 22:16:18.3331|2018-05-31 22:16:18.3331
NCT01410916|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-04-04|2011-08-04|2011-08-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|STEC-HUS||Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)|An Open-Label, Multi-Center Trial of Eculizumab in Patients With Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)|Completed||Phase 2/Phase 3|198|Actual|Alexion Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:16:18.390948|2018-05-31 22:16:18.390948
NCT01410903|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2015-08-18|2011-08-04|2011-08-05|Estimate|||||||2015-08-18|2015-08-19|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Immunoadsorption in Patients With Severe Systemic Sclerosis|Immunoadsorption in Addition to the Established Therapy in Patients With Systemic Sclerosis|Terminated||N/A|1|Actual|GWT-TUD GmbH||1||inadequately recruitment rate, funding is not secured|f||||f||||||||||2018-05-31 22:16:18.46872|2018-05-31 22:16:18.46872
NCT01410890|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-05-29|2011-08-04|2011-08-05|Estimate|||||||2018-05-29|2018-05-30|Actual|November 3, 2014||2014-11-03|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|PAPAYA||Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease|A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease|Recruiting||Phase 4|20|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 22:16:18.539518|2018-05-31 22:16:18.539518
NCT01410877|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-06-04|2011-08-03|2011-08-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Assessment of Inspiratory Profiles Through Airflow Resistances Designed to Mimic Inhalers|Assessment of Inspiratory Profiles Through Airflow Resistances Designed to Mimic Inhalers|Completed|||20|Actual|Virginia Commonwealth University|||1||f||||t||||||||||2018-05-31 22:16:18.62682|2018-05-31 22:16:18.62682
NCT01410864|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2017-02-28|2011-08-04|2011-08-05|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2011||2011-08-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|DuraSeal PAS||DuraSeal Exact Spine Sealant System Post-Approval Study|DuraSeal Exact Spine Sealant System Post-Approval Study|Completed|||924|Actual|Integra LifeSciences Corporation|||2||f||||f||||||||||2018-05-31 22:16:18.690573|2018-05-31 22:16:18.690573
NCT01410851|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2011-08-03|2011-08-03|2011-08-05|Estimate|||||||2011-08-03|2011-08-05|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Pulses, Satiation, Food Intake and Blood Glucose|The Acute Effects of Pulse Consumption on Glycaemic Responses and Measures of Satiety and Satiation|Completed||N/A|24|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 22:16:18.799437|2018-05-31 22:16:18.799437
NCT01410838|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-05-19|2011-08-04|2011-08-05|Estimate|||||||2015-05-19|2015-05-21|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Monosodium Glutamate on Energy Balance and Eating Behavior|Effects of Ingesting Monosodium Glutamate (MSG) on Energy Balance and Eating Behavior Following Moderate Energy Restriction and Weight Loss in Overweight Women|Completed||N/A|44|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:16:18.876215|2018-05-31 22:16:18.876215
NCT01410825|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2018-04-23|2011-08-04|2011-08-05|Estimate|||||||2018-04-23|2018-04-25|Actual|July 2011||2011-07-31|April 2018|2018-04-30|July 2031|Anticipated|2031-07-31|January 2018|Actual|2018-01-31||Interventional|||Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome|Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome|Active, not recruiting||Phase 1/Phase 2|5|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 22:16:18.946245|2018-05-31 22:16:18.946245
NCT01410812|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-12-01|2011-08-04|2011-08-05|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Tying Devices as a Means of Increasing Exercise|Tying Devices as a Means of Increasing Exercise|Completed||N/A|226|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 22:16:19.016469|2018-05-31 22:16:19.016469
NCT01410799|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-03-13|2011-08-03|2011-08-05|Estimate|||||||2017-03-13|2017-03-15|Actual|May 2011||2011-05-31|March 2017|2017-03-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly|Three Month Treatment of GHRH (Growth Hormone Releasing Hormone) in the Elderly|Terminated||Phase 2|13|Actual|University of Pennsylvania||1||Funding ended|f||||t||||||||||2018-05-31 22:16:19.121488|2018-05-31 22:16:19.121488
NCT01410786|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-08-01|2011-08-04|2011-08-05|Estimate|||||||2017-08-01|2017-08-02|Actual|June 2013||2013-06-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Oxford Partial Knee Comparative Instrument Pilot Study|A Comparison of Signature Guides and Conventional Instrumentation With the Oxford Partial Knee System Pilot Study|Completed||N/A|35|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 22:16:19.189536|2018-05-31 22:16:19.189536
NCT01410747|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2018-05-27|2011-08-04|2011-08-05|Estimate|||||||2018-05-27|2018-05-30|Actual|January 1, 2007|Actual|2007-01-01|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|TRUST||A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations|Post Marketing Surveillance For Long Term Treatment With Tacrolimus in Steroid Resistant Lupus Nephritis|Active, not recruiting|||1484|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 22:16:19.450032|2018-05-31 22:16:19.450032
NCT01410734|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2012-12-19|2011-08-04|2011-08-05|Estimate|||||||2012-12-19|2012-12-20|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree (up to 2-weeks Post-operatively)|A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree|Completed||N/A|72|Actual|Intuitive Surgical||1|||f||||t||||||||||2018-05-31 22:16:19.54512|2018-05-31 22:16:19.54512
NCT01410721|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-05-17|2011-08-04|2011-08-05|Estimate|||||||2017-05-17|2017-05-19|Actual|January 2012||2012-01-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Neural Markers and Rehabilitation of Executive Functioning in Veterans With Traumatic Brain Injury and Posttraumatic Stress Disorder|Neural Markers and Rehabilitation of Executive Functioning in Veterans With TBI and PTSD|Completed||N/A|241|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:16:19.615493|2018-05-31 22:16:19.615493
NCT01410708|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2016-02-12|2011-08-04|2011-08-05|Estimate|||||||2016-02-12|2016-02-17|Estimate||||August 2011|2011-08-31||||||||Interventional|||TORI 104 Pre-Surgical Dasatinib|A Pre-Surgical Study to Evaluate Molecular Changes That Occur in Human Breast Cancer Tissue After Short Term Exposure to Dasatinib and To Correlate These Alterations With Pharmacokinetics Parameters|Withdrawn||Phase 2|0|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-05-31 22:16:19.69079|2018-05-31 22:16:19.69079
NCT01410695|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2013-08-13|2011-08-04|2011-08-05|Estimate|||||||2013-08-13|2013-08-14|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase 2b/3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Methotrexate in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate or to Any Disease-Modifying Antirheumatic Drug|A 24-week With Possible Extension, Prospective, Multicenter, Randomised, Double-blind, Controlled, 3-parallel Groups, Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib at 3 and 6 mg/kg/Day to Methotrexate, With a Randomisation 1:1:1, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including at Least One Biologic Drug if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Biologic Drugs|Unknown status|Recruiting|Phase 2/Phase 3|450|Anticipated|AB Science||3|||f||||t||||||||||2018-05-31 22:16:19.745367|2018-05-31 22:16:19.745367
NCT01410682|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2011-08-04|2011-08-04|2011-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|June 2005||2005-06-30|July 2011|2011-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Oral Care and Gram-negative Pathogen in Children|Oral Care and Oropharyngeal and Tracheal Colonization by Gram-negative Pathogens in Children|Completed||N/A|74|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 22:16:19.81308|2018-05-31 22:16:19.81308
NCT01410669|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-08-03|2011-08-03|2011-08-05|Estimate|||||||2011-08-03|2011-08-05|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ISIS||Motivational Interviewing Intervention for Intimate Partner Violence|Is Motivational Interviewing an Effective Intervention for Women Coping With Intimate Partner Violence|Completed||N/A|305|Actual|University of Iowa||1|||f||||t||||||||||2018-05-31 22:16:19.86713|2018-05-31 22:16:19.86713
NCT01410656|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2018-05-01|2011-08-04|2011-08-05|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2011||2011-05-31|May 2018|2018-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PROMOTE||Prostate Cancer Survivors Moving Toward Exercise (PROMOTE) Trial|Prostate Cancer Survivors MOving Toward Exercise (PROMOTE) Trial|Completed||N/A|423|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 22:16:19.925853|2018-05-31 22:16:19.925853
NCT01410643|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-06-16|2011-08-03|2011-08-05|Estimate|||||||2015-06-16|2015-06-18|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PRIMO||Puberty Related Intervention to Improve Metabolic Outcomes (The PRIMO Study)|Puberty Related Intervention to Improve Metabolic Outcomes (The PRIMO Study)|Completed||N/A|92|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 22:16:19.989376|2018-05-31 22:16:19.989376
NCT01410630|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2018-04-27|2011-08-03|2011-08-05|Estimate|||||||2018-04-27|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|September 2017|2017-09-30|October 1, 2024|Anticipated|2024-10-01|October 1, 2023|Anticipated|2023-10-01||Interventional|||FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma|FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma|Suspended||N/A|137|Anticipated|Jonsson Comprehensive Cancer Center||1||Institutional transfer in process|f||||t|f|t|f|f||||||2018-05-31 22:16:20.066132|2018-05-31 22:16:20.066132
NCT01410617|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-03-25|2011-08-04|2011-08-05|Estimate|||||||2013-03-25|2013-03-27|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass||Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|Imam Khomeini Hospital||2|||f||||||||||||||2018-05-31 22:16:20.141861|2018-05-31 22:16:20.141861
NCT01410604|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|2012-03-29||2012-04-23|2011-08-04|2011-08-05|Estimate|2012-03-29|2012-04-23|Estimate||||2012-04-23|2012-04-27|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Adipokines in Obese Adolescents With Insulin Resistance|Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial|Completed||Phase 4|31|Actual|Hospital Regional de Alta Especialidad del Bajio|During the recruitment phase, 83 children who were diagnosed with obesity and acanthosis nigricans were evaluated. Of these, 45 did not have the insulin concentration values (>15 µU/mL) required to biochemically define Insulin Resistance.|2|||f||||f||||||||||2018-05-31 22:16:20.220033|2018-05-31 22:16:20.220033
NCT01410591|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2016-01-23|2011-08-04|2011-08-05|Estimate|||||||2016-01-23|2016-01-26|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|T8/10SVB||TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding|The Effect of TIPS With 8- or 10-mm Covered Stent for Preventing Variceal Rebleeding in Cirrhotic Patients.|Completed||N/A|127|Actual|Fourth Military Medical University||2|||f||||||||||||||2018-05-31 22:16:20.540012|2018-05-31 22:16:20.540012
NCT01410578|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-04|2011-08-04|2011-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO|The Value of Soluble TREM-1, Procalcitonin, and C-reactive Protein Serum Levels as Markers for the Detection of Sepsis and Bacteremia Among Patients With a Fever of Unknown Origin in Intensive Care Units|Completed|||144|Actual|Chinese PLA General Hospital|||3||f||||t||||||||||2018-05-31 22:16:20.699755|2018-05-31 22:16:20.699755
NCT01410565|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2016-10-10||2016-12-12|2011-08-04|2011-08-05|Estimate|2016-12-12|2016-12-13|Estimate||||2016-12-12|2016-12-13|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Safety Analysis Population included all randomized patients in the double blind phase.|Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer|A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)|Terminated||Phase 3|66|Actual|Spectrum Pharmaceuticals, Inc||2||Business reason|f||||f||||||||||2018-05-31 22:16:20.775069|2018-05-31 22:16:20.775069
NCT01410552|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2017-11-10||2018-01-29|2011-08-03|2011-08-05|Estimate|2018-01-29|2018-02-12|Actual||||2018-01-29|2018-02-12|Actual|October 2011||2011-10-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|ISIS-ICD|The PARAD+ algorithm was enabled in implanted devices in 993 subjects, 639 with an ICD and 354 with a CRT-D, who were thus considered for the primary analysis.|Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination|Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination|Completed||N/A|1013|Actual|LivaNova||1|||f||||||||||||||2018-05-31 22:16:21.30311|2018-05-31 22:16:21.30311
NCT01410539|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2014-09-24|2011-08-04|2011-08-05|Estimate|||||||2014-09-24|2014-09-25|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|Most||Mechanism Of Stent Thrombosis (MOST) Study|Mechanism Of Stent Thrombosis (MOST) Study, a Prospective Multicentre Non-randomized Registry|Completed||Phase 4|20|Actual|Careggi Hospital||2|||f||||t||||||||||2018-05-31 22:16:21.583777|2018-05-31 22:16:21.583777
NCT01410526|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-08-04|2011-08-04|2011-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Observational|||Assessment of Peritoneal Immune Response in Patients With Severe Intra-abdominal Sepsis Managed With Laparostomy and Vacuum Assisted Closure (VAC)|Assessment of Peritoneal Immune Response in Patients With Severe Intra-abdominal Sepsis Managed With Laparostomy and Vacuum Assisted Closure (VAC)|Unknown status|Recruiting||60|Anticipated|Aristotle University Of Thessaloniki|||2||f||||t||||||||||2018-05-31 22:16:21.669554|2018-05-31 22:16:21.669554
NCT01410513|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-03-31|2011-08-04|2011-08-05|Estimate|||||||2016-03-31|2016-04-01|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia|A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia|Completed||Phase 1|37|Actual|Sanofi||3|||f||||||||||||||2018-05-31 22:16:21.76431|2018-05-31 22:16:21.76431
NCT01410500|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-04-28|2011-08-04|2011-08-05|Estimate|||||||2017-04-28|2017-05-02|Actual||||April 2017|2017-04-30||||||||Expanded Access|||Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease|Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease|Approved for marketing|||||Amgen|||||||||||||||||||2018-05-31 22:16:21.840225|2018-05-31 22:16:21.840225
NCT01410487|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-12-01|2011-08-04|2011-08-05|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Effects of Weight Loss on Cardio-respiratory Function|Effects of Weight Loss on Cardio-respiratory Function and Patient-centered Outcomes in an Underserved, Minority Population With Clinically Severe Obesity|Completed|||150|Actual|New York University School of Medicine|||1||f||||f||||||||||2018-05-31 22:16:21.894778|2018-05-31 22:16:21.894778
NCT01410474|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2013-03-12||2014-09-16|2011-08-04|2011-08-05|Estimate|2014-09-16|2014-09-22|Estimate||||2014-09-16|2014-09-22|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Analysis was done on all the enrolled subjects.|Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan|A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan|Completed||Phase 3|341|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:16:21.974028|2018-05-31 22:16:21.974028
NCT01410461|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2011-08-04|2011-08-04|2011-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|PBS||Identifying Predictors of Treatment Success in Painful Bladder Syndrome|Prospective Observational Study That Evaluates Predictor Tests for the Success of Myofascial Pelvic Floor Muscles for the Treatment of PBS|Unknown status|Not yet recruiting||35|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 22:16:22.329573|2018-05-31 22:16:22.329573
NCT01410448|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2016-11-21||2017-04-03|2011-08-03|2011-08-05|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|November 2011||2011-11-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|NEVERWOUND||Everolimus in de Novo Kidney Transplant Recipients|A 3-month, Multicenter, Randomized, Open Label Study to Evaluate the Impact of Early Versus Delayed Introduction of Everolimus on Wound Healing in de Novo Kidney Transplant Recipients With a Follow-up Evaluation at 12 Month After Transplant (NEVERWOUND Study)|Completed||Phase 3|383|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:16:22.433869|2018-05-31 22:16:22.433869
NCT01410435|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-11-25|2011-08-04|2011-08-05|Estimate|||||||2013-11-25|2013-11-26|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease|An Open-label, Multi-Centre, Non-Randomised Extension Study to Assess the Ability to Maintain a Stable Haemoglobin and to Assess Safety of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease|Completed||Phase 3|39|Actual|Pharmacosmos A/S||1|||f||||t||||||||||2018-05-31 22:16:24.153805|2018-05-31 22:16:24.153805
NCT01222988|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-01-15|2010-10-15|2010-10-18|Estimate|||||||2013-01-15|2013-01-17|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Improving Maintenance Following Very Low Calorie Diet: The Sustain Lost Weight (SLW) Intervention||Completed||N/A|30|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 23:15:11.166043|2018-05-31 23:15:11.166043
NCT01410422|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2011-08-04|2011-08-04|2011-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|April 2014|Anticipated|2014-04-30|||||Observational|||Metabolomic Analysis of Exhaled Breath Condensates in Patients With COPD and Bronchiectasis|Exhaled Breath Analysis in Patients With COPD and Bronchiectasis|Unknown status|Recruiting||250|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     Breath condensate, blood, urine~   "|||2018-05-31 22:16:24.276265|2018-05-31 22:16:24.276265
NCT01410409|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2015-12-19||2017-09-14|2011-08-04|2011-08-05|Estimate|2015-12-19|2016-01-27|Estimate||||2017-09-14|2017-10-16|Actual|September 2011||2011-09-30|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MEDIC||Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement|Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement. A Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up|Completed||N/A|100|Actual|Northern Orthopaedic Division, Denmark||3|||f||||f||||||||||2018-05-31 22:16:24.615715|2018-05-31 22:16:24.615715
NCT01410396|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-08-14|2011-08-04|2011-08-05|Estimate|||||||2013-08-14|2013-08-15|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Observational|||Occult Paroxysmal Atrial Fibrillation in Patients With Non-cardioembolic Ischemic Stroke of Determined Mechanism|Occult Paroxysmal Atrial Fibrillation in Patients With Non-cardioembolic Ischemic Stroke of Determined Mechanism|Completed|||49|Actual|Northwestern University|||||f||||f||||||||||2018-05-31 22:16:25.386249|2018-05-31 22:16:25.386249
NCT01410383|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-08-31|2011-08-04|2011-08-05|Estimate|||||||2012-08-31|2012-09-03|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Interventional|AKKA||Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care|A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care|Terminated||Phase 3|236|Actual|Karo Bio AB||3|||f||||t||||||||||2018-05-31 22:16:25.543866|2018-05-31 22:16:25.543866
NCT01410370|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-04-22|2011-08-04|2011-08-05|Estimate|||||||2013-04-22|2013-04-24|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Continuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases|Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy for the Treatment of Patients With Brain Metastases|Unknown status|Recruiting|Phase 2|80|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:16:25.804073|2018-05-31 22:16:25.804073
NCT01410357|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2017-04-18||2017-10-03|2011-08-03|2011-08-05|Estimate|2017-10-03|2017-10-04|Actual||||2017-10-03|2017-10-04|Actual|July 2011||2011-07-31|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|TTIM||Improving Outcomes for Individuals With Serious Mental Illness and Diabetes|Improving Outcomes for Individuals With Serious Mental Illness and Diabetes|Completed||N/A|200|Actual|Case Western Reserve University||2|||f||||t||||||||Yes|"The investigators will make deidentified data available to other qualified investigators in the research community. Data will remain under control of the PIs of the research study at CWRU. Copies of electronic data files accompanied by data documentation (metadata) will be shared.~Qualified investigators may contact the PIs for information on how to request data. Investigators will be required (at minimum) to provide 1) the names and qualifications of all individuals who will have any access to primary data files; 2) a research proposal detailing how the data will be used; 3) a statement that the investigators will a) not further share the primary data with third parties, b) protect the privacy of subjects, c) provide a means to protect the confidentiality of the data; and 4) a data transfer/use agreement with CWRU. Only data necessary to meet the goals of the investigators' research proposal will be provided to limit the risk of identifying individual research subjects."|2018-05-31 22:16:27.523403|2018-05-31 22:16:27.523403
NCT01410344|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2018-03-26||2018-04-25|2011-08-03|2011-08-05|Estimate|2018-04-25|2018-05-24|Actual||||2018-04-25|2018-05-24|Actual|September 2011|Actual|2011-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2016|Actual|2016-11-30||Interventional||Transplanted participants|Allogeneic Transplant in HIV Patients (BMT CTN 0903)|Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)|Active, not recruiting||Phase 2|20|Actual|Medical College of Wisconsin||1|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 22:17:07.913258|2018-05-31 22:17:07.913258
NCT01410331|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2014-10-22|2011-08-04|2011-08-05|Estimate|||||||2014-10-22|2014-10-23|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia|A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection to Cohorts of Adults With Critical Limb Ischemia|Completed||Phase 2|48|Anticipated|Juventas Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 22:17:10.800699|2018-05-31 22:17:10.800699
NCT01410318|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-02-03|2011-08-04|2011-08-05|Estimate|||||||2017-02-03|2017-02-06|Estimate|June 2010||2010-06-30|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|PESA||Progression of Early Subclinical Atherosclerosis|Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors|Active, not recruiting|||4184|Actual|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III|||||f||||t||||||Samples With DNA|"~     -  Orine (4 x 5 mL)~        -  Blood (8 x 0.6 mL)~        -  Serum (8 x 0.6 mL)~        -  EDTA plasma (8 x 0.6 mL)~        -  Buffy Coat (2 x 0.6 mL)~        -  Non insultated RNA (2 x 5 mL PAXgene)~        -  Insulated DNA (2 x 0.3 mL, 150 ng/microL + 1 x 0.3 mL, 75 ng/microL)~   "|Undecided||2018-05-31 22:17:10.897312|2018-05-31 22:17:10.897312
NCT01410305|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|||2016-06-24|2011-08-04|2011-08-05|Estimate|||||||2016-06-24|2016-06-28|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Vitamin D and HIV-Cardiovascular Disease in Children and Young Adults|Vitamin D Metabolism Inflammation, and Cardiovascular Risk in HIV-infected Children and Young Adults|Completed|||290|Actual|University Hospitals Cleveland Medical Center|||2||f||||f||||||Samples With DNA|"~     plasma, serum, PBMCs, urine~   "|||2018-05-31 22:17:11.014282|2018-05-31 22:17:11.014282
NCT01410292|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-04|2011-08-04|2011-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|January 2012|Anticipated|2012-01-31|September 2011|Anticipated|2011-09-30||Interventional|||Glycemic and Satiety Response to Fiber and Glycemic Index of Meals in Diabetes|Glycemic and Satiety Response to Meals With Different Fiber Content and Glycemic Index in Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|20|Anticipated|Hospital de Clinicas de Porto Alegre||4|||f||||t||||||||||2018-05-31 22:17:11.111779|2018-05-31 22:17:11.111779
NCT01410279|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-08-04|2011-08-04|2011-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Inspiratory Muscle Training in Pulmonary Hypertension|Inspiratory Muscle Training Effect on the Functional Capacity and the Quality of Life in Chronic Pulmonary Hypertension|Unknown status|Recruiting|N/A|34|Anticipated|Hospital de Clinicas de Porto Alegre|||||f||||f||||||||||2018-05-31 22:17:11.199263|2018-05-31 22:17:11.199263
NCT01410266|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2012-11-30|2011-08-03|2011-08-05|Estimate|||||||2012-11-30|2012-12-03|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Reducing the Need for In-Clinic Follow-Up for Medical Abortion in Moldova and Uzbekistan|The Acceptability and Feasibility of Reducing the Need for In-Clinic Follow-Up for First Trimester Medical Abortion in Moldova and Uzbekistan|Completed||Phase 4|2400|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 22:17:11.329459|2018-05-31 22:17:11.329459
NCT01410253|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2016-03-21|2011-08-03|2011-08-05|Estimate|||||||2016-03-21|2016-03-22|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Effects of Cardiac Rehabilitation on Postoperatory of Coronary Artery Bypass Graft.|Evaluation of the Effects of Different Physical Therapy on Cardiac Rehabilitation in Post Operatory Period of Coronary Artery Bypass Graft: Randomized Clinical Trial.|Completed||Phase 3|40|Actual|Hospital de Clinicas de Porto Alegre||4|||f||||t||||||||||2018-05-31 22:17:11.456068|2018-05-31 22:17:11.456068
NCT01410240|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2014-02-28||2014-05-15|2011-08-04|2011-08-05|Estimate|2014-05-15|2014-06-06|Estimate||||2014-05-15|2014-06-06|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty|A Prospective, Randomized, Controlled, Single-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of FLOSEAL for Hemostasis in Primary Unilateral Total Knee Arthroplasty (TKA)|Completed||Phase 4|137|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 22:17:11.663281|2018-05-31 22:17:11.663281
NCT01410227|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-04|2016-03-21|2015-02-01|2017-10-18|2011-08-04|2011-08-05|Estimate|2016-03-21|2016-04-21|Estimate|2015-02-01|2015-02-19|Estimate|2017-10-18|2017-11-21|Actual|November 2011||2011-11-30|March 2016|2016-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Baseline consists of all participants in study [N=37] so is a total of the four arms described in Participant Flow (Arm 1: PK50 + Treatment [N=8]; Arm 2: PK50 Only [N=8]; Arm 3: PK80 + Treatment [N=15]; Arm 4: Treatment Only [N=6]).|Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)|A Phase 3 Clinical Study to Determine the Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor : Recombinant Factor VIII (rVWF:rFVIII) and rVWF in the Treatment of Bleeding Episodes in Subjects Diagnosed With Von Willebrand Disease|Completed||Phase 3|49|Actual|Shire||4|||f||||t||||||||||2018-05-31 22:17:14.590916|2018-05-31 22:17:14.590916
NCT01410214|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-12-21|2011-08-04|2011-08-05|Estimate|||||||2011-12-21|2011-12-23|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|July 2017|Anticipated|2017-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations|A Phase II Trial of Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation in Exon 19 or 21 and Wild-type K-ras|Unknown status|Recruiting|Phase 2|80|Anticipated|Chinese Lung Cancer Surgical Group||2|||f||||f||||||||||2018-05-31 22:17:15.70929|2018-05-31 22:17:15.70929
NCT01410201|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-07-26|2011-08-04|2011-08-05|Estimate|||||||2016-07-26|2016-07-27|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|OZURDEX2||Dexamethasone Intravitreal Implant After Vitrectomy For Epiretinal Membrane|Dexamethasone Intravitreal Implant After Vitrectomy for Idiopathic Epiretinal Membrane|Terminated||N/A|6|Actual|Barnes Retina Institute||2||recruitment not met|f||||f||||||||||2018-05-31 22:17:15.822488|2018-05-31 22:17:15.822488
NCT01410188|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27||2014-02-07|2014-02-07|2011-08-03|2011-08-05|Estimate||||2014-02-07|2014-03-11|Estimate|2014-02-07|2014-03-11|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension|An Investigator-Masked, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 1/Phase 2|160|Actual|Acucela Inc.||6|||f||||t||||||||||2018-05-31 22:17:15.910774|2018-05-31 22:17:15.910774
NCT01410175|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-05-22|2011-08-03|2011-08-04|Estimate|||||||2014-05-22|2014-05-23|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|SCL01||Comparison of the Impact of Electric Scalpels Versus Cold Scalpels|"Impact on the Incidence of Surgical Site Infection in Abdominal Gynecological Surgery by Comparing the Skin and Subcutaneous Tissue Incision With Cold Scalpel and Electrocautery in a Period of Two Years."|Completed||Phase 3|163|Actual|Barretos Cancer Hospital||2|||f||||f||||||||||2018-05-31 22:17:15.998252|2018-05-31 22:17:15.998252
NCT01410162|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-08-31|2011-08-03|2011-08-04|Estimate|||||||2015-08-31|2015-09-01|Estimate|December 2010||2010-12-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|SG#153||Advagraf/Prograf Conversion Trial|A Randomized, Open Label, Cross Over Study to Examine the Impact of Prograf and Advagraf on Tacrolimus Exposure, Mycophenolic Acid Pharmacokinetics, Renal Allograft Function or Adverse Effects.|Completed||Phase 4|53|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 22:17:16.061781|2018-05-31 22:17:16.061781
NCT01410149|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2012-08-13|2011-08-03|2011-08-04|Estimate|||||||2012-08-13|2012-08-15|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Sleep Quality in Mechanically Ventilated Patients|The Influence of Mode and Patient-ventilator Interaction on Sleep Quality in the ICU|Completed||N/A|13|Actual|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 22:17:16.122171|2018-05-31 22:17:16.122171
NCT01410136|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2014-08-07|2011-08-02|2011-08-04|Estimate|||||||2014-08-07|2014-08-11|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Chondrofix Osteochondral Allograft Prospective Study|A Post Market Study to Evaluate the Chondrofix® Osteochondral Allograft Utilized for Treatment of Subjects With Cartilage Lesions in the Knee|Terminated||N/A|29|Actual|Zimmer Orthobiologics, Inc.||1||Inadequate enrollment and decreased need for clinical data to support product|f||||f||||||||||2018-05-31 22:17:16.19404|2018-05-31 22:17:16.19404
NCT01410123|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2018-01-08|2011-08-02|2011-08-04|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2013||2013-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Integrated Stepped Care for Unhealthy Alcohol Use in HIV|Integrated Stepped Care for Unhealthy Alcohol Use in HIV|Active, not recruiting||N/A|319|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:17:16.396761|2018-05-31 22:17:16.396761
NCT01410110|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2014-12-15||2015-01-14|2011-08-03|2011-08-04|Estimate|2015-01-14|2015-01-19|Estimate||||2015-01-14|2015-01-19|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment|Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment|Completed||Phase 2|48|Actual|Yale University|Use of WT limited recruitment to only those willing to participate in a work program for 13 weeks, reducing generalizability. WT may have powerful effects on sobriety that obscured benefits of CRT. As a pilot, this study was not adequately powered.|2|||f||||f||||||||||2018-05-31 22:17:16.513615|2018-05-31 22:17:16.513615
NCT01410097|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2017-04-17||2017-12-12|2011-08-03|2011-08-04|Estimate|2017-10-17|2017-11-17|Actual||||2017-12-12|2018-01-11|Actual|September 2009|Actual|2009-09-30|December 2017|2017-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||8 participants signed consent but did not return for ancillary visit|Physical and Cognitive Function - Look AHEAD Ancillary Study|Intentional Weight Reduction and Physical and Cognitive Function - A Look AHEAD Ancillary Study|Completed||N/A|1089|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 22:17:17.061037|2018-05-31 22:17:17.061037
NCT01410084|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-11-14|2011-08-03|2011-08-04|Estimate|||||||2013-11-14|2013-11-15|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MOW VitD||Improving Vitamin D Status in Home-bound Elders|Improving Vitamin D Status in Home-bound Elders: a Pilot Study|Completed||N/A|68|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 22:17:17.37199|2018-05-31 22:17:17.37199
NCT01410071|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2005||2005-09-30|August 2011|2011-08-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Observational|||Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction|Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction: Evaluation of the Differences Between Those Undergoing Endoscopic Therapy vs.Conservative Care|Terminated|||153|Actual|Wisconsin Center for Advanced Research|||1|Analysis of designed comparison groups not viable|f||||f||||||||||2018-05-31 22:17:17.462556|2018-05-31 22:17:17.462556
NCT01410058|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-12-02|2011-08-03|2011-08-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Moringa Oleifera- Antiretroviral Pharmacokinetic Drug Interaction|Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo.|Completed|||19|Actual|University of Zimbabwe|||2||f||||t||||||Samples With DNA|"~     Whole blood, plasma, urine~   "|||2018-05-31 22:17:17.52749|2018-05-31 22:17:17.52749
NCT01410045|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2018-03-16|2011-08-03|2011-08-04|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2011||2011-01-31|March 2018|2018-03-31|February 2031|Anticipated|2031-02-28|January 16, 2014|Actual|2014-01-16||Interventional|CRYO-X0||Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome|Cryopreservation of Ovarian Cortex in Girls With Turner Syndrome : Karyotypic, Clinical and Hormonal Criteria to Screen Patients|Active, not recruiting||N/A|47|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 22:17:17.609437|2018-05-31 22:17:17.609437
NCT01410032|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2014-04-25|2011-08-03|2011-08-04|Estimate|||||||2014-04-25|2014-04-28|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Reconstruction Plate Compared With Flexible Intramedullary Nailing for Midshaft Clavicular Fractures|Reconstruction Plate Compared With Flexible Intramedullary Nailing for Midshaft Clavicular Fractures: a Prospective, Randomized Clinical Trial|Completed||Phase 2|59|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:17:17.686676|2018-05-31 22:17:17.686676
NCT01410019|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-08-25|2011-08-03|2011-08-04|Estimate|||||||2016-08-25|2016-08-26|Estimate|December 2010||2010-12-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|July 2015|Actual|2015-07-31||Interventional|SCID2||Gene Therapy for X-linked Severe Combined Immunodeficiency|Protocol No. 2 of Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self Retroviral Vector - SCID2|Unknown status|Active, not recruiting|Phase 1/Phase 2|5|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 22:17:17.767397|2018-05-31 22:17:17.767397
NCT01410006|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-07-21|2011-08-02|2011-08-04|Estimate|||||||2017-07-21|2017-07-25|Actual|May 2011||2011-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31|50 Years|Observational [Patient Registry]|NPRI||Neurofibromatosis Type 1 Patient Registry|Neurofibromatosis Type 1 Patient Registry|Completed|||2391|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 22:17:17.837815|2018-05-31 22:17:17.837815
NCT01409993|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2016-12-07||2017-03-03|2011-08-02|2011-08-04|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|August 2011||2011-08-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis||Terminated||Phase 4|78|Actual|Vanderbilt University Medical Center||4||Aim 1 was stopped by DSMB. Aim 2 was stopped due to ending of funding.|f||||t||||||||||2018-05-31 22:17:17.902389|2018-05-31 22:17:17.902389
NCT01409980|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2014-06-22|2011-08-02|2011-08-04|Estimate|||||||2014-06-22|2014-06-24|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Triphalangeal Thumbs in the Pediatric Population: Long Term Outcomes Following Surgical Intervention|Triphalangeal Thumbs in the Pediatric Population: Long Term Outcomes Following Surgical Intervention|Completed|||3|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 22:17:18.236748|2018-05-31 22:17:18.236748
NCT01409967|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-08-23|2011-08-03|2011-08-04|Estimate|||||||2013-08-23|2013-08-26|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|BÉA/T||The Impact of Red Packed Cells Transfusion on the Main Biological Markers to Determine the Etiology of Anemias|The Impact of Red Packed Cells Transfusion on the Main Biological Markers to Determine the Etiology of Anemias|Completed|||40|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 22:17:18.290117|2018-05-31 22:17:18.290117
NCT01409954|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-01-19|2011-08-03|2011-08-04|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2011||2011-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Collecting Bone Graft During Spinal Decompression and Posterolateral Lumbar Fusion to Better Define Bone Making Cells|Defining the Osteogenic Potential of Mesenchymal Stem Cells and Their Progenitors During Spinal Decompression and Posterolateral Lumbar Fusion|Enrolling by invitation|||60|Anticipated|University of Utah|||1||f||||f||||||Samples Without DNA|"~     Aliquots of bone marrow aspirates and bone fragments~   "|||2018-05-31 22:17:18.3562|2018-05-31 22:17:18.3562
NCT01407237|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2016-08-03|2011-08-01|2011-08-02|Estimate|||||||2016-08-03|2016-08-05|Estimate|January 2012||2012-01-31|August 2016|2016-08-31||||March 2015|Actual|2015-03-31||Observational|||Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV|Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV|Completed|||30|Actual|Massachusetts General Hospital|||2||f||||||||||||||2018-05-31 22:17:52.029693|2018-05-31 22:17:52.029693
NCT01409941|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-12-22|2011-08-03|2011-08-04|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|||The Relation Between Preoperative ScO2 and the Postoperative Course of Humoral Organ Dysfunction Markers.|The Prognostic Relevance of N-terminal Pro B-type Natriuretic Peptide(NTproBNP), Cerebral Oxygen Saturation (ScO2), and Preoperative Creatinine Clearance in Cardiac Surgery Patients - Amendment 2: the Role of NTproBNP and ScO2 in Predicting Mortality and Postoperative Organ Dysfunction.|Completed|||765|Actual|University of Luebeck|||||f||||f||||||Samples Without DNA|"~     Plasma and urinary samples.~   "|||2018-05-31 22:17:18.41223|2018-05-31 22:17:18.41223
NCT01409928|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-03-22|2011-08-02|2011-08-04|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study of the Laparoscopically-placed Adjustable Gastric Band for the Management of Obesity in Adolescent Patients|A Study of the Laparoscopically-placed Adjustable Gastric Band for the Management of Obesity in Adolescent Patients|Terminated||Phase 2|16|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 22:17:18.458184|2018-05-31 22:17:18.458184
NCT01409915|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-01-16|2011-08-03|2011-08-04|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2011||2011-03-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease|Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease|Active, not recruiting||Phase 2|40|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 22:17:18.52004|2018-05-31 22:17:18.52004
NCT01409902|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-04-22|2011-08-03|2011-08-04|Estimate|||||||2013-04-22|2013-04-23|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Using a Sheathed Speculum to Visualize and Access the Cervix In Women With Excessive Vaginal Tissue|Using a Sheathed Speculum to Visualize and Access the Cervix In Women With Excessive Vaginal Tissue|Completed|||38|Actual|University of South Florida|||||f||||t||||||||||2018-05-31 22:17:18.588843|2018-05-31 22:17:18.588843
NCT01409889|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-01-15|2011-08-02|2011-08-04|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparing Diabetes Prevention Programs|Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study|Completed||N/A|92|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 22:17:18.638071|2018-05-31 22:17:18.638071
NCT01409876|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2011||2011-09-30|March 2011|2011-03-31|September 2016|Anticipated|2016-09-30|September 2014|Anticipated|2014-09-30||Interventional|||HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy|HistoScanning- Based Dose-painting Image-guided Interstitial PDR-brachytherapy in Prostate Cancer - a Phase II Trial|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|University Hospital Erlangen||1|||f||||||||||||||2018-05-31 22:17:18.699696|2018-05-31 22:17:18.699696
NCT01409863|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-01-21|2011-08-03|2011-08-04|Estimate|||||||2015-01-21|2015-01-26|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Fractional Laser Therapy and Dermabrasion for Scar Revision|A Comparison Evaluation of Fractional Laser Therapy an Dermabrasion for Scar Revision|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||PI has left University of Minnesota.|f||||f||||||||||2018-05-31 22:17:18.78354|2018-05-31 22:17:18.78354
NCT01409850|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-12-02|2011-08-03|2011-08-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison Study of Two Splints Used for Treatment of Acute Temporomandibular Pain.|Pilot Clinical Trial on the Treatment Effectiveness of Two Splints for Acute Temporomandibular Pain.|Terminated||N/A|36|Actual|Heidelberg University||3||Very slow enrollment of participants|f||||f||||||||||2018-05-31 22:17:19.083651|2018-05-31 22:17:19.083651
NCT01409837|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2013-06-22||2013-09-21|2011-08-03|2011-08-04|Estimate|2013-09-21|2013-11-25|Estimate||||2013-09-21|2013-11-25|Estimate|March 1998||1998-03-31|September 2013|2013-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||The Effect and Safety of Lisinopril in Non-hypertensive Men With Infertility From Low Sperm Count|A 5-year Prospective, Placebo-controlled, Crossover Evaluation of the Efficacy and Tolerability of Low-dose Lisinopril in Normotensives With Idiopathic Oligospermic Infertility|Completed||Phase 2|33|Actual|University Of Nigeria Teaching Hospital|The sample size of the study is small thereby limiting the reliability of generalizing the findings. In addition, three subjects who started the study terminated prematurely and it is difficult to assess how this fact has affected the study results.|2|||f||||t||||||||||2018-05-31 22:17:19.333171|2018-05-31 22:17:19.333171
NCT01409824|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|April 2014|Anticipated|2014-04-30|September 2010|Actual|2010-09-30||Interventional|QUALMAT||Health Care Intervention Research- Improving Pre-natal and Maternal Care|Health Care Intervention Research-Quality of Prenatal and Maternal Care: Bridging the Know-do Gap (QUALMAT)|Unknown status|Recruiting|N/A|36|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-05-31 22:17:20.941473|2018-05-31 22:17:20.941473
NCT01409811|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-06-07|2011-08-03|2011-08-04|Estimate|||||||2017-06-07|2017-06-09|Actual|September 14, 2012|Actual|2012-09-14|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid|A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer|Active, not recruiting||N/A|40|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 22:17:21.290902|2018-05-31 22:17:21.290902
NCT01409798|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-05-11|2011-08-02|2011-08-04|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Observational|||The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry|The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry|Completed|||175|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 22:17:21.635531|2018-05-31 22:17:21.635531
NCT01409785|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-10-04|2011-08-03|2011-08-04|Estimate|||||||2011-10-04|2011-10-05|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Comparison of the LMA Unique and LMA Supreme in Children|A Prospective, Randomized Comparison of the LMA Unique and LMA Supreme in Children|Completed|||50|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-05-31 22:17:21.864459|2018-05-31 22:17:21.864459
NCT01380158|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-07-07|2011-06-22|2011-06-27|Estimate|||||||2011-07-07|2011-07-08|Estimate|January 2011||2011-01-31|June 2011|2011-06-30||||October 2012|Anticipated|2012-10-31||Interventional|PrePPy||Preventing Preterm Birth With a Pessary|Preventing Preterm Birth With a Pessary|Unknown status|Recruiting|N/A|238|Anticipated|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 22:27:33.898112|2018-05-31 22:27:33.898112
NCT01409772|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2012-06-15|2011-08-03|2011-08-04|Estimate|||||||2012-06-15|2012-06-18|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Evaluation of the Clinical Practice of Using of a 70% Ethanol Lock Solution for the Prevention of Catheter Related Blood Stream Infections in Pediatric Patients Undergoing Intestinal Rehabilitation|Evaluation of the Clinical Practice of Using of a 70 % Ethanol Lock Solution for the Prevention of Catheter Related Blood Stream Infections in Pediatric Patients Undergoing Intestinal Rehabilitation|Withdrawn|||0|Actual|University of Nebraska|||1|PI decided to withdraw study|f||||f||||||||||2018-05-31 22:17:22.09597|2018-05-31 22:17:22.09597
NCT01409759|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-06-25|2011-08-03|2011-08-04|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Perforator Based Interposition Plasty|Perforator Based Interposition Flaps for Sustainable Release of Burn Scar Contracture: a Reliable, Simple and Versatile Technique. A Randomised Controlled Trial.|Completed||Phase 2|50|Actual|Association of Dutch Burn Centres||2|||f||||t||||||||||2018-05-31 22:17:22.406866|2018-05-31 22:17:22.406866
NCT01409746|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2018-04-20|2011-08-03|2011-08-04|Estimate|||||||2018-04-20|2018-04-23|Actual|April 2004||2004-04-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Early Brain Development in Twins|Early Brain Development in Twins|Active, not recruiting|||600|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     buccal swabs; MRIs, ultrasounds~   "|||2018-05-31 22:17:22.895382|2018-05-31 22:17:22.895382
NCT01409733|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients|TACE With Drug Eluting Beads Loaded With Doxorubicin in Liver Metastases From Melanoma Patients|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Heidelberg University||1|||f||||f||||||||||2018-05-31 22:17:23.155655|2018-05-31 22:17:23.155655
NCT01409720|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2014-03-19|2011-08-03|2011-08-04|Estimate|||||||2014-03-19|2014-03-20|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|DISPO||Isometric Muscle Training in Patients With Spinal Bony Metastases Under Radiation Therapy|Isometric Muscle Training of the Spine Musculature in Patients With Spinal Bony Metastases Under Radiation Therapy|Completed||Phase 2|60|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 22:17:23.541644|2018-05-31 22:17:23.541644
NCT01409707|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2013-10-29||2014-01-28|2011-08-03|2011-08-04|Estimate|2014-01-28|2014-03-10|Estimate||||2014-01-28|2014-03-10|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|January 2012|Actual|2012-01-31||Interventional|||Mechanisms of Change, Motivation, and Treatment Outcome in Alcohol Dependence - Posttraumatic Stress Disorder|Mechanisms of Change, Motivation, and Treatment Outcome in AD-PTSD|Completed||N/A|126|Actual|University of Mississippi Medical Center|Unclear whether results will generalize to outpatient sample.|3|||f||||f||||||||||2018-05-31 22:17:23.900051|2018-05-31 22:17:23.900051
NCT01409694|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-09-21|2011-08-03|2011-08-04|Estimate|||||||2016-09-21|2016-09-22|Estimate|September 2011||2011-09-30|March 2011|2011-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|AD-IDEA||Alzheimer's Disease - Input of Vitamin D With mEmantine Assay|Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré|Completed||Phase 3|90|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 22:17:24.310747|2018-05-31 22:17:24.310747
NCT01409681|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2014-03-28|2011-08-03|2011-08-04|Estimate|||||||2014-03-28|2014-03-31|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|EBUS||A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer|A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer|Terminated|||41|Actual|University of Michigan Cancer Center|||1|PI decided to terminate the study|f||||t||||||Samples With DNA|"~     Bronchial brush samples Bronchoscopy samples for RNA extraction and RT-PCR expression Blood~     samples~        -  7 mL for measurement of Serum total Vit-D levels and 1,25 (OH)2 D3 levels;~        -  5 ml collected in EDTA tube for CYP24A1 genotype analysis (common metabolizing agent for~          calcitriol) and CYP24 polymorphisms analysis~   "|||2018-05-31 22:17:24.407077|2018-05-31 22:17:24.407077
NCT01409668|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2007||2007-09-30|May 2007|2007-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MPH||Efficacy of Two Yogurt Formulations in Healthy Humans|Efficacy of Two Yogurt Formulations as Health Promoting Agents in Healthy Humans|Completed||Phase 1|30|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 22:17:24.503307|2018-05-31 22:17:24.503307
NCT01409655|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-02-23|2011-08-03|2011-08-04|Estimate|||||||2016-02-23|2016-02-25|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|CARE||Centralized Off-Site Adherence Enhancement Program|Centralized Off-Site Adherence Enhancement Program|Completed||N/A|42|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 22:17:24.569398|2018-05-31 22:17:24.569398
NCT01409642|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-05-11|2011-08-03|2011-08-04|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2008||2008-01-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PFIT||Family Focused Treatment of Pediatric Obsessive Compulsive Disorder|Pilot Feasibility Trial of Positive Family Interaction Therapy|Unknown status|Recruiting|N/A|40|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:17:24.654709|2018-05-31 22:17:24.654709
NCT01409629|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-09-28|2011-08-03|2011-08-04|Estimate|||||||2011-09-28|2011-09-30|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|May 2011|Actual|2011-05-31||Observational|||Influence of a Computer Game on Youth's Choices of Activities|Influence of a Computer Game on Youth's Choices of Activities|Terminated|||80|Anticipated|University at Buffalo|||1||f||||f||||||||||2018-05-31 22:17:24.756078|2018-05-31 22:17:24.756078
NCT01409616|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-03-19|2011-08-03|2011-08-04|Estimate|||||||2013-03-19|2013-03-21|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||To Evaluate Whether Acetyl Salicylic Acid (Aspirin), the Combination of Aspirin and Clopidogrel and Darexaban (YM150) Interact in Their Effects|A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State|Completed||Phase 1|100|Actual|Astellas Pharma Inc||8|||f||||f||||||||||2018-05-31 22:17:24.814961|2018-05-31 22:17:24.814961
NCT01408342|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2014-01-03|2011-08-02|2011-08-03|Estimate|||||||2014-01-03|2014-01-07|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Alemtuzumab and Rituximab in Aplastic Anemia|Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia|Withdrawn||N/A|0|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t||||||||||2018-05-31 22:17:41.708062|2018-05-31 22:17:41.708062
NCT01409603|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-04-09|2011-08-03|2011-08-04|Estimate|||||||2013-04-09|2013-04-11|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||To Evaluate Whether Naproxen and Darexaban (YM150) Interact in Their Effects|A Phase I, Open-Label, Randomized 3-Period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Interactions Between YM150 on Naproxen at Steady-State|Completed||Phase 1|26|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 22:17:24.921814|2018-05-31 22:17:24.921814
NCT01409590|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|May 2005||2005-05-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|September 2006|Actual|2006-09-30||Interventional|||Exercise and Diet Program for Schizophrenia Patients Who Are Taking Atypical Antipsychotic Medications|Exercise and Diet Program for Schizophrenia Patients Who Are Taking Atypical Antipsychotic Medications|Completed||N/A|100|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 22:17:25.001776|2018-05-31 22:17:25.001776
NCT01409577|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-11-19|2011-08-03|2011-08-04|Estimate|||||||2011-11-19|2011-11-22|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Outcome of FFR-guided Intervention Strategy|Clinical Outcome of Fractional Flow Reserve-guided Coronary Intervention Strategy in Koreans|Unknown status|Recruiting||1500|Anticipated|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 22:17:25.079097|2018-05-31 22:17:25.079097
NCT01409564|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|2013-08-19||2014-04-14|2011-08-03|2011-08-04|Estimate|2014-04-14|2014-05-13|Estimate||||2014-04-14|2014-05-13|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional||18 subjects for each group were enrolled in the final list.|Cilostazol Augmentation Study in Dementia|Cilostazol Augmentation Study In Dementia (CASID): A Randomized, Placebo-controlled Pilot Study to Compare the Efficacy Between Donepezil Monotherapy and Cilostazol Augmentation Therapy in Alzheimer's Disease Patients With Subcortical White Matter Hyperintensities|Completed||Phase 4|46|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 22:17:25.171129|2018-05-31 22:17:25.171129
NCT01409551|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-11-14|2011-08-03|2011-08-04|Estimate|||||||2014-11-14|2014-11-17|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Video-assisted Hyperthermic Pleural Chemoperfusion vs Talc Pleurodesis for Refractory Malignant Pleural Effusions.|Video-assisted Hyperthermic Pleural Chemoperfusion Versus Bed-side Talc Slurry Pleurodesis for Refractory Malignant Pleural Effusions.|Completed||N/A|60|Actual|Theagenio Cancer Hospital||2|||f||||f||||||||||2018-05-31 22:17:25.492404|2018-05-31 22:17:25.492404
NCT01409538|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-03-19|2011-08-02|2011-08-04|Estimate|||||||2015-03-19|2015-03-20|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Brain Imaging and Pain: Analysis of Placebo Analgesia|Brain Imaging and Pain: Analysis of Placebo Analgesia|Completed||Phase 1|140|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:17:25.550826|2018-05-31 22:17:25.550826
NCT01409525|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Observational|||Rate of Microbial Colonization Over Native Calcified Cardiac Valves|Observational, Prospective, Exploratory Study to Evaluate the Rate of Microbial Colonization Over Native Calcified Cardiac Valves|Unknown status|Not yet recruiting||200|Anticipated|Rambam Health Care Campus|||1||f||||f||||||Samples Without DNA|"~     cardiac valve tissue~   "|||2018-05-31 22:17:25.7229|2018-05-31 22:17:25.7229
NCT01409512|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder|Observational Study on the Effect of Anticholinergic on the Autonomic System in Women With OAB|Unknown status|Not yet recruiting||30|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 22:17:25.798763|2018-05-31 22:17:25.798763
NCT01409499|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-04-13|2011-08-03|2011-08-04|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|2011PTAHCC||Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)|A Prospective Multicenter Non-randomized Controlled Study of Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|200|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 22:17:25.878071|2018-05-31 22:17:25.878071
NCT01409486|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|LC-MS-MS||Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry|Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry|Unknown status|Not yet recruiting||10000|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 22:17:25.960981|2018-05-31 22:17:25.960981
NCT01409473|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2014-02-10|2011-08-03|2011-08-04|Estimate|||||||2014-02-10|2014-02-12|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|August 2022|Anticipated|2022-08-31|August 2018|Anticipated|2018-08-31||Interventional|Prostate SBRT||Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer|A Prospective Protocol of Stereotactic Body Irradiation With Concurrent Intraprostatic Lesion Boost Utilizing Intensity Modulated Radiotherapy for Patients With Low- and Intermediate-Risk Prostate Cancer|Withdrawn||Phase 2|0|Actual|Rocky Mountain Cancer Centers||1|||f||||f||||||||||2018-05-31 22:17:26.017116|2018-05-31 22:17:26.017116
NCT01409460|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Obturator Nerve Block With Femoral and Sciatic Block|Is an Obturator Nerve Block Required for Every Patient Having Total Knee Arthroplasty With Femoral and Sciatic Nerve Block?|Completed||N/A|16|Actual|Saint Francis Care||2|||f||||f||||||||||2018-05-31 22:17:26.085117|2018-05-31 22:17:26.085117
NCT01409447|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2011-08-19|2011-08-03|2011-08-04|Estimate|||||||2011-08-19|2011-08-22|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Repair of Articular Osteochondral Defect|Repair of Articular Osteochondral Defect|Unknown status|Recruiting|N/A|10|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 22:17:26.149633|2018-05-31 22:17:26.149633
NCT01409434|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2014-07-16||2014-10-10|2011-08-02|2011-08-04|Estimate|2014-10-10|2014-10-16|Estimate||||2014-10-10|2014-10-16|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Patients previously enrolled in the PEAR 1 or 2 study|Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study|Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study|Completed||Phase 4|44|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 22:17:26.22417|2018-05-31 22:17:26.22417
NCT01409421|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-09-30|2011-08-03|2011-08-04|Estimate|||||||2015-09-30|2015-10-01|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence|An Assessment of the Impact of Motivational Interviewing Via Glaucoma Educator on Glaucoma Treatment Adherence and Persistence|Completed||N/A|201|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 22:17:26.409801|2018-05-31 22:17:26.409801
NCT01409408|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-03-05|2011-08-03|2011-08-04|Estimate|||||||2012-03-05|2012-03-06|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|December 2013|Anticipated|2013-12-31|April 2013|Anticipated|2013-04-30||Interventional|||Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan|Comparison Between Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan: Effects on Endothelial Function and Renin Concentration and Activity|Withdrawn||Phase 4|0|Actual|Hospital Universitario Pedro Ernesto||2||Due to preliminary results of Altitude Trial.|f||||f||||||||||2018-05-31 22:17:26.472167|2018-05-31 22:17:26.472167
NCT01409395|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2014-04-09|2011-08-02|2011-08-04|Estimate|||||||2014-04-09|2014-04-10|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Drug-Drug Interaction Study With Metformin and Nizatidine|The Pharmacokinetic Interaction Between Metformin and Nizatidine in Healthy Volunteers|Completed||Phase 1|10|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:17:26.537551|2018-05-31 22:17:26.537551
NCT01409382|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2013-04-26||2016-08-19|2011-08-03|2011-08-04|Estimate|2015-12-13|2016-01-21|Estimate||||2016-08-19|2016-09-29|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|April 2013|Actual|2013-04-30||Interventional||Women with recurrent fetal losses in the first trimester|Maternal Lifestyle and Neonatal Hypoglycemia|Repercussion of Maternal Lifestyle on Obstetric and Neonatal Outcomes|Completed||N/A|480|Actual|Hospital dos Servidores do Estado do Rio de Janeiro||2|||f||||t||||||||Yes||2018-05-31 22:17:26.620633|2018-05-31 22:17:26.620633
NCT01409369|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2016-11-01|2011-08-03|2011-08-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study on The Effect of Multiple Doses of Activated Charcoal on The Pharmacokinetics of a Single Dose of RO4995819|A Single-Center, Open-Label, Two-Period Crossover Study to Investigate the Effect of Multiple Doses of Activated Charcoal on the Pharmacokinetics of a Single Oral Dose of RO4995819 in Healthy Subjects.|Completed||Phase 1|26|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:17:27.896202|2018-05-31 22:17:27.896202
NCT01409356|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2015-03-17|2011-08-03|2011-08-04|Estimate|||||||2015-03-17|2015-03-19|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|SPORTDIET||Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis|Effects of Weight Loss on Portal Pressure in Patients With Compensated Cirrhosis and Overweight/Obesity|Completed||Phase 2|60|Actual|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-05-31 22:17:27.968221|2018-05-31 22:17:27.968221
NCT01409343|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2013-12-19|2011-08-03|2011-08-04|Estimate|||||||2013-12-19|2013-12-20|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||TrasGEX™: Dose Escalation Study|A Phase I Dose-Escalation and Pharmacokinetic Study of TrasGEX™ in Patients With Locally Advanced or Metastatic HER-2-positive Cancer|Completed||Phase 1|45|Anticipated|Glycotope GmbH|||||f||||t||||||||||2018-05-31 22:17:28.110849|2018-05-31 22:17:28.110849
NCT01409330|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-08-21|2011-08-03|2011-08-04|Estimate|||||||2012-08-21|2012-08-22|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|DDIET||German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET)|Short Term Diet Intervention in Newly Diagnosed Type 2 Diabetes. a Randomised, Multicentric, Controlled, Clinical Trial|Unknown status|Recruiting|Phase 4|40|Anticipated|German Diabetes Center||2|||f||||f||||||||||2018-05-31 22:17:28.174236|2018-05-31 22:17:28.174236
NCT01409317|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-05-26|2011-08-03|2011-08-04|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Neural Predictors and Longitudinal Neural Correlates of Deep Transcranial Magnetic Stimulation for Treating Major Depression|Neural Predictors and Longitudinal Neural Correlates of Clinical Improvement After Standard or Deep Transcranial Magnetic Stimulation in Major Depression: A Randomized Study|Completed||Phase 2/Phase 3|10|Actual|Douglas Mental Health University Institute||2|||f||||t||||||||||2018-05-31 22:17:28.265109|2018-05-31 22:17:28.265109
NCT01409304|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-01-16|2011-08-03|2011-08-04|Estimate|||||||2013-01-16|2013-01-18|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Deep Transcranial Magnetic Stimulation in Depression|Effectiveness of Deep Transcranial Magnetic Stimulation for Treating Major Depression: a Pilot Study|Completed||Phase 2/Phase 3|18|Actual|Douglas Mental Health University Institute|||||f||||f||||||||||2018-05-31 22:17:28.354251|2018-05-31 22:17:28.354251
NCT01409291|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2014-08-11||2014-08-11|2011-08-03|2011-08-04|Estimate|2014-08-11|2014-08-26|Estimate||||2014-08-11|2014-08-26|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Impact of a Financial Success Education Program in Women and Children|Impact of a Financial Success Education Program on Perceived Financial Well-being, Hopefulness, Financial Competency, Financial Goal Achievement, Quality of Life, and Quantitative Health Outcomes in Women and Children: A Pilot Study|Completed|||64|Actual|Creighton University|||||f||||f||||||||||2018-05-31 22:17:28.739911|2018-05-31 22:17:28.739911
NCT01409278|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-03|2011-08-03|2011-08-04|Estimate|||||||2011-08-03|2011-08-04|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement|The Evaluation of the Efficacy of Local Infiltration Analgesia and Infusion for Total Hip Arthroplasty|Completed||N/A|105|Actual|Saint Francis Care||3|||f||||f||||||||||2018-05-31 22:17:28.989853|2018-05-31 22:17:28.989853
NCT01409265|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2015-02-10|2011-08-03|2011-08-04|Estimate|||||||2015-02-10|2015-02-11|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Impact of Perceptual Impairment on Social Participation in Stroke Patients|The Impact of Perceptual Impairment on Social Participation in Stroke Patients|Completed|||90|Actual|Chang Gung Memorial Hospital|||1||f||||f||||||||||2018-05-31 22:17:29.069832|2018-05-31 22:17:29.069832
NCT01409252|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-01-10|2011-08-03|2011-08-04|Estimate|||||||2013-01-10|2013-01-14|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Long Term Outcome After Hemorrhagic Stroke Surgery|Long Term Neurological and Cognitive Outcome After Neurosurgical Operation for Hemorrhagic Stroke (Intracerebral Hemorrhage)|Completed|||191|Actual|Chinese University of Hong Kong|||1||f||||f||||||||||2018-05-31 22:17:29.211527|2018-05-31 22:17:29.211527
NCT01409239|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2013-07-02||2013-11-11|2011-08-02|2011-08-04|Estimate|2013-11-11|2013-12-04|Estimate||||2013-11-11|2013-12-04|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes||Completed||Phase 4|42|Actual|Ohio State University|Since this was a pilot study no formal power analysis was possible. It was hypothesized that IV insulin would be associated with lower LF/HF HRV.|2|||f||||f||||||||||2018-05-31 22:17:29.351864|2018-05-31 22:17:29.351864
NCT01409226|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-04-03|2011-08-02|2011-08-04|Estimate|||||||2012-04-03|2012-04-05|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women|A Study to Evaluate 3.0 Tesla Magnetic Resonance Imaging of the Breasts in High Risk Women|Withdrawn||N/A|0|Actual|New York University School of Medicine||1||Due to slow accrual|f||||||||||||||2018-05-31 22:17:29.63301|2018-05-31 22:17:29.63301
NCT01409213|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2011-12-15||2015-08-26|2011-08-02|2011-08-04|Estimate|2011-12-15|2012-01-23|Estimate||||2015-08-26|2015-08-27|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|SIRTA||A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)|Standardized Non-interventional Register Investigating the Daily Clinical Practice for the Treatment of Patients With Diabetes Mellitus Type 2 (SIRTA)|Completed|||1523|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:17:29.729336|2018-05-31 22:17:29.729336
NCT01409200|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-04-10|2011-08-02|2011-08-04|Estimate|||||||2018-04-10|2018-04-12|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Neoadjuvant Axitinib in Prostate Cancer|Pre-surgical Androgen Deprivation Therapy With or Without Axitinib in Previously Untreated Prostate Cancer Patients With Known or Suspected Lymph Node Metastasis|Recruiting||Phase 2|72|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:17:29.930354|2018-05-31 22:17:29.930354
NCT01409187|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-01-25|2011-08-02|2011-08-04|Estimate|||||||2012-01-25|2012-01-26|Estimate|October 2011||2011-10-31|January 2012|2012-01-31||||October 2016|Anticipated|2016-10-31||Interventional|||IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma|IPI-Biotherapy for Patients With Metastatic Melanoma Previously Treated With Cytotoxic Drugs|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:17:30.026741|2018-05-31 22:17:30.026741
NCT01409174|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-05-26|2011-08-02|2011-08-04|Estimate|||||||2017-05-26|2017-05-31|Actual|February 2013||2013-02-28|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma|IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma|Terminated||Phase 1|19|Actual|M.D. Anderson Cancer Center||1||Slow accrual, closed in Phase I.|f||||f||||||||||2018-05-31 22:17:30.104194|2018-05-31 22:17:30.104194
NCT01409161|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2018-05-04|2011-08-02|2011-08-04|Estimate|||||||2018-05-04|2018-05-10|Estimate|October 2011|Actual|2011-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin|Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)|Recruiting||Phase 2|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:17:30.201048|2018-05-31 22:17:30.201048
NCT01409148|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2012-10-10|2011-08-03|2011-08-04|Estimate|||||||2012-10-10|2012-10-11|Estimate|November 2008||2008-11-30|August 2011|2011-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Radioimmunoimaging of AL Amyloidosis|Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4|Completed||Phase 1|38|Actual|University of Tennessee||1|||f||||f||||||||||2018-05-31 22:17:30.372819|2018-05-31 22:17:30.372819
NCT01409135|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2015-10-06|2011-08-02|2011-08-04|Estimate|||||||2015-10-06|2015-10-07|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4|A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E or ASG-22CE Given as Monotherapy Followed by Expansion Cohorts in Subjects With Malignant Solid Tumors That Express Nectin-4|Completed||Phase 1|34|Actual|Astellas Pharma Inc||9|||f||||f||||||||||2018-05-31 22:17:30.492435|2018-05-31 22:17:30.492435
NCT01409122|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-11-08|2011-08-03|2011-08-04|Estimate|||||||2012-11-08|2012-11-09|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects|A Phase 1, Placebo Controlled, Blinded, Multiple Dose Escalation Study of AIR001 (Sodium Nitrite Inhalation Solution) in Healthy Subjects, an Assessment of the Tolerability in Combination With Oral Sildenafil, and an Open-Label Study of Multiple Dose AIR001 in Patients With Pulmonary Arterial Hypertension|Completed||Phase 1|42|Actual|Aires Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 22:17:30.596739|2018-05-31 22:17:30.596739
NCT01409109|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2018-05-16|2011-08-02|2011-08-03|Estimate|||||||2018-05-16|2018-05-17|Actual|March 2010||2010-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Observational|Imaging||Database Registry to Examine Brain Connections and Brain Function in Mental Disorders and Neural Network Biomarkers for Relational Memory and Psychosis in Schizophrenia|Database Registry to Examine Brain Connections and Brain Function in Mental Disorders and Neural Network Biomarkers for Relational Memory and Psychosis in Schizophrenia|Recruiting|||1000|Anticipated|University of Texas Southwestern Medical Center|||2||f||||t||||||||||2018-05-31 22:17:30.74352|2018-05-31 22:17:30.74352
NCT01409096|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2016-01-06|2013-04-22|2016-03-01|2011-08-02|2011-08-03|Estimate|2016-03-01|2016-03-31|Estimate|2013-04-29|2013-05-07|Estimate|2016-03-01|2016-03-31|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study Using Pregnenolone to Treat Bipolar Depression|A Randomized, Double Blind, Placebo-controlled Trial of Pregnenolone for Bipolar Depression|Completed||Phase 4|80|Actual|University of Texas Southwestern Medical Center|Sample size; treatment groups not well matched on gender or depressive symptom scores|2|||f||||t||||||||Undecided||2018-05-31 22:17:31.116648|2018-05-31 22:17:31.116648
NCT01409083|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-12-11|2011-08-02|2011-08-03|Estimate|||||||2012-12-11|2012-12-12|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Children|Evaluating the Use of Intravenous Bicarbonate as a Tool to Verify the Intravascular Position of an IV Catheter in Children|Completed||Phase 1/Phase 2|18|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 22:17:31.942583|2018-05-31 22:17:31.942583
NCT01379794|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-04-12|2011-06-22|2011-06-23|Estimate|||||||2013-04-12|2013-04-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:27:59.309989|2018-05-31 22:27:59.309989
NCT01409070|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2012-10-13|2011-08-02|2011-08-03|Estimate|||||||2012-10-13|2012-10-16|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|H-1012-015-342||Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome|Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome: Retrospective, Multicenter Study|Completed|||300|Actual|Seoul National University Hospital|||2||f||||||||||||||2018-05-31 22:17:32.032256|2018-05-31 22:17:32.032256
NCT01409057|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-12-11|2011-08-02|2011-08-03|Estimate|||||||2012-12-11|2012-12-12|Estimate|June 2010||2010-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Observational|SEOPCAB||Effect of Heart-lung-machine on Selenium Status of Cardiac Surgical Patients Undergoing Coronary Bypass Surgery|SEOPCAB: Effect of Heart-lung-machine on Selenium Status of Cardiac Surgical Patients Undergoing Coronary Bypass Surgery|Completed|||46|Actual|RWTH Aachen University|||2||f||||f||||||||||2018-05-31 22:17:32.155329|2018-05-31 22:17:32.155329
NCT01409044|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-08-09|2011-08-02|2011-08-03|Estimate|||||||2017-08-09|2017-08-10|Actual|June 17, 2011||2011-06-17|August 8, 2017|2017-08-08|August 8, 2017|Actual|2017-08-08|May 9, 2013|Actual|2013-05-09||Interventional|||Effect of Music on Pain and Anxiety After Surgery|The Effect of Music Listening on the Amount of Opioids Used in Surgical Intensive Care Patients|Terminated||Phase 3|62|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:17:32.473375|2018-05-31 22:17:32.473375
NCT01409031|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2016-03-22|2011-08-02|2011-08-03|Estimate|||||||2016-03-22|2016-03-23|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension|Phase II Trial of Sildenafil in Newborns With Persistent Pulmonary Hypertension|Terminated||Phase 2|4|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 22:17:32.686583|2018-05-31 22:17:32.686583
NCT01409018|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2013-11-17|2011-08-02|2011-08-03|Estimate|||||||2013-11-17|2013-11-19|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Pharmacokinetics of Itraconazole in Pediatric Cancer Patients|Pharmacokinetics of Itraconazole in Pediatric Cancer Patients|Completed||Phase 1|6|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:17:32.951008|2018-05-31 22:17:32.951008
NCT01409005|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2014-02-10|2011-08-02|2011-08-03|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2011||2011-06-30|January 2014|2014-01-31||||February 2013|Actual|2013-02-28||Interventional|||Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer|A Phase II Trial of Gemcitabine Plus UFTE Combination Chemotherapy as Salvage Treatment in Oxaliplatin, Irinotecan and Fluoropyrimidine-Refractory Metastatic Colorectal Cancer|Completed||Phase 2|41|Actual|Seoul National University Bundang Hospital||1|||f||||f||||||||||2018-05-31 22:17:33.135348|2018-05-31 22:17:33.135348
NCT01408992|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2011-12-29||2014-04-17|2011-08-02|2011-08-03|Estimate|2014-03-11|2014-04-16|Estimate||||2014-04-17|2014-05-05|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|Thai_FMHT||Thai-version Five Minute Hearing Test|The Evaluation of Thai-version Five Minute Hearing Test to Screen Hearing in Community|Completed||N/A|558|Actual|Khon Kaen University||1|||f||||f||||||||||2018-05-31 22:17:33.251858|2018-05-31 22:17:33.251858
NCT01408979|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-08-20|2011-08-02|2011-08-03|Estimate|||||||2012-08-20|2012-08-22|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|MgSO4||Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia|Postpartum Prophylaxis With Short Course Magnesium Sulfate in Severe Preeclampsia: a Randomized Clinical Trial|Completed||Phase 4|120|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-05-31 22:17:33.614291|2018-05-31 22:17:33.614291
NCT01408966|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-02|2011-08-02|2011-08-03|Estimate|||||||2011-08-02|2011-08-03|Estimate|August 2008||2008-08-31|August 2011|2011-08-31|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Interventional|||Effects of Dark vs. White Chocolate on the Postprandial Increase in Portal Pressure in Cirrhosis|Effects of Dark vs. White Chocolate on the Postprandial Increase in Portal Pressure in Cirrhosis|Completed||Phase 2|22|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 22:17:33.904008|2018-05-31 22:17:33.904008
NCT01408953|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2016-10-17|2011-08-02|2011-08-03|Estimate|||||||2016-10-17|2016-10-18|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue|A Therapeutic Trial of Intralesional Bevacizumab in Patients With Non-pedunculated Keloids|Terminated||Phase 2|2|Actual|Tirgan, Michael H., M.D.||1||Very low accrual rate.|f||||f||||||||Yes|Only two patients were treated on this study, neither responded. The study was closed due to difficulties in accruing patients.|2018-05-31 22:17:34.230563|2018-05-31 22:17:34.230563
NCT01408927|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-08-08|2011-08-02|2011-08-03|Estimate|||||||2014-08-08|2014-08-11|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|VASP||Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population|Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary PCI and CABG Population|Unknown status|Recruiting||1000|Anticipated|Medstar Health Research Institute|||||f||||f||||||||||2018-05-31 22:17:34.328685|2018-05-31 22:17:34.328685
NCT01408914|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2017-05-03||2017-10-17|2011-08-02|2011-08-03|Estimate|2017-06-15|2017-07-13|Actual||||2017-10-17|2017-11-20|Actual|September 2013||2013-09-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|HIRIF||Trial of High-Dose Rifampin in Patients With TB|Randomized Trial of High-Dose Rifampin in Patients With New, Smear-Positive TB|Completed||Phase 2|180|Actual|Harvard University Faculty of Medicine||3|||f||||t||||||||||2018-05-31 22:17:34.426964|2018-05-31 22:17:34.426964
NCT01408901|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2018-03-28|2011-08-02|2011-08-03|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2011||2011-09-30|March 2018|2018-03-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|PROPEL||Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)|PROgenitor Cell Release Plus Exercise to Improve functionaL Performance in PAD: The PROPEL Study|Completed||N/A|210|Actual|Northwestern University||4|||f||||t||||||||Undecided||2018-05-31 22:17:34.956292|2018-05-31 22:17:34.956292
NCT01408888|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2014-10-03||2014-10-03|2011-08-02|2011-08-03|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Participants who received at least one dose of study drug (LY2189265 or Sitagliptin).|A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes|Study to Evaluate the Effect of LY2189265 on Sitagliptin Pharmacokinetics in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|29|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:17:35.074417|2018-05-31 22:17:35.074417
NCT01378208|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2013-11-19|2011-06-20|2011-06-22|Estimate|||||||2013-11-19|2013-11-20|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||How Often Should We Eat|VEK-H-3-2011-023. Fasting and Meal Frequency Project|Completed||N/A|10|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 22:28:29.087817|2018-05-31 22:28:29.087817
NCT01408875|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-03-06|2011-08-02|2011-08-03|Estimate|||||||2015-03-06|2015-03-09|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|CREMS-HF||Cardiac Rehabilitation and Low Frequency Electrical MyoStimulation in Chronic Heart Failure|Cardiac Rehabilitation and Low Frequency Electrical MyoStimulation in Chronic Heart Failure|Completed||N/A|94|Actual|French Cardiology Society||2|||f||||t||||||||||2018-05-31 22:17:35.57496|2018-05-31 22:17:35.57496
NCT01408862|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2014-09-08||2014-09-19|2011-08-02|2011-08-03|Estimate|2014-09-19|2014-09-23|Estimate||||2014-09-19|2014-09-23|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||Platelets from healthy human subjects who were not taken any medication in the previous 10 days were studied. They were subjects with no characteristics of the Metabolic Syndrome components.|Effects of Incretins on Human Platelet Function|Effects of Incretins on Human Platelet Function|Completed|||20|Actual|National Council of Scientific and Technical Research, Argentina|Albeit at high concentrations presumably well above of the physiological range, the use of native and rapidly degradable forms of these peptides may impose a limitation of this study||1||f||||f||||||||||2018-05-31 22:17:35.678556|2018-05-31 22:17:35.678556
NCT01408849|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2016-07-25|2011-08-02|2011-08-03|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Use of Maytenus Ilicifolia in the Treatment of Dyspepsia|Use of Maytenus Ilicifolia Mart. ex Reiss in the Treatment of Dyspepsia|Terminated||Phase 2|4|Actual|Casa Espirita Terra de Ismael||2||Lack of adherence and huge loss of follow up.|f||||f||||||||||2018-05-31 22:17:35.878976|2018-05-31 22:17:35.878976
NCT01408836|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-02|2011-08-02|2011-08-03|Estimate|||||||2011-08-02|2011-08-03|Estimate|March 1995||1995-03-31|July 2011|2011-07-31|December 2003|Actual|2003-12-31|June 2003|Actual|2003-06-30||Interventional|MEPEX||Plasma Exchange for Renal Vasculitis|Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis|Terminated||Phase 2/Phase 3|150|Actual|Cambridge University Hospitals NHS Foundation Trust||2||Completed|f||||f||||||||||2018-05-31 22:17:35.9525|2018-05-31 22:17:35.9525
NCT01408823|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2013-08-07|2011-08-02|2011-08-03|Estimate|||||||2013-08-07|2013-08-09|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Pharmacokinetics of Aminocaproic Acid in Scoliosis Surgery|Pharmacokinetics of Epsilon-Aminocaproic Acid in Children and Adolescents With Scoliosis Undergoing Posterior Spinal Fusion|Completed|||20|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||||||2018-05-31 22:17:36.049542|2018-05-31 22:17:36.049542
NCT01408810|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-12-17|2011-08-02|2011-08-03|Estimate|||||||2012-12-17|2012-12-18|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|HERICA||Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis|Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients|Completed||Phase 4|21|Actual|Grupo de Estudo da Doença Inflamatória Intestinal||1|||f||||f||||||||||2018-05-31 22:17:36.132263|2018-05-31 22:17:36.132263
NCT01408797|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-19|2011-08-02|2011-08-03|Estimate|||||||2011-08-19|2011-08-22|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|DAWN||Clonal Deletion on Living-Relative Donor Kidney Transplantation|A Prospective, Open-Label, Pilot Study of Clonal Deletion on Living-Relative Donor Kidney Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Fuzhou General Hospital||3|||f||||t||||||||||2018-05-31 22:17:36.224759|2018-05-31 22:17:36.224759
NCT01408784|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-04-30|2011-08-02|2011-08-03|Estimate|||||||2012-04-30|2012-05-01|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||A New Method for Self-assessment of Daily Calorie Intake|"Evaluating the Validity of the Categories Method: a New Method for Self-report Assessment of Daily Calorie Intake"|Unknown status|Recruiting||135|Anticipated|Assuta Hospital Systems|||||f||||t||||||||||2018-05-31 22:17:36.358877|2018-05-31 22:17:36.358877
NCT01408771|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-07|2011-08-02|2011-08-03|Estimate|||||||2011-08-07|2011-08-09|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||"Swallow my Urine Back : Inhibition of Detrusor Overactivity by Swallowing Maneuver"|"Swallow my Urine Back : Inhibition of Detrusor Overactivity by Swallowing Maneuver"|Completed|||20|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-05-31 22:17:36.430254|2018-05-31 22:17:36.430254
NCT01408758|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2017-02-24|2011-08-02|2011-08-03|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2011||2011-01-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|VCRT||Virtual Clinician Research Tool|Creating a Virtual Clinician Research Tool|Completed||N/A|79|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 22:17:36.472589|2018-05-31 22:17:36.472589
NCT01408745|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-04-13|2011-08-02|2011-08-03|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|STEPHIX||Sternal Closure With STERNUMFIX in Patients With High Risk|Multicenter Controlled Study on the Safety and Efficacy of Sternal Closure With STERNUMFIX in Patients With High Risk|Terminated||Phase 4|166|Actual|Aesculap AG||2||terminatedd due to insufficient recruitment|f||||f||||||||||2018-05-31 22:17:36.546418|2018-05-31 22:17:36.546418
NCT01408732|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|2015-12-16||2018-04-30|2011-08-02|2011-08-03|Estimate|2018-03-20|2018-04-20|Actual||||2018-04-30|2018-05-30|Actual|February 2011||2011-02-28|April 2018|2018-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia|Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia|Completed||Phase 1/Phase 2|18|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 22:17:36.741184|2018-05-31 22:17:36.741184
NCT01408719|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2013-08-12||2015-10-07|2011-08-02|2011-08-03|Estimate|2014-01-24|2014-03-11|Estimate||||2015-10-07|2015-11-05|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||It is a cross over trial so the total number of participants is same throughout the study.|Effect of Beta-Glucan on Cholesterol Lowering|Effect of Beta-Glucan Molecular Weight and Viscosity on the Mechanism of Cholesterol Lowering in Humans|Completed||N/A|45|Actual|University of Manitoba||4|||f||||f||||||||||2018-05-31 22:17:36.983169|2018-05-31 22:17:36.983169
NCT01408706|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2016-10-24||2017-06-13|2011-08-01|2011-08-03|Estimate|2017-06-13|2017-06-29|Actual||||2017-06-13|2017-06-29|Actual|August 2011||2011-08-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Prostate Immobilization Device Study|The Prostate Immobilization Device Study|Completed||N/A|60|Actual|Wheaton Franciscan Healthcare||2|||f||||f||||||||No||2018-05-31 22:17:37.903573|2018-05-31 22:17:37.903573
NCT01361880|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-06-30|2011-05-26|2011-05-27|Estimate|||||||2017-06-30|2017-07-05|Actual|June 2011||2011-06-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SIDS||Reduce African-American Infant Mortality|Randomized Messaging Trial to Reduce African-American Infant Mortality|Completed||N/A|1200|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 22:34:43.556129|2018-05-31 22:34:43.556129
NCT01408693|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2017-10-23|2011-08-02|2011-08-03|Estimate|||||||2017-10-23|2017-10-25|Actual|August 2011||2011-08-31|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|MIS-CLAS||Minimal Invasive Anterior Approach Versus Trans-gluteal Approach for Hemi-arthroplasty in Femoral Neck Fractures|Minimal Invasive Anterior Approach Versus Trans-gluteal Approach for Hemi-arthroplasty in Femoral Neck Fractures - A Prospective Randomized Trial|Completed||Phase 4|190|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||Undecided||2018-05-31 22:17:38.379374|2018-05-31 22:17:38.379374
NCT01408680|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-12-02|2011-08-01|2011-08-03|Estimate|||||||2014-12-02|2014-12-04|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||CoQ10 Biomarker Trial|Assessing the Effect of the Dietary Supplement Coenzyme Q10 on Biomarkers of Oxidative Stress, Systemic Inflammation, and Endothelial Function in Hemodialysis Patients|Completed||N/A|66|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 22:17:38.470849|2018-05-31 22:17:38.470849
NCT01408667|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2012-07-06|2011-08-02|2011-08-03|Estimate|||||||2012-07-06|2012-07-10|Estimate|November 2011||2011-11-30|July 2012|2012-07-31||||March 2012|Actual|2012-03-31||Interventional|||Hyperinsulinemic Euglycemic Clamp Protocol|A Phase 2A, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Efficacy of TRC150094 in Increasing Insulin Sensitivity in Male Patients With Increased Cardiometabolic Risk|Completed||Phase 1/Phase 2|40|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 22:17:38.561702|2018-05-31 22:17:38.561702
NCT01408654|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-04-20|2011-08-02|2011-08-03|Estimate|||||||2016-04-20|2016-04-22|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|TSC||Social Connections and Healthy Aging (The Senior Connection)|Social Connections and Healthy Aging (The Senior Connection)|Completed||Phase 2|368|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 22:17:38.633536|2018-05-31 22:17:38.633536
NCT01408641|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2018-02-21||2018-04-24|2011-08-02|2011-08-03|Estimate|2018-04-24|2018-05-24|Actual||||2018-04-24|2018-05-24|Actual|September 2012||2012-09-30|April 2018|2018-04-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Topiramate for Alcohol Use in Posttraumatic Stress Disorder|A 14-week Randomized, Placebo-controlled Study of Topiramate for Alcohol Use Disorders in Veterans With Posttraumatic Stress Disorder|Terminated||N/A|4|Actual|University of Maryland||2||Principal Investigator was deployed overseas|f||||t||||||||||2018-05-31 22:17:38.732373|2018-05-31 22:17:38.732373
NCT01408628|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2015-04-28||2015-07-01|2011-08-01|2011-08-03|Estimate|2015-04-28|2015-05-18|Estimate||||2015-07-01|2015-07-24|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|I-KAN||The I-KAN Study: Internet Insulin Education for Kansans|The I-KAN Study: Internet Initiation of Insulin for Type 2 Diabetes in Kansas|Completed||N/A|51|Actual|University of Kansas Medical Center|This was a pilot study designed to compare rates of hypoglycemia among Internet managed type 2 patients to those from large clinical trials. It was not a placebo controlled trial.|1|||f||||t||||||||||2018-05-31 22:17:39.00104|2018-05-31 22:17:39.00104
NCT01408615|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-05-08|2011-08-02|2011-08-03|Estimate|||||||2017-05-08|2017-05-09|Actual|September 20, 2011|Actual|2011-09-20|May 2017|2017-05-31|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Observational|||A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)|Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of ELONVA in Usual Practice|Completed|||472|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:17:39.157506|2018-05-31 22:17:39.157506
NCT01408602|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2014-05-09|2011-08-02|2011-08-03|Estimate|||||||2014-05-09|2014-05-12|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients|A 24-week, Phase 2, Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 2 Doses of MRC375 in Patients With Moderate to Severe Rheumatoid Arthritis|Unknown status|Active, not recruiting|Phase 2|300|Anticipated|Molecular Research Center, Inc.||3|||f||||f||||||||||2018-05-31 22:17:39.210225|2018-05-31 22:17:39.210225
NCT01408589|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-08-02|2011-08-02|2011-08-03|Estimate|||||||2011-08-02|2011-08-03|Estimate|June 2005||2005-06-30|August 2011|2011-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|ATX_COMT||A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol|A Pharmacotherapy Study: A Dose Response Effect of Atomoxetine on Alcohol-elicited Craving and Sensitivity to the Acute Effects of Alcohol|Terminated||Phase 1|86|Actual|University of Colorado, Boulder||4|||f||||t||||||||||2018-05-31 22:17:39.28954|2018-05-31 22:17:39.28954
NCT01408576|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-03-14|2011-08-01|2011-08-03|Estimate|||||||2016-03-14|2016-03-15|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|EMBODY4||Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus|A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects|Completed||Phase 3|1253|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 22:17:39.369095|2018-05-31 22:17:39.369095
NCT01408563|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-09-28|2011-08-02|2011-08-03|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2011||2011-12-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Reduced Intensity Double Umbilical Cord Blood Transplantation|A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation|Completed||Phase 2|32|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:17:39.79205|2018-05-31 22:17:39.79205
NCT01408550|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2013-10-15|2011-08-02|2011-08-03|Estimate|||||||2013-10-15|2013-10-16|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III)|Completed||Phase 3|56|Anticipated|Nihon Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 22:17:39.877617|2018-05-31 22:17:39.877617
NCT01408537|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2013-04-23||2014-11-14|2011-08-02|2011-08-03|Estimate|2014-11-14|2014-11-18|Estimate||||2014-11-14|2014-11-18|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|JE0153||Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children|Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children|Completed||Phase 3|152|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 22:17:39.953763|2018-05-31 22:17:39.953763
NCT01407796|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-04-17|2011-07-29|2011-08-02|Estimate|||||||2014-04-17|2014-04-21|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||PET Imaging of Endotoxin-induced iNOS Activation|PET Imaging of Endotoxin-induced iNOS Activation in Healthy Volunteers|Completed||Phase 1|19|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 22:17:46.307479|2018-05-31 22:17:46.307479
NCT01408524|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2014-03-31|2011-08-02|2011-08-03|Estimate|||||||2014-03-31|2014-04-01|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Interventional|||Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem|A Comparative Study in the Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol (Avexa) and Diltiazem|Completed||Phase 1/Phase 2|184|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 22:17:40.400203|2018-05-31 22:17:40.400203
NCT01408511|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-03-19|2011-08-02|2011-08-03|Estimate|||||||2015-03-19|2015-03-20|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||HPA Axis Study in Adults|A Multicenter, Open Label Study to Evaluate the Adrenal Suppression Potential of Mapracorat 0.1% Ointment in Adults With Atopic Dermatitis|Completed||Phase 2|23|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:17:40.47091|2018-05-31 22:17:40.47091
NCT01408498|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2012-10-12|2011-08-02|2011-08-03|Estimate|||||||2012-10-12|2012-10-16|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance|Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance|Completed||N/A|120|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 22:17:40.543731|2018-05-31 22:17:40.543731
NCT01408485|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|2014-01-22||2017-04-21|2011-08-01|2011-08-03|Estimate|2014-05-23|2014-06-23|Estimate||||2017-04-21|2017-05-30|Actual|November 2011||2011-11-30|May 2014|2014-05-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|FLEXION-AFL||Therapy™ Cool Flex™ Irrigated Ablation System for Typical Atrial Flutter|Clinical Evaluation of Therapy™ Cool Flex™ Irrigated Ablation System for the Treatment of Typical Atrial Flutter|Completed||N/A|200|Actual|St. Jude Medical||1|||f||||t||||||||No||2018-05-31 22:17:40.64881|2018-05-31 22:17:40.64881
NCT01408472|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2016-08-01|2011-08-02|2011-08-03|Estimate|||||||2016-08-01|2016-08-02|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|||NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement|CNTF Cell Implants For Glaucoma: A Phase I Study|Completed||Phase 1|11|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 22:17:40.897684|2018-05-31 22:17:40.897684
NCT01408459|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-08-02|2011-08-02|2011-08-03|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|DAPH||Adherence Dynamics for Whole Food Interventions in African-American Men|Adherence Dynamics for Whole Food Interventions in African-American Men|Completed||N/A|36|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 22:17:40.983307|2018-05-31 22:17:40.983307
NCT01408446|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-10-27|2011-08-02|2011-08-03|Estimate|||||||2013-10-27|2013-10-29|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|ESMAB||Effects and Safety of Menthol on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients|A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of DANSHU Capsule(Menthol) and Placebo on Blood Pressure and Metabolic Parameters in Prehypertensive and Mild Hypertensive Patients|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 22:17:41.090081|2018-05-31 22:17:41.090081
NCT01408433|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-03-25|2011-08-02|2011-08-03|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer|Single Embryo Transfer of a Euploid Embryo Versus Double Embryo Transfer: A Randomized Controlled Trial|Completed||N/A|175|Actual|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 22:17:41.17363|2018-05-31 22:17:41.17363
NCT01408420|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-03-26|2011-08-02|2011-08-03|Estimate|||||||2014-03-26|2014-03-27|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|PPC||Perfusion - Pressure - Creatinine Trial|Impact of Perfusion Pressure During Extracorporeal Circulation on Postoperative Kidney Function|Completed||N/A|100|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 22:17:41.251774|2018-05-31 22:17:41.251774
NCT01408407|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-05-22|2011-08-02|2011-08-03|Estimate|||||||2015-05-22|2015-05-25|Estimate|December 2011||2011-12-31|May 2015|2015-05-31||||May 2014|Actual|2014-05-31||Interventional|||Alkagin Paste in the Prevention of Radiation Dermatitis|A Phase II Study Designed to Evaluate the Value of Alkagin Paste in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy|Terminated||Phase 2|2|Actual|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||f||||||||||2018-05-31 22:17:41.319549|2018-05-31 22:17:41.319549
NCT01408394|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-08-01|2011-08-02|2011-08-03|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam|A Phase 1, Single Center, Randomized (2-Sequence), Single Blind, 3-Period Study Comparing the Safety, Tolerability, and Pharmacokinetics of Ecopipam Controlled Release Capsules With Ecopipam HCl Immediate Release Tablets in Male Adult Volunteers|Completed||Phase 1|16|Actual|Psyadon Pharma||3|||f||||f||||||||||2018-05-31 22:17:41.381044|2018-05-31 22:17:41.381044
NCT01408381|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-03-15|2011-08-02|2011-08-03|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).|Multicenter Phase II, Randomized Open Clinical Trial on the Therapeutic Use of Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Chronic Ischemia of Lower Limbs (CLI).|Completed||Phase 2|38|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||4|||f||||t||||||||||2018-05-31 22:17:41.466256|2018-05-31 22:17:41.466256
NCT01408368|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2011-08-02|2011-08-02|2011-08-03|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2000||2000-01-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Subtotal Versus Total Thyroidectomy for Graves' Disease|Five-year Follow up of a Randomized Clinical Trial of Bilateral Subtotal Thyroidectomy Versus Total Thyroidectomy for Graves' Disease.|Completed||N/A|200|Actual|Jagiellonian University||2|||f||||t||||||||||2018-05-31 22:17:41.551682|2018-05-31 22:17:41.551682
NCT01408355|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-09-08|2011-08-01|2011-08-03|Estimate|||||||2011-09-08|2011-09-09|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose.|An Exploratory, Open Label, Fixed Sequence Study To Investigate The Pharmacokinetics Of Single Intravenous And Oral Micro Doses Of PF-06273588 In Healthy Male Subjects|Completed||Phase 1|5|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:17:41.637224|2018-05-31 22:17:41.637224
NCT01408329|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2013-05-17||2015-08-19|2011-08-02|2011-08-03|Estimate|2015-08-19|2015-09-22|Estimate||||2015-08-19|2015-09-22|Estimate|January 2007||2007-01-31|August 2015|2015-08-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|CVAC||Effects of Cyclic Variations in Altitude Conditioning (CVAC) on Wellness and Activity Measures|Effects of Cyclic Variations in Altitude Conditioning (CVAC) on Wellness and Activity Measures|Completed||N/A|28|Actual|Palo Alto Veterans Institute for Research|Small Sample size|2|||f||||f||||||||||2018-05-31 22:17:41.789741|2018-05-31 22:17:41.789741
NCT01408316|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2018-05-14|2011-08-01|2011-08-03|Estimate|||||||2018-05-14|2018-05-17|Actual|July 2011||2011-07-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers|A Phase 1 Two-way Cross-over Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules Administered in the Fasting State, and of Crystalline PX-866 Tablets Administered Fed and Fasting, in Healthy Subjects|Completed||Phase 1|39|Actual|Seattle Genetics, Inc.||2|||f||||f||||||||||2018-05-31 22:17:41.993623|2018-05-31 22:17:41.993623
NCT01408303|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|2013-06-21||2014-11-27|2011-08-02|2011-08-03|Estimate|2014-11-27|2014-12-05|Estimate||||2014-11-27|2014-12-05|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ESPRIT|The Baseline Analysis Population comprised the Safety Population defined as subjects who received at least 1 dose of investigational product.|[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL|A 6-Week, Randomized, Double-Blind, Placebo(Olive Oil)-Controlled Study to Assess the Efficacy and Safety of Add-On Epanova® to Statin Therapy in Subjects With Persistent Hypertriglyceridemia and High Risk for Cardiovascular Disease|Completed||Phase 3|646|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:17:42.074703|2018-05-31 22:17:42.074703
NCT01408290|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-05-18|2011-08-01|2011-08-03|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2011||2011-09-30|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People|A Randomized, Double Blind, Multicentre Study to Evaluate Safety and Immunogenicity of Four Fluval AB-Like Influenza Vaccines With 3.5 μgHA, 6 μgHA, 9 μgHA Or 15 μgHA Of A/H1N1, A/H3N2 and B Influenza Antigens in Adult and Elderly Subjects|Completed||N/A|256|Actual|Fluart Innovative Vaccine Ltd, Hungary||4|||f||||f||||||||||2018-05-31 22:17:42.607748|2018-05-31 22:17:42.607748
NCT01408277|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|2014-04-02||2014-06-30|2011-08-02|2011-08-03|Estimate|2014-04-02|2014-05-05|Estimate||||2014-06-30|2014-07-24|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional||20 subjects from each group was a priori considered to be a number sufficient to detect an effect size (Cohen’s d) of 0.80, regarded as a large effect, with α = 0.05 and 1-β = 80%.|Using Santyl on Diabetic Foot Ulcers|A Comparison of Collagenase Santyl® Ointment Used Adjunctively to Sharp Surgical Debridement and Sharp Surgical Debridement in the Care of Diabetic Foot Wounds|Completed||Phase 4|55|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 22:17:42.756463|2018-05-31 22:17:42.756463
NCT01408264|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-07-29|2011-08-02|2011-08-03|Estimate|||||||2013-07-29|2013-07-31|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||A Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation|A Prospective Randomised Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation|Completed||Phase 4|184|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:17:43.096862|2018-05-31 22:17:43.096862
NCT01408251|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-08-01|2011-08-01|2011-08-03|Estimate|||||||2011-08-01|2011-08-03|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate Measurements in the Intensive Care Unit|Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate in the Intensive Care Unit|Completed|||40|Actual|Olive View-UCLA Education & Research Institute|||||f||||t||||||||||2018-05-31 22:17:43.168068|2018-05-31 22:17:43.168068
NCT01408238|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-08-08|2011-08-02|2011-08-03|Estimate|||||||2012-08-08|2012-08-09|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Biological Standardization of Secale Cereale Allergen Extract|Biological Standardization of Secale Cereale Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units|Completed||Phase 2|35|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 22:17:43.216676|2018-05-31 22:17:43.216676
NCT01408225|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2018-02-27|2011-08-02|2011-08-03|Estimate|||||||2018-02-27|2018-03-01|Actual|March 17, 2011|Actual|2011-03-17|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31|10 Years|Observational [Patient Registry]|B-SCR-MM||Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource|Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis|Recruiting|||5000|Anticipated|Ohio State University Comprehensive Cancer Center|||||f||||f|f|f||||||||2018-05-31 22:17:43.286876|2018-05-31 22:17:43.286876
NCT01408212|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-09-01|2011-08-01|2011-08-03|Estimate|||||||2015-09-01|2015-09-02|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients||Terminated||N/A|11|Actual|Korean Medicine Hospital of Pusan National University||1||low recruiting|f||||||||||||||2018-05-31 22:17:43.359135|2018-05-31 22:17:43.359135
NCT01408199|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-08-02|2011-08-02|2011-08-03|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|ORDI-02||Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus|Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus|Completed||Phase 4|15|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||t||||||||||2018-05-31 22:17:43.424204|2018-05-31 22:17:43.424204
NCT01408186|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-04-20|2011-08-02|2011-08-03|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2011||2011-01-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|||ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA|Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)|Completed||Phase 3|264|Actual|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-05-31 22:17:43.493858|2018-05-31 22:17:43.493858
NCT01408173|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2013-10-29|2011-08-01|2011-08-03|Estimate|||||||2013-10-29|2013-10-30|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Clinical Study of Caffeine for Apnea of Prematurity|A Phase III Clinical Study of NPC-11 in the Treatment of Apnea of Prematurity. - Investigation of Safety, Efficacy and Pharmacokinetics of Caffeine Citrate -|Completed||Phase 3|24|Actual|Nobelpharma||1|||f||||f||||||||||2018-05-31 22:17:43.581933|2018-05-31 22:17:43.581933
NCT01408160|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-01-14|2011-08-01|2011-08-03|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 2013||2013-04-30|January 2016|2016-01-31||||June 2016|Anticipated|2016-06-30||Interventional|||Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia|A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-Dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 1|18|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 22:17:43.67232|2018-05-31 22:17:43.67232
NCT01408147|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2017-05-26|2011-08-02|2011-08-03|Estimate|||||||2017-05-26|2017-05-30|Actual|July 2011||2011-07-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Prevention of Postpartum Weight Retention in Low Income WIC Women|Prevention of Postpartum Weight Retention in Low Income WIC Women|Completed||N/A|371|Actual|California Polytechnic State University-San Luis Obispo||2|||f||||t||||||||||2018-05-31 22:17:43.77774|2018-05-31 22:17:43.77774
NCT01408134|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-03-28|2011-08-02|2011-08-03|Estimate|||||||2013-03-28|2013-03-29|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Interventional|VIVA 1||Viability Imaging in Volumetric Angiography (VIVA 1)|Viability Imaging in Volumetric Angiography (VIVA 1): A Single Center Trial of the Detection of Delayed Hyperenhancement on CT Angiography|Terminated||N/A|10|Actual|Medstar Health Research Institute||||PI/Project director no longer at facility|f||||f||||||||||2018-05-31 22:17:43.84197|2018-05-31 22:17:43.84197
NCT01408121|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2014-08-08|2011-08-02|2011-08-03|Estimate|||||||2014-08-08|2014-08-11|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|AA Genetic||African-American Pharmacogenetics|African-American Pharmacogenetics|Unknown status|Active, not recruiting||200|Anticipated|Medstar Health Research Institute|||4||f||||f||||||||||2018-05-31 22:17:43.901282|2018-05-31 22:17:43.901282
NCT01408108|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-10-13|2011-08-02|2011-08-03|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|July 2014|Actual|2014-07-31||Interventional|LARGE||Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias|Prospective Randomized Phase III Study of Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Odessa National Medical University||2|||f||||f||||||||||2018-05-31 22:17:43.967873|2018-05-31 22:17:43.967873
NCT01408095|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-08-23|2011-08-01|2011-08-03|Estimate|||||||2011-08-23|2011-08-25|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||A Study in Patients With Type 2 Diabetes|A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2608204 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus|Withdrawn||Phase 2|240|Anticipated|Eli Lilly and Company||2||Trial terminated no patients were screened or enrolled|f||||f||||||||||2018-05-31 22:17:44.073121|2018-05-31 22:17:44.073121
NCT01408082|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01||2014-06-19|2015-04-16|2011-08-02|2011-08-03|Estimate||||2015-04-16|2015-05-06|Estimate|2015-04-16|2015-05-06|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|DOUBle||Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis|A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 Compared to AzaSite Alone, Dexamethasone Alone, and Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis|Completed||Phase 3|917|Actual|InSite Vision||4|||f||||||||||||||2018-05-31 22:17:44.207562|2018-05-31 22:17:44.207562
NCT01408069|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-03-25|2011-08-02|2011-08-03|Estimate|||||||2013-03-25|2013-03-26|Estimate|March 2014||2014-03-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia|Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane® Versus Parcel ® For Treatment Of Tensional Cephaleia|Suspended||Phase 3|108|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2018-05-31 22:17:44.464903|2018-05-31 22:17:44.464903
NCT01408056|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2014-01-16|2011-08-01|2011-08-03|Estimate|||||||2014-01-16|2014-01-17|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|TOUCH||Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)|The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas|Withdrawn||Phase 2|0|Actual|Children's Hospital of Philadelphia||2||Difficulty with recruitment|f||||f||||||||||2018-05-31 22:17:44.536176|2018-05-31 22:17:44.536176
NCT01408043|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-12-06|2011-08-01|2011-08-03|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2011||2011-10-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma|A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma|Terminated||N/A|25|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||t||||||||||2018-05-31 22:17:44.621996|2018-05-31 22:17:44.621996
NCT01408030|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2014-11-05|2011-08-01|2011-08-02|Estimate|||||||2014-11-05|2014-11-06|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|NOSE||North American Study of Epistaxis in HHT|North American Study of Epistaxis in HHT (NOSE)|Completed||Phase 2|121|Actual|Augusta University||4|||f||||t||||||||||2018-05-31 22:17:44.715271|2018-05-31 22:17:44.715271
NCT01408017|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2013-01-09|2011-08-01|2011-08-02|Estimate|||||||2013-01-09|2013-01-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:17:44.798429|2018-05-31 22:17:44.798429
NCT01408004|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-07-15|2011-08-01|2011-08-02|Estimate|||||||2014-07-15|2014-07-16|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ROPETAR||Rotating Pazopanib and Everolimus to Avoid Resistance|A Randomized Phase II Study to Explore the Efficacy and Feasibility of Upfront Bi-monthly Rotations Between Everolimus and Pazopanib in Patients With Advanced or Metastatic Clear Cell Renal Cancer|Completed||Phase 2|101|Actual|Netherlands Working Group on Immunotherapy of Oncology||2|||f||||t||||||||||2018-05-31 22:17:44.83898|2018-05-31 22:17:44.83898
NCT01407991|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-11-09|2011-08-01|2011-08-02|Estimate|||||||2015-11-09|2015-11-10|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Nasogastric/Oral Gastric Tube Placement in Infants: Comparing 2 Measurement Methods|Placement of NG or OG Tube in Infants by Length Versus Traditional Measuring Methods|Terminated||Phase 2|9|Actual|Children's Hospital of Philadelphia||2||"Study terminated due to change in clinical practice affecting recruitment. For majority of~   patients, NJ tubes are now used instead of NG tubes."|f||||f||||||||||2018-05-31 22:17:45.026609|2018-05-31 22:17:45.026609
NCT01407978|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-05-18|2011-08-01|2011-08-02|Estimate|||||||2012-05-18|2012-05-21|Estimate|August 2009||2009-08-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents|Tolerability and Immunogenicity Study of FLUVAL P H1N1 Monovalent Influenza Vaccine of Omninvest in Children and Adolescents|Completed||N/A|58|Actual|Fluart Innovative Vaccine Ltd, Hungary||3|||f||||t||||||||||2018-05-31 22:17:45.091131|2018-05-31 22:17:45.091131
NCT01407965|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-10-14|2011-08-01|2011-08-02|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pharmacokinetics of Carbapenem Antibiotics in Obese Patients.|Offene, Monozentrische, Nicht Kontrollierte Und Nicht Randomisierte Phase IV-Studie Zur Bestimmung Der Pharmakokinetik Von Carbapenemen in adipösen Patienten.|Completed||Phase 4|13|Actual|University of Ulm||2|||f||||t||||||||||2018-05-31 22:17:45.173918|2018-05-31 22:17:45.173918
NCT01407952|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2018-02-19|2011-08-01|2011-08-02|Estimate|||||||2018-02-19|2018-02-20|Estimate|April 2012||2012-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|HEAT||Hydrogel Endovascular Aneurysm Treatment Trial|New Generation Hydrogel Endovascular Aneurysm Treatment Trial|Active, not recruiting||N/A|600|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 22:17:45.276732|2018-05-31 22:17:45.276732
NCT01407939|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-03-14|2011-08-01|2011-08-02|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|BL||Efficacy of Bitter Blockers on Taste Perception in Children and Adults|Efficacy of Bitter Taste Blockers on Flavor Acceptance in Pediatric Populations|Completed|||215|Actual|Monell Chemical Senses Center|||1||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 22:17:45.474328|2018-05-31 22:17:45.474328
NCT01407926|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2011-08-01|2011-08-01|2011-08-02|Estimate|||||||2011-08-01|2011-08-02|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Nurse-Led Interprofessional Mental Health Promotion Intervention for Older Home Care Clients|The Effects of a Nurse-Led Interprofessional Mental Health Promotion Intervention Among Older Home Care Clients|Unknown status|Active, not recruiting||250|Anticipated|McMaster University|||1||f||||f||||||||||2018-05-31 22:17:45.536966|2018-05-31 22:17:45.536966
NCT01407913|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2015-05-26|2011-08-01|2011-08-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|FIA1||Caudal Epidural Steroid Injections for Low Back Pain/Sciatic Lumbar Pain|Efficacy Study of Caudal Epidural Steroid Injections in Patients With Low Back Pain/Radiculopathy|Completed||Phase 4|42|Actual|University of Ioannina|||||f||||f||||||||||2018-05-31 22:17:45.644177|2018-05-31 22:17:45.644177
NCT01407900|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2014-06-16|2011-08-01|2011-08-02|Estimate|||||||2014-06-16|2014-06-17|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Chimeric Natriuretic Peptide Versus Placebo in Stable Heart Failure and Moderate Renal Dysfunction|A Human Physiologic Study to Evaluate the Renal and Neurohumoral Effects of Dual NPR-A and NPR-B Activation With a Novel Chimeric Natriuretic Peptide (CD-NP)in Subjects With Stable Chronic Heart Failure and Moderate Renal Dysfunction|Withdrawn||Phase 1|0|Actual|Mayo Clinic||2||New technique for administration of drug, this is the old technique of administration.|f||||f||||||||||2018-05-31 22:17:45.706206|2018-05-31 22:17:45.706206
NCT01407887|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-12-04|2011-08-01|2011-08-02|Estimate|||||||2012-12-04|2012-12-05|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children|Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children|Completed||Phase 2|180|Actual|Heidelberg University||2|||f||||t||||||||||2018-05-31 22:17:45.778988|2018-05-31 22:17:45.778988
NCT01407874|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01||2013-10-04|2013-10-28|2011-08-01|2011-08-02|Estimate||||2013-10-04|2013-10-28|Estimate|2013-10-28|2013-11-20|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency|A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency|Completed||Phase 2|20|Actual|BioCryst Pharmaceuticals||3|||f||||t||||||||||2018-05-31 22:17:45.850573|2018-05-31 22:17:45.850573
NCT01407861|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2014-12-02|2011-08-01|2011-08-02|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ARMIG||Aerobic Endurance Training vs. Relaxation Training in Patients With Migraine|Aerobic Endurance Training Versus Relaxation Training in Migraine Prophylaxis|Completed||N/A|56|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 22:17:45.93987|2018-05-31 22:17:45.93987
NCT01407848|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-09-22|2011-08-01|2011-08-02|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea|Trial on Treatment With Inhaled Furosemide of Preterm and Term Neonates With Transient Tachypnoea|Completed||Phase 2|20|Actual|University of Cologne||2|||f||||t||||||||||2018-05-31 22:17:46.001707|2018-05-31 22:17:46.001707
NCT01407835|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2012-08-08|2011-08-01|2011-08-02|Estimate|||||||2012-08-08|2012-08-09|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Biological Standardization of Dactylis Glomerata Allergen Extract|Biological Standardization of Dactylis Glomerata Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units|Completed||Phase 2|31|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 22:17:46.084041|2018-05-31 22:17:46.084041
NCT01407822|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-02-28|2011-08-01|2011-08-02|Estimate|||||||2017-02-28|2017-03-03|Actual|December 5, 2011|Actual|2011-12-05|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|June 2017|Anticipated|2017-06-30||Interventional|EMERGING||Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer|A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING)|Recruiting||Phase 2/Phase 3|90|Anticipated|Guangdong Association of Clinical Trials||2|||f||||t||||||||Undecided||2018-05-31 22:17:46.148674|2018-05-31 22:17:46.148674
NCT01407809|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2018-01-12|2011-07-29|2011-08-02|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2012||2012-01-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|VSSIIH||Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy|Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy|Recruiting||Phase 1|20|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-05-31 22:17:46.245878|2018-05-31 22:17:46.245878
NCT01407783|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2018-05-04|2011-07-29|2011-08-02|Estimate|||||||2018-05-04|2018-05-11|Actual|August 2008||2008-08-31|May 2018|2018-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|NUMOMS||Systems of Care for New Moms: Integrating Depression Treatment|Systems of Care for New Moms: Integrating Depression Treatment|Completed||N/A|29|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 22:17:46.374407|2018-05-31 22:17:46.374407
NCT01407770|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-30|||2017-05-25|2011-07-30|2011-08-02|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2011||2011-09-30|December 2013|2013-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer|Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity|Completed|||1000|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||Samples With DNA|"~     blood and urine samples~   "|||2018-05-31 22:17:46.436876|2018-05-31 22:17:46.436876
NCT01407757|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-30|||2016-05-17|2011-07-30|2011-08-02|Estimate|||||||2016-05-17|2016-05-19|Estimate|July 2011||2011-07-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531|Pharmacogenetics of Gemtuzumab Ozogamicin (GO) Therapy in Acute Myeloid Leukemia|Completed|||1000|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:17:46.519255|2018-05-31 22:17:46.519255
NCT01407744|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-30|||2016-05-16|2011-07-30|2011-08-02|Estimate|||||||2016-05-16|2016-05-18|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial|Examination of the Multiple Genetic and Molecular Targets as Therapeutic Options for Patients With Ependymoma Treated by the Phase II Children's Oncology Group Study ACNS0121|Completed|||80|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Archived tumor tissue~   "|||2018-05-31 22:17:46.574027|2018-05-31 22:17:46.574027
NCT01407731|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-30|||2016-05-13|2011-07-30|2011-08-02|Estimate|||||||2016-05-13|2016-05-17|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Protein Expression in Human Neuroblastoma Tumor Samples|Analysis of Intersectin Expression in Primary Human Neuroblastomas|Completed|||20|Actual|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:17:46.632667|2018-05-31 22:17:46.632667
NCT01407718|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2018-02-25|2011-08-01|2011-08-02|Estimate|||||||2018-02-25|2018-02-27|Actual|June 2010||2010-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Parapatellar Approach to Intramedullary Tibial Nailing|The Parapatellar Approach to Intramedullary Tibial Nailing: Is There a Difference in Anterior Knee Pain When Compared to a Traditional Flexed Approach?|Active, not recruiting|||60|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 22:17:46.682614|2018-05-31 22:17:46.682614
NCT01407705|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2014-05-19|2011-08-01|2011-08-02|Estimate|||||||2014-05-19|2014-05-21|Estimate|May 2007||2007-05-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||High-Resolution Diffusion Tensor Imaging (DTI) of the Cervical Spinal Cord in the Setting of Spinal Cord Injury (SCI)|High-Resolution Diffusion Tensor Imaging (DTI) of the Cervical Spinal Cord in the Setting of Spinal Cord Injury (SCI)|Completed|||31|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 22:17:46.728175|2018-05-31 22:17:46.728175
NCT01407692|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-12-01|2011-07-29|2011-08-02|Estimate|||||||2017-12-01|2017-12-05|Actual|March 2011||2011-03-31|December 2017|2017-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|FL-84||Menstrual Cycle Hormones and Eating Behavior|Effect of Menstrual Cycle Hormone Changes on Eating Behavior and Nutrient Metabolism|Completed|||24|Actual|USDA, Western Human Nutrition Research Center|||||f||||f||||||Samples Without DNA|"~     Serum, plasma and urine samples may be retained for future testing.~   "|||2018-05-31 22:17:46.785923|2018-05-31 22:17:46.785923
NCT01407679|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2016-05-30|2011-08-01|2011-08-02|Estimate|||||||2016-05-30|2016-06-01|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|AliCLE||Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus|Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study|Terminated||Phase 2|7|Actual|University Hospital Muenster||1|||f||||f||||||||||2018-05-31 22:17:46.841256|2018-05-31 22:17:46.841256
NCT01407666|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-12-02|2011-07-29|2011-08-02|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Comparison Between Epidural and Bilateral Paravertebral Blocks in Liver Resection|Prospective Randomized Comparative Study Between Epidural and Bilateral Paravertebral Blocks for Perioperative Pain Management in Patients Undergoing Open Liver Resection|Completed||N/A|100|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:17:47.028428|2018-05-31 22:17:47.028428
NCT01407653|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2016-09-28|2011-08-01|2011-08-02|Estimate|||||||2016-09-28|2016-09-29|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|REVLOC||Analgesic Effect of a Prototype Device of Virtual Reality in a Population of Patients With Chronic Low Back Pain|Evaluation of the Analgesic Effect of a Prototype Device of Virtual Reality in a Population of Patients With Chronic Low Back Pain. A Randomized Controlled Trial Using a Modified ZELEN Method|Completed||N/A|122|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:17:47.093518|2018-05-31 22:17:47.093518
NCT01407640|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2018-03-16|2011-08-01|2011-08-02|Estimate|||||||2018-03-16|2018-03-19|Actual|February 6, 2012|Actual|2012-02-06|March 2018|2018-03-31|July 27, 2016|Actual|2016-07-27|July 27, 2016|Actual|2016-07-27||Interventional|Allerdiab||Diagnosis and Physiopathology of Insulin Allergy|Diagnosis and Physiopathology of Insulin Allergy (IA)|Completed||N/A|55|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:17:47.172605|2018-05-31 22:17:47.172605
NCT01407627|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2018-05-01|2011-08-01|2011-08-02|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2011||2011-07-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans|Evaluation of Fructose Ingestion and the Renin Angiotensin System in Healthy Humans|Recruiting||N/A|30|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 22:17:47.247374|2018-05-31 22:17:47.247374
NCT01407614|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-08-01|2011-08-01|2011-08-02|Estimate|||||||2011-08-01|2011-08-02|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||The Tilburg Vasospasm Study|Prevention of Secondary Ischemia After Aneurysmal Subarachnoid Hemorrhage With Cerebrospinal Fluid Drainage. A Randomized Controlled Trial|Terminated||Phase 2/Phase 3|20|Actual|Elisabeth-TweeSteden Ziekenhuis||2||patient enrollment too slow|f||||t||||||||||2018-05-31 22:17:47.314574|2018-05-31 22:17:47.314574
NCT00889551|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate||||April 2009|2009-04-30||||||||Observational|||Pregnancy and Growth of Adolescent Mothers and Their Child|Pregnancy and Growth of Adolescent Mothers and Their Child|Unknown status|Active, not recruiting||||University of Brasilia|||||f||||||||||||||2018-06-01 01:02:01.376668|2018-06-01 01:02:01.376668
NCT01407601|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-08-01|2011-08-01|2011-08-02|Estimate|||||||2011-08-01|2011-08-02|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|July 2009|Actual|2009-07-31|May 2008|Actual|2008-05-31||Interventional|||Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients|Food Supplementation With Vitamin K2 to Activate MGP as an Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients|Completed||Phase 3|53|Actual|RWTH Aachen University||3|||f||||f||||||||||2018-05-31 22:17:47.379599|2018-05-31 22:17:47.379599
NCT01407588|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2017-03-15|2011-08-01|2011-08-02|Estimate|||||||2017-03-15|2017-03-16|Actual|August 2011|Actual|2011-08-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Manual Compared to Magnetic Navigation in Ablation for Atrial Fibrillation|Manual Compared to Magnetic Navigation in Ablation for Atrial Fibrillation|Completed||N/A|51|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-05-31 22:17:47.445762|2018-05-31 22:17:47.445762
NCT01407575|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2016-01-05||2018-02-09|2011-08-01|2011-08-02|Estimate|2016-02-18|2016-03-17|Estimate||||2018-02-09|2018-03-09|Actual|September 2011||2011-09-30|February 2018|2018-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|BUP-TRD||Buprenorphine for Treatment Resistant Depression|Buprenorphine For Treatment Resistant Depression|Completed||Phase 3|13|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 22:17:47.589189|2018-05-31 22:17:47.589189
NCT01407562|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-11-15|2011-07-29|2011-08-02|Estimate|||||||2017-11-15|2017-11-17|Actual|August 2011||2011-08-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors|Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|34|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 22:17:47.899338|2018-05-31 22:17:47.899338
NCT01407549|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-06-28|2011-08-01|2011-08-02|Estimate|||||||2015-06-28|2015-06-30|Estimate|November 2012||2012-11-30|June 2012|2012-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Influence of Mindfulness Based Intervention on Pain Perception in Chronic Pain Patients|The Influence of Mindfulness Based Intervention on Pain Perception in Chronic Pain Patients Evaluating Personal Characteristics and Possible Mechanism|Completed||N/A|67|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 22:17:47.981954|2018-05-31 22:17:47.981954
NCT01407536|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-26|||2011-08-01|2011-08-01|2011-08-02|Estimate|||||||2011-08-01|2011-08-02|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Thermal Stimulation on Cortical Excitability and Motor Function in Chronic Stroke Patients||Completed||Phase 1/Phase 2|20|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-05-31 22:17:48.069691|2018-05-31 22:17:48.069691
NCT01407523|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2013-01-30||2013-01-30|2011-08-01|2011-08-02|Estimate|2013-01-30|2013-03-07|Estimate||||2013-01-30|2013-03-07|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures|An Open-label, Multicenter Study to Evaluate the Safety of Adjunctive Treatment With Intravenous Levetiracetam (L059 IV) in Epilepsy Patients Aged ≥ 16 Years With Partial Onset Seizures|Completed||Phase 2|16|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 22:17:48.148342|2018-05-31 22:17:48.148342
NCT01407510|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-02-15|2011-08-01|2011-08-02|Estimate|||||||2015-02-15|2015-02-18|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||HPA Axis Study in Japanese Adults|A Multicenter, Open-label Study to Evaluate the Adrenal Suppression Potential of Mapracorat 0.1% Ointment in Japanese Adults With Atopic Dermatitis|Completed||Phase 2|12|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:17:48.362805|2018-05-31 22:17:48.362805
NCT01407497|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2013-12-03|2011-08-01|2011-08-02|Estimate|||||||2013-12-03|2013-12-04|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine|A Phase I Trial to Assess Safety and Immunogenicity of i.d. DNA Priming and i.m. MVA Boosting in Healthy Volunteers in Mozambique and to Develop Further HIV Vaccine Trial Capacity Building in Mozambique|Completed||Phase 1|25|Actual|Instituto Nacional de Saúde, Mozambique||4|||f||||t||||||||||2018-05-31 22:17:48.431945|2018-05-31 22:17:48.431945
NCT01407484|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-03-16|2011-08-01|2011-08-02|Estimate|||||||2018-03-16|2018-03-19|Actual|March 2, 2011|Actual|2011-03-02|March 2018|2018-03-31|May 14, 2015|Actual|2015-05-14|May 14, 2015|Actual|2015-05-14||Interventional|SIGMA||Male Infertility Related With Post Infection Inflammatory Syndrome|Diagnosis and Treatment of Male Infertility Related to Inflammatory Syndrome: Therapeutic Trial|Completed||N/A|200|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 22:17:48.508736|2018-05-31 22:17:48.508736
NCT01407471|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-07-02|2011-08-01|2011-08-02|Estimate|||||||2015-07-02|2015-07-03|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|SPIREPI||Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy|Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy|Completed||Phase 2|26|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-05-31 22:17:48.58557|2018-05-31 22:17:48.58557
NCT01407458|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-08-01|2011-08-01|2011-08-02|Estimate|||||||2011-08-01|2011-08-02|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||The Impact of a Structured Physical Activity Program on Bone Strength and Psycho-Motor Learning of Young Children||Unknown status|Not yet recruiting|N/A|300|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 22:17:48.666268|2018-05-31 22:17:48.666268
NCT01407445|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-11-09|2011-08-01|2011-08-02|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Tribulus Terrestris on Sexual Function in Post-menopausal Women|Study of the Effects of Tribulus Terrestris on Sexuality in Postmenopausal Women|Completed||Phase 4|60|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||f||||||||||2018-05-31 22:17:48.718927|2018-05-31 22:17:48.718927
NCT01407432|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-06-08|2011-08-01|2011-08-02|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FOLFIV||Impact of Folates in the Care of the Male Infertility|Impact of Folates in the Care of the Male Infertility|Completed||Phase 3|162|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:17:48.788271|2018-05-31 22:17:48.788271
NCT01407419|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2015-06-08|2011-08-01|2011-08-02|Estimate|||||||2015-06-08|2015-06-10|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population|Treating to Target (T2T) for Patients With Rheumatoid Arthritis in a US Population: Outcomes and Feasibility|Completed||N/A|538|Actual|Corrona, LLC.||2|||f||||f||||||||||2018-05-31 22:17:48.867842|2018-05-31 22:17:48.867842
NCT01407406|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-09-12|2011-08-01|2011-08-02|Estimate|||||||2013-09-12|2013-09-16|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers|A Single-Dose, Randomized, Double-Blind, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Adult Healthy Volunteers|Completed||Phase 1|48|Actual|Biogen||6|||f||||f||||||||||2018-05-31 22:17:48.934125|2018-05-31 22:17:48.934125
NCT01407393|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2013-10-07|2011-08-01|2011-08-02|Estimate|||||||2013-10-07|2013-10-08|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects|Completed||Phase 4|124|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 22:17:48.999369|2018-05-31 22:17:48.999369
NCT01407380|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-10-23|2011-08-01|2011-08-02|Estimate|||||||2012-10-23|2012-10-25|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Study of PWT33597 Mesylate in Subjects With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered PWT33597 Mesylate in Subjects With Advanced Malignancies|Completed||Phase 1|22|Actual|Pathway Therapeutics, Inc.|||||f||||f||||||||||2018-05-31 22:17:49.184843|2018-05-31 22:17:49.184843
NCT01407367|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2017-05-01|2011-07-31|2011-08-02|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2011||2011-04-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Safe Kidney Care Cohort Study|Does Under-recognition of Kidney Disease Affect Patient Safety?|Active, not recruiting|||350|Anticipated|University of Maryland|||1||f||||f||||||Samples Without DNA|"~     At each yearly research clinic visit (up to 4), 30 cc (6 teaspoons) of blood will be~     processed and stored for future assays related to kidney function.~      At first research clinic visit, 9 cc urine will be processed and stored for future assays~     related to kidney function.~      At each yearly research clinic visit, 1 swab of both nares, 1 pharyngeal swab and 1 skin swab~     will be obtained, processed and stored with future testing for multiple antibiotic resistant~     (MAR) organisms.~   "|||2018-05-31 22:17:49.248565|2018-05-31 22:17:49.248565
NCT01407354|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2016-04-06||2016-04-06|2011-07-31|2011-08-02|Estimate|2016-04-06|2016-04-08|Estimate||||2016-04-06|2016-04-08|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Comparison of Lokomat and Aquatic Exercise for Individuals With Chronic Incomplete Spinal Cord Injury|Lokomat and Aquatic Therapy in Chronic Motor Incomplete Spinal Cord Injury|Completed||N/A|37|Actual|University of Maryland||2|||f||||t||||||||No||2018-05-31 22:17:49.321726|2018-05-31 22:17:49.321726
NCT01407341|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2014-02-05|2011-07-29|2011-08-02|Estimate|||||||2014-02-05|2014-02-06|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine Cancer|ChronOS Stability Study: For Metastatic Cancer|Terminated||Phase 1|1|Actual|University of Southern California||1||Lack of funding|f||||t||||||||||2018-05-31 22:17:49.525417|2018-05-31 22:17:49.525417
NCT01407328|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-04-28|2011-07-31|2011-08-02|Estimate|||||||2013-04-28|2013-04-30|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||The Effect of the Shoulder Arthroscopic Surgery on Respiratory Mechanics|The Effect of the Shoulder Arthroscopic Surgery on Respiratory Mechanics|Completed|||60|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 22:17:49.601967|2018-05-31 22:17:49.601967
NCT01407315|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-04-19|2011-07-29|2011-08-02|Estimate|||||||2012-04-19|2012-04-20|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Accuracy, Reliability and Safety of GlucoMen®Day, a New Generation Microdialysis Continuous Glucose Monitor|Accuracy, Reliability and Safety of GlucoMen®Day, a New Generation Microdialysis Continuous Glucose Monitor|Completed||Phase 1|20|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 22:17:49.658729|2018-05-31 22:17:49.658729
NCT01407302|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-12-24|2011-07-31|2011-08-02|Estimate|||||||2013-12-24|2013-12-25|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Optimal Head Rotation and External Landmark for Internal Jugular Vein Cannulation After Placement of Proseal Laryngeal Mask Airway|Optimal Head Rotation and External Landmark for Internal Jugular Vein Cannulation After Placement of Proseal Laryngeal Mask Airway|Completed|||100|Actual|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 22:17:49.729222|2018-05-31 22:17:49.729222
NCT01407289|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-02-04|2011-07-29|2011-08-02|Estimate|||||||2013-02-04|2013-02-05|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia|An Open, Single-centre, Controlled Trial to Investigate the Efficacy and Usability of Published Best Practice to Control Glycaemia in Hospitalised Patients With Type 2 Diabetes|Completed||Phase 4|74|Actual|Medical University of Graz||2|||f||||||||||||||2018-05-31 22:17:49.793138|2018-05-31 22:17:49.793138
NCT01407276|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2015-09-29||2017-06-05|2011-07-29|2011-08-02|Estimate|2015-10-30|2015-12-03|Estimate||||2017-06-05|2017-07-02|Actual|August 8, 2011|Actual|2011-08-08|June 2017|2017-06-30|March 23, 2012|Actual|2012-03-23|March 23, 2012|Actual|2012-03-23||Interventional|||A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)|An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function|Completed||Phase 1|49|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 22:17:49.878554|2018-05-31 22:17:49.878554
NCT01407263|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2017-11-27|2011-07-29|2011-08-02|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Trial of Modifications to Radical Prostatectomy|A Randomized Trial of Modifications to Radical Prostatectomy|Recruiting||Phase 3|2300|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 22:17:51.879087|2018-05-31 22:17:51.879087
NCT01407250|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-24|||2011-07-31|2011-07-31|2011-08-02|Estimate|||||||2011-07-31|2011-08-02|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|November 2011|Anticipated|2011-11-30||Observational|CommwellPG||PhysioGlove Versus Clinic Electrocardiogram Comparison|Reliability of Outpatient Electrocardiogram Recordings in Patients Refered for a Cardiology Consultation|Unknown status|Not yet recruiting||100|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 22:17:51.972494|2018-05-31 22:17:51.972494
NCT01199484|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-10|2010-09-10|2010-09-13|Estimate|||||||2010-09-10|2010-09-13|Estimate||||September 2010|2010-09-30||||||||Interventional|||Specific Oral Tolerance Induction to Cow's Milk Allergy|Specific Oral Tolerance Induction as an Useful Treatment in Two-year-old Children With Cow's Milk Allergy.|Completed||N/A|||Valencia University General Hospital|||||f||||t||||||||||2018-05-31 23:22:04.703669|2018-05-31 23:22:04.703669
NCT01407224|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-31|2011-07-31|2011-08-02|Estimate|||||||2011-07-31|2011-08-02|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|iycfch||Assessing Cost and Effectiveness of Training and Supervision of Front Line Workers on Early Breastfeeding Practices|Assessing the Cost and Effectiveness of Training and Supervision of Front Line Workers on Early Breastfeeding Practices (Bangladesh)|Completed||Phase 1|1200|Actual|Eminence||3|||f||||t||||||||||2018-05-31 22:17:52.096903|2018-05-31 22:17:52.096903
NCT01407211|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2012-07-17|2011-07-30|2011-08-02|Estimate|||||||2012-07-17|2012-07-18|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|September 2013|Anticipated|2013-09-30|April 2013|Anticipated|2013-04-30||Interventional|MS||Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient|The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients|Unknown status|Enrolling by invitation|Phase 4|30|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:17:52.260389|2018-05-31 22:17:52.260389
NCT01407198|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2018-01-23|2011-07-29|2011-08-02|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2011||2011-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|February 2016|Actual|2016-02-29||Interventional|||Nilotinib With Radiation for High Risk Chordoma|Phase I Study of Nilotinib Given With Radiation For Patients With High Risk Chordoma|Active, not recruiting||Phase 1|29|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 22:17:52.332753|2018-05-31 22:17:52.332753
NCT01407185|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2012-12-31|2011-07-30|2011-08-02|Estimate|||||||2012-12-31|2013-01-03|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy of a Home-Based Exercise Program for Heart Failure|Efficacy of a Home-Based Exercise Program in the Management of Heart Failure: An Evidenced-Based Multi-Disciplinary Approach|Terminated||N/A|9|Actual|Catholic Home Care||1||Lack of enrollment. Difficult to obtain Physician approval.|f||||t||||||||||2018-05-31 22:17:52.408428|2018-05-31 22:17:52.408428
NCT01407172|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-04-26|2011-08-01|2011-08-02|Estimate|||||||2013-04-26|2013-04-30|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Hydrogen Sulfide and Peripheral Arterial Disease|Hydrogen Sulfide and Peripheral Arterial Disease|Completed|||252|Actual|Louisiana State University Health Sciences Center Shreveport|||3||f||||f||||||Samples Without DNA|"~     Plasma for additional biomarker evaluation will be stored.~   "|||2018-05-31 22:17:52.482077|2018-05-31 22:17:52.482077
NCT01407159|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2014-04-25|2011-08-01|2011-08-02|Estimate|||||||2014-04-25|2014-04-28|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|ASSIST||A Study in SurvIvors of Type B Aortic Dissection Undergoing Stenting|ASSIST - A Study in SurvIvors of Type B Aortic Dissection Undergoing Stenting|Completed|||40|Actual|JOTEC GmbH|||2||f||||||||||||||2018-05-31 22:17:52.554035|2018-05-31 22:17:52.554035
NCT01407146|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2016-07-11|2011-07-29|2011-08-02|Estimate|||||||2016-07-11|2016-07-13|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study|Acute Coronary Syndrome and Care-Seeking Delay: A Web Based Behavioral Study|Completed|||2381|Actual|Yale University|||||f||||f||||||||Undecided||2018-05-31 22:17:52.63516|2018-05-31 22:17:52.63516
NCT01407133|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2012-08-09|2011-08-01|2011-08-02|Estimate|||||||2012-08-09|2012-08-10|Estimate|May 2005||2005-05-31|July 2011|2011-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MagTIN||Conventional Repetitive Transcranial Magnetic Stimulation for Tinnitus Treatment|Assessment of Conventional Repetitive Transcranial Magnetic Stimulation for the Treatment of Chronic Tinnitus|Completed||Phase 1/Phase 2|64|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 22:17:52.700157|2018-05-31 22:17:52.700157
NCT01407120|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-08-01|2011-08-01|2011-08-02|Estimate|||||||2011-08-01|2011-08-02|Estimate|July 2006||2006-07-31|July 2011|2011-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|NBF15||15 Year Follow-up of New Beginnings Program for Divorced Families|Effects of NBP for Children of Divorce 15 Years Later|Completed||Phase 2/Phase 3|240|Actual|Arizona State University||3|||f||||f||||||||||2018-05-31 22:17:52.780537|2018-05-31 22:17:52.780537
NCT01407107|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2016-05-31|2011-07-29|2011-08-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer|Phase I Dose Escalation Trial of Nitroglycerin in Addition to 5-flourouracil and Radiation Therapy for Neo-adjuvant Treatment of Operable Rectal Cancer|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 22:17:52.850017|2018-05-31 22:17:52.850017
NCT01407094|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2018-03-20|2011-07-29|2011-08-01|Estimate|||||||2018-03-20|2018-03-22|Actual|July 29, 2011|Actual|2011-07-29|March 2018|2018-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|EMBARC||Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression|Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) for Depression|Completed||Phase 4|309|Actual|University of Texas Southwestern Medical Center||3|||f||||t||||||||Yes||2018-05-31 22:17:52.93306|2018-05-31 22:17:52.93306
NCT01407081|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-07-31|2011-07-29|2011-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SMARTease||SMARTease Trial: Evaluating Stroke Help Distance Interventions to Improve Cognitive Performance Post-Stroke|SMARTease Trial - Turning SMART Goals Into Smart Actions: Evaluating Stroke Help Distance Interventions to Improve Cognitive Performance Post-Stroke|Terminated||Phase 3|10|Anticipated|Nova Scotia Health Authority||1||Poor recruitment|f||||f||||||||||2018-05-31 22:17:53.049039|2018-05-31 22:17:53.049039
NCT01407068|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|2015-02-04||2017-09-07|2011-07-29|2011-08-01|Estimate|2015-02-04|2015-02-20|Estimate||||2017-09-07|2017-10-05|Actual|September 2011||2011-09-30|September 2017|2017-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Administration of Two Injections for Multiple Dupuytren's Contractures|An Open-label Study to Assess the Safety and Efficacy of Concurrent Administration of Two Injections of AA4500 0.58 mg Into the Same Hand of Subjects With Multiple Dupuytren's Contractures|Completed||Phase 3|60|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:17:53.13822|2018-05-31 22:17:53.13822
NCT01407055|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-02-02|2011-07-29|2011-08-01|Estimate|||||||2016-02-02|2016-02-03|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Optimizing Expectations in Cardiac Surgery Patients|Clinical Applications of Placebo Research: Optimizing Expectation Effects in Cardiac Surgery Patients|Completed||Phase 2|124|Actual|Philipps University Marburg Medical Center||3|||f||||f||||||||||2018-05-31 22:17:53.464859|2018-05-31 22:17:53.464859
NCT01407042|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-07-16|2011-07-29|2011-08-01|Estimate|||||||2016-07-16|2016-07-19|Estimate|September 2011||2011-09-30|July 2016|2016-07-31||||December 2014|Actual|2014-12-31||Observational|||Patellofemoral Pain After Unicondylar Knee Arthroplasty||Completed|||24|Actual|Medical University Innsbruck|||1||f||||||||||||||2018-05-31 22:17:53.565104|2018-05-31 22:17:53.565104
NCT01407029|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2017-04-24|2011-07-29|2011-08-01|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2009|Actual|2009-10-31|April 2017|2017-04-30|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Observational|||R3® Acetabular System in Patients With Degenerative Hip Disease|A Prospective, Multicenter, Non-randomized, Clinical Outcomes Study of the R3® Acetabular System in Patients With Degenerative Hip Disease|Completed|||158|Actual|Smith & Nephew, Inc.|||||f||||f||||||||No||2018-05-31 22:17:53.638733|2018-05-31 22:17:53.638733
NCT01407016|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-09-27|2011-07-29|2011-08-01|Estimate|||||||2011-09-27|2011-09-28|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects|A Phase 1, Open Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Following Single And Multiple Intravenous Infusion In Healthy Japanese Adult Subjects|Completed||Phase 1|6|Actual|Pfizer||1|||f||||||||||||||2018-05-31 22:17:53.754502|2018-05-31 22:17:53.754502
NCT01407003|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20||2014-03-27|2014-04-24|2011-07-29|2011-08-01|Estimate||||2014-03-27|2014-04-24|Estimate|2014-04-24|2014-05-13|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)|A Randomized, Double-blind, Placebo-controlled, 4-part, Interwoven Single- and Multiple-ascending Dose Study to Assess Safety, Tolerability, PK and PD of LIK066 in Healthy Subjects and in Patients With T2DM|Completed||Phase 1/Phase 2|138|Actual|Novartis||4|||f||||||||||||||2018-05-31 22:17:53.92503|2018-05-31 22:17:53.92503
NCT01406990|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2012-08-28||2012-08-28|2011-07-29|2011-08-01|Estimate|2012-08-28|2012-09-28|Estimate||||2012-08-28|2012-09-28|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Aspirin Responsiveness in Women With Coronary Artery Disease|Aspirin Responsiveness in Women With Coronary Artery Disease|Completed|||15|Actual|Creighton University|||1||f||||f||||||||||2018-05-31 22:17:54.089717|2018-05-31 22:17:54.089717
NCT01406977|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2013-03-18|2011-07-29|2011-08-01|Estimate|||||||2013-03-18|2013-03-20|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)|An Open-label, Intra-patient Dose-escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP).|Completed||Phase 2|9|Actual|Novartis||1|||f||||f||||||||||2018-05-31 22:17:54.352358|2018-05-31 22:17:54.352358
NCT01406964|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2012-03-30|2011-07-29|2011-08-01|Estimate|||||||2012-03-30|2012-04-02|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Chlamidia Antibodies Test for Tubal Factor Screening|Chlamidia Antibodies Test for Tubal Factor Screening|Completed||N/A|60|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 22:17:54.445677|2018-05-31 22:17:54.445677
NCT01406951|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-07-29|2011-07-29|2011-08-01|Estimate|||||||2011-07-29|2011-08-01|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Diagnostic Value of sTREM-1 and PCT Level as Well as CPIS Score for Ventilator-Associated Pneumonia Among ICU Sepsis Patients||Completed|||92|Actual|Chinese PLA General Hospital|||3||f||||t||||||||||2018-05-31 22:17:54.567811|2018-05-31 22:17:54.567811
NCT01406938|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2015-02-13||2015-04-30|2011-07-29|2011-08-01|Estimate|2015-04-30|2015-05-19|Estimate||||2015-04-30|2015-05-19|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SCULPTURE|The Full analysis set (FAS) was comprised of all patients to whom study treatment had been assigned.|Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens|A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen|Completed||Phase 3|967|Actual|Novartis|A limitation of this study is the lack of a placebo group; however, because the placebo response is very low in psoriasis, it is inappropriate to maintain patients on placebo for 52 weeks. .|6|||f||||t||||||||||2018-05-31 22:17:54.861406|2018-05-31 22:17:54.861406
NCT01406925|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-07-29|2011-07-29|2011-08-01|Estimate|||||||2011-07-29|2011-08-01|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers|A Randomised, Placebo-controlled, Double-blind, Cross-over Study in Healthy Men and Women to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intra-anal Doses of NRL001 for Three Doses Using a Cream Formulation Relative to a Matched Placebo Formulation for Reference|Completed||Phase 1|12|Actual|Norgine||4|||f||||f||||||||||2018-05-31 22:17:59.182267|2018-05-31 22:17:59.182267
NCT01406912|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-11-11|2011-07-29|2011-08-01|Estimate|||||||2015-11-11|2015-11-13|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy of Virtual Reality Exercises in STroke Rehabilitation: A Multicentre Study (EVREST Multicentre)|Efficacy of Virtual Reality Exercises Using Wii Gaming Technology in STroke Rehabilitation: A Multicentre Randomized Clinical Trial (EVREST Multicentre)|Completed||N/A|141|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 22:17:59.257174|2018-05-31 22:17:59.257174
NCT01406899|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2014-12-22|2011-07-28|2011-08-01|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Computer-Based Training in Cognitive Behavior Therapy (CBT4CBT)|Computer-Assisted Cognitive Behavior Therapy for Veterans With Substance Use Disorder|Completed||Phase 1|80|Actual|VA Connecticut Healthcare System||2|||f||||t||||||||||2018-05-31 22:17:59.361372|2018-05-31 22:17:59.361372
NCT01406886|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2017-10-15|2011-07-29|2011-08-01|Estimate|||||||2017-10-15|2017-10-17|Actual|December 2009||2009-12-31|October 2017|2017-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Combined Effects of Energy Density and Eating Rate on Appetite|Combined Effects of Energy Density and Eating Rate on Energy Intake and Biomarkers of Satiety|Completed||N/A|20|Actual|United States Army Research Institute of Environmental Medicine||1|||f||||f||||||||||2018-05-31 22:17:59.442033|2018-05-31 22:17:59.442033
NCT01406873|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2018-03-01||2018-03-01|2011-07-28|2011-08-01|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-01|2018-03-29|Actual|June 2011||2011-06-30|March 2018|2018-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1|A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1)|Completed||Phase 2|42|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 22:17:59.561012|2018-05-31 22:17:59.561012
NCT01406860|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2017-06-21||2017-11-27|2011-07-29|2011-08-01|Estimate|2017-11-27|2017-12-05|Actual||||2017-11-27|2017-12-05|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches|Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches in the Emergency Department: A Prospective Randomized, Double-blinded Trial.|Terminated||N/A|19|Actual|University of Iowa||2||lack of enrollment/drug shortages|f||||t||||||||||2018-05-31 22:18:00.186982|2018-05-31 22:18:00.186982
NCT01406847|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-04-04|2011-07-28|2011-08-01|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2012||2012-08-31|April 2018|2018-04-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Central Mechanisms of Intervention for Low Back Pain|Central Mechanisms of Body Based Intervention for Musculoskeletal Low Back Pain|Completed||N/A|159|Actual|University of Florida||3|||f||||t||||||||||2018-05-31 22:18:00.483318|2018-05-31 22:18:00.483318
NCT01406834|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-08-14|2011-07-28|2011-08-01|Estimate|||||||2014-08-14|2014-08-18|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Treatment for the Mental Health Impact of Killing in War|Treatment for the Mental Health Impact of Killing in War: Augmentation of Existing Evidence-Based Mental Health Interventions|Completed|||8|Actual|University of California, San Francisco|||||f||||f||||||||||2018-05-31 22:18:00.662053|2018-05-31 22:18:00.662053
NCT01406821|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2018-04-16|2011-07-29|2011-08-01|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2009|Actual|2009-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Acute and Chronic Ligament and Tendon Injuries With Platelet Rich Plasma|Randomized, Double-blind Clinical Trial of Platelet Rich Plasma for Treatment of Acute and Chronic Patellar Tendinosis|Recruiting||N/A|100|Anticipated|Stanford University||2|||f||||||||||||No||2018-05-31 22:18:00.748334|2018-05-31 22:18:00.748334
NCT01406808|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-10-03|2011-07-29|2011-08-01|Estimate|||||||2017-10-03|2017-10-05|Actual|August 2011||2011-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|October 2016|Actual|2016-10-31||Interventional|||Personal Genomics for Preventive Cardiology|A Pilot Randomized Trial of Personal Genomics for Preventive Cardiology|Completed||N/A|100|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 22:18:00.864194|2018-05-31 22:18:00.864194
NCT01406795|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|2016-11-24||2017-01-06|2011-07-28|2011-08-01|Estimate|2017-01-06|2017-02-27|Actual||||2017-01-06|2017-02-27|Actual|December 2010||2010-12-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The GORE Viabahn Endoprosthesis for the Treatment of Venous Occlusions and Stenoses|Evaluation of GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface for the Treatment of Venous Occlusions and Stenoses|Terminated||N/A|1|Actual|Stanford University|The study was underpowered, enrolling only a single patient (goal enrollment was 15 patients).|1||Poor enrollment and advances in venoplasty only techniques of the femoral vein|f||||||||||||||2018-05-31 22:18:00.957468|2018-05-31 22:18:00.957468
NCT01406782|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2017-05-16|2011-07-29|2011-08-01|Estimate|||||||2017-05-16|2017-05-17|Actual|December 13, 2011|Actual|2011-12-13|May 2017|2017-05-31|January 13, 2012|Actual|2012-01-13|January 13, 2012|Actual|2012-01-13||Observational|||DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402|The Influence of KIR and HLA Genotype on the Response to Rituximab Immunotherapy in Patients With Follicular Lymphoma|Completed|||200|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 22:18:01.234237|2018-05-31 22:18:01.234237
NCT01406769|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2017-05-03|2011-07-29|2011-08-01|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2012||2012-07-31|May 2017|2017-05-31||||July 2017|Anticipated|2017-07-31||Interventional|||Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy|A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer|Active, not recruiting||Phase 2|120|Anticipated|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 22:18:01.317831|2018-05-31 22:18:01.317831
NCT01406743|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-01-13|2011-07-29|2011-08-01|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|EOS-SPINE||Spine Reference Parameters on EOS Imaging|PARAMETRES GLOBAUX DE REFERENCE DU RACHIS CALCULES SUR DES PATIENTS ASYMPTOMATIQUES PAR IMAGERIE EOS™|Completed|||161|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 22:18:01.42643|2018-05-31 22:18:01.42643
NCT01406730|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-08-11|2011-07-29|2011-08-01|Estimate|||||||2012-08-11|2012-08-14|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Running Effect on Cardiovascular and Muscular Parameters|Effect of 16 Weeks of Running Exercise on Parameters Related to the Cardiovascular System, Blood and Muscle in Untrained Males 30-50 Years Old. A Randomized Controlled Study|Completed||Phase 3|80|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 22:18:01.769315|2018-05-31 22:18:01.769315
NCT01406717|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-02-04|2011-07-29|2011-08-01|Estimate|||||||2017-02-04|2017-02-07|Estimate|January 2013||2013-01-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus|Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|360|Actual|Sun Pharmaceutical Industries Limited||2|||f||||f||||||||||2018-05-31 22:18:01.878189|2018-05-31 22:18:01.878189
NCT01406704|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2011-08-18|2011-07-28|2011-08-01|Estimate|||||||2011-08-18|2011-08-19|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|December 2013|Anticipated|2013-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH|Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH (Non-alcoholic Steato-hepatitis)|Terminated||Phase 4|26|Actual|Seoul St. Mary's Hospital||4||because of withdrawal of Avandia sale due to its risks outweigh its benefits|f||||t||||||||||2018-05-31 22:18:02.013603|2018-05-31 22:18:02.013603
NCT01406691|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2016-11-01|2011-07-29|2011-08-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)|Treating Sleep Disruption in Teens With Millisecond Light Exposure During Sleep|Completed||Phase 4|104|Actual|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 22:18:02.09608|2018-05-31 22:18:02.09608
NCT01406678|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2016-05-11|2011-07-29|2011-08-01|Estimate|||||||2016-05-11|2016-05-12|Estimate|July 2008||2008-07-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|October 2012|Actual|2012-10-31||Interventional|||Remote Ischemic Preconditioning in Coronary Artery Bypass Grafting With Cold Crystalloid Cardioplegic Arrest|Effect of Remote Ischemic Preconditioning in Patients Undergoing On-pump Coronary Artery Bypass Graft Surgery With Crystalloid Cardioplegic Arrest|Recruiting||Phase 2/Phase 3|500|Anticipated|University Hospital, Essen||2|||f||||t||||||||||2018-05-31 22:18:02.173773|2018-05-31 22:18:02.173773
NCT01406665|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2011-07-29|2011-07-29|2011-08-01|Estimate|||||||2011-07-29|2011-08-01|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Skin Autofluorescence (AF) Decision Tree in Detecting Impaired Glucose Tolerance (IGT) or Diabetes Mellitus (DM)|Assessment of Value of Skin Autofluorescence in Detecting Diabetes Mellitus or Impaired Glucose Tolerance. Comparison With Fasting Plasma Glucose and Glycated Hb|Completed|||218|Actual|University Medical Center Groningen|||1||f||||f||||||None Retained|"~     none retained~   "|||2018-05-31 22:18:02.339013|2018-05-31 22:18:02.339013
NCT01406652|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-07-29|2011-07-29|2011-08-01|Estimate|||||||2011-07-29|2011-08-01|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Optimisation of the Treatment of Infectious Bursitis|One-stage Versus Two-stage Surgical Treatement of Infectious Bursitis|Unknown status|Recruiting|Phase 3|240|Anticipated|University Hospital, Geneva||1|||f||||t||||||||||2018-05-31 22:18:02.408531|2018-05-31 22:18:02.408531
NCT01406639|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2013-04-26|2011-07-29|2011-08-01|Estimate|||||||2013-04-26|2013-04-29|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Ranibizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Withdrawn||Phase 1|0|Actual|University of California, San Diego||1||Study withdrawn due to lack of study population.|f||||f||||||||||2018-05-31 22:18:02.519586|2018-05-31 22:18:02.519586
NCT01406626|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2016-01-15|2011-07-29|2011-08-01|Estimate|||||||2016-01-15|2016-01-20|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|January 2016|Actual|2016-01-31||Interventional|LINK LA||Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care|Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care|Unknown status|Active, not recruiting|N/A|360|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 22:18:02.611164|2018-05-31 22:18:02.611164
NCT01406613|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2012-06-14|2011-07-29|2011-08-01|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis|A 2-year Observational Study of Bone Density and Bone Turnover After Prior Treatment With Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care|Unknown status|Enrolling by invitation||200|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     A venous blood sample will be collected from each participant at each visit to analyse~     biochemical bone markers, and basic biochemistry analysis for eligibility screening.~      Two urine samples will be collected from each participant at each study visit, one collected~     on the morning prior to the study visit and a second sample on the morning of the study~     visit.~   "|||2018-05-31 22:18:02.715089|2018-05-31 22:18:02.715089
NCT01406600|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-23|||2013-04-11|2011-07-28|2011-08-01|Estimate|||||||2013-04-11|2013-04-12|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles|Optimal rhCG(Ovidrel®) Dose for Final Oocyte Maturation Triggering in Poor Responder During IVF and ICSI Cycles|Unknown status|Recruiting|N/A|70|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:18:02.81575|2018-05-31 22:18:02.81575
NCT01406587|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-10-18|2011-07-28|2011-08-01|Estimate|||||||2011-10-18|2011-10-19|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg PP4001 Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated With Uncomplicated Urinary Tract Infection|Completed||Phase 2|261|Actual|Pinnacle Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 22:18:02.906793|2018-05-31 22:18:02.906793
NCT01406574|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2015-04-14||2015-05-21|2011-07-29|2011-08-01|Estimate|2015-05-21|2015-06-08|Estimate||||2015-05-21|2015-06-08|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma|A Multicenter, Open-label, Non-randomized, Dose-escalation, Therapeutic Exploratory Trial to Evaluate the Safety and Efficacy of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|23|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 22:18:03.067021|2018-05-31 22:18:03.067021
NCT01406561|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-01-03|2011-07-29|2011-08-01|Estimate|||||||2013-01-03|2013-01-07|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy|A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy|Completed||Phase 3|344|Actual|Omeros Corporation||2|||f||||f||||||||||2018-05-31 22:18:03.337682|2018-05-31 22:18:03.337682
NCT01406548|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2015-02-18|2011-07-28|2011-08-01|Estimate|||||||2015-02-18|2015-02-19|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density|Completed||Phase 2|44|Actual|Novartis||6|||f||||||||||||||2018-05-31 22:18:03.438783|2018-05-31 22:18:03.438783
NCT01406535|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-07-29|2011-07-29|2011-08-01|Estimate|||||||2011-07-29|2011-08-01|Estimate||||January 2011|2011-01-31||||||||Expanded Access|SYDNEY||Improvement of Myocardial Blood Flow by PhosphoDiesterase 5 Inhibition in Coronary Artery Disease|Sustained Improvement of MYocardial Blood Flow by Intermittent PhosphoDiesterase 5 INhibition in REfractory Coronary ArterY Disease Suggests Enhanced Angiogenesis (SYDNEY)|Temporarily not available|||||Medical University of Vienna|||||f||||||||||||||2018-05-31 22:18:03.536074|2018-05-31 22:18:03.536074
NCT01406522|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-12-17|2011-07-28|2011-08-01|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Interventional|||Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics|Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics|Withdrawn||Phase 2|0|Actual|Midwest Biomedical Research Foundation||2||One of the study medications, tacrine, is no longer clinically available|f||||t||||||||||2018-05-31 22:18:03.597431|2018-05-31 22:18:03.597431
NCT01161043|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2011-09-19|2010-07-12|2010-07-13|Estimate|||||||2011-09-19|2011-09-20|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Observational|||New Glucose Sensor Pediatric|An Evaluation of a New Subcutaneous Glucose Sensor in Pediatric Subjects|Completed|||60|Anticipated|Medtronic Diabetes|||||f||||f||||||||||2018-05-31 23:35:45.290101|2018-05-31 23:35:45.290101
NCT01406509|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2012-04-17|2011-07-29|2011-08-01|Estimate|||||||2012-04-17|2012-04-19|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children|A Phase I Clinical Trial for Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children|Completed||Phase 1|40|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 22:18:03.703849|2018-05-31 22:18:03.703849
NCT01406496|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-02-21|2011-07-29|2011-08-01|Estimate|||||||2013-02-21|2013-02-22|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Best Timing of Insulin Bolus Before Meals of Different Contents|The Effect of Food Content and Optimal Timing of Pre-meal Insulin Bolus on the Postprandial Glycemic Control in Children With Type 1 Diabetes|Unknown status|Recruiting|N/A|24|Anticipated|Kaplan Medical Center||1|||f||||t||||||||||2018-05-31 22:18:03.922473|2018-05-31 22:18:03.922473
NCT01406483|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2014-08-08|2011-07-29|2011-08-01|Estimate|||||||2014-08-08|2014-08-11|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|July 2016|Anticipated|2016-07-31|February 2016|Anticipated|2016-02-29||Interventional|Serial CABG||Platelet Reactivity in Patients on a Thienopyridine and Awaiting Coronary Artery Bypass Grafting|Platelet Reactivity in Patients on a Thienopyridine and Awaiting Coronary Artery Bypass Grafting|Unknown status|Active, not recruiting|N/A|100|Anticipated|Medstar Health Research Institute||1|||f||||f||||||||||2018-05-31 22:18:04.007725|2018-05-31 22:18:04.007725
NCT01406470|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-01-09|2011-07-29|2011-08-01|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency|An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) IVIG-SN™ in Subjects With Primary Immunodeficiency|Completed||Phase 3|45|Actual|Green Cross Corporation||1|||f||||t||||||||||2018-05-31 22:18:04.073793|2018-05-31 22:18:04.073793
NCT01406457|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-10-20|2011-07-29|2011-08-01|Estimate|||||||2015-10-20|2015-10-21|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|December 2012|Actual|2012-12-31||Observational|MODISH||Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage|Monitoring of Delayed Ischemia After Subarachnoid Hemorrhage|Completed|||7|Actual|University of Cincinnati|||||f||||f|||||||"~     No specimens are to be retained.~   "|||2018-05-31 22:18:04.171208|2018-05-31 22:18:04.171208
NCT01406444|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-01-17|2011-07-28|2011-08-01|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2011||2011-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||IGF-1 and Bone Loss in Women With Anorexia Nervosa|IGF-1 and Bone Loss in Women With Anorexia Nervosa|Recruiting||N/A|200|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 22:18:04.231784|2018-05-31 22:18:04.231784
NCT01406431|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2013-01-01|2011-07-28|2011-08-01|Estimate|||||||2013-01-01|2013-01-03|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects|A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatin and Valsartan Co-administration and Livalo® Fixed Combination Drug in Healthy Male Subjects|Completed||Phase 1|48|Actual|JW Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:18:04.315244|2018-05-31 22:18:04.315244
NCT01406418|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-12-18|2011-07-29|2011-08-01|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR6261, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose Intravenous Administration|Completed||Phase 1|64|Actual|Crucell Holland BV||12|||f||||t||||||||||2018-05-31 22:18:04.404826|2018-05-31 22:18:04.404826
NCT01406405|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2018-02-27|2011-07-29|2011-08-01|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2011||2011-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|PEEK||PEEK and Allograft Spacers Evaluation in Spinal Fusion Surgeries|Prospective Randomized Clinical Trial Comparing PEEK and Allograft Spacers in Patients Undergoing Spinal Intervertebral Fusion Surgeries|Active, not recruiting|||240|Anticipated|Justin Parker Neurological Institute|||2||f||||f||||||||||2018-05-31 22:18:04.554843|2018-05-31 22:18:04.554843
NCT01406392|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-07-29|2011-07-29|2011-08-01|Estimate|||||||2011-07-29|2011-08-01|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|July 2011|Actual|2011-07-31||Interventional|SUBMISO||Sublingual Misoprostol for Induction of Labor|Sublingual Misoprostol 12,5 Mcg Versus Vaginal Misoprostol 25 Mcg for Induction of Labour of Alive and Term Fetus : Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|150|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||t||||||||||2018-05-31 22:18:04.632576|2018-05-31 22:18:04.632576
NCT01406379|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2013-08-18|2011-07-29|2011-08-01|Estimate|||||||2013-08-18|2013-08-20|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Comparison of Prophylactic Clip and Detachable Snare|Comparison of Clip and Detachable Snare in Preventing Postpolypectomy Bleeding for Pedunculated Colonic Polyps: a Prospective, Randomized Study|Completed||N/A|203|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 22:18:04.723303|2018-05-31 22:18:04.723303
NCT01406366|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-29|||2011-07-29|2011-07-29|2011-08-01|Estimate|||||||2011-07-29|2011-08-01|Estimate|September 2005||2005-09-30|August 2010|2010-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|BFOH||Evaluation of a Bright Futures Oral Health Intervention|Evaluation of a Bright Futures Oral Health Intervention for Pediatric Residents|Completed|||27|Actual|Continuity Research Network|||2||f||||f||||||||||2018-05-31 22:18:04.801305|2018-05-31 22:18:04.801305
NCT01406353|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2018-03-05|2011-07-29|2011-08-01|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2011|Actual|2011-07-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|MITIGATE||Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis|Early Percutaneous Mitral Intervention Versus Conventional Management in Asymptomatic Moderate Mitral Stenosis|Active, not recruiting||N/A|167|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 22:18:04.904371|2018-05-31 22:18:04.904371
NCT01406340|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-06-06|2011-07-28|2011-08-01|Estimate|||||||2017-06-06|2017-06-07|Actual|August 30, 2011|Actual|2011-08-30|June 2017|2017-06-30|August 31, 2013|Actual|2013-08-31|August 31, 2013|Actual|2013-08-31||Interventional|||Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment|A Repeat-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Impaired Renal Function|Terminated||Phase 1|22|Actual|GlaxoSmithKline||2||Difficulty enrolling last cohort of subjects|f||||f||||||||||2018-05-31 22:18:05.018524|2018-05-31 22:18:05.018524
NCT01406327|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-08-28|2011-07-28|2011-08-01|Estimate|||||||2017-08-28|2017-08-29|Actual|December 14, 2010|Actual|2010-12-14|August 2017|2017-08-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)|Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)|Active, not recruiting|||900|Anticipated|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:18:05.114654|2018-05-31 22:18:05.114654
NCT01406314|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-06-07|2011-07-28|2011-08-01|Estimate|||||||2017-06-07|2017-06-09|Actual|October 13, 2011|Actual|2011-10-13|June 2017|2017-06-30|November 14, 2012|Actual|2012-11-14|November 14, 2012|Actual|2012-11-14||Interventional|||SAP Depleter Dose Assessment Study in Patients|A Phase 1, Open Label, Dose Characteristic Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intravenous and Subcutaneous Doses of GSK2315698A in Patients With Systemic Amyloidosis|Completed||Phase 1|17|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:18:05.207201|2018-05-31 22:18:05.207201
NCT01406301|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-04-23|2011-07-28|2011-08-01|Estimate|||||||2015-04-23|2015-04-27|Estimate|March 2008||2008-03-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Fondaparinux EU-RMP (Adherence)|Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA® (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:18:05.305186|2018-05-31 22:18:05.305186
NCT01406288|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2012-11-19|2011-07-28|2011-08-01|Estimate|||||||2012-11-19|2012-11-20|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|SHU O104 CUB||Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4|Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 in Bordeaux Urban Area, June 2011: Evaluation of Diagnostic, Prognostic and Pathophysiological Data|Completed|||9|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 22:18:05.380152|2018-05-31 22:18:05.380152
NCT01406275|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-05-15|2011-07-28|2011-08-01|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2008||2008-01-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)|Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)|Completed|||363|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:18:05.452991|2018-05-31 22:18:05.452991
NCT01406262|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-06-07|2011-07-28|2011-08-01|Estimate|||||||2017-06-07|2017-06-08|Actual|July 6, 2011|Actual|2011-07-06|June 2017|2017-06-30|December 29, 2011|Actual|2011-12-29|December 29, 2011|Actual|2011-12-29||Interventional|||Albiglutide Thorough ECG Study in Healthy Volunteers|A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)|Completed||Phase 1|94|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:18:05.529834|2018-05-31 22:18:05.529834
NCT01406249|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-07-26|2011-07-29|2011-08-01|Estimate|||||||2017-07-26|2017-07-27|Actual|August 2011||2011-08-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer|A Randomized Phase II Trial Comparing Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer (XParTS II)|Active, not recruiting||Phase 2|100|Anticipated|Epidemiological and Clinical Research Information Network||2|||f||||t||||||||||2018-05-31 22:18:05.639571|2018-05-31 22:18:05.639571
NCT01406236|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-01-16|2011-07-29|2011-08-01|Estimate|||||||2015-01-16|2015-01-21|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|SAFE-PCI||SAFE-PCI for Women|Study of Access Site for Enhancement of PCI for Women (SAFE-PCI for Women)|Terminated||N/A|1787|Actual|Duke University||2||"Study stopped for Statistical Futility. Low rate of bleeding events made it unlikely there~   would be statistical power to show a difference in the 2 arms."|f||||t||||||||||2018-05-31 22:18:05.731267|2018-05-31 22:18:05.731267
NCT01406223|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|2017-07-31|2015-06-18|2017-10-12|2011-07-28|2011-08-01|Estimate|2017-07-31|2017-08-31|Actual|2015-06-18|2015-07-15|Estimate|2017-10-12|2017-11-14|Actual|July 2011||2011-07-31|October 2017|2017-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|ConNicBrain||Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation|Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation|Completed||Phase 3|282|Actual|Duke University|Statistical comparisons of imaging data between groups are limited due to small sample size in each condition.|4|||f||||t||||||||||2018-05-31 22:18:05.83912|2018-05-31 22:18:05.83912
NCT01406210|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2014-09-10|2011-07-29|2011-08-01|Estimate|||||||2014-09-10|2014-09-12|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|RESULT||RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol|Prospective and Retrospective Study to Develop a Multi-center Randomized Study, to Determine if Prevention of GERD Related Aspiration by Surgical Fundoplication Improves Lung Allograft Function|Completed|||647|Actual|Duke University|||2||f||||f||||||Samples Without DNA|"~     The bronchiolar lavage fluid (BALF) will be drawn during the bronchoscopy site and~     approximately up to 10 ml of the bronchiolar lavage (BAL) fluid will be placed in 7 storage~     vials (approximately 1.5 ml per vial), frozen using liquid nitrogen as the freezing agent,~     and shipped on dry ice to Duke University Medical Center and/or University of Toronto. Frozen~     samples will be stored at -80 °C to -85 °C until shipping, and the time between collection~     and freezing will be recorded.~      The tests used to assess the bronchiolar lavage fluid (BALF) may include, but are not limited~     to the following: Gastrin, Pepsinogen I, Pepsinogen II, Lipopolysaccharide (LPS), Bile acids~     (colorimetric and enzymatic approaches), and proteome assessment by mass spectrometry.~   "|||2018-05-31 22:18:06.531596|2018-05-31 22:18:06.531596
NCT01406197|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2017-08-09|2011-07-28|2011-08-01|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2011|Actual|2011-07-31|August 2017|2017-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor|Uterine Abdominal Electromyography Measurements Before and After Progesterone Treatments for Preterm Labor|Withdrawn||N/A|0|Actual|St. Joseph's Hospital and Medical Center, Phoenix||3||Investigator left organization prior to study initiation|f||||f||||||||||2018-05-31 22:18:06.619197|2018-05-31 22:18:06.619197
NCT01406184|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2018-04-09|2011-07-29|2011-08-01|Estimate|||||||2018-04-09|2018-04-10|Actual|July 2009||2009-07-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Durham Connects RCT Evaluation|RCT Evaluation of the Durham Connects Universal Newborn Nurse Home Visiting Program|Active, not recruiting||N/A|2329|Actual|Duke University||2|||f||||t||||||||No||2018-05-31 22:18:06.716383|2018-05-31 22:18:06.716383
NCT01406171|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-28|2011-07-28|2011-08-01|Estimate|||||||2011-07-28|2011-08-01|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Drug Interaction Study of Isavuconazole and Midazolam|A Phase 1, Open-Label, Drug Interaction Study of the Pharmacokinetics of Isavuconazole and Midazolam After Separate and Concomitant Administration to Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:18:06.804001|2018-05-31 22:18:06.804001
NCT01406158|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-08-23|2011-07-28|2011-08-01|Estimate|||||||2011-08-23|2011-08-24|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation|A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation B) Versus Solifenacin Liquid Suspension 10 mg (Formulation A) and to Assess the Relative Bioavailability of Solifenacin Liquid Suspension 10 mg (Formulation A and B) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet in Healthy Volunteers|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 22:18:07.030092|2018-05-31 22:18:07.030092
NCT01406145|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-11-17|2011-07-28|2011-08-01|Estimate|||||||2011-11-17|2011-11-18|Estimate|June 2011||2011-06-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil|A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil|Completed||Phase 1|60|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 22:18:07.135459|2018-05-31 22:18:07.135459
NCT01406132|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-28|2011-07-28|2011-08-01|Estimate|||||||2011-07-28|2011-08-01|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects|A Phase 1, Open-Label, Mass Balance Study to Evaluate the Pharmacokinetics of ASP015K After a Single Oral Dose of 14C-Labeled ASP015K in Healthy Male Subjects|Completed||Phase 1|6|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:18:07.22919|2018-05-31 22:18:07.22919
NCT01406119|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-01-26|2011-07-28|2011-08-01|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors|An Extension Study of ABT-806 for Subjects With Advanced Solid Tumors|Completed||Phase 1|14|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 22:18:07.312574|2018-05-31 22:18:07.312574
NCT01406106|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Plant Sterols on the Lipid Profile of Patients With Hypercholesterolaemia|EFFECT OF PLANT STEROLS ON THE LIPID PROFILE OF PATIENTS WITH HYPERCHOLESTEROLAEMIA. RANDOMISED, EXPERIMENTAL STUDY|Unknown status|Active, not recruiting|N/A|182|Actual|Gerencia de Atención Primaria, Albacete||2|||f||||f||||||||||2018-05-31 22:18:07.401035|2018-05-31 22:18:07.401035
NCT01406093|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-12-02|2011-07-28|2011-07-29|Estimate|||||||2014-12-02|2014-12-04|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Observational|||Early- and Late-onset Candidemia|Early- and Late-onset Candidemia: A Retrospective Study|Completed|||400|Actual|University of Turin, Italy|||1||f||||f||||||||||2018-05-31 22:18:07.518044|2018-05-31 22:18:07.518044
NCT01406080|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-04-05|2011-07-28|2011-07-29|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2013||2013-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|FOTEN||A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging|Single-blinded, Multicenter, Randomized, Comparative Study of Efficacy and Safety of Adapalene Gel 0.3% Versus Tretinoin Emollient Cream 0.05% in the Treatment of Cutaneous Photoaging.|Completed||Phase 3|128|Actual|Galderma Brasil Ltda.||2|||f||||t||||||||||2018-05-31 22:18:07.603882|2018-05-31 22:18:07.603882
NCT01406067|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-04-14|2011-07-28|2011-07-29|Estimate|||||||2014-04-14|2014-04-15|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Treatment of Children With Peer Related Aggressive Behavior|Treatment of Children With Peer Related Aggressive Behavior With the Treatment Programme THAV - a Randomized Controlled Trial|Completed||Phase 3|100|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 22:18:07.772137|2018-05-31 22:18:07.772137
NCT01406054|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2016-01-26|2011-07-28|2011-07-29|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|June 2014|Actual|2014-06-30||Interventional|KIPP at CPS||Role of Neuromuscular Training in Reducing Sports Injuries and Improving Fitness Among Chicago Public Elementary and Middle School Students|Role of Neuromuscular Training in Reducing Sports Injuries and Improving Fitness Among Chicago Public Elementary and Middle School Students|Unknown status|Active, not recruiting|N/A|905|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 22:18:07.863502|2018-05-31 22:18:07.863502
NCT01406041|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Observational|||Disturbance of Water and Sodium Metabolism After Surgery of Sellar Lesions, and Correspond Clinical Strategy||Unknown status|Recruiting||350|Anticipated|Southern Medical University, China|||1||f||||t||||||||||2018-05-31 22:18:07.970118|2018-05-31 22:18:07.970118
NCT01406028|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Does Emotional Support Decrease In Vitro Fertilization Stress?|Does Emotional Support During the Luteal Phase Decrease the Stress of IVF?|Completed||N/A|131|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:18:08.073807|2018-05-31 22:18:08.073807
NCT01406015|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|2017-01-29||2017-03-20|2011-07-28|2011-07-29|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|February 2009||2009-02-28|March 2017|2017-03-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional||Baseline characteristics are based on the total number of participants who completed the study.|Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications|Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications|Completed||N/A|38|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:18:08.188975|2018-05-31 22:18:08.188975
NCT01406002|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-04-09|2011-07-28|2011-07-29|Estimate|||||||2013-04-09|2013-04-11|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||To Evaluate if Multiple Doses of Rifampicin Change the Blood Concentration of YM150 (Darexaban)|An Open-label, One-sequence Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Pharmacokinetics of YM150 (Darexaban) and Metabolites in Young Healthy Male Subjects|Completed||Phase 1|26|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:18:08.597081|2018-05-31 22:18:08.597081
NCT01405989|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-03-03|2011-07-28|2011-07-29|Estimate|||||||2014-03-03|2014-03-05|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||To Evaluate if Multiple Doses of Ketoconazole Change the Blood Concentration of YM150 (Darexaban)|An Open-label, Randomized, Two-period Crossover Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Pharmacokinetics of Darexaban and Metabolites in Young Healthy Male Subjects|Completed||Phase 1|26|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:18:08.703169|2018-05-31 22:18:08.703169
NCT01405976|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-09-22|2011-07-28|2011-07-29|Estimate|||||||2017-09-22|2017-09-25|Actual|May 2009|Actual|2009-05-31|January 2017|2017-01-31|July 2017|Actual|2017-07-31|May 2013|Actual|2013-05-31||Interventional|||Alternative of Treatment in Obesity Hypoventilation Syndrome|Mid-and Long-term Efficacy of Ventilation Non-invasive and Continuos Positive Airway Pressure in Obesity Hypoventilation Syndrome|Completed||N/A|440|Actual|Sociedad Española de Neumología y Cirugía Torácica||5|||f||||t||||||||No||2018-05-31 22:18:08.782022|2018-05-31 22:18:08.782022
NCT01405963|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-09-16|2011-07-28|2011-07-29|Estimate|||||||2013-09-16|2013-09-18|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Double-blind, Multiple Dose Study in Subjects With Mild Atopic Asthma|A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma|Completed||Phase 1|31|Actual|Amgen||2|||f||||f||||||||||2018-05-31 22:18:08.871003|2018-05-31 22:18:08.871003
NCT01405950|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2013-03-27||2013-06-10|2011-07-28|2011-07-29|Estimate|2013-03-27|2013-05-13|Estimate||||2013-06-10|2013-06-17|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy|Single-Dose, Phase 1b Study to Assess Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects With Mild to Moderate Spasticity Due to Cerebral Palsy|Terminated||Phase 1|10|Actual|Acorda Therapeutics||4||"Please see 'Further study details as provided by Acorda Therapeutics' for explanation of why~   study stopped."|f||||t||||||||||2018-05-31 22:18:08.952894|2018-05-31 22:18:08.952894
NCT01405937|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2014-10-03||2017-03-03|2011-07-28|2011-07-29|Estimate|2014-10-03|2014-10-13|Estimate||||2017-03-03|2017-03-31|Actual|August 2011||2011-08-31|March 2017|2017-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)|A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Concomitantly Administered With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Relapsed After Previous Treatment|Completed||Phase 3|51|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 22:18:09.267028|2018-05-31 22:18:09.267028
NCT01405924|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2014-10-24||2017-02-14|2011-07-28|2011-07-29|Estimate|2014-10-24|2014-10-29|Estimate||||2017-02-14|2017-03-21|Actual|October 2011||2011-10-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EVADE||Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)|EMEND® IV In Salvage Treatment of Chemotherapy-Induced Vomiting|Terminated||Phase 2|111|Actual|Merck Sharp & Dohme Corp.||1||Low enrollment|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:18:09.780926|2018-05-31 22:18:09.780926
NCT01405911|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-04-10|2011-07-28|2011-07-29|Estimate|||||||2017-04-10|2017-04-12|Actual|August 8, 2011|Actual|2011-08-08|April 2017|2017-04-30|April 9, 2012|Actual|2012-04-09|April 9, 2012|Actual|2012-04-09||Interventional|||Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)|A Phase II, Randomized, Placebo-Controlled, Parallel-group, Double-Blind, Dose Response Finding Clinical Trial to Study the Efficacy and Safety of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance Who Have Inadequate Glycemic Control on Diet/Exercise Therapy|Completed||Phase 2|251|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:18:10.166095|2018-05-31 22:18:10.166095
NCT01405898|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2015-11-03||2015-12-08|2011-07-28|2011-07-29|Estimate|2015-11-03|2015-12-09|Estimate||||2015-12-08|2016-01-08|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|May 2014|Actual|2014-05-31|April 2013|Actual|2013-04-30||Interventional|||The Chronic Effects of Beetroot Juice in Hypertensive Subjects|The Chronic Effects of Beetroot Juice on Circulating Plasma Nitrate and Nitrite Levels and Blood Pressure in Hypertensive Subjects|Completed||N/A|68|Actual|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 22:18:10.251358|2018-05-31 22:18:10.251358
NCT01405885|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2014-02-28|2011-07-28|2011-07-29|Estimate|||||||2014-02-28|2014-03-03|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus|Phase I, Open Label Study to Evaluate Safety, Tolerability and Immunogenicity of Multiple Combinations of H1 and H5 Influenza Hemagglutinin Plasmids Administered ID Followed by in Vivo Electroporation With CELLECTRA®-3P in Healthy Adults|Completed||Phase 1|116|Actual|Inovio Pharmaceuticals||10|||f||||f||||||||||2018-05-31 22:18:10.512715|2018-05-31 22:18:10.512715
NCT01405872|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-09-05|2011-07-28|2011-07-29|Estimate|||||||2014-09-05|2014-09-09|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PERSIST||Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.|An Observational Study to Assess Persistence, Adherence, Quality of Life, and Treatment Satisfaction in Patients Beginning Therapy With the Avonex® PEN™.|Completed|||270|Actual|Biogen|||||f||||f||||||||||2018-05-31 22:18:10.615571|2018-05-31 22:18:10.615571
NCT01405859|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2016-05-10|2011-07-27|2011-07-29|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||MRI Study of Tic Remission in Tourette Syndrome|Neuroimaging to Elucidate the Mechanism of Tic Resolution in Tourette Syndrome|Completed|||21|Actual|University of Utah|||3||f||||f||||||||||2018-05-31 22:18:10.742496|2018-05-31 22:18:10.742496
NCT01405846|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2016-08-18|2011-07-28|2011-07-29|Estimate|||||||2016-08-18|2016-08-19|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|TIDAL1||Feasibility Study to Estimate Number of Patients With Precancerous Areas in Their Airways and the Response to Gefitinib|Tyrosine Kinase Inhibitors in DyplAsia of Lung Epithelium|Terminated||Phase 2|32|Actual|Papworth Hospital NHS Foundation Trust||1||Futility|f||||t||||||||||2018-05-31 22:18:10.802258|2018-05-31 22:18:10.802258
NCT01405833|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-09-05|2011-07-28|2011-07-29|Estimate|||||||2014-09-05|2014-09-09|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.|Phase 1: A Multi-Centered, Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of BG00010 (Neublastin) in Subjects With Sciatica|Completed||Phase 1|56|Actual|Biogen||2|||f||||t||||||||||2018-05-31 22:18:10.869899|2018-05-31 22:18:10.869899
NCT01405820|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2015-06-29||2015-08-03|2011-07-28|2011-07-29|Estimate|2015-06-29|2015-07-29|Estimate||||2015-08-03|2015-08-21|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|REFINE||Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)|A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis|Completed||Phase 2|290|Actual|Biogen||6|||f||||t||||||||||2018-05-31 22:18:10.958352|2018-05-31 22:18:10.958352
NCT01405807|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|February 2011||2011-02-28|July 2011|2011-07-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|ALEVIATE||Alemtuzumab for ANCA Associated Refractory Vasculitis|Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy|Unknown status|Recruiting|Phase 4|24|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:18:13.487627|2018-05-31 22:18:13.487627
NCT01405794|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2013-07-12||2016-05-25|2011-07-28|2011-07-29|Estimate|2015-09-24|2015-10-26|Estimate||||2016-05-25|2016-07-04|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm||Completed||Phase 1/Phase 2|12|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:18:13.70398|2018-05-31 22:18:13.70398
NCT01405781|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2018-02-27|2011-07-28|2011-07-29|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2011||2011-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Functional and Radiographic Outcomes After Shoulder Surgery|Functional and Radiographic Outcomes After Shoulder Surgery|Enrolling by invitation|||550|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 22:18:14.470901|2018-05-31 22:18:14.470901
NCT01405768|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2014-05-19||2014-06-26|2011-07-28|2011-07-29|Estimate|2014-06-26|2014-07-28|Estimate||||2014-06-26|2014-07-28|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional||4 women from the lidocaine arm who did not complete the questionnaire correctly were excluded from analysis|Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs)|A Randomized Trial of Buffered vs Nonbuffered Lidocaine With Epinephrine for Cervical Loop Excision|Completed||Phase 2|56|Actual|Washington University School of Medicine|"Small sample - may have missed a significant difference when one really exists~Procedures performed by 2nd year residents vs. procedure performed by more skilled surgeon (less pain)~Used needle extenders/27-gauge needles vs. Potocki needles"|2|||f||||f||||||||||2018-05-31 22:18:14.602367|2018-05-31 22:18:14.602367
NCT01405755|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2013-04-01|2011-07-28|2011-07-29|Estimate|||||||2013-04-01|2013-04-04|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|August 2011|Actual|2011-08-31||Interventional|||Partnering With Media and Vaccination Program to Improve Infant and Young Child Feeding|Partnering With Media and Vaccination Program to Improve Infant and Young Child Feeding|Completed||N/A|420|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 22:18:15.465221|2018-05-31 22:18:15.465221
NCT01405742|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2016-06-08||2016-09-16|2011-07-28|2011-07-29|Estimate|2016-07-27|2016-09-19|Estimate||||2016-09-16|2016-10-07|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A|R34 Pilot Feasibility Randomized, Noninferiority, Cross-Over Trial of Once-Weekly vs. Thrice-Weekly Prophylaxis With Recombinant Factor VIII in Adults With Severe Hemophilia A|Terminated||Phase 3|4|Actual|University of Pittsburgh||2||study was non-feasible per DSMB|f||||t||||||||Yes|The data from this trial will be available, pending NIH approval, through BioLINCC https://biolincc.nhlbi.nih.gov.|2018-05-31 22:18:15.646201|2018-05-31 22:18:15.646201
NCT01405729|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2014-02-12|2011-07-28|2011-07-29|Estimate|||||||2014-02-12|2014-02-14|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|MPFL||Medial Patellofemoral Ligament Reconstruction: A Review of Technique, Accuracy, and Outcome|Medial Patellofemoral Ligament Reconstruction: A Review of Technique, Accuracy, and Outcome|Completed|||13|Actual|University of Utah|||||f||||f||||||||||2018-05-31 22:18:15.964461|2018-05-31 22:18:15.964461
NCT01405716|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2017-09-30|2011-07-28|2011-07-29|Estimate|||||||2017-09-30|2017-10-03|Actual|February 2011||2011-02-28|September 2017|2017-09-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Aging Successfully With Pain|Effectiveness of a Mind-Body Program for Older Adults With Chronic Low Back Pain|Completed||N/A|282|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:18:16.052813|2018-05-31 22:18:16.052813
NCT01405703|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2015-07-08|2011-07-28|2011-07-29|Estimate|||||||2015-07-08|2015-07-09|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Percutaneous Versus Open Plate Fixation of Diaphyseal Clavicle Fractures|Percutaneous Versus Open Plate Fixation of Diaphyseal Clavicle Fractures|Completed|||35|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 22:18:16.146596|2018-05-31 22:18:16.146596
NCT01405690|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2016-12-02|2011-07-28|2011-07-29|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|June 2014|Actual|2014-06-30||Observational|||The Role Of Noninvasive 320-Row Multidetector Computer Tomography|A Pilot Study: The Role Of Noninvasive 320-Row Multidetector Computer Tomography Coronary Angiogram In Predicting Perioperative Cardiac Complications In Patients Referred For Noncardiac Surgery|Completed|||100|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 22:18:16.251592|2018-05-31 22:18:16.251592
NCT01405677|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-07-28|2011-07-28|2011-07-29|Estimate|||||||2014-07-28|2014-07-29|Estimate|June 2004||2004-06-30|December 2013|2013-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine|A Phase II Open, Randomised, Controlled Study to Evaluate the Safety and Immunogenicity of a Paediatric Dose (0.25 mL) and the Standard Dose (0.5 mL) of Epaxal® With Reference to Havrix Junior® Healthy in Healthy Children and Adolescents (>=12 Months - 16 Years of Age) Using a 0/6 Month Schedule|Completed||Phase 2|308|Actual|Crucell Holland BV||3|||f||||t||||||||||2018-05-31 22:18:16.333858|2018-05-31 22:18:16.333858
NCT01404286|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-07-27|2011-07-27|2011-07-28|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||Resistance Training and Sleep in the Elderly|The Effects of a Session of Resistance Training on Sleep Patterns in the Elderly|Completed||N/A|40|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 22:18:45.188057|2018-05-31 22:18:45.188057
NCT01405664|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2011-08-11|2011-07-28|2011-07-29|Estimate|||||||2011-08-11|2011-08-12|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Study of the Effect of Weight Bearing Status on Patient Outcomes After Surgery for Osteochondral Defects of the Ankle|A Randomized, Controlled Clinical Trial to Evaluate the Effect on Patient Outcomes of Weight Bearing Status After Forage of Osteochondral Defects of the Ankle|Unknown status|Not yet recruiting|N/A|68|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 22:18:16.446525|2018-05-31 22:18:16.446525
NCT01405651|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2012-06-12|2011-07-27|2011-07-29|Estimate|||||||2012-06-12|2012-06-14|Estimate|July 2011||2011-07-31|June 2012|2012-06-30||||October 2011|Actual|2011-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 22:18:16.561287|2018-05-31 22:18:16.561287
NCT01405638|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2015-11-11|2011-07-28|2011-07-29|Estimate|||||||2015-11-11|2015-11-13|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|FAITH-CRC||Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention|Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention|Completed||N/A|451|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 22:18:16.663793|2018-05-31 22:18:16.663793
NCT01405625|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-05-02|2011-07-28|2011-07-29|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2011|Actual|2011-07-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|March 2018|Actual|2018-03-31||Interventional|||Improving Parent Understanding of Instructions About Asthma Care|Improving Parent Understanding of Instructions About Asthma Care|Active, not recruiting||N/A|500|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 22:18:16.783914|2018-05-31 22:18:16.783914
NCT01405612|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2012-10-15|2011-07-28|2011-07-29|Estimate|||||||2012-10-15|2012-10-16|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers|An Open-label, Single Centre, Randomised, Cross-over Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam After Repeat Dose Administration of Ulimorelin in Healthy Volunteers|Completed||Phase 1|14|Actual|Norgine||2|||f||||t||||||||||2018-05-31 22:18:16.900483|2018-05-31 22:18:16.900483
NCT01405599|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2012-10-15|2011-07-28|2011-07-29|Estimate|||||||2012-10-15|2012-10-16|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects|Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ulimorelin in Subjects With Mild, Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects|Completed||Phase 1|32|Actual|Norgine||4|||f||||t||||||||||2018-05-31 22:18:17.024956|2018-05-31 22:18:17.024956
NCT01405586|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2017-10-05|2011-07-28|2011-07-29|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2011||2011-03-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|November 2016|Actual|2016-11-30||Interventional|MILES-3||MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer|Randomized Phase III Study of the Addition of Cisplatin in Combination With Gemcitabine as First-line Therapy for Elderly Patients With Advanced Non Small Cell Lung Cancer.|Active, not recruiting||Phase 3|299|Actual|National Cancer Institute, Naples||2|||f||||f||||||||||2018-05-31 22:18:17.145872|2018-05-31 22:18:17.145872
NCT01405573|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2017-03-27|2011-07-28|2011-07-29|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2011||2011-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|BOOST||Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma|Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial|Terminated||Phase 3|35|Actual|National Cancer Institute, Naples||2||lack of enrolment|f||||t||||||||||2018-05-31 22:18:17.31658|2018-05-31 22:18:17.31658
NCT01405560|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|2014-10-06||2017-03-03|2011-07-28|2011-07-29|Estimate|2014-10-06|2014-10-09|Estimate||||2017-03-03|2017-03-31|Actual|September 2011||2011-09-30|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)|A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Were Non-responders to Previous Treatment|Completed||Phase 3|42|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-05-31 22:18:17.502351|2018-05-31 22:18:17.502351
NCT01405547|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-12-19|2011-07-27|2011-07-29|Estimate|||||||2012-12-19|2012-12-20|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Gestational Metabolic Abnormalities and Maternal and Infant Nutrition and Health|Impact of Maternal Metabolic Abnormalities in Pregnancy on Human Milk and Subsequent Infant Metabolic Development|Completed|||271|Actual|University of Toronto|||||f||||||||||||||2018-05-31 22:18:17.881794|2018-05-31 22:18:17.881794
NCT01405534|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-09-11|2011-07-28|2011-07-29|Estimate|||||||2014-09-11|2014-09-12|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|VVC||Evaluation of the Occurrence of Acute Complications Caused by a Central Venous Catheter Placement|Evaluation of the Occurrence of Acute Complications Caused by a Central Venous Catheter Placement: Observational, Prospective, Monocentric Study|Completed|||1780|Actual|Centre Leon Berard|||1||f||||f||||||||||2018-05-31 22:18:17.972685|2018-05-31 22:18:17.972685
NCT01405521|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-03-30|2011-07-28|2011-07-29|Estimate|||||||2017-03-30|2017-03-31|Actual|December 2011||2011-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Understanding Typhoid Disease After Vaccination|Understanding Typhoid Disease After Vaccination: a Single Centre, Randomised, Doubleblind, Placebo Controlled Study to Evaluate M01ZH09 in a Healthy Adult Challenge Model, Using Ty21a Vaccine as a Positive Control.|Active, not recruiting||Phase 2|99|Actual|University of Oxford||3|||f||||t||||||||||2018-05-31 22:18:18.066612|2018-05-31 22:18:18.066612
NCT01405508|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2016-03-14|2013-06-03|2016-07-04|2011-07-28|2011-07-29|Estimate|2016-03-14|2016-04-13|Estimate|2013-06-03|2013-06-11|Estimate|2016-07-04|2016-08-01|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Baseline Characetristics refer to the Safety Population consisting of all subjects who took at least 1 dose of study drug.|Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy|A Multi-center, Open-label, Four-arm, Randomized Trial Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 70 Years Suffering From Epilepsy|Completed||Phase 3|105|Actual|UCB Pharma||4|||f||||f||||||||||2018-05-31 22:18:18.19127|2018-05-31 22:18:18.19127
NCT01405495|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2017-05-03|2011-07-28|2011-07-29|Estimate|||||||2017-05-03|2017-05-04|Actual|February 2012||2012-02-29|May 2017|2017-05-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Observational|COPTSD||PTSD Among Victims of Sexual Abuse and Changes in Structural and Functional Brain Connectivity|Posttraumatic Stress Disorder (PTSD) Among Victims of Sexual Abuse and Changes in Structural and Functional Brain Connectivity: A Cognitive and Neuroanatomical Markers Study Using fMRI,(DTI) and(ASL)|Completed|||60|Actual|University Hospital, Tours|||3||f||||t||||||Samples Without DNA|"~     Salivary cortisol~   "|||2018-05-31 22:18:18.686797|2018-05-31 22:18:18.686797
NCT01405482|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Botulinum Toxin Injections for Thoracic Outlet Syndrome|Botulin Toxin Type A Injections for Thoracic Outlet Syndrome: A Double-Blind, Randomized Control Trial|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 22:18:18.774009|2018-05-31 22:18:18.774009
NCT01405469|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2014-09-04||2017-05-05|2011-07-28|2011-07-29|Estimate|2014-12-01|2014-12-02|Estimate||||2017-05-05|2017-05-08|Actual|November 2010||2010-11-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|June 2011|Actual|2011-06-30||Interventional|POEM||Endoscopic Peroral Myotomy for Treatment of Achalasia|Endoscopic Peroral Myotomy for Treatment of Achalasia: Pilot Study|Completed||N/A|16|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||t||||||||Undecided||2018-05-31 22:18:18.911634|2018-05-31 22:18:18.911634
NCT01405456|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2018-04-16||2018-04-16|2011-07-28|2011-07-29|Estimate|2018-04-16|2018-05-16|Actual||||2018-04-16|2018-05-16|Actual|January 2012||2012-01-31|April 2018|2018-04-30|November 1, 2017|Actual|2017-11-01|May 3, 2017|Actual|2017-05-03||Interventional|||Eplerenone in HIV Associated Abdominal Fat Accumulation|Randomized Placebo-controlled Trial to Investigate the Effects of Eplerenone in Patients With HIV-associated Abdominal Fat Accumulation|Completed||N/A|46|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:18:19.22276|2018-05-31 22:18:19.22276
NCT01405443|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-04-15|2011-07-28|2011-07-29|Estimate|||||||2014-04-15|2014-04-16|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Simulator Training for Gastrointestinal Endoscopy|Simulator Training for Gastrointestinal Endoscopy - How Much Simulator Training is Required to Acquire Proficiency in Gastrointestinal Endoscopy?|Terminated|||20|Actual|Universitätsklinikum Hamburg-Eppendorf|||3|invalid data|f||||t||||||||||2018-05-31 22:18:20.031326|2018-05-31 22:18:20.031326
NCT01405430|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-06-26|2011-07-27|2011-07-29|Estimate|||||||2015-06-26|2015-06-29|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|AVECC||Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab|Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab|Completed||N/A|63|Actual|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 22:18:20.115347|2018-05-31 22:18:20.115347
NCT01405417|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-11-08|2011-07-28|2011-07-29|Estimate|||||||2017-11-08|2017-11-09|Actual|April 2011|Actual|2011-04-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|July 2012|Actual|2012-07-31||Interventional|||Endoscopic Peroral Myotomy for Treatment of Achalasia|Endoscopic Peroral Myotomy for Treatment of Achalasia: Multicenter Study|Terminated||N/A|70|Actual|Universitätsklinikum Hamburg-Eppendorf||1||not enough data collected|f||||t||||||||||2018-05-31 22:18:20.239156|2018-05-31 22:18:20.239156
NCT01405404|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-05-06|2011-07-28|2011-07-29|Estimate|||||||2013-05-06|2013-05-07|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Engaging Low-Income Families in Prevention Programs|Engaging Low-Income Families in Prevention Programs|Completed||Phase 2|323|Actual|Rush University Medical Center||3|||f||||t||||||||||2018-05-31 22:18:20.386215|2018-05-31 22:18:20.386215
NCT01405391|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-01-14|2011-07-27|2011-07-29|Estimate|||||||2016-01-14|2016-01-15|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 on Days 1 and 8 Every Three Weeks (q3wk) in Non-Colorectal Cancer (Non-CRC) Patients|Completed||Phase 1|42|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 22:18:20.562326|2018-05-31 22:18:20.562326
NCT01405378|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2016-06-22|2011-07-28|2011-07-29|Estimate|||||||2016-06-22|2016-06-23|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Non-invasive Brain Stimulation for People With Stroke|Combining Transcranial Direct Current Stimulation (tDCS) With Robot Therapy for the Impaired Upper Limb in Stroke Rehabilitation.|Completed||Early Phase 1|23|Actual|University of Southampton||2|||f||||t||||||||||2018-05-31 22:18:20.637794|2018-05-31 22:18:20.637794
NCT01405365|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Impact of Obesity on Nonsurgical Periodontal Therapy|The Impact of Obesity on Nonsurgical Periodontal Treatment of Destructive Periodontal Diseases|Unknown status|Recruiting|N/A|96|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 22:18:20.729166|2018-05-31 22:18:20.729166
NCT01405352|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|August 2013|Anticipated|2013-08-31|February 2013|Anticipated|2013-02-28||Interventional|||The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity|The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals|Unknown status|Enrolling by invitation|Phase 4|84|Actual|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-05-31 22:18:20.903134|2018-05-31 22:18:20.903134
NCT01405339|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-03-07|2011-07-28|2011-07-29|Estimate|||||||2014-03-07|2014-03-10|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|May 2013|Actual|2013-05-31||Interventional|||Budesonide Application Via Mucosal Atomization Device as a Treatment for Chronic Rhinosinusitis When Utilized as a Topical Nasal Steroid Spray|The Effect of Budesonide Spray Via Mucosal Atomization Device on the Hypothalamic-Pituitary Axis|Completed||Phase 1/Phase 2|20|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:18:21.100856|2018-05-31 22:18:21.100856
NCT01405326|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|REWARD||REstore Working Ability in RheumatoiD Arthritis|The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work|Unknown status|Recruiting|Phase 4|160|Anticipated|The Rheumatological Center of Helsinki||2|||f||||f||||||||||2018-05-31 22:18:21.201665|2018-05-31 22:18:21.201665
NCT01405313|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-09-20||2017-01-30|2011-07-28|2011-07-29|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|July 2011||2011-07-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||All 21 patients completed the cross over study design|Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV|Comparison of Modified Adaptive Servoventilation Therapy With Conventional Adaptive Servoventilation Therapy in Patients With Periodic Breathing|Completed||N/A|21|Actual|ResMed|None to report|2|||f||||f||||||||No||2018-05-31 22:18:21.417959|2018-05-31 22:18:21.417959
NCT01405300|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2014-06-23|2011-07-28|2011-07-29|Estimate|||||||2014-06-23|2014-06-24|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function|The Effects of Peanuts and Peanut Products on Glucose Control and Vascular Function|Completed||Phase 1|20|Anticipated|Penn State University||2|||f||||f||||||||||2018-05-31 22:18:21.74985|2018-05-31 22:18:21.74985
NCT01405287|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-03-21|2011-07-28|2011-07-29|Estimate|||||||2014-03-21|2014-03-24|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|August 2012|Actual|2012-08-31||Interventional|REMEDEE-OCT||Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT|A Prospective Randomized Study to Compare Vascular Healing After Deployment of the Abluminal Sirolimus Coated Bio-Engineered (Combo) Stent Versus the Everolimus Eluting Stent in Patients With Acute Coronary Syndrome by Means of OCT|Completed||Phase 2|60|Actual|OrbusNeich||2|||f||||t||||||||||2018-05-31 22:18:21.827821|2018-05-31 22:18:21.827821
NCT01405274|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-12-11|2011-07-28|2011-07-29|Estimate|||||||2015-12-11|2015-12-14|Estimate|July 2011||2011-07-31|December 2015|2015-12-31||||March 2016|Anticipated|2016-03-31||Interventional|||Impact of Physiotherapy Intervention for Children With Ankle Sprains|Exploring the Impact of a Physiotherapy Intervention on the Risk of Re-injury and Recovery in Children and Adolescents With Acute Ankle Sprains: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:18:21.942947|2018-05-31 22:18:21.942947
NCT01405261|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2013-11-27|2011-07-28|2011-07-29|Estimate|||||||2013-11-27|2013-11-28|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects|Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects|Completed||Phase 1|101|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 22:18:22.016179|2018-05-31 22:18:22.016179
NCT01405248|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-10-22|2011-07-28|2011-07-29|Estimate|||||||2015-10-22|2015-10-26|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|BPRIAS||Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting|Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting|Completed||Phase 3|100|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 22:18:22.11088|2018-05-31 22:18:22.11088
NCT01405235|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2012-04-11|2011-07-28|2011-07-29|Estimate|||||||2012-04-11|2012-04-12|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|January 2015|Anticipated|2015-01-31|June 2012|Anticipated|2012-06-30||Interventional|AGO-Zervix-1||Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma|A Prospective, Randomized Phase III Study to Compare the Effects of Paclitaxel and Topotecan to Those of Cisplatin and Topotecan for Treatment of Patients With Recurrent and Persistent Cervical Cancer|Unknown status|Active, not recruiting|Phase 3|312|Anticipated|Institut fuer Frauengesundheit||2|||f||||t||||||||||2018-05-31 22:18:22.236504|2018-05-31 22:18:22.236504
NCT01405222|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2013-12-16|2011-07-28|2011-07-29|Estimate|||||||2013-12-16|2013-12-17|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Cough Frequency in Chronic Obstructive Pulmonary Disease|Objective Measure of COPD Exacerbation Using the Hull Automated Cough Recorder. Verifying Use of Automated Recording Systems in Measuring Symptoms Associated With a COPD Exacerbation|Completed|||24|Actual|Hull and East Yorkshire Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 22:18:22.363318|2018-05-31 22:18:22.363318
NCT01405209|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2015-03-19|2011-07-28|2011-07-29|Estimate|||||||2015-03-19|2015-03-24|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|EKG||Electrocardiogram Variations in the Prediction of Development of Atrial Fibrillation|Variaciones En El Elctrocardiograma Como Prediccion Del Desarrollo De Fibrilacion AURIC|Completed|||100|Actual|Hospital Italiano de Buenos Aires|||2||f||||f||||||||||2018-05-31 22:18:22.435704|2018-05-31 22:18:22.435704
NCT01405196|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2016-11-18|2015-12-14|2017-12-18|2011-07-27|2011-07-29|Estimate|2017-12-18|2017-12-19|Actual|2015-12-14|2016-01-14|Estimate|2017-12-18|2017-12-19|Actual|December 2011|Actual|2011-12-31|December 2017|2017-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BUTTERFLY||Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus|A Double-blind, Randomized, Placebo-controlled, Multicenter Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)|Completed||Phase 2|183|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 22:18:22.704927|2018-05-31 22:18:22.704927
NCT01405183|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-09-16|2011-07-28|2011-07-29|Estimate|||||||2014-09-16|2014-09-17|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||Association Between Hepatitis C Infection and Renal Cell Carcinoma|Association Between Hepatitis C Infection and Renal Cell Carcinoma, a Case Control Study|Completed|||240|Actual|Henry Ford Health System|||2||f||||t||||||Samples Without DNA|"~     Hepatits C antibody Hepatitis C RNA quantitative Hepatitis C Genotype~   "|||2018-05-31 22:18:25.568125|2018-05-31 22:18:25.568125
NCT01405170|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-10-25|2011-07-27|2011-07-29|Estimate|||||||2011-10-25|2011-10-27|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 mg/mL To Methylprednisolone 32 mg Tablet Under Fed Conditions|Withdrawn||Phase 1|16|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:18:25.668515|2018-05-31 22:18:25.668515
NCT01405157|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-10-17|2011-07-27|2011-07-29|Estimate|||||||2011-10-17|2011-10-19|Estimate|January 2012||2012-01-31|October 2011|2011-10-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 mg/mL To Methylprednisolone 16 Mg Tablet Under Fasting Conditions|Withdrawn||Phase 1|16|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:18:25.736224|2018-05-31 22:18:25.736224
NCT01405144|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-28|2011-07-28|2011-07-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|August 2010||2010-08-31|May 2011|2011-05-31|March 2012|Anticipated|2012-03-31|September 2011|Anticipated|2011-09-30||Interventional|||5fluorouracil for Advanced Photoaging|Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging|Unknown status|Recruiting|Phase 3|30|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:18:25.834144|2018-05-31 22:18:25.834144
NCT01405131|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-10-24|2011-07-27|2011-07-29|Estimate|||||||2011-10-24|2011-10-25|Estimate|January 2012||2012-01-31|October 2011|2011-10-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder for Oral Suspension 4 mg/mL to Methylprednisolone 32 mg Tablet Under Fasted Conditions|Withdrawn||Phase 1|16|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:18:25.943634|2018-05-31 22:18:25.943634
NCT01405118|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-08-17|2011-07-27|2011-07-29|Estimate|||||||2011-08-17|2011-08-18|Estimate|June 2011||2011-06-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers|A Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers|Completed||Phase 1|24|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 22:18:26.035877|2018-05-31 22:18:26.035877
NCT01405105|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2014-02-13|2011-07-28|2011-07-29|Estimate|||||||2014-02-13|2014-02-14|Estimate|August 2009||2009-08-31|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Exacerbating Factors in Inflammatory Bowel Disease|Exacerbating Factors in Inflammatory Bowel Disease|Completed|||134|Actual|Dallas VA Medical Center|||2||f||||t||||||||||2018-05-31 22:18:26.156263|2018-05-31 22:18:26.156263
NCT01405092|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2012-08-07|2011-07-28|2011-07-29|Estimate|||||||2012-08-07|2012-08-08|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Continuous Versus Conventional Volume Management During CRRT (Continuous Renal Replacement Therapy)||Completed||N/A|28|Actual|Dallas VA Medical Center||2|||f||||f||||||||||2018-05-31 22:18:26.227864|2018-05-31 22:18:26.227864
NCT01405079|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-06-05|2011-07-27|2011-07-29|Estimate|||||||2017-06-05|2017-06-06|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|March 2017|Actual|2017-03-31||Interventional|ADJUVANT||Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation|A Randomized, Open-label Trial of Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With EGFR Mutation|Active, not recruiting||Phase 3|222|Actual|Guangdong Association of Clinical Trials||2|||f||||f||||||||Undecided||2018-05-31 22:18:26.331931|2018-05-31 22:18:26.331931
NCT01405066|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-08-25|2011-07-28|2011-07-29|Estimate|||||||2015-08-25|2015-08-26|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Radiation Dose Audit Reports to Reduce Radiation Exposure From CT Exams|CT Technologists Dose Audit Reports and Educational Seminar to Reduce Patient Radiation Exposure From Medical Imaging|Completed||N/A|19|Actual|Kaiser Permanente||1|||f||||f||||||||||2018-05-31 22:18:26.45388|2018-05-31 22:18:26.45388
NCT01405053|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2016-03-21|2011-07-27|2011-07-29|Estimate|||||||2016-03-21|2016-03-23|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs|A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome|Completed||Phase 3|37|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:18:26.538288|2018-05-31 22:18:26.538288
NCT01405040|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-04-01|2011-07-28|2011-07-29|Estimate|||||||2013-04-01|2013-04-04|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess Thermodilution Cardiac Output, Global End Diastolic Volume and Extravascular Lung Water|Clinical Evaluation of a New Transpulmonary Thermodilution Method to Assess TPTD, GEDV and EVLW|Completed|||97|Actual|Edwards Lifesciences|||1||f||||f||||||||||2018-05-31 22:18:26.647832|2018-05-31 22:18:26.647832
NCT01405027|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2014-11-17||2014-12-22|2011-07-27|2011-07-29|Estimate|2014-12-22|2015-01-06|Estimate||||2014-12-22|2015-01-06|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|OPTIMAL||Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy|Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program|Completed||Phase 4|197|Actual|Chronic Liver Disease Foundation|Smaller sample size than expected due to changing treatment landscape for HCV during course of study.|2|||f||||t||||||||||2018-05-31 22:18:26.739832|2018-05-31 22:18:26.739832
NCT01405014|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2012-03-06|2011-07-27|2011-07-29|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2012||2012-01-31|September 2011|2011-09-30|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Interventional|||Outcome Study of Hold Me Tight Program With Acquired Brian Injury (ABI) Populations|Pilot Study of the Hold Me Tight Relationship Enhancement Program With Couples Where One Partner Has an Acquired Brian Injury|Withdrawn||Phase 3|0|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 22:18:28.433653|2018-05-31 22:18:28.433653
NCT01405001|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2017-05-12|2011-07-27|2011-07-28|Estimate|||||||2017-05-12|2017-05-15|Actual|December 2004||2004-12-31|May 2017|2017-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|REACH||Registry of Emergency Airways Arriving at Combat Hospitals|Registry of Emergency Airways Arriving at Combat Hospitals (REACH)|Completed|||292|Actual|William Beaumont Army Medical Center|||||f||||f||||||||Undecided||2018-05-31 22:18:28.515153|2018-05-31 22:18:28.515153
NCT01404988|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2015-02-23||2015-05-06|2011-07-27|2011-07-28|Estimate|2015-05-06|2015-05-25|Estimate||||2015-05-06|2015-05-25|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|VIP||Veterans Intensive Personalized Treatment in Heart Failure|VIP (Veterans Intensive Personalized) Treatment in Heart Failure|Completed||N/A|99|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-05-31 22:18:28.709678|2018-05-31 22:18:28.709678
NCT01404975|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2018-04-13|2011-07-27|2011-07-28|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2011||2011-06-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|June 10, 2016|Actual|2016-06-10||Interventional|TAVI PVB||TAVI Protocol - Paravertebral Block Study|Reducing Delirium After Trans-Apical Aortic Valve Replacement (TAVI): A Multifaceted Approach of Perioperative Care|Completed||N/A|44|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 22:18:29.784823|2018-05-31 22:18:29.784823
NCT01404962|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-11-30|2011-07-27|2011-07-28|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children|A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxem™Hib When Administered According to the Prescribing Information in Korea|Completed||Phase 4|764|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:18:30.08944|2018-05-31 22:18:30.08944
NCT01404949|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2018-03-07|2011-07-27|2011-07-28|Estimate|||||||2018-03-07|2018-03-08|Actual|July 2011||2011-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy|Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy|Active, not recruiting||Phase 2|39|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:18:30.433662|2018-05-31 22:18:30.433662
NCT01404936|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|2012-12-21||2013-01-30|2011-07-27|2011-07-28|Estimate|2013-01-30|2013-02-01|Estimate||||2013-01-30|2013-02-01|Estimate|July 1996||1996-07-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease|A Phase II Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) for Patients With Hodgkin's Disease|Completed||Phase 2|35|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:18:30.807606|2018-05-31 22:18:30.807606
NCT01404923|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2014-10-14||2014-11-03|2011-07-27|2011-07-28|Estimate|2014-11-03|2014-11-04|Estimate||||2014-11-03|2014-11-04|Estimate|December 2009||2009-12-31|November 2014|2014-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)|Assessment of On-demand MeteoSpasmyl® Use Effectiveness in Irritable Bowel Syndrome|Completed||Phase 4|436|Actual|Laboratoires Mayoly Spindler||2|||f||||f||||||||||2018-05-31 22:18:31.439342|2018-05-31 22:18:31.439342
NCT01404910|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-03-14|2011-07-27|2011-07-28|Estimate|||||||2017-03-14|2017-03-16|Actual|May 2013||2013-05-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|RAAPID-II||Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery|Phase 1b Proof-of-Concept Study of Apheresis to Reduce Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women With Preeclampsia Using a Dextran Sulfate Adsorption (DSA) Column (LIPOSORBER® LA-15 System)|Completed||N/A|11|Actual|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 22:18:32.573533|2018-05-31 22:18:32.573533
NCT01404897|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2015-03-25|2011-07-27|2011-07-28|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals|Effects of a Modified Lower Carbohydrate, Higher Fat DASH Diet Plan on Plasma Lipids, Lipoprotein Particle Size, and Blood Pressure in Healthy Adults|Completed||N/A|36|Actual|Children's Hospital & Research Center Oakland||3|||f||||f||||||||||2018-05-31 22:18:32.902581|2018-05-31 22:18:32.902581
NCT01404884|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2015-05-19|2011-07-27|2011-07-28|Estimate|||||||2015-05-19|2015-05-20|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|SUPRACOR||SUPRACOR for Myopia and Myopic Astigmatism|A Prospective Study To Evaluate The Safety And Effectiveness Of The SUPRACOR Presbyopic Treatment Algorithm For Myopia And Myopic Astigmatism Using LASIK|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|Technolas Perfect Vision GmbH||1|||f||||f||||||||||2018-05-31 22:18:33.200216|2018-05-31 22:18:33.200216
NCT01404871|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2013-01-30|2011-07-27|2011-07-28|Estimate|||||||2013-01-30|2013-01-31|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Predicting Medication Response in Obsessive Compulsive Disorder|Predicting Medication Response in Obsessive Compulsive Disorder|Completed||N/A|26|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:18:33.574325|2018-05-31 22:18:33.574325
NCT01404858|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2016-02-03|2011-07-27|2011-07-28|Estimate|||||||2016-02-03|2016-02-04|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Observational|||The Impact of Lifestyle Behavior on in Vitro Fertilization (IVF) Outcome|The Impact of Lifestyle Behavior on in Vitro Fertilization (IVF) Outcome|Completed|||12800|Actual|Boston IVF|||1||f||||f||||||||No||2018-05-31 22:18:33.963946|2018-05-31 22:18:33.963946
NCT01404845|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2015-06-23|2011-07-27|2011-07-28|Estimate|||||||2015-06-23|2015-06-24|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation|Assessment of the Evolution of Macular Pigment Density in Two Distinct Populations, Before and After Supplementation With Nutrof Total Versus Dietary Supplement Without Lutein and Zeaxanthin, Using the Macular Pigment Module of Visucam 200 or Visucam 500 (Zeiss).|Completed||N/A|200|Actual|Affordance||2|||f||||f||||||||||2018-05-31 22:18:34.287935|2018-05-31 22:18:34.287935
NCT01404832|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2013-02-26||2013-02-26|2011-07-27|2011-07-28|Estimate|2013-02-26|2013-02-27|Estimate||||2013-02-26|2013-02-27|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors|The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors|Terminated||Phase 4|102|Actual|Dallas VA Medical Center||||Inadequate recruitment|f||||f||||||||||2018-05-31 22:18:34.611421|2018-05-31 22:18:34.611421
NCT01404819|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2015-03-26|2011-07-27|2011-07-28|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Brain Damage Resulting From Carotid Endarterectomy With Xenon Anesthesia|Evaluation of Brain Damage Resulting From Carotid Endarterectomy With Xenon Anesthesia|Completed||N/A|86|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||t||||||||||2018-05-31 22:18:35.185257|2018-05-31 22:18:35.185257
NCT01404806|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-07-03|2011-07-26|2011-07-28|Estimate|||||||2013-07-03|2013-07-04|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects|A Phase 1, Open Label, Study in Healthy Female Subjects to Describe GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue Following Single and Multiple Dosing of GSK1349572|Completed||Phase 1|10|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 22:18:35.484787|2018-05-31 22:18:35.484787
NCT01403935|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-03-19|2011-07-26|2011-07-27|Estimate|||||||2015-03-19|2015-03-24|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|SIR||Sepsis Institutional Registry in Hospital Italiano de Buenos Aires|Sepsis Institutional Registry in Hospital Italiano de Buenos Aires|Completed|||7472|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 22:18:55.469136|2018-05-31 22:18:55.469136
NCT01404793|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-04-23|2011-07-27|2011-07-28|Estimate|||||||2015-04-23|2015-04-24|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Observational|||SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation|The Use Of Solid Phase Micro Extraction For Metabolomic Profiling And Concomitant Measurements Of Rocuronium Bromide Levels In Recipients Of Orthotopic Liver Transplantations|Completed|||28|Actual|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 22:18:35.851253|2018-05-31 22:18:35.851253
NCT01404780|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-02-20|2011-07-27|2011-07-28|Estimate|||||||2013-02-20|2013-02-22|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Interventional|||Comparison of the Glidescope and Macintosh Laryngoscope for Double Lumen Endotracheal Tube Intubation|Comparison of the Glidescope and Macintosh Laryngoscope for Double Lumen Endotracheal Tube Intubation|Completed||N/A|70|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:18:36.433616|2018-05-31 22:18:36.433616
NCT01404767|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2015-04-17|2011-07-27|2011-07-28|Estimate|||||||2015-04-17|2015-04-21|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|April 2011|Actual|2011-04-30||Interventional|||Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol|Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol: A Study Comparing the Post Op Continuation of the Preoperative Oral Dose Beta Blockers to Intravenous Esmolol Titrated to a Target Heart Rate (HR)|Terminated||Phase 4|20|Actual|University Health Network, Toronto||2||"Enrollment slow over 2 years a change in the population less on metoprolol than initially~   anticipated"|f||||t||||||||||2018-05-31 22:18:37.460234|2018-05-31 22:18:37.460234
NCT01404754|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2018-05-23|2011-07-26|2011-07-28|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2011||2011-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|MT-1||Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers|A Phase 1 Placebo-Controlled, Double-Blind Crossover Study to Assess Psychological Effects of MDMA When Administered to Healthy Volunteers|Enrolling by invitation||Phase 1|100|Anticipated|Multidisciplinary Association for Psychedelic Studies||2|||f||||f||||||||||2018-05-31 22:18:37.737397|2018-05-31 22:18:37.737397
NCT01404741|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-05-26|2011-07-27|2011-07-28|Estimate|||||||2017-05-26|2017-05-31|Actual|July 2011|Actual|2011-07-31|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)|Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability|Active, not recruiting||Phase 2|191|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||Undecided||2018-05-31 22:18:37.910501|2018-05-31 22:18:37.910501
NCT01404728|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-04-27|2011-07-27|2011-07-28|Estimate|||||||2017-04-27|2017-05-01|Actual|January 8, 2013|Actual|2013-01-08|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|January 22, 2013|Actual|2013-01-22||Observational|||Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy|Prospective Longitudinal Evaluation of Vaginal Stenosis and Sexual Function in Women With Pelvic Malignancies Treated With and Without Pelvic Radiation Therapy|Completed|||8|Actual|University of Colorado, Denver|||1||f||||t||||||||No||2018-05-31 22:18:38.163291|2018-05-31 22:18:38.163291
NCT01404715|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-04-09|2011-07-27|2011-07-28|Estimate|||||||2014-04-09|2014-04-10|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Drug-drug Interaction Study With Metformin and Imatinib|Pharmacokinetic Interaction Between Metformin and Imatinib in Healthy Volunteers.|Completed||Phase 1|11|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:18:38.363801|2018-05-31 22:18:38.363801
NCT01404702|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-12-01|2011-07-26|2011-07-28|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma|Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells|Terminated||Phase 1|4|Actual|University of Alabama at Birmingham||1||Accrual slower than anticipated|f||||t||||||||||2018-05-31 22:18:38.481157|2018-05-31 22:18:38.481157
NCT01404689|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-24|||2013-07-13|2011-07-27|2011-07-28|Estimate|||||||2013-07-13|2013-07-16|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DEMMER||Study to Determine if the Midazolam-Meperidine-Dexmedetomidine is Superior to the Midazolam-Meperidine for Sedation During ERCP|Midazolam With Meperidine and Dexmedetomidine vs Midazolam With Meperidine for Sedation During ERCP|Completed||Phase 4|110|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:18:38.729116|2018-05-31 22:18:38.729116
NCT01404676|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2011-07-27|2011-07-27|2011-07-28|Estimate|||||||2011-07-27|2011-07-28|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes|The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes|Unknown status|Recruiting|N/A|46|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 22:18:38.971351|2018-05-31 22:18:38.971351
NCT01404663|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-03-06|2011-07-27|2011-07-28|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2011||2011-10-31|August 2010|2010-08-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Side Effects of Bone Marrow Derived CD133 Transplantation in Cerebral Palsy|Evaluation the Side Effects of Bone Marrow Derived CD133 Cells Transplantation in Cerebral Palsy Patients|Completed||Phase 1|12|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 22:18:39.161856|2018-05-31 22:18:39.161856
NCT01404650|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2016-05-13||2016-08-10|2011-07-26|2011-07-28|Estimate|2016-08-10|2016-10-04|Estimate||||2016-08-10|2016-10-04|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor|A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor|Completed||Phase 2|25|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 22:18:39.555145|2018-05-31 22:18:39.555145
NCT01404637|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-07-30|2011-07-27|2011-07-28|Estimate|||||||2011-07-30|2011-08-02|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Interventional|||Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)|The Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic BPH|Unknown status|Not yet recruiting|N/A|150|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 22:18:40.152379|2018-05-31 22:18:40.152379
NCT01404624|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-07-27|2011-07-27|2011-07-28|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 2005||2005-01-31|July 2011|2011-07-31|December 2006|Actual|2006-12-31|||||Observational|||Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic Obesity|Increased Density of Ghrelin-Expressing Cells in the Gastric Fundus and Body in Prader-Willi Syndrome|Completed|||58|Actual|Samsung Medical Center|||||f||||t||||||||||2018-05-31 22:18:40.313052|2018-05-31 22:18:40.313052
NCT01404611|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|2015-07-23||2017-10-03|2011-07-27|2011-07-28|Estimate|2015-10-22|2015-11-23|Estimate||||2017-10-03|2017-10-04|Actual|June 2011||2011-06-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients|A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution Compared to DF289 Otic Solution and to DF277 Otic Solution in the Treatment of Acute Otitis Media With Tympanostomy Tubes (AOMT) in Pediatric Patients|Completed||Phase 3|331|Actual|Salvat||3|||f||||f||||||||||2018-05-31 22:18:40.506631|2018-05-31 22:18:40.506631
NCT01404598|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-08-10|2011-07-27|2011-07-28|Estimate|||||||2011-08-10|2011-08-11|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male|A Phase 1 Study to Assess the Pharmacokinetics of Nitrates and Gamma-Hydroxybutyric Acid (GHB) After Oral Administration of Therapeutic and Supratherapeutic Doses of Naproxcinod in Healthy Male Subjects|Completed||Phase 1|24|Actual|NicOx||3|||f||||f||||||||||2018-05-31 22:18:40.903662|2018-05-31 22:18:40.903662
NCT01404585|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27||2015-09-23|2015-09-23|2011-07-27|2011-07-28|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|RA||Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate|Completed||Phase 2|123|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-05-31 22:18:41.092468|2018-05-31 22:18:41.092468
NCT01404572|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|2013-03-13||2013-05-03|2011-07-27|2011-07-28|Estimate|2013-05-03|2013-06-10|Estimate||||2013-05-03|2013-06-10|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects|Randomized, Double Blind, Crossover Taste Assessment Study of Two Atazanavir Powder Formulations As Compared to a Reference Atazanavir Powder Formulation in Healthy Subjects|Completed||Phase 1|12|Actual|Bristol-Myers Squibb|This was a taste assessment only; participants did not swallow any treatment blends.|3|||f||||f||||||||||2018-05-31 22:18:41.342157|2018-05-31 22:18:41.342157
NCT01404559|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2014-11-17||2014-12-04|2011-07-26|2011-07-28|Estimate|2014-12-04|2014-12-15|Estimate||||2014-12-04|2014-12-15|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Measures of Gait Efficiency of Three Multi-Axial, Vertical Shock and Energy Storing-Return Prosthetic Feet During Simple & Complex Mobility Activities|Metabolic and Biomechanical Measures of Gait Efficiency of Three Multi-Axial, Vertical Shock and Energy Storing-Return Prosthetic Feet During Simple & Complex Mobility Activities|Completed||N/A|28|Actual|University of South Florida||4|||f||||t||||||||||2018-05-31 22:18:42.02612|2018-05-31 22:18:42.02612
NCT01404546|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-03-10|2011-07-26|2011-07-28|Estimate|||||||2015-03-10|2015-03-11|Estimate|August 2008||2008-08-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cost Free Pharmacotherapy for Smoking Cessation in Stroke Patients|A Randomized Controlled Pilot Study of Standardized Counselling and Cost-free Pharmacotherapy for Smoking Cessation Among Stroke and TIA Patients|Completed||N/A|28|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 22:18:42.339418|2018-05-31 22:18:42.339418
NCT01404533|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2016-01-05|2011-07-27|2011-07-28|Estimate|||||||2016-01-05|2016-01-06|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|NTBIwomen||Iron Interventions and Non-transferrin-bound Iron (NTBI) in Women|The Influence of Iron Interventions on Formation of Non-transferrin-bound Iron (NTBI) in Women|Completed||N/A|32|Actual|Swiss Federal Institute of Technology||3|||f||||f||||||||||2018-05-31 22:18:42.454961|2018-05-31 22:18:42.454961
NCT01404520|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2015-11-30|2011-07-27|2011-07-28|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|PACE-AL||Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL)|Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL) Health Promoting Rehabilitation. A Multimodal Exercise-based Intervention in Patients With Acute Leukaemia Undergoing Re-induction or Consolidation Chemotherapy|Completed||N/A|70|Actual|Universitetshospitalernes Center for Sygepleje||2|||f||||t||||||||||2018-05-31 22:18:42.625465|2018-05-31 22:18:42.625465
NCT01404507|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2013-01-14|2011-07-27|2011-07-28|Estimate|||||||2013-01-14|2013-01-16|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ICAT||Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI|Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in Patients With Acute ST-segment Elevation Myocardial Infarction; ICAT Trial|Completed||Phase 4|40|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 22:18:42.751772|2018-05-31 22:18:42.751772
NCT01404494|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2017-06-30|2011-07-27|2011-07-28|Estimate|||||||2017-06-30|2017-07-02|Actual|April 5, 2011||2011-04-05|February 6, 2015|2015-02-06|February 6, 2015||2015-02-06|||||Observational|||Testing Devices That Involve the Sense of Touch in Subjects With Traumatic Brain Injury|Testing Subjects With Traumatic Brain Injury Using Haptic Technology|Completed|||19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:18:42.974767|2018-05-31 22:18:42.974767
NCT01404481|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2015-07-22|2011-07-27|2011-07-28|Estimate|||||||2015-07-22|2015-07-24|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|SURE||Clean Intermittant Self Catheterisation: A Trial Comparing Single Use vs Reuse of Nelaton Catheters|Clean Intermittant Self Catheterisation: A Randomised Control Trial Comparing Single Use vs Reuse of Nelaton Catheters|Completed|||23|Actual|St George Hospital, Australia|||2||f||||f||||||||||2018-05-31 22:18:43.06621|2018-05-31 22:18:43.06621
NCT01404468|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-27|2011-07-27|2011-07-28|Estimate|||||||2011-07-27|2011-07-28|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|September 2008|Actual|2008-09-30||Interventional|||The Phonophoresis of Lidocaine Gel and Its Effect on Sensory Blockage|Effect of Lidocaine Phonophoresis on Sensory Blockade: Pulsed or Continuous Mode of Therapeutic Ultrasound?|Completed||Early Phase 1|93|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-05-31 22:18:43.17205|2018-05-31 22:18:43.17205
NCT01404455|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2012-01-16|2011-07-27|2011-07-28|Estimate|||||||2012-01-16|2012-01-18|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Wide Pulse Pressure on the Predictability of Stroke Volume Variation for Fluid Responsiveness in Patients Undergoing Off-pump Coronary Artery Bypass Graft||Completed||N/A|66|Actual|Severance Hospital||2|||f||||||||||||||2018-05-31 22:18:43.298661|2018-05-31 22:18:43.298661
NCT01404442|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-05-16|2011-07-27|2011-07-28|Estimate|||||||2012-05-16|2012-05-17|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Evaluation of the Analgesic Effect of Midazolam and Ketamine as an Additive to Intrathecal Bupivacaine in Patients Undergoing Cesarean Section||Completed||Phase 1/Phase 2|90|Actual|Qazvin University Of Medical Sciences||3|||f||||t||||||||||2018-05-31 22:18:43.40082|2018-05-31 22:18:43.40082
NCT01404429|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|2014-08-09||2014-09-05|2011-07-27|2011-07-28|Estimate|2014-08-25|2014-09-05|Estimate||||2014-09-05|2014-09-16|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|DMIRA||Study of Two Different Starting Doses of Methotrexate When Starting Treatment in Rheumatoid Arthritis|Randomized Controlled Trial of Two Different Starting Doses of Methotrexate in Rheumatoid Arthritis|Completed||Phase 4|100|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 22:18:43.582737|2018-05-31 22:18:43.582737
NCT01404416|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2015-06-04|2011-07-27|2011-07-28|Estimate|||||||2015-06-04|2015-06-08|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Effect of Antenatal Iron-contained Multiple Micronutrient Supplementation, Cesarean Delivery, and CDMR on Child Health|Effect of Antenatal Iron-contained Multiple Micronutrient Supplementation, Cesarean Delivery, and CDMR on Child Health- A Post-trial Follow-up Chinese Study|Completed|||17000|Actual|Peking University|||||f||||t||||||||||2018-05-31 22:18:43.979289|2018-05-31 22:18:43.979289
NCT01404403|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2013-11-04|2011-07-26|2011-07-28|Estimate|||||||2013-11-04|2013-11-05|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety Study of the Rapid System for Acute Ischemic Stroke||Completed||Phase 1|12|Actual|Rapid Medical||1|||f||||||||||||||2018-05-31 22:18:44.084156|2018-05-31 22:18:44.084156
NCT01404390|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2017-12-13|2011-07-27|2011-07-28|Estimate|||||||2017-12-13|2017-12-14|Actual|August 18, 2011|Actual|2011-08-18|December 2017|2017-12-31|July 12, 2012|Actual|2012-07-12|March 22, 2012|Actual|2012-03-22||Interventional|||Japanese BAY80-6946 Monotherapy Phase I Study|An Open Label, Single Centre, Phase I Study of PI3K Inhibitor BAY80-6946 to Evaluate the Safety, Tolerability and Pharmacokinetics in Japanese Patients With Advanced or Refractory Solid Tumours|Completed||Phase 1|10|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:18:44.206501|2018-05-31 22:18:44.206501
NCT01404377|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-07-27|2011-07-27|2011-07-28|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 2006||2006-01-31|May 2011|2011-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Wound Infiltration and Breast Cancer Surgery|Double Blind Randomized Trial of Wound Infiltration With Ropivacaine After Breast Cancer Surgery|Completed||Phase 4|50|Actual|Tenon Hospital, Paris||2|||f||||f||||||||||2018-05-31 22:18:44.317358|2018-05-31 22:18:44.317358
NCT01404364|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-27|2011-07-27|2011-07-28|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye|Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye|Completed||N/A|36|Actual|Hospital Governador Celso Ramos||2|||f||||f||||||||||2018-05-31 22:18:44.423551|2018-05-31 22:18:44.423551
NCT01404351|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-01-03|2011-07-27|2011-07-28|Estimate|||||||2013-01-03|2013-01-07|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction|A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade® 4.0 in Bilateral Breast Reduction|Withdrawn||N/A|0|Actual|Medtronic Surgical Technologies||2||Study terminated due to the acquisition of PEAK Surgical by Medtronic|f||||f||||||||||2018-05-31 22:18:44.557508|2018-05-31 22:18:44.557508
NCT01404338|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-27|2011-07-27|2011-07-28|Estimate|||||||2011-07-27|2011-07-28|Estimate|June 2011||2011-06-30|July 2011|2011-07-31||||||||Interventional|Tachyphylaxis||Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis|An Investigator-Initiated, Double-Blind, Vehicle-Controlled Study: Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis|Completed||Phase 1|10|Actual|Patel, Rita Vikram, M.D.||2|||f||||f||||||||||2018-05-31 22:18:44.660578|2018-05-31 22:18:44.660578
NCT01404325|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2017-04-20|2011-07-27|2011-07-28|Estimate|||||||2017-04-20|2017-04-21|Actual|February 1, 2012|Actual|2012-02-01|April 2017|2017-04-30|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|4EVERLUNG||Efficacy of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients|A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, MPA and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients|Completed||Phase 3|131|Actual|Novartis||2|||f||||t|f|f||||||Undecided|Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.|2018-05-31 22:18:44.754767|2018-05-31 22:18:44.754767
NCT01404312|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-12-01|2011-07-26|2011-07-28|Estimate|||||||2017-12-01|2017-12-04|Actual|May 2012|Actual|2012-05-31|December 2017|2017-12-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection|Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection|Completed||Phase 3|3000|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 22:18:44.90827|2018-05-31 22:18:44.90827
NCT01404299|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-27|||2012-01-10|2011-07-27|2011-07-28|Estimate|||||||2012-01-10|2012-01-12|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Effects of a Nutritional Supplementation on the Functional Status of Frail Elders With Low Socioeconomic Status (SES)|Effects of a Protein-Energy Nutritional Supplementation on the Functional Status of Frail Older Adults With Low Socioeconomic Status: A Community-based Randomized Trial|Completed||N/A|87|Actual|Gangbuk-gu Community Health Center||2|||f||||t||||||||||2018-05-31 22:18:45.088829|2018-05-31 22:18:45.088829
NCT01404273|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-07-29|2011-07-26|2011-07-28|Estimate|||||||2013-07-29|2013-07-31|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ADHD||Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder|Functional MRI of an Open Trial of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder|Completed||N/A|12|Actual|Massachusetts General Hospital||1|||f||||||||||||||2018-05-31 22:18:45.299271|2018-05-31 22:18:45.299271
NCT01404260|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|2016-08-09||2016-12-04|2011-07-27|2011-07-28|Estimate|2016-12-04|2017-01-27|Estimate||||2016-12-04|2017-01-27|Estimate|June 2011||2011-06-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|ISCAN||Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer|Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study|Completed||Phase 3|219|Actual|Guangdong Association of Clinical Trials||2|||f||||t||||||||Yes||2018-05-31 22:18:45.408072|2018-05-31 22:18:45.408072
NCT01404247|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-07-10|2011-07-27|2011-07-28|Estimate|||||||2017-07-10|2017-07-13|Actual|January 2011||2011-01-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|OCT||Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates|Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates|Completed||Phase 1|20|Actual|Los Angeles Biomedical Research Institute||1|||f||||t||||||||||2018-05-31 22:18:45.848223|2018-05-31 22:18:45.848223
NCT01404234|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|2014-03-31||2014-05-12|2011-07-27|2011-07-28|Estimate|2014-03-31|2014-05-01|Estimate||||2014-05-12|2014-05-29|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PALS|The safety analysis set included all participants who received at least 1 dose of study drug.|Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways|Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways|Completed||Phase 3|61|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 22:18:45.995081|2018-05-31 22:18:45.995081
NCT01404221|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-04-13|2011-07-26|2011-07-27|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Biochemical Markers and 2 and 3D Ultrasound to ID Maternal & Fetal Complications|The Combination of Biochemical Markers and Two and Three Dimensional Ultrasound Using Geometric Morphometrics in the Identification of Congenital Anomalies and Maternal or Fetal Complications|Terminated|||350|Actual|Northwell Health||||No safety issues. Need to rewrite protocol|f||||t||||||||||2018-05-31 22:18:46.69126|2018-05-31 22:18:46.69126
NCT01404208|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2016-09-30||2017-02-24|2011-07-26|2011-07-27|Estimate|2017-01-06|2017-02-27|Actual||||2017-02-24|2017-03-28|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional||206 subjects were initially enrolled at MGH and USF. Of those, 32 were considered screen fails and 32 were not randomized either because they did not meet inclusion or exclusion criteria at randomization or because they withdrew consent or dropped out. Thus, 142 participants were randomized.|2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD|2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD|Completed||N/A|206|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:18:46.813258|2018-05-31 22:18:46.813258
NCT01404195|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2016-02-04|2011-07-26|2011-07-27|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HIPERPROT||Hyperprotein Nutritional Intervention in Elderly Patients With Hip Fracture and Sarcopenia|High-protein Nutritional Intervention Based on β-hydroxy-β-methylbutirate, Vitamin D3 and Calcium on Obese and Lean Aged Patients With Hip Fractures and Sarcopenia. The HIPERPROT-GER Study.|Completed||N/A|110|Actual|Hospital Viamed Valvanera, Spain||2|||f||||t||||||||||2018-05-31 22:18:47.972534|2018-05-31 22:18:47.972534
NCT01404182|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2012-05-18|2011-07-26|2011-07-27|Estimate|||||||2012-05-18|2012-05-21|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons|Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine (Trivalent, Seasonal, Active Ingredient Content: 15 μg HA/Strain/0.5 mL) in Adults and Elderly Persons|Completed||Phase 4|121|Actual|Fluart Innovative Vaccine Ltd, Hungary||1|||f||||f||||||||||2018-05-31 22:18:48.835616|2018-05-31 22:18:48.835616
NCT01404169|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-03-07|2011-07-26|2011-07-27|Estimate|||||||2017-03-07|2017-03-08|Actual|September 2011|Actual|2011-09-30|March 2017|2017-03-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease|A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease|Completed||Phase 3|260|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:18:49.654521|2018-05-31 22:18:49.654521
NCT01404156|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-05-16|2011-07-26|2011-07-27|Estimate|||||||2018-05-16|2018-05-18|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|POWERRANGER||Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma|PreOperative Treatment With chEmotheRapy or chemoRAdiatioN in esophaGeal or gastroEsophageal adenocaRcinoma|Recruiting||Phase 2/Phase 3|60|Anticipated|CancerCare Manitoba||2|||f||||t||||||||||2018-05-31 22:18:50.013236|2018-05-31 22:18:50.013236
NCT01404143|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-03-29|2011-07-26|2011-07-27|Estimate|||||||2018-03-29|2018-03-30|Actual|August 2011||2011-08-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Comparison of Two Methods of Subscapularis Management in Shoulder Arthroplasty: Tenotomy Versus Peel|Comparison of Two Methods of Subscapularis Management in Shoulder Arthroplasty: Tenotomy Versus Peel: A Multicenter, Randomized Controlled|Completed||N/A|100|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||Undecided||2018-05-31 22:18:50.188954|2018-05-31 22:18:50.188954
NCT01404130|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory|A Pilot Study of the Effects of Isotretinoin on Cognition, Learning and Memory|Completed||Phase 4|18|Actual|University of Aberdeen||1|||f||||f||||||||||2018-05-31 22:18:50.412001|2018-05-31 22:18:50.412001
NCT01404117|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2013-08-26|2011-07-26|2011-07-27|Estimate|||||||2013-08-26|2013-08-27|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability||Withdrawn||Phase 2|0|Actual|Teva Pharmaceutical Industries||3||Study is being redesigned|f||||||||||||||2018-05-31 22:18:50.655801|2018-05-31 22:18:50.655801
NCT01404104|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-07-26|2011-07-26|2011-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma|A Pilot Study of Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy: Analysis if Serum and Tissue Biomarkers|Completed||N/A|11|Actual|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||||2018-05-31 22:18:50.919923|2018-05-31 22:18:50.919923
NCT01404091|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-02-01|2011-07-26|2011-07-27|Estimate|||||||2017-02-01|2017-02-03|Estimate|July 2011||2011-07-31|February 2017|2017-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects|Assessment of Nociceptin/Orphanin FQ Peptide Receptor Occupancy After Single Oral Doses of LY2940094 as Measured by Positron Emission Tomography With the Radioligand LY2959530 in Healthy Subjects|Completed||Phase 1|12|Actual|BlackThorn Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 22:18:51.157371|2018-05-31 22:18:51.157371
NCT01404078|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-24|2014-05-19||2014-11-26|2011-07-26|2011-07-27|Estimate|2014-11-26|2014-12-01|Estimate||||2014-11-26|2014-12-01|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|TIPSK||Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium|A RCT With Factorial Design to Compare Safety and Efficacy of 2 Capsules of the Indian Polycap Versus a Single Capsule Along With or Without Oral Potassium Among Patients With Stable Cardiovascular Disease|Completed||N/A|518|Actual|St. John's Research Institute||2|||f||||t||||||||||2018-05-31 22:18:51.257759|2018-05-31 22:18:51.257759
NCT01404065|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-03-17|2011-07-26|2011-07-27|Estimate|||||||2017-03-17|2017-03-21|Actual|December 2010||2010-12-31|March 2017|2017-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) and Visual Illusion on Chronic Pain Due to Spinal Cord Injury|Investigation of the Mechanisms of Transcranial Direct Current Stimulation of Motor Cortex Coupled With Visual Illusion for the Treatment of Chronic Pain in Spinal Cord Injury|Terminated||N/A|23|Actual|Spaulding Rehabilitation Hospital||3||Recruitment difficulties and stopped funding|f||||f||f||||||||2018-05-31 22:18:51.599692|2018-05-31 22:18:51.599692
NCT01404052|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-03-17|2011-07-26|2011-07-27|Estimate|||||||2017-03-17|2017-03-21|Actual|January 2011||2011-01-31|March 2017|2017-03-31|July 30, 2014|Actual|2014-07-30|July 30, 2014|Actual|2014-07-30||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound on Osteoarthritis Pain of the Knee|Effects of Transcranial Direct Current Stimulation and Transcranial Ultrasound on the Perception of Pain Due to Osteoarthritis of the Knee|Completed||N/A|38|Actual|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 22:18:51.734208|2018-05-31 22:18:51.734208
NCT01404039|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2015-04-07||2017-03-14|2011-07-26|2011-07-27|Estimate|2017-03-14|2017-03-16|Actual||||2017-03-14|2017-03-16|Actual|September 2010||2010-09-30|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Investigating Motor Cortex Processing for Pain Modulation|Investigating Motor Cortex Processing for Pain Modulation|Terminated||Phase 1|115|Actual|Spaulding Rehabilitation Hospital||13||Study was halted due to lack of funding.|f||||f||||||||||2018-05-31 22:18:51.993271|2018-05-31 22:18:51.993271
NCT01404026|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-03-17|2011-07-26|2011-07-27|Estimate|||||||2017-03-17|2017-03-21|Actual|June 2011||2011-06-30|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Due to Burn Injury|Cortical Modulation With Transcranial Direct Current Stimulation (tDCS) for Neuropathic Symptoms Following Burn Injury.|Completed||N/A|3|Actual|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 22:18:52.788649|2018-05-31 22:18:52.788649
NCT01404013|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-07-11|2011-07-26|2011-07-27|Estimate|||||||2014-07-11|2014-07-14|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma|Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Leukotriene Modulator Montelukast Alone or Combined With Inhaled Corticosteroid on Cough Variant Asthma|Unknown status|Recruiting|Phase 4|99|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||3|||f||||t||||||||||2018-05-31 22:18:53.10678|2018-05-31 22:18:53.10678
NCT01404000|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2013-11-14|2011-07-26|2011-07-27|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Iodinated Activated Charcoal|Phase II Study Exploring Efficacy and Safety of Iodinated Activated Charcoal in COPD|Completed||Phase 2|40|Actual|PharmaLundensis AB||2|||f||||t||||||||||2018-05-31 22:18:53.273901|2018-05-31 22:18:53.273901
NCT01403987|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|2012-07-09||2012-09-30|2011-07-26|2011-07-27|Estimate|2012-09-30|2012-10-31|Estimate||||2012-09-30|2012-10-31|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Improving Performance of Paracentesis in Medical Residency Training|Improving Performance of Paracentesis in Medical Residency Training|Completed||N/A|136|Actual|Boston Medical Center|Large number of participants lost to analysis because they forgot their secret personal ID number. The IRB had required we not have a way to link surveys to particular residents, and so lost power with loss of many residents.|3|||f||||f||||||||||2018-05-31 22:18:53.407255|2018-05-31 22:18:53.407255
NCT01403974|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-01-06|2011-07-26|2011-07-27|Estimate|||||||2016-01-06|2016-01-08|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Phase I Trial of BI 836845 for Various Solid Cancer|A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit|Completed||Phase 1|61|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:18:54.009341|2018-05-31 22:18:54.009341
NCT01403961|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-11-09|2011-07-26|2011-07-27|Estimate|||||||2016-11-09|2016-11-10|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|HbA1c||Hemoglobin A1c and Immediate Postsurgical Complications Diabetes Type 2|Hemoglobin A1c and Immediate Postsurgical Complications Diabetes Type 2 (HbA1c)|Recruiting|||1760|Anticipated|Hospital Italiano de Buenos Aires|||2||f||||t||||||||No||2018-05-31 22:18:54.170795|2018-05-31 22:18:54.170795
NCT01403948|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2018-03-23|2011-07-26|2011-07-27|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 1, 2011|Actual|2011-08-01|March 2018|2018-03-31|January 3, 2018|Actual|2018-01-03|November 14, 2017|Actual|2017-11-14||Interventional|||BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)|A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin|Completed||Phase 1|48|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:18:54.312095|2018-05-31 22:18:54.312095
NCT01403922|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2012-10-01|2011-07-26|2011-07-27|Estimate|||||||2012-10-01|2012-10-02|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension|A Phase I Randomised, Placebo-Controlled, Double-Blind Study in Hypertensive Patients of the Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors)|Terminated||Phase 1|80|Actual|AstraZeneca||4||Sponsor's decision to terminate|f||||||||||||||2018-05-31 22:18:55.567094|2018-05-31 22:18:55.567094
NCT01403909|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-03-24|2011-07-26|2011-07-27|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Effect of Pneumatic Intermittent Venous Compression on Fluid Volumes Infused During Major Abdominal Surgery|Effect of Pneumatic Intermittent Venous Compression on Fluid Volumes Infused During Major Abdominal Surgery in Non-obese American Soceity of Anesthesiologists (ASA) 1-3 Patients|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nīmes||2||We need somebody to replace the principal inestigator.|f||||t||||||||||2018-05-31 22:18:55.693331|2018-05-31 22:18:55.693331
NCT01403896|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-07-31|2011-07-26|2011-07-27|Estimate|||||||2017-07-31|2017-08-02|Actual|April 2012|Actual|2012-04-30|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor|A Pilot Study To Design a Clinical Trial That Will Compare the Ability of Plerixafor Alone Versus Plerixafor Plus G-CSF To Generate a Bone Marrow Versus Blood Transplant Product In Normal Healthy Adults|Completed||Phase 2|10|Actual|Nova Scotia Health Authority||2|||f||||f|f|f||||||||2018-05-31 22:18:55.785442|2018-05-31 22:18:55.785442
NCT01403883|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2015-01-15|2011-07-26|2011-07-27|Estimate|||||||2015-01-15|2015-01-16|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|PROSPER||Psychological and Enterostomal Therapy Care|Impact of Psychological and Enterostomal Therapy Care for Patient Undergoing Rectal Cancer Resection With a Temporary Stoma. Monocentric Randomized Study|Unknown status|Recruiting|N/A|50|Anticipated|Association de Recherche Experimentale et Clinique en Chirurgie Digestive||2|||f||||f||||||||||2018-05-31 22:18:55.886525|2018-05-31 22:18:55.886525
NCT01403870|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-11-17|2011-07-26|2011-07-27|Estimate|||||||2011-11-17|2011-11-18|Estimate|April 2011||2011-04-30|November 2011|2011-11-30||||||||Observational|||Post Market Study of the Electrophysiological Course of Low Back Pain Using CERSR Technology|Post Market Study of the Electrophysiological Course of Low Back Pain Using CERSR Technology|Terminated|||6|Actual|Verium Diagnostics, Inc.|||1|Company no longer has funding for the study.|f||||f||||||||||2018-05-31 22:18:55.976751|2018-05-31 22:18:55.976751
NCT01403857|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2014-04-21|2011-07-25|2011-07-27|Estimate|||||||2014-04-21|2014-04-22|Estimate|April 2010||2010-04-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|FL75||Evaluating Liking, Acceptability and Health Benefits of Grain Products|Evaluating Liking, Acceptability and Health Benefits of Grain Products|Completed||N/A|45|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:18:56.11597|2018-05-31 22:18:56.11597
NCT01403844|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2017-09-22|2011-07-26|2011-07-27|Estimate|||||||2017-09-22|2017-09-26|Actual|June 2011|Actual|2011-06-30|September 2017|2017-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Carotenoid Response to the Intake of Vegetables and Fruits|Skin Carotenoid Response to Intake of Vegetables and Fruits Recommended by the Dietary Guidelines|Completed||N/A|29|Actual|USDA Grand Forks Human Nutrition Research Center||1|||f||||t||||||||No||2018-05-31 22:18:56.336529|2018-05-31 22:18:56.336529
NCT01403831|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-06-18|2011-07-26|2011-07-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|TExT-MED||Trial to Examine Text-message Based mHealth in Emergency Department Patients With Diabetes|Trial to Examine Text-message Based mHealth in Emergency Department Patients With Diabetes|Completed||N/A|200|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 22:18:56.458627|2018-05-31 22:18:56.458627
NCT01403818|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-10-10|2011-07-26|2011-07-27|Estimate|||||||2011-10-10|2011-10-12|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration|Pharmacokinetic Study of ASP1941 -A Pharmacokinetic Study to Assess Drug-Drug Interaction Between ASP1941 and Mitiglinide Calcium Hydrate|Completed||Phase 1|60|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:18:56.601525|2018-05-31 22:18:56.601525
NCT01403805|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2011-08-02||2012-04-29|2011-07-26|2011-07-27|Estimate|2012-04-29|2012-05-01|Estimate||||2012-04-29|2012-05-01|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist|The Interventional Study in the Effects of Oral Care With Vaccines at Nursing Home; the Role of the Partnership With Physician, Dentist and Other Co-medical Stuff|Completed||N/A|199|Actual|Yubari Kibounomori|small numbers of subjects analyzed|2|||f||||t||||||||||2018-05-31 22:18:56.751596|2018-05-31 22:18:56.751596
NCT01403792|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-12-21|2011-07-26|2011-07-27|Estimate|||||||2011-12-21|2011-12-22|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects|A Double-Blind, Placebo-Controlled, Randomised, Dose-Escalation Phase I Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects|Completed||Phase 1|11|Actual|University of Surrey||4|||f||||f||||||||||2018-05-31 22:18:57.3586|2018-05-31 22:18:57.3586
NCT01403779|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2015-12-29|2011-07-26|2011-07-27|Estimate|||||||2015-12-29|2015-12-30|Estimate|July 2010||2010-07-31|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Interventional|KOSIMA||Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated IMRT in Treatment of Breast Cancer|Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated Intensity Modulated Radiotherapy (IMRT) in Treatment of Breast Cancer: The KOSIMA Trial|Unknown status|Recruiting|Phase 3|226|Anticipated|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 22:18:57.519592|2018-05-31 22:18:57.519592
NCT01403766|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Comparison of Markers of Kidney Function|Comparison of Estimated GFR Using Cystatin C Versus Creatinine in Pediatric Renal Transplant Patients|Unknown status|Not yet recruiting||70|Anticipated|University of California, Los Angeles|||1||f||||f||||||||||2018-05-31 22:18:57.685994|2018-05-31 22:18:57.685994
NCT01403753|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-08-12|2011-07-26|2011-07-27|Estimate|||||||2011-08-12|2011-08-15|Estimate|August 2008||2008-08-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Children's Familiarity With Snack Foods Changes Expectations About Fullness|Children's Familiarity With Snack Foods Changes Expectations About Fullness|Completed|||70|Actual|University of Bristol|||1||f||||f||||||||||2018-05-31 22:18:57.818804|2018-05-31 22:18:57.818804
NCT01403740|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|EHEM||Turkish Acquired Haemophilia Registry|Observational Acquired Haemophilia Registry|Unknown status|Not yet recruiting||250|Anticipated|Turkish Society of Hematology|||1||f||||f||||||Samples Without DNA|"~     Blood sample for coagulation factor determination~   "|||2018-05-31 22:18:57.914564|2018-05-31 22:18:57.914564
NCT01403727|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2013-05-28|2011-07-26|2011-07-27|Estimate|||||||2013-05-28|2013-05-29|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Observational|||Electromagnetic Tracking of Devices During Biopsy Procedures|Electromagnetic Tracking of Devices During Biopsy Procedures|Completed|||50|Actual|Philips Healthcare|||2||f||||f||||||||||2018-05-31 22:18:58.246508|2018-05-31 22:18:58.246508
NCT01403714|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-03-29|2011-07-25|2011-07-27|Estimate|||||||2012-03-29|2012-04-02|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|STRETCH||Study of Percutaneous Renal Artery Intervention for Patient With Heart Failure|A Randomized Trial of Percutaneous Renal Intervention With Stenting for Patients With Heart Failure and Hemodynamically Significant Renal Artery Stenosis|Withdrawn||N/A|0|Actual|University of Pennsylvania||2||Inability to recruit eligible subjects|f||||f||||||||||2018-05-31 22:18:58.458953|2018-05-31 22:18:58.458953
NCT01403701|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-02-17|2011-07-26|2011-07-27|Estimate|||||||2014-02-17|2014-02-19|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|PT and QOL||Physical Therapy on Quality of Life and Function Following Vaginal Surgery Reconstructive Surgery|Effects of Physical Therapy on Quality of Life and Function Following Vaginal Reconstructive Surgery; a Randomized Trial|Completed||N/A|49|Actual|TriHealth Inc.||2|||f||||f||||||||||2018-05-31 22:18:58.575043|2018-05-31 22:18:58.575043
NCT01403688|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2014-09-16|2011-07-25|2011-07-27|Estimate|||||||2014-09-16|2014-09-17|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin|Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin in Women at High Risk for Breast Cancer|Completed|||9|Actual|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 22:18:58.811865|2018-05-31 22:18:58.811865
NCT01403675|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2014-12-02|2011-07-25|2011-07-27|Estimate|||||||2014-12-02|2014-12-04|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Human Ovarian Autotransplantation|Human Ovarian Autotransplantation Using Cryopreserved Ovarian Tissue in Women Treated for Cancer|Completed||N/A|1|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 22:18:58.923628|2018-05-31 22:18:58.923628
NCT01403662|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-12-15|2011-07-25|2011-07-27|Estimate|||||||2016-12-15|2016-12-19|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression|A Pilot, Open-label, 8-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Minocycline for the Treatment of Bipolar Depression|Completed||Phase 3|29|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 22:18:59.031228|2018-05-31 22:18:59.031228
NCT01403649|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-05-29|2011-07-25|2011-07-27|Estimate|||||||2015-05-29|2015-06-02|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|CollabFlu||Collaborative Efforts to Increase Flu Vaccination|Strategies to Vaccinate All Children for Influenza in a Practice Setting|Completed||N/A|117175|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:18:59.174827|2018-05-31 22:18:59.174827
NCT01403636|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26||2016-02-17|2016-02-17|2011-07-26|2011-07-27|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia|A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma|Completed||Phase 2|167|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 22:18:59.333257|2018-05-31 22:18:59.333257
NCT01403623|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-08-19|2011-07-26|2011-07-27|Estimate|||||||2013-08-19|2013-08-21|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates|A Randomized Trial to Evaluate the Use of Plastic Bags in Preventing and Treating Hypothermia in Neonates in Developing Countries|Completed||Phase 4|106|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 22:18:59.490463|2018-05-31 22:18:59.490463
NCT01403610|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22||2017-01-24|2017-01-24|2011-07-25|2011-07-27|Estimate||||2017-01-24|2017-01-25|Estimate|2017-01-24|2017-01-25|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab|A Phase 2, Investigator Initiated Study to Determine the Safety, Efficacy and CNS Penetration of TH-302 in Recurrent High Grade Astrocytoma Following Bevacizumab|Completed||Phase 2|29|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||f||||||||||2018-05-31 22:18:59.613568|2018-05-31 22:18:59.613568
NCT01403597|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-11-28|2011-07-26|2011-07-27|Estimate|||||||2014-11-28|2014-12-02|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Evaluation of Non-ablative and Fractional Combination Treatment for Improvement in Skin's Appearance|Clinical Evaluation of the Impact of Non-ablative and Fractional Ablative Combination Treatment: a Prospective, Open Label, Single Group With Before-after Study Design|Completed||N/A|9|Actual|Syneron Medical||1|||f||||f||||||||||2018-05-31 22:18:59.781047|2018-05-31 22:18:59.781047
NCT01403584|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-08-04|2011-07-26|2011-07-27|Estimate|||||||2015-08-04|2015-08-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:18:59.88029|2018-05-31 22:18:59.88029
NCT01403571|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-10-04|2011-07-25|2011-07-27|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|LOSS||Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes|Efficacy and Safety of Whole Grain Salba (Salvia Hispanica L.) on Weight Loss in Overweight and Obese Individuals With Type 2 Diabetes|Completed||Phase 2|77|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 22:18:59.938772|2018-05-31 22:18:59.938772
NCT01403558|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2017-05-09|2011-07-26|2011-07-27|Estimate|||||||2017-05-09|2017-05-10|Actual|September 2011||2011-09-30|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|PSYMO||Personality and Eating Behaviors in Morbidly Obese Patients|Personality and Eating Behaviors in Morbidly Obese Patients|Active, not recruiting||N/A|102|Actual|Sykehuset i Vestfold HF||3|||f||||f||||||||||2018-05-31 22:19:00.046401|2018-05-31 22:19:00.046401
NCT01403545|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-05-23|2011-07-26|2011-07-27|Estimate|||||||2014-05-23|2014-05-26|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Liposomal Curcumin in Healthy Volunteers|Safety, Tolerability and Pharmacokinetics of Liposomal Curcumin in Healthy Volunteers - A Phase I Dose Escalation Study|Completed||Phase 1|50|Actual|SignPath Pharma, Inc.||2|||f||||t||||||||||2018-05-31 22:19:00.164734|2018-05-31 22:19:00.164734
NCT01403532|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2014-02-10|2011-07-26|2011-07-27|Estimate|||||||2014-02-10|2014-02-11|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Sequential Therapy for Hypogonadotropic Hypogonadism|Efficacy and Safety of Human Chorionic Gonadotropin (HCG) and Follicle Stimulating Hormone (FSH) in the Treatment of Hypogonadotropic Hypogonadism|Completed||Phase 4|100|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||||2018-05-31 22:19:00.306524|2018-05-31 22:19:00.306524
NCT01403519|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized|Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized|Unknown status|Not yet recruiting||70|Anticipated|Rambam Health Care Campus|||3||f||||f||||||Samples Without DNA|"~     Blood and CSF~   "|||2018-05-31 22:19:00.45544|2018-05-31 22:19:00.45544
NCT01403506|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|November 2012|Anticipated|2012-11-30|April 2012|Anticipated|2012-04-30||Interventional|||Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL)|Phase 3 Study of N-acetyl Cysteine as an Antioxidant and Glutathione Synthesis Inducer on Biomarkers of Delayed Renal Graft Function Including NGAL and IL-18|Unknown status|Recruiting|Phase 3|60|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:19:00.644523|2018-05-31 22:19:00.644523
NCT01403493|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-08-09|2011-07-26|2011-07-27|Estimate|||||||2011-08-09|2011-08-11|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Multidisciplinary Versus a Nurse Based Patient Education For Patients With Irritable Bowel Syndrome|A Comparison of a Short Nurse Based and a Long Multidisciplinary Version of Structured Patient Education in Irritable Bowel Syndrome.|Completed||N/A|80|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 22:19:00.776209|2018-05-31 22:19:00.776209
NCT01403480|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|January 2008||2008-01-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Rates of Positive Basal Cell Carcinomas (BCCs) in Re-excisions|Rates of Positive BCCs in Re-excisions|Completed|||600|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 22:19:00.904468|2018-05-31 22:19:00.904468
NCT01403467|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation|Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation|Completed||Phase 4|86|Actual|Ramathibodi Hospital||1|||f||||t||||||||||2018-05-31 22:19:00.99872|2018-05-31 22:19:00.99872
NCT01403454|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2016-04-18|2011-07-26|2011-07-27|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|WISHED||Web-based Interactive Health Communication Application (IHCA) for Successful Home Dialysis|Web-based IHCA for Successful Home Dialysis|Unknown status|Recruiting|N/A|152|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||t||||||||||2018-05-31 22:19:01.228101|2018-05-31 22:19:01.228101
NCT01403441|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2016-10-10||2017-08-03|2011-07-26|2011-07-27|Estimate|2017-08-03|2017-09-05|Actual||||2017-08-03|2017-09-05|Actual|July 2010||2010-07-31|August 2017|2017-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Treatment Resistant Depression|Radiosurgical Neuromodulation for Refractory Depression|Radiosurgical Neuromodulation for Refractory Depression|Terminated||N/A|3|Actual|Stanford University||1||Potential AE|f||||t||||||||Undecided||2018-05-31 22:19:01.412453|2018-05-31 22:19:01.412453
NCT01403428|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-12-11|2011-07-25|2011-07-27|Estimate|||||||2014-12-11|2014-12-12|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Non Invasive Positive Pressure Ventilation in Status Asthmaticus|Effect Of Early Initiation Of Noninvasive Positive Pressure Ventilation On ICU Length Of Stay In Children With Status Asthmaticus, A Prospective Randomized Trial|Withdrawn||Phase 2|0|Actual|Southern Illinois University||2||"In a pilot of early noninvasive positive pressure ventilation, the children did so well that~   early NPPV is now used in all children who meet criteria."|f||||t||||||||||2018-05-31 22:19:01.71321|2018-05-31 22:19:01.71321
NCT01403415|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-07-09|2011-07-26|2011-07-27|Estimate|||||||2015-07-09|2015-07-10|Estimate|September 2011||2011-09-30|March 2015|2015-03-31||||May 2015|Actual|2015-05-31||Interventional|||Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma|A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma|Completed||Phase 1|13|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:19:01.936142|2018-05-31 22:19:01.936142
NCT01403402|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2017-05-05|2011-07-26|2011-07-27|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2009||2009-09-30|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30|10 Years|Observational [Patient Registry]|CMDPROS||Congenital Muscle Disease Study of Patient and Family Reported Medical Information|Congenital Muscle Disease Patient and Proxy Reported Outcome Study|Recruiting|||1000|Anticipated|Cure CMD|||1||f||||f||||||||||2018-05-31 22:19:02.28691|2018-05-31 22:19:02.28691
NCT01403389|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-01-25|2011-07-25|2011-07-27|Estimate|||||||2013-01-25|2013-01-28|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|||A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant|Pilot Study of the Clinical Activity of Eculizumab for Prevention of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation|Unknown status|Recruiting|Phase 2|20|Anticipated|Schroppel, Bernd, M.D.||2|||f||||t||||||||||2018-05-31 22:19:02.484279|2018-05-31 22:19:02.484279
NCT01403376|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2013-01-22||2016-01-21|2011-07-26|2011-07-27|Estimate|2013-01-22|2013-02-26|Estimate||||2016-01-21|2016-02-18|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|TERIVA||Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide|Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide Treatment and Using a Population of Patients With Multiple Sclerosis as a Reference|Completed||Phase 2|128|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 22:19:02.710154|2018-05-31 22:19:02.710154
NCT01403363|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-06-14|2011-07-26|2011-07-27|Estimate|||||||2015-06-14|2015-06-16|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Use of Fentanyl Patch in Partial Doses Than the Original|Use of Fentanyl Patch in Partial Doses Than the Original|Unknown status|Active, not recruiting|N/A|95|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:19:03.447871|2018-05-31 22:19:03.447871
NCT01403350|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-02-06|2011-07-26|2011-07-27|Estimate|||||||2014-02-06|2014-02-07|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan|Effectiveness of Community Level Deployment of Rapid Diagnostic Tests for Malaria in Afghanistan: Cluster Randomised Trial|Completed||Phase 4|2421|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 22:19:03.54019|2018-05-31 22:19:03.54019
NCT01403337|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-03-14|2011-07-26|2011-07-27|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|CRIPES||Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery|Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery (CRIPES)|Completed||Phase 1/Phase 2|205|Actual|Minnesota Veterans Medical Research and Education Foundation||2|||f||||t||||||||||2018-05-31 22:19:03.653156|2018-05-31 22:19:03.653156
NCT01403324|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2016-07-12|2011-07-26|2011-07-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|DOSIMETA||Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer|Comparison of Dosimetry Following Preparation With Either rhTSH or After Withdrawal of Thyroid Hormone Suppression Therapy in Patients With Metastatic or Locally Advanced Differentiated Thyroid Cancer|Terminated||N/A|4|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1||Recruitment difficulties|f||||f||||||||||2018-05-31 22:19:03.782341|2018-05-31 22:19:03.782341
NCT01403311|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-03-24|2011-07-26|2011-07-27|Estimate|||||||2014-03-24|2014-03-26|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2015|Anticipated|2015-03-31|December 2011|Actual|2011-12-31||Interventional|ALA||A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|Unknown status|Active, not recruiting|Phase 2|18|Anticipated|Legacy Health System||1|||f||||||||||||||2018-05-31 22:19:03.990802|2018-05-31 22:19:03.990802
NCT01403298|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2017-07-03|2011-07-26|2011-07-27|Estimate|||||||2017-07-03|2017-07-06|Actual|December 2009||2009-12-31|July 2017|2017-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Project RAP||Project RAP: Family-based HIV Prevention in the Juvenile Drug Court|Project RAP: Family-based HIV Prevention in the Juvenile Drug Court|Completed||N/A|120|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:19:04.114268|2018-05-31 22:19:04.114268
NCT01403285|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-05-16|2011-07-26|2011-07-27|Estimate|||||||2014-05-16|2014-05-19|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma|A Phase 1 Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM)|Terminated||Phase 1|6|Actual|immatics Biotechnologies GmbH||||"Due to poor accrual. This decision was taken without any safety reasons. Since beginning of the~   study (June 2011) only six patients were enrolled."|f||||t||||||||||2018-05-31 22:19:04.375781|2018-05-31 22:19:04.375781
NCT01403272|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-07-26|2011-07-26|2011-07-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting|Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting|Completed||N/A|75|Anticipated|Precision Fabrics Group, Inc.||1|||f||||f||||||||||2018-05-31 22:19:05.320301|2018-05-31 22:19:05.320301
NCT01403259|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-08-19|2011-07-26|2011-07-27|Estimate|||||||2014-08-19|2014-08-20|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||SOX as Salvage Treatment in Nasopharyngeal Carcinoma|Phase II Study of SOX in Patients With Platinum-resistant Nasopharyngeal Carcinoma|Terminated||Phase 2|16|Actual|Fudan University||1||poor accrual of eligible patients|f||||f||||||||||2018-05-31 22:19:05.915728|2018-05-31 22:19:05.915728
NCT01403246|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2015-01-27|2011-07-26|2011-07-27|Estimate|||||||2015-01-27|2015-01-28|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)|Phase I-II Multicenter Study to Assess the Efficacy and Safety of the Chlorambucil + Lenalidomide Combination and Lenalidomide Maintenance Therapy in Untreated Elderly Pts With CLL. EudraCT Number 2009-013415-35|Completed||Phase 1/Phase 2|9|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-05-31 22:19:06.021299|2018-05-31 22:19:06.021299
NCT01403233|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-06-13|2011-07-26|2011-07-27|Estimate|||||||2012-06-13|2012-06-14|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|StevReb-PK||Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects|An Open-label, Sequential Supplementation Study Comparing the Bioavailability of Two Doses of cogniVida™ With One Dose of Rebaudioside A in Healthy Male Subjects|Completed||Phase 1|10|Actual|DSM Nutritional Products, Inc.||3|||f||||f||||||||||2018-05-31 22:19:06.279387|2018-05-31 22:19:06.279387
NCT01403220|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-03-26|2011-07-26|2011-07-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Efficacity of Hemodiafiltration Versus Hemofiltration for Renal Insufficiency During Intensive Care|The Efficacity of Hemodiafiltration Versus Hemofiltration for Renal Insufficiency During Intensive Care: a Randomized, Open, Cross-over Study|Completed||N/A|163|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 22:19:06.449537|2018-05-31 22:19:06.449537
NCT01403207|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-03-12|2011-07-25|2011-07-27|Estimate|||||||2014-03-12|2014-03-14|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Observational|||An Analysis of Potential Sex Differences in Knee Osteoarthritis|An Analysis of Potential Sex Differences in Knee Osteoarthritis|Completed|||20|Actual|Mayo Clinic|||1||f||||t||||||||||2018-05-31 22:19:06.553068|2018-05-31 22:19:06.553068
NCT01403194|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2014-04-14||2014-04-14|2011-07-25|2011-07-27|Estimate|2014-04-14|2014-05-13|Estimate||||2014-04-14|2014-05-13|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Continuous Positive Airway Pressure and Cardiometabolic Risk|Impact of Treatment of Sleep Disordered Breathing With Continuous Positive Airway Pressure (CPAP) on Cardiometabolic Risk Markers|Terminated||N/A|11|Actual|Mayo Clinic|Analysis was not done because only 1 subject was able to come back for the 3 month follow up visit.|1||"Analysis was not done because only 1 subject was able to come back for the 3 month follow up~   visit."|f||||f||||||||||2018-05-31 22:19:06.681873|2018-05-31 22:19:06.681873
NCT01403181|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2013-11-05|2011-07-26|2011-07-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|April 2012||2012-04-30|November 2013|2013-11-30||||October 2013|Actual|2013-10-31||Observational|Boce-Par||Effect of Boceprevir on HCV-specific T Cell Responses|Effect of Boceprevir Therapy on HCV-specific T Cell Responses: Perspectives of Immune Monitoring and Immune Therapy|Completed|||30|Actual|Azienda Ospedaliero-Universitaria di Parma|||1||f||||t||||||Samples With DNA|"~     Sera and peripheral blood lymphomononuclear cells~   "|||2018-05-31 22:19:07.065002|2018-05-31 22:19:07.065002
NCT01403168|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-06-26|2011-07-26|2011-07-27|Estimate|||||||2015-06-26|2015-06-29|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|OSTEOPATHIE||Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology|Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology|Terminated||N/A|28|Actual|Centre Leon Berard||2||Recruitment difficulties|f||||f||||||||||2018-05-31 22:19:07.217087|2018-05-31 22:19:07.217087
NCT01403155|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2017-09-11|2011-07-26|2011-07-27|Estimate|||||||2017-09-11|2017-09-13|Actual|May 2011||2011-05-31|September 2017|2017-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001|PHASE I, OPEN-LABEL, SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF AN H5 INFLUENZA PLASMID VACCINE (INO-3401) IN HEALTHY ADULTS PREVIOUSLY VACCINATED WITH VGX-3400X|Completed||Phase 1|22|Actual|Inovio Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:19:07.414788|2018-05-31 22:19:07.414788
NCT01403142|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2017-08-30|2011-07-26|2011-07-27|Estimate|||||||2017-08-30|2017-08-31|Actual|August 18, 2011|Actual|2011-08-18|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|OCTCAV||Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant|Optical Coherence Tomography to Evaluate Cardiac Allograft Vasculopathy in Patients Undergoing Clinically Indicated Angiographies Post Heart Transplant|Completed|||60|Actual|Columbia University|||||f||||f|f|f||||||No||2018-05-31 22:19:07.553737|2018-05-31 22:19:07.553737
NCT01403129|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-05-17|2011-07-26|2011-07-27|Estimate|||||||2016-05-17|2016-05-18|Estimate|December 2010||2010-12-31|May 2016|2016-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Keratoconus Detection by Ultrasound|Early Detection of Keratoconus Using Ultrasound|Enrolling by invitation|||1000|Anticipated|Columbia University|||3||f||||f||||||||||2018-05-31 22:19:07.798405|2018-05-31 22:19:07.798405
NCT01403116|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-12-17|2011-07-25|2011-07-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men|Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men|Completed||Phase 3|325|Actual|Clarus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 22:19:07.939357|2018-05-31 22:19:07.939357
NCT01403103|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-01-16|2011-07-25|2011-07-27|Estimate|||||||2014-01-16|2014-01-17|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer|Evaluation of the Effect of 25-OH-Vitamin D3 Therapy on 15-Prostaglandin Dehydrogenase Expression in Primary Tumor and Normal Colorectal Mucosa in Patients With Colorectal Cancer|Withdrawn||Early Phase 1|0|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||t||||||||||2018-05-31 22:19:08.074811|2018-05-31 22:19:08.074811
NCT01403090|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2012-08-15||2013-04-10|2011-07-26|2011-07-27|Estimate|2013-04-10|2013-05-20|Estimate||||2013-04-10|2013-05-20|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism|A Single Treatment, Open Label, Multicenter, Safety Study of the Angel™ Catheter in Hospitalized Human Subjects With a Temporary Risk of Pulmonary Embolism|Completed||Phase 1|8|Actual|BiO2 Medical||1|||f||||t||||||||||2018-05-31 22:19:08.211503|2018-05-31 22:19:08.211503
NCT01403077|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-02-09|2011-07-26|2011-07-27|Estimate|||||||2016-02-09|2016-02-10|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|March 2014|Actual|2014-03-31||Interventional|STANCE||480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions|A Safety Assessment of the 480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo SFA Lesions|Completed||N/A|46|Actual|480 Biomedical, Inc.||1|||f||||t||||||||||2018-05-31 22:19:08.446554|2018-05-31 22:19:08.446554
NCT01403064|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25||2014-06-23|2018-04-20|2011-07-25|2011-07-27|Estimate||||2014-06-23|2014-06-25|Estimate|2018-04-20|2018-04-24|Actual|July 2011||2011-07-31|April 2018|2018-04-30|March 2014|Actual|2014-03-31|April 2013|Actual|2013-04-30||Interventional|||Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy|Terminated||Phase 2|81|Actual|Vitaeris INC||4||due to lack of efficacy|f||||t||||||||||2018-05-31 22:19:08.551797|2018-05-31 22:19:08.551797
NCT01403051|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2014-02-05||2015-12-22|2011-07-25|2011-07-27|Estimate|2014-02-05|2014-03-19|Estimate||||2015-12-22|2016-01-28|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Includes only subjects who did not have eligibility violations|High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART|A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 2|167|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 22:19:08.785552|2018-05-31 22:19:08.785552
NCT01403038|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-01-04|2011-07-25|2011-07-27|Estimate|||||||2013-01-04|2013-01-08|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females|A Phase 1, Open-Label Study of the Effects of Elagolix on Ovarian Activity, Ovulation and Ovarian Reserve in Premenopausal Females|Completed||Phase 1|216|Actual|AbbVie||7|||f||||f||||||||||2018-05-31 22:19:09.618982|2018-05-31 22:19:09.618982
NCT01403025|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2018-02-09|2011-07-26|2011-07-27|Estimate|||||||2018-02-09|2018-02-12|Actual|July 19, 2011|Actual|2011-07-19|February 2018|2018-02-28|December 28, 2015|Actual|2015-12-28|December 28, 2015|Actual|2015-12-28||Observational|||Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes|A Multi-centre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Victoza® in Subjects With Type 2 Diabetes Mellitus|Completed|||4121|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:19:09.77266|2018-05-31 22:19:09.77266
NCT01403012|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-03-16|2011-07-26|2011-07-27|Estimate|||||||2016-03-16|2016-03-17|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Observational|Bostrip||BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis|Differential Analysis of Metabolomic Profiles in Patients With Chronic Plaque Psoriasis Undergoing Systemic Treatment|Terminated|||34|Actual|Technische Universität München|||||f||||f||||||Samples With DNA|"~     Psoriasis patients~   "|||2018-05-31 22:19:09.875238|2018-05-31 22:19:09.875238
NCT01402999|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2017-12-22|2011-07-26|2011-07-27|Estimate|||||||2017-12-22|2017-12-26|Actual|May 31, 2012|Actual|2012-05-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS HUN||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Hungary|Completed|||83|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:19:09.977619|2018-05-31 22:19:09.977619
NCT01402986|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2016-05-31||2017-03-03|2011-07-26|2011-07-27|Estimate|2017-01-10|2017-03-06|Actual||||2017-03-03|2017-04-04|Actual|August 2011||2011-08-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Interventional||The intention-to-treat (ITT) population included all participants who were randomized into the study.|A Safety and Efficacy Study of Tralokinumab in Adults With Asthma|A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma|Completed||Phase 2|689|Actual|MedImmune LLC||4|||f||||f||||||||||2018-05-31 22:19:10.166105|2018-05-31 22:19:10.166105
NCT01402973|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-11-22|2011-07-25|2011-07-26|Estimate|||||||2011-11-22|2011-11-23|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pilot Study of a Dietary Intervention Based Upon Advanced Glycation End Products||Completed||N/A|24|Anticipated|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:19:17.163201|2018-05-31 22:19:17.163201
NCT01402960|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-03-17|2011-07-25|2011-07-26|Estimate|||||||2017-03-17|2017-03-21|Actual|April 2011||2011-04-30|March 2017|2017-03-31|February 13, 2013|Actual|2013-02-13|February 2012|Actual|2012-02-29||Interventional|||Exploration of Parameters of Transcranial Direct Current Stimulation (tDCS) in Chronic Pain|Exploration of Parameters of tDCS in Chronic Pain Patients|Completed||N/A|18|Actual|Spaulding Rehabilitation Hospital||3|||f||||f||f||||||||2018-05-31 22:19:17.356642|2018-05-31 22:19:17.356642
NCT01402947|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-06-01||2012-06-01|2011-07-25|2011-07-26|Estimate|2012-06-01|2012-07-06|Estimate||||2012-06-01|2012-07-06|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine|A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Ciprofloxacin XR Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Shire||2|||f||||||||||||||2018-05-31 22:19:17.473942|2018-05-31 22:19:17.473942
NCT01402934|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-29|||2016-04-20|2011-07-25|2011-07-26|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Pulse Pressure Variation in Spontaneously Breathing Patients|The Ability of Pulse Pressure Variation to Predict Fluid Responsiveness in Spontaneously Breathing Patients Undergoing Thoracic Surgery|Completed||N/A|70|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:19:17.988813|2018-05-31 22:19:17.988813
NCT01402921|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2016-11-09|2011-07-25|2011-07-26|Estimate|||||||2016-11-09|2016-11-10|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema|Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema. International, Multicentric, Randomised, Controlled, Double Blind Study, in Two Parallel Groups v0322 bc Versus Placebo|Completed||Phase 3|92|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-05-31 22:19:18.086383|2018-05-31 22:19:18.086383
NCT01402908|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-03-30|2011-07-25|2011-07-26|Estimate|||||||2016-03-30|2016-03-31|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|PATRON||A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection|A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel-group, International Multicenter Phase III Trial of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection|Terminated||Phase 3|520|Actual|Medigen Biotechnology Corporation||2||Due to Interim Analysis and business concerns|f||||t||||||||||2018-05-31 22:19:18.156705|2018-05-31 22:19:18.156705
NCT01402895|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2012-02-07|2011-07-25|2011-07-26|Estimate|||||||2012-02-07|2012-02-08|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effect Of A Neurodynamic Treatment On Nerve Conduction In Clients With Low Back Pain|The Effect Of A Neurodynamic Treatment On Nerve Conduction In Clients With Low Back Pain|Completed||N/A|9|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:19:18.291182|2018-05-31 22:19:18.291182
NCT01402882|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2018-03-05|2011-07-25|2011-07-26|Estimate|||||||2018-03-05|2018-03-07|Actual|September 2011||2011-09-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|January 2019|Anticipated|2019-01-31||Interventional|CRASH-3||Clinical Randomisation of an Antifibrinolytic in Significant Head Injury|Tranexamic Acid for the Treatment of Significant Traumatic Brain Injury: an International Randomised, Double Blind Placebo Controlled Trial|Recruiting||Phase 3|13000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||Yes|After all relevant publications are completed, totally anonymised data will be available at https://ctu-app.lshtm.ac.uk/freebird/|2018-05-31 22:19:18.38546|2018-05-31 22:19:18.38546
NCT01402700|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2015-08-11||2018-02-05|2011-07-25|2011-07-26|Estimate|2015-08-14|2015-09-16|Estimate||||2018-02-05|2018-03-07|Actual|July 2011||2011-07-31|February 2018|2018-02-28|September 2015|Actual|2015-09-30|July 2013|Actual|2013-07-31||Interventional|||VISIBILITY™ Iliac Study|Visi-Pro™ Balloon Expandable Iliac Study (VISIBILITY™ Iliac)|Completed||N/A|75|Actual|Medtronic Endovascular||1|||f||||||||||||||2018-05-31 22:19:21.896108|2018-05-31 22:19:21.896108
NCT01402869|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2013-10-15||2014-03-25|2011-07-25|2011-07-26|Estimate|2014-03-25|2014-04-25|Estimate||||2014-03-25|2014-04-25|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||1 subject was withdrawn from the no local anesthetic group as the subject required 1 or more dental tooth extractions and required local anesthetic|Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Local Anesthetics|Methemoglobin Levels in Generally Anesthetized Pediatric Dental Patients Receiving Prilocaine Versus Lidocaine|Completed||N/A|91|Actual|Loma Linda University|Did not compare locals anesthetics with equivalent concentrations of epinephrine; unable to control length of time methemoglobin blood levels were monitored as all subjects varied in extent of restorative dental procedures needed.|3|||f||||f||||||||||2018-05-31 22:19:19.509411|2018-05-31 22:19:19.509411
NCT01402856|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-10-13|2011-07-25|2011-07-26|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|May 2012|Actual|2012-05-31|May 2008|Actual|2008-05-31||Observational|||Teenage Driving Safety Study: An Emergency Medicine-Trauma Collaborative Study|Teenage Driving Safety Study: An Emergency Medicine-Trauma Collaborative Study|Completed|||3750|Actual|Lehigh Valley Hospital|||3||f||||f||||||||No||2018-05-31 22:19:20.048084|2018-05-31 22:19:20.048084
NCT01402843|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2014-05-12|2011-07-25|2011-07-26|Estimate|||||||2014-05-12|2014-05-14|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|COCTAIL||Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia|A Randomized, Double Blind, Double Dummy, Placebo Controlled Phase III Trial to Evaluate the Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia(COCTAIL Study)|Completed||Phase 3|150|Anticipated|JW Pharmaceutical||4|||f||||f||||||||||2018-05-31 22:19:20.194899|2018-05-31 22:19:20.194899
NCT01402830|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-02-08|2011-07-25|2011-07-26|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)|DPRESS Study. Case-control Study in Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients|Completed|||271|Actual|Janssen-Cilag, S.A.|||1||f||||||||||||||2018-05-31 22:19:20.314029|2018-05-31 22:19:20.314029
NCT01402817|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2016-03-30||2018-02-14|2011-07-25|2011-07-26|Estimate|2016-03-30|2016-05-04|Estimate||||2018-02-14|2018-03-14|Actual|March 2012||2012-03-31|February 2018|2018-02-28|February 14, 2018|Actual|2018-02-14|October 2015|Actual|2015-10-31||Interventional|||Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas|A Pilot Study of Sutent®/Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor in Subjects With NF-1 Plexiform Neurofibromas|Terminated||Phase 2|19|Actual|Indiana University||1||1 patient died of uncertain cause but possibly related to drug.|f||||t||||||||||2018-05-31 22:19:20.596|2018-05-31 22:19:20.596
NCT01402804|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-11-08|2011-07-25|2011-07-26|Estimate|||||||2013-11-08|2013-11-11|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||NSAIDs in Coronary Artery Disease Patients|Non-steroidal Anti-inflammatory Drugs Impair the Platelet Inhibiting Effect of Acetylsalicylic Acid in Coronary Artery Disease Patients|Completed|||85|Actual|Heinrich-Heine University, Duesseldorf|||2||f||||f||||||||||2018-05-31 22:19:20.94834|2018-05-31 22:19:20.94834
NCT01402791|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-03-25|2011-07-25|2011-07-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|DYSEXTRIOSE||Endometriosis: Sexual Dysfunction and Adaptation Strategies Among Couples|Endometriosis: Sexual Dysfunction and Adaptation Strategies Among Couples|Completed|||60|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 22:19:21.037985|2018-05-31 22:19:21.037985
NCT01402778|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-12-19|2011-07-25|2011-07-26|Estimate|||||||2011-12-19|2011-12-20|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|TDPAFD||Fixation of Thoracic Epidurals Influencing Catheter-related Infections and Dislocation|Fixation of Thoracic Epidural Catheters Influencing Catheter-related Infections and Dislocation|Completed|||140|Actual|Heinrich-Heine University, Duesseldorf|||2||f||||f||||||||||2018-05-31 22:19:21.122746|2018-05-31 22:19:21.122746
NCT01402765|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-03-25|2011-07-25|2011-07-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Interface Pressure Measures for Matresses: Nimbus 3 Versus Summit|Interface Pressure Measures for Matresses: a Randomized, Cross-over, Non-inferiority Study Comparing the Nimbus 3 Versus Summit Matresses|Completed||N/A|31|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 22:19:21.213529|2018-05-31 22:19:21.213529
NCT01402752|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2017-06-16|2011-07-25|2011-07-26|Estimate|||||||2017-06-16|2017-06-19|Actual|November 2013||2013-11-30|June 2017|2017-06-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||System for Measuring Non-invasive Blood Flow in the Tracheobronchial Mucosa: Validation of Reproducibility|System for Measuring Non-invasive Blood Flow in the Tracheobronchial Mucosa: Validation of Reproducibility|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nīmes||1||20131209 Regulatory authorization is currently blocked at the ANSM.|f||||f||||||||||2018-05-31 22:19:21.316601|2018-05-31 22:19:21.316601
NCT01402739|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-06-12|2011-07-25|2011-07-26|Estimate|||||||2015-06-12|2015-06-15|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|HEART-PoC||Algorithm-Guided Transfusions in Cardiac Surgery Patients for Reduction of Drainage Blood Losses|Monocentric Pilot Study of Algorithm-Guided Transfusions in Cardiac Surgery Patients for Reduction of Drainage Blood Losses|Terminated||N/A|100|Actual|Charite University, Berlin, Germany||2||Study terminated prematurely due to futility|f||||f||||||||||2018-05-31 22:19:21.401138|2018-05-31 22:19:21.401138
NCT01402726|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2017-07-13|2011-07-25|2011-07-26|Estimate|||||||2017-07-13|2017-07-17|Actual|July 2011|Actual|2011-07-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Renal Sympathetic Modification in Patients With Heart Failure|Renal Sympathetic Modification in Patients With Heart Failure|Recruiting||N/A|200|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 22:19:21.525704|2018-05-31 22:19:21.525704
NCT01402713|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-01-23|2011-07-25|2011-07-26|Estimate|||||||2015-01-23|2015-01-26|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children|Randomized, Double Blind, Multicenter, Phase II/III Study to Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children|Completed||Phase 2/Phase 3|311|Actual|Green Cross Corporation||3|||f||||f||||||||||2018-05-31 22:19:21.637138|2018-05-31 22:19:21.637138
NCT01402687|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-07-15|2011-07-25|2011-07-26|Estimate|||||||2013-07-15|2013-07-16|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|||SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)|Single Nucleotide Polymorphism (SNP)-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants|Completed|||181|Actual|Dana-Farber Cancer Institute|||2||f||||t||||||Samples With DNA|"~     Saliva sample~   "|||2018-05-31 22:19:22.188405|2018-05-31 22:19:22.188405
NCT01402674|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-23|||2013-01-25|2011-07-25|2011-07-26|Estimate|||||||2013-01-25|2013-01-28|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PC-II||Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal|Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal|Completed||N/A|269|Actual|Center for Weight Management, California||2|||f||||f||||||||||2018-05-31 22:19:22.357248|2018-05-31 22:19:22.357248
NCT01402661|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2017-11-07|2011-07-25|2011-07-26|Estimate|||||||2017-11-07|2017-11-09|Actual|February 2002||2002-02-28|August 2016|2016-08-31||||December 2100|Anticipated|2100-12-31||Observational|CORRONA||The Corrona RA Data Collection Program|The Corrona RA Data Collection Program|Enrolling by invitation|||33312|Actual|Corrona, LLC.|||1||f||||f||||||||||2018-05-31 22:19:22.460659|2018-05-31 22:19:22.460659
NCT01402648|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|October 2009||2009-10-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|CRC||Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence|Effects of the Dietary Supplementation With a Blend of ER Beta Agonists on the Expression of ER Beta and Related Biomarkers of Cell Proliferation and Apoptosis, in Sporadic Colon Adenopolyposis|Completed||Phase 1/Phase 2|60|Actual|CM&D Pharma Limited||2|||f||||f||||||||||2018-05-31 22:19:22.6|2018-05-31 22:19:22.6
NCT01402635|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2012-07-22|2011-07-25|2011-07-26|Estimate|||||||2012-07-22|2012-07-24|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|POCTED||Can the Point-Of-Care Chemistry Test (POCT) Solve the Emergency Department (ED) Crowding?|A Randomized Controlled Trial Comparing Central Laboratory and Point-of-care Chemistry Test for Solving the Emergency Department Crowding|Completed||N/A|10244|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:19:22.704643|2018-05-31 22:19:22.704643
NCT01402622|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||The Effect of Total Intravenous Anesthesia With Propofol on Postoperative Nausea and Vomiting in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy|The Effect of Total Intravenous Anesthesia With Propofol on Postoperative Nausea and Vomiting in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy|Completed||Phase 4|93|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 22:19:22.791723|2018-05-31 22:19:22.791723
NCT01402609|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-07-28|2011-07-25|2011-07-26|Estimate|||||||2016-07-28|2016-08-01|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|December 2013|Actual|2013-12-31||Interventional|||Assessing the Efficacy of an Electronic Discharge Communication Tool|A Randomized Controlled Trial Assessing the Efficacy of an Electronic Discharge Communication Tool for Preventing Death or Hospital Readmission|Completed||N/A|1399|Actual|Ward of the 21st Century||2|||f||||f||||||||Yes||2018-05-31 22:19:22.889129|2018-05-31 22:19:22.889129
NCT01402596|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-06-19|2011-07-25|2011-07-26|Estimate|||||||2013-06-19|2013-06-20|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam|Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam - a Randomized Controlled Trial|Withdrawn||Phase 2|0|Actual|University of Sao Paulo||2||"Institution decided on starting a new protocol of sedation, with another methods and that´s why~   this study has not started."|f||||f||||||||||2018-05-31 22:19:23.047131|2018-05-31 22:19:23.047131
NCT01402583|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-10-20|2011-07-25|2011-07-26|Estimate|||||||2011-10-20|2011-10-21|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|MEN_EPID||Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C|Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C - An Epidemiological Study|Completed|||1000|Actual|University of Modena and Reggio Emilia|||1||f||||f||||||||||2018-05-31 22:19:23.138753|2018-05-31 22:19:23.138753
NCT01402570|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|2016-01-22||2016-12-22|2011-07-25|2011-07-26|Estimate|2016-12-22|2017-02-17|Actual||||2016-12-22|2017-02-17|Actual|August 2011||2011-08-31|December 2016|2016-12-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional||The target population for this study was individuals between the ages of 50 and 65 who self-reported symptoms consistent with post-polio syndrome and able to ambulate 100 feet without assistive devices.|Glutathione and Health With Post-Polio Syndrome|Oral Glutathione and Health Outcomes Among Persons With Post-Polio Syndrome|Completed||N/A|20|Actual|University of Michigan|Sample size of 20 was quite small to make generalizations to the larger population. Dosing and duration of the intervention may not have been sufficient to effect change.|1|||f||||f||||||||||2018-05-31 22:19:23.289363|2018-05-31 22:19:23.289363
NCT01402557|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-12-26|2011-07-25|2011-07-26|Estimate|||||||2016-12-26|2016-12-28|Estimate|August 2007||2007-08-31|December 2016|2016-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||"Telehealth for Weight Maintenance of African-American Women (Exercise Your Faith)"|Telehealth for Weight Maintenance of African-American Women|Completed||N/A|88|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 22:19:23.636296|2018-05-31 22:19:23.636296
NCT01402544|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-07-14|2011-07-25|2011-07-26|Estimate|||||||2016-07-14|2016-07-18|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|COMPASS||Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab|Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab (COMPASS)|Terminated||Phase 2/Phase 3|20|Actual|University of California, San Diego||1||Per study sponsor decision.|f||||f||||||||No||2018-05-31 22:19:23.732803|2018-05-31 22:19:23.732803
NCT01402531|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Unknown status|Recruiting|Phase 2|30|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 22:19:23.851297|2018-05-31 22:19:23.851297
NCT01402518|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2018-04-30|2011-07-25|2011-07-26|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2009||2009-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|POEM||Per-Oral Endoscopic Myotomy|Observational Study of the Per-Oral Endoscopic Myotomy (POEM) Procedure|Recruiting|||100|Anticipated|University of California, San Diego|||1||f||||f||||||||||2018-05-31 22:19:23.99953|2018-05-31 22:19:23.99953
NCT01402505|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2018-04-30|2011-07-25|2011-07-26|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2008||2008-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Transvaginal NOTES Sleeve Gastrectomy|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Trans-Vaginal Sleeve Gastrectomy|Recruiting|||50|Anticipated|University of California, San Diego|||1||f||||f||||||||||2018-05-31 22:19:24.142883|2018-05-31 22:19:24.142883
NCT01402492|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2016-01-27|2011-07-25|2011-07-26|Estimate|||||||2016-01-27|2016-01-29|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|CURB||Cocaine Use Reduction With Buprenorphine|Cocaine Use Reduction With Buprenorphine (CURB)|Completed||Phase 2/Phase 3|302|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 22:19:24.253327|2018-05-31 22:19:24.253327
NCT01402479|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-24|||2011-08-05|2011-07-24|2011-07-26|Estimate|||||||2011-08-05|2011-08-08|Estimate|October 2004||2004-10-31|July 2011|2011-07-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||An Open-labeled Trial of Ramipril in Patients With Migraine|An Open-labeled Trial of Ramipril in Patients With Migraine|Completed||Phase 2|50|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:19:24.368273|2018-05-31 22:19:24.368273
NCT01402466|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-03-25|2011-07-25|2011-07-26|Estimate|||||||2016-03-25|2016-03-28|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Urban Health Study II|Finding, Testing and Treating High-Risk Probationers and Parolees With HIV|Completed||Phase 2|49|Actual|RTI International||2|||f||||f||||||||||2018-05-31 22:19:24.439712|2018-05-31 22:19:24.439712
NCT01402453|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-03-07|2011-07-25|2011-07-26|Estimate|||||||2015-03-07|2015-03-10|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Monetary Incentives and Intrinsic Motivation to Sustain Hypertension Control|Monetary Incentives and Intrinsic Motivation to Sustain Hypertension Control Pilot Study|Completed||N/A|207|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:19:24.51844|2018-05-31 22:19:24.51844
NCT01402440|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2015-01-06|2011-07-24|2011-07-26|Estimate|||||||2015-01-06|2015-01-07|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma|An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma|Terminated||Phase 1|15|Actual|Novartis||1||"Study terminated due to enrolment challenges and availability of other options for DLBCL~   patients. The termination is not a consequence of any safety concern."|f||||||||||||||2018-05-31 22:19:25.03105|2018-05-31 22:19:25.03105
NCT01402427|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2014-04-17||2014-04-30|2011-07-25|2011-07-26|Estimate|2014-04-30|2014-06-02|Estimate||||2014-04-30|2014-06-02|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|VITRIOL||Is Verapamil In TransRadial Interventions OmittabLe?|Omission of Prophylactic Verapamil Use in Transradial Coronary Interventions|Completed||N/A|591|Actual|State Health Center, Hungary|The trial was conducted in a single, high-volume institution by experienced operators. The results may not be applicable to lower-volume centers or to operators with less experience.|2|||f||||f||||||||||2018-05-31 22:19:25.246817|2018-05-31 22:19:25.246817
NCT01402414|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-02-20|2011-07-25|2011-07-26|Estimate|||||||2014-02-20|2014-02-21|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis|Study Comparing the Effectiveness of Narrow-band UVB vs. Bath-PUVA and Narrow-band UVB + Salt Water Baths in Atopic Dermatitis|Terminated||N/A|10|Actual|Ruhr University of Bochum||3||Difficulties with the Recruitement|f||||f||||||||||2018-05-31 22:19:25.689615|2018-05-31 22:19:25.689615
NCT01402401|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-24|||2014-02-20|2011-07-24|2011-07-26|Estimate|||||||2014-02-20|2014-02-24|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients|An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer|Terminated||Phase 2|21|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:19:25.778485|2018-05-31 22:19:25.778485
NCT01402388|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Lifestyle Intervention in Patients With New Onset Type 2 Diabetes.|Effect of Intensive Lifestyle Intervention on Hormonal Factors Regulating Food Intake and Blood Glucose Control in Patients With New Onset Type 2 Diabetes.|Completed||N/A|22|Actual|The Royal Bournemouth Hospital||1|||f||||f||||||||||2018-05-31 22:19:25.892128|2018-05-31 22:19:25.892128
NCT01402375|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-24|2018-03-01||2018-04-27|2011-07-25|2011-07-26|Estimate|2018-04-27|2018-05-01|Actual||||2018-04-27|2018-05-01|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||"Patients excluded from data analysis:~First trial - patients did not take study medication Second trial - 7 patients unable to be reached for follow up, 18 did not take study medication Third trial - 5 patients unable to be reached for follow up, 15 did not take study medication"|Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge|Comparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge|Completed||Phase 3|720|Actual|Montefiore Medical Center||6|||f||||f||||||||||2018-05-31 22:19:25.996647|2018-05-31 22:19:25.996647
NCT01402362|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-24|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|September 2011||2011-09-30|June 2011|2011-06-30||||||||Observational|||Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study.||Unknown status|Not yet recruiting||550|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-05-31 22:19:27.732281|2018-05-31 22:19:27.732281
NCT01402349|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-08-01|2011-07-25|2011-07-26|Estimate|||||||2011-08-01|2011-08-02|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Chronic Rhinosinusitis in a Danish Population: Evaluation of Causes of Disease, Progress and Treatment|Chronic Rhinosinusitis in a Danish Population: Evaluation of Causes of Disease, Progress and Treatment|Completed|||5000|Actual|Odense University Hospital|||||f||||f||||||Samples With DNA|"~     Blodsamples.~   "|||2018-05-31 22:19:27.928327|2018-05-31 22:19:27.928327
NCT01402336|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2017-10-07|2011-07-25|2011-07-26|Estimate|||||||2017-10-07|2017-10-10|Actual|June 2011||2011-06-30|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer|'A Multicentre, Prospective Randomized Study to Assess the Effect When GnRH Antagonist is Started Either on Stimulation Day 1 and Day 6 vs. Conventional GnRH Agonist Long Protocol in Patients With Polycystic Ovary Syndrome Undergoing IVF-ET|Completed||Phase 3|43|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 22:19:28.484281|2018-05-31 22:19:28.484281
NCT01402323|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-05-19|2011-07-25|2011-07-26|Estimate|||||||2014-05-19|2014-05-20|Estimate|July 2011||2011-07-31|July 2011|2011-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Gingival Clefts and Orthodontic Movement|A Prospective Split-mouth Designed Study on the Incidence of Gingival Clefts During Orthodontic Space Closure Into Recent or Healed Extraction Sockets.|Unknown status|Recruiting|N/A|25|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-05-31 22:19:28.616805|2018-05-31 22:19:28.616805
NCT01402310|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2013-12-08|2011-07-25|2011-07-26|Estimate|||||||2013-12-08|2013-12-10|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Bishop Score, Cervical Length and Multiple Proteins in Cervicovaginal Fluid at 40 Weeks to Predict Onset of Labor||Completed|||220|Actual|Seoul National University Hospital|||1||f||||f||||||Samples Without DNA|"~     cervicovaginal fluid~   "|||2018-05-31 22:19:28.759095|2018-05-31 22:19:28.759095
NCT01402297|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Hydrogen Peroxide and Nitrite Reduction in Exhaled Breath Condensate of COPD Patients|Hydrogen Peroxide and Nitrite Reduction in Exhaled Breath Condensate of COPD Patients|Completed||Phase 1|13|Actual|Medical Universtity of Lodz||1|||f||||f||||||||||2018-05-31 22:19:28.99316|2018-05-31 22:19:28.99316
NCT01402284|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-23|2017-03-01||2018-04-17|2011-07-23|2011-07-26|Estimate|2017-04-14|2017-05-16|Actual||||2018-04-17|2018-05-17|Actual|July 21, 2011|Actual|2011-07-21|April 2018|2018-04-30|September 1, 2026|Anticipated|2026-09-01|July 10, 2016|Actual|2016-07-10||Interventional|||Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients|Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study|Active, not recruiting||Phase 2|45|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-05-31 22:19:29.12654|2018-05-31 22:19:29.12654
NCT01402271|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-23|||2016-10-11|2011-07-23|2011-07-26|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2012||2012-07-31|October 2016|2016-10-31||||May 2019|Anticipated|2019-05-31||Interventional|||Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma|Recruiting||Phase 1/Phase 2|88|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-05-31 22:19:30.00231|2018-05-31 22:19:30.00231
NCT01402258|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2013-04-26|2011-07-25|2011-07-26|Estimate|||||||2013-04-26|2013-04-29|Estimate|April 2011||2011-04-30|April 2013|2013-04-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|NOVA-IV||Internet-administrated Treatment of Anxiety Symptoms for Young Adults|Tailored Internet-administrated Treatment of Anxiety Symptoms for Young Adults|Unknown status|Recruiting|N/A|30|Anticipated|Linkoeping University||1|||f||||f||||||||||2018-05-31 22:19:30.164499|2018-05-31 22:19:30.164499
NCT01402245|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PncHR||Targeting of Immune Response After Pneumococcal Vaccination|Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination|Completed||Phase 4|42|Actual|Helsinki University Central Hospital||3|||f||||t||||||||||2018-05-31 22:19:30.244692|2018-05-31 22:19:30.244692
NCT01402232|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-08-20|2011-07-25|2011-07-26|Estimate|||||||2015-08-20|2015-08-21|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|REICIN||Reduction of Risk for Contrast Nephropathy|Reduction of Risk for Contrast-Induced Nephropathy: A Multicentre Observational Study of Contrast-Induced Nephropathy Following Coronary Angiography or Percutaneous Coronary Intervention|Unknown status|Recruiting||5000|Anticipated|Guangdong General Hospital|||1||f||||t||||||||||2018-05-31 22:19:30.387851|2018-05-31 22:19:30.387851
NCT01402219|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2013-08-27|2011-07-25|2011-07-26|Estimate|||||||2013-08-27|2013-08-28|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|NEIHR||Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients|Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients:A Multicentre Randomized Double-Blind Trail of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease|Terminated||Phase 4|204|Actual|Guangdong General Hospital||2||There were few eligible subjects from other centers.|f||||t||||||||||2018-05-31 22:19:30.535859|2018-05-31 22:19:30.535859
NCT01402206|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-08-15|2011-07-25|2011-07-26|Estimate|||||||2016-08-15|2016-08-16|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Management of Depression in Primary Care|Management of Depression in Primary Health Care: a Controlled Trial on the Effectiveness of Regular, Structured, Patient-centered Visits|Completed||N/A|258|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 22:19:30.66532|2018-05-31 22:19:30.66532
NCT01402193|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2014-06-24|2011-07-25|2011-07-26|Estimate|||||||2014-06-24|2014-06-25|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||Study of Arimidex and Radiotherapy Sequencing|A Prospective, Randomized, Bi-center Study to Compare the Outcome of Adjuvant Radiotherapy With Concomitant or Sequential Arimidex in Postmenopausal Women With Breast Cancer|Unknown status|Recruiting|Phase 3|220|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:19:30.773957|2018-05-31 22:19:30.773957
NCT01402180|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|Nimotuzumab||Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy|A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence|Unknown status|Recruiting|Phase 2/Phase 3|128|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:19:30.881856|2018-05-31 22:19:30.881856
NCT01145131|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2011-09-13|2010-06-15|2010-06-16|Estimate|||||||2011-09-13|2011-09-14|Estimate|May 2011||2011-05-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Dietary Interventions for Muscle Mass|Dietary Interventions for Muscle Mass|Completed||N/A|12|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 23:40:46.994123|2018-05-31 23:40:46.994123
NCT01402167|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2015-03-24|2011-07-25|2011-07-26|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Evaluating Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures|Evaluating Transcutaneous Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures: a Randomized Pilot Study Using Catscan Volumetry|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nīmes||2||Patients refuse randomization.|f||||f||||||||||2018-05-31 22:19:31.001711|2018-05-31 22:19:31.001711
NCT01402154|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-25|||2017-06-16|2011-07-25|2011-07-26|Estimate|||||||2017-06-16|2017-06-19|Actual|January 2012||2012-01-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients|The Pre-treatment Detection of Circulating, Functional, Prostate Cells Among Adenocarcinoma Patients: an Evaluation of the EPISPOT Technique|Active, not recruiting|||361|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples Without DNA|"~     Following the completion of the biological analyses required for this study, leftover tubes~     may be placed in the Nîmes University Hospital biological collection for future ancillary~     studies, if patients are agreed with this. The samples concerned include EDTA and CellSave~     tubes for each patient.~   "|||2018-05-31 22:19:31.083637|2018-05-31 22:19:31.083637
NCT01402141|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-07-11||2012-11-21|2011-07-25|2011-07-26|Estimate|2012-10-11|2012-11-12|Estimate||||2012-11-21|2012-11-22|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||A Human Trial to Evaluate the Effects of Chungkookjang on Histamine-induced Wheal Size in Healthy Subjects|Efficacy and Safety of Chungkookjang, a Fermented Soy Paste, on Histamine-induced Wheal Size|Completed||Phase 2/Phase 3|60|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 22:19:31.285181|2018-05-31 22:19:31.285181
NCT01402128|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-07-26||2012-11-26|2011-07-25|2011-07-26|Estimate|2012-11-26|2012-12-25|Estimate||||2012-11-26|2012-12-25|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects|The Effect of Barley Beta-glucan on Serum Lipids and Body Weight|Completed||Phase 2/Phase 3|80|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 22:19:31.760291|2018-05-31 22:19:31.760291
NCT01402115|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-07-26||2012-10-10|2011-07-25|2011-07-26|Estimate|2012-09-05|2012-10-05|Estimate||||2012-10-10|2012-10-12|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||A 12-week Human Trial to Compare the Efficacy and Safety of Polycan on Bone Metabolism|Efficacy and Safety Study of Polycan on Bone Metabolism|Completed||Phase 2/Phase 3|60|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 22:19:32.197597|2018-05-31 22:19:32.197597
NCT01402102|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-07-26||2012-10-11|2011-07-25|2011-07-26|Estimate|2012-09-05|2012-10-04|Estimate||||2012-10-11|2012-10-12|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia|Efficacy and Safety of Aged Garlic Powder on Lipids|Completed||Phase 2/Phase 3|60|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 22:19:32.794138|2018-05-31 22:19:32.794138
NCT01402089|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2016-01-31|2011-07-25|2011-07-26|Estimate|||||||2016-01-31|2016-02-02|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients|Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients|Completed||Phase 4|54|Actual|Cantonal Hospital of St. Gallen|||||f||||t||||||||||2018-05-31 22:19:33.277163|2018-05-31 22:19:33.277163
NCT01402076|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-02-14|2011-07-22|2011-07-26|Estimate|||||||2014-02-14|2014-02-17|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects|An Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes Using Midazolam and Rosiglitazone as Substrates in Healthy Subjects|Completed||Phase 1|24|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:19:33.389139|2018-05-31 22:19:33.389139
NCT01402063|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2015-04-30||2015-07-08|2011-07-25|2011-07-26|Estimate|2015-06-09|2015-06-11|Estimate||||2015-07-08|2015-07-30|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Interventional|||PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation|PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study|Completed||Phase 2|63|Actual|Brown University||2|||f||||t||||||||||2018-05-31 22:19:33.52626|2018-05-31 22:19:33.52626
NCT01402050|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2016-11-21|2011-07-25|2011-07-26|Estimate|||||||2016-11-21|2016-11-22|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Foley Catheter Versus Cervidil for Induction of Labor at Term|A Randomized Controlled Trial of Transcervical Foley Balloon Compared to Controlled Release Prostaglandin (Cervidil) for Labor Induction and Cervical Ripening in Term and Near Term Women|Completed||N/A|330|Actual|Mednax Center for Research, Education, Quality and Safety||2|||f||||t||||||||No||2018-05-31 22:19:34.111253|2018-05-31 22:19:34.111253
NCT01402037|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2013-12-27|2011-07-25|2011-07-26|Estimate|||||||2013-12-27|2013-12-30|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Beta Cell Function in (Pre)Type 1 Diabetes|Relation Between Residual Beta Cell Function and Glycemic Variability in (Pre) Type 1 Diabetes.|Unknown status|Recruiting|N/A|100|Anticipated|AZ-VUB||4|||f||||f||||||||||2018-05-31 22:19:34.188455|2018-05-31 22:19:34.188455
NCT01402024|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-01-16|2011-07-25|2011-07-26|Estimate|||||||2015-01-16|2015-01-19|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Aprepitant||Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy|A Study to Evaluate the Anti-emetic Effect of Aprepitant Versus Placebo as an Add-on Therapy in Children and Adolescent Receiving Chemotherapy: A Randomized, Doubly Blinded Controlled Trial|Completed||Phase 3|96|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 22:19:34.366569|2018-05-31 22:19:34.366569
NCT01402011|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-09-02|2011-07-22|2011-07-26|Estimate|||||||2013-09-02|2013-09-04|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Prolotherapy||Study of 25% Dextrose Injections in Shoulder Ligaments and Tendons to Promote Their Healing|Prolotherapy in the Treatment of Rotator Cuff Tendinopathy, a Randomized Double-blind Placebo-controlled Study|Completed||N/A|72|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 22:19:34.452115|2018-05-31 22:19:34.452115
NCT01401998|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2017-09-15|2011-07-22|2011-07-26|Estimate|||||||2017-09-15|2017-09-18|Actual|June 2011||2011-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||UAB HRFD Core Center: Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource|Core A: The Hepato/Renal Fibrocystic Diseases Translational Resource (Hepato/Renal Fibrocystic Diseases Core Center (UAB HFRDCC))|Recruiting|||200|Anticipated|Children's Research Institute|||||f||||t||||||Samples With DNA|"~     Blood-derived DNA and lymphocytes for EBV-immortalized cell lines. Remnant tissue samples~     affected with Hepato/Renal Fibrocystic Diseases~   "|||2018-05-31 22:19:34.573796|2018-05-31 22:19:34.573796
NCT01401985|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19||2013-06-05|2014-09-03|2011-07-25|2011-07-26|Estimate||||2013-06-05|2013-06-13|Estimate|2014-09-03|2014-09-10|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)|A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects With Opioid-Induced Constipation|Completed||Phase 2|95|Actual|Theravance Biopharma Antibiotics, Inc.||1|||f||||f||||||||||2018-05-31 22:19:34.66|2018-05-31 22:19:34.66
NCT01401972|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-05-01|2011-07-25|2011-07-26|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2008||2008-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Conventional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients|Conventional and Contrast-Assisted Frequency Functional Ultrasound for Imaging of Prostate Cancer Extent and Response in Human Cancer Patients|Recruiting|||10|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||Samples With DNA|"~     Prostate speciments are retained after radical prostatectomy surgery~   "|||2018-05-31 22:19:34.741034|2018-05-31 22:19:34.741034
NCT01401959|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2018-04-04||2018-04-04|2011-07-25|2011-07-26|Estimate|2018-04-04|2018-05-07|Actual||||2018-04-04|2018-05-07|Actual|September 23, 2011|Actual|2011-09-23|April 2018|2018-04-30|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional||All patients who receive at least one dose of treatment.|Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy|Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy|Completed||Phase 2|127|Actual|SCRI Development Innovations, LLC||3|||f||||f|t|f|||f|||||2018-05-31 22:19:34.84632|2018-05-31 22:19:34.84632
NCT01401946|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2011-07-25|2011-07-25|2011-07-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|May 2000||2000-05-31|July 2011|2011-07-31|January 2001|Actual|2001-01-31|October 2000|Actual|2000-10-31||Interventional|||Soy Isoflavone Tablets: Effects on Sleep, Quality of Life, Symptoms and Cognitive Function in Menopausal Women|Soy Isoflavone Tablets: Effects on Questionnaire and Actigraphic Measures of Sleep, Symptoms as Measured by the Women's Health Questionnaire and Cognitive Function as Measured by Computerized Cognitive Performance Tests in Menopausal Women|Completed||Phase 4|88|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:19:35.389701|2018-05-31 22:19:35.389701
NCT01401933|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-10-31|2011-07-22|2011-07-26|Estimate|||||||2011-10-31|2011-11-02|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1 Study To Assess the Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|14|Actual|Abbott||1|||f||||f||||||||||2018-05-31 22:19:35.474208|2018-05-31 22:19:35.474208
NCT01401920|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2013-12-24|2011-07-22|2011-07-25|Estimate|||||||2013-12-24|2013-12-25|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||The Influence of Passive Leg Elevation on the Cross-sectional Area of the Internal Jugular Vein in Infants or Young Children Undergoing Open Heart Surgery|The Influence of Passive Leg Elevation on the Cross-sectional Area of the Internal Jugular Vein in Infants or Young Children Undergoing Open Heart Surgery|Completed|||90|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 22:19:35.535353|2018-05-31 22:19:35.535353
NCT01401907|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2017-02-16||2017-12-27|2011-07-22|2011-07-25|Estimate|2017-04-15|2017-07-13|Actual||||2017-12-27|2018-01-26|Actual|May 2011||2011-05-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|April 2016|Actual|2016-04-30||Interventional|||Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies|Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Advanced Lung and Non-colorectal Gastrointestinal Malignancies|Active, not recruiting||N/A|350|Actual|Massachusetts General Hospital||2|||f||||t||||||||Yes|will share deidentified data with proper IRB approval|2018-05-31 22:19:35.624489|2018-05-31 22:19:35.624489
NCT01401894|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-01-28|2011-07-22|2011-07-25|Estimate|||||||2017-01-28|2017-01-31|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|October 2012|Actual|2012-10-31||Observational|||Perception Prognosis, Goals of Treatment, and Communication|Pilot Study to Investigate Advanced Cancer Patient's Perspective of Their Prognosis, Goals of Treatment, and Quality of Communication With Their Oncologists|Completed|||50|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 22:19:37.042698|2018-05-31 22:19:37.042698
NCT01401881|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2013-04-22|2011-07-22|2011-07-25|Estimate|||||||2013-04-22|2013-04-23|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|ITEMMRI||Ischemic Time and Extent of Myocardial Infarction (MI) With Cardiac Magnetic Resonance Imaging (CMRI) in Patients With ST Elevation Myocardial Infarction (STEMI) and Primary Percutaneous Coronary Intervention (PCI) Study|Ischemic Time and Extent of Myocardial Infarction With Cardiac Magnetic Resonance Image in Patients With STEMI and Primary Percutaneous Coronary Intervention Study|Unknown status|Active, not recruiting||80|Anticipated|Medstar Health Research Institute|||1||f||||f||||||||||2018-05-31 22:19:37.112729|2018-05-31 22:19:37.112729
NCT01401868|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2013-06-20|2011-07-22|2011-07-25|Estimate|||||||2013-06-20|2013-06-24|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors|Phase I Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors|Completed||Phase 1|18|Actual|MEI Pharma, Inc.||1|||f||||t||||||||||2018-05-31 22:19:37.204928|2018-05-31 22:19:37.204928
NCT01401855|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2016-06-15|2011-07-22|2011-07-25|Estimate|||||||2016-06-15|2016-06-17|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Use of an In Vivo Optical Probe to Discriminate Benign From Malignant Thyroid Nodules|Optical Probe In Thyroid Cancer|Completed|||300|Actual|Boston Medical Center|||2||f||||f||||||||||2018-05-31 22:19:37.290363|2018-05-31 22:19:37.290363
NCT01394185|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2017-04-18||2017-08-02|2011-07-13|2011-07-14|Estimate|2017-08-02|2017-08-03|Actual||||2017-08-02|2017-08-03|Actual|February 2011||2011-02-28|August 2017|2017-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Dronabinol (Oral THC) on Cannabis Use|Effects of Dronabinol (Oral THC) on Cannabis Use|Completed||Phase 1/Phase 2|25|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 22:21:58.954639|2018-05-31 22:21:58.954639
NCT01401842|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|2015-05-05||2015-05-22|2011-07-22|2011-07-25|Estimate|2015-05-22|2015-05-25|Estimate||||2015-05-22|2015-05-25|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|April 2014|Actual|2014-04-30||Interventional||All enrolled participants who were deemed eligible, completed baseline assessments, and were randomized.|Reduction of Risk for Low Back Injury in Theater of Operations|Reduction of Risk for Low Back Injury in Theater of Operations|Completed||N/A|582|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 22:19:37.453622|2018-05-31 22:19:37.453622
NCT01401829|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-05-11|2011-07-22|2011-07-25|Estimate|||||||2015-05-11|2015-05-12|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Psychosocial Benefits of Exercise in Endometrial Cancer Survivors|Psychosocial Benefits of Exercise in Endometrial Cancer Survivors|Terminated||Phase 1|2|Actual|University of Alabama at Birmingham||3||Terminated due to lack of funding required to continue the study.|f||||f||||||||||2018-05-31 22:19:40.135399|2018-05-31 22:19:40.135399
NCT01401816|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-07-06|2011-07-22|2011-07-25|Estimate|||||||2012-07-06|2012-07-10|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Advanced Provision of Emergency Contraception: Utilizing Technology to Increase Prescription Fill Rates|Advanced Provision of Emergency Contraception: Utilizing Technology to Increase Prescription Fill Rates|Completed||N/A|60|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 22:19:40.362181|2018-05-31 22:19:40.362181
NCT01401803|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2013-09-24|2011-07-22|2011-07-25|Estimate|||||||2013-09-24|2013-09-26|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Brow Lifting With Dysport|Brow Lifting With Dysport|Completed||Phase 4|24|Actual|Beer, Kenneth R., M.D., PA||1|||f||||f||||||||||2018-05-31 22:19:40.452642|2018-05-31 22:19:40.452642
NCT01401790|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2011-07-22|2011-07-22|2011-07-25|Estimate|||||||2011-07-22|2011-07-25|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Use of a Telehomecare Program for Young Patients With New Onset Type 1 Diabetes|Use of a Telehomecare Program for Young Patients With New Onset Type 1 Diabetes|Completed||N/A|86|Actual|Huot, Celine, M.D.||2|||f||||f||||||||||2018-05-31 22:19:40.5572|2018-05-31 22:19:40.5572
NCT01401777|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-05-28|2011-07-22|2011-07-25|Estimate|||||||2013-05-28|2013-05-29|Estimate|December 2014||2014-12-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Observational|||Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study|Electromagnetic Tracking of Devices During Interventional Procedures - A Cryoablation Study|Suspended|||40|Anticipated|Philips Healthcare|||2|On hold pending product development|f||||f||||||||||2018-05-31 22:19:40.650775|2018-05-31 22:19:40.650775
NCT01401764|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2013-01-30|2011-07-22|2011-07-25|Estimate|||||||2013-01-30|2013-01-31|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjects|Randomized, Double Blind, Crossover, Single Centre Study Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjects|Completed||Phase 1|30|Actual|Ablynx||1|||f||||f||||||||||2018-05-31 22:19:40.714101|2018-05-31 22:19:40.714101
NCT01401751|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2017-07-28|2011-07-22|2011-07-25|Estimate|||||||2017-07-28|2017-08-01|Actual|July 1, 2011|Actual|2011-07-01|July 2017|2017-07-31|December 1, 2011|Actual|2011-12-01|November 1, 2011|Actual|2011-11-01||Interventional|||Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting|Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting|Completed||N/A|13|Actual|Animas Corporation||1|||f||||f|f|t|f|||||||2018-05-31 22:19:40.842528|2018-05-31 22:19:40.842528
NCT01401738|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-25|Estimate|||||||2011-07-21|2011-07-25|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|May 2013|Anticipated|2013-05-31|||||Observational|||Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule|Results of Shoulder Arthroscopic Surgery for Rotator Cuff, Biceps Tendon, Labrum and Capsule|Unknown status|Active, not recruiting||170|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:19:40.983837|2018-05-31 22:19:40.983837
NCT01401725|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-10-14|2011-07-22|2011-07-25|Estimate|||||||2015-10-14|2015-10-16|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|E-SENTRY||Electronic Strategies to Enhance Venous Thromboemboli (VTE) Prophylaxis in Hospitalized Medical Patients|Electronic Strategies to Enhance Venous Thromboprophylaxis in Hospitalized Medical Patients|Completed||N/A|600|Actual|McMaster University||3|||f||||f||||||||||2018-05-31 22:19:41.034662|2018-05-31 22:19:41.034662
NCT01401712|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-10-28|2011-07-22|2011-07-25|Estimate|||||||2013-10-28|2013-10-29|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Interventional|||Optimal Method of Pain Management in Patients With Multiple Rib Fractures|Thoracic Epidural Analgesia Compared to Thoracic Paravertebral Pump Infusion for Pain Management in Patients With Three or More Rib Fractures|Unknown status|Recruiting|N/A|96|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:19:41.115431|2018-05-31 22:19:41.115431
NCT01401699|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2016-04-14|2011-07-22|2011-07-25|Estimate|||||||2016-04-14|2016-04-18|Estimate|September 2006||2006-09-30|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction|Optical Coherence Tomography Based Screening and Surveillance of Esophagus and Gastroesophageal Junction|Completed||Phase 1|110|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:19:41.239882|2018-05-31 22:19:41.239882
NCT01401673|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-22|2011-07-22|2011-07-25|Estimate|||||||2011-07-22|2011-07-25|Estimate|October 2009||2009-10-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Phase II Open-Label Pilot Study of V3381 in Chronic Cough|Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients Attending a Specialist Clinic|Terminated||Phase 2|12|Actual|Vernalis (R&D) Ltd||||Lack of efficacy|f||||f||||||||||2018-05-31 22:19:41.449801|2018-05-31 22:19:41.449801
NCT01401660|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-07-29|2011-07-21|2011-07-25|Estimate|||||||2011-07-29|2011-08-01|Estimate|May 2011||2011-05-31|July 2011|2011-07-31||||||||Observational|||Study of Low Back Pain Using CERSR® Imaging Technology|Observational Study of the Electrophysiological Course of Low Back Pain Using CERSR® Imaging Technology|Terminated|||290|Anticipated|Verium Diagnostics, Inc.|||3|Principal Investigator withdrew from the study.|f||||f||||||||||2018-05-31 22:19:41.529691|2018-05-31 22:19:41.529691
NCT01400802|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-01-24|2011-07-20|2011-07-22|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Interventional|||Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects||Withdrawn||Phase 1|0|Actual|Wockhardt||2||Study was not initiated|f||||f||||||||||2018-05-31 22:20:00.61295|2018-05-31 22:20:00.61295
NCT01401647|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2016-12-05||2017-03-18|2011-07-21|2011-07-25|Estimate|2016-12-05|2017-01-30|Estimate||||2017-03-18|2017-04-17|Actual|May 2012||2012-05-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|ALPS||Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia|Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT)|Completed||Phase 3|3024|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 22:19:41.664289|2018-05-31 22:19:41.664289
NCT01401634|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-22|2011-07-22|2011-07-25|Estimate|||||||2011-07-22|2011-07-25|Estimate|January 2011||2011-01-31|July 2011|2011-07-31||||June 2011|Actual|2011-06-30||Interventional|||Oral Hydration for Mild to Moderate Hyperglycemia in the Emergency Department||Completed||Phase 1|80|Anticipated|University of Southern California||2|||f||||||||||||||2018-05-31 22:19:42.243028|2018-05-31 22:19:42.243028
NCT01401621|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-10-08|2011-07-22|2011-07-25|Estimate|||||||2015-10-08|2015-10-12|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||The Effect of a Scratch Off Prompt on Health Engagement|The Effect of a Scratch Off Prompt on Health Engagement|Completed||N/A|84953|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 22:19:42.325284|2018-05-31 22:19:42.325284
NCT01401608|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-05-18|2011-07-22|2011-07-25|Estimate|||||||2015-05-18|2015-05-20|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Stereotaxis Idiopathic Ventricular Tachycardia (VT) Study|RF Ablation of Idiopathic VT and PVCs Using Remote Magnetic Navigation|Terminated|||6|Actual|Stereotaxis|||1|Difficult to recruit eligible subjects|f||||f||||||||||2018-05-31 22:19:42.529957|2018-05-31 22:19:42.529957
NCT01401595|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2014-12-01||2017-03-28|2011-07-21|2011-07-25|Estimate|2017-03-28|2017-05-09|Actual||||2017-03-28|2017-05-09|Actual|December 2009||2009-12-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|NES||Brain Imaging and Treatment Studies of the Night Eating Syndrome|Brain Imaging and Treatment Studies of the Night Eating Syndrome|Completed||Phase 3|87|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 22:19:42.644382|2018-05-31 22:19:42.644382
NCT01401582|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2016-10-17||2017-11-13|2011-07-22|2011-07-25|Estimate|2017-04-03|2017-06-16|Actual||||2017-11-13|2017-12-18|Actual|January 2012||2012-01-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2016|Actual|2016-03-31||Interventional|DelpHi|published in Thyrian et al. (2016). Journal of Alzheimer´s Disease (52); 69-617.|Intervention Study to Improve Life and Care for People With Dementia and Their Caregivers in Primary Care|Dementia: Life- and Personcentered Help in Germany|Active, not recruiting||N/A|634|Actual|German Center for Neurodegenerative Diseases (DZNE)||2|||f||||t||||||||No||2018-05-31 22:19:43.211925|2018-05-31 22:19:43.211925
NCT01401569|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2016-05-31|2011-07-22|2011-07-25|Estimate|||||||2016-05-31|2016-06-01|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|STOB-ACTIV||Efficacy of Exercise and Counseling Intervention on Relapse in Smoker With Depressive Disorders|STOB-ACTIV: The Efficacy of Exercise and Counseling for Depressed Patients as an Aid for Smoking Cessation, a Randomized Controlled Trial|Terminated||Phase 3|70|Actual|University Hospital, Montpellier||2||Difficulties for recruiting patients|f||||f||||||||||2018-05-31 22:19:43.561118|2018-05-31 22:19:43.561118
NCT01401556|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-09-16|2011-07-21|2011-07-25|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|July 2016|Actual|2016-07-31||Interventional|C-STOP#||C-STOP Fracture Trial|Comparing Strategies Targeting Osteoporosis to Prevent Recurrent Fractures: C-STOP# Randomized Trial|Active, not recruiting||Phase 3|360|Actual|University of Alberta||2|||f||||f||||||||Undecided||2018-05-31 22:19:43.697788|2018-05-31 22:19:43.697788
NCT01401543|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-09-12|2011-07-22|2011-07-25|Estimate|||||||2011-09-12|2011-09-13|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Bioavailability Study of LY2452473 and Tadalafil|LY2452473 Formulation Exploratory Bioavailability Study|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:19:43.827773|2018-05-31 22:19:43.827773
NCT01401530|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-02-05|2011-07-21|2011-07-25|Estimate|||||||2016-02-05|2016-02-08|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma|Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma|Completed||Phase 1|13|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 22:19:43.927737|2018-05-31 22:19:43.927737
NCT01401517|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2014-05-29||2014-05-29|2011-07-21|2011-07-25|Estimate|2014-05-29|2014-07-01|Estimate||||2014-05-29|2014-07-01|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC|A Randomized, Double-blinded, Placebo-controlled, Phase IIa Dose-ranging Study to Assess the Safety, Pharmacokinetics, and Tolerability of Multiple Doses of Sodium Nitrite in Patients With Peripheral Arterial Disease (PAD) - SONIC|Completed||Phase 2|55|Actual|TheraVasc Inc.||3|||f||||f||||||||||2018-05-31 22:19:44.127164|2018-05-31 22:19:44.127164
NCT01401504|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2014-06-10|2011-07-22|2011-07-25|Estimate|||||||2014-06-10|2014-06-11|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors|A Phase I, Non-randomized, Open-label, Repeat Oral Administration Study of ASP3026 in Patients With Solid Tumors|Completed||Phase 1|29|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-05-31 22:19:44.53079|2018-05-31 22:19:44.53079
NCT01401491|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-07-21|2011-07-21|2011-07-25|Estimate|||||||2011-07-21|2011-07-25|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine|Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and Fluvoxamine|Completed||Phase 4|80|Actual|Taipei Medical University Hospital||2|||f||||f||||||||||2018-05-31 22:19:44.630201|2018-05-31 22:19:44.630201
NCT01401478|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|2014-01-14||2014-02-28|2011-07-22|2011-07-25|Estimate|2014-01-14|2014-02-28|Estimate||||2014-02-28|2014-03-03|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation|Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation|Completed|||86|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:19:44.919323|2018-05-31 22:19:44.919323
NCT01400789|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-01-24|2011-07-21|2011-07-22|Estimate|||||||2013-01-24|2013-01-25|Estimate||||January 2013|2013-01-31||||||||Interventional|||Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Listro Mix 50/50® and Humalog Mix50/50® in Healthy Subjects||Withdrawn||Phase 1|0|Actual|Wockhardt||2||Study was not initiated|f||||f||||||||||2018-05-31 22:20:00.994341|2018-05-31 22:20:00.994341
NCT01401465|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-11-09||2013-04-29|2011-07-21|2011-07-25|Estimate|2013-04-29|2013-04-30|Estimate||||2013-04-29|2013-04-30|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray|A Randomized Two Period Two-Way Crossover Study To Evaluate Patient Preference, Satisfaction And Efficacy Of A Nasal Aerosol Versus An Aqueous Nasal Spray Used For The Treatment Of Allergic Rhinitis|Completed||Phase 3|327|Actual|Sunovion||2|||f||||f||||||||||2018-05-31 22:19:45.303818|2018-05-31 22:19:45.303818
NCT01401452|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|2017-05-12||2017-05-12|2011-07-22|2011-07-25|Estimate|2017-05-12|2017-10-04|Actual||||2017-05-12|2017-10-04|Actual|August 2011||2011-08-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|EPIC||Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities|Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities|Completed|||246|Actual|AbbVie|||1||f||||f||||||||No||2018-05-31 22:19:46.391454|2018-05-31 22:19:46.391454
NCT01401439|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2016-08-05|2011-07-22|2011-07-25|Estimate|||||||2016-08-05|2016-08-09|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|GAIA||Assessment of Fat Free Mass Index and Its Impact on Health in Children With Cystic Fibrosis|Longitudinal Assessment of Fat Free Mass Index and Its Impact on Lung Health and Overall Health Metrics in Pediatric Patients With Cystic Fibrosis|Completed|||24|Actual|University of Arkansas|||||f||||f||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 22:19:46.774739|2018-05-31 22:19:46.774739
NCT01401426|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2016-05-18|2011-07-22|2011-07-25|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Randomized Prospective Trial: Single Port Laparoscopic Vertical Sleeve Gastrectomy Versus Conventional Five Port Laparoscopic Vertical Sleeve Gastrectomy Surgery|Randomized Prospective Trial: Single Port Laparoscopic Vertical Sleeve Gastrectomy Versus Conventional Five Port Laparoscopic Vertical Sleeve Gastrectomy Surgery|Withdrawn||N/A|0|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||||||||||||2018-05-31 22:19:46.86939|2018-05-31 22:19:46.86939
NCT01401413|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2011-07-22|2011-07-22|2011-07-25|Estimate|||||||2011-07-22|2011-07-25|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Determine Whether Ramelteon Helps People With REM Sleep Behavior Disorder|A Prospective Randomized, Placebo-Controlled Double-Blind Study to Determine the Efficacy of Ramelteon in REM Sleep Behavior Disorder|Completed||Phase 4|20|Anticipated|Sleep Medicine Centers of WNY||2|||f||||f||||||||||2018-05-31 22:19:46.97869|2018-05-31 22:19:46.97869
NCT01401400|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2015-08-13|2011-07-22|2011-07-25|Estimate|||||||2015-08-13|2015-08-14|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|GIANT-B||Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study|Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study|Completed|||1350|Actual|Foundation for Liver Research|||1||f||||f||||||Samples With DNA|"~     whole blood samples from which DNA can be isolated~   "|||2018-05-31 22:19:47.132121|2018-05-31 22:19:47.132121
NCT01401387|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-02-21|2011-07-22|2011-07-25|Estimate|||||||2013-02-21|2013-02-22|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|EPC||Pancreatic Enzyme Suppletion in Pancreatic Cancer|Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy|Withdrawn||Phase 4|0|Actual|Foundation for Liver Research||2||study never started|f||||f||||||||||2018-05-31 22:19:47.19022|2018-05-31 22:19:47.19022
NCT01401374|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2017-04-07|2011-07-22|2011-07-25|Estimate|||||||2017-04-07|2017-04-10|Actual|March 2011||2011-03-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo|Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo|Completed|||3258|Actual|St. Luke's-Roosevelt Hospital Center|||2||f||||f||||||||||2018-05-31 22:19:47.274498|2018-05-31 22:19:47.274498
NCT01401361|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2013-11-04||2016-09-14|2011-07-21|2011-07-25|Estimate|2013-11-04|2013-12-23|Estimate||||2016-09-14|2016-10-25|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|CONTACT_AFL||Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System|Clinical Evaluation of Contact™ Therapy™ Cool Path™ Cardiac Ablation System in Conjunction With EnSite Velocity Contact™ Technology for the Treatment of Typical Atrial Flutter|Completed||Phase 3|150|Actual|St. Jude Medical||1|||f||||t||||||||No||2018-05-31 22:19:47.351672|2018-05-31 22:19:47.351672
NCT01401348|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-07-15|2011-07-22|2011-07-25|Estimate|||||||2015-07-15|2015-07-16|Estimate|December 2010||2010-12-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Stanford Universities: The Stanford HIV Aging Cohort|The Stanford HIV Aging Cohort (SHAC)|Unknown status|Active, not recruiting||300|Anticipated|Stanford University|||||f||||f||||||Samples Without DNA|"~     PBMC's~   "|||2018-05-31 22:19:47.559266|2018-05-31 22:19:47.559266
NCT01401335|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-21|2011-07-21|2011-07-25|Estimate|||||||2011-07-21|2011-07-25|Estimate|October 2009||2009-10-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||HIV Prevention and Care of Psychological Trauma in Vulnerable Rwandan Youth|A PILOT STUDY Integrating HIV Prevention and Care With Treatment of Psychological Trauma in Vulnerable Rwandan Youth: A Community-based Pilot Intervention|Completed||N/A|120|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 22:19:47.6245|2018-05-31 22:19:47.6245
NCT01401322|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2014-10-27||2016-10-17|2011-07-22|2011-07-25|Estimate|2014-11-03|2014-11-10|Estimate||||2016-10-17|2016-11-28|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional||Relapsed or refractory ALL (at least 1 failed prior treatment regimen)|Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia|Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|Terminated||Phase 2|5|Actual|Stanford University||1||low accrual|f||||t||||||||||2018-05-31 22:19:47.704343|2018-05-31 22:19:47.704343
NCT01401309|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2014-02-20|2011-07-21|2011-07-25|Estimate|||||||2014-02-20|2014-02-21|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|November 2011|Actual|2011-11-30||Observational|||PET Respiratory Gating to Detect Hepatic Metastasis in Patients With Colon Cancer|Effects of Respiratory Gating on FDG/PET Detection of Hepatic Metastasis in Patients With Colon Cancer|Completed|||81|Actual|Southwestern Regional Medical Center|||||f||||t||||||||||2018-05-31 22:19:47.866038|2018-05-31 22:19:47.866038
NCT01400256|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2016-05-06|2011-07-21|2011-07-22|Estimate|||||||2016-05-06|2016-05-09|Estimate|August 2007||2007-08-31|May 2016|2016-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|BLAST||Blood Pressure Lowering in Acute Stroke Trial|The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Affects on Cerebral Blood Flow|Withdrawn||Phase 4|0|Actual|Stanford University||||lack of recruitment/patient population|f||||t||||||||||2018-05-31 22:20:11.932053|2018-05-31 22:20:11.932053
NCT01401296|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-12-11|2011-07-22|2011-07-25|Estimate|||||||2014-12-11|2014-12-12|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of the Effectiveness of a Web-based Treatment Program for Depression for the Reduction of Depressive Symptoms|Evaluation of the Effectiveness of a Web-based Treatment Program for Depression (Deprexis) for the Reduction of Depressive Symptoms. A Randomized Controlled Trial|Completed||N/A|200|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 22:19:47.927142|2018-05-31 22:19:47.927142
NCT01401283|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2015-12-01||2016-01-06|2011-07-22|2011-07-25|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||GDT by Cardiac Index Trending Via a Radial Arterial Line in General Surgery|Multi-center, Prospective, Randomized Outcome Study Comparing Continuous Cardiac Index Trending Via a Radial Arterial Line Versus Standard Care in General Surgical Patients|Completed||N/A|160|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 22:19:48.020148|2018-05-31 22:19:48.020148
NCT01401270|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2018-05-08|2011-07-22|2011-07-25|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2011|Actual|2011-11-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Prize Contingency Management for Cocaine-Dependent Methadone Patients|Prize Contingency Management for Cocaine-Dependent Methadone Patients|Active, not recruiting||N/A|300|Anticipated|UConn Health||6|||f||||f||||||||||2018-05-31 22:19:48.235341|2018-05-31 22:19:48.235341
NCT01401257|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2016-12-23||2017-10-19|2011-07-22|2011-07-25|Estimate|2016-12-23|2017-02-16|Actual||||2017-10-19|2017-11-22|Actual|December 2010||2010-12-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A|A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A.|Completed||Phase 2|80|Actual|Pharnext SA||4|||f||||t||||||||No||2018-05-31 22:19:48.320164|2018-05-31 22:19:48.320164
NCT01401244|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-02-23|2011-07-22|2011-07-25|Estimate|||||||2017-02-23|2017-02-24|Actual|July 14, 2011|Actual|2011-07-14|February 2017|2017-02-28|September 27, 2011|Actual|2011-09-27|September 27, 2011|Actual|2011-09-27||Interventional|||Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers|A Trial to Examine the Bioequivalence of Norditropin® Versus Genotropin® in Healthy Adult Volunteers|Completed||Phase 1|30|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:19:48.625055|2018-05-31 22:19:48.625055
NCT01401231|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2017-10-11|2011-07-22|2011-07-25|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2011||2011-08-31|October 2017|2017-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Behavioral Activation for Perinatal Depression|Pilot Trial of Behavioral Activation Psychotherapy for Perinatal Depression|Completed||N/A|163|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 22:19:48.693175|2018-05-31 22:19:48.693175
NCT01401218|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-12-24|2011-07-22|2011-07-25|Estimate|||||||2013-12-24|2013-12-25|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Thoracic Aortic Surgery|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Thoracic Aortic Surgery|Completed|||799|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 22:19:48.759335|2018-05-31 22:19:48.759335
NCT01401205|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-12-24|2011-07-22|2011-07-25|Estimate|||||||2013-12-24|2013-12-25|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Predictor of Respiratory Discomfort After the Shoulder Arthroscopic Surgery|The Predictor of Respiratory Discomfort After the Shoulder Arthroscopic Surgery as Measured by Upper Airway Ultrasonography|Completed|||100|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 22:19:48.826215|2018-05-31 22:19:48.826215
NCT01401192|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-22|2011-07-22|2011-07-25|Estimate|||||||2011-07-22|2011-07-25|Estimate|July 2011||2011-07-31|July 2011|2011-07-31||||December 2013|Anticipated|2013-12-31||Interventional|||Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression|A Randomized Phase II Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Non-squamous Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|304|Anticipated|Samsung Medical Center||4|||f||||f||||||||||2018-05-31 22:19:48.89522|2018-05-31 22:19:48.89522
NCT01401179|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-08-05|2011-07-22|2011-07-25|Estimate|||||||2011-08-05|2011-08-08|Estimate|April 2005||2005-04-30|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|PPROM||Antibiotics Study in Preterm Premature Rupture of the Membranes|Randomized Phase III Trial of Cefazolin or Combination of Cefazolin and Erythromycin or Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of the Membranes|Completed||Phase 3|101|Actual|Samsung Medical Center||3|||f||||t||||||||||2018-05-31 22:19:48.992444|2018-05-31 22:19:48.992444
NCT01401166|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|2015-02-09||2017-01-19|2011-07-22|2011-07-25|Estimate|2015-06-03|2015-06-08|Estimate||||2017-01-19|2017-03-06|Actual|October 2011||2011-10-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|May 2013|Actual|2013-05-31||Interventional|PrefHER|Safety Population: All participants who received at least one dose of Herceptin.|Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer|A Randomized, Multi-Center Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC)|Completed||Phase 2|488|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 22:19:49.132773|2018-05-31 22:19:49.132773
NCT01401153|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2012-08-31||2012-10-09|2011-07-21|2011-07-25|Estimate|2012-10-09|2012-11-09|Estimate||||2012-10-09|2012-11-09|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CogniDO||Cognition Intervention Study Dortmund|Cross-over Trial Determining the Short-term Effects of Lunch on Children's Cognitive Functioning|Completed||N/A|105|Actual|Research Institute of Child Nutrition, Dortmund|"Open-label study, in which everyone involved knew about group assignment~Only one cognitive assessment per test day"|2|||f||||f||||||||||2018-05-31 22:19:50.266118|2018-05-31 22:19:50.266118
NCT01401140|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-03-16|2011-07-22|2011-07-25|Estimate|||||||2012-03-16|2012-03-19|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Cardioplégie||Comparing the Protective Effects of Two Cardioplegic Solutions, on Cardiac Metabolism, as Assessed Using Microdialysis|Coronary Surgery: Comparing the Protective Effects of Two Cardioplegic Solutions: Custodiol Versus St Thomas, on Cardiac Metabolism, as Assessed Using Microdialysis|Completed||Phase 3|29|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 22:19:50.771169|2018-05-31 22:19:50.771169
NCT01103778|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2018-04-30|2010-04-14|2010-04-15|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2010||2010-07-31|April 2018|2018-04-30|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Interventional|||Pilot Study of Velcade® in IgA Nephropathy|Velcade Therapy for Severe IgA Nephropathy|Completed||Phase 4|11|Actual|The Rogosin Institute||1|||f||||f||||||||||2018-05-31 23:54:13.355137|2018-05-31 23:54:13.355137
NCT01401127|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-11-07|2011-07-22|2011-07-25|Estimate|||||||2011-11-07|2011-11-08|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Managing Insulin Pumps for Exercise - Study 1|A Comparison of Metabolism During Moderate Exercise Between Healthy Volunteers and People With T1DM Treated With CSII Using 70% of Their Usual Insulin Basal Rate|Completed|||16|Anticipated|Buckinghamshire Healthcare NHS Trust|||2||f||||f||||||Samples Without DNA|"~     All samples retained will be plasma samples. Any samples remaining after analysis will be~     retained until the 3 trials in this research study have been completed, and will then be~     destroyed.~   "|||2018-05-31 22:19:50.859589|2018-05-31 22:19:50.859589
NCT01401114|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2015-09-25|2011-07-22|2011-07-25|Estimate|||||||2015-09-25|2015-09-28|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|WELLNARA||Wellnara Post-marketing Surveillance in Japan|Drug Use Investigation of Wellnara Tablet|Completed|||411|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:19:50.939766|2018-05-31 22:19:50.939766
NCT01401101|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2015-06-28||2016-07-21|2011-07-22|2011-07-25|Estimate|2016-07-21|2016-09-02|Estimate||||2016-07-21|2016-09-02|Estimate|June 2010||2010-06-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|ViStA|We randomized 206 patients to the PCM condition and 198 to the ECE conditions. However, only 355 patients of the 404 patients randomized completed the baseline survey, So, 49 patients have missing data in the evaluation.|Violence and Stress Assessment (ViStA) Project to Improve Post Traumatic Stress Disorder Management in Primary Care|Improving PTSD Management in Primary Care|Completed||Phase 2|404|Actual|RAND||2|||f||||f||||||||No|No data sharing plan was associated with this project at the time it was funded.|2018-05-31 22:19:51.019276|2018-05-31 22:19:51.019276
NCT01401088|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-01-02|2011-07-22|2011-07-25|Estimate|||||||2013-01-02|2013-01-03|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|AADI||Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma|Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma|Unknown status|Recruiting|Phase 4|30|Anticipated|Aurolab||1|||f||||f||||||||||2018-05-31 22:19:51.373429|2018-05-31 22:19:51.373429
NCT01401075|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2012-11-06|2011-07-22|2011-07-25|Estimate|||||||2012-11-06|2012-11-07|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients|Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation|Completed||Phase 4|32|Actual|Abnoba Gmbh||2|||f||||f||||||||||2018-05-31 22:19:51.491972|2018-05-31 22:19:51.491972
NCT01401062|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2017-02-21||2018-02-14|2011-07-21|2011-07-25|Estimate|2017-02-21|2017-04-06|Actual||||2018-02-14|2018-03-16|Actual|July 2011||2011-07-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2014|Actual|2014-06-30||Interventional|||Fresolimumab and Radiotherapy in Metastatic Breast Cancer|Fresolimumab and Radiotherapy in Metastatic Breast Cancer|Active, not recruiting||Phase 2|23|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 22:19:51.684956|2018-05-31 22:19:51.684956
NCT01401049|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2014-12-22||2017-12-04|2011-07-22|2011-07-25|Estimate|2014-12-22|2015-01-26|Estimate||||2017-12-04|2017-12-29|Actual|August 2010||2010-08-31|December 2017|2017-12-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional||Due to flooding from Hurricane Sandy at our site, all files and pertinent patient data were lost.|Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol|Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol|Completed||Phase 4|116|Actual|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 22:19:52.15215|2018-05-31 22:19:52.15215
NCT01401036|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-11-27|2011-07-22|2011-07-25|Estimate|||||||2014-11-27|2014-12-02|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Nobori And Uncoated Stent In Coronary Attack|Clinical Trial of Nobori Versus Uncoated Stents In Acute Myocardial Infarction|Unknown status|Recruiting|N/A|1400|Anticipated|NAUSICA Investigators||2|||f||||t||||||||||2018-05-31 22:19:53.456943|2018-05-31 22:19:53.456943
NCT01401023|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2013-07-30||2015-10-12|2011-07-21|2011-07-25|Estimate|2013-07-30|2013-10-14|Estimate||||2015-10-12|2015-10-14|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)|Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)|Completed||N/A|10|Actual|Michigan State University||1|||f||||t||||||||||2018-05-31 22:19:53.861523|2018-05-31 22:19:53.861523
NCT01401010|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2012-03-06||2015-10-12|2011-07-22|2011-07-25|Estimate|2012-05-02|2012-06-05|Estimate||||2015-10-12|2015-10-14|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients|Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection|Completed||Phase 4|12|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 22:19:54.370659|2018-05-31 22:19:54.370659
NCT01400997|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2017-12-22|2011-07-22|2011-07-25|Estimate|||||||2017-12-22|2017-12-26|Actual|September 30, 2011|Actual|2011-09-30|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS CZ||Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Czech Republic|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Czech Republic|Completed|||206|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:19:55.032536|2018-05-31 22:19:55.032536
NCT01400984|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2017-12-22|2011-07-22|2011-07-25|Estimate|||||||2017-12-22|2017-12-26|Actual|December 31, 2011|Actual|2011-12-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS SVK||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Slovakia|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Slovakia|Completed|||92|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:19:55.187731|2018-05-31 22:19:55.187731
NCT01400971|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-10-26|2011-07-21|2011-07-25|Estimate|||||||2015-10-26|2015-10-27|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|MOSAIc||An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes|A Multinational Observational Study Assessing Insulin Use: Understanding the Challenges Associated With Progression of Therapy - The MOSAIc Type 2 Diabetes Study|Completed|||4530|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-05-31 22:19:55.328558|2018-05-31 22:19:55.328558
NCT01400958|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2013-08-06||2013-10-25|2011-07-22|2011-07-25|Estimate|2013-10-25|2013-12-16|Estimate||||2013-10-25|2013-12-16|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional||All participants|Nuvigil or Placebo in Newly Diagnosed Malignant Glioma|A Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Nuvigil® (Armodafinil) in Newly Diagnosed Malignant Glioma Patients Experiencing Fatigue Secondary to External Beam Radiation Therapy and Concurrent Temozolomide|Terminated||Phase 2|6|Actual|H. Lee Moffitt Cancer Center and Research Institute|Planned accrual of 60 participants for analysis was not met. Recruitment was closed early due to slow accrual and initiating Principal Investigator (PI) leaving Moffitt.|2||Slow Accrual, Initiating Principal Investigator (PI) left Moffitt|f||||t||||||||||2018-05-31 22:19:55.669578|2018-05-31 22:19:55.669578
NCT01400945|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-09-19|2011-07-22|2011-07-25|Estimate|||||||2011-09-19|2011-09-21|Estimate|December 2009||2009-12-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|AGSPT||Efficacy Study of AGSPT201 Tablet to Treat Gastroesophageal Reflux Disease|Double Blinded, Randomized, Active Drug Comparative, Therapeutic Confirmatory Clinical Study to Evaluate the Efficacy and Safety of AGSPT201 in GERD Patients|Completed||Phase 3|154|Actual|Ahn-Gook Pharmaceuticals Co.,Ltd||1|||f||||t||||||||||2018-05-31 22:19:56.044491|2018-05-31 22:19:56.044491
NCT01400932|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2014-07-10||2014-07-10|2011-07-21|2011-07-25|Estimate|2014-07-10|2014-08-05|Estimate||||2014-07-10|2014-08-05|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects|Study STF115288, a Clinical Confirmation Study of GI148512 (Benzoyl Peroxide 3% Gel) in the Treatment of Acne Vulgaris in Japanese Subjects.- A Multicenter, Randomized, Double-blinded, Vehicle-controlled, Parallel-group Study -|Completed||Phase 3|360|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:19:56.220782|2018-05-31 22:19:56.220782
NCT01400919|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2015-06-08||2018-02-05|2011-07-21|2011-07-25|Estimate|2015-06-08|2015-06-24|Estimate||||2018-02-05|2018-03-07|Actual|July 2011||2011-07-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|November 2013|Actual|2013-11-30||Interventional|||DURABILITY™ Iliac Study|Protege® EverFlex™ and GPS™ Self-Expanding Iliac Study (DURABILITY™ Iliac)|Completed||N/A|75|Actual|Medtronic Endovascular||1|||f||||||||||||||2018-05-31 22:19:57.06338|2018-05-31 22:19:57.06338
NCT01400906|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2013-07-18||2016-11-18|2011-07-21|2011-07-25|Estimate|2013-07-30|2013-09-30|Estimate||||2016-11-18|2017-01-09|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.|A Randomized, Double Blind, Placebo-controlled Three-way Crossover Study in Mild Asthmatics to Evaluate the Effect of Smoking Status on the Attenuation by Inhaled Corticosteroids of the Allergen-induced Asthmatic Response.|Completed||Phase 2|36|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:19:57.391548|2018-05-31 22:19:57.391548
NCT01400893|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2017-03-14||2017-08-29|2011-07-21|2011-07-25|Estimate|2017-07-28|2017-08-29|Actual||||2017-08-29|2017-09-27|Actual|August 2011||2011-08-31|May 2017|2017-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury|A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)|Terminated||Phase 2|134|Actual|CytoPherx, Inc||2|||f||||t||||||||||2018-05-31 22:19:58.025483|2018-05-31 22:19:58.025483
NCT01400880|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2014-09-09||2015-02-10|2011-07-21|2011-07-22|Estimate|2015-02-10|2015-02-12|Estimate||||2015-02-10|2015-02-12|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational||The number of participants was determined by the time allowable by the IRB approval for the site study.|Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability|Electrode-based Sensor for Non-invasive Fetal Heart Rate and EMG Monitoring With Improved Reliability|Completed|||103|Actual|Convergent Engineering, Inc.|||1||f||||f||||||||||2018-05-31 22:19:58.450265|2018-05-31 22:19:58.450265
NCT01400867|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-01-12|2011-07-21|2011-07-22|Estimate|||||||2015-01-12|2015-01-13|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections|A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 2/Phase 3|163|Actual|Forest Laboratories||2|||f||||t||||||||||2018-05-31 22:19:58.60534|2018-05-31 22:19:58.60534
NCT01400854|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-10-23|2011-07-21|2011-07-22|Estimate|||||||2012-10-23|2012-10-24|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|ERKENTNIS||Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability|ERKENTNIS: Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability|Completed|||600|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-05-31 22:19:58.775538|2018-05-31 22:19:58.775538
NCT01400841|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2016-09-30||2016-11-27|2011-07-21|2011-07-22|Estimate|2016-09-30|2016-11-22|Estimate||||2016-11-27|2017-01-13|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|September 2014|Actual|2014-09-30|April 2013|Actual|2013-04-30||Interventional|||HAART Model 300 Annuloplasty Ring|A Prospective, Non-randomized, Multi-center Trial to Evaluate the Safety and Effectiveness of the HAART Model 300 Annuloplasty Ring When Used to Surgically Repair a Leaking Aortic Valve Using a 3-D Intra-annular Mounting Frame|Completed||N/A|18|Actual|Biostable Science & Engineering||1|||f||||t||||||||Undecided||2018-05-31 22:19:58.881269|2018-05-31 22:19:58.881269
NCT01400828|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-07-08|2011-07-21|2011-07-22|Estimate|||||||2014-07-08|2014-07-10|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis|Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|239|Actual|Yuhan Corporation||3|||f||||f||||||||||2018-05-31 22:20:00.229649|2018-05-31 22:20:00.229649
NCT01400815|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-10-25|2011-07-21|2011-07-22|Estimate|||||||2011-10-25|2011-10-26|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|January 2012|Anticipated|2012-01-31|November 2011|Anticipated|2011-11-30||Interventional|||Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid|A Prospective, Double-blind, Randomized, Active Controlled, Parallel Group, Multicenter Phase II Clinical Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid|Unknown status|Active, not recruiting|Phase 2|216|Anticipated|22nd Century Limited, LLC||2|||f||||f||||||||||2018-05-31 22:20:00.369109|2018-05-31 22:20:00.369109
NCT01400776|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20||2013-02-28|2015-02-24|2011-07-20|2011-07-22|Estimate||||2013-02-28|2013-03-08|Estimate|2015-02-24|2015-03-17|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|VENUS||Safety & Efficacy WC3011 in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women|A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of WC3011 in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women|Completed||Phase 3|722|Actual|Warner Chilcott||4|||f||||f||||||||||2018-05-31 22:20:01.192115|2018-05-31 22:20:01.192115
NCT01400763|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|METC-11/07||Lutein Bioavailability From Fresh and Dried Beverages|Bioavailability of Lutein From a Lutein-enriched Egg-yolk-beverage and Its Dried Re-suspended Versions.|Completed||N/A|103|Actual|Wageningen University|||||f||||t||||||||||2018-05-31 22:20:01.610059|2018-05-31 22:20:01.610059
NCT01400750|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-08-03|2011-07-21|2011-07-22|Estimate|||||||2011-08-03|2011-08-04|Estimate|August 2001||2001-08-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|August 2010|Actual|2010-08-31||Interventional|CCTOBI||Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis|Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.|Completed||Phase 4|61|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 22:20:01.719785|2018-05-31 22:20:01.719785
NCT01400737|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|OIP||Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants|Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants|Unknown status|Recruiting|N/A|200|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||1|||f||||f||||||||||2018-05-31 22:20:01.957925|2018-05-31 22:20:01.957925
NCT01400724|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-07-15|2011-07-21|2011-07-22|Estimate|||||||2013-07-15|2013-07-16|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Inofolic NRT and the Metabolic Syndrome|Effects of Inofolic NRT on Post-menopausal Women Affected by the Metabolic Syndrome|Completed||N/A|80|Actual|University of Messina||1|||f||||f||||||||||2018-05-31 22:20:02.766753|2018-05-31 22:20:02.766753
NCT01400711|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|October 2010||2010-10-31|August 2010|2010-08-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Enhanced Recovery After Surgery in Major Intrabdominal Procedures.|Enhanced Recovery After Surgery (ERAS) Versus Conventional Postoperative Care in Patients Undergoing Major Intra-abdominal Surgery.|Completed||N/A|54|Actual|St. Andrew's General Hospital, Patras, Greece||2|||f||||f||||||||||2018-05-31 22:20:03.794582|2018-05-31 22:20:03.794582
NCT01400698|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2012-06-27||2013-09-09|2011-07-21|2011-07-22|Estimate|2012-08-24|2012-09-25|Estimate||||2013-09-09|2013-09-18|Estimate|November 1998||1998-11-30|September 2013|2013-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Saizen in Intra-uterine Growth Retardation|An Open Study of the Safety and Efficacy of Saizen®, (Recombinant Human Growth Hormone, r-hGH), in Children Born With Serious Intra-uterine Growth Retardation (IUGR) Treated to Final Height|Completed||Phase 3|91|Actual|Merck KGaA||3|||f||||||||||||||2018-05-31 22:20:03.885612|2018-05-31 22:20:03.885612
NCT01400685|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2018-01-23|2011-07-21|2011-07-22|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2012||2012-12-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL|Lenalidomide in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma(CLL/SLL): a Phase I Study|Completed||Phase 1|34|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-05-31 22:20:05.102152|2018-05-31 22:20:05.102152
NCT01400672|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-11-29|2011-07-21|2011-07-22|Estimate|||||||2017-11-29|2017-12-02|Actual|July 17, 2012|Actual|2012-07-17|November 2017|2017-11-30|October 10, 2015|Actual|2015-10-10|June 17, 2015|Actual|2015-06-17||Interventional|||Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma|Imiquimod/BTIC Lysate-Based Vaccine Immunotherapy for Diffuse Intrinsic Pontine Glioma in Children and Young Adults|Completed||Phase 1|8|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 22:20:05.184621|2018-05-31 22:20:05.184621
NCT01400659|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-12-17|2011-07-21|2011-07-22|Estimate|||||||2015-12-17|2015-12-18|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Pizza-Salami Study in Children and Adolescents With Type 1 Diabetes|The PIZZA-Salami Trial: Monocentric Randomised Cross-over Study of Carb Counting vs. Carb Plus Fat/Protein Counting Based Insulin Bolus Used for Sensor-augmented Continuous Subcutaneous Insulin Infusion (CSII) in Pediatric Patients|Completed||Phase 4|42|Actual|Kinderkrankenhaus auf der Bult||2|||f||||f||||||||||2018-05-31 22:20:05.260461|2018-05-31 22:20:05.260461
NCT01400646|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2017-01-23|2011-07-21|2011-07-22|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers|An Open-Label, Non-Randomized, Sequential Two-Treatment Period Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin|Completed||Phase 1|46|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 22:20:05.349229|2018-05-31 22:20:05.349229
NCT01400633|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-05-22|2011-07-21|2011-07-22|Estimate|||||||2015-05-22|2015-05-25|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome|A Prospective Multicenter Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome|Completed|||156|Actual|Janssen Korea, Ltd., Korea|||1||f||||||||||||||2018-05-31 22:20:05.550744|2018-05-31 22:20:05.550744
NCT01400620|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2018-03-12|2011-07-21|2011-07-22|Estimate|||||||2018-03-12|2018-03-13|Actual|March 2012||2012-03-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer|Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer|Completed||Phase 2|110|Actual|Izun Pharma Ltd||2|||f||||f||||||||||2018-05-31 22:20:05.65218|2018-05-31 22:20:05.65218
NCT01400607|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-08-29|2011-07-21|2011-07-22|Estimate|||||||2017-08-29|2017-08-31|Actual|July 2011||2011-07-31|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Neocartilage Implant to Treat Cartilage Lesions of the Knee|Randomized Controlled Trial to Evaluate the Efficacy of a Neocartilage Implant in the Management of ICRS Grade 3 to 4 Articular Cartilage Lesions of the Knee|Terminated||Phase 3|14|Actual|ISTO Technologies, Inc.||2||Poor enrollment|f||||t||||||||||2018-05-31 22:20:05.859119|2018-05-31 22:20:05.859119
NCT01400594|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20||2015-03-17|2015-05-12|2011-07-21|2011-07-22|Estimate||||2015-05-12|2015-06-04|Estimate|2015-05-12|2015-06-04|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail|A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety & Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail|Completed||Phase 2|182|Actual|Hisamitsu Pharmaceutical Co., Inc.||2|||f||||f||||||||||2018-05-31 22:20:05.960429|2018-05-31 22:20:05.960429
NCT01400581|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2017-10-11|2011-07-21|2011-07-22|Estimate|||||||2017-10-11|2017-10-13|Actual|November 2011||2011-11-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CHOICE||Considering Healthier Drinking Options in Collaborative Care|Collaborative Care for Primary Care Patients With Alcohol Use Disorders|Completed||N/A|304|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 22:20:06.11747|2018-05-31 22:20:06.11747
NCT01400568|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-03-09|2011-07-21|2011-07-22|Estimate|||||||2012-03-09|2012-03-12|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Suitability of a Low Dose Lipopolysaccharide (LPS) Inhalation as a Challenge Model|A Methodological Pilot Study to Assess the Suitability of a Low Dose LPS Inhalation as a Challenge Model in Early Translational Drug Development|Completed||N/A|12|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f||||f||||||||||2018-05-31 22:20:06.239781|2018-05-31 22:20:06.239781
NCT01400555|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2018-03-19|2011-07-21|2011-07-22|Estimate|||||||2018-03-19|2018-03-21|Actual|September 1, 2011|Actual|2011-09-01|March 2018|2018-03-31|February 28, 2017|Actual|2017-02-28|May 12, 2014|Actual|2014-05-12||Interventional|mCRPC||A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|A Phase 1b Safety Study of Abiraterone Acetate (JNJ-212082) and Docetaxel in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Completed||Phase 1|22|Actual|Cougar Biotechnology, Inc.||4|||f||||t||f||||||||2018-05-31 22:20:06.317515|2018-05-31 22:20:06.317515
NCT01400542|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2016-08-09|2011-07-21|2011-07-22|Estimate|||||||2016-08-09|2016-08-11|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|AZAP||Sleep Apnea in Early to Mid-Stage Alzheimer's Disease|Sleep Apnea in Early to Mid-Stage Alzheimer's Disease: What Impact of Treatment on the Cognitive Functions of Elderly Patients With Memory Loss?|Terminated|||22|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2|End of the study because of the inclusions were too difficult|f||||f||||||||No||2018-05-31 22:20:06.413454|2018-05-31 22:20:06.413454
NCT01400529|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|March 2007||2007-03-31|July 2007|2007-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|3000ARTHROSE||Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey|Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey. Programme de Recherche du Groupe Qualité de Vie, de la Section Epidémiologie et de la Section Arthrose de la Société Française de Rhumatologie|Completed|||3000|Actual|Central Hospital, Nancy, France|||||f||||t||||||||||2018-05-31 22:20:06.51266|2018-05-31 22:20:06.51266
NCT01400516|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2017-02-28||2017-02-28|2011-07-21|2011-07-22|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|August 2011||2011-08-31|February 2017|2017-02-28|July 28, 2016|Actual|2016-07-28|July 30, 2015|Actual|2015-07-30||Interventional|TERA|Analysis includes 24 participants who were randomized, 2 participants withdrew prematurely and are not included.|Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial|Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial|Completed||Phase 4|26|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 22:20:06.598782|2018-05-31 22:20:06.598782
NCT01400503|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2018-03-01||2018-04-25|2011-07-21|2011-07-22|Estimate|2018-03-01|2018-03-29|Actual||||2018-04-25|2018-05-22|Actual|April 1, 2011|Actual|2011-04-01|April 2018|2018-04-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease|An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease|Completed||Phase 2|60|Actual|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 22:20:06.998007|2018-05-31 22:20:06.998007
NCT01400490|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study|Evaluation of the Biologic Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)-Enriched Oils (EPA-DHA Study)|Unknown status|Active, not recruiting|N/A|120|Anticipated|Cardiovascular Research Associates||4|||f||||f||||||||||2018-05-31 22:20:07.626862|2018-05-31 22:20:07.626862
NCT01400477|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-02-28|2011-07-20|2011-07-22|Estimate|||||||2017-02-28|2017-03-03|Actual|July 2011||2011-07-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Nicotinic Receptors and Schizophrenia|Nicotinic Receptors and Schizophrenia: Phase II|Completed||Phase 2|97|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 22:20:07.717187|2018-05-31 22:20:07.717187
NCT01400464|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-04-08|2011-07-21|2011-07-22|Estimate|||||||2014-04-08|2014-04-09|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|PREDICORT||Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis|Study the Link Between Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|University Hospital, Caen|||||f||||f||||||||||2018-05-31 22:20:07.831332|2018-05-31 22:20:07.831332
NCT01400451|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2014-04-21||2014-12-10|2011-07-21|2011-07-22|Estimate|2014-04-21|2014-05-19|Estimate||||2014-12-10|2015-01-01|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional||All participants who received at least one dose of study drug.|Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)|A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma|Terminated||Phase 1|18|Actual|Bristol-Myers Squibb|In Phase 1 of the study, MTD was not reached because more than 2 of 6 treated participants experienced DLTs with the combination therapy. Enrollments in Phase 1 were terminated and Phase 2 was not started so only overall safety was summarized.|1||More than 2 of 6 patients treated experienced dose limiting toxicities.|f||||f||||||||||2018-05-31 22:20:07.940194|2018-05-31 22:20:07.940194
NCT01400438|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-07-20|2011-07-21|2011-07-22|Estimate|||||||2016-07-20|2016-07-21|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|HER-ception||Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer|Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer: Fatigue and Quality of Life During and Waning of Treatment, Psychosocial Aspects (Environment, Work)|Completed||N/A|70|Actual|Centre Francois Baclesse||2|||f||||f||||||||||2018-05-31 22:20:09.09783|2018-05-31 22:20:09.09783
NCT01400425|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2012-12-06||2013-03-22|2011-07-21|2011-07-22|Estimate|2013-02-15|2013-03-22|Estimate||||2013-03-22|2013-03-29|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline|Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline|Completed||Phase 3|239|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 22:20:09.199744|2018-05-31 22:20:09.199744
NCT01400412|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|2015-06-17||2018-01-24|2011-07-21|2011-07-22|Estimate|2015-06-17|2015-07-15|Estimate||||2018-01-24|2018-02-22|Actual|December 2011||2011-12-31|January 2018|2018-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Participants who started study treatment|Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen|A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1|Completed||Phase 2|262|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 22:20:09.525655|2018-05-31 22:20:09.525655
NCT01400399|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-12-08|2011-07-20|2011-07-22|Estimate|||||||2015-12-08|2015-12-09|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|August 2020|Anticipated|2020-08-31|August 2016|Anticipated|2016-08-31||Observational|||Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer|Phase II Evaluation of Hypofractionated Breast Irradiation in Patients Undergoing Standard Lumpectomy or Oncolytic Mammoplasty With Bilateral Breast Reduction|Recruiting|||84|Anticipated|Coastal Carolina Radiation Oncology|||||f||||f||||||||||2018-05-31 22:20:10.149227|2018-05-31 22:20:10.149227
NCT01400386|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-05-21|2011-07-21|2011-07-22|Estimate|||||||2014-05-21|2014-05-22|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2011|Actual|2011-06-30||Interventional|||Bioavailability of Chlorogenic and Phenolic Acids From Soluble Coffees|Bioavailability of Chlorogenic and Phenolic Acids From Soluble Coffees|Completed||N/A|14|Actual|Nestlé||4|||f||||t||||||||||2018-05-31 22:20:10.205616|2018-05-31 22:20:10.205616
NCT01400373|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-05-16|2011-07-21|2011-07-22|Estimate|||||||2018-05-16|2018-05-18|Actual|June 2010||2010-06-30|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|January 31, 2018|Actual|2018-01-31||Interventional|PRINCESS||Prehospital Resuscitation Intra Nasal Cooling Effectiveness Survival Study|PRINCESS - Prehospital Resuscitation Intra Nasal Cooling Effectiveness Survival Study|Completed||Phase 2|700|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:20:10.307662|2018-05-31 22:20:10.307662
NCT01400360|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|August 2009||2009-08-31|May 2011|2011-05-31||||August 2011|Anticipated|2011-08-31||Interventional|IMCVS||Invasive Diagnostic and Therapeutic Management of Cerebral Vasospasm After Aneurysmatic Subarachnoid Hemorrhage|Invasive Diagnostic and Therapeutic Management of Cerebral Vasospasm After Aneurysmatic Subarachnoid Hemorrhage|Unknown status|Recruiting|N/A|92|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 22:20:10.38676|2018-05-31 22:20:10.38676
NCT01400347|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-07-20|2011-07-20|2011-07-22|Estimate|||||||2011-07-20|2011-07-22|Estimate|July 2012||2012-07-31|November 2009|2009-11-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|||Electromyography During Common Exercises Used in Rehabilitation|Influence of Fatigue and Speed on Electromyographic Activity of Lower Extremity Muscles During Selected Weight Bearing Exercises Commonly Used for Fitness and Rehabilitation|Unknown status|Not yet recruiting||20|Anticipated|State University of New York - Upstate Medical University|||||f||||t||||||||||2018-05-31 22:20:10.463682|2018-05-31 22:20:10.463682
NCT01400334|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-12-08|2011-07-20|2011-07-22|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2004||2004-07-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|PAREPET||Prediction of ARrhythmic Events With Positron Emission Tomography|Hibernating Myocardium and Sudden Cardiac Death|Completed|||257|Actual|State University of New York at Buffalo|||1||f||||t||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 22:20:10.51735|2018-05-31 22:20:10.51735
NCT01400321|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2012-11-15|2011-07-21|2011-07-22|Estimate|||||||2012-11-15|2012-11-16|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|GAST||PEERS Multicenter Osseospeed TM TX Profile Implant: German Astra Soft Tissue (GAST) Maintenance Study|PEERS Multicenter OsseoSpeedTM TX Profile Implant: German Astra Soft Tissue (GAST) Maintenance Study An Open, Prospective Observational Study to Evaluate Implant Stability, Marginal Bone and Soft Tissue Maintenance of the Astra Tech Dental Implant System: OsseoSpeedTM TX Profile Implant in Patients With Tooth Loss in the Aesthetic Zone or the Posterior Atrophied Mandible|Unknown status|Recruiting||300|Anticipated|Johannes Gutenberg University Mainz|||2||f||||f||||||||||2018-05-31 22:20:10.592499|2018-05-31 22:20:10.592499
NCT01400308|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-08-01|2011-07-21|2011-07-22|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA)|Clinical Trial to Compare the Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by MRSA (Methicillin Resistant Staphylococcus Aureus)|Terminated||Phase 4|99|Actual|B. Braun Medical SA||2||"The differences seen between treatments led to recalculation of the sample, unattainable in a~   reasonable time"|f||||f||||||||||2018-05-31 22:20:10.704333|2018-05-31 22:20:10.704333
NCT01400295|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-09-14|2011-07-21|2011-07-22|Estimate|||||||2014-09-14|2014-09-16|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PRECOMIN||PREdictive Value of COntrast voluMe to creatinINe Clearance Ratio|Predictive Value of the Contrast Media Volume to Creatinine Clearance Ratio for the Risk of Contrast-Induced Nephropathy After Coronary Angiography|Completed|||3000|Actual|Guangdong General Hospital|||1||f||||t||||||||||2018-05-31 22:20:11.713922|2018-05-31 22:20:11.713922
NCT01400282|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||Analgesic Efficacy of High Frequency Spinal Cord Stimulation|Analgesic Efficacy of High Frequency Spinal Cord Stimulation: a Placebo-controlled Study|Unknown status|Recruiting|Phase 4|30|Anticipated|Ensemble Hospitalier de la Côte||2|||f||||t||||||||||2018-05-31 22:20:11.775981|2018-05-31 22:20:11.775981
NCT01400269|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2016-08-12|2011-07-21|2011-07-22|Estimate|||||||2016-08-12|2016-08-16|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||An Evaluation of a Developmentally-Based Parent Training Program for Children With Autism|An Evaluation of a Developmentally-Based Parent Training Program for Children With Autism|Completed||N/A|48|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 22:20:11.854355|2018-05-31 22:20:11.854355
NCT01400243|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2015-02-20||2015-04-16|2011-07-21|2011-07-22|Estimate|2015-04-16|2015-04-30|Estimate||||2015-04-16|2015-04-30|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|NMW||Nicotine Patch for Marijuana Withdrawal|Nicotine for Marijuana Withdrawal|Completed||Phase 4|127|Actual|Southern Illinois University Carbondale|The modest sample size limited the ability to precisely characterize how the effects of patch type may be modified by tobacco smoker status, gender, personality traits, and individual differences in marijuana use history.|2|||f||||t||||||||||2018-05-31 22:20:12.026274|2018-05-31 22:20:12.026274
NCT01400230|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2015-03-23|2011-07-20|2011-07-22|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|IMAGES-FFR||Diagnostic Performances of Computed TomographIc Coronary Angiography and Intravascular Ultrasound|Diagnostic Performances of the Computed Tomographic Coronary Angiography and IntraVascular UltraSound to Evaluate Ischemia Causing Coronary Artery Stenosis|Completed|||150|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 22:20:12.673247|2018-05-31 22:20:12.673247
NCT01400217|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-10-29|2011-07-21|2011-07-22|Estimate|||||||2012-10-29|2012-10-30|Estimate|January 1991||1991-01-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Qvar Versus Clenil, a General Practice Research Database Study|HFA Beclomethasone in Asthma, a General Practice Research Database Study: Real-life Observational Evaluation of Extra-fine With Standard Particle Size Beclometasone Dipropionate Using the Propellant Hydrofluoroalkane 134a for the Management of Asthma in a Representative UK Primary Care Population|Completed|||56985|Actual|Research in Real-Life Ltd|||6||f||||t||||||||||2018-05-31 22:20:12.767745|2018-05-31 22:20:12.767745
NCT01400204|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Naturalistic Study Into the Hangover Effects of MDMA|A Naturalistic Study Comparing the Hangover Effects of MDMA, Other Drugs, and Alcohol in a Sample of Recreational Polydrug Users|Completed|||39|Actual|Utrecht Institute for Pharmaceutical Sciences|||3||f||||f||||||||||2018-05-31 22:20:12.875727|2018-05-31 22:20:12.875727
NCT01400191|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-06-25|2011-07-21|2011-07-22|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1|The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1 (OCT1) in Healthy Volunteers|Completed||Phase 4|37|Actual|University of Southern Denmark||3|||f||||t||||||||||2018-05-31 22:20:12.944849|2018-05-31 22:20:12.944849
NCT01400178|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-10-28|2011-07-21|2011-07-22|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Observational|||Cochlear Implants in Post-lingually Children: Results After 10 Years|Cochlear Implants in Post-lingually Children: Results After 10 Years|Completed|||10|Actual|University of Sao Paulo|||||f||||t||||||||||2018-05-31 22:20:13.004294|2018-05-31 22:20:13.004294
NCT01400165|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Comparison of the Pharmacokinetics of Three Generic Medications and Their Respective Brand Preparations|Examination of the Pharmacokinetic Properties of Three Generic Medications and Their Respective Brand Preparations in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1|30|Anticipated|University of Ottawa||3|||f||||f||||||||||2018-05-31 22:20:13.083854|2018-05-31 22:20:13.083854
NCT01400152|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|December 2007||2007-12-31|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Active Warming in Prehospital Trauma Care|The Effect of Active Warming in Prehospital Trauma Care During Road and Air Ambulance Transportation - a Clinical Randomized Trial|Completed||N/A|48|Actual|Umeå University||2|||f||||t||||||||||2018-05-31 22:20:13.174399|2018-05-31 22:20:13.174399
NCT01400139|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2014-12-01||2017-09-22|2011-07-20|2011-07-22|Estimate|2014-12-01|2014-12-04|Estimate||||2017-09-22|2017-10-24|Actual|July 2011||2011-07-31|September 2017|2017-09-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.|An Open-label, Multicenter Study to Assess the Long -Term Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain|Completed||Phase 3|922|Actual|Purdue Pharma LP||1|||f||||t||||||||||2018-05-31 22:20:13.278835|2018-05-31 22:20:13.278835
NCT01400126|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|August 2011||2011-08-31|November 2010|2010-11-30|January 2013|Anticipated|2013-01-31|August 2012|Anticipated|2012-08-31||Observational|||Ultrapure Water System for Hemodialysis Therapy|The Effect of Ultrapure Water System on Hemodialysis Therapy- a Single Center Trial|Unknown status|Not yet recruiting||150|Anticipated|Tel Aviv Medical Center|||||f||||f||||||||||2018-05-31 22:20:14.059458|2018-05-31 22:20:14.059458
NCT01400113|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2013-12-03||2016-04-26|2011-07-21|2011-07-22|Estimate|2016-04-26|2016-05-16|Estimate||||2016-04-26|2016-05-16|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Treating Acutely Agitated Patients With Asenapine Sublingual Tablets|Treating Acutely Agitated Patients With Asenapine Sublingual Tablets: A Single-Dose, Randomized, Double-Blind Placebo Controlled Trial|Completed||Phase 4|120|Actual|St. Joseph Hospital Health Center|"The short observation period of 2 hours.~Dependence on spontaneous self reporting of adverse effects.~Specific inquiry was not made regarding adverse events."|2|||f||||t||||||||Yes|All data available upon request.|2018-05-31 22:20:14.130374|2018-05-31 22:20:14.130374
NCT01400100|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2012-03-04|2011-07-21|2011-07-22|Estimate|||||||2012-03-04|2012-03-06|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Effects of Intraarterial Octreotide on Pancreatic Texture|Changes in Pancreatic Texture After Single-shot Administration of 500 µg Octreotide in the Gastroduodenal Artery During Pancreatoduodenectomy - a Double-Blinded Randomized Controlled Trial|Completed||N/A|26|Actual|St. Josef Hospital Bochum||2|||f||||t||||||||||2018-05-31 22:20:14.371794|2018-05-31 22:20:14.371794
NCT01400087|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|June 2011||2011-06-30|June 2011|2011-06-30||||November 2013|Anticipated|2013-11-30||Interventional|||Cap-attached Colonoscopy Versus Regular Colonoscopy for Trainees||Unknown status|Recruiting|N/A|500|Anticipated|Showa University||2|||f||||f||||||||||2018-05-31 22:20:14.456382|2018-05-31 22:20:14.456382
NCT01394172|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2015-08-11|2011-07-13|2011-07-14|Estimate|||||||2015-08-11|2015-08-13|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|May 2014|Actual|2014-05-31||Observational|||A Novel Method of Non-invasive Ventilation in Children|Non-invasive Ventilation Generated by External Chest Pressure in Children|Completed|||100|Anticipated|University of Alberta|||||f||||f||||||||||2018-05-31 22:21:59.308178|2018-05-31 22:21:59.308178
NCT01400074|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2014-01-10|2011-07-21|2011-07-22|Estimate|||||||2014-01-10|2014-01-13|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|RE-NICE||Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib|A Phase III Multi-center, Open-label, Randomized Study of the Efficacy of Nilotinib Versus Imatinib in Adult Patients With Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib|Unknown status|Recruiting|Phase 3|100|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 22:20:14.545131|2018-05-31 22:20:14.545131
NCT01400061|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Relation of Blood-boron Levels With Body Mass Index|Phase 1 Study of Blood Boron Levels According to Body Mas Index|Unknown status|Not yet recruiting||80|Anticipated|SB Istanbul Education and Research Hospital|||4||f||||f||||||Samples Without DNA|"~     blood serum analyses~   "|||2018-05-31 22:20:14.628939|2018-05-31 22:20:14.628939
NCT01400048|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-04-12|2011-07-21|2011-07-22|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Aloe Vera in Irritable Bowel Syndrome|Aloe Vera Versus Placebo for Patients With Irritable Bowel Syndrome|Unknown status|Recruiting|N/A|150|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 22:20:14.700327|2018-05-31 22:20:14.700327
NCT01400035|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-08-14|2011-07-21|2011-07-22|Estimate|||||||2013-08-14|2013-08-16|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Observational|CAVIN||Chinese Assessment for Vinpocetine In Neurology|The Investigation of Vinpocetine (Cavinton) for Treatment of Acute Cerebral Infarction, an Open, Multicenter, Randomized, Control Study|Completed|||610|Actual|Shanghai Rxmidas Pharmaceuticals Co. Ltd.|||1||f||||t||||||||||2018-05-31 22:20:14.778972|2018-05-31 22:20:14.778972
NCT01400022|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2013-05-29|2011-07-21|2011-07-22|Estimate|||||||2013-05-29|2013-05-30|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Topical 0.05% Clobetasol Propionate in Vaseline Versus UVA-1 Phototherapy in Vulvar Lichen Sclerosus|A Randomized Clinical Study Comparing Topical 0.05% Clobetasol Propianate in Vaseline With UVA-1 Phototherapy in the Treatment of Vulvar Lichen Sclerosus|Completed||N/A|30|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 22:20:14.845873|2018-05-31 22:20:14.845873
NCT01400009|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-04-06|2011-07-21|2011-07-22|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Vitamin D Replacement in Statin-Induced Myopathy|Vitamin D Replacement in Statin-Induced Myopathy|Withdrawn||N/A|0|Actual|McGill University Health Center||2||lack of enrollment|f||||f||||||||||2018-05-31 22:20:15.036247|2018-05-31 22:20:15.036247
NCT01399996|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-12-16|2011-07-21|2011-07-22|Estimate|||||||2014-12-16|2014-12-18|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Influence of a Delivery System on the Efficacy of a Probiotic Intervention|Influence of a Delivery System on the Efficacy of a Probiotic Intervention|Completed||Phase 1|36|Actual|Penn State University||4|||f||||f||||||||||2018-05-31 22:20:15.142929|2018-05-31 22:20:15.142929
NCT01399983|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-03-08|2011-07-20|2011-07-22|Estimate|||||||2012-03-08|2012-03-09|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Standardization of 6 Minute Walk Test|Assessment of Exercise Capacity and Standardization of Six Minute Walk Test in Patients With Pulmonary Hypertension|Completed|||29|Actual|Medical University of Graz|||1||f||||f||||||||||2018-05-31 22:20:15.225167|2018-05-31 22:20:15.225167
NCT01399970|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2014-01-12|2011-07-20|2011-07-22|Estimate|||||||2014-01-12|2014-01-14|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|Teleacne||Use of Mobile Teledermatology in the Care of Acne Patients|Use of Mobile Teledermatology in the Care of Acne Patients - A Randomized Controlled Trial|Completed||N/A|69|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 22:20:15.29848|2018-05-31 22:20:15.29848
NCT01399957|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-11-09|2011-07-21|2011-07-22|Estimate|||||||2015-11-09|2015-11-10|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Observational|||Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients|Responsiveness to Dalfampridine Treatment Among Multiple Sclerosis Patients Followed at the Mandell MS Center: Characterizing Clinical Predictors of Response and Identifying Additional Outcomes|Completed|||52|Actual|Mount Sinai Rehabilitation Hospital|||1||f||||f||||||Samples With DNA|"~     15 mL of blood will be collected into an EDTA tube from participants at assessment~     appointments. Both serum and cells will be frozen and stored in a -80 degree freezer.~   "|||2018-05-31 22:20:15.365706|2018-05-31 22:20:15.365706
NCT01399944|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-12-14|2011-07-21|2011-07-22|Estimate|||||||2017-12-14|2017-12-18|Actual|July 2011||2011-07-31|December 2017|2017-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||The Molecular Basis for a Broad Range of Phenotypes Related to hTAS2R38|The Molecular Basis for a Broad Range of Phenotypes Related to hTAS2R38|Completed|||70|Actual|Monell Chemical Senses Center|||||f||||f||||||Samples With DNA|"~     Saliva and taste tissue will be collected from individuals enrolled in the study.~   "|||2018-05-31 22:20:15.443204|2018-05-31 22:20:15.443204
NCT01399931|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-10-16|2011-07-21|2011-07-22|Estimate|||||||2015-10-16|2015-10-19|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|October 2015|Anticipated|2015-10-31||Observational|2P-HD-10||Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions|Dual Point Acquisition in the Interim Pet Scan Performed During ABVD Treatment, in Early-Stage Hodgkin's Lymphoma Patients With Bulky Lesions|Unknown status|Recruiting||150|Anticipated|Ospedale Santa Croce-Carle Cuneo|||1||f||||t||||||||||2018-05-31 22:20:15.512468|2018-05-31 22:20:15.512468
NCT01399918|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2018-01-02|2011-07-21|2011-07-22|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2011||2011-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)|A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)|Active, not recruiting||Phase 2|55|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:20:15.631794|2018-05-31 22:20:15.631794
NCT01399905|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||High and Low Dose Carbidopa Treatment of Parkinson's Disease|A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.|Completed||Phase 2|12|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 22:20:15.769319|2018-05-31 22:20:15.769319
NCT01399892|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Fiber Supplementation in Children With Type 1 Diabetes|Effects of Fiber Supplementation on Glycemic Excursions and Incidence of Hypoglycemia in Children With Type 1 Diabetes|Completed||N/A|10|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:20:15.850603|2018-05-31 22:20:15.850603
NCT01399879|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2011-07-20|2011-07-20|2011-07-22|Estimate|||||||2011-07-20|2011-07-22|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Measuring Skin Electrical Potential With the Kelvin Probe: Minimizing Noise|Measuring Skin Electrical Potential With the Kelvin Probe: Minimizing Noise|Completed|||24|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 22:20:15.89511|2018-05-31 22:20:15.89511
NCT01399866|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2015-04-15||2017-12-21|2011-07-21|2011-07-22|Estimate|2015-04-15|2015-05-04|Estimate||||2017-12-21|2018-01-23|Actual|May 2011||2011-05-31|December 2017|2017-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||After 4 wks of smoking cessation treatment and CBT, participants who had 18 hrs of abstinence, smoking no cigarettes for at least 18 hrs and CO<10ppm were randomized|Cognitive Remediation With D-Cycloserine|Cognitive Remediation With D-cycloserine to Improve Smoking Cessation Outcomes|Completed||Phase 3|150|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:20:15.961021|2018-05-31 22:20:15.961021
NCT01399853|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-05-29|2011-07-19|2011-07-22|Estimate|||||||2012-05-29|2012-05-31|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants|A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants|Completed||Phase 2|1200|Actual|Jiangsu Province Centers for Disease Control and Prevention||10|||f||||t||||||||||2018-05-31 22:20:16.270959|2018-05-31 22:20:16.270959
NCT01399840|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2017-09-14|2011-07-19|2011-07-22|Estimate|||||||2017-09-14|2017-09-15|Actual|June 30, 2011|Actual|2011-06-30|September 2017|2017-09-30|May 31, 2014|Actual|2014-05-31|March 31, 2014|Actual|2014-03-31||Interventional|||Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies|Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies|Completed||Phase 1|33|Actual|Pfizer||2|||f||||||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 22:20:16.352219|2018-05-31 22:20:16.352219
NCT01399827|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2018-04-10|2011-07-21|2011-07-22|Estimate|||||||2018-04-10|2018-04-11|Actual|February 2012||2012-02-29|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits|Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial|Active, not recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:20:16.43072|2018-05-31 22:20:16.43072
NCT01399814|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer||Completed||Phase 3|179|Actual|Nanjing PLA General Hospital||2|||f||||f||||||||||2018-05-31 22:20:16.506796|2018-05-31 22:20:16.506796
NCT01399801|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-07-17|2011-07-20|2011-07-22|Estimate|||||||2012-07-17|2012-07-18|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|CARE/VOLCANO||Optimizing Left Ventricular Lead To Improve Cardiac Output|Optimizing the Left Ventricular Contractility in Cardiac Resynchronization Therapy Using a Doppler Wire|Unknown status|Recruiting|N/A|40|Anticipated|Main Line Health||2|||f||||t||||||||||2018-05-31 22:20:16.563799|2018-05-31 22:20:16.563799
NCT01399788|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2012-02-22||2017-03-07|2011-07-20|2011-07-22|Estimate|2012-02-22|2012-03-16|Estimate||||2017-03-07|2017-04-05|Actual|July 2011||2011-07-31|March 2017|2017-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults|An Open Label, Single Dose, 2-Way Cross-Over Randomized Bioequivalence Study Comparing a Fixed Dose Combination Formulation, Myrin®-p Forte, (Contains 150 Mg Rifampicin, 75 Mg Isoniazid, 275 Mg Ethambutol and 400 Mg Pyrazinamide Per Tablet) to an Equivalent Dose of Single Drug Reference Preparations of Rifampicin, Isoniazid, Ethambutol and Pyrazinamide Following Oral Administration in Healthy Adults Under Fasting Conditions|Completed||Phase 1|36|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:20:16.656161|2018-05-31 22:20:16.656161
NCT01399775|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2015-04-07|2011-07-21|2011-07-22|Estimate|||||||2015-04-07|2015-04-08|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Ridge Dimensional Changes After Immediate Implantation and Efficacy of This Procedure|Evaluation of Implant Stability and Dimensional Changes in Alveolar Ridge Following Immediate Implantation|Completed||Phase 1/Phase 2|24|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:20:17.344147|2018-05-31 22:20:17.344147
NCT01399762|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|January 2011||2011-01-31|July 2011|2011-07-31||||||||Observational|ENDOSTROKE||International Multicenter Registry for Mechanical Recanalization Procedures in Acute Stroke|International Multicenter Registry for Mechanical Recanalization Procedures in Acute Stroke (ENDOSTROKE)|Unknown status|Recruiting||500|Anticipated|Goethe University|||1||f||||t||||||||||2018-05-31 22:20:17.448426|2018-05-31 22:20:17.448426
NCT01399749|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|ASCROD||Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects|A Comparative Clinical Trial for the Repair of Chondral Knee Defects: Transplantation of Autologous Cultured Chondrocytes vs. Autologous Mesenchymal Stem Cells Derived From Adipose Tissue|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||2|||f||||f||||||||||2018-05-31 22:20:17.546944|2018-05-31 22:20:17.546944
NCT01399736|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-04-26|2011-07-21|2011-07-22|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2011||2011-07-31|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|October 31, 2016|Actual|2016-10-31||Interventional|CompareAcute||Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.|Fractional Flow Reserve Guided Primary Multivessel Percutaneous Coronary Intervention to Improve Guideline Indexed Actual Standard of Care for Treatment of ST-elevation Myocardial Infarction in Patients With Multivessel Coronary Disease|Active, not recruiting||Phase 4|885|Anticipated|Maasstad Hospital||2|||f||||t||||||||No||2018-05-31 22:20:17.695301|2018-05-31 22:20:17.695301
NCT01399723|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2015-01-28||2015-01-28|2011-07-21|2011-07-22|Estimate|2015-01-28|2015-02-13|Estimate||||2015-01-28|2015-02-13|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia|Amoxicillin Versus Benzyl Penicillin for Severe Childhood Pneumonia Amongst Inpatients: An Open Label Randomised Controlled Non-inferiority Trial|Completed||Phase 3|561|Actual|KEMRI-Wellcome Trust Collaborative Research Program||2|||f||||t||||||||||2018-05-31 22:20:17.866996|2018-05-31 22:20:17.866996
NCT01399710|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|July 2007||2007-07-31|July 2011|2011-07-31|March 2010|Actual|2010-03-31|May 2009|Actual|2009-05-31||Interventional|CAD-IMPACT||Impact of Computer-Aided Detection (CAD) as Second Reader in CT Colonography|Measure of Performances of CT Colonography With Computer-Aided Detection (CAD) as Second Reader in Detecting Colorectal Lesion|Completed||Phase 3|651|Actual|im3D S.p.A.|||||f||||t||||||||||2018-05-31 22:20:18.181375|2018-05-31 22:20:18.181375
NCT01399697|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2015-06-18||2015-06-18|2011-07-20|2011-07-22|Estimate|2015-06-18|2015-07-13|Estimate||||2015-06-18|2015-07-13|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||All treated population|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|A Multi-center Study of the Safety and Effect on Disease Activity of Tocilizumab (TCZ) in Combination With MTX Versus Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis, With Inadequate Response to MTX (Defined as DAS 28 > 3,2)|Completed||Phase 4|261|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:20:18.276661|2018-05-31 22:20:18.276661
NCT01399684|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20||2016-07-12|2016-08-24|2011-07-20|2011-07-22|Estimate||||2016-07-12|2016-07-14|Estimate|2016-08-24|2016-08-26|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer|Completed||Phase 2|127|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:20:18.886972|2018-05-31 22:20:18.886972
NCT01399671|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-03-02|2011-07-20|2011-07-22|Estimate|||||||2012-03-02|2012-03-05|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of the Effectiveness of Vestibular Stimulation as a Coadjuvant Treatment in Major Depression|Clinical Randomized Trial to Evaluate the Efficacy of Vestibular Stimulation as Coadjuvant Therapy in Major Depression|Completed||N/A|80|Actual|Fuerza Aérea de Chile|||||f||||t||||||||||2018-05-31 22:20:18.996435|2018-05-31 22:20:18.996435
NCT01399658|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-08-09|2011-07-20|2011-07-22|Estimate|||||||2016-08-09|2016-08-11|Estimate|September 2011||2011-09-30|August 2016|2016-08-31||||February 2017|Anticipated|2017-02-28||Interventional|AMIGO||Image-Guided Gynecologic Brachytherapy|A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO)|Active, not recruiting||Phase 2|93|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 22:20:19.0572|2018-05-31 22:20:19.0572
NCT01399645|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-08-25|2011-07-21|2011-07-22|Estimate|||||||2014-08-25|2014-08-27|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|LIRAINS||Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes|Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study|Completed||Phase 2|35|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 22:20:19.134299|2018-05-31 22:20:19.134299
NCT01399632|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2016-07-05|2011-07-21|2011-07-22|Estimate|||||||2016-07-05|2016-07-06|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake|Dietary Fat and High-Density Lipoprotein (HDL) Metabolism-Effect of Carbohydrate and Fat Intake|Completed||N/A|21|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:20:19.209018|2018-05-31 22:20:19.209018
NCT01399619|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2015-07-03|2014-06-02|2016-07-28|2011-07-21|2011-07-22|Estimate|2015-08-06|2015-09-04|Estimate|2014-06-02|2014-06-17|Estimate|2016-07-28|2016-08-29|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional||FAS (All patients who were randomized and received at least one dose of assigned therapy)|Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)|Safety and Efficacy of 120mg and 240mg BI 201335 Once Daily in Combination With Pegylated Interferon Alpha and Ribavirin for Treatment of Chronic Hepatitis C (HCV) Genotype 1 Infection in HIV/HCV Co-infected Patients. A Multinational, Randomised, Parallel Group, Open-label Trial.|Completed||Phase 3|310|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:20:19.389598|2018-05-31 22:20:19.389598
NCT01399606|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2017-01-30|2011-07-21|2011-07-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|October 2013|Actual|2013-10-31||Interventional|HARMONYIII||Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)|An Open-label Naturalistic Pragmatic Study to Assess the Long Term Safety of BF2.649 (Pitolisant) in the Treatment of Excessive Daytime Sleepiness (EDS) in Narcolepsy (12 Months Follow-up, Followed by a Prolonged Follow up)|Completed||Phase 3|102|Actual|Bioprojet||1|||f||||t||||||||||2018-05-31 22:20:20.620814|2018-05-31 22:20:20.620814
NCT01399593|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2017-03-09|2016-11-18|2017-09-04|2011-07-20|2011-07-22|Estimate|2017-03-09|2017-04-19|Actual|2016-11-18|2016-11-21|Estimate|2017-09-04|2017-10-03|Actual|November 2, 2011|Actual|2011-11-02|September 2017|2017-09-30|November 13, 2015|Actual|2015-11-13|May 13, 2014|Actual|2014-05-13||Interventional|||Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization|A Randomized, Open-label, Multicenter Trial to Determine Safety and Efficacy of Eculizumab in the Prevention of Antibody Mediated Rejection (AMR) in Living Donor Kidney Transplant Recipients Requiring Desensitization Therapy|Terminated||Phase 2|102|Actual|Alexion Pharmaceuticals|Data interpretation confounded by open-label study with potential reporting bias, unequal exposure to randomized prevention therapy between groups, some patients in SOC arm received eculizumab for treatment of AMR, all patients immunosuppressed.|2||Did not achieve statistical significance for primary endpoint|f||||t|t|f||||||No||2018-05-31 22:20:20.756701|2018-05-31 22:20:20.756701
NCT01397604|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-09-19|2011-07-18|2011-07-19|Estimate|||||||2013-09-19|2013-09-23|Estimate|July 2011||2011-07-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effects of GLA on Human Volunteers|A Randomized, Blinded, Placebo-Controlled Phase 1 Study to Evaluate the Safety and Immunogenicity of GLA in Healthy Volunteers|Completed||Phase 1|32|Anticipated|Rockefeller University||4|||f||||f||||||||||2018-05-31 22:20:48.948909|2018-05-31 22:20:48.948909
NCT01399580|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20||2013-09-25|2013-09-25|2011-07-20|2011-07-22|Estimate||||2013-09-25|2013-10-25|Estimate|2013-09-25|2013-10-25|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy|A Phase 2b, Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy|Completed||Phase 2|48|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 22:20:21.867938|2018-05-31 22:20:21.867938
NCT01399567|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-07-21|2011-07-21|2011-07-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|September 2006||2006-09-30|July 2011|2011-07-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Nursing Home Pain Management Algorithm Clinical Trial|Nursing Home Pain Management Algorithm Clinical Trial|Completed||Phase 2|396|Actual|Swedish Medical Center||2|||f||||t||||||||||2018-05-31 22:20:22.044528|2018-05-31 22:20:22.044528
NCT01399554|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-04-04|2011-07-19|2011-07-22|Estimate|||||||2014-04-04|2014-04-07|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Exercise as Alcohol Use Disorders Intervention for Non-Treatment Seeking Adults|Exercise as Alcohol Use Disorders Intervention for Non-Treatment Seeking Adults|Completed||Phase 1|38|Actual|St. Louis University||2|||f||||t||||||||||2018-05-31 22:20:22.118759|2018-05-31 22:20:22.118759
NCT01399541|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Observational|||Recovery and Rehabilitation After Lung Cancer Surgery|Recovery and Rehabilitation After Lung Cancer Surgery|Unknown status|Recruiting||300|Anticipated|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 22:20:22.202137|2018-05-31 22:20:22.202137
NCT01399528|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2012-12-05|2011-07-20|2011-07-21|Estimate|||||||2012-12-05|2012-12-07|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||A Pharmacogenomic Exploration of Lacosamide Response|A Pharmacogenomic Exploration of Lacosamide Response|Unknown status|Recruiting||660|Anticipated|Royal College of Surgeons, Ireland|||5||f||||f||||||Samples With DNA|"~     Collecting DNA from blood samples~   "|||2018-05-31 22:20:22.306423|2018-05-31 22:20:22.306423
NCT01399515|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2016-04-12|2011-07-20|2011-07-21|Estimate|||||||2016-04-12|2016-04-14|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|August 2013|Actual|2013-08-31||Interventional|VPA_RP||Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa||Completed||Phase 2|200|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:20:22.43156|2018-05-31 22:20:22.43156
NCT01399502|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-12-09|2011-07-20|2011-07-21|Estimate|||||||2013-12-09|2013-12-11|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Promotion of Self-help Strategies for Depression||Completed||Phase 1/Phase 2|1736|Actual|Orygen Youth Health Research Centre||2|||f||||f||||||||||2018-05-31 22:20:22.523943|2018-05-31 22:20:22.523943
NCT01399489|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2014-01-22|2011-07-20|2011-07-21|Estimate|||||||2014-01-22|2014-01-23|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Aerobic Training and Arterial Stiffness in Chronic Kidney Disease (CKD) Patients|The Effect of Short-term Aerobic Training on Arterial Stiffness and Blood in Chronic Kidney Disease (CKD) Patients|Completed||N/A|51|Actual|Springfield College||2|||f||||f||||||||||2018-05-31 22:20:22.603466|2018-05-31 22:20:22.603466
NCT01399476|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-12-28|2011-07-20|2011-07-21|Estimate|||||||2017-12-28|2018-01-02|Actual|September 2010||2010-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|POEM||Endoscopic Myotomy of the Lower Esophageal Sphincter for Achalasia|Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia|Recruiting||N/A|350|Anticipated|The Oregon Clinic||1|||f||||f||||||||||2018-05-31 22:20:22.698929|2018-05-31 22:20:22.698929
NCT01399463|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|August 2011||2011-08-31|July 2011|2011-07-31||||||||Interventional|||Pressure-wire Guided PTCA: Drug Eluting Stent Versus Drug Eluting Balloon (WinDEB Study)|Pressure Wire-guided Percutaneous Coronary Intervention of Small Vessels or Side Branches: Functional Outcome of Drug-Eluting Stent (DES) Versus Drug-Eluting Balloon (DEB) With Provisional Bare Metal Stent Implantation|Unknown status|Not yet recruiting|N/A|||Medical University of Vienna||2|||f||||||||||||||2018-05-31 22:20:22.796582|2018-05-31 22:20:22.796582
NCT01399450|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-12-07|2011-07-20|2011-07-21|Estimate|||||||2015-12-07|2015-12-08|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients|Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study|Unknown status|Recruiting|Phase 4|70|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:20:22.873296|2018-05-31 22:20:22.873296
NCT01399437|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2018-04-04|2011-07-20|2011-07-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 3, 2011||2011-07-03|December 24, 2014|2014-12-24|December 24, 2014||2014-12-24|||||Observational|||Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia|Default Network Dysfunction Underlying Visuospatial Attention Deficits in Schizophrenia|Completed|||64|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:20:22.974018|2018-05-31 22:20:22.974018
NCT01399424|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-06-30|2011-07-20|2011-07-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 16, 2011||2011-07-16|April 25, 2012|2012-04-25|April 25, 2012|Actual|2012-04-25|April 25, 2012|Actual|2012-04-25||Interventional|||Shigella Sonnei OSPC-rDT Conjugate Vaccine|Shigella Sonnei OSPC-rDT Conjugate Vaccine|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:20:23.040208|2018-05-31 22:20:23.040208
NCT01399411|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2018-04-04|2011-07-20|2011-07-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 20, 2011||2011-07-20|August 17, 2017|2017-08-17||||||||Observational|||Agricultural Health Study Follow-up|Agricultural Health Study: Health Follow-up|Enrolling by invitation|||2175|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:20:23.202935|2018-05-31 22:20:23.202935
NCT01399398|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2018-05-18|2011-07-20|2011-07-21|Estimate|||||||2018-05-18|2018-05-21|Actual|June 22, 2011||2011-06-22|December 18, 2013|2013-12-18|December 18, 2013|Actual|2013-12-18|December 18, 2013|Actual|2013-12-18||Interventional|||Imaging of CB1 Receptors Using (11C)SD5024|PET Imaging of CB1 Receptors Using [11C]SD5024|Terminated||Phase 1|8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:20:23.464497|2018-05-31 22:20:23.464497
NCT01399216|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-12-13|2011-07-20|2011-07-21|Estimate|||||||2012-12-13|2012-12-17|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effects of a Supplement Containing Fucoidan on Basal Body Temperature|Effects of a Supplement Containing Fucoidan as a Major Component on Basal Body Temperature: a Placebo Controlled, Cross-over Study|Completed||N/A|19|Actual|Hiroshima University||2|||f||||f||||||||||2018-05-31 22:20:27.873271|2018-05-31 22:20:27.873271
NCT01399385|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2018-04-19|2011-07-20|2011-07-21|Estimate|||||||2018-04-19|2018-04-20|Actual|July 20, 2011||2011-07-20|February 22, 2018|2018-02-22||||||||Observational|||New Heart Imaging Techniques to Evaluate Possible Heart Disease|Magnetic Resonance of Body, Arterial Wall and Angiography Imaging for Non-Invasive Assessment of Arterial Distensibility, Endothelial Dysfunction and Atherosclerotic Disease Using 1.5T High Field (3T) MRI: A Technical Development Study of Cardiac and Body|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:20:23.561917|2018-05-31 22:20:23.561917
NCT01399372|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2017-12-21|2011-07-20|2011-07-21|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2011||2011-09-30|December 2017|2017-12-31|September 2026|Anticipated|2026-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma|Active, not recruiting||Phase 2|91|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 22:20:23.691|2018-05-31 22:20:23.691
NCT01399359|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2015-03-05|2011-07-20|2011-07-21|Estimate|||||||2015-03-05|2015-03-09|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer|A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer|Completed|||1023|Actual|NSABP Foundation Inc|||2||f||||f||||||||||2018-05-31 22:20:24.242071|2018-05-31 22:20:24.242071
NCT01399346|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-04-19|2011-07-20|2011-07-21|Estimate|||||||2012-04-19|2012-04-20|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Investigation of the Impact of Different Application Volumes of Insulin Aspart in Subjects With Type 1 Diabetes|A Single-center, Randomized, Controlled, 2-period Cross-over, Open-labelled Trial to Evaluate the Impact of Different Application Volumes on Pharmacokinetic and Pharmacodynamic Properties of Insulin Aspart in Subjects With Type 1 Diabetes|Completed||Phase 1|12|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 22:20:24.532109|2018-05-31 22:20:24.532109
NCT01399333|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-22|2011-07-20|2011-07-21|Estimate|||||||2011-07-22|2011-07-26|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|January 2012|Anticipated|2012-01-31|August 2011|Anticipated|2011-08-31||Interventional|PDCAAS||Comparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method|Comparison of Meal Replacements Versus Protein Supplements and Utilizing the PDCAAS Method in the Bariatric Patient|Unknown status|Recruiting|Phase 4|60|Anticipated|Southeast Bariatrics, PA||3|||f||||f||||||||||2018-05-31 22:20:24.716881|2018-05-31 22:20:24.716881
NCT01399320|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|June 2010|Actual|2010-06-30|September 2009|Actual|2009-09-30||Interventional|||Ghnnam Excision Technique for Pilonidal Sinus|Ghnnam Excision Technique for Pilonidal Sinus|Completed||Phase 1|40|Actual|Mansoura University||1|||f||||f||||||||||2018-05-31 22:20:25.019333|2018-05-31 22:20:25.019333
NCT01399307|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-16|||2012-01-18|2011-07-20|2011-07-21|Estimate|||||||2012-01-18|2012-01-19|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Extraction of Stromal Vascular Fraction and Stem Cells From Fat Tissue|A Proof of Concept Study to Demonstrate the Effectiveness of Antria Cell Preparation Process (Ace Process) in Extraction of Stromal Vascular Fraction From Adipose Tissue|Completed||N/A|4|Actual|Antria||1|||f||||f||||||||||2018-05-31 22:20:25.286171|2018-05-31 22:20:25.286171
NCT01399294|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-19|2011-07-19|2011-07-21|Estimate|||||||2011-07-19|2011-07-21|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|July 2010|Actual|2010-07-31||Observational|||Cross Sectional Study of Constipation in Advanced Cancer Patients|Traditional Chinese Medicine Syndrome Distribution of Advanced Cancer Patients With Constipation|Completed|||255|Actual|Yan Chai Hospital|||||f||||t||||||||||2018-05-31 22:20:25.459114|2018-05-31 22:20:25.459114
NCT01399281|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2018-03-02|2011-07-20|2011-07-21|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2011||2011-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|PharmaChild||Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate|Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated With Biologic Agents and/or Methotrexate. A PRINTO/PRES Registry|Recruiting|||9000|Anticipated|Istituto Giannina Gaslini|||3||f||||t||||||||||2018-05-31 22:20:26.809137|2018-05-31 22:20:26.809137
NCT01399268|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2017-03-23||2017-07-27|2011-07-20|2011-07-21|Estimate|2017-07-27|2017-07-31|Actual||||2017-07-27|2017-07-31|Actual|February 2009||2009-02-28|July 2017|2017-07-31|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Interventional|||Steroids in Bilateral Total Knee Replacement|Effect of Steroids Given Over 24 Hours on Cytokine Release and Urinary Desmosine Levels in Patients Undergoing Bilateral Total Knee Replacement|Completed||Phase 4|30|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 22:20:27.135581|2018-05-31 22:20:27.135581
NCT01399255|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-01-24|2011-07-19|2011-07-21|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Interventional|||Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects||Withdrawn||Phase 1|0|Actual|Wockhardt||2||Study was not initiated|f||||f||||||||||2018-05-31 22:20:27.46338|2018-05-31 22:20:27.46338
NCT01399242|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|August 2011||2011-08-31|March 2011|2011-03-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|HUSJ1||Efficacy of Certican® in Combination With Myfortic® in Renal|Efficacy and Safety of Certican® in Combination With Myfortic® in Adult Renal Allograft Recipients Following Calcineurin Inhibitor Withdrawal at Week 16 Compared to Patients Who Are Maintained on Tacrolimus and Myfortic®|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Hospital Universitário São José||2|||f||||t||||||||||2018-05-31 22:20:27.563464|2018-05-31 22:20:27.563464
NCT01399229|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2012-11-15||2013-08-28|2011-07-19|2011-07-21|Estimate|2013-05-20|2013-08-27|Estimate||||2013-08-28|2013-09-12|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women|Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women|Completed|||30|Actual|Reproductive Research Technologies, LP|||3||f||||f||||||||||2018-05-31 22:20:27.670269|2018-05-31 22:20:27.670269
NCT01398865|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2015-03-12|2011-07-19|2011-07-21|Estimate|||||||2015-03-12|2015-03-13|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Escitalopram Neuroimaging Supplement|Cerebral Metabolic Correlates of Treatment Response to Escitalopram in Body Dysmorphic Disorder|Completed|||23|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 22:20:32.559178|2018-05-31 22:20:32.559178
NCT01399203|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-08-02|2011-07-20|2011-07-21|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2012|Anticipated|2012-01-31|October 2011|Anticipated|2011-10-31||Observational|CONVIN||Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention|Contrast Medium Volume and Contrast-induced Nephropathy After Percutaneous Coronary Intervention|Unknown status|Recruiting||2000|Anticipated|Guangdong General Hospital|||1||f||||t||||||||||2018-05-31 22:20:27.990385|2018-05-31 22:20:27.990385
NCT01399190|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|2016-08-04||2016-08-04|2011-07-20|2011-07-21|Estimate|2016-08-04|2016-09-28|Estimate||||2016-08-04|2016-09-28|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational||Includes enrolled participants eligible for inclusion in the final analysis.|An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer|An Open Label Study of the Effect of First Line Treatment With Bevacizumab in Combination With Capecitabine and Oxaliplatin on Progression-free Survival in Patients With Metastatic Cancer of the Colon and Rectum|Completed|||68|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:20:28.082668|2018-05-31 22:20:28.082668
NCT01399177|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2018-04-03|2011-07-19|2011-07-21|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2011|Actual|2011-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Influence of Changes in Food Group Variety on Food Cravings, Energy Intake, and Weight Loss After Bariatric Surgery|Influence of Changes in Food Group Variety on Food Cravings, Energy Intake, and Weight Loss After Bariatric Surgery|Active, not recruiting|||90|Anticipated|The University of Tennessee, Knoxville|||||f||||f||||||||||2018-05-31 22:20:28.270615|2018-05-31 22:20:28.270615
NCT01399164|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-10-21|2011-07-19|2011-07-21|Estimate|||||||2013-10-21|2013-10-22|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|FL-72||Cobalamin Absorption From Fortified Food|Cobalamin Absorption From Fortified Food in Older Adults With and Without Proton Pump Inhibitor Induced Achlorhydria|Completed||N/A|6|Actual|USDA, Western Human Nutrition Research Center||1|||f||||t||||||||||2018-05-31 22:20:28.331974|2018-05-31 22:20:28.331974
NCT01399151|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2014-04-21|2011-07-19|2011-07-21|Estimate|||||||2014-04-21|2014-04-22|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|FL-82||Assessment of Vitamin D Supplementation and Immune Function|Assessment of Vitamin D Supplementation and Immune Function|Completed||N/A|23|Actual|USDA, Western Human Nutrition Research Center||3|||f||||t||||||||||2018-05-31 22:20:28.393227|2018-05-31 22:20:28.393227
NCT01399138|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-12-04|2011-07-20|2011-07-21|Estimate|||||||2013-12-04|2013-12-05|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|April 2014|Anticipated|2014-04-30|July 2012|Actual|2012-07-31||Interventional|||The Effect of Blueberry Powder Supplementation on Cardiovascular Risk Factors in Subjects With the Metabolic Syndrome||Unknown status|Active, not recruiting|N/A|50|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 22:20:28.466484|2018-05-31 22:20:28.466484
NCT01399125|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2014-05-05||2014-07-10|2011-07-20|2011-07-21|Estimate|2014-07-10|2014-08-04|Estimate||||2014-07-10|2014-08-04|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease|A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)|Completed||Phase 3|501|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:20:28.569128|2018-05-31 22:20:28.569128
NCT01399112|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2012-12-31|2011-07-20|2011-07-21|Estimate|||||||2012-12-31|2013-01-03|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Interventional|||A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis|A Usability Study of a Smoking Cessation Decision Aid in People With a Recent First Episode of Psychosis|Completed||N/A|11|Actual|Northwell Health||2|||f||||f||||||||||2018-05-31 22:20:29.192462|2018-05-31 22:20:29.192462
NCT01399099|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2014-12-17||2014-12-17|2011-07-19|2011-07-21|Estimate|2014-12-17|2014-12-25|Estimate||||2014-12-17|2014-12-25|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|REFINE|After meeting all eligibility criteria, 67 patients were enrolled.|A Study of a Novel Silicone Dressing to Minimize Scar Formation|Scar Prevention and the Clinical Effectiveness of a Novel Mechanomodulating Polymer|Completed||N/A|67|Actual|Neodyne Biosciences, Inc.|"The Neodyne Dressing is referred to as the embrace device.~Grant/Funding source: Armed Forces Institute of Regenerative Medicine is funded by US Army Medical Research and Materiel Command (our collaborator) http://www.afirm.mil/"|1|||f||||f||||||||||2018-05-31 22:20:29.277166|2018-05-31 22:20:29.277166
NCT01399086|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-03-12|2011-07-20|2011-07-21|Estimate|||||||2012-03-12|2012-03-13|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer|A Retrospective Study of Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer in Greece (The 'RESPONSE' Study)|Completed|||140|Actual|Hellenic Oncology Research Group|||1||f||||f||||||||||2018-05-31 22:20:29.628597|2018-05-31 22:20:29.628597
NCT01399073|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2018-02-01|2011-07-20|2011-07-21|Estimate|||||||2018-02-01|2018-02-02|Estimate|May 2011||2011-05-31|February 2018|2018-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|KMS-Neglect||Virtual Reality for Neglect Diagnostics|Virtual Reality for Neglect Diagnostics|Completed|||27|Actual|Charite University, Berlin, Germany|||3||f||||f||||||||||2018-05-31 22:20:29.735482|2018-05-31 22:20:29.735482
NCT01399060|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-10-23|2011-07-20|2011-07-21|Estimate|||||||2013-10-23|2013-10-24|Estimate|April 2011||2011-04-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|CAP||Cough Sensitivity and Taste Preferences|Cough and Taste Preferences in Adolescents and Adults|Completed|||80|Actual|Monell Chemical Senses Center|||||f||||f||||||Samples With DNA|"~     Saliva samples will be obtained from the subjects, if consented. These saliva samples will be~     genotyped at the Monell Center for genes that may play a role in chemical irritation and~     flavor-perception. This testing is exploratory in nature.~   "|||2018-05-31 22:20:29.837329|2018-05-31 22:20:29.837329
NCT01399047|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|2016-11-28||2016-11-28|2011-07-19|2011-07-21|Estimate|2016-11-28|2017-01-23|Estimate||||2016-11-28|2017-01-23|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|JUMP||Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis|Phase II, Randomized, Placebo Controlled Trial of the Safety and Tolerability of Mycophenolate in Children With Juvenile Neuronal Ceroid Lipofuscinosis|Completed||Phase 2|19|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 22:20:29.915618|2018-05-31 22:20:29.915618
NCT01399034|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|SZU||Epigenetics, DNA Methylation Patterns and Periodontal Disease|Host DNA Methylation Patterns in Association With Periodontal Disease : MiRNA Changes in Obesity|Completed|||98|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     -  Gingiva biopsy samples (epithelium, connective tissue)~        -  Gingival crevicular fluid~        -  Saliva~        -  Plaque samples~   "|||2018-05-31 22:20:30.336317|2018-05-31 22:20:30.336317
NCT01399021|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Timing of Postoperative Drain Removal Following Parotidectomy - a Prospective Randomized Controlled Study|Timing of Postoperative Drain Removal Following Parotidectomy and Its Effects on Hematoma and Infection Rate and Length of Hospital Stay- a Prospective Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|400|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 22:20:30.437906|2018-05-31 22:20:30.437906
NCT01399008|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2014-03-20||2015-09-03|2011-07-19|2011-07-21|Estimate|2014-07-02|2014-07-28|Estimate||||2015-09-03|2015-09-18|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in Combination With Allopurinol in Gout Patients With an Inadequate Hypouricemic Response to Allopurinol Alone|Completed||Phase 2|100|Actual|CymaBay Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 22:20:30.56783|2018-05-31 22:20:30.56783
NCT01398995|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Managing Insulin Pumps for Exercise (Study 2)|To Consider the Effect of the Timing of a Reduction in Basal Insulin Infusion Rate to 50% of Normal Prior to Exercise on Glycaemic Control in People With Type 1 Diabetes Treated With CSII|Terminated||N/A|6|Actual|Buckinghamshire Healthcare NHS Trust||4||Recruitment was terminated due to elevated levels of hypoglycaemia|f||||f||||||||||2018-05-31 22:20:30.894376|2018-05-31 22:20:30.894376
NCT01398982|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2014-07-07||2015-03-30|2011-07-19|2011-07-21|Estimate|2015-03-30|2015-04-01|Estimate||||2015-03-30|2015-04-01|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT|The Use of Transversus Abdominis Plane (TAP) Block in Autologous Breast Reconstruction Donor Site: A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 4|93|Actual|University Health Network, Toronto|The study limitations include the difficulty in capturing data at all points postoperatively. The repeated measure pain scores at rest and with movement were not recorded for all patients (recorded for 75% at rest and 53% with movement).|2|||f||||f||||||||||2018-05-31 22:20:30.992842|2018-05-31 22:20:30.992842
NCT01398969|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2018-04-03|2011-07-20|2011-07-21|Estimate|||||||2018-04-03|2018-04-04|Actual|July 2012||2012-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI|A Prospective Randomized Multi-Centre Trial of Fresh vs. Frozen-and-Thawed Human Biotherapy (Fecal Transplant) for Recurrent Clostridium Difficile Infection|Completed||Phase 2|232|Actual|McMaster University||2|||f||||t||||||||||2018-05-31 22:20:31.32058|2018-05-31 22:20:31.32058
NCT01398956|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2016-09-29||2017-07-06|2011-07-19|2011-07-21|Estimate|2017-02-27|2017-03-09|Actual||||2017-07-06|2017-08-15|Actual|June 2011||2011-06-30|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||The Baseline Characteristics refer to the Safety Set (SS) which consisted of all subjects who took at least one dose of study medication in this study.|An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures|An Open-label, Multicenter, Long-term, Follow-up Study in Japan to Evaluate the Safety, Tolerability, and Efficacy of Adjunctive Treatment With Oral L059 (Levetiracetam) in Epilepsy Subjects With Generalized Tonic-clonic (GTC) Seizures|Completed||Phase 3|44|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 22:20:31.421275|2018-05-31 22:20:31.421275
NCT01398943|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2016-11-17||2017-11-09|2011-07-20|2011-07-21|Estimate|2017-06-27|2017-07-25|Actual||||2017-11-09|2017-12-11|Actual|September 2010||2010-09-30|November 2017|2017-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)|Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach|Completed||N/A|60|Actual|Augusta University||2|||f||||t||||||||Yes||2018-05-31 22:20:31.687425|2018-05-31 22:20:31.687425
NCT01398930|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Acupuncture as an Adjunctive Therapy to the Pharmacological Treatment in Patients With Chronic Pain in Osteoarthritis of the Knee: a Three Armed Randomized Placebo Controlled Trial||Completed||N/A|120|Actual|National and Kapodistrian University of Athens||3|||f||||f||||||||||2018-05-31 22:20:32.095826|2018-05-31 22:20:32.095826
NCT01398917|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-07-05|2011-07-20|2011-07-21|Estimate|||||||2012-07-05|2012-07-09|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis|Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis|Unknown status|Recruiting|Phase 3|100|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 22:20:32.177521|2018-05-31 22:20:32.177521
NCT01398904|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2014-12-02|2011-07-19|2011-07-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|VAB||Attentional Bias in Body Dysmorphic Disorder|Attentional Bias in Body Dysmorphic Disorder|Completed|||51|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 22:20:32.286294|2018-05-31 22:20:32.286294
NCT01398891|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2013-03-04|2011-07-19|2011-07-21|Estimate|||||||2013-03-04|2013-03-05|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|HOPE||Development of a Positive Psychology Intervention to Reduce Suicide Risk|Development of a Positive Psychology Intervention to Reduce Suicide Risk|Completed||N/A|60|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:20:32.39568|2018-05-31 22:20:32.39568
NCT01398878|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-22|2011-07-19|2011-07-21|Estimate|||||||2011-07-22|2011-07-25|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Assessing the Impact of a Change to the Work Schedule of Resident Physicians: a Mixed Methods Study|Assessing the Impact of a Change to the Work Schedule of Resident Physicians: a Mixed Methods Study|Unknown status|Recruiting|N/A|80|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:20:32.47518|2018-05-31 22:20:32.47518
NCT01398852|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2012-12-13||2013-01-25|2011-07-19|2011-07-21|Estimate|2013-01-25|2013-03-04|Estimate||||2013-01-25|2013-03-04|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and Ectasia|Long Term Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Post-Refractive Corneal Ectasia|Terminated||Phase 3|500|Actual|Topcon Medical Systems, Inc.||1|||f||||f||||||||||2018-05-31 22:20:32.630779|2018-05-31 22:20:32.630779
NCT01398839|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-10|2012-12-13||2016-12-05|2011-07-19|2011-07-21|Estimate|2013-01-25|2013-03-04|Estimate||||2016-12-05|2017-02-01|Estimate|December 2010||2010-12-31|December 2016|2016-12-31||||July 2012|Actual|2012-07-31||Interventional|||Safety Study of the VEGA UV-A System to Treat Ectasia||Terminated||Phase 3|103|Actual|Topcon Medical Systems, Inc.||2|||f||||f||||||||||2018-05-31 22:20:32.869443|2018-05-31 22:20:32.869443
NCT01398826|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2011-07-20|2011-07-20|2011-07-21|Estimate|||||||2011-07-20|2011-07-21|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||Glycemic Response to Road Cycling in Type 1 Diabetes|A Pilot Study Assessing the Glycemic Response and Its Relationship to Performance During Road Cycling in Elite Athletes With Type 1 Diabetes and Non-Diabetic Controls|Unknown status|Active, not recruiting||30|Anticipated|Team Type 1, Inc.|||||f||||f||||||||||2018-05-31 22:20:33.131276|2018-05-31 22:20:33.131276
NCT01398813|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-07-07|2011-07-20|2011-07-21|Estimate|||||||2013-07-07|2013-07-09|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|X-CORS||X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey|Survey of X-Linked Hypohidrotic Ectodermal Dysplasia Carrier Women's Outlook Towards Reproduction, Potential XLHED Treatments and Genetic Testing|Completed|||500|Anticipated|Edimer Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:20:33.18329|2018-05-31 22:20:33.18329
NCT01398800|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-02-01|2011-07-20|2011-07-21|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2011||2011-07-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MBT||Early Clinical Results of Mobile-Bearing Revision Total Knee Arthroplasty|Early Clinical Results of Mobile-Bearing Revision Total Knee Arthroplasty|Active, not recruiting|||320|Anticipated|Colorado Joint Replacement|||||f||||f||||||||Undecided||2018-05-31 22:20:33.259616|2018-05-31 22:20:33.259616
NCT01398787|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2014-02-18||2014-02-18|2011-07-19|2011-07-21|Estimate|2014-02-18|2014-03-28|Estimate||||2014-02-18|2014-03-28|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||The analysis population includes all enrolled and exposed participants.|Evaluation of the Cosmetic Performance of AIR OPTIX® COLORS|Cosmetic Validation (US): AIR OPTIX® COLORS Among Habitual Wearers of FRESHLOOK®|Completed||N/A|198|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:20:33.345499|2018-05-31 22:20:33.345499
NCT01398774|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-05-01|2011-07-20|2011-07-21|Estimate|||||||2017-05-01|2017-05-03|Actual|June 2011||2011-06-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|September 2015|Actual|2015-09-30||Observational|||Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a|Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study|Active, not recruiting|||519|Actual|Children's Hospital of Philadelphia|||||f||||t||||||||||2018-05-31 22:20:33.626162|2018-05-31 22:20:33.626162
NCT01398761|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2014-04-24|2011-07-19|2011-07-21|Estimate|||||||2014-04-24|2014-04-28|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Development of a Sign-Out Tool to Improve Handoffs in Care|Development and Pilot Testing of a Web-Based, Multi-Disciplinary Sign-Out Tool to Improve Handoffs in Care|Completed||N/A|295|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 22:20:33.692698|2018-05-31 22:20:33.692698
NCT01398748|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-07-27|2011-07-20|2011-07-21|Estimate|||||||2017-07-27|2017-07-31|Actual|July 2012||2012-07-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Intranasal Glutathione in Parkinson's Disease|A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease|Completed||Phase 1|34|Actual|Bastyr University||4|||f||||t||||||||||2018-05-31 22:20:33.78779|2018-05-31 22:20:33.78779
NCT01398722|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-19|2011-07-19|2011-07-20|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Effect of Intensive Insulin Therapy on Clinical Prognosis of Infants Undergoing Cardiac Surgery|Study of the Relationship Between Intensive Insulin Therapy and Clinical Prognosis in Infants Undergoing Cardiac Surgery|Unknown status|Not yet recruiting|Phase 2|800|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 22:20:33.873799|2018-05-31 22:20:33.873799
NCT01398709|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-19|2011-07-19|2011-07-20|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Effect of Rewarming Rate During Cardiopulmonary Bypass on Clinical Prognosis of Infants Undergoing Cardiac Surgery|Study of the Relationship Between Rewarming Rate During Cardiopulmonary Bypass and Clinical Prognosis in Infants Undergoing Cardiac Surgery|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 22:20:33.967168|2018-05-31 22:20:33.967168
NCT01398696|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-10-11|2011-07-19|2011-07-20|Estimate|||||||2011-10-11|2011-10-12|Estimate|November 2009||2009-11-30|October 2011|2011-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|PIL||Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour|Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour : a Randomised Controlled Trial in Primary Care.|Completed||Phase 4|400|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 22:20:34.055298|2018-05-31 22:20:34.055298
NCT01398683|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-11-15|2011-07-19|2011-07-20|Estimate|||||||2012-11-15|2012-11-16|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|April 2014|Anticipated|2014-04-30|June 2013|Anticipated|2013-06-30||Observational|||Comparison Epidural Anesthesia and General Anesthesia in Laparoscopic Cholecystectomy|Comparison Epidural Anesthesia and General Anesthesia in Laparoscopic Cholecystectomy|Unknown status|Enrolling by invitation||100|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 22:20:34.153596|2018-05-31 22:20:34.153596
NCT01398670|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-01-24|2011-07-19|2011-07-20|Estimate|||||||2013-01-24|2013-01-25|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|||Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics|Comparison of the Immunogenicity of Wockhardt's Insulin Analogue Lispro and Lispro Mix With Eli Lilly's Insulin Analogue Humalog® and Humalog® Mix in Type 1 Diabetic Patients|Withdrawn||Phase 3|0|Actual|Wockhardt||2||Study was not initiated|f||||f||||||||||2018-05-31 22:20:34.194229|2018-05-31 22:20:34.194229
NCT01397929|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-04-06|2011-07-19|2011-07-20|Estimate|||||||2016-04-06|2016-04-07|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors|An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|73|Actual|Basilea Pharmaceutica||2|||f||||f||||||||||2018-05-31 22:20:41.380708|2018-05-31 22:20:41.380708
NCT01398657|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2012-11-13|2011-07-19|2011-07-20|Estimate|||||||2012-11-13|2012-11-14|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer|Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy for High-Risk Localized Prostate Cancer — Open-Label Randomized Clinical Study|Unknown status|Recruiting|Phase 3|182|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 22:20:34.249749|2018-05-31 22:20:34.249749
NCT01398644|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-12-03|2011-07-19|2011-07-20|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Hereditary Hemochromatosis (HH) Patients|Erythrocytapheresis Versus Phlebotomy as Maintenance Therapy in Patients With Hereditary Hemochromatosis; a Randomised, Single Blinded Sequential, Cross-over Trial|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Sanquin Research & Blood Bank Divisions||2|||f||||f||||||||||2018-05-31 22:20:34.324953|2018-05-31 22:20:34.324953
NCT01398631|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2016-02-16|2011-07-19|2011-07-20|Estimate|||||||2016-02-16|2016-02-17|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Observational|HEART||A Comparison of the TIMI, GRACE and HEART Scores|A Prospective Comparison of the TIMI, GRACE and HEART Scores for Predicting Cardiovascular Events in Chest Pain Patients in the Emergency Room|Completed|||2440|Actual|R&D Cardiologie|||1||f||||f||||||||||2018-05-31 22:20:34.390984|2018-05-31 22:20:34.390984
NCT01398618|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-19|2011-07-19|2011-07-20|Estimate|||||||2011-07-19|2011-07-20|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)|Comparing the Efficacy of Two Preventive Regimens for Adult Household Contacts With Latent Tuberculosis Infection|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 22:20:34.460506|2018-05-31 22:20:34.460506
NCT01398605|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-08-16|2011-07-19|2011-07-20|Estimate|||||||2011-08-16|2011-08-18|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Physical Activity in Postmenopausal Women|Physical Activity and Exercise Dose-response on Cardiovascular Risk Factors in Postmenopausal Women|Completed||N/A|200|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 22:20:34.647576|2018-05-31 22:20:34.647576
NCT01398592|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2013-02-11|2011-07-19|2011-07-20|Estimate|||||||2013-02-11|2013-02-12|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|FPG-VISIT||Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy|Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus®/Eucreas®) and Sitagliptin (Januvia®/Janumet®) After Two Weeks|Completed||Phase 4|187|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:20:34.721174|2018-05-31 22:20:34.721174
NCT01398579|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-26|||2012-07-10|2011-07-19|2011-07-20|Estimate|||||||2012-07-10|2012-07-12|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|pCLE-GCEP||Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy|Prospective Comparison Between Probe-based Confocal Laser Endomicroscopy, White-light Endoscopy and Virtual Chromoendoscopy for the Diagnosis of Gastric Pre-neoplastic and Neoplastic Lesions (pCLE-GCEP)|Unknown status|Recruiting|Phase 1|20|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 22:20:34.81122|2018-05-31 22:20:34.81122
NCT01398566|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-04-09|2011-07-19|2011-07-20|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SuperBetter||Clinical Trial of a Rehabilitation Game - SuperBetter|Clinical Trial of a Novel Rehabilitation Game (Phase I - Feasibility)|Completed||Phase 1|20|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 22:20:34.903529|2018-05-31 22:20:34.903529
NCT01398553|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2016-09-05|2011-07-19|2011-07-20|Estimate|||||||2016-09-05|2016-09-07|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Automated Versus Standard Physiotherapy for Upper Limb Rehabilitation in Patients With Acquired Brain Lesions|Armeo® Versus Standard Physiotherapy for Upper Limb Rehabilitation in Patients With Acquired Brain Lesions|Withdrawn||N/A|0|Actual|Krankenhaus Bozen||2||the human resources in the organisation are to limited to do the trial|f||||f||||||||||2018-05-31 22:20:34.98698|2018-05-31 22:20:34.98698
NCT01398540|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2018-03-26|2011-07-19|2011-07-20|Estimate|||||||2018-03-26|2018-03-29|Actual|November 2010||2010-11-30|March 2018|2018-03-31|November 2013|Actual|2013-11-30|October 2012|Actual|2012-10-31||Interventional|||Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine|Characterisation of Cellular and Humoral Immunity in Elderly People After Immunization With a Purified, Inactivated Japanese Encephalitis Vaccine.|Completed||Phase 4|60|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 22:20:35.076215|2018-05-31 22:20:35.076215
NCT01398527|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-05-02|2011-07-19|2011-07-20|Estimate|||||||2013-05-02|2013-05-03|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|ViDOS||Vitamin D Osteoporosis Long-Term Care Study|An Interdisciplinary Knowledge Translation Intervention in Long-term Care: The Vitamin D and Osteoporosis Study (ViDOS) Pilot Cluster Randomized Controlled Trial|Completed||N/A|40|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:20:35.138977|2018-05-31 22:20:35.138977
NCT01398514|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2013-07-25||2014-06-05|2011-07-19|2011-07-20|Estimate|2013-07-25|2013-09-27|Estimate||||2014-06-05|2014-06-11|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Influence of Escitalopram on Fear Conditioning|Pharmacologic Influence of Escitalopram on the Reduction of Fear Acquisition and Triggered Renewal During Fear Conditioning: a Model for the Prevention and Persistence of Learned Fear and Anxiety in Response to Trauma and Stress|Completed||Phase 4|65|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:20:35.210411|2018-05-31 22:20:35.210411
NCT01398501|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-03-21|2011-07-19|2011-07-20|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2011||2011-08-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|September 2015|Actual|2015-09-30||Interventional|||Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant|Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation|Completed||Phase 1|22|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:20:35.469611|2018-05-31 22:20:35.469611
NCT01398488|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-06-05|2011-07-19|2011-07-20|Estimate|||||||2013-06-05|2013-06-06|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Interventional|||Patient Education After Lung Transplantation Via Tablet Computers Versus Conventional Education|Patient Education After Lung Transplantation Via Tablet Computers Versus Conventional Education - a Randomized Open Controlled Trial|Completed||Phase 2|64|Actual|Hannover Medical School||2|||f||||f||||||||||2018-05-31 22:20:35.534363|2018-05-31 22:20:35.534363
NCT01398475|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2017-03-10||2017-03-10|2011-07-19|2011-07-20|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|July 2011||2011-07-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||All randomized participants.|A Relative Bioavailability and Food Effect Study of New Formulations|Relative Bioavailability of the LY3009104 Free Base Test Formulation Compared to the Reference Phosphate Salt Formulation and the Effect of Food on the Bioavailability of the Test Formulation in Healthy Subjects|Completed||Phase 1|15|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:20:35.59529|2018-05-31 22:20:35.59529
NCT01398462|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-17|||2016-03-07|2011-07-19|2011-07-20|Estimate|||||||2016-03-07|2016-03-08|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients|A Phase I Clinical Study of CWP232291 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome Having Failed Hypomethylating Treatment, and High-Risk Myelofibrosis|Completed||Phase 1|69|Actual|JW Pharmaceutical||1|||f||||t||||||||||2018-05-31 22:20:36.776182|2018-05-31 22:20:36.776182
NCT01398449|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-07-19|2011-07-19|2011-07-20|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0|Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial|Unknown status|Recruiting|Phase 3|874|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:20:36.841514|2018-05-31 22:20:36.841514
NCT01398436|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-04-19|2011-07-19|2011-07-20|Estimate|||||||2013-04-19|2013-04-22|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Hemoglobin Saturation in Superior Vena Cava and Right Atrium|Comparison Between Hemoglobin Saturation in the Superior Vena Cava and in the Right Atrium|Completed||N/A|61|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 22:20:36.924732|2018-05-31 22:20:36.924732
NCT01398423|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-08-05|2011-07-19|2011-07-20|Estimate|||||||2012-08-05|2012-08-07|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria|A 12 Week, Phase II Trial of the Safety, Pharmacokinetics, and Efficacy of INV-144 Compared With Losartan Potassium in Patients With Hypertension and Type 2 Diabetes Mellitus With Nephropathy|Completed||Phase 2|88|Actual|InVasc Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 22:20:36.994241|2018-05-31 22:20:36.994241
NCT01398410|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2015-10-16||2015-11-19|2011-07-19|2011-07-20|Estimate|2015-10-16|2015-11-16|Estimate||||2015-11-19|2015-12-21|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)|Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Open-label Trial-|Completed||Phase 2/Phase 3|405|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:20:37.191503|2018-05-31 22:20:37.191503
NCT01398397|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-06-26|2011-07-19|2011-07-20|Estimate|||||||2012-06-26|2012-06-28|Estimate|April 2011||2011-04-30|June 2012|2012-06-30||||||||Observational|ECP-006||Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype|Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype|Completed|||11|Actual|Edimer Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:20:37.656006|2018-05-31 22:20:37.656006
NCT01398384|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2014-05-20|2011-07-19|2011-07-20|Estimate|||||||2014-05-20|2014-05-21|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|NOMI||Effects of Nitric Oxide for Inhalation in Myocardial Infarction Size|The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size|Completed||Phase 2|250|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 22:20:37.709673|2018-05-31 22:20:37.709673
NCT01398371|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-05-30|2011-07-19|2011-07-20|Estimate|||||||2016-05-30|2016-06-01|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Digoxin Withdrawal in Stable Heart Failure|A Randomised, Blinded, Placebo Controlled Trial to Assess the Effect of Digoxin Withdrawal in Stable Heart Failure Patients Receiving Optimal Background Therapy|Completed||N/A|16|Actual|The Alfred||2|||f||||f||||||||||2018-05-31 22:20:37.789952|2018-05-31 22:20:37.789952
NCT01398358|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|2017-04-11||2017-07-18|2011-07-19|2011-07-20|Estimate|2017-07-18|2018-02-02|Estimate||||2017-07-18|2018-02-02|Estimate|March 2011||2011-03-31|July 2017|2017-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Enhancing Self Regulation as a Strategy for Obesity Prevention in Head Start Preschoolers|Enhancing Self Regulation as a Strategy for Obesity Prevention in Head Start Preschoolers|Completed||N/A|697|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 22:20:37.865732|2018-05-31 22:20:37.865732
NCT01398345|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2014-07-01|2011-07-19|2011-07-20|Estimate|||||||2014-07-01|2014-07-02|Estimate|April 2003||2003-04-30|July 2014|2014-07-31||||December 2006|Actual|2006-12-31||Interventional|||Exercise and Respiratory Training as Supportive Treatments for Patients With Chronic Pulmonary Hypertension|Phase 3 Study of Physical Exercise and Respiratory Training as Supportive Treatments for Patients With Severe Chronic Pulmonary Hypertension|Completed||Phase 3|30|Anticipated|Heidelberg University||1|||f||||||||||||||2018-05-31 22:20:38.226155|2018-05-31 22:20:38.226155
NCT01398332|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2017-09-07|2011-07-19|2011-07-20|Estimate|||||||2017-09-07|2017-09-08|Actual|January 2011||2011-01-31|September 2017|2017-09-30|November 2022|Anticipated|2022-11-30|November 2012|Actual|2012-11-30||Observational|||Evaluation of the GORE® C3 Delivery System Module|Global Registry for Endovascular Aortic Treatment(GREAT)|Active, not recruiting|||400|Actual|W.L.Gore & Associates|||1||f||||t||||||||||2018-05-31 22:20:38.295031|2018-05-31 22:20:38.295031
NCT01398319|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-10-31|2011-07-18|2011-07-20|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|AFIV||Prevention of Alcohol Related Incidents in Air Force Technical Training|Predictors of Smokeless Tobacco and Dual Use in the US Military and the Prevention of Alcohol Related Incidents Using a Brief Alcohol Intervention in Air Force Technical Training|Recruiting||N/A|35000|Anticipated|University of Tennessee||1|||f||||t||||||||||2018-05-31 22:20:38.466752|2018-05-31 22:20:38.466752
NCT01398306|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2012-05-07|2011-07-19|2011-07-20|Estimate|||||||2012-05-07|2012-05-08|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|BANN||Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.|Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.|Completed|||40|Actual|University Medical Center Groningen|||2||f||||f||||||Samples With DNA|"~     2 x 10mL whole blood, stored as platelet rich and platelet poor plasma.~   "|||2018-05-31 22:20:38.581715|2018-05-31 22:20:38.581715
NCT01398293|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-11-01|2011-07-19|2011-07-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects|A Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of Danoprevir With Low Dose Ritonavir (DNV/r) on the QT/QTc Interval in Healthy Subjects|Completed||Phase 1|52|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 22:20:38.679409|2018-05-31 22:20:38.679409
NCT01398280|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-01-14|2011-07-19|2011-07-20|Estimate|||||||2013-01-14|2013-01-15|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ACA||Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation|A Single Site Evaluation of the Effect of Topical Application of Aminocaproic Acid (ACA) to Inhibit Kallikrein 5 Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation.|Completed||Early Phase 1|15|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 22:20:38.762821|2018-05-31 22:20:38.762821
NCT01398267|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-11-01|2011-07-19|2011-07-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Aleglitazar 150 µg in Type 2 Diabetic Patients Treated With Lisinopril 20 mg on Renal Function, the Renin-angiotensin System and the Pharmacokinetics of Lisinopril|Completed||Phase 1|55|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:20:38.832278|2018-05-31 22:20:38.832278
NCT01398254|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2018-05-10|2011-07-18|2011-07-20|Estimate|||||||2018-05-10|2018-05-11|Actual|July 2011||2011-07-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|August 2019|Anticipated|2019-08-31||Interventional|SAFARI-STEMI||Femoral Versus Radial Access for Primary PCI|The Safety and Efficacy of Femoral Access Versus Radial for Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction (SAFARI-STEMI Trial)|Recruiting||N/A|4884|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 22:20:38.912413|2018-05-31 22:20:38.912413
NCT01398241|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-11-01|2011-07-19|2011-07-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of RO5267683 in Healthy Subjects|Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5267683 in an Adaptive, Randomized, Investigator-blind and Subject-blind, Multiple-ascending Dose, Placebo-controlled, Study Following Oral Administrations in Healthy Subjects for 28 Days|Completed||Phase 1|38|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:20:39.00816|2018-05-31 22:20:39.00816
NCT01398228|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-08-08|2011-07-19|2011-07-20|Estimate|||||||2016-08-08|2016-08-10|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|CPACS-3||Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3|Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3|Completed||N/A|29934|Actual|The George Institute for Global Health, China||4|||f||||t||||||||||2018-05-31 22:20:39.099116|2018-05-31 22:20:39.099116
NCT01398215|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2018-04-30|2011-07-19|2011-07-20|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2009||2009-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|NOTES||Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Transvaginal Ventral Hernia Repair|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Transvaginal Ventral Hernia Repair|Recruiting|||50|Anticipated|University of California, San Diego|||1||f||||f||||||||||2018-05-31 22:20:39.293206|2018-05-31 22:20:39.293206
NCT01398202|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-11-30|2011-07-19|2011-07-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Dietary Supplementation With 25-hydroxyvitamin D3 in Older Adults|Comparison of the Bioefficacy of Oral 25-hydroxyvitamin D3 and Vitamin D3 Supplements on Vitamin D Status in Older Adults|Completed||N/A|56|Actual|University College Cork||4|||f||||t||||||||||2018-05-31 22:20:39.355933|2018-05-31 22:20:39.355933
NCT01398189|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-11-19|2011-07-19|2011-07-20|Estimate|||||||2013-11-19|2013-11-21|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|APC||F-18 Altanserin PET Study of Patients Receiving Clozapine|Validation of Molecular Imaging Technologies for Early Clinical Trials|Unknown status|Recruiting|N/A|12|Anticipated|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-05-31 22:20:39.419443|2018-05-31 22:20:39.419443
NCT01398176|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2013-09-25||2013-12-02|2011-07-19|2011-07-20|Estimate|2013-12-02|2013-12-30|Estimate||||2013-12-02|2013-12-30|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Immune Benefits From Mushroom Consumption|Immune Benefits From Mushroom Consumption|Completed||N/A|52|Actual|University of Florida|No specific limitations outside of the normal limitations to human interventions studies.|2|||f||||f||||||||||2018-05-31 22:20:39.496451|2018-05-31 22:20:39.496451
NCT01398163|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2016-11-23|2011-07-19|2011-07-20|Estimate|||||||2016-11-23|2016-11-25|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||A f-MRI Study Of Affective Changes Associated With Four Weeks Consumption Of A Fermented Dairy Product In Healthy Women|A f-MRI STUDY OF AFFECTIVE CHANGES ASSOCIATED WITH FOUR WEEKS CONSUMPTION OF A FERMENTED DAIRY PRODUCT IN HEALTHY WOMEN|Completed||N/A|51|Actual|Danone Research||3|||f||||f||||||||||2018-05-31 22:20:39.686806|2018-05-31 22:20:39.686806
NCT01398150|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-09-16|2011-07-19|2011-07-20|Estimate|||||||2011-09-16|2011-09-20|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Cranberry Enhances Human Immune Function and Reduces Illness|Cranberry Enhances Human Immune Function and Reduces Illness|Completed||N/A|54|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:20:39.831352|2018-05-31 22:20:39.831352
NCT01398137|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-10-26|2011-07-19|2011-07-20|Estimate|||||||2011-10-26|2011-10-27|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Ragweed Observational Study|An Observational Multi-Centre Field Study to Assess Symptom Scores and Rescue Medication Usage in Subjects With a History of Ragweed Allergen-Induced Rhinoconjunctivitis|Completed|||90|Actual|Circassia Limited|||1||f||||f||||||||||2018-05-31 22:20:39.902528|2018-05-31 22:20:39.902528
NCT01398124|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2017-08-21|2011-07-19|2011-07-20|Estimate|||||||2017-08-21|2017-08-22|Actual|December 2012||2012-12-31|August 2017|2017-08-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer|A Pilot Study of Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Patients With Resectable Non-Small Cell Lung Cancer|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||||We will not be pursuing this study.|f||||t||||||||||2018-05-31 22:20:39.975738|2018-05-31 22:20:39.975738
NCT01398111|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2012-04-02|2011-07-19|2011-07-20|Estimate|||||||2012-04-02|2012-04-03|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TRIPLE 1||Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers|Open-label, Randomized, Single-dose, Placebo-controlled, 4-way Crossover Study to Investigate the Pharmacokinetic Interaction of Glycopyrrolate and Formoterol in Healthy Subjects.|Completed||Phase 1|44|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-05-31 22:20:40.040964|2018-05-31 22:20:40.040964
NCT01398098|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-11-28|2011-07-19|2011-07-20|Estimate|||||||2012-11-28|2012-11-29|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Measurement of Gastric Emptying During and After COLOKIT® Intake|Gastric Emptying Time Assessment During Bowel Preparation With COLOKIT®|Completed||Phase 2|30|Actual|Laboratoires Mayoly Spindler||1|||f||||f||||||||||2018-05-31 22:20:40.144233|2018-05-31 22:20:40.144233
NCT01398085|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-10-25|2011-07-18|2011-07-20|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|January 2021|Anticipated|2021-01-31|November 2020|Anticipated|2020-11-30||Interventional|IoN||IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients|Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients|Recruiting||Phase 2/Phase 3|570|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 22:20:40.216614|2018-05-31 22:20:40.216614
NCT01398072|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-05-31|2011-07-19|2011-07-20|Estimate|||||||2012-05-31|2012-06-01|Estimate|December 2011||2011-12-31|May 2012|2012-05-31|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Interventional|||Development of an Optimal Antibiotic Regime for Long-term Therapy in Stable Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Single-blind, Randomised Placebo Controlled Trial of Long Term Therapy in Patients With Stable COPD Using Moxifloxacin, Azithromycin and Doxycycline: a Bayesian Decision Analysis, Including Other Criteria, Will be Used to Distinguish the Optimal Antibiotic Treatment|Unknown status|Recruiting|Phase 3|200|Anticipated|University College, London||4|||f||||f||||||||||2018-05-31 22:20:40.399611|2018-05-31 22:20:40.399611
NCT01398059|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-09-24|2011-07-19|2011-07-20|Estimate|||||||2012-09-24|2012-09-25|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Metabolic Effects of Breaks in Sedentary Time|The Metabolic Effects of Breaks in Sedentary Time|Completed||N/A|20|Actual|Children's Hospital of Eastern Ontario||3|||f||||f||||||||||2018-05-31 22:20:40.499|2018-05-31 22:20:40.499
NCT01398046|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2015-04-24|2011-07-18|2011-07-20|Estimate|||||||2015-04-24|2015-04-28|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Gastric pH on the Pharmacokinetics of Dasatinib|Effects of Gastric pH on the Pharmacokinetics of Dasatinib in Healthy Volunteers|Completed||Phase 1|10|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 22:20:40.598721|2018-05-31 22:20:40.598721
NCT01398033|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-08-03|2011-07-19|2011-07-20|Estimate|||||||2015-08-03|2015-08-05|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|BAIR||Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis|Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis|Withdrawn||Phase 3|0|Actual|Herz-Zentrums Bad Krozingen||2||Study stopped due to lack of patient inclusion|f||||t||||||||||2018-05-31 22:20:40.69592|2018-05-31 22:20:40.69592
NCT01398020|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-09-17|2011-07-18|2011-07-20|Estimate|||||||2013-09-17|2013-09-19|Estimate|July 2011||2011-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparing 2L Bi-Pegyte to 4L PegLyte Regiments for Outpatient Colonic Preparation|Oral 2L Bi-PegLyte Versus 4L PegLyte Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial|Completed||N/A|318|Actual|University of British Columbia||2|||f||||||||||||||2018-05-31 22:20:40.777344|2018-05-31 22:20:40.777344
NCT01398007|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-03-10|2011-07-19|2011-07-20|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2005||2005-10-31|July 2011|2011-07-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Use of the Camouflage Syringe to Reduce Dental Anxiety and Fear in Children|Evaluation of the Efficacy of Camouflage Syringe in Reducing Dental Anxiety and Fear in Children|Completed||Phase 2|100|Actual|Government Dental College and Hospital, India||2|||f||||t||||||||||2018-05-31 22:20:40.853817|2018-05-31 22:20:40.853817
NCT01397994|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-12-07|2011-07-19|2011-07-20|Estimate|||||||2011-12-07|2011-12-08|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.|A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina.|Unknown status|Recruiting|Phase 4|40|Anticipated|Ferozsons Laboratories Ltd.||2|||f||||f||||||||||2018-05-31 22:20:40.940973|2018-05-31 22:20:40.940973
NCT01397981|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2013-03-05|2011-07-19|2011-07-20|Estimate|||||||2013-03-05|2013-03-06|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|||Gait Retraining to Reduce Knee Osteoarthritis Pain|Evaluation of Haptic Technologies for Movement Retraining|Completed||Phase 1/Phase 2|25|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 22:20:41.037314|2018-05-31 22:20:41.037314
NCT01397968|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18||2014-11-17|2017-10-30|2011-07-19|2011-07-20|Estimate||||2014-11-17|2014-12-03|Estimate|2017-10-30|2017-11-06|Actual|May 2011||2011-05-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2013|Actual|2013-06-30||Interventional|||Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures|A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures|Active, not recruiting||Phase 2|222|Actual|SK Life Science||2|||f||||t||||||||||2018-05-31 22:20:41.130064|2018-05-31 22:20:41.130064
NCT01397955|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2015-04-16|2011-07-19|2011-07-20|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Observational|||Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan|Drug Use Investigation of Julina Tablets 0.5 mg (Postmenopausal Osteoporosis)|Completed|||148|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:20:41.233551|2018-05-31 22:20:41.233551
NCT01397942|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-03-10|2011-07-19|2011-07-20|Estimate|||||||2015-03-10|2015-03-11|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|MAXVEG||Maximising the Taste and Health Value of Plant Food Products|Maximising the Taste and Health Value of Plant Food Products - Impact on Vegetable Consumption, Consumer Preferences and Human Health Factors.|Completed||N/A|92|Actual|Aarhus University Hospital||3|||f||||t||||||||||2018-05-31 22:20:41.300637|2018-05-31 22:20:41.300637
NCT01397123|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||The Impact of an Intervention Taught by Trained Teachers on Childhood BMI z Score||Completed||N/A|464|Actual|University of Minho||1|||f||||t||||||||||2018-05-31 22:20:58.712552|2018-05-31 22:20:58.712552
NCT01397916|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-03-29|2011-07-19|2011-07-20|Estimate|||||||2012-03-29|2012-03-30|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|KLL3||Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)|The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)|Completed|||73|Actual|Tampere University Hospital|||2||f||||f||||||Samples With DNA|"~     Ido expression~   "|||2018-05-31 22:20:41.436637|2018-05-31 22:20:41.436637
NCT01397903|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-06-22|2011-07-19|2011-07-20|Estimate|||||||2012-06-22|2012-06-25|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|MADDRE||Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response|A Cross-sectional Observational Study to Describe Treatment Management of Patients With Major Depressive Disorder (MDD) and Inadequate Response to Antidepressants in Greece|Completed|||545|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 22:20:41.494249|2018-05-31 22:20:41.494249
NCT01397890|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2014-06-18||2015-03-25|2011-07-19|2011-07-20|Estimate|2014-08-12|2014-08-27|Estimate||||2015-03-25|2015-03-27|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SECURE 1|Overall Number of Baseline Participants is not different from the Milestones.|Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Parallel-group, Open-label, Multicentre, 3-month Phase IV, Efficacy and Tolerability Study of Budesonide/Formoterol (Symbicort® Turbuhaler® 160/4.5μg/Inhalation, 2 Inhalations Twice Daily) Added to Tiotropium (SpirivaTM 18 μg/Inhalation, 1 Inhalation Once Daily) Compared With Tiotropium (SpirivaTM18 μg/Inhalation, 1 Inhalation Once Daily) Alone in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||Phase 4|793|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:20:41.696191|2018-05-31 22:20:41.696191
NCT01397877|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-03-15|2011-07-19|2011-07-20|Estimate|||||||2016-03-15|2016-03-17|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|October 2014|Actual|2014-10-31||Interventional|ENDOPIK||GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial Cancer|Phase 2 Multicenter Study to Assess the Safety and Efficacy of BKM120 as Monotherapy in Treatment of Initial or Recurrent Metastatic Endometrial Cancer After 1st Line Therapy in Patients Who Cannot Undergo Local Surgery and/or Radiotherapy|Completed||Phase 2|24|Actual|ARCAGY/ GINECO GROUP||1|||f||||t||||||||||2018-05-31 22:20:42.561953|2018-05-31 22:20:42.561953
NCT01397864|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2018-04-03|2011-07-19|2011-07-20|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 2011||2011-07-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks|C1 Inhibitor Treatment Registry to Assess the Safety and Immunological Profile of Ruconest in the Treatment of HAE Attacks|Recruiting|||300|Anticipated|Pharming Technologies B.V.|||1||f||||f||||||||||2018-05-31 22:20:42.73098|2018-05-31 22:20:42.73098
NCT01397851|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2014-11-20||2015-01-07|2011-07-18|2011-07-20|Estimate|2015-01-07|2015-01-15|Estimate||||2015-01-07|2015-01-15|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|Outgrowers||Stimulating Private Sector Malaria Control|Stimulating Private Sector Malaria Control: The Outgrower Opportunity|Completed||N/A|81597|Actual|PATH||2|||f||||f||||||||||2018-05-31 22:20:43.007298|2018-05-31 22:20:43.007298
NCT01397838|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-19|2011-07-19|2011-07-20|Estimate|||||||2011-07-19|2011-07-20|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Interventional|||Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women|Phase 1 Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|OsteoBuild Ltd.||1|||f||||f||||||||||2018-05-31 22:20:43.572208|2018-05-31 22:20:43.572208
NCT01397825|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-17|2018-01-04|2016-11-17|2018-02-27|2011-07-19|2011-07-20|Estimate|2018-02-27|2018-03-27|Actual|2016-11-17|2016-11-18|Estimate|2018-02-27|2018-03-27|Actual|August 9, 2011|Actual|2011-08-09|February 2018|2018-02-28|October 5, 2016|Actual|2016-10-05|February 5, 2015|Actual|2015-02-05||Interventional||Safety Population was defined as all participants who receive any amount of alisertib.|MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine|A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine|Completed||Phase 1/Phase 2|45|Actual|Takeda|The Phase 2 portion of the study was cancelled by the sponsor; this was an administrative decision not based on any clinical or safety outcomes.|5|||f||||f|t|f||||||||2018-05-31 22:20:43.714341|2018-05-31 22:20:43.714341
NCT01397812|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-04-06|2011-07-19|2011-07-20|Estimate|||||||2015-04-06|2015-04-07|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|September 2016|Anticipated|2016-09-30|December 2013|Actual|2013-12-31||Observational|Heartsbreath||Heartsbreath Test for Heart Transplant Rejection|Validation of Heartsbreath Test for Heart Transplant Rejection|Unknown status|Active, not recruiting||1200|Anticipated|Menssana Research, Inc.|||1||f||||f||||||||||2018-05-31 22:20:45.418431|2018-05-31 22:20:45.418431
NCT01397799|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-12-04|2011-07-19|2011-07-20|Estimate|||||||2015-12-04|2015-12-07|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)|A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy|Completed||Phase 1|24|Actual|Athenex, Inc.||1|||f||||f||||||||||2018-05-31 22:20:45.508267|2018-05-31 22:20:45.508267
NCT01397786|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2017-02-03||2017-04-03|2011-07-19|2011-07-20|Estimate|2017-02-03|2017-03-27|Actual||||2017-04-03|2017-05-10|Actual|September 2011||2011-09-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ZENITH||Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia|A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia|Completed||Phase 3|1044|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 22:20:45.673661|2018-05-31 22:20:45.673661
NCT01397773|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-19|2011-07-19|2011-07-20|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Pentraxin-3 in Chronic Renal Failure|The Role Pentraxin-3 in the Inflammatory Process in Chronic Renal Failure, and the Association With Other Inflammatory Parameters|Completed|||85|Anticipated|Haseki Training and Research Hospital|||4||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:20:46.797281|2018-05-31 22:20:46.797281
NCT01387919|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-08|2011-07-05|2011-07-06|Estimate|||||||2011-07-08|2011-07-11|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Time Course and Nature of Nutrient Sensing During Fasting in Humans|Time Course and Nature of Nutrient Sensing During Fasting in Humans|Completed||N/A|12|Actual|Leiden University Medical Center||1|||f||||f||||||||||2018-05-31 22:24:15.85919|2018-05-31 22:24:15.85919
NCT01397760|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-07-19|2011-07-19|2011-07-20|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||Retrospective Study for Description of The Use Of Omalizumab In Patients With Difficult To Control Asthma|Retrospective Study for Description of The Use Of Omalizumab In Patients With Difficult To Control Asthma|Unknown status|Not yet recruiting||20|Anticipated|Fiks, Iara Nely, M.D.|||||f||||f||||||||||2018-05-31 22:20:46.880856|2018-05-31 22:20:46.880856
NCT01397747|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2015-12-01||2015-12-01|2011-07-19|2011-07-20|Estimate|2015-12-01|2015-12-03|Estimate||||2015-12-01|2015-12-03|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Observational|DeeP-C|All evaluable participants except for participants who had multitargeted sDNA or colonoscopy excluded.|Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer|Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer: DeeP-C Study|Completed|||12776|Actual|Exact Sciences Corporation|||1||f||||f||||||Samples With DNA|"~     Residual stool samples may be archived for further research. Clinical data and samples will~     be kept in a manner that preserves anonymity of the subjects, using the subject ID as the~     only tracking information. Specimens will be stored in a commercial biorepository contracted~     by Exact Sciences or at Exact Sciences and may be used for future research.~   "|||2018-05-31 22:20:46.95174|2018-05-31 22:20:46.95174
NCT01397734|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2018-05-10|2011-07-19|2011-07-20|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2011||2011-09-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)|Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML|Active, not recruiting||Phase 1|7|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 22:20:47.476062|2018-05-31 22:20:47.476062
NCT01397721|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2015-04-22|2011-07-19|2011-07-20|Estimate|||||||2015-04-22|2015-04-23|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Observational|MESA-COPD||Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary|Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)|Unknown status|Active, not recruiting||360|Actual|Columbia University|||||f||||t||||||Samples With DNA|"~     Blood will be stored at Columbia and at University of Vermont, identified only by study ID~     and following standard procedures. It will be accessible only to study investigators and, if~     the participant approves, outside investigators following MESA/NIH protocols and with IRB~     approval. Blood will be kept indefinitely.~   "|||2018-05-31 22:20:47.780056|2018-05-31 22:20:47.780056
NCT01397708|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-01-23|2011-07-18|2011-07-19|Estimate|||||||2015-01-23|2015-01-26|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma|A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma|Completed||Phase 1/Phase 2|26|Actual|Ziopharm||1|||f||||f||||||||||2018-05-31 22:20:47.872604|2018-05-31 22:20:47.872604
NCT01397695|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Unknown status|Recruiting|Phase 2|50|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 22:20:47.98997|2018-05-31 22:20:47.98997
NCT01397682|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2012-10-16|2011-07-18|2011-07-19|Estimate|||||||2012-10-16|2012-10-17|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|report-AGE||Epidemiological Observatory on the Health Conditions of Inpatients Aged 65 or Older at the INRCA Research Hospitals|Epidemiological Observatory on the Health Conditions of Inpatients Aged 65 or Older at the INRCA Research Hospitals|Unknown status|Enrolling by invitation||2250|Anticipated|Istituto Nazionale di Ricovero e Cura per Anziani|||||f||||||||||Samples With DNA|"~     plasma, serum, whole blood~   "|||2018-05-31 22:20:48.097853|2018-05-31 22:20:48.097853
NCT01397669|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2018-04-17|2011-07-18|2011-07-19|Estimate|||||||2018-04-17|2018-04-19|Actual|July 2011||2011-07-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Characteristics of Immune Cells in Gut Mucosa of HIV Negative and HIV Positive Thais||Recruiting||N/A|200|Anticipated|South East Asia Research Collaboration with Hawaii||1|||f||||f||||||||||2018-05-31 22:20:48.200144|2018-05-31 22:20:48.200144
NCT01397656|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-03-01|2011-07-18|2011-07-19|Estimate|||||||2012-03-01|2012-03-05|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Bystander Fatigue and CPR Quality Using Continuous Compressions Versus 30:2 Compressions to Ventilation|Comparison of Bystander Fatigue and CPR Quality When Using the 2010 Continuous Chest Compression Versus the 2005 30:2 Chest Compression to Ventilation Resuscitation Guidelines for Laymen: A Randomized Crossover Trial|Completed||N/A|62|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 22:20:48.273415|2018-05-31 22:20:48.273415
NCT01397643|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-10-05|2011-07-18|2011-07-19|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||A Trial of Non-operative Versus Operative Management of Olecranon Fractures in the Elderly|A Prospective Randomised Trial of Non-operative Versus Operative Management of Olecranon Fractures in the Elderly|Terminated||N/A|19|Actual|Royal Infirmary of Edinburgh||2||Complication rate in operative group on interim analysis and safety monitoring.|f||||f||||||||Yes|Peer reviewed publication - undergoing review|2018-05-31 22:20:48.367203|2018-05-31 22:20:48.367203
NCT01397630|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-06-23|2011-07-18|2011-07-19|Estimate|||||||2015-06-23|2015-06-25|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|ACTION||Accelerated Titration of Oxytocin for Nulliparous Patients With Labour Dystocia: ACTION Pilot Study|Accelerate Versus Gradual Titration of Oxytocin Dose for Labour Dystocia: A Pilot Study|Terminated||Phase 3|79|Actual|Ottawa Hospital Research Institute||2||"Due to budgetary concerns, the TSC decided it best to adjust sample size as there was~   sufficient data to assess feasibility. Recruitment was terminated early."|f||||t||||||||||2018-05-31 22:20:48.540151|2018-05-31 22:20:48.540151
NCT01397617|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|2015-12-08||2016-03-22|2011-07-18|2011-07-19|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|April 2006||2006-04-30|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Randomized, Open Investigation Evaluating the Efficacy of Nobel Biocare SFB and CFB Implants|Evaluation of NobelBiocare SFB and CFB Implants|Completed||N/A|177|Actual|Nobel Biocare||3|||f||||f||||||||No||2018-05-31 22:20:48.627257|2018-05-31 22:20:48.627257
NCT01397591|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2014-06-18||2014-07-28|2011-07-18|2011-07-19|Estimate|2014-07-28|2014-07-30|Estimate||||2014-07-28|2014-07-30|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma|Phase II Trial of Ofatumumab and Bortezomib in Subjects With Relapsed Cluster of Differentiation Antigen 20 (CD20)+ Diffuse Large B Cell Lymphoma, Follicular Lymphoma, or Mantle Cell Lymphoma|Terminated||Phase 2|3|Actual|OHSU Knight Cancer Institute||1||Study closed by PI due to lower than expected accrual.|f||||t||||||||||2018-05-31 22:20:49.029526|2018-05-31 22:20:49.029526
NCT01397578|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18||2016-08-10|2017-07-10|2011-07-18|2011-07-19|Estimate||||2016-08-10|2016-08-12|Estimate|2017-07-10|2017-07-12|Actual|August 31, 2011|Actual|2011-08-31|July 2017|2017-07-31|April 30, 2014|Actual|2014-04-30|April 30, 2014|Actual|2014-04-30||Interventional|||A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|91|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 22:20:49.273165|2018-05-31 22:20:49.273165
NCT01397565|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2015-09-26|2011-07-18|2011-07-19|Estimate|||||||2015-09-26|2015-09-29|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Minilaparoscopic Versus Conventional Laparoscopic Cholecystectomy|Minilaparoscopic Versus Conventional Laparoscopic Cholecystectomy: A Randomized Trial|Completed||Phase 4|115|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:20:49.371157|2018-05-31 22:20:49.371157
NCT01397552|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2017-04-25|2011-07-18|2011-07-19|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2009||2009-09-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Dexamethasone Versus Depo Medrol in Lumbar Epidurals|A Prospective, Randomized, Double-Blind Study to Compare the Effects of Dexamethasone Versus Depo-Medrol When Used in Lumbar Epidural Injections|Terminated||N/A|8|Actual|State University of New York - Upstate Medical University||2||Low enrollment, too many subjects getting second injection|f||||f||||||||No||2018-05-31 22:20:49.437733|2018-05-31 22:20:49.437733
NCT01397539|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-03-19|2011-07-18|2011-07-19|Estimate|||||||2015-03-19|2015-03-23|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease|A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|53|Actual|Biogen||2|||f||||t||||||||||2018-05-31 22:20:49.509501|2018-05-31 22:20:49.509501
NCT01397526|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2014-06-30|2011-07-18|2011-07-19|Estimate|||||||2014-06-30|2014-07-01|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|||Colloid Osmotic Pressure During Heart Surgery in Children|Colloid Osmotic Pressure During Heart Surgery in Children|Completed|||9|Actual|Oslo University Hospital|||||f||||f||||||Samples Without DNA|"~     Interstitial fluid Serum~   "|||2018-05-31 22:20:49.698989|2018-05-31 22:20:49.698989
NCT01397513|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|February 2011|Actual|2011-02-28|July 2010|Actual|2010-07-31||Interventional|||Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes|Effects of Low and High Doses of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes and Possible Influence of the Glycemic Control.|Completed||Phase 4|48|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 22:20:49.762734|2018-05-31 22:20:49.762734
NCT01397500|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2016-01-08|2011-07-18|2011-07-19|Estimate|||||||2016-01-08|2016-01-11|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Hormone Treatment in Growth Hormone and Testosterone Deficient Patients|Growth Hormone and Gonadotropin Deficiency After Brain Injury (Traumatic Brain Injury, Subarachnoidal Hemorrhage, Ischemic Stroke): the Effects of Hormone Replacement on Cognition, Quality of Life and Body Composition|Terminated||Phase 2|54|Actual|Max-Planck-Institute of Psychiatry||3||Recruitment problems due to change of patient population at site.|f||||f||||||||||2018-05-31 22:20:49.844183|2018-05-31 22:20:49.844183
NCT01397487|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-27|2011-07-18|2011-07-19|Estimate|||||||2011-07-27|2011-07-28|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|September 2013|Anticipated|2013-09-30|January 2012|Anticipated|2012-01-31||Interventional|BB||Effects of Day 3 Blastomere Biopsy on Human Embryos|Effects of the Blastomere Biopsy of Day 3 Human Embryos on Blastocyst Percentage, Cell Number of Obtained Blastocyst and Implantation Rate|Unknown status|Recruiting|Early Phase 1|22|Anticipated|Fundacion Para La Investigacion Hospital La Fe||1|||f||||t||||||||||2018-05-31 22:20:49.917254|2018-05-31 22:20:49.917254
NCT01397474|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-01-03|2011-07-18|2011-07-19|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Peripheral Perfusion Targeted Fluid Management|Peripheral Perfusion Targeted Fluid Management in Critically Ill Patients: a Pilot Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 22:20:50.082124|2018-05-31 22:20:50.082124
NCT01397461|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2016-02-25||2016-06-01|2011-07-18|2011-07-19|Estimate|2016-04-12|2016-05-18|Estimate||||2016-06-01|2016-07-01|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||"The baseline analysis population was considered the safety populations. The safety population was defined as all patients who had at least one application of study drug.~One patient was randomised to retapamulin but treated with ozenoxacin. One patient was randomised to retapamulin but not treated."|Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo|A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo|Completed||Phase 3|465|Actual|Ferrer Internacional S.A.||3|||f||||t||||||||||2018-05-31 22:20:50.198172|2018-05-31 22:20:50.198172
NCT01397448|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2014-10-20||2014-11-25|2011-07-18|2011-07-19|Estimate|2014-10-20|2014-10-23|Estimate||||2014-11-25|2014-11-26|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)|Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment. - A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial-|Completed||Phase 2/Phase 3|472|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 22:20:50.834263|2018-05-31 22:20:50.834263
NCT01090635|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2011-02-03|2010-03-19|2010-03-22|Estimate|||||||2011-02-03|2011-02-04|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Imaging the Uterine Cervix - UltraSightHD™|Imaging the Uterine Cervix - UltraSightHD™|Completed|||12|Actual|STI-Medical Systems|||||f||||f||||||||||2018-05-31 23:58:02.88751|2018-05-31 23:58:02.88751
NCT01397435|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2015-02-03|2011-07-18|2011-07-19|Estimate|||||||2015-02-03|2015-02-04|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|MRS in Gaucher||MR Spectroscopy and Disease Severity Score for Gaucher in Pediatric Population|Quantification of Bone Marrow Involvement in Gaucher Disease With Proton MR Spectroscopy, Correlation With Bone Marrow Burden Score, Genotype and Disease Severity Score for Pediatric Patients|Completed|||24|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||||||2018-05-31 22:20:52.056468|2018-05-31 22:20:52.056468
NCT01397422|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2017-10-07|2014-04-07|2017-11-17|2011-07-18|2011-07-19|Estimate|2017-10-07|2017-11-06|Actual|2014-04-07|2014-05-01|Estimate|2017-11-17|2017-12-13|Actual|July 2011||2011-07-31|November 2017|2017-11-30|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|EASED|Safety Analysis Population (all randomized subjects who received ≥ 1 dose of study drug)|Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)|Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)|Completed||Phase 2/Phase 3|83|Actual|Adamas Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 22:20:52.292494|2018-05-31 22:20:52.292494
NCT01397409|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2015-06-02||2015-06-02|2011-07-18|2011-07-19|Estimate|2015-06-02|2015-06-18|Estimate||||2015-06-02|2015-06-18|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)||Completed||Phase 2|271|Actual|Allergan||10|||f||||f||||||||||2018-05-31 22:20:54.877726|2018-05-31 22:20:54.877726
NCT01397396|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2017-03-12|2011-07-18|2011-07-19|Estimate|||||||2017-03-12|2017-03-14|Actual|February 2012|Actual|2012-02-29|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|IMTCO||Effects of Inspiratory Muscle Training in COPD|Effects of Inspiratory Muscle Training in Patients With Chronic Obstructive Pulmonary Disease - a Randomized Controlled Trial|Completed||Phase 3|208|Actual|Katholieke Universiteit Leuven||2|||f||||||||||||||2018-05-31 22:20:56.330501|2018-05-31 22:20:56.330501
NCT01397383|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2017-03-16|2011-07-18|2011-07-19|Estimate|||||||2017-03-16|2017-03-20|Actual|March 2010||2010-03-31|March 2017|2017-03-31|February 3, 2014|Actual|2014-02-03|June 2011|Actual|2011-06-30||Observational|||Vitamin D and Functional Outcomes After Total Hip Arthroplasty (THA)|The Effect of Serum Vitamin D Level and the Short Term Functional Outcomes After Total Hip Arthroplasty|Completed|||219|Actual|Hospital for Special Surgery, New York|||2||f||||t||||||||||2018-05-31 22:20:56.405688|2018-05-31 22:20:56.405688
NCT01397370|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-02-17|2011-07-18|2011-07-19|Estimate|||||||2012-02-17|2012-02-20|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects|Double Blind, Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0492 in Healthy Subjects|Completed||Phase 1|24|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 22:20:56.502528|2018-05-31 22:20:56.502528
NCT01397357|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-09-30|2011-07-18|2011-07-19|Estimate|||||||2016-09-30|2016-10-03|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|CARDIO-RM||Cardiac Magnetic Resonance Utilities in the Evaluation of Ischemic Heart Disease|CARDIAC MAGNETIC RESONANCE UTILITIES IN THE EVALUATION OF ISCHEMIC HEART DISEASE: Topographical Correlation Between Ischemic Territory Injury and Coronary Angiography|Completed|||146|Actual|Ettore Sansavini Health Science Foundation|||1||f||||t||||||||No||2018-05-31 22:20:56.617461|2018-05-31 22:20:56.617461
NCT01397344|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-09-01|2011-07-18|2011-07-19|Estimate|||||||2015-09-01|2015-09-02|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Observational|||Patients' Preferences for Traditional Medicine Doctor's Attire|Patients' Preferences for Traditional Medicine Doctor's Attire|Completed|||175|Actual|Korean Medicine Hospital of Pusan National University|||||f||||f||||||||||2018-05-31 22:20:56.699015|2018-05-31 22:20:56.699015
NCT01397331|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2018-04-23|2011-07-18|2011-07-19|Estimate|||||||2018-04-23|2018-04-24|Actual|July 1, 2010|Actual|2010-07-01|July 2011|2011-07-31|June 27, 2012|Actual|2012-06-27|June 27, 2012|Actual|2012-06-27||Interventional|||Influence of Anesthesia on Mechanical Efficiency of Left Ventricle in Patients Undergoing Open Heart Surgery|Influence of Anesthesia on Mechanical Efficiency of Left Ventricle in Patients Undergoing Open Heart Surgery|Terminated||Phase 4|28|Actual|Sheba Medical Center||2||Technical problems with data acquisition and interpretation; problems with recruitment|f||||f||||||||||2018-05-31 22:20:56.774434|2018-05-31 22:20:56.774434
NCT01397318|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|July 2013|Anticipated|2013-07-31|||||Observational|||Effects of Modified TaiChi Exercise on Maternal Stress, Fatigue, Sleep Quality, Biomarkers, and Infant Gestational Age and Birthweight|Effects of Modified TaiChi Exercise on Maternal Stress, Fatigue, Sleep Quality, Biomarkers, and Infant Gestational Age and Birthweight|Unknown status|Active, not recruiting||300|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:20:56.845468|2018-05-31 22:20:56.845468
NCT01397305|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2016-04-19|2011-07-18|2011-07-19|Estimate|||||||2016-04-19|2016-04-20|Estimate|April 2011||2011-04-30|April 2016|2016-04-30||||November 2014|Actual|2014-11-30||Interventional|||An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer|An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer|Completed||Phase 1/Phase 2|24|Actual|Isofol Medical AB||1|||f||||f||||||||||2018-05-31 22:20:56.921883|2018-05-31 22:20:56.921883
NCT01397292|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2013-03-15|2011-07-15|2011-07-19|Estimate|||||||2013-03-15|2013-03-19|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Registry for Patients Undergoing Pulmonary Procedures|Registry Examining Retrospective and Prospective Data for Patients Undergoing Pulmonary Procedures|Terminated|||220|Actual|Virginia Commonwealth University||||funding/ enrollment|f||||f||||||||||2018-05-31 22:20:57.029348|2018-05-31 22:20:57.029348
NCT01397279|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-11-26|2011-07-18|2011-07-19|Estimate|||||||2012-11-26|2012-11-27|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|April 2012|Actual|2012-04-30||Interventional|CLAVA||Assessment of Liver Glucose Metabolism in Diabetic Subjects|Assessment of Liver Glucose Metabolism in Diabetic Subjects|Unknown status|Active, not recruiting|N/A|40|Anticipated|German Diabetes Center||2|||f||||t||||||||||2018-05-31 22:20:57.081564|2018-05-31 22:20:57.081564
NCT01397266|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|March 2010||2010-03-31|August 2010|2010-08-31|July 2013|Anticipated|2013-07-31|January 2012|Anticipated|2012-01-31||Interventional|TMSCOCAINE||Study of the Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence|Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence.|Unknown status|Recruiting|Phase 2|20|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 22:20:57.167227|2018-05-31 22:20:57.167227
NCT01397253|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|2015-03-12||2015-03-27|2011-07-18|2011-07-19|Estimate|2015-03-12|2015-03-25|Estimate||||2015-03-27|2015-04-16|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Hospitalized medical patients with ≥2 comorbidities and ≥5 chronic medications, at a single center|Virtual Continuity and Its Impact on Complex Hospitalized Patients' Care|Virtual Continuity and Its Impact on Complex Hospitalized Patients' Care|Completed||Phase 3|835|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 22:20:57.28267|2018-05-31 22:20:57.28267
NCT01397240|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-01-08|2011-07-18|2011-07-19|Estimate|||||||2012-01-08|2012-01-10|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|June 2013|Anticipated|2013-06-30|January 2012|Anticipated|2012-01-31||Interventional|AL-PA||The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients|The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients Taking Low-dose Aspirin, A Pilot Study|Unknown status|Recruiting|Phase 4|80|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||t||||||||||2018-05-31 22:20:57.564966|2018-05-31 22:20:57.564966
NCT01397227|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12||2012-09-03|2012-09-03|2011-07-18|2011-07-19|Estimate||||2012-09-03|2012-09-07|Estimate|2012-09-03|2012-09-07|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model|A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-escalation Clinical Study Evaluating Safety, Tolerability and Immunogenicity of Two Dose Levels of Recombinant Adenoviral Serotype Ad35 and Serotype Ad26 Vectors Expressing the Malaria Plasmodium Falciparum Circumsporozoite Antigen Administered as Heterologous Prime-boost Regimen, and Assessing Protective Efficacy of the Higher Dose in a Malaria Challenge Model in Unblinded Conditions|Completed||Phase 1/Phase 2|36|Actual|Crucell Holland BV||4|||f||||t||||||||||2018-05-31 22:20:57.629319|2018-05-31 22:20:57.629319
NCT01397214|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2012-06-29|2011-07-18|2011-07-19|Estimate|||||||2012-06-29|2012-07-02|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|MGF||Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Cross-over Study to Investigate Safety and Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers|Completed||Phase 1|103|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 22:20:57.707625|2018-05-31 22:20:57.707625
NCT01397201|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18||2014-04-30|2014-04-30|2011-07-18|2011-07-19|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|July 2011||2011-07-31|April 2014|2014-04-30||||December 2011|Actual|2011-12-31||Interventional|||Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 45.5, 90.9 and 181.8 mcg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA 220 mcg b.i.d. in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy|Terminated||Phase 2|30|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 22:20:57.79241|2018-05-31 22:20:57.79241
NCT01397188|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2013-08-20|2011-07-18|2011-07-19|Estimate|||||||2013-08-20|2013-08-22|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|PiCCO||Effect of Monitoring of Pulse Index Continuous Cardiac Output (PiCCO) on Shock Patients in Intensive Care Unit|Effect of Monitoring of Pulse Index Continuous Cardiac Output on Shock Patients in ICU|Unknown status|Recruiting|N/A|320|Anticipated|Zhejiang University||2|||f||||f||||||||||2018-05-31 22:20:58.123226|2018-05-31 22:20:58.123226
NCT01397175|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-11-14|2011-07-18|2011-07-19|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|December 2015|Actual|2015-12-31||Interventional|CHOICE||BES, EES, and ZES-R in Real World Practice|A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice|Active, not recruiting||Phase 4|1960|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 22:20:58.236706|2018-05-31 22:20:58.236706
NCT01397162|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18||2014-04-30|2014-04-30|2011-07-18|2011-07-19|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|July 2011||2011-07-31|April 2014|2014-04-30||||December 2011|Actual|2011-12-31||Interventional|||Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 22.7, 45.5 and 90.9 Doses b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA MDI 88 mcg b.i.d. in Patients With Asthma Inadequately Controlled on SABA Therapy|Terminated||Phase 2|29|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 22:20:58.349462|2018-05-31 22:20:58.349462
NCT01397149|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-05-27|2011-07-18|2011-07-19|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)|A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy|Terminated||Phase 1/Phase 2|4|Actual|University of Ulm||2||Insufficient recruitment|f||||t||||||||||2018-05-31 22:20:58.536099|2018-05-31 22:20:58.536099
NCT01397136|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-02-04|2011-07-18|2011-07-19|Estimate|||||||2015-02-04|2015-02-05|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|||Cell-free DNA: a Non-invasive Test for Assessing Embryo Quality|Cell-free DNA: a Non-invasive Test for Assessing Embryo Quality|Completed|||600|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||||f||||f||||||Samples With DNA|"~     After normally fertilized oocytes will be identified, they will be transferred into Sydney~     IVF Cleavage Medium (Cook Medical) for culture from day 1 to day 3 (up to 8 cell stage). For~     a subset of embryos we will also perform culture until blastocyst stage. For this purpose,~     embryos will be transferred into Sydney IVF Blastocist medium (Cook Medical) from day 3 to~     day 5/6. We will focus on embryo development in a single embryo culture medium. Embryos will~     be cultured at 37°C, 6.0% CO2, 5.0% O2 into Galaxy 48R incubators (New Brunswick Scientific).~     At the moment of transfer of embryos into the uterine cavity, we will collect embryo culture~     media into DNase- and RNase-free 1.5 ml tubes (Eppendorf AG). The media will be immediately~     frozen and stored at -20° until nucleic acid purification.~   "|||2018-05-31 22:20:58.648159|2018-05-31 22:20:58.648159
NCT01397110|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2015-06-19|2011-07-18|2011-07-19|Estimate|||||||2015-06-19|2015-06-22|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart Defects|Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life in Patients With Severe Associated Pulmonary Arterial Hypertension (APAH) as Part of a Congenital Heart Defect With / Without Eisenmenger's Syndrome|Unknown status|Recruiting|Phase 2|50|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 22:20:58.791548|2018-05-31 22:20:58.791548
NCT01397097|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-07-22|2011-07-18|2011-07-19|Estimate|||||||2016-07-22|2016-07-25|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|April 2015|Actual|2015-04-30|June 2013|Actual|2013-06-30||Interventional|||LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study|Multicenter, Open-label, Randomized, Controlled Parallel-group Study to Assess Discontinuation Rates, Bleeding Patterns, User Satisfaction and Adverse Event Profile of LCS12 in Comparison to Etonorgestrel Subdermal Implant Over 12 Months of Use in Women 18 to 35 Years of Age|Completed||Phase 3|766|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:20:58.871895|2018-05-31 22:20:58.871895
NCT01397084|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|2013-01-16||2013-02-18|2011-07-18|2011-07-19|Estimate|2013-01-16|2013-02-18|Estimate||||2013-02-18|2013-02-21|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole|An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 20 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole|Completed||Phase 4|107|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 22:20:59.010466|2018-05-31 22:20:59.010466
NCT01397071|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-11-23|2011-07-18|2011-07-19|Estimate|||||||2016-11-23|2016-11-28|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Effects of Avocado When Added to a Meat Patty on Inflammation in Healthy Men|Hass Avocado Flesh Inhibition of Appearance of Lipid Peroxidation Products When Added to a Ground Beef Patty Consumed by Healthy Volunteers|Completed||Phase 3|11|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:20:59.180582|2018-05-31 22:20:59.180582
NCT01397058|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-08-12|2011-07-18|2011-07-19|Estimate|||||||2011-08-12|2011-08-15|Estimate|June 2011||2011-06-30|July 2011|2011-07-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|RECYSTRESS||Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress|Observational Study of CMV Reactivation in Immunocompetent Children and Adult ICU Patients|Unknown status|Recruiting||275|Anticipated|University of Athens|||||f||||t||||||Samples With DNA|"~     As described above, whole blood will be collected on a weekly basis and DNA will be extracted~     to detect CMV-DNA. The remaining DNA will be retained~   "|||2018-05-31 22:20:59.256179|2018-05-31 22:20:59.256179
NCT01397045|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2014-03-26|2011-07-18|2011-07-19|Estimate|||||||2014-03-26|2014-03-28|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Fast Track Rehabilitation Following Video-assisted Lung Segmentectomy||Completed||N/A|120|Actual|Theagenio Cancer Hospital||2|||f||||||||||||||2018-05-31 22:20:59.337156|2018-05-31 22:20:59.337156
NCT01397032|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-05-25|2011-07-18|2011-07-19|Estimate|||||||2015-05-25|2015-05-27|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Attention Bias Modification Treatment for Children With Social Anxiety|Attention Bias Modification Treatment for Children With Social Anxiety|Completed||Phase 2|67|Actual|Tel Aviv University||2|||f||||f||||||||||2018-05-31 22:20:59.401419|2018-05-31 22:20:59.401419
NCT01397019|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-09-23|2011-07-18|2011-07-19|Estimate|||||||2015-09-23|2015-09-25|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours|Chemotherapy for Patients With Locally Advanced Pancreatic Cancer With Additional Chemo-radiotherapy for Patients With Borderline Resectable Tumours|Unknown status|Recruiting|Phase 2|50|Anticipated|Odense University Hospital||1|||f||||t||||||||||2018-05-31 22:20:59.48461|2018-05-31 22:20:59.48461
NCT01397006|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2014-04-11|2011-07-18|2011-07-19|Estimate|||||||2014-04-11|2014-04-14|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Fibromyalgia of Less Than One Year Duration. Study of Pregabalin|Fibromyalgia of Less Than One Year Duration in Primary Care: Treatment Response in a Double Blind, Placebo Controlled Study of Pregabalin|Withdrawn||Phase 4|0|Actual|Newton-Wellesley Hospital||2|||f||||f||||||||||2018-05-31 22:20:59.569834|2018-05-31 22:20:59.569834
NCT01396993|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-09-22|2011-07-18|2011-07-19|Estimate|||||||2015-09-22|2015-09-23|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|July 2015|Actual|2015-07-31||Observational|iTOP||Prospective Non-randomized Evaluation of Oncoplastic Surgery|Prospective Trial Evaluating Cosmetic And Oncologic Outcome Of Immediate Techniques For Oncoplastic Surgery In Breast Cancer|Unknown status|Active, not recruiting||150|Anticipated|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 22:20:59.656682|2018-05-31 22:20:59.656682
NCT01396980|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-02-20|2011-07-18|2011-07-19|Estimate|||||||2012-02-20|2012-02-22|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Observational|||Microcirculation During Haemodialysis|Sublingual Microcirculatory Flow Measurements During Haemodialysis in Relation to Blood Volume Change|Completed|||8|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||||2018-05-31 22:20:59.717487|2018-05-31 22:20:59.717487
NCT01396967|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-08-02|2011-07-17|2011-07-19|Estimate|||||||2011-08-02|2011-08-03|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Trying a New Device for Performing Capsulorhexis in Cataract Surgery Surgery|The Efficiency of a New Device for Performing Capsulorhexis in Cataract Surgery|Unknown status|Enrolling by invitation|Phase 1|20|Anticipated|Ziv Hospital|||||f||||t||||||||||2018-05-31 22:20:59.770426|2018-05-31 22:20:59.770426
NCT01396954|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Observational|CH-DM||Cirrhosis-Diabetes|Prevalence and Clinical Characteristics of the Patients With Liver Cirrhosis and Different Glucose Metabolism Disorders - A Prospective Study.|Unknown status|Active, not recruiting||130|Actual|Hospital Universitario Dr. Jose E. Gonzalez|||||f||||f||||||||||2018-05-31 22:20:59.829282|2018-05-31 22:20:59.829282
NCT01396941|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2014-10-25|2011-07-18|2011-07-19|Estimate|||||||2014-10-25|2014-10-28|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of Sleep Duration and Architecture on Insulin Sensitivity|Effects of Sleep Duration and Architecture on Insulin Sensitivity|Unknown status|Recruiting|N/A|20|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 22:20:59.879852|2018-05-31 22:20:59.879852
NCT01396928|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-10-01|2011-07-18|2011-07-19|Estimate|||||||2012-10-01|2012-10-02|Estimate|November 2000||2000-11-30|November 2000|2000-11-30|July 2010|Actual|2010-07-31|December 2005|Actual|2005-12-31||Observational|||Study of Two Techniques of Rectal Reservoir in Low Anterior Resection of Rectum|Prospective Randomized Study of Two Techniques of Rectal Reservoir in Low Anterior Resection of Rectum|Completed|||106|Actual|Hospital Universitari de Bellvitge|||2||f||||f||||||||||2018-05-31 22:20:59.944469|2018-05-31 22:20:59.944469
NCT01396915|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2016-02-02|2011-07-15|2011-07-19|Estimate|||||||2016-02-02|2016-02-04|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|S25||Effects of Increased, Egg-Based Protein Intake on Muscle Composition,|Effects of Increased, Egg-Based Protein Intake on Muscle Composition,|Completed|||22|Actual|Purdue University|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, and muscle tissue~   "|||2018-05-31 22:20:59.992058|2018-05-31 22:20:59.992058
NCT01396902|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-17|||2012-03-09|2011-07-18|2011-07-19|Estimate|||||||2012-03-09|2012-03-12|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Text Reminders for Immunization Compliance in Kids (TRICKS) Pilot Study|Text Reminders for Immunization Compliance in Kids|Completed||N/A|90|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 22:21:00.056213|2018-05-31 22:21:00.056213
NCT01396889|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-20|2011-07-18|2011-07-19|Estimate|||||||2011-07-20|2011-07-22|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years|Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years in Bandarabbas Children' Hospital|Completed||N/A|100|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:21:00.105862|2018-05-31 22:21:00.105862
NCT01396876|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-17|||2014-06-18|2011-07-18|2011-07-19|Estimate|||||||2014-06-18|2014-06-19|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of Medical Clowns in Children Undergoing Blood Tests|Evaluation of the Effect of Hospital Clown's Performance in the Procedure Room of a Pediatric Emergency Department: A Randomized Controlled Trial|Completed||N/A|60|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 22:21:00.169051|2018-05-31 22:21:00.169051
NCT01396863|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-03-21|2011-07-15|2011-07-19|Estimate|||||||2012-03-21|2012-03-22|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|BRASE||Brain Swelling During Dialysis|Acute Brain Volume Changes in Haemodialysis: Comparison of Low Flux Haemodialysis With Pre-dilution Haemodiafiltration|Completed||N/A|12|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:21:00.372168|2018-05-31 22:21:00.372168
NCT01396850|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-17|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate||||July 2011|2011-07-31||||||||Observational|||Measurments Of BBB Breakdown In The Pathogenesis Of Psychiatric Disorders|THE ROLE OF BBB BREAKDOWN IN THE PATHOGENESIS OF PSYCHIATRIC DISORDERS|Unknown status|Not yet recruiting||120|Anticipated|Soroka University Medical Center|||4||f||||||||||||||2018-05-31 22:21:00.453378|2018-05-31 22:21:00.453378
NCT01396837|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2017-04-13|2011-07-17|2011-07-19|Estimate|||||||2017-04-13|2017-04-17|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|August 2016|Actual|2016-08-31||Interventional|||Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.|A Multi-Center, Prospective, Open Label Safety Trial of the RedDress Wound Care System (RD1) in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers.|Completed||Phase 2|20|Actual|RedDress Ltd.||1|||f||||f||||||||||2018-05-31 22:21:00.511124|2018-05-31 22:21:00.511124
NCT01396824|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2016-06-01|2011-07-18|2011-07-19|Estimate|||||||2016-06-01|2016-06-02|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Observational|PLICA||Nutritional Status and Prognosis in Heart Failure.|Nutrition Status and Body Composition in Ambulatory Patients With Heart Failure and Its Prognostic Significance (PLiegues en Insuficiencia Cardiaca-PLICA).|Completed|||214|Actual|Germans Trias i Pujol Hospital|||1||f||||f||||||||||2018-05-31 22:21:00.595155|2018-05-31 22:21:00.595155
NCT01396811|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15||2013-01-22|2013-08-20|2011-07-18|2011-07-19|Estimate||||2013-01-22|2013-01-29|Estimate|2013-08-20|2013-08-28|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Topical Antifungal Treatment for Tinea Pedis|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis|Completed||Phase 3|322|Actual|Medicis Global Service Corporation||2|||f||||f||||||||||2018-05-31 22:21:00.675809|2018-05-31 22:21:00.675809
NCT01396798|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2012-09-13|2011-07-18|2011-07-19|Estimate|||||||2012-09-13|2012-09-14|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|ERNIE3||Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in the Paediatric A&E.|Validation of Vital Signs and Symptoms for the Diagnosis of Serious Infections in Children in a High Prevalent Setting: the Paediatric A&E.|Completed|||1500|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-05-31 22:21:00.767551|2018-05-31 22:21:00.767551
NCT01396785|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15||2013-01-22|2013-08-20|2011-07-18|2011-07-19|Estimate||||2013-01-22|2013-01-29|Estimate|2013-08-20|2013-08-28|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Topical Antifungal Treatment for Tinea Pedis|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis|Completed||Phase 3|321|Actual|Medicis Global Service Corporation||2|||f||||f||||||||||2018-05-31 22:21:00.858335|2018-05-31 22:21:00.858335
NCT01396772|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|May 2011||2011-05-31|July 2011|2011-07-31||||June 2013|Anticipated|2013-06-30||Interventional|PREPARE||"PREPARE: Prediabetes Research and Education Promoting Activity & Responsible Eating"|A Community-based Healthy Lifestyle Patient-centred Education Program for Middle & Older Adults With Prediabetes, Which Strengthens the Delivery of Health Services and Assists Individuals at High-risk for Diabetes in London, Ontario.|Unknown status|Recruiting|N/A|240|Anticipated|Brescia University College||2|||f||||t||||||||||2018-05-31 22:21:01.024014|2018-05-31 22:21:01.024014
NCT01396759|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2015-07-26|2011-07-17|2011-07-19|Estimate|||||||2015-07-26|2015-07-28|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Use of Bubble Continuous Positive Airway Pressure Compared to Nasal Prong Oxygen or Humidified High Flow in Children Under Five With Severe Pneumonia and Hypoxaemia|Use of Bubble CPAP Compared to Nasal Prong Oxygen or Humidified High Flow in Children Under Five With Severe Pneumonia and Hypoxaemia: a Randomized Trial|Completed||N/A|975|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||t||||||||||2018-05-31 22:21:01.13679|2018-05-31 22:21:01.13679
NCT01396746|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-07-17|2011-07-17|2011-07-19|Estimate|||||||2011-07-17|2011-07-19|Estimate|June 2011||2011-06-30|July 2011|2011-07-31||||||||Observational|||Cardiovascular Function in Sub Maximal Exercise and Performance in Three Daily Activity Tests After Stroke|Cardiovascular Function in Sub Maximal Exercise and Performance in Three Daily Activity Tests in Persons With Post Stroke Conditions|Unknown status|Recruiting||30|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 22:21:01.240671|2018-05-31 22:21:01.240671
NCT01396733|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|RALT||Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer|Clinical Trial to Evaluate Efficacy of Redifferentiation Therapy Using Alpha-lipoic Acid in Thyroid Cancer Patients With Decreased Radioactive Iodine Uptake|Unknown status|Recruiting|Phase 2|40|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 22:21:01.347711|2018-05-31 22:21:01.347711
NCT01396720|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-01-26|2011-07-17|2011-07-19|Estimate|||||||2013-01-26|2013-01-29|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel|Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel, a Randomized, Double-blind, Crossover Trial|Completed||Phase 1|15|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 22:21:01.439404|2018-05-31 22:21:01.439404
NCT01396707|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2017-07-13|2011-07-18|2011-07-19|Estimate|||||||2017-07-13|2017-07-17|Actual|June 2011||2011-06-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|Her+XELOX||Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC)|A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer|Active, not recruiting||Phase 2|55|Actual|Asan Medical Center||1|||f||||f||||||||Undecided||2018-05-31 22:21:01.510913|2018-05-31 22:21:01.510913
NCT01396694|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-02-16|2011-07-17|2011-07-19|Estimate|||||||2016-02-16|2016-02-17|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2012|Actual|2012-12-31||Observational|||An Evaluation of Psychological Parameters That May Influence the Outcome Following Arthroscopy and Arthroplasty for Temporomandibular Joint Surgery|Phase 4 Study of the Influence of Psychological Factors on the Outcomes Following Arthroscopy and Arthroplasty for Temporomandibular Joint Dysfunction|Completed|||105|Actual|Emory University|||1||f||||f||||||||||2018-05-31 22:21:01.60961|2018-05-31 22:21:01.60961
NCT01396681|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-15|2011-07-15|2011-07-19|Estimate|||||||2011-07-15|2011-07-19|Estimate|December 2004||2004-12-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer|Phase Ⅱ Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Gemcitabine in Patients With Resected Pancreatic Cancer|Completed||Phase 2|70|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 22:21:01.673882|2018-05-31 22:21:01.673882
NCT01396668|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-15|2011-07-15|2011-07-19|Estimate|||||||2011-07-15|2011-07-19|Estimate|December 2004||2004-12-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer|Phase Ⅱ Trial of Fixed Dose Rate Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Capecitabine in Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 2|35|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 22:21:01.752177|2018-05-31 22:21:01.752177
NCT01396655|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-07-15|2011-07-15|2011-07-19|Estimate|||||||2011-07-15|2011-07-19|Estimate|July 2006||2006-07-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|September 2008|Actual|2008-09-30||Interventional|DA-PET||PET in Breast Cancer Receiving Neoadjuvant Chemotherapy|Analysis of Clinical Outcome, Predictive and Prognostic Factors of Therapeutic Responses in Patients Who Treated With Doxorubicin & Docetaxel Neoadjuvant Chemotherapy in Clinical Stage II or III Breast Cancer|Completed||Phase 2|78|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 22:21:01.827839|2018-05-31 22:21:01.827839
NCT01396642|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-04-05|2011-07-18|2011-07-19|Estimate|||||||2015-04-05|2015-04-07|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Topical Emollient Therapy|Effect of Topical Emollient Therapy on Clinical Outcomes in Preterm Neonates - A Clinical Trial|Completed||N/A|258|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 22:21:01.902467|2018-05-31 22:21:01.902467
NCT01396629|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2012-11-15|2011-07-17|2011-07-19|Estimate|||||||2012-11-15|2012-11-16|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Clinical Evaluation of a New Cartridge for the Implantation of Foldable Intraocular Lenses|Clinical Evaluation of a New Cartridge for the Implantation of Foldable Intraocular Lenses|Completed|||99|Actual|Aurolab|||1||f||||f||||||||||2018-05-31 22:21:01.984903|2018-05-31 22:21:01.984903
NCT01396616|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-01-07|2011-07-17|2011-07-19|Estimate|||||||2013-01-07|2013-01-08|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|TORICIOL||Clinical Evaluation of Toric Intraocular Lens Made by Aurolab|Clinical Evaluation of Toric Intraocular Lens Made by Aurolab|Unknown status|Recruiting|Phase 4|120|Anticipated|Aurolab||1|||f||||f||||||||||2018-05-31 22:21:02.049973|2018-05-31 22:21:02.049973
NCT01396603|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2018-03-20|2011-07-15|2011-07-19|Estimate|||||||2018-03-20|2018-03-21|Actual|December 2008||2008-12-31|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease||Completed|||30|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 22:21:02.125452|2018-05-31 22:21:02.125452
NCT01396590|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-05-02|2011-07-18|2011-07-19|Estimate|||||||2012-05-02|2012-05-04|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects|A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects|Completed||Phase 1|54|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:21:02.179748|2018-05-31 22:21:02.179748
NCT01396577|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-05-02|2011-07-18|2011-07-19|Estimate|||||||2012-05-02|2012-05-04|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects|A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects|Completed||Phase 1|54|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:21:02.242867|2018-05-31 22:21:02.242867
NCT01396564|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2011-07-18|2011-07-18|2011-07-19|Estimate|||||||2011-07-18|2011-07-19|Estimate|October 2005||2005-10-31|January 2005|2005-01-31|July 2011|Actual|2011-07-31|October 2006|Actual|2006-10-31||Interventional|||Pioglitazone and Metformin in Diabetic Children|Comparison of the Effects of Pioglitazone and Metformin on Resistin Plasma Levels in Children With Type 2 Diabetes|Completed||Phase 1/Phase 2|56|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 22:21:02.30166|2018-05-31 22:21:02.30166
NCT01396551|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-05-19|2011-07-18|2011-07-19|Estimate|||||||2017-05-19|2017-05-22|Actual|October 2010|Actual|2010-10-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy|Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy|Completed||N/A|69|Actual|Varian Medical||1|||f||||f|f|t|t|||||No||2018-05-31 22:21:02.384435|2018-05-31 22:21:02.384435
NCT01396538|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2011-10-11|2011-07-14|2011-07-18|Estimate|||||||2011-10-11|2011-10-12|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|May 2012|Anticipated|2012-05-31|||||Observational|||Prevalence of Occult HBV Infection Among Anti-HBc Alone Group in Northern Taiwan|Prevalence of Occult HBV Infection Among Anti-HBc Alone Group in Northern Taiwan|Unknown status|Active, not recruiting||200|Anticipated|Taipei Medical University WanFang Hospital|||||f||||t||||||||||2018-05-31 22:21:02.459441|2018-05-31 22:21:02.459441
NCT01396525|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2012-08-29||2016-01-08|2011-07-15|2011-07-18|Estimate|2012-08-29|2012-10-01|Estimate||||2016-01-08|2016-02-08|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|September 2011|Actual|2011-09-30||Interventional|MOBILITY OE||Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery|A Prospective, Non-randomized, Two Arm, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System and the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.|Completed||Phase 3|153|Actual|Abbott Vascular||1|||f||||t||||||||||2018-05-31 22:21:02.739272|2018-05-31 22:21:02.739272
NCT01396512|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2014-03-24||2014-03-24|2011-07-15|2011-07-18|Estimate|2014-03-24|2014-04-25|Estimate||||2014-03-24|2014-04-25|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers|Immunogenicity and Safety of a Single Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) in Comparison With a Single Dose of SA14-14-2 Vaccine (CD.JEVAX™, Chengdu Institute of Biological Products, China) Administered in Healthy Toddlers in South-Korea|Completed||Phase 3|274|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:21:04.790646|2018-05-31 22:21:04.790646
NCT01396499|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2016-10-31|2011-07-15|2011-07-18|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias|A Phase I Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, in Patients With Advanced Leukemias|Completed||Phase 1|16|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:21:05.435582|2018-05-31 22:21:05.435582
NCT01396486|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2018-01-16|2011-07-15|2011-07-18|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2012||2012-02-29|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Inositol and Omega-3 Fatty Acids in Pediatric Mania|A Randomized Controlled Trial of Inositol and Omega-3 Fatty Acids in Pediatric Mania|Recruiting||Phase 4|60|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||No||2018-05-31 22:21:05.520037|2018-05-31 22:21:05.520037
NCT01396473|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-07-15|2011-07-15|2011-07-18|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|OSNAP||Study on Out of School Nutrition and Physical Activity Environments|Study on Out of School Nutrition and Physical Activity Environments|Completed||N/A|590|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 22:21:05.611084|2018-05-31 22:21:05.611084
NCT01396460|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2012-09-07|2011-07-15|2011-07-18|Estimate|||||||2012-09-07|2012-09-10|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|RQ||Respiratory Quotient in Post Roux-en-Y Gastric Bypass Patients|Respiratory Quotient in Post Roux-en-Y Gastric Bypass Patients|Completed|||69|Actual|Gastrocirurgia, Brazil|||2||f||||f||||||||||2018-05-31 22:21:05.682523|2018-05-31 22:21:05.682523
NCT01396447|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|2018-03-29|2015-02-27|2018-03-29|2011-07-15|2011-07-18|Estimate|2018-03-29|2018-05-01|Actual|2015-02-27|2015-03-18|Estimate|2018-03-29|2018-05-01|Actual|July 26, 2011|Actual|2011-07-26|March 2018|2018-03-31|January 10, 2014|Actual|2014-01-10|January 10, 2014|Actual|2014-01-10||Interventional||Safety population: All randomized participants who received at least 1 dose of investigational product.|Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression|Completed||Phase 2|584|Actual|Forest Laboratories||4|||f||||f||||||||||2018-05-31 22:21:05.820614|2018-05-31 22:21:05.820614
NCT01396434|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2016-12-05||2016-12-05|2011-07-15|2011-07-18|Estimate|2016-12-05|2017-01-30|Estimate||||2016-12-05|2017-01-30|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||All participants who received at least 1 dose of 13vPnC.|Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos|A Non-interventional Study Of The Safety Of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) In The Philippines: A Post Marketing Surveillance Study|Completed|||3006|Actual|Pfizer|The use of 13vPnC was based on the investigator's clinical judgment and was assumed to be consistent with the product's approved label.||1||f||||f||||||||||2018-05-31 22:21:06.547563|2018-05-31 22:21:06.547563
NCT01396421|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2015-08-04|2015-01-16|2015-09-29|2011-07-15|2011-07-18|Estimate|2015-09-29|2015-10-29|Estimate|2015-01-28|2015-02-02|Estimate|2015-09-29|2015-10-29|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|VECTOR||Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia|Completed||Phase 3|636|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||||||||||||2018-05-31 22:21:07.589433|2018-05-31 22:21:07.589433
NCT01396408|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2018-03-21|2011-07-15|2011-07-18|Estimate|||||||2018-03-21|2018-03-22|Actual|July 14, 2011|Actual|2011-07-14|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2015|Actual|2015-07-31||Interventional|||A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours|A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours|Active, not recruiting||Phase 2|137|Actual|Canadian Cancer Trials Group||2|||f||||f||||||||||2018-05-31 22:21:09.095422|2018-05-31 22:21:09.095422
NCT01396395|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|2015-09-14||2016-03-15|2011-07-15|2011-07-18|Estimate|2016-03-15|2016-04-14|Estimate||||2016-03-15|2016-04-14|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SIGMART|Full analysis set (FAS) included all randomized subjects who received at least one dose of study treatment.|Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina|A Prospective, Multi-center, Random, Open-label Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina|Completed||Phase 4|402|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 22:21:09.280648|2018-05-31 22:21:09.280648
NCT01396382|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2016-01-14||2016-02-25|2011-07-14|2011-07-18|Estimate|2016-02-25|2016-03-29|Estimate||||2016-02-25|2016-03-29|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|68Ga|patients with known or suspected pulmonary or gastroenteropancreatic (GEP) neuroendocrine tumors (NETS)|68Ga-DOTATATE PET Scan in Neuroendocrine Cancer|Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors|Completed||Phase 2|97|Actual|Vanderbilt-Ingram Cancer Center|Long term follow-up of lab values was limited in some patients who lived outside the local region.|1|||f||||t||||||||No|Data are primarily imaging data and toxicity data submitted for peer-review publication and US FDA review, but not shared with a public data archive.|2018-05-31 22:21:10.172131|2018-05-31 22:21:10.172131
NCT01396369|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-01-06|2011-07-15|2011-07-18|Estimate|||||||2016-01-06|2016-01-08|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Flaxseed Lignan (Brevail)|Impact of Flaxseed Lignan (Brevail) on Polycystic Ovarian Syndrome|Completed||Early Phase 1|9|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 22:21:10.38238|2018-05-31 22:21:10.38238
NCT01396356|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-01-08|2011-07-14|2011-07-18|Estimate|||||||2013-01-08|2013-01-10|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||"Atrial Fibrillation Ablation on Gastric Motility The AF Gut Study"|"Impact of Atrial Fibrillation Ablation on Gastric Motility The AF Gut Study"|Completed|||25|Anticipated|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 22:21:10.488332|2018-05-31 22:21:10.488332
NCT01396343|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-07-17|2011-07-14|2011-07-18|Estimate|||||||2017-07-17|2017-07-19|Actual|October 2011||2011-10-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis|Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis|Enrolling by invitation|||1920|Anticipated|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     Total 41ml sample: 17ml plasma/DNA, 10ml serum, 9ml lymphocytes and 5ml RNA frozen.~   "|||2018-05-31 22:21:10.562992|2018-05-31 22:21:10.562992
NCT01396330|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-02-28|2011-07-14|2011-07-18|Estimate|||||||2012-02-28|2012-02-29|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|EMSOD||Effect of Mental Stress on Glucose Control in Patients With Diabetes Mellitus|Effect of Prolonged Mental Stress During Safe Driving Training Courses on Glucose Control in Patients With Diabetes Mellitus Type 2|Completed||N/A|40|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-05-31 22:21:10.703159|2018-05-31 22:21:10.703159
NCT01396317|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2017-04-21||2018-01-15|2011-07-15|2011-07-18|Estimate|2018-01-15|2018-01-17|Actual||||2018-01-15|2018-01-17|Actual|April 2011||2011-04-30|January 2018|2018-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Study of Tocilizumab to Treat Polymyalgia Rheumatica|Phase IIa of Tocilizumab In the Treatment of Polymyalgia Rheumatica|Completed||Phase 2|10|Actual|Hospital for Special Surgery, New York||1|||f||||t||||||||||2018-05-31 22:21:10.796644|2018-05-31 22:21:10.796644
NCT01396304|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-02-12|2011-07-15|2011-07-18|Estimate|||||||2013-02-12|2013-02-15|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers|Restore Calcium Alginate Dressing, Silver vs Aquacel Ag in the Treatment of Critically Colonized Venous Leg Ulcers|Terminated||Phase 4|19|Actual|Hollister Wound Care LLC||2||slow accrual|f||||f||||||||||2018-05-31 22:21:11.205371|2018-05-31 22:21:11.205371
NCT01396291|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-12-03|2011-07-15|2011-07-18|Estimate|||||||2015-12-03|2015-12-04|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)|A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phase 3B, Protocol P06384)|Completed||Phase 3|561|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 22:21:11.312844|2018-05-31 22:21:11.312844
NCT01396278|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15||2014-04-30|2014-04-30|2011-07-15|2011-07-18|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|July 2011||2011-07-31|April 2014|2014-04-30||||December 2011|Actual|2011-12-31||Interventional|||Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).|A Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 90.9, 181.8 and 363.6 µg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA MDI 440 µg b.i.d. in Patients With Asthma Inadequately Controlled on Medium Dose ICS Therapy|Terminated||Phase 2|9|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 22:21:11.481539|2018-05-31 22:21:11.481539
NCT01396265|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|2013-08-08||2014-06-03|2011-07-15|2011-07-18|Estimate|2013-10-15|2013-12-09|Estimate||||2014-06-03|2014-06-09|Estimate|July 2011||2011-07-31|October 2013|2013-10-31||||August 2011|Actual|2011-08-31||Interventional|||Drug Interaction Study With Rifampicin and Afatinib|Relative Bioavailability of a Single Oral Dose of 40 mg Afatinib Given Alone and After Multiple Doses of Rifampicin - an Open-label, Two-period, Fixed Sequence Clinical Phase I Trial in Healthy Male Volunteers|Completed||Phase 1|22|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:21:11.631204|2018-05-31 22:21:11.631204
NCT01396252|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-15|||2013-06-07|2011-07-15|2011-07-18|Estimate|||||||2013-06-07|2013-06-10|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Japanese Phase 1 Multiple Ascending Dose (MAD) Study|Randomized, Placebo-Controlled, Double-Blind, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Japanese Subjects and Japanese Patients With Depression|Completed||Phase 1|57|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 22:21:12.091731|2018-05-31 22:21:12.091731
NCT01395771|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-18|||2011-07-15|2011-07-15|2011-07-18|Estimate|||||||2011-07-15|2011-07-18|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|EPCIPHA||Effects of a Phone Call Intervention to Promote HAART Adherence|Effects of a Phone Call Intervention to Promote HAART Adherence in Baoshan, China|Unknown status|Recruiting|N/A|300|Anticipated|Baoshan Prefecture Center for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 22:21:38.439987|2018-05-31 22:21:38.439987
NCT01396239|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2013-07-02||2015-10-12|2011-07-15|2011-07-18|Estimate|2015-10-12|2015-11-09|Estimate||||2015-10-12|2015-11-09|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Efficacy, Safety, Tolerability and Pharmacokinetics Study of AVI-4658(Eteplirsen),in the Treatment of Ambulant Subjects With Duchenne Muscular Dystrophy|Completed||Phase 2|12|Actual|Sarepta Therapeutics|"Due to the small number of study participants, a single adverse event (AE) in 1 patient exceeds the reporting threshold of 5%. Refer to the Post-Hoc Outcome Measures #4 and #5 for a summary of frequent and related AEs."|2|||f||||f||||||||||2018-05-31 22:21:12.271704|2018-05-31 22:21:12.271704
NCT01396226|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2012-09-24||2012-11-22|2011-07-15|2011-07-18|Estimate|2012-09-24|2012-10-23|Estimate||||2012-11-22|2012-11-27|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure|Completed||Phase 2|20|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:21:18.979096|2018-05-31 22:21:18.979096
NCT01396213|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14||2017-09-11|2017-09-15|2011-07-15|2011-07-18|Estimate||||2017-09-15|2017-09-20|Actual|2017-09-15|2017-09-20|Actual|November 7, 2011|Actual|2011-11-07|September 2017|2017-09-30|August 20, 2013|Actual|2013-08-20|August 20, 2013|Actual|2013-08-20||Interventional|||A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease|A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Different Doses of Larazotide Acetate for the Treatment of Celiac Disease|Completed||Phase 2|342|Actual|Innovate Biopharmaceuticals||4|||f||||f|t|f||||||No||2018-05-31 22:21:20.26598|2018-05-31 22:21:20.26598
NCT01396200|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-02-25|2011-07-15|2011-07-18|Estimate|||||||2013-02-25|2013-02-26|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine|A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Early Phase 1|6|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 22:21:20.53378|2018-05-31 22:21:20.53378
NCT01396187|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|2014-12-30||2014-12-30|2011-07-14|2011-07-18|Estimate|2014-12-30|2015-01-12|Estimate||||2014-12-30|2015-01-12|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Safety analysis population included all participants who received at least 1 dose of study medication.|Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes|A Phase 1, Placebo-Controlled Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|50|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:21:20.896126|2018-05-31 22:21:20.896126
NCT01396174|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2015-04-16|2011-07-14|2011-07-18|Estimate|||||||2015-04-16|2015-04-17|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors|A Novel Prosocial Online Support Group for Distressed Breast Cancer Survivors|Completed||N/A|184|Actual|Temple University||2|||f||||||||||||||2018-05-31 22:21:21.947086|2018-05-31 22:21:21.947086
NCT01396161|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2016-04-01||2016-09-19|2011-07-14|2011-07-18|Estimate|2016-09-19|2016-11-07|Estimate||||2016-09-19|2016-11-07|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients|A Phase 1 Placebo-controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Oral Doses Of Pf-05175157 In Healthy Volunteers And In Patients With Type 2 Diabetes Mellitus (t2dm)|Completed||Phase 1|64|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 22:21:22.026819|2018-05-31 22:21:22.026819
NCT01396148|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2018-02-12||2018-02-12|2011-07-14|2011-07-18|Estimate|2018-02-12|2018-03-12|Actual||||2018-02-12|2018-03-12|Actual|June 25, 2012|Actual|2012-06-25|February 2018|2018-02-28|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional||The full analysis set (FAS) included all enrolled participants regardless of what treatment, if any, was received.|A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor|A Phase I/ii Study Of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor|Completed||Phase 2|6|Actual|Pfizer|Data for outcome measures 1, 2 and 3 will be estimated and reported separately as part of the Non-linear Mixed Effects Modeling analysis and will be provided once available.|2|||f||||f||||||||||2018-05-31 22:21:22.79949|2018-05-31 22:21:22.79949
NCT01396135|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-09-03|2011-07-14|2011-07-18|Estimate|||||||2011-09-03|2011-09-07|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects|A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Single- And Multiple-Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects|Withdrawn||Phase 1|19|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:21:23.265007|2018-05-31 22:21:23.265007
NCT01396122|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-12-25|2011-07-14|2011-07-18|Estimate|||||||2012-12-25|2012-12-27|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Clinical Performance of GYNECARE PROSIMA* Pelvic Floor Repair System for Symptomatic Pelvic Organ Prolapse|A Prospective, Multicenter Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Symptomatic POP-Q Stage II-III Pelvic Organ Prolapse|Unknown status|Recruiting|N/A|150|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||||2018-05-31 22:21:23.366685|2018-05-31 22:21:23.366685
NCT01396109|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-12-25|2011-07-15|2011-07-18|Estimate|||||||2012-12-25|2012-12-27|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||GYNECARE PROSIMA* Procedure Versus Modified Total Pelvic Floor Reconstructive Surgery for Uterine Prolapse Stage III|A Prospective, Multicenter Trial to Compare GYNECARE PROSIMA* Pelvic Floor Repair System Procedure With Modified Total Pelvic Floor Reconstruction Surgery Concomitantly With TVH to Treat Symptomatic POP-Q Stage III Uterine Prolapse|Unknown status|Recruiting|N/A|200|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 22:21:23.515936|2018-05-31 22:21:23.515936
NCT01358019|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-01-25|2011-05-19|2011-05-23|Estimate|||||||2013-01-25|2013-01-28|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|2523355-001||A Study of LY2523355 in Patients With Solid Cancer|A Phase 1 Study of LY2523355 in Patients With Solid Cancer|Completed||Phase 1|18|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-05-31 22:36:02.044908|2018-05-31 22:36:02.044908
NCT01396096|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2018-05-23|2011-07-15|2011-07-18|Estimate|||||||2018-05-23|2018-05-24|Actual|June 2011||2011-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Comparison of Obesity Alleles Among Diverse Demographic Patients|Comparison of Obesity Alleles Among Diverse Demographic Patient Populations Undergoing Bariatric Surgery|Recruiting|||2500|Anticipated|New York University School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     DNA will be extracted from 0.35ml of EDTA-anticoagulated whole blood using the Qiagen~     MagAttract DNA Blood Midi M48 Kit and Qiagen BioRobot M48 Workstation (Qiagen, Valencia,~     California) according to the manufacturer's directions.~   "|||2018-05-31 22:21:23.646824|2018-05-31 22:21:23.646824
NCT01396083|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2015-01-12||2016-09-21|2011-07-15|2011-07-18|Estimate|2015-01-28|2015-02-18|Estimate||||2016-09-21|2016-09-27|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|COMRADE-C||Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)|A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Central Retinal Vein Occlusion (CRVO)|Completed||Phase 3|243|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:21:23.749194|2018-05-31 22:21:23.749194
NCT01396070|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2016-12-28||2017-02-17|2011-07-15|2011-07-18|Estimate|2017-02-17|2017-04-05|Actual||||2017-02-17|2017-04-05|Actual|May 2011||2011-05-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|April 2015|Actual|2015-04-30||Interventional|||Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level|Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level|Completed||Phase 2|36|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 22:21:24.39334|2018-05-31 22:21:24.39334
NCT01396057|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2014-06-13||2014-08-04|2011-07-15|2011-07-18|Estimate|2014-06-13|2014-07-16|Estimate||||2014-08-04|2014-08-07|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|COMRADE-B||Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)|A 6-month Multicenter, Randomized, Double-masked Phase IIIb-study Comparing the Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO)|Completed||Phase 3|244|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:21:24.786099|2018-05-31 22:21:24.786099
NCT01396044|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2012-11-05||2012-11-05|2011-07-14|2011-07-18|Estimate|2012-11-05|2012-12-04|Estimate||||2012-11-05|2012-12-04|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Daily Checklists and Outcome in the Intensive Care Unit|Daily Checklists and Outcome in the Intensive Care Unit|Completed||N/A|451|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 22:21:25.534747|2018-05-31 22:21:25.534747
NCT01396031|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-14|2011-07-14|2011-07-18|Estimate|||||||2011-07-14|2011-07-18|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Feasibility Study of Exercises for Myeloablative Allogeneic Blood and Marrow Transplantation (BMT) Patients|Matched-Status Exercise Program in Patients Undergoing Myeloablative Allogeneic Blood and Marrow Transplantation: A Feasibility Study|Unknown status|Active, not recruiting|N/A|16|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 22:21:26.036144|2018-05-31 22:21:26.036144
NCT01396005|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2012-12-06||2017-03-09|2011-07-14|2011-07-18|Estimate|2013-02-05|2013-03-11|Estimate||||2017-03-09|2017-04-07|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)|An Open-Label, One-Period Study in Patients Receiving Methadone or Buprenorphine/Naloxone Maintenance Therapy to Evaluate the Effect of SCH 503034 (Boceprevir) on Either Methadone or Buprenorphine/Naloxone Plasma Concentrations (Protocol No. P08123)|Completed||Phase 1|21|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:21:26.153709|2018-05-31 22:21:26.153709
NCT01395992|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-05-26|2011-07-15|2011-07-18|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)|A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])|Completed||Phase 3|165|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 22:21:26.572669|2018-05-31 22:21:26.572669
NCT01395979|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2018-03-29|2011-07-15|2011-07-18|Estimate|||||||2018-03-29|2018-03-30|Actual|October 2011|Actual|2011-10-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|THRIVE||HIV Prevention and Trauma Treatment for Men Who Have Sex With Men With Childhood Sexual Abuse Histories||Completed||N/A|232|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:21:26.655854|2018-05-31 22:21:26.655854
NCT01395966|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2015-07-22||2015-09-22|2011-07-14|2011-07-18|Estimate|2015-09-22|2015-10-22|Estimate||||2015-09-22|2015-10-22|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients|Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients|Completed||Phase 3|331|Actual|Salvat||3|||f||||f||||||||||2018-05-31 22:21:26.782279|2018-05-31 22:21:26.782279
NCT01395953|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-04-06|2011-07-14|2011-07-18|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||2||This study was withdrawn due to competing research interests and slow recruitment.|f||||f||||||||||2018-05-31 22:21:27.074425|2018-05-31 22:21:27.074425
NCT01395940|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-10-29|2011-07-14|2011-07-18|Estimate|||||||2013-10-29|2013-10-30|Estimate||||October 2013|2013-10-31||||||||Interventional|||A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)|A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(1)|Completed||Phase 2|20|Anticipated|Kissei Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:21:27.14635|2018-05-31 22:21:27.14635
NCT01395927|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-05-03|2011-07-14|2011-07-18|Estimate|||||||2013-05-03|2013-05-06|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers|An Open-Label, Fixed-Sequence Study to Assess Effects of Steady-State Rifampin on the Single-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects|Completed||Phase 1|14|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 22:21:27.205437|2018-05-31 22:21:27.205437
NCT01395914|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2017-03-15|2014-02-12|2017-08-16|2011-07-15|2011-07-18|Estimate|2017-06-09|2017-07-11|Actual|2014-07-23|2014-07-25|Estimate|2017-08-16|2017-09-14|Actual|July 2011||2011-07-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional||The intent-to-treat (ITT) Population included all randomized patients.|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study|Completed||Phase 3|513|Actual|Helsinn Therapeutics (U.S.), Inc||2|||f||||t||||||||||2018-05-31 22:21:27.296707|2018-05-31 22:21:27.296707
NCT01395901|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2014-06-27|2013-03-28|2014-07-29|2011-07-15|2011-07-18|Estimate|2014-07-29|2014-07-30|Estimate|2013-03-28|2013-04-04|Estimate|2014-07-29|2014-07-30|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional||Full Analysis Set Population|Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients|A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients.|Completed||Phase 3|670|Actual|Helsinn Healthcare SA||2|||f||||t||||||||||2018-05-31 22:21:27.936591|2018-05-31 22:21:27.936591
NCT01395888|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2013-06-06|2013-03-07|2018-01-18|2011-07-14|2011-07-18|Estimate|2013-06-06|2013-08-09|Estimate|2013-03-07|2013-03-15|Estimate|2018-01-18|2018-02-15|Actual|June 30, 2011||2011-06-30|January 2018|2018-01-31|August 6, 2012|Actual|2012-08-06|August 1, 2012|Actual|2012-08-01||Interventional|||A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD|A 12 Week Study to Evaluate the Effect of Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) on Arterial Stiffness Compared With Tiotropium Bromide 18 mcg Delivered Once Daily Via a HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|260|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:21:28.378342|2018-05-31 22:21:28.378342
NCT01395875|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-05-15|2011-07-14|2011-07-18|Estimate|||||||2017-05-15|2017-05-16|Actual|March 2011||2011-03-31|May 2017|2017-05-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Observational|||Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment|Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment|Completed|||2849|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:21:31.246818|2018-05-31 22:21:31.246818
NCT01395862|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-08-20|2011-07-14|2011-07-18|Estimate|||||||2013-08-20|2013-08-21|Estimate|November 2007||2007-11-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)|Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)|Completed|||1001|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:21:31.611155|2018-05-31 22:21:31.611155
NCT01395849|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-05-15|2011-07-14|2011-07-18|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2007||2007-10-31|May 2017|2017-05-31|March 2011|Actual|2011-03-31|September 2009|Actual|2009-09-30||Observational|||Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)|Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)|Completed|||2116|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:21:32.510062|2018-05-31 22:21:32.510062
NCT01395836|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-11-03|2011-07-15|2011-07-18|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|Monitor-AF||Management of New-Onset Postoperative Atrial Fibrillation|Management of New-Onset Postoperative Atrial Fibrillation Utilizing Insertable Cardiac Monitor Technology to Observe Recurrence of AF|Completed|||23|Actual|Emory University|||2||f||||t||||||||||2018-05-31 22:21:34.363251|2018-05-31 22:21:34.363251
NCT01395823|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|2016-01-08||2016-02-15|2011-07-15|2011-07-18|Estimate|2016-02-15|2016-03-14|Estimate||||2016-02-15|2016-03-14|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients|Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients: A Randomized Clinical Trial|Completed||Phase 4|470|Actual|Dialysis Clinic, Inc.||2|||f||||f||||||||||2018-05-31 22:21:35.818575|2018-05-31 22:21:35.818575
NCT01395810|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2017-11-28|2016-11-09|2018-04-09|2011-07-15|2011-07-18|Estimate|2018-04-09|2018-05-09|Actual|2016-11-09|2016-11-10|Estimate|2018-04-09|2018-05-09|Actual|April 15, 2012|Actual|2012-04-15|April 2018|2018-04-30|March 30, 2014|Actual|2014-03-30|March 30, 2014|Actual|2014-03-30||Interventional|paradigm™ 4|The full analysis set (FAS) consisted of all subjects exposed to nonacog beta pegol.|Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773|Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B|Completed||Phase 3|71|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 22:21:36.487616|2018-05-31 22:21:36.487616
NCT01395797|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2015-08-31||2017-07-11|2011-07-14|2011-07-18|Estimate|2017-07-11|2017-07-13|Actual||||2017-07-11|2017-07-13|Actual|March 2011||2011-03-31|July 2017|2017-07-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Pioglitazone for Heroin and for Nicotine Dependence|Effects of Pioglitazone, a PPARγ Agonist, on the Abuse Liability of Heroin and of Nicotine|Terminated||Phase 1/Phase 2|82|Actual|New York State Psychiatric Institute||6||The funding period ended.|f||||t||||||||Yes|Data will be presented at conferences and published in a peer-reviewed journal.|2018-05-31 22:21:37.459381|2018-05-31 22:21:37.459381
NCT01395784|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2015-08-31||2016-01-26|2011-07-14|2011-07-18|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional||Recreational prescription opioid users.|Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone|Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone|Completed||Phase 2|32|Actual|New York State Psychiatric Institute||3|||f||||t||||||||Yes|Data has been presented at conferences and being prepared for a peer-review publication.|2018-05-31 22:21:38.170055|2018-05-31 22:21:38.170055
NCT01385982|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2016-01-15|2011-06-29|2011-06-30|Estimate|||||||2016-01-15|2016-01-18|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|OutptATR||Improving Management of Outpatient Actionable Test Results|Improving Management of Outpatient Actionable Test Results|Completed||Phase 3|6000|Actual|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 22:25:00.917954|2018-05-31 22:25:00.917954
NCT01395758|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|2018-01-31||2018-03-05|2011-07-14|2011-07-18|Estimate|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|July 2011||2011-07-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|96|Actual|ArQule||2|||f||||f||||||||||2018-05-31 22:21:38.615643|2018-05-31 22:21:38.615643
NCT01395745|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-02-02|2011-07-15|2011-07-18|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|CHABLIS-SC1||CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus|Completed||Phase 3|442|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:21:40.029811|2018-05-31 22:21:40.029811
NCT01395732|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2014-01-06|2011-07-14|2011-07-18|Estimate|||||||2014-01-06|2014-01-07|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|HOME||Bosentan in Systemic Sclerosis|Effects of Bosentan in a Homogenous Population of Systemic Sclerosis Subjects With a Predefined Restriction of Blood Flow in the Hands|Completed||Phase 4|18|Actual|Actelion||1|||f||||f||||||||||2018-05-31 22:21:40.211206|2018-05-31 22:21:40.211206
NCT01395719|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-08-17|2011-07-14|2011-07-15|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2015|Actual|2015-06-30||Interventional|Context||Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function|Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function|Unknown status|Active, not recruiting|N/A|220|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 22:21:40.357667|2018-05-31 22:21:40.357667
NCT01395706|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-07-15|2011-07-14|2011-07-15|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Interventional|||ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes|Determination of the Sensitifity of ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer - a Monocenter Prospective Open-label Clinical Trial|Unknown status|Not yet recruiting|Phase 2|125|Anticipated|Pulsion Medical Systems SE||1|||f||||t||||||||||2018-05-31 22:21:40.444905|2018-05-31 22:21:40.444905
NCT01395693|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-04-19|2011-07-14|2011-07-15|Estimate|||||||2012-04-19|2012-04-20|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Performance of the Salt Lake Mask System|Assessment of the Performance of the Salt Lake Mask System as a Patient Interface in the Provision of Positive Airway Pressure (PAP) Therapy|Completed||Phase 2|20|Actual|ResMed||1|||f||||t||||||||||2018-05-31 22:21:40.544545|2018-05-31 22:21:40.544545
NCT01395680|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-07-14|2011-07-14|2011-07-15|Estimate|||||||2011-07-14|2011-07-15|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|||Trajectories of Regenerating Family Resilience in Adolescents With Cancer|Trajectories of Regenerating Family Resilience in Adolescents With Cancer|Unknown status|Not yet recruiting||60|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 22:21:40.613846|2018-05-31 22:21:40.613846
NCT01395667|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-11-08|2011-07-14|2011-07-15|Estimate|||||||2016-11-08|2016-11-10|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX|A Phase I Dose Escalation Trial of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy(IMRT)in Combination With Bevacizumab-FOLFOX for Patients With Locally Advanced Rectal Cancer|Completed||Phase 1|15|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:21:40.707763|2018-05-31 22:21:40.707763
NCT01395654|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-12-26|2011-07-14|2011-07-15|Estimate|||||||2012-12-26|2012-12-27|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment|Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment|Unknown status|Recruiting|Phase 4|100|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:21:40.823166|2018-05-31 22:21:40.823166
NCT01395641|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|||2017-10-18|2011-07-14|2011-07-15|Estimate|||||||2017-10-18|2017-10-20|Actual|October 1, 2014|Actual|2014-10-01|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|AADC||A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC|A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC|Active, not recruiting||Phase 1/Phase 2|10|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 22:21:40.931416|2018-05-31 22:21:40.931416
NCT01395628|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-05-17|2011-07-14|2011-07-15|Estimate|||||||2016-05-17|2016-05-19|Estimate|July 2011||2011-07-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Cell Samples From Patients With Leukemia|Xenotransplantation of Primary Leukemia Samples Into Zebrafish|Completed|||10|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     cell samples~   "|||2018-05-31 22:21:41.011208|2018-05-31 22:21:41.011208
NCT01395615|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-11-01|2011-07-14|2011-07-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia|Utility Measurement Study for Patients With Chronic Lymphocytic Leukaemia|Completed|||34|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:21:41.072131|2018-05-31 22:21:41.072131
NCT01395602|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-10-13|2011-07-14|2011-07-15|Estimate|||||||2015-10-13|2015-10-14|Estimate|April 2002||2002-04-30|October 2015|2015-10-31|July 2011|Actual|2011-07-31|September 2003|Actual|2003-09-30||Interventional|||Effect of Cabergoline on Weight and Glucose Tolerance|Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults|Completed||Phase 1/Phase 2|40|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 22:21:41.139052|2018-05-31 22:21:41.139052
NCT01395589|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-09-27|2011-07-14|2011-07-15|Estimate|||||||2017-09-27|2017-09-29|Actual|February 2011||2011-02-28|September 2017|2017-09-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations.|Rapid vs Maintenance Vitamin D Supplementation in Deficient Children With Asthma to Prevent Exacerbations|Completed||Phase 1|597|Actual|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 22:21:41.309822|2018-05-31 22:21:41.309822
NCT01395576|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2014-05-18|2011-07-14|2011-07-15|Estimate|||||||2014-05-18|2014-05-20|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluation of the Genu Neurexa Orthosis in Post Stroke Patients|Evaluation of the Genu Neurexa Orthosis in Post Stroke Patients|Terminated||Phase 2|60|Anticipated|Hadassah Medical Organization||||"statistical significance of the results was reached for the 34 subjects who participated in teh~   study."|f||||||||||||||2018-05-31 22:21:41.422652|2018-05-31 22:21:41.422652
NCT01395563|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2015-03-12|2011-07-14|2011-07-15|Estimate|||||||2015-03-12|2015-03-13|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|STOPC||Strength Training on Pancreatic Cancer|Strength Training on Pancreatic Cancer|Withdrawn||N/A|0|Actual|German Cancer Research Center||2|||f||||t||||||||||2018-05-31 22:21:41.48042|2018-05-31 22:21:41.48042
NCT01395550|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-08-29|2011-07-14|2011-07-15|Estimate|||||||2011-08-29|2011-08-30|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event|Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event.|Completed|||88|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:21:41.557992|2018-05-31 22:21:41.557992
NCT01395537|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2014-12-15|2011-07-14|2011-07-15|Estimate|||||||2014-12-15|2014-12-17|Estimate|August 2011||2011-08-31|December 2014|2014-12-31||||December 2014|Actual|2014-12-31||Interventional|||Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)|Phase I/II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ)|Terminated||Phase 1/Phase 2|13|Actual|Case Comprehensive Cancer Center||1||Research Cancelled|f||||t||||||||||2018-05-31 22:21:41.597508|2018-05-31 22:21:41.597508
NCT01395524|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2014-10-13||2017-01-09|2011-07-14|2011-07-15|Estimate|2015-06-15|2015-06-17|Estimate||||2017-01-09|2017-02-23|Actual|July 2011||2011-07-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||A total of 6 patients (1 patient in the NKTR-118 25 mg group, 2 patients in the NKTR-118 12.5 mg group, 3 patients in the placebo group) had been previously randomized within the NKTR-118 program at a different study center and were excluded from the ITT and Safety analysis sets. Baseline characteristics are summarized using the ITT analysis set.|A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation|A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)|Completed||Phase 3|302|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:21:41.799595|2018-05-31 22:21:41.799595
NCT01395511|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2011-07-14|2011-07-14|2011-07-15|Estimate|||||||2011-07-14|2011-07-15|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Acupuncture for Whiplash Associated Disorder|Acupuncture for Whiplash Associated Disorder: a Randomised, Waiting-list Controlled, Open-label, Parallel-group Pilot Trial|Completed||Phase 2|40|Actual|Kyunghee University Medical Center||2|||f||||f||||||||||2018-05-31 22:21:42.538254|2018-05-31 22:21:42.538254
NCT01395498|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-07-27|2011-07-14|2011-07-15|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Observational|PCP-CMV||Prevalence of Pneumocystis Jirovecii and of Cytomegalovirus in Bronchial Wash Fluid of Patients Undergoing Bronchoscopy|Prevalence of Positive DNA of Pneumocystis Jirovecii and of Cytomegalovirus in Bronchial Wash Fluid of Patients Undergoing Fiberoptic Bronchoscopy|Completed|||93|Actual|Carmel Medical Center|||1||f||||f||||||Samples With DNA|"~     samples of bronchoalveolar lavage fluid and blood.~   "|No||2018-05-31 22:21:42.62819|2018-05-31 22:21:42.62819
NCT01395485|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2013-11-20|2011-07-14|2011-07-15|Estimate|||||||2013-11-20|2013-11-25|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescent (12 to <18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma|Withdrawn||Phase 1|0|Actual|Amgen||4||The study had been cancelled and replaced with protocol 20130250.|f||||||||||||||2018-05-31 22:21:42.70396|2018-05-31 22:21:42.70396
NCT01395472|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-07-27|2011-07-14|2011-07-15|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 2010||2010-01-31|April 2011|2011-04-30|February 2012|Anticipated|2012-02-29|October 2011|Anticipated|2011-10-31||Interventional|||Influence of Physical Exercise on Cognitive Functioning of Traumatic Brain Injury Patients|Influence of Physical Exercise on Cognitive Functioning of Traumatic Brain Injury Patients|Unknown status|Recruiting|N/A|36|Anticipated|Federal University of São Paulo||3|||f||||f||||||||||2018-05-31 22:21:42.812745|2018-05-31 22:21:42.812745
NCT01395459|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-09|||2015-04-07|2011-07-14|2011-07-15|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|March 2011|Actual|2011-03-31||Interventional|CATCH||A Sustainable Approach to Increasing Cancer Screening|A Sustainable Approach to Increasing Cancer Screening|Completed||N/A|13675|Actual|Harvard School of Public Health||3|||f||||f||||||||||2018-05-31 22:21:42.896771|2018-05-31 22:21:42.896771
NCT01395446|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-06-23|2011-07-14|2011-07-15|Estimate|||||||2015-06-23|2015-06-24|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Observational|AENEAS||Application of an Electronic Nose in the Early Detection of ASpergillosis|The Application of an Electronic Nose in the Early Detection of ASpergillosis|Completed|||52|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples Without DNA|"~     BAL~   "|||2018-05-31 22:21:42.984337|2018-05-31 22:21:42.984337
NCT01395433|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-12-07|2011-07-14|2011-07-15|Estimate|||||||2012-12-07|2012-12-10|Estimate|January 2010||2010-01-31|December 2012|2012-12-31||||March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study Comparing Two Formulations of Escitalopram|A Single-dose, Open-label, Randomised, Crossover Bioequivalence Study in Healthy Young Men Comparing Two Formulations of Escitalopram|Completed||Phase 1|32|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 22:21:43.052998|2018-05-31 22:21:43.052998
NCT01395420|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-08-31|2011-07-14|2011-07-15|Estimate|||||||2017-08-31|2017-09-01|Actual|August 2011||2011-08-31|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid and Plasma|A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid (ELF) and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers|Completed||Phase 1|45|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:21:43.129019|2018-05-31 22:21:43.129019
NCT01395407|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-12-02|2011-07-14|2011-07-15|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2011||2011-07-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases|Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases|Completed||Phase 1|9|Actual|Emory University||3|||f||||t||||||||||2018-05-31 22:21:43.210372|2018-05-31 22:21:43.210372
NCT01395394|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2014-07-30||2014-08-27|2011-07-14|2011-07-15|Estimate|2014-08-27|2014-08-28|Estimate||||2014-08-27|2014-08-28|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Phenylketonuria, Oxidative Stress, and BH4|The Ability of Kuvan® (Sapropterin Dihydrochloride) to Prevent Meal-induced Lipid Peroxidation and Endothelial Dysfunction in Patients With Phenylketonuria: a Pilot Study|Terminated||Phase 2|12|Actual|Emory University|Early termination leading to small number of subjects analyzed.|3||Difficulty with recruitment and agreed with Sponsor to report completed data as case reports|f||||t||||||||||2018-05-31 22:21:43.318916|2018-05-31 22:21:43.318916
NCT01395381|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2014-01-24|2011-07-13|2011-07-15|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2013||2013-01-31|January 2014|2014-01-31||||January 2014|Anticipated|2014-01-31||Interventional|||Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition|Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Benefit of Antihelminthic Therapy in the Community-Based Treatment of Severe Acute Malnutrition in Malawian Children|Withdrawn||N/A|0|Actual|Washington University School of Medicine||2||not funded|f||||f||||||||||2018-05-31 22:21:43.595626|2018-05-31 22:21:43.595626
NCT01395368|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2012-04-13||2012-07-18|2011-07-14|2011-07-15|Estimate|2012-07-18|2012-08-23|Estimate||||2012-07-18|2012-08-23|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|COMeT||Cognitive Speed as an Objective Measure of Tinnitus|Cognitive Speed as an Objective Measure of Tinnitus|Completed|||108|Actual|Washington University School of Medicine|Tinnitus subjects with moderate or greater depression were excluded from the study. This study may not be reflective of the population of bothersome tinnitus patients due to this exclusion||1||f||||f||||||||||2018-05-31 22:21:43.66135|2018-05-31 22:21:43.66135
NCT01395355|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-05-06|2011-07-13|2011-07-15|Estimate|||||||2015-05-06|2015-05-08|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Integrative Intervention for Loss of Control Eating Among Adolescent Girls|An Integrative Intervention for Binge Eating Among Adolescent Girls|Completed||N/A|59|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 22:21:43.776054|2018-05-31 22:21:43.776054
NCT01395342|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2012-07-11|2011-07-13|2011-07-15|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Assessment of Physical Exercise Using Stationary Bicycle for Pregnant Women With Risk for Preeclampsia Development|Assessment of Physical Exercise Using Stationary Bicycle for Pregnant Women With Risk for Preeclampsia Development|Completed||Phase 1|116|Actual|University of Campinas, Brazil||1|||f||||t||||||||||2018-05-31 22:21:43.944581|2018-05-31 22:21:43.944581
NCT01395329|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-04-04|2011-07-13|2011-07-15|Estimate|||||||2017-04-04|2017-04-05|Actual|May 2011||2011-05-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|NETS||Nebivolol and the Endothelin (ET)-1 System|Nebivolol and the Endothelin (ET)-1 System|Completed||Phase 4|48|Actual|University of Colorado, Boulder||3|||f||||t||||||||||2018-05-31 22:21:44.016722|2018-05-31 22:21:44.016722
NCT01395316|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2017-01-12|2011-07-14|2011-07-15|Estimate|||||||2017-01-12|2017-01-13|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|October 2015|Actual|2015-10-31||Interventional|||Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis|Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis|Active, not recruiting||Phase 4|8|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 22:21:44.101062|2018-05-31 22:21:44.101062
NCT01395303|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-11-10|2011-07-14|2011-07-15|Estimate|||||||2016-11-10|2016-11-11|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Polymorphisms in the Vitamin D System and Health|Polymorphisms in the Vitamin D System and Health|Completed|||9700|Actual|University of Tromso|||8||f||||f||||||Samples With DNA|"~     DNA from blood clots~   "|||2018-05-31 22:21:44.167058|2018-05-31 22:21:44.167058
NCT01395290|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2012-09-03|2011-07-14|2011-07-15|Estimate|||||||2012-09-03|2012-09-05|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Vitamin D and Staphylococcus Aureus in the Diabetes Study|Vitamin D and Staphylococcus Aureus in the Diabetes Study|Completed||Phase 3|280|Actual|University of Tromso||1|||f||||f||||||||||2018-05-31 22:21:44.236842|2018-05-31 22:21:44.236842
NCT01395277|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2015-03-24||2015-07-13|2011-07-14|2011-07-15|Estimate|2015-07-13|2015-08-10|Estimate||||2015-07-13|2015-08-10|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||15 young and 15 elderly subjects participated in portion of the protocol|Role of Flavanols In Cardiovascular Function in Healthy Aging|Effects of Dietary Flavanols on Cutaneous, Peripheral, and Cerebral Vascular Function in Young and Old Humans|Completed||N/A|30|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 22:21:44.304128|2018-05-31 22:21:44.304128
NCT01395264|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2017-10-27|2011-07-14|2011-07-15|Estimate|||||||2017-10-27|2017-10-31|Actual|August 2011||2011-08-31|October 2017|2017-10-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Observational|||Saccadometry in Primary Headache Syndromes|Saccadometry in Primary Headache Syndromes|Terminated|||42|Actual|University College London Hospitals|||4|Lack of available clinical time to complete|f||||f||||||||||2018-05-31 22:21:44.601408|2018-05-31 22:21:44.601408
NCT01395251|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2015-05-15|2011-07-14|2011-07-15|Estimate|||||||2015-05-15|2015-05-18|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|TryCort||Diagnostic Value of Oral Prednisolone Test for Rheumatoid Arthritis|Phase II/III Study of Oral Prednisolone Test in Patients With Rheumatoid Arthritis|Completed||Phase 2/Phase 3|130|Actual|Rheumazentrum Ruhrgebiet||1|||f||||t||||||||||2018-05-31 22:21:44.661125|2018-05-31 22:21:44.661125
NCT01395238|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2011-07-14|2011-07-14|2011-07-15|Estimate|||||||2011-07-14|2011-07-15|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Enhancing Father's Ability to Support Their Preschool Child|Enhancing Father's Ability to Support Their Preschool Child|Unknown status|Recruiting|Phase 1/Phase 2|125|Anticipated|Queens College, The City University of New York||2|||f||||f||||||||||2018-05-31 22:21:44.742081|2018-05-31 22:21:44.742081
NCT01385085|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|November 2011||2011-11-30|June 2011|2011-06-30||||||||Observational|||Impact of Work Environment Absent of Natural Light on Vitamin D Levels|Impact of Work Environment Absent of Natural Light on Vitamin D Levels|Unknown status|Not yet recruiting||300|Anticipated|Medical Corps, Israel Defense Force|||3||f||||f||||||||||2018-05-31 22:25:25.827462|2018-05-31 22:25:25.827462
NCT01395225|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-03-12|2011-07-14|2011-07-15|Estimate|||||||2014-03-12|2014-03-13|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Observational|||Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer|Standardising an Approach for Analysis of Lymph Node Specimens From Radical Cystectomy With Pelvic Lymph Node Dissection Through the Use of an Organic Fat-emulsifying Agent|Completed|||32|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 22:21:44.814085|2018-05-31 22:21:44.814085
NCT01395212|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2013-10-26|2011-07-14|2011-07-15|Estimate|||||||2013-10-26|2013-10-29|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|MYSTAR-5-YEAR||MYSTAR-5-YEAR: Long-term Follow-up of Patients With Ischemic Heart Disease Treated With Cell Therapy|Long-term Follow-up of Patients With Ischemic Heart Disease Treated With Combined Delivery of Autologous Bone-marrow Mononuclear Cells: 5-year Clinical Outcome of the MYSTAR Study|Completed|||60|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 22:21:44.877402|2018-05-31 22:21:44.877402
NCT01395199|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2015-09-04|2011-07-14|2011-07-15|Estimate|||||||2015-09-04|2015-09-09|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|AmloThal||Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major|Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial|Completed||Phase 3|62|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 22:21:44.942467|2018-05-31 22:21:44.942467
NCT01395186|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-14|2011-07-14|2011-07-15|Estimate|||||||2011-07-14|2011-07-15|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Varicocelectomy To Treat Pain, Predictors Of Success|Varicocelectomy To Treat Pain, Predictors Of Success : A Prospective Study|Completed||N/A|145|Actual|Mansoura University||1|||f||||t||||||||||2018-05-31 22:21:45.013778|2018-05-31 22:21:45.013778
NCT01395173|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-09-29|2011-07-14|2011-07-15|Estimate|||||||2014-09-29|2014-09-30|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional|||Position Changes During Colonoscope Withdrawal and Polyp Detection|Position Changes During Colonoscope Withdrawal to Increase Polyp Detection: a Prospective Randomized Trial|Completed||N/A|776|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:21:45.092263|2018-05-31 22:21:45.092263
NCT01395160|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-08-30|2011-07-14|2011-07-15|Estimate|||||||2013-08-30|2013-09-02|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|FEBA||Female Experiences and Brain Activity|Female Experiences and Brain Activity: an EEG Investigation Across Psychiatric Disorders|Completed|||60|Actual|King's College London|||3||f||||f||||||Samples With DNA|"~     Buccal swab samples will be collected for DNA extraction.~   "|||2018-05-31 22:21:45.167679|2018-05-31 22:21:45.167679
NCT01395147|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2013-11-02|2011-07-13|2011-07-15|Estimate|||||||2013-11-02|2013-11-05|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder|An Open-label, Long-Term Extension Study to Assess the Safety and Efficacy of Lu AA21004 in Patients With Major Depressive Disorder (Extension to Lu AA21004/CCT-003 Study)|Completed||Phase 3|119|Actual|Takeda||1|||f||||f||||||||||2018-05-31 22:21:45.254509|2018-05-31 22:21:45.254509
NCT01395134|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-07-14|2011-07-14|2011-07-15|Estimate|||||||2011-07-14|2011-07-15|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.|Randomized Controlled Trial of Visualization Versus Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroidectomy.|Completed||N/A|210|Actual|Jagiellonian University||2|||f||||t||||||||||2018-05-31 22:21:45.37955|2018-05-31 22:21:45.37955
NCT01395121|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2017-06-07|2011-07-14|2011-07-15|Estimate|||||||2017-06-07|2017-06-08|Actual|December 2009|Actual|2009-12-31|June 2017|2017-06-30|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|NICAM||A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread|A Phase II Trial of Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma|Completed||Phase 2|29|Actual|Institute of Cancer Research, United Kingdom||1|||f||||t||||||||||2018-05-31 22:21:45.467635|2018-05-31 22:21:45.467635
NCT01395108|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-07-13|2011-07-13|2011-07-15|Estimate|||||||2011-07-13|2011-07-15|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Clinical Study on Oral Nemonoxacin Malate Capsules|Phase I Clinical Study on Oral Nemonoxacin Malate Capsules|Completed||Phase 1|76|Actual|TaiGen Biotechnology Co., Ltd.||6|||f||||f||||||||||2018-05-31 22:21:45.546176|2018-05-31 22:21:45.546176
NCT01395095|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2016-03-14|2011-07-14|2011-07-15|Estimate|||||||2016-03-14|2016-03-15|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|OPTICARE||OPTImal CArdiac REhabilitation (OPTICARE) Following Acute Coronary Syndromes|OPTImal CArdiac REhabilitation (OPTICARE)Following Acute Coronary Syndromes: A Randomized, Controlled Trial to Investigate the Benefits of an Expanded Educational and Behavioural Intervention Program.|Completed||N/A|914|Actual|Erasmus Medical Center||3|||f||||f||||||||Yes||2018-05-31 22:21:45.62358|2018-05-31 22:21:45.62358
NCT01395082|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2018-01-26|2011-07-13|2011-07-15|Estimate|||||||2018-01-26|2018-01-30|Actual|April 2011||2011-04-30|January 2018|2018-01-31|April 2024|Anticipated|2024-04-30|April 2024|Anticipated|2024-04-30||Observational|||ACAM2000® Myopericarditis Registry|ACAM2000® Myopericarditis Registry|Active, not recruiting|||200|Anticipated|Emergent BioSolutions|||1||f||||f||||||||||2018-05-31 22:21:45.738793|2018-05-31 22:21:45.738793
NCT01395069|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-01-12|2011-07-13|2011-07-15|Estimate|||||||2016-01-12|2016-01-13|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PNK||Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery|Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK)|Completed||Phase 4|162|Actual|Queen's University||3|||f||||f||||||||||2018-05-31 22:21:45.799777|2018-05-31 22:21:45.799777
NCT01395056|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-14|||2015-07-20|2011-07-14|2011-07-15|Estimate|||||||2015-07-20|2015-07-22|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|DCCIK||Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients|Study of Chemotherapy Combined With Adoptive Cellular Therapy With Dendritic and Cytokine-induced Killer Cells in Triple Negative Breast Cancer Patients|Completed|||23|Actual|Beijing Cancer Hospital|||||f||||t||||||None Retained|"~     about 4ml peripheral vein blood，paraffin section on metastatic tissue，~   "|||2018-05-31 22:21:45.870905|2018-05-31 22:21:45.870905
NCT01395043|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2011-10-06||2012-01-05|2011-07-14|2011-07-15|Estimate|2012-01-05|2012-02-07|Estimate||||2012-01-05|2012-02-07|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Transversus Abdominis Plane Catheter: a Study of Method|TAP-catheter With Intermittent Bolus Injections of Bupivacain, an Alternative to Epidural Catheter Infusion After Colon Surgery?|Completed||N/A|15|Actual|Aalborg Universitetshospital|Not randomised or blinded. Limited number of patients. Dermatome level of the block and the incidence of postoperative nausea and vomiting was not registered. The study does not compare TAP-catheter and epidural catheter.|1|||f||||f||||||||||2018-05-31 22:21:45.93987|2018-05-31 22:21:45.93987
NCT01395030|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-05-31|2011-07-13|2011-07-15|Estimate|||||||2017-05-31|2017-06-02|Actual|July 2011||2011-07-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 31, 2017|Actual|2017-05-31||Interventional|||Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer|Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer|Active, not recruiting||Phase 1/Phase 2|60|Actual|Queen's Medical Centre||1|||f||||t||||||||||2018-05-31 22:21:46.114666|2018-05-31 22:21:46.114666
NCT01395017|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2014-10-24||2016-03-10|2011-07-14|2011-07-15|Estimate|2015-03-04|2015-03-17|Estimate||||2016-03-10|2016-04-08|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|October 2013|Actual|2013-10-31||Interventional|LAPC||Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer|Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer|Completed||Phase 2|202|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|5 participants (who had not experienced disease progression at the time of event-driven data cut-off) were told the study results and were instructed to indicate “sponsor discontinued study” if they did not want to continue in the study.|2|||f||||t||||||||||2018-05-31 22:21:46.204697|2018-05-31 22:21:46.204697
NCT01395004|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-10-31|2011-07-13|2011-07-15|Estimate|||||||2017-10-31|2017-11-06|Actual|November 2011||2011-11-30|October 2017|2017-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis|A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis|Completed||Phase 2|17|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:21:47.005688|2018-05-31 22:21:47.005688
NCT01394991|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2010-09-10||2012-04-03|2011-06-16|2011-07-15|Estimate|2011-06-16|2011-07-15|Estimate||||2012-04-03|2012-04-05|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia|A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia|Completed||Phase 4|504|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 22:21:47.167024|2018-05-31 22:21:47.167024
NCT01394978|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2017-04-17||2017-06-09|2011-07-13|2011-07-15|Estimate|2017-06-09|2017-07-11|Actual||||2017-06-09|2017-07-11|Actual|June 2011||2011-06-30|June 2017|2017-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study|AirTight: A Prospective Controlled Post-Approval Study of NeoMend ProGEL™ Pleural Air Leak Sealant in the Treatment of Visible Pleural Air Leaks After Standard Pleural Closure|Completed||N/A|444|Actual|C. R. Bard||2|||f||||t||||||||||2018-05-31 22:21:47.974259|2018-05-31 22:21:47.974259
NCT01394965|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2013-10-18|2011-07-14|2011-07-15|Estimate|||||||2013-10-18|2013-10-21|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Electrocardiographic Mapping and Imaging|Electrocardiographic Mapping and Imaging|Withdrawn||Early Phase 1|0|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 22:21:48.33372|2018-05-31 22:21:48.33372
NCT01394952|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2018-01-11|2011-07-13|2011-07-15|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2011||2011-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|REWIND||Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)|The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)|Active, not recruiting||Phase 3|9622|Anticipated|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 22:21:48.438024|2018-05-31 22:21:48.438024
NCT01394939|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2016-01-06|2011-07-14|2011-07-15|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma|A Phase 1/2a Dose-escalation Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma.|Completed||Phase 1/Phase 2|52|Actual|SillaJen, Inc.||2|||f||||f||||||||||2018-05-31 22:21:48.914833|2018-05-31 22:21:48.914833
NCT01394926|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2014-03-07||2014-04-16|2011-07-14|2011-07-15|Estimate|2014-03-07|2014-04-16|Estimate||||2014-04-16|2014-05-02|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease|A Multi-Center, Open-Label, Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease|Terminated||Phase 2|21|Actual|GE Healthcare||1||Lack of Subject Recruitment|f||||f||||||||||2018-05-31 22:21:49.925721|2018-05-31 22:21:49.925721
NCT01394913|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2013-03-01|2011-07-13|2011-07-15|Estimate|||||||2013-03-01|2013-03-04|Estimate|August 2013||2013-08-31|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|||Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis|A Prospective, Double-blind, Randomized Study to Compare Efficacy of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis|Suspended||Phase 3|216|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2018-05-31 22:21:50.074411|2018-05-31 22:21:50.074411
NCT01394900|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2017-02-03|2011-07-13|2011-07-15|Estimate|||||||2017-02-03|2017-02-06|Estimate|July 2012||2012-07-31|February 2017|2017-02-28|April 30, 2017|Anticipated|2017-04-30|December 31, 2016|Actual|2016-12-31||Interventional|CNU||Connect 'n Unite: Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM|Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM|Active, not recruiting||N/A|424|Actual|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 22:21:50.163902|2018-05-31 22:21:50.163902
NCT01394887|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-07-15|2011-07-14|2011-07-15|Estimate|||||||2011-07-15|2011-07-18|Estimate|July 2002||2002-07-31|July 2002|2002-07-31|July 2011|Actual|2011-07-31|July 2003|Actual|2003-07-31||Interventional|||Metformin & Inflammation in Pre-diabetic Children|Metformin Decreases Plasma Resistin Concentrations in Pediatric Patients With Impaired Glucose Tolerance: A Placebo-controlled Randomized Clinical Trial|Completed||Phase 2/Phase 3|52|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 22:21:50.26204|2018-05-31 22:21:50.26204
NCT01394874|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-05-01|2011-07-13|2011-07-15|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|BOOST||Can Computer-based Telephone Counseling Improve Long-term Adherence to Strength Training in Elders With Knee OA?|Can Computer-based Telephone Counseling Improve Long-term Adherence to Strength Training in Elders With Knee OA?|Unknown status|Recruiting|N/A|100|Anticipated|Boston University||2|||f||||f||||||||||2018-05-31 22:21:50.344981|2018-05-31 22:21:50.344981
NCT01394861|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-03-04|2011-07-14|2011-07-15|Estimate|||||||2012-03-04|2012-03-06|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|ESD||Endoscopic Submucosal Dissection (ESD)- Master Slave Robotic System - Human Study||Completed||Early Phase 1|3|Actual|Asian Institute of Gastroenterology, India||1|||f||||t||||||||||2018-05-31 22:21:50.424494|2018-05-31 22:21:50.424494
NCT01394848|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2013-12-03|2011-07-13|2011-07-14|Estimate|||||||2013-12-03|2013-12-04|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|INNOVATION||Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy|EndothelIal progeNitor Cell Capture steNt With 1-mOnth Dual Antiplatelet Therapy Versus eVerolimus-eluting Stent With stAndard 12-month Dual anTIplatelet Therapy in Elderly (≥ 70 Year) With Stable corONary Artery Disease - INNOVATION Trial|Terminated||Phase 4|1|Actual|Yonsei University||4||"Previous other study including EPC capture stent raised the issue of safety (significant high~   incidence of instent restenosis)"|f||||t||||||||||2018-05-31 22:21:50.599866|2018-05-31 22:21:50.599866
NCT01394835|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-13|2011-07-13|2011-07-14|Estimate|||||||2011-07-13|2011-07-14|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients||Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Rabin Medical Center||1|||f||||||||||||||2018-05-31 22:21:50.733857|2018-05-31 22:21:50.733857
NCT01394822|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2017-11-02|2011-07-13|2011-07-14|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2011||2011-09-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Neuromuscular Ultrasound for Focal Neuropathies|Neuromuscular Ultrasound for Focal Neuropathies|Completed|||120|Actual|Wake Forest University Health Sciences|||2||f||||f|f|f||||||||2018-05-31 22:21:50.805536|2018-05-31 22:21:50.805536
NCT01394809|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2014-12-02|2011-07-13|2011-07-14|Estimate|||||||2014-12-02|2014-12-04|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PROFinD-TP4||Effects of Motor Cognitive Training on Functional Loss After Osteoporotic Wrist Fractures|Effects of Motor Cognitive Training on Functional Loss Through Immobilization After Osteoporotic Distal Radius Fractures: a Randomised Clinical Pilot Study in Elderly Patients|Completed||N/A|27|Actual|University of Stuttgart||3|||f||||f||||||||||2018-05-31 22:21:50.873769|2018-05-31 22:21:50.873769
NCT01394796|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2013-03-12|2011-07-13|2011-07-14|Estimate|||||||2013-03-12|2013-03-13|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.|Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.|Completed||Phase 2|31|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 22:21:50.969044|2018-05-31 22:21:50.969044
NCT01394783|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-11-17|2011-07-13|2011-07-14|Estimate|||||||2014-11-17|2014-11-19|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Videolaryngoscope vs Classic Laryngoscope in Teaching Neonatal Endotracheal Intubation: a Randomized Controlled Trial.|Videolaryngoscope vs Classic Laryngoscope in Teaching Neonatal Endotracheal Intubation: a Randomized Controlled Trial.|Completed||Phase 4|268|Actual|St. Justine's Hospital||2|||f||||t||||||||||2018-05-31 22:21:51.084498|2018-05-31 22:21:51.084498
NCT01394770|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-07-09|2011-07-13|2011-07-14|Estimate|||||||2012-07-09|2012-07-10|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients|Cardiovascular Events in Hypertensive Hemodialysed Patients: Aliskiren Versus Amlodipine. A Randomized, Double-blind Study.|Unknown status|Active, not recruiting|Phase 4|350|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-05-31 22:21:51.166302|2018-05-31 22:21:51.166302
NCT01394757|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2013-12-29|2011-07-13|2011-07-14|Estimate|||||||2013-12-29|2013-12-31|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)|Brain Network Dysfunction as a Model for Schizophrenia: Connectivity Alterations Using Ketamine and Pharmacological Magnetic Resonance Imaging|Completed||N/A|52|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 22:21:51.249387|2018-05-31 22:21:51.249387
NCT01394744|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2017-09-01|2011-07-13|2011-07-14|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2011||2011-08-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Observational|||Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement|Determination of Metal Ion Levels in the Serum and Assessment of the Respective Cytokine Production of Peripheral Blood Cells in Patients With a Hard-on-hard Bearing Total Hip Replacement|Active, not recruiting|||30|Actual|Ludwig-Maximilians - University of Munich|||||f||||f||||||Samples Without DNA|"~     Blood serum samples for metal ion and cytokine measurement; blood cells for cytokine-RNA~     assessment~   "|||2018-05-31 22:21:51.313334|2018-05-31 22:21:51.313334
NCT01394731|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-07-13|2011-07-13|2011-07-14|Estimate|||||||2011-07-13|2011-07-14|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Analgesic Effects of Intravenous Paracetamol on Labor Pain|Analgesic Effects of Intravenous Acetaminophen on Labor Pain|Completed||Phase 4|||King Abdulaziz University||3|||f||||||||||||||2018-05-31 22:21:51.362842|2018-05-31 22:21:51.362842
NCT01394562|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-05-16|2011-07-12|2011-07-14|Estimate|||||||2017-05-16|2017-05-18|Actual|July 2011||2011-07-31|December 2015|2015-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|EFFECT-HF||Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure|Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency|Completed||Phase 3|174|Actual|Vifor Inc.||2|||f||||t||||||||||2018-05-31 22:21:53.176423|2018-05-31 22:21:53.176423
NCT01394718|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2016-03-17||2016-03-17|2011-07-13|2011-07-14|Estimate|2016-03-17|2016-04-18|Estimate||||2016-03-17|2016-04-18|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|June 2014|Actual|2014-06-30||Interventional|IV APAP SF|Analysis population includes only those subjects who completed at least 24 hours of post-operative data collection. 3 subjects who were enrolled and received at least 1 dose were removed before reaching the 24 hour post-operative milestone.|Analgesic Efficacy of Repeated Doses of Intravenous (IV) Acetaminophen in Post-operative Pediatric Spine Fusion Patients|Analgesia Efficacy of Repeated Doses of Intravenous Acetaminophen (Paracetamol) in the Pediatric Spinal Fusion Population|Completed||Phase 3|67|Actual|Children's Hospital of Philadelphia|This is a single center study with subjects confined to a single surgical procedure with a small sample size, possibly limiting generalizability of results.|2|||f||||f||||||||||2018-05-31 22:21:51.434759|2018-05-31 22:21:51.434759
NCT01394705|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-11-15|2011-07-13|2011-07-14|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2011||2011-06-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||FITT Exercise Counseling With Interactive Accelerometry and Physical Activity in Adolescents at Increased Risk of Early Cardiovascular Disease: A Pilot Study|FITT Exercise Counseling With Interactive Accelerometry and Physical Activity in Adolescents at Increased Risk of Early Cardiovascular Disease: A Pilot Study|Completed||N/A|38|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 22:21:51.691524|2018-05-31 22:21:51.691524
NCT01394692|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2012-09-20||2012-10-29|2011-07-13|2011-07-14|Estimate|2012-10-29|2012-11-28|Estimate||||2012-10-29|2012-11-28|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery|Resection Control of Primary Brain Tumours Using a Low-Field Intraoperative MRI|Completed||N/A|58|Actual|Goethe University||2|||f||||f||||||||||2018-05-31 22:21:51.761976|2018-05-31 22:21:51.761976
NCT01394679|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-09-27|2011-07-13|2011-07-14|Estimate|||||||2017-09-27|2017-09-29|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer|A Multicenter Phase 3 Study Comparing the Diagnostic Accuracy of 99mTc EC DG SPECT/CT Versus 18F FDG PET/CT for Diagnosing and Staging Patients Who Have Clinical and Radiological (CT) Evidence Consistent With a Diagnosis of Lung Cancer|Recruiting||Phase 3|154|Anticipated|Cell>Point LLC||2|||f||||t|t|f||||||||2018-05-31 22:21:52.12209|2018-05-31 22:21:52.12209
NCT01394666|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-07-08|2011-07-13|2011-07-14|Estimate|||||||2016-07-08|2016-07-11|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)|Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily|Completed|||150|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 22:21:52.217103|2018-05-31 22:21:52.217103
NCT01394653|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-10-10|2011-07-13|2011-07-14|Estimate|||||||2011-10-10|2011-10-12|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake|Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion With Water -|Completed||Phase 1|36|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:21:52.281212|2018-05-31 22:21:52.281212
NCT01394640|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-29|2011-07-13|2011-07-14|Estimate|||||||2011-07-29|2011-08-01|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|January 2011|Actual|2011-01-31|May 2010|Actual|2010-05-31||Observational|||Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients|Evaluation of Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Oncologic and Hematologic Patients|Completed|||124|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||2||f||||f||||||Samples Without DNA|"~     Serum and blood sample~   "|||2018-05-31 22:21:52.353399|2018-05-31 22:21:52.353399
NCT01394627|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2017-07-14||2017-10-16|2011-07-13|2011-07-14|Estimate|2017-10-16|2017-11-17|Actual||||2017-10-16|2017-11-17|Actual|January 2011||2011-01-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|HypoMR||Hypoglycemia and the Mineralocorticoid Receptor|Hypoglycemia and the Mineralocorticoid Receptor|Completed||N/A|21|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 22:21:52.440217|2018-05-31 22:21:52.440217
NCT01394614|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2014-11-28||2015-05-12|2011-07-13|2011-07-14|Estimate|2015-03-19|2015-04-02|Estimate||||2015-05-12|2015-05-14|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Risk of Narcolepsy Associated With Administration of H1N1 Vaccine|Risk of Narcolepsy Associated With Administration of Inactivated Adjuvanted (AS03) A/H1N1 Pandemic Influenza Vaccine in Quebec|Completed|||24|Actual|Hopital du Sacre-Coeur de Montreal|Small number of subjects; Impossibility to completely exclude a confounding effect of the A/H1N1 virus infection itself.||2||f||||f||||||Samples With DNA|"~     HLA typing~   "|||2018-05-31 22:21:52.68517|2018-05-31 22:21:52.68517
NCT01394601|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-11-02|2011-07-13|2011-07-14|Estimate|||||||2012-11-02|2012-11-05|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|RECONNECT-S||A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia|RECONNECT-S ALPHA: A Non-interventional Study to Observe Real-life Allocation of Antipsychotics in the Acute Inpatient Management of Schizophrenia|Completed|||600|Actual|AstraZeneca|||||f||||f||||||None Retained|"~     Clinical Practice~   "|||2018-05-31 22:21:52.947795|2018-05-31 22:21:52.947795
NCT01394588|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2014-05-02|2011-07-13|2011-07-14|Estimate|||||||2014-05-02|2014-05-05|Estimate|August 2010||2010-08-31|May 2014|2014-05-31||||||||Observational|||Continuous Glucose Monitoring Technology in the Perioperative Period During Cardiac Surgery|A Prospective Observational Trial of Continuous Glucose Monitoring Technology in the Perioperative Period During Cardiac Surgery|Withdrawn|||0|Actual|Yale University|||1|"On further investigation, it was found that the continuous glucose monitors required a~   calibration period that precluded reliable data collection."|f||||f||||||||||2018-05-31 22:21:53.026239|2018-05-31 22:21:53.026239
NCT01394575|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2013-03-26|2011-07-13|2011-07-14|Estimate|||||||2013-03-26|2013-03-27|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|IMRT-SIB||Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients|Phase 2 Study of Whole Breast Irradiation With Inversely Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients|Unknown status|Recruiting|Phase 2|190|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 22:21:53.092048|2018-05-31 22:21:53.092048
NCT01059240|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2018-05-18|2010-01-28|2010-01-29|Estimate|||||||2018-05-18|2018-05-21|Actual|January 21, 2010||2010-01-21|May 18, 2017|2017-05-18|May 18, 2017||2017-05-18|||||Observational|||SMN Copy Number Distribution in Mali, West Africa|SMN Copy Number Distribution in Mali, West Africa|Completed|||701|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:08:36.971247|2018-06-01 00:08:36.971247
NCT01394549|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-06-20|2011-07-13|2011-07-14|Estimate|||||||2012-06-20|2012-06-21|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|CASSANDRE||Causes, Analysis of the Sub-evaluating Coronary Syndromes Acute and Disparities in France in Women|Causes, Analysis of the Sub-evaluating Coronary Syndromes Acute and Disparities in France in Women|Completed|||319|Actual|French Cardiology Society|||1||f||||t||||||||||2018-05-31 22:21:53.241916|2018-05-31 22:21:53.241916
NCT01394536|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-10-16|2011-07-12|2011-07-14|Estimate|||||||2012-10-16|2012-10-17|Estimate|June 2011||2011-06-30|October 2012|2012-10-31||||May 2012|Actual|2012-05-31||Interventional|||Overnight Use of Electroacustimulation on Postoperative Nausea and Vomiting in the Outpatient Surgery Population|The Effect of Overnight Use of Electroacustimulation on Postoperative Nausea and Vomiting in the Outpatient Surgery Population|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||2||"The study was closed prior to enrollment of any subjects. No subjects were enrolled in this~   study."|f||||f||||||||||2018-05-31 22:21:53.302562|2018-05-31 22:21:53.302562
NCT01394523|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2017-11-21||2017-11-21|2011-07-13|2011-07-14|Estimate|2017-11-21|2017-12-19|Actual||||2017-11-21|2017-12-19|Actual|August 2011||2011-08-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Caudal Versus Rectus Sheath Study|A Prospective, Double-blinded, Randomized Comparison of Caudal Analgesia Versus Ultrasound Guided Rectus Sheath Blocks for Umbilical Herniorrhaphy in the Pediatric Population|Terminated||Phase 2/Phase 3|39|Actual|Nationwide Children's Hospital||3||Interim power analysis was prohibitive to continuing the study|f||||f||||||||||2018-05-31 22:21:53.376671|2018-05-31 22:21:53.376671
NCT01394510|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2016-05-10||2016-05-10|2011-07-13|2011-07-14|Estimate|2016-05-10|2016-06-17|Estimate||||2016-05-10|2016-06-17|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Interventional||Patients with type 2 diabetes either on metformin alone or treated with diet and lifestyle only.|Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes|Effect of Anti-oxidants on Beta-cell Function in Humans|Completed||N/A|13|Actual|Utzschneider, Kristina, M.D.||1|||f||||f||||||||No|The study sample size is very small. The data will be made available upon request.|2018-05-31 22:21:53.59153|2018-05-31 22:21:53.59153
NCT01394497|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2013-02-15|2011-07-13|2011-07-14|Estimate|||||||2013-02-15|2013-02-18|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Use of N-Acetylcysteine During Liver Procurement|Infusione Sistemica e Loco-regionale di N-Acetilcisteina Nel Prelievo di Fegato: Uno Studio Prospettico Randomizzato Controllato. Fase II.|Completed||Phase 2|140|Actual|Azienda Ospedaliera di Padova||2|||f||||t||||||||||2018-05-31 22:21:53.876656|2018-05-31 22:21:53.876656
NCT01394484|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2013-02-25|2011-07-12|2011-07-14|Estimate|||||||2013-02-25|2013-02-26|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|FL-83||Dairy Foods Compared to Dietary Supplements and Bone Health|Milk and Yogurt vs. Calcium and Vitamin D Supplements for Bone Health of Women|Completed||N/A|12|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:21:54.119229|2018-05-31 22:21:54.119229
NCT01394471|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2015-06-09|2011-07-12|2011-07-14|Estimate|||||||2015-06-09|2015-06-11|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|OTS-12WK||Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia|Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia|Completed||Phase 1|68|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:21:54.343726|2018-05-31 22:21:54.343726
NCT01394458|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2015-12-03|2011-07-13|2011-07-14|Estimate|||||||2015-12-03|2015-12-04|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution: A Pilot Study|Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution to Prevent Hemodialysis Catheter-Related Infections: A Pilot Study|Completed||N/A|40|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 22:21:54.523465|2018-05-31 22:21:54.523465
NCT01394445|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-02-20|2011-07-13|2011-07-14|Estimate|||||||2012-02-20|2012-02-22|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PHANOS||Pilot Study of Physostigmine-Enhanced Opioid Analgesia|Influence of Physostigmine on Patient-Controlled Analgesia|Completed||Phase 3|20|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 22:21:54.64281|2018-05-31 22:21:54.64281
NCT01394432|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2015-09-21|2011-07-13|2011-07-14|Estimate|||||||2015-09-21|2015-09-23|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2012|Actual|2012-11-30||Interventional|ESTIMATION||"ESTIMATION Study for Endocardial Mesenchymal Stem Cells Implantation in Patients After Acute Myocardial Infarction"|Endocardial Mesenchymal Stem Cells Implantation in Patients After Acute Myocardial Infarction|Unknown status|Recruiting|Phase 3|50|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 22:21:54.729135|2018-05-31 22:21:54.729135
NCT01394419|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2013-03-04|2011-07-13|2011-07-14|Estimate|||||||2013-03-04|2013-03-06|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft|Effect of N-acetylcysteine on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass Graft|Completed||Phase 4|115|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:21:54.831309|2018-05-31 22:21:54.831309
NCT01394406|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-03-04|2011-07-13|2011-07-14|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Ketamine Added to Intravenous Patient-controlled Analgesia on Postoperative Pain, Nausea and Vomiting in Patients Undergoing Lumbar Spinal Surgery|Effect of Ketamine Added to Intravenous Patient-controlled Analgesia on Postoperative Pain, Nausea and Vomiting in Patients Undergoing Lumbar Spinal Surgery|Completed||Phase 4|50|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:21:54.923365|2018-05-31 22:21:54.923365
NCT01394393|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-05-30|2011-07-13|2011-07-14|Estimate|||||||2012-05-30|2012-05-31|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|AVATOB||Virtual Environments For Supporting Obesity Treatment|Ambientes Virtuales Como Auxiliares en el Tratamiento de la Obesidad|Unknown status|Recruiting|Phase 1|40|Anticipated|Universidad Nacional Autonoma de Mexico||3|||f||||t||||||||||2018-05-31 22:21:54.993967|2018-05-31 22:21:54.993967
NCT01394380|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2014-06-03|2011-07-13|2011-07-14|Estimate|||||||2014-06-03|2014-06-04|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|REDUCS||Reduction of Sweetened Beverages and Intrahepatic Fat|Effects of a Reduction of Sweetened Beverages Consumption in Overweight High Consumers on Cardiometabolic Risk Factors|Completed||N/A|29|Actual|University of Lausanne||2|||f||||f||||||||||2018-05-31 22:21:55.110538|2018-05-31 22:21:55.110538
NCT01394367|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2014-07-01|2011-07-13|2011-07-14|Estimate|||||||2014-07-01|2014-07-02|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Ventricular Function in Severe Pulmonary Hypertension|Study of Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Ventricular Function in Severe Pulmonary Hypertension|Unknown status|Recruiting|Phase 3|90|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 22:21:55.191474|2018-05-31 22:21:55.191474
NCT01394354|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-04-05|2011-07-13|2011-07-14|Estimate|||||||2016-04-05|2016-04-06|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VBDD||Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)|Safety of Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma, A Phase I/II Study, Short Title: VBDD|Completed||Phase 1/Phase 2|34|Actual|University Hospital Freiburg||1|||f||||f||||||||||2018-05-31 22:21:55.281935|2018-05-31 22:21:55.281935
NCT01394341|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2013-10-08|2011-07-13|2011-07-14|Estimate|||||||2013-10-08|2013-10-09|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Liraglutide Treatment to Patients With Severe Renal Insufficiency|Safety and Effect of Liraglutide in Patients With Type 2 Diabetes and Severe Renal Insufficiency|Completed||Phase 4|40|Actual|Rigshospitalet, Denmark||4|||f||||t||||||||||2018-05-31 22:21:55.409788|2018-05-31 22:21:55.409788
NCT01394328|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2018-01-11|2011-07-13|2011-07-14|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2006||2006-04-30|January 2018|2018-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Delirium in Persons With Dementia|Delirium in Persons With Dementia|Completed|||308|Actual|Penn State University|||1||f||||f||||||||||2018-05-31 22:21:55.533084|2018-05-31 22:21:55.533084
NCT01394315|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2013-05-02|2011-07-13|2011-07-14|Estimate|||||||2013-05-02|2013-05-03|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|DOT||Diffuse Optical Tomography (DOT) for Monitoring Response to Neoadjuvant (Preoperative) Chemotherapy in Breast Cancer|Diffuse Optical Tomography (DOT) for Monitoring Response to Neoadjuvant (Preoperative) Chemotherapy in Breast Cancer|Terminated|||8|Actual|National Cancer Centre, Singapore|||||f||||f||||||Samples With DNA|"~     Pre-operative biopsy specimens and definitive surgical specimens~   "|||2018-05-31 22:21:56.012374|2018-05-31 22:21:56.012374
NCT01394302|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-07-13|2011-07-13|2011-07-14|Estimate|||||||2011-07-13|2011-07-14|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||The Functional Profile of People Suffering From Trigger Finger|Functional Profile of People Suffering From Trigger Finger|Unknown status|Not yet recruiting||60|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 22:21:56.080782|2018-05-31 22:21:56.080782
NCT01394289|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-08-24|2011-07-13|2011-07-14|Estimate|||||||2012-08-24|2012-08-27|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Biological Standardization of Lolium Perenne Allergen Extract|Biological Standardization of Lolium Perenne Allergen Extract to Determine the Biological Activity in HEP Units|Completed||Phase 2|31|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 22:21:56.19459|2018-05-31 22:21:56.19459
NCT01394276|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2016-04-30||2016-04-30|2011-07-13|2011-07-14|Estimate|2016-04-30|2016-06-07|Estimate||||2016-04-30|2016-06-07|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational||The total population included all participants who met all inclusion/exclusion criteria described in the study and received at least one dose of study medication.|An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)|Rheumatoid Arthritis Patients Treated With Tocilizumab in Real Clinical Practice: Effectiveness and Safety (TRUST Study)|Completed|||322|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:21:56.474177|2018-05-31 22:21:56.474177
NCT01394263|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-09-27|2011-07-13|2011-07-14|Estimate|||||||2012-09-27|2012-09-28|Estimate|May 2000||2000-05-31|September 2012|2012-09-30|December 2003|Actual|2003-12-31|December 2001|Actual|2001-12-31||Interventional|||Study of Histrelin Subdermal Implant in Patients With Prostate Cancer|Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate Cancer|Completed||Phase 3|59|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:21:58.055305|2018-05-31 22:21:58.055305
NCT01394250|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2015-03-27||2016-07-27|2011-07-13|2011-07-14|Estimate|2015-04-29|2015-05-15|Estimate||||2016-07-27|2016-09-16|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||"Baseline analysis population includes all subjects who were randomized and whose first attempt at IV access was successful (i.e., subjects in the Successful IV Placement & Follow-Up group)"|Vibrating, Cold Device for Pediatric Intravenous (IV) Cannulation Pain Relief|Testing the Efficacy of a Vibrating, Cold Device for Pediatric IV Cannulation Pain Relief in the Emergency Department|Completed||Phase 2|240|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 22:21:58.145839|2018-05-31 22:21:58.145839
NCT01394237|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2014-03-11|2011-07-13|2011-07-14|Estimate|||||||2014-03-11|2014-03-12|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||Laparoscopic Sacrocolpopexy: Long Term Follow-up|Laparoscopic Sacrocolpopexy: Long Term Results With Special Focus on Anatomical Results and Quality of Life|Completed|||75|Actual|Kantonsspital Aarau|||1||f||||t||||||||||2018-05-31 22:21:58.499589|2018-05-31 22:21:58.499589
NCT01394224|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-10-05|2011-07-13|2011-07-14|Estimate|||||||2011-10-05|2011-10-06|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects|A Single Site, Open-label, Randomized, Single-dose, Two-way Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence, Safety & Tolerability of Levetiracetam Administered as an Oral Tablet or Intravenous Infusion|Completed||Phase 1|25|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 22:21:58.581371|2018-05-31 22:21:58.581371
NCT01394211|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-03-29|2011-07-12|2011-07-14|Estimate|||||||2017-03-29|2017-03-31|Actual|July 13, 2011|Actual|2011-07-13|March 2017|2017-03-31|April 12, 2012|Actual|2012-04-12|April 12, 2012|Actual|2012-04-12||Interventional|||Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer|Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer|Terminated||Phase 2|2|Actual|University of Arizona||1||Slow accrual|f||||t||||||||||2018-05-31 22:21:58.749124|2018-05-31 22:21:58.749124
NCT01394198|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2014-01-07|2011-07-13|2011-07-14|Estimate|||||||2014-01-07|2014-01-08|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Correlation of Somatic Dysfunction With Gastrointestinal Endoscopic Findings|Correlation of Somatic Dysfunction With Gastrointestinal Endoscopic Findings|Completed|||70|Actual|A.T. Still University of Health Sciences|||||f||||f||||||||||2018-05-31 22:21:58.863559|2018-05-31 22:21:58.863559
NCT01394159|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2015-03-18||2018-02-09|2011-07-13|2011-07-14|Estimate|2015-03-30|2015-04-01|Estimate||||2018-02-09|2018-03-09|Actual|July 2011||2011-07-31|February 2018|2018-02-28|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||22G FNA Needle vs. 22G ProCore Needle|Randomized Trial Comparing the 22-gauge Aspiration and 22-gauge Biopsy Needles for EUS-guided Sampling of Solid Pancreatic Mass Lesions|Completed||N/A|56|Actual|Florida Hospital||2|||f||||f||||||||No||2018-05-31 22:21:59.392375|2018-05-31 22:21:59.392375
NCT01394146|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2015-09-28|2011-07-13|2011-07-14|Estimate|||||||2015-09-28|2015-09-30|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Impact of Food Additives on Phosphorus Metabolism|Impact of Food Additives on Phosphorus Metabolism|Completed||N/A|54|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 22:21:59.770547|2018-05-31 22:21:59.770547
NCT01394133|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2013-04-29|2011-07-12|2011-07-14|Estimate|||||||2013-04-29|2013-04-30|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women|Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women|Withdrawn|||0|Actual|University of Alabama at Birmingham|||1|Lack of enrollment|f||||t||||||Samples Without DNA|"~     5 mL of plasma~   "|||2018-05-31 22:21:59.848937|2018-05-31 22:21:59.848937
NCT01394120|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-03-24|2011-07-13|2011-07-14|Estimate|||||||2012-03-24|2012-03-27|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer|Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Grupo Hospital de Madrid||2|||f||||t||||||||||2018-05-31 22:22:00.011516|2018-05-31 22:22:00.011516
NCT01394107|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2015-07-27|2011-07-13|2011-07-14|Estimate|||||||2015-07-27|2015-07-29|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Evaluation of the LMWH Thromboprophylaxis in Pregnancy|Evaluation of the Impact of the Thromboprophylactic Dose of LMWH on Coagulation in Pregnant Women.|Unknown status|Recruiting||50|Anticipated|Charles University, Czech Republic|||2||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 22:22:00.087611|2018-05-31 22:22:00.087611
NCT01394094|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2011-07-13|2011-07-13|2011-07-14|Estimate|||||||2011-07-13|2011-07-14|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Effects of Gum Chewing on Recovery of Bowel Function Following Benign Gynecologic Surgery|Effects of Gum Chewing on Recovery of Bowel Function Following Benign Gynecologic Surgery: a Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2/Phase 3|124|Anticipated|ChaingMai University||2|||f||||t||||||||||2018-05-31 22:22:00.206759|2018-05-31 22:22:00.206759
NCT01394081|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2014-01-08||2017-09-12|2011-07-12|2011-07-14|Estimate|2017-09-12|2018-04-23|Actual||||2017-09-12|2018-04-23|Actual|October 1, 2008|Actual|2008-10-01|September 2017|2017-09-30|October 1, 2013|Actual|2013-10-01|October 1, 2010|Actual|2010-10-01||Interventional|AVRHI||Alabama Veterans Rural Health Initiative|Alabama Veterans Rural Health Initiative|Completed||N/A|203|Actual|Tuscaloosa Research & Education Advancement Corporation|Single geographic location; open label; bundled components of EEE intervention.|2|||f||||f|f|f||||||No|Individual participant data will not be shared|2018-05-31 22:22:00.379231|2018-05-31 22:22:00.379231
NCT01394068|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-08-17|2011-07-13|2011-07-14|Estimate|||||||2011-08-17|2011-08-18|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|SICS||Prospective, Non-randomized Observational Trial of Selenium in Cardiac Surgery|SICS: A Prospective, Non-randomized Observational Trial of Selenium in Cardiac Surgery|Completed|||100|Anticipated|RWTH Aachen University|||||f||||f||||||Samples Without DNA|"~     Procalcitonin, CRP, IL-6, IL-10, Leukocytes, Thrombocytes, Bilirubin, Creatinine, Lactate,~     Albumin, AT-III~   "|||2018-05-31 22:22:00.705814|2018-05-31 22:22:00.705814
NCT01394055|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-09-21|2011-07-12|2011-07-14|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis|Official Title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose, 2-Period Crossover Study to Evaluate the Pharmacodynamics of RM-131 Administered to Patients With Diabetic Gastroparesis|Completed||Phase 1|20|Actual|Motus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 22:22:00.763387|2018-05-31 22:22:00.763387
NCT01394042|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-12|2011-07-12|2011-07-14|Estimate|||||||2011-07-12|2011-07-14|Estimate|June 2011||2011-06-30|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint|Exploratory Evaluation of a Transrectal Scintigraphic Detector (Proxiscan) for Detection of Primary Prostate Cancer Utilizing a Radiotracer Targeting Prostate Specific Membrane Antigen (PMSA)|Unknown status|Enrolling by invitation|Early Phase 1|12|Anticipated|Radiological Associates of Sacramento Medical Group Inc.||1|||f||||t||||||||||2018-05-31 22:22:00.839025|2018-05-31 22:22:00.839025
NCT01394029|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-02-01|2011-07-13|2011-07-14|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox|International Sentinel Site Surveillance of Patients With Transfusional Hemosiderosis Treated With Deferasirox in Actual Practice Setting|Completed|||120|Actual|Novartis|||1||f||||||||||||||2018-05-31 22:22:00.923564|2018-05-31 22:22:00.923564
NCT01394016|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2018-01-17|2011-07-12|2011-07-14|Estimate|||||||2018-01-17|2018-01-19|Actual|December 7, 2009|Actual|2009-12-07|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|May 29, 2014|Actual|2014-05-29||Interventional|||A Phase 1 Study of LY2835219 In Participants With Advanced Cancer|A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer|Active, not recruiting||Phase 1|220|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:22:01.042047|2018-05-31 22:22:01.042047
NCT01394003|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2012-08-01|2011-07-12|2011-07-14|Estimate|||||||2012-08-01|2012-08-02|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of LY2584702 in Patients With Advanced Cancer|A Phase I Study of LY2584702 in Patient With Advanced or Metastatic Cancer|Terminated||Phase 1|34|Actual|Eli Lilly and Company||1||"The pharmacokinetic properties of the molecule do not allow for further dose escalation or~   development."|f||||f||||||||||2018-05-31 22:22:01.10666|2018-05-31 22:22:01.10666
NCT01393990|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2014-01-17|2011-07-12|2011-07-14|Estimate|||||||2014-01-17|2014-01-22|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||A Study of LY2228820 in Patients With Advanced Cancer|A Phase 1 Study of an Oral p38 MAPK Inhibitor in Patients With Advanced Cancer|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:22:01.178801|2018-05-31 22:22:01.178801
NCT01393977|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-10-07|2011-07-12|2011-07-14|Estimate|||||||2011-10-07|2011-10-10|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|May 2012|Anticipated|2012-05-31|December 2011|Anticipated|2011-12-31||Interventional|||Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China|Efficacy Difference Between Rehabilitation Therapy and Umbilical Cord Derived Mesenchymal Stem Cells Transplantation in Patients With Acute or Chronic Spinal Cord Injury in China|Unknown status|Recruiting|Phase 2|60|Anticipated|General Hospital of Chinese Armed Police Forces||3|||f||||t||||||||||2018-05-31 22:22:01.258535|2018-05-31 22:22:01.258535
NCT01393964|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2015-12-18||2017-06-27|2011-07-13|2011-07-14|Estimate|2015-12-18|2016-01-27|Estimate||||2017-06-27|2017-08-03|Actual|January 6, 2012|Actual|2012-01-06|June 2017|2017-06-30|July 18, 2016|Actual|2016-07-18|March 21, 2014|Actual|2014-03-21||Interventional||All participants who received at least one dose of study drug (Treated Population).|Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function|PH Ib Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Normal Renal Function, Severe Renal Impairment, or End Stage Renal Disease Requiring Dialysis|Completed||Phase 1|35|Actual|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 22:22:01.390936|2018-05-31 22:22:01.390936
NCT01393951|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-09-27|2011-07-12|2011-07-14|Estimate|||||||2017-09-27|2017-09-29|Actual|May 2011||2011-05-31|September 2017|2017-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers|Study for Immunogenicity and Safety of ASP7374 for Subcutaneous and Intramuscular Vaccination in Healthy Adults|Completed||Phase 1/Phase 2|165|Actual|UMN Pharma Inc.||3|||f||||f||||||||||2018-05-31 22:22:02.735904|2018-05-31 22:22:02.735904
NCT01393938|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2015-01-06|2011-07-12|2011-07-13|Estimate|||||||2015-01-06|2015-01-08|Estimate|April 2010||2010-04-30|January 2015|2015-01-31|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Interventional|MDA-3DUS||Comparison of MRI Versus Three Dimensional Ultrasound in the Diagnosis of Mullerian Duct Anomalies|Comparison of MRI Versus Three Dimensional Ultrasound in the Diagnosis of Mullerian Duct Anomalies|Terminated||N/A|16|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 22:22:02.80348|2018-05-31 22:22:02.80348
NCT01393925|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-11-19|2011-07-12|2011-07-13|Estimate|||||||2011-11-19|2011-11-22|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effect of Parecoxib on Postoperative Shoulder Pain After Gynecological Laparoscopy.||Completed||N/A|126|Actual|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 22:22:02.857967|2018-05-31 22:22:02.857967
NCT01393912|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-04-24|2011-07-12|2011-07-13|Estimate|||||||2017-04-24|2017-04-26|Actual|July 2011||2011-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2014|Actual|2014-09-30||Interventional|||PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma|Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma|Completed||Phase 1|55|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-05-31 22:22:02.910443|2018-05-31 22:22:02.910443
NCT01393899|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2016-08-29||2016-11-10|2011-07-12|2011-07-13|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||The safety analysis set consisted of all participants who received at least 1 dose of study medication in this study.|The Safety And Efficacy Of Maintenance Therapy With CP-690,550|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease|Completed||Phase 2|180|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:22:03.039278|2018-05-31 22:22:03.039278
NCT01393886|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-02-01|2011-07-12|2011-07-13|Estimate|||||||2013-02-01|2013-02-05|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|LGCP||LGCP (Laparoscopic Greater Curvature Plication)|A Prospective, Open-label Study to Evaluate the Safety and Efficacy of Laparoscopic Greater Curvature Plication (LGCP) in the Treatment of Obese Patients|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 22:22:04.728979|2018-05-31 22:22:04.728979
NCT01393873|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-09-26|2011-07-12|2011-07-13|Estimate|||||||2012-09-26|2012-09-27|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Progression of Diabetic Retinopathy Post Bariatric Surgery (BS)|The Effect of Bariatric Surgery on the Progression of Diabetic Retinopathy|Terminated|||2|Actual|New York University School of Medicine|||1|Investigator has moved to other state.|f||||f||||||||||2018-05-31 22:22:04.810405|2018-05-31 22:22:04.810405
NCT01393860|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-13|2011-07-12|2011-07-13|Estimate|||||||2011-07-13|2011-07-14|Estimate|December 2010||2010-12-31|July 2011|2011-07-31||||June 2011|Actual|2011-06-30||Observational|||Real-world Aliskiren Use in Diabetic Patients|Aliskiren Use in Diabetic Patients: Who's Using it, Why, and How is it Working ?|Completed|||200|Anticipated|Novartis|||1||f||||||||||||||2018-05-31 22:22:04.874033|2018-05-31 22:22:04.874033
NCT01393847|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-06-30|2011-07-12|2011-07-13|Estimate|||||||2017-06-30|2017-07-02|Actual|June 17, 2011||2011-06-17|December 5, 2013|2013-12-05|December 5, 2013||2013-12-05|||||Observational|||Nitric Oxide and Sickle Cell Pain|Biochemical and Genetic Mechanisms for Etiology of Sickle Cell Pain|Terminated|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:22:04.9385|2018-05-31 22:22:04.9385
NCT01393834|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-02-20|2011-07-12|2011-07-13|Estimate|||||||2013-02-20|2013-02-22|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Delayed Umbilical Cord Clamping Versus Cord Milking in Preterm Neonate|Delayed Umbilical Cord Clamping Versus Cord Milking in Preterm Neonate - a Randomized, Controlled Trial|Terminated||N/A|2|Actual|Medstar Health Research Institute||3||difficulty with enrollment|f||||t||||||||||2018-05-31 22:22:05.010338|2018-05-31 22:22:05.010338
NCT01393821|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2018-02-05|2011-07-12|2011-07-13|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab|A Randomized, Double-Blind Placebo-Controlled Exploration of a Topical Menadione-Containing Lotion to the Face for Prevention and Palliation of Epidermal Growth Factor Receptor Inhibitor-Induced Cutaneous Discomfort and Psychological Distress|Active, not recruiting||N/A|40|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:22:05.13792|2018-05-31 22:22:05.13792
NCT01037465|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2017-03-08|2009-12-21|2009-12-23|Estimate|||||||2017-03-08|2017-03-10|Actual|September 2008||2008-09-30|March 2017|2017-03-31|March 26, 2016|Actual|2016-03-26|December 2015|Actual|2015-12-31||Interventional|||ROS Signaling in Endothelial Function|ROS Signaling in Endothelial Function|Completed||N/A|72|Actual|Boston University||2|||f||||f|f|f||||||No||2018-06-01 00:14:21.990863|2018-06-01 00:14:21.990863
NCT01393808|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2017-03-02|2011-07-12|2011-07-13|Estimate|||||||2017-03-02|2017-03-03|Actual|September 2011||2011-09-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PROCEED||Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes|A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor Therapy|Completed||Phase 2|112|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 22:22:05.433182|2018-05-31 22:22:05.433182
NCT01393795|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-02-19|2011-07-12|2011-07-13|Estimate|||||||2013-02-19|2013-02-20|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients|A Double-blind, Randomized, Crossover Clinical Study to Assess the Efficacy of Qutenza® for the Reduction of Site Pain Caused by Continuous Subcutaneous Infusion of Remodulin®, in Pulmonary Arterial Hypertension Patients|Completed||Phase 2|11|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 22:22:05.644598|2018-05-31 22:22:05.644598
NCT01393782|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2014-02-18|2011-07-12|2011-07-13|Estimate|||||||2014-02-18|2014-02-19|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ATHOS||Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study|Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study|Completed||Phase 1|20|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 22:22:05.78624|2018-05-31 22:22:05.78624
NCT01393769|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2016-08-01|2011-07-12|2011-07-13|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage|An Open, Single-centre Non-randomized Phase II Clinical Trial on Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage|Terminated||Phase 2|5|Actual|Hospital Sant Joan de Deu||1||Only 5 subjects could be enrolled. Sample of 25 pat. not be achieved (rare disease).|f||||f||||||||||2018-05-31 22:22:05.850947|2018-05-31 22:22:05.850947
NCT01393756|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2016-02-16|2011-07-12|2011-07-13|Estimate|||||||2016-02-16|2016-02-17|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|July 2013|Actual|2013-07-31||Interventional|R2-CHOP2||Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma|A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma|Completed||Phase 2|80|Actual|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 22:22:05.943196|2018-05-31 22:22:05.943196
NCT01393743|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|2015-05-29||2017-07-27|2011-07-12|2011-07-13|Estimate|2015-12-07|2016-01-11|Estimate||||2017-07-27|2017-08-28|Actual|September 2011||2011-09-30|July 2017|2017-07-31|November 2015|Actual|2015-11-30|May 2014|Actual|2014-05-31||Interventional||The Core Study Full Analysis Set (FAS) and Extension Phase FAS included participants who were randomized to study drug, received at least 1 dose of study drug in that phase, had baseline and any postbaseline seizure frequency data during the Randomization Phase, and at least 1 observation of valid seizure diary data during treatment duration.|A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures|Completed||Phase 3|163|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:22:06.067524|2018-05-31 22:22:06.067524
NCT01393730|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2017-03-17||2018-02-16|2011-07-12|2011-07-13|Estimate|2017-05-12|2017-06-14|Actual||||2018-02-16|2018-03-15|Actual|September 2011||2011-09-30|February 2018|2018-02-28|March 15, 2017|Actual|2017-03-15|January 2016|Actual|2016-01-31||Interventional|||Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer|Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression|Completed||Phase 2|40|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No|This will not be done.|2018-05-31 22:22:07.968689|2018-05-31 22:22:07.968689
NCT01393717|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2018-01-31||2018-03-28|2011-07-12|2011-07-13|Estimate|2018-03-28|2018-04-26|Actual||||2018-03-28|2018-04-26|Actual|October 20, 2011|Actual|2011-10-20|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma|A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation|Completed||Phase 2|57|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 22:22:08.443114|2018-05-31 22:22:08.443114
NCT01393704|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2016-11-28||2018-01-18|2011-07-12|2011-07-13|Estimate|2017-04-07|2017-04-10|Actual||||2018-01-18|2018-02-15|Actual|July 2011||2011-07-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial|Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial|Completed||Phase 4|152|Actual|Brigham and Women's Hospital|Due to practice pattern differences among sites, there was some missing data for the change in hematocrit variable, and a smaller amount of data missing for suction canister blood loss calculation.|2|||f||||f||||||||No||2018-05-31 22:22:08.97234|2018-05-31 22:22:08.97234
NCT01393691|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2015-07-08|2011-07-12|2011-07-13|Estimate|||||||2015-07-08|2015-07-09|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Clinical Research Studying Interventions for Nighttime Fears in Preschool Children|Interventions for Nighttime Fears in Preschool Children: Assessment of Predictors and Outcomes|Completed||N/A|90|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 22:22:09.294415|2018-05-31 22:22:09.294415
NCT01393678|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|November 1997||1997-11-30|July 2011|2011-07-31|May 1998|Actual|1998-05-31|March 1998|Actual|1998-03-31||Interventional|||Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease|A Multicenter, Randomized, Double-blind, 2 Parallel Group, Phase 3 Study of PENNEL Capsule in Chronic Liver Disease|Completed||Phase 3|220|Actual|PharmaKing||2|||f||||t||||||||||2018-05-31 22:22:09.364632|2018-05-31 22:22:09.364632
NCT01393665|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|December 1996||1996-12-31|July 2011|2011-07-31|October 1997|Actual|1997-10-31|May 1997|Actual|1997-05-31||Interventional|||Study to Evaluate Efficacy, Safety and Tolerability of PENNEL Capsule in the Patients With Chronic Liver Disease|Multicenter, Randomized, Placebo-Controlled, Double-blind Phase 2 Study to Evaluate the Short-term Efficacy, Safety and Tolerance and to Find an Optimal Dosage of the PENNEL Capsule for the Patients With Chronic Liver Disease|Completed||Phase 2|88|Actual|PharmaKing||2|||f||||t||||||||||2018-05-31 22:22:09.434081|2018-05-31 22:22:09.434081
NCT01393652|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2011-09-30|2011-07-11|2011-07-13|Estimate|||||||2011-09-30|2011-10-03|Estimate|May 2011||2011-05-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SINGLE DOSE||Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679|A Phase I, Randomized, Placebo-Controlled, Dose Escalating Cross Over Study To Evaluate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of PF-05105679 Under Fasted Conditions In Healthy Volunteers|Completed||Phase 1|32|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:22:09.503821|2018-05-31 22:22:09.503821
NCT01393639|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2014-08-12|2011-07-11|2011-07-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis|A Phase 2, Randomized, Double Blind Assessment Of Efficacy And Safety Of PF-04171327 (1, 5, 10, 15 Mg Dose, Daily) Compared To 5 Mg And 10 Mg Prednisone Daily And Placebo Daily In Subjects With Rheumatoid Arthritis Over An 8 Week Period Followed By A 4 Week Period Of Tapering Of Study Drug|Completed||Phase 2|323|Actual|Pfizer||7|||f||||t||||||||||2018-05-31 22:22:09.627641|2018-05-31 22:22:09.627641
NCT01393626|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2016-02-22||2017-03-17|2011-07-11|2011-07-13|Estimate|2017-03-17|2017-04-28|Actual||||2017-03-17|2017-04-28|Actual|October 2011||2011-10-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional||Safety analysis set - included all participants who received at least one dose of study medication.|A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease|Completed||Phase 2|280|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:22:10.129586|2018-05-31 22:22:10.129586
NCT01393613|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2015-08-11|2015-02-27|2015-10-26|2011-07-11|2011-07-13|Estimate|2015-10-26|2015-11-26|Estimate|2015-02-27|2015-03-19|Estimate|2015-10-26|2015-11-26|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|BEACON||Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed-dose OPC-34712 in the Treatment of Adults With Acute Schizophrenia|Completed||Phase 3|674|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||f||||||||||2018-05-31 22:22:11.82004|2018-05-31 22:22:11.82004
NCT01393600|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2017-05-11|2013-04-30|2017-07-14|2011-07-11|2011-07-13|Estimate|2017-07-14|2017-08-10|Actual|2013-04-30|2013-05-08|Estimate|2017-07-14|2017-08-10|Actual|August 2011||2011-08-31|July 2017|2017-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Cross-Over Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 2|37|Actual|Neurocrine Biosciences||2|||f||||f||||||||||2018-05-31 22:22:12.910663|2018-05-31 22:22:12.910663
NCT01393587|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2012-07-17|2011-07-12|2011-07-13|Estimate|||||||2012-07-17|2012-07-18|Estimate||||July 2011|2011-07-31||||||||Interventional|||A New Exogenous Marker for Diagnosis of Oxidative Stress During Laproscopic Surgery|A New Exogenous Marker for Diagnosis of Oxidative Stress During Laproscopic Surgery|Unknown status|Not yet recruiting|N/A|||Western Galilee Hospital-Nahariya||1|||f||||||||||||||2018-05-31 22:22:13.243151|2018-05-31 22:22:13.243151
NCT01393574|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|June 2011||2011-06-30|July 2011|2011-07-31||||June 2012|Anticipated|2012-06-30||Interventional|||Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties|Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties|Unknown status|Recruiting|Phase 4|46|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 22:22:13.358813|2018-05-31 22:22:13.358813
NCT01393561|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2016-10-27|2011-07-12|2011-07-13|Estimate|||||||2016-10-27|2016-10-31|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis|Multicenter Clinical Trial, Phase III, Randomized, Double-blind, Placebo Controlled, Comparative for Evaluate the Efficacy and Safety of Fixed Dose Combination of Brompheniramine Maleate + Phenylephrine Chlorhydrate for the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis (Common Cold) and Allergic Reactions, in Patients Over 12 Years Old|Completed||Phase 3|167|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f||||||||||2018-05-31 22:22:13.691533|2018-05-31 22:22:13.691533
NCT01393548|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2017-01-12|2011-07-12|2011-07-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis|Multicenter, Phase III, Randomized, Open, Parallel, Comparative to Evaluate the Efficacy and Safety of the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis and Allergic Reactions, in Pediatric Patients|Completed||Phase 3|879|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f||||||||||2018-05-31 22:22:13.792846|2018-05-31 22:22:13.792846
NCT01393535|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-11|2011-07-11|2011-07-13|Estimate|||||||2011-07-11|2011-07-13|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Observational|||Study of the Relationship Between Serum Adiponectin and Clinical Prognosis in Patients Undergoing Cardiac Surgery|Study of the Relationship Between Serum Adiponectin and Clinical Prognosis in Patients Undergoing Cardiac Surgery|Unknown status|Not yet recruiting||800|Anticipated|Xijing Hospital|||||f||||t||||||||||2018-05-31 22:22:14.086149|2018-05-31 22:22:14.086149
NCT01393522|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-12-16|2011-07-12|2011-07-13|Estimate|||||||2013-12-16|2013-12-18|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Milnacipran for Migraine Pain|A Randomized Double Blind Placebo Control Trial of Milnacipran for Migraine Pain|Completed||N/A|37|Actual|Mercy Research||2|||f||||f||||||||||2018-05-31 22:22:14.158488|2018-05-31 22:22:14.158488
NCT01393509|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-09|||2018-02-06|2011-07-12|2011-07-13|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2011|Actual|2011-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies|The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|47|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:22:14.265083|2018-05-31 22:22:14.265083
NCT01344928|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate||||April 2011|2011-04-30||||||||Interventional|HITPET||The Effects of Short-time High-intensity Interval Training on Tissue Glucose and Fat Metabolism in Healthy Subjects and Patients With Type 2 Diabetes||Unknown status|Recruiting|N/A|||Turku University Hospital||2|||f||||f||||||||||2018-05-31 22:39:41.438572|2018-05-31 22:39:41.438572
NCT01393496|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2018-05-09|2011-07-12|2011-07-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 2011||2011-07-31|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|April 30, 2017|Actual|2017-04-30||Interventional|ETTNO||Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants|Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants (ETTNO)- a Blinded Randomized Controlled Multicenter Trial|Active, not recruiting||Phase 4|920|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 22:22:14.394942|2018-05-31 22:22:14.394942
NCT01393483|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-08-31|2011-07-12|2011-07-13|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2011|Actual|2011-03-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)|A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)|Recruiting|||400|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples Without DNA|"~     tissue and serum~   "|||2018-05-31 22:22:14.53914|2018-05-31 22:22:14.53914
NCT01393470|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2014-05-14|2011-07-12|2011-07-13|Estimate|||||||2014-05-14|2014-05-15|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|||Evaluation of Long-term HPV Vaccine Efficacy|A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland|Enrolling by invitation|||10000|Anticipated|University of Tampere|||3||f||||f||||||Samples With DNA|"~     Cytological cervical (liquid based and/or conventional) samples. Colposcopy directed cervical~     biopsy samples fixed in formalin.~   "|||2018-05-31 22:22:14.682608|2018-05-31 22:22:14.682608
NCT01393457|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2018-02-23||2018-03-23|2011-07-12|2011-07-13|Estimate|2018-03-23|2018-03-29|Actual||||2018-03-23|2018-03-29|Actual|June 2011||2011-06-30|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Cognitive Remediation for Cocaine Dependence|Cognitive-enhancing DA Medications for Cocaine Dependence|Completed||Phase 2|119|Actual|The University of Texas Health Science Center, Houston||4|||f||||t||||||||||2018-05-31 22:22:14.813832|2018-05-31 22:22:14.813832
NCT01393444|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2016-08-17||2016-10-18|2011-07-11|2011-07-13|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All individuals were English speaking, with a disability of at least one hand/arm, but no other health issues which would interfere with or be made worse by study participation.|ECoG Direct Brain Interface for Individuals With Upper Limb Paralysis|Acute Electrocorticography (ECoG) Direct Brain Interface for Individuals With Upper Limb Paralysis|Completed||N/A|6|Actual|University of Pittsburgh||1|||f||||t||||||||Yes|Study sponsors, as well as the FDA, will have access to research data and documents in order to monitor the integrity of the study.|2018-05-31 22:22:15.37453|2018-05-31 22:22:15.37453
NCT01393431|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-08-03|2011-07-11|2011-07-13|Estimate|||||||2011-08-03|2011-08-04|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Futility of Exhaled Breath Condensate pH Measurements in Ventilated Patients in Intensive Care Unit (ICU)|Exhaled Breath Condensate pH in Mechanically Ventilated Patients|Terminated|||34|Actual|Universidad Nacional de Rosario|||1|"IRB recommended to stop the trial becasue none of the 4 procedures showed a predictive value~   for VAP, duration of MV or mortality."|f||||t||||||||||2018-05-31 22:22:15.629114|2018-05-31 22:22:15.629114
NCT01393418|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-12-14|2011-07-12|2011-07-13|Estimate|||||||2016-12-14|2016-12-15|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|EPO||Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery|EPO: A Renal Biomarker After Cardiac Surgery|Completed|||80|Actual|University of Michigan|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 22:22:15.952164|2018-05-31 22:22:15.952164
NCT01393405|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2018-01-09||2018-03-19|2011-07-12|2011-07-13|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|February 2012|Actual|2012-02-29|March 2018|2018-03-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|Merit-UC||Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis|Randomized, Double Blind, Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis (MEthotrexate Response In Treatment of UC - MERIT-UC)|Completed||Phase 2|179|Actual|University of North Carolina, Chapel Hill|There were no limitations for this trial|2|||f||||t||||||||||2018-05-31 22:22:16.293433|2018-05-31 22:22:16.293433
NCT01393392|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-05-05|2011-07-11|2011-07-13|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Developing a Smoking Cessation Intervention for Methadone Maintained Smokers|Developing a Smoking Cessation Intervention for Methadone Maintained Smokers|Completed||Phase 1|91|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 22:22:16.729343|2018-05-31 22:22:16.729343
NCT01393379|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2015-06-19|2011-07-12|2011-07-13|Estimate|||||||2015-06-19|2015-06-22|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||ELVR in PH Patients With Severe Emphysema|Effect of Endoscopic Lung Volume Reduction (ELVR) on Pulmonary Hypertension (PH) in Patients With Severe Emphysema and Pulmonary Hypertension|Completed|||10|Actual|Heidelberg University|||||f||||f||||||||||2018-05-31 22:22:16.842077|2018-05-31 22:22:16.842077
NCT01393366|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2017-02-21|2011-07-11|2011-07-13|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2011||2011-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|FORTIS||Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy|Facing Obstacles to RDI(Relative Dose Intensity)Through Telephone Intervention Strategy|Completed||N/A|60|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 22:22:16.914805|2018-05-31 22:22:16.914805
NCT01393353|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2014-12-12|2011-07-11|2011-07-13|Estimate|||||||2014-12-12|2014-12-15|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Cognitive Training in Parkinson's Disease|A Computerized, Multidimensional and Disease Specific Training of Cognition in Patients With M. Parkinson|Completed||N/A|39|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 22:22:17.013703|2018-05-31 22:22:17.013703
NCT01393340|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-11|2011-07-11|2011-07-13|Estimate|||||||2011-07-11|2011-07-13|Estimate|December 2006||2006-12-31|July 2011|2011-07-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma|Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma|Completed||Phase 2|23|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:22:17.073513|2018-05-31 22:22:17.073513
NCT01393327|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-06-19|2011-07-12|2011-07-13|Estimate|||||||2015-06-19|2015-06-22|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Influence of Respiratory and Exercise Therapy on Oxygen Uptake and Right Heart Function in CTEPH Patients After PEA|Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Heart Function in Chronic Thromboembolic Pulmonary Hypertension After Thromboendarterectomy|Unknown status|Recruiting|Phase 3|90|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 22:22:17.206677|2018-05-31 22:22:17.206677
NCT01393314|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Trial of Telemonitoring in Adults With Heart Failure|A Randomized Controlled Trial of Telemonitoring in Older Adults With Heart Failure|Completed||N/A|105|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 22:22:17.288355|2018-05-31 22:22:17.288355
NCT01393301|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-04-25|2011-07-12|2011-07-13|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2011||2011-10-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Project Quit||Integrated Treatment for Smoking Cessation & Anxiety in People With HIV|Integrated Treatment for Smoking Cessation & Anxiety in People With HIV|Completed||N/A|72|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:22:17.364437|2018-05-31 22:22:17.364437
NCT01393288|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2013-11-12|2011-07-12|2011-07-13|Estimate|||||||2013-11-12|2013-11-14|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|November 2015||2015-11-30|November 2014||2014-11-30||Interventional|PDNVF||Developing Individualized Strategies to Prevent Nausea and Vomiting|Developing Individualized Strategies to Prevent Nausea and Vomiting|Withdrawn||N/A|0|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 22:22:17.463958|2018-05-31 22:22:17.463958
NCT01393275|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-11-05|2011-07-12|2011-07-13|Estimate|||||||2011-11-05|2011-11-08|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Interventional|||Effects of Exercise Intervention and Rehabilitation Exercise Intervention in Patients With Type 2 Diabetes|Effects of Exercise Intervention in Patients With Type 2 Diabetes - Strength Endurance Exercise Intervention Versus Combination of Strength Endurance Exercise Intervention and Rehabilitation Exercise Intervention|Completed||N/A|68|Actual|University of Giessen||2|||f||||f||||||||||2018-05-31 22:22:17.57257|2018-05-31 22:22:17.57257
NCT01393262|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-12-07|2011-07-12|2011-07-13|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2009||2009-11-30|December 2016|2016-12-31||||January 2018|Anticipated|2018-01-31||Observational|||Orthopaedic Hand Service Data Repository|Orthopaedic Hand Service Data Repository|Enrolling by invitation|||2000|Anticipated|Massachusetts General Hospital|||2||f||||t||||||||||2018-05-31 22:22:17.718607|2018-05-31 22:22:17.718607
NCT01393249|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-12-08|2011-07-12|2011-07-13|Estimate|||||||2016-12-08|2016-12-09|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|AAP2008||PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL|PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL|Completed|||31|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 22:22:17.788258|2018-05-31 22:22:17.788258
NCT01393236|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-12-13|2011-07-12|2011-07-13|Estimate|||||||2011-12-13|2011-12-14|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Heart Rate Variability During Sleep After Fast-track Surgery||Completed|||10|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 22:22:17.873553|2018-05-31 22:22:17.873553
NCT01393223|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-09-11|2011-07-12|2011-07-13|Estimate|||||||2017-09-11|2017-09-12|Actual|April 2015||2015-04-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome|A Single-Center, Double-Blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-08 With Placebo in Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)|Recruiting||Phase 2|36|Anticipated|Lipella Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 22:22:17.950265|2018-05-31 22:22:17.950265
NCT01393210|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-03-29|2011-07-12|2011-07-13|Estimate|||||||2016-03-29|2016-03-30|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Beta-glucan and Insulin Sensitivity in Obese Humans|The Influence of Beta-glucan 1.3D-1.6D, Added to the Low-calorie Diet, on Insulin Sensitivity and the Expression of Selected Proinflammatory Cytokines in Adipose Tissue and Peripheral Blood Mononuclear Cells in Obese Humans|Completed||N/A|40|Actual|Polish Academy of Sciences||2|||f||||f||||||||No||2018-05-31 22:22:18.071349|2018-05-31 22:22:18.071349
NCT01393197|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2015-12-17|2011-07-12|2011-07-13|Estimate|||||||2015-12-17|2015-12-18|Estimate|March 2011||2011-03-31|November 2010|2010-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|TACE-KMG||Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)|Clinical Trial of Transcatheter Arterial Chemoembolization (TACE)With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas|Unknown status|Recruiting|N/A|2480|Anticipated|Tianjin Medical University Cancer Institute and Hospital||4|||f||||f||||||||||2018-05-31 22:22:18.177558|2018-05-31 22:22:18.177558
NCT01393184|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Interventional|||Safety and Efficacy Study of Target Therapy Combined With Radiotherapy to Treat Senile Locally Advanced SCCHN|Prospective, Randomized, Controlled, Phase II，Multiple Centered Clinical Trial of Nimotuzumab Combined With Radiotherapy for Senile Locally Advanced SCCHN|Unknown status|Enrolling by invitation|Phase 2|92|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 22:22:18.264775|2018-05-31 22:22:18.264775
NCT01393171|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2018-05-24|2011-07-12|2011-07-13|Estimate|||||||2018-05-24|2018-05-25|Actual|October 2005|Actual|2005-10-31|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|December 2015|Actual|2015-12-31||Interventional|OARS||Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis|Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis|Completed||N/A|100|Actual|Kaiser Permanente||3|||f||||f||||||||No||2018-05-31 22:22:18.348152|2018-05-31 22:22:18.348152
NCT01393158|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate||||April 2010|2010-04-30||||||||Interventional|||Apremilast for Atopic Dermatitis|Apremilast for Atopic Dermatitis - A Pilot Study in Adults|Completed||N/A|10|Actual|Oregon Health and Science University||1|||f||||||||||||||2018-05-31 22:22:18.464233|2018-05-31 22:22:18.464233
NCT01392794|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-11|2011-07-11|2011-07-13|Estimate|||||||2011-07-11|2011-07-13|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet|Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion Without Water|Completed||Phase 1|36|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:22:27.084999|2018-05-31 22:22:27.084999
NCT01393145|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2017-02-14|2011-07-12|2011-07-13|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2011||2011-08-31|February 2017|2017-02-28|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD|Multicenter, Phase III, Randomized, Open Label Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f||||||||||2018-05-31 22:22:18.594379|2018-05-31 22:22:18.594379
NCT01393132|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2015-12-08||2015-12-21|2011-07-12|2011-07-13|Estimate|2015-12-21|2015-12-23|Estimate||||2015-12-21|2015-12-23|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye|Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye|Completed||Phase 2|9|Actual|Michigan Cornea Consultants, PC||2|||f||||f||||||||||2018-05-31 22:22:18.782835|2018-05-31 22:22:18.782835
NCT01393119|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2014-04-23|2011-07-12|2011-07-13|Estimate|||||||2014-04-23|2014-04-24|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase II, Dose Finding Study of GTx-758|Phase II, Open-label, Loading and Maintenance Dose Finding Study of GTx-758 in Men With Prostate Cancer|Terminated||Phase 2|43|Actual|GTx||4||FDA Clinical Hold|f||||f||||||||||2018-05-31 22:22:20.071786|2018-05-31 22:22:20.071786
NCT01393106|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2015-08-28||2015-11-20|2011-07-11|2011-07-13|Estimate|2015-11-20|2015-12-24|Estimate||||2015-11-20|2015-12-24|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Intent-to-treat (ITT) Analysis Set: participants who received at least one dose of study drug.|Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma|A Phase 2 Study to Assess the Efficacy and Safety of GS-1101 (CAL-101) in Patients With Relapsed or Refractory Hodgkin Lymphoma|Completed||Phase 2|25|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|1|||f||||f||||||||||2018-05-31 22:22:20.223818|2018-05-31 22:22:20.223818
NCT01393093|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-06-09|2011-07-12|2011-07-13|Estimate|||||||2017-06-09|2017-06-12|Actual|March 2011||2011-03-31|November 2010|2010-11-30|December 2018|Anticipated|2018-12-31|November 2016|Actual|2016-11-30||Interventional|TACE-KMG||Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas|Clinical Trial of Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas|Recruiting||N/A|2840|Anticipated|Tianjin Medical University Cancer Institute and Hospital||4|||f||||f||||||||||2018-05-31 22:22:20.849675|2018-05-31 22:22:20.849675
NCT01393080|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-02-14|2011-07-12|2011-07-13|Estimate|||||||2016-02-14|2016-02-17|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|NSCLC||Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients|The Study of Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for Patient With the Advanced Non-small Cell Lung Cancer( NSCLC)|Unknown status|Recruiting|N/A|160|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 22:22:22.570685|2018-05-31 22:22:22.570685
NCT01393067|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2016-08-27|2011-07-12|2011-07-13|Estimate|||||||2016-08-27|2016-08-30|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||cSEMS vs. NEPS in Stricture of Biliary Anastomosis After Liver Transplantation|Comparison of Use of Covered, Self-expandable Metal Stents (cSEMS) and Non-expandable Plastic Stents (NEPS) in Temporary Endoscopic Treatment of Stenosis of the Bilio-biliary Anastomosis After Liver Transplantation|Completed||N/A|60|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 22:22:23.27167|2018-05-31 22:22:23.27167
NCT01393054|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Effect of Nigella Sativa Seed Extract on the Blood Pressure of Elderly With Hypertension|Effect of Nigella Sativa Seed Extract on the Blood Pressure of Elderly With Hypertension|Unknown status|Recruiting|Phase 3|76|Anticipated|Indonesia University|||||f||||t||||||||||2018-05-31 22:22:23.608515|2018-05-31 22:22:23.608515
NCT01393041|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2012-08-10|2011-07-11|2011-07-13|Estimate|||||||2012-08-10|2012-08-13|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||St. Jude Medical Angio-Seal VIP Vascular Closure Device|Clinical Study of the St. Jude Medical Angio-Seal VIP Vascular Closure Device Following Diagnostic and/or Interventional Endovascular Procedures|Completed||N/A|50|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 22:22:23.746796|2018-05-31 22:22:23.746796
NCT01393028|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2014-11-11|2011-07-12|2011-07-13|Estimate|||||||2014-11-11|2014-11-13|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CRESCENT||Computed Tomography Versus Exercise Testing in Suspected Coronary Artery Disease|Computed Tomography Versus Exercise Testing in Suspected Coronary Artery Disease|Terminated||N/A|350|Actual|Erasmus Medical Center||2||Insufficient funds|f||||t||||||||||2018-05-31 22:22:23.905169|2018-05-31 22:22:23.905169
NCT01393015|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|July 2011||2011-07-31|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygentherapy in Patients With COPD Exacerbation|Using a Closed-loop System for Oxygen Delivery (FreeO2) to Optimize Oxygentherapy in Patients With Exacerbations of Chronic Obstructive Pulmonary Disease.|Unknown status|Recruiting|N/A|50|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f||||f||||||||||2018-05-31 22:22:24.032655|2018-05-31 22:22:24.032655
NCT01393002|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-10-17|2011-07-12|2011-07-13|Estimate|||||||2013-10-17|2013-10-18|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Observational|IFI_ICU||Perception and Prevalence of Fungal Infections in Berlin - Brandenburg|Web-based Structured Survey of Retrospective Data of Invasive Mycosis in Intensive Care Patients in Berlin - Brandenburg|Completed|||25|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 22:22:24.186223|2018-05-31 22:22:24.186223
NCT01392989|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-12-05|2011-07-11|2011-07-13|Estimate|||||||2016-12-05|2016-12-06|Estimate|March 2011||2011-03-31|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders|Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders|Active, not recruiting||Phase 2|44|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 22:22:24.317882|2018-05-31 22:22:24.317882
NCT01392976|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2014-08-13|2011-07-11|2011-07-13|Estimate|||||||2014-08-13|2014-08-15|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|April 2013|Actual|2013-04-30|October 2011|Actual|2011-10-31||Interventional|||Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors|A Phase I, Open-Label, Two-stage, Randomized, Crossover, Comparative Pharmacokinetic and Safety Study of Two Formulations of CO-1.01 for Injection in Patients With Advanced Solid Tumors|Completed||Phase 1|17|Actual|Clovis Oncology, Inc.||2|||f||||f||||||||||2018-05-31 22:22:24.395676|2018-05-31 22:22:24.395676
NCT01392963|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2014-01-22|2011-07-11|2011-07-13|Estimate|||||||2014-01-22|2014-01-23|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|November 2012|Actual|2012-11-30||Interventional|||The Treatment of Depression With Botulinum Type A Toxin|The Treatment of Depression With Botulinum Type A Toxin (Botox): A Randomized, Double Blind, Crossover Study|Completed||Phase 2|30|Actual|Seton Healthcare Family||2|||f||||t||||||||||2018-05-31 22:22:24.473227|2018-05-31 22:22:24.473227
NCT01392950|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-27|2011-07-11|2011-07-13|Estimate|||||||2011-07-27|2011-07-29|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||Clinical Study of Clariti Monthly Contact Lens|Clinical Performance of the Clariti Monthly Contact Lens for Daily Wear|Completed||N/A|90|Actual|Sauflon Pharmaceuticals Ltd||2|||f||||f||||||||||2018-05-31 22:22:24.597272|2018-05-31 22:22:24.597272
NCT01392937|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-11|2011-07-11|2011-07-13|Estimate|||||||2011-07-11|2011-07-13|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||Clinical Performance of All-in-One Light Multi-purpose for Silicone Hydrogel Contact Lenses|The Clinical Performance of the All-in-One Light Multi-purpose Care Regimen for Silicone Hydrogel Contact Lenses|Completed||N/A|257|Actual|Sauflon Pharmaceuticals Ltd||2|||f||||f||||||||||2018-05-31 22:22:24.682599|2018-05-31 22:22:24.682599
NCT01392924|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2014-12-02|2011-07-11|2011-07-13|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|February 2012|Actual|2012-02-29||Interventional|||Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors|An Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of SAR245408 Administered Orally Daily in Patients With Solid Tumors|Completed||Phase 1|10|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:22:25.916628|2018-05-31 22:22:25.916628
NCT01392911|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2014-06-06|2011-07-12|2011-07-13|Estimate|||||||2014-06-06|2014-06-09|Estimate|June 2011||2011-06-30|June 2014|2014-06-30||||September 2014|Anticipated|2014-09-30||Interventional|HR1||Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB|A Phase IIA Dose Ranging Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Higher Doses of Rifampicin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|Unknown status|Active, not recruiting|Phase 2|128|Anticipated|Radboud University||9|||f||||t||||||||||2018-05-31 22:22:26.071073|2018-05-31 22:22:26.071073
NCT01392898|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2013-08-01|2011-07-12|2011-07-13|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2012||2012-02-29|July 2011|2011-07-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|ELEGANT||Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes|The Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)|Unknown status|Active, not recruiting|N/A|50|Actual|Radboud University||2|||f||||||||||||||2018-05-31 22:22:26.157785|2018-05-31 22:22:26.157785
NCT01392885|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2018-01-16|2011-07-12|2011-07-13|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2011||2011-07-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2016|Actual|2016-06-30||Observational|PEHP||Brain Health and Exercise in Schizophrenia|Brain Health: Effects of Exercise on Hippocampal Volume and Memory Deficits in Persons With Schizophrenia|Enrolling by invitation|||60|Anticipated|BC Mental Health and Addictions Research Institute|||||f||||f||||||Samples With DNA|"~     No Biospecimens to be retained~   "|||2018-05-31 22:22:26.236189|2018-05-31 22:22:26.236189
NCT01392872|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-07-28|2011-07-12|2011-07-13|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2009||2009-11-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CoQualSEP||Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant|Evaluation of Cognitive Disability and Quality of Life of Patients Suffering From Multiple Scleroses and Treat With Immunosuppressant|Completed||N/A|48|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 22:22:26.304763|2018-05-31 22:22:26.304763
NCT01392859|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|June 2011||2011-06-30|July 2011|2011-07-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Characterization of the Role of Histamine in Children With Asthma|Characterization of the Role of Histamine in Children With Asthma|Unknown status|Recruiting|N/A|204|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-05-31 22:22:26.405258|2018-05-31 22:22:26.405258
NCT01392846|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-12-19|2011-07-12|2011-07-13|Estimate|||||||2017-12-19|2017-12-20|Actual|July 2011||2011-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||The IRIS-Resolute Integrity (IRIS-Integrity)|Evaluation of Effectiveness and Safety of Resolute Integrity DES in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study (IRIS-Integrity)|Active, not recruiting|||3000|Actual|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:22:26.573968|2018-05-31 22:22:26.573968
NCT01392833|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|December 1999||1999-12-31|March 2011|2011-03-31|January 2008|Actual|2008-01-31|November 2006|Actual|2006-11-30||Interventional|||Steroids and Azathioprine in Advanced IgAN|Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial|Completed||Phase 3|46|Actual|A. Manzoni Hospital||2|||f||||f||||||||||2018-05-31 22:22:26.806946|2018-05-31 22:22:26.806946
NCT01392820|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-11-14|2011-07-12|2011-07-13|Estimate|||||||2011-11-14|2011-11-15|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers|A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers|Completed||Phase 1|48|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:22:26.905053|2018-05-31 22:22:26.905053
NCT01392807|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2014-10-13|2011-07-12|2011-07-13|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function|An Open-label, Single-center Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function Following Administration of a Single Dose of 25mg NKTR-118|Completed||Phase 1|24|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 22:22:26.987424|2018-05-31 22:22:26.987424
NCT01392781|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-12|2011-07-12|2011-07-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|January 2012|Anticipated|2012-01-31|October 2011|Anticipated|2011-10-31||Observational|||Markers and Calculation of Cardiovascular Risk in the Distinct Phenotypes of Polycystic Ovary Syndrome||Unknown status|Recruiting||300|Anticipated|Aristotle University Of Thessaloniki|||4||f||||t||||||Samples Without DNA|"~     blood serum~   "|||2018-05-31 22:22:27.171516|2018-05-31 22:22:27.171516
NCT01392768|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-10-27|2011-07-12|2011-07-13|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|Mozart||Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization|A Double-blind, Phase III, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam as Adjunctive Therapy, in Partial Seizures Control Associated With Refractory Focal Epilepsy|Completed||Phase 3|126|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f||||||||||2018-05-31 22:22:27.283138|2018-05-31 22:22:27.283138
NCT01392755|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-11-01|2011-07-11|2011-07-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers|A Study to Evaluate the Effects of Two Different Meal Types, Omeprazole and Ranitidine on Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Subjects|Completed||Phase 1|32|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:22:27.445534|2018-05-31 22:22:27.445534
NCT01392742|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2015-11-09||2017-03-10|2011-07-11|2011-07-12|Estimate|2015-11-09|2015-12-14|Estimate||||2017-03-10|2017-04-10|Actual|May 31, 2011|Actual|2011-05-31|March 2017|2017-03-31|July 31, 2014|Actual|2014-07-31|July 31, 2014|Actual|2014-07-31||Observational||Intent-to-treat (ITT) population included all screened participants.|An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in HCV-infected Patients Receiving Peginterferon Alfa-2a Plus Ribavirin|Completed|||443|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:22:27.575945|2018-05-31 22:22:27.575945
NCT01392729|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-11-01|2011-07-11|2011-07-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)|An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)|Completed|||40|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:22:27.911714|2018-05-31 22:22:27.911714
NCT01392716|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-11-01|2011-07-11|2011-07-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 1997||1997-10-31|November 2016|2016-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma|An Open-label Study of MabThera on Objective Overall Tumor Response in Treatment-naïve Patients With Non-bulky Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|48|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:22:28.098852|2018-05-31 22:22:28.098852
NCT01392703|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2012-11-05||2013-01-04|2011-07-11|2011-07-12|Estimate|2013-01-04|2013-02-11|Estimate||||2013-01-04|2013-02-11|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations|Open-label, Randomized, 3-period, 3-treatment Crossover, Bioequivalence Study Comparing Dasatinib (BMS-354825) Liquid Formulation and the Dispersed Tablet Formulation Relative to the Reference Tablet Formulation in Health Subjects|Completed||Phase 1|141|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 22:22:28.214659|2018-05-31 22:22:28.214659
NCT01392690|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-27|2011-07-11|2011-07-12|Estimate|||||||2011-07-27|2011-07-28|Estimate|March 2000||2000-03-31|July 2011|2011-07-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|TrucsDeDom||Evaluation of a Primary Prevention Program for Anxiety Disorders Using Story Books|Evaluation of a Primary Prevention Program for Anxiety Disorders Using Story Books|Completed||N/A|73|Actual|Universite du Quebec en Outaouais||2|||f||||f||||||||||2018-05-31 22:22:28.685297|2018-05-31 22:22:28.685297
NCT01392677|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2013-11-05||2014-02-11|2011-07-11|2011-07-12|Estimate|2013-11-05|2013-12-27|Estimate||||2014-02-11|2014-03-12|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of study medication during the 24-week short-term double blind treatment period who have a non-missing baseline value and at least one post-baseline value for at least one efficacy variable to be analyzed at week 24.|Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea|A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea|Completed||Phase 3|311|Actual|AstraZeneca|For participants who did not complete 8 and/or 24 weeks, respectively, last observation carried forward (LOCF) was used for analyses of secondary endpoints. All endpoints were evaluated by excluding data after rescue.|2|||f||||f||||||||||2018-05-31 22:22:28.831589|2018-05-31 22:22:28.831589
NCT01392664|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2016-06-06|2011-07-11|2011-07-12|Estimate|||||||2016-06-06|2016-06-07|Estimate|February 2009||2009-02-28|June 2016|2016-06-30|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Observational|||TVTO Versus TVTFFM for Urinary Stress Incontinence||Completed|||200|Actual|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-05-31 22:22:29.291508|2018-05-31 22:22:29.291508
NCT01392651|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2014-07-02|2011-07-11|2011-07-12|Estimate|||||||2014-07-02|2014-07-03|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Observational|||Tension-free-vaginal-tape-obturator (TVTO) Versus Tension-free-vaginal-tape-Secur (TVTS) for Treatment of SUI|Outcome of Treatment of Women With Urinary Stress Incontinence Treated by Tension-free-vaginal-tape-obturator (TVTO) Compared to Tension-free-vaginal-tape-Secur (TVTS)|Completed|||200|Actual|Western Galilee Hospital-Nahariya|||1||f||||f||||||||||2018-05-31 22:22:29.353859|2018-05-31 22:22:29.353859
NCT01392482|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-09-14|2011-07-11|2011-07-12|Estimate|||||||2012-09-14|2012-09-17|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|IBIS||IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder|IBIS: Italian Burden of Illness on Schizophrenia & Bipolar Disorder|Completed|||751725|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:22:32.199543|2018-05-31 22:22:32.199543
NCT01392638|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2012-10-29|2011-07-10|2011-07-12|Estimate|||||||2012-10-29|2012-10-30|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism|Influence of the Nitric Oxide Synthase T-786C Polymorphism on the Response to Acute Inhibition of Phosphodiesterase 5 in Resistant Hypertension|Completed||N/A|120|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 22:22:29.428417|2018-05-31 22:22:29.428417
NCT01392625|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2017-08-03||2018-01-19|2011-07-11|2011-07-12|Estimate|2018-01-19|2018-02-15|Actual||||2018-01-19|2018-02-15|Actual|May 19, 2011|Actual|2011-05-19|January 2018|2018-01-31|August 28, 2017|Actual|2017-08-28|August 28, 2016|Actual|2016-08-28||Interventional|PoseidonDCM||PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)|A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy.|Completed||Phase 1/Phase 2|37|Actual|University of Miami||2|||f||||t|t|f||||||Undecided||2018-05-31 22:22:29.563565|2018-05-31 22:22:29.563565
NCT01392612|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2011-07-13|2011-07-11|2011-07-12|Estimate|||||||2011-07-13|2011-07-14|Estimate|November 2006||2006-11-30|July 2011|2011-07-31|July 2007|Actual|2007-07-31|February 2007|Actual|2007-02-28||Interventional|||Erythropoietin and Platelet Activation Markers|The Effect of Erythropoietin on Platelet Activation Markers: a Prospective Study in Healthy Volunteers|Completed||Phase 4|12|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 22:22:30.280784|2018-05-31 22:22:30.280784
NCT01392599|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|October 2013|Anticipated|2013-10-31|January 2013|Anticipated|2013-01-31||Interventional|||Surgical Treatment Of Complex Regional Pain Syndrome Type II (CRPS II)|Surgical Treatment of Complex Regional Pain Syndrome Type II (CRPS II) by Regional Subcutaneous Venous Sympathectomy|Unknown status|Recruiting|Phase 3|20|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 22:22:30.366235|2018-05-31 22:22:30.366235
NCT01392586|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2014-02-02|2011-07-11|2011-07-12|Estimate|||||||2014-02-02|2014-02-04|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|SUBMIT||Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer|Systemic Therapy With or Without Up Front Surgery of the Primary Tumor in Breast Cancer Patients With Distant Metastases at Initial presenTation|Terminated||Phase 3|10|Actual|Jeroen Bosch Ziekenhuis||2||due to low accrual rate|f||||t||||||||||2018-05-31 22:22:30.458258|2018-05-31 22:22:30.458258
NCT01392573|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2016-11-23|2012-12-19|2017-12-06|2011-07-11|2011-07-12|Estimate|2016-11-23|2017-01-20|Estimate|2012-12-19|2012-12-24|Estimate|2017-12-06|2017-12-08|Actual|November 28, 2011|Actual|2011-11-28|December 2017|2017-12-31|October 4, 2012|Actual|2012-10-04|October 1, 2012|Actual|2012-10-01||Interventional|DUAL™ II|Full analysis set (FAS) included all randomised subjects except 15 subjects (8 in IDegLira arm and 7 in IDeg arm) that were excluded due to site closure.|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes|A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes|Completed||Phase 3|413|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:22:30.601305|2018-05-31 22:22:30.601305
NCT01392560|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2014-05-16||2014-05-16|2011-07-11|2011-07-12|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Treated Set|Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration|An Open-label 8-week Adjunctive-to-insulin and Renal Mechanistic Pilot Trial of BI 10773 in Type 1 Diabetes Mellitus (the ATIRMA Trial)|Completed||Phase 2|52|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:22:31.053684|2018-05-31 22:22:31.053684
NCT01392547|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2013-09-27|2012-09-20|2017-03-29|2011-07-11|2011-07-12|Estimate|2013-10-08|2013-12-06|Estimate|2012-10-17|2012-10-18|Estimate|2017-03-29|2017-05-15|Actual|July 2011||2011-07-31|February 2015|2015-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|adept™2||Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors|Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors|Completed||Phase 3|72|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:22:31.262011|2018-05-31 22:22:31.262011
NCT01392534|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2012-07-03|2011-07-11|2011-07-12|Estimate|||||||2012-07-03|2012-07-04|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|POTASSIUM||Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting|Evaluation of the Real-life Efficacy and Safety of a Fixed-dose Telmisartan/Hydrochlorothiazide, Including Its Effect on Plasma Potassium and on Glucose and Lipid Metabolism Parameters in Patients With Essential Arterial Hypertension|Completed|||1586|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:22:31.532238|2018-05-31 22:22:31.532238
NCT01392521|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-04-16|2011-07-11|2011-07-12|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer|Phase Ib Trial of the Combination of PI3K Inhibitor BAY 80-6946 and Allosteric-MEK Inhibitor BAY 86-9766 in Subjects With Advanced Cancer|Completed||Phase 1|64|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:22:31.604572|2018-05-31 22:22:31.604572
NCT01392508|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-04-13|2011-07-11|2011-07-12|Estimate|||||||2017-04-13|2017-04-14|Actual|March 2011||2011-03-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|IMPRESSED||IMproved PREdiction of Severe Sepsis in the Emergency Department|Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein (HBP) Assay for Indicating the Presence, or Outcome, of Severe Sepsis (Including Septic Shock), Over 72 Hours, in Patients With Suspected Infection Following Emergency Department Admission.|Completed|||759|Actual|Axis Shield Diagnostics Ltd|||||f||||f||||||Samples With DNA|"~     Plasma (LiHep and citrate)~   "|||2018-05-31 22:22:31.687055|2018-05-31 22:22:31.687055
NCT01392495|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2015-03-24||2015-07-13|2011-07-11|2011-07-12|Estimate|2015-06-16|2015-07-13|Estimate||||2015-07-13|2015-08-10|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)|An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension|Terminated||Phase 3|17|Actual|Novartis||1||"Novartis discontinued the development of imatinib in PAH due to requirement of regulatory~   authorities for additional data to secure marketing approval in PAH."|f||||t||||||||||2018-05-31 22:22:31.753835|2018-05-31 22:22:31.753835
NCT01392469|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-02-20|2011-07-11|2011-07-12|Estimate|||||||2017-02-20|2017-02-23|Actual|April 20, 2011||2011-04-20|February 2017|2017-02-28|December 24, 2012|Actual|2012-12-24|December 24, 2012|Actual|2012-12-24||Interventional|||Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients|A Non-randomized, Multiple Dose, Three Treatment Period, Open-label, Single Sequence, Single Group Study to Evaluate the Pharmacokinetic Effect of Two Doses of QTI571 (Imatinib) on the Co-administered Drugs Sildenafil and Bosentan in Pulmonary Arterial Hypertension (PAH) Patients|Terminated||Phase 3|21|Actual|Novartis||1||"Termination due to not achieving the recruitment target because of change in the development~   program for QTI571 in PAH."|f|||||f|f||||||||2018-05-31 22:22:32.295994|2018-05-31 22:22:32.295994
NCT01392456|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2015-02-02|2011-07-11|2011-07-12|Estimate|||||||2015-02-02|2015-02-04|Estimate|June 2004||2004-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|September 2010|Actual|2010-09-30||Interventional|ROM-OHIP-ED||Validation and Cross-Cultural Adaptation of the Romanian Version of Oral Health Impact Profile in Edentulous Adults|Patient Satisfaction With the Use of Three Different Systems as Retention for Implant Supported Mandibular Overdentures.|Completed||N/A|69|Actual|Concordia Dent Srl||3|||f||||f||||||||||2018-05-31 22:22:32.398755|2018-05-31 22:22:32.398755
NCT01392443|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-10-12|2011-07-11|2011-07-12|Estimate|||||||2017-10-12|2017-10-16|Actual|August 1, 2011|Actual|2011-08-01|October 2017|2017-10-31|November 9, 2017|Anticipated|2017-11-09|November 9, 2017|Anticipated|2017-11-09||Interventional|||Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF|A Multi-national Open-label Phase II Study of the JAK Inhibitor INC424 in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis|Active, not recruiting||Phase 2|120|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:22:32.483814|2018-05-31 22:22:32.483814
NCT01392430|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2012-05-16|2011-07-11|2011-07-12|Estimate|||||||2012-05-16|2012-05-17|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients|Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients Who Had CD4+ Cell Count <200 Cells/mm3 But Undetectable Plasma HIV-1 RNA|Completed||N/A|74|Actual|Chiang Mai University||2|||f||||f||||||||||2018-05-31 22:22:32.587967|2018-05-31 22:22:32.587967
NCT01392417|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-07-02|2011-07-10|2011-07-12|Estimate|||||||2014-07-02|2014-07-03|Estimate|February 2009||2009-02-28|July 2011|2011-07-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Observational|||Anterior Prolift Versus Posterior Prolift for Pelvic Floor Prolapse||Completed|||140|Actual|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-05-31 22:22:32.658517|2018-05-31 22:22:32.658517
NCT01392391|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-10-28|2011-07-11|2011-07-12|Estimate|||||||2016-10-28|2016-11-01|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|JAMMS||Exercise For Sub-acute Stroke Patients in Jamaica|Jamaica and Maryland Mobility in Stroke|Recruiting||Phase 2|150|Anticipated|Baltimore VA Medical Center||2|||f||||t||||||||||2018-05-31 22:22:32.712253|2018-05-31 22:22:32.712253
NCT01392378|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2014-01-10||2014-01-10|2011-07-08|2011-07-12|Estimate|2014-01-10|2014-02-26|Estimate||||2014-01-10|2014-02-26|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®|A Phase 4, Randomized, Open-Label Trial To Assess The Impact Of Prophylactic Antipyretic Medication On The Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations In Healthy Infants|Completed||Phase 4|908|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 22:22:32.977471|2018-05-31 22:22:32.977471
NCT01392365|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-06-12|2011-07-11|2011-07-12|Estimate|||||||2016-06-12|2016-06-14|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Development of a Prediction Model for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease|Development of a Prediction Model for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease|Completed|||117|Actual|Asan Medical Center|||2||f||||f||||||||No||2018-05-31 22:22:37.643802|2018-05-31 22:22:37.643802
NCT01392352|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2016-01-04|2011-07-11|2011-07-12|Estimate|||||||2016-01-04|2016-01-05|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|HYPAZ||HYPAZ: Hypertension Induced by Pazopanib|HYPAZ: An Open-label Investigation Into Hypertension Induced by Pazopanib Therapy|Terminated||Phase 2|31|Actual|Cambridge University Hospitals NHS Foundation Trust||1||Following DMC review, due to slow recruitment of evaluable patients.|f||||t||||||||||2018-05-31 22:22:37.722826|2018-05-31 22:22:37.722826
NCT01392339|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|July 2011|Actual|2011-07-31||Interventional|HIP||Obstructive Sleep Apnea and Genes Expression|Sleep Apnea: Interface Between Basic and Clinical Research|Unknown status|Recruiting|N/A|35|Anticipated|Associacao Fundo de Incentivo a Psicofarmcologia||1|||f||||t||||||||||2018-05-31 22:22:37.799238|2018-05-31 22:22:37.799238
NCT01392326|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2015-10-20||2016-01-05|2011-07-11|2011-07-12|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|FUTURE 1||Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis|Completed||Phase 3|606|Actual|Novartis||3|||f||||t||||||||||2018-05-31 22:22:37.984958|2018-05-31 22:22:37.984958
NCT01392313|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Measurement of Renal Function With Iohexol in Subjects Ingesting Carnitine|Measurement of Glomerular Filtration Rate (GFR) Using Iohexol in Healthy Subjects Taking Creatinine Supplements|Withdrawn||N/A|5|Anticipated|Montefiore Medical Center|||||f||||f||||||||||2018-05-31 22:22:39.300761|2018-05-31 22:22:39.300761
NCT01392300|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2016-01-13|2014-03-19|2016-11-29|2011-07-11|2011-07-12|Estimate|2016-01-13|2016-02-11|Estimate|2014-03-19|2014-04-15|Estimate|2016-11-29|2017-01-16|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|March 2013|Actual|2013-03-31||Interventional|PURE|Safety evaluation set (The subset of all subjects who were exposed to investigational product in the main period)|Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Upper Limb|Completed||Phase 3|317|Actual|Merz Pharmaceuticals GmbH||2|||f||||t||||||||||2018-05-31 22:22:39.467527|2018-05-31 22:22:39.467527
NCT01392287|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2017-01-30|2011-07-11|2011-07-12|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 2010|Actual|2010-05-31|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Treatment Resistant Geriatric Depression in Primary Care|Treatment Resistant Geriatric Depression in Primary Care: Is NAAG (N-Acetylaspartylglutamate), Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS) at 3 Tesla, a Predictor of Treatment Response?|Completed||Phase 1|12|Actual|Mclean Hospital||1|||f||||f||||||||No||2018-05-31 22:22:42.071017|2018-05-31 22:22:42.071017
NCT01392274|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-12-02|2011-07-11|2011-07-12|Estimate|||||||2014-12-02|2014-12-04|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|FOCUS||pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture|pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture|Completed|||121|Actual|Mauna Kea Technologies|||1||f||||f||||||||||2018-05-31 22:22:42.180184|2018-05-31 22:22:42.180184
NCT01392261|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-07-08|2011-07-08|2011-07-12|Estimate|||||||2011-07-08|2011-07-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:22:42.248246|2018-05-31 22:22:42.248246
NCT01392248|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-11-26|2011-07-11|2011-07-12|Estimate|||||||2013-11-26|2013-11-28|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Prediction of Pain After Breast Cancer Surgery With EEG|EEG as a Predictor for Postoperative Pain and the Development of Chronic Postsurgical Pain After Breast Cancer Surgery|Terminated|||4|Actual|Maastricht University Medical Center||||funding and recruiting problems|f||||f||||||||||2018-05-31 22:22:42.299234|2018-05-31 22:22:42.299234
NCT01392235|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2018-04-16|2011-07-11|2011-07-12|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2011||2011-06-30|July 2011|2011-07-31|August 2016|Actual|2016-08-31|April 2015|Actual|2015-04-30||Interventional|||Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)|A Single-arm, Open, Multicenter, Phase II Study of Famitinib as ≥Third Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)|Completed||Phase 2|58|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:22:42.384121|2018-05-31 22:22:42.384121
NCT01392222|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-06-20|2011-07-08|2011-07-12|Estimate|||||||2017-06-20|2017-06-21|Actual|June 2011|Actual|2011-06-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others|Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others|Completed|||21|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 22:22:42.44386|2018-05-31 22:22:42.44386
NCT01392209|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2018-04-04|2011-07-11|2011-07-12|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2011|Actual|2011-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma|A PHASE I DOSE ESCALATION STUDY OF HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY WITH BEVACIZUMAB IN THE TREATMENT OF RECURRENT MALIGNANT GLIOMA|Active, not recruiting||Phase 1|15|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:22:42.537706|2018-05-31 22:22:42.537706
NCT01392196|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-01-30|2011-07-11|2011-07-12|Estimate|||||||2017-01-30|2017-02-01|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|SymplicityHF||Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment Clinical Trial|Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment|Terminated||N/A|39|Actual|Medtronic Vascular||1||"No evidence of a physiological response; no significant safety concerns; post 24-month~   follow-up; Data Monitoring Committee agreed"|f||||t||||||||||2018-05-31 22:22:42.637211|2018-05-31 22:22:42.637211
NCT01392183|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2018-01-03|2011-07-11|2011-07-12|Estimate|||||||2018-01-03|2018-01-05|Actual|October 24, 2012|Actual|2012-10-24|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)|A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma|Active, not recruiting||Phase 2|69|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:22:42.704365|2018-05-31 22:22:42.704365
NCT01392170|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2015-03-31||2015-04-13|2011-07-11|2011-07-12|Estimate|2015-03-31|2015-04-14|Estimate||||2015-04-13|2015-05-04|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pegasys in Patients With Chronic Myeloid Leukemia (CML)|Phase II Study of Pegylated Ifná-2a (Pegasys) in Patients With Chronic Myeloid Leukemia Who Have Minimal Residual Disease While Receiving Therapy With Tyrosine Kinase Inhibitors|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center|Early termination due to slow accrual, no analysis possible.|1||Slow Accrual|f||||f||||||||||2018-05-31 22:22:42.79795|2018-05-31 22:22:42.79795
NCT01392157|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-11-26|2011-07-11|2011-07-12|Estimate|||||||2013-11-26|2013-11-27|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional|||Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector|Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector|Completed||Phase 4|300|Actual|University of Campinas, Brazil||3|||f||||f||||||||||2018-05-31 22:22:42.924936|2018-05-31 22:22:42.924936
NCT01392144|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2013-04-01|2011-07-08|2011-07-12|Estimate|||||||2013-04-01|2013-04-04|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Phase II Evaluation of Exhaled Nitric Oxide (NO)|Phase II Evaluation of Exhaled Nitric Oxide as a Predictive Biomarker for Radiation Pneumonitis|Completed|||36|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 22:22:43.140462|2018-05-31 22:22:43.140462
NCT01392131|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2012-12-11|2011-07-11|2011-07-12|Estimate|||||||2012-12-11|2012-12-12|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)|Study to Evaluate Safety and Therapeutic Efficacy of a Nutritional Supplement 'Oncoxin' in Patients With Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|Clinical Research Organization, Dhaka, Bangladesh||2|||f||||t||||||||||2018-05-31 22:22:43.223625|2018-05-31 22:22:43.223625
NCT01392118|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-10|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|July 2011||2011-07-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|||||Observational|||Recurrent ESBL-producing Enterobacteriaceae Bacteremia: Risk Factor, Molecular Character and Susceptibility Change|Recurrent ESBL-producing Enterobacteriaceae Bacteremia: Risk Factor, Molecular Character and Susceptibility Change|Unknown status|Not yet recruiting||400|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||Samples Without DNA|"~     ESBL strains of E. coli or K. pneumoniae from blood cultures under normal practice~   "|||2018-05-31 22:22:43.307239|2018-05-31 22:22:43.307239
NCT01392105|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|SEED-MSC||Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction|A Randomized, Open-label, Multicenter Trial for the Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction|Completed||Phase 2/Phase 3|80|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:22:43.396693|2018-05-31 22:22:43.396693
NCT01392092|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2018-04-03|2011-07-11|2011-07-12|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2011||2011-07-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|NAC||Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers (NAC)|Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers|Completed|||16|Actual|Wayne State University|||||f||||t||||||||||2018-05-31 22:22:43.474339|2018-05-31 22:22:43.474339
NCT01392079|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-05-27|2011-07-11|2011-07-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine|A Prospective, Multi-center Phase II Study of Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Stem-cell Transplantation, in Chronic Lymphocytic Leukemia Which is Associated With 17p Deletion or is Refractory to Fludarabine|Unknown status|Active, not recruiting|Phase 2|135|Actual|University of Ulm||1|||f||||t||||||||||2018-05-31 22:22:43.545508|2018-05-31 22:22:43.545508
NCT01392066|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2014-04-22|2011-07-11|2011-07-12|Estimate|||||||2014-04-22|2014-04-23|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Observational|||Psychosocial Adjustment of Patients and Their Partners Following Breast Cancer Diagnosis|Psychosocial Adjustment of Patients and Their Partners Following Breast Cancer Diagnosis. A Prospective Cohort Study.|Completed|||1584|Actual|University of Southern Denmark|||1||f||||f||||||||||2018-05-31 22:22:43.793596|2018-05-31 22:22:43.793596
NCT01392053|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|2012-05-16||2015-02-18|2011-07-11|2011-07-12|Estimate|2015-02-18|2015-03-05|Estimate||||2015-02-18|2015-03-05|Estimate|September 2009||2009-09-30|February 2015|2015-02-28|July 2011|Actual|2011-07-31|September 2010|Actual|2010-09-30||Interventional|||Massage for Pain Relief During the Active Phase of Labor|Assessment of the Effects of Massage Pain Relief in Nulliparous Women During the Active Phase of Labor|Completed||Phase 4|46|Actual|University of Sao Paulo|The influence of the pain of other women in labor or under the effect of childbirth analgesia; Accompanying with no physical or emotional preparation; Brazilian culture, which associates pain with suffering.|2|||f||||t||||||||||2018-05-31 22:22:44.076173|2018-05-31 22:22:44.076173
NCT01392040|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2013-01-16|2011-07-11|2011-07-12|Estimate|||||||2013-01-16|2013-01-17|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Observational|||Clinical Validation of a New Algorithm for Computerized Dosing of Vitamin K Antagonist Therapy|Clinical Validation of a New Algorithm for Computerized Dosing of Vitamin K Antagonist Therapy|Completed|||100|Actual|University Of Perugia|||1||f||||t||||||||||2018-05-31 22:22:44.544249|2018-05-31 22:22:44.544249
NCT01392027|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-11-06|2011-07-11|2011-07-12|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2011||2011-04-30|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|SPORE-PANC||Biospecimens for Identification of Diseases of the Pancreas.|Biospecimens for the Early Detection, Prevention, Diagnosis and Treatment of Diseases of the Pancreas.|Completed||N/A|712|Actual|University of Michigan|||||f||||t||||||||||2018-05-31 22:22:44.841333|2018-05-31 22:22:44.841333
NCT01392014|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-07-08|2011-07-08|2011-07-12|Estimate|||||||2011-07-08|2011-07-12|Estimate|December 2008||2008-12-31|August 2008|2008-08-31|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|DHP+PQ||Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases|Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia|Completed||Phase 4|374|Actual|Indonesia University||2|||f||||f||||||||||2018-05-31 22:22:44.900964|2018-05-31 22:22:44.900964
NCT01392001|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-11-01|2011-07-11|2011-07-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)|Evaluation of Glucocorticoid Sparing Effect in Patients Receiving RoActemra® for Rheumatoid Arthritis in Real Life.|Completed|||322|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:22:45.046548|2018-05-31 22:22:45.046548
NCT01391988|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2014-03-06|2011-07-08|2011-07-12|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|Harmonic||Trial Comparing Electric and Harmonic Scalpel in Mastectomy|Prospective Trial Comparing the Use of Conventional Electric Scalpel and Harmonic Scalpel in Mastectomy|Completed||Phase 3|97|Actual|Barretos Cancer Hospital||2|||f||||f||||||||||2018-05-31 22:22:45.530469|2018-05-31 22:22:45.530469
NCT01391975|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|May 2012||2012-05-31|July 2011|2011-07-31|October 2014|Anticipated|2014-10-31|May 2014|Anticipated|2014-05-31||Interventional|SPIDA||Surveillance and Proactive Intervention for Dialysis Access|A Multi Centre Randomized Controlled Trial of the Clinical and Cost Effectiveness of Duplex Ultrasound Surveillance With Proactive Intervention Versus no Surveillance and Reactive Intervention for the Management of Stenosis in Arterio-venous Fistulae for Dialysis Vascular Access.|Unknown status|Not yet recruiting|N/A|850|Anticipated|University of Hull||2|||f||||f||||||||||2018-05-31 22:22:45.59961|2018-05-31 22:22:45.59961
NCT01391962|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-09|||2018-03-20|2011-07-09|2011-07-12|Estimate|||||||2018-03-20|2018-03-21|Actual|June 20, 2011||2011-06-20|March 8, 2018|2018-03-08|June 15, 2019|Anticipated|2019-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Sunitinib or Cediranib for Alveolar Soft Part Sarcoma|A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression|Recruiting||Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:22:45.707152|2018-05-31 22:22:45.707152
NCT01391949|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-05-14|2011-07-11|2011-07-12|Estimate|||||||2016-05-14|2016-05-17|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PEDAL||Pedaling Exercises for Disability and Activity Limitations|UCFit Pedaling Exercises to Limit Disability in the Outpatient Setting|Terminated||Phase 1/Phase 2|1|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:22:45.791762|2018-05-31 22:22:45.791762
NCT01384006|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-30|2011-06-27|2011-06-28|Estimate|||||||2011-06-30|2011-07-04|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Observational|EXPAND||Extended Pancreas Donor Program - The EXPAND Study|EXTENDED PANCREAS DONOR PROGRAM - THE EXPAND STUDY|Unknown status|Recruiting||110|Anticipated|University of Regensburg|||2||f||||t||||||||||2018-05-31 22:25:42.330373|2018-05-31 22:25:42.330373
NCT01391936|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2016-10-05|2011-07-11|2011-07-12|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||A Trial of Plate Fixation Versus Tension Band Wire for Olecranon Fractures|A Prospective Randomised Trial of Plate Fixation Versus Tension Band Wire for Olecranon Fractures|Completed||N/A|67|Actual|Royal Infirmary of Edinburgh||2|||f||||f||||||||Yes|Peer reviewed publication - under review|2018-05-31 22:22:45.856945|2018-05-31 22:22:45.856945
NCT01391923|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2017-06-20|2011-07-08|2011-07-12|Estimate|||||||2017-06-20|2017-06-22|Actual|July 2011||2011-07-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Non-Invasive Reduction of Fat in the Arms With the CoolFlex Applicator|Non-Invasive Reduction of Fat in the Arms With the CoolFlex Applicator|Completed||N/A|20|Actual|Zeltiq Aesthetics|||||f||||f||||||||No||2018-05-31 22:22:46.004317|2018-05-31 22:22:46.004317
NCT01391910|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2013-12-11|2011-07-11|2011-07-12|Estimate|||||||2013-12-11|2013-12-12|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Response Shift in Sinus Surgery Outcomes|Response Shift in Sinus Surgery Outcomes|Completed|||32|Actual|University of Washington|||1||f||||f||||||||||2018-05-31 22:22:46.082128|2018-05-31 22:22:46.082128
NCT01391897|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|September 2012|Anticipated|2012-09-30|January 2012|Anticipated|2012-01-31||Observational|TREPS||Epigenetics of Posttraumatic Stress Disorder and Somatoform Disorders in the Course of Psychotherapy||Unknown status|Recruiting||300|Anticipated|Hannover Medical School|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 22:22:46.187931|2018-05-31 22:22:46.187931
NCT01391884|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2012-09-18|2011-07-11|2011-07-12|Estimate|||||||2012-09-18|2012-09-19|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Elimination of Incretin Hormones in Patients With Severe Kidney Failure|Elimination and Biodegradation of the Incretin Hormones GLP-1 and GIP in Patients With End-stage Renal Disease|Completed|||24|Actual|Rigshospitalet, Denmark|||2||f||||t||||||||||2018-05-31 22:22:46.265255|2018-05-31 22:22:46.265255
NCT01391871|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2013-08-01|2011-07-08|2011-07-12|Estimate|||||||2013-08-01|2013-08-02|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Observational|HAT-TRICK-OCT||Vascular Healing of DES at 3 Months|A Randomized Prospective Multicenter Trial to Compare Vascular Healing and Vasodilation at 3 Months After Deployment of PRO-Kinetic Drug-eluting Stent and Endeavor Resolute Zotarolimus-eluting Stent in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography and Coronary Flow Reserve|Completed|||46|Actual|University of Turku|||2||f||||f||||||Samples With DNA|"~     Serum, plasma~   "|||2018-05-31 22:22:46.35212|2018-05-31 22:22:46.35212
NCT01391858|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2013-12-31||2014-08-08|2011-07-11|2011-07-12|Estimate|2014-06-09|2014-06-11|Estimate||||2014-08-08|2014-08-12|Estimate|December 2006||2006-12-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|November 2012|Actual|2012-11-30||Interventional|||Postoperative Pain and Morphine Consumption After Mastectomy - Lyrica|Effects of Oral Pregabalin Versus Placebo on Postoperative Pain and Morphine Consumption After Mastectomy|Completed||Phase 3|80|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 22:22:46.470922|2018-05-31 22:22:46.470922
NCT01391845|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-07-19|2011-07-11|2011-07-12|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2011||2011-07-31|May 2011|2011-05-31|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|||Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern|Effect of Ulipristal Acetate Administration on Serum Progesterone Levels and Glycodelin-A Endometrial Pattern in Women Undergoing Controlled Ovulation Stimulation.|Unknown status|Not yet recruiting|N/A|16|Anticipated|Programa de Asistencia Reproductiva de Rosario||4|||f||||t||||||||||2018-05-31 22:22:46.931103|2018-05-31 22:22:46.931103
NCT01391832|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2018-05-02|2011-07-08|2011-07-12|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2011||2011-07-31|May 2018|2018-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Novel Treatment of Emotional Dysfunction in Post Traumatic Stress Disorder (PTSD)|Novel Treatment of Emotional Dysfunction in PTSD|Completed||N/A|106|Actual|The University of Texas at Dallas||2|||f||||t||||||||||2018-05-31 22:22:47.054055|2018-05-31 22:22:47.054055
NCT01391819|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2017-03-16||2018-01-08|2011-07-11|2011-07-12|Estimate|2017-03-16|2017-04-26|Actual||||2018-01-08|2018-02-01|Actual|September 1, 2011||2011-09-01|March 2017|2017-03-31|January 30, 2015|Actual|2015-01-30|January 30, 2015|Actual|2015-01-30||Interventional|||Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children|An Epidemiological Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children|Completed||N/A|2117|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 22:22:47.185309|2018-05-31 22:22:47.185309
NCT01391806|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Impact of Preoperative Breast MRI in Patients With Breast Cancer Selected for Breast Conserving Surgery|The Impact of Preoperative Breast MRI in Newly Diagnosed Breast Cancer. A Prospective Study of Treatment Outcome in Patients Selected for Breast Conserving Surgery in a Norwegian Multidisciplinary Breast Cancer Clinic.|Completed|||145|Actual|Nordlandssykehuset HF|||1||f||||f||||||||||2018-05-31 22:22:47.60577|2018-05-31 22:22:47.60577
NCT01391793|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2018-04-19|2011-07-11|2011-07-12|Estimate|||||||2018-04-19|2018-04-23|Actual|September 2011||2011-09-30|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|STARRS||Corticosteroids for Children With Febrile Urinary Tract Infections|Corticosteroids for Children With Febrile Urinary Tract Infections|Completed||Phase 3|505|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 22:22:47.824655|2018-05-31 22:22:47.824655
NCT01391780|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2013-12-10|2011-07-11|2011-07-12|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 1997||1997-03-31|March 2011|2011-03-31|December 1998|Actual|1998-12-31|||||Observational|||Pelvic Floor Muscle Evaluation in Women With Stress Urinary and Urgency Urinary Incontinence|Pelvic Floor Muscle Evaluation in Women With Stress Urinary and Urgency Urinary Incontinence. A Prospective Trial|Completed|||51|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||f||||||||||2018-05-31 22:22:47.916147|2018-05-31 22:22:47.916147
NCT01391767|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2013-07-05|2011-07-08|2011-07-12|Estimate|||||||2013-07-05|2013-07-08|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Observational|||Histologic Evaluation of Healing Following Tooth Extraction With Ridge Preservation Using NuOss XC and NuOss Particulate|Histologic Evaluation of Healing Following Tooth Extraction With Ridge Preservation Using NuOss XC and NuOss Particulate|Completed|||22|Actual|University of Oklahoma|||2||f||||f||||||Samples Without DNA|"~     Hard tissue histological evaluation~   "|||2018-05-31 22:22:47.981658|2018-05-31 22:22:47.981658
NCT01391754|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-07-08|2011-07-08|2011-07-12|Estimate|||||||2011-07-08|2011-07-12|Estimate|October 2003||2003-10-31|July 2011|2011-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effectiveness Trial for Project SafeCare for Child Neglect|Effectiveness Trial for Project SafeCare for Child Neglect|Completed||N/A|2175|Actual|University of Oklahoma||4|||f||||t||||||||||2018-05-31 22:22:48.067597|2018-05-31 22:22:48.067597
NCT01391741|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|April 2008||2008-04-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD)|The Effect of High-Volume Walking With Visual Cues on Gait in People With Parkinson´s Disease. A Randomized Controlled Trial|Completed||Phase 3|26|Actual|University of Iceland||2|||f||||f||||||||||2018-05-31 22:22:48.15094|2018-05-31 22:22:48.15094
NCT01391728|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2013-02-06|2011-07-11|2011-07-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Active Lifestyle All Your Life-an Intervention Programme for Preventing Fall Injuries||Completed||N/A|138|Actual|Karolinska Institutet||2|||f||||||||||||||2018-05-31 22:22:48.223584|2018-05-31 22:22:48.223584
NCT01391715|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2012-01-16|2011-07-11|2011-07-12|Estimate|||||||2012-01-16|2012-01-18|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|DRNERD||Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD|Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD: a Randomized Controlled Trial|Withdrawn||Phase 3|0|Actual|Inje University||2||patients could not be recuited within study duration|f||||f||||||||||2018-05-31 22:22:48.291997|2018-05-31 22:22:48.291997
NCT01391702|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2012-04-05|2011-07-08|2011-07-12|Estimate|||||||2012-04-05|2012-04-09|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||How Sweet is it? Measurement of Glucose in Epidural and Spinal Fluid|How Sweet is it? Measurement of Glucose in Epidural Fluid and Fluid Obtained During Spinal Anesthesia After a Failed Epidural Using a Bedside Monitor|Completed|||65|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 22:22:48.380268|2018-05-31 22:22:48.380268
NCT01391689|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-10-31|2011-07-11|2011-07-12|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2011||2011-02-28|April 2016|2016-04-30|July 31, 2016|Actual|2016-07-31|September 2014|Actual|2014-09-30||Interventional|||Diindolylmethane in Treating Patients With Breast Cancer|Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study|Completed||N/A|144|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 22:22:48.514312|2018-05-31 22:22:48.514312
NCT01391676|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2013-09-09|2011-07-11|2011-07-12|Estimate|||||||2013-09-09|2013-09-10|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|SDOCT-TE||Imaging of Trabeculectomy Blebs Using the Spectral Domain Optical Coherence Tomography|Imaging of Blebs After Trabeculectomy With Mitomycin C 0,02% Using the Spectral Domain Optical Coherence Tomography|Completed|||30|Actual|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 22:22:48.608558|2018-05-31 22:22:48.608558
NCT01391663|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2012-10-29||2013-02-17|2011-07-11|2011-07-12|Estimate|2013-02-17|2013-03-22|Estimate||||2013-02-17|2013-03-22|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Dose Study of the Pharmacokinetics and Pharmacodynamics of Alogliptin 12.5 mg, 25 mg and 50 mg in Healthy Korean Subjects|Completed||Phase 1|48|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:22:48.694284|2018-05-31 22:22:48.694284
NCT01391650|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2012-05-22|2011-07-11|2011-07-12|Estimate|||||||2012-05-22|2012-05-23|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Stability of the Knee Joint After Single and Double Bundle Anterior Cruciate Ligament Reconstruction|Rotational and Anteroposterior Stability of the Knee Joint After Single- and Double- Bundle ACL Reconstruction|Completed||N/A|60|Actual|Hospital Znojmo||1|||f||||f||||||||||2018-05-31 22:22:49.170529|2018-05-31 22:22:49.170529
NCT01391637|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-05-11|2011-07-08|2011-07-12|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)|Long-Term Follow-Up Safety and Preliminary Efficacy Study of Human Central Nervous System Stem Cell (HuCNS-SC®) Transplantation in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)|Completed|||4|Actual|StemCells, Inc.|||1||f||||f||||||||||2018-05-31 22:22:49.253031|2018-05-31 22:22:49.253031
NCT01391624|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|OMEGA3CHOCO||Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers|Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers|Completed||Phase 2/Phase 3|30|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:22:49.323596|2018-05-31 22:22:49.323596
NCT01391611|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2016-12-19||2017-02-22|2011-07-11|2011-07-12|Estimate|2017-02-22|2017-04-07|Actual||||2017-02-22|2017-04-07|Actual|July 2011||2011-07-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)|A Phase II Study of Pazopanib in Patients With Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)|Terminated||Phase 2|25|Actual|Stanford University||1||Lack of efficacy - Futility endpoint reached|f||||t||||||||||2018-05-31 22:22:49.418095|2018-05-31 22:22:49.418095
NCT01391598|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Lidocaine on Pain Relief and IL and Substance P in Fibromyalgia|Evaluation of the Effect of Intravenous Lidocaine on Pain Relief and Plasma Concentrations of Interleukins (IL-1 and IL-6) and Substance P in Patients With Fibromyalgia|Unknown status|Recruiting|Phase 3|40|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:22:49.729992|2018-05-31 22:22:49.729992
NCT01391585|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2014-02-10|2011-07-11|2011-07-12|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management|Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management|Completed||N/A|135|Actual|Denver Health and Hospital Authority||1|||f||||f||||||||||2018-05-31 22:22:49.800974|2018-05-31 22:22:49.800974
NCT01391572|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2011-07-20|2011-07-11|2011-07-12|Estimate|||||||2011-07-20|2011-07-22|Estimate|April 2011||2011-04-30|March 2011|2011-03-31||||December 2013|Anticipated|2013-12-31||Interventional|||A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal Cancer|A Randomized Phase II Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Locoregionally Advanced Thoracic Esophageal Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 2|300|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:22:49.935278|2018-05-31 22:22:49.935278
NCT01391559|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2013-04-01||2013-07-05|2011-07-11|2011-07-12|Estimate|2013-07-05|2013-08-07|Estimate||||2013-07-05|2013-08-07|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease|Efficacy of Inhaling Bronchodilator Medications in Patients With Chronic Obstructive Pulmonary Disease Who Have a Low Peak Inspiratory Flow Rate|Completed||N/A|20|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 22:22:50.126843|2018-05-31 22:22:50.126843
NCT01391546|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2017-10-20||2018-01-18|2011-07-08|2011-07-12|Estimate|2017-10-20|2017-11-20|Actual||||2018-01-18|2018-02-14|Actual|June 20, 2011|Actual|2011-06-20|January 2018|2018-01-31|October 15, 2012|Actual|2012-10-15|October 15, 2012|Actual|2012-10-15||Interventional|||Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)|An Open-label, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ZOSTAVAX When Administered by Intramuscular Route or Subcutaneous Route to Subjects of 50 Years of Age and Older|Completed||Phase 3|354|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f|||t|||||2018-05-31 22:22:50.639299|2018-05-31 22:22:50.639299
NCT01391533|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-04-12|2011-07-08|2011-07-12|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SARMET||Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors|Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic, First in Man Study, of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|72|Actual|Sanofi||1|||f||||||||||||||2018-05-31 22:22:51.527835|2018-05-31 22:22:51.527835
NCT01391520|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-08|2011-07-08|2011-07-12|Estimate|||||||2011-07-08|2011-07-12|Estimate|January 2012||2012-01-31|July 2011|2011-07-31|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Interventional|||Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Deferiprone in the Reduction of Morbidity and Mortality in Patients With Chronic Kidney Disease Undergoing Diagnostic or Interventional Cardiac Procedures and Receiving an Iodinated Radiocontrast Agent|Unknown status|Not yet recruiting|Phase 3|800|Anticipated|CorMedix||2|||f||||||||||||||2018-05-31 22:22:51.636619|2018-05-31 22:22:51.636619
NCT01391507|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|2014-08-11||2014-10-08|2011-07-11|2011-07-12|Estimate|2014-08-11|2014-08-26|Estimate||||2014-10-08|2014-10-17|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Intention-to-treat (ITT) population included all participants who were randomly assigned to treatment.|Pilot Study of COR-1 in Heart Failure|COR-1, an Anti-Beta1 Receptor Antibody Cyclopeptide in Heart Failure: a Phase II, Multicentre, Randomised, Double-Blind and Placebo-Controlled Study With Parallel Groups|Completed||Phase 2|36|Actual|Corimmun GmbH|Due to the decision to amend protocol to a pilot study coupled with the high study agent discontinuation rate, safety or efficacy of JNJ-54452840 could not be concluded due to the insufficient sample size and drug exposure to investigational agent.|4|||f||||t||||||||||2018-05-31 22:22:51.916748|2018-05-31 22:22:51.916748
NCT01391494|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-11|||2012-04-26|2011-07-11|2011-07-12|Estimate|||||||2012-04-26|2012-04-27|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants|A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants|Completed||Phase 1|288|Actual|Chinese Academy of Medical Sciences||15|||f||||t||||||||||2018-05-31 22:22:54.413673|2018-05-31 22:22:54.413673
NCT01391481|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2012-04-09|2011-07-11|2011-07-12|Estimate|||||||2012-04-09|2012-04-10|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|April 2015|Anticipated|2015-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome|The Randomized Controlled Trial (RCT) on the Vaporized Perfluorocarbon (PFC) Inhalation Treatment of Acute Respiratory Distress Syndrome With the Invasive Mechanical Ventilation（IMV）|Unknown status|Recruiting|Phase 2|200|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 22:22:54.775292|2018-05-31 22:22:54.775292
NCT01391468|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2015-02-02||2015-10-09|2011-07-11|2011-07-12|Estimate|2015-07-27|2015-08-24|Estimate||||2015-10-09|2015-11-03|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Beneficial Effect of Probiotics on Chronic Kidney Disease|Beneficial Effect of Probiotics on Chronic Kidney Disease|Completed||Phase 4|47|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 22:22:54.869163|2018-05-31 22:22:54.869163
NCT01391455|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|August 2013|Anticipated|2013-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Isolation of the Spermatic Cord in Mesh Inguinal Hernia Repair|Isolation of the Spermatic Cord Following Mesh Inguinal Hernia Repair|Unknown status|Recruiting|N/A|220|Anticipated|Chatham Kent Health Alliance||2|||f||||t||||||||||2018-05-31 22:22:55.532633|2018-05-31 22:22:55.532633
NCT01391442|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2016-03-07|2011-07-11|2011-07-12|Estimate|||||||2016-03-07|2016-03-08|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|STANISLASV4||- 4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF|Family Heritability, Investigating Gene-gene and Gene-environment Interactions in the Field of Cardiovascular Diseases - 4th VISIT (at 17 Years) of the STANISLAS COHORT|Unknown status|Recruiting|N/A|4006|Anticipated|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 22:22:55.616005|2018-05-31 22:22:55.616005
NCT01391429|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-02-22|2011-07-11|2011-07-12|Estimate|||||||2016-02-22|2016-02-23|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Testing a Video Decision Support Tool to Supplement Goals-of-Care Discussions|Testing a Video Decision Support Tool to Supplement Goals-of-Care Discussions With Patients and Surrogates Receiving an Inpatient Palliative Care Consult|Completed||N/A|37|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 22:22:55.987208|2018-05-31 22:22:55.987208
NCT01391416|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2011-07-11|2011-07-11|2011-07-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Observational|||Prevalence Of Hyperhomocysteinemia In Thai Chronic Kidney Disease (CKD) Patients|Prevalence Of Hyperhomocysteinemia In Thai CKD Patients And Relationship To Cardiovascular Events: Subgroup Analysis From Thai SEEK Study|Completed|||98|Actual|Bangkok Metropolitan Administration Medical College and Vajira Hospital|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:22:56.123791|2018-05-31 22:22:56.123791
NCT01391403|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2016-07-10|2011-07-11|2011-07-12|Estimate|||||||2016-07-10|2016-07-12|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia|A Double-Blind, Randomized, Placebo-Controlled Trial of Artemisinin as an Add-on Therapy to Risperidone in the Treatment of Drug-Naive First-Episode Patients With Schizophrenia|Completed||Phase 3|88|Actual|Beijing HuiLongGuan Hospital||2|||f||||t||||||||||2018-05-31 22:22:56.200628|2018-05-31 22:22:56.200628
NCT01391390|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2016-07-10|2011-07-11|2011-07-12|Estimate|||||||2016-07-10|2016-07-12|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Melatonin Treatment for Tardive Dyskinesia in Schizophrenia|The Effect of Melatonin Treatment on Tardive Dyskinesia and Oxidative Stress: A Double-Blind Placebo-Controlled Trial|Completed||N/A|120|Actual|Beijing HuiLongGuan Hospital||2|||f||||t||||||||||2018-05-31 22:22:56.320945|2018-05-31 22:22:56.320945
NCT01391377|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-02-25|2011-07-11|2011-07-12|Estimate|||||||2013-02-25|2013-02-27|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease|The Effects of Chronic High-density Lipoprotein (HDL) Elevation With Extended Release Niacin on Peripheral Arterial Disease|Terminated||N/A|7|Actual|Bayside Health||2||Tredaptive has been suspended worldwide|f||||f||||||||||2018-05-31 22:22:56.503499|2018-05-31 22:22:56.503499
NCT01391364|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-08-10|2011-07-08|2011-07-12|Estimate|||||||2012-08-10|2012-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:22:56.640239|2018-05-31 22:22:56.640239
NCT01391351|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-07-20|2011-07-11|2011-07-12|Estimate|||||||2016-07-20|2016-07-21|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|November 2015|Actual|2015-11-30||Interventional|miRSa||Search for Predictors of Therapeutic Response in Ovarian Carcinoma|Search for Predictors of Therapeutic Response in Patients With Carcinoma of the Ovary, the Fallopian Tube or Peritoneal Serous-type Advanced|Completed||N/A|107|Actual|Centre Francois Baclesse||2|||f||||f||||||||||2018-05-31 22:22:56.688564|2018-05-31 22:22:56.688564
NCT01391338|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2013-03-19|2011-07-08|2011-07-12|Estimate|||||||2013-03-19|2013-03-21|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|AZURE||A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)|A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS|Completed||Phase 2|239|Actual|Astellas Pharma Inc||6|||f||||t||||||||||2018-05-31 22:22:56.795763|2018-05-31 22:22:56.795763
NCT01391325|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2014-04-01||2014-05-16|2011-07-11|2011-07-12|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|LASSO|All subjects who received at least one dose of allopurinol.|Allopurinol Outcome Study|Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)|Completed||Phase 4|1735|Actual|Ardea Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 22:22:56.984291|2018-05-31 22:22:56.984291
NCT01391312|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2012-08-24||2012-08-24|2011-07-11|2011-07-12|Estimate|2012-08-24|2012-09-25|Estimate||||2012-08-24|2012-09-25|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines|A Pilot Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Glabellar Lines - Establishing Patient Satisfaction|Completed||Phase 4|40|Actual|Allergan||2|||f||||f||||||||||2018-05-31 22:22:58.973391|2018-05-31 22:22:58.973391
NCT01391299|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2012-10-26||2012-10-26|2011-07-11|2011-07-12|Estimate|2012-10-26|2012-11-26|Estimate||||2012-10-26|2012-11-26|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines|A Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Single Treatment Cycle Study of BOTOX® Cosmetic (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects With Forehead and Glabellar Rhytides|Completed||N/A|175|Actual|Allergan||3|||f||||f||||||||||2018-05-31 22:22:59.303229|2018-05-31 22:22:59.303229
NCT01391286|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2013-05-21||2013-05-21|2011-07-08|2011-07-12|Estimate|2013-05-21|2013-07-09|Estimate||||2013-05-21|2013-07-09|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis|A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-daily Application of Bimatoprost Solution 0.03% Compared to Vehicle to Treat Chemotherapy-induced Hypotrichosis of the Eyelashes in Japanese Subjects|Completed||Phase 3|36|Actual|Allergan||2|||f||||f||||||||||2018-05-31 22:22:59.629298|2018-05-31 22:22:59.629298
NCT01391273|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2013-05-21||2013-05-21|2011-07-08|2011-07-12|Estimate|2013-05-21|2013-07-09|Estimate||||2013-05-21|2013-07-09|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis|A Multicenter, Double-masked, Randomized, Parallel-group Study Assessing the Safety and Efficacy of Once-Daily Application of Bimatoprost Solution 0.03% Compared to Vehicle in Increasing Overall Eyelash Prominence in Japanese Subjects With Hypotrichosis of the Eyelashes|Completed||Phase 3|173|Actual|Allergan||2|||f||||f||||||||||2018-05-31 22:22:59.947118|2018-05-31 22:22:59.947118
NCT01391260|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-08-01|2011-07-08|2011-07-11|Estimate|||||||2011-08-01|2011-08-02|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|July 2017|Anticipated|2017-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations|Unknown status|Recruiting|Phase 2|30|Anticipated|ZhuGuangYing||1|||f||||f||||||||||2018-05-31 22:23:00.287016|2018-05-31 22:23:00.287016
NCT01391247|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-02-05|2011-07-08|2011-07-11|Estimate|||||||2013-02-05|2013-02-06|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Validation of Retinal Oximetry in Glaucoma Patients: a Structural and Functional Correlation|Validation of Retinal Oximetry in Glaucoma Patients: a Structural and Functional Correlation|Completed|||59|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 22:23:00.391194|2018-05-31 22:23:00.391194
NCT01390883|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-03-26|2011-07-07|2011-07-11|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)|Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)|Completed|||475|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:23:07.379691|2018-05-31 22:23:07.379691
NCT01391234|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-05-04|2011-07-07|2011-07-11|Estimate|||||||2017-05-04|2017-05-08|Actual|June 2011||2011-06-30|May 2017|2017-05-31|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|||Rapid Radiation Therapy for Painful Osseous Metastatic Disease|Phase II Pilot Single Arm Prospective Clinical Trial of Rapid Institution of Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease|Completed||N/A|28|Actual|University of Virginia||1|||f||||t||||||||No||2018-05-31 22:23:00.459227|2018-05-31 22:23:00.459227
NCT01391221|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2012-07-17|2011-07-07|2011-07-11|Estimate|||||||2012-07-17|2012-07-19|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Inflammatory Markers and Cognitive Function in Major Depression|Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study|Unknown status|Recruiting|Phase 4|20|Anticipated|Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal||1|||f||||f||||||||||2018-05-31 22:23:00.537063|2018-05-31 22:23:00.537063
NCT01391208|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2012-10-10|2011-07-07|2011-07-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Esophageal Protocol for Detection of Neoplasia in the Digestive Tract|A Phase I In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract|Completed||Phase 1|25|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 22:23:00.639856|2018-05-31 22:23:00.639856
NCT01391195|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-12|2011-07-08|2011-07-11|Estimate|||||||2011-07-12|2011-07-13|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|October 2007|Actual|2007-10-31|April 2007|Actual|2007-04-30||Interventional|||Effects of Low Level Laser Therapy (808nm) on Muscle Performance of Young Women Submitted to Physical Training|Effects of Low Level Laser Therapy (808nm) on Muscle Performance of Young Women Submitted to Physical Training|Completed||Phase 1|45|Actual|Universidade Federal de Sao Carlos||1|||f||||t||||||||||2018-05-31 22:23:00.726222|2018-05-31 22:23:00.726222
NCT01391182|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-02-25|2011-07-08|2011-07-11|Estimate|||||||2015-02-25|2015-02-26|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)|Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)|Completed||N/A|60|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:23:00.803635|2018-05-31 22:23:00.803635
NCT01391169|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-08|2011-07-08|2011-07-11|Estimate|||||||2011-07-08|2011-07-11|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Pedicled Seromuscular Flap For Enforcement Of High Risk Intestinal Anastomoses|Pedicled Seromuscular Flap For Enforcement Of High Risk Intestinal Anastomoses|Completed||N/A|60|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 22:23:00.869953|2018-05-31 22:23:00.869953
NCT01391156|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-07-19|2011-07-07|2011-07-11|Estimate|||||||2012-07-19|2012-07-20|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss|Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study|Completed||Phase 3|40|Actual|Mae Fah Luang University Hospital||2|||f||||f||||||||||2018-05-31 22:23:00.946269|2018-05-31 22:23:00.946269
NCT01391143|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2018-03-21|2011-07-07|2011-07-11|Estimate|||||||2018-03-21|2018-03-23|Actual|July 2011||2011-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety Study of MGA271 in Refractory Cancer|A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer|Active, not recruiting||Phase 1|179|Actual|MacroGenics||1|||f||||f||||||||||2018-05-31 22:23:01.022734|2018-05-31 22:23:01.022734
NCT01391130|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07||2015-01-16|2017-04-21|2011-07-07|2011-07-11|Estimate||||2015-01-16|2015-01-29|Estimate|2017-04-21|2017-04-24|Actual|August 2011||2011-08-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|September 2014|Actual|2014-09-30||Interventional|||A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma|Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|108|Anticipated|Eli Lilly and Company||2||Study Terminated due to Insufficient Efficacy|f||||f||||||||||2018-05-31 22:23:01.114782|2018-05-31 22:23:01.114782
NCT01391117|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-10-25|2011-07-07|2011-07-11|Estimate|||||||2012-10-25|2012-10-26|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin|A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin|Terminated||Phase 1|14|Actual|Tibotec BVBA||10||"Antiviral activity was considered insufficient to warrant further clinical development of~   TMC649128."|f||||f||||||||||2018-05-31 22:23:01.215708|2018-05-31 22:23:01.215708
NCT01391104|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2012-10-03|2011-07-07|2011-07-11|Estimate|||||||2012-10-03|2012-10-04|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|RESPONS||Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension|Reproducibility and Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension|Completed||N/A|22|Actual|Laval University||2|||f||||t||||||||||2018-05-31 22:23:01.309396|2018-05-31 22:23:01.309396
NCT01391091|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2016-10-17|2011-07-07|2011-07-11|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|CONFIRM||Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With or Without Previous History of Migraine|Effect of Catheter Ablation on the Prevalence, Clinical Manifestation and MRI Findings of Migraine in AF Patients With or Without a Previous History of Migraine|Completed||Phase 3|173|Actual|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-05-31 22:23:01.400084|2018-05-31 22:23:01.400084
NCT01391078|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2012-11-27|2011-07-07|2011-07-11|Estimate|||||||2012-11-27|2012-11-28|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Comparison of Sensimed Triggerfish With Goldmann Applanation Tonometry and Perkins Tonometry|Comparison of Sensimed Triggerfish (TF) 24 Hour IOP Monitoring With Goldmann Applanation Tonometry (GAT) and Perkins Tonometry in Glaucoma Patients|Completed||N/A|12|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 22:23:01.480105|2018-05-31 22:23:01.480105
NCT01391065|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-07|2011-07-07|2011-07-11|Estimate|||||||2011-07-07|2011-07-11|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|March 2017|Anticipated|2017-03-31|March 2014|Anticipated|2014-03-31||Interventional|MR-PET Brachy||MR-PET Guided Biologically Optimised Interstitial Brachytherapy|MR-PET Guided Biologically Optimised Interstitial Brachytherapy for Postoperative Recurrent Cervical Cancers|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Tata Memorial Hospital|||||f||||t||||||||||2018-05-31 22:23:01.554563|2018-05-31 22:23:01.554563
NCT01391052|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-07|2011-07-07|2011-07-11|Estimate|||||||2011-07-07|2011-07-11|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|Mirena IUD||Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding|Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding|Unknown status|Recruiting|Phase 4|80|Anticipated|Scott and White Hospital & Clinic||2|||f||||f||||||||||2018-05-31 22:23:01.626167|2018-05-31 22:23:01.626167
NCT01391039|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2015-11-26|2011-07-07|2011-07-11|Estimate|||||||2015-11-26|2015-11-30|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Diagnostic Study of Early Breast Cancer Using Ultrasound|Microbubble Contrast Ultrasound and Transient Elastography Imaging of Early Breast Cancer|Terminated||N/A|12|Actual|Sunnybrook Health Sciences Centre||1||Low recruitment|f||||f||||||||||2018-05-31 22:23:01.793219|2018-05-31 22:23:01.793219
NCT01391026|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-08-31|2011-07-07|2011-07-11|Estimate|||||||2015-08-31|2015-09-02|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|CASE||Computer Assisted Symptom Evaluation of Complex Patients|Computer Assisted Quality of Life and Symptom Assessment of Complex Patients|Completed||N/A|200|Actual|John H. Stroger Hospital||2|||f||||f||||||||||2018-05-31 22:23:01.865372|2018-05-31 22:23:01.865372
NCT01391013|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2013-02-13||2013-05-22|2011-07-08|2011-07-11|Estimate|2013-05-22|2013-06-27|Estimate||||2013-05-22|2013-06-27|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|MONARCH||A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients|A Randomised, Controlled, Open-Label Trial to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg O.D. Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Subjects With Undetectable Plasma HIV-1 RNA on Their Current Treatments.|Completed||Phase 2|30|Actual|Janssen-Cilag S.p.A.||2|||f||||f||||||||||2018-05-31 22:23:01.972923|2018-05-31 22:23:01.972923
NCT01391000|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|2017-02-03||2018-01-16|2011-07-07|2011-07-11|Estimate|2017-04-20|2017-08-02|Actual||||2018-01-16|2018-02-13|Actual|July 2011||2011-07-31|January 2018|2018-01-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|||Laser CO2 Versus TENS After Reconstruction of the Rotator Cuff|Light Amplification by Simulated Emission Radiation Carbon Dioxide (Laser CO2) Versus Transcutaneous Electrical Stimulation (TENS) for the Reduction of Pain in Patients After Reconstruction of the Rotator Cuff. A Randomized Controlled Trial|Completed||N/A|70|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 22:23:02.802523|2018-05-31 22:23:02.802523
NCT01390987|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-01-17|2011-07-08|2011-07-11|Estimate|||||||2014-01-17|2014-01-20|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|TBsurvey||Access to Care and Adherence Tuberculosis (TB) Survey|Survey Nazionale Sui Determinanti Del Ritardato Accesso Alle Cure e Della Mancata Aderenza al Trattamento Antitubercolare (National Survey on the Determinats of Delayed Access to Care and Non-adherence to Tuberculosis Treatment)|Completed|||137|Actual|Azienda Ospedaliera San Gerardo di Monza|||||f||||f||||||||||2018-05-31 22:23:03.091925|2018-05-31 22:23:03.091925
NCT01390974|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-02-07|2011-07-08|2011-07-11|Estimate|||||||2014-02-07|2014-02-10|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|GAMMA||Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome|Bedside Genetic Approach to Identify Clopidogrel CYP2C19 Metabolizer and Optimize Maintenance Thienopyridine Treatment After an Acute Coronary Syndrome: The GAMMA Study|Completed|||270|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 22:23:03.15537|2018-05-31 22:23:03.15537
NCT01390961|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-07|2011-07-07|2011-07-11|Estimate|||||||2011-07-07|2011-07-11|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Interventional|||Comparison of Tolerability Between Two Allergy Drops|Comparison of Tolerability Between Two Allergy Drops|Unknown status|Enrolling by invitation|Phase 4|48|Anticipated|Hom, Milton M., OD, FAAO|||||f||||f||||||||||2018-05-31 22:23:03.251971|2018-05-31 22:23:03.251971
NCT01390948|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2016-09-01||2018-05-22|2011-07-07|2011-07-11|Estimate|2017-04-27|2017-08-04|Actual||||2018-05-22|2018-05-24|Actual|October 18, 2011|Actual|2011-10-18|May 2018|2018-05-31|March 10, 2020|Anticipated|2020-03-10|February 5, 2016|Actual|2016-02-05||Interventional|||A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma|A Phase II Open-Label, Randomized, Multi-Centre Comparative Study Of Bevacizumab-Based Therapy In Paediatric Patients With Newly Diagnosed Supratentorial, Infratentorial Cerebellar, or Peduncular High-Grade Glioma|Active, not recruiting||Phase 2|124|Actual|Hoffmann-La Roche||3|||f||||t||||||||||2018-05-31 22:23:03.406842|2018-05-31 22:23:03.406842
NCT01390935|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2012-11-28|2011-07-07|2011-07-11|Estimate|||||||2012-11-28|2012-11-30|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|SUGAR||SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World|SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real WorldMulticenter, Retrospective Observation Study in Korea|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:04.857359|2018-05-31 22:23:04.857359
NCT01390922|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-03-26|2011-07-07|2011-07-11|Estimate|||||||2015-03-26|2015-03-27|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)|Special Drug Use Investigation for Botox® (Botulinum) Spasticity|Completed|||1038|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:05.018487|2018-05-31 22:23:05.018487
NCT01390909|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2011-10-13||2012-10-04|2011-07-07|2011-07-11|Estimate|2012-01-05|2012-02-14|Estimate||||2012-10-04|2012-10-08|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database|Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database|Completed|||12386|Actual|GlaxoSmithKline|||6||f||||f||||||||||2018-05-31 22:23:05.288069|2018-05-31 22:23:05.288069
NCT01390896|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-07-24|2011-07-07|2011-07-11|Estimate|||||||2014-07-24|2014-07-28|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery|Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery|Completed|||329|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:07.31471|2018-05-31 22:23:07.31471
NCT01344551|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-02-20|2011-04-28|2011-04-29|Estimate|||||||2013-02-20|2013-02-21|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Cocoa Flavanols on Human Cognitive Function||Completed||N/A|63|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 22:39:45.894263|2018-05-31 22:39:45.894263
NCT01390870|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2012-02-16||2017-05-15|2011-07-07|2011-07-11|Estimate|2012-02-16|2012-03-21|Estimate||||2017-05-15|2017-05-17|Actual|May 2009||2009-05-31|May 2017|2017-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence|Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence|Completed|||400|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:07.46982|2018-05-31 22:23:07.46982
NCT01390857|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2011-08-18||2017-05-15|2011-07-07|2011-07-11|Estimate|2011-08-18|2011-09-26|Estimate||||2017-05-15|2017-05-17|Actual|November 2007||2007-11-30|May 2017|2017-05-31|May 2010|Actual|2010-05-31|September 2008|Actual|2008-09-30||Observational|||Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)|Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)|Completed|||379|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:07.694392|2018-05-31 22:23:07.694392
NCT01390844|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2016-05-20||2017-03-10|2011-07-07|2011-07-11|Estimate|2016-05-20|2016-06-28|Estimate||||2017-03-10|2017-04-10|Actual|October 2011||2011-10-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||All Participants Randomized|Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)|Safety and Efficacy of Boceprevir in Combination With Peginterferon Plus Ribavirin for Treatment of Asia Pacific Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Pegylated Interferon Plus Ribavirin|Completed||Phase 3|282|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:23:08.100429|2018-05-31 22:23:08.100429
NCT01390831|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-08|2011-07-08|2011-07-11|Estimate|||||||2011-07-08|2011-07-11|Estimate|November 2011||2011-11-30|April 2011|2011-04-30|June 2015|Anticipated|2015-06-30|November 2014|Anticipated|2014-11-30||Interventional|||Renal Denervation in Patients With Uncontrolled Hypertension in Chinese|Renal Denervation in Patients With Uncontrolled Hypertension in Chinese|Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|The Second People's Hospital of Chengdu||2|||f||||t||||||||||2018-05-31 22:23:08.891546|2018-05-31 22:23:08.891546
NCT01390818|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2016-05-01||2017-01-17|2011-07-08|2011-07-11|Estimate|2017-01-17|2017-03-07|Actual||||2017-01-17|2017-03-07|Actual|May 2011||2011-05-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||The Safety analysis set (SAF) included subjects who received at least one (non-zero) administration of the trial IMPs (pimasertib and/or SAR245409).|Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy With MSC1936369B and SAR245409 in Subjects With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|146|Actual|EMD Serono||2|||f||||t||||||||||2018-05-31 22:23:09.288322|2018-05-31 22:23:09.288322
NCT01390805|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-05-15|2011-07-07|2011-07-11|Estimate|||||||2017-05-15|2017-05-16|Actual|November 2006||2006-11-30|May 2017|2017-05-31|March 2011|Actual|2011-03-31|April 2009|Actual|2009-04-30||Observational|||Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)|Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)|Completed|||462|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:20.076821|2018-05-31 22:23:20.076821
NCT01390792|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-05-15|2011-07-07|2011-07-11|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2007||2007-01-31|May 2017|2017-05-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Observational|||Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)|Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)|Completed|||622|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:20.168411|2018-05-31 22:23:20.168411
NCT01390779|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2013-06-04||2013-12-03|2011-07-08|2011-07-11|Estimate|2013-12-03|2014-01-20|Estimate||||2013-12-03|2014-01-20|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor|Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor|Completed||N/A|33|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 22:23:20.369302|2018-05-31 22:23:20.369302
NCT01390766|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-08-30|2011-07-07|2011-07-11|Estimate|||||||2012-08-30|2012-09-03|Estimate|August 2002||2002-08-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)|Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)|Completed|||41|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:23:20.577676|2018-05-31 22:23:20.577676
NCT01390753|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-02-13|2011-07-08|2011-07-11|Estimate|||||||2017-02-13|2017-02-14|Actual|April 2012||2012-04-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Role of Human Milk Bank in the Protection of Severe Respiratory Disease in Very Low Birth Weight Premature Infants|Preventing Respiratory Disease Hospitalizations in Premature Infants Fed Donor Human Milk|Completed||N/A|300|Actual|Fundacion Infant||4|||f||||f||||||||No||2018-05-31 22:23:20.659465|2018-05-31 22:23:20.659465
NCT01390740|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-11-21|2011-07-08|2011-07-11|Estimate|||||||2017-11-21|2017-11-24|Actual|May 2011||2011-05-31|November 2017|2017-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|E2T3A||Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey|Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey|Completed|||1412|Actual|French Cardiology Society|||1||f||||t||||||||||2018-05-31 22:23:20.903604|2018-05-31 22:23:20.903604
NCT01390727|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2016-05-06|2011-07-08|2011-07-11|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Slow Breathing on Blood Pressure and Autonomic Function|Effects of Slow Breathing on Blood Pressure and Autonomic Function in Hypertensive Patients|Completed||Phase 4|32|Actual|Fundação de Amparo à Pesquisa do Estado de São Paulo||2|||f||||f||||||||No||2018-05-31 22:23:21.074838|2018-05-31 22:23:21.074838
NCT01390714|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-03-13|2011-07-07|2011-07-11|Estimate|||||||2012-03-13|2012-03-14|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects|An Open-label, Cross-over, Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects|Completed||Phase 1|30|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:23:21.245478|2018-05-31 22:23:21.245478
NCT01390701|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-07|2011-07-07|2011-07-11|Estimate|||||||2011-07-07|2011-07-11|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|HyperTENSion||Blood Pressure Lowering Effect of Transcutaneous Electrical Nerve Stimulation|Blood Pressure Lowering Effect of Low-frequency Transcutaneous Electrical Nerve Stimulation and Felodipin|Completed||N/A|41|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 22:23:21.43452|2018-05-31 22:23:21.43452
NCT01390688|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-07|2011-07-07|2011-07-11|Estimate|||||||2011-07-07|2011-07-11|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|March 2012|Anticipated|2012-03-31|December 2010|Actual|2010-12-31||Observational|||Brain-derived Neurotrophic Factor and Cogntive Function|Brain-derived Neurotrophic Factor: A Link to Obesity, Insulin Resistance and Cognitive Dysfunktion?|Unknown status|Active, not recruiting||200|Actual|Rigshospitalet, Denmark|||3||f||||t||||||Samples With DNA|"~     Plasma, Serum, DNA, Muscle tissue and fat tissue~   "|||2018-05-31 22:23:21.515816|2018-05-31 22:23:21.515816
NCT01390675|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-07-25|2011-07-08|2011-07-11|Estimate|||||||2017-07-25|2017-07-26|Actual|June 2011||2011-06-30|August 2016|2016-08-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Observational|AVIATOR||Anesthesia for Catheter Aortic Valve ImplantATIOn Registry||Recruiting|||5000|Anticipated|Deutsches Herzzentrum Muenchen|||||f||||f||||||||||2018-05-31 22:23:21.64033|2018-05-31 22:23:21.64033
NCT01390662|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-03-27|2011-07-08|2011-07-11|Estimate|||||||2012-03-27|2012-03-28|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|May 2012|Anticipated|2012-05-31||Interventional|D3-vit-dep||Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression|Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression|Unknown status|Recruiting|Phase 4|150|Anticipated|Region Syddanmark||2|||f||||t||||||||||2018-05-31 22:23:21.797163|2018-05-31 22:23:21.797163
NCT01390649|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2015-09-16||2016-03-10|2011-07-07|2011-07-11|Estimate|2015-09-16|2015-10-19|Estimate||||2016-03-10|2016-04-08|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Subjects treated with Privigen|A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)|An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis|Completed||Phase 4|57|Actual|CSL Behring||1|||f||||t||||||||||2018-05-31 22:23:21.97696|2018-05-31 22:23:21.97696
NCT01390636|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-11-25|2011-07-07|2011-07-11|Estimate|||||||2015-11-25|2015-11-26|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|July 2011|Actual|2011-07-31||Observational|REACT5||Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns|Characterizing Diurnal Glucose Patterns of Individuals With Type 1 Diabetes and Eating Disorders|Terminated|||1|Actual|HealthPartners Institute|||1|The study was a collaboration that could not be effectively run.|f||||f||||||||||2018-05-31 22:23:22.808303|2018-05-31 22:23:22.808303
NCT01390623|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2014-07-04|2011-07-08|2011-07-11|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy and Safety Study of Short-term Antibiotic for Pyelonephritis in Women|Efficacy and Safety Study of Short Term Antibiotic During Seven Days With Ceftriaxone Intravenous the First Day Then Cefixime the Second Day Till the Seventh Day of Acute Uncomplicated Pyelonephritis in Women Between 18 and 65 Years Old|Completed||Phase 4|39|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:23:22.961548|2018-05-31 22:23:22.961548
NCT01390610|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-11-25|2011-07-07|2011-07-11|Estimate|||||||2015-11-25|2015-11-26|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|REACT4||Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition|Observational Evaluation Using Continuous Glucose Monitoring to Determine Timing and Frequency of Self-Monitored Blood Glucose by Therapy Type in Patients With Type 2 Diabetes (REACT-4 Matrix Definition Study)|Completed|||27|Actual|HealthPartners Institute|||||f||||f||||||||||2018-05-31 22:23:23.073942|2018-05-31 22:23:23.073942
NCT01390597|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-05-16|2011-07-07|2011-07-11|Estimate|||||||2017-05-16|2017-05-17|Actual|June 28, 2011|Actual|2011-06-28|May 2017|2017-05-31|August 28, 2011|Actual|2011-08-28|August 28, 2011|Actual|2011-08-28||Observational|||Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms|The Molecular Mechanisms of Transformation in Peripheral T-cell and NK Lymphomas|Completed|||32|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 22:23:23.216043|2018-05-31 22:23:23.216043
NCT01390584|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-07-07|2011-07-07|2011-07-11|Estimate|||||||2017-07-07|2017-07-11|Actual|April 2, 2012|Actual|2012-04-02|July 2017|2017-07-31|January 24, 2014|Actual|2014-01-24|January 24, 2014|Actual|2014-01-24||Interventional|ACRIN-6700||Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma|Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)|Terminated||Phase 2|6|Actual|American College of Radiology Imaging Network||1||slow accrual|f||||t|f|f||||||No||2018-05-31 22:23:23.402846|2018-05-31 22:23:23.402846
NCT01390571|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2018-02-01|2011-07-07|2011-07-11|Estimate|||||||2018-02-01|2018-02-05|Actual|July 2011||2011-07-31|February 2018|2018-02-28|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma|A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma|Completed||Phase 1|34|Anticipated|Cancer Research UK|||||f||||||||||||||2018-05-31 22:23:23.532177|2018-05-31 22:23:23.532177
NCT01390558|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2014-11-06|2011-07-08|2011-07-11|Estimate|||||||2014-11-06|2014-11-07|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2020|Anticipated|2020-06-30|June 2015|Anticipated|2015-06-30||Observational|||Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite|Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite|Recruiting|||300|Anticipated|Oregon Health and Science University|||2||f||||t||||||||||2018-05-31 22:23:23.732354|2018-05-31 22:23:23.732354
NCT01390545|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05||2016-03-13|2016-03-13|2011-07-07|2011-07-11|Estimate||||2016-03-13|2016-04-13|Estimate|2016-03-13|2016-04-13|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|VELVET||VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis|VELVET (Veltuzumab Various Doses Exploratory Trial), a Randomized, Double Blind, Placebo Controlled, Multicentre, Multinational Phase II Dose Range Finding Trial in Subjects With Moderate to Severe Rheumatoid Arthritis Insufficiently Controlled With Either Methotrexate Alone or Methotrexate Plus Anti-tumour Necrosis Factor Biological Treatment, Comparing 3 Different Subcutaneous Dosages of Anti-CD20 Monoclonal Antibody Veltuzumab to Placebo as an add-on Therapy to Methotrexate.|Terminated||Phase 2|300|Anticipated|Takeda||4||Trial re-design; no safety issues identified|f||||||||||||||2018-05-31 22:23:24.021628|2018-05-31 22:23:24.021628
NCT01390532|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2011-07-08|2011-07-08|2011-07-11|Estimate|||||||2011-07-08|2011-07-11|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|October 2011|Anticipated|2011-10-31|August 2011|Anticipated|2011-08-31||Interventional|||Rest/Stress Quantification Of Left Ventricular Dyssynchrony By 3D Gated Blood Pool D-SPECT|Left Ventricular Dyssynchrony: Rest/Stress 3D Blood-Pool Gated D-SPECT Quantification With a High-Speed Dedicated Cardiac Camera Before CRT|Unknown status|Recruiting|N/A|30|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:23:24.26216|2018-05-31 22:23:24.26216
NCT01390519|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2016-01-12|2011-07-07|2011-07-11|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|OSAT||A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor|Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment|Completed|||30|Actual|Novartis|||1||f||||||||||None Retained|"~     None Retained~   "|||2018-05-31 22:23:24.367516|2018-05-31 22:23:24.367516
NCT01390506|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2017-12-12|2011-07-07|2011-07-11|Estimate|||||||2017-12-12|2017-12-13|Actual|January 2017||2017-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|SCPR||Selenium to Improve Neurological Outcome After Cardiac Arrest|Effect of High Dose Selenium on Inflammation and Neurological Outcome After Cardiac Arrest: A Randomized, Double Blind Placebo Controlled Phase 2a Study|Withdrawn||Phase 2|0|Actual|Medical University of Graz||2||The company did not provide the study product|f||||t||||||||||2018-05-31 22:23:24.456158|2018-05-31 22:23:24.456158
NCT01390493|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-03-10|2011-07-08|2011-07-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Therapeutic Effects of Neurofeedback in Anorexia Nervosa|Therapeutic Effects of Alpha-neurofeedback in the Treatment of Anorexia Nervosa|Completed||Phase 1/Phase 2|12|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 22:23:24.558895|2018-05-31 22:23:24.558895
NCT01390480|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2015-04-16|2011-07-07|2011-07-11|Estimate|||||||2015-04-16|2015-04-17|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes|Placebo Controlled Pilot Study on Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes on Immunological, Endocrine and Metabolic Parameters: Step 2 in the Austrian Diabetes Prevention Programme|Completed||Phase 4|31|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 22:23:24.634141|2018-05-31 22:23:24.634141
NCT01390467|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2012-01-26|2011-07-08|2011-07-11|Estimate|||||||2012-01-26|2012-01-30|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|ICP||Cognitive Impact of Paracetamol in Healthy Volunteers|Cognitive Impact of Paracetamol in Healthy Volunteers|Completed||Phase 1|44|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:23:24.726629|2018-05-31 22:23:24.726629
NCT01390454|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2018-03-29|2011-07-08|2011-07-11|Estimate|||||||2018-03-29|2018-03-30|Actual|March 5, 2012|Actual|2012-03-05|March 2018|2018-03-31|June 18, 2013|Actual|2013-06-18|June 18, 2013|Actual|2013-06-18||Interventional|EPICORE||Relationships Between Ultrasound Data and the Impact of Lateral Epicondylar Pain|Study of the Relationship Between Functional Ultrasound Data and the Impact of Lateral Epicondylar Pain|Completed||N/A|40|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 22:23:24.813985|2018-05-31 22:23:24.813985
NCT01390441|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2016-03-24||2016-06-08|2011-07-07|2011-07-11|Estimate|2016-06-08|2016-07-20|Estimate||||2016-06-08|2016-07-20|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)|A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera® and US-licensed Rituxan® in Patients With Rheumatoid Arthritis (RA)|Terminated||Phase 1|100|Actual|Merck Sharp & Dohme Corp.||5||The study was terminated early by the Sponsor for business reasons.|f||||f||||||||||2018-05-31 22:23:25.008845|2018-05-31 22:23:25.008845
NCT01390428|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2016-02-03||2017-10-11|2011-07-07|2011-07-11|Estimate|2016-02-03|2016-03-04|Estimate||||2017-10-11|2017-11-13|Actual|July 28, 2011|Actual|2011-07-28|October 2017|2017-10-31|September 12, 2014|Actual|2014-09-12|September 5, 2014|Actual|2014-09-05||Interventional|||Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)|An Open-label, 3-Part, Multiple Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172)|Completed||Phase 1|50|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:23:26.39494|2018-05-31 22:23:26.39494
NCT01390415|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2011-08-09||2015-10-20|2011-07-07|2011-07-11|Estimate|2011-08-09|2011-09-13|Estimate||||2015-10-20|2015-10-21|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)|A Retrospective Survey to Evaluate the Renoprotective Effect of Losartan in Type II Diabetic Patients With Microalbuminuria and Hypertension in Real Life|Completed|||136|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-05-31 22:23:27.730383|2018-05-31 22:23:27.730383
NCT01390402|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2015-11-25||2016-01-04|2011-07-07|2011-07-11|Estimate|2015-11-25|2015-12-31|Estimate||||2016-01-04|2016-02-03|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG|Natural Killer (NK) Cells and Nonmyeloablative Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)|Completed||Phase 2|6|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:23:28.004074|2018-05-31 22:23:28.004074
NCT01390389|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2013-08-26||2017-11-02|2011-07-08|2011-07-11|Estimate|2013-10-30|2013-11-25|Estimate||||2017-11-02|2017-12-07|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression|Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression: A 31 Phosphorus MR Spectroscopy Study|Completed||N/A|19|Actual|Mclean Hospital||2|||f||||t||||||||||2018-05-31 22:23:28.280456|2018-05-31 22:23:28.280456
NCT01390376|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2016-03-29|2011-07-08|2011-07-11|Estimate|||||||2016-03-29|2016-03-31|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||DAAOI-1 Treatment for Treatment-resistant Schizophrenia|DAAOI-1 Treatment for Treatment-resistant Schizophrenia|Completed||Phase 2|60|Actual|China Medical University Hospital||3|||f||||f||||||||||2018-05-31 22:23:28.64106|2018-05-31 22:23:28.64106
NCT01390363|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2017-04-12|2011-07-07|2011-07-11|Estimate|||||||2017-04-12|2017-04-13|Actual|May 1, 2010|Actual|2010-05-01|April 2017|2017-04-30|July 31, 2011|Actual|2011-07-31|July 31, 2011|Actual|2011-07-31||Interventional|||Study of Adolescent Immunization Recall Systems|Adolescent Immunization Recall Systems: A Randomized Controlled Trial|Completed||N/A|420|Actual|Boston Children’s Hospital||3|||f||||f||||||||||2018-05-31 22:23:28.702267|2018-05-31 22:23:28.702267
NCT01036074|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-05-15|2009-12-18|2009-12-21|Estimate|||||||2018-05-15|2018-05-16|Actual|March 17, 2005||2005-03-17|April 8, 2013|2013-04-08|April 8, 2013||2013-04-08|||||Observational|||Reward Processing in Cocaine Addiction|Reward Processing in Cocaine Addiction|Completed|||90|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:40.631469|2018-06-01 00:14:40.631469
NCT01390350|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2018-02-22|2011-07-08|2011-07-11|Estimate|||||||2018-02-22|2018-02-23|Actual|July 2011||2011-07-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|December 21, 2017|Actual|2017-12-21||Interventional|ILESCH||Ilaris® Effects in Schnitzler Syndrome (ILESCH)|A Multi-center, Double-blind, Placebo-controlled Phase II Study of the Efficacy and Safety of Canakinumab in Subjects With Schnitzler Syndrome|Active, not recruiting||Phase 2|20|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:23:28.773785|2018-05-31 22:23:28.773785
NCT01390337|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-10-29|2011-07-07|2011-07-11|Estimate|||||||2015-10-29|2015-11-02|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)|A Phase 1 Study of AC220 (ASP2689) in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 1|19|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 22:23:28.849517|2018-05-31 22:23:28.849517
NCT01390324|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2016-10-18|2011-07-08|2011-07-11|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Atenéia||Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine|A Multicenter, National, Double-blind, Randomized Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Naratriptan 2,5 mg + Naproxen 500 mg Relative to Efficacy and Safety of Each Monotherapy for the Acute Treatment of Migraine|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||3|||f||||f||||||||||2018-05-31 22:23:28.941506|2018-05-31 22:23:28.941506
NCT01390311|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-04-24|2011-07-06|2011-07-11|Estimate|||||||2015-04-24|2015-04-27|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2014|Actual|2014-03-31||Interventional|||Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant|A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation|Completed||Phase 1|14|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 22:23:29.041133|2018-05-31 22:23:29.041133
NCT01390298|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-01-29|2011-07-07|2011-07-11|Estimate|||||||2017-01-29|2017-01-31|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Pain and Function After Orthopedic Surgery|Pain and Function After Orthopedic Surgery|Recruiting|||75|Anticipated|Wake Forest University Health Sciences|||1||f||||f||||||Samples With DNA|"~     Plasma~   "|||2018-05-31 22:23:29.154909|2018-05-31 22:23:29.154909
NCT01390285|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-07-06|2011-07-06|2011-07-11|Estimate|||||||2011-07-06|2011-07-11|Estimate|February 2012||2012-02-29|April 2011|2011-04-30|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Interventional|TENSSENS||Transcutaneous Electrical Nerve Stimulation in Relation to Central Sensitization in Osteoarthritis of the Knee|Effect of Transcutaneous Electrical Nerve Stimulation in Relation to Central Sensitization in Patients With Osteoarthritis of the Knee: a Randomized Controlled Clinical Trial.|Unknown status|Not yet recruiting|N/A|98|Anticipated|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 22:23:29.240064|2018-05-31 22:23:29.240064
NCT01390272|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-02-28|2011-07-06|2011-07-11|Estimate|||||||2017-02-28|2017-03-01|Actual|July 27, 2012|Actual|2012-07-27|February 2017|2017-02-28|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|TDM||Titrated Disease Management for Patients With Hypertension|Randomized Trial of Titrated Disease Management for Patients With Hypertension|Completed||N/A|385|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 22:23:29.310961|2018-05-31 22:23:29.310961
NCT01390259|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|2014-06-27||2014-07-24|2011-07-07|2011-07-11|Estimate|2014-07-24|2014-08-15|Estimate||||2014-07-24|2014-08-15|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|MDB005||Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System|Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System|Completed||N/A|11|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 22:23:29.633662|2018-05-31 22:23:29.633662
NCT01390246|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2017-12-08||2018-02-14|2011-07-06|2011-07-08|Estimate|2018-01-16|2018-02-13|Actual||||2018-02-14|2018-03-16|Actual|July 2011||2011-07-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Bupropion for Smoking Cessation During Pregnancy|Bupropion for Smoking Cessation During Pregnancy|Completed||Phase 4|65|Actual|The University of Texas Medical Branch, Galveston|Factors affecting enrollment included social stigma of prenatal smoking and use of medications; high rate of early withdrawal/lost to follow since longitudinal|2|||f||||t||||||||No|No plan|2018-05-31 22:23:29.84346|2018-05-31 22:23:29.84346
NCT01390233|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|2014-05-01||2014-05-01|2011-07-06|2011-07-08|Estimate|2014-05-01|2014-05-30|Estimate||||2014-05-01|2014-05-30|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Comparison of Pre-Induction Cervical Ripening|Comparison of Pre-Induction Cervical Ripening Using Prepidil Gel Administered Through a Urinary Balloon Catheter.|Completed||N/A|102|Actual|University of South Carolina|Limits included: patients enrolled who did not meet inclusion criteria (Bishop score too favorable, but recruited by clinician), patients who were enrolled but catheter could not be placed, patient enrolled who ultimately decided to undergo cesarean.|3|||f||||f||||||||||2018-05-31 22:23:30.286994|2018-05-31 22:23:30.286994
NCT01390220|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06||2018-03-15|2018-03-15|2011-07-07|2011-07-08|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|June 2011||2011-06-30|March 2018|2018-03-31||||March 2017|Actual|2017-03-31||Interventional|ARTEMIS1||Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters|A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters. ARTEMIS-1: Acute Rescue Therapy in Epilepsy With Midazolam Intranasal Spray-1|Terminated||Phase 3|201|Actual|Proximagen, LLC||2|||f||||t||||||||||2018-05-31 22:23:30.676881|2018-05-31 22:23:30.676881
NCT01390207|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-08-03|2011-07-07|2011-07-08|Estimate|||||||2011-08-03|2011-08-04|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|16mm||Earlier Triggering in Rec-FSH/GnRH Antagonist Cycles|Does Earlier Administration Of Human Chorionic Gonadotropin (hCG) Improve The Probability Of Pregnancy In Cycles Stimulated With Rec-FSH AND GnRH Antagonists? A Prospective Randomized Trial|Completed||Phase 2/Phase 3|100|Actual|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 22:23:30.902533|2018-05-31 22:23:30.902533
NCT01390194|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2015-11-12|2011-07-07|2011-07-08|Estimate|||||||2015-11-12|2015-11-13|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||A Rapid 10-minute Liver MRI|A Rapid 10-minute Liver MRI|Completed|||25|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 22:23:30.973449|2018-05-31 22:23:30.973449
NCT01390181|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2017-03-02||2017-03-02|2011-07-07|2011-07-08|Estimate|2017-03-02|2017-04-14|Actual||||2017-03-02|2017-04-14|Actual|September 2011||2011-09-30|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Losartan in Bicuspid Aortic Valve Patients|The Effect of Losartan Treatment on Matrix Metalloproteinase Levels and Outcomes in Bicuspid Aortic Valve Patients|Terminated||N/A|4|Actual|University of Michigan||1||"Due to low enrollment the decision was made to terminate study prior to final data collection~   for any individual."|f||||||||||||||2018-05-31 22:23:31.056501|2018-05-31 22:23:31.056501
NCT01390168|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2013-03-04|2011-07-06|2011-07-08|Estimate|||||||2013-03-04|2013-03-05|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|NOVA II||Internet-administrated Treatment of Anxiety Disorders|Tailored Internet-administrated Treatment of Anxiety Disorders - A Randomised Controlled Trial (NOVA II)|Completed||N/A|100|Actual|Umeå University||2|||f||||||||||||||2018-05-31 22:23:31.224173|2018-05-31 22:23:31.224173
NCT01390155|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2013-05-23|2011-07-06|2011-07-08|Estimate|||||||2013-05-23|2013-05-24|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Characterization of Ischemia Related Changes in Esophageal Electrocardiography|Characterization of Ischemia Related Changes in Esophageal Electrocardiography|Completed|||45|Actual|University Hospital Inselspital, Berne|||4||f||||f||||||||||2018-05-31 22:23:31.31124|2018-05-31 22:23:31.31124
NCT01390142|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-10-17|2011-07-06|2011-07-08|Estimate|||||||2013-10-17|2013-10-18|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|RIRE-1||Remote Ischemic Preconditioning Combined to Local Ischemic Postconditioning in Acute Myocardial Infarction|Remote Ischemic Preconditioning Combined to Local Ischemic Postconditioning in Acute Myocardial Infarction (RIRE-1)|Completed||Phase 3|60|Actual|University Hospital, Angers||3|||f||||||||||||||2018-05-31 22:23:31.645626|2018-05-31 22:23:31.645626
NCT01390129|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2012-10-23|2011-07-06|2011-07-08|Estimate|||||||2012-10-23|2012-10-24|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|RIP-Valve||Remote Ischemic Preconditioning in Aortic Valve Surgery|Remote Ischemic Preconditioning in Aortic Valve Surgery (RIP-Valve)|Completed||N/A|100|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 22:23:31.740459|2018-05-31 22:23:31.740459
NCT01390116|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-11-12|2011-07-06|2011-07-08|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Effect of Aged Garlic Extract Supplementation on Immune System|The Effect of Aged Garlic Extract Supplementation on Immune System|Completed||N/A|120|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:23:31.813698|2018-05-31 22:23:31.813698
NCT01390103|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-04-18|2011-07-06|2011-07-08|Estimate|||||||2013-04-18|2013-04-22|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain|Do Hip Injections Improve Short-Term Biomechanical Outcomes In Patients With Hip Pain|Completed|||29|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 22:23:31.883055|2018-05-31 22:23:31.883055
NCT01390090|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2016-11-17|2011-07-06|2011-07-08|Estimate|||||||2016-11-17|2016-11-21|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Ultrasound Confirmation of Fluoroscopically Guided Piriformis Muscle Injections|Ultrasound Confirmation of Fluoroscopically Guided Piriformis Muscle Injections: Does Accuracy Improve Efficacy?|Withdrawn|||0|Actual|University of Florida||||The Principal Investigator left the University|f||||f||||||||||2018-05-31 22:23:31.952975|2018-05-31 22:23:31.952975
NCT01390077|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-05-12|2011-07-06|2011-07-08|Estimate|||||||2016-05-12|2016-05-16|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria|Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria|Unknown status|Active, not recruiting|Phase 2/Phase 3|8|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 22:23:32.002687|2018-05-31 22:23:32.002687
NCT01390064|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-08-30|2011-07-07|2011-07-08|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2011||2011-07-31|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Vaccination of High Risk Breast Cancer Patients|Phase 1 Safety Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDE ISA 51 VG Adjuvant|Active, not recruiting||Phase 1|24|Anticipated|University of Arkansas||3|||f||||t||||||||||2018-05-31 22:23:32.110925|2018-05-31 22:23:32.110925
NCT01390051|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-08-17|2011-07-07|2011-07-08|Estimate|||||||2016-08-17|2016-08-18|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|IUGR||Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?|Can Treatment With Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?|Completed||Phase 4|50|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 22:23:32.23271|2018-05-31 22:23:32.23271
NCT01390038|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2016-02-16||2016-03-14|2011-07-06|2011-07-08|Estimate|2016-03-14|2016-04-14|Estimate||||2016-03-14|2016-04-14|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty|Simpliciti IDE Trial|Completed||Phase 3|157|Actual|Tornier, Inc.||1|||f||||f||||||||||2018-05-31 22:23:32.432379|2018-05-31 22:23:32.432379
NCT01390025|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-03-30|2011-07-07|2011-07-08|Estimate|||||||2012-03-30|2012-04-02|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza|Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Theraclone Sciences, Inc.||2|||f||||t||||||||||2018-05-31 22:23:32.700598|2018-05-31 22:23:32.700598
NCT01390012|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2014-01-14|2011-07-07|2011-07-08|Estimate|||||||2014-01-14|2014-01-15|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|OVID||Oral Versus Intravenous Dexamethasone|Oral Versus Intravenous Dexamethasone in Community-Acquired Pneumonia|Completed||Phase 3|30|Actual|St. Antonius Hospital||2|||f||||f||||||||||2018-05-31 22:23:32.772463|2018-05-31 22:23:32.772463
NCT01389999|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|||2015-03-24|2011-07-07|2011-07-08|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|BBQ||Validation of the French Version of the Back Belief Questionnaire|Validation of the French Version of the Back Belief Questionnaire|Terminated|||131|Actual|Centre Hospitalier Universitaire de Nīmes|||1|difficult recruitment curve|f||||f||||||||||2018-05-31 22:23:32.83567|2018-05-31 22:23:32.83567
NCT01389635|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-07|2011-07-07|2011-07-08|Estimate|||||||2011-07-07|2011-07-08|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Observational|||Abdominoplasty Under Epidural Anesthesia|Abdominoplasty Under Epidural Anesthesia: Safer for the Patient, Easier for the Surgeon.|Completed|||31|Actual|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 22:23:41.021387|2018-05-31 22:23:41.021387
NCT01389986|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-08-29|2011-07-07|2011-07-08|Estimate|||||||2016-08-29|2016-08-30|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer|Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer: a Randomized Controlled Trial|Withdrawn||Phase 2/Phase 3|0|Actual|Chiang Mai University||2|||f||||f||||||||||2018-05-31 22:23:32.893584|2018-05-31 22:23:32.893584
NCT01389973|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-07|2014-08-19|2013-05-22|2016-06-17|2011-07-07|2011-07-08|Estimate|2014-10-14|2014-10-15|Estimate|2013-09-09|2013-09-17|Estimate|2016-06-17|2016-06-20|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Efficacy analysis set included all participants who received at least 1 administration of ustekinumab (full or partial).|A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects With Primary Biliary Cirrhosis Who Had an Inadequate Response to Ursodeoxycholic Acid (UDCA)|Completed||Phase 2|20|Actual|Janssen Research & Development, LLC|Based on the efficacy results of Part 1, Part 2 of the study was not initiated and as per the study design, the study was considered completed after part 1.|5|||f||||||||||||||2018-05-31 22:23:32.998868|2018-05-31 22:23:32.998868
NCT01389947|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2012-02-08|2011-07-07|2011-07-08|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Observational|CITRON4||Microcirculation During Extracorporeal Circulation|Study of Non Major Microcirculation During Extracorporeal Circulation : Relation Between Endothelial Dysfunction and Digestive|Completed|||66|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||t||||||Samples Without DNA|"~     Plasma measurments Tissular oxygen saturation using NIRS probe~   "|||2018-05-31 22:23:33.387979|2018-05-31 22:23:33.387979
NCT01389934|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-02-02|2011-07-07|2011-07-08|Estimate|||||||2012-02-02|2012-02-03|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Infusion of a Local Anaesthetic in the Surgical After Modified Radical Mastectomy With Expander|Infusion of a Local Anaesthetic in the Surgical After Modified Radical Mastectomy With Expander|Completed||Phase 4|80|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 22:23:33.49745|2018-05-31 22:23:33.49745
NCT01389921|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-03-22|2011-07-07|2011-07-08|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|April 2014|Actual|2014-04-30|September 2011|Actual|2011-09-30||Interventional|||Study of Electroencephalogram (EEG) Measurement During Different Stimulations of the Lower Urinary Tract|Investigation of Lower Urinary Tract Afferent and Cortical Brain Activity During Lower Urinary Tract Stimulation Using Electroencephalogram Measurements|Completed||N/A|83|Actual|University of Zurich||3|||f||||f||||||||||2018-05-31 22:23:33.602584|2018-05-31 22:23:33.602584
NCT01389908|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-07|2011-07-07|2011-07-08|Estimate|||||||2011-07-07|2011-07-08|Estimate|June 2011||2011-06-30|June 2011|2011-06-30||||July 2014|Anticipated|2014-07-31||Interventional|||A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder||Unknown status|Recruiting|N/A|2|Anticipated|Shalvata Mental Health Center||1|||f||||t||||||||||2018-05-31 22:23:33.699153|2018-05-31 22:23:33.699153
NCT01389895|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-01-09|2011-07-07|2011-07-08|Estimate|||||||2014-01-09|2014-01-10|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus|Terminated||Phase 1|1|Actual|Amgen||2||slow enrollment|f||||f||||||||||2018-05-31 22:23:33.812588|2018-05-31 22:23:33.812588
NCT01389882|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|2011-09-18||2012-01-05|2011-07-06|2011-07-08|Estimate|2011-09-21|2011-10-28|Estimate||||2012-01-05|2012-01-09|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Randomized Crossover Study of Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants|Application of Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants and Assessment of Its Benefits Compared to Synchronized Intermittent Mandatory Ventilation (SIMV) With Pressure Support (PS)|Completed||Phase 2|26|Actual|Seoul National University Hospital|Two patients were excluded prior to the study and five patients were interrupted the study because of a developed exclusion criterion during the protocol. Because of eliminated participants, the number of subjects analyzed was reduced.|1|||f||||t||||||||||2018-05-31 22:23:33.924564|2018-05-31 22:23:33.924564
NCT01389869|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-12-05|2011-07-07|2011-07-08|Estimate|||||||2013-12-05|2013-12-09|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Appetite Regulation by Human Chemosignals From Tears and Plasma||Completed||N/A|22|Actual|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 22:23:34.513084|2018-05-31 22:23:34.513084
NCT01389856|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2015-03-09||2015-04-09|2011-07-07|2011-07-08|Estimate|2015-03-09|2015-03-23|Estimate||||2015-04-09|2015-05-01|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|FUTURE 4|Randomized and treated patients|Persistent Pulmonary Hypertension of the Newborn|Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)|Terminated||Phase 3|23|Actual|Actelion||2||"To be compliant with the timelines as agreed with Paediatric Committee (PC) within the~   Paediatric Investigational Plan"|f||||t||||||||||2018-05-31 22:23:34.675253|2018-05-31 22:23:34.675253
NCT01389843|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-04-25|2011-07-07|2011-07-08|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2011||2011-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|KorAHF||Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)|Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)|Active, not recruiting|||5625|Actual|Seoul National University Hospital|||1||f||||t||||||||Yes|Data be shared with participating institution and NNIH|2018-05-31 22:23:35.835688|2018-05-31 22:23:35.835688
NCT01389830|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-08-01|2011-07-07|2011-07-08|Estimate|||||||2017-08-01|2017-08-03|Actual|June 2011|Actual|2011-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer|End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer|Active, not recruiting|||230|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 22:23:35.932081|2018-05-31 22:23:35.932081
NCT01383486|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2012-08-30||2015-09-24|2011-06-27|2011-06-28|Estimate|2012-11-28|2012-11-29|Estimate||||2015-09-24|2015-10-15|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|KEIFER SST||Self Selection Trial of Naproxen Sodium|A Pilot Self Selection Trial of an Extended-Release Over-the-Counter Analgesic|Completed||Phase 3|253|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:25:58.051925|2018-05-31 22:25:58.051925
NCT01389817|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|2014-09-23||2014-09-23|2011-07-07|2011-07-08|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|LHON||Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)|Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)|Terminated||Phase 1/Phase 2|4|Actual|Medical College of Wisconsin||2||"Unable to record n95 pERG peak (primary measure), as LHON subjects are unable to focus on~   target."|f||||f||||||||||2018-05-31 22:23:36.035343|2018-05-31 22:23:36.035343
NCT01389804|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2012-04-19|2011-07-07|2011-07-08|Estimate|||||||2012-04-19|2012-04-23|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Parents of Pediatric Solid Organ Transplant Recipients: Transition to Home and Chronic Illness Care|Parents of Pediatric Solid Organ Transplant Recipients: Transition to Home and Chronic Illness Care|Completed|||51|Actual|Medical College of Wisconsin|||1||f||||f||||||||||2018-05-31 22:23:36.31472|2018-05-31 22:23:36.31472
NCT01389791|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2012-01-06|2011-07-06|2011-07-08|Estimate|||||||2012-01-06|2012-01-10|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||MgSO4 Combined With Rocuronium Priming|MgSO4 Combined With Rocuronium Priming|Unknown status|Recruiting|N/A|100|Anticipated|Seoul National University Bundang Hospital||4|||f||||t||||||||||2018-05-31 22:23:36.385296|2018-05-31 22:23:36.385296
NCT01389778|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-03-21|2011-07-07|2011-07-08|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2011||2011-06-30|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Polycystic Ovary Syndrome Genetics and Treatment Response|Polycystic Ovary Syndrome Genetics and Treatment Response|Active, not recruiting||N/A|200|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:23:36.455326|2018-05-31 22:23:36.455326
NCT01389765|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-09-12|2011-07-06|2011-07-08|Estimate|||||||2011-09-12|2011-09-13|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Evaluate the Effect of Food on LY2216684|Effect of Food on the Pharmacokinetics of LY2216684 in Healthy Subjects|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:23:36.540959|2018-05-31 22:23:36.540959
NCT01389752|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-09-23|2011-07-06|2011-07-08|Estimate|||||||2011-09-23|2011-09-26|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects|Effect of Activated Charcoal on the Pharmacokinetics of LY2216684 in Healthy Subjects|Completed||Phase 1|22|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:23:36.62087|2018-05-31 22:23:36.62087
NCT01389739|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-03-31|2011-07-06|2011-07-08|Estimate|||||||2015-03-31|2015-04-01|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Intervention to Improve Continuity of Care in Lung Cancer Patients|Evaluation of a Multi-faceted Intervention to Improve Continuity of Care for Patients With Lung Cancer|Completed||N/A|206|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:23:36.687365|2018-05-31 22:23:36.687365
NCT01389726|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-06|2011-07-06|2011-07-08|Estimate|||||||2011-07-06|2011-07-08|Estimate|January 2012||2012-01-31|July 2011|2011-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|COPE||Comparing Interventions To Improve The Well-Being Of Custodial Grandfamilies|Comparing Interventions To Improve The Well-Being Of Custodial Grandfamilies|Unknown status|Not yet recruiting|Phase 2/Phase 3|504|Anticipated|Kent State University||3|||f||||t||||||||||2018-05-31 22:23:36.763634|2018-05-31 22:23:36.763634
NCT01389713|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-11|2011-07-07|2011-07-08|Estimate|||||||2011-07-11|2011-07-12|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|clomid||Clomifene Citrate as First Line Treatment in in Vitro Fertilization Cycles for Patients With Lower Ovarian Reserve|Patients With Reduced Ovarian Reserve and In Vitro Fertilization (IVF) Cycles. A Randomized Multicentric Comparison of a Protocol With High Doses of Gonadotropins and a Protocol With Clomiphene Citrate Only. Evaluation of Clinical Effectiveness and Economic Issues|Completed||N/A|289|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||||2018-05-31 22:23:36.867543|2018-05-31 22:23:36.867543
NCT01389700|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06||2014-03-17|2014-11-25|2011-07-06|2011-07-08|Estimate||||2014-03-17|2014-04-14|Estimate|2014-11-25|2014-12-12|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients|A Randomized, Double-blind, Placebo-controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation|Terminated||Phase 2|7|Actual|Sanofi||3||Difficulty in patient recruitment in the participating sites|f||||||||||||||2018-05-31 22:23:37.083846|2018-05-31 22:23:37.083846
NCT01389687|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-03-28|2011-07-06|2011-07-08|Estimate|||||||2013-03-28|2013-03-29|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan|Immunogenicity and Safety of the SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan|Completed||Phase 3|74|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:23:37.352321|2018-05-31 22:23:37.352321
NCT01389674|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2014-06-06|2011-07-06|2011-07-08|Estimate|||||||2014-06-06|2014-06-09|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Hybrid Intraprocedural Imaging Based on 2 Different Imaging Methods|Hybrid Intraprocedural Imaging From 2D-Strain-echocardiography and X-ray Based Biplane Coronary Angiography for Guiding Interventional Revascularization Therapy|Withdrawn||N/A|0|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 22:23:37.66054|2018-05-31 22:23:37.66054
NCT01389661|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2017-04-25|2011-07-07|2011-07-08|Estimate|||||||2017-04-25|2017-04-27|Actual|April 2011|Actual|2011-04-30|April 2017|2017-04-30|April 25, 2016|Actual|2016-04-25|April 25, 2016|Actual|2016-04-25||Interventional|BIOMAX||Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)|Regeneration of Maxillary Bone Cystic Cavities by Bio Implant of MSHV-H Cells Associated to a Cross-linked Serum Scaffold|Completed||Phase 1/Phase 2|11|Actual|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 22:23:38.176675|2018-05-31 22:23:38.176675
NCT01389648|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-09-15|2011-07-07|2011-07-08|Estimate|||||||2013-09-15|2013-09-17|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pre-operative Physiotherapy to Prevent Post-operative Complications|The Effect of Pre-operative Chest Physiotherapy on Post-operative Complications After Major Abdominal Surgery.|Completed||N/A|157|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:23:38.570032|2018-05-31 22:23:38.570032
NCT01389622|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-11-17|2011-07-06|2011-07-08|Estimate|||||||2014-11-17|2014-11-18|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Self-administered Auricular Acupressure on Smoking Cessation—a Pilot Study|Effect of Self-administered Auricular Acupressure on Smoking Cessation—a Pilot Study|Unknown status|Recruiting|Phase 2|60|Anticipated|Queen's University||3|||f||||f||||||||||2018-05-31 22:23:43.479137|2018-05-31 22:23:43.479137
NCT01389609|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-10-05|2011-07-06|2011-07-08|Estimate|||||||2011-10-05|2011-10-07|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition|Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:23:43.625008|2018-05-31 22:23:43.625008
NCT01389596|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|2017-01-31||2017-11-13|2011-07-06|2011-07-08|Estimate|2017-01-31|2017-03-21|Actual||||2017-11-13|2017-12-12|Actual|September 2011|Actual|2011-09-30|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PERIWINKLE|Safety population included all randomized participants who received at least 1 dose of study drug.|A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years|A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 4 -16 Years Of Age With Partial Onset Seizures|Completed||Phase 3|295|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:23:43.796671|2018-05-31 22:23:43.796671
NCT01389583|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2015-02-23|2011-07-07|2011-07-08|Estimate|||||||2015-02-23|2015-02-25|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|October 2019|Anticipated|2019-10-31|May 2015|Anticipated|2015-05-31||Interventional|||A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients|A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy|Recruiting||Phase 2|25|Anticipated|National Health Research Institutes, Taiwan||1|||f||||t||||||||||2018-05-31 22:23:46.189372|2018-05-31 22:23:46.189372
NCT01389570|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-07-15|2011-07-06|2011-07-08|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|Acunausea||Postoperative Nausea/Vomiting and Acupressure|Postoperative Nausea/Vomiting and Acupressure Can Acupressure With Wristbands Reduce the Use of Antiemetics for the Treatment of Postoperative Nausea and Vomiting?|Unknown status|Not yet recruiting|Phase 2|2000|Anticipated|National Research Centre of Complementary and Alternative Medicine, Norway||1|||f||||f||||||||||2018-05-31 22:23:46.305611|2018-05-31 22:23:46.305611
NCT01389557|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2012-03-22|2011-07-07|2011-07-08|Estimate|||||||2012-03-22|2012-03-23|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra|Evaluation of Impact Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lempasing Village, Lampung Province, Southern Sumatra|Completed||Phase 4|77|Actual|Indonesia University|||||f||||f||||||||||2018-05-31 22:23:46.431402|2018-05-31 22:23:46.431402
NCT01389544|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2016-11-01|2011-07-06|2011-07-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study on the Interaction Between Danoprevir/Ritonavir and Methadone|Investigation of the Effect of Multiple Doses of Danoprevir/Ritonavir on Methadone in Subjects on Stable Methadone Maintenance Therapy (MMT)|Completed||Phase 1|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:23:46.63352|2018-05-31 22:23:46.63352
NCT01389531|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2014-12-30|2011-07-07|2011-07-08|Estimate|||||||2014-12-30|2014-12-31|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Efficacy and Safety Evaluation of HCPA-1 Silicone Stent in the Treatment of Central Airway Obstructions|Evaluation of the Efficacy and Safety of the HCPA-1 Silicone Stent in the Treatment of Central Airway Obstructions|Unknown status|Recruiting|N/A|110|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-05-31 22:23:46.713862|2018-05-31 22:23:46.713862
NCT01389518|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-11-24|2011-07-06|2011-07-08|Estimate|||||||2011-11-24|2011-11-28|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome|Evaluation of the Efficacy and Safety of Fixed Combination of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Symptomatic Common Cold and Flu Syndrome in Adults|Completed||Phase 3|146|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 22:23:46.832602|2018-05-31 22:23:46.832602
NCT01389505|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-07|2011-07-07|2011-07-08|Estimate|||||||2011-07-07|2011-07-08|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Structural and Functional Evaluation of the Macula in Patients With Proliferative Diabetic Retinopathy Treated With Panretinal Photocoagulation and Bevacizumab (Avastin ®)|Unknown status|Recruiting|Phase 2|30|Anticipated|Instituto do Coracao||2|||f||||f||||||||||2018-05-31 22:23:46.921924|2018-05-31 22:23:46.921924
NCT01389492|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2011-07-06|2011-07-06|2011-07-08|Estimate|||||||2011-07-06|2011-07-08|Estimate|October 2010||2010-10-31|October 2009|2009-10-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||The Effect of Meat and Food Drived Polyphenols on Oxidize LDL Level|Nutritional Study:The Effect of Meat and Food Drived Polyphenols on Oxidize LDL Level|Completed||N/A|14|Actual|Hadassah Medical Organization||4|||f||||t||||||||||2018-05-31 22:23:47.003172|2018-05-31 22:23:47.003172
NCT01389479|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2017-06-07|2011-07-06|2011-07-08|Estimate|||||||2017-06-07|2017-06-08|Actual|January 2005||2005-01-31|May 2017|2017-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults|Active-control Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ S/F Influenza Vaccine in Healthy Adults Aged 18-64 Years of Age|Completed||Phase 3|1000|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:23:47.153381|2018-05-31 22:23:47.153381
NCT01389466|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-19|||2014-11-20|2011-07-07|2011-07-08|Estimate|||||||2014-11-20|2014-11-21|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers|Randomized Phase I/II Study to Evaluate the Safety and Immunogenicity of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers|Completed||Phase 1/Phase 2|346|Actual|Green Cross Corporation||3|||f||||f||||||||||2018-05-31 22:23:47.21745|2018-05-31 22:23:47.21745
NCT01389453|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-02-26|2011-07-07|2011-07-08|Estimate|||||||2013-02-26|2013-02-28|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Clinical Trial Research of Stem Cell Transplantation Treats Cerebral|Umbilical Cord Mesenchyma Stem Cell Transplantation in Patients With Cerebral Hemorrhage and Cerebral Infarction|Withdrawn||Phase 2|0|Actual|General Hospital of Chinese Armed Police Forces||2||There were not enough number of patients recruited till DEC 31th in 2012.|f||||t||||||||||2018-05-31 22:23:47.313649|2018-05-31 22:23:47.313649
NCT01389440|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2018-05-15|2011-07-07|2011-07-08|Estimate|||||||2018-05-15|2018-05-18|Actual|May 2011||2011-05-31|August 2017|2017-08-31|January 22, 2017|Actual|2017-01-22|November 2016|Actual|2016-11-30||Interventional|GEMCAD1003||Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer|Phase II Study Open, Not Randomized to Evaluate the Efficacy and Safety of Neoadjuvant Treatment With Gemcitabine and Erlotinib Followed by Gemcitabine, Erlotinib and Radiotherapy in Patients With Resectable Pancreatic Adenocarcinoma|Completed||Phase 2|24|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||t||||||||||2018-05-31 22:23:47.405799|2018-05-31 22:23:47.405799
NCT01389427|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2017-03-08|2011-07-07|2011-07-08|Estimate|||||||2017-03-08|2017-03-09|Actual|November 2011|Actual|2011-11-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|T³||Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).|A Multicenter Phase IB Dose Escalation Study to Evaluate the Safety, Feasibility and Efficacy of the Torisel-Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (T-R-CHOP), Torisel-Rituximab-Fludarabine-Cyclophosphamide (T-R-FC) and Torisel-Rituximab-Aracytine High Dose-Dexamethasone (T-R-DHA) for the Treatment of Patients in Relapsed/Refractory Mantle Cell Lymphoma|Completed||Phase 1/Phase 2|41|Actual|The Lymphoma Academic Research Organisation||4|||f||||t||||||||||2018-05-31 22:23:47.498536|2018-05-31 22:23:47.498536
NCT01389414|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2015-05-27|2011-07-07|2011-07-08|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|September 2013|Actual|2013-09-30||Interventional|Vecti-BIL||Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma|Phase II, Open-label, Randomized Clinical Trial of Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX) Versus GEMOX Alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma|Completed||Phase 2|89|Actual|Fondazione del Piemonte per l'Oncologia||2|||f||||f||||||||||2018-05-31 22:23:47.639175|2018-05-31 22:23:47.639175
NCT01389401|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-03-05|2011-07-07|2011-07-08|Estimate|||||||2013-03-05|2013-03-06|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Observational|||Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis|Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis: Final Results|Completed|||36|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo|||3||f||||f||||||Samples Without DNA|"~     whole saliva~   "|||2018-05-31 22:23:47.77466|2018-05-31 22:23:47.77466
NCT01389388|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2015-05-06|2011-07-07|2011-07-08|Estimate|||||||2015-05-06|2015-05-07|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|RORAAS||Effects of Rosuvastatin on Carotid Artery Plaques in Patients With Inflammatory Joint Disease|Cholesterol Plaques in Carotid and Coronary Arteries and the Effect of Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases|Completed||N/A|114|Actual|Diakonhjemmet Hospital||1|||f||||f||||||||||2018-05-31 22:23:49.08796|2018-05-31 22:23:49.08796
NCT01389375|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-06-08|2011-07-06|2011-07-08|Estimate|||||||2016-06-08|2016-06-10|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ISAR-CLOSURE||Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial|Instrumental Sealing of Arterial Puncture Site Closure Device Versus Manual Compression Trial|Completed||Phase 4|4524|Actual|Deutsches Herzzentrum Muenchen||3|||f||||f||||||||||2018-05-31 22:23:49.470182|2018-05-31 22:23:49.470182
NCT01389362|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-27|2011-07-07|2011-07-08|Estimate|||||||2011-07-27|2011-07-28|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes|The Healing Effect of a Two-Herb Recipe on Foot Ulcer in Chinese Patients With Type 2 Diabetes: A Randomized, Placebo-Controlled Study|Completed||Phase 2/Phase 3|16|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 22:23:49.700582|2018-05-31 22:23:49.700582
NCT01389349|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2012-05-17|2011-07-07|2011-07-08|Estimate|||||||2012-05-17|2012-05-18|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Acupuncture for Tonsillectomy Pain|Acupuncture for Tonsillectomy Pain|Completed||N/A|130|Anticipated|Children's ENT of San Diego, Inc.||2|||f||||f||||||||||2018-05-31 22:23:49.820473|2018-05-31 22:23:49.820473
NCT01389336|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2013-05-07|2011-07-06|2011-07-08|Estimate|||||||2013-05-07|2013-05-08|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|KAFA||Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone|Kontrollierte Klinische Nicht-randomisierte Pilotstudie Zur Komplexen Āyurveda-Therapie Beim Fibromyalgiesyndrom im Vergleich Zur Konventionellen Standardbehandlung|Completed|||31|Actual|Charite University, Berlin, Germany|||2||f||||t||||||||||2018-05-31 22:23:49.934901|2018-05-31 22:23:49.934901
NCT01389323|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|2015-08-17||2015-09-19|2011-07-07|2011-07-08|Estimate|2015-08-17|2015-09-16|Estimate||||2015-09-19|2015-10-12|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional||All treated participants.|BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C|Open-Label, Single Arm Evaluation of BMS-790052 (Daclatasvir) in Combination With Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos and White-Caucasians With Chronic Hepatitis C Genotype 1 Infection|Completed||Phase 3|448|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 22:23:50.115334|2018-05-31 22:23:50.115334
NCT01389310|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2014-12-22|2011-07-07|2011-07-08|Estimate|||||||2014-12-22|2014-12-23|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe|Post-marketing Safety Surveillance Program in HIV-infected Children Exposed to Atazanavir in Europe|Completed|||249|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 22:23:50.957841|2018-05-31 22:23:50.957841
NCT01389297|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2014-02-24|2011-07-06|2011-07-08|Estimate|||||||2014-02-24|2014-02-25|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery|Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery|Completed||N/A|189|Actual|Behavior Therapy Associates, LLP||3|||f||||f||||||||||2018-05-31 22:23:51.098484|2018-05-31 22:23:51.098484
NCT01389284|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|2012-09-14||2015-08-12|2011-07-07|2011-07-08|Estimate|2013-03-24|2013-05-07|Estimate||||2015-08-12|2015-08-25|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|VERNE||Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium|A Randomized, Double-Blind, Placebo Controlled Trial to Assess the Analgesic Efficacy and Safety of Extended Release Naproxen Sodium Tablets in Postsurgical Dental Pain|Completed||Phase 3|300|Actual|Bayer||3|||f||||f||||||||||2018-05-31 22:23:51.252182|2018-05-31 22:23:51.252182
NCT01389271|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2018-05-11|2011-07-06|2011-07-08|Estimate|||||||2018-05-11|2018-05-14|Actual|February 3, 2011|Actual|2011-02-03|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|March 8, 2017|Actual|2017-03-08||Observational|OPTION||Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years|Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years|Active, not recruiting|||118|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:23:52.19371|2018-05-31 22:23:52.19371
NCT01389258|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-08-21|2011-07-07|2011-07-08|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2011||2011-06-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2014|Actual|2014-08-31||Interventional|||Study on OsseoSpeed™ TX Narrow Implants in the Upper Jaw in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate OsseoSpeed™ TX Single Implant 3 mm Diameter in the Anterior Maxilla. A 3-years Follow-up Study.|Completed||N/A|45|Actual|Dentsply Sirona Implants||1|||f||||||||||||||2018-05-31 22:23:52.2725|2018-05-31 22:23:52.2725
NCT01389245|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2017-08-21|2011-07-07|2011-07-08|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2011||2011-06-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|July 2015|Actual|2015-07-31||Interventional|||Study on OsseoSpeed™ TX Implants in the Upper Jaw in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate the OsseoSpeed™ TX Implant With an Early Loading Protocol in Patients With Tooth Loss in the Posterior Maxilla. A 3-years Follow-up Study.|Active, not recruiting||N/A|42|Actual|Dentsply Sirona Implants||1|||f||||||||||||||2018-05-31 22:23:52.355142|2018-05-31 22:23:52.355142
NCT01389232|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06||2014-08-22|2015-04-24|2011-07-07|2011-07-08|Estimate||||2014-10-03|2014-10-13|Estimate|2015-04-24|2015-05-12|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|August 2013|Actual|2013-08-31||Interventional|||The SeriScaffold® Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery in Europe||Completed||N/A|100|Actual|Allergan||1|||f||||||||||||||2018-05-31 22:23:52.472506|2018-05-31 22:23:52.472506
NCT01389219|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2011-07-07|2011-07-07|2011-07-08|Estimate|||||||2011-07-07|2011-07-08|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Post Partum Maternal and Neonatal Intervention Package|Post Partum Maternal and Neonatal Intervention Package: A Cluster Randomized Control Trial in District Sukkur, Pakistan|Completed||N/A|1200|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 22:23:52.567236|2018-05-31 22:23:52.567236
NCT01389206|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2018-03-08|2011-07-07|2011-07-08|Estimate|||||||2018-03-08|2018-03-12|Actual|June 1, 2011||2011-06-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30|3 Years|Observational [Patient Registry]|PAH QuERI Ext||Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program|Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program|Active, not recruiting|||797|Actual|Actelion|||1||f||||f|t|f||||||||2018-05-31 22:23:52.654935|2018-05-31 22:23:52.654935
NCT01389193|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-12-28|2011-07-07|2011-07-08|Estimate|||||||2015-12-28|2015-12-29|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IBU-003||Ibudilast in the Treatment of Patients With Chronic Migraine.|Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST|Completed||Phase 1|33|Actual|Aalborg University||2|||f||||t||||||||||2018-05-31 22:23:52.985387|2018-05-31 22:23:52.985387
NCT01389180|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2016-09-28|2011-07-06|2011-07-07|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Behavioral Drug and HIV Risk Reduction Counseling With MMT in China|Behavioral Drug and HIV Risk Reduction Counseling With MMT in China|Completed||Phase 3|300|Actual|Yale University||3|||f||||f||||||||||2018-05-31 22:23:53.121925|2018-05-31 22:23:53.121925
NCT01389167|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2018-01-09|2011-07-06|2011-07-07|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2011||2011-09-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|September 2016|Actual|2016-09-30||Interventional|||Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia|Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia|Completed||Phase 3|320|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 22:23:53.296323|2018-05-31 22:23:53.296323
NCT01389154|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2014-07-16|2011-07-05|2011-07-07|Estimate|||||||2014-07-16|2014-07-18|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|ALOSPNDY||Pilot Study to Measure Lung Biopsy Diagnostic Yield Using Always On Electromagnetic Tip Tracked Devices|A Pilot Prospective Study Evaluating the SPiN Drive(TM)Electromagnetic Tip Tracked Devices Used in Diagnostic Bronchoscopy|Withdrawn||Phase 4|0|Actual|Veran Medical Technologies||1||Product Enhancements completed|f||||t||||||||||2018-05-31 22:23:53.454821|2018-05-31 22:23:53.454821
NCT01389141|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-08-11|2011-07-05|2011-07-07|Estimate|||||||2011-08-11|2011-08-15|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Age-related Changes in Ovarian Follicular Wave Dynamics|Ovarian Follicular Wave Dynamics During The Menstrual Cycle: Relationship To Age, Reproductive Hormones And Musculoskeletal Health|Completed|||70|Actual|University of Saskatchewan|||3||f||||f||||||Samples Without DNA|"~     Serum samples are isolated and frozen for retrospective analyses.~   "|||2018-05-31 22:23:53.62011|2018-05-31 22:23:53.62011
NCT01389128|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2012-05-29|2011-07-06|2011-07-07|Estimate|||||||2012-05-29|2012-05-31|Estimate|October 2011||2011-10-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Non-pharmacological Resources in Assisting Labor|Application of Non-pharmacological Resources in Assisting Labor: Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:23:53.730792|2018-05-31 22:23:53.730792
NCT01389115|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2015-12-10|2011-07-05|2011-07-07|Estimate|||||||2015-12-10|2015-12-11|Estimate|July 2001||2001-07-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Observational|||Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation|Fatty Acids Lipidome and Oxidative Stress Markers as Indicators of Liver Transplant Outcome|Unknown status|Recruiting||320|Anticipated|University of Roma La Sapienza|||3||f||||t||||||Samples With DNA|"~     Blood samples and liver biopsy specimens~   "|||2018-05-31 22:23:53.994185|2018-05-31 22:23:53.994185
NCT01333566|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2016-07-01|2011-04-11|2011-04-12|Estimate|||||||2016-07-01|2016-07-04|Estimate|July 2009||2009-07-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Qigong Exercise May Benefit Patients With Fibromyalgia|Qigong Exercise May Benefit Patients With Fibromyalgia|Completed||N/A|35|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 22:42:41.975299|2018-05-31 22:42:41.975299
NCT01389102|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|2012-02-29||2012-06-08|2011-07-06|2011-07-07|Estimate|2012-06-08|2012-06-11|Estimate||||2012-06-08|2012-06-11|Estimate|December 2004||2004-12-31|June 2012|2012-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Estradiol Metered-Dose Transdermal Spray (MDTS) in the Treatment of Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 3|454|Actual|Lumara Health, Inc.||6|||f||||f||||||||||2018-05-31 22:23:54.239576|2018-05-31 22:23:54.239576
NCT01389089|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-07-06|2011-07-06|2011-07-07|Estimate|||||||2011-07-06|2011-07-07|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|||Effective Treatment of Posttraumatic and Postoperative Edema|Effective Treatment of Posttraumatic and Postoperative Edema in Patients With Ankle- and Hindfoot Fractures. A Randomized Controlled Trial Comparing Multi-layer Compression Therapy and A-V Impulse Compression to the Standard Treatment With Ice|Completed||Phase 4|64|Actual|Luzerner Kantonsspital||3|||f||||t||||||||||2018-05-31 22:23:54.89418|2018-05-31 22:23:54.89418
NCT01389076|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|2016-06-02||2016-12-01|2011-07-06|2011-07-07|Estimate|2016-06-02|2016-07-12|Estimate||||2016-12-01|2017-01-30|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|February 2014|Actual|2014-02-28||Interventional|||Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma|Phase II Trial of Low-Dose Methotrexate and Iodine I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma|Terminated||Phase 2|22|Actual|University of Michigan Cancer Center|This trial was abandoned prematurely due to the withdrawal of Bexxar by the manufacturer and failure to find another supplier.|1||Bexxar isn't being produced by the manufacturer as of Feb. 2014|f||||t||||||||||2018-05-31 22:23:55.021941|2018-05-31 22:23:55.021941
NCT01389063|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2013-12-17|2011-07-06|2011-07-07|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|MASTER||Maraviroc Abacavir STudy - Effect on Endothelial Recovery|Maraviroc Abacavir STudy - Effect on Endothelial Recovery|Unknown status|Recruiting|Phase 4|24|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 22:23:55.316416|2018-05-31 22:23:55.316416
NCT01389050|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-01-22|2011-07-05|2011-07-07|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2011||2011-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||High Precision RT For Soft-Tissue Sarcoma|Use of High Precision Radiotherapy in the Management of Soft-Tissue Sarcomas|Active, not recruiting||Phase 2|70|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:23:55.54435|2018-05-31 22:23:55.54435
NCT01389037|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2017-12-07|2011-07-06|2011-07-07|Estimate|||||||2017-12-07|2017-12-11|Actual|October 2011|Actual|2011-10-31|December 2017|2017-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Understanding Health Care Information for African Americans With High Blood Pressure|Promoting Health Literacy of African Americans With High Blood Pressure|Completed||N/A|198|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:23:55.629322|2018-05-31 22:23:55.629322
NCT01389024|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2016-09-03|2011-07-06|2011-07-07|Estimate|||||||2016-09-03|2016-09-07|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|HUPrevent||Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease|Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children|Recruiting||Phase 2|40|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 22:23:55.738677|2018-05-31 22:23:55.738677
NCT01389011|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-09-06|2011-07-06|2011-07-07|Estimate|||||||2011-09-06|2011-09-07|Estimate|September 2010||2010-09-30|July 2011|2011-07-31||||||||Observational|PI-PVI||Perfusion Index (PI) and Pleth Variability Index (PVI) in Patients With Interscalene Blocks in Orthopedic Surgery|An Evaluation of PI and PVI (Masimo) in Patients With Interscalene Blocks in Orthopedic Surgery|Completed|||30|Anticipated|Johannes Gutenberg University Mainz|||||f||||f||||||||||2018-05-31 22:23:55.974105|2018-05-31 22:23:55.974105
NCT01388998|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-04-22|2011-07-06|2011-07-07|Estimate|||||||2012-04-22|2012-04-24|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Fluid Management Study to Evaluate Changes in Intravascular Volume After Applying Various Pressure Levels on the Caval Vein|External Pressure Applied on the Caval Vein and Its Effects on Difference in Pulse Pressure (dPP) and Pleth Variability Index (PVI)|Completed||N/A|24|Actual|Johannes Gutenberg University Mainz|||||f||||f||||||||||2018-05-31 22:23:56.027057|2018-05-31 22:23:56.027057
NCT01388985|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-03-04|2011-07-06|2011-07-07|Estimate|||||||2016-03-04|2016-03-07|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Simplifying the Rabies Pre-exposure Vaccination|Simplifying the Rabies Pre-exposure Vaccination|Completed||Phase 3|500|Actual|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-05-31 22:23:56.138214|2018-05-31 22:23:56.138214
NCT01388972|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2015-03-22|2011-07-06|2011-07-07|Estimate|||||||2015-03-22|2015-03-24|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Assessment of Food Environment and Physical Activity Opportunities in Three Neighbourhoods of Buenos Aires City|Assessment of Food Environment and Physical Activity Opportunities in Three Neighbourhoods of Buenos Aires City|Completed|||2924|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 22:23:56.209319|2018-05-31 22:23:56.209319
NCT01388959|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-11-01|2011-07-05|2011-07-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 1998||1998-11-30|November 2016|2016-11-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma|Multicentre, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab in Patients Suffering From Follicular Non-Hodgkin's Lymphoma (FNHL) With Residual Minimal Disease After Autologous Transplantation of hematopoïetic Stem Cell (Bone Marrow or Peripheral Blood)|Completed||Phase 2|40|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:23:56.266834|2018-05-31 22:23:56.266834
NCT01388946|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2015-05-06||2016-07-05|2011-07-06|2011-07-07|Estimate|2016-07-05|2016-07-06|Estimate||||2016-07-05|2016-07-06|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||To assess differences in patients’ characteristics between the two groups, two-independent samples t-tests for normally distributed variables (age and duration of surgery) and Mann-Whitney tests for abnormally distributed variables (BMI and CO2 total volume consumed) were carried out.|Analgesia in Laparoscopic Cholecystectomy|Perioperative Ropivacaine Wound Infusion in Laparoscopic Cholecystectomy. A Randomized Controlled Double-blind Trial|Completed||N/A|110|Actual|University of Athens||2|||f||||f||||||||No|No plan to share data. The study has been published|2018-05-31 22:23:56.359857|2018-05-31 22:23:56.359857
NCT01388933|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05||2015-05-18|2015-05-18|2011-07-05|2011-07-07|Estimate||||2015-05-18|2015-06-11|Estimate|2015-05-18|2015-06-11|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease|A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects With Moderate Crohn's Disease|Terminated||Phase 2|79|Actual|Tsumura USA||2||Study stopped due to low enrollment|f||||f||||||||||2018-05-31 22:23:56.766697|2018-05-31 22:23:56.766697
NCT01388920|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|2014-04-04||2014-04-04|2011-07-05|2011-07-07|Estimate|2014-04-04|2014-05-07|Estimate||||2014-04-04|2014-05-07|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting|Terminated||Phase 2|3|Actual|Theratechnologies||3||The study was terminated based on a non-safety related corporate decision.|f||||f||||||||||2018-05-31 22:23:56.875969|2018-05-31 22:23:56.875969
NCT01388907|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|2013-06-21||2016-11-16|2011-07-05|2011-07-07|Estimate|2016-11-16|2016-11-17|Estimate||||2016-11-16|2016-11-17|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery|Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study|Completed||Phase 4|61|Actual|Medtronic - MITG|the surgeons were not blinded to the patients’ allocation group at second-look laparoscopy.Recruitment was stopped early. 2 data analyses have been performed over the study period for primary endpoint, without any error type I adjustment.|2|||f||||f||||||||||2018-05-31 22:23:57.054419|2018-05-31 22:23:57.054419
NCT01388894|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-05|2011-07-05|2011-07-07|Estimate|||||||2011-07-05|2011-07-07|Estimate|December 2010||2010-12-31|May 2011|2011-05-31||||||||Observational|||Functional MRI and MRA in Migraine With Aura|Functional MRI and MRA in Migraine With Aura|Unknown status|Recruiting||80|Anticipated|Glostrup University Hospital, Copenhagen|||||f||||f||||||||||2018-05-31 22:23:57.333431|2018-05-31 22:23:57.333431
NCT01388881|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-07-22|2011-07-05|2011-07-07|Estimate|||||||2011-07-22|2011-07-25|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Effects of Music Education for Children With Reading Difficulties|Effects of Music Education on Domain of Reading and Cognitive Abilities in Children With Reading Difficulties: a Cluster Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|270|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:23:57.383585|2018-05-31 22:23:57.383585
NCT01388868|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-05-11|2011-07-05|2011-07-07|Estimate|||||||2012-05-11|2012-05-15|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Strategy for Maintaining Partial Neuromuscular Blocking Adequate for Motor Evoked Potential During Neurosurgery|Determination of ED50 and ED95 of Vecuronium Infusion Dose for Maintaining Response of Train of Four Less Than 2 During the MEP Monitoring for Neurosurgery|Completed||N/A|90|Actual|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 22:23:57.445449|2018-05-31 22:23:57.445449
NCT01388855|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-06-18|2011-07-05|2011-07-07|Estimate|||||||2015-06-18|2015-06-19|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pilot Study of Vitamin D Supplementation in Heart Failure|A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin D in Heart Failure: A Pilot Study|Completed||N/A|13|Actual|Fraser Health||2|||f||||f||||||||||2018-05-31 22:23:57.52618|2018-05-31 22:23:57.52618
NCT01388842|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2016-02-29|2011-07-05|2011-07-07|Estimate|||||||2016-02-29|2016-03-02|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children|Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide (iNO) as Adjunctive Treatment for Cerebral Malaria in Children: A Randomized Open Label Phase II Clinical Trial|Completed||Phase 2|92|Actual|Epicentre||2|||f||||t||||||||No||2018-05-31 22:23:57.625086|2018-05-31 22:23:57.625086
NCT01388829|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-08-09|2011-07-05|2011-07-07|Estimate|||||||2011-08-09|2011-08-10|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532|A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of 2 Different Formulations Of PF-04991532|Completed||Phase 1|10|Anticipated|Pfizer||1|||f||||||||||||||2018-05-31 22:23:57.697509|2018-05-31 22:23:57.697509
NCT01388816|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|2014-03-18||2014-03-18|2011-07-06|2011-07-07|Estimate|2014-03-18|2014-04-22|Estimate||||2014-03-18|2014-04-22|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional||All randomized patients|A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients With Type II Hyperlipidemia|Completed||Phase 2|176|Actual|Dr. Reddy's Laboratories Limited||4|||f||||f||||||||||2018-05-31 22:23:57.790425|2018-05-31 22:23:57.790425
NCT01388803|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-19|2011-07-06|2011-07-07|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Observational|||The Depth of Right Bronchial Blocker Placement in Taiwanese in Video-assisted Thoracoscopic Surgery(VATS)|Right Side Bronchial Blocker in Video-assisted Thoracoscopic Surgery|Completed|||60|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 22:23:58.582478|2018-05-31 22:23:58.582478
NCT01388790|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2013-09-09||2013-09-09|2011-07-05|2011-07-07|Estimate|2013-09-09|2013-11-20|Estimate||||2013-09-09|2013-11-20|Estimate|June 2011||2011-06-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|August 2012|Actual|2012-08-31||Interventional||Intent-to-treat (ITT) population included all participants who received at least one dose of study treatment.|Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer|Open-label, Single-arm, Multicenter Phase II Trial Investigating Cetuximab in Combination With S-1 and Cisplatin as First-line Treatment for Patients With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction|Completed||Phase 2|40|Actual|Merck KGaA||1|||f||||t||||||||||2018-05-31 22:23:58.702373|2018-05-31 22:23:58.702373
NCT01388777|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2017-06-19|2011-07-05|2011-07-07|Estimate|||||||2017-06-19|2017-06-20|Actual|January 24, 2012|Actual|2012-01-24|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy|A Pilot Study to Determine the Efficacy of Cryoablation for the Treatment of Invasive Breast Carcinoma Following Neoadjuvant Therapy|Completed||Phase 2|1|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:23:59.197997|2018-05-31 22:23:59.197997
NCT01388764|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-06-30|2011-07-05|2011-07-07|Estimate|||||||2012-06-30|2012-07-03|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids|Pilot Study: To Assess the Safety, Tolerability and Effects of L-Arginine on Muscles in Boys With Dystrophinopathy on Corticosteroids|Completed||Phase 1|7|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:23:59.281024|2018-05-31 22:23:59.281024
NCT01388751|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-10-30|2011-07-06|2011-07-07|Estimate|||||||2012-10-30|2012-10-31|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Mallet Finger Splinting Study|Night Splinting After 6 to 8 Weeks of Continuous Splinting for Mallet Finger|Completed||N/A|52|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:23:59.393864|2018-05-31 22:23:59.393864
NCT01388738|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-12-22|2011-07-06|2011-07-07|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|3C||Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.|Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.|Completed||Phase 3|30|Anticipated|Clinical Institute of the Brain, Russia||3|||f||||t||||||||||2018-05-31 22:23:59.55814|2018-05-31 22:23:59.55814
NCT01388725|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-06|2011-07-06|2011-07-07|Estimate|||||||2011-07-06|2011-07-07|Estimate|September 2009||2009-09-30|July 2010|2010-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Comparison the Value of Several Biomarkers of Sepsis|Comparison of the Value of Serum sTREM-1, sCD163, PCT, CRP Concentrations, WBC Count and SOFA Score During Sepsis and Their Clinical Informative Value in Predicting Outcome|Completed|||130|Actual|Chinese PLA General Hospital|||2||f||||t||||||||||2018-05-31 22:23:59.730769|2018-05-31 22:23:59.730769
NCT01388712|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2012-04-01|2011-07-06|2011-07-07|Estimate|||||||2012-04-01|2012-04-03|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|April 2012|Anticipated|2012-04-30||Interventional|||Lactobacillus Reuteri in Children With Constipation|The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial|Unknown status|Recruiting|Phase 4|128|Anticipated|Children's Memorial Health Institute, Poland||2|||f||||t||||||||||2018-05-31 22:23:59.792165|2018-05-31 22:23:59.792165
NCT01388699|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2011-07-06|2011-07-06|2011-07-07|Estimate|||||||2011-07-06|2011-07-07|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Observational|||Migraine and Endothelial Dysfunction|Migraine and Endothelial Dysfunction|Unknown status|Recruiting||60|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 22:23:59.962594|2018-05-31 22:23:59.962594
NCT01388686|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2016-11-22|2011-07-06|2011-07-07|Estimate|||||||2016-11-22|2016-11-23|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|December 2010|Actual|2010-12-31||Observational|||Prevalence of CVC-associated Sepsis and Use of Blood Cultures in Berlin - Brandenburg|Retrospective Analysis of Proven Bacteremia, CVC-associated Infections and Sepsis|Terminated|||13|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 22:24:00.111069|2018-05-31 22:24:00.111069
NCT01388673|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-02-07|2011-07-06|2011-07-07|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Safety and Preliminary Effectiveness of the BaroSense Articulating Circular Endoscopic (ACE) Stapler for Plication of Dilated Post-surgical Gastric Anatomy|Open Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for Plication of Dilated Post-surgical Gastric Anatomy|Withdrawn||N/A|0|Actual|BaroSense Inc.||1|||f||||f||||||||||2018-05-31 22:24:00.221232|2018-05-31 22:24:00.221232
NCT01388660|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|||2014-03-25|2011-07-06|2011-07-07|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Pharmacokinetic Assessment of Simultaneous Administration of Clopidogrel and Aspirin|A Randomized, Open-label, Single-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a Tablet Containing 75 mg of Clopidogrel and 100 mg of Aspirin and The Simultaneous Administration of The Separate Formulations of The Two Drugs in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1|60|Anticipated|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 22:24:00.31673|2018-05-31 22:24:00.31673
NCT01388647|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-05|2015-05-28||2015-07-30|2011-07-06|2011-07-07|Estimate|2015-07-30|2015-08-28|Estimate||||2015-07-30|2015-08-28|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer|Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer|Terminated||Phase 1/Phase 2|12|Actual|Vector Oncology|Although MTD of eribulin with carboplatin & trastuzuamb as neoadjuvant therapy was determined by protocol definitions, study closed early due to increased hematologic toxicity & possible reduced efficacy. Phase II of this trial was not initiated.|1||Closed early due to increased hematologic toxicity and possible reduced efficacy|f||||f||||||||||2018-05-31 22:24:00.535485|2018-05-31 22:24:00.535485
NCT01388634|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-11-30|2011-07-05|2011-07-06|Estimate|||||||2011-11-30|2011-12-01|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Observational|LOSHERNIA||Prolonged Hospital Stay and Readmission After Elective Ventral Hernia Repair|Nationwide Analysis of Prolonged Hospital Stay and Readmission After Elective Ventral Hernia Repair|Completed|||2258|Actual|Zealand University Hospital|||2||f||||f||||||||||2018-05-31 22:24:01.3821|2018-05-31 22:24:01.3821
NCT01388621|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-08-19|2011-07-04|2011-07-06|Estimate|||||||2013-08-19|2013-08-20|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|PROVE||Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer|PROVE A Randomized Phase II Trial of Standard Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer|Unknown status|Recruiting|Phase 2|140|Anticipated|WiSP Wissenschaftlicher Service Pharma GmbH||2|||f||||t||||||||||2018-05-31 22:24:01.440398|2018-05-31 22:24:01.440398
NCT01388608|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-08-20|2011-07-04|2011-07-06|Estimate|||||||2013-08-20|2013-08-21|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Observational|||Standard Disease Activity Parameters and Step Activity in Patients With Rheumatoid Arthritis Receiving Etanercept|Correlation of Standard Disease Activity Parameters in Rheumatoid Arthritis With Activities of Daily Living Measured With the Step Activity Monitor, Based on the Influence of Etanercept Therapy on the Disease Activity|Completed|||28|Actual|University Hospital Muenster|||1||f||||f||||||||||2018-05-31 22:24:01.683559|2018-05-31 22:24:01.683559
NCT01388595|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2014-04-21|2011-07-05|2011-07-06|Estimate|||||||2014-04-21|2014-04-22|Estimate|November 2006||2006-11-30|December 2013|2013-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Fluticasone and Salmeterol in Allergic Rhinitis|A Proof of Concept Study to Evaluate Effects of Intranasal Salmeterol and Fluticasone Given Alone and in Combination in Allergic Rhinitis|Completed||Phase 4|23|Actual|University of Dundee||3|||f||||t||||||||||2018-05-31 22:24:01.760584|2018-05-31 22:24:01.760584
NCT01388582|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-05-16|2011-07-05|2011-07-06|Estimate|||||||2012-05-16|2012-05-17|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth|The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women|Completed||Phase 4|40|Actual|University of Campinas, Brazil||4|||f||||f||||||||||2018-05-31 22:24:03.382163|2018-05-31 22:24:03.382163
NCT01388569|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-02|||2017-05-16|2011-07-02|2011-07-06|Estimate|||||||2017-05-16|2017-05-17|Actual|June 28, 2011|Actual|2011-06-28|May 2017|2017-05-31|September 28, 2011|Actual|2011-09-28|September 28, 2011|Actual|2011-09-28||Observational|||Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim|Immune Counter-Regulation in Melanoma Patients Vaccinated With GM-CSF|Completed|||48|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 22:24:03.559959|2018-05-31 22:24:03.559959
NCT01388556|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-12-07|2011-07-05|2011-07-06|Estimate|||||||2015-12-07|2015-12-09|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PD4PD||PD4PD:Partnered Dance for Parkinson Disease|PD4PD:Partnered Dance for Parkinson Disease|Completed||Phase 2/Phase 3|62|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 22:24:03.615186|2018-05-31 22:24:03.615186
NCT01388543|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-05-01|2011-07-01|2011-07-06|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2006||2006-09-30|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Genetics and HIV-1 Protease Inhibitors|Genetic-determinants of Protease Inhibitor Pharmacology|Completed||Phase 4|31|Actual|University of Colorado, Denver||2|||f||||t||||||||No|No plan to share|2018-05-31 22:24:03.724474|2018-05-31 22:24:03.724474
NCT01388530|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2013-01-26||2016-03-23|2011-07-01|2011-07-06|Estimate|2016-03-23|2016-04-11|Estimate||||2016-03-23|2016-04-11|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)|An Eight-Week, Open Trial Pilot Investigation of Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Early Phase 1|25|Actual|University of California, Los Angeles|Early terminations were due to ambivalence about participation of social difficulties with compliance. No one left the study for adverse events or safety reasons. There were no clinically meaningful adverse events related to treatment.|1|||f||||f||||||||||2018-05-31 22:24:03.870254|2018-05-31 22:24:03.870254
NCT01388517|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2012-09-25|2011-07-05|2011-07-06|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba|A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba|Completed||Phase 4|39|Actual|Universidad Autonoma de San Luis Potosí||3|||f||||f||||||||||2018-05-31 22:24:04.186743|2018-05-31 22:24:04.186743
NCT01388504|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2016-01-20|2011-07-05|2011-07-06|Estimate|||||||2016-01-20|2016-01-21|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|NIAMI||Nitrites in Acute Myocardial Infarction|Does Sodium Nitrite Administration Reduce Ischaemia-reperfusion Injury in Patients Presenting With Acute ST Segment Elevation Myocardial Infarction?|Completed||Phase 2/Phase 3|200|Actual|University of Aberdeen||2|||f||||t||||||||||2018-05-31 22:24:04.587218|2018-05-31 22:24:04.587218
NCT01388491|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|2013-09-23||2017-03-09|2011-07-05|2011-07-06|Estimate|2013-09-23|2013-11-27|Estimate||||2017-03-09|2017-04-07|Actual|October 2011||2011-10-31|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Safety Population (all randomized participants who took 1 or more doses of study drug)|A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women|A Multinational, Multicenter, Randomized, Open-label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women|Completed||Phase 2|293|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 22:24:04.779302|2018-05-31 22:24:04.779302
NCT01388478|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30||2016-03-22|2016-03-22|2011-07-01|2011-07-06|Estimate||||2016-03-22|2016-04-25|Estimate|2016-03-22|2016-04-25|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease|Safety/Tolerability and Effects on Cognitive Impairment, Impaired Cerebral Cortical Metabolism and Oxidative Stress of R(+)Pramipexole Administered to Subjects With Early Alzheimer's Disease|Completed||Phase 2|20|Actual|Virginia Commonwealth University||1|||f||||t||||||||No||2018-05-31 22:24:05.977758|2018-05-31 22:24:05.977758
NCT01388465|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-05-18|2011-07-05|2011-07-06|Estimate|||||||2012-05-18|2012-05-21|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ImpACT||Text-message Support to Improve Oral Antibiotic Adherence After ED Discharge|Feasibility of Using Text-Message Support to Improve Antibiotic Adherence After ED Discharge|Completed||N/A|200|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:24:06.080626|2018-05-31 22:24:06.080626
NCT01388452|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-05-13|2011-07-01|2011-07-06|Estimate|||||||2013-05-13|2013-05-14|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||HIV Diagnosis in Hospitalized Malawian Infants|Presumptive and Definitive Virologic HIV Diagnosis in Hospitalized Malawian Infants|Completed||N/A|300|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:24:06.144649|2018-05-31 22:24:06.144649
NCT01388296|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2013-12-02|2011-07-05|2011-07-06|Estimate|||||||2013-12-02|2013-12-03|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients|Minimum Alveolar Concentrations of Sevoflurane for Maintaining Bispectral Index Below 50 in Morbidly Obese Patients|Unknown status|Recruiting||30|Anticipated|Procare Riaya Hospital|||3||f||||f||||||None Retained|"~     Bisbectral index (BIS)~   "|||2018-05-31 22:24:11.59695|2018-05-31 22:24:11.59695
NCT01388283|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|January 1999||1999-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2004|Actual|2004-05-31||Observational|||Inflammatory Markers in Pregnant Women Destined to Develop Preeclampsia||Completed|||129|Actual|Oslo University Hospital|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:24:11.717658|2018-05-31 22:24:11.717658
NCT01388439|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Pharmacokinetics of Oseltamivir in Newborns and Infants|Pharmacokinetics of Oseltamivir in Newborns and Infants|Completed|||19|Actual|St. Louis Children's Hospital|||1||f||||f||||||Samples With DNA|"~     Two whole blood samples (0.5 mL) were obtained at steady state (day 3 of therapy or later),~     collected in K3EDTA mini-collection tubes labeled with a sample identification number. Plasma~     specimens were separated by centrifugation of 1500 g for 10 minutes at 4 degrees Celsius~     within 60 minutes of sample collection. Plasma supernatant was transferred into a cryovial~     labeled with the same sample identification number. Cryovials were immediately stored at -70~     degrees Celsius. Sample obtainment and processing was directly supervised by the principle~     investigator.~      The blood samples are currently being stored at -70 degrees Celsius in a research laboratory~     operated by medical faculty of the Washington University School of Medicine Department of~     Pediatrics Division of Infectious Diseases in the McDonnell Medical Sciences Building.~   "|||2018-05-31 22:24:06.229502|2018-05-31 22:24:06.229502
NCT01388426|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-01-08|2011-07-01|2011-07-06|Estimate|||||||2013-01-08|2013-01-10|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Moisture Chamber Glasses for Dry Eye in Asian Population|Moisture Chamber Glasses for Dry Eye in Asian Population|Completed||N/A|11|Actual|Singapore National Eye Centre||1|||f||||t||||||||||2018-05-31 22:24:06.298133|2018-05-31 22:24:06.298133
NCT01388413|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-02-23|2011-07-01|2011-07-06|Estimate|||||||2017-02-23|2017-02-24|Actual|August 2011||2011-08-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2016|Actual|2016-01-31||Interventional|PACHIU||Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder|A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder|Completed||Phase 4|45|Actual|University Hospital, Tours||2|||f||||t|f|f||||||No||2018-05-31 22:24:06.602512|2018-05-31 22:24:06.602512
NCT01388400|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|||2011-07-10|2011-07-04|2011-07-06|Estimate|||||||2011-07-10|2011-07-12|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Enriched Environments for Upper Limb Stroke Rehabilitation|Enriched Environments for Stroke Rehabilitation; Pilot Study to Determine Appropriate Outcome Measures and Their Sensitivity to Different Training Protocols|Completed||N/A|12|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 22:24:07.04182|2018-05-31 22:24:07.04182
NCT01388387|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2017-04-19|2011-07-05|2011-07-06|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2012||2012-01-31|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)|Impact of Donor and Recipient CYP3A5 Genetic Polymorphism on Tacrolimus Exposure in Patients With Hepatic Transplant|Recruiting||N/A|150|Anticipated|Rennes University Hospital||1|||f||||t||||||||||2018-05-31 22:24:07.253948|2018-05-31 22:24:07.253948
NCT01388374|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2015-04-21|2011-07-05|2011-07-06|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||The (Cost-)Effectiveness of Nurse Practitioners Working at the Primary Out of Hours Emergency Service|A Study on the (Cost-)Effectiveness of Nurse Practitioners Working at the Primary Out of Hours Emergency Service and the Feasibility of Implementing These Nurses|Completed||N/A|12092|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 22:24:07.794713|2018-05-31 22:24:07.794713
NCT01388361|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|2015-10-23|2013-11-28|2017-01-20|2011-07-04|2011-07-06|Estimate|2015-10-23|2015-11-26|Estimate|2013-11-28|2013-12-25|Estimate|2017-01-20|2017-03-06|Actual|September 2011||2011-09-30|January 2017|2017-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|BEGIN™|The full analysis set (FAS) included all randomised patients except for 7 subjects (2 subjects with IDeg+ liraglutide; 5 subjects with IDeg+IAsp arm) fasting plasma glucose (FPG) values were missing at baseline. Non-randomised set (NAS) included all non-randomised subjects, the FPG values were missing for 10 subjects at baseline.|Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin|A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart With the Largest Meal to Insulin Degludec, Both in Combination With Metformin, in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification (BEGIN™: VICTOZA® ADD-ON)|Completed||Phase 3|413|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 22:24:08.073481|2018-05-31 22:24:08.073481
NCT01388348|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-07-04|2011-07-04|2011-07-06|Estimate|||||||2011-07-04|2011-07-06|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||"Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration Holter in Comparison to Pressure Flow Study"|"Diagnosis of Bladder Outlet Obstruction Using Dynamic Urine Vibration Holter in Comparison to Pressure Flow Study"|Unknown status|Not yet recruiting|N/A|100|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:24:10.753715|2018-05-31 22:24:10.753715
NCT01388335|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2012-12-17|2011-07-04|2011-07-06|Estimate|||||||2012-12-17|2012-12-18|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin|The Effect of Enzastaurin on CYP2C9: Enzastaurin - S-Warfarin Drug Interaction Study in Patients With Cancer|Completed||Phase 1|20|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:24:10.825648|2018-05-31 22:24:10.825648
NCT01388322|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-12-20|2011-07-04|2011-07-06|Estimate|||||||2016-12-20|2016-12-21|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|HOPPE||Low Weight Heparin prOphylaxis for Placental‐Mediated Complications of PrEgnancy|Enoxaparin for the Prevention of Placental‐Mediated Complications of Pregnancy in Women With Obstetric History or Abnormal Uterine Artery Doppler at First Trimester Ultrasound and Without Thrombophilia: a Multicenter Randomized Controlled Trial|Completed||Phase 3|361|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 22:24:11.022779|2018-05-31 22:24:11.022779
NCT01388309|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2016-11-01|2011-07-04|2011-07-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs|DAS Evaluation of RA Activity in Patients Treated With Tocilizumab|Completed|||64|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:24:11.341742|2018-05-31 22:24:11.341742
NCT01332032|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2015-05-28|2011-04-07|2011-04-08|Estimate|||||||2015-05-28|2015-06-01|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Observational|||Promoting Breast Cancer Screening in Non-adherent Women|Promoting Breast Cancer Screening in Non-adherent Women|Completed|||36348|Actual|University of Massachusetts, Worcester|||3||f||||f||||||||||2018-05-31 22:43:18.373725|2018-05-31 22:43:18.373725
NCT01388270|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2016-02-03|2011-07-01|2011-07-06|Estimate|||||||2016-02-03|2016-02-04|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis|The Effect of a Heparin-coated Dialysis Filter (Evodial) on Clotting and Intravascular Coagulation During Hemodialysis (HD) When Compared to a Conventional Polyflux Filter (170H)|Completed||Phase 4|12|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:24:11.958568|2018-05-31 22:24:11.958568
NCT01388257|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2012-06-06|2011-07-04|2011-07-06|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|FACC||Anal Crohn Fistula Surgery|"A National, Multicenter, Randomized Open-Label Study of Proctological Surgery Efficacy on Anoperineal Fistulas Healing in Crohn's Disease Patients Treated With Adalimumab. (Official French Title: Étude Nationale, Multicentrique, randomisée et en Ouvert de l'efficacité de la Chirurgie Proctologique Sur la Cicatrisation Des Fistules anopérinéales de la Maladie de Crohn Chez Des Patients traités Par Adalimumab)"|Unknown status|Recruiting|N/A|180|Anticipated|French Society of Coloproctology||2|||f||||f||||||||||2018-05-31 22:24:12.199725|2018-05-31 22:24:12.199725
NCT01388244|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-10-23|2011-07-05|2011-07-06|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|ROSE||Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE)|Risk-stratified Osteoporosis Strategy Evaluation Study (ROSE)|Active, not recruiting||N/A|35000|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 22:24:12.558132|2018-05-31 22:24:12.558132
NCT01388231|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-07-07|2011-07-04|2011-07-06|Estimate|||||||2011-07-07|2011-07-08|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice|Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice (SophoPrax)|Unknown status|Recruiting|Phase 2/Phase 3|116|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 22:24:12.742988|2018-05-31 22:24:12.742988
NCT01388218|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2018-04-26|2011-07-04|2011-07-06|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2011||2011-07-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Non-interventional Cross-over Study to Reduce Items of PROactive Tools Measuring Physical Activity in Chronic Obstructive Pulmonary Disease (COPD)|Non-interventional Cross-over Study to Reduce Items of the Draft PROactive Tools as a Measure of Physical Activity in Daily Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||236|Actual|Barcelona Institute for Global Health|||2||f||||t||||||||||2018-05-31 22:24:12.901953|2018-05-31 22:24:12.901953
NCT01388205|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-10-08|2011-07-01|2011-07-06|Estimate|||||||2015-10-08|2015-10-12|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|FIT||Trial of a Novel Family-Based Intervention to Increase Outdoor Time and Fitness|An Exploratory Randomized Controlled Trial of a Novel Family-Based Intervention to Increase Outdoor Time for the Prevention of Myopia and Increase Physical Activity Among Singapore Youth|Completed||Phase 3|285|Actual|National University, Singapore||2|||f||||t||||||||||2018-05-31 22:24:13.06625|2018-05-31 22:24:13.06625
NCT01388192|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-01-24|2011-07-05|2011-07-06|Estimate|||||||2016-01-24|2016-01-26|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Effects of Pancreaticoduodenectomy on Glucose Metabolism|Effects of Pancreaticoduodenectomy on Glucose Metabolism|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 22:24:13.236054|2018-05-31 22:24:13.236054
NCT01388179|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2018-04-15|2011-07-05|2011-07-06|Estimate|||||||2018-04-15|2018-04-17|Actual|January 23, 2013|Actual|2013-01-23|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children.|Deep rTMS(Repetitive Transcranial Magnetic Stimulation) for Treatment of Autism Symptoms in Children With Low Functioning ASD (Autism Spectrum Disorders)|Terminated||Phase 2|20|Anticipated|Brainsway||2||Sponsor decision to stop the study|f||||f|f|f||||||||2018-05-31 22:24:13.511024|2018-05-31 22:24:13.511024
NCT01388166|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|2014-11-28||2014-11-28|2011-07-04|2011-07-06|Estimate|2014-11-28|2014-12-04|Estimate||||2014-11-28|2014-12-04|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||Patients from the Treated Set: This patient set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment. As it was an inclusion criterion that all patients were treated with Spiriva within the last month, TS consists of all patients involved in the trial.|ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice|ADESPI: Adherence to Spiriva® in Patients With COPD, Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice in Central & Eastern European Region|Completed|||1253|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 22:24:13.643249|2018-05-31 22:24:13.643249
NCT01388153|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2013-08-27|2011-07-04|2011-07-06|Estimate|||||||2013-08-27|2013-08-28|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet|Randomized, Non-blinded, 3-fold Crossover Study to Investigate the Bioequivalence Between Glucobay ODT Taken Without and With Water and the Glucobay Standard Tablet Following Single Oral Dosing in Healthy Male Subjects|Completed||Phase 1|33|Actual|Bayer||3|||f||||f||||||||||2018-05-31 22:24:14.075375|2018-05-31 22:24:14.075375
NCT01388140|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Psychopathology of Dissociative Disorders|A Psychopathological Study of Dissociative Disorders in Psychiatric Inpatients at an Acute Stage|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 22:24:14.162679|2018-05-31 22:24:14.162679
NCT01388127|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|Minocycline||Minocycline Treatment in Acute Hemorrhagic Stroke|Minocycline Treatment in Acute Hemorrhagic Stroke for Evaluation of Treatment Efficacy and Blood Brain Barrier Permeability|Unknown status|Not yet recruiting||150|Anticipated|Wolfson Medical Center|||||f||||f||||||||||2018-05-31 22:24:14.277081|2018-05-31 22:24:14.277081
NCT01388114|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-11-15|2011-07-05|2011-07-06|Estimate|||||||2012-11-15|2012-11-16|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Clinical Evaluation of e- Ab Sensor - Based Real-time Diagnosis of Serum Procalcitonin Level|Clinical Evaluation of e- Ab Sensor - Based Real-time Diagnosis of Serum Procalcitonin Level|Completed||N/A|200|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:24:14.378066|2018-05-31 22:24:14.378066
NCT01388101|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-12-20|2011-07-05|2011-07-06|Estimate|||||||2012-12-20|2012-12-21|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)|Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)|Unknown status|Recruiting|N/A|80|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:24:14.442739|2018-05-31 22:24:14.442739
NCT01388088|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2012-03-27|2011-07-03|2011-07-06|Estimate|||||||2012-03-27|2012-03-28|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|hass||The Effect of Amiloride and Spironolactone in Patients With Hypertension|Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study.|Completed||Phase 4|23|Actual|Regional Hospital Holstebro||3|||f||||t||||||||||2018-05-31 22:24:14.605413|2018-05-31 22:24:14.605413
NCT01388075|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|July 2011||2011-07-31|July 2011|2011-07-31||||June 2018|Anticipated|2018-06-30||Interventional|||Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9||Not yet recruiting||N/A|150|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:24:14.694534|2018-05-31 22:24:14.694534
NCT01388062|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-12-26|2011-07-05|2011-07-06|Estimate|||||||2012-12-26|2012-12-27|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Interventional|||e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus|e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:24:14.780158|2018-05-31 22:24:14.780158
NCT01388049|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-12-26|2011-07-05|2011-07-06|Estimate|||||||2012-12-26|2012-12-27|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||e- Ab Sensor - Based Real-time Diagnosis of Enterovirus Type 71|e- Ab Sensor - Based Real-time Diagnosis of Enterovirus Type 71|Unknown status|Recruiting|N/A|72|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:24:14.865635|2018-05-31 22:24:14.865635
NCT01388036|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|July 2011||2011-07-31|July 2011|2011-07-31||||May 2015|Anticipated|2015-05-31||Interventional|||Genetic Determinants of Hemodynamic Response to Esmolol|A Study in Healthy Subjects to Evaluate Genetic Determinants of the Variability in Hemodynamic Response to Esmolol|Unknown status|Recruiting|N/A|100|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:24:14.932332|2018-05-31 22:24:14.932332
NCT01388023|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2012-11-19|2011-07-05|2011-07-06|Estimate|||||||2012-11-19|2012-11-20|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SmellX||Day Long Prevention of Oral Malodor With a Palatal Patch (SmellX) Containing A Herbal Formula|Phase 2 Clinical Study of a Day Long Effect of SmellX Palatal Patch Containing A Herbal Formula on Malodor|Completed||Phase 2|60|Actual|Hadassah Medical Organization||4|||f||||f||||||||||2018-05-31 22:24:14.993846|2018-05-31 22:24:14.993846
NCT01388010|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-03|||2016-10-26|2011-07-05|2011-07-06|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Study of the Effect of a Fermented Dairy Product on Gastrointestinal Well Being in Adult Women|"Effect of the Consumption of a Fermented Dairy Product on Gastrointestinal Well-being in a Healthy Population of Women With Minor Digestive Symptoms"|Completed||N/A|336|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 22:24:15.210835|2018-05-31 22:24:15.210835
NCT01387997|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-11-19|2011-07-05|2011-07-06|Estimate|||||||2012-11-19|2012-11-20|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses|Nano-mechanical and Nano-electrosensing Devices Based Interaction Force and Interaction Kinetics Analysis of Oncogenic Human Papilloma Viruses|Unknown status|Recruiting|N/A|72|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:24:15.301988|2018-05-31 22:24:15.301988
NCT01387984|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||YKL-40 and Complications in Type 2 Diabetes|Association Study of the Plasma Concentration of YKL-40 and Vascular Complications in Patients With Type 2 Diabetes|Completed|||473|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 22:24:15.406987|2018-05-31 22:24:15.406987
NCT01387971|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders|Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 22:24:15.495749|2018-05-31 22:24:15.495749
NCT01387958|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-05-06|2011-07-05|2011-07-06|Estimate|||||||2012-05-06|2012-05-08|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients|Double-blind, Randomized, Placebo-controlled, Multi-center Trial, to Determine the Safety and Antiviral Effect of 14 Days of LCQ908 Monotherapy in Hepatitis C Infected Patients|Terminated||Phase 2|32|Actual|Novartis||2||Terminated early due to futility|f||||||||||||||2018-05-31 22:24:15.565167|2018-05-31 22:24:15.565167
NCT01387945|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2016-03-31|2011-07-05|2011-07-06|Estimate|||||||2016-03-31|2016-04-04|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|eBPcontrol||Pilot Study of Home Blood Pressure Control Program (eBP Control)|Pilot Study of Home Blood Pressure Control Program (eBP Control)|Completed||N/A|28|Actual|Memorial Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 22:24:15.643663|2018-05-31 22:24:15.643663
NCT01387932|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2018-04-20|2011-07-05|2011-07-06|Estimate|||||||2018-04-20|2018-04-24|Actual|April 2011||2011-04-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|HiQuality||HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer|Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma|Active, not recruiting||Phase 3|520|Anticipated|Merit Medical Systems, Inc.||2|||f||||t||t|f|f||||||2018-05-31 22:24:15.726819|2018-05-31 22:24:15.726819
NCT01387906|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2012-06-14|2011-07-05|2011-07-06|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo|Latisse(Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo|Completed||Phase 4|20|Actual|Beer, Kenneth R., M.D., PA||1|||f||||t||||||||||2018-05-31 22:24:15.939854|2018-05-31 22:24:15.939854
NCT01387893|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-10-01|2011-07-01|2011-07-06|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||A Self-Administered Maneuver to Relieve Symptoms Suggestive of Benign Prostatic Hyperplasia|Study of a Self-Administered Maneuver to Initiate and Maintain Urine Flow Impeded by Benign Prostatic Hyperplasia|Completed||N/A|48|Actual|Kaiser Permanente||1|||f||||f||||||||||2018-05-31 22:24:16.047719|2018-05-31 22:24:16.047719
NCT01387880|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-03-18|2011-07-05|2011-07-06|Estimate|||||||2012-03-18|2012-03-20|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|ICE||Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer|Phase II Examination of Irinotecan, Cetuximab and Everolimus to Chemotherapy Resistent Patients With Metastatic Colorectal Cancer and KRAS Mutations or After Progression With KRAS Wildtype on Irinotecan and Cetuximab - Effect and Biological Markers|Completed||Phase 2|100|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 22:24:16.147393|2018-05-31 22:24:16.147393
NCT01387867|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-02-05|2011-07-01|2011-07-06|Estimate|||||||2015-02-05|2015-02-06|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Exercise in Patients With Osteoarthritis of the Hip|Effects of Strength Training and Nordic Walking in Patients With Osteoarthritis of the Hip|Completed||N/A|152|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 22:24:16.230829|2018-05-31 22:24:16.230829
NCT01387854|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-03-31|2011-07-05|2011-07-06|Estimate|||||||2014-03-31|2014-04-02|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Observational|||Observational Study of Patients With Mucopolysaccharidosis (MPS) VI Who Previously Participated in ASB-00-02|A Re-Survey Study of Patients With MPS VI (Maroteaux-Lamy Syndrome) Who Previously Participated in ASB-00-02|Completed|||59|Actual|BioMarin Pharmaceutical|||||f||||f||||||||||2018-05-31 22:24:16.439974|2018-05-31 22:24:16.439974
NCT01387841|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2013-07-23|2011-07-05|2011-07-06|Estimate|||||||2013-07-23|2013-07-24|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting|Comparison of Yoga Versus Relaxation on Chemotherapy Induced Nausea and Vomiting (CINV) Outcomes Following Chemotherapy|Completed||Phase 2|120|Actual|Bharath Charitable Cancer Hospital and Institute||3|||f||||t||||||||||2018-05-31 22:24:16.599494|2018-05-31 22:24:16.599494
NCT01387828|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2011-07-06|2011-07-05|2011-07-06|Estimate|||||||2011-07-06|2011-07-07|Estimate|January 2001||2001-01-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Comparison Between Open and Laparoscopic Splenic Aneurysms Repair|Prospective Randomized Comparison of Open Versus Laparoscopic Management of Splenic Artery Aneurysms. A Ten-Year Study|Completed||Phase 3|29|Actual|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t||||||||||2018-05-31 22:24:16.712861|2018-05-31 22:24:16.712861
NCT01387815|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2018-04-27|2011-07-01|2011-07-06|Estimate|||||||2018-04-27|2018-05-01|Actual|August 16, 2011|Actual|2011-08-16|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|Complete-PS||Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis|Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis|Active, not recruiting|||662|Actual|AbbVie|||3||f||||f|f|f|||f|||Undecided||2018-05-31 22:24:16.955109|2018-05-31 22:24:16.955109
NCT01387802|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2018-04-27|2011-07-01|2011-07-06|Estimate|||||||2018-04-27|2018-05-01|Actual|June 29, 2011|Actual|2011-06-29|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|Complete-AS||Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis|Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis (Complete - AS)|Active, not recruiting|||722|Actual|AbbVie|||2||f||||f|f|f|||f|||Undecided||2018-05-31 22:24:17.151452|2018-05-31 22:24:17.151452
NCT01387789|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|2014-03-14||2014-04-21|2011-07-01|2011-07-06|Estimate|2014-03-14|2014-04-21|Estimate||||2014-04-21|2014-05-05|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|RELIVE||A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia|An Observational Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia|Completed|||71|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:24:17.395098|2018-05-31 22:24:17.395098
NCT01387776|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2015-07-24|2011-07-05|2011-07-06|Estimate|||||||2015-07-24|2015-07-28|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PlGF||Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21|Study for the Evaluation of the Benefits of 1 st Trimester Risk Markers in Detecting Early Onset Pre-eclampsia and the Use of the Placental Growth Factor (PlGF) as a Potential Marker for Trisomy 21 and Other Aneuploidies|Terminated|||370|Actual|OVO R & D|||1|The technique has been approved and validated|f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:24:17.6514|2018-05-31 22:24:17.6514
NCT01387763|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-04-04|2011-06-30|2011-07-06|Estimate|||||||2017-04-04|2017-04-05|Actual|January 2012||2012-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|DALIAH||A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms|Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Philadelphia Chromosome Negative (Ph-)Chronic Myeloid Neoplasms.|Active, not recruiting||Phase 3|200|Anticipated|Odense University Hospital||5|||f||||t||||||||||2018-05-31 22:24:17.775837|2018-05-31 22:24:17.775837
NCT01387750|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-05|2011-07-05|2011-07-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Mentholated Cream Containing Oxygenated Glycerol Triesters on Acute Pain of the Muscles and Joints|Evaluating the Efficacy, Tolerance and Acceptability of a Mentholated Cream Containing Oxygenated Glycerol Triesters (OGT) on Acute Pain in Subjects Suffering From a Recent Inflammation of the Muscles and/or Joints|Completed||Phase 1/Phase 2|71|Actual|NEMA Research, Inc.||2|||f||||t||||||||||2018-05-31 22:24:17.936663|2018-05-31 22:24:17.936663
NCT00984789|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2014-04-01|2009-09-24|2009-09-25|Estimate|||||||2014-04-01|2014-04-02|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Birth Control Patch Study|Transdermal Contraception Patch: EU Cycle Control Study Versus EVRA|Completed||Phase 3|393|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:32:29.132314|2018-06-01 00:32:29.132314
NCT01387737|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2014-03-26||2014-05-27|2011-06-30|2011-07-06|Estimate|2014-03-26|2014-04-28|Estimate||||2014-05-27|2014-06-06|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus|An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|1299|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 22:24:18.053364|2018-05-31 22:24:18.053364
NCT01387724|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2016-05-17|2011-07-01|2011-07-04|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2011||2011-06-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma|Neuropeptide Y and Its Receptors in Neuroblastoma|Completed|||300|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     blood and tissue~   "|||2018-05-31 22:24:19.139742|2018-05-31 22:24:19.139742
NCT01387711|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2016-12-01|2011-07-01|2011-07-04|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology|A Phase I, Single-centre, Open Label, Within-subject Comparison Trial to Explore the Biological Effects of PEP005 (Ingenol Mebutate) Gel, 0.05%, Applied Once Daily for 2 Consecutive Days in Patients With Actinic Keratosis on the Upper Extremity|Completed||Phase 1|27|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 22:24:19.261474|2018-05-31 22:24:19.261474
NCT01387698|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-10-28|2011-07-01|2011-07-04|Estimate|||||||2015-10-28|2015-10-29|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|OPTIMUM||Prospective, Longitudinal Multicentric Survey in the Therapeutic Care of Mild to Moderate Ulcerative Colitis|Observatoire Prospectif, Longitudinal Dans la Prise en Charge Thérapeutique de La Rectocolite Hémorragique légère à Modérée|Completed|||812|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:24:19.402915|2018-05-31 22:24:19.402915
NCT01387685|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-06-19|2011-06-30|2011-07-04|Estimate|||||||2014-06-19|2014-06-20|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Treatment of Pelvic Organ Prolapse by PIVS Versus Surgeon Cut Mesh||Withdrawn|||0|Actual|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-05-31 22:24:19.736797|2018-05-31 22:24:19.736797
NCT01387672|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2015-02-17||2015-05-06|2011-07-01|2011-07-04|Estimate|2015-05-06|2015-05-08|Estimate||||2015-05-06|2015-05-08|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NABT;NABT-B||Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study|Nitrates and Bone Turnover (NABT): Trial to Select the Best Nitrate Preparation|Completed||Phase 3|265|Actual|University of Toronto||6|||f||||t||||||||||2018-05-31 22:24:19.829066|2018-05-31 22:24:19.829066
NCT01387659|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-09-30|2011-06-30|2011-07-04|Estimate|||||||2013-09-30|2013-10-01|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations|Study to Evaluate Tolerability of Myfortic With Simulect Induction and Tacrolimus Without Steroids in Three Patient Populations; 1: Kidney/Pancreas Transplants,2: Diabetic Kidney Transplants, and 3: Non-diabetic Kidney Transplants|Terminated||Phase 4|2|Actual|The University of Texas Medical Branch, Galveston||1||Study terminated due to slow enrollment|f||||t||||||||||2018-05-31 22:24:20.524844|2018-05-31 22:24:20.524844
NCT01387646|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-01|2011-07-01|2011-07-04|Estimate|||||||2011-07-01|2011-07-04|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Behavioral Intervention for Minority Adolescent Women|Behavioral Intervention for Minority Adolescent Women|Completed||Phase 2|562|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 22:24:20.599563|2018-05-31 22:24:20.599563
NCT01387633|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-07-01|2011-07-01|2011-07-04|Estimate|||||||2011-07-01|2011-07-04|Estimate|June 2011||2011-06-30|February 2010|2010-02-28||||June 2011|Actual|2011-06-30||Interventional|||Educational Intervention and Social Support in Diabetes Mellitus||Unknown status|Recruiting|N/A|264|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:24:20.666168|2018-05-31 22:24:20.666168
NCT01387620|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-30|2011-06-30|2011-07-04|Estimate|||||||2011-06-30|2011-07-04|Estimate|June 2009||2009-06-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2%|Intraindividual Randomized Clinical Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2% in Phacoemulsification|Completed||Phase 4|39|Actual|University of Sao Paulo|||||f||||f||||||||||2018-05-31 22:24:20.763689|2018-05-31 22:24:20.763689
NCT01387607|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-03-02|2011-06-30|2011-07-04|Estimate|||||||2017-03-02|2017-03-03|Actual|February 2012||2012-02-29|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study For Pregabalin In Patients With Fibromyalgia|A 14-week, Randomized, Double-blind Placebo-controlled Study For Pregabalin In Subjects With Fibromyalgia|Completed||Phase 3|343|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:24:20.843842|2018-05-31 22:24:20.843842
NCT01387594|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2016-11-15||2017-05-04|2011-06-30|2011-07-04|Estimate|2017-04-13|2017-04-26|Actual||||2017-05-04|2017-05-09|Actual|May 2012||2012-05-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|March 2014|Actual|2014-03-31||Interventional|TOSCA||Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs|A Multi-Center, Phase 1, Open-Label Evaluation Of The Effect Of PF-00547659 (Anti Madcam Monoclonal Antibody) On Cerebrospinal Fluid (CSF) Lymphocytes In Volunteers With Crohns Disease Or Ulcerative Colitis Who Are Anti-TNFInadequate Responders (TOSCA)|Completed||Phase 1|49|Actual|Shire||2|||f||||t||||||||||2018-05-31 22:24:20.979402|2018-05-31 22:24:20.979402
NCT01387581|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2014-04-03||2014-11-05|2011-07-01|2011-07-04|Estimate|2014-11-05|2014-11-14|Estimate||||2014-11-05|2014-11-14|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Does the Aid of MelaFind Affect Clinical Management Decisions|To Excise or Not?: Comparing Clinical Management Decisions for Melanoma Between Dermatologists With and Without the Aid of MelaFind|Completed|||227|Actual|MELA Sciences, Inc.|A limitation of this study is the reader study format. Lesions were presented to participating dermatologists as photographs via the online system. This presentation can only approximate an in-person clinical exam.||3||f||||f||||||||||2018-05-31 22:24:21.819524|2018-05-31 22:24:21.819524
NCT01387568|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-04-18|2011-07-01|2011-07-04|Estimate|||||||2012-04-18|2012-04-20|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Lidocaine Infusion for Major Abdominal Pediatric Surgery|The Effects of Intravenous Lidocaine Infusion During and After Major Abdominal Pediatric Surgery. A Randomized Double-blinded Study|Completed||Phase 3|80|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 22:24:23.424296|2018-05-31 22:24:23.424296
NCT01387555|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-03-10|2011-07-01|2011-07-04|Estimate|||||||2015-03-10|2015-03-11|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TRAVERSE||A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib|A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment|Completed||Phase 2|129|Actual|Jennerex Biotherapeutics||2|||f||||t||||||||||2018-05-31 22:24:23.538536|2018-05-31 22:24:23.538536
NCT01387542|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2013-01-29||2013-01-29|2011-07-01|2011-07-04|Estimate|2013-01-29|2013-03-05|Estimate||||2013-01-29|2013-03-05|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PRESENT||Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants|An Open-label, PRospective Study to Evaluate Social Function and Overall Improvement of Paliperidone ER Treatment in Thai Schizophrenia PatieNT (PRESENT)|Completed||Phase 4|40|Actual|Janssen-Cilag Ltd.,Thailand|Study had an open-label trial design with lack of a comparator arm; therefore it was difficult to conclude the efficacy and safety results.|1|||f||||f||||||||||2018-05-31 22:24:23.727437|2018-05-31 22:24:23.727437
NCT01387529|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2014-03-06|2011-06-30|2011-07-04|Estimate|||||||2014-03-06|2014-03-07|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Observational|||Reference Values for Non-invasive Hydration Status Markers H10-14|Reference Values for Non-invasive Hydration Status Markers|Completed|||62|Actual|U.S. Army Medical Research and Materiel Command|||||f||||t||||||||||2018-05-31 22:24:24.087874|2018-05-31 22:24:24.087874
NCT01387516|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2017-06-02|2011-07-01|2011-07-04|Estimate|||||||2017-06-02|2017-06-05|Actual|July 2007|Actual|2007-07-31|June 2017|2017-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Motivation and Skills for Detained Teen Smokers|Motivation and Skills for Detained Teen Smokers|Completed||N/A|314|Actual|University of Rhode Island||4|||f||||t||||||||No||2018-05-31 22:24:24.327395|2018-05-31 22:24:24.327395
NCT01387503|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-01|2011-07-01|2011-07-04|Estimate|||||||2011-07-01|2011-07-04|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging|Controlled Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging Procedures: a Randomized Trial (XXL Trial)|Unknown status|Recruiting|Phase 2/Phase 3|260|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 22:24:24.503847|2018-05-31 22:24:24.503847
NCT01387490|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2016-03-02|2011-07-01|2011-07-04|Estimate|||||||2016-03-02|2016-03-04|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|CONTACT||CONcussion Treatment After Combat Trauma (CONTACT)|The Effect of Telephone Follow up on Outcome for Service Members With Mild TBI/PTSD|Completed||N/A|366|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium||2|||f||||t||||||||||2018-05-31 22:24:24.620075|2018-05-31 22:24:24.620075
NCT01387477|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-01|2011-07-01|2011-07-04|Estimate|||||||2011-07-01|2011-07-04|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Lactate and Hypoglycemia|Comparison of Two Strategies of Hypoglycemia Correction in ICU|Unknown status|Recruiting|Phase 4|50|Anticipated|Institut d'Anesthesiologie des Alpes Maritimes||2|||f||||f||||||||||2018-05-31 22:24:24.709767|2018-05-31 22:24:24.709767
NCT01387464|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2016-04-26|2012-01-30|2016-06-02|2011-07-01|2011-07-04|Estimate|2016-04-26|2016-06-02|Estimate|2012-01-30|2012-02-02|Estimate|2016-06-02|2016-07-04|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Intent-to-treat Population|Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery|A Double-Masked Clinical Study To Determine The Aqueous Humor Concentration Of Bromfenac Sodium In Subjects Administered Multiple Topical Ocular Doses Of ISV-303 Or Bromday™ Once Daily (QD) Prior To Cataract Surgery|Completed||Phase 2|60|Actual|InSite Vision||2|||f||||f||||||||||2018-05-31 22:24:24.804388|2018-05-31 22:24:24.804388
NCT01387451|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-01|2011-07-01|2011-07-04|Estimate|||||||2011-07-01|2011-07-04|Estimate|October 2010||2010-10-31|April 2010|2010-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Detection and Factors of Brown Adipose Tissue in Different Locations of Adults|Cross Sectional Study on the Detection and Factors of Brown Adipose Tissue in Different Locations of Adults|Unknown status|Active, not recruiting||30|Anticipated|Huashan Hospital|||||f||||t||||||Samples Without DNA|"~     Adipose tissue, plasma~   "|||2018-05-31 22:24:25.021222|2018-05-31 22:24:25.021222
NCT01387438|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-07-01|2011-07-01|2011-07-04|Estimate|||||||2011-07-01|2011-07-04|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Incidence,Factors,and Importance of Brown Adipose Tissue in Chinese Adults|Cross-sectional Study on the Incidence,Factors,and Importance of Brown Adipose Tissue in Adult Chinese|Unknown status|Active, not recruiting||200|Anticipated|Huashan Hospital|||||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 22:24:25.072593|2018-05-31 22:24:25.072593
NCT01387425|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2015-12-01|2011-07-01|2011-07-04|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2011||2011-06-30|December 2015|2015-12-31||||December 2015|Actual|2015-12-31||Interventional|DIASMOKE||Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)|Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: A Double-Blind, Placebo-Controlled, Randomized, Trial|Completed||N/A|300|Actual|Universita degli Studi di Catania||2|||f||||||||||||||2018-05-31 22:24:25.145943|2018-05-31 22:24:25.145943
NCT01387412|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-11-30|2011-06-30|2011-07-04|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|VIVA||The Role of Genital Warts in HIV Acquisition in Peru|"The Role of Genital Warts in HIV Acquisition Among MSM in Peru"|Completed|||600|Actual|University of California, Los Angeles|||1||f||||f||||||Samples With DNA|"~     serum, lesion biopsies~   "|||2018-05-31 22:24:25.269108|2018-05-31 22:24:25.269108
NCT01387399|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2013-02-14|2011-07-01|2011-07-04|Estimate|||||||2013-02-14|2013-02-18|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|HIPEC ROC I||Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer|Phase I Study of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion With Cisplatin in Patients With Recurrent Ovarian Cancer|Unknown status|Active, not recruiting|Phase 1|9|Anticipated|University Hospital, Bonn||1|||f||||t||||||||||2018-05-31 22:24:25.358788|2018-05-31 22:24:25.358788
NCT00949832|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2012-07-03|2009-07-29|2009-07-30|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2004||2004-01-31|July 2012|2012-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Vitamin D and Genetics in Nutritional Rickets|Vitamin D and Genetics in Nutritional Rickets|Completed||Phase 4|109|Actual|Mayo Clinic||4|||f||||f||||||||||2018-06-01 00:44:14.499527|2018-06-01 00:44:14.499527
NCT01387373|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-03-20|2011-07-01|2011-07-04|Estimate|||||||2014-03-20|2014-03-21|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer|Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer. A Phase II Trial|Unknown status|Recruiting|Phase 2|100|Anticipated|Herlev Hospital||1|||f||||f||||||||||2018-05-31 22:24:25.453619|2018-05-31 22:24:25.453619
NCT01387360|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-05-19|2011-06-30|2011-07-04|Estimate|||||||2015-05-19|2015-05-20|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|SUPRACOR||Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes|A Prospective Study to Evaluate the Safety and Effectiveness of the Supracor Presbyopic Treatment Algorithm for Pseudophakic Eyes Using Lasik|Completed||Phase 4|33|Actual|Technolas Perfect Vision GmbH||1|||f||||t||||||||||2018-05-31 22:24:25.573604|2018-05-31 22:24:25.573604
NCT01387347|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2012-11-29||2015-06-10|2011-06-30|2011-07-04|Estimate|2012-12-20|2012-12-24|Estimate||||2015-06-10|2015-07-10|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye|A Double-Masked, Randomized, Single-Center Study Evaluating the Safety and Efficacy of 0.1% Tβ4 Ophthalmic Solution Compared to Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model|Completed||Phase 2|72|Actual|ReGenTree, LLC|"There were no limitations to trial RGN-DE-202 entitled:Safety and Efficacy of Thymosin beta 4 Ophthalmic Solution in Patients with Dry Eye. All subjects were enrolled."|2|||f||||f||||||||||2018-05-31 22:24:25.826269|2018-05-31 22:24:25.826269
NCT01387334|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-06-30|2011-06-30|2011-07-04|Estimate|||||||2011-06-30|2011-07-04|Estimate|February 2007||2007-02-28|June 2011|2011-06-30|April 2011|Actual|2011-04-30|February 2009|Actual|2009-02-28||Interventional|RE||The Effectiveness of Resistance Exercise for Glycemic Control in Type 2 Diabetes Mellitus Patients|The Effectiveness of a Home-Based Resistance Exercise Training Program With Rubber Bands for Glycemic Control in Individuals With Type 2 Diabetes Mellitus|Completed||Phase 2|60|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-05-31 22:24:26.223966|2018-05-31 22:24:26.223966
NCT01387321|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-01-26|2011-06-30|2011-07-04|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of BYL719 in Adult Patients With Advanced Solid Malignancies|A Study of BYL719 in Adult Patients With Advanced Solid Malignancies|Completed||Phase 1|33|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:24:26.30327|2018-05-31 22:24:26.30327
NCT01387308|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-10-27|2011-07-01|2011-07-04|Estimate|||||||2011-10-27|2011-10-28|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets|An Open-label, Partially Randomized, 5-way Crossover Study in Healthy Volunteers to Assess the Relative Bioavailability of 100 and 150 mg Fostamatinib Tablets Compared With 50 mg Fostamatinib Tablets|Completed||Phase 1|24|Anticipated|AstraZeneca||5|||f||||||||||||||2018-05-31 22:24:26.38742|2018-05-31 22:24:26.38742
NCT01387295|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-03-20|2011-06-30|2011-07-04|Estimate|||||||2014-03-20|2014-03-21|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease|Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer A Phase II Trial in Patients With Limited Extrahepatic Disease|Unknown status|Recruiting|Phase 2|100|Anticipated|Herlev Hospital||1|||f||||t||||||||||2018-05-31 22:24:26.597294|2018-05-31 22:24:26.597294
NCT01387282|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2017-03-15|2014-02-12|2017-09-26|2011-06-30|2011-07-04|Estimate|2017-06-09|2017-07-11|Actual|2014-02-12|2014-03-03|Estimate|2017-09-26|2017-10-27|Actual|July 2011||2011-07-31|September 2017|2017-09-30|February 2015|Actual|2015-02-28|November 2013|Actual|2013-11-30||Interventional|||Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C|Completed||Phase 3|495|Actual|Helsinn Therapeutics (U.S.), Inc||2|||f||||t||||||||||2018-05-31 22:24:26.851206|2018-05-31 22:24:26.851206
NCT01387269|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2017-03-15|2014-02-12|2017-09-26|2011-06-30|2011-07-04|Estimate|2017-06-09|2017-07-11|Actual|2014-02-12|2014-03-03|Estimate|2017-09-26|2017-10-27|Actual|July 2011||2011-07-31|September 2017|2017-09-30|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Interventional||The intent-to-treat (ITT) Population included all randomized patients.|Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)|Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C|Completed||Phase 3|484|Actual|Helsinn Therapeutics (U.S.), Inc||2|||f||||t||||||||||2018-05-31 22:24:30.039543|2018-05-31 22:24:30.039543
NCT01387256|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-07-18|2011-07-01|2011-07-04|Estimate|||||||2011-07-18|2011-07-20|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone|Comparing Two Regimens for Medical Abortion: Mifepristone + Misoprostol Versus Misoprostol Alone-3 Hour Intervals|Completed||Phase 4|441|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 22:24:35.607291|2018-05-31 22:24:35.607291
NCT01387243|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-10-25|2011-06-30|2011-07-04|Estimate|||||||2012-10-25|2012-10-29|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Survey on the Pharmacy Follow-up of Alli Purchasers|Survey on the Pharmacy Follow up of Alli Purchasers|Completed|||80|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:24:35.786913|2018-05-31 22:24:35.786913
NCT01387230|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2013-12-19||2017-10-09|2011-06-30|2011-07-04|Estimate|2013-12-19|2014-02-11|Estimate||||2017-10-09|2017-11-09|Actual|July 1, 2011||2011-07-01|October 2017|2017-10-31|February 13, 2012|Actual|2012-02-13|February 1, 2012|Actual|2012-02-01||Interventional|||Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD|A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|206|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:24:35.985674|2018-05-31 22:24:35.985674
NCT01387217|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-06-07|2011-06-30|2011-07-04|Estimate|||||||2017-06-07|2017-06-09|Actual|May 21, 2010|Actual|2010-05-21|June 2017|2017-06-30|December 20, 2010|Actual|2010-12-20|December 20, 2010|Actual|2010-12-20||Interventional|P1A114070||GSK2018682 FTIH in Healthy Volunteers|A Single-blind, Placebo-controlled, Two Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of GSK2018682 in Healthy Volunteers|Completed||Phase 1|27|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:24:36.849143|2018-05-31 22:24:36.849143
NCT01387204|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-11-08|2011-06-30|2011-07-04|Estimate|||||||2017-11-08|2017-11-13|Actual|February 15, 2011|Actual|2011-02-15|November 2017|2017-11-30|July 18, 2011|Actual|2011-07-18|July 18, 2011|Actual|2011-07-18||Interventional|||Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212|An Open-label Mass Balance Study to Investigate the Absorption, Distribution, Metabolism and Elimination of a Single Oral Dose of MEK Inhibitor [14C]GSK1120212 in Male Subjects With Solid Tumors|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:24:37.040121|2018-05-31 22:24:37.040121
NCT01387191|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-05-15|2011-06-30|2011-07-04|Estimate|||||||2017-05-15|2017-05-16|Actual|August 1999||1999-08-31|May 2017|2017-05-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Observational|||Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg|Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg|Completed|||748|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:24:37.129081|2018-05-31 22:24:37.129081
NCT01387178|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2011-09-21||2017-05-15|2011-06-30|2011-07-04|Estimate|2011-09-21|2011-10-28|Estimate||||2017-05-15|2017-05-17|Actual|July 2008||2008-07-31|May 2017|2017-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease|Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease|Completed|||22223|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:24:37.251692|2018-05-31 22:24:37.251692
NCT01387165|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-06-07|2011-06-30|2011-07-04|Estimate|||||||2017-06-07|2017-06-08|Actual|October 2004||2004-10-31|May 2017|2017-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|DEAL||Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina|A Multi-center, Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latin America|Completed|||3592|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:24:38.028819|2018-05-31 22:24:38.028819
NCT01387152|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-02-02|2011-06-30|2011-07-04|Estimate|||||||2015-02-02|2015-02-04|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|November 2012|Actual|2012-11-30||Observational|||Prognosis of Very Low Dose SPECT|Prognosis of Very Low Dose Stress First Myocardial Perfusion SPECT in Patients With Chest Pain Using an Alcyone Camera|Completed|||100|Actual|Columbia University|||1||f||||f||||||||||2018-05-31 22:24:38.092514|2018-05-31 22:24:38.092514
NCT01387139|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2015-12-03||2017-11-06|2011-07-01|2011-07-04|Estimate|2016-01-20|2016-02-17|Estimate||||2017-11-06|2017-12-08|Actual|January 2011||2011-01-31|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|January 2014|Actual|2014-01-31||Interventional|||Ketamine Versus Co-administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department|Comparison of Ketamine Versus Co-Administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department|Completed||Phase 3|183|Actual|University of Colorado, Denver||2|||f||||t|t|f||||||||2018-05-31 22:24:38.268466|2018-05-31 22:24:38.268466
NCT01387126|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-07-18|2011-07-01|2011-07-04|Estimate|||||||2017-07-18|2017-07-19|Actual||||July 2017|2017-07-31||||||||Interventional|||Effects of a High Viscosity Dietary Fibre, as Part of a Medically Supervised Weight Management Program|A Randomized, Controlled Trial Evaluating the Effects of a High Viscosity Dietary Fibre, as Part of a Medically Supervised Weight Management Program, on Body Weight in Overweight and Obese Individuals|Suspended||Phase 3|240|Anticipated|Canadian Center for Functional Medicine||2||No grant funding yet for this trial.|f||||||||||||||2018-05-31 22:24:38.758553|2018-05-31 22:24:38.758553
NCT01387113|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2017-01-31|2011-07-01|2011-07-04|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|PERFUSE||The PERFusion Use in Stroke Evaluation Study|Expanding the Time Window for IV Thrombolysis With Rt-PA in Acute Ischemic Stroke Patients Using Computed Tomography Perfusion Imaging: The PERFusion Use in Stroke Evaluation (PERFUSE) Study|Recruiting|||100|Anticipated|California Pacific Medical Center Research Institute|||1||f||||f||||||||||2018-05-31 22:24:38.862576|2018-05-31 22:24:38.862576
NCT01387100|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-02-20|2011-07-01|2011-07-04|Estimate|||||||2015-02-20|2015-02-23|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|Work It||A Modified Rehabilitation Intervention for Working Persons With Arthritis|Efficacy of a Modified Vocational Rehabilitation Intervention for Work Disability|Unknown status|Active, not recruiting|N/A|300|Anticipated|Boston University||2|||f||||f||||||||||2018-05-31 22:24:39.015121|2018-05-31 22:24:39.015121
NCT01387087|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-06-30|2011-06-30|2011-07-04|Estimate|||||||2011-06-30|2011-07-04|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP015K Following Single Oral Doses to Healthy Volunteers|Completed||Phase 1|72|Actual|Astellas Pharma Inc||12|||f||||f||||||||||2018-05-31 22:24:39.122734|2018-05-31 22:24:39.122734
NCT01387074|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2013-12-13||2013-12-13|2011-07-01|2011-07-04|Estimate|2013-12-13|2014-02-03|Estimate||||2013-12-13|2014-02-03|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity|A Prospective, Non-interventional, Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity|Completed|||108|Actual|Allergan|||1||f||||f||||||||||2018-05-31 22:24:39.266411|2018-05-31 22:24:39.266411
NCT01387061|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-09-18|2011-07-01|2011-07-04|Estimate|||||||2011-09-18|2011-09-20|Estimate|June 2001||2001-06-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Resection for Multiple Hepatocellular Carcinomas (HCC)|Hepatic Resection for Multiple Hepatocellular Carcinoma on Cirrhosis|Completed||N/A|87|Actual|University of Milan||1|||f||||||||||||||2018-05-31 22:24:39.744635|2018-05-31 22:24:39.744635
NCT01386892|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2014-02-10|2011-06-30|2011-07-01|Estimate|||||||2014-02-10|2014-02-11|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Immunological Characterization of Blood of Normal Individuals|Immunological Characterization of Blood of Normal Individuals|Active, not recruiting|||1500|Anticipated|Ohio State University|||1||f||||f||||||Samples With DNA|"~     Blood Saliva Urine~   "|||2018-05-31 22:24:42.109697|2018-05-31 22:24:42.109697
NCT01387048|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2013-07-05|2011-07-01|2011-07-04|Estimate|||||||2013-07-05|2013-07-08|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|SKADI||Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin|Phase IV An Evaluator-Blind Controlled Parallel-Group Study To Assess Efficacy And Safety Of Skinoren® 15% Gel And Differin® 0,1% Gel For The Treatment And Maintenance Treatment Of Facial Acne Vulgaris And Late-Type Acne In Females|Completed||Phase 4|60|Actual|University of Magdeburg||3|||f||||t||||||||||2018-05-31 22:24:39.855752|2018-05-31 22:24:39.855752
NCT01387035|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-07-01|2011-07-01|2011-07-04|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases|Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases|Unknown status|Recruiting||50|Anticipated|Heidelberg University|||||f||||f||||||||||2018-05-31 22:24:40.05137|2018-05-31 22:24:40.05137
NCT01387022|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2017-01-30||2017-03-23|2011-06-30|2011-07-01|Estimate|2017-01-30|2017-03-20|Actual||||2017-03-23|2017-04-20|Actual|June 2011||2011-06-30|March 2017|2017-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|TOAST|All participants who were randomised and initiated on ART|Trial to Assess the Impact of PrEP to Tenofovir Gel on the Efficacy of Tenofovir-containing ART on Viral Suppression|Open Label Randomized Controlled Trial to Assess the Impact of Prophylactic Exposure to Tenofovir Gel on the Efficacy of Subsequent Tenofovir-containing Antiretroviral Therapy on Viral Suppression|Completed||N/A|59|Actual|Centre for the AIDS Programme of Research in South Africa|The main limitation of the study was the small sample size. The eligible pool of participants was dependent on two other tenofovir gel trials, one of which experienced long delay in starting.|2|||f||||t||||||||||2018-05-31 22:24:40.14886|2018-05-31 22:24:40.14886
NCT01387009|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-01-23|2011-06-30|2011-07-01|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2011|Actual|2011-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|||Acquisition of Normative Data for Musculoskeletal Ultrasound in Children|Acquisition of Normative Data for Musculoskeletal Ultrasound in Children|Active, not recruiting|||100|Actual|Children's Hospital of Eastern Ontario|||||f||||||||||||||2018-05-31 22:24:40.801692|2018-05-31 22:24:40.801692
NCT01386996|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-12-21|2011-06-30|2011-07-01|Estimate|||||||2011-12-21|2011-12-22|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler|Pharmacokinetic Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 320/9 Microg/Inhalation and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|74|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 22:24:40.846322|2018-05-31 22:24:40.846322
NCT01386983|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2011-02-28||2017-05-15|2011-06-06|2011-07-01|Estimate|2011-06-06|2011-07-01|Estimate||||2017-05-15|2017-05-17|Actual|March 2009||2009-03-31|May 2017|2017-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment|Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment|Completed|||332|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:24:41.018753|2018-05-31 22:24:41.018753
NCT01386970|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-05-01|2011-06-30|2011-07-01|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2005||2005-05-31|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2008|Actual|2008-07-31||Interventional|||Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics|Sex and Disease Dependent Nucleoside Analog Toxicity|Completed||Phase 4|51|Actual|University of Colorado, Denver||2|||f||||t||||||||No|No plan to share.|2018-05-31 22:24:41.3799|2018-05-31 22:24:41.3799
NCT01386957|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2012-03-07|2011-06-30|2011-07-01|Estimate|||||||2012-03-07|2012-03-08|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|July 2015|Anticipated|2015-07-31|July 2013|Anticipated|2013-07-31||Observational|||Steroid Treatment of Idiopathic Nephrotic Syndrome|Steroid Treatment of Childhood Idiopathic Nephrotic Syndrome: Epidemiology, Therapeutic Adequacy, Medium and Long Term Outcomes. A Prospective Observational Cohort Study.|Unknown status|Recruiting||120|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||1||f||||f||||||Samples Without DNA|"~     Whole Blood and Urine~   "|||2018-05-31 22:24:41.451919|2018-05-31 22:24:41.451919
NCT01386944|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2014-07-24||2018-03-09|2011-06-30|2011-07-01|Estimate|2014-07-24|2014-08-15|Estimate||||2018-03-09|2018-04-04|Actual|July 2011||2011-07-31|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|AURORA|The Baseline Analysis Population refers to the Full Analysis Set (FAS). The FAS is a subset of the Safety Set and consists of all patients who received treatment with Neupro at least once and had a Visit 1 and at least one post-Visit 1 measurement on the primary variable documented.|Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation|Non Interventional Observational Study to Collect Data for the Effect of Switching to Neupro® on Severity of Restless Leg Syndrome (RLS) Symptoms and Augmentation as Well as the Change in Treatment Regimen Used, in RLS Patients With Previous Augmentation|Completed|||102|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 22:24:41.562192|2018-05-31 22:24:41.562192
NCT01386931|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2018-05-17|2011-06-29|2011-07-01|Estimate|||||||2018-05-17|2018-05-21|Actual|June 2011||2011-06-30|May 2018|2018-05-31|June 16, 2017|Actual|2017-06-16|June 2013|Actual|2013-06-30||Observational|||On-site Cytopathology EUS-FNA|The Clinical Impact of Immediate On-site Cytopathology Evaluation During Endoscopic Ultrasound-Guided Fine Needle Aspiration of Pancreatic Mass: A Multicenter, Prospective Randomized Controlled Trial|Completed|||111|Actual|University of Colorado, Denver|||2||f||||t||||||||||2018-05-31 22:24:41.895297|2018-05-31 22:24:41.895297
NCT01386918|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-01-04|2011-06-30|2011-07-01|Estimate|||||||2012-01-04|2012-01-06|Estimate|February 2004||2004-02-29|January 2012|2012-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia|A Randomized Double-Blind Sham-Controlled Trial of Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia|Completed||N/A|144|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-05-31 22:24:41.970581|2018-05-31 22:24:41.970581
NCT01386905|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2014-03-11|2011-06-30|2011-07-01|Estimate|||||||2014-03-11|2014-03-12|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||A Study of the TransPyloric Shuttle™ (TPS™) for Weight Reduction in Obese Subjects|A Study of the TransPyloric Shuttle™ (TPS™) for Weight Reduction in Obese Subjects (ENDObesity™ I Study)|Completed||N/A|20|Actual|BaroNova, Inc.|||||f||||t||||||||||2018-05-31 22:24:42.040604|2018-05-31 22:24:42.040604
NCT01386879|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-05-12|2011-06-29|2011-07-01|Estimate|||||||2015-05-12|2015-05-13|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation of Above the Cuff Suctioning During General Anesthesia|Evaluation of Microaspiration and Efficacy of Above the Cuff Suctioning During General Anesthesia: A Comparison of Two Endotracheal Tubes With Suction Above Cuff With a Standard Endotracheal Tube|Terminated||Phase 4|60|Actual|Thomas Jefferson University||3||The study was terminated because of slower than anticipated enrollment|f||||f||||||||||2018-05-31 22:24:42.172619|2018-05-31 22:24:42.172619
NCT01386866|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-07-14|2011-06-30|2011-07-01|Estimate|||||||2011-07-14|2011-07-15|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors|An Open-label, Single Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labelled AMG 706 (Motesanib) Followed by Extended Treatment With Motesanib in Patients With Advanced Solid Tumors|Completed||Phase 1|4|Actual|Amgen||1|||f||||||||||||||2018-05-31 22:24:42.247156|2018-05-31 22:24:42.247156
NCT01386853|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-06-30|2011-06-30|2011-07-01|Estimate|||||||2011-06-30|2011-07-01|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|||Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients|A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, Non-inferiority Study to Compare the Efficacy and Safety of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Tai Tien Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 22:24:42.312206|2018-05-31 22:24:42.312206
NCT01386840|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-25|||2015-05-15|2011-06-30|2011-07-01|Estimate|||||||2015-05-15|2015-05-18|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ISPOT||IndiaCLEN Multicentre Trial of Home Versus Hospital Oral Amoxicillin for Management of Severe Pneumonia in Children|IndiaCLEN Multicentric Trial of Home Versus Hospital Oral Amoxicillin for Management of Severe Pneumonia in Children|Completed||N/A|1118|Actual|Lata Medical Research Foundation, Nagpur||2|||f||||t||||||||||2018-05-31 22:24:42.424745|2018-05-31 22:24:42.424745
NCT01386827|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-10-27|2011-06-30|2011-07-01|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis|Ability of the New Vero-cell-derived Inactivated Japanese Encephalitis Vaccine (IXIARO) to Elicit a Booster Response in Travellers Previously Vaccinated With Traditional Mouse-brain Derived Vaccine (JE-MB)|Completed||Phase 3|120|Actual|Helsinki University Central Hospital||4|||f||||t||||||||||2018-05-31 22:24:42.503823|2018-05-31 22:24:42.503823
NCT01386814|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-06-30|2011-06-30|2011-07-01|Estimate|||||||2011-06-30|2011-07-01|Estimate|July 2011||2011-07-31|May 2009|2009-05-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Observational|Hypoxia||Neuropsychological Sleep Physical Exercise Hypoxia|Aspects of Neuropsychological Assessment, Standard and Sleep Efficiency in People Exposed to Altitude|Unknown status|Not yet recruiting||60|Anticipated|Federal University of São Paulo|||||f||||t||||||||||2018-05-31 22:24:42.578428|2018-05-31 22:24:42.578428
NCT01386801|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2013-09-05|2011-06-30|2011-07-01|Estimate|||||||2013-09-05|2013-09-06|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|June 2050|Anticipated|2050-06-30|December 2049|Anticipated|2049-12-31||Observational|IHS||Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana|Multicenter Research Study to Build a Repository That Will Allow Researchers to Study Chronic Diseases in the Population of Central Indiana|Active, not recruiting|||1000|Anticipated|Fairbanks Institute|||2||f||||t||||||Samples With DNA|"~     DNA = 1 Serum = 2 Plasma = 2 RNA = 2~   "|||2018-05-31 22:24:42.635721|2018-05-31 22:24:42.635721
NCT01386788|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2013-09-13||2016-08-05|2011-06-30|2011-07-01|Estimate|2016-08-05|2016-09-28|Estimate||||2016-08-05|2016-09-28|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|RISK||European Survey: Risk of Cyanide Poisoning in Smoke Inhalation|European Survey: Risk of Cyanide Poisoning in Smoke Inhalation, Symptoms, Key Treatment and Outcome (RISK)|Completed|||102|Actual|Dr. Ernst MW Koch|General limitations of observational study||1||f||||f||||||||||2018-05-31 22:24:42.726727|2018-05-31 22:24:42.726727
NCT01386775|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-06-26|2011-06-30|2011-07-01|Estimate|||||||2012-06-26|2012-06-28|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Observational|||Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation|Completed|||64|Actual|Edimer Pharmaceuticals|||2||f||||f||||||||||2018-05-31 22:24:43.021103|2018-05-31 22:24:43.021103
NCT01386762|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-06-30|2011-06-30|2011-07-01|Estimate|||||||2011-06-30|2011-07-01|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury|Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury|Unknown status|Recruiting|Early Phase 1|30|Anticipated|California State University, San Marcos||1|||f||||f||||||||||2018-05-31 22:24:43.094926|2018-05-31 22:24:43.094926
NCT01386749|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-07-27|2011-06-30|2011-07-01|Estimate|||||||2015-07-27|2015-07-29|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Low-Magnitude, High Frequency Vibration Treatment on Femoral Shaft Fracture Healing|The Efficacy of Low-Magnitude, High Frequency Vibration Treatment on Accelerating the Healing of Femoral Shaft Fracture - A Prospective Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|50|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:24:43.175839|2018-05-31 22:24:43.175839
NCT01386736|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-06-30|2011-06-30|2011-07-01|Estimate|||||||2011-06-30|2011-07-01|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Vitamin D and Glucose Metabolism in Pediatrics|Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics|Unknown status|Recruiting|Phase 4|110|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 22:24:43.261358|2018-05-31 22:24:43.261358
NCT01386723|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-01-31|2011-06-30|2011-07-01|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|June 30, 2019|Anticipated|2019-06-30|March 30, 2019|Anticipated|2019-03-30||Observational|||End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia|End of EXTEND: Observing for Sustained Response Despite Discontinuation of Medication in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Treated With Eltrombopag|Recruiting|||20|Anticipated|Weill Medical College of Cornell University|||1||f||||t|t|f|||f|Samples Without DNA|"~     Blood specimens~   "|Undecided||2018-05-31 22:24:43.350872|2018-05-31 22:24:43.350872
NCT01386710|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-08-22|2011-06-29|2011-07-01|Estimate|||||||2017-08-22|2017-08-23|Actual|September 2011||2011-09-30|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma|Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma|Suspended||Phase 1/Phase 2|60|Anticipated|Northwell Health||2||In the process of transferring IRB to PI's current institution|f||||t||||||||||2018-05-31 22:24:43.431127|2018-05-31 22:24:43.431127
NCT01386697|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2014-10-10|2011-06-30|2011-07-01|Estimate|||||||2014-10-10|2014-10-13|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||DIBH Proton Planning|A Prospective Radiation Oncology Planning Study For Lung, Gastrointestinal And Lymphomatous Malignancies Using Proton Radiotherapy As Compared To 3D Conformal And Intensity-Modulated X-Ray Therapy For Dosimetric Evaluation Of Tumoral Coverage And Dose To Organs-At-Risk.|Completed|||40|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:24:43.509193|2018-05-31 22:24:43.509193
NCT01386684|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2017-08-24||2017-08-24|2011-06-30|2011-07-01|Estimate|2017-08-24|2018-04-02|Actual||||2017-08-24|2018-04-02|Actual|June 28, 2011|Actual|2011-06-28|August 2017|2017-08-31|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Observational|||Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study|Canadian Real-Life Evaluation of the Effectiveness of Lupron in the Management of Prostate Cancer (CRONOS)|Completed|||552|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:24:43.64047|2018-05-31 22:24:43.64047
NCT01386671|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2018-01-26|2011-06-30|2011-07-01|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2014|Actual|2014-06-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|February 2016|Actual|2016-02-29||Interventional|COMET||Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes|Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients|Completed||Phase 3|203|Actual|Laboratorios Silanes S.A. de C.V.||2|||f||||f||||||||Undecided||2018-05-31 22:24:45.095193|2018-05-31 22:24:45.095193
NCT01386658|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2018-03-21|2011-06-30|2011-07-01|Estimate|||||||2018-03-21|2018-03-23|Actual|November 1, 2011|Actual|2011-11-01|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|||A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema|A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents With Hereditary Angioedema|Completed||Phase 3|30|Actual|Shire||1|||f||||f||||||||||2018-05-31 22:24:45.237962|2018-05-31 22:24:45.237962
NCT01386645|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2018-04-16|2011-06-29|2011-07-01|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2011||2011-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|GIdiet||Effect of Dietary Glycemic Index on Beta-cell Function|Effect of Dietary Glycemic Index on Beta-cell Function|Active, not recruiting||N/A|53|Actual|Seattle Institute for Biomedical and Clinical Research||3|||f||||f||||||||||2018-05-31 22:24:45.392761|2018-05-31 22:24:45.392761
NCT01386632|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2016-01-18||2017-05-17|2011-06-30|2011-07-01|Estimate|2017-05-17|2017-06-14|Actual||||2017-05-17|2017-06-14|Actual|May 2011||2011-05-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|August 2014|Actual|2014-08-31||Interventional|||Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma|Phase II Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Stage III-IV Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 2|50|Actual|Sanford Health||2|||f||||t||||||||No||2018-05-31 22:24:45.524882|2018-05-31 22:24:45.524882
NCT01386619|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-09-14|2011-06-30|2011-07-01|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2004||2004-01-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)|Natural Killer Cell Selected T-cell Depleted Donor Lymphocyte Infusions (NK-DLI) in Patients After HLA-haploidentical Allogeneic Stem Cell Transplantation|Completed||Phase 1/Phase 2|15|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-05-31 22:24:46.071795|2018-05-31 22:24:46.071795
NCT01386606|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2014-06-13||2015-08-21|2011-06-29|2011-07-01|Estimate|2015-08-21|2015-09-23|Estimate||||2015-08-21|2015-09-23|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||The baseline analysis consisted of all subjects enrolled.|The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)|A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men|Completed||Phase 2|60|Actual|Repros Therapeutics Inc.||4|||f||||f||||||||||2018-05-31 22:24:46.331258|2018-05-31 22:24:46.331258
NCT01386593|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-04-16|2011-06-30|2011-07-01|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||"Pharmacokinetic Study to Characterize Phenotyping Metrics of the Basel Cocktail After CYP Induction or Inhibition"|"Single-center, Randomized, Open-label, Two-way Crossover Study to Characterize Phenotyping Metrics of the Basel Cocktail After CYP Induction or Inhibition in Healthy Male Subjects"|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 22:24:47.201987|2018-05-31 22:24:47.201987
NCT01386580|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-01-21|2011-06-30|2011-07-01|Estimate|||||||2015-01-21|2015-01-22|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.|An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.|Completed||Phase 1/Phase 2|84|Actual|BBB-Therapeutics B.V.||4|||f||||f||||||||||2018-05-31 22:24:47.308812|2018-05-31 22:24:47.308812
NCT01386567|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2013-05-16|2011-06-30|2011-07-01|Estimate|||||||2013-05-16|2013-05-17|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203|A One Year Open Label Study of Androxal in the Treatment of Secondary Hypogonadism in Men Who Have Completed Protocol ZA-203|Completed||Phase 2|48|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 22:24:47.453456|2018-05-31 22:24:47.453456
NCT01386359|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-12-06|2011-06-30|2011-07-01|Estimate|||||||2017-12-06|2017-12-07|Actual|February 29, 2012|Actual|2012-02-29|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|ENLIST||Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant|Evaluating Nulojix Long-Term Safety in Transplant|Active, not recruiting|||1130|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 22:24:52.06911|2018-05-31 22:24:52.06911
NCT01386554|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2017-12-15||2018-04-02|2011-06-30|2011-07-01|Estimate|2018-02-21|2018-03-26|Actual||||2018-04-02|2018-05-03|Actual|August 2011||2011-08-31|April 2018|2018-04-30|May 5, 2017|Actual|2017-05-05|November 21, 2016|Actual|2016-11-21||Interventional|CHART||Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients|A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)|Completed||Phase 4|60|Actual|Mallinckrodt||3|||f||||||||||||||2018-05-31 22:24:47.592935|2018-05-31 22:24:47.592935
NCT01386541|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-05-04|2011-06-30|2011-07-01|Estimate|||||||2012-05-04|2012-05-07|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Multiple Ascending Dose Trial of BYK324677 in Healthy Volunteers|Investigation of Safety/Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Doses of BYK324677 in Healthy Volunteers. A Monocentre, Placebo-controlled, Cross-over, Double-blind, Randomised Trial|Completed||Phase 1|36|Anticipated|Nycomed||2|||f||||||||||||||2018-05-31 22:24:49.518276|2018-05-31 22:24:49.518276
NCT01386528|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|2017-06-21|2014-01-24|2017-07-24|2011-06-30|2011-07-01|Estimate|2017-06-21|2017-07-24|Actual|2014-01-24|2014-02-24|Estimate|2017-07-24|2017-08-23|Actual|June 7, 2012|Actual|2012-06-07|July 2017|2017-07-31|December 1, 2013|Actual|2013-12-01|December 1, 2013|Actual|2013-12-01||Interventional|paradigm™ 3|The full analysis set consists of all patients exposed to nonacog beta pegol.|Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B|An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B|Completed||Phase 3|13|Actual|Novo Nordisk A/S|This is a single armed study having no comparator.|1|||f||||f||||||||||2018-05-31 22:24:49.696617|2018-05-31 22:24:49.696617
NCT01386515|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-05-24|2011-06-30|2011-07-01|Estimate|||||||2018-05-24|2018-05-25|Actual|June 7, 2011||2011-06-07|January 7, 2016|2016-01-07|January 7, 2016||2016-01-07|||||Observational|||The Role of Family Functioning in Promoting Adaptation in Siblings of Individuals With Duchenne Muscular Dystrophy (DMD)|The Role of Family Functioning in Promoting Adaptation in Siblings of Individuals With Duchenne Muscular Dystrophy (DMD)|Terminated|||33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:24:50.099342|2018-05-31 22:24:50.099342
NCT01386502|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-06-30|2011-06-30|2011-07-01|Estimate|||||||2017-06-30|2017-07-02|Actual|June 15, 2011||2011-06-15|October 31, 2011|2011-10-31|October 31, 2011|Actual|2011-10-31|||||Interventional|||CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors|Phase I Trial of Escalating Doses of Anti-PD1 Monoclonal Antibody (CT-011) in Combination With p53 Vaccine in Adults With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:24:50.16508|2018-05-31 22:24:50.16508
NCT01386489|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-05-17|2011-06-30|2011-07-01|Estimate|||||||2018-05-17|2018-05-18|Actual|June 17, 2011||2011-06-17|March 19, 2014|2014-03-19|March 19, 2014|Actual|2014-03-19|March 9, 2014|Actual|2014-03-09||Interventional|||Immune Responses to Two Experimental HIV Vaccines in Healthy Adults|VRC 016: A Phase 1b Open-Label, Randomized Clinical Trial to Evaluate Early Innate and Adaptive Immune Responses to the Investigational HIV-1 Vaccines: VRC-HIVADV014-00-VP and VRC-HIVDNA016-00-VP in Ad5 Seronegative Healthy Adults|Completed||Phase 1|36|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:24:50.359874|2018-05-31 22:24:50.359874
NCT01386476|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2017-10-05|2011-06-30|2011-07-01|Estimate|||||||2017-10-05|2017-10-06|Actual|June 15, 2011||2011-06-15|September 1, 2016|2016-09-01|September 1, 2016||2016-09-01|||||Observational|||(18F)FCWAY and the Blood-Brain Barrier|The Serotonin-1A Receptor Radioligand (18F)FCWAY as a Potential Substrate for Efflux Transport at the Blood-Brain Barrier|Completed|||18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:24:50.456175|2018-05-31 22:24:50.456175
NCT01386437|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-05-08|2011-06-30|2011-07-01|Estimate|||||||2018-05-08|2018-05-09|Actual|June 30, 2011||2011-06-30|May 3, 2018|2018-05-03||||||||Observational|||Natural History of Individuals With Immune System Problems That Lead to Fungal Infections|The Natural History, Immunologic Correlates and Genetic Defects in Patients With Mucocutaneous and Invasive Fungal Infections|Recruiting|||700|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:24:50.524539|2018-05-31 22:24:50.524539
NCT01386424|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-05-18|2011-06-30|2011-07-01|Estimate|||||||2018-05-18|2018-05-21|Actual|June 30, 2011||2011-06-30|April 17, 2018|2018-04-17||||||||Observational|||Screening for LID Clinical Studies Unit Healthy Volunteer Protocols|Screening for LID Clinical Studies Unit Healthy Volunteer Protocols|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:24:50.615779|2018-05-31 22:24:50.615779
NCT01386411|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-11-06|2011-06-30|2011-07-01|Estimate|||||||2017-11-06|2017-11-08|Actual|June 28, 2011|Actual|2011-06-28|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Observational|||Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer|Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer|Completed|||108|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     peripheral blood leucocytes and/or mouthwash-collected buccal epithelial cells)~   "|||2018-05-31 22:24:50.734566|2018-05-31 22:24:50.734566
NCT01386398|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-01-20|2011-06-30|2011-07-01|Estimate|||||||2015-01-20|2015-01-21|Estimate||||January 2015|2015-01-31||||||||Interventional|||Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma|Progression Free Survival (PFS) Comparison Between Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat TM) in Combination With Bortezomib (Velcade TM) and SAHA Alone in Refractory or Recurrent Advanced CTCL. A Randomized Study.|Withdrawn||Phase 3|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||Company withdrew interest|f||||||||||||||2018-05-31 22:24:50.823206|2018-05-31 22:24:50.823206
NCT01386385|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-05-24|2011-06-30|2011-07-01|Estimate|||||||2018-05-24|2018-05-25|Actual|June 20, 2011|Actual|2011-06-20|May 2018|2018-05-31|January 2, 2021|Anticipated|2021-01-02|January 2, 2021|Anticipated|2021-01-02||Interventional|||Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)|Active, not recruiting||Phase 1/Phase 2|162|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 22:24:51.035225|2018-05-31 22:24:51.035225
NCT01386372|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2016-12-14|2011-06-30|2011-07-01|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|INSERT||Tolvaptan for In-hospital Hyponatremia|A Pilot Study To Evaluate The Incidence Of Hyponatremia In A Medical-Surgical Hospital And To Explore The Efficacy And Safety Of Tolvaptan In The Clinical Practice|Terminated||Phase 2|3|Actual|Mario Negri Institute for Pharmacological Research||2||futility|f||||f||||||||||2018-05-31 22:24:51.892738|2018-05-31 22:24:51.892738
NCT01386346|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2018-01-26|2011-06-29|2011-07-01|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2011|Actual|2011-06-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2014|Actual|2014-08-31||Interventional|VEOX||Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer|Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer|Active, not recruiting||Phase 1|12|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 22:24:52.257231|2018-05-31 22:24:52.257231
NCT01386333|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2013-11-01|2011-06-30|2011-07-01|Estimate|||||||2013-11-01|2013-11-04|Estimate|June 2011||2011-06-30|November 2013|2013-11-30||||October 2013|Actual|2013-10-31||Interventional|FTDOXY10EF||Safety Study of Intranasal Oxytocin in Frontotemporal Dementia|A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF|Completed||Phase 1|23|Actual|Lawson Health Research Institute||4|||f||||f||||||||||2018-05-31 22:24:53.237711|2018-05-31 22:24:53.237711
NCT01386320|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-04-15|2011-06-30|2011-07-01|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|USGAB||Ultrasound Guided Ankle Block Versus Medial Forefoot Block for Forefoot Surgery|A Randomised, Blinded Comparison of an Ultrasound Guided Ankle Block Compared to a Nerve Stimulator Guided Ankle Block for Pain Relief After Forefoot Surgery.|Completed||N/A|60|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 22:24:55.58612|2018-05-31 22:24:55.58612
NCT01386307|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2015-03-19|2011-06-30|2011-07-01|Estimate|||||||2015-03-19|2015-03-20|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Observational|Pain||Prevalence of Pain in Inpatient at the Hospital Italiano de Buenos Aires|¿Cuál es la Prevalencia de Dolor en internación en el Hospital Italiano?|Completed|||800|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 22:24:56.111568|2018-05-31 22:24:56.111568
NCT01386294|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-04-16|2011-06-29|2011-07-01|Estimate|||||||2015-04-16|2015-04-17|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection|A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection|Completed||Phase 3|2059|Actual|CONRAD||2|||f||||t||||||||||2018-05-31 22:24:56.35672|2018-05-31 22:24:56.35672
NCT01386281|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-04-16|2011-06-30|2011-07-01|Estimate|||||||2018-04-16|2018-04-17|Actual|October 20, 2008|Actual|2008-10-20|April 2018|2018-04-30|April 15, 2014|Actual|2014-04-15|April 15, 2014|Actual|2014-04-15||Observational|JULINA-CLIMA||Julina Post-marketing Surveillance for Climacteric Symptoms in Japan|Drug Use Investigation of Julina Tablets 0.5 mg (Postmenopausal Osteoporosis)|Completed|||506|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:24:56.608652|2018-05-31 22:24:56.608652
NCT01386268|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2014-08-20|2011-06-30|2011-07-01|Estimate|||||||2014-08-20|2014-08-21|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Observational|KG0910KR||Kogenate FS Regulatory Post-Marketing Surveillance|KOGENATE® FS , Local Post Authorization Safety Study|Completed|||64|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:24:56.808769|2018-05-31 22:24:56.808769
NCT01386255|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-08-26|2011-06-29|2011-07-01|Estimate|||||||2017-08-26|2017-08-29|Actual|April 2009||2009-04-30|August 2017|2017-08-31|April 30, 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy|Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy|Withdrawn||Phase 4|0|Actual|Boston Children’s Hospital||2||No participants were enrolled|f||||t||||||||||2018-05-31 22:24:57.007069|2018-05-31 22:24:57.007069
NCT01386242|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-01-04|2011-06-30|2011-07-01|Estimate|||||||2016-01-04|2016-01-05|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer|Phase II/III Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Compared With Placebo in Metastatic Colorectal Cancer After Failure of Second-Line and More Than Second-line Treatment|Completed||Phase 2|108|Actual|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||4|||f||||t||||||||||2018-05-31 22:24:57.168866|2018-05-31 22:24:57.168866
NCT01386229|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-06-30|2011-06-30|2011-07-01|Estimate|||||||2011-06-30|2011-07-01|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery||Unknown status|Recruiting|Phase 4|40|Anticipated|Baskent University||2|||f||||f||||||||||2018-05-31 22:24:57.405245|2018-05-31 22:24:57.405245
NCT01386216|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-01-23|2011-06-30|2011-07-01|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2011||2011-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|CLI||Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)|Phase I, Non-Randomized, Feasibility Study for the Use of Bone Marrow Cell Concentrate Prepared Using the Magellan System for the Treatment of Critical Limb Ischemia|Completed||Phase 1|18|Actual|Arteriocyte, Inc.||1|||f||||t||||||||||2018-05-31 22:24:57.521784|2018-05-31 22:24:57.521784
NCT01386203|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2012-02-28|2011-06-29|2011-06-30|Estimate|||||||2012-02-28|2012-02-29|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|May 2018|Anticipated|2018-05-31|May 2016|Anticipated|2016-05-31||Observational|||Exhaled Breath Biomarkers in Lung Cancer|Early Detection of Lung Cancer - Exhaled Breath Nano-Analysis|Unknown status|Recruiting||300|Anticipated|Sheba Medical Center|||3||f||||f||||||Samples Without DNA|"~     exhaled breath and CTC and biomarkers~   "|||2018-05-31 22:24:57.882321|2018-05-31 22:24:57.882321
NCT01386190|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-07-01|2011-06-29|2011-06-30|Estimate|||||||2011-07-01|2011-07-06|Estimate|June 2011||2011-06-30|July 2011|2011-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Impact of Exercise on Body Composition in Premature Infants|Impact of Exercise on Body Composition in Premature Infants: New Approaches|Unknown status|Recruiting|N/A|200|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-05-31 22:24:58.235862|2018-05-31 22:24:58.235862
NCT01386177|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2016-01-20|2011-06-29|2011-06-30|Estimate|||||||2016-01-20|2016-01-21|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)|Interactive Effects of Doxazosin and 3,4-Methylenedioxymethamphetamine (MDMA) in Healthy Subjects|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 22:24:58.362371|2018-05-31 22:24:58.362371
NCT01386164|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-08-15|2011-06-29|2011-06-30|Estimate|||||||2013-08-15|2013-08-16|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|HIPAVAC||Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults|Immune Response to Bivalent and Tetravalent Human Papillomavirus Vaccine in HIV Infected Adults|Completed||Phase 4|92|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:24:58.515035|2018-05-31 22:24:58.515035
NCT01386151|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2016-10-12|2011-06-29|2011-06-30|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients|Safety and Efficacy of Parenteral KGF in Moderate Asthmatic Subjects|Completed||Phase 2|24|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:24:58.614705|2018-05-31 22:24:58.614705
NCT01386138|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2013-10-16|2011-06-29|2011-06-30|Estimate|||||||2013-10-16|2013-10-17|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Treating South African Pregnant Women for Methamphetamine|Treating South African Pregnant Women for Methamphetamine|Completed||N/A|60|Actual|RTI International||2|||f||||t||||||||||2018-05-31 22:24:58.702623|2018-05-31 22:24:58.702623
NCT01386125|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2013-10-31||2017-03-16|2011-06-29|2011-06-30|Estimate|2013-10-31|2013-12-19|Estimate||||2017-03-16|2017-04-13|Actual|June 2011||2011-06-30|March 2017|2017-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Nasal Polyps (Protocol No. P05604)|Completed||Phase 3|748|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:24:58.847622|2018-05-31 22:24:58.847622
NCT01386112|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-10-31|2011-06-29|2011-06-30|Estimate|||||||2012-10-31|2012-11-02|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, in Subjects With Eosinophilic Esophagitis (EoE)|Completed||Phase 1/Phase 2|24|Actual|Forest Laboratories||3|||f||||||||||||||2018-05-31 22:24:59.071169|2018-05-31 22:24:59.071169
NCT01386099|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-08-16|2011-06-29|2011-06-30|Estimate|||||||2012-08-16|2012-08-17|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)|A Phase IIa Study to Build an Understanding of the Pharmacokinetic-Pharmacodynamic Relationship of PSN821 in Type 2 Diabetes Patients (T2DM).|Completed||Phase 2|66|Actual|Prosidion Ltd.||2|||f||||||||||||||2018-05-31 22:24:59.151859|2018-05-31 22:24:59.151859
NCT01386086|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-03-15|2011-06-29|2011-06-30|Estimate|||||||2016-03-15|2016-03-17|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Aripiprazole and Resistant Postpartum Depression|Augmentation Therapy of Resistant Postpartum Depression With Aripiprazole|Completed||Phase 3|10|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 22:24:59.260635|2018-05-31 22:24:59.260635
NCT01386073|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-06-13|2011-06-29|2011-06-30|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity|Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity|Unknown status|Recruiting|Phase 4|40|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-05-31 22:24:59.346561|2018-05-31 22:24:59.346561
NCT01386060|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-04-11|2011-06-29|2011-06-30|Estimate|||||||2017-04-11|2017-04-12|Actual|June 2011||2011-06-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2015|Actual|2015-06-30||Interventional|||Mindfulness Meditation in Chronic Stress|Mindfulness Meditation in Chronic Stress: Measures of Adherence, Ability & Stress|Active, not recruiting||N/A|250|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 22:24:59.431691|2018-05-31 22:24:59.431691
NCT01386047|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-10-03|2011-06-29|2011-06-30|Estimate|||||||2012-10-03|2012-10-04|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|iCPR and EHR||Evidence Based Decision Making: Integrating Clinical Prediction Rules|Evidence Based Decision Making: Integrating Clinical Prediction Rules Into Electronic Health Records|Completed||N/A|168|Actual|Northwell Health||2|||f||||f||||||||||2018-05-31 22:24:59.539634|2018-05-31 22:24:59.539634
NCT01386034|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2018-04-05|2011-06-29|2011-06-30|Estimate|||||||2018-04-05|2018-04-06|Actual|July 2012||2012-07-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CITRUGRELE 2||Effects of Oral Citrulline on Protein Metabolism in Patients With Intestinal Failure (Citrugrêle 2)|Effects of Oral Citrulline on Protein Metabolism in Patients With Intestinal Failure : a Prospective, Randomized, Double-blind, Cross-over Study|Completed||Phase 3|11|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 22:24:59.681855|2018-05-31 22:24:59.681855
NCT01386021|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-12-20|2011-06-29|2011-06-30|Estimate|||||||2011-12-20|2011-12-21|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Observational|||Saphenous Vein Allografts for Coronary Bypass|Single Center Evaluation of CryoVein Saphenous Vein Allografts for Coronary Artery Bypass Grafting|Completed|||1|Actual|CryoLife, Inc.|||1||f||||f||||||||||2018-05-31 22:24:59.780085|2018-05-31 22:24:59.780085
NCT01386008|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22|2013-11-01||2014-02-04|2011-06-29|2011-06-30|Estimate|2014-02-04|2014-03-21|Estimate||||2014-02-04|2014-03-21|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens||Terminated||N/A|28|Actual|Coopervision, Inc.|Incomplete data sets / Data not analyzed / Not all subjects completed the study measures at each outcome measurement time frame before the study was terminated. 20 participants completed V1 and only 1 participant completed the V2 follow-up.|1||unexpected adverse events|f||||f||||||||||2018-05-31 22:24:59.908034|2018-05-31 22:24:59.908034
NCT01385995|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2012-02-21||2014-02-10|2011-06-29|2011-06-30|Estimate|2012-07-24|2012-07-26|Estimate||||2014-02-10|2014-03-12|Estimate|January 2004||2004-01-31|February 2014|2014-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effects of Treatment of Sleep Apnea on Metabolic Syndrome|A Controlled Trial of Continuous Positive Airway Pressure (CPAP) Therapy on Metabolic Control in Individuals With Impaired Glucose Tolerance and Sleep Apnea|Completed||Phase 2|50|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:25:00.230249|2018-05-31 22:25:00.230249
NCT01385969|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-11-05|2011-06-29|2011-06-30|Estimate|||||||2015-11-05|2015-11-06|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||LMA Cuff Pressure and LMA-induced Complications|Using the Natural Recoil of the Inflating Syringe as a Safety Valve to Limit LMA Cuff Pressure and Decrease LMA-Induced Complications|Completed|||360|Actual|Mayo Clinic|||3||f||||f||||||||||2018-05-31 22:25:01.079917|2018-05-31 22:25:01.079917
NCT01385956|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-11-24|2011-06-29|2011-06-30|Estimate|||||||2014-11-24|2014-11-25|Estimate|June 2011||2011-06-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||SOM 230 and Gemcitabine in Advanced Pancreatic Cancer|Phase I Study of Combination of SOM 230 Long Acting Release (LAR) + Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 1|20|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 22:25:01.239788|2018-05-31 22:25:01.239788
NCT01385943|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-09-27|2011-06-29|2011-06-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|EUNET||VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine|VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in Telemedicine|Unknown status|Active, not recruiting||500|Anticipated|Lucid, Inc.|||1||f||||f||||||Samples Without DNA|"~     Cutaneous tissue specimens in the form of histopathology slides and tissue blocks, clinical~     pictures, dermoscopic pictures and confocal microscopy images~   "|||2018-05-31 22:25:01.397633|2018-05-31 22:25:01.397633
NCT01385930|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-07-01|2011-06-29|2011-06-30|Estimate|||||||2011-07-01|2011-07-04|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|DAP_K||Dietary Advice on Prescription in Kungsbacka|A New Concept for Lifestyle Change, Dietary Advice on Prescription (DAP) in Combination With Motivational Interviewing (MI), Social Support and Mobile Services|Unknown status|Recruiting|N/A|200|Anticipated|Halmstad University||2|||f||||f||||||||||2018-05-31 22:25:01.546719|2018-05-31 22:25:01.546719
NCT01385917|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2016-04-11|2011-06-29|2011-06-30|Estimate|||||||2016-04-11|2016-04-12|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|pre U7-53||Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping|Study of Clinical and Radiological Changes in Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping|Recruiting|||45|Anticipated|Genethon|||||f||||f||||||None Retained|"~     Total blood count with differential leukocyte count Assay of immunoglobulins and the various~     sub-classes (IgG, IgM, IgA, IgE) Test for immunisation against all AAV serotypes Serum urea,~     creatinine, AST/ALT , GammaGT, bilirubin, CK, alkalin phosphatase~   "|||2018-05-31 22:25:01.842129|2018-05-31 22:25:01.842129
NCT01385904|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-06-29|2011-06-29|2011-06-30|Estimate|||||||2011-06-29|2011-06-30|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain|Plasma Concentrations of Ketamine and Norketamine in Patients Using Topical Application of 10% Ketamine for Neuropathic Pain.|Unknown status|Recruiting||15|Anticipated|Lawson Health Research Institute|||||f||||f||||||||||2018-05-31 22:25:01.975359|2018-05-31 22:25:01.975359
NCT01385891|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-07-06|2011-06-29|2011-06-30|Estimate|||||||2011-07-06|2011-07-08|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|CLOVE||Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children|Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients|Completed||Phase 2/Phase 3|40|Actual|Istituto Giannina Gaslini||1|||f||||t||||||||||2018-05-31 22:25:02.104693|2018-05-31 22:25:02.104693
NCT01385878|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-06-29|2011-06-29|2011-06-30|Estimate|||||||2011-06-29|2011-06-30|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial|Intraoperative Performance & Postoperative Outcomes Following Phacoemulsification With 1.8 & 2.2mm Incision: Randomized Clinical Trial|Unknown status|Recruiting|N/A|110|Anticipated|Iladevi Cataract and IOL Research Center||2|||f||||t||||||||||2018-05-31 22:25:02.355405|2018-05-31 22:25:02.355405
NCT01385865|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-10-27|2011-06-29|2011-06-30|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Mulberry Leaf Extract on Blood Glucose|Effect of Mulberry Leaf Extract on Blood Glucose in Subjects With Impaired Fasting Glucose|Completed||N/A|40|Anticipated|Ewha Womans University||2|||f||||t||||||||||2018-05-31 22:25:02.566469|2018-05-31 22:25:02.566469
NCT01385852|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-06-05|2011-06-29|2011-06-30|Estimate|||||||2012-06-05|2012-06-06|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||CME With Different Fluidic Parameters|Impact of Different Fluidic Parameters on Development of Cystoid Macular Edema Following Phacoemulsification|Completed||Phase 4|150|Actual|Iladevi Cataract and IOL Research Center||3|||f||||t||||||||||2018-05-31 22:25:02.802873|2018-05-31 22:25:02.802873
NCT01385839|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-12-20|2011-06-29|2011-06-30|Estimate|||||||2016-12-20|2016-12-22|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata|Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata|Terminated||N/A|4|Actual|Icahn School of Medicine at Mount Sinai||1||low enrollment|f||||t||||||||||2018-05-31 22:25:02.958015|2018-05-31 22:25:02.958015
NCT01385826|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-12-20|2011-06-29|2011-06-30|Estimate|||||||2017-12-20|2017-12-21|Actual|June 29, 2011|Actual|2011-06-29|December 2017|2017-12-31|August 27, 2015|Actual|2015-08-27|November 4, 2014|Actual|2014-11-04||Interventional|ADJUVITE||Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis|Evaluation of the Efficacy of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis: Randomized Double-blind Placebo-controlled Trial|Completed||Phase 2/Phase 3|34|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:25:03.148776|2018-05-31 22:25:03.148776
NCT01385813|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2011-07-15|2011-06-29|2011-06-30|Estimate|||||||2011-07-15|2011-07-18|Estimate|January 1999||1999-01-31|May 2011|2011-05-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Observational|||Inflammatory Markers in Preeclampsia||Completed|||129|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 22:25:03.332463|2018-05-31 22:25:03.332463
NCT01385800|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2013-08-14|2011-06-29|2011-06-30|Estimate|||||||2013-08-14|2013-08-15|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||ToleroMune Grass Exposure Unit Study|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit|Completed||Phase 2|280|Anticipated|Circassia Limited||4|||f||||f||||||||||2018-05-31 22:25:03.433713|2018-05-31 22:25:03.433713
NCT01385787|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-09-05|2011-06-29|2011-06-30|Estimate|||||||2017-09-05|2017-09-07|Actual|October 2011|Actual|2011-10-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia|The Role of Minimal Residual Disease Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia|Completed|||150|Actual|Center for International Blood and Marrow Transplant Research|||||f||||t||||||||||2018-05-31 22:25:03.619536|2018-05-31 22:25:03.619536
NCT01385774|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2018-02-12|2011-06-29|2011-06-30|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2010|Actual|2010-11-30|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SUPER||SUPER Study; SUPERvised Exercise or Angioplasty for Intermittent Claudication Due to an Iliac Artery Obstruction.|SUPERvised Exercise Therapy (SET) or Immediate Percutaneous Transluminal Angioplasty (PTA) for Intermittent Claudication (IC) in Patients With an Iliac Artery Obstruction: A Randomized Controlled Trial. SUPER Study|Terminated||N/A|240|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||Study terminated after 240 patients because of slow accrual and lack of additional funding|f||||t||||||||||2018-05-31 22:25:03.811199|2018-05-31 22:25:03.811199
NCT01385761|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-03-09|2011-06-29|2011-06-30|Estimate|||||||2012-03-09|2012-03-13|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||LMA Unique TM & the Self Pressurized Air-Q TM Intubating Laryngeal Airway in Children|A Prospective, Randomized Non- Crossover Investigation of the LMA Unique TM and the Self Pressurized Air-Q TM Intubating Laryngeal Airway in Children|Completed|||60|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-05-31 22:25:04.09116|2018-05-31 22:25:04.09116
NCT01385748|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2016-10-27|2015-07-07|2017-10-23|2011-06-29|2011-06-30|Estimate|2017-07-10|2017-08-09|Actual|2015-07-07|2015-07-29|Estimate|2017-10-23|2017-11-28|Actual|April 2010||2010-04-30|October 2017|2017-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis|A Phase II, Multi-center, Randomised, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Lauriad® 50 μg and 100 μg Mucoadhesive Buccal Tablet (MBT) Applied Once Daily to Those of Placebo in the Prevention and Treatment of Chemoradiation Therapy Induced Oral Mucositis in Patients With Head and Neck Cancer|Completed||Phase 2|183|Actual|Onxeo||3|||f||||f||||||||||2018-05-31 22:25:04.357026|2018-05-31 22:25:04.357026
NCT01385735|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-29|2011-06-29|2011-06-30|Estimate|||||||2011-06-29|2011-06-30|Estimate|October 2011||2011-10-31|June 2011|2011-06-30|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Interventional|RasQ||Emotion, Mood and Executive Function in Parkinson`s Disease (PD)|Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson`s Disease|Unknown status|Not yet recruiting|Phase 4|70|Anticipated|St. Josef Hospital Bochum||2|||f||||t||||||||||2018-05-31 22:25:06.727212|2018-05-31 22:25:06.727212
NCT01385722|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2018-03-20|2011-06-29|2011-06-30|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2011||2011-08-31|March 2018|2018-03-31|June 2031|Anticipated|2031-06-30|June 2031|Anticipated|2031-06-30||Observational|||Molecular Analysis of Thoracic Malignancies|Molecular Analysis of Thoracic Malignancies|Enrolling by invitation|||1000|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     The potential tumor tissues to be collected include paraffin-embedded tissue, frozen tissues,~     or fresh tissue. These will be stored in conjunction with the Stanford Tissue Bank.~   "|||2018-05-31 22:25:06.92087|2018-05-31 22:25:06.92087
NCT01385709|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-02-17|2011-06-28|2011-06-30|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2008||2008-08-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Observational|||The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels|The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels|Completed|||29|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples Without DNA|"~     Whole blood will be drawn.~   "|||2018-05-31 22:25:06.993566|2018-05-31 22:25:06.993566
NCT01385696|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2013-01-14||2015-05-28|2011-06-29|2011-06-30|Estimate|2013-03-12|2013-04-22|Estimate||||2015-05-28|2015-06-24|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients|Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in COPD Diagnosed Patients|Completed||Phase 3|130|Actual|Almirall, S.A.||2|||f||||||||||||||2018-05-31 22:25:07.078343|2018-05-31 22:25:07.078343
NCT01385683|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-03-21|2011-06-29|2011-06-30|Estimate|||||||2012-03-21|2012-03-22|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|IMAGINE||Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin|Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin|Completed||Phase 1|10|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 22:25:07.294132|2018-05-31 22:25:07.294132
NCT01385670|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-29|2011-06-29|2011-06-30|Estimate|||||||2011-06-29|2011-06-30|Estimate|June 2011||2011-06-30|June 2011|2011-06-30||||June 2012|Anticipated|2012-06-30||Interventional|InterSEPT||InterSEPT: In‐Tunnel SeptRx European PFO Trial|InterSEPT: In‐Tunnel SeptRx European PFO Trial: A Prospective, Multi‐Center Study to Evaluate the Safety and Performance of the SeptRx IPO PFO Closure System|Unknown status|Recruiting|N/A|70|Anticipated|SeptRx, Inc.|||||f||||t||||||||||2018-05-31 22:25:07.389812|2018-05-31 22:25:07.389812
NCT01385657|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09||2013-09-27|2013-09-27|2011-06-28|2011-06-30|Estimate||||2013-09-27|2013-10-28|Estimate|2013-09-27|2013-10-28|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Tolerability of REGN668 (SAR231893) in Patients With Moderate to Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 1/Phase 2|37|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:25:07.563786|2018-05-31 22:25:07.563786
NCT01385644|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2015-10-20||2015-11-24|2011-06-29|2011-06-30|Estimate|2015-11-24|2015-12-29|Estimate||||2015-11-24|2015-12-29|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MSC in IPF|All participants meet all inclusion criteria and none of the exclusion criteria|A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis|A Phase I Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis|Completed||Phase 1|8|Actual|The Prince Charles Hospital||2|||f||||t||||||||||2018-05-31 22:25:07.721441|2018-05-31 22:25:07.721441
NCT01385098|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2016-10-25||2018-01-18|2011-06-28|2011-06-29|Estimate|2018-01-18|2018-01-23|Actual||||2018-01-18|2018-01-23|Actual|July 2011||2011-07-31|January 2018|2018-01-31|September 2015|Actual|2015-09-30|May 2013|Actual|2013-05-31||Interventional||Number of completers|Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients|Preoperative Vitamin D Status and Efficacy of Therapeutic Vitamin D Supplementation Postoperatively in Bariatric Surgery Patients|Completed||N/A|37|Actual|The Methodist Hospital System||1|||f||||f|f|f||||||No||2018-05-31 22:25:25.276122|2018-05-31 22:25:25.276122
NCT01385631|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2014-09-01|2011-06-29|2011-06-30|Estimate|||||||2014-09-01|2014-09-03|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|OCTIVUS||Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.|The Effect Of Ezetimibe In Addition To Optimal Cholesterol-Lowering Statin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction - Assessed By Optical Coherence Tomography And Intravascular Ultrasound.|Completed||Phase 4|87|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 22:25:08.116443|2018-05-31 22:25:08.116443
NCT01385618|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2015-03-24|2011-06-29|2011-06-30|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Gene-polymorphisms Relating to Human Subfertility|Analysis of Gene-polymorphisms Relating to Human Subfertility: Estradiol-receptor-polymorphism and Progesterone-receptor-polymorphism|Completed|||150|Actual|Infertility Treatment Center Dortmund|||3||f||||f||||||Samples With DNA|"~     buccal swabs~   "|||2018-05-31 22:25:08.253002|2018-05-31 22:25:08.253002
NCT01385605|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2018-03-19|2011-06-29|2011-06-30|Estimate|||||||2018-03-19|2018-03-20|Actual|August 2015||2015-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|February 28, 2018|Actual|2018-02-28||Observational|||Analysis of Toxins in Follicle Fluid|Analysis of Toxins in Follicle Fluid From Women With Unfulfilled Pregnancy|Recruiting|||250|Anticipated|Infertility Treatment Center Dortmund|||1||f||||f||||||Samples Without DNA|"~     follicular fluid~   "|No||2018-05-31 22:25:08.365058|2018-05-31 22:25:08.365058
NCT01385592|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28||2016-03-22|2016-03-22|2011-06-29|2011-06-30|Estimate||||2016-03-22|2016-04-25|Estimate|2016-03-22|2016-04-25|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|12-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease|Completed||Phase 2|78|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:25:08.477232|2018-05-31 22:25:08.477232
NCT01385579|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2013-11-18||2013-11-18|2011-06-29|2011-06-30|Estimate|2013-11-18|2014-01-06|Estimate||||2013-11-18|2014-01-06|Estimate|January 2010||2010-01-31|November 2013|2013-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population|A Randomized Controlled Trial of a Direct-to-Patient Outreach Program to Improve Rates of Colorectal Cancer Screening in a Low Income and Racially Diverse Population|Completed||N/A|202|Actual|Northwestern University|Single site study|2|||f||||f||||||||||2018-05-31 22:25:08.652865|2018-05-31 22:25:08.652865
NCT01385566|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2012-12-11||2016-05-19|2011-06-28|2011-06-30|Estimate|2013-02-19|2013-02-21|Estimate||||2016-05-19|2016-06-23|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)|A Partially Blinded Randomized Clinical Trial to Study the Immunogenicity and Safety of Intradermal Administration of ZOSTAVAX™ (V211)|Completed||Phase 1|223|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 22:25:10.259188|2018-05-31 22:25:10.259188
NCT01385553|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2014-02-18|2011-06-28|2011-06-30|Estimate|||||||2014-02-18|2014-02-19|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Fathers for Change for Men With Co-occurring Domestic Violence and Substance Abuse|Randomized Trial of Fathers for Change: An Intervention for Fathers With Co-Occuring Domestic Violence and Substance Abuse|Completed||Phase 1/Phase 2|20|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:25:11.308059|2018-05-31 22:25:11.308059
NCT01385540|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-02-29|2011-06-29|2011-06-30|Estimate|||||||2012-02-29|2012-03-02|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Exploration of Cortical Neural Network in Patients With Bothersome Tinnitus|Exploration of Cortical Neural Network in Patients With Bothersome Tinnitus|Terminated|||7|Actual|Washington University School of Medicine|||1|Study tasks to difficult for subjects to complete.|f||||f||||||||||2018-05-31 22:25:11.43176|2018-05-31 22:25:11.43176
NCT01385527|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-10-30|2011-06-28|2011-06-30|Estimate|||||||2017-10-30|2017-11-01|Actual|June 2011|Actual|2011-06-30|October 2017|2017-10-31|October 27, 2014|Actual|2014-10-27|October 27, 2014|Actual|2014-10-27||Interventional|||Pediatric Atopic Dermatitis (AD) Internet Survey|Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2||study was never initiated, No participants enrolled|f||||f||||||||No||2018-05-31 22:25:11.534398|2018-05-31 22:25:11.534398
NCT01385514|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2012-03-22|2011-06-29|2011-06-30|Estimate|||||||2012-03-22|2012-03-23|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|||||Observational|||Staphylococcus Aureus Skin and Soft Tissue Infections|Evaluating Strategies to Prevent Staphylococcus Aureus Skin and Soft Tissue Infections in Soldiers During Infantry Training|Unknown status|Recruiting||1050|Anticipated|Medical Corps, Israel Defense Force|||3||f||||f||||||Samples Without DNA|"~     nasal swabs to detect Staphylococcus aureus skin infection to detect Staphylococcus aureus~   "|||2018-05-31 22:25:11.786123|2018-05-31 22:25:11.786123
NCT01385501|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2015-04-02|2011-06-28|2011-06-30|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|April 2013|Actual|2013-04-30||Interventional|||Educational Intervention to Improve Vaccine Acceptance||Completed||N/A|155|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 22:25:11.974119|2018-05-31 22:25:11.974119
NCT01385488|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2017-04-07|2011-06-28|2011-06-30|Estimate|||||||2017-04-07|2017-04-10|Actual|May 2011||2011-05-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioelectrical Impedance for Self-monitoring of Lymphedema|Bioelectrical Impedance for Self-monitoring of Breast Cancer Related Lymphedema|Completed||N/A|72|Actual|Vanderbilt University||2|||f||||f||||||||Undecided||2018-05-31 22:25:12.099531|2018-05-31 22:25:12.099531
NCT01385475|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-28|2011-06-28|2011-06-30|Estimate|||||||2011-06-28|2011-06-30|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Resistance Training to Improve Physical Function in the Elderly|Efficacy of Resistance Training Guidelines to Improve Function in Older Adults|Completed||N/A|25|Actual|University of Wisconsin, Milwaukee||1|||f||||f||||||||||2018-05-31 22:25:12.195676|2018-05-31 22:25:12.195676
NCT01385449|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-10-06|2011-06-29|2011-06-30|Estimate|||||||2015-10-06|2015-10-08|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Prospective Evaluation of Interscalene Nerve Catheters vs. Single Injection Blocks|Continuous Interscalene Block (CISB) Versus Single Injection Interscalene Block in Those Undergoing Shoulder Surgery in the Ambulatory Setting|Unknown status|Active, not recruiting|N/A|73|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 22:25:12.294314|2018-05-31 22:25:12.294314
NCT01385436|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-29|2011-06-29|2011-06-30|Estimate|||||||2011-06-29|2011-06-30|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|HPV-cancer||Distribution of Human Papillomavirus (HPV) Genotypes in Patients With Cervical Cancer From Croatia|Pre-vaccination Distribution of Human Papillomavirus (HPV) Genotypes in Patients With High Grade Cervical Squamous Intraepithelial Lesion (HSIL) and Cervical Cancer From Croatia|Unknown status|Recruiting||400|Anticipated|University Hospital for Infectious Diseases, Croatia|||1||f||||f||||||Samples With DNA|"~     DNA isolates from biopsy specimens of cervical lesions.~   "|||2018-05-31 22:25:12.403829|2018-05-31 22:25:12.403829
NCT01385423|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-11-29|2011-06-29|2011-06-30|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2011||2011-09-30|November 2017|2017-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)|Haploidentical Donor Natural Killer (NK) Cell Infusion With Intravenous Recombinant Human IL-15 (rhIL-15) in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)|Completed||Phase 1|26|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 22:25:12.551327|2018-05-31 22:25:12.551327
NCT01385410|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-10-24|2011-06-29|2011-06-30|Estimate|||||||2013-10-24|2013-10-25|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Providing Peer Mother Support Through Cell Phone and Group Meetings to Increase Exclusive Breastfeeding in Kenya|Effectiveness of a Baby-friendly Hospital Based Mothers' Support Group, and a Cell-phone Based Peer Support Program in Supporting Exclusive Breastfeeding in an Urban Kenyan Community.|Completed||N/A|823|Actual|University of Toronto||3|||f||||f||||||||||2018-05-31 22:25:12.658096|2018-05-31 22:25:12.658096
NCT01385397|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-10-13|2011-06-29|2011-06-30|Estimate|||||||2011-10-13|2011-10-17|Estimate|September 2006||2006-09-30|October 2011|2011-10-31||||November 2007|Actual|2007-11-30||Interventional|||Integrated Obesity Care Management System|Integrated Obesity Care Management System|Completed||N/A|39|Actual|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 22:25:12.747761|2018-05-31 22:25:12.747761
NCT01385384|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-03-18|2011-06-28|2011-06-30|Estimate|||||||2013-03-18|2013-03-19|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Diaphragmatic Pacemaker in Tetraplegic Patients With Spinal Cord Injuries|Evaluation of the NeuRx RA/4 Diaphragmatic Pacemaker in Tetraplegic Patients With Spinal Cord Injuries in Ventilator Support|Completed||N/A|5|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 22:25:12.81618|2018-05-31 22:25:12.81618
NCT01385371|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2013-07-01||2017-01-18|2011-06-28|2011-06-30|Estimate|2013-07-01|2013-09-10|Estimate||||2017-01-18|2017-03-03|Actual|June 2011||2011-06-30|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Subjects Between 5 and 65 Years of Age, With a History of Grass Pollen-Induced Rhinoconjunctivitis, With or Without Asthma (Protocol No. P08067)|Completed||Phase 3|1501|Actual|ALK-Abelló A/S||2|||f||||t||||||||||2018-05-31 22:25:12.920654|2018-05-31 22:25:12.920654
NCT01385358|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-29|2011-06-29|2011-06-30|Estimate|||||||2011-06-29|2011-06-30|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|CASA-AF||Catheter Versus Thoracoscopic Surgical Ablation Strategy in Persistent Atrial Fibrillation|A Study to Assess Catheter Ablation Versus Thoracoscopically Assisted Surgical Ablation in Persistent Atrial Fibrillation|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:25:13.596208|2018-05-31 22:25:13.596208
NCT01385345|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2015-06-09|2011-06-28|2011-06-30|Estimate|||||||2015-06-09|2015-06-10|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|VITALITY||Vitamin D Replacement in Insulin Resistant South Asians|Can Vitamin D Replacement Reduce Insulin Resistance In South Asians With Vitamin D Deficiency?|Terminated||N/A|3|Actual|University of Leicester||2||"Recommended by DMEC. Poor recruitment, changes in current clinical management of Vit D~   deficiency. Research question no longer relevant"|f||||t||||||||||2018-05-31 22:25:13.687784|2018-05-31 22:25:13.687784
NCT01385332|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2017-09-19|2011-06-29|2011-06-30|Estimate|||||||2017-09-19|2017-09-20|Actual|March 2010||2010-03-31|September 2017|2017-09-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors|A Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg Donors|Completed||N/A|10|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 22:25:13.765046|2018-05-31 22:25:13.765046
NCT01385319|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-10-06|2011-06-28|2011-06-30|Estimate|||||||2012-10-06|2012-10-10|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|December 2017|Anticipated|2017-12-31|September 2012|Actual|2012-09-30||Interventional|ZEUS||Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study|Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study|Unknown status|Active, not recruiting|Phase 3|1606|Actual|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-05-31 22:25:13.854147|2018-05-31 22:25:13.854147
NCT01385306|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2016-02-17|2011-06-29|2011-06-30|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|BC-SA-01||Noninvasive Neurostimulation of the Vagus Nerve for the Relief of Acute Bronchoconstriction Due to Asthma|Noninvasive Neurostimulation of the Vagus Nerve With the AlphaCore System for the Relief of Acute Bronchoconstriction Due to Asthma|Terminated||Phase 1/Phase 2|6|Actual|ElectroCore LLC||1||Slow enrollment|f||||t||||||||||2018-05-31 22:25:13.956581|2018-05-31 22:25:13.956581
NCT01385293|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2017-02-22||2017-04-14|2011-06-29|2011-06-30|Estimate|2017-02-22|2017-04-07|Actual||||2017-04-14|2017-05-19|Actual|August 2011||2011-08-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||BKM120 in Metastatic Castration-resistant Prostate Cancer|Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer|Terminated||Phase 2|30|Actual|Duke University||1||The trial was stopped at the first stage due to futility|f||||f||||||||||2018-05-31 22:25:14.080108|2018-05-31 22:25:14.080108
NCT01385280|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-12-02|2011-06-29|2011-06-30|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer|A Pilot Study Of Estradiol Followed By Exemestane For Post-Menopausal Hormone Receptor Positive Metastatic Breast Cancer After Prior Failed Endocrine Therapy: Reversing Endocrine Resistance|Completed||N/A|13|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 22:25:14.656737|2018-05-31 22:25:14.656737
NCT01385267|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-09-07|2011-06-29|2011-06-30|Estimate|||||||2016-09-07|2016-09-09|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Fetal Lung Maturation in Twin Gestations|Fetal Lung Maturation in Twin Gestations Based on Birth Order and Weight Discordance|Completed|||50|Actual|TriHealth Inc.|||1||f||||t||||||Samples Without DNA|"~     A sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each~     amniotic sac will be aspirated by the obstetrician and sent to the laboratory for~     determination of fetal lung maturity index and lamellar body count. Fetal lung maturity index~     and lamellar body count will be correlated to see if there is an association between Twin A~     and Twin B.~      Fetal Lung Maturity index and lamellar body count will be calculated and compared based on~     fetal weight, sex, zigosity, and birth order. Demographic information, maternal obstetrical~     and medical history, newborn/fetal data, indications for cesarean section and twin A and B~     outcomes will be obtained through OB Traceview or patient chart.~   "|No||2018-05-31 22:25:14.782245|2018-05-31 22:25:14.782245
NCT01385254|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2013-12-10|2011-06-28|2011-06-30|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Observational|||Mother Sibling Interactions Following Very Low Birth Weight (VLBW) Infant Homecoming|Mother Sibling Interactions Following Very Low Birth Weight (VLBW) Infant Homecoming|Completed|||300|Actual|Duke University|||2||f||||t||||||||||2018-05-31 22:25:14.870332|2018-05-31 22:25:14.870332
NCT01385241|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2014-10-20|2011-06-29|2011-06-30|Estimate|||||||2014-10-20|2014-10-22|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women|Feasibility of a Stigma Reduction Intervention for HIV-infected Women|Completed||N/A|99|Actual|Duke University||2|||f||||t||||||||||2018-05-31 22:25:14.970179|2018-05-31 22:25:14.970179
NCT01385228|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|||2017-04-03|2011-06-29|2011-06-30|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2011||2011-06-30|April 2017|2017-04-30|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional|||Pazopanib, Docetaxel, Prednisone Prostate|Phase I Study of Docetaxel, Prednisone and Pazopanib in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and Poor-Risk Factors|Completed||Phase 1|36|Actual|Duke University||2|||f||||f||||||||||2018-05-31 22:25:15.058063|2018-05-31 22:25:15.058063
NCT01385215|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-12-05|2011-06-29|2011-06-30|Estimate|||||||2012-12-05|2012-12-06|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Strategies for Enhancing Mucosal Immunity to Influenza Vaccine|Strategies for Enhancing Mucosal Immunity to Influenza Vaccine|Completed||Early Phase 1|60|Actual|Duke University||4|||f||||f||||||||||2018-05-31 22:25:15.17457|2018-05-31 22:25:15.17457
NCT01385202|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2014-12-17||2015-01-20|2011-06-29|2011-06-30|Estimate|2015-01-20|2015-01-26|Estimate||||2015-01-20|2015-01-26|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional||All enrolled subjects, including all who signed inform consent form.|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation|Completed||Phase 3|172|Actual|Biosense Webster, Inc.||1|||f||||||||||||||2018-05-31 22:25:15.288846|2018-05-31 22:25:15.288846
NCT01385189|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2017-01-13||2017-05-30|2011-06-28|2011-06-30|Estimate|2017-03-10|2017-04-20|Actual||||2017-05-30|2017-06-22|Actual|May 2012||2012-05-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant|Phase I Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With Different Doses of the Novel Immunostimulant GLA-AF in Healthy Adults|Completed||Phase 1|40|Actual|Baylor College of Medicine||5|||f||||t||||||||||2018-05-31 22:25:16.081084|2018-05-31 22:25:16.081084
NCT01385176|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-11-23|2011-06-28|2011-06-30|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|January 2018|Anticipated|2018-01-31|May 2017|Anticipated|2017-05-31||Interventional|NECTAR-HF||Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)|Neural Cardiac Therapy for Heart Failure Study|Unknown status|Active, not recruiting|Phase 2|250|Anticipated|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 22:25:17.545096|2018-05-31 22:25:17.545096
NCT01385163|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-07-15|2011-06-28|2011-06-29|Estimate|||||||2011-07-15|2011-07-18|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|July 2013|Anticipated|2013-07-31|August 2012|Anticipated|2012-08-31||Interventional|||Intervention Effectiveness in Improving Psychosocial and Economic Well-being of Sexual Violence Survivors in DRC|Study of Intervention Effectiveness in Improving Psychosocial and Economic Well-being of Sexual Violence Survivors in DRC|Unknown status|Recruiting|N/A|1000|Anticipated|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||||2018-05-31 22:25:17.962319|2018-05-31 22:25:17.962319
NCT01385150|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-05-18|2011-06-28|2011-06-29|Estimate|||||||2017-05-18|2017-05-19|Actual|January 3, 2012|Actual|2012-01-03|May 2017|2017-05-31|February 3, 2012|Actual|2012-02-03|February 3, 2012|Actual|2012-02-03||Observational|||Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia|Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML)|Completed|||220|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 22:25:18.895619|2018-05-31 22:25:18.895619
NCT01385137|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2016-11-15||2017-02-23|2011-06-28|2011-06-29|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|February 2012||2012-02-29|February 2017|2017-02-28|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy|S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III|Completed||Phase 3|262|Actual|Southwest Oncology Group||2|||f||||t||||||||No||2018-05-31 22:25:19.734626|2018-05-31 22:25:19.734626
NCT01385124|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-06-18|2011-06-28|2011-06-29|Estimate|||||||2015-06-18|2015-06-19|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation|Safety and Efficacy of Oral Cannabidiol for GVHD Prophylaxis in Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 22:25:24.790705|2018-05-31 22:25:24.790705
NCT01385111|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-10-17|2011-06-28|2011-06-29|Estimate|||||||2012-10-17|2012-10-18|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Combined Application of EBUS and EUS in Lung Cancer|Combined Application of EBUS-TBNA and EUS-B-FNA in Mediastinal Staging of Lung Cancer; EBUS-TBNA Centered Procedure vs. EUS-B-FNA Centered Procedure, a Randomized Study.|Completed||N/A|162|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 22:25:25.068507|2018-05-31 22:25:25.068507
NCT01385072|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-11-14|2011-06-28|2011-06-29|Estimate|||||||2011-11-14|2011-11-16|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|April 2015|Anticipated|2015-04-30|August 2014|Anticipated|2014-08-31||Interventional|||Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies|Pilot Study of Hematopoietic Stem Cell Transplantation From Two Matched Sibling Donors in Treating Patients With Poor Prognosis Acute Leukemia and Advanced Lymphoproliferative Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 22:25:25.955459|2018-05-31 22:25:25.955459
NCT01385059|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2017-12-06|2011-06-28|2011-06-29|Estimate|||||||2017-12-06|2017-12-08|Actual|October 28, 2011||2011-10-28|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer|A Randomized, Phase II Study Assessing Axitinib as Pre-Surgical Therapy in Patients With High Risk Prostate Cancer|Active, not recruiting||Phase 2|60|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 22:25:26.230014|2018-05-31 22:25:26.230014
NCT01385046|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|FIT||Project Fit:a School- and Community-based Obesity Intervention|Project Fit:a School- and Community-based Intervention to Address Physical Activity and Healthy Eating Among Low-income Elementary School Children|Completed||N/A|403|Actual|Michigan State University||1|||f||||t||||||||||2018-05-31 22:25:26.330529|2018-05-31 22:25:26.330529
NCT01385033|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2014-01-06||2017-06-01|2011-06-28|2011-06-29|Estimate|2014-01-06|2014-02-20|Estimate||||2017-06-01|2017-07-02|Actual|August 19, 2011|Actual|2011-08-19|June 2017|2017-06-30|May 15, 2012|Actual|2012-05-15|May 15, 2012|Actual|2012-05-15||Interventional|||[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)|A Clinical Trial to Characterize the Performance of [18F]MK-3328 in Subjects With Alzheimer's Disease or Mild Cognitive Impairment, and Healthy Young, and Healthy Elderly Subjects|Terminated||Phase 1|20|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 22:25:26.408588|2018-05-31 22:25:26.408588
NCT01385020|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-10-13|2011-06-28|2011-06-29|Estimate|||||||2011-10-13|2011-10-17|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects|Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects|Completed||Phase 4|12|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:25:26.723864|2018-05-31 22:25:26.723864
NCT01385007|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|PAVED-T||Preventing Aggression In Veterans With Dementia (PAVED) - Telephone Sub-Study With Rural Veterans|Preventing Aggression In Veterans With Dementia (PAVED) - Telephone Sub-Study With Rural Veterans|Unknown status|Not yet recruiting|N/A|40|Anticipated|Michael Debakey Veterans Affairs Medical Center|||||f||||f||||||||||2018-05-31 22:25:26.83557|2018-05-31 22:25:26.83557
NCT01384994|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2012-07-05|2011-06-28|2011-06-29|Estimate|||||||2012-07-05|2012-07-09|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients||Unknown status|Recruiting|Phase 2|111|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 22:25:26.8992|2018-05-31 22:25:26.8992
NCT01384981|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-09-03|2011-06-28|2011-06-29|Estimate|||||||2015-09-03|2015-09-04|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of Non-invasive Ventilation on Rehabilitation Outcome in COPD-patients|Effects of Non-invasive Ventilation on Exercise Capacity and Quality of Life in COPD-patients GOLD III/IV|Terminated||N/A|31|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2||major problems in recruiting patients due to very strict inclusion criteria|f||||f||||||||||2018-05-31 22:25:27.108195|2018-05-31 22:25:27.108195
NCT01384968|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-10-16|2011-06-28|2011-06-29|Estimate|||||||2012-10-16|2012-10-17|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||Acute Nitrate Supplementation in Cyclists|Acute Dietary Nitrate Supplementation to Improve Performance in Endurance Trained Athletes|Completed||N/A|20|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:25:27.232157|2018-05-31 22:25:27.232157
NCT01384955|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-03-31|2011-06-28|2011-06-29|Estimate|||||||2015-03-31|2015-04-02|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||HRQoL and Function of Adults Treated in Adolescence for Scoliosis With Physical Exercises|THE ASSESSMENT OF QUALITY OF LIFE AND FUNCTION OF ADULTS TREATED IN ADOLESCENCE FOR IDIOPATHIC SCOLIOSIS WITH PHYSICAL EXERCISES|Completed|||143|Actual|Józef Piłsudski University of Physical Education|||2||f||||f||||||||||2018-05-31 22:25:27.387876|2018-05-31 22:25:27.387876
NCT01384942|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-11-07|2011-06-28|2011-06-29|Estimate|||||||2013-11-07|2013-11-08|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|October 2013|Actual|2013-10-31|March 2012|Actual|2012-03-31||Interventional|||Meaning-based Group Counselling for Bereavement|The Development and Pilot Testing of Meaning-based Group Counselling Intervention for Bereavement|Completed||Phase 2|26|Actual|Jewish General Hospital||2|||f||||||||||||||2018-05-31 22:25:27.446505|2018-05-31 22:25:27.446505
NCT01384929|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|INDICAPS||Study of Intensive Care Units in India|Indian Intensive Care Case Mix and Practice Patterns Study|Completed|||4236|Actual|Indian Society of Critical Care Medicine|||1||f||||f||||||||||2018-05-31 22:25:27.517676|2018-05-31 22:25:27.517676
NCT01384916|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-04-12|2011-06-28|2011-06-29|Estimate|||||||2016-04-12|2016-04-13|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|HAD||Holistic Approaches to Depression|Holistic Approaches to Depression|Completed||Phase 2|121|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 22:25:27.595512|2018-05-31 22:25:27.595512
NCT01384903|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-03-22|2011-06-28|2011-06-29|Estimate|||||||2017-03-22|2017-03-24|Actual|June 2011||2011-06-30|March 2017|2017-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|3357-004||An Open-label Study of KW-3357|An Open-label Study of KW-3357 Compared to Plasma-derived Antithrombin for Disseminated Intravascular Coagulation (DIC) Associated With Infection|Completed||Phase 3|221|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||||||||||||2018-05-31 22:25:27.726275|2018-05-31 22:25:27.726275
NCT01384708|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-01-07|2011-06-28|2011-06-29|Estimate|||||||2016-01-07|2016-01-11|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer|Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer|Completed||Early Phase 1|70|Actual|Anandasabapathy, Sharmila, M.D.||1|||f||||t||||||||||2018-05-31 22:25:30.057865|2018-05-31 22:25:30.057865
NCT01384890|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-02-05|2011-06-28|2011-06-29|Estimate|||||||2013-02-05|2013-02-06|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Feasibility of VMAT and CBCT for Head and Neck Carcinomas|Feasibility of Volumetric Modulated Arc Therapy and Cone-Beam Computed Tomography for Head and Neck Carinomas: Analysis of Clinical Throughput and Patient Reported Outcomes.|Completed||Phase 1|20|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 22:25:27.825403|2018-05-31 22:25:27.825403
NCT01384877|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-11-30|2011-06-28|2011-06-29|Estimate|||||||2017-11-30|2017-12-04|Actual|December 2011||2011-12-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Subcutaneous Lidocaine For Cancer-Related Pain|A Randomized Double Blind Placebo Controlled Crossover Trial of the Use of Subcutaneous Lidocaine Infusion (SCLI) for Chronic Cancer-related Pain|Suspended||Phase 2/Phase 3|50|Anticipated|British Columbia Cancer Agency||2||study has been suspended pending resolution of staffing issues and external review|f||||t||||||||||2018-05-31 22:25:28.015526|2018-05-31 22:25:28.015526
NCT01384864|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-01-07|2011-06-28|2011-06-29|Estimate|||||||2016-01-07|2016-01-11|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia|Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia|Completed||Early Phase 1|30|Actual|Anandasabapathy, Sharmila, M.D.||1|||f||||t||||||||||2018-05-31 22:25:28.210358|2018-05-31 22:25:28.210358
NCT01384851|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-30|2011-06-28|2011-06-29|Estimate|||||||2011-06-30|2011-07-01|Estimate|July 2011||2011-07-31|February 2011|2011-02-28|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Efficacy of the Chronic Application of Tear Formulations|Therapeutic Efficacy of the Chronic Application of Tear Formulations for Dry Eye and Normal Subjects Under Conditions of Environmental Stress|Unknown status|Not yet recruiting|N/A|38|Anticipated|Glasgow Caledonian University||3|||f||||t||||||||||2018-05-31 22:25:28.370459|2018-05-31 22:25:28.370459
NCT01384838|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-06-03|2011-06-28|2011-06-29|Estimate|||||||2015-06-03|2015-06-04|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Exercise Training in Postmenopausal Patients With Breast Cancer|Randomized Trial of Exercise Training in Postmenopausal Patients With Hormone-receptor Positive Breast Cancer Undergoing Treatment With Aromatase Inhibitors|Completed||N/A|80|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||f||||||||||2018-05-31 22:25:28.454066|2018-05-31 22:25:28.454066
NCT01384825|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2018-01-12|2011-06-28|2011-06-29|Estimate|||||||2018-01-12|2018-01-16|Actual|December 2010|Actual|2010-12-31|January 2018|2018-01-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|COSMO||Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases|Observational Study of the Prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases|Completed|||200|Actual|Fondazione Italiana Sclerosi Multipla|||3||f||||t||||||||||2018-05-31 22:25:28.579725|2018-05-31 22:25:28.579725
NCT01384812|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-11-08|2011-06-28|2011-06-29|Estimate|||||||2011-11-08|2011-11-09|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Prostaglandin E2 in Migraine Suffers Without Aura.|Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of Prostaglandin E2 in Migraine Suffers Without Aura.|Completed||N/A|12|Anticipated|Danish Headache Center||2|||f||||t||||||||||2018-05-31 22:25:28.753507|2018-05-31 22:25:28.753507
NCT01384799|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2018-02-15|2011-06-28|2011-06-29|Estimate|||||||2018-02-15|2018-02-21|Estimate|November 2011||2011-11-30|February 2018|2018-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer|A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer|Completed||Phase 1|12|Actual|Curis, Inc.|||||f||||f||||||||||2018-05-31 22:25:28.860584|2018-05-31 22:25:28.860584
NCT01384786|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|July 2005|Actual|2005-07-31|||||Observational|||The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter|The Incidence of Thyroid Cancer in 4474 Patients Treated for Hyperthyroidism or Goiter|Completed|||4474|Actual|Copenhagen University Hospital at Herlev|||||f||||t||||||||||2018-05-31 22:25:28.951246|2018-05-31 22:25:28.951246
NCT01384773|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-09-27|2011-06-28|2011-06-29|Estimate|||||||2017-09-27|2017-09-29|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Progressive Keratoconus or Ectasia Treatment Plan|Increasing CrossLinking of Corneal Collagen in Eyes With Progressive Keratoconus or Ectasia|No longer available|||||Columbia University|||||||||||||||||||2018-05-31 22:25:29.019326|2018-05-31 22:25:29.019326
NCT01384760|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2014-08-04||2015-02-03|2011-06-28|2011-06-29|Estimate|2015-02-03|2015-02-19|Estimate||||2015-02-03|2015-02-19|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|OSA||Lifestyle Modification Program to Treat Obstructive Sleep Apnea Patients|A Randomized Controlled Study to Examine the Effect of Lifestyle Modification Program in Obstructive Sleep Apnea Patients|Completed||N/A|185|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:25:29.133572|2018-05-31 22:25:29.133572
NCT01384747|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2017-02-23|2011-06-28|2011-06-29|Estimate|||||||2017-02-23|2017-02-24|Actual|July 2011||2011-07-31|February 2017|2017-02-28|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)|A Randomized, Double-blind Study of Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease|Active, not recruiting||Phase 4|186|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 22:25:29.571066|2018-05-31 22:25:29.571066
NCT01384734|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-05-10|2011-06-28|2011-06-29|Estimate|||||||2018-05-10|2018-05-11|Actual|July 26, 2011|Actual|2011-07-26|May 2018|2018-05-31|May 12, 2017|Actual|2017-05-12|February 18, 2013|Actual|2013-02-18||Interventional|||HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections|A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose|Completed||Phase 2|254|Actual|ViiV Healthcare||5|||f||||t||||||||||2018-05-31 22:25:29.67859|2018-05-31 22:25:29.67859
NCT01384721|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2017-01-23|2011-06-28|2011-06-29|Estimate|||||||2017-01-23|2017-01-24|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|PRORECAD||Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease|Computed Tomography Coronary Angiography Prognostic Registry for Coronary Artery Disease - CTCA-PRORECAD|Recruiting|||1000|Anticipated|Azienda Ospedaliero-Universitaria di Parma|||||f||||f||||||||||2018-05-31 22:25:29.909693|2018-05-31 22:25:29.909693
NCT01384695|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-01-08|2011-06-28|2011-06-29|Estimate|||||||2016-01-08|2016-01-12|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1|A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia - Project 1|Terminated||Early Phase 1|67|Actual|Anandasabapathy, Sharmila, M.D.||2||Low/no enrollment. No subjects were enrolled over the past year.|f||||f||||||||||2018-05-31 22:25:30.156375|2018-05-31 22:25:30.156375
NCT01384682|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-01-18|2011-06-28|2011-06-29|Estimate|||||||2016-01-18|2016-01-20|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MARCH||Maraviroc Switch Collaborative Study|Randomised, Openlabel Study Evaluating Efficacy and Safety of Maraviroc as a Switch for Either NRTI or PI/r in HIV-1 Infected Individuals With Stable, Well‐Controlled Plasma HIV‐RNA While Taking Their First N(t)RTI + PI/r Regimen of cART|Completed||Phase 4|399|Actual|Kirby Institute||3|||f||||t||||||||||2018-05-31 22:25:30.243673|2018-05-31 22:25:30.243673
NCT01384669|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-06-01|2011-06-28|2011-06-29|Estimate|||||||2013-06-01|2013-06-04|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis|Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis|Unknown status|Recruiting||80|Anticipated|Yonsei University|||2||f||||f||||||Samples With DNA|"~     mRNA extract from Thyroid tissue 2mmx2mmx2mm (nomal thyroid and papillary thyroid~     microcarcinoma >5mm)~   "|||2018-05-31 22:25:30.400305|2018-05-31 22:25:30.400305
NCT01384656|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-03-04|2011-06-27|2011-06-29|Estimate|||||||2013-03-04|2013-03-06|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome|Effect of Glucose-insulin-potassium Solution on Myocardial Protection During Off-pump Coronary Bypass Surgery in Patients With Acute Coronary Syndrome|Completed||Phase 4|66|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:25:30.521571|2018-05-31 22:25:30.521571
NCT01384643|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-04-10|2011-06-27|2011-06-29|Estimate|||||||2013-04-10|2013-04-12|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery|Effect of Propofol on Renal Injury in Patients Undergoing Valvular Heart Surgery: A Prospective, Randomized Controlled Trial|Completed||Phase 4|112|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:25:30.587906|2018-05-31 22:25:30.587906
NCT01384630|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08||2014-06-05|2014-06-05|2011-06-28|2011-06-29|Estimate||||2014-06-05|2014-06-18|Estimate|2014-06-05|2014-06-18|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis|A Phase II Open Label Study of the Safety, Pharmacokinetics, and Efficacy of a True Human Anti-inflammatory Therapeutic Antibody (RA-18C3) in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|8|Actual|XBiotech, Inc.||1|||f||||f||||||||||2018-05-31 22:25:30.673261|2018-05-31 22:25:30.673261
NCT01384617|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-07-20|2011-06-27|2011-06-29|Estimate|||||||2016-07-20|2016-07-21|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2014|Actual|2014-06-30||Interventional|||Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy|Roux-en-Y Anastomosis of the Pancreatic Stump Following Distal Pancreatectomy|Completed||N/A|136|Anticipated|Wakayama Medical University||2|||f||||t||||||||||2018-05-31 22:25:30.803258|2018-05-31 22:25:30.803258
NCT01384604|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-06-21|2011-06-27|2011-06-29|Estimate|||||||2012-06-21|2012-06-22|Estimate|December 2007||2007-12-31|June 2012|2012-06-30||||August 2012|Anticipated|2012-08-31||Observational|BSNIP||Neurophysiological Studies in Schizophrenia and Psychiatric Disorders|Neurophysiological and Genetic Studies in Schizophrenia and Other Psychiatric Disorders|Unknown status|Recruiting||1189|Anticipated|University of Texas Southwestern Medical Center|||||f||||t||||||Samples With DNA|"~     Blood, no more than 30cc; urine, small collection cup (about 30cc) to administer drug urine~     screen and pregnancy tests for females; buccal swabs (at least 5 swabs from volunteers that~     cannot donate blood); and, optional: 4mm punch of skin for dermal biopsy.~   "|||2018-05-31 22:25:30.907514|2018-05-31 22:25:30.907514
NCT01384591|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2018-02-23||2018-04-05|2011-06-27|2011-06-29|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|July 2011||2011-07-31|April 2018|2018-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly|Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly|Completed||Phase 1/Phase 2|6|Actual|The University of Texas Medical Branch, Galveston||3|||f||||t||||||||||2018-05-31 22:25:31.133418|2018-05-31 22:25:31.133418
NCT01384578|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2015-10-08|2011-06-28|2011-06-29|Estimate|||||||2015-10-08|2015-10-12|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis|A Randomized Controlled Project to Study the Efficacy of Combined Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis|Withdrawn||Phase 3|0|Actual|Institute of Liver and Biliary Sciences, India||2||Lack of funds|f||||f||||||||||2018-05-31 22:25:32.896576|2018-05-31 22:25:32.896576
NCT01384565|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2013-07-30|2011-06-28|2011-06-29|Estimate|||||||2013-07-30|2013-07-31|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease|A Prospective Randomized Double Blind Trial to Study the Efficacy of G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease|Completed||Phase 3|55|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 22:25:33.00086|2018-05-31 22:25:33.00086
NCT01384552|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-25|||2018-04-03|2011-06-27|2011-06-29|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2011||2011-06-30|April 2018|2018-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Do Weight Status and the Level of Dietary Restraint Moderate the Relationship Between Package Unit Size and Food Intake?|Do Weight Status and the Level of Dietary Restraint Moderate the Relationship Between Package Unit Size and Food Intake?|Completed||N/A|64|Actual|The University of Tennessee, Knoxville||8|||f||||f||||||||||2018-05-31 22:25:33.18149|2018-05-31 22:25:33.18149
NCT01384539|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2017-07-14||2017-07-14|2011-06-27|2011-06-29|Estimate|2017-07-14|2017-08-17|Actual||||2017-07-14|2017-08-17|Actual|July 2011|Actual|2011-07-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Vitamin D and Arterial Function in Patients With Chronic Kidney Disease|Vitamin D and Arterial Function in Patients With Chronic Kidney Disease|Completed||N/A|128|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 22:25:33.314477|2018-05-31 22:25:33.314477
NCT01384526|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2015-03-06|2011-06-27|2011-06-29|Estimate|||||||2015-03-06|2015-03-09|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Investigating the Impact of Tamoxifen Therapy on Ovarian Aging|Investigating the Impact of Tamoxifen Therapy on Ovarian Aging|Completed|||266|Actual|University of California, San Francisco|||2||f||||t||||||Samples With DNA|"~     Serum AMH, FSH, estradiol, and Inhibin B will be measured. Blood will be collected and~     processed by the UCSF Center for Reproductive Health. Serum samples will be stored at -80oC~     in a designated freezer with an alarm system. Biomarker assessments will be performed by~     Quest Laboratories under standard quality control.~   "|||2018-05-31 22:25:33.535261|2018-05-31 22:25:33.535261
NCT01384513|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-12-04|2011-06-27|2011-06-29|Estimate|||||||2017-12-04|2017-12-06|Actual|August 4, 2011|Actual|2011-08-04|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|December 1, 2019|Anticipated|2019-12-01||Interventional|||A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies|A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies|Recruiting||Phase 2|50|Anticipated|Thomas Jefferson University||1|||f||||t|f|t|f|f||||||2018-05-31 22:25:33.63076|2018-05-31 22:25:33.63076
NCT01384500|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2016-09-27|2011-06-27|2011-06-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|OCTOPUS||The Ornge Comparison of Tracheal Occlusion Pressures to Ensure Safety Trial|The Ornge Comparison of Tracheal Occlusion Pressures to Ensure Safety (OCTOPUS) Trial|Withdrawn||N/A|0|Actual|Ornge Transport Medicine||2||Workforce issues precluding study completion.|f||||t||||||||||2018-05-31 22:25:33.953211|2018-05-31 22:25:33.953211
NCT01384487|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-02-17|2011-06-28|2011-06-29|Estimate|||||||2012-02-17|2012-02-20|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Nidek RS3000 Comparative Study|Comparative Study of the Nidek Optical Coherence Tomography RS-3000 and the RTVue OCT Predicate Device for the Measurements of Retinal and RNFL Thickness, Optic Disc Analysis, Pachymetry, Anterior Chamber Imaging and SLO Imaging.|Completed|||89|Actual|Nidek Co. LTD.|||4||f||||f||||||||||2018-05-31 22:25:34.075493|2018-05-31 22:25:34.075493
NCT01384474|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-07-17|2011-06-28|2011-06-29|Estimate|||||||2013-07-17|2013-07-18|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Observational|IDILIC||Impact of Crew Resource Management Training to Improve the Effectiveness of Surgical Safety Checklist (IDILIC)|Impact of Crew Resource Management Training to Improve the Effectiveness of Surgical Safety Checklist|Completed|||23056|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 22:25:34.153052|2018-05-31 22:25:34.153052
NCT01384461|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2016-11-01|2011-06-28|2011-06-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)|An Open-label, Multicenter Non-interventional Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis|Completed|||251|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:25:34.240459|2018-05-31 22:25:34.240459
NCT01384448|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2017-03-21|2011-06-27|2011-06-29|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2011||2011-08-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2016|Actual|2016-02-29||Interventional|||Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain|A Randomized Trial Comparing Coronary CT Angiography and Stress Echocardiography for Evaluation of Low-to-Intermediate Risk Emergency Department Chest Pain Patients|Completed||N/A|400|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 22:25:34.41176|2018-05-31 22:25:34.41176
NCT01384435|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-11-29|2011-06-27|2011-06-29|Estimate|||||||2012-11-29|2012-12-03|Estimate||||March 2012|2012-03-31||||||||Interventional|||A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCD|Completed||Phase 2|200|Anticipated|Kissei Pharmaceutical Co., Ltd.||5|||f||||f||||||||||2018-05-31 22:25:34.544542|2018-05-31 22:25:34.544542
NCT01384422|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-08-14|2011-06-28|2011-06-29|Estimate|||||||2012-08-14|2012-08-15|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients||Completed||Phase 2|36|Actual|Galapagos NV||3|||f||||f||||||||||2018-05-31 22:25:36.091775|2018-05-31 22:25:36.091775
NCT01384409|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-03-22|2011-06-28|2011-06-29|Estimate|||||||2017-03-22|2017-03-24|Actual|February 2012||2012-02-29|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|3357-006||A Phase 3 Clinical Study of KW-3357 in Patients With DIC|A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by Japanese Association for Acute Medicine-defined DIC Criteria|Terminated||Phase 3|5|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-05-31 22:25:36.244951|2018-05-31 22:25:36.244951
NCT01384396|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-03-22|2011-06-28|2011-06-29|Estimate|||||||2017-03-22|2017-03-24|Actual|December 2011||2011-12-31|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|3357-005||A Clinical Study of KW-3357 in Patients With DIC|A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by the Diagnostic Criteria for DIC Established by the Japanese Ministry of Health and Welfare|Completed||Phase 3|15|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-05-31 22:25:36.395296|2018-05-31 22:25:36.395296
NCT01384383|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22||2013-11-26|2014-01-02|2011-06-27|2011-06-29|Estimate||||2013-11-26|2013-12-20|Estimate|2014-01-02|2014-02-03|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype|A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype|Terminated||Phase 2|248|Actual|Gilead Sciences||2|||f||||||||||||||2018-05-31 22:25:36.549328|2018-05-31 22:25:36.549328
NCT01384201|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|August 2007||2007-08-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|R-CE-GCEP||Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia|Evaluation of the Use of Confocal Endomicroscopy in Conjunction With Chromoendoscopy in the Detection of Gastric Preneoplastic Neoplasia and Neoplasia in a High-Risk Population (R-CE-GCEP)|Completed|||100|Actual|National University Hospital, Singapore|||2||f||||f||||||None Retained|"~     Biopsies from the stomach~   "|||2018-05-31 22:25:38.942462|2018-05-31 22:25:38.942462
NCT01384370|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-10-04|2011-06-27|2011-06-29|Estimate|||||||2011-10-04|2011-10-06|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|AHPV-GT||APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results|Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens|Completed|||1260|Anticipated|Gen-Probe, Incorporated|||1||f||||f||||||Samples With DNA|"~     Cervical specimens collected in ThinPrep Pap Test vials containing PreservCyt Solution~     (Hologic, Inc., Marlborough, Massachusetts) with commercially available collection devices~     (broom-type collection device or cytobrush/spatula combination)* may be tested with the~     AHPV-GT Assay either pre- or post-Pap processing.~   "|||2018-05-31 22:25:36.847996|2018-05-31 22:25:36.847996
NCT01384357|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-27|2011-06-27|2011-06-29|Estimate|||||||2011-06-27|2011-06-29|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies|Real-time Ultrasound-Guided Needle Biopsy in the Diagnosis of Malignant Cervical Lymphadenopathies|Completed|||116|Actual|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 22:25:37.119947|2018-05-31 22:25:37.119947
NCT01384344|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-12-17|2011-06-27|2011-06-29|Estimate|||||||2012-12-17|2012-12-18|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy|Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Interest on Video Recognition and Actigraphy|Completed||N/A|82|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 22:25:37.204919|2018-05-31 22:25:37.204919
NCT01384331|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||New Treatments for Troublesome Bleeding in Implanon Users|Phase 4 Study Comparison of Two Combined Oral Contraceptive Regimens and an Intravaginal Hormonal Ring Against Placebo for Management of Bleeding Problems in Women Using Implanon, the Sub-dermal Contraceptive Implant|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Family Planning Association New South Wales||4|||f||||f||||||||||2018-05-31 22:25:37.314706|2018-05-31 22:25:37.314706
NCT01384318|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-11-29|2011-06-27|2011-06-29|Estimate|||||||2012-11-29|2012-11-30|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Accuracy of Using the CPAP Technique to Eliminate Air Leak and Prevent Excessive Endotracheal Tube Cuff Pressures||Completed|||200|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 22:25:37.449399|2018-05-31 22:25:37.449399
NCT01384305|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|December 2009||2009-12-31|June 2011|2011-06-30||||||||Observational|||"Establish a Taiwan Rare Disorder Tissue Bank, to Collect and Repost Biological Samples and Disease Information From Patients With Rare Disorders"||Unknown status|Enrolling by invitation||500|Anticipated|China Medical University Hospital|||||f||||f||||||||||2018-05-31 22:25:37.530649|2018-05-31 22:25:37.530649
NCT01384292|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|2014-10-13||2015-05-28|2011-06-28|2011-06-29|Estimate|2015-05-28|2015-06-01|Estimate||||2015-05-28|2015-06-01|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients With Cancer-Related Pain|Terminated||Phase 3|14|Actual|AstraZeneca|Due to recruitment challenges, enrollment was stopped early. 14 patients were randomized (<5% of planned number), thus, there was insufficient data to perform the protocol-specified statistical analyses. Secondary outcome measures are not reported.|3||The study was stopped early due to recruitment challenges|f||||||||||||||2018-05-31 22:25:37.645534|2018-05-31 22:25:37.645534
NCT01384279|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-02-23|2011-06-28|2011-06-29|Estimate|||||||2012-02-23|2012-02-24|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity|The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity|Completed||N/A|25|Actual|Beitou Armed Forces Hospital, Taipei, Taiwan||1|||f||||t||||||||||2018-05-31 22:25:38.294478|2018-05-31 22:25:38.294478
NCT01384266|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-06-28|2011-06-27|2011-06-29|Estimate|||||||2017-06-28|2017-06-29|Actual|May 2010||2010-05-31|June 2017|2017-06-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Observational|||A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery|A Randomized, Multicenter, Masked Evaluation of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate for the Treatment of Inflammation Following Cataract Surgery|Completed|||90|Actual|Associated Eye Care, Minnesota|||1||f||||f||||||||||2018-05-31 22:25:38.362199|2018-05-31 22:25:38.362199
NCT01384253|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-09-29|2011-06-28|2011-06-29|Estimate|||||||2016-09-29|2016-09-30|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|October 2015|Actual|2015-10-31||Interventional|||Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy|Phase I Trial of Intraperitoneal ²¹²Pb-TCMC-Trastuzumab for HER-2 Expressing Malignancy|Completed||Phase 1|18|Actual|Orano Med LLC||1|||f||||t||||||||||2018-05-31 22:25:38.449177|2018-05-31 22:25:38.449177
NCT01384240|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-01-08|2011-06-27|2011-06-29|Estimate|||||||2016-01-08|2016-01-12|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||Evaluation of a Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia|Evaluation of Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia|Terminated||Early Phase 1|183|Actual|Anandasabapathy, Sharmila, M.D.||1||Study is closed as the PI transferred to another institution.|f||||t||||||||||2018-05-31 22:25:38.582199|2018-05-31 22:25:38.582199
NCT01384227|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-01-08|2011-06-27|2011-06-29|Estimate|||||||2016-01-08|2016-01-12|Estimate|February 2009||2009-02-28|January 2016|2016-01-31||||July 2011|Actual|2011-07-31||Interventional|||Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study|Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study|Completed||Early Phase 1|40|Actual|Anandasabapathy, Sharmila, M.D.||1|||f||||t||||||||||2018-05-31 22:25:38.678533|2018-05-31 22:25:38.678533
NCT01384214|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-28|2011-06-28|2011-06-29|Estimate|||||||2011-06-28|2011-06-29|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia|Pilot Study of the Effect of Botulinum Toxin Type A Treatment on Swallowing in Patients With Cervical Dystonia|Completed||Phase 4|28|Actual|Allergan||1|||f||||f||||||||||2018-05-31 22:25:38.80771|2018-05-31 22:25:38.80771
NCT01384188|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-01-17|2011-06-27|2011-06-28|Estimate|||||||2013-01-17|2013-01-18|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Investigate the Effects of Food and Morning Versus Evening on Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women|A Two-part, Crossover Study to Investigate the Effects of Morning Versus Evening Dosing and Food Interaction on the Pharmacodynamics and Pharmacokinetics of Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women|Completed||Phase 1/Phase 2|25|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 22:25:39.043519|2018-05-31 22:25:39.043519
NCT01384175|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-28|2011-06-27|2011-06-28|Estimate|||||||2011-06-28|2011-06-29|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Epidural Anesthesia and Postoperative Analgesia With Ropivacaine and Fentanyl|Epidural Anesthesia and Postoperative Analgesia With Ropivacaine and Fentanyl in Off-pump Coronary Artery Bypass Grafting|Completed||N/A|93|Actual|Northern State Medical University||3|||f||||f||||||||||2018-05-31 22:25:39.252243|2018-05-31 22:25:39.252243
NCT01384162|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-01-26|2011-06-27|2011-06-28|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis|An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump|Terminated||Phase 1/Phase 2|15|Actual|Newron Sweden AB||1||"Issues with development and supply of infusion system for delivery of IMP. Lack of favorable~   benefit risk ratio in sNN0029-003 study (review of interim data)."|f||||t||||||||||2018-05-31 22:25:39.666801|2018-05-31 22:25:39.666801
NCT01384149|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-08-11|2011-06-27|2011-06-28|Estimate|||||||2014-08-11|2014-08-12|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ETSG||EXTERNAL SLT Treatment in Patients With Uncontrolled OPEN ANGLE GLAUCOMA|A Pioneer Study: External Selective Laser Trabeculoplasty for Treating Uncontrolled Open Angle Glaucoma|Completed||Phase 1|32|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 22:25:39.936819|2018-05-31 22:25:39.936819
NCT01384136|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||The Telomere System in Cord Blood and in the Placenta in High Risk Pregnancies|The Telomere System in Cord Blood and in the Placenta in High Risk Pregnancies|Unknown status|Active, not recruiting||100|Anticipated|Meir Medical Center|||2||f||||t||||||||||2018-05-31 22:25:40.285846|2018-05-31 22:25:40.285846
NCT01384123|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-04-08|2011-06-27|2011-06-28|Estimate|||||||2015-04-08|2015-04-09|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study||Unknown status|Recruiting||50|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 22:25:40.583773|2018-05-31 22:25:40.583773
NCT01384110|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-11-14|2011-06-27|2011-06-28|Estimate|||||||2011-11-14|2011-11-15|Estimate|June 2011||2011-06-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human|Efficacy of a Brown Seaweed Extract Rich in Polyphenols on Glycemic Response to Sucrose in Human|Completed||Phase 1|43|Actual|innoVactiv Inc.||2|||f||||f||||||||||2018-05-31 22:25:40.941464|2018-05-31 22:25:40.941464
NCT01384097|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-09-07|2011-06-27|2011-06-28|Estimate|||||||2011-09-07|2011-09-08|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Observational|ERAS_feasi||An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery|An Algorithm for Intra-operative Goal-directed Haemodynamic Management in Non-cardiac Surgery - a Feasibility Study|Completed|||774|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 22:25:41.367727|2018-05-31 22:25:41.367727
NCT01384084|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2014-05-19|2011-06-27|2011-06-28|Estimate|||||||2014-05-19|2014-05-20|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pelvic Organ Prolapse Repair Plus Mini-Sling Versus Pelvic Organ Prolapse Repair Alone|URINARY INCONTINENCE AND URO-GENITAL PROLAPSE: A RANDOMIZED TRIAL OF PELVIC ORGAN PROLAPSE REPAIR PLUS MINI-SLING VERSUS PELVIC ORGAN PROLAPSE REPAIR ALONE|Completed||Phase 3|50|Actual|University Of Perugia||2|||f||||f||||||||||2018-05-31 22:25:41.573836|2018-05-31 22:25:41.573836
NCT01384071|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-02-20|2011-06-27|2011-06-28|Estimate|||||||2012-02-20|2012-02-22|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||The Effects of Unstable Shoes on Chronic Low Back Pain||Completed||N/A|40|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 22:25:41.671901|2018-05-31 22:25:41.671901
NCT01384058|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-06-18|2011-06-27|2011-06-28|Estimate|||||||2012-06-18|2012-06-19|Estimate|November 2007||2007-11-30|June 2012|2012-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|EZE||Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes|The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes|Completed||Phase 4|41|Actual|University Hospital Freiburg||3|||f||||t||||||||||2018-05-31 22:25:41.858083|2018-05-31 22:25:41.858083
NCT01384045|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-12-17|2011-06-27|2011-06-28|Estimate|||||||2012-12-17|2012-12-18|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Outreach for Diabetes Cure|Randomized Trial of Health Promotion Outreach for Diabetes Cure|Completed||N/A|2800|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:25:41.938793|2018-05-31 22:25:41.938793
NCT01384032|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|Satgene||Study Into Genetic Influence on Cholesterol Response to Dietary Fat|Apolipoprotein E Genotype as a Determinant of LDL-cholesterol Response to Dietary Fat Manipulation|Completed||N/A|88|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 22:25:42.012556|2018-05-31 22:25:42.012556
NCT01384019|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2013-01-14||2013-02-14|2011-06-27|2011-06-28|Estimate|2013-02-14|2013-03-18|Estimate||||2013-02-14|2013-03-18|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|June 2008|Actual|2008-06-30||Interventional|||Distal Protection Device in ST-elevation Myocardial Infarction (STEMI)|Distal Protection Device Did Not Improve Microvascular Obstruction Evaluated by Cardiac MR After Primary Percutaneous Intervention for ST-elevation Myocardial Infarction|Completed||Phase 4|126|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 22:25:42.102138|2018-05-31 22:25:42.102138
NCT01383993|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2014-04-07||2014-04-08|2011-06-27|2011-06-28|Estimate|2014-04-08|2014-05-09|Estimate||||2014-04-08|2014-05-09|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection|An Open-Label, Non-Controlled, Multicenter, Intravenous To Oral Switch, Phase 2 Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To Less Than 15 Years Who Are At High Risk For Systemic Fungal Infection|Completed||Phase 2|21|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:25:42.470214|2018-05-31 22:25:42.470214
NCT01383980|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Trial of Continuous Versus Interrupted Feeding for Intubated Intensive Care Unit Patients|A Randomized Trial of Continuous Versus Interrupted Enteral Feeding in Critically Ill Surgical Patients Requiring Mechanical Ventilation|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:25:43.415415|2018-05-31 22:25:43.415415
NCT01383967|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-06-13|2011-06-27|2011-06-28|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of LY2979165 in Healthy Subjects|Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Multiple-Ascending Doses of LY2979165 in Healthy Subjects|Completed||Phase 1|102|Actual|Eli Lilly and Company||8|||f||||f||||||||||2018-05-31 22:25:43.52657|2018-05-31 22:25:43.52657
NCT01383954|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2017-04-05||2017-07-14|2011-06-27|2011-06-28|Estimate|2017-06-07|2017-07-06|Actual||||2017-07-14|2017-08-15|Actual|June 2011|Actual|2011-06-30|July 2017|2017-07-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional||Modified Intent-to-Treat Population, all participants who completed at least 50% of the study (at least 2 weeks of drug treatment).|The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis|The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis|Completed||Phase 4|52|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 22:25:43.619126|2018-05-31 22:25:43.619126
NCT01383941|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-03-14|2011-06-27|2011-06-28|Estimate|||||||2017-03-14|2017-03-16|Actual|August 2011||2011-08-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|APIC||Asthma Phenotypes in the Inner City|Asthma Phenotypes in the Inner City (ICAC-19)|Completed|||717|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Participants had the option of having blood, RNA, and DNA stored for use in future research~     studies.~   "|||2018-05-31 22:25:43.77454|2018-05-31 22:25:43.77454
NCT01383928|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2015-11-16||2018-01-11|2011-06-27|2011-06-28|Estimate|2015-11-16|2015-12-18|Estimate||||2018-01-11|2018-02-07|Actual|October 31, 2011|Actual|2011-10-31|January 2018|2018-01-31|November 27, 2017|Actual|2017-11-27|October 13, 2014|Actual|2014-10-13||Interventional||Safety population included all participants who received at least 1 dose of any study drug.|Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of IXAZOMIB (MLN9708), Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment|Completed||Phase 1/Phase 2|64|Actual|Takeda||1|||f||||f|t|f||||||||2018-05-31 22:25:43.962045|2018-05-31 22:25:43.962045
NCT01383915|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-08-24|2011-06-27|2011-06-28|Estimate|||||||2017-08-24|2017-08-25|Actual|September 2009||2009-09-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Clinical Risk State for Bipolar Disorder in Adolescents|Characterizing the Clinical Risk State for Bipolar Disorder in Adolescents|Recruiting|||112|Anticipated|Northwell Health|||1||f||||f||||||||||2018-05-31 22:25:46.738565|2018-05-31 22:25:46.738565
NCT01383902|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Chocolate Meal Study|The Effect of Meal Type on the Rate of Gastric Emptying|Completed||N/A|4|Actual|Quadram Institute||1|||f||||t||||||||||2018-05-31 22:25:46.79947|2018-05-31 22:25:46.79947
NCT01383889|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-03-04|2011-06-27|2011-06-28|Estimate|||||||2013-03-04|2013-03-05|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|EXPREG||Acute Maternal and Fetal Effects of Exercise in Pregnancy|Acute Effects on the Mother and Fetus in Two Modalities of Exercise in Pregnancy: a Randomized Controlled Trial.|Completed||N/A|120|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-05-31 22:25:46.932546|2018-05-31 22:25:46.932546
NCT01383876|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-10-21|2011-06-27|2011-06-28|Estimate|||||||2013-10-21|2013-10-22|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Collar Immobilization Following a Posterior Cervical Laminectomy and Fusion|Collar Immobilization Following a Posterior Cervical Laminectomy and Fusion: A Randomized Controlled Trial|Terminated||N/A|11|Actual|Brigham and Women's Hospital||2||Enrollment too slow|f||||f||||||||||2018-05-31 22:25:47.051125|2018-05-31 22:25:47.051125
NCT01383863|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2014-07-29|2011-06-27|2011-06-28|Estimate|||||||2014-07-29|2014-07-30|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|TRIPTOCARE LT||A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer|A Prospective Observational Study Cohort to Assess the Rate of Castration Resistance, Disease Progression and Overall Survival Over a 3-year Period Post-androgen Deprivation Therapy Induction in Patients With Advanced Prostate Cancer Who Have Previously Participated in the Triptocare Study (Http://Clinicaltrials.Gov/ct2/Show/Study/NCT01020448)|Completed|||180|Actual|Ipsen|||||f||||f||||||||||2018-05-31 22:25:47.215687|2018-05-31 22:25:47.215687
NCT01383850|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS)||Completed||Phase 2|51|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||||2018-05-31 22:25:47.412486|2018-05-31 22:25:47.412486
NCT01383837|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2015-08-27|2011-06-27|2011-06-28|Estimate|||||||2015-08-27|2015-08-28|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|STYLEnS||HIV/STI Prevention for Adolescents With Substance Use Disorders in Treatment|HIV/STI Prevention for Adolescents With Substance Use Disorders in Treatment|Completed||Phase 1/Phase 2|86|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 22:25:47.528709|2018-05-31 22:25:47.528709
NCT01382108|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2013-06-18||2013-10-31|2011-06-23|2011-06-27|Estimate|2013-10-31|2013-11-26|Estimate||||2013-10-31|2013-11-26|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|KITCHENER||Meibography and Tear Scan Using the Oculus Keratograph 4|Meibography and Tear Scan Using the Oculus Keratograph 4|Completed|||39|Actual|University of Waterloo|||2||f||||f||||||||||2018-05-31 22:26:33.081823|2018-05-31 22:26:33.081823
NCT01383824|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-05-25|2011-06-27|2011-06-28|Estimate|||||||2016-05-25|2016-05-27|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|July 2015|Actual|2015-07-31|July 2013|Actual|2013-07-31||Interventional|||A Multi-centre Study to Assess the Long-term Performance of the Silent Hip™ in Primary Total Hip Replacement Surgery|A Multi-centre, Prospective, Uncontrolled Post Market Clinical Follow-up Study (PMCFS) to Monitor the Survival and Performance of the Silent™ Hip in Subjects Requiring a Total Hip Replacement|Terminated||N/A|89|Actual|DePuy International||1||Rationalization of the Silent Hip Prosthesis for business reasons only|f||||f||||||||||2018-05-31 22:25:47.663435|2018-05-31 22:25:47.663435
NCT01383811|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-03-05|2011-06-27|2011-06-28|Estimate|||||||2014-03-05|2014-03-06|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Exercise in Treatment Resistant Depression (TRD): A Feasibility Study|Clinical and Neuroendocrine/Metabolic Benefits of Exercise in Treatment Resistant Depression (TRD): A Feasibility Study|Completed||N/A|21|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 22:25:47.823192|2018-05-31 22:25:47.823192
NCT01383798|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2014-03-13|2011-06-27|2011-06-28|Estimate|||||||2014-03-13|2014-03-14|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||How Does Iron Supplementation Affect Training and Performance in Female Collegiate Rowers?|How Does Iron Deficiency Without Anemia (IDNA) Affect Endurance Training In Female Collegiate Endurance Athletes?|Completed||N/A|40|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 22:25:48.031834|2018-05-31 22:25:48.031834
NCT01383785|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2012-02-20|2011-06-27|2011-06-28|Estimate|||||||2012-02-20|2012-02-22|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|TOLEDO1||Thrombus Aspiration for OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab|Phase 4 Study of Primary Angioplasty Combined Distal Injection of Abciximab to Thrombus and Aspiration With Catheter|Unknown status|Recruiting|Phase 4|186|Anticipated|Hospital Virgen de la Salud||3|||f||||t||||||||||2018-05-31 22:25:48.18078|2018-05-31 22:25:48.18078
NCT01383772|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2015-04-30|2011-06-27|2011-06-28|Estimate|||||||2015-04-30|2015-05-01|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Retinal Laser by Multi-spot Photocoagulator and Driving Eligibility|A Prospective Clinical Study of the Effects of Panretinal Photocoagulation Delivered With a Multi-spot Photocoagulator on Retinal Sensitivity and Driving Eligibility in Patients With Diabetic Retinopathy|Completed||N/A|43|Actual|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 22:25:48.291562|2018-05-31 22:25:48.291562
NCT01383759|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2018-05-10|2011-06-27|2011-06-28|Estimate|||||||2018-05-10|2018-05-11|Actual|June 24, 2011|Actual|2011-06-24|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis|Pilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis|Active, not recruiting||N/A|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:25:48.385693|2018-05-31 22:25:48.385693
NCT01383746|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2013-08-06|2011-06-27|2011-06-28|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|CHOLANGIOSIR||Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION|Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy|Terminated||Phase 1/Phase 2|5|Actual|Assistance Publique - Hôpitaux de Paris||1||Not enough inclusion|f||||t||||||||||2018-05-31 22:25:48.478472|2018-05-31 22:25:48.478472
NCT01383733|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2016-11-01|2011-06-27|2011-06-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of RO5458640 in Patients With Advanced Solid Tumors|A Phase I Multiple Ascending Dose (MAD) Study of RO5458640, a Humanized Monoclonal Antibody Against the TNF-like Weak Inducer of Apoptosis (TWEAK) Ligand, in Patients With Advanced Solid Tumors|Completed||Phase 1|54|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:25:48.614837|2018-05-31 22:25:48.614837
NCT01383720|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2013-04-16||2017-05-23|2011-06-27|2011-06-28|Estimate|2016-05-01|2016-05-09|Estimate||||2017-05-23|2017-06-20|Actual|April 2012||2012-04-30|May 2017|2017-05-31|May 9, 2017|Actual|2017-05-09|May 2012|Actual|2012-05-31||Interventional|REPRISE I||REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve SystEm|REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve SystEm|Completed||N/A|11|Actual|Boston Scientific Corporation||1|||f||||f||||||||No|There is no plan to make individual participant data (IPD) available.|2018-05-31 22:25:48.75162|2018-05-31 22:25:48.75162
NCT01383707|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2016-07-22||2017-05-17|2011-06-27|2011-06-28|Estimate|2016-07-22|2016-09-07|Estimate||||2017-05-17|2017-06-14|Actual|August 12, 2011|Actual|2011-08-12|May 2017|2017-05-31|May 18, 2016|Actual|2016-05-18|May 28, 2014|Actual|2014-05-28||Interventional||The intent-to-treat analysis set (ITT), which included all enrolled participants, who received at least one dose of any study medication.|A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer|A Multi-center, Open-label Clinical Trial to Evaluate the Objective Response Rate of Bevacizumab in Combination With Modified FOLFOX-6 Followed by One Year of Maintenance With Bevacizumab Alone in Patients With Initially Not or Borderline Resectable Colorectal Liver Metastases (The CLMO-001 Trial)|Completed||Phase 2|77|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:25:49.528329|2018-05-31 22:25:49.528329
NCT01383694|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-02-27|2011-06-27|2011-06-28|Estimate|||||||2015-02-27|2015-03-03|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|FIS 2009_2||Effect Of Piperine In Patients With Oropharyngeal Dysphagia|Effect of Natural Agonists of TRPV1 in the Treatment of Functional Oropharyngeal Dysphagia in Neurological Diseases and the Elderly: Piperine|Completed||Phase 1/Phase 2|40|Actual|Hospital de Mataró||2|||f||||||||||||||2018-05-31 22:25:49.965756|2018-05-31 22:25:49.965756
NCT01383681|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2013-09-09||2013-09-09|2011-06-27|2011-06-28|Estimate|2013-09-09|2013-11-14|Estimate||||2013-09-09|2013-11-14|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Retrospective Study of Patients With Spasticity in the Spanish Population|Observational Study To Establish The Methodology Used In The Evaluation, Treatment And Assessment Of Progression Of Spasticity In The Spanish Population|Completed|||235|Actual|Allergan|Not enough data was collected for analysis of Physician's Assessment of Spasticity outcome measures.||1||f||||f||||||||||2018-05-31 22:25:50.052671|2018-05-31 22:25:50.052671
NCT01383668|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-12-13|2011-06-27|2011-06-28|Estimate|||||||2012-12-13|2012-12-17|Estimate|June 2011||2011-06-30|December 2012|2012-12-31||||||||Interventional|||Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer|Combined PKCiota and mTOR Inhibition for Treatment of Advanced Squamous Lung Cancer|Withdrawn||Phase 1|0|Actual|Mayo Clinic||1||lack of access to study drug|f||||t||||||||||2018-05-31 22:25:50.243499|2018-05-31 22:25:50.243499
NCT01383655|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2016-01-20|2011-06-27|2011-06-28|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Intravenous Magnesium in Wheezy Bronchitis|The Efficacy of Intravenous Magnesium in Acute Wheezy Bronchitis in Small Children - a Randomized, Controlled Study|Completed||N/A|61|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 22:25:50.439416|2018-05-31 22:25:50.439416
NCT01383642|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-03-16|2011-06-27|2011-06-28|Estimate|||||||2018-03-16|2018-03-20|Actual|July 2010|Actual|2010-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2013|Actual|2013-06-30||Observational|||Physiology of Vestibular Dysfunction and Clinical Implications||Active, not recruiting|||50|Actual|Johns Hopkins University|||1||f||||||||||||||2018-05-31 22:25:50.662798|2018-05-31 22:25:50.662798
NCT01383629|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Effect of Preoperative Counseling on Patient Fear From Visual Experience During Vitrectomy Surgery Under Regional Anesthesia|The Effect of Preoperative Counseling on Patient Fear From Visual Experience During Vitrectomy Surgery Under Regional Anesthesia|Completed||N/A|100|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 22:25:51.606721|2018-05-31 22:25:51.606721
NCT01383616|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2017-03-16||2017-06-03|2011-06-27|2011-06-28|Estimate|2017-06-03|2017-07-02|Actual||||2017-06-03|2017-07-02|Actual|July 2006||2006-07-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||21 patients received bipedicular intervention. 3 lost to follow up at 3 months (n=18) and 6 total lost at 12 months (n=15) 23 patients received unipedicular intervention. 5 lost to 3 month follow up (n=18) and 9 total lost at 12 months (n=14) Pre and post-op vertebral height measures were available in 14 unipedicular and 17 bipedicular patients|Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures|Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures|Completed||Phase 4|84|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 22:25:52.155417|2018-05-31 22:25:52.155417
NCT01383603|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-06-10|2011-06-27|2011-06-28|Estimate|||||||2014-06-10|2014-06-11|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis|Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis|Completed||Phase 1|10|Actual|Circassia Limited||1|||f||||f||||||||||2018-05-31 22:25:55.060865|2018-05-31 22:25:55.060865
NCT01383590|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-01-21|2011-06-27|2011-06-28|Estimate|||||||2014-01-21|2014-01-22|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis|Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis|Completed||Phase 1|10|Actual|Circassia Limited||1|||f||||f||||||||||2018-05-31 22:25:55.34466|2018-05-31 22:25:55.34466
NCT01383577|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2013-09-24|2011-06-27|2011-06-28|Estimate|||||||2013-09-24|2013-09-26|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|February 2013|Actual|2013-02-28||Interventional|||Comparison Between Single and Triple Rubber Band Ligation for the Treatment of Hemorrhoids|Double-blind Randomized Controlled Study of Single Versus Triple Rubber Band Ligation of Hemorrhoids|Unknown status|Active, not recruiting|N/A|76|Anticipated|Federal University of Amazonas||2|||f||||t||||||||||2018-05-31 22:25:55.691735|2018-05-31 22:25:55.691735
NCT01383564|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2016-07-28|2011-06-27|2011-06-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OSA||Continuous Positive Airway Pressure Use in Asthma With Moderate to Severe Obstructive Sleep Apnea Patients|Effect of Nasal Continuous Positive Airway Pressure in Uncontrolled Nocturnal Asthmatic Patients With Moderate Obstructive Sleep Apnea Syndrome|Completed||N/A|101|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 22:25:55.871799|2018-05-31 22:25:55.871799
NCT01383551|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2013-12-12|2011-06-26|2011-06-28|Estimate|||||||2013-12-12|2013-12-16|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||"Becoming Parents: A Hospital-community Partnership"|"Becoming Parents: A Hospital-community Partnership to Enhance Transition to Parenthood"|Completed||N/A|290|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:25:56.047231|2018-05-31 22:25:56.047231
NCT01383538|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-08-07|2011-06-26|2011-06-28|Estimate|||||||2017-08-07|2017-08-08|Actual|August 23, 2011|Actual|2011-08-23|August 2017|2017-08-31|May 26, 2015|Actual|2015-05-26|December 13, 2012|Actual|2012-12-13||Interventional|||FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma|A Phase I Study of FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma|Completed||Phase 1|15|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 22:25:56.163496|2018-05-31 22:25:56.163496
NCT01383525|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-08-09|2011-06-26|2011-06-28|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2011||2011-07-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|DSLT||Direct Application of Selective Laser Trabeculoplasty in Open Angle Glaucoma|Direct Application of Selective Laser Trabeculoplasty in Open Angle Glaucoma . Single Site Study|Active, not recruiting||N/A|40|Anticipated|Sheba Medical Center||1|||f||||f||||||||Undecided||2018-05-31 22:25:56.316017|2018-05-31 22:25:56.316017
NCT01383512|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2017-10-18|2011-06-27|2011-06-28|Estimate|||||||2017-10-18|2017-10-19|Actual|June 2011|Actual|2011-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|REM_AVC||Rehabilitation Robotics After a Stroke|Medical and Economical Evaluation of Upper Limb's Rehabilitation Robotics After a Stroke|Active, not recruiting||N/A|238|Actual|University Hospital, Brest||3|||f||||t||||||||||2018-05-31 22:25:56.430707|2018-05-31 22:25:56.430707
NCT01383499|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2013-09-23||2015-03-26|2011-06-27|2011-06-28|Estimate|2013-12-04|2013-12-30|Estimate||||2015-03-26|2015-04-15|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Total number of patients randomised and treated at all in the study.|A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma|A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 µg, 2.5 µg and 5 µg) Delivered Via Respimat® Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma|Completed||Phase 2|101|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 22:25:56.676217|2018-05-31 22:25:56.676217
NCT01383473|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-08-26|2011-06-27|2011-06-28|Estimate|||||||2015-08-26|2015-08-27|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients|Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients|Completed|||14|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||||||2018-05-31 22:25:58.678632|2018-05-31 22:25:58.678632
NCT01383460|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-26|||2016-12-04|2011-06-27|2011-06-28|Estimate|||||||2016-12-04|2016-12-06|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy of Granulocyte Colony-stimulating Factor and Erythropoetin for Patients With Acute-on-chronic Liver Failure|Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF)|Completed||Phase 3|55|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 22:25:58.862718|2018-05-31 22:25:58.862718
NCT01383447|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2017-04-14||2017-07-07|2011-06-27|2011-06-28|Estimate|2017-07-07|2017-08-08|Actual||||2017-07-07|2017-08-08|Actual|October 2010||2010-10-31|July 2017|2017-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|A Phase 1/2 Study of SNDX-275 in Combination With Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Terminated||Phase 1/Phase 2|2|Actual|National Cancer Institute (NCI)||1||This study was halted prematurely by the NCI for low accrual.|f||||||||||||||2018-05-31 22:25:58.959953|2018-05-31 22:25:58.959953
NCT01383434|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-10-12|2011-06-27|2011-06-28|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia|A Phase II Trial of Myeloablative Conditioning and Transplantation of HLA-matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated (MUD) Bone Marrow for Patients With Refractory Severe Aplastic Anemia|Terminated||Phase 2|4|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||New revised SAA BMT study opened to take over this study|f||||t||||||||||2018-05-31 22:25:59.219959|2018-05-31 22:25:59.219959
NCT01383421|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-26|2017-04-10||2017-04-10|2011-06-26|2011-06-28|Estimate|2017-04-10|2017-06-26|Actual||||2017-04-10|2017-06-26|Actual|September 2011||2011-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|PASSION|ITT population: all enrolled participants who received at least 1 dose of study drug.|Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)|A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction With Adalimumab Treatment in Patients With Rheumatoid Arthritis (PASSION Study)|Completed|||1036|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:25:59.374089|2018-05-31 22:25:59.374089
NCT01383408|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2013-05-05|2011-06-27|2011-06-28|Estimate|||||||2013-05-05|2013-05-07|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection|Distinction Between Lung Cancer and Gynecological Cancers by Exhalation Analysis and Canine Scent Detection|Terminated||Phase 2|752|Actual|Schillerhoehe Hospital||4||Inconsistent training status of sniffer dogs|f||||f||||||||||2018-05-31 22:26:02.304636|2018-05-31 22:26:02.304636
NCT01383395|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-05-18|2011-06-27|2011-06-28|Estimate|||||||2015-05-18|2015-05-20|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Cilostazol on the Pharmacokinetics of Simvastatin|Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects|Completed||Phase 1|20|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 22:26:02.387504|2018-05-31 22:26:02.387504
NCT01383382|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2012-09-07|2011-06-27|2011-06-28|Estimate|||||||2012-09-07|2012-09-10|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Observational|PRISM||Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool|Transforming PCI Informed Consent Into an Evidence-based Decision-making Tool|Completed|||1399|Actual|Saint Luke's Health System|||||f||||f||||||||||2018-05-31 22:26:02.446021|2018-05-31 22:26:02.446021
NCT01383369|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-09-27|2011-06-27|2011-06-28|Estimate|||||||2011-09-27|2011-09-28|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Postoperative Sleep Disturbances Role in Cognitive Test Results After Fast-track Hip and Knee Arthroplasty|Postoperative Sleep Disturbances Role in Cognitive Test Results After Fast-track Hip and Knee Arthroplasty|Completed|||20|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 22:26:02.508719|2018-05-31 22:26:02.508719
NCT01383356|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|2012-12-18||2014-02-27|2011-06-27|2011-06-28|Estimate|2012-12-18|2013-01-24|Estimate||||2014-02-27|2014-03-28|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Dosed participants from combined studies|Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet|A Single Dose Comparative Bioavailability Study of Linagliptin/Metformin hydrochloride2.5mg/500mg Combination Tablets Versus Linagliptin 2.5mg Tablets Administered With Glucophage 500mg Tablets Under Fasting Conditions|Completed||Phase 1|58|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:26:02.598997|2018-05-31 22:26:02.598997
NCT01383343|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-25|||2017-04-18|2011-06-25|2011-06-28|Estimate|||||||2017-04-18|2017-04-19|Actual|August 2011||2011-08-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer|Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies|Completed||Phase 1|17|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 22:26:03.043877|2018-05-31 22:26:03.043877
NCT01383330|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|July 2011||2011-07-31|June 2011|2011-06-30||||September 2011|Anticipated|2011-09-30||Interventional|||A Clinical Trial to Evaluate Pharmacokinetics of Daewon DW-ES(A) 625mg/5ml, Daewon DW-ES(B) 625mg/5ml and Megace 800mg/20ml in Healthy Male Volunteers Under Fed Condition|Phase 1 Study of Daewon-ES(A) & Daewon-ES(B) in Healthy Male Volunteers Under Fed Condition|Unknown status|Not yet recruiting|Phase 1|15|Anticipated|Asan Medical Center||3|||f||||f||||||||||2018-05-31 22:26:03.282072|2018-05-31 22:26:03.282072
NCT01383317|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2017-12-15||2018-04-25|2011-06-27|2011-06-28|Estimate|2018-01-10|2018-01-12|Actual||||2018-04-25|2018-05-24|Actual|June 2011||2011-06-30|April 2018|2018-04-30|April 30, 2017|Actual|2017-04-30|April 30, 2016|Actual|2016-04-30||Interventional|RIPCEPP||Remote Ischemic PreConditioning Effect on Postsurgical Pain|Remote Ischemic Preconditioning (RIPC) and Its Effect on the Postoperative Pain Experience Following Intra-abdominal Surgery|Completed||N/A|64|Actual|Wake Forest University Health Sciences||2|||f||||f|f|t||||||||2018-05-31 22:26:03.359722|2018-05-31 22:26:03.359722
NCT01383304|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-05-11|2011-06-27|2011-06-28|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|January 2017|Anticipated|2017-01-31|January 2011|Actual|2011-01-31||Observational|||Aspirin Response in High Risk Patients With Coronary Artery Disease|Is a Reduced Biochemical Response to Aspirin Associated With Increased Cardiovascular Morbidity and Mortality in High Risk Patients With Coronary Artery Disease?|Unknown status|Active, not recruiting||906|Actual|University of Aarhus|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, urine~   "|||2018-05-31 22:26:03.913584|2018-05-31 22:26:03.913584
NCT01383291|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-26|||2014-06-19|2011-06-27|2011-06-28|Estimate|||||||2014-06-19|2014-06-20|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Observational|||Prolift Versus IVS for Pelvic Floor Prolapse|Postoperative Comparison Between Posterior Prolift Mesh Placement and Posterior IVS Sling Placement|Withdrawn|||0|Actual|Western Galilee Hospital-Nahariya|||1||f||||f||||||||||2018-05-31 22:26:03.984501|2018-05-31 22:26:03.984501
NCT01383278|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2015-12-18|2011-06-24|2011-06-28|Estimate|||||||2015-12-18|2015-12-21|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Evaluation of a Computer-Delivered 5 A's Intervention for Smoking|Evaluation of a Computer-Delivered 5 A's Intervention for Smoking|Terminated||N/A|8|Actual|Virginia Commonwealth University||2||Insufficient sample size to complete study and merged with parent grant funded study|f||||t||||||||||2018-05-31 22:26:04.038377|2018-05-31 22:26:04.038377
NCT01383265|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2013-06-13|2011-06-24|2011-06-28|Estimate|||||||2013-06-13|2013-06-17|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Combined Chromoendoscopy and Water Method for Screening Colonoscopy|Randomized Controlled Trial (RCT) to Compare Adenoma Detection Rate of Combined Chromoendoscopy (Indigo Carmine) With Water Infusion in Lieu of Air Insufflation (Water Method) vs. Water Method Alone in Screening Colonoscopy|Completed||N/A|1177|Actual|VA Northern California Health Care System||2|||f||||f||||||||||2018-05-31 22:26:04.102933|2018-05-31 22:26:04.102933
NCT01383252|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-06-13|2011-06-24|2011-06-28|Estimate|||||||2013-06-13|2013-06-17|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Unsedated Colonoscopy for Colorectal Cancer Screening and Surveillance|Comparison of Study Method Versus Conventional Method for Performing Unsedated Colonoscopy for Colorectal Cancer Screening and Surveillance|Completed||N/A|10|Actual|VA Northern California Health Care System||2|||f||||t||||||||||2018-05-31 22:26:04.194712|2018-05-31 22:26:04.194712
NCT01383239|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2016-11-03|2011-06-27|2011-06-28|Estimate|||||||2016-11-03|2016-11-04|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Impact of Postoperative Management on Outcomes and Healing of Rotator Cuff Repairs|Impact of Postoperative Management on Outcomes and Healing of Rotator Cuff Repairs|Completed||N/A|27|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 22:26:04.274051|2018-05-31 22:26:04.274051
NCT01383226|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2013-10-08|2011-06-27|2011-06-28|Estimate|||||||2013-10-08|2013-10-10|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|LASSO||Linear Endosonography for the Assessment of Sarcoidosis Stage O|CT Enlarged Mediastinal/Hilar Lymph Nodes Not Visible on Chest X-ray in the Non Cancer Patient : Diagnosis and Clinical Implications Using Endobronchial or Esophageal Ultrasound Controlled Needle Aspiration E(B)US-NA|Unknown status|Active, not recruiting|N/A|100|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:26:04.351239|2018-05-31 22:26:04.351239
NCT01383213|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2013-12-31||2013-12-31|2011-06-27|2011-06-28|Estimate|2013-12-31|2014-02-14|Estimate||||2013-12-31|2014-02-14|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Helmet Continuous Positive Airway Pressure (CPAP) Versus Oxygen Venturi in Severe Acute Respiratory Failure in Pneumonia|A Prospective, Randomized, Controlled Trial to Evaluate the Efficacy of CPAP Delivered by Helmet in Comparison With Oxygen Therapy by Venturi Mask in Severe Acute Respiratory Failure Caused by Pneumonia|Completed||N/A|81|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 22:26:04.433895|2018-05-31 22:26:04.433895
NCT01383200|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2013-01-14||2017-07-13|2011-06-24|2011-06-28|Estimate|2015-03-16|2015-04-01|Estimate||||2017-07-13|2017-08-11|Actual|June 2011||2011-06-30|June 2017|2017-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Tetracaine Versus Lidocaine Gel for Anesthetic Effect and Comfort in Patients Undergoing LASIK|Comparison of 0.5% Tetracaine Drops Versus 2% Lidocaine Gel for Anesthetic Efficacy and Comfort in Patients Undergoing LASIK|Terminated||Phase 4|11|Actual|University of Miami||2||eyes that received gel had slightly thinner than intended flaps|f||||f||||||||||2018-05-31 22:26:04.677343|2018-05-31 22:26:04.677343
NCT01383187|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-03-21|2011-06-27|2011-06-28|Estimate|||||||2013-03-21|2013-03-22|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Autologous Platelets Concentrate and Autologous Thrombin for the Treatment of Deep Burn Trauma|An Open-label, Non Randomized, Single-Center Registry Study to Assess the Safety and Effects of Autologous Platelets Concentrate and Autologous Thrombin for the Treatment of Deep Burns Trauma|Completed||Phase 2/Phase 3|30|Actual|University Hospital Ostrava||2|||f||||t||||||||||2018-05-31 22:26:04.946964|2018-05-31 22:26:04.946964
NCT01383174|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2015-05-05||2015-06-12|2011-06-24|2011-06-28|Estimate|2015-06-12|2015-06-15|Estimate||||2015-06-12|2015-06-15|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Nuevo Amanecer: Promoting the Psychosocial Health of Latinas|Nuevo Amanecer: Promoting the Psychosocial Health of Latinas|Completed||N/A|151|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:26:05.145165|2018-05-31 22:26:05.145165
NCT01383161|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2018-01-04||2018-03-14|2011-06-24|2011-06-28|Estimate|2018-03-14|2018-03-19|Actual||||2018-03-14|2018-03-19|Actual|March 2012|Actual|2012-03-31|March 2018|2018-03-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|Curcumin||18-Month Study of Memory Effects of Curcumin|18-Month Double-Blind, Placebo-Controlled Study of Curcumin|Completed||Phase 2|46|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 22:26:06.314295|2018-05-31 22:26:06.314295
NCT01383148|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-01-04|2011-06-27|2011-06-28|Estimate|||||||2017-01-04|2017-01-05|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|TIME||Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer|A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2/Phase 3|222|Actual|Transgene||2|||f||||t||||||||||2018-05-31 22:26:06.946829|2018-05-31 22:26:06.946829
NCT01383135|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-11-16|2011-06-24|2011-06-28|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|August 2015|Actual|2015-08-31||Observational|||Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2|Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2|Suspended|||46|Anticipated|Stanford University||||Converting from Exploratory IND to Full IND|f||||t||||||||||2018-05-31 22:26:07.109969|2018-05-31 22:26:07.109969
NCT01383122|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-03-23|2011-06-27|2011-06-28|Estimate|||||||2012-03-23|2012-03-26|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||The Efficacy of Pulsed Electromagnetic Field Therapy for Management of Post-operative Pain Following Cesarean Delivery|The Efficacy of Pulsed Electromagnetic Field Therapy for Management of Post-operative Pain Following Cesarean Delivery: a Randomised, Double-blind, Placebo-controlled Study|Terminated||N/A|125|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||Planned interim analysis-no statistical significance for the primary outcome.|f||||f||||||||||2018-05-31 22:26:07.201059|2018-05-31 22:26:07.201059
NCT01383109|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2012-01-25|2011-06-27|2011-06-28|Estimate|||||||2012-01-25|2012-01-26|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Human Mass Balance Study of Pyronaridine|A Human Mass Balance Study of Pyronaridine Using Accelerator Mass Spectrometry|Completed||Phase 1|6|Actual|Medicines for Malaria Venture||1|||f||||t||||||||||2018-05-31 22:26:07.289208|2018-05-31 22:26:07.289208
NCT01383096|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2014-05-12||2015-01-19|2011-06-27|2011-06-28|Estimate|2015-01-19|2015-01-29|Estimate||||2015-01-19|2015-01-29|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||The Safety population was comprised of all randomized subjects who received any amount of study drug and was based on the actual treatment received at each time point, if this differed from that to which the subject was randomized.|Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers|A Phase I Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers|Completed||Phase 1|52|Actual|Medicines for Malaria Venture||11|||f||||f||||||||||2018-05-31 22:26:09.080997|2018-05-31 22:26:09.080997
NCT01383083|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|November 2012|Anticipated|2012-11-30|June 2011|Anticipated|2011-06-30||Observational|EIGER||Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease|Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease (Eisenmenger Physiology): Safety, Tolerability, Clinical, and Hemodynamic Effect.|Unknown status|Active, not recruiting||42|Anticipated|Maryknoll Medical Center|||1||f||||t||||||||||2018-05-31 22:26:10.655839|2018-05-31 22:26:10.655839
NCT01383070|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|November 2012|Anticipated|2012-11-30|September 2012|Anticipated|2012-09-30||Interventional|BFC||Evaluation of Effectiveness of Cell Phone Technology as Community Based Intervention to Improve Exclusive Breast Feeding|Effectiveness of Cell Phone Counseling to Improve Breast Feeding Indicators|Unknown status|Recruiting|N/A|1036|Anticipated|Lata Medical Research Foundation, Nagpur||2|||f||||f||||||||||2018-05-31 22:26:10.895175|2018-05-31 22:26:10.895175
NCT01383057|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-02-15|2011-06-27|2011-06-28|Estimate|||||||2012-02-15|2012-02-17|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery|Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery|Completed||Phase 4|29|Actual|Innovative Medical||1|||f||||f||||||||||2018-05-31 22:26:11.086759|2018-05-31 22:26:11.086759
NCT01383044|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-27|2011-06-27|2011-06-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding|Banding Ligation With Carvedilol vs. Carvedilol for the Prevention of First Bleeding in Cirrhotics With Moderate Varices|Unknown status|Recruiting|Phase 4|150|Anticipated|E-DA Hospital||2|||f||||t||||||||||2018-05-31 22:26:11.206333|2018-05-31 22:26:11.206333
NCT01383031|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-07-06|2011-06-24|2011-06-28|Estimate|||||||2011-07-06|2011-07-07|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy Study of Transumbilical Laparoendoscopic Single Site Cholecystectomy|Randomized Controlled Trial Of Transumbilical Laparoendoscopic Single Site Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy|Unknown status|Recruiting|Phase 2/Phase 3|600|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 22:26:11.44733|2018-05-31 22:26:11.44733
NCT01383018|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2017-10-10|2011-06-27|2011-06-28|Estimate|||||||2017-10-10|2017-10-12|Actual|June 2011|Actual|2011-06-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PROPPER||PROPPER Prospective Registry of Outcomes With Penile Prosthesis|Prospective Registry of Outcomes With Penile Prosthesis for Erectile Restoration (PROPPER)|Active, not recruiting|||1467|Actual|Boston Scientific Corporation|||1||f||||f|f|t|f|f|t|||||2018-05-31 22:26:11.54612|2018-05-31 22:26:11.54612
NCT01383005|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2012-12-28||2013-04-30|2011-06-24|2011-06-28|Estimate|2013-03-07|2013-04-22|Estimate||||2013-04-30|2013-05-06|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|QD-Kapital||Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)|Treatment Perception of QD Dosed Kaletra (Tablets) Based Treatment in HIV Infected Patients. Observational Cross-Sectional Study (QD-KAPITAL)|Completed|||97|Actual|AbbVie|||2||f||||f||||||||||2018-05-31 22:26:11.90596|2018-05-31 22:26:11.90596
NCT01382992|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|June 2010||2010-06-30|June 2011|2011-06-30||||||||Observational|||A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples||Unknown status|Active, not recruiting||150|Anticipated|Peking Union Medical College Hospital|||2||f||||||||||Samples With DNA|"~     Formalin-fixed, paraffin-embedded tissue slices and plasma samples are to be retained.~   "|||2018-05-31 22:26:12.818954|2018-05-31 22:26:12.818954
NCT01382979|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Evaluation of AlcoholEdu for College|Evaluation of AlcoholEdu: A Randomized Multi-Campus Trial|Completed||N/A|9571|Actual|Pacific Institute for Research and Evaluation||2|||f||||f||||||||||2018-05-31 22:26:12.872899|2018-05-31 22:26:12.872899
NCT01382966|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-06-27|2011-06-24|2011-06-27|Estimate|||||||2011-06-27|2011-06-28|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Observational|||Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients|The Association of Serum Sclerostin Levels,Echocardiographic Parameters, Arteriovenous Fistula Thrombosis and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients|Unknown status|Not yet recruiting||400|Anticipated|RFM Renal Treatment Services|||1||f||||t||||||||||2018-05-31 22:26:13.098522|2018-05-31 22:26:13.098522
NCT01380873|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||A Pharmacodynamic Study of SLM0807, HKB0701 and CJ30001 in Healthy Subject||Completed||Phase 1|30|Actual|CJ HealthCare Corporation||3|||f||||f||||||||||2018-05-31 22:27:09.954032|2018-05-31 22:27:09.954032
NCT01382953|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-01-07|2011-06-24|2011-06-27|Estimate|||||||2012-01-07|2012-01-10|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||The Simple ECG Monitoring Trial (Comparison of a Novel Recording System With a Standard Holter Monitor)|The Simple ECG Monitoring Trial (Comparison of a Simple ECG Recording System With a Standard ECG Recording System for Holter Monitoring)|Completed|||50|Actual|Seattle Institute for Cardiac Research|||||f||||t||||||||||2018-05-31 22:26:13.21885|2018-05-31 22:26:13.21885
NCT01382940|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2014-01-06||2017-07-05|2011-06-24|2011-06-27|Estimate|2014-01-06|2014-02-19|Estimate||||2017-07-05|2017-08-01|Actual|July 26, 2011|Actual|2011-07-26|July 2017|2017-07-31|January 6, 2013|Actual|2013-01-06|January 6, 2013|Actual|2013-01-06||Interventional|RATE-RA||A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis|A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis|Completed||Phase 4|351|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:26:13.382275|2018-05-31 22:26:13.382275
NCT01382927|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|April 2011||2011-04-30|June 2011|2011-06-30||||||||Observational|||Impact of Spontaneous Breathing on Ventilation Distribution in Obese Patients|Impact of Spontaneous Breathing on Ventilation Distribution in Obese Patients|Unknown status|Recruiting||16|Anticipated|Technische Universität Dresden|||2||f||||f||||||||||2018-05-31 22:26:14.81926|2018-05-31 22:26:14.81926
NCT01382914|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-01-16|2011-06-24|2011-06-27|Estimate|||||||2012-01-16|2012-01-18|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Determination of a Threshold for Mouth Rinse Induced Discoloration of Teeth|Determination of a Threshold for Mouth Rinse Induced Discoloration of Teeth|Completed||N/A|16|Actual|Technische Universität Dresden||1|||f||||f||||||||||2018-05-31 22:26:15.292835|2018-05-31 22:26:15.292835
NCT01382901|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2011-02-23||2018-01-22|2011-05-31|2011-06-27|Estimate|2011-05-31|2011-06-27|Estimate||||2018-01-22|2018-02-20|Estimate|March 2006||2006-03-31|January 2018|2018-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)|A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)|Completed||Phase 2|45|Actual|Luitpold Pharmaceuticals||2|||f||||||||||||||2018-05-31 22:26:15.484687|2018-05-31 22:26:15.484687
NCT01382888|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2014-05-07|2011-06-24|2011-06-27|Estimate|||||||2014-05-07|2014-05-08|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis|Efficacy and Local Tolerability of Topically Applied Heparin (Heparin 2,400 IU /ml Cutaneous Spray) on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis. A Multicentre, Randomized, Double-blind and Placebo-controlled Pilot Study|Terminated||Phase 2|30|Actual|Cyathus Exquirere Pharmaforschungsgmbh||2||The Sponsor decided to terminate the study due to the low patient recruitment.|f||||t||||||||||2018-05-31 22:26:16.752207|2018-05-31 22:26:16.752207
NCT01382875|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-07-27|2011-06-24|2011-06-27|Estimate|||||||2015-07-27|2015-07-29|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Comparison of Comprehensive Multi-disciplinary Program and Conventional Care Program on Fragility Fracture Elderly|Medico-social Impact of a Comprehensive Multi-disciplinary Program for the Care of Fragility Fracture of the Elderly -Implications for Healthcare Policy in Hong Kong|Completed||Phase 3|160|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:26:17.702792|2018-05-31 22:26:17.702792
NCT01382862|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2015-09-14|2011-06-24|2011-06-27|Estimate|||||||2015-09-14|2015-09-15|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|PHANTOM-S||PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study|PHANTOM-S: The Pre-Hospital Acute Neurological Therapy and Optimization of Medical Care in Stroke Patients - Study|Completed||Phase 2|614|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:26:18.393716|2018-05-31 22:26:18.393716
NCT01382849|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-11-17|2011-06-24|2011-06-27|Estimate|||||||2014-11-17|2014-11-19|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)|F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)|Withdrawn|||0|Actual|Sunnybrook Health Sciences Centre|||3||f||||f||||||||||2018-05-31 22:26:18.786315|2018-05-31 22:26:18.786315
NCT01382836|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2015-11-05|2011-06-24|2011-06-27|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||The Role of Epigenetics in Inner City Asthma|The Role of Epigenetics in Inner City Asthma (ICAC-15)|Completed|||200|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||Samples With DNA|"~     DNA, RNA, serum, and plasma specimens~   "|||2018-05-31 22:26:18.857826|2018-05-31 22:26:18.857826
NCT01382823|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-10-05|2011-06-24|2011-06-27|Estimate|||||||2011-10-05|2011-10-06|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Laser Cataract Surgery With the Femtosecond Laser Technology|Laser Cataract Surgery With the Femtosecond Laser Technology|Completed||Phase 4|10|Anticipated|Innovative Medical||1|||f||||f||||||||||2018-05-31 22:26:19.065525|2018-05-31 22:26:19.065525
NCT01382810|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-06-13|2011-06-24|2011-06-27|Estimate|||||||2012-06-13|2012-06-14|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms|A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms|Unknown status|Recruiting|Phase 4|100|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-05-31 22:26:19.443159|2018-05-31 22:26:19.443159
NCT01382797|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24||2012-05-07|2012-06-12|2011-06-24|2011-06-27|Estimate||||2012-06-01|2012-06-06|Estimate|2012-06-12|2012-06-13|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)|A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose Study to Evaluate the Safety, Tolerability, and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation|Completed||Phase 2|157|Actual|Alkermes, Inc.||2|||f||||t||||||||||2018-05-31 22:26:19.73376|2018-05-31 22:26:19.73376
NCT01380171|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-06-24|2011-06-23|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|February 2007||2007-02-28|June 2011|2011-06-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||Primary Palatoplasty in Pediatric Patients - A Retrospective Review of Surgical Outcomes|Primary Palatoplasty in Pediatric Patients - A Retrospective Review of Surgical Outcomes|Completed|||1295|Actual|Children's Healthcare of Atlanta|||1||f||||t||||||||||2018-05-31 22:27:33.735974|2018-05-31 22:27:33.735974
NCT01382784|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|May 2011||2011-05-31|May 2011|2011-05-31||||||||Observational|||Psoriasis and the Risk of Cardiovascular Disease. A Prospective Study|Psoriasis and the Risk of Cardiovascular Disease. A Prospective Observational Study to Detect Cardiovascular Risk Factors|Unknown status|Enrolling by invitation||100|Anticipated|Oslo University Hospital|||||f||||t||||||Samples With DNA|"~     blood, tissue~   "|||2018-05-31 22:26:20.563029|2018-05-31 22:26:20.563029
NCT01382771|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-10-10|2011-06-24|2011-06-27|Estimate|||||||2013-10-10|2013-10-14|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population|A Randomized, Double-Blind, Placebo Controlled Perspective Study of Intraarticular Lumbar Zygapophysial Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population|Completed||Early Phase 1|28|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:26:20.816939|2018-05-31 22:26:20.816939
NCT01382758|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2013-01-17|2011-06-24|2011-06-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Near Infrared Spectroscopy for the Detection of Acute Kidney Injury in Children Following Cardiac Surgery|Use of Near Infrared Spectroscopy (NIRS) for the Early Detection of Acute Kidney Injury in Children Post Cardiopulmonary Bypass|Completed|||107|Actual|University of Colorado, Denver|||2||f||||t||||||Samples Without DNA|"~     Serum, Urine~   "|||2018-05-31 22:26:21.075076|2018-05-31 22:26:21.075076
NCT01382745|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2013-01-25|2011-06-24|2011-06-27|Estimate|||||||2013-01-25|2013-01-28|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|||Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers|A Phase II Clinical Study Using Nimotuzumab in Combination With External Beam Radiation Therapy in the Treatment of Patients With Carcinomas of the Anal Canal|Terminated||Phase 2|1|Actual|Sir Mortimer B. Davis - Jewish General Hospital||1||low recruitment|f||||t||||||||||2018-05-31 22:26:21.366959|2018-05-31 22:26:21.366959
NCT01382732|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2015-01-01|2011-06-24|2011-06-27|Estimate|||||||2015-01-01|2015-01-05|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia|Carbetocin Versus Oxytocin for Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia: a Double Blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|636|Anticipated|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 22:26:21.512851|2018-05-31 22:26:21.512851
NCT01382719|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2013-09-05||2014-12-02|2011-06-24|2011-06-27|Estimate|2014-03-07|2014-04-14|Estimate||||2014-12-02|2014-12-18|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder|A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)|Completed||Phase 2|612|Actual|Palatin Technologies||4|||f||||t||||||||||2018-05-31 22:26:21.822047|2018-05-31 22:26:21.822047
NCT01382706|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-05-10|2011-06-24|2011-06-27|Estimate|||||||2018-05-10|2018-05-16|Actual|June 13, 2011|Actual|2011-06-13|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|July 15, 2013|Actual|2013-07-15||Interventional|||Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder|Single Arm Phase II Study of Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder as Second Line Treatment|Terminated||Phase 2|15|Actual|University of Southern California||1||Trial not progressing toward scientific goals|f||||t|t|f|||f|||||2018-05-31 22:26:24.239388|2018-05-31 22:26:24.239388
NCT01382693|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-07-03|2011-06-24|2011-06-27|Estimate|||||||2012-07-03|2012-07-04|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia|Effects of Involvement in a Group-based Creative Expression Program on Psychotropic Drug Use in Persons With Dementia in Long-term Care: a Cluster-randomized Pilot Study|Completed||N/A|20|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 22:26:24.397714|2018-05-31 22:26:24.397714
NCT01382680|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-12-16|2011-06-24|2011-06-27|Estimate|||||||2013-12-16|2013-12-17|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Comparison of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil and a Nitinol Guide Wire|Comparison of the Use of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil Guide Wire With a Nitinol Wire in Patients With Stenosis of the Bile Ducts in ERCP|Completed||N/A|222|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 22:26:24.499431|2018-05-31 22:26:24.499431
NCT01382667|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2012-11-08|2011-06-24|2011-06-27|Estimate|||||||2012-11-08|2012-11-09|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy|Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis|Completed|||70|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|||1||f||||f||||||Samples Without DNA|"~     whole blood serum~   "|||2018-05-31 22:26:24.602593|2018-05-31 22:26:24.602593
NCT01382654|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23||2011-06-24|2015-10-08|2011-06-24|2011-06-27|Estimate||||2011-06-24|2011-06-29|Estimate|2015-10-08|2015-11-02|Estimate|September 2006||2006-09-30|October 2015|2015-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis||Completed||Phase 2|131|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-05-31 22:26:24.710506|2018-05-31 22:26:24.710506
NCT01382641|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2011-10-05|2011-06-24|2011-06-27|Estimate|||||||2011-10-05|2011-10-06|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery|Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-05-31 22:26:24.80375|2018-05-31 22:26:24.80375
NCT01382459|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2011||2011-07-31|June 2011|2011-06-30||||||||Observational|||Constructed Intervention by Home and School Diabetes Nurse Visits on Diabetic Control of Children With Type I Diabetes|The Efficacy of Constructed Intervention by Home and School Visits by Diabetes Nurses on Diabetic Control of Children With Type I Diabetes|Unknown status|Not yet recruiting||100|Anticipated|Soroka University Medical Center|||2||f||||t||||||||||2018-05-31 22:26:26.878644|2018-05-31 22:26:26.878644
NCT01382628|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2017-07-07|2011-06-24|2011-06-27|Estimate|||||||2017-07-07|2017-07-11|Actual|May 2011||2011-05-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Determination of the Pathophysicologic Collagen Changes in the Diabetic Achilles Tendon|Determination of the Pathophysicologic Collagen Changes in the Diabetic Achilles Tendon.|Suspended|||50|Anticipated|Georgetown University|||5|We are currently trying to find someone to assay the collagen|f||||f||||||Samples Without DNA|"~     A tissue sample (20mg) of the Achilles tendon will be collected at this time. This tissue~     will be preserved in a dry ice container and shipped to Midwestern University for processing~     by the sub-investigator (CC). The specimens will be labeled numerically with a predetermined~     subject number. No patient identifying information will be on these samples.~   "|||2018-05-31 22:26:24.862978|2018-05-31 22:26:24.862978
NCT01382615|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2018-04-23|2011-06-24|2011-06-27|Estimate|||||||2018-04-23|2018-04-25|Actual|August 2010||2010-08-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research|Evaluation of Immune Parameters and Function in Multiple Myeloma Patients and Healthy Individuals' Blood and Marrow Samples|Terminated|||29|Actual|Dartmouth-Hitchcock Medical Center|||2|Unable to fill cohort|f||||t||||||Samples With DNA|"~     15mL of peripheral blood 10mL of bone marrow aspirate~   "|||2018-05-31 22:26:25.029713|2018-05-31 22:26:25.029713
NCT01382602|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2018-03-16|2017-02-02|2018-04-18|2011-06-24|2011-06-27|Estimate|2018-04-18|2018-05-17|Actual|2017-02-02|2017-02-03|Estimate|2018-04-18|2018-05-17|Actual|November 4, 2011|Actual|2011-11-04|April 2018|2018-04-30|January 29, 2017|Actual|2017-01-29|February 3, 2016|Actual|2016-02-03||Interventional||150 subjects were enrolled and 143 subjects received at least 1 treatment of either AMDC-USR or placebo. Analysis population is based on 143 subjects that underwent at least 1 study treatment.|Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study|A Double-blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Effectiveness of Cook MyoSite Incorporated AMDC in Female Patients With Stress Urinary Incontinence|Completed||Phase 3|150|Actual|Cook MyoSite|Planned study enrollment was 246 patients; due to limitations in study design related to the primary efficacy endpoint, enrollment was halted early at 150 subjects.|2|||f||||t|t|f|||t|||||2018-05-31 22:26:25.111173|2018-05-31 22:26:25.111173
NCT01382589|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-03-21|2011-06-24|2011-06-27|Estimate|||||||2013-03-21|2013-03-22|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|NSV||Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo|A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo|Completed||Phase 2|15|Actual|Clinuvel Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 22:26:25.702411|2018-05-31 22:26:25.702411
NCT01382576|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2012-03-09|2011-06-24|2011-06-27|Estimate|||||||2012-03-09|2012-03-12|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity|Women With Polycystic Ovary Syndrome Have Increased Plasma Chitotriosidase Activity: A Pathophysiological Link Between Inflammation and Impaired Insulin Sensitivity?|Completed|||78|Actual|Gulhane School of Medicine|||2||f||||f||||||None Retained|"~     No biospecimens were to be retained~   "|||2018-05-31 22:26:25.802458|2018-05-31 22:26:25.802458
NCT01382563|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2017-01-20|2011-06-24|2011-06-27|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|June 2051|Anticipated|2051-06-30|December 2050|Anticipated|2050-12-31||Observational|EoE||Registry for Eosinophilic Gastrointestinal Disorders (REGID)|Registry for Eosinophilic Gastrointestinal Disorders (REGID)|Active, not recruiting|||10000|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-05-31 22:26:25.960909|2018-05-31 22:26:25.960909
NCT01382550|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-09-12|2011-06-24|2011-06-27|Estimate|||||||2012-09-12|2012-09-13|Estimate|March 1993||1993-03-31|September 2012|2012-09-30||||September 2012|Actual|2012-09-30||Observational|||Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.|Prevention of Recurrent Venous Thromboembolism in Patients With Low Circulating Levels of Antithrombin. Extended Anticoagulation vs 12-Month Oral Anticoagulation|Unknown status|Recruiting||900|Anticipated|Federico II University|||1||f||||t||||||||||2018-05-31 22:26:26.143186|2018-05-31 22:26:26.143186
NCT01382537|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2014-07-24|2011-06-24|2011-06-27|Estimate|||||||2014-07-24|2014-07-25|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy of the InterX 5000 in the Treatment of Chronic Neck Pain|Evaluation of the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain|Completed||N/A|89|Actual|Canadian Memorial Chiropractic College||2|||f||||f||||||||||2018-05-31 22:26:26.281218|2018-05-31 22:26:26.281218
NCT01382524|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2013-06-12|2011-06-24|2011-06-27|Estimate|||||||2013-06-12|2013-06-13|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Observational|PIV Secural||Peripheral Intravenous Catheter Complication Rate Comparison of Two Different Catheter-Stabilization Systems|Peripheral I.V. Catheter Complication Rate Comparison of Two Different Catheter-Stabilization Systems|Completed|||682|Actual|3M|||2||f||||f||||||||||2018-05-31 22:26:26.413493|2018-05-31 22:26:26.413493
NCT01382511|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|July 2011||2011-07-31|October 2009|2009-10-31||||December 2014|Anticipated|2014-12-31||Interventional|||Simvastatin Treatment of Pachyonychia Congenita|Simvastatin Treatment of Pachyonychia Congenita|Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-05-31 22:26:26.510747|2018-05-31 22:26:26.510747
NCT01382498|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2009||2009-11-30|April 2011|2011-04-30||||June 2011|Anticipated|2011-06-30||Interventional|||Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy||Unknown status|Enrolling by invitation|Phase 4|90|Actual|Tabriz University||2|||f||||||||||||||2018-05-31 22:26:26.553771|2018-05-31 22:26:26.553771
NCT01382485|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2018-02-21|2011-06-23|2011-06-27|Estimate|||||||2018-02-21|2018-02-22|Actual|August 2012||2012-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Reamer Irrigator Aspirator (RIA) vs Autogenous Iliac Crest Bone Graft (AICBG) for the Treatment of Non-unions|Reamer Irrigator Aspirator Versus Autogenous Iliac Crest Bone Graft for the Treatment of Non-Unions: A Multi-Centre Randomized Controlled Trial|Recruiting||N/A|104|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 22:26:26.615694|2018-05-31 22:26:26.615694
NCT01382472|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2016-08-24|2011-06-24|2011-06-27|Estimate|||||||2016-08-24|2016-08-25|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|MICROS||Microcirculation In Acute Coronary Syndromes|MICROS-Pilot Study Microcirculation In Acute Coronary Syndromes; Effect of Pre-treatment of High Dose Rosuvastatin on Coronary Microcirculation in Primary PCI|Recruiting||Phase 4|40|Anticipated|Helse Stavanger HF||2|||f||||f||||||||No||2018-05-31 22:26:26.720123|2018-05-31 22:26:26.720123
NCT01382446|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2013-07-24||2016-12-12|2011-06-24|2011-06-27|Estimate|2013-09-27|2013-11-28|Estimate||||2016-12-12|2017-02-06|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Chlorhexidine Gluconate Oral Care for Adults Experiencing Trauma|Evaluating Effectiveness of Chlorhexidine Gluconate Oral Care for Adults|Completed||N/A|66|Actual|St. Joseph's Hospital and Medical Center, Phoenix|Enrolling of trauma patients - consenting patients with unknown identification or next of kin status led to small number of subjects analyzed|2|||f||||f||||||||||2018-05-31 22:26:26.995758|2018-05-31 22:26:26.995758
NCT01382433|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-12-29|2011-06-24|2011-06-27|Estimate|||||||2011-12-29|2012-01-02|Estimate|July 2011||2011-07-31|December 2011|2011-12-31||||July 2012|Anticipated|2012-07-31||Interventional|||Chronic Cannabis Users: A Model for Negative Symptoms in Schizophrenia|Clinical Assessment of Negative Symptoms Neurocognitive and Electrophysiological Characteristics in Chronic Cannabis Users|Unknown status|Recruiting|N/A|115|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 22:26:27.426185|2018-05-31 22:26:27.426185
NCT01382420|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2015-11-16|2011-06-23|2011-06-27|Estimate|||||||2015-11-16|2015-11-17|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Long-term Beneficial Metabolic Effects of Adrenalectomy in Subclinical Cushing's Syndrome of Adrenal Incidentaloma|Long-term Effects of Adrenalectomy on Metabolic Syndrome, Glucose Metabolism, Lipid Metabolism, and Bone Metabolism in Subclinical Cushing's Syndrome of Adrenal Incidentaloma|Unknown status|Recruiting|N/A|234|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 22:26:27.587841|2018-05-31 22:26:27.587841
NCT01382407|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-04-26|2011-06-24|2011-06-27|Estimate|||||||2017-04-26|2017-04-27|Actual|July 2011||2011-07-31|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab|Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab?|Completed|||100|Actual|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 22:26:27.66222|2018-05-31 22:26:27.66222
NCT01382394|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-08-03|2011-06-24|2011-06-27|Estimate|||||||2011-08-03|2011-08-04|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Impact of Clinical, Demographic and Laboratory Variables on Brain Natriuretic Peptide Levels|Impact of Clinical, Demographic and Laboratory Variables on Brain Natriuretic Peptide Levels|Withdrawn|||60|Actual|Rambam Health Care Campus|||1|No Patients were recruited during the study period|f||||f||||||||||2018-05-31 22:26:27.739169|2018-05-31 22:26:27.739169
NCT01382381|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2011||2011-07-31|February 2011|2011-02-28|July 2012|Anticipated|2012-07-31|||||Observational|||Intravascular Stents Fracture Effects|Evaluation of Implanted Aortic Arch and Branch Pulmonary Artery Stents Durability and Function|Unknown status|Not yet recruiting||20|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 22:26:27.794318|2018-05-31 22:26:27.794318
NCT01382368|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2012-11-13|2011-06-23|2011-06-27|Estimate|||||||2012-11-13|2012-11-15|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|September 2013|Anticipated|2013-09-30|November 2012|Anticipated|2012-11-30||Interventional|||Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients|Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients|Unknown status|Enrolling by invitation|Phase 4|60|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 22:26:27.991961|2018-05-31 22:26:27.991961
NCT01382355|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-08-02|2011-06-23|2011-06-27|Estimate|||||||2011-08-02|2011-08-04|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Prospective Donor Specific Antibody (DSA) Monitoring Protocol|Prospective Donor Specific Antibody (DSA) Monitoring Protocol To Detect Patient Characteristics and /or Changes In Immunosuppression on the Development of De Novo Antibodies|Unknown status|Recruiting||60|Anticipated|Providence Health & Services|||1||f||||f||||||Samples With DNA|"~     1 ml aliquots of serum collected at specified time points~   "|||2018-05-31 22:26:28.103896|2018-05-31 22:26:28.103896
NCT01382342|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-02-03|2011-06-24|2011-06-27|Estimate|||||||2015-02-03|2015-02-05|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effect of Rasagiline on Cognition in Parkinson's Disease||Completed||Phase 4|50|Actual|Brown University||2|||f||||f||||||||||2018-05-31 22:26:28.208446|2018-05-31 22:26:28.208446
NCT01382329|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2015-10-07|2011-06-24|2011-06-27|Estimate|||||||2015-10-07|2015-10-09|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|||H5N1 Vaccine Study in Japanese Adults|A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years|Completed||Phase 2/Phase 3|340|Actual|Ology Bioservices||4|||f||||t||||||||||2018-05-31 22:26:28.304079|2018-05-31 22:26:28.304079
NCT01382316|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2005||2005-07-31|June 2011|2011-06-30|August 2007|Actual|2007-08-31|May 2006|Actual|2006-05-31||Interventional|MAAEZ||Making Alcoholics Anonymous Easier|Making Alcoholics Anonymous Easier: A Group TSF Approach|Completed||Phase 3|508|Actual|Alcohol Research Group||2|||f||||t||||||||||2018-05-31 22:26:28.399813|2018-05-31 22:26:28.399813
NCT01382303|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2017-02-13||2017-03-31|2011-06-24|2011-06-27|Estimate|2017-03-31|2017-06-16|Actual||||2017-03-31|2017-06-16|Actual|October 25, 2010|Actual|2010-10-25|March 2017|2017-03-31|December 20, 2013|Actual|2013-12-20|December 20, 2013|Actual|2013-12-20||Interventional|||Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients|Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients : Prospective, Randomized, Double Blinded Active Control, Multicenter Study|Completed||Phase 4|174|Actual|Ajou University School of Medicine||2|||f||||t||||||||No||2018-05-31 22:26:28.567035|2018-05-31 22:26:28.567035
NCT01382290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-05|2011-06-24|2011-06-27|Estimate|||||||2016-08-05|2016-08-09|Estimate|March 2008||2008-03-31|August 2016|2016-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MRIS||Magnetic Resonance Imaging of the Spine|Magnetic Resonance Imaging of the Spine|Withdrawn||N/A|0|Actual|Children's Healthcare of Atlanta||||No patients were enrolled, due to logistic difficulties, no funding was acquired.|f||||f||||||||||2018-05-31 22:26:29.24039|2018-05-31 22:26:29.24039
NCT01382277|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|REDUCT||Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume|Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia|Unknown status|Recruiting|Phase 4|600|Anticipated|Peking University First Hospital||1|||f||||t||||||||||2018-05-31 22:26:29.347812|2018-05-31 22:26:29.347812
NCT01382264|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|CADS||Use of a Computer-Assisted Decision Support (CADS) System in Management of Patients With Type 2 Diabetes|The Use of a Computer-Assisted Decision Support (CADS) System to Improve Outcomes in Patients With Type 2 Diabetes|Unknown status|Not yet recruiting|N/A|570|Anticipated|Walter Reed Army Medical Center||1|||f||||t||||||||||2018-05-31 22:26:29.443925|2018-05-31 22:26:29.443925
NCT01382251|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2013-07-03||2013-12-17|2011-06-23|2011-06-27|Estimate|2013-12-17|2014-01-20|Estimate||||2013-12-17|2014-01-20|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|FOCUS|Demographic characteristics shown for those patients and caregivers completing study|Functional Recovery and Caregiver Burden Following Surgery in the Elderly|Functional Recovery and Caregiver Burden Following Surgery in the Elderly|Completed|||123|Actual|Ottawa Hospital Research Institute|Single center, relatively infrequent assessment, assessment of caregiver burden limited to primary caregiver, majority of caregivers were not employed outside the home.||2||f||||f||||||||||2018-05-31 22:26:29.671999|2018-05-31 22:26:29.671999
NCT01382238|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-09-15|2011-06-23|2011-06-27|Estimate|||||||2011-09-15|2011-09-19|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir|Relative Bioavailability Study of a Tablet Formulation vs. Pediatric Granule Formulation of Dolutegravir 50 mg and Effect of Different Types of Water Plus Infant Formula on the Pediatric Granule Formulation in Healthy Male and Female Volunteers|Completed||Phase 1|20|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 22:26:30.181908|2018-05-31 22:26:30.181908
NCT01382225|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2013-05-20||2013-05-20|2011-06-24|2011-06-27|Estimate|2013-05-20|2013-07-08|Estimate||||2013-05-20|2013-07-08|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Of the 1454 subjects randomized, 4 withdrew participation prior to exposure to test article. This reporting group includes the 1450 subjects exposed to test article.|Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome|A Phase 3 Multicenter, Randomized, Controlled, Double-Masked Study of Safety and Efficacy of Sodium Hyaluronate Ophthalmic Solution, 0.18% in Dry Eye Syndrome|Completed||Phase 3|1936|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:26:30.350577|2018-05-31 22:26:30.350577
NCT01382212|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2016-09-16|2016-04-22|2016-11-08|2011-06-24|2011-06-27|Estimate|2016-11-08|2016-11-21|Estimate|2016-04-22|2016-05-23|Estimate|2016-11-08|2016-11-21|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis|A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis|Completed||Phase 3|13|Actual|AbbVie|The sample size of the study was limited to 13 subjects and there was no comparator group, so the study was not designed to analyze efficacy.|1|||f||||f||||||||||2018-05-31 22:26:31.021278|2018-05-31 22:26:31.021278
NCT01382199|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|March 2014|Anticipated|2014-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients|A Phase III Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients|Unknown status|Not yet recruiting|Phase 3|340|Anticipated|Ventria Bioscience||1|||f||||t||||||||||2018-05-31 22:26:31.802042|2018-05-31 22:26:31.802042
NCT01382186|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|2014-10-28||2015-04-06|2011-06-24|2011-06-27|Estimate|2015-02-04|2015-02-23|Estimate||||2015-04-06|2015-04-28|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational||Participants were Veterans registered for My HealtheVet and opted-in to use Secure Messaging in the Tampa FL and Boston MA areas.|Veterans Experiences Using Secure Messaging|Veterans' Experiences Using Secure Messaging on MyHealtheVet|Completed|||852|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-05-31 22:26:31.877009|2018-05-31 22:26:31.877009
NCT01382173|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-09-10|2011-06-23|2011-06-27|Estimate|||||||2015-09-10|2015-09-11|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Observational|||Monitoring of Acute Knee Injuries to Understand Osteoarthritis Development|The Acute Knee Injury Project|Recruiting|||600|Anticipated|Lund University|||||f||||f||||||Samples Without DNA|"~     Joint fluid, Serum & Plasma~   "|||2018-05-31 22:26:32.276801|2018-05-31 22:26:32.276801
NCT01382160|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2013-10-01|2011-06-23|2011-06-27|Estimate|||||||2013-10-01|2013-10-07|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|AFORA||Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)|Serum Concentration of Adalimumab (Humira) as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)|Completed||Phase 4|69|Actual|University Hospital, Tours||1|||f||||t||||||||||2018-05-31 22:26:32.332278|2018-05-31 22:26:32.332278
NCT01382147|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-12-04|2011-06-24|2011-06-27|Estimate|||||||2017-12-04|2017-12-06|Actual|July 1, 2009|Actual|2009-07-01|December 2017|2017-12-31|July 5, 2017|Actual|2017-07-05|August 2012|Actual|2012-08-31||Interventional|AMLCG 2008||"Evaluation of Dose-dense Therapy by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)"|A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia|Completed||Phase 3|396|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 22:26:32.662928|2018-05-31 22:26:32.662928
NCT01382134|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-11-14|2011-06-23|2011-06-27|Estimate|||||||2013-11-14|2013-11-15|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Interventional|||Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction|Effect of Aspirin, in Vitro Hemodilution and Desmopressin on Platelet Dysfunction Associated With Mild Hypothermia in Healthy Volunteers|Completed||N/A|60|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 22:26:32.826446|2018-05-31 22:26:32.826446
NCT01382121|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-06-25|2011-06-23|2011-06-27|Estimate|||||||2012-06-25|2012-06-26|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|AFAP||Adolescent Fitness Assessment Program|Increasing Self-efficacy and VO2 Max Scores in Obese Adolescents: a Peer Modeling Intervention|Completed||Early Phase 1|49|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 22:26:32.925002|2018-05-31 22:26:32.925002
NCT01382095|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-04-24|2011-06-24|2011-06-27|Estimate|||||||2015-04-24|2015-04-27|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional|||Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea|A Phase 1 Dose-Escalating Study of dscCfaE, Co-Administered With and Without LTR192G, by Transcutaneous Immunization (TCI) in Healthy Adult U.S. Volunteers|Completed||Phase 1|40|Actual|U.S. Army Medical Research and Materiel Command||4|||f||||f||||||||||2018-05-31 22:26:33.488572|2018-05-31 22:26:33.488572
NCT01382082|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-01-08|2011-06-24|2011-06-27|Estimate|||||||2018-01-08|2018-01-09|Actual|May 17, 2011|Actual|2011-05-17|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|CANTAB||Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy|Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment,Post-Treatment and at Six Months Follow Up|Active, not recruiting|||1432|Anticipated|University of Rochester|||3||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 22:26:33.62904|2018-05-31 22:26:33.62904
NCT01382069|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2017-06-29|2011-06-23|2011-06-27|Estimate|||||||2017-06-29|2017-07-02|Actual|March 2012||2012-03-31|July 2016|2016-07-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|DMAUPhase1||Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men|Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men|Completed||Phase 1|100|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-05-31 22:26:33.73592|2018-05-31 22:26:33.73592
NCT01382056|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2014-02-11|2011-06-23|2011-06-27|Estimate|||||||2014-02-11|2014-02-12|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PULV-2011||Effects of Pulse Varieties on Blood Vessel Function in Peripheral Artery Disease|Effects of Pulse Varieties on Blood Vessel Function in Individuals With Peripheral Artery Disease (PAD)|Completed||N/A|62|Actual|University of Manitoba||3|||f||||f||||||||||2018-05-31 22:26:33.887012|2018-05-31 22:26:33.887012
NCT01382043|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-03-19|2011-06-24|2011-06-27|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2009||2009-06-30|June 2011|2011-06-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Observational|||Angiographic and IVUS Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals (AIFSIDDES)||Completed|||48|Actual|Liuhuaqiao Hospital|||2||f||||f||||||||||2018-05-31 22:26:34.300581|2018-05-31 22:26:34.300581
NCT01382030|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|June 2005||2005-06-30|June 2011|2011-06-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|NeoWTS||Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma|A Phase II Study Evaluating Neo-/Adjuvant EIA Chemotherapy, Surgical Resection and Radiotherapy in High-risk Soft Tissue Sarcoma|Completed||Phase 2|50|Actual|Heidelberg University||1|||f||||t||||||||||2018-05-31 22:26:34.63925|2018-05-31 22:26:34.63925
NCT01382017|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-08-28|2011-06-24|2011-06-27|Estimate|||||||2012-08-28|2012-08-29|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study||Completed||N/A|18|Actual|University of Kiel||4|||f||||t||||||||||2018-05-31 22:26:34.993709|2018-05-31 22:26:34.993709
NCT01382004|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-04-11|2011-06-24|2011-06-27|Estimate|||||||2012-04-11|2012-04-13|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Single-dose Azithromycin for the Treatment of Yaws|Single-dose Azithromycin Versus Penicillin G Benzathine for the Treatment of Yaws in Children|Completed||Phase 3|255|Actual|Lihir Medical Centre||2|||f||||f||||||||||2018-05-31 22:26:35.31349|2018-05-31 22:26:35.31349
NCT01381991|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||The Efficacy of i-Scan for Detecting Reflux Esophagitis|A Prospective Randomized Controlled Trial of the Efficacy of i-Scan for Detecting Reflux Esophagitis|Completed||N/A|500|Anticipated|Konkuk University Hospital||1|||f||||f||||||||||2018-05-31 22:26:35.655492|2018-05-31 22:26:35.655492
NCT01381978|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-05-21|2011-06-24|2011-06-27|Estimate|||||||2012-05-21|2012-05-23|Estimate|October 2010||2010-10-31|May 2012|2012-05-31||||||||Observational|||Obesity Childhood in Cuenca-Ecuador: Prevalence and Risk Factors|Baseline Study. Obesity Childhood in Cuenca-Ecuador: Prevalence and Risk Factors|Completed|||700|Actual|Universidad de Cuenca|||||f||||||||||||||2018-05-31 22:26:35.753855|2018-05-31 22:26:35.753855
NCT01381965|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-07-31|2011-06-23|2011-06-27|Estimate|||||||2012-07-31|2012-08-02|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|||Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery|Foveal Cone Outer Segment Resumption to Predict Visual Recovery After Macular Hole Surgery|Completed||N/A|72|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 22:26:35.815947|2018-05-31 22:26:35.815947
NCT01381952|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2014-01-28||2014-04-23|2011-06-23|2011-06-27|Estimate|2014-04-23|2014-05-22|Estimate||||2014-04-23|2014-05-22|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Image Quality and Radiation Dose in Angiography|XRES4 Neuro Claim Study|Completed||N/A|20|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 22:26:35.919665|2018-05-31 22:26:35.919665
NCT01381939|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|January 2000||2000-01-31|March 2010|2010-03-31|April 2010|Actual|2010-04-30|December 2006|Actual|2006-12-31||Observational|ILICP||Induction of Labor in Intrahepatic Cholestasis of Pregnancy|Induction of Labor in Intrahepatic Cholestasis of Pregnancy|Completed|||5000|Anticipated|Karolinska Institutet|||3||f||||f||||||||||2018-05-31 22:26:36.315307|2018-05-31 22:26:36.315307
NCT01381926|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2017-01-14||2017-05-19|2011-06-23|2011-06-27|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|February 2011||2011-02-28|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|CMBD|This is a crossover study. Not all patients completed both arms of the study. 14 patients were screened. 10 presented for the baseline study and were provided some study medication. 1 participant's specimen was not analyzed and she is not included in analysis for that reason. 5 started Exenatide; 5 started Placebo.|Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist|Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist (UAB Core Center for Basic Skeletal Research)|Terminated||Phase 4|14|Actual|University of Alabama at Birmingham|Study was closed due to unavailability of study drug/matching placebo prior to recruitment of target participants. The original drug company was bought and new company was unwilling to supply medication. Small participant number limits data analysis.|2||unavailability of study drug and matching placebo|f||||f|t|f||||||Undecided||2018-05-31 22:26:36.380688|2018-05-31 22:26:36.380688
NCT00931177|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2011-09-02|2009-07-01|2009-07-02|Estimate|||||||2011-09-02|2011-09-05|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Observational|VDSS||Validation of a Dehydration Scoring System|Validation of a Dehydration Scoring System|Completed|||102|Actual|Phoenix Children's Hospital|||1||f||||f||||||||||2018-06-01 00:49:53.474165|2018-06-01 00:49:53.474165
NCT01381913|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|May 2011|Actual|2011-05-31|December 2008|Actual|2008-12-31||Observational|||Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer|Feasibility Trial of Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer Combined With Adjacent Tissue Invasion|Completed|||12|Actual|Kagawa University|||||f||||f||||||Samples Without DNA|"~     tissue~   "|||2018-05-31 22:26:37.186025|2018-05-31 22:26:37.186025
NCT01381900|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2013-11-21||2014-04-23|2011-06-24|2011-06-27|Estimate|2013-11-21|2014-01-09|Estimate||||2014-04-23|2014-05-09|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea|Completed||Phase 3|678|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 22:26:37.441902|2018-05-31 22:26:37.441902
NCT01381887|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-04-19|2011-06-24|2011-06-27|Estimate|||||||2013-04-19|2013-04-22|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Placebo-Controlled, Randomized, Crossover, Multicenter Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|37|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-05-31 22:26:40.268663|2018-05-31 22:26:40.268663
NCT01381874|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-12-07|2011-06-23|2011-06-27|Estimate|||||||2017-12-07|2017-12-11|Actual|August 24, 2011|Actual|2011-08-24|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|May 9, 2017|Actual|2017-05-09||Interventional|||A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy|Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy|Active, not recruiting||Phase 2|299|Actual|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-05-31 22:26:40.474641|2018-05-31 22:26:40.474641
NCT01381861|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-12-03|2011-06-23|2011-06-27|Estimate|||||||2013-12-03|2013-12-05|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|23|Actual|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 22:26:40.757272|2018-05-31 22:26:40.757272
NCT01381848|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2013-01-08|2011-06-24|2011-06-27|Estimate|||||||2013-01-08|2013-01-10|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of Doripenem in Infants Less Than 12 Weeks of Age|An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age|Completed||Phase 1|52|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 22:26:40.847|2018-05-31 22:26:40.847
NCT01381835|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-10-11|2011-06-23|2011-06-27|Estimate|||||||2013-10-11|2013-10-14|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|January 2012|Actual|2012-01-31|||||Interventional|||TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435|Phase I, Open-label Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435|Completed||Phase 1|16|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||t||||||||||2018-05-31 22:26:41.046971|2018-05-31 22:26:41.046971
NCT01381822|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-04-18|2011-06-24|2011-06-27|Estimate|||||||2014-04-18|2014-04-21|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|TH-CR-410||Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors|A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination With Sunitinib in Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors|Unknown status|Active, not recruiting|Phase 1|58|Anticipated|Threshold Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:26:41.154234|2018-05-31 22:26:41.154234
NCT01381809|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-03-14|2011-06-23|2011-06-27|Estimate|||||||2016-03-14|2016-03-16|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|||An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes|Completed||Phase 3|130|Actual|Janssen-Cilag International NV||2|||f||||t||||||||||2018-05-31 22:26:41.340506|2018-05-31 22:26:41.340506
NCT01381796|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-10-10|2011-06-23|2011-06-27|Estimate|||||||2017-10-10|2017-10-12|Actual|December 2009||2009-12-31|October 2017|2017-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults|A Phase I, Single Center, Open Label, Randomized, Single-Dose, Three-Way Crossover Study to Compare the Pharmacokinetics and Bioavailability of Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex in Healthy Volunteers and to Collect Resistance Data During Application of NP101|Completed||Phase 1|63|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-05-31 22:26:42.891729|2018-05-31 22:26:42.891729
NCT01381783|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|January 2006||2006-01-31|March 2011|2011-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phacoemulsification Under Topical Anesthesia and Its Complications||Completed||Phase 1|111|Anticipated|Instituto de Oftalmologia Ivo Correa-Meyer||1|||f||||t||||||||||2018-05-31 22:26:43.137333|2018-05-31 22:26:43.137333
NCT01381770|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-08-24|2011-06-24|2011-06-27|Estimate|||||||2015-08-24|2015-08-25|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Platelet-derived Factors for Treatment of Muscular Lesions|Platelet-derived Factors for Treatment of Muscular Lesions: a Phase II Trial|Completed||Phase 2|25|Actual|IRCCS Policlinico S. Matteo||1|||f||||f||||||||||2018-05-31 22:26:43.354219|2018-05-31 22:26:43.354219
NCT00923221|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-02-22|2009-06-17|2009-06-18|Estimate|||||||2018-02-22|2018-02-23|Actual|March 1, 2007||2007-03-01|September 27, 2017|2017-09-27||||||||Observational|||Collection of Blood From Patients With Prostate Cancer|Collection of Blood From Patients With Prostate Cancer|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:21.50436|2018-06-01 00:52:21.50436
NCT01381757|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-04-04|2011-06-23|2011-06-27|Estimate|||||||2018-04-04|2018-04-05|Actual|May 31, 2011||2011-05-31|March 5, 2013|2013-03-05|March 5, 2013||2013-03-05|||||Observational|||Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali|Uitlity of MODS for the Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali|Terminated|||34|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:26:43.417325|2018-05-31 22:26:43.417325
NCT01381744|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-01-28|2011-06-23|2011-06-27|Estimate|||||||2016-01-28|2016-01-29|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers|A Phase I Safety and Immunogenicity Dose Escalation Trial of Plague Vaccine, Flagellin/F1/V, In Healthy Adult Volunteers|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 22:26:43.491263|2018-05-31 22:26:43.491263
NCT01381731|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23||2011-06-24|2015-10-29|2011-06-24|2011-06-27|Estimate||||2011-06-24|2011-06-29|Estimate|2015-10-29|2015-11-25|Estimate|April 2005||2005-04-30|October 2015|2015-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Double-masked, Randomized, Placebo-controlled,Pilot Study of Diquafosol Tetrasodium in Subjects Following Photorefractive Keratectomy (PRK)||Terminated||Phase 2|14|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-05-31 22:26:43.579728|2018-05-31 22:26:43.579728
NCT01381718|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-10-25|2011-06-23|2011-06-27|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2011||2011-08-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor|A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor|Completed||Phase 2|123|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 22:26:43.669572|2018-05-31 22:26:43.669572
NCT01381705|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-05-16|2011-06-23|2011-06-27|Estimate|||||||2017-05-16|2017-05-17|Actual|February 6, 2012|Actual|2012-02-06|May 2017|2017-05-31|July 6, 2012|Actual|2012-07-06|July 6, 2012|Actual|2012-07-06||Observational|||Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma|Validating the Predictive Value (of Response to Rituximab Induction and Maintenance) of the FCGR3A 158V/F Polymorphism Using Complimentary Genotyping Methods|Completed|||259|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 22:26:44.070802|2018-05-31 22:26:44.070802
NCT01381692|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-05-24|2011-06-23|2011-06-27|Estimate|||||||2018-05-24|2018-05-25|Actual|July 20, 2011|Actual|2011-07-20|May 2018|2018-05-31||||June 1, 2020|Anticipated|2020-06-01||Interventional|||Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma|A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom Macroglobulinemia (Phase II)|Active, not recruiting||Phase 1/Phase 2|144|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 22:26:44.182932|2018-05-31 22:26:44.182932
NCT01381679|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2011-11-23||2015-10-12|2011-06-24|2011-06-27|Estimate|2012-02-17|2012-03-22|Estimate||||2015-10-12|2015-10-14|Estimate|May 2009||2009-05-31|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ACT II||Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)|Austrian Cholesterol Screening And Treatment II (ACT II)|Completed|||1682|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:26:44.423996|2018-05-31 22:26:44.423996
NCT01381666|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23||2011-06-24|2015-10-07|2011-06-24|2011-06-27|Estimate||||2011-06-24|2011-06-29|Estimate|2015-10-07|2015-10-29|Estimate|January 2003||2003-01-31|October 2015|2015-10-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)||Terminated||Phase 2|22|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-05-31 22:26:44.714068|2018-05-31 22:26:44.714068
NCT01381653|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-05-30|2011-06-24|2011-06-27|Estimate|||||||2013-05-30|2013-06-03|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||An Innovative HIV Prevention Intervention Using Social Networking Technology|An Innovative HIV Prevention Intervention Using Social Networking Technology|Completed||N/A|60|Actual|Hunter College of City University of New York||1|||f||||t||||||||||2018-05-31 22:26:44.779752|2018-05-31 22:26:44.779752
NCT01381640|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-07-05|2011-06-23|2011-06-27|Estimate|||||||2016-07-05|2016-07-06|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||A Study to Compare Two Paracetamol Tablets|A Single Dose Pharmacoscintigraphic Study Investigating the Differences in Gastrointestinal Behavior and Paracetamol Absorption Between Sustained Release Formula and Standard Release Formula|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2||Study was cancelled prior to enrolling any subjects.|f||||f||||||||||2018-05-31 22:26:44.850939|2018-05-31 22:26:44.850939
NCT01381627|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-02-27|2011-06-23|2011-06-27|Estimate|||||||2013-02-27|2013-02-28|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|EBUSed||Safety Evaluation of Dexmedetomidine for EBUS-TBNA|Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration|Unknown status|Recruiting|Phase 4|60|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||||2018-05-31 22:26:44.917203|2018-05-31 22:26:44.917203
NCT01381614|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-05-09|2011-06-23|2011-06-27|Estimate|||||||2013-05-09|2013-05-13|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)|Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:45.006525|2018-05-31 22:26:45.006525
NCT01381601|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-05-09|2011-06-23|2011-06-27|Estimate|||||||2013-05-09|2013-05-13|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)|Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:45.076609|2018-05-31 22:26:45.076609
NCT01381588|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-05-15|2011-06-23|2011-06-27|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2010||2010-10-31|May 2017|2017-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|TOP||The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women|The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women|Completed|||1136|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:45.273033|2018-05-31 22:26:45.273033
NCT01381575|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2013-06-28||2017-03-13|2011-06-23|2011-06-27|Estimate|2013-10-04|2013-12-05|Estimate||||2017-03-13|2017-04-25|Actual|June 2011||2011-06-30|January 2017|2017-01-31|November 2014|Actual|2014-11-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine When Administered According to Alternative 2-dose Schedules in 9 - 14 Year Old Females|Completed||Phase 3|1447|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:26:45.5009|2018-05-31 22:26:45.5009
NCT01381562|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2017-09-21|2012-11-15|2017-10-23|2011-06-23|2011-06-27|Estimate|2017-10-23|2017-11-29|Actual|2013-06-13|2013-06-21|Estimate|2017-10-23|2017-11-29|Actual|October 3, 2011|Actual|2011-10-03|October 2017|2017-10-31|March 5, 2012|Actual|2012-03-05|March 5, 2012|Actual|2012-03-05||Interventional|||GSK2251052 in the Treatment of Complicated Intra-abdominal Infections|A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the Treatment of Complicated Intra-abdominal Infection in Adults|Terminated||Phase 2|15|Actual|GlaxoSmithKline|This study was terminated early because only 15 participants were enrolled.|3||"Microbiological findings of resistance on therapy in patients with complicated urinary tract~   infection"|f||||t||||||||||2018-05-31 22:26:49.151471|2018-05-31 22:26:49.151471
NCT01381549|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2017-08-09|2012-11-15|2017-08-09|2011-06-23|2011-06-27|Estimate|2017-08-09|2017-09-08|Actual|2013-06-13|2013-06-21|Estimate|2017-08-09|2017-09-08|Actual|June 28, 2011|Actual|2011-06-28|August 2017|2017-08-31|March 6, 2012|Actual|2012-03-06|March 6, 2012|Actual|2012-03-06||Interventional|||GSK2251052 in Complicated Urinary Tract Infection|A Randomised, Double-blind, Dose-finding, Multicenter Study of the Safety, Tolerability, and Efficacy of GSK2251052 Therapy Compared to Imipenem-cilastatin in the Treatment of Adult Subjects With Febrile Complicated Lower Urinary Tract Infections and Acute Pyelonephritis|Terminated||Phase 2|20|Actual|GlaxoSmithKline||3||"Microbiological findings of resistance on therapy in patients with complicated urinary tract~   infection"|f||||t||||||||||2018-05-31 22:26:50.982249|2018-05-31 22:26:50.982249
NCT01381536|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-06-09|2011-06-23|2011-06-27|Estimate|||||||2017-06-09|2017-06-12|Actual|July 20, 2010|Actual|2010-07-20|June 2017|2017-06-30|November 27, 2010|Actual|2010-11-27|November 27, 2010|Actual|2010-11-27||Interventional|||Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)|GSK1550188, A Randomised, Single-blind, Placebo Controlled, Dose Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:26:53.475463|2018-05-31 22:26:53.475463
NCT01381523|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-02-21|2011-06-23|2011-06-27|Estimate|||||||2013-02-21|2013-02-25|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data|A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:26:53.624116|2018-05-31 22:26:53.624116
NCT01381510|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-08-23|2011-06-23|2011-06-27|Estimate|||||||2012-08-23|2012-08-27|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database|Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database|Completed|||54459|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:26:53.703377|2018-05-31 22:26:53.703377
NCT01381497|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-08-23|2011-06-24|2011-06-27|Estimate|||||||2012-08-23|2012-08-27|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy|Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:53.822106|2018-05-31 22:26:53.822106
NCT01381484|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Argireline in Treatment of Periorbital Wrinkles|Efficacy and Safety of Topical Argireline in the Treatment of Periorbital Wrinkles|Completed||Phase 3|70|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 22:26:54.039909|2018-05-31 22:26:54.039909
NCT01381471|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2012-02-02||2012-03-15|2011-06-24|2011-06-27|Estimate|2012-02-02|2012-03-07|Estimate||||2012-03-15|2012-03-29|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||11060|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:54.264518|2018-05-31 22:26:54.264518
NCT01381458|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-05-19|2011-06-23|2011-06-27|Estimate|||||||2017-05-19|2017-05-22|Actual|September 2010||2010-09-30|May 2017|2017-05-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Observational|||Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation|Differences in the Risk of Re-hospitalization and Other COPD-related (Chronic Obstructive Pulmonary Disease) Exacerbations and Costs for Patients Receiving Fluticasone Propionate-salmeterol Xinafoate Combination 250/50mcg (FSC) Versus Anticholinergics [i.e. Tiotropium (TIO) and Ipratropium or Combination Ipratropium-albuterol (IPR) Post-hospitalization or ED Visit for the Treatment of COPD.|Completed|||1936|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:54.812881|2018-05-31 22:26:54.812881
NCT01381445|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-07-18|2011-06-23|2011-06-27|Estimate|||||||2017-07-18|2017-07-21|Actual|April 14, 2011|Actual|2011-04-14|July 2017|2017-07-31|July 7, 2011|Actual|2011-07-07|July 7, 2011|Actual|2011-07-07||Interventional|||A Study Assessing GW870086's Potential to Cause Skin Thinning|A Randomised, Double-blind (for GW870086), Placebo-controlled Study of Topical GW870086 Formulation to Explore the Potential for Skin Thinning in Healthy Adult Volunteers|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:26:54.881422|2018-05-31 22:26:54.881422
NCT01381432|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-05-09|2011-06-23|2011-06-27|Estimate|||||||2013-05-09|2013-05-13|Estimate|December 2004||2004-12-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)|Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)|Completed|||39|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:54.972966|2018-05-31 22:26:54.972966
NCT01381419|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-07-05|2011-06-23|2011-06-27|Estimate|||||||2017-07-05|2017-07-07|Actual|October 20, 2008|Actual|2008-10-20|July 2017|2017-07-31|April 1, 2009|Actual|2009-04-01|April 1, 2009|Actual|2009-04-01||Interventional|||First Time in Human Study (FTIH) With Positron Emission Tomography (PET)|A Single-blind, Randomised, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1144814 in Healthy Male and Female Subjects and an Open-label Positron Emission Tomography Study in Healthy Male Subjects to Evaluate the Neurokinin-1 (NK1) Receptor Occupancy of GSK1144814 in the Living Human Brain Using 11C GR205171.|Completed||Phase 1|21|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 22:26:55.059505|2018-05-31 22:26:55.059505
NCT01381406|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2011-09-15||2017-05-19|2011-06-23|2011-06-27|Estimate|2011-09-15|2011-10-21|Estimate||||2017-05-19|2017-06-14|Actual|July 2008||2008-07-31|May 2017|2017-05-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Observational|||Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations|Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations|Completed|||3333|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:55.170499|2018-05-31 22:26:55.170499
NCT01381393|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-11-28|2011-06-23|2011-06-27|Estimate|||||||2012-11-28|2012-11-30|Estimate|June 2007||2007-06-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|BONPMS||BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Administered in Korean Patients According to the Prescribing Information|Completed|||659|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:26:55.550243|2018-05-31 22:26:55.550243
NCT01381380|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|December 2009|Actual|2009-12-31|November 2007|Actual|2007-11-30||Interventional|||Manual Therapy Treatment for Myofascial Pain|Effect of Manual Therapy After Trigger Point Injection for Myofascial Pain Syndrome|Completed||N/A|30|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 22:26:55.713107|2018-05-31 22:26:55.713107
NCT01381367|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2011-06-24|2011-06-24|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||PPSV23 Pneumococcal Vaccine in Chronic Obstructive Pulmonary Disease (COPD)|Phase 4 Study of PPSV23 Pneumococcal Vaccine in COPD Patients Using High Daily Dose of Inhaled Corticosteroid|Completed||Phase 4|38|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:26:55.834961|2018-05-31 22:26:55.834961
NCT01381354|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2016-11-22|2011-06-24|2011-06-27|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)|Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)|Completed||Phase 1|38|Actual|University of Iowa||1|||f||||t||||||||||2018-05-31 22:26:55.964619|2018-05-31 22:26:55.964619
NCT01381341|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2012-03-21|2011-06-23|2011-06-27|Estimate|||||||2012-03-21|2012-03-23|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.|A Phase 1 Pharmacokinetic Study To Compare the Relative Bioavailability of Two Clinical Formulations of Linifanib in Subjects With Solid Tumors|Completed||Phase 1|13|Actual|Abbott||1|||f||||f||||||||||2018-05-31 22:26:56.219873|2018-05-31 22:26:56.219873
NCT01381328|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-02-08|2011-06-24|2011-06-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Observational|||GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance|GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance|Unknown status|Recruiting||100|Anticipated|Università Vita-Salute San Raffaele|||1||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 22:26:56.337984|2018-05-31 22:26:56.337984
NCT01381315|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-01-06|2011-06-24|2011-06-27|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Axillary Reverse Mapping|ARM: Axillary Reverse Mapping|Completed||Phase 2|210|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 22:26:56.767417|2018-05-31 22:26:56.767417
NCT01381302|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2016-02-08|2011-06-22|2011-06-27|Estimate|||||||2016-02-08|2016-02-09|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Trodat 1 SPECT and Dopamine Polymorphism|Association of Polymorphism in Genes Associated With Control of Dopamine Levels in Parkinson's Disease and Tc-99m-Trodat-1 SPECT Imaging.|Completed|||90|Actual|Wolfson Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood samples with DNA~   "|||2018-05-31 22:26:58.010294|2018-05-31 22:26:58.010294
NCT01381289|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2012-02-08|2011-06-23|2011-06-27|Estimate|||||||2012-02-08|2012-02-09|Estimate||||February 2012|2012-02-29||||||||Expanded Access|||VX-770 Expanded Access Program|VX-770 Expanded Access Program (EAP)|Approved for marketing|||||Vertex Pharmaceuticals Incorporated|||||||||||||||||||2018-05-31 22:26:58.207849|2018-05-31 22:26:58.207849
NCT01381276|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-12-08|2011-06-23|2011-06-27|Estimate|||||||2011-12-08|2011-12-12|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|FL-80||Vitamin A Absorption From Cassava in Women|Vitamin A Equivalence of Carotenoids From Cassava in Women|Completed||Phase 2|10|Actual|USDA, Western Human Nutrition Research Center||3|||f||||t||||||||||2018-05-31 22:26:58.449276|2018-05-31 22:26:58.449276
NCT01381263|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2018-05-23|2011-06-23|2011-06-27|Estimate|||||||2018-05-23|2018-05-25|Actual|January 2011||2011-01-31|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Behavioral Medicine Treatment for Adolescents in Pain|Development, Evaluation and Cost Effectiveness of a Treatment Program With a Behavioural Medicine Approach for Adolescents With Persistent Pain.|Completed||N/A|100|Anticipated|Uppsala University||2|||f||||t||||||||||2018-05-31 22:26:58.542085|2018-05-31 22:26:58.542085
NCT01381250|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-29|2011-06-23|2011-06-27|Estimate|||||||2011-06-29|2011-06-30|Estimate|May 2004||2004-05-31|January 2004|2004-01-31|January 2009|Actual|2009-01-31|January 2006|Actual|2006-01-31||Interventional|||Effects of Internet-based Treatment of Pathological Gambling|Prediction and Treatment Outcome of Internet-based Treatment of Pathological Gambling With Three-year Follow-up|Completed||N/A|284|Actual|Umeå University||1|||f||||f||||||||||2018-05-31 22:26:58.843428|2018-05-31 22:26:58.843428
NCT01381237|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|August 2007||2007-08-31|March 2007|2007-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effects of Game-based Balance Exercise for Older Adults With Fall History|Full Title Interactive Computer Game Exercise Regime, Effects on Balance Impairment in Frail Community-Dwelling Older Adults. A Randomized Controlled Trial|Completed||Phase 2|30|Actual|University of Manitoba|||||f||||t||||||||||2018-05-31 22:26:59.54263|2018-05-31 22:26:59.54263
NCT01381224|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-04-18|2011-06-22|2011-06-27|Estimate|||||||2013-04-18|2013-04-22|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Do Lower Spine Injections Improve Outcomes for Lower Back Pain Patients|Do Lumbar Spine Injections Improve Short-Term Biomechanical Outcomes in Patients With Chronic Low Back Pain|Completed|||30|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 22:26:59.639491|2018-05-31 22:26:59.639491
NCT01381211|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2015-06-02|2011-06-22|2011-06-27|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|September 2015|Anticipated|2015-09-30||Interventional|TRACE||Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)|Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of HCC: A Multicenter Randomized Controlled Trial (TRACE Trial)|Unknown status|Recruiting|Phase 2|140|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:27:00.620202|2018-05-31 22:27:00.620202
NCT01381198|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-07-08|2011-06-23|2011-06-27|Estimate|||||||2011-07-08|2011-07-11|Estimate|June 2007||2007-06-30|January 2011|2011-01-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|RectusTrans||Distal Rectus Femoris Transfer as a Part of Multilevel Surgery in Children With Spastic Diplegia|Distal Rectus Femoris Transfer as a Part of Multilevel Surgery in Children With Spastic Diplegia - a Randomized Clinical Trial|Completed||N/A|36|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 22:27:01.334988|2018-05-31 22:27:01.334988
NCT01381185|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-10-26|2011-06-22|2011-06-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|REACT-MI||REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction|Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction|Completed||Phase 4|154|Actual|University Hospital Ostrava||2|||f||||t||||||||||2018-05-31 22:27:01.57607|2018-05-31 22:27:01.57607
NCT01381172|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2018-02-27|2011-06-23|2011-06-27|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2011||2011-01-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2017|Actual|2017-09-30||Interventional|FIX-HF-5C||Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C|Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C|Active, not recruiting||N/A|160|Actual|Impulse Dynamics||2|||f||||t||||||||||2018-05-31 22:27:02.238319|2018-05-31 22:27:02.238319
NCT01381159|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2018-02-09|2011-06-23|2011-06-27|Estimate|||||||2018-02-09|2018-02-13|Actual|January 2011||2011-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|MI-ACT||Motivational Intervention for Asthma|Motivational Intervention for Asthma Control Trial|Recruiting||N/A|182|Anticipated|Hopital du Sacre-Coeur de Montreal||2|||f||||f||||||||||2018-05-31 22:27:02.657735|2018-05-31 22:27:02.657735
NCT01381146|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-04-21|2011-06-23|2011-06-27|Estimate|||||||2017-04-21|2017-04-25|Actual|July 15, 2016|Actual|2016-07-15|April 2017|2017-04-30|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|||Victim Impact Modules for Jail Inmates|Phase 1-2 Study of Victim Impact Group Modules for Jail Inmates|Withdrawn||N/A|0|Actual|George Mason University||2||"Results from Phase II Study did not support dismantling"|f||||t||||||||||2018-05-31 22:27:02.90011|2018-05-31 22:27:02.90011
NCT01381133|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2013-08-13|2011-06-23|2011-06-27|Estimate|||||||2013-08-13|2013-08-14|Estimate|September 2002||2002-09-30|August 2013|2013-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|AOCCS||Adolescent Outpatient and Continuing Care Study|Adolescent Outpatient and Continuing Care Study|Completed||Phase 3|320|Actual|Chestnut Health Systems||4|||f||||t||||||||||2018-05-31 22:27:03.111801|2018-05-31 22:27:03.111801
NCT01381120|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2012-02-09||2012-08-21|2011-06-23|2011-06-27|Estimate|2012-07-18|2012-08-22|Estimate||||2012-08-21|2012-08-30|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms|Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms (LUTS) Post Ureteroscopy for Stone Management|Completed||Phase 4|84|Actual|Barrie Urology Associates||2|||f||||t||||||||||2018-05-31 22:27:03.414824|2018-05-31 22:27:03.414824
NCT01381107|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16||2011-08-18|2011-08-18|2011-06-23|2011-06-27|Estimate||||2011-08-18|2011-08-23|Estimate|2011-08-18|2011-08-23|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ALKS 33-BUP Administration in Subjects With Major Depressive Disorder (MDD)|Completed||Phase 1/Phase 2|32|Anticipated|Alkermes, Inc.||2|||f||||t||||||||||2018-05-31 22:27:04.159726|2018-05-31 22:27:04.159726
NCT01381094|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23||2012-10-03|2016-03-29|2011-06-23|2011-06-27|Estimate||||2012-10-03|2012-10-05|Estimate|2016-03-29|2016-05-02|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||42-Day Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia|Phase 2a Randomized, Double-Blind, Placebo-Controlled, Dose Range Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 42-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and 4|Completed||Phase 2|93|Actual|Akebia Therapeutics||5|||f||||f||||||||||2018-05-31 22:27:04.405877|2018-05-31 22:27:04.405877
NCT01381081|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-02-23|2011-06-23|2011-06-27|Estimate|||||||2015-02-23|2015-02-24|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Platelet-rich Plasma Intra-articular Knee Injections for Knee Osteoarthritis|A Prospective, Randomized, Double-blinded, Clinical Trial, Comparing Platelet-rich Plasma Intra-articular Knee Injections Versus Corticosteroid Intra-articular Knee Injections for Knee Osteoarthritis|Completed||Phase 3|74|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 22:27:04.825751|2018-05-31 22:27:04.825751
NCT01381068|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-07-08|2011-06-22|2011-06-27|Estimate|||||||2011-07-08|2011-07-11|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|September 2011|Anticipated|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||Quantitative End Tidal CO2 Monitoring in the Delivery Room (DR)|Quantitative End Tidal CO2 Monitoring in the Delivery Room: Can we Prevent Hypo/Hypercapnia Upon Admission to the NICU?|Unknown status|Active, not recruiting|N/A|50|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 22:27:04.976394|2018-05-31 22:27:04.976394
NCT01381055|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-01-25|2011-06-23|2011-06-27|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2012|Actual|2012-03-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|January 2015|Actual|2015-01-31||Interventional|||Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis|Double-blind Placebo Controlled Trial Using Pentoxifylline Associated With Pentavalent Antimony in Cutaneous Leishmaniasis|Completed||Phase 2/Phase 3|164|Actual|Hospital Universitário Professor Edgard Santos||2|||f||||t||||||||||2018-05-31 22:27:05.100598|2018-05-31 22:27:05.100598
NCT01381042|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||The Incidence and Factors of Brown Adipose Tissue in Chinese|Retrospective Study on the Incidence and Factors of Brown Adipose Tissue in Adult Chinese|Unknown status|Active, not recruiting||600|Anticipated|Huashan Hospital|||||f||||t||||||||||2018-05-31 22:27:05.189728|2018-05-31 22:27:05.189728
NCT01381029|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-02-08|2011-06-23|2011-06-27|Estimate|||||||2016-02-08|2016-02-10|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals|A Study to Examine Immunological Response in HIV-Infected Patients Receiving the Seasonal Influenza Vaccine|Completed|||74|Actual|George Washington University|||1||f||||f||||||||No||2018-05-31 22:27:05.298878|2018-05-31 22:27:05.298878
NCT01381016|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2015-02-02||2015-04-02|2011-06-22|2011-06-27|Estimate|2015-02-02|2015-02-18|Estimate||||2015-04-02|2015-04-20|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Estrogen Sensitivity and Ovulatory Dysfunction in Obesity|Estrogen Sensitivity and Ovulatory Dysfunction in Obesity|Completed||N/A|30|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:27:05.696566|2018-05-31 22:27:05.696566
NCT01381003|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-06-01|2011-06-23|2011-06-27|Estimate|||||||2012-06-01|2012-06-04|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD)|Phase I/II Gene Therapy Protocol for X-Linked Chronic Granulomatous Disease|Withdrawn||Phase 1/Phase 2|0|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||1||"Study is withdrawn before recruting participants, new trial will be multi centre, sponsored by~   different organisation."|f||||f||||||||||2018-05-31 22:27:06.532833|2018-05-31 22:27:06.532833
NCT01380990|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2015-09-11|2011-06-23|2011-06-27|Estimate|||||||2015-09-11|2015-09-14|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency|Phase I/II, Non-controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1αS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells From ADA-deficient Individuals|Recruiting||Phase 1/Phase 2|10|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 22:27:06.660676|2018-05-31 22:27:06.660676
NCT01380977|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-05-03|2011-06-23|2011-06-27|Estimate|||||||2013-05-03|2013-05-07|Estimate|August 2002||2002-08-31|May 2013|2013-05-31|July 2016|Anticipated|2016-07-31|August 2013|Anticipated|2013-08-31||Interventional|IOC-1||Trial of Impact of Crime Group Intervention for Jail Inmates||Unknown status|Active, not recruiting|Phase 1/Phase 2|51|Actual|George Mason University||2|||f||||t||||||||||2018-05-31 22:27:06.823844|2018-05-31 22:27:06.823844
NCT01380964|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-08-16|2011-06-23|2011-06-27|Estimate|||||||2016-08-16|2016-08-17|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|IBISD||Research of Biomarkers in Duchenne Muscular Dystrophy Patients|Research of Biomarkers for Disease Diagnosis, Disease Monitoring and Therapeutic Treatment Response in Duchenne Muscular Dystrophy Patients|Completed|||220|Actual|Genethon|||2||f||||f||||||Samples With DNA|"~     DNA, serum, t lymphocytes, urine~   "|||2018-05-31 22:27:06.999005|2018-05-31 22:27:06.999005
NCT01380951|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)|Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B|Unknown status|Recruiting|Phase 4|120|Anticipated|The Fifth People's Hospital of Suzhou||1|||f||||f||||||||||2018-05-31 22:27:07.10687|2018-05-31 22:27:07.10687
NCT01380938|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-04-14|2011-06-23|2011-06-27|Estimate|||||||2012-04-14|2012-04-17|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|WRITE||Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)|RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE)|Unknown status|Recruiting|Phase 3|1150|Anticipated|Casa Sollievo della Sofferenza IRCCS||3|||f||||f||||||||||2018-05-31 22:27:07.232059|2018-05-31 22:27:07.232059
NCT01380925|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-05-10|2011-06-22|2011-06-27|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||The Jewels in Our Genes Study - an African American Family Study of Breast Cancer|Search for Novel Breast Cancer Susceptibility Genes in Pedigrees of African Ancestry|Completed|||330|Actual|University at Buffalo|||||f||||f||||||Samples With DNA|"~     Saliva sample~   "|No||2018-05-31 22:27:07.579575|2018-05-31 22:27:07.579575
NCT01380912|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Observational|||Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer|Can Injection of Methylprednisoloneacetate 80 mg, in the Cavity After Mastectomy for Primary Breast Cancer, at the Time of Removal of the Drain, Prevent Seroma Formation?|Unknown status|Recruiting||160|Anticipated|Copenhagen University Hospital at Herlev|||1||f||||t||||||Samples Without DNA|"~     seroma will be analysed for concentration of cytokines, and eventual growth of bacteria~   "|||2018-05-31 22:27:07.628798|2018-05-31 22:27:07.628798
NCT01380899|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-05-02|2011-06-23|2011-06-27|Estimate|||||||2017-05-02|2017-05-04|Actual|February 2011||2011-02-28|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2014|Actual|2014-10-31||Observational|||Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.|Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.|Enrolling by invitation|||23|Anticipated|Universidad Autonoma de San Luis Potosí|||2||f||||t||||||||||2018-05-31 22:27:07.77799|2018-05-31 22:27:07.77799
NCT01380886|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-02-14|2011-06-23|2011-06-27|Estimate|||||||2013-02-14|2013-02-15|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Growth and Tolerance of Young Infants Fed Infant Formulas|Growth and Tolerance of Young Infants Fed Infant Formulas|Completed||Phase 3|209|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 22:27:07.993051|2018-05-31 22:27:07.993051
NCT01380860|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-10-24|2011-06-23|2011-06-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|GRECCAR 07||Primary Prevention of Peristomial Hernias Via Parietal Prostheses|Primary Prevention of Peristomial Hernias Via Parietal Prostheses: a Randomized, Multicentric Study|Active, not recruiting||N/A|200|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||t||||||||||2018-05-31 22:27:10.081937|2018-05-31 22:27:10.081937
NCT01380847|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2016-01-29|2011-06-23|2011-06-27|Estimate|||||||2016-01-29|2016-02-01|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Observational|Prefigur||Prediction of Chronic Allograft Nephropathy|Early Prediction of Chronic Allograft Nephropathy by Non Invasive Monitoring of Urinary Cell mRNAs|Unknown status|Active, not recruiting||300|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     RNA profiling of urinary cells in kidney transplant recipients~   "|||2018-05-31 22:27:10.315799|2018-05-31 22:27:10.315799
NCT01380834|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2015-04-16||2017-10-17|2011-06-23|2011-06-27|Estimate|2015-05-06|2015-05-21|Estimate||||2017-10-17|2017-11-20|Actual|November 2010||2010-11-30|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Pediatric Patients|Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Laparoscopic Cholecystectomy: a Prospective, Randomized Clinical Study|Completed||N/A|84|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:27:10.55484|2018-05-31 22:27:10.55484
NCT01380821|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-05-02|2011-06-23|2011-06-27|Estimate|||||||2013-05-02|2013-05-03|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|DSB-SPECT||DNA Double-strand Breaks After SPECT|DNA Double-strand Breaks Following Myocardial Scintigraphy|Completed|||40|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 22:27:11.525175|2018-05-31 22:27:11.525175
NCT01380808|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2013-07-25|2011-06-23|2011-06-27|Estimate|||||||2013-07-25|2013-07-26|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)|A Phase II Study of Capecitabine and Pseudomonas Aeruginosa Combination in the Salvage Treatment of Metastatic Breast Cancer|Completed||Phase 2|100|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 22:27:11.624703|2018-05-31 22:27:11.624703
NCT01380795|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-03-25|2011-06-23|2011-06-27|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2011||2011-03-31|September 2014|2014-09-30||||February 2013|Actual|2013-02-28||Interventional|CTC-Poumon||Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas|Biological Study of Feasibility Concerning the Research for Mutation of the Gene of EGFR and for K-Ras in Circulating Tumoral Cells(CTCs) of the Patients Carriers of Metastatic Non Small Cells Bronchial Carcinomas|Completed||Early Phase 1|30|Anticipated|Centre Georges Francois Leclerc||1|||f||||t||||||||||2018-05-31 22:27:11.715126|2018-05-31 22:27:11.715126
NCT01380782|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2014-07-14||2014-08-15|2011-06-23|2011-06-27|Estimate|2014-08-15|2014-08-18|Estimate||||2014-08-15|2014-08-18|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional||One participant from Arm B (GBM) was removed from analysis, aside from the review of adverse events, due to later determining she did not meet eligibility requirements as a result of prior stereotatic radiosurgery received prior to starting the study.|BIBF 1120 for Recurrent High-Grade Gliomas|Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas|Completed||Phase 2|37|Actual|Dana-Farber Cancer Institute|The trial intended to enroll 14 participants onto Arm A GBM, but only 10 enrolled due to futility. In addition, 10 AG participants were to be enrolled onto each Arm as exploratory cohorts, but again due to futility only 4 enrolled onto Arm B.|2|||f||||t||||||||||2018-05-31 22:27:11.839807|2018-05-31 22:27:11.839807
NCT01380769|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2015-10-26||2017-04-18|2011-06-23|2011-06-27|Estimate|2017-04-18|2017-05-24|Actual||||2017-04-18|2017-05-24|Actual|June 2011||2011-06-30|April 2017|2017-04-30|October 2014|Actual|2014-10-31|February 2013|Actual|2013-02-28||Interventional||Intention-to-treat (ITT) and Patient Safety Population (PSP), includes all CRLX101 + BSC subjects who received at least 1 dose of study treatment and all randomized BSC alone subjects who attended at least 1 study visit.|A Phase 2 Study of CRLX101 in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy|Completed||Phase 2|157|Actual|NewLink Genetics Corporation||2|||f||||f||||||||||2018-05-31 22:27:12.743199|2018-05-31 22:27:12.743199
NCT01380756|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-11-01|2011-06-23|2011-06-27|Estimate|||||||2017-11-01|2017-11-06|Actual|October 4, 2011|Actual|2011-10-04|November 2017|2017-11-30|September 4, 2014|Actual|2014-09-04|September 4, 2014|Actual|2014-09-04||Interventional|||Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia|A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia|Completed||Phase 1|35|Actual|Amgen||2|||f||||f||||||||||2018-05-31 22:27:13.400557|2018-05-31 22:27:13.400557
NCT01380743|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23||2013-12-05|2013-12-05|2011-06-23|2011-06-27|Estimate||||2013-12-05|2013-12-30|Estimate|2013-12-05|2013-12-30|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Drug-drug Interaction Study|An Open-Label, Multi-Center, Study to Investigate Drug-Drug Interactions Between AT2220 (Duvoglustat Hydrochloride) and Alglucosidase Alfa in Patients With Pompe Disease|Completed||Phase 2|25|Actual|Amicus Therapeutics||4|||f||||t||||||||||2018-05-31 22:27:13.619516|2018-05-31 22:27:13.619516
NCT01380730|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2015-09-01|2013-03-26|2016-06-09|2011-06-23|2011-06-27|Estimate|2015-09-01|2015-10-01|Estimate|2013-04-02|2013-04-09|Estimate|2016-06-09|2016-07-11|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|LAPLACE|Full analysis set (all randomized participants who received at least 1 dose of investigational product).|LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy|LAPLACE TIMI 57 - A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects|Completed||Phase 2|631|Actual|Amgen||8|||f||||t||||||||||2018-05-31 22:27:13.846834|2018-05-31 22:27:13.846834
NCT01380717|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2014-02-26|2011-06-23|2011-06-27|Estimate|||||||2014-02-26|2014-02-27|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|RenVas||Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)|The Role of Renal and Peripheral Vascular Resistance in Chronic Kidney Disease|Completed||Phase 4|83|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:27:17.377264|2018-05-31 22:27:17.377264
NCT01380704|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-11-17|2011-06-23|2011-06-27|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2011||2011-06-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of ABT-436 in Major Depressive Disorder Subjects|Completed||Phase 1|51|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 22:27:17.74411|2018-05-31 22:27:17.74411
NCT01380691|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-09-16|2011-06-22|2011-06-27|Estimate|||||||2011-09-16|2011-09-20|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of LY2216684 in Healthy Subjects|A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction of LY2216684 With Alcohol in Healthy Subjects|Completed||Phase 1|28|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:27:18.341112|2018-05-31 22:27:18.341112
NCT01380678|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-07-07|2011-06-23|2011-06-27|Estimate|||||||2011-07-07|2011-07-11|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|bevacizumab||Intralesional Bevacizumab Injection on Primary Pterygium|A Randomized Controlled Trial of Intralesional Bevacizumab Injection on Primary Pterygium: Preliminary Results|Unknown status|Recruiting|Phase 3|206|Anticipated|Khon Kaen University||2|||f||||f||||||||||2018-05-31 22:27:18.80528|2018-05-31 22:27:18.80528
NCT01380665|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-08-19|2011-06-23|2011-06-27|Estimate|||||||2013-08-19|2013-08-21|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|Prevena2009-45||Prevena™ Incision Management System Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty|Prospective, Single Arm, Post-Marketing Trial to Examine the Safety and Functionality of the Prevena™ Incision Management System, A Negative Pressure Based Surgical Wound Management System, Over Primarily Closed Hip and Knee Incisions in Patients Immediately Post Total Hip and Knee Arthroplasty|Withdrawn||Phase 4|0|Actual|KCI USA, Inc.||1|||f||||f||||||||||2018-05-31 22:27:19.172214|2018-05-31 22:27:19.172214
NCT01380652|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2015-03-05|2011-06-23|2011-06-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Vibration Training in Chronic Obstructive Pulmonary Disease (COPD)-Patients During a Three-week Rehabilitation|Effects of Whole Body Vibration Training on Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) III/IV-Patients During a Three-week Rehabilitation|Completed||N/A|72|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 22:27:21.711386|2018-05-31 22:27:21.711386
NCT01380639|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2013-09-27||2013-09-27|2011-06-23|2011-06-27|Estimate|2013-09-27|2013-11-28|Estimate||||2013-09-27|2013-11-28|Estimate|September 2010||2010-09-30|September 2013|2013-09-30||||April 2011|Actual|2011-04-30||Interventional|||Effects of Vibration Training on Exercise Capacity in COPD-patients|Effects of Vibration Training During a Three-week Rehabilitation on Exercise Capacity in Chronic Obstructive Pulmonary Disease (COPD) III/IV-Patients|Completed||N/A|72|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 22:27:22.489756|2018-05-31 22:27:22.489756
NCT01380626|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-12-16|2011-06-23|2011-06-27|Estimate|||||||2013-12-16|2013-12-17|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients|Effects of Exercise Training on Quadriceps Gene Expression in COPD-patients in Comparison to Alpha-1-Antitrypsin-deficiency-patients|Completed||N/A|20|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||1|||f||||f||||||||||2018-05-31 22:27:24.826063|2018-05-31 22:27:24.826063
NCT01380613|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-09-04|2011-06-22|2011-06-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2007||2007-09-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Workshop||Neighborhoods, Networks, Depression, and HIV Risk|The Impact of Neighborhoods, Networks, and Depression on Drug Users' HIV Risk|Completed||Phase 2|965|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 22:27:24.919107|2018-05-31 22:27:24.919107
NCT01380600|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-01-06|2011-06-22|2011-06-27|Estimate|||||||2016-01-06|2016-01-08|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|December 2015|Actual|2015-12-31|November 2012|Actual|2012-11-30||Interventional|||Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma|A Phase 1b Dose Escalation Study of JX-594 (Thymidine Kinase-Inactivated Vaccinia Virus Plus GM-CSF) Administered by Biweekly (Every Two Weeks) Intravenous Infusion in Patients With Metastatic, Refractory Colorectal Carcinoma|Completed||Phase 1|15|Actual|SillaJen, Inc.||1|||f||||f||||||||||2018-05-31 22:27:25.082175|2018-05-31 22:27:25.082175
NCT01380587|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2013-08-26|2011-06-23|2011-06-27|Estimate|||||||2013-08-26|2013-08-27|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|XCL1||Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia|Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia|Completed|||25|Actual|Hospital Universitario Dr. Jose E. Gonzalez|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells, blasts~   "|||2018-05-31 22:27:25.493941|2018-05-31 22:27:25.493941
NCT01380574|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-06-26|2011-06-22|2011-06-27|Estimate|||||||2012-06-26|2012-06-28|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|FinCV||Safety of Cardioversion of Acute Atrial Fibrillation|Safety of Cardioversion of Acute Atrial Fibrillation|Completed|||7700|Actual|Turku University Hospital|||||f||||f||||||||||2018-05-31 22:27:25.742197|2018-05-31 22:27:25.742197
NCT01380561|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-10-14|2011-06-23|2011-06-27|Estimate|||||||2011-10-14|2011-10-18|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers|A Metabolite Identification, Mass Balance, and Pharmacokinetic Study of a Single Oral Dose of [14C]-Asimadoline Followed by Twice Daily Oral Dosing of 0.5 mg Asimadoline to Healthy Adult Male Volunteers|Completed||Phase 1|6|Actual|Tioga Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:27:25.828074|2018-05-31 22:27:25.828074
NCT01380548|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-03-26|2011-06-22|2011-06-27|Estimate|||||||2013-03-26|2013-03-28|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of 5-Aminolevulinic Acid on Iron Deficiency Anemia|A Double-blind, Placebo Controlled Study to Assess Efficacy of 5-Aminolevulinic Acid in Subjects With Iron Deficiency Anemia|Completed||N/A|135|Anticipated|Hiroshima University||5|||f||||||||||||||2018-05-31 22:27:26.016223|2018-05-31 22:27:26.016223
NCT01380535|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-08-14|2011-06-23|2011-06-27|Estimate|||||||2017-08-14|2017-08-16|Actual|November 2011|Actual|2011-11-30|August 2017|2017-08-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|||A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease|A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)|Completed||Phase 1|60|Actual|Mallinckrodt||2|||f||||t||||||||||2018-05-31 22:27:26.262239|2018-05-31 22:27:26.262239
NCT01380522|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|August 2002||2002-08-31|June 2011|2011-06-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Bioavailability Study of Metronidazole Capsules Under Fed Conditions|To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules/( G.D. Searle, Inc) Under Fed Conditions|Completed||Phase 1|18|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-05-31 22:27:26.445661|2018-05-31 22:27:26.445661
NCT01380509|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|August 2002||2002-08-31|June 2011|2011-06-30|October 2002|Actual|2002-10-31|September 2002|Actual|2002-09-30||Interventional|||Bioavailability Study of Metronidazole Capsules Under Fasting Conditions|To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules( G.D. Searle, Inc) Under Fasting Conditions|Completed||Phase 1|28|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-05-31 22:27:26.58103|2018-05-31 22:27:26.58103
NCT01380496|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-22|2011-06-22|2011-06-27|Estimate|||||||2017-09-22|2017-09-26|Actual|November 1999||1999-11-30|September 2017|2017-09-30|November 1999|Actual|1999-11-30|November 1999|Actual|1999-11-30||Interventional|||Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions|Randomized, 3-Way Crossover, Comparative Bioequivalence Study of Par Pharmaceutical Inc. (USA) and Oclassen Pharmaceuticals Inc. (USA)(Monodox(R)) Doxycycline Monohydrate Equivalent to 100 mg Doxycycline Administered as a Single Dose of 100 mg In Healthy Adult Males Under Fasting and Fed Conditions|Completed||Phase 1|24|Actual|Par Pharmaceutical, Inc.||3|||f||||f||||||||||2018-05-31 22:27:26.894307|2018-05-31 22:27:26.894307
NCT01380483|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|January 2000||2000-01-31|June 2011|2011-06-30|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions|Randomized, 2-way Crossover, Comparative Bioequivalence Study of Par Pharmaceutical Inc. (USA) and Oclassen Pharmaceuticals Inc. (USA) (Monodox(R)) Doxycycline Monohydrate Equivalent to 100 mg Doxycycline Administered as a Single Dose of 100 mg In Healthy Adult Males Under Fasting Conditions|Completed||Phase 1|40|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-05-31 22:27:27.309046|2018-05-31 22:27:27.309046
NCT01380470|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-12-14|2011-06-23|2011-06-27|Estimate|||||||2017-12-14|2017-12-15|Actual|February 2010||2010-02-28|June 2011|2011-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Prevalence of Undiagnosed Chronic Obstructive Pulmonary Disease Sufferers in the Region of Murcia|Prevalence of Undiagnosed Sufferers in Murcia :Cross-sectional Study|Completed|||1052|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|||1||f||||f||||||||||2018-05-31 22:27:27.766218|2018-05-31 22:27:27.766218
NCT01380457|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions|A Comparative Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions|Completed||Phase 1|69|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-05-31 22:27:27.898775|2018-05-31 22:27:27.898775
NCT01380444|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-04-21|2011-06-22|2011-06-27|Estimate|||||||2017-04-21|2017-04-25|Actual|December 2011|Actual|2011-12-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|INSITE||Intramedullary Nail Versus Sliding Hip Screw Inter-Trochanteric Evaluation|A Multi-Center Randomized Controlled Trial of Intramedullary Nails Versus Sliding Hip Screws in the Management of Intertrochanteric Fractures of the Hip|Completed||N/A|880|Actual|Stryker Trauma GmbH||2|||f||||f|||||f|||No||2018-05-31 22:27:27.987502|2018-05-31 22:27:27.987502
NCT01380431|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|August 1999||1999-08-31|June 2011|2011-06-30|October 1999|Actual|1999-10-31|October 1999|Actual|1999-10-31||Interventional|||A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study|Randomized, Open-label, Three Treatment Crossover Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study|Completed||Phase 1|18|Actual|Par Pharmaceutical, Inc.||3|||f||||f||||||||||2018-05-31 22:27:28.311856|2018-05-31 22:27:28.311856
NCT01380418|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-09-08|2011-06-22|2011-06-27|Estimate|||||||2017-09-08|2017-09-12|Actual|June 2011||2011-06-30|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Factors Associated With Chronic Respiratory Failure in Obesity|Factors Associated With Chronic Respiratory Failure in Obesity: A Cross-sectional Study|Completed|||78|Actual|Oxford University Hospitals NHS Trust|||1||f||||f||||||Samples With DNA|"~     Blood, fat, muscle~   "|||2018-05-31 22:27:28.401962|2018-05-31 22:27:28.401962
NCT01380405|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-12-14|2011-06-23|2011-06-27|Estimate|||||||2017-12-14|2017-12-15|Actual|May 2011||2011-05-31|December 2017|2017-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Educational Intervention for Managing Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effectiveness of an Educational Intervention for Managing Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Patients in Primary Care: A Randomized Clinical Trial|Completed||N/A|91|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||3|||f||||f||||||||||2018-05-31 22:27:28.513196|2018-05-31 22:27:28.513196
NCT01380392|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-23|2011-06-23|2011-06-27|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2011||2011-02-28|June 2011|2011-06-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma|The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 22:27:28.673242|2018-05-31 22:27:28.673242
NCT01380379|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2016-10-11||2016-12-07|2011-06-22|2011-06-27|Estimate|2016-12-07|2017-02-01|Estimate||||2016-12-07|2017-02-01|Estimate|April 2011||2011-04-30|December 2016|2016-12-31|November 2015|Actual|2015-11-30|August 2013|Actual|2013-08-31||Interventional|||Self-Defense Training in Women With Trauma|A Pilot Study of Self-Defense Training in Women With Trauma|Completed||N/A|9|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 22:27:28.765225|2018-05-31 22:27:28.765225
NCT01380366|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2014-02-14||2016-01-12|2011-06-23|2011-06-27|Estimate|2014-02-14|2014-03-31|Estimate||||2016-01-12|2016-02-08|Estimate|October 2006||2006-10-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2011|Actual|2011-02-28||Interventional|rHGH|Patients Consented to be Given rHGH|rHGH and Intestinal Permeability in Intestinal Failure|Influence of Recombinant Human Growth Hormone on Intestinal Permeability and Liver Injury in Intestinal Failure Patients Receiving Parenteral Nutrition (Serono Project)|Completed||Phase 4|15|Actual|Northwestern University|Number of participants is low. Time period of evaluation may not have been adequate for evaluating the impact on liver injury. Parameters used to evaluate the impact of gut permeability changes on hepatic inflammation and injury were very limited.|1|||f||||f||||||||||2018-05-31 22:27:29.132589|2018-05-31 22:27:29.132589
NCT01380353|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-11-21|2011-06-23|2011-06-27|Estimate|||||||2017-11-21|2017-11-24|Actual|June 2011||2011-06-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine|Pilot Study to Test Uniformity of Transdermal Drug Delivery to the Breast Using Diclofenac Epolamine as a Model|Active, not recruiting||Early Phase 1|25|Anticipated|Northwestern University||2|||f||||t|t|f||||||||2018-05-31 22:27:29.383076|2018-05-31 22:27:29.383076
NCT01380340|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-27|2011-06-23|2011-06-27|Estimate|||||||2011-06-27|2011-06-29|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|September 2011|Anticipated|2011-09-30||Interventional|||Seniors Driving Cessation Early Intervention Group|Study of the Effects of a New Concept of Early Intervention on the Driving Cessation, Mental Health, and Quality of Life of Senior Drivers|Unknown status|Not yet recruiting|N/A|20|Anticipated|Fraser Health||2|||f||||f||||||||||2018-05-31 22:27:29.515738|2018-05-31 22:27:29.515738
NCT01380327|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2014-05-02||2014-06-05|2011-06-22|2011-06-27|Estimate|2014-05-02|2014-05-30|Estimate||||2014-06-05|2014-06-11|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|BioCSI-2||Biomarkers of Cockroach Sublingual Immunotherapy 2|A Biomarker-Based Pilot Study of Cockroach Sublingual Immunotherapy in Cockroach Sensitive Children With Asthma and/or Perennial Allergic Rhinitis|Completed||Phase 1/Phase 2|99|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 22:27:29.665998|2018-05-31 22:27:29.665998
NCT01380314|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis|Treatment of Bolivian Cutaneous Leishmaniasis With a Combination of Oral Miltefosine Plus Topical Imiquimod 5%|Completed||Phase 2|60|Anticipated|Foundation Fader||2|||f||||f||||||||||2018-05-31 22:27:30.865761|2018-05-31 22:27:30.865761
NCT01380301|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|March 2007||2007-03-31|June 2011|2011-06-30|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony|Treatment of Bolivian Cutaneous Leishmaniasis With a Combination of Short Courses of Miltefosine and Antimony|Terminated||Phase 2|19|Actual|Foundation Fader||2||Low efficacy rates|f||||f||||||||||2018-05-31 22:27:31.115684|2018-05-31 22:27:31.115684
NCT01380288|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2018-02-02|2011-06-23|2011-06-27|Estimate|||||||2018-02-02|2018-02-05|Actual|June 2011|Actual|2011-06-30|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|CAREER||Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine|Changes of Cognitive Function in Patients With Mild to Moderate Alzheimer's Disease Associated With or Without White Matter Changes After Rivastigmine Patch Therapy - Multi-center, Prospective, Open-label Clinical Trial|Completed||N/A|300|Actual|Dong-A University||2|||f||||t||||||||||2018-05-31 22:27:31.323142|2018-05-31 22:27:31.323142
NCT01380275|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-09-23|2011-06-22|2011-06-27|Estimate|||||||2014-09-23|2014-09-25|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.|Docetaxel, Irinotecan, Recurrent, Refractory, Bone and Soft Tissue Sarcomas|Unknown status|Recruiting|Phase 2|35|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 22:27:31.615535|2018-05-31 22:27:31.615535
NCT01380262|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-24|2011-06-23|2011-06-27|Estimate|||||||2011-06-24|2011-06-27|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|STLDD-1||Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment|Prospective Phase II Study on Skin Toxicity on Low-Dose Doxycycline in Metastatic Colorectal Cancer Patients During Cetuximab and Panitumumab Treatment|Unknown status|Recruiting||40|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center|||1||f||||f||||||||||2018-05-31 22:27:32.081872|2018-05-31 22:27:32.081872
NCT01380249|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2013-01-04|2011-06-23|2011-06-27|Estimate|||||||2013-01-04|2013-01-07|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|||PDM08 Clinical Trial in Advanced Solid Tumors|Phase I Study, Open, Dose Escalation, in Adult Patients With Advanced Solid Tumours, to Evaluate Tolerability, Pharmacokinetics and Pharmacodynamics of PDM08 Administered Twice a Week Cycles of 4 Weeks.|Completed||Phase 1|22|Actual|Prodimed S.A.||1|||f||||t||||||||||2018-05-31 22:27:32.332726|2018-05-31 22:27:32.332726
NCT01380236|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2012-11-29|2011-06-23|2011-06-27|Estimate|||||||2012-11-29|2012-12-03|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|May 2013|Anticipated|2013-05-31|June 2012|Anticipated|2012-06-30||Interventional|||A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma|A Phase II, Two-centre, Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Adult Subjects With Moderate to Severe Asthma|Withdrawn||Phase 2|0|Actual|Pharmaxis||||Protocol not progressed. Study not implemented.|f||||f||||||||||2018-05-31 22:27:32.570581|2018-05-31 22:27:32.570581
NCT01380223|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-10-09|2011-06-22|2011-06-27|Estimate|||||||2015-10-09|2015-10-14|Estimate|August 2005||2005-08-31|October 2015|2015-10-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers|A First-in-Man, Phase I, Double-Blind, Randomized, Four-Way Crossover, Placebo-Controlled, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of CK-1827452 (Omecamtiv Mecarbil) in Healthy Volunteers|Completed||Phase 1|35|Actual|Cytokinetics||4|||f||||f||||||||||2018-05-31 22:27:32.704481|2018-05-31 22:27:32.704481
NCT01380210|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-07-06|2011-06-23|2011-06-27|Estimate|||||||2011-07-06|2011-07-07|Estimate|February 2011||2011-02-28|July 2011|2011-07-31||||||||Observational|||MRI Findings of Encephalopathy Associated With Carbon Dioxide (CO2) Intoxication||Unknown status|Active, not recruiting||6|Actual|China Medical University Hospital|||||f||||t||||||||||2018-05-31 22:27:32.860384|2018-05-31 22:27:32.860384
NCT01380197|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2015-02-02||2018-01-23|2011-06-23|2011-06-27|Estimate|2015-02-02|2015-02-16|Estimate||||2018-01-23|2018-02-20|Actual|May 26, 2010|Actual|2010-05-26|January 2018|2018-01-31|October 18, 2016|Actual|2016-10-18|January 14, 2014|Actual|2014-01-14||Interventional|COMPARE||Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally|Choosing Opioid Management for Pain and Analyzing ACS Rates Equally|Completed||Phase 3|40|Actual|Children's Healthcare of Atlanta||2|||f||||f||||||||||2018-05-31 22:27:32.940913|2018-05-31 22:27:32.940913
NCT01380184|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-02-06|2011-06-22|2011-06-27|Estimate|||||||2015-02-06|2015-02-09|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Pharmacokinetics of Ridaforolimus in Chinese Participants (MK-8669-059)|A Study to Assess the Pharmacokinetics of Ridaforolimus in Chinese Patients|Completed||Phase 1|15|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 22:27:33.599973|2018-05-31 22:27:33.599973
NCT01380145|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2016-09-07||2016-10-31|2011-06-23|2011-06-27|Estimate|2016-10-31|2016-12-22|Estimate||||2016-10-31|2016-12-22|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional||Includes all subjects enrolled in the study.|MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation|Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation|Completed||Phase 1|13|Actual|Ludwig Institute for Cancer Research||1|||f||||f||||||||Yes||2018-05-31 22:27:34.181301|2018-05-31 22:27:34.181301
NCT01380132|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-06-27|2011-06-23|2011-06-27|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2004||2004-02-29|February 2010|2010-02-28|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy of Anorectal Application of Dx-gel for Treatment of Anal Incontinence|Safety and Efficacy of Anorectal Application of Dx-gel for Treatment of Anal Incontinence|Completed||Phase 1/Phase 2|35|Actual|Uppsala University Hospital||1|||f||||f||||||||||2018-05-31 22:27:35.011814|2018-05-31 22:27:35.011814
NCT01380119|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-10-25|2011-06-22|2011-06-27|Estimate|||||||2013-10-25|2013-10-29|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|imm02||Tuberculosis (TB) Immunotherapy Phase 2 Study|Phase 2 Study of Orally Formulated Heat-killed Mycobacterium Vaccae Study in TB Patients|Completed||Phase 2|40|Actual|Lisichansk Regional Tuberculosis Dispensary||2|||f||||f||||||||||2018-05-31 22:27:35.257964|2018-05-31 22:27:35.257964
NCT01380106|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-02-01|2011-06-22|2011-06-27|Estimate|||||||2016-02-01|2016-02-02|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma|A Controlled, Parallel-Group, Randomized, Open-Label Study to Evaluate Two Lenalidomide Dose Regimens When Used in Combination With Low Dose Dexamethasone for the Treatment of Subjects With Relapsed Multiple Myeloma|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Boston VA Research Institute, Inc.||2|||f||||t||||||||No||2018-05-31 22:27:35.456836|2018-05-31 22:27:35.456836
NCT01380093|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2012-04-26||2012-04-26|2011-06-23|2011-06-27|Estimate|2012-04-26|2012-05-31|Estimate||||2012-04-26|2012-05-31|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users|A Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Way Crossover Study to Determine the Abuse Potential of Oral Administration of Crushed EMBEDA Relative to Crushed Controlled-Release Morphine Sulfate and Placebo in Non Dependent, Recreational Opioid Users|Completed||Phase 1|80|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:27:37.058489|2018-05-31 22:27:37.058489
NCT01380080|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2016-01-26||2017-01-24|2011-06-22|2011-06-27|Estimate|2016-01-26|2016-02-23|Estimate||||2017-01-24|2017-03-07|Actual|October 2011||2011-10-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|January 2015|Actual|2015-01-31||Interventional|REMEMBER|Intent to treat: All eligible participants were included in the baseline characteristics.|REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment|Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)|Completed||Phase 4|851|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 22:27:49.044063|2018-05-31 22:27:49.044063
NCT01380067|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-22|2011-06-22|2011-06-27|Estimate|||||||2011-06-22|2011-06-27|Estimate|January 2000||2000-01-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2005|Actual|2005-12-31||Observational|||a New Way for Laparoscopic Inguinal Hernia Repair in Pediatric|Phase 3 Study of a New Way for Laparoscopic Inguinal Hernia Repair in Pediatric|Completed|||486|Actual|The Second People's Hospital of GuangDong Province|||2||f||||t||||||||||2018-05-31 22:27:51.275411|2018-05-31 22:27:51.275411
NCT01380054|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2018-01-04|2011-06-23|2011-06-27|Estimate|||||||2018-01-04|2018-01-05|Actual|May 31, 2011|Actual|2011-05-31|January 2018|2018-01-31|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Observational|HyPsy||Pulmonary Hypertension, Quality of Life and Psychosocial Factors|Pulmonary Hypertension: Impact of the Evolution of a Rare Disease on the Quality of Life and Role of Variables Psychosocial as Predictive of the Current and Later Quality of Life|Completed|||55|Actual|University Hospital, Montpellier|||1||f||||f||||||||||2018-05-31 22:27:51.368502|2018-05-31 22:27:51.368502
NCT01380041|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2015-07-20|2011-06-21|2011-06-27|Estimate|||||||2015-07-20|2015-07-21|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2013|Actual|2013-06-30|June 2011|Actual|2011-06-30||Observational|CYTOSEP||Cytokine in Cerebrospinal Fluid (CSF) From Multiple Sclerosis Patients|Identification of Multiple Sclerosis Biomarkers in Human CSF by Means of Cytokine Array|Terminated|||101|Actual|University Hospital, Montpellier||||Results obtained are sufficient for a publication.|f||||f||||||Samples With DNA|"~     Samples with DNA~   "|||2018-05-31 22:27:51.512291|2018-05-31 22:27:51.512291
NCT01380028|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-05-18|2011-06-21|2011-06-27|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2010||2010-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|hemacort||Interest of Oral Corticosteroids in the Treatment of Chronic Subdural Hematomas|Interest of Oral Corticosteroids in the Treatment of Chronic Subdural Hematomas. Prospective Randomized Multicenter Trial|Active, not recruiting||Phase 3|340|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 22:27:51.699742|2018-05-31 22:27:51.699742
NCT01380015|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-01-21|2011-06-23|2011-06-27|Estimate|||||||2013-01-21|2013-01-23|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Efficacy of Spearmint Tea in Relieving Osteoarthritis of the Knee|Human Clinical Trial to Investigate the Effects of High Rosmarinic Acid Spearmint Tea on Markers of Pain, Physical Function and Disease Activity in Osteoarthritis of the Knee|Completed||Phase 4|49|Actual|University of Guelph||2|||f||||f||||||||||2018-05-31 22:27:51.805709|2018-05-31 22:27:51.805709
NCT01380002|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Home-Care Needs in Liver or Renal Transplantation Recipients and Their Spouses|Home-Care Needs in Liver or Renal Transplantation Recipients and Their Spouses|Unknown status|Recruiting||400|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 22:27:52.035927|2018-05-31 22:27:52.035927
NCT01379989|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2016-04-06|2011-06-22|2011-06-23|Estimate|||||||2016-04-06|2016-04-07|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|INOVATYON||INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer|Phase III International, Randomized Study of Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) Versus Carboplatin Plus PLD in Patients With Ovarian Cancer Progressing Within 6-12 Months of Last Platinum|Recruiting||Phase 3|588|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t||||||||||2018-05-31 22:27:52.384097|2018-05-31 22:27:52.384097
NCT01379976|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2015-04-23|2011-06-22|2011-06-23|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer|Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Assess the Efficacy and Safety of Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer|Terminated||Phase 3|107|Actual|Mario Negri Institute for Pharmacological Research||2||"Recruitment was prematurely stopped due to difficulty of recruitment encountered by the~   experimental centers"|f||||t||||||||||2018-05-31 22:27:53.531582|2018-05-31 22:27:53.531582
NCT01379963|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2015-11-20||2017-06-15|2011-06-22|2011-06-23|Estimate|2015-11-20|2015-12-24|Estimate||||2017-06-15|2017-07-13|Actual|April 30, 2009|Actual|2009-04-30|May 2017|2017-05-31|February 28, 2011|Actual|2011-02-28|February 28, 2011|Actual|2011-02-28||Observational||Baseline population included all enrolled participants.|A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)|Non-interventional Study of Six-month Retrospective Reporting of Hemoglobin Levels in Patients With Renal Anaemia Who Are Treated With MIRCERA® (Methoxy-polyethylene-glycol-epoetin Beta)|Completed|||780|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:27:53.664384|2018-05-31 22:27:53.664384
NCT01379950|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Role of Macrophage in Inflammation Resolution in Periodontal Patients|The Role of Macrophages in the Inflammatory Resolution Phase in Periodontal Patients|Unknown status|Not yet recruiting||30|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 22:27:54.097775|2018-05-31 22:27:54.097775
NCT01379937|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2013-08-02|2012-11-16|2016-09-22|2011-06-22|2011-06-23|Estimate|2014-02-06|2014-03-26|Estimate|2012-11-16|2012-11-21|Estimate|2016-09-22|2016-09-23|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children|Safety and Immunogenicity Study of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine GSK1562902A in Children Aged 3 to 17 Years|Completed||Phase 3|520|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:27:54.564769|2018-05-31 22:27:54.564769
NCT01379924|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-23|2011-06-22|2011-06-23|Estimate|||||||2011-06-23|2011-06-27|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|YPP ProCon||Young Parents Program, Project Connect|Young Parents Program, Project Connect|Unknown status|Recruiting|Early Phase 1|250|Anticipated|Boston Children’s Hospital||3|||f||||t||||||||||2018-05-31 22:27:58.079114|2018-05-31 22:27:58.079114
NCT01379911|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2016-01-20|2011-06-21|2011-06-23|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Developing Methods for Completing Future Satiety Studies|Developing and Validating a Method for Satiety Studies|Completed||N/A|20|Actual|University of Guelph||2|||f||||f||||||||||2018-05-31 22:27:58.159725|2018-05-31 22:27:58.159725
NCT01379898|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2018-01-29|2011-06-21|2011-06-23|Estimate|||||||2018-01-29|2018-01-31|Actual|December 2011||2011-12-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|PRESCRIPT||Phenoxybenzamine Versus Doxazosin in PCC Patients|Pheochromocytoma Randomised Study Comparing Adrenoreceptor Inhibiting Agents for Preoperative Treatment|Completed||Phase 4|134|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 22:27:58.229773|2018-05-31 22:27:58.229773
NCT01379885|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2013-01-30|2011-06-21|2011-06-23|Estimate|||||||2013-01-30|2013-02-01|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|RID||Reducing Immunization Distress (RID)|Childhood Immunization: Reducing Immunization Distress (RID) Using Multi-Modal Distraction|Terminated||N/A|77|Actual|University of California, San Francisco||2||"Estimated sample size not achieved due to decline in number of eligible patients and difficulty~   recruiting and retaining research staff."|f||||f||||||||||2018-05-31 22:27:58.36209|2018-05-31 22:27:58.36209
NCT01379872|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-02-12|2011-06-21|2011-06-23|Estimate|||||||2013-02-12|2013-02-13|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|ANROTAT||Assessment of New Radiation Oncology Technologies and Treatments|The Assessment of New Radiation Oncology Technologies and Treatments (ANROTAT) TROG Research Project TRP11.A|Completed|||138|Actual|Trans-Tasman Radiation Oncology Group (TROG)|||4||f||||f||||||||||2018-05-31 22:27:58.465025|2018-05-31 22:27:58.465025
NCT01379846|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-03-04|2011-06-21|2011-06-23|Estimate|||||||2013-03-04|2013-03-05|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of TAK-816 in Healthy Infants|A Randomized, Double-Blind, Multicenter, Parallel-Group Comparative Phase III Study Evaluating the Efficacy and Safety of TAK-816 Compared With ActHIB in Healthy Infants|Completed||Phase 3|416|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:27:58.630774|2018-05-31 22:27:58.630774
NCT01379833|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-21|2011-06-21|2011-06-23|Estimate|||||||2011-06-21|2011-06-23|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Observational|||Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy|Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy|Unknown status|Recruiting||20|Anticipated|State University of New York at Buffalo|||2||f||||f||||||||||2018-05-31 22:27:58.866177|2018-05-31 22:27:58.866177
NCT01379820|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2011|Anticipated|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Use of Orotracheal Continuous Positive Airway Pressure (CPAP) in Newborns With Respiratory Failure|Use of Orotracheal CPAP ( Gregory System) for Treatment of Respiratory Failure in Newborns|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Hospital Angeles del Pedregal|||||f||||t||||||||||2018-05-31 22:27:59.040298|2018-05-31 22:27:59.040298
NCT01379807|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-03-10|2011-06-22|2011-06-23|Estimate|||||||2015-03-10|2015-03-11|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|SPIGA||Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|Unknown status|Active, not recruiting|Phase 2|55|Anticipated|Grupo Gallego de Investigaciones Oncologicas||1|||f||||f||||||||||2018-05-31 22:27:59.158644|2018-05-31 22:27:59.158644
NCT01379781|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2015-05-12||2015-07-13|2011-06-22|2011-06-23|Estimate|2015-07-13|2015-08-10|Estimate||||2015-07-13|2015-08-10|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression|Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression|Completed||N/A|54|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 22:27:59.377539|2018-05-31 22:27:59.377539
NCT01379768|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2013-01-31||2013-03-06|2011-06-22|2011-06-23|Estimate|2013-03-06|2013-03-08|Estimate||||2013-03-06|2013-03-08|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|CORNWALL||Study of the Cell Response in the Tear Film After Overnight Contact Lens Wear|Polymorphonuclear Leukocyte Response During Overnight Lens Wear|Completed||N/A|65|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:28:00.12048|2018-05-31 22:28:00.12048
NCT01379755|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-07-13|2011-06-22|2011-06-23|Estimate|||||||2011-07-13|2011-07-14|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|July 2011|Anticipated|2011-07-31|December 2010|Actual|2010-12-31||Observational|||Comparison of Stability and Outcomes in Single-radius Femoral Component for Total Knee Arthroplasty|Study of Compare Mid-flexion Stability and Clinical Outcomes in Single-radius Femoral Design or Multi-radius Femoral Design.|Unknown status|Active, not recruiting||213|Anticipated|Chonnam National University Hospital|||||f||||t||||||||||2018-05-31 22:28:00.661264|2018-05-31 22:28:00.661264
NCT01379742|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-02-11|2011-06-22|2011-06-23|Estimate|||||||2013-02-11|2013-02-13|Estimate|April 2010||2010-04-30|February 2013|2013-02-28||||February 2013|Actual|2013-02-28||Interventional|||Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy|Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeed™ and OncoSeed™ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer|Unknown status|Recruiting|Phase 4|240|Anticipated|Prostate Cancer Foundation of Chicago||2|||f||||t||||||||||2018-05-31 22:28:00.755712|2018-05-31 22:28:00.755712
NCT01379729|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2013-12-27|2011-06-22|2011-06-23|Estimate|||||||2013-12-27|2013-12-30|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|May 2018|Anticipated|2018-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Bet Cell Therapy in Diabetes Type 1|Functional Survival of Beta Cell Allografts After Transplantation in the Peritoneal Cavity of Non-uremic Type 1 Diabetic Patients|Unknown status|Recruiting|Phase 2|10|Anticipated|AZ-VUB||2|||f||||t||||||||||2018-05-31 22:28:00.857021|2018-05-31 22:28:00.857021
NCT01379716|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2011||2011-01-31|December 2010|2010-12-31||||January 2012|Anticipated|2012-01-31||Interventional|STTR||Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia and Healthy Controls|Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients With Postherpetic Neuralgia (PHN) and Age and Gender-Matched Normal Controls|Unknown status|Recruiting|Phase 1|10|Anticipated|Albany Medical College|||||f||||f||||||||||2018-05-31 22:28:00.973831|2018-05-31 22:28:00.973831
NCT01379703|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|2011-08-09||2011-10-10|2011-06-22|2011-06-23|Estimate|2011-08-09|2011-09-12|Estimate||||2011-10-10|2011-10-17|Estimate|February 2004||2004-02-29|October 2011|2011-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|KaleEAST||Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use|Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use|Completed|||2288|Actual|Abbott|||1||f||||f||||||||||2018-05-31 22:28:01.191607|2018-05-31 22:28:01.191607
NCT01379690|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2012-02-21|2011-06-22|2011-06-23|Estimate|||||||2012-02-21|2012-02-23|Estimate|April 2011||2011-04-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Retrospective Study: Hip Fractures in Diabetic Patients|Association of HBA1C and Hip Fractures in Elderly Type 2 Diabetic Patients|Completed|||1162|Actual|Changi General Hospital|||2||f||||f||||||||||2018-05-31 22:28:03.753786|2018-05-31 22:28:03.753786
NCT01379677|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-05-13|2011-06-22|2011-06-23|Estimate|||||||2014-05-13|2014-05-14|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison|Diagnosis of Coronary Artery Disease With Rubidium-82 PET and Technetium-99m-MIBI SPET: A Head to Head Comparison, Versus Coronary CT Angiography|Completed||Phase 3|135|Actual|Advanced Accelerator Applications||1|||f||||t||||||||||2018-05-31 22:28:04.046446|2018-05-31 22:28:04.046446
NCT01379664|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2016-11-29||2017-02-25|2011-06-21|2011-06-23|Estimate|2017-02-25|2017-04-10|Actual||||2017-02-25|2017-04-10|Actual|July 2011||2011-07-31|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Volatile Anesthetic Choice and Duration of Hospitalization: A Quality Improvement and Cost-control Project|Volatile Anesthetic Choice and Duration of Hospitalization: A Quality Improvement and Cost-control Project|Completed||N/A|1584|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 22:28:04.439462|2018-05-31 22:28:04.439462
NCT01379651|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2011-06-24||2011-09-19|2011-06-22|2011-06-23|Estimate|2011-08-01|2011-08-30|Estimate||||2011-09-19|2011-09-20|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|EGGSOTI||Time-limited Specific Oral Tolerance Induction in Children With Severe Egg Allergy|Specific Oral Tolerance Induction in Children With Severe Egg Allergy: A Randomized Controlled Trial Using a 6 Months Protocol|Completed||Phase 1/Phase 2|20|Actual|Ospedale Buon Consiglio Fatebenefratelli||2|||f||||t||||||||||2018-05-31 22:28:05.497141|2018-05-31 22:28:05.497141
NCT01379638|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Best Cardiac Output During Cardiopulmonary Bypass|Best Cardiac Output During Cardiopulmonary Bypass|Completed|||20|Actual|Aalborg Universitetshospital|||1||f||||f||||||||||2018-05-31 22:28:06.245346|2018-05-31 22:28:06.245346
NCT01379625|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2016-07-12||2017-03-21|2011-06-22|2011-06-23|Estimate|2017-03-21|2017-03-23|Actual||||2017-03-21|2017-03-23|Actual|September 2011||2011-09-30|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Triheptanoin|Subjects were 7 years of age or greater with one of 3 fatty acid oxidation disorders: CPT2, VLCAD or LCHAD/TFP.|Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder|Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders|Completed||Phase 2|32|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:28:06.425454|2018-05-31 22:28:06.425454
NCT01379612|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-06-14|2011-06-21|2011-06-23|Estimate|||||||2013-06-14|2013-06-17|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|||Ultrasound Elastography in Patients With Rectal Cancer|Ultrasound Elastography of Rectal Cancer Patients Treated With Preoperative Chemoradiation|Completed|||31|Actual|Vejle Hospital|||1||f||||f||||||||||2018-05-31 22:28:07.184388|2018-05-31 22:28:07.184388
NCT01379599|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2016-12-17|2011-06-22|2011-06-23|Estimate|||||||2016-12-17|2016-12-20|Estimate|November 2004||2004-11-30|December 2016|2016-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|SAFE||Brief Intervention to Reduce STDs in ER Drug Users|Brief Intervention to Reduce STDs in ER Drug Users|Completed||Phase 3|1030|Actual|Boston Medical Center||2|||f||||t||||||||Yes|de-identified may be shared on request|2018-05-31 22:28:07.252933|2018-05-31 22:28:07.252933
NCT01379586|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-06-12|2011-06-21|2011-06-23|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2011||2011-06-30|June 2012|2012-06-30||||July 2011|Actual|2011-07-31||Interventional|||A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of ONO-4053 in Healthy Volunteers|A Phase 1, Single Centre, Three-part, Randomised, Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Multiple Ascending Doses of Oral ONO-4053 and the Effects of Food on This Profile in Healthy Male and Female Subjects|Terminated||Phase 1|15|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 22:28:07.498544|2018-05-31 22:28:07.498544
NCT01379573|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-10-11|2011-06-22|2011-06-23|Estimate|||||||2017-10-11|2017-10-13|Actual|January 2011||2011-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PATCH||Preventive Approach to Congenital Heart Block With Hydroxychloroquine|Preventive Approach to Congenital Heart Block With Hydroxychloroquine|Recruiting||Phase 2|54|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 22:28:07.578802|2018-05-31 22:28:07.578802
NCT01379560|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-03-21|2011-06-21|2011-06-23|Estimate|||||||2013-03-21|2013-03-22|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration||Completed||Phase 2|33|Actual|Sucampo Pharma Americas, LLC||2|||f||||||||||||||2018-05-31 22:28:07.830012|2018-05-31 22:28:07.830012
NCT01379547|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-11-26|2011-06-22|2011-06-23|Estimate|||||||2012-11-26|2012-11-27|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|ProShort||Procalcitonin to Shorten Antibiotics Duration in ICU Patients|Procalcitonin to Shorten Antibiotics Duration in ICU Patients- A China, Hong-Kong, Taiwan Multicenter Trial|Unknown status|Recruiting|Phase 3|1700|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 22:28:07.949995|2018-05-31 22:28:07.949995
NCT01379534|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2015-03-18||2015-05-02|2011-06-22|2011-06-23|Estimate|2015-03-18|2015-03-31|Estimate||||2015-05-02|2015-05-20|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer|A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer|Completed||Phase 2|53|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:28:08.206139|2018-05-31 22:28:08.206139
NCT01379521|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2016-06-09||2017-04-13|2011-06-22|2011-06-23|Estimate|2017-04-13|2017-05-03|Actual||||2017-04-13|2017-05-03|Actual|June 2011||2011-06-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TRACER||Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC|A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor®) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study|Terminated||Phase 2|65|Actual|Novartis||2||"The study was terminated due to low enrollment. This resulted in the study being underpowered~   and inconclusive."|f||||t||||||||||2018-05-31 22:28:09.43812|2018-05-31 22:28:09.43812
NCT01379508|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-04-20|2011-06-22|2011-06-23|Estimate|||||||2016-04-20|2016-04-21|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Sebivo/Tyzeka||Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept|OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept|Completed||Phase 4|241|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:28:09.951677|2018-05-31 22:28:09.951677
NCT01379495|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-05-22|2011-06-21|2011-06-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Education Program for Burn Patients|Randomized Controlled Clinical Trial on Telephone Follow-up in Rehabilitation of Burn Patients: Impact on Health Status|Completed||N/A|83|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:28:10.223773|2018-05-31 22:28:10.223773
NCT01379482|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2014-05-05|2011-06-21|2011-06-23|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2005||2005-01-31|May 2011|2011-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer|Phase II Study of Patients With Peritoneal Carcinomatosis From Gastric Cancer Treated With Preoperative Systemic Chemotherapy Followed by Peritonectomy and Intraperitoneal Chemotherapy|Completed||Phase 2|18|Actual|Uppsala University||1|||f||||f||||||||||2018-05-31 22:28:10.371493|2018-05-31 22:28:10.371493
NCT01379469|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2018-05-11|2011-06-21|2011-06-23|Estimate|||||||2018-05-11|2018-05-17|Actual|January 2012||2012-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CBZ||Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency|A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency|Recruiting||Phase 2|30|Anticipated|Washington University School of Medicine||2|||f||||t||||||||Yes|We will share data and liver tissue with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. We may also share research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at the information.|2018-05-31 22:28:10.60772|2018-05-31 22:28:10.60772
NCT01379456|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2017-09-21|2011-06-21|2011-06-23|Estimate|||||||2017-09-21|2017-09-25|Actual|February 2011|Actual|2011-02-28|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Eva-Hip||Eva-Hip, Evaluation of Rehabilitation After Hip-fracture|The Effect on Gait and Activity Level of a Physiotherapy Intervention Aimed at Improving Mediolateral Stability 4 Months After a Hip Fracture|Completed||N/A|223|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 22:28:10.868516|2018-05-31 22:28:10.868516
NCT01379443|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Rehabilitation of Children With Multiple Disabilities|The Comparative Effect and Expense of More and Less Integration of Services That Provide Treatment and Rehabilitation for Children With Multiple Disabilities: A Randomized Controlled Trial|Completed||Phase 1|445|Actual|Children's Treatment Network||2|||f||||f||||||||||2018-05-31 22:28:11.072463|2018-05-31 22:28:11.072463
NCT01379430|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2012-10-02|2011-06-21|2011-06-23|Estimate|||||||2012-10-02|2012-10-03|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas|Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults in a Malaria Endemic Area|Completed||Phase 1|30|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 22:28:11.184844|2018-05-31 22:28:11.184844
NCT01379417|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-08-26|2011-06-21|2011-06-23|Estimate|||||||2011-08-26|2011-08-29|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Probiotics Supplementation in Premature Infants|Probiotics Supplementation and Nutritional Benefit in Premature Infants|Completed||N/A|199|Actual|Nestlé||4|||f||||f||||||||||2018-05-31 22:28:11.252689|2018-05-31 22:28:11.252689
NCT01379404|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-05-19|2011-06-21|2011-06-23|Estimate|||||||2015-05-19|2015-05-20|Estimate|February 2011||2011-02-28|May 2015|2015-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|BIOVISION||Bioimpedance Analysis in Septic Intensive Care Unit (ICU) Patients|Does Bio-impedance Analysis Predict Volume Overload States and Clinically Relevant Outcomes in Septic Intensive Care Unit (ICU) Patients With Acute Kidney Injury? A Prospective Observational Study|Completed|||55|Actual|St. Joseph's Healthcare Hamilton|||||f||||f||||||Samples Without DNA|"~     Blood only for chemistry.~   "|||2018-05-31 22:28:11.319754|2018-05-31 22:28:11.319754
NCT01379391|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-10-07|2011-06-21|2011-06-23|Estimate|||||||2015-10-07|2015-10-09|Estimate|June 2010||2010-06-30|September 2015|2015-09-30||||September 2015|Actual|2015-09-30||Interventional|TPO||Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT|A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China|Unknown status|Recruiting|Phase 4|80|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 22:28:11.403543|2018-05-31 22:28:11.403543
NCT01379378|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-07-20|2011-06-22|2011-06-23|Estimate|||||||2016-07-20|2016-07-22|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Male Stress Urinary Incontinence and Sexual Health|Male Stress Urinary Incontinence and Sexual Health|Withdrawn|||0|Actual|Stanford University|||||f||||t||||||||||2018-05-31 22:28:11.556601|2018-05-31 22:28:11.556601
NCT01379365|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-03-23|2011-06-21|2011-06-23|Estimate|||||||2015-03-23|2015-03-24|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Cryo-Touch III Refinement Study Investigational Plan||Completed||Phase 2/Phase 3|88|Actual|MyoScience, Inc||1|||f||||f||||||||||2018-05-31 22:28:11.674107|2018-05-31 22:28:11.674107
NCT01379352|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-12-24|2011-06-22|2011-06-23|Estimate|||||||2013-12-24|2013-12-25|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia|Vecuronium Requirements According to the Operation Phase During Liver Transplantation Under Desflurane Anesthesia|Completed|||35|Actual|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 22:28:11.758484|2018-05-31 22:28:11.758484
NCT01379339|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2015-02-09|2011-06-22|2011-06-23|Estimate|||||||2015-02-09|2015-02-11|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Cabazitaxel - PF Induction Chemotherapy|Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|40|Actual|Icahn School of Medicine at Mount Sinai||5|||f||||t||||||||||2018-05-31 22:28:11.861918|2018-05-31 22:28:11.861918
NCT01379326|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-12-04|2011-06-22|2011-06-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ConWorm||Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2|The Efficacy of a Single-dose Mebendazole Against Soil-transmitted Helminths in School Children|Completed||Phase 4|250|Actual|University Ghent||1|||f||||f||||||||||2018-05-31 22:28:13.514359|2018-05-31 22:28:13.514359
NCT01379313|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-09-27|2011-06-22|2011-06-23|Estimate|||||||2012-09-27|2012-10-01|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position|The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position|Completed||N/A|100|Actual|Samsung Medical Center||4|||f||||f||||||||||2018-05-31 22:28:13.599901|2018-05-31 22:28:13.599901
NCT01379300|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-10-01|2011-06-21|2011-06-23|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)|A Randomized Clinical Trial to Validate Novel Biomarker Approaches After Single Doses of Anticoagulants in Healthy Young Male Subjects and in Healthy Elderly Subjects|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 22:28:13.71021|2018-05-31 22:28:13.71021
NCT01379287|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-07-05|2011-06-21|2011-06-23|Estimate|||||||2017-07-05|2017-07-06|Actual|June 2011|Actual|2011-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors|A Phase I, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|29|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:28:13.771484|2018-05-31 22:28:13.771484
NCT01379274|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-11-26|2011-06-21|2011-06-23|Estimate|||||||2013-11-26|2013-11-28|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes|A Phase II Trial of Revlimid® (Lenalidomide) and Low Dose Vidaza® (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes|Terminated||Phase 2|2|Actual|Rush University Medical Center||1||Loss of funding.|f||||t||||||||||2018-05-31 22:28:13.836611|2018-05-31 22:28:13.836611
NCT01379261|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-11-05|2011-06-21|2011-06-23|Estimate|||||||2014-11-05|2014-11-06|Estimate|June 2011||2011-06-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|CHILL-MI||Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction|Rapid Endovascular Catheter Core Cooling Combined With Cold Saline as an Adjunct to Percutaneous Coronary Intervention For the Treatment of Acute Myocardial Infarction|Completed||Phase 2/Phase 3|120|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 22:28:13.935128|2018-05-31 22:28:13.935128
NCT01379248|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2016-10-27|2011-06-21|2011-06-23|Estimate|||||||2016-10-27|2016-10-28|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset||Completed||Phase 4|152|Actual|University of Leipzig||2|||f||||||||||||||2018-05-31 22:28:14.111085|2018-05-31 22:28:14.111085
NCT01379235|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2014-11-18|2011-06-22|2011-06-23|Estimate|||||||2014-11-18|2014-11-19|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|July 2013|Actual|2013-07-31|October 2012|Actual|2012-10-31||Interventional|||Association Between Pilatis Exercise, Balance and Stability Measurements, and Quality of Life Among Elderly Population|Association Between Pilatis Exercise, Balance and Stability Measurements, and Quality of Life Among Elderly Population|Completed||N/A|88|Actual|Meir Medical Center||2|||f||||t||||||||||2018-05-31 22:28:14.198415|2018-05-31 22:28:14.198415
NCT01379222|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2017-10-31|2011-06-22|2011-06-23|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2011||2011-08-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|September 2017|Actual|2017-09-30||Interventional|ENGAGE PAS||Endurant Stent Graft System Post Approval Study|Post Approval Study Evaluating the Long Term Safety and Effectiveness of the Endurant Stent Graft System (ENGAGE PAS)|Active, not recruiting||N/A|178|Actual|Medtronic Endovascular||1|||f||||f||||||||No||2018-05-31 22:28:14.282559|2018-05-31 22:28:14.282559
NCT01379209|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2015-10-26|2011-06-21|2011-06-23|Estimate|||||||2015-10-26|2015-10-27|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)|A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)|Unknown status|Active, not recruiting|Phase 1/Phase 2|71|Anticipated|Regimmune Inc.||1|||f||||t||||||||||2018-05-31 22:28:14.36418|2018-05-31 22:28:14.36418
NCT01379196|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2017-04-25|2011-06-22|2011-06-23|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2011||2011-05-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy|Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy|Withdrawn||Phase 1/Phase 2|0|Actual|Rabin Medical Center||1||Patients were not interested in enrolling|f||||t||||||||Undecided||2018-05-31 22:28:14.473653|2018-05-31 22:28:14.473653
NCT01379183|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|2013-12-11||2016-02-19|2011-06-22|2011-06-23|Estimate|2013-12-11|2014-01-27|Estimate||||2016-02-19|2016-03-21|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility|Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility|Completed||Phase 2/Phase 3|40|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 22:28:14.563098|2018-05-31 22:28:14.563098
NCT01379170|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-05-13|2011-06-22|2011-06-23|Estimate|||||||2013-05-13|2013-05-14|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Thyroid Study Type 2 Diabetes Mellitus (T2DM)|Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 4|17|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 22:28:14.835646|2018-05-31 22:28:14.835646
NCT01379157|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2017-09-19|2011-06-21|2011-06-23|Estimate|||||||2017-09-19|2017-09-20|Actual|November 2011||2011-11-30|December 2011|2011-12-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional|||Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia|The Pharmacodynamics of Imipenem in Critically Ill Patients With Ventilator-associated Pneumonia Following Administration by 4 h or 0.5 h Infusion|Completed||Phase 4|8|Actual|Prince of Songkla University||2|||f||||f||||||||||2018-05-31 22:28:14.900349|2018-05-31 22:28:14.900349
NCT01379144|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-21|2011-06-21|2011-06-23|Estimate|||||||2011-06-21|2011-06-23|Estimate|January 2003||2003-01-31|June 2011|2011-06-30|April 2003|Actual|2003-04-30|March 2003|Actual|2003-03-31||Interventional|||A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension|A 4 Week, Dose-Ranging, Multi-Center, Randomized, Double-Masked, Parallel Study Comparing The Efficacy, Safety, And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma Aand Ocular Hypertension|Completed||Phase 2|282|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:28:14.99229|2018-05-31 22:28:14.99229
NCT01379131|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2015-10-01|2011-06-22|2011-06-23|Estimate|||||||2015-10-01|2015-10-02|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Previous Cardiovascular Disease, Cardiovascular Risk Factors and Chest Pain in First Myocardial Infarction|MI as the First Manifestation of Coronary Heart Disease: Distribution of Previous Cardiovascular Disease, Cardiovascular Risk Factors and Chest Pain in First MI|Completed|||9000|Actual|London School of Hygiene and Tropical Medicine|||1||f||||t||||||||||2018-05-31 22:28:15.11153|2018-05-31 22:28:15.11153
NCT01379118|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-09-14|2011-06-22|2011-06-23|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|TKR||Comparison of Clinical Outcomes and Performance of Total Knee Replacement Patients Before and After Surgery|Comparison of Clinical Scales and Quantitative Knee Motion Data in Assessing the Clinical Outcomes and Performance of Total Knee Replacement Patients Before and After Surgery|Completed|||50|Anticipated|Loma Linda University|||||f||||t||||||||||2018-05-31 22:28:15.176299|2018-05-31 22:28:15.176299
NCT01379105|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Electromyographic Responses by Static Stretching and Neural Mobilization|Electromyographic Responses of Sedentary Students Submitted to Static Stretching and Neural Mobilization|Completed||N/A|45|Actual|Euro-American Network of Human Kinetics||1|||f||||t||||||||||2018-05-31 22:28:15.339302|2018-05-31 22:28:15.339302
NCT01378195|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2012-08-30||2013-02-22|2011-06-20|2011-06-22|Estimate|2012-12-05|2013-01-08|Estimate||||2013-02-22|2013-02-28|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|iCare||iCare Stress Management e-Training for Dementia Family Caregivers|iCare Stress Management e-Training for Dementia Family Caregivers|Completed||Phase 2|150|Actual|Photozig, Inc.||2|||f||||||||||||||2018-05-31 22:28:29.184077|2018-05-31 22:28:29.184077
NCT01379092|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2012-03-15|2011-06-21|2011-06-23|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging|An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging|Unknown status|Recruiting|N/A|100|Anticipated|Levine, Gary M. , M.D.||1|||f||||f||||||||||2018-05-31 22:28:15.427814|2018-05-31 22:28:15.427814
NCT01379079|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2014-05-12|2011-06-22|2011-06-23|Estimate|||||||2014-05-12|2014-05-14|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|ASPIRETENSION||Aspirin in Reduction of Tension II Study|Aspirin AM or PM in Reduction of Tension: a Randomized Cross-over Trial|Completed||Phase 4|290|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 22:28:15.521293|2018-05-31 22:28:15.521293
NCT01379066|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-08-12|2011-06-22|2011-06-23|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|TBVOC||Tuberculosis Volatile Organic Compounds|Detection of Mycobacteria in Lungs and Culture Using an Ultra-fast Gas Chromatograph|Completed|||15|Actual|Landon Pediatric Foundation|||2||f||||f||||||||||2018-05-31 22:28:15.604246|2018-05-31 22:28:15.604246
NCT01379053|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-08-12|2011-06-22|2011-06-23|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|MRSAVOC||Volatile Organic Compounds in Staphylococcus Aureus Patients|Detection of Methicillin Resistant Staphylococcus Aureus Colonization Using the zNose®, an Ultra-fast Gas Chromatograph|Completed|||10|Actual|Landon Pediatric Foundation|||2||f||||f||||||||||2018-05-31 22:28:15.665053|2018-05-31 22:28:15.665053
NCT01379040|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-08-12|2011-06-22|2011-06-23|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|VOCCF||Volatile Organic Compounds in Cystic Fibrosis|Detection of Pulmonary Colonization in Cystic Fibrosis Patients|Completed|||24|Actual|Landon Pediatric Foundation|||2||f||||f||||||||||2018-05-31 22:28:15.732412|2018-05-31 22:28:15.732412
NCT01379027|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2018-03-06|2011-06-22|2011-06-23|Estimate|||||||2018-03-06|2018-03-08|Actual|October 2011||2011-10-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||MoodHelper: Internet Cognitive Behavioral Therapy (CBT) for Depression|Internet CBT for Depression: Comparing Pure, Guided, and Stepped Care|Completed||N/A|1816|Actual|Kaiser Permanente||4|||f||||t||||||||||2018-05-31 22:28:15.820266|2018-05-31 22:28:15.820266
NCT01379014|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-11-01|2011-06-22|2011-06-23|Estimate|||||||2011-11-01|2011-11-02|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|CORAL||CORAL Study: Proof of Concept Trial|The CORAL Study of a Decision Aid Tool Regarding Disclosure of Mental Health Status to an Employer: Proof of Concept Randomised Control Trial|Unknown status|Recruiting|N/A|84|Anticipated|Institute of Psychiatry, London||2|||f||||f||||||||||2018-05-31 22:28:15.899486|2018-05-31 22:28:15.899486
NCT01379001|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-01-03|2011-06-22|2011-06-23|Estimate|||||||2013-01-03|2013-01-04|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI|Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI|Completed||N/A|60|Actual|Hebrew Rehabilitation Center, Boston||2|||f||||f||||||||||2018-05-31 22:28:15.984608|2018-05-31 22:28:15.984608
NCT01378988|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2015-05-29|2012-09-12|2015-06-29|2011-06-22|2011-06-23|Estimate|2015-06-29|2015-07-24|Estimate|2012-09-12|2012-09-14|Estimate|2015-06-29|2015-07-24|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Safety Evaluable Population consisted of all subjects who received any amount of study drug.|Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months|A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and Pharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged 12 Months Through <24 Months|Completed||Phase 2|5|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-05-31 22:28:16.107498|2018-05-31 22:28:16.107498
NCT01378975|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2016-06-20||2016-06-20|2011-06-21|2011-06-23|Estimate|2016-06-20|2016-08-01|Estimate||||2016-06-20|2016-08-01|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||The intent-to-treat (ITT) population included all participants who were enrolled in the study.|A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases|An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases|Completed||Phase 2|146|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:28:16.825943|2018-05-31 22:28:16.825943
NCT01378962|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|2015-09-30||2017-12-21|2011-06-21|2011-06-23|Estimate|2015-10-01|2015-10-29|Estimate||||2017-12-21|2018-01-23|Actual|March 31, 2011|Actual|2011-03-31|December 2017|2017-12-31|January 31, 2017|Actual|2017-01-31|June 30, 2013|Actual|2013-06-30||Interventional||Safety population included all participants enrolled in the study who received at least 1 dose of treatment and had at least 1 safety assessment.|A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)|Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (EGFR) - (TRIGGER)|Completed||Phase 2|50|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:28:18.576375|2018-05-31 22:28:18.576375
NCT01378949|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-19|||2011-06-22|2011-06-22|2011-06-23|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Psoas Compartment Block Versus Fascia Iliaca Block After Total Hip Arthroplasty||Unknown status|Not yet recruiting|N/A|90|Anticipated|Hillel Yaffe Medical Center||3|||f||||t||||||||||2018-05-31 22:28:19.105792|2018-05-31 22:28:19.105792
NCT01378936|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-05-03|2011-06-22|2011-06-23|Estimate|||||||2013-05-03|2013-05-07|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|December 2013|Anticipated|2013-12-31||Interventional|IOC||Jail-Based Impact of Crime Intervention|Phase 2 RCT of Jail-Based Impact of Crime Intervention to Reduce Recidivism, Substance Abuse and HIV Risk Behavior|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|George Mason University||2|||f||||t||||||||||2018-05-31 22:28:19.237393|2018-05-31 22:28:19.237393
NCT01378923|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-05-03|2011-06-22|2011-06-23|Estimate|||||||2013-05-03|2013-05-07|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|REVAMP||Evaluation of Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates|Pilot Evaluation of the Re-Entry Values and Mindfulness Program (REVAMP) With Jail Inmates|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|George Mason University||2|||f||||t||||||||||2018-05-31 22:28:19.569696|2018-05-31 22:28:19.569696
NCT01378910|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2014-07-02|2011-06-22|2011-06-23|Estimate|||||||2014-07-02|2014-07-03|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia|Use Of Genotypic HIV-1 Tropism Testing In Proviral DNA To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia|Completed||Phase 4|74|Actual|Fundacio Lluita Contra la SIDA||1|||f||||f||||||||||2018-05-31 22:28:19.751011|2018-05-31 22:28:19.751011
NCT01378897|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-08-10|2011-06-22|2011-06-23|Estimate|||||||2016-08-10|2016-08-11|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Bariatric Surgery Telemedicine Study|A Telehealth Innovation to Support Weight Loss|Withdrawn||Phase 1|0|Actual|Baystate Medical Center||||PI decided to not initiate this study.|f||||f||||||||||2018-05-31 22:28:19.989396|2018-05-31 22:28:19.989396
NCT01378884|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2013-03-18|2011-06-22|2011-06-23|Estimate|||||||2013-03-18|2013-03-19|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|March 2012|Anticipated|2012-03-31||Interventional|||The Use of Domperidone for Gastroparesis|Monitoring Study for the Use of Gastroparesis for Patient Who Have Failed Standard Therapy|Withdrawn||Phase 3|0|Actual|Allegiance Health||1|||f||||t||||||||||2018-05-31 22:28:20.056994|2018-05-31 22:28:20.056994
NCT01378871|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-02-12|2011-06-22|2011-06-23|Estimate|||||||2015-02-12|2015-02-13|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma|Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma|Completed||Phase 2|1|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||f||||||||||2018-05-31 22:28:20.137031|2018-05-31 22:28:20.137031
NCT01378858|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2018-04-24|2011-06-22|2011-06-23|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2011||2011-07-31|April 2018|2018-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients|Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients|Completed||N/A|112|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 22:28:20.290238|2018-05-31 22:28:20.290238
NCT01378845|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2014-12-12|2011-06-20|2011-06-22|Estimate|||||||2014-12-12|2014-12-15|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|Anti-Vasospasm||Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands|Monocenter, IIT, Open Controlled and Prospectiv Study to Define the Prognostic Influence of Light Rheography Measurement of Patients With Secundary Raynaud Syndrome With Ulcers at Fingertips Throughout the Medicinal Therapy|Unknown status|Recruiting|N/A|30|Anticipated|University of Freiburg||2|||f||||f||||||||||2018-05-31 22:28:20.450343|2018-05-31 22:28:20.450343
NCT01378832|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|lavage||Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Colorectal Cancer Infection in Elective Surgery|Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Infection in Elective Surgery|Completed||Phase 3|102|Actual|Universidad Miguel Hernandez de Elche|||||f||||f||||||||||2018-05-31 22:28:20.720061|2018-05-31 22:28:20.720061
NCT01378819|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||3-midline-ports Cholecystectomy|Three Ports Placed in the Line Alba of the Abdomen (3-midline-ports Technique): an Alternative Approach for Laparoscopic Cholecystectomy|Completed||Phase 3|100|Actual|Universidad Miguel Hernandez de Elche|||||f||||f||||||||||2018-05-31 22:28:20.84401|2018-05-31 22:28:20.84401
NCT01378806|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2012-07-12|2011-06-20|2011-06-22|Estimate|||||||2012-07-12|2012-07-13|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|WEIGHT||Family Partners for Health|Children and Parents Partnering Together to Manage Their Weight|Completed||N/A|718|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 22:28:20.952989|2018-05-31 22:28:20.952989
NCT01378793|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-02-02|2011-06-20|2011-06-22|Estimate|||||||2017-02-02|2017-02-06|Estimate|June 15, 2011|Actual|2011-06-15|February 2017|2017-02-28|December 15, 2013|Actual|2013-12-15|December 15, 2013|Actual|2013-12-15||Interventional|AcuSnooze||Acupressure for Insomnia|Acupressure for Chronic Insomnia in Adults With Chronic Low Back Pain|Terminated||N/A|5|Actual|University of Michigan||3||Inadequate enrollement|f||||f||||||||||2018-05-31 22:28:21.061996|2018-05-31 22:28:21.061996
NCT01378780|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2015-04-27|2011-06-21|2011-06-22|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SHARE||Stroke Health and Risk Education (SHARE)|Stroke Health and Risk Education (SHARE)|Completed||N/A|760|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:28:21.155411|2018-05-31 22:28:21.155411
NCT01378767|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-20|2011-06-20|2011-06-22|Estimate|||||||2011-06-20|2011-06-22|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Health Benefits of a 21-day Daniel Fast|Biochemical, Hemodynamic, and Anthropometric Effects of a 21-day Daniel Fast in Men and Women|Completed||N/A|39|Actual|University of Memphis||2|||f||||f||||||||||2018-05-31 22:28:21.22565|2018-05-31 22:28:21.22565
NCT01378754|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-10-02|2011-06-20|2011-06-22|Estimate|||||||2012-10-02|2012-10-03|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia|A DOSE RANGING STUDY TO EVALUATE THE EFFECTIVENESS OF FOSPROPOFOL (LUSEDRA®) FOR INDUCTION OF ANESTHESIA FOR OUTPATIENT UROLOGIC HYDRODILATION THERAPY|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||3||Loss of funding before enrollment.|f||||t||||||||||2018-05-31 22:28:21.307639|2018-05-31 22:28:21.307639
NCT01378741|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-04-17|2011-06-21|2011-06-22|Estimate|||||||2015-04-17|2015-04-21|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|July 2014|Actual|2014-07-31||Interventional|||Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care|Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care|Completed||N/A|185|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:28:21.447396|2018-05-31 22:28:21.447396
NCT01378728|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-05-18|2011-06-21|2011-06-22|Estimate|||||||2017-05-18|2017-05-19|Actual|February 2009||2009-02-28|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Clinical Validation of a 'Hand-held' Fluorescence Digital Imaging Device for Wound Care Applications|Clinical Validation Study of a 'Hand-held' Point-of-Care Fluorescence Digital Imaging Device for Real-time Detection and Diagnosis of Wound Infections and Longitudinal Monitoring of Wound Healing Status|Completed|||75|Actual|University Health Network, Toronto|||1||f||||t||||||||||2018-05-31 22:28:21.675832|2018-05-31 22:28:21.675832
NCT01378715|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-20|2011-06-20|2011-06-22|Estimate|||||||2011-06-20|2011-06-22|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|TIPS-3||Rosuvastatin Pre-Treatment Influences the Risk of Coronary Intervention Study|Rosuvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study (TIPS-3)|Unknown status|Recruiting|Phase 3|400|Anticipated|University Hospital, Motol||2|||f||||f||||||||||2018-05-31 22:28:21.798092|2018-05-31 22:28:21.798092
NCT01378702|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-06-20|2011-06-20|2011-06-22|Estimate|||||||2011-06-20|2011-06-22|Estimate|January 2008||2008-01-31|May 2007|2007-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Immunological Effects of Two Mistletoe Preparations in Healthy Volunteers|Safety and Immunological Effects of Iscucin Populi and Viscum Mali e Planta Tota in Healthy Volunteers|Completed||Phase 1|71|Actual|University Hospital Freiburg||3|||f||||t||||||||||2018-05-31 22:28:21.951999|2018-05-31 22:28:21.951999
NCT01378689|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-01-14|2011-06-20|2011-06-22|Estimate|||||||2013-01-14|2013-01-16|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids|Improving Bone Health Among RA Patients on Chronic Glucocorticoids|Completed||Phase 4|4659|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 22:28:22.153275|2018-05-31 22:28:22.153275
NCT01378676|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-09-16|2011-06-21|2011-06-22|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|50|Actual|Cytokinetics||4|||f||||f||||||||||2018-05-31 22:28:22.319836|2018-05-31 22:28:22.319836
NCT01378663|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2012-03-19|2011-06-21|2011-06-22|Estimate|||||||2012-03-19|2012-03-20|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Review of Pain Management After Congenital Cardiac Surgery|Review of Pain Management After Congenital Cardiac Surgery|Completed|||92|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 22:28:22.55906|2018-05-31 22:28:22.55906
NCT01378650|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2014-05-21|2011-06-21|2011-06-22|Estimate|||||||2014-05-21|2014-05-22|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|CITI-ESR||A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus|A Randomized, Prospective, Placebo-controlled Double-blind, Pilot Study on the Effect of Cilostazol for 4 Weeks in Patients With Chronic Tinnitus|Completed||N/A|50|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 22:28:22.755694|2018-05-31 22:28:22.755694
NCT01378637|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-12-07|2011-06-21|2011-06-22|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|December 2016|Actual|2016-12-31||Interventional|AMES||AMES Treatment of the Impaired Leg in Chronic Stroke Patients|AMES Treatment of the Impaired Leg in Chronic Stroke Patients|Active, not recruiting||Phase 1/Phase 2|22|Actual|AMES Technology||1|||f||||t||||||||No||2018-05-31 22:28:22.878905|2018-05-31 22:28:22.878905
NCT01378624|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-10-30|2011-06-21|2011-06-22|Estimate|||||||2013-10-30|2013-10-31|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Ex Vivo Effect of Surfactant Protein D on Pulmonary Cells in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging|Ex Vivo Effect of Fragments and Modified Forms of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma and Pilot Study to Assess Local Inflammation Induced by Segmental Allergen Challenge by Magnetic Resonance Imaging|Completed||N/A|15|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f||||f||||||||||2018-05-31 22:28:23.007868|2018-05-31 22:28:23.007868
NCT01378611|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-28|2011-06-21|2011-06-22|Estimate|||||||2011-06-28|2011-06-29|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|March 2013|Anticipated|2013-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy?|Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy? A Randomized Clinical Study.|Unknown status|Active, not recruiting|Phase 2/Phase 3|45|Anticipated|Epilepsiecentrum Kempenhaeghe||2|||f||||t||||||||||2018-05-31 22:28:23.13564|2018-05-31 22:28:23.13564
NCT01378598|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2012-06-22|2011-06-21|2011-06-22|Estimate|||||||2012-06-22|2012-06-26|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer|Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer: A Feasibility Pilot Study|Completed||N/A|30|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-05-31 22:28:23.278921|2018-05-31 22:28:23.278921
NCT01378585|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2012-08-21|2011-06-21|2011-06-22|Estimate|||||||2012-08-21|2012-08-23|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Efficacy of DLBS1033 in Healthy Subjects|A Randomized, Double Blind, Placebo Controlled, Cross-over, and Fixed Dose Study to Evaluate the Safety and Efficacy of DLBS1033 in Healthy Subjects|Completed||N/A|20|Actual|Dexa Medica Group||2|||f||||||||||||||2018-05-31 22:28:23.391432|2018-05-31 22:28:23.391432
NCT01378572|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2009||2009-11-30|June 2011|2011-06-30||||||||Observational|EMOSIDD||Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implantation of Defibrillators in Dilated Cardiomyopathy||Unknown status|Recruiting||200|Anticipated|Catholic University of the Sacred Heart|||||f||||t||||||||||2018-05-31 22:28:23.483116|2018-05-31 22:28:23.483116
NCT01378559|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-02-21|2011-06-21|2011-06-22|Estimate|||||||2012-02-21|2012-02-22|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Patient Satisfaction and Complications With the New Titan® One Touch Release (OTR) Penis Prosthesis|Patient Satisfaction and Complications With the New Titan® One Touch Release (OTR) Penis Prosthesis|Completed|||26|Actual|Copenhagen University Hospital at Herlev|||1||f||||f||||||||||2018-05-31 22:28:23.586224|2018-05-31 22:28:23.586224
NCT01378546|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-07-17|2011-06-21|2011-06-22|Estimate|||||||2013-07-17|2013-07-18|Estimate|May 2005||2005-05-31|July 2013|2013-07-31||||May 2015|Anticipated|2015-05-31||Expanded Access|||Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP|Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes With 3, 4-Diaminopyridine|No longer available|||||Columbia University|||||||||f||||||||||2018-05-31 22:28:23.735373|2018-05-31 22:28:23.735373
NCT01373385|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-01-03|2011-06-14|2011-06-15|Estimate|||||||2017-01-03|2017-01-05|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Prospective Pediatric Vesicoureteral Reflux Surgery Database|Prospective Pediatric Vesicoureteral Reflux Surgery Database|Completed|||134|Actual|Connecticut Children's Medical Center|||1||f||||f||||||||No||2018-05-31 22:30:41.47251|2018-05-31 22:30:41.47251
NCT01378533|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-12-27|2011-06-21|2011-06-22|Estimate|||||||2011-12-27|2011-12-28|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|||The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC|Randomized Phase Ⅲ Trial Comparing Dose-dense Epirubicin and Cyclophosphamide Followed by Paclitaxel With Paclitaxel Plus Carboplatin as Adjuvant Therapy for Triple-negative Breast Cancer.|Unknown status|Recruiting|Phase 3|100|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:28:23.824999|2018-05-31 22:28:23.824999
NCT01378520|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2013-09-11||2013-09-11|2011-06-21|2011-06-22|Estimate|2013-09-11|2013-11-14|Estimate||||2013-09-11|2013-11-14|Estimate|June 2011||2011-06-30|September 2013|2013-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|KetoRLB||Effect of Ketoconazole on Breathlessness|The Effect of Ketoconazole on Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|20|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 22:28:23.912482|2018-05-31 22:28:23.912482
NCT01378507|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2009||2009-01-31|May 2011|2011-05-31|April 2013|Anticipated|2013-04-30|June 2011|Anticipated|2011-06-30||Interventional|||Endoscopic Submucosal Dissection for Gastrointestinal Neoplasms|Endoscopic Submucosal Dissection for Gastrointestinal Neoplasms|Unknown status|Recruiting|N/A|500|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 22:28:24.192069|2018-05-31 22:28:24.192069
NCT01378494|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2016-05-31|2011-06-20|2011-06-22|Estimate|||||||2016-05-31|2016-06-02|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Bone Mineral Density in HIV+ Patients|Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)|Completed|||200|Anticipated|University of Alabama at Birmingham|||1||f||||f||||||||||2018-05-31 22:28:24.311619|2018-05-31 22:28:24.311619
NCT01378481|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2014-12-22|2011-06-21|2011-06-22|Estimate|||||||2014-12-22|2014-12-23|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma|High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:28:24.41341|2018-05-31 22:28:24.41341
NCT01378468|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2017-01-30|2011-06-21|2011-06-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2009||2009-01-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Observational|||Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke|The Berlin 'Cream&Sugar' Study: the Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke|Active, not recruiting|||573|Actual|Charite University, Berlin, Germany|||1||f||||t||||||||||2018-05-31 22:28:24.572163|2018-05-31 22:28:24.572163
NCT01378455|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-10-03|2011-06-21|2011-06-22|Estimate|||||||2016-10-03|2016-10-05|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|February 2015|Actual|2015-02-28|March 2012|Actual|2012-03-31||Interventional|||Effectiveness of Handwriting Training Program on Handwriting Performance in Cerebral Palsy|Effectiveness of Interactive Computerized Handwriting Training Program on Handwriting Performance in Children With Cerebral Palsy|Completed||N/A|20|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:28:24.693417|2018-05-31 22:28:24.693417
NCT01378442|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-06-10|2011-06-21|2011-06-22|Estimate|||||||2013-06-10|2013-06-12|Estimate|August 2007||2007-08-31|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Relationship of Bone Strength and Fitness Training in Children With Cerebral Palsy|The Relationship of Bone Strength and Fitness Training in Children With Cerebral Palsy|Completed||N/A|60|Actual|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 22:28:24.821606|2018-05-31 22:28:24.821606
NCT01378429|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2013-12-19|2012-11-02|2014-04-29|2011-06-21|2011-06-22|Estimate|2014-04-29|2014-05-26|Estimate|2012-11-02|2012-11-06|Estimate|2014-04-29|2014-05-26|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis|A 6-Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|89|Actual|Sunovion||2|||f||||f||||||||||2018-05-31 22:28:25.103116|2018-05-31 22:28:25.103116
NCT01378416|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2008-09-30||2011-07-02|2011-05-25|2011-06-22|Estimate|2011-05-25|2011-06-22|Estimate||||2011-07-02|2011-07-12|Estimate|April 2005||2005-04-30|July 2011|2011-07-31|June 2007|Actual|2007-06-30|January 2006|Actual|2006-01-31||Interventional|||Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|A Phase I Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Completed||Phase 1|16|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 22:28:25.979358|2018-05-31 22:28:25.979358
NCT01378403|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Evaluation of Dorsal Visual Stream in Patients With Schizophrenia|Evaluation of Dorsal Visual Stream in Patients With Schizophrenia|Completed|||22|Actual|Sheba Medical Center|||||f||||f||||||||||2018-05-31 22:28:26.730341|2018-05-31 22:28:26.730341
NCT01378390|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|FATT||Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease|Randomized, Single-blind, Placebo Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Expanded Autologous Adipose-derived Stem Cells (ASCs) (CX-401), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease|Terminated||Phase 3|56|Actual|Cellerix||2||"After the investigators and experts in the field imput it became apparent that the protocol was~   not reflective of clinical reality. No safety issues reported."|f||||t||||||||||2018-05-31 22:28:26.920066|2018-05-31 22:28:26.920066
NCT01378377|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2014-06-13|2011-06-21|2011-06-22|Estimate|||||||2014-06-13|2014-06-16|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Combination Trial MSC1936369B With Temsirolimus|Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors|Completed||Phase 1|46|Actual|EMD Serono||1|||f||||f||||||||||2018-05-31 22:28:27.14187|2018-05-31 22:28:27.14187
NCT01377610|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2018-05-17|2011-06-20|2011-06-21|Estimate|||||||2018-05-17|2018-05-21|Actual|June 2011||2011-06-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Improved Strategies for Outpatient Opioid Detoxification|Long-acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone vs. Buprenorphine|Completed||Phase 1|150|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 22:28:40.529741|2018-05-31 22:28:40.529741
NCT01378364|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-10-31|2011-06-21|2011-06-22|Estimate|||||||2013-10-31|2013-11-01|Estimate|June 2011||2011-06-30|October 2013|2013-10-31||||November 2011|Actual|2011-11-30||Interventional|||Phase I Study of AbGn-168H in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics Study of Single Rising Doses of AbGn-168H Administered by Intravenous Infusion (125 μg/kg, 500 μg/kg, 1 mg/kg, 2 mg/kg) or Subcutaneous Injection (125 μg/kg, 1 mg/kg) to Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 22:28:27.356045|2018-05-31 22:28:27.356045
NCT01378351|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2013-08-22|2011-06-21|2011-06-22|Estimate|||||||2013-08-22|2013-08-26|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Survey|Vestibular Dysfunction as a Cause of Chronic Nausea & Vomiting: A Follow up Study|Terminated|||2|Actual|Baylor Research Institute||||Inadequate recruitment, investigator left institution|f||||f||||||||||2018-05-31 22:28:27.492777|2018-05-31 22:28:27.492777
NCT01378338|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2013-09-30|2011-06-21|2011-06-22|Estimate|||||||2013-09-30|2013-10-01|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|Refresh||Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational|Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational Study|Completed|||855|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 22:28:27.58272|2018-05-31 22:28:27.58272
NCT01378325|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2014-07-02||2014-08-11|2011-06-21|2011-06-22|Estimate|2014-08-11|2014-08-26|Estimate||||2014-08-11|2014-08-26|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||with β of 0.2 and α of 0.05 and two-sided test for comparing two means (http://www.stat.ubc.ca/~rollin/stats/ssize/n2.html), the calculated number of patients was 37 in each group.|Variable Rate Phenylephrine Infusion for Prevention of Spinal-induced Hypotension for Cesarean Delivery|Crystalloid Coload Combined With Variable Rate Phenylephrine Infusion for Prevention of Hypotension During Spinal Anesthesia for Elective Cesarean Delivery vs Crystalloid Coload Alone|Completed||Phase 4|80|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 22:28:27.706158|2018-05-31 22:28:27.706158
NCT01378312|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2014-03-14|2011-06-21|2011-06-22|Estimate|||||||2014-03-14|2014-03-17|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Evaluate Safety and Immunogenicity of AERAS-402|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-402 When Administered to HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection|Completed||Phase 1|12|Actual|Aeras||2|||f||||t||||||||||2018-05-31 22:28:27.93038|2018-05-31 22:28:27.93038
NCT01378299|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-05-31|2011-06-20|2011-06-22|Estimate|||||||2017-05-31|2017-06-01|Actual|October 1, 2011|Actual|2011-10-01|May 2017|2017-05-31|October 31, 2017|Anticipated|2017-10-31|November 7, 2016|Actual|2016-11-07||Interventional|||CYP19A1 Gene and Pharmacogenetics of Response to Testosterone Therapy|CYP19A1 Gene and Pharmacogenetics of Response|Active, not recruiting||Phase 1|105|Anticipated|VA Office of Research and Development||1|||f||||t|t|f|||f|||Yes|"People who ensure quality from the institutions where the research is being done, federal and other regulatory agencies will have access to all of the research data such as Food and Drug Administration (FDA) and Data Monitoring Committee (DMC). The purpose of collecting information covered under 38 U.S.C. 7332 is to conduct scientific research and no personnel involved in this study will identify, directly or indirectly, any individual patient or subject in any report of such research.~The only research data that will leave the MEDVA MC will be emailed to the FDA and Data Monitoring Committee, and will include only data on subjects who developed side effects including heart attacks, strokes, high hematocrit, high PSA, psychiatric problems and other adverse events, and the results of their tests. None of the 18 HIPAA identifiers will be included."|2018-05-31 22:28:28.064515|2018-05-31 22:28:28.064515
NCT01378286|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-07-17|2011-06-20|2011-06-22|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria|A Randomised Comparative Study to Assess the Efficacy and Tolerability of Blood Schizonticidal Treatments With Artesunate Amodiaquine Winthrop® / Coarsucam (ASAQ) Versus Chloroquine (CQ) for Uncomplicated Plasmodium Vivax Monoinfection Malaria|Completed||Phase 3|380|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:28:28.18902|2018-05-31 22:28:28.18902
NCT01378273|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-10-24|2011-06-21|2011-06-22|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2013||2013-12-31|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PENUT||Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)|Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)|Active, not recruiting||Phase 3|941|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 22:28:28.271241|2018-05-31 22:28:28.271241
NCT01378260|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-05-16|2011-06-20|2011-06-22|Estimate|||||||2017-05-16|2017-05-18|Actual|July 2011||2011-07-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Observational|||Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)|Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)|Completed|||323|Actual|University of Washington|||3||f||||f||||||||||2018-05-31 22:28:28.388676|2018-05-31 22:28:28.388676
NCT01378247|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-04-14|2011-06-20|2011-06-22|Estimate|||||||2017-04-14|2017-04-18|Actual|June 2011||2011-06-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Multicenter Study of Family Nursing to Treat Heart Failure|Family Focused Nursing for Outpatients With Heart Failure|Completed||N/A|468|Actual|University of Southern Denmark||2|||f||||f||||||||Yes|Data will be entered into Odense Patient data Explorative Network (OPEN) database|2018-05-31 22:28:28.479941|2018-05-31 22:28:28.479941
NCT01378234|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|EDPP||Enhanced Discharge Planning Program -- Prospective|The Impact of a Social Work Driven Transitional Care Model on Health Outcomes for At-Risk Older Adults|Completed||N/A|740|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 22:28:28.583998|2018-05-31 22:28:28.583998
NCT01378221|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2013-12-11||2013-12-11|2011-06-20|2011-06-22|Estimate|2013-12-11|2014-01-30|Estimate||||2013-12-11|2014-01-30|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Observational|VISE||VItamin D Metabolism in SEnescent Cardiac Surgery Patients|Vitamin D Metabolism in Senescent Cardiac Surgery Patients|Completed|||75|Actual|Heart and Diabetes Center North-Rhine Westfalia|||2||f||||f||||||||||2018-05-31 22:28:28.77566|2018-05-31 22:28:28.77566
NCT01378182|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2014-12-30|2011-06-21|2011-06-22|Estimate|||||||2014-12-30|2014-12-31|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis|Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis|Completed||N/A|10|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi|||||f||||f||||||||||2018-05-31 22:28:29.569601|2018-05-31 22:28:29.569601
NCT01378169|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-10-15|2011-06-20|2011-06-22|Estimate|||||||2017-10-15|2017-10-17|Actual|January 1, 2011|Actual|2011-01-01|March 2017|2017-03-31|June 1, 2013|Actual|2013-06-01|January 1, 2013|Actual|2013-01-01||Observational|Captain||SIRS and Bacterial Sepsis Discrimination by Biomarkers in ICU|Early Detection and Diagnostic Performance of Bio-markers During Bacterial Sepsis: Multicentre Cohort Study in Intensive Care|Completed|||300|Actual|Groupe Hospitalier Paris Saint Joseph|||1||f||||f||||||Samples Without DNA|"~     blood, urin, CSF, BAL~   "|||2018-05-31 22:28:29.727219|2018-05-31 22:28:29.727219
NCT01378156|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-11-09|2011-06-20|2011-06-22|Estimate|||||||2017-11-09|2017-11-14|Actual|June 2010||2010-06-30|November 2017|2017-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test|Completed||Phase 1|9|Actual|GeoVax, Inc.||1|||f||||f||||||||||2018-05-31 22:28:29.812951|2018-05-31 22:28:29.812951
NCT01378143|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2014-10-20|2011-06-21|2011-06-22|Estimate|||||||2014-10-20|2014-10-21|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy|A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment|Completed||Phase 2|53|Actual|Oncozyme Pharma Inc.||1|||f||||t||||||||||2018-05-31 22:28:29.950529|2018-05-31 22:28:29.950529
NCT01378130|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-04-25|2011-06-21|2011-06-22|Estimate|||||||2013-04-25|2013-04-26|Estimate|April 2011||2011-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Central Serous Chorioretinopathy: Etiology, Course and Prognosis|Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis|Completed|||50|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 22:28:30.067518|2018-05-31 22:28:30.067518
NCT01378117|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2013-07-09||2014-06-07|2011-06-20|2011-06-22|Estimate|2014-06-07|2014-06-12|Estimate||||2014-06-07|2014-06-12|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||DPP4 Inhibitor in the Hospital|Randomized Controlled Study of DPP4 Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes|Completed||Phase 4|90|Actual|Emory University||3|||f||||t||||||||||2018-05-31 22:28:30.13677|2018-05-31 22:28:30.13677
NCT01378104|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2012-12-14||2013-02-03|2011-06-20|2011-06-22|Estimate|2013-02-03|2013-03-08|Estimate||||2013-02-03|2013-03-08|Estimate|October 2008||2008-10-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)|The Response of Reducing Dose of Peginterferon Alfa-2a in Koreans With Chronic Hepatitis C Genotype 1; Randomized Controlled Multicenter Study 100% Versus 80%|Completed||Phase 4|178|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 22:28:31.869082|2018-05-31 22:28:31.869082
NCT01378091|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2016-05-06|2011-06-21|2011-06-22|Estimate|||||||2016-05-06|2016-05-09|Estimate|August 2005||2005-08-31|May 2016|2016-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer|Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Every Three Week Docetaxel (Taxotere®) In Subjects With Androgen Independent Prostate Cancer|Completed||Phase 1|64|Actual|Columbia University||1|||f||||t||||||||Undecided||2018-05-31 22:28:33.038555|2018-05-31 22:28:33.038555
NCT01378078|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-07-19|2011-06-21|2011-06-22|Estimate|||||||2013-07-19|2013-07-22|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) for Treatment of Negative Syndrome in Patients With Schizophrenia|Transcranial Direct Current Stimulation (tDCS) for Treatment of Negative Syndrome in Patients With Schizophrenia|Completed||N/A|20|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 22:28:33.343556|2018-05-31 22:28:33.343556
NCT01378065|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2015-08-20||2015-09-29|2011-06-21|2011-06-22|Estimate|2015-09-29|2015-10-28|Estimate||||2015-09-29|2015-10-28|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|(A&P)||Restorelle Direct Fix Anterior and Posterior (A&P) for Female Pelvic Organ Prolapse: A Prospective Post Market Study|Restorelle Direct Fix A&P for Female Pelvic Organ Prolapse: A Prospective Post Market Study|Completed|||31|Actual|Coloplast A/S|The study N was small.||||f||||f||||||||||2018-05-31 22:28:33.834684|2018-05-31 22:28:33.834684
NCT01378052|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|June 2011||2011-06-30|June 2011|2011-06-30||||June 2012|Anticipated|2012-06-30||Observational|||DNA Methylation and Urothelial Carcinoma|Level of DNA Methylation in People With Urothelial Carcinoma|Unknown status|Recruiting||200|Anticipated|China Medical University Hospital|||2||f||||t||||||||||2018-05-31 22:28:35.402521|2018-05-31 22:28:35.402521
NCT01378039|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-04-11|2011-06-20|2011-06-22|Estimate|||||||2012-04-11|2012-04-12|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|June 2009|Actual|2009-06-30|December 2006|Actual|2006-12-31||Interventional|CAPTA||Pathogenetic Mechanisms of Chronic Obstructive Pulmonary Diseases|Evaluation of Pathogenetic Mechanisms of Chronic Obstructive Pulmonary Diseases|Completed||N/A|200|Actual|Lithuanian University of Health Sciences||1|||f||||f||||||||||2018-05-31 22:28:35.510739|2018-05-31 22:28:35.510739
NCT01378026|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-20|2011-06-20|2011-06-22|Estimate|||||||2011-06-20|2011-06-22|Estimate|January 2012||2012-01-31|June 2011|2011-06-30||||||||Observational|||Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation||Unknown status|Not yet recruiting||120|Anticipated|China Medical University Hospital|||||f||||||||||Samples With DNA|"~     whole blood, serum and DNA~   "|||2018-05-31 22:28:35.623858|2018-05-31 22:28:35.623858
NCT01378013|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-03-24|2011-06-21|2011-06-22|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|SaMPLE||SurgicAl Metabolic Phenotyping Longitudinal Evaluation Study|Metabolic Phenotyping and Systems Biology in Surgery|Completed|||50|Actual|Imperial College London|||2||f||||t||||||Samples With DNA|"~     1. Urine~        2. Blood (plasma)~        3. Stool / small bowel content~        4. Tissue (Colon, small bowel,stomach,eosophagus, breast, lymph nodes)~   "|||2018-05-31 22:28:35.710952|2018-05-31 22:28:35.710952
NCT01378000|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-20|2011-06-20|2011-06-22|Estimate|||||||2011-06-20|2011-06-22|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|UHPCI||Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction|Study Effects of Ultra-slow Continuous Intravenous Infusion of Unfractionated Heparin on Progressive Cerebral Infarction - a Clinical Study|Completed|||480|Actual|Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine|||4||f||||t||||||Samples With DNA|"~     serum~   "|||2018-05-31 22:28:35.904713|2018-05-31 22:28:35.904713
NCT01377987|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2017-01-04|2011-06-20|2011-06-22|Estimate|||||||2017-01-04|2017-01-06|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|HF-ACZ||Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients|Physiological Study to Predict Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients|Completed||N/A|29|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:28:36.190762|2018-05-31 22:28:36.190762
NCT01377974|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-06-08|2011-06-20|2011-06-22|Estimate|||||||2015-06-08|2015-06-09|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis|Randomized Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis at Federal District, Brazil|Completed||Phase 2|40|Actual|Brasilia University Hospital||2|||f||||f||||||||||2018-05-31 22:28:36.329086|2018-05-31 22:28:36.329086
NCT01377961|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-06-24|2011-06-21|2011-06-22|Estimate|||||||2015-06-24|2015-06-26|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Lycopene and Isoflavones on Glucose Metabolism|Effect of Lycopene and Isoflavones on Glucose Metabolism|Withdrawn||N/A|0|Actual|The University of Texas Medical Branch, Galveston||2||FDA needs more information from the manufacturing company of the supplements.|f||||t||||||||||2018-05-31 22:28:36.485835|2018-05-31 22:28:36.485835
NCT01377948|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-03-08|2011-06-20|2011-06-22|Estimate|||||||2012-03-08|2012-03-12|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Reducing Aggression in Children and Adolescent on an Inpatient Unit|Phase 1 Study of Anger Control Therapy Augmented With RAGE-Control (Regulate and Gain Emotional-Control)Delivered on an Inpatient Psychiatric Unit|Completed||Phase 1|20|Actual|Gonzalez-Heydrich, Joseph, M.D.||1|||f||||f||||||||||2018-05-31 22:28:36.640379|2018-05-31 22:28:36.640379
NCT01377935|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2016-09-19|2011-06-20|2011-06-22|Estimate|||||||2016-09-19|2016-09-20|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments|Comparison of Risk of Hospitalization for Acute Kidney Injury Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments|Completed|||113505|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 22:28:36.740419|2018-05-31 22:28:36.740419
NCT01377922|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2017-09-28||2018-01-03|2011-06-20|2011-06-22|Estimate|2018-01-03|2018-01-04|Actual||||2018-01-03|2018-01-04|Actual|June 2011||2011-06-30|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)|A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)|Completed||Phase 3|38|Actual|Catalyst Pharmaceuticals, Inc.||2|||f||||t||||||||No||2018-05-31 22:28:36.879069|2018-05-31 22:28:36.879069
NCT01377909|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-08-21|2011-06-20|2011-06-22|Estimate|||||||2013-08-21|2013-08-22|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity|An Investigator-initiated Pilot Study Using Statins to Improve the Anti-HCV Response to Peginterferon Alfa 2-b and Ribavirin in Previous Non-responders|Terminated||Phase 1|20|Actual|Bader, Ted, M.D.||1||Principal Investigator retiring|f||||f||||||||||2018-05-31 22:28:37.530087|2018-05-31 22:28:37.530087
NCT01377896|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-27|2011-06-20|2011-06-22|Estimate|||||||2011-06-27|2011-06-28|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours|The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours|Completed|||221|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:28:37.603187|2018-05-31 22:28:37.603187
NCT01377883|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-19|||2011-06-21|2011-06-21|2011-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Clown Care for Botulinum Toxin (BTX)||Completed||N/A|25|Actual|Shaare Zedek Medical Center||2|||f||||||||||||||2018-05-31 22:28:37.645872|2018-05-31 22:28:37.645872
NCT01377870|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-19|||2018-03-06|2011-06-20|2011-06-21|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2011||2011-12-31|August 2010|2010-08-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis|Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis|Completed||Phase 1/Phase 2|22|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 22:28:37.715048|2018-05-31 22:28:37.715048
NCT01377857|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-18|||2015-05-13|2011-06-20|2011-06-21|Estimate|||||||2015-05-13|2015-05-14|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies|HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies|Completed||N/A|8572|Actual|University of California, San Francisco||10|||f||||f||||||||||2018-05-31 22:28:37.836447|2018-05-31 22:28:37.836447
NCT01377844|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13||2014-07-23|2015-03-04|2011-06-19|2011-06-21|Estimate||||2014-08-27|2014-08-29|Estimate|2015-03-04|2015-03-24|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus|Efficacy and Safety of EGT0001442 Compared With Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Diet and Exercise and up to One Oral Anti-diabetes Agent|Completed||Phase 2|288|Actual|Theracos||2|||f||||t||||||||||2018-05-31 22:28:37.951656|2018-05-31 22:28:37.951656
NCT01377831|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-19|||2015-03-06|2011-06-20|2011-06-21|Estimate|||||||2015-03-06|2015-03-10|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Study of Ketamine Administered Intravenously and by Sublingual Wafer|An Open Label, Two Way Crossover Study to Evaluate the Bioavailability and Clinical Tolerability of a Novel Sublingual Wafer Formulation of Ketamine in Healthy Male Volunteers|Completed|||8|Actual|iX Biopharma Ltd.|||||f||||t||||||Samples With DNA|"~     Whole blood will be drawn into Vacuette brand, lithium heparin separator tubes (green/yellow~     top).~   "|||2018-05-31 22:28:38.05937|2018-05-31 22:28:38.05937
NCT01377818|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|COPD||Non Invasive Mechanical Ventilation Versus Respiratory Rehabilitation in Hypercapnic COPD|Prospective Aleatory Study of Non Invasive Mechanical Ventilation Versus Respiratory Rehabilitation in Hypercapnic Stable Severe COPD|Completed||Phase 4|45|Actual|Hospitales Universitarios Virgen del Rocío||3|||f||||f||||||||||2018-05-31 22:28:38.126313|2018-05-31 22:28:38.126313
NCT01377805|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-19|||2015-04-02|2011-06-20|2011-06-21|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life|Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in Life -- a Retrospective Analysis|Withdrawn|||0|Actual|Genetic Disease Investigators|||1|No participants|f||||t||||||||||2018-05-31 22:28:38.209902|2018-05-31 22:28:38.209902
NCT01377792|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-01-29|2011-06-20|2011-06-21|Estimate|||||||2013-01-29|2013-01-30|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|May 2011|Actual|2011-05-31||Interventional|||Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis|Phase 4 Study of the Efficacy of Long-term Treatment With Hypertonic Saline on Pulmonary Exacerbations in Patients With Cystic Fibrosis|Completed||Phase 4|71|Actual|Hospital Universitario Ramon y Cajal||2|||f||||t||||||||||2018-05-31 22:28:38.303475|2018-05-31 22:28:38.303475
NCT01377779|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Efficiency of Intercoat (Oxiplex/AP Gel)in Decreasing Intrauterine Adhesions|Intercoat (Oxiplex/AP Gel) for Preventing Intrauterine Adhesions Following Operative Hysteroscopy for Suspected Retained Products of Conception - a Prospective Randomized Pilot Study|Completed||N/A|60|Actual|Assaf-Harofeh Medical Center||2|||f||||t||||||||||2018-05-31 22:28:38.406308|2018-05-31 22:28:38.406308
NCT01377766|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-11-05|2011-06-20|2011-06-21|Estimate|||||||2011-11-05|2011-11-08|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|November 2011|Anticipated|2011-11-30|October 2010|Actual|2010-10-31||Observational|||The Relationship Between Psychological Factors and Bell's Palsy|Study of Psychological Factors on the Occurence of Bell's Palsy|Unknown status|Recruiting||800|Anticipated|Huazhong University of Science and Technology|||||f||||t||||||||||2018-05-31 22:28:38.679241|2018-05-31 22:28:38.679241
NCT01377753|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-18|||2018-01-04|2011-06-18|2011-06-21|Estimate|||||||2018-01-04|2018-01-05|Actual|June 18, 2011||2011-06-18|November 13, 2017|2017-11-13|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||MR Image Guided Therapy in Prostate Cancer|MR Image Guided Focal Therapy in Prostate Cancer|Active, not recruiting||Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:28:38.830401|2018-05-31 22:28:38.830401
NCT01377740|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-06-20|2011-06-17|2011-06-21|Estimate|||||||2017-06-20|2017-06-22|Actual|July 2011||2011-07-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Non-Invasive Reduction of Abdominal Fat Utilizing the CoolFlex and eZ App 6.3 Applicators|Non-Invasive Reduction of Abdominal Fat Utilizing the CoolFlex and eZ App 6.3 Applicators|Completed||N/A|20|Actual|Zeltiq Aesthetics|||||f||||f||||||||No||2018-05-31 22:28:38.975187|2018-05-31 22:28:38.975187
NCT01377701|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor|The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor|Unknown status|Recruiting||150|Anticipated|Huashan Hospital|||||f||||t||||||||||2018-05-31 22:28:39.102098|2018-05-31 22:28:39.102098
NCT01377688|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2014-06-02|2011-06-20|2011-06-21|Estimate|||||||2014-06-02|2014-06-03|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|DKDPilot||Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes|Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes|Completed|||19|Actual|Duke University|||1||f||||f||||||||||2018-05-31 22:28:39.223713|2018-05-31 22:28:39.223713
NCT01377675|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2014-12-01|2011-06-17|2011-06-21|Estimate|||||||2014-12-01|2014-12-03|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|WipeCOPD||Web-based, Interactive Professional Education for Chronic Obstructive Pulmonary Disease|Assessment of an Interactive Education Tool to Disseminate Best Practice Recommendations on Chronic Obstructive Pulmonary Disease to Primary Care|Completed|||10|Actual|The University of Texas Health Science Center at San Antonio|||1||f||||f||||||||||2018-05-31 22:28:39.295643|2018-05-31 22:28:39.295643
NCT01377662|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12||2014-09-27|2014-09-27|2011-06-20|2011-06-21|Estimate||||2014-09-27|2014-10-07|Estimate|2014-09-27|2014-10-07|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)|PHASE IIA: Randomized, Double Blind, Placebo Controlled, Single Center Clinical Trial of a Combination of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)|Completed||Phase 2|30|Actual|Duke University||2|||f||||f||||||||||2018-05-31 22:28:39.37137|2018-05-31 22:28:39.37137
NCT01377649|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2016-09-26|2011-06-20|2011-06-21|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Contrast Ultrasound Perfusion Imaging in Peripheral Arterial Disease (PAD)|Contrast Ultrasound Perfusion Imaging in Peripheral Arterial Disease|Completed|||18|Actual|Oregon Health and Science University|||2||f||||t||||||||||2018-05-31 22:28:39.531905|2018-05-31 22:28:39.531905
NCT01377636|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|2013-12-02||2015-02-17|2011-06-20|2011-06-21|Estimate|2015-02-17|2015-02-23|Estimate||||2015-02-17|2015-02-23|Estimate|August 2009||2009-08-31|February 2015|2015-02-28|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol|Study to Measure BIS and Awareness in Patients Receiving Isoproterenol During Catheter Ablation for Atrial Fibrillation|Completed||N/A|20|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 22:28:39.656815|2018-05-31 22:28:39.656815
NCT01377623|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2016-03-14||2017-06-09|2011-06-20|2011-06-21|Estimate|2016-10-24|2016-12-14|Estimate||||2017-06-09|2017-07-11|Actual|September 2010||2010-09-30|June 2017|2017-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Baseline data is only available for those participants who completed the study|Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion|Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion|Terminated||N/A|66|Actual|New York University School of Medicine||2|||f||||f||||||||Yes||2018-05-31 22:28:40.041021|2018-05-31 22:28:40.041021
NCT01377597|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2016-11-16|2011-06-20|2011-06-21|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|RVO in Japan||Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion|A 3-month, Phase III, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Monthly Intravitreal Injections as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Branch or Central Retinal Vein Occlusion (RVO)|Completed||Phase 3|47|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:28:40.690042|2018-05-31 22:28:40.690042
NCT01377584|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2017-07-12||2017-09-29|2011-06-17|2011-06-21|Estimate|2017-09-29|2017-10-02|Actual||||2017-09-29|2017-10-02|Actual|March 2014||2014-03-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|COMMENCE||COMMunication and Education for the New CPAP Experience|COMMENCE Study: COMMunication and Education for the New CPAP Experience|Completed||N/A|60|Actual|University of Pittsburgh||6|||f||||f||||||||||2018-05-31 22:28:40.86178|2018-05-31 22:28:40.86178
NCT01377571|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-06-30|2011-06-20|2011-06-21|Estimate|||||||2016-06-30|2016-07-04|Estimate|October 2009||2009-10-31|June 2016|2016-06-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants|A Phase II, Randomized, Double-blind, Vaccine-controlled Dose-escalating Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotavin-M1) in Healthy Infants in Vietnam|Completed||Phase 2|200|Actual|National Institute of Hygiene and Epidemiology, Vietnam||4|||f||||t||||||||||2018-05-31 22:28:41.911507|2018-05-31 22:28:41.911507
NCT01377558|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-22|2011-06-20|2011-06-21|Estimate|||||||2011-06-22|2011-06-23|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|June 2012|Anticipated|2012-06-30|November 2011|Anticipated|2011-11-30||Interventional|||Effects of Different Types of Exercise Interventions in Patients With Type 2 Diabetes|Effects of Different Types of Exercise Interventions in Patients With Type 2 Diabetes - Aerobic Endurance Training Versus Strength Endurance Training Versus Combined Aerobic Endurance and Strength Endurance Training -|Unknown status|Active, not recruiting|N/A|100|Actual|University of Giessen||4|||f||||t||||||||||2018-05-31 22:28:42.059848|2018-05-31 22:28:42.059848
NCT01377545|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-01-16|2011-06-20|2011-06-21|Estimate|||||||2013-01-16|2013-01-18|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Continuous Infraclavicular Nerve Blocks: Needle Versus Catheter Local Anesthetic Bolus|Continuous Infraclavicular Nerve Blocks: Needle Versus Catheter Local Anesthetic Bolus|Withdrawn||Phase 4|0|Actual|University of California, San Diego||2||lack of funding|f||||f||||||||||2018-05-31 22:28:42.176351|2018-05-31 22:28:42.176351
NCT01377532|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-12-11|2011-06-17|2011-06-21|Estimate|||||||2017-12-11|2017-12-13|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma|Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma|Available|||||University of California, San Francisco||||Study has been suspended after the event of an serious adverse event.|||||||||||||||2018-05-31 22:28:42.281231|2018-05-31 22:28:42.281231
NCT01377519|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2014-01-15|2011-06-17|2011-06-21|Estimate|||||||2014-01-15|2014-01-16|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|PROMISe||Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids|Magnetic Resonance-Guided Focused Ultrasound to Treat Uterine Fibroids: A Pilot Randomized, Placebo-Controlled Trial|Completed||N/A|20|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:28:42.540494|2018-05-31 22:28:42.540494
NCT01377506|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2012-06-21|2011-06-17|2011-06-21|Estimate|||||||2012-06-21|2012-06-25|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Coaches||Translation of Obesity and Cognitive Program by Lay Health Educators|Translation of Obesity and Cognitive Research in a Rural State Via Senior Centers|Completed||N/A|16|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 22:28:42.663601|2018-05-31 22:28:42.663601
NCT01377493|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|February 2010|Actual|2010-02-28||Interventional|||Effects of a Chewing Gum Containing POs-Ca and Fluoride on Enamel|Effects of a Chewing Gum Containing POs-Ca and Fluoride on Remineralization of Enamel Subsurface Lesions in Situ|Completed||Early Phase 1|36|Actual|Tokyo Medical and Dental University||3|||f||||f||||||||||2018-05-31 22:28:42.795377|2018-05-31 22:28:42.795377
NCT01377480|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2015-07-13||2017-04-17|2011-06-20|2011-06-21|Estimate|2015-07-13|2015-08-10|Estimate||||2017-04-17|2017-05-18|Actual|July 6, 2011|Actual|2011-07-06|April 2017|2017-04-30|January 12, 2015|Actual|2015-01-12|July 22, 2014|Actual|2014-07-22||Interventional|STOP CHAGAS||A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)|Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)|Completed||Phase 2|120|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:28:42.915648|2018-05-31 22:28:42.915648
NCT01377467|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2016-01-22||2016-04-26|2011-06-20|2011-06-21|Estimate|2016-03-23|2016-04-26|Estimate||||2016-04-26|2016-05-26|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|POSTOP|Randomized patients with a functioning graft|Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients|A Phase 3, Investigator-initiated, Randomized, Open-label Single-center Study of the Effect of Denosumab on the Prevention of Bone Mineral Density Loss After Renal Transplantation|Completed||Phase 3|90|Actual|University of Zurich||2|||f||||f||||||||No||2018-05-31 22:28:43.576429|2018-05-31 22:28:43.576429
NCT01377454|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2012-08-07|2011-06-20|2011-06-21|Estimate|||||||2012-08-07|2012-08-08|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Balance and Mild Traumatic Brain Injury (TBI)|Wearable Sensor to Detect Postural Instability in People After Mild Traumatic Brain Injury (mTBI)|Completed|||47|Actual|Oregon Health and Science University|||||f||||f||||||||||2018-05-31 22:28:45.046211|2018-05-31 22:28:45.046211
NCT01377441|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2014-12-12||2017-11-24|2011-06-20|2011-06-21|Estimate|2014-12-12|2014-12-22|Estimate||||2017-11-24|2017-12-22|Actual|September 2011||2011-09-30|November 2017|2017-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All data was lost after Hurricane Sandy.|Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.|Randomized, Double-blind, Pilot Study on the Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia: Correlation With Clinical Outcomes|Terminated||Phase 4|6|Actual|New York University School of Medicine||2||Samples lost during Hurricane Sandy. Study now taking place at other medical centers.|f||||t|t|f|||t|||||2018-05-31 22:28:45.291946|2018-05-31 22:28:45.291946
NCT01377428|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-04-19|2011-06-20|2011-06-21|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2011||2011-09-30|May 2012|2012-05-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Efficacy of Indacaterol 150 µg Versus Formoterol|A 12-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Parallel-group Study to Assess the Efficacy of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 μg b.i.d.) as an Active Control|Withdrawn||Phase 4|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:28:45.98388|2018-05-31 22:28:45.98388
NCT01377415|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-21|2011-06-20|2011-06-21|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Continuous Subacromial Bupivacaine|The Analgesic Effect of Continuous Subacromial Bupivacaine Infusion After Arthroscopic Shoulder Surgery: a Randomized Controlled Trial|Completed||N/A|90|Anticipated|Turku University Hospital||2|||f||||||||||||||2018-05-31 22:28:46.091435|2018-05-31 22:28:46.091435
NCT01377402|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2015-07-28||2017-03-19|2011-06-20|2011-06-21|Estimate|2015-11-16|2015-12-17|Estimate||||2017-03-19|2017-05-02|Actual|November 2005||2005-11-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ARRA-RACS|Patients with suspected ACS.|ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study|ARgentinean Risk Assessment Registry in Acute Coronary Syndrome; the ARRA-RACS Study.|Completed|||982|Actual|Helse Stavanger HF|||1||f||||t||||||Samples Without DNA|"~     Serum, Citrated plasma, EDTA-plasma and packed red blood cells are kept in suitable aliquots~     at -80 degrees Celcius.~   "|No||2018-05-31 22:28:46.182257|2018-05-31 22:28:46.182257
NCT01377389|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2018-04-11|2011-06-17|2011-06-21|Estimate|||||||2018-04-11|2018-04-12|Actual|June 17, 2011|Actual|2011-06-17|April 2018|2018-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer|A Phase II Study of Ipilimumab PLUS Androgen Deprivation Therapy in Castrate Sensitive Prostate Carcinoma|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:28:46.366247|2018-05-31 22:28:46.366247
NCT01377376|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2016-12-05|2011-06-17|2011-06-21|Estimate|||||||2016-12-05|2016-12-07|Estimate|July 2011||2011-07-31|December 2016|2016-12-31||||November 2015|Actual|2015-11-30||Interventional|ATTENTION||A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib|A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer With Wild-type Epidermal Growth Factor Receptor|Terminated||Phase 3|||Kyowa Hakko Kirin Co., Ltd||2|||f||||||||||||||2018-05-31 22:28:46.476135|2018-05-31 22:28:46.476135
NCT01377363|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|December 2009||2009-12-31|June 2011|2011-06-30||||||||Observational|||Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis|Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis|Completed|||236|Actual|Spanish Breast Cancer Research Group|||1||f||||f||||||Samples Without DNA|"~     primary tumor sample and metastasis sample~   "|||2018-05-31 22:28:46.593417|2018-05-31 22:28:46.593417
NCT01377350|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|June 2011||2011-06-30|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System|Non-invasive Heart Failure Monitoring Using Novel Acceleration Sensors System|Unknown status|Not yet recruiting|N/A|50|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 22:28:46.709433|2018-05-31 22:28:46.709433
NCT01377337|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-11-06|2011-06-20|2011-06-21|Estimate|||||||2011-11-06|2011-11-08|Estimate|December 2011||2011-12-31|November 2011|2011-11-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|SB CAT||Sodium Bicarbonate in Cardiopulmonary Resuscitation|Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 4|2130|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 22:28:46.897034|2018-05-31 22:28:46.897034
NCT01377324|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2013-10-14|2011-06-20|2011-06-21|Estimate|||||||2013-10-14|2013-10-16|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites|In Vivo Imaging of the Effect of Fulvestrant on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Tumor Lesions Using FES-PET|Completed||Phase 2|16|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 22:28:46.996944|2018-05-31 22:28:46.996944
NCT01377311|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||The Application of Cultured Cornea Stem Cells in Patients Suffering From Corneal Stem Cell Insufficiency|Phase 1 Study of Cornea Stem Cells Cultured on Amniotic Membrane Transplanted on Patients Suffering From Corneal Stem Cell Insufficiency|Terminated||Phase 1|0|Actual|National Taiwan University Hospital||1||We didn't use this tech in patient.|f||||t||||||||||2018-05-31 22:28:47.138523|2018-05-31 22:28:47.138523
NCT01377298|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|May 2014|Anticipated|2014-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase II Study of Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Refractory to Platinum-Based Chemotherapy|Unknown status|Recruiting|Phase 2|45|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 22:28:47.31331|2018-05-31 22:28:47.31331
NCT01377285|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-10-13|2011-06-20|2011-06-21|Estimate|||||||2016-10-13|2016-10-14|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CKD||Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)|Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease|Recruiting||Phase 4|350|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No|if the subject have serious adverse event and Data Monitoring Committee decide need to make individual participant data,study team will provide data.|2018-05-31 22:28:47.438069|2018-05-31 22:28:47.438069
NCT01377272|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2011-07-01|2011-06-20|2011-06-21|Estimate|||||||2011-07-01|2011-07-04|Estimate|October 2008||2008-10-31|May 2011|2011-05-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Observational|||Spatial Epidemiology of HIV Infection|Spatial Epidemiology of HIV Infection|Completed|||1264|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 22:28:47.57305|2018-05-31 22:28:47.57305
NCT01330992|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-08-19|2011-04-06|2011-04-07|Estimate|||||||2011-08-19|2011-08-23|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Human Circadian Sensitivity to Very Short Light Pulses|Human Circadian Sensitivity to Very Short Light Pulses|Completed||N/A|400|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 22:43:34.319497|2018-05-31 22:43:34.319497
NCT01377259|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-14|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|September 2008||2008-09-30|May 2011|2011-05-31|June 2011|Anticipated|2011-06-30|December 2009|Actual|2009-12-31||Observational|||The Changes of Tissue Oxygen Saturation Under Spinal Anesthesia|The Changes of Tissue Oxygen Saturation Under Spinal Anesthesia|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 22:28:47.686696|2018-05-31 22:28:47.686696
NCT01377246|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2018-01-09|2011-06-20|2011-06-21|Estimate|||||||2018-01-09|2018-01-10|Actual|May 2011|Actual|2011-05-31|January 2018|2018-01-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|ALADIN2||Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency|A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY|Completed||Phase 3|100|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 22:28:47.867194|2018-05-31 22:28:47.867194
NCT01377233|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|2016-01-15|2014-05-14|2016-02-22|2011-06-20|2011-06-21|Estimate|2016-02-22|2016-03-22|Estimate|2014-05-14|2014-05-28|Estimate|2016-02-22|2016-03-22|Estimate|July 2011||2011-07-31|February 2016|2016-02-29||||February 2012|Actual|2012-02-29||Interventional||Baseline characteristics for the 4 patients enrolled in the open-label period but not randomized to the double blinded period, are reported in the first (open-label) study arm. Baseline characteristics for the 42 patients who were subsequently randomized to the double-blind period are reported across the last four (randomized) study arms.|Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia|A Randomised, Double-blind, Parallel-group, Explorative Study of the Safety, Tolerability, and Pharmacokinetics of Daily Dosing Compared to Weekly Dosing of Zicronapine in Patients With Schizophrenia|Completed||Phase 2|46|Actual|H. Lundbeck A/S||5|||f||||t||||||||||2018-05-31 22:28:48.045843|2018-05-31 22:28:48.045843
NCT01377220|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|June 2011||2011-06-30|January 2011|2011-01-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|CHOLPET||Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma|Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Commissariat A L'energie Atomique|||||f||||f||||||||||2018-05-31 22:28:49.407563|2018-05-31 22:28:49.407563
NCT01377207|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-04-18|2011-06-20|2011-06-21|Estimate|||||||2013-04-18|2013-04-19|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|OCTAVIA||Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty. The OCTAVIA Trial|Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty. The OCTAVIA Trial|Completed||Phase 4|140|Actual|Italian Society of Invasive Cardiology||2|||f||||t||||||||||2018-05-31 22:28:49.668741|2018-05-31 22:28:49.668741
NCT01377194|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2013-08-22|2012-04-27|2013-08-22|2011-06-17|2011-06-21|Estimate|2013-08-22|2013-10-29|Estimate|2012-04-27|2012-05-01|Estimate|2013-08-22|2013-10-29|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||The Baseline Participant population is based on the 562 randomized patients who went on to receive double-blind treatment (Safety Population).|Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Fixed-Dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder|Completed||Phase 3|568|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 22:28:49.906073|2018-05-31 22:28:49.906073
NCT01377181|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2011-06-21|2011-06-20|2011-06-21|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2000||2000-01-31|January 2000|2000-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Laparoscopic Hernia Repair With Lateral Umbilicus Ligament for Children|Phase 3 Study of Laparoscopic Hernia Repair With Lateral Umbilicus Ligament for Children|Completed|||575|Actual|The Second People's Hospital of GuangDong Province|||2||f||||t||||||||||2018-05-31 22:28:50.871052|2018-05-31 22:28:50.871052
NCT01377168|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-06-14|2011-06-17|2011-06-21|Estimate|||||||2017-06-14|2017-06-16|Actual|May 2014||2014-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder|Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder|Completed||Phase 4|159|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 22:28:50.968354|2018-05-31 22:28:50.968354
NCT01377155|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-08-23|2011-06-20|2011-06-21|Estimate|||||||2013-08-23|2013-08-27|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Comparison of Two Initial Dosing Formulas|A Comparison of Two Initial Dosing Formulas for Basal Insulin in Type 2 Diabetes Mellitus|Completed||N/A|20|Actual|Diabetes Care Center||1|||f||||f||||||||||2018-05-31 22:28:51.104212|2018-05-31 22:28:51.104212
NCT01377142|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2016-06-13|2011-06-20|2011-06-21|Estimate|||||||2016-06-13|2016-06-14|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|VAULT||Vaginal Uphold Hysteropexy and Laparoscopic Sacral Hysteropexy for the Treatment of Uterovaginal Pelvic Organ Prolapse|Vaginal Uphold Hysteropexy and Laparoscopic Sacral Hysteropexy for the Treatment of Uterovaginal Pelvic Organ Prolapse|Completed|||148|Actual|The Cleveland Clinic|||2||f||||t||||||||No||2018-05-31 22:28:51.27341|2018-05-31 22:28:51.27341
NCT01377129|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2015-03-24|2011-06-20|2011-06-21|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|LCA IRM||Anterior Cruciate Ligament Reconstruction: Residual Rotational Laxity for Single Versus Double Bundle Techniques|Reconstruction of the Anterior Cruciate Ligament: a Comparative MRI Study Evaluating Residual Rotational Laxity for Single Versus Double Bundle Surgical Techniques|Terminated||N/A|46|Actual|Centre Hospitalier Universitaire de Nīmes||2||Patient enrolment proved to be more difficult than foreseen and was stopped at 46 inclusions.|f||||f||||||||||2018-05-31 22:28:51.384806|2018-05-31 22:28:51.384806
NCT01377103|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2017-07-14|2011-06-20|2011-06-21|Estimate|||||||2017-07-14|2017-07-19|Actual|July 2011||2011-07-31|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Testosterone Therapy in Heart Failure|Cardiovascular and Functional Effects of Testosterone Therapy for Hypogonadal Patients With Heart Failure|Withdrawn||N/A|0|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 22:28:51.48507|2018-05-31 22:28:51.48507
NCT01377090|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-07-11|2011-06-17|2011-06-21|Estimate|||||||2013-07-11|2013-07-15|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Observational|CAP||Digital Ulceration|A Multicenter, Prospective Cohort Study Using Nailfold VideoCAPillaroscopy(NVC) and Other Factors to Determine the Risk of Developing Digital Ulceration in Patients With Systemic Sclerosis (SSc)|Completed|||630|Actual|Actelion|||2||f||||f||||||||||2018-05-31 22:28:51.598471|2018-05-31 22:28:51.598471
NCT01377077|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-20|2011-06-20|2011-06-21|Estimate|||||||2011-06-20|2011-06-21|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|MiniSNIP||Punchgrafting Techniques for Vitiligo|Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize|Unknown status|Recruiting|Phase 4|35|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||4|||f||||f||||||||||2018-05-31 22:28:51.782323|2018-05-31 22:28:51.782323
NCT01377064|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-12-10|2011-06-16|2011-06-20|Estimate|||||||2013-12-10|2013-12-12|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Home-based Exercise for Management of HIV-associated Cardiovascular Disease Risk|Home-based Exercise for Management of HIV-associated Cardiovascular Disease|Completed||Phase 1|60|Actual|University of South Carolina||2|||f||||t||||||||||2018-05-31 22:28:51.941098|2018-05-31 22:28:51.941098
NCT01377051|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2014-10-28|2011-06-17|2011-06-20|Estimate|||||||2014-10-28|2014-10-29|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea|Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects.|Completed||Phase 4|60|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 22:28:52.050023|2018-05-31 22:28:52.050023
NCT01377038|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2016-10-24|2011-06-16|2011-06-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|OASIS||OASIS: Osteoarthritis Sensitivity Integration Study|Central Pain Mechanisms in Osteoarthritis: A Longitudinal Cohort|Withdrawn||N/A|0|Actual|University of Michigan||2||Funding|f||||t||||||||||2018-05-31 22:28:52.154769|2018-05-31 22:28:52.154769
NCT01377025|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2014-12-02|2011-06-17|2011-06-20|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|STREAM||A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma|A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|University Hospital, Essen||3|||f||||f||||||||||2018-05-31 22:28:52.244215|2018-05-31 22:28:52.244215
NCT01377012|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2016-05-24||2017-02-09|2011-06-17|2011-06-20|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|August 30, 2011|Actual|2011-08-30|February 2017|2017-02-28|September 9, 2015|Actual|2015-09-09|September 9, 2015|Actual|2015-09-09||Interventional|REASSURE||Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents|A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2302) and a Three Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2302E1)|Completed||Phase 3|637|Actual|Novartis||3|||f||||t||||||||||2018-05-31 22:28:52.592386|2018-05-31 22:28:52.592386
NCT01376999|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-09-19|2011-06-17|2011-06-20|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2010||2010-04-30|September 2017|2017-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Step Up Versus Step Down in Controlled Ovarian Stimulation|Step Up Versus Step Down in Controlled Ovarian Stimulation for Intrauterine Insemination. A Controlled Randomised Trial.|Completed||Phase 4|158|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 22:28:54.678292|2018-05-31 22:28:54.678292
NCT01376986|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2014-06-26|2011-06-17|2011-06-20|Estimate|||||||2014-06-26|2014-06-27|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|MOPO||Activation of Young Men - Population-Based Randomised Controlled Trial|Activation of Young Men - Population-Based Randomised Controlled Trial|Completed||N/A|507|Actual|University of Oulu||2|||f||||t||||||||||2018-05-31 22:28:54.814982|2018-05-31 22:28:54.814982
NCT01376973|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Observational|||Efficiency of Two Occlusal Splints on TMD Treatment of Police Officers|Efficiency of Two Occlusal Splints on TMD Treatment: Randomised Clinical Trial|Completed|||30|Actual|University of Campinas, Brazil|||2||f||||t||||||||||2018-05-31 22:28:54.885363|2018-05-31 22:28:54.885363
NCT01376960|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2016-08-19|2011-06-17|2011-06-20|Estimate|||||||2016-08-19|2016-08-22|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Interventional|||Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures|Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures: A Prospective Comparison|Completed||Phase 4|202|Actual|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 22:28:54.952114|2018-05-31 22:28:54.952114
NCT01376947|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-24|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|October 2011|Anticipated|2011-10-31|June 2011|Anticipated|2011-06-30||Observational|||Comparison of the Difficulty on Insertion of IUD Devices Between Nulliparous and Multiparous Women|Comparison of the Difficulty on Insertion of IUD Devices Between Nulliparous and Multiparous and Evaluation of Cause of Failure of Insertion|Unknown status|Active, not recruiting||100|Anticipated|University of Campinas, Brazil|||3||f||||f||||||||||2018-05-31 22:28:55.03446|2018-05-31 22:28:55.03446
NCT01376934|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|March 2011||2011-03-31|June 2011|2011-06-30||||March 2011|Actual|2011-03-31||Interventional|||Clinical Trial of Hysteroscopy in Postmenopausal Women to Compare Techniques|Phase 1 Study of Two Techniques in Hysteroscopy That Compare Carbon Dioxide Versus Saline Solution|Unknown status|Recruiting|N/A|140|Anticipated|University of Campinas, Brazil|||||f||||f||||||||||2018-05-31 22:28:55.123182|2018-05-31 22:28:55.123182
NCT01376921|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2017-12-22|2011-06-17|2011-06-20|Estimate|||||||2017-12-22|2017-12-26|Actual|September 30, 2012|Actual|2012-09-30|December 2017|2017-12-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Observational|ECOS ESP||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Spain|Completed|||300|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:28:55.202229|2018-05-31 22:28:55.202229
NCT01376752|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2017-10-30|2011-06-17|2011-06-20|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2011||2011-04-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|CHIPOR||Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment|A Phase III Randomized Study of Phase III Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer|Recruiting||Phase 3|444|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 22:29:01.516223|2018-05-31 22:29:01.516223
NCT01376908|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2015-07-31||2017-08-17|2011-06-17|2011-06-20|Estimate|2016-04-06|2016-05-12|Estimate||||2017-08-17|2017-09-15|Actual|June 2011||2011-06-30|August 2017|2017-08-31|February 17, 2017|Actual|2017-02-17|July 2014|Actual|2014-07-31||Interventional|SPARK|Intention-to-treat (ITT) population consisted of all the randomized subjects at the start of the study and were analyzed according to the group allocated.|Kuvan® in Phenylketonuria Patients Less Than 4 Years Old|A Phase IIIb, Multicentre, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan®) in Phenylketonuria (PKU) Patients <4 Years Old.|Completed||Phase 3|56|Actual|BioMarin Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:28:55.375275|2018-05-31 22:28:55.375275
NCT01376895|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2014-03-07|2011-06-17|2011-06-20|Estimate|||||||2014-03-07|2014-03-11|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Power||Project Power: An HIV Risk Reduction Intervention for Black Men Who Have Sex With Men and Women (BMSM/W)|Developing and Testing of an HIV Prevention Intervention Targeting Black Men Who Have Sex With Men and Women (BMSM/W)|Completed||Phase 1/Phase 2|211|Actual|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 22:28:57.685523|2018-05-31 22:28:57.685523
NCT01376882|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-03-28|2011-06-16|2011-06-20|Estimate|||||||2013-03-28|2013-03-29|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Cognitive and Cerebral Blood Flow Effects of 2-week Caffeine Abstinence or Maintenance|Behavioural and Cerebral Haemodynamic Effects of Caffeine Withdrawal and Caffeine Administration Following 2-week Maintenance or Abstinence|Completed||N/A|110|Actual|Northumbria University||4|||f||||f||||||||||2018-05-31 22:28:57.836821|2018-05-31 22:28:57.836821
NCT01376869|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-06-22|2011-06-16|2011-06-20|Estimate|||||||2012-06-22|2012-06-25|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants|Investigation of the Acute Cognitive, Mood and Autonomic Effects of Hops in Healthy Participants|Completed||N/A|150|Anticipated|Northumbria University||5|||f||||f||||||||||2018-05-31 22:28:58.041722|2018-05-31 22:28:58.041722
NCT01376856|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-06-01|2011-06-17|2011-06-20|Estimate|||||||2013-06-01|2013-06-04|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Characteristics of Mediastinal Lymph Node With False Positive FDG PET/CT Results in Lung Cancer Staging : Relation With TB and Latent TB Infection|Characteristics of Mediastinal Lymph Node With False Positive FDG PET/CT Results in Lung Cancer Staging : Relation With TB and Latent TB Infection|Terminated|||33|Actual|Yonsei University|||1||f||||f||||||Samples Without DNA|"~     whole blood for perfoming Quantiferon-TB Gold in tube assay~   "|||2018-05-31 22:28:58.193537|2018-05-31 22:28:58.193537
NCT01376843|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-03-04|2011-06-17|2011-06-20|Estimate|||||||2013-03-04|2013-03-06|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers|Conversion Rate of TST and Quantiferon-TB Gold In Tube Assay in Health Care Workers|Completed|||53|Actual|Yonsei University|||1||f||||f||||||Samples Without DNA|"~     whole blood for perfoming Quantiferon-TB Gold in tube assay~   "|||2018-05-31 22:28:58.368498|2018-05-31 22:28:58.368498
NCT01376830|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2015-08-21|2011-06-17|2011-06-20|Estimate|||||||2015-08-21|2015-08-24|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Characteristics That Identify Exacerbation Risk Following Colds in COPD Patients|Biomarkers and Clinical Characteristics That Identify the Risk of an Exacerbation Following Viral Upper Respiratory Tract Infections in COPD Patients|Completed|||35|Actual|Imperial College London|||1||f||||f||||||Samples Without DNA|"~     Sputum,nasal lavage, serum~   "|||2018-05-31 22:28:58.573568|2018-05-31 22:28:58.573568
NCT01376817|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Comparative Study About the Impact of Two Oil Emulsions Administered Intravenously on Severe Acute Pancreatitis|Comparative Study About the Impact of Two Oil Emulsions, One of Them Formulated With MCT, LCT, Olive Oil and Omega 3 Fatty Acids Versus Another One Formulated With MCT and LCT, Administered Intravenously on Severe Acute Pancreatitis Clinical Evolution|Unknown status|Recruiting|Phase 4|60|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 22:28:58.832707|2018-05-31 22:28:58.832707
NCT01376804|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2014-03-27||2017-06-15|2011-06-17|2011-06-20|Estimate|2014-03-27|2014-04-28|Estimate||||2017-06-15|2017-07-11|Actual|July 31, 2011|Actual|2011-07-31|June 2017|2017-06-30|May 31, 2013|Actual|2013-05-31|May 31, 2013|Actual|2013-05-31||Interventional||Baseline measures were based on the Intent-to-treat population that included all enrolled patients who had taken at least one dose of study drug.|A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients|Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients|Completed||Phase 4|57|Actual|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 22:28:59.358282|2018-05-31 22:28:59.358282
NCT01376791|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2013-04-19|2011-06-17|2011-06-20|Estimate|||||||2013-04-19|2013-04-23|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Assess the Effect of Treating Periodontal Disease on Cardiovascular Function in Young Adults|Oral Flora, Periodontitis, and Vascular Dysfunction in Young Native Americans.|Completed|||92|Actual|San Diego State University|||||f||||f||||||Samples With DNA|"~     Serum, dental scrapings and saliva~   "|||2018-05-31 22:29:00.62107|2018-05-31 22:29:00.62107
NCT01376778|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2017-07-19|2011-06-16|2011-06-20|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2012||2012-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|CMV||A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)|A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)|Recruiting||Phase 3|800|Anticipated|The George Washington University Biostatistics Center||2|||f||||t||||||||Yes|The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.|2018-05-31 22:29:00.866724|2018-05-31 22:29:00.866724
NCT01376765|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-02-14|2011-06-16|2011-06-20|Estimate|||||||2013-02-14|2013-02-15|Estimate||||April 2012|2012-04-30||||||||Interventional|||Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study|Phase I, Double-Blinded, Placebo-Controlled, Dose- Escalation Study of the Safety and Immunogenicity of Recombinant SARS-CoV deltaTM S Protein Vaccine Formulated With and Without Alhydrogel® in Healthy Adults When Administered by the Intramuscular Route|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-05-31 22:29:01.259597|2018-05-31 22:29:01.259597
NCT01376739|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-16|2011-06-16|2011-06-20|Estimate|||||||2011-06-16|2011-06-20|Estimate|August 2007||2007-08-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Magnevist Post-marketing Surveillance in Japan|Drug Use Investigation of Magnevist|Completed|||2051|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:29:01.954495|2018-05-31 22:29:01.954495
NCT01376726|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-03-30|2011-06-16|2011-06-20|Estimate|||||||2017-03-30|2017-03-31|Actual|July 2011||2011-07-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials|A Phase I Open-Label Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Subtype C gp140 Vaccine With MF59 Adjuvant in Healthy, HIV-1 Uninfected Adult Participants Previously Primed or Unprimed With HIV-1 Subtype B Envelope Subunit Vaccines With MF59|Completed||Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 22:29:02.121041|2018-05-31 22:29:02.121041
NCT01376713|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2015-10-04|2011-06-17|2011-06-20|Estimate|||||||2015-10-04|2015-10-06|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma|CD20-Immunotargeting in Metastatic Melanoma Patients- A Prospective, Open Label, Sequential Pilot Study|Completed||Phase 2|10|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 22:29:02.320199|2018-05-31 22:29:02.320199
NCT01376700|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2014-09-17||2017-10-19|2011-06-17|2011-06-20|Estimate|2014-10-07|2014-10-09|Estimate||||2017-10-19|2017-11-22|Actual|August 2011||2011-08-31|October 2014|2014-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|EPIC||Early Prophylaxis Immunologic Challenge (EPIC) Study|A Phase 3b Clinical Study to Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients With Hemophilia A|Terminated||Phase 3|22|Actual|Shire|"Early termination lead to:~No statistical tests done on risk factors & inhibitor formation.~FVIII consumption by participant not calculated due to large variation in # of EDs.~FVIII-Specific Antibody Isotypes summary statistics not done."|1||"It became unlikely to achieve the study objective of 50% reduction over published inhibitor~   rates. The Data Monitoring Committee supported this decision."|f||||t||||||||||2018-05-31 22:29:02.62698|2018-05-31 22:29:02.62698
NCT01376687|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-11-30|2011-06-16|2011-06-20|Estimate|||||||2011-11-30|2011-12-01|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Observational|||Osteopathic Manipulative Medicine and Kinetics||Completed|||41|Actual|Michigan State University|||2||f||||f||||||||||2018-05-31 22:29:03.487765|2018-05-31 22:29:03.487765
NCT01376674|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-08-15|2011-06-16|2011-06-20|Estimate|||||||2013-08-15|2013-08-16|Estimate|March 2011||2011-03-31|August 2013|2013-08-31||||||||Observational|||T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer|Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer|Completed|||22|Actual|University Hospital Tuebingen|||||f||||f||||||Samples With DNA|"~     Peripheral blood mononuclear cells and serum are frozen and stored.~   "|||2018-05-31 22:29:03.592775|2018-05-31 22:29:03.592775
NCT01376661|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2012-09-12|2011-06-16|2011-06-20|Estimate|||||||2012-09-12|2012-09-14|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study|Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study|Recruiting|||500|Anticipated|St. Joseph Hospital of Orange|||1||f||||f||||||||||2018-05-31 22:29:03.77133|2018-05-31 22:29:03.77133
NCT01376648|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|||Thyroid Hormones Effect on Brown Adipose Tissue|Study on the Relationship Between the Thyroid Hormones and the Activity of Brown Adipose Tissue in Human|Unknown status|Recruiting||20|Anticipated|Huashan Hospital|||||f||||t||||||Samples Without DNA|"~     TSH, TT3, TT4, fT3, fT4,~     γT3,Norepinephrine,Blood-fat,FPG,Insulin,Leptin,Aadiponectin,Retinol-binding protein 4,Fatty~     acid binding protein 4,IL-6,TNF-α,CRP,Monocyte chemotactic protein 1~   "|||2018-05-31 22:29:03.907385|2018-05-31 22:29:03.907385
NCT01376635|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|May 2009|Actual|2009-05-31|||||Observational|HRV||Depressed Cardiac Autonomic Modulation in Patients With Chronic Kidney Disease Diagnosed by Spectral Analysis|Depressed Cardiac Autonomic Modulation in Patients With Chronic Kidney Disease Diagnosed by Spectral Analysis of Heart Rate Variability Upon Postural Stress|Completed|||46|Actual|Core Educational Research and Treatment in Nephrology|||||f||||t||||||||||2018-05-31 22:29:04.001975|2018-05-31 22:29:04.001975
NCT01376622|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|November 2008||2008-11-30|July 2010|2010-07-31||||||||Observational|||Changes in Pituitary Iron and Volume With Deferasirox|Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload|Completed|||130|Actual|Children's Hospital Los Angeles|||2||f||||f||||||||||2018-05-31 22:29:04.076359|2018-05-31 22:29:04.076359
NCT01376609|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2011-07-29|2011-06-17|2011-06-20|Estimate|||||||2011-07-29|2011-08-01|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|August 2013|Anticipated|2013-08-31|March 2012|Anticipated|2012-03-31||Observational|COIG||The Correlation Between Outcome and Infarct Growth in Patients With Acute Ischemic Stroke|A MRI-based Study of Ischaemic Penumbra: the Correlation Between Outcome and Infarct Growth in Patients With Acute Ischemic Stroke|Unknown status|Not yet recruiting||80|Anticipated|Beijing Hospital of Traditional Chinese Medicine|||||f||||f||||||||||2018-05-31 22:29:04.16354|2018-05-31 22:29:04.16354
NCT01376596|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2014-04-09|2011-06-17|2011-06-20|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Group Cognitive-behavioral Intervention for Social Anxiety in Schizophrenia|Manualized Group Cognitive-behavioral Intervention for Social Anxiety in Schizophrenia: An Efficacy Pilot Study.|Completed||Phase 1/Phase 2|49|Actual|McGill University||2|||f||||t||||||||||2018-05-31 22:29:04.269909|2018-05-31 22:29:04.269909
NCT01376583|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-11-28|2011-06-16|2011-06-20|Estimate|||||||2013-11-28|2013-12-02|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Exercise Controls Tumor Cell Growth Through AMPK Activation|Running From Cancer|Unknown status|Recruiting||10|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||Samples Without DNA|"~     Bloodsamples wherefrom, serum is isolated and kept at -20 degrees celsius~   "|||2018-05-31 22:29:04.408619|2018-05-31 22:29:04.408619
NCT01376570|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-04-19|2011-06-17|2011-06-20|Estimate|||||||2018-04-19|2018-04-20|Actual|June 2012||2012-06-30|April 2018|2018-04-30|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|Project FIRST||Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment|A Randomized Trial of an Abstinence-reinforcing Contingency Management Intervention to Suppress HIV Viral Load|Completed||N/A|242|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 22:29:04.478014|2018-05-31 22:29:04.478014
NCT01376557|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2014-10-27||2014-10-29|2011-06-17|2011-06-20|Estimate|2014-10-29|2014-10-31|Estimate||||2014-10-29|2014-10-31|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 2|299|Actual|Lexicon Pharmaceuticals||5|||f||||f||||||||||2018-05-31 22:29:04.786635|2018-05-31 22:29:04.786635
NCT01376544|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Trial of Weaning by Synchronized Ventilation|Randomised Trial Comparing Assist Control Ventilation to Pressure Support Ventilation During Weaning|Completed||N/A|36|Actual|King's College London||2|||f||||f||||||||||2018-05-31 22:29:06.132512|2018-05-31 22:29:06.132512
NCT01376531|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2013-04-12|2011-06-17|2011-06-20|Estimate|||||||2013-04-12|2013-04-15|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|dARICUCVVH||Influence Continuous Veno-venous Hemodialysis the Autoregulation|Influence of Continuous Veno-venous Hemodialysis on Cerebrovascular Autoregulation in Patients With Acute Renal Failure|Completed|||20|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-05-31 22:29:06.251127|2018-05-31 22:29:06.251127
NCT01376518|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|January 2011||2011-01-31|August 2010|2010-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|dARICUPEEP||Influence Positive End-expiratory Pressure on Autoregulation in Patients With Respiratory Insufficiency|Influence of Positive End-expiratory Pressure on the Cerebrovascular Autoregulation in Patients With Respiratory Failure|Completed|||20|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-05-31 22:29:06.437752|2018-05-31 22:29:06.437752
NCT01376505|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2018-04-03|2011-06-16|2011-06-20|Estimate|||||||2018-04-03|2018-04-05|Actual|June 21, 2011||2011-06-21|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Solid Tumors|Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||Undecided||2018-05-31 22:29:06.58939|2018-05-31 22:29:06.58939
NCT01376492|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-03-07|2011-06-17|2011-06-20|Estimate|||||||2013-03-07|2013-03-08|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain|Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain|Completed|||709|Actual|Janssen-Cilag, S.A.|||2||f||||||||||||||2018-05-31 22:29:06.750998|2018-05-31 22:29:06.750998
NCT01376479|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2015-05-05|2011-06-17|2011-06-20|Estimate|||||||2015-05-05|2015-05-06|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Immunogenicity Study of an Inactivated Vaccine Against Hand, Foot and Mouth Disease Caused by Enterovirus 71|Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults|Completed||Phase 1|36|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:29:06.852429|2018-05-31 22:29:06.852429
NCT01376466|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2012-11-08|2011-06-17|2011-06-20|Estimate|||||||2012-11-08|2012-11-09|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|October 2012|Actual|2012-10-31|February 2011|Actual|2011-02-28||Observational|||Impact of CT on Diagnosis of Acute Appendicitis|The Impact Of Computed Tomography On The Diagnoses Of Acute Appendicitis|Completed|||102|Actual|University of Aarhus|||1||f||||t||||||||||2018-05-31 22:29:06.984209|2018-05-31 22:29:06.984209
NCT01376453|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2016-09-09|2011-06-17|2011-06-20|Estimate|||||||2016-09-09|2016-09-12|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|November 2014|Actual|2014-11-30||Interventional|||Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer|Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma|Completed||Phase 1|18|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 22:29:07.115359|2018-05-31 22:29:07.115359
NCT01376440|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-01-23|2011-06-16|2011-06-20|Estimate|||||||2012-01-23|2012-01-24|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Acceptability and Effectiveness of Household Water Treatment in Reducing Diarrhea Among Under Five Children|Acceptability and Effectiveness of Household Water Chlorination in Reducing the Prevalence of Diarrhea Among Under Five Children in Eastern Ethiopia|Completed||Phase 1|845|Actual|Haramaya Unversity||2|||f||||t||||||||||2018-05-31 22:29:07.236814|2018-05-31 22:29:07.236814
NCT01376427|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-04-23|2011-06-17|2011-06-20|Estimate|||||||2017-04-23|2017-04-25|Actual|January 2007||2007-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years|PROTOCOL TREATMENT for Acute Lymphoblastic Leukemia Ph '(BCR / ABL) POSITIVE PATIENTS AGED> 55 YEARS|Recruiting||N/A|100|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-05-31 22:29:07.381122|2018-05-31 22:29:07.381122
NCT01376414|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2016-08-24|2011-06-17|2011-06-20|Estimate|||||||2016-08-24|2016-08-26|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Observational|||H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department|Pilot Study to Estimate the Prevalence of Helicobacter Pylori (H. Pylori) Infection in Patients Presenting With Non-specific Upper Abdominal Pain to the Emergency Department (ED.)|Completed|||212|Actual|George Washington University|||1||f||||f||||||||||2018-05-31 22:29:07.452672|2018-05-31 22:29:07.452672
NCT01376401|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2016-05-16|2011-06-17|2011-06-20|Estimate|||||||2016-05-16|2016-05-17|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma||Completed||Phase 2|60|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-05-31 22:29:07.615817|2018-05-31 22:29:07.615817
NCT01370512|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2017-07-31|2011-06-09|2011-06-10|Estimate|||||||2017-07-31|2017-08-01|Actual|November 2011||2011-11-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Droxidopa / Pyridostigmine in Orthostatic Hypotension|Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine Hypertension|Recruiting||Phase 2|45|Anticipated|Mayo Clinic||3|||f||||f||||||||||2018-05-31 22:32:03.526804|2018-05-31 22:32:03.526804
NCT01376388|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2013-12-19||2016-11-18|2011-06-16|2011-06-20|Estimate|2014-02-13|2014-03-14|Estimate||||2016-11-18|2017-01-09|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DB2115362||Long-term Safety Study for GSK573719/GW642444 in Japanese|A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily in Combination With GW642444 25 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.|Completed||Phase 3|131|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:29:07.818052|2018-05-31 22:29:07.818052
NCT01376375|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2018-05-23|2011-06-17|2011-06-20|Estimate|||||||2018-05-23|2018-05-24|Actual|June 10, 2011||2011-06-10|April 26, 2013|2013-04-26|April 26, 2013|Actual|2013-04-26|April 26, 2013|Actual|2013-04-26||Interventional|||Acupuncture to Reduce Signs of Inflammation in Participants With Chronic Low Back Pain|A Pilot Study to Evaluate the Effect of Acupuncture on Epigenetic Regulation of Inflammatory Mediators in Participants With Chronic Low Back Pain|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:29:08.976355|2018-05-31 22:29:08.976355
NCT01376362|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2012-08-03||2012-09-06|2011-06-17|2011-06-20|Estimate|2012-09-06|2012-10-08|Estimate||||2012-09-06|2012-10-08|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|JakStat2||Topical Interferon Gamma for Macular Edema Secondary to Uveitis|The Treatment of Macular Edema Secondary to Uveitis Using Topical Interferon Gamma|Completed||Phase 1/Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 22:29:09.156047|2018-05-31 22:29:09.156047
NCT01376349|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|2016-12-08||2017-07-25|2011-06-17|2011-06-20|Estimate|2017-07-25|2017-08-25|Actual||||2017-07-25|2017-08-25|Actual|July 2011||2011-07-31|July 2017|2017-07-31||||August 2013|Actual|2013-08-31||Interventional||All patients that were randomized to treatment were included in baseline characteristics.|Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms|Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial|Active, not recruiting||Phase 3|464|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-05-31 22:29:09.980021|2018-05-31 22:29:09.980021
NCT01376336|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Trial of Safe Water Storage Among People Living With HIV|Randomized Controlled Trial of Safe Water Storage Among People Living With HIV|Unknown status|Not yet recruiting|N/A|1600|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 22:29:12.099261|2018-05-31 22:29:12.099261
NCT01376323|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2017-08-10|2013-03-21|2017-09-11|2011-06-16|2011-06-20|Estimate|2017-09-11|2017-10-11|Actual|2013-03-21|2013-04-01|Estimate|2017-09-11|2017-10-11|Actual|July 13, 2011|Actual|2011-07-13|August 2017|2017-08-31|September 17, 2012|Actual|2012-09-17|September 16, 2012|Actual|2012-09-16||Interventional|||A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin|A Multicenter, Two Part, Randomized, Parallel Group, Placebo and Sitagliptin Controlled Study to Evaluate the Safety and Efficacy of GSK256073 Administered Once or Twice Daily for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin|Completed||Phase 2|92|Actual|GlaxoSmithKline||10|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:29:13.061229|2018-05-31 22:29:13.061229
NCT01376310|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2018-01-10|2011-06-16|2011-06-20|Estimate|||||||2018-01-10|2018-01-12|Actual|March 28, 2011|Actual|2011-03-28|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||GSK1120212 Rollover Study|MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors and Leukemia|Active, not recruiting||Phase 2|250|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 22:29:15.606568|2018-05-31 22:29:15.606568
NCT01376297|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2014-11-06|2013-01-16|2014-11-06|2011-06-17|2011-06-20|Estimate|2014-11-06|2014-11-17|Estimate|2013-01-16|2013-01-25|Estimate|2014-11-06|2014-11-17|Estimate|July 2011||2011-07-31|November 2014|2014-11-30||||September 2012|Actual|2012-09-30||Interventional||Safety Population, i.e. patients receiving study drugs (either netupitant/palonosetron combination or aprepitant/palonosetron regimen, both with dexamethasone)|A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting|A Phase III, Multicenter, Randomized, Double-blind, Unbalanced (3:1) Active Control Study to Assess the Safety and Describe the Efficacy of Netupitant and Palonosetron for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles.|Completed||Phase 3|413|Actual|Helsinn Healthcare SA||2|||f||||t||||||||||2018-05-31 22:29:15.803082|2018-05-31 22:29:15.803082
NCT01376284|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-07-24|2011-06-16|2011-06-20|Estimate|||||||2014-07-24|2014-07-28|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Observational|||Drug Use Investigation for AVOLVE(BPH)|Drug Use Investigation for AVOLVE(BPH)|Completed|||1000|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:16.355341|2018-05-31 22:29:16.355341
NCT01376271|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-06-30|2011-06-16|2011-06-20|Estimate|||||||2014-06-30|2014-07-02|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)|Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)|Completed|||600|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:17.060853|2018-05-31 22:29:17.060853
NCT01376258|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-05-19|2011-06-16|2011-06-20|Estimate|||||||2017-05-19|2017-05-22|Actual|October 2010||2010-10-31|May 2017|2017-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database|Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database|Completed|||28903|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:29:17.235289|2018-05-31 22:29:17.235289
NCT01375881|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-05-03|2011-06-16|2011-06-17|Estimate|||||||2013-05-03|2013-05-06|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice|Post Authorization Non-interventional Study in HIV1-Infected Patients Starting or Already in Treatment With Darunavir|Completed|||31|Actual|Janssen-Cilag S.p.A.|||1||f||||||||||||||2018-05-31 22:29:26.282656|2018-05-31 22:29:26.282656
NCT01376245|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2013-12-10||2016-11-20|2011-06-16|2011-06-20|Estimate|2013-12-10|2014-01-28|Estimate||||2016-11-20|2017-01-11|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD|A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily Via a Dry Powder Inhaler Compared With Placebo in Subjects of Asian Ancestry With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|646|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:29:17.436072|2018-05-31 22:29:17.436072
NCT01376232|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-06-07|2011-06-16|2011-06-20|Estimate|||||||2017-06-07|2017-06-09|Actual|November 8, 2010|Actual|2010-11-08|June 2017|2017-06-30|December 20, 2010|Actual|2010-12-20|December 20, 2010|Actual|2010-12-20||Interventional|DDI||Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)|Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)|Completed||Phase 1|23|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:29:18.550787|2018-05-31 22:29:18.550787
NCT01376219|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2014-08-11|2011-06-16|2011-06-20|Estimate|||||||2014-08-11|2014-08-13|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|EU-COAST||European Cost of Asthma Treatment|EU-COAST STUDY: European Cost of Asthma Treatment Economic Impact of Asthma Control|Completed|||2752|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:18.754313|2018-05-31 22:29:18.754313
NCT01376206|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-05-19|2011-06-16|2011-06-20|Estimate|||||||2017-05-19|2017-05-22|Actual|December 2009||2009-12-31|May 2017|2017-05-31|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Observational|||Drug Use Investigation for ALLERMIST|Drug Use Investigation for ALLERMIST|Completed|||2000|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:18.924877|2018-05-31 22:29:18.924877
NCT01376193|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-05-16|2011-06-16|2011-06-20|Estimate|||||||2013-05-16|2013-05-20|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet|Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet|Completed|||500|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:19.061073|2018-05-31 22:29:19.061073
NCT01376180|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2016-11-08|2011-06-16|2011-06-20|Estimate|||||||2016-11-08|2016-11-09|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Drug Use Investigation for LAMICTAL|Drug Use Investigation for LAMICTAL|Completed|||3000|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:19.162934|2018-05-31 22:29:19.162934
NCT01376167|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2017-10-27||2018-03-23|2011-06-16|2011-06-20|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|April 24, 2014|Actual|2014-04-24|February 2018|2018-02-28|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Interventional|||Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse|A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.|Completed||Phase 2|851|Actual|GlaxoSmithKline||9|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:29:19.429533|2018-05-31 22:29:19.429533
NCT01376154|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-05-19|2011-06-16|2011-06-20|Estimate|||||||2017-05-19|2017-05-22|Actual|June 2006||2006-06-30|May 2017|2017-05-31|February 2011|Actual|2011-02-28|December 2009|Actual|2009-12-31||Observational|||Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)|Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)|Completed|||342|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:21.940978|2018-05-31 22:29:21.940978
NCT01376141|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2017-05-19|2011-06-16|2011-06-20|Estimate|||||||2017-05-19|2017-05-22|Actual|September 2001||2001-09-30|May 2017|2017-05-31|November 2005|Actual|2005-11-30|February 2005|Actual|2005-02-28||Observational|||Drug Use Investigation for IMIGRAN Tablet|Drug Use Investigation for IMIGRAN Tablet|Completed|||3571|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:22.052003|2018-05-31 22:29:22.052003
NCT01376128|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-05-19|2011-06-16|2011-06-20|Estimate|||||||2017-05-19|2017-05-22|Actual|March 2008||2008-03-31|May 2017|2017-05-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Observational|||Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)|Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)|Completed|||96|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:22.119725|2018-05-31 22:29:22.119725
NCT01376115|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-10-30|2011-06-16|2011-06-20|Estimate|||||||2017-10-30|2017-11-01|Actual|January 18, 2008|Actual|2008-01-18|October 2017|2017-10-31|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Observational|||Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg|Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg|Completed|||343|Actual|Novartis|||1||f||||f|t|f||||||||2018-05-31 22:29:22.184217|2018-05-31 22:29:22.184217
NCT01376102|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2014-06-12|2011-06-16|2011-06-20|Estimate|||||||2014-06-12|2014-06-16|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|BONINJPMS||BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Injection Administered in Korean Patients According to the Prescribing Information|Completed|||657|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:29:22.256531|2018-05-31 22:29:22.256531
NCT01376089|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2013-05-30||2013-11-05|2011-06-17|2011-06-20|Estimate|2013-11-05|2013-12-19|Estimate||||2013-11-05|2013-12-19|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|||Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis|A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis|Completed||Phase 4|304|Actual|GE Healthcare||2|||f||||t||||||||||2018-05-31 22:29:22.467542|2018-05-31 22:29:22.467542
NCT01376076|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-02-07|2011-06-17|2011-06-20|Estimate|||||||2012-02-07|2012-02-08|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia|Evaluation of the Effects of Sequential Multiple-Dose Regimens of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia|Completed||Phase 1|129|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 22:29:22.894636|2018-05-31 22:29:22.894636
NCT01376063|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-17|2011-06-17|2011-06-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects|A Phase 1, Single-Center, One-Sequence, Open-Label Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects|Completed||Phase 1|20|Actual|FibroGen||1|||f||||f||||||||||2018-05-31 22:29:23.112813|2018-05-31 22:29:23.112813
NCT01376050|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2015-07-10||2015-11-07|2011-06-17|2011-06-20|Estimate|2015-11-07|2015-12-11|Estimate||||2015-11-07|2015-12-11|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Venous Stasis Ulcers|Terminated||N/A|24|Actual|Erchonia Corporation||2||recruitment difficulties|f||||f||||||||||2018-05-31 22:29:23.210423|2018-05-31 22:29:23.210423
NCT01376037|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2013-04-11||2014-05-07|2011-06-17|2011-06-20|Estimate|2013-04-11|2013-05-29|Estimate||||2014-05-07|2014-05-30|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy Study of the Effect of Low Level Laser Light Therapy on Reducing Upper Arm Circumference|An Evaluation of the Effectiveness of the Erchonia ML Scanner (MLS) as a Non-invasive Dermatological Aesthetic Treatment for the Reduction of Circumference of the Upper Arms Clinical Study|Completed||N/A|62|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-05-31 22:29:23.642053|2018-05-31 22:29:23.642053
NCT01376024|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2015-03-11|2011-06-17|2011-06-20|Estimate|||||||2015-03-11|2015-03-12|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|August 2025|Anticipated|2025-08-31|August 2025|Anticipated|2025-08-31||Observational|BJAM||Basal Joint Arthritis Prospective|Multicenter Prospective Study on Basal Joint Arthritis of the Thumb|Recruiting|||500|Anticipated|Columbia University|||||f||||f||||||||||2018-05-31 22:29:23.962984|2018-05-31 22:29:23.962984
NCT01376011|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2015-01-26|2011-06-17|2011-06-20|Estimate|||||||2015-01-26|2015-01-28|Estimate|June 2009||2009-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|June 2012|Actual|2012-06-30||Interventional|Quercetin||Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement|Hypoxia-inducible Transcription Factor 1 (HIF-1) in Vascular Aging|Completed||Early Phase 1|106|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 22:29:24.087189|2018-05-31 22:29:24.087189
NCT01375998|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-04-02|2011-06-17|2011-06-20|Estimate|||||||2018-04-02|2018-04-03|Actual|June 9, 2011|Actual|2011-06-09|April 2018|2018-04-30|March 8, 2018|Actual|2018-03-08|December 5, 2017|Actual|2017-12-05||Observational|||YAZ Post-marketing Surveillance in Japan|Drug Use Investigation of YAZ|Completed|||3273|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:29:24.178094|2018-05-31 22:29:24.178094
NCT01375985|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-06-10|2011-06-17|2011-06-20|Estimate|||||||2013-06-10|2013-06-11|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Safety Study of Single Administration Intravenous Treatment for Influenza|A Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects|Terminated||Phase 1|8|Actual|Sarepta Therapeutics||2||The study was halted after enrollment of the first cohort because of lack of funding|f||||t||||||||||2018-05-31 22:29:24.244969|2018-05-31 22:29:24.244969
NCT01375972|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-12-05|2011-06-17|2011-06-20|Estimate|||||||2011-12-05|2011-12-06|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma|Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer|Completed||Phase 2|92|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 22:29:24.306504|2018-05-31 22:29:24.306504
NCT01375959|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-06-16|2011-06-16|2011-06-20|Estimate|||||||2011-06-16|2011-06-20|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|RSV||Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance|The Effect of Resveratrol in Older Adults With Impaired Glucose Tolerance: a Double-Blind Crossover Study|Unknown status|Recruiting|N/A|30|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 22:29:24.39049|2018-05-31 22:29:24.39049
NCT01375946|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2017-07-24||2017-07-25|2011-06-16|2011-06-20|Estimate|2017-07-25|2017-12-21|Actual||||2017-07-25|2017-12-21|Actual|May 2011||2011-05-31|July 2017|2017-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Safety Population|Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers|A Pharmacokinetic And Wearability Study of the Agile TCDS AG200-15 Following Weekly Application Under Various External Conditions in Healthy Female Volunteers|Completed||Phase 1|24|Actual|Agile Therapeutics||1|||f||||f||||||||||2018-05-31 22:29:24.513083|2018-05-31 22:29:24.513083
NCT01375933|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-05-10|2011-06-17|2011-06-20|Estimate|||||||2012-05-10|2012-05-14|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers|A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Assess Comparability of a Single Phase 3 Lot and a Single Commercial Lot of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Healthy Adult Smokers|Completed||Phase 3|260|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 22:29:25.024512|2018-05-31 22:29:25.024512
NCT01375920|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-17|||2014-07-16|2011-06-17|2011-06-20|Estimate|||||||2014-07-16|2014-07-17|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|ADD||Antiglucocorticoid Augmentation of antiDepressants in Depression|Antiglucocorticoid Augmentation of antiDepressants in Depression|Completed||Phase 3|190|Actual|Northumberland, Tyne and Wear NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:29:25.323739|2018-05-31 22:29:25.323739
NCT01375907|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-07-01|2011-06-16|2011-06-17|Estimate|||||||2016-07-01|2016-07-04|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults|A Phase 1 Study to Evaluate Safety and Reactogenicity of a Vietnamese Rotavirus Vaccine (Rotavin-M1 at 10e6.3FFU/Dose) Among Healthy Adults in Vietnam|Completed||Phase 1|29|Actual|National Institute of Hygiene and Epidemiology, Vietnam||1|||f||||t||||||||||2018-05-31 22:29:25.653588|2018-05-31 22:29:25.653588
NCT01375894|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-12-29|2011-06-16|2011-06-17|Estimate|||||||2011-12-29|2012-01-02|Estimate|March 2012||2012-03-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Body Movement Imitation and Perspective Perception Among Psychiatric Patients||Unknown status|Not yet recruiting|N/A|60|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 22:29:26.019153|2018-05-31 22:29:26.019153
NCT01368861|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-07-28|2011-06-07|2011-06-08|Estimate|||||||2015-07-28|2015-07-29|Estimate|June 2010||2010-06-30|July 2015|2015-07-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Observational|||Effective Analgesia During Routine Immunizations|Effective Analgesia Using the 5 S's During Routine Immunizations at 2 and 4 Months|Completed|||230|Actual|Children's Hospital of The King's Daughters|||4||f||||f||||||||||2018-05-31 22:32:42.564041|2018-05-31 22:32:42.564041
NCT01375868|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-03-01|2011-06-16|2011-06-17|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2011||2011-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis|Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis|Active, not recruiting||Phase 3|50|Anticipated|Institute of Hematology and Blood Transfusion, Czech Republic||1|||f||||t||||||||||2018-05-31 22:29:26.396065|2018-05-31 22:29:26.396065
NCT01375855|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-06-16|2011-06-16|2011-06-17|Estimate|||||||2011-06-16|2011-06-17|Estimate|October 2007||2007-10-31|February 2007|2007-02-28||||||||Interventional|LISAII||Late Incomplete Stent Apposition Evaluation II: Comparison Between Polimer-based and No-polimer Stent System. IVUS Based Study|Late Incomplete Stent Apposition Evaluation II: Vascular Effects Evaluation After Polimer and No-polimer Based Coronary Artery Drug Eluting Stent Ilmplantation. An IVUS Based Study|Unknown status|Recruiting|Phase 4|320|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 22:29:26.680963|2018-05-31 22:29:26.680963
NCT01375842|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-03-29|2011-06-16|2011-06-17|Estimate|||||||2018-03-29|2018-04-02|Actual|June 21, 2011|Actual|2011-06-21|March 2018|2018-03-31|May 7, 2018|Anticipated|2018-05-07|May 7, 2018|Anticipated|2018-05-07||Interventional|||A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies|Active, not recruiting||Phase 1|661|Actual|Genentech, Inc.||9|||f||||||||||||||2018-05-31 22:29:27.161001|2018-05-31 22:29:27.161001
NCT01375829|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-03-02|2011-06-16|2011-06-17|Estimate|||||||2018-03-02|2018-03-05|Actual|June 27, 2011|Actual|2011-06-27|January 2018|2018-01-31||||February 3, 2017|Actual|2017-02-03||Interventional|||Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of Ixabepilone and Temsirolimus in Adult Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:29:27.787856|2018-05-31 22:29:27.787856
NCT01375816|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2015-06-03|2011-06-16|2011-06-17|Estimate|||||||2015-06-03|2015-06-04|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|PEPCOL||Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|A Randomized Phase II Study of PEP02 or Irinotecan in Combination With Leucovorin and 5-Fluorouracil in Second Line Therapy of Metastatic Colorectal Cancer|Terminated||Phase 2|55|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||2||efficacy interim analysis as per protocol|f||||t||||||||||2018-05-31 22:29:28.43028|2018-05-31 22:29:28.43028
NCT01375803|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-16|2011-06-16|2011-06-17|Estimate|||||||2011-06-16|2011-06-17|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity|Novel Fiber Effects on Glucose Metabolism and Insulin Sensitivity for Individuals at High Risk for Diabetes|Completed||N/A|45|Actual|Cargill||3|||f||||f||||||||||2018-05-31 22:29:29.784216|2018-05-31 22:29:29.784216
NCT01375790|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2012-08-28|2011-06-16|2011-06-17|Estimate|||||||2012-08-28|2012-08-29|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|GERIAPLAT||Whole-body Vibration Training in Older People|Neuromuscular Training With Whole Body Vibration in Older People: A Randomized Multicentre Clinical Trial With Blinded to Evaluator|Completed||Phase 3|160|Actual|Asociacion Colaboracion Cochrane Iberoamericana||2|||f||||f||||||||||2018-05-31 22:29:30.21527|2018-05-31 22:29:30.21527
NCT01375777|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2015-09-03|2013-03-26|2015-09-03|2011-06-16|2011-06-17|Estimate|2015-09-03|2015-10-05|Estimate|2013-04-02|2013-04-09|Estimate|2015-09-03|2015-10-05|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|MENDEL|Full analysis set (all randomized participants who received at least 1 dose of investigational product).|Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels|A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less|Completed||Phase 2|411|Actual|Amgen||9|||f||||t||||||||||2018-05-31 22:29:31.228611|2018-05-31 22:29:31.228611
NCT01375764|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2015-09-02|2013-03-26|2015-11-19|2011-06-16|2011-06-17|Estimate|2015-11-19|2015-12-23|Estimate|2013-04-02|2013-04-09|Estimate|2015-11-19|2015-12-23|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|GAUSS|Full analysis set (all randomized participants who received at least 1 dose of investigational product).|Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects|A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor|Completed||Phase 2|160|Actual|Amgen||5|||f||||t||||||||||2018-05-31 22:29:34.353478|2018-05-31 22:29:34.353478
NCT01375751|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2015-08-28|2013-04-02|2015-08-28|2011-06-16|2011-06-17|Estimate|2015-08-28|2015-09-29|Estimate|2013-04-02|2013-04-09|Estimate|2015-08-28|2015-09-29|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|RUTHERFORD|Full analysis set (all randomized participants who received at least 1 dose of investigational product).|Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial Hypercholesterolemia|Completed||Phase 2|168|Actual|Amgen||3|||f||||t||||||||||2018-05-31 22:29:36.255183|2018-05-31 22:29:36.255183
NCT01375738|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-09-12|2011-06-15|2011-06-17|Estimate|||||||2012-09-12|2012-09-13|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|May 2014|Anticipated|2014-05-31|June 2013|Anticipated|2013-06-30||Interventional|||Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With Diabetes Mellitus|The Effect and Mechanism of Improving Diabetes by Reconstruction Methods in Gastric Cancer Patients With DM Who Receive Surgical Treatment|Unknown status|Recruiting|N/A|40|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 22:29:39.081952|2018-05-31 22:29:39.081952
NCT01375725|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-06-16|2011-06-16|2011-06-17|Estimate|||||||2011-06-16|2011-06-17|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Study to Determine the Accuracy of Prothrombin Time of Warfarinised Blood|Mobius PT-INR Accuracy Clinical Study|Completed|||60|Actual|Universal Biosensors Pty Ltd|||1||f||||f||||||||||2018-05-31 22:29:39.207408|2018-05-31 22:29:39.207408
NCT01375712|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-01-26|2011-06-15|2011-06-17|Estimate|||||||2012-01-26|2012-01-31|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy Evaluation of Probiotic Product on Bowel Habits in Healthy Subjects|Evaluation of the Impact of a Fermented Milk Containing Lactobacillus Casei Strain Shirota on Stool Consistency, Stool Frequency, Constipation-related Symptoms and Quality of Life in People Who Frequently Have Hard or Lumpy Stools|Completed||N/A|238|Actual|Yakult Honsha Co., LTD||2|||f||||f||||||||||2018-05-31 22:29:39.355427|2018-05-31 22:29:39.355427
NCT01375699|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2018-01-22|2011-06-16|2011-06-17|Estimate|||||||2018-01-22|2018-01-23|Actual|August 11, 2011|Actual|2011-08-11|January 2018|2018-01-31|January 19, 2018|Actual|2018-01-19|August 4, 2017|Actual|2017-08-04||Interventional|||Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers|Randomized Open-label Phase 1b Study of Doxorubicin-based Chemotherapy Regimens, With and Without Sildenafil, With Exploratory Analysis of Intermediate Cardiac Markers|Completed||Phase 1|26|Actual|Virginia Commonwealth University||2|||f||||t|t|f|||t|||||2018-05-31 22:29:39.470955|2018-05-31 22:29:39.470955
NCT01375686|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-12-03|2011-06-16|2011-06-17|Estimate|||||||2012-12-03|2012-12-04|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|NSEEDS||Noninvasive Screening for Early Evidence of Diabetes With SCOUT DS|Noninvasive Screening for Early Evidence of Diabetes With SCOUT DS|Completed|||486|Actual|VeraLight, Inc.|||1||f||||f||||||Samples Without DNA|"~     Serum will be stored to later analyze lipids and insulin. This will be useful in~     understanding metabolic disorders experienced by the patients measured. These measurements~     can be used directly, or combined in a manner similar to the McAuley index to understand the~     risk of insulin insensitivity.~   "|||2018-05-31 22:29:39.568084|2018-05-31 22:29:39.568084
NCT01375673|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-04-06|2011-06-15|2011-06-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Exercise Training on Fluid Instability in Heart Failure Patients|Effects of Exercise Training on Fluid Instability in Heart Failure Patients|Completed||N/A|60|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 22:29:39.666639|2018-05-31 22:29:39.666639
NCT01375660|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|2014-11-25||2015-02-17|2011-06-15|2011-06-17|Estimate|2015-02-03|2015-02-05|Estimate||||2015-02-17|2015-03-06|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|October 2013|Actual|2013-10-31||Interventional|DIVA||D Vitamin Intervention in VA|Vitamin D Deficiency and Treatment in Male Veterans at Risk for Diabetes|Completed||N/A|205|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 22:29:39.816257|2018-05-31 22:29:39.816257
NCT01375647|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-04-13|2011-06-15|2011-06-17|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|PROVIDE||Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh|Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh|Completed||Phase 3|700|Actual|University of Vermont||4|||f||||f||||||||||2018-05-31 22:29:40.504749|2018-05-31 22:29:40.504749
NCT01375634|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2013-07-19|2011-06-16|2011-06-17|Estimate|||||||2013-07-19|2013-07-22|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|NIMED||Nasogastric Tube Insertion Using Midazolam in the Emergency Department|Nasogastric Tube Insertion Using Midazolam in the Emergency Department|Completed||Phase 4|49|Actual|University of Vermont||2|||f||||f||||||||||2018-05-31 22:29:40.688207|2018-05-31 22:29:40.688207
NCT01375621|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-05-24|2011-06-16|2011-06-17|Estimate|||||||2018-05-24|2018-05-25|Actual|June 16, 2011||2011-06-16|July 10, 2017|2017-07-10||||||||Observational|||Livestock Contact and MRSA in Rural Areas|Epidemiology of Rural MRSA : Is Livestock Contact a Risk Factor?|Completed|||1342|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:29:40.811667|2018-05-31 22:29:40.811667
NCT01375608|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2017-01-10||2017-01-10|2011-06-16|2011-06-17|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|June 2011||2011-06-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Decitabine for High-Risk Sickle Cell Disease|An Extended Phase 2 Study of Decitabine in Subjects With High Risk Sickle Cell Disease|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 22:29:41.00462|2018-05-31 22:29:41.00462
NCT01375595|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-06-30|2011-06-16|2011-06-17|Estimate|||||||2017-06-30|2017-07-02|Actual|May 26, 2011||2011-05-26|October 30, 2015|2015-10-30|October 30, 2015||2015-10-30|||||Observational|||Brain Areas Involved in Sound and Spoken Word Memory|The Role of the Inferior Frontal Gyrus in Long-Term Auditory Memory a rTMS Study|Terminated|||45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:29:41.345721|2018-05-31 22:29:41.345721
NCT01375582|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-12-13|2011-06-15|2011-06-17|Estimate|||||||2013-12-13|2013-12-16|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Objective Evaluation of Ocular Surface Lubricants in Two Environments|Objective Evaluation of Ocular Surface Lubricants|Completed||Early Phase 1|20|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 22:29:41.446514|2018-05-31 22:29:41.446514
NCT01375569|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|2015-03-04||2017-06-29|2011-06-16|2011-06-17|Estimate|2015-03-04|2015-03-17|Estimate||||2017-06-29|2017-07-28|Actual|June 22, 2011|Actual|2011-06-22|June 2017|2017-06-30|December 1, 2015|Actual|2015-12-01|February 1, 2014|Actual|2014-02-01||Interventional|||TRC105 for Liver Cancer That Has Not Responded to Sorafenib|A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib|Completed||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||Undecided||2018-05-31 22:29:41.543325|2018-05-31 22:29:41.543325
NCT01375556|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-05-24|2011-06-16|2011-06-17|Estimate|||||||2018-05-24|2018-05-25|Actual|May 26, 2011||2011-05-26|January 20, 2016|2016-01-20|January 20, 2016|Actual|2016-01-20|January 20, 2016|Actual|2016-01-20||Interventional|||Genetics of the Acute Response to Alcohol in Social Drinkers|Genetics of the Acute Response to Alcohol in Humans|Terminated||Phase 1|33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:29:42.005978|2018-05-31 22:29:42.005978
NCT01375543|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-04-24|2011-06-16|2011-06-17|Estimate|||||||2018-04-24|2018-04-25|Actual|June 16, 2011||2011-06-16|April 9, 2018|2018-04-09||||||||Observational|||Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols|Next Generation Sequencing to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols|Enrolling by invitation|||104|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:29:42.295056|2018-05-31 22:29:42.295056
NCT01375530|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2018-05-24|2011-06-16|2011-06-17|Estimate|||||||2018-05-24|2018-05-25|Actual|June 16, 2011||2011-06-16|May 23, 2018|2018-05-23||||||||Observational|||Screening Volunteers for Clinical Trials|VRC 500:Screening of Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:29:42.420624|2018-05-31 22:29:42.420624
NCT01375504|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-04-18|2011-06-16|2011-06-17|Estimate|||||||2012-04-18|2012-04-19|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Self Regulation With Mindfulness Training on Body Mass Index and Cardiovascular Risk Markers in Obese Adults|Enhancing Self Regulation With Mindfulness Training and Its Effect on Body Mass Index and Cardiovascular Risk Markers in Obese Adults: A Randomized Pilot Clinical Trial|Completed||N/A|36|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:29:42.555041|2018-05-31 22:29:42.555041
NCT01375491|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2013-05-17|2011-06-16|2011-06-17|Estimate|||||||2013-05-17|2013-05-20|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|DOXY||Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans|Blockade of Receptor Cleavage in Diabetes Mellitus With an MMP Inhibitor|Completed||Phase 4|50|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 22:29:42.71039|2018-05-31 22:29:42.71039
NCT01375478|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2016-11-01|2011-06-16|2011-06-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis|Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION Study)|Completed|||197|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:29:42.876495|2018-05-31 22:29:42.876495
NCT01375465|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2013-09-20|2011-06-16|2011-06-17|Estimate|||||||2013-09-20|2013-09-23|Estimate|February 2011||2011-02-28|September 2013|2013-09-30||||July 2013|Actual|2013-07-31||Interventional|||The 001-DIOR Multicenter Registry|The 001-DIOR Multicenter Registry (A Novel Percutaneous Coronary Intervention With the New Paclitaxel-eluting Balloon DIOR in Ostial Bifurcated Lesions)|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Eurocor GmbH||1|||f||||f||||||||||2018-05-31 22:29:43.000599|2018-05-31 22:29:43.000599
NCT01375452|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-23|2011-06-16|2011-06-17|Estimate|||||||2011-06-23|2011-06-27|Estimate|March 2008||2008-03-31|May 2011|2011-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) of Dr.Reddy's Laboratories Ltd and Femara 2.5 mg Tablets (Reference)of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fasting Conditions|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:29:43.13694|2018-05-31 22:29:43.13694
NCT01375439|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2015-06-19|2011-06-15|2011-06-17|Estimate|||||||2015-06-19|2015-06-23|Estimate|August 2011||2011-08-31|July 2011|2011-07-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy|Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy and Submitted to Active Search of Genital Infection|Completed||N/A|280|Actual|UPECLIN HC FM Botucatu Unesp||1|||f||||f||||||||||2018-05-31 22:29:43.253727|2018-05-31 22:29:43.253727
NCT01375426|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-16|2011-06-16|2011-06-17|Estimate|||||||2011-06-16|2011-06-17|Estimate|September 2003||2003-09-30|June 2011|2011-06-30|June 2004||2004-06-30|||||Interventional|||Efficacy Study for Standard Versus Double Dose of Amoxicillin in WHO Defined Non-severe Pneumonia|Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-centre Randomized Double Blind Controlled Trial in Pakistan|Completed||Phase 1/Phase 2|900||ARI Research Cell|||||f||||||||||||||2018-05-31 22:29:43.391783|2018-05-31 22:29:43.391783
NCT01375413|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2015-10-30|2011-06-16|2011-06-17|Estimate|||||||2015-10-30|2015-11-02|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Duality-PD||Dual Task Practice in Parkinson's Disease|Motor Learning in Parkinson's Disease: a Randomized Comparison of Integrated Versus Consecutive Dual Task Training|Completed||Phase 3|121|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 22:29:43.51887|2018-05-31 22:29:43.51887
NCT01375400|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2011-06-20|2011-06-16|2011-06-17|Estimate|||||||2011-06-20|2011-06-21|Estimate|December 2010||2010-12-31|June 2011|2011-06-30||||July 2011|Anticipated|2011-07-31||Interventional|Aspirin||Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.|Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.|Unknown status|Recruiting|N/A|50|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||||2018-05-31 22:29:43.634864|2018-05-31 22:29:43.634864
NCT01375387|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-08-19|2011-06-15|2011-06-17|Estimate|||||||2011-08-19|2011-08-23|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males|A Phase I, Randomized Double-blind, Placebo-controlled, Single-center, Single-dose, Three-way Cross-over Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Lacosamide Tablets in Healthy Male Chinese and Japanese Subjects|Completed||Phase 1|33|Actual|UCB Pharma||8|||f||||f||||||||||2018-05-31 22:29:43.803814|2018-05-31 22:29:43.803814
NCT01375374|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2014-11-20|2013-12-13|2017-07-28|2011-06-16|2011-06-17|Estimate|2014-11-20|2014-11-26|Estimate|2013-12-13|2014-01-15|Estimate|2017-07-28|2017-08-28|Actual|July 2011||2011-07-31|July 2017|2017-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|VICTOR|The Baseline Analysis Population refers to the Safety Set (SS). The SS consists of all patients who received at least 1 dose of Lacosamide.|Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide|Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Levetiracetam|Terminated||Phase 3|11|Actual|UCB Pharma|The results of this study are limited due to the small sample size.|1||"Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading~   study center Investigators; decision thus made to terminate."|f||||f||||||||||2018-05-31 22:29:43.976846|2018-05-31 22:29:43.976846
NCT01375361|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2013-10-09|2011-06-16|2011-06-17|Estimate|||||||2013-10-09|2013-10-10|Estimate|April 2009||2009-04-30|October 2013|2013-10-31||||July 2010|Actual|2010-07-31||Interventional|ACHE||Nebulized Albuterol for Congestive Heart Failure Exacerbation||Withdrawn||Phase 2/Phase 3|0|Actual|University of California, San Francisco||2||Low enrollment.|f||||t||||||||||2018-05-31 22:29:44.478119|2018-05-31 22:29:44.478119
NCT01375348|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-02-13|2011-06-16|2011-06-17|Estimate|||||||2012-02-13|2012-02-14|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Relationship Between Cognitive Function and Pain|Cognitive Function in Healthy Volunteers Exposed to Acute Pain Before and After Administration of Remifentanil|Completed||Phase 3|23|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:29:44.602035|2018-05-31 22:29:44.602035
NCT01375335|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-08-06|2011-06-15|2011-06-17|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2011||2011-06-30|August 2013|2013-08-31||||August 2013|Actual|2013-08-31||Interventional|||The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve Replacement|The Effects of Dobutamine on Postoperative Systolic Deformation and Diastolic Function in Patients With Hypertrophic Cardiomyopathy Operated for Aortic Valve Stenosis|Suspended||Phase 4|10|Anticipated|University of Aarhus||1||Insufficient patient eligible for recruitment|f||||t||||||||||2018-05-31 22:29:44.724725|2018-05-31 22:29:44.724725
NCT01375322|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-06-16|2011-06-16|2011-06-17|Estimate|||||||2011-06-16|2011-06-17|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria|Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria|Completed||Phase 4|226|Actual|TSH Biopharm Corporation Limited||2|||f||||f||||||||||2018-05-31 22:29:44.818651|2018-05-31 22:29:44.818651
NCT01375309|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2012-03-28|2011-06-16|2011-06-17|Estimate|||||||2012-03-28|2012-03-30|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|Bifido(RCT)||Bifidobacterium Supplementation for Very Low Birth Weight Infants|Effect of Bifidobacterium Bifidum Supplementation on Morbidity of Very Low Birth Weight Infants|Completed||N/A|246|Actual|Tokyo Women's Medical University||2|||f||||t||||||||||2018-05-31 22:29:44.895991|2018-05-31 22:29:44.895991
NCT01375296|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-06-16|2011-06-16|2011-06-17|Estimate|||||||2011-06-16|2011-06-17|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|November 2011|Anticipated|2011-11-30|October 2011|Anticipated|2011-10-31||Interventional|SESIL||China Made Sirolimus Eluting Stent for Intermediate Lesion|China Made Sirolimus Eluting Stent for Treatment of Coronary Intermediate Lesion|Unknown status|Recruiting|Phase 2/Phase 3|600|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 22:29:45.076072|2018-05-31 22:29:45.076072
NCT01375283|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-01-04|2011-06-16|2011-06-17|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2011||2011-06-30|January 2012|2012-01-31||||August 2012|Anticipated|2012-08-31||Observational|||Sensory Mapping Following Video-assisted Thoracic Surgery|Sensory Mapping Following Video-assisted Thoracic Surgery|Unknown status|Recruiting||48|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 22:29:45.167423|2018-05-31 22:29:45.167423
NCT01375270|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2014-12-02|2011-06-16|2011-06-17|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Glucolipotoxicity and Type 2 Diabetes|The Effects of Experimental Elevation of Plasma Glucose and Lipid on Pancreatic Beta-cell Function in Humans|Completed||N/A|30|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 22:29:45.253538|2018-05-31 22:29:45.253538
NCT01375257|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-07-20|2011-06-16|2011-06-17|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2011||2011-06-30|July 2017|2017-07-31||||July 2017|Anticipated|2017-07-31||Interventional|POET||Partial Oral Treatment of Endocarditis|Partial Oral Treatment of Endocarditis|Recruiting||Phase 4|400|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 22:29:45.36848|2018-05-31 22:29:45.36848
NCT01375244|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-06-16|2011-06-16|2011-06-17|Estimate|||||||2011-06-16|2011-06-17|Estimate|June 1999||1999-06-30|April 2008|2008-04-30|October 1999|Actual|1999-10-31|October 1999|Actual|1999-10-31||Interventional|||Comparative Bioavailability Study of Lisinopril Tablets, 10 mg|Randomized, Open-label, Two-treatment Crossover, of a 10 mg Single Oral Dose, Study to Compare the Lisinopril Plasma Levels Produced After Administration of the Test Formulation With Those Produced After Administration of a Marketed Reference Product, Zestril(R), Under Fasting Conditions.|Completed||Phase 1|36|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-05-31 22:29:45.504148|2018-05-31 22:29:45.504148
NCT01375231|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2014-06-26|2011-06-16|2011-06-17|Estimate|||||||2014-06-26|2014-06-30|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Anatomic Reconstruction of the Patellofemoral Joint|Anatomic Reconstruction of the Patellofemoral Joint: A Solution for Anterior Knee Pain|Completed||Phase 4|52|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 22:29:45.616099|2018-05-31 22:29:45.616099
NCT01375218|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2015-01-16|2011-06-16|2011-06-17|Estimate|||||||2015-01-16|2015-01-19|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy and Satisfaction Comparing Two Braces in the Treatment of Developmental Dysplasia of the Hip (DDH) in Infants|Efficacy and Satisfaction Comparing Two Braces in the Treatment of DDH in Infants: A Randomized Clinical Trial|Completed||Phase 4|30|Actual|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 22:29:45.734795|2018-05-31 22:29:45.734795
NCT01375205|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-06-20|2011-06-16|2011-06-17|Estimate|||||||2011-06-20|2011-06-22|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants|A Randomized Pilot Trial Comparing Cetaphil® Restoraderm® System and Standard Skin Care in Infants at Risk for Atopic Dermatitis|Unknown status|Recruiting|N/A|250|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 22:29:45.828404|2018-05-31 22:29:45.828404
NCT01375179|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-05-11|2011-06-16|2011-06-17|Estimate|||||||2015-05-11|2015-05-13|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients|A Multi-centre, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of KRP203 in Subjects With Moderately Active Refractory Ulcerative Colitis|Terminated||Phase 2|27|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:29:45.956032|2018-05-31 22:29:45.956032
NCT01375166|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2018-01-08|2011-06-15|2011-06-17|Estimate|||||||2018-01-08|2018-01-09|Actual|March 6, 2013|Actual|2013-03-06|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|||Coupling of Neural Activity and Retinal Blood Flow in Diabetes||Recruiting|||48|Anticipated|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 22:29:46.094757|2018-05-31 22:29:46.094757
NCT01375153|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2017-04-04|2011-06-16|2011-06-17|Estimate|||||||2017-04-04|2017-04-06|Actual|November 2010||2010-11-30|April 2017|2017-04-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|BNP/Appetite||Brain Natriuretic Peptide Effects on Appetite Regulating Hormones and Endothelial Derived Peptides|Effects of Brain Natriuretic Peptide on Appetite-regulating Hormones and Endothelial-derived Peptides|Completed||N/A|10|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 22:29:46.173991|2018-05-31 22:29:46.173991
NCT01375140|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-06-26|2011-06-15|2011-06-17|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2011|Actual|2011-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ruxolitinib and Lenalidomide for Patients With Myelofibrosis|Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis|Active, not recruiting||Phase 2|49|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:29:46.294504|2018-05-31 22:29:46.294504
NCT01375127|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2013-05-17||2013-09-25|2011-06-16|2011-06-17|Estimate|2013-05-17|2013-08-14|Estimate||||2013-09-25|2013-10-29|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients|An Observational Study To Collect Follow-up Clinical Data From Kidney Transplant Recipients Who Received Tofacitinib (CP-690,550) In Completed Phase 2 Studies|Completed|||83|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 22:29:46.436324|2018-05-31 22:29:46.436324
NCT01375114|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2017-11-07|2011-06-15|2011-06-17|Estimate|||||||2017-11-07|2017-11-09|Actual|October 2011|Actual|2011-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Effects of Ginseng on Cancer-Related Fatigue|The Effects of Ginseng on Cancer-Related Fatigue|Active, not recruiting||Phase 2|158|Anticipated|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-05-31 22:29:46.97559|2018-05-31 22:29:46.97559
NCT01375101|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-07-25|2011-06-16|2011-06-17|Estimate|||||||2011-07-25|2011-07-26|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus||Unknown status|Recruiting|Phase 1|30|Anticipated|Mashhad University of Medical Sciences||2|||f||||||||||||||2018-05-31 22:29:47.058699|2018-05-31 22:29:47.058699
NCT01375088|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2012-11-21|2011-06-16|2011-06-17|Estimate|||||||2012-11-21|2012-11-22|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers|Phase I Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers|Completed||Phase 2|20|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:29:47.122998|2018-05-31 22:29:47.122998
NCT01375075|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15||2012-05-24|2012-05-24|2011-06-15|2011-06-17|Estimate||||2012-05-24|2012-06-01|Estimate|2012-05-24|2012-06-01|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of LY2484595 in Japanese Subjects|A Phase 2 Dose Response Study of LY2484595 in Japanese Subjects|Completed||Phase 2|150|Anticipated|Eli Lilly and Company||6|||f||||t||||||||||2018-05-31 22:29:47.207292|2018-05-31 22:29:47.207292
NCT01375062|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-10-16|2011-06-16|2011-06-17|Estimate|||||||2015-10-16|2015-10-19|Estimate|May 2009||2009-05-31|March 2014|2014-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Obtaining Undifferentiated Cells From Testis Biopsy|Isolation, Culture and Characterization Stem Cells From Testis Biopsy|Completed||N/A|65|Actual|Igenomix||1|||f||||f||||||||||2018-05-31 22:29:47.391528|2018-05-31 22:29:47.391528
NCT01375049|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|2014-05-29||2014-07-07|2011-06-16|2011-06-17|Estimate|2014-05-29|2014-07-01|Estimate||||2014-07-07|2014-07-17|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|ALPINE|Safety Analysis Set: participants who received at least 1 dose of study drug|Aztreonam Lysine for Pseudomonas Infection Eradication Study|Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients With Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Culture Positive for Pseudomonas Aeruginosa (PA)|Completed||Phase 2|105|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 22:29:47.531572|2018-05-31 22:29:47.531572
NCT01375036|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2017-01-09|2011-06-16|2011-06-17|Estimate|||||||2017-01-09|2017-01-11|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|AIR-CF5||Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients|A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates From Patients With Cystic Fibrosis in the United States [AIR-CF5]|Completed|||510|Actual|Gilead Sciences|||||f||||f||||||Samples Without DNA|"~     Pseudomonas aeruginosa isolates from sputum or throat swab specimens~   "|||2018-05-31 22:29:48.438973|2018-05-31 22:29:48.438973
NCT01375023|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2015-06-19|2011-06-16|2011-06-17|Estimate|||||||2015-06-19|2015-06-22|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||"Allogenic Haematopoietic Cell Transplantation for Patients With Refractory Triple Negative Breast Cancer"|"Allogenic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Refractory Triple Negative Breast Cancer"|Terminated||Phase 2|3|Actual|European Institute of Oncology||1||Very low accrual rate|f||||f||||||||||2018-05-31 22:29:48.637431|2018-05-31 22:29:48.637431
NCT01375010|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15||2017-05-17|2017-05-25|2011-06-16|2011-06-17|Estimate||||2017-05-17|2017-05-19|Actual|2017-05-25|2017-06-14|Actual|January 2011|Actual|2011-01-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Vitamin D HIV Study on Postmenopausal Women|The Effect of Vitamin D Repletion on Postmenopausal Women With HIV|Completed||Phase 1/Phase 2|83|Actual|Columbia University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 22:29:48.782614|2018-05-31 22:29:48.782614
NCT01374997|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2011-07-07|2011-06-16|2011-06-17|Estimate|||||||2011-07-07|2011-07-08|Estimate|June 2011||2011-06-30|March 2011|2011-03-31||||March 2012|Anticipated|2012-03-31||Interventional|||Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur|Screening Project for a Detection of Fabry Disease in Chronic Renal Failure Patients in Area PACA|Unknown status|Active, not recruiting|N/A|380|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||||||||||||2018-05-31 22:29:48.891649|2018-05-31 22:29:48.891649
NCT01374984|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2018-02-14|2011-06-15|2011-06-17|Estimate|||||||2018-02-14|2018-02-16|Estimate|August 2007||2007-08-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|||VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection|Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection|Enrolling by invitation|||100|Anticipated|Cangene Corporation|||1||f||||f||||||Samples With DNA|"~     A plasma sample for the determination of anti-vaccinia antibody level collected 5 days after~     VIGIV administration and 5 days after VIGIV re-dosing as well (if applicable). Samples~     collected Day 5 ±3 days will still provide valuable information for assessing anti-vaccinia~     antibody levels in these subjects post-VIGIV administration. While plasma samples are~     preferred, serum samples will also be accepted if available. Failure to obtain a Day 5 sample~     does not preclude retrospective enrollment into the VA-005 study to provide observational~     data only.~   "|Undecided||2018-05-31 22:29:48.983018|2018-05-31 22:29:48.983018
NCT01374633|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-03-26|2011-06-15|2011-06-16|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SEPIA||Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients|Effect on Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients|Terminated||Phase 2|10|Actual|Assistance Publique - Hôpitaux de Paris||1||Sponsor decision|f||||t||||||||||2018-05-31 22:29:58.289418|2018-05-31 22:29:58.289418
NCT01374971|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2014-01-10||2014-02-26|2011-06-16|2011-06-17|Estimate|2014-02-26|2014-04-08|Estimate||||2014-02-26|2014-04-08|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All subjects who meet screening criteria were enrolled until target number of 12 subjects was met.|Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)|Open-Label Pre and Post Treatment Arthroscopic Synovial Biopsy Study for the Assessment of Certolizumab Pegol Immunomodulatory Synovial Effects on Select Biomarkers and Gene Expression|Completed||Phase 3|12|Actual|Arthritis Treatment Center, Maryland|Small sample size|1|||f||||f||||||||||2018-05-31 22:29:49.107965|2018-05-31 22:29:49.107965
NCT01374945|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2013-02-26|2011-06-15|2011-06-16|Estimate|||||||2013-02-26|2013-02-27|Estimate||||February 2013|2013-02-28||||||||Interventional|||Clearpath Miniprep Colonoscopy Study||Withdrawn||N/A|0|Actual|EasyGlide||2||Withdrawn for business reasons|f||||f||||||||||2018-05-31 22:29:49.483199|2018-05-31 22:29:49.483199
NCT01374932|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2012-06-21|2011-06-15|2011-06-16|Estimate|||||||2012-06-21|2012-06-22|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|CPASMA||CPASMA: Is There an Improvement in Asthma in Patients With Both Asthma and OSAS Treated With CPAP?|The CPASMA Trial: Is There an Improvement in Asthma in Patients With Both Asthma and Obstructive Sleep Apnoea Syndrome (OSAS) Treated With Continuous Positive Airway Pressure (CPAP) After Six Months?|Unknown status|Recruiting|Phase 3|120|Anticipated|Cimera||1|||f||||f||||||||||2018-05-31 22:29:49.554329|2018-05-31 22:29:49.554329
NCT01374919|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2013-03-18||2014-03-13|2011-06-15|2011-06-16|Estimate|2014-03-13|2014-03-14|Estimate||||2014-03-13|2014-03-14|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia|Total Dose Infusion of Ferumoxytol (1020mg) in 15 Minutes for Iron Defeciency Anemia|Completed||N/A|60|Actual|Auerbach Hematology Oncology Associates P C||1|||f||||f||||||||||2018-05-31 22:29:49.710765|2018-05-31 22:29:49.710765
NCT01374906|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2017-12-11||2018-04-25|2011-06-15|2011-06-16|Estimate|2018-03-13|2018-04-11|Actual||||2018-04-25|2018-05-22|Actual|November 4, 2011|Actual|2011-11-04|April 2018|2018-04-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional||Full analysis set (FAS): The FAS comprises all randomized patients who received at least one dose of study drug.|Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease|A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease|Completed||Phase 3|150|Actual|Novartis|All analyses in this study were descriptive in nature. No comparisons were made between the two arms, and no p-values are reported. For the primary and key-secondary, success was based on estimating the response rate (and 95% CI) in each arm.|2|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 22:29:50.110826|2018-05-31 22:29:50.110826
NCT01374893|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-15|2011-06-15|2011-06-16|Estimate|||||||2011-06-15|2011-06-16|Estimate|September 2011||2011-09-30|May 2011|2011-05-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|AGECAR||Physical Training in Hospitalized Elderly|Effects of an Intrahospital Exercise Program in Functional Capacity of Old Inpatients|Unknown status|Not yet recruiting|N/A|150|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 22:29:52.288442|2018-05-31 22:29:52.288442
NCT01374880|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2013-08-13|2011-06-15|2011-06-16|Estimate|||||||2013-08-13|2013-08-14|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|September 2013|Anticipated|2013-09-30||Observational|||Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease|Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease|Unknown status|Recruiting||3000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||6||f||||t||||||Samples Without DNA|"~     Biomarkers assessment in plasma at different times according to the study cohort.~   "|||2018-05-31 22:29:52.427065|2018-05-31 22:29:52.427065
NCT01374867|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-01-02|2011-06-15|2011-06-16|Estimate|||||||2014-01-02|2014-01-03|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CardShock||CardShock Study and Registry|Pathophysiology and Prognostic Factors in Cardiogenic Shock - CardShock Study|Completed|||220|Actual|Helsinki University Central Hospital|||||f||||f||||||Samples Without DNA|"~     plasma, urine~   "|||2018-05-31 22:29:52.695904|2018-05-31 22:29:52.695904
NCT01374854|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2012-11-18|2011-06-15|2011-06-16|Estimate|||||||2012-11-18|2012-11-20|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2010|Actual|2010-12-31||Interventional|||Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus|Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus: A Randomized Controlled Open-label Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|44|Actual|Fuzhou General Hospital||2|||f||||t||||||||||2018-05-31 22:29:52.909777|2018-05-31 22:29:52.909777
NCT01374841|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2016-08-09|2011-06-15|2011-06-16|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors|Nonmyeloablative Hematopoietic Stem Cell Transplantation (SCT) for High-Risk Hematologic Malignancies With Related, HLA-Haploidentical Donors: A Phase II Trial of Immunosuppression With Cyclophosphamide Administered Before and After SCT|Recruiting||Phase 2|20|Anticipated|European Institute of Oncology||1|||f||||f||||||||||2018-05-31 22:29:53.102456|2018-05-31 22:29:53.102456
NCT01374828|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2013-01-09|2011-06-15|2011-06-16|Estimate|||||||2013-01-09|2013-01-10|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Ketolorac Versus Saline at Laparoscopic Incision Sites|Prospective Randomized Double-blind Study of Incisional Local Anesthesia in Laparoscopic Surgery (Ketorolac Versus Normal Saline)|Withdrawn||Phase 4|0|Actual|The Cleveland Clinic||1||lack of funding|f||||f||||||||||2018-05-31 22:29:53.320016|2018-05-31 22:29:53.320016
NCT01374815|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2014-03-04|2011-06-15|2011-06-16|Estimate|||||||2014-03-04|2014-03-05|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Online Advocate: Health Related Social Problems And Diet Quality Pilot Study|The Online Advocate: Health Related Social Problems And Diet Quality Pilot Study|Completed||N/A|350|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 22:29:53.482148|2018-05-31 22:29:53.482148
NCT01374802|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2015-07-03||2015-07-03|2011-06-15|2011-06-16|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|June 2011||2011-06-30|July 2015|2015-07-31||||July 2011|Actual|2011-07-31||Interventional||The study was performed as an open-label, multiple-dose, single-group, fixed-sequence study in 14 healthy volunteers.|Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers|Effect of Multiple Dosing With 240 mg QD BI 201335 on the Steady-state Pharmacokinetics of 800 mg QD Darunavir Coadministered With 100 mg QD Ritonavir (DRV/r) in Healthy Male and Female Volunteers (an Open-label, Multiple-dose, Single Group, Single Fixed Sequence Phase I Study)|Completed||Phase 1|14|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:29:53.67774|2018-05-31 22:29:53.67774
NCT01374789|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-06-02|2011-06-15|2011-06-16|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PURO||PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer|PURO - An Open-label, Randomised, Multicentre, Phase II Study to Evaluate the Efficacy of Chemotherapy With Gemcitabine and Cisplatin in Combination With the EGF Receptor Antibody Panitumumab (GemCisP) Versus GemCis in the First-line Therapy of Locally Advanced/Metastatic Urothelial Carcinoma in Patients With Wild-type HRAS|Terminated||Phase 2|2|Actual|WiSP Wissenschaftlicher Service Pharma GmbH||2||The study was terminated due to insufficient recruitment.|f||||t||||||||||2018-05-31 22:29:55.039132|2018-05-31 22:29:55.039132
NCT01374776|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2013-12-12|2011-06-15|2011-06-16|Estimate|||||||2013-12-12|2013-12-13|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels||Unknown status|Recruiting|Phase 4|24|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 22:29:55.277948|2018-05-31 22:29:55.277948
NCT01374763|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2012-02-17|2011-06-15|2011-06-16|Estimate|||||||2012-02-17|2012-02-20|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery|A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery|Completed||Phase 4|165|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 22:29:55.445897|2018-05-31 22:29:55.445897
NCT01374750|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-05-30|2011-06-15|2011-06-16|Estimate|||||||2016-05-30|2016-06-01|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Sirolimus||Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)|A Randomized Phase Ⅱ, Trial With Sirolimus-containing Versus mTOR-inhibitor Free Immunosuppression in Patients Undergoing Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria|Completed||Phase 2|45|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:29:55.669615|2018-05-31 22:29:55.669615
NCT01374737|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-15|2011-06-15|2011-06-16|Estimate|||||||2011-06-15|2011-06-16|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||ED50 of Dexmedetomidine to Prevent Emergence Agitation in Children|ED50 of Dexmedetomidine for Reduction of Emergence Agitation Incidence Undergoing Tonsillectomy or Adenoidectomy in Desflurane Anesthesia Following Sevoflurane Induction in Children|Unknown status|Recruiting|Phase 4|25|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:29:55.971863|2018-05-31 22:29:55.971863
NCT01374724|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2016-10-31|2011-06-15|2011-06-16|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|AFV||Preventing Relapse Following Involuntary Smoking Abstinence|Preventing Relapse Following Involuntary Smoking Abstinence|Unknown status|Active, not recruiting|N/A|23000|Anticipated|University of Tennessee||3|||f||||t||||||||||2018-05-31 22:29:56.19165|2018-05-31 22:29:56.19165
NCT01374711|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2013-06-26|2011-06-15|2011-06-16|Estimate|||||||2013-06-26|2013-06-27|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia|The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia. A Parallel Randomized Double-blind Placebo-controlled Study|Completed||N/A|18|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 22:29:56.388007|2018-05-31 22:29:56.388007
NCT01374698|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2013-05-13|2011-06-15|2011-06-16|Estimate|||||||2013-05-13|2013-05-14|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.|Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study|Completed||Phase 4|100|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 22:29:56.526093|2018-05-31 22:29:56.526093
NCT01374685|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2018-05-22|2011-06-15|2011-06-16|Estimate|||||||2018-05-22|2018-05-23|Actual|June 7, 2011||2011-06-07|January 7, 2016|2016-01-07|January 7, 2016||2016-01-07|||||Observational|||Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans|Family Communication of Hereditary Cancer Risk Among African Americans|Terminated|||8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:29:56.720973|2018-05-31 22:29:56.720973
NCT01374672|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2015-05-08|2011-06-15|2011-06-16|Estimate|||||||2015-05-08|2015-05-12|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma|Observational - Methylation Status as Predictor of Response to Neoadjuvant Chemotherapy in Osteosarcoma|Completed|||20|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 22:29:56.963936|2018-05-31 22:29:56.963936
NCT01374659|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-15|||2011-06-15|2011-06-15|2011-06-16|Estimate|||||||2011-06-15|2011-06-16|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|August 2012|Anticipated|2012-08-31|June 2011|Actual|2011-06-30||Observational|||Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma|Effectiveness of [124I]-PET/CT and [18F]-FDG-PET/CT for Localizing Recurrence in Patients With Differentiated Thyroid Carcinoma Who Have Elevated Serum Thyroglobulin Levels But Are Tumor-negative on Conventional Imaging Studies|Unknown status|Recruiting||50|Anticipated|Korean Association of Endocrine Surgeons|||1||f||||t||||||||||2018-05-31 22:29:57.219913|2018-05-31 22:29:57.219913
NCT01374646|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-07-01|2011-06-14|2011-06-16|Estimate|||||||2011-07-01|2011-07-04|Estimate|November 2010||2010-11-30|January 2011|2011-01-31|January 2012|Anticipated|2012-01-31|August 2011|Anticipated|2011-08-31||Interventional|||Community-based Program to Treat Childhood Obesity|Effects of a Community-based Program to Treat Childhood and Adolescent Obesity|Unknown status|Active, not recruiting|N/A|150|Anticipated|UnitedHealth Group|||||f||||f||||||||||2018-05-31 22:29:57.707266|2018-05-31 22:29:57.707266
NCT01374620|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2016-07-28|2011-06-15|2011-06-16|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|PAL-ANGI2||Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel|Phase I Study : Dose Escalation of Intravenous Weekly Paclitaxel in Association With Metronomic Administration of Cyclophosphamide|Completed||Phase 1|28|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 22:29:58.722844|2018-05-31 22:29:58.722844
NCT01374607|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2016-01-24|2011-06-14|2011-06-16|Estimate|||||||2016-01-24|2016-01-26|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||Comparison Between High-sensitivity Cardiac Troponin T and Standard Tnl Assays in Early Cardiac Ischemia Detection|Assessment of Highly Sensible T Troponin (Hs-TnT) Assay Compared to Standard Troponin Assay in the Early Detection of Cardiac Ischemia in Patients With Acute Coronary Syndrome|Completed|||80|Actual|University of Lausanne Hospitals|||||f||||f||||||||No||2018-05-31 22:29:59.0066|2018-05-31 22:29:59.0066
NCT01374594|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-01-22|2011-06-15|2011-06-16|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Observational|||Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients||Completed|||30|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||f|||||||"~     blood samples~   "|||2018-05-31 22:29:59.166214|2018-05-31 22:29:59.166214
NCT01374581|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-10-21|2011-06-15|2011-06-16|Estimate|||||||2014-10-21|2014-10-22|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|QuinAct||Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria|A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains|Completed||Phase 3|2117|Actual|Universiteit Antwerpen||3|||f||||t||||||||||2018-05-31 22:30:02.418623|2018-05-31 22:30:02.418623
NCT01374568|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2017-01-18||2017-06-23|2011-06-14|2011-06-16|Estimate|2017-05-02|2017-05-31|Actual||||2017-06-23|2017-07-24|Actual|July 2010||2010-07-31|June 2017|2017-06-30|September 2015|Actual|2015-09-30|July 6, 2012|Actual|2012-07-06||Interventional|DRTC|6 patients were screened. 1 patient did not return for baseline visit. 5 patients were provided study medication.|Changes in Bone Turnover With Increased Incretin Hormone Exposure|Changes in Bone Turnover With Increased Incretin Hormone Exposure (UAB Diabetes Research and Training Center Pilot and Feasibility Study)|Terminated||Phase 4|6|Actual|University of Alabama at Birmingham|Study was closed due to end of funding prior to recruitment of target participants. Small participant number limits data analysis. We were unable to obtain additional funding to complete the study.|2||Study closed by sponsor. Funding ended.|f||||f||||||||||2018-05-31 22:30:02.943657|2018-05-31 22:30:02.943657
NCT01374555|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2018-04-16|2011-06-15|2011-06-16|Estimate|||||||2018-04-16|2018-04-18|Actual|September 29, 2010|Actual|2010-09-29|February 2013|2013-02-28|April 27, 2011|Actual|2011-04-27|April 27, 2011|Actual|2011-04-27||Observational|||Evaluation of the CardioSond Electronic Stethoscope in the Detection of Coronary Artery Disease|Validation of the CardioSond Sonospectrographic Digital Electronic Stethoscope in Diagnosing Coronary Artery Disease Versus CT Angiography|Terminated|||107|Actual|SonoMedica, Inc.||||Inconsistent data taken from Phase I cohort|f||||f||||||||||2018-05-31 22:30:03.552953|2018-05-31 22:30:03.552953
NCT01374542|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-02-12|2011-06-15|2011-06-16|Estimate|||||||2017-02-12|2017-02-14|Actual|June 2011||2011-06-30|February 2017|2017-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Respiratory Endoscopy: Diagnostic Yield, Technical Factors and Complications|Respiratory Endoscopy: Diagnostic Yield, Technical Factors and Complications|Recruiting|||4000|Anticipated|Singapore General Hospital|||1||f||||f||||||||||2018-05-31 22:30:03.656201|2018-05-31 22:30:03.656201
NCT01374516|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14||2016-01-11|2016-03-24|2011-06-15|2011-06-16|Estimate||||2016-01-11|2016-02-08|Estimate|2016-03-24|2016-04-26|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|November 2014|Actual|2014-11-30||Interventional|||Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America|Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America|Unknown status|Active, not recruiting|Phase 3|20869|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:30:03.927423|2018-05-31 22:30:03.927423
NCT01374503|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2012-04-16|2011-06-15|2011-06-16|Estimate|||||||2012-04-16|2012-04-17|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4|A Phase I, Single-centre, Randomised, Single-blinded, Placebo-controlled Single Ascending Dose Study, Followed by an Open-label Extension, Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of ALX-0651, Administered Intravenously to Healthy Male Volunteers|Terminated||Phase 1|52|Actual|Ablynx||2||Proof of principle established with completed SAD part|f||||t||||||||||2018-05-31 22:30:04.57335|2018-05-31 22:30:04.57335
NCT01374490|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2013-05-17|2011-06-15|2011-06-16|Estimate|||||||2013-05-17|2013-05-20|Estimate|June 2011||2011-06-30|July 2012|2012-07-31||||October 2012|Actual|2012-10-31||Interventional|||Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea|A Phase 3, Multicenter, Open-Label Evaluation of the Safety and Tolerability of Crofelemer in HIV-Positive Subjects With Diarrhea|Completed||Phase 3|251|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:30:04.873539|2018-05-31 22:30:04.873539
NCT01374477|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2015-01-01|2011-06-15|2011-06-16|Estimate|||||||2015-01-01|2015-01-05|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Observational|||Hypertensive Disorders of Pregnancy in Adolescence and Primipaternity|Hypertensive Disorders of Pregnancy in Adolescence and the Primipaternity Concept. Cases and Control Trial|Unknown status|Recruiting||110|Anticipated|Saint Thomas Hospital, Panama|||2||f||||f||||||||||2018-05-31 22:30:05.274167|2018-05-31 22:30:05.274167
NCT01374464|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-15|2011-06-15|2011-06-16|Estimate|||||||2011-06-15|2011-06-16|Estimate|August 2012||2012-08-31|June 2011|2011-06-30|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Interventional|||Reducing Respiratory Side Effects of Interscalene Brachial Plexus Block|A Double Blind Randomised Control Trial Assessing Effects of Local Anaesthetic Concentration (0.5% vs 0.75%) and Volume (5mls vs 15mls) on the Respiratory Consequences of Ultrasound Guided Interscalene Brachial Plexus Nerve Block|Unknown status|Not yet recruiting|Phase 4|92|Anticipated|Royal Surrey County Hospital||4|||f||||f||||||||||2018-05-31 22:30:05.460645|2018-05-31 22:30:05.460645
NCT01374295|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2014-03-21|2011-06-14|2011-06-15|Estimate|||||||2014-03-21|2014-03-24|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Video Assisted Informed Consent for Lortab to Improve Patient Satisfaction and Knowledge|Video Assisted Informed Consent for Lortab to Improve Patient Satisfaction and Knowledge: A Randomized Control Study|Completed||N/A|120|Actual|Albany Medical College||2|||f||||t||||||||||2018-05-31 22:30:16.974483|2018-05-31 22:30:16.974483
NCT01374451|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2016-02-16||2016-10-26|2011-06-15|2011-06-16|Estimate|2016-10-26|2016-12-20|Estimate||||2016-10-26|2016-12-20|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|COOPERATE-2|Full analysis set (FAS) was defined according to the intention to treat principle. The FAS consisted of all randomized patients. Following the intention to treat principle patients were analyzed according to the treatment (and stratum) they were assigned to at randomization.|Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET|A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study|Terminated||Phase 2|160|Actual|Novartis|A planned primary analysis was completed with data cut of 02-Apr-2014. The study did not meet its primary objective, which was based on progression-free survival as per local radiology assessment and was prematurely terminated.|2||The study was stopped for not meeting the primary endpoint for PFS.|f||||t||||||||||2018-05-31 22:30:05.687522|2018-05-31 22:30:05.687522
NCT01374438|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2014-09-25||2014-11-05|2011-06-15|2011-06-16|Estimate|2014-11-03|2014-11-05|Estimate||||2014-11-05|2014-11-18|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional||All randomized subjects completed the full study and are included in the analysis.|3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease|A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease|Completed||Phase 2|29|Actual|Metabolic Solutions Development Company||2|||f||||f||||||||||2018-05-31 22:30:08.905693|2018-05-31 22:30:08.905693
NCT01374425|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2016-06-30||2016-06-30|2011-06-15|2011-06-16|Estimate|2016-06-30|2016-08-11|Estimate||||2016-06-30|2016-08-11|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|MAVERICC|Intent-to-Treat (ITT) Population: All randomized participants regardless of receiving any study drug.|Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)|MAVERICC (Marker Evaluation for Avastin Research in CRC): A Randomized Phase II Study of Bevacizumab+mFOLFOX6 Vs. Bevacizumab+FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer|Completed||Phase 2|376|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:30:10.468176|2018-05-31 22:30:10.468176
NCT01374412|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-12-06|2011-06-15|2011-06-16|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|July 2022|Anticipated|2022-07-31|July 2018|Anticipated|2018-07-31||Observational|||Investigation of Bone Defects and Microcirculation With Computed Tomography and Magnetic Resonance Imaging|Examination of Bone Defects and Microcirculation Using Volume Computed Tomography and Dynamic Contrast-enhanced Magnetic Resonance Imaging|Recruiting|||60|Anticipated|German Cancer Research Center|||1||f||||f||||||||||2018-05-31 22:30:14.338777|2018-05-31 22:30:14.338777
NCT01374399|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2017-07-13|2011-06-15|2011-06-16|Estimate|||||||2017-07-13|2017-07-14|Actual|February 2011||2011-02-28|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|PETRA||Physical Exercise Therapy vs Relaxation in Allogeneic Stem Cell Transplantation (PETRA)|Effects of an One-year Physical Exercise Intervention on Prognosis, Side-effects and Complications After Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 3|256|Anticipated|German Cancer Research Center||2|||f||||f||||||||||2018-05-31 22:30:14.710414|2018-05-31 22:30:14.710414
NCT01374386|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-11-08|2011-06-15|2011-06-16|Estimate|||||||2017-11-08|2017-11-13|Actual|October 2010||2010-10-31|November 2017|2017-11-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Impact of Exergaming on Adolescent Youth|RCMI Clinical Research Infrastructure Initiative: Exergaming|Withdrawn||N/A|0|Actual|Charles Drew University of Medicine and Science||2||The study did not receive funding.|f||||f||||||||||2018-05-31 22:30:15.119268|2018-05-31 22:30:15.119268
NCT01374373|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2016-04-06|2011-06-15|2011-06-16|Estimate|||||||2016-04-06|2016-04-07|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia|A Phase 4 Study in the Treatment of Anemia With Weekly Epoetin Alfa Doses in Patients With Solid Tumors or Lymphoma Receiving Chemotherapy|Completed||Phase 4|30|Actual|Bio Sidus SA||1|||f||||f||||||||||2018-05-31 22:30:15.49537|2018-05-31 22:30:15.49537
NCT01374360|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2018-02-22|2011-06-15|2011-06-16|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2007|Actual|2007-01-31|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry|Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry|Recruiting|||5000|Anticipated|Alexion Pharmaceuticals|||2||f||||f||||||||No||2018-05-31 22:30:15.947098|2018-05-31 22:30:15.947098
NCT01374347|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2016-02-08|2011-06-14|2011-06-15|Estimate|||||||2016-02-08|2016-02-09|Estimate|May 2011||2011-05-31|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|CIALIS||Brain SPECT Following Cialis (Tadalafil ) Administration|Brain SPECT Perfusion Imaging Following Cialis (Tadalafil ) Administration in Patients With Vascular Risk Factors|Completed|||30|Actual|Wolfson Medical Center|||2||f||||f||||||||||2018-05-31 22:30:16.26537|2018-05-31 22:30:16.26537
NCT01374334|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-07-06|2011-06-14|2011-06-15|Estimate|||||||2011-07-06|2011-07-07|Estimate|December 2008||2008-12-31|August 2010|2010-08-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Observational|||Lower Extremities Muscle Strength and Power Thresholds Required for Mobility Independence|Lower Extremities Muscle Strength and Power Thresholds Required for Mobility Independence in Older Adults|Unknown status|Active, not recruiting||53|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-05-31 22:30:16.39203|2018-05-31 22:30:16.39203
NCT01374321|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-11-21|2011-06-14|2011-06-15|Estimate|||||||2013-11-21|2013-11-25|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction|Phase II, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction|Completed||Phase 2|168|Actual|Trophos||2|||f||||t||||||||||2018-05-31 22:30:16.563532|2018-05-31 22:30:16.563532
NCT01374308|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|||2012-12-11|2011-06-14|2011-06-15|Estimate|||||||2012-12-11|2012-12-12|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|NASVAC||NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients|Phase IIII Study of a Therapeutic Vaccine Candidate Containing Hepatitis B Virus (HBV) Core Antigen (HBcAg) and HBV Surface Antigen (HBsAg) for Treatment of Patients With Chronic HBV Infection|Unknown status|Active, not recruiting|Phase 3|160|Anticipated|Clinical Research Organization, Dhaka, Bangladesh||2|||f||||f||||||||||2018-05-31 22:30:16.757242|2018-05-31 22:30:16.757242
NCT01374269|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2013-09-20||2014-03-18|2011-06-14|2011-06-15|Estimate|2014-03-18|2014-04-29|Estimate||||2014-03-18|2014-04-29|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|DLSEA||Improvement in Pain,Function and HRQoL ( Health Related Quality of Life) in Subacute Low Back Pain: A Controlled Clinical Trial of Exercise vs NSAIDs (Nonsteroidal Antiinflammatory)|Improvement in Pain, Function and Quality of Life With a Protocolized Exercise Program Compared With Non-steroidal Anti-inflammatory Analgesics in Patients With Subacute Low Back Pain in Medellín, Colombia, 2009-2010|Completed||Phase 4|90|Actual|Grupo Rehabilitacion en Salud|The study population was associated with the university’s health service. Female subjects predominated. The 6-month follow-up prevents conclusions about the improvement duration. No subgroup classification was performed. No control group was planned.|2|||f||||t||||||||||2018-05-31 22:30:17.247831|2018-05-31 22:30:17.247831
NCT01374256|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||Imipenem and Sulbactam in the Treatment of Imipenem-resistant Acinetobacter Baumannii Bacteremia|Effectiveness of Imipenem and Sulbactam in the Treatment of Bacteremic Patients Contracted With Imipenem-resistant Acinetobacter Baumannii|Unknown status|Not yet recruiting||200|Anticipated|Taipei Veterans General Hospital, Taiwan|||2||f||||f||||||Samples Without DNA|"~     Acinetobacter baumannii isolates from the blood samples of patients~   "|||2018-05-31 22:30:19.795941|2018-05-31 22:30:19.795941
NCT01374243|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-11-05|2011-06-14|2011-06-15|Estimate|||||||2012-11-05|2012-11-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:30:20.453976|2018-05-31 22:30:20.453976
NCT01374230|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-05-02|2011-06-14|2011-06-15|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2011||2011-09-30|May 2017|2017-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Long-Term Multicenter Evaluation of the E1® Tibial Bearing|Long-Term Multicenter Evaluation of the E1® Tibial Bearing|Active, not recruiting||N/A|50|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:30:20.721108|2018-05-31 22:30:20.721108
NCT01374217|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2016-10-12|2011-06-14|2011-06-15|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|January 2014|Actual|2014-01-31||Interventional|||Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma|Administration of an Oral PDE5 Inhibitor, Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma|Terminated||Phase 2|14|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||early stopping rule|f||||t||||||||||2018-05-31 22:30:21.215206|2018-05-31 22:30:21.215206
NCT01374204|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2015-08-31|2011-06-14|2011-06-15|Estimate|||||||2015-08-31|2015-09-01|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|EPISTIGMA||Epilepsy-Associated Stigma|EPILEPSY-ASSOCIATED STIGMA AND ILLNESS EXPERIENCE IN PEOPLE WITH EPILEPSY|Unknown status|Active, not recruiting||200|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 22:30:22.896325|2018-05-31 22:30:22.896325
NCT01374191|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2015-08-25|2011-06-14|2011-06-15|Estimate|||||||2015-08-25|2015-08-26|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Botulinum Toxin Type A for Neuroma Pain|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Trial of Botulinum Toxin Type A for Neuroma Pain|Withdrawn||Phase 2|0|Actual|Southern Illinois University||3|||f||||t||||||||||2018-05-31 22:30:23.363836|2018-05-31 22:30:23.363836
NCT01374178|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2014-10-03||2014-10-03|2011-06-14|2011-06-15|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects|Relative Bioavailability of LY2963016 to LANTUS® After Single Dose Subcutaneous Administration to Healthy Subjects|Completed||Phase 1|16|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:30:24.099156|2018-05-31 22:30:24.099156
NCT01374165|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2018-05-23|2011-06-14|2011-06-15|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2015|Actual|2015-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients|A Phase I Open Label, Unblinded, Single Dose Study for Evaluating the Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients|Withdrawn|||0|Actual|Prolong Pharmaceuticals|||2|Study cancelled.|f||||t||||||Samples Without DNA|"~     Whole blood and urine~   "|||2018-05-31 22:30:25.628286|2018-05-31 22:30:25.628286
NCT01374152|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2012-07-15|2011-06-14|2011-06-15|Estimate|||||||2012-07-15|2012-07-17|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Perfetti Method in Upper Extremity of Stroke Patients|A Randomized Controlled Trial of Cognitive Sensory Motor Training Therapy on the Recovery of Upper Extremity Function in Acute Stroke Patients|Completed||Phase 3|40|Actual|Prasat Neurological Institute||2|||f||||f||||||||||2018-05-31 22:30:26.073035|2018-05-31 22:30:26.073035
NCT01374139|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-11-28|2011-06-14|2011-06-15|Estimate|||||||2011-11-28|2011-11-30|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects|A Phase 1, Open-Label, Randomized, Single-Dose, 2-Cohort, 2-Way Crossover Bioequivalence Study To Compare The Bosutinib Clinical Tablet And Clinical Capsule And To Investigate Food Effect On Bosutinib Commercial Formulation in Healthy Subjects|Completed||Phase 1|88|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:30:26.597793|2018-05-31 22:30:26.597793
NCT01374126|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2013-08-22|2011-06-14|2011-06-15|Estimate|||||||2013-08-22|2013-08-23|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Azithromycin Combination Therapy for the Treatment of Severe Malaria|Azithromycin Combination Therapy for the Treatment of Severe Malaria - A Pilot Safety and Efficacy Study in Uncomplicated Falciparum Malaria in Bangladesh|Completed||Phase 2|75|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 22:30:26.776951|2018-05-31 22:30:26.776951
NCT01374113|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-03-28|2011-06-14|2011-06-15|Estimate|||||||2013-03-28|2013-03-29|Estimate|June 2011||2011-06-30|October 2011|2011-10-31||||October 2011|Actual|2011-10-31||Interventional|||Safinamide Renal Impairment Trial|An Open-label, Parallel-group, Single Center, Single Oral Dose Trial to Investigate the Pharmacokinetics (PK) of 50 mg Safinamide in Subjects With Moderate and Severe Renal Impairment Compared to Matched Subjects With Normal Renal Function|Completed||Phase 1|24|Actual|Newron Pharmaceuticals SPA||3|||f||||f||||||||||2018-05-31 22:30:26.921332|2018-05-31 22:30:26.921332
NCT00833430|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2016-02-18|2009-01-29|2009-02-02|Estimate|||||||2016-02-18|2016-02-19|Estimate|June 2006||2006-06-30|February 2016|2016-02-29|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Avascular Necrosis (AVN) Long-Term Follow-up|Hedrocel Avascular Necrosis (AVN) Intervention Implant|Terminated|||35|Actual|Zimmer Biomet|||||f||||f||||||||||2018-06-01 01:21:37.272634|2018-06-01 01:21:37.272634
NCT01374100|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2018-05-11|2011-06-14|2011-06-15|Estimate|||||||2018-05-11|2018-05-16|Actual|February 2009||2009-02-28|May 2018|2018-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy|Effect of Qigong Therapy in Patients With Advanced NSCLC and GI Cancer Undergoing Chemotherapy|Terminated||N/A|52|Actual|McGill University||2||Slow accrual, and revised power calculation for primary end-points|f||||t||||||||Yes|Peer-reviewed manuscripts and conference proceedings|2018-05-31 22:30:27.074205|2018-05-31 22:30:27.074205
NCT01374087|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|2016-12-28||2016-12-28|2011-06-14|2011-06-15|Estimate|2016-12-28|2017-02-23|Actual||||2016-12-28|2017-02-23|Actual|November 2011||2011-11-30|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ANABRAQ|Safety population: Safety population consisted of all randomised subjects who received at least one dose of study medication. Subjects were allocated to the treatment they actually received.|Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer|Proof-of-concept Multicentre, Prospective, Randomised, Open-label- Parallel-group Clinical Trial to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy Using Triptorelin 22.5 mg 6-month Formulation in Patients With Recurrence of Prostate Cancer Previously Treated With Radiotherapy|Terminated||Phase 2|32|Actual|Ipsen|The study was prematurely stopped due to the slow enrolment of subjects and therefore no efficacy analyses were conducted.|2||Slow enrollment of patients.|f||||f||||||||||2018-05-31 22:30:27.321783|2018-05-31 22:30:27.321783
NCT01374074|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2015-09-21|2011-06-14|2011-06-15|Estimate|||||||2015-09-21|2015-09-23|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Racial Disparity in Barrett's Esophagus|Racial Disparity in Barrett's Esophagus|Completed|||255|Actual|University of North Carolina, Chapel Hill|||4||f||||t||||||Samples With DNA|"~     serum, plasma, buffy, esophageal biopsies~   "|||2018-05-31 22:30:28.395136|2018-05-31 22:30:28.395136
NCT01374061|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2014-05-07|2011-06-14|2011-06-15|Estimate|||||||2014-05-07|2014-05-08|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|EVE||Pre Hospital Evaluation of Video Laryngoscopy|Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger®|Withdrawn||Phase 4|0|Actual|Assistance Publique - Hôpitaux de Paris||2||Sponsor decision|f||||f||||||||||2018-05-31 22:30:28.660988|2018-05-31 22:30:28.660988
NCT01374048|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-06-13|2011-06-13|2011-06-15|Estimate|||||||2011-06-13|2011-06-15|Estimate||||June 2011|2011-06-30||||||||Observational|||Intracranial Pressure Waves Via Lumbar Puncture|Are Intracranial Pressure Waves Measurable Through Lumbar Puncture?|Completed|||10|Actual|Umeå University|||||f||||f||||||||||2018-05-31 22:30:28.996661|2018-05-31 22:30:28.996661
NCT01374035|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-03-17|2011-06-14|2011-06-15|Estimate|||||||2015-03-17|2015-03-18|Estimate|August 2010||2010-08-31|April 2011|2011-04-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Western Norway Mental Health Interface Study on Referral Letters|Interface Between Primary Care and Specialist Mental Health Care - the Referral Letters|Unknown status|Active, not recruiting|N/A|100|Anticipated|Helse Fonna||2|||f||||f||||||||||2018-05-31 22:30:29.124702|2018-05-31 22:30:29.124702
NCT01374022|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-05-08|2011-06-14|2011-06-15|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2011|Actual|2011-06-30|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|ART||ART - Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial|Randomized Controlled Trial of Maximum Alveolar Recruitment Maneuver Plus Titrated PEEP Versus ARDSNet Strategy for ARDS|Active, not recruiting||N/A|1013|Actual|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 22:30:29.248517|2018-05-31 22:30:29.248517
NCT01374009|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-01-17|2011-06-14|2011-06-15|Estimate|||||||2017-01-17|2017-01-19|Estimate|April 2010||2010-04-30|January 2017|2017-01-31|December 2012|Actual|2012-12-31|July 2010|Actual|2010-07-31||Observational|||H1N1 Vaccine in Pregnancy: a Registry for the Fall and Winter of 2009|H1N1 Vaccine in Pregnancy: a Registry for the Fall and Winter of 2009|Terminated|||504|Actual|Dalhousie University||||Participants were consented but registry was not developed due to low numbers|f||||f||||||||||2018-05-31 22:30:29.627504|2018-05-31 22:30:29.627504
NCT01373996|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Clinical Investigation of Wireless Transmission of Invasive Blood Pressure Signal|Feasibility and Accuracy of Wireless Transmission of Invasive Blood Pressure Signal From Patient to Patient's Bedside Monitor|Completed|||12|Actual|University Medical Centre Ljubljana|||2||f||||t||||||||||2018-05-31 22:30:29.820702|2018-05-31 22:30:29.820702
NCT01373983|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2014-12-28|2011-06-14|2011-06-15|Estimate|||||||2014-12-28|2014-12-30|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ZicBol||Intrathecal Bolus Doses of Ziconotide|Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study|Completed||Phase 4|26|Actual|University Hospital, Linkoeping||1|||f||||t||||||||||2018-05-31 22:30:30.040081|2018-05-31 22:30:30.040081
NCT01373970|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-12-05|2011-06-13|2011-06-15|Estimate|||||||2013-12-05|2013-12-06|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|CLARIFY||The Clinical Significance of Acid Rebound in Functional Dyspepsia|The Clinical Significance of Acid Rebound: Symptoms of Reflux After PPI Treatment in Patients With Functional Dyspepsia|Terminated||Phase 4|184|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 22:30:30.29113|2018-05-31 22:30:30.29113
NCT01373957|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2014-07-10|2011-06-14|2011-06-15|Estimate|||||||2014-07-10|2014-07-11|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|EPICOR-RUS||Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Russia|Long-tErm Follow-uP of Antithrombotic Management Patterns In Acute CORonary Syndrome Patients in RUSsia|Completed|||600|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:30:30.445763|2018-05-31 22:30:30.445763
NCT01373944|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-12-20|2011-06-14|2011-06-15|Estimate|||||||2013-12-20|2013-12-23|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI|Rapid-Acquisition Low-Dosimetry Tc-99m Stress-Only Myocardial Perfusion SPECT on the Spectrum Dynamics System: Comparison of Efficiency and Outcomes With Stress-Only Anger SPECT|Completed|||500|Actual|Aspire Foundation|||2||f||||f||||||||||2018-05-31 22:30:30.692547|2018-05-31 22:30:30.692547
NCT01373931|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-01-24|2011-06-13|2011-06-15|Estimate|||||||2012-01-24|2012-01-25|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of LY2216684 in Healthy Females|Effect of LY2216684 on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects|Completed||Phase 1|20|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:30:30.823078|2018-05-31 22:30:30.823078
NCT01373918|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2016-02-22||2016-05-10|2011-06-14|2011-06-15|Estimate|2016-05-10|2016-06-16|Estimate||||2016-05-10|2016-06-16|Estimate|December 2010||2010-12-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders|Low Dose Parenteral Fat for the Prevention of Parenteral Nutrition Associated Cholestasis in Neonates With Congenital/Acquired Gastrointestinal Disorders|Terminated||Phase 4|41|Actual|University of California, Los Angeles|Early termination leading to small number of subjects analyzed.|2||The study was terminated due to slow enrollment.|f||||t||||||||No||2018-05-31 22:30:31.151575|2018-05-31 22:30:31.151575
NCT01373905|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Stepwise Positive End Expiratory Pressure Elevation For Lung Recruitment in Acute Respiratory Distress Syndrome (ARDS)|Stepwise PEEP Elevation With Determination of the Alveolar Collapsing Pressure Versus Sustained Lung Inflation as a Recruitment Maneuver in Patients With ARDS|Completed||N/A|24|Actual|Faculty of Medicine, University of Alexandria||2|||f||||f||||||||||2018-05-31 22:30:31.973165|2018-05-31 22:30:31.973165
NCT01373892|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2017-03-05|2011-06-14|2011-06-15|Estimate|||||||2017-03-05|2017-03-07|Actual|January 2011||2011-01-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|December 2013|Actual|2013-12-31||Interventional|Sleevepet2||Prospective, Randomised Study: Metabolic and Functional Effects of Bariatric Surgery Accessed Using PET and MRI.|Prospective, Randomised Study: Metabolic and Functional Effects of Bariatric Surgery Accessed Using PET and MRI|Completed||N/A|50|Actual|Turku University Hospital||2|||f||||f||||||||No||2018-05-31 22:30:32.194436|2018-05-31 22:30:32.194436
NCT01373879|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2013-03-13|2011-06-14|2011-06-15|Estimate|||||||2013-03-13|2013-03-14|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area|Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults and Children in a Malaria Endemic Area|Completed||Phase 1|52|Actual|University of Oxford||8|||f||||t||||||||||2018-05-31 22:30:32.312934|2018-05-31 22:30:32.312934
NCT01373866|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2017-12-21|2011-06-14|2011-06-15|Estimate|||||||2017-12-21|2017-12-22|Actual|November 15, 2010|Actual|2010-11-15|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|MULTIMODHAL||Multimodal MRI-guided rTMS to Treat Refractory Hallucinations|Multimodal MRI-guided Repetitive Transcranial Magnetic Stimulation to Treat Drug-resistant Hallucinations: a Randomized Control Trial|Recruiting||N/A|70|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||No||2018-05-31 22:30:32.547919|2018-05-31 22:30:32.547919
NCT01373853|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-05-19|2011-06-14|2011-06-15|Estimate|||||||2015-05-19|2015-05-20|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|1103||A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery|A Single Centre Study to Compare the Efficacy and Safety of Femtosecond Laser-Assisted Versus Manual Cataract Surgery|Completed||Phase 3|131|Actual|Technolas Perfect Vision GmbH||2|||f||||t||||||||||2018-05-31 22:30:32.76592|2018-05-31 22:30:32.76592
NCT01373840|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2018-05-09|2011-06-14|2011-06-15|Estimate|||||||2018-05-09|2018-05-15|Actual|September 2011||2011-09-30|May 2018|2018-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Role of Dopamine Receptors in Primary Focal Dystonias|Role of Dopamine Receptors in Primary Focal Dystonias|Completed|||40|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-05-31 22:30:33.010979|2018-05-31 22:30:33.010979
NCT01373827|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2012-03-23|2011-06-14|2011-06-15|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Protocol To Evaluate Patient Measurements After Ultrasonic Treatment|Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.|Completed|||7|Actual|Sound Surgical Technologies, LLC.|||1||f||||f||||||||||2018-05-31 22:30:33.2142|2018-05-31 22:30:33.2142
NCT01373814|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-03-29|2011-06-14|2011-06-15|Estimate|||||||2017-03-29|2017-03-30|Actual|September 2010||2010-09-30|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Nutritional Therapy for Diabetic Cardiomyopathy|Nutritional Therapy for Diabetic Cardiomyopathy|Enrolling by invitation|||20|Anticipated|Washington University School of Medicine|||||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 22:30:33.308492|2018-05-31 22:30:33.308492
NCT01373801|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-08-09|2011-06-14|2011-06-15|Estimate|||||||2011-08-09|2011-08-10|Estimate|July 2011||2011-07-31|April 2011|2011-04-30||||July 2012|Anticipated|2012-07-31||Interventional|||Hemcon© Bandage for Postpartum Bleeding Due to the Multiple Vaginal Lacerations|THE EFFICACY AND SAFETY OF HEMCON© BANDAGE FOLLOWING SURGICAL REPAIR IN MANAGEMENT OF POSTPARTUM BLEEDING DUE TO THE MULTIPLE VAGINAL LACERATIONS|Unknown status|Recruiting|N/A|85|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 22:30:33.509855|2018-05-31 22:30:33.509855
NCT01373775|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Observational|||Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department Siriraj Hospital|Risk Factors of the Revisit of the Adult Heart Failure Patients in Emergency Department in Siriraj Hospital: The One Year Period.|Completed|||533|Actual|Mahidol University|||2||f||||f||||||||||2018-05-31 22:30:33.689364|2018-05-31 22:30:33.689364
NCT01373762|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2014-12-11|2011-06-13|2011-06-15|Estimate|||||||2014-12-11|2014-12-15|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|FitGAME||The Fitness, Game Bike Adherence, Motivation and Exercise Study|Interactive Videogame Bikes and Their Effect on Exercise Adherence and Health Related Fitness Among Families|Completed||N/A|74|Actual|University of Victoria||2|||f||||t||||||||||2018-05-31 22:30:33.865264|2018-05-31 22:30:33.865264
NCT01373749|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Nitro Oxide Inhalation Continued With Sildenafil on Neonatal Persistent Pulmonary Hypertension|Compare of Continued Nitro Oxide Inhalation and Nitro Oxide Inhalation Continued With Oral Sildenafil on Treatment of Neonatal Persistent Pulmonary Hypertension|Unknown status|Recruiting|N/A|40|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 22:30:34.140745|2018-05-31 22:30:34.140745
NCT01373736|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-06-13|2011-06-13|2011-06-15|Estimate|||||||2011-06-13|2011-06-15|Estimate||||June 2011|2011-06-30||||||||Interventional|||123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors||Unknown status|Not yet recruiting|Phase 3|||Vancouver Coastal Health|||||f||||t||||||||||2018-05-31 22:30:34.211454|2018-05-31 22:30:34.211454
NCT01373723|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|CRICERVA||Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer|Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer in the County of Valles Occidental: CRICERVA Clinical Trial.|Unknown status|Recruiting|N/A|20994|Anticipated|Jordi Gol i Gurina Foundation||3|||f||||t||||||||||2018-05-31 22:30:34.281293|2018-05-31 22:30:34.281293
NCT01373710|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-11-02|2011-06-14|2011-06-15|Estimate|||||||2017-11-02|2017-11-06|Actual|May 19, 2011|Actual|2011-05-19|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|HIT||Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis|Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis|Active, not recruiting||Phase 1/Phase 2|34|Actual|Institut Curie||1|||f||||t||||||||||2018-05-31 22:30:34.640474|2018-05-31 22:30:34.640474
NCT01373697|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel|Clinical Multicenter, Phase III, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ibuprofen 50mg/g Gel in the Treatment of Patients With Muscle Pain, Joint, or Pain Caused by Sprains, Contusions, Tendinitis, or Myofascial Compared to Profenid ® 25mg/g. Gel|Unknown status|Not yet recruiting|Phase 3|144|Anticipated|Laboratório Teuto Brasileiro S/A||2|||f||||t||||||||||2018-05-31 22:30:34.825028|2018-05-31 22:30:34.825028
NCT01373684|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-12-19|2011-06-14|2011-06-15|Estimate|||||||2017-12-19|2017-12-21|Actual|March 2012||2012-03-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|PAS||PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients|Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS)|Recruiting||Phase 4|90|Anticipated|Foundation for Liver Research||2|||f||||f||||||||||2018-05-31 22:30:34.971763|2018-05-31 22:30:34.971763
NCT01373671|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2016-04-27||2016-11-18|2011-06-14|2011-06-15|Estimate|2016-11-18|2017-01-13|Estimate||||2016-11-18|2017-01-13|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|DBT||Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging|Multi-center Case Collection Study to Create a Library of Images From Various Approved Full Field Digital Mammography (FFDM) Systems and 3D Images From Siemens Inspiration Digital Breast Tomosynthesis (DBT) System for Studies in Support of the Inspiration Digital Breast Tomosynthesis Approval|Completed||N/A|764|Actual|Siemens Medical Solutions USA - CSG||1|||f||||f||||||||No||2018-05-31 22:30:35.320664|2018-05-31 22:30:35.320664
NCT01373658|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-06-13|2011-06-13|2011-06-15|Estimate|||||||2011-06-13|2011-06-15|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|SERY-II||Safety and Efficacy Registry of Yinyi Stent (SERY-II)|Safety and Efficacy Registry of Yinyi Polymer-free Paclitaxel-eluting Stent|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||||2018-05-31 22:30:35.625135|2018-05-31 22:30:35.625135
NCT01373645|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2015-07-27|2011-06-13|2011-06-15|Estimate|||||||2015-07-27|2015-07-29|Estimate|January 2009||2009-01-31|October 2008|2008-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SERY-I||Safety and Efficacy Registry of Yinyi Stent|Safety and Efficacy Registry of Yinyi Polymer-free Paclitaxel-eluting Stent|Completed||Phase 2/Phase 3|1045|Actual|Shanghai Jiao Tong University School of Medicine||1|||f||||||||||||||2018-05-31 22:30:35.829845|2018-05-31 22:30:35.829845
NCT01373632|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|September 2013|Anticipated|2013-09-30|June 2012|Anticipated|2012-06-30||Interventional|FESTA||Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease|Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease|Unknown status|Recruiting|Phase 4|570|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 22:30:36.003977|2018-05-31 22:30:36.003977
NCT01373619|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2012-01-18|2011-06-14|2011-06-15|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine|Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine|Completed||Phase 4|150|Actual|"University of Campania Luigi Vanvitelli"||1|||f||||t||||||||||2018-05-31 22:30:36.162765|2018-05-31 22:30:36.162765
NCT01373606|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2012-02-13|2011-06-14|2011-06-15|Estimate|||||||2012-02-13|2012-02-14|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|HRS||A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1|An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1|Completed||Phase 1/Phase 2|8|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:30:36.316548|2018-05-31 22:30:36.316548
NCT01373593|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-06-19|2011-06-14|2011-06-15|Estimate|||||||2012-06-19|2012-06-20|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients|Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients|Terminated||Phase 4|12|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 22:30:36.452148|2018-05-31 22:30:36.452148
NCT01373580|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2017-10-11||2018-03-01|2011-06-13|2011-06-15|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-01|2018-03-29|Actual|April 2010||2010-04-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near Vision in Presbyopic Patients|A Prospective, Multinational Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc. PresbyLens Corneal Inlay for the Improvement of Near Vision in Presbyopic Subjects With MRSE From -0.50 to +1.00|Completed||N/A|373|Actual|ReVision Optics, Inc.||1|||f||||f||||||||No||2018-05-31 22:30:36.590223|2018-05-31 22:30:36.590223
NCT01373567|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2012-11-21|2011-06-13|2011-06-15|Estimate|||||||2012-11-21|2012-11-22|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis|An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis|Completed||Phase 4|298|Actual|Piramal Enterprises Limited||1|||f||||f||||||||||2018-05-31 22:30:37.130355|2018-05-31 22:30:37.130355
NCT01373554|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2013-12-08|2011-06-13|2011-06-15|Estimate|||||||2013-12-08|2013-12-10|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|PMK-N01GI1||Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)|Completed||Phase 2|60|Actual|PharmaKing||2|||f||||t||||||||||2018-05-31 22:30:37.298045|2018-05-31 22:30:37.298045
NCT01373541|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2014-02-11|2011-06-14|2011-06-15|Estimate|||||||2014-02-11|2014-02-13|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Effect of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Infants in China|Effect of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Infants in China: a Double Blind, Multi-center, Randomized, Controlled Trial|Completed||N/A|171|Actual|Enzymotec||3|||f||||f||||||||||2018-05-31 22:30:37.513293|2018-05-31 22:30:37.513293
NCT01373528|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|||2012-05-16|2011-06-14|2011-06-15|Estimate|||||||2012-05-16|2012-05-18|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Impact of Topical Sinonasal Budesonide Irrigation on Hypothalamic-Pituitary-Adrenal Axis Function|Impact of Topical Sinonasal Budesonide Irrigation on Hypothalamic-Pituitary-Adrenal (HPA) Axis Function|Terminated||N/A|2|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 22:30:37.773315|2018-05-31 22:30:37.773315
NCT01373515|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2013-06-03|2011-06-14|2011-06-15|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia|Phase 1 Study of Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|12|Actual|DCPrime BV||4|||f||||t||||||||||2018-05-31 22:30:38.139906|2018-05-31 22:30:38.139906
NCT01373502|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2018-04-27|2011-06-14|2011-06-15|Estimate|||||||2018-04-27|2018-04-30|Actual|October 2009|Actual|2009-10-31|April 2018|2018-04-30|October 2015|Actual|2015-10-31|April 2011|Actual|2011-04-30||Interventional|NEXT||International Randomized Comparison Between DES Limus Carbostent and Taxus DES in the Treatment of De-novo Coronary Lesions|International Randomized Comparison Between DES Limus Carbostent and Taxus Drug Eluting Stents in the Treatment of De-novo Coronary Lesions. The NEXT Study.|Completed||N/A|323|Actual|CID - Carbostent & Implantable Devices||2|||f||||f||||||||||2018-05-31 22:30:38.312243|2018-05-31 22:30:38.312243
NCT01373489|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2016-09-29|2011-06-14|2011-06-15|Estimate|||||||2016-09-29|2016-09-30|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TACM-DM||Technology-assisted Case Management in Adults With Type 2 Diabetes|Effectiveness of Technology-Assisted Case Management in Low Income Adults With Type 2 Diabetes|Completed||N/A|113|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 22:30:38.462473|2018-05-31 22:30:38.462473
NCT01373476|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2013-05-10|2011-06-14|2011-06-15|Estimate|||||||2013-05-10|2013-05-13|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy|Multicentre,Randomized,Double-blind, Multiple-dose, Placebo-controlled, Parallel-Group Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy With Blood Stasis Syndrome and Deficiency of Qi-Yin Syndrome|Completed||Phase 2|240|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 22:30:38.615896|2018-05-31 22:30:38.615896
NCT01373463|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-07-24|2011-06-14|2011-06-15|Estimate|||||||2012-07-24|2012-07-26|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CisPemXetSrg||Cisplatin and Pemetrexed With Radiation Followed by Lobectomy|A Phase I Trial of Preoperative Carboplatin or Cisplatin and Pemetrexed With Thoracic Radiation Therapy Followed by Lobectomy in Resectable Stage III Patients With Non-Squamous Non Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|48|Actual|Medical University of South Carolina||2||Investigator left site|f||||t||||||||||2018-05-31 22:30:38.724256|2018-05-31 22:30:38.724256
NCT01373450|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2013-05-20||2015-09-01|2011-06-13|2011-06-15|Estimate|2013-05-20|2013-07-08|Estimate||||2015-09-01|2015-09-02|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)|Evaluation of the Glucoregulatory Effects of GLP-1 Receptor Activation in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 22:30:38.868287|2018-05-31 22:30:38.868287
NCT01373437|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-14|2011-06-14|2011-06-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Ultrasonography in Confirming Proper Position of Endotracheal Tube|Ultrasonography in Confirming Proper Position of Endotracheal Tube in Emergency Department at Siriraj Hospital: Applicability and Accuracy|Completed|||80|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 22:30:39.435457|2018-05-31 22:30:39.435457
NCT01373424|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-08-01|2011-06-14|2011-06-15|Estimate|||||||2017-08-01|2017-08-02|Actual|January 2011||2011-01-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Observational|DCP||The Dystonia Coalition Natural History and Biospecimen Repository for Isolated Dystonias|Natural History and Biospecimen Repository for Dystonia; Comprehensive Rating Tools for Cervical Dystonia; Validity & Reliability of Diagnostic Methods & Measures of Spasmodic Dysphonia|Recruiting|||5000|Anticipated|Emory University|||8||f||||f||||||Samples With DNA|"~     Whole blood, DNA, white blood cells, cell lines~   "|Yes|Data is available to researchers with appropriate ethics board approvals. Researchers may contact the Dystonia Coalition PI or coordinator at Emory University or the RDCRN Data Management and Coordination Center for more information.|2018-05-31 22:30:40.8371|2018-05-31 22:30:40.8371
NCT01373411|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2015-03-24|2011-06-14|2011-06-15|Estimate|||||||2015-03-24|2015-03-26|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|TAP-CABG||Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery|Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG)|Completed||Phase 4|70|Actual|Cardiology Research UBC||2|||f||||t||||||||||2018-05-31 22:30:41.123417|2018-05-31 22:30:41.123417
NCT01373398|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2012-03-12|2011-06-13|2011-06-15|Estimate|||||||2012-03-12|2012-03-13|Estimate|May 2011||2011-05-31|March 2012|2012-03-31||||February 2012|Actual|2012-02-29||Interventional|||Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)|Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetics of Intravesical Instillation of EO9 in Patients With Non-muscle Invasive Bladder Cancer(NMIBC)|Completed||Phase 1|11|Actual|Handok Pharmaceuticals Co., Ltd.|||||f||||f||||||||||2018-05-31 22:30:41.296813|2018-05-31 22:30:41.296813
NCT01373372|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2014-09-03|2011-06-14|2011-06-15|Estimate|||||||2014-09-03|2014-09-05|Estimate|December 2014||2014-12-31|September 2014|2014-09-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia|CRH Responsiveness in Children With Functional Dyspepsia: A Pilot Study|Unknown status|Not yet recruiting|N/A|24|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 22:30:41.705703|2018-05-31 22:30:41.705703
NCT01373359|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-13|2011-06-13|2011-06-14|Estimate|||||||2011-06-13|2011-06-14|Estimate|March 2007||2007-03-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Prevention of Postpartum Haemorrhage With Sublingual Misoprostol or Oxytocin|A One Year Double Blind Randomized Controlled Trial of Sublingual Misoprostol (400 µg) Versus Intramuscular Oxytocin (10 IU) in the Prevention of Postpartum Bloodloss at KLE Hospital, Belgaum|Completed||Phase 3|652|Actual|Jawaharlal Nehru Medical College||2|||f||||f||||||||||2018-05-31 22:30:41.852345|2018-05-31 22:30:41.852345
NCT01373346|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2012-03-11||2012-08-30|2011-06-13|2011-06-14|Estimate|2012-08-29|2012-08-31|Estimate||||2012-08-30|2012-09-03|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|LoLiRoRe||Safety and Efficacy of Long Limb Roux-en Y Reconstruction|Long Limb Roux-en Y Reconstruction After Gastrectomy As A Potential Cure for Type 2 Diabetes Mellitus in Non-Obese Gastric Cancer Patients - a Pilot Project to Validate a Prospective Randomized Control Trial|Completed||N/A|15|Actual|Gangnam Severance Hospital|One mortality due to early recurrence leading to reduced number of subject analyzed.|1|||f||||t||||||||||2018-05-31 22:30:42.066049|2018-05-31 22:30:42.066049
NCT01373333|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2016-07-18|2011-06-13|2011-06-14|Estimate|||||||2016-07-18|2016-07-20|Estimate|September 1997||1997-09-30|July 2016|2016-07-31||||September 2012|Anticipated|2012-09-30||Expanded Access|34-DAP||Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome|Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome|No longer available|||||The Cleveland Clinic|||||||||||||||||||2018-05-31 22:30:42.864201|2018-05-31 22:30:42.864201
NCT01373320|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2013-10-21|2011-06-13|2011-06-14|Estimate|||||||2013-10-21|2013-10-23|Estimate|March 2010||2010-03-31|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Faith Moves Mountains: A Community Based Participatory Research (CBPR) Appalachian Wellness & Cancer Prevention Program|Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program|Completed||N/A|1415|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 22:30:43.348774|2018-05-31 22:30:43.348774
NCT01373307|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-07-10|2011-06-13|2011-06-14|Estimate|||||||2015-07-10|2015-07-13|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|July 2012|Actual|2012-07-31||Interventional|||An Intergenerational Community Based Participatory Research (CBPR) Intervention to Reduce Appalachian Health Disparities|An Intergenerational CBPR Intervention to Reduce Appalachian Health Disparities|Completed||N/A|1250|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 22:30:43.521095|2018-05-31 22:30:43.521095
NCT01373294|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2015-12-28||2017-12-08|2011-06-13|2011-06-14|Estimate|2016-04-05|2016-05-12|Estimate||||2017-12-08|2018-01-03|Actual|November 30, 2011|Actual|2011-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|January 9, 2015|Actual|2015-01-09||Interventional||The Primary Outcome Measure addresses Arm A only, whose participants received the experimental drug. Too few participants were enrolled into Arm B to conduct the planned per arm comparison. Demographic details and Adverse Events have been reported for all participants in both arms.|Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer|Immune Modulation by Addition of Oral Lenalidomide to Intravesical BCG (Bacille Calmette-Guerrin) for Therapy of Non-muscle-invasive Transitional Cell Bladder Cancer|Active, not recruiting||Phase 2|17|Actual|H. Lee Moffitt Cancer Center and Research Institute|This study closed to accrual early, due to slow accrual. Too few participants were enrolled into Arm B to conduct the planned per arm comparisons.|2|||f||||f||||||||||2018-05-31 22:30:43.701113|2018-05-31 22:30:43.701113
NCT01373281|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2015-09-15||2016-03-24|2011-06-13|2011-06-14|Estimate|2015-10-16|2015-11-16|Estimate||||2016-03-24|2016-04-27|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|November 2017|Anticipated|2017-11-30|August 2014|Actual|2014-08-31||Interventional|||Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia|Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia|Unknown status|Active, not recruiting|Phase 3|10275|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:30:46.650471|2018-05-31 22:30:46.650471
NCT01373255|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2015-06-14|2011-06-13|2011-06-14|Estimate|||||||2015-06-14|2015-06-16|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Accreta||Balloon Catheters in Cases of Abnormal Placentation|Balloon Catheter for Occlusion of the Pelvic Vasculature as an Adjuvant Therapy in Cases of Placenta Accreta|Completed||N/A|24|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 22:30:48.209636|2018-05-31 22:30:48.209636
NCT01373242|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|||2017-12-18|2011-06-13|2011-06-14|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2011|Actual|2011-06-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|SLIT-TLC||Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance|Peanut Sublingual Immunotherapy and Induction of Clinical Tolerance in Peanut Allergic Children (SLIT Tolerance TLC) {Sublingual Immunotherapy for Peanut Allergy}|Active, not recruiting||Phase 1/Phase 2|49|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-05-31 22:30:48.312645|2018-05-31 22:30:48.312645
NCT01373229|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|2017-01-25||2017-07-26|2011-06-13|2011-06-14|Estimate|2017-07-26|2018-02-05|Actual||||2017-07-26|2018-02-05|Actual|January 2012|Actual|2012-01-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)|Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia|Completed||Phase 1|21|Actual|Duke University||1|||f||||f||||||||||2018-05-31 22:30:48.460303|2018-05-31 22:30:48.460303
NCT01373216|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2016-01-31|2011-06-13|2011-06-14|Estimate|||||||2016-01-31|2016-02-02|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|Executive||Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass|EXEnatide in Patients Undergoing Coronary Artery Bypass Grafting for Improved glUcose conTrol and hemodynamIc ValuEs|Completed||Phase 3|38|Actual|Charles University, Czech Republic||2|||f||||t||||||||||2018-05-31 22:30:48.984782|2018-05-31 22:30:48.984782
NCT01373203|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-06-13|2011-06-13|2011-06-14|Estimate|||||||2011-06-13|2011-06-14|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|||||Observational|||The Role of Fibrocytes in Acute Lung Injury|The Role of Fibrocytes in Acute Lung Injury|Unknown status|Active, not recruiting||20|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:30:49.158861|2018-05-31 22:30:49.158861
NCT01373190|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2013-06-20|2011-06-13|2011-06-14|Estimate|||||||2013-06-20|2013-06-21|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Thermographic Examination of Skin Temperatures in Individuals With Focal Onset Epilepsy|Thermographic Examination of Low Back and Abdominal Area Skin Temperatures in Individuals With and Without Focal Onset Epilepsy|Completed|||100|Actual|Atlantic University|||2||f||||f||||||||||2018-05-31 22:30:49.242082|2018-05-31 22:30:49.242082
NCT01373177|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2015-03-17|2011-06-13|2011-06-14|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Differences Between the Bayley-II and the Bayley-III in Very Preterm Infants at 2 Years|A Randomized Crossover Study to Evaluate Differences Between the Bayley-II and the Bayley-III in Very Preterm Infants at 2 Years|Completed|||211|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||||||2018-05-31 22:30:49.31637|2018-05-31 22:30:49.31637
NCT01373164|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2018-02-23|2015-12-23|2018-04-17|2011-06-13|2011-06-14|Estimate|2018-04-17|2018-05-16|Actual|2016-02-10|2016-03-11|Estimate|2018-04-17|2018-05-16|Actual|June 2011||2011-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional||All participants who received at least one dose of study drug.|A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer|A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)|Completed||Phase 1/Phase 2|170|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 22:30:49.50216|2018-05-31 22:30:49.50216
NCT01373151|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13||2015-07-24|2017-09-13|2011-06-13|2011-06-14|Estimate||||2015-07-24|2015-08-13|Estimate|2017-09-13|2017-09-19|Actual|June 2011||2011-06-30|September 2017|2017-09-30|June 2015|Actual|2015-06-30|September 2012|Actual|2012-09-30||Interventional|||Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate|A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.|Completed||Phase 2|418|Actual|Vitaeris INC||7|||f||||t||||||||||2018-05-31 22:30:51.477289|2018-05-31 22:30:51.477289
NCT01373138|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-13|2011-06-13|2011-06-14|Estimate|||||||2011-06-13|2011-06-14|Estimate|April 2006||2006-04-30|June 2006|2006-06-30|May 2006|Actual|2006-05-31|||||Interventional|||Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Desloratadine and Pseudoephedrine 5 mg/240 mg Extended-Release Tablet and Clarinex-D® 24-Hour (Reference) Following a 5 mg/240 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:30:51.812432|2018-05-31 22:30:51.812432
NCT01373125|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2015-09-21|2011-06-13|2011-06-14|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||"Is the Neosquamous Epithelium Normal Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?"|"Is the Neosquamous Epithelium Normal Following Endoscopic Ablation of Dysplastic Barrett's Esophagus?"|Completed|||99|Actual|University of North Carolina, Chapel Hill|||4||f||||f||||||Samples With DNA|"~     esophageal biopsies~   "|||2018-05-31 22:30:51.943072|2018-05-31 22:30:51.943072
NCT01373112|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2017-04-10|2011-06-13|2011-06-14|Estimate|||||||2017-04-10|2017-04-11|Actual|December 2011||2011-12-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection|Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Knee Infection|Recruiting||N/A|140|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 22:30:52.040514|2018-05-31 22:30:52.040514
NCT01373099|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2017-04-10|2011-06-13|2011-06-14|Estimate|||||||2017-04-10|2017-04-11|Actual|August 2011||2011-08-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SPACERHIP||Study of Antibiotic Spacer Design to Treat Infection After Hip Replacement|Articulating Versus Static Antibiotic Loaded Spacers for the Treatment of Prosthetic Hip Infection|Recruiting||N/A|80|Anticipated|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 22:30:52.218456|2018-05-31 22:30:52.218456
NCT01373086|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24||2012-11-30|2012-11-30|2011-06-13|2011-06-14|Estimate||||2012-11-30|2012-12-04|Estimate|2012-11-30|2012-12-04|Estimate|May 2011||2011-05-31|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension|Terminated||Phase 2|19|Actual|Novartis||4|||f||||f||||||||||2018-05-31 22:30:52.367323|2018-05-31 22:30:52.367323
NCT01373073|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-02-19|2011-06-13|2011-06-14|Estimate|||||||2013-02-19|2013-02-20|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of a Novel Human Milk Fortifier in Preterm Infants|Evaluation of a Novel Human Milk Fortifier in Preterm Infants|Completed||Phase 3|147|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 22:30:52.486915|2018-05-31 22:30:52.486915
NCT01373060|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-10-10|2011-06-13|2011-06-14|Estimate|||||||2011-10-10|2011-10-12|Estimate|February 2011||2011-02-28|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ASP1941 in Healthy Male Taiwanese Subjects|A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of ASP1941 in Healthy Male Taiwanese Subjects|Completed||Phase 1|56|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:30:52.614383|2018-05-31 22:30:52.614383
NCT01373047|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-07-29|2011-06-13|2011-06-14|Estimate|||||||2013-07-29|2013-07-30|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|HITM||CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells|Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases|Completed||Phase 1|8|Actual|Roger Williams Medical Center||1|||f||||t||||||||||2018-05-31 22:30:52.731049|2018-05-31 22:30:52.731049
NCT01373034|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-06-13|2011-06-13|2011-06-14|Estimate|||||||2011-06-13|2011-06-14|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome|The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome: Double-blind, Randomized, Placebo-controlled, Cross Over Clinical Trial|Unknown status|Not yet recruiting|N/A|36|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:30:52.852478|2018-05-31 22:30:52.852478
NCT01373021|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-03-06|2011-06-13|2011-06-14|Estimate|||||||2012-03-06|2012-03-08|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Effect of Dexmedetomidine on Postoperative Analgesia|Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia|Completed||Phase 4|95|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 22:30:53.018288|2018-05-31 22:30:53.018288
NCT01373008|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2015-08-11|2011-06-13|2011-06-14|Estimate|||||||2015-08-11|2015-08-13|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD)|Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD); Prospective, Double Blind, Randomized Placebo-control, Multi-center Study|Unknown status|Recruiting|Phase 2|60|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||||2018-05-31 22:30:53.14345|2018-05-31 22:30:53.14345
NCT01372995|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|2016-07-28||2016-11-10|2011-06-13|2011-06-14|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|R21 HL-110044|The participant randomized to the 250,000 IU of Vitamin D3 study arm, whose spouse withdrew consent to participate in the study, is not represented in the Baseline Analysis Population.|Vitamin D in Ventilated ICU Patients|High-Dose Vitamin D and Antimicrobial Peptide Expression in Lung Failure|Completed||Phase 2|31|Actual|Emory University|Limitations to generalizability of this pilot study include the small sample size and imbalances in chronic conditions between treatment arms at study entry.|3|||f||||t||||||||||2018-05-31 22:30:53.323571|2018-05-31 22:30:53.323571
NCT01372982|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2011-06-13|2011-06-13|2011-06-14|Estimate|||||||2011-06-13|2011-06-14|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) Of Dr.Reddy's Laboratories Ltd And Femara 2.5 mg Tablets (Reference) Of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fed Conditions|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:30:54.75377|2018-05-31 22:30:54.75377
NCT01372969|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-06-13|2011-06-13|2011-06-14|Estimate|||||||2011-06-13|2011-06-14|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.|Multicenter Phase I/IIa Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.|Completed||Phase 1/Phase 2|24|Actual|Cellerix||1|||f||||f||||||||||2018-05-31 22:30:54.825454|2018-05-31 22:30:54.825454
NCT01372956|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-12-21|2011-06-13|2011-06-14|Estimate|||||||2011-12-21|2011-12-22|Estimate|August 2011||2011-08-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|CRESENDO||Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea|Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea (CRESCENDO)|Completed|||4950|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:30:54.96006|2018-05-31 22:30:54.96006
NCT01372943|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-10-19|2011-06-13|2011-06-14|Estimate|||||||2015-10-19|2015-10-21|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection|"A Study Using Synthetic Stool or Pure Cultures of Probiotic Intestinal Bacteria From Healthy Donor Stool That Can be Used as an Enema to Replace the Use of Stool Transplant, for Treatment of Recurrent and Refractory CDI"|Unknown status|Active, not recruiting|N/A|30|Anticipated|Queen's University||1|||f||||f||||||||||2018-05-31 22:30:55.056204|2018-05-31 22:30:55.056204
NCT01372930|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-11|2011-06-11|2011-06-14|Estimate|||||||2011-06-11|2011-06-14|Estimate|April 2010||2010-04-30|March 2010|2010-03-31||||July 2014|Anticipated|2014-07-31||Interventional|||Etanercept Treating Patient With Acute ST Segment Elevated Myocardial Infarction|The Safety and Efficacy of Etanercept in Treating Patient With Acute ST Segment Elevated Myocardial Infarction|Unknown status|Recruiting|Phase 4|200|Anticipated|Xijing Hospital||2|||f||||f||||||||||2018-05-31 22:30:55.124105|2018-05-31 22:30:55.124105
NCT01372917|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2012-06-11|2011-06-13|2011-06-14|Estimate|||||||2012-06-11|2012-06-13|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Observational|||Evaluating AlloMax in Immediate Expander-Based Breast Reconstruction Study|Evaluating Sterile Human Acellular Dermal Matrix in Immediate Expander-Based Breast Reconstruction: A Multi-centered Prospective Cohort Study|Completed|||39|Actual|National Center for Plastic Surgery, Virginia|||1||f||||f||||||Samples Without DNA|"~     A 1 cm square of AlloMax will be harvested from the first 20 patients for histologic~     examination to determine wether or not there is neovascularization and collagen deposition.~   "|||2018-05-31 22:30:55.231604|2018-05-31 22:30:55.231604
NCT01372904|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2014-07-16|2011-06-13|2011-06-14|Estimate|||||||2014-07-16|2014-07-17|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment|Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment.|Completed||Phase 4|30|Actual|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:30:55.320076|2018-05-31 22:30:55.320076
NCT01372891|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-11-21|2011-06-13|2011-06-14|Estimate|||||||2011-11-21|2011-11-22|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|December 2014|Anticipated|2014-12-31|April 2013|Anticipated|2013-04-30||Observational|||Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy|Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy|Unknown status|Recruiting||400|Anticipated|Xijing Hospital|||1||f||||f||||||Samples Without DNA|"~     serum,urine~   "|||2018-05-31 22:30:55.542903|2018-05-31 22:30:55.542903
NCT01372878|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-05|2014-04-02||2014-05-13|2011-06-13|2011-06-14|Estimate|2014-04-02|2014-05-06|Estimate||||2014-05-13|2014-05-20|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||CRC population|Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon|MA-204: Evaluation of Capsule Endoscopy With PillCam® COLON 2 in Visualization of the Colon|Completed||N/A|884|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-05-31 22:30:55.649501|2018-05-31 22:30:55.649501
NCT01372865|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-13|||2017-09-15|2011-06-13|2011-06-14|Estimate|||||||2017-09-15|2017-09-18|Actual|June 2012|Actual|2012-06-30|September 2017|2017-09-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA)|A Phase III, Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis With Eurofarma Mometasone or Reference Mometasone.|Completed||Phase 3|364|Actual|Eurofarma Laboratorios S.A.||2|||f||||t|f|f||||||||2018-05-31 22:30:55.942093|2018-05-31 22:30:55.942093
NCT01372852|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-11|||2011-06-13|2011-06-13|2011-06-14|Estimate|||||||2011-06-13|2011-06-14|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated Type 2 Diabetes Mellitus|Plasma Adiponectin Concentration, Activity and Isoforms in Newly Diagnosed and Untreated T2DM Patients in Chinese Population|Unknown status|Recruiting||300|Anticipated|Xijing Hospital|||2||f||||f||||||Samples Without DNA|"~     blood，abdominal fat tissue~   "|||2018-05-31 22:30:56.030701|2018-05-31 22:30:56.030701
NCT01372839|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-11|2011-06-11|2011-06-14|Estimate|||||||2011-06-11|2011-06-14|Estimate|July 2010||2010-07-31|July 2010|2010-07-31||||July 2012|Anticipated|2012-07-31||Interventional|PCI||Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome|The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome|Unknown status|Recruiting|Phase 4|300|Anticipated|Xijing Hospital||2|||f||||f||||||||||2018-05-31 22:30:56.12337|2018-05-31 22:30:56.12337
NCT01372826|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2014-10-13|2011-06-13|2011-06-14|Estimate|||||||2014-10-13|2014-10-15|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function|An Open-Label, Parallel-Group, Phase I Study to Compare the Pharmacokinetics of NKTR-118 Following a Single Oral Dose in Subjects With Renal Impairment and Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 22:30:56.227969|2018-05-31 22:30:56.227969
NCT01372813|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-11|2011-12-19||2015-10-02|2011-06-11|2011-06-14|Estimate|2012-02-08|2012-03-12|Estimate||||2015-10-02|2015-10-23|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Vandetanib to Treat Advanced Kidney Cancer|A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|Study was designed to accrue up to 37 patients but only 3 were enrolled. Study was terminated due to low accrual.|1||Terminated for insufficient accrual.|f||||f||||||||||2018-05-31 22:30:56.379899|2018-05-31 22:30:56.379899
NCT01372800|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2013-11-19|2011-06-11|2011-06-14|Estimate|||||||2013-11-19|2013-11-21|Estimate|May 2011||2011-05-31|November 2011|2011-11-30||||October 2016|Anticipated|2016-10-31||Observational|||Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases|Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases|Unknown status|Recruiting||30000|Anticipated|Xijing Hospital|||1||f||||f||||||None Retained|"~     blood~   "|||2018-05-31 22:30:56.81379|2018-05-31 22:30:56.81379
NCT01372787|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-11|||2017-05-03|2011-06-11|2011-06-14|Estimate|||||||2017-05-03|2017-05-08|Actual|April 2011||2011-04-30|May 2017|2017-05-31||||January 2014|Actual|2014-01-31||Observational|||Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|Quality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer|Active, not recruiting|||103|Actual|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 22:30:56.959129|2018-05-31 22:30:56.959129
NCT01372774|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-11|||2016-10-04|2011-06-11|2011-06-14|Estimate|||||||2016-10-04|2016-10-05|Estimate|July 2011||2011-07-31|October 2016|2016-10-31||||August 2016|Actual|2016-08-31||Interventional|||Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery|A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease|Active, not recruiting||Phase 3|192|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 22:30:57.269034|2018-05-31 22:30:57.269034
NCT01372761|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-12-28|2011-06-10|2011-06-14|Estimate|||||||2011-12-28|2011-12-30|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pharmacokinetics, Safety, Tolerability and Efficacy of Intravenous Doses of ZGN-433 in Obese Female Volunteers|Phase 1b Trial of Beloranib, a Novel Methionine Aminopeptidase 2 (MetAP-2) Inhibitor for Treatment of Extreme Obesity: Randomized, Double-Blind, Placebo-Controlled, Escalating Doses in Female Volunteers|Completed||Phase 1|25|Actual|Zafgen, Inc.||2|||f||||f||||||||||2018-05-31 22:30:57.388213|2018-05-31 22:30:57.388213
NCT01372748|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2016-08-08||2016-11-03|2011-06-13|2011-06-14|Estimate|2016-08-08|2016-10-05|Estimate||||2016-11-03|2016-12-28|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|CCC||Continuous Chest Compressions vs AHA Standard CPR of 30:2|Trial Of Continuous Compressions Versus Standard CPR In Patients With Out-Of-Hospital Cardiac Arrest|Completed||Phase 4|23711|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 22:30:57.472599|2018-05-31 22:30:57.472599
NCT01372735|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-10|2011-06-10|2011-06-14|Estimate|||||||2011-06-10|2011-06-14|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|August 2017|Anticipated|2017-08-31|August 2013|Anticipated|2013-08-31||Interventional|NEOPANC||Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer|Clinical Phase I/II Trial to Investigate Neoadjuvant Intensity-Modulated Short Term Radiation Therapy (5x5 Gy) and Intraoperative Radiation Therapy (15 Gy) in Patients With Primarily Resectable Pancreatic Cancer - NEOPANC|Unknown status|Not yet recruiting|Phase 1/Phase 2|46|Anticipated|University Hospital Heidelberg|||||f||||f||||||||||2018-05-31 22:30:58.10079|2018-05-31 22:30:58.10079
NCT01372722|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2013-10-28|2011-06-13|2011-06-14|Estimate|||||||2013-10-28|2013-10-29|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Interventional|DBS-BIPO||Deep Brain Stimulation (DBS) for Treatment Resistant Bipolar Disorder|Phase I Study of Bilateral DBS to the Nucleus Accumbens (NAcc-DBS) for Treatment Resistant Bipolar Disorder|Unknown status|Recruiting|Phase 2/Phase 3|12|Anticipated|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 22:30:58.207101|2018-05-31 22:30:58.207101
NCT01372709|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2017-05-01|2011-06-10|2011-06-14|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2011||2011-05-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|December 2014|Actual|2014-12-31||Observational|||TriVascular Post-Market Registry|A Post-Market Study to Evaluate the Safety and Performance of the Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Active, not recruiting|||501|Actual|TriVascular, Inc.|||1||f||||t||||||||||2018-05-31 22:30:58.306191|2018-05-31 22:30:58.306191
NCT01372696|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-11-14|2011-06-13|2011-06-14|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2009||2009-11-30|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|C-LST||Endoscopic Characteristics of Colonic Tumours|A Correlation of the Endoscopic Characteristics of Colonic LSTs With Their Somatic or Germline Mutations. A Prospective, Genome Wide Study|Recruiting||N/A|350|Anticipated|Western Sydney Local Health District||1|||f||||f||||||||||2018-05-31 22:30:58.419232|2018-05-31 22:30:58.419232
NCT01372683|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-12-19|2011-06-10|2011-06-14|Estimate|||||||2011-12-19|2011-12-20|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Oat Breakfast Satiety Study|The Effect of Oat Based Breakfast Cereals on Satiety|Completed||Phase 4|96|Actual|PepsiCo Global R&D||3|||f||||f||||||||||2018-05-31 22:30:58.519866|2018-05-31 22:30:58.519866
NCT01372670|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2016-11-14|2011-06-13|2011-06-14|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder|Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study|Withdrawn||Phase 4|0|Actual|HealthPartners Institute||2||Due to unforseen recruiting difficulties, the study was closed.|f||||t||||||||||2018-05-31 22:30:58.641687|2018-05-31 22:30:58.641687
NCT01372657|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-01-07|2011-06-13|2011-06-14|Estimate|||||||2015-01-07|2015-01-08|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Intraocular Lens (IOL) Calculation Improvement|Intraocular Lens (IOL) Formula Calculation Improvement|Terminated|||11|Actual|University Hospital, Basel, Switzerland|||1|slow recruitment|f||||f||||||||||2018-05-31 22:30:58.785328|2018-05-31 22:30:58.785328
NCT01372644|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2016-12-02|2011-06-10|2011-06-14|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|November 2013|Actual|2013-11-30|December 2010|Actual|2010-12-31||Interventional|||Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial|Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial|Completed||Phase 1|15|Actual|New York University School of Medicine||1|||f||||t||||||||Undecided||2018-05-31 22:30:59.01031|2018-05-31 22:30:59.01031
NCT01372631|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|||2018-04-09|2011-06-13|2011-06-14|Estimate|||||||2018-04-09|2018-04-10|Actual|April 2011||2011-04-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins|A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins|Recruiting||N/A|210|Anticipated|Duke University||3|||f||||||||||||Undecided||2018-05-31 22:30:59.173679|2018-05-31 22:30:59.173679
NCT01372618|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2017-10-17||2017-11-24|2011-06-10|2011-06-14|Estimate|2017-11-24|2017-12-27|Actual||||2017-11-24|2017-12-27|Actual|June 2011|Actual|2011-06-30|November 2017|2017-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Study Terminated. No Data analyzed|Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor|Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor|Terminated||Phase 1/Phase 2|9|Actual|New York University School of Medicine||1||PI has passed away. Requested by department to terminate study.|f||||t|t|f||||||||2018-05-31 22:30:59.669447|2018-05-31 22:30:59.669447
NCT01372605|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-12|2016-04-11||2016-10-19|2011-06-12|2011-06-14|Estimate|2016-08-25|2016-10-19|Estimate||||2016-10-19|2016-11-29|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|SLAM DUNC|All randomized participants|Trial of Collaborative Depression Care Management for HIV Patients|SLAM DUNC: Strategies to Link Antidepressant and Antiretroviral Management at Duke University, University of Alabama at Birmingham, Northern Outreach Clinic (Henderson, NC), and University of North Carolina|Completed||N/A|304|Actual|Duke University||2|||f||||t||||||||||2018-05-31 22:31:00.596089|2018-05-31 22:31:00.596089
NCT01372592|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2018-03-27|2011-06-10|2011-06-14|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2011||2011-03-31|March 2018|2018-03-31|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Observational|||SpineTRACK Registry - Spinal Outcomes Registry|SpineTRACK (Translating Radiographic and Clinical Knowledge) Registry: Outcomes Data Collection in Degenerative, Deformity, and Trauma Patients|Completed|||8079|Actual|NuVasive|||3||f||||f||||||||No||2018-05-31 22:31:04.771806|2018-05-31 22:31:04.771806
NCT01372579|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-07-05|2011-06-10|2011-06-14|Estimate|||||||2017-07-05|2017-07-06|Actual|August 2011||2011-08-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients|Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients|Active, not recruiting||Phase 2|30|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 22:31:05.006924|2018-05-31 22:31:05.006924
NCT01372566|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-03-16|2011-06-10|2011-06-14|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2011||2011-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Platelet Rich Plasma on Photoaged Skin|Effect of Autologous Platelet-rich Plasma on Photoaged Skin: A Prospective Randomized Controlled Trial (Phases A and B)|Active, not recruiting||Phase 1/Phase 2|23|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 22:31:05.207521|2018-05-31 22:31:05.207521
NCT01372553|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-04-15|2011-06-10|2011-06-14|Estimate|||||||2014-04-15|2014-04-16|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|GGMI||Guilford Genomic Medicine Initiative (GGMI)|Guilford Genomic Medicine Initiative (GGMI)|Completed|||1184|Actual|The Moses H. Cone Memorial Hospital|||1||f||||f||||||Samples With DNA|"~     Total number of project participants that completed family health history tool was 1,184..~     Out of the 1,184 subjects, 75 DNA saliva samples were collected.~   "|||2018-05-31 22:31:05.342137|2018-05-31 22:31:05.342137
NCT01372540|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2018-05-17|2011-06-13|2011-06-14|Estimate|||||||2018-05-17|2018-05-21|Actual|February 2012|Actual|2012-02-29|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma|A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1|75|Actual|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 22:31:05.568834|2018-05-31 22:31:05.568834
NCT01372527|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2014-10-02|2011-06-13|2011-06-14|Estimate|||||||2014-10-02|2014-10-03|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|TopCare||Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT|Technology for Optimizing Population Care in a Resource-limited Environment|Completed||N/A|103870|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:31:05.735187|2018-05-31 22:31:05.735187
NCT01372514|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2015-12-16|2011-06-10|2011-06-14|Estimate|||||||2015-12-16|2015-12-17|Estimate|August 2006||2006-08-31|December 2015|2015-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|IRTD||Institutional Registry of Thromboembolic Disease|Institutional Registry of Thromboembolic Disease|Recruiting|||4500|Anticipated|Hospital Italiano de Buenos Aires|||1||f||||t||||||||||2018-05-31 22:31:05.869789|2018-05-31 22:31:05.869789
NCT01372501|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2016-02-13||2016-12-29|2011-06-10|2011-06-14|Estimate|2016-02-13|2016-03-11|Estimate||||2016-12-29|2017-02-15|Actual|September 2010||2010-09-30|December 2016|2016-12-31|September 2012|Actual|2012-09-30|November 2011|Actual|2011-11-30||Interventional|||Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner|A Pilot Trial of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner|Completed||Phase 2|19|Actual|GI Dynamics||1|||f||||f||||||||Yes|De-identified individual data is available on site at Sponsor|2018-05-31 22:31:05.975761|2018-05-31 22:31:05.975761
NCT01372488|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-06-22|2011-06-13|2011-06-14|Estimate|||||||2011-06-22|2011-06-23|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Are Patients Willing and Capable of Removing Their Own Non-absorbable Sutures|Are Patients Willing and Capable of Removing Their Own Non-absorbable Sutures|Completed||N/A|160|Actual|Fraser Health||2|||f||||f||||||||||2018-05-31 22:31:06.37283|2018-05-31 22:31:06.37283
NCT01372475|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10||2014-03-11|2014-03-11|2011-06-13|2011-06-14|Estimate||||2014-03-11|2014-04-08|Estimate|2014-03-11|2014-04-08|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|Hymovis||Hymovis™ Versus Placebo in Knee Osteoarthritis|A Multi-Centre, Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Safety And Effectiveness Of A New Viscoelastic Hydrogel (Hymovis) In The Treatment Of Knee OA With An Open-Label Extension|Completed||Phase 3|800|Actual|Fidia Farmaceutici s.p.a.||2|||f||||f||||||||||2018-05-31 22:31:06.483312|2018-05-31 22:31:06.483312
NCT01372462|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2015-03-08||2016-08-18|2011-06-10|2011-06-14|Estimate|2016-08-18|2016-10-12|Estimate||||2016-08-18|2016-10-12|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||The primary endpoint is difference in endurance between cannula oxygen and NIOV+O2. Assuming 153 sec clinically important difference, 183 sec SD of increase and α=0.05, a sample size of 15 yields 85% power.|Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease|A Pilot Study of the Physiologic Effects of Using the Breathe Technologies Noninvasive Open Ventilation System During Constant Work Rate Exercise in Subjects With Chronic Obstructive Pulmonary Disease|Completed||N/A|15|Actual|Breathe Technologies, Inc.||4|||f||||f||||||||||2018-05-31 22:31:06.688314|2018-05-31 22:31:06.688314
NCT01372449|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-03-17|2011-06-13|2011-06-14|Estimate|||||||2017-03-17|2017-03-20|Actual|December 2011||2011-12-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism (MEM)|A Multi-site Double-blind Placebo-controlled Trial of Memantine Versus Placebo in Children With Autism Targeting Memory and Motor Planning|Completed||Phase 2|23|Actual|Anagnostou, Evdokia, M.D.||2|||f||||t||||||||No||2018-05-31 22:31:07.069054|2018-05-31 22:31:07.069054
NCT01372436|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2013-01-23|2011-06-13|2011-06-14|Estimate|||||||2013-01-23|2013-01-24|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Caries Risk Assessment in Children and Adolescents in the Alpes Maritimes (France)|Caries Risk Assessment in Children and Adolescents in the Alpes Maritimes (France)|Unknown status|Recruiting||678|Anticipated|Centre Hospitalier Universitaire de Nice|||2||f||||f||||||||||2018-05-31 22:31:07.175432|2018-05-31 22:31:07.175432
NCT01372423|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2012-07-10|2011-06-13|2011-06-14|Estimate|||||||2012-07-10|2012-07-12|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of Clinical Equivalence Between Two Lubiprostone Products|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of Lubiprostone 24 Mcg Capsules (Anchen Pharmaceuticals, Inc.) With AMITIZA® (Lubiprostone) 24 Mcg Capsules (Sucampo Pharmaceuticals, Inc.) in the Treatment of Chronic Idiopathic Constipation|Completed||Phase 3|808|Actual|Anchen Pharmaceuticals, Inc||3|||f||||f||||||||||2018-05-31 22:31:07.251217|2018-05-31 22:31:07.251217
NCT01372410|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2013-12-19|2012-05-17|2017-10-09|2011-06-09|2011-06-13|Estimate|2013-12-19|2014-02-11|Estimate|2012-05-17|2012-05-22|Estimate|2017-10-09|2017-11-08|Actual|July 1, 2011||2011-07-01|October 2017|2017-10-31|October 27, 2011|Actual|2011-10-27|October 1, 2011|Actual|2011-10-01||Interventional|AC4115321||A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|163|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:31:08.625553|2018-05-31 22:31:08.625553
NCT01372397|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2018-02-06|2011-06-10|2011-06-13|Estimate|||||||2018-02-06|2018-02-07|Actual|May 2010||2010-05-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Reversal of Obesity Cardiomyopathy|Reversal of Obesity Cardiomyopathy After Gastric Bypass|Active, not recruiting|||50|Anticipated|Washington University School of Medicine|||||f||||t||||||Samples With DNA|"~     Blood Samples~   "|||2018-05-31 22:31:09.671651|2018-05-31 22:31:09.671651
NCT01372384|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2015-10-16||2016-01-03|2011-06-10|2011-06-13|Estimate|2015-10-16|2015-11-16|Estimate||||2016-01-03|2016-02-02|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations|Phase II, Open-label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor|Completed||Phase 2|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:31:09.780929|2018-05-31 22:31:09.780929
NCT01372371|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Efficacy of Local Powder Prophylactics|Effects of Applying Powdered Prophylactics Verses Intravenous Antibiotics Only on Post-operative Infection Rate|Unknown status|Recruiting|N/A|1844|Anticipated|Ganga Hospital||3|||f||||f||||||||||2018-05-31 22:31:10.194176|2018-05-31 22:31:10.194176
NCT01372358|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|February 2005|Actual|2005-02-28|January 2005|Actual|2005-01-31||Interventional|||Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions|Single Dose, Randomized, Two-period, Two-treatment, Two-sequence Crossover Relative Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets Under Non-Fasting Condition.|Completed||Phase 1|32|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:31:10.331849|2018-05-31 22:31:10.331849
NCT01372345|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|February 2005||2005-02-28|January 2011|2011-01-31|March 2005|Actual|2005-03-31|February 2005|Actual|2005-02-28||Interventional|||Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions|Single Dose, Randomized, Two-period, Two-treatment, Two-sequence Crossover Relative Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets Under Fasting Condition|Completed||Phase 1|43|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:31:10.438915|2018-05-31 22:31:10.438915
NCT01372332|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2014-05-27|2011-06-10|2011-06-13|Estimate|||||||2014-05-27|2014-05-28|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|Hemi-Drive||Assessment of Homonymous Visual Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|Assessment of Homonymous Visual Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|Completed|||60|Actual|University Hospital Tuebingen|||2||f||||f||||||||||2018-05-31 22:31:10.571457|2018-05-31 22:31:10.571457
NCT01372319|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2014-05-27|2011-06-10|2011-06-13|Estimate|||||||2014-05-27|2014-05-28|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Observational|GlaucomaEXPLOR||Assessment of Advanced Glaucomatous Visual Field Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|Assessment of Advanced Glaucomatous Visual Field Loss and Its Impact on Visual Exploration, Activities of Daily Living (ADL) and Quality of Life (QoL)|Completed|||60|Actual|University Hospital Tuebingen|||2||f||||f||||||||||2018-05-31 22:31:10.663922|2018-05-31 22:31:10.663922
NCT01372306|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-06-29|2011-06-10|2011-06-13|Estimate|||||||2011-06-29|2011-06-30|Estimate|October 2004||2004-10-31|October 2004|2004-10-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fed Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:31:10.781589|2018-05-31 22:31:10.781589
NCT01372293|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-09-08|2011-06-10|2011-06-13|Estimate|||||||2011-09-08|2011-09-12|Estimate|January 2005||2005-01-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|January 2008|Actual|2008-01-31||Interventional|17b-ACO||71A/G HSD17B5 SNP and Effects of Oral Contraceptive Pill in PCOS Women|17-hydroxysteroid Dehydrogenase Type 5 Gene Polymorphism (71A/G HSD17B5 SNP) and Effects of Oral Contraceptive Pill on Hirsutism, Androgens and Metabolic Profile in Non-obese PCOS Women: a Pilot Study|Completed||N/A|49|Actual|Federal University of Rio Grande do Sul|||||f||||f||||||||||2018-05-31 22:31:10.88131|2018-05-31 22:31:10.88131
NCT01372280|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-06-29|2011-06-10|2011-06-13|Estimate|||||||2011-06-29|2011-06-30|Estimate|October 2004||2004-10-31|January 2011|2011-01-31|November 2004|Actual|2004-11-30|October 2004|Actual|2004-10-31||Interventional|||Galantamine Bioequivalence Study of Dr. Reddy's Under Fasting Condition|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fasting Conditions|Completed||Phase 1|28|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:31:10.98205|2018-05-31 22:31:10.98205
NCT01372267|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2017-07-21|2011-06-10|2011-06-13|Estimate|||||||2017-07-21|2017-07-24|Actual|October 2011||2011-10-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|January 2016|Actual|2016-01-31||Interventional|||Psychosocial Pain Management During Addictions Treatment to Improve Outcomes||Completed||N/A|510|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:31:11.08161|2018-05-31 22:31:11.08161
NCT01372254|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-07-12|2011-06-10|2011-06-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|BA-DAS||Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment|Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment|Unknown status|Recruiting|Phase 1/Phase 2|90|Anticipated|University of Maryland||2|||f||||f||||||||||2018-05-31 22:31:11.208968|2018-05-31 22:31:11.208968
NCT01372241|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2017-04-20|2011-06-10|2011-06-13|Estimate|||||||2017-04-20|2017-04-21|Actual|December 2005||2005-12-31|June 2011|2011-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|FMM||Faith Moves Mountains: An Appalachian Cervical Cancer Prevention Project|An Appalachian Cervical Cancer Prevention Project|Completed||N/A|345|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 22:31:11.334046|2018-05-31 22:31:11.334046
NCT01372228|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2018-05-18|2011-06-10|2011-06-13|Estimate|||||||2018-05-18|2018-05-22|Actual|April 2011||2011-04-30|May 2018|2018-05-31|April 2028|Anticipated|2028-04-30|April 2025|Anticipated|2025-04-30||Interventional|||Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders|Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|University of Louisville||1|||t||||t|t|f||||||Undecided||2018-05-31 22:31:11.439911|2018-05-31 22:31:11.439911
NCT01372215|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2015-05-12|2011-06-10|2011-06-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Multi-Compression Spot Mammography|Multi-Compression Spot Mammography|Terminated|||3|Actual|State University of New York - Upstate Medical University||||Referral physician no longer available|f||||f||||||||||2018-05-31 22:31:11.580661|2018-05-31 22:31:11.580661
NCT01372202|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2017-05-11||2017-07-28|2011-06-10|2011-06-13|Estimate|2017-07-28|2017-08-30|Actual||||2017-07-28|2017-08-30|Actual|June 2011||2011-06-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2014|Actual|2014-06-30||Interventional|J10130||CHFR Methylation Status Esophageal Cancer Study|A Phase 2 Study of Paclitaxel With Cisplatin Versus Fluoropyrimidine With a Platinum Agent for Neoadjuvant Therapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies|Active, not recruiting||Phase 2|31|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-05-31 22:31:11.823748|2018-05-31 22:31:11.823748
NCT01372189|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-01-30|2011-06-10|2011-06-13|Estimate|||||||2012-01-30|2012-02-01|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Molecular Imaging of Epidermal Growth Factor Receptor in Colorectal Neoplasia Using Confocal Laser Endomicroscopy|In Vivo Molecular Imaging of Epidermal Growth Factor Receptor in Patients With Colorectal Neoplasia Using Confocal Laser Endomicroscopy|Completed|||40|Actual|Shandong University|||2||f||||t||||||Samples With DNA|"~     Take biospecimen during colonoscopy.~   "|||2018-05-31 22:31:12.496949|2018-05-31 22:31:12.496949
NCT01372176|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2017-01-04|2011-06-10|2011-06-13|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|EAT-ICU||Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial|Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial|Completed||Phase 4|203|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 22:31:12.613865|2018-05-31 22:31:12.613865
NCT01372163|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2012-05-22|2011-06-10|2011-06-13|Estimate|||||||2012-05-22|2012-05-23|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Doses Of PF-05190457 In Healthy And Type 2 Diabetic Adults|Terminated||Phase 1|35|Actual|Pfizer||7||"B3301002 was discontinued on 18 April 2012 for strategic reasons.There were no safety concerns~   leading to discontinuation of this study."|f||||f||||||||||2018-05-31 22:31:12.833372|2018-05-31 22:31:12.833372
NCT01372150|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2015-10-19||2016-04-29|2011-06-10|2011-06-13|Estimate|2015-10-19|2015-11-20|Estimate||||2016-04-29|2016-05-27|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety population - included all randomized participants who received at least 1 dose of study drug.|A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Fluoxetine-referenced, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder|Completed||Phase 3|340|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:31:13.054284|2018-05-31 22:31:13.054284
NCT01372137|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2016-01-22|2011-06-10|2011-06-13|Estimate|||||||2016-01-22|2016-01-25|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94|First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94|Completed||Phase 1|64|Actual|NOXXON Pharma AG||2|||f||||f||||||||||2018-05-31 22:31:14.158344|2018-05-31 22:31:14.158344
NCT01372124|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-10-18|2011-06-10|2011-06-13|Estimate|||||||2012-10-18|2012-10-19|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36|A Phase I, Open Label, Parallel Group, Multi-center Single Dose Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36|Completed||Phase 1|32|Actual|NOXXON Pharma AG||1|||f||||f||||||||||2018-05-31 22:31:14.272675|2018-05-31 22:31:14.272675
NCT01372111|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-12-08|2011-06-10|2011-06-13|Estimate|||||||2015-12-08|2015-12-09|Estimate|March 2011||2011-03-31|December 2015|2015-12-31||||March 2016|Anticipated|2016-03-31||Interventional|||Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer|Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial|Unknown status|Active, not recruiting|Phase 2|76|Anticipated|Coastal Carolina Radiation Oncology|||||f||||f||||||||||2018-05-31 22:31:14.361964|2018-05-31 22:31:14.361964
NCT01372098|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2015-06-08|2011-06-10|2011-06-13|Estimate|||||||2015-06-08|2015-06-09|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Nurse-family Partnership (NFP) Curriculum Study|Development and Evaluation of an Intervention for Intimate Partner Violence in the Context of Nurse Home Visits|Completed||N/A|492|Actual|McMaster University||2|||f||||t||||||||||2018-05-31 22:31:14.601598|2018-05-31 22:31:14.601598
NCT01372085|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-10-07|2011-06-10|2011-06-13|Estimate|||||||2011-10-07|2011-10-12|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Single Dose Study in Healthy Volunteers to Investigate the Safety and Absorption of LY2584702|A Single Ascending Dose and Relative Bioavailability Study of LY2584702 in Healthy Subjects|Completed||Phase 1|40|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 22:31:14.73154|2018-05-31 22:31:14.73154
NCT01372072|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|June 2011||2011-06-30|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||A Study to Investigate the Effects of Heated Humidification During Non-Invasive Ventilation|A Pilot Study to Investigate the Physiological and Clinical Effects of Heated Humidification During Non-Invasive Ventilation|Unknown status|Not yet recruiting|N/A|16|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:31:14.888025|2018-05-31 22:31:14.888025
NCT01372059|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-08-04|2011-06-10|2011-06-13|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2010||2010-01-31|August 2017|2017-08-31|June 2, 2014|Actual|2014-06-02|May 30, 2014|Actual|2014-05-30||Interventional|||The Effects of a Rhythm and Music-based Therapy Program and Therapeutic Riding in Late Recovery Phase Following Stroke|The Effects of a Rhythm and Music-based Therapy Program and Therapeutic Riding in Late Recovery Phase Following Stroke|Completed||N/A|123|Actual|Göteborg University||3|||f||||t||||||||||2018-05-31 22:31:14.970668|2018-05-31 22:31:14.970668
NCT01372046|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|JAARP||Implementing & Testing Assessment and Referral Technologies in Juvenile Justice||Completed||Phase 3|1000|Anticipated|George Mason University||3|||f||||t||||||||||2018-05-31 22:31:15.090677|2018-05-31 22:31:15.090677
NCT01372033|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|June 2007||2007-06-30|June 2009|2009-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Man Tx||Effects of Manualized Treatment in a Seamless System|Effects of Manualized Treatment in a Seamless System of Care: Handling Probation|Completed||Phase 3|251|Actual|George Mason University||1|||f||||t||||||||||2018-05-31 22:31:15.323814|2018-05-31 22:31:15.323814
NCT01372020|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2013-12-21|2011-06-10|2011-06-13|Estimate|||||||2013-12-21|2013-12-24|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Neuromuscular Electrical Therapy in Venous Ulcers|The Effect of Neuromuscular Electrical Therapy on Pain in Patients With Venous Ulcers: a Controlled Clinical Trial|Completed||Phase 4|20|Actual|Faculdade Evangelica do Parana||2|||f||||f||||||||||2018-05-31 22:31:15.670771|2018-05-31 22:31:15.670771
NCT01372007|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2016-10-06|2011-06-10|2011-06-13|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma|Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma|Completed||Phase 3|24|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:31:16.115869|2018-05-31 22:31:16.115869
NCT01371370|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-08-04|2011-06-09|2011-06-10|Estimate|||||||2014-08-04|2014-08-05|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Low-intensity Resistance Exercise and Diet on Arterial Function and Blood Pressure|Effects of Low-intensity Resistance Exercise Training and Diet on Central Hemodynamics and Arterial Stiffness in Obese Middle-aged Women With High Blood Pressure|Completed||N/A|41|Actual|Florida State University||4|||f||||f||||||||||2018-05-31 22:31:43.104243|2018-05-31 22:31:43.104243
NCT01371994|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|2014-10-06||2014-10-06|2011-06-10|2011-06-13|Estimate|2014-10-06|2014-10-09|Estimate||||2014-10-06|2014-10-09|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Safety analysis set, defined as all participants who took at least one dose of study drug.|A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy|A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare® (Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy|Completed||Phase 4|640|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||f||||||||||2018-05-31 22:31:16.662958|2018-05-31 22:31:16.662958
NCT01371981|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2018-05-28|2011-06-10|2011-06-13|Estimate|||||||2018-05-28|2018-05-30|Actual|June 20, 2011|Actual|2011-06-20|May 2018|2018-05-31||||September 30, 2018|Anticipated|2018-09-30||Interventional|||Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD|Active, not recruiting||Phase 3|1750|Anticipated|National Cancer Institute (NCI)||16|||f||||t||||||||||2018-05-31 22:31:18.197569|2018-05-31 22:31:18.197569
NCT01371968|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-10-25|2011-06-10|2011-06-13|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2011||2011-02-28|October 2017|2017-10-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia|Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia|Completed||N/A|30|Actual|University of Malaya||1|||f||||t||||||||Yes||2018-05-31 22:31:19.038271|2018-05-31 22:31:19.038271
NCT01371955|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2013-11-14|2011-06-10|2011-06-13|Estimate|||||||2013-11-14|2013-11-15|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|NEPHRODIANOX||Impact of c242T Polymorphism of p22phox in Diabetic type1 Nephropathy|Impact of c242T Polymorphism of p22phox in the Development of Diabetic Nephropathy,in Caucasian Diabetic Type 1 Patient.|Completed|||162|Actual|University Hospital, Grenoble|||3||f||||t||||||Samples With DNA|"~     We will include 60 patients to reach the required number. We take 2 blood samples: one for~     genetic analysis and one to determine HBA1c and plasma creatinine. We also take one urinary~     sample to determine the urinary albumine / creatinine ratio~   "|||2018-05-31 22:31:19.210336|2018-05-31 22:31:19.210336
NCT01371942|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|May 2013|Anticipated|2013-05-31|||||Observational|||Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management|Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management|Unknown status|Active, not recruiting||300|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:31:19.327378|2018-05-31 22:31:19.327378
NCT01371929|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2017-04-12|2011-06-10|2011-06-13|Estimate|||||||2017-04-12|2017-04-14|Actual|February 2013||2013-02-28|April 2017|2017-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|PliNOSa® Test||Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study|Evaluation of the PliNOSa® Test as an Aid in the Risk Assessment for the Onset of Sepsis|Suspended|||300|Anticipated|Research & Diagnostic Antibodies|||2|NIH funding ended prior to full enrollment in the clinical study|f||||t||||||Samples Without DNA|"~     heparinized plasma samples~   "|||2018-05-31 22:31:19.416575|2018-05-31 22:31:19.416575
NCT01371916|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2014-08-18|2011-06-10|2011-06-13|Estimate|||||||2014-08-18|2014-08-20|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Observational|||Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF|Diagnosis of Tuberculous Meningitis by a Secretory Antigenic Target 6 (ESAT-6) in CSF|Completed|||316|Actual|Xijing Hospital|||2||f||||f||||||||||2018-05-31 22:31:19.550529|2018-05-31 22:31:19.550529
NCT01371903|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-10|||2014-03-20|2011-06-10|2011-06-13|Estimate|||||||2014-03-20|2014-03-24|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|Capno||The Effects of Patient Features on Opioid Induced End-Tidal CO2|The Effect of Patient Features on Opioid Induced End-Tidal CO2|Completed|||278|Actual|Albany Medical College|||||f||||t||||||||||2018-05-31 22:31:19.659061|2018-05-31 22:31:19.659061
NCT01371890|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-01-27|2011-06-10|2011-06-13|Estimate|||||||2014-01-27|2014-01-29|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|MATCH-Sodium||Mechanisms and Treatment of Intradialytic Hypertension - Sodium|Mechanisms and Treatment of Intradialytic Hypertension - Sodium|Completed|||18|Actual|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples Without DNA|"~     Samples stored for nitric oxide and endothelin-1 measurements~   "|||2018-05-31 22:31:19.951088|2018-05-31 22:31:19.951088
NCT01371877|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2014-12-01||2017-08-30|2011-06-09|2011-06-13|Estimate|2014-12-12|2014-12-16|Estimate||||2017-08-30|2017-09-28|Actual|November 2011|Actual|2011-11-30|August 2017|2017-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment|The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment|Completed||N/A|42|Actual|University of Nebraska||2|||f||||f||||||||||2018-05-31 22:31:21.351875|2018-05-31 22:31:21.351875
NCT01371864|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-04-21|2011-06-10|2011-06-13|Estimate|||||||2017-04-21|2017-04-25|Actual|August 2011||2011-08-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Families and Pediatric Cardiac Surgery Multidisciplinary Teams: How Well Do We Communicate|Families and Pediatric Cardiac Surgery Multidisciplinary Teams: How Well Do We Communicate?|Completed|||23|Actual|University of North Carolina, Chapel Hill|||4||f||||f||||||||||2018-05-31 22:31:24.645263|2018-05-31 22:31:24.645263
NCT01371851|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2015-06-22||2015-07-24|2011-06-10|2011-06-13|Estimate|2015-07-24|2015-07-27|Estimate||||2015-07-24|2015-07-27|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Those eligible participants who received at least one dose of study medication.|Doxazosin for Psychostimulant Dependence|Clinical Efficacy of Doxazosin for Psychostimulant Dependence|Completed||Phase 1/Phase 2|22|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 22:31:24.855605|2018-05-31 22:31:24.855605
NCT01371357|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-12-18|2011-06-09|2011-06-10|Estimate|||||||2011-12-18|2011-12-20|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effects of 8-week Choline, Betaine, and Folic Acid Supplementation on Plasma Homocysteine Concentration During Guanidinoacetic Acid Loading in Young Healthy Volunteers||Completed||Phase 3|40|Actual|Center for Health, Exercise and Sport Sciences, Serbia||4|||f||||t||||||||||2018-05-31 22:31:43.581198|2018-05-31 22:31:43.581198
NCT01371838|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2014-05-28||2017-09-01|2011-06-10|2011-06-13|Estimate|2014-09-22|2014-09-23|Estimate||||2017-09-01|2017-09-06|Actual|December 2011||2011-12-31|September 2017|2017-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All randomized subjects who were intended to receive study treatment and were of PORT risk class III and IV. There was one patient with PORT risk class II who was not included in baseline analysis population.|A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia|A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia|Completed||Phase 3|848|Actual|Pfizer||2|||f||||||||||||||2018-05-31 22:31:25.813465|2018-05-31 22:31:25.813465
NCT01371825|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2016-01-14||2017-10-12|2011-06-09|2011-06-13|Estimate|2016-04-05|2016-04-18|Estimate||||2017-10-12|2017-11-14|Actual|May 2011||2011-05-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|August 2014|Actual|2014-08-31||Interventional|VITAL||SurVival of Lysosomal Acid Lipase Deficiency (LAL-D) Infants Treated With SebelipAse aLfa|An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency|Active, not recruiting||Phase 2/Phase 3|9|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||Undecided||2018-05-31 22:31:27.416025|2018-05-31 22:31:27.416025
NCT01371812|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2017-07-18|2011-06-09|2011-06-13|Estimate|||||||2017-07-18|2017-07-21|Actual|March 29, 2011|Actual|2011-03-29|July 2017|2017-07-31|July 1, 2011|Actual|2011-07-01|July 1, 2011|Actual|2011-07-01||Interventional|||GSK2239633 FTIH Study|A Randomised, Double-blind, Placebo-controlled, Cross-over Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of GSK2239633 in Healthy Male Subjects.|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:31:28.469238|2018-05-31 22:31:28.469238
NCT01371799|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-06-12|2011-06-09|2011-06-13|Estimate|||||||2017-06-12|2017-06-14|Actual|December 17, 2009|Actual|2009-12-17|June 2017|2017-06-30|June 18, 2010|Actual|2010-06-18|June 18, 2010|Actual|2010-06-18||Interventional|MAA113746||A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers|A Double Blind, Randomized, Placebo Controlled, Cross-over Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers|Completed||Phase 1|9|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:31:28.64638|2018-05-31 22:31:28.64638
NCT01371786|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2012-08-03||2012-09-05|2011-06-10|2011-06-13|Estimate|2012-08-03|2012-09-06|Estimate||||2012-09-05|2012-09-10|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose Inhaler|A Phase 1, Open Label, Two Period, Randomized, Cross Over Scintigraphy Study Assessing Nasal Deposition of a Single Dose of a Ciclesonide Radiolabeled Solution Following Nasal Inhalation of a Novel Nasal Metered Dose Inhaler (MDI) and of a Mometasone Furoate Monohydrate Radiolabeled Suspension Via an Aqueous (AQ) Nasal Spray|Completed||Phase 1|14|Actual|Sunovion|Both the formulations used in this study were radiolabeled and not the individual corticosteroid molecules. Therefore the distribution of the corticosteroid molecules over 10 minutes post-administration was not quantified.|2|||f||||f||||||||||2018-05-31 22:31:28.894558|2018-05-31 22:31:28.894558
NCT01371773|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-12-07|2011-06-09|2011-06-13|Estimate|||||||2011-12-07|2011-12-08|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Repositioning Method for Left-sided Double Lumen Tubes|Repositioning Method for Left-sided Double Lumen Tubes Introduced Into Right Mainstem Bronchus|Completed||N/A|50|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:31:29.556647|2018-05-31 22:31:29.556647
NCT01371760|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-12-16|2011-06-10|2011-06-13|Estimate|||||||2015-12-16|2015-12-17|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|BRAVE-DREAMS||BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis)|Randomized Multi-centered Study for Evaluating the Efficacy and Safety of Angioplastic Surgery of the Extracranial Veins in the Treatment of Multiple Sclerosis. Studio Randomizzato Multicentrico Per la Valutazione Dell'Efficacia e Sicurezza Dell'Intervento di Disostruzione Delle Vene Extracraniche Nel Trattamento Della Sclerosi Multipla|Completed||N/A|212|Actual|S. Anna Hospital||2|||f||||t||||||||Yes|Data analysis on behalf of the independent Biostatistic Center will be completed within May 2016|2018-05-31 22:31:29.672188|2018-05-31 22:31:29.672188
NCT01371747|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2015-11-11|2014-10-30|2017-04-24|2011-06-10|2011-06-13|Estimate|2015-11-11|2015-12-17|Estimate|2014-10-30|2014-11-06|Estimate|2017-04-24|2017-04-26|Actual|June 2011||2011-06-30|April 2017|2017-04-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|AMETHYST-DN|306 participants were randomized and stratified by baseline serum potassium (2 randomized participants in Stratum 1 did not receive any study drug: 1 participant withdrew consent and 1 participant was randomized in error and was withdrawn from the study); 304 participants were analyzed for safety.|Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)|A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone|Completed||Phase 2|324|Actual|Relypsa, Inc.||6|||f||||f||||||||||2018-05-31 22:31:29.870103|2018-05-31 22:31:29.870103
NCT01371734|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2016-03-07||2017-01-30|2011-06-10|2011-06-13|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|August 2011||2011-08-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Safety population - included all randomized participants who received at least 1 dose of study drug.|A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-release (Dvs Sr) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder|Completed||Phase 3|363|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:31:31.857137|2018-05-31 22:31:31.857137
NCT01367600|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-18|2011-06-06|2011-06-07|Estimate|||||||2011-07-18|2011-07-19|Estimate|February 2003||2003-02-28|July 2011|2011-07-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Open-Label Treatment Extension of Protocol MNTX 301|A Three-Month Open-Label Treatment Extension of Protocol MNTX 301|Completed||Phase 3|27|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||t||||||||||2018-05-31 22:33:02.118252|2018-05-31 22:33:02.118252
NCT01371721|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2016-04-19||2016-12-16|2011-06-10|2011-06-13|Estimate|2016-12-16|2017-02-08|Estimate||||2016-12-16|2017-02-08|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Safety population - included all randomized participants who received at least 1 dose of study drug.|A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD|A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder|Completed||Phase 3|269|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 22:31:34.442148|2018-05-31 22:31:34.442148
NCT01371708|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2016-10-14||2017-06-28|2011-06-10|2011-06-13|Estimate|2016-10-14|2016-12-08|Estimate||||2017-06-28|2017-07-27|Actual|February 2, 2012|Actual|2012-02-02|June 2017|2017-06-30|April 22, 2016|Actual|2016-04-22|April 22, 2016|Actual|2016-04-22||Interventional||All participants who received at least 1 dose of study drug|A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD|A 6-month, Open-label, Multi-center, Flexible Dose Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder|Completed||Phase 3|283|Actual|Pfizer||1|||f||||t|t|f||||||||2018-05-31 22:31:35.417397|2018-05-31 22:31:35.417397
NCT01371695|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-10|2011-06-10|2011-06-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|September 2013|Anticipated|2013-09-30|September 2011|Anticipated|2011-09-30||Observational|||Serum IGF-II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer|Phase 1 of Serum IGF II and Cancer: Can IGF II Levels be Used to Monitor and Screen Patients Specifically for Cervical Cancer|Unknown status|Enrolling by invitation||60|Actual|Onconix, Inc|||||f||||f||||||Samples With DNA|"~     frozen serum~   "|||2018-05-31 22:31:36.530109|2018-05-31 22:31:36.530109
NCT01371682|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2018-05-17|2011-06-09|2011-06-13|Estimate|||||||2018-05-17|2018-05-21|Actual|September 18, 2009|Actual|2009-09-18|May 2018|2018-05-31|December 2, 2009|Actual|2009-12-02|December 2, 2009|Actual|2009-12-02||Interventional|||A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda|An Open Label Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets (Ropinirole XL, Marketed as REQUIP-MODUTAB™, REQUIP XL™ at 2 mg) Manufactured at Crawley and Aranda|Completed||Phase 1|50|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:31:36.617062|2018-05-31 22:31:36.617062
NCT01371669|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2013-03-27|2011-06-08|2011-06-13|Estimate|||||||2013-03-27|2013-03-29|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|Sommeil_HTAP||Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension|Study Searching for Hypoxemic Sleep Breathing Disorders in a Cohort of Patients With Idiopathic Pulmonary Arterial Hypertension (IPAH) and Chronic Post-embolic Pulmonary Hypertension (CPEPH)|Completed|||50|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 22:31:36.761307|2018-05-31 22:31:36.761307
NCT01371656|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-04|||2018-05-07|2011-06-10|2011-06-13|Estimate|||||||2018-05-07|2018-05-11|Actual|September 2011|Actual|2011-09-30|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation|A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|Completed||Phase 3|624|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 22:31:36.934102|2018-05-31 22:31:36.934102
NCT01371643|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2016-02-05||2016-07-25|2011-06-10|2011-06-13|Estimate|2016-06-10|2016-07-22|Estimate||||2016-07-25|2016-08-29|Estimate|April 2004||2004-04-30|July 2016|2016-07-31|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31||Interventional|||Surgical Debulking of Pituitary Adenomas|Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study|Completed||Phase 4|41|Actual|New York University School of Medicine||2|||f||||||||||||||2018-05-31 22:31:37.40031|2018-05-31 22:31:37.40031
NCT01371630|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2018-04-25|2011-06-10|2011-06-13|Estimate|||||||2018-04-25|2018-04-27|Actual|August 2011|Actual|2011-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)|Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 1/Phase 2|256|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:31:37.92643|2018-05-31 22:31:37.92643
NCT01371617|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2012-11-14|2011-06-10|2011-06-13|Estimate|||||||2012-11-14|2012-11-15|Estimate|October 2011||2011-10-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Phase 2 Study With IPI-926 in Patients With Myelofibrosis|A Phase 2 Study of IPI-926 in Patients With Myelofibrosis|Completed||Phase 2|14|Actual|Infinity Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:31:38.220338|2018-05-31 22:31:38.220338
NCT01371604|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2015-02-05|2011-06-10|2011-06-13|Estimate|||||||2015-02-05|2015-02-06|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)|A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection|Completed||Phase 2|68|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 22:31:38.328537|2018-05-31 22:31:38.328537
NCT01371591|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2018-02-20|2011-06-10|2011-06-13|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CHEER||Capsule Endoscopy for Hemorrhage in the Emergency Room|Pilot Study to Investigate the Use of Wireless Capsule Endoscopy for Emergency Department Patients With Suspected Acute Upper Gastrointestinal Bleeding|Not yet recruiting||N/A|100|Anticipated|George Washington University||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 22:31:38.465549|2018-05-31 22:31:38.465549
NCT01370837|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2015-03-30||2015-04-16|2011-06-09|2011-06-10|Estimate|2015-03-30|2015-04-10|Estimate||||2015-04-16|2015-05-06|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Neurogenic Inflammation in Diabetes|Neurogenic Inflammation in Diabetic Polyneuropathy and Charcot Neuro-osteoarthropathy: Response to Intracutaneous Candida Albicans|Completed||N/A|41|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 22:31:51.503251|2018-05-31 22:31:51.503251
NCT01371578|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09||2014-01-14|2014-01-14|2011-06-10|2011-06-13|Estimate||||2014-01-14|2014-02-11|Estimate|2014-01-14|2014-02-11|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy Using Combinations of Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol GS US 256 0124)|Completed||Phase 2|163|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 22:31:38.629716|2018-05-31 22:31:38.629716
NCT01371565|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2013-09-19||2014-02-19|2011-06-09|2011-06-13|Estimate|2013-09-19|2013-11-20|Estimate||||2014-02-19|2014-03-18|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional||Subjects who received one dose of study drug were included in the safety analysis.|Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome|Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome|Completed||Phase 3|4|Actual|Corcept Therapeutics||1|||f||||f||||||||||2018-05-31 22:31:38.891826|2018-05-31 22:31:38.891826
NCT01371552|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2012-10-02||2012-10-02|2011-06-09|2011-06-13|Estimate|2012-10-02|2012-10-31|Estimate||||2012-10-02|2012-10-31|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TUNGSTEN||Performance Evaluation of a New Daily Disposable Silicone Hydrogel Lens|Performance Evaluation of a New Daily Disposable Silicone Hydrogel Lens (TUNGSTEN)|Completed||N/A|119|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:31:39.287649|2018-05-31 22:31:39.287649
NCT01371539|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2012-06-28||2012-06-28|2011-06-09|2011-06-13|Estimate|2012-06-28|2012-08-03|Estimate||||2012-06-28|2012-08-03|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Clinical Comparison of Two Multifocal Contact Lenses Made of Silicone Hydrogel Materials|Clinical Comparison of Two Multifocal Contact Lenses Made of Silicone Hydrogel Materials|Completed||N/A|109|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:31:39.661183|2018-05-31 22:31:39.661183
NCT01371526|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2013-02-05|2011-06-09|2011-06-13|Estimate|||||||2013-02-05|2013-02-06|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|RoSA||Revival of Stem Cells in Addison's Study|Revival of Autochthonous Adrenocortical Stem Cells in Autoimmune Addison's Disease|Completed||Phase 4|13|Actual|Newcastle University||1|||f||||t||||||||||2018-05-31 22:31:39.939428|2018-05-31 22:31:39.939428
NCT01371513|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-05-19|2011-06-09|2011-06-10|Estimate|||||||2017-05-19|2017-05-22|Actual|May 2010||2010-05-31|May 2017|2017-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|RESPECT||Korean Practice Patterns for Screening PCA(Prostate Cancer)|Korean's Practice Patterns for Screening PCA(Prostate Cancer) According to PSA(Prostate-specific Antigen) Level|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:31:40.257512|2018-05-31 22:31:40.257512
NCT01371487|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-11-08|2011-06-09|2011-06-10|Estimate|||||||2017-11-08|2017-11-13|Actual|May 2, 2011|Actual|2011-05-02|November 2017|2017-11-30|September 30, 2011|Actual|2011-09-30|September 30, 2011|Actual|2011-09-30||Interventional|||GSK1120212 Food-effect Study|An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of the MEK Inhibitor, GSK1120212, in Subjects With Solid Tumors|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:31:40.447175|2018-05-31 22:31:40.447175
NCT01371474|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-05-19|2011-06-09|2011-06-10|Estimate|||||||2017-05-19|2017-05-22|Actual|April 2006||2006-04-30|May 2017|2017-05-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Observational|||Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)|Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)|Completed|||1483|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:31:40.733204|2018-05-31 22:31:40.733204
NCT01371461|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-06-07|2011-06-09|2011-06-10|Estimate|||||||2017-06-07|2017-06-08|Actual|January 2004||2004-01-31|May 2017|2017-05-31|October 2004|Actual|2004-10-31|July 2004|Actual|2004-07-31||Observational|||Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)|Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)|Completed|||390|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:31:40.82183|2018-05-31 22:31:40.82183
NCT01371448|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-06-07|2011-06-09|2011-06-10|Estimate|||||||2017-06-07|2017-06-08|Actual|May 2001||2001-05-31|May 2017|2017-05-31|September 2005|Actual|2005-09-30|September 2004|Actual|2004-09-30||Observational|||Special Drug Use Investigation for PAXIL Tablet (Long-term)|Special Drug Use Investigation for PAXIL Tablet (Long-term)|Completed|||339|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:31:40.923962|2018-05-31 22:31:40.923962
NCT01371435|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-06-07|2011-06-09|2011-06-10|Estimate|||||||2017-06-07|2017-06-08|Actual|April 2001||2001-04-30|May 2017|2017-05-31|December 2005|Actual|2005-12-31|September 2005|Actual|2005-09-30||Observational|||Drug Use Investigation for PAXIL Tablet|Drug Use Investigation for PAXIL Tablet|Completed|||3708|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:31:41.214141|2018-05-31 22:31:41.214141
NCT01371422|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-05-03|2011-06-09|2011-06-10|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2011||2011-08-31|May 2018|2018-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Trial Comparing the Effect of a Paravertebral Block on Pain Post Percutaneous Nephrolithotomy|Randomized Controlled Trial Comparing the Effect of a Paravertebral Block on Pain Post Percutaneous Nephrolithotomy|Terminated||N/A|3|Actual|University of British Columbia||2||There was no resources to complete the study at this time|f||||f||||||||||2018-05-31 22:31:41.34205|2018-05-31 22:31:41.34205
NCT01371409|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2016-06-27|2011-06-09|2011-06-10|Estimate|||||||2016-06-27|2016-06-28|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|February 2014|Actual|2014-02-28||Interventional|InHIb||Interhemispheric Inhibitory Interactions|Interhemispheric Contributions to Neuroplasticity and Motor Learning After Stroke|Completed||N/A|49|Actual|University of British Columbia||2|||f||||f||||||||Undecided||2018-05-31 22:31:41.473284|2018-05-31 22:31:41.473284
NCT01371396|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2012-04-20|2011-06-09|2011-06-10|Estimate|||||||2012-04-20|2012-04-23|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|June 2014|Anticipated|2014-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Effect of Dietary Macronutrient Composition|Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism|Unknown status|Active, not recruiting|N/A|24|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 22:31:41.96587|2018-05-31 22:31:41.96587
NCT01371383|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2012-05-11|2011-06-09|2011-06-10|Estimate|||||||2012-05-11|2012-05-14|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Effect of Fish Oil in Major Depressive Disorder|The Effect of Fish Oil in Major Depressive Disorder: a Double-blind Placebo-controlled Monotherapy Trail to Demonstrate the Therapeutic Effects of Depression|Completed||Phase 2/Phase 3|120|Actual|National Science Council, Taiwan||2|||f||||t||||||||||2018-05-31 22:31:42.762251|2018-05-31 22:31:42.762251
NCT01371344|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-12-08|2011-06-09|2011-06-10|Estimate|||||||2017-12-08|2017-12-11|Actual|June 24, 2011|Actual|2011-06-24|December 2017|2017-12-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|PROGRESSION||A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients|A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in Paediatric Solid Allograft Recipients|Terminated||Phase 4|47|Actual|Astellas Pharma Inc||2||"Trial will not complete until at least 2025 and evolution of immunosuppressant therapy has made~   it unlikely that patients will convert from Modigraf to Prograf."|f||||f||||||||||2018-05-31 22:31:43.722217|2018-05-31 22:31:43.722217
NCT01371331|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-03-07|2011-06-09|2011-06-10|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2011||2011-06-30|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|OPTION||A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation|A Multicentre, Open-label, Pharmacokinetic Study of Modigraf® (Tacrolimus Granules) in de Novo Paediatric Allograft Recipients|Completed||Phase 4|52|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:31:43.946281|2018-05-31 22:31:43.946281
NCT01371318|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-12-29|2011-06-09|2011-06-10|Estimate|||||||2014-12-29|2014-12-31|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|OWEMR||Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics|Wound EMR to Decrease Limb Amputations in Persons With Diabetes|Completed||N/A|1609|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 22:31:44.176131|2018-05-31 22:31:44.176131
NCT01371305|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03||2018-03-23|2018-03-23|2011-06-09|2011-06-10|Estimate||||2018-03-23|2018-03-29|Actual|2018-03-23|2018-03-29|Actual|July 16, 2012|Actual|2012-07-16|March 2018|2018-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 2|41|Actual|Biogen||2|||f||||t||||||||||2018-05-31 22:31:44.319507|2018-05-31 22:31:44.319507
NCT01371292|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2014-09-15|2011-06-09|2011-06-10|Estimate|||||||2014-09-15|2014-09-17|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|AIM||A Transformational Teaching Intervention: Adolescents in Motion (AIM) Trial|A Transformational Teaching Intervention: Adolescents in Motion (AIM) Trial|Completed||N/A|2160|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:31:44.44415|2018-05-31 22:31:44.44415
NCT01371279|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2011-06-16|2011-06-09|2011-06-10|Estimate|||||||2011-06-16|2011-06-17|Estimate|June 2011||2011-06-30|March 2011|2011-03-31|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Interventional|ActionICE||EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography|EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography|Unknown status|Recruiting|Phase 4|100|Anticipated|Centre of Postgraduate Medical Education|||||f||||f||||||||||2018-05-31 22:31:44.575798|2018-05-31 22:31:44.575798
NCT01371266|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-08-12|2011-06-08|2011-06-10|Estimate|||||||2015-08-12|2015-08-13|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Glycemic Effects of Honey|Glycemic Effects of Honey|Completed||N/A|55|Actual|USDA Grand Forks Human Nutrition Research Center||3|||f||||t||||||||||2018-05-31 22:31:44.720568|2018-05-31 22:31:44.720568
NCT01371253|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2012-01-18|2011-06-09|2011-06-10|Estimate|||||||2012-01-18|2012-01-19|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|WIICAN||10 Weeks of NIntendo wIi Fit balanCe Training Improved Postural balANce and Muscle Strength in Elderly Individuals|10 Weeks of NIntendo wIi Fit balanCe Training Improved Postural balANce and Muscle Strength in Elderly Individuals: Double Blinded, Randomised Controlled Trial|Completed||N/A|58|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-05-31 22:31:44.824598|2018-05-31 22:31:44.824598
NCT01371240|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-06-10|2011-06-09|2011-06-10|Estimate|||||||2011-06-10|2011-06-13|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity|Evaluation of Efficiency of Secretin-Assisted Computed Tomography Scan and Secretin-Assisted Magnetic Resonance Imaging in Improving Pancreatic Enhancement and Tumor Conspicuity: Prospective Study|Unknown status|Recruiting|Early Phase 1|40|Anticipated|University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-05-31 22:31:44.928067|2018-05-31 22:31:44.928067
NCT01371227|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2013-07-03|2011-06-09|2011-06-10|Estimate|||||||2013-07-03|2013-07-04|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma|A Phase 1 of JNS002 (Doxorubicin HCl Liposome Injection) in Combination With Bortezomib for Japanese Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|3|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 22:31:45.209146|2018-05-31 22:31:45.209146
NCT01371214|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-06-02|2011-06-08|2011-06-10|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PLIÉ-pilot||Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot|Maintaining Independence in Alzheimer's Disease|Completed||Phase 1|12|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:31:45.36262|2018-05-31 22:31:45.36262
NCT01371201|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2017-01-25|2011-06-09|2011-06-10|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|FIRSTMAPPP||First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma|First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)|Recruiting||Phase 2|74|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 22:31:45.482912|2018-05-31 22:31:45.482912
NCT01371188|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Observational|||Effects of Exposure to Biomass-burning Air Pollution on Lung Function, Heart Rate Variability and Inflammatory Markers in Sugarcane Workers|Effects of Exposure to Outdoor Air Pollution From Biomass Burning on Lung Function, Heart Rate Variability and Systemic Inflammatory Blood Markers in Sugarcane Workers|Completed|||222|Actual|InCor Heart Institute|||2||f||||f||||||Samples With DNA|"~     Whole blood.~   "|||2018-05-31 22:31:45.612791|2018-05-31 22:31:45.612791
NCT01371175|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|April 2003||2003-04-30|June 2011|2011-06-30||||May 2005|Actual|2005-05-31||Interventional|||A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers|A Randomized, Placebo-Controlled, Dosage-Escalating Phase 2A Study, Double-Blinded With Respect to Assignment to Either Vaccine or Placebo, to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Administered Intramuscularly Followed by an MVA HIV-1 Vaccine Administered at Three Different Dosage Levels and by Three Different Routes to HIV-Uninfected, Healthy, Volunteers.|Completed||Phase 2|115|Actual|International AIDS Vaccine Initiative||9|||f||||t||||||||||2018-05-31 22:31:45.8585|2018-05-31 22:31:45.8585
NCT01371162|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2016-11-01|2011-06-09|2011-06-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C|A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HCV Nucleoside Inhibitor RO5428029 in Healthy Subjects and in CHC Genotype 1 Infected Patients|Completed||Phase 1|42|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 22:31:46.081904|2018-05-31 22:31:46.081904
NCT01371149|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-04-02|2011-06-09|2011-06-10|Estimate|||||||2014-04-02|2014-04-03|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Patient -Ventilator Interaction in Chronic Respiratory Failure|A Clinical Trial to Optimise Patient-ventilator Interaction in Patients With Chronic Respiratory Failure|Completed||Phase 2|58|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:31:46.284604|2018-05-31 22:31:46.284604
NCT01371136|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-11-16|2011-06-09|2011-06-10|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Developing a Curriculum to Teach Laparoscopic Colorectal Surgery||Completed||N/A|25|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 22:31:46.421531|2018-05-31 22:31:46.421531
NCT01371123|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-07-26|2011-06-09|2011-06-10|Estimate|||||||2013-07-26|2013-07-29|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition|Serum Aluminum Concentration of Pediatric Patients Receiving Long-Term Parenteral Nutrition: Is There a Problem in Canada?|Completed|||50|Actual|The Hospital for Sick Children|||2||f||||f||||||None Retained|"~     serum~   "|||2018-05-31 22:31:46.529339|2018-05-31 22:31:46.529339
NCT01371110|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2017-04-18||2018-01-16|2011-06-09|2011-06-10|Estimate|2017-09-27|2017-10-02|Actual||||2018-01-16|2018-01-18|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|IVKetamine||Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder|Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder|Terminated||Phase 1/Phase 2|3|Actual|Baylor College of Medicine|Early termination due to limited funding lead to small numbers of subjects analyzed (n=3) compared to what was planned (n=12).|2||no funding|f||||t|t|f||||||||2018-05-31 22:31:46.674078|2018-05-31 22:31:46.674078
NCT01371097|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2015-03-09|2011-06-09|2011-06-10|Estimate|||||||2015-03-09|2015-03-11|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|B15||Progressive Resistance Strength Training (PRT) in Hospitalised Elderly Patients|The Effect of Progressive Resistance Strength Training in Hospitalised Elderly Patients|Completed||N/A|71|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 22:31:47.550035|2018-05-31 22:31:47.550035
NCT01371084|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2014-01-16|2011-06-09|2011-06-10|Estimate|||||||2014-01-16|2014-01-17|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|Pedal@Work||Pedal@Work: A Worksite Wellness Program|Pilot Study to Test the Efficacy of a Worksite Intervention for Reducing Daily Sedentary Time and Improving Risk Factors for Cardiometabolic Disease Among Sedentary, Overweight, Full-time Working Adults|Completed||N/A|40|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 22:31:47.704233|2018-05-31 22:31:47.704233
NCT01371071|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CIS-COHORT||Cohort Study of Clinically Isolated Syndrome and Early Multiple Sclerosis|Clinically Isolated Syndrome and Newly Diagnosed Multiple Sclerosis: Diagnostic, Prognostic and Therapy - Response Markers - a Prospective Observational Study (Berlin CIS-COHORT)|Unknown status|Recruiting||200|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||Samples With DNA|"~     blood samples (serum and plasma, with DNA), urine, saliva, CSF (if routine lumbar puncture~     was performed, no additional lumbar punctures for the study)~   "|||2018-05-31 22:31:47.805409|2018-05-31 22:31:47.805409
NCT01371058|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-12-15|2011-06-09|2011-06-10|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|spirit||Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI)|Study of Policosanol to Improve High on Clopidogrel Platelet Reactivity After Percutaneous Coronary Stent Implantation(Spirit)|Completed||Phase 4|350|Actual|Shenyang Northern Hospital||3|||f||||t||||||||||2018-05-31 22:31:47.977643|2018-05-31 22:31:47.977643
NCT01371045|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|June 2011||2011-06-30|June 2011|2011-06-30||||||||Observational|||Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs|Hormonal and Metabolic Responses to Oral Glucose During Somatostatin Analog Use|Unknown status|Recruiting||36|Anticipated|Cedars-Sinai Medical Center|||3||f||||f||||||Samples With DNA|"~     Blood will be drawn (approx. 64cc) to gather baseline hormone and metabolic panels. Blood~     will again be collected (approx. 36cc) during the Oral Glucose Tolerance Test.~   "|||2018-05-31 22:31:48.132619|2018-05-31 22:31:48.132619
NCT01371032|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2018-04-03|2011-06-09|2011-06-10|Estimate|||||||2018-04-03|2018-04-04|Actual|June 2011||2011-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Study: Study to Compare Video Miller Device to Direct Laryngoscopy|A Randomized, Prospective Study to Compare the Video Miller Device to Direct Laryngoscopy Using a Standard Pediatric Miller Blade for Tracheal Intubation of Children < 3 Years of Age Undergoing General Anesthesia|Enrolling by invitation||N/A|120|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|f||||||||2018-05-31 22:31:48.27725|2018-05-31 22:31:48.27725
NCT01371019|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2015-06-09|2011-06-08|2011-06-10|Estimate|||||||2015-06-09|2015-06-11|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Observational|PAPR||Proteomic Assessment of Preterm Birth|Proteomic Assessment of Preterm Birth|Completed|||5500|Actual|Sera Prognostics, Inc.|||2||f||||t||||||Samples Without DNA|"~     Serum, plasma~   "|||2018-05-31 22:31:48.363375|2018-05-31 22:31:48.363375
NCT01371006|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|2015-07-03||2015-07-03|2011-06-09|2011-06-10|Estimate|2015-07-03|2015-08-03|Estimate||||2015-07-03|2015-08-03|Estimate|June 2011||2011-06-30|July 2015|2015-07-31||||September 2011|Actual|2011-09-30||Interventional|||Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers|Effect of Multiple Dosing With 240mg q 12hrs BI 201335 on the Pharmacokinetics of 50 mg Single Dose Efavirenz and Effect of Multiple Dosing With 600mg QD Efavirenz on Cyp 3A4 and the Pharmacokinetics of BI 201335 in Healthy Volunteers|Completed||Phase 1|29|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:31:48.565043|2018-05-31 22:31:48.565043
NCT01370993|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||The Prediction Model of Hypoxemia for Safe Bronchoscopy|The Prediction Model of Hypoxemia for Safe Bronchoscopy Under MAC Anesthesia|Unknown status|Recruiting||150|Anticipated|Seoul National University Bundang Hospital|||||f||||t||||||||||2018-05-31 22:31:49.660149|2018-05-31 22:31:49.660149
NCT01370980|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2012-07-16|2011-06-09|2011-06-10|Estimate|||||||2012-07-16|2012-07-17|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|September 2014|Anticipated|2014-09-30|December 2011|Actual|2011-12-31||Observational|||Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment|Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment|Unknown status|Recruiting||80|Anticipated|Policlinique Médicale Universitaire|||1||f||||f||||||||||2018-05-31 22:31:49.772608|2018-05-31 22:31:49.772608
NCT01370967|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-12-23|2011-06-08|2011-06-10|Estimate|||||||2013-12-23|2013-12-24|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Gastrointestinal Tolerance And General Health Status Of Healthy Term Infants Fed A New Infant Formula|Gastrointestinal Tolerance And General Health Status Of Healthy Term Infants Fed A New Infant Formula: A Prospective, Observational Cohort Study In China|Completed|||460|Actual|Nestlé|||3||f||||f||||||||||2018-05-31 22:31:49.840476|2018-05-31 22:31:49.840476
NCT01370954|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-05-07|2011-06-08|2011-06-10|Estimate|||||||2013-05-07|2013-05-09|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)|NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)|Completed|||204|Actual|Pamlab, Inc.|||1||f||||f||||||||||2018-05-31 22:31:49.971868|2018-05-31 22:31:49.971868
NCT01370941|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2012-03-20|2011-06-09|2011-06-10|Estimate|||||||2012-03-20|2012-03-21|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Chymosin||The Effect of Chymosin on the Intestinal Absorption of Calcium|The Effect of Chymosin on the Intestinal Absorption of Calcium: A Randomized Controlled Cross-over Trial|Completed||Phase 1|125|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 22:31:50.092688|2018-05-31 22:31:50.092688
NCT01370928|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-04-26|2011-06-09|2011-06-10|Estimate|||||||2012-04-26|2012-04-27|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Colonoscopy Screening Using a Novel Slim Colonoscope - a Randomized Controlled Trial|Colonoscopy Screening Using a Novel Slim Colonoscope - a Randomized Controlled Trial|Completed||Phase 3|190|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-05-31 22:31:50.207914|2018-05-31 22:31:50.207914
NCT01370915|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Perioperative Administration of Pregabalin for Pain After Septoplasty|Perioperative Administration of Pregabalin for Pain After Septoplasty|Unknown status|Recruiting|N/A|100|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 22:31:50.37529|2018-05-31 22:31:50.37529
NCT01370902|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-12-20|2011-06-09|2011-06-10|Estimate|||||||2014-12-20|2014-12-23|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Single-dose and Multiple-dose, Dose-escalation Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis|Completed||Phase 1|92|Actual|Innate Pharma||3|||f||||f||||||||||2018-05-31 22:31:50.532968|2018-05-31 22:31:50.532968
NCT01370889|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-10-08|2011-06-09|2011-06-10|Estimate|||||||2014-10-08|2014-10-09|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Resveratrol in Postmenopausal Women With High Body Mass Index|Pilot Study of Resveratrol in Postmenopausal Women With High Body Mass Index|Completed||Phase 1|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:31:50.674738|2018-05-31 22:31:50.674738
NCT01370876|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2013-12-09|2011-06-09|2011-06-10|Estimate|||||||2013-12-09|2013-12-10|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Trial Evaluating Efficacy and Safety of Opatin® (Oxaliplatin)/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer|Terminated||Phase 2|46|Anticipated|Nang Kuang Pharmaceutical Co., Ltd.||1||company policy|f||||t||||||||||2018-05-31 22:31:50.772265|2018-05-31 22:31:50.772265
NCT01370863|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2013-04-15||2014-06-25|2011-06-09|2011-06-10|Estimate|2013-04-22|2013-06-07|Estimate||||2014-06-25|2014-07-11|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||The Safety Population was used defined as all subjects randomized into the study with at least 1 administration of the investigational product. Two subjects never received investigational product (n = 65).|An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients|An Explorative, Randomized, Placebo-controlled, DB, Parallel-group Trial, to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Subjects With GERD & With Persistent Symptoms Despite Taking a Stable Dose of PPIs|Terminated||Phase 2|67|Actual|Shire|Results data should be interpreted with caution since the study’s early termination affects the statistical power to detect true differences between treatment groups.|2||This study was terminated early due to recruitment difficulties. There were no safety concerns.|f||||f||||||||||2018-05-31 22:31:50.904155|2018-05-31 22:31:50.904155
NCT01370850|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Clinical Validation Study of RTVue Features|Clinical Validation Study of RTVue Features|Completed|||53|Actual|Optovue|||3||f||||f||||||||||2018-05-31 22:31:51.388766|2018-05-31 22:31:51.388766
NCT01323023|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2015-09-30|2011-03-23|2011-03-25|Estimate|||||||2015-09-30|2015-10-01|Estimate|June 2005||2005-06-30|September 2015|2015-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||A Study to Examine Health Behavior Change Strategies for Primary Care|Common Measures, Better Outcomes (COMBO)|Completed|||4463|Actual|University of Colorado, Denver|||||f||||||||||||||2018-05-31 22:45:38.395856|2018-05-31 22:45:38.395856
NCT01370824|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-05-16|2011-06-09|2011-06-10|Estimate|||||||2013-05-16|2013-05-17|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Clinical Diagnosis of Basal Cell Carcinoma Subtype|Clinical Diagnosis Versus Histological Diagnosis by Punch Biopsy to Determine the Subtype of Basal Cell Carcinoma|Completed|||150|Actual|Maastricht University Medical Center|||1||f||||f||||||Samples Without DNA|"~     A punch biopsy and surgical excision of the BCC will be performed. Both biospecimens will be~     prepared with either frozen section histology, or paraffin embedded fixed tissue pathology.~   "|||2018-05-31 22:31:51.912557|2018-05-31 22:31:51.912557
NCT01370811|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-06-14|2011-06-08|2011-06-10|Estimate|||||||2013-06-14|2013-06-17|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease|A Phase II, Double-blind, Randomized, Placebo-controlled 4-way Crossover Study to Evaluate the Relative Efficacy and Safety of OC Oral Solution (Oxybutynin and Clonidine) for Sialorrhoea in Patients With Parkinson's Disease|Completed||Phase 2|24|Actual|Orient Pharma Co., Ltd.||4|||f||||f||||||||||2018-05-31 22:31:52.024175|2018-05-31 22:31:52.024175
NCT01370798|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-02-23|2011-06-09|2011-06-10|Estimate|||||||2018-02-23|2018-02-26|Actual|May 26, 2011|Actual|2011-05-26|October 2017|2017-10-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|HYPOSPADES||Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications|Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications.|Completed||Phase 3|244|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 22:31:52.128044|2018-05-31 22:31:52.128044
NCT01370785|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:31:52.227711|2018-05-31 22:31:52.227711
NCT01370772|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2016-03-15|2011-06-09|2011-06-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|September 2014|Actual|2014-09-30||Interventional|||Intensified Rituimab Prephase Before FCR in Untreated B-CLL|Phase II Multicentric, Randomized Trial, Exploring Intensified Rituximab Prephase Monotherapy Before Standard Fludarabine-Cyclophosphamide-Rituximab Regimen in Previously Untreated Symptomatic B-cell Chronic Lymphocytic Leukemia|Completed||Phase 2|140|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||No||2018-05-31 22:31:52.282064|2018-05-31 22:31:52.282064
NCT01370759|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-09|||2014-04-09|2011-06-09|2011-06-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|RD-400||Feasibility Study to Evaluate the Performance of Flocculation-Adsorption System for Colon Cleansing Enhancement|Flocculation-Adsorption System for Colon Cleansing Enhancement: A Feasibility Study|Terminated||Phase 1|81|Actual|Given Imaging Ltd.||1||Terminated due to sponsor desicioun|f||||f||||||||||2018-05-31 22:31:52.435512|2018-05-31 22:31:52.435512
NCT01370746|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2017-06-01|2011-06-08|2011-06-10|Estimate|||||||2017-06-01|2017-06-05|Actual|April 2012||2012-04-30|June 2017|2017-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation|Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation (CTOTC-05)|Completed|||502|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||||||2018-05-31 22:31:52.561835|2018-05-31 22:31:52.561835
NCT01370733|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2015-06-02||2015-10-05|2011-06-09|2011-06-10|Estimate|2015-06-18|2015-07-14|Estimate||||2015-10-05|2015-10-26|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|NEST-MDD||Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder|Evaluation of Low Emission NeoSync EEG Synchronized TMS Technology for the Treatment of Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Sham-Controlled, Trial|Completed||Phase 3|202|Actual|NeoSync, Inc.||2|||f||||f||||||||||2018-05-31 22:31:52.757791|2018-05-31 22:31:52.757791
NCT01370720|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-06-16|2011-06-09|2011-06-10|Estimate|||||||2012-06-16|2012-06-19|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|CMD-IBS09(2)||Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients|Effect of the Oral Administration in IBS Patients of the Association of 200 mg Micronised Palmitoylethanolamide (PEA) and 20 mg Polydatin, on Parameters of Intestinal Inflammation and Visceral Hyperalgesia.|Unknown status|Recruiting|Phase 2|60|Anticipated|CM&D Pharma Limited||2|||f||||f||||||||||2018-05-31 22:31:53.766619|2018-05-31 22:31:53.766619
NCT01370707|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2013-02-13|2011-06-09|2011-06-10|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients|A Randomized, Double-blind, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Patients With Type 2 Diabetes and Inadequate Glycemic Control ; Phase III Study|Completed||Phase 3|187|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 22:31:53.956696|2018-05-31 22:31:53.956696
NCT01370694|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2015-10-23||2017-06-06|2011-06-09|2011-06-10|Estimate|2015-10-23|2015-11-25|Estimate||||2017-06-06|2017-07-07|Actual|August 19, 2011|Actual|2011-08-19|June 2017|2017-06-30|December 1, 2014|Actual|2014-12-01|December 1, 2014|Actual|2014-12-01||Interventional|||Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)|An Open-Label, Single Arm Study of MK-8808 in Patients With Advanced CD20-Positive Follicular Lymphoma|Terminated||Phase 1|7|Actual|Merck Sharp & Dohme Corp.|The study was terminated for business reasons. Not all planned analyses were performed|1||The study was terminated for business reasons.|f||||f||||||||||2018-05-31 22:31:54.296145|2018-05-31 22:31:54.296145
NCT01370681|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Pharmacokinetic Study of CJ30001 and HKB0701/SLM0807 in Healthy Subject|An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetics After Administration of CJ30001 and Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects|Completed||Phase 1|30|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 22:31:54.864763|2018-05-31 22:31:54.864763
NCT01370668|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Functional Remediation for Bipolar Disorder|Comparative Efficacy of Two Psychosocial Strategies of Intervention (Neurocognitive vs Psychoeducative) as add-on Therapy Versus Treatment as Usual in Bipolar Disorder|Completed||N/A|198|Actual|Centro de Investigación Biomédica en Red de Salud Mental||3|||f||||f||||||||||2018-05-31 22:31:54.92158|2018-05-31 22:31:54.92158
NCT01370655|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2017-02-17||2017-04-17|2011-06-08|2011-06-10|Estimate|2017-02-17|2017-04-04|Actual||||2017-04-17|2017-05-18|Actual|June 2011||2011-06-30|April 2017|2017-04-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)|A Phase Ib, Randomized, Double-Blind, 4-Treatment, 2-Period Incomplete Block Study to Evaluate the Multiple Dose Effects of MK-7145 and Hydrochlorothiazide Compared to Placebo on Blood Pressure in Male Patients With Hypertension|Completed||Phase 1|46|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 22:31:55.005128|2018-05-31 22:31:55.005128
NCT01370642|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2014-09-26||2017-03-03|2011-06-09|2011-06-10|Estimate|2014-09-26|2014-10-06|Estimate||||2017-03-03|2017-03-31|Actual|June 2011||2011-06-30|March 2017|2017-03-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)|A Phase III Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Treatment-Naïve Patients With Chronic Hepatitis C Infection|Completed||Phase 3|294|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 22:31:56.391192|2018-05-31 22:31:56.391192
NCT01370629|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-05-09|2011-06-09|2011-06-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2011||2011-08-31|May 2018|2018-05-31|May 8, 2018|Actual|2018-05-08|April 5, 2018|Actual|2018-04-05||Observational|||Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)|A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate|Completed|||2013|Actual|Cardiome Pharma|||1||f||||t||||||||||2018-05-31 22:31:57.705589|2018-05-31 22:31:57.705589
NCT01370616|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2014-11-24||2017-02-17|2011-06-09|2011-06-10|Estimate|2014-11-24|2014-12-02|Estimate||||2017-02-17|2017-03-22|Actual|September 2011||2011-09-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All Randomized Participants|Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults|Completed||Phase 3|565|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:31:57.864908|2018-05-31 22:31:57.864908
NCT01370603|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2013-05-21||2015-01-21|2011-06-08|2011-06-10|Estimate|2013-05-21|2013-07-10|Estimate||||2015-01-21|2015-02-02|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)|A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy of Ezetimibe/Atorvastatin 10 mg/40 mg Fixed-Dose Combination Tablet Compared to Co-Administration of Marketed Ezetimibe 10 mg and Atorvastatin 40 mg in Patients With Primary Hypercholesterolemia|Completed||Phase 3|328|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:31:58.362701|2018-05-31 22:31:58.362701
NCT01370590|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2013-05-17||2015-01-21|2011-06-08|2011-06-10|Estimate|2013-05-17|2013-08-05|Estimate||||2015-01-21|2015-02-02|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)|A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin 10 mg/20 mg Fixed-Dose Combination Tablet Compared to Co-administration of Marketed Ezetimibe 10 mg and Atorvastatin 20 mg in Patients With Primary Hypercholesterolemia|Completed||Phase 3|406|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:31:59.485432|2018-05-31 22:31:59.485432
NCT01370577|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-01-11|2011-06-09|2011-06-10|Estimate|||||||2013-01-11|2013-01-14|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|Prelude||The Predictors for Asthma Control by Stepwise Treatment During 6 Months in Korean Elderly|The Predictors for Asthma Control by Stepwise Treatment During 6 Months in Korean Elderly|Completed|||297|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:32:00.123995|2018-05-31 22:32:00.123995
NCT01370564|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-12-02|2011-06-09|2011-06-10|Estimate|||||||2011-12-02|2011-12-05|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|IPC||Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures|Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures|Unknown status|Active, not recruiting|Phase 2|21|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 22:32:01.675107|2018-05-31 22:32:01.675107
NCT01370551|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2012-08-21|2011-06-08|2011-06-10|Estimate|||||||2012-08-21|2012-08-22|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Gynoflor||Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients|A Clinical Study of Pharmacokinetics, Efficacy and Safety of Vaginal Application of Lyophilised Lactobacilli and 0.03 mg Estriol (Gynoflor®) on Atrophic Vaginitis in Postmenopausal Breast Cancer Patients Treated With Aromatase Inhibitors|Completed||Phase 1|16|Actual|Medinova AG||1|||f||||f||||||||||2018-05-31 22:32:01.937899|2018-05-31 22:32:01.937899
NCT01370538|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2012-10-19||2013-03-01|2011-06-09|2011-06-10|Estimate|2013-03-01|2013-04-11|Estimate||||2013-03-01|2013-04-11|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|NEXT2||Efficacy of Esomeprazole in Patients With Frequent Heartburn|A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Esomeprazole 20 mg Once Daily in Subjects With Frequent Heartburn|Completed||Phase 3|341|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:32:02.152754|2018-05-31 22:32:02.152754
NCT01370525|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2012-10-19||2013-02-12|2011-06-09|2011-06-10|Estimate|2013-02-12|2013-03-14|Estimate||||2013-02-12|2013-03-14|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|NEXT1||Efficacy of Esomeprazole in Patients With Frequent Heartburn|A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Esomeprazole 20 mg Once Daily in Subjects With Frequent Heartburn|Completed||Phase 3|340|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:32:02.802127|2018-05-31 22:32:02.802127
NCT01370499|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08||2014-04-14|2014-04-14|2011-06-08|2011-06-10|Estimate||||2014-04-14|2014-05-06|Estimate|2014-04-14|2014-05-06|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of LY2216684 in Patients With Major Depression Disorder|Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients With Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment|Completed||Phase 3|237|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:32:03.642593|2018-05-31 22:32:03.642593
NCT01370486|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects|Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects|Unknown status|Not yet recruiting|Phase 4|6|Anticipated|Institution de Lavigny||2|||f||||f||||||||||2018-05-31 22:32:03.786422|2018-05-31 22:32:03.786422
NCT01370473|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2015-03-19|2011-06-09|2011-06-10|Estimate|||||||2015-03-19|2015-03-20|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|Hyponatremia||Institutional Registry of Hyponatremia|Institutional Registry of Hyponatremia|Completed|||2000|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 22:32:03.907775|2018-05-31 22:32:03.907775
NCT01370460|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2013-03-27||2013-07-03|2011-06-08|2011-06-10|Estimate|2013-07-03|2013-07-09|Estimate||||2013-07-03|2013-07-09|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty|Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty|Completed||Phase 2|101|Actual|Henry Ford Health System|Blood loss was calculated taking change in hemoglobin as described (units g/dL) and converting to blood loss (mL) according to the formulas includes in the papers cited in this entry (Good 2003 Br J Anesthesia; Nadler 1962 Surgery).|2|||f||||f||||||||||2018-05-31 22:32:04.005914|2018-05-31 22:32:04.005914
NCT01370447|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2016-03-18|2011-06-09|2011-06-10|Estimate|||||||2016-03-18|2016-03-21|Estimate|February 2010||2010-02-28|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||EPI-743 for Mitochondrial Respiratory Chain Diseases|Emergency Use Protocol for EPI-743 in Acutely Ill Patients With Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-Life Care|Unknown status|Active, not recruiting|Phase 2|87|Actual|Edison Pharmaceuticals Inc||1|||f||||f||||||||||2018-05-31 22:32:04.291309|2018-05-31 22:32:04.291309
NCT01370434|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-06-09|2011-06-09|2011-06-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|PADinMM||Two Cycles of PAD Combination by AHCT in MM|Two Cycles of Pad Combination (Ps-341/Bortezomib, Adriamycin, and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients|Completed||Phase 2|43|Actual|Cooperative Study Group A for Hematology||1|||f||||t||||||||||2018-05-31 22:32:04.383817|2018-05-31 22:32:04.383817
NCT01370421|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-04-02|2011-06-08|2011-06-10|Estimate|||||||2014-04-02|2014-04-03|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Observational|POKR||Prediction of Outcomes Following Total Knee Replacement|Prediction of Outcomes Following Total Knee Replacement|Unknown status|Recruiting||200|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||Samples With DNA|"~     saliva and blood~   "|||2018-05-31 22:32:04.459229|2018-05-31 22:32:04.459229
NCT01370408|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2016-10-06||2017-03-16|2011-06-08|2011-06-09|Estimate|2016-12-12|2017-02-06|Estimate||||2017-03-16|2017-04-17|Actual|February 2012||2012-02-29|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients|A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy|Completed||Phase 2|85|Actual|Northside Hospital, Inc.||1|||f||||f||||||||No||2018-05-31 22:32:04.568088|2018-05-31 22:32:04.568088
NCT01370395|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-09-28|2011-06-08|2011-06-09|Estimate|||||||2012-09-28|2012-10-01|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|BOSCH1||Assessment of Biomarkers for Diagnosis in Geriatric Patients|Assessment of Biomarkers for Diagnosis in Geriatric Patients With the Symptom of Chest Pain in the Emergency Room|Unknown status|Active, not recruiting||250|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma blood samples~   "|||2018-05-31 22:32:05.085823|2018-05-31 22:32:05.085823
NCT01370382|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-04-16|2011-06-08|2011-06-09|Estimate|||||||2013-04-16|2013-04-17|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|BOSCH2||Comparison Between the New Highly Sensitive Troponin T and the Conventional Troponin T Test in Elderly Patients|Comparison Between the New Highly Sensitive Troponin T and the Conventional Troponin T Test of the 4th Generation for the Early Identification of Myocardial Necrosis in Elderly Patients With Acute Coronary Syndromes Without ST-segment Elevation|Completed|||180|Actual|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma blood samples~   "|||2018-05-31 22:32:05.188618|2018-05-31 22:32:05.188618
NCT01370369|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2017-06-29|2012-07-16|2017-08-15|2011-06-08|2011-06-09|Estimate|2017-06-29|2017-08-01|Actual|2012-07-16|2012-07-25|Estimate|2017-08-15|2017-09-13|Actual|May 2011||2011-05-31|August 2017|2017-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||The data are presented for Intent-to-treat (ITT) population, which comprised of all subjects who received at least one dose of the Investigational Medicinal Product (IMP). In this study, the safety, ITT, full analysis set (FAS) and per protocol (PP) populations were identical.|Efficacy, Pharmacokinetics and Safety of Testosterone|A Phase 2 Open-Label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes (1.25, 2.50 and 3.75 mL) of Testosterone Gel 2% (FE 999303) Equivalent to 23, 46 And 70 mg of Testosterone in Hypogonadal Males|Completed||Phase 2|20|Actual|Ferring Pharmaceuticals||6|||f||||f||||||||||2018-05-31 22:32:05.329297|2018-05-31 22:32:05.329297
NCT01370356|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2014-07-02||2014-08-29|2011-06-08|2011-06-09|Estimate|2014-08-29|2014-09-01|Estimate||||2014-08-29|2014-09-01|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction|A Phase 4, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction|Completed||Phase 4|1510|Actual|Pfizer|Two cases of fetal exposure during pregnancy occurred but are not included in the SAE section as they did not meet the criteria of serious in the safety database. One of them relates to a non-study participant who was the study participant`s partner.|2|||f||||t||||||||||2018-05-31 22:32:07.299721|2018-05-31 22:32:07.299721
NCT01370343|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-09-03|2011-06-08|2011-06-09|Estimate|||||||2011-09-03|2011-09-07|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Single Dose Study Of The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Health Volunteers|A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:32:08.514062|2018-05-31 22:32:08.514062
NCT01370330|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2017-11-07|2011-06-06|2011-06-09|Estimate|||||||2017-11-07|2017-11-09|Actual||||November 2017|2017-11-30||||||||Expanded Access|||131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol|131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol|Available|||||University of California, San Francisco|||||||||||||||||||2018-05-31 22:32:08.654637|2018-05-31 22:32:08.654637
NCT01370317|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2016-01-19|2011-06-08|2011-06-09|Estimate|||||||2016-01-19|2016-01-20|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma|Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma|Completed||Phase 1|27|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:32:08.749824|2018-05-31 22:32:08.749824
NCT01370304|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-02-13|2011-06-08|2011-06-09|Estimate|||||||2012-02-13|2012-02-15|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation Compared or Associated With Venlafaxine for Depressive Disorder|Repetitive Transcranial Magnetic Stimulation (rTMS) Compared or Associated With Venlafaxine for Depressive Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study|Unknown status|Recruiting|Phase 3|60|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 22:32:08.833179|2018-05-31 22:32:08.833179
NCT01370291|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-02-13|2011-06-08|2011-06-09|Estimate|||||||2012-02-13|2012-02-15|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|rTMSfMRI||Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients|Repetitive Transcranial Magnetic Stimulation (rTMS) for First-episode Schizophrenia Patients:A Double-blinded , Randomized and Functional Magnetic Resonance Imaging (fMRI)Study|Unknown status|Recruiting|Phase 3|60|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 22:32:09.041499|2018-05-31 22:32:09.041499
NCT01370278|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-02-28|2011-06-08|2011-06-09|Estimate|||||||2018-02-28|2018-03-02|Actual|June 16, 2011|Actual|2011-06-16|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Clearance Of Mucus In Stents (COMIS)|Clearance Of Mucus In Stents (COMIS)|Active, not recruiting||N/A|43|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 22:32:09.211445|2018-05-31 22:32:09.211445
NCT01370265|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2012-10-06||2013-09-03|2011-06-08|2011-06-09|Estimate|2013-09-03|2013-09-05|Estimate||||2013-09-03|2013-09-05|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress|Quantification of Myocardial Blood Flow by Positron Emission Tomography and N-13 Ammonia During Regadenoson vs Adenosine Stress|Completed||N/A|12|Actual|Mayo Clinic|Small sample size; Subjects had no evidence of overt coronary artery disease, occult coronary artery disease affecting stress drug induced hyperemic PET MBF is a possibility; however, hyperemic MBF with both stress drugs would be equally affected.|2|||f||||f||||||||||2018-05-31 22:32:09.336321|2018-05-31 22:32:09.336321
NCT01370252|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-08|2011-06-08|2011-06-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|June 2011||2011-06-30|June 2011|2011-06-30||||||||Observational|||Arthroscopic Ankle Arthrodesis: Measuring Post-operative Pain to Assess the Potential for Outpatient Surgery.|Arthroscopic Ankle Arthrodesis: Measuring Post-operative Pain to Assess the Potential for Outpatient Surgery.|Unknown status|Recruiting||40|Anticipated|Hammond, Allan, M.D.|||2||f||||f||||||||||2018-05-31 22:32:09.897667|2018-05-31 22:32:09.897667
NCT01370239|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2018-04-17|2011-06-08|2011-06-09|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2013||2013-11-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2015|Actual|2015-10-31||Interventional|||HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy|A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy|Suspended||Phase 2|60|Anticipated|Instituto do Cancer do Estado de São Paulo||1||futility|f||||t||||||||||2018-05-31 22:32:09.997196|2018-05-31 22:32:09.997196
NCT01370226|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2016-04-06|2011-06-08|2011-06-09|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Health Explorer - Optimizing Alcohol Brief Interventions|Optimizing Alcohol Brief Interventions in the ED: Computer vs. Clinician Delivery|Completed||N/A|750|Actual|University of Michigan||3|||f||||f||||||||No||2018-05-31 22:32:10.103596|2018-05-31 22:32:10.103596
NCT01370213|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2016-03-24|2011-06-08|2011-06-09|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases|Multi-Center Phase II Trial of NK Cell Based Non-Myeloablative Haploidentical Transplantation for Patients With High-Risk Acute Myeloid Diseases|Active, not recruiting||Phase 2|25|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 22:32:10.186766|2018-05-31 22:32:10.186766
NCT01370200|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2015-05-26|2011-06-08|2011-06-09|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Regional Citrate Anticoagulation in Plasma Exchange Treatment|Regional Citrate Anticoagulation in Plasma Exchange Treatment|Completed||N/A|140|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 22:32:10.325831|2018-05-31 22:32:10.325831
NCT01370187|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-13|2011-06-08|2011-06-09|Estimate|||||||2011-06-13|2011-06-14|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing|Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing in Infants 3 to 12 Months of Age in Bandar Abbas Children' Hospital|Completed||N/A|146|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:32:10.474402|2018-05-31 22:32:10.474402
NCT01370174|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2017-08-09|2011-06-08|2011-06-09|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2011||2011-07-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|December 9, 2016|Actual|2016-12-09||Interventional|LIFT||Intervention to Enhance Lateral Balance Function and Prevent Falls in Aging|Intervention to Enhance Lateral Balance Function and Prevent Falls in Aging|Active, not recruiting||N/A|100|Anticipated|University of Maryland||4|||f||||t||||||||||2018-05-31 22:32:10.76357|2018-05-31 22:32:10.76357
NCT01370161|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2018-02-08|2011-06-08|2011-06-09|Estimate|||||||2018-02-08|2018-02-09|Actual|July 2011||2011-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for High Risk Acute Variceal Bleeding in Cirrhotic Patients|Early Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene Covered Stents Versus Standard Medical Therapy for High Risk Acute Variceal Bleeding in Cirrhotic Patients|Recruiting||N/A|120|Anticipated|Fourth Military Medical University||2|||f||||||||||||||2018-05-31 22:32:10.870093|2018-05-31 22:32:10.870093
NCT01370148|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2014-04-30|2011-06-08|2011-06-09|Estimate|||||||2014-04-30|2014-05-02|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan|A Phase 1, Open-Label Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan|Completed||Phase 1|17|Actual|Cumberland Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:32:10.989361|2018-05-31 22:32:10.989361
NCT01370135|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2013-01-15|2011-06-08|2011-06-09|Estimate|||||||2013-01-15|2013-01-16|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|LucNVG0108||Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma|An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma|Completed||N/A|20|Actual|University of Luebeck||1|||f||||t||||||||||2018-05-31 22:32:11.10031|2018-05-31 22:32:11.10031
NCT01370122|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2016-07-18|2011-06-08|2011-06-09|Estimate|||||||2016-07-18|2016-07-20|Estimate|May 2011||2011-05-31|July 2016|2016-07-31||||October 2012|Actual|2012-10-31||Observational|||Pelvic Floor Disorders in Survivors of Gynecologic Malignancies|The Prevalence and Predictive Factors of Pelvic Floor Disorders in Gynecologic Malignancy Survivors|Active, not recruiting|||225|Actual|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 22:32:11.205543|2018-05-31 22:32:11.205543
NCT01370109|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2016-12-06|2011-06-08|2011-06-09|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2011||2011-04-30|December 2016|2016-12-31||||April 2017|Anticipated|2017-04-30||Observational|||Cardiovascular Effects of Sunitinib Therapy (CREST)|The Cardiovascular Effects of Sunitinib Therapy: Off Target Changes in Cardiac Metabolism and Ventricular Vascular Mechanics (CREST)|Recruiting|||20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||4||f||||t||||||||||2018-05-31 22:32:11.278667|2018-05-31 22:32:11.278667
NCT01370096|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2016-10-24|2011-06-08|2011-06-09|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension|Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension|Terminated||Phase 2|3|Actual|University of Alberta||||Difficulty with patient recruitment|f||||t||||||||No||2018-05-31 22:32:11.388417|2018-05-31 22:32:11.388417
NCT01370083|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2015-11-24||2016-01-14|2011-06-08|2011-06-09|Estimate|2015-11-24|2015-12-30|Estimate||||2016-01-14|2016-02-08|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TPPT|Individuals with dysphagia following stroke (within 4-16 weeks post onset) with radiographically confirmed difficulties with thin liquid bolus control.|Tongue Pressure Profile Training for Dysphagia Post Stroke|Tongue Pressure Profile Training for Dysphagia Post Stroke|Completed||Phase 2|14|Actual|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-05-31 22:32:11.476367|2018-05-31 22:32:11.476367
NCT01370070|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-01-11|2011-06-08|2011-06-09|Estimate|||||||2017-01-11|2017-01-13|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|MC1079||MK-2206 in Recurrent Nasopharyngeal Carcinoma|Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|12|Actual|Chinese University of Hong Kong||1|||f||||||||||||||2018-05-31 22:32:11.880348|2018-05-31 22:32:11.880348
NCT01370057|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2017-07-18|2011-06-08|2011-06-09|Estimate|||||||2017-07-18|2017-07-21|Actual|May 2011||2011-05-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||The Use of Thoraco-lumbo-sacral Orthoses (TLSOs) in the Treatment of Adolescent Idiopathic Scoliosis (AIS)|The Use of TLSOs in the Treatment of Adolescent Idiopathic Scoliosis: A Prospective, Randomized Controlled Study|Terminated||N/A|2|Actual|Chinese University of Hong Kong||2||Failure of Subject Recruitment|f||||f||||||||||2018-05-31 22:32:11.974991|2018-05-31 22:32:11.974991
NCT01370044|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-01-24|2011-06-08|2011-06-09|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2012||2012-08-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CARDIF||Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures|Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures|Terminated||Phase 2/Phase 3|96|Actual|Charite University, Berlin, Germany||2||results of interim analysis (not safety relevant)|f||||||||||||||2018-05-31 22:32:12.037062|2018-05-31 22:32:12.037062
NCT01370031|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2017-03-28|2011-06-08|2011-06-09|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2011||2011-04-30|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Pilot Pharmacokinetic Clenil Study With AeroChamber Plus™ or Volumatic™ Spacer Devices|Pilot, Open-Label, Randomized, Repeated Dose, 4-Way Cross-Over, Clinical Pharmacology Study of Beclomethasone Dipropionate (Clenil® Modulite®) 250 µg HFA pMDI Using the Aerochamber Plus™ Spacer Device Versus the Volumatic™ Spacer Device Without or With Charcoal Block in Asthmatic Adults Patients|Completed||Phase 2|16|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-05-31 22:32:12.1051|2018-05-31 22:32:12.1051
NCT01370018|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-08|2011-06-08|2011-06-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Therapy to Elevate CD4 Counts in HIV-1 Disease|Zemaira (Alpha-1-Proteinase Inhibitor) Therapy in HIV-1 Disease|Completed||N/A|4|Actual|Cabrini Medical Centre||1|||f||||f||||||||||2018-05-31 22:32:12.290126|2018-05-31 22:32:12.290126
NCT01370005|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2014-05-16||2016-01-22|2011-06-08|2011-06-09|Estimate|2014-05-16|2014-06-17|Estimate||||2016-01-22|2016-02-22|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Full analysis set (FAS) included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h SBP value. Treatment assignment as randomized|12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|825|Actual|Boehringer Ingelheim||3|||f||||||||||||Yes|Boehringer Ingelheim Policy on Transparency and Publication http://trials.boehringer-ingelheim.com/transparency_policy.html|2018-05-31 22:32:12.507931|2018-05-31 22:32:12.507931
NCT01369992|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2011-06-08|2011-06-08|2011-06-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|May 2013|Anticipated|2013-05-31|||||Observational|||Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites|Molecular Profiling of Metastatic Cancer in Pleural Effusion and Ascites|Unknown status|Active, not recruiting||20|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:32:13.592383|2018-05-31 22:32:13.592383
NCT01369979|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2012-06-25|2011-06-08|2011-06-09|Estimate|||||||2012-06-25|2012-06-26|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Hepatic Sugar Metabolism Measured by PET/CT in Patients and Healthy Subjects|Hepatic Glucose Metabolism Measured by FDG PET/CT in Patients With Liver Disease and Healthy Subjects|Completed|||13|Actual|University of Aarhus|||2||f||||f||||||Samples Without DNA|"~     Plasma for measuring levels of ICG, insulin, c.peptide, FFA, glucagon,and 3H-glucose.~   "|||2018-05-31 22:32:13.656849|2018-05-31 22:32:13.656849
NCT01369966|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-04-04|2011-06-08|2011-06-09|Estimate|||||||2018-04-04|2018-04-05|Actual|May 16, 2011||2011-05-16|December 24, 2014|2014-12-24|December 24, 2014||2014-12-24|||||Observational|||Brain Circuits in Schizophrenia and Smoking|Brain Circuits in Schizophrenia and Smoking|Completed|||42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:32:13.738289|2018-05-31 22:32:13.738289
NCT01369953|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-04-04|2011-06-08|2011-06-09|Estimate|||||||2018-04-04|2018-04-05|Actual|May 29, 2011||2011-05-29|January 31, 2014|2014-01-31|January 31, 2014||2014-01-31|||||Observational|||Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants|Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:32:13.822452|2018-05-31 22:32:13.822452
NCT01369940|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2017-09-01|2011-06-08|2011-06-09|Estimate|||||||2017-09-01|2017-09-05|Actual|May 29, 2011||2011-05-29|September 2017|2017-09-30|September 30, 2014|Actual|2014-09-30|August 25, 2013|Actual|2013-08-25||Observational|||The NICHD Fetal Growth Study: Twin Gestations|NICHD Fetal Growth Study: Twin Gestations|Completed|||171|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 22:32:13.897658|2018-05-31 22:32:13.897658
NCT01369927|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-05-23|2011-06-08|2011-06-09|Estimate|||||||2018-05-23|2018-05-24|Actual|May 15, 2011||2011-05-15|April 24, 2013|2013-04-24|April 24, 2013|Actual|2013-04-24|April 24, 2013|Actual|2013-04-24||Interventional|||Shigella Sonnel O-SPC/rBRU Conjugate Vaccine|Shigella Sonnel O-SPC/rBRU Conjugate Vaccine|Completed||Phase 1|60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:32:14.056621|2018-05-31 22:32:14.056621
NCT01369914|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-05-19|2011-06-08|2011-06-09|Estimate|||||||2018-05-19|2018-05-22|Actual|May 20, 2011||2011-05-20|February 5, 2016|2016-02-05|February 5, 2016||2016-02-05|||||Observational|||The Natural History of Graft-Versus-Host Disease in the Eyes|The Natural History of Ocular Graft-Versus Host Disease|Completed|||61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:32:14.147224|2018-05-31 22:32:14.147224
NCT01369901|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2018-05-15|2011-06-08|2011-06-09|Estimate|||||||2018-05-15|2018-05-16|Actual|June 8, 2011||2011-06-08|February 28, 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|||||Interventional|||Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy|Effect of Functional Exercise in Patients With Spinal and Bulbar Muscular Atrophy|Completed||Phase 1/Phase 2|61|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:32:14.220422|2018-05-31 22:32:14.220422
NCT01369888|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2015-01-15||2015-01-26|2011-06-08|2011-06-09|Estimate|2015-01-26|2015-01-27|Estimate||||2015-01-26|2015-01-27|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma|A Phase I/II Study of IL-15 Administration Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen and Autologous Lymphocyte Transfer in Metastatic Melanoma|Terminated||Phase 1/Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||4||Closed this protocol due to autoimmune toxicity.|f||||f||||||||||2018-05-31 22:32:14.321261|2018-05-31 22:32:14.321261
NCT01369875|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2013-02-14||2015-10-06|2011-06-08|2011-06-09|Estimate|2013-02-14|2013-03-21|Estimate||||2015-10-06|2015-10-28|Estimate|May 2011||2011-05-31|September 2015|2015-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma|Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion|Completed||Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-05-31 22:32:14.797191|2018-05-31 22:32:14.797191
NCT01369862|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2014-01-09|2011-06-08|2011-06-09|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults|Randomised, Double-blind, Placebo-controlled, Phase I/II Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults|Completed||Phase 1/Phase 2|80|Anticipated|AVIR Green Hills Biotechnology AG||2|||f||||f||||||||||2018-05-31 22:32:15.148364|2018-05-31 22:32:15.148364
NCT01369849|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|2016-05-20||2017-08-17|2011-06-08|2011-06-09|Estimate|2016-05-20|2016-06-28|Estimate||||2017-08-17|2017-09-15|Actual|September 2011||2011-09-30|August 2017|2017-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||All patients that began protocol treatment were included in the baseline analysis.|Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Completed||Phase 1/Phase 2|15|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:32:15.230474|2018-05-31 22:32:15.230474
NCT01369836|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-09-12|2011-06-07|2011-06-09|Estimate|||||||2011-09-12|2011-09-13|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects|An Investigator And Subject-Blind Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06291826 (Tafamidis) After Single Oral Administration To Japanese And Western Healthy Subjects|Completed||Phase 1|21|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:32:16.091143|2018-05-31 22:32:16.091143
NCT01369823|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-06-08|2011-06-08|2011-06-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|||||Observational|DIAMOND-1||Diabetes Multicenter Observational Study (DIAMOND-1-)|Prospective, Multicenter, Non-interventional Post Market Release Study , to Examine Whether Pump Treatment Combined With the Use of Continuous Glucose Monitoring System is a Mean to Normalize Glycaemic Control.|Unknown status|Enrolling by invitation||100|Anticipated|Medtronic Hellas Medical Devices ΑEE|||||f||||f||||||||||2018-05-31 22:32:16.189743|2018-05-31 22:32:16.189743
NCT01369810|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-08|||2013-11-29|2011-06-08|2011-06-09|Estimate|||||||2013-11-29|2013-12-02|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or Chronic Obstructive Pulmonary Disease|Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or COPD in Iceland|Completed|||20000|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:32:16.289247|2018-05-31 22:32:16.289247
NCT01369797|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-02-23|2011-06-07|2011-06-09|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2011||2011-05-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|GEROPASS||Prospective Randomized Study of the Impact on the Autonomy of the Elderly of 75 Years of Age and Older by the UPSAV|Prospective Randomized Study of the Impact on the Autonomy of the Elderly of 75 Years of Age and Older by the Unit for Prevention, Monitoring and Analysis of Aging (UPSAV).|Completed||N/A|440|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 22:32:16.378687|2018-05-31 22:32:16.378687
NCT01369784|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2014-07-21||2016-03-17|2011-06-08|2011-06-09|Estimate|2016-03-17|2016-04-18|Estimate||||2016-03-17|2016-04-18|Estimate|February 2009||2009-02-28|March 2016|2016-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|PRO-R-IPI|12 patients were not included in the data analysis for not fulfilling selection criteria|Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma|Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma|Completed|||158|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|||1||f||||f||||||||||2018-05-31 22:32:16.53775|2018-05-31 22:32:16.53775
NCT01369771|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2014-10-27|2011-06-08|2011-06-09|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma|An Open-label, Phase IV, Pilot Study, to Evaluate Confocal Microscopic Findings of Cornea, Ocular Signs and Symptoms in Patients With OH or OAG Switching From Latanoprost 0.005% to Preservative Free Tafluprost 0.0015% Eye Drops|Completed||Phase 4|30|Actual|FinnMedi Oy||1|||f||||f||||||||||2018-05-31 22:32:17.232877|2018-05-31 22:32:17.232877
NCT01369758|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2014-10-23||2017-08-09|2011-06-07|2011-06-09|Estimate|2017-08-09|2017-09-13|Actual||||2017-08-09|2017-09-13|Actual|November 2010||2010-11-30|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||290 Subjects enrolled. Nine (9) subjects removed from analysis because they did not meet the inclusion criteria. Three (3) subjects removed from analysis because they met the exclusion criteria.|MyoSure Hysteroscopic Tissue Removal System Registry Study|MyoSure Hysteroscopic Tissue Removal System Registry Study|Completed||N/A|290|Actual|Hologic, Inc.||1|||f||||f||||||||No||2018-05-31 22:32:17.361568|2018-05-31 22:32:17.361568
NCT01369745|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2014-02-10||2014-04-29|2011-06-08|2011-06-09|Estimate|2014-03-27|2014-04-30|Estimate||||2014-04-29|2014-05-15|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|Synergy|population randomized to double blind phase of study and recieved at least one dose of study drug|A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis|A Phase II, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Withdrawal Design Trial Using Adaptive Randomization Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis|Completed||Phase 2|294|Actual|Zalicus|The study did not progress past the first stage of adaptive randomization. The number of subjects allocated to the dipyridamole 360 mg, prednisolone 2.7 mg, and prednisone 5 mg arms was insufficient to allow analysis of the secondary objectives.|5|||f||||t||||||||||2018-05-31 22:32:17.57208|2018-05-31 22:32:17.57208
NCT01369732|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2013-07-10||2013-07-24|2011-06-08|2011-06-09|Estimate|2013-07-24|2013-09-26|Estimate||||2013-07-24|2013-09-26|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest|Prevention of Acute Kidney Injury by Erythropoietin in Patients Undergoing Thoracic Aorta Surgery With Hypothermic Cardiac Arrest|Completed||Phase 4|66|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:32:18.152989|2018-05-31 22:32:18.152989
NCT01369719|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-13|2011-06-08|2011-06-09|Estimate|||||||2011-06-13|2011-06-14|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload|Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload Patients With β-Thalassemia and Intermediate Thalassemia in Bandarabbas|Completed||N/A|138|Actual|Hormozgan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 22:32:18.521132|2018-05-31 22:32:18.521132
NCT01369706|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2015-10-27||2017-04-10|2011-06-08|2011-06-09|Estimate|2015-10-27|2015-11-30|Estimate||||2017-04-10|2017-04-12|Actual|September 2009||2009-09-30|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety of Screening Procedures With Hand-held Metal Detectors Among Patients With Implanted Cardiac Rhythm Devices|Safety of Screening Procedures With Hand-held Metal Detectors Among Patients With Implanted Cardiac Rhythm Devices|Completed||N/A|388|Actual|Deutsches Herzzentrum Muenchen|Convenience sample of patients|1|||f||||f||||||||||2018-05-31 22:32:18.611629|2018-05-31 22:32:18.611629
NCT01369693|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2011-06-08|2011-06-08|2011-06-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|May 2004||2004-05-31|June 2011|2011-06-30|April 2005|Actual|2005-04-30|August 2004|Actual|2004-08-31||Interventional|SMWS03||In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus|In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Four Brands of Swedish 'Snus' in Regular Snus Users.|Completed||Phase 1|32|Actual|Contract Research Organization el AB||4|||f||||f||||||||||2018-05-31 22:32:18.756616|2018-05-31 22:32:18.756616
NCT01369680|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2012-10-24||2013-02-11|2011-06-07|2011-06-09|Estimate|2013-02-07|2013-02-11|Estimate||||2013-02-11|2013-02-15|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|KETA-2011||Oral Ketamine for Control of Chronic Pain in Children|Oral Ketamine for Control of Chronic Pain in Children|Completed||Phase 1|12|Actual|University of Rochester|Three subjects were lost to follow-up, limiting the data available for neuro-cognitive assessment at the last visit.|4|||f||||f||||||||||2018-05-31 22:32:18.864561|2018-05-31 22:32:18.864561
NCT01369667|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-08-15|2011-06-07|2011-06-09|Estimate|||||||2015-08-15|2015-08-18|Estimate|April 2012||2012-04-30|June 2011|2011-06-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|VITD-CD||Vitamin D Supplementation in Adult Crohn's Disease|Vitamin D and Immunomodulation: Effects in Crohn's Disease|Completed||Phase 4|117|Actual|University of Dublin, Trinity College||2|||f||||||||||||||2018-05-31 22:32:21.664729|2018-05-31 22:32:21.664729
NCT01369654|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-06-02|2011-06-08|2011-06-09|Estimate|||||||2015-06-02|2015-06-04|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|September 2012|Actual|2012-09-30||Interventional|BSO||Development and Pilot Test of an Elective Bilateral Salpingo-Oophorectomy (BSO) Decision Support Guide|Development and Pilot Test of an Elective Bilateral Salpingo-Oophorectomy (BSO) Decision Support Guide|Completed||N/A|63|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 22:32:21.964981|2018-05-31 22:32:21.964981
NCT01369641|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2014-01-24||2017-09-15|2011-06-07|2011-06-09|Estimate|2014-03-28|2014-05-01|Estimate||||2017-09-15|2017-10-18|Actual|August 24, 2011|Actual|2011-08-24|September 2017|2017-09-30|May 2, 2013|Actual|2013-05-02|March 10, 2013|Actual|2013-03-10||Interventional|||The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy|A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy|Terminated||N/A|1|Actual|Thomas Jefferson University|Study terminated due to poor accrual, prior to subjects being analyzed.|2||Poor accrual|f||||t||||||||||2018-05-31 22:32:22.313363|2018-05-31 22:32:22.313363
NCT01369628|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-10-21|2011-06-08|2011-06-09|Estimate|||||||2013-10-21|2013-10-22|Estimate|June 2011||2011-06-30|October 2013|2013-10-31||||November 2011|Actual|2011-11-30||Interventional|||Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil|A Phase Ib, Multicenter, Open Label, Dose-Escalating, Repeat-Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept When Administered to Subjects With Lupus Nephritis on a Stable Regimen of Mycophenolate Mofetil (MMF) With or Without Corticosteroids|Terminated||Phase 1|1|Actual|EMD Serono||1||Please see Purpose Statement below|f||||t||||||||||2018-05-31 22:32:23.208613|2018-05-31 22:32:23.208613
NCT01369615|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2015-01-07||2015-08-26|2011-06-08|2011-06-09|Estimate|2015-01-07|2015-01-15|Estimate||||2015-08-26|2015-09-09|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional||The extension safety population was the group of patients who received at least 1 dose of study drug during the Extension Study.|Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001|An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study|Completed||Phase 3|23|Actual|Purdue Pharma LP|"Enrollment for study OTR3002 was closed by Purdue Pharma L.P. on 01-January-2014 due to administrative reasons not related to safety.~Interpretation is limited by the small number of patients in each age group in this study."|1|||f||||t||||||||||2018-05-31 22:32:23.416833|2018-05-31 22:32:23.416833
NCT01369602|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2012-02-21|2011-06-07|2011-06-09|Estimate|||||||2012-02-21|2012-02-22|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532|A Phase 1, Single-Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532|Completed||Phase 1|27|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:32:23.982728|2018-05-31 22:32:23.982728
NCT01369589|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2016-04-02|2011-06-07|2011-06-09|Estimate|||||||2016-04-02|2016-04-05|Estimate|November 2010||2010-11-30|July 2014|2014-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness|An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's Syndrome|Completed||Phase 1/Phase 2|24|Actual|Parion Sciences||2|||f||||f||||||||||2018-05-31 22:32:24.072136|2018-05-31 22:32:24.072136
NCT01369576|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-07-16|2011-06-08|2011-06-09|Estimate|||||||2015-07-16|2015-07-17|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Effect of Zopiclone on Compliance With Continuous Positive Airway Pressure in Obstructive Sleep Apnea|A Double-blind, Randomized, Parallel Group Study to Determine the Effect of Initial Prescription of Zopiclone on the Level of Compliance With CPAP in Adult Patients Treated for OSA at 26 Weeks|Completed||Phase 3|264|Actual|OSR Medical Inc.||2|||f||||t||||||||||2018-05-31 22:32:24.161444|2018-05-31 22:32:24.161444
NCT01369563|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2016-12-02|2011-06-08|2011-06-09|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|SISRIP||Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis|Non-interventional Clinical Trial, to Assess the Efficacy, Safety and Tolerability of Ciclesonide 200 Mcg Once Daily, Applied as a Nasal Spray for Four Weeks, in the Treatment of Intermittent and Persistent Rhinitis|Completed|||1630|Actual|AstraZeneca|||||f||||t||||||||||2018-05-31 22:32:24.263682|2018-05-31 22:32:24.263682
NCT01369550|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-08|2011-06-08|2011-06-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy Study of Stearidonic Acid (SDA) Soybean Oil-containing Foods on Red Blood Cell Fatty Acid Content|A Randomized, Controlled Trial to Assess the Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels of Red Blood Cells and the Omega-3 Index|Completed||N/A|127|Actual|Monsanto Company, LLC||3|||f||||f||||||||||2018-05-31 22:32:24.329861|2018-05-31 22:32:24.329861
NCT01369537|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-09-05|2011-06-08|2011-06-09|Estimate|||||||2013-09-05|2013-09-06|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Neurological Impact of Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN Pilot Study|Neurological Impact of Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN Pilot Study|Completed|||100|Actual|McMaster University|||1||f||||f||||||||||2018-05-31 22:32:24.410291|2018-05-31 22:32:24.410291
NCT01369524|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-08|2011-06-08|2011-06-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Observational|||Effect of Fluid Resuscitation and Microcirculation|Evaluation of Effect of Fluid Resuscitation on Sublingual Microcirculation by SDF Imaging in Intensive Care Patients, a Pilot Study|Completed|||50|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||||2018-05-31 22:32:24.460694|2018-05-31 22:32:24.460694
NCT01369511|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07||2014-04-14|2014-04-14|2011-06-07|2011-06-09|Estimate||||2014-04-14|2014-05-06|Estimate|2014-04-14|2014-05-06|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement|A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty|Completed||Phase 2|384|Anticipated|Eli Lilly and Company||4|||f||||t||||||||||2018-05-31 22:32:24.546405|2018-05-31 22:32:24.546405
NCT01367652|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2018-01-19|2011-06-06|2011-06-07|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2008||2008-03-31|January 2018|2018-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fasted Conditions|Completed||Phase 1|28|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:33:01.875803|2018-05-31 22:33:01.875803
NCT01369498|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06||2015-10-22|2015-10-22|2011-06-07|2011-06-09|Estimate||||2015-10-22|2015-11-13|Estimate|2015-10-22|2015-11-13|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis|A Phase 2 Study to Evaluate the Efficacy and Safety of GS-6624 in Adult Subjects With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis|Completed||Phase 2|54|Actual|Gilead Sciences||4|||f||||f||||||||||2018-05-31 22:32:24.746542|2018-05-31 22:32:24.746542
NCT01369485|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2014-04-14||2014-09-04|2011-06-08|2011-06-09|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-04|2014-09-11|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|Beacon|Intent to treat population|Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder|Multi-center, Prospective, Randomized, Double-blind, Sham-controlled Clinical Study to Evaluate Safety and Effectiveness of a Transcutaneous, High-frequency, Amplitude-modulated, Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Subjects With Overactive Bladder (OAB)|Completed||N/A|163|Actual|Ethicon Endo-Surgery|There was a higher than anticipated rate of patient withdrawals observed in both groups due to skin irritation.|2|||f||||f||||||||||2018-05-31 22:32:24.995372|2018-05-31 22:32:24.995372
NCT01369472|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-02-13|2011-06-08|2011-06-09|Estimate|||||||2012-02-13|2012-02-15|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule|A Randomized, Open-label, Single Dose, Dose-rising 10-sequence, 3-period Balanced Incomplete Blocked Clinical Trial to Evaluate Dose-proportionality of Dilatrend SR in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Chong Kun Dang Pharmaceutical||5|||f||||f||||||||||2018-05-31 22:32:25.77996|2018-05-31 22:32:25.77996
NCT01369459|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-08-03|2011-06-08|2011-06-09|Estimate|||||||2015-08-03|2015-08-05|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|MIP||Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder|Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD|Completed||Phase 1|14|Actual|The National Center on Addiction and Substance Abuse at Columbia University||2|||f||||t||||||||||2018-05-31 22:32:25.873814|2018-05-31 22:32:25.873814
NCT01369446|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2012-07-20|2011-06-08|2011-06-09|Estimate|||||||2012-07-20|2012-07-24|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|Eeva||Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage|Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage|Completed|||160|Actual|Progyny, Inc.|||1||f||||f||||||||||2018-05-31 22:32:25.984681|2018-05-31 22:32:25.984681
NCT01369433|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-06-20|2011-06-07|2011-06-09|Estimate|||||||2017-06-20|2017-06-21|Actual|June 2010||2010-06-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols|A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols|Completed||N/A|225|Actual|AVEO Pharmaceuticals, Inc.||6|||f||||f||||||||No||2018-05-31 22:32:26.079739|2018-05-31 22:32:26.079739
NCT01369420|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2016-11-07|2011-06-08|2011-06-09|Estimate|||||||2016-11-07|2016-11-08|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer|A Safety Evaluation of the NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer - A Pilot Study|Completed||Phase 2|10|Anticipated|Angiodynamics, Inc.|||||f||||f||||||||||2018-05-31 22:32:26.246695|2018-05-31 22:32:26.246695
NCT01369407|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-05-21|2011-06-07|2011-06-08|Estimate|||||||2018-05-21|2018-05-22|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31|2 Years|Observational [Patient Registry]|REVIVAL||REGISTRY EVALUATION OF VITAL INFORMATION FOR VADs IN AMBULATORY LIFE|REVIVE-IT Registry (REVIVAL: Registry Evaluation of Vital Information For VADs in Ambulatory Life)|Active, not recruiting|||400|Anticipated|University of Michigan|||1||f||||f||||||Samples With DNA|"~     Biomarker Samples will be collected at the Baseline B assessment. Samples for Genomic~     Analysis will be collected at the Baseline B visit for subjects that consented to collection~     of this sample type.~   "|||2018-05-31 22:32:26.349959|2018-05-31 22:32:26.349959
NCT01369394|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2014-12-08|2011-06-07|2011-06-08|Estimate|||||||2014-12-08|2014-12-10|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Making Decisions About the Measles-Mumps-Rubella Vaccine|Developing a Computer-based Intervention That Provides Individually-tailored Educational Information for MMR Vaccine-hesitant Parents|Completed||N/A|79|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 22:32:26.478097|2018-05-31 22:32:26.478097
NCT01369381|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-08-03|2011-06-07|2011-06-08|Estimate|||||||2012-08-03|2012-08-07|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Cervical Spine Biomechanics During Endotracheal Intubation|Intubation Mechanics of the Stable and Unstable Cervical Spine|Completed||N/A|14|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 22:32:27.006322|2018-05-31 22:32:27.006322
NCT01369368|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-06-23|2011-06-07|2011-06-08|Estimate|||||||2015-06-23|2015-06-24|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Treatment of Acute Leukemia Relapse After Allotransplantation|Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation: Disease Stabilization Through Chemotherapy, Immunomodulatory Treatment and Immunotherapy|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Bergen||1|||f||||t||||||||||2018-05-31 22:32:27.226297|2018-05-31 22:32:27.226297
NCT01369355|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2016-10-17|2016-04-14|2018-04-25|2011-06-07|2011-06-08|Estimate|2017-01-03|2017-02-23|Actual|2016-04-14|2016-05-16|Estimate|2018-04-25|2018-04-27|Actual|September 13, 2011|Actual|2011-09-13|April 2018|2018-04-30|October 21, 2019|Anticipated|2019-10-21|June 10, 2015|Actual|2015-06-10||Interventional|||A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease|Active, not recruiting||Phase 3|1282|Actual|Janssen Research & Development, LLC|The global study was interrupted due to issues with the clinical supply.|6|||f||||t||f||||||||2018-05-31 22:32:27.44404|2018-05-31 22:32:27.44404
NCT00833235|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2017-07-22|2009-01-30|2009-02-02|Estimate|||||||2017-07-22|2017-07-25|Actual|February 1, 2009|Actual|2009-02-01|July 2017|2017-07-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Observational|||A Natural History Study of Patients With Dry Eye||Completed|||284|Actual|Allergan|||2||f||||f||||||Samples With DNA|"~     Tear collection~   "|||2018-06-01 01:21:40.820984|2018-06-01 01:21:40.820984
NCT01369342|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2016-09-01|2015-07-02|2016-11-09|2011-06-07|2011-06-08|Estimate|2016-11-09|2017-01-06|Estimate|2015-07-02|2015-07-27|Estimate|2016-11-09|2017-01-06|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)|Completed||Phase 3|640|Actual|Janssen Research & Development, LLC|The global study was interrupted due to issues with the clinical supply.|3|||f||||t||||||||||2018-05-31 22:32:30.740442|2018-05-31 22:32:30.740442
NCT01369329|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2016-08-01|2014-05-07|2016-10-14|2011-06-07|2011-06-08|Estimate|2016-10-14|2016-12-07|Estimate|2014-05-07|2014-05-22|Estimate|2016-10-14|2016-12-07|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)|Completed||Phase 3|769|Actual|Janssen Research & Development, LLC|The global study was interrupted due to issues with the clinical supply.|3|||f||||t||||||||||2018-05-31 22:32:32.086859|2018-05-31 22:32:32.086859
NCT01369316|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2018-03-13|2011-06-07|2011-06-08|Estimate|||||||2018-03-13|2018-03-15|Actual|December 30, 2018|Anticipated|2018-12-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|CSIEMR||Circumferential Submucosal Incision Endoscopic Mucosal Resection Versus Conventional Endoscopic Mucosal Resection of Colonic Polyps|Circumferential Submucosal Incision Endoscopic Mucosal Resection Versus Conventional Endoscopic Resection for the Removal of Large Laterally Spreading Tumours and Sessile Polyps of the Colon|Not yet recruiting||N/A|160|Anticipated|Western Sydney Local Health District||2|||f||||f|f|f||||||||2018-05-31 22:32:33.537648|2018-05-31 22:32:33.537648
NCT01369303|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-12-11|2011-06-07|2011-06-08|Estimate|||||||2013-12-11|2013-12-12|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel|Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel Using the Bat 24 Regimen Versus Daily and Pericoital Dosing|Completed||Phase 1|194|Actual|CONRAD||3|||f||||f||||||||||2018-05-31 22:32:33.693944|2018-05-31 22:32:33.693944
NCT01369290|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-18|||2011-11-28|2011-06-07|2011-06-08|Estimate|||||||2011-11-28|2011-11-30|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Observational|EEG-SP||Electroencephalography (EEG) Signal Processing|EEG Signal Processing as a Predictor of Antidepressant Response|Unknown status|Recruiting||150|Anticipated|St. Joseph's Healthcare Hamilton|||5||f||||f||||||||||2018-05-31 22:32:33.901048|2018-05-31 22:32:33.901048
NCT01369277|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-09-20|2011-06-07|2011-06-08|Estimate|||||||2011-09-20|2011-09-22|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532|A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Dose Escalation Study In Japanese Healthy Subjects, And Open Label, Single Dose Study In Western Healthy Subjects To Investigate The Safety, Tolerability, And Pharmacokinetics of PF-04991532.|Completed||Phase 1|22|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:32:34.055827|2018-05-31 22:32:34.055827
NCT01369264|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-18|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|ERP||The Effect of Repetitive Transcranial Magnetic Stimulation on Brain Activity in Healthy Human Volunteers|Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Brain Electrical Activity in Healthy Human Volunteers|Completed||N/A|17|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 22:32:34.214562|2018-05-31 22:32:34.214562
NCT01369251|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Simple Hygiene Versus Alcohol Based Usual Care for Umbilical Cord|Simple Hygiene Versus Alcohol Based Usual Care for Umbilical Cord: a Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|400|Anticipated|ASST Fatebenefratelli Sacco||2|||f||||f||||||||||2018-05-31 22:32:34.347553|2018-05-31 22:32:34.347553
NCT01369238|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|||East-West Collaborative Medicine Using Bee-Venom Acupuncture on Whiplash-Associated Disorders|Clinical Research on the Efficacy of East-West Collaborative Medicine Using Bee-Venom Acupuncture Therapy on Whiplash-Associated Disorders After Traffic Collisions; A Randomized, Controlled, Parallel Trial|Unknown status|Not yet recruiting|N/A|90|Anticipated|Korean Pharmacoacupuncture Institute||3|||f||||t||||||||||2018-05-31 22:32:34.448147|2018-05-31 22:32:34.448147
NCT01369225|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2016-06-15||2017-01-19|2011-06-07|2011-06-08|Estimate|2017-01-19|2017-03-10|Actual||||2017-01-19|2017-03-10|Actual|July 2011||2011-07-31|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The baseline analysis population included all participants who were enrolled in the study and received at least 1 infusion of study medication.|Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease|A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001|Completed||Phase 1|52|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 22:32:34.633861|2018-05-31 22:32:34.633861
NCT01369212|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2017-08-22|2011-06-07|2011-06-08|Estimate|||||||2017-08-22|2017-08-24|Actual|November 2012||2012-11-30|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|August 2019|Anticipated|2019-08-31||Interventional|HBRN||Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B|Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B|Active, not recruiting||N/A|201|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||No||2018-05-31 22:32:36.456574|2018-05-31 22:32:36.456574
NCT01367067|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-07-01|2011-06-03|2011-06-06|Estimate|||||||2011-07-01|2011-07-04|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|CLAUSTRO II||Prediction of Claustrophobia During MR Imaging|Prediction of Claustrophobia During MR Imaging: An Observational 18-Months Single Center Study|Completed|||8000|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 22:33:12.291512|2018-05-31 22:33:12.291512
NCT01369199|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2018-02-22|2011-06-07|2011-06-08|Estimate|||||||2018-02-22|2018-02-26|Actual|May 2012||2012-05-31|February 2018|2018-02-28|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|HBRN||Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B|Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B|Completed||Phase 3|28|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t|t|f||||||No||2018-05-31 22:32:36.64022|2018-05-31 22:32:36.64022
NCT01369186|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2017-03-23|2011-06-07|2011-06-08|Estimate|||||||2017-03-23|2017-03-27|Actual|May 2011||2011-05-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Drug Drug Interactions of Aspirin and P2Y12-inhibitors|Drug Drug Interactions of Antiplatelet Drugs and Morphine|Completed||Phase 4|95|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 22:32:36.812924|2018-05-31 22:32:36.812924
NCT01369173|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-05-04|2011-06-07|2011-06-08|Estimate|||||||2015-05-04|2015-05-06|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|COMIDAS||COMIDAS Comparing Original Mexican Diets and Standard US Diets|Metabolic Response to Western vs. Indigenous Diets in Hispanic Women|Completed||N/A|50|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 22:32:36.890552|2018-05-31 22:32:36.890552
NCT01369160|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2014-05-23|2011-06-07|2011-06-08|Estimate|||||||2014-05-23|2014-05-28|Estimate|May 2005||2005-05-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|May 2007|Actual|2007-05-31||Observational|SCD_Cross||Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease|Curative vs Disease-Modifying Therapies in Children With Severe Sickle Cell Disease: A Pilot, Cross-Sectional Study|Completed|||33|Actual|Emory University|||4||f||||t||||||||||2018-05-31 22:32:37.033093|2018-05-31 22:32:37.033093
NCT01369147|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2017-09-20|2011-06-07|2011-06-08|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2011||2011-07-31|September 2017|2017-09-30||||July 2019|Anticipated|2019-07-31||Interventional|||The Energy Dose Study|Comparative Effectiveness of Energy Doses in Critical Illness|Active, not recruiting||Phase 2|60|Anticipated|Emory University||3|||f||||t|t|f||||||||2018-05-31 22:32:37.115383|2018-05-31 22:32:37.115383
NCT01369134|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2014-05-29|2011-06-07|2011-06-08|Estimate|||||||2014-05-29|2014-05-30|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Clinical Evaluation of a Self-etch Adhesive Using a Selective Etch Technique|Clinical Evaluation of 3M ESPE Adper Easy Bond Self-Etch Adhesive Using a Selective Etch Technique|Completed|||40|Actual|3M|||||f||||f||||||||||2018-05-31 22:32:37.223113|2018-05-31 22:32:37.223113
NCT01369121|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-07-29|2011-06-07|2011-06-08|Estimate|||||||2013-07-29|2013-07-30|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Tolerability Study of Xerecept® in Pediatric Patients|A Phase I/II Open Label Individual Dose Titration Trial of the Human Corticotropin- Releasing Factor (hCRF), Corticorelin Acetate Injection (Xerecept®), to Determine the Tolerability of Xerecept® in a Pediatric Population|Terminated||Phase 1/Phase 2|15|Actual|Celtic Pharma Development Services||1||Single subject remained on study - transferred to compassionate use|f||||f||||||||||2018-05-31 22:32:37.307578|2018-05-31 22:32:37.307578
NCT01369108|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2017-09-19||2017-11-07|2011-06-07|2011-06-08|Estimate|2017-11-07|2017-11-09|Actual||||2017-11-07|2017-11-09|Actual|January 2011||2011-01-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Clinical Study on a New Flowable Composite as a Restorative in Adult Teeth|Clinical Evaluation of a Low Shrinkage Flowable Resin Composite in Adult Teeth|Completed||N/A|60|Actual|3M||2|||f||||f||||||||||2018-05-31 22:32:37.44951|2018-05-31 22:32:37.44951
NCT01369095|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07||2015-09-23|2015-09-23|2011-06-07|2011-06-08|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression|A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).|Completed||Phase 2|976|Actual|Bristol-Myers Squibb||5|||f||||t||||||||||2018-05-31 22:32:37.868119|2018-05-31 22:32:37.868119
NCT01369082|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2017-11-07|2011-06-07|2011-06-08|Estimate|||||||2017-11-07|2017-11-09|Actual|May 2011||2011-05-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Extended Follow-Up After Islet Transplantation in T1D|Extended Follow-Up After Islet Transplantation in Type 1 Diabetes (CIT-08)|Completed|||75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Participants are given the option to provide consent for:~        1. the collection and storage of blood samples for future research studies~        2. the collection and storage of blood samples for future genetic (i.e., DNA) testing.~   "|||2018-05-31 22:32:38.071997|2018-05-31 22:32:38.071997
NCT01369069|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2017-11-09|2011-06-07|2011-06-08|Estimate|||||||2017-11-09|2017-11-14|Actual|April 2012||2012-04-30|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|SHINE||Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial|Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial|Recruiting||Phase 3|1400|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 22:32:38.229902|2018-05-31 22:32:38.229902
NCT01369056|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2016-05-24|2011-06-06|2011-06-08|Estimate|||||||2016-05-24|2016-05-26|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence|HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence|Completed||N/A|150|Actual|University of Tartu||2|||f||||f||||||||No||2018-05-31 22:32:38.793874|2018-05-31 22:32:38.793874
NCT01369043|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-03-06|2011-06-07|2011-06-08|Estimate|||||||2015-03-06|2015-03-09|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effects of Vitamin E and Vitamin C and Exercise|Modulation of Insulin and Exercise Responses by Vitamin E and Vitamin C|Terminated||N/A|1|Actual|USDA Grand Forks Human Nutrition Research Center||2||Lack of successful recruiting, budget cuts, and potential study flaws.|f||||t||||||||||2018-05-31 22:32:38.902048|2018-05-31 22:32:38.902048
NCT01369030|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|2013-04-18||2014-05-08|2011-06-07|2011-06-08|Estimate|2014-05-08|2014-06-03|Estimate||||2014-05-08|2014-06-03|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational||A total of 594 completed the baseline and follow-up surveys and of those only 554 with a baseline PHQ-9>=5 were included in the analysis. Majority of the participants were female, and the study was approximately equal distribution across the four depression severity groups of interest.|Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)|Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)|Completed|||554|Actual|Pamlab, Inc.|Patients self-enrolled in the program and data presented was based on self-reported close-ended questions; selection bias may be present for those who chose not to enroll or complete the surveys. No clinical evaluations were conducted.||1||f||||f||||||||||2018-05-31 22:32:39.009743|2018-05-31 22:32:39.009743
NCT01369017|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2013-07-11|2011-06-07|2011-06-08|Estimate|||||||2013-07-11|2013-07-15|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Kintox||Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers|A Study of the Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers|Completed||Phase 1|17|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:32:39.237329|2018-05-31 22:32:39.237329
NCT01369004|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-04-21|2011-06-07|2011-06-08|Estimate|||||||2017-04-21|2017-04-25|Actual|February 2011||2011-02-28|September 2012|2012-09-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|WEIGH||The WEIGH Study: Weighing to Improve and Gain Health|The Use of Weight Tracking Technology to Promote Weight Loss Among Overweight Adults|Completed||N/A|91|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:32:39.379477|2018-05-31 22:32:39.379477
NCT01368991|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|July 2011||2011-07-31|April 2011|2011-04-30|July 2013|Anticipated|2013-07-31|September 2012|Anticipated|2012-09-30||Interventional|Kryptonite||Clinical Trial of Kryptonite for Prevention of Sternal Complications in High Risk Patients Undergoing Cardiac Surgery|Randomized Clinical Trial of Kryptonite for Prevention of Sternal Complications in High Risk Patients Undergoing Cardiac Surgery|Unknown status|Not yet recruiting|Phase 3|48|Anticipated|Cardiology Research UBC||2|||f||||t||||||||||2018-05-31 22:32:39.472019|2018-05-31 22:32:39.472019
NCT01368978|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2014-09-04|2011-06-07|2011-06-08|Estimate|||||||2014-09-04|2014-09-05|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pediatric Diabetics Type 1 Using InsuPatch|Evaluation of the Effect of lnsuPatch on the Pharmacokinetic and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Given as a Bolus by Continuous Subcutaneous Insulin Infusion (CSII)|Completed||Phase 3|27|Actual|Insuline Medical Ltd.||2|||f||||f||||||||||2018-05-31 22:32:39.604219|2018-05-31 22:32:39.604219
NCT01368965|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2014-02-10||2017-11-16|2011-06-07|2011-06-08|Estimate|2014-02-10|2014-03-26|Estimate||||2017-11-16|2017-12-13|Actual|March 2011||2011-03-31|November 2017|2017-11-30|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional||Fifty-four subjects were consented and enrolled. Two subjects withdrew consent prior to treatment. Data analyses are based on 52 treated subjects.|Lifting and Tightening of the Face in Subjects With Skin of Darker Color|Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity in Patients With Fitzpatrick Skin Phototypes 3 Through 6|Completed||N/A|54|Actual|Merz North America, Inc.|"Study Limitations:~Masked assessment was not completed as photos were not usable, i.e., poor image quality, positioning and timing.~Site staffing changes.~Overburdened site staff.~Poor photography quality~Subject selection"|1|||f||||f||||||||||2018-05-31 22:32:39.735306|2018-05-31 22:32:39.735306
NCT01368952|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Effect of Pure Prone Positioning Therapy for the Patients With Mild to Moderate Obstructive Sleep Apnea|Efficacy Study of Pure Prone Positioning Therapy in Patients With Mild to Moderate Obstructive Sleep Apnea|Completed||N/A|29|Actual|Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital||2|||f||||f||||||||||2018-05-31 22:32:39.965021|2018-05-31 22:32:39.965021
NCT01368939|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2012-04-20|2011-06-07|2011-06-08|Estimate|||||||2012-04-20|2012-04-23|Estimate|March 2012||2012-03-31|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|September 2012|Anticipated|2012-09-30||Observational|ROSE||Investigation of High Resolution Nuclear Breast Imaging Camera (MBI) in Patients Administered Tc-99m Sestamibi (ROSE)|A Pilot, Single Centre, Prospective Clinical Study Investigation of the Acceptability of a Dedicated High Resolution Nuclear Breast Imaging Camera (MBI) in Breast Imaging of Patients Administered Tc-99m Sestamibi (ROSE)|Unknown status|Recruiting||150|Anticipated|Hamilton Health Sciences Corporation|||||f||||f||||||||||2018-05-31 22:32:40.063986|2018-05-31 22:32:40.063986
NCT01368926|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2016-11-01|2011-06-07|2011-06-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects|A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics, Safety and Tolerability of RO4917523 Conducted in 2 Phases: a Single-Dose, Cross-Over Administration to Healthy Japanese Subjects and a Multiple-Dose Administration to Healthy Japanese and Caucasian Subjects.|Completed||Phase 1|42|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:32:40.137603|2018-05-31 22:32:40.137603
NCT01368913|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-06-11|2011-06-07|2011-06-08|Estimate|||||||2013-06-11|2013-06-12|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|MELT||MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis|MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis With Special Focus on Patient Satisfaction|Completed|||138|Actual|Ferring Pharmaceuticals|||2||f||||f||||||||||2018-05-31 22:32:40.221133|2018-05-31 22:32:40.221133
NCT01368900|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2013-04-17||2017-11-16|2011-06-07|2011-06-08|Estimate|2013-06-13|2013-07-31|Estimate||||2017-11-16|2017-12-13|Actual|March 2011||2011-03-31|September 2013|2013-09-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional||Adults between 30 and 65 years of age who provided informed consent and who met the inclusion/exclusion criteria and required infraorbital, lateral orbit, and brow regions to be treated bilaterally.|Reducing Wrinkles Around the Eyes Using the Ulthera® System|Evaluation of the Ulthera® System for Obtaining a Reduction of Wrinkles Around the Eyes|Completed||N/A|68|Actual|Merz North America, Inc.|"FWCS scores assessed globally, not per eye, leading to limited data for analysis.~FWCS protocol amended to 3+ after enrollment of 19 subjects with FWCS of 2.~Unacceptable lighting, focus, exposure making some photos impossible to evaluate."|1|||f||||f||||||||||2018-05-31 22:32:40.907585|2018-05-31 22:32:40.907585
NCT01368887|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|April 2013||2013-04-30|June 2011|2011-06-30|April 2014|Anticipated|2014-04-30|November 2013|Anticipated|2013-11-30||Interventional|||Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis|Phase II Study of a Non-Steroidal Novel Treatment for Scalp Psoriasis|Suspended||Phase 2|160|Anticipated|DermiPsor, Ltd.||4||Sponsor seeking additional financial support before starting the study|f||||t||||||||||2018-05-31 22:32:41.639336|2018-05-31 22:32:41.639336
NCT01368874|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2013-06-03||2017-11-16|2011-06-07|2011-06-08|Estimate|2013-09-16|2013-11-20|Estimate||||2017-11-16|2017-12-13|Actual|March 2011||2011-03-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Lifting and Tightening of the Face and Neck Utilizing the Ulthera® System|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck|Completed||N/A|71|Actual|Merz North America, Inc.||3|||f||||f||||||||||2018-05-31 22:32:41.793914|2018-05-31 22:32:41.793914
NCT01368848|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2013-08-29|2011-06-07|2011-06-08|Estimate|||||||2013-08-29|2013-08-30|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)|Phase II Study to Investigate the Treatment of Patients With NSCLC Stage IIIB and IV Without the Option of Surgery With a Combination of Cisplatin, Docetaxel and Bevacizumab|Completed||Phase 2|7|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie|||||f||||f||||||||||2018-05-31 22:32:42.643701|2018-05-31 22:32:42.643701
NCT01368835|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2013-03-25||2017-11-16|2011-06-06|2011-06-08|Estimate|2013-07-15|2013-08-15|Estimate||||2017-11-16|2017-12-13|Actual|July 2010||2010-07-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional||N=33 Excluded from analysis: N=22 excluded for inclusion criteria/photo lighting/positional/makeup issues and N=11 lost to follow-up.|Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue|Evaluation of the Ulthera™ System For Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity|Completed||N/A|103|Actual|Merz North America, Inc.||1|||f||||t||||||||||2018-05-31 22:32:42.721804|2018-05-31 22:32:42.721804
NCT01368822|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2012-11-08|2011-06-07|2011-06-08|Estimate|||||||2012-11-08|2012-11-09|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|R-21||Effect of Obesity on Long-term Clinical Outcomes After Kidney Donation||Completed|||150|Actual|University of California, San Francisco|||||f||||f||||||||||2018-05-31 22:32:43.134291|2018-05-31 22:32:43.134291
NCT01368809|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|2015-09-10||2016-03-09|2011-06-07|2011-06-08|Estimate|2015-09-10|2015-10-08|Estimate||||2016-03-09|2016-04-05|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|LMA||Effect of Fentanyl on Coughing and Recovery After Anesthesia With an LMA Laryngeal Mask Airway)for Airway Management|Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of Fentanyl on the Incidence of Coughing and Recovery After Propofol-Desflurane Anesthesia With an LMA for Airway Management|Completed||Phase 4|100|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 22:32:43.222342|2018-05-31 22:32:43.222342
NCT01368796|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-04-14|2011-06-07|2011-06-08|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|PCIRNRT09||Comparison of 4 Influenza Vaccines in Seniors|Controlled Comparison in Canadian Seniors of Seasonal Influenza Vaccines for 2011-2012|Completed||Phase 4|953|Actual|University of British Columbia||4|||f||||f||||||||||2018-05-31 22:32:43.481513|2018-05-31 22:32:43.481513
NCT01368783|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|June 2011||2011-06-30|May 2011|2011-05-31||||||||Interventional|||Two Clinical Trials to Evaluate Pharmacokinetics of Unboosted and Boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers|Two Randomized, Open-labeled, Parallel Designed Multiple-dose Clinical Trials to Evaluate Pharmacokinetics of Ritonavir-unboosted and Ritonavir-boosted Atazanavir Used Alone or Co-administered With Tenofovir DF in Healthy Korean and Caucasian Male Volunteers|Unknown status|Not yet recruiting|Phase 1|32|Anticipated|Asan Medical Center||4|||f||||||||||||||2018-05-31 22:32:43.577704|2018-05-31 22:32:43.577704
NCT01368770|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-04-01|2011-06-07|2011-06-08|Estimate|||||||2015-04-01|2015-04-02|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Stress Testing Compared to Coronary Computed Tomographic Angiography in Patients With Suspected Coronary Artery Disease|Stress-rest Single Photon-Emission Computed Tomography(SPECT)Compared to Coronary Computed Tomographic Angiography in the Initial Evaluation of Patients With Suspected Coronary Artery Disease-A Pilot Randomized Controlled Trial|Completed||Phase 3|303|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-05-31 22:32:43.646163|2018-05-31 22:32:43.646163
NCT01368757|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2015-03-06|2011-06-07|2011-06-08|Estimate|||||||2015-03-06|2015-03-09|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Lenalidomide in Patients With Chronic Myelomonocytic Leukemia|A Phase I/II Study of Lenalidomide in Patients With Chronic Myelomonocytic Leukemia|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie|||||f||||f||||||||||2018-05-31 22:32:43.837549|2018-05-31 22:32:43.837549
NCT01368744|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-06|2011-06-06|2011-06-08|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology|Intraoperative Examination of Sentinel Lymph Nodes: Comparison of the OSNA Breast Cancer System to Extensive Frozen Section Histopathology|Completed|||150|Anticipated|Sysmex America, Inc.|||1||f||||t||||||Samples With DNA|"~     Samples of the tissue homogenate will be retained and may be used for for further testing.~   "|||2018-05-31 22:32:43.977191|2018-05-31 22:32:43.977191
NCT01368731|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2017-11-14|2011-06-07|2011-06-08|Estimate|||||||2017-11-14|2017-11-17|Actual|May 2011||2011-05-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2014|Actual|2014-01-31||Interventional|||Prophylactic Coagulation for the Prevention of Bleeding in Endoscopic Mucosal Resection of Large Sessile Colonic Polyps|Prophylactic Endoscopic Coagulation for the Prevention of Bleeding in Endoscopic Mucosal Resection (EMR) of Large Sessile Colonic Polyps: A Multi-centre, Randomised Control Trial|Active, not recruiting||N/A|328|Anticipated|Western Sydney Local Health District||2|||f||||f||||||||||2018-05-31 22:32:44.05207|2018-05-31 22:32:44.05207
NCT01368718|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-06-02|2011-06-07|2011-06-08|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing|The Effect of Nasal CPAP in Patients With Chronic Fatigue and Sleep-disordered Breathing|Unknown status|Recruiting|Phase 4|55|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 22:32:44.156996|2018-05-31 22:32:44.156996
NCT01368705|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2013-08-16|2011-06-07|2011-06-08|Estimate|||||||2013-08-16|2013-08-19|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Nitrogen Balance in Infants After Post Cardiothoracic Surgery|Determination of Protein Needs Using Nitrogen Balance in Infants Immediately Post Cardiothoracic Surgery|Completed||Phase 4|24|Actual|The Hospital for Sick Children||3|||f||||t||||||||||2018-05-31 22:32:44.24064|2018-05-31 22:32:44.24064
NCT01368692|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22|||2013-01-14|2011-06-06|2011-06-08|Estimate|||||||2013-01-14|2013-01-15|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Shoulder Retraction on Success Rate of Subclavian Vein Catheterization||Completed||N/A|362|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:32:44.329516|2018-05-31 22:32:44.329516
NCT01368679|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2014-11-18|2011-06-07|2011-06-08|Estimate|||||||2014-11-18|2014-11-19|Estimate||||November 2014|2014-11-30||||||||Interventional|Stent-Graft||A Clinical Study to Evaluate the Safety and Performance of the Modular AAA Stent-Graft System|Phase III of the Prospective, Non-randomized and Multicenter Clinical Evaluation of the Safety and Performance of the Modular AAA Stent-Graft System When Used in the Treatment of Subjects With Abdominal Aortic Aneurysms (AAA)|Withdrawn||Phase 3|0|Actual|Scitech Produtos Medicos Ltda||1|||f||||t||||||||||2018-05-31 22:32:44.397688|2018-05-31 22:32:44.397688
NCT01368666|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2015-05-21|2011-06-07|2011-06-08|Estimate|||||||2015-05-21|2015-05-22|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|September 2018|Anticipated|2018-09-30|October 2014|Actual|2014-10-31||Interventional|CAVALIER||Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark|Perceval S Valve Clinical Trial for Extended CE Mark|Active, not recruiting||Phase 2/Phase 3|658|Actual|LivaNova||1|||f||||t||||||||||2018-05-31 22:32:44.482542|2018-05-31 22:32:44.482542
NCT01368653|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2014-11-07||2014-11-17|2011-06-06|2011-06-08|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-17|2014-11-18|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional||The total number of participants in the sample was 93. The 40 participants randomly assigned to Very low nicotine cigarettes or Advice and encouragement only were a subset of the 93 participants randomly assigned to initial experimental conditions (Standard treatment or Standard treatment+practice quitting) if still smoking at 4-week follow-up.|Evaluation of Learning-Theory-Based Smoking Cessation Strategies|Evaluation of Learning-Theory-Based Smoking Cessation Strategies|Completed||N/A|93|Actual|Rutgers University||4|||f||||f||||||||||2018-05-31 22:32:44.616121|2018-05-31 22:32:44.616121
NCT01368640|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2012-10-02|2011-06-07|2011-06-08|Estimate|||||||2012-10-02|2012-10-03|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|September 2011|Actual|2011-09-30||Observational|||Generation of Prediction Equations to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)|Generation of Prediction Equations to Analyze Body Composition of Adults Based on Bioelectrical Impedance Analysis (BIA)|Completed|||153|Actual|Seca GmbH & Co. Kg.|||1||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 22:32:44.975941|2018-05-31 22:32:44.975941
NCT01368627|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2012-08-22|2011-06-07|2011-06-08|Estimate|||||||2012-08-22|2012-08-23|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions|"A Prospective, Multinational Investigation of the Supralimus® Sirolimus-Eluting Stent for the Treatment of Unselected Patients With Coronary Lesions in the Real- World Clinical Practice"|Completed||Phase 4|1274|Actual|Sahajanand Medical Technologies Pvt. Ltd.||1|||f||||t||||||||||2018-05-31 22:32:45.048406|2018-05-31 22:32:45.048406
NCT01368614|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2015-09-18|2011-06-07|2011-06-08|Estimate|||||||2015-09-18|2015-09-22|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||AVAPS-AE Efficacy Study|Randomized Controlled Trial Evaluating the Feasibility of AVAPS-AE vs. CPAP vs.Bilevel Pressure Support Ventilation in Obesity Hypoventilation Syndrome|Completed||N/A|32|Actual|Philips Respironics||3|||f||||f||||||||||2018-05-31 22:32:45.144145|2018-05-31 22:32:45.144145
NCT01368601|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2016-10-17|2011-06-07|2011-06-08|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Intraoperative Continuous Airway Pressure (CPAP) on the Inflammatory Response to One-lung Ventilation|Effects of Intraoperative Continuous Airway Pressure (CPAP) on the Inflammatory Response of the Lung With Cancer Undergoing Lobectomy. A Randomised Placebo-controlled Trial|Recruiting||N/A|60|Anticipated|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 22:32:45.213319|2018-05-31 22:32:45.213319
NCT01368588|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2017-05-18|2011-06-07|2011-06-08|Estimate|||||||2017-05-18|2017-05-19|Actual|July 2011|Actual|2011-07-31|May 2017|2017-05-31||||July 2027|Anticipated|2027-07-31||Interventional|||Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer|Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial|Recruiting||Phase 3|2580|Anticipated|Radiation Therapy Oncology Group||2|||f||||t||||||||No||2018-05-31 22:32:45.302523|2018-05-31 22:32:45.302523
NCT01368575|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-09-21|2011-06-07|2011-06-08|Estimate|||||||2015-09-21|2015-09-23|Estimate|May 2011||2011-05-31|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|May 2014|Actual|2014-05-31||Interventional|TIME||Surgical Treatment of Ischemic Mitral Regurgitation|The Effect of Different Surgical Methods in the Treatment of Patients With Ischemic Mitral Regurgitation and Assess the Dynamics of Heart Failure and the Effectiveness of Surgical Treatment of Mitral Valve.|Unknown status|Recruiting|Phase 4|420|Anticipated|Meshalkin Research Institute of Pathology of Circulation||5|||f||||t||||||||||2018-05-31 22:32:45.794608|2018-05-31 22:32:45.794608
NCT01368562|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-06|2011-06-08|Estimate|||||||2011-07-17|2011-07-19|Estimate|January 2003||2003-01-31|July 2011|2011-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Compassionate Use Study of Methylnaltrexone|A Compassionate Use Study of Methylnaltrexone in Patients With Opioid-Induced Side Effects|Completed||N/A|26|Actual|Valeant Pharmaceuticals International, Inc.||1|||t||||f||||||||||2018-05-31 22:32:45.873539|2018-05-31 22:32:45.873539
NCT01368549|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-01-09|2011-06-07|2011-06-08|Estimate|||||||2012-01-09|2012-01-11|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)|Metanx® P.L.U.S. Program (Progress Through Learning, Understanding & Support)|Unknown status|Active, not recruiting||800|Anticipated|Pamlab, Inc.|||1||f||||f||||||||||2018-05-31 22:32:45.926932|2018-05-31 22:32:45.926932
NCT01368536|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2013-02-14||2013-03-18|2011-06-07|2011-06-08|Estimate|2013-02-14|2013-03-19|Estimate||||2013-03-18|2013-03-21|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|VALENCIA||Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes|A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes|Terminated||Phase 4|975|Actual|Novartis||3||"Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with~   an ACE inhibitor or ARB, in diabetics with renal impairment"|f||||f||||||||||2018-05-31 22:32:46.014233|2018-05-31 22:32:46.014233
NCT01367639|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2013-11-22|2011-06-06|2011-06-07|Estimate|||||||2013-11-22|2013-11-25|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers|Pilot Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers|Completed||Phase 2|67|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 22:33:01.936895|2018-05-31 22:33:01.936895
NCT01368523|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2016-11-15|2011-06-07|2011-06-08|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2008||2008-12-31|November 2016|2016-11-30||||January 2010|Actual|2010-01-31||Interventional|||Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial|An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial|Completed||Phase 4|19|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:32:47.390792|2018-05-31 22:32:47.390792
NCT01368510|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2014-12-16|2011-06-06|2011-06-08|Estimate|||||||2014-12-16|2014-12-18|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Intensive Cognitive-Behavioral Therapy For Obsessive-Compulsive Disorder|Cognitive-Behavioral Therapy and Glutamate in Cingulate Gyrus in OCD|Unknown status|Recruiting|N/A|75|Anticipated|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 22:32:47.476406|2018-05-31 22:32:47.476406
NCT01368497|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2018-02-22|2011-06-07|2011-06-08|Estimate|||||||2018-02-22|2018-02-26|Actual|September 2012||2012-09-30|February 2018|2018-02-28|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|||Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection|Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN)|Completed||Phase 3|60|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t|t|f||||||No||2018-05-31 22:32:47.559383|2018-05-31 22:32:47.559383
NCT01368484|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-07|||2011-06-07|2011-06-07|2011-06-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Dietary DHA Supplementation on Sperm Quality|Effect of Dietary DHA Supplementation on Sperm Quality.|Completed||N/A|120|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 22:32:47.674235|2018-05-31 22:32:47.674235
NCT01368471|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2013-05-28|2011-06-07|2011-06-08|Estimate|||||||2013-05-28|2013-05-29|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MASTER||Safety and Efficacy Study of MGuard Stent After a Heart Attack|MASTER: MGUARD for Acute ST Elevation Reperfusion|Completed||Phase 4|433|Actual|InspireMD||2|||f||||t||||||||||2018-05-31 22:32:47.855158|2018-05-31 22:32:47.855158
NCT01368458|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2017-02-07|2011-06-06|2011-06-08|Estimate|||||||2017-02-07|2017-02-09|Estimate|December 2007||2007-12-31|February 2017|2017-02-28|July 2008|Actual|2008-07-31|||||Interventional|MOPE||Conversion to Antipsychotic Monotherapy|A Randomized, Rater-Blind, Controlled, Clinical Trial of Conversion to Antipsychotic Monotherapy vs. Continued Polypharmacy for Patients With Schizophrenia or Schizoaffective Disorder|Terminated||N/A|24|Anticipated|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-05-31 22:32:47.938735|2018-05-31 22:32:47.938735
NCT01368445|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-10-05|2011-06-07|2011-06-08|Estimate|||||||2011-10-05|2011-10-06|Estimate|August 2006||2006-08-31|October 2011|2011-10-31|April 2008|Actual|2008-04-30|November 2006|Actual|2006-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|617|Actual|Meda Pharmaceuticals||4|||f||||f||||||||||2018-05-31 22:32:48.024325|2018-05-31 22:32:48.024325
NCT01368432|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2016-07-13||2016-08-31|2011-06-07|2011-06-08|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions|Escitalopram (Lexapro) for the Treatment of TBI Depression and Other Comorbid Psychiatric Conditions|Completed||Phase 2|16|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 22:32:48.246656|2018-05-31 22:32:48.246656
NCT01368419|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-04-22|2011-06-06|2011-06-08|Estimate|||||||2013-04-22|2013-04-24|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients|Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients|Unknown status|Recruiting|Phase 2|40|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 22:32:48.838636|2018-05-31 22:32:48.838636
NCT01368406|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|2012-09-12||2013-04-12|2011-06-07|2011-06-08|Estimate|2013-04-12|2013-05-22|Estimate||||2013-04-12|2013-05-22|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Lifestyle Intervention for Weight Gain Management for Patients With Schizophrenia|Efficacy of a Non-pharmacological Intervention for Weight Gain Management for Patients With Schizophrenia: Multicentric, Randomized Clinical Trial|Completed||N/A|160|Actual|Federal University of São Paulo|short duration of the intervention (12 weeks) and duration of follow up. This lifestyle intervention was previously conducted in all sites that participated of this study.|2|||f||||f||||||||||2018-05-31 22:32:48.945875|2018-05-31 22:32:48.945875
NCT01368393|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2012-12-14|2011-06-06|2011-06-08|Estimate|||||||2012-12-14|2012-12-17|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Electroacupuncture Analgesia for Colonoscopy|Electroacupuncture Analgesia for Colonoscopy: a Prospective, Randomized, Double-blind, Sham-controlled Study|Completed||Phase 3|128|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:32:49.236551|2018-05-31 22:32:49.236551
NCT01368380|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2015-02-25|2011-06-06|2011-06-07|Estimate|||||||2015-02-25|2015-02-26|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|HIH||Hand in Hand. Psychological Support and Counseling to Breast Cancer Patients and Their Partners|Hand in Hand. Psychological Intervention for Breast Cancer Patients and Their Partners. A Randomised, Controlled Trial.|Completed||N/A|198|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 22:32:49.313456|2018-05-31 22:32:49.313456
NCT01368367|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|December 2007||2007-12-31|November 2010|2010-11-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Exercise Training Post Burn Injury|Safety and Efficacy of Exercise Training Post Burn Injury: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|36|Anticipated|The University of Queensland||2|||f||||f||||||||||2018-05-31 22:32:49.423926|2018-05-31 22:32:49.423926
NCT01368354|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2015-02-10|2011-06-06|2011-06-07|Estimate|||||||2015-02-10|2015-02-11|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SANTOSOIL||Taenia Solium Control Case Study in Zambia|Impact of Community-Led Total Sanitation on the Control of Taenia Solium and Soil Transmitted Helminths in the Eastern Province of Zambia|Completed||N/A|1197|Actual|University of Zambia||2|||f||||f||||||||||2018-05-31 22:32:49.59493|2018-05-31 22:32:49.59493
NCT01368341|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2014-12-11|2011-06-06|2011-06-07|Estimate|||||||2014-12-11|2014-12-12|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|NorTick_EM||Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice|Tick Borne Diseases in Norwegian General Practice. A Randomized, Controlled Trial for Treatment of Erythema Migrans in Norwegian General Practice. A Comparison of Phenoxymethylpenicillin, Amoxicillin and Doxycycline.|Completed||Phase 4|225|Anticipated|University of Oslo||3|||f||||t||||||||||2018-05-31 22:32:49.677901|2018-05-31 22:32:49.677901
NCT01368328|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|September 2011|Anticipated|2011-09-30|July 2011|Anticipated|2011-07-31||Interventional|||Effect of the Chromium Nicotinate on Type 2 Diabetes|Effect of Chromium Supplementation on Insulin Sensitivity in Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 3|57|Anticipated|Universidade Federal de Goias||3|||f||||f||||||||||2018-05-31 22:32:49.771346|2018-05-31 22:32:49.771346
NCT01368315|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate||||June 2011|2011-06-30||||||||Interventional|CT327 AD01-09||"CT 327 in the Atopy Patch Test Model"|"CT 327 in the Atopy Patch Test Model"|Withdrawn||Phase 1|20|Anticipated|Creabilis SA||4||Strategic decision|f||||f||||||||||2018-05-31 22:32:49.875226|2018-05-31 22:32:49.875226
NCT01368302|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-12-01|2011-06-06|2011-06-07|Estimate|||||||2014-12-01|2014-12-02|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)|Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)|Completed||Phase 2|52|Actual|Tel Aviv University||2|||f||||f||||||||||2018-05-31 22:32:49.959813|2018-05-31 22:32:49.959813
NCT01368289|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2018-03-13|2011-06-06|2011-06-07|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2008||2008-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|ACEEMR||Australian Multicentre Colonic Endoscopic Mucosal Resection Study|Australian Multicentre Colonic Endoscopic Mucosal Resection (ACE/EMR) Study|Recruiting|||2000|Anticipated|Western Sydney Local Health District|||1||f||||f||||||||||2018-05-31 22:32:50.02878|2018-05-31 22:32:50.02878
NCT01368276|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2015-09-22||2015-11-12|2011-06-06|2011-06-07|Estimate|2015-11-12|2015-12-18|Estimate||||2015-11-12|2015-12-18|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma|An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05|Completed||Phase 3|31|Actual|BioVex Limited||2|||f||||||||||||||2018-05-31 22:32:50.134221|2018-05-31 22:32:50.134221
NCT01368263|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2015-01-23||2015-03-16|2011-06-06|2011-06-07|Estimate|2015-02-18|2015-02-20|Estimate||||2015-03-16|2015-04-03|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer|A Multisite International Collaborative Phase 2 Study of Neoadjuvant Goserelin and a Non-steroidal Aromatase Inhibitor for Premenopausal Women With Estrogen Receptor Positive HER2 Negative Clinical Stage 2 and 3 Breast Cancer|Terminated||Phase 2|8|Actual|Washington University School of Medicine||3||Due to funding source and lack of accrual|f||||t||||||||||2018-05-31 22:32:50.64781|2018-05-31 22:32:50.64781
NCT01368250|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2018-03-14|2011-06-06|2011-06-07|Estimate|||||||2018-03-14|2018-03-15|Actual|February 2011||2011-02-28|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||SWISS TAVI Registry|SWISS TAVI Registry: Prospective, National, Multi-Center Registry of Patients Undergoing Transcatheter Aortic Valve Implantation|Recruiting|||3000|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||||||2018-05-31 22:32:50.970358|2018-05-31 22:32:50.970358
NCT01368237|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2014-10-27|2011-06-06|2011-06-07|Estimate|||||||2014-10-27|2014-10-28|Estimate|May 2006||2006-05-31|October 2014|2014-10-31||||June 2014|Actual|2014-06-30||Observational|||Dynamic Myocardial Perfusion Imaging by 320 Multidetector Computed Tomography|Dynamic Myocardial Perfusion Imaging by 320 Multidetector Computed Tomography|Completed|||75|Anticipated|University of Edinburgh|||1||f||||f||||||||||2018-05-31 22:32:51.040361|2018-05-31 22:32:51.040361
NCT01368224|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|June 2004||2004-06-30|June 2011|2011-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Two Supplemented Against Skin Reactivity|PLACEBO-CONTROLLED STUDY OF THE EFFECT OF TWO FOOD SUPPLEMENTS ON SKIN REACTIVITY|Completed||Phase 3|96|Actual|L'Oreal||3|||f||||t||||||||||2018-05-31 22:32:51.101703|2018-05-31 22:32:51.101703
NCT01368211|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2014-02-27||2016-05-23|2011-06-06|2011-06-07|Estimate|2014-02-27|2014-04-07|Estimate||||2016-05-23|2016-06-28|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|PRESS||Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)|PRESS Pathogen Reduction Extended Storage Study PRESS (Pathogen Reduction Extended Storage Study) A Pilot Study of Mirasol Platelets Treated in Platelet Additive Solution in Thrombocytopenic Patients|Terminated||Phase 2/Phase 3|16|Actual|Terumo BCTbio|Small numbers of subjects|2||Part 1 completed, part 2 not done due to slow enrollment|f||||t||||||||||2018-05-31 22:32:51.175202|2018-05-31 22:32:51.175202
NCT01368198|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2012-01-31|2011-06-06|2011-06-07|Estimate|||||||2012-01-31|2012-02-02|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion|The Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion|Completed||N/A|50|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:32:51.429371|2018-05-31 22:32:51.429371
NCT01368185|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2011-08-02||2015-10-09|2011-06-06|2011-06-07|Estimate|2011-08-02|2011-09-01|Estimate||||2015-10-09|2015-10-12|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)|A Retrospective Survey to Evaluate the Impact of Hyzaar on Uric Acid in the Management of Hypertensive Patients in Normal Practice|Completed|||1705|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:32:51.583714|2018-05-31 22:32:51.583714
NCT01368172|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2014-04-07|2011-06-06|2011-06-07|Estimate|||||||2014-04-07|2014-04-08|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Physical Activity Guidelines for People With Spinal Cord Injury (SCI)|Implementation and Evaluation of the New Physical Activity Guidelines for People With Spinal Cord Injury.|Completed||Phase 1|30|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:32:51.816304|2018-05-31 22:32:51.816304
NCT01367626|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2018-01-19|2011-06-06|2011-06-07|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2008||2008-03-31|January 2018|2018-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Letrozole Tablets Under Fed Conditions|Completed||Phase 1|28|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:33:01.995434|2018-05-31 22:33:01.995434
NCT01368159|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-09-13|2011-06-06|2011-06-07|Estimate|||||||2011-09-13|2011-09-14|Estimate|November 2010||2010-11-30|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the Great Saphenous Vein|Randomised, Comparative Trial in Parallel Groups and Blinded, to Compare Efficacy on Pain Following a Procedure for Injecting Sclerotherapeutic Foam Into the G.S V. Under Echography Control, Between Three Types of Medical Compression Hose|Completed||Phase 4|120|Actual|Le Club Mousse||3|||f||||f||||||||||2018-05-31 22:32:51.885718|2018-05-31 22:32:51.885718
NCT01368146|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-04-15|2011-06-06|2011-06-07|Estimate|||||||2015-04-15|2015-04-16|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Human Repeat Insult Patch Test of Wound Dressings||Completed||Phase 1|216|Actual|Covalon Technologies Inc.||3|||f||||f||||||||||2018-05-31 22:32:51.960304|2018-05-31 22:32:51.960304
NCT01368133|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2013-09-24|2011-06-06|2011-06-07|Estimate|||||||2013-09-24|2013-09-26|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Observational Study of Growth Hormone-secreting Pituitary Tumors|The Observational Study of the Structures and Functions of Multiple Organs in Patients With Growth Hormone-secreting Tumors|Unknown status|Recruiting||60|Anticipated|Huashan Hospital|||||f||||t||||||Samples With DNA|"~     Plasma, DNA and pituitary tumor tissues~   "|||2018-05-31 22:32:52.037472|2018-05-31 22:32:52.037472
NCT01368120|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-04-15|2011-06-06|2011-06-07|Estimate|||||||2015-04-15|2015-04-16|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Antimicrobial Activity of IV Clear™ Dressing - Prevention of Antimicrobial Regrowth||Completed||Phase 1|37|Actual|Covalon Technologies Inc.||3|||f||||f||||||||||2018-05-31 22:32:52.135214|2018-05-31 22:32:52.135214
NCT01368107|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2015-02-06|2011-06-06|2011-06-07|Estimate|||||||2015-02-06|2015-02-09|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|||Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients|A Randomised, Multicentric, Phase 2a Study Evaluating the Impact of an Immunotherapy by IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients|Completed||Phase 2|24|Actual|Centre Leon Berard||4|||f||||t||||||||||2018-05-31 22:32:52.235554|2018-05-31 22:32:52.235554
NCT01368094|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2016-05-02|2011-06-06|2011-06-07|Estimate|||||||2016-05-02|2016-05-03|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Early (4 Days) Versus Standard Drainage of the Abdominal Cavity After Pancreaticoduodenectomy|Early (4 Days) Versus Standard Drainage Removal of the Abdominal Cavity After Pancreaticoduodenectomy- - A Randomized Multicenter Study|Completed||N/A|141|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 22:32:52.344023|2018-05-31 22:32:52.344023
NCT01368081|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2014-05-16||2014-05-16|2011-06-06|2011-06-07|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus|A 52-week, Randomised, Multi-centre, Parallel Group Study to Investigate the Safety and Efficacy of BI 10773 (10 mg or 25 mg Administered Orally Once Daily) as add-on Therapy to an Oral Antidiabetic Drug (Sulfonylurea, Biguanide, Thiazolidinedione, Alpha Glucosidase Inhibitor, DPP-IV Inhibitor, or Glinide) in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control|Completed||Phase 3|1162|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:32:52.503322|2018-05-31 22:32:52.503322
NCT01368068|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-03-29|2011-06-06|2011-06-07|Estimate|||||||2015-03-29|2015-03-31|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Investigation of Tibolone and Escitalopram in Perimenopausal Depression|Double-Blind Randomised Investigation of Tibolone or Escitalopram in First Onset Perimenopausal Depression|Terminated||Phase 4|2|Actual|The Alfred||3||Difficulty in recruiting|f||||t||||||||||2018-05-31 22:32:54.75187|2018-05-31 22:32:54.75187
NCT01368055|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-01-17|2011-06-06|2011-06-07|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2011||2011-09-30|January 2018|2018-01-31|September 2036|Anticipated|2036-09-30|July 2018|Anticipated|2018-07-31||Interventional|PR07||Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer|An Expanded Phase II Study of Hypofractionated Dose Intense Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate|Active, not recruiting||N/A|360|Anticipated|University of Florida||2|||f||||t|f|f||||||||2018-05-31 22:32:54.816581|2018-05-31 22:32:54.816581
NCT01368042|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|2014-06-26||2014-07-29|2011-06-06|2011-06-07|Estimate|2014-06-26|2014-07-24|Estimate||||2014-07-29|2014-08-01|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|QUALITIZE|All participants in the enrolled population, regardless of whether or not they completed the study (i.e., the 6-month post-enrollment follow-up). Of the 265 participants enrolled, 11 were considered to have protocol deviations and were excluded from the enrolled population; therefore, 254 participants were included in the study analyses.|Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous|Quality of Life in Greek Hemodialysis Patients Receiving Zemplar i.v (QualitiZe)|Completed|||265|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:32:55.11859|2018-05-31 22:32:55.11859
NCT01368029|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-01-10|2011-06-06|2011-06-07|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine|Double Blind Randomized Controlled Trial to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine|Completed||Phase 1|28|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:32:55.774839|2018-05-31 22:32:55.774839
NCT01368016|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2012-07-06|2011-06-06|2011-06-07|Estimate|||||||2012-07-06|2012-07-10|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Therapy and Nicotine Gum|Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Product and Nicotine Gum 4 mg. A Study in Healthy Smokers|Completed||N/A|346|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 22:32:55.851806|2018-05-31 22:32:55.851806
NCT01368003|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2015-08-29|2011-06-06|2011-06-07|Estimate|||||||2015-08-29|2015-09-01|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling|A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||2||Loss of funding.|f||||t||||||||||2018-05-31 22:32:55.938119|2018-05-31 22:32:55.938119
NCT01367990|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-05|||2012-03-22|2011-06-05|2011-06-07|Estimate|||||||2012-03-22|2012-03-23|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy|Alopecia Prevention Trial of Topical Vasoconstrictor Therapy in Head and Neck Cancer Patients Treated With Intensity Modulated Radiotherapy (IMRT)|Terminated||Phase 1|3|Actual|ProCertus BioPharm, Inc||1||Study site has terminated the study due to the complexity of the study|f||||f||||||||||2018-05-31 22:32:56.021388|2018-05-31 22:32:56.021388
NCT01367977|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-05|||2015-04-02|2011-06-05|2011-06-07|Estimate|||||||2015-04-02|2015-04-03|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life|"Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia (POTS -- Postural Orthostatic Tachycardia Syndrome)Later in Life -- a Retrospective Analysis"|Completed|||21|Actual|Genetic Disease Investigators|||1||f||||t||||||||||2018-05-31 22:32:56.172665|2018-05-31 22:32:56.172665
NCT01367964|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-02-03|2011-06-05|2011-06-07|Estimate|||||||2015-02-03|2015-02-04|Estimate|July 2011||2011-07-31|February 2015|2015-02-28||||June 2015|Anticipated|2015-06-30||Interventional|PREVENT-WS||Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)|Early Treatment of Infants at High Risk of Developing West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)|Unknown status|Recruiting|N/A|28|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||f||||||||||2018-05-31 22:32:56.259506|2018-05-31 22:32:56.259506
NCT01367951|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2017-11-23|2011-06-04|2011-06-07|Estimate|||||||2017-11-23|2017-11-27|Actual|July 2011||2011-07-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment of Acute, Unstable Chest Wall Injuries|A Multi Centered Randomized Controlled Trial of Operative Versus Non-operative Treatment of Acute, Unstable Chest Wall Injuries|Recruiting||N/A|206|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 22:32:56.373633|2018-05-31 22:32:56.373633
NCT01367938|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22|||2017-12-11|2011-06-06|2011-06-07|Estimate|||||||2017-12-11|2017-12-13|Actual|November 2009||2009-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Clinical Outcomes With Omni Apex Ultracongruent Knee System|OMNI Apex Knee Ultracongruent vs. Triathlon® Posterior Stabilized & Cruciate Substituting Outcomes Study|Active, not recruiting|||69|Actual|Spokane Joint Replacement Center|||1||f||||t||||||||||2018-05-31 22:32:56.503842|2018-05-31 22:32:56.503842
NCT01367925|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22|||2017-12-11|2011-06-06|2011-06-07|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2007||2007-12-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Stryker Triathlon® Cruciate Substituting vs. Posterior Stabilized Outcomes Study|A Prospective, Randomized, Comparison of Total Knee Arthroplasty With the Triathlon® CS Tibial Insert vs. the Triathlon® PS Tibial Insert.|Completed|||125|Actual|Spokane Joint Replacement Center|||2||f||||t||||||||||2018-05-31 22:32:56.565514|2018-05-31 22:32:56.565514
NCT01367912|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|February 2008||2008-02-29|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Timing of Estrogen Support During the Luteal Phase of in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycle|Timing of Estrogen Support During the Luteal Phase of IVF / Intracytoplasmic Sperm Injection Cycle: a Randomized Controlled Trial|Completed||N/A|301|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||3|||f||||f||||||||||2018-05-31 22:32:56.633276|2018-05-31 22:32:56.633276
NCT01367899|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2014-10-24|2011-06-03|2011-06-07|Estimate|||||||2014-10-24|2014-10-28|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||CONSERVE Plus Post-Approval Study (PAS)|Conserve Plus Total Hip Resurfacing System: A Non-Randomized, Multi-center, NewEnrollement Post Approval Study|Terminated|||199|Actual|MicroPort Orthopedics Inc.|||1||f||||f||||||||||2018-05-31 22:32:56.726105|2018-05-31 22:32:56.726105
NCT01367886|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2013-07-09||2015-02-10|2011-06-06|2011-06-07|Estimate|2014-12-30|2015-01-12|Estimate||||2015-02-10|2015-02-27|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||The overall number of participants is 21. The 21 participants that took Fesoterodine were the basis for analysis.|Comparative Urine Proteomic Studies of Overactive Bladder in Humans|Comparative Urine Proteomic Studies of Overactive Bladder in Humans|Completed||N/A|21|Actual|Washington University School of Medicine|No serious adverse events.|1|||f||||t||||||||||2018-05-31 22:32:56.803219|2018-05-31 22:32:56.803219
NCT01367873|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2012-01-18|2011-06-03|2011-06-07|Estimate|||||||2012-01-18|2012-01-19|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects|A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects|Completed||Phase 1|72|Actual|Madrigal Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 22:32:57.178839|2018-05-31 22:32:57.178839
NCT01367860|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2013-04-01||2014-05-19|2011-06-06|2011-06-07|Estimate|2014-05-19|2014-06-04|Estimate||||2014-05-19|2014-06-04|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|PDOP_TLR||Percutaneous Diskectomy SpineJet x Open Microdiskectomy in Treatment of Lumbar Radiculopathy|Comparison of Percutaneous Diskectomy SpineJet x Open Microdiscectomy for Treatment of Lumbar Radiculopathy in Contained Disc Herniation: Randomized Clinical Trial|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:32:57.714396|2018-05-31 22:32:57.714396
NCT01367847|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2014-06-13|2011-06-06|2011-06-07|Estimate|||||||2014-06-13|2014-06-16|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|TE-HNC||Technology-Enhanced Helping the Noncompliant Child|Technology Enhanced Delivery of Treatment for Early Conduct Problems|Completed||Phase 1|22|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:32:59.30198|2018-05-31 22:32:59.30198
NCT01367834|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2016-12-12||2017-02-03|2011-06-06|2011-06-07|Estimate|2017-02-03|2017-03-24|Actual||||2017-02-03|2017-03-24|Actual|May 2010||2010-05-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome|Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome|Completed||N/A|17|Actual|University of North Carolina, Chapel Hill|Low scan success rate and subject drop out resulted in small sample size (5 GH treated, 1 control).|2|||f||||f||||||||No||2018-05-31 22:32:59.428562|2018-05-31 22:32:59.428562
NCT01367613|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-18|2011-06-06|2011-06-07|Estimate|||||||2011-07-18|2011-07-19|Estimate|March 2004||2004-03-31|July 2011|2011-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Open-Label Treatment Extension of Protocol MNTX 302|A Three-Month Open-Label Treatment Extension of Protocol MNTX 302|Completed||Phase 3|89|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||t||||||||||2018-05-31 22:33:02.054022|2018-05-31 22:33:02.054022
NCT01367821|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-10-04|2011-06-06|2011-06-07|Estimate|||||||2012-10-04|2012-10-05|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Immune Function in Patients With Obstructive Jaundice|Quorum Sensing Signal Molecules (QSSMs) and Immune Dysfunction in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) for Obstructive Jaundice|Unknown status|Recruiting||50|Anticipated|University of Nottingham|||2||f||||f||||||Samples Without DNA|"~     Plasma Bile~   "|||2018-05-31 22:33:00.062949|2018-05-31 22:33:00.062949
NCT01367808|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PosaBupre||Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine|Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine: A Three-phase Cross-over Study in Healthy Subjects|Completed||Phase 1|12|Anticipated|Turku University Hospital||3|||f||||f||||||||||2018-05-31 22:33:00.178621|2018-05-31 22:33:00.178621
NCT01367795|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2015-03-26|2011-06-03|2011-06-07|Estimate|||||||2015-03-26|2015-03-27|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Surgical Procedures for Advanced Tumor Disease. A Prospective Study Evaluating Quality of Life|Surgical Procedures for Advanced Tumor Disease. A Prospective Study Evaluating Quality of Life|Completed|||26|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-05-31 22:33:00.272374|2018-05-31 22:33:00.272374
NCT01367782|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2014-09-10|2011-06-06|2011-06-07|Estimate|||||||2014-09-10|2014-09-11|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Double Blind Sham-controled Study to Evaluate the Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease|A Double Blind Sham-controled Study to Evaluate the Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease|Unknown status|Recruiting|N/A|51|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 22:33:00.36207|2018-05-31 22:33:00.36207
NCT01367769|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2017-04-21|2011-06-06|2011-06-07|Estimate|||||||2017-04-21|2017-04-24|Actual|March 2011||2011-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Observational|||Venous Vascularization and Inflammation on Contrast-enhanced Ultrasound (CEUS) in Patients With Thrombosis|Evaluation of Perivascular Venous Vascularization and Inflammation by Contrast-enhanced Ultrasound (CEUS) in Patients With Acute Deep Vein Thrombosis and Superficial Thrombophlebitis - a Pilot Study|Terminated|||20|Actual|University Hospital, Basel, Switzerland|||1|insufficient recruitment|f||||f||||||Samples Without DNA|"~     The investigators will also determine level of inflammatory markers as the cytokines~     interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant-1 (MCP-1), Vascular~     cellular adhesion molecule-1 (VCAM-1), von Willebrand factor (vWF) and C-reactive protein~     (CRP) at each visit (baseline, 2 weeks, and 3 months).~   "|||2018-05-31 22:33:00.448239|2018-05-31 22:33:00.448239
NCT01367756|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2016-11-01|2011-06-06|2011-06-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers|A Single Center, Randomized, Double-blind, Parallel-design Study to Investigate the Safety and Tolerability of RO4995819 in Combination With Citalopram Following Oral Administration in Healthy Volunteers|Completed||Phase 1|32|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:33:00.533344|2018-05-31 22:33:00.533344
NCT01367743|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-04-21|2011-06-06|2011-06-07|Estimate|||||||2017-04-21|2017-04-24|Actual|September 2011||2011-09-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|OptimaCC||Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock|Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine|Completed||Phase 4|58|Actual|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 22:33:00.629159|2018-05-31 22:33:00.629159
NCT01367730|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-12-01|2011-06-06|2011-06-07|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Assessment of Bone Micro-Architecture Using HR-pQCT|Non-Invasive Assessment of Bone Micro-architecture and Strength Changes in Men With Osteopenia and Osteoporosis|Completed|||80|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-05-31 22:33:00.741793|2018-05-31 22:33:00.741793
NCT01367717|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2012-09-14|2011-06-06|2011-06-07|Estimate|||||||2012-09-14|2012-09-17|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ECSUC||Effect of Creatine on Serum and Urine Creatinine|Effect of Creatine Monohydrate and Creatine Ethyl Ester on Serum and Urinary Creatinine|Completed||N/A|25|Actual|Beth Israel Medical Center||2|||f||||t||||||||||2018-05-31 22:33:00.803373|2018-05-31 22:33:00.803373
NCT01367704|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2014-05-29||2014-07-16|2011-06-03|2011-06-07|Estimate|2014-07-16|2014-08-08|Estimate||||2014-07-16|2014-08-08|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CBIM||"Evaluation Of Coaching Boys Into Men (CBIM) Program"|"A Randomized Controlled Trial of an Adolescent Relationship Abuse Prevention Program Entitled Coaching Boys Into Men"|Completed||N/A|2006|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 22:33:00.887225|2018-05-31 22:33:00.887225
NCT01367691|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2014-01-31|2011-06-06|2011-06-07|Estimate|||||||2014-01-31|2014-02-03|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Cardiac MR (CMR) in Cardiac Resynchronization Therapy Non-responders|Cardiac MR (CMR) in Cardiac Resynchronization Therapy (CRT) Non-responders: Therapy Optimization by Means of Tissue Characterization, Hemodynamic Analysis and Analysis of Myocardial Activation|Terminated||N/A|1|Actual|University Hospital, Bonn|||||f||||f||||||||||2018-05-31 22:33:01.304081|2018-05-31 22:33:01.304081
NCT01367678|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2011-08-23|2011-06-06|2011-06-07|Estimate|||||||2011-08-23|2011-08-24|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Mucosal Pressure of the Laryngeal Mask Airway Supreme Versus the i-Gel in Paralyzed Anesthetized Female Patients|Directly Measured Mucosal Pressure for Two Different Extraglottic Airway Devices|Completed||N/A|30|Anticipated|Schulthess Klinik||2|||f||||t||||||||||2018-05-31 22:33:01.405908|2018-05-31 22:33:01.405908
NCT01367665|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2017-08-29|2011-06-06|2011-06-07|Estimate|||||||2017-08-29|2017-08-30|Actual|July 1, 2011|Actual|2011-07-01|August 2017|2017-08-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)|Completed||Phase 2|1226|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:33:01.614309|2018-05-31 22:33:01.614309
NCT01367587|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-07-18|2011-06-03|2011-06-07|Estimate|||||||2011-07-18|2011-07-19|Estimate|April 2002||2002-04-30|July 2011|2011-07-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone|Safety and Gastrointestinal Effects of Multiple-Dosed Intravenous Methylnaltrexone in Healthy Human Volunteers|Completed||Phase 2|12|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:33:02.201481|2018-05-31 22:33:02.201481
NCT01367574|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-18|2011-06-06|2011-06-07|Estimate|||||||2011-07-18|2011-07-19|Estimate|April 2002||2002-04-30|July 2011|2011-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction|A Phase II Double-Blind, Randomized, Parallel Group, Dose Ranging Study of Subcutaneous Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction|Completed||Phase 2|39|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||f||||||||||2018-05-31 22:33:03.269201|2018-05-31 22:33:03.269201
NCT01367561|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-18|2011-06-06|2011-06-07|Estimate|||||||2011-07-18|2011-07-19|Estimate|October 2002||2002-10-31|July 2011|2011-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function|A Phase I Urodynamic Study of the Opioid Antagonist, Naloxone and Intravenous Methylnaltrexone Reverse Opioid Effects on Bladder Function in Healthy Volunteers|Completed||Phase 1|15|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||f||||||||||2018-05-31 22:33:03.36526|2018-05-31 22:33:03.36526
NCT01367548|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-18|2011-06-03|2011-06-07|Estimate|||||||2011-07-18|2011-07-19|Estimate|July 2003||2003-07-31|July 2011|2011-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus|A Phase II Double-Blind Randomized Parallel Group Study of Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus|Completed||Phase 2|65|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 22:33:03.431546|2018-05-31 22:33:03.431546
NCT01367535|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-03|2011-06-07|Estimate|||||||2011-07-17|2011-07-19|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan|A Phase I, Randomized, Open-Label, Active- and Placebo-Controlled Parallel Group Study of the Effect of Subcutaneous and Intravenous Methylnaltrexone on CYP450 2D6 Activity in Healthy Extensive Metabolizers of Dextromethorphan|Completed||Phase 1|54|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||||2018-05-31 22:33:03.516641|2018-05-31 22:33:03.516641
NCT01367522|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-06|2011-06-07|Estimate|||||||2011-07-17|2011-07-19|Estimate|March 2004||2004-03-31|July 2011|2011-07-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function|A Phase 1, Open-Label, Study to Evaluate Single Dose Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Volunteers With Impaired Hepatic Function|Completed||Phase 1|24|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:33:03.589903|2018-05-31 22:33:03.589903
NCT01367509|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-06|2011-06-07|Estimate|||||||2011-07-17|2011-07-19|Estimate|March 2004||2004-03-31|July 2011|2011-07-31|June 2005|Actual|2005-06-30|January 2005|Actual|2005-01-31||Interventional|||Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function|A Phase 1, Open-Label Study to Evaluate Single Dose Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function|Completed||Phase 1|32|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:33:03.651943|2018-05-31 22:33:03.651943
NCT01367496|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-06|2011-06-07|Estimate|||||||2011-07-17|2011-07-19|Estimate|June 2002||2002-06-30|July 2011|2011-07-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose|An Open-Label, Phase I Study of the Pharmacokinetics and Bioavailability of Single, Ascending Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose in Normal, Healthy Male Volunteers|Completed||Phase 1|6|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||||2018-05-31 22:33:03.737127|2018-05-31 22:33:03.737127
NCT01367483|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-03|2011-06-07|Estimate|||||||2011-07-17|2011-07-19|Estimate|June 2005||2005-06-30|July 2011|2011-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Study of the Pharmacokinetics of Intravenous Administered 14C-MNTX|An Open-Label, Phase I, Single Dose Study of the Pharmacokinetics, Mass Balance and Disposition of Intravenously Administered 14C-Methylnaltrexone in Normal, Healthy Volunteers|Completed||Phase 1|6|Anticipated|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:33:03.902971|2018-05-31 22:33:03.902971
NCT01367470|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-01-09|2011-06-03|2011-06-07|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Influence of Probiotic VSL#3 Administration on Metabolic and Immunological Profile of the Milk of Breastfeeding Mothers|Effects on Cytokines, Immunoglobulins, Antibodies, Sphingomyelinase and PAF Hydrolysis Capacity in the Maternal Milk After Probiotic VSL#3 Administration in the Last Four Weeks of Gestation and First Month of Lactation|Completed||Phase 4|67|Actual|Policlinico Hospital||2|||f||||t||||||||||2018-05-31 22:33:03.979527|2018-05-31 22:33:03.979527
NCT01367457|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2016-03-25||2016-03-25|2011-06-06|2011-06-07|Estimate|2016-03-25|2016-04-27|Estimate||||2016-03-25|2016-04-27|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational||Baseline population included all participants with RCC or MCL who received atleast 1 dose of study treatment.|INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus|Inhibitor - Estudio Retrospectivo De Casos Clinicos De Pacientes Con Carcinoma De Celulas Renales Y Con Linforma De Celulas Del Manto Tratados Con Temsirolimus|Completed|||243|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:33:04.108016|2018-05-31 22:33:04.108016
NCT01367444|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2018-05-29|2011-06-06|2011-06-07|Estimate|||||||2018-05-29|2018-05-30|Actual|June 10, 2011||2011-06-10|May 2018|2018-05-31|November 27, 2019|Anticipated|2019-11-27|November 27, 2019|Anticipated|2019-11-27||Interventional|||Phase I/II Study of SAR422459 in Patients With Stargardt's Macular Degeneration|A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration|Recruiting||Phase 1/Phase 2|46|Anticipated|Sanofi||3|||f||||t||||||||||2018-05-31 22:33:04.870998|2018-05-31 22:33:04.870998
NCT01367431|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2015-07-23|2011-06-03|2011-06-07|Estimate|||||||2015-07-23|2015-07-24|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Xanthohumol and Metabolic Syndrome|Xanthohumol and Metabolic Syndrome|Completed|||48|Actual|Oregon State University|||3||f||||t||||||||||2018-05-31 22:33:04.94398|2018-05-31 22:33:04.94398
NCT01367418|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2012-03-16|2011-06-06|2011-06-07|Estimate|||||||2012-03-16|2012-03-19|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|AIMS||Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy|Comparison Between Epidural and Patient Controlled Analgesia on Immunological and Inflammatory Systems Following Radical Retropubic Prostatectomy|Completed||Phase 3|26|Actual|Örebro University, Sweden||2|||f||||t||||||||||2018-05-31 22:33:05.067728|2018-05-31 22:33:05.067728
NCT01367405|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2016-10-12|2011-06-06|2011-06-07|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|COSMIC||Comparing Surgical Decompression Versus Conservative Treatment in Incomplete Spinal Cord Injury|COSMIC: Conservative or Early Surgical Management of Incomplete Cervical Cord Syndrome Without Spinal Instability. Randomized Controlled Trial|Terminated||N/A|1|Actual|Radboud University||2||only 1 inclusion in 1.5 years due to strict exclusion criteria|f||||f||||||||||2018-05-31 22:33:05.200021|2018-05-31 22:33:05.200021
NCT01367392|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-06|||2012-02-14|2011-06-06|2011-06-07|Estimate|||||||2012-02-14|2012-02-15|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effectiveness and Safety of CT-guided Needle Placement in the Liver With the Aid of the ActiSight Needle Guidance System|Confirmation of Clinical Effectiveness and Safety of CT-guided Needle Placement in the Liver With the Aid of the ActiSight Needle Guidance System|Completed||Phase 4|20|Actual|ActiViews Ltd.||1|||f||||f||||||||||2018-05-31 22:33:05.388466|2018-05-31 22:33:05.388466
NCT01367379|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2012-01-03|2011-06-06|2011-06-07|Estimate|||||||2012-01-03|2012-01-05|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||The Effect of the Duty Loading on the Stress Response of Physician|The Effect of the Duty Loading on the Stress Response of Physician|Unknown status|Recruiting||15|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 22:33:05.508167|2018-05-31 22:33:05.508167
NCT01367366|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|May 2010||2010-05-31|May 2011|2011-05-31||||April 2012|Anticipated|2012-04-30||Observational|||Dx Mediastinal Malignant LAP:Compare PET and EBUS-TBNA|Dx Mediastinal Malignant LAP:Compare PET and EBUS-TBNA|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 22:33:05.680966|2018-05-31 22:33:05.680966
NCT01367353|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Characterization of Ovarian Cancer Stem Cell|Characterization of Ovarian Cancer Stem Cell: Focus on Identification of Biomarker and Drug Resistance|Unknown status|Recruiting|N/A|250|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:33:05.747493|2018-05-31 22:33:05.747493
NCT01367340|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-05-16|2011-06-03|2011-06-07|Estimate|||||||2012-05-16|2012-05-17|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effect of Physical Activity Intervention Children With Spastic Diplegia After Resistance Training|Effect of Physical Activity Intervention on Mobility Changes and Participation for School-Age Children With Spastic Diplegia and After Resistance Training|Unknown status|Active, not recruiting|N/A|32|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 22:33:05.909052|2018-05-31 22:33:05.909052
NCT01367327|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-05-16|2011-06-03|2011-06-07|Estimate|||||||2012-05-16|2012-05-17|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Therapeutic Music Combined With Loaded Sit-to-Stand Resistance Exercise for Children With Spastic Diplegia|Effects of Therapeutic Music Combined With Loaded Sit-to-Stand Resistance Exercise for Children With Spastic Diplegia|Completed||N/A|36|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 22:33:06.110558|2018-05-31 22:33:06.110558
NCT01367314|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2011-06-06|2011-06-06|2011-06-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of Topical NVC-422 Gel in Impetigo|A Phase IIa, Double Blind, Randomized, Sequential Group Study to Evaluate the Safety and Efficacy of Topical NVC-422 Dermal Gel in Impetigo|Completed||Phase 2|129|Actual|NovaBay Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 22:33:06.215596|2018-05-31 22:33:06.215596
NCT01367301|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-01-16|2011-06-06|2011-06-07|Estimate|||||||2015-01-16|2015-01-19|Estimate|May 2011||2011-05-31|January 2015|2015-01-31||||January 2016|Anticipated|2016-01-31||Interventional|||Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer|"A Pilot Trial of Radiation Therapy Sandwiched Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma"|Unknown status|Recruiting|N/A|18|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 22:33:06.458681|2018-05-31 22:33:06.458681
NCT01367288|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2014-05-28|2011-06-06|2011-06-07|Estimate|||||||2014-05-28|2014-05-29|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|NEOZOL||Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers|Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers|Completed||Phase 2|53|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 22:33:06.574803|2018-05-31 22:33:06.574803
NCT01367275|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2015-01-07|2011-06-06|2011-06-07|Estimate|||||||2015-01-07|2015-01-08|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF|Phase II Study of Second-line Irinotecan Plus Brivanib, a Dual Tyrosine Inhibitor of VEGFR and FGFR, in Metastatic Colorectal Cancer Patients Enriched for Elevated Levels of Plasma FGF Following Progression on Bevacizumab-based Treatment|Terminated||Phase 2|8|Actual|M.D. Anderson Cancer Center||1||Sponsor closed study|f||||f||||||||||2018-05-31 22:33:06.68501|2018-05-31 22:33:06.68501
NCT01367262|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2011-08-09|2011-06-03|2011-06-07|Estimate|||||||2011-08-09|2011-08-11|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Disposition of 14C-LY2886721 Following Oral Administration in Healthy Human Subjects|Disposition of [14C]-LY2886721 Following Oral Administration in Healthy Human Subjects|Completed||Phase 1|8|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:33:06.773921|2018-05-31 22:33:06.773921
NCT01367249|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2014-04-04|2013-02-04|2014-04-04|2011-06-06|2011-06-07|Estimate|2014-04-04|2014-05-06|Estimate|2013-02-04|2013-02-06|Estimate|2014-04-04|2014-05-06|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional||Intent to treat population (ITT), all randomized participants|Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery|Efficacy and Safety of Bromfenac Ophthalmic Solution vs. Placebo for the Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery.|Completed||Phase 3|440|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:33:06.848302|2018-05-31 22:33:06.848302
NCT01367236|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2017-01-09|2011-06-06|2011-06-07|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CogUK||Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa|A Randomised, Prospective Study, Assessing Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa.|Completed||Phase 4|60|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 22:33:07.190131|2018-05-31 22:33:07.190131
NCT01367223|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2013-09-05|2011-06-06|2011-06-07|Estimate|||||||2013-09-05|2013-09-06|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Interventional|||Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation|Modulation of Systemic Inflammatory Response in Critically Ill Children After Glutamine Supplementation|Completed||Phase 4|101|Actual|Hospital Sant Joan de Deu||2|||f||||f||||||||||2018-05-31 22:33:07.271043|2018-05-31 22:33:07.271043
NCT01367210|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2016-02-05|2011-06-03|2011-06-07|Estimate|||||||2016-02-05|2016-02-08|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|GUSTA||Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)|Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial|Terminated||Phase 4|165|Actual|Catholic University of the Sacred Heart||2||Because a higher rate of virological failures in study versus control arm.|f||||f||||||||||2018-05-31 22:33:07.374966|2018-05-31 22:33:07.374966
NCT01367197|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-06-03|2011-06-03|2011-06-07|Estimate|||||||2011-06-03|2011-06-07|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Study of the Effect of Exercise Training on Patients in Atrial Fibrillation|Randomised Study of the Effect of Exercise Training on Patients in Atrial Fibrillation|Completed||N/A|49|Actual|Copenhagen University Hospital, Hvidovre||2|||f||||f||||||||||2018-05-31 22:33:07.452581|2018-05-31 22:33:07.452581
NCT01367184|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2013-06-20|2011-06-06|2011-06-07|Estimate|||||||2013-06-20|2013-06-21|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|May 2014|Anticipated|2014-05-31|April 2013|Actual|2013-04-30||Observational|||National Inferior Vena Cava (IVC) Filter Registry|IVC Filter Study to Monitor and Measure Patients Outcomes Through Standardized Collection and Analysis of Clinical Information|Terminated|||20000|Actual|American Venous Forum|||||f||||t||||||||||2018-05-31 22:33:07.533741|2018-05-31 22:33:07.533741
NCT01367171|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2015-10-29|2011-06-03|2011-06-06|Estimate|||||||2015-10-29|2015-10-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:33:07.723464|2018-05-31 22:33:07.723464
NCT01367158|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|2014-02-11||2014-11-17|2011-06-03|2011-06-06|Estimate|2014-11-17|2014-11-19|Estimate||||2014-11-17|2014-11-19|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines|Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY in Adolescents Who Previously Received the Same Study Vaccines|Completed||Phase 2|440|Actual|Novartis||11|||f||||f||||||||||2018-05-31 22:33:07.857906|2018-05-31 22:33:07.857906
NCT01367145|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2014-08-24|2011-06-03|2011-06-06|Estimate|||||||2014-08-24|2014-08-26|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease|OMEGA-3-POLYUNSATURATED FATTY-ACIDS (n3-PUFA) IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: EFFECTS ON ENDOTHELIAL FUNCTION - A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL|Completed||Phase 3|71|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 22:33:11.2709|2018-05-31 22:33:11.2709
NCT01367132|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-02-20|2011-06-03|2011-06-06|Estimate|||||||2013-02-20|2013-02-22|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Assessment of the Number of Umbilical Cord Vessels at the Time of Nuchal Translucency Screening|Assessment of the Number of Umbilical Cord Vessels at the Time of Nuchal Translucency Screening|Completed|||123|Actual|Medstar Health Research Institute|||||f||||f||||||||||2018-05-31 22:33:11.364709|2018-05-31 22:33:11.364709
NCT01367119|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2013-03-18||2013-08-05|2011-06-03|2011-06-06|Estimate|2013-07-03|2013-08-06|Estimate||||2013-08-05|2013-08-08|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Ketamine Anesthesia in Electroconvulsive Therapy|A Randomized Comparison of Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy (ECT) in Depression|Completed||N/A|38|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:33:11.457308|2018-05-31 22:33:11.457308
NCT01367106|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-12-20|2011-06-03|2011-06-06|Estimate|||||||2017-12-20|2017-12-21|Actual|November 2012|Actual|2012-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|GLUCODEX||"Effects of in UTERO Exposure to Glucocorticoids"|"Study of the Effects in Carbohydrate Metabolism and Renal Function of in UTERO Exposure to Glucocorticoids in Adult Offsprings (GLUCODEX)"|Active, not recruiting||N/A|46|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:33:11.731946|2018-05-31 22:33:11.731946
NCT01367093|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2017-05-02|2011-06-03|2011-06-06|Estimate|||||||2017-05-02|2017-05-05|Actual|July 2011||2011-07-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|FROG-ICU||French and EuRopean Outcome Registry in Intensive Care Unit|French and EuRopean Outcome Registry in Intensive Care Unit|Completed|||2137|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Plasma and urine at admission and ICU discharge~   "|||2018-05-31 22:33:11.797134|2018-05-31 22:33:11.797134
NCT01367080|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2013-02-20||2014-08-06|2011-06-03|2011-06-06|Estimate|2014-08-06|2014-08-22|Estimate||||2014-08-06|2014-08-22|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|DWETR||A Study to Compare the Pharmacokinetic Profiles of Etravil® Tablet 10mg and Etravil® Tablet 25mg|Clinical Trials to Compare the Pharmacokinetics Profile of Etravil®(Amitriptyline Hydrochloride) Tablet 10mg and Etravil®(Amitriptyline Hydrochloride) Tablet 25mg After a Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Dong Wha Pharmaceutical Co. Ltd.|"When collecting blood samples, few subjects were drawn blood later than that stated in protocol for about 1 ~ 2 minutes where results may not be effected.~One of the subjects came in late for Post-study visit for about 4~6 days."|2|||f||||t||||||||||2018-05-31 22:33:11.883137|2018-05-31 22:33:11.883137
NCT01367054|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-06-03|2011-06-03|2011-06-06|Estimate|||||||2011-06-03|2011-06-06|Estimate|June 2008||2008-06-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Adverse Events in Pharmaceutical Bioequivalence Study of Two Formulations of Metformine Hydrochloride 500 mg|Adverse Events in Pharmaceutical Bioequivalence Study of Two Formulations of Metformine Hydrochloride 500 mg|Unknown status|Active, not recruiting|N/A|26|Anticipated|Biocinese||1|||f||||f||||||||||2018-05-31 22:33:12.352938|2018-05-31 22:33:12.352938
NCT01367041|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-01-29|2011-06-03|2011-06-06|Estimate|||||||2013-01-29|2013-01-30|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|PMO-WBV-sEMG||Effect of Bone on Vibration-Induced Muscle Electrical Activity|Effect of Hip Bone Mineral Density / Content on Vibration-Induced Hip Adductors Muscle Electrical Activity in Postmenopausal Women|Completed||N/A|80|Actual|Bagcilar Training and Research Hospital||2|||f||||t||||||||||2018-05-31 22:33:12.435337|2018-05-31 22:33:12.435337
NCT01367028|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-05-12|2011-06-03|2011-06-06|Estimate|||||||2014-05-12|2014-05-13|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ABCSG 32||A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer|Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Breast Cancer|Completed||Phase 2|100|Actual|Austrian Breast & Colorectal Cancer Study Group||4|||f||||t||||||||||2018-05-31 22:33:12.515967|2018-05-31 22:33:12.515967
NCT01367015|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-06-03|2011-06-03|2011-06-06|Estimate|||||||2011-06-03|2011-06-06|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|AREDF||Early Versus Late Initiation of Feeding in Premature Growth Restricted Newborns With Absent or Reversed End Diastolic Flow On Umbilical Artery Doppler (AREDF)|A Randomized Clinical Trial on Comparison of Early Versus Late Initiation of Feeding in Preterm Small for Gestation Infants Below 35 Weeks Gestation With Prenatal Absent or Reversal of End Diastolic Flow (AREDF) in Umbilical Artery|Completed||N/A|60|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 22:33:12.660193|2018-05-31 22:33:12.660193
NCT01367002|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2018-03-05|2011-06-02|2011-06-06|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2011||2011-06-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer|Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma|Active, not recruiting||Phase 2|61|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:33:12.736875|2018-05-31 22:33:12.736875
NCT01366989|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-02-15|2011-06-02|2011-06-06|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2010|Actual|2010-10-31|February 2017|2017-02-28|June 4, 2013|Actual|2013-06-04|June 4, 2013|Actual|2013-06-04||Observational|||INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation|INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation|Terminated|||24|Actual|Wright Medical Technology|||1|"The retrospective data review did not provide adequate information to continue the~   investigation."|f||||t||||||||||2018-05-31 22:33:12.831252|2018-05-31 22:33:12.831252
NCT01366976|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2015-01-06||2015-01-14|2011-06-03|2011-06-06|Estimate|2015-01-06|2015-01-14|Estimate||||2015-01-14|2015-01-27|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Patients were eligible for the study if he/she was 18-80 years of age and undergoing elective cardiac surgery requiring cardiopulmonary bypass.|Inhibition of Lipid Peroxidation During Cardiac Surgery|Inhibition of Lipid Peroxidation During Cardiopulmonary Bypass|Completed||N/A|67|Actual|Vanderbilt University|The exploratory analysis of acute kidney injury (AKI) was limited by the low incidence of postoperative AKI in the current study, so we were underpowered to detect small differences in creatinine or NGAL concentrations.|2|||f||||f||||||||||2018-05-31 22:33:12.914363|2018-05-31 22:33:12.914363
NCT01366963|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-08-15|2011-06-02|2011-06-06|Estimate|||||||2016-08-15|2016-08-17|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Cognitive Dysfunction in Postural Tachycardia Syndrome|Origins of Cognitive Dysfunction in Postural Tachycardia Syndrome (POTS)|Completed|||60|Actual|Vanderbilt University|||2||f||||f||||||||||2018-05-31 22:33:13.400171|2018-05-31 22:33:13.400171
NCT01366950|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2016-12-28|2011-06-03|2011-06-06|Estimate|||||||2016-12-28|2016-12-29|Estimate|June 2011||2011-06-30|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|HEALTHCHANGE||Work Place Health Promotion: a Change Project|Work Place Health Promotion as a Change Project|Completed||Phase 2|406|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 22:33:13.522022|2018-05-31 22:33:13.522022
NCT01366937|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2011-08-03|2011-06-02|2011-06-06|Estimate|||||||2011-08-03|2011-08-04|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Assessment of Vitamin B12 Bioavailability From Egg|Assessment of Vitamin B12 Bioavailability From Egg|Completed|||10|Anticipated|USDA, Western Human Nutrition Research Center|||||f||||f||||||Samples With DNA|"~     Plasma, serum, buffy coat, urine, stool~   "|||2018-05-31 22:33:13.60934|2018-05-31 22:33:13.60934
NCT01366924|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-07-19|2011-06-02|2011-06-06|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2007||2007-05-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Essential Amino Acids Supplementation and Muscle Protein Synthesis|The Effect of Amino Acid Supplementation on Skeletal Muscle Protein Turnover Following Endurance Exercise|Completed||Phase 1/Phase 2|23|Actual|United States Army Research Institute of Environmental Medicine||4|||f||||f||||||||||2018-05-31 22:33:13.696098|2018-05-31 22:33:13.696098
NCT01366911|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-09-12|2011-06-03|2011-06-06|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2011||2011-04-30|September 2017|2017-09-30|January 10, 2014|Actual|2014-01-10|January 10, 2014|Actual|2014-01-10||Observational|||Stem Cells Predicting Orthopedic Outcomes|Can Stem Cells Predict Orthopaedic Outcomes? The Correlation of Bone Density Findings Post Total Hip Arthoplasty With Stem Cell Assays Obtaned at Time of Surgery|Completed|||203|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 22:33:13.77599|2018-05-31 22:33:13.77599
NCT01366898|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2018-03-19|2011-06-03|2011-06-06|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2010|Actual|2010-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)|PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years)|Recruiting||Phase 4|100|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 22:33:13.905383|2018-05-31 22:33:13.905383
NCT01321749|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2012-01-11||2012-03-30|2011-03-23|2011-03-24|Estimate|2012-03-30|2012-04-25|Estimate||||2012-03-30|2012-04-25|Estimate|January 2008||2008-01-31|March 2012|2012-03-31||||December 2011|Actual|2011-12-31||Interventional|||The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease||Completed||Phase 1/Phase 2|196|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 22:45:53.999063|2018-05-31 22:45:53.999063
NCT01366885|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2016-04-02||2016-05-05|2011-06-02|2011-06-06|Estimate|2016-05-05|2016-06-14|Estimate||||2016-05-05|2016-06-14|Estimate|February 2008||2008-02-29|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Mothers of at least one child with autism and pregnant before the third trimester|Vitamin D to Prevent Autism in Newborn Siblings|Study of Vitamin D to Prevent Autism in Newborn Siblings|Completed||Phase 2|20|Actual|Oregon Health and Science University||1|||f||||t||||||||Yes|Please see publication in Medical Hypotheses-88(2016) 74-78-entitled: Autism: Will vitamin D Supplementation during pregnancy and early childhood reduce the recurrence rate of autism in newborn siblings? G. Stubbs et al.|2018-05-31 22:33:14.093085|2018-05-31 22:33:14.093085
NCT01366872|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2012-10-16||2012-11-20|2011-06-03|2011-06-06|Estimate|2012-11-20|2012-12-20|Estimate||||2012-11-20|2012-12-20|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|||Agility LP Ankle Arthroplasty Outcomes|Agility LP Ankle Arthroplasty: Clinical and Radiographic Outcomes|Completed|||50|Actual|Orthopaedic Associates of Michigan, PC|||||f||||f||||||||||2018-05-31 22:33:14.284208|2018-05-31 22:33:14.284208
NCT01366859|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2016-11-02|2011-06-02|2011-06-06|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior|Nutritional Intervention Using Supplementation With Cysteine-Rich Whey Protein Isolate (Immunocal®) in Children With Autism: Effects in Core Areas of Behavior- A Randomized Double-Blind Study|Completed||Phase 2|81|Actual|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 22:33:14.443108|2018-05-31 22:33:14.443108
NCT01366846|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2016-11-08||2017-01-30|2011-06-02|2011-06-06|Estimate|2016-11-08|2017-01-06|Estimate||||2017-01-30|2017-03-10|Actual|May 2011||2011-05-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|LEAP-On|Intent-to-treat|Persistence of Oral Tolerance to Peanut|The Persistence of Oral Tolerance Induction to Peanut and Its Immunological Basis (ITN049AD)|Completed||Phase 2|556|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|ITN049AD (LEAP-On) is a continuation of the ITN032AD LEAP Study. The plan is to share data in: 1.) ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network.|2018-05-31 22:33:14.549314|2018-05-31 22:33:14.549314
NCT01366833|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-06-03|2011-06-03|2011-06-06|Estimate|||||||2011-06-03|2011-06-06|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Optimal Management of Malignant Dysphagia|Management of Malignant Dysphagia: Stent vs. Stent Plus Endoluminal Brachytherapy for the Palliation of Dysphagia in Metastatic Esophageal Cancer|Unknown status|Not yet recruiting|Phase 1|72|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 22:33:15.00502|2018-05-31 22:33:15.00502
NCT01366820|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-29||2018-01-31|2018-02-01|2011-06-02|2011-06-06|Estimate||||2018-01-31|2018-02-02|Estimate|2018-02-01|2018-02-05|Actual|February 2013||2013-02-28|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|INTREPID2566||Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC|A Randomized, Double-Blind, Placebo-Controlled, Study of NNZ-2566 in Patients With Traumatic Brain Injury (TBI) Conducted Under an Exception From Informed Consent (EFIC)|Completed||Phase 2|261|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||No||2018-05-31 22:33:15.080088|2018-05-31 22:33:15.080088
NCT01366807|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-03-23|2011-06-03|2011-06-06|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Screening of Nutritional Status in Cardiac Surgery|Screening of Nutritional Status and Predictors of Adverse Outcome in Cardiac Surgery|Completed|||894|Actual|Meshalkin Research Institute of Pathology of Circulation|||||f||||t||||||Samples Without DNA|"~     Serum, white cells~   "|||2018-05-31 22:33:15.159286|2018-05-31 22:33:15.159286
NCT01366794|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-03-14|2011-06-02|2011-06-06|Estimate|||||||2014-03-14|2014-03-17|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|||Macronutrients and Gut Hormone Secretion|Effects of Macronutrients on Gut Hormone and Islet Hormone Secretion in Healthy Volunteers and Type 2 Diabetes|Completed||N/A|36|Anticipated|Lund University||2|||f||||t||||||||||2018-05-31 22:33:15.213371|2018-05-31 22:33:15.213371
NCT01366781|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-09-29|2011-06-02|2011-06-06|Estimate|||||||2014-09-29|2014-09-30|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Gut Hormones After Meal Ingestion in Males Versus Females|Effects of Varying Meal Size on Gut Hormone and Islet Hormone Secretion in Males Versus Females|Completed||N/A|24|Actual|Lund University||2|||f||||t||||||||||2018-05-31 22:33:15.293195|2018-05-31 22:33:15.293195
NCT01366768|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-10-09|2011-06-03|2011-06-06|Estimate|||||||2012-10-09|2012-10-10|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Gut Hormones After Oral Versus Intravenous Amino Acids|Release of Gut Hormones After Oral Versus Intravenous Amino Acids|Completed||N/A|12|Actual|Lund University||2|||f||||t||||||||||2018-05-31 22:33:15.371703|2018-05-31 22:33:15.371703
NCT01366742|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2016-05-13|2011-06-03|2011-06-06|Estimate|||||||2016-05-13|2016-05-17|Estimate|December 1987||1987-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women|Natural History of Human Papillomavirus From Infection to Neoplasia in Adolescents and Young Women - Effect of Tobacco on Cervical Neoplasia in Young Women|Completed|||900|Actual|University of California, Los Angeles|||1||f||||f||||||Samples With DNA|"~     Rbc, WBC vaginal lavages ,cytology,saliva ,anal samples~   "|||2018-05-31 22:33:15.598075|2018-05-31 22:33:15.598075
NCT01366729|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2015-07-07|2011-06-02|2011-06-06|Estimate|||||||2015-07-07|2015-07-08|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Gait Rehabilitation Post Stroke:the Long Term Effect of Two Walking Aids -Canes and TheraTogs|How to Improve Walking, Balance and Social Participation Following Stroke: a Comparison of Cane Walking to an Orthosis TheraTogs in Early Post-stroke Gait Rehabilitation. A Multi-centred, Single Blind,Randomized Control Trial.|Terminated||N/A|12|Actual|Technical University of Bern||2||Unable to recruite enough subjects to reach statistical power|f||||f||||||||||2018-05-31 22:33:15.672709|2018-05-31 22:33:15.672709
NCT01366716|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-07-26|2011-06-02|2011-06-06|Estimate|||||||2013-07-26|2013-07-30|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Contingency Management for Cocaine Dependence: Cash Versus Vouchers|Contingency Management for Cocaine Dependence: Cash Versus Vouchers|Completed||N/A|352|Actual|Treatment Research Institute||3|||f||||t||||||||||2018-05-31 22:33:15.74918|2018-05-31 22:33:15.74918
NCT00821249|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09||2015-03-06|2016-04-21|2009-01-12|2009-01-13|Estimate||||2015-03-06|2015-03-27|Estimate|2016-04-21|2016-05-19|Estimate|January 2009||2009-01-31|April 2016|2016-04-30||||March 2016|Actual|2016-03-31||Interventional|||A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma||Completed||Phase 1/Phase 2|55|Actual|Array BioPharma||3|||f||||f||||||||||2018-06-01 01:25:04.003333|2018-06-01 01:25:04.003333
NCT01366703|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2012-05-12|2011-06-03|2011-06-06|Estimate|||||||2012-05-12|2012-05-15|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|pharao||Optimized Heart Failure Therapy Through Continuous Monitoring|Optimized Heart Failure Therapy Through Continuous Monitoring. The PHARAO Multi-centre Study|Unknown status|Recruiting||50|Anticipated|Kennemer Gasthuis|||1||f||||t||||||||||2018-05-31 22:33:15.867286|2018-05-31 22:33:15.867286
NCT01366690|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-09-08|2011-06-02|2011-06-06|Estimate|||||||2014-09-08|2014-09-09|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|PeerCARE||The PeerCARE Study (Peer Community-based Assistant in REtention)|The PeerCARE Study (Peer Community-based Assistant in REtention): Effect of Peer Health Workers on People Living With HIV Not on Antiretroviral Therapy—A Randomized Trial|Completed||N/A|250|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:33:16.036841|2018-05-31 22:33:16.036841
NCT01366677|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-05-23|2011-06-02|2011-06-06|Estimate|||||||2014-05-23|2014-05-26|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|RPY||Yoga for Persons With Severe Visual Impairment|Development of a Yoga Intervention for Symptoms Related to Severe Visual Impairment|Completed||N/A|21|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 22:33:16.101166|2018-05-31 22:33:16.101166
NCT01366664|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-10-03|2011-06-03|2011-06-06|Estimate|||||||2014-10-03|2014-10-07|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin|A Randomized, Double-blind, Placebo-Controlled, Crossover Study Assessing the Pharmacodynamic Effects of Dapoxetine Concomitantly Administered in Subjects Taking Terazosin|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 22:33:16.190868|2018-05-31 22:33:16.190868
NCT01366651|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2013-12-04|2011-06-02|2011-06-06|Estimate|||||||2013-12-04|2013-12-06|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age|An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age|Terminated||Phase 1|1|Actual|Janssen Research & Development, LLC||1||Trial terminated early per business decision.|f||||f||||||||||2018-05-31 22:33:16.326845|2018-05-31 22:33:16.326845
NCT01366638|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2013-10-17|2013-04-23|2014-04-10|2011-06-03|2011-06-06|Estimate|2013-12-16|2014-01-20|Estimate|2013-04-23|2013-05-01|Estimate|2014-04-10|2014-05-05|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection|A Phase III, Open-Label Study in Japan to Assess the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2b and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects|Completed||Phase 3|79|Actual|Janssen Pharmaceutical K.K.|"All outcome measures reported in this study are Exploratory; not Primary as indicated. Primary was chosen for each outcome measure because Exploratory is not available as an outcome measure type on this form."|3|||f||||f||||||||||2018-05-31 22:33:16.437017|2018-05-31 22:33:16.437017
NCT01366625|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-01-25|2011-06-03|2011-06-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2011|Actual|2011-07-31|January 2017|2017-01-31|November 28, 2016|Actual|2016-11-28|February 8, 2016|Actual|2016-02-08||Interventional|||Renal Denervation in Patients With Resistant Hypertension and Obstructive Sleep Apnea|Effects of Renal Denervation on Blood Pressure and Clinical Course of Obstructive Sleep Apnea in Patients With Resistant Hypertension|Completed||N/A|60|Actual|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-05-31 22:33:17.075978|2018-05-31 22:33:17.075978
NCT01366612|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-08-08|2011-06-03|2011-06-06|Estimate|||||||2017-08-08|2017-08-09|Actual|June 16, 2010|Actual|2010-06-16|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|FLUBUTBI||PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation|PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant|Recruiting||Phase 3|54|Anticipated|Hackensack University Medical Center||2|||f||||t||||||||||2018-05-31 22:33:17.184582|2018-05-31 22:33:17.184582
NCT01366599|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-05-23|2011-06-02|2011-06-06|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2009||2009-05-31|May 2017|2017-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||CV Events in Emetogenic Chemotherapy|Cardiovascular Events in Cancer Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy|Completed|||12058|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:33:17.283828|2018-05-31 22:33:17.283828
NCT01366586|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-12-27|2011-06-02|2011-06-06|Estimate|||||||2011-12-27|2011-12-30|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-Ag|Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7 Antigen|Completed|||5|Actual|Shandong University|||||f||||t||||||Samples With DNA|"~     Taken biopsies during endoscopy~   "|||2018-05-31 22:33:17.381968|2018-05-31 22:33:17.381968
NCT01366573|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-07-18|2011-06-02|2011-06-06|Estimate|||||||2017-07-18|2017-07-21|Actual|May 13, 2011|Actual|2011-05-13|July 2017|2017-07-31|September 16, 2011|Actual|2011-09-16|September 16, 2011|Actual|2011-09-16||Interventional|||GSK1521498 Alcohol Interaction Study|A Randomised, Double-Blind, Single-Dose, Four-Period Cross-Over Study to Determine the Effects of Alcohol on the Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects|Completed||Phase 1|1|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:33:17.43597|2018-05-31 22:33:17.43597
NCT01366560|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-07-14|2011-06-02|2011-06-06|Estimate|||||||2017-07-14|2017-07-18|Actual|August 31, 2010|Actual|2010-08-31|July 2017|2017-07-31|October 22, 2010|Actual|2010-10-22|October 22, 2010|Actual|2010-10-22||Interventional|||Effect of GSK962040 on Oesophageal Function|A Double Blind Randomised Placebo Controlled Two Way Cross Over Study to Determine the Effect of GSK962040 on Oesophageal Function and Gastric Emptying in Healthy Male Volunteers.|Completed||Phase 1|14|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:33:17.684699|2018-05-31 22:33:17.684699
NCT01366378|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-18|2011-06-02|2011-06-06|Estimate|||||||2011-07-18|2011-07-19|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX|A Phase 1, Open-Label, Study of the Effect of Cimetidine, a Known Inhibitor of Active Renal Secretion, on the Single-Dose Pharmacokinetics of Intravenously-Administered Methylnaltrexone in Healthy Adults|Completed||Phase 1|18|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:33:22.581975|2018-05-31 22:33:22.581975
NCT01366547|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-08-04|2011-06-02|2011-06-06|Estimate|||||||2011-08-04|2011-08-08|Estimate|June 2011||2011-06-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets|A Randomized, Open-Label, Single‑Dose, 3‑Period, Crossover Evaluation of the Relative Bioavailability of Two Experimental Fixed-Dose Combination Tablet Formulations of Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared to Co‑Administered Dolutegravir 50 mg and EPZICOM™ (Abacavir 600 mg/Lamivudine 300 mg) Tablets in Healthy Adult Subjects|Completed||Phase 1|18|Actual|ViiV Healthcare||1|||||||f||||||||||2018-05-31 22:33:17.776481|2018-05-31 22:33:17.776481
NCT01366534|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2017-05-04|2012-11-16|2017-10-23|2011-06-02|2011-06-06|Estimate|2017-05-04|2017-06-09|Actual|2012-11-16|2012-11-21|Estimate|2017-10-23|2017-11-27|Actual|August 10, 2011|Actual|2011-08-10|October 2017|2017-10-31|July 3, 2012|Actual|2012-07-03|February 27, 2012|Actual|2012-02-27||Interventional|||Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults|Safety, Immunogenicity and Efficacy Against Malaria in the Sporozoite Challenge Model of One Dose of Ad35.CS.01 Malaria Vaccine Followed by Two Doses of Malaria 257049 Vaccine in Healthy Malaria-naïve Adults|Completed||Phase 2|68|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:33:17.913865|2018-05-31 22:33:17.913865
NCT01366521|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2015-11-05|2013-01-04|2016-11-21|2011-06-02|2011-06-06|Estimate|2015-11-05|2015-12-10|Estimate|2013-01-04|2013-01-10|Estimate|2016-11-21|2017-01-11|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils|A Multicenter, Open-label, Dose Ranging Study to Determine the Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Intravenously or Subcutaneously to Adult Asthmatic Subjects With Elevated Blood Eosinophil Levels|Completed||Phase 2|70|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:33:18.944531|2018-05-31 22:33:18.944531
NCT01366508|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-08-11|2011-06-02|2011-06-06|Estimate|||||||2014-08-11|2014-08-13|Estimate|October 2009||2009-10-31|August 2014|2014-08-31|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Characterize Event Related Potential Markers of Attentional Bias Towards Words and Images of Food|An Experimental Medicine Study to Characterize Event Related Potential Markers of Attentional Bias Towards Words and Images of Food in Healthy Volunteers|Terminated||Phase 1|5|Actual|GlaxoSmithKline||2||"Results of the study would unfortunately no longer be of any scientific interest to the sponsor~   and would not be used to inform future studies."|f||||f||||||||||2018-05-31 22:33:20.976976|2018-05-31 22:33:20.976976
NCT01366495|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-02-14|2011-06-02|2011-06-06|Estimate|||||||2017-02-14|2017-02-16|Actual|April 2011||2011-04-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Randomized Controlled Trial of HIV Testing and Linkage to Care at Community Corrections|A Randomized Controlled Trial and Cohort Study of HIV Testing and Linkage to Care Corrections|Completed||N/A|697|Actual|Friends Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 22:33:21.082102|2018-05-31 22:33:21.082102
NCT01366482|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2015-08-14|2011-06-02|2011-06-06|Estimate|||||||2015-08-14|2015-08-18|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|DEFINITIVE AR||Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease|Directional AthErectomy Followed by a PaclItaxel-Coated BallooN to InhibiT RestenosIs and Maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment|Completed||Phase 1/Phase 2|121|Actual|Medtronic Endovascular||3|||f||||t||||||||||2018-05-31 22:33:21.166966|2018-05-31 22:33:21.166966
NCT01366469|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-02-18|2011-06-03|2011-06-06|Estimate|||||||2014-02-18|2014-02-19|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|CABG BALF||Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting|Inflammatory Biomarkers Predict Pulmonary Outcomes in Coronary Artery Bypass Grafting|Completed|||10|Actual|Emory University|||||f||||t||||||Samples With DNA|"~     BAL fluid, Serum~   "|||2018-05-31 22:33:21.251038|2018-05-31 22:33:21.251038
NCT01366456|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-06-08|2011-06-03|2011-06-06|Estimate|||||||2011-06-08|2011-06-09|Estimate|June 2011||2011-06-30|April 2010|2010-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Clinical Trials for Comparison of Two Kinds of Moxibustion|Clinical Trials for Comparison Between Shingigu and Charcoal Moxa on CV-12|Unknown status|Recruiting|N/A|40|Anticipated|Semyung University||2|||f||||t||||||||||2018-05-31 22:33:21.346577|2018-05-31 22:33:21.346577
NCT01366443|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2012-04-26||2012-07-30|2011-06-03|2011-06-06|Estimate|2012-07-30|2012-07-31|Estimate||||2012-07-30|2012-07-31|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Analysis of ROM Plus to Detect Rupture of Membranes|Analysis of ROM Plus to Detect Rupture of Membranes|Completed|||288|Actual|Clinical Innovations, LLC|||1||f||||t||||||||||2018-05-31 22:33:21.574275|2018-05-31 22:33:21.574275
NCT01366430|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-02|2011-06-02|2011-06-06|Estimate|||||||2011-06-02|2011-06-06|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|HC BPPV||Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo|Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo; Randomized Controlled Trial of Barbeque Rotation and Gufoni Maneuver|Completed||Phase 3|170|Actual|Chonbuk National University||3|||f||||f||||||||||2018-05-31 22:33:22.017756|2018-05-31 22:33:22.017756
NCT01366417|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2012-02-16||2012-08-31|2011-06-03|2011-06-06|Estimate|2012-07-31|2012-08-31|Estimate||||2012-08-31|2012-09-10|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Topical Antimicrobial Effectiveness Testing|Test for Preinjection Skin Preparation|Completed||Phase 4|25|Actual|CareFusion|||||f||||f||||||||||2018-05-31 22:33:22.09816|2018-05-31 22:33:22.09816
NCT01366404|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-12-17|2011-06-02|2011-06-06|Estimate|||||||2017-12-17|2017-12-19|Actual|June 2011|Actual|2011-06-30|December 2017|2017-12-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|IRIS FFR||Study of the Natural History of FFR Guided Percutaneous Coronary Intervention|A Multicenter, Prospective Cohort to Evaluate the Natural History of FFR Guided Percutaneous Coronary Intervention|Recruiting|||10000|Anticipated|CardioVascular Research Foundation, Korea|||1||f||||t||||||||No|This is not publicly funded trial|2018-05-31 22:33:22.316096|2018-05-31 22:33:22.316096
NCT01366391|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-06-03|2011-06-03|2011-06-06|Estimate|||||||2011-06-03|2011-06-06|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|October 2011|Anticipated|2011-10-31|August 2011|Anticipated|2011-08-31||Interventional|||Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome|Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome|Unknown status|Recruiting|Phase 4|24|Anticipated|Biocinese||1|||f||||f||||||||||2018-05-31 22:33:22.494708|2018-05-31 22:33:22.494708
NCT01366365|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-02|2011-06-06|Estimate|||||||2011-07-17|2011-07-19|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone Bromide|A Phase 1 Randomized, Double-Blind, Placebo Controlled Parallel Group Study of the Pharmacokinetics, Safety and Tolerability of Methylnaltrexone Bromide Administered as Single and Multiple Intravenous Doses to Healthy Adults and Elderly Male and Female Subjects|Completed||Phase 1|28|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 22:33:22.686899|2018-05-31 22:33:22.686899
NCT01366352|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-03|2011-06-06|Estimate|||||||2011-07-17|2011-07-19|Estimate|February 2004||2004-02-29|July 2011|2011-07-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets|Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets: A Double-Blind, Single Dose, Crossover, Phase 1 Study in Normal Volunteers|Completed||Phase 1|24|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 22:33:22.773407|2018-05-31 22:33:22.773407
NCT01366339|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-02|2011-06-06|Estimate|||||||2011-07-17|2011-07-19|Estimate|October 2003||2003-10-31|July 2011|2011-07-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Tolerance and Pharmacokinetics Study of MNTX Tablets|A Replicate Design, Double-Blind, Randomized, Placebo-Controlled Tolerance and Pharmacokinetics Study of N-Methylnaltrexone Tablets in Normal, Healthy Volunteers|Completed||Phase 1|37|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||||2018-05-31 22:33:22.834192|2018-05-31 22:33:22.834192
NCT01366326|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-06-02|2011-06-06|Estimate|||||||2011-07-17|2011-07-19|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects|A Multiple-Dose, Open-Label Study to Evaluate the Pharmacokinetics of MNTX in Healthy Adult Subjects|Completed||Phase 1|20|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:33:23.995131|2018-05-31 22:33:23.995131
NCT01366313|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2012-12-07|2011-06-03|2011-06-06|Estimate|||||||2012-12-07|2012-12-10|Estimate|September 2007||2007-09-30|January 2011|2011-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Median Effective Dose (ED50) of Paracetamol and Morphine : A Study of Interaction Study|The Median Effective Dose (ED50) of Paracetamol and Morphine for Postoperative Patients: A Study of Interaction.|Completed||N/A|90|Actual|Procare Riaya Hospital||3|||f||||t||||||||||2018-05-31 22:33:24.075584|2018-05-31 22:33:24.075584
NCT01366300|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2011-06-03|2011-06-03|2011-06-06|Estimate|||||||2011-06-03|2011-06-06|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effect of Intravenous Lidocaine on BIS-guided Propofol Requirements During General Anesthesia|Estimation of the Effect of Intravenous Lidocaine on BIS-guided Propofol Requirements During General Anesthesia|Completed||Phase 4|40|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 22:33:24.163367|2018-05-31 22:33:24.163367
NCT01366287|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-06-02|2011-06-02|2011-06-06|Estimate|||||||2011-06-02|2011-06-06|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption|A Randomized, Open-Label, Single Dose, Crossover Study To Estimate The Relative Oral Bioavailability And Food Effect Of PF-03882845 In Healthy Adult Volunteers|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:33:24.246979|2018-05-31 22:33:24.246979
NCT01366274|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-03|2011-06-03|2011-06-06|Estimate|||||||2011-06-03|2011-06-06|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Protective Manual Hyperinflation in Acute Mechanically Ventilated Trauma Patients|Comparison of Protective Manual Hyperinflation With Current Methods in Ventilated Acute Trauma Patients: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|40|Anticipated|The University of Queensland||2|||f||||f||||||||||2018-05-31 22:33:24.346307|2018-05-31 22:33:24.346307
NCT01366261|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-11-09|2011-06-03|2011-06-06|Estimate|||||||2011-11-09|2011-11-11|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Rigid Versus Semirigid Thoracoscopy in Diagnosing Pleural Diseases: a Randomized Study|Rigid Versus Semirigid Thoracoscopy in Diagnosing Pleural Diseases: a Randomized Study|Completed||Phase 3|84|Actual|The University Clinic of Pulmonary and Allergic Diseases Golnik||2|||f||||t||||||||||2018-05-31 22:33:24.422918|2018-05-31 22:33:24.422918
NCT01366248|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2018-03-21|2011-06-02|2011-06-06|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2010||2010-08-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|IO-OS-BC||Integrative Oncology Outcomes Study in Breast Cancer|Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study|Completed|||750|Actual|Bastyr University|||2||f||||t||||||||||2018-05-31 22:33:24.494495|2018-05-31 22:33:24.494495
NCT01366235|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-01-23|2011-06-02|2011-06-06|Estimate|||||||2015-01-23|2015-01-26|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug|Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug|Completed||Phase 1|10|Actual|Asan Medical Center||4|||f||||||||||||||2018-05-31 22:33:24.56073|2018-05-31 22:33:24.56073
NCT01366222|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-06-02|2011-06-02|2011-06-06|Estimate|||||||2011-06-02|2011-06-06|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|FSAC||Food Concentrates Supplementation to Alleviate Asthma in Children|Food Concentrates Supplementation to Alleviate Asthma in Children|Completed||N/A|192|Actual|Academia Sinica, Taiwan||2|||f||||f||||||||||2018-05-31 22:33:24.718352|2018-05-31 22:33:24.718352
NCT01366209|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2015-02-27||2017-03-08|2011-06-02|2011-06-03|Estimate|2015-02-27|2015-03-12|Estimate||||2017-03-08|2017-04-05|Actual|June 2011||2011-06-30|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ASCEND||Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial)|Completed||Phase 3|555|Actual|Genentech, Inc.||2|||f||||t||||||||||2018-05-31 22:33:24.837527|2018-05-31 22:33:24.837527
NCT01366196|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2017-03-23||2018-03-28|2011-06-02|2011-06-03|Estimate|2017-05-22|2017-06-21|Actual||||2018-03-28|2018-03-30|Actual|October 2008||2008-10-31|March 2018|2018-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pregabalin for the Treatment of Pain After Posterior Spinal Fusions|Pregabalin for the Treatment of Pain After Posterior Spinal Fusions.|Completed||N/A|86|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 22:33:25.508277|2018-05-31 22:33:25.508277
NCT01366183|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-05-03|2011-06-02|2011-06-03|Estimate|||||||2017-05-03|2017-05-08|Actual|August 2011||2011-08-31|May 2017|2017-05-31||||December 2019|Anticipated|2019-12-31||Observational|||Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer|Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Active, not recruiting|||290|Anticipated|Gynecologic Oncology Group|||1||f||||f||||||||||2018-05-31 22:33:25.847921|2018-05-31 22:33:25.847921
NCT01366170|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2016-05-17|2011-06-02|2011-06-03|Estimate|||||||2016-05-17|2016-05-19|Estimate|May 2011||2011-05-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma|Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)|Completed|||7|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:33:26.709209|2018-05-31 22:33:26.709209
NCT01366157|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2016-05-13|2011-06-02|2011-06-03|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma|Investigation to Evaluate the Levels of Human Germinal-center-Associated Lymphoma (HGAL) Protein in Pediatric Hodgkin Lymphoma and Correlate With Early Response|Completed|||23|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 22:33:26.79703|2018-05-31 22:33:26.79703
NCT01366144|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2017-07-25|2011-06-02|2011-06-03|Estimate|||||||2017-07-25|2017-07-26|Actual|June 20, 2011|Actual|2011-06-20|July 2017|2017-07-31||||July 31, 2017|Anticipated|2017-07-31||Interventional|||Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction|An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors|Recruiting||Phase 1|276|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:33:26.916871|2018-05-31 22:33:26.916871
NCT01366131|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02||2016-08-10|2016-11-01|2011-06-02|2011-06-03|Estimate||||2016-08-10|2016-08-12|Estimate|2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30||||February 2013|Actual|2013-02-28||Interventional|||Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease|Completed||Phase 2|104|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:33:27.168042|2018-05-31 22:33:27.168042
NCT01366118|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-02|2011-06-02|2011-06-03|Estimate|||||||2011-06-02|2011-06-03|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|TT||Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients|Prospective Pilot Study of Therapeutic Targets (TT) Tailored Chemotherapy (Ch) and Intensity Modulated Radiotherapy (IMRT) as Neoadjuvant Treatment in Patients With Rectal Carcinoma|Completed||N/A|16|Actual|Grupo Hospital de Madrid||1|||f||||f||||||||||2018-05-31 22:33:27.324026|2018-05-31 22:33:27.324026
NCT01366105|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2013-04-01|2011-06-02|2011-06-03|Estimate|||||||2013-04-01|2013-04-04|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||VAC NPWT KCI Dressing Study|Use of Negative Pressure Wound Therapy for At Risk Surgical Closures|Withdrawn||N/A|0|Actual|Georgetown University||2|||f||||f||||||||||2018-05-31 22:33:27.417406|2018-05-31 22:33:27.417406
NCT01366092|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|2014-12-18||2017-10-03|2011-06-02|2011-06-03|Estimate|2015-01-07|2015-01-15|Estimate||||2017-10-03|2017-11-06|Actual|July 2011||2011-07-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|October 2014|Actual|2014-10-31||Interventional|||Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-Disease|Active, not recruiting||Phase 2|35|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 22:33:27.687674|2018-05-31 22:33:27.687674
NCT01366079|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2015-03-30|2011-06-02|2011-06-03|Estimate|||||||2015-03-30|2015-03-31|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Dynamic Position Change in Colonic Adenoma Detection|Dynamic Position Change in Colonic Adenoma Detection: a Prospective, Randomized, Multicenter Study|Completed||N/A|1072|Actual|The Catholic University of Korea||2|||f||||||||||||||2018-05-31 22:33:28.026497|2018-05-31 22:33:28.026497
NCT01366066|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2013-05-23|2011-06-02|2011-06-03|Estimate|||||||2013-05-23|2013-05-24|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|||Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Stress Incontinence and Urge Incontinence|Terminated||Phase 3|4|Actual|Copenhagen University Hospital at Herlev||4||Failure to recruit participants|f||||f||||||||||2018-05-31 22:33:28.135041|2018-05-31 22:33:28.135041
NCT01366053|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2016-12-21|2011-06-02|2011-06-03|Estimate|||||||2016-12-21|2016-12-22|Estimate|March 2011||2011-03-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|DELAY||Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists|Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists: A Prospective, Observational, Phase IV Study (DELAY)|Completed|||125|Actual|CMX Research|||1||f||||f||||||||Undecided||2018-05-31 22:33:28.210614|2018-05-31 22:33:28.210614
NCT01366040|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2013-09-12|2011-06-02|2011-06-03|Estimate|||||||2013-09-12|2013-09-16|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|ASPECT||Avonex PEN Satisfaction and Patients Experience Clinical Trial|An Open-Label, Survey-Based, Multicenter Study to Determine Patient Satisfaction With Single-Use Prefilled Avonex® PEN Autoinjector in Multiple Sclerosis Patients|Completed|||89|Actual|Biogen|||||f||||f||||||||||2018-05-31 22:33:28.297634|2018-05-31 22:33:28.297634
NCT01366027|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2014-04-15|2011-06-02|2011-06-03|Estimate|||||||2014-04-15|2014-04-16|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||PRISM Registry: Pseudobulbar Affect Registry Series|PRISM Registry: Pseudobulbar Affect Registry Series|Completed|||5290|Actual|Avanir Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:33:28.532291|2018-05-31 22:33:28.532291
NCT01366014|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02||2013-06-06|2013-06-06|2011-06-02|2011-06-03|Estimate||||2013-06-06|2013-06-14|Estimate|2013-06-06|2013-06-14|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee||Completed||Phase 2|157|Actual|Array BioPharma||3|||f||||f||||||||||2018-05-31 22:33:28.730958|2018-05-31 22:33:28.730958
NCT01366001|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2012-03-08|2011-06-02|2011-06-03|Estimate|||||||2012-03-08|2012-03-09|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine|A Phase 1, Multiple-dose, Parallel Group Study to Evaluate the Safety and Pharmacodynamic Effects of RDC-0313-buprenorphine (ALKS 33-BUP) Administered Alone and Co-administered With Cocaine to Opioid-experienced Cocaine Abusers|Completed||Phase 1|33|Actual|Alkermes, Inc.||3|||f||||t||||||||||2018-05-31 22:33:28.821986|2018-05-31 22:33:28.821986
NCT01365988|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-04-04|2011-06-01|2011-06-03|Estimate|||||||2018-04-04|2018-04-05|Actual|May 15, 2011||2011-05-15|February 26, 2013|2013-02-26|February 26, 2013||2013-02-26|||||Observational|||Neutral Correlates of Risk-taking in Adolescents Exposed to Drugs Prenatally|Neural Correlates of Risk-Taking in Urban Adolescents|Completed|||43|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:33:28.90817|2018-05-31 22:33:28.90817
NCT01365975|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-05-17|2011-06-01|2011-06-03|Estimate|||||||2018-05-17|2018-05-18|Actual|June 1, 2011||2011-06-01|January 24, 2018|2018-01-24||||||||Observational|||Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study|Follow-up Study of Late Effects of Periconceptional Folic Acid in Mothers and Offspring in the Community Intervention Program Population: The Chinese Children and Families Study|Completed|||1382|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:33:28.994419|2018-05-31 22:33:28.994419
NCT01365962|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2016-05-17|2011-06-01|2011-06-03|Estimate|||||||2016-05-17|2016-05-19|Estimate|June 2011||2011-06-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma|A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue|Completed|||60|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:33:29.066285|2018-05-31 22:33:29.066285
NCT01365949|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2016-07-07|2011-06-01|2011-06-03|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2011||2011-05-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Biomarker in Tissue Samples From Patients With Ewing Sarcoma|INI-1 Deletions in Ewing Sarcoma|Completed|||40|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 22:33:29.130001|2018-05-31 22:33:29.130001
NCT01365936|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-03-28|2011-06-02|2011-06-03|Estimate|||||||2012-03-28|2012-03-29|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF|Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF|Completed||Phase 4|80|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 22:33:29.260659|2018-05-31 22:33:29.260659
NCT01365923|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-06-29|2011-06-02|2011-06-03|Estimate|||||||2014-06-29|2014-07-01|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparison of Dexmedetomidin and Remifentanil for the Effect on Airway Reflex and Hemodynamic Response During Emergence in Patients Undergoing Craniotomy|Comparison of Dexmedetomidin and Remifentanil for the Effect on Airway Reflex and Hemodynamic Response During Emergence in Patients Undergoing Craniotomy|Completed||Phase 4|74|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:33:29.349453|2018-05-31 22:33:29.349453
NCT01365910|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2014-06-13||2014-08-24|2011-06-02|2011-06-03|Estimate|2014-08-24|2014-08-26|Estimate||||2014-08-24|2014-08-26|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|May 2012|Actual|2012-05-31||Interventional|||Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer|An Investigator Initiated, Phase II Study of Linifanib in Patients With Advanced, Refractory Colorectal Cancer Expressing Mutated kRas|Terminated||Phase 2|30|Actual|Vanderbilt-Ingram Cancer Center||1||Interim analysis determined the study did not meet criteria to proceed|f||||t||||||||||2018-05-31 22:33:29.508943|2018-05-31 22:33:29.508943
NCT01365897|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-02|2011-06-02|2011-06-03|Estimate|||||||2011-06-02|2011-06-03|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effectiveness of Modafinil in Improving Cognitive Performance of University Students|Effectiveness of Modafinil in Improving Mnesic Performance and Executive Functions of University Students From Careers of High Academic Performance|Completed||Phase 4|128|Actual|Universidad de Valparaiso||2|||f||||f||||||||||2018-05-31 22:33:29.870159|2018-05-31 22:33:29.870159
NCT01365884|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2012-06-13|2011-06-02|2011-06-03|Estimate|||||||2012-06-13|2012-06-14|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age|Proof of Concept Study for First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age|Unknown status|Recruiting||40|Anticipated|University of Nebraska|||||f||||f||||||||||2018-05-31 22:33:29.969852|2018-05-31 22:33:29.969852
NCT01365871|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-01-17|2011-06-01|2011-06-03|Estimate|||||||2012-01-17|2012-01-18|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||CREMS Prostate Biopsy Pain Relief Study|Pain Relief With Local Anesthetic at Time of Prostate Biopsy: Comparing Apical and Basal Injection Versus Basal Injection Alone|Completed||N/A|300|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:33:30.050744|2018-05-31 22:33:30.050744
NCT01365858|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2014-11-12|2011-06-01|2011-06-03|Estimate|||||||2014-11-12|2014-11-13|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|VAPS REHAB||Virtual Action Planning in Stroke: a Control Rehabilitation Study|Effectiveness of Virtual Reality-based Cognitive Training in Daily Living in Stroke Patients Using Virtual Action Planning Supermarket (VAP-S)|Completed||N/A|29|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 22:33:30.119708|2018-05-31 22:33:30.119708
NCT01365845|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2014-09-11||2018-02-01|2011-06-01|2011-06-03|Estimate|2014-12-03|2014-12-05|Estimate||||2018-02-01|2018-03-01|Actual|April 2012||2012-04-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|March 2014|Actual|2014-03-31||Interventional|BR01||Proton Therapy for Lymph Nodes in Breast Cancer|Proton Therapy for Peripheral Lymph Nodes in Breast Cancer|Active, not recruiting||N/A|18|Actual|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 22:33:30.235617|2018-05-31 22:33:30.235617
NCT01365832|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-06-03|2011-06-02|2011-06-03|Estimate|||||||2011-06-03|2011-06-06|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Change in C-reactive Protein (CRP) in Men and Women With Sleep Apnea After Continuous Positive Airway Pressure (CPAP)|CRP Evolution Pattern in CPAP Treated Obstructive Sleep Apnea Patients. Does Gender Play a Role?|Completed||N/A|436|Actual|University of Crete||1|||f||||f||||||||||2018-05-31 22:33:30.464228|2018-05-31 22:33:30.464228
NCT01365819|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2017-01-05||2018-01-17|2011-06-02|2011-06-03|Estimate|2017-01-05|2017-02-24|Actual||||2018-01-17|2018-01-18|Actual|February 2012||2012-02-29|January 2018|2018-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Varenicline for Methamphetamine Dependence|Varenicline for Methamphetamine Dependence: Phase II Clinical Trial|Completed||Phase 2|52|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 22:33:30.69756|2018-05-31 22:33:30.69756
NCT01365806|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-03-06|2011-06-01|2011-06-03|Estimate|||||||2017-03-06|2017-03-08|Actual|August 2011||2011-08-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Observational|NEW HEART||Home Electrocardiogram (ECG) Monitoring After Heart Transplantation|Home ECG Monitoring to Detect Allograft Rejection Following Heart Transplantation|Completed|||345|Actual|University of California, Los Angeles|||||f||||t||||||||||2018-05-31 22:33:30.996822|2018-05-31 22:33:30.996822
NCT01365793|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-10-27|2011-06-02|2011-06-03|Estimate|||||||2017-10-27|2017-10-31|Actual|November 2010||2010-11-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis|Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis|Completed||Phase 3|1405|Actual|University of California, Davis||4|||f||||t|t|f||||||No||2018-05-31 22:33:31.049519|2018-05-31 22:33:31.049519
NCT01365780|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2012-11-27|2011-06-02|2011-06-03|Estimate|||||||2012-11-27|2012-11-28|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|HBOTRadius||Hyperbaric Oxygen Therapy in Distal Radius Fractures: Can it Shorten Recovery Time and Increase Fracture Healing?|Identification of Microcirculation in Distal Radius Fractures After Surgical Treatment With and Without Hyperbaric Oxygen Therapy (HBOT)|Suspended||N/A|100|Anticipated|RWTH Aachen University||2||"nump~    acceptence by patient too low"|f||||f||||||||||2018-05-31 22:33:31.183666|2018-05-31 22:33:31.183666
NCT01365767|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2013-07-15|2011-06-01|2011-06-03|Estimate|||||||2013-07-15|2013-07-16|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|KULT||Contrast Ultrasound of the Small Intestine in Patients With Crohns Disease|Kontrast UltraLydsskanning af Tyndtarmen Hos Patienter Med Crohns Sygdom - et Pilotstudie. (Danish) Contrast Ultrasound of the Small Intestine in Patients With Crohns Disease - a Pilot Study (English)|Completed|||5|Actual|Regionshospitalet Silkeborg|||1||f||||t||||||||||2018-05-31 22:33:31.404752|2018-05-31 22:33:31.404752
NCT01365754|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-09-19|2011-06-02|2011-06-03|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2011||2011-09-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|DYNORFUSE||Dynamic Stabilization Versus Fusion|Posterior Dynamic Stabilization Versus Fusion in the Treatment of Lumbar Degenerative Disease|Active, not recruiting||N/A|440|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 22:33:31.474716|2018-05-31 22:33:31.474716
NCT01365741|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2017-09-28|2011-06-01|2011-06-03|Estimate|||||||2017-09-28|2017-10-02|Actual|February 2011||2011-02-28|September 2017|2017-09-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient|Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient|Completed||N/A|20|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 22:33:31.556399|2018-05-31 22:33:31.556399
NCT01365728|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-04-22|2011-06-02|2011-06-03|Estimate|||||||2018-04-22|2018-04-24|Actual|April 2011||2011-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||An Outcomes Study Comparing the Intralase FS 60 to the Intralase iFS When Performing LASIK Surgery for Nearsightedness|A Prospective Randomized Comparison of Fellow Eyes Undergoing LASIK With the Intralase FS 60 Versus the Intralase IFS|Active, not recruiting|||60|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 22:33:31.628462|2018-05-31 22:33:31.628462
NCT01365715|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2014-02-25|2011-06-01|2011-06-03|Estimate|||||||2014-02-25|2014-02-26|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Preoperative Embolization in Surgical Treatment of Spinal Metastases.|Preoperative Embolization in Surgical Treatment of Spinal Metastases. A Randomized Controlled Trial.|Completed||N/A|48|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 22:33:31.695082|2018-05-31 22:33:31.695082
NCT01365702|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-06|2011-06-02|2011-06-03|Estimate|||||||2011-06-06|2011-06-07|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Tiotropium in Patients With Tuberculosis (TB) Destroyed Lung|Clinical Efficacy of Tiotripium in Patients With Airflow Obstruction Due to TB Destroyed Lung|Unknown status|Recruiting||70|Anticipated|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 22:33:31.815646|2018-05-31 22:33:31.815646
NCT01365689|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2012-02-14|2011-06-02|2011-06-03|Estimate|||||||2012-02-14|2012-02-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:33:31.958243|2018-05-31 22:33:31.958243
NCT01365676|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-12-05|2011-06-01|2011-06-03|Estimate|||||||2011-12-05|2011-12-06|Estimate|March 2012||2012-03-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|657/10UFCSPA||GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms|Phase 3 Study Efficacy and Tolerance: The Use of 2 Phytomedicines in Association GAMALINE® 900mg + HIPERICIN® 300mg for the Treatment of Pre-Menstrual Syndrome (PMS) and Vasomotor Symptoms|Unknown status|Not yet recruiting|Phase 3|240|Anticipated|Phytopharm Consulting Brazil||4|||f||||t||||||||||2018-05-31 22:33:31.993821|2018-05-31 22:33:31.993821
NCT01365663|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2012-01-26|2011-06-01|2011-06-03|Estimate|||||||2012-01-26|2012-01-31|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Multiple Ascending Dose Study of SPC4955 in Healthy Subjects|A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC4955 Administered to Healthy Subjects|Completed||Phase 1|18|Actual|Santaris Pharma A/S||6|||f||||f||||||||||2018-05-31 22:33:32.154403|2018-05-31 22:33:32.154403
NCT01365650|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2012-08-06||2018-03-02|2011-06-01|2011-06-03|Estimate|2015-06-24|2015-07-23|Estimate||||2018-03-02|2018-03-06|Actual|December 2007||2007-12-31|March 2018|2018-03-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of Oxymetazoline Hydrochloride and Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis|Open Label, Three-Way Study to Assess the Absorption and Tolerability of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride and Multiple Doses of Fluticasone Propionate on the Absorption and Tolerability of Intranasal Ketorolac Tromethamine in Participants With Allergic Rhinitis|Completed||Phase 1|24|Actual|Egalet Ltd||3|||f||||f||||||||||2018-05-31 22:33:32.268041|2018-05-31 22:33:32.268041
NCT01365637|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-10-04|2011-06-01|2011-06-03|Estimate|||||||2011-10-04|2011-10-06|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Parallel Group Multiple Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of PF-05089771 In Healthy Subjects.|Completed||Phase 1|30|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:33:32.546763|2018-05-31 22:33:32.546763
NCT01365624|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2012-08-02||2013-01-03|2011-06-01|2011-06-03|Estimate|2013-01-03|2013-02-06|Estimate||||2013-01-03|2013-02-06|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects|A Phase 1 Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects|Completed||Phase 1|30|Actual|Luitpold Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:33:32.631124|2018-05-31 22:33:32.631124
NCT01365611|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2012-08-09||2017-02-06|2011-06-01|2011-06-03|Estimate|2013-03-18|2013-04-30|Estimate||||2017-02-06|2017-03-15|Actual|February 2007||2007-02-28|February 2017|2017-02-28|March 2008|Actual|2008-03-31|May 2007|Actual|2007-05-31||Interventional|||Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Fluticasone Propionate in Healthy Subjects|Open Label Study to Assess the Pharmacokinetics of Intranasal Ketorolac Tromethamine Following Multiple Doses of Fluticasone Propionate in Healthy Subjects|Completed||Phase 1|36|Actual|Egalet Ltd||1|||f||||f||||||||||2018-05-31 22:33:32.94737|2018-05-31 22:33:32.94737
NCT01365598|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2013-06-11|2011-06-02|2011-06-03|Estimate|||||||2013-06-11|2013-06-12|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda|Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda|Completed||Phase 3|468|Actual|London School of Hygiene and Tropical Medicine||4|||f||||t||||||||||2018-05-31 22:33:33.226195|2018-05-31 22:33:33.226195
NCT01365585|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2012-10-05||2017-03-07|2011-06-01|2011-06-03|Estimate|2012-10-05|2012-10-31|Estimate||||2017-03-07|2017-04-05|Actual|July 2011||2011-07-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension|Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension|Completed|||227|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:33:33.328739|2018-05-31 22:33:33.328739
NCT01365572|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-02|2011-06-02|2011-06-03|Estimate|||||||2011-06-02|2011-06-03|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|September 2011|Anticipated|2011-09-30||Interventional|Restenosis||New Generation Drug Eluting Stent for In-stent Restenosis of Drug Eluting Stent( RESTENT-ISR Trial )|Prospective, Single-blinded, Randomized Comparison of the Clinical and Angiographic Results With Intravascular Analysis of EverolimuS-Eluting Versus ZoTarolimus-Eluting steNTs for In-Stent Restenosis(ISR) Lesions: Volumetric Analysis With Intravascular Ultrasound(IVUS) : Phase IV Multicenter Trial ( RESTENT-ISR Trial )|Unknown status|Recruiting|Phase 4|292|Anticipated|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 22:33:33.594288|2018-05-31 22:33:33.594288
NCT01365559|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2018-03-01|2011-06-01|2011-06-03|Estimate|||||||2018-03-01|2018-03-05|Actual|May 2, 2011|Actual|2011-05-02|March 2018|2018-03-31|March 1, 2016|Actual|2016-03-01|June 13, 2014|Actual|2014-06-13||Interventional|||Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments|A Phase I/II Study of Carfilzomib as a Replacement for Multiple Myeloma Patients Failing Bortezomib-containing Regimens|Completed||Phase 1/Phase 2|39|Actual|Oncotherapeutics||2|||f||||f||||||||||2018-05-31 22:33:33.663186|2018-05-31 22:33:33.663186
NCT01365546|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2015-01-06||2015-03-05|2011-06-02|2011-06-03|Estimate|2015-03-05|2015-03-09|Estimate||||2015-03-05|2015-03-09|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|WONDERS||Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery|Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures|Completed||Phase 3|30|Actual|Octapharma||1|||f||||t||||||||||2018-05-31 22:33:33.755065|2018-05-31 22:33:33.755065
NCT01365533|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2016-10-24|2011-06-01|2011-06-03|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2004||2004-12-31|September 2016|2016-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Roflumilast on Airway Inflammation and Function Following Allergen Challenge in Subjects With Allergic Asthma|Completed||Phase 2|48|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:33:33.922515|2018-05-31 22:33:33.922515
NCT01365520|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2017-02-09|2011-06-01|2011-06-03|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2011||2011-06-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A|Multi-Centre, Open-Label, Randomised Trial Investigating the Pharmacokinetics of a Single Dose of NNC 0155-0000-0004 (N8) in Patients With Haemophilia A|Completed||Phase 1|4|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 22:33:33.982524|2018-05-31 22:33:33.982524
NCT01365507|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2015-10-19|2012-05-09|2017-02-09|2011-06-01|2011-06-03|Estimate|2015-10-19|2015-11-20|Estimate|2012-05-09|2012-05-10|Estimate|2017-02-09|2017-03-17|Actual|June 2011||2011-06-30|February 2017|2017-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|BOOST™||Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily in Insulin-naïve Subjects With Type 2 Diabetes Mellitus When Using Two Different Titration Algorithms (BOOST™: SIMPLE USE)|Completed||Phase 3|276|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:33:34.064243|2018-05-31 22:33:34.064243
NCT01365494|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|2014-01-28||2014-04-03|2011-06-01|2011-06-03|Estimate|2014-04-03|2014-05-05|Estimate||||2014-04-03|2014-05-05|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules|A Phase IV, Multi-center, Randomized, Open-label Study of PCECV (Rabipur®) Comparing the Immunogenicity and Safety of Two Different Simulated Post Exposure Schedules (Zagreb 2-1-1 Versus Essen Regimen 1-1-1-1-1) in Healthy Indian Subjects|Completed||Phase 4|250|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:33:34.529055|2018-05-31 22:33:34.529055
NCT01365481|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2016-03-09||2016-06-13|2011-06-01|2011-06-03|Estimate|2016-04-19|2016-04-21|Estimate||||2016-06-13|2016-07-13|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age|A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease|Completed||Phase 3|150|Actual|Novartis||1|||f||||f||||||||||2018-05-31 22:33:34.785065|2018-05-31 22:33:34.785065
NCT01365468|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2016-03-15||2016-05-10|2011-06-02|2011-06-03|Estimate|2016-05-10|2016-05-12|Estimate||||2016-05-10|2016-05-12|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)|A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1)|Terminated||Phase 2|9|Actual|Novartis|Study got terminated because of poor patient's accrual.|1||Poor patients' accrual|f||||||||||||||2018-05-31 22:33:36.199179|2018-05-31 22:33:36.199179
NCT01365455|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2015-02-16||2016-01-19|2011-06-02|2011-06-03|Estimate|2015-05-07|2015-05-29|Estimate||||2016-01-19|2016-02-17|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ERASURE||Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 3|738|Actual|Novartis||5|||f||||||||||||||2018-05-31 22:33:36.94543|2018-05-31 22:33:36.94543
NCT01365442|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2013-05-21|2011-06-01|2011-06-03|Estimate|||||||2013-05-21|2013-05-23|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Observational|||Pilot Introduction of Oral Cholera Vaccine in Orissa, India|Pilot Introduction of the Modified Bivalent Killed Whole Cell Oral Cholera Vaccine in Orissa|Completed|||31552|Actual|International Vaccine Institute|||1||f||||f||||||||||2018-05-31 22:33:41.604747|2018-05-31 22:33:41.604747
NCT01365429|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-02|||2018-03-05|2011-06-02|2011-06-03|Estimate|||||||2018-03-05|2018-03-07|Actual|May 2011||2011-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2017|Actual|2017-12-31||Interventional|||Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs|Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs|Active, not recruiting||N/A|252|Actual|XVIVO Perfusion||2|||f||||t||||||||||2018-05-31 22:33:41.759364|2018-05-31 22:33:41.759364
NCT01365416|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2016-11-10|2011-06-02|2011-06-03|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Personalised Medicine for Morbid Obesity|Genetic Analysis for Personalised Medicine for Morbid Obesity|Completed|||2000|Actual|Imperial College London|||||f||||f||||||Samples With DNA|"~     SALIVA BLOOD URINE AND FAECES TISSUE (Muscle, Liver, Subcutaneous fat, Visceral fat)~   "|No||2018-05-31 22:33:41.916117|2018-05-31 22:33:41.916117
NCT01365403|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2016-11-01|2011-06-02|2011-06-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers|A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE CARBAMAZEPINE ON SINGLE DOSE PHARMACOKINETICS OF RO4917838 IN HEALTHY MALE VOLUNTEERS|Completed||Phase 1|16|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:33:42.116662|2018-05-31 22:33:42.116662
NCT01365390|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-07-24|2011-06-01|2011-06-03|Estimate|||||||2014-07-24|2014-07-28|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||To Evaluate the Incidence of Acute Otitis Media in Children in Five East European Countries|To Evaluate Incidence of Acute Otitis Media in Children Aged < 6 Years in Five East European Countries|Completed|||2258|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:33:42.197007|2018-05-31 22:33:42.197007
NCT01365377|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-02|2011-06-02|2011-06-03|Estimate|||||||2011-06-02|2011-06-03|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Interventional|FAMILLE||Impact of Information Strategy Based on Booklet on Anxiety in Family in ICU|Impact of the Deliverance and Use of a Written Detailed Information Brochure on Anxiety Felt by the Family Members of Patients Admitted in Intensive Care Unit|Unknown status|Recruiting|N/A|180|Anticipated|Groupe Hospitalier Pitie-Salpetriere||2|||f||||f||||||||||2018-05-31 22:33:42.371662|2018-05-31 22:33:42.371662
NCT01365364|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-06-02|2011-06-02|2011-06-03|Estimate|||||||2011-06-02|2011-06-03|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|DOPATRANSPLM||Dopamine Transporter Density Profiles in Patients With Periodic Limb Movements|Dopamine Transporter Density Profiles Assessed by Tc-TRODAT and SPECT in Patients With Periodic Limb Movements|Completed||N/A|16|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:33:42.5651|2018-05-31 22:33:42.5651
NCT01365351|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-06-01|2011-06-02|2011-06-03|Estimate|||||||2017-06-01|2017-06-02|Actual|December 1, 2007|Actual|2007-12-01|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON|Non-interventional Study With ZOMACTON in Children With Growth Hormone Deficiency|Completed|||1034|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:33:42.759097|2018-05-31 22:33:42.759097
NCT01365338|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2012-12-21|2011-06-02|2011-06-03|Estimate|||||||2012-12-21|2012-12-24|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects|Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, Parallel Group Study To Assess Effects Of PF-04958242 On Bold Functional MRI During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects|Completed||Phase 1|112|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:33:43.117339|2018-05-31 22:33:43.117339
NCT01365325|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-06-01|2011-06-01|2011-06-03|Estimate|||||||2011-06-01|2011-06-03|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Handled Echocardiography and Chronic Heart Failure|Management of Chronic Heart Failure: Role of the Handled Echocardiography in Home Monitoring Care Programs|Completed||N/A|118|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 22:33:43.195463|2018-05-31 22:33:43.195463
NCT01364766|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2016-04-13|2011-05-31|2011-06-02|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Continuous Glucose Monitor Use in School|The Impact of Continuous Glucose Monitor Use in the Classroom/School Environment|Completed|||40|Actual|Stanford University|||||f||||f||||||||Undecided||2018-05-31 22:33:50.97585|2018-05-31 22:33:50.97585
NCT01365312|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-10-02|2011-06-02|2011-06-03|Estimate|||||||2014-10-02|2014-10-03|Estimate|February 2010||2010-02-28|October 2014|2014-10-31||||June 2011|Actual|2011-06-30||Interventional|||Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature Neonates|A Prospective, Randomized, Blinded, Placebo-Controlled Trial of Periodic, Brief Ethanol Locks to Prevent Peripherally-Inserted Central Catheter (PICC) Infections in Preterm Infants in the Neonatal Intensive Care Unit|Terminated||N/A|10|Actual|East Carolina University||2||Primary investigator relocated|f||||t||||||||||2018-05-31 22:33:43.269546|2018-05-31 22:33:43.269546
NCT01365286|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-06-11|2011-06-01|2011-06-03|Estimate|||||||2012-06-11|2012-06-12|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease|Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease|Completed||Phase 4|40|Actual|Medical Universtity of Lodz||2|||f||||t||||||||||2018-05-31 22:33:43.379325|2018-05-31 22:33:43.379325
NCT01365273|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2012-05-02||2014-01-17|2011-06-02|2011-06-03|Estimate|2012-08-15|2012-09-14|Estimate||||2014-01-17|2014-02-13|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts|Open, Prospective, Randomised Investigation Evaluating Pain With the Use of Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts|Completed||Phase 4|43|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 22:33:43.507271|2018-05-31 22:33:43.507271
NCT01365260|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-12-04|2011-06-02|2011-06-03|Estimate|||||||2012-12-04|2012-12-05|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy of an Injectable Medical Device to Treat Knee Osteoarthritis|A Double-Blind, Randomized, Feasibility Controlled Study to Assess the Safety and Efficacy of MM-II, an Injectable Intraarticular Medical Device, Intended to the Treatment of Symptomatic Knee Osteoarthritis|Completed||Phase 1/Phase 2|40|Actual|Moebius Medical Ltd.||2|||f||||f||||||||||2018-05-31 22:33:43.931559|2018-05-31 22:33:43.931559
NCT01365247|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2015-05-13|2011-06-02|2011-06-03|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)|A Randomized Trial of Concurrent Treatment for PTSD and Substance Dependence|Completed||N/A|110|Actual|The City College of New York||3|||f||||t||||||||||2018-05-31 22:33:44.022784|2018-05-31 22:33:44.022784
NCT01365234|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2016-10-10|2011-06-01|2011-06-03|Estimate|||||||2016-10-10|2016-10-12|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Model 20066 Left Ventricular (LV) Lead Study|Model 20066 Left Ventricular (LV) Lead Study|Completed||Phase 1|40|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||Undecided||2018-05-31 22:33:44.10007|2018-05-31 22:33:44.10007
NCT01365221|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-10-31|2011-06-01|2011-06-03|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|SWITCH 600/60||The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel|SWITCH 600/60: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel|Unknown status|Active, not recruiting|Phase 4|260|Anticipated|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 22:33:44.187798|2018-05-31 22:33:44.187798
NCT01365208|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2017-03-22|2011-06-01|2011-06-03|Estimate|||||||2017-03-22|2017-03-24|Actual|July 2011||2011-07-31|March 2017|2017-03-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Observational|||New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer|Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma|Completed|||70|Actual|Chinese University of Hong Kong|||1||f||||f||||||Samples With DNA|"~     EBV DNA~   "|||2018-05-31 22:33:44.268954|2018-05-31 22:33:44.268954
NCT01365195|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-04-03|2011-06-01|2011-06-03|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2011||2011-05-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|||Effect of Ketamine on Postoperative Clinical Outcomes|Intraoperative Ketamine Administration in Colorectal Surgery: Effect on Postoperative Clinical Outcomes|Enrolling by invitation||Phase 4|102|Anticipated|Cedars-Sinai Medical Center||3|||f||||f||||||||||2018-05-31 22:33:44.353535|2018-05-31 22:33:44.353535
NCT01365182|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2015-02-16|2011-06-01|2011-06-03|Estimate|||||||2015-02-16|2015-02-18|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Improving Urinary Continence and Quality of Life in Prostate Cancer Patients|Improving Urinary Continence and Quality of Life in Prostate Cancer Patients|Completed||Phase 3|279|Actual|Case Western Reserve University||3|||f||||t||||||||||2018-05-31 22:33:44.434651|2018-05-31 22:33:44.434651
NCT01365169|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-05-17|2011-06-01|2011-06-03|Estimate|||||||2018-05-17|2018-05-21|Actual|June 2011|Actual|2011-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial|CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial|Recruiting|||290|Anticipated|M.D. Anderson Cancer Center|||6||f||||f|f|f||||||||2018-05-31 22:33:44.599804|2018-05-31 22:33:44.599804
NCT01365156|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2018-04-12|2011-06-01|2011-06-03|Estimate|||||||2018-04-12|2018-04-17|Actual|August 2011|Actual|2011-08-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix|A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy|Active, not recruiting||Phase 3|600|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 22:33:44.73697|2018-05-31 22:33:44.73697
NCT01365143|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2014-05-30|2011-06-01|2011-06-03|Estimate|||||||2014-05-30|2014-06-02|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy||Terminated||Phase 4|10|Actual|Mayo Clinic||2||Closing due to slow enrollment|f||||||||||||||2018-05-31 22:33:44.826764|2018-05-31 22:33:44.826764
NCT01365130|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2014-02-20||2018-04-27|2011-06-01|2011-06-03|Estimate|2014-04-02|2014-04-28|Estimate||||2018-04-27|2018-05-24|Actual|June 2011||2011-06-30|April 2018|2018-04-30|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional||Patients with metastatic gastroesophageal cancer that have relapsed after at least one line of chemotherapy|Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen|A Phase II Study Of Cabazitaxel For Metastatic Gastroesophageal Adenocarcinomas That Have Relapsed After At Least One Line Of Chemotherapy|Terminated||Phase 2|15|Actual|Brown University||1||As of 12/12/12 study closed to enrollment because study was determined to be ineffective.|f||||t||||||||||2018-05-31 22:33:44.904908|2018-05-31 22:33:44.904908
NCT01365117|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2012-06-12|2011-06-01|2011-06-03|Estimate|||||||2012-06-12|2012-06-14|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Pharmacokinetic Study in Healthy Volunteers|Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Trial in Healthy Normal Volunteers to Evaluate Insulin Exposure and Dose-proportionality Following Inhalation of Technosphere® Insulin Inhalation Powder (3 U and 4 U Insulin/mg) Using the Gen2 Inhaler|Completed||Phase 1|50|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-05-31 22:33:45.098058|2018-05-31 22:33:45.098058
NCT01365104|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-01-26|2011-06-01|2011-06-03|Estimate|||||||2015-01-26|2015-01-28|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|June 2012|Actual|2012-06-30||Interventional|DFO||Modulation of Cerebral Blood Flow Using Iron Chelators|Hypoxia-Inducible Transcription Factor 1 (HIF-1)in Vascular Aging|Completed||Early Phase 1|97|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 22:33:45.172523|2018-05-31 22:33:45.172523
NCT01365091|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2013-03-20||2015-04-21|2011-06-01|2011-06-03|Estimate|2013-08-16|2013-08-19|Estimate||||2015-04-21|2015-05-08|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil|Bioequivalence Study of Fixed Dose Combinations of Saxagliptin/Metformin Extended Release (XR) Relative to Co-administration of the Individual Components in Healthy Subjects in the Fasted and Fed States|Completed||Phase 1|112|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 22:33:45.288236|2018-05-31 22:33:45.288236
NCT01365078|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2012-03-07|2011-06-02|2011-06-03|Estimate|||||||2012-03-07|2012-03-08|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Stearidonic Acid and Lipid Metabolism|Effects of Stearidonic Acid on Serum Triacylglycerol Concentrations in Overweight and Obese Subjects|Completed||N/A|36|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:33:46.030121|2018-05-31 22:33:46.030121
NCT01365065|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-04-24|2011-06-02|2011-06-03|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2011|Actual|2011-05-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy|A Pilot Study to Assess the Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy|Active, not recruiting||Phase 2|20|Actual|Bayside Health||1|||f||||t||||||||||2018-05-31 22:33:46.134296|2018-05-31 22:33:46.134296
NCT01365052|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|2014-01-24|2012-05-30|2015-05-13|2011-06-01|2011-06-03|Estimate|2014-05-16|2014-06-16|Estimate|2012-05-30|2012-06-05|Estimate|2015-05-13|2015-06-08|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|MUST||Safety Trial of Naproxen Sodium/ Diphenhydramine|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Safety and Tolerability Trial of Naproxen Sodium/ Diphenhydramine Combination in an OTC Population|Completed||Phase 3|326|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:33:46.231555|2018-05-31 22:33:46.231555
NCT01365039|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2013-11-20||2013-11-20|2011-06-02|2011-06-03|Estimate|2013-11-20|2014-01-08|Estimate||||2013-11-20|2014-01-08|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of a Contact Lens for Daily Disposable Use|A Study to Evaluate the Safety and Efficacy of a Novel Contact Lens for Daily Disposable Use|Completed||N/A|173|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:33:46.751851|2018-05-31 22:33:46.751851
NCT01365026|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2017-01-30|2011-06-02|2011-06-03|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 6, 2016|Actual|2016-01-06|January 2017|2017-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|PVS||PVS: Innovative Programs For Healthy Lifestyle Promotion in Primary Care: 'Prescribe Healthy Life'|Feasibility and Effectiveness of Innovative Programs for Health Promotion in Primary Care: The 'Prescribe Healthy Life' Project (PVS)|Recruiting||N/A|4017|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 22:33:46.998599|2018-05-31 22:33:46.998599
NCT01365013|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2016-07-28|2011-06-01|2011-06-03|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|June 2013|Actual|2013-06-30||Interventional|DE-PLAN E||Evaluation of the Translation of the DE-PLAN Program for the Primary Prevention of Type 2 Diabetes in Routine Primary Care|Effectiveness of the Translation of a Type 2 Diabetes Primary Prevention Program in Routine Context of Primary Heath Care|Completed||Phase 4|1113|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 22:33:47.0824|2018-05-31 22:33:47.0824
NCT01365000|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-10-13|2011-06-01|2011-06-03|Estimate|||||||2014-10-13|2014-10-15|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects|A Phase I, Open-label, Randomized, Balanced, Single-dose, Two-Part Study to Assess the Relative Bioavailability of NKTR-118 in Three Formulations Under Fasted (3-Way Crossover) and Fed (2-Way Crossover) Conditions in Male and Non-fertile Female Subjects|Completed||Phase 1|21|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 22:33:47.158514|2018-05-31 22:33:47.158514
NCT01364987|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-06-01|2011-06-01|2011-06-03|Estimate|||||||2011-06-01|2011-06-03|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers|A Phase 1, Open Label, Single Sequence, Drug Interaction Study of the Pharmacokinetics of ASP015K and Mycophenolate Mofetil (MMF) After Separate and Concomitant Administration to Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:33:47.237974|2018-05-31 22:33:47.237974
NCT01364974|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-06-01|2011-06-01|2011-06-03|Estimate|||||||2011-06-01|2011-06-03|Estimate|January 2009||2009-01-31|May 2011|2011-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP015K in Healthy, Non-Elderly Male and Female Adult Volunteers|Completed||Phase 1|48|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 22:33:47.382697|2018-05-31 22:33:47.382697
NCT01364961|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2013-11-12|2011-06-01|2011-06-03|Estimate|||||||2013-11-12|2013-11-13|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||Resveratrol and Serum Apo A-I|The Effects of Resveratrol on Serum Apolipoprotein A-I Concentrations in Men and Women With Low HDL-cholesterol Concentrations|Completed||N/A|50|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:33:47.456129|2018-05-31 22:33:47.456129
NCT01364753|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2016-12-05|2011-05-31|2011-06-02|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2006||2006-01-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Age-related Longitudinal Changes in Aviator Performance|Age-related Longitudinal Changes in Aviator Performance|Completed|||139|Actual|Stanford University|||1||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-05-31 22:33:51.053072|2018-05-31 22:33:51.053072
NCT01364948|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|||2011-06-01|2011-06-01|2011-06-03|Estimate|||||||2011-06-01|2011-06-03|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|TopOilTewl||Effect of Coconut Oil Application in Reducing Water Loss From Skin of Premature Babies in First Week of Life (TEWL)|Effect of Topical Oil Application on Trans-epidermal Water Loss (TEWL) in Preterm Very Low Birth Weight (VLBW) Infants - A Randomized Clinical Trial|Completed||N/A|74|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 22:33:47.721584|2018-05-31 22:33:47.721584
NCT01364935|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-06-24|2011-06-01|2011-06-03|Estimate|||||||2014-06-24|2014-06-25|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Comparison of DuoFertility, LadyComp/BabyComp and Clearblue Monitors|Pilot Study Comparing Fertility Monitors: DuoFertility Monitor, LadyComp/Babycomp Monitor and Clearblue Ovulation Tests in Support of FDA Application|Completed|||30|Actual|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 22:33:47.823604|2018-05-31 22:33:47.823604
NCT01364922|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-01|2013-11-01|2012-10-26|2013-12-23|2011-06-01|2011-06-03|Estimate|2013-11-01|2013-12-23|Estimate|2012-10-26|2012-10-31|Estimate|2013-12-23|2014-01-29|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Phase 2 Chronic Low Back Pain Study|A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects With Chronic Low Back Pain|Completed||Phase 2|168|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 22:33:47.98109|2018-05-31 22:33:47.98109
NCT01364909|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-06-02|2011-06-02|2011-06-03|Estimate|||||||2011-06-02|2011-06-03|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Exercise in Critically Ill Patients With Sepsis|Early Intervention With Exercise in Critically Ill Patients With Sepsis: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|40|Anticipated|The University of Queensland||2|||f||||f||||||||||2018-05-31 22:33:48.725209|2018-05-31 22:33:48.725209
NCT01364896|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2015-12-03||2016-03-09|2011-06-02|2011-06-03|Estimate|2016-02-10|2016-03-09|Estimate||||2016-03-09|2016-04-05|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Observational|AnalHPV&IBD||Anal Human Papillomavirus in Inflammatory Bowel Disease Study|Characterization of Anal Human Papillomavirus (HPV) Infection in the University of Pittsburgh Inflammatory Bowel Disease (IBD) Cohort Study|Completed|||46|Actual|University of Pittsburgh|||1||f||||f||||||Samples Without DNA|"~     Venous blood, anal swabs, vaginal swabs, high resolution anoscopy (HRA), anal biopsy samples~   "|No||2018-05-31 22:33:48.812285|2018-05-31 22:33:48.812285
NCT01364883|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2013-07-26|2011-06-02|2011-06-03|Estimate|||||||2013-07-26|2013-07-29|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP|A Phase I Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP|Completed||Phase 1|39|Actual|University of Oxford||7|||f||||t||||||||||2018-05-31 22:33:49.283702|2018-05-31 22:33:49.283702
NCT01364870|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2017-03-31||2017-10-24|2011-06-02|2011-06-03|Estimate|2017-10-24|2017-11-30|Actual||||2017-10-24|2017-11-30|Actual|May 2008||2008-05-31|October 2017|2017-10-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|TANK||Effect of TENS for Pain and Function After Total Knee Replacement|Effect of TENS on Hyperalgesia, Pain With Movement, and Function After TKR|Completed||N/A|317|Actual|University of Iowa||3|||f||||t|f|t|f|f||||||2018-05-31 22:33:49.641026|2018-05-31 22:33:49.641026
NCT01364857|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2017-02-23|2011-06-02|2011-06-03|Estimate|||||||2017-02-23|2017-02-24|Actual|November 2010|Actual|2010-11-30|February 2017|2017-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|CONAPE||French National Cohort of Children With Port Wine Stain|"French National Prospective Cohort of Children With Port Wine Stain on a Limb = Cohorte Nationale d'Enfants Avec Angiome Plan de Membre inférieur"|Active, not recruiting||N/A|150|Anticipated|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 22:33:50.347099|2018-05-31 22:33:50.347099
NCT01364844|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-02-24|2011-06-02|2011-06-03|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors|A Phase 1, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Solid Tumors|Completed||Phase 1|42|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 22:33:50.465149|2018-05-31 22:33:50.465149
NCT01364831|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2013-12-31|2011-06-01|2011-06-02|Estimate|||||||2013-12-31|2014-01-01|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Connection Between Sleep and Athletic Performance|Connection Between Sleep Quality and Duration and Performance in Young Athletes|Completed||N/A|19|Actual|Wingate Institute|||||f||||f||||||||||2018-05-31 22:33:50.572198|2018-05-31 22:33:50.572198
NCT01364818|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-04-14|2011-05-31|2011-06-02|Estimate|||||||2016-04-14|2016-04-18|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment|Characterization of Potential Biomarkers to Assess Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment|Completed|||25|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||No||2018-05-31 22:33:50.695586|2018-05-31 22:33:50.695586
NCT01364805|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-07-20|2011-06-01|2011-06-02|Estimate|||||||2017-07-20|2017-07-24|Actual|April 2011||2011-04-30|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||New Treatment Option for Pancreatic Cancer|Translation of in Vitro and in Vivo Ascorbate Research Into a New Treatment Option for Pancreatic Cancer: Phase I/IIa Clinical Trial|Completed||Phase 1|14|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 22:33:50.749285|2018-05-31 22:33:50.749285
NCT01364792|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2016-11-30|2011-06-01|2011-06-02|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||To Rescue Cognition With Valaciclovir|A Double Blind Placebo Controlled Study of Valaciclovir in Treatment of Psychosis in Patients With Schizophrenia|Completed||Phase 2|24|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 22:33:50.815305|2018-05-31 22:33:50.815305
NCT01364779|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2013-05-14|2011-06-01|2011-06-02|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients|Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients|Completed|||15|Actual|Northwell Health|||||f||||t||||||Samples Without DNA|"~     Blood draw~   "|||2018-05-31 22:33:50.913367|2018-05-31 22:33:50.913367
NCT01364740|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2016-10-10||2016-12-02|2011-06-01|2011-06-02|Estimate|2016-12-02|2017-01-27|Estimate||||2016-12-02|2017-01-27|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|PMP-300E||PMP-300E (Smart Watch): Portable Monitoring Device Study|PMP-300E: Validation of Portable Monitoring Device PMP-300E for Identification of Obstructive Sleep Apnea.|Completed||Phase 3|10|Actual|Stanford University||1|||f||||f||||||||Yes||2018-05-31 22:33:51.119562|2018-05-31 22:33:51.119562
NCT01364727|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2017-01-23||2018-04-17|2011-05-31|2011-06-02|Estimate|2017-01-23|2017-03-14|Actual||||2018-04-17|2018-05-17|Actual|June 2011||2011-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2014|Actual|2014-07-31||Interventional|||A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies|A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies|Active, not recruiting||Phase 2|33|Actual|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 22:33:51.426032|2018-05-31 22:33:51.426032
NCT01364714|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2017-09-27|2011-06-01|2011-06-02|Estimate|||||||2017-09-27|2017-09-29|Actual|January 2010|Actual|2010-01-31|September 2017|2017-09-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Observational|||Biomechanical Properties in Intensive Care Unit (ICU) Survivors 12-month After Discharge|Biomechanical Properties in ICU Survivors 12-month After Discharge|Completed|||32|Actual|Rigshospitalet, Denmark|||2||f||||||||||||||2018-05-31 22:33:51.838277|2018-05-31 22:33:51.838277
NCT01364701|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-06-17|2011-06-01|2011-06-02|Estimate|||||||2011-06-17|2011-06-20|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|PDE5i||Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment|A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Rambam Health Care Campus||3|||f||||f||||||||||2018-05-31 22:33:51.890394|2018-05-31 22:33:51.890394
NCT01364688|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-05-31|2011-05-31|2011-06-02|Estimate|||||||2011-05-31|2011-06-02|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease|Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease|Unknown status|Recruiting|Phase 2|80|Anticipated|Ramathibodi Hospital||2|||f||||f||||||||||2018-05-31 22:33:51.975016|2018-05-31 22:33:51.975016
NCT01364675|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|January 2012||2012-01-31|May 2011|2011-05-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|PPCVD||Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects|Primary Prevention of Cardiovascular Disease in Pre-diabetic & Pre-hypertensive Subjects Using Multiple Risks Reduction Strategy: A Multi-center, Double-blind, Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|8900|Anticipated|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 22:33:52.053501|2018-05-31 22:33:52.053501
NCT01364662|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25||2013-05-22|2015-11-16|2011-06-01|2011-06-02|Estimate||||2013-05-22|2013-06-05|Estimate|2015-11-16|2015-12-15|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|121|Actual|Supernus Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 22:33:52.151198|2018-05-31 22:33:52.151198
NCT01364649|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2014-10-06||2014-10-06|2011-06-01|2011-06-02|Estimate|2014-10-06|2014-10-09|Estimate||||2014-10-06|2014-10-09|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All randomized set (N=447): All study participants who were screened and randomized to one of two treatment arms.|Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction|A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction|Completed||Phase 3|447|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:33:52.266597|2018-05-31 22:33:52.266597
NCT01364636|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2018-03-19|2011-06-01|2011-06-02|Estimate|||||||2018-03-19|2018-03-21|Actual|February 2011|Actual|2011-02-28|April 2011|2011-04-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Observational|CYNDERELA-HF||Accuracy of Urinary NGAL in Predicting CardioRenal Syndrome in Acute Heart Failure at Emergency - CYNDERELA-HF Study|Accuracy of Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Cardio-renal Syndrome in Acute Decompensated Heart Failure at Emergency - CYNDERELA-HF Study|Terminated|||180|Actual|Pro-Cardiaco Hospital|||1|problems with the stability of samples collected|f||||t||||||Samples Without DNA|"~     Urine plasma serum~   "|||2018-05-31 22:33:52.938111|2018-05-31 22:33:52.938111
NCT01364623|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-06-04|2011-06-01|2011-06-02|Estimate|||||||2012-06-04|2012-06-05|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women|An Open-label, Single and Multiple Application of Intranasal Testosterone Gel (TBS-2) in Healthy Premenopausal Female Subjects at Three Dose Levels|Completed||Phase 1|24|Actual|Acerus Pharmaceuticals Corporation||3|||f||||t||||||||||2018-05-31 22:33:53.160573|2018-05-31 22:33:53.160573
NCT01364610|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-06-19|2011-05-31|2011-06-02|Estimate|||||||2015-06-19|2015-06-22|Estimate|July 2008||2008-07-31|June 2015|2015-06-30|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||An Assessment of pH Testing Methods|A Prospective Assessment of pH Testing Methods in Alberta|Completed||N/A|86|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 22:33:53.266179|2018-05-31 22:33:53.266179
NCT01364597|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2018-05-24|2011-05-31|2011-06-02|Estimate|||||||2018-05-24|2018-05-25|Actual|August 2011|Actual|2011-08-31|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy|Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy|Enrolling by invitation||Phase 3|600|Anticipated|UCB Pharma||1|||f||||f||||||||||2018-05-31 22:33:53.349902|2018-05-31 22:33:53.349902
NCT01364584|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2016-07-20|2011-05-31|2011-06-02|Estimate|||||||2016-07-20|2016-07-22|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Exenatide||Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes|Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes|Completed||N/A|46|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:33:53.488702|2018-05-31 22:33:53.488702
NCT01364571|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31||2014-07-25|2014-07-25|2011-05-31|2011-06-02|Estimate||||2014-07-25|2014-07-30|Estimate|2014-07-25|2014-07-30|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years|Phase I/2 Placebo-Controlled, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years|Completed||Phase 1/Phase 2|456|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 22:33:53.57258|2018-05-31 22:33:53.57258
NCT01364558|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2012-07-20||2014-05-20|2011-06-01|2011-06-02|Estimate|2014-05-20|2014-06-20|Estimate||||2014-05-20|2014-06-20|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers|"A Three-Period, Three-Treatment, Six-Sequence Randomized Crossover Study of the Bioavailability and Pharmacokinetics of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers,"|Completed||Phase 1|24|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 22:33:53.773309|2018-05-31 22:33:53.773309
NCT01364545|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|May 2011||2011-05-31|May 2011|2011-05-31||||May 2012|Anticipated|2012-05-31||Interventional|||Ketogenic Diets for Symptoms of Parkinson's Disease|Ketogenic Diets for Symptoms of Parkinson's Disease|Unknown status|Recruiting|N/A|20|Anticipated|University of Oxford||1|||f||||t||||||||||2018-05-31 22:33:54.072675|2018-05-31 22:33:54.072675
NCT01364532|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-05-31|2011-05-31|2011-06-02|Estimate|||||||2011-05-31|2011-06-02|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|AURA||Transradial Versus Transulnar Artery Approach for Coronary Interventions|A Randomized Study of Transradial Versus Transulnar Artery Approach for Coronary Interventions|Unknown status|Recruiting|Phase 3|572|Anticipated|University of Patras||2|||f||||f||||||||||2018-05-31 22:33:54.28271|2018-05-31 22:33:54.28271
NCT01364519|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-02-10|2011-05-31|2011-06-02|Estimate|||||||2012-02-10|2012-02-13|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers|A Randomized, Double-Blind (3rd Party Open), Placebo-Controlled, 2-Way Crossover Study To Determine The Effects Of A Single Inhaled Dose Of 500 MCG Fluticasone Propionate On Induced Sputum Neutrophils Following Inhaled Lipopolysaccharide (LPS) Challenge In Healthy Volunteers|Completed||Phase 1|17|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:33:54.369994|2018-05-31 22:33:54.369994
NCT01364506|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|January 2000||2000-01-31|May 2011|2011-05-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||The Effects of Aerobic Water Exercise on Pregnancy|Randomized Clinical Study of the Effects of Aerobic Water Exercise on Maternal Cardiovascular Adaptation to Pregnancy|Completed||N/A|41|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||f||||||||||2018-05-31 22:33:54.443552|2018-05-31 22:33:54.443552
NCT01364493|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2017-05-07|2011-06-01|2011-06-02|Estimate|||||||2017-05-07|2017-05-09|Actual|May 2011||2011-05-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|August 2012|Actual|2012-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer|An Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) as a First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer|Completed||Phase 2|51|Actual|Peking University||1|||f||||f||||||||||2018-05-31 22:33:54.516003|2018-05-31 22:33:54.516003
NCT01364480|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2018-01-12|2011-05-31|2011-06-02|Estimate|||||||2018-01-12|2018-01-16|Actual|May 2011||2011-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Microelectrode Brain-Machine Interface for Individuals With Tetraplegia|Microelectrode Brain-Machine Interface for Individuals With Tetraplegia|Recruiting||N/A|5|Anticipated|University of Pittsburgh||1|||f||||t||||||||Yes|We may share de-identified data with collaborators.|2018-05-31 22:33:54.600851|2018-05-31 22:33:54.600851
NCT01364467|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2018-02-09|2011-05-31|2011-06-02|Estimate|||||||2018-02-09|2018-02-13|Actual|May 2011||2011-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study|The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study|Recruiting||Phase 2|36|Anticipated|Virginia Commonwealth University||2|||f||||f|t|f||||||||2018-05-31 22:33:54.697894|2018-05-31 22:33:54.697894
NCT01364454|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2016-08-18|2011-06-01|2011-06-02|Estimate|||||||2016-08-18|2016-08-19|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||General Practitioners (GP) Involvement in Colorectal Cancer (CRC) Screening|Effect of Eligible Patients Paper-based Reminder for General Practitioners on Colorectal Cancer Screening Participation|Completed||Early Phase 1|8140|Actual|Paris 12 Val de Marne University||2|||f||||f||||||||||2018-05-31 22:33:54.773148|2018-05-31 22:33:54.773148
NCT01364441|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2012-06-12|2011-05-31|2011-06-02|Estimate|||||||2012-06-12|2012-06-13|Estimate|May 2011||2011-05-31|June 2012|2012-06-30||||August 2011|Actual|2011-08-31||Interventional|||Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Single-Dose Escalation and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects|Completed||Phase 1|48|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 22:33:54.83617|2018-05-31 22:33:54.83617
NCT01364428|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2015-10-16|2012-05-09|2017-01-20|2011-05-31|2011-06-02|Estimate|2015-10-16|2015-11-18|Estimate|2012-05-09|2012-05-10|Estimate|2017-01-20|2017-03-06|Actual|June 2011||2011-06-30|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|BEGIN™||Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Subjects With Type 2 Diabetes Mellitus (BEGIN™: COMPARE)|Completed||Phase 3|373|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:33:54.930693|2018-05-31 22:33:54.930693
NCT01364415|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-06-27|2011-06-01|2011-06-02|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)|A Phase I, Multi-center, Open-label, Dose Escalation Study of Pasireotide (SOM230) LAR in Patients With Advanced Neuroendocrine Tumors (NETs)|Completed||Phase 1|29|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:33:55.294661|2018-05-31 22:33:55.294661
NCT01364402|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-10-09|2011-06-01|2011-06-02|Estimate|||||||2012-10-09|2012-10-10|Estimate|August 2011||2011-08-31|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Prevention of Contrast Induced Nephropathy by Erythropoietin|Prevention of Contrast Induced Nephropathy by Erythropoietin in Patients With Diabetes Mellitus and eGFR<60 ml/Min/1.73m2 Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 3|142|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||t||||||||||2018-05-31 22:33:55.373395|2018-05-31 22:33:55.373395
NCT01364389|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2015-02-17||2018-04-02|2011-05-31|2011-06-02|Estimate|2015-02-17|2015-03-04|Estimate||||2018-04-02|2018-05-04|Actual|February 14, 2011|Actual|2011-02-14|April 2018|2018-04-30|January 29, 2013|Actual|2013-01-29|January 29, 2013|Actual|2013-01-29||Interventional|||A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica|A 2-week Single-blind, Randomized, 3-arm Proof of Concept Study of the Effects of AIN457 (Anti-IL17 Antibody), ACZ885 (Canakinumab, Anti-IL1b Antibody), or Corticosteroids in Patients With Polymyalgia Rheumatica, Followed by an Open Label Phase to Assess Safety and Long Term Efficacy|Terminated||Phase 2|16|Actual|Novartis|This study was terminated because the data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period.|3||"Data did not show that the two biologic treatments impacted PMR disease activity to the same~   degree as steroid treatment within a 2-week treatment period."|f||||||||||||||2018-05-31 22:33:55.461155|2018-05-31 22:33:55.461155
NCT01364376|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-08-20|2011-05-31|2011-06-02|Estimate|||||||2016-08-20|2016-08-23|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Focus||S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma|S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma: a Multi-center, Open-labeled, Randomized Controlled Trial|Completed||N/A|583|Actual|Zhejiang University||2|||f||||||||||||||2018-05-31 22:33:55.912396|2018-05-31 22:33:55.912396
NCT01364363|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-12-05|2011-06-01|2011-06-02|Estimate|||||||2013-12-05|2013-12-06|Estimate|March 2005||2005-03-31|December 2013|2013-12-31|January 2023|Anticipated|2023-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Unrelated Donor Stem Cell Transplantation|Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors|Recruiting||N/A|50|Anticipated|Scripps Health||7|||f||||f||||||||||2018-05-31 22:33:55.992278|2018-05-31 22:33:55.992278
NCT01364350|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-03-27|2011-06-01|2011-06-02|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2011||2011-03-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|T2P1||TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study|TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study of the TODAY Clinical Trial Cohort|Completed|||550|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||1||f||||t||||||Samples Without DNA|"~     Blood and urine are collected on an annual basis and sent to the Central Biospecimen~     Laboratory for analysis and storage.~      Analyses performed on an annual basis are: HbA1c, insulin sensitivity and secreation (fasting~     glucose, insulin, C-peptide, and proinsulin), 2-hour OGTT, pancreatic autoimmunity, serum~     creatinine, liver function tests, lipids (LDL, triglycerides, free fatty acids, lipoprotein~     subclass levels, average LDL particle density, and total apoB levels), cardiovascular risk~     factors (fibrinogen, c-reactive protein, homocysteine vitamin B-12, plasminogran activator~     inhibitor-1, interleukin-6), microalbumin.~      HbA1c is also analyzed quarterly.~   "|||2018-05-31 22:33:56.111389|2018-05-31 22:33:56.111389
NCT01364337|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|Taiwan_DASH||Blood Pressure and Glucose Lowering Diet for Taiwanese|Design and Testing Efficacy of Blood Pressure and Glucose Lowering Diet for Taiwanese Pre-/1st Staged Hypertension Patients and/or Pre-diabetes Patients|Unknown status|Active, not recruiting|N/A|50|Anticipated|National Health Research Institutes, Taiwan||2|||f||||f||||||||||2018-05-31 22:33:56.214113|2018-05-31 22:33:56.214113
NCT01364324|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2017-04-12|2011-06-01|2011-06-02|Estimate|||||||2017-04-12|2017-04-13|Actual|September 2010||2010-09-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients|Absorption of Anti-tuberculosis Drugs and Its Effect to Treatment Response in Gastrectomized Patients|Recruiting|||40|Anticipated|National Cancer Center, Korea|||2||f||||t||||||||||2018-05-31 22:33:56.286218|2018-05-31 22:33:56.286218
NCT01364311|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2015-04-14|2011-05-31|2011-06-02|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Treatment of Dry Eye With Supplements|Treatment of Dry Eye With Supplements|Withdrawn||N/A|0|Actual|Medical University of Vienna|||||f||||t||||||||||2018-05-31 22:33:56.361919|2018-05-31 22:33:56.361919
NCT01364298|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2013-07-30||2013-12-18|2011-06-01|2011-06-02|Estimate|2013-12-18|2014-02-06|Estimate||||2013-12-18|2014-02-06|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Safety population included all the randomized participants who received at least one dose of study drug.|Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management|Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain|Completed||Phase 4|353|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 22:33:56.429514|2018-05-31 22:33:56.429514
NCT01364285|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||A Study of Patient Reported Outcomes After Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia|A Study of Patient Reported Outcomes After Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia|Unknown status|Recruiting||200|Anticipated|Stanford University|||||f||||||||||||||2018-05-31 22:33:56.754233|2018-05-31 22:33:56.754233
NCT01364272|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|September 2008||2008-09-30|May 2011|2011-05-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia|Investigation of Diffusion Tensor Imaging Magnetic Resonance Imaging (DTI MRI) as a Correlate to Pain Relief and Facial Numbness in Patients Following Stereotactic Radiosurgical Rhizotomy for Trigeminal Neuralgia|Unknown status|Recruiting||50|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 22:33:56.805451|2018-05-31 22:33:56.805451
NCT01364259|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2016-12-16||2017-02-16|2011-06-01|2011-06-02|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|September 2008||2008-09-30|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia|A Randomized, Placebo-controlled Trial of Amifostine for Prevention of Facial Numbness in Patients Receiving Stereotactic Radiosurgery for Trigeminal Neuralgia|Terminated||Phase 3|17|Actual|Stanford University||2||Patterns of practice changed and this technique is no longer used.|f||||t||||||||No||2018-05-31 22:33:57.866022|2018-05-31 22:33:57.866022
NCT01364246|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-11-26|2011-05-31|2011-06-02|Estimate|||||||2012-11-26|2012-11-28|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|March 2013|Anticipated|2013-03-31||Interventional|||Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica|Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen Beike Bio-Technology Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:33:58.086276|2018-05-31 22:33:58.086276
NCT01364233|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2014-03-24|2011-05-31|2011-06-02|Estimate|||||||2014-03-24|2014-03-26|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety Study of MotifMESH (cPTFE) in Abdominal Surgery|A Prospective Outcome Study of Condensed Fenestrated PTFE Mesh (MotifMESH) in Non-sterile Abdominal Wall Defects|Completed||Phase 4|10|Actual|Medline Industries||1|||f||||f||||||||||2018-05-31 22:33:58.151873|2018-05-31 22:33:58.151873
NCT01364220|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2014-11-19|2011-05-31|2011-06-02|Estimate|||||||2014-11-19|2014-11-20|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|EUREKA||The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke|An Investigator-Sponsored,Double Blind,Placebo-controlled,Randomised,Multi-centre Study to Assess the Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke|Terminated||Phase 3|318|Actual|Severance Hospital||2||Slow enrollment|f||||t||||||||||2018-05-31 22:33:58.219428|2018-05-31 22:33:58.219428
NCT01364207|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2012-06-08||2012-10-01|2011-06-01|2011-06-02|Estimate|2012-10-01|2012-10-31|Estimate||||2012-10-01|2012-10-31|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|August 2011|Actual|2011-08-31||Interventional|||The Effects of Caffeinated Coffee on Intraocular Pressure|The Effects of Caffeinated Coffee on Intraocular Pressure|Completed||N/A|112|Actual|Massachusetts Eye and Ear Infirmary|We gave subjects caffeinated coffee on one visit and decaffeinated coffee on the other visit. The changes in outcome parameters we observed (ie IOP changes) could be due to other non-caffeine components in the coffee.|2|||f||||f||||||||||2018-05-31 22:33:58.337558|2018-05-31 22:33:58.337558
NCT01364194|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Local Infiltration With Bupivacaine to Increase Quality of Post-operative Pain Control in Total Knee Replacement|Periarticular Injection With Bupivacaine For Post-Operative Pain Control In Total Knee Replacement: A Prospective Randomized Double-Blind Controlled Trial|Completed||Phase 4|60|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 22:33:58.576728|2018-05-31 22:33:58.576728
NCT01364181|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-17|2011-06-01|2011-06-02|Estimate|||||||2011-06-17|2011-06-20|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients|The Impact of Udenafil on Exercise Capacity in Severe COPD Patients|Completed||Phase 3|23|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:33:58.654796|2018-05-31 22:33:58.654796
NCT01364168|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2018-03-15|2011-06-01|2011-06-02|Estimate|||||||2018-03-15|2018-03-16|Actual|February 2011||2011-02-28|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Observational|PROSCIS||Prospective Cohort With Incident Stroke|Prospective Cohort With Incident Stroke|Recruiting|||850|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, RNA~   "|||2018-05-31 22:33:58.733238|2018-05-31 22:33:58.733238
NCT01364155|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-05-31|2011-05-31|2011-06-02|Estimate|||||||2011-05-31|2011-06-02|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR|A Randomized, Single-Blind, Placebo-Controlled Phase 2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR|Unknown status|Recruiting|Phase 2|50|Anticipated|Limerick BioPharma||2|||f||||f||||||||||2018-05-31 22:33:58.809503|2018-05-31 22:33:58.809503
NCT01364142|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-06-20|2011-05-31|2011-06-02|Estimate|||||||2012-06-20|2012-06-22|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Observational|||A Blind Maneuver to Position an Endobronchial Blocker|A Blind Maneuver to Position an Endobronchial|Completed|||56|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 22:33:58.889945|2018-05-31 22:33:58.889945
NCT01364129|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-03-07|2011-06-01|2011-06-02|Estimate|||||||2016-03-07|2016-03-09|Estimate|August 2006||2006-08-31|March 2016|2016-03-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy|The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy|Completed||N/A|567|Actual|Legacy Health System||2|||f||||f||||||||||2018-05-31 22:33:58.960272|2018-05-31 22:33:58.960272
NCT01364116|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-06-05|2011-05-31|2011-06-02|Estimate|||||||2012-06-05|2012-06-06|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|December 2011|Actual|2011-12-31|||||Observational|||The Accuracy of Noninvasive and Continuous Hemoglobin Measurement by Pulse CO-Oximetry™ in Children Undergoing Volume Expansion||Completed|||46|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 22:33:59.03336|2018-05-31 22:33:59.03336
NCT01364103|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-01-31|2011-05-31|2011-06-02|Estimate|||||||2012-01-31|2012-02-02|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study About Predicting Fluid Responsiveness in Children Undergoing Neurosurgery||Completed||N/A|33|Actual|Seoul National University Hospital|||||f||||||||||||||2018-05-31 22:33:59.091629|2018-05-31 22:33:59.091629
NCT01364090|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2017-05-24||2017-05-24|2011-06-01|2011-06-02|Estimate|2017-05-24|2017-10-18|Actual||||2017-05-24|2017-10-18|Actual|June 2012||2012-06-30|May 2017|2017-05-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|ACTIVATE||A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3|A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b and Self Administered Ribavirin for Patients With Chronic HCV Genotype 2 or 3 and Injection Drug Use|Completed||Phase 4|93|Actual|Kirby Institute||2|||f||||t||||||||||2018-05-31 22:33:59.164487|2018-05-31 22:33:59.164487
NCT01364077|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2012-06-20|2011-06-01|2011-06-02|Estimate|||||||2012-06-20|2012-06-21|Estimate|January 2010||2010-01-31|June 2012|2012-06-30||||January 2011|Actual|2011-01-31||Interventional|||Ivabradine in Hemodialysed Patients With Increased Heart Rate|Efficacy and Safety of Ivabradine in Hemodialysed Patients With Increased Heart Rate|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||||2018-05-31 22:33:59.464396|2018-05-31 22:33:59.464396
NCT01364064|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2016-02-24|2011-06-01|2011-06-02|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2007||2007-01-31|September 2013|2013-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma|Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma|Completed||Phase 3|1153|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||t||||||||||2018-05-31 22:33:59.598057|2018-05-31 22:33:59.598057
NCT01364051|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2018-04-09|2011-05-26|2011-06-02|Estimate|||||||2018-04-09|2018-04-10|Actual|May 25, 2011|Actual|2011-05-25|April 2018|2018-04-30||||June 1, 2016|Actual|2016-06-01||Interventional|||Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies|Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies|Active, not recruiting||Phase 1|19|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 22:33:59.718582|2018-05-31 22:33:59.718582
NCT01364025|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-05-19|2011-06-01|2011-06-02|Estimate|||||||2015-05-19|2015-05-21|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Prophylactic Uterosacral Ligament Suspension at the Time of Hysterectomy for Prevention of Vaginal Vault Prolapse|Prophylactic Uterosacral Ligament Suspension at the Time of Hysterectomy for Prevention of Vaginal Vault Prolapse (PULS)|Active, not recruiting||N/A|800|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 22:33:59.906992|2018-05-31 22:33:59.906992
NCT01364012|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2018-02-01|2011-05-31|2011-06-02|Estimate|||||||2018-02-01|2018-02-05|Actual|May 23, 2011|Actual|2011-05-23|February 2018|2018-02-28|August 17, 2017|Actual|2017-08-17|January 27, 2013|Actual|2013-01-27||Interventional|||A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy|A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase III Study Comparing Bevacizumab Plus Carboplatin/Paclitaxel Versus Placebo Plus Carboplatin/Paclitaxel in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy For Advanced Disease|Completed||Phase 3|276|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:33:59.987377|2018-05-31 22:33:59.987377
NCT01363999|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2016-11-01|2011-06-01|2011-06-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers|A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers|Completed||Phase 1|24|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 22:34:00.163|2018-05-31 22:34:00.163
NCT01363986|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|2014-05-07||2014-07-23|2011-06-01|2011-06-02|Estimate|2014-07-23|2014-08-11|Estimate||||2014-07-23|2014-08-11|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Intent to treat (ITT) population included all consented participants who received study treatment.|A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer|A Multicenter, Open Label Study to Assess the Effect of Trastuzumab + Whole Brain Radiotherapy (WBRT) on Brain Metastases From HER-2 Positive Breast Cancer. (bHERt-2)|Terminated||Phase 2|3|Actual|Hoffmann-La Roche||1||"Study was prematurely terminated due to difficulties experienced in recruiting patients in a~   reasonable timeframe."|f||||||||||||||2018-05-31 22:34:00.331285|2018-05-31 22:34:00.331285
NCT01363973|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2015-02-27|2011-06-01|2011-06-02|Estimate|||||||2015-02-27|2015-03-03|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|EETI-01||Effect of Transcutaneous Electrical Stimulation on Post-stroke Dysphagic Patients|Pilot Study to Evaluate the Efficacy and Safety of Transcutaneous Electrical Stimulation on Swallowing in Patients With Oropharyngeal Dysphagia After Stroke|Completed||N/A|20|Actual|Hospital de Mataró||2|||f||||t||||||||||2018-05-31 22:34:00.595641|2018-05-31 22:34:00.595641
NCT01363960|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-05-31|2011-05-31|2011-06-02|Estimate|||||||2011-05-31|2011-06-02|Estimate|March 1999||1999-03-31|June 2009|2009-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Retinopathy of Prematurity:Summary of a Decade||Completed|||609|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi|||1||f||||t||||||||||2018-05-31 22:34:00.690744|2018-05-31 22:34:00.690744
NCT01363947|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-06-05|2011-05-31|2011-06-02|Estimate|||||||2017-06-05|2017-06-07|Actual|June 14, 2011|Actual|2011-06-14|June 2017|2017-06-30|June 3, 2016|Actual|2016-06-03|June 3, 2016|Actual|2016-06-03||Interventional|||Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer|Completed||Phase 1|87|Actual|Genentech, Inc.||2|||f||||f|t|f||||||||2018-05-31 22:34:00.772408|2018-05-31 22:34:00.772408
NCT01363934|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-07-17|2011-06-01|2011-06-02|Estimate|||||||2012-07-17|2012-07-19|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin|A Dose-Block Randomized, Double-blind Placebo Controlled, Open-label Active Controlled, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GC1113 After Single Intravenous/Subcutaneous Administration in Healthy Male Subjects|Completed||Phase 1|100|Actual|Green Cross Corporation||10|||f||||t||||||||||2018-05-31 22:34:00.874325|2018-05-31 22:34:00.874325
NCT01363921|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-04-04|2011-06-01|2011-06-02|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2011||2011-04-30|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|HicoCARD||Effect of HCO1100 on Cardiovascular Function|Effect of High Cut-off Membranes on Cardiovascular Function in Patients With End-stage Renal Disease (HICOCARD)|Terminated||N/A|10|Actual|Baxter Healthcare Corporation||1||insufficient patient recruiting|f||||f||||||||||2018-05-31 22:34:00.971879|2018-05-31 22:34:00.971879
NCT01363609|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2015-02-17|2011-05-31|2011-06-01|Estimate|||||||2015-02-17|2015-02-18|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|LIBRA||Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes|Central Effects of Endogenous Glucagon Like Peptide-1 (GLP-1) and the GLP-1 Analog Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes|Completed||N/A|50|Actual|VU University Medical Center||3|||f||||f||||||||||2018-05-31 22:34:04.749722|2018-05-31 22:34:04.749722
NCT01363908|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|2015-05-06||2015-05-27|2011-05-31|2011-06-02|Estimate|2015-05-06|2015-05-27|Estimate||||2015-05-27|2015-06-24|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The Safety Analysis Set, defined as all participants who had taken at least 1 dose of investigational product.|Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload|A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload|Terminated||Phase 2|30|Actual|Shire|This study was terminated early because of non-clinical safety results. As such, not all subjects completed the study. The available efficacy data were summarized and analyzed as specified in the SAP; however, no efficacy conclusions could be drawn.|3||"This study was terminated due to treatment stop resulting in an inability to draw conclusions~   from the data. Evaluation of nonclinical rat findings is ongoing."|f||||t||||||||||2018-05-31 22:34:01.081944|2018-05-31 22:34:01.081944
NCT01363895|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2017-04-10|2011-06-01|2011-06-02|Estimate|||||||2017-04-10|2017-04-11|Actual|November 2010||2010-11-30|April 2017|2017-04-30|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|ISAR-AF||Interventional Strategies in Treatment of Atrial Fibrillation: Percutaneous Closure of the Left Atrial Appendage Versus Catheter Ablation|Interventional Strategies in Treatment of Atrial Fibrillation: Percutaneous Closure of the Left Atrial Appendage Versus Catheter Ablation|Completed||N/A|120|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-05-31 22:34:01.693586|2018-05-31 22:34:01.693586
NCT01363882|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-05-31|2011-05-31|2011-06-02|Estimate|||||||2011-05-31|2011-06-02|Estimate|February 2008||2008-02-29|May 2011|2011-05-31||||January 2011|Actual|2011-01-31||Interventional|||Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)|Progression of Respiratory Dysfunction in Amyotrophic Lateral Sclerosis (ALS) Patients: A Comparison of Standard of Practice vs Polysomnography-Directed Nocturnal Non-Invasive Positive Pressure Ventilation|Unknown status|Active, not recruiting|N/A|40|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 22:34:01.754116|2018-05-31 22:34:01.754116
NCT01363869|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2013-04-23|2011-05-31|2011-06-02|Estimate|||||||2013-04-23|2013-04-25|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals|Effects of Green Tea on Level of Serum Uric Acid in Healthy Individuals|Completed||N/A|30|Actual|Chiang Mai University||3|||f||||t||||||||||2018-05-31 22:34:01.822645|2018-05-31 22:34:01.822645
NCT01363856|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-06-01|2011-06-01|2011-06-02|Estimate|||||||2011-06-01|2011-06-02|Estimate|February 2010||2010-02-28|May 2011|2011-05-31|June 2015|Anticipated|2015-06-30|June 2013|Anticipated|2013-06-30||Observational|CSB_PROSCIS||Center for Stroke Research Berlin (CSB) Prospective Stroke Cohort|Center for Stroke Research Berlin (CSB) Prospective Stroke Cohort|Unknown status|Recruiting||750|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||Samples With DNA|"~     Samples with DNA whole blood, serum, RNA~   "|||2018-05-31 22:34:02.014243|2018-05-31 22:34:02.014243
NCT01363843|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2014-06-17||2018-01-17|2011-05-31|2011-06-02|Estimate|2014-06-17|2014-07-16|Estimate||||2018-01-17|2018-02-13|Actual|May 2010||2010-05-31|January 2018|2018-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)|Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)|Completed||Phase 2|39|Actual|Brown University||1|||f||||t||||||||||2018-05-31 22:34:02.107151|2018-05-31 22:34:02.107151
NCT01363830|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2013-10-18|2011-06-01|2011-06-02|Estimate|||||||2013-10-18|2013-10-22|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Short Versus Long Post-Operative Restrictions Following Lumbar Discectomy|Short (2-weeks) Versus Long (6-weeks) Post-Operative Restrictions Following Lumbar Discectomy: A Prospective Randomized Control Study|Unknown status|Recruiting|N/A|420|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:34:02.412964|2018-05-31 22:34:02.412964
NCT01363817|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2018-05-29|2011-05-31|2011-06-02|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 28, 2011|Actual|2011-09-28|May 2018|2018-05-31|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Completed||Phase 1|42|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 22:34:02.520925|2018-05-31 22:34:02.520925
NCT01363804|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-06-01|2011-06-01|2011-06-02|Estimate|||||||2012-06-01|2012-06-05|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects|A Phase 1, Open-label, Two-period, Single-sequence Study to Evaluate the Effect of Rifampin on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Tivozanib in Healthy Subjects|Completed||Phase 1|30|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:34:02.617225|2018-05-31 22:34:02.617225
NCT01363791|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2015-05-26|2011-06-01|2011-06-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|March 2014|Actual|2014-03-31||Observational|||Meta-analyses of Fructose and Cardiometabolic Risk|Effect of Fructose on Metabolic Control in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 22:34:02.720228|2018-05-31 22:34:02.720228
NCT01363778|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2012-06-01|2011-06-01|2011-06-02|Estimate|||||||2012-06-01|2012-06-05|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects|A Phase 1, Open-label Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Tivozanib in Healthy Subjects|Completed||Phase 1|30|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:34:02.800765|2018-05-31 22:34:02.800765
NCT01363596|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2017-05-05|2011-05-27|2011-06-01|Estimate|||||||2017-05-05|2017-05-09|Actual|January 2006||2006-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|iNEST||International NaProTechnology Evaluation and Surveillance of Treatment for Infertility and Miscarriage (iNEST)|International Natural Procreative Technology Evaluation and Surveillance of Treatment for Infertility and Miscarriage (iNEST)|Active, not recruiting|||798|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 22:34:04.833132|2018-05-31 22:34:04.833132
NCT01363765|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2013-08-05||2014-03-11|2011-06-01|2011-06-02|Estimate|2014-03-11|2014-03-12|Estimate||||2014-03-11|2014-03-12|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Those are notified patients with pulmonary TB by the clinics which drain to the 14 participant labs all participants who were notified whether or not they were linked to the lab database. Further analyses do not correspond to all notified patients, it included only those linked in both databases.|Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil|Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial|Completed||Phase 4|34758|Actual|Ataulpho de Paiva Foundation|The design has potential for bias, due to delayed treatment effects or to conditions that change over time. Both are unlikely: outcome (notification) was shortly after test and adjustment for time in multilevel mixed model confirmed primary analysis.|2|||f||||f||||||||||2018-05-31 22:34:02.917942|2018-05-31 22:34:02.917942
NCT01363752|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2015-06-12|2011-05-31|2011-06-02|Estimate|||||||2015-06-12|2015-06-16|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ADHERE||A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.|A Multicenter, Two Arm, Randomized, Open Label Clinical Study Investigating Renal Function in an Advagraf® Based Immunosuppressive Regimen With or Without Sirolimus in Kidney Transplant Patients|Completed||Phase 4|853|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-05-31 22:34:03.223277|2018-05-31 22:34:03.223277
NCT01363739|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2011-05-31|2011-05-31|2011-06-02|Estimate|||||||2011-05-31|2011-06-02|Estimate|April 2009||2009-04-30|May 2011|2011-05-31||||||||Observational|PROVETTA||Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab|Prospective Evaluation of -1498 c/t VEGF Polymorphism in the Prediction of Benefit From First-line Folfiri Plus Bevacizumab in Metastatic Colorectal Cancer Patients|Unknown status|Recruiting||265|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||||f||||f||||||||||2018-05-31 22:34:03.375036|2018-05-31 22:34:03.375036
NCT01363726|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2011-05-31|2011-05-31|2011-06-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|October 2005||2005-10-31|October 2005|2005-10-31||||||||Observational|||Surveillance of Rotavirus Gastroenteritis in Children <5 Years|Surveillance of Rotavirus Gastroenteritis Among Children <5 Years of Age Visiting the Pediatric Emergency Room in Southern Israel|Unknown status|Recruiting||30000|Anticipated|Soroka University Medical Center|||1||f||||f||||||||||2018-05-31 22:34:03.449261|2018-05-31 22:34:03.449261
NCT01363713|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|2014-09-16||2014-09-25|2011-05-30|2011-06-01|Estimate|2014-09-16|2014-09-23|Estimate||||2014-09-25|2014-10-06|Estimate||||September 2014|2014-09-30||||September 2012|Actual|2012-09-30||Interventional|||A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis|A Long-term Open-label Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3 -|Completed||Phase 3|130|Actual|Santen Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 22:34:03.514351|2018-05-31 22:34:03.514351
NCT01363700|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|2014-10-22||2014-11-05|2011-05-30|2011-06-01|Estimate|2014-10-29|2014-11-05|Estimate||||2014-11-05|2014-11-19|Estimate||||November 2014|2014-11-30||||June 2012|Actual|2012-06-30||Interventional|||Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis|Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -|Completed||Phase 3|87|Actual|Santen Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 22:34:03.654158|2018-05-31 22:34:03.654158
NCT01363687|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2013-12-24|2011-05-31|2011-06-01|Estimate|||||||2013-12-24|2013-12-25|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Effect of Remote Postconditioning on Graft Function in Patients Undergoing Living-related Kidney Transplantation|The Effect of Remote Postconditioning on Graft Function in Patients Undergoing Living-related Kidney Transplantation|Completed||N/A|60|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 22:34:03.888545|2018-05-31 22:34:03.888545
NCT01363674|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2017-12-22|2011-05-30|2011-06-01|Estimate|||||||2017-12-22|2017-12-26|Actual|April 30, 2013|Actual|2013-04-30|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS GRE||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Greece|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Greece|Completed|||180|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:34:03.980343|2018-05-31 22:34:03.980343
NCT01363661|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2014-09-15||2014-09-25|2011-05-29|2011-06-01|Estimate|2014-09-20|2014-09-26|Estimate||||2014-09-25|2014-10-06|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MEDCOR|This population corresponded to the per protocol cohort: patients who had been randomized to placebo or molsidomine and who had completed the study in accordance with the protocol.|Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris|Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention|Completed||Phase 4|165|Actual|Therabel Pharma SA/NV|Too limited sample size. Huge variability in all measurements. High drop-out rate. Add-on treatment was a challenge to demonstrate a difference between Coruno and placebo.|2|||f||||t||||||||||2018-05-31 22:34:04.136059|2018-05-31 22:34:04.136059
NCT01363648|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-29|||2013-10-11|2011-05-31|2011-06-01|Estimate|||||||2013-10-11|2013-10-14|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|GLITTER||The Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia|A Randomized, Double-blind, Placebo-controlled Phase IV Trial for an Evaluation of the Efficacy of Gliatiline® on Post-stroke Patients With Vascular Cognitive Impairment no Dementia|Completed||Phase 4|222|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:34:04.505296|2018-05-31 22:34:04.505296
NCT01363635|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-28|||2011-06-02|2011-05-28|2011-06-01|Estimate|||||||2011-06-02|2011-06-06|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Observational|||Severe Sepsis/Septic Shock on Admission to the General Surgical ICU|Severe Sepsis/Septic Shock on Admission to the General Surgical ICU|Unknown status|Not yet recruiting||800|Anticipated|Mahidol University|||1||f||||f||||||||||2018-05-31 22:34:04.591228|2018-05-31 22:34:04.591228
NCT01363622|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-06-01|2011-05-31|2011-06-01|Estimate|||||||2011-06-01|2011-06-02|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Observational|||Vaspin Levels Compared With Serum Insulin and Blood Glucose Levels in Neonates|Zekai Tahir Burak Maternity Teaching Hospital|Unknown status|Recruiting||82|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||3||f||||f||||||||||2018-05-31 22:34:04.680139|2018-05-31 22:34:04.680139
NCT01363583|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-05-27|2011-05-27|2011-06-01|Estimate|||||||2011-05-27|2011-06-01|Estimate|January 2002||2002-01-31|September 2001|2001-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study on the Effect of Prostacyclin Compared to Placebo in Traumatic Brain Injury|Prostacyclin Treatment in Severe Traumatic Brain Injury: a Microdialysis and Outcome Study|Completed||Phase 1|48|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 22:34:04.932927|2018-05-31 22:34:04.932927
NCT01363570|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2016-03-15|2011-05-31|2011-06-01|Estimate|||||||2016-03-15|2016-03-17|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes|Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes|Completed||N/A|70|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 22:34:05.00772|2018-05-31 22:34:05.00772
NCT01363557|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2014-05-12|2011-05-31|2011-06-01|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|August 2012|Actual|2012-08-31||Interventional|ARPEGE||Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis|Randomized to Assess the Efficacy of Whole Brain Radiation Therapy (WBRT) With Concomitant Gefitinib Followed by Maintenance Gefitinib, and Gefitinib Alone, in Lung Cancer Patients With Brain Metastasis|Terminated||N/A|1|Actual|Assistance Publique - Hôpitaux de Paris||2||Decision of Sponsor|f||||f||||||||||2018-05-31 22:34:05.075617|2018-05-31 22:34:05.075617
NCT01363544|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2015-12-08|2011-05-27|2011-06-01|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD)|Train Your Brain? Exercise and Neurofeedback Intervention for ADHD|Completed||Phase 2/Phase 3|112|Actual|VU University of Amsterdam||3|||f||||f||||||||||2018-05-31 22:34:05.140065|2018-05-31 22:34:05.140065
NCT01363531|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2015-08-26|2011-05-30|2011-06-01|Estimate|||||||2015-08-26|2015-08-27|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PDA||Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies|Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies in the Non-complicated Acute Respiratory Tract Infections in General Practice|Completed||Phase 4|405|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||4|||f||||t||||||||||2018-05-31 22:34:05.221981|2018-05-31 22:34:05.221981
NCT01363518|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2018-03-06|2011-05-31|2011-06-01|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2010||2010-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Operative Versus Nonoperative Treatment of Humeral Shaft Fractures: A Prospective Cohort Comparison Study|Operative Versus Nonoperative Treatment of Humeral Shaft Fractures: A Prospective Cohort Comparison Study|Enrolling by invitation|||164|Anticipated|St. Louis University|||2||f||||t||||||||No|Results will be shared|2018-05-31 22:34:05.296712|2018-05-31 22:34:05.296712
NCT01363505|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2014-01-31|2011-05-31|2011-06-01|Estimate|||||||2014-01-31|2014-02-03|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Bladder Pressure Predicting Renal Failure in Critically Ill Patients as Compared to Hemodynamic Parameters|Is Intravesicular Pressure a Better Tool to Predict Renal Failure in Critically Ill Patients Compared With Routine Hemodynamic Parameters?|Completed|||16|Actual|Northwell Health|||1||f||||t||||||||||2018-05-31 22:34:05.369235|2018-05-31 22:34:05.369235
NCT01363492|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2014-03-25||2014-04-17|2011-05-27|2011-06-01|Estimate|2014-04-17|2014-05-20|Estimate||||2014-04-17|2014-05-20|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Safety Study of Replagal® Therapy in Children With Fabry Disease|An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy|Completed||Phase 2|15|Actual|Shire||1|||f||||f||||||||||2018-05-31 22:34:05.456176|2018-05-31 22:34:05.456176
NCT01363479|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|2014-11-06|2013-01-16|2014-11-06|2011-05-31|2011-06-01|Estimate|2014-11-06|2014-11-17|Estimate|2013-01-16|2013-01-28|Estimate|2014-11-06|2014-11-17|Estimate|July 2011||2011-07-31|November 2014|2014-11-30||||November 2012|Actual|2012-11-30||Interventional||Safety population ie patients receiving either oral or IV palonosetron plus dexamethasone|An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting|Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy|Completed||Phase 3|743|Actual|Helsinn Healthcare SA||2|||f||||f||||||||||2018-05-31 22:34:05.901193|2018-05-31 22:34:05.901193
NCT01363466|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2011-05-30|2011-05-30|2011-06-01|Estimate|||||||2011-05-30|2011-06-01|Estimate|May 2003||2003-05-31|May 2011|2011-05-31|November 2006|Actual|2006-11-30|||||Interventional|||Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer|Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer|Terminated||Phase 3|61|Actual|UNICANCER||2||low recruitment|f||||f||||||||||2018-05-31 22:34:06.920319|2018-05-31 22:34:06.920319
NCT01363453|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2011-05-31|2011-05-31|2011-06-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|October 2007||2007-10-31|May 2011|2011-05-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Observational|CARE||User Surveillance in Ulcerative Colitis|Acute and Remission Therapy of Ulcerative Colitis With Oral Mesalazine|Completed|||500|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:34:07.035405|2018-05-31 22:34:07.035405
NCT01363440|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2014-08-28|2014-02-11|2016-04-25|2011-05-31|2011-06-01|Estimate|2015-04-02|2015-04-20|Estimate|2014-02-11|2014-03-13|Estimate|2016-04-25|2016-05-30|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|January 2013|Actual|2013-01-31||Interventional|VISTA DME|Baseline population analyzed using the SAF|Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema|A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema|Completed||Phase 3|466|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 22:34:07.547001|2018-05-31 22:34:07.547001
NCT01363427|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2011-05-31|2011-05-31|2011-06-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2007||2007-03-31|May 2011|2011-05-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Observational|Crohn 2||Retrospective Data Analysis in Crohn's Disease|Retrospective Data Analysis of Newly Diagnosed Crohn's Disease Patients in Gastroenterological Surgeries|Completed|||161|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:34:11.9576|2018-05-31 22:34:11.9576
NCT01363414|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-05-31|2011-05-31|2011-06-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|January 2007||2007-01-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes|Randomized Controlled Trial of the Effects of Sodium Hyaluronate on Wavefront Aberrations in Dry Eye Patients|Completed||N/A|50|Actual|Ramathibodi Hospital||2|||f||||f||||||||||2018-05-31 22:34:12.032688|2018-05-31 22:34:12.032688
NCT01363401|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|2015-12-08||2017-02-02|2011-05-30|2011-06-01|Estimate|2016-06-08|2016-07-20|Estimate||||2017-02-02|2017-03-14|Actual|February 2011||2011-02-28|February 2017|2017-02-28|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis|An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis|Completed||Phase 1/Phase 2|72|Actual|Corestem, Inc.||2|||f||||f||||||||No||2018-05-31 22:34:12.131106|2018-05-31 22:34:12.131106
NCT01363388|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2016-07-25|2011-05-30|2011-06-01|Estimate|||||||2016-07-25|2016-07-26|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment|Completed||Phase 2|67|Actual|ChemoCentryx||2|||f||||t||||||||||2018-05-31 22:34:12.539368|2018-05-31 22:34:12.539368
NCT01363375|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-31|2011-05-31|2011-06-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2009||2009-06-30|February 2008|2008-02-29|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Effects of Different Foot Structures on Plantar Fasciitis and Therapeutic Footwear Intervention|The Investigation of Biomechanical Mechanism of Different Foot Structures on Plantar Fasciitis and the Evaluation of Efficacy on Therapeutic Footwear|Unknown status|Recruiting||40|Anticipated|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-05-31 22:34:12.672159|2018-05-31 22:34:12.672159
NCT01363362|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-12-17|2011-05-31|2011-06-01|Estimate|||||||2012-12-17|2012-12-18|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SLT/OBF||Selective Lasertrabeculoplasty and Ocular Hemodynamics in Glaucoma|Effect of Selective Lasertrabeculoplasty (SLT) on Ocular Hemodynamics in Glaucoma|Completed||N/A|150|Actual|Technische Universität Dresden||1|||f||||f||||||||||2018-05-31 22:34:12.779117|2018-05-31 22:34:12.779117
NCT01363349|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|2014-04-22||2014-09-17|2011-05-31|2011-06-01|Estimate|2014-09-17|2014-09-18|Estimate||||2014-09-17|2014-09-18|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|CLARITY||Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia|A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia|Terminated||Phase 2/Phase 3|269|Actual|BioLineRx, Ltd.||2||"pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the~   trial would not meet the pre-specified primary efficacy endpoint."|f||||f||||||||||2018-05-31 22:34:12.871486|2018-05-31 22:34:12.871486
NCT01363336|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-04-03|2011-05-30|2011-06-01|Estimate|||||||2015-04-03|2015-04-06|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease|Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease|Completed|||1882|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:34:13.224094|2018-05-31 22:34:13.224094
NCT01363323|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-07-17|2011-05-27|2011-06-01|Estimate|||||||2011-07-17|2011-07-19|Estimate|November 2004||2004-11-30|July 2011|2011-07-31|February 2005|Actual|2005-02-28|January 2005|Actual|2005-01-31||Interventional|||Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization|A Randomized, Double-Blind, Placebo/Positive Controlled, Evaluation of the Effects of MNTX on ECG Parameters and Cardiac Repolarization in Normal Volunteers|Completed||Phase 1|546|Actual|Valeant Pharmaceuticals International, Inc.||5|||f||||f||||||||||2018-05-31 22:34:13.305368|2018-05-31 22:34:13.305368
NCT01363310|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2014-01-07|2011-05-27|2011-06-01|Estimate|||||||2014-01-07|2014-01-08|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||The Quietude Study: Quetiapine Use for Agitated Depression|A Multi-Centre, Double-Blind, Randomised, Parallel Group, Escitalopram Controlled Phase III-B Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR TM) as Monotherapy in the Treatment of Adult Patients With Agitated Major Depressive Disorder|Terminated||Phase 3|250|Anticipated|Physicians Research And Education Network||2||Termination of sponsorship|f||||||||||||||2018-05-31 22:34:13.373378|2018-05-31 22:34:13.373378
NCT01363297|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2015-08-25|2015-07-31|2017-03-02|2011-05-27|2011-06-01|Estimate|2017-03-02|2017-04-13|Actual|2015-07-31|2015-08-21|Estimate|2017-03-02|2017-04-13|Actual|August 2011||2011-08-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|August 2014|Actual|2014-08-31||Interventional||Safety analysis set - included all enrolled participants who received at least 1 dose of study medication.|Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia|An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia|Completed||Phase 2|72|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:34:13.725451|2018-05-31 22:34:13.725451
NCT01363284|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-10-10|2011-05-29|2011-06-01|Estimate|||||||2017-10-10|2017-10-11|Actual|June 2010|Actual|2010-06-30|October 2017|2017-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients|Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients Based on Assessment of Endogenous Analgesia Capabilities|Completed||N/A|51|Actual|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 22:34:16.325617|2018-05-31 22:34:16.325617
NCT01363271|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-05-21|2011-05-27|2011-06-01|Estimate|||||||2012-05-21|2012-05-22|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients|Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients|Completed|||7260|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 22:34:16.394755|2018-05-31 22:34:16.394755
NCT01363258|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2015-12-09|2011-05-27|2011-06-01|Estimate|||||||2015-12-09|2015-12-11|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Reducing Care-Resistant Behaviors During Oral Hygiene in Persons With Dementia|Reducing Care-Resistant Behaviors During Oral Hygiene in Persons With Dementia|Completed||N/A|91|Actual|Penn State University||2|||f||||t||||||||||2018-05-31 22:34:16.536547|2018-05-31 22:34:16.536547
NCT01363245|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2015-07-01|2011-05-27|2011-06-01|Estimate|||||||2015-07-01|2015-07-02|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients|Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients.|Completed||N/A|1618|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 22:34:16.631441|2018-05-31 22:34:16.631441
NCT00782158|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2018-05-24|2008-10-29|2008-10-31|Estimate|||||||2018-05-24|2018-05-25|Actual|October 27, 2008||2008-10-27|January 17, 2018|2018-01-17||||||||Observational|||Hepatitis B and HIV Co-Infection in Patients in Uganda|Hepatitis B and HIV Co-Infection in Uganda|Completed|||6303|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:37:26.378838|2018-06-01 01:37:26.378838
NCT01363232|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2018-01-22|2011-05-31|2011-06-01|Estimate|||||||2018-01-22|2018-01-23|Actual|August 2011||2011-08-31|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|March 2014|Actual|2014-03-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors|Completed||Phase 1|89|Actual|Array BioPharma||1|||f||||||||||||||2018-05-31 22:34:16.745672|2018-05-31 22:34:16.745672
NCT01363206|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2014-03-06|2011-05-31|2011-06-01|Estimate|||||||2014-03-06|2014-03-10|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|GIPI||Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma|GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study|Unknown status|Active, not recruiting|Phase 2|43|Anticipated|Northern California Melanoma Center||1|||f||||f||||||||||2018-05-31 22:34:16.870107|2018-05-31 22:34:16.870107
NCT01363193|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2013-05-13|2011-05-27|2011-06-01|Estimate|||||||2013-05-13|2013-05-14|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients|Assessing Safety and Efficacy of Lean Body Weight-based Intravenous Heparin Dosing in Obese/Morbidly Obese Patients. A Pilot Study|Unknown status|Recruiting|N/A|100|Anticipated|Nazareth Hospital|||||f||||f||||||||||2018-05-31 22:34:16.96598|2018-05-31 22:34:16.96598
NCT01363180|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-11-15|2011-05-31|2011-06-01|Estimate|||||||2012-11-15|2012-11-16|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|ARC5||Stress-induced Drinking in Emerging Adults: the Role of Trauma History|Stress-induced Drinking in Emerging Adults: the Role of Trauma History|Unknown status|Recruiting||240|Anticipated|Medical University of South Carolina|||3||f||||f||||||||||2018-05-31 22:34:17.047036|2018-05-31 22:34:17.047036
NCT01363167|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-11-21|2011-05-31|2011-06-01|Estimate|||||||2014-11-21|2014-11-24|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Identifying Vitamin D Deficiency in Very Low Birth Weight Infant (VLBW) Infants Part 2|Identifying Vit D Deficiency in VLBW Infants Part 2|Completed||N/A|68|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 22:34:17.129265|2018-05-31 22:34:17.129265
NCT01363154|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2013-06-02|2011-05-27|2011-06-01|Estimate|||||||2013-06-02|2013-06-04|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Prevention of Photoparoxysmal Abnormalities by Mozart K448|Prevention of Photoparoxysmal Abnormalities Through Patterned Auditory Stimulation|Terminated||N/A|10|Actual|Medical University of South Carolina||3||terminated|f||||t||||||||||2018-05-31 22:34:17.197192|2018-05-31 22:34:17.197192
NCT01363141|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2015-05-06|2011-05-31|2011-06-01|Estimate|||||||2015-05-06|2015-05-08|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of a Low Advanced Glycation End Products (AGE) Diet in the Metabolic Syndrome|Effects of Glycooxidative Stress on Human Aging- Study #3|Completed||N/A|383|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 22:34:17.277805|2018-05-31 22:34:17.277805
NCT01363128|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2018-05-29|2011-05-27|2011-06-01|Estimate|||||||2018-05-29|2018-05-30|Actual|July 12, 2011|Actual|2011-07-12|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)|Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|72|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:34:17.705458|2018-05-31 22:34:17.705458
NCT01363115|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-05-27|2011-05-27|2011-06-01|Estimate|||||||2011-05-27|2011-06-01|Estimate|July 2005||2005-07-31|May 2011|2011-05-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|CaSHeW||Calcium Supplementation for a Healthy Weight (CaSHeW)|Calcium Supplementation for a Healthy Weight (CaSHeW)|Completed||N/A|130|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:34:17.813255|2018-05-31 22:34:17.813255
NCT01363102|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2016-03-16|2011-05-31|2011-06-01|Estimate|||||||2016-03-16|2016-03-17|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|July 2015|Actual|2015-07-31||Interventional|mSOMS||Systematic Team Approach to Guide Early Mobilization in Surgical Intensive Care Unit Patients|Effects of a Systematic Team Approach to Guide Early Mobilization in Surgical ICU Patients|Unknown status|Active, not recruiting|N/A|200|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:34:17.907519|2018-05-31 22:34:17.907519
NCT01363089|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2017-02-07|2011-05-27|2011-06-01|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2007||2007-01-31|February 2017|2017-02-28|February 2008|Actual|2008-02-29|March 2007|Actual|2007-03-31||Interventional|||Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine|Open Label, 2-Way Crossover Study to Assess the PK of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride on the PK of Intranasal Ketorolac Tromethamine in Healthy Male Subjects|Completed||Phase 1|21|Actual|Egalet Ltd||2|||f||||t||||||||||2018-05-31 22:34:17.993936|2018-05-31 22:34:17.993936
NCT01363076|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2012-03-08||2017-02-07|2011-05-27|2011-06-01|Estimate|2012-03-08|2012-04-09|Estimate||||2017-02-07|2017-03-16|Actual|June 2007||2007-06-30|February 2017|2017-02-28|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||The Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years|A Study of the Pharmacokinetics of Ketorolac Tromethamine Administered Intranasally (IN) for Postoperative Pain in Children Aged 12 Through 17 Years|Completed||Phase 1|20|Actual|Egalet Ltd||2|||f||||||||||||||2018-05-31 22:34:18.081369|2018-05-31 22:34:18.081369
NCT01363063|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2018-03-02|2011-05-27|2011-06-01|Estimate|||||||2018-03-02|2018-03-06|Actual|December 2006||2006-12-31|March 2018|2018-03-31|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Interventional|||Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers|A Phase 1, Double-Blind, Study of the Tolerability of Formulations of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers|Completed||Phase 1|40|Actual|Egalet Ltd||2|||f||||||||||||||2018-05-31 22:34:18.47774|2018-05-31 22:34:18.47774
NCT01363050|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2012-08-29||2017-02-07|2011-05-27|2011-06-01|Estimate|2013-03-19|2013-05-03|Estimate||||2017-02-07|2017-03-16|Actual|January 2006||2006-01-31|February 2017|2017-02-28|September 2006|Actual|2006-09-30|February 2006|Actual|2006-02-28||Interventional|||Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers|A Phase 1, Open Label, Multiple Dose Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers|Completed||Phase 1|15|Actual|Egalet Ltd||1|||f||||f||||||||||2018-05-31 22:34:18.556402|2018-05-31 22:34:18.556402
NCT01363037|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2015-09-09|2011-05-31|2011-06-01|Estimate|||||||2015-09-09|2015-09-10|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring|Phase 1 Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring|Completed||Phase 1|48|Actual|International Partnership for Microbicides, Inc.||4|||f||||t||||||||||2018-05-31 22:34:18.810985|2018-05-31 22:34:18.810985
NCT01363024|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2016-11-01|2011-05-31|2011-06-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors|An Open-Label, Multicenter, Phase I Dose-Escalation Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors|Completed||Phase 1|24|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:34:18.903376|2018-05-31 22:34:18.903376
NCT01363011|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2014-10-27|2014-01-10|2016-03-29|2011-05-27|2011-06-01|Estimate|2014-10-27|2014-10-31|Estimate|2014-01-10|2014-02-10|Estimate|2016-03-29|2016-05-02|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|January 2013|Actual|2013-01-31||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study drug|Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment|A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment|Completed||Phase 3|106|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 22:34:19.077372|2018-05-31 22:34:19.077372
NCT01362998|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-05-31|2011-05-31|2011-06-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Epidural Morphine Versus Epidural Fentanyl Infusion Following Cesarean Section|A Comparison of Single Dose Preservative Free Morphine With Fentanyl Infusion for Post-Cesarean Section Analgesia|Unknown status|Recruiting|N/A|200|Anticipated|Goodman, Evan, M.D.||2|||f||||t||||||||||2018-05-31 22:34:21.037284|2018-05-31 22:34:21.037284
NCT01362985|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2015-08-12|2011-05-27|2011-06-01|Estimate|||||||2015-08-12|2015-08-13|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor|Monitoring of Plerixafor Off-Label Use in the European Group for Blood and Bone Marrow Transplantation (EBMT) Registry|Completed|||201|Actual|Sanofi|||||f||||f||||||||||2018-05-31 22:34:21.219624|2018-05-31 22:34:21.219624
NCT01362972|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2016-08-23|2011-05-27|2011-06-01|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor|Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor|Completed|||7801|Actual|Sanofi|||4||f||||f||||||||||2018-05-31 22:34:21.268266|2018-05-31 22:34:21.268266
NCT01362959|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2016-08-26|2011-05-27|2011-06-01|Estimate|||||||2016-08-26|2016-08-29|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|NicGoWell||Nicotine Replacement Therapy in the Intensive Care Unit|Nicotine Replacement Therapy in the Intensive Care Unit: a Randomized, Controlled Pilot Study|Completed||Phase 4|47|Actual|Gelderse Vallei Hospital||2|||f||||t||||||||||2018-05-31 22:34:21.326558|2018-05-31 22:34:21.326558
NCT01362946|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2015-03-03||2015-12-10|2011-05-27|2011-06-01|Estimate|2015-12-10|2016-01-15|Estimate||||2015-12-10|2016-01-15|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits|Designing a Novel Behavioral Treatment Protocol for Children Characterized by Conduct Problems and Callous-unemotional Traits|Completed||N/A|48|Actual|Florida International University||2|||f||||t||||||||||2018-05-31 22:34:21.568012|2018-05-31 22:34:21.568012
NCT01362933|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2015-03-05|2011-05-27|2011-06-01|Estimate|||||||2015-03-05|2015-03-06|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Observational|CARMEN||National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients|National Evaluation of the Adherence to Recommendations of VTE Treatment in Cancer Patients|Completed|||502|Actual|Floralis|||1||f||||f||||||||||2018-05-31 22:34:22.42216|2018-05-31 22:34:22.42216
NCT01362920|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-02-15|2011-05-27|2011-06-01|Estimate|||||||2013-02-15|2013-02-18|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|PCT||Diagnostic and Prognostic Value of Serial Procalcitonin (PCT) Measurements in Critically Ill Patients|Diagnostic and Prognostic Value of Serial PCT Measurements in Critically Ill Patients|Completed|||300|Actual|The Cleveland Clinic|||2||f||||f||||||||||2018-05-31 22:34:22.544619|2018-05-31 22:34:22.544619
NCT01362907|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2012-06-28||2012-06-28|2011-05-27|2011-06-01|Estimate|2012-06-28|2012-08-03|Estimate||||2012-06-28|2012-08-03|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Clinical Comparison of Silicone Hydrogel and HEMA-based Daily Disposable Contact Lenses||Completed||N/A|40|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:34:22.629618|2018-05-31 22:34:22.629618
NCT01362894|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|2012-07-03||2012-07-03|2011-05-27|2011-06-01|Estimate|2012-07-03|2012-08-09|Estimate||||2012-07-03|2012-08-09|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Clinical Comparison of Two Daily Disposable Toric Lenses|Clinical Comparison of Two Daily Disposable Toric Lenses|Completed||N/A|240|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:34:22.848154|2018-05-31 22:34:22.848154
NCT01362881|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2017-08-31|2011-05-27|2011-05-30|Estimate|||||||2017-08-31|2017-09-01|Actual|January 2012|Actual|2012-01-31|June 2017|2017-06-30|August 31, 2017|Actual|2017-08-31|February 2016|Actual|2016-02-29||Observational|||Study of the Surgical Treatment of Early Onset Scoliosis Using a Non-invasive Growing Rod|A Prospective Cohort Study of the Surgical Treatment of Early Onset Scoliosis Using a Remotely Expandable Device for Non-invasive Lengthening of a Growing Rod (Magec™) and Its Performance in Prevention of Progression of Scoliosis.|Completed|||14|Actual|Ellipse Technologies, Inc.|||||f||||f||||||||||2018-05-31 22:34:23.090054|2018-05-31 22:34:23.090054
NCT01362868|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-11-08|2011-05-27|2011-05-30|Estimate|||||||2011-11-08|2011-11-09|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Water Drinking Test During Intraocular Pressure Fluctuation (IOP) Monitoring|Water Drinking Test (WDT) During Continuous Recording of Intraocular Pressure Fluctuation|Terminated||N/A|32|Anticipated|Sensimed AG||||Too low effect on the output and low rate of responders|f||||f||||||||||2018-05-31 22:34:23.14969|2018-05-31 22:34:23.14969
NCT00781651|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:37:32.615959|2018-06-01 01:37:32.615959
NCT01362855|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2015-02-09|2011-05-27|2011-05-30|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Observational|ACCEPT||Advance Care Planning Evaluation in Hospitalized Elderly Patients|Advance Care Planning Evaluation in Hospitalized Elderly Patients: A Multicenter, Prospective Study|Unknown status|Recruiting||900|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital|||||f||||f||||||||||2018-05-31 22:34:23.214987|2018-05-31 22:34:23.214987
NCT01362842|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2011-05-27|2011-05-27|2011-05-30|Estimate|||||||2011-05-27|2011-05-30|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Psychological and Physical Distress and Care Needs in Operable Lung Cancer Patients Receiving Surgery|Psychological and Physical Distress and Care Needs in Operable Lung Cancer Patients Receiving Surgery|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 22:34:23.272653|2018-05-31 22:34:23.272653
NCT01362829|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-06-20|2011-05-27|2011-05-30|Estimate|||||||2011-06-20|2011-06-21|Estimate|August 2009||2009-08-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Outcome Predictors in Patients With Severe Sepsis and Optimized Central Venous Oxygen Saturation|Outcome Predictors in Patients With Severe Sepsis and Optimized Central Venous Oxygen Saturation|Completed|||90|Actual|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     For each patient enrolled, 10mL blood is collected in EDTA-coated tube, which will be used~     for plasma separation and for peripheral blood mononuclear cell collection.~   "|||2018-05-31 22:34:23.459497|2018-05-31 22:34:23.459497
NCT01362816|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2016-08-01|2011-05-27|2011-05-30|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|EPCCS||The European Palliative Care Cancer Symptom Study (EPCCS)|The European Palliative Care Cancer Symptom Study (EPCCS). A Prospective Data Collection|Completed|||1739|Actual|Norwegian University of Science and Technology|||1||f||||f||||||||||2018-05-31 22:34:23.556711|2018-05-31 22:34:23.556711
NCT01362803|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2018-02-13|2011-05-27|2011-05-30|Estimate|||||||2018-02-13|2018-02-14|Actual|May 27, 2011||2011-05-27|July 26, 2017|2017-07-26|July 2, 2024|Anticipated|2024-07-02|September 10, 2019|Anticipated|2019-09-10||Interventional|||AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors|A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)|Recruiting||Phase 1/Phase 2|104|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:34:23.624031|2018-05-31 22:34:23.624031
NCT01362790|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2017-04-20|2011-05-27|2011-05-30|Estimate|||||||2017-04-20|2017-04-21|Actual|May 11, 2011||2011-05-11|September 26, 2016|2016-09-26|September 4, 2017|Anticipated|2017-09-04|August 3, 2016|Actual|2016-08-03||Interventional|||SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma|A Pilot/ Phase 2 Study of Pentostatin Plus Cyclophosphamide Immune Depletion to Decrease Immunogenicity of SS1P in Patients With Mesothelioma, Lung Cancer or Pancreatic Cancer|Active, not recruiting||Phase 1/Phase 2|55|Actual|National Institutes of Health Clinical Center (CC)||7|||f||||||||||||||2018-05-31 22:34:23.712457|2018-05-31 22:34:23.712457
NCT01362777|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-09-19|2011-05-27|2011-05-30|Estimate|||||||2011-09-19|2011-09-20|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|Rehsolvas||Rehabilitation Program as an Alternative Therapy for Moderate to Severe Obstructive Sleep Apnea Syndrome|Effects of an In-Patient Individualized Rehabilitation Program on Severity and Symptoms of Obstructive Sleep Apnea Syndrome (OSAS):Results of a Randomized Controlled Pilot Study|Completed||Phase 3|26|Actual|5 Santé||2|||f||||f||||||||||2018-05-31 22:34:23.820373|2018-05-31 22:34:23.820373
NCT01362764|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-27|||2012-11-26|2011-05-27|2011-05-30|Estimate|||||||2012-11-26|2012-11-27|Estimate|May 2011||2011-05-31|November 2012|2012-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers|A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation Under Fasted Condition in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Cougar Biotechnology, Inc.||3|||f||||f||||||||||2018-05-31 22:34:23.911615|2018-05-31 22:34:23.911615
NCT01362751|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2012-09-02|2011-05-27|2011-05-30|Estimate|||||||2012-09-02|2012-09-05|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Orthostatic Hypotension in Elderly Nursing Home Residents||Completed|||290|Actual|Medical Research Foundation, The Netherlands|||1||f||||f||||||||||2018-05-31 22:34:23.970596|2018-05-31 22:34:23.970596
NCT01362738|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-04-25|2011-05-27|2011-05-30|Estimate|||||||2017-04-25|2017-04-26|Actual|November 2010||2010-11-30|October 2016|2016-10-31|November 2016|Actual|2016-11-30|June 2014|Actual|2014-06-30||Interventional|BELIEF||Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation|Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outcome in Patients With Persistent or Long-standing Persistent Atrial Fibrillation Undergoing Catheter Ablation|Completed||Phase 3|156|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-05-31 22:34:24.098924|2018-05-31 22:34:24.098924
NCT01362725|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2016-07-19|2011-05-27|2011-05-30|Estimate|||||||2016-07-19|2016-07-21|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|August 2014|Actual|2014-08-31||Interventional|SCS HEART||Spinal Cord Stimulation For Heart Failure|Spinal Cord Stimulation For Heart Failure As A Restorative Treatment|Completed||Phase 2/Phase 3|20|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 22:34:24.187138|2018-05-31 22:34:24.187138
NCT01362712|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2012-05-17|2011-05-26|2011-05-30|Estimate|||||||2012-05-17|2012-05-21|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects|An Exploratory, Phase I, Open Label, Multi-Center, Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects|Terminated||Phase 1|7|Actual|Siemens Molecular Imaging||||Unable to enroll breast cancer patients with current I/E criteria.|f||||f||||||||||2018-05-31 22:34:24.288187|2018-05-31 22:34:24.288187
NCT01362699|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-04-27|2011-05-26|2011-05-30|Estimate|||||||2012-04-27|2012-04-30|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|August 2012|Anticipated|2012-08-31|||||Interventional|||Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults|A Single Center, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy of JNJ 31001074 on Cue Induced Craving for Alcohol in Adult Subjects With Alcohol DependenceH3 Alcoholism|Withdrawn||Phase 2|0|Actual|Janssen Research & Development, LLC||2||Re-prioritization lead to study cancellation.|f||||t||||||||||2018-05-31 22:34:24.375388|2018-05-31 22:34:24.375388
NCT01362686|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2016-07-22||2017-01-08|2011-05-27|2011-05-30|Estimate|2017-01-08|2017-02-27|Actual||||2017-01-08|2017-02-27|Actual|April 2011||2011-04-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|COMET-AD||Comparative Research of Alzheimer's Disease Drugs|Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs|Terminated||N/A|200|Actual|Indiana University|Small sample size limits generalizability and may introduce type II error. The study took place at a time when most third-party payers declared donepezil the preferred AChEI due to cost that may have influenced study’s results.|3||Low study accrual caused the study to be ended early.|f||||t||||||||||2018-05-31 22:34:24.510336|2018-05-31 22:34:24.510336
NCT01362673|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-10-05|2011-05-26|2011-05-30|Estimate|||||||2011-10-05|2011-10-07|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions|A Phase 1, Randomized, Subject- And Investigator Blind, Sponsor Open, Placebo Controlled, Single- And Multiple-Dose Escalation Study Of PF-04171327 In Healthy Adult Japanese And Western Subjects In Fasting And Fed Conditions|Completed||Phase 1|27|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:34:24.952775|2018-05-31 22:34:24.952775
NCT01362660|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2013-02-05|2011-05-26|2011-05-30|Estimate|||||||2013-02-05|2013-02-06|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth|A Protocol to Monitor the Neurological Development of Infants With Exposure In-utero From Birth to Aged 15 Months in Tanezumab Clinical Studies at Investigational Sites Overseen by Schulman and Associates Institutional Review Board|Completed|||7|Actual|Pfizer|||1||f||||t||||||||||2018-05-31 22:34:25.053126|2018-05-31 22:34:25.053126
NCT01362647|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-10-04|2011-05-26|2011-05-30|Estimate|||||||2011-10-04|2011-10-05|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit|A Non-interventional / Observational Study on Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit After Spontaneous Recovery or After Reversal of the Neuromuscular Block|Completed|||625|Actual|Onze Lieve Vrouw Hospital|||||f||||f||||||||||2018-05-31 22:34:25.126744|2018-05-31 22:34:25.126744
NCT01362634|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-12-06|2011-05-26|2011-05-30|Estimate|||||||2017-12-06|2017-12-07|Actual|August 2011||2011-08-31|December 2017|2017-12-31|July 31, 2017|Actual|2017-07-31|December 2015|Actual|2015-12-31||Interventional|||A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV|A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV|Completed||N/A|750|Actual|Nova Southeastern University||3|||f||||t||||||||||2018-05-31 22:34:25.192351|2018-05-31 22:34:25.192351
NCT01362621|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-06-15|2011-05-27|2011-05-30|Estimate|||||||2011-06-15|2011-06-16|Estimate|February 2008||2008-02-29|June 2011|2011-06-30||||February 2010|Actual|2010-02-28||Observational|||Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma|A 2-year Prospective, Multi-center, Observational and Epidemiologic Outcomes Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma|Completed|||474|Actual|Novartis|||1||f||||||||||Samples With DNA|"~     A venous blood sample was collected at either screening (Visit 1) or enrollment (Visit 2).~     These samples were collected for DNA extraction. The extracted DNA is stored at Novartis~     Pharmaceuticals Corporation for pharmacogenetic analysis and storage.~   "|||2018-05-31 22:34:25.259105|2018-05-31 22:34:25.259105
NCT01362608|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2016-05-19||2017-06-07|2011-05-26|2011-05-30|Estimate|2017-06-07|2017-06-08|Actual||||2017-06-07|2017-06-08|Actual|June 20, 2011|Actual|2011-06-20|June 2017|2017-06-30|May 19, 2015|Actual|2015-05-19|May 19, 2015|Actual|2015-05-19||Interventional|||Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective|A Randomized, Double-blind, Double-dummy, Active Controlled Study of Canakinumab (ACZ885) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective|Terminated||Phase 3|136|Actual|Novartis|This study was terminated early. The decision to terminate study was not out of concerns for efficacy or safety of canakinumab|2|||f||||||||||||||2018-05-31 22:34:25.399771|2018-05-31 22:34:25.399771
NCT01362595|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-04-10|2011-05-26|2011-05-30|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|LeucineDBA||Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia|The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Northwell Health||1|||f||||t||||||||No||2018-05-31 22:34:26.364971|2018-05-31 22:34:26.364971
NCT01362582|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2014-09-24|2011-05-27|2011-05-30|Estimate|||||||2014-09-24|2014-09-25|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|PANUSCO||Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic Cancer|Open-label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution Versus Best Supportive Nutritional Care in Patients With Pancreatic Cancer Receiving 2nd Line Chemotherapy|Terminated||Phase 3|32|Actual|National Center for Tumor Diseases, Heidelberg||2|||f||||t||||||||||2018-05-31 22:34:26.450501|2018-05-31 22:34:26.450501
NCT01362569|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2017-10-10|2011-05-27|2011-05-30|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2011||2011-07-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Observational|ENARI||Endotoxin, Neutrophil Function and Albumin in Renal Insufficiency|Endotoxin, Neutrophil Function and Albumin in Renal Insufficiency|Completed|||239|Actual|Medical University of Graz|||6||f||||t||||||Samples Without DNA|"~     Serum, Plasma, Urine~   "|Undecided||2018-05-31 22:34:26.511443|2018-05-31 22:34:26.511443
NCT01362556|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2014-06-02|2011-05-26|2011-05-30|Estimate|||||||2014-06-02|2014-06-03|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|BABICA||Blood Gas Analysis and Buffering In Cardiac Arrest|Blood Gas Analysis and Buffering In Cardiac Arrest - A Multicenter, Prospective, Randomised, Double Blind Prehospital Trial to Evaluate the Impact of Early Blood-gas-analysis Targeted Buffer Therapy on ROSC After OOHCA|Completed||N/A|700|Anticipated|Medical University of Graz||2|||f||||t||||||||||2018-05-31 22:34:26.600488|2018-05-31 22:34:26.600488
NCT01362543|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2014-05-13|2011-05-27|2011-05-30|Estimate|||||||2014-05-13|2014-05-14|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Traumatized Refugees -Stress Management Versus Cognitive Re-structuring|Treatment With Cognitive Behavioural Therapy in Traumatised Refugees - Stress Management Versus Cognitive Restructuring - a Randomised Clinical Trial|Completed||Phase 3|143|Actual|Mental Health Services in the Capital Region, Denmark||2|||f||||t||||||||||2018-05-31 22:34:27.626751|2018-05-31 22:34:27.626751
NCT01362530|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2014-02-24||2017-04-24|2011-05-26|2011-05-30|Estimate|2014-02-24|2014-04-04|Estimate||||2017-04-24|2017-06-05|Actual|September 13, 2011|Actual|2011-09-13|April 2017|2017-04-30|August 16, 2013|Actual|2013-08-16|March 14, 2013|Actual|2013-03-14||Interventional||Intent-to-treat (ITT) population: all randomized participants who received study medication.|A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Patients|Completed||Phase 3|307|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:34:27.727996|2018-05-31 22:34:27.727996
NCT01362517|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2013-03-27||2013-08-29|2011-05-27|2011-05-30|Estimate|2013-05-15|2013-06-24|Estimate||||2013-08-29|2013-09-09|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|April 2011|Actual|2011-04-30|July 2010|Actual|2010-07-31||Interventional|||Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B|Assessment of the Immunogenicity and Safety of Quinvaxem Vaccine (DTwP-HepB-Hib) Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by H. Influenzae Among Healthy Vietnamese Children|Completed||Phase 3|131|Actual|Crucell Holland BV||1|||f||||f||||||||||2018-05-31 22:34:28.410576|2018-05-31 22:34:28.410576
NCT01362504|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-10-07|2011-05-27|2011-05-30|Estimate|||||||2011-10-07|2011-10-12|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||Pro-adrenomedullin as a Prognostic Marker in Neonatal Sepsis|Zekai Tahir Burak Maternity Teaching Hospital Neonatal Intensive Care Unit|Completed|||80|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||3||f||||f||||||||||2018-05-31 22:34:28.661586|2018-05-31 22:34:28.661586
NCT01362491|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2013-03-07||2014-07-29|2011-05-26|2011-05-30|Estimate|2014-07-29|2014-07-30|Estimate||||2014-07-29|2014-07-30|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Ibuprofen Sodium Tension Headache Study|Ibuprofen Sodium Tension Headache Study|Completed||Phase 3|226|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:34:28.781073|2018-05-31 22:34:28.781073
NCT01362478|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2012-06-27|2011-05-27|2011-05-30|Estimate|||||||2012-06-27|2012-06-29|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|July 2014|Anticipated|2014-07-31|||||Observational|||Gene Promoter DNA Methylations and Their Relationships With Endophenotypes in Patients With Schizophrenia|Gene Promoter DNA Methylations and Their Relationships With Endophenotypes in Patients With Schizophrenia|Unknown status|Recruiting||120|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||Samples With DNA|"~     Gene promoter DNA methylations~   "|||2018-05-31 22:34:29.657986|2018-05-31 22:34:29.657986
NCT01362465|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2012-09-18|2011-05-27|2011-05-30|Estimate|||||||2012-09-18|2012-09-20|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|ICM||Characterization of Interventricular Conduction Measurements|Characterization of Interventricular Conduction Measurements|Completed||Early Phase 1|25|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 22:34:29.732718|2018-05-31 22:34:29.732718
NCT01362452|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-08-02|2011-05-27|2011-05-30|Estimate|||||||2017-08-02|2017-08-03|Actual|December 7, 2012|Actual|2012-12-07|August 2017|2017-08-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells|Donor-Derived, CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Umbilical Cord Blood Transplantation|Completed||Phase 1|5|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 22:34:29.818246|2018-05-31 22:34:29.818246
NCT01362439|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2013-02-14||2013-04-29|2011-05-27|2011-05-30|Estimate|2013-04-29|2013-06-05|Estimate||||2013-04-29|2013-06-05|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years|Efficacy and Tolerability of Flexible Doses of Paliperidone ER in Symptomatic Subjects With Schizophrenia With Duration of Illness < 10 Years|Completed||Phase 4|133|Actual|Janssen-Cilag S.p.A.||1|||f||||f||||||||||2018-05-31 22:34:29.923526|2018-05-31 22:34:29.923526
NCT01362426|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2016-03-09|2011-05-26|2011-05-30|Estimate|||||||2016-03-09|2016-03-10|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)|A Quality Use of Medicine Clinical Registry to Assess Clinical Outcomes in Patients With Schizophrenia Treated With Intramuscular Injections of Paliperidone Palmitate|Completed|||127|Actual|Janssen-Cilag Pty Ltd|||1||f||||||||||||||2018-05-31 22:34:30.316621|2018-05-31 22:34:30.316621
NCT01362413|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2015-03-27|2011-05-27|2011-05-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Observational|Rebone-test||Validation of Laboratory Test for Predicting Bone Tissue Regeneration|Validation of Laboratory Test for Predicting Bone Tissue Regeneration in Patient Affected by Aseptic Pseudarthrosis and Treated With Platelet Gel|Completed|||20|Actual|Istituto Ortopedico Rizzoli|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:34:30.430413|2018-05-31 22:34:30.430413
NCT01362400|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2014-05-16|2011-05-26|2011-05-30|Estimate|||||||2014-05-16|2014-05-19|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer|A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer|Completed||Phase 2|226|Actual|Infinity Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 22:34:30.580499|2018-05-31 22:34:30.580499
NCT01362387|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2013-02-13|2011-05-27|2011-05-30|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2011||2011-04-30|May 2011|2011-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||R U OK? The Acceptability and Feasibility of New Communication Technologies for Follow-up After Medical Abortion|R U OK? The Acceptability and Feasibility of New Communication Technologies for Follow-up After Medical Abortion|Completed||N/A|999|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 22:34:31.498528|2018-05-31 22:34:31.498528
NCT01362374|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2018-05-30|2011-05-26|2011-05-30|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 11, 2011|Actual|2011-07-11|May 2018|2018-05-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors|A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|123|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 22:34:31.634644|2018-05-31 22:34:31.634644
NCT01362361|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2012-04-05|2011-05-27|2011-05-30|Estimate|||||||2012-04-05|2012-04-06|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|AIO-KRK-0111||TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)|TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)|Unknown status|Recruiting|Phase 2|2|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-05-31 22:34:31.906333|2018-05-31 22:34:31.906333
NCT01362348|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2017-07-18|2012-10-04|2017-08-23|2011-05-26|2011-05-30|Estimate|2017-07-18|2017-08-21|Actual|2012-10-04|2012-10-08|Estimate|2017-08-23|2017-09-21|Actual|July 7, 2011|Actual|2011-07-07|August 2017|2017-08-31|April 16, 2012|Actual|2012-04-16|April 16, 2012|Actual|2012-04-16||Interventional|||12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)|An Open-label, Phase 2a Study to Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients With Neovascular Age-related Macular Degeneration|Terminated||Phase 2|19|Actual|GlaxoSmithKline||1||Lack of efficacy identified during a preliminary analysis|f||||f||||||||||2018-05-31 22:34:32.05811|2018-05-31 22:34:32.05811
NCT01362335|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2013-01-15|2011-05-26|2011-05-30|Estimate|||||||2013-01-15|2013-01-16|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Nexfin®-Monitoring System|Electronic Registration of Noninvasively Acquired Hemodynamic Parameters Using Nexfin®-Monitoring System|Completed|||120|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 22:34:32.537617|2018-05-31 22:34:32.537617
NCT01362322|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19||2012-11-16|2016-08-29|2011-05-26|2011-05-30|Estimate||||2012-11-16|2012-11-21|Estimate|2016-08-29|2016-08-30|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents|Immunogenicity and Safety Study of GSK Biologicals' Boostrix™ Vaccine Using a New Syringe Presentation in Healthy Adolescents Aged 10-15 Years|Completed||Phase 4|671|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:34:32.618369|2018-05-31 22:34:32.618369
NCT01362309|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2014-02-14|2011-05-26|2011-05-30|Estimate|||||||2014-02-14|2014-02-19|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||D-Cycloserine to Enhance Extinction to Alcohol Cues|D-Cycloserine to Enhance Extinction to Alcohol Cues|Completed||N/A|37|Actual|University of Georgia||2|||f||||f||||||||||2018-05-31 22:34:32.742768|2018-05-31 22:34:32.742768
NCT01362296|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2013-06-06||2014-06-26|2011-05-26|2011-05-30|Estimate|2014-04-24|2014-05-26|Estimate||||2014-06-26|2014-07-11|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer|A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared With Docetaxel in 2nd Line Subjects With Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC Stage IV)|Completed||Phase 2|134|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:34:32.950677|2018-05-31 22:34:32.950677
NCT01362283|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-11-30|2011-05-26|2011-05-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|WONDeR||Epidemiologic Study to Evaluate the Proportion of Cardiovascular Disease Risk Factors in Korean Hypertensive Patients|A Multi-center, Observational, Cross-sectional Study to Evaluate CVD Risk Factors in Korean Hypertensive Patients|Completed|||3109|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:34:34.653128|2018-05-31 22:34:34.653128
NCT01362270|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2016-05-18|2011-05-27|2011-05-30|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Acupuncture for Sedation in the Intensive Care Unit (ICU)|Acupuncture for Sedation in the Intensive Care Unit|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:34:34.800687|2018-05-31 22:34:34.800687
NCT01362257|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-06-26|2011-05-26|2011-05-30|Estimate|||||||2017-06-26|2017-06-27|Actual|April 29, 2011|Actual|2011-04-29|June 2017|2017-06-30|June 22, 2011|Actual|2011-06-22|June 22, 2011|Actual|2011-06-22||Interventional|||A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719|An Open-label, Two Period Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719, Administered as Single Dose of an Oral Solution and an Intravenous Infusion, to Healthy Male Adults|Completed||Phase 1|6|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:34:34.888272|2018-05-31 22:34:34.888272
NCT01362244|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2015-11-23||2018-03-08|2011-05-26|2011-05-30|Estimate|2016-02-25|2016-03-28|Estimate||||2018-03-08|2018-04-04|Actual|May 12, 2009|Actual|2009-05-12|March 2018|2018-03-31|December 5, 2014|Actual|2014-12-05|December 5, 2014|Actual|2014-12-05||Interventional|||Mepolizumab in Nasal Polyposis|A Randomised, Double-Blind, Placebo Controlled, Multi-Center Study To Investigate The Use Of Mepolizumab (Sb-240563) In Reducing The Need For Surgery In Subjects With Severe Bilateral Nasal Polyposis|Completed||Phase 2|109|Actual|GlaxoSmithKline|Part B was removed due to the low numbers of participants enrolling into Part B. GSK determined it was no longer feasible to achieve a meaningful number of participants and therefore recruitment into this portion of the study was stopped.|3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:34:35.152436|2018-05-31 22:34:35.152436
NCT01362231|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2015-07-07|2011-05-27|2011-05-30|Estimate|||||||2015-07-07|2015-07-09|Estimate|December 2010||2010-12-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis|Completed||Phase 1|48|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 22:34:37.398402|2018-05-31 22:34:37.398402
NCT01362218|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2013-04-23|2011-05-26|2011-05-30|Estimate|||||||2013-04-23|2013-04-24|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol|Cardiovascular Fixed Combination Pill ASR: Pharmacodynamic Clinical Trial of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin, and Ramipril (Cardiovascular Polypill); LDL Cholesterol|Terminated||Phase 2|107|Actual|Ferrer Internacional S.A.||2||Per sponsor's decision|f||||||||||||||2018-05-31 22:34:37.500617|2018-05-31 22:34:37.500617
NCT01362205|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2017-05-16||2017-10-04|2011-05-26|2011-05-30|Estimate|2017-06-19|2017-07-17|Actual||||2017-10-04|2017-11-06|Actual|March 2012||2012-03-31|October 2017|2017-10-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)|Terminated||Phase 4|49|Actual|Denver Health and Hospital Authority|Early termination due to slow enrollment leading to small numbers of subjects analyzed|2||DSMB recommendation for slow enrollment|f||||t||||||||No||2018-05-31 22:34:38.070419|2018-05-31 22:34:38.070419
NCT01362192|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|2013-06-17||2015-01-26|2011-05-26|2011-05-30|Estimate|2015-01-26|2015-01-29|Estimate||||2015-01-26|2015-01-29|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Treatment of Lower Extremity Spider Veins With Excel V|A Clinical Evaluation of the Treatment of Lower Extremity Spider Veins Using a Dual Wavelength Laser Emitting 532 nm and 1064 nm Laser Energy|Completed||Phase 4|20|Actual|Cutera Inc.||1|||f||||f||||||||||2018-05-31 22:34:39.012491|2018-05-31 22:34:39.012491
NCT01362179|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-06-13|2011-05-27|2011-05-30|Estimate|||||||2017-06-13|2017-06-14|Actual|October 2010||2010-10-31|October 2016|2016-10-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|LTDFU||National Marrow Donor Program Long-Term Donor Follow-Up|Incidence of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Normal Donors Undergoing Bone Marrow Harvest Versus Peripheral Blood Stem Cell Mobilization With Recombinant Human Granulocyte Colony-Stimulating Factor (rHuG-CSF)|Active, not recruiting|||21932|Anticipated|Center for International Blood and Marrow Transplant Research|||2||f||||t||||||||||2018-05-31 22:34:39.449856|2018-05-31 22:34:39.449856
NCT01362166|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-05-27|2011-05-27|2011-05-30|Estimate|||||||2011-05-27|2011-05-30|Estimate|May 2011||2011-05-31|May 2011|2011-05-31||||||||Observational|YCFR||Frequency Response of the Foot-Yangming Stomach Channel: Zu-San-Li and Xian-Gu|With Different Frequency Electric Signals Study the Frequency Response of the Foot-Yangming Stomach Channel: Zu-San-Li and Xian-Gu|Unknown status|Recruiting||30|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 22:34:39.543203|2018-05-31 22:34:39.543203
NCT01362153|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-09-28|2011-05-27|2011-05-30|Estimate|||||||2017-09-28|2017-10-02|Actual|December 26, 2007|Actual|2007-12-26|September 2017|2017-09-30|February 27, 2009|Actual|2009-02-27|February 27, 2009|Actual|2009-02-27||Interventional|||A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)|An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis|Completed||Phase 1|49|Actual|Centocor, Inc.||2|||f||||f||f||||||||2018-05-31 22:34:39.705843|2018-05-31 22:34:39.705843
NCT01362140|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2016-10-12|2016-01-06|2017-11-21|2011-05-27|2011-05-30|Estimate|2016-10-12|2016-12-05|Estimate|2016-01-06|2016-02-05|Estimate|2017-11-21|2017-12-19|Actual|December 21, 2011|Actual|2011-12-21|November 2017|2017-11-30|September 14, 2017|Actual|2017-09-14|February 11, 2015|Actual|2015-02-11||Interventional||Primary Analysis Set includes all randomized and consented participants who received at least 1 dose of investigational product.|Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 3|147|Actual|Amgen||2|||f||||t||||||||||2018-05-31 22:34:39.819785|2018-05-31 22:34:39.819785
NCT01362127|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2017-02-17|2011-05-26|2011-05-27|Estimate|||||||2017-02-17|2017-02-20|Actual|October 2006||2006-10-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2013|Actual|2013-06-30||Interventional|NeoRes||Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia|Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy|Active, not recruiting||Phase 2|180|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 22:34:40.591923|2018-05-31 22:34:40.591923
NCT01362114|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2012-04-16|2011-05-26|2011-05-27|Estimate|||||||2012-04-16|2012-04-18|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Interventional|||The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung|Phase 4 Study of The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung : A Randomized, Double Blind, Placebo-control Trial|Unknown status|Recruiting|Phase 4|160|Anticipated|Korea Health Industry Development Institute||2|||f||||t||||||||||2018-05-31 22:34:40.675557|2018-05-31 22:34:40.675557
NCT01362101|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2013-07-09|2011-05-26|2011-05-27|Estimate|||||||2013-07-09|2013-07-11|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|physio||Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol|Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol|Completed||Phase 4|56|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:34:40.754445|2018-05-31 22:34:40.754445
NCT01362088|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2012-10-31|2011-05-26|2011-05-27|Estimate|||||||2012-10-31|2012-11-01|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Microcirculation in Continuous Venovenous Hemofiltration Patients on the Intensive Care Unit|Evaluation of Sublingual Microcirculation by Means of SDF Imaging by Stepwise Ultrafiltration in CVVH Patients on the ICU|Completed|||14|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||||2018-05-31 22:34:41.055755|2018-05-31 22:34:41.055755
NCT01362075|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2014-08-07|2011-05-26|2011-05-27|Estimate|||||||2014-08-07|2014-08-08|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Pain Management After Shoulder Prosthesis: A Clinical Trial of Nerve Block and Local Infiltration|Pain Management After Shoulder Arthroplasty: A Randomised Clinical Trial of Interscalene Block and Local Infiltration Analgesia|Terminated||N/A|74|Actual|Horsens Hospital||2||After 3 years of recruitment, the study was stopped due to time constraints.|f||||f||||||||||2018-05-31 22:34:41.122862|2018-05-31 22:34:41.122862
NCT01362062|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2016-03-03||2017-06-28|2011-05-26|2011-05-27|Estimate|2016-03-03|2016-04-04|Estimate||||2017-06-28|2017-08-02|Actual|October 26, 2010|Actual|2010-10-26|June 2017|2017-06-30|January 1, 2015|Actual|2015-01-01|January 1, 2015|Actual|2015-01-01||Observational||All enrolled participants who were considered evaluable for analysis.|Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy|A Study to Observe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti TNF Therapy.|Completed|||110|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:34:41.264697|2018-05-31 22:34:41.264697
NCT01362049|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2016-11-28||2017-05-01|2011-05-26|2011-05-27|Estimate|2017-03-31|2017-04-04|Actual||||2017-05-01|2017-06-05|Actual|March 2010||2010-03-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|July 2011|Actual|2011-07-31||Interventional|||Mechanisms of Specific Trunk Exercises in Low Back Pain|Mechanisms of Specific Trunk Exercises in Low Back Pain|Completed||N/A|102|Actual|University of Vermont|The sample size was relatively small, providing adequate power for only comparing the matched to unmatched treatments (and not the stabilization vs. Movement System Impairment exercises).|4|||f||||t||||||||No||2018-05-31 22:34:42.138201|2018-05-31 22:34:42.138201
NCT01362036|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|||2016-08-29|2011-05-26|2011-05-27|Estimate|||||||2016-08-29|2016-08-31|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia|Phase 1 Open-Label Dose-Escalating Study Evaluating the Safety and Preliminary Efficacy of TXA127 in Patients With Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia|Terminated||Phase 1|2|Actual|Tarix Pharmaceuticals||1||Enrollment feasibility issues, new study in design|f||||f||||||||||2018-05-31 22:34:42.590198|2018-05-31 22:34:42.590198
NCT01362023|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2011-06-09|2011-05-26|2011-05-27|Estimate|||||||2011-06-09|2011-06-10|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|EDAL2||Efficacy of an Educational School-based Intervention to Reduce Prevalence of Obesity in Childhood-EdAl-2|A Primary-school-based Study to Reduce Prevalence of Childhood Obesity in Terres de l'Ebre (Catalunya (Spain) - EDAL-Educació en Estils Saludables de Vida alimentació-2: Study Protocol for a Randomized Controlled Trial|Unknown status|Enrolling by invitation|N/A|800|Anticipated|University Rovira i Virgili||2|||f||||t||||||||||2018-05-31 22:34:42.660143|2018-05-31 22:34:42.660143
NCT01362010|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2013-08-14|2011-05-26|2011-05-27|Estimate|||||||2013-08-14|2013-08-15|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris Patients|Pilot, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Acne Vulgaris Patients|Completed||Phase 2|150|Actual|Foamix Ltd.||3|||f||||f||||||||||2018-05-31 22:34:42.71552|2018-05-31 22:34:42.71552
NCT01361997|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2016-08-17|2011-05-26|2011-05-27|Estimate|||||||2016-08-17|2016-08-19|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination|Comparative Study of 70% Isopropyl Alcohol Against 2% Chlorhexidine- 70% Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination|Completed||Phase 3|1102|Actual|Universidad de Guanajuato||2|||f||||f||||||||||2018-05-31 22:34:42.787169|2018-05-31 22:34:42.787169
NCT01361984|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-07-18|2011-05-26|2011-05-27|Estimate|||||||2012-07-18|2012-07-20|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography|Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent)|Unknown status|Recruiting|Phase 4|20|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:34:42.862506|2018-05-31 22:34:42.862506
NCT01361971|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2013-09-17|2011-05-26|2011-05-27|Estimate|||||||2013-09-17|2013-09-19|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|HOTAIR||Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance|Hyperbaric Oxygen Treatment Ameliorates Insulin Resistance|Completed||N/A|20|Actual|University of Adelaide|||||f||||f||||||||||2018-05-31 22:34:42.937126|2018-05-31 22:34:42.937126
NCT01361958|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-05-26|2011-05-26|2011-05-27|Estimate|||||||2011-05-26|2011-05-27|Estimate|February 1997||1997-02-28|May 2011|2011-05-31|September 1998|Actual|1998-09-30|November 1997|Actual|1997-11-30||Interventional|||Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol|Double-blind, Comparative, Randomized, Single Center, Between-subject, Dose-finding Clinical Trial to Compare 4 Doses of the Combination 17beta-estradiol/Nomegestrol Acetate Administered From Day 1 to Day 21 of the Menstrual Cycle on the Inhibition of Ovulation|Completed||Phase 2|38|Actual|Theramex||4|||f||||f||||||||||2018-05-31 22:34:42.9904|2018-05-31 22:34:42.9904
NCT01361945|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-05-05|2011-05-26|2011-05-27|Estimate|||||||2017-05-05|2017-05-09|Actual|July 2011|Actual|2011-07-31|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer|A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Texas Tech University Health Sciences Center, El Paso||1||Closed due to no enrollment|f||||f||||||||No|the study has not been completed|2018-05-31 22:34:43.170573|2018-05-31 22:34:43.170573
NCT01361932|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2013-03-25|2011-05-26|2011-05-27|Estimate|||||||2013-03-25|2013-03-27|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Interventional|||Using Online Videos to Supplement Emergency Department Discharge Instructions|Speak Fast, Use Jargon, and Don't Repeat Yourself: Using Online Videos to Supplement Emergency Department Discharge Instructions|Completed||N/A|133|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:34:43.247276|2018-05-31 22:34:43.247276
NCT01361919|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2015-10-13|2011-05-26|2011-05-27|Estimate|||||||2015-10-13|2015-10-15|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|BLS Pilot||Three Different Cardiopulmonary Resuscitation (CPR) Training Methods|The Benefits of a Simplified Method for CPR Training of Medical Professionals: A Randomized Controlled Study|Completed||N/A|298|Actual|St. Michael's Hospital, Toronto||3|||f||||f||||||||||2018-05-31 22:34:43.321925|2018-05-31 22:34:43.321925
NCT01361906|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2014-05-28|2011-05-26|2011-05-27|Estimate|||||||2014-05-28|2014-05-29|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Effects of Sensomotoric Training on Neck/Scapular Pain in People With Visual Disability|Effects of Sensomotoric Training on Neck/Scapular Pain in People With Visual Disability|Completed||Phase 4|52|Actual|Centre for Rehabilitation Research, Örebro||2|||f||||f||||||||||2018-05-31 22:34:43.420685|2018-05-31 22:34:43.420685
NCT01361893|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-06-30|2011-05-26|2011-05-27|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2004||2004-12-31|June 2017|2017-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SIDS||Factors Influencing the Racial Disparity in Sudden Infant Death Syndrome (SIDS)|Factors Influencing the Racial Disparity in Sudden Infant Death Syndrome (SIDS)|Completed||N/A|616|Actual|University of Virginia||1|||f||||t||||||||||2018-05-31 22:34:43.487717|2018-05-31 22:34:43.487717
NCT01361867|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|2017-04-10||2017-05-23|2011-05-26|2011-05-27|Estimate|2017-05-23|2017-05-30|Actual||||2017-05-23|2017-05-30|Actual|November 2009|Actual|2009-11-30|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Robotic Assessment of Lower Extremity Motor Learning|Robotic Assessment of Lower Extremity Motor Learning|Completed||N/A|15|Actual|Spaulding Rehabilitation Hospital|The study was based on pilot experiments (N=35) aimed to determine how to use the robot to perturb step length and step height during gait. In the actual study (N=15), the investigators assessed how individuals adapted to the perturbations.|1|||f||||f||t|f|f|f|||No||2018-05-31 22:34:43.642209|2018-05-31 22:34:43.642209
NCT01361854|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|2015-02-20||2015-05-22|2011-05-26|2011-05-27|Estimate|2015-05-22|2015-06-08|Estimate||||2015-05-22|2015-06-08|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||patients suspected of OSA|Comparison of 2 Different Hook-up Protocols to Perform Home-based Polysomnography|Comparison of 2 Different Hook-up Protocols to Perform Home-based Polysomnography|Completed||N/A|102|Actual|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||||2018-05-31 22:34:43.905581|2018-05-31 22:34:43.905581
NCT01361841|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-05-26|2011-05-26|2011-05-27|Estimate|||||||2011-05-26|2011-05-27|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma|Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma|Unknown status|Recruiting|N/A|141|Anticipated|Centre de recherche du Centre hospitalier universitaire de Sherbrooke||1|||f||||t||||||||||2018-05-31 22:34:44.064453|2018-05-31 22:34:44.064453
NCT01361828|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-05-26|2011-05-26|2011-05-27|Estimate|||||||2011-05-26|2011-05-27|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Optic Nerve and Retinal Functions With Bevacizumab|Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin).|Completed|||45|Actual|Cairo University|||1||f||||f||||||||||2018-05-31 22:34:44.139587|2018-05-31 22:34:44.139587
NCT01361815|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2018-01-24|2011-05-26|2011-05-27|Estimate|||||||2018-01-24|2018-01-25|Actual|July 2011||2011-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)|A Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI) for Subjects With MDD Who Complete/ Discontinued the CTP-0001-00 Protocol|Completed||Phase 3|75|Actual|Brainsway||1|||f||||t||||||||||2018-05-31 22:34:44.209398|2018-05-31 22:34:44.209398
NCT01361802|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16||2014-04-30|2014-04-30|2011-05-26|2011-05-27|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|May 2011||2011-05-31|April 2014|2014-04-30||||August 2011|Actual|2011-08-31||Interventional|||Ambroxol Spray Sore Throat Study|A Multi-centre, Randomised, Double-blind, Placebo Controlled Parallel Group, Dose Finding Study to Assess the Efficacy and Safety of Ambroxol Spray (2.5mg, 5mg or 10mg) Versus Placebo for the Temporary Relief of Sore Throat Pain in Patients With Acute Pharyngitis|Completed||Phase 2|494|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 22:34:44.30142|2018-05-31 22:34:44.30142
NCT01361789|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2011-05-26|2011-05-26|2011-05-27|Estimate|||||||2011-05-26|2011-05-27|Estimate|January 2004||2004-01-31|May 2011|2011-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined|COX-2 Inhibitor Versus Glucocorticoid Versus Both Combined|Completed||Phase 4|93|Actual|Asker & Baerum Hospital||3|||f||||f||||||||||2018-05-31 22:34:44.403447|2018-05-31 22:34:44.403447
NCT01361776|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2015-11-17|2011-05-26|2011-05-27|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Humoral Response to Tick-borne Encephalitis Vaccine in Elderly|Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses?|Completed||Phase 2/Phase 3|200|Actual|Sormland County Council, Sweden||4|||f||||t||||||||||2018-05-31 22:34:44.501345|2018-05-31 22:34:44.501345
NCT01361763|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-02-10|2011-05-26|2011-05-27|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Interventional|SONICA||Safety Study of Dabigatran in CADASIL|Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL|Unknown status|Recruiting|Phase 2|50|Anticipated|S. Andrea Hospital||2|||f||||t||||||||||2018-05-31 22:34:44.582838|2018-05-31 22:34:44.582838
NCT01361750|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-26|2011-05-26|2011-05-27|Estimate|||||||2011-05-26|2011-05-27|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|May 2013|Anticipated|2013-05-31|May 2012|Anticipated|2012-05-31||Interventional|||The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy|The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy: A Randomized Control Trial and Physiological Study|Unknown status|Recruiting|Phase 3|144|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 22:34:44.686157|2018-05-31 22:34:44.686157
NCT01361737|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-07-03|2011-05-26|2011-05-27|Estimate|||||||2011-07-03|2011-07-06|Estimate|January 1999||1999-01-31|May 2011|2011-05-31|May 2004|Actual|2004-05-31|January 1999|Actual|1999-01-31||Observational|||Serum Markers in Preeclamptic Women||Completed|||||Oslo University Hospital|||1||f||||t||||||||||2018-05-31 22:34:44.741733|2018-05-31 22:34:44.741733
NCT01361724|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-10-06|2011-05-25|2011-05-27|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2011||2011-03-31|October 2017|2017-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|COPE||COPE-Co-morbidities, Parkinson's Disease and Exercise|COPE-Co-morbidities, Parkinson's Disease and Exercise|Completed||N/A|58|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-05-31 22:34:44.791265|2018-05-31 22:34:44.791265
NCT01361711|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2018-02-14|2011-05-25|2011-05-27|Estimate|||||||2018-02-14|2018-02-16|Estimate|June 2011||2011-06-30|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia|A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 2|60|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 22:34:44.859503|2018-05-31 22:34:44.859503
NCT01361698|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2016-02-07|2011-05-26|2011-05-27|Estimate|||||||2016-02-07|2016-02-09|Estimate|February 2011||2011-02-28|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|IMR||Illness Management and Recovery (IMR) in Danish Community Mental Health Centres|Illness Management and Recovery (IMR) in Danish Community Mental Health Centres: Protocol of a Randomized, Assessor-blinded Multi-centre Clinical Trial of a Recovery-oriented Program for People With Schizophrenia or Bipolar Disorder|Completed||N/A|198|Actual|Mental Health Centre Copenhagen||2|||f||||f||||||||No||2018-05-31 22:34:44.930607|2018-05-31 22:34:44.930607
NCT01361685|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2017-11-29|2011-05-25|2011-05-27|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2011||2011-05-31|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|February 2021|Anticipated|2021-02-28||Observational|||Model 4396 Left Ventricular (LV) Lead Chronic Performance Study|Attain Ability® Family Left Ventricular Lead Chronic Performance Study|Active, not recruiting|||367|Actual|Medtronic|||||f||||f||||||||||2018-05-31 22:34:45.202425|2018-05-31 22:34:45.202425
NCT01361672|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2017-10-04|2011-05-26|2011-05-27|Estimate|||||||2017-10-04|2017-10-06|Actual|May 2011||2011-05-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Model 4296 Left Ventricular (LV) Lead Chronic Performance Study|Attain Ability® Family Left Ventricular Lead Chronic Performance Study|Active, not recruiting|||1141|Actual|Medtronic|||||f||||f||||||||||2018-05-31 22:34:45.36171|2018-05-31 22:34:45.36171
NCT01361659|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-07-11|2011-05-26|2011-05-27|Estimate|||||||2011-07-11|2011-07-12|Estimate|May 2007||2007-05-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|SWAAM||Shockwave Treatment for Advanced Angina in Maastricht|Shockwave Treatment for Advanced Angina in Maastricht (SWAAM-study).|Unknown status|Recruiting|N/A|60|Anticipated|Maastricht University Medical Center|||||f||||f||||||||||2018-05-31 22:34:45.605737|2018-05-31 22:34:45.605737
NCT01361646|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2013-06-10|2011-05-25|2011-05-27|Estimate|||||||2013-06-10|2013-06-11|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189||Completed||Phase 1|129|Actual|LG Life Sciences||3|||f||||||||||||||2018-05-31 22:34:45.680881|2018-05-31 22:34:45.680881
NCT01361633|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2011-06-22||2012-05-18|2011-05-25|2011-05-27|Estimate|2012-05-18|2012-06-21|Estimate||||2012-05-18|2012-06-21|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly|The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly|Completed||Phase 2|51|Actual|Hartford Hospital|DCS dosing was 1 hour prior to testing, rather than 4-8; the sample had homogenous cognitive capabilities; repeatedly administering DCS may have enhanced cognitive functioning; the measures may not have adequately tapped hippocampal-based learning.|2|||f||||f||||||||||2018-05-31 22:34:45.744444|2018-05-31 22:34:45.744444
NCT01361620|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|2013-08-19||2013-10-29|2011-05-26|2011-05-27|Estimate|2013-10-29|2013-12-16|Estimate||||2013-10-29|2013-12-16|Estimate|December 2007||2007-12-31|January 2011|2011-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ARSENAL||Genotypic and Phenotypic Correlates of Resistance to Aspirin|Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population|Completed||N/A|190|Actual|George Washington University||1|||f||||f||||||||||2018-05-31 22:34:45.965355|2018-05-31 22:34:45.965355
NCT01361607|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|2018-03-23|2016-06-24|2018-03-23|2011-05-26|2011-05-27|Estimate|2018-03-23|2018-04-23|Actual|2016-07-04|2016-07-06|Estimate|2018-03-23|2018-04-23|Actual|May 27, 2011|Actual|2011-05-27|March 2018|2018-03-31|November 24, 2014|Actual|2014-11-24|November 24, 2014|Actual|2014-11-24||Interventional|SPRAY III|All participants who were randomized in the study.|Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer|A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy|Completed||Phase 3|399|Actual|GW Pharmaceuticals Ltd.||2|||f||||t||||||||||2018-05-31 22:34:46.122058|2018-05-31 22:34:46.122058
NCT01361594|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2014-12-18||2014-12-18|2011-05-26|2011-05-27|Estimate|2014-12-18|2014-12-31|Estimate||||2014-12-18|2014-12-31|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CABG|Only subjects that completed the study were accounted for in the baseline characteristics.|Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery|Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery|Completed||Phase 3|338|Actual|Emory University||2|||f||||t||||||||||2018-05-31 22:34:46.693799|2018-05-31 22:34:46.693799
NCT01361581|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-05-26|2011-05-26|2011-05-27|Estimate|||||||2011-05-26|2011-05-27|Estimate|January 2008||2008-01-31|May 2011|2011-05-31||||||||Observational|Citrate||Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy|Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy|Unknown status|Recruiting||120|Anticipated|Charles University, Czech Republic|||3||f||||f||||||Samples Without DNA|"~     frozen plasma~   "|||2018-05-31 22:34:46.927061|2018-05-31 22:34:46.927061
NCT01361568|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|2013-02-18||2014-05-20|2011-05-26|2011-05-27|Estimate|2014-04-20|2014-05-19|Estimate||||2014-05-20|2014-05-29|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery|A Multi-Center, Double-Randomized, Double Blind, Placebo Controlled Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 Dosed Preoperatively and Postoperatively in Patients Undergoing a Laparoscopic Hysterectomy|Completed||Phase 2|203|Actual|Cara Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 22:34:47.007584|2018-05-31 22:34:47.007584
NCT01361555|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25||2015-09-23|2015-09-23|2011-05-25|2011-05-27|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression|A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression|Terminated||Phase 2|789|Actual|Bristol-Myers Squibb||3||Failure to meet primary endpoint|f||||t||||||||||2018-05-31 22:34:47.97518|2018-05-31 22:34:47.97518
NCT01361542|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-01-25|2011-05-26|2011-05-27|Estimate|||||||2012-01-25|2012-01-26|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Effect Of Anti TNF Alpha Therapy And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population|Effect Of Anti TNF Alpha Therapy On Disease Activity And Bone Health, And Their Adverse Effects In Ankylosing Spondylitis In A North Indian Population|Completed||N/A|24|Actual|All India Institute of Medical Sciences, New Delhi||1|||f||||f||||||||||2018-05-31 22:34:48.326483|2018-05-31 22:34:48.326483
NCT01361529|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-26|2011-05-26|2011-05-27|Estimate|||||||2011-05-26|2011-05-27|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Safety Study of FLP Injection to Treat Tumor Patients|Phase 1 Study of FLP Injection on Tumor Patients|Unknown status|Recruiting|Phase 1|30|Anticipated|Acea Bio (Hangzhou) Co., Ltd.||1|||f||||f||||||||||2018-05-31 22:34:48.418163|2018-05-31 22:34:48.418163
NCT01361516|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|July 2011||2011-07-31|April 2011|2011-04-30|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|||Comparison of General Anaesthesia and Sedation on the Stone Fragmentation in Lithotripsy|Comparison of General Anaesthesia and Sedation on the Stone Fragmentation Efficacy of the Third Generation Lithotriptor|Unknown status|Not yet recruiting|N/A|180|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:34:48.512148|2018-05-31 22:34:48.512148
NCT01361503|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2015-02-03|2011-05-25|2011-05-26|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum Disorders|Magnetic Resonance Spectroscopic and Diffusion Tensor Imaging of Adolescents With Autism Spectrum Disorders|Completed|||20|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 22:34:48.590807|2018-05-31 22:34:48.590807
NCT01361490|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2017-12-30|2011-05-25|2011-05-26|Estimate|||||||2017-12-30|2018-01-03|Actual|November 2010||2010-11-30|December 2017|2017-12-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Observational|ARRO||Rehabilitating Overweight People Back to Working Life|Rehabilitating Overweight People Back to Working Life|Completed|||405|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-05-31 22:34:48.653937|2018-05-31 22:34:48.653937
NCT01361477|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Observational|||Data Registry of Intensive Care Unit (ICU) Siamitra and Intensive Care Unit (ICU) Salad-Samung|Data Registry of ICU Siamitra and ICU Salad-Samung|Unknown status|Recruiting||1000|Anticipated|Mahidol University|||1||f||||f||||||||||2018-05-31 22:34:48.702833|2018-05-31 22:34:48.702833
NCT01361464|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2013-11-15||2015-03-19|2011-05-25|2011-05-26|Estimate|2013-11-15|2014-01-06|Estimate||||2015-03-19|2015-04-08|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia|Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)|Due to trial not meeting primary endpoint of at least 3 CR/CRi after 2 cycles, accrual was suspended. 1 year survival was not calculated, not relevant in the setting of a median survival of 6.6 months and with study not meeting its primary endpoint.|1|||f||||||||||||||2018-05-31 22:34:48.779061|2018-05-31 22:34:48.779061
NCT01361451|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-10-22|2011-05-25|2011-05-26|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Observational|||Myotrace: An Evaluation of a Novel Critical Illness Monitoring System|Myotrace: A Phase II Evaluation of a Novel Critical Illness Monitoring System|Completed|||120|Actual|Guy's and St Thomas' NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     It is envisaged that a subset of patients will have venous blood samples taken for future~     analysis for inflammatory cytokines~   "|||2018-05-31 22:34:48.989947|2018-05-31 22:34:48.989947
NCT01361438|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2018-02-20|2011-05-25|2011-05-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2011|Actual|2011-06-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|October 2014|Actual|2014-10-31||Interventional|LAL1509||De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients|A Multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. GIMEMA Protocol LAL1509, EudraCT Number 2010-019119-39|Active, not recruiting||Phase 2|60|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 22:34:49.046246|2018-05-31 22:34:49.046246
NCT01361425|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-27|2011-05-25|2011-05-26|Estimate|||||||2011-05-27|2011-05-30|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|February 2013|Anticipated|2013-02-28|May 2012|Anticipated|2012-05-31||Interventional|METILDOPAPE||Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)|Effectiveness Of Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia: Randomized Placebo-Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||t||||||||||2018-05-31 22:34:49.143099|2018-05-31 22:34:49.143099
NCT01361412|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-10-06|2011-05-25|2011-05-26|Estimate|||||||2011-10-06|2011-10-07|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Identification of Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy|An Optional Research Study to Identify Potential Biomarkers of Response to Peptide Immunotherapy for Ragweed Allergy in Subjects Already Enrolled in Clinical Study TR002|Completed||Phase 2|20|Anticipated|Circassia Limited||5|||f||||||||||||||2018-05-31 22:34:49.210787|2018-05-31 22:34:49.210787
NCT01361399|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|November 2004||2004-11-30|May 2011|2011-05-31|May 2005|Actual|2005-05-31|||||Interventional|||Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold|A 4-arm, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Single Dose, Parallel Group Study Comparing Efficacy and Safety of a Fixed Combination of 500 mg Acetylsalicylic Acid + 4 mg Lidocaine With 500 mg Acetylsalicylic Acid and 4 mg Lidocaine Monotherapy as Well as Placebo in Adult Patients With Sore Throat Associated With a Common Cold.|Completed||Phase 3|1088|Actual|Bayer||4|||f||||f||||||||||2018-05-31 22:34:49.413656|2018-05-31 22:34:49.413656
NCT01361386|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2014-06-13|2011-05-25|2011-05-26|Estimate|||||||2014-06-13|2014-06-16|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|EPICOR ASIA||Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia|Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia|Completed|||13011|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:34:49.530701|2018-05-31 22:34:49.530701
NCT01361373|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-06|||2011-05-26|2011-05-25|2011-05-26|Estimate|||||||2011-05-26|2011-05-27|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|August 2012|Anticipated|2012-08-31|May 2012|Anticipated|2012-05-31||Interventional|||Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study||Unknown status|Recruiting|Phase 4|50|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-05-31 22:34:49.722604|2018-05-31 22:34:49.722604
NCT01361360|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2017-07-24|2011-05-25|2011-05-26|Estimate|||||||2017-07-24|2017-07-25|Actual|May 2011||2011-05-31|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Permissive Hypercapnia and Brain Development in Premature Infants||Completed|||10|Actual|Arkansas Children's Hospital Research Institute|||2||f||||||||||||||2018-05-31 22:34:49.782575|2018-05-31 22:34:49.782575
NCT01361347|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2017-01-02|2011-05-25|2011-05-26|Estimate|||||||2017-01-02|2017-01-04|Estimate|February 2008||2008-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children|Phase 4 Study: Milk Oral Immunotherapy for Cow's Milk Allergy in School-aged Children|Completed||Phase 4|28|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 22:34:49.82554|2018-05-31 22:34:49.82554
NCT01360294|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2013-06-27|2011-05-23|2011-05-25|Estimate|||||||2013-06-27|2013-06-28|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|SADQ||Development of Small Airway Disease Questionnaire|The Development of a Questionnaire to Assess Symptoms of Small Airways Disease in Patients With Asthma|Completed|||65|Actual|University Medical Center Groningen|||2||f||||f||||||||||2018-05-31 22:35:14.620539|2018-05-31 22:35:14.620539
NCT01361334|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-03-14|2011-05-25|2011-05-26|Estimate|||||||2017-03-14|2017-03-15|Actual|June 2011||2011-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PAZOPANIB-AML||Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible|Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible|Completed||Phase 2|20|Actual|University Hospital Muenster||1|||f||||t||||||||||2018-05-31 22:34:49.885384|2018-05-31 22:34:49.885384
NCT01361321|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2017-11-29|2011-05-25|2011-05-26|Estimate|||||||2017-11-29|2017-11-30|Actual|February 2012||2012-02-29|September 2013|2013-09-30|February 21, 2013|Actual|2013-02-21|February 21, 2013|Actual|2013-02-21||Observational|||Bone Quality and Quantity Following Guided Bone Regeneration|Examining Bone Quantity and Quality Following Standard Guided Bone Regeneration Procedures|Completed|||13|Actual|Hadassah Medical Organization|||1||f||||f||||||Samples Without DNA|"~     Reisdual bone tissue formed while preparing alveolar bone for dental implant (by drilling~     with a trephine bur)~   "|||2018-05-31 22:34:49.941595|2018-05-31 22:34:49.941595
NCT01361308|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2013-07-16|2013-04-09|2015-10-14|2011-05-25|2011-05-26|Estimate|2014-04-22|2014-05-20|Estimate|2013-04-09|2013-04-16|Estimate|2015-10-14|2015-10-15|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|N30-003||Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)|A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|614|Actual|Noven Therapeutics||2|||f||||t||||||||||2018-05-31 22:34:50.028723|2018-05-31 22:34:50.028723
NCT01361295|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-03-05|2011-05-25|2011-05-26|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Interventional|CE-AF||Cerebral Embolism (CE) in Catheter Ablation of Atrial Fibrillation (AF)|The Occurrence of Cerebral Embolism (CE) in Catheter Ablation of Atrial Fibrillation (AF) Using Two Different Ablation Catheters|Completed||N/A|70|Actual|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 22:34:52.702713|2018-05-31 22:34:52.702713
NCT01361282|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2017-03-08|2011-05-25|2011-05-26|Estimate|||||||2017-03-08|2017-03-13|Actual|November 9, 2010|Actual|2010-11-09|March 2017|2017-03-31|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Observational|||Using the Optovue OCT to Select IOL Power|Evaluation of Total Corneal Power Calculations for Intraocular Lens Selection Using the Optovue OCT in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Patients|Terminated|||50|Actual|Legacy Health System|||1|The DSAEK procedure was discontinued as the standard of care for the intended cohort.|f||||f||||||||||2018-05-31 22:34:52.780161|2018-05-31 22:34:52.780161
NCT01361269|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria|Multicentre Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in African Children|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Zentopharm GmbH||1|||f||||f||||||||||2018-05-31 22:34:52.83247|2018-05-31 22:34:52.83247
NCT01361256|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2016-10-27|2011-05-25|2011-05-26|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|May 2016|Anticipated|2016-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration|Pilot Study of WA-NG Telescope Prosthesis in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration|Withdrawn||Early Phase 1|0|Actual|VisionCare, Inc.||1||No participants enrolled|f||||f||||||||||2018-05-31 22:34:52.907101|2018-05-31 22:34:52.907101
NCT01361243|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2018-02-21|2011-05-24|2011-05-26|Estimate|||||||2018-02-21|2018-02-22|Actual|April 2011||2011-04-30|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|NOURISH+||NOURISH+: Nourishing Our Understanding of Role Modeling to Improve Support and Health|NOURISHing Families to Promote Healthy Eating and Exercise in Overweight Children|Completed||N/A|730|Actual|Virginia Commonwealth University||2|||f||||t||||||||No||2018-05-31 22:34:53.082997|2018-05-31 22:34:53.082997
NCT01361230|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|||IMPROVE Critical Care Study (Pilot)|PILOT STUDY: A Randomized Controlled Trial of Intensive Care Management of Sedation Using Patient Responsiveness in Critical Care IMPROVE Critical Care Study Pilot|Completed||N/A|74|Actual|GE Healthcare||2|||f||||f||||||||||2018-05-31 22:34:53.160183|2018-05-31 22:34:53.160183
NCT01361217|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2012-06-18|2011-05-24|2011-05-26|Estimate|||||||2012-06-18|2012-06-20|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|FLUOXETINE||The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity|The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity|Completed||N/A|36|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 22:34:53.219327|2018-05-31 22:34:53.219327
NCT01361204|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2013-07-14|2011-05-24|2011-05-26|Estimate|||||||2013-07-14|2013-07-16|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Anti-stress Effect of Theanine on Students During Long-term Pharmacy Practices|Measurement of Stress Symptom in Students During Long-term Pharmacy Practices and Evaluation of Anti-stress Effect of Theanine Consumption on Students|Completed||N/A|20|Actual|University of Shizuoka||1|||f||||t||||||||||2018-05-31 22:34:53.296826|2018-05-31 22:34:53.296826
NCT01361191|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2013-10-29|2011-05-25|2011-05-26|Estimate|||||||2013-10-29|2013-10-30|Estimate|June 2007||2007-06-30|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|R-MEGACHOP||Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma|Early Treatment Stratification Based on PET Scan Response to R-MEGACHOP Followed by R-MEGACHOP or R-IFE Plus Peripheral Autologous Stem Cell Transplant (PBSCT) in Patients With Poor Prognosis DLBCL|Completed||Phase 2|71|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|||||f||||t||||||||||2018-05-31 22:34:53.366201|2018-05-31 22:34:53.366201
NCT01361178|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2017-02-01||2017-02-01|2011-05-24|2011-05-26|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|January 2011||2011-01-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement|Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement - Observational Arm|Completed||N/A|133|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:34:53.466141|2018-05-31 22:34:53.466141
NCT01361165|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-24|2011-05-24|2011-05-26|Estimate|||||||2011-05-24|2011-05-26|Estimate|September 2006||2006-09-30|May 2011|2011-05-31|October 2008|Actual|2008-10-31|||||Observational|||Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism|Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism|Completed|||10|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:34:53.783546|2018-05-31 22:34:53.783546
NCT01361152|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-10-04|2011-05-25|2011-05-26|Estimate|||||||2011-10-04|2011-10-05|Estimate|April 1993||1993-04-30|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 1996|Actual|1996-03-31||Interventional|||Long-Term Comparison of Fixed- and Mobile-Bearing Total Knee Arthroplasties (TKAs) in Patients With OA ≤50 Years Old|Long-Term Comparison of Fixed- and Mobile-Bearing Total Knee Arthroplasties in Patients With Osteoarthritis Younger Than Fifty Years of Age|Completed||Phase 4|216|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 22:34:53.915743|2018-05-31 22:34:53.915743
NCT01361139|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2015-01-14|2011-05-25|2011-05-26|Estimate|||||||2015-01-14|2015-01-16|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)|Detection and Characterization of Cardio-Pulmonary Patho-Physiological States and Diseases by Transthoracic Parametric Doppler (TPD)|Completed|||500|Actual|Echosense Ltd.|||||f||||f||||||||||2018-05-31 22:34:54.101131|2018-05-31 22:34:54.101131
NCT01361126|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|2016-04-03|2015-11-05|2016-04-03|2011-05-25|2011-05-26|Estimate|2016-04-03|2016-05-09|Estimate|2015-11-05|2015-12-04|Estimate|2016-04-03|2016-05-09|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional||Safety Population|A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B|A Phase I/II Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B|Completed||Phase 1/Phase 2|17|Actual|CSL Behring||2|||f||||t||||||||||2018-05-31 22:34:54.201376|2018-05-31 22:34:54.201376
NCT01361113|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2017-03-30||2018-03-27|2011-05-25|2011-05-26|Estimate|2017-03-30|2017-05-10|Actual||||2018-03-27|2018-04-25|Actual|June 2011||2011-06-30|March 2018|2018-03-31|February 15, 2017|Actual|2017-02-15|January 7, 2015|Actual|2015-01-07||Interventional|||Neoadjuvant Pazopanib in Renal Cell Carcinoma|Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Establish Predictive Biomarkers of Drug Activity in Renal Cell Carcinoma|Completed||Phase 2|21|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:34:54.519549|2018-05-31 22:34:54.519549
NCT01361100|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2012-10-01|2011-05-25|2011-05-26|Estimate|||||||2012-10-01|2012-10-02|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract|Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract|Unknown status|Recruiting|N/A|485|Anticipated|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 22:34:54.906483|2018-05-31 22:34:54.906483
NCT01361087|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2016-02-04|2011-05-25|2011-05-26|Estimate|||||||2016-02-04|2016-02-05|Estimate|April 2011||2011-04-30|February 2016|2016-02-29||||December 2014|Actual|2014-12-31||Interventional|||Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome|Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With|Withdrawn||Phase 3|0|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||||No outside recruitment of subjects from Main Atenolol VS Losartan NIH study|f||||f||||||||Undecided||2018-05-31 22:34:55.020697|2018-05-31 22:34:55.020697
NCT01361074|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2015-12-03|2011-05-25|2011-05-26|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|January 2013|Actual|2013-01-31|May 2011|Actual|2011-05-31||Interventional|VARESAP||In Vivo Versus Augmented Reality Exposure for Small Animal Phobia|In Vivo Versus Augmented Reality Exposure for Small Animal Phobia Treatment: A Randomized Controlled Trial|Completed||N/A|60|Actual|Universitat Jaume I||2|||f||||f||||||||||2018-05-31 22:34:55.090594|2018-05-31 22:34:55.090594
NCT01361061|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-12-14|2011-05-24|2011-05-26|Estimate|||||||2011-12-14|2011-12-15|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|September 2014|Anticipated|2014-09-30|December 2013|Anticipated|2013-12-31||Observational|||AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver|AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver- am Multicenter HCC- Surveillance Study|Unknown status|Recruiting||600|Anticipated|University Hospital Freiburg|||1||f||||f||||||Samples Without DNA|"~     measurement of tumor markers AFP, AFP-L3 and DCP in serum samples every 6 months~   "|||2018-05-31 22:34:55.183366|2018-05-31 22:34:55.183366
NCT01361048|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2013-11-18||2017-12-19|2011-05-25|2011-05-26|Estimate|2014-01-06|2014-02-20|Estimate||||2017-12-19|2018-01-19|Actual|December 2011||2011-12-31|December 2017|2017-12-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|||Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis|Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis|Completed||Phase 2|40|Actual|University of Alabama at Birmingham|pilot study|3|||f||||f||||||||||2018-05-31 22:34:55.280107|2018-05-31 22:34:55.280107
NCT01361035|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-03-09|2011-05-24|2011-05-26|Estimate|||||||2017-03-09|2017-03-10|Actual|June 2008||2008-06-30|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients|Using Effective Provider-Patient Communication to Improve Cancer Screening Among Low Literacy Patients|Completed||N/A|168|Actual|Tulane University||2|||f||||f||||||||||2018-05-31 22:34:55.973675|2018-05-31 22:34:55.973675
NCT01361022|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2013-10-31|2011-05-25|2011-05-26|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2011||2011-08-31|October 2013|2013-10-31||||November 2011|Actual|2011-11-30||Interventional|||To Assess the Bioequivalence of Brotizolam Tablets 250 Mcg vs. Lendormin Tablets 250 Mcg Administered to Healthy Adult Volunteers|A Randomized, Single-dose, Two-way Cross-over Study to Assess the Bioequivalence of Lendormin Tablets 0.25 mg (Delpharm Reims) vs. Lendormin Tablets 0.25 mg (Synmosa Biopharma Co. Ltd.) Administered to Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:34:56.21321|2018-05-31 22:34:56.21321
NCT01361009|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2013-01-31||2014-05-07|2011-05-25|2011-05-26|Estimate|2013-06-17|2013-08-30|Estimate||||2014-05-07|2014-05-16|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients|Safety of Pramipexole Monotherapy or Combination Therapy in Chinese Patients With Parkinson¿s Disease: a 12 Week Post Marketing Surveillance|Completed|||2017|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 22:34:56.343862|2018-05-31 22:34:56.343862
NCT01360099|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2017-06-30|2011-05-20|2011-05-25|Estimate|||||||2017-06-30|2017-07-02|Actual|May 4, 2011||2011-05-04|January 11, 2017|2017-01-11|January 11, 2017||2017-01-11|||||Observational|||Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study|Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study|Completed|||120|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:35:18.106969|2018-05-31 22:35:18.106969
NCT01360996|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|2016-04-19||2017-03-30|2011-05-25|2011-05-26|Estimate|2017-03-30|2017-03-31|Actual||||2017-03-30|2017-03-31|Actual|August 2011||2011-08-31|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|BEYAZ-PCOS|oligomenorrhea and biochemical hyperandrogenism (total T >1.38 nmol/l or free androgen index [FAI] >3.87) and exclusion of other etiologies (non-classic congenital adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, Cushing syndrome, thyroid dysfunction and primary ovarian insufficiency|Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism|Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism|Completed||Phase 4|64|Actual|Woman's|Limitations include evaluation after 24 weeks in a limited number of patients, The time may be too short and sample size too small to measure differences between normal and overweight PCOS women and the use of indirect measures of insulin action.|3|||f||||t||||||||No||2018-05-31 22:34:56.75115|2018-05-31 22:34:56.75115
NCT01360970|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-11-17|2011-05-25|2011-05-26|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Hepatitis A Vaccine in Patients With Immunomodulating Drugs|Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate|Completed||Phase 2|68|Actual|Sormland County Council, Sweden|||||f||||t||||||||||2018-05-31 22:34:58.31679|2018-05-31 22:34:58.31679
NCT01360957|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-11-17|2011-05-24|2011-05-26|Estimate|||||||2015-11-17|2015-11-18|Estimate||||February 2011|2011-02-28|June 2011|Actual|2011-06-30|||||Interventional|||Effect of Consumption of Black Cumin (Nigella Sativa L.) Water Extract on Weight Loss in Overweight Women||Withdrawn||N/A|0|Actual|Shahid Beheshti University of Medical Sciences||2||"Mahnaz Kazemipoor has not handed over human subject review board approval letter to her~   colleague."|f||||f||||||||||2018-05-31 22:34:58.601731|2018-05-31 22:34:58.601731
NCT01360944|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-06-04|2011-05-25|2011-05-26|Estimate|||||||2015-06-04|2015-06-08|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test|An Investigator-blind, Controlled Exploratory Study to Assess the Efficacy and Safety of Different Concentrations of Active Ingredients in the Project LAS 41004 Compared to a Bland Ointment and to Active Control in a Psoriasis- Plaque- Test|Completed||Phase 2|22|Actual|Almirall, S.A.||8|||f||||f||||||||||2018-05-31 22:34:58.863694|2018-05-31 22:34:58.863694
NCT01360931|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-27|2011-05-25|2011-05-26|Estimate|||||||2011-05-27|2011-05-30|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||The Roles of Neutrophil Elastase in Lung Cancer|The Roles of Neutrophil Elastase in Lung Cancer|Unknown status|Recruiting||60|Anticipated|The University of Hong Kong|||2||f||||f||||||Samples With DNA|"~     Small bronchial biopsy alongside with the corresponding Bronchoalveolar lavage and bronchial~     aspirate will be collected in the same one bronchoscopy session~   "|||2018-05-31 22:34:59.163951|2018-05-31 22:34:59.163951
NCT01360918|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2016-07-06|2011-05-25|2011-05-26|Estimate|||||||2016-07-06|2016-07-07|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|CONTROL-AF||Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery|Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery|Terminated||N/A|2|Actual|Medisch Spectrum Twente||2||Inclusion rate insufficiënt|f||||f||||||||||2018-05-31 22:34:59.468867|2018-05-31 22:34:59.468867
NCT01360905|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2014-01-17|2011-05-25|2011-05-26|Estimate|||||||2014-01-17|2014-01-20|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|July 2012|Actual|2012-07-31||Observational|||Study to Support Fetal Heart Rate and Uterine Contraction for Preterm Labor in Singleton and Multiple Pregnancies|Study to Determine the Equivalence of the Monica AN24 Monitor to Predicate Devices for (FHR) and (UC) During Pre-term Labor and Multiples|Terminated|||8|Actual|Monica Healthcare Ltd||||Difficulty in recruiting|f||||f||||||||||2018-05-31 22:34:59.762258|2018-05-31 22:34:59.762258
NCT01360892|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-21|||2011-05-24|2011-05-24|2011-05-26|Estimate|||||||2011-05-24|2011-05-26|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Observational|PICTURE||Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography|Prediction of Incidence of Liver Cancer or PorTal Hypertension in Patients With Viral Hepatitis by Use of Real-time Tissue Elastography|Unknown status|Recruiting||1000|Anticipated|Japan Liver Oncology Group|||||f||||t||||||||||2018-05-31 22:35:00.010916|2018-05-31 22:35:00.010916
NCT01360879|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-21|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Observational|FIBROELAST||Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease|Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease|Unknown status|Recruiting||500|Anticipated|Japan Liver Oncology Group|||||f||||t||||||Samples Without DNA|"~     whole blood, serum, liver tissue~   "|||2018-05-31 22:35:00.300026|2018-05-31 22:35:00.300026
NCT01360866|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-12-08|2011-05-25|2011-05-26|Estimate|||||||2017-12-08|2017-12-12|Actual|October 2011|Actual|2011-10-31|December 2017|2017-12-31|May 18, 2017|Actual|2017-05-18|April 18, 2017|Actual|2017-04-18||Interventional|Orion||Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)|A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial|Completed||Phase 3|2944|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||No||2018-05-31 22:35:00.618142|2018-05-31 22:35:00.618142
NCT01360853|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24||2016-08-01|2016-08-02|2011-05-25|2011-05-26|Estimate||||2016-08-01|2016-08-03|Estimate|2016-08-02|2016-08-04|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|ONTRAC||Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer|A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined With Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Cancer|Completed||Phase 3|160|Actual|Onconova Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 22:35:01.338197|2018-05-31 22:35:01.338197
NCT01360840|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2015-07-24||2015-11-09|2011-05-25|2011-05-26|Estimate|2015-11-09|2015-12-14|Estimate||||2015-11-09|2015-12-14|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|April 2013|Actual|2013-04-30||Interventional|PERSEUS|All Subjects (ALL) analysis set included subjects who signed the Informed consent document.|EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)|Completed||Phase 2|180|Actual|EMD Serono||3|||f||||t||||||||||2018-05-31 22:35:02.062523|2018-05-31 22:35:02.062523
NCT01360827|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2014-06-16|2011-05-25|2011-05-26|Estimate|||||||2014-06-16|2014-06-17|Estimate|August 2010||2010-08-31|June 2014|2014-06-30||||April 2011|Actual|2011-04-30||Interventional|||EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase Ib Trial of Multiple-ascending Doses of EMD 1201081 in Combination With 5-FU/Cisplatin and Cetuximab in First-line Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1|13|Actual|Merck KGaA||2||Study terminated due to potential safety concerns in combination with platinum-based therapies|f||||f||||||||||2018-05-31 22:35:04.835231|2018-05-31 22:35:04.835231
NCT01360814|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2018-04-09|2011-05-24|2011-05-26|Estimate|||||||2018-04-09|2018-04-11|Actual|January 2005||2005-01-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 13, 2009|Actual|2009-03-13||Interventional|||Structured Multidisciplinary Intervention or Standard Medical Care in Improving Quality of Life in Patients Receiving Active Cancer Treatment|A Structured Multidisciplinary Intervention to Improve Quality of Life of Patients Receiving Active Oncological Treatment: A Randomized Trial|Active, not recruiting||N/A|138|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:35:04.928854|2018-05-31 22:35:04.928854
NCT01360801|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2014-04-08|2011-05-25|2011-05-26|Estimate|||||||2014-04-08|2014-04-10|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||High Definition White Light Endoscopy and Narrow Band Imaging for the Assessment of Barrett's Disease After Endoscopic Therapy|High Definition White Light Endoscopy and Narrow Band Imaging for the Assessment of Barrett's Disease After Endoscopic Therapy|Terminated|||21|Actual|Mayo Clinic||||enrollment moved very slowly which was not anticipated, and, funding issues|f||||f||||||||||2018-05-31 22:35:05.003519|2018-05-31 22:35:05.003519
NCT01360788|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-05-24|2011-05-24|2011-05-26|Estimate|||||||2011-05-24|2011-05-26|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|February 2011|Actual|2011-02-28|||||Observational|GOLD||GOLD Stage I Chronic Obstructive Pulmonary Disease (COPD)|GOLD Stage I COPD: Is it Really a Disease ? Exercise Tolerance, Muscle Function and Response to Bronchodilation in GOLD Stage I COPD Patients|Completed|||53|Actual|Laval University|||3||f||||t||||||Samples Without DNA|"~     Muscle biopsies Venous blood samples~   "|||2018-05-31 22:35:05.052976|2018-05-31 22:35:05.052976
NCT01360775|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|January 2010||2010-01-31|October 2009|2009-10-31||||June 2012|Anticipated|2012-06-30||Interventional|atdom_nut||Nutritional Education for Dependant Patients|Intervention of Nutritional Education Addressed to Carers of Dependant Patients|Unknown status|Recruiting|Phase 1|200|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||||||||||||2018-05-31 22:35:05.119386|2018-05-31 22:35:05.119386
NCT01360762|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2016-02-04|2011-05-25|2011-05-26|Estimate|||||||2016-02-04|2016-02-05|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study|Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study|Completed||Phase 3|72|Actual|Institute of Tropical Medicine, Belgium||1|||f||||t||||||||||2018-05-31 22:35:05.176376|2018-05-31 22:35:05.176376
NCT01360749|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-04-12|2011-05-25|2011-05-26|Estimate|||||||2012-04-12|2012-04-13|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal|Multicentre, Double-Blind Trial to Evaluate the Efficacy and Safety of Lambdalina vs Placebo as an Anesthetic for Laser Hair Removal|Completed||Phase 2|42|Actual|ISDIN||2|||f||||f||||||||||2018-05-31 22:35:05.332453|2018-05-31 22:35:05.332453
NCT01360736|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2018-04-02|2011-05-25|2011-05-26|Estimate|||||||2018-04-02|2018-04-03|Actual|September 2009||2009-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SAFEMIL||A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans - Study 2 (SAFEMIL)|A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans - Study 2|Active, not recruiting||N/A|186|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t||||||||No||2018-05-31 22:35:05.407816|2018-05-31 22:35:05.407816
NCT01360723|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-26|2011-05-25|2011-05-26|Estimate|||||||2011-05-26|2011-05-27|Estimate|May 2011||2011-05-31|May 2011|2011-05-31||||May 2014|Anticipated|2014-05-31||Observational|||DNA Methylation and Arsenic-associated Urothelial Carcinoma|Comparison of DNA Methylation Between Urothelial Carcinoma and Healthy Controls|Unknown status|Recruiting||600|Anticipated|China Medical University Hospital|||2||f||||f||||||||||2018-05-31 22:35:05.507629|2018-05-31 22:35:05.507629
NCT01360710|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-02-01|2011-05-25|2011-05-26|Estimate|||||||2012-02-01|2012-02-03|Estimate|January 2012||2012-01-31|February 2012|2012-02-29||||January 2014|Anticipated|2014-01-31||Interventional|||The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension|The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Baker IDI Heart and Diabetes Institute||2|||f||||||||||||||2018-05-31 22:35:05.579009|2018-05-31 22:35:05.579009
NCT01360697|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-07-31|2011-05-25|2011-05-26|Estimate|||||||2015-07-31|2015-08-03|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|JADE-JA||An Evaluation of the Effectiveness and Acceptability of Delivering Structured Care in Chinese Type 2 Diabetic Patients|A Multi-Centre Demonstration Project to Evaluate the Effectiveness and Acceptability of the Joint Asia Diabetes Evaluation (JADE) in Chinese Type 2 Diabetic Patients in Jiangsu and Anhui (JA), China|Unknown status|Active, not recruiting|N/A|4800|Anticipated|Asia Diabetes Foundation||2|||f||||t||||||||||2018-05-31 22:35:05.680818|2018-05-31 22:35:05.680818
NCT01360684|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-25|2011-05-25|2011-05-26|Estimate|||||||2011-05-25|2011-05-26|Estimate|July 2010||2010-07-31|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Study of Axillary Skin Temperature as a Marker of Ovulation|Pilot Study of Measuring Axillary Skin Temperature, Using DuoFertility, as a Marker of Ovulation in 10 Women of Childbearing Age|Unknown status|Recruiting||10|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 22:35:05.815499|2018-05-31 22:35:05.815499
NCT01360671|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2012-05-24|2011-05-24|2011-05-26|Estimate|||||||2012-05-24|2012-05-28|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn|An Open Label Single Arm, Single Centre Study to Investigate the Safety and Efficacy of IV Sildenafil in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN)|Withdrawn||Phase 2|0|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 22:35:05.916216|2018-05-31 22:35:05.916216
NCT01360658|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2013-07-29|2011-05-24|2011-05-25|Estimate|||||||2013-07-29|2013-07-30|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|IGUS||Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria|Phase 2 Multicentric Study Evaluating the Efficacy of Polyvalent Intravenous Immunoglobulins in Idiopathic Severe and Refractory Solar Urticaria|Completed||Phase 2|10|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 22:35:06.072851|2018-05-31 22:35:06.072851
NCT01360645|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2015-08-10|2014-05-01|2015-10-26|2011-05-24|2011-05-25|Estimate|2015-10-26|2015-11-26|Estimate|2014-05-01|2014-05-19|Estimate|2015-10-26|2015-11-26|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|Pyxis|Randomized sample were used. Randomized sample comprises all who were randomized in Phase B.|Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial|Completed||Phase 3|826|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 22:35:06.257305|2018-05-31 22:35:06.257305
NCT01360632|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|2015-08-11|2014-10-14|2015-11-30|2011-05-24|2011-05-25|Estimate|2015-11-30|2016-01-01|Estimate|2014-10-14|2014-10-24|Estimate|2015-11-30|2016-01-01|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|Polaris||Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPDC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Polaris Trial|Completed||Phase 3|1539|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-05-31 22:35:08.207356|2018-05-31 22:35:08.207356
NCT01360619|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-24|2011-05-24|2011-05-25|Estimate|||||||2011-05-24|2011-05-25|Estimate|June 2007||2007-06-30|October 2007|2007-10-31|October 2007||2007-10-31|September 2007|Actual|2007-09-30||Observational|||Clinical Study About Fat Measurement on Multifunction Keito by Comparison Versus Its Predicate K014009||Completed|||177||Aguiflai Iberica, S.L.|||||f||||f||||||||||2018-05-31 22:35:10.619623|2018-05-31 22:35:10.619623
NCT01360606|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2018-01-25|2011-05-24|2011-05-25|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2011||2011-09-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) for Liver Mets|A Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases|Recruiting||Phase 1|18|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:35:10.701104|2018-05-31 22:35:10.701104
NCT01360593|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-06-23|2011-05-24|2011-05-25|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2011||2011-07-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma|Induction Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma A Prospective Evaluation in Patients With Locally Advanced Pancreas Cancer|Active, not recruiting||Phase 2|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:35:10.804469|2018-05-31 22:35:10.804469
NCT01360580|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2013-01-23|2011-05-24|2011-05-25|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Observational|Deglutube||Swallowing Disorders After Prolonged Mechanical Ventilation|Current Care Study of Incidence and Consequences of Swallowing Disorders After Invasive Mechanical Ventilation|Completed|||138|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-05-31 22:35:10.900714|2018-05-31 22:35:10.900714
NCT01360567|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-04-27|2011-05-24|2011-05-25|Estimate|||||||2013-04-27|2013-04-30|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||The Effect of Green Tea Extract on Type 2 Diabetes With Hyperlipidemia|Taipei City Hospital, Taipei, Taiwan|Completed||Phase 3|102|Actual|Taipei City Hospital||2|||f||||t||||||||||2018-05-31 22:35:10.961651|2018-05-31 22:35:10.961651
NCT01360554|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2016-09-07|2014-10-27|2017-04-24|2011-05-24|2011-05-25|Estimate|2017-04-24|2017-05-24|Actual|2014-10-27|2014-11-03|Estimate|2017-04-24|2017-05-24|Actual|June 16, 2011||2011-06-16|April 2017|2017-04-30|September 14, 2015|Actual|2015-09-14|September 30, 2013|Actual|2013-09-30||Interventional|ARCHER 1009|The baseline analysis population included all treated participants.|ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer|Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy|Completed||Phase 3|878|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:35:11.09862|2018-05-31 22:35:11.09862
NCT01360541|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2018-03-16|2011-05-24|2011-05-25|Estimate|||||||2018-03-16|2018-03-19|Actual|December 22, 2010|Actual|2010-12-22|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|RF-DBG||Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia|Endoscopic Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia: a Randomised Controlled Trial vs Endoscopic Surveillance|Active, not recruiting||Phase 2|125|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:35:12.759795|2018-05-31 22:35:12.759795
NCT01360528|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-02-15|2011-05-24|2011-05-25|Estimate|||||||2012-02-15|2012-02-17|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Observational|FALIPI||Serum Folic Acid Levels in Preterm Infants|Zekai Tahir Burak Maternity and Teaching Hospital|Completed|||100|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital|||3||f||||f||||||||||2018-05-31 22:35:12.833348|2018-05-31 22:35:12.833348
NCT01360515|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-02-01|2011-05-24|2011-05-25|Estimate|||||||2012-02-01|2012-02-02|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||A Study of Disposable Transnasal Esophagoscope|A Novel Disposable Transnasal Esophagoscope: a Prospective Pilot Trial of Feasibility, Safety and Tolerance|Completed|||50|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 22:35:12.890293|2018-05-31 22:35:12.890293
NCT01360502|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2011-05-24|2011-05-24|2011-05-25|Estimate|||||||2011-05-24|2011-05-25|Estimate|December 2009||2009-12-31|September 2009|2009-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Safety of Capsule Endoscopy in Patients With Implantable Cardiac Devices|Safety of Capsule Endoscopy Using Human Body Communication in Patients With Cardiac Pacemakers and Implantable Cardiac Defibrillators|Completed|||6|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 22:35:12.945746|2018-05-31 22:35:12.945746
NCT01359774|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-09-20|2011-05-23|2011-05-25|Estimate|||||||2012-09-20|2012-09-21|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|PRO-MH||31P-MRS and Huntington Disease|31Phosphorus-Magnetic Resonance Spectroscopy and Huntington Disease|Completed||N/A|30|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||||||||||||2018-05-31 22:35:25.296256|2018-05-31 22:35:25.296256
NCT01360476|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-12-08|2011-05-24|2011-05-25|Estimate|||||||2015-12-08|2015-12-09|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|AdDReaCH||Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients|Adjunct Vitamin D Therapy as a Means to Reduce the Disparity in Subclinical Target Organ Cardiac Damage Among Vulnerable Hypertensive Patients|Completed||N/A|354|Actual|Wayne State University||2|||f||||t||||||||||2018-05-31 22:35:12.99997|2018-05-31 22:35:12.99997
NCT01360463|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2016-08-15|2011-05-24|2011-05-25|Estimate|||||||2016-08-15|2016-08-17|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|JAKPRO||Efficacy of Drug and Risk Counseling Among Methadone Patients in Jakarta, Indonesia|Efficacy of Drug-HIV Counseling Among IDU at Methadone Clinics in Jakarta|Completed||Phase 2|276|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:35:13.072852|2018-05-31 22:35:13.072852
NCT01360450|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2017-06-09||2017-08-15|2011-05-24|2011-05-25|Estimate|2017-08-15|2017-09-13|Actual||||2017-08-15|2017-09-13|Actual|July 2011||2011-07-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|July 2011|Actual|2011-07-31||Interventional||The gestational age of the infant and the birth weight were collected as baseline measurements|Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants|Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants:|Terminated||Phase 2/Phase 3|12|Actual|Johns Hopkins University||2||The study was treminated because of low accural|f||||t||||||||No||2018-05-31 22:35:13.258801|2018-05-31 22:35:13.258801
NCT01360437|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-06-21|2011-05-24|2011-05-25|Estimate|||||||2012-06-21|2012-06-22|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention|Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI|Completed||Phase 3|44|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 22:35:13.555637|2018-05-31 22:35:13.555637
NCT01360424|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2015-09-27|2011-05-24|2011-05-25|Estimate|||||||2015-09-27|2015-09-29|Estimate|May 2011||2011-05-31|September 2015|2015-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Teriparatide Treatment in Patients With Inherited Osteoporosis|Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis|Completed||Phase 4|6|Actual|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 22:35:13.625227|2018-05-31 22:35:13.625227
NCT01360411|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-09-04|2011-05-24|2011-05-25|Estimate|||||||2012-09-04|2012-09-05|Estimate|January 2007||2007-01-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Tissue Characterisation by Endoscopic GI-elastography|Tissue Characterisation Using Ultrasound Based Strain Imaging(Elastography)Examining Lesions in the Gastrointestinal Wall, Adjacent Lymph Nodes and Pancreatic Lesions|Completed|||137|Actual|Haukeland University Hospital|||3||f||||f||||||Samples With DNA|"~     Tissue samples are stored as pathological slides in the diognostic biobank of Dep. of~     Pathology, Helse Bergen.~   "|||2018-05-31 22:35:13.692555|2018-05-31 22:35:13.692555
NCT01360398|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2014-08-07|2011-05-24|2011-05-25|Estimate|||||||2014-08-07|2014-08-11|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly|Contribution of Infectious Pathogens to Acute Respiratory Illness in Adults and Elderly|Completed||N/A|152|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 22:35:13.763973|2018-05-31 22:35:13.763973
NCT01360385|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-09-11|2011-05-24|2011-05-25|Estimate|||||||2012-09-11|2012-09-12|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|LuRVO||Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab|Objective Measurement of Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With a Vascular Endothelial Growth Factor Inhibitor.|Completed|||24|Actual|Glostrup University Hospital, Copenhagen|||1||f||||f||||||||||2018-05-31 22:35:13.838872|2018-05-31 22:35:13.838872
NCT01360372|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2015-03-10|2011-05-24|2011-05-25|Estimate|||||||2015-03-10|2015-03-17|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates|The Effect Of Methylnaltrexone (Relistor™) on Gut Motility and Tolerance to Tube Feeding in Patients Treated With Opiate Therapy|Withdrawn||Phase 3|0|Actual|Drexel University||2||No eligible subjects identified|f||||t||||||||||2018-05-31 22:35:13.987951|2018-05-31 22:35:13.987951
NCT01360359|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2015-03-09|2011-05-24|2011-05-25|Estimate|||||||2015-03-09|2015-03-11|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Recurrent Low Back Pain: Linking Mechanism to Outcomes (RCT)|Recurrent Low Back Pain: Linking Mechanism to Outcomes (RCT)|Completed||N/A|17|Actual|Drexel University||2|||f||||f||||||||||2018-05-31 22:35:14.064179|2018-05-31 22:35:14.064179
NCT01360346|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2012-04-23|2011-05-24|2011-05-25|Estimate|||||||2012-04-23|2012-04-24|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients|Multicentric, Single Blind, Randomized Controlled Trial on Enteral Sedation Versus Intravenous Sedation in Critically Ill High-risk ICU Patients|Unknown status|Recruiting|Phase 3|300|Anticipated|University of Milan||2|||f||||t||||||||||2018-05-31 22:35:14.150929|2018-05-31 22:35:14.150929
NCT01360333|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-05-11|2011-05-23|2011-05-25|Estimate|||||||2012-05-11|2012-05-14|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|OFVEX||Oral Fluid Volume Expansion|Oral Fluid: Absorption and Expansion of the Blood Volume|Completed||N/A|10|Actual|University Hospital, Linkoeping||1|||f||||f||||||||||2018-05-31 22:35:14.266894|2018-05-31 22:35:14.266894
NCT01360320|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-04-05|2011-05-24|2011-05-25|Estimate|||||||2012-04-05|2012-04-06|Estimate|November 2011||2011-11-30|April 2012|2012-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|MIRACLE||Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-|Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-|Unknown status|Recruiting|Phase 2|2941|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 22:35:14.352876|2018-05-31 22:35:14.352876
NCT01360307|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-12-05|2011-05-24|2011-05-25|Estimate|||||||2011-12-05|2011-12-06|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|CUDOS||Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale|Psychometric Validation of the Spanish Version of the CUDOS Scale (Clinically Useful Depression Outcome Scale) in Major Depressive Disorder|Completed|||330|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:35:14.536685|2018-05-31 22:35:14.536685
NCT01360281|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-23|2011-05-23|2011-05-25|Estimate|||||||2011-05-23|2011-05-25|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Neuromuscular Electrical Stimulation and Strength Training in Patients With Knee Osteoarthritis|Neuromuscular Electrical Stimulation and Strength Training in Patients With Knee Osteoarthritis|Unknown status|Recruiting|N/A|34|Anticipated|Universidade Gama Filho||3|||f||||f||||||||||2018-05-31 22:35:14.684736|2018-05-31 22:35:14.684736
NCT01360268|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2011-05-24|2011-05-24|2011-05-25|Estimate|||||||2011-05-24|2011-05-25|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|||||Observational|||The Metabolic Profile and Adipocytokine Alterations of Patients With HCV Infection Before and After HCV Therapy|"The Metabolic Profile and Adipocytokine Alterations of Patients With HCV Infection Before and After HCV Therapy"|Unknown status|Recruiting||100|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||||||2018-05-31 22:35:14.760522|2018-05-31 22:35:14.760522
NCT01360255|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-12-14|2011-05-24|2011-05-25|Estimate|||||||2011-12-14|2011-12-15|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)|AFP - L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)|Unknown status|Recruiting||80|Anticipated|University Hospital Freiburg|||1||f||||f||||||Samples Without DNA|"~     measurement of tumor markers AFP, AFP-L3 and DCP in serum samples~   "|||2018-05-31 22:35:14.816305|2018-05-31 22:35:14.816305
NCT01360242|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-03-05|2011-05-24|2011-05-25|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|MIMI||Minimal Invasive Procedure for Myocardial Infarction|Patients Presenting With Acute STEMI Treated With Primary PCI : Comparison of the Impact of the MIMI Approach With a Conventional Strategy of Immediate Stenting|Completed||Phase 3|160|Actual|Centre Hospitalier de la Région d'Annecy||2|||f||||f||||||||||2018-05-31 22:35:14.893289|2018-05-31 22:35:14.893289
NCT01360229|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2015-08-10|2011-05-24|2011-05-25|Estimate|||||||2015-08-10|2015-08-11|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Acupuncture for Fatigue in Parkinson's Disease|Acupuncture as a Symptomatic Treatment for Fatigue in Parkinson's Disease|Completed||N/A|88|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:35:15.025955|2018-05-31 22:35:15.025955
NCT01360216|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-09-25|2011-05-24|2011-05-25|Estimate|||||||2013-09-25|2013-09-26|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|LARC||Cluster, Randomized Trial on Long Acting Reversible Contraception (LARC) Education and Training|Cluster, Randomized Trial on Provider LARC Education and Training|Completed||N/A|1500|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:35:15.323112|2018-05-31 22:35:15.323112
NCT01360203|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-05-10|2011-05-23|2011-05-25|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BEAT-HF||Better Effectiveness After Transition - Heart Failure|Variations in Care: Comparing Heart Failure Care Transition Intervention Effects|Completed||N/A|1437|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 22:35:15.625584|2018-05-31 22:35:15.625584
NCT01360190|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2011-05-24|2011-05-24|2011-05-25|Estimate|||||||2011-05-24|2011-05-25|Estimate|August 1994||1994-08-31|May 2011|2011-05-31|August 1996|Actual|1996-08-31|August 1996|Actual|1996-08-31||Interventional|Lilly||Neurophysiologic Monitoring of Antidepressant Treatment|Neurophysiologic Monitoring of Antidepressant Treatment|Completed||Phase 4|24|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:35:15.904118|2018-05-31 22:35:15.904118
NCT01360177|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2016-07-18|2011-05-23|2011-05-25|Estimate|||||||2016-07-18|2016-07-20|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers|Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers|Withdrawn||N/A|0|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 22:35:16.171096|2018-05-31 22:35:16.171096
NCT01360164|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-11-26|2011-05-24|2011-05-25|Estimate|||||||2012-11-26|2012-11-28|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia|Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Shenzhen Beike Bio-Technology Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:35:16.480153|2018-05-31 22:35:16.480153
NCT01360151|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-05-27|2011-05-24|2011-05-25|Estimate|||||||2011-05-27|2011-05-30|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy||Unknown status|Recruiting|N/A|16|Anticipated|Seoul St. Mary's Hospital||3|||f||||t||||||||||2018-05-31 22:35:16.774605|2018-05-31 22:35:16.774605
NCT01360138|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-24|2011-05-24|2011-05-25|Estimate|||||||2011-05-24|2011-05-25|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||A Clinical Comparison in Cervical Epidural Pressure Changes Between Midline and Paramedian Approaches|Advantages of the Paramedian Approach for Cervical Epidural Steroid Injections: A Clinical Comparison in Cervical Epidural Pressure Changes Between Midline and Paramedian Approaches|Unknown status|Recruiting|N/A|25|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 22:35:17.086342|2018-05-31 22:35:17.086342
NCT01360125|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-21|||2016-04-14|2011-05-21|2011-05-25|Estimate|||||||2016-04-14|2016-04-15|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy|S0106A, Proteomic Signatures Associated With Complete Response (CR) and Complete Continuous Response at One Year (CCR1) Following Cytarabine-Based Induction Chemotherapy in Younger Adult Patients (18-60 Years of Age) With a Newly Diagnosed Non-M3 AML|Completed|||310|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-05-31 22:35:17.373506|2018-05-31 22:35:17.373506
NCT01360112|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-05-22|2011-05-20|2011-05-25|Estimate|||||||2018-05-22|2018-05-23|Actual|May 20, 2011||2011-05-20|November 16, 2017|2017-11-16|November 16, 2017||2017-11-16|||||Observational|||Preventing the Spread of Malaria in Mali|Malaria Transmission Blocking Assay Development and Gametocyte Carriage in a Vaccine Testing Site in Mali|Completed|||816|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:35:17.825625|2018-05-31 22:35:17.825625
NCT01358591|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2012-06-02|2011-05-20|2011-05-23|Estimate|||||||2012-06-02|2012-06-05|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effect of a High Calcium Breakfast on Exercise Metabolism and Appetite||Completed||N/A|9|Actual|Northumbria University||2|||f||||||||||||||2018-05-31 22:35:49.546316|2018-05-31 22:35:49.546316
NCT01360086|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2016-05-27|2011-05-20|2011-05-25|Estimate|||||||2016-05-27|2016-05-30|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction|Trial Evaluating the Efficacy and Tolerance of Perioperative Chemotherapy With 5FU-Cisplatin-Cetuximab in Adenocarcinomas of the Stomach and Gastroesophageal Junction. Phase II Single Arm, Multicenter.|Completed||Phase 2|65|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||f||||||||No||2018-05-31 22:35:18.441724|2018-05-31 22:35:18.441724
NCT01360073|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-11-13|2011-05-24|2011-05-25|Estimate|||||||2012-11-13|2012-11-14|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death|Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death - Nested Case Control Analyses in a Cohort of Patients With Acute Serious Coronary Heart Disease|Completed|||42542|Actual|AstraZeneca|||2||f||||||||||||||2018-05-31 22:35:18.908819|2018-05-31 22:35:18.908819
NCT01360060|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-05-24|2011-05-24|2011-05-25|Estimate|||||||2011-05-24|2011-05-25|Estimate|December 2010||2010-12-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Analgesia After Cesarean Section||Completed|||503|Actual|Seoul National University Bundang Hospital|||2||f||||||||||||||2018-05-31 22:35:19.203366|2018-05-31 22:35:19.203366
NCT01360047|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2012-11-13|2011-05-24|2011-05-25|Estimate|||||||2012-11-13|2012-11-14|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Death|Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death - Nested Case Control Analyses in a Cohort of First-time Users of Low Dose ASA for Secondary Prevention of Cerebrovascular and Cardiovascular Outcomes.|Completed|||39513|Actual|AstraZeneca|||2||f||||||||||||||2018-05-31 22:35:19.433668|2018-05-31 22:35:19.433668
NCT01360034|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2015-01-01|2011-05-24|2011-05-25|Estimate|||||||2015-01-01|2015-01-05|Estimate|December 2015||2015-12-31|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Nifedipine Versus Indomethacin in the Treatment of Preterm Labour|Nifedipine vs. Indomethacin in the Treatment of Preterm Labour and Short Cervix. A Randomized, Controlled Trial.|Unknown status|Not yet recruiting|Phase 3|216|Anticipated|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 22:35:19.541752|2018-05-31 22:35:19.541752
NCT01360021|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2013-07-19||2014-01-27|2011-05-24|2011-05-25|Estimate|2014-01-27|2014-03-11|Estimate||||2014-01-27|2014-03-11|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|BAI|All Randomized patients|New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day|A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy Safety, and Patient Use (User Study) of Symbicort® (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler (BA MDI) 2x160/4.5 μg Twice Daily Compared With Symbicort (Budesonide/Formoterol) AC (Actuation Counter) pMDI® 2x160/4.5 μg Twice Daily and Budesonide AC pMDI 2x160 μg Twice Daily in Adult and Adolescent Asthmatics|Completed||Phase 3|214|Actual|AstraZeneca|No. of participants in the safety analysis set is (71 for all the group) as 1 patients from the Budesonide group has not taken any dose of the IP, so not included in the Safety population.|3|||f||||||||||||||2018-05-31 22:35:19.708068|2018-05-31 22:35:19.708068
NCT01360008|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2016-06-16|2011-05-23|2011-05-25|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|January 2016|Actual|2016-01-31||Observational|||FREEZE Cohort Study|FREEZE Cohort Study|Active, not recruiting|||4071|Actual|Stiftung Institut fuer Herzinfarktforschung|||2||f||||t||||||||Yes|De-identified patient data will be published after end of follow up period|2018-05-31 22:35:20.693661|2018-05-31 22:35:20.693661
NCT01359995|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-23|2011-05-23|2011-05-25|Estimate|||||||2011-05-23|2011-05-25|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis|Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis|Unknown status|Recruiting||7|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 22:35:21.781932|2018-05-31 22:35:21.781932
NCT01359982|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2015-05-19|2011-05-23|2011-05-25|Estimate|||||||2015-05-19|2015-05-20|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|DINAMIC||Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects|A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies|Completed||Phase 1|26|Actual|EpicentRx, Inc.||1|||f||||||||||||||2018-05-31 22:35:21.848203|2018-05-31 22:35:21.848203
NCT01359969|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-10-14|2011-05-24|2011-05-25|Estimate|||||||2016-10-14|2016-10-17|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients|Open-label, Phase II, Single Arm Study to Evaluate the Safety, Immunogenicity, Pharmacokinetics and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Pediatric Patients With Hereditary Angioedema, From 2 up to and Including 13 Years of Age|Recruiting||Phase 2|20|Anticipated|Pharming Technologies B.V.||1|||f||||f||||||||||2018-05-31 22:35:21.933003|2018-05-31 22:35:21.933003
NCT01359956|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-04-01|2011-05-24|2011-05-25|Estimate|||||||2014-04-01|2014-04-03|Estimate|April 2002||2002-04-30|April 2014|2014-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SICOG 0109||Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma|Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study|Completed||Phase 3|269|Actual|National Cancer Institute, Naples||4|||f||||f||||||||||2018-05-31 22:35:22.054331|2018-05-31 22:35:22.054331
NCT01359943|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2015-02-12||2015-02-12|2011-05-23|2011-05-25|Estimate|2015-02-12|2015-03-02|Estimate||||2015-02-12|2015-03-02|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate|A Randomized, Double-blind, Placebo-controlled Study of Efficacy, Safety and Tolerability of Secukinumab at 12 Weeks Administered With an Intravenous (i.v.) or Subcutaneous (s.c.) Loading Regimen Compared to Placebo in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate|Completed||Phase 2|221|Actual|Novartis||3|||f||||f||||||||||2018-05-31 22:35:22.948767|2018-05-31 22:35:22.948767
NCT01359930|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2017-01-11|2011-05-23|2011-05-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study|Phase 1 Study of Interactions Between Oral Naltrexone and Bupropion and Intravenous Methamphetamine in Methamphetamine Experienced Volunteers|Completed||Phase 1|16|Anticipated|National Institute on Drug Abuse (NIDA)||2|||f||||||||||||||2018-05-31 22:35:23.923842|2018-05-31 22:35:23.923842
NCT01359917|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2011-06-09|2011-05-23|2011-05-25|Estimate|||||||2011-06-09|2011-06-13|Estimate|August 2006||2006-08-31|March 2006|2006-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome|Psychological Morbidity and Facial Volume in HIV Lipodystrophy:|Completed|||50|Actual|NHS Lothian|||3||f||||t||||||||||2018-05-31 22:35:23.999468|2018-05-31 22:35:23.999468
NCT01359904|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2014-03-25||2017-02-10|2011-05-24|2011-05-25|Estimate|2016-10-06|2016-11-28|Estimate||||2017-02-10|2017-03-21|Actual|May 2011||2011-05-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||forty subjects were needed to detect a difference in the mean change in the HbA1c from baseline to at the end of the study of 1% in the two dialysate concentration groups with a two-tailed t-test and variance of 1%, the required sample size will be 20 for each group with a power of 88% and alpha set at 0.05.|Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)|The Effect of Glucose Concentration in the Dialysate Bath on Glycemic Control Among Hemodialysis Patients With Type 2 Diabetes Mellitus|Completed||N/A|33|Actual|McGill University Health Center|The study was only short term.|2|||f||||f||||||||No||2018-05-31 22:35:24.07075|2018-05-31 22:35:24.07075
NCT01359891|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2018-03-10|2011-05-24|2011-05-25|Estimate|||||||2018-03-10|2018-03-13|Actual|November 2010||2010-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|NOBIS||Clinical Evaluation of Novel Biomarkers in Patients With Septicemia|Clinical Evaluation of Novel Biomarkers for Diagnosis, Therapy- Monitoring and Prognosis of Outcome in Patients With Septicemia|Recruiting|||750|Anticipated|Medical University of Graz|||3||f||||t||||||Samples Without DNA|"~     Left over EDTA-whole blood samples will be used for both, the Presage™ST2 assay and the~     suPARnostic™ assay except for the additional EDTA-whole blood samples taken on day 1 and 2 of~     study enrollment being only tested for sST2.~   "|||2018-05-31 22:35:24.456046|2018-05-31 22:35:24.456046
NCT01359878|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-09-19|2011-05-23|2011-05-25|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|FIB-PPH||Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage: A Randomised Clinically Controlled Trial|Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage - A Randomised Clinically Controlled Trial|Completed||Phase 2/Phase 3|249|Actual|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 22:35:24.537513|2018-05-31 22:35:24.537513
NCT01359865|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2015-09-30|2011-05-24|2011-05-25|Estimate|||||||2015-09-30|2015-10-02|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Anesthetic Techniques on Total Hip Arthroplasty|The Influence of Anesthetic Technique on Post-operative Pain Scores and Range of Motion in Primary Total Hip Arthroplasty|Terminated||N/A|70|Anticipated|Milton S. Hershey Medical Center||1||change in clinical practice- both surgeons have left the institution|f||||t||||||||||2018-05-31 22:35:24.625406|2018-05-31 22:35:24.625406
NCT01359852|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-07-21|2011-05-24|2011-05-25|Estimate|||||||2011-07-21|2011-07-22|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers|An Open-Label Study to Investigate the Dosimetry of the Positron Emission Tomography Ligand for the Metabotropic Glutamate Receptor-2 (mGlu2R), [11C]JNJ-42491293, and Displacement by the mGlu2R Positive Allosteric Modulator JNJ-40411813 in Healthy Male Subjects|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 22:35:24.710535|2018-05-31 22:35:24.710535
NCT01359839|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2013-05-08|2011-05-23|2011-05-25|Estimate|||||||2013-05-08|2013-05-10|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effectiveness of a Relaxation-Response Based Cognitive Behavioral Therapy Group for Depressed Chinese Patients|Relaxation-Response Based Cognitive Behavioral Therapy Group for Depressed Chinese Patients in the Community|Completed||N/A|40|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:35:24.792514|2018-05-31 22:35:24.792514
NCT01359826|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2015-09-17|2011-05-24|2011-05-25|Estimate|||||||2015-09-17|2015-09-18|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients|The Effect of Milnacipran on Fatigue and Quality of Life in a Lupus Cohort|Withdrawn||Phase 4|0|Actual|Loma Linda University||2||"PI has let the institution. We are unable to locate any study documents that would indicate~   study enrollment"|f||||f||||||||||2018-05-31 22:35:24.858379|2018-05-31 22:35:24.858379
NCT01359813|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2014-05-12|2011-05-23|2011-05-25|Estimate|||||||2014-05-12|2014-05-13|Estimate|December 2008||2008-12-31|July 2010|2010-07-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Interventional|ALB-CIRINF||Albumin Administration in Cirrhotic Patients With Bacterial Infection and a Systemic Inflammatory Response Syndrome Unrelated to Spontaneous Bacterial Peritonitis|Effects of Albumin Administration in Septic Cirrhotic Patients With Child > 8 Unrelated to Spontaneous Bacterial Peritonitis on Renal Function and Survival: A Multicenter Randomized Controlled Trial Comparing Use and Non-use of Human Albumin (Vialebex ®)|Terminated||Phase 3|193|Actual|Centre Hospitalier Universitaire de Besancon||2||"decision of independent monitoring committee:Risk of death at 3 months higher in Albumin group~   than in control group, without reaching significance level."|f||||t||||||||||2018-05-31 22:35:25.053981|2018-05-31 22:35:25.053981
NCT01359800|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2016-03-03|2011-05-24|2011-05-25|Estimate|||||||2016-03-03|2016-03-04|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Observational|ISS OBS T-004||Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients|A Multicentre, Observational, Cross-sectional Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients in Selected Areas of Gauteng and Eastern Cape|Completed|||531|Actual|Istituto Superiore di Sanità|||2||f||||f||||||Samples With DNA|"~     Whole blood, cervical samples~   "|||2018-05-31 22:35:25.160862|2018-05-31 22:35:25.160862
NCT01359787|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2015-01-19|2011-05-24|2011-05-25|Estimate|||||||2015-01-19|2015-01-21|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)|Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of Mapracorat Ointment in Three Concentrations Over Max. 4 Weeks in Subjects With Atopic Dermatitis (AD)|Completed||Phase 2|197|Actual|Bayer||4|||f||||f||||||||||2018-05-31 22:35:25.229237|2018-05-31 22:35:25.229237
NCT01359761|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-06-12|2011-05-23|2011-05-25|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2011||2011-02-28|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors|Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors: A Multi-Site Randomized Controlled Trial|Recruiting||N/A|218|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t||||||||No||2018-05-31 22:35:25.415701|2018-05-31 22:35:25.415701
NCT01359748|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2011-06-02||2014-07-22|2011-05-24|2011-05-25|Estimate|2013-09-04|2013-11-07|Estimate||||2014-07-22|2014-07-29|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Clinical Study About Blood Pressure Measurement Efficacy on Multifunction KEITO|Clinical Study About Blood Pressure Measurement Efficacy on Multifunction KEITO|Completed||N/A|89|Actual|Aguiflai Iberica, S.L.||4|||f||||f||||||||||2018-05-31 22:35:25.548927|2018-05-31 22:35:25.548927
NCT01359735|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2016-09-13|2013-09-12|2017-05-31|2011-05-24|2011-05-25|Estimate|2017-05-31|2017-06-29|Actual|2013-09-19|2013-09-26|Estimate|2017-05-31|2017-06-29|Actual|May 2011||2011-05-31|May 2017|2017-05-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients|A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients|Completed||Phase 2|8|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 22:35:25.843909|2018-05-31 22:35:25.843909
NCT01359722|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-05-24|2011-05-24|2011-05-25|Estimate|||||||2011-05-24|2011-05-25|Estimate|March 2010||2010-03-31|October 2009|2009-10-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||N-acetylcysteine to Prevent Renal Failure|N-acetylcysteine to Prevent Renal Failure in Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Surgery|Unknown status|Recruiting|N/A|50|Anticipated|Instituto do Coracao||2|||f||||t||||||||||2018-05-31 22:35:26.273501|2018-05-31 22:35:26.273501
NCT01359709|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-05-11|2011-05-24|2011-05-25|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking|Effects of Contingency Management and Nicotine Replacement Therapy on Youth Smoking|Completed||Phase 1|60|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:35:26.363895|2018-05-31 22:35:26.363895
NCT01359696|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2017-04-11|2011-05-24|2011-05-25|Estimate|||||||2017-04-11|2017-04-12|Actual|July 11, 2011|Actual|2011-07-11|April 2017|2017-04-30|May 29, 2014|Actual|2014-05-29|May 29, 2014|Actual|2014-05-29||Interventional|||A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma|An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma|Completed||Phase 1|40|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:35:26.441948|2018-05-31 22:35:26.441948
NCT01359683|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2013-06-12|2011-05-24|2011-05-25|Estimate|||||||2013-06-12|2013-06-14|Estimate|September 2007||2007-09-30|April 2008|2008-04-30||||September 2009|Actual|2009-09-30||Interventional|||Heart Rate Variability Changes During Cardiac Surgery And The Incidence Of Post-Operative Cardiac Arrhythmias|Heart Rate Variability Changes During Cardiac Surgery And The Incidence Of Post-Operative Cardiac Arrhythmias|Withdrawn||N/A|0|Actual|Drexel University||1|||f||||f||||||||||2018-05-31 22:35:26.501637|2018-05-31 22:35:26.501637
NCT01359670|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2018-04-13|2011-05-24|2011-05-25|Estimate|||||||2018-04-13|2018-04-17|Actual|May 2011||2011-05-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Tadalafil and Sildenafil for Duchenne Muscular Dystrophy|Functional Muscle Ischemia and PDE5A Inhibition in Duchenne Muscular Dystrophy|Completed||N/A|30|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 22:35:26.559668|2018-05-31 22:35:26.559668
NCT01359657|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2016-03-15|2011-05-24|2011-05-25|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma|A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|46|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 22:35:26.636557|2018-05-31 22:35:26.636557
NCT01359644|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2015-08-21||2015-09-23|2011-05-24|2011-05-25|Estimate|2015-09-23|2015-10-23|Estimate||||2015-09-23|2015-10-23|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care|Parallel, Open-Label, Randomized Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PSI-7977 in Combination With BMS-790052 With or Without Ribavirin in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotypes 1, 2, or 3|Completed||Phase 2|350|Actual|Bristol-Myers Squibb||10|||f||||f||||||||||2018-05-31 22:35:26.843333|2018-05-31 22:35:26.843333
NCT01359631|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-05-13|2011-05-23|2011-05-25|Estimate|||||||2012-05-13|2012-05-15|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Cephalic Vascular Recording Upon SPG Stimulation|Cephalic Vascular Recording Upon SPG Stimulation in CH Patients - Amendment to the Pathway CH-1 Trial|Completed|||7|Actual|Autonomic Technologies, Inc.|||||f||||||||||||||2018-05-31 22:35:27.857666|2018-05-31 22:35:27.857666
NCT01359618|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2012-12-11|2011-05-23|2011-05-25|Estimate|||||||2012-12-11|2012-12-12|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart|A Single-centre, Randomised, Double-blind, Placebo Controlled Phase I Study in Two Parts: Part A to Assess a Safe and Tolerable Supratherapeutic Dose of TC-5214 After Single Ascending Oral Doses in Healthy Male Subjects, Followed by Part B: A Four-period Double-dummy Crossover Study to Investigate the Effect of 2 Single Doses (Therapeutic and Supratherapeutic) of TC-5214 on the QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Subjects|Terminated||Phase 1|16|Actual|AstraZeneca||6||Sponsor decision to terminate|f||||f||||||||||2018-05-31 22:35:27.93147|2018-05-31 22:35:27.93147
NCT01359605|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-12-16|2011-05-23|2011-05-25|Estimate|||||||2011-12-16|2011-12-20|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects|An Open-Label, Single-Dose, Study to Assess the Metabolism and Elimination of Varespladib After Oral Administration of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects|Completed||Phase 1|6|Actual|Anthera Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:35:28.079271|2018-05-31 22:35:28.079271
NCT01359592|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-21|||2017-10-03|2011-05-24|2011-05-25|Estimate|||||||2017-10-03|2017-10-05|Actual|September 2011||2011-09-30|October 2017|2017-10-31|March 2024|Anticipated|2024-03-31|June 2020|Anticipated|2020-06-30||Interventional|||S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma|A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)|Active, not recruiting||Phase 2|159|Actual|Southwest Oncology Group||2|||f||||f||||||||||2018-05-31 22:35:28.291077|2018-05-31 22:35:28.291077
NCT01359579|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-03-19|2011-05-23|2011-05-25|Estimate|||||||2012-03-19|2012-03-20|Estimate|June 2011||2011-06-30|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Interventional|||A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function|A Phase 1, Open-label, Pharmacokinetic, Safety, and Tolerability Study of a Single Oral Dose of Varespladib Methyl in Subjects With Normal Renal Function, and Subjects With Mild, Moderate, or Severe Renal Impairment|Terminated||Phase 1|28|Actual|Anthera Pharmaceuticals||4||Lack of efficacy|f||||f||||||||||2018-05-31 22:35:28.974431|2018-05-31 22:35:28.974431
NCT01359566|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22||2015-12-28|2017-04-24|2011-05-23|2011-05-24|Estimate||||2015-12-28|2016-02-01|Estimate|2017-04-24|2017-04-26|Actual|May 2011||2011-05-31|April 2017|2017-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis|A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis|Completed||Phase 3|228|Actual|Indivior Inc.||4|||f||||f||||||||No||2018-05-31 22:35:29.065989|2018-05-31 22:35:29.065989
NCT01359553|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22|||2016-10-24|2011-05-22|2011-05-24|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Clinical Study of Novel Diagnostic Techniques for Knee Osteoarthritis|Comparison Between Intra-articular Ultrasound Imaging, Non-invasive Ultrasound Imaging, Quantitative MRI Imaging, Contrast-enhanced CT Imaging and Arthroscopy for Diagnostics of Knee Osteoarthritis|Completed|||12|Actual|University of Oulu|||1||f||||f||||||||||2018-05-31 22:35:29.279785|2018-05-31 22:35:29.279785
NCT01359540|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22|||2017-12-11|2011-05-23|2011-05-24|Estimate|||||||2017-12-11|2017-12-13|Actual|November 2009|Actual|2009-11-30|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Femoral Remodeling Following Total Hip Arthroplasty With OMNI Apex Modular™ and OMNI Apex ARC™ Stem Compared to Competitive Designs|A Dual Energy X-Ray Absorptiometry (DXA) Evaluation Of Bone Density Changes After Hip Replacement. Performance Of The OMNI Apex Modular™ Hip Stem And The OMNI Apex ARC™ Hip Stem In Primary Total Hip Arthroplasty, Five-Year Clinical And DXA Analysis|Active, not recruiting|||73|Actual|Spokane Joint Replacement Center|||2||f||||t||||||||||2018-05-31 22:35:29.380044|2018-05-31 22:35:29.380044
NCT01359527|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-22|||2017-12-11|2011-05-23|2011-05-24|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2008||2008-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Dual Energy X-ray Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)|A Dual Energy X-Ray Absorptiometry Comparison Of Periprosthetic Bone Loss Between Patients Undergoing Hip Resurfacing Surgery And Total Hip Arthroplasty|Active, not recruiting|||31|Actual|Spokane Joint Replacement Center|||2||f||||t||||||||||2018-05-31 22:35:29.492708|2018-05-31 22:35:29.492708
NCT01359514|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-10|||2017-10-10|2011-05-23|2011-05-24|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2008|Actual|2008-04-30|October 2017|2017-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Mechanism-based Choice of Therapy for Neuropathic Pain|Mechanism-based Choice of Therapy for Neuropathic Pain: Can Treatments Success in Neuropathic Post-operative Pain be Coupled to Psychophysical Pain Modulation Profile?|Completed||N/A|32|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:35:29.569641|2018-05-31 22:35:29.569641
NCT01359501|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-01|||2012-10-21|2011-05-23|2011-05-24|Estimate|||||||2012-10-21|2012-10-23|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients|Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients|Unknown status|Recruiting|Phase 2|100|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 22:35:29.675604|2018-05-31 22:35:29.675604
NCT01359488|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2012-07-19|2011-05-23|2011-05-24|Estimate|||||||2012-07-19|2012-07-23|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||VRS-317 in Adult Subjects With Growth Hormone Deficiency|A Blinded Placebo Controlled Single Ascending Dose Phase 1 for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration of VRS-317 in Adults With Growth Hormone Deficiency|Completed||Phase 1|50|Actual|Versartis Inc.||5|||f||||f||||||||||2018-05-31 22:35:29.862232|2018-05-31 22:35:29.862232
NCT01359475|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-15|||2013-07-02|2011-05-23|2011-05-24|Estimate|||||||2013-07-02|2013-07-03|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|December 2011|Actual|2011-12-31||Interventional|||A Clinical Trial of an Acetal Resin Crown for Restoration of Primary Molars|Phase 3- Clinical Trial on Children. PROTOCOL 465-549|Completed||Phase 3|52|Actual|Barzilai Medical Center||1|||f||||f||||||||||2018-05-31 22:35:30.083795|2018-05-31 22:35:30.083795
NCT01359462|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-05-23|2011-05-23|2011-05-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|April 2009||2009-04-30|May 2011|2011-05-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis|A Clinical Study of Multiple-dose Pharmacokinetics of Tolvaptan Tablets Administered Orally (15mg Daily) for Consecutively 7 Days in Chinese Patients With Hepatocirrhosis|Completed||Phase 1|11|Actual|Otsuka Beijing Research Institute||1|||f||||f||||||||||2018-05-31 22:35:30.252762|2018-05-31 22:35:30.252762
NCT01359449|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2013-04-04||2016-07-20|2011-05-23|2011-05-24|Estimate|2013-04-04|2013-05-24|Estimate||||2016-07-20|2016-08-19|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations|Safety and Immunogenicity of Two Doses of Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) or One Dose of Monovalent Meningococcal Group C Conjugate Vaccine Administered Concomitantly With Routine Immunizations Between 12 and 18 Months of Age in Canada|Completed||Phase 3|123|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:35:30.729711|2018-05-31 22:35:30.729711
NCT01359436|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-11-14|2011-05-23|2011-05-24|Estimate|||||||2012-11-14|2012-11-15|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer|e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer|Unknown status|Recruiting|N/A|200|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:35:32.201634|2018-05-31 22:35:32.201634
NCT01359423|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2017-11-26|2011-05-20|2011-05-24|Estimate|||||||2017-11-26|2017-11-28|Actual|September 26, 2011|Actual|2011-09-26|November 2017|2017-11-30|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||Comparison of Primary Long Full Coverage Stenting vs Primary Short Spot Stenting for Long Femoropopliteal Artery Disease.||Completed||N/A|89|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:35:32.310737|2018-05-31 22:35:32.310737
NCT01359410|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2017-03-29||2017-03-29|2011-05-23|2011-05-24|Estimate|2017-03-29|2017-05-10|Actual||||2017-03-29|2017-05-10|Actual|June 2007||2007-06-30|March 2017|2017-03-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Reinforced Staple Line on Leak Rate in Distal Pancreatectomy|Effect of a Reinforced Staple Line on Leak Rate in Distal Pancreatectomy|Terminated||N/A|112|Actual|Washington University School of Medicine|The investigators were unable to identify any complications directly due to the mesh materials. It is possible these complications are very rare and that the study did not include enough participants to potentially identify these potential harms.|2||The 3rd interim analysis found superiority in the mesh reinforcement arm|f||||t|f|t|f|f|f|||No||2018-05-31 22:35:32.410037|2018-05-31 22:35:32.410037
NCT01359397|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2015-11-03|2011-05-23|2011-05-24|Estimate|||||||2015-11-03|2015-11-04|Estimate|March 2011||2011-03-31|October 2015|2015-10-31||||May 2015|Actual|2015-05-31||Interventional|B-DOCT||Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer|Phase II Study of Docetaxel, Oxaliplatin, Capecitabine With Bevacizumab and Trastuzumab in Case of Human Epidermal Growth Factor Receptor 2 (HER2)-Positivity in Patients With Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT Study)|Unknown status|Active, not recruiting|Phase 2|||The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 22:35:32.951189|2018-05-31 22:35:32.951189
NCT01359384|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-23|2011-05-23|2011-05-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|||Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment||Unknown status|Not yet recruiting||50|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||||||||Samples With DNA|"~     whole blood, serum and sputum~   "|||2018-05-31 22:35:33.041451|2018-05-31 22:35:33.041451
NCT01359371|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2014-10-28||2015-04-06|2011-05-20|2011-05-24|Estimate|2014-11-21|2014-12-01|Estimate||||2015-04-06|2015-04-28|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||Evaluation of Peer Telephone Cessation Counseling for Smokers|Evaluation of Peer Telephone Cessation Counseling for Smokers|Completed|||41|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-05-31 22:35:33.11095|2018-05-31 22:35:33.11095
NCT01359358|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2011-05-23|2011-05-23|2011-05-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|July 2011||2011-07-31|May 2011|2011-05-31||||||||Observational|MRSABrazil||Study of Methicillin-resistant Staphylococcus Aureus (MRSA) Isolated From Infected Patients in Brazil|Epidemiological Study of Methicillin-resistant Staphylococcus Aureus (MRSA) Isolated From Infected Patients During a Hospital Surveillance Period|Unknown status|Not yet recruiting||20|Anticipated|University of Sao Paulo|||||f||||t||||||||||2018-05-31 22:35:33.302852|2018-05-31 22:35:33.302852
NCT01359345|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2012-06-21|2011-05-23|2011-05-24|Estimate|||||||2012-06-21|2012-06-22|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|May 2011|Actual|2011-05-31||Interventional|NSF||Nephrogenic Systemic Fibrosis With Gadollinum|The Prevalence and Severity of Nephrogenic Systemic Fibrosis in Patients Whom Underwent Imaging With Gadollinium(MRI/MRA) in University Hospital of Tehran Heart Center in 2003-2008|Unknown status|Enrolling by invitation|Phase 2/Phase 3|200|Anticipated|Imam Khomeini Hospital||1|||f||||t||||||||||2018-05-31 22:35:33.434174|2018-05-31 22:35:33.434174
NCT01359332|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2016-09-28|2011-05-23|2011-05-24|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|HYBERNATUS||Evaluation of Therapeutic Hypothermia in Convulsive Status EPILEPTICUS in Adults in Intensive Care|Evaluation of the Interests of a Therapeutic Hypothermia Procedure in Convulsive Status EPILEPTICUS in Adults in Intensive Care - HYBERNATUS Study|Completed||Phase 3|270|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:35:33.523319|2018-05-31 22:35:33.523319
NCT01359319|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2012-05-17|2011-05-23|2011-05-24|Estimate|||||||2012-05-17|2012-05-21|Estimate|July 2011||2011-07-31|February 2012|2012-02-29|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)|A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of Sialic Acid Extended Release (SA-ER) Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)|Completed||Phase 1|26|Actual|Ultragenyx Pharmaceutical Inc||5|||f||||f||||||||||2018-05-31 22:35:33.618304|2018-05-31 22:35:33.618304
NCT01359306|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2011-05-23|2011-05-23|2011-05-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|February 2006||2006-02-28|May 2011|2011-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Right Ventricular Damage in Cardiovascular Magnetic Resonance|Right Ventricular Damage in ST-Elevation Myocardial Infarction. Risk Stratification by Visualization of Wall Motion, Edema and Delayed Enhancement Cardiovascular Magnetic Resonance|Completed|||524|Actual|University of Leipzig|||||f||||f||||||Samples Without DNA|"~     serum for assessment of creatine kinase myocardial band~   "|||2018-05-31 22:35:33.713604|2018-05-31 22:35:33.713604
NCT01359280|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2014-12-02|2011-05-20|2011-05-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PIU||Nurse Delivered Cell Phone Adherence Intervention (Pick It UP)|Nurse Delivered Cell Phone Adherence Intervention|Completed||Phase 1/Phase 2|600|Actual|University of Connecticut||4|||f||||f||||||||||2018-05-31 22:35:33.790782|2018-05-31 22:35:33.790782
NCT01359267|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2017-10-09|2011-05-23|2011-05-24|Estimate|||||||2017-10-09|2017-10-11|Actual|April 19, 2011|Actual|2011-04-19|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer|A Pilot Feasibility Study of 99mTc EC DG SPECT/CT Imaging in the Treatment Response Evaluation in Patients With Locally Advanced Head and Neck Cancer|Active, not recruiting||N/A|20|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 22:35:33.855252|2018-05-31 22:35:33.855252
NCT01359254|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2015-04-10||2015-04-10|2011-05-23|2011-05-24|Estimate|2015-04-10|2015-04-30|Estimate||||2015-04-10|2015-04-30|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Interventional|||Cord Blood Transplantation for Patients With Cancer|Combined Transplantation of Unmanipulated Haploidentical and a SingleCord Blood Unit for Patients With Hematologic Malignancies|Terminated||Phase 2|1|Actual|University of Chicago||2||did not accrue enough patients.|f||||f||||||||||2018-05-31 22:35:33.967524|2018-05-31 22:35:33.967524
NCT01359241|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-11-09|2011-05-23|2011-05-24|Estimate|||||||2012-11-09|2012-11-12|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Angie01||Achieving Normal Glucose In Hospital Settings|An Open-label, Single-centre, Randomised, Two-period Crossover Study to Assess the Efficacy and Safety of 24-hour Closed-loop Glucose Control in Comparison With Conventional Treatment in Adults With Type 2 Diabetes on Non-insulin Glucose-lowering Agents|Completed||N/A|16|Actual|University of Cambridge||2|||f||||f||||||||||2018-05-31 22:35:34.237066|2018-05-31 22:35:34.237066
NCT01359228|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-04-25|2011-05-23|2011-05-24|Estimate|||||||2014-04-25|2014-04-28|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Rifaximin Treatment of Papulopustular Rosacea|Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study|Withdrawn||Phase 2|0|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:35:34.31826|2018-05-31 22:35:34.31826
NCT01359215|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-12-11|2011-05-23|2011-05-24|Estimate|||||||2013-12-11|2013-12-12|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|UCSF-Anes-01||Childhood Anesthesia and Cognitive Function|Is Pediatric Anesthesia Associated With Long-term Hippocampal Dysfunction?|Completed|||30|Actual|University of California, San Francisco|||2||f||||f||||||||||2018-05-31 22:35:34.536853|2018-05-31 22:35:34.536853
NCT01359202|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-05-19|2011-05-20|2011-05-24|Estimate|||||||2018-05-19|2018-05-22|Actual|May 2011||2011-05-31|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|SPOTLIGHT||"Spot Sign Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy"|"Spot Sign Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy: SPOTLIGHT"|Active, not recruiting||Phase 2|50|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 22:35:34.617579|2018-05-31 22:35:34.617579
NCT01359189|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-08-31|2011-05-20|2011-05-24|Estimate|||||||2016-08-31|2016-09-02|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer|Initial Exploratory Evaluation of a Transrectal Scintigraphic Detector (ProxiScanTM) for Detection of Primary Prostate Cancer Utilizing a Prostate Specific Membrane Antigen (PSMA) Based Radiotracer (ProstaScint®)|Completed||Phase 1|4|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 22:35:34.739946|2018-05-31 22:35:34.739946
NCT01359176|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-04-24|2011-05-23|2011-05-24|Estimate|||||||2016-04-24|2016-04-26|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Observational|||Capnography Data Collection From Healthy Participants|The Capnography Library: Data Collection From Healthy Participants|Completed|||160|Actual|Shaare Zedek Medical Center|||1||f||||f||||||||||2018-05-31 22:35:34.815485|2018-05-31 22:35:34.815485
NCT01359163|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2012-04-03|2011-05-23|2011-05-24|Estimate|||||||2012-04-03|2012-04-04|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study To Determine Bioequivalence Between The Commercial Femulen Tablets And A Reformulation Of Femulen Tablets In Healthy Female Subjects|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study Of Commercial Femulen Tablets Versus Reformulated Femulen Tablets In Healthy Female Subjects|Completed||Phase 1|20|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:35:34.909072|2018-05-31 22:35:34.909072
NCT01359150|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2013-01-07||2013-02-20|2011-05-20|2011-05-24|Estimate|2013-02-20|2013-03-29|Estimate||||2013-02-20|2013-03-29|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo|A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Background Methotrexate|Completed||Phase 2|223|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:35:35.028913|2018-05-31 22:35:35.028913
NCT01359137|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-04-06|2011-05-23|2011-05-24|Estimate|||||||2018-04-06|2018-04-10|Actual|January 2011|Actual|2011-01-31|April 2018|2018-04-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||An Assessment of SAFE (Swift Accountable Fair Enforcement) in Cochise County|An Assessment of Arizona's SAFE (Swift Accountable Fair Enforcement) Program in Cochise County|Completed||N/A|105|Actual|Pepperdine University||3|||f||||f||||||||||2018-05-31 22:35:35.865374|2018-05-31 22:35:35.865374
NCT01359124|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2015-02-25|2011-05-20|2011-05-24|Estimate|||||||2015-02-25|2015-02-27|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Reaching Exercise Goals: Comparison of Exercise Means in Patients With Knee Osteoarthritis|Reaching Exercise Goals: Comparison of the Underwater Treadmill, Land Based Treadmill, and Exercise Cycle in Patients With Knee Osteoarthritis|Completed|||60|Actual|Milton S. Hershey Medical Center|||3||f||||f||||||||||2018-05-31 22:35:35.945376|2018-05-31 22:35:35.945376
NCT01359111|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|2012-04-16||2012-05-10|2011-05-20|2011-05-24|Estimate|2012-04-16|2012-05-11|Estimate||||2012-05-10|2012-05-18|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Performance and Safety Evaluation of an Intradermal Delivery Device|Phase I Performance and Safety Evaluation of an Intradermal Delivery Device|Completed||Phase 1|20|Actual|PATH|||||f||||f||||||||||2018-05-31 22:35:36.068102|2018-05-31 22:35:36.068102
NCT01359098|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2011-11-01|2011-05-20|2011-05-24|Estimate|||||||2011-11-01|2011-11-02|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|Ciprodexa Foam||Efficacy and Safety of Once-Daily Ciprodexa Otic Foam Compared to Twice-daily Ciprodex Ear Drops in Acute Otitis Externa|Safety and Efficacy of Once-Daily Dosing of Ciprodexa Otic Foam (Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Foam) Compared to Twice-Daily Dosing of Ciprodex (0.3% Ciprofloxacin and Dexamethasone 0.1% Otic Suspension) in Patients With Acute Otitis Externa|Completed||Phase 2|100|Anticipated|Otic Pharma||2|||f||||f||||||||||2018-05-31 22:35:36.233629|2018-05-31 22:35:36.233629
NCT01359085|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-06-06|2011-05-23|2011-05-24|Estimate|||||||2011-06-06|2011-06-07|Estimate|June 2011||2011-06-30|June 2011|2011-06-30||||June 2012|Anticipated|2012-06-30||Interventional|||Pain Relief Following Arthroscopic Rotator Cuff Repair: Perioperative Pregabalin Administration Versus Interscalene Brachial Plexus Block|Pain Relief Following Arthroscopic Rotator Cuff Repair: Perioperative Pregabalin Administration Versus Interscalene Brachial Plexus Block. a Prospective, Randomized, Double Blinded, Multicenter Trial|Unknown status|Not yet recruiting|N/A|56|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 22:35:36.341601|2018-05-31 22:35:36.341601
NCT01358409|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2017-07-12|2011-05-20|2011-05-23|Estimate|||||||2017-07-12|2017-07-14|Actual|April 1, 2011||2011-04-01|July 2017|2017-07-31|February 11, 2013|Actual|2013-02-11|February 11, 2013|Actual|2013-02-11||Interventional|||Regression of Myocardial Steatosis by Nebivolol|Regression of Myocardial Steatosis by Nebivolol|Completed||Early Phase 1|31|Actual|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 22:35:55.263045|2018-05-31 22:35:55.263045
NCT01359072|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2012-08-21|2011-05-20|2011-05-24|Estimate|||||||2012-08-21|2012-08-22|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Enhancing Coping Skills in Patients With Cancer|Enhancing Coping Skills in Patients With Cancer - a Randomized Controlled Study|Terminated||N/A|1|Actual|McGill University Health Center||2||This study is currently terminated due to low recruitment rate.|f||||f||||||||||2018-05-31 22:35:36.416436|2018-05-31 22:35:36.416436
NCT01359059|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-06-09|2011-05-23|2011-05-24|Estimate|||||||2011-06-09|2011-06-10|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Pre- Versus Post-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Orthopedic Oncologic Patients|Pre- vs. Post-incisional Pregabalin for Postoperative Pain Attenuation and Analgesics Spare in Orthopedic Oncologic Patients: A Comparative, Randomized, Double Blind Study Protocol|Unknown status|Not yet recruiting|N/A|80|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 22:35:36.489924|2018-05-31 22:35:36.489924
NCT01359046|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2017-08-07|2011-05-23|2011-05-24|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2011||2011-07-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology|Randomized Control Trial of Silver-alloy Impregnated Suprapubic Catheters in Urogynecology Patients|Recruiting||N/A|444|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:35:36.563528|2018-05-31 22:35:36.563528
NCT01359033|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2017-11-14|2011-05-23|2011-05-24|Estimate|||||||2017-11-14|2017-11-17|Actual|March 2011||2011-03-31|February 2014|2014-02-28|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||MI Mortality Risk and Between-hospital Risk Variation in the United Kingdom and Sweden|Compare the Patient Risk and Between-hospital Variation in Myocardial Infarction Mortality in the United Kingdom and Sweden|Completed|||510863|Actual|University College, London|||2||f||||t||||||||||2018-05-31 22:35:36.63043|2018-05-31 22:35:36.63043
NCT01359020|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2011-05-23|2011-05-23|2011-05-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|January 2007||2007-01-31|May 2011|2011-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Ibuprofen, Acetaminophen and Dipyrone to Fever Control in Children|Randomized, Open Label, Comparative, Parallel, Multicenter Trial to Determinate the Efficacy Anf Tolerability of Ibuprofen, Acetaminophen and Dipyrone Drops to Fever Control in Children|Completed||Phase 4|396|Actual|Mantecorp Industria Quimica e Farmaceutica Ltd.||3|||f||||t||||||||||2018-05-31 22:35:36.690809|2018-05-31 22:35:36.690809
NCT01359007|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2017-04-14||2018-02-23|2011-05-23|2011-05-24|Estimate|2018-02-23|2018-03-09|Actual||||2018-02-23|2018-03-09|Actual|May 2011||2011-05-31|February 2018|2018-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||FOLFIRINOX in Patients With Inoperable Pancreatic Cancer|A Phase II Study Evaluating the Rate of R0 Resection (Microscopically Negative Margins) After Induction Therapy With 5- Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan (FOLFIRINOX) in Patients With Borderline Resectable or Locally Advanced Inoperable Pancreatic Cancer.|Terminated||Phase 2|5|Actual|University of Oklahoma||1||The principal investigator terminated the study due to inactivity and low enrollment|f||||f||||||||||2018-05-31 22:35:36.752357|2018-05-31 22:35:36.752357
NCT01358994|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-20|2011-05-20|2011-05-24|Estimate|||||||2011-05-20|2011-05-24|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Observational|||Metformin Treatment, Renal Function and Lactic Acidosis|Metformin Treatment, Renal Function and Lactic Acidosis. A Population Based|Completed|||4500|Actual|Skane University Hospital|||||f||||f||||||||||2018-05-31 22:35:36.915159|2018-05-31 22:35:36.915159
NCT01358981|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2011-08-26|2011-05-20|2011-05-24|Estimate|||||||2011-08-26|2011-08-29|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study of LY2881835 in Healthy People and People With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|40|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:35:36.962392|2018-05-31 22:35:36.962392
NCT01358968|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-01-16|2011-05-20|2011-05-24|Estimate|||||||2013-01-16|2013-01-17|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine|A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:35:37.032492|2018-05-31 22:35:37.032492
NCT01358955|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-08-27|2011-05-20|2011-05-24|Estimate|||||||2013-08-27|2013-08-28|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|CogMCI||Efficacy Study of Cognitive Intervention in Amnestic Mild Cognitive Impairment|A Multicenter, Randomized Trial to Assess Efficacy of Home-based and Group Cognitive Intervention Programs in Amnestic Mild Cognitive Impairment|Completed||N/A|293|Actual|Inha University Hospital||3|||f||||f||||||||||2018-05-31 22:35:37.229376|2018-05-31 22:35:37.229376
NCT01358942|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2016-11-01|2011-05-20|2011-05-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)|Observational, Epidemiological and Non Interventional Study Evaluating the Evolution of Lung Cancer Related Symptoms and Its Correlation With Disease Control Rate in Patients With Non-Small Cell Lung Cancer (NSCLC) Initiating First-line Treatment With Platinum Based Standard Chemotherapy.|Completed|||156|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:35:37.336466|2018-05-31 22:35:37.336466
NCT01358929|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-11-01|2011-05-20|2011-05-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of RO6807952 in Patients With Diabetes Mellitus Type 2|A Randomized, Placebo-Controlled, Sequential, Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR701/RO6807952 in Type 2 Diabetic Patients|Completed||Phase 1|45|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:35:37.455569|2018-05-31 22:35:37.455569
NCT01358916|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2013-03-27|2011-05-23|2011-05-24|Estimate|||||||2013-03-27|2013-03-29|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SAPI||Intervention Study to Improve Antibiotic Prescription in Outpatient Care|Improvement of Antibiotic Prescription in Outpatient Care: a Cluster-randomised Intervention Study Using a Sentinel Surveillance Network of Physicians|Completed||N/A|140|Actual|University of Bern||2|||f||||f||||||||||2018-05-31 22:35:37.515704|2018-05-31 22:35:37.515704
NCT01358903|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-11-01|2011-05-20|2011-05-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors|Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors|Completed||Phase 1|65|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:35:37.660602|2018-05-31 22:35:37.660602
NCT01358890|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2012-02-27|2011-05-23|2011-05-24|Estimate|||||||2012-02-27|2012-02-28|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Low-Carbohydrate Diet Intervention on Body Weight|Effect of Low-Carbohydrate or Restricted-Calories Diet on Body Weight|Completed||Phase 2/Phase 3|50|Actual|Chinese Academy of Sciences||2|||f||||||||||||||2018-05-31 22:35:37.746194|2018-05-31 22:35:37.746194
NCT01358877|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2017-12-04||2018-03-02|2011-05-20|2011-05-24|Estimate|2017-12-04|2018-01-05|Actual||||2018-03-02|2018-03-06|Actual|November 8, 2011|Actual|2011-11-08|March 2018|2018-03-31|December 1, 2023|Anticipated|2023-12-01|December 19, 2016|Actual|2016-12-19||Interventional|APHINITY|Intent-to-treat (ITT) population included all randomized participants regardless of treatment received.|A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer|A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer|Active, not recruiting||Phase 3|4804|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:35:38.085468|2018-05-31 22:35:38.085468
NCT01358864|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|2015-07-03|2014-04-30|2016-07-28|2011-05-23|2011-05-24|Estimate|2015-09-22|2015-10-28|Estimate|2014-05-19|2014-05-29|Estimate|2016-07-28|2016-08-29|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|May 2014|Actual|2014-05-31|February 2013|Actual|2013-02-28||Interventional||Full Analysis Set (FAS)|Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)|A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment|Completed||Phase 3|678|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:35:43.432348|2018-05-31 22:35:43.432348
NCT01358851|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2015-05-28|2011-05-23|2011-05-24|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||LAS41005 in Hyperkeratotic Actinic Keratosis|A Prospective Comparator Controlled Randomized Exploratory Study on the Efficacy of LAS 41005 Compared to Cryotherapy in Subjects With Hyperkeratotic Actinic Keratosis|Completed||Phase 2|67|Actual|Almirall, S.A.||2|||f||||||||||||||2018-05-31 22:35:45.236144|2018-05-31 22:35:45.236144
NCT01358838|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2013-02-06|2011-05-23|2011-05-24|Estimate|||||||2013-02-06|2013-02-07|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Ablative 10600 nm Fractional Laser Therapy for the Treatment of Scars|Ablative 10600 nm Fractional Laser Therapy for the Treatment of Scars; a Randomized Controlled Trial|Completed||N/A|25|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||||||||||||2018-05-31 22:35:45.298763|2018-05-31 22:35:45.298763
NCT01358825|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2016-11-02||2017-02-03|2011-05-20|2011-05-24|Estimate|2016-11-02|2016-12-29|Estimate||||2017-02-03|2017-03-15|Actual|May 2011||2011-05-31|February 2017|2017-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™|Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexa™ or Infanrix-IPV/Hib™|Completed||Phase 4|58|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:35:45.378001|2018-05-31 22:35:45.378001
NCT01358812|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-03-10|2011-05-23|2011-05-24|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2010||2010-03-31|March 2015|2015-03-31||||October 2011|Actual|2011-10-31||Interventional|TRIP||FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer|Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer|Completed||Phase 2|37|Actual|Gruppo Oncologico del Nord-Ovest||1|||f||||t||||||||||2018-05-31 22:35:45.665914|2018-05-31 22:35:45.665914
NCT01358799|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-03-08|2011-05-23|2011-05-24|Estimate|||||||2013-03-08|2013-03-12|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System|Clinical Evaluation of the APTIMA® Assay for Chlamydia Trachomatis Using the PANTHER™ System|Withdrawn|||0|Actual|Gen-Probe, Incorporated||||Assay not evaluated for purpose of clearance|f||||f||||||Samples With DNA|"~     4 specimens will be collected from each female subject in the following order: 1 first-catch~     urine specimen, 1 vaginal swab specimen (patient or clinician-collected), 1 cervical specimen~     (using a broomlike collection device or a brush/spatula combination), and 1 endocervical swab~     specimen. An additional cervical specimen may be collected from female subjects for other~     clinical trial purposes or research studies. Up to 2 specimens will be collected from each~     male subject in the following order: 1 urethral swab specimen and 1 first-catch urine~     specimen.~   "|||2018-05-31 22:35:45.829847|2018-05-31 22:35:45.829847
NCT01358786|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-25|2011-05-20|2011-05-24|Estimate|||||||2011-05-25|2011-05-26|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|STRAMQUSG||Seroma at the Donor Site of the TRAM Flap, With or Without Quilting Suture: A Comparative Study Using Ultrasound|Seroma at the Donor Site of the TRAM Flap, With or Without Quilting Suture.|Completed||Phase 1|48|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 22:35:45.894615|2018-05-31 22:35:45.894615
NCT01358773|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2016-06-29|2011-05-23|2011-05-24|Estimate|||||||2016-06-29|2016-06-30|Estimate|February 2004||2004-02-29|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2004|Actual|2004-12-31||Interventional|||The Effect of 1 Year of Multiprofessional Therapy on Obesity|Multiprofessional Impact on Body Composition, Central and Peripheric Adiposity, Lipid Profile, Hormonal Regulation, Lung, Sleep and Humor Disorders in Adolescents|Recruiting||Early Phase 1|150|Anticipated|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 22:35:45.959077|2018-05-31 22:35:45.959077
NCT01358396|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-20|2011-05-20|2011-05-23|Estimate|||||||2011-05-20|2011-05-23|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Observational|||Glycemic Control and Diabetic Macular Edema|The Effect of Glycemic Control on Visual and Anatomical Outcomes in Response to Therapy for Diabetic Macular Edema.|Completed|||52|Actual|Cairo University|||1||f||||f||||||||||2018-05-31 22:35:55.346543|2018-05-31 22:35:55.346543
NCT01358760|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2017-03-17|2013-05-01|2017-06-08|2011-05-23|2011-05-24|Estimate|2017-06-08|2017-06-12|Actual|2013-05-01|2013-05-09|Estimate|2017-06-08|2017-06-12|Actual|June 2011||2011-06-30|June 2017|2017-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional||Baseline Analysis Population corresponds to the Safety Population which includes all subjects who received any amount of DHEA (prasterone) or placebo, and who have any safety information available.|Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy||Completed||Phase 3|450|Actual|EndoCeutics Inc.||3|||f||||t||||||||||2018-05-31 22:35:46.045212|2018-05-31 22:35:46.045212
NCT01358747|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2014-05-20|2011-05-20|2011-05-24|Estimate|||||||2014-05-20|2014-05-21|Estimate|May 2011||2011-05-31|January 2013|2013-01-31||||||||Interventional|AHL 2011||Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL|Randomized Phase III Study of a Treatment Driven by Early PET Response Compared to a Treatment Not Monitored by Early PET in Patients With Ann Arbor Stage III-IV or High Risk IIB Hodgkin Lymphoma|Completed||Phase 3|||Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-05-31 22:35:46.621316|2018-05-31 22:35:46.621316
NCT01358734|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2016-04-04||2018-03-05|2011-05-20|2011-05-24|Estimate|2016-05-25|2016-07-04|Estimate||||2018-03-05|2018-03-30|Actual|April 27, 2012|Actual|2012-04-27|March 2018|2018-03-31|May 5, 2018|Anticipated|2018-05-05|April 28, 2015|Actual|2015-04-28||Interventional||Intent To Treat (ITT) includes all randomized participants|A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia|A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) Plus Lenalidomide (Revlimid®) Regimen Versus an Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia|Active, not recruiting||Phase 2|88|Actual|Celgene||3|||f||||t||||||||||2018-05-31 22:35:46.99793|2018-05-31 22:35:46.99793
NCT01358721|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-01-18|2011-05-20|2011-05-24|Estimate|||||||2018-01-18|2018-01-23|Actual|August 11, 2011|Actual|2011-08-11|January 2018|2018-01-31|November 16, 2018|Anticipated|2018-11-16|December 1, 2014|Actual|2014-12-01||Interventional|||Phase I Biomarker Study (BMS-936558)|An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Subjects With Metastatic Clear Cell Renal Cell Carcinoma (RCC).|Active, not recruiting||Phase 1|119|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 22:35:48.422288|2018-05-31 22:35:48.422288
NCT01358708|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-16|2013-06-20||2017-02-14|2011-05-20|2011-05-24|Estimate|2013-11-08|2013-12-30|Estimate||||2017-02-14|2017-03-21|Actual|June 2010||2010-06-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Analysis conducted on the Intent-to-Treat population defined as all randomized subjects|Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg|Treatment of Diarrhea-predominant Irritable Bowel Syndrome With LACTEOL® 340 mg: A Pilot Study Evaluating Safety and Efficacy|Terminated||Phase 3|26|Actual|Forest Laboratories|Because of early termination of this trial, the number of subjects analyzed was too small to perform statistical analyses and draw conclusions relative to the efficacy and safety of LACTEOL®.|2||Administrative reasons|f||||f||||||||||2018-05-31 22:35:48.509913|2018-05-31 22:35:48.509913
NCT01358695|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20||2013-06-21|2013-06-21|2011-05-20|2011-05-24|Estimate||||2013-06-21|2013-07-01|Estimate|2013-06-21|2013-07-01|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet|Clinical Trial To Evaluate ANT-1207 In Subjects With Lateral Canthal Lines|Completed||Phase 2|111|Actual|Anterios Inc.||6|||f||||t||||||||||2018-05-31 22:35:48.963262|2018-05-31 22:35:48.963262
NCT01358682|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2017-02-15|2011-05-23|2011-05-24|Estimate|||||||2017-02-15|2017-02-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:35:49.060302|2018-05-31 22:35:49.060302
NCT01358669|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2017-05-04|2011-05-23|2011-05-24|Estimate|||||||2017-05-04|2017-05-05|Actual|December 2011|Actual|2011-12-31|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty|Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip|Recruiting||Phase 2|30|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:35:49.096047|2018-05-31 22:35:49.096047
NCT01358656|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-23|2011-05-23|2011-05-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|January 2012|Anticipated|2012-01-31|July 2011|Anticipated|2011-07-31||Interventional|KR||Anterior Cruciate Ligament Reconstruction Using Single Bundle and Double Bundle Techniques|Comparison of the Anterior Cruciate Ligament Reconstruction Using Single Bundle and Double Bundle Techniques: Prospective Clinical Study|Unknown status|Recruiting|N/A|40|Anticipated|Vita Care||2|||f||||t||||||||||2018-05-31 22:35:49.186063|2018-05-31 22:35:49.186063
NCT01358643|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-06-01|2011-05-23|2011-05-24|Estimate|||||||2011-06-01|2011-06-02|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|May 2012|Anticipated|2012-05-31|January 2012|Anticipated|2012-01-31||Interventional|||Operations Enduring Freedom and Iraqi Freedom (OEF/OIF)Veteran Preferences for Automated Physical Activity Interventions|Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) Veteran Preferences for and Feasibility of Automated Physical Activity Interventions: A Pilot Study|Unknown status|Enrolling by invitation|N/A|30|Anticipated|VA Ann Arbor Healthcare System||3|||f||||f||||||||||2018-05-31 22:35:49.247506|2018-05-31 22:35:49.247506
NCT01358630|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-23|2011-05-23|2011-05-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|October 2008||2008-10-31|November 2010|2010-11-30|October 2015|Anticipated|2015-10-31|March 2011|Actual|2011-03-31||Observational|||Vascular and Periodontal Disease - Microbial, Genetic and Histological Causalities|Periodontal-, Cardiovascular- and Aneurysmal Diseases.|Unknown status|Recruiting||100|Anticipated|University of Oslo|||||f||||t||||||Samples With DNA|"~     Whole blood, samples from vascular tissues (atherosclerotic plaques and aneurysmal wall),~     saliva~   "|||2018-05-31 22:35:49.305026|2018-05-31 22:35:49.305026
NCT01358617|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-05-11|2011-05-19|2011-05-23|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma|Observational - Expression of Ubiquitin Carboxyl-Terminal Hydrolase 1 (UCHL1) in Neuroblastoma Cancer Stem Cells and Its Relationship to Patient Prognosis|Completed|||90|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Tumor Tissue~   "|||2018-05-31 22:35:49.43001|2018-05-31 22:35:49.43001
NCT01358604|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-04-14|2011-05-18|2011-05-23|Estimate|||||||2016-04-14|2016-04-15|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Biomarkers in Samples From Young Patients With Neuroblastoma|ROR1 as a Novel Target for Neuroblastoma|Completed|||20|Actual|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:35:49.490737|2018-05-31 22:35:49.490737
NCT01358578|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2015-02-16||2016-01-19|2011-05-20|2011-05-23|Estimate|2015-08-20|2015-09-23|Estimate||||2016-01-19|2016-02-17|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|FIXTURE||Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis|A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 3|1306|Actual|Novartis||6|||f||||t||||||||||2018-05-31 22:35:49.678219|2018-05-31 22:35:49.678219
NCT01358565|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2011-06-21|2011-05-20|2011-05-23|Estimate|||||||2011-06-21|2011-06-23|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction|Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:35:52.754655|2018-05-31 22:35:52.754655
NCT01358552|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2013-04-30|2011-05-20|2011-05-23|Estimate|||||||2013-04-30|2013-05-01|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)|Néevo®/NéevoDHA® P.L.U.S. Program (Progress Through Learning, Understand & Support)|Terminated|||53|Actual|Pamlab, Inc.|||1|Insufficient number of participants|f||||f||||||||||2018-05-31 22:35:52.861461|2018-05-31 22:35:52.861461
NCT01358539|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-06-23|2011-05-20|2011-05-23|Estimate|||||||2016-06-23|2016-06-24|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PEEP||Palliation: the Effect of Education on Pain|Pain Education for Patients With Painful Bone Metastases Undergoing Palliative Radiotherapy: Reducing Pain by Increasing Patient's Knowledge and Self-management|Completed||Phase 3|354|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 22:35:52.930406|2018-05-31 22:35:52.930406
NCT01358526|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|2014-07-29||2015-10-14|2011-05-20|2011-05-23|Estimate|2014-08-21|2014-09-03|Estimate||||2015-10-14|2015-11-11|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain|A Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Enriched Study Design to Assess the Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Pain Due to Chronic Low Back Pain Who Require Around-the-clock Opioid Therapy|Completed||Phase 3|1095|Actual|Purdue Pharma LP||2|||f||||t||||||||||2018-05-31 22:35:53.038913|2018-05-31 22:35:53.038913
NCT01358513|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-01-09|2011-05-20|2011-05-23|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2014|Actual|2014-07-31||Observational|||Role of Active Valvular Calcification and Inflammation in Patients With Aortic Stenosis|An Observational PET/CT Study Examining the Role of Active Valvular Calcification and Inflammation in Patients With Aortic Stenosis|Unknown status|Active, not recruiting||168|Anticipated|University of Edinburgh|||5||f||||t||||||Samples With DNA|"~     In patients undergoing aortic valve replacement during the course of the trial we will retain~     samples of their aortic valve for histological studies.~   "|||2018-05-31 22:35:54.283611|2018-05-31 22:35:54.283611
NCT01358500|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2013-02-04|2011-05-20|2011-05-23|Estimate|||||||2013-02-04|2013-02-06|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|FEN001||An Assessment of Fentanyl Dose Requirements in Opioid-maintained Individuals|An Assessment of Fentanyl Dose Requirements in Opioid-maintained Individuals|Unknown status|Recruiting|N/A|24|Anticipated|University of Adelaide||1|||f||||f||||||||||2018-05-31 22:35:54.442511|2018-05-31 22:35:54.442511
NCT01358487|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-03-11|2011-05-19|2011-05-23|Estimate|||||||2013-03-11|2013-03-13|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Healthy Mood Internet Intervention Research Project|Internet Intervention to Prevent Major Depressive Episodes|Completed||Phase 1|116|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:35:54.589688|2018-05-31 22:35:54.589688
NCT01358474|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2018-02-09|2011-05-20|2011-05-23|Estimate|||||||2018-02-09|2018-02-12|Actual|July 2011||2011-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2014|Actual|2014-10-31||Observational|||Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism|Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism|Active, not recruiting|||60|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||||||2018-05-31 22:35:54.692334|2018-05-31 22:35:54.692334
NCT01358461|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2017-09-07|2011-05-20|2011-05-23|Estimate|||||||2017-09-07|2017-09-08|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Validation of a Non Invasive Blood Marker of SIDS and Vagal Disorders|Circulating Biomarker(s) of Muscarinic Receptor Overexpression and Vagal Disorders.|Completed|||240|Actual|University Hospital, Strasbourg, France|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 22:35:54.756598|2018-05-31 22:35:54.756598
NCT01358448|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2018-04-03|2011-05-20|2011-05-23|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2011|Actual|2011-04-30|April 2018|2018-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Pilot Study of the Efficacy and Program Cost-effectiveness of Prevention Plus for Childhood Obesity|A Pilot Study of the Efficacy and Program Cost-effectiveness of Prevention Plus for Childhood Obesity|Completed||N/A|22|Actual|The University of Tennessee, Knoxville||3|||f||||||||||||||2018-05-31 22:35:54.82071|2018-05-31 22:35:54.82071
NCT01358435|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2012-12-26|2011-05-20|2011-05-23|Estimate|||||||2012-12-26|2012-12-27|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects|Randomized,Single Center,Double Blind,Two-period,Crossover Glucose Clamp Trial Study to Test Bioequivalence Between Two Recombinant Human Mixed Insulins-Wockhardt's Human/Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects|Completed||Phase 1|53|Actual|Wockhardt||2|||f||||f||||||||||2018-05-31 22:35:54.898145|2018-05-31 22:35:54.898145
NCT01358422|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-20|||2015-10-12|2011-05-20|2011-05-23|Estimate|||||||2015-10-12|2015-10-14|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|OBTAIN||Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery|Occurrence of Bleeding and Thrombosis During Antiplatelet Therapy in Non-cardiac Surgery. A Prospective Observational Study (OBTAIN Study)|Completed|||830|Actual|European Society of Anaesthesiology|||1||f||||f||||||||||2018-05-31 22:35:55.168324|2018-05-31 22:35:55.168324
NCT01358383|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2012-06-21|2011-05-20|2011-05-23|Estimate|||||||2012-06-21|2012-06-22|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers|A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects|Completed||Phase 1|28|Actual|AstraZeneca|||||f||||||||||||||2018-05-31 22:35:55.420286|2018-05-31 22:35:55.420286
NCT01358370|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-06-23|2011-05-19|2011-05-23|Estimate|||||||2016-06-23|2016-06-27|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype|A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype|Completed|||40|Actual|Alexion Pharmaceuticals|||||f||||f||||||||No||2018-05-31 22:35:55.538437|2018-05-31 22:35:55.538437
NCT01358357|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2016-03-24||2016-07-29|2011-05-20|2011-05-23|Estimate|2016-06-14|2016-07-26|Estimate||||2016-07-29|2016-09-07|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PERSIST||Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex|A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder|Completed||Phase 3|965|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 22:35:55.688375|2018-05-31 22:35:55.688375
NCT01358344|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-09-28|2011-05-19|2011-05-23|Estimate|||||||2015-09-28|2015-09-29|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)|A Study to Determine the Bioequivalence of SCH 530348 2.5 mg Tablets Containing a High and Low Percentage of Drug as the Free Base Within the Range Used in the Pivotal Phase 3 Efficacy and Safety Trials. (Protocol No. P06558)|Completed||Phase 1|173|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:35:56.845356|2018-05-31 22:35:56.845356
NCT01358331|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-06-05|2011-05-19|2011-05-23|Estimate|||||||2015-06-05|2015-06-08|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)|A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203))|Terminated||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 22:35:56.917674|2018-05-31 22:35:56.917674
NCT01358318|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-06-06|2011-05-20|2011-05-23|Estimate|||||||2012-06-06|2012-06-07|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||Effects of Soy Protein/Soy Fiber on Measures of Satiety|Effect of Addition of Soy Protein and Soy Fiber to a Snack Bar on Satiety and Food Intake|Completed||N/A|40|Actual|Solae, LLC||4|||f||||||||||||||2018-05-31 22:35:56.992495|2018-05-31 22:35:56.992495
NCT01358305|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2014-12-04|2011-05-20|2011-05-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Protein Blends (Soy, Whey and Casein) for Muscle Synthesis|A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown|Completed||N/A|19|Actual|Solae, LLC||2|||f||||t||||||||||2018-05-31 22:35:57.04948|2018-05-31 22:35:57.04948
NCT01358292|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2016-06-16|2011-05-20|2011-05-23|Estimate|||||||2016-06-16|2016-06-17|Estimate|February 2011||2011-02-28|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|TrigenMETA||Efficacy Study of Surgical Technique in Intramedullary Tibia Nailing, Using Trigen META Tibia Nails|Semi-extended Position vs. 90 Degrees of Flexion for Intramedullary Nailing of the Tibia: a Randomized Clinical Trial|Completed||Phase 4|95|Actual|Smith & Nephew, Inc.||2|||f||||t||||||||No||2018-05-31 22:35:57.111199|2018-05-31 22:35:57.111199
NCT01358279|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-10-23|2011-05-20|2011-05-23|Estimate|||||||2016-10-23|2016-10-25|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|March 2011|Actual|2011-03-31|October 2009|Actual|2009-10-31||Interventional|||Transcranial Direct Current Stimulation for Migraine Attack|Manho Kim, MD, PhD Professor, Neurology Seoul National University Hospital,|Completed||N/A|32|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 22:35:57.177324|2018-05-31 22:35:57.177324
NCT01358266|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2017-09-26|2011-05-20|2011-05-23|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2011||2011-05-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|SAKURA||Study Assessing Double-masked Uveitis Treatment|A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis|Completed||Phase 3|592|Actual|Santen Inc.||3|||f||||t||||||||||2018-05-31 22:35:57.395379|2018-05-31 22:35:57.395379
NCT01358253|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2014-05-19|2011-05-20|2011-05-23|Estimate|||||||2014-05-19|2014-05-20|Estimate|December 2010||2010-12-31|May 2011|2011-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia|Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia|Completed||Phase 4|100|Actual|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 22:35:57.734971|2018-05-31 22:35:57.734971
NCT01358240|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-09-27|2011-05-20|2011-05-23|Estimate|||||||2012-09-27|2012-09-28|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis|A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis|Completed||Phase 3|336|Actual|AmDerma||4|||f||||f||||||||||2018-05-31 22:35:57.852043|2018-05-31 22:35:57.852043
NCT01358227|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-05-23|2011-05-19|2011-05-23|Estimate|||||||2011-05-23|2011-05-24|Estimate|December 2006||2006-12-31|May 2011|2011-05-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors|A Phase I, Multi-center, Open-label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given Weekly in Subjects With Solid Tumors|Completed||Phase 1|26|Actual|Proacta, Incorporated||1|||f||||f||||||||||2018-05-31 22:35:57.954641|2018-05-31 22:35:57.954641
NCT01358214|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2012-08-22|2011-05-20|2011-05-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)|Single-center, Non-randomized, Comparative, Post-marketing Surveillance Cohort Study on Validation of a Questionnaire on Quality of Life After Surgical Stabilization of the Urethra With Titanized Polypropylene Mesh (TiLOOP® Tape)|Terminated|||21|Actual|pfm medical ag|||3|major recruitment failure|f||||f||||||||||2018-05-31 22:35:58.032007|2018-05-31 22:35:58.032007
NCT01358201|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2017-10-25|2011-05-20|2011-05-23|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2010||2010-05-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years|Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years|Recruiting||Phase 4|100|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-05-31 22:35:58.132582|2018-05-31 22:35:58.132582
NCT01358188|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2017-04-03|2011-05-20|2011-05-23|Estimate|||||||2017-04-03|2017-04-04|Actual|April 2011||2011-04-30|April 2017|2017-04-30|May 2, 2016|Actual|2016-05-02|May 2, 2016|Actual|2016-05-02||Observational|||Exploration of Immunity in Gaucher Disease|Prospective Study of Macrophage Activation and Cross Talk Between Immune System Elements in Subjects With Gaucher Disease|Completed|||33|Actual|O & O Alpan LLC|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 22:35:58.392429|2018-05-31 22:35:58.392429
NCT01358175|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2015-12-14||2017-01-27|2011-05-20|2011-05-23|Estimate|2016-12-01|2017-01-27|Estimate||||2017-01-27|2017-03-09|Actual|October 2011||2011-10-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MEASURE 1||16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis|Completed||Phase 3|371|Actual|Novartis||3|||f||||t||||||||||2018-05-31 22:35:58.501612|2018-05-31 22:35:58.501612
NCT01358162|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-05-10|2011-05-19|2011-05-23|Estimate|||||||2013-05-10|2013-05-14|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Phase IC Study of Safety and PK of SQ109 300mg Daily|A Phase 1C, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 300 mg of SQ109 Given Once Daily for 14 Days in Normal, Healthy Male and Female Volunteers|Completed||Phase 1|10|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 22:36:00.019073|2018-05-31 22:36:00.019073
NCT01358149|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2013-10-29|2011-05-20|2011-05-23|Estimate|||||||2013-10-29|2013-10-30|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Trial of Cocoa-based Food in Children|Double Blind Controlled Trial of Cocoa-based Food in Children|Completed||N/A|25|Actual|Nestlé||2|||f||||t||||||||||2018-05-31 22:36:00.112142|2018-05-31 22:36:00.112142
NCT01358136|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2012-04-24|2011-05-20|2011-05-23|Estimate|||||||2012-04-24|2012-04-25|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|August 2012|Anticipated|2012-08-31||Observational|ThyrOp||ThyrOp: A Study of Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter|ThyrOp: Individual Subclinical Hypothyroidism After Hemithyroidectomy for Benign Nontoxic Goiter - Focus on Weight Gain and Mitochondrial Dysfunction|Unknown status|Recruiting||30|Anticipated|Naestved Hospital|||1||f||||f||||||||||2018-05-31 22:36:00.188248|2018-05-31 22:36:00.188248
NCT01358123|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2015-09-24|2011-05-20|2011-05-23|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Observational|||Value of Von Willebrand Factor in Portal Hypertension|Von Willebrand Factor As Non-Invasive Predictor Of Clinically Significant Portal Hypertension And Mortality In Patients With Liver Cirrhosis|Unknown status|Recruiting||300|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-05-31 22:36:00.300741|2018-05-31 22:36:00.300741
NCT01358110|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-06-25|2011-05-20|2011-05-23|Estimate|||||||2015-06-25|2015-06-26|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Emergency Department-Based Palliative Care for Advanced Cancer Patients|Emergency Department-Based Palliative Care for Advanced Cancer Patients|Completed||N/A|136|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 22:36:00.368066|2018-05-31 22:36:00.368066
NCT01358097|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2014-04-08|2011-05-20|2011-05-23|Estimate|||||||2014-04-08|2014-04-10|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy|Biomarkers of Immune Function as Predictors of Head and Neck Squamous Cell Carcinoma (HNSCC) in Response to Therapy|Completed|||33|Actual|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||Samples With DNA|"~     Serum, peripheral blood mononuclear cells~   "|||2018-05-31 22:36:00.588476|2018-05-31 22:36:00.588476
NCT01358084|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2016-05-27|2011-05-20|2011-05-23|Estimate|||||||2016-05-27|2016-05-30|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|NGR019||Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma|NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)|Unknown status|Recruiting|Phase 2|100|Anticipated|MolMed S.p.A.||2|||f||||f||||||||||2018-05-31 22:36:00.889473|2018-05-31 22:36:00.889473
NCT01358071|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-10-08|2011-05-20|2011-05-23|Estimate|||||||2015-10-08|2015-10-09|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|NGR018||Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer|NGR018: Randomized Phase II Study of NGR-hTNF Plus an Anthracycline Versus an Anthracycline Alone in Platinum-resistant Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|124|Anticipated|MolMed S.p.A.||2|||f||||f||||||||||2018-05-31 22:36:01.129938|2018-05-31 22:36:01.129938
NCT01358058|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-12-19|2011-05-19|2011-05-23|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2011||2011-05-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Proton Radiation Therapy for Gliomas|Phase II Study of Proton Radiation Therapy for Low Grade and Favorable Grade 3 Gliomas|Recruiting||Phase 2|50|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:36:01.615177|2018-05-31 22:36:01.615177
NCT01358045|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2015-01-12|2011-05-19|2011-05-23|Estimate|||||||2015-01-12|2015-01-13|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma|Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma|Completed||Phase 2|128|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 22:36:01.775958|2018-05-31 22:36:01.775958
NCT01358032|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-07-09|2011-05-19|2011-05-23|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Evaluating an In-home Multicomponent Program to Manage Concerns About Falling in Frail Community Dwelling Older People|Evaluating the Effectiveness of an In-home Self-management Intervention to Prevent Psychological Distress in Frail Older People Living in the Community|Completed||N/A|389|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 22:36:01.875946|2018-05-31 22:36:01.875946
NCT01358006|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2013-07-08|2011-05-19|2011-05-23|Estimate|||||||2013-07-08|2013-07-09|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Dose-Ranging Study of JNJ-40411813 in Healthy Male Volunteers|An Open Label Dose-Ranging Study in Healthy Male Subjects to Investigate the Binding Potential of JNJ-40411813 to Serotonin 2A Receptors in the Central Nervous System|Completed||Phase 1|13|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 22:36:02.114954|2018-05-31 22:36:02.114954
NCT01357993|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2014-03-27|2011-05-19|2011-05-23|Estimate|||||||2014-03-27|2014-03-28|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder|An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day|Completed||Phase 3|253|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 22:36:02.219963|2018-05-31 22:36:02.219963
NCT01357980|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|2014-03-27||2014-08-21|2011-05-20|2011-05-23|Estimate|2014-08-21|2014-09-01|Estimate||||2014-08-21|2014-09-01|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Demographic characteristics of the Intent to Treat (ITT) population: All randomised subjects who received at least one injection of study treatment and had an assessment for the averaged daily IEF both at Baseline and Day 84.|Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis|A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.|Completed||Phase 2|47|Actual|Ipsen||4|||f||||f||||||||||2018-05-31 22:36:02.517175|2018-05-31 22:36:02.517175
NCT01357967|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-10-31|2011-05-20|2011-05-23|Estimate|||||||2012-10-31|2012-11-01|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope|The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope|Unknown status|Recruiting|Phase 4|60|Anticipated|Inje University||2|||f||||f||||||||||2018-05-31 22:36:03.380062|2018-05-31 22:36:03.380062
NCT01357954|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2013-03-19|2011-05-19|2011-05-23|Estimate|||||||2013-03-19|2013-03-20|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|May 2012|Actual|2012-05-31||Interventional|||The Efficacy of Targeted Training on the Postural Control and Gross Motor Function in Children With Cerebral Palsy||Unknown status|Active, not recruiting|N/A|28|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 22:36:03.647502|2018-05-31 22:36:03.647502
NCT01357941|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-06-02|2011-05-20|2011-05-23|Estimate|||||||2011-06-02|2011-06-03|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Observational|ROCITP2||Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)|Prospective Study Assessing the Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism|Unknown status|Not yet recruiting||203|Anticipated|Hamilton Health Sciences Corporation|||2||f||||t||||||||||2018-05-31 22:36:03.807224|2018-05-31 22:36:03.807224
NCT01357928|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-09-04|2011-05-20|2011-05-23|Estimate|||||||2012-09-04|2012-09-05|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Observational|||Thromboelastography (TEG) Reference Range Study|Procedure for the Reference Range Study for Haemoscope Reagents|Completed|||159|Actual|Haemonetics Corporation|||1||f||||f||||||||||2018-05-31 22:36:03.988714|2018-05-31 22:36:03.988714
NCT01357915|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2017-05-12||2017-05-12|2011-05-19|2011-05-23|Estimate|2017-05-12|2017-10-06|Actual||||2017-05-12|2017-10-06|Actual|June 24, 2011|Actual|2011-06-24|May 2017|2017-05-31|September 13, 2012|Actual|2012-09-13|September 13, 2012|Actual|2012-09-13||Interventional|||Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine|A Follow-up Study to Evaluate the Long-term Persistence of GSK Biologicals' Candidate CMV Vaccine Administered to Male Adults|Completed||N/A|47|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:36:04.086162|2018-05-31 22:36:04.086162
NCT01357902|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-09-18|2011-05-19|2011-05-23|Estimate|||||||2017-09-18|2017-09-20|Actual|April 18, 2011|Actual|2011-04-18|September 2017|2017-09-30|May 23, 2011|Actual|2011-05-23|May 23, 2011|Actual|2011-05-23||Interventional|||Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China|An Open Label, Randomized, Cross-Over Study to Investigate the Single Dose Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg) Compared to Lamotrigine Compressed/Standard Tablets (25mg) in Chinese Healthy Male Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 22:36:04.683119|2018-05-31 22:36:04.683119
NCT01357889|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2014-04-24|2013-05-02|2016-11-18|2011-05-19|2011-05-23|Estimate|2014-04-24|2014-05-23|Estimate|2013-05-02|2013-05-09|Estimate|2016-11-18|2017-01-09|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pharmacokinetics/Pharmacodynamics of Albiglutide|A Multidose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Pharmacokinetics and Pharmacodynamics of Albiglutide|Completed||Phase 2|283|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:36:04.820226|2018-05-31 22:36:04.820226
NCT01357876|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-06-21|2011-05-19|2011-05-23|Estimate|||||||2017-06-21|2017-06-22|Actual|October 1, 2010|Actual|2010-10-01|June 2017|2017-06-30|July 7, 2011|Actual|2011-07-07|July 7, 2011|Actual|2011-07-07||Interventional|||Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics|Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics|Completed||Phase 1|8|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:36:06.970607|2018-05-31 22:36:06.970607
NCT01357863|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2017-05-23|2011-05-19|2011-05-23|Estimate|||||||2017-05-23|2017-05-24|Actual|July 2010||2010-07-31|May 2017|2017-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|(TYCO1)||Role of Early Versus Late Switch to Lapatinib-Capecitabine|Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil|Terminated|||3|Actual|GlaxoSmithKline|||2|This study was terminated because the National Ethics Committee has not approved the protocol.|f||||f||||||||||2018-05-31 22:36:07.10878|2018-05-31 22:36:07.10878
NCT01357681|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-06-15|2011-05-20|2011-05-23|Estimate|||||||2015-06-15|2015-06-16|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ETON||Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)|Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -|Completed||Phase 2|54|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:36:10.686171|2018-05-31 22:36:10.686171
NCT01357850|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2014-04-17|2013-04-05|2017-07-14|2011-05-19|2011-05-23|Estimate|2014-09-29|2014-10-01|Estimate|2013-04-05|2013-04-11|Estimate|2017-07-14|2017-08-17|Actual|September 15, 2010|Actual|2010-09-15|July 2017|2017-07-31|September 18, 2012|Actual|2012-09-18|September 18, 2012|Actual|2012-09-18||Interventional|||A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure|A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure|Completed||Phase 2|82|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:36:07.282045|2018-05-31 22:36:07.282045
NCT01357837|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2013-01-22|2011-05-20|2011-05-23|Estimate|||||||2013-01-22|2013-01-23|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Assessment of GRT6005 in Painful Osteoarthritis of the Knee|A Randomized 4 Week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee|Completed||Phase 2|207|Actual|Grünenthal GmbH||4|||f||||f||||||||||2018-05-31 22:36:09.181483|2018-05-31 22:36:09.181483
NCT01357824|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-01-29|2011-05-20|2011-05-23|Estimate|||||||2012-01-29|2012-01-31|Estimate|June 2011||2011-06-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Observational|||Fibreoptic Intubation With and Without Sellick´s Maneuver|View af Larynx and Intubation With a Flexible Fibreoptic Scope With and Without Sellick´s Maneuver.|Completed|||50|Anticipated|Glostrup University Hospital, Copenhagen|||1||f||||f||||||||||2018-05-31 22:36:09.403131|2018-05-31 22:36:09.403131
NCT01357811|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2015-03-19|2011-05-19|2011-05-23|Estimate|||||||2015-03-19|2015-03-23|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults|A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics and Safety and Tolerability of Digoxin in Healthy Adult Subjects|Completed||Phase 1|28|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:36:09.48504|2018-05-31 22:36:09.48504
NCT01357798|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2011-05-20|2011-05-20|2011-05-23|Estimate|||||||2011-05-20|2011-05-23|Estimate|December 2010||2010-12-31|May 2011|2011-05-31||||April 2011|Actual|2011-04-30||Interventional|||Botulinum Toxin Type A in Treatment of Cranial Allodynia in Patients With Headache|Botulinum Toxin Type A Versus 0,9% Saline in Treatment of Cranial Allodynia in Patients With Headache|Completed||Phase 3|40|Anticipated|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 22:36:09.575494|2018-05-31 22:36:09.575494
NCT01357785|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-09-12|2011-05-20|2011-05-23|Estimate|||||||2011-09-12|2011-09-13|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|December 2014|Anticipated|2014-12-31|June 2013|Anticipated|2013-06-30||Interventional|PDLSC||Periodontal Tissue Regeneration Using Autologous Periodontal Ligament Stem Cells|Periodontal Tissue Regeneration Using Autologous Periodontal Ligament Stem Cells: Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 1|35|Anticipated|Fourth Military Medical University|||||f||||t||||||||||2018-05-31 22:36:09.661579|2018-05-31 22:36:09.661579
NCT01357772|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2015-08-03|2011-05-20|2011-05-23|Estimate|||||||2015-08-03|2015-08-04|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|TAM-01||Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia|Randomized Placebo-controlled Phase III Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia|Active, not recruiting||Phase 3|1400|Anticipated|Ente Ospedaliero Ospedali Galliera||2|||f||||t||||||||||2018-05-31 22:36:09.787996|2018-05-31 22:36:09.787996
NCT01357759|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2015-11-13|2011-05-19|2011-05-23|Estimate|||||||2015-11-13|2015-11-16|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Trial of MORAb-022 in Healthy Subjects and Subjects With Rheumatoid Arthritis|Completed||Phase 1|20|Actual|Morphotek||2|||f||||f||||||||||2018-05-31 22:36:09.886494|2018-05-31 22:36:09.886494
NCT01357746|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-08-17|2011-05-20|2011-05-23|Estimate|||||||2013-08-17|2013-08-20|Estimate|July 2011||2011-07-31|May 2011|2011-05-31||||June 2012|Actual|2012-06-30||Interventional|||Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)|Detection, Estimation and Characterization of Pulmonary Blood Pressure by Transthoracic Parametric Doppler (TPD)|Terminated||Phase 1|60|Actual|Echosense Ltd.||||Low recruitment|f||||f||||||||||2018-05-31 22:36:09.96429|2018-05-31 22:36:09.96429
NCT01357733|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2018-03-30|2011-05-19|2011-05-23|Estimate|||||||2018-03-30|2018-04-03|Actual|March 2, 2012|Actual|2012-03-02|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients|Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma|Recruiting||N/A|130|Anticipated|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 22:36:10.035261|2018-05-31 22:36:10.035261
NCT01357720|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|2013-03-27||2013-08-29|2011-05-20|2011-05-23|Estimate|2013-03-27|2013-05-22|Estimate||||2013-08-29|2013-09-09|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination|A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age|Completed||Phase 4|400|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 22:36:10.143291|2018-05-31 22:36:10.143291
NCT01357707|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2018-02-08|2011-05-20|2011-05-23|Estimate|||||||2018-02-08|2018-02-12|Actual|July 2010||2010-07-31|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Clinical-genetic Investigations in Children With Early Infantile Epilepsies|Clinical-genetic Investigations in Children With Early Infantile Epilepsies|Completed|||75|Actual|Charite University, Berlin, Germany|||1||f||||f||||||Samples With DNA|"~     DNA isolated from blood cells or from saliva~   "|||2018-05-31 22:36:10.425267|2018-05-31 22:36:10.425267
NCT01357694|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2015-01-23|2011-05-19|2011-05-23|Estimate|||||||2015-01-23|2015-01-26|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|February 2013|Actual|2013-02-28||Interventional|BRIA||BRIA - Bridging Intervention in Anesthesiology|Open Monocentric Randomized Clinical Trial on the Efficacy of the Psychotherapeutic Bridging Intervention in Anesthesiology (BRIA)|Completed||N/A|220|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:36:10.593033|2018-05-31 22:36:10.593033
NCT01357668|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2018-05-01|2011-05-20|2011-05-23|Estimate|||||||2018-05-01|2018-05-02|Actual|January 31, 2013|Actual|2013-01-31|May 2018|2018-05-31|December 31, 2029|Anticipated|2029-12-31|December 31, 2029|Anticipated|2029-12-31||Observational|||An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis|An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis|Recruiting|||900|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:36:10.828135|2018-05-31 22:36:10.828135
NCT01357655|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2017-01-24||2017-01-24|2011-05-19|2011-05-23|Estimate|2017-01-24|2017-03-14|Actual||||2017-01-24|2017-03-14|Actual|September 2011||2011-09-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||All Treated Participants|Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)|An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML).|Terminated||Phase 2|70|Actual|Bristol-Myers Squibb|No recommended phase 2 dose of the SMO antagonist was determined (in a separate trial). It was decided to discontinue enrollment and end this trial early. The decision was not made due to any new safety signals for dasatinib or the SMO antagonist.|2||"No participants enrolled in this trial could receive the SMO antagonist as a recommended phase~   2 dose was not determined by a different, concurrently-run trial."|f||||f||||||||||2018-05-31 22:36:11.16358|2018-05-31 22:36:11.16358
NCT01357642|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19||2016-02-11|2016-02-11|2011-05-20|2011-05-23|Estimate||||2016-02-11|2016-03-11|Estimate|2016-02-11|2016-03-11|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients|Epinephrine Inhalation Aerosol USP, an HFA-MDI: Clinical Study-C For Evaluation Of Efficacy And Safety In Asthma Patients|Completed||Phase 3|373|Actual|Amphastar Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 22:36:11.617935|2018-05-31 22:36:11.617935
NCT01357629|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-12-10|2011-05-20|2011-05-23|Estimate|||||||2013-12-10|2013-12-11|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Observational|||Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease|Observational Follow-up Extension Study to Evaluate Long-term Safety and Tolerability of Immunizations With AFFITOPE AD02 Applied During AFFiRiS002 and AFF004A in Patients With Alzheimer's Disease|Terminated|||11|Actual|Affiris AG||||"The Study could not be done for every potential participant as planned in the protocol for~   organizational reasons."|f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:36:11.74786|2018-05-31 22:36:11.74786
NCT01357616|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2014-01-30||2014-03-13|2011-05-19|2011-05-20|Estimate|2014-01-30|2014-03-13|Estimate||||2014-03-13|2014-04-10|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||This reporting group includes all subjects who received study medication, satisfied pre-randomization inclusion/exclusion criteria and completed at least 1 scheduled on-therapy study visit.|Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension|Comparison of Efficacy and Safety of Brinzolamide/Timolol Fixed Combination (AZARGA™) vs Brinzolamide (AZOPT®) and Timolol in Chinese Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|328|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:36:11.818883|2018-05-31 22:36:11.818883
NCT01357603|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2013-01-24|2011-05-18|2011-05-20|Estimate|||||||2013-01-24|2013-01-25|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM|A Randomized, Double-blind, Two Period, Cross Over Glucose Clamp Study to Test for Bioeqivalence Between Two Long Acting Insulin Analogs-Wockhardt's Glaritus™ (Insulin Glargine) and Lantus (Insulin Glargine) in Subjects With Type 1 Diabetes|Completed||Phase 1|111|Actual|Wockhardt||2|||f||||f||||||||||2018-05-31 22:36:12.05526|2018-05-31 22:36:12.05526
NCT01357590|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-03-01|2011-05-19|2011-05-20|Estimate|||||||2012-03-01|2012-03-02|Estimate||||March 2012|2012-03-31||||||||Interventional|||Evaluation of Thoraflex in the Treatment of Aneurysm or Penetrating Ulcer of the Descending Thoracic Aorta|Evaluation of the Vascutek Ltd. Thoracic Endovascular Stent Graft System (ThoraflexTM)in the Treatment of Aneurysm or Penetrating Ulcer of the Descending Thoracic Aorta|Withdrawn||N/A|0|Actual|Vascutek Ltd.|||||f||||t||||||||||2018-05-31 22:36:12.122902|2018-05-31 22:36:12.122902
NCT01357577|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2018-05-09|2011-05-18|2011-05-20|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 1, 2013|Actual|2013-01-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|October 31, 2017|Actual|2017-10-31||Interventional|CBT||Cognitive Behavioral Therapy (CBT) for PTSD in Veterans With Co-Occurring SUDs|CBT for PTSD in Veterans With Co-Occurring Substance Use Disorders|Active, not recruiting||N/A|129|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 22:36:12.315241|2018-05-31 22:36:12.315241
NCT01357564|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2017-01-04|2011-05-18|2011-05-20|Estimate|||||||2017-01-04|2017-01-06|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|June 2016|Actual|2016-06-30||Interventional|||Tailored Activity Program-VA|Nonpharmacologic Management of Challenging Behaviors in Veterans With Dementia|Active, not recruiting||Phase 1|160|Actual|VA Office of Research and Development||1|||f||||t||||||||No||2018-05-31 22:36:12.391706|2018-05-31 22:36:12.391706
NCT01357551|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2016-09-13||2016-09-13|2011-05-18|2011-05-20|Estimate|2016-09-13|2016-11-02|Estimate||||2016-09-13|2016-11-02|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MAINTAIN||Maintenance After Initiation of Nutrition TrAINing|Maintenance After Initiation of Nutrition TrAINing (MAINTAIN)|Completed||N/A|222|Actual|VA Office of Research and Development|May not generalize to other populations; relatively short length of follow-up; use of self-reported secondary outcome measures|2|||f||||f||||||||||2018-05-31 22:36:12.487205|2018-05-31 22:36:12.487205
NCT01357538|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis|Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis - a Multi-centre, Randomised, Double-masked, Parallel-group, Phase IV Comparison|Completed||Phase 4|197|Actual|Ursapharm Arzneimittel GmbH||2|||f||||f||||||||||2018-05-31 22:36:13.010002|2018-05-31 22:36:13.010002
NCT01357525|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2018-01-25|2011-05-19|2011-05-20|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2011||2011-07-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Radiosurgery for Resected Pancreas|SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer|Recruiting||Phase 2|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:36:13.115254|2018-05-31 22:36:13.115254
NCT01357512|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2015-06-01||2017-10-25|2011-05-19|2011-05-20|Estimate|2015-06-01|2015-06-17|Estimate||||2017-10-25|2017-12-02|Actual|April 2011||2011-04-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|December 2014|Actual|2014-12-31||Interventional||Population with protocol violations excluded|Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer|Evaluation of Diagnostic Value of 3-T MRI in Suspected Prostate Cancer|Completed||N/A|130|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 22:36:13.21385|2018-05-31 22:36:13.21385
NCT01357499|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2016-11-15|2011-05-19|2011-05-20|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|REMOTE||Lower Leg Remote Ischemic Preconditioning in Elective Percutaneous Coronary Intervention (PCI)|Effects of Lower Leg Remote Ischemic Preconditioning in Combination With Electric Muscle Stimulation in Elective Coronary Artery Revascularisation|Withdrawn|||0|Actual|University Medicine Greifswald|||3|PI left center|f||||f||||||Samples Without DNA|"~     venous blood samples (10 ml) will be taken from the femoral vein of the preconditioned leg~     immediately before and after the preconditioning cycles.~      Also arterial blood samples (10 ml)will be taken immediately before and after the~     preconditioning cycle.~   "|||2018-05-31 22:36:13.419064|2018-05-31 22:36:13.419064
NCT01357486|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2017-04-28|2011-05-18|2011-05-20|Estimate|||||||2017-04-28|2017-05-01|Actual|November 14, 2011|Actual|2011-11-14|April 2017|2017-04-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|PRODIGE 21||Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis|Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis|Completed||Phase 2|160|Actual|University Hospital, Bordeaux||4|||f||||t||||||||||2018-05-31 22:36:13.509839|2018-05-31 22:36:13.509839
NCT01357473|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|November 2009||2009-11-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|February 2010|Actual|2010-02-28||Observational|||Stop Menstruation and Pregnancy Rates in Antagonist Protocol|Is Hormonal Exposure of Endometrium on the First Day After Menstruation Associated With the Probability of Pregnancy in Patients Treated With Rec-FSH/ GnRH Antagonist? A Prospective Trial|Completed|||90|Anticipated|Universitair Ziekenhuis Brussel|||||f||||f||||||||||2018-05-31 22:36:13.650299|2018-05-31 22:36:13.650299
NCT01357460|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency|Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency|Unknown status|Recruiting|Phase 2/Phase 3|25|Anticipated|Heidelberg University|||||f||||||||||||||2018-05-31 22:36:13.703967|2018-05-31 22:36:13.703967
NCT01357447|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2012-03-29|2011-05-19|2011-05-20|Estimate|||||||2012-03-29|2012-04-02|Estimate|May 2011||2011-05-31|March 2012|2012-03-31||||May 2012|Anticipated|2012-05-31||Interventional|||Pulmozyme for Sjogren's Associated Cough|A Double-blind, Placebo-controlled Cross-over Trial of Pulmozyme for Sjogren's Associated Cough|Withdrawn||Phase 1|0|Actual|UConn Health||2||No patients enrolled.|f||||f||||||||||2018-05-31 22:36:13.781683|2018-05-31 22:36:13.781683
NCT01357434|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-06-23|2011-05-19|2011-05-20|Estimate|||||||2011-06-23|2011-06-27|Estimate|May 2011||2011-05-31|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Observational|||Comparing Calories at Fast Food Restaurants|Rating Fast Food on Healthiness|Completed|||97|Actual|University of California, Los Angeles|||1||f||||f||||||||||2018-05-31 22:36:13.85128|2018-05-31 22:36:13.85128
NCT01357421|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2013-06-04|2011-05-18|2011-05-20|Estimate|||||||2013-06-04|2013-06-06|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of TT301 on Cytokine Levels Post Endotoxin Challenge|A Phase 1 Double-blind, Randomized, Placebo-controlled Study Evaluating the Effects of a Single Intravenous Dose of TT301 on LPS-induced Changes in Blood Cytokine Levels in Healthy Male Volunteers|Completed||Phase 1|18|Actual|Transition Therapeutics||2|||f||||f||||||||||2018-05-31 22:36:13.919664|2018-05-31 22:36:13.919664
NCT01357408|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2013-01-04|2011-05-19|2011-05-20|Estimate|||||||2013-01-04|2013-01-07|Estimate|May 2011||2011-05-31|January 2013|2013-01-31||||December 2012|Actual|2012-12-31||Observational|HF-RADAR||Heart Failure and Risk of Re-Admissions Determined by Abnormal REVEAL Parameters|Phase 4 Registry Study Will Evaluate the Ability of Cardiac Rhythm (Cardiac Compass) Data to Predict Future Cardiac Events in Heart Failure (HF) Patients Recently Discharged After a Hospitalization for Heart Failure Who Have or Plan to Have a Implanted Loop Recorder (ILR), Specifically, the Reveal XT Device.|Terminated|||40|Actual|Thomas Jefferson University|||1|enrollment futility|f||||f||||||||||2018-05-31 22:36:13.982562|2018-05-31 22:36:13.982562
NCT01357395|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17||2017-10-20|2017-10-20|2011-05-18|2011-05-20|Estimate||||2017-10-20|2017-10-24|Actual|2017-10-20|2017-10-24|Actual|May 2011||2011-05-31|October 2017|2017-10-31|May 28, 2012|Actual|2012-05-28|May 2012|Actual|2012-05-31||Interventional|ESCAPE||A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer|A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer Subjects Who Have Not Responded to Standard Treatment or Relapsed After Standard Treatment|Completed||Phase 2|23|Actual|Astex Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:36:14.037227|2018-05-31 22:36:14.037227
NCT01357382|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome|The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome|Unknown status|Not yet recruiting|Phase 4|72|Anticipated|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:36:14.118549|2018-05-31 22:36:14.118549
NCT01357369|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2016-04-19|2011-05-18|2011-05-20|Estimate|||||||2016-04-19|2016-04-21|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Study of Drug Concentration of Ondansetron and Cefazolin in Mothers and Neonates|Pharmacokinetics and Placental Transfer of Ondansetron and Cefazolin: A Preliminary Analysis|Completed|||20|Actual|Stanford University|||1||f||||||||||Samples Without DNA|"~     Blood samples for pharmacokinetics.~   "|||2018-05-31 22:36:14.189248|2018-05-31 22:36:14.189248
NCT01357356|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18||2015-11-23|2015-11-23|2011-05-19|2011-05-20|Estimate||||2015-11-23|2015-12-24|Estimate|2015-11-23|2015-12-24|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|October 2012|Actual|2012-10-31||Interventional|||Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia|Completed||Phase 2/Phase 3|816|Actual|Serenity Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 22:36:14.258971|2018-05-31 22:36:14.258971
NCT01357343|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-06-24|2011-05-18|2011-05-20|Estimate|||||||2015-06-24|2015-06-25|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Integrated Chiropractic and Acupuncture Treatment for Low Back Pain|Effect of an Integrative Approach of Chiropractic and Traditional Chinese Medicine Care on Low Back Pain: A Randomized Controlled Trial|Completed||Phase 2|103|Actual|Southern California University of Health Sciences||3|||f||||f||||||||||2018-05-31 22:36:14.404512|2018-05-31 22:36:14.404512
NCT01357330|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-03-31|2011-05-19|2011-05-20|Estimate|||||||2016-03-31|2016-04-01|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase 1 Dose Escalation Study of Combination Therapy With Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|18|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:36:14.506359|2018-05-31 22:36:14.506359
NCT01357317|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-06-11|2011-05-19|2011-05-20|Estimate|||||||2012-06-11|2012-06-12|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|March 2014|Anticipated|2014-03-31|October 2013|Anticipated|2013-10-31||Interventional|||Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction|Changes in Biochemical and Vascular Parameters w/Lanthanum Carbonate & Calcium Acetate Therapy Compared to Dietary Intervention in Pts w/Stage 3 & 4 Chronic Kidney Disease & Abnormal Phosphorus Homeostasis: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|120|Anticipated|Salem Veterans Affairs Medical Center||3|||f||||t||||||||||2018-05-31 22:36:14.598257|2018-05-31 22:36:14.598257
NCT01357304|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2012-11-23|2011-05-19|2011-05-20|Estimate|||||||2012-11-23|2012-11-27|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|10PAR||10 Prescriptions an Hour. Group Treatment and Physical Activity Referral in a Primary Health Care Setting|Randomized Controlled Trial of Group Treatment With Physical Activity Referral in a Primary Health Care Setting|Completed||N/A|105|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:36:14.728904|2018-05-31 22:36:14.728904
NCT01357291|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2018-04-06|2011-05-19|2011-05-20|Estimate|||||||2018-04-06|2018-04-10|Actual|March 2011|Actual|2011-03-31|April 2018|2018-04-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|RRP||Evaluating New Mexico's Recidivism Reduction Program|Evaluating New Mexico's Prison-Based Recidivism Reduction Program|Completed||N/A|159|Actual|Pepperdine University||2|||f||||f||||||||||2018-05-31 22:36:15.087135|2018-05-31 22:36:15.087135
NCT01357278|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2015-10-14|2011-05-18|2011-05-20|Estimate|||||||2015-10-14|2015-10-16|Estimate|January 2007||2007-01-31|October 2015|2015-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ARO||Active Rehabilitation in Osteoporotic Patients|Effect of Active Rehabilitation on Risk Factors for Fall, Bone Mineral Density, and the Quality of Life in Osteoporotic Patients. A Randomized, Controlled Intervention Study|Completed||N/A|80|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:36:15.172691|2018-05-31 22:36:15.172691
NCT01357265|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2011-12-06|2011-05-19|2011-05-20|Estimate|||||||2011-12-06|2011-12-07|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects|A Phase II Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine, Formulation 2011/2012, When Administered to Adult and Elderly Subjects|Completed||Phase 2|125|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:36:15.300264|2018-05-31 22:36:15.300264
NCT01357252|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-04-02|2011-05-18|2011-05-20|Estimate|||||||2014-04-02|2014-04-03|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes|A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50mg qd to Placebo as add-on Therapy to Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy.|Completed||Phase 3|279|Actual|Novartis||2|||f||||t||||||||||2018-05-31 22:36:15.371523|2018-05-31 22:36:15.371523
NCT01357239|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2014-12-29||2015-05-10|2011-05-18|2011-05-20|Estimate|2015-05-10|2015-05-12|Estimate||||2015-05-10|2015-05-12|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AFQ056 in Adolescent Patients With Fragile X Syndrome|Completed||Phase 2|139|Actual|Novartis||4|||f||||||||||||||2018-05-31 22:36:15.498481|2018-05-31 22:36:15.498481
NCT01357226|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2012-04-25|2011-05-19|2011-05-20|Estimate|||||||2012-04-25|2012-04-26|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Using the Blood Pressure TRU in Clinical Settings: a Knowledge Translation Study|Using the Bp TRU in Clinical Settings: a Knowledge Translation Study|Completed|||50|Actual|North Toronto Primary Care Research Network|||1||f||||f||||||||||2018-05-31 22:36:16.420608|2018-05-31 22:36:16.420608
NCT01357213|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2014-12-04|2011-05-19|2011-05-20|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||Phase 1 PK Study of XOMA 3AB|A Phase I, Blinded, Placebo-controlled, Dose-escalation Study of the Safety and Pharmacokinetics of XOMA 3AB Administered Intravenously in Healthy Adults|Completed||Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 22:36:16.491605|2018-05-31 22:36:16.491605
NCT01357200|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-15|||2014-01-29|2011-05-18|2011-05-20|Estimate|||||||2014-01-29|2014-01-30|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Feeding Trial in the Obese Critical Care Population|Enteral Formula Tolerance in the Obese Critical Care Population|Completed|||26|Actual|Nestlé|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:36:16.562786|2018-05-31 22:36:16.562786
NCT01357187|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2015-03-16|2011-05-19|2011-05-20|Estimate|||||||2015-03-16|2015-03-17|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||An Evaluation of the Effect of the AmnioFix Amniotic Membrane Allograft in Patients Undergoing Posterior Instrumentation Removal|An Evaluation of the Effect of the AmnioFix™ Amniotic Membrane Allograft on Scar Tissue and Adhesions in Patients Undergoing Posterior Instrumentation Removal|Completed||N/A|5|Actual|MiMedx Group, Inc.||2|||f||||||||||||||2018-05-31 22:36:16.631474|2018-05-31 22:36:16.631474
NCT01357174|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2015-10-29|2011-05-18|2011-05-20|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||ROTATEQ™ Post-Marketing Surveillance in the Philippines|Protocol for ROTATEQ™ Post-Marketing Surveillance|Terminated|||915|Actual|Merck Sharp & Dohme Corp.|||1|"Merck Sharp & Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing~   surveillance (PMS) study"|f||||f||||||||||2018-05-31 22:36:16.704001|2018-05-31 22:36:16.704001
NCT01357161|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2017-08-08||2017-08-08|2011-05-19|2011-05-20|Estimate|2017-08-08|2017-09-07|Actual||||2017-08-08|2017-09-07|Actual|July 26, 2011|Actual|2011-07-26|August 2017|2017-08-31|August 8, 2016|Actual|2016-08-08|August 8, 2016|Actual|2016-08-08||Interventional||All enrolled participants|A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)|A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer|Completed||Phase 2|136|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 22:36:16.789333|2018-05-31 22:36:16.789333
NCT01357148|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2012-02-01||2015-08-07|2011-05-19|2011-05-20|Estimate|2012-02-01|2012-03-07|Estimate||||2015-08-07|2015-08-10|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)|Sitagliptin Phosphate/Metformin HCl (JANUMET®) Post Marketing Surveillance Protocol|Terminated|||143|Actual|Merck Sharp & Dohme Corp.|||1|"Completion of MK-0431A-235 was rendered unnecessary, as the local oversight authority accepted~   in its stead the results of another study [MK-0431-234]."|f||||f||||||||||2018-05-31 22:36:17.703713|2018-05-31 22:36:17.703713
NCT01357135|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2014-11-14||2017-05-04|2011-05-19|2011-05-20|Estimate|2014-12-04|2014-12-05|Estimate||||2017-05-04|2017-06-05|Actual|July 15, 2009|Actual|2009-07-15|May 2017|2017-05-31|August 31, 2013|Actual|2013-08-31|August 31, 2013|Actual|2013-08-31||Observational||Baseline gender data is missing for 8 participants in the Metformin + Sitagliptin group.|An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)|Observational Study of the Treatment and Follow-up of Patients With Type II Diabetes Receiving Bitherapy With or Without Sitagliptin (Januvia®/Xelevia®).|Completed|||3453|Actual|Merck Sharp & Dohme Corp.|The adverse events in this study were not systematically collected or assessed and therefore no direct comparison can be made between adverse events in the 3 study groups/arms.||3||f||||f||||||||||2018-05-31 22:36:17.908508|2018-05-31 22:36:17.908508
NCT01357122|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|July 2009||2009-07-31|May 2011|2011-05-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)|A Randomized, Observer-masked, Clinical Trial Comparing the Neusidl Corneal Inserter Corneal Transplant Technique to the Standard Forceps Insertion Technique for Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)|Unknown status|Active, not recruiting|Phase 4|100|Actual|Legacy Health System||2|||f||||t||||||||||2018-05-31 22:36:18.635|2018-05-31 22:36:18.635
NCT01357109|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-05-18|2011-05-18|2011-05-20|Estimate|||||||2011-05-18|2011-05-20|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|January 2011|Actual|2011-01-31|April 2010|Actual|2010-04-30||Interventional|BANDY||Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes|Effect of Bosentan on Macro- and Microvascular Function in Patients With Type 2 Diabetes|Completed||Phase 2|56|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:36:18.712911|2018-05-31 22:36:18.712911
NCT01357096|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|January 2011||2011-01-31|July 2010|2010-07-31||||January 2012|Anticipated|2012-01-31||Interventional|||Development and Efficacy Evaluation of Integrated Chronic Care and Health Promotion Model for Patients With Coronary Artery Disease in Taiwan||Unknown status|Recruiting|N/A|400|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||||||||||||2018-05-31 22:36:18.788839|2018-05-31 22:36:18.788839
NCT01357083|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|August 2010||2010-08-31|August 2009|2009-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||The Study of Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder|The Study of Morning and Nocturnal Serum Melatonin Rhythm Levels in Patients With Major Depressive Disorder|Completed|||92|Anticipated|Science & Research Islamic Azad University Branch Khozestan|||1||f||||t||||||||||2018-05-31 22:36:18.861086|2018-05-31 22:36:18.861086
NCT01357070|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2016-11-10|2011-05-19|2011-05-20|Estimate|||||||2016-11-10|2016-11-11|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Broccoli Sprout on Blood Levels of Sulforaphane to Reduce Responsiveness of Immune System|Does Broccoli Sprout Consumption Result in Plasma Sulforaphane Levels That Can Attenuate Leukocyte Activation Ex-vivo in Healthy Human Volunteers?|Completed||N/A|6|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 22:36:18.952802|2018-05-31 22:36:18.952802
NCT01357057|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-12-27|2011-05-19|2011-05-20|Estimate|||||||2011-12-27|2011-12-29|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Observational|ABCSAH||Admission Bio-clinical Score to Predict One-year Outcomes in Coiled Subarachnoid Hemorrhage (SAH)|Biological Markers in Patients Presenting Aneurism Coiling for Subarachnoid Hemorrhage|Completed|||530|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||||||2018-05-31 22:36:19.014871|2018-05-31 22:36:19.014871
NCT01357044|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2014-10-08|2011-05-19|2011-05-20|Estimate|||||||2014-10-08|2014-10-09|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Plant Extracts on Semen Quality|An Extract of Pomegranate Fruit and Galangal Rhizome Increases the Numbers of Motile Sperm: A Prospective, Randomised, Controlled, Double-Blinded Trial|Completed||N/A|70|Actual|Horsens Hospital||2|||f||||f||||||||||2018-05-31 22:36:19.091456|2018-05-31 22:36:19.091456
NCT01357031|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2015-12-29|2011-05-19|2011-05-20|Estimate|||||||2015-12-29|2015-12-30|Estimate|May 2010||2010-05-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|EDUMAP||Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine|Double Blind Randomized Study Controlled by Placebo and Amitriptylin to Evaluate the Efficacy of Melatonin in the Preventive Treatment of Migraine|Completed||Phase 3|192|Actual|Hospital Israelita Albert Einstein||3|||f||||t||||||||||2018-05-31 22:36:19.147504|2018-05-31 22:36:19.147504
NCT01357018|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2014-02-19|2011-05-19|2011-05-20|Estimate|||||||2014-02-19|2014-02-20|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Observational|||Quality of Life in Chronic Arthritis|A Study on Quality of Life in Patients With Chronic Arthritis|Completed|||139|Actual|Far Eastern Memorial Hospital|||2||f||||f||||||||||2018-05-31 22:36:19.221459|2018-05-31 22:36:19.221459
NCT01357005|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|October 2010||2010-10-31|May 2011|2011-05-31||||December 2013|Anticipated|2013-12-31||Observational|||Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan|Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan|Unknown status|Recruiting||300|Anticipated|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 22:36:19.291527|2018-05-31 22:36:19.291527
NCT01356992|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2015-06-17|2011-05-19|2011-05-20|Estimate|||||||2015-06-17|2015-06-18|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|VECOR||Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation|A Multicenter, Randomized, Open-label, Non-inferiority Phase III Study, Between Low-Molecular Weight Heparins, Versa® (Enoxaparin - Eurofarma) and Clexane® (Enoxaparin - Sanofi-Aventis), in Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation.|Terminated||Phase 3|62|Actual|Eurofarma Laboratorios S.A.||2||Change in strategy regarding the product by the company|f||||f||||||||||2018-05-31 22:36:19.35236|2018-05-31 22:36:19.35236
NCT01356979|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2012-09-24|2011-05-18|2011-05-20|Estimate|||||||2012-09-24|2012-09-25|Estimate|February 2002||2002-02-28|September 2012|2012-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Observational|||Outcome of Patients Undiagnosed Under Medical Thoracoscopy|Outcome of Patients Who Could Not Have Been Diagnosed by Medical Thoracoscopy|Completed|||355|Anticipated|Eskisehir Osmangazi University|||1||f||||t||||||||||2018-05-31 22:36:19.432484|2018-05-31 22:36:19.432484
NCT01356966|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2015-05-11||2015-05-29|2011-05-19|2011-05-20|Estimate|2015-05-29|2015-06-01|Estimate||||2015-05-29|2015-06-01|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|EIRF|All subjects that were randomized in the study are included in baseline analysis.|Exercise Intolerance in Renal Failure|The Role of Neurovascular Dysfunction and Oxidative Stress in the Exercise Intolerance of Renal Failure|Completed||Phase 2|74|Actual|Emory University||2|||f||||f||||||||||2018-05-31 22:36:19.508312|2018-05-31 22:36:19.508312
NCT01356953|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|EIT2D||Exercise Intensity and Type 2 Diabetics|Effects of Exercise Intensity on 24-h Ambulatory Blood Pressure in Type 2 Diabetics|Completed||N/A|10|Actual|Catholic University of Brasília||1|||f||||t||||||||||2018-05-31 22:36:19.715175|2018-05-31 22:36:19.715175
NCT01356940|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2014-12-09||2015-04-08|2011-05-19|2011-05-20|Estimate|2015-04-08|2015-04-09|Estimate||||2015-04-08|2015-04-09|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis|A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis|Completed||Phase 4|43|Actual|Brown, Theodore R., M.D., MPH||2|||f||||f||||||||||2018-05-31 22:36:19.767027|2018-05-31 22:36:19.767027
NCT01356927|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2017-04-06|2011-05-19|2011-05-20|Estimate|||||||2017-04-06|2017-04-07|Actual|May 2011||2011-05-31|April 2017|2017-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|SaLMA||Same-day Long-acting Reversible Contraception for Medication Abortion|Etonogestrel Implant or Depot Medroxyprogesterone Acetate for Medication Abortion|Completed|||40|Actual|Boston University|||2||f||||f|f|f||||||No||2018-05-31 22:36:19.94602|2018-05-31 22:36:19.94602
NCT01356914|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15||2015-09-23|2015-09-23|2011-05-19|2011-05-20|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|May 2011||2011-05-31|September 2015|2015-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden|Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients With Paroxysmal Atrial Fibrillation and Permanent Pacemaker|Completed||Phase 2|20|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 22:36:20.111842|2018-05-31 22:36:20.111842
NCT01356901|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-07-03|2011-05-18|2011-05-20|Estimate|||||||2015-07-03|2015-07-07|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients|Persistence, Adherence and Clinical Effectiveness in Patients With Chronic Hepatitis B Viral Infection Treated With Entecavir in Real Life|Completed|||230|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 22:36:20.191087|2018-05-31 22:36:20.191087
NCT01356888|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2018-05-30|2011-05-19|2011-05-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 2011||2011-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2013|Actual|2013-07-31||Interventional|BIOFLOW-II||Study of the Orsiro Drug Eluting Stent System|BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With Single de Novo Coronary Artery Lesions - II|Active, not recruiting||N/A|452|Actual|Biotronik AG||2|||f||||t||||||||No||2018-05-31 22:36:20.25908|2018-05-31 22:36:20.25908
NCT01356875|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|September 2011||2011-09-30|April 2011|2011-04-30|January 2015|Anticipated|2015-01-31|September 2014|Anticipated|2014-09-30||Interventional|||Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy|Phase II Clinical Trial for Treatment of Myelodysplastic Syndromes Comparing Hydralazine / Ac.Valproico and Supportive Care in Patients Not Candidates, Refractory and / or Intolerant to Intensive Chemotherapy|Unknown status|Not yet recruiting|Phase 2|42|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 22:36:20.344089|2018-05-31 22:36:20.344089
NCT01356862|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2017-01-24|2011-05-19|2011-05-20|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|SOM 230||Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer|Evaluation of the Effect of Pasireotide LAR Administration in the Lymphocele Prevention After Axillary Node Dissection for Breast Cancer|Completed||Phase 2|91|Actual|Alliance Pour La Recherche en Cancerologie||2|||f||||t||||||||||2018-05-31 22:36:20.411851|2018-05-31 22:36:20.411851
NCT01356849|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19||2013-08-20|2013-08-20|2011-05-18|2011-05-20|Estimate||||2013-08-20|2013-08-28|Estimate|2013-08-20|2013-08-28|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|RADAR||Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor|RADAR: Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy|Completed||Phase 2|149|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 22:36:20.477895|2018-05-31 22:36:20.477895
NCT01356836|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-05-19|2011-05-19|2011-05-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||The Association Between Different Monocyte Subsets and Coronary Collateral Development||Completed|||105|Actual|Yuksek Ihtisas Hospital|||2||f||||t||||||||||2018-05-31 22:36:20.659226|2018-05-31 22:36:20.659226
NCT00765362|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2010-06-16||2011-05-10|2008-09-30|2008-10-02|Estimate|2011-03-21|2011-04-19|Estimate||||2011-05-10|2011-05-11|Estimate|January 2000||2000-01-31|May 2011|2011-05-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Mobile - Bearing Knee Study|Encore Mobile - Bearing Knee Study #200|Completed||Phase 3|419|Actual|Encore Medical, L.P.||1|||f||||f||||||||||2018-06-01 01:42:13.322487|2018-06-01 01:42:13.322487
NCT01356823|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2016-01-03|2011-05-17|2011-05-20|Estimate|||||||2016-01-03|2016-01-05|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|December 2011|Actual|2011-12-31||Interventional|||Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine|A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 25 Years|Completed||Phase 2|1600|Actual|Xiamen University||4|||f||||f||||||||||2018-05-31 22:36:20.734852|2018-05-31 22:36:20.734852
NCT01356810|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-20|2011-05-17|2011-05-20|Estimate|||||||2011-05-20|2011-05-23|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MAPDI||Prophylactic Environmental Management of Delirium|Manejo Ambiental Profilactico Del Delirium Intrahospitalario|Completed||N/A|287|Actual|Universidad de Valparaiso||2|||f||||f||||||||||2018-05-31 22:36:20.831781|2018-05-31 22:36:20.831781
NCT01356797|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-09-07|2011-05-18|2011-05-19|Estimate|||||||2011-09-07|2011-09-09|Estimate|May 2011||2011-05-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Selective Unilateral Spinal Anesthesia Versus Selective Sensory Spinal Anesthesia for Knee Arthroscopy Surgery|Selective Unilateral Spinal Anesthesia Versus Selective Sensory Spinal Anesthesia for Knee Arthroscopy Surgery|Completed||Phase 4|54|Actual|USP Hospital La Colina||2|||f||||t||||||||||2018-05-31 22:36:21.144007|2018-05-31 22:36:21.144007
NCT01356784|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-04-22|2011-05-18|2011-05-19|Estimate|||||||2014-04-22|2014-04-24|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|July 2013|Actual|2013-07-31||Interventional|||"Returning to Work. Efficacy of Tailored Physical Activity or Chronic Pain Self-management Program in Sicklisted Citizens With Chronic Musculoskeletal Pain"|"Efficacy of Tailored Physical Activity or Chronic Pain Self-management Program on Returning to Work: a Randomized Controlled Trial in Sicklisted Citizens With Chronic Pain Related to the Spine or Upper Body"|Completed||Phase 1/Phase 2|141|Actual|University of Southern Denmark||3|||f||||t||||||||||2018-05-31 22:36:21.232102|2018-05-31 22:36:21.232102
NCT01356771|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2016-08-17|2011-05-17|2011-05-19|Estimate|||||||2016-08-17|2016-08-19|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PennSCAPE||Melanoma Risk Assessment & Tailored Intervention|Melanoma Risk Assessment and Skin Cancer Awareness, Prevention, and Education in a Primary Care Setting|Completed||N/A|323|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:36:21.306771|2018-05-31 22:36:21.306771
NCT01356758|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2015-12-18|2011-05-18|2011-05-19|Estimate|||||||2015-12-18|2015-12-21|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Observational|||Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents|Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents|Completed|||126|Actual|University of Aarhus|||4||f||||f||||||Samples With DNA|"~     blood and skin samples.~   "|Undecided||2018-05-31 22:36:21.372113|2018-05-31 22:36:21.372113
NCT01356745|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-05-10|2011-05-18|2011-05-19|Estimate|||||||2017-05-10|2017-05-12|Actual|February 2010||2010-02-28|May 2017|2017-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|MEOPA||Efficacy of Premixed Nitrous Oxide and Oxygen in Patient With Out-of-hospital Moderate Acute Pain|Efficacy of Premixed Nitrous Oxide and Oxygen in Patient With Out-of-hospital Moderate Acute Pain: a Randomized Double-blind Study|Completed||Phase 4|60|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 22:36:21.438753|2018-05-31 22:36:21.438753
NCT01356732|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2017-05-10|2011-05-17|2011-05-19|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2010||2010-01-31|May 2017|2017-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|REANURSUF||Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients|Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients.|Completed||Phase 4|25|Actual|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 22:36:21.509438|2018-05-31 22:36:21.509438
NCT01356719|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 2011||2011-07-31|May 2011|2011-05-31|February 2012|Anticipated|2012-02-29|November 2011|Anticipated|2011-11-30||Observational|||Scoring Method for Describing the Position of a Tracheostomy Tube|LUNAR Study - Develop and Validate a Bedside Scoring Method for Describing the Position and Orientation of a Tracheostomy Tube Tip When Viewed Endoscopically From a Standardised Position|Unknown status|Not yet recruiting||20|Anticipated|Manchester University NHS Foundation Trust|||||f||||f||||||||||2018-05-31 22:36:21.567371|2018-05-31 22:36:21.567371
NCT01356706|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-07-01|2011-05-17|2011-05-19|Estimate|||||||2012-07-01|2012-07-03|Estimate|October 2002||2002-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|December 2008|Actual|2008-12-31||Observational|||Minimally Invasive Liver Surgery for Metastases From Colorectal Cancer: Oncologic Outcome and Prognostic Factors||Completed|||274|Actual|University Hospital, Gasthuisberg|||1||f||||f||||||Samples With DNA|"~     Tissue samples for histopathology diagnosis & staging~   "|||2018-05-31 22:36:21.71293|2018-05-31 22:36:21.71293
NCT01356693|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-06-27|2011-05-18|2011-05-19|Estimate|||||||2011-06-27|2011-06-28|Estimate|June 2011||2011-06-30|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|November 2011|Anticipated|2011-11-30||Interventional|BROMETOSS||Bromelin, a Compound Prepared With Ananas Comocus Extract and Honey, for Acute Cough|"Randomized,Double-blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of the Phytotherapic Compound Bromelin on Acute Irritative Cough"|Unknown status|Recruiting|Phase 4|102|Anticipated|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 22:36:21.773905|2018-05-31 22:36:21.773905
NCT01356680|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2017-05-02|2011-05-17|2011-05-19|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2011||2011-12-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||HD17 for Intermediate Stage Hodgkin Lymphoma|HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma|Active, not recruiting||Phase 3|1100|Actual|University of Cologne||2|||f||||t||||||||||2018-05-31 22:36:21.870894|2018-05-31 22:36:21.870894
NCT01356667|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2014-05-19||2016-01-26|2011-05-17|2011-05-19|Estimate|2014-12-04|2014-12-12|Estimate||||2016-01-26|2016-02-26|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Drum-Assisted Therapy for Native Americans|Drum-Assisted Recovery Therapy for Native Americans|Terminated||Phase 1|10|Actual|University of California, Los Angeles||2||Study period is over and recruitment was stopped due to time constraints.|f||||t||||||||||2018-05-31 22:36:21.956334|2018-05-31 22:36:21.956334
NCT01356654|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Transcranial Direct Current Stimulation in Stroke Rehabilitation|The Use of Transcranial Direct Current Stimulation in the Recovery of Postural Control in Stroke|Unknown status|Recruiting|N/A|34|Anticipated|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 22:36:22.157279|2018-05-31 22:36:22.157279
NCT01356641|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2017-01-12|2011-05-18|2011-05-19|Estimate|||||||2017-01-12|2017-01-13|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Antibiotic Treatment Alone for Acute Simple Appendicitis in Children|Antibiotic Treatment Alone for Acute Simple Appendicitis in Children; a Prospective Cohort Study Part of the Antibiotic Versus Primary Appendectomy in Children (APAC) Trial|Completed||N/A|50|Actual|VU University of Amsterdam||2|||f||||t||||||||||2018-05-31 22:36:22.253265|2018-05-31 22:36:22.253265
NCT01356628|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2017-12-07||2018-01-12|2011-05-17|2011-05-19|Estimate|2017-12-07|2018-01-05|Actual||||2018-01-12|2018-02-08|Actual|May 25, 2011|Actual|2011-05-25|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|April 9, 2015|Actual|2015-04-09||Interventional|||A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer|A Phase II Study of PD-0332991 in Adult Patients With Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 2|23|Actual|Thomas Jefferson University||1|||f||||t|t|f||||||||2018-05-31 22:36:22.367275|2018-05-31 22:36:22.367275
NCT01356615|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Low Molecular Weight Heparin for Hemodialysis Anticoagulation|Low Molecular Weight Heparin (Enoxaparin Sodium) and Standard Unfractionated Heparin for Hemodialysis Anticoagulation|Completed||N/A|27|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:36:22.735396|2018-05-31 22:36:22.735396
NCT01356602|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2013-09-06||2013-12-10|2011-05-18|2011-05-19|Estimate|2013-12-10|2014-01-29|Estimate||||2013-12-10|2014-01-29|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients|A Randomized, Double-blind, Active-controlled Study of Canakinumab Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients|Completed||Phase 3|397|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:36:22.834969|2018-05-31 22:36:22.834969
NCT01356589|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2015-11-23||2017-06-13|2011-05-18|2011-05-19|Estimate|2015-11-23|2015-12-28|Estimate||||2017-06-13|2017-07-05|Actual|September 30, 2010|Actual|2010-09-30|May 2017|2017-05-31|July 31, 2012|Actual|2012-07-31|July 31, 2012|Actual|2012-07-31||Observational||Analysis population included all treated participants.|A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)|Retrospective Study on Intrapatient VAriabiLity of the Hemoglobin Levels in Anemic CKD Patients in Predialysis (Stage 3-4) and Dialysis (Stage 5) Treated With MIRCERA® (RIVAL Study)|Completed|||1288|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:36:24.246309|2018-05-31 22:36:24.246309
NCT01356576|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-02-06|2011-05-18|2011-05-19|Estimate|||||||2014-02-06|2014-02-07|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Effect of Hemodialysis Membranes on Platelet Count|Effect of Hemodialysis Membranes on Platelet Count|Completed|||99|Actual|Northwell Health|||||f||||f||||||||||2018-05-31 22:36:24.877196|2018-05-31 22:36:24.877196
NCT01356563|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-14|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2012|Anticipated|2012-05-31|December 2011|Anticipated|2011-12-31||Interventional|||Efficacy Study of Pharmacist Intervention on Medication-related Problems in Hemodialysis Patients|Effects of Pharmacist on Medication-related Problems in Hemodialysis Patients: a Randomized,Controlled, Double-blind Study|Unknown status|Recruiting|N/A|150|Anticipated|Sin-Lau Hospital||2|||f||||t||||||||||2018-05-31 22:36:25.110705|2018-05-31 22:36:25.110705
NCT01356550|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2016-11-01|2011-05-18|2011-05-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838||Completed||Phase 1|35|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:36:25.47979|2018-05-31 22:36:25.47979
NCT01356537|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-02-01|2011-05-17|2011-05-19|Estimate|||||||2017-02-01|2017-02-03|Estimate|April 2011||2011-04-30|February 2017|2017-02-28|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|||Home Therapy With VPRIV in Gaucher's Disease|Non Interventional Study of VPRIV® (Velaglucerase Alfa) Home Therapy in Patients With Gaucher's Disease|Recruiting|||50|Anticipated|Shire|||1||f||||f||||||||||2018-05-31 22:36:25.716529|2018-05-31 22:36:25.716529
NCT01356524|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 2011||2011-07-31|May 2011|2011-05-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Relationship Between Mid-luteal Serum Progesterone Levels to Pregnancy Rates in Assisted Reproductive Techniques (ART)||Unknown status|Not yet recruiting|N/A|160|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 22:36:25.813258|2018-05-31 22:36:25.813258
NCT01356511|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2016-04-18|2011-05-18|2011-05-19|Estimate|||||||2016-04-18|2016-04-20|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial|Completed||Phase 4|261|Actual|Shandong University||2|||f||||t||||||||No||2018-05-31 22:36:25.90574|2018-05-31 22:36:25.90574
NCT01356498|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2011-08-05||2011-10-28|2011-05-18|2011-05-19|Estimate|2011-10-28|2011-12-02|Estimate||||2011-10-28|2011-12-02|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout|Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout|Completed||Phase 3|151|Actual|Savient Pharmaceuticals||3|||f||||f||||||||||2018-05-31 22:36:26.270417|2018-05-31 22:36:26.270417
NCT01356485|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-08-15|2011-05-17|2011-05-19|Estimate|||||||2013-08-15|2013-08-19|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of MP4CO in Adult Sickle Cell Patients|A Multi-center, Randomized, Double Blind, Dose Escalation Safety Study of MP4CO in Clinically Stable Adult Sickle Cell Patients|Completed||Phase 1|32|Actual|Sangart||2|||f||||t||||||||||2018-05-31 22:36:27.885563|2018-05-31 22:36:27.885563
NCT01356472|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2011||2011-06-30|April 2011|2011-04-30||||June 2013|Anticipated|2013-06-30||Interventional|||Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia|Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Vitro and in Ventilator-associated Pneumonia|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Ruijin Hospital||1|||f||||t||||||||||2018-05-31 22:36:27.978181|2018-05-31 22:36:27.978181
NCT01356459|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2015-05-08|2011-05-18|2011-05-19|Estimate|||||||2015-05-08|2015-05-12|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Pressure Ulcer Prevention in Intensive Care Unit (ICU)|A Prospective Randomised Controlled Trial of the Effectiveness of Absorbent Silicone Self Adherent Dressings in the Prevention of Sacral and Heel Pressure Ulcers in Trauma and Critically Ill ED/ICU Patients|Completed||N/A|440|Actual|Melbourne Health||2|||f||||t||||||||||2018-05-31 22:36:28.052657|2018-05-31 22:36:28.052657
NCT01356446|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2015-05-04|2011-05-18|2011-05-19|Estimate|||||||2015-05-04|2015-05-05|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Checklist Application and Mortality|Impact of the Surgical Checklist on 30-day and 90-day Mortality in Elective Non-cardiac Surgery|Withdrawn||N/A|0|Actual|Regional Hospital of Bolzano||2|||f||||t||||||||||2018-05-31 22:36:28.262525|2018-05-31 22:36:28.262525
NCT01356433|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2012-09-19|2011-05-18|2011-05-19|Estimate|||||||2012-09-19|2012-09-21|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients|Effect of Oral Vitamin C on The Inflammatory Biomarkers in Hemodialysis|Completed||Phase 4|128|Actual|Peking University First Hospital||2|||f||||t||||||||||2018-05-31 22:36:28.362702|2018-05-31 22:36:28.362702
NCT01356420|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2012-09-18|2011-05-18|2011-05-19|Estimate|||||||2012-09-18|2012-09-20|Estimate|January 2011||2011-01-31|September 2012|2012-09-30||||January 2016|Anticipated|2016-01-31||Interventional|STAIR-SLOS||Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome|Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation|Unknown status|Recruiting|N/A|100|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-05-31 22:36:28.441901|2018-05-31 22:36:28.441901
NCT01356407|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|2012-09-19||2012-12-17|2011-05-18|2011-05-19|Estimate|2012-12-17|2013-01-28|Estimate||||2012-12-17|2013-01-28|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Investigation of PICOPREP and PEG-ELS for Bowel Preparation for Colonoscopy|A Multi-center, Randomized, Single-blind Clinical Study of the Efficacy and Safety of PICOPREP and Polyethylene Glycol-electrolyte 4000 Powder for Oral Solution (PEG-ELS) for the Bowel Preparation Prior Colonoscopy|Completed||Phase 3|300|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:36:28.634834|2018-05-31 22:36:28.634834
NCT01356394|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Weight Loss Improves Renal Hemodynamics|Weight Loss Improves Renal Hemodynamics in Patients With Metabolic Syndrome|Completed||Phase 4|58|Actual|Nucleus of Education Interdisciplinary Research and Treatment in Nephrology|||||f||||f||||||||||2018-05-31 22:36:29.01741|2018-05-31 22:36:29.01741
NCT01356381|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-08-29|2011-05-18|2011-05-19|Estimate|||||||2013-08-29|2013-08-30|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes|A Single-center,Double-blind,Randomised,Placebo-controlled,Parallel-group Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin on Insulin Sensitivity and Its Underlying Mechanism in Patients With T2DM Treated With Metformin|Completed||Phase 4|43|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:36:29.100312|2018-05-31 22:36:29.100312
NCT01356368|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2014-01-19|2011-05-18|2011-05-19|Estimate|||||||2014-01-19|2014-01-22|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Customizing||Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer|A Pilot Study of Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer Based on Molecular Markers|Terminated||Phase 2|3|Actual|National Guard Health Affairs||1||slow accrual rate|f||||f||||||||||2018-05-31 22:36:29.169098|2018-05-31 22:36:29.169098
NCT01356355|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-01-04|2011-05-18|2011-05-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Study of Herbmed Plus in Ureteral Stent Discomfort|Double Blind Exploratory Three Arm Randomized Trial to Evaluate the Safety and Efficacy of Herbal Preparation 'Herbmed Plus' in Ureteral Stent Discomfort|Completed||Phase 2|140|Actual|Amai Charitable Trust||3|||f||||f||||||||||2018-05-31 22:36:29.24413|2018-05-31 22:36:29.24413
NCT01356342|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2012-12-27|2011-05-18|2011-05-19|Estimate|||||||2012-12-27|2012-12-28|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old||Completed||Phase 4|181|Actual|Adimmune Corporation||3|||f||||||||||||||2018-05-31 22:36:29.353042|2018-05-31 22:36:29.353042
NCT01356329|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2016-05-12|2011-05-17|2011-05-19|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|Lovenox||Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients|A Randomized, Controlled, Open Label Study of the Efficacy and Safety of the Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin) Versus HeparinTM (Unfractionated Heparin) for Prevention of Venous Thromboembolism (VTE) in Gynecologic Oncology Patients|Suspended||Phase 3|150|Anticipated|National Guard Health Affairs||2||Difficulty in enrolling patients|f||||f||||||||||2018-05-31 22:36:29.417124|2018-05-31 22:36:29.417124
NCT01356316|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-12-27|2011-05-18|2011-05-19|Estimate|||||||2012-12-27|2012-12-28|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Interventional|||Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects||Completed||Phase 4|120|Actual|Adimmune Corporation||1|||f||||||||||||||2018-05-31 22:36:29.482184|2018-05-31 22:36:29.482184
NCT01356303|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2016-05-12|2011-05-17|2011-05-19|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|TAXIS01||Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer|A Phase II Study of Docetaxel Combined With Cisplatin as the First Line Chemotherapy in Patients With Metastatic Non-small Cell Lung Cancer|Suspended||Phase 2|50|Anticipated|National Guard Health Affairs||1||Difficulty in enrolling patients|f||||f||||||||||2018-05-31 22:36:29.543255|2018-05-31 22:36:29.543255
NCT01356290|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-05-15|2011-05-18|2011-05-19|Estimate|||||||2017-05-15|2017-05-16|Actual|April 2014||2014-04-30|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|MEMMAT||Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma|A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma|Recruiting||Phase 2|40|Anticipated|Medical University of Vienna|||||f||||t||||||||||2018-05-31 22:36:29.635872|2018-05-31 22:36:29.635872
NCT01356277|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2016-06-27|2011-05-18|2011-05-19|Estimate|||||||2016-06-27|2016-06-28|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TAKE-IT||Intervention to Improve Adherence in Teen Kidney Transplant|TAKE-IT: Teen Adherence in Kidney Transplant Effectiveness of Intervention Trial|Completed||Phase 3|170|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 22:36:29.80215|2018-05-31 22:36:29.80215
NCT01356264|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2015-09-26|2011-05-18|2011-05-19|Estimate|||||||2015-09-26|2015-09-29|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Multimodal Prehabilitation for Colorectal Surgery|Multimodal Prehabilitation to Enhance Functional Recovery After Colorectal Surgery: a Randomized Controlled Trial|Completed||Phase 2|89|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:36:29.930524|2018-05-31 22:36:29.930524
NCT01356251|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2018-05-07|2011-05-18|2011-05-19|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2011|Actual|2011-05-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma|Mesothelioma From a Patient Perspective: A Survey of Psychosocial Needs and Exploration of Online Support for Patients|Active, not recruiting||N/A|107|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 22:36:30.02633|2018-05-31 22:36:30.02633
NCT01356238|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Application of Two Different Synthetic Sequential Media for the Human IVF-Embryo Transfer (IVF-ET) Program|Application of Two Different Synthetic Sequential Media for the Human IVF-ET Program|Completed||N/A|360|Actual|Maria Fertility Hospital||2|||f||||t||||||||||2018-05-31 22:36:30.092251|2018-05-31 22:36:30.092251
NCT01356225|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-02-07|2011-05-18|2011-05-19|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2004||2004-02-29|February 2017|2017-02-28||||March 2004|Actual|2004-03-31||Interventional|||A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery|A Randomized, Double-blind, Placebo-controlled, Parallel, Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery|Completed||Phase 2|80|Actual|Egalet Ltd||2|||f||||f||||||||||2018-05-31 22:36:30.173651|2018-05-31 22:36:30.173651
NCT01356212|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-02-06|2011-05-17|2011-05-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2002||2002-09-30|February 2017|2017-02-28|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device|Scintigraphic Assessment of Nasal Deposition and Clearance of 99mTc DTPA Ketorolac Solution Administered Using the Valois Nasal Spray Device|Completed||Phase 1|13|Actual|Egalet Ltd||3|||||||||||||||||2018-05-31 22:36:30.262198|2018-05-31 22:36:30.262198
NCT01356199|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2014-03-17|2011-05-18|2011-05-19|Estimate|||||||2014-03-17|2014-03-18|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Artronat on the Quality of Life of Patient With Osteoarthritis|Effet du complément Alimentaire ARTRONAT(R) Sur la réduction de la Gonalgie Chez Des Sujets Arthrosiques|Completed||N/A|7|Actual|Lescuyer Laboratory||2|||f||||f||||||||||2018-05-31 22:36:30.324439|2018-05-31 22:36:30.324439
NCT01356186|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2018-04-02|2011-05-18|2011-05-19|Estimate|||||||2018-04-02|2018-04-03|Actual|July 2008||2008-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CDMRP||Pilot Trial of Inpatient Cognitive Therapy for the Prevention of Suicide in Military Personnel|Pilot Trial of Inpatient Cognitive Therapy for the Prevention of Suicide in Military Personnel With Acute Stress Disorder of Post Traumatic Stress Disorder|Active, not recruiting||N/A|50|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t||||||||No||2018-05-31 22:36:30.392189|2018-05-31 22:36:30.392189
NCT01356173|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2016-11-01|2011-05-18|2011-05-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma|An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma|Completed||Phase 1|10|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:36:30.463747|2018-05-31 22:36:30.463747
NCT01356160|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02||2013-11-26|2014-01-02|2011-05-18|2011-05-19|Estimate||||2013-11-26|2013-12-20|Estimate|2014-01-02|2014-02-03|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy With GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection|Completed||Phase 2|351|Actual|Gilead Sciences||2|||f||||||||||||||2018-05-31 22:36:30.526359|2018-05-31 22:36:30.526359
NCT01356147|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|2016-12-15||2017-05-18|2011-05-18|2011-05-19|Estimate|2016-12-15|2017-02-08|Estimate||||2017-05-18|2017-06-14|Actual|May 2011||2011-05-31|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|January 2015|Actual|2015-01-31||Interventional|PVAIN||Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)|Pilot Study of Dornase Alfa (Pulmozyme) Therapy for Acquired Ventilator Associated Infection in Preterm and Late Preterm Infants in the Neonatal Intensive Care Unit|Completed||Phase 4|11|Actual|Georgetown University||2|||f||||f||||||||Undecided||2018-05-31 22:36:30.8171|2018-05-31 22:36:30.8171
NCT01356134|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-04-02|2011-05-17|2011-05-19|Estimate|||||||2015-04-02|2015-04-03|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)|Vascular Fundus Changes in Patients With High Probability of CCSVI (Chronic Cerebrospinal Venous Insufficiency)|Completed|||60|Actual|Genetic Disease Investigators|||2||f||||t||||||||||2018-05-31 22:36:31.02208|2018-05-31 22:36:31.02208
NCT01356121|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-17|2011-05-17|2011-05-19|Estimate|||||||2011-05-17|2011-05-19|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics|Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics|Unknown status|Recruiting|Phase 4|120|Anticipated|Govind Ballabh Pant Hospital||3|||f||||t||||||||||2018-05-31 22:36:31.092922|2018-05-31 22:36:31.092922
NCT01355744|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-10-01|2011-05-17|2011-05-18|Estimate|||||||2013-10-01|2013-10-07|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|SSSB||Swiss Study on Spider Bites|Swiss Study on Spider Bites|Completed|||17|Actual|University of Zurich|||1||f||||f||||||None Retained|"~     Species of biting spider will be assessed if specimen is sent to us.~   "|||2018-05-31 22:36:33.633301|2018-05-31 22:36:33.633301
NCT01356108|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-04-11|2011-05-18|2011-05-19|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2011|Actual|2011-01-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|July 2013|Actual|2013-07-31||Observational|PREMIER||Pulmonic Valve REplacement Multi-discIpline EMEA Registry|Implantation of the SAPIEN™ Transcatheter Heart Valve (THV) in the Pulmonic Position|Active, not recruiting|||127|Actual|Edwards Lifesciences|||||f||||t|f|t|f|f|t|||||2018-05-31 22:36:31.179692|2018-05-31 22:36:31.179692
NCT01356095|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-08-28|2011-05-18|2011-05-19|Estimate|||||||2012-08-28|2012-08-29|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi|A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi|Completed||N/A|28|Actual|Dignitas International||3|||f||||f||||||||||2018-05-31 22:36:31.26524|2018-05-31 22:36:31.26524
NCT01356082|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-05-01|2011-05-18|2011-05-19|Estimate|||||||2012-05-01|2012-05-02|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||CNAP™ Monitor Study|Accuracy of the CNAP™ Monitor in Providing Beat-to-beat Non-invasive Blood Pressure Readings|Completed|||46|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 22:36:31.40433|2018-05-31 22:36:31.40433
NCT01356069|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2004||2004-01-31|May 2011|2011-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|HUMSH||Efficacy of Time-limited Psychodynamic Psychotherapy and Informed Clinical Management in BPD High MHS Users|Sequential Brief Adlerian Psychodynamic Psychotherapy in Heavy Users of a Mental Health Service With Borderline Personality Disorder: a Two Years Follow-up Preliminary Randomized Study.|Completed||N/A|35|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 22:36:31.471523|2018-05-31 22:36:31.471523
NCT01356056|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2013-03-11|2011-05-18|2011-05-19|Estimate|||||||2013-03-11|2013-03-12|Estimate|May 2011||2011-05-31|March 2013|2013-03-31||||December 2011|Actual|2011-12-31||Observational|||Tele-diagnostics for Remote Parkinson's Monitoring||Completed|||12|Actual|Great Lakes NeuroTechnologies Inc.|||2||f||||||||||||||2018-05-31 22:36:31.544997|2018-05-31 22:36:31.544997
NCT01356043|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-08-29|2011-05-18|2011-05-19|Estimate|||||||2011-08-29|2011-08-30|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||CKD-828 Drug Interaction Study (S-amlodipine)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate the Pharmacokinetic Drug Interaction and Safety of S-amlodipine Between Free Combination of S-amlodipine and Telmisartan and S-amlodipine Monotherapy in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:36:31.609813|2018-05-31 22:36:31.609813
NCT01356030|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2013-07-08|2011-05-18|2011-05-19|Estimate|||||||2013-07-08|2013-07-09|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer|Prospective Comparison of EUS-guided FNA and ERCP Tissue Sampling for the Diagnosis of Suspected Pancreato-biliary Neoplasms|Completed||N/A|51|Actual|California Pacific Medical Center Research Institute||2|||f||||f||||||||||2018-05-31 22:36:31.704938|2018-05-31 22:36:31.704938
NCT01356017|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-09-04|2011-05-18|2011-05-19|Estimate|||||||2011-09-04|2011-09-07|Estimate|June 2011||2011-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||CKD-828 Drug Interaction Study (Telmisartan)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Telmisartan Between Free Combination of Telmisartan and S-amlodipine and Telmisartan Monotherapy in Healthy Male Volunteers|Completed||Phase 1|32|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:36:31.795804|2018-05-31 22:36:31.795804
NCT01356004|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-05-18|2011-05-18|2011-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis|Live Attenuated Varicella Vaccine: A New Effective Adjuvant Weapon in the Battlefield Against Severe Resistant Psoriasis, a Randomized Controlled Trial|Completed||Phase 4|35|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 22:36:31.870729|2018-05-31 22:36:31.870729
NCT01355991|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-10-22|2011-05-17|2011-05-19|Estimate|||||||2015-10-22|2015-10-23|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31||Interventional|||Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI|Acute and Chronic Effects of an Anticholinergic Agent or a Long-Acting Beta 2 Agonist on Levels of Exhaled Nitric Oxide and Pulmonary Function in Persons With Tetraplegia|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 22:36:31.952575|2018-05-31 22:36:31.952575
NCT01355978|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|2015-03-07||2016-08-18|2011-05-18|2011-05-19|Estimate|2016-08-18|2016-10-12|Estimate||||2016-08-18|2016-10-12|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|PRIDE|Adult subjects with chronic obstructive lung disease.|Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)|Acceptability, Comfort, and Exercise Tolerance Using a Non-invasive Ventilation System in Patients With Moderate-to-Severe COPD (PRIDE)|Completed||N/A|22|Actual|Breathe Technologies, Inc.||1|||f||||f||||||||||2018-05-31 22:36:32.048776|2018-05-31 22:36:32.048776
NCT01355965|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-09-16|2011-05-18|2011-05-19|Estimate|||||||2017-09-16|2017-09-19|Actual|May 2011||2011-05-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Autologous Redirected RNA Meso-CIR T Cells|Phase 1 Clinical Trial of Autologous Mesothelin Re-Directed T Cells Administered Intravenously in Patients With Progressive Malignant Pleural Mesothelioma|Completed||Phase 1|18|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 22:36:32.253648|2018-05-31 22:36:32.253648
NCT01355952|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2015-11-04|2011-05-18|2011-05-19|Estimate|||||||2015-11-04|2015-11-05|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ALA||An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia|An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia|Completed||N/A|17|Actual|Yale University||1|||f||||f||||||||||2018-05-31 22:36:32.318134|2018-05-31 22:36:32.318134
NCT01355939|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2015-02-19|2011-05-18|2011-05-19|Estimate|||||||2015-02-19|2015-02-23|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Comparative Effectiveness Multicenter Trial for Adhesion Characteristics of Ventral Hernia Repair Mesh|A Prospective Multicenter Trial to Evaluate Adhesion Characteristics and Adhesiolysis-related Complications of Barrier-coated and Non-barrier-coated Intraperitoneal Mesh During Abdominal Re-exploration After Prior Ventral Hernia Repair|Completed|||173|Actual|Washington University School of Medicine|||4||f||||t||||||||||2018-05-31 22:36:32.396282|2018-05-31 22:36:32.396282
NCT01355926|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-10-03|2011-05-17|2011-05-18|Estimate|||||||2017-10-03|2017-10-04|Actual|May 2011|Actual|2011-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery|Flexible Fiber-based CO2 Laser Versus Monopolar Cautery for Resection of Benign, Pre-malignant And Malignant Oral Cavity Lesions: A Single Center Randomized Controlled Trial Assessing Pain and Quality of Life Following Surgery|Recruiting||N/A|68|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 22:36:32.514691|2018-05-31 22:36:32.514691
NCT01355913|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-10-24|2011-05-17|2011-05-18|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2008|Actual|2008-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2016|Actual|2016-10-31||Observational|||Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells|Screening and Genetic Monitoring of Patients With MDS Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells|Active, not recruiting|||300|Anticipated|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|||||f||||f||||||||||2018-05-31 22:36:32.592937|2018-05-31 22:36:32.592937
NCT01355900|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-03-02|2011-05-17|2011-05-18|Estimate|||||||2014-03-02|2014-03-04|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparison of Three Tourniquet Application Methods in Primary Total Knee Arthroplasty Surgery|Influence of the Intraoperative Tourniquet Application Method on the Perioperative Blood Loss, Frequency of Transfusion and Close Postoperative Outcomes in Primary Total Knee Arthroplasty Patients|Completed||N/A|120|Actual|Vilnius University||4|||f||||f||||||||||2018-05-31 22:36:32.660277|2018-05-31 22:36:32.660277
NCT01355887|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-17|2011-05-17|2011-05-18|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||A Trial to Compare Pringle Maneuver With Either Infrahepatic Inferior Vena Cava Clamping or Low Central Venous Pressure|A Prospective Randomized Comparative Trial to Compare Pringle Maneuver With Either Infrahepatic Inferior Vena Cava Clamping or Low Central Venous Pressure in Complex Liver Resections|Unknown status|Recruiting||192|Anticipated|Huazhong University of Science and Technology|||||f||||t|||||||"~     No biospecimens~   "|||2018-05-31 22:36:32.744332|2018-05-31 22:36:32.744332
NCT01355874|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-01-26|2011-05-17|2011-05-18|Estimate|||||||2014-01-26|2014-01-28|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|VEN309||Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Intra-Anal Application of Iferanserin (10 mg) as a 0.5% Ointment in Subjects With Symptomatic Internal Hemorrhoids|Terminated||Phase 3|403|Actual|Ventrus Biosciences, Inc||3||The primary endpoint was not met on the double blind data|f||||f||||||||||2018-05-31 22:36:32.811117|2018-05-31 22:36:32.811117
NCT01355861|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-06-25|2011-05-16|2011-05-18|Estimate|||||||2015-06-25|2015-06-26|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|REPAiRS||Resistance Exercise for the Prevention of Age-related Sarcopenia|Negative Work Exercise as a Novel Treatment for Sarcopenia in Older Men|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Project has been withdrawn from funding consideration|f||||f||||||||||2018-05-31 22:36:32.947321|2018-05-31 22:36:32.947321
NCT01355848|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2015-03-06|2011-05-17|2011-05-18|Estimate|||||||2015-03-06|2015-03-10|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Improving Care Provided to Patients Treated in a Level 1 Trauma Center Post-suicide Attempt|Improving Care Provided to Patients Treated in a Level 1 Trauma Center Post-suicide Attempt|Completed||Phase 1|40|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 22:36:33.009241|2018-05-31 22:36:33.009241
NCT01355835|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2012-08-07|2011-05-17|2011-05-18|Estimate|||||||2012-08-07|2012-08-08|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|STN/SNr||Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease|Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease: Design of a Two-armed Double-blind Cross-over Study|Completed||Phase 2|12|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 22:36:33.082267|2018-05-31 22:36:33.082267
NCT01355822|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-26|2011-05-16|2011-05-18|Estimate|||||||2011-05-26|2011-05-27|Estimate|April 2002||2002-04-30|May 2011|2011-05-31||||January 2008|Actual|2008-01-31||Interventional|||Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies|Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies: a Prospective Randomized Pilot Study|Completed||Phase 1/Phase 2|111|Actual|University of Jena||2|||f||||f||||||||||2018-05-31 22:36:33.145493|2018-05-31 22:36:33.145493
NCT01355809|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2014-08-08|2011-05-17|2011-05-18|Estimate|||||||2014-08-08|2014-08-11|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|rehabilitate||Six-Minute Walk Test Comparing Helium/Oxygen to Nitrogen/Oxygen for COPD Rehabilitation|Single Centre, Exploratory, Phase II, Cross-over, Randomised Trial, Evaluating the Effect of Spontaneously Breathing He/O2 65%/35% to Either Spontaneously Breathing N2/O2 65%35% or Non-Invasive Ventilated N2/O2 65%/35% on a 6 Minute Walk Test in Severe COPD Patients|Terminated||Phase 2|3|Actual|Air Liquide SA||3||Due to low recruitment rate the sponsor decided to discontinue the study.|f||||t||||||||||2018-05-31 22:36:33.316362|2018-05-31 22:36:33.316362
NCT01355796|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-10-25|2011-05-17|2011-05-18|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis|Randomized Cross Over Study of Inhaled Hypertonic Xylitol Versus Hypertonic Saline in Stable Subjects With Cystic Fibrosis|Completed||Phase 1/Phase 2|30|Anticipated|University of Iowa||2|||f||||t||||||||||2018-05-31 22:36:33.395825|2018-05-31 22:36:33.395825
NCT01355783|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2013-11-14|2011-05-17|2011-05-18|Estimate|||||||2013-11-14|2013-11-18|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma|A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma|Withdrawn||Phase 3|0|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:36:33.501332|2018-05-31 22:36:33.501332
NCT01355757|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-05-16|2011-05-17|2011-05-18|Estimate|||||||2014-05-16|2014-05-19|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Post-Operative Quality of Life Evaluation for Different Anesthesia Techniques for Arthroscopic Shoulder Surgery|Post-Operative Quality of Life Evaluation for Different Anesthesia Techniques for Arthroscopic Shoulder Surgery|Completed||Early Phase 1|70|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||||||||||||2018-05-31 22:36:33.560726|2018-05-31 22:36:33.560726
NCT01355731|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-09-14|2011-05-16|2011-05-18|Estimate|||||||2011-09-14|2011-09-15|Estimate|May 2011||2011-05-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Observational|EBABN||Evaluating Therapeutic Boundaries Among Bedside Nurses At A Pediatric Hematology/Oncology Research Hospital|Evaluating Therapeutic Boundaries Among Bedside Nurses At A Pediatric Hematology/Oncology Research Hospital|Completed|||121|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 22:36:33.692775|2018-05-31 22:36:33.692775
NCT01355718|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-08-08|2011-05-17|2011-05-18|Estimate|||||||2014-08-08|2014-08-11|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea|A 26-week, Multicentre, Open-labelled, Non-randomised, Non-interventional, Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea|Completed|||120|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:36:33.749375|2018-05-31 22:36:33.749375
NCT01355705|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2017-01-11||2017-04-28|2011-05-17|2011-05-18|Estimate|2017-01-11|2017-03-03|Actual||||2017-04-28|2017-05-30|Actual|August 2011||2011-08-31|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma|A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|14|Actual|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 22:36:33.830035|2018-05-31 22:36:33.830035
NCT01355692|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-15|||2016-09-06|2011-05-17|2011-05-18|Estimate|||||||2016-09-06|2016-09-07|Estimate|December 2009||2009-12-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|SRT||Evaluation of the Effects of Selective Photocoagulation for the Treatment of Diabetic Macular Edema|Phase III Multi Center Study Study of the Effects of Selective Retinal Photocoagulation for the Treatment of Diabetic Macular Edema|Completed||Phase 2/Phase 3|32|Actual|Lumenis Ltd.||1|||f||||f||||||||||2018-05-31 22:36:34.136943|2018-05-31 22:36:34.136943
NCT01355679|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2015-05-18||2016-06-16|2011-05-17|2011-05-18|Estimate|2016-06-16|2016-07-28|Estimate||||2016-06-16|2016-07-28|Estimate|May 2011||2011-05-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|September 2013|Actual|2013-09-30||Interventional||Multiply relapsed or refractory neuroblastoma.|Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma|A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Refractory or Recurrent Neuroblastoma|Completed||N/A|16|Actual|Spectrum Health Hospitals||1|||f||||t||||||||||2018-05-31 22:36:34.243608|2018-05-31 22:36:34.243608
NCT01355666|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2011-05-17|2011-05-17|2011-05-18|Estimate|||||||2011-05-17|2011-05-18|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Interventional|||Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting|Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting|Unknown status|Recruiting|N/A|75|Anticipated|Precision Fabrics Group, Inc.||1|||f||||f||||||||||2018-05-31 22:36:34.486584|2018-05-31 22:36:34.486584
NCT01355653|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-08-26|2011-05-17|2011-05-18|Estimate|||||||2011-08-26|2011-08-29|Estimate|April 2011||2011-04-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Heat Wrap Device Safety With Age and Body Fat|An Open Label Study To Compare The Effects Of Age And Body Fat On The Safety Of Two Heat Wrap Devices In Healthy Subjects|Completed||N/A|57|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:36:34.580867|2018-05-31 22:36:34.580867
NCT01355640|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2012-01-26|2011-05-17|2011-05-18|Estimate|||||||2012-01-26|2012-01-31|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|||Two Methods of Analgesia for Chinese Term Infants Receiving Heel Lance|A Randomized Controlled Trial of Breast-feeding and/or Non-nutritive Sucking as Analgesia for Chinese Term Infants Receiving Heel Lance|Completed||N/A|90|Actual|Peking Union Medical College||3|||f||||t||||||||||2018-05-31 22:36:34.65788|2018-05-31 22:36:34.65788
NCT01355627|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2014-06-26||2014-06-26|2011-05-17|2011-05-18|Estimate|2014-06-26|2014-07-25|Estimate||||2014-06-26|2014-07-25|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Baseline Measures were based on the Full Analysis Set that included all enrolled randomized patients.|TASALL - TachoSil® Against Liquor Leak|TachoSil® Versus Current Practice in Dura Sealing Techniques for the Prevention of Post-operative Cerebrospinal Fluid (CSF) Leaks in Patients Undergoing Skull Base Surgery: An Open Label, Randomised, Controlled, Multi-centre, Parallel Group Efficacy and Safety Trial.|Completed||Phase 3|726|Actual|Takeda||2|||f||||t||||||||||2018-05-31 22:36:34.789766|2018-05-31 22:36:34.789766
NCT01355614|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-02-20|2011-05-17|2011-05-18|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2011||2011-06-30|February 2017|2017-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients|A Multi-center, Randomized, Double-blind, Active Controlled Study to Assess Efficacy, Safety and Tolerability of the Anti-IL13 Monoclonal Antibody QAX576 in the Treatment of Perianal Fistulas in Patients Suffering From Crohn's Disease|Completed||Phase 2|10|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:36:35.776851|2018-05-31 22:36:35.776851
NCT01355601|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-02-26|2011-05-17|2011-05-18|Estimate|||||||2014-02-26|2014-02-27|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effect of Carbohydrates From Nutritional Beverages in Children|Effect of Carbohydrates From Nutritional Beverages in Children|Terminated||N/A|88|Anticipated|Mead Johnson Nutrition||2||Terminated due to slow recruitment. 41 of 50 participants had enrolled at time of termination.|f||||||||||||||2018-05-31 22:36:35.856797|2018-05-31 22:36:35.856797
NCT01355588|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2012-11-16||2017-02-07|2011-05-17|2011-05-18|Estimate|2013-03-19|2013-05-03|Estimate||||2017-02-07|2017-03-16|Actual|August 2005||2005-08-31|February 2017|2017-02-28|March 2006|Actual|2006-03-31|September 2005|Actual|2005-09-30||Interventional|||Tolerability, Safety and Pharmacokinetics of Four Formulations of Ketorolac Tromethamine in Healthy Volunteers|A Phase 1, Double-blind, 4-way Crossover Study of the Tolerability, Safety and Pharmacokinetics of 4 Formulations of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers|Completed||Phase 1|16|Actual|Egalet Ltd||4|||f||||f||||||||||2018-05-31 22:36:35.933305|2018-05-31 22:36:35.933305
NCT01355575|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-10-16|2011-05-17|2011-05-18|Estimate|||||||2012-10-16|2012-10-17|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|RiFL||Rifaximin in Fatty Liver Disease|RiFL:Rifaximin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?|Terminated||Phase 4|15|Actual|Imperial College London||2||Review of primary endpoint data by study Investigators concluded no further patients required.|f||||f||||||||||2018-05-31 22:36:36.319093|2018-05-31 22:36:36.319093
NCT00749814|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2008-09-08|2008-09-08|2008-09-09|Estimate|||||||2008-09-08|2008-09-09|Estimate|October 2008||2008-10-31|August 2008|2008-08-31||||December 2010|Anticipated|2010-12-31||Interventional|||Sleep Disturbances in Hospitalized Children||Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||||||||||||2018-06-01 01:46:34.849087|2018-06-01 01:46:34.849087
NCT01355562|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2012-10-03|2011-05-16|2011-05-18|Estimate|||||||2012-10-03|2012-10-05|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer|Phase II Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer|Withdrawn||Phase 2|0|Actual|Loma Linda University||||Primary Investigator is no longer employed at LLU as of 02/29/12.|f||||f||||||||||2018-05-31 22:36:36.392917|2018-05-31 22:36:36.392917
NCT01355549|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2013-01-14|2011-05-17|2011-05-18|Estimate|||||||2013-01-14|2013-01-15|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Platelet-Rich Plasma Therapy for Shoulder Pain in Persons With Spinal Cord Injury|A Pilot Study to Evaluate the Feasibility of Platelet-Rich Plasma Therapy as a Treatment for Chronic Shoulder Pain in Persons With Spinal Cord Injury|Completed||Phase 1|6|Actual|Kessler Foundation||1|||f||||f||||||||||2018-05-31 22:36:36.448206|2018-05-31 22:36:36.448206
NCT01355536|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-17|2011-05-17|2011-05-18|Estimate|||||||2011-05-17|2011-05-18|Estimate|October 2006||2006-10-31|May 2011|2011-05-31||||April 2008|Actual|2008-04-30||Observational|||Metabolic and Endocrine Status in Women With Prior Preterm Birth|Metabolic and Endocrine Status in Women With Prior Preterm Birth. A Cross Sectional, Case- Control Study|Completed|||262|Actual|Namsos Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum,endometrial biopsy~   "|||2018-05-31 22:36:36.507581|2018-05-31 22:36:36.507581
NCT01355523|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2013-08-14||2014-04-04|2011-05-17|2011-05-18|Estimate|2014-04-04|2014-05-06|Estimate||||2014-04-04|2014-05-06|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MELODY||The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients|The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients|Terminated||Phase 2/Phase 3|54|Actual|Herlev Hospital|Premature termination (54/260). Only included about 8% (54/703) of the patients assessed for eligibility.|2||Inclusion rate not as expected. Not financially possible to involve other centres.|f||||f||||||||||2018-05-31 22:36:36.576053|2018-05-31 22:36:36.576053
NCT01355510|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2013-09-18|2011-05-16|2011-05-18|Estimate|||||||2013-09-18|2013-09-19|Estimate|January 2011||2011-01-31|September 2013|2013-09-30||||||||Observational|CVRX-ReSy||Effects of Electrical Baroreflex Stimulation on Sympathetic Activity, Renal Hemodynamics, and Insulin Sensitivity|Electrical Baroreflex Stimulation - Sympathetic Activity|Unknown status|Recruiting||30|Anticipated|Hannover Medical School|||||f||||f||||||||||2018-05-31 22:36:38.370096|2018-05-31 22:36:38.370096
NCT01355497|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-03-18|2011-05-16|2011-05-18|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|||Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum|Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy|Completed||Phase 3|330|Actual|GTx||2|||f||||t||||||||||2018-05-31 22:36:38.443948|2018-05-31 22:36:38.443948
NCT01355484|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2016-02-04||2016-02-04|2011-05-17|2011-05-18|Estimate|2016-02-04|2016-03-03|Estimate||||2016-02-04|2016-03-03|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional||Subjects included in the Full Analysis Set|Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy|Completed||Phase 3|321|Actual|GTx||2|||f||||t||||||||||2018-05-31 22:36:38.598937|2018-05-31 22:36:38.598937
NCT01355471|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2013-09-19|2012-07-23|2013-09-19|2011-05-17|2011-05-18|Estimate|2013-09-19|2013-11-21|Estimate|2012-07-23|2012-07-31|Estimate|2013-09-19|2013-11-21|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea|Completed||Phase 3|293|Actual|Galderma||2|||f||||f||||||||||2018-05-31 22:36:39.194785|2018-05-31 22:36:39.194785
NCT01355458|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2013-09-19|2012-07-23|2013-09-19|2011-05-17|2011-05-18|Estimate|2013-09-19|2013-11-21|Estimate|2012-07-23|2012-07-31|Estimate|2013-09-19|2013-11-21|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea|Completed||Phase 3|260|Actual|Galderma||2|||f||||f||||||||||2018-05-31 22:36:39.486911|2018-05-31 22:36:39.486911
NCT01355445|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-07-19|2011-05-17|2011-05-18|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2012||2012-01-31|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|December 2017|Anticipated|2017-12-31||Interventional|VIT-0910||Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma|International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma|Recruiting||Phase 2|120|Anticipated|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 22:36:39.764293|2018-05-31 22:36:39.764293
NCT01355432|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-05-01|2011-05-17|2011-05-18|Estimate|||||||2012-05-01|2012-05-02|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Heart Rate Changes With Propofol|Changes in Heart Rate Following Administration of Propofol After Inhalational Induction|Completed|||40|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 22:36:40.00788|2018-05-31 22:36:40.00788
NCT01355419|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2015-02-20||2015-04-27|2011-05-17|2011-05-18|Estimate|2015-04-27|2015-05-12|Estimate||||2015-04-27|2015-05-12|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Sleep Schedules Modifications in Sleep Apnea Patients Treated by nCPAP|Evaluation of Sleep Schedules Modifications in Moderate to Severe Sleep Apnea Patients Treated by nCPAP|Completed|||150|Actual|Centre Hospitalier Universitaire Saint Pierre|||1||f||||f||||||||||2018-05-31 22:36:40.085593|2018-05-31 22:36:40.085593
NCT01355406|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16||2017-10-13|2017-10-13|2011-05-16|2011-05-18|Estimate||||2017-10-13|2017-10-17|Actual|2017-10-13|2017-10-17|Actual|September 2011||2011-09-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|January 2016|Actual|2016-01-31||Interventional|OPEN||Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System|Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System Study|Active, not recruiting||N/A|257|Actual|Cordis Corporation||1|||f||||t||||||||||2018-05-31 22:36:40.268798|2018-05-31 22:36:40.268798
NCT01355393|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16||2017-04-03|2018-05-01|2011-05-16|2011-05-18|Estimate||||2017-04-03|2017-04-05|Actual|2018-05-01|2018-05-03|Actual|July 2011||2011-07-31|May 2018|2018-05-31||||November 2013|Actual|2013-11-30||Interventional|||Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer|Phase I-II Study of HER2 Vaccination With Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients|Active, not recruiting||Phase 1/Phase 2|50|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 22:36:40.404709|2018-05-31 22:36:40.404709
NCT01355380|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2017-10-16|2011-05-17|2011-05-18|Estimate|||||||2017-10-16|2017-10-17|Actual|August 5, 2010|Actual|2010-08-05|October 2017|2017-10-31|September 22, 2016|Actual|2016-09-22|April 28, 2016|Actual|2016-04-28||Observational|SPHERA||Efficacy of Ventavis Used in Real-life Setting.|"The Efficacy of Inhaled Iloprost in Patients Treated Within the Pulmonary Arterial Hypertension Therapeutic Programme."|Completed|||55|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:36:40.490081|2018-05-31 22:36:40.490081
NCT01355367|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-01-28|2011-05-17|2011-05-18|Estimate|||||||2014-01-28|2014-01-29|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||High Dose BAYA1040 CR: a Long Term Extension Study|A Multicenter, Open Label, Long Term Extension Study of Oral BAYA1040 CR 80 mg (40 mg Bid) for 44 Weeks in Patients With Essential Hypertension (Extension From Study 13176)|Completed||Phase 3|120|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:36:40.579588|2018-05-31 22:36:40.579588
NCT01355354|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2011-10-05|2011-05-17|2011-05-18|Estimate|||||||2011-10-05|2011-10-06|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Administration of Fostamatinib on Blood Concentrations of Digoxin in Healthy Subjects|An Open-Label, Non-Randomised, 2-Period, Single Centre Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily|Completed||Phase 1|21|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 22:36:40.676032|2018-05-31 22:36:40.676032
NCT01355341|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-17|2011-05-17|2011-05-18|Estimate|||||||2011-05-17|2011-05-18|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|HerbmedPlus||Safety and Efficacy of Herbmed Plus in Patients withRenal Calculi|A Phase II, 28 Week, Randomized, Double- Blind, Placebo- Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 'Herbmed Plus' an Ayurvedic Formulation in Patients With Renal Calculi|Unknown status|Recruiting|Phase 2|84|Anticipated|Amai Charitable Trust||1|||f||||f||||||||||2018-05-31 22:36:40.772387|2018-05-31 22:36:40.772387
NCT01355328|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-05-17|2011-05-17|2011-05-18|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Evaluating Light-tissue Reaction and Transdermal Drug Delivery by Multiphoton Microscopy|Evaluating Light-tissue Reaction and Transdermal Drug Delivery by Multiphoton Microscopy|Unknown status|Recruiting|N/A|||Far Eastern Memorial Hospital||2|||f||||||||||||||2018-05-31 22:36:40.871458|2018-05-31 22:36:40.871458
NCT01355315|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2011-05-17|2011-05-17|2011-05-18|Estimate|||||||2011-05-17|2011-05-18|Estimate|April 2006||2006-04-30|June 2008|2008-06-30||||December 2007|Actual|2007-12-31||Observational|||Enhanced External Counterpulsation|Enhanced External Counterpulsation for Ischemic Cardiomyopathy|Completed|||19|Actual|Far Eastern Memorial Hospital|||||f||||t||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 22:36:40.94721|2018-05-31 22:36:40.94721
NCT01355302|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2017-01-19|2013-05-21|2017-04-07|2011-05-17|2011-05-18|Estimate|2017-01-19|2017-03-13|Actual|2013-05-21|2013-05-29|Estimate|2017-04-07|2017-05-15|Actual|November 2011||2011-11-30|March 2017|2017-03-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer|Terminated||Phase 1/Phase 2|7|Actual|Eisai Inc.|The study was terminated prior to enrollment in Phase 2.|2||Sites not recruiting|f||||f||||||||||2018-05-31 22:36:41.021554|2018-05-31 22:36:41.021554
NCT01355289|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2015-11-17|2015-06-29|2018-01-25|2011-05-17|2011-05-18|Estimate|2018-01-25|2018-02-22|Actual|2015-06-29|2015-07-22|Estimate|2018-01-25|2018-02-22|Actual|November 2011||2011-11-30|January 2018|2018-01-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501|A Phase II, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, With an Open-Label Extension, to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects With Chronic Hepatitis C Virus Related Thrombocytopenia Who Are Potential Candidates for Antiviral Treatment|Completed||Phase 2|65|Actual|Eisai Inc.||5|||f||||t||||||||||2018-05-31 22:36:41.471693|2018-05-31 22:36:41.471693
NCT01355276|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-11-29|2011-05-17|2011-05-18|Estimate|||||||2011-11-29|2011-11-30|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia|A Randomized, Double-blind, Double-dummy, Active Drug Parallel Controlled, Multi-center Clinical Trial on the Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia|Completed||Phase 3|400|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:36:42.317661|2018-05-31 22:36:42.317661
NCT01355263|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-02-18|2011-05-17|2011-05-18|Estimate|||||||2013-02-18|2013-02-20|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Effect of Vitamin A Supplementation on Iron Metabolic Homeostasis of Preschool Children in Sichuan,China|Effect of Vitamin A Supplementation on Iron Metabolic Homeostasis of Preschool Children in Sichuan,China|Completed||N/A|450|Actual|Chengdu Maternal and Children's Health Care Hospital||1|||f||||t||||||||||2018-05-31 22:36:42.410257|2018-05-31 22:36:42.410257
NCT01355237|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-06-12|2011-05-16|2011-05-18|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2012||2012-02-29|June 2017|2017-06-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Observational|||Observational Cohort Study of Chronic Low Back Pain|Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study II - Observational Cohort Study of Chronic Low Back Pain|Completed|||309|Actual|Brigham and Women's Hospital|||2||f||||t||||||||||2018-05-31 22:36:42.473144|2018-05-31 22:36:42.473144
NCT01355224|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2016-08-08||2017-01-24|2011-05-16|2011-05-18|Estimate|2017-01-24|2017-03-14|Actual||||2017-01-24|2017-03-14|Actual|September 2011||2011-09-30|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Based on participants who completed the baseline survey|Communicating Risk Information for Obesity|Communicating Genetic Information for Obesity|Completed||N/A|798|Actual|Boston University||4|||f||||f||||||||No|No plan to share data|2018-05-31 22:36:42.566994|2018-05-31 22:36:42.566994
NCT01355211|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2012-02-29|2011-05-17|2011-05-18|Estimate|||||||2012-02-29|2012-03-02|Estimate|April 2011||2011-04-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Putting Electroencephalography (EEG) in the Emergency Department|Diagnostic Utility of Emergency Electroencephalography in Identifying Non-convulsive Seizure and Subclinical Status Epilepticus in Patients With Altered Mental Status|Completed|||261|Actual|Bio-Signal Group Corp.|||||f||||t||||||||||2018-05-31 22:36:43.065253|2018-05-31 22:36:43.065253
NCT01355198|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2013-02-05|2011-05-17|2011-05-18|Estimate|||||||2013-02-05|2013-02-07|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Role of HIV on Glutathione Synthesis and Oxidative Stress|Role of HIV on Glutathione Synthesis and Oxidative Stress|Completed||Phase 1|10|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-05-31 22:36:43.130225|2018-05-31 22:36:43.130225
NCT01355185|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-10-01|2011-05-17|2011-05-18|Estimate|||||||2014-10-01|2014-10-03|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences|Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences|Unknown status|Recruiting||20|Anticipated|AHS Cancer Control Alberta|||||f||||f||||||||||2018-05-31 22:36:43.188845|2018-05-31 22:36:43.188845
NCT01355172|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-15|||2012-07-12|2011-05-17|2011-05-18|Estimate|||||||2012-07-12|2012-07-16|Estimate|November 2010||2010-11-30|July 2012|2012-07-31||||September 2011|Actual|2011-09-30||Interventional|||Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old|Clinical Study Protocol Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011， in Infants Aged Between 6-12months Old|Completed||Phase 4|59|Actual|Adimmune Corporation|||||f||||t||||||||||2018-05-31 22:36:43.248672|2018-05-31 22:36:43.248672
NCT01355159|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2017-08-28|2011-05-16|2011-05-17|Estimate|||||||2017-08-28|2017-08-30|Actual|April 2011||2011-04-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|FACT||High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention|Effect of Folic Acid Supplementation in Pregnancy on Preeclampsia-Folic Acid Clinical Trial (FACT)|Completed||Phase 3|2464|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 22:36:43.404446|2018-05-31 22:36:43.404446
NCT01355146|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-02-01|2011-05-16|2011-05-17|Estimate|||||||2017-02-01|2017-02-03|Estimate|May 2011||2011-05-31|February 2017|2017-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Home Therapy With Replagal in Fabry Disease|Non Interventional Study of Replagal® Home Therapy in Patients With Fabry Disease|Recruiting|||50|Anticipated|Shire|||1||f||||f||||||||||2018-05-31 22:36:43.581217|2018-05-31 22:36:43.581217
NCT01355133|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-05-16|2011-05-16|2011-05-17|Estimate|||||||2011-05-16|2011-05-17|Estimate|August 2009||2009-08-31|May 2011|2011-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy Study of Intrasphincteric Autologous Myoblast Injection to Treat Stress Urinary Incontinence|Transurethral Ultrasound-directed Injection of Autologous Myoblasts in Combination With Functional Electrical Stimulation in Patients With Intrinsic Urinary Sphincter Deficiency|Completed||Phase 1/Phase 2|40|Actual|University Medical Centre Ljubljana|||||f||||f||||||||||2018-05-31 22:36:43.72805|2018-05-31 22:36:43.72805
NCT01355120|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2014-06-20|2011-05-16|2011-05-17|Estimate|||||||2014-06-20|2014-06-23|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|DeCOG||THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease|THE IPI - Multibasket Trial in Advanced Melanoma: Prospective Clinical Phase II Multibasket Study in Melanoma Patients With Advanced Disease (DeCOG MM-PAL11)|Completed||Phase 2|171|Actual|University Hospital, Essen||1|||f||||t||||||||||2018-05-31 22:36:43.793169|2018-05-31 22:36:43.793169
NCT01355107|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-12-13|2011-05-16|2011-05-17|Estimate|||||||2011-12-13|2011-12-14|Estimate|April 2011||2011-04-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease|Comparison of Selenium Levels in HCV- Infected Patients at Different Stages of Disease - a Pilot Trial|Completed|||32|Actual|University Hospital Freiburg|||3||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 22:36:43.904654|2018-05-31 22:36:43.904654
NCT01355094|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-10-24|2011-05-16|2011-05-17|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2011||2011-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|SAD||Peritoneal Vacuum Therapy to Reduce Inflammatory Response From Abdominal Sepsis/Injury|Peritoneal Vacuum Therapy to Reduce the Systemic Inflammatory Insult From Intraperitoneal Sepsis/Injury/Hypertension: A Randomized Comparison of Baseline Wall Suction Versus the KCI AbThera™ Abdominal Dressing|Active, not recruiting||N/A|50|Anticipated|University of Calgary||2|||f||||f||||||||No|No plan|2018-05-31 22:36:44.264625|2018-05-31 22:36:44.264625
NCT01355081|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2014-11-04||2014-11-04|2011-05-16|2011-05-17|Estimate|2014-11-04|2014-11-11|Estimate||||2014-11-04|2014-11-11|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder|Completed||Phase 3|366|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:36:44.431312|2018-05-31 22:36:44.431312
NCT01355068|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2011-11-10||2011-11-10|2011-05-16|2011-05-17|Estimate|2011-11-10|2011-12-14|Estimate||||2011-11-10|2011-12-14|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Epanutin Infatabs 50 mg (Sourced From Germany) Verses Dilantin Infatabs 50 mg (Sourced From Australia) in Healthy Subjects|Completed||Phase 1|26|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:36:45.624485|2018-05-31 22:36:45.624485
NCT01355055|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-16|2011-05-16|2011-05-17|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||||||Observational|ReD||Sympathetic Activity and Renal Denervation|Influences of Catheter-based Renal Denervation on Central Sympathetic Nervous System Regulation in Refractory Hypertension|Unknown status|Recruiting||26|Anticipated|Hannover Medical School|||||f||||f||||||||||2018-05-31 22:36:45.899281|2018-05-31 22:36:45.899281
NCT01355042|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2017-09-19|2011-05-16|2011-05-17|Estimate|||||||2017-09-19|2017-09-20|Actual|November 2010|Actual|2010-11-30|September 2017|2017-09-30|September 2016|Actual|2016-09-30|June 2012|Actual|2012-06-30||Observational|DYNAMICS||Studies of Blood DNA in Patients With Severe Infection DYNAMICS|DYNAMICS: DNA as a Prognostic Marker in ICU Patients Study|Completed|||792|Actual|Hamilton Health Sciences Corporation|||2||f||||f||||||Samples With DNA|"~     plasma~   "|||2018-05-31 22:36:45.948383|2018-05-31 22:36:45.948383
NCT01355029|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2016-03-14|2011-05-16|2011-05-17|Estimate|||||||2016-03-14|2016-03-16|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FICSS||Evaluation of the Stroke Caregiver Education and Support Program|A Pilot Study of the Evaluation of the Family Informal Caregiver Stroke Self Management (FICSS) Research Project: Impact on Caregiver Psychosocial, Emotional and Health Needs|Completed||N/A|43|Actual|March of Dimes, Canada|||||f||||f||||||||||2018-05-31 22:36:46.026146|2018-05-31 22:36:46.026146
NCT01355016|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2012-04-10|2011-05-16|2011-05-17|Estimate|||||||2012-04-10|2012-04-12|Estimate|September 2011||2011-09-30|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 in Healthy Volunteers|Completed||Phase 1|48|Anticipated|MicroDose Therapeutx, Inc||2|||f||||||||||||||2018-05-31 22:36:46.08238|2018-05-31 22:36:46.08238
NCT01355003|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2015-08-11|2011-05-16|2011-05-17|Estimate|||||||2015-08-11|2015-08-13|Estimate|February 2008||2008-02-29|August 2015|2015-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol|Terminated|||1080|Actual|Merck Sharp & Dohme Corp.|||1|"Merck Sharp & Dohme Corp (MSD) received exemption from PFDA on conduct of post-marketing~   surveillance (PMS) study"|f||||f||||||||||2018-05-31 22:36:46.147019|2018-05-31 22:36:46.147019
NCT01354990|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2012-02-01||2015-08-26|2011-05-16|2011-05-17|Estimate|2012-05-01|2012-06-04|Estimate||||2015-08-26|2015-08-27|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)|Sitagliptin (JANUVIA®) Post Marketing Surveillance Protocol|Completed|||2974|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:36:46.1923|2018-05-31 22:36:46.1923
NCT01354977|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2018-04-19|2011-05-16|2011-05-17|Estimate|||||||2018-04-19|2018-04-23|Actual|March 2008|Actual|2008-03-31|April 2018|2018-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans|Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans|Completed||Phase 2|80|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 22:36:46.498645|2018-05-31 22:36:46.498645
NCT01354964|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-05-16|2011-05-16|2011-05-17|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation|Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation|Unknown status|Recruiting|Phase 2|25|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 22:36:46.597265|2018-05-31 22:36:46.597265
NCT01354951|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2018-03-07|2011-05-16|2011-05-17|Estimate|||||||2018-03-07|2018-03-08|Actual|May 2011||2011-05-31|November 2017|2017-11-30|October 6, 2017|Actual|2017-10-06|October 6, 2017|Actual|2017-10-06||Interventional|||Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer|Phase II Study Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy Early Stage, Low Volume in Prostate Cancer|Terminated||Phase 2|3|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 22:36:46.676248|2018-05-31 22:36:46.676248
NCT01354938|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2012-12-20||2013-02-01|2011-05-16|2011-05-17|Estimate|2012-12-20|2013-01-30|Estimate||||2013-02-01|2013-02-06|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis|Outcome Study to Evaluate the Role of Klaricid XL (Clarithromycin Modified Release) in the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Its Impact on Quality of Life Measured by St. George's Respiratory Questionnaire (SGRQ)|Completed|||220|Actual|Abbott|||1||f||||f||||||||||2018-05-31 22:36:46.762943|2018-05-31 22:36:46.762943
NCT01354925|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2013-04-11|2011-05-16|2011-05-17|Estimate|||||||2013-04-11|2013-04-12|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|DMR||Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan|Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan An Interventional, Community Based, Comparative Study|Completed||Phase 4|245|Actual|Meir Medical Center||2|||f||||||||||||||2018-05-31 22:36:46.97887|2018-05-31 22:36:46.97887
NCT01354912|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2013-03-10|2011-05-16|2011-05-17|Estimate|||||||2013-03-10|2013-03-12|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||The Incidence of Nontuberculous Mycobacterial Pulmonary Infection in Bilateral Bronchiectasis and Bronchiolitis||Unknown status|Recruiting||150|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 22:36:47.129448|2018-05-31 22:36:47.129448
NCT01354899|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|2016-02-25||2016-04-05|2011-05-16|2011-05-17|Estimate|2016-04-05|2016-05-09|Estimate||||2016-04-05|2016-05-09|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Open Study to Evaluate the Performance of Dressing on Subject With High Risk of Skin Breakdown|A Multi-Centre, Post CE Mark, Open Study to Evaluate the Performance of Thin Self-adherent Dressing Coated With a Soft Silicone Layer on Subjects With a High Risk of Skin Breakdown|Completed|||24|Actual|Molnlycke Health Care AB|||||f||||f||||||||||2018-05-31 22:36:47.205793|2018-05-31 22:36:47.205793
NCT01354886|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-11-25|2011-05-16|2011-05-17|Estimate|||||||2011-11-25|2011-11-28|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Single Dose FSH-GEX™ in Healthy Volunteers|A Phase I, Monocenter, Randomized, Placebo and Comparator Controlled, Single Blind, Rising Dose, Clinical Study to Determine Single Dose Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Four Doses of FSH-GEX™ According to Adaptive Design (25, 75, 150 and 300 IU) Administered Subcutaneously in Healthy Pituitary-suppressed Female Volunteers|Completed||Phase 1|18|Anticipated|Glycotope GmbH|||||f||||f||||||||||2018-05-31 22:36:47.348126|2018-05-31 22:36:47.348126
NCT01354873|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-01-08|2011-05-16|2011-05-17|Estimate|||||||2014-01-08|2014-01-10|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging|Colorectal Polyp Discrimination Using High-Definition Narrow Band Imaging|Completed|||556|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:36:47.402119|2018-05-31 22:36:47.402119
NCT01354860|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-16|2011-05-16|2011-05-17|Estimate|||||||2011-05-16|2011-05-17|Estimate|December 2010||2010-12-31|September 2010|2010-09-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Moxibustion for Knee Osteoarthritis|Moxibustion for Knee Osteoarthritis: a Randomized Pilot Clinical Trial|Completed||Phase 1/Phase 2|40|Actual|Korea Institute of Oriental Medicine||2|||f||||t||||||||||2018-05-31 22:36:47.456959|2018-05-31 22:36:47.456959
NCT01354847|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2013-10-25|2011-05-16|2011-05-17|Estimate|||||||2013-10-25|2013-10-28|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Influence of Extracorporeal Circulation on Platelet Function of Patients Undergoing Cardiac Surgery|Influence of Extracorporeal Circulation on Platelet Function of Patients Undergoing Cardiac Surgery - a Prospective Observational Study|Completed|||25|Actual|Goethe University|||1||f||||f||||||||||2018-05-31 22:36:47.520482|2018-05-31 22:36:47.520482
NCT01354834|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2011-05-16|2011-05-16|2011-05-17|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2004||2004-03-31|May 2011|2011-05-31|April 2006|Actual|2006-04-30|December 2005|Actual|2005-12-31||Observational|||Assessment of the Effectiveness of Menopur in Intrauterine Insemination|Assessment of the Clinical Efficacy of Menopur® in Intrauterine Artificial Insemination (From Partner or From Donor)|Completed|||207|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:36:47.576718|2018-05-31 22:36:47.576718
NCT01354821|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2014-10-29|2011-05-16|2011-05-17|Estimate|||||||2014-10-29|2014-10-30|Estimate|November 2009||2009-11-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|January 2014|Actual|2014-01-31||Interventional|Windows2||Medical & Economical Evaluation of Fenestrated & Branched Stent-grafts to Treat Complex Thoracal Abdominal Aneurysms|Medical & Economical Evaluation of Endovascular Therapy of Complex Thoracal Abdominal Aneurysms (Type 1-3 Thoracal Abdominal Aneurysms) by Fenestrated & Branched Stent-grafts|Unknown status|Active, not recruiting|N/A|49|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 22:36:47.655257|2018-05-31 22:36:47.655257
NCT01354808|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-15|||2013-09-23|2011-05-16|2011-05-17|Estimate|||||||2013-09-23|2013-09-24|Estimate|July 2010||2010-07-31|September 2013|2013-09-30||||July 2012|Actual|2012-07-31||Interventional|||ACCEL-LOADING-ACS Study|ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome|Completed||Phase 4|220|Anticipated|Gyeongsang National University Hospital||2|||f||||t||||||||||2018-05-31 22:36:47.740171|2018-05-31 22:36:47.740171
NCT01354795|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-24|||2011-05-16|2011-05-16|2011-05-17|Estimate|||||||2011-05-16|2011-05-17|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|EUS-FNA||Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass|Prospective Study Comparing Methods of Obtainment of Specimen After EUS-FNA in Patients With Peri-pancreatic Mass|Completed||N/A|80|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 22:36:47.840983|2018-05-31 22:36:47.840983
NCT01354782|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-10-24|2011-05-16|2011-05-17|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects|An Open, Single Centre, Single and Repeated Dose Study to Investigate the Pharmacokinetic Profile of Roflumilast and Roflumilast N-oxide After Administration of 500 μg Dose of Roflumilast in Healthy Chinese Subjects|Completed||Phase 1|32|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 22:36:47.918829|2018-05-31 22:36:47.918829
NCT01354769|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2016-04-24|2011-05-16|2011-05-17|Estimate|||||||2016-04-24|2016-04-26|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Observational|||Capnography Library - Data Collection in the Critical Care Environment Stage 2|Capnography Library - Data Collection in the Critical Care Environment Stage 2|Completed|||75|Actual|Shaare Zedek Medical Center|||2||f||||f||||||||Undecided||2018-05-31 22:36:47.98461|2018-05-31 22:36:47.98461
NCT01354756|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2015-03-09|2011-05-16|2011-05-17|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Validation of Apnea LinkTM for Sleep Apnea Syndrome Screening in a Bariatric Population|Validation of Apnea LinkTM (ResMed Corporation, Poway, California) for Sleep Apnea Syndrome Screening in a Bariatric Population|Terminated|||9|Actual|Centre Hospitalier Universitaire Saint Pierre|||1|device was stolen|f||||f||||||||||2018-05-31 22:36:48.069186|2018-05-31 22:36:48.069186
NCT01354743|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-09-24|2011-05-16|2011-05-17|Estimate|||||||2013-09-24|2013-09-26|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|DPL-2010||Upper Facial Remodeling With Perlane-L and Dysport|Upper Facial Remodeling With Perlane-L and Dysport.|Completed||Phase 4|20|Actual|Beer, Kenneth R., M.D., PA||1|||f||||f||||||||||2018-05-31 22:36:48.121663|2018-05-31 22:36:48.121663
NCT01354730|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-15|||2011-05-16|2011-05-16|2011-05-17|Estimate|||||||2011-05-16|2011-05-17|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Observational|||A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women||Completed|||398|Actual|Adimmune Corporation|||2||f||||||||||||||2018-05-31 22:36:48.182055|2018-05-31 22:36:48.182055
NCT01354717|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-14||2014-09-07|2014-10-09|2011-05-14|2011-05-17|Estimate||||2014-10-09|2014-10-20|Estimate|2014-10-09|2014-10-20|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo|Phase 3 Study of Brand Generic and Placebo in Treatment of Actinic Keratosis|Completed||Phase 3|377|Actual|Spear Pharmaceuticals||3|||f||||f||||||||||2018-05-31 22:36:48.230938|2018-05-31 22:36:48.230938
NCT01354704|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-14|||2015-11-02|2011-05-16|2011-05-17|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|PRENOXA||Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin|Echo-Doppler Assessment of the Occurrence of Asymptomatic Deep Vein Thrombosis (DVT) in Orthopedic Replacement Surgery Under Enoxaparine (PRENOXA)|Completed||Phase 4|153|Actual|Les Laboratoires des Médicaments Stériles||4|||f||||t||||||||||2018-05-31 22:36:48.294594|2018-05-31 22:36:48.294594
NCT01354691|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-01|||2013-07-22|2011-05-14|2011-05-17|Estimate|||||||2013-07-22|2013-07-23|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease|A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period|Completed||Phase 2|201|Actual|Avraham Pharmaceuticals Ltd||1|||f||||t||||||||||2018-05-31 22:36:48.358958|2018-05-31 22:36:48.358958
NCT01354678|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2016-08-01|2011-05-16|2011-05-17|Estimate|||||||2016-08-01|2016-08-02|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|IMPI||Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia|Phase 1 Study to Evaluate the Efficacy and Safety of Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia|Active, not recruiting||Phase 1|30|Anticipated|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health||2|||f||||f||||||||||2018-05-31 22:36:48.573224|2018-05-31 22:36:48.573224
NCT01354665|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-16|||2015-01-19|2011-05-16|2011-05-17|Estimate|||||||2015-01-19|2015-01-21|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|FADO||Depression and Fatigue in MS Patients Treated With Betaferon.|The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.|Completed|||567|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:36:48.651421|2018-05-31 22:36:48.651421
NCT01354652|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2015-01-18||2018-04-10|2011-05-16|2011-05-17|Estimate|2015-02-04|2015-02-20|Estimate||||2018-04-10|2018-05-09|Actual|May 2011||2011-05-31|April 2018|2018-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ETV||Lactic Acidosis During Entecavir(ETV)Treatment|The Incidence of Lactic Acidosis During Entecavir Treatment in Chronic Hepatitis B Patients With Severe Cirrhosis or Hepatic Failure|Terminated||Phase 4|5|Actual|Asan Medical Center||3||Tenofovir has become available in Korea.|f||||t||||||||||2018-05-31 22:36:48.749646|2018-05-31 22:36:48.749646
NCT01354639|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-02-04|2011-05-16|2011-05-17|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy|Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy|Completed|||150|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 22:36:49.086507|2018-05-31 22:36:49.086507
NCT01354626|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2012-03-14|2011-05-16|2011-05-17|Estimate|||||||2012-03-14|2012-03-15|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|LiF-Pro||Dietary Protein and Hepatic Fat Accumulation|Influence of Increasing Dietary Protein on Hepatic Fat Accumulation and Postprandial Metabolism|Completed||N/A|29|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 22:36:49.133979|2018-05-31 22:36:49.133979
NCT01354613|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2015-10-06|2011-05-16|2011-05-17|Estimate|||||||2015-10-06|2015-10-08|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)|Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction|Completed||N/A|14|Actual|University of Wisconsin, Madison||4|||f||||t||||||||||2018-05-31 22:36:49.256612|2018-05-31 22:36:49.256612
NCT01354600|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2013-07-22|2011-05-16|2011-05-17|Estimate|||||||2013-07-22|2013-07-23|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Effects of Positive Energy Balance and Exercise on Appetite Hormones in Sedentary Men and Women|Short-term Positive Energy Balance and Exercise on 24-hour Plasma Levels of Hunger and Satiety Hormones in Sedentary Lean and Obese Men and Women|Completed||N/A|13|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 22:36:49.327897|2018-05-31 22:36:49.327897
NCT01354587|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-07-16|2011-05-16|2011-05-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Evaluation of Efficacy and Tolerability of Hizentra®|Evaluation of Efficacy and Tolerability of Hizentra® in Subjects Transitioning From Vivaglobin® (16% SCIG Product) to Hizentra® (20% SCIG Product)|Unknown status|Recruiting|N/A|50|Anticipated|University of South Florida||1|||f||||t||||||||||2018-05-31 22:36:49.405667|2018-05-31 22:36:49.405667
NCT01354574|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2011-07-12|2011-05-16|2011-05-17|Estimate|||||||2011-07-12|2011-07-13|Estimate|October 2002||2002-10-31|July 2011|2011-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|FL33||Thermic & Lipemic Properties of Dietary Carbohydrates|Thermic & Lipemic Properties of Dietary Carbohydrates|Completed||N/A|28|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:36:49.512244|2018-05-31 22:36:49.512244
NCT01354561|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-13|2011-05-13|2011-05-17|Estimate|||||||2011-05-13|2011-05-17|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Respiratory Physical Therapy on the Cardiac Autonomic Modulation Paediatric Patients|Effect of Airway Clearance Therapy on the Cardiac Autonomic Modulation in Hospitalized Paediatric Patients|Completed||N/A|24|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:36:49.616566|2018-05-31 22:36:49.616566
NCT01354548|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-04-13|2011-05-16|2011-05-17|Estimate|||||||2016-04-13|2016-04-14|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Prevention of Trismus During Radiotherapy and Quality of Life in Head and Neck Cancer Patients|Prophylactic Training for the Prevention of Radiotherapy-induced Trismus - a Randomised Study. Health-related Quality of Life up to One Year After Radiotherapy in Patients With Head and Neck Cancer|Unknown status|Active, not recruiting|N/A|60|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 22:36:49.694194|2018-05-31 22:36:49.694194
NCT01354535|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2017-11-15|2011-05-16|2011-05-17|Estimate|||||||2017-11-15|2017-11-17|Actual|February 2013||2013-02-28|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Types of Fixation of Vancouver B1 Periprosthetic Fractures|Isolated Locked Compression Plating Versus Cable Plating and Strut Allografts With Cerclage Wiring for Vancouver B1 Periprosthetic Femoral Fractures: A Randomized Controlled Trial|Recruiting||N/A|89|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 22:36:49.768415|2018-05-31 22:36:49.768415
NCT01354522|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2014-01-14|2011-05-13|2011-05-17|Estimate|||||||2014-01-14|2014-01-16|Estimate|May 2011||2011-05-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer|A Randomized, Phase III Study Comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) With TCX ( Docetaxel, Cyclophosphamide, Capecitabine) as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer|Unknown status|Recruiting|Phase 3|400|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 22:36:49.840963|2018-05-31 22:36:49.840963
NCT01354509|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-05-17|2011-05-13|2011-05-17|Estimate|||||||2011-05-17|2011-05-18|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2013|Anticipated|2013-05-31|May 2012|Anticipated|2012-05-31||Observational|||Normothermia Protocol for Traumatic Brain Injury Patients|Normothermia Protocol for Traumatic Brain Injury Patients: An Outcome Study|Unknown status|Recruiting||80|Anticipated|Medivance, Inc.|||2||f||||t||||||||||2018-05-31 22:36:49.924074|2018-05-31 22:36:49.924074
NCT01354496|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2011-11-07|2011-05-13|2011-05-17|Estimate|||||||2011-11-07|2011-11-09|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of LY2409021 Formulations and the Effect of Food|LY2409021 Formulation Bridging and Food Effect Study|Completed||Phase 1|42|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 22:36:49.999127|2018-05-31 22:36:49.999127
NCT01354119|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2015-01-13|2011-05-13|2011-05-16|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Long-term Benefit of Aortic Stent-graft in Patients With Distal Aortic Dissection||Terminated||Phase 4|7|Actual|Asan Medical Center||2||Not enough participants enrolled|f||||f||||||||||2018-05-31 22:36:59.931712|2018-05-31 22:36:59.931712
NCT01354483|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2014-08-20|2011-05-16|2011-05-17|Estimate|||||||2014-08-20|2014-08-21|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury|Feasibility and Safety of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Trial|Completed||Phase 1/Phase 2|20|Actual|China Spinal Cord Injury Network||5|||f||||f||||||||||2018-05-31 22:36:50.087449|2018-05-31 22:36:50.087449
NCT01354470|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2013-07-01|2011-05-13|2011-05-17|Estimate|||||||2013-07-01|2013-07-02|Estimate|October 2011||2011-10-31|July 2013|2013-07-31||||February 2013|Actual|2013-02-28||Interventional|||A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence|A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence|Completed||Phase 2|72|Anticipated|California Pacific Medical Center Research Institute||2|||f||||||||||||||2018-05-31 22:36:50.177691|2018-05-31 22:36:50.177691
NCT01354457|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2014-06-24|2011-05-13|2011-05-16|Estimate|||||||2014-06-24|2014-06-25|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|RIT 90YEpra||Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+|Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy With 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients|Unknown status|Active, not recruiting|Phase 1/Phase 2|21|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 22:36:50.249078|2018-05-31 22:36:50.249078
NCT01354444|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2017-10-26||2018-01-08|2011-05-13|2011-05-16|Estimate|2018-01-08|2018-02-06|Actual||||2018-01-08|2018-02-06|Actual|June 2011|Actual|2011-06-30|January 2018|2018-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Trial of Carvedilol in Alzheimer's Disease|Pilot Trial of Carvedilol in Alzheimer's Disease|Completed||Phase 4|29|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 22:36:50.325261|2018-05-31 22:36:50.325261
NCT01354431|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2015-09-08|2015-02-12|2018-01-24|2011-05-13|2011-05-16|Estimate|2015-09-21|2015-10-20|Estimate|2015-02-12|2015-03-03|Estimate|2018-01-24|2018-01-26|Actual|May 17, 2011|Actual|2011-05-17|January 2018|2018-01-31|July 16, 2018|Anticipated|2018-07-16|May 15, 2013|Actual|2013-05-15||Interventional||All Randomized participants were included.|BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)|A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy|Active, not recruiting||Phase 2|198|Actual|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 22:36:50.725185|2018-05-31 22:36:50.725185
NCT01354418|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2015-02-20|2011-05-13|2011-05-16|Estimate|||||||2015-02-20|2015-02-23|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)|A Randomized Crossover Bioequivalence Study Comparing a Single Dose of Phenylephrine HCl 30 mg Extended Release Tablet to Three Phenylephrine HCl 10 mg Immediate Release Tablets Each Consecutively Dosed Four Hours Apart Under Fed and Fasting Conditions|Completed||Phase 1|24|Actual|Bayer||4|||f||||f||||||||||2018-05-31 22:36:51.833325|2018-05-31 22:36:51.833325
NCT01354405|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-07-08|2011-05-13|2011-05-16|Estimate|||||||2014-07-08|2014-07-09|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|RESOLVE||Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)|The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease|Completed|||43|Actual|Radboud University|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 22:36:51.914746|2018-05-31 22:36:51.914746
NCT01354392|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-07-01|2011-05-13|2011-05-16|Estimate|||||||2014-07-01|2014-07-02|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||AZD1152 in Diffuse Large B-cell Lymphoma|A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-cell Lymphoma|Completed||Phase 1/Phase 2|15|Actual|Oxford University Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 22:36:52.107079|2018-05-31 22:36:52.107079
NCT01354379|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2013-03-26|2011-05-13|2011-05-16|Estimate|||||||2013-03-26|2013-03-28|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer|A Phase 1 Randomized, Observer-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 in Healthy Adult Volunteers Administered by Nasal Sprayer and Pipette|Completed||Phase 1|125|Actual|NanoBio Corporation||5|||f||||t||||||||||2018-05-31 22:36:52.270978|2018-05-31 22:36:52.270978
NCT01354366|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2013-08-28|2011-05-13|2011-05-16|Estimate|||||||2013-08-28|2013-08-29|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Growth and Tolerance of Hypoallergenic Formulas|The Effects on Growth and Tolerance of Hypoallergenic Formulas Fed to Term Infants|Completed|||511|Actual|Mead Johnson Nutrition|||3||f||||f||||||||||2018-05-31 22:36:52.374475|2018-05-31 22:36:52.374475
NCT01354353|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2012-08-09|2011-05-13|2011-05-16|Estimate|||||||2012-08-09|2012-08-10|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Safety and Tolerability in Subjects With Schizophrenia|Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia|Completed||Phase 1|120|Anticipated|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 22:36:52.482916|2018-05-31 22:36:52.482916
NCT01354340|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2012-04-18|2011-05-13|2011-05-16|Estimate|||||||2012-04-18|2012-04-19|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Dose Effect of Limicol on (LDL)-Cholesterol Levels|Dose Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia|Completed||N/A|45|Actual|Lescuyer Laboratory||3|||f||||f||||||||||2018-05-31 22:36:52.599114|2018-05-31 22:36:52.599114
NCT01354327|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2011-05-13|2011-05-13|2011-05-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|December 2008||2008-12-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Limicol on LDL-cholesterol|Study of the Effects of Limicol (a Food Supplement) on LDL-cholesterol in Moderate Hypercholesterolemia Subjects|Completed||N/A|47|Actual|Lescuyer Laboratory||2|||f||||t||||||||||2018-05-31 22:36:52.697522|2018-05-31 22:36:52.697522
NCT01354314|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2017-04-03||2017-05-11|2011-05-13|2011-05-16|Estimate|2017-04-03|2017-05-12|Actual||||2017-05-11|2017-06-09|Actual|November 2010||2010-11-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ParaFlu||Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder|Pilot Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder (HAND)|Completed||Phase 1/Phase 2|45|Actual|Johns Hopkins University||4|||f||||t||||||||||2018-05-31 22:36:52.840614|2018-05-31 22:36:52.840614
NCT01354301|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2015-03-20|2011-05-13|2011-05-16|Estimate|||||||2015-03-20|2015-03-23|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate|Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate|Completed||Phase 4|300|Actual|Hospital do Rim e Hipertensão||3|||f||||f||||||||||2018-05-31 22:36:54.619463|2018-05-31 22:36:54.619463
NCT01354288|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-04-20|2011-05-13|2011-05-16|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|DIAB-EDUC||Therapeutic Education in Very Young Children With Diabetes Mellitus|Therapeutic Education in Very Young Children With Diabetes Mellitus. Evaluation of the Impact of a Specific Tool for Parents on Glycemic Control and Prevention of Acute Events (Hypoglycemia and Ketosis)|Unknown status|Active, not recruiting|N/A|24|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:36:54.741277|2018-05-31 22:36:54.741277
NCT01354275|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2012-02-01|2011-05-13|2011-05-16|Estimate|||||||2012-02-01|2012-02-03|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|PCOS and ivf||In Vitro Fertilization Outcomes of Two Treatment Protocols in Women With Polycystic Ovary Syndrome|IVF/ICSI Outcomes of OCP Plus GnRH Agonist Protocol Versus OCP Plus GnRH Antagonist Fixed Protocol in Women With PCOS|Terminated||N/A|300|Actual|Baskent University||2||". The trial would be continued if there was a difference of ≥3 % between trial arms. However,~   the difference between ongoing pregnancy rates was <1 %"|f||||t||||||||||2018-05-31 22:36:54.837986|2018-05-31 22:36:54.837986
NCT01354262|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2015-04-22|2011-05-13|2011-05-16|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Effect of Vitamin D Supplementation on Hemoglobin A1c|Does Vitamin D Supplement Alter Serum Level of Glycosylated Hemoglobin in Adult Patients Between 34-74 Years With Type 2 Diabetes Mellitus and Vitamin D Deficiency?|Completed||Phase 2|150|Actual|Genesys Regional Medical Center||3|||f||||f||||||||||2018-05-31 22:36:54.926339|2018-05-31 22:36:54.926339
NCT01354249|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-13|2011-05-13|2011-05-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|July 2010||2010-07-31|May 2011|2011-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Preoperative Feeding With a Whey Protein Plus Carbohydrate Drink on the Acute Phase Response and Insulin Resistance|Effects of Preoperative Feeding With a Whey Protein Plus Carbohydrate Drink on the Acute Phase Response and Insulin Resistance.|Completed||N/A|20|Actual|Federal University of Mato Grosso do Sul||2|||f||||t||||||||||2018-05-31 22:36:54.996565|2018-05-31 22:36:54.996565
NCT01354236|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-13|2011-05-13|2011-05-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|January 2011||2011-01-31|May 2011|2011-05-31||||||||Observational|||Mental Health Related to School Dropout in Luxembourg|Psychosocial Risk- and Protective Factors of Secondary School Dropout in Luxembourg: an Exploratory Case-control Study|Unknown status|Enrolling by invitation||200|Anticipated|Public Research Centre Health, Luxembourg|||2||f||||t||||||||||2018-05-31 22:36:55.082391|2018-05-31 22:36:55.082391
NCT01354223|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2013-10-23||2014-02-04|2011-05-13|2011-05-16|Estimate|2014-02-04|2014-03-21|Estimate||||2014-02-04|2014-03-21|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Clinical Evaluation of Stenfilcon A Soft Contact Lens When Compared to Ocufilcon B Soft Contact Lens|Evaluation of the CooperVision Stenfilcon A Soft Contact Lens for Daily Wear When Compared to the CooperVision Ocufilcon B Soft Contact Lens|Completed||Early Phase 1|90|Actual|Coopervision, Inc.||2|||f||||t||||||||||2018-05-31 22:36:55.153659|2018-05-31 22:36:55.153659
NCT01354210|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2018-01-25|2011-05-13|2011-05-16|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2010||2010-10-31|January 2018|2018-01-31|February 2014|Actual|2014-02-28|March 2013|Actual|2013-03-31||Interventional|TXTXT||Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth|Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth|Completed||N/A|110|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 22:36:55.435955|2018-05-31 22:36:55.435955
NCT01354197|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2016-10-04||2017-02-05|2011-05-13|2011-05-16|Estimate|2017-02-05|2017-03-27|Actual||||2017-02-05|2017-03-27|Actual|April 2011||2011-04-30|February 2017|2017-02-28|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|THAI-SICU||The Thai Surgical Intensive Care Study (Thai-SICU Study)|Multicenter Study of Outcome and Adverse Events in Surgical Intensive Care Unit of Thai University Hospital|Completed|||4652|Actual|Royal College of Anesthesiologists of Thailand|||1||f||||t||||||||Yes|All the data was managed by the the Medical Research Network of the Consortium of Thai Medical Schools (MedResNet)|2018-05-31 22:36:55.502269|2018-05-31 22:36:55.502269
NCT01354184|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2012-11-05|2011-05-13|2011-05-16|Estimate|||||||2012-11-05|2012-11-06|Estimate||||November 2012|2012-11-30||||||||Interventional|||CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial)|An International, Multi-centre, Randomised, Stratified, Double-blinded, Placebo-controlled, 4-parallel Group Trial Investigating the Efficacy and Safety of Three Different Dose Levels of CRD007 (The AORTA Trial)|Completed||Phase 2|||RSPR Pharma AB||4|||f||||||||||||||2018-05-31 22:36:56.707781|2018-05-31 22:36:56.707781
NCT01354171|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2016-10-13|2011-05-13|2011-05-16|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2011||2011-11-30|March 2012|2012-03-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Interventional|ASIST||Active Surveillance Magnetic Resonance Imaging Study|Active Surveillance Magnetic Resonance Imaging Study|Unknown status|Active, not recruiting|Phase 3|250|Anticipated|Canadian Urology Research Consortium||2|||f||||t||||||||||2018-05-31 22:36:56.802878|2018-05-31 22:36:56.802878
NCT01354158|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2013-07-29|2011-05-13|2011-05-16|Estimate|||||||2013-07-29|2013-07-30|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Dose Titration of Droxidopa in Patients With Spinal Cord Injury|A Dose Response Trial of Droxidopa to Treat Hypotension in Persons With SCI|Completed||Phase 1|11|Actual|Bronx VA Medical Center||1|||f||||f||||||||||2018-05-31 22:36:56.901874|2018-05-31 22:36:56.901874
NCT01354145|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2016-02-18||2016-07-12|2011-05-13|2011-05-16|Estimate|2016-07-12|2016-08-19|Estimate||||2016-07-12|2016-08-19|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|MOSAIC||Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI|Twenty-four Month Exploratory Study of the Effect of Chondroitin Sulphate on Structural Changes in Knee Osteoarthritis Patients as Assessed by MRI|Completed||Phase 3|194|Actual|Bioiberica||2|||f||||t||||||||No||2018-05-31 22:36:57.021346|2018-05-31 22:36:57.021346
NCT01354132|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2017-03-17||2017-06-13|2011-05-13|2011-05-16|Estimate|2017-05-09|2017-06-07|Actual||||2017-06-13|2017-07-05|Actual|May 2011||2011-05-31|June 2017|2017-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NACPSY||N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis|Effects of Oral N-Acetyl-Cysteine (NAC) in the Early Phase of Schizophrenia Spectrum Psychosis: Randomized, Parallel, Double- Blind, Placebo Controlled Trial|Completed||Phase 2|20|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 22:36:58.192768|2018-05-31 22:36:58.192768
NCT01354106|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2012-07-20||2012-10-10|2011-05-13|2011-05-16|Estimate|2012-10-10|2012-10-12|Estimate||||2012-10-10|2012-10-12|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Adhesive Tape Trauma Evaluation of Two Gentle Tapes|Adhesive Tape Trauma Evaluation of Two Gentle Tapes in Healthy Human Infant Subjects|Completed||N/A|26|Actual|3M||2|||f||||f||||||||||2018-05-31 22:36:59.998659|2018-05-31 22:36:59.998659
NCT01354093|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-06-21|2011-05-13|2011-05-16|Estimate|||||||2017-06-21|2017-06-23|Actual|November 2011||2011-11-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)|Utah Center for the Collaborative Study of the Role of the Macular Pigment Carotenoids in the Pathogenesis and Treatment of MacTel|Completed|||8|Actual|University of Utah|||2||f||||t||||||||||2018-05-31 22:37:00.387507|2018-05-31 22:37:00.387507
NCT01354080|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-05-13|2011-05-13|2011-05-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|June 2007||2007-06-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||The Effectiveness of Massage in Treating Constipation|Comparison of the Effectiveness of Massage Based on the Tensegrity Rule and Classical Abdominal Massage in Persons With Constipation|Completed||N/A|29|Actual|University School of Physical Education in Wroclaw||2|||f||||f||||||||||2018-05-31 22:37:00.475116|2018-05-31 22:37:00.475116
NCT01354067|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2012-06-19|2011-05-13|2011-05-16|Estimate|||||||2012-06-19|2012-06-21|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|COPD||Single Limb Resistance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effects of High-repetitive Single Limb Training on Exercise Capacity and Quality of Life in Patients With COPD Compared to a Control Group - A Prospective, Single Blind, Randomized Controlled Multicenter Trial|Completed||N/A|44|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 22:37:00.569075|2018-05-31 22:37:00.569075
NCT01354054|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-12|2011-05-12|2011-05-16|Estimate|||||||2011-05-12|2011-05-16|Estimate|November 2006||2006-11-30|May 2011|2011-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TOPS||TENS Effectiveness and Knee Osteoarthritis in Humans|Effects of a Single Treatment of High or Low Frequency TENS on Pain, Hyperalgesia and Function in Patients With Knee Osteoarthritis|Completed||N/A|100|Actual|University of Iowa||4|||f||||t||||||||||2018-05-31 22:37:00.652676|2018-05-31 22:37:00.652676
NCT01354041|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2014-01-23|2011-05-13|2011-05-16|Estimate|||||||2014-01-23|2014-01-27|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|WiLLoW||Fear of Recurrence Pilot Intervention for Women With Breast Cancer|A Pilot Intervention to Address Fear of Recurrence in Breast Cancer Survivors|Completed||Phase 1|28|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:37:00.770052|2018-05-31 22:37:00.770052
NCT01354028|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2013-01-30||2013-04-25|2011-05-12|2011-05-16|Estimate|2013-04-25|2013-06-03|Estimate||||2013-04-25|2013-06-03|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effects of Massage Therapy to Induce Sleep in Preterm Infants|Effects of Massage Therapy to Induce Sleep in Preterm Infants|Completed||N/A|30|Actual|University of Arkansas|The sample size was small. 30 infants were enrolled, but 7 infants were discharged or became ineligible and could not start the study.|2|||f||||t||||||||||2018-05-31 22:37:00.875465|2018-05-31 22:37:00.875465
NCT01354015|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2014-12-30||2017-03-25|2011-05-12|2011-05-16|Estimate|2015-01-12|2015-01-13|Estimate||||2017-03-25|2017-05-09|Actual|May 2011||2011-05-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|DRMS||Diabetes Remote Care Management System|Diabetes Remote Care Management System|Completed||N/A|98|Actual|Tulane University||2|||f||||f||||||||||2018-05-31 22:37:01.082636|2018-05-31 22:37:01.082636
NCT01354002|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-10-17|2011-05-12|2011-05-16|Estimate|||||||2017-10-17|2017-10-18|Actual|September 1, 2009|Actual|2009-09-01|October 2017|2017-10-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|||Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility|Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility|Recruiting|||100000|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Samples collected and processed from patients include any tumor or non-tumor sample,~     including blood, ascites, pleural effusion, bone marrow, solid tumors, brain tumors, tissue~     uninvolved by tumor, cerebrospinal fluid, and urine samples. Non-tumor samples are also~     collected and processed from patients' relatives and controls. Samples are processed under~     sterile conditions whenever possible, and tumor cells and tissues are cryopreserved viable.~     Cellular subfractions are also isolated including DNA, RNA, and protein.~   "|||2018-05-31 22:37:01.438769|2018-05-31 22:37:01.438769
NCT01353989|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2016-06-27|2011-05-12|2011-05-16|Estimate|||||||2016-06-27|2016-06-28|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Hepatitis A Vaccination in the Elderly|Hepatitis A Vaccination in the Elderly|Completed|||60|Actual|Rijnstate Hospital|||2||f||||f||||||Samples With DNA|"~     5 times 7 ml of blood will be collected~   "|||2018-05-31 22:37:01.573066|2018-05-31 22:37:01.573066
NCT01353976|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2012-12-05||2012-12-05|2011-05-12|2011-05-16|Estimate|2012-12-05|2013-01-09|Estimate||||2012-12-05|2013-01-09|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis|A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Interdigital Tinea Pedis|Completed||Phase 3|264|Actual|AmDerma||2|||f||||f||||||||||2018-05-31 22:37:01.647041|2018-05-31 22:37:01.647041
NCT01353963|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2015-12-04||2015-12-04|2011-05-12|2011-05-16|Estimate|2015-12-04|2016-01-18|Estimate||||2015-12-04|2016-01-18|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational||Safety population included all participants who received at least 1 dose of study medication during the observation period.|Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients|An Open Label, Non-interventional Study Of The Safety Of Desvenlafaxine Succinate (Pristiq) In The Treatment Of Major Depressive Disorder (Mdd) And Vasomotor Symptoms (Vms) Associated With Menopause In Filipino Adult Patients: A Post Marketing Surveillance Study|Terminated|||13|Actual|Pfizer|Due to the low number of subjects with data available, only descriptive summaries have been presented. The outcomes measures were prioritized as per study team's discretion.||1||f||||f||||||||||2018-05-31 22:37:02.06744|2018-05-31 22:37:02.06744
NCT01353950|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-04-04|2011-05-13|2011-05-16|Estimate|||||||2017-04-04|2017-04-06|Actual|July 2011||2011-07-31|April 2017|2017-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Costimulatory Molecules as Biomarkers in Cystic Fibrosis|Costimulatory Molecules as Biomarkers in Cystic Fibrosis|Completed|||40|Actual|Oregon Health and Science University|||1||f||||f||||||Samples Without DNA|"~     Plasma, Serum, urine~   "|||2018-05-31 22:37:02.296562|2018-05-31 22:37:02.296562
NCT01353937|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2016-03-02|2011-05-12|2011-05-16|Estimate|||||||2016-03-02|2016-03-04|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|AMD3100||Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers|Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers|Withdrawn||Phase 1|0|Actual|New York University School of Medicine||3||Never Activated|f||||t||||||||||2018-05-31 22:37:02.464705|2018-05-31 22:37:02.464705
NCT01353924|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-12|2011-05-12|2011-05-16|Estimate|||||||2011-05-12|2011-05-16|Estimate|August 2011||2011-08-31|April 2011|2011-04-30|December 2013|Anticipated|2013-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1|Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 22:37:02.616721|2018-05-31 22:37:02.616721
NCT01353911|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2016-02-03||2017-03-01|2011-05-13|2011-05-16|Estimate|2016-02-03|2016-03-02|Estimate||||2017-03-01|2017-03-30|Actual|June 2011||2011-06-30|March 2017|2017-03-31|March 2015|Actual|2015-03-31|January 2013|Actual|2013-01-31||Interventional||Full Analysis Set (FAS); all randomized/enrolled participants who received ≥1 dose of study treatment. Results for participants who received grazoprevir 400 or 800 mg and were then down-dosed to receive grazoprevir 100 mg are reported separately from participants who completed the 400 mg and 800 mg regimens.|Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)|A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection|Completed||Phase 2|368|Actual|Merck Sharp & Dohme Corp.||8|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:37:02.781112|2018-05-31 22:37:02.781112
NCT01353898|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2016-01-06||2017-02-23|2011-05-12|2011-05-16|Estimate|2016-01-06|2016-02-05|Estimate||||2017-02-23|2017-03-27|Actual|June 2011||2011-06-30|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||All randomized participants|Study of MK-1972 in Human Immunodeficiency Virus (HIV)-1 Infected Participants Who Have Not Previously Received Antiretroviral Therapy (MK-1972-003)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1972 in HIV-1 Infected Patients|Terminated||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 22:37:04.588481|2018-05-31 22:37:04.588481
NCT01353885|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2014-08-12|2011-05-12|2011-05-16|Estimate|||||||2014-08-12|2014-08-13|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|AAP||Outcomes Following Anterior Approach to Total Hip Arthroplasty|Outcomes Following Anterior Approach to Total Hip Arthroplasty: A Multi-Centre Observational Cohort Study|Terminated|||50|Actual|McMaster University|||3||f||||f||||||||||2018-05-31 22:37:05.06686|2018-05-31 22:37:05.06686
NCT01353872|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2011-05-13|2011-05-13|2011-05-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Nutrition Effects on Fatigue During Tennis Playing|Effects of Ingestion of Different Sports Drinks on Fatigue During Playing Tennis|Completed||N/A|8|Actual|Lescuyer Laboratory||2|||f||||t||||||||||2018-05-31 22:37:05.164703|2018-05-31 22:37:05.164703
NCT01353859|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|2014-04-22||2014-05-08|2011-05-13|2011-05-16|Estimate|2014-05-08|2014-06-06|Estimate||||2014-05-08|2014-06-06|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Intent to treat (ITT) population: all participants included in the study who received at least one dose of study medication. Participants prematurely withdrawn from the study will be considered as nonresponders at the end of the study in all analyses of treatment response variables.|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs|An Open Label, Local, Multicenter , Phase IIIb Interventional Study to Assess the Efficacy of Tocilizumab (TCZ) in Combination With Methotrexate (MTX) in Indonesian Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs|Completed||Phase 3|39|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:37:05.25468|2018-05-31 22:37:05.25468
NCT01353846|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2012-03-30|2011-05-13|2011-05-16|Estimate|||||||2012-03-30|2012-04-02|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients|Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients|Unknown status|Recruiting|Phase 4|70|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 22:37:05.564716|2018-05-31 22:37:05.564716
NCT01353833|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2012-04-20|2011-05-13|2011-05-16|Estimate|||||||2012-04-20|2012-04-23|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|DF-IL2||Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes|Dose-effect Relationship of Repeated Administration of Low-dose IL-2 Versus Placebo on the Kinetic of Regulatory T Cells in Patients With Type 1 Diabetes|Completed||Phase 1/Phase 2|25|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||t||||||||||2018-05-31 22:37:05.647813|2018-05-31 22:37:05.647813
NCT01353820|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2016-10-26|2011-05-13|2011-05-16|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Lactobacillus Delbruckii Lactis DN111244 Fermented Milk Consumption on Plasma Lipids Levels in Hypercholesterolaemic Adults|Proof of Concept -Effects of Lactobacillus Delbruckii Lactis DN111244 Fermented Milk Consumption on Plasma Lipids Levels in Hypercholesterolaemic Adults.|Completed||N/A|100|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 22:37:05.72236|2018-05-31 22:37:05.72236
NCT01353807|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2014-02-27|2011-05-13|2011-05-16|Estimate|||||||2014-02-27|2014-02-28|Estimate|November 1989||1989-11-30|February 2014|2014-02-28|May 2011|Actual|2011-05-31|December 1990|Actual|1990-12-31||Interventional|||Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health|Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health|Completed||N/A|533|Actual|Centre for Fetal Programming, Denmark||3|||f||||t||||||||||2018-05-31 22:37:05.778967|2018-05-31 22:37:05.778967
NCT01353794|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2015-01-29|2011-05-13|2011-05-16|Estimate|||||||2015-01-29|2015-01-30|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|April 2018|Anticipated|2018-04-30|September 2017|Anticipated|2017-09-30||Observational|POWER-NEXT||Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer|Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar® in Advanced Renal Cell Carcinoma|Withdrawn|||0|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:37:05.858526|2018-05-31 22:37:05.858526
NCT01353781|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2016-04-25|2011-05-13|2011-05-16|Estimate|||||||2016-04-25|2016-04-26|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Japanese Patients With Advanced Solid Malignancies|Completed||Phase 1|39|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-05-31 22:37:05.923922|2018-05-31 22:37:05.923922
NCT01353768|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-11-21|2011-05-12|2011-05-16|Estimate|||||||2016-11-21|2016-11-23|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study|Medical Record Review and Data Abstraction for Pediatric, Adolescent and Pregnant Patients Treated With IV Zanamivir in the Relenza Compassionate Use Program|Completed|||113|Actual|GlaxoSmithKline|||1||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:37:05.988098|2018-05-31 22:37:05.988098
NCT01353755|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2014-11-12|2011-05-13|2011-05-16|Estimate|||||||2014-11-12|2014-11-13|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|August 2012|Actual|2012-08-31||Interventional|||2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma|Randomised Double Blind Placebo Controlled Pivotal Study to Evaluate Efficacy and Safety of rPhleum in Adult and Adolescent Patients Suffering From Rhinoconjunctivitis +/- Controlled Asthma|Completed||Phase 3|195|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-05-31 22:37:06.072237|2018-05-31 22:37:06.072237
NCT01353742|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2017-08-02|2011-05-12|2011-05-16|Estimate|||||||2017-08-02|2017-08-04|Actual|February 21, 2011|Actual|2011-02-21|August 2017|2017-08-31|April 12, 2011|Actual|2011-04-12|April 12, 2011|Actual|2011-04-12||Interventional|||Lamivudine and Adefovir Dipivoxil Fixed Dose Combination|A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of Lamivudine and Adefovir Dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg)|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:37:06.315585|2018-05-31 22:37:06.315585
NCT01353729|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-07-18|2011-05-13|2011-05-16|Estimate|||||||2017-07-18|2017-07-21|Actual|May 19, 2011|Actual|2011-05-19|July 2017|2017-07-31|August 2, 2011|Actual|2011-08-02|August 2, 2011|Actual|2011-08-02||Interventional|||A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers|A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) With Moxifloxacin as a Positive Control in Healthy Volunteers|Completed||Phase 1|40|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:37:06.419392|2018-05-31 22:37:06.419392
NCT01353716|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2012-04-26|2011-05-12|2011-05-16|Estimate|||||||2012-04-26|2012-04-30|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Dolutegravir Renal Impairment Study|A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of Dolutegravir in Subjects With Renal Impairment and Healthy Matched Control Subjects (ING113125)|Completed||Phase 1|16|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 22:37:06.525668|2018-05-31 22:37:06.525668
NCT01353703|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12||2013-04-18|2014-07-10|2011-05-12|2011-05-16|Estimate||||2013-04-18|2013-04-26|Estimate|2014-07-10|2014-07-14|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa™ Vaccine in Healthy Infants in India|Completed||Phase 3|214|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:37:06.597402|2018-05-31 22:37:06.597402
NCT01353690|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2014-07-28|2011-05-12|2011-05-16|Estimate|||||||2014-07-28|2014-07-29|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Autologous Cell Therapy for Ischemic Heart Failure|A Prospective, Multicenter, Feasibility Study of Autologous Muscle-derived Cell (AMDC) Transplantation for Treatment of Advanced Ischemic Heart Failure|Terminated||Phase 1/Phase 2|9|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 22:37:06.675232|2018-05-31 22:37:06.675232
NCT01353677|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-07-24|2011-05-13|2011-05-16|Estimate|||||||2017-07-24|2017-07-25|Actual|July 2011|Actual|2011-07-31|July 2017|2017-07-31|October 30, 2014|Actual|2014-10-30|October 30, 2014|Actual|2014-10-30||Observational|09-SQOL||Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database|Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database|Completed|||390|Actual|Center for International Blood and Marrow Transplant Research|||1||f||||t||||||||||2018-05-31 22:37:06.734839|2018-05-31 22:37:06.734839
NCT01353664|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2013-10-29||2016-04-15|2011-05-13|2011-05-16|Estimate|2013-10-29|2013-12-19|Estimate||||2016-04-15|2016-04-19|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Rollover Study for Patients Who Participated in Other Romidepsin Protocols|An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols|Completed||Phase 2|19|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 22:37:06.882979|2018-05-31 22:37:06.882979
NCT01353651|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2015-12-22|2011-05-11|2011-05-13|Estimate|||||||2015-12-22|2015-12-23|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|September 2015|Actual|2015-09-30|October 2013|Actual|2013-10-31||Interventional|TECCO||Endovascular Versus Open Repair of the Common Femoral Artery|Endovascular Versus Open Repair of the Common Femoral Artery: a Randomized Trial (TECCO)|Completed||Phase 4|120|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 22:37:07.176808|2018-05-31 22:37:07.176808
NCT01353638|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2015-09-09|2011-05-11|2011-05-13|Estimate|||||||2015-09-09|2015-09-11|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis|An Open Label, Randomized, Two-Period Crossover Study to Evaluate the Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solutions in Peritoneal Dialysis (PD) (Ala-Gln in PD)|Terminated||Phase 1/Phase 2|25|Actual|Medical University of Vienna||2||"Primary endpoint (HSP) could not be analyzed with the specified method in the planned interim~   analysis; a method of increased sensitivity had to be established."|f||||t||||||||||2018-05-31 22:37:07.276911|2018-05-31 22:37:07.276911
NCT01353625|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2018-02-28|2011-05-12|2011-05-13|Estimate|||||||2018-02-28|2018-03-01|Actual|April 25, 2011|Actual|2011-04-25|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.|A Phase 1a/1b, Multicenter, Open Label, Dosefinding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual Dna-pk and Tor Kinase Inhibitor, Cc-115, Administered Orally to Subjects With Advanced Solid Tumors and Hematologic Malignancies|Active, not recruiting||Phase 1|119|Actual|Celgene||1|||f||||f||||||||||2018-05-31 22:37:07.363238|2018-05-31 22:37:07.363238
NCT01353612|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-02-02|2011-05-12|2011-05-13|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|||Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes|Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes|Unknown status|Active, not recruiting||300|Anticipated|Canadian Atherosclerosis Imaging Network|||||f||||f||||||Samples With DNA|"~     samples stored for potential correlation with imaging and cardiovascular outcomes endpoints~     in subset of patients (optional)~   "|||2018-05-31 22:37:07.472985|2018-05-31 22:37:07.472985
NCT01353599|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-10-22|2011-05-12|2011-05-13|Estimate|||||||2015-10-22|2015-10-23|Estimate|August 2011||2011-08-31|October 2015|2015-10-31||||March 2016|Anticipated|2016-03-31||Interventional|||Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury|Acute and Chronic Effects of Inhaled Steroids on Pulmonary Function in Persons With Spinal Cord Injury|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|James J. Peters Veterans Affairs Medical Center||1|||f||||f||||||||||2018-05-31 22:37:07.585286|2018-05-31 22:37:07.585286
NCT01353586|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|2015-09-20||2017-05-09|2011-05-12|2011-05-13|Estimate|2015-12-22|2016-02-02|Estimate||||2017-05-09|2017-06-06|Actual|March 1, 2011|Actual|2011-03-01|May 2017|2017-05-31|September 1, 2013|Actual|2013-09-01|September 1, 2013|Actual|2013-09-01||Interventional|REVOLUTION|Safety population (cohort): For the main study, this population includes enrolled subjects who underwent insertion of study catheters. For the NAVISTAR® THERMOCOOL® arm, this population includes enrolled subjects, but excludes two subjects (1 with low pre-ablation international normalized ratio (INR) and 1 missing post procedure neurological exam).|REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation|REVOLUTION (WFCC-133): Clinical Workflow Study for the Evaluation of the Multi-Electrode Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation (PAF)|Completed||Phase 2|186|Actual|Biosense Webster, Inc.||1|||f||||t|f|t|t|f|t|||||2018-05-31 22:37:07.705275|2018-05-31 22:37:07.705275
NCT01353573|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-12|2011-05-12|2011-05-13|Estimate|||||||2011-05-12|2011-05-13|Estimate|July 2011||2011-07-31|May 2011|2011-05-31|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Interventional|TRICK||Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases|A Randomized Trial of Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 22:37:08.250822|2018-05-31 22:37:08.250822
NCT01353560|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-06-12|2011-05-12|2011-05-13|Estimate|||||||2017-06-12|2017-06-14|Actual|May 2011||2011-05-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study 1-Survey|Use and Effectiveness of a Model Integrative Care Clinic in an Academic Hospital: Study 1-Survey|Completed|||1509|Actual|Brigham and Women's Hospital|||1||f||||t||||||||||2018-05-31 22:37:08.332207|2018-05-31 22:37:08.332207
NCT01353547|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2016-01-26|2011-05-12|2011-05-13|Estimate|||||||2016-01-26|2016-01-28|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Observational|GEMS||Genes and Environment in Multiple Sclerosis|Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility|Recruiting|||5000|Anticipated|Brigham and Women's Hospital|||3||f||||t||||||Samples With DNA|"~     Saliva Sample (required), Blood Sample (optional)~   "|||2018-05-31 22:37:08.490577|2018-05-31 22:37:08.490577
NCT01353534|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2012-10-17|2011-05-12|2011-05-13|Estimate|||||||2012-10-17|2012-10-18|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|||Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine|A Phase 1/2, Randomized, Open-Label, Study to Assess the Immunogenicity and Safety of a Vaccine Enhancement Patch (VEP) When Administered With Two Doses of Intramuscular Inactivated Influenza H5N1 Vaccine in Healthy Adults|Completed||Phase 1/Phase 2|276|Actual|Intercell USA, Inc.||4|||f||||t||||||||||2018-05-31 22:37:08.557958|2018-05-31 22:37:08.557958
NCT01353521|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2018-04-02|2011-05-12|2011-05-13|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2013||2013-12-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Contrast-enhanced Ultrasound for the Evaluation of Complex Renal Cysts|Contrast-enhanced Ultrasound for the Evaluation of Complex Renal Cysts|Recruiting||N/A|40|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||||2018-05-31 22:37:08.642227|2018-05-31 22:37:08.642227
NCT01353508|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2015-07-15|2014-01-21|2015-10-20|2011-05-12|2011-05-13|Estimate|2015-10-20|2015-11-23|Estimate|2014-01-21|2014-02-14|Estimate|2015-10-20|2015-11-23|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers|A Randomized, Double-blind, Controlled, Crossover Study to Evaluate the Sodium Excretion of LCZ696 in Patients With Stable Heart Failure, in Patients With Hypertension, and in Healthy Volunteers|Completed||Phase 2|32|Actual|Novartis|Regarding LSM = 1218.56 for LCZ696 HTN cohort arm at Day 1, 1.0 hr post dose, the value was heavily inflated due to one participant with a very high change from baseline.|4|||f||||||||||||||2018-05-31 22:37:08.790487|2018-05-31 22:37:08.790487
NCT01353495|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-06-06|2011-05-12|2011-05-13|Estimate|||||||2011-06-06|2011-06-07|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers|A Prospective, Randomized Comparative Parallel Study of Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers|Completed||Phase 3|40|Actual|Wright Medical Technology|||||f||||t||||||||||2018-05-31 22:37:10.399643|2018-05-31 22:37:10.399643
NCT01353482|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2012-03-21|2011-05-12|2011-05-13|Estimate|||||||2012-03-21|2012-03-22|Estimate||||March 2012|2012-03-31||||||||Interventional|MESO-02||A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma|A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma|Withdrawn||Phase 1/Phase 2|0|Actual|University College, London||2||"UCL CTC were informed by Merck Sharp & Dohme on 22.08.11 that support for the trial had been~   withdrawn in light of results from another trial with trial drug."|f||||||||||||||2018-05-31 22:37:10.498045|2018-05-31 22:37:10.498045
NCT01353469|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2013-02-26|2011-05-12|2011-05-13|Estimate|||||||2013-02-26|2013-02-27|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Insuman-C25-CN||Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy|A Multicenter, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Insuman Comb 25 (Insulin Human) Versus Novolin® 30R Twice Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus Who Are Under Insulin Therapy|Completed||Phase 3|485|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:37:10.618572|2018-05-31 22:37:10.618572
NCT01353456|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-04-02|2011-05-12|2011-05-13|Estimate|||||||2013-04-02|2013-04-04|Estimate|May 2008||2008-05-31|April 2013|2013-04-30|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery|Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery|Completed||Phase 3|100|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:37:10.77388|2018-05-31 22:37:10.77388
NCT01353443|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-11-18|2011-05-12|2011-05-13|Estimate|||||||2014-11-18|2014-11-19|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair|Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair. A Prospective, Randomised, Controlled Study|Unknown status|Active, not recruiting|Phase 4|282|Anticipated|Universitätsklinikum Hamburg-Eppendorf||3|||f||||f||||||||||2018-05-31 22:37:10.861789|2018-05-31 22:37:10.861789
NCT01353430|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-05-12|2011-05-12|2011-05-13|Estimate|||||||2011-05-12|2011-05-13|Estimate|January 2000||2000-01-31|May 2011|2011-05-31||||December 2025|Anticipated|2025-12-31||Observational|||Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)|Characterization of Familial Myopathy and Paget Disease of Bone|Recruiting|||50|Anticipated|University of California, Irvine|||1||f||||f||||||Samples With DNA|"~     Whole blood, skin and muscle biopsy, urine sample, if available samples obtained from~     previous diagnostic evaluations such as muscle biopsy.~   "|||2018-05-31 22:37:10.934657|2018-05-31 22:37:10.934657
NCT01353417|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2017-04-05|2011-05-12|2011-05-13|Estimate|||||||2017-04-05|2017-04-07|Actual|April 2011||2011-04-30|April 2017|2017-04-30|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Observational|||Non-interventional-study With Tacrolimus Sandoz© Capsules for Prophylaxis of Renal Graft Rejection|A Single-site, Prospective Non-interventional-study With Adport Sandoz© Capsules for Prophylaxis of Graft Rejection in Patients With Stable Kidney Function After Renal Allograft.|Completed|||102|Actual|Sandoz|||1||f||||t||||||Samples Without DNA|"~     Retained types of biospecimen: whole blood, serum, urine~   "|||2018-05-31 22:37:10.996702|2018-05-31 22:37:10.996702
NCT01353404|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2012-12-16|2011-05-12|2011-05-13|Estimate|||||||2012-12-16|2012-12-18|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)|Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg) in Normal Healthy Subjects|Completed||Phase 1|24|Actual|Samyang Biopharmaceuticals Corporation||3|||f||||f||||||||||2018-05-31 22:37:11.073975|2018-05-31 22:37:11.073975
NCT01353391|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2017-10-17|2011-05-12|2011-05-13|Estimate|||||||2017-10-17|2017-10-19|Actual|May 2011||2011-05-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|MiTy||Metformin in Women With Type 2 Diabetes in Pregnancy Trial|Metformin in Women With Type 2 Diabetes in Pregnancy Trial|Recruiting||Phase 3|500|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-05-31 22:37:11.141719|2018-05-31 22:37:11.141719
NCT01353378|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-05-02|2011-05-11|2011-05-13|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2011||2011-06-30|May 2017|2017-05-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Use of Dexmedetomidine in Children Undergoing Oral Maxillofacial Surgery to Decrease Emergence Delirium|Use of Dexmedetomidine in Children Undergoing Oral Maxillofacial Surgery to Decrease Emergence Delirium|Withdrawn||Phase 4|0|Actual|Shanghai 9th People's Hospital||1||The study was not approved by Hospital's Medical Ethics Committee.|f||||t||||||||||2018-05-31 22:37:11.385806|2018-05-31 22:37:11.385806
NCT01353365|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2011-05-12|2011-05-12|2011-05-13|Estimate|||||||2011-05-12|2011-05-13|Estimate|June 2011||2011-06-30|April 2011|2011-04-30||||||||Observational|||Surfactant Associated Protein - A Novel Marker for the Diagnosis of Pulmonary Embolism|Surfactant Associated Protein - A Novel Marker for the Diagnosis of Pulmonary Embolism|Unknown status|Not yet recruiting||150|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 22:37:11.467304|2018-05-31 22:37:11.467304
NCT01353352|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2011-05-12|2011-05-12|2011-05-13|Estimate|||||||2011-05-12|2011-05-13|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Evaluation of the Nursing C-Spine (Phase IV)|Evaluation of the Safety of C-Spine Clearance by Emergency Department Triage Nurses (Phase IV)|Completed||Phase 4|3633|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 22:37:11.524945|2018-05-31 22:37:11.524945
NCT01353339|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2014-10-14|2011-05-12|2011-05-13|Estimate|||||||2014-10-14|2014-10-15|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study|Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study|Completed||Phase 4|154|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 22:37:11.595677|2018-05-31 22:37:11.595677
NCT01353326|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2018-03-29|2011-05-12|2011-05-13|Estimate|||||||2018-03-29|2018-04-02|Actual|May 15, 2009|Actual|2009-05-15|March 2018|2018-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bone Mineral Density (BMD) in Cemented Versus Cementless Hip Resurfacing|Randomized Clinical Trial of a Cemented Versus Cementless Femoral Component for Metal on Metal Hip Resurfacing Assessing Bone Mineral Density|Completed||N/A|120|Actual|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||||2018-05-31 22:37:11.687084|2018-05-31 22:37:11.687084
NCT01353313|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-12-13|2011-05-11|2011-05-13|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2011||2011-09-30|December 2017|2017-12-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Hydrocortisone for BPD|A Randomized Controlled Trial of the Effect Of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age|Recruiting||Phase 3|800|Anticipated|NICHD Neonatal Research Network||2|||f||||t|t|f||||||Yes|NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov)|2018-05-31 22:37:11.831703|2018-05-31 22:37:11.831703
NCT01353300|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2016-07-07|2011-05-12|2011-05-13|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2011||2011-05-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer|Investigation of DICER1 in Cystic Nephroma and Cystic Partially Differentiated Nephroblastoma|Completed|||31|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:37:11.991197|2018-05-31 22:37:11.991197
NCT01353287|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-07-30|2011-05-12|2011-05-13|Estimate|||||||2013-07-30|2013-08-01|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|VERITAS||Transcatheter Aortic Valve Intervention-Live Transmission|Transcatheter Aortic Valve Intervention-Live Transmission (VERITAS)Study|Completed|||110|Actual|Medstar Health Research Institute|||2||f||||t||||||||||2018-05-31 22:37:12.067416|2018-05-31 22:37:12.067416
NCT01353274|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2014-07-30||2014-07-30|2011-05-12|2011-05-13|Estimate|2014-07-30|2014-08-18|Estimate||||2014-07-30|2014-08-18|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension|Survey on Drug Use of Micamlo Combination Tablets AP in Patients With Hypertension|Completed|||1157|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 22:37:12.222243|2018-05-31 22:37:12.222243
NCT01353261|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-10-31|2011-05-12|2011-05-13|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Platelet Function Monitoring in Patients With Acute Myocardial Infarction|Platelet Function Monitoring in Patients With Acute Myocardial Infarction|Completed|||63|Actual|Medstar Health Research Institute|||3||f||||f||||||||||2018-05-31 22:37:13.053473|2018-05-31 22:37:13.053473
NCT01353248|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22||2013-11-26|2013-11-26|2011-05-11|2011-05-13|Estimate||||2013-11-26|2013-12-20|Estimate|2013-11-26|2013-12-20|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection|A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 2|141|Actual|Gilead Sciences||2|||f||||||||||||||2018-05-31 22:37:13.145254|2018-05-31 22:37:13.145254
NCT01353235|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-07-31|2011-05-12|2011-05-13|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2010||2010-04-30|July 2017|2017-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|A Prospective Randomized Trial of Systemic Corticosteroids (Oral Prednisolone) in Severe Exacerbation of COPD Requiring Ventilatory Assistance|Completed||Phase 3|317|Actual|Hôpital Universitaire Fattouma Bourguiba||2|||f||||f||||||||No|There is no plan to IPD so far|2018-05-31 22:37:13.288325|2018-05-31 22:37:13.288325
NCT01353222|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2017-03-08||2017-04-21|2011-05-11|2011-05-13|Estimate|2017-04-21|2017-05-25|Actual||||2017-04-21|2017-05-25|Actual|June 2011||2011-06-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Intent to treat population|DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma|A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma|Terminated||Phase 2|142|Actual|Dendreon||2||Administrative reasons.|f||||t||||||||Undecided||2018-05-31 22:37:13.402011|2018-05-31 22:37:13.402011
NCT01353209|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2015-08-24|2011-05-11|2011-05-12|Estimate|||||||2015-08-24|2015-08-26|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|TRAIL||Trial of Aromatase Inhibition in Lymphangioleiomyomatosis|A TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS|Completed||Phase 2|17|Actual|University of Cincinnati||2|||f||||t||||||||||2018-05-31 22:37:14.008476|2018-05-31 22:37:14.008476
NCT01353196|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2018-03-14|2011-05-11|2011-05-12|Estimate|||||||2018-03-14|2018-03-15|Actual|May 15, 2011|Actual|2011-05-15|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|ACCOF||Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates|Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates|Completed|||184|Actual|VA Office of Research and Development|||2||f||||f|f|f|||f|Samples With DNA|"~     blood samples for inflammatory markers~   "|No||2018-05-31 22:37:14.083862|2018-05-31 22:37:14.083862
NCT01353183|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2013-09-18|2011-05-11|2011-05-12|Estimate|||||||2013-09-18|2013-09-19|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ColoBioParker||Analysis of the Enteric Nervous System Using Colonic Biopsies|Analysis of the Enteric Nervous System Using Colonic Biopsies: a Useful Biomarker for the Differential Diagnosis of Parkinsonian Syndromes?|Completed||N/A|34|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 22:37:14.13491|2018-05-31 22:37:14.13491
NCT01353170|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Calcium Concentration in Bicarbonate Hemodialysis (HD)|Comparison Among Different Dialysate Calcium Concentrations in Bicarbonate Hemodialysis|Completed||N/A|22|Actual|Miulli General Hospital||1|||f||||f||||||||||2018-05-31 22:37:14.327902|2018-05-31 22:37:14.327902
NCT01353157|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery|Prediction for Systemic Inflammation With Clinical Scoring Systems and Inflammatory Cytokine Levels in Adult Cardiac and Major Abdominal Surgical Patients|Completed|||20|Actual|Khon Kaen University|||1||f||||f||||||Samples Without DNA|"~     whole blood taken from arterial line~   "|||2018-05-31 22:37:14.549879|2018-05-31 22:37:14.549879
NCT01353144|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2015-09-14||2016-09-12|2011-05-11|2011-05-12|Estimate|2015-09-14|2015-10-14|Estimate||||2016-09-12|2016-11-01|Estimate|June 2007||2007-06-30|September 2016|2016-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers|A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers|Completed||Phase 4|178|Actual|Kaohsiung Veterans General Hospital.|The trial was performed in a single country|2|||f||||t||||||||||2018-05-31 22:37:14.825912|2018-05-31 22:37:14.825912
NCT01353131|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2015-09-01|2011-05-11|2011-05-12|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2010||2010-05-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Observational|PRIMERI||Personalized Risk Identification and Management for Arrhythmias and Heart Failure by ECG and MRI|Personalized Risk Identification and Management for Arrhythmias and Heart Failure by 12 Lead Electrocardiogram and Cardiac Magnetic Resonance Imaging.|Unknown status|Active, not recruiting||160|Anticipated|Johns Hopkins University|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, plasma.~   "|||2018-05-31 22:37:15.192663|2018-05-31 22:37:15.192663
NCT01353118|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2017-08-09|2011-05-11|2011-05-12|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2011||2011-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|GLUCOSURG2||The Effects of Glycemic Optimization Before Gastric Bypass Surgery|Investigation of the Effects of Glycaemic Optimisation Before Gastric Bypass Surgery on the Glycaemic Remission and Microvascular Complication Rates of Type 2 Diabetes Mellitus|Completed||N/A|50|Actual|Imperial College London||3|||f||||t||||||||Yes||2018-05-31 22:37:15.281229|2018-05-31 22:37:15.281229
NCT01353105|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|August 2011||2011-08-31|October 2010|2010-10-31|August 2015|Anticipated|2015-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion|Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|InCor Heart Institute||1|||f||||f||||||||||2018-05-31 22:37:15.367337|2018-05-31 22:37:15.367337
NCT01353092|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-08-25|2011-05-11|2011-05-12|Estimate|||||||2015-08-25|2015-08-26|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PEMFII||Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression|PEMF Treatment in Patients With Treatment Resistant Depression in On-going Antidepressant Drug Therapy. A Randomized, Double-blind, Clinically Controlled, Dose-response PEMF Trial for a Duration of Eight Weeks|Completed||Phase 3|65|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-05-31 22:37:15.469367|2018-05-31 22:37:15.469367
NCT01353079|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2014-09-08||2015-01-22|2011-05-11|2011-05-12|Estimate|2015-01-22|2015-02-05|Estimate||||2015-01-22|2015-02-05|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy|Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen|Completed||Phase 3|429|Actual|Greer Laboratories||2|||f||||f||||||||||2018-05-31 22:37:15.629442|2018-05-31 22:37:15.629442
NCT01353066|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate||||May 2011|2011-05-31||||||||Interventional|EURDSS||Gastric Bypass Versus Best Medical Treatment on Progression of Carotid-intima Media Thickness in Type 2 Diabetes Mellitus (T2DM)|Multicenter Randomized Prospective Trial on the Effects of Intensive Medical Treatment of Type 2 Diabetes With and Without Roux-in-Y Gastric Bypass Surgery on Carotid Intima Media Thickness in Grade I Obesity (BMI 30,0-34,9 kg/m2)|Unknown status|Not yet recruiting|Phase 2/Phase 3|240|Anticipated|Hospital Clinic of Barcelona||2|||f||||||||||||||2018-05-31 22:37:15.922787|2018-05-31 22:37:15.922787
NCT01353053|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|July 2010||2010-07-31|May 2010|2010-05-31||||||||Observational|||Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection|Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection|Unknown status|Recruiting||82|Anticipated|Federal University of São Paulo|||1||f||||f||||||||||2018-05-31 22:37:15.993472|2018-05-31 22:37:15.993472
NCT01353040|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2012-05-04|2011-05-11|2011-05-12|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6003 in Healthy Adult Volunteers|Completed||Phase 1|30|Anticipated|Sarepta Therapeutics||2|||f||||t||||||||||2018-05-31 22:37:16.060599|2018-05-31 22:37:16.060599
NCT01353027|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2012-03-27|2011-05-11|2011-05-12|Estimate|||||||2012-03-27|2012-03-28|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus|A Phase I Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-6002 in Healthy Adult Volunteers|Completed||Phase 1|30|Actual|Sarepta Therapeutics||2|||f||||t||||||||||2018-05-31 22:37:16.159684|2018-05-31 22:37:16.159684
NCT01353014|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2014-06-29|2011-05-11|2011-05-12|Estimate|||||||2014-06-29|2014-07-01|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Genetic Information and Dietary Intake Behaviour|Genetic Information and Dietary Intake Behaviour|Completed||Early Phase 1|138|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 22:37:16.246212|2018-05-31 22:37:16.246212
NCT01353001|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2016-01-04|2011-05-11|2011-05-12|Estimate|||||||2016-01-04|2016-01-05|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Weight Loss on Cardiovascular Disease Risk Factors in Obese Women|The Effect of Weight Loss and Exercise on Cardiovascular Disease Risk Factors in Class II and III Obese Women|Completed||N/A|24|Actual|University of Pittsburgh||3|||f||||f||||||||||2018-05-31 22:37:16.32526|2018-05-31 22:37:16.32526
NCT01352988|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2014-02-27|2011-05-11|2011-05-12|Estimate|||||||2014-02-27|2014-02-28|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|FumaCLE||Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus|Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Mono-Centre, Open-Label, Prospective Pilot Study|Completed||Phase 2|11|Actual|University Hospital Muenster||1|||f||||f||||||||||2018-05-31 22:37:16.398155|2018-05-31 22:37:16.398155
NCT01352975|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2018-03-27|2011-05-11|2011-05-12|Estimate|||||||2018-03-27|2018-03-29|Actual|May 11, 2011||2011-05-11|February 9, 2018|2018-02-09||||||||Observational|||Study of Dark Adaptation in Age-Related Macular Degeneration|Longitudinal Investigation of Dark Adaptation in Participants With Age-Related Macular Degeneration|Recruiting|||280|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:37:16.476473|2018-05-31 22:37:16.476473
NCT01352962|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2018-02-13|2011-05-11|2011-05-12|Estimate|||||||2018-02-13|2018-02-14|Actual|May 11, 2011||2011-05-11|August 4, 2017|2017-08-04|August 1, 2020|Anticipated|2020-08-01|February 7, 2017|Actual|2017-02-07||Interventional|||Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors|A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors|Active, not recruiting||Phase 1|18|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:37:16.560673|2018-05-31 22:37:16.560673
NCT01352949|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2018-05-22|2011-05-11|2011-05-12|Estimate|||||||2018-05-22|2018-05-23|Actual|May 11, 2011||2011-05-11|May 16, 2018|2018-05-16||||||||Observational|||Stereophotogrammetry of the Torso in Healthy Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity|Stereophotogrammetry of the Torso in Normal Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity|Recruiting|||525|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:37:16.646057|2018-05-31 22:37:16.646057
NCT01352936|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|||||Observational|||Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy|Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy|Unknown status|Active, not recruiting||190|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:37:16.71044|2018-05-31 22:37:16.71044
NCT01352923|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|May 2011||2011-05-31|May 2011|2011-05-31||||May 2012|Anticipated|2012-05-31||Interventional|||Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations|Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations|Unknown status|Recruiting|N/A|100|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:37:16.76696|2018-05-31 22:37:16.76696
NCT01352910|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2016-08-16|2011-05-11|2011-05-12|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PARALYSTIM||rTMS and Functional Paralysis||Completed||N/A|66|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 22:37:16.836631|2018-05-31 22:37:16.836631
NCT01352897|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|August 2010||2010-08-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In Hypercholesterolaemia|A Registry to Collect Data of Efficacy and Safety Between Rosuvastatin, and Atorvastatin and Simvastatin In Subjects With Type IIa and IIb Hypercholesterolaemia Under Real Clinical Settings|Completed|||800|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:37:16.896578|2018-05-31 22:37:16.896578
NCT01352884|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2016-09-02|2011-05-11|2011-05-12|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer||Completed||Phase 1|44|Actual|MedImmune LLC||2|||f||||||||||||||2018-05-31 22:37:16.950388|2018-05-31 22:37:16.950388
NCT01352871|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2011-06-06|2011-05-11|2011-05-12|Estimate|||||||2011-06-06|2011-06-07|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Observational|||The Effects of Concentration/Meditation on the Innate Immune Response During Human Endotoxemia|The Effects of Concentration/Meditation on the Innate Immune Response During|Completed|||1|Anticipated|Radboud University|||1||f||||t||||||||||2018-05-31 22:37:17.022324|2018-05-31 22:37:17.022324
NCT01352858|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-03-10|2011-05-11|2011-05-12|Estimate|||||||2013-03-10|2013-03-12|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|AutoDECRA||Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA)|Phase 1 Study of Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis|Unknown status|Recruiting|Phase 1|12|Anticipated|Newcastle University||2|||f||||t||||||||||2018-05-31 22:37:17.082682|2018-05-31 22:37:17.082682
NCT01352845|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2016-01-26||2016-01-26|2011-05-11|2011-05-12|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|B1971016|Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.|A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.|A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years|Completed||Phase 3|3301|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:37:17.370072|2018-05-31 22:37:17.370072
NCT01352832|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-03-08|2011-05-11|2011-05-12|Estimate|||||||2013-03-08|2013-03-11|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||The Alabama NSAIDs Patient Safety Survey, Phase II: Reducing Disparities in Risk Awareness and Communication|Phase II of The Alabama NSAID Patient Safety Survey: Reducing Disparities in Risk Awareness and Communication|Completed||N/A|422|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 22:37:19.00993|2018-05-31 22:37:19.00993
NCT01352819|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2015-08-06|2011-05-11|2011-05-12|Estimate|||||||2015-08-06|2015-08-10|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Observational|||Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study|A Post Market Clinical Evaluation of Deep Brain Stimulation as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-responsive Parkinson's Disease That Are Not Adequately Controlled With Medication|Completed|||21|Actual|St. Jude Medical|||||f||||||||||||||2018-05-31 22:37:19.070094|2018-05-31 22:37:19.070094
NCT01352806|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|September 2011||2011-09-30|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Identification of the Lumbar Interspinous Spaces; Palpation Versus Ultrasound Versus Fluoroscopy|Identification of the Lumbar Interspinous Spaces; Palpation Versus Ultrasound Versus Fluoroscopy|Unknown status|Not yet recruiting|N/A|60|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 22:37:19.240074|2018-05-31 22:37:19.240074
NCT01352793|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|2015-02-25||2015-02-25|2011-05-11|2011-05-12|Estimate|2015-02-25|2015-03-11|Estimate||||2015-02-25|2015-03-11|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Intent-to-treat (ITT) population included all participants who were randomized.|A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years|A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years|Completed||Phase 3|5715|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:37:19.565313|2018-05-31 22:37:19.565313
NCT01352247|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-10-24|2011-05-10|2011-05-11|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2010||2010-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|TOPKAT||Total or Partial Knee Arthroplasty Trial|Total or Partial Knee Arthroplasty Trial|Active, not recruiting||N/A|500|Anticipated|University of Oxford||2|||f||||t||||||||No||2018-05-31 22:37:31.567604|2018-05-31 22:37:31.567604
NCT01352780|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2015-05-28|2011-05-11|2011-05-12|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|June 2016|Anticipated|2016-06-30|December 2012|Actual|2012-12-31||Interventional|||Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters|Psoriasis and Climate Therapy- Effect of Motivational Follow- up Calls on Clinical and Health Economic Parameters|Unknown status|Active, not recruiting|Phase 3|169|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 22:37:20.456979|2018-05-31 22:37:20.456979
NCT01352767|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2014-09-04|2011-05-11|2011-05-12|Estimate|||||||2014-09-04|2014-09-05|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The InsuPad in Daily Life Study - Effect of Local Heating on Postprandial Glucose Excursions Using the InsuPad Device|A Randomised, Controlled, Cross-over Study With Inpatient and Outpatient Phases|Completed||Phase 4|20|Actual|Insuline Medical Ltd.||2|||f||||f||||||||||2018-05-31 22:37:20.587242|2018-05-31 22:37:20.587242
NCT01352754|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2013-12-11|2011-05-11|2011-05-12|Estimate|||||||2013-12-11|2013-12-12|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Observational|||Troponin T Elevation in Patient Undergoing Hip Fracture Surgery|Prognosis Significance of Troponin T Elevation as Detected by Highly Sensitive Assay in Patient Undergoing Hip Fracture Surgery|Unknown status|Active, not recruiting||100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 22:37:23.023017|2018-05-31 22:37:23.023017
NCT01352741|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2016-05-10||2016-06-29|2011-05-11|2011-05-12|Estimate|2016-06-29|2016-08-12|Estimate||||2016-06-29|2016-08-12|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin|Evaluation of the Effectiveness, Safety, and Tolerability of Tapentadol PR Versus a Combination of Tapentadol PR and Pregabalin in Subjects With Severe Chronic Low Back Pain With a Neuropathic Pain Component|Completed||Phase 4|622|Actual|Grünenthal GmbH||2|||f||||f||||||||||2018-05-31 22:37:23.31937|2018-05-31 22:37:23.31937
NCT01352728|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2018-01-12|2011-05-11|2011-05-12|Estimate|||||||2018-01-12|2018-01-16|Actual|May 18, 2011|Actual|2011-05-18|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib|A Phase II Study of Transarterial Chemoembolisation and Axitinib for the Treatment of Unresectable Hepatocellular Carcinoma|Active, not recruiting||Phase 2|50|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 22:37:25.904566|2018-05-31 22:37:25.904566
NCT01352715|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2015-10-29||2015-12-02|2011-05-11|2011-05-12|Estimate|2015-12-02|2016-01-06|Estimate||||2015-12-02|2016-01-06|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SELECT|Intention to treat: All 512 participants without a major eligibility violation.|Study of Options for Second-Line Effective Combination Therapy (SELECT)|Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)|Completed||Phase 3|515|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 22:37:26.029291|2018-05-31 22:37:26.029291
NCT01352702|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2015-02-04|2011-05-11|2011-05-12|Estimate|||||||2015-02-04|2015-02-05|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Dabi-ADP-2||Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Terminated||Phase 4|46|Actual|Deutsches Herzzentrum Muenchen||2||Slow recruitment; Study was terminated for futility reasons|f||||f||||||||||2018-05-31 22:37:26.965524|2018-05-31 22:37:26.965524
NCT01352689|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-11|||2011-06-06|2011-05-11|2011-05-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||CKD-828(80/2.5mg) Pharmacokinetic Study_2nd|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 80mg and S-Amlodipine 2.5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers|Completed||Phase 1|67|Actual|Chong Kun Dang Pharmaceutical||2|||f||||||||||||||2018-05-31 22:37:27.088254|2018-05-31 22:37:27.088254
NCT01352676|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2014-07-08|2011-05-11|2011-05-12|Estimate|||||||2014-07-08|2014-07-09|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|Prospective||Limit Computed Tomography (CT) Scanning in Suspected Renal Colic|Validation of a Decision Rule to Limit CT Scanning in Suspected Renal Colic|Completed|||635|Actual|Yale University|||||f||||f||||||||||2018-05-31 22:37:27.151733|2018-05-31 22:37:27.151733
NCT01352663|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2014-05-28|2011-05-10|2011-05-12|Estimate|||||||2014-05-28|2014-05-29|Estimate|May 2015||2015-05-31|May 2014|2014-05-31|January 2017|Anticipated|2017-01-31|July 2016|Anticipated|2016-07-31||Interventional|||Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients|An Open Label, Randomized Comparison of Wockhardt's Recombinant Insulin Analogue With Innovator's Glargine in Type 1 Diabetic Patients.|Unknown status|Not yet recruiting|Phase 3|500|Anticipated|Wockhardt||2|||f||||f||||||||||2018-05-31 22:37:27.240258|2018-05-31 22:37:27.240258
NCT01352650|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2018-04-11|2011-05-11|2011-05-12|Estimate|||||||2018-04-11|2018-04-12|Actual|June 17, 2011|Actual|2011-06-17|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|April 2018|Anticipated|2018-04-30||Interventional|||Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)|Induction Therapy With Decitabine and Plerixafor Priming for Patients ≥ 60 Years With Acute Myeloid Leukemia|Active, not recruiting||Phase 1|71|Actual|Weill Medical College of Cornell University||4|||f||||t||||||||No||2018-05-31 22:37:27.300897|2018-05-31 22:37:27.300897
NCT01352637|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2018-05-18|2011-05-11|2011-05-12|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2011|Actual|2011-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Enhancing Exposure Therapy for Post Traumatic Stress Disorder (PTSD): Virtual Reality and Imaginal Exposure With a Cognitive Enhancer|Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer|Active, not recruiting||Phase 3|192|Actual|Weill Medical College of Cornell University||4|||f||||t||||||||||2018-05-31 22:37:27.371846|2018-05-31 22:37:27.371846
NCT01352624|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2014-09-05|2011-05-11|2011-05-12|Estimate|||||||2014-09-05|2014-09-08|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Improving Money Management Skills for Veterans With Psychiatric Disabilities|Improving Money Management Skills for Veterans With Psychiatric Disabilities|Completed||N/A|183|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:37:27.448916|2018-05-31 22:37:27.448916
NCT01352611|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2016-10-05|2011-05-11|2011-05-12|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen|Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||1||No subjects enrolled.|f||||f||||||||No||2018-05-31 22:37:27.510822|2018-05-31 22:37:27.510822
NCT01352598|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-03-21|2011-05-11|2011-05-12|Estimate|||||||2017-03-21|2017-03-23|Actual|June 2011||2011-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Stereotactic Body Radiotherapy for Prostate Cancer|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer|Recruiting||Phase 4|30|Anticipated|Mercy Research||1|||f||||f||||||||||2018-05-31 22:37:27.58344|2018-05-31 22:37:27.58344
NCT01352585|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2014-06-27||2014-06-27|2011-05-11|2011-05-12|Estimate|2014-06-27|2014-07-29|Estimate||||2014-06-27|2014-07-29|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|EMIX||Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®|An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)|Completed|||47|Actual|Shire|||1||f||||f||||||||||2018-05-31 22:37:27.808223|2018-05-31 22:37:27.808223
NCT01352572|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2015-12-30|2011-05-11|2011-05-12|Estimate|||||||2015-12-30|2015-12-31|Estimate|January 2002||2002-01-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients|Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients|Active, not recruiting||N/A|300|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 22:37:28.15209|2018-05-31 22:37:28.15209
NCT01352559|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2015-12-30|2011-05-11|2011-05-12|Estimate|||||||2015-12-30|2015-12-31|Estimate|November 2001||2001-11-30|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|March 2007|Actual|2007-03-31||Interventional|||Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype|Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype|Active, not recruiting||N/A|1000|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 22:37:28.236073|2018-05-31 22:37:28.236073
NCT01352546|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2017-08-01||2017-08-01|2011-05-11|2011-05-12|Estimate|2017-08-01|2017-08-07|Actual||||2017-08-01|2017-08-07|Actual|August 2010||2010-08-31|August 2017|2017-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Botox Injection for Treatment of Vaginismus|Open Label, Single Center, Pilot Study of the Use of BOTOX Injections, Sensorcaine Injections and Progressive Dilation Under Anesthesia for the Treatment of Primary Vaginismus|Completed||Phase 1|31|Actual|Plastic Surgery Professional Association||1|||f||||t||||||||||2018-05-31 22:37:28.313109|2018-05-31 22:37:28.313109
NCT01352533|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2016-10-06|2011-05-10|2011-05-12|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Closure Techniques and Scar Appearance|A Randomized Prospective Trial of 2-Octyl Cyanoacrylate (Derma-Bond) Tissue Adhesive Versus Running Subcuticular Suture Combined With Tissue Adhesive Versus Epidermal Sutures in Dermatologic Surgery Procedures of the Head and Neck|Withdrawn||N/A|0|Actual|Northwestern University||3|||f||||t||||||||||2018-05-31 22:37:28.43664|2018-05-31 22:37:28.43664
NCT01352520|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-08-02|2011-05-11|2011-05-12|Estimate|||||||2017-08-02|2017-08-03|Actual|June 2011|Actual|2011-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)|Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)|Active, not recruiting||Phase 2|84|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:37:28.560798|2018-05-31 22:37:28.560798
NCT01352507|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2013-03-13||2013-03-13|2011-05-10|2011-05-12|Estimate|2013-03-13|2013-04-26|Estimate||||2013-03-13|2013-04-26|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional||All randomized participants.|A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China|An Evaluation of Tadalafil and Sildenafil Treatment in Men With Erectile Dysfunction in China|Completed||Phase 4|383|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:37:28.692212|2018-05-31 22:37:28.692212
NCT01352494|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-25|2011-05-10|2011-05-12|Estimate|||||||2011-05-25|2011-05-27|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|May 2015|Anticipated|2015-05-31|May 2013|Anticipated|2013-05-31||Interventional|NeoTG||Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer|A Multi-center Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Chemotherapy With DoceTaxel(Doxotel) and Gemcitabine(Gemcibine)in Locally Advanced Breast Cancer|Unknown status|Not yet recruiting|Phase 2|99|Anticipated|Korean Breast Cancer Study Group||1|||f||||t||||||||||2018-05-31 22:37:29.323387|2018-05-31 22:37:29.323387
NCT01352481|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-11|2011-05-11|2011-05-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|April 2011||2011-04-30|May 2011|2011-05-31||||April 2013|Anticipated|2013-04-30||Interventional|||Early Intervention in Very Preterm Children|Early Intervention for Speech Sound Disorder in Very Preterm Children|Unknown status|Recruiting|N/A|25|Anticipated|Erasmus Medical Center||2|||f||||||||||||||2018-05-31 22:37:29.472031|2018-05-31 22:37:29.472031
NCT01352468|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2017-01-19||2017-06-19|2011-05-11|2011-05-12|Estimate|2017-06-19|2017-08-01|Actual||||2017-06-19|2017-08-01|Actual|April 2011||2011-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|December 2013|Actual|2013-12-31||Interventional|||Development of a Multi-faceted Cognitive Training Program for Children With Attention Deficit Hyperactivity Disorder (ADHD)|Development of a Multi-faceted Cognitive Training Program for Children With ADHD|Completed||N/A|44|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 22:37:29.546542|2018-05-31 22:37:29.546542
NCT01352455|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-12-27|2011-05-10|2011-05-11|Estimate|||||||2013-12-27|2013-12-31|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||More Frequent In-Center Hemodialysis in Pediatric End Stage Renal Disease|A Pilot Study of More Frequent In-Center Hemodialysis to Improve Outcomes in Pediatric End Stage Renal Disease|Completed||N/A|7|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-05-31 22:37:29.883663|2018-05-31 22:37:29.883663
NCT01352442|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2015-08-19||2017-02-27|2011-05-10|2011-05-11|Estimate|2015-08-19|2015-09-18|Estimate||||2017-02-27|2017-03-28|Actual|May 2011||2011-05-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes|A Prospective Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT Implanted Intrastromally for Modified Monovision in Presbyopic Subjects|Completed||N/A|151|Actual|AcuFocus, Inc.||1|||f||||f||||||||No||2018-05-31 22:37:29.959059|2018-05-31 22:37:29.959059
NCT01351714|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-04-26|2011-05-10|2011-05-11|Estimate|||||||2017-04-26|2017-04-27|Actual|May 2011||2011-05-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safe D3 Right Hemicolectomy for Cancer Through Multidetector Computed Tomography (MDCT) Angio|Safe D3 Right Hemicolectomy for Cancer Through 3D MDCT Angiography Reconstruction|Recruiting||N/A|700|Anticipated|Sykehuset i Vestfold HF||1|||f||||t||||||||||2018-05-31 22:37:38.272184|2018-05-31 22:37:38.272184
NCT01352429|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-09-23|2011-05-10|2011-05-11|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2009||2009-08-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Observational|||Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer|A Phase II Trial of Proton Radiation Therapy or Intensity-Modulated Radiation Therapy Using Mild Hypofractionation for Low-and Intermediate -Risk Adenocarcinoma of the Prostate|Recruiting|||200|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 22:37:30.280504|2018-05-31 22:37:30.280504
NCT01352416|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2016-06-14||2016-11-08|2011-05-10|2011-05-11|Estimate|2016-11-08|2017-01-06|Estimate||||2016-11-08|2017-01-06|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Subjects scheduled/undergoing cardiac surgery.|Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery|Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery|Terminated||Phase 3|15|Actual|William Beaumont Hospitals|Early termination due to lack of enrollment. 15 pts enrolled, 6 withdrawn due breathing tube not removed by 10 pm day of surgery. 1 withdrawn after day 3 as he was in afib and placed on amio. All pts were male.|4||lack of enrollment|f||||t||||||||Undecided||2018-05-31 22:37:30.383972|2018-05-31 22:37:30.383972
NCT01352403|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|May 2011||2011-05-31|December 2008|2008-12-31|June 2016|Anticipated|2016-06-30|||||Interventional|WAS||Severe Obesity: Bariatric Surgery vs. Life-Style-Intervention|Severe Obesity: Bariatric Surgery vs. Life-Style-Intervention Wurzburg Adipositas Study - WAS|Unknown status|Recruiting|N/A|60|Anticipated|University of Wuerzburg||2|||f||||f||||||||||2018-05-31 22:37:30.670221|2018-05-31 22:37:30.670221
NCT01352390|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2017-05-03|2011-05-10|2011-05-11|Estimate|||||||2017-05-03|2017-05-04|Actual|May 2011|Actual|2011-05-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Effect of a Coloring Prompt on Health Engagement|The Effect of a Coloring Prompt on Health Engagement|Completed||N/A|8711|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:37:30.771199|2018-05-31 22:37:30.771199
NCT01352377|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Observational|||Impact of New CLSI Guidelines on Antibiotic Susceptability Pattern|A STUDY ASSESSING THE IMPACT OF THE NEW CLSI GUIDELINES ON ANTIBIOTIC SUSCEPTABILITY TESTING PATTERNS|Unknown status|Not yet recruiting||50|Anticipated|University of Southern Nevada|||||f||||t||||||||||2018-05-31 22:37:30.829238|2018-05-31 22:37:30.829238
NCT01352364|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-26|2011-05-10|2011-05-11|Estimate|||||||2011-05-26|2011-05-30|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Analysis Of Equilibrium And Motor Coordination Of Deaf Children's Pre And Post Intervention Physiotherapeutic|Analysis Of Equilibrium And Motor Coordination Of Deaf Children's Pre And Post Intervention Physiotherapeutic|Completed||N/A|10|Actual|University of the Sinos Valley||1|||f||||f||||||||||2018-05-31 22:37:30.934871|2018-05-31 22:37:30.934871
NCT01352351|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2013-02-06|2011-05-10|2011-05-11|Estimate|||||||2013-02-06|2013-02-08|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Linking Microcredit, Technology, and Promotion of IYCF Breastfeeding Guidelines in Bauchi State, Nigeria|Linking Microcredit, Technology, and Promotion of IYCF Breastfeeding Guidelines in Bauchi State, Nigeria|Completed||N/A|485|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:37:30.998987|2018-05-31 22:37:30.998987
NCT01352338|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-02-25|2011-05-10|2011-05-11|Estimate|||||||2016-02-25|2016-02-26|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2014|Actual|2014-11-30||Interventional|REPEAT||Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)|A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|82|Actual|UMC Utrecht||1|||f||||t||||||||||2018-05-31 22:37:31.058838|2018-05-31 22:37:31.058838
NCT01352325|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2012-02-08|2011-05-10|2011-05-11|Estimate|||||||2012-02-08|2012-02-09|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy of System Constellations in a General Population|Randomized Controlled Trial on the Efficacy of System Constellations on Psychological Well-being in a General Population Based Sample|Completed||Phase 2/Phase 3|216|Actual|Heidelberg University||2|||f||||t||||||||||2018-05-31 22:37:31.153847|2018-05-31 22:37:31.153847
NCT01352312|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2018-05-23|2011-05-10|2011-05-11|Estimate|||||||2018-05-23|2018-05-25|Actual|May 25, 2011|Actual|2011-05-25|May 2018|2018-05-31|May 10, 2018|Actual|2018-05-10|April 8, 2016|Actual|2016-04-08||Interventional|||Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma|Phase I Trial With Cohort Expansion of Pentostatin, Bendamustine and Ofatumumab (PBO) for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma|Terminated||Phase 1|10|Actual|Thomas Jefferson University||1||Insufficient accrual over 12 mo period|f||||t|t|f|||t|||||2018-05-31 22:37:31.214471|2018-05-31 22:37:31.214471
NCT01352299|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|August 2008||2008-08-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Glottic Visualization & Ease of Intubation With Different Laryngoscope Blades|Comparison of Visualisation of Laryngeal Inlet and Ease of Intubation With Different Laryngoscope Blades.|Completed||N/A|120|Actual|Tata Memorial Hospital||4|||f||||f||||||||||2018-05-31 22:37:31.299042|2018-05-31 22:37:31.299042
NCT01352286|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-10-16|2011-05-10|2011-05-11|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2011||2011-03-31|October 2017|2017-10-31|April 2031|Anticipated|2031-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Redirected Auto T Cells for Advanced Myeloma|A Phase I/IIa, Dual-cohort, Two-site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma|Active, not recruiting||Phase 1/Phase 2|26|Anticipated|Adaptimmune||1|||f||||t|t|f||||||||2018-05-31 22:37:31.374994|2018-05-31 22:37:31.374994
NCT01352273|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-02-11|2011-05-10|2011-05-11|Estimate|||||||2016-02-11|2016-02-12|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations|A Phase Ib Open-label Dose Escalation Study of MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations|Completed||Phase 1|69|Actual|Array BioPharma||1|||f||||||||||||||2018-05-31 22:37:31.443379|2018-05-31 22:37:31.443379
NCT01352260|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2012-05-18|2011-05-10|2011-05-11|Estimate|||||||2012-05-18|2012-05-21|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Near-Infrared Spectroscopy Comparison Study|Validation of Near-Infrared Spectroscopy for Neuromonitoring During Moderate Hypothermic Circulatory Arrest for Total Aortic Arch Replacement: A Comparison of Two Technologies With Jugular Venous Bulb Oximetry|Completed|||17|Actual|Nonin Medical, Inc|||1||f||||f||||||||||2018-05-31 22:37:31.51443|2018-05-31 22:37:31.51443
NCT01352234|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2016-12-13|2011-05-10|2011-05-11|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia|Evaluation of Dose-response Effect of Acetylsalicylic Acid on Placental Development, Preterm Birth, Fetal Growth and Hypertension in Pregnancy in Women With Previous History of Preeclampsia|Completed||Phase 4|104|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||Undecided||2018-05-31 22:37:31.64732|2018-05-31 22:37:31.64732
NCT01352221|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|2017-06-12||2017-10-26|2011-05-10|2011-05-11|Estimate|2017-10-26|2017-10-27|Actual||||2017-10-26|2017-10-27|Actual|August 2011||2011-08-31|October 2017|2017-10-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|AEGIS-2|Potential subjects were screened for eligibility to participate based on their demographics, medical/surgical history, physical examination, concomitant medications, vital signs, clinical laboratory tests (including pregnancy test for females of child-bearing potential) and current IBD disease status (based on CDAI clinical score). FAS - Safety|Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)|A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Crohn's Disease Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 2)|Completed||Phase 3|128|Actual|Shield Therapeutics||2|||f||||f||||||||No||2018-05-31 22:37:31.749594|2018-05-31 22:37:31.749594
NCT01352208|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-03-21|2011-05-10|2011-05-11|Estimate|||||||2014-03-21|2014-03-24|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients|Phase I/II, Multi-center, Open Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of ASP9521 in Patients With Metastatic Castrate-resistant Prostate Cancer|Terminated||Phase 1/Phase 2|13|Actual|Astellas Pharma Inc||1||It was decided to discontinue the development in consideration of the results of a P1 study|f||||f||||||||||2018-05-31 22:37:32.524125|2018-05-31 22:37:32.524125
NCT01352195|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2018-03-27|2011-05-10|2011-05-11|Estimate|||||||2018-03-27|2018-03-29|Actual|January 23, 2009|Actual|2009-01-23|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|February 18, 2014|Actual|2014-02-18||Interventional|||Extended Self-Help for Smoking Cessation|Extended Self-Help for Smoking Cessation|Active, not recruiting||N/A|2124|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f||||||||||2018-05-31 22:37:32.583262|2018-05-31 22:37:32.583262
NCT01352182|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2017-01-05|2011-05-10|2011-05-11|Estimate|||||||2017-01-05|2017-01-09|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Interventional|||Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock|Pharmacokinetic Characteristics of Pioglitazone and Preliminary Biomarker Response in Adolescents Aged 12 to 17 Years With Severe Sepsis and Septic Shock|Completed||Phase 1/Phase 2|12|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 22:37:32.76797|2018-05-31 22:37:32.76797
NCT01352143|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2013-11-19|2011-05-10|2011-05-11|Estimate|||||||2013-11-19|2013-11-20|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass|Measurements of Thrombin Generation in Response to Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Neonatal Plasma After Cardiopulmonary Bypass|Completed|||24|Actual|Emory University|||||f||||t||||||Samples Without DNA|"~     Blood samples only~   "|||2018-05-31 22:37:32.846387|2018-05-31 22:37:32.846387
NCT01352130|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|March 2007||2007-03-31|May 2011|2011-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Granisetron Versus Ondansetron: Comparative Effects on ECG, QTc|Comparative Electrocardiographic Effects of Intravenous Ondansetron and Granisetron in Patients Undergoing Surgery for Carcinoma Breast: A Prospective Single Blind Randomised Trial|Completed||Phase 4|70|Actual|Tata Memorial Hospital||2|||f||||f||||||||||2018-05-31 22:37:32.913308|2018-05-31 22:37:32.913308
NCT01352117|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2017-03-17||2017-10-17|2011-05-10|2011-05-11|Estimate|2017-05-12|2017-07-31|Actual||||2017-10-17|2017-11-17|Actual|November 18, 2011|Actual|2011-11-18|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|March 16, 2016|Actual|2016-03-16||Interventional|REACT-KS|All eligible participants who initiated study treatment.|Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma|A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067|Active, not recruiting||Phase 3|192|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||Undecided||2018-05-31 22:37:33.058584|2018-05-31 22:37:33.058584
NCT01352104|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|January 2004||2004-01-31|April 2011|2011-04-30|December 2006|Actual|2006-12-31|March 2005|Actual|2005-03-31||Interventional|PEP-TE||Effectiveness of the Teacher Module of the Prevention Program for Externalizing Problem Behaviour in Preschoolers|Effectiveness of Guiding Teachers in Individualized Behavioral Intervention Strategies With Preschool Children Indicated for Externalizing Problem Behavior|Completed||N/A|144|Actual|German Research Foundation||1|||f||||f||||||||||2018-05-31 22:37:34.187621|2018-05-31 22:37:34.187621
NCT01352091|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|April 2018|Anticipated|2018-04-30|May 2015|Anticipated|2015-05-31||Interventional|||Adjuvant AI Combined With Zoladex|A Randomized ,Open Label Study Comparing the Efficacy of Zoladex® Combined With Arimidex® for 3-2 Years After Selective Estrogen Receptor Modulators (SERMs) as an Adjuvant Therapy for 2-3 Years Versus Continuing Tamoxifen up to 5 Years for Premenopausal Early Breast Cancer Patients With Hormone Receptor Positive, Lymph Node Positive or Tumor≥ 4cm.|Unknown status|Recruiting|Phase 3|670|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:37:34.254338|2018-05-31 22:37:34.254338
NCT01352078|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-08-28|2011-05-10|2011-05-11|Estimate|||||||2017-08-28|2017-08-30|Actual|May 2011||2011-05-31|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|WE-HEAL||Wound Etiology and Healing Study|The Wound Etiology and Healing Study|Recruiting|||1000|Anticipated|George Washington University|||1||f||||f||||||Samples With DNA|"~     1. Residual tissue left over after routine debridement surgery~        2. Wound fluid that would otherwise be discarded~        3. Residual blood/ serum samples left over after pre-surgery blood tests have been~          performed.~        4. Wound biofilm~        5. Wound photographs~   "|||2018-05-31 22:37:34.336934|2018-05-31 22:37:34.336934
NCT01351363|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Prediction Of Post Operative Pain Following Arthroscopic Shoulder Surgery|PREDICTION OF POST OPERATIVE PAIN FOLLOWING ARTHROSCOPIC SHOULDER SURGERY|Completed||N/A|43|Actual|NHS Fife||1|||f||||f||||||||||2018-05-31 22:37:42.364142|2018-05-31 22:37:42.364142
NCT01352065|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-05-07|2011-05-10|2011-05-11|Estimate|||||||2013-05-07|2013-05-08|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|ERAATH||Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration|Phase 3 Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration|Completed||Phase 2/Phase 3|30|Actual|Center for Health, Exercise and Sport Sciences, Serbia||3|||f||||t||||||||||2018-05-31 22:37:34.405929|2018-05-31 22:37:34.405929
NCT01352052|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2016-08-09|2011-05-10|2011-05-11|Estimate|||||||2016-08-09|2016-08-10|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|IMPROvE||Interdisciplinary Rehabilitation of Patients With Chronic Widespread Pain|Interdisciplinary Rehabilitation and Evaluation Programme for Patients With Chronic Widespread Pain: Randomized Controlled Trial, the IMPROvE Study|Completed||N/A|192|Actual|Frederiksberg University Hospital||2|||f||||f||||||||||2018-05-31 22:37:34.468682|2018-05-31 22:37:34.468682
NCT01352039|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2012-10-15|2011-05-10|2011-05-11|Estimate|||||||2012-10-15|2012-10-16|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|HEP-SC||A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery|A Phase III, Non-inferiority, Randomized, Double-blind Trial Comparing Eurofarma Unfractionated Sodium Heparin 5,000 IU to APP Pharmaceuticals Unfractionated Sodium Heparin 5,000 IU in the Thromboprophylaxis of Geriatric Patients Who Underwent Hip Fracture Surgery.|Terminated||Phase 3|544|Actual|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-05-31 22:37:34.536035|2018-05-31 22:37:34.536035
NCT01352026|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2012-08-03|2011-05-10|2011-05-11|Estimate|||||||2012-08-03|2012-08-06|Estimate|May 2011||2011-05-31|August 2012|2012-08-31||||||||Interventional|MetHTAP||Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH)||Withdrawn||Phase 2|0|Actual|Nantes University Hospital||1||"Several therapeutic have been developed making more difficult the eligibility of patients -~   Recruitment of new centers wasn't possible due to competing trials"|f||||||||||||||2018-05-31 22:37:34.596137|2018-05-31 22:37:34.596137
NCT01352013|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2015-04-15|2011-05-10|2011-05-11|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||The Impact of Omega-3 Fatty Acid Supplements on Fibromyalgia Symptoms|The Impact of Omega-3 Fatty Acid Supplements on Fibromyalgia (FM) Symptoms: A Randomized, Double-blind, Placebo-controlled Exploratory Study.|Completed||Phase 2|19|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:37:34.644571|2018-05-31 22:37:34.644571
NCT01352000|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-02-21|2011-05-10|2011-05-11|Estimate|||||||2017-02-21|2017-02-23|Actual|December 2008||2008-12-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||"Relapse-Prevention Booklets as an Adjunct to a Tobacco Telephone Helpline(Quitline)"|Relapse-Prevention Booklets as an Adjunct to a Tobacco Quitline|Completed||N/A|3830|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f||||||||||2018-05-31 22:37:34.723796|2018-05-31 22:37:34.723796
NCT01351987|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|December 2010||2010-12-31|May 2011|2011-05-31|December 2013|Anticipated|2013-12-31|||||Observational|||An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL|An Observational Study of Dutasteride and Alpha-Blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL|Unknown status|Active, not recruiting||855|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:37:34.780412|2018-05-31 22:37:34.780412
NCT01351974|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2011-05-27|2011-05-10|2011-05-11|Estimate|||||||2011-05-27|2011-05-30|Estimate|September 2000||2000-09-30|June 2000|2000-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Observational|||Sentinel Node Biopsy in Breast Cancer Patients|Cohort Study of Axillary Recurrences and Survival After Negative Negative Sentinel Node Biopsy Without Completion Axillary Clearance|Completed|||3369|Actual|Uppsala University|||||f||||f||||||Samples Without DNA|"~     Routine specimens from the surgery are kept at the respective pathology departments~   "|||2018-05-31 22:37:34.844982|2018-05-31 22:37:34.844982
NCT01351961|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2014-02-24|2011-05-10|2011-05-11|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ADELAHYDE2||Vascular Alteration and Evolution of Cognitive Impairment|Arterial Function and Structure and Evolution of Cognitive Impairment in Elderly Hypertensive Subjects With Subjective Memory Complaints|Completed||N/A|131|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-05-31 22:37:35.082939|2018-05-31 22:37:35.082939
NCT01351948|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-03-13|2011-05-10|2011-05-11|Estimate|||||||2013-03-13|2013-03-14|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909|A Phase Ia Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines; AdCh63 AMA1, MVA AMA1 & AMA1-C1/Alhydrogel® +/- CPG 7909|Completed||Phase 1|35|Actual|University of Oxford||5|||f||||t||||||||||2018-05-31 22:37:35.417301|2018-05-31 22:37:35.417301
NCT01351935|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2015-08-25|2011-05-10|2011-05-11|Estimate|||||||2015-08-25|2015-08-27|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia|Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia|Completed||Phase 1|113|Actual|Celgene||1|||f||||f||||||||||2018-05-31 22:37:35.541038|2018-05-31 22:37:35.541038
NCT01351922|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-01-18|2011-05-10|2011-05-11|Estimate|||||||2017-01-18|2017-01-19|Estimate|April 2011||2011-04-30|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|DiabCare India||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in India and to Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in India (DiabCare India 2011)|Completed|||12000|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:37:35.688661|2018-05-31 22:37:35.688661
NCT01351909|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2018-05-24|2011-05-10|2011-05-11|Estimate|||||||2018-05-24|2018-05-25|Actual|May 2, 2011|Actual|2011-05-02|May 2018|2018-05-31||||November 25, 2016|Actual|2016-11-25||Interventional|||Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer|Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer|Active, not recruiting||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 22:37:35.78836|2018-05-31 22:37:35.78836
NCT01351896|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-04-24|2011-05-10|2011-05-11|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2011||2011-09-30|April 2017|2017-04-30||||July 31, 2016|Actual|2016-07-31||Interventional|||Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features|Active, not recruiting||Phase 2|48|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 22:37:35.878302|2018-05-31 22:37:35.878302
NCT01351883|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|January 2011|Actual|2011-01-31||Interventional|ANOM||Enteric Immune-nutrition Formula (ANOM®) for Patients Receiving Major Upper Gastrointestinal Surgery|Peri-operative Usage of Enteric Immune-nutrition Formula (ANOM®) Versus Standard Formula for Patients Received Major Upper Gastrointestinal Surgery|Unknown status|Recruiting|Phase 3|64|Anticipated|National Cheng-Kung University Hospital||1|||f||||t||||||||||2018-05-31 22:37:36.039979|2018-05-31 22:37:36.039979
NCT01351870|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-09-15|2011-05-10|2011-05-11|Estimate|||||||2017-09-15|2017-09-18|Actual|April 2004||2004-04-30|September 2017|2017-09-30|February 2021|Anticipated|2021-02-28|December 2008|Actual|2008-12-31||Interventional|SIOP-PNET-4||Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma|A Prospective Randomised Controlled Trial of Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma|Active, not recruiting||Phase 3|52|Actual|Institut Curie||2|||f||||t||||||||||2018-05-31 22:37:36.220282|2018-05-31 22:37:36.220282
NCT01351857|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-03-21|2011-05-10|2011-05-11|Estimate|||||||2017-03-21|2017-03-24|Actual|April 2012||2012-04-30|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|TransClin||Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes|Multicentre Randomized Controlled Trial of Structured Transition on Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes|Active, not recruiting||Phase 4|188|Anticipated|Western University, Canada||2|||f||||t||||||||||2018-05-31 22:37:36.289274|2018-05-31 22:37:36.289274
NCT01351844|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-08-28|2011-05-10|2011-05-11|Estimate|||||||2017-08-28|2017-08-30|Actual|May 2011||2011-05-31|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|CEASE||The CEASE Study: Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer|Computer Based Educational Module for the Reduction of Arthralgia Syndrome Associated With Endocrine Therapy for Breast Cancer|Terminated||N/A|12|Actual|George Washington University||2||Unable to recruit sufficient patients|f||||f||||||||||2018-05-31 22:37:36.376718|2018-05-31 22:37:36.376718
NCT01351831|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2013-09-10|2011-05-10|2011-05-11|Estimate|||||||2013-09-10|2013-09-11|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TKA||The Difference Between Rehabilitation With or Without Strength Training After Total Knee Replacement|The Difference Between Rehabilitation With or Without Progressive Strength Training After Fast-track Total Knee Arthroplasty: A Randomized Controlled Trial|Completed||Phase 2|72|Actual|Copenhagen University Hospital, Hvidovre||2|||f||||t||||||||||2018-05-31 22:37:36.462316|2018-05-31 22:37:36.462316
NCT01351818|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Observational|FAYDS||Adipocyte Function and Somtropin Deficiency|The Fayds Project: Adipocyte Function and Somtropin Deficiency|Completed|||62|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:37:36.536102|2018-05-31 22:37:36.536102
NCT01351805|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-07-11|2011-05-10|2011-05-11|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2011||2011-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain|Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain|Active, not recruiting||N/A|25876|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 22:37:37.554457|2018-05-31 22:37:37.554457
NCT01351792|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2017-03-28|2011-05-10|2011-05-11|Estimate|||||||2017-03-28|2017-03-30|Actual|September 2011||2011-09-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|FAIR||A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)|A 12-week, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Symbicort® 200/6 (Budesonide 200 µg Plus Formoterol 6 µg/Actuation), 2 Inhalations b.i.d., on Parameters of Small Airway Function in Patients With Chronic Obstructive Pulmonary Disease.|Terminated||Phase 3|113|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 22:37:37.656416|2018-05-31 22:37:37.656416
NCT01351779|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-09|2011-05-09|2011-05-11|Estimate|||||||2011-05-09|2011-05-11|Estimate|May 2011||2011-05-31|May 2011|2011-05-31||||May 2012|Anticipated|2012-05-31||Observational|||The Effect of Body Posture on Intraocular Pressure in Progressive Glaucoma|The Effect of Body Posture on Intraocular Pressure in Progressive Glaucoma|Unknown status|Recruiting||20|Anticipated|University of Toronto|||1||f||||t||||||||||2018-05-31 22:37:37.741097|2018-05-31 22:37:37.741097
NCT01351766|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-06-10|2011-05-10|2011-05-11|Estimate|||||||2011-06-10|2011-06-13|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|||Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation|Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation|Unknown status|Recruiting|Phase 3|30|Anticipated|University of Maryland||1|||f||||f||||||||||2018-05-31 22:37:37.811146|2018-05-31 22:37:37.811146
NCT01351753|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-08-22|2011-05-09|2011-05-11|Estimate|||||||2017-08-22|2017-08-24|Actual|March 2011||2011-03-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|REVIVE||Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity|Does Reversal of Visceral Obesity by Drug Therapy Improve Vascular Function?|Suspended||Phase 2|150|Anticipated|University of Iowa||6||Change of staff|f||||f||||||||||2018-05-31 22:37:37.885581|2018-05-31 22:37:37.885581
NCT01351740|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2016-06-16|2011-05-10|2011-05-11|Estimate|||||||2016-06-16|2016-06-20|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|SUAT||Switch to Unboosted Atazanavir With Tenofovir Study|Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study|Completed||Phase 4|50|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 22:37:38.037039|2018-05-31 22:37:38.037039
NCT01351727|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-11-01|2011-05-10|2011-05-11|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2011||2011-01-31|November 2017|2017-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Epidemiologic Follow Up Study of Newly Diagnosed Epilepsy Among Seniors|Epidemiologic Follow Up Study of Newly Diagnosed Epilepsy Among Seniors From Different Ethnic Groups|Completed|||97|Actual|University of Arizona|||1||f||||f||||||||||2018-05-31 22:37:38.110337|2018-05-31 22:37:38.110337
NCT01351701|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|June 2011||2011-06-30|April 2011|2011-04-30||||||||Observational|||Bacteriological Study of Diabetic Foot and Antibiotic Sensitivity Pattern in Eastern India|An Observational, Prospective, Multicentre Study in Eastern India to Understand the Bacteriological Epidemiology in Diabetic Foot and Sensitivity Pattern of Antibiotics Along With the Pattern of Empirical Therapy|Unknown status|Not yet recruiting||200|Anticipated|Sun Valley Hospital, Guwahati|||||f||||f||||||||||2018-05-31 22:37:38.384558|2018-05-31 22:37:38.384558
NCT01351688|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-07-02|2011-05-10|2011-05-11|Estimate|||||||2013-07-02|2013-07-03|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||An Open Label Prostate Cancer Study in Japanese Patients|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 1|13|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 22:37:38.460002|2018-05-31 22:37:38.460002
NCT01351675|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03||2014-04-28|2014-04-28|2011-05-09|2011-05-11|Estimate||||2014-04-28|2014-05-14|Estimate|2014-04-28|2014-05-14|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|BEACON||Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes|Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)|Terminated||Phase 3|2185|Actual|Reata Pharmaceuticals, Inc.||2||IDMC recommendation for safety concerns|f||||t||||||||||2018-05-31 22:37:38.541215|2018-05-31 22:37:38.541215
NCT01351662|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-04-18|2011-05-10|2011-05-11|Estimate|||||||2013-04-18|2013-04-22|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|BLESS||Balancing Lupus Experiences With Stress Strategies|An Intervention to Reduce Psychosocial and Biological Indicators of Stress in African American Lupus Patients: The Balancing Lupus Experiences With Stress Strategies (BLESS) Study|Completed||Phase 1/Phase 2|30|Anticipated|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 22:37:38.618524|2018-05-31 22:37:38.618524
NCT01351649|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2015-09-17|2011-05-10|2011-05-11|Estimate|||||||2015-09-17|2015-09-18|Estimate|April 2009||2009-04-30|September 2015|2015-09-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Middle School Physical Activity Intervention for Girls|Middle School Physical Activity Intervention for Girls|Completed||Phase 1/Phase 2|90|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 22:37:38.695883|2018-05-31 22:37:38.695883
NCT01351636|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2015-11-19|2011-05-10|2011-05-11|Estimate|||||||2015-11-19|2015-11-23|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|AHOCEP||Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients|Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients: An Open Labelled, Randomized, Multicentered, Controlled Trial|Active, not recruiting||Phase 4|300|Anticipated|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.||2|||f||||t||||||||||2018-05-31 22:37:38.791526|2018-05-31 22:37:38.791526
NCT01351623|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2017-01-03||2017-03-15|2011-05-10|2011-05-11|Estimate|2017-01-20|2017-03-13|Actual||||2017-03-15|2017-04-13|Actual|May 9, 2011||2011-05-09|March 2017|2017-03-31|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional|||Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma|Phase II Study of Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|44|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:37:38.881751|2018-05-31 22:37:38.881751
NCT01351610|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2015-12-14|2011-05-10|2011-05-11|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia|Open, Randomized, Mono-Centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous Infusion of Human Bone Marrow Derived Autologous, CD34-Negative Mesenchymal Stem Cells for the Treatment of Critical Limb Ischemia in Patients With Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty|Completed||Phase 1/Phase 2|25|Actual|Apceth GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 22:37:39.106714|2018-05-31 22:37:39.106714
NCT01351597|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-10|2011-05-10|2011-05-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|April 2011||2011-04-30|May 2011|2011-05-31|September 2013|Anticipated|2013-09-30|April 2013|Anticipated|2013-04-30||Interventional|STORM||A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer|An Open-label, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of Combination Chemotherapy With DoceTaxel(Detaxel) and Oxaliplatin(Oxalitin)in Recurrent or Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|51|Anticipated|Korean Breast Cancer Study Group||1|||f||||t||||||||||2018-05-31 22:37:39.17529|2018-05-31 22:37:39.17529
NCT01351584|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-08-24|2011-05-09|2011-05-11|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2007||2007-02-28|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Observational|TMK||Tumour Registry Breast Cancer|Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany|Active, not recruiting|||4500|Anticipated|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 22:37:39.280146|2018-05-31 22:37:39.280146
NCT01351571|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-10-02|2011-05-10|2011-05-11|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2010||2010-08-31|October 2017|2017-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma|An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma|Completed|||5|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:37:39.347077|2018-05-31 22:37:39.347077
NCT01351558|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2012-10-04|2011-05-09|2011-05-11|Estimate|||||||2012-10-04|2012-10-05|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Exercise and Pain Sensitivity|Exercise and Alterations in Pain Sensitivity|Terminated||N/A|33|Actual|Frederiksberg University Hospital||4||Recruitment difficulties.|f||||f||||||||||2018-05-31 22:37:39.403411|2018-05-31 22:37:39.403411
NCT01351545|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2018-05-15|2011-05-10|2011-05-11|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2011||2011-10-31|May 2018|2018-05-31||||October 2021|Anticipated|2021-10-31||Observational|||A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)|A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications|Recruiting|||99999|Anticipated|Center for International Blood and Marrow Transplant Research|||1||f||||t||||||||||2018-05-31 22:37:39.611434|2018-05-31 22:37:39.611434
NCT01351532|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2012-01-30|2011-05-10|2011-05-11|Estimate|||||||2012-01-30|2012-02-01|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention|Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention|Completed||N/A|67|Actual|China Medical University Hospital||2|||f||||||||||||||2018-05-31 22:37:40.12931|2018-05-31 22:37:40.12931
NCT01351519|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-07|||2016-03-15|2011-05-09|2011-05-11|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|Terminated||Phase 2|16|Actual|MultiCare Health System Research Institute||1||Limited staff available for enrollment and limited availability of drug|f||||t||||||||||2018-05-31 22:37:40.189077|2018-05-31 22:37:40.189077
NCT01351506|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2014-11-03||2014-11-03|2011-05-10|2011-05-11|Estimate|2014-11-03|2014-11-07|Estimate||||2014-11-03|2014-11-07|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Effect of Body Weight Change to Surgical ICU Outcomes|Effect and Determinant Level of Admission Body Weight and Daily Weight Change and Prognoses of Critically and High Risk Surgical Patients|Completed|||465|Actual|Chiang Mai University|||||f||||t||||||||||2018-05-31 22:37:40.272284|2018-05-31 22:37:40.272284
NCT01351493|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2012-07-10|2011-05-10|2011-05-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Pressure Sore|A Randomized, Double-blind, Placebo-controlled Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Pressure Sore|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 22:37:40.448089|2018-05-31 22:37:40.448089
NCT01351480|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2015-10-01||2017-01-23|2011-05-10|2011-05-11|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|June 2011|Actual|2011-06-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients|Assessment of Structural Benefits of Injectable Abatacept as Measured by MRI in RA Patients Who Have Failed Prior Anti-Tumor Necrosis (TNF) Therapy and Correlated With Clinical Outcomes|Completed||Phase 3|34|Actual|Arthritis & Rheumatic Disease Specialties Research||1|||f||||t||||||||||2018-05-31 22:37:40.527369|2018-05-31 22:37:40.527369
NCT01351467|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2018-01-09|2011-05-10|2011-05-11|Estimate|||||||2018-01-09|2018-01-11|Actual|April 2009||2009-04-30|January 2018|2018-01-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||Web-based Genetic Research on Parkinson's Disease|Ongoing, Web-Based Genome-Wide Association Studies for Targeted Disease Initiatives|Active, not recruiting|||25000|Anticipated|23andMe, Inc.|||1||f||||f||||||Samples With DNA|"~     Saliva samples are collected for DNA analysis~   "|||2018-05-31 22:37:40.6939|2018-05-31 22:37:40.6939
NCT01351454|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-04-10|2011-05-09|2011-05-10|Estimate|||||||2017-04-10|2017-04-12|Actual|September 2008||2008-09-30|May 2011|2011-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Behavioral Depression Treatment for African American HIV-infected Substance Users|Behavioral Depression Treatment for African American HIV-infected Substance Users|Completed||N/A|122|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:37:40.747641|2018-05-31 22:37:40.747641
NCT01351441|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through Integrated Clinical Pharmacy Services in an Innovative Model of Community Practice|Minimizing Risk and Maximizing Outcomes in Geriatric Patients Through Integrated Clinical Pharmacy Services in an Innovative Model of Community Practice|Unknown status|Recruiting|N/A|50|Anticipated|VascuScript Pharmacy||1|||f||||f||||||||||2018-05-31 22:37:40.81745|2018-05-31 22:37:40.81745
NCT01351428|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2012-11-08|2011-05-09|2011-05-10|Estimate|||||||2012-11-08|2012-11-12|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia|Non-invasive Hemodynamic Monitoring and Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia|Completed||N/A|20|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||1|||f||||f||||||||||2018-05-31 22:37:40.973071|2018-05-31 22:37:40.973071
NCT01351415|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2017-06-20||2017-08-17|2011-05-09|2011-05-10|Estimate|2017-08-17|2017-09-18|Actual||||2017-08-17|2017-09-18|Actual|June 25, 2011|Actual|2011-06-25|August 2017|2017-08-31|June 25, 2016|Actual|2016-06-25|June 25, 2016|Actual|2016-06-25||Interventional||Intent-to-treat population includes all randomized participants.|A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)|An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy|Completed||Phase 3|485|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:37:41.107934|2018-05-31 22:37:41.107934
NCT01351402|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|June 2006||2006-06-30|August 2005|2005-08-31|January 2007|Actual|2007-01-31|August 2006|Actual|2006-08-31||Interventional|||Effects of Massage Versus Rest on Hormones|Investigating the Effects of Massage vs. Rest on Oxytocin, ACTH, and B-endorphins|Completed||N/A|95|Actual|Claremont Graduate University|||||f||||f||||||||||2018-05-31 22:37:42.172268|2018-05-31 22:37:42.172268
NCT01351389|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2014-09-12|2011-05-09|2011-05-10|Estimate|||||||2014-09-12|2014-09-15|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|SAFER||Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk|Brief Interventions in the Emergency Department for Alcohol and HIV/Sexual Risk|Completed||N/A|400|Actual|Brown University||2|||f||||t||||||||||2018-05-31 22:37:42.227937|2018-05-31 22:37:42.227937
NCT01351376|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2017-09-08|2011-05-09|2011-05-10|Estimate|||||||2017-09-08|2017-09-12|Actual|May 2011||2011-05-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Interventional|||LLLT Combined With CDT in Breast Cancer-Related Lymphedema|The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study|Completed||N/A|150|Actual|New York University School of Medicine||2|||f||||f|f|t|f|f||||||2018-05-31 22:37:42.298161|2018-05-31 22:37:42.298161
NCT00745836|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|||||Interventional|||Effects of Atorvastatin on Adiponectin Levels and Insulin Sensitivity In Hypercholesterolemic Patients||Completed||Phase 4|||Gachon University Gil Medical Center||1|||f||||t||||||||||2018-06-01 01:47:26.733854|2018-06-01 01:47:26.733854
NCT01351350|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2018-02-22|2011-05-09|2011-05-10|Estimate|||||||2018-02-22|2018-02-26|Actual|February 28, 2011|Actual|2011-02-28|February 2018|2018-02-28|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies|A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies|Completed||Phase 1|68|Actual|Takeda||10|||f||||f|t|f||||||||2018-05-31 22:37:42.431346|2018-05-31 22:37:42.431346
NCT01351337|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2014-02-24||2015-04-04|2011-05-09|2011-05-10|Estimate|2015-04-04|2015-04-20|Estimate||||2015-04-04|2015-04-20|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|February 2013|Actual|2013-02-28|June 2009|Actual|2009-06-30||Interventional||Age (range), y 44 (10-72) Female/male, n/n 21/37|Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area|Clinical Efficiency of Motor Pathway Mapping Using Diffusion Tensor Imaging Tractography and Intraoperative Subcortical Stimulation in Cerebral Glioma Surgery|Completed||N/A|58|Actual|Huashan Hospital|The imaged motor pathway was reconstructed based on pre-opimages. An additional study that integrates real-time DTI tractography with high-field intraoperative MRI and DsCS for eloquent cerebral glioma surgery is currently underway in our department.|1|||f||||t||||||||||2018-05-31 22:37:42.516098|2018-05-31 22:37:42.516098
NCT01351324|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|March 2009||2009-03-31|April 2011|2011-04-30|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|eFAIRE||A Study of Different Types of Fatty Acid on Risk Factors for Heart Disease|Acute Elevation of Non-esterified Fatty Acids on Endothelial Function and Insulin Sensitivity: A Comparison of Saturated and Long Chain n-3 Polyunsaturated Fatty Acids During the Postprandial Phase|Completed||N/A|59|Actual|University of Reading||2|||f||||f||||||||||2018-05-31 22:37:42.760493|2018-05-31 22:37:42.760493
NCT01351311|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2012-11-29|2011-05-09|2011-05-10|Estimate|||||||2012-11-29|2012-11-30|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Resistance Training Exercise Using the Swiss Ball in Ankylosing Spondylitis|Assessment of Effectiveness of Resistance Training Exercise Using the Swiss Ball in Patients With Ankylosing Spondylitis|Completed||N/A|60|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:37:42.842862|2018-05-31 22:37:42.842862
NCT01351298|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2012-12-04|2011-05-09|2011-05-10|Estimate|||||||2012-12-04|2012-12-06|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Nasal Prep for Nasendoscopy in Children|Intra-nasal Topical Local Anesthetic and Decongestant for Flexible Nasendoscopy in Children: a Randomised Double-blind Placebo Controlled Trial|Completed||Phase 4|69|Actual|Children's & Women's Health Centre of British Columbia||3|||f||||f||||||||||2018-05-31 22:37:42.931217|2018-05-31 22:37:42.931217
NCT01351285|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-06-01|2011-05-09|2011-05-10|Estimate|||||||2013-06-01|2013-06-04|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Effect-site Concentration of Remifentanil for Preventing Cough Against Endotracheal Tube During Anesthetic Emergence According to Anesthetics (Sevoflurane, Desflurane, and Propofol)||Completed||N/A|78|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 22:37:43.003682|2018-05-31 22:37:43.003682
NCT01351272|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2014-12-09|2011-05-09|2011-05-10|Estimate|||||||2014-12-09|2014-12-10|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|BEAS||Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)|Genetic Modulation of Functional Brain Activity of Attention-deficit/Hyperactivity Disorder-related Working Memory Processes|Completed||Phase 3|41|Actual|Wuerzburg University Hospital||1|||f||||t||||||||||2018-05-31 22:37:43.083502|2018-05-31 22:37:43.083502
NCT01351259|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-08-31|2011-05-09|2011-05-10|Estimate|||||||2013-08-31|2013-09-04|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Nosten||Continuous Control of Polyurethane Tracheal-cuff Pressure: Efficiency of a Pneumatic Device|Continuous Control of Polyurethane Tracheal-cuff Pressure: Efficiency of a Pneumatic Device|Completed||Phase 4|64|Actual|University Hospital, Lille||4|||f||||t||||||||||2018-05-31 22:37:43.156337|2018-05-31 22:37:43.156337
NCT01351246|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2014-04-14|2011-05-09|2011-05-10|Estimate|||||||2014-04-14|2014-04-15|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD): A Feasibility and Effectiveness Study|Completed||N/A|300|Actual|University of Cologne||1|||f||||f||||||||||2018-05-31 22:37:43.272046|2018-05-31 22:37:43.272046
NCT01351233|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2012-07-04|2011-05-09|2011-05-10|Estimate|||||||2012-07-04|2012-07-06|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Evaluation of the Rotational Stability of The AcrySof Toric Intraocular Lens in the Capsular Bag in High Myopic Subjects|Evaluation of the Rotational Stability of The AcrySof Toric Intraocular Lens in the Capsular Bag in High Myopic Subjects|Completed||N/A|30|Actual|Wenzhou Medical University|||||f||||t||||||||||2018-05-31 22:37:43.345064|2018-05-31 22:37:43.345064
NCT01351220|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2016-07-28|2011-05-09|2011-05-10|Estimate|||||||2016-07-28|2016-08-01|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention|Community Dissemination of an Evidence-based CRC Screening Intervention|Completed||N/A|1100|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||No||2018-05-31 22:37:43.408047|2018-05-31 22:37:43.408047
NCT01351207|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2014-11-18|2011-05-09|2011-05-10|Estimate|||||||2014-11-18|2014-11-19|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Eggs on Postprandial Metabolism|The Effect of Eggs on Postprandial Metabolism: A Randomized, Controlled Crossover Pilot Study in Older, Overweight Adults|Completed||N/A|20|Actual|Tufts University||3|||f||||||||||||||2018-05-31 22:37:43.483702|2018-05-31 22:37:43.483702
NCT01351194|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-05-24|2011-05-09|2011-05-10|Estimate|||||||2011-05-24|2011-05-26|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|May 2013|Anticipated|2013-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm|Radiofrequency Ablation vs. Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm.A Prospective and Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|180|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:37:43.547722|2018-05-31 22:37:43.547722
NCT01350999|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2016-06-01||2016-07-28|2011-05-09|2011-05-10|Estimate|2016-07-28|2016-09-20|Estimate||||2016-07-28|2016-09-20|Estimate|November 2009||2009-11-30|July 2016|2016-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia|A Phase 3 Long-term Study of TAK-085 in Subjects With Hypertriglyceridemia|Completed||Phase 3|503|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:37:46.546645|2018-05-31 22:37:46.546645
NCT01351181|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|June 2011||2011-06-30|May 2011|2011-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|PAADAR||Physical Activity Advice in Diabetics at Annual Review|A Case Control Study to Assess the Effectiveness of Written Advice to Increase Physical Activity Given to Type II Diabetics by Nursing Staff During the Diabetic Annual Review in UK General Practice|Unknown status|Not yet recruiting|N/A|80|Anticipated|Ship Street Surgery||2|||f||||f||||||||||2018-05-31 22:37:43.619649|2018-05-31 22:37:43.619649
NCT01351168|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2012-11-30|2011-05-09|2011-05-10|Estimate|||||||2012-11-30|2012-12-03|Estimate||||November 2012|2012-11-30||||||||Interventional|||Use of Zolpidem in Parkinson's Disease|A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease|Withdrawn||Phase 2|0|Actual|Rush University Medical Center||4||study not funded|f||||f||||||||||2018-05-31 22:37:43.697024|2018-05-31 22:37:43.697024
NCT01351155|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2014-12-29|2011-05-09|2011-05-10|Estimate|||||||2014-12-29|2014-12-31|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|May 2015|Anticipated|2015-05-31||Interventional|3PROSNIV||Prevention of Damage Induced by Facial Mask Ventilation|Comparison of Three Devices to Prevent Skin Damage Induced by Facial Mask Ventilation During Acute Respiratory Failure: a Multicenter Randomised Controlled Study|Unknown status|Recruiting|N/A|252|Anticipated|Ospedale San Donato||4|||f||||t||||||||||2018-05-31 22:37:43.880588|2018-05-31 22:37:43.880588
NCT01351142|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2016-10-10|2011-05-09|2011-05-10|Estimate|||||||2016-10-10|2016-10-11|Estimate|November 2009||2009-11-30|October 2016|2016-10-31||||November 2013|Actual|2013-11-30||Interventional|||Cytokines and Cognitive Decline in Alzheimer's Disease||Completed||N/A|133|Actual|Poitiers University Hospital|||||f||||||||||||||2018-05-31 22:37:43.976263|2018-05-31 22:37:43.976263
NCT01351129|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2011-07-05|2011-05-09|2011-05-10|Estimate|||||||2011-07-05|2011-07-06|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers|A Phase 1, Single-Dose, Open-Label, Crossover Study To Estimate The Relative Bioavailability Of Two Controlled-Release Formulations Vs. An Immediate Release Formulation Of PF-04991532 In Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:37:44.031548|2018-05-31 22:37:44.031548
NCT01351116|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2017-01-20|2011-05-09|2011-05-10|Estimate|||||||2017-01-20|2017-01-24|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|BRACHY||A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy|A Phase III, Multi-centre, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy|Completed||Phase 3|134|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-05-31 22:37:44.091783|2018-05-31 22:37:44.091783
NCT01351103|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2018-05-16|2011-05-09|2011-05-10|Estimate|||||||2018-05-16|2018-05-18|Actual|December 1, 2011|Actual|2011-12-01|May 2018|2018-05-31|January 9, 2020|Anticipated|2020-01-09|January 9, 2020|Anticipated|2020-01-09||Interventional|||A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands|A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands|Recruiting||Phase 1|170|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 22:37:44.262277|2018-05-31 22:37:44.262277
NCT01351090|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2012-09-14||2012-09-14|2011-05-09|2011-05-10|Estimate|2012-09-14|2012-10-18|Estimate||||2012-09-14|2012-10-18|Estimate||||September 2012|2012-09-30|October 2007|Actual|2007-10-31|||||Interventional|||Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine (IN) for Postoperative Pain|A Phase 2, Double-blind, Randomized Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain|Completed||Phase 2|127|Actual|Luitpold Pharmaceuticals||3|||||||||||||||||2018-05-31 22:37:44.425579|2018-05-31 22:37:44.425579
NCT01351077|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2016-12-08||2017-04-10|2011-05-09|2011-05-10|Estimate|2017-04-10|2017-06-26|Actual||||2017-04-10|2017-06-26|Actual|May 2011||2011-05-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The CHICA Developmental Screening Study|A Study to Determine if CHICA Can Improve Developmental Screening|Completed||N/A|360|Actual|Indiana University||2|||f||||f||||||||No||2018-05-31 22:37:44.895361|2018-05-31 22:37:44.895361
NCT01351064|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2015-11-17||2015-12-18|2011-05-09|2011-05-10|Estimate|2015-11-17|2015-12-18|Estimate||||2015-12-18|2016-01-25|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)|Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)|Completed||N/A|84|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 22:37:45.202701|2018-05-31 22:37:45.202701
NCT01351051|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2013-05-29|2011-05-09|2011-05-10|Estimate|||||||2013-05-29|2013-05-30|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|FEELING||A Study of the Potential Risk Factors Linked to the Development of Severe Forms of Endometriosis|A Multi-centre, Multinational, Cross-sectional, Incident Case-control Study on Factors Associated With the Development of Endometrioma and Deep Infiltrating Endometriosis|Completed|||1008|Actual|Ipsen|||4||f||||f||||||||||2018-05-31 22:37:45.429557|2018-05-31 22:37:45.429557
NCT01351038|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-06-03|2011-05-09|2011-05-10|Estimate|||||||2013-06-03|2013-06-04|Estimate||||June 2013|2013-06-30||||||||Interventional|||Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma|A Two Stage Multicenter Phase II Trial of Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma|Terminated||Phase 2|43|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1||REAL trial showed a significant difference in OS for reduced EOX and standard EOX|f||||t||||||||||2018-05-31 22:37:45.56467|2018-05-31 22:37:45.56467
NCT01351025|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2015-05-01||2016-05-18|2011-05-09|2011-05-10|Estimate|2015-07-07|2015-08-04|Estimate||||2016-05-18|2016-06-27|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Participants who started study treatment are included|Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells|A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL|Completed||Phase 2|98|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 22:37:45.658505|2018-05-31 22:37:45.658505
NCT01351012|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-02-18|2011-05-09|2011-05-10|Estimate|||||||2014-02-18|2014-02-19|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|COMIT||Canola Oil Multicentre Intervention Trial|Canola and Flax Oils in Modulation of Vascular Function and Biomarkers of Cardiovascular Disease Risk|Completed||N/A|140|Actual|University of Manitoba||5|||f||||f||||||||||2018-05-31 22:37:46.360701|2018-05-31 22:37:46.360701
NCT01350986|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|FLOH||Guided Self-Help for Parents of Children With Externalizing Problem Behavior|Efficacy of Cognitive-Behavioral Based Guided Self-Help for Parents of Children With Externalizing Problem Behavior|Unknown status|Recruiting|N/A|146|Anticipated|German Research Foundation||2|||f||||f||||||||||2018-05-31 22:37:47.80919|2018-05-31 22:37:47.80919
NCT01350973|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2016-06-01||2016-07-28|2011-05-09|2011-05-10|Estimate|2016-07-28|2016-09-20|Estimate||||2016-07-28|2016-09-20|Estimate|November 2009||2009-11-30|July 2016|2016-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy of TAK-085 in Participants With Hypertriglyceridemia|A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.|Completed||Phase 3|611|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:37:48.392139|2018-05-31 22:37:48.392139
NCT01350960|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2011-11-21|2011-05-09|2011-05-10|Estimate|||||||2011-11-21|2011-11-22|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH|A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)|Terminated||Phase 1|24|Actual|Santaris Pharma A/S||6|||f||||||||||||||2018-05-31 22:37:50.352456|2018-05-31 22:37:50.352456
NCT01350947|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2015-09-28||2016-05-10|2011-05-09|2011-05-10|Estimate|2015-09-28|2015-10-29|Estimate||||2016-05-10|2016-06-13|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia|A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML)|Completed||Phase 2|11|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 22:37:50.429306|2018-05-31 22:37:50.429306
NCT01350934|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2014-06-20||2017-01-27|2011-05-09|2011-05-10|Estimate|2014-06-20|2014-07-22|Estimate||||2017-01-27|2017-03-09|Actual|June 2011||2011-06-30|January 2017|2017-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Full Analysis Set (FAS) population, which consisted of all randomized participants who received at least one dose of study treatment, had at least one post-randomization observation for the analysis endpoint subsequent to at least one dose of study treatment, and had baseline data for analyses that required baseline data.|A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)|A 6-Month, Randomized, Open-Label, Active-Comparator Controlled, Parallel-Group Study With a 6-Month Extension to Evaluate the Safety and Efficacy of Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination Tablets Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China|Completed||Phase 4|219|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:37:50.742202|2018-05-31 22:37:50.742202
NCT01350921|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2012-03-29|2011-05-09|2011-05-10|Estimate|||||||2012-03-29|2012-03-30|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers|A Sequential, Open Label Study to Compare the Pharmacokinetics, Safety and Tolerability of Ticagrelor and Venlafaxine Given Concomitantly in Healthy Subjects Aged 18 to 45 Years|Completed||Phase 1|22|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:37:51.107793|2018-05-31 22:37:51.107793
NCT01350908|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2017-01-20|2011-05-09|2011-05-10|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Study of Circulating Tumoral DNA in Ovarian Cancer|Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Ovarian Cancer|Completed||N/A|25|Actual|Institut Curie||1|||f||||f||||||||||2018-05-31 22:37:51.171711|2018-05-31 22:37:51.171711
NCT01350895|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-11-04|2011-05-09|2011-05-10|Estimate|||||||2013-11-04|2013-11-06|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group|Clinical and Biochemical Presentation of Polycystic Ovary Syndrome in Different Age Group|Completed|||781|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:37:51.229444|2018-05-31 22:37:51.229444
NCT01350882|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2018-02-07|2011-05-09|2011-05-10|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2008||2008-10-31|February 2018|2018-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|RITUX-ERAH||Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation|Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation|Completed||Phase 3|40|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 22:37:51.324078|2018-05-31 22:37:51.324078
NCT01350869|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2015-11-10|2011-05-09|2011-05-10|Estimate|||||||2015-11-10|2015-11-11|Estimate|June 2008||2008-06-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|December 2011|Actual|2011-12-31||Observational|||Evaluation of Everolimus-Eluting Stents (The K-XIENCE Registry)|Evaluation of Effectiveness and Safety of Everolimus-Eluting Stents in Routine Clinical Practice|Completed|||3000|Anticipated|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:37:51.438182|2018-05-31 22:37:51.438182
NCT01350856|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2015-05-29|2011-05-09|2011-05-10|Estimate|||||||2015-05-29|2015-06-01|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|TRAC||Tracking Resistance to Artemisinin (TRAC)|A Multicentre, Randomised Trial to Detect in Vivo Resistance of Plasmodium Falciparum to Artesunate in Patients With Uncomplicated Malaria.|Completed||Phase 4|1700|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 22:37:51.531248|2018-05-31 22:37:51.531248
NCT01350843|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2018-03-23|2011-05-09|2011-05-10|Estimate|||||||2018-03-23|2018-03-27|Actual|May 2011||2011-05-31|March 2018|2018-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||The Effects of Orange Juice on Plasma Lipids|An Investigation Into the Effects of Orange Juice on Plasma Lipids - an Extension to J/06/2010|Completed||N/A|36|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 22:37:51.643099|2018-05-31 22:37:51.643099
NCT01350830|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|November 2007||2007-11-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2008|Actual|2008-12-31||Interventional|PPTHR||Preperitoneal Versus Pre-trasversalis Hernia Repair|Early and Late Results of Transinguinal Preperitoneal Patch Repair Versus Anterior Pre-Trasversalis Mesh Repair. A Randomised Study|Completed||Phase 4|253|Actual|San Bonifacio Hospital||2|||f||||t||||||||||2018-05-31 22:37:51.726472|2018-05-31 22:37:51.726472
NCT01350817|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2015-04-01|2011-05-09|2011-05-10|Estimate|||||||2015-04-01|2015-04-03|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|TARSEQ||Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer|Randomized Open Non Comparative Multicenter Phase II Study of Sequential Erlotinib With Docetaxel Versus Docetaxel Alone in Second Line of Treatment in Patients With Non Small Cell Lung Cancer After Failure of First Line Chemotherapy|Completed||Phase 2|156|Actual|University Hospital, Limoges||2|||f||||t||||||||||2018-05-31 22:37:51.793949|2018-05-31 22:37:51.793949
NCT01350804|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|2016-01-26||2016-05-04|2011-05-09|2011-05-10|Estimate|2016-05-04|2016-05-23|Estimate||||2016-05-04|2016-05-23|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|NURTURE 1||Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)|A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2309) and A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2309E1)|Completed||Phase 3|551|Actual|Novartis||4|||f||||t||||||||||2018-05-31 22:37:52.198705|2018-05-31 22:37:52.198705
NCT01350791|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2017-07-19|2011-05-09|2011-05-10|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2010|Actual|2010-05-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|October 2013|Actual|2013-10-31||Observational|||Evaluation of Effectiveness and Safety of PROMUS Element Stent (IRIS-ELEMENT )|Evaluation of Effectiveness and Safety of PROMUS Element™ in Routine Clinical Practice; A Multicenter, PROSPECTIVE OBSERVATIONAL STUDY|Completed|||3001|Actual|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:37:55.633706|2018-05-31 22:37:55.633706
NCT01350778|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-12-19|2011-05-09|2011-05-10|Estimate|||||||2017-12-19|2017-12-20|Actual|May 2010||2010-05-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Observational|||Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)|Evaluation of Effectiveness and Safety of BIOMATRIX in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Active, not recruiting|||1000|Anticipated|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:37:55.722882|2018-05-31 22:37:55.722882
NCT01350765|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2018-01-09|2011-05-09|2011-05-10|Estimate|||||||2018-01-09|2018-01-10|Actual|March 2010||2010-03-31|January 2018|2018-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|AKU||Naushero Feroze Neonatal Survival Project|Naushero Feroze Neonatal Survival Project: A Cluster Randomized Trial to Determine the Effectiveness of Package of Community Based Interventions to Reduce Neonatal Deaths Due to Birth Asphyxia, Low Birth Weight & Neonatal Sepsis|Completed||N/A|37201|Actual|Aga Khan University||2|||f||||t||||||||Yes||2018-05-31 22:37:55.856684|2018-05-31 22:37:55.856684
NCT01350752|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2016-09-08|2011-05-09|2011-05-10|Estimate|||||||2016-09-08|2016-09-09|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|January 2015|Actual|2015-01-31|September 2012|Actual|2012-09-30||Interventional|REACT||Research on the Economics of Artemisinin Combination Therapy (ACTs) for the Treatment of Malaria|A Cost-effectiveness Analysis of Alternative Strategies for the Deployment of ACTs at the Community Level in Cameroon and Nigeria|Completed||N/A|6513|Actual|London School of Hygiene and Tropical Medicine||3|||f||||f||||||||||2018-05-31 22:37:55.932559|2018-05-31 22:37:55.932559
NCT01350739|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-08|||2015-11-17|2011-05-09|2011-05-10|Estimate|||||||2015-11-17|2015-11-18|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Umbilical Access in Laparoscopic Surgery|Comparative, Randomized, Open-label Study: Different Incisions to Access the Abdominal Cavity Within the Umbilicus|Withdrawn||N/A|0|Actual|St John of God Hospital, Vienna||2|||f||||f||||||||||2018-05-31 22:37:56.025957|2018-05-31 22:37:56.025957
NCT01350726|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-08|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|July 2011|Anticipated|2011-07-31|May 2011|Actual|2011-05-31||Observational|GSA||Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan|Functional-three-dimensional Reconstruction and Functional Evaluation of Liver by 99MTc-GSA-SPECT Scintigraphy|Unknown status|Recruiting||0|Anticipated|Peking Union Medical College Hospital|||2||f||||t||||||||||2018-05-31 22:37:56.094372|2018-05-31 22:37:56.094372
NCT01350713|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-08|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|July 2011||2011-07-31|May 2011|2011-05-31|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Interventional|||The Counter-irritating Efficacy of Topical Povidone-iodine in Thermal Burns|Testing the Counter-irritating Efficacy of Topical Povidone-iodine in Thermal Burns; Comparison to Conventional Treatments|Unknown status|Not yet recruiting|N/A|280|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 22:37:56.162843|2018-05-31 22:37:56.162843
NCT01350700|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-08|||2017-10-31|2011-05-09|2011-05-10|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2011||2011-06-30|May 2011|2011-05-31|November 22, 2011|Actual|2011-11-22|November 2011|Actual|2011-11-30||Observational|||Long Term Follow up of Scars Formation and Quality of Life Assessment Study|Scar Formation and Quality of Life Assessment in Subjects (Adults & Children) Following Treatment With Debrase Compared to Standard of Care (SOC)|Completed|||148|Anticipated|MediWound Ltd|||2||f||||f||||||||||2018-05-31 22:37:56.248408|2018-05-31 22:37:56.248408
NCT01350687|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-08|||2011-05-09|2011-05-09|2011-05-10|Estimate|||||||2011-05-09|2011-05-10|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Observational|||Pulmonary Hypertension Prevention in Hemodialysis|New Phosphore Binders in Prevention of Pulmonary Hypertension|Unknown status|Not yet recruiting||40|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||f||||||||||2018-05-31 22:37:56.312675|2018-05-31 22:37:56.312675
NCT01350674|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2017-10-13|2011-05-09|2011-05-10|Estimate|||||||2017-10-13|2017-10-16|Actual|December 2010||2010-12-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Role of EBUS-TBNA in Diagnosing TB in Mediastinal/Hilar Lymph Nodes|Role of EBUS-TBNA (Endobronchial Ultrasound Transbronchial Needle Aspiration- in Diagnosing Tuberculosis in Mediastinal and/or Hilar Lymph Nodes|Suspended||N/A|50|Anticipated|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||||2018-05-31 22:37:56.395239|2018-05-31 22:37:56.395239
NCT01350661|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2015-08-07|2011-05-09|2011-05-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Observational|||Correlation Between Five Asthma Control Questionnaires|Assessment of Correlation Between Five Asthma Control Questionnaires|Completed|||99|Actual|Centre Hospitalier Universitaire Saint Pierre|||1||f||||f||||||||||2018-05-31 22:37:56.487509|2018-05-31 22:37:56.487509
NCT01350648|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-07|||2018-04-27|2011-05-07|2011-05-10|Estimate|||||||2018-04-27|2018-04-30|Actual|May 11, 2011||2011-05-11|January 30, 2018|2018-01-30||||||||Observational|||Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection|The Natural History of Liver Disease in a Cohort of Participants With Hepatitis B and/or Hepatitis C With or Without HIV Infection|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:37:56.557386|2018-05-31 22:37:56.557386
NCT01350635|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-07|||2015-12-17|2011-05-09|2011-05-10|Estimate|||||||2015-12-17|2015-12-18|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Skin Test Study of BM32|Evaluation of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, by Skin Testing|Completed||Phase 1/Phase 2|60|Actual|Biomay AG|||||f||||f||||||||||2018-05-31 22:37:56.649606|2018-05-31 22:37:56.649606
NCT01350622|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2016-12-19|2011-05-09|2011-05-10|Estimate|||||||2016-12-19|2016-12-21|Estimate|December 2011||2011-12-31|December 2016|2016-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy of PENNSAID® for Pain Management in the Emergency Department|Efficacy of PENNSAID® for Pain Management in the Emergency Department|Withdrawn||N/A|0|Actual|University of Utah||2||Study never initiated|f||||f||||||||||2018-05-31 22:37:57.265145|2018-05-31 22:37:57.265145
NCT01350609|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2015-12-08|2011-05-09|2011-05-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed|Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan and the Loose Combination of Both Components and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Subjects Under Fed Conditions in an Open Label, Randomized, 2-way-crossover Design|Completed||Phase 1|49|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:37:57.343496|2018-05-31 22:37:57.343496
NCT01350596|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-08-02|2011-05-06|2011-05-10|Estimate|||||||2011-08-02|2011-08-03|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|B4371004||A Bioequivalence Study Of Ibuprofen 50mg/ml (laboratórios Pfizer Ltda) In The Oral Suspension Form.|An Open Label, Randomized, 2x2 Crossover, Single Dose, Phase 4 Study To Determine The Pharmaceutical Bioequivalence Of Ibuprofen 50mg/Ml (Laboratórios Pfizer Ltda) Oral Suspension Versus Alivium ® 50mg/Ml (Mantecorp Indústria Química E Farmacêutica Ltda.) Oral Suspension, In Healthy Fasting Volunteers.|Completed||Phase 4|24|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:37:57.4473|2018-05-31 22:37:57.4473
NCT01350583|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2013-06-05||2013-08-07|2011-05-09|2011-05-10|Estimate|2013-06-05|2013-08-08|Estimate||||2013-08-07|2013-08-14|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Bicarbonate for Tumor Related Pain|A Pilot Study of Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain|Terminated||N/A|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|This Pilot Supportive Care study ended prematurely due to slow accrual and the initiating principal investigator leaving the institution. The outcome measures were based on 25 evaluable participants and there were only 2 participants enrolled.|1||PI Left Moffitt|f||||t||||||||||2018-05-31 22:37:57.591928|2018-05-31 22:37:57.591928
NCT01350570|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2015-04-09|2011-05-09|2011-05-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial|Acupuncture for Functional Bowel Disease|Completed||Phase 2/Phase 3|449|Actual|Chengdu University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 22:37:57.79018|2018-05-31 22:37:57.79018
NCT01350557|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2017-02-02|2011-05-09|2011-05-10|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2005||2005-01-31|February 2017|2017-02-28|July 2010|Actual|2010-07-31|September 2005|Actual|2005-09-30||Interventional|||Three Care Models for Elderly Patients With Hip Fracture|Three Care Models for Elderly Patients With Hip Fracture|Completed||N/A|299|Actual|Chang Gung Memorial Hospital||3|||f||||t||||||||No||2018-05-31 22:37:57.87111|2018-05-31 22:37:57.87111
NCT01350544|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2016-05-19||2017-04-07|2011-05-06|2011-05-09|Estimate|2017-04-07|2017-04-11|Actual||||2017-04-07|2017-04-11|Actual|April 2013||2013-04-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|TA|One participant was administratively withdrawn from the intervention condition because it was found that she was ineligible (not on medications) after being randomized to the intervention.|Treatment Advocacy Intervention for HIV-Positive African Americans|Treatment Advocacy Intervention for HIV-Positive African Americans|Completed||N/A|216|Actual|Boston Children’s Hospital|We did not assess long-term effects, as the 6-month follow-up assessment occurred immediately after the last booster session. In addition, we did not assess the effects of the intervention on viral suppression.|2|||f||||f||||||||No||2018-05-31 22:37:58.19913|2018-05-31 22:37:58.19913
NCT01350531|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Interventionist Procedures for Adherence to Weight Loss Recommendations in Black Adolescents|Interventionist Procedures for Adherence to Weight Loss Recommendations in Black Adolescents, Phase Two|Unknown status|Recruiting|N/A|200|Anticipated|Wayne State University||2|||f||||t||||||||||2018-05-31 22:37:59.378644|2018-05-31 22:37:59.378644
NCT01350518|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2017-11-03|2011-05-06|2011-05-09|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2011||2011-02-28|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|March 2013|Actual|2013-03-31||Interventional|DIVA-Pilot||Dietary Intervention for Visceral Adiposity|Dietary Intervention for Visceral Adiposity-Pilot|Active, not recruiting||N/A|30|Anticipated|Wake Forest University Health Sciences||4|||f||||t|f|f||||||No||2018-05-31 22:37:59.670806|2018-05-31 22:37:59.670806
NCT01350505|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2017-03-30|2011-05-06|2011-05-09|Estimate|||||||2017-03-30|2017-04-04|Actual|October 15, 2013|Actual|2013-10-15|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|January 31, 2017|Actual|2017-01-31||Interventional|||Toileting at Night in Older Adults: Light to Maximize Balance, Minimize Insomnia|Toileting at Night in Older Adults: Light to Maximize Vision, Minimize Insomnia|Active, not recruiting||N/A|40|Anticipated|VA Office of Research and Development||5|||f||||f||||||||Yes|All relevant summary data is presented in a publication under review. Anonymized, individual participant data would be made available upon request and completion of necessary documentation.|2018-05-31 22:37:59.759088|2018-05-31 22:37:59.759088
NCT01350492|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2018-03-06|2011-05-06|2011-05-09|Estimate|||||||2018-03-06|2018-03-07|Actual|April 16, 2013|Actual|2013-04-16|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Impact of Exericse Training on Pain and Brain Function in Gulf War Veteans|Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans|Recruiting||N/A|68|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 22:37:59.913626|2018-05-31 22:37:59.913626
NCT01350479|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2016-11-16||2017-09-06|2011-05-06|2011-05-09|Estimate|2017-01-24|2017-03-15|Actual||||2017-09-06|2017-10-05|Actual|October 1, 2012|Actual|2012-10-01|September 2017|2017-09-30|November 1, 2016|Actual|2016-11-01|January 15, 2016|Actual|2016-01-15||Observational|||Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers|Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers|Completed|||203|Actual|VA Office of Research and Development|||2||f||||f||||||Samples Without DNA|"~     Swabs of the gowns and gloves of health care workers that interact with the participants will~     be tested for MRSA and other types of bacteria. Swabs from body sites (e.g. nose) of~     participants will be tested for MRSA and other types of bacteria.~   "|No||2018-05-31 22:38:00.062693|2018-05-31 22:38:00.062693
NCT01350466|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|August 2011||2011-08-31|May 2011|2011-05-31|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Observational|||Prospective Study Investigating the Role of Occupational Exposure on Sinus Surgery Outcome|Prospective Study Investigating the Role of Occupational Exposure on Sinus Surgery Outcome|Unknown status|Not yet recruiting||200|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 22:38:00.244441|2018-05-31 22:38:00.244441
NCT01350453|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2012-08-01|2011-05-06|2011-05-09|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Development and Pilot Evaluation of a Web-supported Programme of Constraint Induced Therapy Following Stroke (LifeCIT)|Development and Pilot Evaluation of a Web-supported Programme of Constraint Induced Therapy Following Stroke (LifeCIT)|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|University of Southampton||2|||f||||f||||||||||2018-05-31 22:38:00.29324|2018-05-31 22:38:00.29324
NCT01350440|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2013-07-19|2011-05-06|2011-05-09|Estimate|||||||2013-07-19|2013-07-23|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia|Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia|Completed||Phase 2|5|Actual|University of South Florida||1|||f||||||||||||||2018-05-31 22:38:00.413812|2018-05-31 22:38:00.413812
NCT01350427|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2013-02-22|2011-05-06|2011-05-09|Estimate|||||||2013-02-22|2013-02-25|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Branched-chain Amino Acids, and Resistance Exercise on Skeletal Muscle Signaling Pathways|Effects of Leucine, Branched-chain Amino Acids, and Resistance Exercise on Skeletal Muscle Remodelling Signaling Pathways: a Randomized, Double-blind, and Placebo-controlled Study|Completed||N/A|18|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 22:38:00.639217|2018-05-31 22:38:00.639217
NCT01350414|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2015-06-17||2016-08-03|2011-05-06|2011-05-09|Estimate|2016-08-03|2016-09-26|Estimate||||2016-08-03|2016-09-26|Estimate|October 2005||2005-10-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|PAS1|AIR2 Extension Subjects Completing Follow-up at Year 1|AIR2 Extension Study to Demonstrate Longer-term (> 1 Year) Durability of Effectiveness|AIR2 Extension Study to Demonstrate Longer-term (> 1 Year) Durability of Effectiveness|Completed|||181|Actual|Boston Scientific Corporation|||1||f||||t||||||||||2018-05-31 22:38:00.751645|2018-05-31 22:38:00.751645
NCT01350401|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|2018-01-11||2018-05-07|2011-05-06|2011-05-09|Estimate|2018-05-07|2018-05-08|Actual||||2018-05-07|2018-05-08|Actual|June 1, 2011|Actual|2011-06-01|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|February 17, 2016|Actual|2016-02-17||Interventional||Participants who received cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T|Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma|Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma|Terminated||Phase 1/Phase 2|4|Actual|Adaptimmune||1||Lack of enrollment|f||||t|t|f||||||||2018-05-31 22:38:01.641215|2018-05-31 22:38:01.641215
NCT01350388|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2016-06-06||2016-08-09|2011-05-06|2011-05-09|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease|Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease|Completed||N/A|80|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:38:02.029256|2018-05-31 22:38:02.029256
NCT01350375|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|September 2009||2009-09-30|April 2011|2011-04-30||||||||Interventional|||Safety and Efficacy Study of Botox in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder|A Randomized Double-Blind Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|The Research Center of Southern California||2|||f||||f||||||||||2018-05-31 22:38:02.537798|2018-05-31 22:38:02.537798
NCT01350362|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2012-10-01|2011-05-06|2011-05-09|Estimate|||||||2012-10-01|2012-10-02|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|ARGO||Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimes of Tideglusib vs Placebo in Mild-to-Moderate AD Patients|Completed||Phase 2|306|Actual|Noscira SA||4|||f||||t||||||||||2018-05-31 22:38:02.627767|2018-05-31 22:38:02.627767
NCT01350349|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2018-03-19|2011-05-06|2011-05-09|Estimate|||||||2018-03-19|2018-03-21|Actual|April 2011||2011-04-30|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Home-delivered Intervention for Depressed, Cognitively Impaired Elders|Home-delivered Intervention for Depressed, Cognitively Impaired Elders|Completed||N/A|134|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 22:38:02.766592|2018-05-31 22:38:02.766592
NCT01350336|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2017-06-29|2011-05-06|2011-05-09|Estimate|||||||2017-06-29|2017-07-02|Actual|April 2011||2011-04-30|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PAS2||Bronchial Thermoplasty in Severe Persistent Asthma|Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma|Active, not recruiting||N/A|284|Actual|Boston Scientific Corporation||1|||f||||t||||||||Undecided||2018-05-31 22:38:02.838787|2018-05-31 22:38:02.838787
NCT01350323|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|May 2009||2009-05-31|March 2009|2009-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization|Aqueous Humor Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Bevacizumab in Type 3 Versus Type 1 and 2 Neovascularization. A Prospective, Case-control Study.|Completed||N/A|33|Actual|University of Molise||4|||f||||f||||||||||2018-05-31 22:38:02.947364|2018-05-31 22:38:02.947364
NCT01350310|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2015-04-05|2011-05-06|2011-05-09|Estimate|||||||2015-04-05|2015-04-07|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|NOGA-DCM||Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy|Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy|Completed||Phase 2|110|Actual|University Medical Centre Ljubljana||3|||f||||f||||||||||2018-05-31 22:38:03.069971|2018-05-31 22:38:03.069971
NCT01350297|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2013-06-17|2011-05-06|2011-05-09|Estimate|||||||2013-06-17|2013-06-18|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TETRADIA-UNI||Diaphragmatic Reinnervation of Tetraplegic Patients With Respiratory Insufficiency|Phrenic Reinnervation in Central Ventilatory Paralysis Due to Medullary Trauma With Phrenic Motoneuron Destruction|Completed||Phase 4|5|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 22:38:03.168594|2018-05-31 22:38:03.168594
NCT01350284|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|CinnGastEmpt||The Effect of Natural Food Flavourings on Gastrointestinal and Cardiovascular Physiological Responses.|Effect of Cinnamon on Gastric Emptying, Arterial Stiffness, Postprandial Lipaemia, Glycaemia, and Appetite Responses to High-fat Breakfast|Completed||N/A|9|Actual|University of Limerick||1|||f||||f||||||||||2018-05-31 22:38:03.228248|2018-05-31 22:38:03.228248
NCT01350271|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2011-08-23||2013-04-18|2011-05-06|2011-05-09|Estimate|2013-04-18|2013-04-22|Estimate||||2013-04-18|2013-04-22|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||All those found positive for hookworm infection, from among the population screened at baseline|Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections|Comparative Efficacy of Different Mebendazole Polymorphs in the Treatment of Soil-transmitted Helminth Infections|Completed||Phase 3|214|Actual|University of Kelaniya|Small sample size owing to limitation in available funds.|3|||f||||f||||||||||2018-05-31 22:38:03.294596|2018-05-31 22:38:03.294596
NCT01350258|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2014-10-21||2016-11-28|2011-05-06|2011-05-09|Estimate|2014-10-21|2014-10-24|Estimate||||2016-11-28|2016-11-29|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps|A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Using Melphalan for T-Cell Tolerization|Terminated||Phase 1/Phase 2|8|Actual|Thomas Jefferson University|Study was terminated due to extreme toxicity. The study was closed before any data could be collected.|1||Poor accrual|f||||t||||||||||2018-05-31 22:38:03.754666|2018-05-31 22:38:03.754666
NCT01350245|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2014-10-07||2016-10-19|2011-05-06|2011-05-09|Estimate|2014-10-07|2014-10-13|Estimate||||2016-10-19|2016-11-29|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies in Remission From HLA Partially-Matched Related Donors|Completed||Phase 2|28|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 22:38:04.211025|2018-05-31 22:38:04.211025
NCT01350232|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2014-11-13||2016-10-19|2011-05-06|2011-05-09|Estimate|2014-11-13|2014-11-20|Estimate||||2016-10-19|2016-11-29|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Treatment of Sickle Cell Anemia With Stem Cell Transplant|Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors|Terminated||N/A|2|Actual|Thomas Jefferson University|Study was terminated due to poor accrual. No reportable data has been collected.|1||Poor accrual|f||||t||||||||||2018-05-31 22:38:04.735557|2018-05-31 22:38:04.735557
NCT01350219|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2013-11-25|2011-05-06|2011-05-09|Estimate|||||||2013-11-25|2013-11-27|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Stem Cell Educator Therapy in Type 1 Diabetes|Phase 2 Study of Stem Cell Educator Therapy in Type 1 Diabetes|Unknown status|Recruiting|Phase 2|100|Anticipated|Tianhe Stem Cell Biotechnologies Inc.||1|||f||||t||||||||||2018-05-31 22:38:05.011331|2018-05-31 22:38:05.011331
NCT01350206|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|May 2013|Anticipated|2013-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis|Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|180|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:38:05.09879|2018-05-31 22:38:05.09879
NCT01350193|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2013-12-02|2011-05-06|2011-05-09|Estimate|||||||2013-12-02|2013-12-04|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Manuka Honey Irrigation After Sinus Surgery|Manuka Honey Irrigation After Endoscopic Sinus Surgery|Completed||Phase 1/Phase 2|78|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:38:05.170657|2018-05-31 22:38:05.170657
NCT01350180|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2017-03-16|2011-05-06|2011-05-09|Estimate|||||||2017-03-16|2017-03-17|Actual|September 2010||2010-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis|A Prospective Study Assessing the Predictive Value of TMPRSS2-ERG Gene Fusion and PTEN Deletion in High Risk Prostate Cancer Patients|Recruiting|||132|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital|||||f||||f||||||||||2018-05-31 22:38:05.260705|2018-05-31 22:38:05.260705
NCT01350167|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-23|2011-05-06|2011-05-09|Estimate|||||||2011-05-23|2011-05-24|Estimate|November 2001||2001-11-30|December 2010|2010-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease|Screening for Hepatocellular Carcinoma With Triphasic Helical CT vs. US With Alpha-fetoprotein in Patients With Advanced Liver Disease|Recruiting||N/A|300|Anticipated|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 22:38:05.347453|2018-05-31 22:38:05.347453
NCT01350154|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-04-09|2011-05-06|2011-05-09|Estimate|||||||2013-04-09|2013-04-10|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients|Does Modulation of the nNOS System in Patients With Muscular Dystrophy and Defect nNOS Signalling Affect Cardiac, Muscular or Cognitive Function?|Completed||Phase 2|17|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 22:38:05.424561|2018-05-31 22:38:05.424561
NCT01350141|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2017-10-02|2013-11-19|2017-10-04|2011-05-06|2011-05-09|Estimate|2017-10-04|2017-11-08|Actual|2013-11-19|2013-12-13|Estimate|2017-10-04|2017-11-08|Actual|June 2011|Actual|2011-06-30|October 2017|2017-10-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional||Safety analysis set included all participants who received at least 1 dose of study medication.|A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins|A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.|Completed||Phase 2|46|Actual|Pfizer|Due to an inadvertent omission in the protocol at Day 85, presented limitations in data collection and the assessment of treatment effect on ApoA1 and ApoB for Day 85.|3|||f||||t||||||||||2018-05-31 22:38:05.547519|2018-05-31 22:38:05.547519
NCT01350128|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2017-05-08|2013-05-16|2017-05-08|2011-05-06|2011-05-09|Estimate|2017-05-08|2017-06-08|Actual|2013-05-16|2013-05-24|Estimate|2017-05-08|2017-06-08|Actual|May 2011||2011-05-31|April 2017|2017-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Intent-to-Treat (ITT) Population includes all subjects who were randomized, received at least 1 dose of study treatment, and had both baseline and post-baseline efficacy data for that treatment.|PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Chronic Dosing (7 Days), Three-Period, Six-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Four Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Atrovent® HFA Inhalation Aerosol (Open-Label) as An Active Control|Completed||Phase 2|103|Actual|Pearl Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 22:38:06.381708|2018-05-31 22:38:06.381708
NCT01350115|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2015-08-18||2015-09-23|2011-05-06|2011-05-09|Estimate|2015-09-23|2015-10-19|Estimate||||2015-09-23|2015-10-19|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)|A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome|Completed||Phase 2|10|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:38:06.85578|2018-05-31 22:38:06.85578
NCT01350102|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2017-06-28|2015-04-14|2017-11-13|2011-05-06|2011-05-09|Estimate|2017-11-13|2017-12-12|Actual|2015-05-06|2015-05-25|Estimate|2017-11-13|2017-12-12|Actual|February 2012||2012-02-29|November 2017|2017-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Relationship of Hemoglobin A1c and Diabetic Wound Healing|The Relationship of Hemoglobin A1c and Diabetic Wound Healing|Terminated||Phase 4|2|Actual|Milton S. Hershey Medical Center|Study terminated due to recruitment issues - only two subjects enrolled in study.|4||study closed due to recruitment problems|f||||f||||||||No||2018-05-31 22:38:07.247502|2018-05-31 22:38:07.247502
NCT01350089|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication|A Double Blind, Randomised, Placebo-controlled, Within-subject Crossover Study to Examine the Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication|Unknown status|Active, not recruiting|N/A|52|Anticipated|Medical University of Vienna||4|||f||||f||||||||||2018-05-31 22:38:07.704289|2018-05-31 22:38:07.704289
NCT01350076|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-05-06|2011-05-06|2011-05-09|Estimate|||||||2011-05-06|2011-05-09|Estimate|October 2011||2011-10-31|May 2011|2011-05-31|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Interventional|GDT||Liberal Versus Goal-directed Intraoperative Fluid Therapy in Pediatric Patients|Liberal VS Goal-directed Intraoperative Fluid Therapy in Pediatric Patients|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 22:38:07.800994|2018-05-31 22:38:07.800994
NCT01350063|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-01-01|2011-05-06|2011-05-09|Estimate|||||||2013-01-01|2013-01-03|Estimate|February 2011||2011-02-28|May 2011|2011-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Health Impact of Treating and Safely Storing Shallow Tubewell Drinking Water|Health Impact of Treating and Safely Storing Shallow Tubewell Drinking Water|Completed||N/A|1800|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||t||||||||||2018-05-31 22:38:07.8842|2018-05-31 22:38:07.8842
NCT01350050|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|||2012-07-04|2011-05-06|2011-05-09|Estimate|||||||2012-07-04|2012-07-06|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Topical Pharyngeal Anesthesia With Articaine for Gastroscopy|Topical Pharyngeal Anaesthesia With Articaine for Gastroscopy. A Randomized Double-blind Study on Volunteers|Completed||Phase 4|18|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 22:38:07.999547|2018-05-31 22:38:07.999547
NCT01350037|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2012-07-04|2011-05-06|2011-05-09|Estimate|||||||2012-07-04|2012-07-06|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Alfentanil Versus Remifentanil in Patient-controlled Sedation During Endoscopic Retrograde Cholangiopancreatography (ERCP)|Alfentanil vs Remifentanil in Patient-controlled Sedation During ERCP.A Randomized Double-blind Study|Completed||Phase 4|81|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 22:38:08.317171|2018-05-31 22:38:08.317171
NCT01350024|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2017-05-24|2011-05-06|2011-05-09|Estimate|||||||2017-05-24|2017-05-30|Actual|May 1, 2011|Actual|2011-05-01|May 2017|2017-05-31|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Interventional|||Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid|Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid|Completed||N/A|34|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 22:38:08.399347|2018-05-31 22:38:08.399347
NCT01350011|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2014-12-08|2011-05-06|2011-05-09|Estimate|||||||2014-12-08|2014-12-10|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|IBIS||Tobacco Intervention in Buprenorphine Treatment|Extended Tobacco Dependence Intervention in Buprenorphine Treatment|Unknown status|Active, not recruiting|Phase 3|175|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:38:08.471682|2018-05-31 22:38:08.471682
NCT01349998|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03||2013-01-22|2013-01-22|2011-05-06|2011-05-09|Estimate||||2013-01-22|2013-01-29|Estimate|2013-01-22|2013-01-29|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis|An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris|Completed||Phase 3|604|Actual|Tinea Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:38:08.547709|2018-05-31 22:38:08.547709
NCT01349985|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2014-05-09|2011-05-06|2011-05-09|Estimate|||||||2014-05-09|2014-05-13|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|AGATE||Adaptive Goal-Directed Adherence Tracking and Enhancement|"SBIR-PhaseII, Adaptive Goal-Directed Adherence Tracking and Enhancement"|Completed||Phase 2|136|Actual|Talaria, Inc||2|||f||||f||||||||||2018-05-31 22:38:08.631318|2018-05-31 22:38:08.631318
NCT01349972|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2015-09-04||2017-07-03|2011-05-06|2011-05-09|Estimate|2017-05-03|2017-06-06|Actual||||2017-07-03|2017-07-31|Actual|April 2011||2011-04-30|July 2017|2017-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|"Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. 7+3 for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML)"|Completed||Phase 2|172|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 22:38:08.736731|2018-05-31 22:38:08.736731
NCT01349959|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2016-02-19||2018-03-20|2011-05-06|2011-05-09|Estimate|2016-02-19|2016-03-17|Estimate||||2018-03-20|2018-04-18|Actual|April 21, 2011|Actual|2011-04-21|March 2018|2018-03-31||||March 27, 2014|Actual|2014-03-27||Interventional|||Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer|Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:38:09.440758|2018-05-31 22:38:09.440758
NCT01349946|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-04-12|2011-05-06|2011-05-09|Estimate|||||||2016-04-12|2016-04-14|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Diffusion Weighted Imaging Evaluation for Understanding Stroke Evolution Study-2 (DEFUSE-2)|Diffusion Weighted Imaging Evaluation for Understanding Stroke Evolution Study-2 (DEFUSE-2)|Completed|||138|Actual|Stanford University|||||f||||||||||||||2018-05-31 22:38:09.859974|2018-05-31 22:38:09.859974
NCT01349933|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-06|2014-12-23||2017-10-30|2011-05-06|2011-05-09|Estimate|2014-12-23|2015-01-08|Estimate||||2017-10-30|2017-12-05|Actual|April 2011||2011-04-30|October 2017|2017-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:38:09.955165|2018-05-31 22:38:09.955165
NCT01349920|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2016-08-04||2016-08-04|2011-05-06|2011-05-09|Estimate|2016-08-04|2016-09-28|Estimate||||2016-08-04|2016-09-28|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)|An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD)|Completed|||15|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||Samples With DNA|"~     stool, serum, peripheral blood mononuclear cells (PBMC)~   "|||2018-05-31 22:38:10.287909|2018-05-31 22:38:10.287909
NCT01349907|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2015-02-24||2016-09-13|2011-05-05|2011-05-09|Estimate|2015-02-24|2015-03-09|Estimate||||2016-09-13|2016-10-24|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ADDRESS-98|Participants who received at least one dose of trial medication, and were 17 years old or younger. One 18 year old participant from the Placebo/Asenapine group, was excluded due to being overage.|Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)|A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Subjects With Acute Manic or Mixed Episodes Associated With Bipolar I Disorder|Completed||Phase 3|322|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 22:38:11.719147|2018-05-31 22:38:11.719147
NCT01349894|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2012-12-11|2011-05-06|2011-05-09|Estimate|||||||2012-12-11|2012-12-12|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||SNaP Wound Care System Over Skin Cancer Excision Sites and Split Thickness Skin Grafts (STSGs)|Post-Market Clinical Evaluation of the Spiracur SNaP™ Wound Care System for Treatment of Skin Cancer Excision Sites and Split Thickness Skin Grafts|Completed|||7|Actual|Spiracur, Inc.|||1||f||||f||||||||||2018-05-31 22:38:12.21165|2018-05-31 22:38:12.21165
NCT01349881|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2018-03-20|2011-05-06|2011-05-09|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2013||2013-03-31|March 2018|2018-03-31|June 2029|Anticipated|2029-06-30|June 2024|Anticipated|2024-06-30||Interventional|PACES||S0820, Adenoma and Second Primary Prevention Trial|A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)|Recruiting||Phase 3|1340|Anticipated|Southwest Oncology Group||4|||f||||t||||||||||2018-05-31 22:38:13.814538|2018-05-31 22:38:13.814538
NCT01349868|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05||2012-09-10|2012-09-10|2011-05-06|2011-05-09|Estimate||||2012-09-10|2012-09-12|Estimate|2012-09-10|2012-09-12|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||PT005 MDI Dose Ranging Versus Foradil Aerolizer Study|A Randomized, Double-Blind, Single Dose, Six-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Three Doses of PT005, in Patients With Moderate to Severe COPD, Compared With Foradil® Aerolizer® (12 and 24 µg Open-Label) as Active Controls|Completed||Phase 2|50|Actual|Pearl Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 22:38:17.806898|2018-05-31 22:38:17.806898
NCT01349855|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-05-31|2011-05-06|2011-05-09|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus|A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Assess the Safety and Tolerability of Two Dose Levels of a New Formulation of Insulin Glargine and to Compare Its Pharmacodynamic and Pharmacokinetic Properties With 0.4 U/kg/Day Lantus® in an 8-days Multiple Dosing Regimen in Patients With Diabetes Mellitus Type 1|Completed||Phase 1|30|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 22:38:17.880704|2018-05-31 22:38:17.880704
NCT01349842|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-08-01|2011-05-06|2011-05-09|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2016|Actual|2016-01-31||Interventional|CirCé01||Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer|CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer|Active, not recruiting||Phase 3|265|Actual|Institut Curie||2|||f||||f||||||||No||2018-05-31 22:38:17.94207|2018-05-31 22:38:17.94207
NCT01349309|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2015-12-03|2011-05-05|2011-05-06|Estimate|||||||2015-12-03|2015-12-04|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients|The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients|Completed||N/A|26|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 22:38:26.706676|2018-05-31 22:38:26.706676
NCT01349829|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2013-10-25||2013-10-25|2011-05-06|2011-05-09|Estimate|2013-10-25|2013-12-17|Estimate||||2013-10-25|2013-12-17|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children|A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule|Completed||Phase 4|251|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 22:38:18.163347|2018-05-31 22:38:18.163347
NCT01349816|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2016-05-21|2013-05-16|2017-04-26|2011-05-06|2011-05-09|Estimate|2017-04-26|2017-04-27|Actual|2013-05-16|2013-05-24|Estimate|2017-04-26|2017-04-27|Actual|June 2011||2011-06-30|April 2017|2017-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Analysis population included all randomized subjects|PT003 MDI Dose Confirmation Study|A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls|Completed||Phase 2|185|Actual|Pearl Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 22:38:18.669936|2018-05-31 22:38:18.669936
NCT01349803|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2016-05-24|2013-05-16|2016-12-07|2011-05-06|2011-05-09|Estimate|2016-12-07|2017-01-31|Estimate|2013-05-16|2013-05-24|Estimate|2016-12-07|2017-01-31|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Safety Population (all randomized subjects)|PT003 MDI Cardiovascular Safety Study|A Randomized, Double-blind, Parallel Group, 14-day, Multi-Center Study to Evaluate the Safety of PT003, PT005, PT001 and Foradil® Aerolizer® (12 µg, Open Label) as Evaluated by Holter Monitoring, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|237|Actual|Pearl Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 22:38:19.611956|2018-05-31 22:38:19.611956
NCT01349790|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2017-03-22|2015-06-05|2017-05-04|2011-05-06|2011-05-09|Estimate|2017-05-04|2017-06-07|Actual|2015-12-10|2016-01-13|Estimate|2017-05-04|2017-06-07|Actual|October 2011||2011-10-31|May 2017|2017-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Safety set: All participants enrolled in the study who received at least part of 1 dose of NewGam.|Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia|Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia|Completed||Phase 3|40|Actual|Octapharma||1|||f||||t||||||||||2018-05-31 22:38:20.888649|2018-05-31 22:38:20.888649
NCT01349777|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2017-06-15|2011-05-06|2011-05-09|Estimate|||||||2017-06-15|2017-06-16|Actual|March 15, 2010|Actual|2010-03-15|June 2017|2017-06-30|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Effectiveness of Clopidogrel Resinate in PCI(PRIDE)|Effectiveness of Clopidogrel Resinate(PRegrel®) in Patients Undergoing Percutaneous Coronary Intervention Compared With ClopiDogrEl Bisulfate(Plavix®)|Completed||Phase 4|1056|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 22:38:21.342999|2018-05-31 22:38:21.342999
NCT01349764|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-05-04|2011-05-06|2011-05-09|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Effect of Vitamin D Replacement in Patients With Urolithiasis|Effect of Vitamin D Replacement in Vitamin D Deficient Patients With History of Urolithiasis: A Randomized Controlled Trial|Terminated|||10|Actual|McGill University Health Center|||2|Unable to recruit required sample size|f||||t||||||||||2018-05-31 22:38:21.46516|2018-05-31 22:38:21.46516
NCT01349751|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2013-11-05|2011-05-06|2011-05-09|Estimate|||||||2013-11-05|2013-11-07|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution|Clinical Characteristics of Spinal Levobupivacaine: Hyperbaric Compared With Isobaric Solution|Completed||N/A|20|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 22:38:21.557048|2018-05-31 22:38:21.557048
NCT01349738|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-08-31|2011-05-05|2011-05-09|Estimate|||||||2011-08-31|2011-09-01|Estimate|May 2011||2011-05-31|August 2011|2011-08-31|May 2013|Anticipated|2013-05-31|||||Observational|ASB||Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants|Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants|Unknown status|Enrolling by invitation||200|Anticipated|Rice, James C., M.D.|||2||f||||t||||||Samples Without DNA|"~     The investgators have a repository of bacteria specimens from transplant patients with UTI~     and plan to save bacteria from this study. The investigators will also plan to save discarded~     aliquots of supernatent of urine and discarded aliquots of blood, all samples from~     centrifuged specimens devoid of human cells.~   "|||2018-05-31 22:38:21.673254|2018-05-31 22:38:21.673254
NCT01349725|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2011-10-19|2011-05-06|2011-05-09|Estimate|||||||2011-10-19|2011-10-20|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Safety Study of ARRY-502 in Healthy Subjects||Completed||Phase 1|32|Actual|Array BioPharma||2|||f||||f||||||||||2018-05-31 22:38:21.754026|2018-05-31 22:38:21.754026
NCT01349712|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-05-05|2011-05-05|2011-05-09|Estimate|||||||2011-05-05|2011-05-09|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Study to Test the Accuracy of a Prototype Handheld PT/INR Device|Correlation of Feasibility Batches Using Warfarinised Blood|Unknown status|Enrolling by invitation||200|Anticipated|Universal Biosensors Pty Ltd|||1||f||||f||||||||||2018-05-31 22:38:21.824129|2018-05-31 22:38:21.824129
NCT01349699|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2015-11-16|2011-05-05|2011-05-06|Estimate|||||||2015-11-16|2015-11-17|Estimate|February 2010||2010-02-28|November 2015|2015-11-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia|Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia|Completed||N/A|30|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 22:38:21.920687|2018-05-31 22:38:21.920687
NCT01349686|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2013-02-17|2011-05-05|2011-05-06|Estimate|||||||2013-02-17|2013-02-20|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Fluid Oral Intake During Labour|Fluid Oral Intake vs. Fasting During Labour: A Randomized, Controlled Trial.|Completed||N/A|348|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 22:38:21.999302|2018-05-31 22:38:21.999302
NCT01349673|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-01-26|2011-05-05|2011-05-06|Estimate|||||||2015-01-26|2015-01-27|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis|A Phase 3, Open Label, Multicenter Study to Assess the Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis|Completed||Phase 3|114|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-05-31 22:38:22.063582|2018-05-31 22:38:22.063582
NCT01349660|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2017-11-30||2018-01-03|2011-05-05|2011-05-06|Estimate|2018-01-03|2018-01-31|Actual||||2018-01-03|2018-01-31|Actual|December 2011||2011-12-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|December 2016|Actual|2016-12-31||Interventional||Patients that received at least one dose of study treatment|Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme|Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)|Active, not recruiting||Phase 1/Phase 2|88|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 22:38:22.150227|2018-05-31 22:38:22.150227
NCT01349647|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-01-04|2011-05-05|2011-05-06|Estimate|||||||2016-01-04|2016-01-05|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid|Immunization of Small Cell Lung Cancer Patients With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid|Completed||Phase 1|21|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 22:38:23.2345|2018-05-31 22:38:23.2345
NCT01349634|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2016-06-08|2011-05-05|2011-05-06|Estimate|||||||2016-06-08|2016-06-09|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effects of Iodized Salt on Cognitive Development in Ethiopia|A Study to Measure the Effect of Switching the Salt Supply From Non-iodized to Iodized on Cognitive Development in Ethiopia|Completed||N/A|5704|Actual|McGill University||2|||f||||f||||||||||2018-05-31 22:38:23.310834|2018-05-31 22:38:23.310834
NCT01349621|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2015-03-09|2011-05-05|2011-05-06|Estimate|||||||2015-03-09|2015-03-10|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Clinical Evaluation of Polarized Light Assisted Colposcopy|Clinical Evaluation of Polarized Light Assisted Colposcopy|Completed|||330|Actual|Augusta University|||1||f||||f||||||||||2018-05-31 22:38:23.383639|2018-05-31 22:38:23.383639
NCT01349608|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2013-04-01|2011-05-05|2011-05-06|Estimate|||||||2013-04-01|2013-04-04|Estimate|April 2011||2011-04-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PACC||Physical Activity Coaching in Chronic Obstructive Pulmonary Disease (COPD)|Physical Activity Coaching in COPD|Completed||N/A|50|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 22:38:23.439192|2018-05-31 22:38:23.439192
NCT01349595|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|2015-08-10||2015-10-05|2011-05-05|2011-05-06|Estimate|2015-08-10|2015-09-09|Estimate||||2015-10-05|2015-10-28|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation|Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation|Terminated||Phase 2|4|Actual|Mayo Clinic|Although subjects completed the cycles of drug, long term follow-up visits were not possible due to funding discontinuation.|2||Study halted due to lack of funding|f||||t||||||||||2018-05-31 22:38:23.49914|2018-05-31 22:38:23.49914
NCT01349582|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-12-13|2011-05-05|2011-05-06|Estimate|||||||2017-12-13|2017-12-15|Actual|May 2, 2011|Actual|2011-05-02|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|FIAT||Flow Diversion in Intracranial Aneurysm Treatment|A Randomized Trial Comparing Flow Diversion and Best-standard Treatment - the FIAT Trial|Recruiting||Phase 4|344|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||f||||||||||2018-05-31 22:38:23.669513|2018-05-31 22:38:23.669513
NCT01349569|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-10-12|2011-05-05|2011-05-06|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission|Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction With a Lenalidomide Containing Regimen in Myeloma Patients With Near Complete Remission|Completed||Phase 2|18|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 22:38:23.871106|2018-05-31 22:38:23.871106
NCT01349556|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2014-04-21|2011-05-05|2011-05-06|Estimate|||||||2014-04-21|2014-04-23|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream|Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin|Withdrawn||N/A|0|Actual|Johns Hopkins University||1||Study withdrawn due to volunteer disinterest in participating.|f||||||||||||||2018-05-31 22:38:23.964476|2018-05-31 22:38:23.964476
NCT01349543|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2015-06-03|2011-05-05|2011-05-06|Estimate|||||||2015-06-03|2015-06-04|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|September 2014|Actual|2014-09-30|October 2013|Actual|2013-10-31||Interventional|||The Development of a Human Model of Respiratory Syncytial Virus Infection|The Development of a Human Model of Respiratory Syncytial Virus Infection|Completed||N/A|40|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 22:38:24.02658|2018-05-31 22:38:24.02658
NCT01349530|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2017-01-03|2011-05-05|2011-05-06|Estimate|||||||2017-01-03|2017-01-04|Estimate|May 2011||2011-05-31|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|CREATIF||Evaluating of CREATIF an Anti-coagulation Clinic|Evaluating of the Benefit to the Patient by Managing of His Anticoagulation Treatment by an Anti-coagulation Clinic|Completed||N/A|110|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:38:24.095164|2018-05-31 22:38:24.095164
NCT01349517|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-11-10|2011-05-05|2011-05-06|Estimate|||||||2011-11-10|2011-11-11|Estimate|May 2011||2011-05-31|January 2011|2011-01-31|December 2016|Anticipated|2016-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Health-related Quality of Life of Patients With Esophageal Cancer After Surgery|Health-related Quality of Life of Patients With Esophageal Cancer After Surgery in China: A Prospective Cohort Study From Multi-center|Unknown status|Not yet recruiting|Phase 2|400|Anticipated|Fudan University||4|||f||||t||||||||||2018-05-31 22:38:24.164864|2018-05-31 22:38:24.164864
NCT01349504|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2013-08-16|2011-05-05|2011-05-06|Estimate|||||||2013-08-16|2013-08-19|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease|Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease|Completed|||106|Actual|Beth Israel Deaconess Medical Center|||1||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 22:38:24.245782|2018-05-31 22:38:24.245782
NCT01349491|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2017-01-10||2017-03-16|2011-05-05|2011-05-06|Estimate|2017-03-16|2017-04-27|Actual||||2017-03-16|2017-04-27|Actual|March 2012||2012-03-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|GILEAD||Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion|Ranolazine for the Prevention of Recurrent Persistent Atrial Fibrillation After Electrical Cardioversion: A Pilot Study|Terminated||Phase 3|10|Actual|University of Oklahoma||2||low recruitement rates|f||||t||||||||Undecided||2018-05-31 22:38:24.309011|2018-05-31 22:38:24.309011
NCT01349478|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-12-26|2011-05-05|2011-05-06|Estimate|||||||2016-12-26|2016-12-28|Estimate|May 2011||2011-05-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI)|Electrical Stimulation Induced Lower Limb Exercise Capacity, Cardiorespiratory Response, Cardiovascular Risk Factors and Muscle Activity Patterns in Response to Robotic Assisted Treadmill Gait Training in Individuals With Complete Motor Spinal Cord Injury|Completed||Phase 1/Phase 2|11|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 22:38:24.530801|2018-05-31 22:38:24.530801
NCT01349465|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2016-12-23||2017-03-10|2011-05-05|2011-05-06|Estimate|2016-12-23|2017-02-16|Actual||||2017-03-10|2017-04-10|Actual|July 4, 2011|Actual|2011-07-04|March 2017|2017-03-31|January 5, 2016|Actual|2016-01-05|January 5, 2016|Actual|2016-01-05||Interventional|||3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection|A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) Infection|Completed||Phase 3|249|Actual|Janssen R&D Ireland||2|||f||||f||||||||||2018-05-31 22:38:24.628776|2018-05-31 22:38:24.628776
NCT01349452|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-05-05|2011-05-05|2011-05-06|Estimate|||||||2011-05-05|2011-05-06|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis|Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis|Completed||N/A|33|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 22:38:25.049538|2018-05-31 22:38:25.049538
NCT01349439|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2014-06-23|2011-05-05|2011-05-06|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2011||2011-03-31|June 2014|2014-06-30||||January 2015|Anticipated|2015-01-31||Interventional|||Reducing Reconsolidation of Trauma Memories With Propranolol|Reduction of the Reconsolidation of the Trauma Memory With Propranolol|Unknown status|Recruiting|Phase 2|76|Anticipated|Douglas Mental Health University Institute||5|||f||||f||||||||||2018-05-31 22:38:25.111631|2018-05-31 22:38:25.111631
NCT01349426|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-07-27|2011-05-05|2011-05-06|Estimate|||||||2015-07-27|2015-07-28|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Ligasure II: Standard Stapling Versus Ligasure|Standard Stapling Technique Versus Bipolar Fusion (With The Ligasure Impact and Force Triad Generator) To Complete The Fissure During Major Lung Resection: A Prospective Randomized Controlled Trial|Terminated||Phase 3|172|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||diffculty to include patients|f||||f||||||||||2018-05-31 22:38:25.197414|2018-05-31 22:38:25.197414
NCT01349413|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2017-04-20|2011-05-05|2011-05-06|Estimate|||||||2017-04-20|2017-04-21|Actual|August 2011||2011-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BD||BRAVO Study for Functional Dyspepsia|Role of Gastroesophageal Acid Reflux at Squamo-columnar Junction in Functional Dyspepsia|Recruiting||Phase 4|130|Anticipated|Chinese University of Hong Kong||2|||f||||||||||||No||2018-05-31 22:38:25.293434|2018-05-31 22:38:25.293434
NCT01349400|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2018-04-25|2011-05-05|2011-05-06|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2011||2011-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|AWARE||Watchful Waiting Versus Repair of Oligosymptomatic Incisional Hernias|Watchful Waiting vs. Repair of Oligosymptomatic Incisional Hernias|Recruiting||Phase 3|636|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:38:25.422655|2018-05-31 22:38:25.422655
NCT01349387|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2012-02-08|2011-05-05|2011-05-06|Estimate|||||||2012-02-08|2012-02-09|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|METFORGENE||Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing|Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing Whose Maturation Depends on the Protein HuR, Including Gene Encoding Insulin Receptor|Completed||N/A|25|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||1|||f||||f||||||||||2018-05-31 22:38:25.499825|2018-05-31 22:38:25.499825
NCT01349374|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2012-07-11|2011-05-05|2011-05-06|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Skin Samples of Diabetic Patients and Healthy Volunteers Collection|Study Aiming to Collect Skin Samples of Diabetic Patients and Healthy Volunteers for Cellular Reprogramming, Within the Framework of New Therapeutic Strategies in Diabetes Treatment|Terminated||N/A|80|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||4|||f||||f||||||||||2018-05-31 22:38:25.565987|2018-05-31 22:38:25.565987
NCT01349361|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2011-05-05|2011-05-05|2011-05-06|Estimate|||||||2011-05-05|2011-05-06|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||January 2013||2013-01-31||Interventional|||Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight|Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight|Unknown status|Recruiting|Phase 2|||Bispebjerg Hospital||1|||f||||||||||||||2018-05-31 22:38:25.624736|2018-05-31 22:38:25.624736
NCT01349348|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2012-10-10|2011-05-05|2011-05-06|Estimate|||||||2012-10-10|2012-10-12|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites|A Randomized, Double-blinded, Multicenter, Placebo Controlled, Parallel Designed Study, to Evaluate the Efficacy and Safety of Tolvaptan Tablet in Treatment of Patients With Cirrhosis Ascites, Using Diuretics as Initial Treatment|Completed||Phase 3|535|Actual|Otsuka Beijing Research Institute||3|||f||||f||||||||||2018-05-31 22:38:25.689602|2018-05-31 22:38:25.689602
NCT01349335|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2012-10-10|2011-05-05|2011-05-06|Estimate|||||||2012-10-10|2012-10-12|Estimate|April 2009||2009-04-30|May 2011|2011-05-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites|A Phase 2 Randomized, Double-blinded, Multicenter and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Different Doses of Tolvaptan Tablet in Patients With Cirrhotic Ascites|Completed||Phase 2|180|Actual|Otsuka Beijing Research Institute||3|||f||||f||||||||||2018-05-31 22:38:25.841518|2018-05-31 22:38:25.841518
NCT01349322|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2017-05-18|2011-05-05|2011-05-06|Estimate|||||||2017-05-18|2017-05-19|Actual|May 2011|Actual|2011-05-31|May 2017|2017-05-31||||August 2020|Anticipated|2020-08-31||Interventional|||Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery|A Phase III Trial of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer|Active, not recruiting||Phase 3|2354|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 22:38:26.006284|2018-05-31 22:38:26.006284
NCT01349296|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2016-05-19|2011-05-05|2011-05-06|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|October 2014|Actual|2014-10-31||Interventional|BARIS||BIBF 1120 and RAD001 in Solid Tumors - Phase I|BARIS - BIBF1120 and RAD001 in Solid Tumors. A Phase I Trial to Evaluate the Safety and Tolerability of Combined BIBF 1120 and RAD001 in Solid Tumors and to Determine the Maximum Tolerated Dose (MTD) of the Combination|Completed||Phase 1|18|Actual|University of Cologne||1|||f||||t||||||||||2018-05-31 22:38:26.804201|2018-05-31 22:38:26.804201
NCT01349283|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2014-03-03|2011-05-05|2011-05-06|Estimate|||||||2014-03-03|2014-03-04|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|||Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns|A Prospective, Randomized, Double-blind, Parallel-group, Controlled Study of the Immunogenicity and Safety of the Recombinant Hepatitis B Vaccine (Hepavax-Gene TF) and a Comparator Univalent Hepatitis B Vaccine in Neonates|Completed||Phase 3|1738|Actual|Crucell Holland BV||6|||f||||f||||||||||2018-05-31 22:38:26.87893|2018-05-31 22:38:26.87893
NCT01349270|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-05|||2014-09-25|2011-05-05|2011-05-06|Estimate|||||||2014-09-25|2014-09-26|Estimate|June 2004||2004-06-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PRNC||Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg|Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up|Completed||Phase 3|40|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 22:38:26.992329|2018-05-31 22:38:26.992329
NCT01349257|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2017-03-28|2011-05-05|2011-05-06|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2011||2011-05-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI|Study Title: A Single-dose, Open-label, Randomised, 2-way Crossover, Clinical Pharmacology Study of Four Inhalations of CHF 1535 100/6 NEXT DPI® (Fixed Combination of Beclomethasone Diproponate 100 µg Plus Formoterol Fumarate 6 µg) Versus the Same Dose of CHF 1535 100/6 pMDI Both Administered With Charcoal Block.|Completed||Phase 2|24|Actual|Chiesi Farmaceutici S.p.A.|||||f||||f||||||||||2018-05-31 22:38:27.075683|2018-05-31 22:38:27.075683
NCT01349244|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2014-07-08|2011-05-05|2011-05-06|Estimate|||||||2014-07-08|2014-07-09|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Hydronephrosis on Ultrasound With CT Finding in Patients With Renal Colic|Correlation of Hydronephrosis on Point of Care Ultrasound With CT Finding in Patients With Expected Renal Colic|Completed|||97|Actual|Yale University|||||f||||f||||||||||2018-05-31 22:38:27.176471|2018-05-31 22:38:27.176471
NCT01349231|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-09|2014-03-04||2014-05-08|2011-05-04|2011-05-06|Estimate|2014-05-08|2014-06-09|Estimate||||2014-05-08|2014-06-09|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Ketamine Infusion for Obsessive-Compulsive Disorder|Ketamine Infusion for Obsessive-Compulsive Disorder|Completed||Phase 2|10|Actual|Yale University||1|||f||||f||||||||||2018-05-31 22:38:27.239306|2018-05-31 22:38:27.239306
NCT01349218|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2016-05-12|2011-05-05|2011-05-06|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PS||Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns|In Infants and Newborns, is There a Relation Between the Potassium Level in Blood Samples Drawn From a Vein and Those Drawn From a Heel Stick?|Completed||N/A|31|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 22:38:27.496039|2018-05-31 22:38:27.496039
NCT01349205|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2016-05-12|2011-05-05|2011-05-06|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study|Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study|Terminated||N/A|42|Actual|The University of Texas Health Science Center, Houston||3||The study medication was no longer available in the market|f||||t||||||||||2018-05-31 22:38:27.568386|2018-05-31 22:38:27.568386
NCT01349192|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2016-11-02||2017-04-05|2011-05-05|2011-05-06|Estimate|2017-04-05|2017-05-15|Actual||||2017-04-05|2017-05-15|Actual|April 2011|Actual|2011-04-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|STAR-Too||Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)|Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe)|Terminated||Phase 2|47|Actual|University of North Carolina, Chapel Hill|The study was completed prior to reaching the pre-specified number of participants as the Data Safety Monitoring committee observed that efficacy had been reached.|2||"Interim review showed a statistically significant treatment effect and the DMC recommended that~   the study be stopped with ongoing follow-up of enrolled subjects"|f||||t||||||||No||2018-05-31 22:38:27.754171|2018-05-31 22:38:27.754171
NCT01349179|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2014-07-04|2011-05-05|2011-05-06|Estimate|||||||2014-07-04|2014-07-08|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ETOSA||Scan Hip Evaluation|Scan Evaluation at 9 Years of the Bone Acetabular Supporting Cups Without Cement (Couple Metal/Metal in Diameter 28 mm)|Completed||N/A|54|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:38:28.796392|2018-05-31 22:38:28.796392
NCT01349166|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2011-05-05|2011-05-05|2011-05-06|Estimate|||||||2011-05-05|2011-05-06|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|February 2012|Anticipated|2012-02-29|August 2011|Anticipated|2011-08-31||Interventional|||Effects of 3 Months of Supervised Exercise Training|Effects of 3 Months of Supervised Exercise Training on Cardiometabolic and Inflammatory Biomarkers According to Glucose Tolerance (Normal, Intolerance and Type 2 Diabetes): Measures in Unstimulated and Stimulated Conditions|Unknown status|Active, not recruiting|N/A|45|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:38:28.95587|2018-05-31 22:38:28.95587
NCT01349153|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-12-12|2011-05-04|2011-05-06|Estimate|||||||2011-12-12|2011-12-13|Estimate|April 2011||2011-04-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|FITNET||Facebook-based Physical Activity Intervention for Young Adult Cancer Survivors: the FITNET Randomized Pilot Study|Facebook-based Physical Activity Intervention for Young Adult Cancer Survivors: the FITNET Randomized Pilot Study|Completed||Early Phase 1|97|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:38:29.003839|2018-05-31 22:38:29.003839
NCT01349140|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2012-08-07|2011-05-05|2011-05-06|Estimate|||||||2012-08-07|2012-08-08|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks|EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks: A Pharmacodynamics Investigation in Healthy Volunteers|Completed||Phase 1/Phase 2|14|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 22:38:29.068046|2018-05-31 22:38:29.068046
NCT01349127|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-05-02|2011-05-05|2011-05-06|Estimate|||||||2017-05-02|2017-05-04|Actual|August 2008||2008-08-31|May 2017|2017-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|DMUMs||Trial to Assess Vitamin D Requirements in Lactating Women|Randomised Placebo-controlled Supplementation Study With Vitamin D and Calcium in Breastfeeding Mothers|Completed||N/A|136|Actual|University College Cork||3|||f||||t||||||||||2018-05-31 22:38:29.127817|2018-05-31 22:38:29.127817
NCT01349114|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2013-07-11||2017-04-05|2011-05-05|2011-05-06|Estimate|2014-05-21|2014-06-30|Estimate||||2017-04-05|2017-05-11|Actual|June 2011||2011-06-30|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects|Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects|Terminated||Phase 4|21|Actual|University of Alabama at Birmingham|Early termination leading to smaller number of subjects analyzed then anticipated, no adverse effects within the aliskiren group|2||Sponsor requested termination.|f||||f||||||||||2018-05-31 22:38:29.22209|2018-05-31 22:38:29.22209
NCT01349101|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2017-11-13|2011-05-04|2011-05-06|Estimate|||||||2017-11-13|2017-11-17|Actual|February 10, 2011|Actual|2011-02-10|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors|Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies|Recruiting||Phase 2|81|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 22:38:29.83833|2018-05-31 22:38:29.83833
NCT01349088|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2016-10-19|2011-05-05|2011-05-06|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer|Phase I/II Trial of Motesanib in Combination With Ixabepilone and Capecitabine in Women With Locally Recurrent or Metastatic Breast Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 22:38:31.028248|2018-05-31 22:38:31.028248
NCT01349075|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-09-15|2011-05-05|2011-05-06|Estimate|||||||2017-09-15|2017-09-19|Actual|October 2007||2007-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma|A Humanitarian Device Exemption Treatment Protocol of Therasphere for the Treatment of Unresectable Hepatocellular Carcinoma|Recruiting|||500|Anticipated|Thomas Jefferson University|||1||f||||f||||||||||2018-05-31 22:38:31.132468|2018-05-31 22:38:31.132468
NCT01349062|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2017-03-01|2011-05-04|2011-05-06|Estimate|||||||2017-03-01|2017-03-03|Actual|February 27, 2012|Actual|2012-02-27|March 2017|2017-03-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS|Phase III Clinical Studies on Traditional CAM Therapy in the Treatment of HIV/AIDS|Completed||Phase 3|1000|Actual|Traditional Alternative Medicine Research, India||1|||f||||t|f|f||||||No||2018-05-31 22:38:31.264928|2018-05-31 22:38:31.264928
NCT01349049|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2018-04-04|2011-05-05|2011-05-06|Estimate|||||||2018-04-04|2018-04-06|Actual|November 2011||2011-11-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)|Completed||Phase 1/Phase 2|90|Actual|Plexxikon||9|||f||||f||||||||||2018-05-31 22:38:31.428654|2018-05-31 22:38:31.428654
NCT01349036|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04||2015-04-06|2015-04-06|2011-05-05|2011-05-06|Estimate||||2015-04-06|2015-04-27|Estimate|2015-04-06|2015-04-27|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|||A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma|A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma|Completed||Phase 2|38|Actual|Plexxikon||2|||f||||f||||||||||2018-05-31 22:38:31.604488|2018-05-31 22:38:31.604488
NCT01349023|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2012-03-15|2011-05-05|2011-05-06|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|EDEN||Energy Content and Energy Density of Pre-portioned Entrees|Effects of Energy Density and Energy Content of Pre-portioned entrées on Energy Intake|Completed||N/A|73|Actual|Penn State University||4|||f||||f||||||||||2018-05-31 22:38:31.716511|2018-05-31 22:38:31.716511
NCT01349010|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2013-06-04|2011-05-05|2011-05-06|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Interventional|||Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia|A Randomized, Double Blind, Placebo Control, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Imported Probucol in Hyperlipidemia Patients|Completed||Phase 3|264|Actual|Otsuka Beijing Research Institute||2|||f||||f||||||||||2018-05-31 22:38:32.564943|2018-05-31 22:38:32.564943
NCT01348997|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2014-10-06|2011-05-05|2011-05-06|Estimate|||||||2014-10-06|2014-10-07|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||E-health Intervention for Cancer Survivors 2.0|E-Health Intervention for Cancer Survivors 2.0|Withdrawn||Phase 1|0|Actual|Northwestern University||2||Study ended prior to completion of planning stage. No participants enrolled.|f||||f||||||||||2018-05-31 22:38:32.64578|2018-05-31 22:38:32.64578
NCT01348984|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-05|2011-05-05|2011-05-06|Estimate|||||||2011-05-05|2011-05-06|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|TFP||Study of Transdermal Fentanyl Patch to Treat Postoperative Pain in Total Knee Arthroplasty|Transdermal Fentanyl Patch for Postoperative Analgesia in Total Knee Arthroplasty|Completed||Phase 4|40|Actual|Khon Kaen University||2|||f||||f||||||||||2018-05-31 22:38:32.745167|2018-05-31 22:38:32.745167
NCT01348971|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-09-24|2011-05-04|2011-05-06|Estimate|||||||2013-09-24|2013-09-26|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CABANOS||Coronary Artery Bypass and Nitrate Oral Supplementation|Effects of Oral Nitrate During Coronary Artery Bypass Surgery|Completed||Phase 2|100|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:38:32.866571|2018-05-31 22:38:32.866571
NCT01348958|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2017-06-20|2011-05-04|2011-05-06|Estimate|||||||2017-06-20|2017-06-22|Actual|July 2011||2011-07-31|June 2017|2017-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Orthopedic Knee Measurement Using Lunar iDXA|Evaluation of Orthopedic Knee Measurement Using Lunar iDXA|Completed||N/A|36|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 22:38:32.966279|2018-05-31 22:38:32.966279
NCT01348425|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2013-07-25|2013-03-12|2015-12-29|2011-05-04|2011-05-05|Estimate|2014-03-11|2014-04-16|Estimate|2013-03-12|2013-03-19|Estimate|2015-12-29|2016-02-02|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Zilver PTX Drug-Eluting Peripheral Stent Study|Evaluation of the Zilver PTX Drug-Eluting Peripheral Stent|Completed||N/A|45|Actual|Cook Group Incorporated||2|||f||||||||||||||2018-05-31 22:38:37.305013|2018-05-31 22:38:37.305013
NCT01348945|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-05|2011-05-05|2011-05-06|Estimate|||||||2011-05-05|2011-05-06|Estimate|May 2011||2011-05-31|December 2010|2010-12-31|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Proprioceptive Function, Postural Stability & Clinical Outcome After Stump Preserving Anterior Cruciate Ligament Reconstruction Surgery|Proprioceptive Function, Postural Stability & Clinical Outcome After Stump Preserving Anterior Cruciate Ligament Reconstruction Surgery - A Comparative Study|Unknown status|Active, not recruiting|N/A|48|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:38:33.053667|2018-05-31 22:38:33.053667
NCT01348932|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-05|2011-05-05|2011-05-06|Estimate|||||||2011-05-05|2011-05-06|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|December 2013|Anticipated|2013-12-31|June 2011|Anticipated|2011-06-30||Observational|CHI3L1||The Relationship Between Single Nucleotide Polymorphisms of Chitinase 3-like 1 Gene,YKL-40 Serum Levels and Adult Asthma|The Relationship Between Single Nucleotide Polymorphisms of Chitinase 3-like 1 Gene,YKL-40 Serum Levels and Adult Asthma|Unknown status|Recruiting||1|Anticipated|China Medical University Hospital|||1||f||||t||||||Samples With DNA|"~     The objective of this study was to investigate the relationship between single nucleotide~     polymorphism of chitinase 3-like 1 and human asthma. The association between CHI3L1 SNPs and~     the continuous outcomes were examined by real time PCR and gene sequencing analysis.~   "|||2018-05-31 22:38:33.173941|2018-05-31 22:38:33.173941
NCT01348919|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04||2013-08-30|2016-07-19|2011-05-04|2011-05-06|Estimate||||2013-08-30|2013-09-13|Estimate|2016-07-19|2016-07-21|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma|An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1/Phase 2|11|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-05-31 22:38:33.340246|2018-05-31 22:38:33.340246
NCT01348906|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-05|2011-05-05|2011-05-06|Estimate|||||||2011-05-05|2011-05-06|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|INCPB||Intermittent Normoxia Reduces Myocardial Reperfusion Injury|Effect of Intermittent Normoxic Cardiopulmonary Bypass on Myocardial Reperfusion Injury in Adult Valve Replacement|Unknown status|Recruiting|N/A|70|Anticipated|Central South University||1|||f||||t||||||||||2018-05-31 22:38:33.49499|2018-05-31 22:38:33.49499
NCT01348893|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2016-02-12|2011-05-05|2011-05-06|Estimate|||||||2016-02-12|2016-02-15|Estimate|August 2008||2008-08-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Evaluation of a Yoga Program in Schools|Evaluation of Yoga During School as a Behavioral Prevention Program for Adolescent Health|Unknown status|Active, not recruiting|N/A|1800|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:38:33.605099|2018-05-31 22:38:33.605099
NCT01348880|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2014-05-16|2011-05-04|2011-05-06|Estimate|||||||2014-05-16|2014-05-19|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study|A Double-Blind Study to Evaluate the Pharmacodynamic Interaction Between 10 mg Vardenafil ODT (Orally Disintegrating Tablet) and Procardia XL® (Nifedipine GITS) in Elderly Male Patients With Both Hypertension and Erectile Dysfunction|Completed||Phase 1|42|Actual|Bayer||2|||f||||t||||||||||2018-05-31 22:38:33.696061|2018-05-31 22:38:33.696061
NCT01348867|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-06-23|2011-05-05|2011-05-06|Estimate|||||||2015-06-23|2015-06-24|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Effectiveness of a Treat-to-target Clinic Led by a Nurse Consultants|A Randomised Study to Evaluate the Effectiveness of a Treat-to-target Clinic Led by a Nurse Consultant in Managing Patients With Type 2 Diabetes in Hong Kong|Completed||N/A|242|Actual|Asia Diabetes Foundation||2|||f||||t||||||||||2018-05-31 22:38:33.812367|2018-05-31 22:38:33.812367
NCT01348854|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2014-01-31||2014-05-06|2011-05-04|2011-05-06|Estimate|2014-05-06|2014-06-04|Estimate||||2014-05-06|2014-06-04|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Data analysis was performed for eyes treated. Subjects may have had one or both eyes treated. If both eyes, one eye may have been in Natural Astigmatism group and the other eye in the Post Cataract with Residual Astigmatism group.|Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser System|A Multi-Center Prospective Study to Evaluate the Safety and Effectiveness of Arcuate Incisions Performed With the IntraLase iFS Femtosecond Laser System|Completed||Phase 2|40|Actual|Abbott Medical Optics|"BSCVA determination in eyes with progressing cataracts was sometimes unevaluable, although data are shown as reported.~The number of eyes in Post Cataract Surgery with Astigmatism Arm was small, limiting data analysis."|2|||f||||f||||||||||2018-05-31 22:38:33.906548|2018-05-31 22:38:33.906548
NCT01348841|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-10-24|2011-05-04|2011-05-05|Estimate|||||||2013-10-24|2013-10-25|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|WIT||Wound Interdisciplinary Teams (WIT): A Community- Based Pragmatic Randomized Controlled Trial|Wound Interdisciplinary Teams (WIT): A Community- Based Pragmatic Randomized Controlled Trial|Completed||N/A|451|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 22:38:34.139157|2018-05-31 22:38:34.139157
NCT01348828|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2013-06-04|2011-05-04|2011-05-05|Estimate|||||||2013-06-04|2013-06-06|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|May 2017|Anticipated|2017-05-31|May 2012|Actual|2012-05-31||Interventional|||Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System|Prospective, Multicenter, Single Arm Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Endologix|||||f||||t||||||||||2018-05-31 22:38:34.222986|2018-05-31 22:38:34.222986
NCT01348802|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-09-22|2011-05-04|2011-05-05|Estimate|||||||2015-09-22|2015-09-23|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||"A Randomized Trial Comparing Push Versus Pull Technology for Mobilizing Pain Evidence Into Practice Across Different Health Professions"|"A Randomized Trial Comparing Push Versus Pull Technology for Mobilizing Pain Evidence Into Practice Across Different Health Professions"|Completed||N/A|675|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:38:34.304731|2018-05-31 22:38:34.304731
NCT01348789|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2012-12-04||2013-02-15|2011-05-04|2011-05-05|Estimate|2013-02-15|2013-02-18|Estimate||||2013-02-15|2013-02-18|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|OHR-3||Safety for Frequent Use Conditions of Hair Removal Device|Safety of Hair2Go Device in Frequent Use Conditions: A Prospective, Open Label Study With Before-After Design|Completed||N/A|37|Actual|Syneron Medical||1|||f||||t||||||||||2018-05-31 22:38:34.399859|2018-05-31 22:38:34.399859
NCT01348776|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|2012-12-27||2013-04-02|2011-05-04|2011-05-05|Estimate|2013-04-02|2013-04-04|Estimate||||2013-04-02|2013-04-04|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Efficiency of the Hair2Go Device: A Prospective, Open, Label Study With Before-After Design|The Efficiency of the Hair2Go Device: A Prospective, Open, Label Study With Before-After Design|Completed||N/A|87|Actual|Syneron Medical||1|||f||||t||||||||||2018-05-31 22:38:34.733705|2018-05-31 22:38:34.733705
NCT01348763|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2014-05-20|2011-05-04|2011-05-05|Estimate|||||||2014-05-20|2014-05-21|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study|A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects|Completed||Phase 1|12|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 22:38:34.996588|2018-05-31 22:38:34.996588
NCT01348750|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Healing Touch & Guided Imagery for Posttraumatic Stress Disorder Symptoms|Healing Touch and Guided Imagery Intervention in Post-deployment Military Personnel With Posttraumatic Stress Disorder Symptoms|Completed||N/A|123|Actual|Scripps Center for Integrative Medicine||2|||f||||f||||||||||2018-05-31 22:38:35.094308|2018-05-31 22:38:35.094308
NCT01348737|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2012-04-05|2011-05-04|2011-05-05|Estimate|||||||2012-04-05|2012-04-06|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential|Completed||Phase 1|72|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:38:35.20776|2018-05-31 22:38:35.20776
NCT01348724|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-10-13|2011-05-04|2011-05-05|Estimate|||||||2014-10-13|2014-10-15|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118|A Phase I, Open-Label, Single-Centre Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After [14C]-Labelled Oral Administration of NKTR-118 to Healthy Male Volunteers|Completed||Phase 1|6|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 22:38:35.299505|2018-05-31 22:38:35.299505
NCT01348711|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|May 2007||2007-05-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Observational|BIODOP-T1||Early Placental Insufficiency Screening|Placental Insufficiency Screening During First Trimester by a Combination of Uterine Artery Dopppler, Maternal PlGF and sFLT-1 in Hight Risk Population|Completed|||300|Anticipated|University Hospital, Tours|||||f||||t||||||Samples Without DNA|"~     SERUM~   "|||2018-05-31 22:38:35.380073|2018-05-31 22:38:35.380073
NCT01348698|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2018-02-13|2011-05-04|2011-05-05|Estimate|||||||2018-02-13|2018-02-14|Actual|May 4, 2011||2011-05-04|January 12, 2018|2018-01-12|January 12, 2018||2018-01-12|||||Observational|||Evaluation of Molecular Markers in Adrenal Tumors|Evaluation of Diagnostic and Prognostic Molecular Markers in Adrenal Neoplasm|Terminated|||74|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:38:35.448531|2018-05-31 22:38:35.448531
NCT01348685|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|January 2007||2007-01-31|February 2011|2011-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Comparing Liquid Versus Solid Forms of Sugars and Whey Protein|Effect of Drinking Liquid Compared to Eating Solid Treatment of Sugars or Whey Protein on Short-term Appetite and Food Intake|Completed||N/A|43|Actual|University of Toronto|||||f||||t||||||||||2018-05-31 22:38:35.510264|2018-05-31 22:38:35.510264
NCT01348672|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-27|||2013-01-16|2011-05-04|2011-05-05|Estimate|||||||2013-01-16|2013-01-17|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye|Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye|Unknown status|Recruiting||381|Anticipated|University of Toronto|||3||f||||f||||||||||2018-05-31 22:38:35.571509|2018-05-31 22:38:35.571509
NCT01348659|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2012-05-04|2011-05-04|2011-05-05|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Hypertonic Saline-HES Solution on Extracellular Water in Cardiac Surgery Patients|Effects of Hypertonic Saline-hydroxyethyl Starch Solution on Extracellular Water in Cardiac Surgery Patients|Completed||Phase 4|48|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 22:38:35.690253|2018-05-31 22:38:35.690253
NCT01348646|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2011-05-31|2011-05-04|2011-05-05|Estimate|||||||2011-05-31|2011-06-01|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TuNAMI||Adult Follow-up of Preventive Study With Brief Smoking Intervention for Adolescents||Completed||N/A|2582|Actual|Tampere University Hospital||1|||f||||||||||||||2018-05-31 22:38:35.761962|2018-05-31 22:38:35.761962
NCT01348633|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-01-16|2011-05-04|2011-05-05|Estimate|||||||2013-01-16|2013-01-17|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye|Phase 1. Validation and Calibration Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye|Unknown status|Recruiting||275|Anticipated|University of Toronto|||5||f||||f||||||||||2018-05-31 22:38:35.826044|2018-05-31 22:38:35.826044
NCT01348620|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|March 2011||2011-03-31|May 2011|2011-05-31||||January 2012|Anticipated|2012-01-31||Interventional|||Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy: Impact on Postoperative Pain||Unknown status|Recruiting|N/A|58|Anticipated|Sacro Cuore Don Calabria General Hospital||2|||f||||t||||||||||2018-05-31 22:38:35.897635|2018-05-31 22:38:35.897635
NCT01348438|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2018-04-26|2011-05-04|2011-05-05|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2011|Actual|2011-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|January 2013|Actual|2013-01-31||Interventional|||Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial|Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial|Active, not recruiting||N/A|150|Anticipated|Medtronic Cardiovascular||1|||f||||t||||||||||2018-05-31 22:38:37.21734|2018-05-31 22:38:37.21734
NCT01348607|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|2013-07-05||2014-01-23|2011-05-04|2011-05-05|Estimate|2013-09-17|2013-09-19|Estimate||||2014-01-23|2014-02-21|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy|A Randomized, Phase II Placebo-controlled Study of the Use of Extended-release Methylphenidate or Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy|Terminated||Phase 2|1|Actual|University of South Florida|This study was closed prior to completion due to a lack of feasibility and low accrual by the Data Monitoring and Safety Board (DSMB).|3||Study only randomized 1 subject and was determined not feasible by DSMB|f||||t||||||||||2018-05-31 22:38:35.984108|2018-05-31 22:38:35.984108
NCT01348594|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2012-06-18|2011-05-04|2011-05-05|Estimate|||||||2012-06-18|2012-06-19|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Observational|||The Impact of Vitamin D Status on in Vitro Fertilization (IVF) Outcomes|The Impact of Vitamin D on Implantation and Clinical Pregnancy Rates Following in Vitro Fertilization|Completed|||182|Actual|University of Toronto|||2||f||||f||||||||||2018-05-31 22:38:36.175975|2018-05-31 22:38:36.175975
NCT01348581|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-02-28|2011-05-04|2011-05-05|Estimate|||||||2017-02-28|2017-03-03|Actual|November 2010||2010-11-30|May 2011|2011-05-31|January 1, 2013|Actual|2013-01-01|December 2012|Actual|2012-12-31||Interventional|||Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing|Chronic Wound Treatment With Extracellular Matrix (ECM) Scaffold Made From Fish Proteins|Completed||N/A|37|Actual|Kerecis Ltd.||1|||f||||t||||||||||2018-05-31 22:38:36.229583|2018-05-31 22:38:36.229583
NCT01348568|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-12-07|2011-05-04|2011-05-05|Estimate|||||||2015-12-07|2015-12-08|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|April 2013|Actual|2013-04-30||Interventional|||Low Glycemic Index Diet (With Canola Oil) for Type 2 Diabetics|Effect of Low Glycemic Index Diets (With Canola Oil) on Glucose Control in Non-Insulin Dependent Diabetics|Completed||Phase 2|141|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 22:38:36.289675|2018-05-31 22:38:36.289675
NCT01348555|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-06-03|2011-05-04|2011-05-05|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2011||2011-04-30|May 2011|2011-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162||Completed||Phase 1/Phase 2|108|Actual|Pierre Fabre Medicament||2|||f||||t||||||||||2018-05-31 22:38:36.445844|2018-05-31 22:38:36.445844
NCT01348542|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2018-03-09|2011-05-04|2011-05-05|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2011|Actual|2011-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia|Efficacy of Trazodone vs. Cognitive Behavioral Therapy in Patients With Chronic Insomnia Associated With Objective Short Sleep Duration|Active, not recruiting||N/A|24|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 22:38:36.520792|2018-05-31 22:38:36.520792
NCT01348529|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2018-03-19|2011-05-04|2011-05-05|Estimate|||||||2018-03-19|2018-03-21|Actual|September 2010|Actual|2010-09-30|September 2010|2010-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)|Internet-based Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Pilot Study|Completed||N/A|23|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 22:38:36.60311|2018-05-31 22:38:36.60311
NCT01348516|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2012-07-24|2011-05-04|2011-05-05|Estimate|||||||2012-07-24|2012-07-26|Estimate|May 2011||2011-05-31|July 2012|2012-07-31||||March 2012|Actual|2012-03-31||Interventional|||Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of KM-023 After Oral Administration in Healthy Subjects|Completed||Phase 1|83|Actual|Kainos Medicine Inc.||2|||f||||||||||||||2018-05-31 22:38:36.684949|2018-05-31 22:38:36.684949
NCT01348503|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-08-28|2011-05-04|2011-05-05|Estimate|||||||2015-08-28|2015-08-31|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|December 2012|Actual|2012-12-31||Interventional|||Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma|A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma|Terminated||Phase 1|5|Actual|Indiana University||1||Treatment was ineffective|f||||t||||||||||2018-05-31 22:38:36.748622|2018-05-31 22:38:36.748622
NCT01348490|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2018-04-03|2011-05-04|2011-05-05|Estimate|||||||2018-04-03|2018-04-04|Actual|June 2011||2011-06-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis|An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L|Active, not recruiting||Phase 2|66|Actual|Incyte Corporation||1|||t||||t||||||||||2018-05-31 22:38:36.822817|2018-05-31 22:38:36.822817
NCT01348477|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Comparison Between Elliptical Domed Mesh Technique and Lichtenstein Technique in Inguinal Hernia|Comparison Between Elliptical Domed Mesh Technique and Lichtenstein Technique, to Reduce Postoperative Pain in Open Inguinal Hernia Repair|Unknown status|Recruiting|N/A|168|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 22:38:36.955207|2018-05-31 22:38:36.955207
NCT01348464|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2012-04-02|2011-05-04|2011-05-05|Estimate|||||||2012-04-02|2012-04-04|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|||||Observational|||A Trial on Laparoscopic Appendectomy Versus Single Port Appendectomy|Transumbilical Single Port Laparoscopic Appendectomy Versus Conventional Laparoscopic Appendectomy in Adult Patients: A Prospective Randomized Control Study|Completed|||150|Actual|Gachon University Gil Medical Center|||1||f||||f||||||||||2018-05-31 22:38:37.048231|2018-05-31 22:38:37.048231
NCT01348451|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2016-03-09|2011-05-04|2011-05-05|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|ALS||Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis|A Phase l, Open-label, First in Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|Neuralstem Inc.||1|||f||||t||||||||||2018-05-31 22:38:37.134656|2018-05-31 22:38:37.134656
NCT01348412|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2017-06-19|2011-05-04|2011-05-05|Estimate|||||||2017-06-19|2017-06-20|Actual|December 2010|Actual|2010-12-31|June 2017|2017-06-30|May 18, 2020|Anticipated|2020-05-18|May 18, 2019|Anticipated|2019-05-18||Interventional|HEARTO||Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure|Phase II Randomized Study Comparing the Association of Intraarterial Perfusion of Raltitrexed and Oxaliplatin Versus Standard Chemotherapy Using Intravenous Perfusion for Colorectal Cancer Patient With Metastases Localized to Liver After Failure of Conventional Treatments.|Recruiting||Phase 2|80|Anticipated|Centre Georges Francois Leclerc||2|||f||||t||||||||||2018-05-31 22:38:37.48357|2018-05-31 22:38:37.48357
NCT01348399|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-07-19|2011-05-04|2011-05-05|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2011|Actual|2011-04-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2014|Actual|2014-07-31||Observational|||Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)|Evaluation of Effectiveness and Safety of XIENCE PRIME™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Active, not recruiting|||2000|Actual|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:38:37.571196|2018-05-31 22:38:37.571196
NCT01348386|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-09-30|2011-05-04|2011-05-05|Estimate|||||||2015-09-30|2015-10-01|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|EKOH-MOL 2008||Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum|Efficacy and Tolerance of the Topical Application of Potassium Hydroxide (10% and 15%) in the Treatment of Molluscum Contagiosum|Completed||Phase 2/Phase 3|53|Actual|Jordi Gol i Gurina Foundation||3|||f||||||||||||||2018-05-31 22:38:37.671013|2018-05-31 22:38:37.671013
NCT01348373|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2015-11-10|2011-05-04|2011-05-05|Estimate|||||||2015-11-10|2015-11-11|Estimate|May 2010||2010-05-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Evaluation of Effectiveness and Safety of the GENOUS STENT (IRIS-GENOUS STEMI)|Evaluation of Effectiveness and Safety of the GENOUS STENT in ST-Segment Elevation Myocardial Infarction|Completed|||464|Actual|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:38:37.735854|2018-05-31 22:38:37.735854
NCT01348360|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-07-19|2011-05-04|2011-05-05|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2010|Actual|2010-05-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|May 2016|Actual|2016-05-31||Observational|IRIS-NOBORI||Evaluation of Effectiveness and Safety of NOBORI Stent|Evaluation of Effectiveness and Safety of NOBORI Stent in Routine Clinical Practice; A Multicenter, Prospective, Observational Study|Active, not recruiting|||2000|Actual|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:38:37.849771|2018-05-31 22:38:37.849771
NCT01348347|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2014-08-06|2011-05-04|2011-05-05|Estimate|||||||2014-08-06|2014-08-07|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours|An Open-label Phase I Study of Once Every Three Weeks Intravenous Treatment With BI 6727 in Japanese Patients With Advanced Solid Tumours|Completed||Phase 1|15|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:38:37.941321|2018-05-31 22:38:37.941321
NCT01348334|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|July 2004||2004-07-31|July 2004|2004-07-31|November 2010|Actual|2010-11-30|July 2007|Actual|2007-07-31||Interventional|||Synthetic Mesh Materials In Sling Surgery|Use Of Three Types Of Synthetic Mesh Materials In Sling Surgery: A Prospective Randomized Clinical Trial Evaluating Effectiveness And Complications|Completed||N/A|144|Actual|Ataturk Training and Research Hospital||3|||f||||f||||||||||2018-05-31 22:38:38.001569|2018-05-31 22:38:38.001569
NCT01348321|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of Efficacy of Azithromycin and Levamisole Versus of Azithromycin in in the Treatment of Acne|Superior Efficacy of Azithromycin and Levamisole Versus of Azithromycin Alone in the Treatment of Inflammatory Acne Vulgaris: An Investigator Blind Randomized Clinical Trial on 169 Patients|Completed||Phase 2/Phase 3|169|Actual|Ahvaz Jundishapur University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:38:38.068123|2018-05-31 22:38:38.068123
NCT01348308|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-07-11|2011-05-04|2011-05-05|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|OPTIMAL||Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients|Optimized Phase III Trial of Immuno-stimulation With Maraviroc, a CCR5 (Chemokine Receptor 5) Antagonist, Combined With Anti Retroviral Therapy in Advanced, Late Diagnosed HIV-1 Infected Patients With an AIDS-defining Event and/or CD4 (Cluster of Differentiation 4) Counts Below 200 Cells/mm³. ANRS 146 OPTIMAL|Completed||Phase 3|407|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 22:38:38.138381|2018-05-31 22:38:38.138381
NCT01348295|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-04|2011-05-04|2011-05-05|Estimate|||||||2011-05-04|2011-05-05|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Pediatric Ventilatory Care in Finland 2010|Pediatric Ventilatory Care in Finland 2010|Completed|||210|Actual|University of Oulu|||1||f||||f||||||||||2018-05-31 22:38:38.200941|2018-05-31 22:38:38.200941
NCT01348282|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-03-31|2011-05-04|2011-05-05|Estimate|||||||2014-03-31|2014-04-01|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study|Exploratory Controlled Prospective Randomized Trial to Compare the Efficacy and Safety of Two Different Pharmacology Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study|Completed||Phase 4|33|Actual|Fundacio Lluita Contra la SIDA||3|||f||||f||||||||||2018-05-31 22:38:38.358614|2018-05-31 22:38:38.358614
NCT01348269|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2017-06-07|2011-05-04|2011-05-05|Estimate|||||||2017-06-07|2017-06-08|Actual|May 2011|Actual|2011-05-31|April 2017|2017-04-30|August 26, 2015|Actual|2015-08-26|August 26, 2015|Actual|2015-08-26||Interventional|ZoMARS||Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome|A Prospective, Bi-centric,Randomized, Primary Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome|Completed||Phase 3|63|Actual|Wuerzburg University Hospital||2|||f||||f||||||||||2018-05-31 22:38:38.462379|2018-05-31 22:38:38.462379
NCT01348256|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2017-10-23|2011-05-04|2011-05-05|Estimate|||||||2017-10-23|2017-10-24|Actual|November 2010||2010-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma|Randomized Phase II Study With Dendritic Cell Immunotherapy in Patients With Resected Hepatic Metastasis of Colorectal Carcinoma|Recruiting||Phase 2|58|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-05-31 22:38:38.574319|2018-05-31 22:38:38.574319
NCT01348243|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2017-03-28|2011-05-04|2011-05-05|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2011||2011-10-31|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis|MULTICENTRE, RANDOMIZED, OPEN-LABEL, TWO-ARM PARALLEL GROUPS, ACTIVE CONTROLLED STUDY DESIGN TO DEMONSTRATE EFFICACY AND TOLERABILITY OF CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK VS CLODRONATE 100 MG/3,3ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK IN A 1-YEAR TREATMENT PERIOD OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS|Completed||Phase 3|260|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 22:38:38.66299|2018-05-31 22:38:38.66299
NCT01348230|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2017-04-19|2011-05-04|2011-05-05|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2011||2011-05-31|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Glycoproteomic Analysis of Urine in Women Undergoing Spontaneous Preterm Delivery|Glycoproteomic Analysis of Urine in Women Undergoing Spontaneous Preterm Delivery|Withdrawn|||0|Actual|University of Missouri-Columbia|||3|Investigator left institution|f||||t||||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 22:38:38.75403|2018-05-31 22:38:38.75403
NCT01348217|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2017-06-20|2011-05-04|2011-05-05|Estimate|||||||2017-06-20|2017-06-21|Actual|June 2011|Actual|2011-06-30|June 2017|2017-06-30|February 2022|Anticipated|2022-02-28|May 2019|Anticipated|2019-05-31||Interventional|CONCORDE||Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus|Prodige 26: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus|Recruiting||Phase 2/Phase 3|252|Anticipated|Centre Georges Francois Leclerc||2|||f||||t||||||||||2018-05-31 22:38:38.851947|2018-05-31 22:38:38.851947
NCT01348204|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2012-01-27|2011-05-04|2011-05-05|Estimate|||||||2012-01-27|2012-01-31|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators|Nasal Potential Studies Utilizing CFTR Modulators (UAB Center for Clinical and Translational Science)|Completed||Phase 2|32|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 22:38:38.988635|2018-05-31 22:38:38.988635
NCT01348191|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-04|||2013-05-23|2011-05-04|2011-05-05|Estimate|||||||2013-05-23|2013-05-24|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Observational|||Detection of Thyrotrophin Receptor in Human Myometrium|Detection of Thyrotrophin Receptor in Human Myometrium|Completed|||10|Actual|Catharina Ziekenhuis Eindhoven|||1||f||||t||||||Samples Without DNA|"~     Biopsy of human myometrium~   "|||2018-05-31 22:38:39.098269|2018-05-31 22:38:39.098269
NCT01348178|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2012-01-06|2011-05-04|2011-05-05|Estimate|||||||2012-01-06|2012-01-09|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Retrospective Follow-up Study After Periacetabular Osteotomy in Adults|Retrospective Follow-up Study After Periacetabular Osteotomy in Adults|Completed|||401|Actual|University of Aarhus|||1||f||||t||||||||||2018-05-31 22:38:39.214111|2018-05-31 22:38:39.214111
NCT01348165|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2014-03-12||2016-08-04|2011-05-04|2011-05-05|Estimate|2014-05-12|2014-06-04|Estimate||||2016-08-04|2016-09-16|Estimate|May 2011||2011-05-31|August 2016|2016-08-31||||August 2011|Actual|2011-08-31||Interventional||Treated Set which included all subjects who received one dose of trial medication|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers (A Randomised, Single-blind, Placebo-controlled Phase I Study)|Terminated||Phase 1|40|Actual|Boehringer Ingelheim|The trial was put on hold due to a serious adverse event (post-treatment period) which was evaluated to be not drug related and the trial was subsequently terminated.|10|||f||||||||||||||2018-05-31 22:38:39.319672|2018-05-31 22:38:39.319672
NCT01348152|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03||2013-08-09|2013-09-09|2011-05-04|2011-05-05|Estimate||||2013-08-09|2013-08-23|Estimate|2013-09-09|2013-09-17|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of TU-100 in Patients With Functional Constipation|A Randomized, Double-Blinded, Placebo-Controlled Exploratory Study of Daikenchuto (TU-100) in Patients With Functional Constipation|Completed||Phase 2|50|Actual|Tsumura USA||2|||f||||t||||||||||2018-05-31 22:38:40.614831|2018-05-31 22:38:40.614831
NCT01348139|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2013-01-28||2013-01-28|2011-05-04|2011-05-05|Estimate|2013-01-28|2013-03-05|Estimate||||2013-01-28|2013-03-05|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 Administered Via Single Inhalation Device Compared to AZD3199 Administered Via Turbuhaler™ Inhaler in Patients With Asthma|Completed||Phase 2|39|Actual|AstraZeneca||6|||f||||||||||||||2018-05-31 22:38:40.71714|2018-05-31 22:38:40.71714
NCT01348126|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2015-11-04|2011-05-03|2011-05-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|April 2014|Actual|2014-04-30||Interventional|GALAXY||Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer|A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Stage IIIb or IV Non-Small-Cell Lung Cancer|Terminated||Phase 2/Phase 3|385|Actual|Synta Pharmaceuticals Corp.||2|||f||||f||||||||||2018-05-31 22:38:41.352428|2018-05-31 22:38:41.352428
NCT01348113|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2014-04-30|2011-05-03|2011-05-05|Estimate|||||||2014-04-30|2014-05-01|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|ITBCHIR||Efficacy of a Brief Alcohol Intervention for Non Dependant Alcohol-misusing Patients Undergoing a Scheduled Surgery|Efficacy of a Brief Alcohol Intervention for Non Dependant Alcohol-misusing Patients Undergoing a Scheduled Surgery: a Randomized Controlled Trial|Terminated||Phase 3|3|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 22:38:41.513734|2018-05-31 22:38:41.513734
NCT01348100|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2013-07-25||2013-12-17|2011-05-03|2011-05-05|Estimate|2013-07-25|2013-10-08|Estimate||||2013-12-17|2014-01-22|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Safety population: All participants who received at least 1 dose of study drug and had at least 1 post-baseline safety assessment.|Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients|An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Two Iloperidone Depot Formulations Followed by a Dose-ranging Phase of One Selected Formulation in Schizophrenic Patients Given Depot Injections Every 28 Days|Completed||Phase 1/Phase 2|81|Actual|Novartis||7|||f||||||||||||||2018-05-31 22:38:41.657814|2018-05-31 22:38:41.657814
NCT01348087|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2015-09-09||2016-04-11|2011-05-04|2011-05-05|Estimate|2016-04-11|2016-05-25|Estimate||||2016-04-11|2016-05-25|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome|An Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome|Terminated||Phase 2|148|Actual|Novartis|The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).|1||"Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X~   Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212)"|f||||t||||||||||2018-05-31 22:38:43.442206|2018-05-31 22:38:43.442206
NCT01348074|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2016-04-01|2011-05-04|2011-05-05|Estimate|||||||2016-04-01|2016-04-05|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DOSIDO||Reinitiation of Anticoagulation After Temporary Withdrawal of Vitamin K Antagonist|Phase II Study of Double Versus Single Reinitiation Dose of Warfarin After Interruption for Surgery|Completed||Phase 2|104|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 22:38:43.837777|2018-05-31 22:38:43.837777
NCT01348061|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2014-10-22|2011-05-04|2011-05-05|Estimate|||||||2014-10-22|2014-10-24|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls|Experimental Medicine Study to Evaluate the Kinetics of Cerebrospinal Fluid Biomarkers in Subjects With Alzheimer's Disease and Progressive Supranuclear Palsy Compared to Healthy Subjects Using a Heavy Water Labeling Method|Completed|||16|Actual|KineMed|||3||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 22:38:43.974429|2018-05-31 22:38:43.974429
NCT01348048|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2015-03-02|2011-05-04|2011-05-05|Estimate|||||||2015-03-02|2015-03-03|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|DanPaCT||A Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction|Danish Palliative Care Trial (DanPaCT): A Randomised Clinical Multi-centre Trial Investigating the Effect of Specialised Palliative Care on Symptoms, Survival, Economical Factors and Satisfaction in Patients With Cancer Reporting Palliative Needs|Completed||Phase 4|306|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 22:38:44.097124|2018-05-31 22:38:44.097124
NCT01348035|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2018-03-14|2011-05-04|2011-05-05|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2011||2011-04-30|March 2018|2018-03-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|ESWP||Efficacy Study of Water Drinking on PKD Progression.|Efficacy Study of Long-term Water Intake on the Progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).|Completed|||30|Actual|Kyorin University|||2||f||||f||||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 22:38:44.263173|2018-05-31 22:38:44.263173
NCT01348022|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2015-11-18|2011-05-04|2011-05-05|Estimate|||||||2015-11-18|2015-11-20|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|December 2012|Actual|2012-12-31||Observational|||Evaluation of Outcomes of EES Implantation for Unprotected Left Main Coronary Artery Stenosis (PRE-COMBAT 2)|Prospective Evaluation of Outcomes of Everolimus-Eluting Stent (XIENCE V) Implantation for Unprotected Left Main Coronary Artery Stenosis: Multicenter Trial|Completed|||397|Actual|CardioVascular Research Foundation, Korea|||1||f||||t||||||||||2018-05-31 22:38:44.378018|2018-05-31 22:38:44.378018
NCT01348009|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2012-03-11|2011-05-03|2011-05-05|Estimate|||||||2012-03-11|2012-03-13|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Interventional|||Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer|A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer|Unknown status|Recruiting|Phase 1/Phase 2|63|Anticipated|Genta Incorporated||1|||f||||t||||||||||2018-05-31 22:38:44.470518|2018-05-31 22:38:44.470518
NCT01347996|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2017-11-27|2011-05-04|2011-05-05|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2009||2009-07-31|November 2017|2017-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia|Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission|Completed||Phase 4|84|Actual|Cytovia, Inc.||1|||f||||f||||||||||2018-05-31 22:38:44.565036|2018-05-31 22:38:44.565036
NCT01347983|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2013-04-03|2011-05-04|2011-05-05|Estimate|||||||2013-04-03|2013-04-04|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients|Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients|Completed||Phase 3|72|Actual|Chugai Pharma Taiwan|||||f||||f||||||||||2018-05-31 22:38:44.641751|2018-05-31 22:38:44.641751
NCT01347970|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2018-01-09|2011-05-04|2011-05-05|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2012||2012-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial|Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial|Active, not recruiting||Phase 2|250|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 22:38:44.730423|2018-05-31 22:38:44.730423
NCT01347957|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2013-02-12|2011-05-04|2011-05-05|Estimate|||||||2013-02-12|2013-02-15|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia||Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 22:38:44.833793|2018-05-31 22:38:44.833793
NCT01347944|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2016-03-23|2011-05-04|2011-05-05|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|MORE||MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry|Observational, Non-interventional, Multicenter Study Aimed at Collecting Retrospective/Prospective 648/96 Italian Registry Data Related to Lenalidomide (Revlimid®) Prescription to Patients With Myelodysplastic Syndromes|Completed|||149|Actual|Celgene Corporation|||||f||||t||||||||||2018-05-31 22:38:44.926122|2018-05-31 22:38:44.926122
NCT01347762|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-04-09|2011-05-03|2011-05-04|Estimate|||||||2018-04-09|2018-04-11|Actual|June 2010||2010-06-30|April 2018|2018-04-30|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|NAB CAN||Nabilone for Cannabis Dependence: A Pilot Study|Nabilone for Cannabis Dependence: A Pilot Study|Completed||Phase 2/Phase 3|70|Actual|Mclean Hospital||2|||f||||f||||||||||2018-05-31 22:38:47.757971|2018-05-31 22:38:47.757971
NCT01347931|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2015-03-08||2016-08-17|2011-05-04|2011-05-05|Estimate|2016-08-17|2016-10-11|Estimate||||2016-08-17|2016-10-11|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Per protocol|In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency|In-home Evaluation of the Breathe Technologies Noninvasive Open Ventilation (NIOV™) System in Patients With Severe Respiratory Insufficiency|Completed||N/A|30|Actual|Breathe Technologies, Inc.||2|||f||||f||||||||||2018-05-31 22:38:45.053767|2018-05-31 22:38:45.053767
NCT01347918|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2015-04-08|2011-05-03|2011-05-05|Estimate|||||||2015-04-08|2015-04-09|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||1H-19F Gastrointestinal MRI in Health and IBS|Small Intestinal Transit and Motor Function in Health and IBS Patients Studied by Combined 1H and 19F Magnetic Resonance Imaging|Suspended|||24|Anticipated|University of Zurich|||2|Technical problems|f||||f||||||||||2018-05-31 22:38:45.479181|2018-05-31 22:38:45.479181
NCT01347905|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2015-06-05|2011-05-03|2011-05-05|Estimate|||||||2015-06-05|2015-06-09|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Changes in Iron Absorption and Availability Before and After Weight Loss in Obese Pre-menopausal Women and Men.|Changes in Iron Absorption and Availability Before and After Weight Loss in Obese Pre-menopausal Women and Men.|Completed|||43|Actual|Wageningen University|||1||f||||t||||||Samples With DNA|"~     whole blood and serum~   "|||2018-05-31 22:38:45.648697|2018-05-31 22:38:45.648697
NCT01347892|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2017-01-25|2011-05-03|2011-05-05|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Observational|||DeNovo NT Ankle LDC Study|Post Market, Longitudinal Data Collection Study of Articular Cartilage Lesions in the Ankle Treated With DeNovo(R) NT Natural Tissue Graft|Active, not recruiting|||205|Actual|Zimmer Orthobiologics, Inc.|||1||f||||f||||||||||2018-05-31 22:38:45.899295|2018-05-31 22:38:45.899295
NCT01347879|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2013-09-23||2013-12-02|2011-05-03|2011-05-04|Estimate|2013-12-02|2014-01-16|Estimate||||2013-12-02|2014-01-16|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris|PCTA206/11 A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi Center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris.|Completed||Phase 2|153|Actual|Photocure||2|||f||||f||||||||||2018-05-31 22:38:46.084998|2018-05-31 22:38:46.084998
NCT01347866|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-01-13|2011-05-03|2011-05-04|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer|A Multi-Arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer|Terminated||Phase 1|105|Actual|Pfizer||2||Refer to Detailed Description for documentaion of Termination Statement.|f||||f||||||||||2018-05-31 22:38:46.69631|2018-05-31 22:38:46.69631
NCT01347853|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2017-02-06|2011-05-03|2011-05-04|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2003||2003-06-30|February 2017|2017-02-28|June 2007|Actual|2007-06-30|June 2005|Actual|2005-06-30||Interventional|||Safety and Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain|A Phase 3, Double-blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain|Completed||Phase 3|300|Actual|Egalet Ltd||2|||f||||f||||||||||2018-05-31 22:38:46.879628|2018-05-31 22:38:46.879628
NCT01347840|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2012-04-19||2012-04-19|2011-05-03|2011-05-04|Estimate|2012-04-19|2012-05-21|Estimate||||2012-04-19|2012-05-21|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|Cassini||Metabolic Factors of Outcomes From Gastric Bypass Surgery|Metabolic Factors of Outcomes From Gastric Bypass Surgery|Terminated|||1|Actual|Ethicon Endo-Surgery|Trial termination due to business needs. One subject enrolled and withdrew consent. Zero subjects completed study. No subject data analyzed.||1|Study was terminated for business reasons.|f||||f||||||||||2018-05-31 22:38:46.957298|2018-05-31 22:38:46.957298
NCT01347827|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-01-09|2011-05-03|2011-05-04|Estimate|||||||2013-01-09|2013-01-10|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Tissue Oxygenation During Heart Surgery|Comparison of Cerebral Tissue Oxygen Desaturation in Patients Undergoing On-pump or Off-pump Coronary Artery Bypass Grafting|Completed|||60|Actual|University Medical Center Groningen|||2||f||||f||||||||||2018-05-31 22:38:47.144067|2018-05-31 22:38:47.144067
NCT01347814|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of 10mg Domperidone on Gastric Emptying of a High-fat Meal and Appetite Sensations in Healthy Adults|Does Domperidone, a D2-antagonist Alter Gastric Emptying Rates and Appetite Sensations in Healthy Adults?|Completed||N/A|13|Actual|University of Limerick|||||f||||f||||||||||2018-05-31 22:38:47.257003|2018-05-31 22:38:47.257003
NCT01347801|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2014-09-19|2011-05-03|2011-05-04|Estimate|||||||2014-09-19|2014-09-22|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1|Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1|Completed||N/A|40|Actual|Rigshospitalet, Denmark||9|||f||||f||||||||||2018-05-31 22:38:47.328778|2018-05-31 22:38:47.328778
NCT01347788|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|2014-09-15||2016-10-17|2011-05-03|2011-05-04|Estimate|2015-10-16|2015-11-17|Estimate||||2016-10-17|2016-11-28|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||See Lee et al CCR 2013|Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer|Dose-Finding Pilot Study of XL184 in Men With Castrate-Resistant Prostate Cancer and Bone Metastases|Completed||Phase 1|34|Actual|Massachusetts General Hospital|Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. Clin Cancer Res. 2013 Jun 1;19(11):3088-94. doi: 10.1158/1078-0432.CCR-13-0319. Epub 2013 Apr 3.|3|||f||||t||||||||Undecided||2018-05-31 22:38:47.500316|2018-05-31 22:38:47.500316
NCT01347775|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|December 2007||2007-12-31|May 2011|2011-05-31|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Inspiratory Muscle Training in Patients With End Stage Renal Failure|Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 4|48|Anticipated|The University of Queensland||2|||f||||t||||||||||2018-05-31 22:38:47.678756|2018-05-31 22:38:47.678756
NCT01347749|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2014-11-14|2011-05-03|2011-05-04|Estimate|||||||2014-11-14|2014-11-18|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Mindfulness and Present Centered Therapies for PTSD: Efficacy and Mechanisms|Mindfulness and Self-Compassion Meditation for Combat Posttraumatic Stress Disorder: Randomized Controlled Trial and Mechanistic Study|Completed||N/A|65|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 22:38:47.863869|2018-05-31 22:38:47.863869
NCT01347736|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2018-04-02|2011-05-03|2011-05-04|Estimate|||||||2018-04-02|2018-04-04|Actual|March 2011|Actual|2011-03-31|February 2018|2018-02-28|November 7, 2014|Actual|2014-11-07|November 7, 2012|Actual|2012-11-07||Interventional|||Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection|Scrambler Therapy for the Treatment of Chronic Zoster Pain|Completed||N/A|10|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 22:38:47.953041|2018-05-31 22:38:47.953041
NCT01347723|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2016-01-06|2011-05-03|2011-05-04|Estimate|||||||2016-01-06|2016-01-08|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Scrambler Therapy in Treating Pain and Peripheral Neuropathy in Patients Previously Treated With Chemotherapy|Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Open Access Trial|Completed||N/A|194|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 22:38:48.046445|2018-05-31 22:38:48.046445
NCT01347710|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|2016-01-24||2016-03-06|2011-05-03|2011-05-04|Estimate|2016-03-06|2016-04-05|Estimate||||2016-03-06|2016-04-05|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional||Safety population, received at least one dose of flurpiridaz F 18|A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.|A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)|Completed||Phase 3|795|Actual|Lantheus Medical Imaging||1|||f||||t||||||||||2018-05-31 22:38:48.156614|2018-05-31 22:38:48.156614
NCT01347697|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2016-06-02|2011-05-03|2011-05-04|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|NEAPE||Collagen Implant Compared to Gluteus Maximus Flap for Reconstruction of Pelvic Floor After ELAPE/EAPE in Rectal Cancer|Nordic Extended Abdominoperineal Excision (NEAPE) Study, a Randomized Clinical Trial Comparing a Collagen Implant With a Gluteus Maximus Flap for Reconstruction of Pelvic Floor After Extended Abdominoperineal Excision of Rectum in Rectal Cancer|Unknown status|Recruiting|Phase 3|80|Anticipated|Umeå University||2|||f||||t||||||||||2018-05-31 22:38:48.800613|2018-05-31 22:38:48.800613
NCT01347684|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2016-12-06|2011-05-03|2011-05-04|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Assessing the Effectiveness of Two Treatment Strategies for Tension-type Headache|Assessing the Effectiveness of Two Treatment Strategies for Tension-type Headache|Withdrawn||Phase 3|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||PI left University of Minnesota|f||||f||||||||||2018-05-31 22:38:48.914936|2018-05-31 22:38:48.914936
NCT01347671|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2012-06-05|2011-05-03|2011-05-04|Estimate|||||||2012-06-05|2012-06-06|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy|A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.|Completed||Phase 2|189|Actual|Grünenthal GmbH||4|||f||||f||||||||||2018-05-31 22:38:49.038222|2018-05-31 22:38:49.038222
NCT01347658|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-09-29|2011-05-03|2011-05-04|Estimate|||||||2011-09-29|2011-09-30|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Drug Interactions Between Echinacea Purpurea and Etravirine|DRUG INTERACTIONS BETWEEN ECHINACEA PURPUREA AND ETRAVIRINE|Completed||Phase 1|15|Anticipated|Fundacio Lluita Contra la SIDA||1|||f||||f||||||||||2018-05-31 22:38:49.138406|2018-05-31 22:38:49.138406
NCT01347645|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2017-08-25|2011-05-03|2011-05-04|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2011|Actual|2011-09-30|August 2017|2017-08-31|June 22, 2016|Actual|2016-06-22|June 22, 2015|Actual|2015-06-22||Interventional|||Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer|Completed||Phase 1/Phase 2|82|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 22:38:49.214105|2018-05-31 22:38:49.214105
NCT01347632|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2013-11-01||2017-11-20|2011-05-03|2011-05-04|Estimate|2014-08-12|2014-08-26|Estimate||||2017-11-20|2017-12-19|Actual|April 2011||2011-04-30|November 2017|2017-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CONRADBV||Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue|Prospective Evaluation of the Impact of Bacterial Vaginosis and Its Treatment on Mucosal Susceptibility to HIV-1 Infection and Endpoints of Cervico-Vaginal Safety|Completed||N/A|35|Actual|CONRAD|There were no serious adverse events related to product or procedures.|1|||f||||t||||||||No|Cohort data will be published but not IPD|2018-05-31 22:38:49.352011|2018-05-31 22:38:49.352011
NCT01347619|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2014-03-28|2011-05-03|2011-05-04|Estimate|||||||2014-03-28|2014-04-01|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||iADAPT: Off Label Use of Antipsychotics in the Nursing Home|iADAPT: Off Label Use of Antipsychotics in the Nursing Home|Completed||N/A|42|Actual|University of Massachusetts, Worcester||3|||f||||t||||||||||2018-05-31 22:38:49.498415|2018-05-31 22:38:49.498415
NCT01347606|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|July 2011|Anticipated|2011-07-31|January 2011|Actual|2011-01-31||Observational|bluethyroid||Secured Thyroidectomy With Intraoperative Methylene Blue Using|Prospective Randomized Technical Study|Unknown status|Recruiting||20|Anticipated|SB Istanbul Education and Research Hospital|||||f||||f||||||Samples Without DNA|"~     thyroid tissue~   "|||2018-05-31 22:38:49.569824|2018-05-31 22:38:49.569824
NCT01347593|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2013-01-16|2011-05-03|2011-05-04|Estimate|||||||2013-01-16|2013-01-17|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery|Prophylactic Ceftizoxime (Cefizox) for Elective Cesarean Delivery in Soba Hospital Sudan|Completed||Phase 4|220|Actual|University of Khartoum||1|||f||||t||||||||||2018-05-31 22:38:49.638973|2018-05-31 22:38:49.638973
NCT01347398|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2013-02-06|2011-05-03|2011-05-04|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|||Validity of a Supersimplified Device for Diagnosis of Patients With Suspected Obstructive Sleep Apnoea-hypopnoea (OSAH)|Validity of a Supersimplified Device for Diagnosis of Patients With Suspected Obstructive Sleep Apnoea-hypopnoea (OSAH).|Unknown status|Active, not recruiting|N/A|815|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 22:38:52.103265|2018-05-31 22:38:52.103265
NCT01347580|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2014-11-13||2015-07-20|2011-05-03|2011-05-04|Estimate|2015-01-26|2015-02-11|Estimate||||2015-07-20|2015-07-22|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ATLANTIC||A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)|A 30 Day International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for PCI.|Completed||Phase 4|1875|Actual|AstraZeneca|"This urgent setting study included 8.6% of patients with symptoms of MI in ambulance but having finally not a STEMI diagnosis in cathlab.~No prespecified hypothesis and procedure for adjustment was made on secondary endpoints."|2|||f||||f||||||||||2018-05-31 22:38:49.811604|2018-05-31 22:38:49.811604
NCT01347567|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2014-02-04|2011-05-03|2011-05-04|Estimate|||||||2014-02-04|2014-02-06|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|HOME||Heart Failure (HF) Outpatient Monitoring Evaluation (HOME) Study|HF Outpatient Monitoring Evaluation (HOME) Study|Completed||N/A|145|Actual|Alere San Diego||3|||f||||f||||||||||2018-05-31 22:38:50.794061|2018-05-31 22:38:50.794061
NCT01347554|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2014-09-23||2014-09-23|2011-05-02|2011-05-04|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EVERZOTA||Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction|Comparison of the Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Stent for Coronary Lesions in Acute Myocardial Infarction|Completed||Phase 4|461|Actual|Yonsei University|Relatively small number of sample size. Therefore, our result may be underpowerd. The incidence of clinical events were low. And we did not record the compliance of dual antiplatelet therapy for at least 1 year.|2|||f||||t||||||||||2018-05-31 22:38:50.864645|2018-05-31 22:38:50.864645
NCT01347541|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2012-06-19|2011-05-02|2011-05-04|Estimate|||||||2012-06-19|2012-06-20|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|TSOS III||Piloting Acute Care to Primary Care Linkage of Safety Net Patients|Piloting Acute Care to Primary Care Linkage of Safety Net Patients|Unknown status|Active, not recruiting|Phase 1|60|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 22:38:51.188156|2018-05-31 22:38:51.188156
NCT01347528|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2015-12-01|2011-05-02|2011-05-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|TELEMED-HF||Improving MEDication Adherence in Chronic Heart Failure Using a TELEmedicine Device (TELEMED-HF)|A Randomized, Controlled Trial Using a TELEmedicine Solution to Improve MEDication Adherence in Chronic Heart Failure (TELEMED-HF)|Withdrawn||N/A|0|Actual|University of Tilburg||2||logistic and financial accounting reasons|f||||t||||||||||2018-05-31 22:38:51.268142|2018-05-31 22:38:51.268142
NCT01347515|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-05-27|2011-05-03|2011-05-04|Estimate|||||||2011-05-27|2011-05-30|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|VOHF1||Bioactivity of Olive Oils Enriched With Their Own Phenolic Compounds (VOHF1)|Bioavailability and Bioactivity of Olive Oils Enriched With Their Own Phenolic Compounds in a Dose-response Study (VOHF1)|Unknown status|Recruiting|Phase 1/Phase 2|12|Anticipated|University Rovira i Virgili||3|||f||||t||||||||||2018-05-31 22:38:51.3346|2018-05-31 22:38:51.3346
NCT01347502|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2012-07-05|2011-05-03|2011-05-04|Estimate|||||||2012-07-05|2012-07-09|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Observational|||Prevalence of Bacterial Contamination on Smart Cell Phone vs. Non-smart Phone|Bacterial Contamination of Smart Phones of Health Care Workers|Completed|||203|Actual|Seoul National University Hospital|||2||f||||f||||||||||2018-05-31 22:38:51.397344|2018-05-31 22:38:51.397344
NCT01347489|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2011-05-04|2011-05-03|2011-05-04|Estimate|||||||2011-05-04|2011-05-05|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2012|Anticipated|2012-12-31|June 2011|Anticipated|2011-06-30||Observational|preswound||Cronic Pressure Wounds and Relation With Gender|Cronic Pressure Wounds and Relation With Gender|Unknown status|Recruiting||2|Anticipated|SB Istanbul Education and Research Hospital|||||f||||f||||||||||2018-05-31 22:38:51.448051|2018-05-31 22:38:51.448051
NCT01347476|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-05-18|2011-05-03|2011-05-04|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Aggressive Prostate Cancers in Elderly Patients|Patients Aged More Than 70 Had More Aggressive Prostate Cancers and Higher Risk of Biochemical Recurrence in Korea|Completed|||1333|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 22:38:51.503174|2018-05-31 22:38:51.503174
NCT01347463|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2013-05-20|2011-05-03|2011-05-04|Estimate|||||||2013-05-20|2013-05-21|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Validation of the Ipsilateral Nipple as the Directional Guide for Internal Jugular Vein (IJV) Catheterization||Completed||N/A|100|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:38:51.557199|2018-05-31 22:38:51.557199
NCT01347450|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|October 2007||2007-10-31|September 2004|2004-09-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Protective Effects of Cocoa Ingestion Over Healthy Males Plasma Lipids Subjected to Peroxidative Conditions|Protective Effects of Cocoa Ingestion Over Healthy Males Plasma Lipids Subjected to Peroxidative Conditions|Completed||N/A|136|Actual|Fundación Santa Fe de Bogota||1|||f||||t||||||||||2018-05-31 22:38:51.614359|2018-05-31 22:38:51.614359
NCT01347437|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2017-04-13|2011-05-03|2011-05-04|Estimate|||||||2017-04-13|2017-04-17|Actual|July 2011|Actual|2011-07-31|April 2017|2017-04-30|March 6, 2013|Actual|2013-03-06|January 2013|Actual|2013-01-31||Interventional|||Improving Antiretroviral Medication Adherence Among HIV-infected Youth|Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase II|Completed||N/A|17|Actual|Fenway Community Health||2|||f||||f||||||||No||2018-05-31 22:38:51.839898|2018-05-31 22:38:51.839898
NCT01347424|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-12-05|2011-05-03|2011-05-04|Estimate|||||||2013-12-05|2013-12-09|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|October 2014|Anticipated|2014-10-31|May 2014|Anticipated|2014-05-31||Interventional|||Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography||Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:38:51.932283|2018-05-31 22:38:51.932283
NCT01347411|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|September 2007||2007-09-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effectiveness of the Treatment With Continuous Positive Airway Pressure(CPAP)in Stable Heart Failure With Ejection Fraction More Than 45% and Sleep Disordered Breathing|Effectiveness of the Treatment With CONTINUOUS POSITIVE AIRWAY PRESSURE (CPAP) in Stable Heart Failure With Ejection Fraction More Than 45% and Sleep Disordered Breathing|Completed||N/A|420|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 22:38:52.033746|2018-05-31 22:38:52.033746
NCT01347385|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-05-02|2011-05-02|2011-05-04|Estimate|||||||2011-05-02|2011-05-04|Estimate|January 2012||2012-01-31|April 2011|2011-04-30||||January 2014|Anticipated|2014-01-31||Interventional|||Barbed Suture Versus Traditional Suture Material for Laparoscopic Myomectomy|Barbed Suture Versus Traditional Suture Material for Laparoscopic Myomectomy: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|80|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:38:52.174821|2018-05-31 22:38:52.174821
NCT01347372|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2018-04-11|2011-05-03|2011-05-04|Estimate|||||||2018-04-11|2018-04-12|Actual|May 2011|Actual|2011-05-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|P2P EIA RCT||Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentor Training|Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentor Training|Completed||N/A|20|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-05-31 22:38:52.276308|2018-05-31 22:38:52.276308
NCT01347359|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2018-04-11|2011-05-03|2011-05-04|Estimate|||||||2018-04-11|2018-04-12|Actual|May 2011|Actual|2011-05-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|P2P EIA RCT||Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentoring Program|Peer to Peer Mentoring For Individuals With Early Inflammatory Arthritis: An Effectiveness Study (Pilot RCT)- Peer Mentoring Program|Completed||N/A|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:38:52.351343|2018-05-31 22:38:52.351343
NCT01347346|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2018-05-18|2011-05-03|2011-05-04|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2011||2011-05-31|May 2018|2018-05-31|January 9, 2017|Actual|2017-01-09|January 13, 2016|Actual|2016-01-13||Interventional|||Gene Therapy for WAS|Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome|Completed||Phase 1/Phase 2|5|Actual|Genethon|||||f||||t||||||||||2018-05-31 22:38:52.458021|2018-05-31 22:38:52.458021
NCT01347333|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2018-01-24|2011-05-03|2011-05-04|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2008||2008-09-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Stereotactic Body Radiotherapy for Liver Tumors|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors|Completed||N/A|23|Actual|Mercy Research||2|||f||||f||||||||||2018-05-31 22:38:52.531946|2018-05-31 22:38:52.531946
NCT01347320|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2013-12-27|2011-05-03|2011-05-04|Estimate|||||||2013-12-27|2013-12-30|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Preoperative Magnetic Resonance (MR) Imaging of Prostate Cancer|Clinical Impact of MR Imaging in Patients With Prostate Cancer|Completed||N/A|400|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 22:38:52.609993|2018-05-31 22:38:52.609993
NCT01347307|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2017-09-20|2011-05-02|2011-05-04|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2008||2008-09-30|September 2017|2017-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Stereotactic Body Radiotherapy for Spine Tumors|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Spine Metastases and Primary Spine Tumors|Active, not recruiting||N/A|50|Anticipated|Mercy Research||2|||f||||f||||||||||2018-05-31 22:38:52.7554|2018-05-31 22:38:52.7554
NCT01347294|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2017-02-17|2011-05-03|2011-05-04|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2011||2011-08-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations|Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations|Recruiting||Phase 4|126|Anticipated|Oslo University Hospital||3|||f||||f||||||||No||2018-05-31 22:38:52.966149|2018-05-31 22:38:52.966149
NCT01347281|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2017-01-27|2011-05-03|2011-05-04|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||PET With [18F]HX4 in Head and Neck Cancer|Non Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET) in Head and Neck Cancer.|Completed||N/A|23|Actual|Maastricht Radiation Oncology||1|||f||||t||||||||Undecided||2018-05-31 22:38:53.432302|2018-05-31 22:38:53.432302
NCT01347268|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-05-02|2011-05-02|2011-05-04|Estimate|||||||2011-05-02|2011-05-04|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist|A Prospective Randomized Study Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Administration in Patients at Risk for Severe OHSS|Unknown status|Recruiting|Phase 4|120|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:38:54.979306|2018-05-31 22:38:54.979306
NCT01347255|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2015-11-13||2016-07-13|2011-05-03|2011-05-04|Estimate|2016-01-26|2016-02-24|Estimate||||2016-07-13|2016-08-15|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Intra-individual baseline analysis population|A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris|A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris|Completed||Phase 2|24|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 22:38:56.036785|2018-05-31 22:38:56.036785
NCT01347242|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2018-05-18|2011-05-03|2011-05-04|Estimate|||||||2018-05-18|2018-05-21|Actual|March 2011||2011-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Gene Therapy for Wiskott-Aldrich Syndrome (WAS)|Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome|Recruiting||Phase 1/Phase 2|5|Anticipated|Genethon|||||f||||t||||||||||2018-05-31 22:38:56.600168|2018-05-31 22:38:56.600168
NCT01347229|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2012-04-16|2011-05-03|2011-05-04|Estimate|||||||2012-04-16|2012-04-17|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||SENSIMED Triggerfish® in Sitting and Supine Position|Assessment of Sitting and Supine Position IOP Using SENSIMED Triggerfish® and Standard Tonometers|Completed||N/A|20|Actual|Sensimed AG|||||f||||f||||||||||2018-05-31 22:38:56.693321|2018-05-31 22:38:56.693321
NCT01347216|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2017-07-31|2011-05-03|2011-05-04|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2007|Actual|2007-06-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|COMPERA||COMPERA / COMPERA-KIDS|Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension|Recruiting|||8000|Anticipated|Technische Universität Dresden|||||f||||t||||||||No|Data sharing has not been planned.|2018-05-31 22:38:56.779482|2018-05-31 22:38:56.779482
NCT01347203|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-07-06|2011-05-03|2011-05-04|Estimate|||||||2011-07-06|2011-07-07|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting|A Randomized, Open-label, 4-period Crossover Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD) and the PK/PD Relationship of DPOC-4088 After Single Oral Dosing of 100 and 200 mg in 2 Prolonged Release Formulations (16 and 20 hr) in 12 Healthy Young Male Subjects|Completed||Phase 1|12|Anticipated|Diakron Pharmaceuticals||4|||f||||f||||||||||2018-05-31 22:38:56.914103|2018-05-31 22:38:56.914103
NCT01347190|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2012-04-03|2011-05-03|2011-05-04|Estimate|||||||2012-04-03|2012-04-05|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis|A Double Blind, Randomized, Placebo Controlled, Single Dose, Phase I Study of the Safety and Tolerability of Alpha1 Proteinase Inhibitor (Human) Inhalation Solution (CR002) in Subjects With Cystic Fibrosis|Completed||Phase 1|25|Actual|CSL Behring||2|||f||||||||||||||2018-05-31 22:38:56.993575|2018-05-31 22:38:56.993575
NCT01347177|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2012-02-08|2011-05-02|2011-05-04|Estimate|||||||2012-02-08|2012-02-09|Estimate|April 2012||2012-04-30|January 2011|2011-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Clinical Trial of Zirconia and Metal Adhesive Bridges|A Single-centre Randomised Controlled Clinical Trial of Zirconia-based Versus Metal-based Adhesive Bridges for Replacing 2 Missing Teeth or Less in Adults.|Unknown status|Not yet recruiting|N/A|176|Anticipated|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 22:38:57.192572|2018-05-31 22:38:57.192572
NCT01347164|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2018-04-13|2011-05-03|2011-05-04|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2010||2010-12-31|April 2018|2018-04-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|RISE||Evaluation of a New HIV Prevention Intervention for Black Bisexually-active Men|Development and Testing of HIV Prevention Interventions Targeting Black MSM/W|Completed||Phase 2|169|Actual|Public Health Management Corporation||2|||f||||f||||||||||2018-05-31 22:38:57.270032|2018-05-31 22:38:57.270032
NCT01347151|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||A Comparison of Cervical Spine Movement During Tracheal Intubation Using the Pentax or the Glidescope||Unknown status|Active, not recruiting|N/A|200|Anticipated|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 22:38:57.357871|2018-05-31 22:38:57.357871
NCT01347138|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-03-10|2011-05-03|2011-05-04|Estimate|||||||2016-03-10|2016-03-11|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Health Care Management for the Elderly in Community Through Screening||Completed||N/A|57|Actual|National Clinical Research Coordination Center, Seoul, Korea||2|||f||||||||||||||2018-05-31 22:38:57.48744|2018-05-31 22:38:57.48744
NCT01347125|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|April 2008||2008-04-30|May 2011|2011-05-31|May 2012|Anticipated|2012-05-31|April 2011|Actual|2011-04-30||Interventional|ImCardia||ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study|ImCardia for DHF - Safety and Functionality|Terminated||Early Phase 1|19|Actual|CorAssist Cadiovascular Ltd.||2||CorAssist believes that certain improvements are needed to the device|f||||t||||||||||2018-05-31 22:38:57.634033|2018-05-31 22:38:57.634033
NCT01347112|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|2014-05-01||2018-01-09|2011-05-03|2011-05-04|Estimate|2014-05-01|2014-05-30|Estimate||||2018-01-09|2018-02-05|Actual|June 2011||2011-06-30|January 2018|2018-01-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional||Intention to treat all randomized subjects included in study|Varenicline Treatment for Active Alcoholic Smokers|Varenicline Treatment for Active Alcoholic Smokers|Completed||Phase 2/Phase 3|33|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:38:57.787962|2018-05-31 22:38:57.787962
NCT01347099|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2018-03-19|2011-05-03|2011-05-04|Estimate|||||||2018-03-19|2018-03-21|Actual|February 2011|Actual|2011-02-28|May 2011|2011-05-31|June 2011||2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Internet-based Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)|Internet-based Cognitive Behavior Therapy for Obsessive Compulsive Disorder: A Randomized Controlled Trial|Completed||Phase 2|101|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:38:58.256342|2018-05-31 22:38:58.256342
NCT01347086|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|2016-01-21||2016-03-16|2011-05-03|2011-05-04|Estimate|2016-03-16|2016-04-15|Estimate||||2016-03-16|2016-04-15|Estimate|May 2011||2011-05-31|March 2016|2016-03-31||||June 2011|Actual|2011-06-30||Interventional||The treated set (full analysis set according to ICH-E9): all subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.|Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400mg, 800mg, 1200mg) of BI 207127 NA in Healthy Male Asian Volunteers and Single Oral Dose (1200 mg) of BI 207127 NA in Healthy Male Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Group)|Completed||Phase 1|60|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 22:38:58.443134|2018-05-31 22:38:58.443134
NCT01347073|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2015-04-03||2017-01-13|2011-05-03|2011-05-04|Estimate|2015-05-06|2015-05-28|Estimate||||2017-01-13|2017-01-16|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||Analyses were based on the safety population, defined as all patients who received any amount of study medication.|Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)|A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)|Completed||Phase 3|23|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|The protocol was designed to capture information important for evaluating safety, pharmacokinetics, and efficacy while recognizing sampling limitations in young children and current standard of care.|1|||f||||t||||||||||2018-05-31 22:39:00.288282|2018-05-31 22:39:00.288282
NCT01347060|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2011-05-05||2017-05-23|2011-05-03|2011-05-04|Estimate|2011-05-05|2011-06-01|Estimate||||2017-05-23|2017-05-25|Actual|July 2009||2009-07-31|May 2017|2017-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy|Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy|Completed|||17448|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:39:00.532294|2018-05-31 22:39:00.532294
NCT01347047|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2017-02-22|2011-05-03|2011-05-04|Estimate|||||||2017-02-22|2017-02-23|Actual|April 2011||2011-04-30|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Institutional Registry of Amyloidosis|Institutional Registry of Amyloidosis|Recruiting|||120|Anticipated|Hospital Italiano de Buenos Aires|||||f||||f|f|f||||||No||2018-05-31 22:39:00.787561|2018-05-31 22:39:00.787561
NCT01347034|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|2014-07-14||2016-04-21|2011-05-03|2011-05-04|Estimate|2014-08-07|2014-08-08|Estimate||||2016-04-21|2016-05-23|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|August 2013|Actual|2013-08-31||Interventional||All participants|Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)|A Phase II Study Evaluating Neoadjuvant Administration of High Dose Radiation Therapy and Intratumoral Autologous Dendritic Cells in Patients With High-risk Soft Tissue Sarcomas|Completed||Phase 2|20|Actual|H. Lee Moffitt Cancer Center and Research Institute|Investigators planned to accrue 21 patients in each arm for a total of 42 participants.|2|||f||||f||||||||||2018-05-31 22:39:01.70107|2018-05-31 22:39:01.70107
NCT01347021|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|May 2011|Anticipated|2011-05-31|December 2009|Actual|2009-12-31||Interventional|||Compare Sacrospinous Fixation Versus High Uterosacral Ligament Fixation for Uterus Vaginal Prolapse III/IV|Sacrospinous Colpopexy Versus High Uterosacral Colpopexy in the Treatment of Genital Prolapse Grade III/IV in Women With Uterus|Unknown status|Enrolling by invitation|Phase 4|51|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:39:01.998388|2018-05-31 22:39:01.998388
NCT01347008|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|2016-08-20||2016-10-12|2011-05-03|2011-05-04|Estimate|2016-10-12|2016-12-05|Estimate||||2016-10-12|2016-12-05|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis|Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 3|41|Actual|Federal University of São Paulo|Small numbers of subjects analyzed; blood flow differences due to outside temperature variations|2|||f||||f||||||||No||2018-05-31 22:39:02.095595|2018-05-31 22:39:02.095595
NCT01346995|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Effect of Experimental Knee Pain During Strengthening Exercises on Muscle Strength Gain|The Effect of Experimental Knee Pain During Strengthening Exercises on Muscle Strength Gain|Completed||N/A|36|Actual|Frederiksberg University Hospital||2|||f||||f||||||||||2018-05-31 22:39:02.347761|2018-05-31 22:39:02.347761
NCT01346982|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-09-29|2011-05-03|2011-05-04|Estimate|||||||2011-09-29|2011-09-30|Estimate|March 2011||2011-03-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Drug Interactions Between Silimarine and Darunavir/Ritonavir|Drug Interactions Between Silimarine And Darunavir/Ritonavir|Completed||Phase 4|15|Anticipated|Fundacio Lluita Contra la SIDA||1|||f||||f||||||||||2018-05-31 22:39:02.400124|2018-05-31 22:39:02.400124
NCT01346969|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-01||2013-05-30|2013-05-30|2011-05-03|2011-05-04|Estimate||||2013-05-30|2013-06-07|Estimate|2013-05-30|2013-06-07|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery|A Phase 2, Randomized, Double-blind, Within-subject Controlled Study to Evaluate Efficacy and Safety of Various Doses and Regimens of EXC 001 for the Amelioration of Scarring Following Revision of Scars From Prior Breast Surgery in Adult Subjects|Completed||Phase 2|68|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:39:02.57554|2018-05-31 22:39:02.57554
NCT01346956|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-05-03|2011-05-03|2011-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|July 2002||2002-07-31|January 2003|2003-01-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Observational|||Acute Cardiovascular Effects of Cigarette Smoking|Acute Cardiovascular Effects of Cigarette Smoking|Completed|||20|Actual|Andhra Medical College|||||f||||f||||||||||2018-05-31 22:39:02.666741|2018-05-31 22:39:02.666741
NCT01346943|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2015-01-13|2011-05-03|2011-05-04|Estimate|||||||2015-01-13|2015-01-15|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Altura Abdominal Aortic Aneurysm (AAA) Endograft Safety and Feasibility Study|The Altura AAA Endograft Safety and Feasibility Study For Exclusion of Abdominal Aortic Aneurysms|Active, not recruiting||Phase 1|50|Anticipated|Altura Medical Inc.||1|||f||||f||||||||||2018-05-31 22:39:02.724112|2018-05-31 22:39:02.724112
NCT01346930|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2014-09-02|2011-05-03|2011-05-04|Estimate|||||||2014-09-02|2014-09-03|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|MUSIC OL||Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis|Long Term, Single-arm, Open-label Extension Study of the MUSIC Study to Assess the Safety and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis|Withdrawn||Phase 2|0|Actual|Actelion||1||Due to Protocol AC-055B201 (MUSIC) not meeting it's primary end point|f||||f||||||||||2018-05-31 22:39:02.794709|2018-05-31 22:39:02.794709
NCT01346917|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2012-10-15|2011-05-02|2011-05-03|Estimate|||||||2012-10-15|2012-10-17|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery|Prospective Randomized Controlled Study for the Effect of Intravenous Lidocaine on the Tolerability of Early Oral Feeding After Laparoscopic Colorectal Surgery in Patients With Colorectal Cancer|Completed||N/A|77|Actual|Kangbuk Samsung Hospital||2|||f||||t||||||||||2018-05-31 22:39:02.869001|2018-05-31 22:39:02.869001
NCT01346904|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-05-02|2011-05-02|2011-05-03|Estimate|||||||2011-05-02|2011-05-03|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||a 3.0T Magnetic Resonance Imaging Study|The Central Nerve System Injury in Patients With Primary Open Angle Glaucoma|Unknown status|Not yet recruiting||200|Anticipated|Huazhong University of Science and Technology|||||f||||t||||||||||2018-05-31 22:39:02.952288|2018-05-31 22:39:02.952288
NCT01346891|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-07-05|2011-05-02|2011-05-03|Estimate|||||||2011-07-05|2011-07-06|Estimate|July 2010||2010-07-31|July 2010|2010-07-31||||||||Observational|||Polymorphisms of the Thiazide's Receptor Gene SLC12A3 and Development of Hyponatremia|Polymorphisms of the Thiazide's Receptor Gene SLC12A3 and Development of Hyponatremia|Completed|||40|Anticipated|Hospital Italiano de Buenos Aires|||2||f||||f||||||||||2018-05-31 22:39:03.012409|2018-05-31 22:39:03.012409
NCT01346878|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2012-10-24|2011-05-02|2011-05-03|Estimate|||||||2012-10-24|2012-10-25|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment|Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment|Completed|||143|Actual|Fundacio Lluita Contra la SIDA|||||f||||f||||||Samples With DNA|"~     Plasma samples~   "|||2018-05-31 22:39:03.088621|2018-05-31 22:39:03.088621
NCT01346865|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2015-11-13|2011-05-02|2011-05-03|Estimate|||||||2015-11-13|2015-11-16|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)|A Randomized, Placebo Controlled, Double-blind, Phase 4 Study to Evaluate Efficacy and Safety of Triple Anti-platelet Therapy Compared With Dual Antiplatelet Therapy in Patients Treated With Drug Eluting Stent for Coronary Artery Disease|Terminated||Phase 4|402|Actual|CardioVascular Research Foundation, Korea||2||Low Recruitment|f||||t||||||||||2018-05-31 22:39:03.152392|2018-05-31 22:39:03.152392
NCT01346332|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2017-07-21|2011-05-02|2011-05-03|Estimate|||||||2017-07-21|2017-07-24|Actual|April 1, 2011|Actual|2011-04-01|July 2017|2017-07-31|February 1, 2012|Actual|2012-02-01|February 1, 2012|Actual|2012-02-01||Observational|IPSHS||Healthy Volunteer Study|Performance of the Iontophoresis System With Headset in Healthy Volunteers|Completed|||106|Actual|Acclarent|||1||f||||f||||||||||2018-05-31 22:39:12.583417|2018-05-31 22:39:12.583417
NCT01346852|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2011-05-05||2017-05-25|2011-05-02|2011-05-03|Estimate|2011-05-05|2011-06-01|Estimate||||2017-05-25|2017-05-30|Actual|July 2009||2009-07-31|May 2017|2017-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients|Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients|Completed|||101437|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:39:03.262436|2018-05-31 22:39:03.262436
NCT01346839|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2015-08-24||2016-01-12|2011-05-02|2011-05-03|Estimate|2016-01-12|2016-02-09|Estimate||||2016-01-12|2016-02-09|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care|Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care|Completed||N/A|1256|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 22:39:03.469681|2018-05-31 22:39:03.469681
NCT01346826|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-07-11|2011-05-02|2011-05-03|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)|Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial|Completed||Phase 4|145|Actual|Asan Medical Center||3|||f||||t||||||||No||2018-05-31 22:39:03.888523|2018-05-31 22:39:03.888523
NCT01346813|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2011-10-24|2011-05-02|2011-05-03|Estimate|||||||2011-10-24|2011-10-26|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|EPIPPAIN||Epidemiology of Painful Procedures in Neonates|Epidémiologie Des Gestes Douloureux ou Stressants Chez Les Nouveau-nés Pris en Charge Dans Les unités de réanimation néonatale et pédiatrique et Par Les équipes de SMUR de la région d'Ile de France|Completed|||1000|Anticipated|Hôpital Armand Trousseau|||||f||||f||||||||||2018-05-31 22:39:04.001073|2018-05-31 22:39:04.001073
NCT01346800|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-10-05|2011-04-29|2011-05-03|Estimate|||||||2011-10-05|2011-10-06|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers||Completed||Phase 1|10|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 22:39:04.106927|2018-05-31 22:39:04.106927
NCT01346787|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2016-05-09|2011-05-02|2011-05-03|Estimate|||||||2016-05-09|2016-05-10|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|October 2019|Anticipated|2019-10-31|October 2012|Actual|2012-10-31||Interventional|CCD||Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients|A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS|Active, not recruiting||Phase 2|53|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||t||||||||||2018-05-31 22:39:04.178059|2018-05-31 22:39:04.178059
NCT01346774|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2015-04-28||2015-05-26|2011-05-02|2011-05-03|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|PUPS||Preventing Urinary Tract Infection Post-Surgery|Phase II Efficacy of Cranberry Powder in Preventing Catheter-associated Urinary Tract Infection Post Elective Gynecological Surgery|Completed||Phase 2|200|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 22:39:04.326236|2018-05-31 22:39:04.326236
NCT01346761|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2016-04-12|2011-05-02|2011-05-03|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2009||2009-08-31|April 2016|2016-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|REACH||Risk Education and Assessment for Cancer Heredity|Bridging Geographic Barriers: Remote Cancer Genetic Counseling for Rural Women|Completed||N/A|1012|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:39:05.230502|2018-05-31 22:39:05.230502
NCT01346748|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-05-02|2011-05-02|2011-05-03|Estimate|||||||2011-05-02|2011-05-03|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|February 2013|Anticipated|2013-02-28|August 2012|Anticipated|2012-08-31||Interventional|||The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage|The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-05-31 22:39:05.314256|2018-05-31 22:39:05.314256
NCT01346735|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-08-30|2011-05-02|2011-05-03|Estimate|||||||2016-08-30|2016-09-01|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|MOSER||Multi-center Observational Study to Evaluate Epidemiology and Resistance Patterns of Common ICU-Infections (MOSER)|Multi-center Observational Study to Evaluate Epidemiology and Resistance Patterns of Common ICU-Infections (MOSER)|Completed|||381|Actual|Indian Society of Critical Care Medicine|||1||f||||t||||||||||2018-05-31 22:39:05.383205|2018-05-31 22:39:05.383205
NCT01346722|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-05-02|2011-05-02|2011-05-03|Estimate|||||||2011-05-02|2011-05-03|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Zinc Absorption From Zinc Biofortified Rice|Absorption of Zinc From Mixed Diets Containing Conventional Bangladeshi Rice, Zinc-biofortified Bangladeshi Rice, or Conventional Bangladeshi Rice With Added Zinc Among Young Children in a Peri-urban Community.|Completed||Phase 1/Phase 2|42|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||||2018-05-31 22:39:05.440841|2018-05-31 22:39:05.440841
NCT01346709|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2014-03-04|2011-05-02|2011-05-03|Estimate|||||||2014-03-04|2014-03-05|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|PERISCOPE||Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe|Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe: Predicting Postoperative Pulmonary Complications in Europe: a 7-day Data Collection, Prospective, Observational Study|Completed|||5183|Actual|European Society of Anaesthesiology|||1||f||||f||||||||||2018-05-31 22:39:05.511763|2018-05-31 22:39:05.511763
NCT01346696|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-03-21|2011-05-02|2011-05-03|Estimate|||||||2016-03-21|2016-03-22|Estimate|February 2011||2011-02-28|March 2016|2016-03-31||||March 2016|Actual|2016-03-31||Interventional|||Study on OsseoSpeed™ TX Short Implants in a Chinese Population|An Open, Prospective, Multi-center Study Assessing the OsseoSpeed™ TX Length 6 mm in in the Posterior Maxilla and Mandible. A 3-years Follow-up Study.|Completed||N/A|45|Actual|Dentsply Sirona Implants||1|||f||||||||||||||2018-05-31 22:39:05.762893|2018-05-31 22:39:05.762893
NCT01346683|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-02|||2016-09-15|2011-05-02|2011-05-03|Estimate|||||||2016-09-15|2016-09-16|Estimate|February 2011||2011-02-28|September 2016|2016-09-30||||March 2016|Actual|2016-03-31||Interventional|||Study on OsseoSpeed™ TX Implants in a Chinese Population|An Open, Prospective, Multi-center Study to Evaluate the OsseoSpeed™ TX Implant With an Early Loading Protocol in Patients With Tooth Loss in the Posterior Mandible. A 3-years Follow-up Study.|Completed||N/A|45|Actual|Dentsply Sirona Implants||1|||f||||||||||||||2018-05-31 22:39:05.842839|2018-05-31 22:39:05.842839
NCT01346670|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-05-01|2011-05-01|2011-05-03|Estimate|||||||2011-05-01|2011-05-03|Estimate|October 2006||2006-10-31|May 2011|2011-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects|An Open-randomized, Balanced, Crossover Relative Bioavailability Study of Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects|Completed||Phase 4|14|Actual|Taipei Medical University WanFang Hospital||1|||f||||f||||||||||2018-05-31 22:39:05.914795|2018-05-31 22:39:05.914795
NCT01346657|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-05-01|2011-05-01|2011-05-03|Estimate|||||||2011-05-01|2011-05-03|Estimate|July 2009||2009-07-31|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects|The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects|Completed||Phase 4|14|Actual|Taipei Medical University WanFang Hospital||1|||f||||f||||||||||2018-05-31 22:39:06.011686|2018-05-31 22:39:06.011686
NCT01346644|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-01|||2013-05-15|2011-05-02|2011-05-03|Estimate|||||||2013-05-15|2013-05-16|Estimate|February 2009||2009-02-28|May 2013|2013-05-31||||||||Interventional|||Safety of Lactobacillus Fermentum in Newborn Infants|Study of Tolerance of an Infant Formula Supplemented With Lactobacillus Fermentum CECT5716|Completed||N/A|137|Actual|Puleva Biotech||2|||f||||||||||||||2018-05-31 22:39:06.08653|2018-05-31 22:39:06.08653
NCT01346631|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-01|||2015-06-21|2011-05-02|2011-05-03|Estimate|||||||2015-06-21|2015-06-23|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||The Paleolithic Diet and Male Factor Infertility|The Impact of a Paleolithic Diet on Sperm Parameters for Men Suffering From Male Infertility|Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel||1||We didn't start the study|f||||||||||||||2018-05-31 22:39:06.153154|2018-05-31 22:39:06.153154
NCT01346618|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-11-03|2011-05-02|2011-05-03|Estimate|||||||2011-11-03|2011-11-04|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||The Validity of Bone Age Assessment by an Ultrasound Apparatus (SonicBone)|A Comparison of Bone Age Assessment by an Ultrasound Apparatus (SonicBone) and the X-ray Based Grulich and Pyle Method|Unknown status|Recruiting||150|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-05-31 22:39:06.211639|2018-05-31 22:39:06.211639
NCT01346605|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-30|||2012-12-08|2011-05-02|2011-05-03|Estimate|||||||2012-12-08|2012-12-11|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|RECRUIT||Registry for CARDIAC PERFUSION CT|Registry for CARDIAC PERFUSION CT|Withdrawn|||0|Actual|MDDX LLC|||1|No funding|f||||t||||||||||2018-05-31 22:39:06.287625|2018-05-31 22:39:06.287625
NCT01346592|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-30|2014-01-27|2012-11-16|2015-03-04|2011-05-02|2011-05-03|Estimate|2014-04-03|2014-05-06|Estimate|2012-11-16|2012-11-22|Estimate|2015-03-04|2015-03-26|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age|A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non-adjuvanted Trivalent Influenza Vaccine Fluzone in Children 6 to < 72 Months of Age|Completed||Phase 3|6104|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:39:06.459287|2018-05-31 22:39:06.459287
NCT01346579|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-30|||2016-07-01|2011-04-30|2011-05-03|Estimate|||||||2016-07-01|2016-07-04|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Biomarkers in Tissue Samples From Older Women With Breast Cancer|PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer|Terminated|||505|Actual|Alliance for Clinical Trials in Oncology||||Study closed prematurely.|f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 22:39:08.974248|2018-05-31 22:39:08.974248
NCT01346566|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-30|||2011-05-18|2011-05-02|2011-05-03|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Prospective Study of Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses|Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses: A Prospective Case Series|Completed||Phase 3|33|Actual|Iladevi Cataract and IOL Research Center|||||f||||t||||||||||2018-05-31 22:39:09.089844|2018-05-31 22:39:09.089844
NCT01346553|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-30|||2011-05-02|2011-05-02|2011-05-03|Estimate|||||||2011-05-02|2011-05-03|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Interventional|||Safety and Efficacy of the External Synchronized Vein Valve (ESVV) in Treatment of Chronic Venous Insufficiency (CVI)|Safety and Primary Efficacy of the External Synchronized Vein Valve (ESVV) in Treatment of Chronic Venous Insufficiency (CVI) Sequel - A Pilot Study|Unknown status|Not yet recruiting|N/A|15|Anticipated|GB-Veintech||1|||f||||f||||||||||2018-05-31 22:39:09.162697|2018-05-31 22:39:09.162697
NCT01346540|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2017-06-29|2011-05-02|2011-05-03|Estimate|||||||2017-06-29|2017-07-02|Actual|April 14, 2011|Actual|2011-04-14|June 2017|2017-06-30|January 17, 2017|Actual|2017-01-17|April 25, 2013|Actual|2013-04-25||Interventional|||A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.|LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:39:09.23566|2018-05-31 22:39:09.23566
NCT01346527|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2018-05-03|2011-05-02|2011-05-03|Estimate|||||||2018-05-03|2018-05-10|Estimate|April 2011||2011-04-30|May 2018|2018-05-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Observational|||Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes|Maternal Lipid Metabolism and Neonatal Heart Function in Diabetes|Completed|||79|Actual|Washington University School of Medicine|||3||f||||t||||||Samples Without DNA|"~     Maternal and umbilical cord serum~   "|||2018-05-31 22:39:09.313711|2018-05-31 22:39:09.313711
NCT01346514|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2016-10-31||2017-01-09|2011-04-29|2011-05-03|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|October 2011||2011-10-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|AHCM|Participants were eligible to participate if they 1) were homeless (i.e. on the streets, in emergency shelter or doubled up without paying rent) ; 2) initiated a new substance use treatment episode within 30 days; and 3) intended to reside locally for one year.|Addiction Housing Case Management for Homeless Veterans|Addiction Housing Case Management for Homeless Veterans Enrolled in Addictions Treatment|Completed||N/A|181|Actual|VA Office of Research and Development|Study limitations include lower than expected recruitment, conducted at a single VA facility, research staff members were not blinded to study condition after baseline, high attrition rates.|2|||f||||t||||||||Undecided||2018-05-31 22:39:09.39157|2018-05-31 22:39:09.39157
NCT01346501|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2015-11-25||2016-02-15|2011-05-02|2011-05-03|Estimate|2016-02-15|2016-03-11|Estimate||||2016-02-15|2016-03-11|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069|An Extended Observational Study (P12-707: HOPEFUL III Study) of Follow-up Survey (P12-069: HOPEFUL II Study) of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)|Completed|||172|Actual|AbbVie|||2||f||||||||||||||2018-05-31 22:39:09.975772|2018-05-31 22:39:09.975772
NCT01346488|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2017-01-12||2017-03-16|2011-05-02|2011-05-03|Estimate|2017-01-12|2017-03-03|Actual||||2017-03-16|2017-04-13|Actual|June 2011||2011-06-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational||Safety Analysis Set (all evaluable participant CRFs)|Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)|The Documentation of the Effects on Quality of Life (QOL) and Working Productivity and Activity Impairment (WPAI) in Patients With Rheumatoid Arthritis (RA) Under HUMIRA® (Adalimumab) in Routine Clinical Practice|Completed|||2088|Actual|AbbVie|||1||f||||||||||||||2018-05-31 22:39:10.426171|2018-05-31 22:39:10.426171
NCT01346475|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2012-03-23||2017-03-06|2011-04-29|2011-05-03|Estimate|2017-03-06|2017-03-09|Actual||||2017-03-06|2017-03-09|Actual|November 2008||2008-11-30|March 2017|2017-03-31|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|||Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2|A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults|Completed||Phase 4|50|Actual|University of Washington|This trial was performed at a single site and enrolled healthy, mostly white adults with frequent genital herpes outbreaks. Whether these finding are generalizable to other populations is unknown.|2|||f||||f||||||||||2018-05-31 22:39:11.345325|2018-05-31 22:39:11.345325
NCT01346462|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2014-04-30|2011-05-02|2011-05-03|Estimate|||||||2014-04-30|2014-05-01|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PaCT||IMPaCT (Individualized Management Towards Patient-Centered Targets)|A Randomized Controlled Trial of a Novel Community Health Worker Care Transitions Intervention.|Completed||N/A|513|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:39:11.690368|2018-05-31 22:39:11.690368
NCT01346449|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-04-11|2011-05-02|2011-05-03|Estimate|||||||2017-04-11|2017-04-13|Actual|January 2011||2011-01-31|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Making Calories Count: Information Format and Food Choice|Making Calories Count: Information Format and Food Choice|Completed||N/A|292|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 22:39:11.756551|2018-05-31 22:39:11.756551
NCT01346436|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2017-05-04|2011-04-29|2011-05-03|Estimate|||||||2017-05-04|2017-05-05|Actual|April 2011||2011-04-30|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Value of Robotic Rectopexy for the Treatment of Complex Pelvic Floor Dysfunction|Randomized Double Blind Controlled Trial of the Value of Robotic Rectopexy for the Treatment of Complex Pelvic Floor Dysfunction|Recruiting||Phase 4|50|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 22:39:11.83168|2018-05-31 22:39:11.83168
NCT01346423|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2016-08-02|2011-05-02|2011-05-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Interdisciplinary Intervention Versus Brief Intervention for Patients With Musculoskeletal Pain|Is Interdisciplinary Intervention for Patients Sicklisted With Musculoskeletal Pain More Effective in Helping Patients Back to Work Than Than The Less Resource Demanding Brief Intervention Method?|Completed||N/A|284|Actual|Sykehuset Innlandet HF||2|||f||||t||||||||No||2018-05-31 22:39:11.91107|2018-05-31 22:39:11.91107
NCT01346410|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2018-01-24||2018-02-20|2011-04-29|2011-05-03|Estimate|2018-02-20|2018-02-21|Estimate||||2018-02-20|2018-02-21|Estimate|September 2008||2008-09-30|February 2018|2018-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer|Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Unresectable Pancreatic Cancer|Completed||N/A|1|Actual|Mercy Research||1|||f||||f||||||||||2018-05-31 22:39:11.991058|2018-05-31 22:39:11.991058
NCT01346397|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2016-10-04||2016-10-04|2011-05-02|2011-05-03|Estimate|2016-10-04|2016-11-29|Estimate||||2016-10-04|2016-11-29|Estimate|April 2009||2009-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2013|Actual|2013-05-31|10 Years|Observational [Patient Registry]|RSCS-Campath||Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation|Prospective Randomized Trial Comparing CsA Versus Tacro After Campath Induction In Kidney Transplant Recipients|Completed|||170|Actual|Russian Academy of Medical Sciences|||2||f||||f||||||Samples With DNA|"~     blood and urine, taken at the time of protocol or case biopsies will be deeply freeze and~     stocked for future examination for NAT or other molecules - candidates for diagnostic~     markers.~   "|||2018-05-31 22:39:12.109828|2018-05-31 22:39:12.109828
NCT01346384|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-05-03|2011-05-02|2011-05-03|Estimate|||||||2011-05-03|2011-05-05|Estimate|May 2008||2008-05-31|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Time - Related Cuff Pressure and Volume of the Laryngeal Tube With the Use of Nitrous Oxide|Time - Related Cuff Pressure and Volume of the Laryngeal Tube With the Use of Nitrous Oxide|Completed|||75|Actual|Prince of Songkla University|||1||f||||t||||||||||2018-05-31 22:39:12.307123|2018-05-31 22:39:12.307123
NCT01346371|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2012-08-07|2011-05-02|2011-05-03|Estimate|||||||2012-08-07|2012-08-08|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer|The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer|Unknown status|Active, not recruiting|Phase 4|40|Actual|Minnesota Eye Consultants, P.A.||2|||f||||t||||||||||2018-05-31 22:39:12.37009|2018-05-31 22:39:12.37009
NCT01346358|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2017-11-15|2011-04-29|2011-05-03|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2011||2011-06-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of IMC-CS4 in Subjects With Advanced Solid Tumors|Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available|Active, not recruiting||Phase 1|72|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:39:12.451851|2018-05-31 22:39:12.451851
NCT01346345|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-05-02|2011-05-02|2011-05-03|Estimate|||||||2011-05-02|2011-05-03|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Observational|||Aesthetic Evaluation of Two Piece 3mm Implants for Single Tooth Replacement of Maxillary Laterals and Mandibular Incisors|Aesthetic Evaluation of Two Piece 3mm Implants for Single Tooth Replacement of Maxillary Laterals and Mandibular Incisors|Unknown status|Enrolling by invitation||60|Anticipated|Dr.Suzanne Caudry Implant Dentistry and Periodontics|||||f||||t||||||||||2018-05-31 22:39:12.525592|2018-05-31 22:39:12.525592
NCT01346319|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-11-01|2011-05-02|2011-05-03|Estimate|||||||2011-11-01|2011-11-03|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.|A Randomized Double-Blind, Placebo-controlled Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Testosterone Undecanoate (ABT-SLV361) in Hypogonadal Males|Completed||Phase 1|0|Actual|Abbott||2|||f||||f||||||||||2018-05-31 22:39:12.767559|2018-05-31 22:39:12.767559
NCT01346306|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2018-03-25|2011-04-29|2011-05-02|Estimate|||||||2018-03-25|2018-03-27|Actual|April 2011||2011-04-30|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Trial of Transcranial Direct Current Stimulation (tDCS)|Investigating Direct Current Stimulation as a Treatment for Depression: A Controlled Clinical Trial|Recruiting||N/A|120|Anticipated|The University of New South Wales||2|||f||||t||||||||||2018-05-31 22:39:12.860141|2018-05-31 22:39:12.860141
NCT01346293|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2015-04-23|2013-11-18|2015-05-28|2011-04-29|2011-05-02|Estimate|2015-05-27|2015-05-29|Estimate|2013-11-18|2013-12-12|Estimate|2015-05-28|2015-06-03|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|||Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age|Safety and Immunogenicity of DTap-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined With Inactivated Poliovirus Vaccine) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age|Completed||Phase 3|3372|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 22:39:12.966481|2018-05-31 22:39:12.966481
NCT01346280|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2018-05-24|2011-04-29|2011-05-02|Estimate|||||||2018-05-24|2018-05-25|Actual|April 16, 2011||2011-04-16|October 5, 2015|2015-10-05|October 5, 2015||2015-10-05|||||Observational|||Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs|Quality of Care: The Impact of Multidisciplinary Care on Processes and Outcomes of Cancer Care|Completed|||1079|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:39:13.769471|2018-05-31 22:39:13.769471
NCT01346267|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2017-10-25|2011-04-29|2011-05-02|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2011||2011-05-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SCUSF1202||Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy|Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy|Completed||Phase 3|187|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 22:39:13.836973|2018-05-31 22:39:13.836973
NCT01346254|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-12-02|2011-04-29|2011-05-02|Estimate|||||||2011-12-02|2011-12-05|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|GCPD||Glucose Control in Pre-Diabetic Renal Transplant Patients|Glucose Control in Pre-Diabetic Renal Transplant Patients: Efficacy and Safety of Vildagliptin and Pioglitazone|Completed||Phase 2|51|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 22:39:14.008171|2018-05-31 22:39:14.008171
NCT01346241|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Improving Access To Services to Community Based Outpatient Clinics (CBOC's)|Improving Access To Services With An Intensive Two-Day Treatment For Panic|Unknown status|Recruiting|N/A|50|Anticipated|Michael Debakey Veterans Affairs Medical Center|||||f||||f||||||||||2018-05-31 22:39:14.106982|2018-05-31 22:39:14.106982
NCT01346228|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Using Smart Phone Technology To Rural Veterans|USING SMART PHONE TECHNOLOGY AS A PLATFORM FOR DELIVERING MENTAL HEALTH CARE TO RURAL VETERANS|Unknown status|Not yet recruiting|N/A|15|Anticipated|Michael Debakey Veterans Affairs Medical Center|||||f||||f||||||||||2018-05-31 22:39:14.201161|2018-05-31 22:39:14.201161
NCT01346215|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|October 2011||2011-10-31|April 2011|2011-04-30|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure|Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure|Unknown status|Not yet recruiting|Phase 3|132|Anticipated|Laboratório Químico Farmacêutico Bergamo Ltda.||2|||f||||t||||||||||2018-05-31 22:39:14.293186|2018-05-31 22:39:14.293186
NCT01346202|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-07-12|2011-04-29|2011-05-02|Estimate|||||||2013-07-12|2013-07-15|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|IMPERApain||Effects of Multimodal Pain Therapy in Patients With Mixed Chronic Pain Syndromes|Influence of a Multimodal Day-unit Pain Therapy on Pain Experience, Pain-related Disability and Depression in Patients With Chronic Pain Syndromes|Completed|||260|Actual|Klinikum St. Georg gGmbH|||1||f||||f||||||||||2018-05-31 22:39:14.452057|2018-05-31 22:39:14.452057
NCT01346189|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2017-09-21||2017-10-31|2011-04-29|2011-05-02|Estimate|2017-10-31|2017-12-06|Actual||||2017-10-31|2017-12-06|Actual|September 2011||2011-09-30|October 2017|2017-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Trial of Behavioral Economic Interventions to Reduce Cardiovascular Disease (CVD) Risk|A Randomized Trial of Behavioral Economic Interventions to Reduce CVD Risk|Completed||N/A|1503|Actual|University of Pennsylvania|Patients in the control group received electronic pill bottles and may have been more adherent than is typical; Mean of about 6 patients per physician enrolled, limiting total size of potential reward; Adherence info came from pill bottle opening|4|||f||||t||||||||||2018-05-31 22:39:14.617317|2018-05-31 22:39:14.617317
NCT01346176|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2012-12-21||2016-01-04|2011-04-29|2011-05-02|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||The Influence of Default Options in Advance Directives|The Influence of Default Options in Advance Directives for Older Patients: A Pilot Study|Completed||N/A|132|Actual|University of Pennsylvania|"This is a small sample from a single health system~Limited to patients with serious thoracic diseases~We did not randomly assign the ordering of options within the standard advance directive"|3|||f||||t||||||||||2018-05-31 22:39:15.849606|2018-05-31 22:39:15.849606
NCT01346163|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Add On Treatment for Cognitive Deficits in Schizophrenia|A Phase1B Study: A Placebo Controlled Study of PF-03654746 Given as Add-On Treatment of Cognitive Deficits in Schizophrenia|Completed||Phase 1|16|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:39:16.813234|2018-05-31 22:39:16.813234
NCT01346150|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2017-11-07|2011-04-29|2011-05-02|Estimate|||||||2017-11-07|2017-11-09|Actual|May 2011||2011-05-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Patients Treated for SCID (1968-Present)|A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902)|Recruiting|||1146|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||f||||||Samples With DNA|"~     Biospecimens may include blood, other tissues (e.g., buccal swab or brushing), and/or bone~     marrow.~   "|||2018-05-31 22:39:16.948564|2018-05-31 22:39:16.948564
NCT01346137|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-05-02|2011-04-29|2011-05-02|Estimate|||||||2011-05-02|2011-05-03|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|September 2011|Anticipated|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Study of a COX-2 Inhibitor for Prevention of Ovulation|An Exploratory Study of a COX-2 Inhibitor(Meloxicam) for Prevention of Ovulation|Unknown status|Recruiting|Phase 2|56|Anticipated|Instituto Chileno de Medicina Reproductiva||1|||f||||t||||||||||2018-05-31 22:39:17.284788|2018-05-31 22:39:17.284788
NCT01346124|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2018-05-11|2011-04-29|2011-05-02|Estimate|||||||2018-05-11|2018-05-15|Actual|December 2012||2012-12-31|May 2018|2018-05-31|March 2032|Anticipated|2032-03-31|March 20, 2022|Anticipated|2022-03-20||Interventional|||High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull|Phase II Study of High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull|Active, not recruiting||N/A|64|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:39:17.509784|2018-05-31 22:39:17.509784
NCT01346111|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2015-03-19|2011-04-29|2011-05-02|Estimate|||||||2015-03-19|2015-03-20|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|||Multicenter Study of Generation Comorbidity Score|Multicenter Study for the Generation of a Score of Comorbidities|Completed|||2640|Actual|Hospital Italiano de Buenos Aires|||1||f||||f||||||||||2018-05-31 22:39:17.610279|2018-05-31 22:39:17.610279
NCT01346098|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2018-02-07|2011-04-29|2011-05-02|Estimate|||||||2018-02-07|2018-02-09|Actual|July 2010||2010-07-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|PAN-IT||Islet Autotransplantation in Patients at Very High-risk Pancreatic Anastomosis|Total Pancreatectomy With Islet Autotransplantation as a Superior Alternative to Pancreatoduodenectomy in Patients at Very High-risk of Complications of the Pancreatic Anastomosis: a Single-center Prospective Randomised Clinical Trial|Recruiting||Phase 2|60|Anticipated|Ospedale San Raffaele||2|||f||||t||||||||||2018-05-31 22:39:17.671165|2018-05-31 22:39:17.671165
NCT01346085|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2014-04-09||2014-04-09|2011-04-29|2011-05-02|Estimate|2014-04-09|2014-05-09|Estimate||||2014-04-09|2014-05-09|Estimate|October 2006||2006-10-31|April 2014|2014-04-30|June 2012|Actual|2012-06-30|June 2009|Actual|2009-06-30||Interventional|ECIT-1||Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation|A Multi-step Trial Towards Single Donor Islet Transplantation in Type 1 Diabetic Patients, Using Calcineurin Inhibitor-free Immunosuppression|Completed||Phase 1/Phase 2|10|Actual|Ospedale San Raffaele||1|||f||||t||||||||||2018-05-31 22:39:17.799457|2018-05-31 22:39:17.799457
NCT01346072|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2017-02-24||2017-04-11|2011-04-29|2011-05-02|Estimate|2017-04-11|2017-05-17|Actual||||2017-04-11|2017-05-17|Actual|April 2011||2011-04-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional||All patients in Low Copeptin group were included in analysis. One patient in High Copeptin group had reduced renal function at baseline versus screening and transient hypovolemia during hospitalization indicative of volume depletion. This patient was excluded prior to review of blinded copeptin results and study data analysis for a final N of 20.|Pilot Study of Using Copeptin to Predict Response to Tolvaptan|Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure|Completed||Phase 4|21|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 22:39:17.982278|2018-05-31 22:39:17.982278
NCT01346059|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2016-12-13||2017-02-08|2011-04-29|2011-05-02|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|April 2011||2011-04-30|December 2016|2016-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Intracolonic Vancomycin Therapy in Severe C. Diff Colitis|Intracolonic Vancomycin Therapy in Severe C. Diff Colitis: A Double Blinded Randomized Prospective Trial|Terminated||N/A|2|Actual|William Beaumont Hospitals|Early termination leading to small numbers of subjects analyzed. Technical problems with catheters becoming dislodged from the ideal site of placement (cecum) leading to unreliable data.|2||Technical issues with catheter placement; researcher left institution|f||||t||||||||No||2018-05-31 22:39:18.325545|2018-05-31 22:39:18.325545
NCT01346046|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2012-12-03|2011-04-29|2011-05-02|Estimate|||||||2012-12-03|2012-12-05|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|TCOYD2||Evaluation of SCOUT DS in Subjects With Type 2 Diabetes #2|An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at the TCOYD Diabetes Conference|Completed|||264|Anticipated|VeraLight, Inc.|||2||f||||f||||||||||2018-05-31 22:39:18.524904|2018-05-31 22:39:18.524904
NCT01346033|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2012-12-03|2011-04-29|2011-05-02|Estimate|||||||2012-12-03|2012-12-04|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|TCOYD||Evaluation of SCOUT DS in Subjects With Type 2 Diabetes|An Evaluation of a Non-invasive Diabetes Screening Device in Subjects With Type 2 Diabetes|Completed|||270|Actual|VeraLight, Inc.|||1||f||||f||||||||||2018-05-31 22:39:18.579608|2018-05-31 22:39:18.579608
NCT01346020|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|April 2010||2010-04-30|April 2011|2011-04-30||||||||Observational|||Genomic Analysis of Patients With Chronic Lymphocytic Leukemia|Genomic Analysis of Patients With Chronic Lymphocytic Leukemia|Unknown status|Active, not recruiting||53|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||||||||||||2018-05-31 22:39:18.633271|2018-05-31 22:39:18.633271
NCT01346007|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|June 2011|Anticipated|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome|Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|National and Kapodistrian University of Athens||2|||f||||f||||||||||2018-05-31 22:39:19.730292|2018-05-31 22:39:19.730292
NCT01345994|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Brain Plasticity in Carpal Tunnel Syndrome and Its Response to Acupuncture||Unknown status|Recruiting|Early Phase 1|||Martinos Center for Biomedical Imaging||2|||f||||t||||||||||2018-05-31 22:39:20.155874|2018-05-31 22:39:20.155874
NCT01345981|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Comparison of Pain Severity on Injection of MCT/LCT Propofol Between Lidocaine 20 mg, 40 mg, and Without Lidocaine.|A Comparison of Pain Severity on Injection of MCT/LCT Propofol Between Lidocaine 20 mg, 40 mg, and Without Lidocaine.|Completed||N/A|210|Actual|Prince of Songkla University||3|||f||||t||||||||||2018-05-31 22:39:20.25941|2018-05-31 22:39:20.25941
NCT01345968|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2013-08-07|2011-04-29|2011-05-02|Estimate|||||||2013-08-07|2013-08-09|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|PRIVIRON||Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery|Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients With Orthopedic Surgery and High Risk of Blood Loss|Terminated||Phase 4|3|Actual|University Hospital Muenster||2||Less patients than expected for inclusion, therefore recruitment is too low|f||||f||||||||||2018-05-31 22:39:20.40166|2018-05-31 22:39:20.40166
NCT01345942|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2016-11-01|2011-04-29|2011-05-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study on the Effect of Food on the Pharmacokinetics of RO5428029 in Healthy Volunteers|A Randomized, Open Label, Single Dose, Two Period, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of RO5428029 Following Oral Administration in Healthy Subjects|Completed||Phase 1|12|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:39:20.522365|2018-05-31 22:39:20.522365
NCT01345929|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2015-01-09||2017-03-29|2011-04-29|2011-05-02|Estimate|2015-01-09|2015-01-15|Estimate||||2017-03-29|2017-05-01|Actual|June 1, 2011|Actual|2011-06-01|March 2017|2017-03-31|September 1, 2013|Actual|2013-09-01|August 1, 2013|Actual|2013-08-01||Interventional|||Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis|A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis|Completed||Phase 3|558|Actual|Cubist Pharmaceuticals LLC|Two identical P3 protocols were initiated (NCT01345929 and NCT01345955) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.|2|||f||||f||||||||||2018-05-31 22:39:20.699572|2018-05-31 22:39:20.699572
NCT01345916|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2017-03-28|2011-04-29|2011-05-02|Estimate|||||||2017-03-28|2017-03-30|Actual|March 2011||2011-03-31|March 2017|2017-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Neptune||Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients|A Phase 3,8-week Clinical Trial to Test the Efficacy of CHF1535 Via NEXT DPI® Versus Same Dose of CHF1535 pMDI and Beclomethasone DPI 100µg on PEF in Adult Asthmatic Patients After 1 Month of Treatment With FOSTER®|Completed||Phase 3|932|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 22:39:21.334994|2018-05-31 22:39:21.334994
NCT01345903|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2012-11-08|2011-04-29|2011-05-02|Estimate|||||||2012-11-08|2012-11-09|Estimate|December 2012||2012-12-31|November 2012|2012-11-30||||June 2013|Anticipated|2013-06-30||Interventional|||Robotic-Assisted Surgery in Treating Patients With Spine Tumors|A Pilot Feasibility and Safety Study Using Robotic Assisted Surgery in Patients With Spine Tumors|Withdrawn||N/A|0|Actual|City of Hope Medical Center||1||The protocol needs to be re-designed.|f||||t||||||||||2018-05-31 22:39:21.468012|2018-05-31 22:39:21.468012
NCT01345890|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-06-17|2011-04-29|2011-05-02|Estimate|||||||2013-06-17|2013-06-18|Estimate|January 2007||2007-01-31|June 2013|2013-06-30|June 2010|Actual|2010-06-30|June 2008|Actual|2008-06-30||Interventional|||Cortical Neuromodulation in Post Stroke Dysphagia|Neuromodulation in Post Stroke Dysphagia|Completed||N/A|20|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 22:39:21.540256|2018-05-31 22:39:21.540256
NCT01345877|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2016-11-23|2011-04-29|2011-05-02|Estimate|||||||2016-11-23|2016-11-28|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|February 2011|Actual|2011-02-28|July 2010|Actual|2010-07-31||Interventional|PASORI||Pain Sensitivity in Acute Inflammatory Pain|Pain Sensitivity in Acute Inflammatory Pain - Gender Differences and Validity of Sensory Tests|Completed||N/A|100|Actual|University of Copenhagen||1|||f||||t||||||||||2018-05-31 22:39:21.657654|2018-05-31 22:39:21.657654
NCT01345864|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-11-16|2011-04-28|2011-05-02|Estimate|||||||2011-11-16|2011-11-17|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults|A Randomized, Double-Blind, Sponsor Unblinded, Placebo- And Positive- Controlled Study To Evaluate The Effects Of Single Oral Administrations Of PF-04995274, Alone Or In Combination With Donepezil, On Scopolamine-Induced Deficits In Psychomotor And Cognitive Function In Healthy Adults|Terminated||Phase 1|88|Actual|Pfizer||1||See termination reason in detailed description.|f||||f||||||||||2018-05-31 22:39:21.819437|2018-05-31 22:39:21.819437
NCT01345851|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2017-06-12|2011-04-29|2011-05-02|Estimate|||||||2017-06-12|2017-06-14|Actual|March 23, 2011|Actual|2011-03-23|September 2016|2016-09-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer|Recruiting||N/A|45|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:39:21.919707|2018-05-31 22:39:21.919707
NCT01345838|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2013-08-15|2011-04-29|2011-05-02|Estimate|||||||2013-08-15|2013-08-16|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Acetabular Labral Tear in Dysplastic Hips||Unknown status|Active, not recruiting||104|Actual|University of Aarhus|||1||f||||t||||||||||2018-05-31 22:39:22.008273|2018-05-31 22:39:22.008273
NCT01345825|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2015-05-13|2011-04-29|2011-05-02|Estimate|||||||2015-05-13|2015-05-14|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|June 2013|Actual|2013-06-30||Interventional|||Early Progressive Strength Training to Patients With Unicompartmental Knee Replacement|A Randomized Controlled Trial: The Effectiveness of 8-weeks Progressive Strength Training to Patients With Unicompartmental Knee Replacement, Initiated Within the First Postoperative Week|Completed||Phase 3|57|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 22:39:22.063326|2018-05-31 22:39:22.063326
NCT01345812|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2012-09-13|2011-04-29|2011-05-02|Estimate|||||||2012-09-13|2012-09-14|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Time-lapse Evaluation of Embryo Development After Stimulation With One of Two Different Gonadotrophins.|Time-lapse Assessed Evaluation of Embryo Development After Stimulation With Either Recombinant Follicle Stimulating Hormone (FSH) or Urine-derived Follicle Stimulating Hormone (FSH).|Terminated||Phase 4|291|Actual|University of Aarhus||2||Lack of patients for recruitment|f||||f||||||||||2018-05-31 22:39:22.242493|2018-05-31 22:39:22.242493
NCT01345799|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2014-06-11|2011-04-29|2011-05-02|Estimate|||||||2014-06-11|2014-06-12|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|||||Interventional|||A Study of TRK-170 for the Treatment of Crohn's Disease|A Two Part, Multi-Centre, Randomized, Placebo-Controlled, Double-Blind Study of TRK-170 for the Treatment of Crohn's Disease|Completed||Phase 2|123|Actual|Toray Industries, Inc||4|||f||||f||||||||||2018-05-31 22:39:22.345823|2018-05-31 22:39:22.345823
NCT01345786|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2011-07-28||2015-08-26|2011-04-29|2011-05-02|Estimate|2011-07-28|2011-08-29|Estimate||||2015-08-26|2015-08-27|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)|A 2-part, Cross-over Trial of NOMAC-E2 to Assess Bioequivalence Between the Phase 3 Pivotal Clinical Batches and a Batch Prepared Using the Commercial Drug Manufacturing Process|Completed||Phase 1|158|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-05-31 22:39:22.5023|2018-05-31 22:39:22.5023
NCT01345773|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2011-11-16|2011-04-29|2011-05-02|Estimate|||||||2011-11-16|2011-11-17|Estimate|May 2010||2010-05-31|November 2011|2011-11-30||||September 2011|Actual|2011-09-30||Observational|||Incidence of Venous Thromboembolism Following Surgery in Patients With Gastric Cancer|Incidence of Venous Thromboembolism Following Surgery in Patients With Gastric Cancer; a Prospective Study|Completed|||375|Actual|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 22:39:23.150583|2018-05-31 22:39:23.150583
NCT01345760|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2012-10-15|2011-04-29|2011-05-02|Estimate|||||||2012-10-15|2012-10-16|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Expression Levels of RISC and Microprocessor Complex Components in Epithelial Skin Cancer|Expression Levels of RNA-induced Silencing Complex (RISC) Components TARBP1, TARBP2, Argonaute-1, Argonaute-2, PACT and Microprocessor Complex Component DGCR8 in Epithelial Skin Cancer|Completed|||44|Actual|Ruhr University of Bochum|||4||f||||t||||||Samples With DNA|"~     human skin~   "|||2018-05-31 22:39:23.244771|2018-05-31 22:39:23.244771
NCT01345747|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|June 2008||2008-06-30|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Laryngeal Tube Suction Versus Endotracheal Tube for Ventilation in Gynecological Laparoscopic Surgery|The Laryngeal Tube Suction vs Endotracheal Tube for Ventilation in Gynecological Laparoscopic Surgery|Completed||N/A|120|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 22:39:23.346267|2018-05-31 22:39:23.346267
NCT01345734|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2015-11-11|2011-04-29|2011-05-02|Estimate|||||||2015-11-11|2015-11-13|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|Lead-Ph||Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes|Liraglutide Effectiveness and Safety Data From Routine Clinical Practice in Philippines Study. A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes Mellitus in Philippines|Completed|||1056|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:39:23.424342|2018-05-31 22:39:23.424342
NCT01345721|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|2013-08-13|2012-02-24|2013-08-13|2011-04-29|2011-05-02|Estimate|2013-08-13|2013-10-18|Estimate|2012-02-24|2012-02-28|Estimate|2013-08-13|2013-10-18|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine|A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine|Completed||Phase 3|205|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:39:23.535021|2018-05-31 22:39:23.535021
NCT01345708|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-04-29|2011-04-29|2011-05-02|Estimate|||||||2011-04-29|2011-05-02|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia|A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia|Completed||Phase 2|23|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||t||||||||||2018-05-31 22:39:24.121124|2018-05-31 22:39:24.121124
NCT01345695|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2015-12-14|2011-04-29|2011-05-02|Estimate|||||||2015-12-14|2015-12-16|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Observational|BEST||Bihar Evaluation of Social Franchising and Telemedicine|Bihar Evaluation of Social Franchising and Telemedicine in India|Completed|||106380|Anticipated|Duke University|||2||f||||f||||||||||2018-05-31 22:39:24.188996|2018-05-31 22:39:24.188996
NCT01345682|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2015-03-13||2018-01-19|2011-04-29|2011-05-02|Estimate|2015-04-10|2015-04-14|Estimate||||2018-01-19|2018-02-15|Actual|January 5, 2012|Actual|2012-01-05|January 2018|2018-01-31|December 6, 2016|Actual|2016-12-06|March 15, 2014|Actual|2014-03-15||Interventional||The randomised set (RS) included all patients who were randomised to receive treatment, whether treated or not|LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy|A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy|Completed||Phase 3|483|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:39:24.312483|2018-05-31 22:39:24.312483
NCT01345669|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2017-08-17||2017-11-03|2011-04-29|2011-05-02|Estimate|2017-09-21|2017-10-23|Actual||||2017-11-03|2017-12-07|Actual|October 17, 2011|Actual|2011-10-17|November 2017|2017-11-30|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional||Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)|LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy|A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma|Terminated||Phase 3|617|Actual|Boehringer Ingelheim|The trial was stopped prematurely due to futility.|2|||f||||||||||||||2018-05-31 22:39:25.472856|2018-05-31 22:39:25.472856
NCT01345656|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-29|||2016-04-07|2011-04-29|2011-05-02|Estimate|||||||2016-04-07|2016-04-08|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|ARTS||BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease|A Randomized, Double-blind, Multi-center Study to Assess Safety and Tolerability of Different Oral Doses of BAY94-8862 in Subjects With Stable Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease Versus Placebo (Part A) or Versus Placebo and Spironolactone (Part B)|Completed||Phase 2|458|Actual|Bayer||6|||f||||t||||||||||2018-05-31 22:39:26.47731|2018-05-31 22:39:26.47731
NCT01345643|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2013-04-05|2011-04-29|2011-05-02|Estimate|||||||2013-04-05|2013-04-08|Estimate|February 2011||2011-02-28|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|WCPTS||Clinical Trial of West-China Perioperative Transfusion Score (WCPTS）for Massive Hemorrhagic Surgery|A Randomized Controlled Clinical Trial of Transfusion Under the Guidance of West-China Perioperative Transfusion Score(WCPTS）for Massive Hemorrhagic Surgery|Unknown status|Recruiting|Phase 3|120|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 22:39:26.637841|2018-05-31 22:39:26.637841
NCT01345630|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2014-08-14||2015-12-11|2011-04-28|2011-05-02|Estimate|2015-12-11|2016-01-14|Estimate||||2015-12-11|2016-01-14|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|MODERN||Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1|A Multicenter, Randomized, Double‑Blind, Comparative Trial Of Maraviroc + Darunavir/Ritonavir Versus Emtricitabine/Tenofovir + Darunavir/Ritonavir For The Treatment Of Antiretroviral‑Naive Hiv‑Infected Patients With Ccr5‑Tropic Hiv‑1|Terminated||Phase 3|813|Actual|ViiV Healthcare|The study was terminated following a preliminary review of the 48- week primary clinical efficacy data by the study’s external independent Data Monitoring Committee’s recommendation based on inferior efficacy of the investigational MVC+DRV/r arm.|2||See termination reason in detailed description.|f||||t||||||||||2018-05-31 22:39:26.810481|2018-05-31 22:39:26.810481
NCT01345617|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2013-11-14|2011-04-29|2011-05-02|Estimate|||||||2013-11-14|2013-11-18|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||A Study of Sweat Testing Using a Quantitative Patch|A Study of Sweat Testing Using a Quantitative Patch|Completed|||170|Actual|Polychrome Medical, Inc.|||2||f||||f||||||||||2018-05-31 22:39:28.066923|2018-05-31 22:39:28.066923
NCT01345604|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2016-11-10|2011-04-29|2011-05-02|Estimate|||||||2016-11-10|2016-11-15|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Intraoperative Posterior Cruciate Ligament (Transcruciate) Injection After Total Knee Arthroplasty (TKA)|Reducing Posterior Knee Pain Following Total Knee Arthroplasty Using an Intraoperative Posterior Cruciate Ligament (Transcruciate) Injection|Completed||Phase 4|50|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 22:39:28.12964|2018-05-31 22:39:28.12964
NCT01345591|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2016-11-14||2017-06-09|2011-04-28|2011-05-02|Estimate|2017-05-10|2017-05-12|Actual||||2017-06-09|2017-07-11|Actual|September 2009||2009-09-30|June 2017|2017-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|BTI||A Study to Evaluate the Results of Facial Soft Tissue Reconstruction in Patients Who Have Suffered Traumatic Injury|Structural Fat Grafting for Craniofacial Trauma|Completed||N/A|20|Actual|University of Pittsburgh||1|||f||||t||||||||Yes|It is the Principal Investigator's intention to make stored samples and subject information de-identified available to secondary investigators (investigators not listed on the front page of this consent document) after all research study testing has been completed. These stored samples and associated subject information will not include subject identifiers.|2018-05-31 22:39:28.197883|2018-05-31 22:39:28.197883
NCT01345578|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-01-17|2011-04-28|2011-05-02|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2011||2011-03-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Hepatocyte Transplantation for Liver Based Metabolic Disorders|Hepatocyte Transplantation for Liver Based Metabolic Disorders|Suspended||Phase 1|10|Anticipated|University of Pittsburgh||1||seeking additional funding|f||||t|t|f||||||Undecided||2018-05-31 22:39:28.371232|2018-05-31 22:39:28.371232
NCT01345565|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-01-17|2011-04-28|2011-05-02|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2011||2011-03-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Hepatocyte Transplantation for Acute Decompensated Liver Failure|Hepatocyte Transplantation for Acute Decompensated Liver Failure|Suspended||Phase 1|15|Anticipated|University of Pittsburgh||1||seeking additional funding|f||||t||||||||Undecided||2018-05-31 22:39:28.4489|2018-05-31 22:39:28.4489
NCT01345552|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2018-01-25|2011-04-28|2011-05-02|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2011||2011-06-30|January 2018|2018-01-31|February 2024|Anticipated|2024-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Radiosurgery for Patients Recurrent Oligometastatic Disease|Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease (UPCI# 10-028)|Recruiting||Phase 2|44|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:39:28.524994|2018-05-31 22:39:28.524994
NCT01345539|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2018-01-25|2011-04-28|2011-05-02|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2011||2011-06-30|January 2018|2018-01-31|February 2024|Anticipated|2024-02-29|December 2020|Anticipated|2020-12-31||Interventional|||Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation|Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation (UPCI #10-027)|Recruiting||Phase 2|44|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:39:28.604997|2018-05-31 22:39:28.604997
NCT01345526|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-04-28|2011-04-28|2011-05-02|Estimate|||||||2011-04-28|2011-05-02|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream|A Double Blind Placebo Controlled Randomized Phase II Study Evaluating the Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream in First Line mCRC Patients Treated With Erbitux and FOLFIRI.|Unknown status|Recruiting|Phase 2|124|Anticipated|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 22:39:28.689665|2018-05-31 22:39:28.689665
NCT01345513|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-11-06|2011-04-28|2011-05-02|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2011|Actual|2011-03-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Feasibility Clinical Study of Targeted and Genome-Wide Sequencing|Feasibility Clinical Study of Targeted and Genome-Wide Sequencing|Active, not recruiting|||45|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Archival tumor tissue, fresh tumor biopsy, blood sample, pleural effusion (if available)or~     ascites (if available)~   "|||2018-05-31 22:39:28.772168|2018-05-31 22:39:28.772168
NCT01345500|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2013-11-13|2011-04-28|2011-05-02|Estimate|||||||2013-11-13|2013-11-14|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||UCSD Take Charge Study|Randomized Clinical Trial of a Weight Loss Program in Type 2 Diabetes|Completed||N/A|227|Actual|University of California, San Diego||3|||f||||t||||||||||2018-05-31 22:39:28.855194|2018-05-31 22:39:28.855194
NCT01345487|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-03-24|2011-04-28|2011-05-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|PAVA||Effect of Protein From Animal and Vegetable Sources on Appetite|Effect of Protein From Animal and Vegetable Sources on Appetite|Completed||N/A|48|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 22:39:28.916642|2018-05-31 22:39:28.916642
NCT01345461|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2017-09-27|2011-04-28|2011-05-02|Estimate|||||||2017-09-27|2017-09-29|Actual|January 2010|Actual|2010-01-31|September 2017|2017-09-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Observational|||Fatigability of the Quadriceps Muscle in Non-cooperating Subjects|Fatigability of the Quadriceps Muscle in Non-cooperating Subjects|Completed|||12|Actual|Rigshospitalet, Denmark|||1||f||||t||||||||||2018-05-31 22:39:28.971329|2018-05-31 22:39:28.971329
NCT01345448|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-04-28|2011-04-28|2011-05-02|Estimate|||||||2011-04-28|2011-05-02|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy|Study of Safety and IOP Lowering Efficacy of Transdermal Brimonidine Therapy|Unknown status|Recruiting|Phase 2|22|Anticipated|Nanduri, Padma, M.D., FACS|||||f||||f||||||||||2018-05-31 22:39:29.026239|2018-05-31 22:39:29.026239
NCT01345435|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-05-12|2011-04-29|2011-05-02|Estimate|||||||2015-05-12|2015-05-14|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|Smart-DM||Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care|A Multi-center, Randomized, Parallel, Interventional, Open Label Trial to Compare Hemoglobin A1C-lowering Effect of Conventional Treatment and Smart Care Service in Patients With Type 2 Diabetes|Completed||N/A|417|Actual|LG Electronics Inc.||3|||f||||t||||||||||2018-05-31 22:39:29.101954|2018-05-31 22:39:29.101954
NCT01345422|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-12-07|2011-04-28|2011-05-02|Estimate|||||||2015-12-07|2015-12-09|Estimate||||December 2015|2015-12-31||||||||Interventional|||Wii Balance Board in Dizziness|A Pilot Study to Assess the Usefulness of the Wii Balance Board for Dizziness|Withdrawn||N/A|0|Actual|Kaiser Permanente||1||The study never started since it did not receive IRB approval|f||||f||||||||No|this study did not receive IRB approval|2018-05-31 22:39:29.16769|2018-05-31 22:39:29.16769
NCT01345409|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2016-12-22|2011-04-29|2011-05-02|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2010||2010-12-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Observational|Relief||Acupuncture and Chiropractic Care for Chronic Pain in an Integrated Health Plan|Acupuncture and Chiropractic Care for Chronic Pain in an Integrated Health Plan|Completed|||1242|Actual|Kaiser Permanente|||||f||||f||||||||No||2018-05-31 22:39:29.281865|2018-05-31 22:39:29.281865
NCT01345396|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2013-10-11|2011-04-29|2011-05-02|Estimate|||||||2013-10-11|2013-10-14|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||Influence of an Asthma Education Programme on Asthma Control During Pregnancy|Assessment of an Educational Programme for Pregnant Asthmatic Women on the Level of Asthma Control and Unscheduled Doctor Visits During the Pregnancy|Suspended||N/A|80|Anticipated|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f||||||||||2018-05-31 22:39:29.332061|2018-05-31 22:39:29.332061
NCT01345383|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-03-09|2011-04-29|2011-05-02|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Impact of Current Smoking in the Tolerance of Bronchoscopy|Impact of Current Smoking in the Tolerance of Bronchoscopy|Terminated|||100|Actual|Centre Hospitalier Universitaire Saint Pierre|||1|the physician responsable for this protocol left our hospital|f||||f||||||||||2018-05-31 22:39:29.39068|2018-05-31 22:39:29.39068
NCT01345370|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2016-01-28|2011-04-29|2011-05-02|Estimate|||||||2016-01-28|2016-01-29|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|ECOM||Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients|Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas.|Completed|||300|Actual|Center Eugene Marquis|||1||f||||f||||||Samples With DNA|"~     Freezed or/and parffine embedded tumor samples.~   "|||2018-05-31 22:39:29.449846|2018-05-31 22:39:29.449846
NCT01345357|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2013-01-17|2011-04-28|2011-05-02|Estimate|||||||2013-01-17|2013-01-18|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma|A Dose-Escalation Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP 1 and PARP 2 Inhibitor) in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma|Completed||Phase 1|24|Actual|Teva Pharmaceutical Industries||1|||f||||t||||||||||2018-05-31 22:39:29.533537|2018-05-31 22:39:29.533537
NCT01345344|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-07-18|2011-04-28|2011-05-02|Estimate|||||||2016-07-18|2016-07-19|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Neuroimaging Effects of Cognitive Behavioral Therapy in Fibromyalgia|Neuroimaging Effects of Cognitive Behavioral Therapy in Fibromyalgia|Recruiting||N/A|200|Anticipated|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 22:39:29.599099|2018-05-31 22:39:29.599099
NCT01345331|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-04-28|2011-04-28|2011-05-02|Estimate|||||||2011-04-28|2011-05-02|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|RAVANS||Ear Electro-stimulation for Chronic Pelvic Pain|Ear Electro-stimulation for Chronic Pelvic Pain|Completed||N/A|18|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:39:29.746329|2018-05-31 22:39:29.746329
NCT01345318|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2017-01-30||2017-01-30|2011-04-28|2011-05-02|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|June 2011||2011-06-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ANDANTE II|Included all participants who received at least 1 dose of study treatment during the study B0151005|B0151005 Open-Label Extension Study|A Multicenter Open-label Extension Study For Subjects Who Participated In Study B0151003 (Andante Ii)|Completed||Phase 2|191|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 22:39:29.851259|2018-05-31 22:39:29.851259
NCT01345305|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2013-07-31|2011-04-28|2011-05-02|Estimate|||||||2013-07-31|2013-08-01|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|Pilot||Biomarker Development in Sturge-Weber Syndrome|Establishing Reliability for Quantitative EEG, Transcranial Doppler, Behavioral Outcomes and Optical Coherence Tomography in SWS: The Next Step Toward Biomarker Development|Completed|||40|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|||||f||||f||||||||||2018-05-31 22:39:30.364206|2018-05-31 22:39:30.364206
NCT01345292|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2015-05-20||2015-06-08|2011-04-28|2011-05-02|Estimate|2015-06-08|2015-06-10|Estimate||||2015-06-08|2015-06-10|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of the Relief of Tooth Sensitivity of an Experimental Mouthrinse Device|Assessment of a Potassium Oxalate-Containing Formulation for the Relief of Dentinal Hypersensitivity|Completed||N/A|226|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 22:39:30.471243|2018-05-31 22:39:30.471243
NCT01345279|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2017-05-25|2011-04-28|2011-05-02|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2009||2009-06-30|May 2017|2017-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Indirect Comparison Topotecan Cervical Carcinoma|Indirect Comparison of the Efficacy Between Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix|Completed|||1|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 22:39:30.892247|2018-05-31 22:39:30.892247
NCT01345266|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-06-21|2011-04-28|2011-05-02|Estimate|||||||2017-06-21|2017-06-22|Actual|February 1, 2010|Actual|2010-02-01|June 2017|2017-06-30|June 28, 2010|Actual|2010-06-28|June 28, 2010|Actual|2010-06-28||Interventional|||Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry|Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry|Completed||Phase 1|106|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:39:30.952066|2018-05-31 22:39:30.952066
NCT01345253|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2016-06-09||2018-02-26|2011-04-28|2011-05-02|Estimate|2016-11-17|2016-12-02|Estimate||||2018-02-26|2018-02-28|Actual|May 23, 2011|Actual|2011-05-23|February 2018|2018-02-28|September 28, 2018|Anticipated|2018-09-28|September 15, 2015|Actual|2015-09-15||Interventional|||GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia|GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia|Active, not recruiting||Phase 3|709|Actual|GlaxoSmithKline||2|||f||||f|t|f|||t|||||2018-05-31 22:39:31.043697|2018-05-31 22:39:31.043697
NCT01345240|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2013-12-19||2017-07-31|2011-04-28|2011-05-02|Estimate|2013-12-19|2014-02-10|Estimate||||2017-07-31|2017-08-30|Actual|November 1, 2011||2011-11-01|June 2017|2017-06-30|February 9, 2017|Actual|2017-02-09|January 9, 2013|Actual|2013-01-09||Interventional|||Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)|Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)|Completed||Phase 3|705|Actual|GlaxoSmithKline||11|||f||||||||||||||2018-05-31 22:39:31.696782|2018-05-31 22:39:31.696782
NCT01345227|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-03-04|2011-04-28|2011-05-02|Estimate|||||||2015-03-04|2015-03-06|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Bone Marrow as an Alternative Site for Islet Transplantation|Pilot Study to Assess Feasibility and Safety of Bone Marrow as Alternative Site in Islet Transplant Patients|Completed||N/A|8|Actual|Ospedale San Raffaele||1|||f||||t||||||||||2018-05-31 22:39:33.733193|2018-05-31 22:39:33.733193
NCT01345214|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-03-31|2011-04-28|2011-04-29|Estimate|||||||2014-03-31|2014-04-01|Estimate|May 2011||2011-05-31|March 2014|2014-03-31||||February 2014|Actual|2014-02-28||Interventional|||A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia|An Open-label, Multiple-Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia|Terminated||Phase 1|17|Actual|Ono Pharmaceutical Co. Ltd||1||The study was terminated due to slow accrual of subjects.|f||||f||||||||||2018-05-31 22:39:34.343148|2018-05-31 22:39:34.343148
NCT01345201|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-09-16|2011-04-28|2011-04-29|Estimate|||||||2016-09-16|2016-09-20|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors|Completed||Phase 1|35|Actual|OncoMed Pharmaceuticals, Inc.|||||f||||f||||||||||2018-05-31 22:39:34.467654|2018-05-31 22:39:34.467654
NCT01345188|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2014-09-24|2011-04-28|2011-04-29|Estimate|||||||2014-09-24|2014-09-25|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Ranolazine in Ischemic Cardiomyopathy|Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study|Completed||Phase 4|28|Actual|Midwest Cardiovascular Research Foundation||2|||f||||t||||||||||2018-05-31 22:39:34.570059|2018-05-31 22:39:34.570059
NCT01345175|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2018-02-23|2011-04-28|2011-04-29|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2011||2011-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer|Randomized Control Trial Comparing Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer|Active, not recruiting||Phase 3|70|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 22:39:34.761193|2018-05-31 22:39:34.761193
NCT01345162|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2014-03-17||2014-05-21|2011-04-28|2011-04-29|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PTSM04APHP|patients enrolled who completed the evaluations|Assessment and Prevention of Acute Post-herniotomy Pain|Randomized, Prospective Study of the Assessment, Prevention and Management of Acute Post-herniotomy Pain|Completed||Phase 4|200|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 22:39:34.887698|2018-05-31 22:39:34.887698
NCT01345149|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2012-09-05|2011-04-28|2011-04-29|Estimate|||||||2012-09-05|2012-09-06|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Intervention With Diet and Physical Activity in Obese Pregnant Women|Effect of Lifestyleintervention With Diet and Physical Activity in Obese Pregnant Women|Completed||N/A|420|Actual|Hvidovre University Hospital||3|||f||||t||||||||||2018-05-31 22:39:35.999113|2018-05-31 22:39:35.999113
NCT01345136|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2018-02-20|2011-04-28|2011-04-29|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 1, 2015|Actual|2015-07-01|November 2017|2017-11-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma|A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma|Active, not recruiting||Phase 2|4|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:39:36.066319|2018-05-31 22:39:36.066319
NCT01345123|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2013-03-18||2013-08-26|2011-04-28|2011-04-29|Estimate|2013-08-26|2013-10-30|Estimate||||2013-08-26|2013-10-30|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Supporting Decision Making for Musculoskeletal Preference-Sensitive Care|A Prospective, Randomized Trial to Assess the Impact of Decision Aids and Health Coaching on Health Care Costs, Surgery Rates, and Decision Quality for Individuals At Risk for Musculoskeletal Preference-Sensitive Surgical Decisions|Completed||N/A|9925|Actual|Health Dialog||3|||f||||f||||||||||2018-05-31 22:39:36.17623|2018-05-31 22:39:36.17623
NCT01345110|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2015-12-10|2011-04-28|2011-04-29|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|InveCeAb||A Longitudinal Multidimensional Population Study on Brain Aging|A Longitudinal Population Study on Brain Aging and Mental Performances for the 1935-1939 Born People Living in Abbiategrasso (a Small Town Near Milan)|Completed|||1321|Actual|Fondazione Golgi Cenci|||||f||||t||||||Samples With DNA|"~     whole blood and serum~   "|||2018-05-31 22:39:36.55788|2018-05-31 22:39:36.55788
NCT01345097|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate|May 2004||2004-05-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2006|Actual|2006-03-31||Interventional|||A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients|A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients|Completed||Phase 4|200|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 22:39:36.689811|2018-05-31 22:39:36.689811
NCT01345084|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-07-24|2011-04-28|2011-04-29|Estimate|||||||2015-07-24|2015-07-27|Estimate|November 2013||2013-11-30|August 2013|2013-08-31|November 2017|Anticipated|2017-11-30|November 2013|Anticipated|2013-11-30||Interventional|NICAP||Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab|A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||2||change company strategy|f||||f||||||||||2018-05-31 22:39:36.778209|2018-05-31 22:39:36.778209
NCT01345071|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-04-26|2011-04-28|2011-04-29|Estimate|||||||2016-04-26|2016-04-28|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|May 2025|Anticipated|2025-05-31|June 2021|Anticipated|2021-06-30||Observational|PreCARA||Preconceptional Counselling in Active Rheumatoid Arthritis|PreConceptional Counselling in Active Rheumatoid Arthritis|Recruiting|||150|Anticipated|Erasmus Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood of mother before, during and after pregnancy; cordblood of newborn; blood of newborn if~     anti-TNF in cord blood was above reference level.~   "|Undecided|This will be discussed in the research group|2018-05-31 22:39:36.874134|2018-05-31 22:39:36.874134
NCT01345058|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2017-03-15||2017-04-25|2011-04-28|2011-04-29|Estimate|2017-03-15|2017-04-25|Actual||||2017-04-25|2017-05-30|Actual|August 1, 2011|Actual|2011-08-01|April 2017|2017-04-30|October 21, 2014|Actual|2014-10-21|February 15, 2014|Actual|2014-02-15||Interventional||All participants.|Add on Lacosamide Versus High Dose Monotherapy|Open Label Trial of Add on Lacosamide Versus High Dose Monotherapy in Patients With a Seizure Disorder|Completed||Phase 3|56|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 22:39:37.006785|2018-05-31 22:39:37.006785
NCT01345045|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28||2012-10-26|2013-01-03|2011-04-28|2011-04-29|Estimate||||2012-10-26|2012-10-31|Estimate|2013-01-03|2013-01-08|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects With Diabetic Neuropathic Pain|Completed||Phase 2|193|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 22:39:37.372272|2018-05-31 22:39:37.372272
NCT01345032|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-12-30|2011-04-28|2011-04-29|Estimate|||||||2015-12-30|2015-12-31|Estimate|June 2011||2011-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Nutrition Follow up After Hospital Discharge in Undernourished Elderly|The Effect of Follow up on Nutrition Intervention After Discharge in Undernourished Geriatric Patients|Completed||N/A|208|Actual|Aarhus University Hospital||3|||f||||f||||||||||2018-05-31 22:39:37.494911|2018-05-31 22:39:37.494911
NCT01345019|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2018-01-17|2017-03-21|2018-03-05|2011-04-28|2011-04-29|Estimate|2018-03-05|2018-03-07|Actual|2017-03-21|2017-03-22|Actual|2018-03-05|2018-03-07|Actual|May 17, 2012|Actual|2012-05-17|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|July 19, 2016|Actual|2016-07-19||Interventional|||Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 3|1718|Actual|Amgen||2|||f||||t||||||||||2018-05-31 22:39:37.726443|2018-05-31 22:39:37.726443
NCT01345006|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28||2016-08-09|2017-02-20|2011-04-28|2011-04-29|Estimate||||2016-08-09|2016-08-11|Estimate|2017-02-20|2017-02-23|Actual|April 2011||2011-04-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy|A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)|Completed||Phase 1/Phase 2|13|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 22:39:40.741545|2018-05-31 22:39:40.741545
NCT01344993|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28||2016-08-17|2017-02-17|2011-04-28|2011-04-29|Estimate||||2016-08-17|2016-08-19|Estimate|2017-02-17|2017-02-20|Actual|April 2011||2011-04-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Dry AMD||Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration|A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry AMD|Completed||Phase 1/Phase 2|13|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 22:39:40.832137|2018-05-31 22:39:40.832137
NCT01344980|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate|June 2011||2011-06-30|February 2011|2011-02-28|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||The Effects of a Stainless Steel Suture MGH Flexor Tendon Repair Coupled With Early Aggressive Range of Motion Rehabilitation: a Randomized Controlled Trial|A Pilot Study of a Randomized Controlled Trial Comparing Stainless Steel Suture Repair Coupled With Aggressive Post-Operative Rehabilitation to Polypropylene Suture Paired With Active Range of Motion Rehabilitation|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 22:39:40.945054|2018-05-31 22:39:40.945054
NCT01344967|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-06-22|2011-04-28|2011-04-29|Estimate|||||||2015-06-22|2015-06-23|Estimate|February 2009||2009-02-28|June 2015|2015-06-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|SuBDuE||Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect||Completed||Phase 2/Phase 3|21|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-05-31 22:39:41.05673|2018-05-31 22:39:41.05673
NCT01344954|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-08-22|2011-04-28|2011-04-29|Estimate|||||||2012-08-22|2012-08-23|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery|Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery: A Phase 2b, Multicentre, Randomised, Active-Controlled, Double Blind, Double Dummy, Parallel Group Study|Completed||Phase 2|632|Actual|ThromboGenics||3|||f||||t||||||||||2018-05-31 22:39:41.141348|2018-05-31 22:39:41.141348
NCT01344941|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-11-04|2011-04-28|2011-04-29|Estimate|||||||2015-11-04|2015-11-05|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|HIVBLD||Human Immune Responses Toward HIV-1 Envelope Antigens|Human Immune Responses Toward HIV-1 Envelope Antigens|Completed|||8|Actual|St. Jude Children's Research Hospital|||3||f||||f||||||Samples Without DNA|"~     Maximally, there will be up to 30 draws per study participant with no more than 120 ml of~     blood collected at any one time and no more than 2.5 L collected for the entire study.~     Samples will be used for continued B-cell and T-cell studies supportive of the 2 study~     objectives. The volume of blood drawn will be closely monitored and will remain below the~     defined criteria for minimal risk research.~   "|||2018-05-31 22:39:41.288066|2018-05-31 22:39:41.288066
NCT01344915|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-04-29|2011-04-28|2011-04-29|Estimate|||||||2011-04-29|2011-05-02|Estimate|December 2005||2005-12-31|January 2005|2005-01-31|June 2011|Anticipated|2011-06-30|January 2007|Actual|2007-01-31||Interventional|||Restricted vs. Free Knee Range Of Motion For Primary Traumatic Patellar Dislocation|RESTRICTED VS. FREE KNEE RANGE OF MOTION FOR PRIMARY TRAUMATIC PATELLAR DISLOCATION: A PROSPECTIVE RANDOMIZED STUDY|Unknown status|Active, not recruiting|N/A|||Tampere University Hospital||2|||f||||f||||||||||2018-05-31 22:39:41.516738|2018-05-31 22:39:41.516738
NCT01344902|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2013-10-22|2011-04-28|2011-04-29|Estimate|||||||2013-10-22|2013-10-23|Estimate|February 2009||2009-02-28|October 2013|2013-10-31||||October 2009|Actual|2009-10-31||Interventional|||An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon||Terminated||Phase 1/Phase 2|13|Actual|Photocure||1||The study was stopped due to inadequate efficacy after 13 patients were evaluated.|f||||f||||||||||2018-05-31 22:39:41.583926|2018-05-31 22:39:41.583926
NCT01344889|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-11-01|2011-04-27|2011-04-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)|Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin|Completed|||4459|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:39:41.675713|2018-05-31 22:39:41.675713
NCT01344876|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2015-04-08||2015-05-20|2011-04-28|2011-04-29|Estimate|2015-05-20|2015-06-08|Estimate||||2015-05-20|2015-06-08|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Phase I Study of OPB-51602 in Patients With Hematologic Malignancies|A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1)|Completed||Phase 1|20|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 22:39:42.250633|2018-05-31 22:39:42.250633
NCT01344863|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2016-11-01|2011-04-28|2011-04-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe|A Randomized, Open-label, 2-arm, Parallel Group, Single Dose, Multi-center Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of Trastuzumab Administered Subcutaneously as the Trastuzumab/rHuPH20 Formulation Using a Handheld Syringe or Using the Proprietary Single-use Injection Device (SID)|Completed||Phase 1|119|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:39:42.530577|2018-05-31 22:39:42.530577
NCT01344837|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-05-27|2011-04-28|2011-04-29|Estimate|||||||2015-05-27|2015-05-29|Estimate|January 2100||2100-01-31|May 2015|2015-05-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer|The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma|Not yet recruiting|||360|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 22:39:42.662633|2018-05-31 22:39:42.662633
NCT01344824|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|2017-05-02||2017-09-28|2011-04-28|2011-04-29|Estimate|2017-06-07|2017-07-11|Actual||||2017-09-28|2017-10-30|Actual|March 2010||2010-03-31|June 2017|2017-06-30|July 20, 2016|Actual|2016-07-20|May 24, 2016|Actual|2016-05-24||Interventional|||Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers|A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History|Completed||Phase 2|38|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||No||2018-05-31 22:39:42.781353|2018-05-31 22:39:42.781353
NCT01344811|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2015-05-12|2011-04-28|2011-04-29|Estimate|||||||2015-05-12|2015-05-14|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|Smart-OB||Effects of Telemonitoring Service for Obesity Care|A Randomized, Open, Parallel, Multi-center Trial to Evaluate Weight Loss Efficacy of Smart Care Service in Obese Patients With Metabolic Syndrome.|Completed||N/A|661|Actual|LG Electronics Inc.||2|||f||||t||||||||||2018-05-31 22:39:43.364007|2018-05-31 22:39:43.364007
NCT01344798|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C|Phase I Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C|Completed||Phase 1|9|Actual|Genethon||3|||f||||t||||||||||2018-05-31 22:39:43.504222|2018-05-31 22:39:43.504222
NCT01344785|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2013-10-21|2011-04-28|2011-04-29|Estimate|||||||2013-10-21|2013-10-22|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Observational|PLAIN||The Effect of Loss of Offset After Pertrochanteric Fracture Treated With a Intramedullary Nail|The Effect of Loss of Offset After Pertrochanteric Fracture Treated With a Intramedullary Nail|Completed|||100|Actual|Danderyd Hospital|||1||f||||f||||||||||2018-05-31 22:39:43.576726|2018-05-31 22:39:43.576726
NCT01344772|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2012-11-23|2011-04-28|2011-04-29|Estimate|||||||2012-11-23|2012-11-27|Estimate|February 1990||1990-02-28|November 2012|2012-11-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Total Hip Arthroplasty Compared to Internal Fixation for Displaced Intracapsular Fractures of the Femoral Neck|Total Hip Arthroplasty Compared to Internal Fixation for Displaced Intracapsular Fractures of the Femoral Neck. A Randomized, Controlled Trial With a Seventeen Year Follow-up|Completed||N/A|100|Actual|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 22:39:43.648702|2018-05-31 22:39:43.648702
NCT01344759|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2015-08-20||2018-02-12|2011-04-28|2011-04-29|Estimate|2016-01-26|2016-02-23|Estimate||||2018-02-12|2018-03-12|Actual|June 2009||2009-06-30|February 2018|2018-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea|Effect of Increasing Depth of Dexmedetomidine and Propofol Anesthesia on Upper Airway Morphology in Children With History of Obstructive Sleep Apnea|Completed||Phase 4|60|Actual|Children's Hospital Medical Center, Cincinnati|Failure to standardize mouth opening, due to stimulation of the subject during manipulation of the mouth No baseline measurements were obtained while awake Many patients had Downs syndrome so the results may not apply across all patients with OSA|2|||f||||t||||||||||2018-05-31 22:39:43.713286|2018-05-31 22:39:43.713286
NCT01344746|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-28|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate|December 2010||2010-12-31|August 2010|2010-08-31|April 2012|Anticipated|2012-04-30|November 2011|Anticipated|2011-11-30||Observational|||Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing|Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing|Unknown status|Enrolling by invitation||225|Anticipated|Beijing Children's Hospital|||2||f||||t||||||Samples With DNA|"~     blood and adenotonsillar tissue~   "|||2018-05-31 22:39:44.179383|2018-05-31 22:39:44.179383
NCT01344733|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-03-22|2011-04-28|2011-04-29|Estimate|||||||2012-03-22|2012-03-23|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|Improve||A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)|A Non - Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient Diagnosed as With Treatment Resistant Major Depressive Disorder (MDD)|Completed|||660|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:39:44.248608|2018-05-31 22:39:44.248608
NCT01344720|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Interventional|||Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain|Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain|Unknown status|Not yet recruiting|Phase 4|250|Anticipated|Azienda Sanitaria Locale 4, Teramo||2|||f||||f||||||||||2018-05-31 22:39:44.351588|2018-05-31 22:39:44.351588
NCT01344707|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2015-03-31|2011-04-28|2011-04-29|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)|Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor|Completed||Phase 1|36|Anticipated|4SC AG|||||f||||f||||||||||2018-05-31 22:39:44.436503|2018-05-31 22:39:44.436503
NCT01344694|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-05-13|2011-04-28|2011-04-29|Estimate|||||||2011-05-13|2011-05-16|Estimate|July 2011||2011-07-31|April 2011|2011-04-30|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Observational|||Epicardial Fat, Visceral Fat and Coronary Atherosclerosis|Association Between Epicardial Fat, Visceral Fat Accumulation & Cardiovascular Atherosclerosis|Unknown status|Not yet recruiting||110|Anticipated|Ziv Hospital|||3||f||||t||||||||||2018-05-31 22:39:44.513742|2018-05-31 22:39:44.513742
NCT01344681|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2014-12-04|2011-04-27|2011-04-29|Estimate|||||||2014-12-04|2014-12-08|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases|A Randomized Phase II, Multi-center, Non-inferiority Clinical Trial for Efficacy and Safety of Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases|Completed||Phase 2|153|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:39:44.584794|2018-05-31 22:39:44.584794
NCT01344668|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-10-12|2011-04-28|2011-04-29|Estimate|||||||2016-10-12|2016-10-14|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|PRIDE||The Public Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care|The Public Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care|Completed||N/A|411|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 22:39:44.715484|2018-05-31 22:39:44.715484
NCT01344655|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2017-03-28|2011-04-28|2011-04-29|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2011||2011-04-30|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Imperial||Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients|A Single-centre, Double-blind, Double-dummy, Randomised, Crossover Study to Investigate the Effect of Formoterol HFA-pMDI Versus Salmeterol HFA-pMDI on Small Airways Physiological Parameters in COPD Patients|Completed||Phase 4|16|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 22:39:44.788723|2018-05-31 22:39:44.788723
NCT01344642|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|December 2010|Actual|2010-12-31|May 2008|Actual|2008-05-31||Observational|||Qualitative and Quantitative HIV RNA Detection in Saliva Using the Oragene RNA Kit|Qualitative and Quantitative HIV RNA Detection in Saliva Using the Oragene RNA Kit|Completed|||40|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 22:39:44.907849|2018-05-31 22:39:44.907849
NCT01344629|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2012-07-10||2014-02-28|2011-04-28|2011-04-29|Estimate|2012-08-24|2012-08-27|Estimate||||2014-02-28|2014-03-28|Estimate|April 2011||2011-04-30|February 2014|2014-02-28||||July 2011|Actual|2011-07-31||Interventional|||Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use|Bioequivalence of Telmisartan Administrated in Two Different Ways: Both in Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Telmisartan 80 mg Tablet and Amlodipine 5mg Tablet in Concomitant Use in Healthy Male Volunteers. (an Open-label, Randomized, Single-dose, Four-period Replicated Crossover Study)|Completed||Phase 1|64|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:39:44.977156|2018-05-31 22:39:44.977156
NCT01344616|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2014-11-10||2014-11-19|2011-04-28|2011-04-29|Estimate|2014-11-19|2014-11-24|Estimate||||2014-11-19|2014-11-24|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Reducing Preterm Births in Underserved Pregnant Women|Reducing Preterm Births in Underserved Pregnant Women|Completed||Phase 2|482|Actual|PHCC LP||2|||f||||f||||||||||2018-05-31 22:39:45.362731|2018-05-31 22:39:45.362731
NCT01344603|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-04-28|2011-04-28|2011-04-29|Estimate|||||||2011-04-28|2011-04-29|Estimate||||April 2011|2011-04-30||||||||Observational|||Epidural and Cardiac Surgery|Epidural Analgesia in Cardiac Surgery|Completed|||||Università Vita-Salute San Raffaele|||2||f||||||||||||||2018-05-31 22:39:45.627678|2018-05-31 22:39:45.627678
NCT01344590|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-04-27|2011-04-27|2011-04-29|Estimate|||||||2011-04-27|2011-04-29|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Ethanol Lock for Prevention of Central Line-Associated Blood Stream Infections|Ethanol Lock for Prevention of Central Line-Associated Blood Stream Infections|Unknown status|Recruiting|N/A|50|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 22:39:45.678994|2018-05-31 22:39:45.678994
NCT01344577|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2017-02-21|2011-04-28|2011-04-29|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2011|Actual|2011-05-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Buccal Plate Augmentation With Different Hydroxyapatite Based Material|Buccal Plate Augmentation Associated With Different Hydroxyapatite-based Biomaterials. A Multicenter Randomized Controlled Clinical Trial|Completed|||96|Actual|University of Trieste|||3||f||||t||||||||||2018-05-31 22:39:45.769237|2018-05-31 22:39:45.769237
NCT01344564|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-03-15|2011-04-28|2011-04-29|Estimate|||||||2013-03-15|2013-03-18|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide|Initiation of Androgen Deprivation Therapy for the Treatment of Prostate Cancer Using Degarelix Acetate Followed by Leuprolide Acetate|Completed||N/A|50|Actual|Urology of Virginia||1|||f||||f||||||||||2018-05-31 22:39:45.822701|2018-05-31 22:39:45.822701
NCT01344538|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2014-06-16||2016-06-30|2011-04-28|2011-04-29|Estimate|2016-06-30|2016-08-11|Estimate||||2016-06-30|2016-08-11|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Interventional||33 people enrolled with 3 withdrawn|Ginger for Colorectal Cancer Prevention|Phase II Study of the Effects of Ginger Root Extract on Eicosanoids in Colon Mucosa in People at Normal Risk for Colorectal Cancer|Completed||Phase 2|30|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 22:39:45.954611|2018-05-31 22:39:45.954611
NCT01344525|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-04-05|2011-04-28|2011-04-29|Estimate|||||||2016-04-05|2016-04-06|Estimate|May 2009||2009-05-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pilot Project on Interdisciplinary Therapy of Obesity|Pilot Project on Interdisciplinary Therapy of Obesity and Its Consequences on Body Weight, Quality of Life and Gastrointestinal Parameters|Unknown status|Active, not recruiting|N/A|480|Anticipated|University of Hohenheim||4|||f||||||||||||||2018-05-31 22:39:46.125558|2018-05-31 22:39:46.125558
NCT01344512|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-03-17|2011-04-27|2011-04-29|Estimate|||||||2015-03-17|2015-03-18|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PHARMA-A||Population Pharmacokinetics of Anti-infectious Drugs in Children|Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (< 12 Years Old)|Completed||N/A|214|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 22:39:46.195229|2018-05-31 22:39:46.195229
NCT01344499|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2013-06-03|2011-04-27|2011-04-29|Estimate|||||||2013-06-03|2013-06-04|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Clearance Rate of Peritoneal Fluid After Full Conditioning Pneumoperitoneum|Clearance Rate of Peritoneal Fluid Assessed by Post-operative Ultrasound Decreases After Full Conditioning Pneumoperitoneum|Completed||N/A|20|Actual|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-05-31 22:39:46.276678|2018-05-31 22:39:46.276678
NCT01344486|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-10-24|2011-04-27|2011-04-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Peritoneal Cavity Conditioning Decreases Pain, Inflammation and Adhesions|Peritoneal Cavity Conditioning During Laparoscopic Surgery Decreases Postoperative Pain, Inflammatory Reaction and Postoperative Adhesions|Terminated||Phase 4|22|Actual|University Hospital, Gasthuisberg||2||Investigator no longer works fulltime at investigational site|f||||f||||||||No||2018-05-31 22:39:46.343612|2018-05-31 22:39:46.343612
NCT01344473|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-01-10|2011-04-28|2011-04-29|Estimate|||||||2014-01-10|2014-01-13|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||A Trial of Tooth Mousse to Remineralise Post-orthodontic Treatment White Spot Lesions|A Randomised Controlled Trial of Tooth Mousse to Remineralise Post-orthodontic Treatment White Spot Lesions|Completed||N/A|90|Actual|University of Dundee||2|||f||||t||||||||||2018-05-31 22:39:46.401863|2018-05-31 22:39:46.401863
NCT01344460|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2015-05-27|2013-06-20|2015-07-29|2011-04-28|2011-04-29|Estimate|2015-07-29|2015-08-26|Estimate|2013-06-20|2013-06-28|Estimate|2015-07-29|2015-08-26|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|GRAMS||Gadobutrol Enhanced MRA of the Renal Arteries|Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease|Completed||Phase 3|317|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:39:46.644745|2018-05-31 22:39:46.644745
NCT01344447|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2015-05-27||2015-07-29|2011-04-28|2011-04-29|Estimate|2015-07-29|2015-08-26|Estimate||||2015-07-29|2015-08-26|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|GEMSAV||Gadobutrol Enhanced MRA of the Supra-aortic Vessels|Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels|Completed||Phase 3|479|Actual|Bayer||1|||f||||t||||||||||2018-05-31 22:39:47.740037|2018-05-31 22:39:47.740037
NCT01344434|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-04-09|2011-04-28|2011-04-29|Estimate|||||||2014-04-09|2014-04-10|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|ACToR||ACToR-study : Angiographic CT of Renal Transplantation Candidate - Study|Angiographic CT of Renal Transplantation Candidate - Study|Completed|||167|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 22:39:48.654638|2018-05-31 22:39:48.654638
NCT01344421|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-04-04|2011-04-28|2011-04-29|Estimate|||||||2013-04-04|2013-04-05|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Movement Pattern in Patients With Hip Dysplasia|Movement Pattern in Patients With Hip Dysplasia Operated With Minimally Invasive Approach in Peri-acetabular Osteotomy (PAO)|Completed|||55|Actual|University of Aarhus|||2||f||||t||||||||||2018-05-31 22:39:48.706556|2018-05-31 22:39:48.706556
NCT01344408|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2016-05-19|2011-04-27|2011-04-29|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effectiveness of Computer Assisted Training for Older People With Vestibular Dysfunction|Effectiveness of Computer Assisted Training in Vestibular Rehabilitation for Older Patients With Vestibular Dysfunction|Unknown status|Active, not recruiting|N/A|63|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 22:39:48.772075|2018-05-31 22:39:48.772075
NCT01344395|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-01-21|2011-04-27|2011-04-29|Estimate|||||||2013-01-21|2013-01-23|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Use of Local Infiltration Analgesia Following Total Hip Arthroplasty|Local Infiltration Analgesia in Total Hip Arthroplasty - Efficacy of Multiple Bolus Injections With Ropivacaine and Ketorolac|Completed||Phase 4|80|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:39:48.841024|2018-05-31 22:39:48.841024
NCT01344382|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-08-31|2011-04-28|2011-04-29|Estimate|||||||2016-08-31|2016-09-02|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|FTP||Family Training Program for Parents of Substance Using Adolescents|CRAFT: Helping Parents Initiate and Support Their Adolescent's Treatment|Completed||Phase 1/Phase 2|126|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-05-31 22:39:48.903774|2018-05-31 22:39:48.903774
NCT01344369|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2011-05-04||2011-05-04|2011-04-27|2011-04-29|Estimate|2011-05-04|2011-05-30|Estimate||||2011-05-04|2011-05-30|Estimate|August 2008||2008-08-31|May 2011|2011-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions|A Study to Evaluate the Relative Bioavailability of Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva Pharmaceuticals, USA) Compared to FEMCON® Fe (Norethindrone/Ethinyl Estradiol) 0.4 mg/0.035 mg Chewable Tablets (Warner Chilcott) in Healthy Female Volunteers Under Non-Fasted Conditions|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 22:39:48.983791|2018-05-31 22:39:48.983791
NCT01344356|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-04-18|2011-04-27|2011-04-29|Estimate|||||||2016-04-18|2016-04-20|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Stereotactic Body Radiotherapy for Head and Neck Tumors|Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|St. John's Mercy Research Institute, St. Louis||2|||f||||f||||||||||2018-05-31 22:39:49.286372|2018-05-31 22:39:49.286372
NCT01344343|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2012-11-05|2011-04-28|2011-04-29|Estimate|||||||2012-11-05|2012-11-06|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|HIPATTACK||HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial|HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial - Feasibility Pilot|Completed||N/A|60|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-05-31 22:39:49.34773|2018-05-31 22:39:49.34773
NCT01344330|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-05-06|2011-04-28|2011-04-29|Estimate|||||||2016-05-06|2016-05-10|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients|Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients|Unknown status|Recruiting||150|Anticipated|Texas A&M University|||1||f||||t||||||||No|Group information (High versus Low Cruciferous Vegetable Intake) will be made available. No IPD will be made available.|2018-05-31 22:39:50.412267|2018-05-31 22:39:50.412267
NCT01344317|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-10-30|2011-04-28|2011-04-29|Estimate|||||||2015-10-30|2015-11-02|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|November 2010|Actual|2010-11-30||Observational|||The Effect of Stimulating Substances on Brain Activity of Preterm Infants|The Effect of Stimulating Substances on Brain Activity Measured by Amplitude-integrated EEG and Long-term Neurodevelopmental Outcome of Preterm Infants Born Below 30 Weeks of Gestation|Unknown status|Active, not recruiting||60|Anticipated|Medical University of Vienna|||3||f||||f||||||||||2018-05-31 22:39:50.551814|2018-05-31 22:39:50.551814
NCT01344304|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2012-10-22|2011-04-28|2011-04-29|Estimate|||||||2012-10-22|2012-10-24|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial|Multicenter Randomized Controlled Trial of Combination Antiemetic Therapy With Aprepitant / Fosaprepitant in Patients With Colorectal Cancer Receiving Oxaliplatin-based Chemotherapy|Unknown status|Recruiting|N/A|400|Anticipated|Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group||2|||f||||f||||||||||2018-05-31 22:39:50.913499|2018-05-31 22:39:50.913499
NCT01344291|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-10-29|2011-04-27|2011-04-29|Estimate|||||||2011-10-29|2011-11-01|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients||Unknown status|Recruiting|Phase 1|30|Anticipated|Mashhad University of Medical Sciences|||||f||||t||||||||||2018-05-31 22:39:51.124522|2018-05-31 22:39:51.124522
NCT01344278|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-04-22|2011-04-28|2011-04-29|Estimate|||||||2016-04-22|2016-04-25|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|December 2013|Actual|2013-12-31||Interventional|||Diabetes Prevention Strategies in Women With Gestational Diabetes Mellitus (GDM)|Comparative Effectiveness of Diabetes Prevention Strategies in Women With GDM|Completed||N/A|2480|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 22:39:51.188478|2018-05-31 22:39:51.188478
NCT01344265|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-04-01|2011-04-28|2011-04-29|Estimate|||||||2013-04-01|2013-04-04|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||The Correlation Between B-type Natriuretic Peptide (BNP) and Global End Diastolic Volume|The Correlation Between BNP and Global End Diastolic Volume|Completed|||46|Actual|Jinhua Central Hospital|||1||f||||||||||||||2018-05-31 22:39:51.332449|2018-05-31 22:39:51.332449
NCT01344252|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2015-03-23|2011-04-28|2011-04-29|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2011||2011-04-30|March 2015|2015-03-31||||||||Interventional|||Topical Jelly and Intracameral Anesthesia Versus Subtenon Anesthesia, in Cataract Surgery|Topical Jelly and Intracameral Anesthesia Versus Subtenon Anesthesia, in Cataract Surgery: Preference and Surgical Conditions|Withdrawn||Phase 4|0|Actual|Hospital Italiano de Buenos Aires||2|||f||||||||||||||2018-05-31 22:39:51.526183|2018-05-31 22:39:51.526183
NCT01344239|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2013-05-11|2011-04-27|2011-04-29|Estimate|||||||2013-05-11|2013-05-14|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Limb Remote Ischemic Preconditioning Reduces Heart and Lung Injury After Abdominal Aortic Aneurysm Repair|Limb Remote Ischemic Preconditioning Reduces Heart and Lung Injury After Abdominal Aortic Aneurysm Repair:A Randomized Controlled Trial|Completed||N/A|62|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 22:39:51.622289|2018-05-31 22:39:51.622289
NCT01344226|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-05-13|2011-04-28|2011-04-29|Estimate|||||||2013-05-13|2013-05-15|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Observational|||Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery|Clinical Outcomes and Evaluation of Lotemax (Loteprednol Ophthalmic Solution ) 0.5% QID for Treatment of Ocular Inflammation Associated With Cataract Surgery|Unknown status|Active, not recruiting||100|Anticipated|Discover Vision Centers|||||f||||t||||||||||2018-05-31 22:39:51.809672|2018-05-31 22:39:51.809672
NCT01344213|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-08-02|2011-04-27|2011-04-29|Estimate|||||||2011-08-02|2011-08-04|Estimate|July 2008||2008-07-31|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2009|Actual|2009-10-31||Interventional|PCTKA||Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine|Comparison of Analgesic Efficacy Among Pregabalin, Celecoxib, Pregabalin With Celecoxib and Placebo After Total Knee Arthroplasty Under Intrathecal Morphine|Completed||Phase 4|100|Actual|Chulalongkorn University||4|||f||||t||||||||||2018-05-31 22:39:52.094783|2018-05-31 22:39:52.094783
NCT01344200|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2018-01-17|2011-04-28|2011-04-29|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children|The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children|Not yet recruiting||Phase 4|20|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||t|f|f||||||||2018-05-31 22:39:52.214352|2018-05-31 22:39:52.214352
NCT01344187|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27||2016-06-27|2017-06-20|2011-04-28|2011-04-29|Estimate||||2016-06-27|2016-06-29|Estimate|2017-06-20|2017-06-23|Actual|July 2012|Actual|2012-07-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus|Completed||Phase 3|236|Actual|Avedro, Inc.||2|||f||||f||||||||No||2018-05-31 22:39:52.389469|2018-05-31 22:39:52.389469
NCT01344174|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-06-02|2011-04-27|2011-04-28|Estimate|||||||2011-06-02|2011-06-03|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|November 2013|Anticipated|2013-11-30|August 2011|Anticipated|2011-08-31||Interventional|preACLF||A Study Evaluating the Efficacy of Glucocorticoids in Patients With Pre-ACLF-HBV|A Randomized, Open Label Study Evaluating the Efficacy and Safety of Glucocorticoids in Patients With Pre-ACLF-HBV|Unknown status|Recruiting|N/A|200|Anticipated|Third Military Medical University||1|||f||||t||||||||||2018-05-31 22:39:52.536707|2018-05-31 22:39:52.536707
NCT01344161|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2011-07-25||2012-10-09|2011-04-27|2011-04-28|Estimate|2012-05-31|2012-07-03|Estimate||||2012-10-09|2012-10-11|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women|Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women|Completed||Phase 3|85|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:39:52.648982|2018-05-31 22:39:52.648982
NCT01344148|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-04-27|2011-04-27|2011-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|February 2009||2009-02-28|August 2008|2008-08-31|June 2013|Anticipated|2013-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.|AIDS and Tuberculosis Co-infection Treatment Strategies Study of China.[ Eleven Fifth Key Research Grant From the Ministry of Science and Technology, the People's Republic of China]|Unknown status|Recruiting|N/A|400|Anticipated|Shanghai Public Health Clinical Center||1|||f||||t||||||||||2018-05-31 22:39:53.098017|2018-05-31 22:39:53.098017
NCT01344135|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2018-04-26|2011-04-27|2011-04-28|Estimate|||||||2018-04-26|2018-04-30|Actual|September 2011|Actual|2011-09-30|September 2011|2011-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|NUTRAIN||Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy|Cost Effectiveness Analysis and Clinical Outcome of Nutritional Rehabilitation on Physical Functioning and Cardiometabolic Risk Profile in COPD Patients With Muscle Atrophy|Completed||N/A|81|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 22:39:53.225237|2018-05-31 22:39:53.225237
NCT01344122|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-10-28|2011-04-27|2011-04-28|Estimate|||||||2014-10-28|2014-10-30|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MATICCE||Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE)|Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE)|Completed||N/A|20|Actual|Rhode Island Hospital||2|||f||||||||||||||2018-05-31 22:39:53.313165|2018-05-31 22:39:53.313165
NCT01344109|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2017-07-18|2011-04-27|2011-04-28|Estimate|||||||2017-07-18|2017-07-21|Actual|February 2011||2011-02-28|July 2017|2017-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy|A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy|Withdrawn|||0|Actual|Leo W. Jenkins Cancer Center|||2|Lab company that was to do testing was sold|f||||f||||||Samples With DNA|"~     Serum will be centrifuged to plasma which will be transferred to alliquots, and frozen prior~     to shipping. Exosomes will be extracted from the frozen plasma with half of the sample used~     for antibody testing and the remaining sample will be used for RNA analysis.~   "|||2018-05-31 22:39:53.475528|2018-05-31 22:39:53.475528
NCT01344096|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-10-27|2011-04-27|2011-04-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Thrombocytopathy in Gaucher Disease Patients|A 1.5 Years Prospective Study Designed to Delineate the Cause of the Thrombocytopathy in Gaucher Disease Patients|Recruiting|||70|Anticipated|Rabin Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood Samples~   "|||2018-05-31 22:39:53.546478|2018-05-31 22:39:53.546478
NCT01344083|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-04-11|2011-04-27|2011-04-28|Estimate|||||||2012-04-11|2012-04-12|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis||Completed||Phase 2|60|Anticipated|Laboratoires Thea||2|||f||||||||||||||2018-05-31 22:39:53.630161|2018-05-31 22:39:53.630161
NCT01344070|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-03|||2015-08-31|2011-04-27|2011-04-28|Estimate|||||||2015-08-31|2015-09-01|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Generic Formulations of Commonly-used Oral Drugs in Saudi Arabia:Interchangeability & Post-marketing Quality|Generic Formulations of Commonly-Used, Immediate-Release, Solid, Oral, Drugs in Saudi Arabia: Interchangeability & Post-Marketing Quality|Completed||N/A|500|Anticipated|King Faisal Specialist Hospital & Research Center||4|||f||||f||||||||||2018-05-31 22:39:53.708774|2018-05-31 22:39:53.708774
NCT01344057|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2015-12-21||2015-12-21|2011-04-27|2011-04-28|Estimate|2015-12-21|2016-01-28|Estimate||||2015-12-21|2016-01-28|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Baseline analysis population was defined as all participants who were enrolled into the study.|Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2011-2012, When Administered to Elderly Subjects|Completed||Phase 2|63|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:39:53.821845|2018-05-31 22:39:53.821845
NCT01344044|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2017-03-29|2011-04-27|2011-04-28|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2011||2011-01-31|March 2017|2017-03-31|May 13, 2016|Actual|2016-05-13|May 13, 2016|Actual|2016-05-13||Interventional|||Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)|A Randomised Controlled Trial of a Brain-Computer Interface Based Intervention for the Treatment of ADHD|Completed||Phase 2/Phase 3|192|Actual|National Healthcare Group, Singapore||3|||f||||t||||||||||2018-05-31 22:39:54.058627|2018-05-31 22:39:54.058627
NCT01344031|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2018-05-23|2011-04-27|2011-04-28|Estimate|||||||2018-05-23|2018-05-24|Actual|April 21, 2011|Actual|2011-04-21|May 2018|2018-05-31||||July 1, 2011|Actual|2011-07-01||Interventional|||MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase 1 Trial of MK-2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer|Active, not recruiting||Phase 1|31|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-05-31 22:39:54.281446|2018-05-31 22:39:54.281446
NCT01343849|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-11-20|2011-04-27|2011-04-28|Estimate|||||||2011-11-20|2011-11-22|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|September 2012|Anticipated|2012-09-30|||||Observational|||Blood Test for Breast Cancer Associated Auto Antibodies|Blood Test for Breast Cancer Associated Auto Antibodies|Unknown status|Recruiting||1000|Anticipated|Eventus Diagnostics Ltd|||1||f||||f||||||Samples With DNA|"~     serum plasma~   "|||2018-05-31 22:39:57.513714|2018-05-31 22:39:57.513714
NCT01344018|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2016-10-11|2011-04-27|2011-04-28|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|STRASS||Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma|A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS)|Recruiting||Phase 3|256|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 22:39:54.441634|2018-05-31 22:39:54.441634
NCT01344005|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-08-23|2011-04-27|2011-04-28|Estimate|||||||2013-08-23|2013-08-26|Estimate|June 2011||2011-06-30|April 2011|2011-04-30||||June 2013|Anticipated|2013-06-30||Interventional|||Standard Medical Care or Urgent Chest X-ray in Diagnosing Lung Cancer in Smokers With Chest Symptoms Who Are Older Than 60 Years|A Pilot Clinical Trial Looking at the Effect on Lung Cancer Diagnosis of Giving a CXR to Smokers Aged Over 60 With Chest Symptoms|Unknown status|Not yet recruiting|N/A|386|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:39:54.6731|2018-05-31 22:39:54.6731
NCT01343992|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-04-22|2011-04-27|2011-04-28|Estimate|||||||2015-04-22|2015-04-23|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bed Rest or no Bed Rest?|Evaluation of the Influence of Bed Rest After Embryo Transfer in Outcome of IVF Treatment With Ovum Donation.|Completed||N/A|240|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 22:39:54.733325|2018-05-31 22:39:54.733325
NCT01343979|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-04-02|2011-04-27|2011-04-28|Estimate|||||||2015-04-02|2015-04-06|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome.|Influenza A H1N1: Retrospective Analysis of PCR Confirmed Cases of H1N1 Infections in Styria - Risk Factors, Clinical Features and Outcome. Development of a Clinical Score for Suspected H1N1 Infection.|Completed|||800|Actual|Medical University of Graz|||2||f||||t||||||||||2018-05-31 22:39:54.794602|2018-05-31 22:39:54.794602
NCT01343966|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27||2016-08-10|2017-07-10|2011-04-27|2011-04-28|Estimate||||2016-08-10|2016-08-12|Estimate|2017-07-10|2017-07-12|Actual|April 30, 2011|Actual|2011-04-30|July 2017|2017-07-31|February 28, 2014|Actual|2014-02-28|February 28, 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)|A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)|Completed||Phase 2|448|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 22:39:54.863861|2018-05-31 22:39:54.863861
NCT01343953|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2017-06-13|2011-04-27|2011-04-28|Estimate|||||||2017-06-13|2017-06-15|Actual|May 2011||2011-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|APCORD||Cord Blood Transplantation in Severe Aplastic Anemia|A Prospective Phase II Study to Evaluate Cord Blood Transplantation in Inherited or Acquired Severe Aplastic Anemia Refractory or in Relapse After Immunosuppressive Therapy|Completed||Phase 2|26|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:39:55.137526|2018-05-31 22:39:55.137526
NCT01343940|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-05-16|2011-04-27|2011-04-28|Estimate|||||||2016-05-16|2016-05-18|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|dulce||Strengthening Families and Reducing Risk Thru Developmental and Legal Collaboration|Project Dulce: Developmental Understanding and Legal Collaboration for Everyone|Completed||Phase 2/Phase 3|402|Actual|Boston Medical Center||2|||f||||t||||||||No||2018-05-31 22:39:55.227395|2018-05-31 22:39:55.227395
NCT01343927|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2016-06-07|2011-04-27|2011-04-28|Estimate|||||||2016-06-07|2016-06-08|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|Back to Health||Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations|Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations (Back to Health)|Completed||Phase 2|320|Actual|Boston Medical Center||3|||f||||t||||||||||2018-05-31 22:39:55.364145|2018-05-31 22:39:55.364145
NCT01343914|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2016-11-01|2011-04-27|2011-04-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy|Retrospective Study to Determinate the Clinical Phenotype of Patients With Non Squamous NSCLC Treated With First Line Bevacizumab-based Therapy That Reached a Long PFS|Completed|||118|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:39:55.511716|2018-05-31 22:39:55.511716
NCT01343901|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2017-03-15||2017-03-15|2011-04-27|2011-04-28|Estimate|2017-03-15|2017-04-25|Actual||||2017-03-15|2017-04-25|Actual|September 30, 2010|Actual|2010-09-30|March 2017|2017-03-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Observational|PICASSO|Efficacy population included all participants having at least one dose of bevacizumab without protocol deviations.|An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases|A Cohort Study of Patients With Metastatic Colorectal Cancer Treated With Avastin® as First-line Therapy for Liver Metastases Considered as Potentially Resectable|Completed|||210|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:39:55.674688|2018-05-31 22:39:55.674688
NCT01343888|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2015-07-03|2014-03-27|2015-08-18|2011-04-27|2011-04-28|Estimate|2015-08-18|2015-09-18|Estimate|2014-03-27|2014-04-24|Estimate|2015-08-18|2015-09-18|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose.|Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)|A Phase III, Randomised, Double-blind and Placebo-controlled Study of Once Daily BI 201335 120 mg for 12 or 24 Weeks or BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Patients With Genotype 1 Chronic Hepatitis C Infection|Completed||Phase 3|656|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:39:56.351883|2018-05-31 22:39:56.351883
NCT01343875|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-12-25|2011-04-27|2011-04-28|Estimate|||||||2011-12-25|2011-12-28|Estimate||||December 2011|2011-12-31||||||||Observational|||Evaluation the Operative Procedure Among Patients That Suffer From Tear of the Distal Tendon of the Biceps||Unknown status|Not yet recruiting||||Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 22:39:57.356479|2018-05-31 22:39:57.356479
NCT01343862|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2011-04-27|2011-04-27|2011-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|August 2011||2011-08-31|April 2011|2011-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|DCS||The Effect of Single Dose D-Cycloserine on Cognitive Outcome in Moderate Traumatic Brain Injury (TBI) Patients|The Effect of Single Dose D-Cycloserine on Cognitive Outcome in Moderate TBI Patients|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 22:39:57.421754|2018-05-31 22:39:57.421754
NCT01343836|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2015-02-12|2011-04-27|2011-04-28|Estimate|||||||2015-02-12|2015-02-16|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|ATI||Autologous Tenocyte Implantation in Patients With Chronic Achilles Tendinopathy|The Value of Autologous Tenocyte Implantation in Patients With Chronic Achilles Tendinopathy: a Double-blind Randomised Clinical Trial|Completed||Phase 2/Phase 3|90|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 22:39:57.590189|2018-05-31 22:39:57.590189
NCT01343823|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|2013-09-04||2016-06-28|2011-04-27|2011-04-28|Estimate|2013-09-04|2013-11-18|Estimate||||2016-06-28|2016-07-27|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||2 patients did not complete because the study terminated early and one patient did not complete because they withdrew from the study.|Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema|Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema|Terminated||Phase 2|76|Actual|Shire|The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.|4||"Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was~   substantially higher than described in medical literature."|f||||t||||||||||2018-05-31 22:39:57.706681|2018-05-31 22:39:57.706681
NCT01343810|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2014-03-06|2011-04-27|2011-04-28|Estimate|||||||2014-03-06|2014-03-10|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Interventional|||Stress Reduction Training to Improve Sleep Quality, Stress Physiology & Cardiovascular Disease (CVD) Risk Markers|The Effect of Mindfulness-Based Stress Reduction on Sleep Quality, Stress Physiology & CVD Risk|Completed||N/A|87|Actual|Duke University||2|||f||||t||||||||||2018-05-31 22:39:58.280406|2018-05-31 22:39:58.280406
NCT01343797|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-04-27|2011-04-27|2011-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|May 2011|Anticipated|2011-05-31|March 2011|Actual|2011-03-31||Interventional|IGNUT||Glycemic and Insulinemic Index Determination of Two Products: Fructilight® and A Fruit Fructo-Oligosaccharides in Sweet Matrix|Glycemic and Insulinemic Index Determination of 2 Products: Fructilight® and A Fruit Fructo-Oligosaccharides in Sweet Matrix|Unknown status|Active, not recruiting|N/A|12|Actual|CRITT Bio-Industries|||||f||||||||||||||2018-05-31 22:39:58.351095|2018-05-31 22:39:58.351095
NCT01343784|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2014-02-18|2011-04-27|2011-04-28|Estimate|||||||2014-02-18|2014-02-19|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|AVAS||Assessment of Voiding After Sling|Assessment of Voiding After Sling (AVAS): A Randomized Trial of Two Methods of Post-operative Catheter Management After Midurethral Sling for Female Stress Urinary Incontinence|Completed||N/A|105|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 22:39:58.413603|2018-05-31 22:39:58.413603
NCT01343771|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-04-12|2011-04-27|2011-04-28|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2011||2011-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|January 2015|Actual|2015-01-31||Interventional|||Hormonal Therapy for Teens With Anorexia Nervosa|Effect of Adrenal and Gonadal Hormones on Bone Marrow and Appendicular BMD|Completed||Phase 3|70|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 22:39:58.475813|2018-05-31 22:39:58.475813
NCT01343758|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2012-02-22|2011-04-27|2011-04-28|Estimate|||||||2012-02-22|2012-02-24|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children|A Double-blind Randomized Controlled Clinical Trial Investigating the Use of Intravenous Dextrose for Dehydration and Ketosis in Children With Gastroenteritis and Dehydration.|Completed||N/A|188|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 22:39:58.550604|2018-05-31 22:39:58.550604
NCT01343745|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2018-04-12|2011-04-27|2011-04-28|Estimate|||||||2018-04-12|2018-04-13|Actual|February 2008||2008-02-29|April 2018|2018-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)|Dose Response Evaluation of CHF 1535 HFA pMDI in Asthmatic Patients Using Lung Function, Adenosine Monophosphate Bronchial Challenge and Fractional Exhaled Nitric Oxide (FENO)|Completed||Phase 2|18|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 22:39:58.60576|2018-05-31 22:39:58.60576
NCT01343732|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2018-01-24|2011-04-27|2011-04-28|Estimate|||||||2018-01-24|2018-01-25|Actual|June 2011||2011-06-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Tolerability, Safety and Efficacy of the HAC-Coil Deep Transcranial Magnetic Stimulation in Medication Resistance Obsessive Compulsive Disorder (OCD) Subjects||Recruiting||N/A|40|Anticipated|Brainsway||4|||f||||||||||||||2018-05-31 22:39:58.679952|2018-05-31 22:39:58.679952
NCT01343719|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2013-10-30|2011-04-27|2011-04-28|Estimate|||||||2013-10-30|2013-10-31|Estimate|April 2011||2011-04-30|October 2013|2013-10-31||||July 2011|Actual|2011-07-31||Interventional|||Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to a) Assess Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of 2 mg to 350 mg of BI 661051 Administered as Oral Drinking Solution (Powder in Bottle) in Healthy Male Volunteers, b) to Explore the Relative Oral Bioavailability of a Tablet Formulation and c) to Assess the Impact of a High Fat Meal on the Oral Bioavailability of the Oral Drinking Solution (Powder in Bottle)|Completed||Phase 1|64|Actual|Boehringer Ingelheim||11|||f||||||||||||||2018-05-31 22:39:58.741745|2018-05-31 22:39:58.741745
NCT01343706|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-10-31|2011-04-27|2011-04-28|Estimate|||||||2013-10-31|2013-11-01|Estimate|April 2011||2011-04-30|October 2013|2013-10-31||||August 2011|Actual|2011-08-31||Interventional|||Safety Tolerability and Pharmacokinetic of BI 409306|A Randomized, Double-blind, Placebo-controlled (Within Dose Groups) Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses 0.5 mg to 500 mg of BI 409306 Administered Orally in Healthy Male Volunteers|Completed||Phase 1|80|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 22:39:58.907146|2018-05-31 22:39:58.907146
NCT01343693|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2018-03-05|2011-04-27|2011-04-28|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2011||2011-06-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|MaxAn||MaxAn Post Market Surveillance Validation|A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate|Completed|||109|Actual|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-05-31 22:39:58.993309|2018-05-31 22:39:58.993309
NCT01343680|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2012-05-29|2011-04-27|2011-04-28|Estimate|||||||2012-05-29|2012-05-30|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients|A Randomized Controlled Crossover Trial of Two Different Central Venous Catheter Flushing Schemes in Pediatric Hematology and Oncology Patients in Alberta, Canada|Terminated||Phase 3|2|Actual|Alberta Children's Hospital||2||Poor patient accrual|f||||f||||||||||2018-05-31 22:39:59.077|2018-05-31 22:39:59.077
NCT01343667|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2015-12-15||2016-01-22|2011-04-27|2011-04-28|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|FREEDOM|All Enrolled Subjects|GORE Flow Reversal System and GORE Embolic Filter Extension Study|The Gore FREEDOM Study: GORE Flow Reversal System and GORE Embolic Filter Extension Study for the Ongoing Collection of Patient Outcomes|Completed||N/A|1397|Actual|W.L.Gore & Associates||2|||f||||f||||||||||2018-05-31 22:39:59.153722|2018-05-31 22:39:59.153722
NCT01343654|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-02-13|2011-04-27|2011-04-28|Estimate|||||||2018-02-13|2018-02-15|Actual|May 2011||2011-05-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|TEXTR34||Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users|RCT of a Text Messaging Adherence Assessment & Intervention Tool for Rural HIV+ Drug Users|Completed||N/A|54|Actual|University of Virginia||2|||f||||t||||||||No||2018-05-31 22:39:59.469933|2018-05-31 22:39:59.469933
NCT01343641|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2018-05-08|2011-04-26|2011-04-28|Estimate|||||||2018-05-08|2018-05-14|Actual|March 2009||2009-03-31|April 2012|2012-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects|A Phase 2, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Determine Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Subjects With Stage 4 and Stage 5 Kidney Disease|Withdrawn||Phase 2|0|Actual|University of Virginia||2||Could not obtain drug supply from manufacturer|f||||t||||||||||2018-05-31 22:39:59.539611|2018-05-31 22:39:59.539611
NCT01343628|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2012-05-30|2011-04-26|2011-04-28|Estimate|||||||2012-05-30|2012-05-31|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|ATX||A Gene by Medication Interaction to the Acute Effects of Alcohol|A Gene by Medication Interaction to the Acute Effects of Alcohol|Terminated||Phase 1|43|Actual|University of Virginia||2||Terminated due to lack of funding|f||||t||||||||||2018-05-31 22:39:59.60424|2018-05-31 22:39:59.60424
NCT01343615|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-28|2011-04-26|2011-04-28|Estimate|||||||2011-04-28|2011-04-29|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|||Study of Blood Flow Changes and Microemboli During Carotid Surgery|Hemodynamic Alterations in Middle Cerebral Artery and Intraoperative Microemboli During Carotid Endarterectomy and Angioplasty|Unknown status|Recruiting|N/A|40|Anticipated|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 22:39:59.690167|2018-05-31 22:39:59.690167
NCT01343602|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2014-12-14|2011-04-27|2011-04-28|Estimate|||||||2014-12-14|2014-12-16|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HOMECIMT||Enhancing Participation of Chronic Stroke Patients by Constraint Induced Movement Therapy (HOMECIMT)|Enhancing Participation of Chronic Stroke Patients in Primary Care by Modified Constraint Induced Movement Therapy (HOMECIMT)|Completed||N/A|156|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 22:39:59.7705|2018-05-31 22:39:59.7705
NCT01343589|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-04-27|2011-04-27|2011-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk|Effects of Milk Derived From Mountain-pasture Grazing Cows on Risk Markers of the Metabolic Syndrome Compared to Conventional Danish Milk|Completed||N/A|38|Actual|University of Copenhagen|||||f||||f||||||||||2018-05-31 22:39:59.859087|2018-05-31 22:39:59.859087
NCT01343576|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-04-26|2011-04-26|2011-04-28|Estimate|||||||2011-04-26|2011-04-28|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Effect of Dairy Fat on Plasma Phytanic Acid in Human|Effect of Dairy Fat on Plasma Phytanic Acid in Healthy Volunteers - A Randomized Controlled Study|Completed||N/A|14|Actual|University of Copenhagen|||||f||||f||||||||||2018-05-31 22:39:59.93654|2018-05-31 22:39:59.93654
NCT01343563|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-02-04|2011-04-27|2011-04-28|Estimate|||||||2013-02-04|2013-02-06|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Trigeminal Nerve Stimulation for Depression: Dose Finding|Trigeminal Nerve Stimulation for Depression: Dose Finding|Completed||Phase 2|20|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:40:00.035643|2018-05-31 22:40:00.035643
NCT01343550|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-04-27|2011-04-27|2011-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Creativity Group for Borderline Personality Disorder|Creativity Group for Borderline Personality Disorder|Unknown status|Recruiting|Phase 1|80|Anticipated|State University of New York - Upstate Medical University||1|||f||||t||||||||||2018-05-31 22:40:00.113717|2018-05-31 22:40:00.113717
NCT01343537|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2015-12-30|2011-04-26|2011-04-28|Estimate|||||||2015-12-30|2016-01-01|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Continuous Neurophysiological Monitoring Detection of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage Subjects|Real Time Continuous Neurophysiological Monitoring for Early Detection of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage Subjects|Terminated||Early Phase 1|2|Actual|State University of New York - Upstate Medical University||1||Low enrollment|f||||f||||||||||2018-05-31 22:40:00.203759|2018-05-31 22:40:00.203759
NCT01343524|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2012-01-04|2011-04-27|2011-04-28|Estimate|||||||2012-01-04|2012-01-05|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Observational|||Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis|Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis|Completed|||14|Actual|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-05-31 22:40:00.278327|2018-05-31 22:40:00.278327
NCT01343511|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-10-13|2011-04-26|2011-04-28|Estimate|||||||2011-10-13|2011-10-14|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of Stem Cell Therapy in Patients With Autism|Phase Ι/Π Study of Stem Cell Therapy in Patients With Autism|Completed||Phase 1/Phase 2|37|Actual|Shenzhen Beike Bio-Technology Co., Ltd.||2|||f||||t||||||||||2018-05-31 22:40:00.349875|2018-05-31 22:40:00.349875
NCT01343498|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2015-04-30|2011-04-27|2011-04-28|Estimate|||||||2015-04-30|2015-05-01|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors|A Phase I PK/PD Study of the PI3 Kinase/mTOR Inhibitor BEZ235 Given Twice Daily for the Treatment of Patients With Advanced Solid Tumors|Completed||Phase 1|33|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 22:40:00.425583|2018-05-31 22:40:00.425583
NCT01343485|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2013-09-30||2013-09-30|2011-04-27|2011-04-28|Estimate|2013-09-30|2013-12-02|Estimate||||2013-09-30|2013-12-02|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series|Staying on Track: Increasing Completion of the HPV Vaccine Series With the Use of an Innovative Patient and Provider Information and Tracking Tool|Completed||N/A|365|Actual|Planned Parenthood Federation of America||2|||f||||f||||||||||2018-05-31 22:40:00.621251|2018-05-31 22:40:00.621251
NCT01343472|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-04-06|2011-04-27|2011-04-28|Estimate|||||||2018-04-06|2018-04-10|Actual|January 2011||2011-01-31|April 2018|2018-04-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Evaluation of the Washington Intensive Supervision Program|Evaluation of the Washington Intensive Supervision Program|Completed||N/A|70|Actual|Pepperdine University||2|||f||||f||||||||||2018-05-31 22:40:00.844225|2018-05-31 22:40:00.844225
NCT01343459|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-01-06|2011-04-27|2011-04-28|Estimate|||||||2018-01-06|2018-01-09|Actual|January 2011||2011-01-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|March 2021|Anticipated|2021-03-31||Interventional|HIOB||Intra-Operative Electron Boost and Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment (BCT)|Hypofractionated Whole-Breast Irradiation Preceded by Intra-Operative Radiotherapy With Electrons as Anticipated Boost HIOB A New Option in Breast-Conserving Treatment for Operated Breast Cancer Stages I and II|Recruiting||N/A|1300|Anticipated|Paracelsus Medical University||1|||f||||t||||||||No||2018-05-31 22:40:00.924453|2018-05-31 22:40:00.924453
NCT01343446|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-04-27|2011-04-27|2011-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|Diabetesleep||Sleep Impairment and Coping Style in Diabetes|Sleep Impairment Can Influence The Coping Style Of Patients With Diabetes|Completed|||105|Actual|Istanbul University|||1||f||||f||||||||||2018-05-31 22:40:01.046685|2018-05-31 22:40:01.046685
NCT01343433|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-26|2011-04-26|2011-04-28|Estimate|||||||2011-04-26|2011-04-28|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Influence of Light Therapy on Confusion in Patients at the Intensive Care Unit|Influence of Bright Light Therapy on Delirium in Patients at the Intensive Care Unit: a Pilot-study|Unknown status|Recruiting||70|Anticipated|Onze Lieve Vrouwe Gasthuis|||2||f||||f||||||||||2018-05-31 22:40:01.109681|2018-05-31 22:40:01.109681
NCT01343420|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2017-03-27|2011-04-26|2011-04-28|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2010||2010-11-30|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Dog Hair Extract Study|Dog Hair Evaluation Potency by Prick Skin Testing|Completed||N/A|15|Actual|National Jewish Health||1|||f||||f||||||||||2018-05-31 22:40:01.177717|2018-05-31 22:40:01.177717
NCT01343407|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2016-02-24|2011-04-26|2011-04-28|Estimate|||||||2016-02-24|2016-02-25|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Two-part Study of the Effects of MK-1029 in Allergen-challenged Asthmatics (MK-1029-003 AM1)|A Two-Part, Multicenter, Randomized, Clinical Trial to Study the Effects of Multiple Doses of MK-1029 on the Late Asthmatic Response to Lung Allergen Challenge in Asthmatics|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 22:40:01.331377|2018-05-31 22:40:01.331377
NCT01343394|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2014-01-21|2011-04-27|2011-04-28|Estimate|||||||2014-01-21|2014-01-23|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|April 2016|Anticipated|2016-04-30|January 2013|Actual|2013-01-31||Interventional|||Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children|Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children|Suspended||Phase 1|10|Anticipated|Memorial Hermann Health System||1||"UT-IRB insists on protocol design change -Not rel to any pt. safety/non-compliance-Recruiting~   halted at UT/MHHS but may resume at FLHosp for Children-OrlandoFL"|f||||t||||||||||2018-05-31 22:40:01.413241|2018-05-31 22:40:01.413241
NCT01343381|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2012-05-14|2011-04-27|2011-04-28|Estimate|||||||2012-05-14|2012-05-15|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of Heparin Types; Efficacy and Safety|Anticoagulant Effect and Reversal of Hepalean Compared With PPC Heparin in Patients Undergoing Cardiopulmonary Bypass: a Pilot Randomized Trial|Completed||Phase 4|21|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:40:01.504796|2018-05-31 22:40:01.504796
NCT01343368|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2017-06-19||2017-12-03|2011-04-27|2011-04-28|Estimate|2017-06-19|2017-07-17|Actual||||2017-12-03|2017-12-05|Actual|July 2011||2011-07-31|December 2017|2017-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Preservation of Ovarian Function After Hematopoietic Cell Transplant|A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT)|Terminated||Phase 2|19|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||f||||||||||2018-05-31 22:40:01.609932|2018-05-31 22:40:01.609932
NCT01343355|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-07-21|2011-04-26|2011-04-28|Estimate|||||||2011-07-21|2011-07-22|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)|Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)|Unknown status|Active, not recruiting|Phase 2/Phase 3|15|Anticipated|St. Marianna University School of Medicine|||||f||||f||||||||||2018-05-31 22:40:02.22356|2018-05-31 22:40:02.22356
NCT01343342|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-09-06|2011-04-27|2011-04-28|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|December 2011|Actual|2011-12-31||Interventional|FAS||Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors|Genes, Omega-3 Fatty Acids and Cardiovascular Disease Risk Factors|Active, not recruiting||Phase 1|200|Anticipated|Laval University||1|||f||||f||||||||||2018-05-31 22:40:02.295181|2018-05-31 22:40:02.295181
NCT01343329|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2017-04-18|2011-04-27|2011-04-28|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2011|Actual|2011-07-31|April 2017|2017-04-30|February 14, 2014|Actual|2014-02-14|February 14, 2014|Actual|2014-02-14||Interventional|CHAIN||Controlling Hyperadrenergic Activity in Neurologic Injury|Controlling Hyperadrenergic Activity in Neurologic Injury|Withdrawn||Phase 1/Phase 2|0|Actual|Johns Hopkins University||2||Unable to enroll subjects that fit study criteria.|f||||t||||||||No||2018-05-31 22:40:02.375009|2018-05-31 22:40:02.375009
NCT01343316|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2013-09-17|2011-04-27|2011-04-28|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients|Benefits of Post-Pyloric Feeding Tubes in Critically Ill Patients|Terminated|||21|Actual|Johns Hopkins University|||3|lack of funding|f||||f||||||||||2018-05-31 22:40:02.507222|2018-05-31 22:40:02.507222
NCT01321736|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-12-05|2011-03-22|2011-03-23|Estimate|||||||2013-12-05|2013-12-06|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Gut Health Response to Dietary Fiber|Gut Health Response to a New Fiber Blend|Completed||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 22:45:54.380016|2018-05-31 22:45:54.380016
NCT01343303|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-08-08|2011-04-26|2011-04-28|Estimate|||||||2012-08-08|2012-08-09|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|||||Interventional|||A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis|A Double-Blind, Randomized, Placebo-and Active-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Subjects With Osteoarthritis|Completed||Phase 1|43|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 22:40:02.650755|2018-05-31 22:40:02.650755
NCT01343290|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2012-09-29|2011-04-26|2011-04-28|Estimate|||||||2012-09-29|2012-10-02|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers|A Single-Dose, Open-Label, Randomized, 2-Period, 2-Sequence, Crossover Study to Determine the Effect of Food Coadministration on the Pharmacokinetics of 300 mg Canagliflozin in Healthy Subjects|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 22:40:02.749649|2018-05-31 22:40:02.749649
NCT01343277|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2015-12-22||2016-07-15|2011-04-27|2011-04-28|Estimate|2015-12-22|2016-01-28|Estimate||||2016-07-15|2016-08-26|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|January 2015|Actual|2015-01-31||Interventional|||A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma|A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma|Completed||Phase 3|579|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 22:40:02.878112|2018-05-31 22:40:02.878112
NCT01343264|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-26|2011-04-26|2011-04-28|Estimate|||||||2011-04-26|2011-04-28|Estimate|November 2002||2002-11-30|April 2011|2011-04-30||||December 2012|Anticipated|2012-12-31||Observational|||Trimodality Therapy for Malignant Pleural Mesothelioma|Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy|Unknown status|Recruiting||200|Anticipated|HSK Wiesbaden|||||f||||f||||||||||2018-05-31 22:40:03.981419|2018-05-31 22:40:03.981419
NCT01343251|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2014-02-24||2017-08-08|2011-04-27|2011-04-28|Estimate|2016-02-16|2016-03-14|Estimate||||2017-08-08|2017-09-08|Actual|January 2011||2011-01-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving Hemodialysis|Prospective Analysis of Hemodialysis Reliable Outflow (HeRO) Vascular Access Graft vs. Cuffed Catheter Access in Hemodialysis|Completed|||33|Actual|Merit Medical Systems, Inc.|Target sample size (statistical power) was not achieved. Catheter reduction and fistula first policies limited recruitment. Additionally, study patients were not blind to exposure and this knowledge may have had an impact on QoL measurement.||2||f||||f||||||||No||2018-05-31 22:40:04.120176|2018-05-31 22:40:04.120176
NCT01343238|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2016-09-08|2011-04-27|2011-04-28|Estimate|||||||2016-09-08|2016-09-09|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Interventional|LEVA||Short- and Longterm Effects of Physical Activity and Dietary Restriction Postpartum|Short- and Longterm Effects of Physical Activity and Dietary Restriction Postpartum on Women's Weight and Body Composition: a Randomized Study|Completed||N/A|76|Actual|Göteborg University||4|||f||||f||||||||||2018-05-31 22:40:05.378665|2018-05-31 22:40:05.378665
NCT01343225|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-04-27|2011-04-27|2011-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection|Pilot Study of the Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|East Carolina University||2|||f||||f||||||||||2018-05-31 22:40:05.440663|2018-05-31 22:40:05.440663
NCT01343212|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-05-17|2011-04-27|2011-04-28|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||Stiffness Measurement of Liver Tumors and Visceral Parenchyma|Clinical Applications of Acoustic Radiation Force Impulse Technology in Stiffness Measurement of Liver Tumors and Visceral Parenchyma|Unknown status|Recruiting||50|Anticipated|China Medical University Hospital|||1||f||||f||||||||||2018-05-31 22:40:05.539026|2018-05-31 22:40:05.539026
NCT01343186|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-24|||2012-01-30|2011-04-26|2011-04-27|Estimate|||||||2012-01-30|2012-01-31|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects|A Single-centre, Randomised, Positive-controlled, Single-dose, Dose-escalation Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ypeginterferon Alfa-2a in Healthy Subjects|Completed||Phase 1|39|Actual|Xiamen Amoytop Biotech Co., Ltd.||4|||f||||t||||||||||2018-05-31 22:40:05.764515|2018-05-31 22:40:05.764515
NCT01343173|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2018-03-12|2011-04-26|2011-04-27|Estimate|||||||2018-03-12|2018-03-13|Actual|April 6, 2011|Actual|2011-04-06|March 2018|2018-03-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|STIM 2||Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib|Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib|Completed||N/A|220|Anticipated|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 22:40:05.853965|2018-05-31 22:40:05.853965
NCT01343160|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-10-12|2011-04-26|2011-04-27|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Multicenter Study of Removable GORE VIABIL® Biliary Endoprosthesis for Treatment of Benign Biliary Strictures|Multicenter Study of Removable GORE VIABIL® Biliary Endoprosthesis for Treatment of Benign Biliary Strictures|Completed||N/A|43|Actual|W.L.Gore & Associates||1|||f||||f||||||||||2018-05-31 22:40:06.068064|2018-05-31 22:40:06.068064
NCT01343147|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2014-03-04|2011-04-26|2011-04-27|Estimate|||||||2014-03-04|2014-03-05|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Deep Versus Superficial Heating in Patients With Knee Osteoarthritis|Deep Versus Superficial Heating in Patients With Knee Osteoarthritis: a Double-blind Randomized Clinical Trial|Completed||N/A|54|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 22:40:06.186082|2018-05-31 22:40:06.186082
NCT01343134|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-05-12|2011-04-26|2011-04-27|Estimate|||||||2011-05-12|2011-05-16|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Anatomical and Functional Macular Changes in Retinal Detachment||Completed|||30|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 22:40:06.359661|2018-05-31 22:40:06.359661
NCT01343121|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2016-01-26|2011-04-26|2011-04-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|September 2015|Actual|2015-09-30||Interventional|Gemtrans||Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy|Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy|Unknown status|Active, not recruiting|N/A|50|Anticipated|The Christie NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 22:40:06.514977|2018-05-31 22:40:06.514977
NCT01343108|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-04-27|2011-04-26|2011-04-27|Estimate|||||||2011-04-27|2011-04-29|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|||||Observational|||The Impact of Nurses' Emotional Labor on Job Satisfaction and Burnout|The Impact of Nurses' Emotional Labor on Job Satisfaction and Burnout|Unknown status|Active, not recruiting||157|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:40:06.63923|2018-05-31 22:40:06.63923
NCT01343095|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2016-05-03||2017-12-21|2011-04-26|2011-04-27|Estimate|2017-11-21|2017-12-20|Actual||||2017-12-21|2018-01-23|Actual|May 2011||2011-05-31|December 2017|2017-12-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones|A Randomized Controlled Trial of Direct Noise Reduction in the ICU Using Overnight Application of In-ear Earplugs or In-ear Earplugs Plus Noise-Canceling Headphones to Reduce the Incidence and Duration of ICU Delirium|Terminated||N/A|8|Actual|Wake Forest University Health Sciences||3||Loss of study staff|f||||f|f|t||||||Yes|de-identified data was shared with another investigator as part of a review and meta-analysis|2018-05-31 22:40:06.741527|2018-05-31 22:40:06.741527
NCT01343082|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-24|2015-04-28||2015-05-19|2011-04-26|2011-04-27|Estimate|2015-04-28|2015-05-14|Estimate||||2015-05-19|2015-06-15|Estimate|May 2011||2011-05-31|May 2015|2015-05-31||||March 2013|Actual|2013-03-31||Interventional|||DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension|A Long-term Open-label Study of DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension -Phase 3-|Completed||Phase 3|148|Actual|Santen Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 22:40:07.206781|2018-05-31 22:40:07.206781
NCT01343069|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2015-05-04|2011-04-26|2011-04-27|Estimate|||||||2015-05-04|2015-05-05|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|SICA||Safety Improvement and Checklist Application|Safety Analysis in Regard to the Introduction of Surgical Checklists in the Operation Rooms in a Tertiary Care Center|Withdrawn||N/A|0|Actual|Regional Hospital of Bolzano||2||insufficient quality of data|f||||t||||||||||2018-05-31 22:40:07.457478|2018-05-31 22:40:07.457478
NCT01343056|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2015-12-07||2017-05-04|2011-04-26|2011-04-27|Estimate|2017-03-06|2017-04-18|Actual||||2017-05-04|2017-06-02|Actual|April 2011||2011-04-30|March 2017|2017-03-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|PRISM|recruited type 2 diabetes patients who were referred for diabetes education|Program Reinforcement Impacts Self Management (PRISM)|Program Reinforcement Impacts Self Management|Completed||N/A|141|Actual|University of Pittsburgh||4|||f||||f|f|f||||||No||2018-05-31 22:40:07.587869|2018-05-31 22:40:07.587869
NCT01343043|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-04-10|2011-04-26|2011-04-27|Estimate|||||||2018-04-10|2018-04-11|Actual|March 2011||2011-03-31|April 2018|2018-04-30|March 2028|Anticipated|2028-03-31|October 2018|Anticipated|2018-10-31||Interventional|NY-ESO-1||A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma|A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma|Recruiting||Phase 1/Phase 2|65|Anticipated|Adaptimmune||4|||f||||t|t|||||||||2018-05-31 22:40:08.088433|2018-05-31 22:40:08.088433
NCT01343030|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2014-06-09|2011-04-26|2011-04-27|Estimate|||||||2014-06-09|2014-06-11|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Prospective Radiologic Evaluation of Changes Following Fat Grafting|Prospective Radiologic Evaluation of Changes That Might Affect Breast Cancer Diagnosis Following Fat Grafting and Silicone Breast Implants|Unknown status|Enrolling by invitation||35|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t||||||||||2018-05-31 22:40:08.210017|2018-05-31 22:40:08.210017
NCT01343017|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-04-26|2011-04-26|2011-04-27|Estimate|||||||2011-04-26|2011-04-27|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Impact of Increased Tidal Volumes on Oxygenation and Cardiac Output|Increased Tidal Volume During Anaesthesia Compared to PEEP. Impact on Arterial Concentration of Sevoflurane, Oxygenation and Cardiac Output in a Randomised Clinical Study of Overweight Patients.|Completed||N/A|30|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:40:08.287201|2018-05-31 22:40:08.287201
NCT01343004|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2016-10-25||2017-01-10|2011-04-26|2011-04-27|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|April 2011||2011-04-30|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ACTIVE|Intent-to-treat (ITT) Population included all patients who were randomized into the study by assigning the randomized study medication kit on Day 1.|Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women|A Randomized, Double-blind, Placebo-Controlled, Comparative Multicenter Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women With Severe Osteoporosis and at Risk of Fracture|Completed||Phase 3|2463|Actual|Radius Health, Inc.||3|||f||||t||||||||||2018-05-31 22:40:08.478732|2018-05-31 22:40:08.478732
NCT01342991|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-11-27|2011-04-26|2011-04-27|Estimate|||||||2011-11-27|2011-11-29|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Trial of Open Milligan-Morgan Haemorrhoidectomy Versus Laser Closed Haemorrhoidectomy|Randomised Controlled Trial of Open Milligan-Morgan Haemorrhoidectomy Versus Laser Closed Haemorrhoidectomy|Completed||N/A|40|Actual|Northern Lincolnshire and Goole Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:40:09.48752|2018-05-31 22:40:09.48752
NCT01342978|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-02-28|2011-04-26|2011-04-27|Estimate|||||||2017-02-28|2017-03-03|Actual|October 2009||2009-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|December 2014|Actual|2014-12-31||Observational|HOTSPOT||Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time|Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time|Completed|||242|Actual|Johns Hopkins Bloomberg School of Public Health|||3||f||||f||||||Samples With DNA|"~     Serum, oral rinse/saliva and some tumor samples~   "|||2018-05-31 22:40:09.54755|2018-05-31 22:40:09.54755
NCT01342822|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-03-12|2011-04-26|2011-04-27|Estimate|||||||2012-03-12|2012-03-13|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|PLATINUM+||Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization|A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization in a Population of Unrestricted Patients|Unknown status|Active, not recruiting||2980|Anticipated|European Cardiovascular Research Center|||2||f||||t||||||||||2018-05-31 22:40:15.633694|2018-05-31 22:40:15.633694
NCT01342965|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2015-02-05||2015-02-05|2011-04-26|2011-04-27|Estimate|2015-02-05|2015-02-24|Estimate||||2015-02-05|2015-02-24|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|July 2012|Actual|2012-07-31||Interventional||Full analysis set: All randomized participants.|A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations|A Multicenter, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva®) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumors|Completed||Phase 3|217|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:40:09.642702|2018-05-31 22:40:09.642702
NCT01342952|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2018-05-29|2011-04-26|2011-04-27|Estimate|||||||2018-05-29|2018-05-30|Actual|June 1, 2011||2011-06-01|May 2018|2018-05-31|October 24, 2024|Anticipated|2024-10-24|October 27, 2022|Anticipated|2022-10-27||Interventional|||Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529|An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired|Recruiting||Phase 2|66|Anticipated|GlaxoSmithKline||1|||f||||t||||||||||2018-05-31 22:40:11.071377|2018-05-31 22:40:11.071377
NCT01342939|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-01-14|2011-04-26|2011-04-27|Estimate|||||||2013-01-14|2013-01-15|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)|Postprandial Secretion of of Incretin Hormones and Incretin Effect in Patients With Maturity-onset Diabetes of the Young (MODY)|Completed|||31|Actual|University Hospital, Gentofte, Copenhagen|||3||f||||f||||||Samples With DNA|"~     Buffy coat~   "|||2018-05-31 22:40:11.233171|2018-05-31 22:40:11.233171
NCT01342926|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2016-11-30||2017-03-27|2011-04-26|2011-04-27|Estimate|2017-03-27|2017-05-05|Actual||||2017-03-27|2017-05-05|Actual|June 1, 2011||2011-06-01|March 2017|2017-03-31|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Interventional|||Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration|A Phase 2, Multi-centre, Randomised, Double-masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)|Completed||Phase 2|191|Actual|GlaxoSmithKline||4|||f||||t||||||||||2018-05-31 22:40:11.580661|2018-05-31 22:40:11.580661
NCT01342913|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2013-05-30|2012-04-26|2017-01-19|2011-04-26|2011-04-27|Estimate|2013-05-30|2013-07-30|Estimate|2012-04-26|2012-04-30|Estimate|2017-01-19|2017-03-03|Actual|February 2011||2011-02-28|January 2017|2017-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))|A 12-week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared With Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|528|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:40:14.173705|2018-05-31 22:40:14.173705
NCT01342900|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2013-02-20|2011-04-26|2011-04-27|Estimate|||||||2013-02-20|2013-02-21|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intraoperative Optimisation of Tissue Oxygenation|Intraoperative Monitoring and Optimisation of Tissue Oxygenation In High-Risk Surgical Patients for Reduction of Postoperative Complications: a Pilot Study|Completed||N/A|48|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 22:40:14.727285|2018-05-31 22:40:14.727285
NCT01342887|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|2017-04-05||2017-06-27|2011-04-26|2011-04-27|Estimate|2017-06-27|2017-07-02|Actual||||2017-06-27|2017-07-02|Actual|April 2011||2011-04-30|June 2017|2017-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study|Terminated||Phase 1/Phase 2|6|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 22:40:14.827339|2018-05-31 22:40:14.827339
NCT01342874|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2012-02-08|2011-04-26|2011-04-27|Estimate|||||||2012-02-08|2012-02-09|Estimate|August 2010||2010-08-31|April 2011|2011-04-30|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Observational|inositol||Improved Outcomes Associated With Inositol Dietary Supplementation in Women With Gestational Diabetes Mellitus|Improved Maternal and Fetal Outcomes Associated With Inositol Dietary Supplementation in Women With Early Gestational Diabetes Mellitus|Completed|||30|Actual|G. d'Annunzio University|||2||f||||t||||||||||2018-05-31 22:40:15.118545|2018-05-31 22:40:15.118545
NCT01342861|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-04-26|2011-04-26|2011-04-27|Estimate|||||||2011-04-26|2011-04-27|Estimate|October 2009||2009-10-31|April 2011|2011-04-30||||June 2011|Anticipated|2011-06-30||Interventional|INAPEN||INAPEN Protocol for Impact of Breakfast Improvement|INAPEN Protocol for Impact of Breakfast Improvement on the Nutritional Status of Hospitalized Patients (INcidence de l'Amélioration du Petit-déjeuner Sur l'Etat Nutritinonel Des Patients hospitalisés)|Unknown status|Recruiting|N/A|800|Anticipated|Centre Hospitalier de Meaux||2|||f||||t||||||||||2018-05-31 22:40:15.193806|2018-05-31 22:40:15.193806
NCT01342848|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2015-06-04|2011-04-26|2011-04-27|Estimate|||||||2015-06-04|2015-06-08|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|REMNANT||Effectiveness of Thrombus Aspiration in Plaque Reduction for Patients With Acute Coronary Syndromes|REduction of Myocardial Necrosis Achieved With Nose-dive Manual Thrombus Aspiration|Completed|||76|Actual|G. d'Annunzio University|||||f||||t||||||Samples Without DNA|"~     Histopathology assessment of aspirated material during manual TA. Quantitative analysis: size~     and weight. Qualitative evaluation: a) thrombus containing only platelets, b) a thrombus with~     an erythrocyte component c) any fragment of vessel wall, cholesterol crystals, inflammatory~     cells or collagen tissue~   "|||2018-05-31 22:40:15.299067|2018-05-31 22:40:15.299067
NCT01342835|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-04-26|2011-04-26|2011-04-27|Estimate|||||||2011-04-26|2011-04-27|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|July 2011|Anticipated|2011-07-31|January 2011|Actual|2011-01-31||Interventional|propan||Postoperative Analgesia in Children After Propofol Anesthesia|Postoperative Analgesia in Children After Propofol Anesthesia|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|University Clinical Centre of Kosova||2|||f||||t||||||||||2018-05-31 22:40:15.382263|2018-05-31 22:40:15.382263
NCT01342809|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-05-06|2011-04-26|2011-04-27|Estimate|||||||2014-05-06|2014-05-07|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||Follow up by General Practitioner After Self-poisoning|Follow up After Self-poisoning by General Practitioner- a Randomised Clinical Trial|Completed||N/A|202|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:40:15.803517|2018-05-31 22:40:15.803517
NCT01342796|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26||2012-08-23|2012-08-23|2011-04-26|2011-04-27|Estimate||||2012-08-23|2012-08-30|Estimate|2012-08-23|2012-08-30|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects|A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of MF59C.1-adjuvanted Subunit Influenza Vaccine or Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Aged 6 to <36 Months|Completed||Phase 2|84|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:40:15.886311|2018-05-31 22:40:15.886311
NCT01342783|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|||2016-05-17|2011-04-26|2011-04-27|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2011||2011-05-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma|Next Generation Sequencing of Childhood Soft Tissue Sarcomas to Identify Drivers of Primary and Metastatic Disease|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 22:40:15.964165|2018-05-31 22:40:15.964165
NCT01342770|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|2015-09-04||2017-10-30|2011-04-26|2011-04-27|Estimate|2015-09-04|2015-10-06|Estimate||||2017-10-30|2017-12-05|Actual|April 2011||2011-04-30|October 2017|2017-10-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional||Participants who met eligibility criteria that were registered and received study agent.|Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer|Pioglitazone as a Candidate Chemoprevention Agent for Lung Cancer: A Pilot Trial Using a Pre-surgical Model in Early Stage NSCLC|Terminated||Phase 2|6|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:40:16.051932|2018-05-31 22:40:16.051932
NCT01342757|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2013-05-03||2018-01-04|2011-04-26|2011-04-27|Estimate|2014-05-13|2014-06-11|Estimate||||2018-01-04|2018-01-29|Actual|December 2010||2010-12-31|January 2018|2018-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma|Using Proton Magnetic Resonance Spectroscopy (MRS) to Predict Response of Vorinostat Treatment in Glioblastoma|Completed||N/A|12|Actual|National Cancer Institute (NCI)|In five of the twelve cases spectroscopic indices could not be calculated because the tumor volume was outside of reliably measured voxels. These were primarily accounted for by tumor closeness to the skull or the small size of residual tumor.|1|||f||||t||||||||||2018-05-31 22:40:16.462761|2018-05-31 22:40:16.462761
NCT01342744|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-05-14|2011-04-26|2011-04-27|Estimate|||||||2011-05-14|2011-05-17|Estimate|April 2011||2011-04-30|May 2011|2011-05-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Metformin in Postmenopausal Women With Metabolic Syndrome|Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome|Unknown status|Recruiting|Phase 4|40|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 22:40:16.742366|2018-05-31 22:40:16.742366
NCT01342731|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-01-16|2011-04-26|2011-04-27|Estimate|||||||2012-01-16|2012-01-18|Estimate|July 2011||2011-07-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii|Effectiveness and Safety of Tigecycline for Therapy of Infections Caused by Multi-Drug Resistant Acinetobacter Baumannii|Unknown status|Recruiting|Phase 4|30|Anticipated|Mahidol University||1|||f||||f||||||||||2018-05-31 22:40:16.823045|2018-05-31 22:40:16.823045
NCT01342718|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-06-01|2011-04-26|2011-04-27|Estimate|||||||2012-06-01|2012-06-05|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea|Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea|Completed||N/A|48|Actual|Kyunghee University Medical Center||4|||f||||t||||||||||2018-05-31 22:40:16.917278|2018-05-31 22:40:16.917278
NCT01342705|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2015-04-20|2011-04-26|2011-04-27|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2011||2011-05-31|November 2012|2012-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CIRROX||Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis|Influence of Iron Depletion by Phlebotomy on the Risk of Hepatocellular Carcinoma Occurrence in Patients With Compensated Alcoholic Cirrhosis. Prospective, Multicentre, Randomized Trial|Terminated||Phase 3|17|Actual|Assistance Publique - Hôpitaux de Paris||2||delayed recruitment as compared to that expected|f||||f||||||||||2018-05-31 22:40:17.04435|2018-05-31 22:40:17.04435
NCT01342692|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-06-13|2011-04-26|2011-04-27|Estimate|||||||2017-06-13|2017-06-15|Actual|June 2011||2011-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|AZA-PLUS||Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes|Randomized Phase II Trial Seeking the Most Promising Drug Association With Azacitidine- in Higher Risk Myelodysplastic Syndromes|Recruiting||Phase 2|320|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||t||||||||||2018-05-31 22:40:17.136257|2018-05-31 22:40:17.136257
NCT01342679|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2015-09-14|2011-04-26|2011-04-27|Estimate|||||||2015-09-14|2015-09-15|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|September 2014|Actual|2014-09-30|March 2013|Actual|2013-03-31||Interventional|CMR-CML||A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib|A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib|Completed||Phase 2|21|Actual|Kanto CML Study Group||1|||f||||t||||||||||2018-05-31 22:40:17.221783|2018-05-31 22:40:17.221783
NCT01342666|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2013-01-10||2013-02-23|2011-04-26|2011-04-27|Estimate|2013-01-10|2013-02-12|Estimate||||2013-02-23|2013-02-28|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Tomato Consumption and High Density Lipoprotein-cholesterol|Effect of Tomato Consumption on Serum High Density Lipoprotein-cholesterol Levels. A Randomized, Open-label, Single Blind, Clinical Trial|Completed||N/A|50|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 22:40:17.304783|2018-05-31 22:40:17.304783
NCT01342328|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2017-05-10|2011-04-26|2011-04-27|Estimate|||||||2017-05-10|2017-05-11|Actual|May 2012||2012-05-31|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|ASRV||"Providing Good Sleep for ICU Sedation"|"Providing Good Sleep for ICU Sedation"|Active, not recruiting||N/A|10|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 22:40:23.862728|2018-05-31 22:40:23.862728
NCT01342653|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2016-11-18|2011-04-26|2011-04-27|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|HIPEC||Clinical Trial at Neoadjuvant Peritoneal and Systemic Chemotherapy Plus HIPEC in Gastric Carcinomatosis|Phase II Multicentric Exploratory Single Cohort Clinical Trial to Assess Efficacy and Safety on a New Treatment Scheme by Systemic and Peritoneal Chemotherapy Plus Cytoreduction and HIPEC Plus Adjuvant Treatment in Patients With Peritoneal Carcinomatosis From Gastric Cancer|Suspended||Phase 2|50|Anticipated|Hospital General Universitario Gregorio Marañon||1||unable to reach planned recruitment|f||||f||||||||||2018-05-31 22:40:17.517131|2018-05-31 22:40:17.517131
NCT01342640|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2015-09-28||2017-06-15|2011-04-26|2011-04-27|Estimate|2015-09-28|2015-10-26|Estimate||||2017-06-15|2017-07-12|Actual|July 18, 2011|Actual|2011-07-18|June 2017|2017-06-30|November 30, 2012|Actual|2012-11-30|November 30, 2012|Actual|2012-11-30||Interventional||Intent-to-Treat (ITT) Population: All participants who received at least 1 dose of methoxy polyethylene glycol-epoetin beta treatment and for whom at least 1 follow-up data was available.|A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia|A Single Arm, Open Label, Multicenter Phase IIIb/IV Clinical Trial to Assess the Efficacy, Safety and Tolerability of Monthly Administration of C.E.R.A. for the Treatment of Not on Dialysis Chronic Renal Anemia Not Currently Treated With ESA|Completed||Phase 4|70|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 22:40:17.589171|2018-05-31 22:40:17.589171
NCT01342627|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2015-10-05|2011-04-26|2011-04-27|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|SERCC||Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma|Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib|Terminated||Phase 2|4|Actual|Centro di Riferimento Oncologico - Aviano||1||low enrollment rate|f||||f||||||||||2018-05-31 22:40:17.768554|2018-05-31 22:40:17.768554
NCT01342614|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2011-05-11|2011-04-26|2011-04-27|Estimate|||||||2011-05-11|2011-05-13|Estimate|May 2006||2006-05-31|November 2005|2005-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension|The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension|Completed||N/A|140|Actual|China-Japan Friendship Hospital||2|||f||||t||||||||||2018-05-31 22:40:17.990026|2018-05-31 22:40:17.990026
NCT01342601|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-10-12|2011-04-26|2011-04-27|Estimate|||||||2011-10-12|2011-10-13|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents|Evaluation of the Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents: a Multicenter, Double-blind, Randomised, Placebo Controlled, Parallel Group Clinical Investigation|Completed||N/A|72|Actual|Bitop AG||2|||f||||f||||||||||2018-05-31 22:40:18.07246|2018-05-31 22:40:18.07246
NCT01342588|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-04-26|2011-04-26|2011-04-27|Estimate|||||||2011-04-26|2011-04-27|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|May 2012|Anticipated|2012-05-31|April 2012|Anticipated|2012-04-30||Interventional|||Accuracy of Lumbar Pedicle Screw Placement Assisted With Continuous Pulse-train Stimulation|Accuracy of Lumbar Pedicle Screw Placement Assisted With Continuous Pulse-train Stimulation During Track Creation and Screw Insertion|Unknown status|Recruiting|N/A|60|Anticipated|American British Cowdray Medical Center||1|||f||||f||||||||||2018-05-31 22:40:18.160673|2018-05-31 22:40:18.160673
NCT01342575|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2012-03-16|2011-04-26|2011-04-27|Estimate|||||||2012-03-16|2012-03-20|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|May 2012|Anticipated|2012-05-31||Interventional|||Improvement of Trans-operatory X-ray Visualization During Anterior Cervical Surgery|Improvement of Trans-operatory X-ray Visualization During Anterior Cervical Surgery. Comparison of the Podalic Compression and Shoulder Traction Maneuvers|Unknown status|Recruiting|N/A|50|Anticipated|American British Cowdray Medical Center||1|||f||||f||||||||||2018-05-31 22:40:18.247942|2018-05-31 22:40:18.247942
NCT01342562|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-03-04|2011-04-26|2011-04-27|Estimate|||||||2013-03-04|2013-03-06|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly||Completed||N/A|54|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:40:18.319768|2018-05-31 22:40:18.319768
NCT01342549|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2016-05-02||2016-05-02|2011-04-26|2011-04-27|Estimate|2016-05-02|2016-06-09|Estimate||||2016-05-02|2016-06-09|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AUD|1. Veterans age 18 to 60 2. Presence of a diagnosis of alcohol dependence (DSM-IV criteria); 3. A recent history of heavy drinking defined as 5 or more drinks in a sitting at least twice in a week during the previous 2 months;4. Absence of withdrawal symptoms CIWA-Ar (94);5. Presence of a knowledgeable informant|Treatment Strategy for Alcohol Use Disorders in Veterans With TBI|Treatment Strategy for Alcohol Use Disorders in Veterans With TBI|Completed||Phase 3|62|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-05-31 22:40:18.392339|2018-05-31 22:40:18.392339
NCT01342536|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2015-10-06|2011-04-26|2011-04-27|Estimate|||||||2015-10-06|2015-10-08|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|AADI||African American Depression Intervention Trial (AADI)|A Culturally Adapted Depression Intervention for African American Adults|Unknown status|Recruiting|Phase 3|190|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 22:40:18.689151|2018-05-31 22:40:18.689151
NCT01342523|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|2013-12-12||2015-10-09|2011-04-26|2011-04-27|Estimate|2014-03-03|2014-03-05|Estimate||||2015-10-09|2015-10-14|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|October 2013|Actual|2013-10-31|May 2012|Actual|2012-05-31||Interventional|NCI||Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources|Evaluation of NCI Smoking Intervention Resources|Completed||Phase 4|1034|Actual|University of Wisconsin, Madison||32|||f||||t||||||||||2018-05-31 22:40:18.796764|2018-05-31 22:40:18.796764
NCT01342510|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2012-04-20||2015-10-01|2011-04-26|2011-04-27|Estimate|2012-05-21|2012-06-25|Estimate||||2015-10-01|2015-10-21|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol|The Evaluation of the Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol.|Completed||Phase 4|200|Actual|University of Wisconsin, Madison|Problems with designation of ASA score differing from that given by anesthesiologist, insertion of a 20 gauge angiocatheter into the dorsum of the hand and anesthesia plan changing (general to monitored) prior to going to the operating room.|4|||f||||t||||||||||2018-05-31 22:40:20.578974|2018-05-31 22:40:20.578974
NCT01342497|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-12-22|2011-04-26|2011-04-27|Estimate|||||||2011-12-22|2011-12-23|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|BBR-012||Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study|A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diabetic Patients With Complicated Skin Ulceration on the Foot (Diabetic Foot Ulcer)|Unknown status|Recruiting|Phase 2|60|Anticipated|Bridge BioResearch Ltd.||2|||f||||t||||||||||2018-05-31 22:40:20.923285|2018-05-31 22:40:20.923285
NCT01342484|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|2016-07-27||2016-07-27|2011-04-26|2011-04-27|Estimate|2016-07-27|2016-09-15|Estimate||||2016-07-27|2016-09-15|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Treated set (TS) including all patients who were treated with at least one dose of study drug.|Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Parallel Group Dose-finding Study of Linagliptin (1 and 5 mg Administered Orally Once Daily) Over 12 Weeks in Children and Adolescents, From 10 to 17 Years of Age, With Type 2 Diabetes Mellitus|Completed||Phase 2|40|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:40:21.023263|2018-05-31 22:40:21.023263
NCT01342471|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2012-09-05||2012-10-10|2011-04-25|2011-04-27|Estimate|2012-10-10|2012-11-09|Estimate||||2012-10-10|2012-11-09|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PALS||Physical Activity and Leisure-time Study (PALS)|TV Commercial Stepping: Can America's Top Sedentary Activity be Made More Active|Completed||Phase 1|58|Actual|University of Tennessee|Small sample size, disproportionate female gender participation, and limited ethnic diversity. No follow up after 6 months. No control group, that received no intervention.|2|||f||||f||||||||||2018-05-31 22:40:21.548931|2018-05-31 22:40:21.548931
NCT01342458|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2014-11-06||2015-01-11|2011-04-25|2011-04-27|Estimate|2015-01-09|2015-01-12|Estimate||||2015-01-11|2015-01-26|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|OA|Tests t were used to provide similar characteristics between the both groups for the baseline analysis.|Effect of Footwear on the Clinical, Functional, and Biomechanical Aspects in Elderly Women With Knee Osteoarthritis (OA)|Therapeutic Effect of Inexpensive, Flexible and Non-heeled Footwear on the Clinical, Functional and Gait Biomechanics in Elderly Women With Knee Osteoarthritis: a Randomized Clinical Trial|Completed||Phase 1|56|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 22:40:21.849643|2018-05-31 22:40:21.849643
NCT01342445|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2013-08-06||2014-04-07|2011-04-26|2011-04-27|Estimate|2014-04-07|2014-04-08|Estimate||||2014-04-07|2014-04-08|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of LDX on Functioning of College Students With ADHD|Effects of Vyvanse on the Behavioral, Academic, and Psychosocial Functioning of College Students With ADHD|Completed||Phase 4|50|Actual|University of Rhode Island|No notable limitations or caveats are noted.|1|||f||||f||||||||||2018-05-31 22:40:22.408994|2018-05-31 22:40:22.408994
NCT01342432|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-26|2011-04-26|2011-04-27|Estimate|||||||2011-04-26|2011-04-27|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Impact of a Balance Reeducation Protocol on Pain, Function and Postural Control of Low Back Pain Patients|Comparison of Balance Reeducation Plus General Exercises Versus General Exercises Only: Impact on Pain, Function and Postural Control of Low Back Pain Patients|Completed||N/A|35|Actual|Centro Universitari Fieo||2|||f||||t||||||||||2018-05-31 22:40:22.924607|2018-05-31 22:40:22.924607
NCT01342419|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-06-13|2011-04-26|2011-04-27|Estimate|||||||2012-06-13|2012-06-14|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Circadian Rhythms of Aqueous Humor Dynamics When Using Brimonidine in Humans With Ocular Hypertension|Circadian Rhythms of Aqueous Humor Dynamics When Using Brimonidine in Humans With Ocular Hypertension|Completed|||35|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 22:40:23.028207|2018-05-31 22:40:23.028207
NCT01342406|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2014-02-14|2011-04-26|2011-04-27|Estimate|||||||2014-02-14|2014-02-19|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics|Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics|Completed|||31|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 22:40:23.076365|2018-05-31 22:40:23.076365
NCT01342393|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-01-09|2011-04-25|2011-04-27|Estimate|||||||2012-01-09|2012-01-11|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Proof of Concept Study for First-Sight Refractive Error Correction: Direct Comparison to Manifest Refraction and Autorefraction Results|Proof of Concept Study for First-Sight Refractive Error Correction:Direct Comparison to Manifest Refraction and Autorefraction Results|Completed|||41|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 22:40:23.131483|2018-05-31 22:40:23.131483
NCT01342380|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2016-10-03|2011-04-26|2011-04-27|Estimate|||||||2016-10-03|2016-10-04|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Pioglitazone and Quetiapine XR Pharmacogenetic Study|Pharmacogenetic Study of Pioglitazone and Quetiapine XR Treatment Response in Mood Disorders|Completed|||42|Actual|University Hospitals Cleveland Medical Center|||2||f||||t||||||||||2018-05-31 22:40:23.190137|2018-05-31 22:40:23.190137
NCT01342367|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2018-03-22|2011-04-25|2011-04-27|Estimate|||||||2018-03-22|2018-03-23|Actual|December 17, 2010|Actual|2010-12-17|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer|A Feasibility Study of Oral Hormonal Therapy and Radiation for Non-metastatic, Intermediate or High Risk Prostate Cancer in Men 70 and Older or With Medical Comorbidities|Recruiting||N/A|40|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 22:40:23.241529|2018-05-31 22:40:23.241529
NCT01342354|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2018-02-06|2011-04-25|2011-04-27|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2009||2009-04-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer|A Phase I Study of Stereotactic Body Radiation Therapy in Patients With Unresected Carcinoma of the Pancreas or Ampulla|Active, not recruiting||Phase 1|17|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 22:40:23.559586|2018-05-31 22:40:23.559586
NCT01342341|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2014-04-22||2014-05-23|2011-04-25|2011-04-27|Estimate|2014-05-23|2014-06-26|Estimate||||2014-05-23|2014-06-26|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake|Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake|Completed||Phase 4|40|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:40:23.642286|2018-05-31 22:40:23.642286
NCT01342315|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25||2013-01-22|2013-08-20|2011-04-26|2011-04-27|Estimate||||2013-01-22|2013-01-29|Estimate|2013-08-20|2013-08-28|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Topical Antifungal Treatment for Tinea Cruris|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris|Completed||Phase 3|483|Actual|Medicis Global Service Corporation||2|||f||||f||||||||||2018-05-31 22:40:23.947074|2018-05-31 22:40:23.947074
NCT01342302|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-04-09|2011-04-26|2011-04-27|Estimate|||||||2013-04-09|2013-04-10|Estimate|September 2008||2008-09-30|April 2011|2011-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|OPIC||An Online Psychoeducational Intervention for Young Women With Breast Cancer and Their Partners|An Online Psychoeducational Intervention for Young Women With Breast Cancer and Their Partners|Completed||N/A|20|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 22:40:24.079543|2018-05-31 22:40:24.079543
NCT01342289|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-07-12|2011-04-26|2011-04-27|Estimate|||||||2017-07-12|2017-07-13|Actual|July 2011||2011-07-31|July 2017|2017-07-31|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide|Shortened-duration Tacrolimus Following Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide|Active, not recruiting||Phase 1/Phase 2|127|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-05-31 22:40:24.150657|2018-05-31 22:40:24.150657
NCT01342276|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2016-04-13|2011-04-26|2011-04-27|Estimate|||||||2016-04-13|2016-04-15|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|vHFC||Trial of an Internet-based Platform for Monitoring Heart Failure Patients|Using the Internet for Self-management and Monitoring Patients With Heart Failure at a Distance|Terminated||N/A|38|Actual|Simon Fraser University||2||Due to futility of recruitment.|f||||f||||||||||2018-05-31 22:40:24.28872|2018-05-31 22:40:24.28872
NCT01342263|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-10-03|2011-04-26|2011-04-27|Estimate|||||||2017-10-03|2017-10-04|Actual|May 2011||2011-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|iCDM||Trial of an Internet-based Platform for Managing Chronic Diseases at a Distance|Utilization of an Interactive Internet-based Platform for Managing Chronic Diseases at a Distance|Active, not recruiting||N/A|318|Anticipated|Simon Fraser University||2|||f||||f||||||||||2018-05-31 22:40:24.362136|2018-05-31 22:40:24.362136
NCT01342250|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-10-13|2011-04-25|2011-04-27|Estimate|||||||2011-10-13|2011-10-14|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis|Phase Ι/Π Study of Human Umbilical Cord Mesenchymal Stem Cells Transplantation for Patients With Decompensated Liver Cirrhosis|Completed||Phase 1/Phase 2|20|Actual|Shenzhen Beike Bio-Technology Co., Ltd.||3|||f||||t||||||||||2018-05-31 22:40:24.439084|2018-05-31 22:40:24.439084
NCT01342237|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2013-11-17|2011-04-26|2011-04-27|Estimate|||||||2013-11-17|2013-11-19|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors||Unknown status|Recruiting|Phase 2|33|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:40:24.520681|2018-05-31 22:40:24.520681
NCT01342224|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2018-04-10|2011-04-26|2011-04-27|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2011|Actual|2011-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|June 2012|Actual|2012-06-30||Interventional|||Immunochemoradiotherapy in Patients With Pancreatic Cancer|Exploratory Trial of Immunochemoradiotherapy for Locally Advanced Pancreatic Adenocarcinoma|Completed||Phase 1|11|Actual|Providence Health & Services||1|||f||||f||||||||No||2018-05-31 22:40:24.601122|2018-05-31 22:40:24.601122
NCT01342211|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2017-09-08|2013-04-02|2017-09-11|2011-04-25|2011-04-27|Estimate|2017-09-11|2017-10-11|Actual|2013-04-02|2013-04-10|Estimate|2017-09-11|2017-10-11|Actual|July 2011|Actual|2011-07-31|September 2017|2017-09-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional||Safety analysis population included all participants who received at least 1 dose of study drug.|A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins|A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin.|Completed||Phase 2|93|Actual|Pfizer|Due to an inadvertent omission in the protocol at Day 85, presented limitations in the assessment of treatment effect on ApoA1, ApoB and Lp(a) for Day 85.|5|||f||||t||||||||||2018-05-31 22:40:24.770509|2018-05-31 22:40:24.770509
NCT01342198|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-07-27|2011-04-25|2011-04-27|Estimate|||||||2011-07-27|2011-07-28|Estimate|June 2011||2011-06-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet|A Phase 1, Open-Label, Randomized, Cross-Over Study to Evaluate the Effects of Multiple Doses of Erythromycin on the Pharmacokinetics of a Single Dose of Pregabalin Controlled Release in Healthy Subjects|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:40:27.22398|2018-05-31 22:40:27.22398
NCT01342185|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-10-17|2011-04-25|2011-04-27|Estimate|||||||2012-10-17|2012-10-18|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|EMOTCHB||Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B|A Randomized, Controlled, Open-label, Multicenter Clinical Study of Treatment of Chronic Hepatitis B With TY—CZ—9999 Ozone Therapy System|Unknown status|Enrolling by invitation|Phase 3|189|Anticipated|Nanfang Hospital of Southern Medical University||3|||f||||t||||||||||2018-05-31 22:40:27.55448|2018-05-31 22:40:27.55448
NCT01342172|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2014-11-20||2014-11-26|2011-04-26|2011-04-27|Estimate|2014-11-20|2014-11-26|Estimate||||2014-11-26|2014-12-15|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma|Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma|Terminated||Phase 1/Phase 2|9|Actual|Icahn School of Medicine at Mount Sinai|"The trial was terminated because the regimen was deemed poorly tolerated for chronic administration because of the need for repeated dose delays and reductions coupled with slow accrual.~There are no results for this study."|1||low accrual|f||||t||||||||||2018-05-31 22:40:27.898265|2018-05-31 22:40:27.898265
NCT01342159|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-26|2011-04-26|2011-04-27|Estimate|||||||2011-04-26|2011-04-27|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema|Comparative Treatment of Intravitreal Bevacizumab and Triamcinolone Acetonide on Diabetic Macular Edema|Completed||N/A|80|Actual|Hallym University Medical Center||3|||f||||t||||||||||2018-05-31 22:40:28.292481|2018-05-31 22:40:28.292481
NCT01342146|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-07-27|2011-04-25|2011-04-27|Estimate|||||||2017-07-27|2017-07-31|Actual|May 2006||2006-05-31|May 2011|2011-05-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|PD||Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children|Efficiency and Safety of Pegylated Somatropin(PEG-somatropin) in the Treatment of Children With Growth Hormone Deficiency: a Multicenter, Randomized, Open-label, Controlled Phase 2 Study|Completed||Phase 2|101|Actual|GeneScience Pharmaceuticals Co., Ltd.|||||f||||t||||||||||2018-05-31 22:40:28.362647|2018-05-31 22:40:28.362647
NCT01342133|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2012-06-26|2011-04-25|2011-04-27|Estimate|||||||2012-06-26|2012-06-28|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Observational|||Sweat Duct Imaging in Mother/Newborn Dyads|Sweat Duct Imaging in Mother/Newborn Dyads|Completed|||28|Actual|Edimer Pharmaceuticals|||2||f||||f||||||||||2018-05-31 22:40:28.428286|2018-05-31 22:40:28.428286
NCT01342120|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-08-31|2011-04-25|2011-04-27|Estimate|||||||2011-08-31|2011-09-02|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|PHARMO II||PHARMO Institute Seroquel Safety Study|Seroquel Safety Study|Completed|||18325|Actual|AstraZeneca|||4||f||||f||||||||||2018-05-31 22:40:28.48996|2018-05-31 22:40:28.48996
NCT01342107|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2012-03-21||2012-03-21|2011-04-25|2011-04-27|Estimate|2012-03-21|2012-04-13|Estimate||||2012-03-21|2012-04-13|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effect of FID 114675A on Lens Wettability|The Effect of Alcon Multi-Purpose Disinfecting Solution (MPDS) on Lens Wettability|Completed||N/A|66|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:40:28.563778|2018-05-31 22:40:28.563778
NCT01342094|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-24|2015-04-28||2015-06-14|2011-04-25|2011-04-26|Estimate|2015-04-28|2015-05-15|Estimate||||2015-06-14|2015-07-10|Estimate|May 2011||2011-05-31|June 2015|2015-06-30||||September 2012|Actual|2012-09-30||Interventional||Subjects who have instilled the investigational drug at least once.|DE-111 Against Timolol Ophthalmic Solution 0.5%|A Double-masked Study of DE-111 Ophthalmic Solution Versus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension - Phase 3, Confirmatory Study -|Completed||Phase 3|166|Actual|Santen Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 22:40:28.795784|2018-05-31 22:40:28.795784
NCT01342081|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2015-04-28||2015-05-19|2011-04-25|2011-04-26|Estimate|2015-04-28|2015-05-14|Estimate||||2015-05-19|2015-06-15|Estimate|May 2011||2011-05-31|May 2015|2015-05-31||||September 2012|Actual|2012-09-30||Interventional||"Subjects who have instilled the investigational drug at least once. Excluded from analysis in Tafluprost (n=1).~Reason: Protocol Violation"|DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%|A Double-masked Study of DE-111 Ophthalmic Solution Versus Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension -Phase 3, Confirmatory Study-|Completed||Phase 3|489|Actual|Santen Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 22:40:29.010738|2018-05-31 22:40:29.010738
NCT01342068|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2013-04-24|2011-04-25|2011-04-26|Estimate|||||||2013-04-24|2013-04-25|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||The Effectiveness of Diagnosis and Treatment of Thoracic Outlet Syndrome|The Effectiveness of Diagnosis and Treatment of Thoracic Outlet Syndrome|Completed|||31|Actual|Nova Southeastern University|||||f||||f||||||||||2018-05-31 22:40:29.242646|2018-05-31 22:40:29.242646
NCT01342055|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-10-08|2011-04-25|2011-04-26|Estimate|||||||2012-10-08|2012-10-10|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers|Phase I Study of Apetrol ES and Megace® in Healthy Male Volunteers|Completed||Phase 1|38|Actual|LG Life Sciences||6|||f||||f||||||||||2018-05-31 22:40:29.307335|2018-05-31 22:40:29.307335
NCT01342042|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|||2011-04-25|2011-04-25|2011-04-26|Estimate|||||||2011-04-25|2011-04-26|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|SPPS||The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus|The Safety, Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese T2DM|Unknown status|Recruiting|Phase 2|36|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f||||t||||||||||2018-05-31 22:40:29.367451|2018-05-31 22:40:29.367451
NCT01342029|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|2017-04-21||2017-12-19|2011-04-25|2011-04-26|Estimate|2017-11-08|2017-12-12|Actual||||2017-12-19|2018-01-19|Actual|May 2011|Actual|2011-05-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|RWISE|Total 10 dropout (4 dropout during period 1, 4 dropout during washout, 2 dropout during period 2)|Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia|Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia|Completed||N/A|142|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||Yes||2018-05-31 22:40:29.448743|2018-05-31 22:40:29.448743
NCT01342016|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2014-10-15|2011-04-25|2011-04-26|Estimate|||||||2014-10-15|2014-10-17|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients|A Randomized, Double-blind Double Dummy, Parallel Control and Multi-center Clinical Trial to Compare the Efficacy and Safety of Tacrolimus Capsules in Treatment of Lupus Nephritis With Leflunomide Tablets|Terminated||Phase 3|84|Actual|Astellas Pharma Inc||2||Due to safety concern of active control drug|f||||f||||||||||2018-05-31 22:40:29.674515|2018-05-31 22:40:29.674515
NCT01342003|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-25|2011-04-25|2011-04-26|Estimate|||||||2011-04-25|2011-04-26|Estimate|February 2007||2007-02-28|October 2010|2010-10-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Observational|genotype||HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b|HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b|Completed|||388|Actual|Azienda Ospedaliera San Camillo Forlanini|||2||f||||f||||||Samples With DNA|"~     HCVRNA determination was performed quantitatively before the treatment (TaqMan Roche~     Diagnostics). The TaqMan value utilized to determine the response was 15 IU/ml. TaqMan method~     was a standardized method utilized from December 2007 in all the center of the CLEO group.~     HCVRNA value was expressed as log10 IU/ml.~   "|||2018-05-31 22:40:29.770581|2018-05-31 22:40:29.770581
NCT01341990|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2012-03-21||2012-03-21|2011-04-25|2011-04-26|Estimate|2012-03-21|2012-04-13|Estimate||||2012-03-21|2012-04-13|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of an Investigational Multi-Purpose Solution on Lens Moisture|Effect of SiH MPDS FID 114675A vs. a Marketed Multi-Purpose Solution on Lens Moisture|Completed||N/A|68|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:40:29.84486|2018-05-31 22:40:29.84486
NCT01341977|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2011-09-08||2011-09-08|2011-04-25|2011-04-26|Estimate|2011-09-08|2011-10-13|Estimate||||2011-09-08|2011-10-13|Estimate|November 2009||2009-11-30|September 2011|2011-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution|Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution (MPDS)|Completed||N/A|573|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:40:30.042482|2018-05-31 22:40:30.042482
NCT01341964|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2015-04-27|2011-04-25|2011-04-26|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Interaction2||Clopidogrel and Aspirin Interaction Study-2|Randomized Controlled Trial to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent|Completed||Phase 4|220|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-05-31 22:40:30.241531|2018-05-31 22:40:30.241531
NCT01341951|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-25|2011-04-25|2011-04-26|Estimate|||||||2011-04-25|2011-04-26|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|G-CSF||Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis|G-CSF in Acute Liver Failure and Alcoholic Hepatitis - A Pilot Study|Unknown status|Recruiting|N/A|60|Anticipated|Postgraduate Institute of Medical Education and Research||1|||f||||f||||||||||2018-05-31 22:40:30.308108|2018-05-31 22:40:30.308108
NCT01341938|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2018-04-03|2011-04-25|2011-04-26|Estimate|||||||2018-04-03|2018-04-04|Actual|July 2011||2011-07-31|April 2018|2018-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|LASH||Nicotine Lozenges and Assisted Self-help for Smokeless Tobacco Cessation|Nicotine Lozenges and Assisted Self-help for Smokeless Tobacco Cessation|Completed||Phase 2|1067|Actual|Oregon Research Institute||3|||f||||f||||||||||2018-05-31 22:40:30.540708|2018-05-31 22:40:30.540708
NCT01341925|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2016-03-04|2011-04-25|2011-04-26|Estimate|||||||2016-03-04|2016-03-08|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|OATS||Omega-3 and Therapy Study for Depression|Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Depression|Completed||Phase 1|73|Actual|Ohio State University||4|||f||||t||||||||||2018-05-31 22:40:30.616391|2018-05-31 22:40:30.616391
NCT01341912|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|2013-10-11||2013-12-16|2011-04-25|2011-04-26|Estimate|2013-12-16|2014-02-03|Estimate||||2013-12-16|2014-02-03|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)|Clinical Study to Investigate the Long-Term Efficacy, Safety and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Haemophilia A - Extension Study to GENA-01|Completed||Phase 3|3|Actual|Octapharma|Only 3 patients participated in the study and all 3 patients withdrew consent prematurely. Therefore the results are summarized descriptively only.|1|||f||||t||||||||||2018-05-31 22:40:30.71037|2018-05-31 22:40:30.71037
NCT01341899|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-10-31|2011-04-25|2011-04-26|Estimate|||||||2016-10-31|2016-11-01|Estimate|June 2006||2006-06-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes|Prospective Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes|Completed||Phase 2|50|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||t||||||||||2018-05-31 22:40:30.870764|2018-05-31 22:40:30.870764
NCT01341886|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-04-25|2011-04-25|2011-04-26|Estimate|||||||2011-04-25|2011-04-26|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Metformin on Decrement in Levothyroxin Dose Required for Thyroid Stimulating Hormone (TSH) Suppression in Patients With Differentiated Thyroid Cancer||Completed||N/A|51|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:40:30.945657|2018-05-31 22:40:30.945657
NCT01341873|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-04-20|2011-04-25|2011-04-26|Estimate|||||||2012-04-20|2012-04-23|Estimate|May 2012||2012-05-31|April 2012|2012-04-30||||October 2016|Anticipated|2016-10-31||Interventional|||Nursing Intervention in Supporting Family Caregivers of Patients Undergoing Stem Cell Transplant|Nursing Intervention for Family Caregivers of HCT Patients|Withdrawn||N/A|0|Actual|City of Hope Medical Center||2||The protocol was not funded by the NCI|f||||t||||||||||2018-05-31 22:40:31.013876|2018-05-31 22:40:31.013876
NCT01341860|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2011-04-25|2011-04-25|2011-04-26|Estimate|||||||2011-04-25|2011-04-26|Estimate|January 2000||2000-01-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|December 2003|Actual|2003-12-31||Observational|IGM-OK||Investigation of Genetic Marker Associated With Obesity in Koreans|Investigation of Genetic Marker Associated With Obesity in Koreans, A Single-nucleotide Polymorphism(SNP) Analysis for Korean Obese|Terminated|||260|Actual|Kyunghee University Medical Center|||2||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 22:40:31.092054|2018-05-31 22:40:31.092054
NCT01341847|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2012-07-03|2011-04-25|2011-04-26|Estimate|||||||2012-07-03|2012-07-04|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||The Water Method Colonoscopy in Routine Unsedated Colonoscopy Examinations|The Water Method Colonoscopy in Routine Unsedated Colonoscopy Examinations : A Randomized Controlled Trial(RCT) in Diagnostic Cases in Indonesian Patients|Completed||Phase 2|110|Actual|Gadjah Mada University||2|||f||||||||||||||2018-05-31 22:40:31.223537|2018-05-31 22:40:31.223537
NCT01341834|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2018-04-22|2011-04-25|2011-04-26|Estimate|||||||2018-04-22|2018-04-24|Actual|March 2010|Actual|2010-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2016|Actual|2016-06-30||Interventional|||Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors|A Safety and Tolerability Study of RAD001 (mTOR Inhibitor) in Combination With Two Dosing Schedules of LBH589B (Histone Deacetylase Inhibitor) in Solid Tumors/ Lymphomas With Enrichment for EBV-Driven Tumors|Active, not recruiting||Phase 1|49|Actual|National Cancer Centre, Singapore||1|||f||||f||||||||||2018-05-31 22:40:31.313462|2018-05-31 22:40:31.313462
NCT01341821|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-24|||2011-04-27|2011-04-25|2011-04-26|Estimate|||||||2011-04-27|2011-04-29|Estimate|May 2010||2010-05-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|||||Observational|||Influences of Leadership Style on Team Climate for Quality|Influences of Leadership Style on Team Climate for Quality|Completed|||500|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:40:31.402338|2018-05-31 22:40:31.402338
NCT01341808|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|||2013-03-16|2011-04-25|2011-04-26|Estimate|||||||2013-03-16|2013-03-19|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients|Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease|Completed||Phase 4|493|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:40:31.479049|2018-05-31 22:40:31.479049
NCT01341795|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-03-25|2011-04-25|2011-04-26|Estimate|||||||2014-03-25|2014-03-26|Estimate|July 2011||2011-07-31|March 2014|2014-03-31||||||||Observational|||Genetic Variation in the Transporters and Hypoglycemic Agents|Effect of Genetic Variation in the Transporters on Glycemic Response and Pharmacokinetics of Sitagliptin and Metformin|Unknown status|Recruiting||100|Anticipated|Ajou University School of Medicine|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 22:40:31.584913|2018-05-31 22:40:31.584913
NCT01341782|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-25|2013-04-17||2013-04-17|2011-04-25|2011-04-26|Estimate|2013-04-17|2013-06-06|Estimate||||2013-04-17|2013-06-06|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism|Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism|Completed||Phase 3|255|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 22:40:31.739551|2018-05-31 22:40:31.739551
NCT01341769|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2011-06-01|2011-04-22|2011-04-26|Estimate|||||||2011-06-01|2011-06-03|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Blood Glucose and Insulin Responses to Snack Food Products|A Study to Determine the Effects of Added Ingredients on Glycaemic and Insulinemic Responses to a Snack Food|Withdrawn||N/A|20|Anticipated|Mondelēz International, Inc.||4||Test ingredient production did not meet specification|f||||f||||||||||2018-05-31 22:40:32.350531|2018-05-31 22:40:32.350531
NCT01341756|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-05-06|2011-04-24|2011-04-26|Estimate|||||||2011-05-06|2011-05-09|Estimate|July 2009||2009-07-31|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial|Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial|Unknown status|Recruiting|Phase 2|63|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 22:40:32.443623|2018-05-31 22:40:32.443623
NCT01341743|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2013-10-28|2011-04-25|2011-04-26|Estimate|||||||2013-10-28|2013-10-30|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy|A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy|Unknown status|Active, not recruiting|Phase 4|360|Anticipated|Nanfang Hospital of Southern Medical University||3|||f||||t||||||||||2018-05-31 22:40:32.527214|2018-05-31 22:40:32.527214
NCT01341730|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2012-11-23|2011-04-25|2011-04-26|Estimate|||||||2012-11-23|2012-11-27|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|PIONEER||The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)|Evaluation of the Effect of Atorvastatin and Pioglitazone in Carotid Atherosclerosis With the Use of 18Fluoride-Fludeoxyglucose(FDG) Positron Emission Tomography-computed Tomography (PET-CT)Imaging|Completed||Phase 4|40|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 22:40:32.608449|2018-05-31 22:40:32.608449
NCT01341717|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|||2014-05-29|2011-04-25|2011-04-26|Estimate|||||||2014-05-29|2014-05-30|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin|Open-labelled, Randomized, Active-controlled, Parallel-arm, Single-center Study on Effect of Sitagliptin on T2DM Patients on Treatment With Metformin and Insulin|Completed||Phase 4|440|Actual|Jothydev's Diabetes and Research Centre||2|||f||||t||||||||||2018-05-31 22:40:32.679097|2018-05-31 22:40:32.679097
NCT01341704|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|||2015-08-27|2011-04-25|2011-04-26|Estimate|||||||2015-08-27|2015-08-31|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|March 2013|Actual|2013-03-31|December 2011|Actual|2011-12-31||Interventional|MSP3-POC||Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa|Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali|Completed||Phase 2|800|Actual|Vac4All||2|||f||||t||||||||||2018-05-31 22:40:32.748856|2018-05-31 22:40:32.748856
NCT01341691|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|||2011-04-25|2011-04-25|2011-04-26|Estimate|||||||2011-04-25|2011-04-26|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease (CKD)|A 2 Week Single Blind Study to Evaluate Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease|Completed||Early Phase 1|12|Actual|Denver Nephrologists, P.C.||6|||f||||f||||||||||2018-05-31 22:40:32.827756|2018-05-31 22:40:32.827756
NCT01341678|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-23|||2014-02-10|2011-04-25|2011-04-26|Estimate|||||||2014-02-10|2014-02-11|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease|Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease (CKD)|Completed||N/A|15|Actual|Denver Nephrologists, P.C.||3|||f||||f||||||||||2018-05-31 22:40:32.894042|2018-05-31 22:40:32.894042
NCT01341665|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-04-25|2011-04-25|2011-04-26|Estimate|||||||2011-04-25|2011-04-26|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Subclassification of the Syndrome of Inappropriate ADH Secretion|Subclassification of the Syndrome of Inappropriate Antidiuresis Via Copeptin - What is the Genesis of ADH-independent SIADH?|Completed|||50|Anticipated|University of Wuerzburg|||||f||||f||||||||||2018-05-31 22:40:33.1184|2018-05-31 22:40:33.1184
NCT01341652|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2017-09-18|2011-04-22|2011-04-26|Estimate|||||||2017-09-18|2017-09-19|Actual|April 2011||2011-04-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer|Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer|Active, not recruiting||Phase 2|99|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 22:40:33.197686|2018-05-31 22:40:33.197686
NCT01341639|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2017-02-27|2011-04-22|2011-04-26|Estimate|||||||2017-02-27|2017-02-28|Actual|May 2011||2011-05-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)|A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months (V419-007-03)|Completed||Phase 3|1250|Actual|MCM Vaccines B.V.||2|||f||||f||||||||||2018-05-31 22:40:33.287816|2018-05-31 22:40:33.287816
NCT01341626|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2017-04-20|2011-04-22|2011-04-26|Estimate|||||||2017-04-20|2017-04-24|Actual|January 1997||1997-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Juvenile Justice Girls Randomized Control Trial: Young Adult Follow-up|Juvenile Justice Girls: Pathways to Adjustment and System Use in Young Adulthood|Completed||Phase 1|166|Actual|Oregon Social Learning Center||2|||f||||f|f|f||||||Undecided||2018-05-31 22:40:33.447572|2018-05-31 22:40:33.447572
NCT01341613|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2011-11-01|2011-04-22|2011-04-26|Estimate|||||||2011-11-01|2011-11-02|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation|Efficacy of a Supplement Capsule Containing L. Reuteri Cardioviva™ on Managing Cholesterol Levels in Hypercholesterolemic Humans|Completed||Phase 2|131|Actual|Micropharma Limited||2|||f||||f||||||||||2018-05-31 22:40:33.546791|2018-05-31 22:40:33.546791
NCT01341600|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|2016-08-23||2017-06-28|2011-04-22|2011-04-25|Estimate|2017-06-28|2017-07-27|Actual||||2017-06-28|2017-07-27|Actual|July 2010||2010-07-31|June 2017|2017-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PGXB2B||Clopidogrel Pharmacogenetics (PGX) Bench to Bedside|Clopidogrel Pharmacogenetics Bench to Bedside - A Practical Application|Completed||N/A|18|Actual|University of Maryland||6|||f||||t||||||||||2018-05-31 22:40:33.619023|2018-05-31 22:40:33.619023
NCT01341587|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2018-02-08||2018-03-07|2011-04-22|2011-04-25|Estimate|2018-03-07|2018-03-12|Actual||||2018-03-07|2018-03-12|Actual|April 2011||2011-04-30|February 2018|2018-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Smart Glucose Meter Project|Comparison of a Cellular-embedded Glucose Meter With Two-way Personalized Communication Between Patients and Care Managers With a Glucose Meter in Standard Practice in the Care of Diabetic Patients.|Terminated||N/A|14|Actual|University of Maryland||2||participants lost to follow-up;|f||||t||||||||||2018-05-31 22:40:33.91599|2018-05-31 22:40:33.91599
NCT01341574|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2015-06-03|2011-04-22|2011-04-25|Estimate|||||||2015-06-03|2015-06-04|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Early Versus Delayed Treatment of Unilateral Neglect After Stroke|Influence of Prism Adaptation on Spatial Neglect in the Early Versus Delayed Phase After Stroke: a Randomized, Placebo-controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|University Ghent||5|||f||||f||||||||||2018-05-31 22:40:34.120841|2018-05-31 22:40:34.120841
NCT01341561|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-22|2011-04-22|2011-04-25|Estimate|||||||2011-04-22|2011-04-25|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Observational|||Relevance of Biomarkers in the Process of Weaning|The Relevance of Biochemical Markers in the Process of Weaning|Unknown status|Recruiting||100|Anticipated|Heidelberg University|||1||f||||f||||||Samples With DNA|"~     routine blood parameters~   "|||2018-05-31 22:40:34.196708|2018-05-31 22:40:34.196708
NCT01341548|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2018-05-01|2011-04-22|2011-04-25|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2019|Anticipated|2019-11-30|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|November 2021|Anticipated|2021-11-30||Interventional|ECH||Civamide Nasal Solution for Cluster Headache|A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Headache Period|Not yet recruiting||Phase 3|180|Anticipated|Winston Laboratories||2|||f||||f|t|f||||||No||2018-05-31 22:40:35.290645|2018-05-31 22:40:35.290645
NCT01341535|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2018-05-17|2011-04-21|2011-04-25|Estimate|||||||2018-05-17|2018-05-21|Actual|September 2011||2011-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|C-ART-2||Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer.|A Two-arm Phase II Randomized Study, Comparing Adaptive Biological Imaging - Voxel Intensity - Based Radiotherapy (Adaptive Dose Escalation) Versus Standard Radiotherapy for Head and Neck Cancer.|Active, not recruiting||Phase 2|95|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:40:35.390673|2018-05-31 22:40:35.390673
NCT01341522|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2013-07-16|2011-04-22|2011-04-25|Estimate|||||||2013-07-16|2013-07-17|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System|Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System|Withdrawn||Phase 3|0|Actual|LivaNova||2|||f||||t||||||||||2018-05-31 22:40:35.471212|2018-05-31 22:40:35.471212
NCT01341509|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2013-06-10|2011-04-22|2011-04-25|Estimate|||||||2013-06-10|2013-06-11|Estimate|April 2011||2011-04-30|June 2013|2013-06-30||||April 2014|Anticipated|2014-04-30||Interventional|||A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon|Insertional Achilles Tendinopathy: A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon|Unknown status|Recruiting|Phase 4|20|Anticipated|OAD Orthopaedics||2|||f||||f||||||||||2018-05-31 22:40:35.536504|2018-05-31 22:40:35.536504
NCT01341496|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2017-08-03|2011-04-22|2011-04-25|Estimate|||||||2017-08-03|2017-08-04|Actual|April 18, 2011||2011-04-18|July 21, 2016|2016-07-21|July 21, 2016|Actual|2016-07-21|May 12, 2016|Actual|2016-05-12||Interventional|||Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal|Epigenetically-Modified Autologous Tumor Cell Vaccs and ISCOMATRIX(TM) Adjuvant With Metronomic Oral Cyclophosphamide and Celecoxib in Pts Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura or Mediastinum|Terminated||Phase 1|41|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:40:35.621029|2018-05-31 22:40:35.621029
NCT01341483|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2016-01-28|2011-04-22|2011-04-25|Estimate|||||||2016-01-28|2016-02-01|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|IMPASSE||Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study|Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study|Terminated|||19|Actual|Medtronic Endovascular||||Sufficient information gathered|f||||f||||||||||2018-05-31 22:40:35.702693|2018-05-31 22:40:35.702693
NCT01341470|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2012-05-30|2011-04-22|2011-04-25|Estimate|||||||2012-05-30|2012-05-31|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of LY2495655 in Healthy Subjects|A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2495655 in Japanese Subjects|Completed||Phase 1|44|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 22:40:35.764587|2018-05-31 22:40:35.764587
NCT01341457|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2016-08-11|2011-04-22|2011-04-25|Estimate|||||||2016-08-11|2016-08-12|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2013|Actual|2013-06-30||Interventional|||A Study of LY2603618 in Combination With Gemcitabine in Patients With Solid Tumors|A Phase 1 Dose-Escalation Study of LY2603618 in Combination With Gemcitabine in Japanese Patients With Solid Tumors|Completed||Phase 1|16|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:40:35.926626|2018-05-31 22:40:35.926626
NCT01341444|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2017-02-03||2017-06-01|2011-04-22|2011-04-25|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|August 2013||2013-08-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PIMS||The Use of the Prevena Incision Management System (PIMS) on Closed Incisions in Renal Transplant Subjects|The Use of the Prevena Incision Management System on Closed Recipient Site Incisions in Renal Transplant Subjects|Terminated||N/A|63|Actual|KCI USA, Inc.||2||Enrollment Difficulties|f||||f||||||||||2018-05-31 22:40:36.025534|2018-05-31 22:40:36.025534
NCT01341431|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-06-13|2011-04-22|2011-04-25|Estimate|||||||2014-06-13|2014-06-16|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MIREILLE||Bee Venom for the Treatment of Parkinson Disease|Evaluation of the Symptomatic and Neuroprotective Effects of Bee Venom for the Treatment of Parkinson Disease|Completed||Phase 2|50|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:40:36.460603|2018-05-31 22:40:36.460603
NCT01341418|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-02-13|2011-04-22|2011-04-25|Estimate|||||||2017-02-13|2017-02-14|Actual|April 2011||2011-04-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2014|Actual|2014-01-31||Interventional|SP-Pilot||Suprapatellar Versus Infrapatellar Nailing in Tibial Fractures: A Pilot Study|Randomized Clinical Trial of Suprapatellar Versus Infrapatellar Tibial Nailing: A Pilot Study|Completed||N/A|40|Actual|Florida Orthopaedic Institute||2|||f||||f||||||||||2018-05-31 22:40:36.573474|2018-05-31 22:40:36.573474
NCT01341405|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2012-10-09|2011-04-22|2011-04-25|Estimate|||||||2012-10-09|2012-10-10|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Study of CG100649 Versus Celecoxib in Osteoarthritis Patients|A Double-blind, Randomized, Multicenter, Noninferiority, Phase II Repeat Dose Study of CG100649 Versus Celecoxib in Osteoarthritis Patients|Completed||Phase 2|125|Actual|CrystalGenomics, Inc.||3|||f||||t||||||||||2018-05-31 22:40:36.664172|2018-05-31 22:40:36.664172
NCT01341392|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2011-08-11|2011-04-22|2011-04-25|Estimate|||||||2011-08-11|2011-08-15|Estimate|April 2011||2011-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Drug-drug Interaction Study(CKD-501, Amlodipine)|A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Amlodipine After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|25|Actual|Chong Kun Dang Pharmaceutical||3|||f||||f||||||||||2018-05-31 22:40:36.93324|2018-05-31 22:40:36.93324
NCT01341379|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2014-05-28|2011-04-22|2011-04-25|Estimate|||||||2014-05-28|2014-05-29|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate|Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate|Withdrawn||Phase 2|0|Actual|Children's Hospital of Philadelphia||1||Lack of funding|f||||t||||||||||2018-05-31 22:40:37.103615|2018-05-31 22:40:37.103615
NCT01341366|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2013-04-29|2011-04-22|2011-04-25|Estimate|||||||2013-04-29|2013-04-30|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Fast-track Perioperative Program for Laparoscopic Colorectal Surgery|The Impact of Fast-track Perioperative Program on the Clinical and Immunological Outcomes After Laparoscopic Colorectal Surgery in Hong Kong Chinese Patients: A Prospective Randomized Trial|Completed||Phase 3|128|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:40:37.444295|2018-05-31 22:40:37.444295
NCT01341353|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-04-21|2011-04-21|2011-04-25|Estimate|||||||2011-04-21|2011-04-25|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China|Atrial Fibrillation Therapy: A Multi-Center Clinical Study|Unknown status|Recruiting|Phase 4|1800|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 22:40:37.550421|2018-05-31 22:40:37.550421
NCT01341340|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-12-13|2011-04-22|2011-04-25|Estimate|||||||2013-12-13|2013-12-17|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The ABSORB BTK (Below The Knee) Clinical Investigation|A Clinical Evaluation of the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) for the Treatment of Subjects With Critical Limb Ischemia (CLI) From Occlusive Vascular Disease of the Tibial Arteries|Terminated||N/A|2|Actual|Abbott Vascular||1||"Discontinued due to poor enrollment. Insufficient number of patients enrolled to permit a~   statistically rigorous assessment of safety and efficacy."|f||||t||||||||||2018-05-31 22:40:37.696668|2018-05-31 22:40:37.696668
NCT01341327|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2017-07-19|2011-04-22|2011-04-25|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2007|Actual|2007-07-31|July 2017|2017-07-31|July 2030|Anticipated|2030-07-31|July 2020|Anticipated|2020-07-31||Observational|IRIS-MAIN||Observational Study for Left Main Disease Treatment|A GLOBAL, MULTICENTER, PROSPECTIVE, REAL WORLD OBSERVATIONAL STUDY FOR LEFT MAIN DISEASE TREATMENT|Recruiting|||10000|Anticipated|CardioVascular Research Foundation, Korea|||1||f||||t||||||||No|This is not a publicly funded trial|2018-05-31 22:40:37.953567|2018-05-31 22:40:37.953567
NCT01341314|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2012-05-23|2011-04-22|2011-04-25|Estimate|||||||2012-05-23|2012-05-24|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Observational|||Finding Early Rheumatoid Arthritis|Proof of Concept of an Internet-based Series Design Case-finding System for Very Early Rheumatoid Arthritis.|Unknown status|Active, not recruiting||200|Anticipated|Brigham and Women's Hospital|||||f||||f||||||Samples Without DNA|"~     Frozen serum for future assay development~   "|||2018-05-31 22:40:38.132154|2018-05-31 22:40:38.132154
NCT01341301|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2017-06-07||2018-04-23|2011-04-21|2011-04-25|Estimate|2018-02-19|2018-03-16|Actual||||2018-04-23|2018-04-25|Actual|May 2010||2010-05-31|April 2018|2018-04-30|August 7, 2014|Actual|2014-08-07|November 4, 2013|Actual|2013-11-04||Interventional|||Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Human Leukocyte Antigen Partially-Matched Related Donor|Completed||Phase 2|25|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 22:40:38.222787|2018-05-31 22:40:38.222787
NCT01341288|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2017-04-10|2011-04-21|2011-04-25|Estimate|||||||2017-04-10|2017-04-12|Actual|July 29, 2008|Actual|2008-07-29|April 2017|2017-04-30|February 27, 2015|Actual|2015-02-27|February 26, 2015|Actual|2015-02-26||Interventional|EUCLIDIAN||Robotic Seed Implantation for Prostate Cancer Brachytherapy|Phase I Study Using EUCLIDIAN Robotic Assistance During Prostate Brachytherapy|Terminated||Phase 1|2|Actual|Thomas Jefferson University||1||Slow accrual|f||||t|f|t|f|||||||2018-05-31 22:40:38.783479|2018-05-31 22:40:38.783479
NCT01341275|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-22|||2011-04-22|2011-04-22|2011-04-25|Estimate|||||||2011-04-22|2011-04-25|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|REACH||Adolescents' Response to Hepatitis B Vaccine Booster Dose|Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood|Unknown status|Recruiting|Phase 4|400|Anticipated|Baylor College of Medicine||4|||f||||f||||||||||2018-05-31 22:40:38.877644|2018-05-31 22:40:38.877644
NCT01341262|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2011-04-22|2011-04-22|2011-04-25|Estimate|||||||2011-04-22|2011-04-25|Estimate|March 2002||2002-03-31|March 2011|2011-03-31|January 2009|Actual|2009-01-31|October 2007|Actual|2007-10-31||Interventional|||THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)|Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation for Patients Less Than 65 Years of Age With Newly Diagnosed Multiple Myeloma|Completed||Phase 2|378|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||||f||||t||||||||||2018-05-31 22:40:38.966393|2018-05-31 22:40:38.966393
NCT01341249|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-07-15|2011-04-21|2011-04-25|Estimate|||||||2011-07-15|2011-07-18|Estimate|April 2011||2011-04-30|July 2011|2011-07-31||||May 2011|Actual|2011-05-31||Interventional|||A Study to Compare the Pharmacokinetic Profiles of DW224aa and DW224a|Clinical Trial to Compare the Pharmacokinetic Profiles of DW224aa (Aspartate) Tablet and DW224a (Hydrochloride) Capsule After a Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|32|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:40:39.038939|2018-05-31 22:40:39.038939
NCT01341236|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2013-03-21|2011-04-21|2011-04-25|Estimate|||||||2013-03-21|2013-03-22|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Near Infrared Spectroscopy (NIRS) and Superior Mesenteric Artery (SMA) Doppler Patterns as Predictor of Feeding Tolerance in Very Low Birth Weight (VLBW) IntraUterine Growth Restricted (IUGR) and NON IUGR Infants|Evaluation of Splanchnic Oximetry,Doppler Flow Velocimetry in the Superior Mesenteric Artery and Feeding Tolerance in VERY LOW BIRTH WEIGHT IUGR and NON-IUGR Infants Receiving Bolus Versus Continuous Enteral Nutrition|Completed||Phase 4|41|Actual|San Gerardo Hospital||2|||f||||f||||||||||2018-05-31 22:40:39.105599|2018-05-31 22:40:39.105599
NCT01341223|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-03-04|2011-04-21|2011-04-25|Estimate|||||||2012-03-04|2012-03-06|Estimate|March 2011||2011-03-31|March 2012|2012-03-31||||March 2016|Anticipated|2016-03-31||Observational|||Using Amniotic Membrane as the Carrier for ex Vivo Cell Culture for Cell Therapy in Ocular Surface Reconstruction|Using Amniotic Membrane as the Carrier for ex Vivo Cell Culture for Cell Therapy in Ocular Surface Reconstruction|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 22:40:39.187361|2018-05-31 22:40:39.187361
NCT01341210|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2013-08-23|2011-04-22|2011-04-25|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Observational Study of the Decision Making Towards Clinical Trials in Cancer Patients|The Study of the Knowledge, Attitudes, and Decision Making Towards Clinical Trials in Cancer Patients|Unknown status|Recruiting||116|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 22:40:39.26764|2018-05-31 22:40:39.26764
NCT01341197|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-11-30|2011-04-21|2011-04-25|Estimate|||||||2012-11-30|2012-12-03|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Fecal Screening Assay for Taiwanese Population|A Pan-detecting Assay Based on Stool Samples for Taiwanese Population|Completed|||3172|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 22:40:39.325237|2018-05-31 22:40:39.325237
NCT01341184|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-04-20|2011-04-21|2011-04-25|Estimate|||||||2017-04-20|2017-04-21|Actual|October 21, 2011|Actual|2011-10-21|April 14, 2017|2017-04-14|May 23, 2012|Actual|2012-05-23|May 23, 2012|Actual|2012-05-23||Interventional|||TMC207 +/- Rifabutin/Rifampin|A Phase I Open-Label Trial To Investigate the Pharmacokinetic Interaction Between Rifabutin Or Rifampin And A Single Dose Of TMC207 In Healthy Subjects|Completed||Phase 1|33|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 22:40:39.397824|2018-05-31 22:40:39.397824
NCT01341171|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-04-21|2011-04-21|2011-04-25|Estimate|||||||2011-04-21|2011-04-25|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|September 2012|Anticipated|2012-09-30|October 2010|Actual|2010-10-31||Observational|||The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins|Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins|Unknown status|Active, not recruiting||60|Anticipated|University of Vermont|||1||f||||f||||||Samples Without DNA|"~     serum, plasma, platelet activated samples~   "|||2018-05-31 22:40:39.587447|2018-05-31 22:40:39.587447
NCT01341158|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2014-11-11|2011-04-21|2011-04-25|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||NAM-Trial: Multiferon in Malignant Melanoma|Neoadjuvant Treatment of Locoregional Metastases in Malignant Melanoma (AJCC Stage IIIB/C) With Multiferon: a Phase IIa DeCOG Trial|Completed||Phase 2|42|Actual|University Hospital Tuebingen||1|||f||||t||||||||||2018-05-31 22:40:39.655157|2018-05-31 22:40:39.655157
NCT01341145|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-04-10|2011-04-21|2011-04-25|Estimate|||||||2014-04-10|2014-04-14|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Physical Fitness, Cardiovascular and Brain Health|Physical Fitness, Cardiovascular and Brain Health|Completed||N/A|41|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 22:40:39.766826|2018-05-31 22:40:39.766826
NCT01341132|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-04-21|2011-04-21|2011-04-25|Estimate|||||||2011-04-21|2011-04-25|Estimate|May 2011||2011-05-31|April 2011|2011-04-30||||June 2012|Anticipated|2012-06-30||Observational|||Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents|Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents|Unknown status|Enrolling by invitation||75|Anticipated|San Francisco Veterans Affairs Medical Center|||1||f||||f||||||||||2018-05-31 22:40:39.851952|2018-05-31 22:40:39.851952
NCT01341119|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-08-06|2011-04-22|2011-04-25|Estimate|||||||2012-08-06|2012-08-07|Estimate|November 2010||2010-11-30|August 2012|2012-08-31||||||||Observational|||Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma|Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma|Completed|||40|Anticipated|Samsung Medical Center|||||f||||||||||||||2018-05-31 22:40:39.916159|2018-05-31 22:40:39.916159
NCT01341106|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2015-09-22|2011-04-21|2011-04-25|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|INFIRE||Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection|Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection|Terminated||Phase 4|7|Actual|RWTH Aachen University||1||insufficient patient numbers have been recruited|f||||f||||||||||2018-05-31 22:40:39.981121|2018-05-31 22:40:39.981121
NCT01341093|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-05-14|2011-04-22|2011-04-25|Estimate|||||||2014-05-14|2014-05-15|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Education Program for Cardiac Patients|Educational Program With Telephone Follow-up for Patients After Percutaneous Coronary Intervention: Randomized Controlled Trial|Completed||N/A|60|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:40:40.079685|2018-05-31 22:40:40.079685
NCT01339767|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2018-05-24|2011-04-20|2011-04-21|Estimate|||||||2018-05-24|2018-05-25|Actual|April 18, 2011||2011-04-18|June 30, 2017|2017-06-30|June 30, 2017||2017-06-30|||||Observational|||Study of Toddlers With Language Delay|Markers of Autism Spectrum Disorders in At-Risk Toddlers: A Pilot Study|Completed|||77|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:41:11.715088|2018-05-31 22:41:11.715088
NCT01341080|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-08-28|2011-04-22|2011-04-25|Estimate|||||||2017-08-28|2017-08-30|Actual|November 2010||2010-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Chantix-PD||Varenicline for Gait and Balance Impairment in Parkinson Disease|Varenicline for the Treatment of Postural and Gait Dysfunction in Parkinson Disease|Recruiting||Phase 2|40|Anticipated|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 22:40:40.182804|2018-05-31 22:40:40.182804
NCT01341067|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2013-03-22||2014-04-01|2011-04-22|2011-04-25|Estimate|2014-04-01|2014-05-02|Estimate||||2014-04-01|2014-05-02|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|DexlonT2||Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes|Continuous Glucose Monitoring in Subjects With Type 2 Diabetes|Completed|||30|Actual|Rocky Mountain Diabetes and Osteoporosis Center|||1||f||||||||||||||2018-05-31 22:40:40.296492|2018-05-31 22:40:40.296492
NCT01341054|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2013-01-11|2011-04-21|2011-04-25|Estimate|||||||2013-01-11|2013-01-14|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Use of Chamomilla Recutita in Mucositis|Chamomilla Recutita Use of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation|Completed||Phase 2|40|Actual|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 22:40:40.501682|2018-05-31 22:40:40.501682
NCT01341041|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-21|2011-04-21|2011-04-25|Estimate|||||||2011-04-21|2011-04-25|Estimate|August 2004||2004-08-31|April 2011|2011-04-30|June 2009|Actual|2009-06-30|December 2007|Actual|2007-12-31||Interventional|||Chlorine Dioxide Versus Saline for Wound Irrigation|Wound Irrigation: Comparison of Normal Saline With Chlorous Acid Chlorine Dioxide Solution|Completed||Early Phase 1|201|Actual|Rhode Island Hospital||2|||f||||||||||||||2018-05-31 22:40:40.587466|2018-05-31 22:40:40.587466
NCT01341028|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-04-21|2011-04-21|2011-04-25|Estimate|||||||2011-04-21|2011-04-25|Estimate|May 2007||2007-05-31|February 2007|2007-02-28|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Gut Hormones After Roux-en-Y Gastric Bypass (RYGBP) Plus Gastric Fundus Resection|Effects of the Resection of the Gastric Fundus on the Secretion of Ghrelin, Peptide-YY, Glucagon-like Peptide-1 and Insulin Secretion in Morbidly Obese Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass|Completed||N/A|24|Actual|University of Patras||2|||f||||t||||||||||2018-05-31 22:40:40.650497|2018-05-31 22:40:40.650497
NCT01341015|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-12-03|2011-04-21|2011-04-25|Estimate|||||||2012-12-03|2012-12-05|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Bedside Ultrasound in the Diagnosis of Ankle Fractures in Children|Bedside Ultrasound in the Diagnosis of Ankle Fractures in Children|Completed||Early Phase 1|50|Actual|Rhode Island Hospital||1|||f||||f||||||||||2018-05-31 22:40:40.769554|2018-05-31 22:40:40.769554
NCT01341002|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2015-05-12|2011-04-22|2011-04-25|Estimate|||||||2015-05-12|2015-05-13|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||Red Blood Cells (RBC) Transfusion Related to Central Venous O2 Saturation (ScvO2) Measurement|Red Blood Cells (RBC) Transfusion Related to Central Venous O2 Saturation|Completed||N/A|100|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 22:40:40.874532|2018-05-31 22:40:40.874532
NCT01340989|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-10-25|2011-04-22|2011-04-25|Estimate|||||||2011-10-25|2011-10-26|Estimate|August 2006||2006-08-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||CO2 Absorption During Laparoscopy|Evaluation of Adding 4% of Oxygen and 10% of Nitrous Oxide to the CO2 Pneumoperitoneum Upon CO2 Resorption.|Completed||N/A|60|Anticipated|University Hospital, Gasthuisberg||3|||f||||f||||||||||2018-05-31 22:40:40.950423|2018-05-31 22:40:40.950423
NCT01340976|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2014-12-17|2011-04-22|2011-04-25|Estimate|||||||2014-12-17|2014-12-18|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase 1 Study of LY2787106 in Cancer and Anemia|A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia|Completed||Phase 1|19|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 22:40:41.031877|2018-05-31 22:40:41.031877
NCT01340963|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2013-12-09|2011-04-22|2011-04-25|Estimate|||||||2013-12-09|2013-12-10|Estimate|June 1995||1995-06-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|March 2001|Actual|2001-03-31||Observational|SEARCH-Rio||The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort|Prognostic Value of the Spectral Turbulence Analysis of the Signal-averaged Electrocardiogram in Chagas Heart Disease|Completed|||100|Actual|Universidade Gama Filho|||3||f||||t||||||||||2018-05-31 22:40:41.125678|2018-05-31 22:40:41.125678
NCT01340950|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-03-31|2011-04-22|2011-04-25|Estimate|||||||2016-03-31|2016-04-04|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|||Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China|Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China|Completed||Phase 4|250|Actual|University of California, San Diego||2|||f||||t||||||||Yes|Data will be shared in conference presentations and peer-reviewed publications. Data will also be made available on approval of requests for appropriate use.|2018-05-31 22:40:41.218662|2018-05-31 22:40:41.218662
NCT01340937|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2016-02-18||2017-11-29|2011-04-22|2011-04-25|Estimate|2016-03-29|2016-05-02|Estimate||||2017-11-29|2017-12-26|Actual|May 10, 2011|Actual|2011-05-10|November 2017|2017-11-30|July 26, 2013|Actual|2013-07-26|December 18, 2012|Actual|2012-12-18||Interventional|||A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)|A Phase III Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq ™|Completed||Phase 3|2808|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 22:40:41.401363|2018-05-31 22:40:41.401363
NCT01340924|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2017-02-13|2011-04-21|2011-04-25|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2009||2009-09-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Observational|GDM||Relationship Between Gestational Diabetes and Type 2 Diabetes|Key Determinants of Type 2 Diabetes Prevention Among Women With a History of Gestational Diabetes Mellitus|Active, not recruiting|||450|Anticipated|Laval University|||||f||||f||||||Samples With DNA|"~     whole blood; serum; white cell.~   "|Yes||2018-05-31 22:40:43.34907|2018-05-31 22:40:43.34907
NCT01340911|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-10-27|2011-04-21|2011-04-25|Estimate|||||||2017-10-27|2017-10-30|Actual|June 3, 2011|Actual|2011-06-03|October 2017|2017-10-31|November 24, 2011|Actual|2011-11-24|November 24, 2011|Actual|2011-11-24||Interventional|||A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases|A Randomized, Placebo-Controlled, Single-Blind, Dose-Escalation, First-Time-in-Human Study to Assess the Safety and Pharmacokinetics of Single and Repeat Doses of SRT3025 in Normal Healthy Volunteers|Completed||Phase 1|78|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:40:43.407902|2018-05-31 22:40:43.407902
NCT01340898|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14||2015-03-12|2017-01-16|2011-04-21|2011-04-25|Estimate||||2015-03-12|2015-04-01|Estimate|2017-01-16|2017-01-18|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK 134612) When Co-administered With Routine Vaccines in Healthy Infants and Toddlers|Completed||Phase 3|753|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 22:40:43.53933|2018-05-31 22:40:43.53933
NCT01340885|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2012-11-09|2011-04-21|2011-04-25|Estimate|||||||2012-11-09|2012-11-12|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Cognitive Decline in Non-demented PD|Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study|Unknown status|Recruiting|Phase 4|50|Anticipated|Oregon Health and Science University||3|||f||||f||||||||||2018-05-31 22:40:43.623328|2018-05-31 22:40:43.623328
NCT01340872|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2016-08-30|2011-04-21|2011-04-25|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|AEGIS-1||Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)|A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1)|Completed||Phase 3|58|Actual|Shield Therapeutics||2|||f||||f||||||||No||2018-05-31 22:40:43.725395|2018-05-31 22:40:43.725395
NCT01340859|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2018-04-02|2011-04-22|2011-04-25|Estimate|||||||2018-04-02|2018-04-03|Actual|April 2011||2011-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Inpatient Post Admission Cognitive Therapy (PACT) for the Prevention of Suicide Attempts|Inpatient Post Admission Cognitive Therapy (PACT) for the Prevention of Suicide Attempts: A Pilot Study|Active, not recruiting||N/A|24|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t||||||||No||2018-05-31 22:40:43.810784|2018-05-31 22:40:43.810784
NCT01340846|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-11-08|2011-04-21|2011-04-25|Estimate|||||||2017-11-08|2017-11-13|Actual|September 3, 2012|Actual|2012-09-03|November 2017|2017-11-30|November 14, 2012|Actual|2012-11-14|November 14, 2012|Actual|2012-11-14||Interventional|||A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors|A Four-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin, the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on the Repeat Dose Pharmacokinetics of GSK2118436, and the Repeat Dose Pharmacokinetics of GSK2118436 in Subjects With BRAF Mutant Solid Tumors|Completed||Phase 1|48|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 22:40:43.979153|2018-05-31 22:40:43.979153
NCT01340833|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-11-08|2011-04-21|2011-04-25|Estimate|||||||2017-11-08|2017-11-13|Actual|June 8, 2011|Actual|2011-06-08|November 2017|2017-11-30|September 12, 2011|Actual|2011-09-12|September 12, 2011|Actual|2011-09-12||Interventional|||Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors|Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:40:44.091945|2018-05-31 22:40:44.091945
NCT01340820|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-08-15|2011-04-21|2011-04-25|Estimate|||||||2012-08-15|2012-08-16|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Study of AERAS 422 in Healthy Adults|A Phase 1, Randomized, Controlled, Double-blind, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of AERAS-422 in Healthy Adults|Completed||Phase 1|24|Actual|Aeras||3|||f||||t||||||||||2018-05-31 22:40:44.191153|2018-05-31 22:40:44.191153
NCT01340807|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-04-22|2011-04-22|2011-04-25|Estimate|||||||2011-04-22|2011-04-25|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|SEW||A Comparison of External Mechanical Work Between Different Prosthetic Feet|A Comparison of External Mechanical Work Between Bionic and Conventional Prosthetic Feet in Transtibial Amputees During Functional Activities|Completed||N/A|15|Actual|Miami VA Healthcare System||1|||f||||t||||||||||2018-05-31 22:40:44.260587|2018-05-31 22:40:44.260587
NCT01340794|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2016-03-23||2017-09-19|2011-04-21|2011-04-25|Estimate|2016-06-09|2016-07-21|Estimate||||2017-09-19|2017-09-21|Actual|May 2011||2011-05-31|September 2017|2017-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All 6 patients that began protocol treatment were included in the baseline analysis.|Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma|A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma|Terminated||Phase 2|7|Actual|National Cancer Institute (NCI)||1||Slow Accrual|f||||t||||||||||2018-05-31 22:40:44.379911|2018-05-31 22:40:44.379911
NCT01340781|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2013-07-18|2011-04-21|2011-04-25|Estimate|||||||2013-07-18|2013-07-19|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|STOMP||Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patients|Evaluation of Screening Tools for OSA in Hospitalized Medical Patients: A Validation Study|Completed|||110|Actual|MetroHealth Medical Center|||1||f||||t||||||||||2018-05-31 22:40:44.813152|2018-05-31 22:40:44.813152
NCT01340768|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2012-09-07||2017-05-04|2011-04-21|2011-04-25|Estimate|2012-09-07|2012-10-08|Estimate||||2017-05-04|2017-06-05|Actual|June 22, 2010|Actual|2010-06-22|May 2017|2017-05-31|September 21, 2011|Actual|2011-09-21|September 21, 2011|Actual|2011-09-21||Interventional|||Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)|An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting|Completed||Phase 3|870|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:40:44.899434|2018-05-31 22:40:44.899434
NCT01340755|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-09-01|2011-04-21|2011-04-25|Estimate|||||||2017-09-01|2017-09-06|Actual|March 2011||2011-03-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2012|Actual|2012-05-31||Interventional|||Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer|A Pilot Study of Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer|Completed||N/A|5|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 22:40:45.097388|2018-05-31 22:40:45.097388
NCT01340742|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-06-29|2011-04-21|2011-04-25|Estimate|||||||2011-06-29|2011-07-01|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Remote Ischemic Preconditioning Before Abdominal Surgery|Remote Ischemic Preconditioning Before Abdominal Surgery and the Prevalence of Perioperative Complications|Unknown status|Recruiting|Phase 2|440|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 22:40:45.161123|2018-05-31 22:40:45.161123
NCT01340729|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2013-04-04|2011-04-20|2011-04-25|Estimate|||||||2013-04-04|2013-04-05|Estimate|September 2013||2013-09-30|April 2013|2013-04-30||||September 2016|Anticipated|2016-09-30||Interventional|||Open-Label Study of TPI 287 for Patients With Metastatic Melanoma|A Phase I/II Open-Label Study of TPI 287 for Patients With Metastatic Melanoma|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:40:45.228959|2018-05-31 22:40:45.228959
NCT01340716|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-03-10|2011-04-21|2011-04-22|Estimate|||||||2017-03-10|2017-03-14|Actual|March 2011||2011-03-31|February 2016|2016-02-29|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Tai Chi Chuan in Patients After Recent Acute Myocardial Infarction|Effects of Tai Chi Chuan on Blood Pressure, Respiratory Muscle Strength and Functional Capacity in Patients After Recent Acute Myocardial Infarction: a Randomized Clinical Trial|Completed||N/A|61|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||Undecided||2018-05-31 22:40:45.335827|2018-05-31 22:40:45.335827
NCT01340703|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2011-04-21|2011-04-21|2011-04-22|Estimate|||||||2011-04-21|2011-04-22|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Vitrectomy for Optic Disc Pit Maculopathy|Vitrectomy Without Laser or Gas Tamponade for Optic Disc Pit Maculopathy|Completed||N/A|8|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 22:40:45.444939|2018-05-31 22:40:45.444939
NCT01340690|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-09-19|2011-04-21|2011-04-22|Estimate|||||||2017-09-19|2017-09-20|Actual|March 8, 2011|Actual|2011-03-08|September 2017|2017-09-30|March 1, 2017|Actual|2017-03-01|March 31, 2016|Actual|2016-03-31||Interventional|PAD||Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder|PAD-study: Nutritional Efficacy of Polyunsaturated Fatty Acids (Omega-3 and Omega-6) in Combination With Zinc and Magnesium Versus Placebo in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder (ADHD)|Terminated||Phase 3|284|Actual|Johannes Gutenberg University Mainz||2||The sample size of the planned interims analysis was achieved|f||||t||||||||Undecided||2018-05-31 22:40:45.530732|2018-05-31 22:40:45.530732
NCT01340677|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2012-08-16|2011-04-21|2011-04-22|Estimate|||||||2012-08-16|2012-08-17|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers|An Open-Label, Single-Dose, Randomized, 3-Period, Crossover Study to Evaluate the Pharmacokinetic Dose Proportionality of Canagliflozin of 50, 100, and 300 mg Under Fasted Conditions in Healthy Subjects|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 22:40:45.711852|2018-05-31 22:40:45.711852
NCT01340664|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2014-08-20|2012-03-30|2014-09-05|2011-04-21|2011-04-22|Estimate|2014-08-20|2014-09-01|Estimate|2012-04-24|2012-04-25|Estimate|2014-09-05|2014-09-16|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin|Completed||Phase 2|279|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 22:40:45.816164|2018-05-31 22:40:45.816164
NCT01340651|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2013-07-23||2014-02-05|2011-04-21|2011-04-22|Estimate|2013-07-23|2013-09-25|Estimate||||2014-02-05|2014-03-10|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Intent-to-treat population: All enrolled participants.|Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients|An Open-label Assessment of Once-daily Dosing of a Sustained Release (SR) Formulation of INCB018424 in Patients With Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, and Post-polycythemia Vera Myelofibrosis|Completed||Phase 2|41|Actual|Incyte Corporation||1|||f||||f||||||||||2018-05-31 22:40:46.380695|2018-05-31 22:40:46.380695
NCT01340638|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-04-20|2011-04-20|2011-04-22|Estimate|||||||2011-04-20|2011-04-22|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Seal Pressure With Classical Laryngeal Mask and Cookgas Mask in Adult Patients|EFFECTIVENESS OF SEAL PRESSURE IN AIRWAY OF THE CLASSIC LARYNGEAL MASK AND THE COOKGAS LARYNGEAL MASK IN ADULT PATIENTS UNDERGOING SURGERY IN AMBULATORY SETTINGS|Unknown status|Not yet recruiting|Phase 3|106|Anticipated|Universidad de Antioquia||2|||f||||f||||||||||2018-05-31 22:40:46.761232|2018-05-31 22:40:46.761232
NCT01340625|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2011-04-27||2011-04-27|2011-04-20|2011-04-22|Estimate|2011-04-27|2011-05-25|Estimate||||2011-04-27|2011-05-25|Estimate|December 2006||2006-12-31|April 2011|2011-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions|A Relative Bioavailability Study of 0.4 mg/35 Mcg Norethindrone and Ethinyl Estradiol Chewable Tablets Under Fasting Conditions|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 22:40:46.856036|2018-05-31 22:40:46.856036
NCT01340612|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-12-13|2011-04-21|2011-04-22|Estimate|||||||2017-12-13|2017-12-15|Actual|August 25, 2011|Actual|2011-08-25|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|STAT||Stenting in the Treatment of Aneurysm Trial|Stenting in the Treatment of Large, Wide-necked or Recurring Intracranial Aneurysms|Recruiting||Phase 4|600|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 22:40:47.277177|2018-05-31 22:40:47.277177
NCT01340599|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2012-03-14|2011-04-21|2011-04-22|Estimate|||||||2012-03-14|2012-03-15|Estimate|October 2006||2006-10-31|March 2012|2012-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery|Phase II, Randomized, Double Blind, Placebo Controlled Pilot Study of Polyphenon E in Men With Localized Prostate Cancer Scheduled to Undergo Radical Prostatectomy|Terminated||Phase 2|5|Actual|Case Comprehensive Cancer Center||2||Slow accrual|f||||t||||||||||2018-05-31 22:40:47.461409|2018-05-31 22:40:47.461409
NCT01340586|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|2016-03-29||2016-08-17|2011-04-21|2011-04-22|Estimate|2016-08-17|2016-10-11|Estimate||||2016-08-17|2016-10-11|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||All treated participants|Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis|Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects on Hemodialysis|Completed||Phase 1|18|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 22:40:47.584694|2018-05-31 22:40:47.584694
NCT01340573|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2011-10-04||2015-01-20|2011-04-20|2011-04-22|Estimate|2011-12-22|2012-01-30|Estimate||||2015-01-20|2015-02-02|Estimate|March 2007||2007-03-31|January 2015|2015-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)|Non-Interventional Study Evaluating The Safety and Efficacy In Patients Receiving New PegIntron Pen for Hepatitis C|Terminated|||3|Actual|Merck Sharp & Dohme Corp.|||2|Terminated early due to low enrollment.|f||||||||||Samples With DNA|"~     Efficacy measurements for sustained viral response HCV RNA were collected at week 24 of study~     treatment and at week 24 of follow-up in Non-genotype-1 participants. Efficacy measurements~     for Genotype-1 participants for sustained viral response HCV RNA were collected at week 24~     and at week 48 of study treatment, and at week 24 of follow-up.~   "|||2018-05-31 22:40:48.194166|2018-05-31 22:40:48.194166
NCT01340560|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-20|2011-04-20|2011-04-22|Estimate|||||||2011-04-20|2011-04-22|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Endometrial Injury Increases Implantation and Pregnancy Rates|The Effect of Local Injury to the Endometrium for Implantation and Pregnancy Rates in ICSI -ET Cycles With Recurrent Implantation Failure: a Randomised Controlled Study|Completed||N/A|100|Anticipated|Selcuk University|||||f||||f||||||||||2018-05-31 22:40:48.372496|2018-05-31 22:40:48.372496
NCT01340547|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-07-17|2011-04-19|2011-04-22|Estimate|||||||2013-07-17|2013-07-18|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors|A Phase I Multicenter, Open-label Study of the Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|Ziopharm||1|||f||||f||||||||||2018-05-31 22:40:48.422045|2018-05-31 22:40:48.422045
NCT01340534|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2015-01-01|2011-04-20|2011-04-22|Estimate|||||||2015-01-01|2015-01-05|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Supplemental Perioperative Oxygen to Reduce the Incidence of Post-cesarean Wound Infection|Supplemental Perioperative Oxygen at 80% FIO2 to Reduce the Incidence of Post-cesarean Wound Infection. A Randomised, Clinical Trial|Completed||Phase 3|370|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 22:40:48.480063|2018-05-31 22:40:48.480063
NCT01340521|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2012-12-19|2011-04-20|2011-04-22|Estimate|||||||2012-12-19|2012-12-20|Estimate|March 1991||1991-03-31|December 2012|2012-12-31|March 1994|Actual|1994-03-31|March 1994|Actual|1994-03-31||Interventional|||Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women|FSH and LH Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women|Completed||Phase 1/Phase 2|25|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-05-31 22:40:48.651801|2018-05-31 22:40:48.651801
NCT01340508|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-04-20|2011-04-20|2011-04-22|Estimate|||||||2011-04-20|2011-04-22|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal Cancer|A Phase II Trial of Preoperative Concurrent Chemotherapy and (IMRT) in Locally Advanced Rectal Cancer|Unknown status|Recruiting|Phase 2|63|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 22:40:48.726433|2018-05-31 22:40:48.726433
NCT01340495|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2018-03-22||2018-03-22|2011-04-20|2011-04-22|Estimate|2018-03-22|2018-04-20|Actual||||2018-03-22|2018-04-20|Actual|June 2011||2011-06-30|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|April 2017|Actual|2017-04-30||Interventional|||Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy|Pilot Study of Proton Radiation Therapy for Invasive Breast Carcinoma Following Mastectomy|Active, not recruiting||N/A|70|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:40:48.821549|2018-05-31 22:40:48.821549
NCT01340482|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15||2015-01-12|2016-06-10|2011-04-20|2011-04-22|Estimate||||2015-01-12|2015-01-26|Estimate|2016-06-10|2016-06-14|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia|A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia|Completed||Phase 1/Phase 2|29|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-05-31 22:40:49.098071|2018-05-31 22:40:49.098071
NCT01340469|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-04-20|2011-04-20|2011-04-22|Estimate|||||||2011-04-20|2011-04-22|Estimate|January 2005||2005-01-31|March 2011|2011-03-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Effect of Oral Probiotic Supplementation on The Rate of Hospital Acquired Infection and Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants|Nosocomial Infections and Necrotizing Enterocolitis in Preterm Neonates Treated With Lactobacillus Acidophilus and Bifidobacterium Infantis in An Intensive Care Unit : A Randomized Controlled Study|Completed||Phase 3|160|Anticipated|King Chulalongkorn Memorial Hospital||2|||f||||f||||||||||2018-05-31 22:40:49.220313|2018-05-31 22:40:49.220313
NCT01340456|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-07-08|2011-04-20|2011-04-22|Estimate|||||||2011-07-08|2011-07-11|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Cholesterol Metabolites as Markers for CYP3A Induction|Induction of Drug Metabolism by Rifampicin to Compare the Endogenous Biomarker 4beta-OHcholesterol With the Probe Drug Midazolam as Quantitative Markers for Cytochrome P450 3A4 Induction|Completed||N/A|24|Actual|Karolinska University Hospital||3|||f||||f||||||||||2018-05-31 22:40:49.305503|2018-05-31 22:40:49.305503
NCT01340443|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-11-09|2011-04-20|2011-04-22|Estimate|||||||2017-11-09|2017-11-14|Actual|January 19, 2011|Actual|2011-01-19|November 2017|2017-11-30|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Observational|||An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma|A Multi Centre, Single Arm, Observational Study on Safety and Efficacy of MabThera Plus Chemotherapy as 1st Line Treatment in Patients With DLBCL or FL|Completed|||314|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:40:49.396256|2018-05-31 22:40:49.396256
NCT01340430|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2016-10-31|2011-04-21|2011-04-22|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|May 2025|Anticipated|2025-05-31|December 2015|Actual|2015-12-31||Interventional|||Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer|Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study.|Active, not recruiting||Phase 2|43|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||1|||f||||f||||||||Undecided||2018-05-31 22:40:49.529296|2018-05-31 22:40:49.529296
NCT01340417|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2013-09-17|2011-04-21|2011-04-22|Estimate|||||||2013-09-17|2013-09-18|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|MELIP||Melatonin Levels in Preterm and Term Newborn Infants|Melatonin Levels in Preterm and Term Newborn Infants|Completed||N/A|380|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:40:49.63661|2018-05-31 22:40:49.63661
NCT01340404|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-12-02|2011-04-21|2011-04-22|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|April 2013|Actual|2013-04-30||Interventional|DREPAGREFFE||Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy|A Multicenter Study Comparing the Results of Allogeneic Stem Cell Genoidentical in Children With Sickle Cell Anemia and Cerebral Vascular Disease Detected by Transcranial Doppler|Completed||N/A|63|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 22:40:49.727772|2018-05-31 22:40:49.727772
NCT01340391|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-04-21|2011-04-21|2011-04-22|Estimate|||||||2011-04-21|2011-04-22|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Safety Study on a Wood-plastic Composite Cast|A Wood-plastic Composite Cast - a New Ecological Splinting Method|Unknown status|Enrolling by invitation|N/A|33|Anticipated|Helsinki University Central Hospital||1|||f||||t||||||||||2018-05-31 22:40:49.827309|2018-05-31 22:40:49.827309
NCT01340378|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-12-10|2011-04-21|2011-04-22|Estimate|||||||2014-12-10|2014-12-12|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Observational|||A Pilot Study of Thrombin Generation Changes in Neonates Undergoing Placement of a Blalock-Taussig Shunt|A Pilot Study of Thrombin Generation Changes in Neonates Undergoing Placement of a Blalock-Taussig Shunt|Completed|||20|Actual|Emory University|||||f||||t||||||Samples Without DNA|"~     Serum samples only~   "|||2018-05-31 22:40:49.905956|2018-05-31 22:40:49.905956
NCT01340365|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2013-11-26|2011-04-21|2011-04-22|Estimate|||||||2013-11-26|2013-11-28|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Tai Chi, Physiologic Complexity, and Healthy Aging|Tai Chi, Physiologic Complexity, and Healthy Aging|Completed||Phase 2|60|Actual|Harvard University Faculty of Medicine||2|||f||||t||||||||||2018-05-31 22:40:49.987009|2018-05-31 22:40:49.987009
NCT01340352|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2015-06-14|2011-04-21|2011-04-22|Estimate|||||||2015-06-14|2015-06-16|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|May 2012|Actual|2012-05-31||Observational|||Is It Possible to Predict Pre Term Labor by Measuring Cervical Length in the Non-pregnant Uterus?|Is It Possible to Predict Pre Term Labor by Measuring Cervical Length in the Non-pregnant Uterus?|Completed|||62|Actual|HaEmek Medical Center, Israel|||2||f||||t||||||||||2018-05-31 22:40:50.066567|2018-05-31 22:40:50.066567
NCT01340339|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-04-21|2011-04-21|2011-04-22|Estimate|||||||2011-04-21|2011-04-22|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|January 2012|Anticipated|2012-01-31|October 2011|Anticipated|2011-10-31||Interventional|||Reverse Phototherapy With Super Light-emitting Diode(Super-LED) for Hyperbilirubinemia in Term and Late Preterm Infants|Efficacy of Reverse Phototherapy With Super Light-emitting Diode(Super-led) in Term and Late Preterm Infants:Randomized and Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|144|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f||||||||||2018-05-31 22:40:50.151929|2018-05-31 22:40:50.151929
NCT01340326|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2015-11-30|2011-04-21|2011-04-22|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2007||2007-11-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|VALID||The Impact of Dose of Angiotensin-receptor Blocker Valsartan and Genetic Polymorphism on the Post-MI Ventricular Remodeling||Completed||Phase 4|800|Actual|Dong-A University||2|||f||||f||||||||||2018-05-31 22:40:50.28512|2018-05-31 22:40:50.28512
NCT01340313|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-03-04|2011-04-19|2011-04-22|Estimate|||||||2013-03-04|2013-03-06|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Ultrasonographic Evaluation of Drug Spread in Epidural Space During Caudal Block in Children||Completed|||72|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 22:40:50.374202|2018-05-31 22:40:50.374202
NCT01340300|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2017-07-11|2017-02-06|2017-09-14|2011-04-21|2011-04-22|Estimate|2017-09-14|2017-09-18|Actual|2017-03-28|2017-03-31|Actual|2017-09-14|2017-09-18|Actual|May 2011||2011-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|January 2016|Actual|2016-01-31||Interventional|||Exercise and Metformin in Colorectal and Breast Cancer Survivors|Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors|Active, not recruiting||Phase 2|139|Actual|Dana-Farber Cancer Institute|Limited sample size, higher than anticipated dropout, short duration of therapy|4|||f||||t||||||||||2018-05-31 22:40:50.476415|2018-05-31 22:40:50.476415
NCT01340287|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2016-10-26|2011-04-21|2011-04-22|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols|Effects of the Consumption of a Plant Sterols-enriched Dairy Fermented Product on Hypercholesterolemia Management in Hypercholesterolemic Adults|Completed||N/A|168|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 22:40:51.335259|2018-05-31 22:40:51.335259
NCT01340274|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2011-04-21|2011-04-21|2011-04-22|Estimate|||||||2011-04-21|2011-04-22|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling|Evaluating the Benefits of the Community Reinforcement and Family Training(CRAFT) Approach to Concerned Significant Others(CSO) of Individuals Engaged in Problem Gambling (IPGs)|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Colchester East Hants Health Authority||2|||f||||f||||||||||2018-05-31 22:40:51.3907|2018-05-31 22:40:51.3907
NCT01340261|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2018-01-25|2011-04-21|2011-04-22|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2007||2007-03-31|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|December 2022|Anticipated|2022-12-31||Observational|||Pediatric Pain Rehabilitation Program|Registry: Pediatric Pain Rehabilitation Program|Recruiting|||1000|Anticipated|The Cleveland Clinic|||1||f||||f||||||||||2018-05-31 22:40:51.558355|2018-05-31 22:40:51.558355
NCT01340248|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-12-20|2011-04-21|2011-04-22|Estimate|||||||2011-12-20|2011-12-22|Estimate|July 2011||2011-07-31|April 2011|2011-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|24|Anticipated|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||||2018-05-31 22:40:51.651622|2018-05-31 22:40:51.651622
NCT01339234|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-04-19|2011-04-19|2011-04-20|Estimate|||||||2011-04-19|2011-04-20|Estimate|April 2008||2008-04-30|April 2011|2011-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Supported Treadmill Training for Progressive Multiple Sclerosis|Body-weight Supported Treadmill Training in Primary Progressive Multiple Sclerosis: A Pilot Trial|Completed||N/A|6|Actual|Hicks, Audrey, Ph.D.||1|||f||||f||||||||||2018-05-31 22:41:18.607653|2018-05-31 22:41:18.607653
NCT01340235|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-10-13|2011-04-21|2011-04-22|Estimate|||||||2011-10-13|2011-10-14|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin|Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin|Unknown status|Recruiting|Phase 3|8|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 22:40:51.728435|2018-05-31 22:40:51.728435
NCT01340222|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2013-01-04|2011-04-21|2011-04-22|Estimate|||||||2013-01-04|2013-01-07|Estimate|March 2011||2011-03-31|January 2013|2013-01-31||||March 2011|Actual|2011-03-31||Interventional|PHENOMAP||Monocyte Chemotactic Protein-1 (MCP-1) Expressing Monocytes to Predict Preterm Delivery: PhenoMAP Study|Evaluation of the Prognostic Value of Monocytes and Lymphocyte Phenotyping, Along With Intracellular MCP-1 Expression, to Predict Preterm Delivery for Women Hospitalized for Threat of Preterm Labor Between 24 and 34 Weeks of Amenorrhea: PhenoMAP Study|Unknown status|Recruiting|N/A|200|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||t||||||||||2018-05-31 22:40:51.798128|2018-05-31 22:40:51.798128
NCT01340209|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2014-04-22||2014-06-04|2011-04-21|2011-04-22|Estimate|2014-06-04|2014-07-04|Estimate||||2014-06-04|2014-07-04|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo Over 52 Weeks in Patients With Moderate to Severe Persistent Asthma|Completed||Phase 3|285|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:40:51.888158|2018-05-31 22:40:51.888158
NCT01340196|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2015-07-03||2015-07-03|2011-04-21|2011-04-22|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|April 2011||2011-04-30|July 2015|2015-07-31||||June 2011|Actual|2011-06-30||Interventional|||Drug Drug Interaction of BI 201335 and Tenofovir|Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers|Completed||Phase 1|16|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:40:52.607024|2018-05-31 22:40:52.607024
NCT01340183|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-11-30|2011-04-21|2011-04-22|Estimate|||||||2011-11-30|2011-12-01|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy Subjects|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics in Intravenous AZD5099 After Single Ascending Doses in Healthy Male and Female Subjects|Suspended||Phase 1|80|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 22:40:53.976407|2018-05-31 22:40:53.976407
NCT01340170|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2017-08-22|2011-04-21|2011-04-22|Estimate|||||||2017-08-22|2017-08-23|Actual|April 2011|Actual|2011-04-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study Evaluating OsseoSpeed TX Using Different Drilling Protocols With Immediate Loading|An Open, Non-randomized, Prospective Multi-centre Study Evaluating a Soft Bone Drilling Protocol for Single Tooth Restoration in the Posterior Area With Immediate Loading|Completed||N/A|202|Actual|Dentsply Sirona Implants||2|||f||||||||||||||2018-05-31 22:40:54.18948|2018-05-31 22:40:54.18948
NCT01340157|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-03-29|2011-04-20|2011-04-22|Estimate|||||||2017-03-29|2017-03-31|Actual|February 2011||2011-02-28|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions|Randomized, Open Study to Assess the Impact of Two Different Types of Food on the Relative Bioavailability of Fexinidazole Tablets After Single Oral Dose in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Drugs for Neglected Diseases||3|||f||||f||||||||||2018-05-31 22:40:54.333797|2018-05-31 22:40:54.333797
NCT01340144|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2015-02-19||2015-03-04|2011-04-21|2011-04-22|Estimate|2015-02-19|2015-03-05|Estimate||||2015-03-04|2015-03-25|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|||Evaluation of Patellar Crepitus Following Total Knee Arthroplasty|Evaluation of Patellar Crepitus Following PFC Sigma vs. PFC Sigma HP Total Knee Arthroplasty: Does Femoral Component Design Make a Difference?|Completed|||1250|Actual|Colorado Joint Replacement|||2||f||||f||||||||||2018-05-31 22:40:54.415099|2018-05-31 22:40:54.415099
NCT01340131|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-27|2011-04-20|2011-04-22|Estimate|||||||2011-04-27|2011-04-28|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||CKD-828 (40/5mg) Pharmacokinetic Study|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 40mg and S-Amlodipine 5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers|Completed||Phase 1|68|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:40:54.663512|2018-05-31 22:40:54.663512
NCT01340118|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-20|2011-04-20|2011-04-22|Estimate|||||||2011-04-20|2011-04-22|Estimate|May 2010||2010-05-31|April 2011|2011-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Improvement of FeNO and FEF25-75 After Inhaled Corticosteroid Treatment of Asthma|Concurrent Improvement of Exhaled Nitric Oxide and FEF25-75 After Treatment With Inhaled Corticosteroid in Children With Controlled Asthma|Completed||Phase 4|93|Actual|Chungbuk National University||2|||f||||f||||||||||2018-05-31 22:40:55.586845|2018-05-31 22:40:55.586845
NCT01340105|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2015-02-02|2011-04-21|2011-04-22|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation|Microwave Versus Radiofrequency Ablation for Hepatocellular Carcinoma: a Prospective Randomized Control Trial|Unknown status|Recruiting|Phase 3|92|Anticipated|Chinese University of Hong Kong||2|||f||||||||||||||2018-05-31 22:40:55.669092|2018-05-31 22:40:55.669092
NCT01340092|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2016-04-22|2011-04-20|2011-04-22|Estimate|||||||2016-04-22|2016-04-25|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Use of a Family Navigator in Families With Children Newly Diagnosed With Autism Spectrum Disorder|Use of a Family Navigator in Families With Children Newly Diagnosed With Autism Spectrum Disorder|Completed||N/A|192|Actual|Boston Medical Center||2|||f||||f||||||||No||2018-05-31 22:40:55.747589|2018-05-31 22:40:55.747589
NCT01340079|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-09-20|2011-04-20|2011-04-22|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Virtual World Health Behavior Counseling for Patients With Diabetes|Virtual World Health Behavior Counseling for Patients With Diabetes|Completed||Phase 1/Phase 2|89|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 22:40:55.814354|2018-05-31 22:40:55.814354
NCT01340066|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2013-02-18||2013-03-22|2011-04-20|2011-04-22|Estimate|2013-03-22|2013-05-03|Estimate||||2013-03-22|2013-05-03|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Baseline characteristics only for subjects that were randomized into the study.|Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence|A Randomized, Double-blind, Parallel, Placebo-controlled Study for the Assessment of the Safety and Efficacy of UISH001 for the Symptomatic Improvement of Urinary Incontinence|Completed||Phase 1/Phase 2|94|Actual|Beech Tree Labs, Inc.||2|||f||||f||||||||||2018-05-31 22:40:55.924731|2018-05-31 22:40:55.924731
NCT01340053|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2012-02-29|2011-04-20|2011-04-22|Estimate|||||||2012-02-29|2012-03-02|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|Completed||Phase 2|186|Actual|Ardelyx||4|||f||||f||||||||||2018-05-31 22:40:56.229894|2018-05-31 22:40:56.229894
NCT01340040|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2014-12-10|2011-04-20|2011-04-21|Estimate|||||||2014-12-10|2014-12-11|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects|A Phase 1, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Japanese Subjects With Advanced Solid Tumours Refractory to Standard Therapy or for Which No Standard Therapy Exists|Completed||Phase 1|10|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-05-31 22:40:56.420181|2018-05-31 22:40:56.420181
NCT01340027|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2015-06-23|2013-06-17|2015-07-27|2011-04-20|2011-04-21|Estimate|2015-06-23|2015-07-21|Estimate|2013-06-17|2013-06-25|Estimate|2015-07-27|2015-08-17|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Symphony|Baseline Measure data are provided for all randomized patients who took at least 1 dose of double-blind study drug (Safety Analysis Set). One participant randomized to the Mirabegron 25 mg arm received treatment with Solifenacin 5 mg + Mirabegron 50 mg in error and is counted in that arm for safety analysis set analyses.|A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder|A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.|Completed||Phase 2|1307|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|12|||f||||t||||||||||2018-05-31 22:40:57.182554|2018-05-31 22:40:57.182554
NCT01340014|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2013-10-18||2014-01-13|2011-04-20|2011-04-21|Estimate|2013-10-18|2013-12-13|Estimate||||2014-01-13|2014-02-10|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||This reporting group includes all participants who completed both treatment periods and completed the preference questionnaire, per planned treatment sequence (ITT full analysis population).|Patient Preference Comparison of AZARGA Versus COSOPT|Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 4|112|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:41:04.569656|2018-05-31 22:41:04.569656
NCT01340001|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2018-04-26|2011-04-20|2011-04-21|Estimate|||||||2018-04-26|2018-04-30|Actual|October 24, 2012|Actual|2012-10-24|April 2018|2018-04-30|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|DEMENSTIM||Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies|Effects of Nucleus Basalis of Meynert Area Electrical Stimulation on Cognitive Behavioral Disorders in Dementia With Lewy Bodies : A Pilot Phase 1 Study|Completed||N/A|6|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 22:41:04.787418|2018-05-31 22:41:04.787418
NCT01339988|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-04-20|2011-04-20|2011-04-21|Estimate|||||||2011-04-20|2011-04-21|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|June 2019|Anticipated|2019-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)|Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants|Not yet recruiting||Phase 4|10|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 22:41:04.860986|2018-05-31 22:41:04.860986
NCT01339975|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2018-04-10|2011-04-20|2011-04-21|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2011||2011-06-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2014|Actual|2014-05-31||Observational|ChemoRenCan||Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma|Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma|Active, not recruiting|||310|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||Samples With DNA|"~     whole blood, urine and tissues~   "|No||2018-05-31 22:41:04.937036|2018-05-31 22:41:04.937036
NCT01339962|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-08-15|2011-04-20|2011-04-21|Estimate|||||||2014-08-15|2014-08-18|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.|Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.|Completed|||1073|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:41:05.028709|2018-05-31 22:41:05.028709
NCT01339949|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-12-28|2011-04-20|2011-04-21|Estimate|||||||2011-12-28|2011-12-30|Estimate|June 2011||2011-06-30|December 2011|2011-12-31|October 2014|Anticipated|2014-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)|A Double-masked, Sham Controlled, Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Wet AMD Patients With Recurrent Leakage Secondary to CNV|Withdrawn||N/A|0|Actual|Oraya Therapeutics, Inc.||2||Sponsor decision to withdraw study to pursue others.|f||||t||||||||||2018-05-31 22:41:05.143843|2018-05-31 22:41:05.143843
NCT01339936|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2013-01-30||2013-09-26|2011-04-20|2011-04-21|Estimate|2013-09-26|2013-11-28|Estimate||||2013-09-26|2013-11-28|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional||The analysis was per protocol hence on 35 participants|Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers||Completed||Phase 2/Phase 3|40|Actual|Optometric Technology Group Ltd||1|||f||||f||||||||||2018-05-31 22:41:05.22793|2018-05-31 22:41:05.22793
NCT01339923|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2015-12-14|2015-02-03|2016-03-30|2011-04-20|2011-04-21|Estimate|2015-12-14|2016-01-20|Estimate|2015-02-03|2015-02-23|Estimate|2016-03-30|2016-05-09|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years|A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years|Completed||Phase 3|1409|Actual|Novartis||7|||f||||f||||||||||2018-05-31 22:41:05.675066|2018-05-31 22:41:05.675066
NCT01339910|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2018-03-12||2018-05-01|2011-04-20|2011-04-21|Estimate|2018-05-01|2018-05-30|Actual||||2018-05-01|2018-05-30|Actual|June 2011|Actual|2011-06-30|May 2018|2018-05-31|October 16, 2017|Actual|2017-10-16|January 16, 2017|Actual|2017-01-16||Interventional|||Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)|A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)|Terminated||Phase 3|272|Actual|Medical College of Wisconsin||2||Accrual terminated as recommended by the data and safety monitoring board.|f||||t||||||||Yes|Findings will be published in a manuscript|2018-05-31 22:41:07.722812|2018-05-31 22:41:07.722812
NCT01339897|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2013-11-26||2015-01-15|2011-04-20|2011-04-21|Estimate|2015-01-15|2015-01-19|Estimate||||2015-01-15|2015-01-19|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All randomized subjects who received any amount of IMP|A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of N6022 in Healthy Subjects|Completed||Phase 1|25|Actual|Nivalis Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 22:41:09.998057|2018-05-31 22:41:09.998057
NCT01339884|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-01-19|2011-04-20|2011-04-21|Estimate|||||||2014-01-19|2014-01-22|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||A Study of Resveratrol as Treatment for Friedreich Ataxia|An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia|Completed||Phase 1/Phase 2|27|Actual|Murdoch Childrens Research Institute||2|||f||||t||||||||||2018-05-31 22:41:10.57569|2018-05-31 22:41:10.57569
NCT01339871|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2017-06-14|2011-04-20|2011-04-21|Estimate|||||||2017-06-14|2017-06-16|Actual|April 20, 2011|Actual|2011-04-20|June 2017|2017-06-30|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies|A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies|Completed||Phase 1|152|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:41:10.67429|2018-05-31 22:41:10.67429
NCT01339858|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2018-03-08|2011-04-20|2011-04-21|Estimate|||||||2018-03-08|2018-03-09|Actual|May 2011||2011-05-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Breier-Stanley||The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia||Completed||Phase 4|60|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 22:41:10.746782|2018-05-31 22:41:10.746782
NCT01339845|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2017-03-05|2011-04-20|2011-04-21|Estimate|||||||2017-03-05|2017-03-07|Actual|September 2009||2009-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ICVB||Introduction of Cholera Vaccine in Bangladesh|"Introduction of Cholera Vaccine in Bangladesh:  Impact Evaluation of Cholera Vaccine and Behaviour Change Interventions in Urban Dhaka"|Completed||N/A|240000|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||t||||||||||2018-05-31 22:41:10.822152|2018-05-31 22:41:10.822152
NCT01339832|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|2015-12-29||2017-04-12|2011-04-20|2011-04-21|Estimate|2015-12-29|2016-02-04|Estimate||||2017-04-12|2017-05-17|Actual|August 2010||2010-08-31|April 2017|2017-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational||Full Analysis Set (FAS) included all the participants who fulfilled the inclusion criteria for this study. This population includes participants who gave informed consent and also those who died or were lost to follow-up before start of ML21875 study.|An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer|Capecitabine and Oxaliplatin Prior and Concurrent to Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer: A Survival Analysis.|Completed|||51|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:41:10.92311|2018-05-31 22:41:10.92311
NCT01339819|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-07-01|2011-04-20|2011-04-21|Estimate|||||||2013-07-01|2013-07-02|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|Dabi-ADP-1||Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation|Completed||Phase 4|70|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 22:41:11.194862|2018-05-31 22:41:11.194862
NCT01339806|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-02-06|2011-04-20|2011-04-21|Estimate|||||||2015-02-06|2015-02-09|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|SCORE||The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury|Phase IV Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury|Completed||Phase 4|143|Actual|Brooke Army Medical Center||4|||f||||t||||||||||2018-05-31 22:41:11.442473|2018-05-31 22:41:11.442473
NCT01339793|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-04-27|2011-04-20|2011-04-21|Estimate|||||||2011-04-27|2011-04-29|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|||||Observational|||Exploring the Relationships Among Hospital's Corporate Social Responsibility, Job Attitudes and Job Performance|Exploring the Relationships Among Hospital's Corporate Social Responsibility, Job Attitudes and Job Performance|Completed|||50|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:41:11.582671|2018-05-31 22:41:11.582671
NCT01339780|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2014-02-26|2011-04-20|2011-04-21|Estimate|||||||2014-02-26|2014-02-28|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques||Completed||N/A|53|Actual|Turku University Hospital||2|||f||||||||||||||2018-05-31 22:41:11.647727|2018-05-31 22:41:11.647727
NCT01339754|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2014-08-08|2011-04-20|2011-04-21|Estimate|||||||2014-08-08|2014-08-11|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|PACT-18||Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy|Salvage Therapy With Trabectedin in Metastatic Pancreatic Adenocarcinoma: A Single-Arm Phase II Trial|Completed||Phase 2|25|Actual|IRCCS San Raffaele||1|||f||||f||||||||||2018-05-31 22:41:11.77705|2018-05-31 22:41:11.77705
NCT01339741|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-20|||2011-04-20|2011-04-20|2011-04-21|Estimate|||||||2011-04-20|2011-04-21|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency|The Efficacy of Vitamin D3 for the Treatment of Chronic Plaque Type Psoriatic Patients With Vitamin D Deficiency and Insufficiency: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|30|Anticipated|Chulalongkorn University||2|||f||||||||||||||2018-05-31 22:41:11.851852|2018-05-31 22:41:11.851852
NCT01339728|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-04-20|2011-04-20|2011-04-21|Estimate|||||||2011-04-20|2011-04-21|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Far-infrared Ray Effect on CV12 Acupoint|Far-infrared Ray Illuminates Area of CV12 Acupoint to Investigate the Correlation of Skin Temperature and Skin Blood Flow Between CV12 Acupoint and Palm Central Part of Right Hand|Completed||N/A|22|Actual|China Medical University Hospital|||||f||||t||||||||||2018-05-31 22:41:11.935074|2018-05-31 22:41:11.935074
NCT01339715|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-17|||2012-07-20|2011-04-20|2011-04-21|Estimate|||||||2012-07-20|2012-07-23|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Difference Between Acupuncture and Far-infrared Ray Illumination at CV12 Acupoint|From the Changes of Ryodoraku Value at 12 Source Acupoints, and Heart Rate Viability to Explain the Difference Between Acupuncture and Far-infrared Ray Illumination at CV12（Zhongwan）Acupoint|Completed||N/A|25|Actual|China Medical University Hospital|||||f||||t||||||||||2018-05-31 22:41:12.056903|2018-05-31 22:41:12.056903
NCT01339702|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2017-02-27|2011-04-20|2011-04-21|Estimate|||||||2017-02-27|2017-03-01|Actual|September 2011||2011-09-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|EPIC||The EPIC Project: Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines|Impact of Implementing the EMS Traumatic Brain Injury Treatment Guidelines|Recruiting|||20000|Anticipated|University of Arizona|||2||f||||f||||||||||2018-05-31 22:41:12.115029|2018-05-31 22:41:12.115029
NCT01339689|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19||2015-06-08|2015-10-01|2011-04-20|2011-04-21|Estimate||||2015-10-01|2015-10-21|Estimate|2015-10-01|2015-10-21|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Ganaxolone in Posttraumatic Stress Disorder (PTSD)|A Proof-of-Concept, Double-blind, Randomized, Placebo-controlled Study of Ganaxolone in Posttraumatic Stress Disorder|Completed||Phase 2|114|Actual|Marinus Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:41:12.187846|2018-05-31 22:41:12.187846
NCT01339676|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-05-18|2011-04-20|2011-04-21|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Interventional|||Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)|Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS|Unknown status|Active, not recruiting|Phase 4|70|Actual|University of Turku||2|||f||||f||||||||||2018-05-31 22:41:12.270489|2018-05-31 22:41:12.270489
NCT01339663|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-04-17|2011-04-19|2011-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|March 2012||2012-03-31|April 2014|2014-04-30||||December 2012|Actual|2012-12-31||Interventional|||Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma|Phase I Study To Evaluate The Use Of Autologous T- Antigen-Presenting Cells (T-APC) To Enhance The Persistence Of Adoptively Transferred CD8+ Antigen-Specific T Cells (CTL) Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma|Completed||Phase 1|12|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 22:41:12.333464|2018-05-31 22:41:12.333464
NCT01339650|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2017-12-28|2011-04-20|2011-04-21|Estimate|||||||2017-12-28|2018-01-02|Actual|May 6, 2011|Actual|2011-05-06|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed||Phase 1|93|Actual|AbbVie||1|||f||||f|f|f|||f|||No||2018-05-31 22:41:12.425702|2018-05-31 22:41:12.425702
NCT01339637|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2012-12-03|2011-04-19|2011-04-20|Estimate|||||||2012-12-03|2012-12-05|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|LSS||Evaluation of Low Source of Signal in SCOUT DS|Evaluation of Low Source of Signal in SCOUT DS|Completed|||196|Actual|VeraLight, Inc.|||1||f||||f||||||||||2018-05-31 22:41:12.493688|2018-05-31 22:41:12.493688
NCT01339624|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-19|2011-04-19|2011-04-20|Estimate|||||||2011-04-19|2011-04-20|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Nasal Fentanyl And Renal Colic||Completed||N/A|65|Actual|Valduce Hospital||2|||f||||||||||||||2018-05-31 22:41:12.557032|2018-05-31 22:41:12.557032
NCT01339611|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-06-17|2011-04-19|2011-04-20|Estimate|||||||2011-06-17|2011-06-20|Estimate|May 2011||2011-05-31|March 2010|2010-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Education Program for Patients Receiving Oral Anticoagulation||Unknown status|Recruiting|N/A|160|Anticipated|University of Sao Paulo||2|||f||||||||||||||2018-05-31 22:41:12.618633|2018-05-31 22:41:12.618633
NCT01339598|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2015-11-02|2011-04-19|2011-04-20|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Remediation of Cognitive Dysfunction in Euthymic Bipolar Disorder Patients Using Transcranial Direct Current Stimulation (tDCS)||Completed||Phase 1|15|Actual|The University of New South Wales||3|||f||||t||||||||||2018-05-31 22:41:12.689062|2018-05-31 22:41:12.689062
NCT01339585|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-08-11|2011-04-19|2011-04-20|Estimate|||||||2014-08-11|2014-08-12|Estimate|May 2011||2011-05-31|August 2014|2014-08-31||||May 2014|Actual|2014-05-31||Interventional|||The Effect of Timing of Transcranial Direct Current Stimulation (tDCS) for Enhancing Learning During Cognitive Training|The Effect of Timing of Transcranial Direct Current Stimulation (tDCS) for Enhancing Learning During Cognitive Training|Completed||N/A|20|Actual|The University of New South Wales||2|||f||||t||||||||||2018-05-31 22:41:12.748002|2018-05-31 22:41:12.748002
NCT01339572|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2017-07-27|2011-04-19|2011-04-20|Estimate|||||||2017-07-27|2017-08-01|Actual|April 2011||2011-04-30|July 2017|2017-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation|Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation|Completed||Phase 2|72|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 22:41:12.80178|2018-05-31 22:41:12.80178
NCT01339559|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2018-03-23|2011-04-19|2011-04-20|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 11, 2011|Actual|2011-05-11|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BRITE™||Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy|An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy|Active, not recruiting||Phase 3|767|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 22:41:12.887047|2018-05-31 22:41:12.887047
NCT01339546|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-11-21|2011-04-19|2011-04-20|Estimate|||||||2017-11-21|2017-11-24|Actual|June 9, 2010|Actual|2010-06-09|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||National Trends in Otitis Media in Children Under 5 Years of Age|National Trends In Ambulatory Care Visits For Otitis Media In Children Under The Age Of Five In The United States|Completed|||1|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 22:41:13.31135|2018-05-31 22:41:13.31135
NCT01339533|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2015-08-24|2011-04-19|2011-04-20|Estimate|||||||2015-08-24|2015-08-26|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation|Airway Pressure Release Ventilation (APRV) vs. Conventional Volume Control Mechanical Ventilation for Patients With Respiratory Failure Requiring Invasive Mechanical Ventilator Support|Unknown status|Recruiting|Phase 2|246|Anticipated|Intermountain Health Care, Inc.||3|||f||||t||||||||||2018-05-31 22:41:13.373626|2018-05-31 22:41:13.373626
NCT01339520|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2017-08-10|2011-04-19|2011-04-20|Estimate|||||||2017-08-10|2017-08-11|Actual|November 2008||2008-11-30|August 2017|2017-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Diabetes Scorecard Educational Intervention Study|Use of a Card to Improve Risk Factor Control in Patients With Type II Diabetes|Completed||N/A|104|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 22:41:13.460368|2018-05-31 22:41:13.460368
NCT01339507|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2016-01-26|2011-04-19|2011-04-20|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Observational|||A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft|A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft in Patients With a History of Allergic Conjunctivitis|Completed|||25|Actual|Cunningham, Derek N., O.D., P.A.|||2||f||||t||||||||||2018-05-31 22:41:13.525854|2018-05-31 22:41:13.525854
NCT01339494|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2016-04-01|2011-04-19|2011-04-20|Estimate|||||||2016-04-01|2016-04-05|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Nitric Oxide Production in MELAS Syndrome|Arginine Flux and Nitric Oxide Production in Patients With MELAS Syndrome and the Effect of Arginine and Citrulline Supplementation|Completed||Early Phase 1|30|Actual|Baylor College of Medicine||2|||f||||f||||||||Yes|Yes the data have been made available to|2018-05-31 22:41:13.656809|2018-05-31 22:41:13.656809
NCT01339481|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-11-28|2011-04-19|2011-04-20|Estimate|||||||2011-11-28|2011-11-29|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept|A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept|Completed|||26|Actual|Astellas Pharma Inc|||1||f||||f||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-05-31 22:41:13.744641|2018-05-31 22:41:13.744641
NCT01339468|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2017-07-17|2011-04-19|2011-04-20|Estimate|||||||2017-07-17|2017-07-19|Actual|April 27, 2011|Actual|2011-04-27|July 2017|2017-07-31|May 27, 2014|Actual|2014-05-27|May 27, 2014|Actual|2014-05-27||Interventional|MAIN||A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation|A Phase IV, Randomized, Open-label, Comparative, Single-center Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf® (Modified Release Tacrolimus) and Prograf® (Tacrolimus) in de Novo Living Donor Liver Transplant Recipients|Completed||Phase 4|100|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:41:13.850824|2018-05-31 22:41:13.850824
NCT01339455|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2018-04-30|2011-04-19|2011-04-20|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2011||2011-03-31|April 2018|2018-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SCT-NMO||Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica|Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica|Terminated||Phase 1/Phase 2|3|Actual|University of Calgary||1||recruitment failure|f||||f||||||||||2018-05-31 22:41:13.957071|2018-05-31 22:41:13.957071
NCT01339442|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2017-01-23|2011-04-19|2011-04-20|Estimate|||||||2017-01-23|2017-01-25|Estimate|November 14, 2011|Actual|2011-11-14|January 2017|2017-01-31|December 28, 2016|Actual|2016-12-28|December 21, 2016|Actual|2016-12-21||Interventional|||BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer|A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer|Completed||Phase 1|31|Actual|Washington University School of Medicine||4|||f||||t|t|f||||||No||2018-05-31 22:41:14.062722|2018-05-31 22:41:14.062722
NCT01339429|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2014-02-12||2015-05-19|2011-04-19|2011-04-20|Estimate|2015-05-19|2015-05-20|Estimate||||2015-05-19|2015-05-20|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Simplified Negative Pressure Wound Therapy|Evaluation of the Performance and Safety of a Simplified Negative Pressure Wound Therapy Device|Completed||Phase 1|41|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 22:41:14.187347|2018-05-31 22:41:14.187347
NCT01339416|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2014-03-14||2014-03-14|2011-04-19|2011-04-20|Estimate|2014-03-14|2014-04-21|Estimate||||2014-03-14|2014-04-21|Estimate|March 2009||2009-03-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational||Analysis population included all participants enrolled in the study.|HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University|Clinical Adverse Events In HIV-Infected Patients|Completed|||8202|Actual|ViiV Healthcare|Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.||1||f||||f||||||||||2018-05-31 22:41:14.356139|2018-05-31 22:41:14.356139
NCT01339403|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2014-10-27||2015-04-02|2011-04-19|2011-04-20|Estimate|2015-04-02|2015-04-03|Estimate||||2015-04-02|2015-04-03|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational||Analysis population included all participants enrolled in the study.|Kaiser Permanente HIV Cohort Study|Hiv Infection, Antiretroviral Therapy Use And Other Predictors Of Selected Clinical Events In Kaiser Permanente|Completed|||282368|Actual|ViiV Healthcare|Designation of endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.||2||f||||f||||||||||2018-05-31 22:41:14.564189|2018-05-31 22:41:14.564189
NCT01339390|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2016-03-28||2016-03-28|2011-04-19|2011-04-20|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in the Veterans Health Administration (VHA)|MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in VHA|Completed||N/A|3169|Actual|VA Office of Research and Development|Because passive enrollment was allowed by our Institutional Review Board, we were able to enroll all eligible patients identified by our automated record review. However, very few of the veterans randomized to the intervention used the program.|2|||f||||f||||||||No||2018-05-31 22:41:15.096904|2018-05-31 22:41:15.096904
NCT01339377|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2016-07-13|2011-04-19|2011-04-20|Estimate|||||||2016-07-13|2016-07-15|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety and Effectiveness Study of the AO-1000 Device to Treat Contained Herniated Discs|A Pilot Study to Evaluate the Safety and Effectiveness of Ozone Generated and Injected by the AO-1000 Device in the Treatment of Contained Herniated Discs|Completed||Phase 1|39|Actual|ActiveO Inc.||1|||f||||f||||||||||2018-05-31 22:41:15.327006|2018-05-31 22:41:15.327006
NCT01339364|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-07-25|2011-04-19|2011-04-20|Estimate|||||||2011-07-25|2011-07-26|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Impact of Three Continuing Education Meetings for Community Pharmacists on Weight Management|Evaluation of Three 1-day Educational Intervention to Promote Knowledge and Attitude of Community Pharmacists About Evidence-based Weight Management|Completed||N/A|180|Anticipated|Tehran University of Medical Sciences||3|||f||||f||||||||||2018-05-31 22:41:15.409843|2018-05-31 22:41:15.409843
NCT01339351|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2015-03-10|2011-04-19|2011-04-20|Estimate|||||||2015-03-10|2015-03-11|Estimate|June 2005||2005-06-30|April 2011|2011-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|STORY||Teleconference Group: Breast Cancer in African Americans (STORY)|Teleconference Group: Breast Cancer in African Americans|Completed||N/A|185|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 22:41:15.490832|2018-05-31 22:41:15.490832
NCT01339338|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-04-19|2011-04-19|2011-04-20|Estimate|||||||2011-04-19|2011-04-20|Estimate|January 2010||2010-01-31|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Warming Contrast Media for Hysterosalpingography|Comparison of the Warm and Cold Contrast Media for Hysterosalpingography: a Prospective, Randomized Study|Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Taizhou Hospital||2|||f||||t||||||||||2018-05-31 22:41:15.5722|2018-05-31 22:41:15.5722
NCT01339325|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-19|2011-04-19|2011-04-20|Estimate|||||||2011-04-19|2011-04-20|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|LESSCHO||Laparo-endoscopic Single Site (LESS) Cholecystectomy Versus Standard LAP-CHOLE|Laparo-endoscopic Single Site Cholecystectomy Versus Standard Laparoscopic Cholecystectomy|Unknown status|Not yet recruiting|Phase 4|180|Anticipated|San Giovanni Addolorata Hospital||3|||f||||f||||||||||2018-05-31 22:41:15.675014|2018-05-31 22:41:15.675014
NCT01339312|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2014-05-27|2011-04-19|2011-04-20|Estimate|||||||2014-05-27|2014-05-28|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine|Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China|Completed||Phase 3|816|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 22:41:15.768664|2018-05-31 22:41:15.768664
NCT01339299|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2013-09-25||2013-09-25|2011-04-19|2011-04-20|Estimate|2013-09-25|2013-11-27|Estimate||||2013-09-25|2013-11-27|Estimate|October 2009||2009-10-31|April 2011|2011-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART)|The Endocrine Efficacy of Either Recombinant Luteinizing Hormone (r-LH) or Low Dose Recombinant Human Chorionic Gonadotropin (r-hCG) Supplementation for Recombinant Follicle Stimulating Hormone (r-FSH) Stimulation in Normogonadotrophic Women Undergoing in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Therapy Following a Long-term Gonadotropin Releasing Hormone (GnRH) Agonist Down Regulation Protocol|Completed||Phase 4|100|Actual|Regionshospitalet Viborg, Skive||2|||f||||f||||||||||2018-05-31 22:41:15.853501|2018-05-31 22:41:15.853501
NCT01339286|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-04-19|2011-04-19|2011-04-20|Estimate|||||||2011-04-19|2011-04-20|Estimate|March 2011||2011-03-31|April 2011|2011-04-30||||December 2011|Anticipated|2011-12-31||Interventional|||Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)|Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment|Unknown status|Recruiting|Phase 4|100|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 22:41:16.040208|2018-05-31 22:41:16.040208
NCT01339273|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2013-12-05|2011-04-19|2011-04-20|Estimate|||||||2013-12-05|2013-12-09|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection|Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection- a Double Blind Randomised Controlled Trial|Completed||N/A|72|Actual|Oxford University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 22:41:16.100828|2018-05-31 22:41:16.100828
NCT01339260|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2014-11-06|2013-01-16|2014-11-19|2011-04-19|2011-04-20|Estimate|2014-11-19|2014-11-26|Estimate|2013-01-16|2013-01-25|Estimate|2014-11-19|2014-11-26|Estimate|April 2011||2011-04-30|November 2014|2014-11-30||||November 2012|Actual|2012-11-30||Interventional||Safety population ie patients receiving either netupitant/palonosetron combination or palonosetron, both plus dexamethasone|An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting|A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy|Completed||Phase 3|1455|Actual|Helsinn Healthcare SA||4|||f||||t||||||||||2018-05-31 22:41:16.193757|2018-05-31 22:41:16.193757
NCT01339247|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2011-03-24||2018-05-17|2011-03-24|2011-04-20|Estimate|2011-03-24|2011-04-20|Estimate||||2018-05-17|2018-05-22|Actual|October 20, 2009|Actual|2009-10-20|May 2018|2018-05-31|November 16, 2009|Actual|2009-11-16|November 16, 2009|Actual|2009-11-16||Interventional|||Paxil CR Bioequivalence Study Brazil - Fed Administration|Relative Bioavailability Study Between the Formulations: Paroxetine 25 mg Tablets With Controlled Release Manufactured by GSK Mississauga and Paroxetine 25 mg Tablets With Controlled Release Manufactured by SmithKline Beecham (Cidra), Fed Administration in Healthy Volunteers of Both Genders|Completed||Phase 1|60|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:41:18.355624|2018-05-31 22:41:18.355624
NCT01339221|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-01-16|2011-04-19|2011-04-20|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in Belgium|Epidemiological, Observational, Post Marketing Study of the Genetic Stability of GSK Biologicals' Rotavirus Vaccine (Rotarix™) in Children <5 Years of Age Diagnosed With Severe Gastroenteritis, in Belgium|Completed|||72|Actual|GlaxoSmithKline|||2||f||||||||||Samples Without DNA|"~     Stool samples~   "|||2018-05-31 22:41:18.699196|2018-05-31 22:41:18.699196
NCT01339208|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2015-05-26|2011-04-19|2011-04-20|Estimate|||||||2015-05-26|2015-05-28|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|TREAT||TREAT (Telemedicine for Reach, Education, Access, and Treatment)|TREAT (Telemedicine for Reach, Education, Access, and Treatment)|Completed||N/A|35|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:41:18.778167|2018-05-31 22:41:18.778167
NCT01339195|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-01-30|2011-04-19|2011-04-20|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|GRECogVASC||Post-stroke Cognitive Impairment and Dementia|Post-stroke Cognitive Impairment and Dementia: Frequency and Anatomical Correlates With the French Version of the National Institute of Neurological Disorders and Stroke (NINDS)-Canadian Stroke Network Battery|Completed||N/A|1635|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 22:41:18.942687|2018-05-31 22:41:18.942687
NCT01339182|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2013-01-31|2011-04-19|2011-04-20|Estimate|||||||2013-01-31|2013-02-04|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Somatropin||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers|A Randomized, Open-label, Single-dose, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated-Somatropin in Healthy Volunteers|Completed||Phase 1|36|Actual|Xiamen Amoytop Biotech Co., Ltd.||5|||f||||t||||||||||2018-05-31 22:41:19.055462|2018-05-31 22:41:19.055462
NCT01339169|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2017-10-17|2011-04-19|2011-04-20|Estimate|||||||2017-10-17|2017-10-18|Actual|January 2011||2011-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||YF476 and Type I Gastric Carcinoids|A Single Centre, Pilot Trial of YF476 in Patients With Chronic Atrophic Gastritis, Hypergastrinaemia and Type I Gastric Carcinoids|Active, not recruiting||Phase 2|10|Anticipated|Trio Medicines Ltd.||1|||f||||f||||||||||2018-05-31 22:41:19.132173|2018-05-31 22:41:19.132173
NCT01339156|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2012-11-21|2011-04-19|2011-04-20|Estimate|||||||2012-11-21|2012-11-22|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain|Randomized, Double-blind, Placebo-controlled Phase I-Ib Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain|Terminated||Phase 1|46|Actual|Piramal Enterprises Limited||2|||f||||f||||||||||2018-05-31 22:41:19.203833|2018-05-31 22:41:19.203833
NCT01339143|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-05-05|2011-04-19|2011-04-20|Estimate|||||||2011-05-05|2011-05-09|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|||Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes|An Open-label, Randomized, Active-controlled Study to Compare the Effect of DPP-IV Inhibitor and TZD as add-on Therapy to Metformin on Glycemic Variability and Oxidative Stress in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy|Unknown status|Recruiting|Phase 4|80|Anticipated|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 22:41:19.282498|2018-05-31 22:41:19.282498
NCT01339130|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-09-04|2011-04-19|2011-04-20|Estimate|||||||2015-09-04|2015-09-07|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Emotion||Assessment of Social-emotional Functioning in Neurological Diseases|Assessment of Social-emotional Functioning in Stroke, Frontotemporal Dementia, Alzheimer and Parkinson Diseases|Completed||N/A|177|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 22:41:19.383185|2018-05-31 22:41:19.383185
NCT01339117|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-08-01|2011-04-19|2011-04-20|Estimate|||||||2017-08-01|2017-08-02|Actual|January 2011||2011-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Delivered Dietary Intervention for Children With Irritable Bowel Syndrome|Delivered Dietary Intervention for Children With Irritable Bowel Syndrome|Active, not recruiting||N/A|40|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 22:41:19.464192|2018-05-31 22:41:19.464192
NCT01339104|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2014-09-30|2011-04-19|2011-04-20|Estimate|||||||2014-09-30|2014-10-01|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity|An Open-label, Non-randomized Phase I Study of Regorafenib (BAY73-4506) to Evaluate Cardiovascular Safety Parameters, Tolerability, Pharmacokinetics, and Anti-tumor Activity in Patients With Advanced Solid Tumors|Completed||Phase 1|53|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:41:19.535733|2018-05-31 22:41:19.535733
NCT01339091|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2013-11-07||2013-12-26|2011-04-19|2011-04-20|Estimate|2013-11-07|2013-12-25|Estimate||||2013-12-26|2014-01-31|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 3|573|Actual|Durata Therapeutics Inc., an affiliate of Allergan plc||2|||f||||f||||||||||2018-05-31 22:41:19.639967|2018-05-31 22:41:19.639967
NCT01339078|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2015-06-02|2011-04-19|2011-04-20|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial Comparing Kaffes Stent With Plastic Prosthesis in the Treatment of Anastomotic Biliary Strictures Post Orthotopic Liver Transplantation|Randomized Controlled Trial Comparing Kaffes Stent With Plastic Prosthesis in the Treatment of Anastomotic Biliary Strictures Post Orthotopic Liver Transplantation|Unknown status|Recruiting|N/A|25|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:41:20.126386|2018-05-31 22:41:20.126386
NCT01339065|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2011-04-19|2011-04-19|2011-04-20|Estimate|||||||2011-04-19|2011-04-20|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Interventional|||The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital|The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital: A Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|30|Anticipated|Makerere University||2|||f||||t||||||||||2018-05-31 22:41:20.264535|2018-05-31 22:41:20.264535
NCT01339052|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2017-03-14||2018-02-15|2011-04-19|2011-04-20|Estimate|2017-05-15|2017-06-14|Actual||||2018-02-15|2018-03-15|Actual|September 2011|Actual|2011-09-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|October 2016|Actual|2016-10-31||Interventional|||Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma|A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway|Active, not recruiting||Phase 2|65|Actual|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 22:41:20.397743|2018-05-31 22:41:20.397743
NCT01339039|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2017-11-15|2011-04-19|2011-04-20|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2011||2011-12-31|November 2017|2017-11-30|April 8, 2017|Actual|2017-04-08|April 2014|Actual|2014-04-30||Interventional|||Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma|Phase I Study of Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma|Terminated||Phase 1|26|Actual|Dana-Farber Cancer Institute||3||Low accrual rate|f||||t||||||||||2018-05-31 22:41:21.387104|2018-05-31 22:41:21.387104
NCT01339026|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2014-09-17|2011-04-19|2011-04-20|Estimate|||||||2014-09-17|2014-09-18|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|APACS-HPR||Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention|Evaluating the Benefit of Additional Platelet Inhibition in Acute Coronary Syndrome Patients With High Platelet Reactivity Undergoing PCI|Terminated||Phase 4|44|Actual|Royal Brompton & Harefield NHS Foundation Trust||2||Change in guidelines favouring newer antiplatelet drugs in ACS|f||||f||||||||||2018-05-31 22:41:21.464512|2018-05-31 22:41:21.464512
NCT01339013|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2014-03-14||2014-09-12|2011-04-19|2011-04-20|Estimate|2014-09-10|2014-09-11|Estimate||||2014-09-12|2014-09-25|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||A total of 6 patients participated. All 6 started with HME, then AnaConDa, finally HME|Rebreathing of Carbon Dioxide With a Device Used for Giving Inhalational Anaesthesia|Dead Space Effect of an Anaesthesia Gas Reflector (AnaConDa)|Completed||N/A|6|Actual|Region Skane||1|||f||||f||||||||||2018-05-31 22:41:21.535014|2018-05-31 22:41:21.535014
NCT01339000|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|2016-05-16||2016-05-16|2011-04-19|2011-04-20|Estimate|2016-05-16|2016-06-22|Estimate||||2016-05-16|2016-06-22|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy|A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects Following Chemotherapy|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|The company supplying interleukin-7 (IL-7) declared bankruptcy, thus the study was closed due to lack of drug supply.|2||Company supplying drug declared bankruptcy, thus there was no drug supply.|f||||f||||||||No||2018-05-31 22:41:21.737087|2018-05-31 22:41:21.737087
NCT01338987|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2018-04-19|2011-04-19|2011-04-20|Estimate|||||||2018-04-19|2018-04-20|Actual|April 19, 2011||2011-04-19|March 9, 2018|2018-03-09|November 19, 2020|Anticipated|2020-11-19|November 19, 2020|Anticipated|2020-11-19||Interventional|||Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation|Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation|Active, not recruiting||Phase 2|76|Actual|National Institutes of Health Clinical Center (CC)||7|||f||||||||||||||2018-05-31 22:41:22.012254|2018-05-31 22:41:22.012254
NCT01338974|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-19|||2015-03-05|2011-04-19|2011-04-20|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia|Proteomic Signature Associated With Clinical Response to Cytarabine Based Induction Therapy in Patients With AML 56 Years and Older|Completed|||290|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-05-31 22:41:22.208014|2018-05-31 22:41:22.208014
NCT01338961|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2013-10-30|2011-04-19|2011-04-20|Estimate|||||||2013-10-30|2013-11-01|Estimate|April 2011||2011-04-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Normothermia Versus Hypothermia for Valvular Surgery Patients|Normothermia Versus Hypothermia for Patients With Valvular Heart Disease Operated Under Cardiopulmonary Bypass.|Completed||N/A|140|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 22:41:22.311716|2018-05-31 22:41:22.311716
NCT01338948|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-04-19|2011-04-19|2011-04-20|Estimate|||||||2011-04-19|2011-04-20|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Image-guided Minimally Invasive Robotic Surgery Using Preoperative CT Scan for Gastric Cancer Patients|A Feasibility Study on Image-guided Minimally Invasive Robotic Surgery Using Preoperative CT Scan for Gastric Cancer Patients|Completed||Phase 1/Phase 2|12|Actual|Yonsei University|||||f||||f||||||||||2018-05-31 22:41:22.395954|2018-05-31 22:41:22.395954
NCT01338935|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-02-03|2011-04-19|2011-04-20|Estimate|||||||2014-02-03|2014-02-04|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|CW002||Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002|A Phase I, Single-Site, Tri-Institutional, Open-Label, Three-Part, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of CW002 in Healthy Adult Anesthetized Volunteers|Terminated||Phase 1|136|Actual|Weill Medical College of Cornell University||3||Pharmacokinetic stopping criteria for the study were met.|f||||t||||||||||2018-05-31 22:41:22.454485|2018-05-31 22:41:22.454485
NCT01338922|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2018-01-31|2011-04-19|2011-04-20|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2011||2011-04-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|July 2015|Actual|2015-07-31||Interventional|pumpkin||Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM)|Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 DM - a Randomised Controlled Trial|Completed||N/A|211|Actual|University of Schleswig-Holstein||2|||f||||t||||||||No||2018-05-31 22:41:22.541434|2018-05-31 22:41:22.541434
NCT01338909|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-09-29|2011-04-19|2011-04-20|Estimate|||||||2011-09-29|2011-09-30|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PRO-GR-4||Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)|Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)and Presenting With High Platelet Reactivity, as Assessed With a Point of Care Assay, After 600mg Clopidogrel Loading Dose|Completed||Phase 3|35|Anticipated|University of Patras||2|||f||||f||||||||||2018-05-31 22:41:22.636239|2018-05-31 22:41:22.636239
NCT01317706|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparison Between Ultrasonographic Cervical Length and Bishop Score in Preinduction Cervical Assessment||Completed||N/A|154|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:46:48.739013|2018-05-31 22:46:48.739013
NCT01338896|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-08-26|2011-04-19|2011-04-20|Estimate|||||||2011-08-26|2011-08-30|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations|A Multicenter, Randomized, Double-blind, Two-way Cross-over Study to Compare the Adhesiveness of Two Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease|Completed||Phase 1|56|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 22:41:22.706966|2018-05-31 22:41:22.706966
NCT01338883|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18||2013-06-19|2013-07-03|2011-04-19|2011-04-20|Estimate||||2013-07-03|2013-07-10|Estimate|2013-07-03|2013-07-10|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus|A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR 652) or Once-Daily EFV, Each With Open-Label FTC/TDF, in HIV 1-Infected, Antiretroviral Treatment-Naïve, Adult Patients With Only CCR5-Tropic Virus|Completed||Phase 2|143|Actual|Tobira Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 22:41:22.802793|2018-05-31 22:41:22.802793
NCT01338870|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2013-03-11|2013-01-15|2013-03-11|2011-04-18|2011-04-20|Estimate|2013-03-11|2013-04-23|Estimate|2013-01-15|2013-01-24|Estimate|2013-03-11|2013-04-23|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes|A 12-week, Phase 2, Randomized, Double-blind, Placebo Controlled, Dose-ranging, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf-04991532 and Once Daily Sitagliptin in Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin|Completed||Phase 2|301|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 22:41:22.96993|2018-05-31 22:41:22.96993
NCT01338857|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2013-06-24||2016-12-28|2011-04-19|2011-04-20|Estimate|2016-01-25|2016-02-22|Estimate||||2016-12-28|2017-02-17|Actual|April 2011||2011-04-30|December 2016|2016-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas|Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas|Terminated||Phase 2|12|Actual|New York University School of Medicine||1||Sorafenib ineffective for tx of recurrent or progressive PLGA|f||||t||||||||||2018-05-31 22:41:24.224401|2018-05-31 22:41:24.224401
NCT01338844|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-05-31|2011-04-19|2011-04-20|Estimate|||||||2011-05-31|2011-06-01|Estimate||||April 2011|2011-04-30||||||||Interventional|||Role of Myo-inositol and D-chiro-inositol on Oocyte Quality|A Prospective, Randomized, Double Blind, Study on the Clinical Efficacy Myo-inositol Versus D-chiro-inositol in Women Undergoing in Vitro Fertilization Embryo Transfer.|Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||f||||||||||2018-05-31 22:41:24.455596|2018-05-31 22:41:24.455596
NCT01338831|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-02-28|2011-04-19|2011-04-20|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2011||2011-09-30|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer|A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer|Completed||Phase 1|73|Actual|Novartis||4|||f||||||||||||||2018-05-31 22:41:24.566953|2018-05-31 22:41:24.566953
NCT01338818|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2014-02-05||2014-11-04|2011-04-18|2011-04-20|Estimate|2014-04-25|2014-05-26|Estimate||||2014-11-04|2014-11-24|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder|A 6-month, Open-label Extension to a 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD|Completed||Phase 3|299|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:41:24.667173|2018-05-31 22:41:24.667173
NCT01338805|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15||2016-03-22|2016-03-22|2011-04-18|2011-04-20|Estimate||||2016-03-22|2016-04-25|Estimate|2016-03-22|2016-04-25|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Phase II BGG492 Capsule Extension for Partial Epilepsy|A Multicenter, Open-label, Follow-up Study to Evaluate the Long-term Safety and Tolerability of BGG492 TID as Adjunctive Therapy in Patients With Partial Onset Seizures Completing Double-blind, Placebo-controlled Study CBGG492A2207 or CBGG492A2211|Completed||Phase 2|56|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:41:24.888953|2018-05-31 22:41:24.888953
NCT01338792|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2013-10-16||2014-02-05|2011-04-18|2011-04-20|Estimate|2013-10-16|2013-12-11|Estimate||||2014-02-05|2014-03-10|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer|A Phase II Trial of Oxaliplatin and Pemetrexed in Hormone Refractory Prostate Cancer|Completed||Phase 2|47|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 22:41:24.998012|2018-05-31 22:41:24.998012
NCT01338779|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2016-09-29|2011-04-18|2011-04-20|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2004||2004-05-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|FACTOR||Study of Tolerant Kidney Transplant Recipients|Identification and Mechanistic Investigations of Tolerant Transplant Recipients|Completed|||197|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||11||f||||t||||||Samples With DNA|"~     blood, urine and tissue samples~   "|Yes|Participant level data access is available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal.|2018-05-31 22:41:25.452471|2018-05-31 22:41:25.452471
NCT01338766|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-04-21|2011-04-19|2011-04-20|Estimate|||||||2014-04-21|2014-04-23|Estimate|April 2011||2011-04-30|April 2014|2014-04-30||||December 2014|Anticipated|2014-12-31||Interventional|STRiDE||Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression|Spondylolisthesis Treated With an iO-Flex® System Enabled Decompression (STRiDE)|Unknown status|Active, not recruiting|N/A|100|Anticipated|Baxano Surgical, Inc.||1|||f||||f||||||||||2018-05-31 22:41:25.548809|2018-05-31 22:41:25.548809
NCT01338753|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2013-09-09|2011-04-18|2011-04-19|Estimate|||||||2013-09-09|2013-09-10|Estimate|October 2009||2009-10-31|September 2013|2013-09-30|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|IMAGING||Study to Evaluate Markers of Response in Locally Advanced Breast Cancer|A Multicenter Phase II Study, to Evaluate the Predictive Markers of Response in Locally Advanced Breast Cancer, Treated With Bevacizumab Combined With Neoadjuvant Chemotherapy|Completed||Phase 2|74|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||||f||||t||||||||||2018-05-31 22:41:25.637652|2018-05-31 22:41:25.637652
NCT01338740|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-12-04|2011-04-18|2011-04-19|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|ADA-IFX||Switching From Adalimumab to Infliximab|Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab|Unknown status|Recruiting||40|Anticipated|University Hospital, Ghent|||1||f||||f||||||Samples Without DNA|"~     At regular intervals, the results of interim blood tests will be documented (3x).~      After 10, 26 and 52 weeks, additional serum samples will be taken for determination of~     antibodies against Adalimumab and Infliximab. The serum levels of Adalimumab (week 0) and~     Infliximab (week 10, 26 and 52) will be determined.~   "|||2018-05-31 22:41:25.801013|2018-05-31 22:41:25.801013
NCT01338727|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|September 2006||2006-09-30|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|BESTOW||Breastfeeding Education and Support Trial for Obese Women (BESTOW)|Breastfeeding Education and Support Trial for Obese Women (BESTOW)|Completed||N/A|206|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 22:41:25.934217|2018-05-31 22:41:25.934217
NCT01338714|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2014-05-06|2011-04-18|2011-04-19|Estimate|||||||2014-05-06|2014-05-07|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function|The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function: a Randomized Controlled Trial|Completed||Phase 3|58|Actual|Taipei City Hospital||2|||f||||t||||||||||2018-05-31 22:41:26.021374|2018-05-31 22:41:26.021374
NCT01338701|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2016-05-11|2011-04-18|2011-04-19|Estimate|||||||2016-05-11|2016-05-13|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Exploratory Study to Evaluate 2 Acupuncture Methods for the Treatment of Headaches Associated With TBI|A Randomized Exploratory Study to Evaluate Two Acupuncture Methods for the Treatment of Headaches Associated With Traumatic Brain Injury|Completed||Phase 2/Phase 3|45|Actual|Samueli Institute for Information Biology||3|||f||||f||||||||Yes|Results will be shared in a published manuscript.|2018-05-31 22:41:26.266763|2018-05-31 22:41:26.266763
NCT01338688|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Observational|||The Change of the Tetanus Antibody Titer After Single Injection of Td and Simultaneous Injection of TIG With Td|the Change of the Tetanus Antibody Titer After Single Injection of Tetanus Vaccine and Simultaneous Injection of Tetanus Immunoglobulin With Tetanus Vaccine?|Completed|||250|Actual|Seoul National University Hospital|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:41:26.365896|2018-05-31 22:41:26.365896
NCT01338675|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2013-11-17|2011-04-18|2011-04-19|Estimate|||||||2013-11-17|2013-11-19|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)||Unknown status|Recruiting|Phase 1/Phase 2|5|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:41:26.427182|2018-05-31 22:41:26.427182
NCT01338662|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2017-05-02|2011-04-18|2011-04-19|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2011||2011-05-31|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Observational|||Comparison of the Incidence of Dyskinesia in Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist|A 10-year Observational Study of the Incidence of Dyskinesia in Patients With Early Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist|Recruiting|||500|Anticipated|Seoul National University Hospital|||3||f||||f||||||||||2018-05-31 22:41:26.538909|2018-05-31 22:41:26.538909
NCT01338649|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2014-07-22||2014-09-03|2011-04-18|2011-04-19|Estimate|2014-09-03|2014-09-05|Estimate||||2014-09-03|2014-09-05|Estimate|November 2007||2007-11-30|September 2014|2014-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence|Effects of Bright Light Treatment on Daytime Sleepiness and Nocturnal Sleep in Patients With Parkinson's Disease|Completed||N/A|27|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 22:41:26.642922|2018-05-31 22:41:26.642922
NCT01338636|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2017-04-13||2017-04-13|2011-04-18|2011-04-19|Estimate|2017-04-13|2017-05-22|Actual||||2017-04-13|2017-05-22|Actual|September 2008||2008-09-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|EiPAH|The analysis population included all participants.|An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)|An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Patients With Exercise Induced Pulmonary Arterial Hypertension|Completed||Phase 4|30|Actual|Brigham and Women's Hospital||1|||f||||f|t|||||||No||2018-05-31 22:41:26.941021|2018-05-31 22:41:26.941021
NCT01338623|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-05-02|2011-04-18|2011-04-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|May 2011|Anticipated|2011-05-31|April 2011|Actual|2011-04-30||Interventional|BET04cap||Bioequivalence Study of Tansulosine 0,4 mg Capsule in Health Subjects -Fed State|Bioequivalence Study of Tansulosine 0,4 mg Capsule in Health Subjects -Fed State|Unknown status|Recruiting|Phase 4|32|Anticipated|Biocinese||1|||f||||f||||||||||2018-05-31 22:41:27.185354|2018-05-31 22:41:27.185354
NCT01338610|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|2013-02-28||2013-04-18|2011-04-18|2011-04-19|Estimate|2013-04-18|2013-04-19|Estimate||||2013-04-18|2013-04-19|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Baseline data is presented for all subjects exposed to product.|ESBA105 in Patients With Severe Dry Eye|Evaluation of ESBA105 in the Persistent Relief of Ocular Discomfort in Patients With Severe Dry Eye|Completed||Phase 2|334|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:41:27.293094|2018-05-31 22:41:27.293094
NCT01338597|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|ET||Impact of Dissection Area on the Clinical Outcome of Endoscopic Thyroidectomy|Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy|Unknown status|Not yet recruiting|N/A|40|Anticipated|Second Military Medical University||2|||f||||f||||||||||2018-05-31 22:41:27.514924|2018-05-31 22:41:27.514924
NCT01338584|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2014-11-01|2011-04-18|2011-04-19|Estimate|||||||2014-11-01|2014-11-04|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Trial Study of the Efficacy of Intensive Preoperative Pelvic Floor Muscle Training to Decrease Post-prostatectomy Urinary Incontinence|A Randomized Controlled Trial Study of the Efficacy of Intensive Preoperative Pelvic Floor Muscle Training to Decrease Post-prostatectomy Urinary Incontinence|Unknown status|Recruiting|N/A|84|Anticipated|Queen Mary Hospital, Hong Kong||1|||f||||f||||||||||2018-05-31 22:41:27.584882|2018-05-31 22:41:27.584882
NCT01338571|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-12-17|2011-04-18|2011-04-19|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Observational|||Horton & Maizy Pilot Study for Resistant to Starch|The Effect of Resistant Starch on the Stool Microflora of Children: A Pilot Study|Completed|||4|Actual|Pennington Biomedical Research Center|||1||f||||f||||||None Retained|"~     collect 3 daily stool samples are retained at baseline and after 4 weeks~   "|||2018-05-31 22:41:27.801528|2018-05-31 22:41:27.801528
NCT01338558|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2016-11-01|2011-04-18|2011-04-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab||Withdrawn||Phase 3|0|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:41:27.851181|2018-05-31 22:41:27.851181
NCT01338545|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2016-11-01|2011-04-18|2011-04-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)|A Multi-centre Observational Study to Describe Usage and Dosification Patterns of RoActemra (Tocilizumab) Treatment in Rheumatoid Arthritis (RA) Patients in the Routine Clinical Practice. ACT-LIFE Study|Completed|||400|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:41:27.914588|2018-05-31 22:41:27.914588
NCT01338532|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2012-08-17|2011-04-18|2011-04-19|Estimate|||||||2012-08-17|2012-08-20|Estimate|March 2005||2005-03-31|August 2012|2012-08-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Time to Total Hip Replacement After Supervised Exercise and Patient Education|Time to Total Hip Replacement in Patients With Hip Osteoarthritis Going Through Both Supervised Exercise and Patient Education Compared to Those Going Through Patient Education Only. A 3.5-6 Year Follow-up of a Randomized, Controlled, Clinical Trial.|Unknown status|Active, not recruiting|N/A|109|Actual|Oslo University Hospital||2|||f||||||||||||||2018-05-31 22:41:28.16881|2018-05-31 22:41:28.16881
NCT01338519|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|January 1997||1997-01-31|January 1997|1997-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Database Study on Patients With PCOS||Recruiting|||2000|Anticipated|Odense University Hospital|||1||f||||f||||||||||2018-05-31 22:41:28.233054|2018-05-31 22:41:28.233054
NCT01338506|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2016-03-14|2011-04-18|2011-04-19|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|COPE||Integrated Treatment of OEF/OIF Veterans With PTSD & Substance Use Disorders|Integrated Treatment of Operation Enduring Freedom/Operation Iraqi Freedom Veterans With Post-traumatic Stress Disorder and Substance Use Disorders|Completed||N/A|70|Actual|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 22:41:28.298628|2018-05-31 22:41:28.298628
NCT01338493|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2014-08-06||2016-01-26|2011-04-18|2011-04-19|Estimate|2014-11-17|2014-11-18|Estimate||||2016-01-26|2016-01-28|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|Maverick||Maverick Total Disc Replacement in a 'Real World' Patient Population|Maverick Total Disc Replacement in a 'Real World' Patient Population - A Prospective, Multicenter, Observational Study|Completed|||139|Actual|Medtronic Spinal and Biologics|Seriousness of AEs was not assessed when the data were collected so it is not possible to separate SAEs and Other (Non-serious) AEs for the Maverick Registry. All events are here-reported as SAEs.||1||f||||f||||||||||2018-05-31 22:41:28.399728|2018-05-31 22:41:28.399728
NCT01338480|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2017-04-05|2011-04-18|2011-04-19|Estimate|||||||2017-04-05|2017-04-07|Actual|November 9, 2009|Actual|2009-11-09|April 2017|2017-04-30|October 22, 2014|Actual|2014-10-22|October 22, 2014|Actual|2014-10-22||Interventional|||Improving Informed Consent Process for Trauma Patients in the Emergency Department|Improving Informed Consent Process for Trauma Patients in the Emergency Department|Completed||N/A|172|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 22:41:28.688475|2018-05-31 22:41:28.688475
NCT01338467|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-06-15|2011-04-18|2011-04-19|Estimate|||||||2015-06-15|2015-06-16|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|||Glaucoma Treatment by Circular Cyclocoagulation Using High Intensity Focused Ultrasound With the EYEOP Medical Device|Glaucoma Treatment by Circular Cyclocoagulation Using High Intensity Focused Ultrasound (HIFU). A Prospective, Multicenter, Open-label, Safety and Efficacy Study of the Treatment With the EYEOP Medical Device in Patients With Refractory Glaucoma|Completed||N/A|52|Actual|EyeTechCare||1|||f||||t||||||||||2018-05-31 22:41:28.757395|2018-05-31 22:41:28.757395
NCT01338454|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-11-16|2011-04-18|2011-04-19|Estimate|||||||2011-11-16|2011-11-17|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Can we Use Intravenous Injection of Tranexamic Acid in Routine Practice With Active Management of the Third Stage of Labor?||Completed||Phase 3|450|Actual|Erzincan Military Hospital||2|||f||||||||||||||2018-05-31 22:41:28.838873|2018-05-31 22:41:28.838873
NCT01338441|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-09-14|2011-04-18|2011-04-19|Estimate|||||||2011-09-14|2011-09-15|Estimate|March 2011||2011-03-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|iQTEST||Selections of Subjects With Important Changes in Their Cardiac Repolarization Parameters for the Procurement of Skin and Blood Samples|Selections of Subjects With Dramatic Changes in Their Cardiac Repolarization Parameters After a Pharmacologic Stimulus Aiming to Collect Their Skin Biopsy and Blood Cells|Completed||Phase 1|130|Anticipated|Ectycell SASU||2|||f||||t||||||||||2018-05-31 22:41:28.925899|2018-05-31 22:41:28.925899
NCT01338428|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2014-11-21|2011-04-18|2011-04-19|Estimate|||||||2014-11-21|2014-11-24|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Sexual Assault Resistance Education for University Women|Sexual Assault Resistance Education for University Women: A Trial in Three Canadian Universities|Completed||Phase 2|916|Actual|University of Windsor||2|||f||||f||||||||||2018-05-31 22:41:29.017779|2018-05-31 22:41:29.017779
NCT01338415|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2017-09-20|2016-02-17|2017-11-09|2011-04-18|2011-04-19|Estimate|2017-11-09|2017-12-11|Actual|2016-02-17|2016-03-16|Estimate|2017-11-09|2017-12-11|Actual|March 8, 2011|Actual|2011-03-08|November 2017|2017-11-30|August 13, 2014|Actual|2014-08-13|August 13, 2014|Actual|2014-08-13||Interventional|FUTURE 3 Ext||FUTURE 3 Study Extension|A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension|Completed||Phase 3|58|Actual|Actelion|The study was uncontrolled and exploratory.|2|||f||||||||||||||2018-05-31 22:41:29.156797|2018-05-31 22:41:29.156797
NCT01338402|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-02-19|2011-04-18|2011-04-19|Estimate|||||||2014-02-19|2014-02-20|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Evaluation of the Performance of AIR OPTIX® COLORS||Completed||N/A|47|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:41:29.930284|2018-05-31 22:41:29.930284
NCT01338389|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2018-02-06|2011-04-18|2011-04-19|Estimate|||||||2018-02-06|2018-02-07|Actual|June 25, 2012|Actual|2012-06-25|February 2018|2018-02-28|June 29, 2023|Anticipated|2023-06-29|June 29, 2013|Actual|2013-06-29||Interventional|||Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy|Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy|Active, not recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 22:41:29.99222|2018-05-31 22:41:29.99222
NCT01338376|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-10-10|2011-04-18|2011-04-19|Estimate|||||||2011-10-10|2011-10-12|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Interventional|OPENING||Organization Program of DiabEtes INsulIN ManaGement|Organization Program of DiabEtes INsulIN ManaGement: An Open, Multi-center, Prospective, Randomized, 16-week, Controlled Clinical Study|Unknown status|Recruiting|Phase 4|1500|Anticipated|Chinese Diabetes Society||2|||f||||t||||||||||2018-05-31 22:41:30.056138|2018-05-31 22:41:30.056138
NCT01338363|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-18|||2016-08-09|2011-04-18|2011-04-19|Estimate|||||||2016-08-09|2016-08-10|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists|Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists|Completed|||23470|Actual|AstraZeneca|||3||f||||||||||||||2018-05-31 22:41:30.12092|2018-05-31 22:41:30.12092
NCT01338350|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2015-01-13|2011-04-18|2011-04-19|Estimate|||||||2015-01-13|2015-01-14|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 After Administration of Single and Multiple Ascending Doses in Healthy Male Japanese Subjects|Completed||Phase 1|96|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:41:30.284232|2018-05-31 22:41:30.284232
NCT01338337|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-01-25|2011-04-18|2011-04-19|Estimate|||||||2016-01-25|2016-01-26|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ABRAZA||Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia|Multicentre, Open-label, Randomized Phase II Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 International Prognostic Scoring System(IPSS )) Without the 5q Deletion and Transfusion Dependent Anaemia|Completed||Phase 2|40|Actual|Asociación Andaluza de Hematología y Hemoterapia||2|||f||||f||||||||||2018-05-31 22:41:30.352155|2018-05-31 22:41:30.352155
NCT01338324|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-12-12|2011-04-18|2011-04-19|Estimate|||||||2011-12-12|2011-12-13|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|Cyp||Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease|Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease|Completed||Phase 2/Phase 3|41|Actual|All India Institute of Medical Sciences, New Delhi|||||f||||t||||||||||2018-05-31 22:41:30.423496|2018-05-31 22:41:30.423496
NCT01338311|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2012-07-19|2011-04-17|2011-04-19|Estimate|||||||2012-07-19|2012-07-20|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Salbutamol Tolerance Onset|Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset|Completed||Phase 4|15|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 22:41:30.484455|2018-05-31 22:41:30.484455
NCT01338298|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-17|2018-04-17||2018-04-17|2011-04-18|2011-04-19|Estimate|2018-04-17|2018-05-16|Actual||||2018-04-17|2018-05-16|Actual|January 2011|Actual|2011-01-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DAAMSEL||Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia|Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia|Completed||N/A|60|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 22:41:30.557715|2018-05-31 22:41:30.557715
NCT01338285|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-16|||2018-04-04|2011-04-16|2011-04-19|Estimate|||||||2018-04-04|2018-04-05|Actual|June 10, 2006||2006-06-10|October 18, 2017|2017-10-18||||||||Observational|||Association of Formaldehyde Exposure to Myeloid Leukemia in Workers in Guangdong, China|Studies of Myeloid Progenitor Cells in Workers Exposed to Formaldehyde, a Putative Leukemogen|Completed|||94|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:41:30.796064|2018-05-31 22:41:30.796064
NCT01338142|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-17|2011-04-17|2011-04-19|Estimate|||||||2011-04-17|2011-04-19|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Amorphous Calcium Carbonate (Acc) Versus Crystalline Calcium Carbonate (Ccc) Using Stable Calcium Isotopes In Postmenopausal Women|A Randomised, Double-Blind, Crossover Bioavailability Study Comparing Amorphous Calcium Carbonate (Acc) Versus Crystalline Calcium Carbonate (Ccc) Using Stable Calcium Isotopes In Postmenopausal Women|Unknown status|Not yet recruiting|Phase 1/Phase 2|15|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 22:41:30.856617|2018-05-31 22:41:30.856617
NCT01338129|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|CRPS||The Effect of Vitamin c on Preventing Complex Regional Pain Syndrome (CRPS Type I) Following Ankle Fracture|The Effect of Vitamin c on Preventing Complex Regional Pain Syndrome (CRPS Type I) Following Ankle Fracture, Prospective Double Blind Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 22:41:30.917152|2018-05-31 22:41:30.917152
NCT01338116|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2016-04-06|2011-04-17|2011-04-19|Estimate|||||||2016-04-06|2016-04-07|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|CDSS||Optimal Antibiotic Treatment of Moderate to Severe Bacterial Infections|Optimal Antibiotic Treatment of Moderate to Severe Bacterial Infections: Integration of PCR Technology and Medical Informatics/Artificial Intelligence|Recruiting||Phase 3|600|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 22:41:30.979329|2018-05-31 22:41:30.979329
NCT01337934|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2018-04-03|2011-04-15|2011-04-19|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2013||2013-10-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|October 2016|Actual|2016-10-31||Interventional|RASP||Lactated Ringer Versus Albumin in Early Sepsis Therapy|Ringer Versus Albumin In Septic Patients: a Randomized Controlled Clinical Trial|Completed||Phase 3|360|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:41:34.15579|2018-05-31 22:41:34.15579
NCT01338103|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-17|||2011-04-29|2011-04-17|2011-04-19|Estimate|||||||2011-04-29|2011-05-02|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex|Treatment of Moderate to Severe Patients With Pemphigus With the Monoclonal Anti CD20 Antibody Rituximab at a Protocol of 1000mgX2 and Assessment of Their Immune Status Via the Cylex Test|Unknown status|Recruiting|N/A|10|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 22:41:31.044984|2018-05-31 22:41:31.044984
NCT01338090|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2012-04-02|2011-04-18|2011-04-19|Estimate|||||||2012-04-02|2012-04-03|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|NETPET||89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors|89Zr-bevacizumab PET Imaging as Predictive Biomarker for Everolimus Efficacy in Patients With Neuroendocrine Tumors|Completed|||14|Actual|University Medical Center Groningen|||1||f||||t||||||||||2018-05-31 22:41:31.104782|2018-05-31 22:41:31.104782
NCT01338077|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-02|||2012-02-09|2011-04-17|2011-04-19|Estimate|||||||2012-02-09|2012-02-10|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease|A Multi-center, Double-blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Sodium Alginate Oral Suspension (50 mg/ml) in Comparison to Omeprazole (20 mg/Cap) to Treat Non-erosive Gastro-esophageal Reflux Disease (NERD)|Completed||Phase 3|195|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:41:31.164202|2018-05-31 22:41:31.164202
NCT01338064|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2011-04-16|2011-04-16|2011-04-19|Estimate|||||||2011-04-16|2011-04-19|Estimate|September 2011||2011-09-30|April 2011|2011-04-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)|Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)|Unknown status|Not yet recruiting||150|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     1. Induced sputum (IS)~        2. Exhaled Breath Condensate~   "|||2018-05-31 22:41:31.227802|2018-05-31 22:41:31.227802
NCT01338051|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-16|||2014-04-16|2011-04-18|2011-04-19|Estimate|||||||2014-04-16|2014-04-21|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|PERCAPS||"The Development of a Mother/Child, Screen, Treat and Vaccinate Program in Manchay and Iquitos, Peru"|"The Development of a Mother/Child, Screen, Treat and Vaccinate Program in Manchay and Iquitos, Peru (PERCAPS)"|Completed||Phase 1|642|Actual|Preventive Oncology International, Inc.|||||f||||f||||||||||2018-05-31 22:41:32.267127|2018-05-31 22:41:32.267127
NCT01338025|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-16|2014-04-24||2015-10-14|2011-04-18|2011-04-19|Estimate|2014-04-24|2014-05-23|Estimate||||2015-10-14|2015-11-13|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|P1094|All eligible participants who entered the study were included in analyses. One participant on Arm A did not meet entry eligibility criteria; was taken off study after the entry visit, and is therefore excluded from all analyses.|Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy|Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation.|Terminated||Phase 4|33|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||2||Study was halted for lack of accrual|f||||t||||||||||2018-05-31 22:41:32.385434|2018-05-31 22:41:32.385434
NCT01338012|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2017-04-26||2017-06-01|2011-04-18|2011-04-19|Estimate|2017-06-01|2017-06-05|Actual||||2017-06-01|2017-06-05|Actual|December 2011||2011-12-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|mCRPC|Men who previously participated in Dendreon's P-11 clinical study, received Sipuleucel-T as part of P-11, and who developed metastatic castrate resistant prostate cancer (mCRPC), Safety population includes all subjects who received at least one infusion in the current study (P10-1).|Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer|An Open-Label Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated With Sipuleucel-T on Dendreon Study P-11 (NCT00779402)|Terminated||Phase 2|8|Actual|Dendreon|This study was terminated early due to administrative reasons. Only 8 subjects were enrolled and treated. Given the small number of patients enrolled, analyses do not provide reliable results.|1||Administrative reasons.|f||||f||||||||Undecided||2018-05-31 22:41:33.04166|2018-05-31 22:41:33.04166
NCT01337999|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-12-16|2011-04-18|2011-04-19|Estimate|||||||2013-12-16|2013-12-17|Estimate|March 2011||2011-03-31|December 2013|2013-12-31||||July 2014|Anticipated|2014-07-31||Observational|||Human Epididymis Protein 4 in Normal Menstruating Women|Human Epididymis Protein 4 in Normal Menstruating Women|Unknown status|Active, not recruiting||60|Anticipated|Women and Infants Hospital of Rhode Island|||1||f||||t||||||Samples With DNA|"~     Serum~   "|||2018-05-31 22:41:33.415654|2018-05-31 22:41:33.415654
NCT01337986|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2014-02-14|2011-04-15|2011-04-19|Estimate|||||||2014-02-14|2014-02-19|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Ampyra for Optic Neuritis in MS|Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis|Completed||Phase 2/Phase 3|53|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 22:41:33.495739|2018-05-31 22:41:33.495739
NCT01337973|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-05-04|2011-04-18|2011-04-19|Estimate|||||||2017-05-04|2017-05-08|Actual|June 20, 2012|Actual|2012-06-20|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 1, 2016|Actual|2016-12-01||Interventional|||Preventing Violence Among Veterans in Substance Use Disorder Treatment|Impact of Interventions to Reduce Violence and Substance Abuse Among VA Patients|Active, not recruiting||N/A|210|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 22:41:33.611402|2018-05-31 22:41:33.611402
NCT01337960|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2015-04-28||2015-05-27|2011-04-18|2011-04-19|Estimate|2015-05-27|2015-06-12|Estimate||||2015-05-27|2015-06-12|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional||Groups were compared at baseline using Friedmans test and Wilcoxon Sign Rank tests|Ankle Robotics Training After Stroke|Ankle Robotics Training After Stroke: Effects on Gait and Balance|Completed||N/A|41|Actual|VA Office of Research and Development|The control group was limited in both numbers and the fact that they were not available for retention testing. The technical challenges for reliable collection of anticipatory postural adjustments meant loss of those data for analysis.|3|||f||||t||||||||||2018-05-31 22:41:33.717126|2018-05-31 22:41:33.717126
NCT01337947|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-09-26|2011-04-15|2011-04-19|Estimate|||||||2014-09-26|2014-09-29|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes|The Impact of Fitness on Vascular Dysfunction in Adolescents With Type 1 Diabetes|Completed|||32|Actual|University of Virginia|||1||f||||f||||||||||2018-05-31 22:41:34.080688|2018-05-31 22:41:34.080688
NCT01337921|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2017-09-12|2011-04-18|2011-04-19|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2011||2011-06-30|September 2017|2017-09-30|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||A Multi-strain Synbiotic Versus a Multi-strain Probiotic in Premature Infants|A Randomized Controlled Trial on a Multi-strain Synbiotic vs. a Multi-strain Probiotic on Fecal Colonization in the Very Low Birth Weight Infant|Withdrawn||N/A|0|Actual|University of Nebraska||2||Pending further safety information regarding polysaccharides and premature infants|f||||f||||||||||2018-05-31 22:41:34.227214|2018-05-31 22:41:34.227214
NCT01337908|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2012-03-19|2011-04-18|2011-04-19|Estimate|||||||2012-03-19|2012-03-20|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Study of Mood and Stress After Spinal Cord Injury|A Survey of Vulnerability Factors, Current Stress and Depression Risk in Spinal Cord Injury|Completed|||377|Actual|University of Michigan|||||f||||f||||||Samples With DNA|"~     Saliva samples collected with Oragene kit.~   "|||2018-05-31 22:41:34.296693|2018-05-31 22:41:34.296693
NCT01337895|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-11-10|2011-04-18|2011-04-19|Estimate|||||||2011-11-10|2011-11-11|Estimate|May 2012||2012-05-31|August 2011|2011-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|DAWL||DAWL (Dairy and Weight Loss) Study|Diet and Weight Loss Study - a Weight Loss Trial to Determine Whether Dairy Products Augment Weight Loss for Adults Following an Energy-restricted Weight Loss Study|Withdrawn||Phase 4|0|Actual|University of Guelph||2||Grant not funded, study will not launch|f||||f||||||||||2018-05-31 22:41:34.358862|2018-05-31 22:41:34.358862
NCT01337882|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-11-30|2011-04-18|2011-04-19|Estimate|||||||2011-11-30|2011-12-01|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|BEAVER||Biodiesel Exhaust, Acute Vascular and Endothelial Responses|Inhalation of Dilute Biodiesel Exhaust: Acute Vascular and Endothelial Responses|Completed||N/A|16|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 22:41:34.522031|2018-05-31 22:41:34.522031
NCT01337869|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Bascom Cleft Lift Versus Limberg Flap for Sacrococcygeal Pilonidal Sinus|Comparison of Bascom Cleft Lift Technique Versus Limberg Flap Closure for Treatment of Sacrococcygeal Pilonidal Disease: A Prospective Randomized Controlled Trial Evaluating for Patient Satisfaction and Early Recurrence|Unknown status|Recruiting|N/A|60|Anticipated|Trabzon Numune Training and Research Hospital||2|||f||||t||||||||||2018-05-31 22:41:34.586617|2018-05-31 22:41:34.586617
NCT01337856|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|October 2007||2007-10-31|April 2011|2011-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|B/07/310||Efficacy of Alcohol Hand-rubbing Covering All Hand Surfaces in Reducing Bacterial Hand Contamination of Healthcare Staff|Efficacy of Alcohol Hand-rubbing Covering All Hand Surfaces in Reducing Bacterial Hand Contamination of Healthcare Staff|Completed||N/A|120|Actual|Tan Tock Seng Hospital||3|||f||||t||||||||||2018-05-31 22:41:34.676842|2018-05-31 22:41:34.676842
NCT01337843|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-05-05|2011-04-18|2011-04-19|Estimate|||||||2014-05-05|2014-05-07|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|WW||Online Cognitive Behavioral Therapy (CBT) Workbook|Wellness Workbook: Efficacy of an Online CBT Workbook for Chronic Low Back Pain|Completed||Phase 2|198|Anticipated|Talaria, Inc||2|||f||||t||||||||||2018-05-31 22:41:34.754448|2018-05-31 22:41:34.754448
NCT01337830|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-10-23|2011-04-15|2011-04-19|Estimate|||||||2014-10-23|2014-10-24|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen in Reducing Cigarette Craving in Smokers|A Randomized, Double-Blind, Crossover, Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, in Reducing Craving for a Cigarette in Daily Smokers|Completed||Phase 1|111|Actual|Star Scientific, Inc||2|||f||||f||||||||||2018-05-31 22:41:34.819842|2018-05-31 22:41:34.819842
NCT01337817|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-10-23|2011-04-15|2011-04-19|Estimate|||||||2014-10-23|2014-10-24|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers|A Randomized, Double-Blinded, Active-Controlled, Crossover, Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, Containing Tobacco and Silver Salt - in Healthy Smokers|Completed||Phase 1|37|Actual|Star Scientific, Inc||2|||f||||f||||||||||2018-05-31 22:41:34.903591|2018-05-31 22:41:34.903591
NCT01337804|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-02-20|2011-04-15|2011-04-19|Estimate|||||||2015-02-20|2015-02-23|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)|A Single Dose, Comparative, Open-label, Randomized, Crossover Bioequivalence Study of Omeprazole Administered as Zegerid® Powder for Oral Suspension 20 mg and Prilosec 40 mg Capsule in Healthy Subjects|Completed||Phase 1|50|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:41:35.010528|2018-05-31 22:41:35.010528
NCT01337791|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy, Safety and Tolerability of Telbivudine in HBeAg Positive Chronic Hepatitis B Pregnant Women With Elevated Alanine Aminotransferase Levels||Completed||Phase 4|88|Actual|Southeast University, China||2|||f||||t||||||||||2018-05-31 22:41:35.087416|2018-05-31 22:41:35.087416
NCT01337778|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-11-01|2011-04-18|2011-04-19|Estimate|||||||2013-11-01|2013-11-04|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Dil Mil (Hearts Together)|Empowering Daughters and Mother-in-laws to Mitigate Gender-based Violence and Promote Women's Health in India|Completed||Phase 2|539|Actual|RTI International||2|||f||||t||||||||||2018-05-31 22:41:35.175206|2018-05-31 22:41:35.175206
NCT01337765|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-02|||2016-02-11|2011-04-15|2011-04-19|Estimate|||||||2016-02-11|2016-02-12|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors|Completed||Phase 1|29|Actual|Array BioPharma||1|||f||||||||||||||2018-05-31 22:41:35.302715|2018-05-31 22:41:35.302715
NCT01337752|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2017-02-20|2011-04-15|2011-04-19|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2012||2012-01-31|February 2017|2017-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency|A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency|Completed||Phase 2|9|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:41:35.378035|2018-05-31 22:41:35.378035
NCT01337739|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2013-05-23||2013-05-23|2011-04-18|2011-04-19|Estimate|2013-05-23|2013-07-12|Estimate||||2013-05-23|2013-07-12|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||All 10 subjects participating were used in final analysis.|Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery|Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery|Terminated||N/A|8|Actual|Northwestern University|Early termination of the study due to increased discharge time from the post anesthesia care unit with subjects receiving dexmedetomidine. The delay was consistent among the group.|2||The study drug delayed time of discharge which is clinically impracticable.|f||||f||||||||||2018-05-31 22:41:35.494101|2018-05-31 22:41:35.494101
NCT01337726|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2017-04-04|2011-04-18|2011-04-19|Estimate|||||||2017-04-04|2017-04-05|Actual|February 2011||2011-02-28|May 2016|2016-05-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|COPE||Combined Illness Management and Psychotherapy in Treating Depressed Elders|Combined Illness Management and Psychotherapy in Treating Depressed Elders|Completed||N/A|226|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 22:41:35.874515|2018-05-31 22:41:35.874515
NCT01337713|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2017-07-25|2011-04-18|2011-04-19|Estimate|||||||2017-07-25|2017-07-27|Actual|September 2010||2010-09-30|July 2017|2017-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|GAD||Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)|Efficacy of Massage and Light Touch Therapy for the Treatment of Generalized Anxiety Disorder|Completed||N/A|40|Actual|Emory University||2|||f||||t||||||||||2018-05-31 22:41:35.980056|2018-05-31 22:41:35.980056
NCT01337700|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2014-11-19|2011-04-18|2011-04-19|Estimate|||||||2014-11-19|2014-11-20|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism|Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism|Completed||Phase 4|10|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 22:41:36.119648|2018-05-31 22:41:36.119648
NCT01337687|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2014-05-27|2011-04-18|2011-04-19|Estimate|||||||2014-05-27|2014-05-29|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|INOT||Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders|Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders|Completed||N/A|1|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 22:41:36.20737|2018-05-31 22:41:36.20737
NCT01337674|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2015-10-30||2017-03-10|2011-04-15|2011-04-19|Estimate|2015-12-22|2016-02-02|Estimate||||2017-03-10|2017-04-10|Actual|April 2011||2011-04-30|March 2017|2017-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)|A Study to Evaluate the Co-Administration of MK-4618 With Antihypertensive Agents|Completed||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 22:41:36.293861|2018-05-31 22:41:36.293861
NCT01337661|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-08-27|2011-04-15|2011-04-19|Estimate|||||||2012-08-27|2012-08-28|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Observational|||A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations|An Exploratory Study of the Cellular Inflammatory Mechanisms Associated With Chronic Obstructive Pulmonary Disease Exacerbations|Completed|||26|Actual|MedImmune LLC|||1||f||||f||||||Samples Without DNA|"~     Blood, Endobronchial tissues and Bronchoalveolar (BAL) samples~   "|||2018-05-31 22:41:36.7884|2018-05-31 22:41:36.7884
NCT01337648|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2016-06-21|2011-04-18|2011-04-19|Estimate|||||||2016-06-21|2016-06-22|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Radiation Biodosimetry in Children Undergoing Total Body Irradiation|Radiation Biodosimetry in Children Undergoing Total Body Irradiation|Completed|||2|Actual|Medical College of Wisconsin|||1||f||||f||||||Samples With DNA|"~     Stool~   "|||2018-05-31 22:41:36.893517|2018-05-31 22:41:36.893517
NCT01337635|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2014-09-16||2015-04-06|2011-04-18|2011-04-19|Estimate|2015-04-06|2015-04-08|Estimate||||2015-04-06|2015-04-08|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Vitamin D Deficiency and Atopic Dermatitis|Treatment Of Vitamin D Deficiency And Effect On Atopic Dermatitis Severity|Terminated||N/A|7|Actual|Medical College of Wisconsin||2||Not meeting enrollment goals.|f||||f||||||||||2018-05-31 22:41:37.042462|2018-05-31 22:41:37.042462
NCT01337622|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-03-26|2011-04-15|2011-04-19|Estimate|||||||2015-03-26|2015-03-30|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Gastric Residuals in Preterm Infants|Gastric Residuals in Preterm Infants (GRIP)|Completed||N/A|87|Actual|McMaster Children's Hospital||2|||f||||f||||||||||2018-05-31 22:41:37.33855|2018-05-31 22:41:37.33855
NCT01337609|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2013-05-29||2013-08-07|2011-04-18|2011-04-19|Estimate|2013-08-07|2013-08-09|Estimate||||2013-08-07|2013-08-09|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder|A Double-Blind, Placebo-Controlled Study of the Probiotic Ganeden BC30 (Bacillus Coagulans GBI-30, 6068) in Irritable Bowel Syndrome Comorbid With Major Depressive Disorder (MDD)|Terminated||Phase 4|5|Actual|Massachusetts General Hospital|Because the study sponsor chose to discontinue funding for this protocol following a change in leadership, the study was terminated early and data were not analyzed.|3||"Because the study sponsor chose to discontinue funding for this protocol following a change in~   leadership, the study was terminated early."|f||||f||||||||||2018-05-31 22:41:37.43296|2018-05-31 22:41:37.43296
NCT01337596|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2012-05-18|2011-04-15|2011-04-19|Estimate|||||||2012-05-18|2012-05-21|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of LY2951742 in Healthy Volunteers|A Safety, Tolerability, and Pharmacokinetic Study of Single, Escalating Subcutaneous Doses of LY2951742 in Healthy Volunteers|Completed||Phase 1|61|Anticipated|Eli Lilly and Company||9|||f||||f||||||||||2018-05-31 22:41:37.925149|2018-05-31 22:41:37.925149
NCT01337583|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-06-08|2011-04-15|2011-04-19|Estimate|||||||2012-06-08|2012-06-11|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Safety and Efficacy Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women|Withdrawn||Phase 3|0|Actual|International Partnership for Microbicides, Inc.||2|||f||||||||||||||2018-05-31 22:41:38.069954|2018-05-31 22:41:38.069954
NCT01337570|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-06-08|2011-04-15|2011-04-19|Estimate|||||||2012-06-08|2012-06-11|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Safety and Efficacy Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women|Withdrawn||Phase 3|0|Actual|International Partnership for Microbicides, Inc.||2|||f||||||||||||||2018-05-31 22:41:38.165417|2018-05-31 22:41:38.165417
NCT01337557|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|November 2011|Anticipated|2011-11-30|September 2011|Anticipated|2011-09-30||Interventional|||Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses|Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses|Unknown status|Enrolling by invitation|Phase 4|24|Anticipated|Hom, Milton M., OD, FAAO||1|||f||||f||||||||||2018-05-31 22:41:38.245625|2018-05-31 22:41:38.245625
NCT01337544|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2013-11-08|2011-04-18|2011-04-19|Estimate|||||||2013-11-08|2013-11-11|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|NK||Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours|Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours|Terminated||Phase 1/Phase 2|6|Actual|Hospital Infantil Universitario Niño Jesús, Madrid, Spain||1||"The parents of two patients enrolled who died, presented a claim against the hospital and the~   study was halted."|f||||f||||||||||2018-05-31 22:41:38.323897|2018-05-31 22:41:38.323897
NCT01337531|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)|Recombinant FSH Versus Highly Purified FSH in PCOS Patients Undergoing Control Ovarian Stimulation and IVF: a Prospective Randomized Study|Unknown status|Enrolling by invitation|Phase 2|200|Anticipated|Genesis Center for Fertility & Human Pre-Implantation Genetics||2|||f||||t||||||||||2018-05-31 22:41:38.394558|2018-05-31 22:41:38.394558
NCT01337518|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2012-12-17|2011-04-18|2011-04-19|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2011||2011-03-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer|A Phase 1a/1b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients With Castration-Resistant Prostate Cancer|Suspended||Phase 1|150|Anticipated|Enzon Pharmaceuticals, Inc.||1||Reassessment of strategic direction|f||||f||||||||||2018-05-31 22:41:38.462529|2018-05-31 22:41:38.462529
NCT01337505|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2013-02-11|2011-04-18|2011-04-19|Estimate|||||||2013-02-11|2013-02-13|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors|An Open-Label Phase 1 Study to Investigate the Safety and Maximum Tolerated Dose of INNO-206 (Doxorubicin-6-Maleimidocaproyl Hydrazone; DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors|Completed||Phase 1|24|Actual|CytRx||1|||f||||f||||||||||2018-05-31 22:41:38.543711|2018-05-31 22:41:38.543711
NCT01337492|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-03-20|2011-04-15|2011-04-19|Estimate|||||||2012-03-20|2012-03-21|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)|Pilot Study: Safety and Feasibility of Using Sorafenib as Neoadjuvant Treatment Prior to Orthotopic Liver Transplantation (OLT) in Patients With Hepatocellular Carcinoma|Terminated||Early Phase 1|2|Actual|Case Comprehensive Cancer Center||1||slow accrual|f||||t||||||||||2018-05-31 22:41:38.605039|2018-05-31 22:41:38.605039
NCT01337479|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-18|2011-04-18|2011-04-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|February 2003||2003-02-28|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials|Long-Term Assessment of Treatment Outcomes With Entecavir and Lamivudine for Chronic Hepatitis B Infection in Patients Who Have Enrolled in Phase III Entecavir Trials|Completed|||1097|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 22:41:38.672016|2018-05-31 22:41:38.672016
NCT01337466|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2013-06-26|2011-04-15|2011-04-19|Estimate|||||||2013-06-26|2013-06-27|Estimate|December 2010||2010-12-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Biodistribution and Dosimetry Evaluation of [124I]FIAU|Biodistribution and Dosimetry of [124i]FIAU in Patients With Prosthetic Joint Infection of The Knee or Hip and Healthy Subjects Using PET-CT Scanning|Completed||Phase 1|12|Actual|BioMed Valley Discoveries, Inc||1|||f||||f||||||||||2018-05-31 22:41:38.746324|2018-05-31 22:41:38.746324
NCT01337453|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2012-08-23|2011-04-18|2011-04-19|Estimate|||||||2012-08-23|2012-08-24|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy|Flu-Like Symptoms as a Complication of Botulinum Toxin Therapy|Completed|||247|Actual|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 22:41:38.807434|2018-05-31 22:41:38.807434
NCT01337440|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2011-04-15|2011-04-15|2011-04-18|Estimate|||||||2011-04-15|2011-04-18|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases|The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases|Unknown status|Recruiting|Phase 4|20|Anticipated|Kanazawa University||2|||f||||t||||||||||2018-05-31 22:41:38.863195|2018-05-31 22:41:38.863195
NCT01337427|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-09-12|2011-04-15|2011-04-18|Estimate|||||||2014-09-12|2014-09-15|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis|Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis|Withdrawn||Phase 3|0|Actual|Johns Hopkins University||3||The study was not feasible to conduct in the US and abroad.|f||||||||||||||2018-05-31 22:41:38.941013|2018-05-31 22:41:38.941013
NCT01337414|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-15|2011-04-15|2011-04-18|Estimate|||||||2011-04-15|2011-04-18|Estimate|May 2010||2010-05-31|April 2011|2011-04-30||||May 2012|Anticipated|2012-05-31||Interventional|||Tools to Optimize Patient Presentation After Onset of Exudative Age-Related Macular Degeneration (AMD)|Tools to Optimize Patient Presentation After Onset of Exudative AMD (Using the VMS Interactive Education and Early Detection Multi-Test)|Unknown status|Recruiting|Phase 2|1000|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 22:41:39.087004|2018-05-31 22:41:39.087004
NCT01337401|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2016-08-02|2011-04-15|2011-04-18|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|June 2017|Anticipated|2017-06-30||Interventional|CASPS||A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)|A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)|Active, not recruiting||Phase 2|36|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-05-31 22:41:39.183464|2018-05-31 22:41:39.183464
NCT01337388|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2016-11-01|2011-04-15|2011-04-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis|An Observational Study of the Efficacy of RoActemra in Smoking vs Non-smoking Patients With Rheumatoid Arthritis.|Completed|||197|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:41:39.267513|2018-05-31 22:41:39.267513
NCT01337375|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-11-01|2011-04-15|2011-04-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy|Pharmacokinetics and Pharmacodynamics of Intravenous Administration of Pegylated Interferon-2a in Patients With Chronic Hepatitis C and Previous Non-response to Standard Combination Therapy With Pegylated Interferon and Ribavirin (Intervention Study)|Completed||Phase 1|31|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:41:39.369162|2018-05-31 22:41:39.369162
NCT01337362|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-10-15|2011-04-15|2011-04-18|Estimate|||||||2014-10-15|2014-10-16|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HypoNeuro||Recurrent Hypoglycaemia in Type 1 Diabetes|Recurrent Hypoglycaemia in Type 1 Diabetes: Effects on Cognitive Function, Cerebral Electrical Activity, and Skin Temperature|Completed||N/A|23|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-05-31 22:41:39.449429|2018-05-31 22:41:39.449429
NCT01337349|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-08-27|2011-04-15|2011-04-18|Estimate|||||||2013-08-27|2013-08-29|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|PENT-CHF||Effects of Pentoxiphylline on Left Ventricular (LV) Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure (CHF)|Effects of Pentoxiphylline on Left Ventricular Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure.|Unknown status|Recruiting|N/A|45|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 22:41:39.517936|2018-05-31 22:41:39.517936
NCT01337336|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2011-04-21||2017-05-25|2011-04-15|2011-04-18|Estimate|2011-04-21|2011-05-20|Estimate||||2017-05-25|2017-05-30|Actual|October 2010||2010-10-31|May 2017|2017-05-31|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Observational|||Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population|Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a Comorbid COPD-Depression/Anxiety Population|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:41:39.610994|2018-05-31 22:41:39.610994
NCT01337323|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2017-05-25|2011-04-15|2011-04-18|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2010||2010-09-30|May 2017|2017-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting|Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting|Terminated|||3|Actual|GlaxoSmithKline|||1|Insufficient number of patient records met inclusion criteria|f||||f||||||||||2018-05-31 22:41:39.881486|2018-05-31 22:41:39.881486
NCT01337310|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-03-11|2011-04-15|2011-04-18|Estimate|||||||2012-03-11|2012-03-13|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|||Study of Tesetaxel in Japanese Patients With Solid Tumors|A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|12|Anticipated|Genta Incorporated||1|||f||||t||||||||||2018-05-31 22:41:39.97187|2018-05-31 22:41:39.97187
NCT01337297|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2013-09-24||2013-12-23|2011-04-15|2011-04-18|Estimate|2013-09-24|2013-11-27|Estimate||||2013-12-23|2014-01-30|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction|Treatment of Crack-cocaine Addiction Through Cognitive Neuromodulation of the Prefrontal Cortex Produced by Transcranial Direct Current Stimulation.|Completed||Phase 1/Phase 2|20|Actual|Federal University of Espirito Santo|Crack-cocaine is highly addictive, extremely difficult to treat and with high dropouts. 7 subjects started with anodal DLPFC tDCS showing high relapses (not shown). The remaining 13 subjects tested with bilateral DLPFC tDCS or sham were considered.|2|||f||||f||||||||||2018-05-31 22:41:40.047368|2018-05-31 22:41:40.047368
NCT01337271|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2013-09-11|2011-04-15|2011-04-18|Estimate|||||||2013-09-11|2013-09-12|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Performance of Neurally Adjusted Ventilatory Assist (NAVA) During Spontaneous Breathing Trial|Performance of Neurally Adjusted Ventilatory Assist (NAVA) During an Spontaneous Breathing Trial|Completed||N/A|20|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 22:41:40.280445|2018-05-31 22:41:40.280445
NCT01337258|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-05-25|2011-04-14|2011-04-18|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2010||2010-01-31|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Economic Analyses of the REDUCE Trial|Economic Analyses Alongside the REDUCE Clinical Trial|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:41:40.356794|2018-05-31 22:41:40.356794
NCT01337245|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2017-12-11|2011-04-15|2011-04-18|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2012||2012-05-31|December 2017|2017-12-31|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|||Emergency Treatment of Coral Snake Envenomation With Antivenom|Emergency Treatment of Coral Snake Envenomation With Antivenom|Completed||Phase 3|26|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 22:41:40.428781|2018-05-31 22:41:40.428781
NCT01337232|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-11-21|2011-04-15|2011-04-18|Estimate|||||||2013-11-21|2013-11-25|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Building Complex Language|Building Complex Language: Effect of Treatment and Dosage|Completed||Phase 1/Phase 2|31|Actual|Governors State University||2|||f||||f||||||||||2018-05-31 22:41:40.505941|2018-05-31 22:41:40.505941
NCT01337219|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-15|2011-04-15|2011-04-18|Estimate|||||||2011-04-15|2011-04-18|Estimate|April 2011||2011-04-30|February 2011|2011-02-28||||September 2011|Anticipated|2011-09-30||Interventional|RM/NEB-03-10||Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis|Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaide® in Patients With Cystic Fibrosis.|Unknown status|Recruiting|Phase 1/Phase 2|36|Anticipated|Erempharma||2|||f||||f||||||||||2018-05-31 22:41:40.572914|2018-05-31 22:41:40.572914
NCT01337206|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2015-02-05|2011-04-15|2011-04-18|Estimate|||||||2015-02-05|2015-02-06|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|DESTINY||SX ELLA Esophageal Degradable BD Stent System|Evaluation of the Effectiveness of the SX ELLA Esophageal Degradable BD (BD Stent) Stent System|Completed||N/A|66|Actual|Cook Group Incorporated||2|||f||||||||||||||2018-05-31 22:41:40.647864|2018-05-31 22:41:40.647864
NCT01337193|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-11-13|2011-04-15|2011-04-18|Estimate|||||||2014-11-13|2014-11-14|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Exercise and Biofeedback on Symptoms of Incontinence in Women With Stress Urinary Incontinence|Effect of Rehabilitative Ultrasound Imaging Biofeedback on Urinary Incontinence, Pelvic Floor Muscle Contractions and Quality of Life in Women With Stress Urinary Incontinence|Terminated||N/A|28|Actual|Texas Woman's University||2||Principal investigator has decided not to continue her PhD studies.|f||||f||||||||||2018-05-31 22:41:40.762049|2018-05-31 22:41:40.762049
NCT01337180|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-11-19|2011-04-15|2011-04-18|Estimate|||||||2015-11-19|2015-11-20|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|February 2014|Anticipated|2014-02-28||Observational|||Airway Inflammation Among Workers in the Silicon Carbide Processing Industry|Exposure to Aerosols and Airway Inflammation Among Workers in the Silicon Carbide Processing Industry|Withdrawn|||0|Actual|Sykehuset Telemark|||1|The industry plant from which we should recruit was closed down.|f||||t||||||Samples With DNA|"~     Induced sputum, serum, citrate- plasma, EDTA-plasma, whole blood and a PaxGene sample for DNA~     isolation. Cell isolation, RNA isolation and gene expression analysis. Fluid phase analyses.~   "|||2018-05-31 22:41:40.82737|2018-05-31 22:41:40.82737
NCT01337167|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2016-02-18||2016-02-18|2011-04-15|2011-04-18|Estimate|2016-02-18|2016-03-16|Estimate||||2016-02-18|2016-03-16|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)|A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq™|Completed||Phase 3|1473|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:41:40.94811|2018-05-31 22:41:40.94811
NCT01337154|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-06-27|2011-04-15|2011-04-18|Estimate|||||||2013-06-27|2013-06-28|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer|A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|140|Actual|CytRx||2||Interim analysis showed that the primary endpoint would not be met.|f||||t||||||||||2018-05-31 22:41:42.227171|2018-05-31 22:41:42.227171
NCT01337141|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2015-01-28|2011-04-15|2011-04-18|Estimate|||||||2015-01-28|2015-01-29|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|||A Telematic Program for Optimization of Metabolic Control in Diabetes Mellitus Type 1 (DM1) Patients|Multicentric Intervention Study Evaluating the Efficiency of the Implementation in the Spanish Health System of a Telematic System Applied to Metabolic Control Optimization for Type 1 Diabetes Mellitus (DM1) Patients|Completed||N/A|154|Actual|Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders||2|||f||||t||||||||||2018-05-31 22:41:42.423984|2018-05-31 22:41:42.423984
NCT01337128|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2014-12-04|2011-04-15|2011-04-18|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|April 2015|Anticipated|2015-04-30||Interventional|||Carotid Endarterectomy Versus Carotid Artery Stenting? A Prospective Comparison of Neuropsychological Outcome in Patients With Carotid Stenosis.|Carotid Endarterectomy Versus Carotid Artery Stenting? A Prospective Comparison of Neuropsychological Outcome in Patients With Carotid Stenosis.|Unknown status|Recruiting|N/A|100|Anticipated|University Ghent||3|||f||||f||||||||||2018-05-31 22:41:42.800972|2018-05-31 22:41:42.800972
NCT01337115|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2012-03-21||2012-05-17|2011-04-15|2011-04-18|Estimate|2012-05-17|2012-06-19|Estimate||||2012-05-17|2012-06-19|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Effect of a Sciatic Block (SNB) Combined With a Continuous Femoral Block (CFNB) on Pain Scores After Knee Arthroplasty|Effect of a Single Shot Sciatic Nerve Block (SNB) Combined With a Continuous Femoral Block (CFNB) on Pain Scores After Knee Arthroplasty. A Randomized Controlled Trial|Completed||N/A|50|Actual|Centro Hospitalar do Porto|"Difficulties in contacting patients by phone and getting reliable answers limit the value of the patient satisfaction parameter.~No analysis was made on the effect of nerve blocks on rehabilitation"|2|||f||||f||||||||||2018-05-31 22:41:42.898954|2018-05-31 22:41:42.898954
NCT01337102|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2017-03-10|2011-04-15|2011-04-18|Estimate|||||||2017-03-10|2017-03-14|Actual|November 2004||2004-11-30|March 2017|2017-03-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|LUNL2||Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)|Randomized Trial to Investigate the Impact of a Computer-Generated Quality of Life Assessment Program on Treatment Patterns for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)|Completed||N/A|103|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 22:41:43.200632|2018-05-31 22:41:43.200632
NCT01337089|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2018-03-23||2018-03-23|2011-04-15|2011-04-18|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|January 19, 2011|Actual|2011-01-19|March 2018|2018-03-31|January 27, 2016|Actual|2016-01-27|January 27, 2016|Actual|2016-01-27||Interventional||Safety Population: All participants who received at least 1 dose of nabiximols.|Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain|A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain|Completed||Phase 3|660|Actual|GW Pharmaceuticals Ltd.||1|||f||||t||||||||||2018-05-31 22:41:43.323459|2018-05-31 22:41:43.323459
NCT01337076|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2014-09-18||2016-09-23|2011-04-15|2011-04-18|Estimate|2014-09-18|2014-09-25|Estimate||||2016-09-23|2016-10-27|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Subjects who met study inclusion and completed the primary endpoint of 6 months postimplant activation.|Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy|Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy|Completed||N/A|21|Actual|Cochlear||1|||f||||f||||||||||2018-05-31 22:41:44.819294|2018-05-31 22:41:44.819294
NCT01337063|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2015-11-11|2011-04-15|2011-04-18|Estimate|||||||2015-11-11|2015-11-13|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MARQUIS||Multi-Center Medication Reconciliation Quality Improvement Study|Multi-Center Medication Reconciliation Quality Improvement Study|Completed||N/A|1836|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:41:44.957699|2018-05-31 22:41:44.957699
NCT01337050|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2015-07-16||2015-10-06|2011-04-15|2011-04-18|Estimate|2015-08-13|2015-08-28|Estimate||||2015-10-06|2015-10-28|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional||Full analysis set included all enrolled participants.|Asian Phase I Study Of PF-03446962|A Phase I Pharmacokinetic And Pharmacodynamic Study Of Pf-03446962 In Asian Patient With Advanced Solid Tumors|Completed||Phase 1|36|Actual|Pfizer|Designation of primary and secondary endpoints was based on study team's inputs, as the endpoints were not prioritized in the study protocol.|1|||f||||f||||||||||2018-05-31 22:41:45.130463|2018-05-31 22:41:45.130463
NCT01337037|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2015-01-24|2011-04-15|2011-04-18|Estimate|||||||2015-01-24|2015-01-27|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|5 Years|Observational [Patient Registry]|||Modified Video-assisted Thoracoscopic Surgery (VATS) Lobectomy for Early-stage Non-small Cell Lung Cancer (NSCLC)||Unknown status|Recruiting||1000|Anticipated|Peking University People's Hospital|||4||f||||t||||||||||2018-05-31 22:41:46.559443|2018-05-31 22:41:46.559443
NCT01337024|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2016-05-16|2011-04-15|2011-04-18|Estimate|||||||2016-05-16|2016-05-17|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|HRV/Botox||Heart Rate Variability (HRV) in Patients With Neurogenic Detrusor Overactivity (NDO) Before and After Botulinum Neurotoxin Type A (BoNT/A) Intradetrusor Injections|Heart Rate Variability in Patients With Neurogenic Detrusor Overactivity Before and After Botulinum Neurotoxin Type A Intradetrusor Injections|Completed|||36|Actual|Balgrist University Hospital|||3||f||||f||||||||||2018-05-31 22:41:46.724404|2018-05-31 22:41:46.724404
NCT01337011|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2018-03-23|2011-04-15|2011-04-18|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2011|Actual|2011-07-31|March 2018|2018-03-31|July 17, 2017|Actual|2017-07-17|March 2, 2016|Actual|2016-03-02||Interventional|AlsterMACS||Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells|Pilot Study Comparing the Effect of Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells for Improving Left Ventricular Function in Chronic Ischemic Cardiomyopathy|Terminated||Phase 1|10|Actual|Asklepios proresearch||2||study was stopped due to funding issues|f||||f||||||||Undecided||2018-05-31 22:41:46.786425|2018-05-31 22:41:46.786425
NCT01336998|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2011-04-15|2011-04-15|2011-04-18|Estimate|||||||2011-04-15|2011-04-18|Estimate|June 2009||2009-06-30|April 2011|2011-04-30||||June 2011|Anticipated|2011-06-30||Interventional|||Administration of Arginine Supplementation in Preterm Infants|Administration of Arginine Supplementation in Preterm Infants and Measurement of Fecal Calprotectin as an Inflammatory Marker of the Intestine|Unknown status|Active, not recruiting|N/A|80|Anticipated|Alexandra Hospital, Athens, Greece|||||f||||t||||||||||2018-05-31 22:41:46.850715|2018-05-31 22:41:46.850715
NCT01336985|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2018-05-23|2011-04-14|2011-04-18|Estimate|||||||2018-05-23|2018-05-24|Actual|March 28, 2011||2011-03-28|November 3, 2014|2014-11-03|March 28, 2011|Actual|2011-03-28|||||Interventional|||Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads|Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases|Terminated||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:41:46.907956|2018-05-31 22:41:46.907956
NCT01336972|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2017-03-28|2012-12-03|2017-05-30|2011-04-15|2011-04-18|Estimate|2017-05-30|2017-06-28|Actual|2012-12-05|2012-12-07|Estimate|2017-05-30|2017-06-28|Actual|October 2010||2010-10-31|May 2017|2017-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|A Phase 2a, Single-center Study Investigating the Short-term Renal Hemodynamic Effects, Safety and Pharmacokinetics/ Pharmacodynamics of Oral Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal Function|Completed||Phase 2|29|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f||||||||||2018-05-31 22:41:47.007104|2018-05-31 22:41:47.007104
NCT01336959|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13||2015-05-20|2015-05-20|2011-04-15|2011-04-18|Estimate||||2015-05-20|2015-06-15|Estimate|2015-05-20|2015-06-15|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery|A Two-part, Randomized, Double-blind, Placebo-controlled, Single Dose Study of BCT197 for the Prevention of Acute Kidney Injury (AKI) in Patients Undergoing Elective Cardiac Surgery With Cardiopulmonary Bypass (CPB)|Terminated||Phase 2|83|Actual|Novartis||3|||f||||t||||||||||2018-05-31 22:41:47.69836|2018-05-31 22:41:47.69836
NCT01336946|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-12-04|2011-04-15|2011-04-18|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|HEPIMEC||HEalth Promotion Intervention in MEntal Health Care|Effectiveness and Cost-effectiveness of a Health Promotion Intervention Targeting Physical Activity and Eating Habits in Persons With Mental Disorders|Completed||N/A|742|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 22:41:47.781324|2018-05-31 22:41:47.781324
NCT01336933|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2018-01-13|2011-04-14|2011-04-18|Estimate|||||||2018-01-13|2018-01-17|Actual|July 2011||2011-07-31|January 2018|2018-01-31|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Interventional|||Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma|A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma|Completed||Phase 2|34|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 22:41:47.990372|2018-05-31 22:41:47.990372
NCT01336920|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-05-23|2011-04-15|2011-04-18|Estimate|||||||2017-05-23|2017-05-25|Actual|June 2011||2011-06-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2015|Actual|2015-04-30||Interventional|||Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma|Phase I Study of Carfilzomib for the Treatment of T-Cell Lymphoma|Active, not recruiting||Phase 1|15|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 22:41:48.124833|2018-05-31 22:41:48.124833
NCT01336907|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-09-20|2011-04-15|2011-04-18|Estimate|||||||2016-09-20|2016-09-21|Estimate||||September 2016|2016-09-30||||||||Observational|||Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)|Comparison Between Home Macular Perimeter and OCT Visual Field Defects in Patients With CNV|Withdrawn|||0|Actual|Notal Vision Ltd|||2|never started|f||||f||||||||||2018-05-31 22:41:48.19594|2018-05-31 22:41:48.19594
NCT01336712|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2015-10-16||2015-12-10|2011-04-15|2011-04-18|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases|A Phase II Trial of Total Body Irradiation-Based Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies|Completed||Phase 2|30|Actual|Northside Hospital, Inc.||1|||f||||f||||||||||2018-05-31 22:41:51.689372|2018-05-31 22:41:51.689372
NCT01336894|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|2016-11-28||2017-04-25|2011-04-15|2011-04-18|Estimate|2017-02-08|2017-03-28|Actual||||2017-04-25|2017-05-30|Actual|May 2011||2011-05-31|April 2017|2017-04-30|March 27, 2017|Actual|2017-03-27|May 2013|Actual|2013-05-31||Interventional|||Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer|A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) Versus Stereotactic Body Radiation Therapy in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|13|Actual|Alliance for Clinical Trials in Oncology||2||"recruiting or enrolling participants has halted prematurely and will not resume; participants~   are no longer being examined or treated"|f||||t||||||||||2018-05-31 22:41:48.282237|2018-05-31 22:41:48.282237
NCT01336881|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2016-05-17|2011-04-15|2011-04-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2011||2011-04-30|May 2016|2016-05-31||||July 2011|Actual|2011-07-31||Observational|||Biomarkers in Tissue Samples From Young Patients With Liver Cancer|Genetics and Biology of Liver Tumorigenesis in Children|Completed|||99|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Archived tumor tissue samples~   "|||2018-05-31 22:41:48.919206|2018-05-31 22:41:48.919206
NCT01336868|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-04-15|2011-04-15|2011-04-18|Estimate|||||||2011-04-15|2011-04-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:41:48.991063|2018-05-31 22:41:48.991063
NCT01336855|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2017-03-28|2011-04-15|2011-04-18|Estimate|||||||2017-03-28|2017-03-30|Actual|January 1988||1988-01-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Collection of Blood for Multiple Collaborative Studies|Collection and Preservation of Blood and Serum Specimens From HIV Positive or HIV Negative Patients for Multiple Collaborative Studies|Recruiting|||2000|Anticipated|University of California, San Francisco|||2||f||||f|f|f||||Samples With DNA|"~     Plasma, PBMCs, buffy coat, serum, saliva, urine~   "|No||2018-05-31 22:41:49.032455|2018-05-31 22:41:49.032455
NCT01336842|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2018-01-05|2011-04-14|2011-04-18|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2011||2011-04-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors|Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer|Completed||Phase 1|23|Actual|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 22:41:49.107061|2018-05-31 22:41:49.107061
NCT01336829|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-08-28|2011-04-15|2011-04-18|Estimate|||||||2012-08-28|2012-08-29|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.|A Phase I, Open Label, Randomized, 2-Panel, 2-Way Crossover Trial to Investigate the Pharmacokinetic Interaction Between Etravirine or TMC278 and Telaprevir at Steady-State in Healthy Subjects.|Completed||Phase 1|33|Actual|Tibotec Pharmaceuticals, Ireland||4|||f||||||||||||||2018-05-31 22:41:49.201732|2018-05-31 22:41:49.201732
NCT01336816|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-10-23|2011-04-15|2011-04-18|Estimate|||||||2014-10-23|2014-10-24|Estimate|July 2009||2009-07-31|October 2014|2014-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge|A Randomized, Double-Blinded, Placebo-Controlled, Crossover, Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge, Containing Tobacco and Silver Salt - in Healthy Smokers|Completed||Phase 1|43|Actual|Star Scientific, Inc||2|||f||||f||||||||||2018-05-31 22:41:49.778243|2018-05-31 22:41:49.778243
NCT01336803|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2018-01-12|2011-04-14|2011-04-18|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2011||2011-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI|Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI|Recruiting||N/A|50|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 22:41:49.865738|2018-05-31 22:41:49.865738
NCT01336790|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2018-02-28|2011-04-14|2011-04-18|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2009||2009-03-31|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31||Observational|||International Lymphatic Disease and Lymphedema Registry|The International Lymphatic Disease and Lymphedema Patient Registry and Tissue Bank|Recruiting|||5000|Anticipated|Stanford University|||||f||||f||||||||Undecided|grouped data may be shared|2018-05-31 22:41:50.039667|2018-05-31 22:41:50.039667
NCT01336777|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2013-12-02|2011-04-15|2011-04-18|Estimate|||||||2013-12-02|2013-12-03|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Regional Fat Depots and Insulin Resistance|Heterogeneity of Fat Depots|Unknown status|Active, not recruiting||50|Anticipated|Stanford University|||2||f||||t||||||Samples With DNA|"~     adipose tissue samples will be frozen for gene expression analysis.~   "|||2018-05-31 22:41:50.129067|2018-05-31 22:41:50.129067
NCT01336764|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2017-02-16||2017-04-03|2011-04-14|2011-04-18|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|April 2011||2011-04-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Enhancing Emotion Regulation During Driving in OEF/OIF Veterans|Enhancing Emotion Regulation During Driving in OEF/OIF Veterans|Completed||N/A|22|Actual|Palo Alto Veterans Institute for Research||2|||f||||f|f|f||||||No||2018-05-31 22:41:50.219723|2018-05-31 22:41:50.219723
NCT01336751|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-04-15|2011-04-15|2011-04-18|Estimate|||||||2011-04-15|2011-04-18|Estimate|July 2001||2001-07-31|April 2011|2011-04-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment|Lantus® (Insulin Glargine[rDNA Origin] Injection) vs Humalog® Mix 75/25 (75% Insulin Lispro Protamine Suspension and 25% Insulin Lispro Injection) as add-on Therapy in Type 2 Diabetes Patients Failing Sulfonylurea and Glucophage (Metformin) Combination Treatment: a Randomized, Open, Parallel Study|Completed||Phase 3|212|Actual|Sanofi||2|||f||||||||||||||2018-05-31 22:41:50.386166|2018-05-31 22:41:50.386166
NCT01336738|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2013-06-05|2013-04-09|2013-06-05|2011-04-14|2011-04-18|Estimate|2013-06-05|2013-08-06|Estimate|2013-04-09|2013-04-16|Estimate|2013-06-05|2013-08-06|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus|A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-04991532 And Sitagliptin In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Completed||Phase 2|266|Actual|Pfizer||5|||f||||t||||||||||2018-05-31 22:41:50.681617|2018-05-31 22:41:50.681617
NCT01336725|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-04-15|2011-04-15|2011-04-18|Estimate|||||||2011-04-15|2011-04-18|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Learning and Coping With Chronic Illness|Learning and Coping With Chronic Illness|Completed|||150|Anticipated|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 22:41:51.598847|2018-05-31 22:41:51.598847
NCT01336699|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2015-10-01|2011-04-14|2011-04-18|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3|Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3|Completed||Phase 1|90|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-05-31 22:41:52.302351|2018-05-31 22:41:52.302351
NCT01336686|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14||2015-02-19|2015-03-30|2011-04-15|2011-04-18|Estimate||||2015-03-09|2015-03-30|Estimate|2015-03-30|2015-04-17|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout|A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout|Completed||Phase 2|67|Actual|CymaBay Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 22:41:52.42939|2018-05-31 22:41:52.42939
NCT01336673|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-06-18|2011-04-14|2011-04-18|Estimate|||||||2014-06-18|2014-06-19|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Glucophage XR® Observational Study|An Observational Study on the Use of Glucophage XR® Therapy in the Management of Patients With Type 2 Diabetes|Terminated|||518|Actual|Merck KGaA||||"The study was scheduled for completion February 2013. Because of difficulties encountered in~   completing the trial the study was terminated by sponsor June 2013."|f||||f||||||||||2018-05-31 22:41:52.52062|2018-05-31 22:41:52.52062
NCT01336660|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2018-03-07|2011-04-15|2011-04-18|Estimate|||||||2018-03-07|2018-03-09|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco|Phase 2/3 Study for Scorpion North Africa Middle East Envenomation With a Immune F(ab')2 (Equine) Antivenom Alacramyn NAMO. A Randomized, Double-Blind, Placebo-controlled, Prospective and Multicenter Study|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|Instituto Bioclon S.A. de C.V.||2|||f||||t|f|f||||||Undecided|not yet decided|2018-05-31 22:41:52.595814|2018-05-31 22:41:52.595814
NCT01336647|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2013-12-04||2015-01-13|2011-04-14|2011-04-18|Estimate|2015-01-13|2015-01-19|Estimate||||2015-01-13|2015-01-19|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation|An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation|Completed||Phase 2|142|Actual|Hatchtech Pty Ltd||3|||f||||t||||||||||2018-05-31 22:41:52.737823|2018-05-31 22:41:52.737823
NCT01336634|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2016-10-05||2018-05-07|2011-04-14|2011-04-18|Estimate|2017-11-03|2017-12-07|Actual||||2018-05-07|2018-05-09|Actual|June 20, 2011|Actual|2011-06-20|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|October 1, 2015|Actual|2015-10-01||Interventional|||Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.|A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer|Active, not recruiting||Phase 2|174|Actual|Novartis||3|||f||||t|t|f||||||||2018-05-31 22:41:53.127955|2018-05-31 22:41:53.127955
NCT01336621|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2017-12-06||2018-05-17|2011-04-14|2011-04-18|Estimate|2018-01-26|2018-02-26|Actual||||2018-05-17|2018-05-22|Actual|February 21, 2011|Actual|2011-02-21|May 2018|2018-05-31|September 13, 2017|Actual|2017-09-13|December 14, 2016|Actual|2016-12-14||Interventional|IR||Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)|A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partial-Onset Seizures (Extension of Study RGB113905)|Completed||Phase 3|98|Actual|GlaxoSmithKline|17 parts. withdrew due to AE, however only 16 had a TEAE leading to withdrawal of RTG. 1 part. with a TEAE of seizure, withdrew due to lack of efficacy. 2 further parts. withdrew due to AE but had no TEAEs which led to withdrawal of RTG.|1|||f||||f|t|f|||t|||||2018-05-31 22:41:55.155729|2018-05-31 22:41:55.155729
NCT01336608|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2015-06-15||2017-10-09|2011-04-14|2011-04-18|Estimate|2015-06-15|2015-07-10|Estimate||||2017-10-09|2017-11-08|Actual|March 4, 2011|Actual|2011-03-04|October 2017|2017-10-31|November 4, 2014|Actual|2014-11-04|November 4, 2014|Actual|2014-11-04||Interventional|||A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD|A 24-week Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler on Arterial Stiffness Compared With Placebo and Vilanterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|446|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:41:58.217879|2018-05-31 22:41:58.217879
NCT01336595|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-10-04|2011-04-15|2011-04-18|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2003||2003-01-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|March 2004|Actual|2004-03-31||Interventional|||Comparison of Total Knee Arthroplasties With Oxidized Zirconium and Cobalt Chromium Femoral Components|Comparison of Total Knee Arthroplasties With Oxidized Zirconium and Cobalt Chromium Femoral Components in the Same Patients: A Prospective, Double Blinded, and Randomized Controlled Study|Completed||Phase 4|331|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 22:41:59.952367|2018-05-31 22:41:59.952367
NCT01336582|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-12-19|2011-04-14|2011-04-18|Estimate|||||||2012-12-19|2012-12-21|Estimate|August 2009||2009-08-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer|Phase I Trial to Compare Pharmacokinetics and Safety of SYP-0704A With Taxotere in Subjects With Advanced Solid Tumor|Completed||Phase 1|42|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 22:42:00.072805|2018-05-31 22:42:00.072805
NCT01336569|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2013-05-17||2013-05-17|2011-04-14|2011-04-18|Estimate|2013-05-17|2013-07-08|Estimate||||2013-05-17|2013-07-08|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||This reporting group includes all participants who received study product.|Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol|Safety and Efficacy of Using the Travoprost/Timolol Fixed Combination (DuoTrav®) in Patients With Open-Angle Glaucoma or Uncontrolled Ocular Hypertension by Beta-blocker Monotherapy (Timolol 0.5%)|Completed||Phase 4|50|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:42:00.156312|2018-05-31 22:42:00.156312
NCT01335178|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2015-12-08|2011-04-13|2011-04-14|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Program to Protect Young Children From Tobacco Smoke Exposure|A Program to Protect Young Children From Tobacco Smoke Exposure|Completed||Phase 2|29|Actual|Tel Aviv University||1|||f||||f||||||||||2018-05-31 22:42:24.682371|2018-05-31 22:42:24.682371
NCT01336556|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-10-25|2011-04-14|2011-04-18|Estimate|||||||2011-10-25|2011-10-26|Estimate|October 2010||2010-10-31|October 2011|2011-10-31||||November 2011|Anticipated|2011-11-30||Interventional|||Titration of Continuous Positive Airway Pressure Could Predict Success of Oral Appliance to Treat Sleep Apnea|Optimal Titration of Continuous Positive Airway Pressure Could Predict Success of Oral Appliance to Treat Obstructive Sleep Apnea Syndrome|Unknown status|Recruiting|N/A|60|Anticipated|Associacao Fundo de Incentivo a Psicofarmcologia|||||f||||t||||||||||2018-05-31 22:42:00.355818|2018-05-31 22:42:00.355818
NCT01336543|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-12-16|2011-04-14|2011-04-18|Estimate|||||||2014-12-16|2014-12-18|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)|A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Louisiana State University Health Sciences Center Shreveport||1||Low accrual, small patient population at center.|f||||t||||||||||2018-05-31 22:42:00.509337|2018-05-31 22:42:00.509337
NCT01336530|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2017-05-18|2011-04-14|2011-04-18|Estimate|||||||2017-05-18|2017-05-19|Actual|April 2011|Actual|2011-04-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Tepilta® Versus Oxetacaine, Antacids and Placebo|Clinical Trial to Assess the Efficacy of Fixed Combination Product Tepilta® in the Treatment of Radiation-induced Oesophagitis Compared to Its Active Ingredients Oxetacaine and Antacids, and to Placebo|Terminated||Phase 3|40|Actual|MEDA Pharma GmbH & Co. KG||4||"The study stopped prematurely due to and administrative reasons, not based on grounds of~   safety."|f||||t||||||||||2018-05-31 22:42:00.625393|2018-05-31 22:42:00.625393
NCT01336517|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2011-04-14|2011-04-14|2011-04-18|Estimate|||||||2011-04-14|2011-04-18|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Evaluation of the Effect of an Ankle Foot Orthoses for Ambulatory Function|Comprehensive Evaluations of the Effect of an Ankle Foot Orthoses for Ambulatory Function in Adults With Hemiplegia|Completed|||20|Actual|Kessler Foundation|||||f||||f||||||||||2018-05-31 22:42:00.828809|2018-05-31 22:42:00.828809
NCT01336478|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-06-03|2011-04-14|2011-04-18|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation|Safety and Toxicity of Escalating Doses of Adoptively Infused ex Vivo Selected CD56+CD3- NK Cells on Day 7 Following Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies.|Withdrawn||Phase 1|0|Actual|Imperial College London|||||f||||f||||||||||2018-05-31 22:42:00.887592|2018-05-31 22:42:00.887592
NCT01336465|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14||2016-08-10|2016-08-10|2011-04-14|2011-04-18|Estimate||||2016-08-10|2016-08-12|Estimate|2016-08-10|2016-08-12|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|||Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis|Phase II Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis|Completed||Phase 2|124|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:42:00.968555|2018-05-31 22:42:00.968555
NCT01336452|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-06-01|2011-04-14|2011-04-15|Estimate|||||||2013-06-01|2013-06-04|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers|Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers|Unknown status|Recruiting|N/A|30|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 22:42:01.135367|2018-05-31 22:42:01.135367
NCT01336439|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-18|2011-04-13|2011-04-15|Estimate|||||||2011-04-18|2011-04-19|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|BBP||Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism|Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism by Different Injection Sites Evaluated by Polysomnography|Unknown status|Recruiting|Phase 4|24|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 22:42:01.203325|2018-05-31 22:42:01.203325
NCT01336426|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-12-16|2011-04-14|2011-04-15|Estimate|||||||2013-12-16|2013-12-17|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|PAD-001||Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease|Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease|Completed|||1033|Actual|Vermillion, Inc.|||||f||||t||||||Samples Without DNA|"~     Serum, Plasma and Frozen Red Blood Cells~   "|||2018-05-31 22:42:01.297077|2018-05-31 22:42:01.297077
NCT01336413|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2017-05-19||2017-09-19|2011-04-13|2011-04-15|Estimate|2017-09-19|2017-10-20|Actual||||2017-09-19|2017-10-20|Actual|October 2013||2013-10-31|September 2017|2017-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans|Neuroactive Steroids and TBI in OEF/OIF Veterans|Completed||Phase 2|53|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-05-31 22:42:01.385546|2018-05-31 22:42:01.385546
NCT01336400|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-14|2011-04-14|2011-04-15|Estimate|||||||2011-04-14|2011-04-15|Estimate|October 2010||2010-10-31|April 2010|2010-04-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Genome-wide Single Cell Haplotyping as a Generic Method for Preimplantation Genetic Diagnosis|Genome-wide Single Cell Haplotyping as a Generic Method for Preimplantation Genetic Diagnosis|Unknown status|Not yet recruiting||60|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples With DNA|"~     Genomic DNA, single blastomere DNA~   "|||2018-05-31 22:42:01.883168|2018-05-31 22:42:01.883168
NCT01336387|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-10-07|2011-04-13|2011-04-15|Estimate|||||||2014-10-07|2014-10-09|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers|A Randomized, Double-Blind, Single-dose and Multi-dose Study of the Novel Retinoid, 9cUAB30, to Determine Pharmacokinetics and Safety|Terminated||Phase 1|50|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 22:42:01.959205|2018-05-31 22:42:01.959205
NCT01336374|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-12-02|2011-04-13|2011-04-15|Estimate|||||||2011-12-02|2011-12-05|Estimate|April 2011||2011-04-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||Vacant Lot Greening and Violence-Related Outcomes|A Pilot Randomized Controlled Trial of Vacant Lot Greening and Violence-related Outcomes|Completed|||29|Actual|University of Pennsylvania|||2||f||||f||||||||||2018-05-31 22:42:02.063057|2018-05-31 22:42:02.063057
NCT01336361|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2014-09-15|2011-04-14|2011-04-15|Estimate|||||||2014-09-15|2014-09-17|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Emerging Physical Therapy Practice in Palliative Care: A Survey of Perceptions of Physical Therapists|Emerging Practice in Palliative Care: A Survey of the Perceptions of Physical Therapists Regarding the Role, Utilization, Goals, and Cultural Issues of Physical Therapy Intervention in the Palliative Care of Functionally Dependent Elderly.|Completed|||228|Actual|University of Montana|||1||f||||f||||||||||2018-05-31 22:42:02.133794|2018-05-31 22:42:02.133794
NCT01336348|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-10-09|2011-04-14|2011-04-15|Estimate|||||||2012-10-09|2012-10-10|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|FABOLUS PRO||Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse|Comparison of Multiple Oral and/or Intravenous Anti-platelet Strategies in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary PCI|Completed||Phase 3|100|Anticipated|Università degli Studi di Ferrara||2|||f||||f||||||||||2018-05-31 22:42:02.222941|2018-05-31 22:42:02.222941
NCT01336335|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-13|2011-04-13|2011-04-15|Estimate|||||||2011-04-13|2011-04-15|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||The Effects of Continuous Positive Airway Pressure (CPAP) on Sympathetic Activity in Different Sites of Activation|The Effects of Continuous Positive Airway Pressure (CPAP) on Sympathetic Activity in Different Sites of Activation|Unknown status|Active, not recruiting|Phase 3|20|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:42:02.309197|2018-05-31 22:42:02.309197
NCT01336322|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2018-01-15|2011-04-13|2011-04-15|Estimate|||||||2018-01-15|2018-01-17|Actual|May 2011||2011-05-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Metformin and Sitagliptin in Women With Previous Gestational Diabetes|Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Women With Previous Gestational Diabetes|Recruiting||Phase 2|45|Anticipated|University of Pisa||3|||f||||t||||||||||2018-05-31 22:42:02.397191|2018-05-31 22:42:02.397191
NCT01336309|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-08-09|2011-04-13|2011-04-15|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Development of a Translational Tool to Study Yoga Therapy|Development of a Translational Tool to Study Yoga Therapy|Completed|||1832|Actual|University of Connecticut|||4||f||||t||||||||No||2018-05-31 22:42:02.501663|2018-05-31 22:42:02.501663
NCT01336296|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2015-04-30||2016-07-05|2011-04-14|2011-04-15|Estimate|2016-03-09|2016-04-11|Estimate||||2016-07-05|2016-08-02|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Intent to treat|Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients|A 12-month, Prospective, Randomized, Dual Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic® (Mycophenolic Acid) Loading Regimens in Combination With Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)] or Simulect® (Basiliximab) Induction and Prograf® (Tacrolimus) in Early Corticosteroid Withdrawal|Completed||Phase 4|61|Actual|University of Cincinnati||2|||f||||f||||||||||2018-05-31 22:42:02.625721|2018-05-31 22:42:02.625721
NCT01336283|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2011-04-14|2011-04-14|2011-04-15|Estimate|||||||2011-04-14|2011-04-15|Estimate|March 2003||2003-03-31|March 2003|2003-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effectiveness of Different Exercise Training Programs to the Profile of COPD Patients|Effectiveness of Different Exercise Training Programs to the Profile of COPD Patients|Completed||Phase 4|66|Actual|Hospitales Universitarios Virgen del Rocío||2|||f||||f||||||||||2018-05-31 22:42:03.154141|2018-05-31 22:42:03.154141
NCT01336270|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2014-08-25|2011-04-14|2011-04-15|Estimate|||||||2014-08-25|2014-08-26|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Observational|IMMUMELA||Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients|Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients: Impact on Immunity Versus Immunosuppression|Completed|||217|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||Samples With DNA|"~     A bank of biological samples (human plasma and cells) will be done~   "|||2018-05-31 22:42:03.235249|2018-05-31 22:42:03.235249
NCT01336257|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2012-04-13|2011-04-14|2011-04-15|Estimate|||||||2012-04-13|2012-04-17|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer|Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer|Unknown status|Recruiting|N/A|2200|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||f||||||||||2018-05-31 22:42:03.32181|2018-05-31 22:42:03.32181
NCT01336244|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-10-17|2011-04-14|2011-04-15|Estimate|||||||2011-10-17|2011-10-18|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0778 in Healthy Male Subjects|Completed||Phase 1|45|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 22:42:03.389411|2018-05-31 22:42:03.389411
NCT01336231|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2016-07-20|2011-04-14|2011-04-15|Estimate|||||||2016-07-20|2016-07-21|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|COG-ANGIO||Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer|Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer : a Pilot Study|Terminated|||82|Actual|Centre Francois Baclesse|||1|lack of recruitment|f||||f||||||||||2018-05-31 22:42:03.458844|2018-05-31 22:42:03.458844
NCT01336218|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2011-07-21|2011-04-14|2011-04-15|Estimate|||||||2011-07-21|2011-07-22|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.|An Open-Label, Non-Randomized, 2-Period, Single Center Study to Assess the Single Dose Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone and in Combination With Rifampicin|Completed||Phase 1|15|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 22:42:03.520445|2018-05-31 22:42:03.520445
NCT01336036|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2016-09-29|2011-04-13|2011-04-15|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|CAP||Causes and Outcomes of Community Acquired Pneumonia|Etiology, Clinical Manifestations and Risk Factors for Community-acquired Pneumonia in Patients Admitted to Hospital|Completed|||300|Actual|Oxford University Clinical Research Unit, Vietnam|||||f||||f||||||Samples Without DNA|"~     Sputum Blood Urine Nasal and Throat swab~   "|||2018-05-31 22:42:05.830512|2018-05-31 22:42:05.830512
NCT01336205|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2014-10-13||2014-10-13|2011-04-14|2011-04-15|Estimate|2014-10-13|2014-10-20|Estimate||||2014-10-13|2014-10-20|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||A total of 36 patients (11 patients in the Usual Care group and 25 new patients in the NKTR-118 25 mg group) had either: a) previously or concurrently participated in the NKTR-118 program at another study center; or b) were randomized at sites where data integrity issues were identified. These patients were excluded from the Safety analysis set.|Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation|An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain|Completed||Phase 3|844|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:42:03.703727|2018-05-31 22:42:03.703727
NCT01336192|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-13|2011-04-13|2011-04-15|Estimate|||||||2011-04-13|2011-04-15|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Interventional|MAGICAL||Maintenance Gemcitabine in the Chinese Advanced Lung Cancer|Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin|Unknown status|Recruiting|Phase 4|240|Anticipated|Tongji University||2|||f||||f||||||||||2018-05-31 22:42:04.617764|2018-05-31 22:42:04.617764
NCT01336179|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-05-31|2011-04-13|2011-04-15|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Comparative Effect of Chewing Sticks and Toothbrushing on Plaque Removal and Gingival Health|The Efficacy of the Miswak Chewing Sticks (Salvadora Persica)on Plaque Removal and Gingival Health: Randomised Clinical Trial|Completed||N/A|18|Anticipated|Taibah University||2|||f||||t||||||||||2018-05-31 22:42:04.705613|2018-05-31 22:42:04.705613
NCT01336166|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-14|2011-04-14|2011-04-15|Estimate|||||||2011-04-14|2011-04-15|Estimate|July 2009||2009-07-31|April 2011|2011-04-30||||July 2011|Anticipated|2011-07-31||Interventional|||The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine||Unknown status|Active, not recruiting|Phase 2|480|Anticipated|Shanghai Institute Of Biological Products||4|||f||||t||||||||||2018-05-31 22:42:04.770755|2018-05-31 22:42:04.770755
NCT01336153|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-29|2011-04-14|2011-04-15|Estimate|||||||2011-04-29|2011-05-02|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|||Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke||Completed||Phase 4|150|Actual|Shahid Beheshti University||2|||f||||t||||||||||2018-05-31 22:42:04.837854|2018-05-31 22:42:04.837854
NCT01336140|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|2012-12-02||2013-01-04|2011-04-14|2011-04-15|Estimate|2013-01-04|2013-02-13|Estimate||||2013-01-04|2013-02-13|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|ASSUAGE-CKD||Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging|Attenuation of the Side Effect Profile Of Regadenoson: A Randomized Double-Blind Placebo-Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging and Have Severe Chronic Kidney Disease (ASSUAGE-CKD Trial)|Completed||Phase 4|300|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 22:42:04.90352|2018-05-31 22:42:04.90352
NCT01336127|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-08-26|2011-04-14|2011-04-15|Estimate|||||||2014-08-26|2014-08-27|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|OTiP||Effectiveness Study of Occupational Therapy in Parkinson's Disease|Effectiveness of Occupational Therapy in Parkinson's Disease: a Randomized Controlled Trial|Completed||N/A|191|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 22:42:05.197293|2018-05-31 22:42:05.197293
NCT01336114|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2014-11-25|2011-04-13|2011-04-15|Estimate|||||||2014-11-25|2014-11-26|Estimate|July 2011||2011-07-31|November 2014|2014-11-30||||||||Observational|MODEL MAKER||A New 3D Geometrical Modelisation of Adolescent Idiopathic Scoliosis and Conception of a Personal Brace|A New 3D Geometrical Modelisation of Adolescent Idiopathic Scoliosis and Conception of a Personal Brace|Completed|||11|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 22:42:05.273136|2018-05-31 22:42:05.273136
NCT01336101|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-04-23|2011-04-14|2011-04-15|Estimate|||||||2014-04-23|2014-04-24|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|SUMMIT||Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent|Evaluation of Efficacy of the EPIC™ Self-Expanding Nitinol Vascular Stent With Delivery System -The SUMMIT Registry|Completed||N/A|100|Actual|Provascular GmbH||1|||f||||t||||||||||2018-05-31 22:42:05.317156|2018-05-31 22:42:05.317156
NCT01336088|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-07-13|2011-04-14|2011-04-15|Estimate|||||||2012-07-13|2012-07-16|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease|Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease|Completed||Phase 2|83|Actual|Addex Pharma S.A.||2|||f||||t||||||||||2018-05-31 22:42:05.408479|2018-05-31 22:42:05.408479
NCT01336075|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2014-01-02|2011-04-14|2011-04-15|Estimate|||||||2014-01-02|2014-01-03|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Atrial Fibrillation: Ablation or Surgical Treatment II: FAST II|Atrial Fibrillation: Ablation or Surgical Treatment II: FAST II A Randomized Study Comparing Non-pharmacologic Therapy in Patients With Drug-refractory Atrial Fibrillation Referred for a First Time Invasive Treatment.|Terminated||N/A|26|Actual|Aalborg Universitetshospital||2||Too few participants|f||||t||||||||||2018-05-31 22:42:05.543832|2018-05-31 22:42:05.543832
NCT01336062|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-05-17|2011-04-14|2011-04-15|Estimate|||||||2015-05-17|2015-05-19|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients|Phase Ib/IIa, Two-stage Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients|Completed||Phase 1/Phase 2|19|Actual|Peking University||1|||f||||f||||||||||2018-05-31 22:42:05.689008|2018-05-31 22:42:05.689008
NCT01336049|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-04-14|2011-04-14|2011-04-15|Estimate|||||||2011-04-14|2011-04-15|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||December 2011|Anticipated|2011-12-31||Interventional|||Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer|Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial|Unknown status|Recruiting|Phase 2|70|Anticipated|Peking University||1|||f||||f||||||||||2018-05-31 22:42:05.748877|2018-05-31 22:42:05.748877
NCT01335373|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-07-22|2011-04-13|2011-04-14|Estimate|||||||2016-07-22|2016-07-25|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|December 2011|Actual|2011-12-31||Observational|||Observational Program Neo-Penotran® Forte|Observational Program Neo-Penotran® Forte|Completed|||13024|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:42:22.495834|2018-05-31 22:42:22.495834
NCT01336023|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2016-12-12|2012-12-19|2018-02-16|2011-04-14|2011-04-15|Estimate|2017-04-26|2017-06-02|Actual|2012-12-19|2012-12-24|Estimate|2018-02-16|2018-02-19|Actual|May 23, 2011|Actual|2011-05-23|February 2018|2018-02-28|November 22, 2012|Actual|2012-11-22|May 24, 2012|Actual|2012-05-24||Interventional|DUAL™ I|The full analysis set (FAS) included all randomised subjects and missing data was imputed using last observation carried forward (LOCF). Three subjects did not have their case book signed off due to discontinuation of an investigator’s participation in the trial, hence 1 subject in each arm was excluded from the FAS.|Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes|A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension|Completed||Phase 3|1663|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 22:42:05.953326|2018-05-31 22:42:05.953326
NCT01336010|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2015-08-31|2011-04-13|2011-04-15|Estimate|||||||2015-08-31|2015-09-02|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ATAHC-II||Treatment of Recently Acquired Hepatitis C Virus Infection|Treatment of Recently Acquired Hepatitis C Virus Infection|Completed||Phase 4|82|Actual|Kirby Institute||6|||f||||t||||||||||2018-05-31 22:42:07.198059|2018-05-31 22:42:07.198059
NCT01335997|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2016-01-13||2017-03-06|2011-04-14|2011-04-15|Estimate|2016-05-12|2016-06-21|Estimate||||2017-03-06|2017-04-04|Actual|May 2011||2011-05-31|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)|A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|Terminated||Phase 3|1139|Actual|Merck Sharp & Dohme Corp.|Study was terminated for business reasons.|2||Business Reasons|f||||f||||||||||2018-05-31 22:42:07.308816|2018-05-31 22:42:07.308816
NCT01335984|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-05-12|2011-04-13|2011-04-15|Estimate|||||||2015-05-12|2015-05-14|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|Smart-HTN||Effects of Telemonitoring and Telemedicine Service for Hypertensive Care|A Multi-center, Randomized, Parallel, Interventional, Open Label Trial to Compare the Blood Pressure-lowering Effect of Conventional Treatment and Smart Care Service in Hypertensive Patients Receiving Any Conventional Treatment|Completed||N/A|440|Actual|LG Electronics Inc.||3|||f||||t||||||||||2018-05-31 22:42:07.706814|2018-05-31 22:42:07.706814
NCT01335971|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2016-08-25||2017-04-11|2011-04-14|2011-04-15|Estimate|2017-04-11|2017-05-19|Actual||||2017-04-11|2017-05-19|Actual|September 2010|Actual|2010-09-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|July 2013|Actual|2013-07-31||Interventional|BEST||Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD|Enhancing Nrf2 by Sulforaphane Treatment in COPD|Completed||Phase 2|89|Actual|Johns Hopkins University||3|||f||||t||||||||Yes|The primary method of data-sharing will be through the traditional mechanism of publication of results in the peer-reviewed medical literature. Following publication of the main results, in accordance with NIH policy, a de-identified, HIPAA-compliant limited use dataset will be made available to qualified investigators who have Institutional Review Board approval and sign a data-use agreement. De-identified specimens collected in the study that are not analyzed for the main study will be made available to qualified investigators along with a limited use dataset in line with University and Office of Human Research Protections guidelines with a materials transfer agreement and/or data-use agreement as applicable. The Center for Clinical Trials has extensive experience in preparation of limited use datasets, and maintains policies and model agreements for data-use agreements and materials-transfer agreements.|2018-05-31 22:42:07.847426|2018-05-31 22:42:07.847426
NCT01335958|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-11-01|2011-04-14|2011-04-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer|A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer|Completed||Phase 1|77|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 22:42:08.75311|2018-05-31 22:42:08.75311
NCT01335945|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2015-05-13|2011-04-14|2011-04-15|Estimate|||||||2015-05-13|2015-05-15|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer|Percutaneous Cryoablation for the Palliation of Abdominal Pain Associated With Pancreatic Cancer|Terminated||Phase 1|14|Actual|Galil Medical||1||Low enrollment & subjects didn't survive to study end due to cancer progression.|f||||f||||||||||2018-05-31 22:42:08.825163|2018-05-31 22:42:08.825163
NCT01335932|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2017-06-21||2017-08-15|2011-04-14|2011-04-15|Estimate|2017-08-15|2017-09-13|Actual||||2017-08-15|2017-09-13|Actual|March 10, 2011|Actual|2011-03-10|August 2017|2017-08-31|October 28, 2016|Actual|2016-10-28|June 17, 2016|Actual|2016-06-17||Interventional|GRAIL||Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure|A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study)|Completed||Phase 2|160|Actual|Fred Hutchinson Cancer Research Center|Inclusion of too few trauma patients to assess treatment effects, a long enrollment window length, discontinuation of BAL sampling due to feasibility and changes in oral drug availability (later part of the study)|2|||f||||t||||||||No||2018-05-31 22:42:08.92749|2018-05-31 22:42:08.92749
NCT01335919|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2013-01-07|2011-04-14|2011-04-15|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Neonatal Non-Invasive Hemoglobin Determination|Non-invasive Continuous Hemoglobin in Pediatric Medicine: a Comparison Between Standard of Care CBC Hemoglobin (ADVIA 2120®) and the New Masimo® SpHb® Neonatal Sensor|Withdrawn|||0|Actual|Children's Hospital of Philadelphia|||1|Company is redesigning measuring tool.|f||||f||||||||||2018-05-31 22:42:09.22493|2018-05-31 22:42:09.22493
NCT01335906|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2014-06-23|2011-04-14|2011-04-15|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evidence-informed Choice for Women Participating in Mammography Screening|A Randomized Trial of an Evidence-informed Choice Based on Appreciation of Risks and Benefits for Women Participating in Mammography Screening|Completed||N/A|332|Actual|Andaluz Health Service||2|||f||||f||||||||||2018-05-31 22:42:09.339712|2018-05-31 22:42:09.339712
NCT01335893|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2018-02-01|2011-04-13|2011-04-14|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2011||2011-05-31|February 2018|2018-02-28|December 14, 2014|Actual|2014-12-14|December 2014|Actual|2014-12-31||Interventional|||Intraoperative Imaging of Thoracic Malignancies With Indocyanine Green|A Phase 1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subjects Undergoing Thoracic Surgery Presenting With Lung Nodules|Completed||Phase 1|10|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 22:42:09.511799|2018-05-31 22:42:09.511799
NCT01335880|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-10-16|2011-04-13|2011-04-14|Estimate|||||||2012-10-16|2012-10-18|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Helping People to Exercise Regularly|Helping People to Exercise Regularly|Completed||N/A|117|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:42:09.585332|2018-05-31 22:42:09.585332
NCT01335867|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2015-06-01||2016-11-04|2011-04-13|2011-04-14|Estimate|2015-06-01|2015-06-12|Estimate||||2016-11-04|2016-12-29|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|VGB||Vigabatrin for Cocaine and Alcohol Dependence|A Phase II, Double-Blind, Placebo-Controlled, Pilot Trial of Vigabatrin for the Treatment of Cocaine and Alcohol Dependence|Terminated||Phase 2|32|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 22:42:09.666176|2018-05-31 22:42:09.666176
NCT01335854|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2014-05-20|2011-04-13|2011-04-14|Estimate|||||||2014-05-20|2014-05-22|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Promoting Continuous Positive Airway Pressure (CPAP) Adherence|Promoting CPAP Adherence and Treatment Outcomes in Patients With Obstructive Sleep Apnea|Completed||Early Phase 1|135|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 22:42:09.945297|2018-05-31 22:42:09.945297
NCT01335841|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2013-01-24|2011-04-13|2011-04-14|Estimate|||||||2013-01-24|2013-01-25|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|FLUORONAV||Evaluation of an 3D Imaging Intensifier Coupled to a Navigation Station in the Surgery of the Spine and Pelvis|Evaluation of an 3D Imaging Intensifier Coupled to a Navigation Station in the Surgery of the Spine and Pelvis|Completed||Phase 3|150|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 22:42:10.077105|2018-05-31 22:42:10.077105
NCT01335828|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2013-01-24|2011-04-13|2011-04-14|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|SWETHY||Elastography Interest in the Management of Thyroid Nodules|"ShearWave Elastography Interest in the Management of Thyroid Nodules"|Completed||Phase 2/Phase 3|125|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 22:42:10.145283|2018-05-31 22:42:10.145283
NCT01335815|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-04-13|2011-04-13|2011-04-14|Estimate|||||||2011-04-13|2011-04-14|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|March 2013|Anticipated|2013-03-31|March 2012|Anticipated|2012-03-31||Observational|||High Sensitive Troponin T (hsTnT) and Copeptin as Prognostic Parameters in Patients With Elective Total Endoprosthesis|High Sensitive Troponin T (hsTnT) and Copeptin as Prognostic Parameters in Patients With Elective Knee and Hip Endoprosthesis|Unknown status|Recruiting||200|Anticipated|Heidelberg University|||1||f||||f||||||Samples Without DNA|"~     normal lab parameters~   "|||2018-05-31 22:42:10.207441|2018-05-31 22:42:10.207441
NCT01335802|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-11-19|2011-04-13|2011-04-14|Estimate|||||||2012-11-19|2012-11-20|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Observational|GravThyr||Relation Between Subclinical Hypothyroidism and Outcome of Pregnancy|Relation Between Thyroid Hormone Stimulated Mitochondrial Function and Spontaneous Abortion and Complications of Pregnancy in Subclinical Hypothyroidism|Unknown status|Recruiting||200|Anticipated|Naestved Hospital|||2||f||||f||||||||||2018-05-31 22:42:10.264953|2018-05-31 22:42:10.264953
NCT01335789|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2014-06-02||2015-12-10|2011-04-13|2011-04-14|Estimate|2014-07-29|2014-08-15|Estimate||||2015-12-10|2015-12-14|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Oxytocin on Stress in Marijuana Users|Effect of Oxytocin on Stress Response in Marijuana-dependent Individuals|Completed||N/A|16|Actual|Medical University of South Carolina|Small sample size, non-treatment seeking sample, predominantly male sample|2|||f||||f||||||||||2018-05-31 22:42:10.350369|2018-05-31 22:42:10.350369
NCT01335776|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2013-06-17|2011-04-13|2011-04-14|Estimate|||||||2013-06-17|2013-06-19|Estimate|September 2008||2008-09-30|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|I-CAN SLEEP||A Comparison of MBSR and CBT for the Treatment of Insomnia in Cancer|An Objective Comparison of Cognitive Behavioral Therapy and Mindfulness-based Stress Reduction for the Treatment of Insomnia in Cancer Survivors Using Wrist Actigraphy: A Randomized Noninferiority Trial|Completed||N/A|111|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 22:42:10.648711|2018-05-31 22:42:10.648711
NCT01335763|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-11-04|2011-04-13|2011-04-14|Estimate|||||||2013-11-04|2013-11-06|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|RxING||Pharmacist Intervention for Glycemic Control in The Community|Pharmacist Intervention for Glycemic Control in The Community (The RxING Study)|Completed||N/A|100|Actual|University of Alberta||1|||f||||f||||||||||2018-05-31 22:42:10.719302|2018-05-31 22:42:10.719302
NCT01335750|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2012-04-30||2015-02-12|2011-04-13|2011-04-14|Estimate|2013-03-04|2013-03-05|Estimate||||2015-02-12|2015-03-03|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand|A Clinical Comparison of Marketed Lens Care Solutions With Avaira Lens Brand|Completed||Phase 4|32|Actual|Coopervision, Inc.||4|||f||||f||||||||||2018-05-31 22:42:10.788992|2018-05-31 22:42:10.788992
NCT01335737|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2015-05-01|2011-04-13|2011-04-14|Estimate|||||||2015-05-01|2015-05-04|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Exercise and Inflammation|Exercise and Inflammation: Autonomic, Affective & Cellular Mechanisms|Completed||N/A|241|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 22:42:11.03574|2018-05-31 22:42:11.03574
NCT01335724|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2012-05-11||2012-06-14|2011-04-13|2011-04-14|Estimate|2012-06-14|2012-07-18|Estimate||||2012-06-14|2012-07-18|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain|A Randomized, Double-blind, Placebo-controlled, Multi-center Parallel Group Phase IV Study to Evaluate the Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain|Completed||Phase 4|72|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:42:11.111119|2018-05-31 22:42:11.111119
NCT01335191|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2012-12-07||2013-01-14|2011-04-13|2011-04-14|Estimate|2013-01-14|2013-02-15|Estimate||||2013-01-14|2013-02-15|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)|Clinical Study of TUTI-16 in Asymptomatic, HIV-1 Infected Subjects Effectively Controlled by Antiretroviral Therapy and the Effects on Viral Load During a Structured Treatment Interruption|Completed||Phase 1/Phase 2|27|Actual|Thymon, LLC||2|||f||||f||||||||||2018-05-31 22:42:24.499613|2018-05-31 22:42:24.499613
NCT01335711|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2011-10-11|2011-04-13|2011-04-14|Estimate|||||||2011-10-11|2011-10-12|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects|A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects|Unknown status|Recruiting|Phase 2|32|Anticipated|ChronTech Pharma AB||4|||f||||t||||||||||2018-05-31 22:42:11.451503|2018-05-31 22:42:11.451503
NCT01335698|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2015-10-26||2018-02-01|2011-04-13|2011-04-14|Estimate|2016-01-08|2016-02-08|Estimate||||2018-02-01|2018-03-01|Actual|May 27, 2011|Actual|2011-05-27|February 2018|2018-02-28|January 22, 2018|Actual|2018-01-22|September 10, 2014|Actual|2014-09-10||Interventional|PRINCE2|All participants who received at least 1 dose of study drug|Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients|A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in Human Immunodeficiency Virus (HIV) Infected, Antiretroviral, Naive and Experienced Pediatric Subjects From 3 Months to Less Than 11 Years.(Pediatric Atazanavir International Clinical Evaluation: the PRINCE II Study)|Completed||Phase 3|160|Actual|Bristol-Myers Squibb||1|||f||||t|t|f||||||||2018-05-31 22:42:11.725163|2018-05-31 22:42:11.725163
NCT01335685|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2017-12-22|2016-11-29|2017-12-22|2011-04-13|2011-04-14|Estimate|2017-12-22|2018-01-23|Actual|2017-02-21|2017-02-23|Actual|2017-12-22|2018-01-23|Actual|June 27, 2011|Actual|2011-06-27|December 2017|2017-12-31|December 29, 2016|Actual|2016-12-29|December 29, 2016|Actual|2016-12-29||Interventional||The safety population consisted of participants who received at least 1 dose of any study drug.|Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment|Completed||Phase 1/Phase 2|61|Actual|Takeda||8|||f||||f|t|f||||||||2018-05-31 22:42:13.471195|2018-05-31 22:42:13.471195
NCT01335672|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2015-04-09|2011-04-13|2011-04-14|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease|Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease|Completed|||2100000|Actual|London School of Hygiene and Tropical Medicine|||1||f||||t||||||||||2018-05-31 22:42:16.43056|2018-05-31 22:42:16.43056
NCT01335659|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-07-20|2011-04-13|2011-04-14|Estimate|||||||2011-07-20|2011-07-21|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Main Branch Versus Side Branch Ostial Lesion|Relationship Between Fractional Flow Reserve and Coronary Angiography/Intravascular Ultrasound Parameters in Ostial Lesions: Major Coronary Ostial Lesions Versus Side Branch Ostial Lesions|Completed|||77|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 22:42:16.530896|2018-05-31 22:42:16.530896
NCT01335646|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2017-07-11|2011-04-13|2011-04-14|Estimate|||||||2017-07-11|2017-07-13|Actual|February 1, 2010|Actual|2010-02-01|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Surgery Versus Standardized Non-operative Care for the Treatment of Lumbar Disc Herniations: A Canadian Trial||Recruiting||Phase 3|128|Anticipated|The London Spine Centre||2|||f||||||||||||||2018-05-31 22:42:16.669513|2018-05-31 22:42:16.669513
NCT01335633|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-05-01|2011-04-13|2011-04-14|Estimate|||||||2012-05-01|2012-05-03|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Psychometric Validation of Cognitive Endpoints|Psychometric Validation of Cognitive Endpoints|Completed|||60|Actual|Kessler Foundation|||||f||||f||||||||||2018-05-31 22:42:16.813955|2018-05-31 22:42:16.813955
NCT01335620|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2014-05-20|2011-04-13|2011-04-14|Estimate|||||||2014-05-20|2014-05-21|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Raltegravir 60+ Study|An Open Label Study to Investigate the Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age|Completed||Phase 1|19|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 22:42:16.867631|2018-05-31 22:42:16.867631
NCT01335607|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2016-01-25|2011-04-13|2011-04-14|Estimate|||||||2016-01-25|2016-01-26|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)|A Phase I, Open-label Study to Evaluate the Relative Bioavailability of IDX184 and Food Effect in Healthy Male Subjects|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:42:16.935305|2018-05-31 22:42:16.935305
NCT01335594|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-04-07|2011-04-13|2011-04-14|Estimate|||||||2012-04-07|2012-04-10|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Swallowing in Patients With Obstructive Sleep Apnea|Clinical, Endoscopical and Manometric Evaluation of Swallowing in Obstructive Sleep Apnea Syndrome|Completed||N/A|21|Actual|Hospital do Servidor Publico Estadual|||||f||||f||||||||||2018-05-31 22:42:17.00098|2018-05-31 22:42:17.00098
NCT01335581|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-03-25|2011-04-13|2011-04-14|Estimate|||||||2014-03-25|2014-03-26|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Laser Treatment of Melasma|A Study of the RevLite Q-Switched Nd:YAG Laser System With Smart Infinite (SI) Handpiece for the Treatment of Refractory Mixed Type Melasma|Completed||N/A|18|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 22:42:17.056308|2018-05-31 22:42:17.056308
NCT01335568|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-13|2011-04-13|2011-04-14|Estimate|||||||2011-04-13|2011-04-14|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|HMIIndo||Hepatocyte Matrix Implant Study Indonesia|Intracorporeal Autologous Hepatocyte Matrix Implant: A New Tissue Engineering Procedure for Treatment of Hepatic Disease|Unknown status|Recruiting|Phase 1|10|Anticipated|Baermed||1|||f||||t||||||||||2018-05-31 22:42:17.11194|2018-05-31 22:42:17.11194
NCT01335555|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-18|2011-04-11|2011-04-14|Estimate|||||||2011-04-18|2011-04-19|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||The Effect of Chemotherapy on Lactate Threshold in Cancer Patients|The Effect of Neoadjuvant Chemotherapy on Lactate Threshold in Patients With Surgically Resectable Upper Gastrointestinal Cancer.|Completed|||89|Actual|Aintree University Hospitals NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 22:42:17.201277|2018-05-31 22:42:17.201277
NCT01335542|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2016-03-21||2016-08-02|2011-04-13|2011-04-14|Estimate|2016-03-21|2016-04-20|Estimate||||2016-08-02|2016-09-14|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|PAI vs FNB|One patient in the local infiltration group was deemed ineligible due to a rheumatoid arthritis. The remaining 90 patients were included in the baseline analysis population.|Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade|Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade|Completed||Phase 4|91|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 22:42:17.257904|2018-05-31 22:42:17.257904
NCT01335529|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2014-10-10|2011-04-13|2011-04-14|Estimate|||||||2014-10-10|2014-10-13|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|BocepreVIH||Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin|Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With Peg-Interferon Alfa and Ribavirin, in Patients With HCV/HIV Co-infection Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin|Completed||Phase 2|69|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 22:42:17.452044|2018-05-31 22:42:17.452044
NCT01335516|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-10-05|2011-04-13|2011-04-14|Estimate|||||||2012-10-05|2012-10-08|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices|Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices|Completed|||20|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:42:17.861015|2018-05-31 22:42:17.861015
NCT01335503|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2013-08-12|2011-04-13|2011-04-14|Estimate|||||||2013-08-12|2013-08-13|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of AN-PEP Enzyme on Gluten Digestion|Effect of AN-PEP Enzyme on Gastrointestinal Breakdown of Gluten|Completed||N/A|12|Actual|DSM Food Specialties||4|||f||||f||||||||||2018-05-31 22:42:17.923317|2018-05-31 22:42:17.923317
NCT01335490|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2017-07-14|2011-04-13|2011-04-14|Estimate|||||||2017-07-14|2017-07-18|Actual|August 2013||2013-08-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Intervening to Improve Infant Health in Ghana|Intervening to Improve Birth Weight and Infant Respiratory Health in Rural Ghana|Completed||N/A|1414|Actual|Columbia University||3|||f||||t||||||||||2018-05-31 22:42:18.006509|2018-05-31 22:42:18.006509
NCT01335477|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2014-11-14|2014-03-28|2016-06-24|2011-04-13|2011-04-14|Estimate|2015-01-29|2015-02-13|Estimate|2014-03-28|2014-04-25|Estimate|2016-06-24|2016-07-25|Estimate|May 2011||2011-05-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Treated Set (TS): The TS consisted of randomized patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II|A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 3|551|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:42:18.198356|2018-05-31 22:42:18.198356
NCT01335464|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|2014-11-14|2014-03-28|2016-06-24|2011-04-13|2011-04-14|Estimate|2015-01-29|2015-02-13|Estimate|2014-03-28|2014-04-25|Estimate|2016-06-24|2016-07-25|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Treated set (TS): The TS consisted of randomised patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment|Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients|A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 3|515|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:42:19.520619|2018-05-31 22:42:19.520619
NCT01335451|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2015-01-27|2011-04-13|2011-04-14|Estimate|||||||2015-01-27|2015-01-28|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Oral Administration of Single and Multiple Ascending Doses in Healthy Young and Elderly J|Completed||Phase 1|48|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:42:21.451128|2018-05-31 22:42:21.451128
NCT01335438|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-10-04|2011-04-13|2011-04-14|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 1997||1997-01-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|February 1998|Actual|1998-02-28||Interventional|||Total Knee Arthroplasty Comparing Cementless to Cemented Fixation|Total Knee Arthroplasty Comparing Cementless to Cemented Fixation, A Prospective Comparison of Long Term Outcomes Using and Identical Design of Prosthesis|Completed||Phase 4|96|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 22:42:21.56105|2018-05-31 22:42:21.56105
NCT01335425|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2015-09-22|2011-04-13|2011-04-14|Estimate|||||||2015-09-22|2015-09-23|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|REL||The Rolandic Epilepsy/ESES/Landau-Kleffner Syndrome and Correlation With Language Impairment Study||Completed|||47|Actual|Maastricht University Medical Center|||||f||||f||||||||||2018-05-31 22:42:21.663688|2018-05-31 22:42:21.663688
NCT01335412|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2015-03-09|2011-04-13|2011-04-14|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Safety Surveillance After Immunization With IXIARO|Active Surveillance for Adverse Events After Immunization With IXIARO(R) Among U.S. Military Service Personnel|Completed|||20000|Actual|Valneva Austria GmbH|||2||f||||t||||||||||2018-05-31 22:42:21.717319|2018-05-31 22:42:21.717319
NCT01335399|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2018-02-15|2011-04-13|2011-04-14|Estimate|||||||2018-02-15|2018-02-16|Estimate|May 18, 2011|Actual|2011-05-18|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 30, 2018|Anticipated|2018-05-30||Interventional|ELOQUENT - 1||Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma|A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma|Active, not recruiting||Phase 3|750|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 22:42:21.84645|2018-05-31 22:42:21.84645
NCT01335386|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2012-02-03|2011-04-13|2011-04-14|Estimate|||||||2012-02-03|2012-02-06|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Investigation of KLYX in Patients With Constipation|Efficacy and Safety of KLYX Versus Glycerine Enema in Chinese Patients With Constipation - a Randomised, Assessor-blind Pilot Study|Completed||Phase 2|60|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:42:22.425041|2018-05-31 22:42:22.425041
NCT01335360|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-04-12|2011-04-12|2011-04-14|Estimate|||||||2011-04-12|2011-04-14|Estimate|May 2003||2003-05-31|April 2011|2011-04-30|June 2003|Actual|2003-06-30|May 2003|Actual|2003-05-31||Observational|NAWS||Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight|Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight|Completed|||21|Actual|Western University of Health Sciences|||3||f||||f||||||None Retained|"~     Levels were drawn prior to dosing, and at the following time intervals: 0.5hr, 1hr, 1.5hr,~     2hr, 4hr, 6hr, 8hr, 12hr. ~10cc of blood were drawn with each sample, centrifuged, and plasma~     separated into 2 cryovials. Samples were then frozen at -20oC. All samples (216) weresent to~     Consolidated Laboratory Services for level determination by appropriate means. All samples~     have now been destroyed.~   "|||2018-05-31 22:42:22.668141|2018-05-31 22:42:22.668141
NCT01335347|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-10|||2013-01-02|2011-04-12|2011-04-14|Estimate|||||||2013-01-02|2013-01-03|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|H5N1||Safety Study of an Oral Vaccine to Prevent Avian Influenza|A Dose Escalation Phase 1 Safety and Immunogenicity Study of an Oral Viral Vector Vaccine Encoding Avian Influenza H5N1 Hemagglutinin Protein and dsRNA Adjuvant in Healthy Adults|Completed||Phase 1|54|Actual|Vaxart||4|||f||||f||||||||||2018-05-31 22:42:22.848664|2018-05-31 22:42:22.848664
NCT01335334|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-04-13|2011-04-13|2011-04-14|Estimate|||||||2011-04-13|2011-04-14|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|August 2011|Anticipated|2011-08-31|June 2011|Anticipated|2011-06-30||Interventional|||H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study|Helicobacter Pylori Eradication Using a Bismuth Quadruple Therapy Among Asymptomatically Infected Adults in El Paso, Texas: A Pilot Study.|Unknown status|Recruiting|Phase 4|50|Anticipated|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-05-31 22:42:22.952497|2018-05-31 22:42:22.952497
NCT01335321|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-12-22|2011-04-13|2011-04-14|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|||Evaluation of the Effect of Adding Corticosteroid to Viscosupplementation|Prospective And Randomized Study Evaluating Tthe Effect Of The Association Of Triamcinolone To The Viscosupplementation Of The Knee|Completed||Phase 4|108|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 22:42:23.035394|2018-05-31 22:42:23.035394
NCT01335308|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2016-10-28||2017-04-26|2011-04-13|2011-04-14|Estimate|2017-04-26|2017-06-27|Actual||||2017-04-26|2017-06-27|Actual|October 2009||2009-10-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|BMi2||Brief Motivational Interviewing to Reduce Child Body Mass Index|Brief Motivational Interviewing to Reduce Child Body Mass Index|Completed||N/A|645|Actual|University of Michigan||3|||f||||t||||||||||2018-05-31 22:42:23.152904|2018-05-31 22:42:23.152904
NCT01335295|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-01-31|2011-04-13|2011-04-14|Estimate|||||||2014-01-31|2014-02-03|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety Study of Flavocoxid in Duchenne Muscular Dystrophy|Open Pilot Trial to Test the Safety and Tolerability of Flavocoxid in Duchenne Muscular Dystrophy|Completed||Phase 1|20|Actual|University of Messina|||||f||||f||||||||||2018-05-31 22:42:23.634955|2018-05-31 22:42:23.634955
NCT01335282|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-04-13|2011-04-13|2011-04-14|Estimate|||||||2011-04-13|2011-04-14|Estimate|April 2007||2007-04-30|April 2011|2011-04-30|December 2017|Anticipated|2017-12-31|December 2010|Actual|2010-12-31||Observational|||Traditional Chinese Medicine Syndrome Identification in Paediatric Neurology|Traditional Chinese Medicine Syndrome Identification in Paediatric Neurology|Unknown status|Recruiting||100|Anticipated|The University of Hong Kong|||||f||||f||||||||||2018-05-31 22:42:23.696302|2018-05-31 22:42:23.696302
NCT01335269|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2015-12-08|2011-04-13|2011-04-14|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2011||2011-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer|An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies|Completed||Phase 1|96|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:42:23.749795|2018-05-31 22:42:23.749795
NCT01335256|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2013-05-01|2011-04-13|2011-04-14|Estimate|||||||2013-05-01|2013-05-03|Estimate|December 2010||2010-12-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies|Completed||Phase 1|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:42:23.821465|2018-05-31 22:42:23.821465
NCT01335243|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2015-01-13|2011-04-12|2011-04-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|MatriBone||Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow|Multicentric, Prospective Study of Efficacy and Safety of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Marrow|Unknown status|Active, not recruiting|Phase 2|82|Anticipated|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 22:42:23.931747|2018-05-31 22:42:23.931747
NCT01335230|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2013-06-24||2015-08-27|2011-04-13|2011-04-14|Estimate|2014-07-08|2014-08-05|Estimate||||2015-08-27|2015-09-11|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients|Exploring the Role of Gut-associated TH17 in Microbial Translocation in HIV and HCV/HIV Co-infected Patients|Completed|||40|Actual|University of Cincinnati|small number of subjects enrolled in the study (10 subjects in each group). It is cross-sectional study.||4||f||||f||||||Samples With DNA|"~     Colon tissues~   "|||2018-05-31 22:42:24.084737|2018-05-31 22:42:24.084737
NCT01335217|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-02-04|2011-04-13|2011-04-14|Estimate|||||||2013-02-04|2013-02-06|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Trigeminal Nerve Stimulation for Post Traumatic Stress Disorder (PTSD) and Depression|Trigeminal Nerve Stimulation for PTSD and Depression|Completed||Phase 1|20|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 22:42:24.34703|2018-05-31 22:42:24.34703
NCT01335204|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-03-20|2011-04-12|2011-04-14|Estimate|||||||2013-03-20|2013-03-21|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer|Phase Ib/IIa Study of Cabazitaxel Plus Bavituximab for Patients With Castration-resistant Prostate Cancer Previously Treated With Chemotherapy|Terminated||Phase 1/Phase 2|4|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 22:42:24.423453|2018-05-31 22:42:24.423453
NCT01335165|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-05-21|2011-04-13|2011-04-14|Estimate|||||||2014-05-21|2014-05-22|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)|A Phase 1, Single Ascending Dose Study of the Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Terminated||Phase 1|10|Actual|Alexion Pharmaceuticals||2||Inability to reach enrollment as planned|f||||f||||||||||2018-05-31 22:42:24.755591|2018-05-31 22:42:24.755591
NCT01335152|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-05-05|2011-04-13|2011-04-14|Estimate|||||||2014-05-05|2014-05-07|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|||Online Stress Management and Coping Skills Training for Women With Breast Cancer|Coping With Breast Cancer and Treatment: An E-Learning Course for Skills and Strategies|Completed||Phase 1/Phase 2|100|Actual|Talaria, Inc||2|||f||||t||||||||||2018-05-31 22:42:24.837636|2018-05-31 22:42:24.837636
NCT01335139|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2017-05-31|2011-04-12|2011-04-14|Estimate|||||||2017-05-31|2017-06-02|Actual|March 2011||2011-03-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Long-Term Effects of Sublingual Grass Therapy|A Randomized, Double-blind, Single-center, Placebo Controlled Study of Sublingual Immunotherapy and Subcutaneous Immunotherapy in Adults With Seasonal Allergic Rhinitis (ITN043AD)|Completed||Phase 2|106|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|f|f||||||Yes|Participant level data and additional relevant materials are available to the public in TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal. ITN TrialShare makes data from the consortium's clinical trials publicly available.|2018-05-31 22:42:24.912166|2018-05-31 22:42:24.912166
NCT01335126|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-04-13|2011-04-13|2011-04-14|Estimate|||||||2011-04-13|2011-04-14|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|November 2011|Anticipated|2011-11-30|October 2011|Anticipated|2011-10-31||Interventional|||Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artificial Tears|Comparison of Tolerability and Clinical Performance of Two Emulsion-type Artificial Tears|Unknown status|Enrolling by invitation|Phase 3|48|Anticipated|Hom, Milton M., OD, FAAO||1|||f||||f||||||||||2018-05-31 22:42:24.992858|2018-05-31 22:42:24.992858
NCT01335113|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-12|2011-04-12|2011-04-14|Estimate|||||||2011-04-12|2011-04-14|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Observational|||A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity|A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity|Unknown status|Recruiting||100|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 22:42:25.04187|2018-05-31 22:42:25.04187
NCT01335100|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-06|||2011-05-01|2011-04-12|2011-04-14|Estimate|||||||2011-05-01|2011-05-03|Estimate|March 2010||2010-03-31|May 2011|2011-05-31||||||||Observational|||Does Botulinum Toxin Injections Improve Outdoor Activity in Children With Cerebral Palsy?- a Pilot Study||Unknown status|Active, not recruiting||10|Anticipated|Shaare Zedek Medical Center|||2||f||||||||||||||2018-05-31 22:42:25.100822|2018-05-31 22:42:25.100822
NCT01335087|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2017-04-25|2011-04-13|2011-04-14|Estimate|||||||2017-04-25|2017-04-26|Actual|April 2011||2011-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|September 2017|Anticipated|2017-09-30||Interventional|ISAACC||Continuous Positive Airway Pressure (CPAP) in Patients With Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA)|Impact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome. Effect of Intervention With Continuous Positive Airway Pressure (CPAP). A Prospective Randomized Study. ISAACC Study|Unknown status|Recruiting|Phase 3|1864|Anticipated|Sociedad Española de Neumología y Cirugía Torácica||3|||f||||t||||||||||2018-05-31 22:42:25.162175|2018-05-31 22:42:25.162175
NCT01335074|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2016-11-14|2011-04-12|2011-04-13|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2011||2011-04-30|April 2011|2011-04-30||||December 2013|Anticipated|2013-12-31||Interventional|||Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)|Temsirolimus for the Treatment of Advanced Hepatocellular Carcinoma in Patients With Intolerance to Sorafenib|Withdrawn||Phase 1/Phase 2|0|Actual|Philipps University Marburg Medical Center||1|||f||||f||||||||||2018-05-31 22:42:25.373373|2018-05-31 22:42:25.373373
NCT01335061|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2015-03-18||2015-05-12|2011-04-12|2011-04-13|Estimate|2015-04-30|2015-05-04|Estimate||||2015-05-12|2015-06-08|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B|A Multicenter, Open-label Study To Compare On-demand Treatment To A Prophylaxis Regimen Of Nonacog-alfa (Benefix) In Subjects With Moderately Severe To Severe Hemophilia B (Fix:c</=2%)|Completed||Phase 3|25|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 22:42:25.467882|2018-05-31 22:42:25.467882
NCT01335048|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-01-24|2011-04-12|2011-04-13|Estimate|||||||2012-01-24|2012-01-26|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|ACHIDO||Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity|Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity|Completed||Phase 4|50|Anticipated|Ospedale Misericordia e Dolce||2|||f||||f||||||||||2018-05-31 22:42:25.750932|2018-05-31 22:42:25.750932
NCT01335035|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-04-27|2011-04-12|2011-04-13|Estimate|||||||2012-04-27|2012-05-01|Estimate|December 2008||2008-12-31|April 2012|2012-04-30||||May 2011|Actual|2011-05-31||Interventional|||Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload|Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload|Completed||Phase 4|30|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:42:25.81368|2018-05-31 22:42:25.81368
NCT01335022|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|AACP-CVD||African American Community Health Project on Cardiovascular Disease|African American Community Health Project on Cardiovascular Disease (AACP-CVD)|Completed||Early Phase 1|45|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 22:42:25.964814|2018-05-31 22:42:25.964814
NCT01335009|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14||2015-06-25|2017-03-06|2011-04-12|2011-04-13|Estimate||||2015-06-25|2015-07-20|Estimate|2017-03-06|2017-03-07|Actual|May 16, 2011|Actual|2011-05-16|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2, 2013|Actual|2013-12-02||Interventional|||Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma|A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects With Metastatic Melanoma|Active, not recruiting||Phase 2|76|Actual|Morphotek||2|||f||||f||||||||||2018-05-31 22:42:26.061929|2018-05-31 22:42:26.061929
NCT01334996|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2014-08-11|2011-04-12|2011-04-13|Estimate|||||||2014-08-11|2014-08-12|Estimate|February 2005||2005-02-28|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Use of Tamoxifen in Systemic Mastocytosis|Treatment of Systemic Mastocytosis With Tamoxifen|Unknown status|Recruiting||6|Anticipated|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:42:26.17994|2018-05-31 22:42:26.17994
NCT01334983|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2015-04-20|2011-04-12|2011-04-13|Estimate|||||||2015-04-20|2015-04-22|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|REST||Rapid Easy Strength Training (REST) to Improve Function in Late Stage Cancer|Phase II Randomized Controlled Trial of Rapid and Easy Strength Training to Preserve Function in Late Stage Cancer|Completed||Phase 2|68|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:42:26.260027|2018-05-31 22:42:26.260027
NCT01334957|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2014-04-15||2016-04-18|2011-04-12|2011-04-13|Estimate|2014-05-20|2014-06-23|Estimate||||2016-04-18|2016-05-18|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional||Formal sample size calculations were not performed. The intent is to enroll 300 patients to provide descriptive safety and efficacy data.|Surgical Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen|A Multi-Center, Open-Label, Surgical Surveillance Trial To Evaluate The Safety And Efficacy Of A Shortened Infusion Time of Intravenous Ibuprofen|Completed||Phase 4|300|Actual|Cumberland Pharmaceuticals||1|||f||||t||||||||||2018-05-31 22:42:26.359798|2018-05-31 22:42:26.359798
NCT01334944|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2014-04-15||2016-07-28|2011-04-12|2011-04-13|Estimate|2014-05-20|2014-06-23|Estimate||||2016-07-28|2016-09-02|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Surveillance Trial to Evaluate a Shortened Infusion Time of Intravenous Ibuprofen|A Multi-Center, Open-Label, Surveillance Trial To Evaluate The Safety and Efficacy of a Shortened Infusion Time of Intravenous Ibuprofen.|Completed||Phase 4|150|Actual|Cumberland Pharmaceuticals||1|||f||||t||||||||||2018-05-31 22:42:26.643462|2018-05-31 22:42:26.643462
NCT01334931|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-05-07|2011-04-12|2011-04-13|Estimate|||||||2012-05-07|2012-05-09|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|XRay Reduction||Use of Large Field of View During Image Acquisition for Coronary Angiography|Preferential Use of Large Field of View During Image Acquisition for Coronary Angiography With Flat Detector Technology: a Simple Step to Reduce Radiation Exposure|Completed||Phase 3|120|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 22:42:26.986764|2018-05-31 22:42:26.986764
NCT01334918|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2013-07-11||2017-11-21|2011-04-12|2011-04-13|Estimate|2013-07-11|2013-09-18|Estimate||||2017-11-21|2017-12-19|Actual|April 26, 2011|Actual|2011-04-26|November 2017|2017-11-30|July 2, 2012|Actual|2012-07-02|July 2, 2012|Actual|2012-07-02||Interventional||Safety Analysis Set (SAF): All randomized participants who received at least 1 dose of regadenoson.|A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)|A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)|Completed||Phase 2|124|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 22:42:27.067407|2018-05-31 22:42:27.067407
NCT01334905|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2013-06-10|2011-04-12|2011-04-13|Estimate|||||||2013-06-10|2013-06-12|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers|A Phase 1, Open-Label, Single Oral Dose Study to Assess the Safety, Pharmacokinetics and Effect of Food on the Pharmacokinetics of Mirabegron (YM178) in Healthy Volunteers|Completed||Phase 1|12|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:42:27.455552|2018-05-31 22:42:27.455552
NCT01334892|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2015-04-13|2011-04-12|2011-04-13|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients|A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients|Terminated||Phase 2/Phase 3|130|Actual|Pari Pharma GmbH||2||"Interim analysis results revealed substantial increase of patient number, with unfeasible study~   prolongation."|f||||t||||||||||2018-05-31 22:42:27.516776|2018-05-31 22:42:27.516776
NCT01334879|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2014-09-30|2011-04-12|2011-04-13|Estimate|||||||2014-09-30|2014-10-02|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy|High Dose (2.0mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy|Completed||Phase 1|10|Actual|The New York Eye Cancer Center||2|||f||||t||||||||||2018-05-31 22:42:27.698324|2018-05-31 22:42:27.698324
NCT01334866|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2013-08-09||2013-11-03|2011-04-12|2011-04-13|Estimate|2013-11-03|2013-11-26|Estimate||||2013-11-03|2013-11-26|Estimate|December 2009||2009-12-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MICS||Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery|Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery|Completed||Phase 4|91|Actual|Medtronic Cardiovascular|||||f||||f||||||||||2018-05-31 22:42:27.795389|2018-05-31 22:42:27.795389
NCT01334853|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-10-10|2011-04-12|2011-04-13|Estimate|||||||2012-10-10|2012-10-11|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Observational|||A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma|A Prospective Observational Study to Assess the Role of Selected Biomarkers in Subjects Requiring Daily Medium- to High-dose Inhaled Corticosteroids for Persistent Asthma|Completed|||97|Actual|MedImmune LLC|||2||f||||f||||||Samples Without DNA|"~     Blood and Sputum~   "|||2018-05-31 22:42:27.997319|2018-05-31 22:42:27.997319
NCT01334840|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-07-29|2011-04-12|2011-04-13|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 2009||2009-11-30|April 2011|2011-04-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Mechanism of Action of Vichy Catalan Water|Mechanism of Action of Vichy Catalan Water|Completed||N/A|21|Actual|National Research Council, Spain||4|||f||||||||||||||2018-05-31 22:42:28.104931|2018-05-31 22:42:28.104931
NCT01334827|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-09-27|2011-04-12|2011-04-13|Estimate|||||||2012-09-27|2012-09-28|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|Project MIST||A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users|Rational Development of Combination Microbicide Therapies: A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users (Project MIST)|Completed|||48|Actual|The Miriam Hospital|||||f||||f||||||||||2018-05-31 22:42:28.186185|2018-05-31 22:42:28.186185
NCT01334814|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2012-01-04|2011-04-12|2011-04-13|Estimate|||||||2012-01-04|2012-01-06|Estimate|January 2002||2002-01-31|January 2012|2012-01-31|January 2010|Actual|2010-01-31|September 2005|Actual|2005-09-30||Interventional|||Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor|Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor|Completed||N/A|8|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:42:28.245843|2018-05-31 22:42:28.245843
NCT01334801|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2018-03-21|2011-04-12|2011-04-13|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2010||2010-07-31|March 2018|2018-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31|2 Years|Observational [Patient Registry]|BASS||Biomarkers in Aortic Stenosis - B.A.S.S.|Biomarkers in Aortic Stenosis, Hypertrophic Cardiomyopathy, Mitral Regurgitation, Aortic Regurgitation, Prosthetic Heart Valve Dysfunction, and Tricuspid Regurgitation From Pacemaker Leads Study|Recruiting|||400|Anticipated|Mayo Clinic|||11||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 22:42:28.306629|2018-05-31 22:42:28.306629
NCT01334788|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-04-27|2011-04-12|2011-04-13|Estimate|||||||2015-04-27|2015-04-28|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Sleep Deprivation and Energy Balance|Sleep Deprivation and Energy Balance|Completed||N/A|17|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:42:28.376259|2018-05-31 22:42:28.376259
NCT01334775|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2018-01-05|2011-04-12|2011-04-13|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2011||2011-06-30|April 2011|2011-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Comparison of Self-adhering Mesh and Conventional Mesh in Inguinal Hernia Repair.|Comparison of Cousin Biotech® Adhesix™ Versus Conventional Mesh in Open Anterior Inguinal Hernia Repair: a Multi-centre, Randomised, Double-blinded, Controlled Clinical Trial.|Terminated||N/A|70|Actual|Maastricht University Medical Center||2||Inclusion speed too slow, no longer relevant and takeover|f||||f||||||||||2018-05-31 22:42:28.437386|2018-05-31 22:42:28.437386
NCT01334762|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|May 2007||2007-05-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy of Letrozole and CC Alone in an IUI Program in Cases With Surgically Treated Minimal to Mild Endometriosis|Letrozole and CC Alone in an IUI Program in Women With Surgically Treated Minimal to Mild Endometriosis|Completed||N/A|136|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 22:42:28.50733|2018-05-31 22:42:28.50733
NCT01334749|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2018-03-15|2011-04-12|2011-04-13|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2011||2011-04-30|March 2018|2018-03-31|August 2028|Anticipated|2028-08-31|April 2028|Anticipated|2028-04-30||Observational|DEDEMAS||Observational Study on Determinants of Dementia After Stroke|Determinants of Dementia After Stroke|Recruiting|||600|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, RNA, CSF~   "|||2018-05-31 22:42:28.57132|2018-05-31 22:42:28.57132
NCT01334736|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2017-08-17|2011-04-12|2011-04-13|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2011|Actual|2011-04-30|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of Novel Smoking Cessation Interventions in Current and Former Injection Drug Users|A Study of Novel Smoking Cessation Interventions in Current and Former Injection Drug Users|Completed||N/A|100|Actual|Johns Hopkins University||4|||f||||f||||||||||2018-05-31 22:42:29.626665|2018-05-31 22:42:29.626665
NCT01334723|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2011-04-14||2017-05-25|2011-04-12|2011-04-13|Estimate|2011-10-20|2011-11-28|Estimate||||2017-05-25|2017-05-30|Actual|April 2010||2010-04-30|May 2017|2017-05-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia|Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia|Completed|||35032|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 22:42:29.73188|2018-05-31 22:42:29.73188
NCT01334710|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2012-09-12||2017-10-19|2011-04-12|2011-04-13|Estimate|2012-09-12|2012-10-12|Estimate||||2017-10-19|2017-11-21|Actual|March 2011|Actual|2011-03-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer|A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer|Terminated||Phase 2|3|Actual|Emory University|A second trial evaluating OSI906 in hepatocellular cancer was being run in parallel to this trial. There were safety signals in the second trial which led to stopping this trial.|1||safety issue observed on another hepatocellular study using OSI906|f||||t||||||||||2018-05-31 22:42:30.066348|2018-05-31 22:42:30.066348
NCT01334697|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-07-29|2011-04-12|2011-04-13|Estimate|||||||2013-07-29|2013-07-30|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers|Phase I, Randomized, Multicenter, Double-blind, Single Dose, Dose-Escalation, Placebo-Controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous Administration of Cardiotrophin-1 (CT-1)in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|33|Anticipated|Digna Biotech S.L.||2|||f||||t||||||||||2018-05-31 22:42:30.214793|2018-05-31 22:42:30.214793
NCT01334684|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|May 2011||2011-05-31|February 2011|2011-02-28|September 2013|Anticipated|2013-09-30|April 2013|Anticipated|2013-04-30||Interventional|||Gene Expression Profiles and Metformin Efficacy in Type 2 Diabetes|White Blood Cells Gene Expression Profiles as a Tool for Predicting Metformin Efficacy in Patients With Type 2 Diabetes Mellitus|Unknown status|Not yet recruiting|N/A|100|Anticipated|Casa Sollievo della Sofferenza IRCCS||1|||f||||t||||||||||2018-05-31 22:42:31.062248|2018-05-31 22:42:31.062248
NCT01334671|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||The Clinical Effect of Intensive Statin Therapy in STEMI Patients Before Emergency PCI|The Clinical Effect of Intensive Statin Therapy in STEMI(ST-elevated Myocardial Infarction) Patients Before Emergency PCI(Percutaneous Coronary Intervention)|Unknown status|Recruiting|Phase 3|150|Anticipated|General Hospital of Chinese Armed Police Forces||3|||f||||t||||||||||2018-05-31 22:42:31.145253|2018-05-31 22:42:31.145253
NCT01334658|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|August 2010||2010-08-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study of Corneas Undergoing Balanced Salt Solution(BSS ®) Versus Glucose-bicarbonate-Ringer Lactate in Cataract Surgery|Study of Endothelial Cell Density of Corneas Undergoing Phacoemulsification Surgery Using Balanced Salt Solution (BSS ®) Versus Glucose-bicarbonate-Ringer Lactate as Irrigating Solution: a Randomized Clinical Trial.|Completed||N/A|64|Actual|Grupo de Estudos em Oftalmologia Clínica e Cirúrgica||2|||f||||f||||||||||2018-05-31 22:42:31.238046|2018-05-31 22:42:31.238046
NCT01334645|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-05-28|2011-04-12|2011-04-13|Estimate|||||||2013-05-28|2013-05-29|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Copeptin and Acute Coronary Syndrome Without ST-segment Elevation|Diagnostic Value of Copeptin Assay for Acute Coronary Syndrome Without ST-segment Elevation|Completed||N/A|134|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:42:31.312229|2018-05-31 22:42:31.312229
NCT01334632|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2014-03-19|2011-04-12|2011-04-13|Estimate|||||||2014-03-19|2014-03-20|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|November 2013|Anticipated|2013-11-30|March 2013|Anticipated|2013-03-31||Interventional|||Incidence of Brachial Plexus Injury After Rotator Cuff Repair With Continuous Interscalene Block|Comparison of Incidence of Brachial Plexus Injury After Rotator Cuff Repair With Continuous Interscalene Block Versus Patient Controlled Analgesia Morphine|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire Vaudois||2||Change of practice in the department (Nerve stimulation technique abandoned)|f||||f||||||||||2018-05-31 22:42:31.390355|2018-05-31 22:42:31.390355
NCT01334619|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Ropivacaine Volume for Ultrasound-guided Retrograde Infraclavicular Brachial Plexus Block|Ropivacaine Volume for Ultrasound-guided Retrograde Infraclavicular Brachial Plexus Block|Completed||Phase 4|30|Actual|Beijing Jishuitan Hospital||1|||f||||t||||||||||2018-05-31 22:42:31.476047|2018-05-31 22:42:31.476047
NCT01334606|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2013-04-26||2013-09-11|2011-04-12|2011-04-13|Estimate|2013-06-18|2013-09-02|Estimate||||2013-09-11|2013-09-19|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units|Evaluation of Glycemic Control and User Acceptability of the BD Ultra-Fine Nano 4 mm x 32G Pen Needle for Injection of Long-acting or Basal Insulin Doses Above 40 Units|Terminated||N/A|21|Actual|Becton, Dickinson and Company||2||This study was terminated due to unanticipated recruitment difficulties.|f||||f||||||||||2018-05-31 22:42:31.585365|2018-05-31 22:42:31.585365
NCT01334593|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-12-29|2011-04-12|2011-04-13|Estimate|||||||2012-12-29|2013-01-03|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Assessment of Fitness After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients|The Effect of Neoadjuvant Chemoradiotherapy on Exercise Capacity in Colrectal Cancer Patients|Completed|||25|Actual|Aintree University Hospitals NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 22:42:31.874503|2018-05-31 22:42:31.874503
NCT01334580|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2016-06-28|2011-04-11|2011-04-13|Estimate|||||||2016-06-28|2016-06-29|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Cognitive-Behavioral Therapy for Pain and Opioid Dependence in Methadone Maintenance Treatment|Comparison of Cognitive-Behavioral Therapy and Methadone Drug Counseling for Methadone-Maintained Patients With Co-occurring Chronic Pain and Opioid Dependence|Completed||Phase 1|40|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:42:31.978729|2018-05-31 22:42:31.978729
NCT01334567|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2014-02-28|2011-04-12|2011-04-13|Estimate|||||||2014-02-28|2014-03-04|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan|A Rollover Protocol to Provide Subjects From Taiwan Continued Access to Tenofovir Disoproxil Fumarate After Completing Study GS-US-174-0108|Completed||Phase 2|30|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 22:42:32.088677|2018-05-31 22:42:32.088677
NCT01334554|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|2015-01-28||2017-02-22|2011-04-12|2011-04-13|Estimate|2015-03-20|2015-04-10|Estimate||||2017-02-22|2017-03-27|Actual|April 2011||2011-04-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of Sildenafil Citrate on Insulin Resistance in African American|Effect of Sildenafil Citrate on Insulin Resistance and Endothelial Function in Obese African American Women|Completed||Phase 1/Phase 2|46|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 22:42:32.18236|2018-05-31 22:42:32.18236
NCT01334541|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2017-06-06|2011-04-12|2011-04-13|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2009||2009-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SAFE VET||A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans- Study 1|A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans- Study 1|Active, not recruiting|||600|Anticipated|VA Eastern Colorado Health Care System|||2||f||||f||||||||||2018-05-31 22:42:32.506669|2018-05-31 22:42:32.506669
NCT01334528|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2016-01-13|2011-04-12|2011-04-13|Estimate|||||||2016-01-13|2016-01-15|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|ANAM||Consistency of Automated Neuropsychological Assessment Metrics (ANAM) Performance in Those With Deployment Acquired Mild Traumatic Brain Injury (TBI)|Consistency of ANAM Performance in Those With Deployment Acquired Mild TBI|Completed|||3|Actual|VA Eastern Colorado Health Care System|||1||f||||t||||||||||2018-05-31 22:42:32.584295|2018-05-31 22:42:32.584295
NCT01334515|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|2015-02-04||2016-05-11|2011-04-12|2011-04-13|Estimate|2015-02-04|2015-02-20|Estimate||||2016-05-11|2016-06-15|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma|Feasibility/Phase II Study of hu14.18-IL2 Immunocytokine + GM-CSF and Isotretinoin in Patients With Relapsed or Refractory Neuroblastoma|Completed||Phase 2|52|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 22:42:32.725951|2018-05-31 22:42:32.725951
NCT01334502|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2017-08-09|2011-04-12|2011-04-13|Estimate|||||||2017-08-09|2017-08-10|Actual|March 2012|Actual|2012-03-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|February 2015|Actual|2015-02-28||Interventional|||Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma|A Phase I and Feasibility Study of Everolimus (RAD001) Plus R-CHOP for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 1|26|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 22:42:33.587297|2018-05-31 22:42:33.587297
NCT01334489|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2017-03-30|2011-04-12|2011-04-13|Estimate|||||||2017-03-30|2017-03-31|Actual|December 2012|Actual|2012-12-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|PECEPLASER||The Trial of Pessary After Laser for TTTS|Arabin Cervical Pessary for Prevention of Preterm Birth in Cases of Twin-to-twin Transfusion Syndrome Treated by Fetoscopic Laser Coagulation: The PECEP Laser Trial|Recruiting||N/A|352|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 22:42:33.700313|2018-05-31 22:42:33.700313
NCT01334476|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2017-05-18|2011-04-12|2011-04-13|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2010||2010-06-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|Repository||VISN 19 MIRECC Research Database|VISN 19 MIRECC Research Database|Recruiting|||2000|Anticipated|VA Eastern Colorado Health Care System|||||f||||f||||||||||2018-05-31 22:42:33.828915|2018-05-31 22:42:33.828915
NCT01334463|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2016-01-22|2011-04-12|2011-04-13|Estimate|||||||2016-01-22|2016-01-25|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Executive Dysfunction and Self-Harm Behavior: An Examination of Veterans With TBI, PTSD, or Both|Executive Dysfunction and Self-Harm Behavior: An Examination of Veterans With Traumatic Brain Injury, Post Traumatic Stress Disorder, or Both|Completed|||186|Actual|VA Eastern Colorado Health Care System|||4||f||||f||||||||||2018-05-31 22:42:33.947978|2018-05-31 22:42:33.947978
NCT01334450|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2011-04-27|2011-04-12|2011-04-13|Estimate|||||||2011-04-27|2011-04-28|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Transcranial Magnetic Stimulation (TMS) Treatment for Alzheimer Patients|Deep-TMS for the Treatment of Alzheimer Disease Patients|Unknown status|Not yet recruiting|Phase 2|42|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 22:42:34.048198|2018-05-31 22:42:34.048198
NCT01334437|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2014-02-19|2011-04-12|2011-04-13|Estimate|||||||2014-02-19|2014-02-20|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Blood Test for Ovarian Cancer Associated Auto Antibodies|Blood Test for Ovarian Cancer Associated Auto Antibodies|Unknown status|Recruiting||250|Anticipated|Eventus Diagnostics Ltd|||||f||||t||||||Samples With DNA|"~     serum~   "|||2018-05-31 22:42:34.217944|2018-05-31 22:42:34.217944
NCT01334424|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-27|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|December 2009||2009-12-31|April 2011|2011-04-30|April 2011|Anticipated|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Oxidative Stress in Robot-assisted Laparoscopic Radical Prostatectomy|Oxidative Stress in Robot-assisted Laparoscopic Radical Prostatectomy|Unknown status|Recruiting|N/A|40|Anticipated|Chang Gung Memorial Hospital||4|||f||||f||||||||||2018-05-31 22:42:34.346795|2018-05-31 22:42:34.346795
NCT01334411|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|||||Observational|||Identifying Good and Poor Surgical Behaviour in the Danish Operating Room||Completed|||||Herlev Hospital|||||f||||f||||||||||2018-05-31 22:42:34.452716|2018-05-31 22:42:34.452716
NCT01334398|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2014-11-24|2011-04-12|2011-04-13|Estimate|||||||2014-11-24|2014-11-25|Estimate|October 2008||2008-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||A Health & Wellness Intervention for Individuals With Traumatic Brain Injury (TBI)|A Health & Wellness Intervention for Individuals With Traumatic Brain Injury|Completed|||74|Actual|VA Eastern Colorado Health Care System|||2||f||||f||||||||||2018-05-31 22:42:34.507684|2018-05-31 22:42:34.507684
NCT01334385|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|March 2007||2007-03-31|April 2011|2011-04-30|November 2010|Actual|2010-11-30|||||Observational|||Operation Enduring Freedom/Operation Iraqi Freedom Veterans' Experiences of Habituation to Pain, Perceived Burdensomeness, and Failed Belongingness|OEF/OIF Veterans' Experiences of Habituation to Painful Stimuli, Perceived Burdensomeness and Failed Belongingness|Completed|||35|Actual|VA Eastern Colorado Health Care System|||1||f||||f||||||||||2018-05-31 22:42:34.583511|2018-05-31 22:42:34.583511
NCT01334372|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-12|2011-04-12|2011-04-13|Estimate|||||||2011-04-12|2011-04-13|Estimate|February 2007||2007-02-28|April 2011|2011-04-30||||December 2009|Actual|2009-12-31||Interventional|CAMS||Intensive Outpatient Treatment for Suicidal Veterans|Intensive Outpatient Treatment for Suicidal Veterans: A Randomized Clinical Trial and Feasibility Investigation|Completed||N/A|48|Actual|VA Eastern Colorado Health Care System||2|||f||||f||||||||||2018-05-31 22:42:34.636687|2018-05-31 22:42:34.636687
NCT01334359|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-07-23|2011-04-11|2011-04-13|Estimate|||||||2014-07-23|2014-07-25|Estimate|July 2008||2008-07-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|FITKids||Exercise Effects on Cognition in School-Aged Children|ERPs to Academics: Exercise Effects on Cognition in School-Aged Children|Completed||Phase 3|252|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||||2018-05-31 22:42:34.735008|2018-05-31 22:42:34.735008
NCT01334346|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-03-27|2011-04-12|2011-04-13|Estimate|||||||2013-03-27|2013-03-29|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Footwear Minimalism Study|An Investigation on Footwear Minimalism and Injury Risk in Runners|Completed||Phase 2|91|Actual|University of British Columbia||3|||f||||||||||||||2018-05-31 22:42:34.806475|2018-05-31 22:42:34.806475
NCT01334333|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2018-05-14|2011-04-12|2011-04-13|Estimate|||||||2018-05-14|2018-05-17|Actual|November 11, 2011|Actual|2011-11-11|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|October 30, 2014|Actual|2014-10-30||Interventional|||Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients|Comparison of Medication Adherence Between Once Daily Tacrolimus (Advagraf®) and Twice Daily Tacrolimus (Prograf®) Administration in Stable Renal Transplant Recipients - a Randomized Study|Completed||Phase 4|46|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:42:34.890184|2018-05-31 22:42:34.890184
NCT01334320|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2015-04-09|2011-04-12|2011-04-13|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|December 2021|Anticipated|2021-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Survival Benefit of Elective Neck Dissection in T1,2N0M0 Oral Squamous Cell Carcinoma|Survival Benefit of Elective Neck Dissection for Patients With T1,2N0M0 Oral Squamous Cell Carcinoma—A Prospective Multicenter Randomized Controlled Study|Recruiting||N/A|448|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:42:35.088293|2018-05-31 22:42:35.088293
NCT01334307|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-01-22|2011-04-11|2011-04-13|Estimate|||||||2014-01-22|2014-01-24|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Randomized Comparison of the RePneu Lung Volume Reduction Coil (LVRC) to Standard of Care for the Treatment of Emphysema (RESET Study)|Randomized Controlled Trial Of RePneu (LVRC) Endobronchial Coils For The Treatment Of Severe Emphysema With Hyperinflation (RESET Study)|Completed||Phase 1|47|Actual|PneumRx, Inc.||2|||f||||f||||||||||2018-05-31 22:42:35.213452|2018-05-31 22:42:35.213452
NCT01334294|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2014-10-02|2011-04-12|2011-04-13|Estimate|||||||2014-10-02|2014-10-03|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|CNV||Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration|Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular AMD|Completed|||120|Actual|Notal Vision Ltd|||1||f||||f||||||||||2018-05-31 22:42:35.292691|2018-05-31 22:42:35.292691
NCT01334281|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2013-04-19|2011-04-12|2011-04-13|Estimate|||||||2013-04-19|2013-04-22|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Observational|||An In-vitro Standardization of B Cell Elispot Assays|A Phase 1, Investigatory Initiated, In-vitro Standardization of B Cell Elispot Assays|Terminated|||19|Actual|Northwestern University|||2|Technical difficulties perfecting laboratory test used on blood samples.|f||||f||||||Samples Without DNA|"~     Subjects will serve as a source of B-lineage cells, which will be tested for their ability to~     produce IgG, tetanus antibodies, (as controls) and HLA specific antibodies that coorespond to~     those detected by the flow PRA assay. They will be retained until they are used up.~   "|||2018-05-31 22:42:35.385546|2018-05-31 22:42:35.385546
NCT01334268|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2017-10-16|2011-04-12|2011-04-13|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2011|Actual|2011-09-30|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|November 2012|Actual|2012-11-30||Interventional|R-China RCT||RESOLUTE China RCT|A Randomized Controlled Trial of the Resolute Zotarolimus-Eluting Stent Versus the Taxus Liberte Paclitaxel-Eluting Stent for Percutaneous Coronary Intervention in a Real-World All-comer Patient Population in China|Completed||N/A|400|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-05-31 22:42:35.471219|2018-05-31 22:42:35.471219
NCT01334255|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2013-04-22|2011-04-11|2011-04-13|Estimate|||||||2013-04-22|2013-04-23|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|PED||iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)|A Phase 1b Multi-Center, Open-Label and Randomized Study of iSONEP (Sonepcizumab/LT1009) Administered as Intravitreous Injections to Subjects With PED Secondary to Exudative Age-Related Macular Degeneration or Polypoidal Choroidal Vasculopathy|Terminated||Phase 1|12|Actual|Lpath, Inc.||2||Sponsor decision; not safety related|f||||f||||||||||2018-05-31 22:42:35.602233|2018-05-31 22:42:35.602233
NCT01334242|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-05-18|2011-04-11|2011-04-13|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2011||2011-03-31|May 2011|2011-05-31||||April 2011|Actual|2011-04-30||Interventional|||A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects|Completed||Phase 1|14|Anticipated|Lexicon Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:42:35.688393|2018-05-31 22:42:35.688393
NCT01334229|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|2014-07-22||2016-03-07|2011-04-12|2011-04-13|Estimate|2014-09-03|2014-09-10|Estimate||||2016-03-07|2016-04-04|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|JANUB48||Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Sitagliptin on the Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and Apolipoprotein B100 in Patients With Type 2 Diabetes|Completed||Phase 3|22|Actual|Laval University||2|||f||||t||||||||||2018-05-31 22:42:35.781563|2018-05-31 22:42:35.781563
NCT01334216|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|2017-01-24||2017-08-15|2011-04-12|2011-04-13|Estimate|2017-01-24|2017-03-14|Actual||||2017-08-15|2017-09-13|Actual|July 2008||2008-07-31|August 2017|2017-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Using Computers to Assist in Parental Smoking Cessation in a Pediatric Setting|Using Computers to Assist in Parental Smoking Cessation in a Pediatric Setting|Completed||N/A|362|Actual|Indiana University||2|||f||||t||||||||No||2018-05-31 22:42:36.133324|2018-05-31 22:42:36.133324
NCT01334203|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-07-27|2011-04-12|2011-04-13|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)|A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus|Withdrawn||Phase 4|0|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 22:42:36.378717|2018-05-31 22:42:36.378717
NCT01334190|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-07-01|2011-04-12|2011-04-13|Estimate|||||||2013-07-01|2013-07-02|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||A Prospective Observational Study of the Performance of Zarin in Kenya|A Prospective Observational Study of the Performance of Zarin in Kenya|Completed|||602|Actual|FHI 360|||||f||||f||||||||||2018-05-31 22:42:36.448068|2018-05-31 22:42:36.448068
NCT01334177|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-03-03|2011-04-11|2011-04-13|Estimate|||||||2015-03-03|2015-03-05|Estimate|June 2011||2011-06-30|March 2015|2015-03-31||||June 2014|Actual|2014-06-30||Interventional|||TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck|Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)|Completed||Phase 1|13|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 22:42:36.511877|2018-05-31 22:42:36.511877
NCT01334164|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2015-07-27|2011-04-12|2011-04-13|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2007||2007-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RMC-WO||Recovery Management Checkups for Women Offenders|Recovery Management Checkups for Women Offenders Experiment|Completed||Phase 2|480|Actual|Chestnut Health Systems||2|||f||||t||||||||||2018-05-31 22:42:36.597061|2018-05-31 22:42:36.597061
NCT01334151|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-07-24|2011-04-12|2011-04-13|Estimate|||||||2013-07-24|2013-07-26|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes|A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration|Completed||Phase 1|13|Actual|Biodel||3|||f||||f||||||||||2018-05-31 22:42:36.660828|2018-05-31 22:42:36.660828
NCT01334138|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2012-04-20|2011-04-11|2011-04-12|Estimate|||||||2012-04-20|2012-04-23|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Dietary Sodium Intake on Blood Pressure in Hypertensive Patients in Primary Care|Effect of Dietary Sodium Intake on Blood Pressure in Hypertensive Patients in Primary Care|Completed||N/A|25|Actual|University Ghent||1|||f||||f||||||||||2018-05-31 22:42:36.724576|2018-05-31 22:42:36.724576
NCT01334125|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2016-01-27||2016-03-03|2011-04-11|2011-04-12|Estimate|2016-03-03|2016-03-04|Estimate||||2016-03-03|2016-03-04|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AMTIDD|Subjects who completed the baseline evaluation at the time of randomization were included in the baseline analysis.|Adjunctive Metformin Therapy in Double Diabetes|Glycemic Control in Children and Adolescents With Double Diabetes: Trial of Optimized Insulin-Metformin Regimen|Completed||Phase 3|28|Actual|University of Massachusetts, Worcester|The trial was stopped before reaching enrollment target because most youth were reluctant to commit to this long-term study.|2|||f||||t||||||||||2018-05-31 22:42:36.788457|2018-05-31 22:42:36.788457
NCT01334112|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2018-02-02|2011-04-11|2011-04-12|Estimate|||||||2018-02-02|2018-02-06|Actual|January 2011||2011-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AXITINIB||Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma|A Phase II Trial of Axitinib (AG-013736) After Prior Antiangiogenic Therapy in Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 2|29|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 22:42:37.025335|2018-05-31 22:42:37.025335
NCT01334099|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-06-19|2011-04-11|2011-04-12|Estimate|||||||2015-06-19|2015-06-22|Estimate|July 2010||2010-07-31|June 2015|2015-06-30||||March 2013|Actual|2013-03-31||Interventional|||Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients|Phase I Study of Local Radiation and CP-675,206 Administration in Patients With Inoperable Locally Recurrent or Metastatic Breast Cancer|Terminated||Phase 1|6|Actual|University Health Network, Toronto||1||Contract with drug supplier expired and was not renewed.|f||||f||||||||||2018-05-31 22:42:37.086383|2018-05-31 22:42:37.086383
NCT01334086|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2015-06-19|2011-04-11|2011-04-12|Estimate|||||||2015-06-19|2015-06-22|Estimate|September 2011||2011-09-30|June 2015|2015-06-30||||August 2013|Actual|2013-08-31||Interventional|||Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy|A Phase II Open Label Study of Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy|Completed||Phase 2|41|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 22:42:37.145157|2018-05-31 22:42:37.145157
NCT01334073|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-07-22|2011-04-11|2011-04-12|Estimate|||||||2015-07-22|2015-07-23|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|May 2013|Actual|2013-05-31||Interventional|EVAX||Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors|Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors|Completed||Phase 1|19|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 22:42:37.207124|2018-05-31 22:42:37.207124
NCT01334060|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2016-10-12|2011-04-11|2011-04-12|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2010||2010-02-28|October 2016|2016-10-31||||April 2013|Actual|2013-04-30||Interventional|WIN||WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation|WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation|Suspended||Phase 2|184|Anticipated|University Hospital Southampton NHS Foundation Trust||4|||f||||t||||||||||2018-05-31 22:42:37.394233|2018-05-31 22:42:37.394233
NCT01334047|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-08-22|2011-04-11|2011-04-12|Estimate|||||||2014-08-22|2014-08-25|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|April 2022|Anticipated|2022-04-30|August 2013|Actual|2013-08-31||Interventional|||Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients|Phase I/II Trial of Vaccine Therapy in Recurrent Platinum Sensitive Epithelial Ovarian Cancer Patients Using Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and Survivin.|Terminated||Phase 1/Phase 2|5|Actual|Oslo University Hospital||1||"The study needed to be terminated due to new knowledge about cancer vaccines. A new protocol~   with an expected more efficient vaccine is currently being written."|f||||f||||||||||2018-05-31 22:42:37.469669|2018-05-31 22:42:37.469669
NCT01334034|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2017-02-28|2011-04-11|2011-04-12|Estimate|||||||2017-02-28|2017-03-01|Actual|April 11, 2011|Actual|2011-04-11|February 2017|2017-02-28|September 16, 2011|Actual|2011-09-16|September 16, 2011|Actual|2011-09-16||Interventional|||Safety of NNC 0123-0000-0338 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0123-0000-0338 in Healthy Subjects|Completed||Phase 1|70|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 22:42:37.546423|2018-05-31 22:42:37.546423
NCT01334021|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2018-05-11|2011-04-11|2011-04-12|Estimate|||||||2018-05-11|2018-05-14|Actual|May 31, 2011|Actual|2011-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Genomic Testing for Primary Breast Cancer|Feasibility, Validation and Implementation of Genomic Testing for Chemotherapy and Endocrine Sensitivity of HER2 Negative Primary Invasive Breast Cancer (Clinical Stage I to III)|Active, not recruiting|||554|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Tumor biopsy performed before receiving any drugs to treat breast cancer.~   "|||2018-05-31 22:42:37.62558|2018-05-31 22:42:37.62558
NCT01334008|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-07-12|2011-04-11|2011-04-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma|Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal Melanoma|Completed||N/A|40|Actual|Institut Curie||1|||f||||t||||||||||2018-05-31 22:42:37.712896|2018-05-31 22:42:37.712896
NCT01333995|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2015-06-11|2011-04-11|2011-04-12|Estimate|||||||2015-06-11|2015-06-12|Estimate|June 2010||2010-06-30|February 2010|2010-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Peer Conselling Infant Feeding Education Program|Peer Counselling to Improve Feeding Practices and Reduce Malnutrition in Children 0-2 Years in Bangladesh|Completed||N/A|2050|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 22:42:37.780301|2018-05-31 22:42:37.780301
NCT01333982|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2014-10-29|2011-04-11|2011-04-12|Estimate|||||||2014-10-29|2014-10-30|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Neonatal Sepsis, Evaluation, Bangladesh|Evaluation of a on Community-Based Management of Neonatal Sepsis|Completed||N/A|20000|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 22:42:37.844306|2018-05-31 22:42:37.844306
NCT01333969|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-01-31|2011-04-11|2011-04-12|Estimate|||||||2013-01-31|2013-02-01|Estimate|April 2011||2011-04-30|January 2013|2013-01-31||||April 2012|Actual|2012-04-30||Interventional|||The Effect of Ischemic Preconditioning on Postoperative Pain After Total Knee Arthroplasty, a Randomized, Controlled Trial|The Effect of Ischemic Preconditioning on Postoperative Pain After Total Knee Arthroplasty, a Randomized, Controlled Trial|Completed||N/A|60|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 22:42:37.912097|2018-05-31 22:42:37.912097
NCT01333956|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2015-07-21||2016-04-12|2011-04-11|2011-04-12|Estimate|2016-04-12|2016-05-18|Estimate||||2016-04-12|2016-05-18|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Effects of Pregabalin on Pain After Total Knee Arthroplasty|Effects of Pregabalin on Pain After Total Knee Arthroplasty: A Randomized, Controlled, Double-Blind Trial|Completed||Phase 1/Phase 2|120|Actual|Hospital for Special Surgery, New York||4|||f||||||||||||||2018-05-31 22:42:38.008938|2018-05-31 22:42:38.008938
NCT01333943|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2016-06-28||2017-05-22|2011-04-11|2011-04-12|Estimate|2017-05-22|2017-12-18|Actual||||2017-05-22|2017-12-18|Actual|March 2011||2011-03-31|May 2017|2017-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty|Saphenous (Adductor Canal) Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty: A Novel Approach for Postoperative Analgesia|Completed||N/A|94|Actual|Hospital for Special Surgery, New York|The duration of analgesia from the ACB block is unclear and was not measured. Also, a large follow-up study is needed to investigate whether ACB improves rehabilitation, incidence of falls, and/or length of hospital stay.|2|||f||||t||||||||||2018-05-31 22:42:38.515023|2018-05-31 22:42:38.515023
NCT01333930|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2012-05-11|2011-04-11|2011-04-12|Estimate|||||||2012-05-11|2012-05-14|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Placebo Controlled Study for Characterisation of Immunological Effects and Safety of Active O2|Characterisation of Immunological Effects and Safety of Active O2 After Strenuous Exercise in Comparison With Placebo: a Double-blind, Placebo Controlled, Balanced Cross-over Study in Healthy Subjects of Both Genders With Good Fitness Level|Completed||N/A|44|Actual|Adelholzener Alpenquellen GmbH||2|||f||||f||||||||||2018-05-31 22:42:38.808898|2018-05-31 22:42:38.808898
NCT01333917|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-02-06|2011-04-11|2011-04-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|October 2011|Actual|2011-10-31||Interventional|||Curcumin Biomarkers|Curcumin Chemoprevention of Colorectal Neoplasia|Completed||Phase 1|40|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 22:42:38.885757|2018-05-31 22:42:38.885757
NCT01333904|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-09-06|2011-04-11|2011-04-12|Estimate|||||||2012-09-06|2012-09-07|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118|A Four-Part Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of PUR118 and Placebo in Normal Healthy Volunteers and Subjects With COPD|Completed||Phase 1|90|Actual|Pulmatrix Inc.||1|||f||||f||||||||||2018-05-31 22:42:38.966466|2018-05-31 22:42:38.966466
NCT01333891|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2014-11-13|2011-04-11|2011-04-12|Estimate|||||||2014-11-13|2014-11-14|Estimate|December 2012||2012-12-31|November 2014|2014-11-30||||December 2012|Actual|2012-12-31||Interventional|||Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure|Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure|Terminated||N/A|1|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 22:42:39.033809|2018-05-31 22:42:39.033809
NCT01333878|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-04-15|2011-04-11|2011-04-12|Estimate|||||||2014-04-15|2014-04-17|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage|An Open-Label, Pilot Trial to Assess the Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage Determined by Low Field Extremity MRI (eMRI) and X-ray|Completed||Phase 2/Phase 3|12|Actual|Orrin M Troum, M.D. and Medical Associates||1|||f||||t||||||||||2018-05-31 22:42:39.10832|2018-05-31 22:42:39.10832
NCT01333865|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2014-09-15||2016-02-26|2011-04-11|2011-04-12|Estimate|2014-09-30|2014-10-06|Estimate||||2016-02-26|2016-03-24|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders|A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders|Completed||Phase 4|25|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 22:42:39.183039|2018-05-31 22:42:39.183039
NCT01333852|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-01-26|2011-04-11|2011-04-12|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|METTAX||Metformin Plus Paclitaxel for Metastatic or Recurrent Head and Neck Cancer|Randomized Phase II Study of Paclitaxel Plus Metformin or Placebo for the Treatment of Platinum-refractory, Recurrent or Metastatic Head and Neck Neoplasms|Terminated||Phase 2|45|Actual|Barretos Cancer Hospital||2||Low accrual|f||||t||||||||||2018-05-31 22:42:39.391643|2018-05-31 22:42:39.391643
NCT01333839|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2015-03-17|2011-04-11|2011-04-12|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Impact of Coronary Artery Bypass Graft (CABG) Surgery on Skeletal Muscle Mass and Insulin Sensitivity, Followed by Exercise Intervention|Impact of CABG Surgery and Subsequent Exercise Intervention on Insulin Sensitivity and Muscle Mass: a Cluster Randomized Trial|Completed||N/A|30|Actual|Hasselt University||3|||f||||f||||||||||2018-05-31 22:42:39.463914|2018-05-31 22:42:39.463914
NCT01333826|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2017-08-14|2011-04-11|2011-04-12|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2007||2007-09-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|September 2012|Actual|2012-09-30||Interventional|SIHR||Schooling, Income, and HIV Risk in Malawi|Does Schooling Protect Young Women From HIV?|Active, not recruiting||N/A|3796|Actual|George Washington University||3|||f||||f||||||||||2018-05-31 22:42:39.529311|2018-05-31 22:42:39.529311
NCT01333813|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2012-07-19||2016-09-22|2011-04-11|2011-04-12|Estimate|2012-07-19|2012-08-22|Estimate||||2016-09-22|2016-09-23|Estimate|April 2011||2011-04-30|September 2016|2016-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children|Long-term Antibody Persistence of Hepatitis B Antibodies and Immune Response to a Hepatitis B Vaccine (Engerix-B Kinder) Challenge in Children Previously Vaccinated With Infanrix Hexa Vaccine|Completed||Phase 4|300|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:42:39.601012|2018-05-31 22:42:39.601012
NCT01333800|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2011-04-11|2011-04-11|2011-04-12|Estimate|||||||2011-04-11|2011-04-12|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma|Phase 4 Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma in a Hospital in Bogotá|Completed||Phase 4|94|Actual|Grünenthal Colombiana S.A.||2|||f||||t||||||||||2018-05-31 22:42:39.860392|2018-05-31 22:42:39.860392
NCT01333787|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2011-04-11|2011-04-11|2011-04-12|Estimate|||||||2011-04-11|2011-04-12|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|December 2010|Actual|2010-12-31|January 2009|Actual|2009-01-31||Interventional|MIXFIBER||Dietary Fiber Mixture in Constipated Pediatric Patients|A Controlled, Randomized, Double-blind Trial to Evaluate the Effect of a Dietary Fiber Mixture During Maintenance Treatment and on Colonic Transit Time in Constipated Pediatric Patients|Completed||Phase 4|54|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:42:39.921178|2018-05-31 22:42:39.921178
NCT01333774|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-05-03|2011-04-11|2011-04-12|Estimate|||||||2012-05-03|2012-05-04|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|CATERING||Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting|Compliance With Dietary Recommendations in Obese Diabetic Patients Undergoing Acarbose Therapy|Completed|||423|Actual|Bayer|||1||f||||f||||||||||2018-05-31 22:42:40.086446|2018-05-31 22:42:40.086446
NCT01333761|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2013-01-08|2011-04-11|2011-04-12|Estimate|||||||2013-01-08|2013-01-09|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Cardiox Shunt Detection Technology Study|FDS-0004 Cardiox Shunt Detection Technology Study|Terminated||Phase 3|71|Actual|Cardiox Corporation||1||1)new FDS device design 2)improved Valsalva procedure 3)improved headbands and earpads.|f||||f||||||||||2018-05-31 22:42:40.176236|2018-05-31 22:42:40.176236
NCT01333748|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-07-12|2011-04-11|2011-04-12|Estimate|||||||2012-07-12|2012-07-13|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EXSAL||Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer|Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer|Completed||Phase 2|530|Anticipated|Centre Francois Baclesse||2|||f||||t||||||||||2018-05-31 22:42:40.286902|2018-05-31 22:42:40.286902
NCT01333735|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2015-09-03|2011-04-11|2011-04-12|Estimate|||||||2015-09-03|2015-09-04|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|COG AGE||Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon|Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon|Completed|||114|Anticipated|Centre Francois Baclesse|||2||f||||f||||||Samples Without DNA|"~     NFS, uree, creatinin, ASAT, ALAT, PAL, GGT, Vit D, B12, Folates, Albumin, lipid, TSH,~     testosteron, oestradiol, LH, FSH, TP, TCA, D-Dimeres, Homocystéine, plasmatic~     biomarkers(protein S100, NSE, CRP, IL6)~   "|||2018-05-31 22:42:40.383183|2018-05-31 22:42:40.383183
NCT01333722|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|2013-11-01|2012-06-29|2014-03-10|2011-04-11|2011-04-12|Estimate|2014-01-22|2014-03-07|Estimate|2012-06-29|2012-07-03|Estimate|2014-03-10|2014-04-08|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Acute Pain Study Following Bunionectomy|A Randomized, Multicenter Study Comparing the Analgesic Efficacy and Safety of Hydrocodone / Acetaminophen Extended Release to Placebo in Subjects With Acute Pain Following Bunionectomy|Completed||Phase 2|100|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 22:42:40.501258|2018-05-31 22:42:40.501258
NCT01333709|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2017-08-16|2011-04-11|2011-04-12|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2011||2011-05-31|August 2017|2017-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|GRECCAR4||Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma|A Randomized Multicenter Phase 2 Study: a Tailored Strategy for Locally Advanced Rectal Carcinoma|Completed||Phase 2|150|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||4|||f||||t||||||||||2018-05-31 22:42:40.837622|2018-05-31 22:42:40.837622
NCT01333696|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-03-02|2011-04-11|2011-04-12|Estimate|||||||2013-03-02|2013-03-05|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|||Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck|Phase II Study of Pemetrexed Monotherapy in Patients With Platinum-resistant Squamous Cell Carcinoma of Head and Neck|Unknown status|Recruiting|Phase 2|32|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 22:42:40.981251|2018-05-31 22:42:40.981251
NCT01333683|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2015-03-04|2011-04-11|2011-04-12|Estimate|||||||2015-03-04|2015-03-06|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Observational|||Tinnitus and Arterial Hypertension|Tinnitus and Arterial Hypertension.is There Any Relationship?|Unknown status|Enrolling by invitation||100|Anticipated|Faculdade de Medicina de Valenca|||2||f||||f||||||||||2018-05-31 22:42:41.106861|2018-05-31 22:42:41.106861
NCT01333670|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2014-01-14|2011-04-11|2011-04-12|Estimate|||||||2014-01-14|2014-01-15|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Efficacy of Prontosan Solution on Chronic Ulcers||Completed||Phase 3|289|Actual|Associazione Infermieristica per lo studio delle Lesioni Cutanee||2|||f||||t||||||||||2018-05-31 22:42:41.186111|2018-05-31 22:42:41.186111
NCT01333657|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-08-02|2011-04-11|2011-04-12|Estimate|||||||2011-08-02|2011-08-03|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||The Application of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Relevant Acute Kidney Injuries|A Prospective Study on the Diagnosis, Severity and Prognosis of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Related Complications|Completed|||104|Actual|Chinese PLA General Hospital|||2||f||||t||||||||||2018-05-31 22:42:41.270941|2018-05-31 22:42:41.270941
NCT01333644|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2015-05-29|2011-04-10|2011-04-12|Estimate|||||||2015-05-29|2015-06-02|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk|The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk|Completed|||270|Anticipated|University of California, San Francisco|||1||f||||t||||||Samples With DNA|"~     Serum, plasma, PBMCs~   "|||2018-05-31 22:42:41.342143|2018-05-31 22:42:41.342143
NCT01333631|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-27|||2011-04-10|2011-04-10|2011-04-12|Estimate|||||||2011-04-10|2011-04-12|Estimate|June 2011||2011-06-30|March 2011|2011-03-31|July 2015|Anticipated|2015-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Valproic Acid With Chemoradiotherapy for Pancreatic Cancer|Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Gemcitabine for Unresectable Locally Advanced Pancreatic Cancer|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Soroka University Medical Center||1|||f||||||||||||||2018-05-31 22:42:41.421123|2018-05-31 22:42:41.421123
NCT01333618|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-25|2011-04-11|2011-04-12|Estimate|||||||2011-04-25|2011-04-26|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter|Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter：A Randomized Double-Blind Comparison|Completed||N/A|108|Actual|China Medical University, China||2|||f||||t||||||||||2018-05-31 22:42:41.487586|2018-05-31 22:42:41.487586
NCT01333605|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-11|||2013-03-02|2011-04-11|2011-04-12|Estimate|||||||2013-03-02|2013-03-05|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma|Phase II Study of IGEV Followed by Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin Lymphoma.|Unknown status|Recruiting|Phase 2|43|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 22:42:41.564894|2018-05-31 22:42:41.564894
NCT01333592|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2014-11-17||2014-11-27|2011-04-10|2011-04-12|Estimate|2014-11-17|2014-11-24|Estimate||||2014-11-27|2014-12-15|Estimate||||November 2014|2014-11-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional||One patient in the KAD-1229 / biguanides group was excluded because of early discontinuation and no evaluable HbA1c.|Long-term Study of KAD-1229 in Type 2 Diabetes Patients|A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy|Completed||Phase 3|136|Actual|Kissei Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 22:42:41.649448|2018-05-31 22:42:41.649448
NCT01333579|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-09-16|2011-04-11|2011-04-12|Estimate|||||||2013-09-16|2013-09-17|Estimate|February 2008||2008-02-29|September 2013|2013-09-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Low-frequency Transcranial Magnetic Stimulation To Enhance Motor Recovery In The Subacute Phase After Stroke|Low-frequency Transcranial Magnetic Stimulation To Enhance Motor Recovery In The Subacute Phase After Stroke|Completed||Phase 1|34|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 22:42:41.911477|2018-05-31 22:42:41.911477
NCT01333553|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2018-04-30|2011-04-08|2011-04-12|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2010||2010-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||Monitoring the Response of Port Wine Stain Birthmarks to Laser Therapy With Wide-field Functional Imaging Technologies|Monitoring the Response of Port Wine Stain Birthmarks to Laser Therapy With Wide-field|Completed|||69|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 22:42:42.047524|2018-05-31 22:42:42.047524
NCT01333540|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30||2013-06-05|2014-09-03|2011-04-11|2011-04-12|Estimate||||2013-06-05|2013-06-13|Estimate|2014-09-03|2014-09-10|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess the Safety, Tolerability and Clinical Activity of TD−1211 in Patients With Opioid-Induced Constipation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD−1211 in Subjects With Opioid-Induced Constipation|Completed||Phase 2|69|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||f||||||||||2018-05-31 22:42:42.117281|2018-05-31 22:42:42.117281
NCT01333527|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2018-05-02|2011-04-08|2011-04-12|Estimate|||||||2018-05-02|2018-05-07|Actual|April 2011||2011-04-30|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|April 2015|Actual|2015-04-30||Interventional|||Early Mobilization Following Arthroscopic Rotator Cuff Repair|Early Mobilization Following Arthroscopic Rotator Cuff Repair: a Randomized Controlled Trial|Completed||N/A|211|Actual|Shoulder & Upper Extremity Research Group of Edmonton||2|||f||||f||||||||||2018-05-31 22:42:42.183994|2018-05-31 22:42:42.183994
NCT01333514|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-01-28|2011-04-11|2011-04-12|Estimate|||||||2014-01-28|2014-01-29|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CARB||Carbohydrate Consumption as a Factor in Aspart Dosing|Carbohydrate Consumption as a Factor in Aspart Dosing Compared to the Regularly Used Standard of Care Basis of Dosing Aspart in the Inpatient Setting (CARB)|Completed||Phase 4|30|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 22:42:42.336313|2018-05-31 22:42:42.336313
NCT01333501|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2016-08-30||2017-01-30|2011-04-11|2011-04-12|Estimate|2017-01-30|2017-03-21|Actual||||2017-01-30|2017-03-21|Actual|May 2011||2011-05-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Cognition||Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms|A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy|Completed||Phase 4|151|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:42:42.546201|2018-05-31 22:42:42.546201
NCT01333488|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2015-08-04||2015-10-27|2011-04-11|2011-04-12|Estimate|2015-08-31|2015-09-30|Estimate||||2015-10-27|2015-10-28|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional||Accrual too low to analyze|Mild Hypothermia and Supplemental Magnesium Sulfate Infusion in Severe Traumatic Brain Injury (TBI) Subjects|A Phase 2, Randomized, Controlled 2x3 Trial Comparing Clinical Outcomes in Patients With Severe Traumatic Brain Injury Using Mild Hypothermia and Concurrent and Supplemental Infusion of Magnesium Sulfate.|Terminated||Phase 2|6|Actual|United States Department of Defense|Low accrual leading to early termination and insufficient numbers for analysis.|3||Low accrual|f||||t||||||||||2018-05-31 22:42:44.216819|2018-05-31 22:42:44.216819
NCT01333475|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-09|2014-11-19||2015-09-29|2011-04-09|2011-04-12|Estimate|2014-11-26|2014-12-04|Estimate||||2015-09-29|2015-09-30|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|November 2013|Actual|2013-11-30||Interventional|||MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma|Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma|Completed||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-05-31 22:42:44.549858|2018-05-31 22:42:44.549858
NCT01333462|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-11|2011-04-11|2011-04-12|Estimate|||||||2011-04-11|2011-04-12|Estimate|March 2009||2009-03-31|April 2011|2011-04-30|September 2010|Actual|2010-09-30|August 2009|Actual|2009-08-31||Interventional|||Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008|A Phase 1 Randomized, Single-Blind, Controlled, Safety, Tolerability and Immunogenicity Study of Intranasal NB-1008 (Fluzone® + 60%W805EC) in Healthy Adult Volunteers|Completed||Phase 1|199|Actual|NanoBio Corporation||12|||f||||||||||||||2018-05-31 22:42:45.152335|2018-05-31 22:42:45.152335
NCT01333449|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2014-06-16|2011-04-10|2011-04-12|Estimate|||||||2014-06-16|2014-06-17|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients|Prospective Phase II Study of Decitabine Induction Therapy to Reduce Pre-transplant Disease Burden Prior to Allogeneic Hematopoietic Cell Transplant in Patients With Newly Diagnosed Myelodysplastic Syndromes.|Terminated||Phase 2|6|Actual|Singapore General Hospital||1||Poor subject accrual|f||||t||||||||||2018-05-31 22:42:45.257065|2018-05-31 22:42:45.257065
NCT01333436|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2013-02-27||2017-03-31|2011-04-08|2011-04-12|Estimate|2013-02-27|2013-04-09|Estimate||||2017-03-31|2017-05-05|Actual|July 20, 2011|Actual|2011-07-20|March 2017|2017-03-31|May 12, 2012|Actual|2012-05-12|May 12, 2012|Actual|2012-05-12||Interventional|||A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)|A Multicenter, Cross-sectional Study to Evaluate Plasma ApoB-48 Concentration Among Korean Diabetic Patients (With Normal to Moderately High LDL-C Levels)|Completed||N/A|93|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:42:45.34626|2018-05-31 22:42:45.34626
NCT01333423|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2012-06-22|2011-04-11|2011-04-12|Estimate|||||||2012-06-22|2012-06-26|Estimate|September 2012||2012-09-30|June 2012|2012-06-30||||September 2015|Anticipated|2015-09-30||Interventional|||Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)|A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Combination With Seliciclib for the Treatment of Patients With Metastatic Triple Negative Breast Cancer|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-05-31 22:42:45.606158|2018-05-31 22:42:45.606158
NCT01333410|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2012-10-07|2011-04-11|2011-04-12|Estimate|||||||2012-10-07|2012-10-10|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo|Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 22:42:45.751648|2018-05-31 22:42:45.751648
NCT01333397|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2015-08-11||2015-09-29|2011-04-08|2011-04-12|Estimate|2015-09-29|2015-10-30|Estimate||||2015-09-29|2015-10-30|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy Study of Dysport RU and Glabellar Lines|A Phase II, Double Blind, Randomised, Placebo and Active Comparator Controlled Study to Assess the Safety and Efficacy of Three Doses of Dysport RU (20 U, 50 U, and 75 U) Administered as a Single Treatment Cycle to Improve the Appearance of Moderate to Severe Glabellar Lines|Completed||Phase 2|176|Actual|Ipsen||5|||f||||f||||||||||2018-05-31 22:42:45.965449|2018-05-31 22:42:45.965449
NCT01333384|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-08-21|2011-04-11|2011-04-12|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Study in Polish Acromegalic Patients Treated With Somatuline Autogel|A Non-Interventional Retrospective (12 Months) and Prospective (at Least 24 Months) Resource Utilization Study, in the Population of Polish Acromegalic Patients Treated With Somatuline Autogel at Normal (4 Weeks) or Extended (6 or 8 Weeks) Dosing Interval|Completed|||150|Actual|Ipsen|||||f||||t||||||||||2018-05-31 22:42:47.815954|2018-05-31 22:42:47.815954
NCT01333371|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2011-04-11|2011-04-11|2011-04-12|Estimate|||||||2011-04-11|2011-04-12|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|DRF||Assessing Volar Locking Plates in Patients Under 65 With a Distal Radius Fracture|Are Volar Locking Plates a Cost Effective Strategy for the Treatment of Distal Radius Fractures in Patients <65 Years of Age?|Unknown status|Not yet recruiting|N/A|64|Anticipated|Hand and Upper Limb Clinic, Canada||2|||f||||f||||||||||2018-05-31 22:42:47.913697|2018-05-31 22:42:47.913697
NCT01333358|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2011-04-22|2011-04-11|2011-04-12|Estimate|||||||2011-04-22|2011-04-25|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|CAMA-2||Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients|Phase III A Prospective, Longitudinal, Rater-blinded Single-arm Study to Evaluate Alemtuzumab as an Effective Treatment in Stabilizing Overall Neurocognitive Function in RRMS Subjects at Specified Timepoints|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Central Texas Neurology Consultants|||||f||||||||||||||2018-05-31 22:42:48.072895|2018-05-31 22:42:48.072895
NCT01333345|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2011-04-11|2011-04-11|2011-04-12|Estimate|||||||2011-04-11|2011-04-12|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Post-Implant Performance of the EC-3 IOL|Post-Implant Performance of the EC-3 IOL ADDENDUM TO THE PROTOCOL: Clinical Evaluation of the EC-3 Hydrophobic Acrylic Posterior Chamber Aphakic Intraocular Lens|Unknown status|Enrolling by invitation||100|Anticipated|Aaren Scientific Inc.|||||f||||f||||||||||2018-05-31 22:42:48.231958|2018-05-31 22:42:48.231958
NCT01333332|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2011-04-08|2011-04-08|2011-04-11|Estimate|||||||2011-04-08|2011-04-11|Estimate|August 2010||2010-08-31|April 2011|2011-04-30||||August 2012|Anticipated|2012-08-31||Interventional|||Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer|Phase II Trial of Accelerated Fraction Radiotherapy With Concomitant Capecitabine as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer|Unknown status|Recruiting|Phase 2|35|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 22:42:48.291774|2018-05-31 22:42:48.291774
NCT01333319|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2016-02-10|2011-04-08|2011-04-11|Estimate|||||||2016-02-10|2016-02-11|Estimate|December 2011||2011-12-31|December 2015|2015-12-31||||June 2015|Actual|2015-06-30||Observational|KILT||The Role of Biomarkers in the Early Detection of Acute Kidney Injury Induced by Liver Transplantation|The Role of Biomarkers in the Early Detection of Acute Kidney Injury Induced by Liver Transplantation : an Observational Analysis.|Unknown status|Active, not recruiting||80|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples Without DNA|"~     Whole blood, urine~   "|||2018-05-31 22:42:48.420859|2018-05-31 22:42:48.420859
NCT01333306|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2013-04-23|2011-04-08|2011-04-11|Estimate|||||||2013-04-23|2013-04-24|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|April 2013|Actual|2013-04-30|||||Interventional|||Enhancing Cognitive Training Using tDCS||Completed||Phase 1|||The University of New South Wales||1|||f||||||||||||||2018-05-31 22:42:48.507651|2018-05-31 22:42:48.507651
NCT01333293|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2016-01-15|2011-04-08|2011-04-11|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|XOLMA||The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients|The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Prospective Double-blind, Placebo-controlled, Multicentre Study, XOLMA-Study|Completed||Phase 2/Phase 3|17|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 22:42:48.588972|2018-05-31 22:42:48.588972
NCT01333280|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-12-09|2011-04-08|2011-04-11|Estimate|||||||2014-12-09|2014-12-10|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy of Dual Focus Mutual Aid for Persons With Co-occurring Disorders|Efficacy of Dual Focus Mutual Aid for Persons With Co-occurring Disorders|Completed||N/A|352|Actual|Western Michigan University||2|||f||||f||||||||||2018-05-31 22:42:48.670071|2018-05-31 22:42:48.670071
NCT01333267|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-12-03|2011-04-08|2011-04-11|Estimate|||||||2014-12-03|2014-12-05|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||One Week Comparison Study of PTH and PTHrP Infusions|Comparison of Skeletal and Mineral Metabolism Responses in Healthy African-Americans and Caucasians Using a Continuous Seven-Day Parathyroid Hormone (PTH) or Parathyroid Hormone-related Protein (PTHrP) Infusion|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:42:48.785397|2018-05-31 22:42:48.785397
NCT01333254|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2016-10-04|2011-04-08|2011-04-11|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients|A Randomised Controlled Trial Comparing Different Methods for Short-Term Bladder Drainage in Patients With Hip Surgery|Completed||N/A|170|Actual|Region Örebro County||2|||f||||f||||||||||2018-05-31 22:42:48.897004|2018-05-31 22:42:48.897004
NCT01333241|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-08|2011-04-08|2011-04-11|Estimate|||||||2011-04-08|2011-04-11|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Healthy Women Prepared for Life|Community-Based Lifestyle Promotion With Latino Women|Unknown status|Active, not recruiting|Phase 1|240|Anticipated|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 22:42:48.961619|2018-05-31 22:42:48.961619
NCT01333228|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2015-05-25|2011-04-08|2011-04-11|Estimate|||||||2015-05-25|2015-05-27|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Evaluate Safety and Efficacy of Autologous Bone Marrow-derived Endothelial Progenitor Cells in Advanced Liver Cirrhosis|Pilot Clinical Trial (Phase I/II) to Evaluate Safety and Therapeutic Effects of the Administration of Autologous Bone Marrow-derived EPCs in Patients With Advanced Liver Cirrhosis|Completed||Phase 1/Phase 2|14|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-05-31 22:42:49.042924|2018-05-31 22:42:49.042924
NCT01333215|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-08|2011-04-08|2011-04-11|Estimate|||||||2011-04-08|2011-04-11|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|ETIC||Study of Cognitive Inhibition Disorders in Depressed Older Suicide Attempters|Etude Des Troubles de l'Inhibition Cognitive Chez le Sujet âgé déprimé Suicidant|Unknown status|Recruiting||40|Anticipated|University Hospital, Angers|||2||f||||t||||||||||2018-05-31 22:42:49.161785|2018-05-31 22:42:49.161785
NCT01333202|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-08|2011-04-08|2011-04-11|Estimate|||||||2011-04-08|2011-04-11|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|LIM||Fresh Lime Alone for Smoking Cessation|Efficacy of Fresh Lime Alone for Smoking Cessation|Completed||N/A|100|Actual|Thai Health Professional Alliance Against Tobacco||2|||f||||f||||||||||2018-05-31 22:42:49.272101|2018-05-31 22:42:49.272101
NCT01333189|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2015-08-07||2015-08-07|2011-04-08|2011-04-11|Estimate|2015-08-07|2015-09-07|Estimate||||2015-08-07|2015-09-07|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RELOAD||Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback|Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback|Completed||N/A|26|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:42:49.445063|2018-05-31 22:42:49.445063
NCT01333176|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-04-24|2011-04-08|2011-04-11|Estimate|||||||2012-04-24|2012-04-25|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Point of Care HbA1c as a Screening Test for Type 2 Diabetes in First Nations|Community-based Screening for Diabetes Using a Validated Point-of-care HbA1c Assay in a British Columbia First Nations Community|Unknown status|Recruiting|N/A|320|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 22:42:49.871824|2018-05-31 22:42:49.871824
NCT01333163|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2011-12-14|2011-04-08|2011-04-11|Estimate|||||||2011-12-14|2011-12-15|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||GLP-1: Acute Effects on Kidney Function in Healthy Men|GLP-1: Acute Effects on Kidney Function in Healthy Men|Completed||N/A|12|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:42:49.965598|2018-05-31 22:42:49.965598
NCT01333150|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-03-23|2011-04-08|2011-04-11|Estimate|||||||2012-03-23|2012-03-26|Estimate|August 2011||2011-08-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Effect of Propranolol on the Autonomic Nervous System and Muscle Pain|Effects of a Low-dose Propranolol on a Stress Induced Autonomic Response and on Muscle Pain|Unknown status|Recruiting|N/A|16|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 22:42:50.051175|2018-05-31 22:42:50.051175
NCT01333137|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-09-03|2011-04-08|2011-04-11|Estimate|||||||2014-09-03|2014-09-04|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|July 2012|Actual|2012-07-31||Interventional|||A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin|An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Phase I Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin|Terminated||Phase 1|11|Actual|Piramal Enterprises Limited||2|||f||||t||||||||||2018-05-31 22:42:50.143041|2018-05-31 22:42:50.143041
NCT01333124|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2017-09-12|2011-04-08|2011-04-11|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2012||2012-04-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma|A Phase 2 Study of Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma|Recruiting||Phase 2|64|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||No||2018-05-31 22:42:50.231956|2018-05-31 22:42:50.231956
NCT01333111|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2017-06-27|2013-07-03|2017-06-27|2011-04-08|2011-04-11|Estimate|2017-06-27|2017-07-28|Actual|2013-07-03|2013-07-10|Estimate|2017-06-27|2017-07-28|Actual|April 27, 2011|Actual|2011-04-27|June 2017|2017-06-30|March 31, 2013|Actual|2013-03-31|March 31, 2013|Actual|2013-03-31||Interventional|paradigm™ 2|Full analysis set included all subjects exposed to nonacog beta pegol.|Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients|A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC-0156-0000-0009 When Used for Treatment and Prophylaxis of Bleeding Episodes in Patients With Haemophilia B|Completed||Phase 3|74|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 22:42:50.346403|2018-05-31 22:42:50.346403
NCT01333098|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-03-19|2011-04-08|2011-04-11|Estimate|||||||2014-03-19|2014-03-20|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Mifepristone||Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders|Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders|Completed||Phase 1/Phase 2|16|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 22:42:50.835698|2018-05-31 22:42:50.835698
NCT01333085|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2016-02-09|2011-04-08|2011-04-11|Estimate|||||||2016-02-09|2016-02-10|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|CAPRA||Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery|Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Completed||Phase 1/Phase 2|49|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||||2018-05-31 22:42:50.919579|2018-05-31 22:42:50.919579
NCT01333072|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2016-03-14|2011-04-08|2011-04-11|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|BAART||Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)|Biomarkers in Autism of Aripiprazole and Risperidone Treatment|Completed||Phase 4|82|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 22:42:50.993169|2018-05-31 22:42:50.993169
NCT01333059|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2012-12-06|2011-04-08|2011-04-11|Estimate|||||||2012-12-06|2012-12-10|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Cycling of Sedative Infusions in Critically Ill Pediatric Patients|A Randomized, Double-blind, Controlled Trial of Cycling Continuous Sedative Infusions in Critically Ill Pediatric Patients Requiring Mechanical Ventilation|Terminated||N/A|120|Anticipated|Cook Children's Health Care System||2||Unable to adequately enroll over a reasonable enrollment period.|f||||t||||||||||2018-05-31 22:42:51.0663|2018-05-31 22:42:51.0663
NCT01333046|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2018-02-20|2011-04-08|2011-04-11|Estimate|||||||2018-02-20|2018-02-22|Actual|January 2012||2012-01-31|February 2018|2018-02-28|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Interventional|TACTAL||Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL|Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma|Recruiting||Phase 1|74|Anticipated|Baylor College of Medicine||4|||f||||t|t|f||||||||2018-05-31 22:42:51.176966|2018-05-31 22:42:51.176966
NCT01333033|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-07-11|2011-04-07|2011-04-11|Estimate|||||||2017-07-11|2017-07-13|Actual|July 2011||2011-07-31|July 2017|2017-07-31||||November 2015|Actual|2015-11-30||Interventional|||PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy|Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer|Active, not recruiting||Phase 2|257|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 22:42:51.32814|2018-05-31 22:42:51.32814
NCT01333020|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2012-06-21|2011-04-08|2011-04-11|Estimate|||||||2012-06-21|2012-06-22|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Cross-linked Emulsion Study|A Pilot Study on the Effect of Protein Cross-linking on Gastric Layering and Emptying of a Food Emulsion|Completed||N/A|4|Actual|Quadram Institute||1|||f||||t||||||||||2018-05-31 22:42:51.587472|2018-05-31 22:42:51.587472
NCT01333007|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2016-11-01|2011-04-08|2011-04-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer|A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.|Completed|||423|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:42:51.680186|2018-05-31 22:42:51.680186
NCT01332994|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2015-08-05||2015-08-05|2011-04-08|2011-04-11|Estimate|2015-08-05|2015-09-07|Estimate||||2015-08-05|2015-09-07|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Main Intent-to-Treat (ITT) Population: All participants who received at least one dose of TCZ.|A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis|Efficacy and Safety Study of a Sequential Therapy of Tocilizumab (TCZ) and, if Initially Inadequately Responded to Tocilizumab (TCZ), Followed by Rituximab (RTX) in DMARD-IR Patients With Rheumatoid Arthritis (MIRAI)|Completed||Phase 3|519|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:42:52.000638|2018-05-31 22:42:52.000638
NCT01332981|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2015-12-15||2016-01-25|2011-04-08|2011-04-11|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational||The full analysis population included participants with HER2+ metastatic breast cancer included in HERMINE study and treated with trastuzumab as first line therapy.|An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)|Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin® as 1st Line Therapy (Post-HERMINE Study)|Completed|||220|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:42:53.588453|2018-05-31 22:42:53.588453
NCT01332968|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|2017-02-03||2018-04-12|2011-04-08|2011-04-11|Estimate|2017-05-05|2017-06-07|Actual||||2018-04-12|2018-05-14|Actual|July 6, 2011|Actual|2011-07-06|April 2018|2018-04-30|October 31, 2022|Anticipated|2022-10-31|February 1, 2016|Actual|2016-02-01||Interventional||The intent-to treat (ITT) population was defined as all randomized participants grouped according to their randomized treatment arm regardless of what treatments were actually received.|A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)|A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders|Active, not recruiting||Phase 3|1401|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:42:54.361723|2018-05-31 22:42:54.361723
NCT01332955|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-01-22|2011-04-08|2011-04-11|Estimate|||||||2014-01-22|2014-01-23|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|TelapreVIH||Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen|Pilot Study of PegInterferon-Ribavirin-Telaprevir Efficacy and Tolerability in HIV-HCV Coinfected Patients Who Had Previously Failed a PegInterferon-Ribavirin Regimen. (ANRS HC26 TelapreVIH)|Completed||Phase 2|70|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 22:43:01.57343|2018-05-31 22:43:01.57343
NCT01332942|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2015-07-12|2011-04-08|2011-04-11|Estimate|||||||2015-07-12|2015-07-14|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)|Randomized, Single-blind, Placebo-controlled, Combined Single / Multiple Dose Escalation, Group Comparison Study to Investigate Safety, Tolerability, Pharmacodynamic Effect and Pharmacokinetics of BAY 85-3934 in Patients With Renal Anemia Due to CKD (Stages 3 and 4)|Completed||Phase 1|44|Actual|Bayer||6|||f||||f||||||||||2018-05-31 22:43:01.860769|2018-05-31 22:43:01.860769
NCT01332929|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-09-11|2011-04-08|2011-04-11|Estimate|||||||2013-09-11|2013-09-12|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis|Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis|Completed||Phase 1|21|Actual|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 22:43:01.982025|2018-05-31 22:43:01.982025
NCT01332916|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-08|||2014-04-24|2011-04-08|2011-04-11|Estimate|||||||2014-04-24|2014-04-25|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|CANMEM||Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging|Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging|Terminated||Phase 2|60|Anticipated|Centre Francois Baclesse||2||lack of patient|f||||f||||||||||2018-05-31 22:43:02.071676|2018-05-31 22:43:02.071676
NCT01332903|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2015-06-24|2011-04-08|2011-04-11|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069|A Phase I, Open-Label Study to Characterise the Absorption, Distribution, Metabolism and Excretion Following a Single Oral Dose of [14C]AZD5069 in Healthy Male Volunteers|Completed||Phase 1|6|Anticipated|AstraZeneca||1|||f||||||||||||||2018-05-31 22:43:02.16441|2018-05-31 22:43:02.16441
NCT01317511|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Protein Supply in Elderly|Overnight Protein Supply as a Dietary Strategy to Improve Muscle Mass in Elderly.|Completed||N/A|16|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:46:52.478982|2018-05-31 22:46:52.478982
NCT01332890|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-07-08|2011-04-08|2011-04-11|Estimate|||||||2014-07-08|2014-07-10|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects|A Randomized, Open-label, Multiple-dose, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Revaprazan and Itopride HCl in Healthy Male Subjects|Completed||Phase 1|30|Actual|Yuhan Corporation||6|||f||||f||||||||||2018-05-31 22:43:02.384998|2018-05-31 22:43:02.384998
NCT01332877|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-08|2011-04-08|2011-04-11|Estimate|||||||2011-04-08|2011-04-11|Estimate|April 2011||2011-04-30|April 2011|2011-04-30||||November 2011|Anticipated|2011-11-30||Interventional|||Breakfast Size and Weight Loss in Overweight/Obese Adults|The Effect of Breakfast Enriched With Protein and Carbohydrates on Weight Loss, Hunger, Satiety and Ghrelin in Overweight and Obese Adults|Unknown status|Recruiting|Phase 3|150|Anticipated|Wolfson Medical Center||1|||f||||t||||||||||2018-05-31 22:43:02.46035|2018-05-31 22:43:02.46035
NCT01332864|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-02-11|2011-04-08|2011-04-11|Estimate|||||||2013-02-11|2013-02-13|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|OMTHA||Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache|Physiological and Behavioral Effects of Osteopathic Manipulative Treatment on Patients With Chronic Headache: A Randomized Clinical Trial|Completed||Phase 4|60|Actual|Western University of Health Sciences||4|||f||||f||||||||||2018-05-31 22:43:02.553774|2018-05-31 22:43:02.553774
NCT01332851|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-01-05|2011-04-08|2011-04-11|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|SPP||Supporting Parents Program|Training Social Work Providers: Intervention for Maltreating Families of Infants|Completed||N/A|251|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 22:43:02.701605|2018-05-31 22:43:02.701605
NCT01332838|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-29|2011-04-08|2011-04-11|Estimate|||||||2011-04-29|2011-05-02|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||A Comparison of Specialized Versus Standard Compression After Saphenous Ablation|A Comparison of Specialized Versus Standard Compression After Saphenous Ablation|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Washington||2|||f||||||||||||||2018-05-31 22:43:02.792847|2018-05-31 22:43:02.792847
NCT01332825|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2013-12-11|2011-04-08|2011-04-11|Estimate|||||||2013-12-11|2013-12-12|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||cAMP (Cyclic Adenosine Monophosphate) Levels in the Nose|cAMP Levels in the Nose|Completed||N/A|41|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 22:43:02.862439|2018-05-31 22:43:02.862439
NCT01332812|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07||2015-09-04|2015-09-04|2011-04-08|2011-04-11|Estimate||||2015-09-04|2015-09-10|Estimate|2015-09-04|2015-09-10|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction|Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction in Elderly Patients Undergoing to General Anesthesia|Completed||Phase 4|300|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:43:02.953416|2018-05-31 22:43:02.953416
NCT01332799|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-03-24|2011-04-08|2011-04-11|Estimate|||||||2017-03-24|2017-03-28|Actual|February 2011||2011-02-28|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|XART||Xanthine Oxidase Inhibition in Renal Transplant Recipients|Xanthine Oxidase Inhibition in Renal Transplant Recipients|Active, not recruiting||Phase 4|120|Anticipated|University of Iowa||2|||f||||f||||||||||2018-05-31 22:43:03.042471|2018-05-31 22:43:03.042471
NCT01332786|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-04-14|2011-04-07|2011-04-11|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia|Phase 1 Study Evaluating the Tolerance and Biologic Activity of Intravenous Infusions of Tigecycline in Patients With Relapsed or Refractory AML|Completed||Phase 1|27|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 22:43:03.152266|2018-05-31 22:43:03.152266
NCT01332773|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-18|2011-04-07|2011-04-11|Estimate|||||||2011-04-18|2011-04-19|Estimate|March 2010||2010-03-31|December 2009|2009-12-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|Artery first||The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer|The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer|Unknown status|Recruiting|Phase 3|124|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 22:43:03.237042|2018-05-31 22:43:03.237042
NCT01332760|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2012-02-21|2011-04-08|2011-04-11|Estimate|||||||2012-02-21|2012-02-22|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Tool Design on Hand Pain in Dental Practitioners|Effect of Tool Design on Hand Pain in Dental Practitioners|Completed||N/A|110|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:43:03.319189|2018-05-31 22:43:03.319189
NCT01332747|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2014-10-18|2011-04-08|2011-04-11|Estimate|||||||2014-10-18|2014-10-21|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation|Clinical Study on Hyperlipidemia and Comparative Evaluation of Efficacy of a Compound Unani Formulation (Safoof e Muhazzil) and Compressed Tablet of Safoof e Muhazzil in Its Management|Completed||Phase 2|128|Actual|Jamia Hamdard University||3|||f||||t||||||||||2018-05-31 22:43:03.390828|2018-05-31 22:43:03.390828
NCT01332734|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-04|2011-04-04|2011-04-11|Estimate|||||||2011-04-04|2011-04-11|Estimate|March 2010||2010-03-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Observational|||Microcirculatory Changes During Magnesium Sulphate Infusion in Sepsis|Microcirculatory Changes During Open Label Magnesium Sulphate Infusion in Severe Sepsis and Septic Shock|Completed|||14|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||||2018-05-31 22:43:03.463099|2018-05-31 22:43:03.463099
NCT01332721|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2014-02-12||2014-02-12|2011-04-08|2011-04-11|Estimate|2014-02-12|2014-03-28|Estimate||||2014-02-12|2014-03-28|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional|||Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated|An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors|Completed||Phase 1|38|Actual|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 22:43:03.672399|2018-05-31 22:43:03.672399
NCT01332708|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-04-08|2011-04-08|2011-04-11|Estimate|||||||2011-04-08|2011-04-11|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Interventional|Choliner stat||Cholinergic Status and the Metabolic Syndrome|Cholinergic Status and the Metabolic Syndrome|Unknown status|Not yet recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-05-31 22:43:03.902462|2018-05-31 22:43:03.902462
NCT01332695|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-01-04|2011-04-08|2011-04-11|Estimate|||||||2012-01-04|2012-01-06|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Pilot Efficacy and Safety Study of ST101 in Essential Tremor|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor|Completed||Phase 2|25|Actual|Sonexa Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 22:43:04.01895|2018-05-31 22:43:04.01895
NCT01332682|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2015-05-09|2011-04-08|2011-04-11|Estimate|||||||2015-05-09|2015-05-12|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Resistance Training and Physical Functioning in Head and Neck Cancer Patients|Resistance Training and Physical Functioning in Head and Neck Cancer Patients|Completed||Phase 1|18|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 22:43:04.091253|2018-05-31 22:43:04.091253
NCT01332669|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2015-05-19|2011-04-08|2011-04-11|Estimate|||||||2015-05-19|2015-05-20|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|December 2013|Actual|2013-12-31||Interventional|REDEBUT||Drug-eluting Bead in Hepatocellular Carcinoma|Multicenter Registry of Chemoembolization Using Drug-eluting Bead in Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 4|200|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:43:04.230231|2018-05-31 22:43:04.230231
NCT01332656|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07||2015-11-18|2015-11-18|2011-04-07|2011-04-11|Estimate||||2015-11-18|2015-12-21|Estimate|2015-11-18|2015-12-21|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|OPSALIN||Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel|A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel|Completed||Phase 2|154|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:43:04.349461|2018-05-31 22:43:04.349461
NCT01332643|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-05-25|2011-04-08|2011-04-11|Estimate|||||||2012-05-25|2012-05-30|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|||Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy|Comparison of Single Embryo Transfer With and Without Previous Analysis of All Chromosome Abnormalities Using Microarrays|Terminated||Phase 3|120|Anticipated|Reprogenetics||2||Not enough patients enrolling|f||||t||||||||||2018-05-31 22:43:04.536419|2018-05-31 22:43:04.536419
NCT01332630|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-04-19|2011-04-08|2011-04-11|Estimate|||||||2017-04-19|2017-04-20|Actual|August 16, 2011|Actual|2011-08-16|April 2017|2017-04-30|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|||TPI 287 in Breast Cancer Metastatic to the Brain|A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain|Completed||Phase 2|24|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:43:04.613187|2018-05-31 22:43:04.613187
NCT01332617|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-12-27|2011-04-08|2011-04-11|Estimate|||||||2017-12-27|2017-12-29|Actual|April 2011||2011-04-30|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Phase II Study of Simvastatin for Relapsed/Refractory Myeloma|Phase II Study of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine and Methylprednisolone for Relapsed/Refractory Myeloma|Withdrawn||Phase 2|0|Actual|University of Louisville||1||Investigators no longer interested in activating study|f||||t||||||||||2018-05-31 22:43:04.698899|2018-05-31 22:43:04.698899
NCT01332604|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-11-01|2011-04-08|2011-04-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors|A Phase Ib, Open Label, Dose Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors|Completed||Phase 1|41|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:43:04.772826|2018-05-31 22:43:04.772826
NCT01332591|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-12-31|2011-04-01|2011-04-11|Estimate|||||||2014-12-31|2015-01-01|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Prague-13||Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy.|Multivessel Coronary Disease Diagnosed at the Time of Primary PCI for STEMI: Complete Revascularization Versus Conservative Strategy. PRAGUE - 13 Trial|Completed||N/A|213|Actual|St. Anne's University Hospital Brno, Czech Republic||2|||f||||t||||||||||2018-05-31 22:43:04.850756|2018-05-31 22:43:04.850756
NCT01332578|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2013-07-18||2015-05-28|2011-04-07|2011-04-11|Estimate|2015-05-28|2015-06-01|Estimate||||2015-05-28|2015-06-01|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies|A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies|Completed||Phase 4|25|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:43:04.933172|2018-05-31 22:43:04.933172
NCT01332565|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2011-06-23|2011-04-07|2011-04-11|Estimate|||||||2011-06-23|2011-06-27|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects|An Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects|Completed||Phase 1|10|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 22:43:05.290245|2018-05-31 22:43:05.290245
NCT01332552|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-07-05|2011-04-07|2011-04-11|Estimate|||||||2017-07-05|2017-07-07|Actual|January 14, 2011|Actual|2011-01-14|July 2017|2017-07-31|April 6, 2011|Actual|2011-04-06|April 6, 2011|Actual|2011-04-06||Interventional|||A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects|A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects|Terminated||Phase 1|27|Actual|GlaxoSmithKline||3||Terminated due to unfavorable human pharmacokinetic properties|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:43:05.411805|2018-05-31 22:43:05.411805
NCT01332539|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2013-05-23|2011-04-07|2011-04-11|Estimate|||||||2013-05-23|2013-05-27|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy|An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy|Completed|||240|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:43:05.510712|2018-05-31 22:43:05.510712
NCT01332526|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2011-04-15|2011-04-08|2011-04-11|Estimate|||||||2011-04-15|2011-04-18|Estimate|May 2011||2011-05-31|March 2011|2011-03-31||||||||Observational|||FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).|The Oral Fructose Load Test and Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease With Comparison With Healthy Controls.|Unknown status|Not yet recruiting||70|Anticipated|Collegium Medicum w Bydgoszczy|||7||f||||||||||||||2018-05-31 22:43:05.563879|2018-05-31 22:43:05.563879
NCT01332513|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2018-05-17|2011-04-07|2011-04-11|Estimate|||||||2018-05-17|2018-05-18|Actual|February 10, 2011|Actual|2011-02-10|May 2018|2018-05-31|May 23, 2011|Actual|2011-05-23|May 23, 2011|Actual|2011-05-23||Interventional|||An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.|An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.|Completed||Phase 1|36|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:43:05.618332|2018-05-31 22:43:05.618332
NCT01332500|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2011-03-21||2017-05-25|2011-03-24|2011-04-11|Estimate|2011-03-24|2011-04-11|Estimate||||2017-05-25|2017-05-30|Actual|July 2009||2009-07-31|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Treximet ™ Pharmacy Budget Impact Model Database Validation Study|Treximet ™ Pharmacy Budget Impact Model Database Validation Study|Completed|||61737|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 22:43:05.725396|2018-05-31 22:43:05.725396
NCT01332487|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2012-02-16||2017-05-25|2011-04-07|2011-04-11|Estimate|2012-02-16|2012-02-29|Estimate||||2017-05-25|2017-06-19|Actual|August 2010||2010-08-31|May 2017|2017-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia|Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia|Completed|||4068|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 22:43:06.341961|2018-05-31 22:43:06.341961
NCT01332474|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-06-06|2011-04-07|2011-04-11|Estimate|||||||2017-06-06|2017-06-07|Actual|May 2010||2010-05-31|June 2017|2017-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||JCP Study of Investigation of Patient Background Characteristics|BOTOX®(BOTOX is a Registered Trade Mark of Allergan, Inc) Injection 50 and 100 Treatment of Equinus Foot Due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older: Investigation of Patient Background Characteristics|Completed|||326|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:06.593484|2018-05-31 22:43:06.593484
NCT01332461|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2011-03-18||2017-06-01|2011-03-18|2011-04-11|Estimate|2011-03-18|2011-04-11|Estimate||||2017-06-01|2017-06-27|Actual|November 2009||2009-11-30|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies|Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies|Completed|||5677|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:06.654073|2018-05-31 22:43:06.654073
NCT01332448|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-06-01|2011-04-07|2011-04-11|Estimate|||||||2017-06-01|2017-06-02|Actual|February 2010||2010-02-28|June 2017|2017-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials|Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials|Completed|||1|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 22:43:06.935283|2018-05-31 22:43:06.935283
NCT01332435|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2011-04-14||2017-06-01|2011-04-07|2011-04-11|Estimate|2011-06-23|2011-07-22|Estimate||||2017-06-01|2017-06-27|Actual|November 2009||2009-11-30|June 2017|2017-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use|Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use|Completed|||6896|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 22:43:07.022934|2018-05-31 22:43:07.022934
NCT01332422|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-07-03|2011-04-07|2011-04-11|Estimate|||||||2014-07-03|2014-07-08|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)|Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)|Completed|||300|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:07.411757|2018-05-31 22:43:07.411757
NCT01332409|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2013-06-06|2011-04-07|2011-04-11|Estimate|||||||2013-06-06|2013-06-10|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Observational|||Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)|Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)|Completed|||2000|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:07.465572|2018-05-31 22:43:07.465572
NCT01332396|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-04-25|2011-04-07|2011-04-11|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2009||2009-06-30|April 2017|2017-04-30|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Observational|||Drug Use Investigation for TYKERB Tablet (All Case Investigation)|Drug Use Investigation for TYKERB Tablet (All Case Investigation)|Completed|||4054|Actual|Novartis|||1||f||||f||||||||||2018-05-31 22:43:07.549829|2018-05-31 22:43:07.549829
NCT01332383|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2015-08-10|2011-04-07|2011-04-11|Estimate|||||||2015-08-10|2015-08-13|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Special Drug Use Investigation for AMERGE® Tablet (Long-term)|Special Drug Use Investigation for AMERGE Tablet (Long-term)|Completed|||300|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:07.605746|2018-05-31 22:43:07.605746
NCT01332370|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-06-01|2011-04-07|2011-04-11|Estimate|||||||2017-06-01|2017-06-02|Actual|December 2009||2009-12-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone|Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone|Completed|||5391|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:07.669438|2018-05-31 22:43:07.669438
NCT01332357|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2011-09-08||2017-06-06|2011-04-07|2011-04-11|Estimate|2011-09-08|2011-10-13|Estimate||||2017-06-06|2017-07-06|Actual|June 2009||2009-06-30|June 2017|2017-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit|Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit|Completed|||6139|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 22:43:07.745202|2018-05-31 22:43:07.745202
NCT01332344|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-06-01|2011-04-07|2011-04-11|Estimate|||||||2017-06-01|2017-06-02|Actual|June 2009||2009-06-30|June 2017|2017-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids|Comparison of Healthcare Utilization and Costs in Patients With Asthma Who Fluticasone/Salmeterol Inhalation Powder Versus Other Inhaled Corticosteroid(s) in Typical Clinical Practice Using Health Insurance Claims Data.|Completed|||5180|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:07.876444|2018-05-31 22:43:07.876444
NCT01332331|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2018-05-29|2011-04-07|2011-04-11|Estimate|||||||2018-05-29|2018-05-30|Actual|January 4, 2011|Actual|2011-01-04|May 2018|2018-05-31|November 19, 2018|Anticipated|2018-11-19|November 19, 2018|Anticipated|2018-11-19||Interventional|||Efficacy and Safety of Ambrisentan in Children 8-18yrs|A Randomized, Open Label Study Comparing Safety and Efficacy Parameters for a High and a Low Dose of Ambrisentan (Adjusted for Body Weight) for the Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years|Suspended||Phase 2|66|Anticipated|GlaxoSmithKline||2||Ongoing juvenile rat toxicology studies.|f||||t||||||||||2018-05-31 22:43:07.950325|2018-05-31 22:43:07.950325
NCT01332318|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2011-04-22||2013-07-15|2011-04-07|2011-04-11|Estimate|2011-06-02|2011-06-28|Estimate||||2013-07-15|2013-07-26|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|XP083|There was one randomized participant (in the GEn 1200 mg and DPH Placebo group) who did not meet the criteria for inclusion in the Safety Population.|Simulated Driving Study in Restless Legs Syndrome|A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome|Completed||Phase 2|130|Actual|XenoPort, Inc.||4|||f||||t||||||||||2018-05-31 22:43:08.130122|2018-05-31 22:43:08.130122
NCT01332305|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2011-04-28||2013-07-15|2011-04-07|2011-04-11|Estimate|2011-04-28|2011-05-26|Estimate||||2013-07-15|2013-07-22|Estimate|January 2007||2007-01-31|May 2011|2011-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|XP081||Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Efficacy, Safety, and Pharmacokinetics of XP13512 (GSK1838262) in Patients With Restless Legs Syndrome|Completed||Phase 2|217|Actual|XenoPort, Inc.||5|||f||||f||||||||||2018-05-31 22:43:09.332782|2018-05-31 22:43:09.332782
NCT01332292|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2013-06-06|2012-03-15|2017-02-20|2011-04-07|2011-04-11|Estimate|2013-09-12|2013-09-16|Estimate|2012-03-15|2012-03-19|Estimate|2017-02-20|2017-03-23|Actual|May 2010||2010-05-31|February 2017|2017-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients|A Randomized, Double-blind, Placebo-controlled, Two-way Crossover 14-day Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled Fluticasone Furoate 100ug (Micrograms) in Children Aged 5-11 Years With Persistent Asthma|Completed||Phase 2|27|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:43:09.8927|2018-05-31 22:43:09.8927
NCT01332279|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2016-03-01|2011-04-07|2011-04-11|Estimate|||||||2016-03-01|2016-03-03|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy|A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer|Withdrawn||Phase 1|0|Actual|Fox Chase Cancer Center||1||Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients.|f||||f||||||||||2018-05-31 22:43:10.803115|2018-05-31 22:43:10.803115
NCT01332266|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-12-13|2011-04-08|2011-04-11|Estimate|||||||2017-12-13|2017-12-15|Actual|May 2011|Actual|2011-05-31|December 2017|2017-12-31|August 26, 2017|Actual|2017-08-26|May 2014|Actual|2014-05-31||Interventional|||E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1/Phase 2|95|Actual|Eisai Inc.||2|||f||||f|t|||||||||2018-05-31 22:43:10.940934|2018-05-31 22:43:10.940934
NCT01332253|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2016-05-10|2014-02-03|2016-09-15|2011-04-07|2011-04-11|Estimate|2016-09-15|2016-11-03|Estimate|2014-02-03|2014-03-06|Estimate|2016-09-15|2016-11-03|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Trial of the Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy|Completed||Phase 3|161|Actual|Cumberland Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:43:11.146029|2018-05-31 22:43:11.146029
NCT01332240|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-10-18|2011-04-08|2011-04-11|Estimate|||||||2011-10-18|2011-10-19|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|July 2013|Anticipated|2013-07-31|April 2013|Anticipated|2013-04-30||Interventional|EVITA||External ValidatIon Trial of ASTER Trial|External ValidatIon Trial of Aster: the Need for Surgical Staging After Echo-endoscopic Mediastinal Staging in Clinical N2/3 Lung Cancer|Unknown status|Recruiting|N/A|255|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:43:11.772682|2018-05-31 22:43:11.772682
NCT01332227|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2014-09-19||2015-02-02|2011-04-08|2011-04-11|Estimate|2014-10-15|2014-10-16|Estimate||||2015-02-02|2015-02-19|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|SPARTAN|All participants who received study drug|Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients|An Open-Label, Randomized Study Evaluating a Switch From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen Plus Any Third Agent to Either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on Their Present Treatment Regimen.|Completed||Phase 4|132|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 22:43:11.922916|2018-05-31 22:43:11.922916
NCT01332214|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-11-18|2011-04-07|2011-04-11|Estimate|||||||2011-11-18|2011-11-21|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses|A Randomised, Single-blind, Placebo-controlled Single-centre Phase I Study in Healthy Male Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses|Completed||Phase 1|90|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:43:12.435773|2018-05-31 22:43:12.435773
NCT01332201|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2015-06-12|2011-04-07|2011-04-11|Estimate|||||||2015-06-12|2015-06-16|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®|A Phase II, Open Label, Parallel Group, Multi-center Study to Compare the Pharmacokinetics of Tacrolimus in Adult Subjects Undergoing Primary Allograft Transplantation Receiving an Advagraf® or Prograf® Based Immunosuppressive Regimen, Including a Long-term Follow-up|Completed||Phase 2|17|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-05-31 22:43:12.497849|2018-05-31 22:43:12.497849
NCT01332188|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2017-06-28|2012-07-10|2017-07-31|2011-04-08|2011-04-11|Estimate|2017-07-31|2017-08-30|Actual|2012-07-10|2012-07-19|Estimate|2017-07-31|2017-08-30|Actual|April 2011||2011-04-30|July 2017|2017-07-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|AC-170||Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model|A Single Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy of Three Different Concentrations of Cetirizine (0.05%, 0.1%, and 0.24%) Ophthalmic Solution Versus Vehicle in the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model (CAC)|Completed||Phase 2/Phase 3|101|Actual|Aciex Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 22:43:12.602964|2018-05-31 22:43:12.602964
NCT01332175|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2012-08-15|2011-04-07|2011-04-08|Estimate|||||||2012-08-15|2012-08-16|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal|The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal: a Randomised Controlled Trial.|Completed||N/A|67|Actual|University of Zurich||3|||f||||f||||||||||2018-05-31 22:43:15.342872|2018-05-31 22:43:15.342872
NCT01332162|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2016-10-19|2011-04-07|2011-04-08|Estimate|||||||2016-10-19|2016-10-20|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CARDIO-HCM||CArdiac Desynchronization In Obstructive HCM, CARDIO-HCM|CArdiac Desynchronization In Obstructive Hypertrophic CardioMyopathy|Recruiting||Phase 2|80|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 22:43:15.460777|2018-05-31 22:43:15.460777
NCT01332149|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2015-03-23||2015-06-01|2011-04-07|2011-04-08|Estimate|2015-06-01|2015-06-19|Estimate||||2015-06-01|2015-06-19|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional||The Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study medication.|Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy|An 11-week Randomized, Double-blind, Multi Center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (300 Mg/Day) Using A Fixed Dosing Schedule In The Treatment Of Subjects S With Pain Associated With Diabetic Peripheral Neuropathy.|Completed||Phase 3|626|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:43:15.715856|2018-05-31 22:43:15.715856
NCT01332136|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2016-03-28|2011-04-07|2011-04-08|Estimate|||||||2016-03-28|2016-03-29|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Determinants of Medical and Surgical Treatment Outcomes in Chronic Sinusitis|Determinants of Medical and Surgical Treatment Outcomes in Chronic Sinusitis|Completed|||966|Actual|Oregon Health and Science University|||2||f||||f||||||Samples Without DNA|"~     Sinonasal mucosal tissue specimens~   "|||2018-05-31 22:43:17.145379|2018-05-31 22:43:17.145379
NCT01332123|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2014-05-21||2016-06-07|2011-04-07|2011-04-08|Estimate|2016-06-07|2016-06-09|Estimate||||2016-06-07|2016-06-09|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||Biomechanical Assessment of Gait in Lower-Extremity-Amputees|Biomechanical Assessment of Gait in Lower-Extremity-Amputees|Completed||N/A|10|Actual|University of Wisconsin, Milwaukee||1|||f||||f||||||||||2018-05-31 22:43:17.225683|2018-05-31 22:43:17.225683
NCT01332110|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-02-18|2011-04-07|2011-04-08|Estimate|||||||2014-02-18|2014-02-19|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Treatment for Patellofemoral Pain Syndrome Using Footwear|Treatment for Patellofemoral Pain Syndrome Using Knee Abduction Moment-Reducing Footwear|Completed||Phase 1/Phase 2|36|Actual|University of Calgary||2|||f||||||||||||||2018-05-31 22:43:17.535018|2018-05-31 22:43:17.535018
NCT01332097|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-02-19|2011-04-07|2011-04-08|Estimate|||||||2014-02-19|2014-02-20|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety & Efficacy of BCT197A2201 in Chronic Obstructive Pulmonary Disease (COPD) Patients Presenting With an Exacerbation|An Exploratory, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy, Safety and Tolerability of a Single and a Repeated Dose of Oral BCT197 in Patients With an Acute COPD Exacerbation|Completed||Phase 2|183|Actual|Novartis||9|||f||||||||||||||2018-05-31 22:43:17.62053|2018-05-31 22:43:17.62053
NCT01332084|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2012-06-21|2011-04-07|2011-04-08|Estimate|||||||2012-06-21|2012-06-22|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Use of Hypoallergenic (H.A.) Cereals in Children With Diagnosed Allergy to Wheat|Assessment of the Feasibility of a SOTI With Hypoallergenic (H.A.) Cereals in Children With Diagnosed IgE-mediated Allergy to Wheat|Completed||N/A|9|Actual|Nestlé||1|||f||||f||||||||||2018-05-31 22:43:17.76511|2018-05-31 22:43:17.76511
NCT01332071|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2011-03-17||2017-06-14|2011-03-17|2011-04-08|Estimate|2011-03-17|2011-04-08|Estimate||||2017-06-14|2017-07-12|Actual|November 24, 2009|Actual|2009-11-24|June 2017|2017-06-30|December 6, 2009|Actual|2009-12-06|December 6, 2009|Actual|2009-12-06||Interventional|||Avandamet Bioequivalence Study Brazil - Fed Administration|Assessment of Relative Bioavailability of Avandamet 4 mg + 1000 mg (GSK) in the Form of Film Coated Tablets Versus Avandamet 2 mg + 500 mg (GSK) in the Form of Film Coated Tablets, in Healthy Volunteers After Feeding Standardized, Using Liquid Chromatography.|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:43:17.917817|2018-05-31 22:43:17.917817
NCT01332058|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-07-18|2011-04-07|2011-04-08|Estimate|||||||2012-07-18|2012-07-20|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Motivational Interviewing (MI) for African Americans With Peripheral Arterial Disease (PAD) Pilot|Promoting Walking in African Americans With Peripheral Arterial Disease|Completed||N/A|2|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 22:43:18.237444|2018-05-31 22:43:18.237444
NCT01332045|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2012-01-18|2011-04-07|2011-04-08|Estimate|||||||2012-01-18|2012-01-19|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Continuous Saphenous Nerve Block for Total Knee Arthroplasty|Continuous Saphenous Nerve Block (Adductor Channel) and Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty|Completed||N/A|40|Actual|Frederiksberg University Hospital||2|||f||||t||||||||||2018-05-31 22:43:18.305196|2018-05-31 22:43:18.305196
NCT01332019|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2016-09-28||2016-11-17|2011-04-07|2011-04-08|Estimate|2016-11-17|2017-01-13|Estimate||||2016-11-17|2017-01-13|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ATTAIN|Intent-to-treat (ITT) population: who entered Study 105MS302 and received at least 1 dose of study treatment.|Long-Term Safety and Efficacy Study of Peginterferon Beta-1a|A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis|Completed||Phase 3|1077|Actual|Biogen||2|||f||||t||||||||||2018-05-31 22:43:18.542632|2018-05-31 22:43:18.542632
NCT01332006|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2015-12-31|2011-04-07|2011-04-08|Estimate|||||||2015-12-31|2016-01-01|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Intra-bone Cord Blood Transplantation|Intra-bone Cord Blood Transplantation for Hematological Malignancies Lacking a HLA Suitable Donor|Unknown status|Recruiting|Phase 2|17|Anticipated|Università degli Studi di Brescia||1|||f||||f||||||||||2018-05-31 22:43:20.25649|2018-05-31 22:43:20.25649
NCT01331993|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-10-17|2011-04-07|2011-04-08|Estimate|||||||2011-10-17|2011-10-18|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation|A Phase I, Open-label, Randomised, 3-way Crossover Study to Demonstrate Bioequivalence of a Single Oral Dose of Naproxen Administered as VIMOVO Manufactured at AstraZeneca AB Compared to That of VIMOVO Manufactured by Patheon Pharmaceuticals and a Marketed Enteric-coated Naproxen Formulation (Manufactured by Roche) in Healthy Volunteers|Completed||Phase 1|36|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 22:43:20.329641|2018-05-31 22:43:20.329641
NCT01331980|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2015-07-02|2011-04-07|2011-04-08|Estimate|||||||2015-07-02|2015-07-03|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls|Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls|Completed|||39|Actual|University of Arkansas|||2||f||||t||||||Samples Without DNA|"~     Serum samples will be frozen and assayed together.~   "|||2018-05-31 22:43:20.501322|2018-05-31 22:43:20.501322
NCT01331967|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2014-03-01|2011-04-07|2011-04-08|Estimate|||||||2014-03-01|2014-03-04|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT)||Completed||Phase 4|94|Anticipated|Korea University Anam Hospital||1|||f||||||||||||||2018-05-31 22:43:20.576921|2018-05-31 22:43:20.576921
NCT01331954|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2018-05-25|2011-04-07|2011-04-08|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2011|Actual|2011-03-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU): a Feasibility Study|Active, not recruiting||N/A|20|Anticipated|Theraclion||1|||f||||||||||||||2018-05-31 22:43:20.646101|2018-05-31 22:43:20.646101
NCT01331941|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2017-11-01|2011-04-07|2011-04-08|Estimate|||||||2017-11-01|2017-11-06|Actual|September 19, 2011|Actual|2011-09-19|November 2017|2017-11-30||||February 26, 2013|Actual|2013-02-26||Interventional|||A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function|An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function|Completed||Phase 1|35|Actual|Amgen||4|||f||||||||||||||2018-05-31 22:43:20.715722|2018-05-31 22:43:20.715722
NCT01331928|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||January 2013|Anticipated|2013-01-31||Interventional|||Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer|A Phase II Study of Sequential Capecitabine Plus Oxaliplatin (XELOX) Followed by Docetaxel Plus Capecitabine (TX) in Patients With Unresectable Gastric|Unknown status|Recruiting|Phase 2|51|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f||||f||||||||||2018-05-31 22:43:20.80054|2018-05-31 22:43:20.80054
NCT01331915|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-10-08|2011-04-07|2011-04-08|Estimate|||||||2012-10-08|2012-10-10|Estimate|September 2010||2010-09-30|October 2012|2012-10-31||||October 2013|Anticipated|2013-10-31||Interventional|THERAVAC||Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients|Phase I/II Study of Therapeutic Vaccination With Escalating Doses of Theravac®, a Proteinic Vector Targeting Dendritic Cells Coupled to a Melanoma Antigen, in Patients With Advanced Metastatic Melanoma.|Unknown status|Recruiting|Phase 1/Phase 2|23|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||||||||||||2018-05-31 22:43:20.872645|2018-05-31 22:43:20.872645
NCT01331902|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement||Unknown status|Recruiting|Phase 4|200|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:43:20.954812|2018-05-31 22:43:20.954812
NCT01331889|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2016-07-06|2011-04-07|2011-04-08|Estimate|||||||2016-07-06|2016-07-11|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2015|Actual|2015-03-31||Observational|||Effect of Rapid Transfusion With Fluid Management System (FMS) on Plasma Potassium in Liver Transplantation Recipients|Potassium Change in the Fluid Management System (FMS) Reservoir and Its Effect on the Plasma Potassium Concentration During Liver Transplantation Surgery|Completed|||10|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 22:43:21.035044|2018-05-31 22:43:21.035044
NCT01331876|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-10-01|2011-04-07|2011-04-08|Estimate|||||||2012-10-01|2012-10-02|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|TOC TOC||Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy|Evaluation and Comparison of Cerebral Activities Modifications Associated With Two Different Cognitive and Behavioral Therapies for Obsessive Compulsive Disorder Patients|Completed||N/A|35|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 22:43:21.098185|2018-05-31 22:43:21.098185
NCT01331863|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2017-08-28|2011-04-07|2011-04-08|Estimate|||||||2017-08-28|2017-08-29|Actual|May 31, 2011|Actual|2011-05-31|August 2017|2017-08-31|November 30, 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|TRACHBRONCAR||Airway and/or Pulmonary Vessels Transplantation|Replacement of the Airways and/or the Pulmonary Vessels Using a Cryopreserved Arterial Allograft|Recruiting||Phase 1/Phase 2|30|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 22:43:21.165369|2018-05-31 22:43:21.165369
NCT01331850|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28||2016-07-08|2016-11-01|2011-04-07|2011-04-08|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C|A Randomized Open-label Study to Evaluate the Sustained Virologic Response of Danoprevir/Ritonavir and Copegus in Combination With RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed Previous Standard Therapy|Completed||Phase 2|381|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 22:43:21.253965|2018-05-31 22:43:21.253965
NCT01331837|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2017-03-24||2017-06-13|2011-04-07|2011-04-08|Estimate|2017-06-13|2017-07-13|Actual||||2017-06-13|2017-07-13|Actual|August 2, 2011|Actual|2011-08-02|June 2017|2017-06-30|March 25, 2016|Actual|2016-03-25|March 25, 2016|Actual|2016-03-25||Interventional||Analysis was conducted on the Intention to treat (ITT) population, i.e. all patients randomized who have taken at least one dose of study medication.|A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors|A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) in Comparison With Etanercept (ETA) on the Rate of Cardiovascular Events in Patients With Moderate to Severe Rheumatoid Arthritis (RA)|Completed||Phase 4|3080|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:43:21.511561|2018-05-31 22:43:21.511561
NCT01331824|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2015-10-15||2018-03-22|2011-04-07|2011-04-08|Estimate|2015-11-21|2015-12-24|Estimate||||2018-03-22|2018-04-23|Actual|February 2011||2011-02-28|March 2018|2018-03-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|||Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma|Multi-Center Phase 2 Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma|Terminated||Phase 2|22|Actual|Icahn School of Medicine at Mount Sinai|The trial was terminated prematurely due to the results of a phase 3 study seeking registration for amrubicin in small cell lung cancer in the United States, leading the industry funder to discontinue further clinical development of amrubicin.|1||due to a development decision by the funder|f||||t||||||||||2018-05-31 22:43:24.061003|2018-05-31 22:43:24.061003
NCT01331811|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-08-04|2011-04-07|2011-04-08|Estimate|||||||2015-08-04|2015-08-05|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)|Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam) and Africa (Burkina Faso, Cameroon) ANRS 12229 PAANTHER 01 (Pediatric Asian African Network for Tuberculosis and HIV Research)|Completed||N/A|441|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||||2018-05-31 22:43:24.268341|2018-05-31 22:43:24.268341
NCT01331798|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|December 2009||2009-12-31|April 2011|2011-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of Cohera TissuGlu in the Management of Wound Drainage Following Abdominoplasty|Clinical Evaluation of the Cohera TissuGlu Device in the Management of Wound Drainage Following Abdominoplasty|Completed||Phase 1/Phase 2|40|Actual|Cohera Medical, Inc.||2|||f||||t||||||||||2018-05-31 22:43:25.360468|2018-05-31 22:43:25.360468
NCT01331785|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2013-07-29|2011-04-07|2011-04-08|Estimate|||||||2013-07-29|2013-07-31|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis|Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis|Withdrawn||N/A|0|Actual|The Cleveland Clinic||1||Lack of enrollment|f||||t||||||||||2018-05-31 22:43:25.427206|2018-05-31 22:43:25.427206
NCT01331772|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2014-10-29|2011-04-07|2011-04-08|Estimate|||||||2014-10-29|2014-10-30|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PASAPAS||Impact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy|Randomized Controlled Study Assessing the Feasibility and the Medico-economic Impact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy|Completed||N/A|60|Anticipated|Centre Leon Berard||2|||f||||f||||||||||2018-05-31 22:43:25.506583|2018-05-31 22:43:25.506583
NCT01331759|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-03-27|2011-04-07|2011-04-08|Estimate|||||||2014-03-27|2014-03-28|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Neuropattern™ for Workplace Health Promotion|Neuropattern™ Stress Diagnostics in Workplace Health Promotion|Completed||N/A|79|Actual|Daacro||2|||f||||t||||||||||2018-05-31 22:43:25.597587|2018-05-31 22:43:25.597587
NCT01331746|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2013-05-15|2011-04-07|2011-04-08|Estimate|||||||2013-05-15|2013-05-16|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Proof-of-concept (PoC) Study of APD515|Randomised, Double-blind, Placebo-controlled Phase II Proof-of-concept Study of APD515 Solution for Oromucosal and Oral Administration for Relief of Xerostomia in Patients With Cancer|Completed||Phase 2|32|Actual|Acacia Pharma Ltd||2|||f||||f||||||||||2018-05-31 22:43:25.689311|2018-05-31 22:43:25.689311
NCT01331733|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Observational|PROMENIA||Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist|Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist Following Two Protocols of Ovulation Induction for Intrauterine Insemination|Completed|||131|Actual|Ferring Pharmaceuticals|||2||f||||f||||||||||2018-05-31 22:43:25.769414|2018-05-31 22:43:25.769414
NCT01331720|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|November 2007||2007-11-30|April 2011|2011-04-30|July 2010|Actual|2010-07-31|March 2009|Actual|2009-03-31||Observational|DESCARTES||Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation|Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation Protocols Which Are the Most Common in Clinical Practice Using High Purified Gonadotrophins (u-FSH-HP y u-hMG-HP) in IVF/ICSI|Completed|||279|Actual|Ferring Pharmaceuticals|||5||f||||f||||||||||2018-05-31 22:43:25.915503|2018-05-31 22:43:25.915503
NCT01331707|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-07-27|2011-04-07|2011-04-08|Estimate|||||||2015-07-27|2015-07-28|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|DUTCH PEERS||DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population|DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2)|Completed||Phase 4|1811|Actual|Cardio Research Enschede BV||2|||f||||t||||||||||2018-05-31 22:43:26.079072|2018-05-31 22:43:26.079072
NCT01331694|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2011-03-10||2017-06-02|2011-03-10|2011-04-08|Estimate|2011-03-10|2011-04-08|Estimate||||2017-06-02|2017-07-02|Actual|July 2009||2009-07-31|August 2011|2011-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||76130|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:26.173842|2018-05-31 22:43:26.173842
NCT01331681|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|2014-08-29|2014-03-31|2016-03-20|2011-04-07|2011-04-08|Estimate|2014-08-29|2014-09-09|Estimate|2014-04-30|2014-05-14|Estimate|2016-03-20|2016-04-19|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|June 2013|Actual|2013-06-30||Interventional|VIVID-DME||Intravitreal Aflibercept Injection in Vision Impairment Due to DME|A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema|Completed||Phase 3|406|Actual|Bayer||3|||f||||t||||||||||2018-05-31 22:43:26.650001|2018-05-31 22:43:26.650001
NCT01331668|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2016-05-10|2011-04-06|2011-04-08|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2004||2004-03-31|May 2016|2016-05-31|December 2099|Anticipated|2099-12-31|December 2099|Anticipated|2099-12-31||Observational|||BIOBANK Renal Transplantation University Hospitals Leuven|Biobank Renal Transplantation University Hospitals Leuven|Recruiting|||5000|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples With DNA|"~     Biopsy material (tissue, RNA, DNA) Peripheral blood samples (serum, plasma, RNA, DNA) Urine~     samples~   "|||2018-05-31 22:43:28.102658|2018-05-31 22:43:28.102658
NCT01331655|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-07|||2014-07-14|2011-04-07|2011-04-08|Estimate|||||||2014-07-14|2014-07-15|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America|A Multicenter, Open-label, 3-arm, Active-controlled, Parallel-group, 1-year Study to Investigate the Efficacy and Safety of a Flexible Regimen of the Combined Oral Contraceptive, With and Without 0.451 mg Levomefolate Calcium (BAY98-7071 and BAY86-5300, Respectively) Versus the Standard 24 + 4 Regimen With Levomefolate (BAY98-7071 + BAY86-7660) and to Assess Compliance With a Device (CADDY) in Healthy Women Who Desire Contraception|Withdrawn||Phase 3|0|Actual|Bayer||3|||f||||f||||||||||2018-05-31 22:43:28.172206|2018-05-31 22:43:28.172206
NCT01331642|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2018-05-18|2011-04-06|2011-04-08|Estimate|||||||2018-05-18|2018-05-21|Actual|April 2011||2011-04-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|BioGaucher||Biomarker for Gaucher Disease|Biomarker for Gaucher Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||200|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 5ml EDTA~     blood and a dry blood spot filter card are taken. To proof the correct Gaucher diagnosis in~     those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing of Gaucher will be done. The analyses are done in the Albrecht-Kossel-Institute~     for Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 22:43:28.235219|2018-05-31 22:43:28.235219
NCT01331629|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2017-03-13|2011-04-07|2011-04-08|Estimate|||||||2017-03-13|2017-03-14|Actual|July 2010|Actual|2010-07-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|May 2015|Actual|2015-05-31||Interventional|ART-THERAPIE||Impact of Art Therapy on Fatigue and Quality of Life of Patients Treated With Adjuvant Radiotherapy for Breast Cancer|Impact of Art Therapy on Fatigue and Quality of Life of Patients Treated With Adjuvant Radiotherapy for Breast Cancer|Completed||Phase 2/Phase 3|322|Actual|Centre Francois Baclesse||2|||f||||f||||||||||2018-05-31 22:43:28.4033|2018-05-31 22:43:28.4033
NCT01331616|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-21|2011-04-07|2011-04-08|Estimate|||||||2011-04-21|2011-04-22|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|||Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab|A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab|Unknown status|Recruiting|Early Phase 1|10|Anticipated|West Penn Allegheny Health System||1|||f||||t||||||||||2018-05-31 22:43:28.460709|2018-05-31 22:43:28.460709
NCT01331603|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis|Assessment of Labile Plasma Iron (LPI) as an Alternative Parameter for Iron Overload in MDS and Primary Myelofibrosis Patients With Iron Overload and Its Correlations With the Classical Iron Overload Parameters.|Unknown status|Not yet recruiting||50|Anticipated|Wolfson Medical Center|||1||f||||f||||||||||2018-05-31 22:43:28.638279|2018-05-31 22:43:28.638279
NCT01331590|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-09-19|2011-04-06|2011-04-08|Estimate|||||||2016-09-19|2016-09-20|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|||Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia|A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia|Completed||Early Phase 1|13|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 22:43:28.718464|2018-05-31 22:43:28.718464
NCT01331577|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-11-04|2011-04-06|2011-04-08|Estimate|||||||2015-11-04|2015-11-05|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|IKSIT||Comparison of the Efficacy of an Integrative-kinesiological to a Cognitive-behavioural Intervention|Psychoneuroendocrinological Efficacy Study of an Integrative-kinesiological to a Cognitive-behavioural Intervention With Healthy Individuals|Completed||Phase 3|64|Actual|University of Zurich||3|||f||||||||||||||2018-05-31 22:43:28.819386|2018-05-31 22:43:28.819386
NCT01331564|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-11-30|2011-04-06|2011-04-08|Estimate|||||||2015-11-30|2015-12-02|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|eMOMS||eMOMS of Rochester|Electronically-Mediated Weight Interventions for Pregnant and Postpartum Women|Completed||Phase 3|1641|Actual|University of Rochester||3|||f||||t||||||||||2018-05-31 22:43:28.881551|2018-05-31 22:43:28.881551
NCT01331551|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2017-08-14|2011-04-07|2011-04-08|Estimate|||||||2017-08-14|2017-08-16|Actual|May 2010||2010-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|MARS||Mesalamine and Reproductive Health Study|Crossover Study on Human Exposure to Phthalates and Male Fertility|Active, not recruiting|||130|Anticipated|Harvard School of Public Health|||1||f||||f||||||Samples With DNA|"~     Blood for hormones, urine for phthalates, semen for DNA and RNA~   "|Yes|Participants may receive semen and hormone analysis if they desire.|2018-05-31 22:43:28.96329|2018-05-31 22:43:28.96329
NCT01331538|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Observational|||Temporomandibular Dysfunction and Cervical Posture|Correlation Between Temporomandibular Dysfunction and Cervical Posture in Different Occlusal Angle Classes in Adolescents|Completed|||296|Actual|University of Nove de Julho|||2||f||||f||||||||||2018-05-31 22:43:29.031033|2018-05-31 22:43:29.031033
NCT01331525|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2016-04-13|2011-04-07|2011-04-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ICE||The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer|A Phase II Trial of the Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (ICE)|Completed||Phase 2|42|Actual|University Hospital Southampton NHS Foundation Trust||1|||f||||t||||||||Yes||2018-05-31 22:43:29.094305|2018-05-31 22:43:29.094305
NCT01331512|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2018-04-04|2011-04-07|2011-04-08|Estimate|||||||2018-04-04|2018-04-05|Actual|January 31, 2003||2003-01-31|January 2, 2015|2015-01-02|January 2, 2015||2015-01-02|||||Observational|||The InChianti Follow-Up Study|The InChianti Follow-Up Study|Completed|||1167|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:43:29.16891|2018-05-31 22:43:29.16891
NCT01331499|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2012-06-06|2011-04-07|2011-04-08|Estimate|||||||2012-06-06|2012-06-07|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Salient Aquamantys Spine Trial|A Post-Market, Prospective, Multicenter, Randomized Trial Comparing the Use of Standard of Care Blood Sparing Techniques With and Without the Aquamantys System to Facilitate Hemostasis in Subjects Undergoing Multi-level Spinal Fusions|Terminated||Phase 4|12|Actual|Salient Surgical Technologies||2||Study terminated due to Medtronic acquisition|f||||f||||||||||2018-05-31 22:43:29.218032|2018-05-31 22:43:29.218032
NCT01331486|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-02-06|2011-04-07|2011-04-08|Estimate|||||||2013-02-06|2013-02-07|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract|Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract|Completed||Phase 1|24|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-05-31 22:43:29.291804|2018-05-31 22:43:29.291804
NCT01331473|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-12-02|2011-04-06|2011-04-08|Estimate|||||||2011-12-02|2011-12-05|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|PROVENON||PROximal Protection VErsus NON-Protection in Carotid Artery Stenting|PROximal Protection VErsus NON-Protection in Carotid Artery Stenting (PROVENON Study) A Randomized Prospective MRI-based Trial.|Unknown status|Recruiting|Phase 3|220|Anticipated|Saarland University||2|||f||||t||||||||||2018-05-31 22:43:29.412747|2018-05-31 22:43:29.412747
NCT01331460|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2016-08-12|2011-04-06|2011-04-08|Estimate|||||||2016-08-12|2016-08-15|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|IMEDI||HIV and Drug Use in Georgian Women|HIV and Drug Use in Georgian Women|Completed||N/A|128|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:43:29.52613|2018-05-31 22:43:29.52613
NCT01331447|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2018-01-19|2011-04-07|2011-04-08|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2004||2004-05-31|January 2018|2018-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions|A Pilot Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions|Completed||N/A|12|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 22:43:29.742664|2018-05-31 22:43:29.742664
NCT01331434|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2018-01-19|2011-04-07|2011-04-08|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2004||2004-10-31|January 2018|2018-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fed Conditions|Completed||N/A|47|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 22:43:29.811337|2018-05-31 22:43:29.811337
NCT01331421|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2018-01-19|2011-04-07|2011-04-08|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2004||2004-07-31|January 2018|2018-01-31|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Bioequivalency Study of Exemestane 25 mg Tablets Under Fasting Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 22:43:29.866116|2018-05-31 22:43:29.866116
NCT01331408|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-05-31|2011-04-06|2011-04-08|Estimate|||||||2012-05-31|2012-06-01|Estimate|September 2008||2008-09-30|April 2011|2011-04-30|May 2011|Actual|2011-05-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks|An Open, Post-marketing, Multi-center Study to Evaluate Efficacy and Safety of Macrolane VRF30 for Volume Restoration and Contouring of the Buttocks|Completed||Phase 4|61|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 22:43:29.930801|2018-05-31 22:43:29.930801
NCT01331395|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-10-27|2011-04-06|2011-04-08|Estimate|||||||2015-10-27|2015-10-29|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TCM-P002||Effect of Traditional Chinese Medicine on In Vitro Fertilization (IVF) Success Rates|A Randomized, Controlled Clinical Trial of the Effect of Traditional Chinese Medicine on IVF Success Rates|Terminated||N/A|8|Actual|Pacific Fertility Center||2||Enrollment rate slower than anticipated.|f||||f||||||||||2018-05-31 22:43:30.010731|2018-05-31 22:43:30.010731
NCT01331382|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Cerebral Blood Flow Effects of Resveratrol and Piperine in Humans|Effects of Resveratrol Alone or in Combination With Piperine on Cerebral Blood Flow Parameters and Cognitive Performance in Humans|Completed||N/A|23|Actual|Northumbria University||3|||f||||f||||||||||2018-05-31 22:43:30.113523|2018-05-31 22:43:30.113523
NCT01331369|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2017-04-08|2011-04-07|2011-04-08|Estimate|||||||2017-04-08|2017-04-11|Actual|November 2010||2010-11-30|April 2017|2017-04-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|HyperCare||Intensification of Care to Improve Adherence to Anti-hypertensives|Intensification of Care to Improve Adherence to Anti-hypertensives in Primary Care: a Pragmatic Clinical Trial.|Completed||N/A|243|Actual|Universidade de Blumenau||2|||f||||f||||||||||2018-05-31 22:43:30.226556|2018-05-31 22:43:30.226556
NCT01331356|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2013-10-04|2011-04-06|2011-04-08|Estimate|||||||2013-10-04|2013-10-07|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Impartox||Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia|Prospective Multicenter Pilot Study Evaluating the Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia According to the Criteria of Rome III|Completed||Phase 2|18|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 22:43:30.323544|2018-05-31 22:43:30.323544
NCT01331343|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-15|2011-04-06|2011-04-08|Estimate|||||||2011-04-15|2011-04-18|Estimate|June 2004||2004-06-30|April 2011|2011-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Effectiveness Study of the Guardian RT in Type 1 Diabetics|The Guard Control Trial - Randomized, Controlled, Muti-centric, Clinical Study to Assess Whether Type 1 Diabetic Patients in Poor Glycemic Control Can Improve Using the Real-time Values of the Guardian RT Versus Conventional Self-Monitoring Blood Glucose|Completed||Phase 4|156|Actual|Medtronic Diabetes|||||f||||f||||||||||2018-05-31 22:43:30.499631|2018-05-31 22:43:30.499631
NCT01331330|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-05-18|2011-04-06|2011-04-08|Estimate|||||||2015-05-18|2015-05-19|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||European Deep Brain Stimulation (DBS) Depression Study|A Clinical Evaluation of Different Device Parameters for the Management of Patients With Treatment Resistant Major Depressive Disorder, Single or Recurrent Episode, With Deep Brain Stimulation|Completed||N/A|9|Actual|St. Jude Medical||2|||f||||||||||||||2018-05-31 22:43:30.594012|2018-05-31 22:43:30.594012
NCT01331317|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2012-04-12|2011-04-07|2011-04-08|Estimate|||||||2012-04-12|2012-04-13|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy|The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy|Completed||Phase 4|48|Actual|Steno Diabetes Center||1|||f||||t||||||||||2018-05-31 22:43:30.715546|2018-05-31 22:43:30.715546
NCT01331304|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2014-01-08||2018-03-29|2011-04-07|2011-04-08|Estimate|2014-05-23|2014-06-04|Estimate||||2018-03-29|2018-04-26|Actual|September 2010||2010-09-30|March 2018|2018-03-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Comparative Effectiveness Study for Bipolar Disorder|Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer And a Classic Mood Stabilizer for Bipolar Disorder|Completed||Phase 4|482|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:43:30.813214|2018-05-31 22:43:30.813214
NCT01331291|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2016-06-09||2016-06-23|2011-04-06|2011-04-08|Estimate|2016-06-09|2016-06-20|Estimate||||2016-06-23|2016-07-25|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Bosutinib in Adult Patients With Recurrent Glioblastoma|An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)|Completed||Phase 2|36|Actual|Massachusetts General Hospital|This study met pre-specified criteria for early closure, as all 9 patients enrolled on Arm B demonstrated disease progression within 6 months.|2|||f||||t||||||||No||2018-05-31 22:43:31.23596|2018-05-31 22:43:31.23596
NCT01331278|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Interventional|Bake-Off||A Comparative Study of Knee Systems|A Comparative Study of Knee Systems Employing Personalized Computer Generated Cutting Guides for Total Knee Arthroplasty|Completed||Phase 4|60|Actual|Foundation for Southwest Orthopedic Research||2|||f||||t||||||||||2018-05-31 22:43:31.514455|2018-05-31 22:43:31.514455
NCT01331265|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-07|2011-04-07|2011-04-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Perceived Lactose Intolerance|Understanding Perceived Lactose Intolerance in White, Black, and Hispanic Adults|Completed|||3815|Actual|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 22:43:31.572189|2018-05-31 22:43:31.572189
NCT01331252|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-09-14|2011-04-06|2011-04-08|Estimate|||||||2011-09-14|2011-09-15|Estimate|August 2000||2000-08-31|September 2011|2011-09-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|BP||Pneumonia in Tetanus Study|Can the Incidence of Nosocomial Pneumonia in Severe Tetanus be Reduced by Nursing Patients Semi-recumbent? A Randomised Comparison of Supine or Semi-recumbent Body Position|Completed||N/A|200|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||f||||||||||2018-05-31 22:43:31.61516|2018-05-31 22:43:31.61516
NCT01331239|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2017-10-12|2011-04-06|2011-04-08|Estimate|||||||2017-10-12|2017-10-16|Actual|March 23, 2011|Actual|2011-03-23|October 2017|2017-10-31|December 21, 2018|Anticipated|2018-12-21|December 21, 2018|Anticipated|2018-12-21||Interventional|||Safety and Efficacy of LCI699 in Cushing's Disease Patients.|A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease|Active, not recruiting||Phase 2|33|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 22:43:31.673285|2018-05-31 22:43:31.673285
NCT01331226|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2015-04-09|2011-04-06|2011-04-07|Estimate|||||||2015-04-09|2015-04-10|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ClearWay #4||Support Person Intervention to Promote a Smoking Helpline|Support Person Effectiveness Study to Promote Smoker Utilization of the QUITPLAN Helpline|Completed||N/A|1020|Anticipated|Mayo Clinic||3|||f||||f||||||||||2018-05-31 22:43:31.741144|2018-05-31 22:43:31.741144
NCT01331213|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2014-01-17||2014-01-17|2011-04-06|2011-04-07|Estimate|2014-01-17|2014-03-03|Estimate||||2014-01-17|2014-03-03|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome|Effect of Pregabalin on Colonic Motor and Sensory Function in Adults With Irritable Bowel Syndrome With Predominant Constipation|Completed||Phase 4|18|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:43:31.807556|2018-05-31 22:43:31.807556
NCT01331200|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2013-02-25|2011-04-06|2011-04-07|Estimate|||||||2013-02-25|2013-02-27|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|EMISTPA||Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-Tissue Plasminogen Activator (IV-tPA)|Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-tPA Infusion.|Completed|||20|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 22:43:32.179927|2018-05-31 22:43:32.179927
NCT01331187|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-05-31|2011-04-06|2011-04-07|Estimate|||||||2012-05-31|2012-06-01|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Influence of Routinely Adding Ultrasound Screening in Medical Department|Influence on Diagnostics and Inpatient Workflow of Routinely Adding Ultrasound Screening by Pocket-size Ultrasound in a Medical Department|Completed||N/A|600|Actual|Levanger Hospital||2|||f||||t||||||||||2018-05-31 22:43:32.253173|2018-05-31 22:43:32.253173
NCT01331174|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-11-26|2011-04-06|2011-04-07|Estimate|||||||2012-11-26|2012-11-27|Estimate|August 2006||2006-08-31|November 2012|2012-11-30|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|PSW||Pulsed Short Wave in Females With Knee Osteoarthritis|Pulsed Short Wave in Females With Knee Osteoarthritis: A Multicenter, Randomized, Placebo-controlled Clinical Trial|Completed||N/A|121|Actual|Irmandade da Santa Casa de Misericordia de Sao Paulo||3|||f||||f||||||||||2018-05-31 22:43:32.331653|2018-05-31 22:43:32.331653
NCT01331161|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2016-01-19|2013-04-23|2016-01-19|2011-04-06|2011-04-07|Estimate|2016-01-19|2016-02-17|Estimate|2013-04-23|2013-05-01|Estimate|2016-01-19|2016-02-17|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly|Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly|Completed||N/A|77|Actual|Emory University||2|||f||||f||||||||||2018-05-31 22:43:32.402461|2018-05-31 22:43:32.402461
NCT01331148|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2012-03-28|2011-04-06|2011-04-07|Estimate|||||||2012-03-28|2012-03-29|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|December 2011|Actual|2011-12-31||Interventional|SCD Vitamin D||Vitamin D for Sickle Cell|Pilot Study of Vitamin D to Ameliorate Chronic Pain in Sickle Cell Disease|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 22:43:32.687122|2018-05-31 22:43:32.687122
NCT01331135|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2018-05-15|2011-04-06|2011-04-07|Estimate|||||||2018-05-15|2018-05-16|Actual|April 2011||2011-04-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|August 2014|Actual|2014-08-31||Interventional|Aflac ST0901||Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors|Sirolimus in Combination With Metronomic Therapy in Children With Recurrent and Refractory Solid Tumors: A Phase I Study|Active, not recruiting||Phase 1|24|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 22:43:32.78284|2018-05-31 22:43:32.78284
NCT01331122|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2013-03-27|2011-04-06|2011-04-07|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease|A Phase II, Double-Blind, Placebo-Controlled Randomized Crossover Study to Assess the Clinical Benefit and Safety of Droxidopa in the Treatment of Freezing of Gait Symptoms in Patients With Parkinson's Disease|Withdrawn||Phase 1/Phase 2|0|Actual|Chelsea Therapeutics||2||Never initiated. Withdrawn by sponsor.|f||||||||||||||2018-05-31 22:43:32.883355|2018-05-31 22:43:32.883355
NCT01331109|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2013-07-31||2013-07-31|2011-04-06|2011-04-07|Estimate|2013-07-31|2013-09-30|Estimate||||2013-07-31|2013-09-30|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|MyFi|All demographic data was based on the safety population, which consists of 57 patients who took at least 1 dose of open-label milnacipran.|Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia|A Multicenter, Open-label, 52-Week Extension Study to Evaluate the Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia|Terminated||Phase 2|57|Actual|Forest Laboratories|This study was terminated early, resulting in a small number of patients analyzed. Only descriptive statistics were presented.|1|||f||||t||||||||||2018-05-31 22:43:32.970354|2018-05-31 22:43:32.970354
NCT01331096|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||||||Observational|||Tele-Anesthesia - Trans-Continental Anesthesia Compared to Standard Practice|Tele-Anesthesia - Trans-Continental Anesthesia Compared to Standard Practice|Unknown status|Recruiting||200|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||2||f||||t||||||||||2018-05-31 22:43:33.236028|2018-05-31 22:43:33.236028
NCT01331083|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-11-27|2011-04-06|2011-04-07|Estimate|||||||2015-11-27|2015-11-30|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|January 2015|Actual|2015-01-31||Interventional|||A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer|A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer|Completed||Phase 2|68|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-05-31 22:43:33.309295|2018-05-31 22:43:33.309295
NCT01331070|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-08-13|2011-04-06|2011-04-07|Estimate|||||||2013-08-13|2013-08-14|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|CHAOSBOLD||Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging|Central Control of Breathing in Patients With Chronic Obstructive Pulmonary Disease: Identification and Dynamics With Cerebral Functional Magnetic Resonance Imaging|Completed||N/A|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:43:33.383962|2018-05-31 22:43:33.383962
NCT01331057|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-02-02|2011-04-06|2011-04-07|Estimate|||||||2015-02-02|2015-02-03|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|BILINGUISME||"Bilingualism: Validation Of Avicenne's Elal"|"Validation of AVICENNE's ELAL: Instrument of Mother Tongue Assessment and Impact of Familial and Transcultural Factors on Early Bilingualism in Migrants' Children Born in France"|Unknown status|Recruiting||450|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||||2018-05-31 22:43:33.460496|2018-05-31 22:43:33.460496
NCT01331044|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2015-07-26|2011-04-06|2011-04-07|Estimate|||||||2015-07-26|2015-07-28|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RUTF||Ready to Use Therapeutic Food (RUTF) in Severe Malnourished Children|Efficacy and Acceptability of Ready to Use Therapeutic Food (RUTF) in Children Aged 6-24 Months With Severe Acute Malnutrition in Bangladesh|Completed||N/A|224|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||||2018-05-31 22:43:33.551224|2018-05-31 22:43:33.551224
NCT01331031|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|February 2008||2008-02-29|October 2010|2010-10-31|January 2011|Actual|2011-01-31|May 2008|Actual|2008-05-31||Observational|||Parafunctional Habits and Temporomandibular Disorder in Adolescents|Association Between Parafunctional Habits and Signs and Symptoms Temporomandibular Disorder in Adolescents|Completed|||244|Actual|University of Nove de Julho|||1||f||||t||||||||||2018-05-31 22:43:33.648601|2018-05-31 22:43:33.648601
NCT01331018|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2018-03-16|2011-04-06|2011-04-07|Estimate|||||||2018-03-16|2018-03-20|Actual|February 22, 2012|Actual|2012-02-22|March 2018|2018-03-31||||December 31, 2027|Anticipated|2027-12-31||Interventional|||Gene Therapy for Fanconi Anemia|Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)|Recruiting||Phase 1|10|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 22:43:33.710839|2018-05-31 22:43:33.710839
NCT01331005|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2014-12-30||2016-08-25|2011-04-06|2011-04-07|Estimate|2015-01-09|2015-01-16|Estimate||||2016-08-25|2016-08-26|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)|A Phase II Evaluation of Topical Non-steroidal Anti-inflammatories in Eyes With Non Central Involved Diabetic Macular Edema|Completed||Phase 2|125|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 22:43:33.840408|2018-05-31 22:43:33.840408
NCT01330979|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06||2014-02-17|2014-03-25|2011-04-06|2011-04-07|Estimate||||2014-03-25|2014-04-21|Estimate|2014-03-25|2014-04-21|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||24-hour Efficacy of AR-12286|A Phase 2 Open Label Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 2|5|Actual|Aerie Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:43:34.389345|2018-05-31 22:43:34.389345
NCT01330966|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2018-03-22|2011-04-06|2011-04-07|Estimate|||||||2018-03-22|2018-03-23|Actual|April 2011||2011-04-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma|A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma|Completed||Phase 2|47|Actual|Vector Oncology||1|||f||||f||||||||||2018-05-31 22:43:34.442541|2018-05-31 22:43:34.442541
NCT01330953|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-09-26|2011-04-06|2011-04-07|Estimate|||||||2011-09-26|2011-09-28|Estimate|March 2011||2011-03-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A First Human Study of a Ferroportin Antibody|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Healthy Subjects|Completed||Phase 1|48|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 22:43:34.62558|2018-05-31 22:43:34.62558
NCT01330940|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-09-06|2011-04-06|2011-04-07|Estimate|||||||2012-09-06|2012-09-10|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Diet Orange Soda on Urinary Lithogenicity|Effect of Diet Orange Soda on Urinary Lithogenicity|Completed||N/A|12|Actual|VA New York Harbor Healthcare System||2|||f||||f||||||||||2018-05-31 22:43:34.75073|2018-05-31 22:43:34.75073
NCT01330927|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-08-01|2011-04-05|2011-04-07|Estimate|||||||2011-08-01|2011-08-02|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)|A Randomised, Double-blind, Placebo-controlled, Five-way Cross-over Dose Response Study to Determine the Effect of VA106483 on Nocturnal Urine Volume in Elderly Male Subjects With Nocturia and Benign Prostatic Hypertrophy (BPH)|Completed||Phase 1|30|Actual|Vantia Ltd||5|||f||||f||||||||||2018-05-31 22:43:34.813476|2018-05-31 22:43:34.813476
NCT01330914|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2015-12-02||2016-04-12|2011-04-06|2011-04-07|Estimate|2015-12-02|2016-01-07|Estimate||||2016-04-12|2016-05-16|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|April 2014|Actual|2014-04-30||Observational|||Effects of Gastric Bypass Surgery and Calcium Metabolism and the Skeleton|Effects of Gastric Bypass Surgery on Calcium Metabolism and the Skeleton|Completed|||55|Actual|VA Office of Research and Development|||1||f||||f||||||Samples Without DNA|"~     serum, urine~   "|||2018-05-31 22:43:34.895239|2018-05-31 22:43:34.895239
NCT01330901|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-06-03|2011-04-06|2011-04-07|Estimate|||||||2013-06-03|2013-06-04|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|TOPAS||Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis|UsTekinumab for the Treatment Of Patients With Active Ankylosing Spondylitis (TOPAS) - a 28-week, Prospective, Open-label, Proof-of-concept Study|Completed||Phase 2|22|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 22:43:35.113855|2018-05-31 22:43:35.113855
NCT01330888|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-02-18|2011-04-06|2011-04-07|Estimate|||||||2015-02-18|2015-02-19|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Exploring Deployment Stress and Reintegration in Army National Guard Chaplains|Exploring Deployment Stress and Reintegration in Army National Guard Chaplains|Completed|||102|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-05-31 22:43:35.17946|2018-05-31 22:43:35.17946
NCT01330875|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-06-02|2011-04-06|2011-04-07|Estimate|||||||2015-06-02|2015-06-03|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Lumbar Infiltration With Steroids - Effects on Pain Reduction|Lumbar Infiltration With Steroids - Effects on Pain Reduction|Completed|||60|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 22:43:35.313127|2018-05-31 22:43:35.313127
NCT01330862|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-12-11|2011-04-06|2011-04-07|Estimate|||||||2012-12-11|2012-12-12|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|EPICLIN||Epidemiological Study to Describe Non-small-cell Lung Carcinoma (NSCLC) Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA|Epidemiological Study to Describe NSCLC Clinical Management Patterns in MENA. Lung-EPICLIN/ KSA|Unknown status|Active, not recruiting||54|Anticipated|AstraZeneca|||||f||||t||||||||||2018-05-31 22:43:35.381848|2018-05-31 22:43:35.381848
NCT01330849|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized Controlled Trial of a Behavior Modification Toolkit in Primary School Children With ADHD Behaviors|Unknown status|Recruiting|N/A|100|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 22:43:35.470842|2018-05-31 22:43:35.470842
NCT01330823|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|June 2006||2006-06-30|April 2011|2011-04-30|July 2010|Anticipated|2010-07-31|October 2009|Anticipated|2009-10-31||Interventional|CARPAN||L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)|L-Carnitine in the Palliative Treatment of Advanced Pancreatic Cancer (CARPAN): a Prospective, Randomised, Placebo Controlled, Double Blinded, Multicentre Trial|Suspended||Phase 3|72|Actual|University Medicine Greifswald||2||"after interims analysis standard errors for inflammatory and nutritional markers varied widely,~   that the power calculation required unattainable goals"|f||||t||||||||||2018-05-31 22:43:35.573621|2018-05-31 22:43:35.573621
NCT01330810|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2017-08-02|2011-04-05|2011-04-07|Estimate|||||||2017-08-02|2017-08-03|Actual|March 2011||2011-03-31|December 2011|2011-12-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Curcumin Pharmacokinetics|Crossover, Multiple Dose Pharmacokinetics of Two Curcumin Formulations in Healthy Volunteers|Completed||Phase 1|12|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:43:35.680358|2018-05-31 22:43:35.680358
NCT01330797|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Observational|||The Effect of Ranibizumab on Eye Lens Opacity in Cases With Age-Related Macular Degeneration|The Effect of Ranibizumab on Eye Lens Opacity in Cases With Age-Related Macular Degeneration|Completed|||13|Actual|Uludag University|||1||f||||t||||||||||2018-05-31 22:43:35.793514|2018-05-31 22:43:35.793514
NCT01330095|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Early Administration of Bifidobacterium to Very Low Birth Weight Infants|Early Administration of Bifidobacterium Bifidum to Very Low Birth Weight Infants: A Pilot Study|Completed||N/A|36|Actual|Tokyo Women's Medical University||2|||f||||f||||||||||2018-05-31 22:43:45.25122|2018-05-31 22:43:45.25122
NCT01330784|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Observational|||Assessment of the Therapeutic Utility of hMG-HP|Assessment of the Therapeutic Utility of hMG-HP Within a Protocol of Controlled Ovarian Hyperstimulation in IVF in Normoresponders Women Undergoing Downregulation With GnRH Antagonist|Completed|||61|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:43:35.86694|2018-05-31 22:43:35.86694
NCT01330771|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Observational|||Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP|Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP Within a Protocol of Controlled Ovarian Hyperstimulation in IVF in Normoresponders Women Undergoing Downregulation With GnRH Antagonist|Completed|||51|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:43:35.929793|2018-05-31 22:43:35.929793
NCT01330758|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-07-28|2011-04-06|2011-04-07|Estimate|||||||2011-07-28|2011-07-29|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females|A Phase I, Randomised, Open-label, Cross-over, Single-centre Study in Healthy Male and Non-fertile Female Volunteers to Determine the Relative Bioavailability of the Phase II Wet Granulation Tablet Formulation Compared to the Phase II/III Roller Compacted Tablet Formulation of AZD8931|Completed||Phase 1|26|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:43:35.994449|2018-05-31 22:43:35.994449
NCT01330745|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2014-09-05|2011-04-06|2011-04-07|Estimate|||||||2014-09-05|2014-09-08|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|MICROCARD||Microcirculation in Cardiac Surgery|Mesenteric Microcirculatory Function Study Through Sublingual Evaluation During Cardiopulmonary Bypass|Completed||N/A|21|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 22:43:36.074414|2018-05-31 22:43:36.074414
NCT01330732|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|December 2008||2008-12-31|August 2008|2008-08-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Observational|||Kyphosis Evaluation Using SPINESCAN®|The Correlation Between Radiological Evaluation of Kyphosis and Evaluation Using SPINESCAN®|Unknown status|Not yet recruiting||50|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-05-31 22:43:36.13314|2018-05-31 22:43:36.13314
NCT01330719|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2018-04-04|2011-04-05|2011-04-07|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2006|Actual|2006-12-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Mechanisms and Treatment Response of Aggressive Periodontitis in Children|Mechanisms and Treatment Response of Aggressive Periodontitis in Children: Aberrant Immunological Phenotypes/Functions in the Progression of AgP|Recruiting||N/A|960|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 22:43:36.201413|2018-05-31 22:43:36.201413
NCT01330706|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|February 2010||2010-02-28|February 2009|2009-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|ribebeva||Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery|Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery|Completed||Phase 4|50|Actual|Universidad Complutense de Madrid||1|||f||||t||||||||||2018-05-31 22:43:36.309507|2018-05-31 22:43:36.309507
NCT01330693|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-08-17|2011-04-06|2011-04-07|Estimate|||||||2015-08-17|2015-08-19|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy|Cortical Excitability: Phenotype and Biomarker in ADHD Therapy|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 22:43:36.397188|2018-05-31 22:43:36.397188
NCT01330680|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|September 2004||2004-09-30|March 2011|2011-03-31|September 2010|Actual|2010-09-30|December 2006|Actual|2006-12-31||Interventional|||Genetic Determinants of Cardiovascular Response to Coffee Drinking|Genetic Determinants of Cardiovascular Response to Coffee Drinking|Completed||N/A|110|Actual|G. d'Annunzio University||2|||f||||t||||||||||2018-05-31 22:43:36.467864|2018-05-31 22:43:36.467864
NCT01330667|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-12-15|2011-04-06|2011-04-07|Estimate|||||||2014-12-15|2014-12-17|Estimate|July 2015||2015-07-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|July 2015|Anticipated|2015-07-31||Interventional|||Effect of Early Limited Formula on Total Serum Bilirubin Among Newborns With Hyperbilirubinemia|Effect of Early Limited Formula on Total Serum Bilirubin Among Newborns With Hyperbilirubinemia|Unknown status|Not yet recruiting|N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:43:36.535121|2018-05-31 22:43:36.535121
NCT01330654|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-06-25|2011-04-06|2011-04-07|Estimate|||||||2012-06-25|2012-06-27|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers|Using Heart Rate Variability to Analyze the Effect of Beta Blockers on Intermediate Risk Patients Undergoing Laparoscopic Surgical Procedures|Withdrawn||N/A|0|Actual|University of California, San Francisco||2||no patients were enrolled. Study was closed prior to study start.|f||||t||||||||||2018-05-31 22:43:36.607911|2018-05-31 22:43:36.607911
NCT01330641|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|September 2008||2008-09-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|||Accuracy of Needle Placement Into The Subacromial Space of The Shoulder|Accuracy of Needle Placement Into The Subacromial Space of The Shoulder|Completed||N/A|75|Actual|University of California, Davis||3|||f||||t||||||||||2018-05-31 22:43:36.678538|2018-05-31 22:43:36.678538
NCT01330628|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2016-05-04||2016-07-19|2011-04-06|2011-04-07|Estimate|2016-05-04|2016-06-15|Estimate||||2016-07-19|2016-08-18|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Interventional|EXCITE ISR||Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis|EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis|Completed||Phase 2/Phase 3|252|Actual|Spectranetics Corporation||2|||f||||f||||||||||2018-05-31 22:43:36.756167|2018-05-31 22:43:36.756167
NCT01330615|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|February 2010||2010-02-28|April 2011|2011-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Efficacy Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA) for Analgesia Prior to Cryotherapy of Verrucae Plantaris|A Double-Blind, Randomized, Placebo-Controlled Trial of Eutectic Lidocaine/Prilocaine Cream 5% (EMLA) for Analgesia Prior to Cryotherapy of Verrucae Plantaris in Adults|Unknown status|Recruiting|N/A|64|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 22:43:37.320768|2018-05-31 22:43:37.320768
NCT01330602|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2013-10-08|2011-04-05|2011-04-07|Estimate|||||||2013-10-08|2013-10-10|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|IMPRESS||Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis|Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onSet Atherosclerosis: The IMPRESS Study- A Multi-centre, Randomised Controlled Trial|Unknown status|Recruiting|N/A|1310|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 22:43:37.398473|2018-05-31 22:43:37.398473
NCT01330589|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2017-10-03|2011-04-06|2011-04-07|Estimate|||||||2017-10-03|2017-10-05|Actual|April 2011|Actual|2011-04-30|October 2017|2017-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|INDUCE-it||Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort|The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel|Withdrawn||N/A|0|Actual|Lancaster General Hospital||2||Inability to enroll subjects and changes in standard of care for PCI|f||||f||||||||||2018-05-31 22:43:37.471448|2018-05-31 22:43:37.471448
NCT01330576|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-03-01|2011-04-05|2011-04-07|Estimate|||||||2012-03-01|2012-03-02|Estimate|August 2010||2010-08-31|March 2012|2012-03-31||||August 2013|Anticipated|2013-08-31||Interventional|CoolNEC||Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis|Therapeutic Controlled Hypothermia in the Treatment of Neonates With Severe Necrotizing Enterocolitis|Unknown status|Recruiting|Phase 2|46|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:43:37.56005|2018-05-31 22:43:37.56005
NCT01330563|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-06-28|2011-04-06|2011-04-07|Estimate|||||||2011-06-28|2011-06-29|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Drug-drug Interaction Study (CKD-501, Ketoconazole)|Drug-Drug Interaction Study to Investigate the Effect of Ketoconazole on the Pharmacokinetic Properties of CKD-501 in Healthy Male Volunteer: Open, Randomised, 2-way Crossover, Clinical Trial|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:43:37.630765|2018-05-31 22:43:37.630765
NCT01330550|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-04-06|2011-04-06|2011-04-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Effect of High Fiber and Sugar Free Biscuits in Prediabetics Population|Effect of High Fiber and Sugar Free Biscuits in Diabetics Population|Unknown status|Recruiting|N/A|60|Anticipated|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 22:43:37.698703|2018-05-31 22:43:37.698703
NCT01330537|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-03-12|2011-04-06|2011-04-07|Estimate|||||||2012-03-12|2012-03-14|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|||||Observational|||Exploring the Visual Sensitivity for Topological Properties in Newborn Infants|Exploring the Visual Sensitivity for Topological Properties in Newborn Infants|Unknown status|Recruiting||80|Anticipated|China Medical University Hospital|||||f||||||||||||||2018-05-31 22:43:37.769653|2018-05-31 22:43:37.769653
NCT01330524|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-04-05|2011-04-05|2011-04-07|Estimate|||||||2011-04-05|2011-04-07|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|November 2011|Anticipated|2011-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo|Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy|Unknown status|Recruiting|Phase 1/Phase 2|16|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 22:43:37.901934|2018-05-31 22:43:37.901934
NCT01330511|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-05|2011-04-05|2011-04-07|Estimate|||||||2011-04-05|2011-04-07|Estimate|January 2005||2005-01-31|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Simplified Diagnostic Algorithm for Evaluation of Neonates With Prenatally Detected Hydronephrosis|Simplified Diagnostic Algorithm for Evaluation of Neonates With Prenatally Detected Hydronephrosis|Completed|||76|Actual|Rush University Medical Center|||4||f||||f||||||||||2018-05-31 22:43:37.972444|2018-05-31 22:43:37.972444
NCT01330498|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2012-01-04|2011-04-05|2011-04-07|Estimate|||||||2012-01-04|2012-01-06|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical|Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical Sample Collection With MRI and Relapse Analysis of a Tysabri Patient Cohort|Completed|||229|Actual|Rocky Mountain MS Research Group, LLC|||1||f||||f||||||Samples Without DNA|"~     Serum for PK/PD, SVCAM back-up samples will be kept.~   "|||2018-05-31 22:43:38.042572|2018-05-31 22:43:38.042572
NCT01330485|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-11-13|2011-04-05|2011-04-07|Estimate|||||||2013-11-13|2013-11-14|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|April 2014|Anticipated|2014-04-30||Interventional|||Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder|Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder|Unknown status|Recruiting|Phase 2|150|Anticipated|Philipps University Marburg Medical Center||3|||f||||f||||||||||2018-05-31 22:43:38.094652|2018-05-31 22:43:38.094652
NCT01330472|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-05-22|2011-04-05|2011-04-07|Estimate|||||||2012-05-22|2012-05-24|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study Of Xanax XR Tablet 3 mg (Sourced From Caguas) Versus Xanax XR Tablet 3 mg (Sourced From Barceloneta) In Healthy Subjects|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:43:38.161626|2018-05-31 22:43:38.161626
NCT01330459|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2012-03-20|2011-04-05|2011-04-07|Estimate|||||||2012-03-20|2012-03-22|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Hydrocodone For Pain Control in First Trimester Surgical Abortion|An Evaluation of Hydrocodone/Acetaminophen for Pain Control in First Trimester Surgical Abortion|Completed||Phase 4|122|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 22:43:38.230097|2018-05-31 22:43:38.230097
NCT01330446|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2017-11-10|2011-04-06|2011-04-07|Estimate|||||||2017-11-10|2017-11-14|Actual|May 2011|Actual|2011-05-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer|Armodafinil for Persistent Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer: a Randomized Phase II Study|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:43:39.312186|2018-05-31 22:43:39.312186
NCT01330433|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2016-07-14||2016-10-24|2011-04-05|2011-04-07|Estimate|2016-07-14|2016-08-25|Estimate||||2016-10-24|2016-12-15|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery|Effects of CoSeal in Reducing Perioperative Bleeding & Adhesions in Pediatric Heart Surgery|Completed||Phase 2|35|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 22:43:39.407225|2018-05-31 22:43:39.407225
NCT01330420|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2013-05-28||2017-10-18|2011-04-05|2011-04-07|Estimate|2013-07-31|2013-10-10|Estimate||||2017-10-18|2017-11-21|Actual|September 2007||2007-09-30|October 2017|2017-10-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||Behavioral Medicine Intervention With Depressed Patients in a Community Health Center Setting|Outcomes and Cost-Effectiveness of a Behavioral Medicine Intervention With Depressed Patients in a Community Health Center Setting|Completed||N/A|28|Actual|Massachusetts General Hospital|4/28 didn't complete both pre/post assessments & thus didn't contribute data for this study & were excluded. It's possible that the 24 completers had a higher degree of motivation & commitment, which enhanced the effectiveness of the intervention.|1|||f||||f||||||||||2018-05-31 22:43:39.795246|2018-05-31 22:43:39.795246
NCT01330407|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-11-18|2011-04-05|2011-04-07|Estimate|||||||2015-11-18|2015-11-20|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|MEEKADEAU||Comparative Assessment of Adjuvant Effect of Cultured Epidermal Autografts Versus Skin Allografts on Wound Healing of Burns Treated With Widely Expanded Skin Autograft Using Meek Micrografting Technique MEEKADEAU|Comparative Assessment of Adjuvant Effect of Cultured Epidermal Autografts Versus Skin Allografts on Wound Healing of Burns Treated With Widely Expanded Skin Autograft Using Meek Micrografting Technique MEEKADEAU|Unknown status|Recruiting|Phase 3|10|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 22:43:40.194387|2018-05-31 22:43:40.194387
NCT01330394|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2013-09-24||2013-11-26|2011-04-06|2011-04-07|Estimate|2013-09-24|2013-11-27|Estimate||||2013-11-26|2013-12-24|Estimate|June 2011||2011-06-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Transcranial Direct Current Stimulation Over Dorsolateral Prefrontal Cortex in Alcoholism|Alcoholism Treatment by Cognitive Neuromodulation Produced by Repeated Transcranial Direct Current Stimulation Over the Left Dorsolateral Prefrontal Cortex|Completed||Phase 2|33|Actual|Federal University of Espirito Santo||2|||f||||f||||||||||2018-05-31 22:43:40.321657|2018-05-31 22:43:40.321657
NCT01330381|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2014-01-07||2015-04-13|2011-04-05|2011-04-06|Estimate|2014-01-07|2014-02-26|Estimate||||2015-04-13|2015-05-05|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|FC|Safety Set was used for baseline characteristics. The Safety Set includes all subjects who were randomized and received at least 1 dose of investigational product. One randomized subject in each group did not receive investigational product and therefore were not included in the Safety Set.|Prucalopride in Pediatric Subjects With Functional Constipation|Trial Consisting of an 8-week Double-blind Placebo-controlled Part to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of Prucalopride in Paediatric Subjects With Functional Constipation, Aged ≥6 Months to <18 Years, Followed by a 16-week Open-label Comparator (PEG) Controlled Part, to Document Safety and Tolerability up to 24 Weeks|Completed||Phase 3|215|Actual|Shire||3|||f||||t||||||||||2018-05-31 22:43:40.641589|2018-05-31 22:43:40.641589
NCT01330368|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-09-29|2011-04-05|2011-04-06|Estimate|||||||2017-09-29|2017-10-03|Actual|October 2010||2010-10-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|July 2013|Actual|2013-07-31||Observational|||Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children|Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children|Completed|||32|Actual|Children's Hospital of Philadelphia|||||f||||f||||||Samples Without DNA|"~     urine~   "|||2018-05-31 22:43:41.474862|2018-05-31 22:43:41.474862
NCT01330355|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2014-08-21||2014-09-02|2011-04-05|2011-04-06|Estimate|2014-09-02|2014-09-03|Estimate||||2014-09-02|2014-09-03|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis|Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age|Terminated||Phase 3|33|Actual|Bausch & Lomb Incorporated||2||Lack of enrollment|f||||f||||||||||2018-05-31 22:43:41.55193|2018-05-31 22:43:41.55193
NCT01330342|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2012-06-08|2011-04-05|2011-04-06|Estimate|||||||2012-06-08|2012-06-11|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|SSAT042||Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma|Evolution of Cellular and Viral Resistance in HIV-infected Patients With Lymphoma|Unknown status|Recruiting||40|Anticipated|St Stephens Aids Trust|||2||f||||f||||||||||2018-05-31 22:43:42.015471|2018-05-31 22:43:42.015471
NCT01330329|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-04-18|2011-04-05|2011-04-06|Estimate|||||||2012-04-18|2012-04-20|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Weight Loss Programs for Individuals With Severe Obesity|Comparison of a Traditional Behavioral Weight Loss Program Versus a Technology - Based Weight Loss Program in Severely Obese Individuals|Completed||N/A|29|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 22:43:42.093254|2018-05-31 22:43:42.093254
NCT01330316|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|2015-07-03|2014-07-23|2016-05-31|2011-04-05|2011-04-06|Estimate|2015-07-03|2015-07-31|Estimate|2014-07-23|2014-07-24|Estimate|2016-05-31|2016-06-30|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Full analysis set (FAS): This set included all patients who entered the trial, were dispensed study medication, and were documented to have taken at least one dose of study medication.|A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients|A Phase III, Open-label Study of Once Daily BI 201335 240 mg for 24 Weeks in Combination With Pegylated interferon-a (PegIFN) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN / RBV Treatment|Completed||Phase 3|119|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:43:42.215199|2018-05-31 22:43:42.215199
NCT01330303|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2011-03-10||2017-06-27|2011-03-10|2011-04-06|Estimate|2011-03-10|2011-04-06|Estimate||||2017-06-27|2017-08-01|Actual|December 8, 2009|Actual|2009-12-08|June 2017|2017-06-30|December 22, 2009|Actual|2009-12-22|December 22, 2009|Actual|2009-12-22||Interventional|||SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin|Randomized, Two-period, Cross-over, Bioequivalence Study on Tamsulosin Hydrochloride 0,4 mg Prolonged Release Hard Gelatin Capsule Versus SECOTEX® (Tamsulosin Hydrochloride) 0,4 mg Prolonged Release Hard Gelatin Capsule Healthy Male Volunteers Under Fed Conditions|Completed||Phase 1|37|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:43:43.204993|2018-05-31 22:43:43.204993
NCT01330108|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2014-01-28||2014-07-17|2011-04-05|2011-04-06|Estimate|2014-07-17|2014-08-11|Estimate||||2014-07-17|2014-08-11|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SCOBA-PH|Subjects described in baseline are those that completed the study|Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension|Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension|Completed||Phase 4|32|Actual|University of Alabama at Birmingham|There is bias in the study due to the fact that subjects have been proven to tolerate the initial drug in the study (bosentan) and adequate time was not allowed for subjects to be able to tolerate ambisentan|1|||f||||f||||||||||2018-05-31 22:43:45.099475|2018-05-31 22:43:45.099475
NCT01330290|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2013-07-19||2013-11-07|2011-04-05|2011-04-06|Estimate|2013-11-07|2013-12-10|Estimate||||2013-11-07|2013-12-10|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|CARE-ACT|The Baseline Characteristics refer to the Enrolled Set (ES). All patients who were entered into the database are included in the Enrolled Set (ES).|Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support|A Multi-site, Non-interventional, Cross-sectional Evaluation of the Caregivers' and the Physicians' Preferred Route of Administration and the Physicians' Rationale for the Choice of Neupro® in Patients With Parkinson Requiring Caregiver Support|Completed|||148|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 22:43:43.505601|2018-05-31 22:43:43.505601
NCT01330277|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2018-05-18|2011-04-04|2011-04-06|Estimate|||||||2018-05-18|2018-05-21|Actual|March 2011||2011-03-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|BioHunt||Biomarker for Hunter Disease|Biomarker for Hunter Disease an International, Multicenter, Epidemiological Protocol|Recruiting|||80|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     After inclusion into the study, blood samples will be drawn to identify a deficiency or~     absence of the enzyme iduronate-2-sulfatase (I2S).~      The laboratory examinations of the blood samples will be done exclusively at the Laboratory~     of the Albrecht-Kossel-Institute, University of Rostock. This laboratory offers an existing~     infrastructure, a highly standardized quality of the workflow, a short examination time of~     the samples and a long period of experiences in the assessment of the biological impact of~     mutations and polymorphism.~   "|Undecided||2018-05-31 22:43:44.100066|2018-05-31 22:43:44.100066
NCT01330264|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-12-10|2011-04-05|2011-04-06|Estimate|||||||2012-12-10|2012-12-11|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|SIM City||Study of Intracranial Pressure (ICP) Monitoring in Critically Ill|Study of ICP Monitoring in Critically Ill|Completed|||30|Actual|Duke University|||1||f||||f||||||||||2018-05-31 22:43:44.267301|2018-05-31 22:43:44.267301
NCT01330251|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-10-31|2011-04-05|2011-04-06|Estimate|||||||2017-10-31|2017-11-01|Actual|January 2011||2011-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||The Effect of Gastric Bypass Surgery on Diabetes|Laihdutusleikkauksen Vaikutus Diabetekseen|Completed|||41|Actual|University of Oulu|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, feces, intestinal tissue~   "|||2018-05-31 22:43:44.353842|2018-05-31 22:43:44.353842
NCT01330238|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2014-01-14|2011-04-05|2011-04-06|Estimate|||||||2014-01-14|2014-01-15|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||The Efficacy of Zoledronic Acid in Modic Changes-related Low Back Pain (LBP)|Phase 2 Study of the Efficacy of Zoledronic Acid in Low Back Pain Related to Vertebral Endplate Signal Changes, the So-called Modic Changes|Completed||Phase 2|40|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 22:43:44.415489|2018-05-31 22:43:44.415489
NCT01330199|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2013-09-16|2011-04-05|2011-04-06|Estimate|||||||2013-09-16|2013-09-17|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions|A Phase I Investigation of Single-Dose Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions|Completed||Phase 1|49|Actual|University of North Carolina, Chapel Hill||6|||f||||t||||||||||2018-05-31 22:43:44.508247|2018-05-31 22:43:44.508247
NCT01330186|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-11|2011-04-05|2011-04-06|Estimate|||||||2011-04-11|2011-04-12|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|May 2012|Anticipated|2012-05-31|February 2012|Anticipated|2012-02-29||Observational|||Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy|18F-FMISO-PET, 18F-FDG-PET/CT, DWI-MRI and DCE-MRI Scans as Predictors of Response to Radiotherapy +/- Chemotherapy in Patients With Anal Cancer.|Unknown status|Recruiting||50|Anticipated|Copenhagen University Hospital at Herlev|||1||f||||f||||||||||2018-05-31 22:43:44.584299|2018-05-31 22:43:44.584299
NCT01330173|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2014-12-19|2011-04-05|2011-04-06|Estimate|||||||2014-12-19|2014-12-23|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma|A Phase 1b Study of GDC-0449 Following Autologous Transplantation in Patients With High Risk First Remission or Relapsed Multiple Myeloma|Completed||Phase 1|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:43:44.694703|2018-05-31 22:43:44.694703
NCT01330160|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2018-04-23|2011-04-04|2011-04-06|Estimate|||||||2018-04-23|2018-04-24|Actual|February 27, 2010|Actual|2010-02-27|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|strokdem||Study of Factors Influencing Post-stroke Dementia|Characterization of Clinical, Biological, Morphological and Pharmacological Factors Influencing Occurrence of Dementia or Cognitive Disorders After Stroke|Recruiting|||1100|Anticipated|University Hospital, Lille|||1||f||||f||||||Samples With DNA|"~     standard biological parameters (ionogram, blood count, glycemia, lipids, renal function,~     vitamin B12, thyroid hormones, homocysteinemia), specialized biology (inflammation,~     oxidative, vascular biomarkers ; amyloid and tau markers), genotype (apolipoprotein E,~     apolipoprotein C, kinesin, Angiotensin Converting Enzyme...).~   "|||2018-05-31 22:43:44.77035|2018-05-31 22:43:44.77035
NCT01330147|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2017-05-16|2011-04-05|2011-04-06|Estimate|||||||2017-05-16|2017-05-18|Actual|March 2013||2013-03-31|May 2017|2017-05-31|September 28, 2015|Actual|2015-09-28|September 28, 2015|Actual|2015-09-28||Observational|Oromouth||HPV Prevalence in the Mouth and Oropharynx of the Tonsillectomy Population|HPV Prevalence in the Mouth and Oropharynx of the Tonsillectomy Population|Completed|||937|Actual|University of Birmingham|||1||f||||f||||||Samples With DNA|"~     Oral rinse, Oral Mucosal Trasudate, Urine, Whole Blood, Nail brushings, Mouth brush biopsies~     (scrapes) and Tonsillectomy specimens~   "|Undecided||2018-05-31 22:43:44.855672|2018-05-31 22:43:44.855672
NCT01330134|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2016-06-22|2011-04-05|2011-04-06|Estimate|||||||2016-06-22|2016-06-24|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Comparison of Two Lidocaine Administration Techniques|Comparison of Two Lidocaine Administration Techniques|Completed||Phase 4|490|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 22:43:44.931646|2018-05-31 22:43:44.931646
NCT01330121|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Bridging the Gap by Transitional Care|Pharmacist Discharge Counseling: Bridging the Gap by Transitional Care|Completed||N/A|130|Actual|John H. Stroger Hospital||2|||f||||t||||||||||2018-05-31 22:43:45.009864|2018-05-31 22:43:45.009864
NCT01330082|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|May 2011|Anticipated|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Adjunctive Photodynamic Therapy in the Treatment of Chronic Periodontitis|Efficacy of Adjunctive Photodynamic Therapy Using Light-emitting Diode in the Treatment of Chronic Periodontitis|Unknown status|Active, not recruiting|Phase 2/Phase 3|16|Actual|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-05-31 22:43:45.321568|2018-05-31 22:43:45.321568
NCT01330056|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2016-07-11|2011-04-05|2011-04-06|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|FOPS||Functional Organ Preservation Surgery|A Prospective Randomized Controlled Trial of Functional Organ Preservation Surgery vs. Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma|Active, not recruiting||N/A|264|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 22:43:45.403516|2018-05-31 22:43:45.403516
NCT01330043|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2016-04-12||2017-07-04|2011-04-05|2011-04-06|Estimate|2017-07-04|2017-08-01|Actual||||2017-07-04|2017-08-01|Actual|March 2010||2010-03-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Extended Treatment for Smoking Cessation|Extended Treatment for Smoking Cessation|Completed||Phase 4|223|Actual|Stanford University|The target sample size of N=400 was not reached due to challenges with recruitment, however, the sample size achieved was sufficient to test main effects of extended treatment on abstinence outcomes.|2|||f||||f|t|f|||f|||Undecided||2018-05-31 22:43:45.467044|2018-05-31 22:43:45.467044
NCT01330030|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2016-03-01||2016-06-29|2011-04-05|2011-04-06|Estimate|2016-03-03|2016-04-04|Estimate||||2016-06-29|2016-08-10|Estimate|July 2005||2005-07-31|May 2016|2016-05-31|July 2011|Actual|2011-07-31|August 2008|Actual|2008-08-31||Interventional|||Selegiline Patch for Treatment of Nicotine Dependence|Selegiline Patch for Treatment of Nicotine Dependence|Completed||Phase 2|243|Actual|Stanford University||2|||f||||t||||||||No||2018-05-31 22:43:45.680284|2018-05-31 22:43:45.680284
NCT01330017|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2012-05-24||2015-02-20|2011-04-05|2011-04-06|Estimate|2012-10-08|2012-11-07|Estimate||||2015-02-20|2015-03-11|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)|A Randomized, Dose-ranging, Placebo-controlled Trial to Evaluate the Effects of Phenylephrine HCl Immediate Release Tablets on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 2|539|Actual|Bayer||5|||f||||f||||||||||2018-05-31 22:43:45.977305|2018-05-31 22:43:45.977305
NCT01330004|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-05-04|2011-04-05|2011-04-06|Estimate|||||||2015-05-04|2015-05-05|Estimate|January 1999||1999-01-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|BP||Blood Pressure Change and Outcome|The Relationship of Systolic and Diastolic Blood Pressure Changes Over Time to Patient Outcomes in Incident Hemodialysis Patients|Completed|||12695|Actual|Renal Research Institute|||1||f||||f||||||||||2018-05-31 22:43:46.645625|2018-05-31 22:43:46.645625
NCT01329991|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-04-10|2011-04-05|2011-04-06|Estimate|||||||2012-04-10|2012-04-12|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate|A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Drug-Drug Interaction of PLX5622 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate|Completed||Phase 1|26|Actual|Plexxikon||5|||f||||f||||||||||2018-05-31 22:43:46.705657|2018-05-31 22:43:46.705657
NCT01329978|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2014-01-06|2013-08-27|2014-04-24|2011-04-04|2011-04-06|Estimate|2014-04-24|2014-05-26|Estimate|2013-08-27|2013-09-04|Estimate|2014-04-24|2014-05-26|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ATOMIC|Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug|Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6|The ATOMIC Study: A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic HCV Infection Genotype 1,4, 5, or 6|Completed||Phase 2|332|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 22:43:46.843558|2018-05-31 22:43:46.843558
NCT01329965|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2013-03-14|2011-04-05|2011-04-06|Estimate|||||||2013-03-14|2013-03-15|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Safety and Feasibility of an Endotoxemia Model|Safety and Feasibility of an Endotoxemia Model: Pilot Study|Completed||Phase 1|6|Actual|Penn State University||2|||f||||t||||||||||2018-05-31 22:43:47.986634|2018-05-31 22:43:47.986634
NCT01329952|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|June 2014|Anticipated|2014-06-30|May 2013|Anticipated|2013-05-31||Observational|||Reinfection and Long Term Outcomes in Intravenous Drug Users (IVDUs) After Hepatitis C Treatment|Reinfection Rates and Long Term Outcomes in Currently Injecting Drug Users Following Successful Treatment for Hepatitis C|Unknown status|Not yet recruiting||90|Anticipated|Pennine Acute Hospitals NHS Trust|||2||f||||f||||||Samples Without DNA|"~     Blood will be taken for Hepatitis C RNA, plus Hepatitis C genotype if positive. Blood will~     also be taken for liver function tests and a full blood count.~   "|||2018-05-31 22:43:48.09448|2018-05-31 22:43:48.09448
NCT01329939|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2015-12-30||2016-03-09|2011-04-05|2011-04-06|Estimate|2016-03-09|2016-04-07|Estimate||||2016-03-09|2016-04-07|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics|The Effect of Montelukast on Asthma Control in Overweight/Obese Atopic Asthmatics|Completed||N/A|26|Actual|Northwell Health||4|||f||||f||||||||Undecided||2018-05-31 22:43:48.22768|2018-05-31 22:43:48.22768
NCT01329926|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-12-02|2011-04-04|2011-04-06|Estimate|||||||2016-12-02|2016-12-05|Estimate|June 2011||2011-06-30|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Observational|||Molecular Analysis of Human Neural Stem Cells|Molecular Analysis of Adult Human-derived Neural Stem Cells|Enrolling by invitation|||20|Anticipated|NeuroGeneration|||1||f||||f||||||Samples With DNA|"~     Brain tissue obtained during neurosurgical procedures yields undifferentiated neural stem~     cells that are subsequently expanded.~   "|||2018-05-31 22:43:48.929574|2018-05-31 22:43:48.929574
NCT01329913|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-02-04|2011-04-05|2011-04-06|Estimate|||||||2015-02-04|2015-02-05|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)|A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-6325 in Hepatitis C Infected Male and Female Patients|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 22:43:49.031842|2018-05-31 22:43:49.031842
NCT01329900|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2018-01-16|2011-04-05|2011-04-06|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2011|Actual|2011-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas|Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas|Active, not recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 22:43:49.13059|2018-05-31 22:43:49.13059
NCT01329887|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2014-05-08|2011-04-05|2011-04-06|Estimate|||||||2014-05-08|2014-05-09|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of Ketanserin on the Microcirculation in Sepsis|Evaluation of the Effect of Ketanserine on Sublingual Microcirculation by SDF Imaging in Septic Patients on the Intensive Care|Completed||Phase 3|10|Actual|Medical Centre Leeuwarden||1|||f||||f||||||||||2018-05-31 22:43:49.454309|2018-05-31 22:43:49.454309
NCT01329874|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|||Anesthetic Efficacy of Gow-Gates Versus Conventional Inferior Alveolar Nerve Block Techniques|Comparison of the Anesthetic Efficacy in Mandibular Molars With Acute Irreversible Pulpitis With Either Conventional Inferior Alveolar or Gow-gates Nerve Block Techniques Plus Buccal or Lingual Infiltration|Unknown status|Recruiting|N/A|80|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:43:49.612976|2018-05-31 22:43:49.612976
NCT01329861|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|June 2004||2004-06-30|April 2011|2011-04-30|August 2005|Actual|2005-08-31|May 2005|Actual|2005-05-31||Interventional|||Internet-based Cognitive Behavioural Treatment for Chronic Back Pain|Guided Internet-based Cognitive Behavioural Treatment for Chronic Back Pain Reduces Catastrophizing:a Randomized Controlled Trial|Completed||N/A|54|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 22:43:49.730421|2018-05-31 22:43:49.730421
NCT01329848|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2014-12-08||2014-12-23|2011-04-04|2011-04-06|Estimate|2014-12-23|2015-01-05|Estimate||||2014-12-23|2015-01-05|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Observational|AD|Graduate students at WesternU|Accommodation Disorders|Using Accommodative Lag to Diagnose Accommodation Disorders|Completed|||83|Actual|Western University of Health Sciences|||1||f||||f||||||||||2018-05-31 22:43:49.868402|2018-05-31 22:43:49.868402
NCT01329835|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-12-05|2011-04-04|2011-04-06|Estimate|||||||2011-12-05|2011-12-06|Estimate|March 2008||2008-03-31|July 2008|2008-07-31|December 2013|Anticipated|2013-12-31|April 2011|Actual|2011-04-30||Interventional|||Effect of Psycho-education on Gestational Weight Gain and Anxiety/Depression in Obese Pregnant Women|Effect of Psycho-education on Gestational Weight Gain and Anxiety/Depression in Obese Pregnant Women|Unknown status|Recruiting|N/A|180|Anticipated|Limburg Catholic University College||3|||f||||f||||||||||2018-05-31 22:43:50.111405|2018-05-31 22:43:50.111405
NCT01329822|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|March 2010||2010-03-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Caloric Restriction on Fetuin-A and Cardiovascular Risk Factors|The Effects of Caloric Restriction on Fetuin-A and Cardiovascular Risk Factors in Rats and Humans: A Randomized Controlled Trial|Completed||N/A|76|Actual|Korea University||2|||f||||t||||||||||2018-05-31 22:43:50.20577|2018-05-31 22:43:50.20577
NCT01329809|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-04-09|2011-04-05|2011-04-06|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2011||2011-10-31|July 2011|2011-07-31|March 2013|Actual|2013-03-31|January 2012|Actual|2012-01-31||Interventional|||Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors|A Phase IIa Study of Neoadjuvant JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion or Intratumoral Injection Followed by Surgical Resection in Patients With Metastatic Colorectal Tumors Within the Liver|Terminated||Phase 2|2|Actual|Jennerex Biotherapeutics||2|||f||||t||||||||||2018-05-31 22:43:50.301052|2018-05-31 22:43:50.301052
NCT01329796|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|March 2007||2007-03-31|April 2011|2011-04-30|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|PLEASE||Pertubation With Lignocaine in Endometriosis|Pertubation With Lignocaine in Endometriosis Associated Symptoms Effect Study|Completed||Phase 2|42|Actual|Isifer AB||2|||f||||t||||||||||2018-05-31 22:43:50.400635|2018-05-31 22:43:50.400635
NCT01329783|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-05-13|2011-04-04|2011-04-06|Estimate|||||||2011-05-13|2011-05-16|Estimate|April 2007||2007-04-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||EuroSIDA As An External Comparator To MOTIVATE Trials|Incidence And Risk Factors For Acquired Immune Deficiency Syndrome (AIDS) Defining And Non-AIDS Defining Malignancies, And Other AIDS Defining Illnesses In The EuroSIDA Study|Completed|||1181|Actual|ViiV Healthcare|||1||f||||f||||||||||2018-05-31 22:43:50.497783|2018-05-31 22:43:50.497783
NCT01329770|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2015-04-13|2011-04-05|2011-04-06|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SXF-TRA152||Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome|Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome|Completed||Phase 2|30|Actual|The Mediterranean Institute for the Advance of Biotechnology and Health Research||2|||f||||t||||||||||2018-05-31 22:43:50.591227|2018-05-31 22:43:50.591227
NCT01329757|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-01-09|2011-04-05|2011-04-06|Estimate|||||||2015-01-09|2015-01-12|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|GHSCI||Efficacy and Safety of Growth Hormone Treatment in Spinal Cord Injury|Efficacy and Safety of Growth Hormone (GH) Treatment in Spinal Cord Injury(SCI): A Triple-blinded, Randomised, Placebo-controlled Trial|Unknown status|Active, not recruiting|Phase 3|76|Anticipated|Hospital Nacional de Parapléjicos de Toledo||2|||f||||t||||||||||2018-05-31 22:43:50.707646|2018-05-31 22:43:50.707646
NCT01329744|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2016-03-22|2011-04-05|2011-04-06|Estimate|||||||2016-03-22|2016-03-23|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of IGF-I in HIV Metabolic Disease|Effects of Recombinant IGF-I in HIV Associated Metabolic Disease|Terminated||Phase 1|16|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 22:43:50.811331|2018-05-31 22:43:50.811331
NCT01329731|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2013-12-10|2011-04-05|2011-04-06|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients|White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months|Completed||Phase 4|48|Actual|Gaba International AG||2|||f||||t||||||||||2018-05-31 22:43:51.124959|2018-05-31 22:43:51.124959
NCT01329718|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2014-08-01|2011-04-05|2011-04-06|Estimate|||||||2014-08-01|2014-08-04|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SPR0012||Specimens for Septin 9 Performance|Specimen Collection Protocol for the Performance Evaluation of the Septin 9 Assay|Completed||Early Phase 1|562|Actual|Epigenomics, Inc||1|||f||||f||||||||||2018-05-31 22:43:51.194673|2018-05-31 22:43:51.194673
NCT01329705|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-08-08|2011-04-05|2011-04-06|Estimate|||||||2013-08-08|2013-08-12|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|||Dynamic Splinting for Plantarflexion in Spastic Hemiplegia|Dynamic Splinting for Excessive Plantarflexion in Patients With Spastic Hemiplegia: A Randomized, Controlled Study of Gait Analysis|Withdrawn||N/A|0|Actual|Dynasplint Systems, Inc.||2|||f||||f||||||||||2018-05-31 22:43:51.2682|2018-05-31 22:43:51.2682
NCT01329692|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-02-07|2011-04-05|2011-04-06|Estimate|||||||2012-02-07|2012-02-08|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Back on Track||Early Intervention for Morbidly Obese Patients After Roux-en-Y Gastric Bypass (RYGB) Surgery|Early Intervention in Patients With Predicted Poor Long-term Outcome Following Laparoscopic Roux-en-Y Gastric Bypass: a Prospective Randomized Study|Terminated||N/A|8|Actual|Duke University||2||The PI has left Duke-the primary study site and the sponsor retreat the support|f||||f||||||||||2018-05-31 22:43:51.344182|2018-05-31 22:43:51.344182
NCT01329679|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2016-08-29||2016-11-13|2011-04-05|2011-04-06|Estimate|2016-11-13|2017-01-10|Estimate||||2016-11-13|2017-01-10|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Impact of Energy Drinks on Cardiovascular Endpoints|Evaluation of 5-Hour ENERGY® Drink on the Blood Pressure and Electrocardiographic Parameters on Young Healthy Volunteers: A Randomized, Double Blind, Crossover, Placebo-controlled Trial|Terminated||N/A|29|Actual|David Grant U.S. Air Force Medical Center|Small sample size and limited to 7 days of consumption.|2||Unable to recruit enough subjects|f||||f||||||||No||2018-05-31 22:43:51.484048|2018-05-31 22:43:51.484048
NCT01329666|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-03-04|2011-04-05|2011-04-06|Estimate|||||||2015-03-04|2015-03-05|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D|Early Effect of Vitamin D in Primary Hyperparathyroidism|Withdrawn||Phase 2/Phase 3|0|Actual|Columbia University||2||Poor enrollment|f||||t||||||||||2018-05-31 22:43:51.865544|2018-05-31 22:43:51.865544
NCT01329653|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2017-03-28|2011-04-05|2011-04-06|Estimate|||||||2017-03-28|2017-03-29|Actual|June 2011||2011-06-30|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Exercise, Age-Related Memory Decline, And Hippocampal Function|Exercise, Age-Related Memory Decline, And Hippocampal Function|Active, not recruiting||N/A|182|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||Yes|We will share our data with other investigators upon request.|2018-05-31 22:43:51.94982|2018-05-31 22:43:51.94982
NCT01329640|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-05-20|2011-04-05|2011-04-06|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)|Phase II Feasibility Study of Weekly Paclitaxel Plus Weekly Trastuzumab Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide Plus Weekly Trastuzumab for Locally Advanced HER2-Positive Breast Cancer|Terminated||Phase 2|9|Actual|Instituto do Cancer do Estado de São Paulo||1|||f||||f||||||||||2018-05-31 22:43:52.021006|2018-05-31 22:43:52.021006
NCT01329627|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-05-20|2011-04-04|2011-04-06|Estimate|||||||2014-05-20|2014-05-21|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|TAME-01||Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer|Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer|Terminated||Phase 2|12|Actual|Instituto do Cancer do Estado de São Paulo||1||Toxicity|f||||f||||||||||2018-05-31 22:43:52.093462|2018-05-31 22:43:52.093462
NCT01329614|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2013-07-24|2011-04-05|2011-04-06|Estimate|||||||2013-07-24|2013-07-25|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving|Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving|Completed||Early Phase 1|40|Actual|New York State Psychiatric Institute||4|||f||||t||||||||||2018-05-31 22:43:52.1846|2018-05-31 22:43:52.1846
NCT01329601|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|ECIF||Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI|Effect of the Stage Specific Cognitive Intervention Program on Functional Cortical Activation in Alzheimer's Disease|Unknown status|Recruiting|Phase 4|24|Anticipated|University of Rostock||2|||f||||f||||||||||2018-05-31 22:43:52.290458|2018-05-31 22:43:52.290458
NCT01329588|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-02-12|2011-04-04|2011-04-06|Estimate|||||||2013-02-12|2013-02-13|Estimate|March 2001||2001-03-31|February 2013|2013-02-28|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers|Periodical Presumptive Treatment of Gonorrhoea in Female Sex Workers: Impact on Prevalence of the Disease in Sex Workers and Their Clients|Completed||Phase 4|636|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 22:43:52.424326|2018-05-31 22:43:52.424326
NCT01329575|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2018-03-29|2011-04-05|2011-04-06|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2011||2011-01-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Observational|CT0024||Predicting Malignancy Using Endoluminal Ultrasound Characteristics in Mediastinal Lymph Nodes|Predicting Malignancy Using Endoluminal Ultrasound Characteristics in Mediastinal Lymph Nodes|Completed|||184|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 22:43:52.540636|2018-05-31 22:43:52.540636
NCT01329562|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2013-10-08||2014-03-11|2011-04-05|2011-04-06|Estimate|2014-03-11|2014-04-09|Estimate||||2014-03-11|2014-04-09|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet|Evaluation of CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Saliva of Menstrual Migraine Patients Before and After Treatment With Treximet™|Completed||Phase 4|41|Actual|Cady, Roger, M.D.||2|||f||||f||||||||||2018-05-31 22:43:52.668461|2018-05-31 22:43:52.668461
NCT01329380|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2018-01-24|2011-04-04|2011-04-05|Estimate|||||||2018-01-24|2018-01-26|Actual|November 29, 2010|Actual|2010-11-29|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)|Special Investigation (All Cases Investigation in Patients With Ankylosing Spondylitis)|Completed|||401|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 22:43:55.443644|2018-05-31 22:43:55.443644
NCT01329549|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2014-11-14||2014-11-26|2011-04-04|2011-04-06|Estimate|2014-11-26|2014-11-27|Estimate||||2014-11-26|2014-11-27|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Treated set: includes all patients who were dispensed study medication and were documented to have received at least 1 dose of study medication.|Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)|An Open-label, Dose Escalation Phase I Study of the Safety and Tolerability of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Japanese Patients With a First, Second or Third Platinum-sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer.|Terminated||Phase 1|2|Actual|Boehringer Ingelheim|The trial was prematurely terminated because of worldwide disruption of pegylated liposomal doxorubicin (PLD) supplies.|3|||f||||||||||||||2018-05-31 22:43:53.711428|2018-05-31 22:43:53.711428
NCT01329536|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-10-04|2011-04-04|2011-04-06|Estimate|||||||2011-10-04|2011-10-06|Estimate|December 2010||2010-12-31|February 2011|2011-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease|The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease Compared to Age- and Gender-Matched, Non-Agitated In-Patients With Late-Onset Alzheimer's Disease|Completed|||50|Actual|Avera McKennan Hospital & University Health Center|||2||f||||t||||||Samples With DNA|"~     saliva and blood~   "|||2018-05-31 22:43:54.035485|2018-05-31 22:43:54.035485
NCT01329523|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-10-04|2011-04-04|2011-04-06|Estimate|||||||2011-10-04|2011-10-06|Estimate|November 2010||2010-11-30|January 2011|2011-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||A Study to Compare Genetic Variations of IGF-I and IGF-II|A Non-Randomized Controlled Cross-Sectional Study to Compare Genetic Variations of IGF-I and IGF-II in Patients With Moderate to Severe Dementia and Younger Family Members, in Relation to Age-Matched Unaffected Controls|Completed|||50|Actual|Avera McKennan Hospital & University Health Center|||3||f||||t||||||Samples With DNA|"~     saliva and blood~   "|||2018-05-31 22:43:54.094232|2018-05-31 22:43:54.094232
NCT01329510|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|May 2007|Actual|2007-05-31|December 2006|Actual|2006-12-31||Interventional|ADHD||Sleep and Nocturnal Melatonin in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|The Effects of Methylphenidate on Sleep Patterns in Adults With ADHD: An Open Label Polysomnographic Study|Completed||N/A|19|Actual|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 22:43:54.270102|2018-05-31 22:43:54.270102
NCT01329497|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-15|2011-04-05|2011-04-06|Estimate|||||||2011-04-15|2011-04-18|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||The Effect of Systemic Dietary Instruction on Management of Plasma Phosphorus Levels in Peritoneal Dialysis (PD) Patients||Unknown status|Recruiting|N/A|50|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||||2018-05-31 22:43:54.355427|2018-05-31 22:43:54.355427
NCT01329484|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-03|2011-04-03|2011-04-06|Estimate|||||||2011-04-03|2011-04-06|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Computerized Personal Interventions for Alzheimer's Patients|Computerized Personal Interventions for Alzheimer's Patients|Unknown status|Enrolling by invitation|N/A|159|Anticipated|Shaare Zedek Medical Center||3|||f||||f||||||||||2018-05-31 22:43:54.422543|2018-05-31 22:43:54.422543
NCT01329471|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Observational|||Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)||Unknown status|Not yet recruiting||75|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 22:43:54.504828|2018-05-31 22:43:54.504828
NCT01329458|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-02|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|HepFocUS||Contrast Enhanced Ultrasound For The Evaluation Of Focal Liver Lesions|Contrast Enhanced Ultrasound for the Evaluation of Focal Liver Lesions - a Multi-center Study on the Usefulness in the Clinical Practice|Unknown status|Recruiting||1500|Anticipated|Societatea Romana de Ultrasonografie in Medicina si Biologie|||1||f||||f||||||||||2018-05-31 22:43:54.563331|2018-05-31 22:43:54.563331
NCT01329445|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2017-01-25|2011-04-05|2011-04-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2011||2011-02-28|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||DeNovo NT Longitudinal Data Collection (LDC) Knee Study|Post Market, Longitudinal Data Collection Study of DeNovo NT for Articular Cartilage Defects of the Knee|Active, not recruiting|||160|Actual|Zimmer Orthobiologics, Inc.|||1||f||||f||||||||||2018-05-31 22:43:54.639771|2018-05-31 22:43:54.639771
NCT01329432|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-05|2011-04-05|2011-04-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|January 2011|Anticipated|2011-01-31||Interventional|TAKE CARE||Surfactant Administration During Spontaneous Breathing|Early Administration of Surfactant in Spontaneous Breathing (TAKE CARE) Versus InSurE (Intubation, Surfactant, Extubation) : A Pilot Study|Unknown status|Recruiting|Phase 4|100|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 22:43:54.715181|2018-05-31 22:43:54.715181
NCT01329419|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2011-03-10||2017-06-06|2011-03-10|2011-04-05|Estimate|2011-03-10|2011-04-05|Estimate||||2017-06-06|2017-07-05|Actual|August 2004||2004-08-31|June 2017|2017-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|HEPSERA PMS||HEPSERA Post Marketing Surveillance|A Post-marketing Surveillance to Monitor the Safety of HEPSERA(Adefovir Dipivoxil 10mg) Adminstered in Korean Subjects According to the Prescribing Information|Completed|||4393|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:43:54.878526|2018-05-31 22:43:54.878526
NCT01329406|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-08-16|2011-04-04|2011-04-05|Estimate|||||||2011-08-16|2011-08-17|Estimate|July 2011||2011-07-31|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|February 2012|Anticipated|2012-02-29||Interventional|||Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis|A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis|Unknown status|Recruiting|Phase 4|50|Anticipated|Analgesic Solutions||2|||f||||||||||||||2018-05-31 22:43:55.213388|2018-05-31 22:43:55.213388
NCT01329393|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-07-16|2011-04-01|2011-04-05|Estimate|||||||2014-07-16|2014-07-17|Estimate|August 2010||2010-08-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Benefits Management for People With Psychiatric Disabilities|Benefits Management for People With Psychiatric Disabilities|Completed||Phase 1|99|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:43:55.317533|2018-05-31 22:43:55.317533
NCT01329367|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2017-05-03|2011-04-04|2011-04-05|Estimate|||||||2017-05-03|2017-05-08|Actual|January 2010||2010-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2011|Actual|2011-09-30||Interventional|NUGENOI||Nutrigenomics And Children Obesity: A Moderate Weight Loss Intervention Study|Efecto de Una Intervención Dietética Sobre La Expresión De Genes De La Inflamación Y El Estrés Oxidativo En Niños Obesos|Active, not recruiting||N/A|42|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||3|||f||||f|f|f||||||No||2018-05-31 22:43:55.762474|2018-05-31 22:43:55.762474
NCT01329354|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2017-10-23|2011-04-04|2011-04-05|Estimate|||||||2017-10-23|2017-10-24|Actual|March 2011||2011-03-31|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy|Phase II Clinical Trial of Immunotherapy With Rituximab and Autologous Effector Lymphocytes in Patients With Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy|Active, not recruiting||Phase 2|38|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-05-31 22:43:55.835072|2018-05-31 22:43:55.835072
NCT01329341|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-05-10|2011-04-04|2011-04-05|Estimate|||||||2017-05-10|2017-05-12|Actual|July 1, 2011|Actual|2011-07-01|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|January 31, 2017|Actual|2017-01-31||Interventional|||Service Dogs for Veterans With PTSD|Service Dogs for Veterans With PTSD: A Randomized Clinical Trial|Terminated||N/A|62|Actual|VA Office of Research and Development||1||Study concluded prematurly|f||||t|f|f|||f|||No||2018-05-31 22:43:55.907631|2018-05-31 22:43:55.907631
NCT01329328|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2012-06-12|2011-04-04|2011-04-05|Estimate|||||||2012-06-12|2012-06-13|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Whole-body Vibration With or Without Localized Radiofrequency on Body Composition of Obese Female Subjects|Vibrazione Corporea Totale Con o Senza Radiofrequenza Localizzata su Composizione Corporea, Adipe Sottocutaneo e Parametri Ormonali in Donne Obese|Completed||N/A|40|Actual|Universita di Verona|||||f||||f||||||||||2018-05-31 22:43:55.961976|2018-05-31 22:43:55.961976
NCT01329315|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2014-04-03|2011-04-01|2011-04-05|Estimate|||||||2014-04-03|2014-04-07|Estimate|September 2005||2005-09-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2010|Actual|2010-11-30||Interventional|||Project Chill: Tailored Youth Drug Intervention In Primary Care|Tailored Youth Drug Intervention In Primary Care|Completed||N/A|1141|Actual|University of Michigan||3|||f||||t||||||||||2018-05-31 22:43:56.019228|2018-05-31 22:43:56.019228
NCT01329302|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2015-09-29|2011-04-01|2011-04-05|Estimate|||||||2015-09-29|2015-09-30|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Benefit of Follicular Flushing During Oocyte Retrieval for Poor Responder Patient in an Assisted Reproductive Technology Program|Follicular Flushing for Poor Responder Patient in an Assisted Reproductive Technology Program: Flush Study|Unknown status|Recruiting|N/A|260|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 22:43:56.073178|2018-05-31 22:43:56.073178
NCT01329289|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-02-11|2011-04-04|2011-04-05|Estimate|||||||2016-02-11|2016-02-12|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma|Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||1||Clinical trial being transferred to Columbia University with the Investigator.|f||||t||||||||||2018-05-31 22:43:56.222742|2018-05-31 22:43:56.222742
NCT01329276|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-01|2011-04-01|2011-04-05|Estimate|||||||2011-04-01|2011-04-05|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.|A Randomized, Double-blind, Placebo-controlled, Two Way Cross-over Study to Assess the Particle Deposition and Acute Effects of Formoterol and Budesonide Combination Therapy (Symbicort® Forte Turbohaler®) on the Upper Airway Dimensions in COPD Patients.|Completed||Phase 4|10|Actual|University Hospital, Antwerp||2|||f||||t||||||||||2018-05-31 22:43:56.296002|2018-05-31 22:43:56.296002
NCT01329263|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2013-01-24||2014-12-15|2011-04-04|2011-04-05|Estimate|2014-12-04|2014-12-15|Estimate||||2014-12-15|2015-01-06|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|MQAT||Smoking Topography and Harm Exposure in Menthol Cigarettes|Smoking Topography and Harm Exposure in Menthol Cigarettes|Completed||N/A|87|Actual|University of Pennsylvania|Attrition rate over 35 day protocol of brand switching cigarette.|2|||f||||t||||||||||2018-05-31 22:43:56.372853|2018-05-31 22:43:56.372853
NCT01329250|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-11-17|2011-04-01|2011-04-05|Estimate|||||||2016-11-17|2016-11-18|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Interventional|MFX468||Pharmacokinetics and Safety of Moxifloxacin|Pharmacokinetics and Safety of Moxifloxacin; a Dose Escalation in Patients With Tuberculosis|Terminated||Phase 4|9|Actual|University Medical Center Groningen||1||slow enrolment of patients and new insights|f||||t||||||||||2018-05-31 22:43:56.642555|2018-05-31 22:43:56.642555
NCT01329237|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-04-04|2011-04-04|2011-04-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|March 2011||2011-03-31|January 2011|2011-01-31||||March 2012|Anticipated|2012-03-31||Interventional|COMPARE-IT||COMPARE-II- Vasomotion and Imaging Substudy|Comparison of the Everolimus Eluting (XIENCE-V® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study The COMPARE II Trial Imaging and Vasomotion Substudy|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Freiburg||1|||f||||f||||||||||2018-05-31 22:43:56.714491|2018-05-31 22:43:56.714491
NCT01329224|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-14|2011-04-01|2011-04-05|Estimate|||||||2011-04-14|2011-04-18|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Observational|TAM||The Antiaggregation Monitoring (TAM) Registry|Acetylsalicylic Acid in Outpatient Practice - Results From The Antiaggregation Monitoring (TAM) Registry|Unknown status|Recruiting||200|Anticipated|University Hospital Freiburg|||1||f||||f||||||||||2018-05-31 22:43:56.797407|2018-05-31 22:43:56.797407
NCT01329211|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2013-05-17|2011-04-01|2011-04-05|Estimate|||||||2013-05-17|2013-05-20|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Needs Assessment Evaluating Quality of Life Issues for Gastroparesis Patients and Caregivers|Needs Assessment Evaluating Quality of Life Issues for Gastroparesis Patients and Caregivers|Terminated|||68|Actual|University of Florida|||2|PI left institution,replacement PI not able to do study.|f||||f||||||||||2018-05-31 22:43:56.868736|2018-05-31 22:43:56.868736
NCT01329198|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|2014-04-08||2016-11-21|2011-04-01|2011-04-05|Estimate|2014-04-08|2014-05-09|Estimate||||2016-11-21|2016-11-23|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2011|Actual|2011-11-30||Interventional|||Brain Stimulation for the Treatment of Tourette Syndrome|Scheduled and Responsive Brain Stimulation for the Treatment of Tourette Syndrome|Active, not recruiting||N/A|5|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 22:43:56.933289|2018-05-31 22:43:56.933289
NCT01329185|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2014-05-19||2015-05-26|2011-04-04|2011-04-05|Estimate|2014-05-19|2014-06-20|Estimate||||2015-05-26|2015-06-23|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Eligible kidney transplant donors were enrolled at the University of Minnesota Medical Center.|Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients|Double Blinded Placebo Controlled Study to Assess Clinical and Antiviral Activity of Valganciclovir (VAL) in Solid Organ Transplant Donors to Reduce Viral Transmission From Donor to Recipient|Completed||Phase 2|17|Actual|University of Minnesota - Clinical and Translational Science Institute|Study was unblinded 2 months following the enrollment of the final donor, when a recipient developed post-transplant lymphoproliferative disorder with evidence of EBV infection at the single cell level by detection of EBV encoded small nuclear RNA.|2|||f||||f||||||||||2018-05-31 22:43:57.180804|2018-05-31 22:43:57.180804
NCT01329172|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-12-21|2011-04-04|2011-04-05|Estimate|||||||2017-12-21|2017-12-22|Actual|September 20, 2010|Actual|2010-09-20|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|NOSTRIL||Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients|Impact of Polyunsaturated Fatty Acids n-3 on Nasal Mucins Expression in Cystic Fibrosis Patients|Terminated||N/A|7|Actual|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 22:43:57.340394|2018-05-31 22:43:57.340394
NCT01329159|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-04|2011-04-04|2011-04-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Observational|||Cardio-Respiratory Health and Indoor Pollution|Cardio-Respiratory Health in High Altitude Residents Exposed to Indoor Pollution|Unknown status|Not yet recruiting||300|Anticipated|Università degli Studi di Ferrara|||||f||||f||||||||||2018-05-31 22:43:57.403768|2018-05-31 22:43:57.403768
NCT01329146|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2016-05-12|2011-04-04|2011-04-05|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2008||2008-10-31|May 2016|2016-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Pulse Pressure Variations as Index of Preload Dependency During Thoracic Surgery|Pulse Pressure Variations as Index of Preload Dependency During Thoracic Surgery|Completed|||17|Actual|University Hospital, Lille|||||f||||f||||||||Undecided||2018-05-31 22:43:58.365744|2018-05-31 22:43:58.365744
NCT01329133|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2017-08-22|2011-04-04|2011-04-05|Estimate|||||||2017-08-22|2017-08-23|Actual|April 4, 2011|Actual|2011-04-04|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|STOC2||Deep Brain Stimulation and Obsessive-compulsive Disorder|Treatment of Severe and Resistant Obsessive-compulsive Disorder by High-frequency Stimulation of the Ventral Striatum and the Subthalamic Nucleus|Recruiting||Phase 3|31|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 22:43:58.431392|2018-05-31 22:43:58.431392
NCT01329120|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2015-05-31|2011-04-04|2011-04-05|Estimate|||||||2015-05-31|2015-06-02|Estimate|September 2015||2015-09-30|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Short and Long-term Effects of Surgical Repair of Pectus Deformities|Short and Long-term Effects of Surgical Repair of Pectus Excavatum and Pectus Carinatum - A Questionnaire Study of Persistent Post-surgical Pain, Health-related Quality of Life, Patient Satisfaction, and Aesthetic Outcome|Unknown status|Not yet recruiting||1000|Anticipated|University of Aarhus|||2||f||||f||||||||||2018-05-31 22:43:58.585446|2018-05-31 22:43:58.585446
NCT01329107|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2013-08-05|2011-04-04|2011-04-05|Estimate|||||||2013-08-05|2013-08-07|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MRPBC||Multimodal Rehabilitation Program to Bladder Cancer Patients|Efficacy of a Multimodal Rehabilitation Program to Bladder Cancer Patients|Completed||N/A|129|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:43:58.662482|2018-05-31 22:43:58.662482
NCT01329094|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-04-04|2011-04-04|2011-04-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|March 2009||2009-03-31|April 2011|2011-04-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|||Physical Activity in Patients With Severe Mental Illness|Physical Activity in Patients With Severe Mental Illness|Completed|||75|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 22:43:58.735564|2018-05-31 22:43:58.735564
NCT01329081|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2011-04-04|2011-04-04|2011-04-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|HOLEST||Rehabilitation After Fast-track Total Knee Arthroplasty|Rehabilitation After Fast-track Total Knee Arthroplasty|Unknown status|Recruiting|N/A|140|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:43:58.785021|2018-05-31 22:43:58.785021
NCT01329068|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2012-01-19|2011-04-04|2011-04-05|Estimate|||||||2012-01-19|2012-01-20|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|GMC||Patient Empowerment by Group Medical Consultations|Patient Empowerment by Group Medical Consultations in the Follow-up of Breast Cancer Survivors and Surveillance of Women With a BRCA Mutation|Unknown status|Recruiting|N/A|320|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 22:43:59.560868|2018-05-31 22:43:59.560868
NCT01329055|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-04|2011-04-04|2011-04-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|January 2000||2000-01-31|April 2011|2011-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Events Before Death|International Comparison of Evolution of Clinical and Laboratory Parameters in Chronic Hemodialysis Patients|Completed|||50000|Actual|Renal Research Institute|||1||f||||t||||||||||2018-05-31 22:43:59.623781|2018-05-31 22:43:59.623781
NCT01329042|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-04-04|2011-04-04|2011-04-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|May 2005||2005-05-31|April 2011|2011-04-30|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis||Completed||Phase 4|80|Actual|Ouiheng International Healthcare Co., Ltd|||||f||||f||||||||||2018-05-31 22:43:59.676358|2018-05-31 22:43:59.676358
NCT01329029|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2015-03-10||2016-10-31|2011-04-04|2011-04-05|Estimate|2015-09-25|2015-10-29|Estimate||||2016-10-31|2016-12-13|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|REACT|Full Analysis Set (FAS) includes all randomised participants who took at least 1 dose of investigational medicinal product (IMP) after randomisation.|Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)|Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial|Completed||Phase 4|1945|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:43:59.892542|2018-05-31 22:43:59.892542
NCT01328834|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-11-01|2011-04-01|2011-04-05|Estimate|||||||2011-11-01|2011-11-03|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis||Completed||Phase 3|20|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 22:44:04.60224|2018-05-31 22:44:04.60224
NCT01329016|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-02-09|2011-04-04|2011-04-05|Estimate|||||||2015-02-09|2015-02-10|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|GDM||Glyburide and Metformin for Gestational Diabetes Mellitus (GDM)|Glyburide and Metformin for Gestational Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 1/Phase 2|360|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||3|||f||||t||||||||||2018-05-31 22:44:02.148775|2018-05-31 22:44:02.148775
NCT01329003|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2011-04-01|2011-04-01|2011-04-05|Estimate|||||||2011-04-01|2011-04-05|Estimate|September 2011||2011-09-30|March 2011|2011-03-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)|DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)|Unknown status|Not yet recruiting||150|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples With DNA|"~     blood 20 ml(cc)~   "|||2018-05-31 22:44:02.230446|2018-05-31 22:44:02.230446
NCT01328990|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2011-09-16|2011-04-04|2011-04-05|Estimate|||||||2011-09-16|2011-09-19|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine for Intermittent Preventive Treatment in Children (IPTc)|Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine When Used for Malaria Intermittent Preventive Treatment in Children|Completed||Phase 1/Phase 2|150|Actual|London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-05-31 22:44:02.29556|2018-05-31 22:44:02.29556
NCT01328977|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-01|2011-04-01|2011-04-05|Estimate|||||||2011-04-01|2011-04-05|Estimate|March 2010||2010-03-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy|Trial to Assess Best Methods for Engaging Academic Physicians in Grateful Patient Philanthropy|Completed||N/A|45|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 22:44:02.352622|2018-05-31 22:44:02.352622
NCT01328964|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2011-04-08||2017-06-06|2011-04-01|2011-04-05|Estimate|2011-04-08|2011-05-05|Estimate||||2017-06-06|2017-07-06|Actual|June 2009||2009-06-30|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population|Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population|Completed|||9906|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:44:02.414879|2018-05-31 22:44:02.414879
NCT01328951|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|2016-01-29||2016-09-06|2011-04-04|2011-04-05|Estimate|2016-01-29|2016-02-29|Estimate||||2016-09-06|2016-10-28|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional||Intent-to-Treat (ITT) Population: All participants who were randomized to treatment.|A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy|A Randomized, Double-Blind, Placebo-Controlled Phase III Study of First-Line Maintenance Tarceva Versus Tarceva at the Time of Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-Based Chemotherapy|Completed||Phase 3|643|Actual|Hoffmann-La Roche|Following the final analysis, the study was closed and all remaining participants were withdrawn from the study and considered “Not Completed” (as presented in the Participant Flow). However, the overall status of study was confirmed as completed.|2|||f||||||||||||||2018-05-31 22:44:02.807589|2018-05-31 22:44:02.807589
NCT01328938|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2013-11-05|2011-04-04|2011-04-05|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||GCPGC in Chemotherapy-induced Neutropenia|A Randomized,Multi-center,Parallel-group, Phase II(Single-blind)/Phase III(Double- Blind)Study to Determine the Optimal Dose and to Evaluate the Efficacy and Safety of GCPGC on Chemotherapy-induced Neutropenia Compared to Neulasta(Pegfilgrastim)|Completed||Phase 2/Phase 3|177|Actual|Green Cross Corporation||4|||f||||f||||||||||2018-05-31 22:44:03.813848|2018-05-31 22:44:03.813848
NCT01328925|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-04-01|2011-04-01|2011-04-05|Estimate|||||||2011-04-01|2011-04-05|Estimate|December 2005||2005-12-31|April 2011|2011-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children|Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children|Completed||Phase 2|100|Actual|Romark Laboratories L.C.||2|||f||||f||||||||||2018-05-31 22:44:03.904942|2018-05-31 22:44:03.904942
NCT01328912|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-02-04|2011-04-04|2011-04-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients|Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients: A Randomized Controlled Trial|Completed||Phase 3|429|Actual|Queen's University||2|||f||||t||||||||||2018-05-31 22:44:03.9682|2018-05-31 22:44:03.9682
NCT01328899|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-03-11|2011-04-04|2011-04-05|Estimate|||||||2014-03-11|2014-03-12|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Feasibility Study of PneumRx's Lung Volume Reduction Coil (LVRC)|Feasibility Study of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema|Completed||Phase 1/Phase 2|60|Actual|PneumRx, Inc.||1|||f||||f||||||||||2018-05-31 22:44:04.097718|2018-05-31 22:44:04.097718
NCT01328886|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2016-11-16|2011-04-04|2011-04-05|Estimate|||||||2016-11-16|2016-11-18|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children|An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment|Completed||Phase 3|38|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:44:04.176245|2018-05-31 22:44:04.176245
NCT01328873|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2016-10-05||2017-06-08|2011-04-04|2011-04-05|Estimate|2017-03-16|2017-04-26|Actual||||2017-06-08|2017-07-11|Actual|March 2011||2011-03-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|October 2015|Actual|2015-10-31||Interventional|||FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates|A Prospective Assessment of the Diagnostic Utility of Emerging Laboratory Assessments Used in Conjunction With FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates|Completed||N/A|49|Actual|Northside Hospital, Inc.||1|||f||||f||||||||No||2018-05-31 22:44:04.298165|2018-05-31 22:44:04.298165
NCT01328860|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-06-06|2011-04-04|2011-04-05|Estimate|||||||2014-06-06|2014-06-10|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|June 2014|Actual|2014-06-30||Interventional|||Autologous Stem Cells for Spinal Cord Injury (SCI) in Children|Safety of Autologous Stem Cell Treatment for Spinal Cord Injury in Children|Terminated||Phase 1|10|Anticipated|Memorial Hermann Health System||1||Principal Investigator relocated to Orlando, Florida.|f||||t||||||||||2018-05-31 22:44:04.52865|2018-05-31 22:44:04.52865
NCT01328821|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-10-25|2011-04-04|2011-04-05|Estimate|||||||2011-10-25|2011-10-26|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499|A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose, Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability Study of CTP-499 in Healthy Adults|Completed||Phase 1|38|Actual|Concert Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:44:04.665673|2018-05-31 22:44:04.665673
NCT01328808|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-08-17|2011-04-01|2011-04-05|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2011||2011-10-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Metabolism and Toxicity of Acetaminophen|Metabolism and Toxicity of Acetaminophen in Preterm Infants|Recruiting||Phase 2/Phase 3|60|Anticipated|Children's Research Institute||1|||f||||f|t|f||||||Yes|There is no plan to share individual participant data. Preliminary data published Published manuscripts in 2015 & 2016|2018-05-31 22:44:04.740637|2018-05-31 22:44:04.740637
NCT01328795|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-04-01|2011-04-01|2011-04-05|Estimate|||||||2011-04-01|2011-04-05|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|CGM@ACS||Cardiogoniometry (CGM) for Early Diagnosis of Acute Coronary Syndromes (ACS)|Cardiogoniometry Zur Früherkennung Akuter Myokardischämien Bei ACS-Symptomatik|Completed||N/A|249|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||||2018-05-31 22:44:04.822136|2018-05-31 22:44:04.822136
NCT01328782|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2012-02-27||2015-05-26|2011-04-04|2011-04-05|Estimate|2012-05-11|2012-06-13|Estimate||||2015-05-26|2015-06-23|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Interventional|||The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures|The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures|Completed||N/A|124|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 22:44:04.889103|2018-05-31 22:44:04.889103
NCT01328769|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|2015-07-07||2015-08-13|2011-04-04|2011-04-05|Estimate|2015-08-13|2015-09-17|Estimate||||2015-08-13|2015-09-17|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)|Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)|Completed||Phase 4|49|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:44:05.279371|2018-05-31 22:44:05.279371
NCT01328756|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|2015-05-15||2015-07-09|2011-04-01|2011-04-05|Estimate|2015-07-09|2015-08-06|Estimate||||2015-07-09|2015-08-06|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 4, Open-Label, Multicentre, Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|314|Actual|Shire|Since this study is an open-label trial, results should be interpreted with caution.|1|||f||||||||||||||2018-05-31 22:44:05.456193|2018-05-31 22:44:05.456193
NCT01328743|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2017-07-03|2011-04-04|2011-04-05|Estimate|||||||2017-07-03|2017-07-06|Actual|May 2011||2011-05-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting|Brief Alcohol Intervention for HIV-Infected Men Who Have Sex With Men (MSM) in a Primary Care Setting|Completed||N/A|180|Actual|Brown University||2|||f||||f||||||||||2018-05-31 22:44:05.892193|2018-05-31 22:44:05.892193
NCT01328730|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-06-13|2011-04-04|2011-04-05|Estimate|||||||2011-06-13|2011-06-14|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|June 2013|Anticipated|2013-06-30|March 2012|Anticipated|2012-03-31||Interventional|REFIRE||The Real-world Firebird 2 Versus Cypher Sirolimus-eluting Stent in Treating Patients With Coronary Artery Disease|Post-marketing Study Comparing the Efficacy and Safety of Firebird 2 Versus Cypher Sirolimus-eluting Stents in Treating Patients With Coronary Artery Disease in China|Withdrawn||Phase 4|430|Anticipated|Shanghai Jiao Tong University School of Medicine||2||the Cypher SES is now withdrawing in China market|f||||t||||||||||2018-05-31 22:44:05.952817|2018-05-31 22:44:05.952817
NCT01328717|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2012-04-27||2016-01-29|2011-04-01|2011-04-05|Estimate|2012-04-27|2012-05-31|Estimate||||2016-01-29|2016-02-29|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Performance of an Investigational Blood Glucose Monitoring System in a Clinical Trial|Clinical Trial Protocol for Contour Link System With Contour Sensor|Completed||N/A|78|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 22:44:06.075583|2018-05-31 22:44:06.075583
NCT01328704|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2014-08-22|2011-04-04|2011-04-05|Estimate|||||||2014-08-22|2014-08-25|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Evaluate the Change in Iron, Vitamin D, and C-Reactive Protein Level (CRP) in a 12 to 24 Week Period|Observational Study to Evaluate Changes in Iron, Vit-D, and CRP During a Twelve to Twenty-Four Week Supervised Triathlon Training Program|Completed|||50|Anticipated|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples Without DNA|"~     Blood samples will be obtained three times throughout the course of the subject's involvement~     in the study: baseline, 3 months, and 6 months.~   "|||2018-05-31 22:44:06.212005|2018-05-31 22:44:06.212005
NCT01328691|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-05-09|2011-04-04|2011-04-05|Estimate|||||||2011-05-09|2011-05-10|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus|Prognostic Factors for Korean Patients With Renal Cell Carcinoma and Venous Tumor Thrombus Extension: Application of the New 2009 TNM Staging System|Completed|||118|Actual|Seoul National University Hospital|||||f||||||||||||||2018-05-31 22:44:06.347292|2018-05-31 22:44:06.347292
NCT01328678|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-07-06|2011-04-04|2011-04-05|Estimate|||||||2011-07-06|2011-07-08|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||A Study of Vitamin D in Subjects With Alopecia Areata|A Pilot Study of Vitamin D in Subjects With Alopecia Areata|Completed|||10|Actual|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:44:06.403151|2018-05-31 22:44:06.403151
NCT01328665|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2013-05-17|2011-04-01|2011-04-05|Estimate|||||||2013-05-17|2013-05-20|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluating an Expressive Writing Intervention About Communicatively-Restricted Organizational Stressors|Evaluating an Expressive Writing Intervention About Communicatively-Restricted Organizational Stressors: A Six-Week Randomized, Controlled Trial|Completed||N/A|44|Actual|Santa Clara University||2|||f||||f||||||||||2018-05-31 22:44:06.467421|2018-05-31 22:44:06.467421
NCT01328652|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-04|2011-04-04|2011-04-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|January 2013|Anticipated|2013-01-31|August 2012|Anticipated|2012-08-31||Interventional|||Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy|A Randomized, Double-blind, Placebo-controlled Study of Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Advanced Center for Specialty Care||1|||f||||f||||||||||2018-05-31 22:44:06.532929|2018-05-31 22:44:06.532929
NCT01328639|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2013-07-09|2011-04-04|2011-04-05|Estimate|||||||2013-07-09|2013-07-11|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|TeamCare-PCN||TeamCare PCN: Collaborative Care for Diabetes and Depression|TeamCare PCN: Collaborative Care for Patients With Diabetes and Depression in Primary Care Networks|Completed||N/A|157|Actual|The Alliance for Canadian Health Outcomes Research in Diabetes||2|||f||||f||||||||||2018-05-31 22:44:06.635978|2018-05-31 22:44:06.635978
NCT01328626|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2018-05-04|2011-04-01|2011-04-05|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 4, 2011|Actual|2011-07-04|May 2018|2018-05-31|November 14, 2019|Anticipated|2019-11-14|November 14, 2019|Anticipated|2019-11-14||Interventional|||A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|221|Actual|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 22:44:06.728793|2018-05-31 22:44:06.728793
NCT01328613|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2018-05-18|2011-04-01|2011-04-04|Estimate|||||||2018-05-18|2018-05-21|Actual|November 9, 2007||2007-11-09|September 29, 2014|2014-09-29|September 29, 2014||2014-09-29|||||Observational|||A Prospective Study of Postpartum Depression in Women With Major Depression|A Prospective Study of Postpartum Depression in Women With Major Depression|Terminated|||85|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:44:06.814258|2018-05-31 22:44:06.814258
NCT01328600|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2018-05-15|2011-04-01|2011-04-04|Estimate|||||||2018-05-15|2018-05-16|Actual|August 16, 2006||2006-08-16|July 29, 2014|2014-07-29|July 29, 2014||2014-07-29|||||Observational|||Marinobufagenin as a Target for DIGIBIND in Preeclampsia|Marinobufagenin as a Target for DIGIBIND in Preeclampsia|Completed|||144|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:44:06.875901|2018-05-31 22:44:06.875901
NCT01328587|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2018-05-23|2011-04-01|2011-04-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 1, 2011||2011-04-01|May 15, 2018|2018-05-15|March 30, 2025|Anticipated|2025-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Eltrombopag for Moderate Aplastic Anemia|A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients|Active, not recruiting||Phase 2|33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:44:06.943317|2018-05-31 22:44:06.943317
NCT01328574|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2015-02-13||2016-11-16|2011-04-01|2011-04-04|Estimate|2015-02-13|2015-03-02|Estimate||||2016-11-16|2017-01-13|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma|A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma|Completed||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||No||2018-05-31 22:44:07.019566|2018-05-31 22:44:07.019566
NCT01328561|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2018-02-13|2011-04-01|2011-04-04|Estimate|||||||2018-02-13|2018-02-14|Actual|March 17, 2011||2011-03-17|March 4, 2015|2015-03-04|March 4, 2015||2015-03-04|||||Observational|||Oxytocin and Arginine Vasopressin in Pain Relief|The Role of Oxytocin and Arginine Vasopressin in Human Placebo Analgesia|Terminated|||167|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:44:07.476714|2018-05-31 22:44:07.476714
NCT01328548|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2016-03-03||2018-03-15|2011-04-01|2011-04-04|Estimate|2017-03-03|2017-04-14|Actual||||2018-03-15|2018-03-19|Actual|May 2011||2011-05-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Zoster Vaccine Response in the Frail Elderly|Immune and Genetic Correlates of Response to Zoster Vaccine in the Frail Elderly: a Pilot Study|Completed|||241|Actual|McMaster University|||3||f||||f||||||Samples With DNA|"~     Retained specimens include DNA and blood cells.~   "|||2018-05-31 22:44:07.538181|2018-05-31 22:44:07.538181
NCT01328535|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2018-04-03|2011-04-01|2011-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2011|Actual|2011-01-31|April 2018|2018-04-30|December 15, 2018|Anticipated|2018-12-15|June 22, 2013|Actual|2013-06-22||Interventional|||Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|Individualized (Timed) Temozolomide Administration as a Means of Immune Reconstitution in Patients With Metastatic Melanoma|Active, not recruiting||Phase 2|25|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 22:44:07.776353|2018-05-31 22:44:07.776353
NCT01328522|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2011-10-21|2011-03-31|2011-04-04|Estimate|||||||2011-10-21|2011-10-24|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients||Completed||Phase 1|32|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:44:07.842833|2018-05-31 22:44:07.842833
NCT01328509|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2013-07-04|2011-03-31|2011-04-04|Estimate|||||||2013-07-04|2013-07-08|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Zinc and Inflammation in Sepsis|Zinc and Inflammation in Sepsis|Completed|||39|Actual|University of Aberdeen|||2||f||||f||||||Samples Without DNA|"~     Peripheral whole blood will be sampled from an indwelling arterial line and plasma will be~     separated. Peripheral blood mononuclear cells will be separated using single density gradient~     centrifugation and RNA extracted. Nuclear extracts of MNC will also be prepared.~   "|||2018-05-31 22:44:07.901249|2018-05-31 22:44:07.901249
NCT01328496|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2017-03-23||2017-05-04|2011-03-31|2011-04-04|Estimate|2017-03-23|2017-05-05|Actual||||2017-05-04|2017-06-05|Actual|June 15, 2011|Actual|2011-06-15|March 2017|2017-03-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen|Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen|Completed||Phase 2|14|Actual|St. Jude Children's Research Hospital||2|||f||||f|t|f|||f|||||2018-05-31 22:44:08.090029|2018-05-31 22:44:08.090029
NCT01328483|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-09-26|2011-04-01|2011-04-04|Estimate|||||||2015-09-26|2015-09-29|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|MSAF-OPS||Effect Of Intrapartum Oropharyngeal (IP-OP) Suction on Meconium Aspiration Syndrome|Role of Intrapartum Oropharyngeal (IP-OP) Suction in Neonates Born Through Meconium Stained Amniotic Fluid on Meconium Aspiration Syndrome|Completed||N/A|540|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 22:44:08.700003|2018-05-31 22:44:08.700003
NCT01328470|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-04-01|2011-04-01|2011-04-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|CKD||Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease|Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel|Completed||Phase 4|85|Actual|Kyunghee University Medical Center||4|||f||||t||||||||||2018-05-31 22:44:08.837934|2018-05-31 22:44:08.837934
NCT01328457|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-04-02|2011-04-01|2011-04-04|Estimate|||||||2014-04-02|2014-04-04|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|May 2011|Actual|2011-05-31||Interventional|||An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh|An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh|Completed||N/A|120|Actual|PATH|||||f||||t||||||||||2018-05-31 22:44:08.957837|2018-05-31 22:44:08.957837
NCT01328444|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2013-12-19|2012-12-13|2017-10-09|2011-04-01|2011-04-04|Estimate|2013-12-19|2014-02-10|Estimate|2012-12-13|2012-12-19|Estimate|2017-10-09|2017-10-11|Actual|March 1, 2011||2011-03-01|October 2017|2017-10-31|June 14, 2012|Actual|2012-06-14|June 1, 2012|Actual|2012-06-01||Interventional|COPD||An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A|An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A|Completed||Phase 3|349|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:44:09.124512|2018-05-31 22:44:09.124512
NCT01328431|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2014-07-08||2014-07-08|2011-03-31|2011-04-04|Estimate|2014-07-08|2014-08-04|Estimate||||2014-07-08|2014-08-04|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|April 2013|Actual|2013-04-30||Interventional|||Treating Low-Income Smokers in the Hospital Emergency Department|Treating Low-Income Smokers in the Hospital Emergency Department|Completed||N/A|780|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:44:10.049199|2018-05-31 22:44:10.049199
NCT01328418|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2011-04-01|2011-04-01|2011-04-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|April 2002||2002-04-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2008|Actual|2008-03-31||Interventional|||Simultaneous Lengthening of Bilateral Femora and Tibiae in Achondroplastic Patients|Simultaneous Lengthening of Bilateral Femora and Tibiae in Achondroplastic Patients|Completed||N/A|22|Actual|Bilen, Fikri Erkal, M.D.||1|||f||||||||||||||2018-05-31 22:44:10.244148|2018-05-31 22:44:10.244148
NCT01328405|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|2012-07-02||2015-10-01|2011-03-31|2011-04-04|Estimate|2012-07-02|2012-08-10|Estimate||||2015-10-01|2015-10-23|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Air-Q Intubating Laryngeal Airway Versus the Laryngeal Mask Airway (LMA)-Proseal|The Air-Q Intubating Laryngeal Airway Versus the LMA-Proseal: A Prospective, Randomized Trial of Airway Seal Pressure|Completed||Phase 4|100|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 22:44:10.303762|2018-05-31 22:44:10.303762
NCT01328392|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-06-30|2011-03-31|2011-04-04|Estimate|||||||2017-06-30|2017-07-05|Actual|May 2011||2011-05-31|March 2011|2011-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Evaluating Treatment Response in Laryngo-Pharyngeal Reflux|Evaluating Treatment Response in Laryngo-Pharyngeal Reflux|Withdrawn||N/A|0|Actual|University of Washington||||The sponsor did not fund the study.|f||||||||||||||2018-05-31 22:44:10.553902|2018-05-31 22:44:10.553902
NCT01328379|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|2013-04-16||2013-09-03|2011-04-01|2011-04-04|Estimate|2013-07-11|2013-08-13|Estimate||||2013-09-03|2013-09-05|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional||Safety Population: All randomized patients who took at least one dose of study medication.|Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis|Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis|Completed||Phase 3|430|Actual|Acorda Therapeutics||3|||f||||t||||||||||2018-05-31 22:44:10.758953|2018-05-31 22:44:10.758953
NCT01328366|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2015-05-29||2015-06-11|2011-04-01|2011-04-04|Estimate|2015-05-29|2015-06-11|Estimate||||2015-06-11|2015-07-09|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|Body Image|The participants had severe disease as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and had not responded to standard systemic therapies. Baseline demographic data was not available for all participants.|Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab|A Real World Observational Study to Evaluate the Impact of Adalimumab Therapy on Quality of Life and Psychological Factors Associated With Severe Psoriasis|Completed|||153|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:44:11.360134|2018-05-31 22:44:11.360134
NCT01328353|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2014-09-03|2011-04-01|2011-04-04|Estimate|||||||2014-09-03|2014-09-05|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Telehealth Nursing Intervention for Children With Complex Health Care Needs (CCHCN)|Telehealth Nursing Intervention for Children With Complex Health Care Needs|Completed||Phase 3|163|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 22:44:12.541628|2018-05-31 22:44:12.541628
NCT01328340|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-10-03|2011-04-01|2011-04-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2005||2005-06-30|October 2016|2016-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||High-speed Power Training in Older Adults With Knee Osteoarthritis (OA)|The Effect of High-speed Power Training on Muscle Performance, Function and Pain in Older Adults With Knee OA|Completed||N/A|48|Actual|University of Missouri-Columbia||3|||f||||f||||||||No||2018-05-31 22:44:12.609248|2018-05-31 22:44:12.609248
NCT01328301|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-03-18|2011-04-01|2011-04-04|Estimate|||||||2015-03-18|2015-03-20|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Speed-dependent Treadmill Training in Patients With Subacute Stroke|Speed-dependent Treadmill Training is Effective to Improve Gait and Balance Performance in Patients With Sub-acute Stroke|Completed||N/A|30|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 22:44:12.685304|2018-05-31 22:44:12.685304
NCT01328288|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2016-02-19|2011-04-01|2011-04-04|Estimate|||||||2016-02-19|2016-02-22|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Progress Pediatric Study|The Thai Pediatric HIV Disease Progression: An Observational Database|Completed|||840|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||f||||||Samples With DNA|"~     serum~   "|||2018-05-31 22:44:12.752119|2018-05-31 22:44:12.752119
NCT01328275|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2016-05-09|2011-04-01|2011-04-04|Estimate|||||||2016-05-09|2016-05-11|Estimate|December 2007||2007-12-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Progress Adult Study|The Thai HIV Disease Progression: An Observational Database|Completed|||5600|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||f||||||Samples With DNA|"~     serum~   "|||2018-05-31 22:44:12.833458|2018-05-31 22:44:12.833458
NCT01327742|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2012-11-16|2011-04-01|2011-04-04|Estimate|||||||2012-11-16|2012-11-19|Estimate||||November 2012|2012-11-30||||||||Expanded Access|||Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft|Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies|Approved for marketing|||||Bolton Medical|||||||||||||||||||2018-05-31 22:44:23.8989|2018-05-31 22:44:23.8989
NCT01328262|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2017-08-09|2011-04-01|2011-04-04|Estimate|||||||2017-08-09|2017-08-10|Actual|November 2010||2010-11-30|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching|A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching|Suspended||N/A|60|Anticipated|Haukeland University Hospital||2||"Few patients, time consuming to find suiting blood bags with the right weight."|f||||f||||||||||2018-05-31 22:44:12.899967|2018-05-31 22:44:12.899967
NCT01328249|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-03-10|2011-04-01|2011-04-04|Estimate|||||||2017-03-10|2017-03-13|Actual|March 2, 2011|Actual|2011-03-02|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|October 27, 2014|Actual|2014-10-27||Interventional|||Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer|A Phase II, Single-Arm, Feasibility Study of Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer|Active, not recruiting||Phase 2|81|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 22:44:13.066762|2018-05-31 22:44:13.066762
NCT01328236|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-09-21|2011-04-01|2011-04-04|Estimate|||||||2011-09-21|2011-09-22|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|September 2015|Anticipated|2015-09-30|September 2013|Anticipated|2013-09-30||Interventional|Bortezomib||Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia|Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia|Unknown status|Recruiting|Phase 2|20|Anticipated|Clinical Service, China||1|||f||||t||||||||||2018-05-31 22:44:13.146311|2018-05-31 22:44:13.146311
NCT01328223|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|||2011-04-01|2011-04-01|2011-04-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Observational|||Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma|Phase II Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting||45|Anticipated|China Medical University Hospital|||1||f||||t||||||||||2018-05-31 22:44:13.246417|2018-05-31 22:44:13.246417
NCT01328210|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-11-05|2011-04-01|2011-04-04|Estimate|||||||2011-11-05|2011-11-08|Estimate|July 2008||2008-07-31|November 2011|2011-11-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Blood Letting in Metabolic Syndrome|Effects of Blood Letting on Insulin Sensitivity and Blood Pressure in Patients With Metabolic Syndrome: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|64|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:44:13.399689|2018-05-31 22:44:13.399689
NCT01328197|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2017-12-18|2011-04-01|2011-04-04|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2011||2011-06-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|April 2013|Actual|2013-04-30||Interventional|||Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms|A Phase I Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms|Completed||Phase 1|30|Actual|Bolton Medical||1|||f||||t||||||||||2018-05-31 22:44:13.566995|2018-05-31 22:44:13.566995
NCT01328184|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2014-05-16||2014-05-16|2011-04-01|2011-04-04|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|April 2011||2011-04-30|May 2014|2014-05-31||||July 2011|Actual|2011-07-31||Interventional|||Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon|An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers|Completed||Phase 1|18|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:44:13.675495|2018-05-31 22:44:13.675495
NCT01328171|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-01-20|2011-04-01|2011-04-04|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2011|Actual|2011-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|VOLFI||FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)|An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type|Recruiting||Phase 2|93|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 22:44:14.151898|2018-05-31 22:44:14.151898
NCT01328158|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|2014-12-12||2014-12-12|2011-04-01|2011-04-04|Estimate|2014-12-12|2014-12-22|Estimate||||2014-12-12|2014-12-22|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.|Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection|Drug Use Investigation of Kaletra Tablets (Quaque Die, QD) on Patients With HIV-infection|Completed|||236|Actual|AbbVie|||1||f||||||||||||||2018-05-31 22:44:14.368743|2018-05-31 22:44:14.368743
NCT01328145|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2012-12-24|2011-04-01|2011-04-04|Estimate|||||||2012-12-24|2012-12-25|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|ASA-COPD||Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease|Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Trial|Unknown status|Recruiting|Phase 2|74|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 22:44:15.247586|2018-05-31 22:44:15.247586
NCT01328132|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2011-03-31|2011-03-31|2011-04-04|Estimate|||||||2011-03-31|2011-04-04|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant||Unknown status|Not yet recruiting|Phase 4|20|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 22:44:15.326049|2018-05-31 22:44:15.326049
NCT01328119|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-06-12|2011-03-31|2011-04-04|Estimate|||||||2013-06-12|2013-06-13|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Uremic Toxin Removal and Hemodynamics in Long-hour Hemodialysis and Hemodiafiltration|Uremic Toxin Removal and Hemodynamics in Long-hour Hemodialysis and Hemodiafiltration; a Randomized Cross-over Study|Completed||N/A|20|Actual|Maastricht University Medical Center||1|||f||||||||||||||2018-05-31 22:44:15.403056|2018-05-31 22:44:15.403056
NCT01328106|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2017-12-08|2011-03-31|2011-04-04|Estimate|||||||2017-12-08|2017-12-12|Actual|November 2010||2010-11-30|December 2017|2017-12-31|May 2012|Anticipated|2012-05-31|August 2011|Anticipated|2011-08-31||Interventional|||Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma|A Single-Arm, Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in Subjects With Metastatic Uveal Melanoma or With Mutation-Positive GNAQ or GNA11 Metastatic Melanoma|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||1||"The study was cancelled by the sponsor prior to initiation of study enrollment. No subjects~   were accrued."|f||||f||||||||||2018-05-31 22:44:15.472851|2018-05-31 22:44:15.472851
NCT01328093|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31||2013-01-11|2013-01-11|2011-03-31|2011-04-04|Estimate||||2013-01-11|2013-01-21|Estimate|2013-01-11|2013-01-21|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients|A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023|Terminated||Phase 3|670|Anticipated|Eli Lilly and Company||2||"The decision to stop the trial was based on efficacy results in the overall schizophrenia~   participant population."|f||||t||||||||||2018-05-31 22:44:15.554019|2018-05-31 22:44:15.554019
NCT01328080|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2014-04-21||2017-02-28|2011-04-01|2011-04-04|Estimate|2014-05-19|2014-06-16|Estimate||||2017-02-28|2017-03-29|Actual|February 2011||2011-02-28|February 2017|2017-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy|Improving Acne Keloidalis Nuchae by Inducing Matrix Metalloproteinases in Vivo Using Targeted Ultraviolet-B Irradiation|Completed||N/A|11|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:44:15.688782|2018-05-31 22:44:15.688782
NCT01328067|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2012-04-26|2011-04-01|2011-04-04|Estimate|||||||2012-04-26|2012-04-27|Estimate|June 2011||2011-06-30|April 2012|2012-04-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids|A Randomized Study to Evaluate the Safety and Effectiveness of MRgFUS Procedure Compared With Myomectomy for the Treatment of Uterine Fibroids|Terminated||Phase 4|440|Anticipated|InSightec||2|||f||||f||||||||||2018-05-31 22:44:15.817021|2018-05-31 22:44:15.817021
NCT01328054|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2016-01-28||2016-05-02|2011-03-31|2011-04-04|Estimate|2016-05-02|2016-06-08|Estimate||||2016-05-02|2016-06-08|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval|A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer|Completed||Phase 4|58|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:44:16.038398|2018-05-31 22:44:16.038398
NCT01328041|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2013-08-15||2015-12-07|2011-03-31|2011-04-04|Estimate|2014-07-17|2014-07-21|Estimate||||2015-12-07|2016-01-07|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2012|Actual|2012-05-31||Interventional|VIKING-3||A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.|A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.|Completed||Phase 3|183|Actual|ViiV Healthcare||1|||f||||t||||||||||2018-05-31 22:44:17.076165|2018-05-31 22:44:17.076165
NCT01328028|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2012-08-23|2011-03-31|2011-04-04|Estimate|||||||2012-08-23|2012-08-27|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand|Hospital-based Epidemiological Study on the Distribution of Human Papillomavirus (HPV) Types in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) in New Zealand|Completed|||244|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Cervical specimen~   "|||2018-05-31 22:44:17.910192|2018-05-31 22:44:17.910192
NCT01328015|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-04-01|2011-04-01|2011-04-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis|The Use of Oxybutynin in Women After Thoracoscopic Sympathectomy and the Effect on Plantar Hyperhidrosis|Completed||Phase 2|32|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:44:17.988048|2018-05-31 22:44:17.988048
NCT01328002|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2012-08-23|2011-04-01|2011-04-04|Estimate|||||||2012-08-23|2012-08-24|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|MyFi||Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia|A Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia|Terminated||Phase 2|118|Actual|Forest Laboratories||2|||f||||t||||||||||2018-05-31 22:44:18.144204|2018-05-31 22:44:18.144204
NCT01327989|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2016-10-12||2016-12-05|2011-04-01|2011-04-04|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Observational|STAR|Pre-stroke mRS scores are missing for 24 subjects as it was not recorded or determinable.|Solitaire FR Thrombectomy for Acute Revascularisation|STAR: Solitaire FR Thrombectomy for Acute Revascularisation|Completed|||202|Actual|Medtronic Neurovascular Clinical Affairs|||1||f||||t||||||||||2018-05-31 22:44:18.288329|2018-05-31 22:44:18.288329
NCT01327976|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2016-03-03||2017-08-01|2011-04-01|2011-04-04|Estimate|2016-04-21|2016-05-27|Estimate||||2017-08-01|2017-08-30|Actual|May 2011||2011-05-31|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|February 2013|Actual|2013-02-28||Interventional|ReCharge||The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity|A Randomized, Double Blind Sham Controlled Clinical Trial to Evaluate the Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity|Active, not recruiting||N/A|239|Actual|EnteroMedics||2|||f||||t||||||||No||2018-05-31 22:44:18.655666|2018-05-31 22:44:18.655666
NCT01327963|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-02-07|2011-03-31|2011-04-04|Estimate|||||||2017-02-07|2017-02-09|Estimate|September 2010||2010-09-30|February 2017|2017-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|RetroTIF||Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study|Long-term Outcomes After Transoral Incisionless Fundoplication (TIF) Performed in Routine Clinical Practice: The Retro TIF Study|Terminated||N/A|28|Actual|EndoGastric Solutions||1||The sponsor is focusing on prospective randomized studies|f||||f||||||||Undecided||2018-05-31 22:44:18.996313|2018-05-31 22:44:18.996313
NCT01327950|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2014-01-29|2011-04-01|2011-04-04|Estimate|||||||2014-01-29|2014-01-30|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Observational|EPIC SFA BR||Efficacy of the EPIC Nitinol Vascular Stent System in Superficial Femoral Artery (SFA) Lesions|EPIC SFA - Physician Initiated Trial Investigating the Efficacy of the EPICTM Nitinol Vascular Stent System (Boston Scientific) in Superficial Femoral Lesions: A Prospective, Multi-center Non- Randomized Study - Endoconsul 003|Completed|||86|Actual|Endovascular Consultoria Limitada|||1||f||||t||||||||||2018-05-31 22:44:19.060985|2018-05-31 22:44:19.060985
NCT01327937|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2015-09-23|2011-03-31|2011-04-04|Estimate|||||||2015-09-23|2015-09-24|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers|A Prospective, Randomized, Controlled, Single-Site Post Marketing Study to Identify & Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers|Completed||Phase 4|30|Actual|Organogenesis||2|||f||||f||||||||||2018-05-31 22:44:19.115966|2018-05-31 22:44:19.115966
NCT01327924|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2014-06-23|2011-03-31|2011-04-04|Estimate|||||||2014-06-23|2014-06-24|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone|Ease of Use and Tolerability of Norditropin NordiFlex® in Growth Hormone naïve Children: Impact on Daily Life|Completed|||77|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:44:19.189705|2018-05-31 22:44:19.189705
NCT01327911|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2016-11-21|2011-04-01|2011-04-04|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)|A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)|Completed||Phase 1|7|Actual|Neurotech Pharmaceuticals||1|||f||||t||||||||||2018-05-31 22:44:19.264957|2018-05-31 22:44:19.264957
NCT01327898|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-07-24|2011-04-01|2011-04-04|Estimate|||||||2014-07-24|2014-07-25|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|December 2011|Actual|2011-12-31||Interventional|||Risk Reduction for Urban Substance Using Men Who Have Sex With Men (MSM)||Completed||Phase 2|515|Actual|Nova Southeastern University||2|||f||||t||||||||||2018-05-31 22:44:19.330755|2018-05-31 22:44:19.330755
NCT01327885|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|2017-01-06||2018-02-13|2011-04-01|2011-04-04|Estimate|2017-01-06|2017-02-28|Actual||||2018-02-13|2018-03-12|Actual|March 2011||2011-03-31|February 2018|2018-02-28|August 2016|Actual|2016-08-31|January 2015|Actual|2015-01-31||Interventional||Full analysis set (FAS) (Intent-to-Treat (ITT) analysis set) included all participants who were randomized.|Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma|A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma|Completed||Phase 3|452|Actual|Eisai Inc.||2|||f||||t||||||||||2018-05-31 22:44:19.510823|2018-05-31 22:44:19.510823
NCT01327872|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-03-08|2011-03-31|2011-04-04|Estimate|||||||2012-03-08|2012-03-09|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects|A Randomized, Open-Label, 4-Group, 2-Period Replicate Design Study to Evaluate Within- and Between-Subject Variability in Exposure of Two Lots of E5501 20 mg Tablets, Administered as Single Doses of 40 mg, in the Fasted and Fed Conditions to Healthy Subjects|Completed||Phase 1|84|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 22:44:20.502107|2018-05-31 22:44:20.502107
NCT01327859|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-11-02|2011-04-01|2011-04-04|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2003||2003-03-31|November 2015|2015-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia|A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia|Completed||Phase 3|357|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 22:44:20.589087|2018-05-31 22:44:20.589087
NCT01327846|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29||2018-02-23|2018-03-19|2011-03-31|2011-04-04|Estimate||||2018-02-23|2018-02-26|Actual|2018-03-19|2018-03-20|Actual|April 11, 2011|Actual|2011-04-11|March 2018|2018-03-31|March 2, 2020|Anticipated|2020-03-02|March 28, 2017|Actual|2017-03-28||Interventional|CANTOS||Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)|A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP|Active, not recruiting||Phase 3|10061|Actual|Novartis||4||||||||t|f||||||||2018-05-31 22:44:20.824522|2018-05-31 22:44:20.824522
NCT01327833|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2011-04-01|2011-04-01|2011-04-04|Estimate|||||||2011-04-01|2011-04-04|Estimate||||March 2011|2011-03-31||||||||Observational|CODE||CODE Registry - Cardiac Arrest Outcomes Data Evaluation|Cardiac Arrest Outcomes Data Evaluation|Completed|||||Instituto Dante Pazzanese de Cardiologia|||1||f||||||||||||||2018-05-31 22:44:22.436054|2018-05-31 22:44:22.436054
NCT01327820|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-03-23|2011-04-01|2011-04-04|Estimate|||||||2016-03-23|2016-03-24|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Study of Post-operative Oxygen Consumption Following Vascular Surgery|Study of Post-operative Oxygen Consumption Following Vascular Surgery|Completed|||27|Actual|NHS Lothian|||3||f||||f||||||||||2018-05-31 22:44:22.484531|2018-05-31 22:44:22.484531
NCT01327807|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2014-03-10|2011-04-01|2011-04-04|Estimate|||||||2014-03-10|2014-03-12|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|CCIR||Cure Cystinosis International Registry|Cure Cystinosis International Registry|Recruiting|||750|Anticipated|Cystinosis Research Foundation|||1||f||||f||||||||||2018-05-31 22:44:22.535203|2018-05-31 22:44:22.535203
NCT01327794|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2016-06-28|2011-03-31|2011-04-04|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer|The Relationship of Serum 25-Hydroxyvitamin D to Overall Survival in Advanced Pancreatic Cancer|Completed|||265|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 22:44:22.603823|2018-05-31 22:44:22.603823
NCT01327781|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2018-04-20|2011-03-31|2011-04-04|Estimate|||||||2018-04-20|2018-04-23|Actual|March 25, 2011|Actual|2011-03-25|April 2018|2018-04-30||||January 15, 2017|Actual|2017-01-15||Interventional|||Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer|Phase I Study of Z-Endoxifen as a Hormonal Therapy for Breast Cancer|Active, not recruiting||Phase 1|41|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 22:44:22.703182|2018-05-31 22:44:22.703182
NCT01327768|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-09-29|2011-04-01|2011-04-04|Estimate|||||||2011-09-29|2011-10-03|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|OECs||Implantation of Olfactory Ensheathing Cells (OECs)|Evaluation of Safety, Feasibility and Treatment Potential for Old Stroke Patients Using Intracerebral Implantation of Olfactory Ensheathing Cells|Unknown status|Recruiting|Phase 1|6|Anticipated|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 22:44:22.786665|2018-05-31 22:44:22.786665
NCT01327755|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-10-28|2011-04-01|2011-04-04|Estimate|||||||2013-10-28|2013-10-29|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|RSST||Rwanda Selenium Supplementation Clinical Trial|Effect of Selenium Supplementation on CD4 + Cell Recovery, Viral Suppression, Morbidity and Quality of Life of HIV Infected Patients in Rwanda: a Prospective, Double-Blinded, Placebo-Controlled Trial|Completed||Phase 3|300|Anticipated|The Canadian College of Naturopathic Medicine||2|||f||||f||||||||||2018-05-31 22:44:23.825293|2018-05-31 22:44:23.825293
NCT01327729|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2011-04-01|2011-04-01|2011-04-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|May 2013|Anticipated|2013-05-31|April 2011|Anticipated|2011-04-30||Interventional|||Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C|Clinical Trial of the Efficacy, Dosing, Safety and Tolerability of Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|BioGeneric Pharma||3|||f||||t||||||||||2018-05-31 22:44:23.972439|2018-05-31 22:44:23.972439
NCT01327703|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2014-03-05||2014-03-05|2011-03-31|2011-04-04|Estimate|2014-03-05|2014-04-10|Estimate||||2014-03-05|2014-04-10|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Intent-to-treat (ITT) population included all randomized participants.|Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|An Open-label, Multicenter, Randomized, Cross-over Study to Compare the Safety and Efficacy of PANZYTRAT® 25,000 to KREON® 25,000 in the Control of Steatorrhea in Subjects Aged 7 Years and Older With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)|Completed||Phase 4|87|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 22:44:24.109523|2018-05-31 22:44:24.109523
NCT01327690|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2018-04-23|2011-03-31|2011-04-01|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2010||2010-12-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Mental Health in Veterans and Families After Group Therapies|Mental Health in Veterans and Families After Group Therapies|Recruiting||Early Phase 1|100|Anticipated|Soul Medicine Institute||3|||f||||t||||||||||2018-05-31 22:44:25.439128|2018-05-31 22:44:25.439128
NCT01327677|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|2017-03-09||2017-05-02|2011-03-31|2011-04-01|Estimate|2017-05-02|2017-05-31|Actual||||2017-05-02|2017-05-31|Actual|May 2011||2011-05-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring|Post Craniotomy Analgesia Safety Monitoring With ET CO2|Completed||Phase 4|137|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 22:44:25.533861|2018-05-31 22:44:25.533861
NCT01327664|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-12-05|2011-03-31|2011-04-01|Estimate|||||||2013-12-05|2013-12-06|Estimate|March 2011||2011-03-31|December 2013|2013-12-31||||May 2014|Anticipated|2014-05-31||Interventional|SUPPORT||Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis|A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis|Withdrawn||Phase 3|0|Actual|Novartis||1||Study will not be initiated as planned.|f||||||||||||||2018-05-31 22:44:25.818609|2018-05-31 22:44:25.818609
NCT01327651|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2017-01-05||2017-08-08|2011-03-31|2011-04-01|Estimate|2017-03-30|2017-05-12|Actual||||2017-08-08|2017-09-08|Actual|August 2011||2011-08-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ADAPT|For daily dosing arm in Cape Town, we dropped one participant from analysis, since retrospective test of HIV infection in central lab shows that this participant was seroconverted on week 6(randomization week), so she was not eligible to be randomized. Because of this, total baseline population dropped from 536 to 535.|The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)|The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)|Completed||Phase 2|622|Actual|HIV Prevention Trials Network||3|||f||||t|t|f|||f|||No||2018-05-31 22:44:26.241815|2018-05-31 22:44:26.241815
NCT01327638|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2017-12-04|2011-03-31|2011-04-01|Estimate|||||||2017-12-04|2017-12-05|Actual|February 15, 2011|Actual|2011-02-15|December 2017|2017-12-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)|Safety Data on Etoricoxib From Swedish Registries of Spondyloarthropathy/Ankylosing Spondylitis Patients|Active, not recruiting|||16671|Anticipated|Merck Sharp & Dohme Corp.|||3||f||||f||||||||||2018-05-31 22:44:31.337281|2018-05-31 22:44:31.337281
NCT01327625|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2014-07-08|2011-03-31|2011-04-01|Estimate|||||||2014-07-08|2014-07-09|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans|A Pilot Study Evaluating the Efficacy of Azithromycin, N-acetylcystein and Inhaled Corticosteroid Combination Therapy for Bronchiolitis Obliterans After Allogeneic Hematopoietic Cell Transpantation|Terminated||N/A|6|Actual|Asan Medical Center||1||Preliminary reports of this study was too bad.|f||||f||||||||||2018-05-31 22:44:31.415379|2018-05-31 22:44:31.415379
NCT01327612|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2017-11-28|2011-03-31|2011-04-01|Estimate|||||||2017-11-28|2017-11-30|Actual|March 3, 2011|Actual|2011-03-03|November 2017|2017-11-30|July 25, 2018|Anticipated|2018-07-25|July 25, 2018|Anticipated|2018-07-25||Interventional|||Open Label Extension Study of Conatumumab and AMG 479|A Phase 2 Open Label Extension Study of Conatumumab and AMG 479|Active, not recruiting||Phase 2|12|Actual|Amgen||2|||f||||f||||||||||2018-05-31 22:44:31.510598|2018-05-31 22:44:31.510598
NCT01327599|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2013-11-22||2014-01-13|2011-03-31|2011-04-01|Estimate|2013-11-22|2014-01-10|Estimate||||2014-01-13|2014-02-10|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||This reporting group includes all participants who received study medication and had at least one on-therapy study visit (Intent-to-treat).|Efficacy of Changing to DUOTRAV® From Prior Therapy|Assessing the Efficacy and Tolerability of Changing to DUOTRAV® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed)|Completed||Phase 4|60|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:44:31.625092|2018-05-31 22:44:31.625092
NCT01327586|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-07-16|2011-03-31|2011-04-01|Estimate|||||||2014-07-16|2014-07-17|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Abstinence-Linked Money Management Multisite|Abstinence-Linked Money Management Multisite|Completed||Phase 2|108|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:44:31.789573|2018-05-31 22:44:31.789573
NCT01327573|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-03-27|2011-03-31|2011-04-01|Estimate|||||||2014-03-27|2014-03-28|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|February 2015|Anticipated|2015-02-28|September 2014|Anticipated|2014-09-30||Interventional|||Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation|Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation: A Randomized, Open-Label, Pilot Intervention Trial|Unknown status|Active, not recruiting|Phase 1|16|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:44:31.892974|2018-05-31 22:44:31.892974
NCT01327560|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|||||Observational|||Sleep Quality and Related Factors in Hemodialysis Patients|Sleep Quality and Related Factors in Hemodialysis Patients|Unknown status|Enrolling by invitation||200|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:44:31.999105|2018-05-31 22:44:31.999105
NCT01327547|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|2014-04-09||2017-11-02|2011-03-31|2011-04-01|Estimate|2014-11-13|2014-11-14|Estimate||||2017-11-02|2017-12-06|Actual|May 18, 2011|Actual|2011-05-18|November 2017|2017-11-30|March 24, 2015|Actual|2015-03-24|April 23, 2013|Actual|2013-04-23||Interventional||A participant was included in the FAS if the participant had taken at least one dose of study drug.|A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B|A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus|Completed||Phase 4|138|Actual|ViiV Healthcare|The median time to development of Grade 3 and 4 ALT abnormalities was not estimable due to too few events reported under each treatment group.|2|||f||||t||||||||||2018-05-31 22:44:32.180792|2018-05-31 22:44:32.180792
NCT01327534|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-06-15|2011-03-30|2011-04-01|Estimate|||||||2016-06-15|2016-06-17|Estimate|May 2011||2011-05-31|June 2016|2016-06-30|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|ETAMI||Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI|ETAMI-Study: Early Thienopyridine Treatment to Improve Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction|Completed||Phase 3|63|Actual|Stiftung Institut fuer Herzinfarktforschung||2|||f||||t||||||||No||2018-05-31 22:44:33.886694|2018-05-31 22:44:33.886694
NCT01327521|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-06-07|2011-03-30|2011-04-01|Estimate|||||||2012-06-07|2012-06-11|Estimate|February 2011||2011-02-28|June 2012|2012-06-30||||February 2014|Anticipated|2014-02-28||Interventional|||Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma|International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma|Withdrawn||Phase 3|0|Actual|Stanford University||||Accrual below target levels|f||||t||||||||||2018-05-31 22:44:34.042055|2018-05-31 22:44:34.042055
NCT01327508|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2014-06-06||2018-02-14|2011-03-31|2011-04-01|Estimate|2016-01-05|2016-02-09|Estimate||||2018-02-14|2018-03-14|Actual|April 2011||2011-04-30|February 2018|2018-02-28|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|Sureshot|Unilateral femoral shaft fracture requiring treatment with intramedullary nails, in which the use of sterotactic surgery may be appropriate.|TRIGEN SURESHOT™ Distal Targeting System Study|A Prospective, Multi-center, Randomized, Comparison Study of the TRIGEN SURESHOT™ Distal Targeting vs. Standard Targeting Instrumentation|Terminated||N/A|60|Actual|Smith & Nephew, Inc.||2||Primary endpoint voided. Dosimeters did not capture radiation dose as expected.|f||||f||||||||||2018-05-31 22:44:34.132553|2018-05-31 22:44:34.132553
NCT01327495|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2017-02-15||2017-09-07|2011-03-31|2011-04-01|Estimate|2017-09-07|2017-10-05|Actual||||2017-09-07|2017-10-05|Actual|October 2011|Actual|2011-10-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|PROS-2|62 subjects started treatment, 11 dropped after drug start & pre-study exit visit (7 dropped post-drug start but pre-drug finish, 2 dropped after drug finish but pre-prostate biopsy, 2 dropped for non-compliance). 51 participants included in the analysis.|PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate|Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2)|Completed||Phase 2/Phase 3|62|Actual|University of Washington||6|||f||||t||||||||No||2018-05-31 22:44:34.35439|2018-05-31 22:44:34.35439
NCT01327482|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2014-12-10||2014-12-18|2011-03-31|2011-04-01|Estimate|2014-12-18|2014-12-19|Estimate||||2014-12-18|2014-12-19|Estimate|October 2011||2011-10-31|December 2014|2014-12-31||||December 2012|Actual|2012-12-31||Interventional|||Levels of Raltegravir in the Female Genital Tissue|Modeling Intracellular and Extracellular Raltegravir (RAL) Pharmacokinetics in the Female Genital Tract and Blood After a Twice Daily 400mg Dose Over the Course of a Menstrual Cycle|Completed||N/A|10|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 22:44:35.293269|2018-05-31 22:44:35.293269
NCT01327469|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||The Efficacy of Five Anthelmintic Regimes Against Trichuris Trichiura Infections in Schoolchildren in Jimma, Ethiopia|The Efficacy of 5 Anthelmintic Regimes Against T. Trichiura Infections in Schoolchildren in Jimma, Ethiopia|Completed||Phase 4|2250|Actual|University Ghent||5|||f||||f||||||||||2018-05-31 22:44:35.427993|2018-05-31 22:44:35.427993
NCT01327456|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effects of a Self-management Intervention on Low Literacy Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized Controlled Trial of a Literacy-sensitive Self-management Intervention for Chronic Obstructive Pulmonary Disease Patients|Completed||N/A|99|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 22:44:35.493604|2018-05-31 22:44:35.493604
NCT01327443|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-10-03|2011-03-31|2011-04-01|Estimate|||||||2016-10-03|2016-10-05|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|September 2012|Actual|2012-09-30||Interventional|||Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease|Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease|Completed||N/A|17|Actual|University of Missouri-Columbia||3|||f||||f||||||||No||2018-05-31 22:44:35.580039|2018-05-31 22:44:35.580039
NCT01327430|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phospholipid Absorption of a Milk Phospholipid|Effect of a Milk Phospholipid Supplementation on the Lipid Metabolism in Healthy Volunteers|Completed||N/A|15|Actual|University of Jena||1|||f||||t||||||||||2018-05-31 22:44:35.669275|2018-05-31 22:44:35.669275
NCT01327417|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Late-Life Depression|Cortical/Subcortical Circuits in Late-Life Depression|Unknown status|Recruiting||400|Anticipated|University of Illinois at Chicago|||2||f||||t||||||||||2018-05-31 22:44:35.882849|2018-05-31 22:44:35.882849
NCT01327404|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Depression in Type 2 Diabetes|Myelin, Glia and Depression in Type 2 Diabetes|Unknown status|Recruiting||400|Anticipated|University of Illinois at Chicago|||4||f||||t||||||||||2018-05-31 22:44:35.961195|2018-05-31 22:44:35.961195
NCT01327391|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2014-12-05|2011-03-31|2011-04-01|Estimate|||||||2014-12-05|2014-12-08|Estimate|May 2005||2005-05-31|March 2011|2011-03-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|on-line-HDF||"Tolerance of on Line Hemodiafiltration in Chronic Renal Failure Patients"|"Tolerance of on Line Hemodiafiltration and Impact on Morbidity and Cardiovascular Risk Factors in Chronic Renal Failure Patients"|Completed||Phase 4|415|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 22:44:36.096746|2018-05-31 22:44:36.096746
NCT01327378|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|March 2009||2009-03-31|June 2010|2010-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|UREMINC||The Incretin Effect in Patients With Kidney Impairment|The Incretin Effect in Non-diabetic Patients With Severe Renal Impairment Depending on Chronic Dialysis Treatment|Completed|||30|Actual|University Hospital, Gentofte, Copenhagen|||3||f||||f||||||Samples Without DNA|"~     Plasma (10 ml per participant)~   "|||2018-05-31 22:44:36.188877|2018-05-31 22:44:36.188877
NCT01327365|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-03-05|2011-03-31|2011-04-01|Estimate|||||||2013-03-05|2013-03-06|Estimate|August 2010||2010-08-31|March 2013|2013-03-31||||September 2013|Anticipated|2013-09-30||Interventional|Sheathless-TRI||Trans-Radial Coronary Interventions Using A Sheathless Guiding Catheter|Trans-Radial Percutaneous Coronary Interventions Using a Sheathless Guiding Catheter-Based Approach|Unknown status|Recruiting|Phase 2|250|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 22:44:36.247774|2018-05-31 22:44:36.247774
NCT01327352|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2012-06-20|2011-03-30|2011-04-01|Estimate|||||||2012-06-20|2012-06-21|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of the Influence of Food Regimen on Oshadi D Absorption|A Single Center, Non-randomized, Placebo Controlled Study for the Evaluation of the Influence of Food Regimen on Oshadi D Absorption|Completed||N/A|8|Actual|Oshadi Drug Administration||1|||f||||f||||||||||2018-05-31 22:44:36.335719|2018-05-31 22:44:36.335719
NCT01327339|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2011-03-03||2017-08-14|2011-03-03|2011-04-01|Estimate|2011-03-03|2011-04-01|Estimate||||2017-08-14|2017-09-12|Actual|April 1, 2006|Actual|2006-04-01|August 2017|2017-08-31|November 30, 2009|Actual|2009-11-30|November 30, 2009|Actual|2009-11-30||Observational|REQUIP RLS PMS||REQUIP RLS Post Marketing Surveillance|An Open-label, Multi-centre, Observational, Post-marketing Surveillance to Monitor the Safety of REQUIP(Ropinirole) Administered in Korean Restless Leg Syndrome Patients According to the Prescribing Information|Completed|||755|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:44:36.40512|2018-05-31 22:44:36.40512
NCT01327326|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2012-07-11|2011-03-31|2011-04-01|Estimate|||||||2012-07-11|2012-07-13|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain|Opioid Modulation of Two Models of Pain Inhibition in Healthy Controls and Patients With Temporomandibular Disorder (TMD)|Withdrawn||N/A|0|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:44:36.683873|2018-05-31 22:44:36.683873
NCT01327313|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2016-04-08||2016-04-08|2011-03-31|2011-04-01|Estimate|2016-04-08|2016-05-13|Estimate||||2016-04-08|2016-05-13|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional||The all-subjects set included all the subjects who signed the informed consent and were treated.|A Study of EMD525797 in Solid Tumor Patients in Japan|A Phase I, Open-label Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of EMD525797 After Single Dose and Repeated Dosing at Different Dose Levels in Japanese Patients With Advanced or Metastatic Solid Tumors and Progressive Diseases Following Prior Chemotherapy|Completed||Phase 1|27|Actual|Merck KGaA||4|||f||||f||||||||||2018-05-31 22:44:36.806704|2018-05-31 22:44:36.806704
NCT01327300|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2013-04-04||2014-01-15|2011-03-31|2011-04-01|Estimate|2014-01-15|2014-02-12|Estimate||||2014-01-15|2014-02-12|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|IBS||Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)|Randomized, Double-blind, Cross-over Study of the Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)|Completed||Phase 2|7|Actual|University of Florida|The recruitment for this study ended on 3/2012 when Dr. Moshiree became adjunct faculty only at the University Florida. This study was limited with over 6 months of follow-up and the need for three endoscopies.|2|||f||||f||||||||||2018-05-31 22:44:37.847502|2018-05-31 22:44:37.847502
NCT01327287|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2015-04-16|2011-03-31|2011-04-01|Estimate|||||||2015-04-16|2015-04-17|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|Thoracic||Early Aggressive Pain Management is Associated With Improved Outcomes in Blunt Thoracic Trauma|Early Aggressive Pain Management is Associated With Improved Outcomes in Blunt Thoracic Trauma|Terminated|||43|Actual|University of California, San Francisco|||2|inability to recruit participants despite numerous attempts|f||||f||||||||||2018-05-31 22:44:38.153256|2018-05-31 22:44:38.153256
NCT01327274|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2017-10-24||2018-05-14|2011-03-31|2011-04-01|Estimate|2018-05-14|2018-05-17|Actual||||2018-05-14|2018-05-17|Actual|December 2011||2011-12-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|November 2016|Actual|2016-11-30||Interventional|3MP||Multicenter Trial of Magnetic Mini-Mover for Pectus Excavatum|Phase 3 Multicenter Study of Magnetic Mini-Mover for Pectus Excavatum|Active, not recruiting||N/A|15|Actual|University of California, San Francisco||1|||f||||t||||||||No|The end results will be published in Journal of Pediatric Surgery June 2017|2018-05-31 22:44:38.209828|2018-05-31 22:44:38.209828
NCT01327261|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-08-03|2011-03-31|2011-04-01|Estimate|||||||2011-08-03|2011-08-04|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|PHOE10903||Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers|Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers: A Single- Dose Randomized- Sequence, Open -Label Crossover Study|Completed||Phase 4|24|Actual|University of Buenos Aires||2|||f||||t||||||||||2018-05-31 22:44:38.383112|2018-05-31 22:44:38.383112
NCT01327248|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-06-26|2011-03-31|2011-04-01|Estimate|||||||2012-06-26|2012-06-27|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|Frabo||Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans|Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans|Completed|||40|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, and Sputum~   "|||2018-05-31 22:44:38.436683|2018-05-31 22:44:38.436683
NCT01327235|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-07-31|2011-03-31|2011-04-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites|A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites|Completed||Phase 2|336|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 22:44:38.822068|2018-05-31 22:44:38.822068
NCT01327222|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|LOW-VISION||Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)|Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration|Completed||Phase 3|20|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-05-31 22:44:39.214324|2018-05-31 22:44:39.214324
NCT01327196|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-09-04|2011-03-31|2011-04-01|Estimate|||||||2014-09-04|2014-09-05|Estimate|June 2010||2010-06-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|DECRIVAM||Cognitive Impairment and Cardiovascular Risk in Older|Detection of Mild Cognitive Impairment in People Older Than 65 Years of Age and Its Relationship to Cardiovascular Risk Factors (DECRIVAM)|Completed|||327|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|||||f||||f||||||||||2018-05-31 22:44:39.399066|2018-05-31 22:44:39.399066
NCT01327183|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30||2016-07-08|2016-11-01|2011-03-31|2011-04-01|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention|A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF 2 DOSES OF RO4905417 (R1512) ADMINISTERED TO PATIENTS WITH NON ST-ELEVATION MYOCARDIAL INFARCTION (NON-STEMI) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)|Completed||Phase 2|532|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:44:39.495181|2018-05-31 22:44:39.495181
NCT01327170|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-03-30|2011-03-30|2011-04-01|Estimate|||||||2011-03-30|2011-04-01|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy|Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography|Completed||N/A|15|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 22:44:39.676049|2018-05-31 22:44:39.676049
NCT01327157|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-03-31|2011-03-31|2011-04-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of a New Technique to Improve the Symptoms of Orofacial Discomfort in Patients With Peripheral Facial Paralysis|Neuro Occlusal Rehabilitation in Patient With Peripheral Facial Paralysis - a Randomized Clinical Trial|Completed||N/A|14|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:44:39.848189|2018-05-31 22:44:39.848189
NCT01327144|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-02-03|2011-03-31|2011-04-01|Estimate|||||||2017-02-03|2017-02-06|Estimate|June 2012|Actual|2012-06-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster|A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 500 mg Comparing To Aciclovir 400mg in Patients With Herpes Zoster|Recruiting||Phase 3|168|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 22:44:40.009869|2018-05-31 22:44:40.009869
NCT01327118|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-04-13|2011-03-30|2011-04-01|Estimate|||||||2011-04-13|2011-04-14|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Prostaglandin F2alpha in a Human Headache Model|Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of Prostaglandin F2alpha|Completed||N/A|12|Anticipated|Danish Headache Center||2|||f||||t||||||||||2018-05-31 22:44:40.147811|2018-05-31 22:44:40.147811
NCT01327105|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2018-05-03|2011-03-31|2011-04-01|Estimate|||||||2018-05-03|2018-05-04|Actual|May 17, 2011|Actual|2011-05-17|May 2018|2018-05-31|July 28, 2023|Anticipated|2023-07-28|July 16, 2014|Actual|2014-07-16||Interventional|||Essure Transvaginal Ultrasound (TVU) Study|Use of Transvaginal Ultrasound to Confirm Essure® Micro-insert Placement in Women: Demonstration of Effectiveness|Active, not recruiting||Phase 4|547|Actual|Bayer||1|||f||||t|f|t|f|f||||||2018-05-31 22:44:40.344718|2018-05-31 22:44:40.344718
NCT01327092|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-12-10|2011-03-31|2011-04-01|Estimate|||||||2015-12-10|2015-12-11|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|CHIP||Cincinnati Home Injury Prevention Study|Injury Prevention in a Home Visitation Population|Unknown status|Active, not recruiting|N/A|650|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 22:44:40.454006|2018-05-31 22:44:40.454006
NCT01327079|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-02-09|2011-03-31|2011-04-01|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2010||2010-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Methadone||The Use of Methadone in Newborn Infants|Optimizing the Use of Methadone in Newborn Infants|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Children's Research Institute||2|||f||||t||||||||||2018-05-31 22:44:40.561587|2018-05-31 22:44:40.561587
NCT01327066|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-03-06|2011-03-31|2011-04-01|Estimate|||||||2012-03-06|2012-03-07|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose|A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough ECG Trial|Completed||Phase 1|52|Actual|Chelsea Therapeutics||4|||f||||f||||||||||2018-05-31 22:44:40.667113|2018-05-31 22:44:40.667113
NCT01327053|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2015-08-24||2017-10-02|2011-03-30|2011-04-01|Estimate|2015-10-20|2015-11-23|Estimate||||2017-10-02|2017-10-04|Actual|June 29, 2011|Actual|2011-06-29|October 2017|2017-10-31|December 22, 2017|Anticipated|2017-12-22|June 28, 2013|Actual|2013-06-28||Interventional|BOLT|The full analysis set (FAS) comprised all patients who were assigned study treatment irrespective of receiving it (all randomized patients). Patients were classified according to the treatment they were assigned in accordance with the intention-to-treat (ITT) principle.|A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|Active, not recruiting||Phase 2|229|Actual|Novartis|230 patients evaluated in the study in the Full Analysis Set: 79 randomized to LDE225 (Sonidegib) 200mg group and 151 randomized to LDE225 800mg group. 1 patient randomized to the 800mg group did not receive study treatment.|2|||f||||t||||||||||2018-05-31 22:44:40.799774|2018-05-31 22:44:40.799774
NCT01327040|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2018-01-16|2011-03-30|2011-04-01|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2010||2010-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Light Sensitization Study|Sensitization of Human Circadian Responses to Light|Active, not recruiting||N/A|40|Anticipated|Brigham and Women's Hospital||4|||f||||f||||||||No||2018-05-31 22:44:41.493661|2018-05-31 22:44:41.493661
NCT01327027|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-11-01|2011-03-31|2011-04-01|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2011||2011-09-30|November 2017|2017-11-30|April 2017|Actual|2017-04-30|December 2015|Actual|2015-12-31||Interventional|AVP||Vasopressin Effects on Human Social Communication|Phase 2 Study of Vasopressin Effects on Human Social Communication|Completed||Phase 1|225|Actual|Bowdoin College||2|||f||||t||||||||No||2018-05-31 22:44:41.565705|2018-05-31 22:44:41.565705
NCT01327014|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2014-07-22|2011-03-31|2011-04-01|Estimate|||||||2014-07-22|2014-07-23|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia|Completed||Phase 2|116|Actual|Beijing Peking University WBL Biotech Co., Ltd.||3|||f||||f||||||||||2018-05-31 22:44:41.643039|2018-05-31 22:44:41.643039
NCT01327001|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-07-22|2011-03-30|2011-03-31|Estimate|||||||2011-07-22|2011-07-25|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|||||Observational|UFO||Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients|Utilization of Fixed Combination (Budesonide/Formoterol and Salmeterol/Fluticasone and Beclomethasone/Formoterol) in Treatment of Asthma Patients in Real Life Condition in Czech Republic (UFO)|Completed|||2815|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:44:41.741508|2018-05-31 22:44:41.741508
NCT01326988|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2012-02-03|2011-03-30|2011-03-31|Estimate|||||||2012-02-03|2012-02-06|Estimate|April 2011||2011-04-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Real-time Ultrasound-guided Spinal Anesthesia:A Feasibility Study|Feasibility Study of the Use of Real-time Ultrasound Guidance to Administer Spinal Anesthesia|Completed|||100|Actual|Sunnybrook Health Sciences Centre|||1||f||||f||||||||||2018-05-31 22:44:42.018168|2018-05-31 22:44:42.018168
NCT01326975|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2015-06-16|2011-03-30|2011-03-31|Estimate|||||||2015-06-16|2015-06-18|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Effect of Continuous Positive Airway Pressure Delivered by Two Different Modalities on Breathing Pattern in Preterm Infants|Effects of Continuous Positive Airway Pressure (CPAP) Delivered by High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure on the Diaphragm Electrical Activity in Very Low Birth Weight Preterm Infants|Completed|||10|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||t||||||||||2018-05-31 22:44:42.092169|2018-05-31 22:44:42.092169
NCT01326962|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2016-01-19||2017-07-06|2011-03-30|2011-03-31|Estimate|2016-02-25|2016-03-28|Estimate||||2017-07-06|2017-08-16|Actual|November 30, 2011|Actual|2011-11-30|July 2017|2017-07-31|May 12, 2013|Actual|2013-05-12|May 12, 2013|Actual|2013-05-12||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF|Tocilizumab Efficacy and Safety in RA Patients After Inadequate Response to DMARDs or Anti-TNF|Completed||Phase 3|28|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:44:42.19279|2018-05-31 22:44:42.19279
NCT01326949|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2017-05-18|2011-03-30|2011-03-31|Estimate|||||||2017-05-18|2017-05-19|Actual|May 2011||2011-05-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis|Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial|Completed||N/A|52|Actual|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 22:44:42.581961|2018-05-31 22:44:42.581961
NCT01326936|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2012-07-23|2011-03-30|2011-03-31|Estimate|||||||2012-07-23|2012-07-25|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Online Primary Care Physician (PCP) Training in Screening, Brief Intervention, Referral, and Treatment|Fast Track SBIR Study Online PCP Training in Screening, Brief Intervention, Referral, and Treatment|Completed||N/A|120|Actual|Medical Directions, Inc||2|||f||||f||||||||||2018-05-31 22:44:43.577864|2018-05-31 22:44:43.577864
NCT01326923|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-04-07|2011-03-30|2011-03-31|Estimate|||||||2015-04-07|2015-04-09|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer|Phase II Trial of Induction Chemotherapy (ICT) Followed by Concurrent Chemoraditherapy (CR) With Monoclonal Antibody Cetuximab in Locally Advanced Head and Nec Squamous Cell Cancer|Terminated||Phase 2|7|Actual|Louisiana State University Health Sciences Center Shreveport||1||Principle Investigator left the institution.|f||||t||||||||||2018-05-31 22:44:43.655833|2018-05-31 22:44:43.655833
NCT01326910|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2012-06-27||2012-06-27|2011-03-30|2011-03-31|Estimate|2012-06-27|2012-08-03|Estimate||||2012-06-27|2012-08-03|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema|A Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of an Over-the-Counter Cream in the Management of Mild to Moderate Atopic Dermatitis in Children|Completed||N/A|90|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 22:44:43.740759|2018-05-31 22:44:43.740759
NCT01326897|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2016-01-08|2011-03-30|2011-03-31|Estimate|||||||2016-01-08|2016-01-12|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|HHHF||Healthy Homes/Healthy Families|Healthy Homes/Healthy Families|Completed||Phase 2|510|Actual|Emory University||2|||f||||f||||||||||2018-05-31 22:44:43.987975|2018-05-31 22:44:43.987975
NCT01326884|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-03-11|2011-03-30|2011-03-31|Estimate|||||||2013-03-11|2013-03-12|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ZLP||Zenith Low Profile AAA Endovascular Graft (ZLP) Clinical Study|ZLP Clinical Study|Completed||N/A|27|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 22:44:44.047852|2018-05-31 22:44:44.047852
NCT01326871|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2016-04-11|2011-03-30|2011-03-31|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer|A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|90|Anticipated|Altor BioScience||2|||f||||t||||||||||2018-05-31 22:44:44.124364|2018-05-31 22:44:44.124364
NCT01326858|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-02-27|2011-03-30|2011-03-31|Estimate|||||||2015-02-27|2015-03-03|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety and Comfort of AL-4943A Ophthalmic Solution|A Randomized, Double-Masked, Crossover Study to Evaluate the Safety and Comfort of AL-4943A Ophthalmic Solution, 0.7%|Completed||Phase 1|50|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:44:44.96983|2018-05-31 22:44:44.96983
NCT01326663|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2012-09-06|2011-03-30|2011-03-31|Estimate|||||||2012-09-06|2012-09-07|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Interventional|||Divalproex Sodium for Mood Swings and Alcohol Use Following Head Injury.|A Double Blind Trial Of Divalproex Sodium For Affective Lability And Alcohol Use Following Traumatic Brain Injury|Unknown status|Recruiting|N/A|50|Anticipated|Denver Research Institute||2|||f||||f||||||||||2018-05-31 22:44:46.767172|2018-05-31 22:44:46.767172
NCT01326845|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|2013-09-11||2017-03-01|2011-03-30|2011-03-31|Estimate|2013-09-11|2013-11-15|Estimate||||2017-03-01|2017-03-03|Actual|December 2011||2011-12-31|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|MACS1574||Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study|A Multicenter, Randomized, Comparative Study of Different Deferasirox Administration Regimens on Gastrointestinal (GI) Tolerability in Low or Intermediate (Int-1) Risk MDS Myelodysplastic Syndrome Patients With Transfusional Iron Overload.|Terminated||Phase 4|12|Actual|Novartis||2||The trial was terminated due to insufficient enrollment.|f||||||||||||||2018-05-31 22:44:45.062762|2018-05-31 22:44:45.062762
NCT01326832|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-09-18|2011-03-30|2011-03-31|Estimate|||||||2017-09-18|2017-09-19|Actual|September 2011||2011-09-30|September 2017|2017-09-30|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Observational|Primoris||10 Year Clinical Evaluation of Primoris Hip Component|Prospective Study for Evaluation of Proximally Anchored (Metaphysis) Cementless Femoral Component for Total Hip Arthroplasty. 10 Year Clinical Evaluation,DXA and RSA Follow-up of Primoris® Femoral Component.|Active, not recruiting|||350|Anticipated|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-05-31 22:44:45.356782|2018-05-31 22:44:45.356782
NCT01326819|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2013-05-09|2011-03-30|2011-03-31|Estimate|||||||2013-05-09|2013-05-13|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Comparison of Normal Readings and Repeatability Across Skin Colors|Comparison Study of Three Regional Oxygen Saturation (rSO2) Systems Across a Wide Range of Skin Colors|Completed|||231|Actual|Nonin Medical, Inc|||||f||||f||||||||||2018-05-31 22:44:45.435645|2018-05-31 22:44:45.435645
NCT01326806|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2017-09-14|2011-03-30|2011-03-31|Estimate|||||||2017-09-14|2017-09-15|Actual|July 19, 2010|Actual|2010-07-19|September 2017|2017-09-30|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||A Parent-Based Intervention to Reduce Sexual Risk Behavior in Adolescents|Reducing Teen Sexual Behavior: A Clinic-Based Approach|Completed||N/A|1800|Actual|New York University||3|||f||||t||||||||||2018-05-31 22:44:45.577853|2018-05-31 22:44:45.577853
NCT01326793|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2015-04-24|2011-03-30|2011-03-31|Estimate|||||||2015-04-24|2015-04-28|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Internet-Based Depression Screening for College Students|Internet-Based Depression Screening for College Students|Completed||N/A|1900|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 22:44:45.672504|2018-05-31 22:44:45.672504
NCT01326780|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2012-12-21|2011-03-30|2011-03-31|Estimate|||||||2012-12-21|2012-12-24|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of a New Drug Treatment for Acne|A Multi-Center, Double-Blind, Vehicle Controlled, Phase II Study of JNJ 10229570-AAA for the Treatment of Acne Vulgaris|Completed||Phase 2|431|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||||2018-05-31 22:44:45.759962|2018-05-31 22:44:45.759962
NCT01326767|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-01-26|2011-03-30|2011-03-31|Estimate|||||||2016-01-26|2016-01-27|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CEPAC-TDM||Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring|An Open-Label, Randomized, Parallel Group Study of Patients Treated With Paclitaxel With Standard Dosing Versus Pharmacokinetic Guided Dose Adjustment in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|366|Actual|Central European Society for Anticancer Drug Research||2|||f||||f||||||||||2018-05-31 22:44:45.964528|2018-05-31 22:44:45.964528
NCT01326754|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2013-02-21|2011-03-30|2011-03-31|Estimate|||||||2013-02-21|2013-02-25|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malawi|Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Malawi|Completed||N/A|498|Actual|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 22:44:46.137019|2018-05-31 22:44:46.137019
NCT01326741|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-03-30|2011-03-30|2011-03-31|Estimate|||||||2011-03-30|2011-03-31|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||||||Observational|||Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis|Detection of Clonal Mast Cell Disorders Among Patients With Exercise-induced Anaphylaxis|Unknown status|Recruiting||10|Anticipated|Brigham and Women's Hospital|||||f||||f||||||||||2018-05-31 22:44:46.21055|2018-05-31 22:44:46.21055
NCT01326728|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-10-20|2011-03-30|2011-03-31|Estimate|||||||2017-10-20|2017-10-23|Actual|March 30, 2011||2011-03-30|October 19, 2017|2017-10-19|October 19, 2017||2017-10-19|||||Observational|||Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation|Study of the Biology and Natural History of Disease Outcomes in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies|Terminated|||56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:44:46.300555|2018-05-31 22:44:46.300555
NCT01326715|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2018-05-22|2011-03-30|2011-03-31|Estimate|||||||2018-05-22|2018-05-23|Actual|March 30, 2011||2011-03-30|May 4, 2018|2018-05-04|December 31, 2018|Anticipated|2018-12-31|August 16, 2018|Anticipated|2018-08-16||Interventional|||Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis|Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:44:46.379344|2018-05-31 22:44:46.379344
NCT01326702|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2015-10-14|2011-03-30|2011-03-31|Estimate|||||||2015-10-14|2015-10-15|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors|A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors|Completed||Phase 1/Phase 2|41|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:44:46.469707|2018-05-31 22:44:46.469707
NCT01326689|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-30|||2017-03-06|2011-03-30|2011-03-31|Estimate|||||||2017-03-06|2017-03-08|Actual|March 2011||2011-03-31|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|2246-004||A Comparative Study of KW-2246|Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)|Completed||Phase 3|42|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||||||||||||2018-05-31 22:44:46.603021|2018-05-31 22:44:46.603021
NCT01326676|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2015-05-28|2011-03-30|2011-03-31|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|PESCA||Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial|PESCA - A Randomised Controlled Trial of a Cardiovascular Polypill Treatment Strategy Compared With Usual Care on Carotid Intima-media Thickness in Individuals at High Risk of Cardiovascular Disease|Completed||Phase 3|665|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 22:44:46.665093|2018-05-31 22:44:46.665093
NCT01326650|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-08-10|2011-03-30|2011-03-31|Estimate|||||||2016-08-10|2016-08-11|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EVITA||Vitamin D and Mortality in Heart Failure|Effect of Vitamin D on All-cause Mortality in Heart Failure Patients|Completed||Phase 4|400|Actual|Heart and Diabetes Center North-Rhine Westfalia||2|||f||||t||||||||||2018-05-31 22:44:46.962323|2018-05-31 22:44:46.962323
NCT01326637|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2015-10-01|2011-03-29|2011-03-31|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|January 2013|Actual|2013-01-31||Interventional|SAFE-C||Human Factors Intervention to Reduce Risk in Primary Care of the Elderly|A Human Factors Intervention to Reduce Risk in Primary Care of the Elderly|Unknown status|Active, not recruiting|N/A|2304|Anticipated|University of Wisconsin, Madison|||||f||||f||||||||||2018-05-31 22:44:47.100772|2018-05-31 22:44:47.100772
NCT01326624|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2017-12-04|2011-03-30|2011-03-31|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2011||2011-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|SWIFT||Study of the Wearable Defibrillator in Heart-Failure Patients|Study of the Wearable Defibrillator In Heart-Failure Patients|Completed|||25|Actual|Zoll Medical Corporation|||4||f||||f||||||||||2018-05-31 22:44:47.179957|2018-05-31 22:44:47.179957
NCT01326611|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-03-29|2011-03-29|2011-03-31|Estimate|||||||2011-03-29|2011-03-31|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants||Completed||Phase 4|273|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 22:44:47.293077|2018-05-31 22:44:47.293077
NCT01326598|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2015-06-01|2011-03-30|2011-03-31|Estimate|||||||2015-06-01|2015-06-02|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Observational|SIMPLE||Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting|Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE)|Completed|||270|Actual|Valeritas, Inc.|||1||f||||f||||||||||2018-05-31 22:44:47.37349|2018-05-31 22:44:47.37349
NCT01326585|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2015-06-02|2011-03-30|2011-03-31|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Interventional|||Study Trial of Dexamethasone Use for Alleviation of Symptoms After Scleral Buckle Eye Surgery|Effect of Dexamethasone on Postoperative Symptoms of Scleral Buckling Surgery Patients: a Randomized Control Trial|Withdrawn||Phase 4|0|Actual|University of Toronto||2||lack of funding|f||||||||||||||2018-05-31 22:44:47.501824|2018-05-31 22:44:47.501824
NCT01326572|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2016-05-10|2011-03-30|2011-03-31|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Observational|MACS||Lung HIV Disease in a Large Cohort-Pitt|Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-Pitt|Completed|||189|Actual|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     blood, sputum, oral wash, bronchial washes~   "|||2018-05-31 22:44:47.576363|2018-05-31 22:44:47.576363
NCT01326559|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-08-13|2011-03-29|2011-03-31|Estimate|||||||2017-08-13|2017-08-16|Actual|June 2010||2010-06-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)|Phase II Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil Followed by Weekly Docetaxel and Cetuximab in Concurrence With Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma (NPC)|Completed||Phase 2|33|Actual|Hong Kong Nasopharyngeal Cancer Study Group Limited||1|||f||||t||||||||||2018-05-31 22:44:47.646924|2018-05-31 22:44:47.646924
NCT01326546|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-06-12|2011-03-30|2011-03-31|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|THBVJEITCHBP||Therapeutic Hepatitis B Vaccine (Synthesized Peptide εPA-44) Joint Entecavir in Treating Chronic Hepatitis B Patients|A Randomized, Double-blind, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Synthesized Peptide) Joint Entecavir in Treating HBeAg Positive Chronic Hepatitis B Patients|Unknown status|Active, not recruiting|Phase 2|378|Actual|Chongqing Jiachen Biotechnology Ltd.||2|||f||||t||||||||||2018-05-31 22:44:47.819186|2018-05-31 22:44:47.819186
NCT01326533|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|2015-12-22||2016-01-28|2011-03-29|2011-03-31|Estimate|2015-12-22|2016-01-29|Estimate||||2016-01-28|2016-02-26|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|March 2013|Actual|2013-03-31||Interventional|||Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes|Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes|Completed||Phase 4|32|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:44:47.898735|2018-05-31 22:44:47.898735
NCT01326520|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-06-19|2011-03-29|2011-03-31|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Dietary Phospholipids on Atopic Dermatitis|Effect of Dietary Milk Phospholipids on Subjects With Atopic Dermatitis|Completed||N/A|39|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 22:44:48.181208|2018-05-31 22:44:48.181208
NCT01326507|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-05-10|2011-03-29|2011-03-31|Estimate|||||||2017-05-10|2017-05-12|Actual|September 2009||2009-09-30|May 2017|2017-05-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism|Performances de l'h-FABP Pour Identifier dès Les Urgences Les Embolies Pulmonaires d'évolution défavorable|Completed||N/A|165|Actual|University Hospital, Toulouse|||||f||||f||||||||||2018-05-31 22:44:48.246457|2018-05-31 22:44:48.246457
NCT01326494|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2017-11-02|2011-03-29|2011-03-31|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2011||2011-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2012|Actual|2012-05-31||Interventional|||Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia|Reducing the Acute Care Burden of Childhood Asthma on Health Services in British Columbia|Active, not recruiting||Phase 4|92|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:44:48.314958|2018-05-31 22:44:48.314958
NCT01326481|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2018-02-05|2011-03-29|2011-03-31|Estimate|||||||2018-02-05|2018-02-07|Actual|June 2011||2011-06-30|December 2017|2017-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|TRC105||Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer|An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer|Completed||Phase 1/Phase 2|19|Actual|Tracon Pharmaceuticals Inc.||1|||f||||t||||||||||2018-05-31 22:44:48.379424|2018-05-31 22:44:48.379424
NCT01315743|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-11-01|2011-03-14|2011-03-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2007||2007-03-31|November 2016|2016-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|Team COOL||Team COOL Pilot Study|Team COOL Pilot Study|Completed||Phase 1/Phase 2|50|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 22:47:16.99599|2018-05-31 22:47:16.99599
NCT01326468|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-10-19|2011-03-29|2011-03-30|Estimate|||||||2016-10-19|2016-10-21|Estimate|January 2011||2011-01-31|October 2016|2016-10-31||||||||Interventional|||Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer|A Pilot Study of Chemoradiotherapy Plus Temsirolimus (Torisel) for Advanced Head and Neck Cancer|Withdrawn||N/A|0|Actual|Thomas Jefferson University||2||funding|f||||t||||||||||2018-05-31 22:44:48.442592|2018-05-31 22:44:48.442592
NCT01326455|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Caring for the Radial Artery Post-angiogram|Caring for the Radial Artery Post-angiogram: A Pilot Study on a Comparison of Three Methods of Compression|Completed||N/A|75|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 22:44:48.520732|2018-05-31 22:44:48.520732
NCT01326442|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2013-06-12|2011-03-29|2011-03-30|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Vitamin D and Omega-3 Inhibit Metabolic Syndrome|Phase 3 Study of Vitamin D and Omega-3 Supplementation to Reduce Risk of Metabolic Syndrome|Completed||Phase 3|40|Actual|University of Guelph||2|||f||||t||||||||||2018-05-31 22:44:48.582607|2018-05-31 22:44:48.582607
NCT01326429|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2015-07-22|2011-03-29|2011-03-30|Estimate|||||||2015-07-22|2015-07-23|Estimate|October 2011||2011-10-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Frequency and Origin of Dysnatremias in the Emergency Department|Frequency and Origin of Dysnatremias in the Emergency Department|Withdrawn|||0|Actual|University Hospital Inselspital, Berne|||2|Job change of responsible investigators|f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 22:44:48.643154|2018-05-31 22:44:48.643154
NCT01326416|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-01-22|2011-03-29|2011-03-30|Estimate|||||||2016-01-22|2016-01-25|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|OBEFITT||Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome|Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome. OBEFITT Study.|Completed||N/A|79|Actual|University Hospital, Rouen||4|||f||||t||||||||||2018-05-31 22:44:48.784369|2018-05-31 22:44:48.784369
NCT01326403|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-06-06|2011-03-29|2011-03-30|Estimate|||||||2012-06-06|2012-06-07|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Tranexamic Acid in Hip Fracture Patients|Tranexamic Acid in Hip Fracture Patients|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||t||||||||||2018-05-31 22:44:48.855365|2018-05-31 22:44:48.855365
NCT01326390|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2016-06-30|2011-03-29|2011-03-30|Estimate|||||||2016-06-30|2016-07-01|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma|Impact of C-arm CT in Patients With Decreased Renal Function Undergoing Transhepatic Arterial Chemoembolization (TACE) for the Treatment of Hepato-Cellular Carcinoma|Terminated|||13|Actual|Stanford University|||||f||||t||||||||||2018-05-31 22:44:48.943309|2018-05-31 22:44:48.943309
NCT01326364|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-06-30|2011-03-29|2011-03-30|Estimate|||||||2016-06-30|2016-07-01|Estimate|March 2010||2010-03-31|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection|Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection|Terminated|||6|Actual|Stanford University|||||f||||t||||||||||2018-05-31 22:44:49.011416|2018-05-31 22:44:49.011416
NCT01326351|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2011-04-18|2011-03-29|2011-03-30|Estimate|||||||2011-04-18|2011-04-19|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Prolotherapy for the Treatment of Plantar Fasciitis|Plantar Fasciitis: Pain Relief and Improvement of Foot Function With Prolotherapy|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Réseau de Santé Vitalité Health Network||3|||f||||f||||||||||2018-05-31 22:44:49.099404|2018-05-31 22:44:49.099404
NCT01326338|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|March 2005||2005-03-31|March 2011|2011-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Nitazoxanide for the Treatment of Prolonged Diarrhea in Children|Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Prolonged Diarrhea in Children|Completed||Phase 3|100|Actual|Romark Laboratories L.C.||2|||f||||f||||||||||2018-05-31 22:44:49.173225|2018-05-31 22:44:49.173225
NCT01326325|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-08-06|2011-03-29|2011-03-30|Estimate|||||||2013-08-06|2013-08-07|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|KEPAL||Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment|Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease|Completed||Phase 3|24|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:44:49.241136|2018-05-31 22:44:49.241136
NCT01326312|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2014-04-23|2011-03-29|2011-03-30|Estimate|||||||2014-04-23|2014-04-24|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GTx758||Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer|Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist|Terminated||Phase 2|156|Actual|GTx||3||FDA Clinical Hold|f||||t||||||||||2018-05-31 22:44:49.353854|2018-05-31 22:44:49.353854
NCT01326299|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Post Prandial Glucose Control Proof-of-Principle|Post Prandial Glucose Control Proof-of-Principle|Completed||Phase 2/Phase 3|50|Actual|Abbott Nutrition||5|||f||||t||||||||||2018-05-31 22:44:49.477848|2018-05-31 22:44:49.477848
NCT01326286|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2017-09-19|2011-03-29|2011-03-30|Estimate|||||||2017-09-19|2017-09-20|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 2017|Actual|2017-08-31||Observational|CEASAR||Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer|Comparative Effectiveness Study of Various Treatments for Localized Prostate Cancer|Active, not recruiting|||3265|Actual|Vanderbilt University Medical Center|||7||f||||f||||||||||2018-05-31 22:44:49.551132|2018-05-31 22:44:49.551132
NCT01325285|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-08-17|2011-03-28|2011-03-29|Estimate|||||||2011-08-17|2011-08-18|Estimate|August 2011||2011-08-31|November 2010|2010-11-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia|The Response of Intraocular Pressure to Systemic Hypercapnia and Hyperoxia|Unknown status|Not yet recruiting||14|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 22:45:05.751793|2018-05-31 22:45:05.751793
NCT01326273|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-06-03|2011-03-29|2011-03-30|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation|Adoptive Transfer of Autologous CMV Specific CD8+ T Cells After Allogeneic Stem Cell Transplantationas Treatment for CMV Reactivation: A Phase I/II Clinical Trial.|Withdrawn||Phase 1/Phase 2|0|Actual|Imperial College London|||||f||||f||||||||||2018-05-31 22:44:49.625222|2018-05-31 22:44:49.625222
NCT01326260|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2014-10-28|2011-03-29|2011-03-30|Estimate|||||||2014-10-28|2014-10-30|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|THAM||Early Aggressive Correction of Severe Acidosis With Tris-hydroxymethylaminomethane (THAM)|Early Aggressive Correction of Severe Acidosis With Tris-hydroxymethylaminomethane (THAM) in Patients With Severe Traumatic Injury: A Retrospective Cohort Study|Unknown status|Recruiting||60|Anticipated|University of California, San Francisco|||2||f||||f||||||||||2018-05-31 22:44:49.686653|2018-05-31 22:44:49.686653
NCT01326247|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-31|2011-03-29|2011-03-30|Estimate|||||||2011-03-31|2011-04-01|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Effectiveness Of Therapy With A Thermal Water Nasal Aerosol In Children With Seasonal Allergic Rhinitis|EFFECTIVENESS OF THERAPY WITH A THERMAL WATER NASAL AEROSOL IN CHILDREN WITH SEASONAL ALLERGIC RHINITIS|Completed||Phase 4|40|Actual|Federico II University||1|||f||||t||||||||||2018-05-31 22:44:49.749852|2018-05-31 22:44:49.749852
NCT01326234|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2017-04-18|2011-03-29|2011-03-30|Estimate|||||||2017-04-18|2017-04-20|Actual|June 2010||2010-06-30|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Computer-Based Program to Facilitate Readiness and Motivation for Smoking Cessation|Further Development and Testing of an Interactive Computer-Based Program to Facilitate Readiness and Motivation for Smoking Cessation|Withdrawn||N/A|0|Actual|University of Oklahoma||2||Due to staff changes the study never started.|f||||t||||||||||2018-05-31 22:44:49.811323|2018-05-31 22:44:49.811323
NCT01326221|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2012-10-09|2011-03-29|2011-03-30|Estimate|||||||2012-10-09|2012-10-10|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|TAIL||Single Dose Truvada in HIV-negative Men and Women|Extracellular and Intracellular TFV/FTC Residues After a Single Dose in HIV-Negative Men and Women: Implications for Pre-exposure HIV Prophylaxis Dosing of Truvada®|Completed|||12|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 22:44:49.874057|2018-05-31 22:44:49.874057
NCT01326208|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|EIT-PEEP||Strategies to Optimize Positive End-expiratory Pressure (PEEP) in Patients With Acute Lung Injury|Influence of Different Strategies to Optimize Positive End-expiratory Pressure on Pulmonary Gas Exchange, Perfusion/Ventilation Matching and Homogeneity of Ventilation in Patients With Acute Lung Injury|Unknown status|Recruiting|Phase 2|40|Anticipated|University Hospital, Bonn||1|||f||||f||||||||||2018-05-31 22:44:49.948838|2018-05-31 22:44:49.948838
NCT01326195|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Dating Violence and HIV Prevention in Girls: Adapting Mental Health Interventions|Dating Violence and HIV Prevention in Girls: Adapting Mental Health Interventions|Unknown status|Recruiting|Phase 1|100|Anticipated|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 22:44:50.032746|2018-05-31 22:44:50.032746
NCT01326182|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|MAADRE||Intervention for Depressed Latina Mothers of Children With Asthma|Intervention for Depressed Latina Mothers of Children With Asthma|Unknown status|Recruiting|Phase 2|64|Anticipated|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 22:44:50.102556|2018-05-31 22:44:50.102556
NCT01326169|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-09-10|2011-03-29|2011-03-30|Estimate|||||||2014-09-10|2014-09-11|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|March 2013|Actual|2013-03-31||Interventional|ReDIAL||ReDIAL: A Telephone Brief Intervention for Injured Emergency Department Patients|ReDIAL: A Telephone Brief Intervention for Injured Emergency Department Patients|Completed||N/A|730|Actual|Rhode Island Hospital||2|||f||||||||||||||2018-05-31 22:44:50.178281|2018-05-31 22:44:50.178281
NCT01326156|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2017-05-02|2011-03-29|2011-03-30|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2007|Actual|2007-06-30|May 2017|2017-05-31|October 2024|Anticipated|2024-10-31|October 2014|Actual|2014-10-31||Interventional|PFA/TKR||Study of Knee Replacements for Patellofemoral Osteoarthritis|Patellofemoral Arthroplasty (PFA) Versus Total Knee Replacement (TKR) for Isolated Patellofemoral Osteoarthritis|Active, not recruiting||N/A|100|Anticipated|University of Aarhus||2|||f||||f||||||||Undecided||2018-05-31 22:44:50.241519|2018-05-31 22:44:50.241519
NCT01326143|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2017-04-11|2011-03-29|2011-03-30|Estimate|||||||2017-04-11|2017-04-12|Actual|May 2011||2011-05-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|ORCADES||Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH)|ORM Narval Mandibular Repositioning Device in the Second-line Treatment of Severe OSAH|Active, not recruiting|||360|Actual|ResMed|||1||f||||f||||||||||2018-05-31 22:44:50.308394|2018-05-31 22:44:50.308394
NCT01326130|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|RCM||Implementation of an Integrated Primary Care Network for Prevention and Management of Cardiometabolic Risks|Implementation of an Integrated Primary Care Network for Prevention and Management of Cardiometabolic Risks (RCM)|Unknown status|Not yet recruiting|N/A|3000|Anticipated|Public Health Department, Montreal||6|||f||||f||||||||||2018-05-31 22:44:50.402684|2018-05-31 22:44:50.402684
NCT01326117|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2014-07-25|2011-03-29|2011-03-30|Estimate|||||||2014-07-25|2014-07-29|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis|Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis|Withdrawn||Phase 4|0|Actual|Duke University||1||lack of patients who meet inclusion criteria; there was one screen failure|f||||t||||||||||2018-05-31 22:44:50.47552|2018-05-31 22:44:50.47552
NCT01326104|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2018-03-21|2011-03-29|2011-03-30|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2010||2010-04-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|Re-MATCH||Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor|Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Florida||1|||f||||t|t|f||||||Undecided||2018-05-31 22:44:50.545999|2018-05-31 22:44:50.545999
NCT01326091|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2015-06-22|2011-03-29|2011-03-30|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction|Operative Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction|Terminated||N/A|7|Actual|Duke University||2||Insufficient study support|f||||t||||||||||2018-05-31 22:44:50.707791|2018-05-31 22:44:50.707791
NCT01326078|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-03-25|2011-03-29|2011-03-30|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures.|Comparison Between Propofol Nanoemulsion and Propofol Lipid Emulsion on Children Undergoing Ambulatory Invasive Procedures.|Withdrawn||Phase 2/Phase 3|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||2||The Sponsor has no interest in continuing the study.|f||||f||||||||||2018-05-31 22:44:50.780116|2018-05-31 22:44:50.780116
NCT01326065|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-27|||2017-05-04|2011-03-29|2011-03-30|Estimate|||||||2017-05-04|2017-05-09|Actual|February 2011|Actual|2011-02-28|May 2017|2017-05-31|February 2017|Actual|2017-02-28|March 2012|Actual|2012-03-31||Observational|||Implementation of Laparoscopy-assisted Surgery for Colon Cancer|Implementation of Laparoscopy-assisted Surgery for Colon Cancer. A Prospective Population-based Study|Terminated|||60|Actual|Helse Stavanger HF||||Study had to be terminated due to lack of funding|f||||f||||||||No||2018-05-31 22:44:50.844633|2018-05-31 22:44:50.844633
NCT01326052|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2012-06-12|2011-03-28|2011-03-30|Estimate|||||||2012-06-12|2012-06-13|Estimate|January 2004||2004-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|IPIMAL||Improvement of Anorectal Function While Preserving of Inferior Mesenteric Artery Performing Left Hemicolectomy for Diverticulosis|Effect of Inferior Mesenteric Artery Preservation Performing Left Hemicolectomy for Diverticulosis in the Anorectal Function|Completed||Phase 3|150|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 22:44:50.919163|2018-05-31 22:44:50.919163
NCT01326039|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-29|2011-03-29|2011-03-30|Estimate|||||||2011-03-29|2011-03-30|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Ultrasound-guided Ilioinguinal-iliohypogastric Block for Inguinal Hernia Repair|Does Ultrasound-guided Ilioinguinal-iliohypogastric Block Improve Postoperative Pain Outcome After Unilateral Inguinal Hernia Repair?|Unknown status|Recruiting|Phase 4|60|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 22:44:50.991903|2018-05-31 22:44:50.991903
NCT01326026|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|2015-10-16|2012-01-17|2017-01-20|2011-03-29|2011-03-30|Estimate|2015-10-16|2015-11-17|Estimate|2012-01-17|2012-01-19|Estimate|2017-01-20|2017-03-06|Actual|March 2011||2011-03-31|January 2017|2017-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|BEGIN™||Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Insulin Degludec Once Daily in Insulin naïve Subjects With Type 2 Diabetes Mellitus When Titrated Using Two Different Titration Algorithms (BEGIN™: ONCE SIMPLE USE)|Completed||Phase 3|222|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:44:51.092217|2018-05-31 22:44:51.092217
NCT01326013|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2012-08-22|2011-03-29|2011-03-30|Estimate|||||||2012-08-22|2012-08-24|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel|A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel (xTAG GPP) in Patients With Signs and Symptoms of Infectious Colitis and Gastroenteritis|Completed|||1534|Actual|Luminex Molecular Diagnostics|||2||f||||f||||||Samples With DNA|"~     Stool~   "|||2018-05-31 22:44:51.826509|2018-05-31 22:44:51.826509
NCT01326000|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2015-02-05|2011-03-29|2011-03-30|Estimate|||||||2015-02-05|2015-02-06|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer|A Randomized, Multicenter, Open-label Phase II Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With KRAS Wild-type or Mutant Metastatic Colorectal Cancer|Completed||Phase 2|169|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 22:44:51.906392|2018-05-31 22:44:51.906392
NCT01325987|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-01-16|2011-03-29|2011-03-30|Estimate|||||||2014-01-16|2014-01-20|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|ACT||African American Children, Glycemic Control, and Type 2 Diabetes|Vitamin D on Glycemic Control in African American Children With Type 2 Diabetes|Completed||N/A|31|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 22:44:52.065517|2018-05-31 22:44:52.065517
NCT01325974|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2015-11-26|2011-03-29|2011-03-30|Estimate|||||||2015-11-26|2015-11-30|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Observational|||Time to Become Negative of Three Rapid Diagnostic Tests for Malaria|Time to Become Negative of Three Rapid Diagnostic Tests for Malaria in Children Under 5 Years of Age. Evaluation in Two Different Malaria Epidemiological Settings in Greater Mbarara District, South Western Uganda|Completed|||424|Actual|Epicentre|||||f||||f||||||Samples Without DNA|"~     Blood smears for microcopy~   "|||2018-05-31 22:44:52.147413|2018-05-31 22:44:52.147413
NCT01325961|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2016-09-02|2011-03-29|2011-03-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|May 2015|Actual|2015-05-31||Interventional|RCMI PELVIS||Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers|Medico-economic Evaluation Comparing Conformal Radiotherapy With Intensity Modulation (IMRT) Performed by, Helical Tomotherapy (Hi Art) and Dynamic Arc Therapy (RapidArc, VMAT) in Cancers With Pelvic Lymph Node Irradiation (Prostate, Cervix, Anal Canal)|Active, not recruiting||N/A|220|Anticipated|Institut Cancerologie de l'Ouest|||||f||||f||||||||||2018-05-31 22:44:52.221355|2018-05-31 22:44:52.221355
NCT01325948|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2011-07-20|2011-03-29|2011-03-30|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|COPD LIFE||Cross-sectional Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life Activities|Cross-sectional Observational Study to Investigate the Effects of Chronic Obstructive Pulmonary Disease on Daily Life Activities|Completed|||497|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:44:52.322723|2018-05-31 22:44:52.322723
NCT01325272|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-05-31|2011-03-28|2011-03-29|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|September 2009||2009-09-30|||||Observational|||Interrelations Between Spontaneous Otoacoustic Emissions and Transient Evoked Emissions|Interrelations Between Spontaneous Otoacoustic Emissions and Transient Evoked Emissions: Indication of Cochlear Damage in Newborn.|Completed|||||UPECLIN HC FM Botucatu Unesp|||2||f||||t||||||||||2018-05-31 22:45:06.036785|2018-05-31 22:45:06.036785
NCT01325935|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-01-05|2011-03-29|2011-03-30|Estimate|||||||2016-01-05|2016-01-07|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|OPERA||Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients|Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients: A Prospective Multicenter Registry (OPERA)|Completed||Phase 4|1187|Actual|Associations for Establishment of Evidence in Interventions||2|||f||||t||||||||||2018-05-31 22:44:52.418348|2018-05-31 22:44:52.418348
NCT01325922|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2011-03-30|2011-03-28|2011-03-30|Estimate|||||||2011-03-30|2011-03-31|Estimate|January 2005||2005-01-31|March 2011|2011-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||50/50% Tilt and Tuned Defibrillation Waveform|50/50% Tilt and Tune Defibrillation Waveforms Utilizing High Voltage Lead Integrity Check Impedance|Completed||N/A|||St. Jude Medical||1|||f||||f||||||||||2018-05-31 22:44:52.609699|2018-05-31 22:44:52.609699
NCT01325909|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2014-04-04|2011-03-29|2011-03-30|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Exercise Training in Colorectal Cancer Patients|Does Short-term Exercise Intervention Improve Pre-operative Physical Fitness Following Neoadjuvant Chemoradiotherapy in Colorectal Cancer Patients?|Completed||N/A|35|Anticipated|Aintree University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:44:52.663338|2018-05-31 22:44:52.663338
NCT01325896|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-30|2011-03-29|2011-03-30|Estimate|||||||2011-03-30|2011-03-31|Estimate|September 2002||2002-09-30|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)|Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)|Unknown status|Active, not recruiting|Phase 2|33|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||1|||f||||f||||||||||2018-05-31 22:44:52.733002|2018-05-31 22:44:52.733002
NCT01325883|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-29|||2016-07-11|2011-03-29|2011-03-30|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|August 2014|Actual|2014-08-31||Observational|||The Effect of Chemotherapy and Surgery for Cancer on Exercise Capacity|The Effect of Neoadjuvant Chemotherapy on Exercise Capacity and Outcome Following Upper Gastrointestinal Cancer Surgery.|Completed|||253|Actual|Aintree University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 22:44:52.804197|2018-05-31 22:44:52.804197
NCT01325870|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2014-06-18||2016-07-12|2011-03-29|2011-03-30|Estimate|2014-07-16|2014-07-17|Estimate||||2016-07-12|2016-08-12|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Hemodynamic Effects of Standard Cardiopulmonary Resuscitation (CPR), Active Compression Decompression CPR With an Inspiratory Impedance Device, and Standard CPR With an Intrathoracic Pressure Regulator During Out-of-hospital Cardiac Arrest|Comparison of Standard Cardiopulmonary Resuscitation Alone Versus Active Compression Decompression Cardiopulmonary Resuscitation Plus an Impedance Threshold Device Versus Standard Cardiopulmonary Resuscitation Plus an Intrathoracic Pressure Regulator on Arterial Blood Pressures During Out-of-Hospital Cardiac Arrest|Completed||N/A|48|Actual|Advanced Circulatory Systems||3|||f||||t||||||||||2018-05-31 22:44:52.858108|2018-05-31 22:44:52.858108
NCT01325857|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-02-26|2011-03-29|2011-03-30|Estimate|||||||2012-02-26|2012-02-28|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach|Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach|Completed||N/A|97|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 22:44:53.262715|2018-05-31 22:44:53.262715
NCT01325844|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-02-02|2011-03-29|2011-03-30|Estimate|||||||2012-02-02|2012-02-06|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effects of Epidural Anesthesia on the Bioavailability of Nitric Oxide and Renal Function in Patients Undergoing Laparoscopic Surgery|The Effects of Epidural Anesthesia on the Bioavailability of Nitric Oxide and Renal Function in Patients Undergoing Laparoscopic Surgery|Completed||N/A|45|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:44:53.376633|2018-05-31 22:44:53.376633
NCT01325831|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2012-01-31|2011-03-29|2011-03-30|Estimate|||||||2012-01-31|2012-02-02|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Changes of Functional Connectivity After rTMS in Depression|Change of Dopamine Pathway After rTMS Treatment in Major Depressive Disorder|Completed||Phase 4|44|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:44:53.449971|2018-05-31 22:44:53.449971
NCT01325818|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-31|2011-03-28|2011-03-30|Estimate|||||||2011-03-31|2011-04-01|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|February 2016|Anticipated|2016-02-29|March 2011|Anticipated|2011-03-31||Interventional|||The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris|The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris|Unknown status|Recruiting|Phase 4|150|Anticipated|Yokohama City University Medical Center||1|||f||||t||||||||||2018-05-31 22:44:53.550431|2018-05-31 22:44:53.550431
NCT01325805|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2016-11-22|2011-03-28|2011-03-30|Estimate|||||||2016-11-22|2016-11-25|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of a Structured Weight Loss Program in Overweight Women With a History of Recurrent Pregnancy Loss|Pregnancy Outcomes in Overweight and Obese Women With a History of Recurrent Pregnancy Loss Randomized to a Structured Weight Loss Program Versus Routine Weight-Loss Counseling: A Pilot Study|Terminated||N/A|7|Actual|Stanford University||2||Difficult to recruit, very poor compliance with interventions|f||||f||||||||No||2018-05-31 22:44:53.650612|2018-05-31 22:44:53.650612
NCT01325792|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2015-04-10||2015-11-18|2011-03-29|2011-03-30|Estimate|2015-11-18|2015-12-24|Estimate||||2015-11-18|2015-12-24|Estimate|February 2011||2011-02-28|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|COBRA||Open Complex Ventral Incisional Hernia Repair Using Biosynthetic Material for Midline Fascial Closure Reinforcement|Prospective, Multicenter, Observational Study Evaluate Single-Staged Open Complex Ventral Incisional Hernia Repair Using a Biosynthetic Material for Midline Fascial Closure Reinforcement|Completed|||104|Actual|W.L.Gore & Associates|||1||f||||f||||||||||2018-05-31 22:44:53.803441|2018-05-31 22:44:53.803441
NCT01325259|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2016-02-05|2011-03-28|2011-03-29|Estimate|||||||2016-02-05|2016-02-08|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|FAIR-AD||FluoroAv45 Imaging Research-in Alzheimer's Disease|Molecular Imaging of Cerebral Amyloid Plaques Using PET With Fluoro Tracker for Early Diagnosis of Alzheimer's Disease|Completed||Phase 2|54|Actual|University Hospital, Tours||3|||f||||t||||||||||2018-05-31 22:45:06.159642|2018-05-31 22:45:06.159642
NCT01325779|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2013-05-17|2011-03-29|2011-03-30|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Comparison of Subcutaneous Heparin and Enoxaparin for Deep Venous Thrombosis (DVT) Prophylaxis in Surgical Intensive Care Patients|Prevention of Lower Extremity Deep Venous Thrombosis in the Surgical Intensive Care Unit: a Randomized Trial Comparing Subcutaneous Heparin and Subcutaneous Enoxaparin|Withdrawn||N/A|0|Actual|William Beaumont Hospitals||2||poor enrollment|f||||t||||||||||2018-05-31 22:44:54.061366|2018-05-31 22:44:54.061366
NCT01325766|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-28|2011-03-28|2011-03-30|Estimate|||||||2011-03-28|2011-03-30|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Study of Yoga as a Therapy for Cystic Fibrosis (CF) Patients|Yoga as a Therapy for Adolescents and Young Adults With Cystic Fibrosis: A Pilot Study|Unknown status|Recruiting|N/A|20|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 22:44:54.262901|2018-05-31 22:44:54.262901
NCT01325753|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2017-05-25|2011-03-29|2011-03-30|Estimate|||||||2017-05-25|2017-05-30|Actual|March 2011||2011-03-31|March 2012|2012-03-31|March 2017|Anticipated|2017-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body|A Pilot Study of Cryoablation for Patients With Oligometastatic Cancer Involving the Lung|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 22:44:54.370425|2018-05-31 22:44:54.370425
NCT01325740|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-12-19|2011-03-28|2011-03-30|Estimate|||||||2012-12-19|2012-12-20|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of STX107 in Adults With Fragile X Syndrome|Suspended||Phase 2|16|Anticipated|Seaside Therapeutics, Inc.||3||pending further evaluation|f||||t||||||||||2018-05-31 22:44:54.453372|2018-05-31 22:44:54.453372
NCT01325727|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-11-13|2011-03-29|2011-03-30|Estimate|||||||2012-11-13|2012-11-15|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Brief Computerized Feedback for Smokers in Recovery|Brief Computerized Feedback for Smokers in Recovery|Completed||N/A|151|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 22:44:54.526686|2018-05-31 22:44:54.526686
NCT01325714|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2016-03-25||2016-05-19|2011-03-29|2011-03-30|Estimate|2016-05-17|2016-05-19|Estimate||||2016-05-19|2016-06-24|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|PAVeD|We evaluated differences in demographics and baseline clinical characteristics between PAVeD and EU-PC subgroups using chi-square tests and independent samples t-tests. however, when distributional assumptions were violated, a non-parametric Fishers Exact or Wilcoxon Mann-Whitney U test was conducted.|Preventing Aggression in Veterans With Dementia|Preventing Aggression in Veterans With Dementia|Completed||Phase 3|203|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 22:44:54.666963|2018-05-31 22:44:54.666963
NCT01325701|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2016-06-30||2017-03-02|2011-03-29|2011-03-30|Estimate|2016-12-22|2017-02-16|Actual||||2017-03-02|2017-03-31|Actual|May 2011||2011-05-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||A total of 78 subjects were enrolled: 70 in PCI-32765: 560 mg , and 8 in PCI-32765: 840 mg . All subjects received at least 1 dose of study drug.|Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)|Completed||Phase 2|78|Actual|Pharmacyclics LLC.|PCI-32765:840 mg:8 subjects were enrolled and followed through their 1st response assessment. Due to a lack of positive responses observed, enrollment was terminated for futility. Response rate should not be generalized due to small sample size.|2|||f||||f||||||||No||2018-05-31 22:44:55.583166|2018-05-31 22:44:55.583166
NCT01325688|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25||2013-12-19|2016-01-27|2011-03-28|2011-03-30|Estimate||||2014-08-05|2014-08-07|Estimate|2016-01-27|2016-02-26|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities|A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities|Completed||Phase 2|75|Actual|Peplin||3|||f||||f||||||||||2018-05-31 22:44:56.253797|2018-05-31 22:44:56.253797
NCT01325675|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2016-01-07|2011-03-29|2011-03-30|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Aerobic Interval Training in Patients With Atrial Fibrillation|Aerobic Interval Training in Patients With Paroxysmal or Persistent Atrial Fibrillation|Completed||N/A|51|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 22:44:56.335028|2018-05-31 22:44:56.335028
NCT01325662|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2015-07-22|2011-03-29|2011-03-30|Estimate|||||||2015-07-22|2015-07-23|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Study to Evaluate the Use of an Indwelling Catheter to Obtain Cerebrospinal Fluid (CSF) by Low-rate Continuous Sampling (MK-0000-211)|A Clinical Study to Evaluate a Modified Serial CSF Sampling Method by Indwelling Lumbar Catheter in Healthy Volunteers|Completed|||11|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||Samples Without DNA|"~     Cerebrospinal fluid (CSF)~   "|||2018-05-31 22:44:57.353698|2018-05-31 22:44:57.353698
NCT01325649|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2016-10-18|2011-03-29|2011-03-30|Estimate|||||||2016-10-18|2016-10-19|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|OCUM||Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma|Optimal Surgery With Total Mesorectal Excision and MRI Based Multimodal Therapy of Rectal Carcinoma|Completed|||1051|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-05-31 22:44:57.451135|2018-05-31 22:44:57.451135
NCT01325636|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2015-04-09|2011-03-29|2011-03-30|Estimate|||||||2015-04-09|2015-04-10|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|CTLantiCMV||Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus|Injection of CD4 and CD8 + T Cells Anti-CMV or Anti-adenovirus for the Treatment of Viral Infections Occurring After Allogenic Hematopoietic Stem Cell Transplantation (HSCT)|Completed||Phase 1/Phase 2|16|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 22:44:57.522167|2018-05-31 22:44:57.522167
NCT01325623|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2015-12-21||2015-12-21|2011-03-29|2011-03-30|Estimate|2015-12-21|2016-01-22|Estimate||||2015-12-21|2016-01-22|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2013|Actual|2013-07-31||Interventional|E-36|Subjects who provided consent and were implanted with the AspireSR VNS Therapy System version 1 or version 2.|Seizure Detection and Automatic Magnet Mode Performance Study|Seizure Detection and Automatic Magnet Mode Performance Study|Completed||N/A|31|Actual|Cyberonics, Inc.||1|||f||||t||||||||||2018-05-31 22:44:57.670507|2018-05-31 22:44:57.670507
NCT01325610|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2012-04-03|2011-03-29|2011-03-30|Estimate|||||||2012-04-03|2012-04-04|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|NEPH-Cal-D||Vitamin D Effect on Calcium Absorption on Persons on Hemodialysis|The Effect of Oral Cholecalciferol (Vitamin D3) on Calcium Absorption in Persons on Long-term Hemodialysis|Completed||N/A|37|Actual|Creighton University|||||f||||f||||||||||2018-05-31 22:44:58.885772|2018-05-31 22:44:58.885772
NCT01325597|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-03-10|2011-03-29|2011-03-30|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Effects of Functional Electrical Stimulation and Inspiratory Muscle Training in Heart Failure Patients|Effects of Functional Electrical Stimulation and Inspiratory Muscle Training in Heart Failure Patients: Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||4|||f||||f||||||||||2018-05-31 22:44:58.995582|2018-05-31 22:44:58.995582
NCT01325584|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2017-08-03|2011-03-29|2011-03-30|Estimate|||||||2017-08-03|2017-08-07|Actual|October 2012||2012-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury|Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury|Terminated||Phase 2|13|Actual|Midwestern Regional Medical Center||1||Alternative product is now approved and available for use.|f||||f||||||||Undecided|At present, no plan to share individual participant data.|2018-05-31 22:44:59.184989|2018-05-31 22:44:59.184989
NCT01325571|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-03-08|2011-03-28|2011-03-30|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis|A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy|Completed||Phase 3|83|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 22:44:59.272303|2018-05-31 22:44:59.272303
NCT01325558|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2016-07-13|2011-03-29|2011-03-30|Estimate|||||||2016-07-13|2016-07-15|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|August 2012|Actual|2012-08-31||Interventional|||A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors|A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|30|Anticipated|Altor BioScience|||||f||||t||||||||No||2018-05-31 22:44:59.363467|2018-05-31 22:44:59.363467
NCT01325545|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-12-21|2011-03-28|2011-03-29|Estimate|||||||2011-12-21|2011-12-23|Estimate|April 2009||2009-04-30|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Detection of Occult Paroxysmal Atrial Fibrillation After Stroke Using Prolonged Ambulatory Cardiac Monitoring|Detection of Occult Paroxysmal Atrial Fibrillation in Patients With Cryptogenic Stroke or TIA Using 21-Day Mobile Cardiac Outpatient Telemetry|Completed|||132|Actual|Mayo Clinic|||2||f||||f||||||||||2018-05-31 22:44:59.441668|2018-05-31 22:44:59.441668
NCT01325532|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2016-03-20||2016-04-23|2011-03-28|2011-03-29|Estimate|2016-04-23|2016-06-01|Estimate||||2016-04-23|2016-06-01|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional||Adults with MDD; the HAM-D score eligibility range was set to include subjects who were partial or non-responders (HAM-D 15-18) but not too severely depressed (HAMD ≤ 23), given CES’s experimental nature.|Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)|Efficacy and Safety of Cranial Electrical Stimulation (CES) for the Treatment of Major Depressive Disorder (MDD): A Pilot Study|Completed||N/A|30|Actual|Massachusetts General Hospital|The main limitations include a small sample and lack of an active comparator. Because CES did not separate from its sham counterpart in this sample of MDD patients, we cannot rule out that the benefit obtained from CES was due to placebo effects.|2|||f||||t||||||||No||2018-05-31 22:44:59.553204|2018-05-31 22:44:59.553204
NCT01325519|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-01-26|2011-03-28|2011-03-29|Estimate|||||||2012-01-26|2012-01-31|Estimate|March 2011||2011-03-31|January 2012|2012-01-31||||March 2012|Anticipated|2012-03-31||Interventional|||A Prospective Randomized Trial Using Video Images in Advance Care Planning in Seriously Ill Hospitalized Patients||Unknown status|Recruiting|N/A|150|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:44:59.899807|2018-05-31 22:44:59.899807
NCT01325506|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2017-10-20|2011-03-28|2011-03-29|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2010||2010-09-30|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|PROSTQA-RP2||Effectiveness of Open and Robotic Prostatectomy|Effectiveness of Open and Robotic Prostatectomy: The PROSTQA-RP2 Study|Active, not recruiting|||600|Anticipated|Dana-Farber Cancer Institute|||1||f||||t||||||||||2018-05-31 22:44:59.979297|2018-05-31 22:44:59.979297
NCT01325493|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2015-06-17||2015-12-14|2011-03-28|2011-03-29|Estimate|2015-10-01|2015-11-02|Estimate||||2015-12-14|2016-01-14|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|KPSF|ASA classifications: ASA Physical Status 1 - A normal healthy patient ASA Physical Status 2 - A patient with mild systemic disease ASA Physical Status 3 - A patient with severe systemic disease|Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia|Modulation of μ Opioid Receptor Mediated Analgesia, Tolerance and Hyperalgesia in Children and Adolescents|Completed||Phase 4|54|Actual|Children's Research Institute|Patient sex and ethnicity could have led to analytical bias.|2|||f||||t||||||||||2018-05-31 22:45:00.089771|2018-05-31 22:45:00.089771
NCT01325480|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-06-20|2011-03-28|2011-03-29|Estimate|||||||2012-06-20|2012-06-21|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Observational|HISTORY||High Septal Pacing for Cardiac Resynchronization Therapy|High Septal Pacing for Cardiac Resynchronization Therapy Acute Research Study|Terminated|||15|Actual|Boston Scientific Corporation|||1||f||||t||||||||||2018-05-31 22:45:00.403661|2018-05-31 22:45:00.403661
NCT01325467|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-03-28|2011-03-28|2011-03-29|Estimate|||||||2012-03-28|2012-03-29|Estimate|May 2011||2011-05-31|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|HyperQ||Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry|Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry|Unknown status|Recruiting||900|Anticipated|BSP Biological Signal Processing Ltd.|||||f||||f||||||||||2018-05-31 22:45:00.485903|2018-05-31 22:45:00.485903
NCT01325454|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions|Angiogenic Cytokines and Fibrinolytic Activity in Parapneumonic Effusions|Unknown status|Recruiting||80|Anticipated|Taipei Medical University Hospital|||1||f||||t||||||Samples Without DNA|"~     Pleural effusions~   "|||2018-05-31 22:45:00.567422|2018-05-31 22:45:00.567422
NCT01325441|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2018-03-30|2011-03-28|2011-03-29|Estimate|||||||2018-03-30|2018-04-03|Actual|April 2011||2011-04-30|March 2018|2018-03-31||||June 2019|Anticipated|2019-06-30||Interventional|||A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies|A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|390|Anticipated|Boston Biomedical, Inc||1|||f||||t||||||||||2018-05-31 22:45:00.648393|2018-05-31 22:45:00.648393
NCT01325428|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2015-11-17||2016-06-17|2011-03-28|2011-03-29|Estimate|2016-01-13|2016-02-11|Estimate||||2016-06-17|2016-07-19|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||"TRT A Treated set (Part A): All patients who were documented to have taken at least one dose of Afatinib in Part A.~TRT B Treated set (Part B): All patients who received at least one dose each of Afatinib and Vinorelbine in Part B."|Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer|An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer|Completed||Phase 2|26|Actual|Boehringer Ingelheim|Boehringer Ingelheim (BI) decided to stop further inclusion of patients and stop further treatment with the combination of Afatinib and Vinorelbine as of 03-May-2013. Recruitment into the trial was stopped by amendment in Jul 2013.|1|||f||||||||||||||2018-05-31 22:45:00.773951|2018-05-31 22:45:00.773951
NCT01325415|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-10-13|2011-03-28|2011-03-29|Estimate|||||||2014-10-13|2014-10-15|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects|A Single Center, Randomized, Double-blinded, Placebo-controlled, Open-label, Positive-controlled, Four-way Crossover Study to Assess the Effect of a Single Oral Dose NKTR-118 Administration on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects|Completed||Phase 1|45|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 22:45:01.462854|2018-05-31 22:45:01.462854
NCT01325402|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-12-07|2011-03-28|2011-03-29|Estimate|||||||2012-12-07|2012-12-10|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease|Open-Label Positron Emission Tomography Study With Selective Beta Amyloid Radioligand (18Fluor)AZD4694 to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease|Completed||Phase 1|16|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:45:01.708195|2018-05-31 22:45:01.708195
NCT01325389|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate||||March 2011|2011-03-31||||||||Interventional|||Myo-inositol Plus Melatonin in Perimenopausal Women|Effects of Myo-inositol Plus Melatonin in Perimenopausal Women|Unknown status|Recruiting|N/A|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||f||||||||||2018-05-31 22:45:01.972245|2018-05-31 22:45:01.972245
NCT01325376|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2011-04-17|2011-03-28|2011-03-29|Estimate|||||||2011-04-17|2011-04-19|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||PH iWell Study to Compare an Online Interactive Technology to Self-directed Care in Overweight or Obese Individuals|SKTA iWell21 Clinical Trial Protocol. This is a Randomized Control Trial of 500 Adult Participants Randomized to Two Arms: Control Arm: Self Directed Program (SDP), Intervention Arm: Dynamic On-line Interactive Technology (DOIT)|Unknown status|Active, not recruiting|N/A|500|Anticipated|SK Telecom Americas, Inc.||2|||f||||f||||||||||2018-05-31 22:45:02.184256|2018-05-31 22:45:02.184256
NCT01325363|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-27|||2012-03-07|2011-03-28|2011-03-29|Estimate|||||||2012-03-07|2012-03-08|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Magnetoencephalographic (MEG) Evidence for Novel Metaphor Processing Among Schizophrenic Patients|Novel Metaphor Processing Among Schizophrenic Patients - Magnetoencephalographic (MEG) Evidence|Completed||N/A|30|Actual|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 22:45:02.349421|2018-05-31 22:45:02.349421
NCT01325350|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2014-03-03|2013-07-31|2014-03-03|2011-03-28|2011-03-29|Estimate|2014-03-03|2014-04-09|Estimate|2013-07-31|2013-08-07|Estimate|2014-03-03|2014-04-09|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss||Completed||Phase 2|306|Actual|Allergan||5|||f||||f||||||||||2018-05-31 22:45:02.59195|2018-05-31 22:45:02.59195
NCT01325337|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|2014-03-03|2013-08-26|2014-04-08|2011-03-28|2011-03-29|Estimate|2014-04-08|2014-04-10|Estimate|2013-08-26|2013-09-02|Estimate|2014-04-08|2014-04-10|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia||Completed||Phase 2|307|Actual|Allergan||5|||f||||f||||||||||2018-05-31 22:45:03.502715|2018-05-31 22:45:03.502715
NCT01325324|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-01-05|2011-03-28|2011-03-29|Estimate|||||||2015-01-05|2015-01-06|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Different Portable Tonometers (Icare Pro, TONO-Pen AVIA, Perkins Tonometer, PASCAL Hand Held Dynamic Contour Tonometer)||Unknown status|Enrolling by invitation|Phase 4|25|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 22:45:04.028253|2018-05-31 22:45:04.028253
NCT01325311|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2015-12-24||2016-06-20|2011-03-28|2011-03-29|Estimate|2016-06-20|2016-08-03|Estimate||||2016-06-20|2016-08-03|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer|Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy|Completed||Phase 2|15|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 22:45:04.136635|2018-05-31 22:45:04.136635
NCT01325298|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|||UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia|UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia|Unknown status|Recruiting|Phase 2|250|Anticipated|Mercy Center for Corrective Eye Surgery||2|||f||||t||||||||||2018-05-31 22:45:05.637958|2018-05-31 22:45:05.637958
NCT01325246|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-12-03|2011-03-28|2011-03-29|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Observational|||Reoperation Rate Versus Clinical Recurrence After Ventral Hernia Repair|Correlation Between Reoperation and Clinical Palpable Recurrence 3 Years After Ventral Hernia Repair|Completed|||945|Actual|Zealand University Hospital|||||f||||f||||||||||2018-05-31 22:45:06.241047|2018-05-31 22:45:06.241047
NCT01325233|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2015-11-03|2011-03-28|2011-03-29|Estimate|||||||2015-11-03|2015-11-04|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke|The Pilot Clinical Study of PG2 Injection on Hemorrhagic Stroke|Completed||Early Phase 1|61|Actual|PhytoHealth Corporation||2|||f||||f||||||||||2018-05-31 22:45:06.314187|2018-05-31 22:45:06.314187
NCT01325220|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2013-07-30|2011-03-28|2011-03-29|Estimate|||||||2013-07-30|2013-07-31|Estimate|June 2011||2011-06-30|July 2013|2013-07-31||||June 2013|Actual|2013-06-30||Interventional|Harbor-C||Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome|Completed||Phase 3|172|Actual|Seaside Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 22:45:06.40813|2018-05-31 22:45:06.40813
NCT01325207|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-12-19|2011-03-28|2011-03-29|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2011||2011-04-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer|Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer|Active, not recruiting||Phase 1/Phase 2|34|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 22:45:06.521913|2018-05-31 22:45:06.521913
NCT01325194|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2017-09-04|2011-03-28|2011-03-29|Estimate|||||||2017-09-04|2017-09-07|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Interventional|CHIC||CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis|Dose Densified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk (aaIPI≥ 2) Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 2|143|Actual|Nordic Lymphoma Group||1|||f||||f||||||||||2018-05-31 22:45:06.714219|2018-05-31 22:45:06.714219
NCT01325181|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|2013-04-02||2013-04-05|2011-03-27|2011-03-29|Estimate|2013-04-05|2013-05-27|Estimate||||2013-04-05|2013-05-27|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy|Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy|Completed||Phase 1/Phase 2|34|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:45:06.839795|2018-05-31 22:45:06.839795
NCT01325168|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|||2015-05-06|2011-03-27|2011-03-29|Estimate|||||||2015-05-06|2015-05-07|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional|||The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With Post Traumatic Stress Disorder (PTSD)|The Effect of Intranasal Oxytocin on Emphatic Abilities in Patients With PTSD|Completed||Phase 4|62|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:45:07.100319|2018-05-31 22:45:07.100319
NCT01325155|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-27|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|April 2011||2011-04-30|March 2011|2011-03-31||||||||Observational|||Effect of Air Pollution in the Haifa Bay Area on Cardiovascular Morbidity and Mortality|Effect of Air Pollution in the Haifa Bay Area on Cardiovascular Morbidity and Mortality|Unknown status|Not yet recruiting||5000|Anticipated|Rambam Health Care Campus|||||f||||t||||||||||2018-05-31 22:45:07.185481|2018-05-31 22:45:07.185481
NCT01325142|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-12-01|2011-03-28|2011-03-29|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer|Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer|Completed|||271|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     paraffin embedded tissue block and/or WBC~   "|||2018-05-31 22:45:07.251144|2018-05-31 22:45:07.251144
NCT01325129|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-02-13|2011-03-28|2011-03-29|Estimate|||||||2014-02-13|2014-02-14|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Observational|ESIN clavicle||Elastic Stable Intramedullary Nailing of Dislocated Clavicle Fractures in Children|Elastic Stable Intramedullary Nailing of Dislocated Clavicle Fractures in Children and Adolescents: Lessons Learned From the First 20 Patients|Completed|||20|Actual|University of Luebeck|||||f||||t||||||||||2018-05-31 22:45:07.387398|2018-05-31 22:45:07.387398
NCT01325116|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-09-17|2011-03-28|2011-03-29|Estimate|||||||2014-09-17|2014-09-19|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|DERLA-STEMI||Delayed Educational Reminders in Acute Myocardial Infarction (MI)|Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI): Cluster-randomized Controlled Trial|Completed||N/A|852|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:45:07.442166|2018-05-31 22:45:07.442166
NCT01325103|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2017-11-27|2011-03-28|2011-03-29|Estimate|||||||2017-11-27|2017-11-28|Actual|July 2010||2010-07-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury|Phase 1 Study of Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury|Completed||N/A|14|Actual|Hospital Sao Rafael||1|||f||||t||||||||||2018-05-31 22:45:07.542379|2018-05-31 22:45:07.542379
NCT01325090|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2016-08-19|2011-03-28|2011-03-29|Estimate|||||||2016-08-19|2016-08-22|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Interventional|APTODON||Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy|Early Administration of Botulinum Toxin Type A (Botox®) in Neuropathic Pain Due to Thoracoscopy or Thoracotomy: a Randomized, Double Blind, Placebo Controlled Study|Withdrawn||Phase 3|0|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 22:45:07.625256|2018-05-31 22:45:07.625256
NCT01325077|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-03-27|2011-03-27|2011-03-29|Estimate|||||||2011-03-27|2011-03-29|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|Nurse-APS||Efficacy of a Nurse-based, Anesthesiologist-supervised Acute Pain Service for Pediatric Patients|Efficacy of a Nurse-based, Anesthesiologist-supervised Acute Pain Service for Pediatric Patients|Unknown status|Recruiting|Phase 3|103|Anticipated|Mahidol University||1|||f||||f||||||||||2018-05-31 22:45:07.700568|2018-05-31 22:45:07.700568
NCT01325064|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-27|||2017-02-28|2011-03-28|2011-03-29|Estimate|||||||2017-02-28|2017-03-01|Actual|June 2010||2010-06-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2010|Actual|2010-12-31||Observational|Vasorisk||Blood Pressure and Subclinical Organ Damage|Central and Peripheral Blood Pressure and Its Relation With Vascular Target Organ Damage in Carotid, Retinal and Arterial Stiffness. Developed and Validation of a Tool|Completed|||500|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|||||f||||f||||||||||2018-05-31 22:45:07.771968|2018-05-31 22:45:07.771968
NCT01325051|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2012-01-03|2011-03-28|2011-03-29|Estimate|||||||2012-01-03|2012-01-05|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers|A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers|Completed||Phase 1|15|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 22:45:07.932508|2018-05-31 22:45:07.932508
NCT01325038|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|August 2009|Actual|2009-08-31|June 2008|Actual|2008-06-30||Interventional|||Effects of Increased Muscle Mass on Resting Metabolic Rate||Completed||N/A|24|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 22:45:08.088316|2018-05-31 22:45:08.088316
NCT01325025|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2016-07-31|2011-03-28|2011-03-29|Estimate|||||||2016-07-31|2016-08-02|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|HCIT-MLD||Imaging Study of the White Matter Lesions in Children With Metachromatic Leucodystrophy|Study of the Natural History of Cerebral White Matter Involvement in Metachromatic Leukodystrophy, Using High-field MRI and Diffusion Tensor Imaging|Completed||N/A|29|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 22:45:08.151312|2018-05-31 22:45:08.151312
NCT01325012|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2013-03-27|2011-03-28|2011-03-29|Estimate|||||||2013-03-27|2013-03-29|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Ultrasound-Guided Continuous Sciatic Nerve Blocks: Popliteal Versus Subgluteal Catheters|Ultrasound-Guided Continuous Sciatic Nerve Blocks: Popliteal Versus Subgluteal Catheters|Terminated||Phase 4|2|Actual|University of California, San Diego||2||Surgeon doing procedures amenable to this study left institution.|f||||f||||||||||2018-05-31 22:45:08.232965|2018-05-31 22:45:08.232965
NCT01324999|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2017-03-21||2017-06-25|2011-03-28|2011-03-29|Estimate|2017-06-25|2017-07-24|Actual||||2017-06-25|2017-07-24|Actual|March 2011||2011-03-31|June 2017|2017-06-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|SAPH||Tadalafil for Sarcoidosis Associated Pulmonary Hypertension|Tadalafil for Sarcoidosis Associated Pulmonary Hypertension|Completed||Phase 2/Phase 3|12|Actual|University of North Carolina, Chapel Hill|Since this was a proof of concept study evaluating safety and tolerability of the intervention in this population, it was not powered to achieve statistical significance in changes observed from baseline to week 24 in any of the endpoints.|1|||f||||t||||||||||2018-05-31 22:45:08.321631|2018-05-31 22:45:08.321631
NCT01324986|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-27|||2011-04-08|2011-03-28|2011-03-29|Estimate|||||||2011-04-08|2011-04-11|Estimate||||March 2011|2011-03-31||||||||Interventional|||A Study on the Effectiveness of Laparoscopic Fundoplication on Extraesophageal Manifestations of Gastroesophageal Reflux Disease (GERD)||Completed||N/A|||General Public Hospital Zell am See||2|||f||||||||||||||2018-05-31 22:45:08.630853|2018-05-31 22:45:08.630853
NCT01324973|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2014-06-30|2011-03-28|2011-03-29|Estimate|||||||2014-06-30|2014-07-02|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|eWellness||Web-Based Weight Management for Individuals With Mental Illness|Web-Based Weight Management for Individuals With Mental Illness|Completed||N/A|60|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 22:45:08.700341|2018-05-31 22:45:08.700341
NCT01324960|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-03-19|2011-03-28|2011-03-29|Estimate|||||||2014-03-19|2014-03-20|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes|A Phase I and Phase II Study of the Efficacy and Safety of Maintenance Treatment With Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes Who Achieved Hematological Response to Azacitidine|Withdrawn||Phase 1/Phase 2|0|Actual|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||||2018-05-31 22:45:08.812033|2018-05-31 22:45:08.812033
NCT01324947|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-27|2015-05-20||2016-10-28|2011-03-27|2011-03-29|Estimate|2015-07-01|2015-07-30|Estimate||||2016-10-28|2016-12-12|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The intent-to-treat (ITT) population was defined as all enrolled participants.|Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma|Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003|Completed||Phase 3|74|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 22:45:08.982267|2018-05-31 22:45:08.982267
NCT01324934|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-04-30|2011-03-28|2011-03-29|Estimate|||||||2015-04-30|2015-05-01|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|IBERICA||Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids|Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression|Terminated||Phase 3|40|Actual|Neovii Biotech||2||Recruitment became very slow.|f||||t||||||||||2018-05-31 22:45:09.508574|2018-05-31 22:45:09.508574
NCT01324921|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-27|||2011-03-29|2011-03-28|2011-03-29|Estimate|||||||2011-03-29|2011-03-30|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics|Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics|Completed||Phase 2/Phase 3|37|Actual|Abbott Nutrition||3|||f||||t||||||||||2018-05-31 22:45:09.588239|2018-05-31 22:45:09.588239
NCT01324908|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-08-11|2011-03-26|2011-03-29|Estimate|||||||2017-08-11|2017-08-15|Actual|July 2011||2011-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis|T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis|Active, not recruiting||N/A|85|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 22:45:09.656526|2018-05-31 22:45:09.656526
NCT01324895|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2012-03-23|2011-03-28|2011-03-29|Estimate|||||||2012-03-23|2012-03-26|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|SIBO||Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing|Retrospective Analysis of Treatment Outcomes in Patients With Bacterial Overgrowth Syndrome Diagnosed by D-Xylose Breath Testing|Completed|||944|Actual|University of Florida|||||f||||f||||||||||2018-05-31 22:45:09.722685|2018-05-31 22:45:09.722685
NCT01324882|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2013-05-08||2017-11-30|2011-03-28|2011-03-29|Estimate|2013-06-17|2013-08-23|Estimate||||2017-11-30|2017-12-02|Actual|June 2010||2010-06-30|November 2017|2017-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Colonoscope Insertion Trial Protocol|Study to Examine Insertion of 2 Colonoscopes Trial|Completed||N/A|57|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 22:45:09.817348|2018-05-31 22:45:09.817348
NCT01324869|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2013-02-28|2011-03-28|2011-03-29|Estimate|||||||2013-02-28|2013-03-01|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|February 2012|Actual|2012-02-29||Interventional|Frontier-1||Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)|An Open-label, Randomized, Uncontrolled, Preliminary Clinical Study to Evaluate the Safety and Efficacy of KH902 Following Multiple Intravitreal Injection in Patients With Diabetic Macular Edema|Completed||Phase 1/Phase 2|20|Actual|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||f||||||||||2018-05-31 22:45:10.086286|2018-05-31 22:45:10.086286
NCT01324856|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-04-08|2011-03-28|2011-03-29|Estimate|||||||2011-04-08|2011-04-11|Estimate|April 2011||2011-04-30|February 2011|2011-02-28|September 2013|Anticipated|2013-09-30|April 2013|Anticipated|2013-04-30||Interventional|PanAm||Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic Duodenopancreatectomy|Results of Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic Duodenopancreatectomy in Patients With Soft Pancreas and Small Pancreatic Duct|Unknown status|Not yet recruiting|Phase 1|100|Anticipated|University of Belgrade||2|||f||||t||||||||||2018-05-31 22:45:10.159909|2018-05-31 22:45:10.159909
NCT01324843|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-26|||2017-06-30|2011-03-26|2011-03-29|Estimate|||||||2017-06-30|2017-07-02|Actual|June 25, 2009||2009-06-25|September 20, 2011|2011-09-20|May 27, 2010|Actual|2010-05-27|May 27, 2010|Actual|2010-05-27||Interventional|||Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects|Safety and Tolerability of the Derma Vax Clinical Intradermal Electroporation System in Healthy Subjects|Completed||Phase 1|24|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:45:10.246406|2018-05-31 22:45:10.246406
NCT01324830|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-12-10|2011-03-28|2011-03-29|Estimate|||||||2013-12-10|2013-12-11|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Monotherapy Dose Finding With BI 847325 in Solid Tumours|An Open Label Phase Ia/Ib Study of Two Dosing Schedules of BI 847325, Orally Administered Once a Day in Patients With Advanced Solid Tumours, With Repeated Cyclic Administration in Patients With Clinical Benefit|Completed||Phase 1|69|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:45:10.304185|2018-05-31 22:45:10.304185
NCT01324817|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-26|||2011-12-12|2011-03-28|2011-03-29|Estimate|||||||2011-12-12|2011-12-14|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitors for Use With Neonates|Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitors for Use With Neonates|Unknown status|Recruiting||50|Anticipated|Kai Medical, Inc.|||1||f||||f||||||||||2018-05-31 22:45:10.363012|2018-05-31 22:45:10.363012
NCT01324804|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|November 2010||2010-11-30|December 2009|2009-12-31||||||||Observational|||Antibiotic Concentration in Internal Mammary Graft Preparation|Target Tissue Concentration of Standard Antibiotic Treatment in Coronary Artery Bypass Grafting Using Left Internal Mammary Artery|Unknown status|Recruiting||12|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 22:45:10.491185|2018-05-31 22:45:10.491185
NCT01324791|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-26|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate||||March 2011|2011-03-31||||||||Interventional|||Laparoscopic Antireflux Surgery Versus Endoscopic Full-thickness Gastroplication for Gastroesophageal Reflux Disease (GERD)||Completed||N/A|||General Public Hospital Zell am See||2|||f||||||||||||||2018-05-31 22:45:10.573044|2018-05-31 22:45:10.573044
NCT01324778|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-05-09|2011-03-28|2011-03-29|Estimate|||||||2017-05-09|2017-05-10|Actual|March 2011||2011-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Multi Centre Study Comparing OsseoSpeed TX With OsseoSpeed|An Open, Randomized, Prospective Multi Centre Study Comparing OsseoSpeedTM TX With OsseoSpeedTM in the Partially and Totally Edentulous Maxillae|Completed||N/A|107|Actual|Dentsply Sirona Implants||2|||f||||||||||||||2018-05-31 22:45:10.6437|2018-05-31 22:45:10.6437
NCT01324765|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|WOMAN||Women Overcoming and Managing Adversity Now (WOMAN) Study|Women Overcoming and Managing Adversity Now (WOMAN) Study|Completed||Phase 2/Phase 3|108|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 22:45:10.73647|2018-05-31 22:45:10.73647
NCT01324752|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2012-12-19|2011-03-28|2011-03-29|Estimate|||||||2012-12-19|2012-12-21|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Drug-Drug Interaction Study of Losartan and PA21|A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults|Completed||Phase 1|36|Actual|Vifor Inc.||3|||f||||f||||||||||2018-05-31 22:45:10.815524|2018-05-31 22:45:10.815524
NCT01324739|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||B-type Natriuretic Peptide and Glucose Metabolism|B-type Natriuretic Peptide Affects the Initial Response to Intravenous Glucose in a Placebo-controlled Cross-over Study in Healthy Volunteers|Completed||N/A|10|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 22:45:10.901136|2018-05-31 22:45:10.901136
NCT01324726|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2015-06-22|2011-03-28|2011-03-29|Estimate|||||||2015-06-22|2015-06-24|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Observational|||Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms|Sites of Colonization in Hospitalized Patients With Infections Caused by Extended-Spectrum Beta-Lactamase Producing Escherichia Coli and Klebsiella Pneumoniae|Completed|||100|Actual|American University of Beirut Medical Center|||||f||||f||||||Samples Without DNA|"~     Cultures of urine, nasopharynx, rectum, skin, and wounds~   "|||2018-05-31 22:45:10.988944|2018-05-31 22:45:10.988944
NCT01324713|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2015-10-01|2011-03-25|2011-03-29|Estimate|||||||2015-10-01|2015-10-05|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Does Gender Play a Role in Bone-mineral Density Measurement Precision?|Does Gender Play a Role in Bone-mineral Density Measurement Precision?|Completed|||180|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 22:45:11.058104|2018-05-31 22:45:11.058104
NCT01324700|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2017-10-17||2018-04-23|2011-03-25|2011-03-29|Estimate|2018-01-22|2018-02-16|Estimate||||2018-04-23|2018-05-22|Actual|July 2010||2010-07-31|April 2018|2018-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Antidepressant Treatment at an Inner City Asthma Clinic|Antidepressant Treatment at an Inner City Asthma Clinic|Completed||Phase 4|139|Actual|University of Texas Southwestern Medical Center||4|||f||||t||||||||||2018-05-31 22:45:11.136978|2018-05-31 22:45:11.136978
NCT01324687|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2016-02-20||2017-04-28|2011-03-25|2011-03-29|Estimate|2016-02-20|2016-03-21|Estimate||||2017-04-28|2017-06-09|Actual|October 2010||2010-10-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Study Of Telemedicine Consultation at Home For Older Adults|Study Of Telemedicine Consultation at Home For Older Adults|Completed|||1537|Actual|University of Rochester|||2||f||||f||||||||No||2018-05-31 22:45:11.653339|2018-05-31 22:45:11.653339
NCT01324674|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2012-01-16|2011-03-28|2011-03-29|Estimate|||||||2012-01-16|2012-01-18|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Relationship Between Treatment With Bach´s Flower Remedy and Spiritual Well-Being of People With Common Mental Disorder|Relationship Between Treatment With Bach´s Flower Remedy and Spiritual Well-Being of People With Common Mental Disorder|Completed||Phase 2|70|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||||2018-05-31 22:45:11.900849|2018-05-31 22:45:11.900849
NCT01324661|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-09-28|2011-03-28|2011-03-29|Estimate|||||||2011-09-28|2011-09-30|Estimate|December 2009||2009-12-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Protective Effect of Friendship on Peer Rejection in Overweight and Normal Weight Youth|The Protective Effect of Friendship on Peer Rejection in Overweight and Normal Weight Youth|Completed||N/A|104|Actual|University at Buffalo||2|||f||||f||||||||||2018-05-31 22:45:11.969605|2018-05-31 22:45:11.969605
NCT01324648|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-09-08|2011-03-28|2011-03-29|Estimate|||||||2014-09-08|2014-09-10|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluation of the Bounce Back Program|A Randomized Controlled Trial Evaluation of Brief, Telephone Supported CBT Self-help in Primary Care Patients With Mild to Moderate Depression|Unknown status|Recruiting|N/A|213|Anticipated|University of British Columbia||3|||f||||t||||||||||2018-05-31 22:45:12.025939|2018-05-31 22:45:12.025939
NCT01324635|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-12-08|2011-03-28|2011-03-29|Estimate|||||||2016-12-08|2016-12-09|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2013|Actual|2013-10-31||Interventional|||Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors|Phase I, Dose Finding Trial of the Combination of Panobinostat and Stereotactic Radiation in the Treatment of Brain Tumors|Terminated||Phase 1|17|Actual|Thomas Jefferson University||2||Arm A - reached goal; Arm B - poor accrual|f||||t||||||||||2018-05-31 22:45:12.117551|2018-05-31 22:45:12.117551
NCT01324622|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2015-04-10||2017-11-03|2011-03-28|2011-03-29|Estimate|2017-04-14|2017-04-17|Actual||||2017-11-03|2017-12-07|Actual|January 1, 2006|Actual|2006-01-01|October 2017|2017-10-31|November 1, 2010|Actual|2010-11-01|November 1, 2010|Actual|2010-11-01||Interventional|||Comparison of Cervical Laminectomy to Laminoplasty|Comparison of Cervical Laminectomy to Cervical Laminoplasty* in Patients With Cervical Myelopathy or Myeloradiculopathy Due to Multiple Level Cervical Spinal Canal Stenosis * ARCH™ Fixation System by SYNTHES|Terminated||N/A|24|Actual|Synthes USA HQ, Inc.|Slow enrollment and a low follow-up rate resulted in the early termination of the study and lead to a small numbers of subjects completing the study and limiting the data analysis.|2||terminated due to failure to meet enrolment goals|f||||f||||||||||2018-05-31 22:45:12.238037|2018-05-31 22:45:12.238037
NCT01324609|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2012-03-22|2011-03-28|2011-03-29|Estimate|||||||2012-03-22|2012-03-26|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Detection of Choroidal Nevus Cells in Vitrectomy Fluid|Detection of Choroidal Nevus Cells in Vitrectomy Fluid|Terminated|||2|Actual|Stanford University||||Could not recruit enough patients|f||||||||||||||2018-05-31 22:45:12.613967|2018-05-31 22:45:12.613967
NCT01324596|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2016-04-14|2011-03-28|2011-03-29|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|REMoDL-B||A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib|A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib|Completed||Phase 3|1132|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||Yes||2018-05-31 22:45:12.677821|2018-05-31 22:45:12.677821
NCT01324583|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-01-06|2011-03-28|2011-03-29|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer|An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase I Study With Cabazitaxel Administered as a 1-hour Intravenous Infusion Every 3 Weeks in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 1|48|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:45:12.85655|2018-05-31 22:45:12.85655
NCT01324570|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2017-03-10||2017-06-07|2011-03-28|2011-03-29|Estimate|2017-06-07|2017-07-06|Actual||||2017-06-07|2017-07-06|Actual|July 2011||2011-07-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||The safety population (N=41) was the group of patients who received at least 1 dose of study drug during the study.|Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children|An Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Buprenorphine Transdermal System (BTDS) in Children From 7 to 16 Years of Age, Inclusive, Who Require Continuous Opioid Analgesia for Moderate to Severe Pain|Completed||Phase 3|41|Actual|Purdue Pharma LP|Patient recruitment in the younger age group was difficult and the sample size is smaller than the older age group. This limitation should be a consideration when interpreting the data.|1|||f||||t||||||||||2018-05-31 22:45:12.974237|2018-05-31 22:45:12.974237
NCT01324557|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-28|2011-03-28|2011-03-29|Estimate|||||||2011-03-28|2011-03-29|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Insulin Pump Therapy and Continuous Glucose Monitoring in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients||Unknown status|Recruiting|Phase 2|44|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 22:45:14.659276|2018-05-31 22:45:14.659276
NCT01324544|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2016-02-03|2011-03-28|2011-03-29|Estimate|||||||2016-02-03|2016-02-04|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain|A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Aged From Birth to 6 Years of Age (Inclusive) Who Require Opioid Analgesia for Acute Moderate to Severe Pain|Withdrawn||Phase 3|0|Actual|Purdue Pharma LP||1||Due to change in development plan.|f||||f||||||||||2018-05-31 22:45:14.760908|2018-05-31 22:45:14.760908
NCT01324531|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-09-18|2011-03-28|2011-03-29|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2011||2011-03-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Arthroscopic Bankart Repair With and Without Remplissage in Anterior Shoulder Instability|Arthroscopic Bankart Repair With and Without Arthroscopic Infraspinatus Remplissage in Anterior Shoulder Instability With a Hill-Sachs Defect: A Randomized Controlled Trial|Active, not recruiting||Phase 2|150|Actual|Panam Clinic||2|||f||||f||||||||||2018-05-31 22:45:14.824094|2018-05-31 22:45:14.824094
NCT01324518|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-10-20|2011-03-25|2011-03-29|Estimate|||||||2014-10-20|2014-10-21|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|ALPO||Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease|Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease|Completed||Phase 2|100|Actual|Orion Corporation, Orion Pharma||3|||f||||t||||||||||2018-05-31 22:45:15.002045|2018-05-31 22:45:15.002045
NCT01324505|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2017-02-06|2011-03-28|2011-03-29|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2011||2011-03-31|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes|An Open-label, One-sequence Cross-over, Single Centre Trial Investigating the Influence of Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug After Multiple Dose Administration of Semaglutide in Subjects With Type 2 Diabetes|Completed||Phase 1|43|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 22:45:15.087695|2018-05-31 22:45:15.087695
NCT01324492|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-12-26|2011-03-28|2011-03-29|Estimate|||||||2014-12-26|2014-12-30|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|\MACS1304||Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor|A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor|Completed||Phase 1|16|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:45:15.171491|2018-05-31 22:45:15.171491
NCT01324479|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2018-03-21|2011-03-28|2011-03-29|Estimate|||||||2018-03-21|2018-03-23|Actual|February 29, 2012|Actual|2012-02-29|March 2018|2018-03-31|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|||Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors|A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors|Completed||Phase 1|131|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 22:45:15.260531|2018-05-31 22:45:15.260531
NCT01324466|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22||2013-05-15|2013-05-15|2011-03-28|2011-03-29|Estimate||||2013-05-15|2013-05-23|Estimate|2013-05-15|2013-05-23|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SHaRCS||A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis|Completed||Phase 3|847|Actual|NanoBio Corporation||2|||f||||f||||||||||2018-05-31 22:45:15.424658|2018-05-31 22:45:15.424658
NCT01324453|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|2018-03-16||2018-04-23|2011-03-28|2011-03-29|Estimate|2018-03-16|2018-04-17|Actual||||2018-04-23|2018-05-22|Actual|March 2011||2011-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2016|Actual|2016-11-30||Interventional|||Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)|Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in STEMI|Active, not recruiting||Phase 1/Phase 2|103|Actual|Minneapolis Heart Institute Foundation||2|||f||||t||||||||||2018-05-31 22:45:15.617126|2018-05-31 22:45:15.617126
NCT01324440|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2011-09-09||2015-03-23|2011-03-28|2011-03-29|Estimate|2011-09-09|2011-10-17|Estimate||||2015-03-23|2015-04-10|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)|A Randomized, Multicenter, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With Merck Aluminum Adjuvant or Without Merck Aluminum Adjuvant in Healthy Adults 18 to 70 Years of Age|Completed||Phase 1|64|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:45:16.312589|2018-05-31 22:45:16.312589
NCT01324427|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-07-16|2011-03-25|2011-03-29|Estimate|||||||2014-07-16|2014-07-18|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Telemedicine Evaluation for Stem Cell Transplant Patients|Pilot Trial of Telemedicine Evaluation for Stem Cell Transplant Patients|Completed||N/A|43|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:45:16.71098|2018-05-31 22:45:16.71098
NCT01324414|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2016-01-07|2011-03-28|2011-03-29|Estimate|||||||2016-01-07|2016-01-11|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|NASHCR20||Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis|Predictive Value of Inflammation and Fibrosis in Skeletal Muscle for Liver Histopathology in Patients With Non Alcoholic Fatty Liver Disease: Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis|Completed|||90|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 22:45:16.78569|2018-05-31 22:45:16.78569
NCT01324401|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2016-11-23||2017-07-07|2011-03-28|2011-03-29|Estimate|2016-11-23|2017-01-20|Estimate||||2017-07-07|2017-08-14|Actual|March 2011||2011-03-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2016|Actual|2016-05-31||Interventional|PNOIT||Oral Peanut Immunotherapy|Oral Peanut Immunotherapy|Active, not recruiting||N/A|30|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:45:16.859999|2018-05-31 22:45:16.859999
NCT01324388|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|2014-10-03||2014-10-03|2011-03-25|2011-03-29|Estimate|2014-10-03|2014-10-08|Estimate||||2014-10-03|2014-10-08|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Participants who received at least one dose of study drug (LY2189265, placebo, or metoprolol).|A Study of the Effect of LY2189265 on Two Blood Pressure Drugs|Pharmacokinetic and Pharmacodynamic Effect of LY2189265 on Lisinopril in Subjects With Hypertension and Metoprolol in Healthy Subjects|Completed||Phase 1|51|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:45:17.19592|2018-05-31 22:45:17.19592
NCT01324375|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2012-09-25|2011-03-25|2011-03-29|Estimate|||||||2012-09-25|2012-09-26|Estimate|March 2011||2011-03-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Prediction of Pain in Total Hip Arthroplasty|Is Preoperative Pain Response Upon Tonic Heat Stimulation Predictive for Pain After Total Hip Arthroplasty?|Completed|||60|Actual|Hvidovre University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 22:45:17.858185|2018-05-31 22:45:17.858185
NCT01323868|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-11-17|2011-03-24|2011-03-28|Estimate|||||||2014-11-17|2014-11-18|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Endogenous Endophthalmitis in the Inpatient Setting|Endogenous Endophthalmitis Rates, Clinical Course, and Outcomes|Completed|||145|Actual|Stanford University|||||f||||||||||||||2018-05-31 22:45:26.003937|2018-05-31 22:45:26.003937
NCT01324362|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-08-31|2011-03-25|2011-03-29|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2003||2003-01-31|August 2016|2016-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||GSK BHR Study (Sont - Second Study)|A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Sameterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo Twice Daily if Asymptomatic)|Completed||Phase 4|446|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:17.937264|2018-05-31 22:45:17.937264
NCT01324349|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2012-06-20||2014-01-29|2011-03-28|2011-03-29|Estimate|2012-08-13|2012-09-12|Estimate||||2014-01-29|2014-03-03|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery|A Prospective, Multi-Center, Randomized, Single-Blind Study to Compare the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery|Completed||N/A|50|Actual|Medtronic - MITG||2|||f||||t||||||||||2018-05-31 22:45:18.126487|2018-05-31 22:45:18.126487
NCT01324336|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2013-05-31|2011-03-28|2011-03-29|Estimate|||||||2013-05-31|2013-06-03|Estimate|July 2011||2011-07-31|May 2013|2013-05-31||||December 2013|Anticipated|2013-12-31||Observational|||Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets|Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets|Unknown status|Recruiting||40|Anticipated|Children's Mercy Hospital Kansas City|||1||f||||f||||||Samples With DNA|"~     whole blood, plasma~   "|||2018-05-31 22:45:18.594909|2018-05-31 22:45:18.594909
NCT01324323|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|2013-03-26||2016-03-30|2011-03-28|2011-03-29|Estimate|2013-03-26|2013-05-13|Estimate||||2016-03-30|2016-05-04|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer|A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Rifampin on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer|Completed||Phase 1|14|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 22:45:18.711625|2018-05-31 22:45:18.711625
NCT01324310|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|2013-03-26||2016-03-30|2011-03-28|2011-03-29|Estimate|2013-05-13|2013-05-15|Estimate||||2016-03-30|2016-05-04|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer|A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Ketoconazole on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer|Completed||Phase 1|15|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 22:45:19.125684|2018-05-31 22:45:19.125684
NCT01324297|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2016-07-27|2011-03-28|2011-03-29|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||The Topical Niacin Skin Flush Test in First Episode Psychosis|The Topical Niacin Skin Flush Test: A Means for Longitudinal Monitoring of Two Different Biological Subgroups of Patients With First Episode Psychosis|Terminated|||107|Actual|Nova Scotia Health Authority|||2|"Unable to secure funding for second phase of study (i.e., niacin skin flush test in early~   psychosis patients)."|f||||f||||||||||2018-05-31 22:45:19.503564|2018-05-31 22:45:19.503564
NCT01324284|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-04-04|2011-03-28|2011-03-29|Estimate|||||||2013-04-04|2013-04-05|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Lubiprostone||Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation for Colonoscopy|Comparative Study of Lubiprostone and PEG Preparation Versus Conventional PEG Preparation to Enhance the Colonoscopy Preparation Quality in an Indian Tertiary Care Center.|Completed||Phase 3|442|Actual|Asian Institute of Gastroenterology, India||2|||f||||f||||||||||2018-05-31 22:45:19.562345|2018-05-31 22:45:19.562345
NCT01324271|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2014-06-01||2014-12-08|2011-03-28|2011-03-29|Estimate|2014-11-18|2014-11-25|Estimate||||2014-12-08|2014-12-31|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|inVENT-IO|Fifty-nine (59) subjects were treated with TTDS in the office under local anesthesia, and 26 were treated with TTDS in the OR under general anesthesia.|inVENT-In-Office Study|A Clinical Study Of The Acclarent Tympanostomy Tube (Tula™) Delivery System In-Office|Completed||N/A|85|Actual|Acclarent||1|||f||||f||||||||||2018-05-31 22:45:19.632055|2018-05-31 22:45:19.632055
NCT01324258|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-22|||2017-11-08|2011-03-24|2011-03-28|Estimate|||||||2017-11-08|2017-11-13|Actual|January 24, 2011|Actual|2011-01-24|November 2017|2017-11-30|July 8, 2013|Actual|2013-07-08|July 8, 2013|Actual|2013-07-08||Interventional|||Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors|A Phase I Trial of GSK1120212 and GSK1120212 in Combination With Gemcitabine in Japanese Subjects With Solid Tumors|Completed||Phase 1|19|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:45:19.812347|2018-05-31 22:45:19.812347
NCT01324245|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2011-03-25|2011-03-25|2011-03-28|Estimate|||||||2011-03-25|2011-03-28|Estimate|November 2002||2002-11-30|November 2003|2003-11-30|May 2006|Actual|2006-05-31|December 2005|Actual|2005-12-31||Interventional|Salt||Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet|Paracrine Regulation of Renal Function by Dopamine in Normotensive Humans|Completed||N/A|45|Actual|Georgetown University||1|||f||||t||||||||||2018-05-31 22:45:19.884147|2018-05-31 22:45:19.884147
NCT01324232|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23||2018-01-08|2018-01-10|2011-03-25|2011-03-28|Estimate||||2018-01-08|2018-01-11|Actual|2018-01-10|2018-01-16|Actual|September 2011||2011-09-30|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PRIME||Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis|A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis|Completed||Phase 2|200|Actual|Avanir Pharmaceuticals||4|||f||||f||||||||||2018-05-31 22:45:19.968637|2018-05-31 22:45:19.968637
NCT01324219|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2017-02-10|2011-03-25|2011-03-28|Estimate|||||||2017-02-10|2017-02-13|Actual|March 2011||2011-03-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2014|Actual|2014-06-30||Interventional|||Changing Talk to Reduce Resistiveness to Care|Changing Talk to Reduce Resistiveness to Care|Completed||N/A|202|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 22:45:20.101193|2018-05-31 22:45:20.101193
NCT01324206|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2018-04-03|2011-03-25|2011-03-28|Estimate|||||||2018-04-03|2018-04-04|Actual|August 5, 2008||2008-08-05|March 19, 2018|2018-03-19||||||||Observational|||Development of 3T Magnetic Resonance Research Methods for NIA Studies|Development of 3T Magnetic Resonance Research Methods for NIA Studies|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:45:20.243163|2018-05-31 22:45:20.243163
NCT01324193|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2013-12-13|2011-03-25|2011-03-28|Estimate|||||||2013-12-13|2013-12-16|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in CKD Patients|Effects of Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in Chronic Kidney Disease Patients|Completed||N/A|33|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||||2018-05-31 22:45:20.334574|2018-05-31 22:45:20.334574
NCT01324180|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2017-08-04|2011-03-25|2011-03-28|Estimate|||||||2017-08-04|2017-08-07|Actual|July 18, 2011|Actual|2011-07-18|August 2017|2017-08-31|July 27, 2017|Actual|2017-07-27|November 16, 2016|Actual|2016-11-16||Interventional|||Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)|A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination With Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin With Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD)|Completed||Phase 1|14|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t|t|f||||||||2018-05-31 22:45:20.404099|2018-05-31 22:45:20.404099
NCT01324167|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-03-25|2011-03-25|2011-03-28|Estimate|||||||2011-03-25|2011-03-28|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|April 2011|Anticipated|2011-04-30|||||Observational|||Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia|Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia|Unknown status|Recruiting||80|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:45:20.505293|2018-05-31 22:45:20.505293
NCT01324141|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2017-06-30|2011-03-25|2011-03-28|Estimate|||||||2017-06-30|2017-07-02|Actual|March 18, 2011||2011-03-18|April 15, 2015|2015-04-15|April 15, 2015|Actual|2015-04-15|April 15, 2015|Actual|2015-04-15||Interventional|||Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer|A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal|Terminated||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:45:20.573363|2018-05-31 22:45:20.573363
NCT01324128|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2013-12-20|2012-12-07|2014-04-03|2011-03-25|2011-03-28|Estimate|2014-03-03|2014-04-01|Estimate|2012-12-10|2012-12-12|Estimate|2014-04-03|2014-04-24|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional||For baseline characteristics, data from All Randomised patients was used.|A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients|An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia|Completed||Phase 3|1059|Actual|Vifor Inc.||3|||f||||t||||||||||2018-05-31 22:45:20.721275|2018-05-31 22:45:20.721275
NCT01324115|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2015-03-04|2011-03-25|2011-03-28|Estimate|||||||2015-03-04|2015-03-05|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of NG-Nitro-L-Arginine (L-NNA), a Nitric Oxide Synthase Inhibitor, Given as a Single Intravenous Infusion Over 10 Minutes in Patients With Advanced Solid Tumors|Terminated||Phase 1|6|Actual|Cancer Research UK||||Sponsor Decision|f||||||||||||||2018-05-31 22:45:22.006124|2018-05-31 22:45:22.006124
NCT01324102|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-12-02||2015-12-03|2011-03-25|2011-03-28|Estimate|2015-05-20|2015-05-22|Estimate||||2015-12-03|2016-01-01|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|April 2013|Actual|2013-04-30||Interventional|YogaCares||Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors|Yoga Cancer Rehabilitation Study|Completed||Phase 1/Phase 2|23|Actual|VA Office of Research and Development|The goals of this study were modest. A small pilot pre-post randomized trial was completed with a Yoga therapy intervention and a Wait list intervention. Additional studies in larger samples are needed.|2|||f||||f||||||||||2018-05-31 22:45:22.115627|2018-05-31 22:45:22.115627
NCT01324089|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2013-05-31|2011-03-25|2011-03-28|Estimate|||||||2013-05-31|2013-06-03|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol|A Randomized, Double-Blind Pilot Trial of Resveratrol With or Without Piperine to Enhance Plasma Levels of Resveratrol|Completed||N/A|24|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 22:45:22.421303|2018-05-31 22:45:22.421303
NCT01324076|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2011-05-12|2011-03-25|2011-03-28|Estimate|||||||2011-05-12|2011-05-13|Estimate|November 2010||2010-11-30|May 2011|2011-05-31||||November 2014|Anticipated|2014-11-30||Interventional|||Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer|Unknown status|Recruiting|Phase 3|412|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:45:22.52791|2018-05-31 22:45:22.52791
NCT01324063|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2012-07-13|2011-03-25|2011-03-28|Estimate|||||||2012-07-13|2012-07-16|Estimate|November 1986||1986-11-30|July 2012|2012-07-31||||June 1994|Actual|1994-06-30||Interventional|||A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)|A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)|Completed||Phase 3|160|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-05-31 22:45:22.649332|2018-05-31 22:45:22.649332
NCT01324050|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2011-08-01|2011-03-25|2011-03-28|Estimate|||||||2011-08-01|2011-08-02|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Internet-delivered Psychodynamic Therapy for Depression|Internet-delivered Psychodynamic Therapy for Depression: a Randomized Controlled Trial|Completed||N/A|92|Actual|Linkoeping University||2|||f||||t||||||||||2018-05-31 22:45:22.804427|2018-05-31 22:45:22.804427
NCT01324037|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2014-12-02|2011-03-25|2011-03-28|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|Armour||Diagnostic Algorithm in Suspected Upper Extremity Deep Vein Thrombosis|Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-dimer Test and Ultrasonography in Suspected Upper Extremity Deep Vein Thrombosis: a Prospective Management Study|Completed||N/A|406|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 22:45:22.88302|2018-05-31 22:45:22.88302
NCT01323036|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2012-11-21|2011-03-24|2011-03-25|Estimate|||||||2012-11-21|2012-11-22|Estimate|May 2011||2011-05-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional|Krill||Krill Oil Study Compared to Fish Oil|Assessment of Bioavailability of Krill Oil Compared to Fish Oil in Healthy Volunteers|Completed||N/A|24|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 22:45:38.335335|2018-05-31 22:45:38.335335
NCT01324024|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2016-05-11||2017-05-25|2011-03-25|2011-03-28|Estimate|2017-05-25|2017-06-28|Actual||||2017-05-25|2017-06-28|Actual|May 2011||2011-05-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Of the 55 subjects who were consented for screening, 20 were excluded and of the remaining 35 subjects, 32 completed both active and placebo treatment trials. There were 3 subjects who withdrew themselves from the study. These 3 subjects are not included in the overall number of baseline participants analyzed.|Attention & Memory Impairments in Menopausal Women|Attention & Memory Impairments in Menopausal Women: A Possible Role for Vyvanse?|Completed||Phase 4|35|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 22:45:23.013419|2018-05-31 22:45:23.013419
NCT01324011|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2013-07-15|2011-03-25|2011-03-28|Estimate|||||||2013-07-15|2013-07-17|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PALS||Family PALS (PArtners in Lifestyle Support)|Family Diabetes Study (Family PALS (PArtners in Lifestyle Support)|Completed||N/A|108|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:45:23.332695|2018-05-31 22:45:23.332695
NCT01323998|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2012-02-16||2017-06-06|2011-03-24|2011-03-28|Estimate|2012-02-16|2012-02-29|Estimate||||2017-06-06|2017-07-06|Actual|April 2010||2010-04-30|June 2017|2017-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan|Evaluating the Treatment Patterns in Men With Benign Prostatic Hypertrophy (Marketscan Database Study)|Completed|||35032|Actual|GlaxoSmithKline|||4||f||||f||||||||||2018-05-31 22:45:23.426333|2018-05-31 22:45:23.426333
NCT01323985|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2017-07-18|2011-03-24|2011-03-28|Estimate|||||||2017-07-18|2017-07-21|Actual|January 6, 2011|Actual|2011-01-06|July 2017|2017-07-31|June 30, 2011|Actual|2011-06-30|June 30, 2011|Actual|2011-06-30||Interventional|||SAP Depleter Dose Escalation Study in Healthy Volunteers|A Phase 1 Dose Escalation Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Intravenous Doses of GSK2315698A in Healthy Volunteers|Completed||Phase 1|21|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:45:23.717172|2018-05-31 22:45:23.717172
NCT01323972|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2017-04-25||2017-10-10|2011-03-24|2011-03-28|Estimate|2017-04-25|2017-08-07|Actual||||2017-10-10|2017-11-09|Actual|May 16, 2011|Actual|2011-05-16|October 2017|2017-10-31|May 4, 2012|Actual|2012-05-04|November 22, 2011|Actual|2011-11-22||Interventional|||Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children|Consistency of Immunogenicity and Non Inferiority of Three Production Lots of GSK Biologicals' Candidate Malaria Vaccine in Children|Completed||Phase 3|327|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:23.849053|2018-05-31 22:45:23.849053
NCT01323959|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2017-02-07|2012-07-26|2017-04-21|2011-03-24|2011-03-28|Estimate|2017-04-21|2017-08-03|Actual|2012-07-26|2012-08-03|Estimate|2017-04-21|2017-08-03|Actual|April 1, 2011||2011-04-01|April 2017|2017-04-30|March 1, 2012|Actual|2012-03-01|March 1, 2012|Actual|2012-03-01||Interventional|||Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults|Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination|Completed||Phase 4|212|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:24.738415|2018-05-31 22:45:24.738415
NCT01323946|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24||2012-11-16|2016-08-04|2011-03-24|2011-03-28|Estimate||||2012-11-16|2012-11-21|Estimate|2016-08-04|2016-08-05|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children|Safety and Immunogenicity of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine (GSK1562902A) in Children Aged 6 to 35 Months|Completed||Phase 2|113|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:25.418946|2018-05-31 22:45:25.418946
NCT01323933|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2012-05-02|2011-03-24|2011-03-28|Estimate|||||||2012-05-02|2012-05-03|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB0024 in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|32|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 22:45:25.51944|2018-05-31 22:45:25.51944
NCT01323920|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2014-02-14||2017-05-23|2011-03-24|2011-03-28|Estimate|2014-02-14|2014-03-31|Estimate||||2017-05-23|2017-05-30|Actual|May 2011||2011-05-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional||One participant signed consent and was enrolled onto study, however, was immediately taken off study because it became evident that the participant needed further therapy and was not ready to proceed to transplant.|Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors|Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study|Completed||Phase 2|35|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 22:45:25.573719|2018-05-31 22:45:25.573719
NCT01323907|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2017-07-18|2011-03-24|2011-03-28|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2011||2011-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Compassionate Use of Omegaven IV Fat Emulsion|Compassionate Use of Omegaven IV Fat Emulsion in Infants With Life Threatening Parenteral Nutrition-associated Liver Disease (PNALD).|Enrolling by invitation||N/A|10|Anticipated|Columbia University||1|||f||||t||||||||||2018-05-31 22:45:25.811712|2018-05-31 22:45:25.811712
NCT01323894|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2016-06-15|2011-03-25|2011-03-28|Estimate|||||||2016-06-15|2016-06-17|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|July 2013|Actual|2013-07-31|August 2012|Actual|2012-08-31||Observational|||﻿Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling|﻿Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons Between Non-viral and Viral Administration in Tissue Engineered Bone Regeneration|Completed|||3|Actual|China Medical University Hospital|||||f||||t||||||||||2018-05-31 22:45:25.883543|2018-05-31 22:45:25.883543
NCT01323881|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-05-23|2011-03-24|2011-03-28|Estimate|||||||2014-05-23|2014-05-26|Estimate|May 2009||2009-05-31|May 2009|2009-05-31||||December 2012|Actual|2012-12-31||Interventional|||Intermittent Theta Burst Stimulation After Acute Stroke|Theta Burst Stimulation on the Motor Cortex in Acute Stroke: a Randomized Controlled Trial|Completed||Phase 1/Phase 2|20|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 22:45:25.935449|2018-05-31 22:45:25.935449
NCT01323855|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2016-02-11||2016-02-11|2011-03-24|2011-03-28|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)|A Study to Assess Pharmacokinetics of Preladenant in Subjects With Chronic Renal Impairment|Completed||Phase 1|46|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 22:45:26.06146|2018-05-31 22:45:26.06146
NCT01323842|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-11-24|2011-03-24|2011-03-28|Estimate|||||||2015-11-24|2015-11-26|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Observational|||Emergency Department Ultrasound in Renal Colic|Hydro II: Emergency Department Ultrasound in Renal Colic|Completed|||414|Actual|Queen's University|||1||f||||f||||||||||2018-05-31 22:45:26.371794|2018-05-31 22:45:26.371794
NCT01323829|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-05-02|2011-03-24|2011-03-28|Estimate|||||||2014-05-02|2014-05-05|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|BTXA EMG||EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction|A Pilot Study: Botulinum Toxin Type A Injections Into Pelvic Muscles for Patients With Refractory High Tone Pelvic Floor Dysfunction|Completed||N/A|28|Actual|Pelvic and Sexual Health Institute|||||f||||f||||||||||2018-05-31 22:45:26.434661|2018-05-31 22:45:26.434661
NCT01323816|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-06-25|2011-03-24|2011-03-28|Estimate|||||||2014-06-25|2014-06-27|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Differences in Care Provided in Intensive Care Units (ICUs) With Physician Versus Nurse Practitioner First Responders|Process and Outcome Differences in Care Provided in Intensive Care Units (ICUs) With Physician Versus Nurse Practitioner First Responders|Completed|||3659|Actual|Ohio State University|||2||f||||f||||||||||2018-05-31 22:45:26.494191|2018-05-31 22:45:26.494191
NCT01323803|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2017-08-24|2011-03-24|2011-03-28|Estimate|||||||2017-08-24|2017-08-28|Actual|April 2011||2011-04-30|August 2017|2017-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|CoFAR5||Eosinophilic Esophagitis Databank|Eosinophilic Esophagitis (EoE) Databank (CoFAR 5)|Completed|||709|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     blood and saliva~   "|||2018-05-31 22:45:26.588615|2018-05-31 22:45:26.588615
NCT01323790|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2014-10-13||2015-06-01|2011-03-25|2011-03-28|Estimate|2015-06-01|2015-06-02|Estimate||||2015-06-01|2015-06-02|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||A total of 4 patients (2 patients in the NKTR-118 25 mg and 1 patient each in the NKTR-118 12.5 mg and placebo groups) had been previously randomized within the NKTR-118 program at a different study center. These patients were excluded from the ITT and Safety analysis sets. Baseline characteristics are summarized based on the ITT analysis set.|Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)|Completed||Phase 3|700|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:45:26.690781|2018-05-31 22:45:26.690781
NCT01323777|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2017-01-13||2017-03-06|2011-03-24|2011-03-28|Estimate|2017-01-13|2017-03-06|Actual||||2017-03-06|2017-04-04|Actual|May 2011||2011-05-31|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||This analysis population includes all implanted subjects.|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL) Clinical Study in Japan|Clinical Investigation of AcrySof® IQ ReSTOR® Multifocal Toric Intraocular Lens Models SND1T3/ SND1T4/ SND1T5/ SND1T6|Completed||N/A|65|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:45:27.555168|2018-05-31 22:45:27.555168
NCT01323764|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-10-19|2011-03-24|2011-03-28|Estimate|||||||2015-10-19|2015-10-20|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|SCNPH||ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH Patients|A Double- Blinded Comparison of the Accuracy of ShuntCheck, a Non-Invasive Device, to Radionuclide Shunt Patency Test in Evaluating Shunt Function in Patients With Adult Hydrocephalus With Possible Shunt Obstruction|Completed||Phase 4|20|Anticipated|NeuroDx Development||1|||f||||f||||||||||2018-05-31 22:45:27.841468|2018-05-31 22:45:27.841468
NCT01323751|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2017-04-05|2011-03-25|2011-03-28|Estimate|||||||2017-04-05|2017-04-06|Actual|July 2011||2011-07-31|April 2017|2017-04-30|December 3, 2016|Actual|2016-12-03|December 2016|Actual|2016-12-31||Interventional|ACY-1215||Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma|A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|120|Anticipated|Celgene||1|||f||||t||||||||Yes||2018-05-31 22:45:27.914309|2018-05-31 22:45:27.914309
NCT01323738|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2011-03-30|2011-03-25|2011-03-28|Estimate|||||||2011-03-30|2011-03-31|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Psychoeducation on Motivation to Change in Traumatized Alcoholics|Effect of Psychoeducation on Motivation to Change in Traumatized Alcoholics|Completed||N/A|50|Actual|University of Konstanz||2|||f||||f||||||||||2018-05-31 22:45:27.990946|2018-05-31 22:45:27.990946
NCT01323725|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2016-05-02|2011-03-25|2011-03-28|Estimate|||||||2016-05-02|2016-05-03|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|StPaulKorea||Team-based Financial Incentives for Smoking Cessation|The Effectiveness of Team-based Financial Incentives for Increasing Long-term Smoking Cessation|Completed||N/A|28|Actual|St.Paul's Hospital, Korea||1|||f||||f||||||||Yes||2018-05-31 22:45:28.065862|2018-05-31 22:45:28.065862
NCT01323712|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2013-12-06|2011-03-25|2011-03-28|Estimate|||||||2013-12-06|2013-12-09|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|5C||Vitamin D Supplementation and Cardiac Hypertrophy in Chronic Kidney Disease (CKD)|Impact of Vitamin D Supplementation on Cardiac Hypertrophy and Function in Chronic Kidney Disease Patients - a Randomised Controlled Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|50|Anticipated|St George's, University of London||1|||f||||t||||||||||2018-05-31 22:45:28.141387|2018-05-31 22:45:28.141387
NCT01323699|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2013-04-30|2011-03-25|2011-03-28|Estimate|||||||2013-04-30|2013-05-01|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|BehTA-D||Behavioral Treatments for Anxiety and Depression in Veterans With Parkinson's Disease|Increasing Access and Implementation of Behavioral Treatments for Anxiety and Depression in Rural Veterans With Parkinson's Disease|Completed||Phase 1/Phase 2|20|Actual|Michael Debakey Veterans Affairs Medical Center||1|||f||||f||||||||||2018-05-31 22:45:28.212178|2018-05-31 22:45:28.212178
NCT01323686|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-25|||2014-09-04|2011-03-25|2011-03-28|Estimate|||||||2014-09-04|2014-09-05|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|ImagingCRT||Empiric Versus Imaging Guided Left Ventricular Lead Placement in Cardiac Resynchronization Therapy|Empiric Versus Imaging Guided Left Ventricular Lead Placement in Cardiac Resynchronization Therapy|Completed||N/A|182|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 22:45:28.274332|2018-05-31 22:45:28.274332
NCT01323673|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2011-11-17||2016-11-29|2011-03-24|2011-03-25|Estimate|2011-11-17|2011-12-21|Estimate||||2016-11-29|2017-01-13|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.|Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.|Completed||Phase 4|125|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:28.417077|2018-05-31 22:45:28.417077
NCT01323660|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2013-12-19|2013-01-10|2018-01-18|2011-03-24|2011-03-25|Estimate|2014-03-13|2014-04-11|Estimate|2013-01-10|2013-01-18|Estimate|2018-01-18|2018-02-15|Actual|March 16, 2011||2011-03-16|January 2018|2018-01-31|July 16, 2012|Actual|2012-07-16|July 1, 2012|Actual|2012-07-01||Interventional|COPD||An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B|An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study B|Completed||Phase 3|307|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:28.943085|2018-05-31 22:45:28.943085
NCT01323647|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2016-10-13|2012-07-26|2016-10-13|2011-03-24|2011-03-25|Estimate|2016-10-13|2016-12-07|Estimate|2012-07-26|2012-08-03|Estimate|2016-10-13|2016-12-07|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers|Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (PoliorixTM) in Healthy Chinese Toddlers|Completed||Phase 3|957|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:45:29.782461|2018-05-31 22:45:29.782461
NCT01323634|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2013-05-30|2012-06-14|2017-10-09|2011-03-24|2011-03-25|Estimate|2013-05-30|2013-07-30|Estimate|2012-06-14|2012-06-18|Estimate|2017-10-09|2017-11-08|Actual|March 18, 2011|Actual|2011-03-18|October 2017|2017-10-31|December 14, 2011|Actual|2011-12-14|December 14, 2011|Actual|2011-12-14||Interventional|||Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease|A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|519|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:30.291322|2018-05-31 22:45:30.291322
NCT01323621|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2013-05-30|2012-12-13|2018-01-18|2011-03-24|2011-03-25|Estimate|2014-01-07|2014-02-06|Estimate|2012-12-13|2012-12-18|Estimate|2018-01-18|2018-02-15|Actual|March 18, 2011||2011-03-18|January 2018|2018-01-31|January 24, 2012|Actual|2012-01-24|January 1, 2012|Actual|2012-01-01||Interventional|||Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|512|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:45:30.662169|2018-05-31 22:45:30.662169
NCT01323608|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-04-18|2011-03-24|2011-03-25|Estimate|||||||2011-04-18|2011-04-19|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study|The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Weill Medical College of Cornell University||4|||f||||f||||||||||2018-05-31 22:45:32.045845|2018-05-31 22:45:32.045845
NCT01323595|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2013-10-29||2017-11-06|2011-03-24|2011-03-25|Estimate|2014-06-10|2014-07-11|Estimate||||2017-11-06|2017-12-08|Actual|January 2011||2011-01-31|November 2017|2017-11-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Celecoxib After Surgical Sperm Retrieval|The Use of Celecoxib (Celebrex (c)) in Post-operative Pain Control After Microdissection Testicular Sperm Extraction|Terminated||N/A|78|Actual|Weill Medical College of Cornell University||2||Interim analysis demonstrated significant benefit in intervention arm|f||||f||||||||||2018-05-31 22:45:32.154058|2018-05-31 22:45:32.154058
NCT01323582|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2014-05-09||2014-12-04|2011-03-24|2011-03-25|Estimate|2014-12-04|2014-12-05|Estimate||||2014-12-04|2014-12-05|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AZI|These are all subjects who were screened, randomized, and entered the protocol.|Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis|Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis|Terminated||Phase 2|26|Actual|University of Florida||2||Original investigator left this institution, replacement investigator retired.|f||||f||||||||||2018-05-31 22:45:32.405215|2018-05-31 22:45:32.405215
NCT01323569|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-06-13|2011-03-24|2011-03-25|Estimate|||||||2013-06-13|2013-06-14|Estimate|February 2008||2008-02-29|June 2013|2013-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Abuse Potential of Sativex|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Abuse Potential of Sativex in Subjects With a History of Recreational Marijuana Use|Completed||Phase 1|58|Actual|GW Pharmaceuticals Ltd.||6|||f||||f||||||||||2018-05-31 22:45:32.875156|2018-05-31 22:45:32.875156
NCT01323556|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-04-08|2011-03-24|2011-03-25|Estimate|||||||2011-04-08|2011-04-11|Estimate|March 2010||2010-03-31|March 2011|2011-03-31|May 2012|Anticipated|2012-05-31|October 2011|Anticipated|2011-10-31||Interventional|||Mechanisms of Panic Disorders Treatment|Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure|Unknown status|Recruiting|Phase 2/Phase 3|180|Anticipated|University Medicine Greifswald||2|||f||||t||||||||||2018-05-31 22:45:33.005801|2018-05-31 22:45:33.005801
NCT01323543|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-11-16|2011-03-24|2011-03-25|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Safety and Performance of the Elaspine System in the Treatment of the Lumbar Spine|"Elaspine™ Implant System Post Marketing Clinical Study: A Prospective, Multicentre Study to Evaluate the Safety and Performance of the Elaspine™ System in the Surgical Treatment of Degenerative Lumbar Spine"|Completed||N/A|40|Actual|Spinelab AG||1|||f||||f||||||||||2018-05-31 22:45:33.120978|2018-05-31 22:45:33.120978
NCT01323530|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2016-08-10|2011-03-24|2011-03-25|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31||Interventional|||A Phase 1b/2, Multicenter, Randomized, Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine|A Phase 1b/2, Multicenter,Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine|Completed||Phase 1/Phase 2|76|Actual|Eisai Inc.||2|||f||||t||||||||||2018-05-31 22:45:33.202721|2018-05-31 22:45:33.202721
NCT01323517|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2018-03-12||2018-04-12|2011-03-24|2011-03-25|Estimate|2018-04-12|2018-05-15|Actual||||2018-04-12|2018-05-15|Actual|February 2011|Actual|2011-02-28|December 2017|2017-12-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity|A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity|Completed||Phase 2|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:45:33.30085|2018-05-31 22:45:33.30085
NCT01323504|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|Musicthérapy||Pain and Music Therapy in Patients Suffering Arteritis|Pain and Music Therapy During the Wound Healing in Patient Suffering Arteritis of Stage 5 or 6.|Unknown status|Not yet recruiting|Phase 3|58|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 22:45:33.523912|2018-05-31 22:45:33.523912
NCT01323491|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-05-15|2011-03-24|2011-03-25|Estimate|||||||2013-05-15|2013-05-16|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||"EASY EFFECTIVE SMOKELESS With NICORETTE®"|"Nicht-interventionelle Studie (NIS) Zur Strukturierten Raucherentwöhnung Nach Dem Konzept EINFACH ERFOLGREICH RAUCHFREI unterstützt Durch NICROETTE®-Produkte"|Completed|||184|Actual|Johnson & Johnson GmbH|||1||f||||f||||||||||2018-05-31 22:45:33.5806|2018-05-31 22:45:33.5806
NCT01323478|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2013-10-31||2013-12-23|2011-03-24|2011-03-25|Estimate|2013-12-23|2014-02-11|Estimate||||2013-12-23|2014-02-11|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional||"Age and Gender: all-patients-treated set (APTS) – all patients who took at least one dose of Vortioxetine.~Study Specific Characteristics: full-analysis set (FAS) – all 71 patients in the APTS who had at least one valid post-Baseline assessment of the MADRS total score in present study, 13267B."|Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults|A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 (15 and 20 mg/Day) in Patients With Major Depressive Disorder|Completed||Phase 3|71|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 22:45:33.747035|2018-05-31 22:45:33.747035
NCT01323465|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-02-22|2011-03-24|2011-03-25|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2008||2008-02-29|February 2017|2017-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex|A Phase I, Open-label, Randomised, Crossover Study in 3 Parallel Groups to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex in Healthy Volunteers|Completed||Phase 1|36|Actual|GW Pharmaceuticals Ltd.||6|||f||||f||||||||||2018-05-31 22:45:33.986505|2018-05-31 22:45:33.986505
NCT01323452|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Observational|||Entecavir for Chronic Hepatitis B|The Antiviral Efficacy of Entecavir in Chronic Hepatitis B Within the European Network of Excellence (VIRGIL)|Completed|||418|Actual|Foundation for Liver Research|||1||f||||f||||||||||2018-05-31 22:45:34.096388|2018-05-31 22:45:34.096388
NCT01323439|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-08-28|2011-03-24|2011-03-25|Estimate|||||||2017-08-28|2017-08-30|Actual|April 2010||2010-04-30|August 2017|2017-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|AMERICA||Axium™ MicroFX™ for Endovascular Repair of IntraCranial Aneurysm-A Multicenter Study|Axium™ MicroFX™ for Endovascular Repair of IntraCranial Aneurysm-A Multicenter Study|Completed|||99|Actual|Medtronic Neurovascular Clinical Affairs|||1||f|||||f|t|f|f||||No||2018-05-31 22:45:34.163697|2018-05-31 22:45:34.163697
NCT01323426|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-01-23|2011-03-24|2011-03-25|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Treatment of Stress Urinary Incontinence by Injection of Autologous Muscle Fibers Into the Urethral Sphincter.|Autologous Muscle Fiber Transplantation for Repair of the Urethral Sphincter in Patients With Stress Urinary Incontinence|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|Copenhagen University Hospital at Herlev||1|||f||||f||||||||||2018-05-31 22:45:34.242268|2018-05-31 22:45:34.242268
NCT01323413|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-05-01|2011-03-24|2011-03-25|Estimate|||||||2014-05-01|2014-05-02|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Determinants of Penumbra in Acute Ischemic Stroke Patients|Determinants of Penumbra in Acute Ischemic Stroke Patients|Unknown status|Recruiting||250|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 22:45:34.340197|2018-05-31 22:45:34.340197
NCT01323400|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2016-02-24|2011-03-24|2011-03-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|April 2014|Actual|2014-04-30||Interventional|PAZOGIST||Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)|A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib|Completed||Phase 2|81|Actual|Centre Leon Berard||2|||f||||f||||||||No||2018-05-31 22:45:34.436378|2018-05-31 22:45:34.436378
NCT01323218|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Interventional|||Sleep Apnea Syndrome and Vitamin D|Effect of the Correction of Vitamin D Deficiency in Patients With Obstructive Sleep Apnea-hypopopnea Syndrome (OSAHS)|Unknown status|Recruiting|Phase 2|80|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:45:36.620108|2018-05-31 22:45:36.620108
NCT01323387|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2016-12-06||2017-12-15|2011-03-24|2011-03-25|Estimate|2017-04-14|2017-05-17|Actual||||2017-12-15|2018-01-16|Actual|April 1, 2004|Actual|2004-04-01|December 2017|2017-12-31|February 1, 2011|Actual|2011-02-01|May 1, 2009|Actual|2009-05-01||Interventional|ATB|"178 subjects were enrolled in the study but 16 of these were never treated. A total of 162 subjects were both enrolled and treated.~Of the 162 enrolled and treated subjects, 12 were excluded for protocol deviations. Therefore, the overall number of baseline participants was 150 subjects per protocol."|Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer|Lumbar Degenerative Disc Disease Treated With|Completed||N/A|178|Actual|Synthes USA HQ, Inc.||1|||f||||f||||||||||2018-05-31 22:45:34.634453|2018-05-31 22:45:34.634453
NCT01323374|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2012-07-18|2011-03-24|2011-03-25|Estimate|||||||2012-07-18|2012-07-19|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|FMS201||Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia|Completed||Phase 2|120|Actual|Chelsea Therapeutics||12|||f||||t||||||||||2018-05-31 22:45:34.867812|2018-05-31 22:45:34.867812
NCT01323361|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2013-01-25|2011-03-24|2011-03-25|Estimate|||||||2013-01-25|2013-01-28|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||CA125 Levels and Other Inflammatory Markers in Laparoscopic Ventral Hernia Repair|Multi-centre Observational Pilot-study for Evaluation of Variation in CA-125 and Other Inflammatory Markers in the Perioperative Period of Laparoscopic Ventral Hernia Repair|Completed||N/A|10|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 22:45:34.97166|2018-05-31 22:45:34.97166
NCT01323348|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2016-08-25|2011-03-24|2011-03-25|Estimate|||||||2016-08-25|2016-08-26|Estimate|October 2011||2011-10-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control|Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control|Completed||Phase 3|1875|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 22:45:35.054412|2018-05-31 22:45:35.054412
NCT01323335|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2018-04-04|2011-03-24|2011-03-25|Estimate|||||||2018-04-04|2018-04-05|Actual|March 31, 2009||2009-03-31|January 31, 2014|2014-01-31|January 31, 2014|Actual|2014-01-31|January 31, 2014|Actual|2014-01-31||Interventional|||The Relationship Between Uric Acid and Inflammatory Markers|The Relationship Between Uric Acid and Inflammatory Markers|Completed||Phase 1|97|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:45:35.207032|2018-05-31 22:45:35.207032
NCT01323322|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2018-04-04|2011-03-24|2011-03-25|Estimate|||||||2018-04-04|2018-04-05|Actual|June 22, 2009||2009-06-22|February 2, 2018|2018-02-02||||||||Observational|||Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)|Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS)|Active, not recruiting|||3720|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:45:35.263292|2018-05-31 22:45:35.263292
NCT01323309|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2018-02-23|2011-03-24|2011-03-25|Estimate|||||||2018-02-23|2018-02-26|Actual|March 2011||2011-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Trial of Individual Psychosocial Interventions for Cancer Patients|A Randomized Controlled Trial of Individual Psychosocial Interventions for Cancer Patients|Active, not recruiting|||346|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-05-31 22:45:35.41099|2018-05-31 22:45:35.41099
NCT01323296|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2014-12-03|2011-03-24|2011-03-25|Estimate|||||||2014-12-03|2014-12-04|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction|Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction|Completed||N/A|15|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 22:45:35.480578|2018-05-31 22:45:35.480578
NCT01323283|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-05-12|2011-03-24|2011-03-25|Estimate|||||||2011-05-12|2011-05-13|Estimate|September 2011||2011-09-30|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|STOPP-8 OM3||Study of Omega-3 Fatty Acids Regarding Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects in 8 Year Old Children|Intervention Study of the Ergogenic, Anti-inflammatory and Obesity Inhibitory Effects of Omega-3 Fatty Acids in 8 Year Old Children|Unknown status|Not yet recruiting|N/A|480|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:45:35.555005|2018-05-31 22:45:35.555005
NCT01323270|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2014-11-21||2015-04-27|2011-03-24|2011-03-25|Estimate|2014-11-21|2014-11-26|Estimate||||2015-04-27|2015-05-15|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.|A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Repevax(Registered) And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged >/= 11 To <19 Years|Completed||Phase 2|753|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:45:35.65984|2018-05-31 22:45:35.65984
NCT01323257|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-10-10|2011-03-24|2011-03-25|Estimate|||||||2012-10-10|2012-10-11|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|||||Interventional|||TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)|A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r)|Completed||Phase 1|49|Actual|Tibotec Pharmaceuticals, Ireland||6|||f||||f||||||||||2018-05-31 22:45:36.226009|2018-05-31 22:45:36.226009
NCT01323244|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2016-03-31|2011-03-24|2011-03-25|Estimate|||||||2016-03-31|2016-04-04|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study|A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study.|Completed||Phase 3|142|Actual|Janssen R&D Ireland||1|||f||||f||||||||||2018-05-31 22:45:36.369285|2018-05-31 22:45:36.369285
NCT01323231|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2013-07-08|2011-03-24|2011-03-25|Estimate|||||||2013-07-08|2013-07-10|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||XY-Zone Program Evaluation: A School-Based Dropout Prevention Program for At-Risk Youth|XY-Zone Phase 1 Program Evaluation: A School-Based Dropout Prevention Program for At-Risk Male Youth|Completed||Phase 1/Phase 2|91|Actual|University of Texas at Austin||1|||f||||f||||||||||2018-05-31 22:45:36.543355|2018-05-31 22:45:36.543355
NCT01323205|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24||2013-11-15|2014-05-22|2011-03-24|2011-03-25|Estimate||||2013-11-15|2013-12-10|Estimate|2014-05-22|2014-05-30|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia|First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia|Completed||Phase 2|100|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 22:45:36.710052|2018-05-31 22:45:36.710052
NCT01323192|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2013-06-27||2013-06-27|2011-03-24|2011-03-25|Estimate|2013-06-27|2013-09-06|Estimate||||2013-06-27|2013-09-06|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder|A Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 36 mg, 54 mg, or 72 mg Per Day|Completed||Phase 3|284|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 22:45:36.823588|2018-05-31 22:45:36.823588
NCT01323179|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2013-06-04|2011-03-24|2011-03-25|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Preopioid Versus Nonopioid in Total Knee Arthroplasty (TKA)|Acute Pain After Fast-track Total Knee Arthroplasty: Preoperative Opioid Versus Non-opioid|Completed|||140|Actual|Hvidovre University Hospital|||3||f||||f||||||||||2018-05-31 22:45:37.200248|2018-05-31 22:45:37.200248
NCT01323166|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-09-03|2011-03-24|2011-03-25|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|APR||Quality of Life After Abdominoperineal Resection for Rectal Cancer, Comparing Two Surgical Techniques|Retrospective Study of APR Results Regarding Patients' Self Reported Quality of Life|Completed|||75|Actual|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||||2018-05-31 22:45:37.332054|2018-05-31 22:45:37.332054
NCT01323153|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24||2016-07-06|2016-11-01|2011-03-24|2011-03-25|Estimate||||2016-07-06|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)|A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)|Completed||Phase 3|300|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:45:37.403941|2018-05-31 22:45:37.403941
NCT01323140|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2012-10-02||2012-11-30|2011-03-23|2011-03-25|Estimate|2012-11-30|2013-01-01|Estimate||||2012-11-30|2013-01-01|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems|An Open Label, Dose-Proportionality, Bioavailability and Dose- Titration Investigation of the Pharmacokinetics, Metabolism, Efficacy and Safety of Two Testosterone Matrix Transdermal Systems (28 cm2 and 48 cm2) in Hypogonadal Men|Completed||Phase 2|40|Actual|Watson Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:45:37.518142|2018-05-31 22:45:37.518142
NCT01323127|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-03-25|2011-03-24|2011-03-25|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Preliminary Study of the Sagittal Alignment of the Lumbo-pelvic Complex in a Sitting Position|Preliminary Study of the Sagittal Alignment of the Lumbo-pelvic Complex in a Sitting Position|Completed|||20|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 22:45:37.656782|2018-05-31 22:45:37.656782
NCT01323114|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-04-12|2011-03-24|2011-03-25|Estimate|||||||2011-04-12|2011-04-13|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study|The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study|Unknown status|Recruiting|N/A|66|Anticipated|McKenzie Health System||2|||f||||t||||||||||2018-05-31 22:45:37.723923|2018-05-31 22:45:37.723923
NCT01323101|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-03-28|2011-03-23|2011-03-25|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2008||2008-04-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Doxycycline Effects on Inflammation in Cystic Fibrosis|Effect of Doxycycline on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Patients With Cystic Fibrosis.|Completed||Phase 4|21|Actual|University of Southern California||2|||f||||t|f|f||||||||2018-05-31 22:45:37.801306|2018-05-31 22:45:37.801306
NCT01323088|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-04-12|2011-03-23|2011-03-25|Estimate|||||||2013-04-12|2013-04-15|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes|Physical Activity in Overweight Girls: Implications for Reversing Risk Factors for Type 2 Diabetes|Completed||N/A|44|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 22:45:37.905165|2018-05-31 22:45:37.905165
NCT01323075|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-03-25|2011-03-24|2011-03-25|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Observational|||Pharmacodynamic Comparison of Truncal Blocks in Patients With or Without Metabolic Disease (Kidney Failure, Diabetes)|Pharmacodynamic Comparison of Truncal Blocks in Patients With or Without Metabolic Disease (Kidney Failure, Diabetes)|Completed|||120|Actual|Centre Hospitalier Universitaire de Nīmes|||3||f||||f||||||||||2018-05-31 22:45:38.011855|2018-05-31 22:45:38.011855
NCT01323062|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2017-06-12|2011-03-23|2011-03-25|Estimate|||||||2017-06-12|2017-06-14|Actual|May 2011||2011-05-31|June 2017|2017-06-30|February 4, 2016|Actual|2016-02-04|May 14, 2014|Actual|2014-05-14||Interventional|||Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects|A Phase 1b Study of Bavituximab Plus Carboplatin and Pemetrexed in Chemotherapy-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 1|26|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:45:38.105793|2018-05-31 22:45:38.105793
NCT01323049|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-03-25|2011-03-24|2011-03-25|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Spontaneous Ventilation Time in Air Without Desaturation After Positive Pressure Extubation Versus Aspiration Extubation When Awakening From General Anesthesia|Comparison of Spontaneous Ventilation Time in Air Without Desaturation After Positive Pressure Extubation Versus Aspiration Extubation When Awakening From General Anesthesia|Completed||N/A|68|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 22:45:38.265677|2018-05-31 22:45:38.265677
NCT01323010|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|2015-09-14||2016-02-15|2011-03-24|2011-03-25|Estimate|2016-02-15|2016-03-14|Estimate||||2016-02-15|2016-03-14|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes|Efficacy and Safety of Increasing Doses of Inhaled Albuterol Administered by Metered Dose Inhalers in Children With Acute Wheezing Episodes|Completed||N/A|119|Actual|University of Sao Paulo|The inclusion of a larger number of patients in this study may have uncovered differences in the efficacy outcomes studied between the groups.|2|||f||||f||||||||||2018-05-31 22:45:38.470769|2018-05-31 22:45:38.470769
NCT01322997|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-23|2011-03-23|2011-03-25|Estimate|||||||2011-03-23|2011-03-25|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Robotic Brace Incorporating Electromyography (EMG) for Moderate Affected Arm Impairment After Stroke|Robotic Brace Incorporating EMG for Moderate Affected Arm Impairment After Stroke|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|University of Cincinnati||3|||f||||f||||||||||2018-05-31 22:45:39.106306|2018-05-31 22:45:39.106306
NCT01322984|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-10-24|2011-03-24|2011-03-25|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2011||2011-03-31|October 2012|2012-10-31||||January 2013|Anticipated|2013-01-31||Interventional|||Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder|Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Tromso||2|||f||||f||||||||||2018-05-31 22:45:39.205786|2018-05-31 22:45:39.205786
NCT01322971|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2016-10-26||2016-11-23|2011-03-24|2011-03-25|Estimate|2016-11-23|2017-01-20|Estimate||||2016-11-23|2017-01-20|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population|Pregnancy Outcomes Following Preconception Treatment of Asymptomatic Bacterial Vaginosis in an Infertility Population: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.|Terminated||N/A|2|Actual|Stanford University|151 screened 2 were randomized both refused to take medication not knowing if it were placebo or drug|2||Disease prevalence lower than expected in population.|f||||f||||||||||2018-05-31 22:45:39.280106|2018-05-31 22:45:39.280106
NCT01322958|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2014-01-14|2011-03-23|2011-03-25|Estimate|||||||2014-01-14|2014-01-16|Estimate|February 2007||2007-02-28|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|SAVE'EM||Sonographic Assessment and Visualization of Ectopics in Emergency Medicine|Sonographic Assessment and Visualization of Ectopics in Emergency Medicine (SAVE'EM)|Completed|||600|Actual|University of California, San Francisco|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 22:45:39.533909|2018-05-31 22:45:39.533909
NCT01322945|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2013-01-30||2013-12-09|2011-03-24|2011-03-25|Estimate|2013-12-09|2013-12-10|Estimate||||2013-12-09|2013-12-10|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|BNI||Barrow Nasal Inventory Survey|Observational Study of Nasal Outcomes Following Endonasal Surgery for Anterior Skull Base Lesions|Completed|||94|Actual|St. Joseph's Hospital and Medical Center, Phoenix|||1||f||||f||||||||||2018-05-31 22:45:39.596377|2018-05-31 22:45:39.596377
NCT01322932|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-12-21|2011-03-24|2011-03-25|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Observational|||Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey|HIV-positive Patients Under Tenofovir, Emtricitabine and Efavirenz Therapy Switching From a Two-pill Regimen to a Single Pill Regimen: Patients'Opinion Survey|Completed|||95|Actual|Policlinique Médicale Universitaire|||||f||||f||||||||||2018-05-31 22:45:39.875843|2018-05-31 22:45:39.875843
NCT01322919|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2015-05-19|2011-03-23|2011-03-25|Estimate|||||||2015-05-19|2015-05-20|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|Supracor||Safety and Efficacy Study to Evaluate the Treatment of Both Near and Distance Vision in a Simultaneous Laser Procedure|A Prospective Study to Evaluate the Safety and Effectiveness of the Presbyopic LASIK Algorithm|Completed||Phase 3|61|Actual|Technolas Perfect Vision GmbH||2|||f||||f||||||||||2018-05-31 22:45:39.931492|2018-05-31 22:45:39.931492
NCT01322906|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-04-08|2011-03-24|2011-03-25|Estimate|||||||2011-04-08|2011-04-11|Estimate|March 2011||2011-03-31|October 2010|2010-10-31|July 2012|Anticipated|2012-07-31|November 2011|Anticipated|2011-11-30||Interventional|||Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV)|Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by HBV|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 22:45:40.007934|2018-05-31 22:45:40.007934
NCT01322893|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2017-02-01|2011-03-24|2011-03-25|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 2011||2011-03-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|CTC-MBC||Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer|Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer|Completed|||150|Actual|Lund University Hospital|||1||f||||f||||||||||2018-05-31 22:45:40.078767|2018-05-31 22:45:40.078767
NCT01322880|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Domestic Violence Discussion Session|Microfinance-Discussion Session Intervention in Post-Conflict Central African States|Completed||N/A|598|Actual|London School of Economics and Political Science||2|||f||||f||||||||||2018-05-31 22:45:40.134717|2018-05-31 22:45:40.134717
NCT01322867|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-10-25|2011-03-23|2011-03-25|Estimate|||||||2011-10-25|2011-10-27|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets|A Phase IV, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine Relative Bioavailability of Alprazolam 0,75mg/ml (laboratórios Pfizer Ltda) in the Oral Solution-drops Form, Versus Frontal® 0,25mg (laboratórios Pfizer Ltda), in the Tablets Form, Under Fasted Conditions in Healthy Volunteers.|Completed||Phase 4|30|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:45:40.289778|2018-05-31 22:45:40.289778
NCT01322854|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-04-06|2011-03-24|2011-03-25|Estimate|||||||2011-04-06|2011-04-07|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|March 2018|Anticipated|2018-03-31|March 2013|Anticipated|2013-03-31||Interventional|IMRT-MC2||Adjuvant Whole Breast Radiotherapy (RT) With Intensity Modulated Radiotherapy (IMRT) and a Simultaneous Integrated Boost Versus Conventional RT and a Sequential Boost|Randomized Phase III Trial Comparing Intensity Modulated Radiotherapy With Integrated Boost to Conventional Radiotherapy With Consecutive Boost in Patients With Breast Cancer After Breast Conserving Surgery|Unknown status|Recruiting|Phase 3|502|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-05-31 22:45:40.393007|2018-05-31 22:45:40.393007
NCT01322841|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2015-11-17||2016-10-21|2011-03-24|2011-03-25|Estimate|2015-11-17|2015-12-18|Estimate||||2016-10-21|2016-12-02|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|September 2010|Actual|2010-09-30|July 2009|Actual|2009-07-31||Interventional|||Universal Screening for Tuberculosis and Anemia With the CHICA System|Universal Screening for Tuberculosis and Anemia With the CHICA System|Completed||N/A|2239|Actual|Indiana University||2|||f||||f||||||||Undecided||2018-05-31 22:45:40.515697|2018-05-31 22:45:40.515697
NCT01322828|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-04-08|2011-03-24|2011-03-25|Estimate|||||||2011-04-08|2011-04-11|Estimate|March 2004||2004-03-31|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|BRT||Trial Comparing Single Versus Double Incision to Repair Distal Bicep Tendon Ruptures|Randomized Control Trial Comparing Single Incision Versus Double Incision Surgery to Repair Distal Bicep Tendon Ruptures|Completed||N/A|92|Actual|Hand and Upper Limb Clinic, Canada||2|||f||||f||||||||||2018-05-31 22:45:40.917757|2018-05-31 22:45:40.917757
NCT01322815|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2016-04-29||2016-07-06|2011-03-23|2011-03-25|Estimate|2016-07-06|2016-08-15|Estimate||||2016-07-06|2016-08-15|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Interventional||Patients with RAS mutant positive metastatic colorectal cancer (CRC), either having received prior 1st-line therapy with an oxaliplatin or irinotecan plus fluoropyrimidine and bevacizumab containing regimen, or no prior therapy.|A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI|A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI in Patients With Ras Mutant Positive Metastatic Colorectal Cancer, Either Newly Diagnosed or Previously Treated.|Terminated||Phase 2|11|Actual|Georgetown University||2||Poor accrual rate|f||||t||||||||No||2018-05-31 22:45:41.015226|2018-05-31 22:45:41.015226
NCT01322802|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2018-04-02|2011-03-23|2011-03-25|Estimate|||||||2018-04-02|2018-04-03|Actual|March 6, 2012|Actual|2012-03-06|April 2018|2018-04-30||||January 9, 2015|Actual|2015-01-09||Interventional|||Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer|A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer|Active, not recruiting||Phase 1|22|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 22:45:41.322589|2018-05-31 22:45:41.322589
NCT01322789|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients|Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 22:45:41.426338|2018-05-31 22:45:41.426338
NCT01322776|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma|Phase 1 and 2 Study of Combination Treatment of Bortezomib, Fludarabine and Cyclophosphamide in Patients With Recurrent Mantle Cell Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 22:45:41.617159|2018-05-31 22:45:41.617159
NCT01322763|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|January 2012|Anticipated|2012-01-31|May 2011|Anticipated|2011-05-31||Observational|NANOS||Prevalence of Sleep Apnea/Hypopnea Syndrome in Obese Children|Prevalence of Sleep Apnea/Hypopnea Syndrome in Obese Children. The Significance of Hormonal Factors|Unknown status|Recruiting||200|Anticipated|Sociedad Española de Neumología y Cirugía Torácica|||||f||||||||||||||2018-05-31 22:45:41.739435|2018-05-31 22:45:41.739435
NCT01322750|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2011-03-24|2011-03-24|2011-03-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|January 2023|Anticipated|2023-01-31|January 2013|Anticipated|2013-01-31||Observational|||Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma|Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma|Recruiting|||3125|Anticipated|Walter Reed Army Medical Center|||2||f||||f||||||||||2018-05-31 22:45:41.906164|2018-05-31 22:45:41.906164
NCT01322737|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-12-12|2011-03-24|2011-03-25|Estimate|||||||2014-12-12|2014-12-16|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SUMO||Feasibility Trial to Evaluate the Ability of the SuMO Tissue Access and Resection System|Evaluation of a Novel Endoscopic Polypectomy Device in Excised Human Colon and Gastric Tissue.|Completed||N/A|9|Actual|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-05-31 22:45:42.011763|2018-05-31 22:45:42.011763
NCT01322724|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2012-05-24|2011-03-24|2011-03-25|Estimate|||||||2012-05-24|2012-05-25|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Comparing Warm Versus Cool Temperature Water During Colonoscopy|Comparing Warm Versus Cool Temperature Water During Colonoscopy|Completed||N/A|175|Actual|OHSU Knight Cancer Institute||2|||f||||f||||||||||2018-05-31 22:45:42.188781|2018-05-31 22:45:42.188781
NCT01322711|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-05-27|2011-03-24|2011-03-25|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes|Effects on Oxidative Stress, Coagulation, Platelet Activation and Inflammatory Indexes of Atorvastatin and/or Aspirin Treatment in Patients at High Risk of Vascular Events|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 22:45:42.259184|2018-05-31 22:45:42.259184
NCT01322698|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-24|||2015-03-26|2011-03-24|2011-03-25|Estimate|||||||2015-03-26|2015-03-27|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Staging Candidiasis in ICU Patients|Staging Candidiasis in ICU Patients|Completed|||422|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples With DNA|"~     Serum sample~   "|||2018-05-31 22:45:42.353621|2018-05-31 22:45:42.353621
NCT01322685|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|||||Observational|||Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens|Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens|Unknown status|Active, not recruiting||40|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:45:42.437665|2018-05-31 22:45:42.437665
NCT01322672|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-03-02|2011-03-23|2011-03-24|Estimate|||||||2017-03-02|2017-03-03|Actual|March 2011|Actual|2011-03-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|PAICOD||Peri-Anesthetic Imaging of Cognitive Dysfunction|Peri-Anesthetic Imaging Compared With Neurocognitive Testing: A Pilot Study|Active, not recruiting|||6|Actual|Vanderbilt University Medical Center|||||f||||f||||||||||2018-05-31 22:45:42.502378|2018-05-31 22:45:42.502378
NCT01322659|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-01-30|2011-03-23|2011-03-24|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 2010||2010-03-31|March 2011|2011-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Weaning Using Noninvasive Positive Pressure Ventilation by Means of Helmet in Patients With Acute Respiratory Failure|Weaning Using Noninvasive Positive Pressure Ventilation by Means of Helmet in Patients With Acute Respiratory Failure|Completed||N/A|250|Actual|University of Padova||2|||f||||t||||||||||2018-05-31 22:45:42.638076|2018-05-31 22:45:42.638076
NCT01322646|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2016-10-14|2011-03-23|2011-03-24|Estimate|||||||2016-10-14|2016-10-17|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|||A Randomized Trial of Interventions for Teenage Drivers With Attention Deficit Hyperactivity Disorder (ADHD)||Completed||N/A|172|Actual|State University of New York at Buffalo||2|||f||||f||||||||||2018-05-31 22:45:42.736757|2018-05-31 22:45:42.736757
NCT01322633|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2014-01-07||2014-01-07|2011-03-23|2011-03-24|Estimate|2014-01-07|2014-02-20|Estimate||||2014-01-07|2014-02-20|Estimate|July 2004||2004-07-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational||Analysis population included all participants who met the inclusion criteria.|Risk of Cancer Among Pantoprazole Users|Long-Term Prospective Observational Study of the Risk of Cancer Among Pantoprazole Users|Completed|||61864|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 22:45:42.917518|2018-05-31 22:45:42.917518
NCT01322620|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-02-20|2011-03-23|2011-03-24|Estimate|||||||2017-02-20|2017-02-23|Actual|June 3, 2011|Actual|2011-06-03|February 2017|2017-02-28|February 29, 2012|Actual|2012-02-29|February 29, 2012|Actual|2012-02-29||Observational|HERO||Survey Evaluating the Psychosocial Effects of Living With Haemophilia|Haemophilia, Experiences, Results and Opportunities (HERO): A Community-based Evaluation of the Psychosocial Effects of Haemophilia on Patients and Their Carers|Completed|||1236|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:45:43.222587|2018-05-31 22:45:43.222587
NCT01322607|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|2015-11-23||2016-03-07|2011-03-22|2011-03-24|Estimate|2016-03-07|2016-04-06|Estimate||||2016-03-07|2016-04-06|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|TOTS||Task-oriented Training for Stroke: Impact on Function Mobility|Task-oriented Training for Stroke: Impact on Function Mobility|Completed||N/A|20|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 22:45:43.350222|2018-05-31 22:45:43.350222
NCT01322594|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|2013-07-19||2013-10-09|2011-03-23|2011-03-24|Estimate|2013-10-09|2013-10-23|Estimate||||2013-10-09|2013-10-23|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease|A Phase 1, Single Ascending Dose Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 1|31|Actual|MedImmune LLC||6|||f||||f||||||||||2018-05-31 22:45:43.866146|2018-05-31 22:45:43.866146
NCT01322581|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2018-05-11|2011-03-23|2011-03-24|Estimate|||||||2018-05-11|2018-05-14|Actual|March 23, 2011||2011-03-23|April 26, 2018|2018-04-26||||||||Observational|||A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali|A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali|Recruiting|||1400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:45:45.45031|2018-05-31 22:45:45.45031
NCT01322568|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2018-05-09|2011-03-23|2011-03-24|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 31, 2003||2003-01-31|February 11, 2014|2014-02-11|February 11, 2014||2014-02-11|||||Observational|||Research on Aging Project in Iceland: Second Stage|Age, Gene/Environment Susceptibility (AGES) Study|Completed|||5764|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:45:45.520158|2018-05-31 22:45:45.520158
NCT01322555|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-07-15|2011-03-23|2011-03-24|Estimate|||||||2017-07-15|2017-07-18|Actual|March 4, 2011||2011-03-04|July 14, 2017|2017-07-14|July 14, 2017||2017-07-14|||||Observational|||A Study of the Association Between Autism and Immune Changes in the Brain|Neuroimmune Activation in Austism: Imaging Translocator Protein Using Positron Emission Tomography (PET)|Terminated|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:45:45.629985|2018-05-31 22:45:45.629985
NCT01322529|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2016-01-11|2011-03-23|2011-03-24|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|nuMoM2b||Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be|Preterm Birth in Nulliparous Women: An Understudied Population at Great Risk|Completed|||10038|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||Samples With DNA|"~     Blood serum, blood plasma, maternal deoxyribonucleic acid (DNA), urine supernatant, urine~     cell pellet, cervico-vaginal fluid, bacterial vaginosis (BV) slide, cord blood (fetal DNA),~     cord blood serum, placenta, fetal membranes, umbilical cord segment, placenta and umbilical~     cord, chorionic villi and maternal decidua from clinical chorionic villus sampling (CVS),~     amniotic fluid supernatant and cell pellet from clinical amniocentesis.~   "|Undecided|Date will be made available to authorized researchers in the future through a yet to be determined government repository.|2018-05-31 22:45:45.720576|2018-05-31 22:45:45.720576
NCT01322516|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-06-14|2011-03-23|2011-03-24|Estimate|||||||2011-06-14|2011-06-15|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|September 2012|Anticipated|2012-09-30|||||Observational|||Outcomes of Pandemic Influenza in Pregnancy|Outcomes of Pandemic Influenza in Pregnancy: an Observational Cohort Study|Unknown status|Active, not recruiting||200|Actual|Dalhousie University|||||f||||f||||||Samples Without DNA|"~     Nasopharyngeal swabs and serum~   "|||2018-05-31 22:45:45.881051|2018-05-31 22:45:45.881051
NCT01322503|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-02-09|2011-03-23|2011-03-24|Estimate|||||||2012-02-09|2012-02-10|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Susceptibility of Human Volunteers With Different Histo-Blood With Different Histo-Blood Group Antigens to Norovirus|Evaluation of the Susceptibility of Human Volunteers With Different Histo-Blood Group Antigens to Norovirus|Completed||Phase 1|40|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 22:45:46.129827|2018-05-31 22:45:46.129827
NCT01322490|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2018-01-08|2011-03-23|2011-03-24|Estimate|||||||2018-01-08|2018-01-09|Actual|November 28, 2011|Actual|2011-11-28|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|September 25, 2017|Actual|2017-09-25||Interventional|Prospect||A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer|A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer|Completed||Phase 3|1298|Actual|Bavarian Nordic, Inc.||3|||f||||t||||||||||2018-05-31 22:45:46.251454|2018-05-31 22:45:46.251454
NCT01322477|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate||||January 2011|2011-01-31||||||||Observational|HCC||Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency||Unknown status|Not yet recruiting||25||Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 22:45:46.653635|2018-05-31 22:45:46.653635
NCT01322464|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-06-13|2011-03-23|2011-03-24|Estimate|||||||2013-06-13|2013-06-14|Estimate|January 2008||2008-01-31|June 2013|2013-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study to Assess Food Effect on Sativex Bioavailability|A Phase I Study to Assess the Effect of Food on the Single-Dose Bioavailability of Sativex, and to Compare the Single and Multiple Dose Pharmacokinetics of Sativex at Three Dose Levels|Completed||Phase 1|25|Actual|GW Pharmaceuticals Ltd.||4|||f||||f||||||||||2018-05-31 22:45:46.721496|2018-05-31 22:45:46.721496
NCT01322451|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Oral Bioavailability of Two Solid Formulations of GLPG0259.|A Randomized, Open Label, 2-way Crossover Study to Compare the Oral Bioavailability of 2 Solid Dose Formulations of GLPG0259 After Single-dose Intake in Healthy Subjects|Completed||Phase 1|12|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 22:45:46.888134|2018-05-31 22:45:46.888134
NCT01322438|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2014-12-18|2011-03-23|2011-03-24|Estimate|||||||2014-12-18|2014-12-19|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effect of Rifampin on the Pharmacokinetics of BAY73-4506|A Phase 1, Non-Randomized, Open Label Study to Determine the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers|Completed||Phase 1|24|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:45:46.990401|2018-05-31 22:45:46.990401
NCT01322425|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2014-08-19|2011-03-22|2011-03-24|Estimate|||||||2014-08-19|2014-08-20|Estimate|July 2010||2010-07-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Effect of Temperature on Pain and Brown Adipose Activity in Fibromyalgia|Urocortins and Musculoskeletal Hyperalgesia|Completed|||24|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 22:45:47.063403|2018-05-31 22:45:47.063403
NCT01322412|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2014-01-10|2011-03-23|2011-03-24|Estimate|||||||2014-01-10|2014-01-13|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Observational|SAPA||Adapted Physical Activity Effect and Fatigue in Patients With Breast Cancer|Adapted Physical Activity Effect on Aerobic Function and Fatigue in Patients With Breast Cancer Treated in Adjuvant Phase|Completed|||44|Actual|University Hospital, Limoges|||2||f||||f||||||||||2018-05-31 22:45:47.137926|2018-05-31 22:45:47.137926
NCT01322399|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-12-09|2011-03-23|2011-03-24|Estimate|||||||2013-12-09|2013-12-10|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Structural Integration for Chronic Low Back Pain|Structural Integration for Chronic Low Back Pain|Completed||N/A|46|Actual|Spaulding Rehabilitation Hospital||2|||f||||t||||||||||2018-05-31 22:45:47.214041|2018-05-31 22:45:47.214041
NCT01322386|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2015-05-22||2016-04-18|2011-03-23|2011-03-24|Estimate|2016-02-05|2016-03-04|Estimate||||2016-04-18|2016-05-18|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|January 2012|Actual|2012-01-31|October 2010|Actual|2010-10-31||Interventional|PSC|Based on the annual progress report sent dated 10/04/2010, all patients completed the study as planned except 2 children with PSC- 1 was non-compliant and the other had severe UC requiring Remicade which resulted in removal from Vancomycin study.|Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin|The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin.|Completed||Phase 1|32|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 22:45:47.325322|2018-05-31 22:45:47.325322
NCT01322373|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test|Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test: A Follow-up Study|Unknown status|Enrolling by invitation||120|Anticipated|Orasi Medical, Inc.|||2||f||||f||||||||||2018-05-31 22:45:47.60365|2018-05-31 22:45:47.60365
NCT01322360|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2013-07-16||2018-01-19|2011-03-22|2011-03-24|Estimate|2014-04-28|2014-05-23|Estimate||||2018-01-19|2018-02-05|Actual|April 2011||2011-04-30|January 2018|2018-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Pharmacokinetic Study of Oral Morphine Sulfate in Pediatric Subjects|A Multicenter, Open Label, Safety and Pharmacokinetic Study of Oral Morphine Sulfate Administration in Pediatric Subjects 2 Years Old Through 17 Years Old With Postoperative Pain|Completed||Phase 4|50|Actual|West-Ward Pharmaceutical||1|||f||||f||||||||||2018-05-31 22:45:47.684966|2018-05-31 22:45:47.684966
NCT01322347|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|2015-03-20||2017-04-24|2011-03-22|2011-03-24|Estimate|2015-04-22|2015-04-24|Estimate||||2017-04-24|2017-04-26|Actual|April 2011||2011-04-30|April 2017|2017-04-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional||intent-to-treat: all randomized subjects, regardless of whether they received any study drug.|Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)|A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 2) Study|Completed||Phase 3|294|Actual|Rockwell Medical Technologies, Inc.||2|||f||||t||||||||||2018-05-31 22:45:47.959244|2018-05-31 22:45:47.959244
NCT01322334|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|November 2005||2005-11-30|March 2011|2011-03-31|November 2007|Actual|2007-11-30|||||Interventional|||Singing Exercises to Improve Symptoms of Snoring and Sleep Apnea|A Single Blinded Prospective Randomized Controlled Trial to Investigate Whether Singing Exercises Can Improve Symptoms of Snoring and Sleep Apnea|Completed||N/A|127|Actual|Royal Devon and Exeter NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 22:45:49.570836|2018-05-31 22:45:49.570836
NCT01322321|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-09-04|2011-03-23|2011-03-24|Estimate|||||||2012-09-04|2012-09-05|Estimate|March 2011||2011-03-31|September 2012|2012-09-30||||June 2011|Anticipated|2011-06-30||Interventional|||ACZ885 in Type 1 Diabetes Mellitus|A Randomized, Double-blind, Multiple-dose, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ACZ885 in Patients With Newly Diagnosed Type-1 Diabetes Mellitus (T1DM)|Withdrawn||Phase 2|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:45:49.664173|2018-05-31 22:45:49.664173
NCT01322308|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2014-09-30|2011-03-23|2011-03-24|Estimate|||||||2014-09-30|2014-10-01|Estimate|March 2007||2007-03-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus|Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 4|30|Actual|National Heart Institute, Mexico||2|||f||||f||||||||||2018-05-31 22:45:49.751342|2018-05-31 22:45:49.751342
NCT01322295|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-09-19|2011-03-23|2011-03-24|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Human Bronchial Microdialysis in Open Aortic Aneurysm Repair|Human Bronchial Microdialysis in Open Aortic Aneurysm Repair|Completed|||16|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-05-31 22:45:49.811538|2018-05-31 22:45:49.811538
NCT01322282|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2012-07-06|2011-03-23|2011-03-24|Estimate|||||||2012-07-06|2012-07-10|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy|A Randomized, Open-Label, Single-Dose, Three-Period Crossover Bioequivalence Study to Compare an Orodispersible Tablet (ODT) Formulation of Cetirizine HCl 10 mg Taken With and Without Water Compared With a Standard Marketed 10 mg Tablet Taken With Water|Completed||Phase 1|36|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 22:45:49.866978|2018-05-31 22:45:49.866978
NCT01322269|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22||2013-06-11|2013-06-11|2011-03-23|2011-03-24|Estimate||||2013-06-11|2013-06-19|Estimate|2013-06-11|2013-06-19|Estimate|April 2011||2011-04-30|June 2013|2013-06-30||||March 2012|Actual|2012-03-31||Interventional|||A Study of HQK-1001 in Patients With Sickle Cell Disease|A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease|Completed||Phase 2|52|Actual|HemaQuest Pharmaceuticals Inc.||3|||f||||t||||||||||2018-05-31 22:45:49.949183|2018-05-31 22:45:49.949183
NCT01322256|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2015-03-24|2011-03-23|2011-03-24|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ISEOD||PET/CT Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot|Positron Emission Tomography - Computed Tomography (PET/CT) Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot|Terminated||N/A|12|Actual|Centre Hospitalier Universitaire de Nīmes||1||The study has proven to be infeasible.|f||||f||||||||||2018-05-31 22:45:50.151191|2018-05-31 22:45:50.151191
NCT01322243|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-05-16|2011-03-23|2011-03-24|Estimate|||||||2013-05-16|2013-05-20|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of Metabolic State on Anxiety in Human Subjects|Effect of Metabolic State on Anxiety in Human Subjects|Terminated||N/A|10|Actual|Rockefeller University||2||Due to mechanical issue with device|f||||f||||||||||2018-05-31 22:45:50.223832|2018-05-31 22:45:50.223832
NCT01322230|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-11-10|2011-03-22|2011-03-24|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|WISE||Trial of Educational Outcomes of WISE-MD|Randomized Trial of Educational Outcomes of WISE-MD|Completed||N/A|1363|Actual|New York University School of Medicine||4|||f||||t||||||||||2018-05-31 22:45:50.294718|2018-05-31 22:45:50.294718
NCT01322217|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-02-27|2011-03-23|2011-03-24|Estimate|||||||2017-02-27|2017-02-28|Actual|April 2011||2011-04-30|March 2016|2016-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Managerial Database II|Network-Wide Assessment of Current Health Status and Behavioral Risk Factors: An Expanded Study for New Sites in ATN III|Completed|||513|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 22:45:50.386449|2018-05-31 22:45:50.386449
NCT01322204|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-02-07|2011-03-22|2011-03-24|Estimate|||||||2012-02-07|2012-02-08|Estimate|August 2008||2008-08-31|February 2012|2012-02-29||||July 2012|Anticipated|2012-07-31||Interventional|||Codeine in Mechanically Ventilated Neonates|Absorption and Metabolism of Oral Codeine in Mechanically Ventilated Neonates|Unknown status|Recruiting|Phase 1|64|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||t||||||||||2018-05-31 22:45:50.465711|2018-05-31 22:45:50.465711
NCT01322191|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-10-26|2011-03-23|2011-03-24|Estimate|||||||2012-10-26|2012-10-29|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Morphine PK Subgroup Analysis|A Randomized Controlled Comparison of Ketorolac Tromethamine and Morphine for Postoperative Analgesia in Critically-ill, 3-18 Year-old Children: A Subgroup Analysis of Developmental Changes in Morphine Kinetics and Efficacy|Completed||Phase 4|48|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||f||||||||||2018-05-31 22:45:50.536855|2018-05-31 22:45:50.536855
NCT01322178|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-08-11|2011-03-23|2011-03-24|Estimate|||||||2011-08-11|2011-08-12|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|June 2012|Anticipated|2012-06-30||Interventional|CLIME||Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients|Open-label, Uncontrolled, Multi-center, Phase II Study of Cetuximab in Combination With mFOLFOX-6 as First-line Treatment in Patients With KRAS Wild-type, Unresectable LIver Metastases of colorEctal Cancer|Unknown status|Recruiting|Phase 2|90|Anticipated|Fudan University|||||f||||t||||||||||2018-05-31 22:45:50.60147|2018-05-31 22:45:50.60147
NCT01322165|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2016-12-19|2011-03-22|2011-03-24|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Observational|GenTAC||National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions|National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions|Completed|||3706|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t||||||Samples With DNA|"~     If a blood specimen is obtained, it is separated and stored as plasma, viable cells, and~     extracted DNA. If a saliva specimen is obtained, it is stored for DNA.~   "|||2018-05-31 22:45:50.669232|2018-05-31 22:45:50.669232
NCT01322152|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-06-10|2011-03-23|2011-03-24|Estimate|||||||2013-06-10|2013-06-11|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal Cancer|Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients|Completed||Phase 2|52|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 22:45:50.743858|2018-05-31 22:45:50.743858
NCT01322139|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-06-13|2011-03-23|2011-03-24|Estimate|||||||2013-06-13|2013-06-14|Estimate|December 2007||2007-12-31|June 2013|2013-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Sativex Thorough QT/QTc Study|A Multiple-Dose, Randomized, Double-Blind, Placebo- and Active-Controlled, Four-Arm, Parallel Group Thorough QT/QTc Study to Evaluate the Electrophysiologic Effects of Sativex.|Completed||Phase 1|258|Actual|GW Pharmaceuticals Ltd.||4|||f||||f||||||||||2018-05-31 22:45:50.817025|2018-05-31 22:45:50.817025
NCT01322126|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-04-07|2011-03-23|2011-03-24|Estimate|||||||2011-04-07|2011-04-11|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Comparison of Safety And Efficacy of Neuraxial Anesthesia, Palpation Versus Ultrasound|Comparison of Safety And Efficacy of Neyraxial Anesthesia,Palpation Versus Ultrasound|Unknown status|Not yet recruiting|N/A|120|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-05-31 22:45:51.022918|2018-05-31 22:45:51.022918
NCT01322113|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-09-25|2011-03-23|2011-03-24|Estimate|||||||2013-09-25|2013-09-26|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|NA\K-MANIA||Involvement of the Sodium Pump and Endogenous Digitalis-like Compounds in Bipolar Disorder|Involvement of the Sodium Pump and Endogenous Digitalis-like Compounds in Bipolar Disorder|Completed|||30|Actual|Hadassah Medical Organization|||1||f||||f||||||Samples Without DNA|"~     30 cc of pperipheral blood will be taken every 4 months to determine circulating DLC levels~     in patients~   "|||2018-05-31 22:45:51.099487|2018-05-31 22:45:51.099487
NCT01322100|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-07-30|2011-03-23|2011-03-24|Estimate|||||||2013-07-30|2013-07-31|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Electrochemotherapy as a Palliative Treatment for Brain Metastases|Electrochemotherapy as a Palliative Treatment for Brain Metastases|Terminated||Phase 1|1|Actual|Copenhagen University Hospital at Herlev||||Due to slow patient recruitment|f||||t||||||||||2018-05-31 22:45:51.159905|2018-05-31 22:45:51.159905
NCT01322087|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|SGG||Does the Access to Small Delicious Dishes, Have a Positive Effect on Nutritional Intake in Patients at Nutritional Risk?|Does the Access to Small Delicious Dishes, 24 Hours a Day, Have a Positive Effect on Nutritional Intake in Patients at Nutritional Risk?|Completed||N/A|40|Actual|Copenhagen University Hospital at Herlev||1|||f||||t||||||||||2018-05-31 22:45:51.224102|2018-05-31 22:45:51.224102
NCT01322074|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-10-14|2011-03-23|2011-03-24|Estimate|||||||2011-10-14|2011-10-17|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Systemic Inflammation Versus Acute Pain in Total Knee Arthroplasty (TKA)|The Relation Between Systemic Inflammatory Markers and Acute Pain in TKA|Completed|||120|Actual|Hvidovre University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood samples for C reactive protein and interleukin 6 analysis.~   "|||2018-05-31 22:45:51.277509|2018-05-31 22:45:51.277509
NCT01322061|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2012-01-06|2011-03-23|2011-03-24|Estimate|||||||2012-01-06|2012-01-09|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Vitamin C Efficacy in Reducing Post Operative Pain|The Role of a Single Oral Dose (2g) of Vitamin C in Reducing Intensity of Pain and Opioids Consumption in Patients Undergoing Laparoscopic Cholecystectomy. A Randomized, Double-blinded, Placebo-controlled Study|Completed||Phase 4|80|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 22:45:51.329467|2018-05-31 22:45:51.329467
NCT01322048|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2017-04-18||2017-07-14|2011-03-22|2011-03-24|Estimate|2017-06-07|2017-06-08|Actual||||2017-07-14|2017-08-17|Actual|August 2011||2011-08-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|January 2015|Actual|2015-01-31||Interventional|||DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury|DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Severe Traumatic Brain Injury, A Pilot Randomized Clinical Trial Using Propranolol and Clonidine|Completed||Phase 2|48|Actual|Vanderbilt University Medical Center||2|||f||||t|t|f||||||||2018-05-31 22:45:51.404594|2018-05-31 22:45:51.404594
NCT01322035|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2016-02-01|2011-03-23|2011-03-24|Estimate|||||||2016-02-01|2016-02-03|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Erythrocyte and Adipocyte G6PD Activity Levels in Obesity|Erythrocyte and Adipocyte G6PD Activity Levels Correlate With Differing Degrees of Dyslipidemia, Insulin Resistance and Obesity|Completed|||16|Actual|University of South Alabama|||||f||||f||||||Samples With DNA|"~     Blood and tissue samples(adipose, omentum and liver biopsies)~   "|||2018-05-31 22:45:51.749349|2018-05-31 22:45:51.749349
NCT01322022|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|2014-12-04||2015-08-11|2011-03-23|2011-03-24|Estimate|2015-01-26|2015-02-02|Estimate||||2015-08-11|2015-08-25|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Treatment of Sleep Disturbances in Young Children With Autism|Treatment of Sleep Disturbances in Young Children With Autism|Completed||N/A|40|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:45:51.827636|2018-05-31 22:45:51.827636
NCT01322009|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|2016-05-19||2016-07-01|2011-03-23|2011-03-24|Estimate|2016-07-01|2016-08-15|Estimate||||2016-07-01|2016-08-15|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|December 2013|Actual|2013-12-31||Interventional|Pro-NAC||Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury|Overcoming Membrane Transporters to Improve CNS Drug Delivery|Completed||Phase 1/Phase 2|14|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:45:52.104719|2018-05-31 22:45:52.104719
NCT01321996|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2015-01-26|2011-03-23|2011-03-24|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis|Employment of 68Ga-DOTA-NOC in Patients With Idiopathic Pulmonary Fibrosis|Terminated||Phase 4|29|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1||enrollment failure (only 29 patients were enrolled during the study period)|f||||t||||||||||2018-05-31 22:45:52.354955|2018-05-31 22:45:52.354955
NCT01321983|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate||||March 2011|2011-03-31||||||||Interventional|||Effects of Preoperative Inspiratory Muscle Training (IMT) in Obese Women Undergoing Open Bariatric Surgery|Effects of Preoperative Inspiratory Muscle Training (IMT) in Obese Women Undergoing Open Bariatric Surgery: Respiratory Muscle Strength, Lung Volumes and Diaphragmatic Excursion|Completed||N/A|||Universidade Federal de Sao Carlos|||||f||||f||||||||||2018-05-31 22:45:52.427971|2018-05-31 22:45:52.427971
NCT01321970|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-06-16|2011-03-23|2011-03-24|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2013|Actual|2013-06-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Validation/Evaluation of Multimodal Imaging Combining 3D Ultrasound and Stress Myocardial Scintigraphy in the Diagnosis of Coronary Artery Disease|Validation and Evaluation of Multimodal Imaging Combining Three-dimensional Ultrasound and Stress Myocardial Scintigraphy in the Diagnosis of Coronary Artery Disease|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nīmes||2||Impossible to start to the study.|f||||f||||||||||2018-05-31 22:45:52.481593|2018-05-31 22:45:52.481593
NCT01321957|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2016-10-25|2011-03-23|2011-03-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|September 2016|Actual|2016-09-30||Interventional|CHARTA||Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer|FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study|Active, not recruiting||Phase 2|250|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 22:45:52.560516|2018-05-31 22:45:52.560516
NCT01321944|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-03-22|2011-03-22|2011-03-24|Estimate|||||||2011-03-22|2011-03-24|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|DTS||Direct to Smoker Outreach in a Health Care Setting|A POPULATION-BASED DIRECT-TO-SMOKER OUTREACH OFFERING TOBACCO TREATMENT IN A HEALTH CARE SETTING: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|590|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:45:52.679745|2018-05-31 22:45:52.679745
NCT01321931|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-07-06|2011-03-23|2011-03-24|Estimate|||||||2012-07-06|2012-07-10|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products|Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.|Completed||Phase 1|50|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||5|||f||||f||||||||||2018-05-31 22:45:52.74397|2018-05-31 22:45:52.74397
NCT01321918|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Register and DNA Bank of Adult Extra-hospital Sudden Death (Protocol FASTER)|Register and DNA Bank of Adult Extra-hospital Sudden Death|Terminated||N/A|2000|Anticipated|Nantes University Hospital||2||Recruitment difficulties|f||||f||||||||||2018-05-31 22:45:52.816005|2018-05-31 22:45:52.816005
NCT01321905|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|April 2010||2010-04-30|March 2011|2011-03-31||||September 2011|Anticipated|2011-09-30||Interventional|D-vitamin||Prospective Intervention Study on Vitamin D in Patients With Cystic Fibrosis|5-month Pilot Intervention Study on Vitamin D in Patients With Cystic Fibrosis|Unknown status|Recruiting|Phase 2|15|Anticipated|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 22:45:53.001085|2018-05-31 22:45:53.001085
NCT01321892|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-06-20|2011-03-22|2011-03-24|Estimate|||||||2012-06-20|2012-06-21|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium|Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium|Completed|||64|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples Without DNA|"~     Retained specimens are punch biopsy specimens from the primary tumor resection.~   "|||2018-05-31 22:45:53.100325|2018-05-31 22:45:53.100325
NCT01321879|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-12-06|2011-03-22|2011-03-24|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2011||2011-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients|Phase II, Open-Label Pilot Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients|Completed||Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:45:53.186695|2018-05-31 22:45:53.186695
NCT01321866|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2016-06-02|2011-03-23|2011-03-24|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PREST||Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients|Randomized Trial Comparing a Cutting Balloon to a Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients|Terminated||N/A|42|Actual|Centre Hospitalier Universitaire de Nīmes||2||Inclusion curve too slow.|f||||t||||||||||2018-05-31 22:45:53.265496|2018-05-31 22:45:53.265496
NCT01321853|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-01-04|2011-03-22|2011-03-24|Estimate|||||||2012-01-04|2012-01-06|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Home Care Medication Management Program for the Frail Elderly|Home Care Medication Management Program for the Frail Elderly|Completed||Phase 1|414|Actual|Arizona State University||3|||f||||t||||||||||2018-05-31 22:45:53.34747|2018-05-31 22:45:53.34747
NCT01321840|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-01-05|2011-03-23|2011-03-24|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2010||2010-03-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cortical Plasticity in a Complex Intervention for Endometriosis|Investigation of Cortical Plasticity in a Complex Intervention for Endometriosis|Completed||N/A|60|Actual|University of Jena||2|||f||||f||||||||||2018-05-31 22:45:53.415281|2018-05-31 22:45:53.415281
NCT01321827|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2017-03-15|2011-03-23|2011-03-24|Estimate|||||||2017-03-15|2017-03-16|Actual|April 2011||2011-04-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|March 2013|Actual|2013-03-31||Interventional|MIPA||Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis||Completed||Phase 2/Phase 3|100|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 22:45:53.479471|2018-05-31 22:45:53.479471
NCT01321814|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2014-05-24|2011-03-23|2011-03-24|Estimate|||||||2014-05-24|2014-05-28|Estimate|June 2004||2004-06-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Cognitive Behavioral Therapy for Hyperacusis||Completed||N/A|62|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 22:45:53.611168|2018-05-31 22:45:53.611168
NCT01321801|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2013-01-28|2011-03-23|2011-03-24|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Pregabalin and Analgesia After Laparoscopic Cholecystectomy|Preoperative Use of Pregabalin and Analgesia Levels After Laparoscopic Cholecystectomy|Completed||N/A|50|Actual|Larissa University Hospital||2|||f||||t||||||||||2018-05-31 22:45:53.685411|2018-05-31 22:45:53.685411
NCT01321788|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-02-03|2011-03-23|2011-03-24|Estimate|||||||2012-02-03|2012-02-06|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|PROCS||Venous Thromboembolism Prophylaxis Post Cesarean Section|Venous Thromboembolism Prophylaxis Post Cesarean Section(PRO-CS-Trial)|Unknown status|Recruiting||300|Anticipated|King Saud University|||2||f||||f||||||||||2018-05-31 22:45:53.772148|2018-05-31 22:45:53.772148
NCT01321775|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2011-03-23|2011-03-23|2011-03-24|Estimate|||||||2011-03-23|2011-03-24|Estimate|August 2009||2009-08-31|June 2010|2010-06-30|November 2013|Anticipated|2013-11-30|February 2013|Anticipated|2013-02-28||Interventional|||Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer|Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer|Unknown status|Recruiting|Phase 2|44|Anticipated|Hospital Universitario Madrid Sanchinarro||1|||f||||f||||||||||2018-05-31 22:45:53.878484|2018-05-31 22:45:53.878484
NCT01321762|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-04-18|2011-03-23|2011-03-24|Estimate|||||||2012-04-18|2012-04-19|Estimate|April 2005||2005-04-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|PAPA||Prolapse and Pregnancy Assessment|Effect of Pregnancy and Childbirth on the Pelvic Floor|Completed|||403|Actual|Croydon University Hospital|||1||f||||t||||||||||2018-05-31 22:45:53.944076|2018-05-31 22:45:53.944076
NCT01321723|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2012-12-12||2013-02-21|2011-03-22|2011-03-23|Estimate|2013-01-17|2013-02-21|Estimate||||2013-02-21|2013-03-01|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women|A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo® in Postmenopausal Women With Osteoporosis|Completed||Phase 2|97|Actual|Unigene Laboratories Inc.||3|||f||||f||||||||||2018-05-31 22:45:54.487634|2018-05-31 22:45:54.487634
NCT01321710|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|2011-08-22||2012-01-27|2011-03-22|2011-03-23|Estimate|2012-01-27|2012-02-29|Estimate||||2012-01-27|2012-02-29|Estimate|December 2004||2004-12-31|January 2012|2012-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|MOMS||Sleep Disruption in New Mothers: An Intervention Trial|Sleep Disruption in New Parents: An Intervention Trial|Completed||N/A|152|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 22:45:54.943258|2018-05-31 22:45:54.943258
NCT01321697|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|2013-06-10||2013-08-23|2011-03-22|2011-03-23|Estimate|2013-08-23|2013-08-27|Estimate||||2013-08-23|2013-08-27|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer||Terminated|||7|Actual|University of Arkansas|Early termination of the study due to investigator decision. No subjects were analyzed.||1|Principal Investigator Request|f||||f||||||||||2018-05-31 22:45:55.233525|2018-05-31 22:45:55.233525
NCT01321684|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-05-26|2011-03-22|2011-03-23|Estimate|||||||2012-05-26|2012-05-30|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effect of Spinal Flexion in the Lateral Decubitus Position on the Unilaterality During Spinal Anesthesia||Completed||N/A|32|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 22:45:55.354375|2018-05-31 22:45:55.354375
NCT01321671|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-06-30|2011-03-22|2011-03-23|Estimate|||||||2011-06-30|2011-07-01|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers|The Pharmacokinetics Of Pregabalin Controlled Release Formulation In Fed State Compared To The Controlled Release And Immediate Release Formulations In The Fasted State|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:45:55.394851|2018-05-31 22:45:55.394851
NCT01321658|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2015-10-20|2011-03-22|2011-03-23|Estimate|||||||2015-10-20|2015-10-21|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Geriatric Intervention in Frail Elderly Patients With Colorectal Cancer|Geriatric Intervention in Elderly Surgical Patients With Colorectal Cancer - a Randomized, Controlled Trial.|Completed||N/A|122|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:45:55.483651|2018-05-31 22:45:55.483651
NCT01321645|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|||2012-10-21|2011-03-22|2011-03-23|Estimate|||||||2012-10-21|2012-10-23|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Efficacy of Azadirachta Indica (Homoeopathic Medicine) in Treatment of Acne Vulgaris|Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Azadirachta Indica|Completed||Phase 1|31|Actual|Miglani, Anjali|||||f||||t||||||||||2018-05-31 22:45:55.542754|2018-05-31 22:45:55.542754
NCT01321632|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|||2012-10-21|2011-03-22|2011-03-23|Estimate|||||||2012-10-21|2012-10-23|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Efficacy of Zingiber Officinalis (Homoeopathic Medicine) in Treatment of Acne Vulgaris|Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Zingiber Officinalis|Completed||Phase 1|32|Actual|Miglani, Anjali|||||f||||t||||||||||2018-05-31 22:45:55.592579|2018-05-31 22:45:55.592579
NCT01321619|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-06-13|2011-03-22|2011-03-23|Estimate|||||||2011-06-13|2011-06-14|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Efficacy and Tolerability of the Use of Varicell Compared With Daflon|Study Clinical, Multicenter,Phase III,Prospective,Randomized,Comparative Double Blind/Double-dummy to Assess the Efficacy and Tolerability of the Use of Varicell in Reducing the Symptoms Caused by Chronic Venous Insufficiency and Hemorrhoidal Syndrome When Compared With Daflon|Unknown status|Not yet recruiting|Phase 3|102|Anticipated|Vidfarma Indústria de Medicamentos Ltda.||2|||f||||t||||||||||2018-05-31 22:45:55.756044|2018-05-31 22:45:55.756044
NCT01321606|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-12-15|2011-03-22|2011-03-23|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study|IMpact of PRObiotics for Reducing Infections in VEterans: The IMPROVE Study|Completed||Phase 2|114|Anticipated|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 22:45:55.839123|2018-05-31 22:45:55.839123
NCT01321593|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2016-11-02|2011-03-22|2011-03-23|Estimate|||||||2016-11-02|2016-11-03|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||"Hemoglobin Measured by Orsense NBM-200MP Device and Laboratory Measurement"|"Comparison of the Hemoglobin Results Obtained With the Orsense NBM-200MP Device and the Clinical Laboratory"|Completed|||300|Actual|Hopital Foch|||1||f||||f||||||||||2018-05-31 22:45:55.914789|2018-05-31 22:45:55.914789
NCT01321580|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2016-11-02|2011-03-22|2011-03-23|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Hemoglobin MASIMO (Pronto 7) and Laboratory Measurement|Comparison of the Hemoglobin Results Obtained With the Masimo Pronto 7 and the Clinical Laboratory Measurement Study|Completed||N/A|300|Actual|Hopital Foch||1|||f||||f||||||||||2018-05-31 22:45:55.967789|2018-05-31 22:45:55.967789
NCT01321567|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2015-05-13|2011-03-22|2011-03-23|Estimate|||||||2015-05-13|2015-05-14|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Observational|||Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis|Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis|Completed|||2157|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 22:45:56.099594|2018-05-31 22:45:56.099594
NCT01321554|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2015-03-13||2017-12-22|2011-03-22|2011-03-23|Estimate|2016-10-19|2016-12-12|Estimate||||2017-12-22|2018-01-23|Actual|March 17, 2011|Actual|2011-03-17|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|November 15, 2013|Actual|2013-11-15||Interventional|SELECT||A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer|Active, not recruiting||Phase 3|392|Actual|Eisai Inc.||4|||f||||t|t|||||||||2018-05-31 22:45:57.013515|2018-05-31 22:45:57.013515
NCT01321541|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2017-08-02|2011-03-22|2011-03-23|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2011||2011-04-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|PIX-R||Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant|A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant|Active, not recruiting||Phase 3|260|Anticipated|CTI BioPharma||2|||f||||t||||||||||2018-05-31 22:45:58.926124|2018-05-31 22:45:58.926124
NCT01321528|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-03-24|2011-03-22|2011-03-23|Estimate|||||||2011-03-24|2011-03-28|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Trial of Inquiry-based Stress Reduction (IBSR) Program for Health Care Professionals|Pilot Clinical Trial of Inquiry-based Stress Reduction (IBSR) Program for Health Care Professionals|Unknown status|Recruiting||35|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 22:45:59.254786|2018-05-31 22:45:59.254786
NCT01321515|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2018-01-19|2011-03-22|2011-03-23|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2007||2007-07-31|January 2018|2018-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fasting Conditions|Completed||N/A|36|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 22:45:59.311675|2018-05-31 22:45:59.311675
NCT01321502|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2018-01-19|2011-03-22|2011-03-23|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2007||2007-07-31|January 2018|2018-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Famciclovir Tablets Under Fed Conditions|Completed||N/A|31|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 22:45:59.367166|2018-05-31 22:45:59.367166
NCT01321489|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-22|2011-03-22|2011-03-23|Estimate|||||||2011-03-22|2011-03-23|Estimate|September 2011||2011-09-30|March 2011|2011-03-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies|A Clinical Phase III, Comparative, Open, Multicenter, Prospectively, to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet, Compared to Viagra ® 50mg Tablet Coated, in the Treatment of Erectile Dysfunction of Different Etiologies|Unknown status|Not yet recruiting|Phase 3|78|Anticipated|Laboratório Teuto Brasileiro S/A||2|||f||||t||||||||||2018-05-31 22:45:59.420613|2018-05-31 22:45:59.420613
NCT01321476|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2013-09-04|2011-03-22|2011-03-23|Estimate|||||||2013-09-04|2013-09-05|Estimate||||July 2011|2011-07-31||||||||Observational|Carotid||Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis|Contribution of Hepatic and Intestinal Lipoproteins to Human Atherosclerosis|Withdrawn|||0|Actual|Piedmont Healthcare||||Study was never initiated and internal decision to discontinue initiation process|f||||f||||||Samples With DNA|"~     Carotid artery tissue Liver biopsy tissue Intestinal biopsy tissue Cell cultures~   "|||2018-05-31 22:45:59.498442|2018-05-31 22:45:59.498442
NCT01321463|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21||2013-07-08|2013-07-08|2011-03-22|2011-03-23|Estimate||||2013-07-08|2013-07-11|Estimate|2013-07-08|2013-07-11|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Salmeterol Xinafoate/ Fluticasone Propionate Combination|Completed||Phase 2|377|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:45:59.558539|2018-05-31 22:45:59.558539
NCT01321450|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-11-05|2011-03-21|2011-03-23|Estimate|||||||2011-11-05|2011-11-08|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Observational|||Economisation of Whipple Resection Using an Ultrasonic Dissection Device|Economisation of Preparation by Using an Ultrasonic Dissection Device in Partial Pancreatoduodenectomy|Completed|||150|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||||||2018-05-31 22:45:59.704341|2018-05-31 22:45:59.704341
NCT01321437|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2018-01-12|2011-03-21|2011-03-23|Estimate|||||||2018-01-12|2018-01-17|Actual|December 2011||2011-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma|Phase 2 Study of the Anti-Angiogenesis Agent Axitinib (AG-013736) in Patients With Stage III Malignant Melanoma|Active, not recruiting||Phase 2|11|Actual|University of California, Irvine||1|||f||||t||||||||||2018-05-31 22:45:59.933219|2018-05-31 22:45:59.933219
NCT01321424|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-04-22|2011-03-22|2011-03-23|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Diurnal Variation in Tear Osmolarity|Investigator Sponsored, Pilot Study to Assess the Diurnal Variation in Tear Osmolarity as a Predictor of Dry Eye Disease Etiology|Completed|||60|Actual|Ophthalmic Consultants of Long Island|||3||f||||f||||||||Yes|PI will present study outcomes to associates|2018-05-31 22:46:00.014041|2018-05-31 22:46:00.014041
NCT01321411|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2014-03-05|2011-03-21|2011-03-23|Estimate|||||||2014-03-05|2014-03-06|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Observational|CREST||Clinical Respiratory Evaluation Using Spectroscopy Trial|Clinical Respiratory Evaluation Using Spectroscopy Trial|Withdrawn|||0|Actual|University of British Columbia|||2|Not started and now discontinued|f||||f||||||||||2018-05-31 22:46:00.086344|2018-05-31 22:46:00.086344
NCT01321398|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2014-03-14|2011-03-21|2011-03-23|Estimate|||||||2014-03-14|2014-03-17|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|July 2011|Actual|2011-07-31||Observational|TPG in HFO||Transpulmonary Pressure Gradients in High Frequency Oscillation|Transpulmonary Pressure Gradients in High Frequency Oscillation Study|Completed|||7|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 22:46:00.164175|2018-05-31 22:46:00.164175
NCT01321385|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2016-05-17|2011-03-22|2011-03-23|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2011||2011-03-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia|Validation of a Classifier for Induction Response Prediction Using Single Cell Network Profiling (SCNP) Assays for Childhood AML|Completed|||97|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     bone marrow~   "|||2018-05-31 22:46:00.233983|2018-05-31 22:46:00.233983
NCT01321372|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-03-18|2011-03-21|2011-03-23|Estimate|||||||2013-03-18|2013-03-19|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Observational|||An Observational Analysis of Voriconazole Therapeutic Drug Concentration Monitoring, Pharmacogenomics and Clinical Outcome Correlations in High-risk Hematology Patients|A Prospective, Observational Analysis of Voriconazole (VOR) Therapeutic Drug Concentration Monitoring, Pharmacogenomics and Clinical Outcome Correlations in High-risk Hematology Patients at Princess Margaret Hospital|Completed|||82|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 22:46:00.29391|2018-05-31 22:46:00.29391
NCT01321359|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22||2013-05-15|2013-05-15|2011-03-22|2011-03-23|Estimate||||2013-05-15|2013-05-23|Estimate|2013-05-15|2013-05-23|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SHaRCS||A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis|Completed||Phase 3|907|Actual|NanoBio Corporation||2|||f||||f||||||||||2018-05-31 22:46:00.352135|2018-05-31 22:46:00.352135
NCT01321346|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-11-20|2011-03-22|2011-03-23|Estimate|||||||2015-11-20|2015-11-24|Estimate|March 2011||2011-03-31|November 2015|2015-11-30||||October 2015|Actual|2015-10-31||Interventional|||A Study Of Panobinostat In Children With Refractory Hematologic Malignancies|A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies|Completed||Phase 1|30|Actual|Therapeutic Advances in Childhood Leukemia Consortium||2|||f||||t||||||||||2018-05-31 22:46:00.524427|2018-05-31 22:46:00.524427
NCT01321333|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-06-16|2011-03-22|2011-03-23|Estimate|||||||2015-06-16|2015-06-18|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury|A Phase I/II Study of the Safety and Preliminary Efficacy of Intramedullary Spinal Cord Transplantation of Human Central Nervous System (CNS) Stem Cells (HuCNS-SC®) in Subjects With Thoracic (T2-T11) Spinal Cord Trauma|Completed||Phase 1/Phase 2|12|Actual|StemCells, Inc.||1|||f||||t||||||||||2018-05-31 22:46:00.630438|2018-05-31 22:46:00.630438
NCT01321320|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-10-16|2011-03-22|2011-03-23|Estimate|||||||2013-10-16|2013-10-17|Estimate|April 2011||2011-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP)|Investigation of the Role of FHL-1 and Myostatin in the Development of Intensive Care Unit Acquired Paresis (ICUAP) and the Effect of Increased Muscle Activity on These Pathways.|Completed||N/A|13|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 22:46:00.718611|2018-05-31 22:46:00.718611
NCT01321307|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-03-22|2011-03-22|2011-03-23|Estimate|||||||2011-03-22|2011-03-23|Estimate|April 2011||2011-04-30|March 2011|2011-03-31||||||||Observational|||Aphtostomatitis and Mucositis Treatment by Natural Herbal Formula (Sorend®)|Aphtostomatitis and Mucositis Treatment by Natural Herbal Formula (Sorend®)|Unknown status|Not yet recruiting||120|Anticipated|Hillel Yaffe Medical Center|||2||f||||f||||||||||2018-05-31 22:46:00.801017|2018-05-31 22:46:00.801017
NCT01321294|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2011-03-22|2011-03-22|2011-03-23|Estimate|||||||2011-03-22|2011-03-23|Estimate||||March 2011|2011-03-31||||||||Interventional|||Laparoscopic Nissen Versus Toupet Fundoplication: Objective and Subjective Results of a Prospective Randomized Trial||Completed||N/A|||General Public Hospital Zell am See||2|||f||||||||||||||2018-05-31 22:46:00.860769|2018-05-31 22:46:00.860769
NCT01321281|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-05-14|2011-03-22|2011-03-23|Estimate|||||||2012-05-14|2012-05-15|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects|Randomised, Placebo Controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects|Completed||Phase 2|36|Actual|University College Cork||2|||f||||t||||||||||2018-05-31 22:46:00.923416|2018-05-31 22:46:00.923416
NCT01321268|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2015-06-04|2011-03-22|2011-03-23|Estimate|||||||2015-06-04|2015-06-08|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Efficacy of a Dietary Supplement in Females With Cellulite|Safety and Efficacy of an Antioxidant Based Dietary Supplement With PUFAs in Healthy Female Volunteers With Cellulite (Orange Peel Skin)|Terminated||N/A|8|Actual|DSM Nutritional Products, Inc.||2||sponsor stopped study due to recruitment problems|f||||f||||||||||2018-05-31 22:46:00.992288|2018-05-31 22:46:00.992288
NCT01321255|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2014-07-14|2011-03-22|2011-03-23|Estimate|||||||2014-07-14|2014-07-15|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|FOCUS||Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.|Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug|Completed||Phase 3|2118|Actual|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III||2|||f||||t||||||||||2018-05-31 22:46:01.100239|2018-05-31 22:46:01.100239
NCT01321242|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-05-31|2011-03-22|2011-03-23|Estimate|||||||2012-05-31|2012-06-01|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|Athena||Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension|"Observational Non-interventional Study - Epidemiological Survey AchievemenT of Goal Resting HEart Rate on Beta-blockers in Patients With Stable angiNA and Hypertension in Routine Practice"|Completed|||400|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 22:46:01.264859|2018-05-31 22:46:01.264859
NCT01321229|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2016-12-12|2011-03-22|2011-03-23|Estimate|||||||2016-12-12|2016-12-13|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|SAS-AVC||The Influence of the Sleep Apnea on the Neurological and Functional Recovery|Influence of the Sleep Apnea Syndrome on the Functional Recovery After Stroke in a Rehabilitation Unit|Completed|||45|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 22:46:01.340666|2018-05-31 22:46:01.340666
NCT01321216|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-01-31|2011-03-22|2011-03-23|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Observational|||Rotavirus Burden and Genotypes in a Sentinel Hospital Surveillance System in Lebanon|ESTIMATION OF THE DISEASE BURDEN AND PREVALENT GENOTYPES OF ROTAVIRUS (RV) CAUSING GASTROENTERITIS (GE) IN CHILDREN <5 YEARS OF AGE IN LEBANON BASED ON A SENTINEL HOSPITAL-BASED SURVEILLANCE PROGRAM.|Unknown status|Recruiting||1600|Anticipated|American University of Beirut Medical Center|||1||f||||f||||||Samples With DNA|"~     Stool samples with rotavirus RNA~   "|||2018-05-31 22:46:01.418509|2018-05-31 22:46:01.418509
NCT01321021|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-05-02|2011-03-22|2011-03-23|Estimate|||||||2012-05-02|2012-05-03|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|LoDi-Basel||Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects|Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects|Completed||N/A|80|Actual|University of Basel||1|||f||||t||||||||||2018-05-31 22:46:03.355171|2018-05-31 22:46:03.355171
NCT01321203|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2011-07-16|2011-03-22|2011-03-23|Estimate|||||||2011-07-16|2011-07-19|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Outcome of Carbon Dioxide Versus Air Insufflations During Endoscopic Retrograde Cholangiopancreatography (ERCP)|A Double-blind, Randomized, Controlled Trial of Air Insufflation Versus Carbon Dioxide Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP).|Completed|||500|Anticipated|Asian Institute of Gastroenterology, India|||2||f||||f||||||||||2018-05-31 22:46:01.503042|2018-05-31 22:46:01.503042
NCT01321190|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-01-10|2011-03-21|2011-03-23|Estimate|||||||2016-01-10|2016-01-12|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Observational|||Pain Quality Study|Pain Quality in Individuals With Low Back Pain, Headache, and Fibromyalgia|Completed|||307|Actual|University of Washington|||3||f||||f||||||||||2018-05-31 22:46:01.559828|2018-05-31 22:46:01.559828
NCT01321177|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-09-07|2011-03-21|2011-03-23|Estimate|||||||2017-09-07|2017-09-08|Actual|July 2010||2010-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2014|Actual|2014-07-31||Interventional|RAISE ETP||An Integrated Program for the Treatment of First Episode of Psychosis|Recovery After an Initial Schizophrenia Episode (RAISE): RAISE Early Treatment Program|Completed||N/A|404|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 22:46:01.794775|2018-05-31 22:46:01.794775
NCT01321164|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2014-05-08|2011-03-22|2011-03-23|Estimate|||||||2014-05-08|2014-05-12|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis|Fumaric Acid Esters Versus Fumaric Acid Esters Plus Narrow Band Type B Ultraviolet (UVB) in Patients With Severe Plaque Psoriasis|Completed||Phase 3|30|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 22:46:01.927281|2018-05-31 22:46:01.927281
NCT01321151|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-01-07|2011-03-22|2011-03-23|Estimate|||||||2012-01-07|2012-01-10|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|REPAIR||Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers|Use of Resveratrol to Decrease Secondary Brain Injury Following Sports-Related Concussions: a Double-Blind, Placebo-Controlled Study|Completed||Phase 1|12|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 22:46:02.040162|2018-05-31 22:46:02.040162
NCT01321138|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-11-25|2011-03-22|2011-03-23|Estimate|||||||2015-11-25|2015-11-30|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|||Femoral Neuropathy After Anterior Cruciate Ligament Reconstruction: Femoral Nerve Block vs Patient-controlled Analgesia (PCA)|Comparison of Incidence of Femoral Neuropathy After Anterior Cruciate Ligament Reconstruction With Femoral Nerve Block Versus Patient-controlled Analgesia (PCA)|Completed||N/A|74|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 22:46:02.128806|2018-05-31 22:46:02.128806
NCT01321125|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-06-20|2011-03-22|2011-03-23|Estimate|||||||2013-06-20|2013-06-24|Estimate|April 2011||2011-04-30|September 2011|2011-09-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Chlorhexidine Against Sodium Hypochlorite as Skin Antiseptics|Comparative Study of 2% Chlorhexidine Gluconate in 70% Isopropyl Alcohol Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers|Completed||Phase 3|30|Actual|Universidad de Guanajuato||2|||f||||f||||||||||2018-05-31 22:46:02.273274|2018-05-31 22:46:02.273274
NCT01321112|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-05-08|2011-03-22|2011-03-23|Estimate|||||||2012-05-08|2012-05-10|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|TBCP||Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil|Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil Monotherapy|Unknown status|Recruiting|N/A|40|Anticipated|Pontificia Universidad Catolica de Chile||1|||f||||t||||||||||2018-05-31 22:46:02.417023|2018-05-31 22:46:02.417023
NCT01321099|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-11-07|2011-03-22|2011-03-23|Estimate|||||||2012-11-07|2012-11-08|Estimate|May 2011||2011-05-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Iron Absorption From Complementary Food Fortificants (CFFs) and Acceptability of CFFs by Beninese Children||Completed||N/A|60|Actual|Swiss Federal Institute of Technology||3|||f||||||||||||||2018-05-31 22:46:02.51025|2018-05-31 22:46:02.51025
NCT01321086|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-01-11|2011-03-21|2011-03-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Motivational Interviewing (MI) for African Americans With Peripheral Arterial Disease (PAD)|Promoting Walking in African Americans With Peripheral Arterial Disease|Completed||N/A|174|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-05-31 22:46:02.608298|2018-05-31 22:46:02.608298
NCT01321073|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2018-01-16|2014-10-21|2018-04-03|2011-03-21|2011-03-23|Estimate|2018-04-03|2018-05-04|Actual|2014-10-21|2014-10-30|Estimate|2018-04-03|2018-05-04|Actual|June 2011|Actual|2011-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|June 2013|Actual|2013-06-30||Interventional|DelIVery|All patients attempting implant|DelIVery for Pulmonary Arterial Hypertension (PAH)|DelIVery for Pulmonary Arterial Hypertension (PAH) Clinical Study|Active, not recruiting||N/A|64|Actual|Medtronic Cardiac Rhythm and Heart Failure|Results are through June, 2013 when 22,000 patient days of implant had been accumulated. This was the pre-specified primary analysis time for the study. The study continued past this point.|1|||f||||t||||||||No||2018-05-31 22:46:02.737414|2018-05-31 22:46:02.737414
NCT01321060|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-06-16|2011-03-22|2011-03-23|Estimate|||||||2012-06-16|2012-06-19|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||December 2012|Anticipated|2012-12-31||Interventional|FCMSAP||Fluid Collections Management in Severe Acute Pancreatitis|Management of Sterile Fluid Collections in Patients With Severe Acute Pancreatitis:a Randomized Controlled Trial|Unknown status|Recruiting|N/A|87|Anticipated|Nanjing University School of Medicine||3|||f||||f||||||||||2018-05-31 22:46:03.052621|2018-05-31 22:46:03.052621
NCT01321047|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-03-22|2011-03-22|2011-03-23|Estimate|||||||2011-03-22|2011-03-23|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|ERCP||Balanced Propofol Sedation Versus Propofol Alone Sedation in Therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP)|Phase 4 Study of Balanced Propofol Sedation Versus Propofol Alone Sedation|Unknown status|Enrolling by invitation|Phase 4|204|Anticipated|Soon Chun Hyang University||2|||f||||t||||||||||2018-05-31 22:46:03.172155|2018-05-31 22:46:03.172155
NCT01321034|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2013-01-08|2011-03-22|2011-03-23|Estimate|||||||2013-01-08|2013-01-10|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Niacin in the Lipoprotein (a) Concentration|Effect of Niacin in the Lipoprotein (a) Concentration With Regard to Apolipoprotein (a) Size and Baseline Lipoprotein (a) Concentration.|Completed||Phase 4|90|Actual|Instituto Aragones de Ciencias de la Salud||1|||f||||t||||||||||2018-05-31 22:46:03.267559|2018-05-31 22:46:03.267559
NCT01321008|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2014-05-20||2015-01-21|2011-03-21|2011-03-23|Estimate|2014-05-20|2014-06-23|Estimate||||2015-01-21|2015-02-05|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Stage I/II Nasal NK Cell Lymphoma|Radiation Therapy Followed by Chemotherapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma|Terminated||Phase 1/Phase 2|1|Actual|M.D. Anderson Cancer Center|Early termination with too small number of subjects to perform analysis.|1||Slow Accrual|f||||f||||||||||2018-05-31 22:46:03.463108|2018-05-31 22:46:03.463108
NCT01320995|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-03-24|2011-03-22|2011-03-23|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|OASIS 1||Perineal Echography in the Delivery Room for the Detection of Anal Lesions|Perineal Echography in the Delivery Room for the Detection of Anal Lesions Among Primiparous Mothers: a Randomized Study|Terminated||N/A|111|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 22:46:03.657399|2018-05-31 22:46:03.657399
NCT01320982|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-03-22|2011-03-22|2011-03-23|Estimate|||||||2011-03-22|2011-03-23|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|MAP-S-01||Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder|A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder|Unknown status|Not yet recruiting|Phase 3|400|Anticipated|Sheba Medical Center||4|||f||||f||||||||||2018-05-31 22:46:03.730194|2018-05-31 22:46:03.730194
NCT01320969|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2012-05-04|2011-03-21|2011-03-23|Estimate|||||||2012-05-04|2012-05-07|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Could Meditation Modulate the Neurobiology of Learning Not to Fear?|Effects of Mindfulness Practice on the Neural Circuitry of Conditioned Fear Extinction in Healthy Participants|Completed||N/A|85|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:46:03.868902|2018-05-31 22:46:03.868902
NCT01320956|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-11-03|2011-03-21|2011-03-23|Estimate|||||||2015-11-03|2015-11-04|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|HYPOPANX||Study of the Effects of Hypnosis Before Undergoing Surgery, on Anxiety in Children Aged 10 to 18 Years|Impact of Pre Operative Hypnosis on Anxiety in Children Aged 10 to 18 Years|Completed||N/A|120|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:46:03.923922|2018-05-31 22:46:03.923922
NCT01320943|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2017-07-27||2017-07-27|2011-03-21|2011-03-23|Estimate|2017-07-27|2017-08-29|Actual||||2017-07-27|2017-08-29|Actual|April 26, 2011|Actual|2011-04-26|July 2017|2017-07-31|August 23, 2016|Actual|2016-08-23|July 28, 2016|Actual|2016-07-28||Interventional|FINITE CHB|Safety Analysis Set: participants who were either randomized to Arm A (Stop TDF) and had a baseline visit, or who were randomized to Arm B (Continue TDF) and received at least one dose of study drug|Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB|FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B|Completed||Phase 4|43|Actual|Gilead Sciences||2|||f||||t|t|f|||t|||||2018-05-31 22:46:04.018913|2018-05-31 22:46:04.018913
NCT01320930|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-03-22|2011-03-22|2011-03-23|Estimate|||||||2011-03-22|2011-03-23|Estimate|January 2007||2007-01-31|January 2011|2011-01-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Rehabilitation in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD)|Early Detection and Rehabilitation of Subjects With COPD - Rehabilitation in Moderate COPD|Completed||N/A|61|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 22:46:04.698027|2018-05-31 22:46:04.698027
NCT01320917|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-04-01|2011-03-22|2011-03-23|Estimate|||||||2011-04-01|2011-04-04|Estimate|February 2009||2009-02-28|July 2009|2009-07-31|September 2011|Anticipated|2011-09-30|July 2011|Anticipated|2011-07-31||Interventional|||Levonorgestrel-releasing Intrauterine Device on Obese Women: Effects on Hemostatic and Arterial Function|Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women|Unknown status|Active, not recruiting|Phase 4|88|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:46:04.752196|2018-05-31 22:46:04.752196
NCT01320904|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2011-03-22|2011-03-22|2011-03-23|Estimate|||||||2011-03-22|2011-03-23|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Exercise and Muscle Stimulation in Patients With Knee Osteoarthritis|Neuromuscular Electrical Stimulation (NMES) on Knee Osteoarthritis(OA): an Equivalence Randomized Clinical Trial|Completed||N/A|19|Actual|Universidade Luterana do Brasil||2|||f||||t||||||||||2018-05-31 22:46:04.812861|2018-05-31 22:46:04.812861
NCT01320891|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2017-05-03|2011-03-22|2011-03-23|Estimate|||||||2017-05-03|2017-05-08|Actual|February 2010|Actual|2010-02-28|May 2017|2017-05-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|||Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators|Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators|Completed||N/A|40|Actual|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-05-31 22:46:04.874533|2018-05-31 22:46:04.874533
NCT01320878|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2012-06-15|2011-03-22|2011-03-23|Estimate|||||||2012-06-15|2012-06-18|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease|A Randomized Controlled Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension After Repair of Congenital Heart Disease|Completed||Phase 2|64|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||||2018-05-31 22:46:04.939125|2018-05-31 22:46:04.939125
NCT01320865|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2014-02-03|2011-03-21|2011-03-23|Estimate|||||||2014-02-03|2014-02-04|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib||Withdrawn|||0|Actual|The Cleveland Clinic|||1||f||||f||||||||||2018-05-31 22:46:05.009468|2018-05-31 22:46:05.009468
NCT01320852|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2013-10-24|2011-03-22|2011-03-23|Estimate|||||||2013-10-24|2013-10-25|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||PET Scan as a Screening Tool for Liver Transplant in Patients With Hepatocellular Carcinoma (HCC)|PET Scan as a Screening Tool for Liver Transplant in Patients With HCC|Completed||N/A|100|Actual|McGill University Health Center||2|||f||||||||||||||2018-05-31 22:46:05.133166|2018-05-31 22:46:05.133166
NCT01320839|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-03-06|2011-03-21|2011-03-23|Estimate|||||||2014-03-06|2014-03-07|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Effects of an Ankle-Foot Orthosis on Gait While Performing an Attention Demanding Task|Effects of an Ankle-Foot Orthosis on Gait While Performing an Attention Demanding Task in People With Poststroke Hemiplegia|Completed|||21|Actual|Nova Scotia Health Authority|||1||f||||f||||||||||2018-05-31 22:46:05.217863|2018-05-31 22:46:05.217863
NCT01320826|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2012-03-17||2012-08-14|2011-03-22|2011-03-23|Estimate|2012-08-14|2012-08-15|Estimate||||2012-08-14|2012-08-15|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Observational|APC-Endo||The Alberta Primary Care Endoscopy (APC-Endo) Study|Prospective Study of the Quality of Colonoscopies Performed by Primary Care Endoscopists in Alberta, Canada|Completed|||577|Actual|University of Alberta|||1||f||||f||||||||||2018-05-31 22:46:05.310498|2018-05-31 22:46:05.310498
NCT01320813|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2015-03-24|2011-03-22|2011-03-23|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy|Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy|Terminated||N/A|5|Actual|Centre Hospitalier Universitaire de Nīmes||2||Unable to find enough patients who accept randomization of surgical procedures.|f||||t||||||||||2018-05-31 22:46:05.691196|2018-05-31 22:46:05.691196
NCT01320800|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2016-01-28|2011-03-21|2011-03-22|Estimate|||||||2016-01-28|2016-01-29|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||CBT for Social Anxiety Disorder Delivered by School Counselors|CBT for Social Anxiety Disorder Delivered by School Counselors|Completed||Phase 2|126|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 22:46:05.768786|2018-05-31 22:46:05.768786
NCT01320787|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2014-10-22|2011-03-21|2011-03-22|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||October 2016|Anticipated|2016-10-31||Interventional|||18-F-Fluoroacetate as PET Imaging Agent|A Phase I Study of 18-F-Fluoroacetate Sodium as a PET Imaging Agent for Tumor Detection|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:46:05.837843|2018-05-31 22:46:05.837843
NCT01320774|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-02-09|2011-03-21|2011-03-22|Estimate|||||||2012-02-09|2012-02-10|Estimate|April 2011||2011-04-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris|Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris|Completed|||588|Actual|LEO Pharma|||||f||||f||||||||||2018-05-31 22:46:05.905461|2018-05-31 22:46:05.905461
NCT01320761|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-21|2011-03-21|2011-03-22|Estimate|||||||2011-03-21|2011-03-22|Estimate||||March 2011|2011-03-31||||||||Interventional|||A Study to Assess Injection Comfort of Two Formulations of ATX-101|A Study to Assess Injection Comfort of Two Formulations of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Administration in the Submental Area|Completed||Phase 1|24|Actual|Kythera Biopharmaceuticals||4|||f||||f||||||||||2018-05-31 22:46:05.968916|2018-05-31 22:46:05.968916
NCT01320748|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-01-29|2011-03-21|2011-03-22|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|January 2013|Actual|2013-01-31|March 2012|Actual|2012-03-31||Interventional|||fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults|fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults|Completed||N/A|29|Actual|Inova Health Care Services||2|||f||||f||||||||||2018-05-31 22:46:06.05613|2018-05-31 22:46:06.05613
NCT01320735|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2015-05-19||2015-06-11|2011-03-21|2011-03-22|Estimate|2015-06-11|2015-07-08|Estimate||||2015-06-11|2015-07-08|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||Data are of measurements collected from the safety analysis set, defined as all participants who signed an informed consent form and were administered at least one dose of Leuprorelin.|Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia|Prospective, Multi-Center, Observational Program to Assess Routine Use of Intermittent Adjuvant Deprivation Therapy With Lucrin Depot in Patients With Advanced Prostate Cancer in the Russian Federation|Completed|||300|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:46:06.163639|2018-05-31 22:46:06.163639
NCT01320722|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2017-03-13||2017-05-31|2011-03-21|2011-03-22|Estimate|2017-05-31|2017-06-29|Actual||||2017-05-31|2017-06-29|Actual|March 2011||2011-03-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|MODERATE|All randomized participants.|Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function|Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE)|Completed||Phase 3|242|Actual|Brigham and Women's Hospital||5|||f||||f||||||||||2018-05-31 22:46:06.479589|2018-05-31 22:46:06.479589
NCT01320709|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-07-09|2011-03-21|2011-03-22|Estimate|||||||2015-07-09|2015-07-10|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Piroxicam on Ovulation|Single-center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Whether a Single-dose of Either 20 mg Piroxicam, 40 mg Piroxicam or 80 mg Piroxicam Shows an Effect on Ovulation After the Onset of LH Surge Compared to Placebo in Healthy Young Women|Completed||Phase 2|72|Actual|Bayer||4|||f||||f||||||||||2018-05-31 22:46:07.25936|2018-05-31 22:46:07.25936
NCT01320696|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-10-05|2011-03-21|2011-03-22|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|May 2012|Actual|2012-05-31|June 2011|Actual|2011-06-30||Interventional|||Reverse Genetic H9N2 Influenza Vaccine Study in Adults|A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years|Completed||Phase 1/Phase 2|275|Actual|Ology Bioservices||2|||f||||t||||||||||2018-05-31 22:46:07.329307|2018-05-31 22:46:07.329307
NCT01320683|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2016-05-11||2016-06-17|2011-03-21|2011-03-22|Estimate|2016-05-11|2016-06-20|Estimate||||2016-06-17|2016-07-19|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer|A Phase II Trial of Radioimmunotherapy (Y-90 M5A) Following Hepatic Resection and FOLFIRI or FOLFOX Chemotherapy [+/-BEVACIZUMAB], or Xelox for Metastatic Colorectal Carcinoma to the Liver|Terminated||Phase 2|1|Actual|City of Hope Medical Center|Early termination due to slow accrual. Unable to perform planned analysis due to the small number of subjects.|1||Slow accrual.|f||||t||||||||No||2018-05-31 22:46:07.415967|2018-05-31 22:46:07.415967
NCT01320670|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-01-17|2011-03-21|2011-03-22|Estimate|||||||2013-01-17|2013-01-21|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|||Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy|Neuroimaging Predictors of Treatment Failure in Adult New-onset Epilepsy|Unknown status|Recruiting||50|Anticipated|Nova Scotia Health Authority|||||f||||f||||||||||2018-05-31 22:46:07.602504|2018-05-31 22:46:07.602504
NCT01320657|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-04-12|2011-03-21|2011-03-22|Estimate|||||||2012-04-12|2012-04-13|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|May 2013|Anticipated|2013-05-31|August 2012|Anticipated|2012-08-31||Interventional|||A Clinical Trial of Three Fixed Orthodontic Appliances|A Randomised Clinical Trial of Orthodontic Treatment With 3 Fixed Appliance Systems Assessed Using Digital Models|Unknown status|Active, not recruiting|N/A|96|Anticipated|Barts & The London NHS Trust||3|||f||||t||||||||||2018-05-31 22:46:07.662911|2018-05-31 22:46:07.662911
NCT01320631|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2017-06-08|2011-03-21|2011-03-22|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2009||2009-09-30|June 2017|2017-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|SEXQ||Male Sexual Experience and Its Impact on Quality of Life Before and After Their Sexual Partners Undergo Polypropylene Mesh Augmented Pelvic Floor Reconstruction||Completed|||80|Actual|Atlantic Health System|||||f||||f||||||||||2018-05-31 22:46:07.779643|2018-05-31 22:46:07.779643
NCT01320618|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-08-10|2011-03-21|2011-03-22|Estimate|||||||2016-08-10|2016-08-11|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|MPATHY||Prospective Cohort Study of Robotic Assisted Laparoscopic Sacrocolpopexy Using MPATHY Restorelle Mesh||Completed|||120|Actual|Atlantic Health System|||||f||||f||||||||||2018-05-31 22:46:07.819738|2018-05-31 22:46:07.819738
NCT01320605|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2011-03-21|2011-03-21|2011-03-22|Estimate|||||||2011-03-21|2011-03-22|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Trial of Compassionate Use of hp802-247 to Treat Venous Leg Ulcers in Subjects Who Have Failed Multiple Other Healing Technologies|TRIAL OF COMPASSIONATE USE OF HP802-247 TO TREAT VENOUS LEG ULCERS IN SUBJECTS WHO HAVE FAILED MULTIPLE OTHER HEALING TECHNOLOGIES|Unknown status|Recruiting|Phase 2|5|Anticipated|Atlantic Health System||1|||f||||f||||||||||2018-05-31 22:46:07.857116|2018-05-31 22:46:07.857116
NCT01320592|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-07-18|2011-03-21|2011-03-22|Estimate|||||||2016-07-18|2016-07-19|Estimate|March 2011||2011-03-31|July 2016|2016-07-31||||October 2015|Actual|2015-10-31||Interventional|||PD0332991/Paclitaxel in Advanced Breast Cancer|A Phase 1 Trial of PD0332991 and Paclitaxel in Patients With Rb-Expressing Advanced Breast Cancer|Active, not recruiting||Phase 1|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:46:07.910951|2018-05-31 22:46:07.910951
NCT01320579|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-06-20|2011-03-21|2011-03-22|Estimate|||||||2012-06-20|2012-06-21|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis|Phase II Study to Investigate the Properties of Topical Twice Daily Doses of 2.5% and 5% Cis-urocanic Acid in Comparison to Active Comparator 0.1% Protopic® for up to 28 Days in Patients With Moderate or Severe Atopic Dermatitis|Completed||Phase 2|159|Actual|BioCis Pharma Ltd||4|||f||||f||||||||||2018-05-31 22:46:07.968694|2018-05-31 22:46:07.968694
NCT01320566|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2013-11-13|2011-03-21|2011-03-22|Estimate|||||||2013-11-13|2013-11-14|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|January 2012|Actual|2012-01-31||Interventional|||A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema|A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema|Terminated||Phase 2/Phase 3|18|Anticipated|Aeris Therapeutics|||||f||||t||||||||||2018-05-31 22:46:09.353423|2018-05-31 22:46:09.353423
NCT01320553|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2016-03-10||2016-05-23|2011-03-19|2011-03-22|Estimate|2016-04-13|2016-05-20|Estimate||||2016-05-23|2016-06-24|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis|Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis|Completed||Phase 2|122|Actual|Sun Pharma Advanced Research Company Limited|Of the total of 122 subjects, 8 subjects did not complete the study: 114 subjects completed the study, PP population, comprised of all subjects who completed the study with no protocol violations, totaled 107 subjects.|4|||f||||f||||||||||2018-05-31 22:46:09.462387|2018-05-31 22:46:09.462387
NCT01320540|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2016-08-02|2011-03-19|2011-03-22|Estimate|||||||2016-08-02|2016-08-03|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|4R||4R for Guideline Indicated BRCA Testing of Breast Center Patients|4R (Right Information and Right Care to the Right Patient at the Right Time) for Guideline Indicated BRCA Genetic Assessment of Breast Center Patients|Completed|||75|Actual|Northwestern University|||2||f||||t||||||||||2018-05-31 22:46:09.837121|2018-05-31 22:46:09.837121
NCT01320527|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-03-02|2011-03-21|2011-03-22|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease|A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease|Completed||Phase 2|135|Actual|University of Massachusetts, Worcester||3|||f||||t||||||||||2018-05-31 22:46:09.900119|2018-05-31 22:46:09.900119
NCT01320514|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2011-03-19|2011-03-19|2011-03-22|Estimate|||||||2011-03-19|2011-03-22|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Efficacy and Safety of Fibrin Sealant (FS) VH S/D-APR for Hemostasis and Wound Healing in Endoscopic Browlift|A Randomized, Controlled Study to Evaluate Safety and Efficacy of Fibrin Sealant VH S/D 4 S-APR (Artiss) for Tissue Adherence and Hemostasis and To Improve Wound Healing in Subjects Undergoing Endoscopic Browlift|Unknown status|Recruiting||10|Anticipated|Nguyen, Davis B., M.D.|||1||f||||t||||||||||2018-05-31 22:46:10.069329|2018-05-31 22:46:10.069329
NCT01320501|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2016-05-12|2011-03-19|2011-03-22|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|REALME||Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer|Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME)|Suspended||Phase 4|100|Anticipated|National Guard Health Affairs||1||Difficulty in enrolling patients|f||||f||||||||||2018-05-31 22:46:10.179026|2018-05-31 22:46:10.179026
NCT01320488|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2016-05-12|2011-03-19|2011-03-22|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|YoungWomen||Breast Cancer in Young Women: Is it Different?|Breast Cancer in Young Women: Is it Different?|Suspended|||600|Anticipated|National Guard Health Affairs||||Difficulty in enrolling patients|f||||f||||||Samples Without DNA|"~     tumor and blood specimens to characterize the pathology and biology of the tumors, and~     establish tumor bank for future studies~   "|||2018-05-31 22:46:10.265223|2018-05-31 22:46:10.265223
NCT01320475|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-19|||2016-09-22|2011-03-19|2011-03-22|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Epidural Levobupivacaine-sufentanil Versus Epidural Levobupivacaine and Intravenous Ketamine|Thoracic Epidural Analgesia: Epidural Levobupivacaine and Sufentanil Versus Epidural Levobupivacaine and Intravenous Ketamine|Terminated||Phase 4|2|Actual|Hopital Foch||2||Difficulty of Recruitment|f||||f||||||||||2018-05-31 22:46:10.336851|2018-05-31 22:46:10.336851
NCT01316783|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2018-05-23|2011-03-15|2011-03-16|Estimate|||||||2018-05-23|2018-05-24|Actual|March 15, 2011||2011-03-15|July 3, 2017|2017-07-03||||||||Observational|||Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations|Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations|Enrolling by invitation|||416|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:47:03.636425|2018-05-31 22:47:03.636425
NCT01320462|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2017-05-04|2011-03-21|2011-03-22|Estimate|||||||2017-05-04|2017-05-05|Actual|December 2010||2010-12-31|June 2016|2016-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Smoking Cessation Program in the Preadmission Clinic|Smoking Cessation Program in the Preadmission Clinic:The Combination of Counseling, Pharmacotherapy and Quit Line|Completed||N/A|296|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 22:46:10.42591|2018-05-31 22:46:10.42591
NCT01320449|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-07-31|2011-03-21|2011-03-22|Estimate|||||||2012-07-31|2012-08-01|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Identification of New Serum Markers for Detection of Abuse With Erythropoietin|Identification of New Serum Markers for Detection of Abuse With Erythropoietin|Completed||N/A|35|Actual|University of Aarhus||4|||f||||f||||||||||2018-05-31 22:46:10.509938|2018-05-31 22:46:10.509938
NCT01320436|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-02-11|2011-03-21|2011-03-22|Estimate|||||||2016-02-11|2016-02-12|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|5ASA||Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis|Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients|Completed||Phase 3|50|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 22:46:10.61834|2018-05-31 22:46:10.61834
NCT01320423|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-18|2011-03-18|2011-03-22|Estimate|||||||2011-03-18|2011-03-22|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|August 2011|Anticipated|2011-08-31|April 2011|Anticipated|2011-04-30||Interventional|||Surgical Trial in Lobar Intracerebral Haemorrhage|Surgical Trial in Lobar Intracerebral Haemorrhage|Unknown status|Active, not recruiting|N/A|600|Anticipated|Taipei Medical University WanFang Hospital||1|||f||||f||||||||||2018-05-31 22:46:10.736944|2018-05-31 22:46:10.736944
NCT01320410|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-04-30|2011-03-21|2011-03-22|Estimate|||||||2014-04-30|2014-05-01|Estimate||||March 2011|2011-03-31||||||||Interventional|||Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM®|Clinical Trial to Evaluate the Pharmacokinetics, Safety, and Tolerance of Single Dose Administration of a New Injectable Prolonged Release Formulation of Risperidone Using ISM® Technology in Healthy Volunteers|Completed||Phase 1|||Rovi Pharmaceuticals Laboratories|||||f||||||||||||||2018-05-31 22:46:10.801804|2018-05-31 22:46:10.801804
NCT01320397|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-22|2011-03-21|2011-03-22|Estimate|||||||2011-03-22|2011-03-23|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations|Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile|Unknown status|Not yet recruiting|Phase 2|240|Anticipated|RostaQuo S.p.A.||4|||f||||t||||||||||2018-05-31 22:46:10.867377|2018-05-31 22:46:10.867377
NCT01320384|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2016-10-10|2011-03-21|2011-03-22|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|FLORALI||Clinical Effect of the Association of Noninvasive Ventilation and High Flow Nasal Oxygen Therapy in Resuscitation of Patients With Acute Lung Injury (FLORALI Study)|Clinical Effect of the Association of Noninvasive Ventilation and High Flow Nasal Oxygen Therapy in Resuscitation of Patients With Acute Lung Injury. A Randomised Study (FLORALI Study)|Completed||Phase 2/Phase 3|313|Actual|Poitiers University Hospital||3|||f||||t||||||||||2018-05-31 22:46:11.01582|2018-05-31 22:46:11.01582
NCT01320371|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2014-02-03|2011-03-18|2011-03-22|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Analysis of Standard Versus Barbed Sutures in Primary Total Knee Arthroplasty.|Clinical Outcomes and Cost Analysis of Standard Versus Barbed Sutures for Closure in Primary Total Knee Arthroplasty: A Single Blinded Multicenter Prospective Randomized Trial.|Completed|||363|Actual|University of Utah|||2||f||||t||||||||||2018-05-31 22:46:11.08376|2018-05-31 22:46:11.08376
NCT01320358|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2017-02-20|2011-03-21|2011-03-22|Estimate|||||||2017-02-20|2017-02-23|Actual|May 10, 2011|Actual|2011-05-10|February 2017|2017-02-28|November 18, 2011|Actual|2011-11-18|November 18, 2011|Actual|2011-11-18||Interventional|||Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients|A 3-month, Exploratory, Non-randomized, Multi-center, Open Label Study to Evaluate the Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients|Completed||Phase 2|30|Anticipated|Novartis||1|||f||||||||||||||2018-05-31 22:46:11.15908|2018-05-31 22:46:11.15908
NCT01320345|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-01-15|2011-03-21|2011-03-22|Estimate|||||||2012-01-15|2012-01-18|Estimate|September 2011||2011-09-30|March 2011|2011-03-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|FAME 1 EYE||A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume|The Fenofibrate And Microvascular Event Eye (FAME 1 EYE) Trial: A Randomised Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Daily Oral Fenofibrate Compared With Placebo on Macular Thickness and Volume|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|University of Sydney||2|||f||||f||||||||||2018-05-31 22:46:11.242121|2018-05-31 22:46:11.242121
NCT01320332|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-07-23|2011-03-21|2011-03-22|Estimate|||||||2012-07-23|2012-07-24|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis|A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of ASP3291 Following a Single Oral Dose in Subjects With Ulcerative Colitis|Completed||Phase 1|16|Actual|Telsar Pharma Inc.||3|||f||||f||||||||||2018-05-31 22:46:11.479408|2018-05-31 22:46:11.479408
NCT01320319|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-12-03|2011-03-18|2011-03-22|Estimate|||||||2012-12-03|2012-12-04|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|EPA-colo||Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients|Effect of EPA Nutritional Supplementation on Markers of Aerobic Performance, Lean Muscle Mass and Quality of Life on Patients Undergoing Curative Resection of Colorectal Cancer|Unknown status|Recruiting|Phase 2/Phase 3|70|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-05-31 22:46:11.584377|2018-05-31 22:46:11.584377
NCT01320306|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-05-11|2011-03-18|2011-03-22|Estimate|||||||2012-05-11|2012-05-14|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Intracranial Aneurysms and Cognitive Function|Intracranial Aneurysms and Cognitive Function|Unknown status|Enrolling by invitation||100|Anticipated|University Hospital of North Norway|||4||f||||t||||||||||2018-05-31 22:46:11.709209|2018-05-31 22:46:11.709209
NCT01320293|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2016-07-08||2016-10-27|2011-03-18|2011-03-22|Estimate|2016-10-27|2016-12-26|Estimate||||2016-10-27|2016-12-26|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.|Effect of Immunomodulatory Therapy With Adalimumab on Endothelial Function in Patients With Moderate to Severe Psoriasis|Completed||N/A|18|Actual|University of North Carolina, Chapel Hill|Smaller number of subjects analyzed due to low enrollment. Technical problems with Elisa measurement leading to unreliable or uninterpretable data.|1|||f||||f||||||||No|no plan to share data|2018-05-31 22:46:11.813919|2018-05-31 22:46:11.813919
NCT01320280|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2013-04-07|2011-03-18|2011-03-22|Estimate|||||||2013-04-07|2013-04-09|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer|Single-arm, Open-label, Single-center Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer After Failure of Treatment With Docetaxel or Ineligible for Treatment With Docetaxel|Completed||Phase 2|29|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-05-31 22:46:12.034135|2018-05-31 22:46:12.034135
NCT01320267|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2014-03-14|2011-03-18|2011-03-22|Estimate|||||||2014-03-14|2014-03-17|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|SILS||Single Port Laparoscopic Colectomy|Single Incision Laparoscopic Right Hemi-colectomy Pilot Study|Withdrawn||Phase 1/Phase 2|0|Actual|University of British Columbia||1||Industry Funding Withdrawn|f||||f||||||||||2018-05-31 22:46:12.133406|2018-05-31 22:46:12.133406
NCT01320254|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2017-10-11|2011-03-21|2011-03-22|Estimate|||||||2017-10-11|2017-10-12|Actual|June 2011||2011-06-30|October 2017|2017-10-31|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional|PiCCA||PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)|Panitumumab in Combination With Cisplatin/Gemcitabine Chemotherapy in Patients With Cholangiocarcinomas - a Randomized Clinical Phase II Study|Completed||Phase 2|93|Actual|Hannover Medical School||2|||f||||t||||||||||2018-05-31 22:46:12.247371|2018-05-31 22:46:12.247371
NCT01320241|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-03-30|2011-03-21|2011-03-22|Estimate|||||||2012-03-30|2012-04-02|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture|An Unicentric RCT About Novel Radiation Stent Versus Nitinol SEMS for Palliative Treatment of Malignant Biliary Stricture|Completed||Phase 2|24|Actual|Southeast University, China||2|||f||||t||||||||||2018-05-31 22:46:12.359171|2018-05-31 22:46:12.359171
NCT01320228|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2014-09-01|2011-03-21|2011-03-22|Estimate|||||||2014-09-01|2014-09-03|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|ORLIFAT||Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor|Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor|Completed||N/A|69|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 22:46:12.428697|2018-05-31 22:46:12.428697
NCT01320215|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2017-01-30|2011-03-21|2011-03-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 12, 2017|Anticipated|2017-09-12||Interventional|RoboLaps||Complications Associated With Promontofixation for Pelvic Organ Prolapse: Comparing Robot Assisted Laparoscopic and Non-robot Assisted Laparoscopic Surgical Procedures|Complications Associated With Promontofixation for Pelvic Organ Prolapse: a Randomized Trial Comparing Robot Assisted Laparoscopic and Non-robot Assisted Laparoscopic Surgical Procedures|Active, not recruiting||N/A|364|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t||||||||||2018-05-31 22:46:12.525271|2018-05-31 22:46:12.525271
NCT01320202|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|2015-03-20||2017-04-24|2011-03-21|2011-03-22|Estimate|2015-04-22|2015-04-28|Estimate||||2017-04-24|2017-04-26|Actual|March 2011||2011-03-31|April 2017|2017-04-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|CRUISE 1|Intent-to-treat population: all randomized subjects, regardless of whether they received any investigational product.|Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients|A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study|Completed||Phase 3|305|Actual|Rockwell Medical Technologies, Inc.||2|||f||||t||||||||||2018-05-31 22:46:12.728598|2018-05-31 22:46:12.728598
NCT01320189|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-07-10|2011-03-21|2011-03-22|Estimate|||||||2013-07-10|2013-07-11|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Dietary Protein Requirements on Unbalanced Diets|Dietary Protein Requirements and Caloric Over-consumption on Unbalanced Diets|Completed||N/A|81|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 22:46:14.477491|2018-05-31 22:46:14.477491
NCT01320176|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2012-02-13|2011-03-21|2011-03-22|Estimate|||||||2012-02-13|2012-02-14|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine|An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.|Completed||Phase 1|36|Actual|Institut Pasteur||2|||f||||||||||||||2018-05-31 22:46:14.562343|2018-05-31 22:46:14.562343
NCT01320163|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2012-05-26|2011-03-18|2011-03-22|Estimate|||||||2012-05-26|2012-05-30|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Clinical Acceptability of I-GEL® in Pediatric Patients: Comparison of Clinical Performance With Classic-LMA™||Completed||N/A|108|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 22:46:14.631464|2018-05-31 22:46:14.631464
NCT01320150|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2018-05-17|2011-03-18|2011-03-22|Estimate|||||||2018-05-17|2018-05-18|Actual|March 2011||2011-03-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|August 2017|Actual|2017-08-31||Observational|PPP-TKA||Risk Factors and Mechanisms for Persistent Postsurgical Pain After Total Knee Replacement|Risk Factors and Mechanisms for Persistent Postsurgical Pain After Total Knee Replacement|Completed|||290|Actual|Rush University Medical Center|||2||f||||f||||||Samples With DNA|"~     DNA, RNA~   "|||2018-05-31 22:46:14.683722|2018-05-31 22:46:14.683722
NCT01320137|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2016-12-06||2017-05-24|2011-03-21|2011-03-22|Estimate|2016-12-06|2017-01-31|Estimate||||2017-05-24|2017-06-20|Actual|March 31, 2011|Actual|2011-03-31|May 2017|2017-05-31|May 11, 2011|Actual|2011-05-11|May 11, 2011|Actual|2011-05-11||Interventional|||Study in Allergic Adults to Support the Development of Immunological Assays|A Study in Adult Subjects With Allergy to Support the Development of Immunological Assays|Completed||N/A|80|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:46:14.749954|2018-05-31 22:46:14.749954
NCT01320124|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2015-04-22|2011-03-18|2011-03-22|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Creating a Tissue Bank of Knee Capsules|Knee Joint Contractures: Reversibility and Molecular Pathways|Withdrawn|||0|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||Samples With DNA|"~     A blood sample will be drawn from each subject and stored with the capsule tissue.~   "|||2018-05-31 22:46:14.9377|2018-05-31 22:46:14.9377
NCT01320111|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2017-02-17|2011-03-21|2011-03-22|Estimate|||||||2017-02-17|2017-02-20|Actual|July 1, 2010|Actual|2010-07-01|July 2014|2014-07-31|August 31, 2014|Actual|2014-08-31|August 31, 2014|Actual|2014-08-31||Interventional|PASO||Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment|Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer|Completed||Phase 2|59|Actual|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||2|||f||||t||||||||||2018-05-31 22:46:14.991123|2018-05-31 22:46:14.991123
NCT01320098|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-12-05|2011-03-18|2011-03-22|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Parent Training for Attention Deficit Hyperactivity Disorder (ADHD) Preschoolers|Home-Based Parent Training in ADHD Preschoolers|Completed||N/A|187|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-05-31 22:46:15.13946|2018-05-31 22:46:15.13946
NCT01320085|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14||2017-01-30|2018-05-25|2011-03-18|2011-03-22|Estimate||||2017-01-30|2017-01-31|Estimate|2018-05-25|2018-05-30|Actual|March 2011||2011-03-31|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|January 7, 2014|Actual|2014-01-07||Interventional|||A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma|A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations|Active, not recruiting||Phase 2|183|Actual|Array BioPharma||3|||f||||||||||||||2018-05-31 22:46:15.213699|2018-05-31 22:46:15.213699
NCT01320072|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2016-01-08||2017-09-26|2011-03-18|2011-03-22|Estimate|2016-04-03|2016-04-05|Estimate||||2017-09-26|2017-10-27|Actual|May 2010||2010-05-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|October 2015|Actual|2015-10-31||Observational|ASAS||Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease|Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease Using a Safe, Low Dose Aspirin Challenge|Completed|||29|Actual|Montefiore Medical Center|||2||f||||t||||||Samples With DNA|"~     urine, peripheral blood mononuclear cells, plasma~   "|No|no, patients signed informed consent that allowed us to collect data for the present study but not to share the data|2018-05-31 22:46:15.32943|2018-05-31 22:46:15.32943
NCT01320059|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2016-06-23|2011-03-18|2011-03-22|Estimate|||||||2016-06-23|2016-06-27|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of 18F-Fluoro-PEG6-IPQA|A Phase I Study of 18F-Fluoro-PEG6-IPQA as a PET Imaging Agent for Active/Mutant EGFR Expression in Tumors|Completed||Phase 1|6|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:46:15.682264|2018-05-31 22:46:15.682264
NCT01320046|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|||2015-04-07|2011-03-21|2011-03-22|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Vulvar Contact Dermatitis Resulting From Urine Incontinence|Vulvar Contact Dermatitis Resulting From Urine Incontinence: Prevalence, Characteristics and Risk Factors|Withdrawn|||0|Actual|Meir Medical Center|||3||f||||f||||||Samples Without DNA|"~     Vaginal smears taken for evaluation of vaginal estrogen status (identifying parabasal cells,~     vaginal flora, vaginal pH)~   "|||2018-05-31 22:46:15.891697|2018-05-31 22:46:15.891697
NCT01320033|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-03-06|2011-03-21|2011-03-22|Estimate|||||||2013-03-06|2013-03-08|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris|A Multi Center, Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group Study Comparing the Efficacy and Safety of CD2475/101 40 mg Tablets Versus Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjects With Acne Vulgaris|Completed||Phase 2|662|Actual|Galderma||3|||f||||f||||||||||2018-05-31 22:46:15.962939|2018-05-31 22:46:15.962939
NCT01320020|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-07-01|2011-03-21|2011-03-22|Estimate|||||||2013-07-01|2013-07-02|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients|A Phase I, Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients|Terminated||Phase 1|16|Actual|Neovii Biotech||1|||f||||t||||||||||2018-05-31 22:46:16.086067|2018-05-31 22:46:16.086067
NCT01320007|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2015-07-08|2011-03-21|2011-03-22|Estimate|||||||2015-07-08|2015-07-09|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|LIMIT-CHF||Lung Impedance Monitoring In Treatment of Chronic Heart Failure|Lung Impedance Monitoring In Treatment of Chronic Heart Failure|Completed||N/A|80|Actual|Barts & The London NHS Trust||2|||f||||f||||||||||2018-05-31 22:46:16.163368|2018-05-31 22:46:16.163368
NCT01319994|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2012-07-24|2011-03-21|2011-03-22|Estimate|||||||2012-07-24|2012-07-26|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Prevention of Metabolic Complications of Glucocorticoid Excess|Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Barts & The London NHS Trust||2|||f||||t||||||||||2018-05-31 22:46:16.238378|2018-05-31 22:46:16.238378
NCT01319981|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2018-01-26|2011-03-18|2011-03-22|Estimate|||||||2018-01-26|2018-01-30|Actual|March 5, 2013|Actual|2013-03-05|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia|Hyper-CVAD With Liposomal Vincristine (Hyper-CMAD) in Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|33|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 22:46:16.331485|2018-05-31 22:46:16.331485
NCT01319968|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|||2015-04-07|2011-03-20|2011-03-22|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Postpartum Dyspareunia Resulting From Vaginal Atrophy|Postpartum Dyspareunia Resulting From Vaginal Atrophy: Prevalence, Characteristics and Risk Factors|Completed|||117|Actual|Meir Medical Center|||1||f||||f||||||Samples Without DNA|"~     Vaginal smears for cytology and pH measurment.~   "|||2018-05-31 22:46:16.553463|2018-05-31 22:46:16.553463
NCT01319955|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2017-09-21|2011-03-21|2011-03-22|Estimate|||||||2017-09-21|2017-09-25|Actual|August 2010||2010-08-31|August 2016|2016-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Flu Vaccine Against Childhood Pneumonia, Bangladesh|Influenza Vaccine Efficacy Against Childhood Pneumonia in an Urban Tropical Setting|Completed||Phase 3|3508|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 22:46:16.628667|2018-05-31 22:46:16.628667
NCT01319942|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2011-03-21|2011-03-21|2011-03-22|Estimate|||||||2011-03-21|2011-03-22|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Observational|||Combined Radiotherapy and Sorafenib in Patients With Hepatoma|Combined Radiotherapy and Sorafenib in Patients With Hepatoma|Unknown status|Recruiting||45|Anticipated|China Medical University Hospital|||1||f||||t||||||||||2018-05-31 22:46:16.703179|2018-05-31 22:46:16.703179
NCT01319929|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18||2012-05-23|2012-05-23|2011-03-18|2011-03-22|Estimate||||2012-05-23|2012-05-31|Estimate|2012-05-23|2012-05-31|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of LY2828360 in Patients With Osteoarthritic Knee Pain|A Proof of Concept Study of the Effects of LY2828360 in the Treatment of Patients With Osteoarthritic Knee Pain.|Completed||Phase 2|39|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:46:16.807332|2018-05-31 22:46:16.807332
NCT01319916|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-18|2011-03-18|2011-03-22|Estimate|||||||2011-03-18|2011-03-22|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue|Open-Label Study to Evaluate the Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 (Sodium Deoxycholate Injection) Into Abdominal Fat Tissue|Completed||Phase 1|10|Actual|Kythera Biopharmaceuticals|||||f||||f||||||||||2018-05-31 22:46:16.929042|2018-05-31 22:46:16.929042
NCT01319903|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-01-12|2011-03-21|2011-03-22|Estimate|||||||2012-01-12|2012-01-13|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29|A Single Ascending, Placebo-controlled, Double-blind Study in Healthy Male Subjects to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the New Humanized Monoclonal Antibody CaCP29|Completed||Phase 1|26|Actual|InflaRx GmbH|||||f||||f||||||||||2018-05-31 22:46:16.978455|2018-05-31 22:46:16.978455
NCT01319890|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-03-31|2011-03-18|2011-03-22|Estimate|||||||2012-03-31|2012-04-03|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Observational|SILVERMAN 1||The 'SILVERMAN1' Trial Single Incision Laparoscopic Versus Existing Resection (Minimal Access) for Neoplasia|The 'SILVERMAN1' Trial Single Incision Laparoscopic Versus Existing Resection (Minimal Access) for Neoplasia|Unknown status|Recruiting||300|Anticipated|Irish Clinical Outcomes in Research and Education|||1||f||||t||||||||||2018-05-31 22:46:17.046552|2018-05-31 22:46:17.046552
NCT01319877|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2016-04-21||2016-07-22|2011-03-21|2011-03-22|Estimate|2016-07-22|2016-09-07|Estimate||||2016-07-22|2016-09-07|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||Safety analysis set and efficacy analysis set|An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer|A Multi-center Observational Study of Bevacizumab Plus 5-FU Based Chemotherapy as First Line and Second Line Treatment for Chinese Patients With Metastatic Colorectal Cancer (ML25391)|Completed|||609|Actual|Hoffmann-La Roche|||2||f||||f||||||||No||2018-05-31 22:46:17.225587|2018-05-31 22:46:17.225587
NCT01319864|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2016-10-17|2011-03-21|2011-03-22|Estimate|||||||2016-10-17|2016-10-19|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients|A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients|Active, not recruiting||Phase 1|21|Anticipated|Seattle Children's Hospital||1|||f||||t||||||||||2018-05-31 22:46:17.718681|2018-05-31 22:46:17.718681
NCT01319851|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2015-02-25||2017-07-24|2011-03-18|2011-03-22|Estimate|2015-02-25|2015-03-09|Estimate||||2017-07-24|2017-07-27|Actual|September 2010|Actual|2010-09-30|July 2017|2017-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation|Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation for Children With Non-Malignant Diseases Who Have Been Multiply Transfused: a Pilot Study|Terminated||N/A|3|Actual|Emory University|Production of alefacept was halted in 2011.|1||drug company is no longer making the drug|f||||t||||||||||2018-05-31 22:46:17.841673|2018-05-31 22:46:17.841673
NCT01319838|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2013-12-09|2011-03-18|2011-03-22|Estimate|||||||2013-12-09|2013-12-10|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Aflac ST1001||Aflac ST1001 Prolonged Isotretinoin|Prolonged Isotretinoin Therapy in Patients With High Risk Neuroblastoma|Withdrawn||Phase 1|0|Actual|Emory University||1||no patient enrollment|f||||t||||||||||2018-05-31 22:46:18.086858|2018-05-31 22:46:18.086858
NCT01319825|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-18|2011-03-18|2011-03-22|Estimate|||||||2011-03-18|2011-03-22|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Preventive Treatment of Episodic and Chronic Migraine|Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine.|Unknown status|Not yet recruiting|Phase 4|45|Anticipated|California Medical Clinic for Headache|||||f||||f||||||||||2018-05-31 22:46:18.157032|2018-05-31 22:46:18.157032
NCT01319812|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2016-09-02||2018-02-12|2011-03-18|2011-03-22|Estimate|2017-05-03|2017-06-05|Actual||||2018-02-12|2018-02-14|Actual|July 2011||2011-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|September 2015|Actual|2015-09-30||Interventional|BIOFLEX-I|The two arms of the BIOFLEX-I study were distinct with no overlap. Totals present here were automatically generated by the clinicaltrials.gov system. Four participants were enrolled in both the Astron and Pulsar stent groups, as allowed in the study protocol. Therefore any presented totals may not be accurate aggregates of data.|Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents|The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents|Active, not recruiting||Phase 2|463|Actual|Biotronik, Inc.||2|||f||||f||||||||No|There is no plan to share IPD.|2018-05-31 22:46:18.286187|2018-05-31 22:46:18.286187
NCT01319799|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2013-05-28||2017-02-20|2011-03-21|2011-03-22|Estimate|2017-02-20|2017-03-29|Actual||||2017-02-20|2017-03-29|Actual|November 2010||2010-11-30|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve Replacement|Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve|Completed|||10|Actual|Sahlgrenska University Hospital, Sweden|100 patients asked for participation; 10 accepted. Large outcome in descriptive study- Ended after 10 cases||1||f||||f||||||Samples Without DNA|"~     Cerebrospinal fluid levels of S100B, NSE , Tau and albumin detected by~     elctrochemoluminescence immunoassay.~   "|No||2018-05-31 22:46:19.871721|2018-05-31 22:46:19.871721
NCT01319786|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2015-10-26|2011-03-21|2011-03-22|Estimate|||||||2015-10-26|2015-10-28|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2013|Actual|2013-08-31||Interventional|PPhIT||Effect of a Polyphenol Rich Diet on Vascular and Platelet Function|Effect of a Polyphenol Rich Diet on Vascular and Platelet Function- a Randomised Control Trial|Completed||N/A|104|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 22:46:20.021343|2018-05-31 22:46:20.021343
NCT01319773|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2012-01-31||2015-08-25|2011-03-21|2011-03-22|Estimate|2012-01-31|2012-03-02|Estimate||||2015-08-25|2015-09-07|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye||Completed||Phase 1|44|Actual|Allergan||5|||f||||f||||||||||2018-05-31 22:46:20.100662|2018-05-31 22:46:20.100662
NCT01319760|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2013-05-01|2011-03-18|2011-03-22|Estimate|||||||2013-05-01|2013-05-03|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|August 2013|Anticipated|2013-08-31|March 2013|Actual|2013-03-31||Interventional|MINI-AMI||MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction|MINI-AMI: Minimizing INfarct Size With IMPELLA® 2.5 System Following PCI for Acute Myocardial Infarction|Terminated||N/A|5|Actual|Abiomed Inc.||2||Change in business priority|f||||t||||||||||2018-05-31 22:46:20.496016|2018-05-31 22:46:20.496016
NCT01319747|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2016-07-06|2011-03-21|2011-03-22|Estimate|||||||2016-07-06|2016-07-07|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|VATCAT||Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial|Video-Assisted Thoracoscopic Pulmonary Vein Isolation Versus Percutaneous Catheter Ablation in Atrial Fibrillation Trial|Terminated||N/A|77|Actual|Medisch Spectrum Twente||2||Inclusion rate insufficient|f||||f||||||||||2018-05-31 22:46:20.581718|2018-05-31 22:46:20.581718
NCT01319734|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-09-17|2011-03-21|2011-03-22|Estimate|||||||2013-09-17|2013-09-18|Estimate|February 2011||2011-02-28|September 2013|2013-09-30||||December 2015|Anticipated|2015-12-31||Interventional|Vit C||Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus|Phase 1 Study of Randomized Clinical Trial Comparing Vitamin C Supplementation Plus Oral Hypoglycemic Drugs Versus Hypoglycemic Drugs Alone on Serum Selenium, Zinc, Copper and Malondialdehyde Levels in Type 2 Diabetes Mellitus and Its Microvascular Complications|Unknown status|Recruiting|Phase 1|50|Anticipated|Al-Neelain University||2|||f||||f||||||||||2018-05-31 22:46:20.695412|2018-05-31 22:46:20.695412
NCT01319721|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|2015-03-04||2015-03-05|2011-03-21|2011-03-22|Estimate|2015-03-05|2015-03-19|Estimate||||2015-03-05|2015-03-19|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||No significant difference of the baseline characteristics was observed between the per-protocol population (n=89 eyes) and the randomized population (n=96 eyes), and there was no significant bias due to patients dropout. Therefore, the baseline participants for analysis were observed in the per-protocol population.|Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane|Limbal Conjunctival Autograft Versus Amniotic Membrane Graft When Combined With Mitomycin C for Recurrent Pterygium: A Randomized Trial|Completed||N/A|96|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:46:20.797984|2018-05-31 22:46:20.797984
NCT01319708|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2015-11-07|2011-03-21|2011-03-22|Estimate|||||||2015-11-07|2015-11-10|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing In Vitro Fertilisation|Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing In Vitro Fertilisation|Completed||Phase 1/Phase 2|50|Actual|National and Kapodistrian University of Athens||2|||f||||t||||||||||2018-05-31 22:46:21.266077|2018-05-31 22:46:21.266077
NCT01319695|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-04-30|2011-03-21|2011-03-22|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2011||2011-01-31|April 2016|2016-04-30|August 2017|Actual|2017-08-31|July 2016|Actual|2016-07-31||Interventional|||Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation||Completed||Phase 1/Phase 2|140|Actual|National and Kapodistrian University of Athens||2|||f||||||||||||||2018-05-31 22:46:21.332696|2018-05-31 22:46:21.332696
NCT01319682|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-08-01|2011-03-21|2011-03-22|Estimate|||||||2013-08-01|2013-08-02|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Effect of Intravenous Lidocaine on Pain After Lumbar Spinal Fusion|Intravenous Lidocaine for Effective Pain Relief After Posterior Lumbar Spinal Fusion: a Prospective, Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 4|54|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||f||||||||||2018-05-31 22:46:21.41458|2018-05-31 22:46:21.41458
NCT01319669|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2017-03-02|2011-03-21|2011-03-22|Estimate|||||||2017-03-02|2017-03-03|Actual|February 2011||2011-02-28|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy|Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy With GC/GP Regimens for Non-small-cell Lung Carcinoma Using Recombinant Human Thrombopoietin (rhTPO)|Terminated||Phase 2/Phase 3|11|Actual|Chinese Society of Lung Cancer||2||recruiting too slowly|f||||f||||||||||2018-05-31 22:46:21.500345|2018-05-31 22:46:21.500345
NCT01319656|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-21|||2013-12-09|2011-03-21|2011-03-22|Estimate|||||||2013-12-09|2013-12-10|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Interventional|PR1MaC||Integration of Chronic Disease Rehabilitation Services Into Primary Care|Adaptation, Implementation and Evaluation of an Intervention Involving the Integration of Chronic Disease Rehabilitation Services Into Primary Care|Completed||N/A|326|Actual|Université de Sherbrooke||3|||f||||f||||||||||2018-05-31 22:46:21.583079|2018-05-31 22:46:21.583079
NCT01319643|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-03-21|2011-03-21|2011-03-22|Estimate|||||||2011-03-21|2011-03-22|Estimate|December 2009||2009-12-31|August 2010|2010-08-31|November 2011|Anticipated|2011-11-30|November 2010|Anticipated|2010-11-30||Interventional|OXYGEN-ICU||Normal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU)|Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|660|Anticipated|University of Modena and Reggio Emilia||2|||f||||f||||||||||2018-05-31 22:46:21.680762|2018-05-31 22:46:21.680762
NCT01319630|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2017-01-24|2011-03-18|2011-03-21|Estimate|||||||2017-01-24|2017-01-26|Estimate|April 2011||2011-04-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|December 2013|Actual|2013-12-31||Observational|||The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients|The Effect of Three Different Fluids(Albumin 5%, Normal Saline, HES 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients Using Sidestream Dark Field (SDF) Microscopy and Near-Infrared Spectroscopy (NIRS) Analysis|Completed|||45|Actual|Mercy Research|||3||f||||f||||||||||2018-05-31 22:46:21.778223|2018-05-31 22:46:21.778223
NCT01319617|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2013-06-04||2013-09-04|2011-03-18|2011-03-21|Estimate|2013-09-04|2013-09-09|Estimate||||2013-09-04|2013-09-09|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||SENSIMED Triggerfish Safety and Tolerability|Evaluation of SENSIMED Triggerfish Safety and Tolerability in Glaucoma Patients and Glaucoma Suspects|Completed||N/A|41|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 22:46:21.867076|2018-05-31 22:46:21.867076
NCT01319604|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-08-07|2011-03-18|2011-03-21|Estimate|||||||2012-08-07|2012-08-08|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||SENSIMED Triggerfish|Randomized Clinical Investigation to Assess the Efficacy of SENSIMED Triggerfish Continuous IOP Monitoring|Completed||N/A|59|Actual|Sensimed AG||9|||f||||f||||||||||2018-05-31 22:46:22.006466|2018-05-31 22:46:22.006466
NCT01319591|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2017-02-06|2011-03-18|2011-03-21|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|September 1, 2018|Anticipated|2018-09-01|August 2014|Actual|2014-08-31||Observational|||Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate|Comparison of Creatinine Clearance Calculation Methods for Estimation of Glomerular Filtration Rate in Patients Receiving High-Dose Methotrexate|Active, not recruiting|||40|Anticipated|Dana-Farber Cancer Institute|||1||f||||t||||||||No||2018-05-31 22:46:22.177985|2018-05-31 22:46:22.177985
NCT01319578|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-11-11|2011-03-18|2011-03-21|Estimate|||||||2011-11-11|2011-11-15|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum|A Single Blind Pharmacodynamic Study to Assess the Phosphate Binding Characteristics of K2CG Chewing Gum|Completed||N/A|36|Anticipated|Denver Nephrologists, P.C.||4|||f||||f||||||||||2018-05-31 22:46:22.238023|2018-05-31 22:46:22.238023
NCT01319565|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2018-05-23|2011-03-18|2011-03-21|Estimate|||||||2018-05-23|2018-05-24|Actual|March 18, 2011||2011-03-18|May 9, 2018|2018-05-09|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI|Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI)|Active, not recruiting||Phase 2|102|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:46:22.31988|2018-05-31 22:46:22.31988
NCT01319552|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2014-03-10||2015-05-15|2011-03-18|2011-03-21|Estimate|2015-05-15|2015-06-02|Estimate||||2015-05-15|2015-06-02|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Fresh Versus Old Red Blood Cells for Transfusion|Immunomodulatory Properties of Fresh Versus Stored Packed Red Blood Cells for Transfusion|Completed||N/A|14|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 22:46:22.40925|2018-05-31 22:46:22.40925
NCT01319539|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2016-10-14||2017-08-01|2011-03-18|2011-03-21|Estimate|2017-07-05|2017-08-01|Actual||||2017-08-01|2017-08-30|Actual|April 2011||2011-04-30|August 2017|2017-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer|Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer|Terminated||Phase 2|12|Actual|National Cancer Institute (NCI)||1||terminated early, due to toxicity|f||||||||||||No||2018-05-31 22:46:22.591836|2018-05-31 22:46:22.591836
NCT01319526|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-18|||2015-10-01|2011-03-18|2011-03-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy|Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)|Terminated|||1|Actual|AIDS Malignancy Consortium||||Parent protocol (SWOG S0816 / AMC-073) discontinued|f||||f||||||Samples With DNA|"~     PBMC~   "|||2018-05-31 22:46:22.876363|2018-05-31 22:46:22.876363
NCT01319513|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-18|2011-03-18|2011-03-21|Estimate|||||||2011-03-18|2011-03-21|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Post-exercise Dietary Protein Strategies|The Effect of the Pattern Post-exercise Aminoacidemia on Myofibrillar Protein Synthesis|Completed||N/A|8|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 22:46:22.957174|2018-05-31 22:46:22.957174
NCT01319500|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2012-08-15||2012-10-17|2011-03-18|2011-03-21|Estimate|2012-10-17|2012-11-20|Estimate||||2012-10-17|2012-11-20|Estimate|February 2009||2009-02-28|October 2012|2012-10-31||||||||Observational|||Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia|Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia|Completed|||3776|Actual|Center for Epidemiology and Health Research, Germany|||2||f||||t||||||||||2018-05-31 22:46:23.066454|2018-05-31 22:46:23.066454
NCT01319487|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-08-22|2011-03-18|2011-03-21|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy|A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy|Completed||Phase 2|267|Actual|Fovea Pharmaceuticals SA||3|||f||||t||||||||||2018-05-31 22:46:23.502119|2018-05-31 22:46:23.502119
NCT01319474|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2018-03-01|2011-03-17|2011-03-21|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2011||2011-02-28|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31||Interventional|CLOT-3||Whole-leg Ultrasound in Pregnant Patients|Use of Whole-leg Ultrasound for Diagnosis of Deep Vein Thrombosis in Pregnant Patients|Recruiting||N/A|268|Anticipated|Intermountain Health Care, Inc.||1|||f||||f||||||||||2018-05-31 22:46:23.70313|2018-05-31 22:46:23.70313
NCT01319461|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-23|2011-03-18|2011-03-21|Estimate|||||||2011-03-23|2011-03-25|Estimate|May 2001||2001-05-31|March 2011|2011-03-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee|Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee: a Randomized, Masked Observed, Double Blind, Placebo Controlled, Multicenter Clinical Trial.|Completed||Phase 3|200|Actual|Med Pharma Co., Ltd.||2|||f||||t||||||||||2018-05-31 22:46:23.788483|2018-05-31 22:46:23.788483
NCT01315730|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-05-09|2011-03-14|2011-03-15|Estimate|||||||2014-05-09|2014-05-12|Estimate|March 2011||2011-03-31|May 2014|2014-05-31||||||||Interventional|||The Effects of Tactile Speech Feedback on Stuttering Frequency|The Effects of Tactile Speech Feedback on Stuttering Frequency|Withdrawn||Phase 1|0|Actual|University of Mississippi, Oxford||1||Patent being pursued prior to trial initiation|f||||f||||||||||2018-05-31 22:47:17.064616|2018-05-31 22:47:17.064616
NCT01319448|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2014-03-20|2011-03-18|2011-03-21|Estimate|||||||2014-03-20|2014-03-21|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease|Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia.|Completed||Phase 1/Phase 2|270|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-05-31 22:46:23.890154|2018-05-31 22:46:23.890154
NCT01319435|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2015-10-09|2011-03-18|2011-03-21|Estimate|||||||2015-10-09|2015-10-12|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|TINN-PK||TINN Pharmacokinetics (PK) Study Treat Infections iN Neonates|Phase I, Open-label Study to Evaluate the Pharmacokinetics and Tolerability of Ciprofloxacin in Neonates With Suspected or Proven Gram Negative Infection|Completed||Phase 1|63|Actual|Liverpool Women's NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 22:46:23.966656|2018-05-31 22:46:23.966656
NCT01319422|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2016-05-09||2016-06-29|2011-03-17|2011-03-21|Estimate|2016-06-29|2016-08-11|Estimate||||2016-06-29|2016-08-11|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma|Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|40|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:46:24.053191|2018-05-31 22:46:24.053191
NCT01319409|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2016-01-04|2011-03-17|2011-03-21|Estimate|||||||2016-01-04|2016-01-05|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Single- vs. Double-Bundle ACL Reconstruction|Single- vs. Double-Bundle ACL Reconstruction: A Prospective Randomized Trial|Completed||Phase 2|57|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:46:24.622423|2018-05-31 22:46:24.622423
NCT01319396|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2011-07-18||2011-07-18|2011-03-18|2011-03-21|Estimate|2011-07-18|2011-08-15|Estimate||||2011-07-18|2011-08-15|Estimate|October 2010||2010-10-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|||Performance Validation of a Non-contact Breathing Frequency Monitor (Model BM07)|Performance Validation of a Non-contact Breathing Frequency Monitor (Model BM07)|Completed|||24|Actual|ResMed|||||f||||f||||||||||2018-05-31 22:46:24.688861|2018-05-31 22:46:24.688861
NCT01319383|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2017-02-09||2017-05-30|2011-03-18|2011-03-21|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|February 2011||2011-02-28|April 2017|2017-04-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|||The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART|A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy|Completed||Phase 1/Phase 2|25|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-05-31 22:46:24.943921|2018-05-31 22:46:24.943921
NCT01319370|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2013-11-06|2011-03-18|2011-03-21|Estimate|||||||2013-11-06|2013-11-07|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia|Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks|Completed||Phase 2|70|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:46:25.232077|2018-05-31 22:46:25.232077
NCT01319357|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-02-11|2011-03-17|2011-03-21|Estimate|||||||2014-02-11|2014-02-12|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ESENDI||Effects of Saxagliptin on Endothelial Function|Effects of Saxagliptin on Endothelial Function in Patients With Type 2 Diabetes|Completed||Phase 3|52|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 22:46:25.308635|2018-05-31 22:46:25.308635
NCT01319344|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2013-04-16|2011-03-17|2011-03-21|Estimate|||||||2013-04-16|2013-04-17|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|MetSyn||Effect of Eplerenone on Endothelial Function in Metabolic Syndrome|Prospective and Open Label Study With Blind End Point Evaluation on the Effect of Mineralocorticoid Receptor Inhibition on Endothelial Function of the Micro- and Macrovasculature in Patients With Metabolic Syndrome|Completed||Phase 3|42|Actual|University of Erlangen-Nürnberg Medical School||1|||f||||t||||||||||2018-05-31 22:46:25.376053|2018-05-31 22:46:25.376053
NCT01319331|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2017-03-23|2011-03-18|2011-03-21|Estimate|||||||2017-03-23|2017-03-24|Actual|October 2010||2010-10-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional|||The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes|The Effects of Open Label Alpha-1 Antitrypsin on the Progression of Type 1 Diabetes in Subjects With Detectable C-peptide|Completed||Phase 1|12|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 22:46:25.434839|2018-05-31 22:46:25.434839
NCT01319318|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2013-04-15||2013-04-15|2011-03-18|2011-03-21|Estimate|2013-04-15|2013-07-02|Estimate||||2013-04-15|2013-07-02|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy||Completed|||25|Actual|Allergan|||1||f||||f||||||||||2018-05-31 22:46:25.498067|2018-05-31 22:46:25.498067
NCT01319305|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-06-27|2011-03-18|2011-03-21|Estimate|||||||2011-06-27|2011-06-28|Estimate|April 2010||2010-04-30|June 2011|2011-06-30||||June 2011|Actual|2011-06-30||Observational|||BREATHE Long-Term Follow-Up Study|BREATHE Long-Term Follow-Up Study|Completed|||70|Anticipated|Entellus Medical, Inc.|||1||f||||f||||||||||2018-05-31 22:46:25.597575|2018-05-31 22:46:25.597575
NCT01319292|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-08-01|2011-03-18|2011-03-21|Estimate|||||||2014-08-01|2014-08-04|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Observational|||To Investigate the Prevalence of Children Asthma in China|To Investigate the Prevalence of Children Asthma in China and Compare With That of the Last 20 Years|Completed|||20000|Actual|Capital Institute of Pediatrics, China|||2||f||||||||||||||2018-05-31 22:46:25.655489|2018-05-31 22:46:25.655489
NCT01319279|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2012-04-20|2011-03-18|2011-03-21|Estimate|||||||2012-04-20|2012-04-24|Estimate|April 2011||2011-04-30|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics of the Hydrocodone Bitartrate Extended-Release Tablet (15 mg) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment|Completed||Phase 1|16|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 22:46:25.70863|2018-05-31 22:46:25.70863
NCT01319266|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2012-04-20|2011-03-17|2011-03-21|Estimate|||||||2012-04-20|2012-04-24|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics of the Hydrocodone Bitartrate Extended-Release Tablet (45 mg) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment|Completed||Phase 1|55|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-05-31 22:46:25.767439|2018-05-31 22:46:25.767439
NCT01319253|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2015-11-05|2011-03-18|2011-03-21|Estimate|||||||2015-11-05|2015-11-06|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2012|Actual|2012-07-31||Observational|||A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies|Comparator Trial Evaluating Microbiological Resistance and Clinical Efficacy in Patients Using Alternation Therapy of Inhaled Antibiotics|Completed|||27|Actual|Indiana University|||3||f||||f||||||||||2018-05-31 22:46:25.829976|2018-05-31 22:46:25.829976
NCT01319240|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2015-10-01|2011-03-18|2011-03-21|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects|A Trial to Investigate Pharmacokinetics, Safety and Tolerability of Insulin Degludec/Liraglutide (A3) Compared With Insulin Degludec and Liraglutide in Healthy Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 22:46:26.827728|2018-05-31 22:46:26.827728
NCT01319227|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2016-08-29|2011-03-18|2011-03-21|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|August 2023|Anticipated|2023-08-31|August 2013|Actual|2013-08-31||Interventional|PeriBRUSBRAC||Periprosthetic Bone Remodeling Around Uncemented Components in Total Hip Arthroplasty|Periprosthetic Bone Remodeling Around Two Different Types of Uncemented Femoral Stems and Two Uncemented Acetabular Components in Total Hip Arthroplasty|Active, not recruiting||N/A|51|Actual|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 22:46:26.894401|2018-05-31 22:46:26.894401
NCT01319214|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-05-18|2011-03-18|2011-03-21|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Reducing Drug Craving Memories|Reconsolidation as a Treatment Target for Cocaine Addiction|Unknown status|Not yet recruiting|N/A|60|Anticipated|McGill University Health Center||4|||f||||f||||||||||2018-05-31 22:46:26.955918|2018-05-31 22:46:26.955918
NCT01319201|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-18|2011-03-18|2011-03-21|Estimate|||||||2011-03-18|2011-03-21|Estimate|April 2010||2010-04-30|March 2011|2011-03-31||||||||Observational|||Subclinical Atherosclerosis Using Dual-source CT Coronary Angiography in Chinese Adults With Different Glycaemic Status|Assessment of Subclinical Atherosclerosis Using Dual-source Computed Tomography Coronary Angiography in Chinese Adults With Different Glycaemic Status|Unknown status|Active, not recruiting||600|Actual|Shanghai Jiao Tong University School of Medicine|||3||f||||t||||||Samples With DNA|"~     Blood and urine samples were collected and retained for biomarker analysis~   "|||2018-05-31 22:46:27.011344|2018-05-31 22:46:27.011344
NCT01319188|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2015-05-17|2011-03-18|2011-03-21|Estimate|||||||2015-05-17|2015-05-19|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|October 2012|Actual|2012-10-31||Interventional|RATE||Ranibizumab and the Risk of Arterial Thromboembolic Events|Ranibizumab for Age-Related Macular Degeneration and the Risk of Arterial Thromboembolic Events (RATE)|Terminated||Phase 4|380|Actual|Ural Medical University||3||"The study was terminated under the political pressure of the Federal Security Service of the~   Russian Federation (FSB) and the Russian Society of Cardiology"|f||||t||||||||||2018-05-31 22:46:27.068993|2018-05-31 22:46:27.068993
NCT01319175|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-18|2011-03-18|2011-03-21|Estimate|||||||2011-03-18|2011-03-21|Estimate||||July 2010|2010-07-31||||||||Interventional|||Hip-Flexion Strength Training: Can Elastic Bands Induce a Relevant Effect?||Completed||N/A|||Amager Hospital||1|||f||||t||||||||||2018-05-31 22:46:27.147443|2018-05-31 22:46:27.147443
NCT01319162|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2017-03-15|2011-03-18|2011-03-21|Estimate|||||||2017-03-15|2017-03-16|Actual|March 30, 2011|Actual|2011-03-30|March 2017|2017-03-31|January 11, 2017|Actual|2017-01-11|January 11, 2017|Actual|2017-01-11||Observational|||Prevalence of Polycystic Ovary Syndrome (PCOS) in Obese Premenopausal Women|To Estimate the Prevalence of PCOS in Obese Premenopausal Women and Elucidate How They Respond to a Weight Reduction Treatment Program|Completed|||300|Actual|Göteborg University|||2||f||||f||||||||||2018-05-31 22:46:27.200198|2018-05-31 22:46:27.200198
NCT01319149|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-09-11|2011-03-18|2011-03-21|Estimate|||||||2012-09-11|2012-09-13|Estimate|November 2010||2010-11-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Study of the Effects of Molecular Diagnostic Directed Wound Gels on Wound Care Outcomes|A Retrospective Study Of the Effects of Molecular Diagnostic Directed Wound Gels on Wound Care Outcomes|Completed|||400|Actual|Southwest Regional Wound Care Center|||1||f||||f||||||||||2018-05-31 22:46:27.337107|2018-05-31 22:46:27.337107
NCT01319136|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2011-03-18|2011-03-18|2011-03-21|Estimate|||||||2011-03-18|2011-03-21|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Improved Analysis Methods for Infusion Tests|Novel Infusion Method for Describing CSF Dynamics|Completed|||48|Actual|Umeå University|||||f||||f||||||||||2018-05-31 22:46:27.39678|2018-05-31 22:46:27.39678
NCT01319123|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-10-29|2011-03-17|2011-03-21|Estimate|||||||2012-10-29|2012-10-30|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluate the Impact of Drawtex in Venous Leg Ulcers|Clinical Study to Comparatively Evaluate the Impact of Drawtex Wound Dressing Against Wound Bioburden in Moderately to Highly Exuding Venous Leg Ulcers|Completed||N/A|10|Actual|Southwest Regional Wound Care Center||1|||f||||f||||||||||2018-05-31 22:46:27.451754|2018-05-31 22:46:27.451754
NCT01319110|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2017-03-20||2017-07-03|2011-03-18|2011-03-21|Estimate|2017-03-20|2017-04-28|Actual||||2017-07-03|2017-07-31|Actual|February 2011|Actual|2011-02-28|July 2017|2017-07-31|December 31, 2011|Actual|2011-12-31|December 31, 2011|Actual|2011-12-31||Interventional|||Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation|Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation|Completed||Phase 2|10|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 22:46:27.560332|2018-05-31 22:46:27.560332
NCT01319097|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-09-07|2011-03-17|2011-03-21|Estimate|||||||2011-09-07|2011-09-08|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study to Evaluate the Effect of Sorbion Sachet S Wound Dressing|Clinical Study of Evaluate the Effect of Sorbion Sachet S Wound Dressing on Soft Tissue Edema and Wound Bioburden in Moderately to Highly Exuding Pressure Ulcers|Completed||N/A|5|Actual|Southwest Regional Wound Care Center||1|||f||||f||||||||||2018-05-31 22:46:27.781102|2018-05-31 22:46:27.781102
NCT01319084|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2012-01-31|2011-03-18|2011-03-21|Estimate|||||||2012-01-31|2012-02-02|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Development of a Versatile Intra-operative On-screen Audiovisual Mentoring System Using TileproTM Program for Robotic Gastrectomy|Development of a Versatile Intra-operative On-screen Audiovisual Mentoring System Using TileproTM Program for Robotic Gastrectomy|Unknown status|Recruiting||60|Anticipated|Yonsei University|||2||f||||t||||||||||2018-05-31 22:46:27.857953|2018-05-31 22:46:27.857953
NCT01319071|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-03-17|2011-03-17|2011-03-21|Estimate|||||||2011-03-17|2011-03-21|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Genetic Polymorphism and Israeli Top-level Athletes||Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 22:46:27.914266|2018-05-31 22:46:27.914266
NCT01319058|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-10-15|2011-03-18|2011-03-21|Estimate|||||||2016-10-15|2016-10-18|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|TVLOD||Outcome of Laser or Debrider Tonsillotomy Versus Tonsillectomy in Obstructive Sleep Apnea|Laser or Debrider Tonsillotomy Versus Monopolar Tonsillectomy in Obstructive Sleep Apnea; Inflammation as a Determinate of Outcome|Completed||N/A|88|Actual|Soroka University Medical Center||3|||f||||f||||||||||2018-05-31 22:46:27.974407|2018-05-31 22:46:27.974407
NCT01319045|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2014-12-03||2015-01-13|2011-03-18|2011-03-21|Estimate|2014-12-16|2014-12-29|Estimate||||2015-01-13|2015-01-26|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease||Terminated||N/A|5|Actual|University of California, Los Angeles|Enrollment was too slow. The trial was discontinued.|1||enrollment was too slow|f||||f||||||||||2018-05-31 22:46:28.062445|2018-05-31 22:46:28.062445
NCT01319032|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-03-17|2011-03-17|2011-03-21|Estimate|||||||2011-03-17|2011-03-21|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Genetic Polymorphism and Israeli Top-level Swimmers' Performance and Expertise||Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 22:46:28.19901|2018-05-31 22:46:28.19901
NCT01319019|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2016-11-30|2011-03-17|2011-03-21|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|437|Actual|GlaxoSmithKline||8|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:46:28.271705|2018-05-31 22:46:28.271705
NCT01319006|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2017-06-22|2011-03-17|2011-03-21|Estimate|||||||2017-06-22|2017-06-26|Actual|February 25, 2011|Actual|2011-02-25|June 2017|2017-06-30|April 18, 2011|Actual|2011-04-18|April 18, 2011|Actual|2011-04-18||Interventional|||Relative Bioavailability Study for GSK1278863A|A Randomized, Open-label, 3-period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of Single Oral 100mg Doses of GSK1278863A|Completed||Phase 1|30|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:46:28.542736|2018-05-31 22:46:28.542736
NCT01318993|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2017-07-05|2014-03-13|2017-08-16|2011-03-17|2011-03-21|Estimate|2017-08-16|2017-09-14|Actual|2014-03-13|2014-04-11|Estimate|2017-08-16|2017-09-14|Actual|April 1, 2011||2011-04-01|July 2017|2017-07-31|October 29, 2013|Actual|2013-10-29|September 1, 2013|Actual|2013-09-01||Interventional|SHIELD-3|The safety population included all the participants who received at least one dose of the study drug.|Open-Label Extension Study of GSK1605786A|An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects With Crohn's Disease|Terminated||Phase 3|399|Actual|GlaxoSmithKline||1||"This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based~   on the results of Study CCX114151."|f||||t||||||||||2018-05-31 22:46:28.813234|2018-05-31 22:46:28.813234
NCT01318980|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2017-08-01|2011-03-17|2011-03-21|Estimate|||||||2017-08-01|2017-08-03|Actual|September 30, 2010|Actual|2010-09-30|August 2017|2017-08-31|March 11, 2011|Actual|2011-03-11|March 11, 2011|Actual|2011-03-11||Interventional|||A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A|A Single Dose, Crossover Study in Healthy Female Subjects to Assess the Regional Absorption and Bioavailability of 100 mg GSK2190915A|Completed||Phase 1|14|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:46:30.04185|2018-05-31 22:46:30.04185
NCT01318967|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2014-12-08||2017-11-02|2011-03-18|2011-03-21|Estimate|2015-04-08|2015-04-10|Estimate||||2017-11-02|2017-11-06|Actual|October 2010||2010-10-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Measurement of Kidney Blood Flow and Oxygen Levels by MRI|MRI for the Non-invasive Determination of Renal Blood Flow and Renal Oxygenation|Completed||N/A|10|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 22:46:30.150844|2018-05-31 22:46:30.150844
NCT01318954|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2015-10-28|2011-03-17|2011-03-21|Estimate|||||||2015-10-28|2015-10-29|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis|The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis|Completed|||17|Actual|Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|||1||f||||f||||||||||2018-05-31 22:46:30.299778|2018-05-31 22:46:30.299778
NCT01318941|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-05-20|2011-03-17|2011-03-21|Estimate|||||||2016-05-20|2016-05-23|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|LUMINOUS||Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting|LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes|Completed|||30490|Actual|Novartis|||1||f||||||||||||||2018-05-31 22:46:30.474864|2018-05-31 22:46:30.474864
NCT01318928|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2013-11-19|2011-03-18|2011-03-21|Estimate|||||||2013-11-19|2013-11-20|Estimate|January 2008||2008-01-31|November 2013|2013-11-30|October 2016|Anticipated|2016-10-31|September 2010|Actual|2010-09-30||Interventional|||The Treatment of Periodontal Diseases|The Treatment of Periodontal Diseases. A Randomized, Blinded, Five Years Follow-up, Four-arm, Placebo Controlled Clinical Intervention Trial|Unknown status|Active, not recruiting|Phase 4|184|Actual|University of Oslo||1|||f||||t||||||||||2018-05-31 22:46:31.328684|2018-05-31 22:46:31.328684
NCT01318915|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2017-05-17||2017-10-25|2011-03-17|2011-03-21|Estimate|2017-10-02|2017-10-04|Actual||||2017-10-25|2017-12-02|Actual|July 25, 2011|Actual|2011-07-25|October 2017|2017-10-31|August 25, 2017|Actual|2017-08-25|June 17, 2016|Actual|2016-06-17||Interventional|RESTARRT|Enrolled participants|Research Study of ATG and Rituximab in Renal Transplantation|Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenolate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients|Terminated||Early Phase 1|10|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The stopping rule for the incidence of rejection was met in December 2015, and enrollment was stopped in January 2016. After another rejection in May 2016, all subjects were removed from protocol therapy and into reduced safety follow-up.|1||The stopping rule for incidence of acute rejection was met.|f||||t|t|f||||||Yes|The plan is to provide data access to the public in the Immunology Database and Analysis Portal (ImmPort, http://www.immport.org/) upon completion of the study. ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 22:46:31.449597|2018-05-31 22:46:31.449597
NCT01318902|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2018-04-12|2011-03-18|2011-03-21|Estimate|||||||2018-04-12|2018-04-13|Actual|May 19, 2011|Actual|2011-05-19|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|December 6, 2013|Actual|2013-12-06||Interventional|||Study of Oral IXAZOMIB in Adult Patients With Relapsed or Refractory Light Chain Amyloidosis|An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of IXAZOMIB (MLN9708) Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain Amyloidosis Who Require Further Treatment|Active, not recruiting||Phase 1|27|Actual|Takeda||1|||f||||f||||||||||2018-05-31 22:46:31.767653|2018-05-31 22:46:31.767653
NCT01318889|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-07-05|2011-03-18|2011-03-21|Estimate|||||||2011-07-05|2011-07-06|Estimate|September 2010||2010-09-30|June 2010|2010-06-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Dexpanthenol Mouthwash to Treat Oral Mucositis|Effects of Topical Dexpanthenol on Chemotherapy and Radiotherapy Induced Oral Mucositis|Unknown status|Recruiting|Phase 2|30|Anticipated|Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:46:31.858793|2018-05-31 22:46:31.858793
NCT01318876|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|2012-07-09||2012-08-15|2011-03-18|2011-03-21|Estimate|2012-07-09|2012-08-14|Estimate||||2012-08-15|2012-08-21|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Surveillance for Adverse Events Following Influenza Immunization|Active Surveillance of Adverse Events Following Immunization Among Healthcare Workers Immunized With the Influenza Vaccine|Completed|||7645|Actual|PHAC/CIHR Influenza Research Network|Only 70% answered the 2 surveys. We don't know why 30% didn't complete the 2 surveys (were they too sick or not motivated).We didn't have a group of comparable unvaccinated individuals (to estimate the risks attributable to the vaccine).||7||f||||f||||||||||2018-05-31 22:46:31.954695|2018-05-31 22:46:31.954695
NCT01318863|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-11-03|2011-03-17|2011-03-21|Estimate|||||||2011-11-03|2011-11-07|Estimate|April 2011||2011-04-30|September 2011|2011-09-30||||September 2011|Actual|2011-09-30||Observational|||A Normal Donor Sample Collection Study in Healthy Adults|A Normal Donor Sample Collection Study in Healthy Adults|Completed|||300|Anticipated|Astute Medical, Inc.|||||f||||f||||||||||2018-05-31 22:46:32.125313|2018-05-31 22:46:32.125313
NCT01318850|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-18|||2016-02-19|2011-03-18|2011-03-21|Estimate|||||||2016-02-19|2016-02-22|Estimate|January 2008||2008-01-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Cognitive Remediation Therapy on Schizophrenia Patients Through Functional Magnetic Resonance Imaging|Analysis of the Effects of Cognitive Remediation Therapy on Schizophrenia Patients Through fMRI Techniques|Completed||N/A|45|Actual|Hospital Clinic of Barcelona||3|||f||||t||||||||||2018-05-31 22:46:32.182621|2018-05-31 22:46:32.182621
NCT01318837|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-07-09|2011-03-17|2011-03-21|Estimate|||||||2014-07-09|2014-07-10|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|RESORT-2||A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment|Reproducibility Study of OABSS and Its Response to Solifenacin Treatment (RESORT) and Validity in Korean Populations; Part 2: Responsiveness and Validity|Completed||Phase 4|100|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:46:32.260492|2018-05-31 22:46:32.260492
NCT01318824|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-03-22|2011-03-18|2011-03-21|Estimate|||||||2011-03-22|2011-03-23|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|February 2013|Anticipated|2013-02-28|January 2011|Actual|2011-01-31||Interventional|BIPAP||A Study of Bi-Level Positive Airway Pressure (BIPAP) Versus Non Invasive Positive Pressure Ventilation (NIPPV) for Neonatal Respiratory Failure|A Study of Bi-Level Positive Airway Pressure (BIPAP) Versus Non Invasive Positive Pressure Ventilation (NIPPV) for Neonatal Respiratory Failure|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 22:46:32.330106|2018-05-31 22:46:32.330106
NCT01318811|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-05-06|2011-03-17|2011-03-18|Estimate|||||||2016-05-06|2016-05-09|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation|A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU|Recruiting||Phase 4|200|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-05-31 22:46:32.390598|2018-05-31 22:46:32.390598
NCT01318798|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2015-02-09|2011-03-17|2011-03-18|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Development and Validation of an Enhanced Prediction Score for Postoperative Acute Renal Failure After Liver Resection|Development and Validation of an Enhanced Prediction Score for Post-operative Acute Renal Failure Following Liver Resection|Completed|||549|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 22:46:32.464032|2018-05-31 22:46:32.464032
NCT01318785|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-09-05|2011-03-17|2011-03-18|Estimate|||||||2011-09-05|2011-09-07|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|November 2011|Anticipated|2011-11-30|October 2011|Anticipated|2011-10-31||Interventional|BF09-PH-01||Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications|Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications (Therapeutische Bewertung Von Armkompressionsstrümpfen für Lymphatische Indikationen BF09-PH-01)|Unknown status|Recruiting|Phase 2|40|Anticipated|University Medicine Greifswald||2|||f||||t||||||||||2018-05-31 22:46:32.527155|2018-05-31 22:46:32.527155
NCT01318772|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-03-17|2011-03-17|2011-03-18|Estimate|||||||2011-03-17|2011-03-18|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Clinical Image Evaluation for the DREX-KL80 Imaging System|Clinical Image Evaluation for the KALARE (DREX-KL80) With New Digital Camera and Image Processor|Completed|||42|Actual|Toshiba America Medical Systems, Inc.|||1||f||||t||||||||||2018-05-31 22:46:32.607779|2018-05-31 22:46:32.607779
NCT01318759|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-03-17|2011-03-17|2011-03-18|Estimate|||||||2011-03-17|2011-03-18|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|MIGA||(MIGA) Mini Geriatric Assessment To Replace the Comprehensive Geriatric Assessment|(MIGA) Mini Geriatric Assessment as Compared to the Current CGA|Unknown status|Recruiting||400|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 22:46:32.806555|2018-05-31 22:46:32.806555
NCT01318746|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2018-01-11|2011-03-17|2011-03-18|Estimate|||||||2018-01-11|2018-01-12|Actual|April 2011||2011-04-30|January 2018|2018-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|Potassium||The Circadian Rhythm of Potassium and Cystatin C|The Circadian Rhythm of Potassium and Cystatin c and the Day-to-day Variability|Completed|||30|Actual|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-05-31 22:46:32.863457|2018-05-31 22:46:32.863457
NCT01318733|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2013-09-19|2012-07-23|2014-03-17|2011-03-17|2011-03-18|Estimate|2013-12-06|2014-01-08|Estimate|2012-07-23|2012-07-31|Estimate|2014-03-17|2014-04-14|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea|Completed||Phase 3|449|Actual|Galderma||1|||f||||f||||||||||2018-05-31 22:46:33.005705|2018-05-31 22:46:33.005705
NCT01318720|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2015-04-06|2011-03-17|2011-03-18|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Short-Term Effects of Combined Manual Therapy to the Cervical and Thoracic Spine|Short-Term Combined Effects of Thoracic Spine Thrust Manipulation and Cervical Spine Non-Thrust Manipulation in Patients With Mechanical Neck Pain: A RCT|Completed||N/A|64|Actual|Masefield and Cavallaro Physical Therapy||1|||f||||f||||||||||2018-05-31 22:46:33.227042|2018-05-31 22:46:33.227042
NCT01318707|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2012-07-23|2011-03-17|2011-03-18|Estimate|||||||2012-07-23|2012-07-24|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Biomarkers Serum Collection Methodology Pilot Study|Biomarkers Serum Collection Methodology Pilot Study|Completed|||20|Actual|Georgetown University|||||f||||f||||||||||2018-05-31 22:46:33.285086|2018-05-31 22:46:33.285086
NCT01318694|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2016-08-05||2016-08-05|2011-03-17|2011-03-18|Estimate|2016-08-05|2016-09-30|Estimate||||2016-08-05|2016-09-30|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Full Analysis Set (FAS), defined as all participants to whom study treatment was correctly assigned.|Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants|A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve Patients|Completed||Phase 3|1081|Actual|Debiopharm International SA|In April 2012, ALV and placebo were discontinued in all participants. Participants remained on PEG and RBV treatment.|4|||f||||t||||||||||2018-05-31 22:46:33.45826|2018-05-31 22:46:33.45826
NCT01318681|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2013-11-07|2011-03-17|2011-03-18|Estimate|||||||2013-11-07|2013-11-08|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Rhinitis, Cognition and Driving Performance|Effects of Treated and Untreated Allergic Rhinitis on Mood, Cognitive Functions and Actual Driving Performance|Completed||N/A|22|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 22:46:34.65037|2018-05-31 22:46:34.65037
NCT01318668|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2013-03-01|2011-03-17|2011-03-18|Estimate|||||||2013-03-01|2013-03-04|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EPU057||A Fmri Study on the Effects of a Conjugate Vaccine and Placebo on CNS Activation and Behavior Following a Nicotine Challenge|An fMRI-study on the Effects of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein a Conjugate Vaccine (NicVAX®) and Placebo on Central Nervous System Activation and Behaviour Following a Nicotine Challenge|Completed||Phase 1/Phase 2|38|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 22:46:34.705943|2018-05-31 22:46:34.705943
NCT01318655|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-08-24|2011-03-17|2011-03-18|Estimate|||||||2011-08-24|2011-08-25|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Japan SMAD||Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of NKTR-118 Following Single and Multiple Ascending Oral Dose Administration in Healthy Young and Elderly Japanese Subjects, and an Open Randomized, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics After Single Oral Doses of NKTR-118 in Healthy Male Japanese Subjects|Completed||Phase 1|50|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:46:34.766312|2018-05-31 22:46:34.766312
NCT01318642|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17||2014-05-29|2014-08-06|2011-03-17|2011-03-18|Estimate||||2014-05-29|2014-06-02|Estimate|2014-08-06|2014-08-08|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of AMG 479 or Placebo in Combination With Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas|Terminated||Phase 2|10|Actual|Amgen||2||NCT01318642: Planned independent DMC Interim review: ended for futility w/no safety concerns|f||||f||||||||||2018-05-31 22:46:34.939772|2018-05-31 22:46:34.939772
NCT01318629|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2013-04-16|2011-03-17|2011-03-18|Estimate|||||||2013-04-16|2013-04-17|Estimate|July 1996||1996-07-31|April 2013|2013-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|HeartQuest||Angina in Non Coronary Artery Disease|Invasive Findings in Patients With Angina Equivalent Symptoms But No Coronary Artery Disease; Results From the Heart Quest Cohort Study|Active, not recruiting|||718|Actual|Luzerner Kantonsspital|||||f||||f||||||||||2018-05-31 22:46:35.059774|2018-05-31 22:46:35.059774
NCT01318616|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2012-01-20|2011-03-17|2011-03-18|Estimate|||||||2012-01-20|2012-01-23|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effect of Strength Training on the Hip Adduction Strength Measured With Hand-held Dynamometry||Completed||N/A|34|Actual|Amager Hospital||1|||f||||t||||||||||2018-05-31 22:46:35.115317|2018-05-31 22:46:35.115317
NCT01318590|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2017-08-02|2011-03-17|2011-03-18|Estimate|||||||2017-08-02|2017-08-03|Actual|March 2011||2011-03-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis|Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis|Recruiting||Phase 3|100|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 22:46:35.186214|2018-05-31 22:46:35.186214
NCT01318564|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-09-09|2011-03-16|2011-03-18|Estimate|||||||2016-09-09|2016-09-12|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Diabetic Treatment Adherence|Treatment Adherence With Compliance Prompting Packaging|Completed|||28|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||Samples With DNA|"~     A fasting blood sample of 10 ml will be collected 2 days after randomization if the physician~     considers the test as a standard of care.~   "|||2018-05-31 22:46:35.326139|2018-05-31 22:46:35.326139
NCT01318551|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2014-10-10|2011-03-17|2011-03-18|Estimate|||||||2014-10-10|2014-10-13|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Single Dose Group Stratified Study in Renal Impaired and Healthy Aged and Gender Matched Subjects|Investigation of Pharmacokinetics, Safety, Tolerability, and Pharmacodynamic Effects of BAY85-3934 in Male and Female Subjects With Renal Impairment and in Age- and Weight-matched Healthy Subjects Following a Single Oral Dose of 20 mg and 40 mg (Optional) BAY 85-3934 Administered as Tablets in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification|Completed||Phase 1|56|Actual|Bayer||3|||f||||f||||||||||2018-05-31 22:46:35.536576|2018-05-31 22:46:35.536576
NCT01318538|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2015-12-14||2017-04-24|2011-03-16|2011-03-18|Estimate|2017-02-07|2017-03-28|Actual||||2017-04-24|2017-06-05|Actual|August 2008||2008-08-31|April 2017|2017-04-30|June 2012|Actual|2012-06-30|August 2011|Actual|2011-08-31||Interventional|||Women's Recovery Group (WRG) Study - A Randomized Controlled Stage II Trial|Recovery Group for Women With Substance Use Disorders - Stage II Trial|Completed||N/A|158|Actual|Mclean Hospital|"relatively small sample~sample was almost all white and well-educated (questionable generalizability)~therapists not blind to study"|2|||f||||f||||||||||2018-05-31 22:46:35.672982|2018-05-31 22:46:35.672982
NCT01318525|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-04-04|2011-03-17|2011-03-18|Estimate|||||||2011-04-04|2011-04-05|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|September 2012|Anticipated|2012-09-30|May 2012|Anticipated|2012-05-31||Interventional|||Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure|A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure|Unknown status|Recruiting|Phase 2|60|Anticipated|Alfact Innovation||2|||f||||t||||||||||2018-05-31 22:46:36.720943|2018-05-31 22:46:36.720943
NCT01318512|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2015-10-29||2017-06-13|2011-03-17|2011-03-18|Estimate|2015-10-29|2015-12-03|Estimate||||2017-06-13|2017-07-05|Actual|July 31, 2010|Actual|2010-07-31|May 2017|2017-05-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Observational||All enrolled participants were included.|An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis|The Dosage of MIRCERA in the Treatment of Renal Anaemia in Patients With Chronic Renal Disease Who do Not Undergo Haemodialysis in Clinical Practice|Completed|||340|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:46:36.826917|2018-05-31 22:46:36.826917
NCT01318499|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2012-11-01|2012-07-17|2012-12-14|2011-03-17|2011-03-18|Estimate|2012-12-14|2012-12-17|Estimate|2012-07-17|2012-07-25|Estimate|2012-12-14|2012-12-17|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Nepafenac 0.3% Two Study|Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% Compared to Nepafenac Ophthalmic Suspension 0.1% and Vehicle for Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery|Completed||Phase 2|1342|Actual|Alcon Research|Study excluded patients who were under the age of 18, had uncontrolled glaucoma, were at risk of developing macular edema (diabetic retinopathy), and women of childbearing potential. Therefore, results may not be generalizable to these populations.|3|||f||||f||||||||||2018-05-31 22:46:37.066593|2018-05-31 22:46:37.066593
NCT01318486|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2017-04-04|2011-03-16|2011-03-18|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2011||2011-03-31|April 2017|2017-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||HepZero:Heparin Free Dialysis With Evodial|HepZero:Heparin Free Dialysis With Evodial: A Prospective Multicenter, Open, Randomized, Controlled Clinical Study With Parallel Groups|Completed||N/A|266|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-05-31 22:46:37.413614|2018-05-31 22:46:37.413614
NCT01318473|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2012-10-02|2011-03-17|2011-03-18|Estimate|||||||2012-10-02|2012-10-03|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|ActiSight||The Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided With Lesions Smaller Than 15 mm|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Use of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy With Lesions Smaller Than 15 mm|Completed||Phase 4|25|Actual|ActiViews Ltd.||1|||f||||t||||||||||2018-05-31 22:46:37.688736|2018-05-31 22:46:37.688736
NCT01318460|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-03-11|2011-03-17|2011-03-18|Estimate|||||||2014-03-11|2014-03-12|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery|Prophylactic Administration of Levosimendan in Patients With Impaired Left Ventricular Function Undergoing Coronary Surgery|Completed||Phase 4|32|Actual|AHEPA University Hospital||2|||f||||f||||||||||2018-05-31 22:46:37.756293|2018-05-31 22:46:37.756293
NCT01318447|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-04-05|2011-03-17|2011-03-18|Estimate|||||||2013-04-05|2013-04-08|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||CyberKnife® for Hepatic Metastases From Colorectal Cancer|International, Phase II Study of CyberKnife® for Hepatic Metastases From Colorectal Cancer|Terminated||Phase 2|15|Actual|Accuray Incorporated||1||Lack of enrollment|f||||t||||||||||2018-05-31 22:46:37.837708|2018-05-31 22:46:37.837708
NCT01318434|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09||2015-08-11|2015-11-05|2011-03-16|2011-03-18|Estimate||||2015-08-11|2015-08-25|Estimate|2015-11-05|2015-12-04|Estimate|February 2011||2011-02-28|November 2015|2015-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)|A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) (Triple Reuptake Inhibitor Anti-Depressant Effects - TRIADE Study)|Completed||Phase 2/Phase 3|342|Actual|Euthymics BioScience, Inc.||4|||f||||f||||||||||2018-05-31 22:46:37.93297|2018-05-31 22:46:37.93297
NCT01318421|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2015-12-10|2011-03-16|2011-03-18|Estimate|||||||2015-12-10|2015-12-14|Estimate|December 2010||2010-12-31|December 2015|2015-12-31||||December 2012|Actual|2012-12-31||Interventional|||A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis|An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis|Terminated||Phase 1|12|Actual|Elan Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:46:38.130919|2018-05-31 22:46:38.130919
NCT01318408|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2014-02-17||2015-06-22|2011-03-16|2011-03-18|Estimate|2015-06-22|2015-06-23|Estimate||||2015-06-22|2015-06-23|Estimate|November 2006||2006-11-30|June 2015|2015-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia|A Prospective, Phase 4, Open-Label, Twelve-Week Study to Examine the Cognitive Impact and Tolerability of Levetiracetam (Keppra) in Elderly Patients With Seizures of Partial Onset|Completed||Phase 4|24|Actual|Drexel University||1|||f||||t||||||||||2018-05-31 22:46:38.188033|2018-05-31 22:46:38.188033
NCT01318395|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2018-01-11|2011-03-17|2011-03-18|Estimate|||||||2018-01-11|2018-01-12|Actual|May 2010||2010-05-31|January 2018|2018-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ARTS||Aliskiren on Retinal Vasculature Treatment Study|Randomized, Double Blind, Active-controlled, Parallel Study to Analyse Effects of the Combination of Aliskiren and Valsartan on the Vascular Structure and Function of Retinal Vessels|Completed||Phase 3|56|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 22:46:38.347746|2018-05-31 22:46:38.347746
NCT01318382|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|2013-04-04||2017-05-08|2011-03-17|2011-03-18|Estimate|2013-04-04|2013-05-22|Estimate||||2017-05-08|2017-05-09|Actual|June 2011||2011-06-30|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|RECITE||Residual Curarization and Its Incidence at Tracheal Extubation (P08194)|Residual Curarization and Its Incidence at Tracheal Extubation|Completed||Phase 4|302|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 22:46:38.43554|2018-05-31 22:46:38.43554
NCT01318369|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2013-07-08|2011-03-17|2011-03-18|Estimate|||||||2013-07-08|2013-07-09|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Delta-pain||Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain|The Safety, Tolerability, and Analgesic Efficacy of Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain|Completed||Phase 2|24|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 22:46:38.685974|2018-05-31 22:46:38.685974
NCT01318356|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2015-10-12|2011-03-17|2011-03-18|Estimate|||||||2015-10-12|2015-10-14|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Qure||The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment|The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment|Completed||Phase 4|156|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 22:46:38.769603|2018-05-31 22:46:38.769603
NCT01318343|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2015-03-30|2011-03-17|2011-03-18|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Observational|||Analysis of CoolSculpting by Zeltiq for Non-Invasive Cooling of Abdominal Fat Using the eZ App Large Applicator|Analysis of CoolSculpting by Zeltiq for Non-Invasive Cooling of Subcutaneous Fat of the Abdomen Using the eZ App Large Applicator|Completed|||20|Actual|Laser and Skin Surgery Center of New York|||3||f||||t||||||||||2018-05-31 22:46:38.841415|2018-05-31 22:46:38.841415
NCT01318330|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2012-07-18|2011-03-17|2011-03-18|Estimate|||||||2012-07-18|2012-07-19|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|Homeo-GH||Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD)|Five-Week, Multi-center, Phase I Clinical Trial to Evaluate Safety of Homeo-GH After Intra Venus Administration for the Treatment of Graft Versus Host Disease Patients|Completed||Phase 1|10|Anticipated|HomeoTherapy Co., Ltd|||||f||||f||||||||||2018-05-31 22:46:38.897859|2018-05-31 22:46:38.897859
NCT01318317|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2018-02-09|2011-03-16|2011-03-18|Estimate|||||||2018-02-09|2018-02-12|Actual|September 19, 2011||2011-09-19|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma|Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1/Phase 2|57|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 22:46:38.967621|2018-05-31 22:46:38.967621
NCT01318304|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2016-05-05|2011-03-16|2011-03-18|Estimate|||||||2016-05-05|2016-05-09|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Vaginal Innate Immunity in Normal and HIV-Infected Women|Vaginal Innate Immunity in Normal and HIV-Infected Women|Completed|||83|Actual|Boston Medical Center|||4||f||||f||||||Samples Without DNA|"~     Vaginal lavage samples~   "|||2018-05-31 22:46:39.059158|2018-05-31 22:46:39.059158
NCT01318291|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-02-03|2011-03-16|2011-03-18|Estimate|||||||2016-02-03|2016-02-04|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Psychological Intervention on Drop-out Rates in IVF|An Assessment of the Effect of a Brief Psychological Intervention on Decreasing Drop-Out Rates in IVF Patients|Completed||N/A|166|Actual|Boston IVF||2|||f||||f||||||||No||2018-05-31 22:46:39.121653|2018-05-31 22:46:39.121653
NCT01318278|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2015-02-09||2015-02-24|2011-03-16|2011-03-18|Estimate|2015-02-24|2015-03-10|Estimate||||2015-02-24|2015-03-10|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants|Dopamine Versus Vasopressin for Cardiovascular Support in Extremely Low Birth Weight Infants: A Randomized, Blinded Pilot Study|Completed||N/A|70|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 22:46:39.201605|2018-05-31 22:46:39.201605
NCT01318265|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2014-10-31|2011-03-16|2011-03-18|Estimate|||||||2014-10-31|2014-11-03|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics|A Phase I, Non-Randomized, Open Label Study to Determine the Effetc of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of Regorafenib (BAY73-4506) in Healthy Volunteers|Completed||Phase 1|24|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:46:39.555961|2018-05-31 22:46:39.555961
NCT01318252|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16||2014-07-28|2014-07-28|2011-03-16|2011-03-18|Estimate||||2014-07-28|2014-07-31|Estimate|2014-07-28|2014-07-31|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||AL-54478 Proof of Concept Study||Completed||Phase 2|64|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:46:39.619685|2018-05-31 22:46:39.619685
NCT01318239|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-03-04|2011-03-17|2011-03-18|Estimate|||||||2014-03-04|2014-03-05|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-anogenic Effect of Chemotherapeutic Regimens in Colorectal Liver Metastasis Patients|Study of Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-angiogenic Effect in Patients With Colorectal Liver Metastasis in Chemotherapeutic Regimens Including Avastin|Completed||N/A|37|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:46:39.690786|2018-05-31 22:46:39.690786
NCT01318226|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-08-19|2011-03-16|2011-03-18|Estimate|||||||2011-08-19|2011-08-23|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Multicenter, Parallel Group Study to Evaluate the Safety and Analgesic Activity of ATx08-001 When Administered to Subjects With Postherpetic Neuralgia|Completed||Phase 2|61|Actual|Aestus Therapeutics||3|||f||||f||||||||||2018-05-31 22:46:39.751014|2018-05-31 22:46:39.751014
NCT01318213|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-01-03|2011-03-16|2011-03-18|Estimate|||||||2012-01-03|2012-01-05|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|BUGG||Benefits of Universal Glove and Gowning|Effect of the Use of Universal Glove and Gowning on Healthcare Associated Infection Rates and Antibiotic Resistant Bacteria|Unknown status|Active, not recruiting||2|Anticipated|Yale New Haven Health System Center for Healthcare Solutions|||2||f||||t||||||Samples Without DNA|"~     Nasal and peri-rectal culture samples will be banked in the research laboratory of Dr. J.~     Kristie Johnson at the University of Maryland, School of Medicine. The samples will be~     labeled with a participant ID without any personal identifiers. The entire sample will not be~     used for this study. The remaining samples will be used for future research to answer any~     infection control questions that arise about infection control in intensive care units that~     may be answered with these samples. The remaining samples will be frozen and stored~     indefinitely. The freezing method that will allow the study of other bacteria has been~     validated. Depending upon the results, there may be some rationale for thawing the samples~     and processing them for other antibiotic-resistant bacteria~   "|||2018-05-31 22:46:39.840239|2018-05-31 22:46:39.840239
NCT01318200|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-02-16|2011-03-16|2011-03-18|Estimate|||||||2012-02-16|2012-02-20|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|February 2016|Anticipated|2016-02-29|February 2014|Anticipated|2014-02-28||Interventional|||Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)|International Randomized Study of Transarterial Chemoembolization Versus CyberKnife® for Recurrent Hepatocellular Carcinoma|Withdrawn||Phase 3|0|Actual|Accuray Incorporated||2|||f||||t||||||||||2018-05-31 22:46:40.028557|2018-05-31 22:46:40.028557
NCT01318187|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2011-03-31|2011-03-17|2011-03-18|Estimate|||||||2011-03-31|2011-04-01|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Intravenous Paracetamol or Morphine for the Treatment of Acute Flank Pain|Intravenous Paracetamol or Morphine for the Treatment of Acute Flank Pain : a Randomized, Double Blind, Controlled Clinical Trial|Completed||Phase 4|73|Actual|Pamukkale University||2|||f||||t||||||||||2018-05-31 22:46:40.121529|2018-05-31 22:46:40.121529
NCT01318174|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-07-07|2011-03-17|2011-03-18|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Observational|||Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease|Prevalence of Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease|Completed|||38|Actual|Sykehuset Innlandet HF|||||f||||f||||||||||2018-05-31 22:46:40.396038|2018-05-31 22:46:40.396038
NCT01318161|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-09-25|2011-03-17|2011-03-18|Estimate|||||||2016-09-25|2016-09-27|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|EPICOL||Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery|Epidural or Patient-controlled Analgesia for Colorectal Cancer Surgery. Long-term Outcomes.|Recruiting||Phase 3|300|Anticipated|Örebro University, Sweden||2|||f||||t||||||||||2018-05-31 22:46:40.500517|2018-05-31 22:46:40.500517
NCT01318148|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2014-01-08|2011-03-17|2011-03-18|Estimate|||||||2014-01-08|2014-01-09|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|CASPHYLAX||Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis|Prospective Trial to Evaluate Pharmacokinetic, Safety and Efficacy of Intermittent Application of Increased Doses of Caspofungin for Antifungal Prophylaxis in High Risk Patients|Completed||Phase 2|25|Actual|Wuerzburg University Hospital||1|||f||||t||||||||||2018-05-31 22:46:40.657074|2018-05-31 22:46:40.657074
NCT01318135|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2011-06-08||2012-07-07|2011-03-16|2011-03-18|Estimate|2012-07-07|2012-08-16|Estimate||||2012-07-07|2012-08-16|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan|A Long-term, Open-label Extension Study to Investigate the Long-term Safety of Alogliptin When Used in Combination With Sulfonylurea or Metformin in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2/Phase 3|576|Actual|Takeda||4|||f||||f||||||||||2018-05-31 22:46:40.791825|2018-05-31 22:46:40.791825
NCT01318122|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2011-06-08||2012-02-01|2011-03-16|2011-03-18|Estimate|2011-07-28|2011-09-02|Estimate||||2012-02-01|2012-02-03|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan|A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2/Phase 3|336|Actual|Takeda|331 participants were randomized in the core phase 2/3 thiazolidine (CCT-004) study and included in the Full Analysis Set in this study. 5 participants from CCT-004 study did not enter this study.|2|||f||||f||||||||||2018-05-31 22:46:42.346634|2018-05-31 22:46:42.346634
NCT01318109|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2011-06-08||2012-02-01|2011-03-17|2011-03-18|Estimate|2011-06-08|2011-07-11|Estimate||||2012-02-01|2012-02-03|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Metformin in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2/Phase 3|288|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:46:43.168196|2018-05-31 22:46:43.168196
NCT01318096|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-17|2011-03-17|2011-03-18|Estimate|||||||2011-03-17|2011-03-18|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|September 2013|Anticipated|2013-09-30|July 2012|Anticipated|2012-07-31||Interventional|||Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients|A Randomized, Pilot Estimation Study to Compare the Safety and Efficacy of Raltegravir+TDF+3TC Versus TDF+3TC+EFV in HBV/HIV Co-infected Patients|Unknown status|Not yet recruiting|N/A|60|Anticipated|Yunnan AIDS Care Center||2|||f||||f||||||||||2018-05-31 22:46:43.545601|2018-05-31 22:46:43.545601
NCT01306448|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2014-12-09|2011-02-28|2011-03-01|Estimate|||||||2014-12-09|2014-12-10|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Vibrant||Safety Evaluation of the Vibrating Capsule|Safety Evaluation of the Vibrating Capsule in Aiding Reliving Constipated Individuals|Completed||N/A|26|Actual|Vibrant Ltd.||1|||f||||f||||||||||2018-05-31 22:49:54.664163|2018-05-31 22:49:54.664163
NCT01318083|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2011-06-08||2012-02-01|2011-03-17|2011-03-18|Estimate|2011-06-08|2011-07-06|Estimate||||2012-02-01|2012-02-03|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Sulfonylurea in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2/Phase 3|312|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:46:43.634869|2018-05-31 22:46:43.634869
NCT01318070|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2011-06-08||2012-02-01|2011-03-17|2011-03-18|Estimate|2011-06-08|2011-07-06|Estimate||||2012-02-01|2012-02-03|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2/Phase 3|339|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:46:44.030309|2018-05-31 22:46:44.030309
NCT01318057|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2015-01-19|2011-03-17|2011-03-18|Estimate|||||||2015-01-19|2015-01-21|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Pharmacogenetics of Warfarin in Puerto Ricans.|Pharmacogenetics of Warfarin in Puerto Rican Patients Using a Physiogenomics Approach.|Completed|||350|Actual|University of Puerto Rico|||2||f||||t||||||Samples With DNA|"~     Whole fresh blood and Genomic DNA samples fom enrolled patients~   "|||2018-05-31 22:46:45.321265|2018-05-31 22:46:45.321265
NCT01318044|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-17|2011-03-17|2011-03-18|Estimate|||||||2011-03-17|2011-03-18|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|||Thiopental Versus Propofol During Magnetic Resonance Imagining in Children: Something Old, Something New|Thiopental Versus Propofol During Magnetic Resonance Imagining in Children|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|University Clinical Centre of Kosova||2|||f||||f||||||||||2018-05-31 22:46:45.398241|2018-05-31 22:46:45.398241
NCT01318031|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2012-06-21|2011-03-16|2011-03-18|Estimate|||||||2012-06-21|2012-06-22|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study To Investigate The Potential Drug Drug Interaction (DDI) Between PF-00299804 And Paroxetine In Healthy Subjects|Phase 1 Single Dose Open Label Study To Investigate The Potential DDI Between PF-00299804 And Paroxetine In Healthy Subjects|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:46:45.478763|2018-05-31 22:46:45.478763
NCT01318018|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2012-04-15|2011-03-17|2011-03-18|Estimate|||||||2012-04-15|2012-04-17|Estimate|February 2011||2011-02-28|April 2012|2012-04-30||||||||Observational|||Investigation on the Value of Bilateral Index (BIS) Monitoring for Magnetic Seizure Versus Electroconvulsive Therapy||Completed|||20|Anticipated|University Hospital, Bonn|||2||f||||f||||||||||2018-05-31 22:46:45.551942|2018-05-31 22:46:45.551942
NCT01318005|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2014-09-09|2011-03-17|2011-03-18|Estimate|||||||2014-09-09|2014-09-10|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|June 2015|Anticipated|2015-06-30||Interventional|OCP2||Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation|The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?|Unknown status|Recruiting|N/A|85|Anticipated|University of Southern California||3|||f||||f||||||||||2018-05-31 22:46:45.642616|2018-05-31 22:46:45.642616
NCT01317992|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2013-02-04|2011-03-17|2011-03-18|Estimate|||||||2013-02-04|2013-02-06|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Ibudilast in the Treatment of Medication Overuse Headache|Ibudilast in the Treatment of Medication Overuse Headache: A Double-blind, Randomised, Placebo-controlled Pilot Study|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|University of Adelaide||2|||f||||f||||||||||2018-05-31 22:46:45.780545|2018-05-31 22:46:45.780545
NCT01317979|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-17|2011-03-17|2011-03-18|Estimate|||||||2011-03-17|2011-03-18|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|December 2013|Anticipated|2013-12-31|March 2012|Anticipated|2012-03-31||Observational|ADSS||Asian Diabetes Surgery Study (ADSS): Clinical Predictor for the Success of Metabolic Surgery|Asian Diabetes Surgery Study:A Multi-institutes Prospective Study Clinical Predictor for the Successful Treatment of Type 2 Diabetes After Metabolic Surgery|Unknown status|Recruiting||200|Anticipated|Min-Sheng General Hospital|||1||f||||t||||||Samples With DNA|"~     Serum stored at a -85 ℃ refrigerator~   "|||2018-05-31 22:46:45.868348|2018-05-31 22:46:45.868348
NCT01317966|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-04-18|2011-03-17|2011-03-18|Estimate|||||||2016-04-18|2016-04-20|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Observational|Incritop||Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia|A Multicentre Investigation of Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)|Withdrawn|||0|Actual|Shandong University|||1|No eligible patients were enrolled.|f||||f||||||||||2018-05-31 22:46:45.945593|2018-05-31 22:46:45.945593
NCT01317953|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2018-03-13|2011-03-17|2011-03-18|Estimate|||||||2018-03-13|2018-03-15|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Oral Green Tea Extract for Small Cell Lung Cancer|Phase ⅠStudy of Oral Green Tea Extract as Maintenance Therapy for Extensive-stage Small Cell Lung Cancer|Available|||||Shandong Cancer Hospital and Institute|||||f||||||||||||||2018-05-31 22:46:46.031856|2018-05-31 22:46:46.031856
NCT01317940|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-17|||2016-01-26|2011-03-17|2011-03-18|Estimate|||||||2016-01-26|2016-01-28|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|||Nutrition and Body Composition in Acute Lymphoblastic Leukemia|Nutrition and Body Composition in Acute Lymphoblastic Leukemia (Environment and Microenvironment in ALL #2)|Completed||Phase 2|77|Actual|Children's Hospital Los Angeles||5|||f||||t||||||||||2018-05-31 22:46:46.123314|2018-05-31 22:46:46.123314
NCT01317927|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2015-09-21|2011-03-16|2011-03-17|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2010||2010-12-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies|A Phase I Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies|Completed||Phase 1|27|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 22:46:46.249066|2018-05-31 22:46:46.249066
NCT01317914|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-09-28|2011-03-16|2011-03-17|Estimate|||||||2017-09-28|2017-10-02|Actual|July 2010||2010-07-31|September 2017|2017-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Prospective Study of Undiagnosed Celiac Disease|Epidemiology of Celiac Disease: A Prospective Study of Undiagnosed Celiac Disease in the Community|Completed||N/A|31|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 22:46:46.337369|2018-05-31 22:46:46.337369
NCT01317901|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2016-08-11||2017-06-26|2011-03-16|2011-03-17|Estimate|2016-08-16|2016-10-06|Estimate||||2017-06-26|2017-06-28|Actual|May 2011||2011-05-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma|A Phase 1 Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma|Completed||Phase 1|12|Actual|Aptevo Therapeutics||1|||f||||t||||||||No||2018-05-31 22:46:46.434146|2018-05-31 22:46:46.434146
NCT01317888|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|January 2010||2010-01-31|January 2011|2011-01-31||||January 2014|Anticipated|2014-01-31||Interventional|||Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas|An Access Protocol for Continued Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFr-425) Monoclonal Antibody Radiolabeled With 1-125 for High Grade Gliomas|Unknown status|Active, not recruiting|N/A|11|Anticipated|Drexel University||1|||f||||||||||||||2018-05-31 22:46:46.967429|2018-05-31 22:46:46.967429
NCT01317875|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2018-02-22|2011-03-16|2011-03-17|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2011||2011-03-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)||Active, not recruiting||Phase 1|69|Actual|Incyte Corporation||1|||t||||t||||||||No||2018-05-31 22:46:47.020348|2018-05-31 22:46:47.020348
NCT01317862|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2013-12-08|2011-03-16|2011-03-17|Estimate|||||||2013-12-08|2013-12-10|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Comparison of Transcervical Foley Catheter and Prostaglandins for Induction of Labor at Term||Completed||N/A|154|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:46:47.187444|2018-05-31 22:46:47.187444
NCT01317849|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2014-08-18|2011-03-16|2011-03-17|Estimate|||||||2014-08-18|2014-08-20|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|CSSPT||China Stroke Secondary Prevention Trial|Folic Acid and B Vitamins for Secondary Prevention of Stroke : A Double-blinded Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Xijing Hospital||2||"financial assistance financial assistance financial assistance financial assistance financial~   assistance without financial assistance"|f||||t||||||||||2018-05-31 22:46:47.255264|2018-05-31 22:46:47.255264
NCT01317836|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2014-02-14|2011-03-16|2011-03-17|Estimate|||||||2014-02-14|2014-02-17|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||PET-CT in Diagnosis of Pancreatic Cystic Neoplasms|PET-CT in Diagnosis of Pancreatic Cystic Neoplasms|Completed|||31|Actual|Turku University Hospital|||1||f||||f||||||||||2018-05-31 22:46:47.345178|2018-05-31 22:46:47.345178
NCT01317823|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-10-21|2011-03-16|2011-03-17|Estimate|||||||2012-10-21|2012-10-23|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Bishop Score and Transvaginal Ultrasound for Preinduction Cervical Assessment in Multiparas||Completed||N/A|154|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:46:47.403007|2018-05-31 22:46:47.403007
NCT01317810|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2015-08-31|2011-03-16|2011-03-17|Estimate|||||||2015-08-31|2015-09-02|Estimate||||August 2015|2015-08-31||||||||Observational|||A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication|A Phase 4, Observational, Non-interventional Study Measuring and Tracking Changes in Overactive Bladder Medication and/or Overactive Bladder Medication Dose in Subjects With Overactive Bladder|Withdrawn|||0|Actual|Astellas Pharma Inc|||1|Corporate decision not to initiate the trial|f||||f||||||||||2018-05-31 22:46:47.461981|2018-05-31 22:46:47.461981
NCT01317797|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2015-07-24||2015-07-24|2011-03-16|2011-03-17|Estimate|2015-07-24|2015-08-20|Estimate||||2015-07-24|2015-08-20|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|PRIORA||A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis|A Phase Ib Double-blind, Placebo-controlled, Randomized, Dose-escalating Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Subcutaneous Injections of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis on Treatment With Methotrexate|Completed||Phase 1|24|Actual|Takeda||3|||f||||f||||||||||2018-05-31 22:46:47.572399|2018-05-31 22:46:47.572399
NCT01317784|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2015-07-27|2011-03-16|2011-03-17|Estimate|||||||2015-07-27|2015-07-29|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|BSARTA||Behavioral Science Aspects of Rapid Test Acceptance|Behavioral Science Aspects of Rapid Test Acceptance|Completed||N/A|1200|Actual|California State University, Long Beach||4|||f||||t||||||||||2018-05-31 22:46:48.35969|2018-05-31 22:46:48.35969
NCT01317771|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate||||March 2011|2011-03-31||||||||Observational|||Analysis of the Fixation of the Proximal Biceps Tendon|Analysis of the Fixation of the Proximal Long Head of the Biceps Tendon|Unknown status|Not yet recruiting||10|Anticipated|West Penn Allegheny Health System|||1||f||||||||||||||2018-05-31 22:46:48.443157|2018-05-31 22:46:48.443157
NCT01317758|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-01-17|2011-03-16|2011-03-17|Estimate|||||||2013-01-17|2013-01-18|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||H5N1 Mix and Match With AS03|A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered at Different Dose Levels Given With and Without AS03 Adjuvant|Completed||Phase 1|245|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-05-31 22:46:48.500108|2018-05-31 22:46:48.500108
NCT01317745|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-01-24|2011-03-16|2011-03-17|Estimate|||||||2013-01-24|2013-01-25|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||H5N1 Mix and Match With MF59|A Randomized, Double-Blinded, Controlled, Phase I Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of Intramuscular Subvirion Inactivated Monovalent Influenza A/H5N1 Virus Vaccine Administered at Different Dose Levels Given With and Without MF59 Adjuvant|Completed||Phase 1|270|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||||||||||||||||2018-05-31 22:46:48.572301|2018-05-31 22:46:48.572301
NCT01317732|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2017-08-17|2011-03-16|2011-03-17|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2010||2010-10-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MOTIONPOD(TM)||MOTIONPOD (TM) Validation and Calibration Study|Calibration and Validation of MOTIONPOD(TM) for Physical Activity Evaluation in Free-living Adults|Completed||N/A|60|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 22:46:48.643263|2018-05-31 22:46:48.643263
NCT01317719|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate||||January 2011|2011-01-31||||||||Observational|||Prospective Biceps Study|Prospective Biceps Study|Unknown status|Enrolling by invitation||||West Penn Allegheny Health System|||1||f||||||||||||||2018-05-31 22:46:48.69366|2018-05-31 22:46:48.69366
NCT01317693|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2012-12-18|2011-03-16|2011-03-17|Estimate|||||||2012-12-18|2012-12-19|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||Extracorporeal Shock Wave Therapy With a Wide Focus Probe for the Treatment of Erectile Dysfunction|Extracorporeal Shock Wave Therapy With a Wide Focus Probe for the Treatment of Erectile Dysfunction|Unknown status|Recruiting|Phase 3|70|Anticipated|Rambam Health Care Campus||1|||f||||t||||||||||2018-05-31 22:46:48.873413|2018-05-31 22:46:48.873413
NCT01317680|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2012-05-23|2011-03-16|2011-03-17|Estimate|||||||2012-05-23|2012-05-24|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|LI-ESWT||Low Intensity Shock Wave Therapy (LI-ESWT) for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors (LI-ESWT)|Low Intensity Shock Wave Therapy for Erectile Dysfunction in Post Radical Prostatectomy Patients Not Responding to PDE5 Inhibitors- a Double Blind Placebo Controlled Study (LI-ESWT)|Unknown status|Recruiting|Phase 3|60|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:46:48.951755|2018-05-31 22:46:48.951755
NCT01317667|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2015-01-26||2016-10-21|2011-03-16|2011-03-17|Estimate|2015-01-26|2015-02-11|Estimate||||2016-10-21|2016-10-25|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)|Phase 1 Escalating, Multiple-Dose Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Healthy Adults|Completed||Phase 1|30|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-05-31 22:46:49.042016|2018-05-31 22:46:49.042016
NCT01317654|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-09-14|2011-03-16|2011-03-17|Estimate|||||||2011-09-14|2011-09-15|Estimate|April 2006||2006-04-30|September 2011|2011-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|ES||Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone|Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone|Completed|||340|Actual|Oxford University Clinical Research Unit, Vietnam|||1||f||||f||||||||||2018-05-31 22:46:49.805359|2018-05-31 22:46:49.805359
NCT01317641|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2016-03-23||2017-02-09|2011-03-16|2011-03-17|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|March 2011||2011-03-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Safety|Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer|Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component|Completed||Phase 1/Phase 2|136|Actual|Orion Corporation, Orion Pharma||4|||f||||t||||||||||2018-05-31 22:46:49.940553|2018-05-31 22:46:49.940553
NCT01317628|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2013-10-28|2011-03-16|2011-03-17|Estimate|||||||2013-10-28|2013-10-29|Estimate|April 2011||2011-04-30|October 2013|2013-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Tobacco Smoke Exposure on Epigenetic Signatures and Immunotoxicological Reactions|Effects of Tobacco Smoke Exposure on Epigenetic Signatures and Immunotoxicological Reactions|Completed||N/A|100|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:46:51.441575|2018-05-31 22:46:51.441575
NCT01317615|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2016-02-17||2016-02-29|2011-03-16|2011-03-17|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation|A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC)|Completed||Phase 4|49|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:46:51.509423|2018-05-31 22:46:51.509423
NCT01317602|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2015-04-15|2011-03-16|2011-03-17|Estimate|||||||2015-04-15|2015-04-16|Estimate|March 2011||2011-03-31|April 2015|2015-04-30||||September 2011|Actual|2011-09-30||Observational|MANAGE-AF||Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study|Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study|Completed|||603|Actual|Hellenic Cardiovascular Research Society|||||f||||f||||||||||2018-05-31 22:46:51.907791|2018-05-31 22:46:51.907791
NCT01317589|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2015-07-15|2011-03-16|2011-03-17|Estimate|||||||2015-07-15|2015-07-16|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|310111-4||Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?|Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective Than Fentanyl?|Completed||Phase 4|134|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:46:52.006507|2018-05-31 22:46:52.006507
NCT01317576|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-02-27|2011-03-16|2011-03-17|Estimate|||||||2016-02-27|2016-03-01|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!|Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!|Completed||N/A|81|Actual|Maastricht University Medical Center||3|||f||||||||||||||2018-05-31 22:46:52.080169|2018-05-31 22:46:52.080169
NCT01317563|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-03-21|2011-03-16|2011-03-17|Estimate|||||||2016-03-21|2016-03-22|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|June 2012|Actual|2012-06-30||Interventional|ALOA||Antioxidant Therapy in Lean and Obese Asthmatics|Phase 2 Study of Antioxidant Therapy in Lean and Obese Asthmatics|Completed||Phase 2|43|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-05-31 22:46:52.151322|2018-05-31 22:46:52.151322
NCT01317550|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2016-03-01|2011-03-16|2011-03-17|Estimate|||||||2016-03-01|2016-03-02|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil|A Pilot Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer|Completed||N/A|14|Actual|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-05-31 22:46:52.219512|2018-05-31 22:46:52.219512
NCT01317537|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Using an Electronic Personal Health Record to Empower Patients With Hypertension|Using an Electronic Personal Health Record to Empower Patients With Hypertension|Completed||N/A|445|Actual|Augusta University||2|||f||||t||||||||||2018-05-31 22:46:52.322632|2018-05-31 22:46:52.322632
NCT01317524|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-11-30|2011-03-16|2011-03-17|Estimate|||||||2011-11-30|2011-12-01|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effects of Homogenized and Unhomogenized Milk on Postprandial Metabolism in Healthy Overweight Men|The Effects of Homogenized and Unhomogenized Milk on Postprandial Metabolism in Healthy Overweight Men|Completed||N/A|18|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 22:46:52.411302|2018-05-31 22:46:52.411302
NCT01317498|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2018-05-10|2011-03-16|2011-03-17|Estimate|||||||2018-05-10|2018-05-15|Actual|April 2011|Actual|2011-04-30|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|VMVN||The VMVN Study: Virological Monitoring in Viet Nam|Effect of Routine Viral Load Monitoring on Clinical and Immunological Outcomes and Antiretroviral Drug Resistance on Patients Taking First-line Antiretroviral Drugs in Vietnam|Active, not recruiting||N/A|650|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 22:46:52.563156|2018-05-31 22:46:52.563156
NCT01317485|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2014-03-20|2011-03-16|2011-03-17|Estimate|||||||2014-03-20|2014-03-21|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|Ladies||Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis|Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis: a Nationwide Multicenter Randomised Trial|Unknown status|Recruiting|Phase 3|283|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 22:46:52.643261|2018-05-31 22:46:52.643261
NCT01317472|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-11-14|2011-03-16|2011-03-17|Estimate|||||||2013-11-14|2013-11-18|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux|A Double-Blinded, Placebo-Controlled Trial to Investigate Dexlansoprazole for the Treatment of Laryngopharyngeal Reflux|Terminated||N/A|11|Actual|Indiana University||2||Principal investigator left institution|f||||t||||||||||2018-05-31 22:46:52.9933|2018-05-31 22:46:52.9933
NCT01317459|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2015-09-09|2011-03-16|2011-03-17|Estimate|||||||2015-09-09|2015-09-10|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Interventional|GSD||Guided Self-determination - Promoting Self-management in Type 1 Diabetes|Using Guided Self-determination (GSD) to Promote Improved Self-management in Adults With Type 1 Diabetes - an Intervention Study.|Active, not recruiting||N/A|216|Anticipated|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 22:46:53.071372|2018-05-31 22:46:53.071372
NCT01317446|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-01-16|2011-03-16|2011-03-17|Estimate|||||||2012-01-16|2012-01-18|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Mouthrinsing on Inflammation of the Gums.|Effect of an Amine Fluoride/Stannous Fluoride Containing Mouthrinse on Gingival Inflammation,Plaque Development, Discoloration and Bacterial Plaque Composition Over Six Months.|Completed||Phase 4|180|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 22:46:53.140615|2018-05-31 22:46:53.140615
NCT01317433|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-02-28|2011-03-16|2011-03-17|Estimate|||||||2012-02-28|2012-02-29|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|November 2015|Anticipated|2015-11-30|November 2012|Anticipated|2012-11-30||Interventional|SKINUX||Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer|Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI.|Unknown status|Recruiting|Phase 3|130|Anticipated|ICO Paul Papin||2|||f||||t||||||||||2018-05-31 22:46:53.207138|2018-05-31 22:46:53.207138
NCT01317420|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2016-05-27|2011-03-16|2011-03-17|Estimate|||||||2016-05-27|2016-05-30|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types|A Phase I Dose Escalation Trial of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours During Escalation and Weekly in Selected Tumour Types During Expansion, With Repeated Administrations in Patients Showing Clinical Benefit.|Completed||Phase 1|64|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:46:53.297407|2018-05-31 22:46:53.297407
NCT01317407|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|April 2011||2011-04-30|March 2011|2011-03-31||||December 2012|Anticipated|2012-12-31||Observational|VIPSafe||Automated Visual Monitoring for Improving Patient Safety (VIPSafe)|Automatisierte Optische Überwachung Mittels Videosensorik Zur Verbesserung Der Patientensicherheit Auf Intensivstation (Automated Visual Monitoring for Improving Patient Safety (VIPSafe))|Unknown status|Not yet recruiting||100|Anticipated|Staedtisches Klinikum Karlsruhe|||||f||||f||||||||||2018-05-31 22:46:53.357547|2018-05-31 22:46:53.357547
NCT01317394|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|||||Observational|||Study and Analysis of Micafungin for Non-albican Candidemia: Efficacy, Risk Factor and Clinical Manifestation|Retrospective Study and Analysis of Micafungin for Non-albican Candidemia: Efficacy, Risk Factor and Clinical Manifestation|Completed|||60|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:46:53.459301|2018-05-31 22:46:53.459301
NCT01317381|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-03-15|2011-03-15|2011-03-17|Estimate|||||||2011-03-15|2011-03-17|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|May 2011||2011-05-31|||||Observational|(Greenpep)||ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill|ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill|Unknown status|Recruiting||100|Anticipated|University of Zurich|||1||f||||||||||||||2018-05-31 22:46:53.51692|2018-05-31 22:46:53.51692
NCT01317368|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-06-19|2011-03-16|2011-03-17|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Following Radical Prostatectomy|The Analgesic Effect of Transversus Abdominis Plane (TAP) Block Versus Wound Infiltration Versus Placebo Following Open Radical Prostatectomy, a Double Blinded, Randomized Clinical Trial|Completed||N/A|75|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 22:46:53.579489|2018-05-31 22:46:53.579489
NCT01317355|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2012-09-26|2011-03-16|2011-03-17|Estimate|||||||2012-09-26|2012-09-27|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Observational|ProKID||Multiple Symptoms in Cancer Patients a Cross Sectional Multi Center Study|Prevalence of Multiple Symptoms in Cancer Patients a Cross Sectional Prospective Multi Center Study|Completed|||697|Actual|Martin-Luther-Universität Halle-Wittenberg|||1||f||||f||||||||||2018-05-31 22:46:53.664466|2018-05-31 22:46:53.664466
NCT01317342|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2016-05-10|2011-03-16|2011-03-17|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Hypothermic Oxygenated Perfusion (HOPE) of Human Liver Grafts|A Double Blinded Randomized Study on the Effects of Hypothermic Oxygenated Perfusion (HOPE) on Human Liver Grafts Before Transplantation|Recruiting||Phase 2|70|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 22:46:53.741079|2018-05-31 22:46:53.741079
NCT01317329|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-09-29|2011-03-15|2011-03-17|Estimate|||||||2015-09-29|2015-10-01|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||"Reversibility of Cardiovascular Injury With CPAP Use: Mechanisms Involved"|"Reversibility of Cardiovascular Injury With Continuous Positive Airway Pressure (CPAP) Use: Mechanisms Involved"|Completed||N/A|90|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 22:46:53.850179|2018-05-31 22:46:53.850179
NCT01317316|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|January 2007||2007-01-31|November 2006|2006-11-30|January 2011|Actual|2011-01-31|||||Observational|||Causes and Characteristics of Occupational Eye Injuries in Western Turkey|Causes and Characteristics of Occupational Eye Injuries in Western Turkey|Completed|||816|Actual|Pamukkale University|||||f||||f||||||||||2018-05-31 22:46:53.939118|2018-05-31 22:46:53.939118
NCT01317303|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-10-31|2011-03-16|2011-03-17|Estimate|||||||2013-10-31|2013-11-04|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Comparison of Measures of Plasticity|Comparison of Measures of Plasticity|Completed||N/A|16|Actual|The University of New South Wales||4|||f||||f||||||||||2018-05-31 22:46:53.986299|2018-05-31 22:46:53.986299
NCT01317290|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2013-11-12|2011-03-16|2011-03-17|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|ALA_KK||Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans|Accumulation of n-3 Long-chain (LC)-PUFA by Supplementation of ALA-rich Oil in Humans Depending on Age, Gender and Physiological Stage.|Completed||Early Phase 1|78|Actual|University of Jena||4|||f||||t||||||||||2018-05-31 22:46:54.159843|2018-05-31 22:46:54.159843
NCT01317277|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2014-06-24|2011-03-16|2011-03-17|Estimate|||||||2014-06-24|2014-06-26|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|iTAB||Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users|Personalized Text Messages to Improve ART Adherence in HIV+ Methamphetamine Users|Completed||N/A|75|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 22:46:54.275219|2018-05-31 22:46:54.275219
NCT01317264|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||β-Glucans and the Metabolic Syndrome - a Human Intervention Study Under BEST|β-Glucans and the Metabolic Syndrome - a Human Intervention Study Under BEST|Completed||N/A|16|Anticipated|University of Copenhagen||4|||f||||f||||||||||2018-05-31 22:46:54.337998|2018-05-31 22:46:54.337998
NCT01317251|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-09-04|2011-03-16|2011-03-17|Estimate|||||||2014-09-04|2014-09-05|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|MOFF||Effect of Milk and Cheese on Fecal Fat Excretion and Blood Lipid|Effect of Milk and Cheese on Fecal Fat Excretion and Blood Lipid|Completed||N/A|15|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 22:46:54.410224|2018-05-31 22:46:54.410224
NCT01317238|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2013-05-30|2011-03-15|2011-03-17|Estimate|||||||2013-05-30|2013-05-31|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers|An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers|Completed||Phase 3|145|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:46:54.474372|2018-05-31 22:46:54.474372
NCT01317225|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2015-01-03|2011-03-16|2011-03-17|Estimate|||||||2015-01-03|2015-01-06|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone|Use of 17α Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor During Current Pregnancy. Double Blind, Randomized, Controlled Trial.|Unknown status|Recruiting|Phase 3|80|Anticipated|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 22:46:54.546036|2018-05-31 22:46:54.546036
NCT01317212|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2015-04-16|2011-03-16|2011-03-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme|A Phase I Trial of Carboplatin Administered by Convection-Enhanced Delivery to Patients With Recurrent/Progressive Glioblastoma Multiforme|Withdrawn||Phase 1|0|Actual|North Bristol NHS Trust||||Sufficient funding could not be secured for the study|f||||t||||||||||2018-05-31 22:46:54.631636|2018-05-31 22:46:54.631636
NCT01317199|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2017-01-26|2011-03-16|2011-03-17|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|November 2015|Actual|2015-11-30||Interventional|||Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer|Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|139|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 22:46:54.696139|2018-05-31 22:46:54.696139
NCT01317186|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||||||Observational|||The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease||Unknown status|Recruiting||100|Anticipated|Ankara Education and Research Hospital|||3||f||||f||||||||||2018-05-31 22:46:54.760388|2018-05-31 22:46:54.760388
NCT01317173|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|||2011-03-16|2011-03-16|2011-03-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Observational|||Factors Related to the Progression of Chronic Kidney Disease|The Impact of FGF23 and Klotho on Progression of Chronic Kidney Disease|Unknown status|Active, not recruiting||90|Anticipated|Ankara Education and Research Hospital|||2||f||||f||||||||||2018-05-31 22:46:54.812405|2018-05-31 22:46:54.812405
NCT01317160|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-16|2016-01-18||2018-01-28|2011-03-16|2011-03-17|Estimate|2016-02-15|2016-03-15|Estimate||||2018-01-28|2018-02-23|Actual|March 2011||2011-03-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2015|Actual|2015-08-31||Interventional|||Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture|Intermittent Pneumatic Compression Effects on Venous Thromboembolism Incidence and Healing of Achilles Tendon Rupture|Active, not recruiting||N/A|150|Actual|Karolinska University Hospital||2|||f||||f||||||||Undecided||2018-05-31 22:46:54.869946|2018-05-31 22:46:54.869946
NCT01317147|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-17|Estimate|||||||2011-03-15|2011-03-17|Estimate|August 2007||2007-08-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|||||Observational|||The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors|The Effect of Gastric Bypass on the Pharmacokinetics of Serotonin Reuptake Inhibitors|Completed|||12|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 22:46:55.099355|2018-05-31 22:46:55.099355
NCT01317134|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2016-01-26|2011-03-15|2011-03-17|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Endothelial Function in Patients With Pulmonary Arterial Hypertension|Serological and Non-invasive Evaluation of Endothelial Function in Patients With Pulmonary Arterial Hypertension|Unknown status|Active, not recruiting|N/A|90|Actual|Universitätsklinikum Hamburg-Eppendorf||3|||f||||f||||||||No||2018-05-31 22:46:55.167894|2018-05-31 22:46:55.167894
NCT01317121|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2015-06-02|2011-03-15|2011-03-17|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|||Multi-site Communication Deficits in Schizophrenia|Multi-site Communication Deficits Underlying Cognitive Dysfunction in the Prodromal Phase and First Episode of Schizophrenia|Unknown status|Recruiting||144|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||3||f||||f||||||||||2018-05-31 22:46:55.351868|2018-05-31 22:46:55.351868
NCT01317108|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2017-05-23|2011-03-15|2011-03-17|Estimate|||||||2017-05-23|2017-05-25|Actual|June 1993||1993-06-30|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ChemoN0||Prognostic and Predictive Impact of uPA/PAI-1|Adjuvant Chemotherapy in Node-negative Breast Cancer: Chemo N0|Completed||Phase 3|689|Actual|Universitätsklinikum Hamburg-Eppendorf||4|||f||||t||||||||||2018-05-31 22:46:55.415441|2018-05-31 22:46:55.415441
NCT01317095|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2017-10-18||2018-01-16|2011-03-15|2011-03-17|Estimate|2018-01-16|2018-02-14|Actual||||2018-01-16|2018-02-14|Actual|March 2011||2011-03-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||A Study of Sternal Closure After Open Heart Surgery: Rigid Versus Wire Closure|A Prospective Randomized Study of Two Types of Sternal Closure After Open Heart Surgery: Rigid Sternal Fixation vs. Sternal Wire Closure|Completed||N/A|80|Actual|Thomas Jefferson University|Small number of enrollment.|2|||f||||t||||||||||2018-05-31 22:46:55.482052|2018-05-31 22:46:55.482052
NCT01317082|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-17|Estimate|||||||2011-03-15|2011-03-17|Estimate||||February 2011|2011-02-28||||||||Expanded Access|||Use of the Pressure Right Device After Laparoscopic Surgery||No longer available|||||Therapeutics: 101 Inc.|||||f||||||||||||||2018-05-31 22:46:55.719529|2018-05-31 22:46:55.719529
NCT01317069|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-17|Estimate|||||||2011-03-15|2011-03-17|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer|A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|Simcere Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 22:46:55.767634|2018-05-31 22:46:55.767634
NCT01317030|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2013-03-15|2011-03-15|2011-03-17|Estimate|||||||2013-03-15|2013-03-18|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers|Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers Using a Schirmer Strip for Tear Collection|Completed||N/A|30|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:46:55.834144|2018-05-31 22:46:55.834144
NCT01317017|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2013-03-04|2011-03-15|2011-03-16|Estimate|||||||2013-03-04|2013-03-05|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Cell Responses to IFN-gamma|Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients|Terminated||Early Phase 1|2|Actual|Rockefeller University||||Unable to isolate sufficient cells from the skin biopsy to perform study experiments.|f||||f||||||||||2018-05-31 22:46:55.975768|2018-05-31 22:46:55.975768
NCT01317004|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2015-05-29||2015-06-18|2011-03-15|2011-03-16|Estimate|2015-06-18|2015-06-22|Estimate||||2015-06-18|2015-06-22|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|EPOC||Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change|A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)|Completed||Phase 4|61|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:46:56.066377|2018-05-31 22:46:56.066377
NCT01316991|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2018-03-15|2011-03-15|2011-03-16|Estimate|||||||2018-03-15|2018-03-16|Actual|December 1, 2010|Actual|2010-12-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|GUM||A Study of Chewing Gum, Snacking and Appetite|Understanding the Role of Chewing Gum in Satiation, Satiety and Hunger Management|Active, not recruiting||N/A|56|Actual|Institute for Food Safety and Health, United States||2|||f||||f||||||||No||2018-05-31 22:46:56.461762|2018-05-31 22:46:56.461762
NCT01316978|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-07-06|2011-03-15|2011-03-16|Estimate|||||||2012-07-06|2012-07-10|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study to Test Bioequivalence Between One Test Formulation of Ibuprofen and Two Reference Treatments|A Single-Dose, Randomised, Crossover Bioequivalence Study to Compare the Rate and Extent of Absorption of a Test Formulation of Ibuprofen Fast Melt Orodispersible Tablet Versus Two Reference Formulations in Healthy Volunteers|Completed||Phase 1|30|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 22:46:56.547126|2018-05-31 22:46:56.547126
NCT01316965|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2017-05-24|2011-03-15|2011-03-16|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2011|Actual|2011-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|CONFUCIUS||Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly|CONFUCIUS Study : Impact of a Multifaceted Program to Prevent Postoperative Delirium in the Elderly|Terminated||N/A|175|Actual|Hospices Civils de Lyon||2||enrollment of patients insufficient|f||||f||||||||||2018-05-31 22:46:56.620429|2018-05-31 22:46:56.620429
NCT01316952|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2015-04-14|2011-03-15|2011-03-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Coreg and HSRs-Updated Analysis|A Nested Case-control Study of the Association Between Coreg IR and Coreg CR and Hypersensitivity Reactions: Anaphylactic Reaction/Angioedema-Updated Analysis|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:46:56.705666|2018-05-31 22:46:56.705666
NCT01316796|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2018-03-27|2011-03-15|2011-03-16|Estimate|||||||2018-03-27|2018-03-29|Actual|March 15, 2011||2011-03-15|October 20, 2017|2017-10-20|September 18, 2015|Actual|2015-09-18|September 18, 2015|Actual|2015-09-18||Interventional|||Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders|A Phase I Study of the Use of Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Hemolytic Disorders|Completed||Phase 1|28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:47:03.582082|2018-05-31 22:47:03.582082
NCT01316939|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2017-06-28|2014-03-13|2017-08-07|2011-03-15|2011-03-16|Estimate|2017-08-07|2017-09-07|Actual|2014-03-13|2014-04-11|Estimate|2017-08-07|2017-09-07|Actual|May 9, 2011|Actual|2011-05-09|August 2017|2017-08-31|October 23, 2013|Actual|2013-10-23|October 23, 2013|Actual|2013-10-23||Interventional|SHIELD-2||GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease|A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease|Terminated||Phase 3|229|Actual|GlaxoSmithKline|The limited data resulting from early termination of Study CCX114157 did not allow any conclusions to be drawn about the efficacy of GSK1605786A in the maintenance of clinical remission in participants with Crohn’s disease.|3||"This study was terminated due to the lack of efficacy of GSK1605786A in Crohn's disease based~   on the results of Study CCX114151."|f||||t||||||||||2018-05-31 22:46:56.903483|2018-05-31 22:46:56.903483
NCT01316926|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2011-03-24||2018-05-17|2011-03-15|2011-03-16|Estimate|2011-03-24|2011-04-18|Estimate||||2018-05-17|2018-05-22|Actual|September 9, 2009|Actual|2009-09-09|May 2018|2018-05-31|October 5, 2009|Actual|2009-10-05|October 5, 2009|Actual|2009-10-05||Interventional|||Paxil CR Bioequivalence Study Brazil|Relative Bioavailability Study Between the Formulations: Paroxetine 25 mg Tablet With Controlled Release Manufactured by GSK Mississauga and Paroxetine 25 mg Tablets With Controlled Release Manufactured by SmithKline Beecham (Cidra), Fasted Administration in Healthy Volunteers for Both Genders.|Completed||Phase 1|60|Actual|GlaxoSmithKline|The number of adverse events per intervention is not available in the final report.|2|||f||||f||||||||||2018-05-31 22:46:59.368045|2018-05-31 22:46:59.368045
NCT01316913|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2014-01-09||2017-03-07|2011-03-15|2011-03-16|Estimate|2014-01-09|2014-02-24|Estimate||||2017-03-07|2017-04-04|Actual|March 2011||2011-03-31|March 2017|2017-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease|A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD|Completed||Phase 3|872|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:46:59.720272|2018-05-31 22:46:59.720272
NCT01316900|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2013-12-19||2018-01-18|2011-03-15|2011-03-16|Estimate|2013-12-19|2014-02-10|Estimate||||2018-01-18|2018-01-24|Actual|March 1, 2011||2011-03-01|January 2018|2018-01-31|April 24, 2012|Actual|2012-04-24|April 1, 2012|Actual|2012-04-01||Interventional|||24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease|A Multicenter Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GW642444 and With Tiotropium Over 24 Weeks in Subjects With COPD|Completed||Phase 3|846|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:47:00.8106|2018-05-31 22:47:00.8106
NCT01316887|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2013-12-19|2013-01-10|2018-04-30|2011-03-15|2011-03-16|Estimate|2014-02-20|2014-03-20|Estimate|2013-01-10|2013-01-18|Estimate|2018-04-30|2018-05-02|Actual|January 1, 2011||2011-01-01|April 2018|2018-04-30|July 21, 2012|Actual|2012-07-21|July 1, 2012|Actual|2012-07-01||Interventional|COPD nDPI||A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 52 Week Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 125mcg Once-daily Alone and in Combination With GW642444 25mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|563|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:47:01.776502|2018-05-31 22:47:01.776502
NCT01316874|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2015-06-10|2011-03-15|2011-03-16|Estimate|||||||2015-06-10|2015-06-12|Estimate|November 1993||1993-11-30|June 2015|2015-06-30|April 1997|Actual|1997-04-30|April 1997|Actual|1997-04-30||Interventional|Bladder Cancer||Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)|Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)|Completed||Phase 2/Phase 3|90|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:47:03.137035|2018-05-31 22:47:03.137035
NCT01316861|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2013-09-24|2011-03-15|2011-03-16|Estimate|||||||2013-09-24|2013-09-25|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus|A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|79|Actual|EMS||2|||f||||t||||||||||2018-05-31 22:47:03.242724|2018-05-31 22:47:03.242724
NCT01316848|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-06-01|2011-03-15|2011-03-16|Estimate|||||||2012-06-01|2012-06-05|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects|A Phase 1, Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects|Completed||Phase 1|30|Actual|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 22:47:03.313153|2018-05-31 22:47:03.313153
NCT01316835|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Effectiveness of Sitagliptin in Glycemic Control in Real World|A Retrospective, Observational Study to Assess the Effectiveness of Glycemic Control of Diabetes in Real World After Sitagliptin Usage|Unknown status|Recruiting||1120|Anticipated|Chang Gung Memorial Hospital|||1||f||||f||||||||||2018-05-31 22:47:03.385136|2018-05-31 22:47:03.385136
NCT01316822|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2012-10-23|2011-03-15|2011-03-16|Estimate|||||||2012-10-23|2012-10-24|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers||Completed||Phase 1|26|Actual|Array BioPharma||1|||f||||||||||||||2018-05-31 22:47:03.446021|2018-05-31 22:47:03.446021
NCT01316809|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2018-05-23|2011-03-15|2011-03-16|Estimate|||||||2018-05-23|2018-05-24|Actual|March 4, 2011||2011-03-04|April 14, 2016|2016-04-14|April 4, 2016|Actual|2016-04-04|April 14, 2014|Actual|2014-04-14||Interventional|||AZD8055 for Adults With Recurrent Gliomas|Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults With Recurrent Gliomas|Completed||Phase 1|22|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:47:03.508605|2018-05-31 22:47:03.508605
NCT01316770|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2017-10-18|2011-03-15|2011-03-16|Estimate|||||||2017-10-18|2017-10-19|Actual|May 1, 2011||2011-05-01|April 17, 2017|2017-04-17|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Interventional|||Dexamethasone Irrigation of the Parotid Glands in Primary Sj(SqrRoot)(Delta)Gren s Syndrome Subjects|A Randomized Within-Subject, Double-Blind, Placebo-Controlled Study of Dexamethasone Irrigation of the Parotid Glands in Primary Sj(SqrRoot)(Delta)Gren's Syndrome Subjects|Completed||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:47:03.723831|2018-05-31 22:47:03.723831
NCT01316757|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-02-23|2011-03-15|2011-03-16|Estimate|||||||2018-02-23|2018-02-26|Actual|February 16, 2011|Actual|2011-02-16|January 2017|2017-01-31|October 3, 2017|Actual|2017-10-03|April 7, 2015|Actual|2015-04-07||Interventional|||Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer|Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.|Completed||Phase 2|24|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 22:47:03.800439|2018-05-31 22:47:03.800439
NCT01316744|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-05-12|2011-03-15|2011-03-16|Estimate|||||||2011-05-12|2011-05-13|Estimate|April 2009||2009-04-30|March 2011|2011-03-31||||October 2011|Anticipated|2011-10-31||Interventional|||Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain|A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients|Unknown status|Recruiting|Phase 3|214|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:47:03.905916|2018-05-31 22:47:03.905916
NCT01316731|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-12-20|2011-03-14|2011-03-16|Estimate|||||||2011-12-20|2011-12-21|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||MyoGene: Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle|Effects of Acute Exercise on (Myokine) Gene Expression in Human Skeletal Muscle|Completed||N/A|12|Actual|Wageningen University||1|||f||||f||||||||||2018-05-31 22:47:04.019008|2018-05-31 22:47:04.019008
NCT01316718|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2014-01-16|2011-03-15|2011-03-16|Estimate|||||||2014-01-16|2014-01-17|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MIBS||Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)|Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).|Completed||Phase 4|108|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 22:47:04.07917|2018-05-31 22:47:04.07917
NCT01316705|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2018-04-03|2011-03-15|2011-03-16|Estimate|||||||2018-04-03|2018-04-04|Actual|April 2010||2010-04-30|April 2018|2018-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Comparison Between Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) And Intra Cytoplasmic Sperm Injection (ICSI) Techniques With Eggs Donated|COMPARISON BETWEEN IMSI AND ICSI TECHNIQUES WITH DONATED EGGS|Completed|||25|Actual|IVI Madrid|||||f||||f||||||||||2018-05-31 22:47:04.146985|2018-05-31 22:47:04.146985
NCT01316692|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2016-04-21||2016-04-21|2011-03-15|2011-03-16|Estimate|2016-04-21|2016-05-30|Estimate||||2016-04-21|2016-05-30|Estimate|October 2011||2011-10-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|November 2014|Actual|2014-11-30||Interventional|||Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma|A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease|Terminated||Phase 2|12|Actual|Vanderbilt-Ingram Cancer Center||1||low accrual|f||||t||||||||||2018-05-31 22:47:04.201331|2018-05-31 22:47:04.201331
NCT01316679|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2017-04-10|2011-03-15|2011-03-16|Estimate|||||||2017-04-10|2017-04-12|Actual|March 2011|Actual|2011-03-31|April 2017|2017-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423|An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423|Completed|||87|Actual|Vanderbilt University Medical Center|||3||f||||f||||||||||2018-05-31 22:47:04.456961|2018-05-31 22:47:04.456961
NCT01316666|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2017-01-04|2011-03-15|2011-03-16|Estimate|||||||2017-01-04|2017-01-06|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|6103||Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension|Norepinephrine Transporter Blockade as a Pathophysiological Biomarker in Neurogenic Orthostatic Hypotension|Completed|||50|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||||2018-05-31 22:47:04.583917|2018-05-31 22:47:04.583917
NCT01316653|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2018-04-09|2011-03-15|2011-03-16|Estimate|||||||2018-04-09|2018-04-11|Actual|June 2011||2011-06-30|April 2018|2018-04-30|July 6, 2017|Actual|2017-07-06|June 13, 2017|Actual|2017-06-13||Interventional|GROW||Growing Right Onto Wellness (GROW): Changing Early Childhood Body Mass Index (BMI) Trajectories|Growing Right Onto Wellness (GROW): Changing Early Childhood Body Mass Index (BMI) Trajectories|Completed||N/A|610|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 22:47:04.683026|2018-05-31 22:47:04.683026
NCT01316627|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-14|2011-03-14|2011-03-16|Estimate|||||||2011-03-14|2011-03-16|Estimate|April 2007||2007-04-30|March 2011|2011-03-31||||December 2014|Anticipated|2014-12-31||Interventional|BDD||Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions|Crooked Mirror Externalization Therapy for Body Dysmorphic Disorder|Unknown status|Recruiting|Phase 2|20|Anticipated|Westwood Institute for Anxiety Disorders, Inc||2|||f||||t||||||||||2018-05-31 22:47:04.774735|2018-05-31 22:47:04.774735
NCT01316614|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2014-11-10||2014-11-24|2011-03-15|2011-03-16|Estimate|2014-11-24|2014-12-03|Estimate||||2014-11-24|2014-12-03|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||EUS-guided Fine Needle Aspiration (FNA) With and Without the Use of a Stylet|Randomized Controlled Trial of Endoscopic Ultrasound Guided Fine Needle Aspiration of Solid Lesions With and Without a Stylet|Completed||N/A|137|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 22:47:04.90333|2018-05-31 22:47:04.90333
NCT01316601|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-05-27|2011-03-15|2011-03-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease||Completed||Phase 2|3|Actual|University of Zurich|||||f||||||||||||||2018-05-31 22:47:05.292087|2018-05-31 22:47:05.292087
NCT01316588|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2016-04-18|2011-03-15|2011-03-16|Estimate|||||||2016-04-18|2016-04-19|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Recolonization Following Preoperative Disinfection Plastic Adhesive Drapes|Recolonization of the Skin Following Pre-operative Disinfection and Impact of the Use of Plastic Adhesive Drapes|Completed||Phase 3|140|Actual|Örebro University, Sweden||2|||f||||t||||||||No||2018-05-31 22:47:05.362949|2018-05-31 22:47:05.362949
NCT01316575|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2012-07-20||2013-01-22|2011-03-14|2011-03-16|Estimate|2013-01-22|2013-02-27|Estimate||||2013-01-22|2013-02-27|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Prophylactic nCPAP Following Bowel Surgery (Bio-REB File 11-27)|Prophylactic Nasal Continuous Positive Airway Pressure (nCPAP) Following Bowel Surgery|Completed||N/A|40|Actual|University of Saskatchewan|"We made an assumption for FiO2, the respiratory quotient and barometric pressure in the alveolar air equation.~We did not standardize the time between extubation and application of nCPAP."|2|||f||||f||||||||||2018-05-31 22:47:05.435522|2018-05-31 22:47:05.435522
NCT01316562|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-03-08|2011-03-14|2011-03-16|Estimate|||||||2012-03-08|2012-03-09|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|July 2012|Anticipated|2012-07-31|July 2011|Actual|2011-07-31||Observational|EVATEM||Predictive Value of Cognitive Tests Performed for the Diagnosis of Alzheimer's Disease and Related Disorders|Valeur prédictive d'Une évaluation Cognitive standardisée en Centre d'Examens de Santé Pour le Diagnostic de la Maladie d'Alzheimer ou Des Maladies apparentées en Population générale Chez Les Plus de 65 Ans Avec Plainte mnésique|Unknown status|Recruiting||500|Anticipated|University Hospital, Angers|||2||f||||t||||||||||2018-05-31 22:47:05.698858|2018-05-31 22:47:05.698858
NCT01316549|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-12-16|2011-03-14|2011-03-16|Estimate|||||||2014-12-16|2014-12-18|Estimate|September 2010||2010-09-30|December 2014|2014-12-31||||June 2015|Anticipated|2015-06-30||Observational|HCT||Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation|Population Pharmacokinetics of Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation|Unknown status|Recruiting||75|Anticipated|University of California, San Francisco|||||f||||f||||||Samples With DNA|"~     whole blood, DNA~   "|||2018-05-31 22:47:05.771977|2018-05-31 22:47:05.771977
NCT01316536|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-04-16|2011-03-14|2011-03-16|Estimate|||||||2015-04-16|2015-04-17|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Music Therapy is Associated With Decreased Pain and Agitation in Intubated ICU Patients|Music Therapy is Associated With Decreased Pain and Agitation in Intubated ICU Patients|Terminated||N/A|5|Actual|University of California, San Francisco||2||inability to recruit participants despite numerous attempts|f||||f||||||||||2018-05-31 22:47:05.865968|2018-05-31 22:47:05.865968
NCT01316523|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2018-03-01|2011-03-14|2011-03-16|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2010|Actual|2010-12-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma|Phase II Study of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non Hodgkin's Lymphoma|Active, not recruiting||Phase 2|30|Actual|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 22:47:05.934467|2018-05-31 22:47:05.934467
NCT01316510|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-01-22|2011-03-14|2011-03-16|Estimate|||||||2015-01-22|2015-01-26|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|||Probiotics in Infants With Gastroschisis|Probiotics in Infants With Gastroschisis|Unknown status|Recruiting|N/A|24|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 22:47:06.018983|2018-05-31 22:47:06.018983
NCT01316497|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-09-13|2011-03-14|2011-03-16|Estimate|||||||2012-09-13|2012-09-14|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Acute Kidney Injury in Children Operated for Congenital Heart Disease|Acute Kidney Injury in Children Operated for Congenital Heart Disease|Completed||N/A|105|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 22:47:06.127286|2018-05-31 22:47:06.127286
NCT01316484|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-05-23|2011-03-14|2011-03-16|Estimate|||||||2011-05-23|2011-05-24|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Patient Understanding (Cognitive Debriefing) of a Daily Diary of Gastroparesis Symptoms|Protocol for the Patient Understanding (Cognitive Debriefing) of a Modified Gastroparesis Cardinal Symptom Index (GCSI) Daily Diary|Completed|||40|Anticipated|Tranzyme, Inc.|||1||f||||f||||||||||2018-05-31 22:47:06.233999|2018-05-31 22:47:06.233999
NCT01316471|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2015-11-30|2011-03-14|2011-03-16|Estimate|||||||2015-11-30|2015-12-02|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Internet Intervention for Adolescents With Chronic Pain|Web-MAP 2: Internet Intervention for Adolescents With Chronic Pain|Completed||Phase 2|273|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 22:47:06.3001|2018-05-31 22:47:06.3001
NCT01316458|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2017-05-31|2011-03-15|2011-03-16|Estimate|||||||2017-05-31|2017-06-01|Actual|June 2003||2003-06-30|March 2011|2011-03-31||||July 2010|Actual|2010-07-31||Interventional|||Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy|An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy|Completed||Phase 2|51|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:47:06.391767|2018-05-31 22:47:06.391767
NCT01316445|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2015-02-02|2011-03-15|2011-03-16|Estimate|||||||2015-02-02|2015-02-04|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|nMDZ-EEG||Pharmacodynamics of Nasal and Buccal Midazolam Using EEG|Comparing the Pharmacodynamics of Nasal and Buccal Midazolam Using EEG|Terminated||Phase 1|9|Actual|Columbia University||1||Funding agency no longer provide support.|f||||f||||||||||2018-05-31 22:47:06.488183|2018-05-31 22:47:06.488183
NCT01316432|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2012-10-16|2011-03-15|2011-03-16|Estimate|||||||2012-10-16|2012-10-18|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||PK/PD Study of Subcutaneous Cenderitide Infusion in CHF Patients|A Study Assessing The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Subcutaneous Bolus And Subcutaneous Infusion Of Cenderitide In Patients With Chronic Heart Failure With Volume Overload (HF)|Completed||Phase 1|58|Actual|Nile Therapeutics||3|||f||||f||||||||||2018-05-31 22:47:06.573654|2018-05-31 22:47:06.573654
NCT01316419|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2015-06-26||2015-09-08|2011-03-15|2011-03-16|Estimate|2015-06-26|2015-07-27|Estimate||||2015-09-08|2015-09-21|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||All treated patients fulfilling the inclusion-exclusion criterias and who have completed the follow-up visits of the study.|Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension|An Observational Study to Evaluate the Effects of Twynsta Tablets (Telmisartan and Amlodipine FDC, q.d.) With Life Style Modifications on Blood Pressure, Quality of Life, and Other Risk Factors in Korean Patients With Hypertension|Completed|||2089|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 22:47:06.686265|2018-05-31 22:47:06.686265
NCT01316094|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-01-18|2011-03-14|2011-03-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment|Long-term Study of ASP1941 - Study to Assess the Efficacy and Safety of ASP1941 in Patients With Type 2 Diabetes Mellitus Who Have Renal Impairment|Completed||Phase 3|165|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 22:47:13.717415|2018-05-31 22:47:13.717415
NCT01316406|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-01-29|2011-03-15|2011-03-16|Estimate|||||||2014-01-29|2014-01-30|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine|A Phase II Placebo Controlled, Multicenter Study to Investigate the Safety and Efficacy of ATH008 Cream in Patients With Palmar-Plantar Erythrodysesthesia Syndrome (PPES) Secondary to Capecitabine Therapy.|Completed||Phase 2|122|Actual|Advancell - Advanced In Vitro Cell Technologies, S.A.||3|||f||||f||||||||||2018-05-31 22:47:07.150153|2018-05-31 22:47:07.150153
NCT01316393|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-11-08|2011-03-15|2011-03-16|Estimate|||||||2011-11-08|2011-11-09|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Effects of Mucoprotective Product on Xerostomia|Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients|Completed||Phase 4|20|Actual|Camurus AB||3|||f||||t||||||||||2018-05-31 22:47:07.290437|2018-05-31 22:47:07.290437
NCT01316380|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2013-04-19||2015-03-25|2011-03-15|2011-03-16|Estimate|2013-07-30|2013-07-31|Estimate||||2015-03-25|2015-04-15|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 ug and 5 ug Once Daily) Compared to Placebo Over 12 Weeks in Mild Persistent Asthma|Completed||Phase 3|465|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:47:07.432655|2018-05-31 22:47:07.432655
NCT01316367|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|February 2003||2003-02-28|March 2003|2003-03-31|March 2005|Actual|2005-03-31|February 2005|Actual|2005-02-28||Interventional|||Effectiveness of PRECEDE Model for Health Education on Changes and Level of Control in Patients With Type 2 Diabetes Mellitus|Effectiveness of PRECEDE Model for Health Education on Cardiovascular Risk Reduction in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|600|Actual|Hospital Carlos III, Madrid||2|||f||||f||||||||||2018-05-31 22:47:08.132099|2018-05-31 22:47:08.132099
NCT01316354|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-04-18|2011-03-15|2011-03-16|Estimate|||||||2012-04-18|2012-04-19|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Dietary Fibre and Whole Grain on the Metabolic Syndrome|Effect of Arabinoxylan and Beta-glucan Compared With Whole Grain and Whole Meal Bread in Subjects With the Metabolic Syndrome|Completed||N/A|15|Actual|Aarhus University Hospital||4|||f||||t||||||||||2018-05-31 22:47:08.21668|2018-05-31 22:47:08.21668
NCT01316341|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2014-05-16||2014-05-16|2011-03-15|2011-03-16|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|March 2011||2011-03-31|May 2014|2014-05-31||||January 2012|Actual|2012-01-31||Interventional|||Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus|Pharmacokinetics and Pharmacodynamics of BI 10773 After Single and Multiple Oral Dose of 10 mg and 25 mg BI 10773 in Chinese Male and Female Type 2 Diabetic Patients|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:47:08.335306|2018-05-31 22:47:08.335306
NCT01316328|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|HYPOPRONE||Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery|Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery|Completed|||||Regina Elena Cancer Institute|||1||f||||||||||||||2018-05-31 22:47:08.847993|2018-05-31 22:47:08.847993
NCT01316315|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2014-01-28||2014-04-17|2011-03-15|2011-03-16|Estimate|2014-01-28|2014-03-11|Estimate||||2014-04-17|2014-05-05|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional||Any patient that received a dose of N6022 or Placebo|Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma|A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma|Completed||Phase 1/Phase 2|14|Actual|Nivalis Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 22:47:08.901802|2018-05-31 22:47:08.901802
NCT01316302|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2014-09-30||2016-08-23|2011-03-14|2011-03-16|Estimate|2014-10-06|2014-10-08|Estimate||||2016-08-23|2016-10-17|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder|A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder|Completed||Phase 4|63|Actual|The Medical Research Network||2|||f||||f||||||||||2018-05-31 22:47:09.285833|2018-05-31 22:47:09.285833
NCT01316289|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2018-01-15|2011-03-15|2011-03-16|Estimate|||||||2018-01-15|2018-01-17|Actual|November 2011|Actual|2011-11-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Observational|||Pilon Fracture Reduction and Functional Outcome|Quality of Fracture Reduction and Its Influence on Functional Outcome in Patients With Pilon Fractures - a Prospective Multicenter Case Series|Completed|||117|Actual|AO Clinical Investigation and Documentation|||||f||||t||||||||||2018-05-31 22:47:09.512045|2018-05-31 22:47:09.512045
NCT01316276|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14||2016-09-29|2016-09-30|2011-03-14|2011-03-16|Estimate||||2016-09-30|2016-10-03|Estimate|2016-09-30|2016-10-03|Estimate|October 2012||2012-10-31|September 2016|2016-09-30||||July 2015|Actual|2015-07-31||Interventional|||Extension Study of Arikayce in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa Infection|Long Term Safety and Tolerability of Open-Label Liposomal Amikacin for Inhalation (Arikayce™) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa|Completed||Phase 3|206|Actual|Insmed Incorporated||1|||f||||t||||||||||2018-05-31 22:47:09.583449|2018-05-31 22:47:09.583449
NCT01316263|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2016-11-18|2013-02-25|2017-01-27|2011-03-15|2011-03-16|Estimate|2016-11-18|2017-01-16|Estimate|2013-02-25|2013-03-01|Estimate|2017-01-27|2017-03-09|Actual|August 2011||2011-08-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional||All participants who received any study drug.|A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors|A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)|Terminated||Phase 2|21|Actual|Eli Lilly and Company|The development of olaratumab (IMC-3G3) was put on hold in this indication due to reasons not related to efficacy and/or safety, Stage 2 of this study was not completed and trial terminated due to poor accrual.|2||Trial terminated strategically due to poor accrual.|f||||f||||||||||2018-05-31 22:47:09.729045|2018-05-31 22:47:09.729045
NCT01316250|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2018-01-09|2011-03-15|2011-03-16|Estimate|||||||2018-01-09|2018-01-10|Actual|August 2010||2010-08-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia|Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia|Recruiting||N/A|25|Anticipated|American University of Beirut Medical Center||1|||f||||t||||||||||2018-05-31 22:47:11.676613|2018-05-31 22:47:11.676613
NCT01316237|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2012-03-22|2011-03-14|2011-03-16|Estimate|||||||2012-03-22|2012-03-26|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection|A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 1|90|Anticipated|Gilead Sciences||9|||f||||||||||||||2018-05-31 22:47:11.78983|2018-05-31 22:47:11.78983
NCT01316224|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2015-04-08||2015-04-27|2011-03-15|2011-03-16|Estimate|2015-04-27|2015-05-12|Estimate||||2015-04-27|2015-05-12|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|TOGETHER||Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment|Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment|Completed|||52|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:47:11.928015|2018-05-31 22:47:11.928015
NCT01316211|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2017-02-02|2011-03-15|2011-03-16|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 2008||2008-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|August 2014|Actual|2014-08-31||Interventional|||Clinical Trial Comparing Decompression With and Without Coflex™ Interlaminar Technology Treating Lumbar Spinal Stenosis|Comparative Evaluation of Clinical Outcome in the Treatment of Degenerative Spinal Stenosis With Concomitant Low Back Pain by Decompression With and Without Additional Stabilization Using the Coflex™ Interlaminar Technology|Active, not recruiting||N/A|245|Actual|Paradigm Spine||2|||f||||f||||||||||2018-05-31 22:47:12.499588|2018-05-31 22:47:12.499588
NCT01316198|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-07-26|2011-03-15|2011-03-16|Estimate|||||||2012-07-26|2012-07-27|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Effects of Xanthophylls on Optical Density|Alteration of Optical Density and Plasma Xanthophylls After Short Term Supplementation With Macular Carotenoids in Patients With AMD|Completed||N/A|20|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 22:47:12.780776|2018-05-31 22:47:12.780776
NCT01316185|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-08-04|2011-03-14|2011-03-16|Estimate|||||||2016-08-04|2016-08-08|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)|An Open Label, Dose-ranging Proof-of-concept Study Assessing the Safety and Efficacy of EBP921 in Therapy-naive Patients Chronically Infected With Delta Hepatitis (HDV)|Terminated||Phase 1|3|Actual|Eiger BioPharmaceuticals||2||the enrollment was slow and never completed.|f||||f||||||||||2018-05-31 22:47:12.855774|2018-05-31 22:47:12.855774
NCT01316172|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|5 Cs||Consultation in the Emergency Department|A Prospective, Randomized Controlled Study Demonstrating a Novel, Effective Model of Communication Among Physicians: The 5 Cs of Consultation|Completed||N/A|43|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 22:47:12.934338|2018-05-31 22:47:12.934338
NCT01316159|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|April 2007||2007-04-30|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|PREDICTION||Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology|Prediction of Progression of Coronary Artery Disease and Clinical Outcome Using Vascular Profiling of Shear Stress and Wall Morphology|Unknown status|Active, not recruiting||506|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-05-31 22:47:13.027348|2018-05-31 22:47:13.027348
NCT01316146|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2018-03-21|2011-03-14|2011-03-16|Estimate|||||||2018-03-21|2018-03-22|Actual|October 3, 2011|Actual|2011-10-03|March 2018|2018-03-31|December 2031|Anticipated|2031-12-31|January 28, 2016|Actual|2016-01-28||Interventional|||Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)|Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CART CD30)|Active, not recruiting||Phase 1|10|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 22:47:13.098169|2018-05-31 22:47:13.098169
NCT01316133|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-09-06|2011-03-14|2011-03-16|Estimate|||||||2016-09-06|2016-09-08|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|APPLE||A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients|A Multicenter, Non-comparative, Open-labeled, Prospective Study to Evaluate the Efficacy and Safety of Tacrolimus (Prograf®) With Steroid in Korean Lupus Nephritis Patients Who Are Non-responders to Steroid Monotherapy|Terminated||Phase 4|37|Actual|Astellas Pharma Inc||1||Study terminated due to poor patient recruitment.|f||||f||||||||||2018-05-31 22:47:13.222486|2018-05-31 22:47:13.222486
NCT01316120|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-12-22|2011-03-15|2011-03-16|Estimate|||||||2011-12-22|2011-12-23|Estimate|November 2010||2010-11-30|December 2011|2011-12-31|December 2011|Anticipated|2011-12-31|August 2011|Actual|2011-08-31||Interventional|HPVDry||Randomized Comparison of Vaginal Self Sampling for Human Papillomavirus (HPV) Testing by Standard Versus Dry Vaginal Swabs|Randomized Comparison of Vaginal Self Sampling for Human Papillomavirus (HPV) Testing by Standard Versus Dry Vaginal Swabs|Unknown status|Enrolling by invitation|N/A|120|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 22:47:13.477588|2018-05-31 22:47:13.477588
NCT01316107|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-01-19|2011-03-14|2011-03-16|Estimate|||||||2016-01-19|2016-01-20|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients|A Phase 3, Open-Label, Non-comparative Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Combination With Nateglinide in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With Nateglinide Alone|Completed||Phase 3|122|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 22:47:13.633378|2018-05-31 22:47:13.633378
NCT01316081|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-06-18|2011-03-15|2011-03-16|Estimate|||||||2012-06-18|2012-06-19|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A 4-month Intervention of Antioxidant Supplementation in Overweight Children|A 4-month, Randomized, Placebo-controlled, Double-blind Intervention of Antioxidant Supplementation in Overweight Children Enrolled in an Outpatient Weight-loss Program: Effects on Oxidative and Inflammatory Markers, Hepcidin, Iron Status, and Components of the Metabolic Syndrome|Completed||N/A|45|Actual|Swiss Federal Institute of Technology||2|||f||||t||||||||||2018-05-31 22:47:13.809967|2018-05-31 22:47:13.809967
NCT01316068|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|March 2011||2011-03-31|August 2010|2010-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|Soften||Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients|Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients|Unknown status|Enrolling by invitation|Phase 4|80|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:47:13.893727|2018-05-31 22:47:13.893727
NCT01316055|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2012-08-24||2012-10-09|2011-03-15|2011-03-16|Estimate|2012-10-09|2012-11-07|Estimate||||2012-10-09|2012-11-07|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment|A Parallel, Three Arm, Open-label, Multi-dose Pharmacokinetic Study of Dalfampridine-ER 7.5 mg Twice Daily in Both Healthy Volunteers and Those With Mild and Moderate Renal Impairment|Completed||Phase 1|42|Actual|Acorda Therapeutics||3|||f||||f||||||||||2018-05-31 22:47:14.029863|2018-05-31 22:47:14.029863
NCT01316042|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|2016-04-07||2016-04-07|2011-03-15|2011-03-16|Estimate|2016-04-07|2016-05-12|Estimate||||2016-04-07|2016-05-12|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Metformin for the Treatment of Premature Pubarche in Girls|A Double Blind Randomized Controlled 12 Month Trial of Metformin for the Treatment of Premature Pubarche in Girls|Terminated||N/A|4|Actual|Milton S. Hershey Medical Center|Early termination of the study due to low recruitment.|2||poor recruitment at collaborating sites|f||||t||||||||||2018-05-31 22:47:14.456018|2018-05-31 22:47:14.456018
NCT01316029|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|February 2007||2007-02-28|January 2007|2007-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|SELH||Safety/Effectiveness Study of a Single Session of Laying-on-of-hands in Various Settings in Japan|A Large Cross-sectional Study of Laying-on-of-hands in Japan: Who Responds to it and What Facilitates the Response?|Completed|||44587|Actual|MOA Health Science Foundation|||1||f||||f||||||||||2018-05-31 22:47:14.711184|2018-05-31 22:47:14.711184
NCT01316016|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|April 2009||2009-04-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|||Antidiabetic Properties of Rose Hip|Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons|Completed||N/A|31|Actual|Lund University||1|||f||||f||||||||||2018-05-31 22:47:14.785635|2018-05-31 22:47:14.785635
NCT01316003|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2012-07-31|2011-03-15|2011-03-16|Estimate|||||||2012-07-31|2012-08-02|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Distinction of Cone Outer Segment Tips by Spectral-Domain Optical Coherence Tomography in Normal Eyes|Distinction of Cone Outer Segment Tips by Spectral-Domain Optical Coherence Tomography in Normal Eyes|Completed|||37|Actual|Kyorin University|||1||f||||f||||||||||2018-05-31 22:47:14.848507|2018-05-31 22:47:14.848507
NCT01315990|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2013-12-17|2011-03-15|2011-03-16|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|March 2018|Anticipated|2018-03-31|March 2015|Anticipated|2015-03-31||Interventional|DERMATUX||FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema|Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema|Unknown status|Active, not recruiting|Phase 4|165|Anticipated|Johannes Gutenberg University Mainz||1|||f||||f||||||||||2018-05-31 22:47:14.915778|2018-05-31 22:47:14.915778
NCT01315977|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|April 2012|Anticipated|2012-04-30|February 2012|Anticipated|2012-02-29||Interventional|||Dietary Antioxidants, Redox Tone and Health Promotion: an Orthomolecular Study of Interactions|Orthomolecular Mechanisms of Health Effects of Antioxidant Rich Diets, With Focus on Green Tea (Camellia Sinensis), DNA Protection and Key Biochemical Products/Effects of the Antioxidant Response Element|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|The Hong Kong Polytechnic University|||||f||||t||||||||||2018-05-31 22:47:15.015723|2018-05-31 22:47:15.015723
NCT01315964|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2013-08-27|2011-03-15|2011-03-16|Estimate|||||||2013-08-27|2013-08-28|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|August 2013|Actual|2013-08-31|December 2011|Actual|2011-12-31||Interventional|BLOOD FLOW||Effects of Plant Stanol Esters on Blood Flow|Effects of Dietary Plant Stanol Esters of Blood Flow Among Healthy Adult Human Subject. The BLOOD FLOW -Study|Completed||N/A|100|Actual|Helsinki University||2|||f||||f||||||||||2018-05-31 22:47:15.071697|2018-05-31 22:47:15.071697
NCT01315951|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Interventional|||Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation|Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation|Unknown status|Recruiting|N/A|8|Anticipated|Genesys Regional Medical Center||1|||f||||f||||||||||2018-05-31 22:47:15.131935|2018-05-31 22:47:15.131935
NCT01315938|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|January 2011||2011-01-31|February 2010|2010-02-28|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|ARTEMIS||Abatacept Treatment in Polymyositis and Dermatomyositis|Abatacept Treatment in Polymyositis and Dermatomyositis|Unknown status|Recruiting|Phase 2|20|Anticipated|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 22:47:15.229281|2018-05-31 22:47:15.229281
NCT01315925|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-15|2011-03-15|2011-03-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|January 2010||2010-01-31|March 2011|2011-03-31||||||||Observational|SEIFEM 2010||Pre-hospital Risk Factors for Invasive Fungal Infection|SEIFEM 2010: Epidemiological Survey on Possible Pre-Hospital Risk Factors for Developing Invasive Fungal Infections in Patients Affected by Acute Myeloid Leukemia|Unknown status|Recruiting||1000|Anticipated|Catholic University of the Sacred Heart|||1||f||||||||||||||2018-05-31 22:47:15.312069|2018-05-31 22:47:15.312069
NCT01315912|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-15|||2011-03-25|2011-03-15|2011-03-16|Estimate|||||||2011-03-25|2011-03-28|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Dosage Optimization for Letrozole Treatment|Dosage Optimization for Letrozole Treatment in Clomiphene Resistant Patients With Polycystic Ovary Syndrome: A Prospective Interventional Study|Completed||Phase 4|44|Actual|Bushehr University of Medical Science|||||f||||t||||||||||2018-05-31 22:47:15.594818|2018-05-31 22:47:15.594818
NCT01315899|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-06-26|2011-03-14|2011-03-15|Estimate|||||||2014-06-26|2014-06-27|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|REINO||Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon|Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis|Terminated||Phase 2|15|Actual|Orion Corporation, Orion Pharma||3||Recommendation by study DSMC to the sponsor following interim analysis of 8 subjects.|f||||t||||||||||2018-05-31 22:47:15.667452|2018-05-31 22:47:15.667452
NCT01315886|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2017-04-03|2011-03-14|2011-03-15|Estimate|||||||2017-04-03|2017-04-05|Actual|February 21, 2011|Actual|2011-02-21|April 2017|2017-04-30|December 7, 2011|Actual|2011-12-07|December 7, 2011|Actual|2011-12-07||Interventional|||Conversion From Fast Acting Oral Opioids to Abstral®|Conversion From Fast Acting Oral Opioids to Abstral® (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain|Terminated||Phase 4|8|Actual|Orexo AB||1||Recruitment difficulties|f||||f||||||||No||2018-05-31 22:47:15.773318|2018-05-31 22:47:15.773318
NCT01315873|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2017-08-17||2018-01-10|2011-03-14|2011-03-15|Estimate|2017-12-05|2017-12-08|Actual||||2018-01-10|2018-02-07|Actual|September 2011||2011-09-30|January 2018|2018-01-31|September 2015|Actual|2015-09-30|February 2014|Actual|2014-02-28||Interventional|||Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma|Phase II Trial of Bortezomib and Bendamustine in the Treatment of Relapsed/Refractory Myeloma|Terminated||Phase 2|24|Actual|New York University School of Medicine||1||PI left the institution before all data analysis was completed|f||||t|t|f|||f|||||2018-05-31 22:47:15.865914|2018-05-31 22:47:15.865914
NCT01315860|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2012-06-17|2011-03-14|2011-03-15|Estimate|||||||2012-06-17|2012-06-19|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Association of Biomechanical Changes and Weight Gain Throughout Pregnancy|Association of Biomechanical Changes and Weight Gain Throughout Pregnancy|Completed|||28|Actual|Nova Southeastern University|||1||f||||t||||||||||2018-05-31 22:47:16.037967|2018-05-31 22:47:16.037967
NCT01315847|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2014-10-21||2017-05-26|2011-03-14|2011-03-15|Estimate|2014-10-21|2014-10-24|Estimate||||2017-05-26|2017-06-20|Actual|January 14, 2010|Actual|2010-01-14|May 2017|2017-05-31|July 26, 2011|Actual|2011-07-26|July 26, 2011|Actual|2011-07-26||Interventional||All participants who received at least one dose of study medication (telcagepant and/or [11C]MK-4232).|Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)|A Three-Part Positron Emission Tomography Study of Brain CGRP Receptor Occupancy Levels Following Administration of MK-0974, Using [11C]MK-4232 as an Imaging Agent|Completed||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:47:16.118344|2018-05-31 22:47:16.118344
NCT01315834|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-03-16|2011-03-14|2011-03-15|Estimate|||||||2012-03-16|2012-03-19|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|psychocardio||Couples Coping With Coronary Heart Disease|The Contribution of Personality Traits to Marital Satisfaction, Well Being and Physical Health in Couples Coping With Coronary Heart Disease Versus a Control Group|Unknown status|Recruiting||130|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 22:47:16.488487|2018-05-31 22:47:16.488487
NCT01315821|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-08-04|2011-03-14|2011-03-15|Estimate|||||||2011-08-04|2011-08-08|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Saccharomyces Boulardii on Necrotizing Enterocolitis in Very Low Birth Weight Infants|Role Of Saccharomyces Boulardii in Preventin Necrotizing Enterocolitis in Very Low Birth Weight Infants|Unknown status|Recruiting|Phase 3|220|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 22:47:16.569951|2018-05-31 22:47:16.569951
NCT01315808|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2012-03-18|2011-03-14|2011-03-15|Estimate|||||||2012-03-18|2012-03-20|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Observational|||Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM|Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM: Comparing the Concept of dx/dt With QD Diabetes Prediction Model. D.E.R.M.S Initiative (Doctor Enabled Risk Management System)|Terminated|||542|Actual|Wyckoff Heights Medical Center|||3|Due to lack of funds to continue this study.|f||||t||||||||||2018-05-31 22:47:16.649|2018-05-31 22:47:16.649
NCT01315795|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2014-07-07|2011-03-14|2011-03-15|Estimate|||||||2014-07-07|2014-07-08|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|LOCKCYST||Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease|An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders|Completed||Phase 2/Phase 3|59|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:47:16.735201|2018-05-31 22:47:16.735201
NCT01315782|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-05-01|2011-03-14|2011-03-15|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis|Alveolar Dead Space as Predictor of Multi-organ Failure and Mortality in Medical Intensive Care Patients With Sepsis Requiring Mechanical Ventilation|Recruiting|||30|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 22:47:16.81408|2018-05-31 22:47:16.81408
NCT01315769|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|September 2006|Actual|2006-09-30|||||Observational|||Pelvic Floor Muscle Function in Nulliparous and Primiparous.|COMPARATIVE STUDY OF PELVIC FLOOR MUSCLE EVALUATION IN NULIPAROUS AND PRIMIPAROUS WOMEN. A Prospective Study|Completed|||100|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||f||||||||||2018-05-31 22:47:16.874868|2018-05-31 22:47:16.874868
NCT01315756|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-12-11|2011-03-14|2011-03-15|Estimate|||||||2014-12-11|2014-12-12|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Self-management in Type 2 Diabetes Patients Using the Few Touch Application|The Norwegian Study in Renewing Health: Stimulating Self-management in Patients With Type 2 Diabetes Mellitus Through Telecare With the Few Touch Application and Health Counseling - a Randomized Controlled Trial|Completed||Early Phase 1|151|Actual|University Hospital of North Norway||3|||f||||f||||||||||2018-05-31 22:47:16.927134|2018-05-31 22:47:16.927134
NCT01315717|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2016-09-21|2011-03-14|2011-03-15|Estimate|||||||2016-09-21|2016-09-22|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|GAIT||Gait and Alzheimer Interaction Tracking (GAIT) Study|Maladie d'Alzheimer et Troubles Locomoteurs : Caracterisation Des Anomalies Temporelles de la Marche et Etude Des Correlats Anatomo-cognitifs|Completed|||912|Actual|University Hospital, Angers|||4||f||||t||||||||||2018-05-31 22:47:17.126352|2018-05-31 22:47:17.126352
NCT01315704|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|MERE||Alzheimer's Disease and Related Disorders|Maladie d'Alzheimer et Maladies apparentées : Caractérisation Des Anomalies Cognitivo-motrices, et Des Effets Des médicaments Anti-démence et de la Vitamine D à Partir de la Mise en Place d'Une Base de données au CMRR du CHU d'Angers|Unknown status|Recruiting||700|Anticipated|University Hospital, Angers|||3||f||||f||||||||||2018-05-31 22:47:17.17893|2018-05-31 22:47:17.17893
NCT01315691|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-01-09|2011-03-14|2011-03-15|Estimate|||||||2015-01-09|2015-01-12|Estimate||||January 2015|2015-01-31||||||||Interventional|||Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa|Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa|Withdrawn||Phase 3|0|Actual|Insmed Incorporated||2|||f||||t||||||||||2018-05-31 22:47:17.253124|2018-05-31 22:47:17.253124
NCT01315678|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14||2015-02-12|2015-03-30|2011-03-14|2011-03-15|Estimate||||2015-02-12|2015-03-03|Estimate|2015-03-30|2015-04-17|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections|Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa|Completed||Phase 3|302|Actual|Insmed Incorporated||2|||f||||t||||||||||2018-05-31 22:47:17.33455|2018-05-31 22:47:17.33455
NCT01315665|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2016-12-06||2017-03-23|2011-03-14|2011-03-15|Estimate|2017-02-10|2017-02-15|Actual||||2017-03-23|2017-04-24|Actual|April 2011||2011-04-30|March 2017|2017-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation|Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects|Completed||N/A|15|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 22:47:17.600672|2018-05-31 22:47:17.600672
NCT01315652|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2016-07-05|2011-03-14|2011-03-15|Estimate|||||||2016-07-05|2016-07-06|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|COMEDRA||Interest of a Standardized Monitoring of Rheumatoid Arthritis: The COMEDRA Trial|Evaluation of the Usefulness of a Center Specialized in the Standardized Management of Rheumatoid Arthritis: The COMEDRA Trial|Completed||N/A|970|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 22:47:17.974729|2018-05-31 22:47:17.974729
NCT01315639|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2018-03-16|2011-03-14|2011-03-15|Estimate|||||||2018-03-16|2018-03-19|Actual|September 3, 2010|Actual|2010-09-03|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|BALTAZAR||New Biomarker for Alzheimer's Disease Diagnostic|Plasma Abeta Peptides and the Risk of Alzheimer's Disease. Diagnostic Performance and Predictive and Prognostic Values of Measurements of Plasma Amyloid Peptides Concentrations for the Diagnosis of Alzheimer's Disease|Active, not recruiting||N/A|1067|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:47:18.066226|2018-05-31 22:47:18.066226
NCT01315626|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2015-03-17|2011-03-14|2011-03-15|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Bronchiectasis: Evaluation of an Educational Intervention|Identification of Patients With a Diagnosis of Bronchiectasis: Evaluation of an Educational Intervention|Withdrawn|||0|Actual|Hill-Rom|||3|Sponsor did not move forward with study|f||||f||||||||||2018-05-31 22:47:18.146866|2018-05-31 22:47:18.146866
NCT01315613|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|September 2008||2008-09-30|September 2008|Actual|2008-09-30||Observational|||Role of ST2 in Acute Pancreatitis|Study of ST2-IL-33 Pathway in Acute Pancreatitis|Completed|||44|Actual|Erasme University Hospital|||1||f||||||||||||||2018-05-31 22:47:18.23114|2018-05-31 22:47:18.23114
NCT01315587|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-08-30|2011-03-14|2011-03-15|Estimate|||||||2015-08-30|2015-09-01|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|January 2017|Anticipated|2017-01-31|November 2015|Anticipated|2015-11-30||Interventional|||Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia|A Double-blind Placebo Controlled Trial the Comparison of Effectiveness of Repetitive TMS and iTBS on Negative Symptoms and Cognition in Patients With Schizophrenia|Unknown status|Recruiting|Phase 2|30|Anticipated|University of Tehran||3|||f||||t||||||||||2018-05-31 22:47:18.296932|2018-05-31 22:47:18.296932
NCT01315574|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2016-08-15||2017-02-07|2011-03-14|2011-03-15|Estimate|2016-12-09|2017-02-03|Estimate||||2017-02-07|2017-03-16|Actual|February 2011||2011-02-28|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BAK|* For IOP the baseline sample size for Latanoprost is 6 patients, whereas for all other outcome measures n= 7 patients.|Effects of Anti-Glaucoma Medications on the Ocular Surface|In Vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells, Epithelium, and Nerves of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study|Terminated||Phase 4|14|Actual|Massachusetts Eye and Ear Infirmary|Early termination due to very slow rate of recruitment, hence reduced power of the study (small sample size); some patients lost to follow-up.|2||Slow Enrollment|f||||f||||||||No||2018-05-31 22:47:18.405565|2018-05-31 22:47:18.405565
NCT01315561|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2012-10-03|2011-03-14|2011-03-15|Estimate|||||||2012-10-03|2012-10-04|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|MSAT||Motion Style Acupuncture Treatment for Low Back Pain With Severe Disability|Motion Style Acupuncture Treatment for Low Back Pain With Severe Disability: a Randomised, Controlled, Trial Protocol|Completed||Phase 3|58|Actual|Jaseng Hospital of Korean Medicine||2|||f||||t||||||||||2018-05-31 22:47:18.827092|2018-05-31 22:47:18.827092
NCT01315548|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-13|||2018-01-15|2011-03-13|2011-03-15|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Observational|||Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) in Focal Pancreatic Masses|Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) Used in the Differentiation of Focal Pancreatic Masses|Completed|||210|Actual|University of Medicine and Pharmacy Craiova|||2||f||||t||||||Samples With DNA|"~     Pathology samples obtained from duodeno-pancreatectomies or caudal pancreatectomies done with~     curative intent, as well as microhistological fragments obtained through EUS-FNA biopsy~     processed by paraffin embedding~   "|||2018-05-31 22:47:18.910286|2018-05-31 22:47:18.910286
NCT01315535|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-06-21|2011-03-14|2011-03-15|Estimate|||||||2011-06-21|2011-06-23|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Observational|||Fast Titration of Oral Appliance at Obstructive Sleep Apnea Syndrome (OSAS) Treatment|Evaluation of the Efficacy and Side Effects of Fast Mandibular Advancement With Oral Appliance in the Treatment of Obstructive Sleep Apnea Syndrome|Unknown status|Recruiting||120|Anticipated|Associacao Fundo de Incentivo a Psicofarmcologia|||4||f||||f||||||||||2018-05-31 22:47:19.008574|2018-05-31 22:47:19.008574
NCT01315522|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-04-20|2011-03-13|2011-03-15|Estimate|||||||2015-04-20|2015-04-21|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents|Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent|Completed||Phase 4|43|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:47:19.086954|2018-05-31 22:47:19.086954
NCT01315509|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2013-03-21|2011-03-14|2011-03-15|Estimate|||||||2013-03-21|2013-03-22|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|SMI-DENTAL||Dental Status of Patients With Severe Mental Illness||Completed|||80|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-05-31 22:47:19.322396|2018-05-31 22:47:19.322396
NCT01315496|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2013-04-29|2011-03-14|2011-03-15|Estimate|||||||2013-04-29|2013-04-30|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock|A Placebo-controlled, Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Administration of 'IV-Globulin S Inj.' in Adult Subjects With Community-Acquired Severe Sepsis or Septic Shock|Terminated||Phase 3|214|Anticipated|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 22:47:19.438678|2018-05-31 22:47:19.438678
NCT01315483|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2013-02-13|2011-03-14|2011-03-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|CHOICE||Diet Composition, Weight Control, and Breast Carcinogenesis|Diet Composition, Weight Control, and Breast Carcinogenesis|Completed||N/A|259|Actual|Colorado State University||3|||f||||f||||||||||2018-05-31 22:47:19.534101|2018-05-31 22:47:19.534101
NCT01315470|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-23|2011-03-14|2011-03-15|Estimate|||||||2011-03-23|2011-03-24|Estimate|June 2011||2011-06-30|March 2011|2011-03-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|||Use of Granulocyte Colony-stimulating Factor for the Treatment of Recurrent Implantation Failure in IVF Patients|Phase 1 Study of the Use of Granulocyte Colony-stimulating Factor for the Treatment of Repeated Implantation Failure in IVF Patients|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 22:47:19.618113|2018-05-31 22:47:19.618113
NCT01315457|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-13|||2012-05-22|2011-03-13|2011-03-15|Estimate|||||||2012-05-22|2012-05-24|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Infections Associated With the Use of Alemtuzumab|Asian Multinational Retrospective Analysis for Infectious Complications in Patients Treated With Alemtuzumab|Completed|||182|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 22:47:19.699012|2018-05-31 22:47:19.699012
NCT01315444|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-13|||2017-10-03|2011-03-14|2011-03-15|Estimate|||||||2017-10-03|2017-10-05|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Gastric Acid Rebound Secretion Measured by Alkaline Tide|Gradual Cessation of Proton Pump Inhibitor (PPI) Treatment May Prevent Rebound Acid Secretion in Dyspeptic and Reflux Patients, Measured by the Alkaline Tide Method.|Withdrawn||Phase 1|0|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 22:47:19.774987|2018-05-31 22:47:19.774987
NCT01315431|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-07-23|2011-03-14|2011-03-15|Estimate|||||||2012-07-23|2012-07-24|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors|A Phase I Study of Tesetaxel Administered in Combination With Capecitabine to Subjects With Solid Tumors|Unknown status|Active, not recruiting|Phase 1|9|Anticipated|Genta Incorporated||1|||f||||f||||||||||2018-05-31 22:47:19.862433|2018-05-31 22:47:19.862433
NCT01315418|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-11-23|2011-03-14|2011-03-15|Estimate|||||||2016-11-23|2016-11-25|Estimate|December 2006||2006-12-31|November 2016|2016-11-30|July 2007|Actual|2007-07-31|May 2007|Actual|2007-05-31||Interventional|||Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation|Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation|Terminated||N/A|239|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 22:47:19.945691|2018-05-31 22:47:19.945691
NCT01315405|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-03-15|2011-03-14|2011-03-15|Estimate|||||||2011-03-15|2011-03-16|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Interventional|||Facial Expression Recognition and Mirror Neurons in Parkinson's Disease|Do Facial Expression Recognition Disorder and Mirror Neurons Subtend Apathy in Parkinson's Disease?|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:47:20.017551|2018-05-31 22:47:20.017551
NCT01315392|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|July 2000||2000-07-31|March 2011|2011-03-31||||||||Interventional|||A Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures|A Randomized Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures: A Pilot Study|Completed||N/A|451|Actual|Carolinas Healthcare System||2|||f||||t||||||||||2018-05-31 22:47:20.084793|2018-05-31 22:47:20.084793
NCT01315379|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2016-10-09|2011-03-13|2011-03-15|Estimate|||||||2016-10-09|2016-10-11|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|TBI||Psychological Treatment for Children Suffering From Post Traumatic Stress Symptoms and Mild Traumatic Brain Injury|Prolonged Exposure Therapy (PE) for Post-traumatic Stress Symptoms and Mild TBI Symptoms in Children Following Motor Vehicle Accident.|Recruiting|||60|Anticipated|Rabin Medical Center|||2||f||||f||||||||No||2018-05-31 22:47:20.154867|2018-05-31 22:47:20.154867
NCT01315366|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2015-11-19|2011-03-14|2011-03-15|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|GEHF-VitD||Hypovitaminosis D : A Link Between Bone/Mineral and Fat/Fuel Metabolism|Phase III Study on the Effect of Vitamin D Supplementation on Indices of Mineral and Musculoskeletal Metabolism and on Parameters of Glucose and Fuel Metabolism in Elderly Subjects|Completed||Phase 3|257|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 22:47:20.239312|2018-05-31 22:47:20.239312
NCT01315353|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2018-02-01||2018-05-10|2011-03-14|2011-03-15|Estimate|2018-05-10|2018-05-11|Actual||||2018-05-10|2018-05-11|Actual|April 4, 2012|Actual|2012-04-04|May 2018|2018-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional||Intent to treat: All eligible participants were included in the analysis.|HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women|A Randomized Trial To Compare An HPV Test-And-Treat Strategy To A Cytology-Based Strategy For Prevention Of CIN 2+ In HIV-Infected Women|Completed||N/A|467|Actual|AIDS Clinical Trials Group||3|||f||||t||||||||||2018-05-31 22:47:20.344449|2018-05-31 22:47:20.344449
NCT01315340|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-16|2011-03-14|2011-03-15|Estimate|||||||2011-03-16|2011-03-17|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|||Ocular Rigidity and Outflow Facility in Glaucomatous and Normal Eyes|Measurement of Ocular Rigidity, Outflow Facility and Ocular Blood Flow in Glaucomatous and Normal Eyes|Unknown status|Recruiting|N/A|50|Anticipated|Larissa University Hospital||2|||f||||||||||||||2018-05-31 22:47:21.49449|2018-05-31 22:47:21.49449
NCT01315327|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-06-30|2011-03-11|2011-03-15|Estimate|||||||2014-06-30|2014-07-01|Estimate|May 2003||2003-05-31|June 2014|2014-06-30|May 2012|Actual|2012-05-31|February 2006|Actual|2006-02-28||Interventional|||Omega-3 Fatty Acids in Tourette's Disorder|A Double-Blind, Placebo-Controlled Study of Omega-3 Fatty Acids in Children and Adolescents With Tourette's Disorder|Completed||N/A|33|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 22:47:21.597354|2018-05-31 22:47:21.597354
NCT01315314|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-16|2011-03-14|2011-03-15|Estimate|||||||2011-03-16|2011-03-17|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction|Effects of Neutral pH and Low Glucose Degradation Product-containing Peritoneal Dialysis Fluid on Systemic Markers of Inflammation and Endothelial Dysfunction: a Randomized, Controlled 1-year Follow-up Study|Completed||Phase 4|146|Actual|Kyungpook National University||2|||f||||f||||||||||2018-05-31 22:47:21.704812|2018-05-31 22:47:21.704812
NCT01315301|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|TB-HAART||Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis|Randomized Clinical Trial to Determine the Most Appropriate Time to Start HIV Treatment in HIV & TB Coinfected Adults Being Treated for Tuberculosis.|Unknown status|Recruiting|N/A|450|Anticipated|Karolinska Institutet||3|||f||||t||||||||||2018-05-31 22:47:21.999979|2018-05-31 22:47:21.999979
NCT01315288|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|October 2008||2008-10-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|||A Randomized Trial of Clinical Decision Making in Asymptomatic Carotid Stenosis|A Randomized Trial of Clinical Decision Making in Asymptomatic Carotid Stenosis|Completed||N/A|409|Actual|Henry Ford Health System||1|||f||||f||||||||||2018-05-31 22:47:22.347572|2018-05-31 22:47:22.347572
NCT01315275|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2017-02-20|2011-03-14|2011-03-15|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2011||2011-02-28|February 2017|2017-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|LUDIC||A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema|An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice|Completed||Phase 4|394|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:47:22.596605|2018-05-31 22:47:22.596605
NCT01315262|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-28|2011-03-14|2011-03-15|Estimate|||||||2011-03-28|2011-03-29|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|URO2010||On Demand Versus Daily Sildenafil for Patients Undergoing Radical Prostatectomy|On Demand Versus Daily Sildenafil for Patients Undergoing Bilateral Nerve Sparing Radical Prostatectomy: a Randomized, Open Label, Parallel Group Trial|Unknown status|Recruiting|Phase 3|200|Anticipated|Università Vita-Salute San Raffaele||2|||f||||t||||||||||2018-05-31 22:47:22.962647|2018-05-31 22:47:22.962647
NCT01315249|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2013-02-28||2013-07-09|2011-03-14|2011-03-15|Estimate|2013-07-09|2013-08-09|Estimate||||2013-07-09|2013-08-09|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ILLUMINATE||QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|523|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:47:23.36457|2018-05-31 22:47:23.36457
NCT01315236|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11||2016-09-29|2016-09-29|2011-03-13|2011-03-15|Estimate||||2016-09-29|2016-10-03|Estimate|2016-09-29|2016-10-03|Estimate|May 2012||2012-05-31|September 2016|2016-09-30||||June 2015|Actual|2015-06-30||Interventional|||Arikayce for Nontuberculous Mycobacteria|A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikayce®) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease|Completed||Phase 2|90|Actual|Insmed Incorporated||2|||f||||t||||||||||2018-05-31 22:47:26.527346|2018-05-31 22:47:26.527346
NCT01315223|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-13|||2016-07-20|2011-03-13|2011-03-15|Estimate|||||||2016-07-20|2016-07-21|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Outpatient Lung Impedance-Guided Preventive Therapy in Patients With Chronic Heart Failure (CHF)||Recruiting||Phase 3|300|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 22:47:26.616096|2018-05-31 22:47:26.616096
NCT01315210|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10||2013-09-11|2013-09-11|2011-03-13|2011-03-15|Estimate||||2013-09-11|2013-09-18|Estimate|2013-09-11|2013-09-18|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||D-Ribose for Fatigue in Subjects With Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of D-Ribose in Subjects With Fibromyalgia|Completed||Phase 2|110|Actual|RiboCor, Inc.||2|||f||||f||||||||||2018-05-31 22:47:26.680014|2018-05-31 22:47:26.680014
NCT01315197|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|Massage||Massage for Low Back Pain in Nursing Staff|Application of Massage for Low Back Pain in Nursing Staff|Completed||N/A|18|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 22:47:26.765527|2018-05-31 22:47:26.765527
NCT01315184|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2013-02-13|2011-03-14|2011-03-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|RLSS||Study of Computer-Based Treatment for Drug Dependence|Pilot Trial of a Therapeutic Interactive Voice Response System for Buprenorphine Maintenance: The Recovery Line Support System|Completed||Phase 2|36|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:47:26.8322|2018-05-31 22:47:26.8322
NCT01315171|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2018-01-12|2011-03-11|2011-03-15|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2012||2012-01-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|August 2015|Actual|2015-08-31||Interventional|||Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.|The Effect of a Long-term Medium Chain Supplemented Diet on Cognitive Function and Brain Activation During Hypoglycemia in Type 1 Diabetes.|Completed||N/A|12|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:47:26.908461|2018-05-31 22:47:26.908461
NCT01315158|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2016-05-26||2016-09-08|2011-03-11|2011-03-15|Estimate|2016-09-08|2016-10-28|Estimate||||2016-09-08|2016-10-28|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Propofol vs Propofol + Benzo/Opiates in High Risk Group|Incidence of Sedation Related Complications With Propofol Alone Versus Propofol With Benzodiazepines and Opiates in a High Risk Group Undergoing Advanced Endoscopic Procedures: A Randomized Controlled Trial|Terminated||N/A|36|Actual|Washington University School of Medicine||2||- The research team is not able to obtain the necessary support to continue the study.|f||||t||||||||||2018-05-31 22:47:27.083067|2018-05-31 22:47:27.083067
NCT01315145|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2015-06-01||2015-08-19|2011-03-11|2011-03-15|Estimate|2015-07-23|2015-08-19|Estimate||||2015-08-19|2015-08-31|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MiDAS III||MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|Completed||N/A|138|Actual|Vertos Medical, Inc.||2|||f||||t||||||||||2018-05-31 22:47:27.426129|2018-05-31 22:47:27.426129
NCT01315132|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2017-11-08|2011-03-11|2011-03-15|Estimate|||||||2017-11-08|2017-11-13|Actual|April 10, 2008|Actual|2008-04-10|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies|A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies|Recruiting||Phase 2|45|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 22:47:27.695932|2018-05-31 22:47:27.695932
NCT01315119|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2017-02-02|2011-03-11|2011-03-15|Estimate|||||||2017-02-02|2017-02-06|Estimate|June 2011||2011-06-30|February 2017|2017-02-28|April 30, 2017|Anticipated|2017-04-30|September 23, 2014|Actual|2014-09-23||Observational|||SPY Intra-Operative Angiography & Skin Perfusion in Immediate Breast Reconstruction w/ Implants|The Role of SPY Intra-Operative Angiography in Determining Adequate Skin Perfusion in Immediate Breast Reconstruction With Implants|Active, not recruiting|||100|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 22:47:27.834245|2018-05-31 22:47:27.834245
NCT01315106|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2018-01-12|2011-03-11|2011-03-15|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||High Resolution 3D Diffusion-weighted Breast MRI|High Resolution 3D Diffusion-weighted Breast MRI|Suspended|||500|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 22:47:27.895376|2018-05-31 22:47:27.895376
NCT01315093|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-04-30|2011-03-14|2011-03-15|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2010||2010-11-30|March 2016|2016-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation||Completed||Phase 2/Phase 3|50|Actual|National and Kapodistrian University of Athens||2|||f||||||||||||||2018-05-31 22:47:27.963325|2018-05-31 22:47:27.963325
NCT01315080|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|September 2012|Anticipated|2012-09-30|March 2012|Anticipated|2012-03-31||Observational|||Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula|Efficacy of Percutaneous Injection of Triamcinolone in the Treatment of Mammillary Fistula|Unknown status|Recruiting||10|Anticipated|Hospital Universitario Virgen de la Arrixaca|||2||f||||t||||||||||2018-05-31 22:47:28.049772|2018-05-31 22:47:28.049772
NCT01315067|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2017-08-09|2011-03-14|2011-03-15|Estimate|||||||2017-08-09|2017-08-10|Actual|October 2011||2011-10-31|August 2017|2017-08-31|June 15, 2017|Actual|2017-06-15|March 2017|Actual|2017-03-31||Observational|||Diagnosis of Acute Rejection in Renal Transplant Patients by Urine Mass Spectrometry|Non-invasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometry of Urine Samples - a Multicentre Diagnostic Phase III Trial|Completed|||600|Actual|Hannover Medical School|||||f||||t||||||Samples Without DNA|"~     Urine samples, kidney allograft biopsies~   "|||2018-05-31 22:47:28.125024|2018-05-31 22:47:28.125024
NCT01315054|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-03-13|2011-03-14|2011-03-15|Estimate|||||||2014-03-13|2014-03-17|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Methadone Maintenance Treatment Outcome Study in Three Provinces in China|A Methadone Maintenance Treatment Outcome Study in Three Provinces in China: Comparative Evaluation of the Impact of an Intensive Health Care Provider Training Program Combined With Expanded Services on Treatment Retention, Heroin Use, Methadone Dosing and HIV Risk Practices|Unknown status|Active, not recruiting|N/A|7700|Anticipated|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 22:47:28.276428|2018-05-31 22:47:28.276428
NCT01315041|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-01-26|2011-03-14|2011-03-15|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||"Pi and Hot Flushes"|"Effects of Homeopathic Medicine Pi on Hot Flushes of Women With Menopausal Symptoms"|Completed||Phase 1/Phase 2|40|Actual|Casa Espirita Terra de Ismael||2|||f||||f||||||||||2018-05-31 22:47:28.359536|2018-05-31 22:47:28.359536
NCT01315028|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2013-11-11||2014-07-29|2011-03-14|2011-03-15|Estimate|2014-07-29|2014-07-30|Estimate||||2014-07-29|2014-07-30|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|BISCIT||Bipolar Intervention Study: Cognitive Interpersonal Therapy|A Pilot Randomised Controlled Trial of Cognitive Behaviour Therapy for Early Bipolar Disorder|Completed||N/A|20|Actual|NHS Greater Glasgow and Clyde|A definitive clinical trial should incorporate an appropriate sample size, incorporate more than one therapist, assess fidelity and competence in therapy delivery and also include measurements of health economic dimensions of outcome.|2|||f||||t||||||||||2018-05-31 22:47:28.43687|2018-05-31 22:47:28.43687
NCT01315015|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2016-05-23|2011-03-14|2011-03-15|Estimate|||||||2016-05-23|2016-05-24|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial|Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial|Active, not recruiting||Phase 4|36185|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 22:47:28.782648|2018-05-31 22:47:28.782648
NCT01315002|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|2014-12-18||2015-01-07|2011-03-14|2011-03-15|Estimate|2015-01-07|2015-01-16|Estimate||||2015-01-07|2015-01-16|Estimate|July 2008||2008-07-31|January 2015|2015-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Nicotine Effects on Endophenotypes of Schizophrenia|Nicotine Effects on Endophenotypes of Schizophrenia|Completed||N/A|121|Actual|University Hospital, Bonn||2|||f||||t||||||||||2018-05-31 22:47:28.925411|2018-05-31 22:47:28.925411
NCT01314989|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|January 2012|Anticipated|2012-01-31|March 2011|Anticipated|2011-03-31||Interventional|||Cyproheptadine as an Appetite Stimulant|Effect of Cyproheptadine on Weight Gain and Feeding Behavior in 2 to 4 Years Old Children With Failure to Thrive|Unknown status|Recruiting|Phase 4|20|Anticipated|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 22:47:29.110831|2018-05-31 22:47:29.110831
NCT01314976|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2013-06-25|2011-03-14|2011-03-15|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|DFPT||Treatment Study of Metronidazole to Treat Dientamoebiasis in Children|Metronidazole for the Treatment of Dientamoebiasis in Children in Denmark - A Randomized, Placebo-controlled, Double-blinded Clinical Trial|Completed||Phase 4|100|Anticipated|Statens Serum Institut||2|||f||||t||||||||||2018-05-31 22:47:29.180117|2018-05-31 22:47:29.180117
NCT01314963|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2018-02-22||2018-03-29|2011-03-11|2011-03-15|Estimate|2018-03-29|2018-04-30|Actual||||2018-03-29|2018-04-30|Actual|June 2008|Actual|2008-06-30|March 2018|2018-03-31|July 26, 2012|Actual|2012-07-26|July 26, 2012|Actual|2012-07-26||Interventional||The required data for baseline results is participant-level data. This study is a comparison of lesion-level data sets, ie, a comparison of intra-participant data. It is not possible to segregate participant baseline data to one group or the other of the intra-participant datasets.|Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy|Efficacy of a Novel, High-Sensitivity, Portable, Hand-Held Gamma Camera Used Intraoperatively for Identification of Sentinel Lymph Nodes With Lymphoscintigraphy|Completed||N/A|50|Actual|Stanford University||2|||f||||t|f|t|f|f|f|||No||2018-05-31 22:47:29.259165|2018-05-31 22:47:29.259165
NCT01314950|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2016-03-07|2011-03-11|2011-03-15|Estimate|||||||2016-03-07|2016-03-08|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ADMIT||Alzheimer's Disease Multiple Intervention Trial|Alzheimer's Disease Multiple Intervention Trial|Completed||N/A|180|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 22:47:29.435524|2018-05-31 22:47:29.435524
NCT01314937|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-08-25|2011-03-14|2011-03-15|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas|Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care|Completed||Phase 4|1760|Anticipated|McGill University Health Center||4|||f||||t||||||||||2018-05-31 22:47:29.534241|2018-05-31 22:47:29.534241
NCT01314924|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2012-01-10|2011-03-14|2011-03-15|Estimate|||||||2012-01-10|2012-01-11|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Effects of Acute Ingestion of Dark Chocolate on Endothelial Function in Hypertensive Patients|Featuring Treated Hypertensive Patients Who Improve Endothelial Function After Dark Chocolate|Completed||Phase 4|21|Actual|Hospital Universitario Pedro Ernesto||2|||f||||t||||||||||2018-05-31 22:47:29.613192|2018-05-31 22:47:29.613192
NCT01314911|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2017-11-16|2011-03-11|2011-03-15|Estimate|||||||2017-11-16|2017-11-20|Actual|April 2011||2011-04-30|November 2017|2017-11-30||||June 2019|Anticipated|2019-06-30||Interventional|||Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults|A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults|Active, not recruiting||N/A|800|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 22:47:29.693978|2018-05-31 22:47:29.693978
NCT01314898|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-07-05|2011-03-11|2011-03-15|Estimate|||||||2011-07-05|2011-07-06|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers|A Phase 1, Double-Blind (Sponsor-Open), Placebo- And Active-Controlled, Single Dose, Crossover Study To Assess Antimineralocorticoid Activity Of Oral Pf-03882845 In Healthy Subjects.|Completed||Phase 1|12|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 22:47:29.862477|2018-05-31 22:47:29.862477
NCT01314885|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2012-02-01|2011-03-14|2011-03-15|Estimate|||||||2012-02-01|2012-02-02|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers|Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Effects Of Single Inhaled Doses Of PF-03715455 (20 Mg) And PH-797804 (30 Mg) On Induced Sputum Neutrophils Following Inhaled Lipopolysaccharide (LPS) Challenge In Healthy Volunteers|Completed||Phase 1|39|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:47:29.996362|2018-05-31 22:47:29.996362
NCT01314872|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2016-05-11||2016-05-11|2011-03-14|2011-03-15|Estimate|2016-05-11|2016-06-17|Estimate||||2016-05-11|2016-06-17|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)|A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder A 52-week Extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder|Completed||Phase 2|1395|Actual|Merck Sharp & Dohme Corp.||15|||f||||f||||||||||2018-05-31 22:47:30.149488|2018-05-31 22:47:30.149488
NCT01314859|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2014-07-28|2011-03-14|2011-03-15|Estimate|||||||2014-07-28|2014-07-29|Estimate|July 2011||2011-07-31|February 2011|2011-02-28|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Nifedipine Treatment in Preterm Labor|ADMINISTRATION OF NIFIDEPINE VERSUS ATOSIBAN IN PREGNANT WOMEN WITH A THREAT OF PREMATURE LABOR|Withdrawn||Phase 3|0|Actual|Hospital Clinico Universitario de Santiago||2|||f||||||||||||||2018-05-31 22:47:32.114142|2018-05-31 22:47:32.114142
NCT01314846|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2016-02-26|2011-03-14|2011-03-15|Estimate|||||||2016-02-26|2016-02-29|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Observational|CC-PGS||Co-culture and Advanced Maternal Age in PGS Program|Co-culture Versus Sequential Culture System in Advanced Maternal Age.|Terminated|||346|Actual|IVI Madrid|||2|difficulty to include patients|f||||||||||||||2018-05-31 22:47:32.195835|2018-05-31 22:47:32.195835
NCT01314833|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|December 2018|Anticipated|2018-12-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients|A Randomized Prospective Open Multicentric Phase III Clinical Trial Compared TC, FEC100 Followed by Docetaxel and EC90 Followed by Paclitaxel as Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients|Active, not recruiting||Phase 3|3200|Anticipated|Fudan University||3|||f||||t||||||||||2018-05-31 22:47:32.340109|2018-05-31 22:47:32.340109
NCT01314820|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Effects of Joint Effusion on Quadriceps Muscle|Effects of Joint Effusion on Quadriceps Muscle in Patients With Knee Osteoarthritis|Completed||N/A|40|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 22:47:32.442024|2018-05-31 22:47:32.442024
NCT01314807|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2014-01-28|2011-03-14|2011-03-15|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|January 2018|Anticipated|2018-01-31|June 2014|Anticipated|2014-06-30||Observational|||Systemic Consequences and Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Action!|Systemic Consequences and Comorbidities in Mild/Moderate COPD, Time for Action!|Unknown status|Active, not recruiting||200|Anticipated|Katholieke Universiteit Leuven|||3||f||||f||||||Samples Without DNA|"~     whole blood, cholesterol, LDL, HDL, creatinine, fibrinogen, glucose, insuline, NTproBNP, CRP,~     Hba1C~   "|||2018-05-31 22:47:32.543219|2018-05-31 22:47:32.543219
NCT01314781|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-05-19|2011-03-14|2011-03-15|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|January 2014|Actual|2014-01-31||Interventional|TOBS||Therapy of the Overactive Bladder Syndrome|Comparison of Solifenacin Combined With Pelvic Floor Muscle and Whole Body Vibration Training With Solifenacin Alone in Patients With Overactive Bladder Syndrome. - A Prospective Randomized Parallel Group Trial|Completed||Phase 4|66|Actual|Cantonal Hospital, Frauenfeld||2|||f||||t||||||||No||2018-05-31 22:47:32.645135|2018-05-31 22:47:32.645135
NCT01314768|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2015-12-29|2011-03-14|2011-03-15|Estimate|||||||2015-12-29|2015-12-30|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Interventional|BIMOH||Brief Intervention for Medication Overuse Headache|RCT of Structured Brief Intervention for Medication Overuse Headache Versus Business as Usual|Completed||N/A|123|Actual|University Hospital, Akershus||4|||f||||f||||||||||2018-05-31 22:47:32.757997|2018-05-31 22:47:32.757997
NCT01314755|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-14|||2011-03-14|2011-03-14|2011-03-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|November 2003||2003-11-30|March 2008|2008-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|IMPACTHN||A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer|A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer|Completed||Phase 2|76|Actual|Aintree University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 22:47:32.915978|2018-05-31 22:47:32.915978
NCT01314742|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2013-12-16||2017-11-06|2011-03-11|2011-03-14|Estimate|2013-12-16|2014-02-04|Estimate||||2017-11-06|2017-12-15|Actual|May 2010||2010-05-31|February 2016|2016-02-29|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates|A Randomized Controlled Clinical Trial of Two Different Oral Care Regimens Combined With Ventilator-Associated Pneumonia (VAP) Bundle Strategy for Reduction of Duration of Mechanical Ventilation in a Neonatal Population|Completed||N/A|41|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 22:47:33.061716|2018-05-31 22:47:33.061716
NCT01314729|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-14|2011-03-11|2011-03-14|Estimate|||||||2011-03-14|2011-03-15|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|May 2011|Anticipated|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||Comparison of the Effect of Two Types of Fixed Retainers on the Health of the Gums|Clinical and Radiographic Comparison and Evaluation of Two Types of Lingual Fixed Retainers on the Health of Periodontium|Unknown status|Recruiting|Phase 3|48|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:47:33.354866|2018-05-31 22:47:33.354866
NCT01314716|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2014-03-07||2014-03-07|2011-03-11|2011-03-14|Estimate|2014-03-07|2014-04-16|Estimate||||2014-03-07|2014-04-16|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|AIR-BX2|ITT Analysis Set|Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)|Completed||Phase 3|274|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 22:47:33.482359|2018-05-31 22:47:33.482359
NCT01314703|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2012-02-08||2012-10-30|2011-03-11|2011-03-14|Estimate|2012-07-31|2012-08-31|Estimate||||2012-10-30|2012-11-01|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Topical Antimicrobial Effectiveness Testing|Test for Preoperative Skin Preparations|Completed||Phase 4|27|Actual|CareFusion|||||f||||f||||||||||2018-05-31 22:47:34.427821|2018-05-31 22:47:34.427821
NCT01314690|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|September 2008||2008-09-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|September 2009|Actual|2009-09-30||Interventional|Micro-Obes||Human Intestinal Microbiota in Obesity and Nutritional Transition|Human Intestinal Microbiota in Obesity and Nutritional Transition|Completed||N/A|49|Actual|Ceprodi S.A. Kot|||||f||||||||||||||2018-05-31 22:47:34.55991|2018-05-31 22:47:34.55991
NCT01314677|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-06-27|2011-03-11|2011-03-14|Estimate|||||||2012-06-27|2012-06-29|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation|Open Label Randomized Trial of Early Assessment of Therapy Response Using 18FDG-PET/CT in Patients With Marginally Resectable Stage IIIA (N2) Non-Small Cell Lung Cancer (NSCLC) Treated With Induction Concurrent Chemoradiation Followed by Resection and Adjuvant Chemotherapy|Withdrawn||N/A|0|Actual|City of Hope Medical Center||3||"No subjects have been accrued to this trial. The PI will no longer be at COH and requests a~   study withdrawal/closure."|f||||t||||||||||2018-05-31 22:47:34.616125|2018-05-31 22:47:34.616125
NCT01314664|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2015-06-10|2011-03-11|2011-03-14|Estimate|||||||2015-06-10|2015-06-12|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)|A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)|Terminated|||15|Actual|Endo Pharmaceuticals||||Business decision, not safety related|f||||f||||||||||2018-05-31 22:47:34.770138|2018-05-31 22:47:34.770138
NCT01314651|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-04-22|2011-03-11|2011-03-14|Estimate|||||||2014-04-22|2014-04-24|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of Behavioral Insomnia Treatment for Chronic Migraine|Efficacy of Behavioral Insomnia Treatment for Chronic Migraine: A Randomized Controlled Pilot Study|Completed||N/A|31|Actual|University of Mississippi, Oxford||2|||f||||f||||||||||2018-05-31 22:47:34.833333|2018-05-31 22:47:34.833333
NCT01314638|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|SIELBLEU||Study of Adherence and Effects of Balance Exercices (SIEL BLEU Associatio)|"Etude de l'adhérence et Des Effets Des Ateliers équilibre Siel Bleu Sur la Marche, la Cognition, l'Autonomie et l'indépendance Des Sujets Atteints d'Une Maladie d'Alzheimer, et Sur le Fardeau de l'Aidant Principal"|Unknown status|Recruiting||100|Anticipated|University Hospital, Angers|||1||f||||t||||||||||2018-05-31 22:47:34.909809|2018-05-31 22:47:34.909809
NCT01314625|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-05-15|2011-03-11|2011-03-14|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Observational|||A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients|A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma|Unknown status|Recruiting||10|Anticipated|University of Arkansas|||1||f||||f||||||||||2018-05-31 22:47:34.988335|2018-05-31 22:47:34.988335
NCT01314612|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-16|2011-03-11|2011-03-14|Estimate|||||||2011-03-16|2011-03-17|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Initial Study of Insomnia/Nightmare Group Treatment for Posttraumatic Stress Disorder (PTSD)|An Investigation Of The Effectiveness of a Cognitive Behavioral Group Treatment Addressing Insomnia and Nightmares In Veterans With PTSD|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Michael Debakey Veterans Affairs Medical Center||2|||f||||t||||||||||2018-05-31 22:47:35.057727|2018-05-31 22:47:35.057727
NCT01314599|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2015-11-04|2011-03-11|2011-03-14|Estimate|||||||2015-11-04|2015-11-05|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome|Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.|Completed||Phase 1|45|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 22:47:35.136545|2018-05-31 22:47:35.136545
NCT01314586|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|December 2007||2007-12-31|March 2011|2011-03-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|ISULignan||Flax Lignans and Heart Health|Iowa State Study on Flax Lignans and Heart Health|Completed||N/A|93|Actual|Iowa State University||3|||f||||f||||||||||2018-05-31 22:47:35.212506|2018-05-31 22:47:35.212506
NCT01314573|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|November 2012|Anticipated|2012-11-30|September 2012|Anticipated|2012-09-30||Interventional|||The Impact of High Intensity Exercise Upon EPC Number and Function in Young Women|The Impact of High Intensity Exercise Upon EPC Number and Function in Young Women|Unknown status|Not yet recruiting|N/A|12|Anticipated|University of Leeds||2|||f||||t||||||||||2018-05-31 22:47:35.282423|2018-05-31 22:47:35.282423
NCT01314560|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-09-16|2011-03-11|2011-03-14|Estimate|||||||2011-09-16|2011-09-19|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|LOWE||Study of the Pathophysiological Mechanisms Involved in Bleeding Events|Study of the Pathophysiological Mechanisms Involved in Bleeding Events Observed in Patients With Lowe Syndrome|Completed||N/A|30|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:47:35.35494|2018-05-31 22:47:35.35494
NCT01314547|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-10-12|2011-03-11|2011-03-14|Estimate|||||||2012-10-12|2012-10-15|Estimate|March 2005||2005-03-31|November 2010|2010-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|CoEnv||Impact of Environmental Factors on Disease Activity in Spondyloarthritis (SPA): Results of the Prospective Co-Env Cohort|Impact of Environmental Factors on Disease Activity in Spondyloarthritis (SPA): Results of the Prospective Co-Env Cohort|Completed|||300|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 22:47:35.417344|2018-05-31 22:47:35.417344
NCT01314534|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2017-11-17|2011-03-11|2011-03-14|Estimate|||||||2017-11-17|2017-11-20|Actual|September 2008||2008-09-30|November 2017|2017-11-30|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Observational|Kabuki||French Kabuki Syndrome Network. Epidemiology, Management of Patients and Research by Array-CGH|French Kabuki Syndrome Network. Epidemiology, Management of Patients and Research by Array-CGH|Completed|||110|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 22:47:35.474041|2018-05-31 22:47:35.474041
NCT01314521|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-10-04|2011-03-11|2011-03-14|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|||||Observational|||Suicidal Ideation and Behavior in Korean Adolescents With Depression|Suicidal Ideation and Behavior in Korean Adolescents With Depression|Unknown status|Recruiting||150|Anticipated|Hallym University Medical Center|||||f||||t||||||||||2018-05-31 22:47:35.530795|2018-05-31 22:47:35.530795
NCT01314508|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-07-12|2011-03-11|2011-03-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|June 2011||2011-06-30|July 2016|2016-07-31||||October 2011|Actual|2011-10-31||Interventional|||Increlex Treatment of Children With Chronic Liver Disease and Short Stature|Increlex Treatment of Children With Chronic Liver Disease and Short Stature|Withdrawn||N/A|0|Actual|University of California, Los Angeles||1||The sponsor has notified us that they are not funding the study|f||||f||||||||||2018-05-31 22:47:35.59457|2018-05-31 22:47:35.59457
NCT01314495|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-11-12|2011-03-11|2011-03-14|Estimate|||||||2012-11-12|2012-11-14|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis|A Randomized, Double Blind, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis|Withdrawn||Phase 2|0|Actual|Columbia University||2||Halt in funding|f||||t||||||||||2018-05-31 22:47:35.65546|2018-05-31 22:47:35.65546
NCT01314482|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2013-02-04|2011-03-11|2011-03-14|Estimate|||||||2013-02-04|2013-02-06|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Minocycline for the Prevention of Post-operative Intercostal Neuralgia|The Efficacy of Prophylactic Administration of Minocycline in Reducing Chronic Intercostal Neuralgia Post-thoracotomy|Unknown status|Recruiting|Phase 2|116|Anticipated|University of Adelaide||1|||f||||f||||||||||2018-05-31 22:47:35.720545|2018-05-31 22:47:35.720545
NCT01314469|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-07-19|2011-03-11|2011-03-14|Estimate|||||||2011-07-19|2011-07-21|Estimate||||March 2011|2011-03-31||||||||Observational|||Quality of Life in Patients With Intermediate Uveitis|Influence of Macular Edema on Quality of Life in Patients With Non-infectious Intermediate Uveitis|Completed|||||St. Franziskus Hospital|||1||f||||||||||||||2018-05-31 22:47:35.802971|2018-05-31 22:47:35.802971
NCT01314456|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-14|2011-03-11|2011-03-14|Estimate|||||||2011-03-14|2011-03-16|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||3D Recording of a Trans-rectal Prostate Biopsy|3D Recording of a Trans-rectal Prostate Biopsy|Unknown status|Not yet recruiting|N/A|50|Anticipated|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-05-31 22:47:35.864393|2018-05-31 22:47:35.864393
NCT01314443|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2012-12-12||2015-01-19|2011-03-11|2011-03-14|Estimate|2013-03-05|2013-03-06|Estimate||||2015-01-19|2015-01-21|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2011|Actual|2011-11-30||Interventional||11 participants from the 67 participants enrolled in the study were excluded from all analysis (including baseline). Five participants withdrew from the study before completion and six participants were identified as non-compliant and were removed from the study. Thus, baseline analysis was performed on the remaining 56 participants.|Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function|Cardioprotective Synergy of Smoking Cessation and γ-Tocopherol in Restoring Vascular Endothelial Function|Completed||Phase 1/Phase 2|67|Actual|University of Connecticut|Very few women were enrolled thereby precluding any assessment of potential gender differences for our outcome variables.|4|||f||||f||||||||||2018-05-31 22:47:35.96607|2018-05-31 22:47:35.96607
NCT01314417|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2013-07-18||2013-10-17|2011-03-11|2011-03-14|Estimate|2013-07-18|2013-09-26|Estimate||||2013-10-17|2013-11-11|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MEXX||Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate|Treatment of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate|Terminated||Phase 1/Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)||1||This study was terminated due to lack of recruitment.|f||||f||||||||||2018-05-31 22:47:36.309533|2018-05-31 22:47:36.309533
NCT01314404|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-07-15|2011-03-11|2011-03-14|Estimate|||||||2011-07-15|2011-07-18|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|September 2012|Anticipated|2012-09-30|March 2012|Anticipated|2012-03-31||Observational|HPV||KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)|KAP/WTP and HPV Prevalence Studies in Preparation for a Phase IV Trial of the Gardasil HPV Vaccine in a Developing World Setting (Bamako, Mali)|Unknown status|Recruiting||460|Anticipated|Global Alliance to Immunize Against AIDS Vaccine Foundation|||2||f||||f||||||Samples With DNA|"~     Two cervical scrapes and 2 blood samples will be collected from each of the 160 selected~     patients.~   "|||2018-05-31 22:47:36.772092|2018-05-31 22:47:36.772092
NCT01314391|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2016-05-17|2011-03-11|2011-03-14|Estimate|||||||2016-05-17|2016-05-18|Estimate|August 2011||2011-08-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor|Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Blood and Tumor tissue~   "|||2018-05-31 22:47:36.844364|2018-05-31 22:47:36.844364
NCT01314378|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-05-01|2011-03-11|2011-03-14|Estimate|||||||2012-05-01|2012-05-02|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|April 2012|Actual|2012-04-30||Interventional|IBTP||Effects of Intensive Behavioral Training Program on Impulsivity and Inhibitory Control in Smokers|Effects of Intensive Behavioral Training Program on Impulsivity and Inhibitory Control in Smokers|Unknown status|Active, not recruiting|N/A|72|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:47:36.898443|2018-05-31 22:47:36.898443
NCT01314365|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2014-04-29|2011-03-11|2011-03-14|Estimate|||||||2014-04-29|2014-04-30|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Observational|ANCHOR-CD||DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia|DYSPORT™ for Injection AbobotulinumtoxinA Neurotoxin Clinical & Health Economics Outcomes Registry in Cervical Dystonia (ANCHOR-CD)|Completed|||350|Actual|Ipsen|||||f||||f||||||||||2018-05-31 22:47:36.975479|2018-05-31 22:47:36.975479
NCT01314352|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-06-07|2011-03-11|2011-03-14|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2005||2005-12-31|June 2011|2011-06-30|March 2006|Actual|2006-03-31|December 2005|Actual|2005-12-31||Interventional|||Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|28|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:47:37.157234|2018-05-31 22:47:37.157234
NCT01314339|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2012-02-17|2011-03-11|2011-03-14|Estimate|||||||2012-02-17|2012-02-20|Estimate|December 2005||2005-12-31|September 2005|2005-09-30|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|28|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:47:37.239905|2018-05-31 22:47:37.239905
NCT01314326|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2018-04-10|2011-03-11|2011-03-14|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2003||2003-09-30|April 2018|2018-04-30|May 15, 2015|Actual|2015-05-15|May 15, 2015|Actual|2015-05-15||Observational|AIGS||Advanced Imaging for Glaucoma Study|Advanced Imaging for Glaucoma Study|Completed|||832|Actual|Oregon Health and Science University|||3||f||||t||||||||||2018-05-31 22:47:37.319138|2018-05-31 22:47:37.319138
NCT01314313|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2016-02-01|2011-03-10|2011-03-14|Estimate|||||||2016-02-01|2016-02-03|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|September 2020|Anticipated|2020-09-30|January 2016|Actual|2016-01-31||Interventional|PARTNER II||The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves|"The PARTNER II Trial Placement of AoRTic TraNscathetER Valves Trial (US) [Edwards Study 2010-12]"|Active, not recruiting||Phase 3|5650|Anticipated|Edwards Lifesciences||6|||f||||t||||||||||2018-05-31 22:47:37.432452|2018-05-31 22:47:37.432452
NCT01314300|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-10-29|2011-03-11|2011-03-14|Estimate|||||||2014-10-29|2014-10-30|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Lidocaine 5% Plasters (Versatis® 5%) in Pediatric Neuropathic Pains and Vasoocclusive Sickle Cell Crisis Pains|VERSATIS - Efficacy and Safety of Lidocaine 5% Plasters (Versatis® 5%) in Child, Adolescents and Young Adults With Neuropathic Pains or Vasoocclusive Sickle Cell Crisis Pains|Completed||Phase 2|39|Anticipated|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 22:47:37.644848|2018-05-31 22:47:37.644848
NCT01314287|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2014-04-10|2011-03-11|2011-03-14|Estimate|||||||2014-04-10|2014-04-11|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Effect of Coughing on Oxygenation in the Post Anaesthetic Care Unit|Observational Study of the Effect of Coughing on Emergence From Anaesthesia on Oxygenation in the Postanaesthetic Care Unit|Completed|||84|Actual|NHS Research and Development|||||f||||t||||||||||2018-05-31 22:47:37.741669|2018-05-31 22:47:37.741669
NCT01314274|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2013-08-08|2011-03-11|2011-03-14|Estimate|||||||2013-08-08|2013-08-12|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|A Randomized Double Blind Placebo Controlled Trial of Intranasal Submucosal Bevacizumab in Hereditary Hemorrhagic Telangiectasia|Completed||Phase 2|15|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 22:47:37.806515|2018-05-31 22:47:37.806515
NCT01314261|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|2014-12-29|2013-01-11|2015-01-21|2011-03-11|2011-03-14|Estimate|2015-01-21|2015-01-26|Estimate|2013-01-11|2013-01-21|Estimate|2015-01-21|2015-01-26|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Interventional||All 37 participants enrolled in the study received at least 1 dose of study drug and were included in the intent-to-treat population for efficacy and safety analyses.|Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects|A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|37|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 22:47:37.918102|2018-05-31 22:47:37.918102
NCT01314248|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2013-07-29|2011-03-11|2011-03-14|Estimate|||||||2013-07-29|2013-07-30|Estimate|December 2010||2010-12-31|July 2013|2013-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||The Laryngeal Mask Airway (LMA) Unique and the Air-Q Intubating Laryngeal Airway (ILA) in Pediatric Patients|A Randomized Crossover Comparison Between the Air-Q Intubating Laryngeal Airway the Laryngeal Mask Airway-Unique in Children|Completed|||50|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||t||||||||||2018-05-31 22:47:38.862005|2018-05-31 22:47:38.862005
NCT01314235|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|October 2010||2010-10-31|March 2011|2011-03-31||||||||Observational|||Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel|The Influence of Clonidine on the Thrombozytes of Patients Under Double Anticagulation With ASS and Clopidogrel - an in Vitro Study|Unknown status|Recruiting||||Goethe University|||||f||||||||||||||2018-05-31 22:47:38.932051|2018-05-31 22:47:38.932051
NCT01314222|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11||2015-09-23|2015-11-06|2011-03-11|2011-03-14|Estimate||||2015-09-23|2015-10-12|Estimate|2015-11-06|2015-12-07|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Diabetic Peripheral Neuropathic Pain (DPNP)|A Randomized, Multicenter, Double-blind, Placebo and Active-controlled, Cross-over Study of the Efficacy and Safety of BMS-954561 in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)|Completed||Phase 2|178|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 22:47:39.009178|2018-05-31 22:47:39.009178
NCT01314209|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2012-10-23|2011-03-11|2011-03-14|Estimate|||||||2012-10-23|2012-10-24|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||March 2014|Anticipated|2014-03-31||Interventional|||Dexmedetomidine Pharmacokinetics During Continuous Renal Replacement Therapy (CRRT)|Dexmedetomidine Pharmacokinetics During Continuous Venovenous Hemodialysis in Critically Ill Patients|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 22:47:39.15573|2018-05-31 22:47:39.15573
NCT01314196|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|December 2008||2008-12-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|PRTB||Progressive Resistance Training of the Biceps in Subacromial Impingement Syndrome|The Influence of Resistance Training Biceps as an Adjunct to Rehabilitation of the Shoulder in Subacromial Impingement Syndrome (SIS)|Completed||N/A|60|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:47:39.255344|2018-05-31 22:47:39.255344
NCT01314183|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-06-22|2011-03-11|2011-03-14|Estimate|||||||2015-06-22|2015-06-23|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Enhancing the Effectiveness of Physical Therapy for People With Knee Osteoarthritis|Enhancing the Effectiveness of Physical Therapy for People With Knee|Completed||Phase 2/Phase 3|300|Actual|Agency for Healthcare Research and Quality (AHRQ)||4|||f||||f||||||||||2018-05-31 22:47:39.329419|2018-05-31 22:47:39.329419
NCT01314170|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2011-05-09|2011-03-11|2011-03-14|Estimate|||||||2011-05-09|2011-05-10|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.|Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.|Unknown status|Not yet recruiting|Phase 3|76|Anticipated|Adapt Produtos Oftalmológicos Ltda.||1|||f||||t||||||||||2018-05-31 22:47:39.414473|2018-05-31 22:47:39.414473
NCT01314157|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|March 2011||2011-03-31|February 2011|2011-02-28||||June 2011|Anticipated|2011-06-30||Interventional|||Evaluation of Isostretching Effects in Patients With Mechanical and Postural Chronic Low Back Pain|Evaluation of Isostretching Effects in Patients With Mechanical and Postural|Unknown status|Not yet recruiting|N/A|54|Anticipated|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 22:47:39.498234|2018-05-31 22:47:39.498234
NCT01314144|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Interventional|||Use of Continuous Wound Infusion of Bupivacaine for Analgesia Following Axillary Clearance Surgery|Does Continuous Wound Infusion of 0.2% Bupivacaine Provide Superior Analgesia Compared to Standard Opioid-based Therapy in Patients Following Axillary Clearance Surgery?|Unknown status|Recruiting|Phase 3|42|Anticipated|Cork University Hospital||2|||f||||f||||||||||2018-05-31 22:47:39.558466|2018-05-31 22:47:39.558466
NCT01314131|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-11|||2011-04-28|2011-03-11|2011-03-14|Estimate|||||||2011-04-28|2011-04-29|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|June 2012|Anticipated|2012-06-30|September 2011|Anticipated|2011-09-30||Interventional|||Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home|Use of Autobiographical and Interest Assessment for a Better Stimulation of Patients in Nursing Home|Unknown status|Recruiting|N/A|48|Anticipated|Association Recherche Méthodologie Evaluation Psychiatrique||1|||f||||t||||||||||2018-05-31 22:47:39.62483|2018-05-31 22:47:39.62483
NCT01314118|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-12-24||2018-05-03|2011-03-10|2011-03-14|Estimate|2014-12-24|2015-01-07|Estimate||||2018-05-03|2018-05-30|Actual|May 4, 2011|Actual|2011-05-04|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|December 24, 2013|Actual|2013-12-24||Interventional||All participants who received at least 1 dose of study drug.|IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen|A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease|Active, not recruiting||Phase 2|131|Actual|Janssen Biotech, Inc.|These results are up to clinical cutoff 31 December 2013 when all enrolled subjects either completed 6 cycles of treatment or withdrew from study prior to end of cycle 6. Primary endpoint results are complete.|1|||f||||f|t|f||||||||2018-05-31 22:47:39.703807|2018-05-31 22:47:39.703807
NCT01313949|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-07-21|2011-03-10|2011-03-14|Estimate|||||||2014-07-21|2014-07-23|Estimate|February 2009||2009-02-28|July 2014|2014-07-31|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|PLATINUM||PLATINUM Program: A Feasibility Study on a Train-the-trainer Course on Peer Support for People With Type 2 Diabetes|Peer Leaders Accelerated Training Initiative to Unleash Potential of Mentorship (PLATINUM) Program: A Feasibility Study on a Train-the-trainer Course on Peer Support for People With Type 2 Diabetes|Completed||N/A|75|Actual|Asia Diabetes Foundation||2|||f||||t||||||||||2018-05-31 22:47:44.008007|2018-05-31 22:47:44.008007
NCT01314105|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|2014-11-14||2017-07-07|2011-03-10|2011-03-14|Estimate|2014-11-14|2014-11-20|Estimate||||2017-07-07|2018-02-01|Actual|March 2011||2011-03-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|July 2013|Actual|2013-07-31||Interventional||Treated set (TS) which included all patients who were administered at least one dose of any study medication|BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer|Phase I Dose Escalation Trial to Determine the Maximum Tolerated Dose of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Patients With a First, Second or Third Platinum Sensitive Relapse of Advanced Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 1|19|Actual|Boehringer Ingelheim|"Due to interference from doxorubicin, doxorubicinol concentrations could not be determined and doxorubicinol PK parameters could not be evaluated.~Statistics of PK parameters are only estimated when at least 2/3 of the data are evaluable."|3|||f||||||||||||||2018-05-31 22:47:41.038945|2018-05-31 22:47:41.038945
NCT01314092|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-11-21|2011-03-11|2011-03-14|Estimate|||||||2016-11-21|2016-11-23|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ANTG-ASC-210||Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula|Phase II Study to Evaluate Efficacy and Safety of ANTG-ASC (Autologous Cultured Adipose-derived Stem Cells) on the Complex Fistula Patients|Terminated||Phase 2|15|Actual|Anterogen Co., Ltd.||2||Difficulty recruiting subjects.|f||||t||||||||Undecided||2018-05-31 22:47:41.840729|2018-05-31 22:47:41.840729
NCT01314079|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-11-21|2011-03-11|2011-03-14|Estimate|||||||2016-11-21|2016-11-23|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|ANTG-ASC-203||Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula|Follow-up Study to Evaluate the Sustained Efficacy and Safety for the Patients With Adipoplus Injected in Phase II Clinical Trials(ANTG-ASC-202)|Completed|||37|Actual|Anterogen Co., Ltd.|||||f||||f||||||||||2018-05-31 22:47:41.940208|2018-05-31 22:47:41.940208
NCT01314066|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2016-04-29|2011-03-10|2011-03-14|Estimate|||||||2016-04-29|2016-05-03|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|VEGF-ARDS||Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)|Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)|Withdrawn||Phase 2|0|Actual|Weill Medical College of Cornell University||3||No funding|f||||t||||||||Undecided||2018-05-31 22:47:42.004468|2018-05-31 22:47:42.004468
NCT01314053|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-03-10|2011-03-10|2011-03-14|Estimate|||||||2011-03-10|2011-03-14|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|April 2011|Anticipated|2011-04-30|||||Observational|||Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections|Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections|Unknown status|Active, not recruiting||60|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:47:42.082993|2018-05-31 22:47:42.082993
NCT01314040|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-05-30|2011-03-10|2011-03-14|Estimate|||||||2011-05-30|2011-06-01|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|Biomarker||Study to Identify Biomarkers for Protein Intake|Study to Identify Biomarkers for Protein Intake; a Randomized, Fully Controlled Feeding Study|Completed||N/A|25|Anticipated|Wageningen University||4|||f||||f||||||||||2018-05-31 22:47:42.133012|2018-05-31 22:47:42.133012
NCT01314027|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-03-10|2011-03-10|2011-03-14|Estimate|||||||2011-03-10|2011-03-14|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer|Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study (NEOPAC Study)|Unknown status|Recruiting|Phase 3|310|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 22:47:42.196391|2018-05-31 22:47:42.196391
NCT01314014|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2014-05-29||2015-12-04|2011-03-10|2011-03-14|Estimate|2014-05-29|2014-07-01|Estimate||||2015-12-04|2016-01-06|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|March 2013|Actual|2013-03-31||Interventional|ULYM11011||Imexon for Relapsed Follicular and Aggressive Lymphomas|A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults|Completed||Phase 2|22|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 22:47:42.378088|2018-05-31 22:47:42.378088
NCT01314001|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2016-01-04||2016-02-03|2011-03-10|2011-03-14|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional||The number of subjects who began treatment period in the project (intention-to-treat).|Pharmacogenetics of Nicotine Addiction Treatment|Pharmacogenetics of Nicotine Addiction Treatment (PNAT)|Completed||Phase 3|1246|Actual|University of Pennsylvania|A limitation is that few Hispanics or Asians were included.|6|||f||||t||||||||||2018-05-31 22:47:42.654486|2018-05-31 22:47:42.654486
NCT01313988|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-02-05|2011-03-10|2011-03-14|Estimate|||||||2012-02-05|2012-02-07|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy Study on the Lipid-lowering Effect of Plant Sterols and Fish Oil|Efficacy Study on the Lipid-lowering Effect of a Spread Enriched With the Recommended Dose of Plant Sterols and 3 Different Doses of Fatty Acids From Fish Oil|Completed||N/A|332|Actual|Unilever R&D||5|||f||||f||||||||||2018-05-31 22:47:43.802846|2018-05-31 22:47:43.802846
NCT01313975|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2013-04-16|2011-03-10|2011-03-14|Estimate|||||||2013-04-16|2013-04-17|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Electrolyte and Fluid Disturbances in Subarachnoid Hemorrhage and Traumatic Brain Injury|Disturbances of the Sodium and Fluid Balance in Patients With Severe Traumatic Brain Injury and Non-traumatic Subarachnoid Hemorrhage. A Systematic Observational Study|Completed|||85|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||Samples With DNA|"~     serum and urine samples~   "|||2018-05-31 22:47:43.872346|2018-05-31 22:47:43.872346
NCT01313962|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-01-12|2011-03-10|2011-03-14|Estimate|||||||2012-01-12|2012-01-16|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of Flufirvitide-3 Nasal Spray in Healthy Subjects|Completed||Phase 1|32|Actual|Autoimmune Technologies, LLC||2|||f||||f||||||||||2018-05-31 22:47:43.945055|2018-05-31 22:47:43.945055
NCT01312740|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-10|2011-03-10|2011-03-11|Estimate|||||||2011-03-10|2011-03-11|Estimate|May 2007||2007-05-31|March 2011|2011-03-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Two Hypocaloric Diets on Weight Loss|Effects of Two Hypocaloric Diets on Weight Loss and Inflammatory Markers|Completed||N/A|13|Actual|Ceprodi S.A. Kot|||||f||||||||||||||2018-05-31 22:48:22.633535|2018-05-31 22:48:22.633535
NCT01313936|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2015-07-14||2017-06-18|2011-03-10|2011-03-14|Estimate|2015-07-14|2015-08-07|Estimate||||2017-06-18|2017-07-14|Actual|March 2011||2011-03-31|June 2017|2017-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma|Pilot Study of High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed High-Risk Neuroblastoma|Completed||N/A|32|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:47:44.090694|2018-05-31 22:47:44.090694
NCT01313923|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2014-12-17||2017-05-08|2011-03-10|2011-03-14|Estimate|2016-02-24|2016-03-25|Estimate||||2017-05-08|2017-06-09|Actual|February 2011||2011-02-28|May 2017|2017-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus|Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus|Terminated||Early Phase 1|3|Actual|University of California, Irvine|No results as study has been terminated early by the investigator.|1||Lack of funding|f||||f||||||||||2018-05-31 22:47:44.372879|2018-05-31 22:47:44.372879
NCT01313910|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2013-09-15||2017-05-24|2011-03-11|2011-03-14|Estimate|2017-01-12|2017-03-03|Actual||||2017-05-24|2017-06-15|Actual|March 2011||2011-03-31|May 2017|2017-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements|CCRC: A Pilot Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements|Completed||Early Phase 1|8|Actual|University of California, Davis|pilot open label study with eight subjects.|1|||f||||f||||||||||2018-05-31 22:47:44.534927|2018-05-31 22:47:44.534927
NCT01313897|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2017-03-01||2017-04-14|2011-03-10|2011-03-14|Estimate|2017-03-01|2017-04-13|Actual||||2017-04-14|2017-05-19|Actual|January 2011||2011-01-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|NK2010-35||UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma|UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma|Completed||Phase 2|10|Actual|University of Arkansas||1|||f||||t|t|f||||||||2018-05-31 22:47:44.774177|2018-05-31 22:47:44.774177
NCT01313884|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2016-12-07||2017-10-20|2011-03-11|2011-03-14|Estimate|2016-12-07|2017-02-02|Estimate||||2017-10-20|2017-11-24|Actual|May 2011||2011-05-31|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma|A Phase II Pilot Study of Cyclophosphamide, Doxorubicin, Vincristine Alternating With Irinotecan and Temozolomide in Patients With Newly Diagnosed Metastatic Ewing's Sarcoma|Terminated||Phase 2|3|Actual|Stanford University|Study did not reach primary objective; study didn't accrue enough patients.|1||Study did not reach primary objective; study did not accrue enough patients.|f||||t||||||||No||2018-05-31 22:47:45.069919|2018-05-31 22:47:45.069919
NCT01313871|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2015-05-29|2011-03-10|2011-03-14|Estimate|||||||2015-05-29|2015-06-01|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|November 2012|Anticipated|2012-11-30|July 2012|Anticipated|2012-07-31||Observational|||Assessment of the Disease Severity and Treatment Patterns of Rheumatoid Arthritis in Eastern Europe, Middle East and North African Countries (P08167)|Cross-sectional Study of Disease Severity and Treatment Patterns of Rheumatoid Arthritis, in Eastern Europe Middle East and North Africa|Withdrawn|||0|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:47:45.345462|2018-05-31 22:47:45.345462
NCT01313858|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2016-09-12||2016-09-12|2011-03-10|2011-03-14|Estimate|2016-09-12|2016-11-01|Estimate||||2016-09-12|2016-11-01|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|GO-NICE|The Modified Intention to Treat Population (mITT) population consists of all participants who were treated with Simponi® and have a baseline assessment and at least one additional visit, regardless of any protocol violations during the study.|A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)|Non-Interventional Study Investigating the Use of Golimumab (Simponi®) in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis|Completed|||1613|Actual|Merck Sharp & Dohme Corp.|||3||f||||f||||||||||2018-05-31 22:47:45.421009|2018-05-31 22:47:45.421009
NCT01313845|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-08-08|2011-03-10|2011-03-14|Estimate|||||||2012-08-08|2012-08-09|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease|Randomized Double-blind Placebo-controlled Trial of Intravenous Amantadine on Gait Freezing in Patients With Parkinson's Disease|Completed||Phase 4|46|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:47:46.328176|2018-05-31 22:47:46.328176
NCT01313832|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-02-01|2011-03-10|2011-03-14|Estimate|||||||2012-02-01|2012-02-02|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension||Completed||N/A|60|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 22:47:46.405507|2018-05-31 22:47:46.405507
NCT01313819|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-11-09|2011-03-10|2011-03-14|Estimate|||||||2011-11-09|2011-11-11|Estimate|April 2011||2011-04-30|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy|A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy|Unknown status|Recruiting|Phase 4|20|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:47:46.474258|2018-05-31 22:47:46.474258
NCT01313806|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-05-27|2011-03-10|2011-03-14|Estimate|||||||2011-05-27|2011-05-30|Estimate|September 2011||2011-09-30|May 2011|2011-05-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Study of Magnetic Fields to Treat Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy of the Application of Magnetic Fields Using the Resonator for the Treatment of Alzheimer‟s Disease in Addition to Standard of Care|Withdrawn||N/A|30|Anticipated|pico-tesla Magnetic Therapies, LLC||2|||f||||t||||||||||2018-05-31 22:47:46.604513|2018-05-31 22:47:46.604513
NCT01313793|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-06-27|2011-03-10|2011-03-14|Estimate|||||||2011-06-27|2011-06-28|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804|A Phase 1 Open-Label Study Of Pf-00299804 In Healthy Volunteers To Demonstrate The Bioequivalence Of The Proposed Commercializable Formulation Administered As One 45-Mg Tablet Relative To Three 15-Mg Clinical Formulation Tablets|Completed||Phase 1|32|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:47:46.682068|2018-05-31 22:47:46.682068
NCT01312727|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2016-08-25|2011-03-09|2011-03-11|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|July 2016|Actual|2016-07-31|February 2014|Actual|2014-02-28||Interventional|NTIH||Hereditary Tubulointerstitial Nephritis|Phenotypical and Genetic Characterization of Adult Hereditary Chronic Tubulointerstitial Renal Diseases|Completed||N/A|225|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:48:22.683536|2018-05-31 22:48:22.683536
NCT01313780|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|2016-07-13||2017-11-29|2011-03-10|2011-03-14|Estimate|2016-09-06|2016-10-27|Estimate||||2017-11-29|2017-12-22|Actual|May 2011||2011-05-31|November 2017|2017-11-30|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional|TOP||A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients|A 4-week Multicentre, Randomized, Open Label, Parallel Group, Active Control Phase IV Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone in Comparison With Oxycontin in Korean Patients With Cancer Pain(TOP)|Completed||Phase 4|128|Actual|Mundipharma Korea Ltd||2|||f||||f||||||||No||2018-05-31 22:47:46.776777|2018-05-31 22:47:46.776777
NCT01313767|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-04-24|2011-03-10|2011-03-14|Estimate|||||||2012-04-24|2012-04-25|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity|A Randomized, Double Blind, Multi-center, Active Drug Controlled Clinical Trial to Compare the Efficacy and Safety of MEDITOXIN® Versus BOTOX® in Treatment of Post Stroke Upper Limb Spasticity|Completed||Phase 3|196|Actual|Medy-Tox||2|||f||||f||||||||||2018-05-31 22:47:47.308927|2018-05-31 22:47:47.308927
NCT01313754|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2013-01-29|2011-03-11|2011-03-14|Estimate|||||||2013-01-29|2013-01-31|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Skin Incision Closure Material for the Transobturator Suburethral Sling Procedure||Completed||N/A|160|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 22:47:47.439282|2018-05-31 22:47:47.439282
NCT01313741|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-03-10|2011-03-10|2011-03-14|Estimate|||||||2011-03-10|2011-03-14|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||This is a 2 Year Follow up Clinical and Radiographic Analysis of a Novel All Polyethelene Glenoid Component in Standard Total Shoulder Arthroplasty.||Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Knoxville Orthopedic Clinic||1|||f||||||||||||||2018-05-31 22:47:47.504087|2018-05-31 22:47:47.504087
NCT01313728|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2011-10-14||2012-02-14|2011-03-10|2011-03-14|Estimate|2011-12-14|2012-01-19|Estimate||||2012-02-14|2012-02-15|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products|An Investigator-Blind, Phase 4 Study Assessing Mitigation of Facial Irritation When Comparing the Use of Two Acne Treatment Products (Retin-A Micro® 0.1 % Pump and Aczone®) With One Treatment Product (Retin-A Micro® 0.1 % Pump) Using a Split-Face Model|Completed||Phase 4|26|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 22:47:47.5776|2018-05-31 22:47:47.5776
NCT01313715|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-12-30|2011-03-10|2011-03-14|Estimate|||||||2011-12-30|2012-01-02|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants|A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants|Completed||Phase 1|360|Actual|Jiangsu Province Centers for Disease Control and Prevention||8|||f||||f||||||||||2018-05-31 22:47:48.043856|2018-05-31 22:47:48.043856
NCT01313702|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-03-15|2011-03-11|2011-03-14|Estimate|||||||2012-03-15|2012-03-16|Estimate|October 2012||2012-10-31|March 2012|2012-03-31|July 2014|Anticipated|2014-07-31|April 2014|Anticipated|2014-04-30||Interventional|SPACE||Single Pill to Avert Cardiovascular Events|Effect of Polipill on Patients at High Cardiovascular Risk : a Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|2000|Anticipated|Hospital do Coracao||3|||f||||f||||||||||2018-05-31 22:47:48.154135|2018-05-31 22:47:48.154135
NCT01313689|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2014-11-06||2017-06-02|2011-03-11|2011-03-14|Estimate|2014-11-17|2014-11-24|Estimate||||2017-06-02|2017-07-02|Actual|April 14, 2011|Actual|2011-04-14|June 2017|2017-06-30|April 30, 2017|Actual|2017-04-30|March 18, 2014|Actual|2014-03-18||Interventional|||Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia|An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL)|Completed||Phase 3|122|Actual|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 22:47:48.342732|2018-05-31 22:47:48.342732
NCT01313676|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2016-03-10||2018-04-30|2011-03-10|2011-03-14|Estimate|2016-06-29|2016-08-09|Estimate||||2018-04-30|2018-05-02|Actual|January 25, 2011|Actual|2011-01-25|April 2018|2018-04-30|July 15, 2015|Actual|2015-07-15|July 15, 2015|Actual|2015-07-15||Interventional|||Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease|A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease|Completed||Phase 3|16568|Actual|GlaxoSmithKline||4|||f||||t||||||||||2018-05-31 22:47:50.879221|2018-05-31 22:47:50.879221
NCT01313663|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-03-07||2014-10-16|2011-03-10|2011-03-14|Estimate|2013-04-25|2013-04-29|Estimate||||2014-10-16|2014-10-27|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population|A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy With Carboplatin + Pemetrexed or Cisplatin + Pemetrexed|Terminated||Phase 2|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:48:00.330153|2018-05-31 22:48:00.330153
NCT01313650|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2014-01-16||2017-09-07|2011-03-10|2011-03-14|Estimate|2014-01-16|2014-03-04|Estimate||||2017-09-07|2017-10-06|Actual|March 1, 2011||2011-03-01|September 2017|2017-09-30|April 5, 2012|Actual|2012-04-05|April 1, 2012|Actual|2012-04-01||Interventional|DB2113373||A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1538|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:48:01.099125|2018-05-31 22:48:01.099125
NCT01313637|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2013-12-19||2018-01-25|2011-03-11|2011-03-14|Estimate|2013-12-19|2014-02-10|Estimate||||2018-01-25|2018-01-29|Actual|March 1, 2011||2011-03-01|January 2018|2018-01-31|April 19, 2012|Actual|2012-04-19|March 1, 2012|Actual|2012-03-01||Interventional|DB2113361||A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1493|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 22:48:02.211518|2018-05-31 22:48:02.211518
NCT01313624|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2014-03-07||2014-03-07|2011-03-11|2011-03-14|Estimate|2014-03-07|2014-04-16|Estimate||||2014-03-07|2014-04-16|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|AIR-BX1|ITT Analysis Set|Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection|Completed||Phase 3|266|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 22:48:03.439875|2018-05-31 22:48:03.439875
NCT01313611|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2018-03-06|2011-03-10|2011-03-14|Estimate|||||||2018-03-06|2018-03-07|Actual|February 2011|Actual|2011-02-28|March 2018|2018-03-31|December 2017|Actual|2017-12-31|October 2012|Actual|2012-10-31||Interventional|BRIEF||BRIEF Bendamustine and Rituximab In Elderly Follicular|BRIEF: Bendamustine and Rituximab In Elderly Follicular: A Multicentric Phase II Study Evaluating the Benefit of a Short Induction Treatment by Bendamustine and Rituximab Followed by Maintenance Therapy With Rituximab In Elderly (≥ 60 Years Old) Patients With Untreated Follicular Lymphoma Patients, With an Intermediate or High FLIPI Score|Terminated||Phase 2|62|Actual|The Lymphoma Academic Research Organisation||1||"Treament with rituximab during maintenance phase was stoped, according to DSMC recommendations,~   since 3 cases of deaths occured."|f||||t||||||||||2018-05-31 22:48:04.297505|2018-05-31 22:48:04.297505
NCT01313598|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-06-09|2011-03-11|2011-03-14|Estimate|||||||2013-06-09|2013-06-11|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors|An Open-label, Dose Escalating Phase Ib Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of GLPG0187 in Subjects With Solid Tumors|Completed||Phase 1|20|Actual|Galapagos NV||1|||f||||t||||||||||2018-05-31 22:48:04.557182|2018-05-31 22:48:04.557182
NCT01313585|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-03-11|2011-03-11|2011-03-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|January 1991||1991-01-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|June 2007|Actual|2007-06-30||Observational|EBsalbutamol||Device Mixing in Asthma, a General Practice Research Database Study|Retrospective, Real-life Observational Evaluation of the Effectiveness of Mixed Maintenance and Reliever Inhaler Types in Patients in the Management of Asthma in a Representative UK Primary Care Population|Completed|||815377|Actual|Research in Real-Life Ltd|||4||f||||t||||||||||2018-05-31 22:48:04.652785|2018-05-31 22:48:04.652785
NCT01313572|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04||2012-04-26|2012-04-27|2011-03-10|2011-03-11|Estimate||||2012-04-27|2012-05-01|Estimate|2012-04-27|2012-05-01|Estimate|August 2011||2011-08-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|ASPECT2||Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI|The ASPECT2 Trial: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)|Terminated||Phase 3|197|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 22:48:04.765333|2018-05-31 22:48:04.765333
NCT01313559|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2016-09-08||2018-04-23|2011-03-10|2011-03-11|Estimate|2017-12-14|2018-01-16|Actual||||2018-04-23|2018-04-25|Actual|June 2011||2011-06-30|April 2018|2018-04-30|November 29, 2012|Actual|2012-11-29|September 15, 2012|Actual|2012-09-15||Interventional|||Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer|An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients|Terminated||Phase 2|6|Actual|Thomas Jefferson University|Study terminated prematurely due to slow accrual|2||Slow accrual|f||||t||||||||||2018-05-31 22:48:04.983334|2018-05-31 22:48:04.983334
NCT01313546|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-03-10|2011-03-10|2011-03-11|Estimate|||||||2011-03-10|2011-03-11|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|September 2012|Anticipated|2012-09-30|May 2012|Anticipated|2012-05-31||Interventional|||A Comparison of Sartorius Vs. Quadriceps Evoked Motor Response for Femoral Nerve to Prevent Secondary Catheter Failure|A Comparison of Sartorius Vs. Quadriceps Evoked Motor Response for Femoral Nerve to Prevent Secondary Catheter Failure|Unknown status|Not yet recruiting|Early Phase 1|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:48:05.452553|2018-05-31 22:48:05.452553
NCT01313533|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2016-10-12|2011-03-10|2011-03-11|Estimate|||||||2016-10-12|2016-10-14|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|November 2021|Anticipated|2021-11-30|December 2019|Anticipated|2019-12-31||Interventional|||Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes|Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes|Recruiting||Phase 1/Phase 2|540|Anticipated|St. Luke's Hospital, Chesterfield, Missouri||2|||f||||t||||||||Undecided||2018-05-31 22:48:05.522467|2018-05-31 22:48:05.522467
NCT01313520|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2013-02-12||2017-04-04|2011-03-10|2011-03-11|Estimate|2013-04-25|2013-07-08|Estimate||||2017-04-04|2017-05-10|Actual|March 1, 2011|Actual|2011-03-01|April 2017|2017-04-30|March 1, 2012|Actual|2012-03-01|March 1, 2012|Actual|2012-03-01||Interventional|||A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)|A Randomized Clinical Trial to Study the Effects of Infliximab on Clinical Efficacy and Hand and Wrist Magnetic Resonance Imaging (MRI) in Patients With Active Rheumatoid Arthritis (RA)(Protocol No. P08136)|Completed||Phase 2|61|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:48:05.598122|2018-05-31 22:48:05.598122
NCT01313507|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2015-10-21||2017-02-08|2011-03-10|2011-03-11|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|May 2011||2011-05-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|NGAM-05|Safety analysis set: All participants who received at least 1 dose of NewGam.|High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)|Clinical Study to Evaluate the Safety and Tolerability of Immunoglobulin Intravenous (Human) 10% (NewGam) Administered at High Infusion Rates to Patients With Primary Immunodeficiency Diseases (Extension of Study NGAM-01)|Completed||Phase 3|21|Actual|Octapharma||1|||f||||t||||||||||2018-05-31 22:48:05.850596|2018-05-31 22:48:05.850596
NCT01313494|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2013-03-18||2016-12-02|2011-03-10|2011-03-11|Estimate|2013-07-31|2013-08-02|Estimate||||2016-12-02|2017-02-01|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|ACROSS||A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:|A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial|Completed||Phase 3|626|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:48:06.097276|2018-05-31 22:48:06.097276
NCT01313481|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2016-07-18|2011-03-10|2011-03-11|Estimate|||||||2016-07-18|2016-07-19|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|FALLFOR||Effect of the Otago Programme Delivered as Home Exercise or Group Exercise|A Randomized Controlled Trial of the Effect of Otago Exercise Delivered as Home Exercise or Group Exercise in Fall-prone Older Persons|Completed||N/A|125|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 22:48:06.829025|2018-05-31 22:48:06.829025
NCT01313468|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-03-29|2011-03-10|2011-03-11|Estimate|||||||2017-03-29|2017-03-30|Actual|February 2011|Actual|2011-02-28|March 2017|2017-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|NEAT||Interval Training and Resting Metabolism|Effect of Aerobic Interval Training on NEAT in Sedentary Men|Completed||N/A|30|Actual|Norwegian University of Science and Technology||3|||f||||f|f|f||||||No||2018-05-31 22:48:06.888801|2018-05-31 22:48:06.888801
NCT01313455|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-10-25|2011-03-10|2011-03-11|Estimate|||||||2017-10-25|2017-10-26|Actual|March 10, 2011||2011-03-10|October 24, 2017|2017-10-24|October 24, 2017||2017-10-24|||||Observational|||Adrenal Hyperplasia Among Young People With PCOS|Adrenal Hyperplasia Among Young Patients With Polycystic Ovarian Syndrome|Completed|||96|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:48:06.942378|2018-05-31 22:48:06.942378
NCT01313442|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-10-18|2011-03-10|2011-03-11|Estimate|||||||2017-10-18|2017-10-19|Actual|March 10, 2011||2011-03-10|August 1, 2017|2017-08-01||||||||Observational|||Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer|Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:48:06.995228|2018-05-31 22:48:06.995228
NCT01313429|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2018-05-23|2011-03-10|2011-03-11|Estimate|||||||2018-05-23|2018-05-24|Actual|March 10, 2011||2011-03-10|April 2, 2018|2018-04-02|June 20, 2014|Actual|2014-06-20|June 20, 2014|Actual|2014-06-20||Interventional|||Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum|Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum|Completed||Phase 1|19|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:48:07.054616|2018-05-31 22:48:07.054616
NCT01313416|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-09-15|2011-03-10|2011-03-11|Estimate|||||||2017-09-15|2017-09-18|Actual|September 2012|Actual|2012-09-30|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Gemcitabine and CT-011 for Resected Pancreatic Cancer|A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer|Terminated||Phase 2|2|Actual|Augusta University||1||Drug supply issues|f||||t||||||||No|Comprehensive data will be reported, not individual participant data.|2018-05-31 22:48:07.125877|2018-05-31 22:48:07.125877
NCT01313403|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2017-06-30|2011-03-10|2011-03-11|Estimate|||||||2017-06-30|2017-07-02|Actual|February 10, 2011||2011-02-10|April 25, 2012|2012-04-25|April 25, 2012|Actual|2012-04-25|April 25, 2012|Actual|2012-04-25||Interventional|||Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder|Imaging Serotonin 5-HT1A Receptors in the High Affinity State in Brains of Patients With Major Depressive Disorder|Withdrawn||N/A|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:48:08.219677|2018-05-31 22:48:08.219677
NCT01313390|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-12-09|2011-03-10|2011-03-11|Estimate|||||||2011-12-09|2011-12-12|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|DORA||Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer|DORA: A Phase I and Randomized Phase II Study of Docetaxel and RAD001 (Everolimus) in Advanced/Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1/Phase 2|4|Actual|University College, London||||Lack of recruitment|f||||t||||||||||2018-05-31 22:48:08.300731|2018-05-31 22:48:08.300731
NCT01313377|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-01-24|2011-03-10|2011-03-11|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2009||2009-07-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery|Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts|Completed||Phase 3|190|Actual|UNICANCER||2|||f||||||||||||||2018-05-31 22:48:08.408939|2018-05-31 22:48:08.408939
NCT01313364|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-08-11|2011-03-10|2011-03-11|Estimate|||||||2011-08-11|2011-08-12|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle|A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle|Terminated||Phase 1|80|Actual|Biogen||1||The objective of the study has been achieved with fewer subjects than planned.|f||||f||||||||||2018-05-31 22:48:08.555752|2018-05-31 22:48:08.555752
NCT01313351|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2012-08-24|2011-03-08|2011-03-11|Estimate|||||||2012-08-24|2012-08-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:48:08.614282|2018-05-31 22:48:08.614282
NCT01313338|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-03-10|2011-03-10|2011-03-11|Estimate|||||||2011-03-10|2011-03-11|Estimate|April 2009||2009-04-30|March 2011|2011-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||Experience in Predicting Decision Making for Receiving Treatment in Acute Coronary Syndrome Patients|Cognitive Representation, Emotional Responses and Hospitalization Experience in Predicting Decision Making for Receiving Treatment Among Patients With Acute Coronary Syndrome|Completed|||132|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 22:48:08.650758|2018-05-31 22:48:08.650758
NCT01313325|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-10|2011-03-10|2011-03-11|Estimate|||||||2011-03-10|2011-03-11|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|HPOT||Hippotherapy to Improve the Balance of Children With Movement Disorders|Hippotherapy to Improve Balance Deficits in a Cohort of Children With Movement Disorders: A Pilot Study|Completed||N/A|16|Actual|Central Michigan University||1|||f||||f||||||||||2018-05-31 22:48:09.46761|2018-05-31 22:48:09.46761
NCT01313312|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2017-03-01|2015-05-07|2017-05-09|2011-03-10|2011-03-11|Estimate|2017-05-09|2017-06-07|Actual|2015-05-07|2015-05-25|Estimate|2017-05-09|2017-06-07|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Baseline characteristics are reported for the 254 Subjects who entered this open label study (223 from Study 145 and 31 de novo subjects) and received at least one open label injection of Dysport®.|Dysport® Adult Upper Limb Spasticity Extension Study|A Phase III, Multicentre, Prospective, Open Label Extension Study to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury|Completed||Phase 3|258|Actual|Ipsen||1|||f||||t||||||||Undecided||2018-05-31 22:48:09.713059|2018-05-31 22:48:09.713059
NCT01313299|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2015-08-11|2015-05-07|2017-01-24|2011-03-10|2011-03-11|Estimate|2015-09-23|2015-10-23|Estimate|2015-05-07|2015-05-25|Estimate|2017-01-24|2017-03-07|Actual|August 2011||2011-08-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Dysport® Adult Upper Limb Spasticity|A Phase III, Multicentre, Prospective, Double Blind, Randomised, Placebo Controlled Study, Assessing the Efficacy and Safety of Dysport® Intramuscular Injections Used for the Treatment of Upper Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury|Completed||Phase 3|243|Actual|Ipsen||3|||f||||||||||||||2018-05-31 22:48:11.027644|2018-05-31 22:48:11.027644
NCT01313286|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-05-05|2011-03-10|2011-03-11|Estimate|||||||2011-05-05|2011-05-09|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Compare Two Forms of LY2608204 in Healthy People|The Relative Bioavailability of a Proposed Phase 2 LY2608204 Test Formulation Compared With the Current Phase 1 LY2608204 Reference Formulation After Administration of a Single Oral 80-mg Dose in Healthy Subjects|Completed||Phase 1|16|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:48:11.65654|2018-05-31 22:48:11.65654
NCT01313273|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2015-04-28||2015-08-28|2011-03-10|2011-03-11|Estimate|2015-08-06|2015-08-14|Estimate||||2015-08-28|2015-09-02|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|POSEIDON||Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients|Randomised, Phase III Multicenter, Open Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients Presenting Elevated Chromogranin A Levels|Terminated||Phase 3|3|Actual|Ipsen|Study terminated due to poor enrollment|2||Poor enrolment|f||||f||||||||||2018-05-31 22:48:11.776043|2018-05-31 22:48:11.776043
NCT01313260|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2012-09-27|2011-03-10|2011-03-11|Estimate|||||||2012-09-27|2012-09-28|Estimate|February 2011||2011-02-28|January 2012|2012-01-31||||||||Observational|||Structural and Functional Connectivity in Partial Epilepsies Studied With MRI and MEG|Structural and Functional Connectivity in Partial Epilepsies Studied With MRI and MEG|Unknown status|Recruiting||45|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||t||||||||||2018-05-31 22:48:12.023949|2018-05-31 22:48:12.023949
NCT01313247|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-03-10|2011-03-10|2011-03-11|Estimate|||||||2011-03-10|2011-03-11|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Paracetamol for Cancer Pain|Optimizing Medication for Cancer Pain. The Effect of Paracetamol. A Clinical and Pharmacological Trial to Research Whether Paracetamol Gives an Additional Effect on Pain Relief When the Patient is Treated With High Doses of Opioids|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Haraldsplass Deaconess Hospital||2|||f||||f||||||||||2018-05-31 22:48:12.087704|2018-05-31 22:48:12.087704
NCT01313234|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-05|||2013-01-05|2011-03-10|2011-03-11|Estimate|||||||2013-01-05|2013-01-08|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Educational Intervention Targeting Nurses Attitudes and Knowledge About Cancer-related Pain Management|A Theory Based Educational Intervention Targeting Nurses Attitudes and Knowledge Concerning Cancer-related Pain Management: A Study Protocol of a Quasi-experimental Study Design|Completed||N/A|60|Actual|Blekinge Institute of Technology||2|||f||||f||||||||||2018-05-31 22:48:12.167676|2018-05-31 22:48:12.167676
NCT01313221|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2013-12-10||2017-02-07|2011-03-10|2011-03-11|Estimate|2014-03-31|2014-05-02|Estimate||||2017-02-07|2017-03-15|Actual|April 2011||2011-04-30|February 2017|2017-02-28|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|REFINE||Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis|A Randomized, Blinded Assessor Study to Evaluate the Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent Versus Etanercept 50 mg Twice Weekly in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|310|Actual|Amgen||2|||f||||||||||||||2018-05-31 22:48:12.267991|2018-05-31 22:48:12.267991
NCT01313208|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|2014-05-07||2017-02-07|2011-03-10|2011-03-11|Estimate|2014-05-07|2014-06-17|Estimate||||2017-02-07|2017-02-09|Estimate|March 2011||2011-03-31|February 2017|2017-02-28|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy|Completed||Phase 4|210|Actual|Amgen||2|||f||||f||||||||||2018-05-31 22:48:13.324519|2018-05-31 22:48:13.324519
NCT01313195|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2011-11-16|2011-03-10|2011-03-11|Estimate|||||||2011-11-16|2011-11-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:48:16.452498|2018-05-31 22:48:16.452498
NCT01313182|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|2014-02-21||2014-04-24|2011-03-10|2011-03-11|Estimate|2014-04-24|2014-05-19|Estimate||||2014-04-24|2014-05-19|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||arthroplasty or spine fusion surgery patients|Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin||Completed||Phase 4|1784|Actual|3M|Study failed to achieve target enrollment. The small sample size precluded a multivariate analysis. Nasal culture alone was used as a screen for S. aureus colonization, which has a sensitivity of only 48% to 66%.|2|||f||||f||||||||||2018-05-31 22:48:16.595027|2018-05-31 22:48:16.595027
NCT01313169|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2017-03-10|2011-03-10|2011-03-11|Estimate|||||||2017-03-10|2017-03-14|Actual|May 2009||2009-05-31|March 2017|2017-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Electronic Medical Record Reminders and Panel Management to Improve Primary Care of Elderly Patients|Electronic Medical Record Reminders and Panel Management to Improve Primary Care of Elderly Patients|Completed||N/A|54|Actual|Beth Israel Deaconess Medical Center||3|||f||||f||||||||||2018-05-31 22:48:17.339572|2018-05-31 22:48:17.339572
NCT01313156|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2018-04-05|2011-03-10|2011-03-11|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2008||2008-11-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|LUPS||LUPS-Lipids and Glucose Under Prospective Surveillance|Lipids and Glucose Under Prospective Surveillance|Active, not recruiting|||1962|Actual|Asklepios proresearch|||||f||||f||||||||||2018-05-31 22:48:17.577046|2018-05-31 22:48:17.577046
NCT01313143|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-10|||2012-07-18|2011-03-10|2011-03-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol|A Prospective, Randomized, Double Blinded, Crossover, Two-treatment, Two-sequence, Short Term Pharmacokinetic, Pharmacodynamic and Tolerability, Single Centre Study to Compare AOP200704 vs. Esmolol in Healthy Subjects.|Completed||Phase 2|16|Actual|AOP Orphan Pharmaceuticals AG||2|||f||||f||||||||||2018-05-31 22:48:17.826248|2018-05-31 22:48:17.826248
NCT01313130|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2014-12-08|2011-03-10|2011-03-11|Estimate|||||||2014-12-08|2014-12-10|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|August 2016|Anticipated|2016-08-31|December 2013|Actual|2013-12-31||Observational|||Advanced MRI In Acute Military TBI|ADVANCED MRI IN ACUTE MILITARY TBI|Unknown status|Enrolling by invitation||400|Anticipated|Washington University School of Medicine|||4||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 22:48:17.91854|2018-05-31 22:48:17.91854
NCT01313117|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2014-09-20||2014-09-26|2011-03-09|2011-03-11|Estimate|2014-09-26|2014-10-02|Estimate||||2014-09-26|2014-10-02|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy|Dose Finding and Tolerability Study of Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Peripheral Neuropathy|Completed||Phase 1/Phase 2|9|Actual|Northwestern University|The small number of enrolled patients precluded any meaningful ALA dose finding or neuropathy prevention efficacy statements. A formal statistical analysis of the data was not able to be performed.|1|||f||||t||||||||||2018-05-31 22:48:18.101397|2018-05-31 22:48:18.101397
NCT01313104|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2012-06-08|2011-03-09|2011-03-11|Estimate|||||||2012-06-08|2012-06-11|Estimate||||June 2012|2012-06-30||||||||Interventional|||Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer|Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia|Withdrawn||N/A|0|Actual|Northwestern University||1||Lack of funding|f||||t||||||||||2018-05-31 22:48:18.682935|2018-05-31 22:48:18.682935
NCT01313078|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2012-08-13||2015-10-08|2011-03-09|2011-03-11|Estimate|2012-08-13|2012-09-12|Estimate||||2015-10-08|2015-10-09|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer|Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer|Completed||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 22:48:18.761407|2018-05-31 22:48:18.761407
NCT01313065|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2014-08-11|2011-03-09|2011-03-11|Estimate|||||||2014-08-11|2014-08-13|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors|A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of VX15/2503 in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|42|Actual|Vaccinex Inc.||1|||f||||f||||||||||2018-05-31 22:48:18.987914|2018-05-31 22:48:18.987914
NCT01313052|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2017-02-24|2011-03-09|2011-03-11|Estimate|||||||2017-02-24|2017-02-28|Actual|May 2008||2008-05-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|FACT||Forensic Assertive Community Treatment: An Emerging Model of Service Delivery|Forensic Assertive Community Treatment: An Emerging Model of Service Delivery|Completed||Phase 3|53|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 22:48:19.073157|2018-05-31 22:48:19.073157
NCT01313039|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2014-05-01||2016-12-14|2011-03-10|2011-03-11|Estimate|2014-05-29|2014-07-02|Estimate||||2016-12-14|2017-02-07|Estimate|February 2011||2011-02-28|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer|Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer|Completed||Early Phase 1|4|Actual|University of Miami|Only 4 patients were enrolled and of these 4 only 1 patient had evaluable study data.|1|||f||||t||||||||||2018-05-31 22:48:19.148584|2018-05-31 22:48:19.148584
NCT01313026|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2016-10-25|2011-03-09|2011-03-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||"Treatment of Low Anterior Resection Syndrome by Percutaneous Nerve Evaluation and Transanal Irrigation"|"Treatment of Low Anterior Resection Syndrome by Percutaneous Nerve Evaluation and Transanal Irrigation. A Randomized Cross Over Study."|Recruiting||N/A|20|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:48:19.311931|2018-05-31 22:48:19.311931
NCT01313013|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-09|2011-03-09|2011-03-11|Estimate|||||||2011-03-09|2011-03-11|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Question Prompt Sheet for Depressive Outpatients||Completed||N/A|100|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 22:48:19.380999|2018-05-31 22:48:19.380999
NCT01313000|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2012-03-23|2011-03-10|2011-03-11|Estimate|||||||2012-03-23|2012-03-26|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Observational|||Study To Evaluate Upper Arm Autologous Fat Transfer|Pilot Study To Evaluate Upper Arm Autologous Fat Transfer|Completed|||10|Actual|Sound Surgical Technologies, LLC.|||1||f||||f||||||||||2018-05-31 22:48:19.428333|2018-05-31 22:48:19.428333
NCT01312987|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-05|||2011-07-31|2011-03-09|2011-03-11|Estimate|||||||2011-07-31|2011-08-02|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|MANI I||Improving Nutrition and Health Outcomes in Intibuca, Honduras (MANI I)|Improving Nutrition and Health Outcomes in Intibuca, Honduras|Completed||N/A|300|Actual|Shoulder to Shoulder||2|||f||||t||||||||||2018-05-31 22:48:19.519351|2018-05-31 22:48:19.519351
NCT01312961|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2017-04-27|2013-12-05|2017-06-07|2011-03-09|2011-03-11|Estimate|2017-06-07|2017-06-08|Actual|2014-01-13|2014-02-10|Estimate|2017-06-07|2017-06-08|Actual|March 2011||2011-03-31|June 2017|2017-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Baseline participants included all randomized participants.|Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma|Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy|Completed||Phase 2|104|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:48:19.601992|2018-05-31 22:48:19.601992
NCT01312948|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|2011-10-31||2017-05-31|2011-03-09|2011-03-11|Estimate|2012-02-14|2012-03-19|Estimate||||2017-05-31|2017-06-26|Actual|January 2011||2011-01-31|May 2017|2017-05-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Study of the Usability and Efficacy of a New Pediatric CPAP Mask|Pediatric Nasal Mask (Pixi) Usability Study|Completed||N/A|6|Actual|ResMed||1|||f||||f||||||||||2018-05-31 22:48:20.126019|2018-05-31 22:48:20.126019
NCT01312935|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2012-05-16|2011-03-09|2011-03-11|Estimate|||||||2012-05-16|2012-05-17|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)|A Phase 2 Proof of Concept Study of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)|Terminated||Phase 2|17|Actual|PolyMedix, Inc.||1||"PolyMedix decided to stop enrollment in both clinical trials due to observations of reductions~   in blood pressure."|f||||f||||||||||2018-05-31 22:48:20.278858|2018-05-31 22:48:20.278858
NCT01312922|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2014-11-18|2011-03-10|2011-03-11|Estimate|||||||2014-11-18|2014-11-19|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)|Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in the Treatment of Moderate to Severe Major Depressive Disorder (MDD): a Randomized, Double-blind Phase III Study of 10 Weeks|Completed||Phase 3|555|Actual|PharmaNeuroBoost N.V.||3|||f||||f||||||||||2018-05-31 22:48:20.409265|2018-05-31 22:48:20.409265
NCT01312909|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2018-03-09|2011-03-09|2011-03-11|Estimate|||||||2018-03-09|2018-03-12|Actual|April 26, 2011|Actual|2011-04-26|March 2018|2018-03-31|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|||Smoking Cessation Study In Healthy Adolescent Smokers|A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers|Completed||Phase 4|313|Actual|Pfizer||3|||f||||t|t|f||||||||2018-05-31 22:48:20.520256|2018-05-31 22:48:20.520256
NCT01312883|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-09|2011-03-09|2011-03-11|Estimate|||||||2011-03-09|2011-03-11|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|MADE IT||Mothers Avoiding Depression Through Empowerment Intervention Trial|Center for Achieving and Sustaining Improved Health in Harlem: Patient Education to Reduce Postpartum Depressive Symptoms Among Minority Women|Completed||N/A|540|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 22:48:20.763385|2018-05-31 22:48:20.763385
NCT01312870|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2015-03-23|2011-03-10|2011-03-11|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of Postoperative Nutritional Support in Cardiac Surgery.|Prospective Randomized Study of Postoperative Nutritional Support in Cardiac Surgery.|Terminated||Phase 3|21|Actual|Meshalkin Research Institute of Pathology of Circulation||2||Slow recruitment|f||||t||||||||||2018-05-31 22:48:20.84792|2018-05-31 22:48:20.84792
NCT01312857|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-04-03|2011-03-10|2011-03-11|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2011|Actual|2011-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer|A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer|Recruiting||Phase 2|78|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 22:48:20.93188|2018-05-31 22:48:20.93188
NCT01312844|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2017-02-08||2017-04-27|2011-03-10|2011-03-11|Estimate|2017-03-06|2017-04-18|Actual||||2017-04-27|2017-05-30|Actual|April 2010||2010-04-30|April 2017|2017-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)|A Pilot Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)|Terminated||Phase 2|7|Actual|Massachusetts General Hospital||2||This was an inpatient study, but PI left inpatient service at MGH|f||||f||||||||No||2018-05-31 22:48:21.071363|2018-05-31 22:48:21.071363
NCT01312831|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2011-03-09|2011-03-09|2011-03-11|Estimate|||||||2011-03-09|2011-03-11|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|December 2010|Actual|2010-12-31|||||Interventional|||Efficacy and Safety Study of Oral Eligen® B12 in Subjects With Low Serum Cobalamin|A 60-DAY, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Eligen® B12 OR Intramuscularly Administered B12 in Subjects With Low Serum Cobalamin With a 30 Day Extension to 90 Days of Dosing|Completed||N/A|49|Actual|Emisphere Technologies, Inc.||2|||f||||f||||||||||2018-05-31 22:48:21.504116|2018-05-31 22:48:21.504116
NCT01312818|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2015-04-22||2017-12-03|2011-03-10|2011-03-11|Estimate|2015-04-29|2015-05-15|Estimate||||2017-12-03|2017-12-28|Actual|June 2011||2011-06-30|December 2017|2017-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|A Therapeutic Trial of Bortezomib (Velcade), Vorinostat (SAHA) and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|Terminated||Phase 2|2|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||t||||||||||2018-05-31 22:48:21.590243|2018-05-31 22:48:21.590243
NCT01312805|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2016-12-08||2017-02-02|2011-03-10|2011-03-11|Estimate|2016-12-08|2017-02-02|Estimate||||2017-02-02|2017-03-14|Actual|July 2005||2005-07-31|February 2017|2017-02-28|July 2008|Actual|2008-07-31|April 2007|Actual|2007-04-30||Interventional|||Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting|Using Computers to Assist in the Treatment of Asthma in a Pediatric Setting|Completed||N/A|2098|Actual|Indiana University||2|||f||||f||||||||No||2018-05-31 22:48:21.795081|2018-05-31 22:48:21.795081
NCT01312792|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2014-07-09|2011-03-09|2011-03-11|Estimate|||||||2014-07-09|2014-07-10|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|OR-pneumonia||Operational Research Management for Children With Severe Pneumonia|Operational Research on Management at First Level Facilities for Children With Severe Pneumonia|Completed||N/A|300|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 22:48:21.965014|2018-05-31 22:48:21.965014
NCT01312779|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2017-11-10|2011-03-09|2011-03-11|Estimate|||||||2017-11-10|2017-11-14|Actual|March 2011||2011-03-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Magna Mitral - 23mm|Clinical Evaluation of the Size 23mm Carpentier-Edwards PERIMOUNT Magna Mitral Bioprosthesis, Model 7000TFX|Active, not recruiting||N/A|20|Anticipated|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 22:48:22.035717|2018-05-31 22:48:22.035717
NCT01312766|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2014-02-28||2016-06-10|2011-03-09|2011-03-11|Estimate|2014-07-28|2014-08-15|Estimate||||2016-06-10|2016-07-22|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients|Safety and Efficacy Study Comparing a New hMG Formulation (hMG-IBSA) to a Reference Product (Menopur®) in Patients Undergoing Ovarian Stimulation for in Vitro Fertilisation (IVF)|Completed||Phase 3|270|Actual|IBSA Institut Biochimique SA||2|||f||||f||||||||||2018-05-31 22:48:22.122749|2018-05-31 22:48:22.122749
NCT01312714|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2013-05-28|2011-03-09|2011-03-11|Estimate|||||||2013-05-28|2013-05-29|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Vitamin D3 Supplementation in Dialysis Patients|A Randomized, Placebo-Controlled, Double Blind Study Evaluating the Effect of Cholecalciferol on Vasoactive Hormones, Heart Function, Arterial Stiffness, and Blood Pressure in Dialysis Patients.|Completed||Phase 2|64|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 22:48:22.774138|2018-05-31 22:48:22.774138
NCT01312701|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-09|2011-03-09|2011-03-11|Estimate|||||||2011-03-09|2011-03-11|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Observational|||Study of Blood Immune Cells in Cancer Patients Compared to Controls|Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls|Unknown status|Recruiting||100|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples Without DNA|"~     The investigators will collect peripheral blood for facts analysis of intracellular levels of~     proteins.~      Some of these cells may be frozen for longer periods of time for comparison with other new~     samples.~   "|||2018-05-31 22:48:22.837543|2018-05-31 22:48:22.837543
NCT01312688|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-09|2011-03-09|2011-03-11|Estimate|||||||2011-03-09|2011-03-11|Estimate|July 2011||2011-07-31|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|SEPT-MD||Early Goal-directed Therapy and Myocardial Dysfunction|The Effect Early Goal-directed Therapy on Myocardial Dysfunction and Survival in ICU Patients With Severe Sepsis and Septic Shock: A Prospective Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|300|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 22:48:22.929807|2018-05-31 22:48:22.929807
NCT01312675|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-02-07|2011-03-09|2011-03-11|Estimate|||||||2018-02-07|2018-02-09|Actual|April 2011||2011-04-30|February 2018|2018-02-28|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|SAFEbt||S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT|Randomized, Multi-Centre, Controlled Clinical Study on Effect of the Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) Therapy on Disease Severity and Inflammation in Mechanically-Ventilated Subjects Due to Severe Sepsis|Terminated||N/A|16|Actual|B. Braun Medical Inc.||2||"Study stopped for operational futility. Due to very small numbers of subjects, insufficient~   data was available for results to provide meaningful conclusions."|f||||t||||||||No||2018-05-31 22:48:22.997667|2018-05-31 22:48:22.997667
NCT01312662|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-11|Estimate|||||||2011-03-08|2011-03-11|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||||||Observational|VisComp||Towards Worldwide Comparability of Visual Acuity Assessment|Towards Worldwide Comparability of Visual Acuity Assessment A Pilot Study Comparing ETDRS Visual Acuity Charts, Projected Landolt Charts and the Freiburg Visual Acuity Test (FrACT) With a View to Developing a Mathematical Transformation Routine Between the Results From These Three Tests|Unknown status|Recruiting||84|Anticipated|University Hospital Tuebingen|||7||f||||f||||||||||2018-05-31 22:48:23.074604|2018-05-31 22:48:23.074604
NCT01312649|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2018-03-21|2011-03-10|2011-03-11|Estimate|||||||2018-03-21|2018-03-22|Actual|April 2011|Actual|2011-04-30|September 2017|2017-09-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Feeling of Being in Control of One's Own Action|Feeling of Being in Control of One's Own Action: Which Mechanisms in Healthy Volunteers and in Mental Diseases|Completed||N/A|198|Actual|University Hospital, Strasbourg, France||5|||f||||f||||||||||2018-05-31 22:48:23.155759|2018-05-31 22:48:23.155759
NCT01312636|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-10-17|2011-03-10|2011-03-11|Estimate|||||||2014-10-17|2014-10-20|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Congenital FVII Deficiency - Registry for All Treated Patients|Completed|||36|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:48:23.241673|2018-05-31 22:48:23.241673
NCT01312623|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-10-31|2011-03-09|2011-03-10|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|RIPHeart||Organ Protection by Remote Ischemic Preconditioning for Surgical Treatment of Pediatric Congenital Heart Disease|Organ Protection by Remote Ischemic Preconditioning for Surgical Treatment of Pediatric Congenital Heart Disease|Terminated||N/A|31|Actual|University of Schleswig-Holstein||2||Terminated, because it is not possible to recruit enough participants|f||||f||||||||No||2018-05-31 22:48:23.296855|2018-05-31 22:48:23.296855
NCT01312610|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-11-22|2011-03-09|2011-03-10|Estimate|||||||2011-11-22|2011-11-23|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|OJOC||Orange Juice Consumption and Cognitive Function|Effect of Chronic Orange Juice Consumption on Cognitive Function in Healthy Older Adults|Completed||N/A|40|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 22:48:23.3593|2018-05-31 22:48:23.3593
NCT01312597|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-11-22|2011-03-09|2011-03-10|Estimate|||||||2011-11-22|2011-11-23|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Effects of Flavonoids on Cognitive Performance in Healthy Young Adults|Effects of Flavonoids on Cognitive Performance in Healthy Young Adults|Completed||Phase 2|30|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 22:48:23.416308|2018-05-31 22:48:23.416308
NCT01312584|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-09|2011-03-09|2011-03-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|June 2010||2010-06-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effects of Alkalised Cocoa on Human Vascular Function|The Effect of Alkalisation on the Absorption, Metabolism and Vascular Reactivity of Cocoa Flavanols|Completed||N/A|10|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 22:48:23.479715|2018-05-31 22:48:23.479715
NCT01312571|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2016-10-29|2011-03-09|2011-03-10|Estimate|||||||2016-10-29|2016-11-01|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SOFIE-8||Treatment of Social Phobia Over the Internet|Functional Magnetic Resonance Imaging (fMRI) and Treatment of Social Phobia Over the Internet: Cognitive Behavioural Therapy (CBT) Versus Computerized Attention Training and the Possible Effect of Genetic Variation. (SOFIE-8)|Completed||N/A|26|Actual|Umeå University||2|||f||||t||||||||||2018-05-31 22:48:24.485226|2018-05-31 22:48:24.485226
NCT01312558|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-02-26|2011-03-09|2011-03-10|Estimate|||||||2014-02-26|2014-02-27|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|MEDOSAHS||The Effect of the Mediterranean Diet on Obstructive Sleep Apnoea-Hypopnoea Syndrome: A Randomised Trial||Completed||N/A|40|Actual|University of Crete||2|||f||||t||||||||||2018-05-31 22:48:24.561862|2018-05-31 22:48:24.561862
NCT01310920|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|February 2011||2011-02-28|March 2011|2011-03-31||||||||Observational|||The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome||Unknown status|Recruiting||400|Anticipated|China Medical University Hospital|||2||f||||||||||||||2018-05-31 22:48:41.887556|2018-05-31 22:48:41.887556
NCT01312545|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2018-01-03|2011-03-09|2011-03-10|Estimate|||||||2018-01-03|2018-01-04|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand|Comparison of Exposure Rate Between Local Made and Imported Porous Polyethylene Orbital Implant for Enucleation in Thailand: A Randomized, Equivalence Controlled Trial and Multicenter Study|Recruiting||Phase 3|120|Anticipated|Mettapracharak Hospital||2|||f||||t||||||||Undecided||2018-05-31 22:48:24.636539|2018-05-31 22:48:24.636539
NCT01312532|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-09|2011-03-09|2011-03-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|June 2004||2004-06-30|June 2004|2004-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparing Fixed-bearing Versus Mobile-bearing Prosthesis in Total Knee Arthroplasty: A Prospective Randomized Trial|Study of Prosthesis in Total Knee Arthroplasty|Completed||Phase 2|100|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:48:24.720065|2018-05-31 22:48:24.720065
NCT01312519|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2013-02-28||2013-07-29|2011-03-08|2011-03-10|Estimate|2013-06-19|2013-07-23|Estimate||||2013-07-29|2013-08-07|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Powered Bone Marrow Aspiration and Core Biopsy System Compared to Manual Devices|A Trial of the Vidacare Powered Bone Marrow Aspiration and Core Biopsy Systems (OnControl by Vidacare) Compared to Traditional Manual Devices|Completed||N/A|50|Actual|Vidacare Corporation||2|||f||||f||||||||||2018-05-31 22:48:24.801257|2018-05-31 22:48:24.801257
NCT01312506|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-07-26|2011-03-08|2011-03-10|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Observational|||Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls|Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Serum/Plasma From Patients With Metastatic Melanoma to the CNS and Respective Controls for Gene Expression and Proteomic Profiling|Withdrawn|||0|Actual|University of Pittsburgh|||3|Trial experienced funding issues, was never opened to accrual.|f||||t||||||||||2018-05-31 22:48:25.016755|2018-05-31 22:48:25.016755
NCT01312493|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2015-08-26|2011-03-08|2011-03-10|Estimate|||||||2015-08-26|2015-08-28|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab|Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab|Withdrawn||Phase 2|0|Actual|UNC Lineberger Comprehensive Cancer Center||||Funding source was terminated before enrollment of first subject|f||||t||||||||||2018-05-31 22:48:25.071863|2018-05-31 22:48:25.071863
NCT01312480|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-01-16|2011-03-09|2011-03-10|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2011||2011-05-31|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2016|Actual|2016-04-30||Interventional|Smokebusters||Adolescent Smoking Cessation in Pediatric Primary Care|Adolescent Smoking Cessation in Pediatric Primary Care|Completed||N/A|10967|Actual|American Academy of Pediatrics||2|||f||||t||||||||||2018-05-31 22:48:25.248608|2018-05-31 22:48:25.248608
NCT01312467|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2015-05-11||2018-04-20|2011-03-09|2011-03-10|Estimate|2015-06-03|2015-06-25|Estimate||||2018-04-20|2018-05-21|Actual|March 2011||2011-03-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional||45 participants were enrolled into the study|Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI|A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction Among Patients With a History of Colorectal Adenomas and Elevated Body Mass Index|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:48:25.342708|2018-05-31 22:48:25.342708
NCT01312454|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04||2013-09-26|2013-09-26|2011-03-09|2011-03-10|Estimate||||2013-09-26|2013-10-25|Estimate|2013-09-26|2013-10-25|Estimate|June 2011||2011-06-30|September 2013|2013-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C|A Proof of Concept Study to Assess the Safety and IOP-Lowering Effect of AL-59412C Injected Intravitreally|Terminated||Phase 2|4|Actual|Alcon Research||4||Management decision|f||||f||||||||||2018-05-31 22:48:25.631831|2018-05-31 22:48:25.631831
NCT01312441|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2016-01-13|2011-03-09|2011-03-10|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D|Sustainability of 25-hydroxyvitamin D Levels, Inflammatory Reduction, and Endothelial Dysfunction After Repletion With Ergocalciferol in CKD Stage 5D|Terminated||Phase 4|20|Actual|Albany College of Pharmacy and Health Sciences||2||Low enrollment|f||||f||||||||||2018-05-31 22:48:25.704492|2018-05-31 22:48:25.704492
NCT01312428|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|2014-08-15||2017-10-16|2011-03-08|2011-03-10|Estimate|2014-08-15|2014-08-28|Estimate||||2017-10-16|2017-11-17|Actual|February 2011||2011-02-28|February 2015|2015-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|PAL||Pelvic Alignment Level (PAL) Instrument Evaluation|A Prospective Clinical Evaluation of Acetabular Cup Placement in Total Hip Replacements Utilizing a Pelvic Alignment Level (PAL) Instrument|Terminated||N/A|7|Actual|Stryker Orthopaedics||2||Lagging enrollment|f||||f||||||||||2018-05-31 22:48:25.794065|2018-05-31 22:48:25.794065
NCT01312415|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-09|2011-03-09|2011-03-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||The Analgesic Efficacy of Local Anaesthetic Wound Infiltration Versus Intrathecal Morphine for Total Knee Replacement|A Comparison of the Analgesic Efficacy of Local Anaesthetic Wound Infiltration Versus Intrathecal Morphine for Total Knee Replacement|Unknown status|Recruiting|Phase 4|42|Anticipated|Cork University Hospital||2|||f||||f||||||||||2018-05-31 22:48:25.955307|2018-05-31 22:48:25.955307
NCT01312402|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-06-24|2011-03-09|2011-03-10|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome|Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome|Completed||Phase 4|5|Actual|Akron Children's Hospital||2|||f||||f||||||||||2018-05-31 22:48:26.029331|2018-05-31 22:48:26.029331
NCT01312389|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-07-28|2011-03-09|2011-03-10|Estimate|||||||2017-07-28|2017-07-31|Actual|March 2011||2011-03-31|July 2017|2017-07-31||||March 2018|Anticipated|2018-03-31||Interventional|||A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Phase I/II Randomized Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 1/Phase 2|29|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 22:48:26.112802|2018-05-31 22:48:26.112802
NCT01310907|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-03-06|2011-03-06|2011-03-09|Estimate|||||||2011-03-06|2011-03-09|Estimate|February 2011||2011-02-28|March 2011|2011-03-31||||||||Observational|||Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia||Unknown status|Recruiting||400|Anticipated|China Medical University Hospital|||3||f||||||||||||||2018-05-31 22:48:41.958429|2018-05-31 22:48:41.958429
NCT01312376|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2016-07-18|2011-03-09|2011-03-10|Estimate|||||||2016-07-18|2016-07-19|Estimate|March 2011||2011-03-31|July 2016|2016-07-31||||October 2015|Actual|2015-10-31||Interventional|||Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer|A Phase-1 Trial of Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Combined With Vaccine Boost and Bevacizumab for Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Previously Vaccinated With Autologous Tumor Vaccine|Active, not recruiting||Phase 1|12|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:48:26.178282|2018-05-31 22:48:26.178282
NCT01312363|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2016-05-02|2011-03-08|2011-03-10|Estimate|||||||2016-05-02|2016-05-04|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|X-MEN||Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients|A Six-month, Open Labeled, Multi-centered, Observational Study for the Tolerability of Exelon Patch (Rivastigmine) for Patients With Alzheimer's Disease|Completed|||300|Actual|Seoul National University Hospital|||||f||||t||||||||Undecided||2018-05-31 22:48:26.24219|2018-05-31 22:48:26.24219
NCT01312350|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2016-04-19|2011-03-08|2011-03-10|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)|Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study|Unknown status|Active, not recruiting|Phase 2|40|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 22:48:26.467444|2018-05-31 22:48:26.467444
NCT01312337|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-03-08|2011-03-08|2011-03-10|Estimate|||||||2011-03-08|2011-03-10|Estimate|September 2010||2010-09-30|March 2011|2011-03-31||||August 2012|Anticipated|2012-08-31||Interventional|||Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)|A Phase II Trial of Gefitinib Monotherapy in Pretreated Patients With Advanced Non-small Cell Lung Cancer Not Harboring Active EGFR Mutations|Unknown status|Recruiting|Phase 2|92|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 22:48:26.54135|2018-05-31 22:48:26.54135
NCT01312324|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2016-04-19|2011-03-08|2011-03-10|Estimate|||||||2016-04-19|2016-04-20|Estimate|February 2007||2007-02-28|April 2016|2016-04-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer|A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors|Completed||Phase 2|27|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 22:48:26.61939|2018-05-31 22:48:26.61939
NCT01312311|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-03-08|2011-03-08|2011-03-10|Estimate|||||||2011-03-08|2011-03-10|Estimate|July 2006||2006-07-31|March 2011|2011-03-31||||May 2011|Anticipated|2011-05-31||Interventional|||Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer|Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer|Unknown status|Recruiting|Phase 2|51|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 22:48:26.688218|2018-05-31 22:48:26.688218
NCT01312298|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2013-03-06|2011-03-09|2011-03-10|Estimate|||||||2013-03-06|2013-03-07|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|||General vs. Intrathecal Anesthesia for Total Knee Arthroplasty|General vs. Intrathecal Anesthesia Fort Total Knee Arthroplasty; a Randomized Clinical Trial|Completed||N/A|120|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 22:48:26.763869|2018-05-31 22:48:26.763869
NCT01312285|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-05-27|2011-03-08|2011-03-10|Estimate|||||||2011-05-27|2011-05-30|Estimate|September 2011||2011-09-30|May 2011|2011-05-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Low Level Magnetic Fields for the Treatment of Osteoarthritis of the Hip|A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Osteoarthritis of the Hip: Pilot Study Protocol|Withdrawn||Phase 2|30|Anticipated|pico-tesla Magnetic Therapies, LLC||2|||f||||t||||||||||2018-05-31 22:48:26.850343|2018-05-31 22:48:26.850343
NCT01312272|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2013-12-20||2014-03-31|2011-03-09|2011-03-10|Estimate|2014-03-31|2014-05-02|Estimate||||2014-03-31|2014-05-02|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?|Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?|Completed||N/A|24|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||||2018-05-31 22:48:26.940848|2018-05-31 22:48:26.940848
NCT01312259|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2014-04-28|2011-03-08|2011-03-10|Estimate|||||||2014-04-28|2014-04-29|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome|Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome|Unknown status|Recruiting|Phase 4|72|Anticipated|Pelvic and Sexual Health Institute||2|||f||||f||||||||||2018-05-31 22:48:27.276778|2018-05-31 22:48:27.276778
NCT01312246|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-09|2011-03-09|2011-03-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||EnSeal Efficacy and Bursting Pressure in Human Vessels|EnSeal Efficacy and Bursting Pressure in Human Vessels|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Illinois at Chicago|||||f||||f||||||||||2018-05-31 22:48:27.36626|2018-05-31 22:48:27.36626
NCT01312233|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2016-09-19|2011-03-08|2011-03-10|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|COCOA||Collaborative Care for Older Adults With Back Pain (COCOA)|Co-Management of Older Adults With Low Back Pain by Medical Physicians and Doctors of Chiropractic|Completed||Phase 2|131|Actual|Palmer College of Chiropractic||3|||f||||t||||||||||2018-05-31 22:48:27.459295|2018-05-31 22:48:27.459295
NCT01312220|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-10|Estimate|||||||2011-03-08|2011-03-10|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|February 2013|Anticipated|2013-02-28|||||Observational|||Growth Factors and Hepatic Progenitor Cells in Acute Liver Failure|Relationship of Serological Growth Factors and Hepatic Progenitor Cells in Acute Liver Failure|Unknown status|Recruiting||10|Anticipated|National Taiwan University Hospital|||||f||||||||||Samples With DNA|"~     Serum Liver piece~   "|||2018-05-31 22:48:27.550843|2018-05-31 22:48:27.550843
NCT01312207|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-10|Estimate|||||||2011-03-08|2011-03-10|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|February 2012|Anticipated|2012-02-29|August 2011|Anticipated|2011-08-31||Observational|||Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy|Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy|Unknown status|Recruiting||32|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 22:48:27.655172|2018-05-31 22:48:27.655172
NCT01312194|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2012-09-17|2011-03-09|2011-03-10|Estimate|||||||2012-09-17|2012-09-18|Estimate|May 2004||2004-05-31|September 2012|2012-09-30|August 2008|Actual|2008-08-31|May 2007|Actual|2007-05-31||Interventional|PHAP||Periapical Healing After One or Two-visits to Endodontic Treatment in Adolescents Patients|Periapical Healing After One or Two-visits to Endodontic Treatment in Adolescents Patients|Completed||N/A|120|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 22:48:27.737834|2018-05-31 22:48:27.737834
NCT01312181|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2018-04-10||2018-05-11|2011-03-09|2011-03-10|Estimate|2018-05-11|2018-05-15|Actual||||2018-05-11|2018-05-15|Actual|June 2011|Actual|2011-06-30|May 2018|2018-05-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics|HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care|Completed||Phase 2|240|Actual|Research Foundation for Mental Hygiene, Inc.||3|||f||||t||||||||||2018-05-31 22:48:27.816575|2018-05-31 22:48:27.816575
NCT01312168|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-12-12|2011-03-09|2011-03-10|Estimate|||||||2016-12-12|2016-12-14|Estimate|March 2011||2011-03-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Endothelial Dysfunction, Monocyte Activation, and Vasculopathy in Patients With Obstructive Sleep Apnea (OSA) and Effect of 6-month CPAP Treatment|Endothelial Dysfunction, Monocyte Activation, and Vasculopathy in Patients With Obstructive Sleep Apnea and Effect of Six-month CPAP Treatment: A Large-scale, Double-blind, Randomized, Placebo-controlled Trial|Active, not recruiting||N/A|150|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 22:48:28.143274|2018-05-31 22:48:28.143274
NCT01312155|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2013-10-24|2011-03-09|2011-03-10|Estimate|||||||2013-10-24|2013-10-25|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Assisted Intubation||Completed|||12|Actual|McGill University Health Center|||1||f||||f||||||||||2018-05-31 22:48:28.209116|2018-05-31 22:48:28.209116
NCT01312142|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-12-19|2011-03-09|2011-03-10|Estimate|||||||2011-12-19|2011-12-20|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Changes of Weaning Parameter in Weaning Failure Patient After Tracheostomy as a Predictor of Subsequent Weaning|Changes of Weaning Parameter in Weaning Failure Patient After Tracheostomy as a Predictor of Subsequent Weaning|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 22:48:28.357279|2018-05-31 22:48:28.357279
NCT01312129|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2013-05-30||2014-09-18|2011-03-09|2011-03-10|Estimate|2014-09-18|2014-09-22|Estimate||||2014-09-18|2014-09-22|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Sulfasalazine on BOLD Response to Alcohol Cues|Effects of Sulfasalazine on BOLD Response to Alcohol Cues|Completed||N/A|23|Actual|The Mind Research Network||2|||f||||f||||||||||2018-05-31 22:48:28.472545|2018-05-31 22:48:28.472545
NCT01312116|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-09|2011-03-09|2011-03-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||Psychodynamic Internet Treatment Versus Cognitive Behavioral Therapy (CBT) for Generalized Anxiety Disorder|Psychodynamic Versus Cognitive Behavioral Internet-Delivered Guided Self-help for Generalized Anxiety Disorder: A Randomized Controlled Trial|Completed||N/A|81|Actual|Linkoeping University||3|||f||||f||||||||||2018-05-31 22:48:28.807255|2018-05-31 22:48:28.807255
NCT01312103|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2017-03-01|2011-03-09|2011-03-10|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2011||2011-03-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|May 2014|Actual|2014-05-31||Interventional|||Internet-Based Intervention to Improve Mental Health Outcomes for Abused Women|Internet-Based Intervention to Improve Mental Health Outcomes for Abused Women|Completed||N/A|720|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 22:48:28.897153|2018-05-31 22:48:28.897153
NCT01312090|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2012-09-05|2011-03-09|2011-03-10|Estimate|||||||2012-09-05|2012-09-06|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CICE||Chronic Intermittent Cold Exposure on Weight Loss|Chronic Intermittent Cold Exposure on Weight Loss|Completed||N/A|20|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 22:48:29.059225|2018-05-31 22:48:29.059225
NCT01312077|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-09|2011-03-09|2011-03-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|October 2010||2010-10-31|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||The Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic for Total Hip Replacement|Postoperative Analgesia in Total Hip Replacement: a Comparison of the Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic With Intrathecal Morphine.|Unknown status|Recruiting|Phase 4|50|Anticipated|Cork University Hospital||2|||f||||f||||||||||2018-05-31 22:48:29.170882|2018-05-31 22:48:29.170882
NCT01312064|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-12-26|2011-03-09|2011-03-10|Estimate|||||||2012-12-26|2012-12-27|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction|Clinical Outcome of de Novo Everolimus-based Immunosuppressive Therapy for Renal Transplantation Using Rituximab Induction|Terminated||Phase 4|2|Actual|National Taiwan University Hospital||2||Difficulty collecting|f||||f||||||||||2018-05-31 22:48:29.275337|2018-05-31 22:48:29.275337
NCT01312051|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2017-10-16|2011-03-09|2011-03-10|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2004||2004-07-31|October 2017|2017-10-31|September 20, 2011|Actual|2011-09-20|September 20, 2011|Actual|2011-09-20||Observational|||Childhood Metabolic Markers of Adult Morbidity in Blacks|Childhood Metabolic Markers of Adult Morbidity in Blacks|Completed|||156|Actual|University of Pittsburgh|||4||f||||f||||||||||2018-05-31 22:48:29.387958|2018-05-31 22:48:29.387958
NCT01312038|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|2016-02-19||2016-06-23|2011-03-09|2011-03-10|Estimate|2016-06-23|2016-06-27|Estimate||||2016-06-23|2016-06-27|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Analysis done by ears with evaluable tests.|Effect of Simethicone on Eustachian Tube Dysfunction|A Pilot Study of the Effect of Simethicone in Adult Subjects With a Common Cold on Eustachian Tube Dysfunction|Completed||Phase 2|25|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 22:48:29.452449|2018-05-31 22:48:29.452449
NCT01312025|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-09|||2011-03-09|2011-03-09|2011-03-10|Estimate|||||||2011-03-09|2011-03-10|Estimate||||August 2009|2009-08-31||||||||Interventional|||Conventional Versus Modified Laparoscopic Cholecystectomy|Randomized Controlled Trial Comparing Between The Conventional Technique of Laparoscopic Cholecystectomy and A Proposed Modified Technique|Completed||N/A|||Mansoura University||2|||f||||||||||||||2018-05-31 22:48:29.761242|2018-05-31 22:48:29.761242
NCT01312012|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2018-03-25|2011-03-08|2011-03-10|Estimate|||||||2018-03-25|2018-03-27|Actual|January 2011||2011-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test|The Effectiveness and Feasibility of Using Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus-drug Test and Follow-up Study|Recruiting||Phase 4|120|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 22:48:29.807894|2018-05-31 22:48:29.807894
NCT01311999|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2013-12-03|2011-03-08|2011-03-10|Estimate|||||||2013-12-03|2013-12-04|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Surveillance and Follow-up for Latent Tuberculosis Infection and Risk of Developing Active Tuberculosis in Patients Receiving Long-term Dialysis|Surveillance and Follow-up for Latent Tuberculosis Infection and Risk of Developing Active Tuberculosis in Patients Receiving Long-term Dialysis|Completed|||234|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 22:48:29.89591|2018-05-31 22:48:29.89591
NCT01311986|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-04-21|2011-03-09|2011-03-10|Estimate|||||||2011-04-21|2011-04-22|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|October 2011|Anticipated|2011-10-31||Observational|||Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis|Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis|Unknown status|Active, not recruiting||120|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples Without DNA|"~     Patient serum, and epidermal keratinocytes for mRNA retrieval~   "|||2018-05-31 22:48:29.980109|2018-05-31 22:48:29.980109
NCT01311973|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-07-21|2011-03-08|2011-03-10|Estimate|||||||2011-07-21|2011-07-22|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Salivary Phosphorus and Level of Kidney Function|Assessment of the Relationship Between Salivary Phosphorus and Level of Kidney Function|Completed|||105|Anticipated|Denver Nephrologists, P.C.|||7||f||||f||||||Samples Without DNA|"~     Blood, urine, and saliva~   "|||2018-05-31 22:48:30.062801|2018-05-31 22:48:30.062801
NCT01311960|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2013-04-06|2011-03-08|2011-03-10|Estimate|||||||2013-04-06|2013-04-09|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Topical Bevacizumab for Preventing Recurrent Pterygium|Topical Bevacizumab 0.05% Eye Drops for Preventing Recurrent Pterygium, A Randomized, Double-masked, Controlled Trial|Completed||Phase 3|24|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 22:48:30.128219|2018-05-31 22:48:30.128219
NCT01311947|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2013-07-29|2011-03-08|2011-03-10|Estimate|||||||2013-07-29|2013-07-30|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B|Relation of Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B|Completed|||103|Actual|China Medical University Hospital|||||f||||t||||||Samples With DNA|"~     Serum specimens~   "|||2018-05-31 22:48:30.249208|2018-05-31 22:48:30.249208
NCT01311934|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-05-24|2011-03-08|2011-03-10|Estimate|||||||2011-05-24|2011-05-26|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|ARFI||Visceral Stiffness Measurement Using Acoustic Radiation Force Impulse|Clinical Application of the Spectrum of Visceral Stiffness Measurement Using Acoustic Radiation Force Impulse Technology|Unknown status|Recruiting||200|Anticipated|China Medical University Hospital|||2||f||||f||||||||||2018-05-31 22:48:30.308244|2018-05-31 22:48:30.308244
NCT01311921|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-10|Estimate|||||||2011-03-08|2011-03-10|Estimate|February 2011||2011-02-28|March 2011|2011-03-31||||||||Observational|DMR100-IRB-010||Children's Susceptibility to Enterovirus 71 in Different Areas of Taiwan|The Specific Aims Are to Find Factors Associated With Different Severe/Fatal Incidences in Different Areas of Taiwan. We Will do 1. Comparison of Gene Variants in EV71 Cases With Different Severity and Normal Children in Different Areas of Taiwan to Find Susceptible Genes and Genetic Polymorphism Related to the Clinical Outcomes 2. Social, Behavioral and Environmental Factors Related to EV71 Infections in Different Areas of Taiwan|Unknown status|Enrolling by invitation||200|Anticipated|China Medical University Hospital|||||f||||t||||||Samples With DNA|"~     DNA,swab,blood~   "|||2018-05-31 22:48:30.360578|2018-05-31 22:48:30.360578
NCT01311908|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-22|2011-03-08|2011-03-10|Estimate|||||||2011-03-22|2011-03-23|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|March 2012|Anticipated|2012-03-31||Observational|||Incidence of Reflux Esophagitis After Pancreaticoduodenectomy|Effect of a Roux-en-Y Reconstruction on Reflux Esophagitis After Pancreaticoduodenectomy|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     esophageal mucosal biopsy for Real-Time PCR for COX-2 activity~   "|||2018-05-31 22:48:30.403352|2018-05-31 22:48:30.403352
NCT01311895|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2017-02-27||2018-04-20|2011-03-08|2011-03-10|Estimate|2018-04-20|2018-05-18|Actual||||2018-04-20|2018-05-18|Actual|January 2011|Actual|2011-01-31|April 2018|2018-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||"The discrepancy between the number of patients enrolled and randomized and those included in analysis is due to the following.~H2O group: never given IV opioids (2), received ketorolac or additional opioids within the 60 min (7).~1+1 group: missing data (3), didn't receive 2nd dose within 60 min (2), received additional opioids within 60 min (2)"|Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone|Randomized Clinical Trial Comparing Two Protocols Using IV Hydromorphone|Completed||Phase 3|350|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 22:48:30.490346|2018-05-31 22:48:30.490346
NCT01311882|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2016-02-19|2011-03-08|2011-03-10|Estimate|||||||2016-02-19|2016-02-22|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)|A Multiple Dose Study to Evaluate Next Day Effects of MK-4305 on Driving Performance in Healthy Non-Elderly Subjects|Completed||Phase 1|28|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 22:48:30.793834|2018-05-31 22:48:30.793834
NCT01311869|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-10-23|2011-03-08|2011-03-10|Estimate|||||||2013-10-23|2013-10-24|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids|Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids|Terminated||Phase 2|43|Actual|Meharry Medical College||2||IRB Decision|f||||t||||||||||2018-05-31 22:48:30.864441|2018-05-31 22:48:30.864441
NCT01311856|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2018-01-09|2011-03-08|2011-03-10|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2011|Actual|2011-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors|Telephone Counseling-Mailed Materials Versus Internet Weight Management Interventions in Overweight Cancer Survivors|Active, not recruiting|||60|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 22:48:30.924282|2018-05-31 22:48:30.924282
NCT01311830|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-22|2011-03-08|2011-03-10|Estimate|||||||2011-03-22|2011-03-23|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons|Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons|Completed||N/A|534|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:48:31.074394|2018-05-31 22:48:31.074394
NCT01311817|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2015-09-30|2011-03-08|2011-03-10|Estimate|||||||2015-09-30|2015-10-02|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine|Transcutaneous Immunization With actA/plcB-Deleted Listeria Monocytogenes Expressing Influenza A Nucleoprotein (BMB72) and Cholera Toxin Adjuvant|Completed||Phase 1|8|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:48:31.137162|2018-05-31 22:48:31.137162
NCT01311804|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-03-08|2011-03-08|2011-03-10|Estimate|||||||2011-03-08|2011-03-10|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|April 2011|Anticipated|2011-04-30||Interventional|||An Efficacy and Safety Study of Periarticular Parecoxib Sodium for Pain Management in Total Knee Arthroplasty|An Open Label,Multicentre, Randomized Trial to Determine the Efficacy of Periarticular Parecoxib Sodium In A Multimodal Cocktail vs Intravenous Parecoxib Sodium for Pain Management in Total Knee Arthroplasty|Unknown status|Not yet recruiting|Phase 3|125|Anticipated|Ministry of Health, Malaysia||2|||f||||f||||||||||2018-05-31 22:48:31.210816|2018-05-31 22:48:31.210816
NCT01311791|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2017-03-13|2011-03-08|2011-03-10|Estimate|||||||2017-03-13|2017-03-15|Actual|August 2012|Actual|2012-08-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|April 2014|Actual|2014-04-30||Interventional|AUGMENT-HF||A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure|A Randomized, Controlled Study to Evaluate the Safety and Cardiovascular Effects of Algisyl-LVR™ as a Method of Left Ventricular Augmentation in Patients With Dilated Cardiomyopathy (AUGMENT-HF)|Completed||Phase 2/Phase 3|78|Actual|LoneStar Heart, Inc.||2|||f||||t||||||||||2018-05-31 22:48:31.309629|2018-05-31 22:48:31.309629
NCT01311778|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-03-20|2011-03-08|2011-03-10|Estimate|||||||2013-03-20|2013-03-22|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study to Test the Safety and Efficacy of Cannabidiol as a Treatment Intervention for Opioid Relapse|Cannabidiol as Treatment Intervention for Opioid Relapse|Completed||Phase 1|18|Actual|Hurd,Yasmin, Ph.D.||3|||f||||t||||||||||2018-05-31 22:48:31.408469|2018-05-31 22:48:31.408469
NCT01311765|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2015-12-08|2011-03-08|2011-03-10|Estimate|||||||2015-12-08|2015-12-09|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|DURAPOP||Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU|Comparison of Two Durations of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in Intensive Care Unit: a Randomised Multicentre Study|Completed||Phase 3|244|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 22:48:31.501233|2018-05-31 22:48:31.501233
NCT01311752|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2012-12-26|2011-03-08|2011-03-09|Estimate|||||||2012-12-26|2012-12-27|Estimate|November 2007||2007-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|ANRS CO17||Study of Human Papillomavirus Related Genital Pathology Among HIV Positive Women|Study of Human Papillomavirus Related Genital Pathology Among HIV Positive|Completed|||676|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||t||||||||||2018-05-31 22:48:31.593866|2018-05-31 22:48:31.593866
NCT01311739|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|May 2008||2008-05-31|March 2011|2011-03-31|June 2008|Actual|2008-06-30|||||Interventional|||Oral Cyanocobalamin (Eligen B12) Bioavailability Study|An Open-label, Single-Dose, Parallel-Group, Randomized Study of Comparative Bioavailability of B12 After Oral Administration of B2 Formulated With an Absorption Promoter (SNAC), Oral B12 Alone and IV B12 in Healthy Male Subjects|Completed||N/A|20|Actual|Emisphere Technologies, Inc.||4|||f||||f||||||||||2018-05-31 22:48:31.66747|2018-05-31 22:48:31.66747
NCT01311726|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:48:31.733775|2018-05-31 22:48:31.733775
NCT01311713|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07||2015-03-19|2016-07-25|2011-03-08|2011-03-09|Estimate||||2016-07-25|2016-07-26|Estimate|2016-07-25|2016-07-26|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors|An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors|Terminated||Phase 1/Phase 2|46|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 22:48:31.768882|2018-05-31 22:48:31.768882
NCT01311700|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2017-12-20|2011-03-08|2011-03-09|Estimate|||||||2017-12-20|2017-12-21|Actual|November 2010||2010-11-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2012|Actual|2012-10-31||Interventional|METOCARD-CNIC||Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.|"Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The MEEffect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion (METOCARD-CNIC): A Randomized, Controlled Parallel-group, Observer-blinded Clinical Trial of Early Pre-reperfusion Metoprolol Administration in ST-segment Elevation Myocardial infarctionTOCARD-CNIC Trial."|Completed||Phase 4|221|Actual|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III||2|||f||||t||||||||||2018-05-31 22:48:31.891154|2018-05-31 22:48:31.891154
NCT01311687|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|2014-03-28||2017-09-25|2011-03-08|2011-03-09|Estimate|2014-03-28|2014-04-30|Estimate||||2017-09-25|2017-10-26|Actual|March 11, 2011|Actual|2011-03-11|September 2017|2017-09-30|August 29, 2017|Actual|2017-08-29|March 1, 2013|Actual|2013-03-01||Interventional|NIMBUS|Intent-to-treat population (all participants who were randomized, regardless of whether they received study treatment or not)|A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study|A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma|Completed||Phase 3|455|Actual|Celgene||2|||f||||t||||||||||2018-05-31 22:48:32.033415|2018-05-31 22:48:32.033415
NCT01311674|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)|Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)|Unknown status|Active, not recruiting|Phase 4|1000|Anticipated|Cangene Corporation||2|||f||||f||||||||||2018-05-31 22:48:33.384683|2018-05-31 22:48:33.384683
NCT01309867|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2012-08-10|2011-03-04|2011-03-07|Estimate|||||||2012-08-10|2012-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:48:57.836825|2018-05-31 22:48:57.836825
NCT01311661|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-03-28||2014-03-28|2011-03-08|2011-03-09|Estimate|2014-03-28|2014-05-01|Estimate||||2014-03-28|2014-05-01|Estimate|March 2011||2011-03-31|March 2014|2014-03-31||||December 2011|Actual|2011-12-31||Interventional|||A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma|Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, Delivered With the Respimat® Inhaler, After 3 Weeks of Olodaterol Once Daily Medium Dose, Twice Daily Low Dose and Placebo or After 3 Weeks of Once Daily High Dose, Twice Daily Medium Dose and Placebo Administration in Patients With Moderate to Severe Persistent Asthma|Completed||Phase 2|206|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:48:33.583434|2018-05-31 22:48:33.583434
NCT01311648|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2018-05-11|2011-03-08|2011-03-09|Estimate|||||||2018-05-11|2018-05-14|Actual|June 9, 2011|Actual|2011-06-09|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||BAY81-8973 Pediatric Safety and Efficacy Trial|A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy|Recruiting||Phase 3|101|Anticipated|Bayer||1|||f||||t|t|f||||||||2018-05-31 22:48:35.01824|2018-05-31 22:48:35.01824
NCT01311635|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-07-06|2011-03-08|2011-03-09|Estimate|||||||2011-07-06|2011-07-07|Estimate|April 2011||2011-04-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||A Bioavailability Study Comparing 3 Different AZD1981 Tablets|A Phase I, Open Label, Randomised, 4-way Crossover Study to Investigate the Relative Bioavailability of Single Dose AZD1981 Via 3 Different Tablets in Healthy Men and Healthy Women of Non-childbearing Potential|Completed||Phase 1|16|Anticipated|AstraZeneca||4|||f||||||||||||||2018-05-31 22:48:35.145498|2018-05-31 22:48:35.145498
NCT01311622|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2013-01-30|2011-03-08|2011-03-09|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects|An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Co-Administered With Fostamatinib in Healthy Subjects|Completed||Phase 1|15|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:48:35.202256|2018-05-31 22:48:35.202256
NCT01311609|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2012-01-31|2011-03-08|2011-03-09|Estimate|||||||2012-01-31|2012-02-02|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients|Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients|Completed||Phase 4|300|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:48:35.289112|2018-05-31 22:48:35.289112
NCT01311596|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2014-06-23|2011-03-08|2011-03-09|Estimate|||||||2014-06-23|2014-06-24|Estimate|February 2011||2011-02-28|June 2014|2014-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Show Me to Help Me|Show Me to Help Me|Completed|||83|Actual|Akron Children's Hospital|||2||f||||f||||||||||2018-05-31 22:48:35.348544|2018-05-31 22:48:35.348544
NCT01311583|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2016-01-07|2011-03-07|2011-03-09|Estimate|||||||2016-01-07|2016-01-08|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Evaluating Teach Back as a Method for Improving Self-Care Behaviours in Heart Failure Patients|Evaluating Teach Back as a Method for Improving Self-Care Behaviours in Heart Failure Patients|Completed||N/A|80|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 22:48:35.42025|2018-05-31 22:48:35.42025
NCT01311570|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2012-09-23|2011-03-07|2011-03-09|Estimate|||||||2012-09-23|2012-09-25|Estimate|October 2012||2012-10-31|September 2012|2012-09-30||||February 2013|Anticipated|2013-02-28||Interventional|||Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients|A Single Center, Open Label, Dose-titration, add-on Study Assessing the Feasibility, Safety and Therapeutic Effect of Buprenorphine in Adult Patients With Diagnosis of Major Depression.|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Shalvata Mental Health Center||1|||f||||t||||||||||2018-05-31 22:48:35.480969|2018-05-31 22:48:35.480969
NCT01311557|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2016-02-02|2012-04-27|2016-04-01|2011-03-07|2011-03-09|Estimate|2016-04-01|2016-04-08|Estimate|2012-04-27|2012-05-01|Estimate|2016-04-01|2016-04-08|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Study of Adacel® Vaccine Administered to Persons 10 Years of Age|Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age|Completed||Phase 4|1302|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 22:48:35.559624|2018-05-31 22:48:35.559624
NCT01311544|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2012-05-15|2011-03-07|2011-03-09|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2011||2011-03-31|May 2012|2012-05-31||||||||Observational|||Evaluation of 4D Magnetic Resonance Angiography (K-t Blast) of Supraortic Vessels in Acute Ischemic Stroke Patients|Evaluation of 4D Magnetic Resonance Angiography (K-t Blast) of Supraortic Vessels in Acute Ischemic Stroke Patients|Completed|||92|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 22:48:36.853012|2018-05-31 22:48:36.853012
NCT01311531|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-01-23|2011-03-07|2011-03-09|Estimate|||||||2014-01-23|2014-01-24|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Volar Locking Plate vs Fragment Specific Fixation in Wrist Fractures|Treatment of Distal Radial Fractures With Volar Locking Plates Versus Fragment-specific Fixation (TriMed Classic). A Randomized Trial|Completed||N/A|50|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 22:48:36.911621|2018-05-31 22:48:36.911621
NCT01311518|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2015-03-19|2011-03-08|2011-03-09|Estimate|||||||2015-03-19|2015-03-24|Estimate|March 2016||2016-03-31|November 2012|2012-11-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction|A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery|Suspended||Phase 2|75|Anticipated|RegeneRx Biopharmaceuticals, Inc.||2||Trial suspended due to drug product manufacturer not GMP compliant|f||||f||||||||||2018-05-31 22:48:36.986934|2018-05-31 22:48:36.986934
NCT01311505|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2012-03-23||2012-06-21|2011-03-07|2011-03-09|Estimate|2012-06-21|2012-07-30|Estimate||||2012-06-21|2012-07-30|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)|An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin© 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane®, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects|Completed||Phase 1|21|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:48:37.09551|2018-05-31 22:48:37.09551
NCT01311492|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-05-23|2011-03-07|2011-03-09|Estimate|||||||2013-05-23|2013-05-27|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|EXTRA||Exercise Trial for Alzheimer's Disease|Exercise Trial for Alzheimer's Disease (EXTRA)|Completed||N/A|10|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-05-31 22:48:37.60208|2018-05-31 22:48:37.60208
NCT01311479|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-04-11|2011-03-07|2011-03-09|Estimate|||||||2014-04-11|2014-04-14|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Osteopathic Manipulation for Female Interstitial Cystitis Patients With Sacroiliac Joint Dysfunction|Osteopathic Manipulation as a Therapeutic Intervention for Female Interstitial Cystitis Patients With Sacroiliac Joint Dysfunction|Recruiting||N/A|40|Anticipated|Pelvic and Sexual Health Institute||2|||f||||f||||||||||2018-05-31 22:48:37.699176|2018-05-31 22:48:37.699176
NCT01311466|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-10-20|2011-03-07|2011-03-09|Estimate|||||||2017-10-20|2017-10-23|Actual|January 2011||2011-01-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Liver Transplantation and Uveal Malignant Melanoma|Open Non-randomized Study to Assess the Benefit of Liver Transplantation in Patients With Liver Metastasis After Ocular Malignant Melanoma (Uveal Melanoma)|Completed||N/A|2|Actual|Oslo University Hospital||1|||f||||||||||||||2018-05-31 22:48:37.905584|2018-05-31 22:48:37.905584
NCT01311440|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-09-18|2011-03-07|2011-03-09|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy|Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy - a Controlled, Randomized Trial|Completed||N/A|75|Actual|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 22:48:37.981952|2018-05-31 22:48:37.981952
NCT01311427|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-03-07|2011-03-07|2011-03-09|Estimate|||||||2011-03-07|2011-03-09|Estimate|August 2006||2006-08-31|March 2011|2011-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Simplified Tai Chi for Reducing Fibromyalgia Pain|Simplified Tai Chi for Reducing Fibromyalgia Pain|Completed||N/A|99|Actual|Oregon Research Institute||2|||f||||t||||||||||2018-05-31 22:48:38.076073|2018-05-31 22:48:38.076073
NCT01311414|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-05-21|2011-03-08|2011-03-09|Estimate|||||||2014-05-21|2014-05-22|Estimate||||May 2014|2014-05-31||||||||Interventional|NIRSMED||Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation|Effect of Cafedrine/Theodrenaline and Urapidil During Carotid Endarterectomy on Cerebral Oxygenation Measured by Near Infrared Spectroscopy|Withdrawn||N/A|0|Actual|University of Schleswig-Holstein||1||The study was suspended due to organizational problems|f||||f||||||||||2018-05-31 22:48:38.146004|2018-05-31 22:48:38.146004
NCT01311401|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2013-02-19|2011-03-08|2011-03-09|Estimate|||||||2013-02-19|2013-02-20|Estimate|October 2009||2009-10-31|February 2013|2013-02-28||||July 2014|Anticipated|2014-07-31||Observational|||Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel|Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel|Unknown status|Recruiting||670|Anticipated|Ziv Hospital|||2||f||||f||||||||||2018-05-31 22:48:38.213626|2018-05-31 22:48:38.213626
NCT01311388|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|December 2013|Anticipated|2013-12-31|||||Observational|||"Construction of the Patient-CenteredMolecular Pathology Diagnostic Center"|"Construction of the Patient-CenteredMolecular Pathology Diagnostic Center"|Unknown status|Active, not recruiting||1500|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:48:38.300798|2018-05-31 22:48:38.300798
NCT01311375|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2012-11-13|2011-03-08|2011-03-09|Estimate|||||||2012-11-13|2012-11-14|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Omega 3 in Intervention Spinal Cord Injured People|Evaluation of Omega 3 Supplementation on Neurological Recovery , Lipid Profile and Antioxidant Enzymes and Hormones After Chronic Spinal Cord Injury.|Completed||Phase 2/Phase 3|100|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:48:38.386593|2018-05-31 22:48:38.386593
NCT01311362|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|2014-07-09||2017-05-03|2011-03-08|2011-03-09|Estimate|2015-05-29|2015-06-02|Estimate||||2017-05-03|2017-05-31|Actual|March 2011||2011-03-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Observational|||Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan|Influence of CYP3A4-induction by St. John's Wort (SJW) on the Steady State Pharmacokinetics of Ambrisentan|Completed|||20|Actual|Heidelberg University|The extent of this interaction was small and thus likely without clinical relevance.||2||f||||f||||||||||2018-05-31 22:48:38.468141|2018-05-31 22:48:38.468141
NCT01311349|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2011-03-07|2011-03-07|2011-03-09|Estimate|||||||2011-03-07|2011-03-09|Estimate|December 2005||2005-12-31|August 2009|2009-08-31|September 2006|Actual|2006-09-30|||||Observational|||Study Evaluating Local Susceptibility Patterns Associated With Tigecycline in Comparison to Other Antibiotics|Evaluation of the Antimicrobial Activity In Vitro of Tigecycline in Comparison to Other Broad Spectrum Antibiotics in Isolates Collected From Patients|Completed|||1575|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-05-31 22:48:38.696817|2018-05-31 22:48:38.696817
NCT01311336|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2013-01-23|2011-03-08|2011-03-09|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain|Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim|Unknown status|Recruiting|Phase 2|55|Anticipated|University of Vermont||2|||f||||t||||||||||2018-05-31 22:48:38.757014|2018-05-31 22:48:38.757014
NCT01311323|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|June 2011||2011-06-30|July 2010|2010-07-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|MILESTONE||Revascularization in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) With Multivessel and/or Unprotected Left Main Coronary Disease|Revascularization Strategy (PCI With DES Implantation vs CABG) in Patients With Non ST Elevation Acute Coronary Syndrome With Multivessel and/or Unprotected Left Main Coronary Disease|Unknown status|Not yet recruiting|N/A|1000|Anticipated|American Heart of Poland||2|||f||||t||||||||||2018-05-31 22:48:38.973163|2018-05-31 22:48:38.973163
NCT01311310|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-20|||2012-04-30|2011-03-06|2011-03-09|Estimate|||||||2012-04-30|2012-05-01|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Remote Ischemic Preconditioning on Children Undergoing Cardiac Surgery|Effect of Remote Ischemic Preconditioning on Children Undergoing Cardiac Surgery: Implication of Preoperative Cyanosis|Completed||N/A|60|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:48:39.078912|2018-05-31 22:48:39.078912
NCT01311297|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2018-05-24|2011-03-08|2011-03-09|Estimate|||||||2018-05-24|2018-05-25|Actual|March 29, 2011|Actual|2011-03-29|May 2018|2018-05-31|September 29, 2012|Actual|2012-09-29|September 29, 2012|Actual|2012-09-29||Observational|||Clinical Monitoring of Endothelial Dysfunction for Pregnant Women and in the Perioperative Course|Clinical Monitoring of Endothelial Dysfunction for Pregnant Women and in the Perioperative Course - a Pilot Study|Terminated|||47|Actual|Charite University, Berlin, Germany|||3||f||||f||||||Samples Without DNA|"~     Whole blood, serum~   "|||2018-05-31 22:48:39.142339|2018-05-31 22:48:39.142339
NCT01311284|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2012-01-03|2011-03-08|2011-03-09|Estimate|||||||2012-01-03|2012-01-05|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|MGR-AR2010A1||Comparison Airway Devices in Nasotracheal Intubation in Manikin|Comparison of Airtraq Nasotracheal Mcgrath and Macintosh Laryngoscope in Nasotracheal Intubation: A Manikin Study|Completed||N/A|63|Actual|Complexo Hospitalario Universitario de A Coruña||3|||f||||f||||||||||2018-05-31 22:48:39.207375|2018-05-31 22:48:39.207375
NCT01311271|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2015-05-18|2011-03-06|2011-03-09|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2011||2011-01-31|May 2015|2015-05-31||||February 2012|Actual|2012-02-29||Interventional|||Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation(rTMS) on the Recovery After Stroke|Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation on the Recovery of Upper Motor Function After Stroke: a Randomized Controlled Trial|Terminated||Phase 2/Phase 3|2|Actual|Seoul National University Bundang Hospital||3||"Only two subjects have been recruited from start of the study. We decided to start the study in~   this topic, after revising the study protocol."|f||||t||||||||||2018-05-31 22:48:39.309895|2018-05-31 22:48:39.309895
NCT01311258|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-10-09|2011-03-08|2011-03-09|Estimate|||||||2017-10-09|2017-10-10|Actual|August 2007||2007-08-31|October 2017|2017-10-31|August 2025|Anticipated|2025-08-31|August 2020|Anticipated|2020-08-31||Observational|MRD||Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome|A Program for Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia or High Grade Myelodysplastic Syndrome|Recruiting|||300|Anticipated|University of Rochester|||||f||||f||||||Samples With DNA|"~     peripheral blood and bone marrow aspirate~   "|||2018-05-31 22:48:39.40975|2018-05-31 22:48:39.40975
NCT01311245|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2015-12-01|2011-03-08|2011-03-09|Estimate|||||||2015-12-01|2015-12-03|Estimate|July 2008||2008-07-31|December 2015|2015-12-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|TOPAS||Testing Alcohol Interventions Among Job-seekers|Testing Stage Tailored vs. Non-stage Tailored Interventions Among Job-seekers With Risky Drinking|Completed||Phase 2|1243|Actual|University Medicine Greifswald||3|||f||||f||||||||||2018-05-31 22:48:39.521473|2018-05-31 22:48:39.521473
NCT01311232|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2017-10-25|2011-03-06|2011-03-09|Estimate|||||||2017-10-25|2017-10-27|Actual|November 1, 2010|Actual|2010-11-01|October 2017|2017-10-31|December 1, 2013|Actual|2013-12-01|December 1, 2012|Actual|2012-12-01||Observational|||Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab|Hepatitis B Virus Reactivation in Asian Patients Treated With Rituximab-containing Treatment|Completed|||600|Anticipated|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 22:48:39.603676|2018-05-31 22:48:39.603676
NCT01311219|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-09-29|2011-03-07|2011-03-09|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Comparing Intramedullary Nailing, Plate Fixation, and Non-operative Treatment of Clavicle Fractures|Comparison of Intramedullary Nailing, Plate Fixation, and Non-operative Treatment of Acute, Displaced, Midshaft Clavicle Fractures: a Prospective Randomized Trial|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||3||PI left institution|f||||f||||||||No||2018-05-31 22:48:39.701392|2018-05-31 22:48:39.701392
NCT01311206|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-06-27|2011-03-07|2011-03-09|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2011||2011-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PBFR||Low Intensity Resistance Training With Partial Blood Flow Restriction for Quadriceps Strengthening|Determining Efficacy of a Tolerable Means of Strengthening for Older Adults With Knee Osteoarthritis: Partial Blood Flow Restriction Low Intensity Resistance Training|Completed||N/A|50|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 22:48:39.774848|2018-05-31 22:48:39.774848
NCT01311193|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-03-07|2011-03-07|2011-03-09|Estimate|||||||2011-03-07|2011-03-09|Estimate||||March 2011|2011-03-31||||||||Interventional|||Circadian Sleep-wake Cycles and Light Therapy in Borderline Personality Disorder|Circadian Sleep-wake Cycles, Well-being and Light Therapy in Borderline Personality Disorder|Completed||N/A|||University Hospital, Basel, Switzerland||1|||f||||||||||||||2018-05-31 22:48:39.8403|2018-05-31 22:48:39.8403
NCT01311180|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2015-04-20|2011-03-06|2011-03-09|Estimate|||||||2015-04-20|2015-04-21|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder|A Phase II Double-Blind, Parallel Group, Randomized, Placebo Controlled Clinical Trial of Sensoril® for Patients With Generalized Anxiety Disorder.|Completed||Phase 2|120|Actual|Natreon, Inc.||2|||f||||||||||||||2018-05-31 22:48:39.905985|2018-05-31 22:48:39.905985
NCT01311167|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-04-17|2011-03-08|2011-03-09|Estimate|||||||2013-04-17|2013-04-18|Estimate|February 2011||2011-02-28|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Treatment of Sodium Retention in Liver Cirrhosis With Dexamethasone|Prospective Randomized Double Blind Placebo Controlled Intervention Study of the Effect of Dexamethasone on the Sodium Retention in Patients With Liver Cirrhosis|Terminated||Phase 3|2|Actual|University Hospital Inselspital, Berne||2||Recruitment problems (not enough patients were found who met eligibility criteria)|f||||t||||||||||2018-05-31 22:48:39.979325|2018-05-31 22:48:39.979325
NCT01311154|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-09|Estimate|||||||2011-03-07|2011-03-09|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|July 2015|Anticipated|2015-07-31|February 2013|Anticipated|2013-02-28||Observational|SATURN||Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria|Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria - WP5|Unknown status|Recruiting||400|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-05-31 22:48:40.056801|2018-05-31 22:48:40.056801
NCT01311141|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-31|2011-03-08|2011-03-09|Estimate|||||||2011-03-31|2011-04-01|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers Dori_MD_1|Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers - a Pilot Study|Completed||Phase 4|6|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-05-31 22:48:40.142232|2018-05-31 22:48:40.142232
NCT01311128|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-05-27|2011-03-08|2011-03-09|Estimate|||||||2011-05-27|2011-05-30|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||September 2011|Anticipated|2011-09-30||Interventional|||Determination of the Accuracy of a Non-Invasive Continuous Blood Pressure Device|Determination of the Accuracy of a Non-Invasive Continuous Blood Pressure Device|Unknown status|Recruiting|N/A|40|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-05-31 22:48:40.225631|2018-05-31 22:48:40.225631
NCT01311115|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|August 2011|Anticipated|2011-08-31|February 2011|Anticipated|2011-02-28||Interventional|||Using Group Commitment for Smoking Cessation|Using Group Commitment for Smoking Cessation|Unknown status|Recruiting|N/A|200|Anticipated|University of California, Berkeley||2|||f||||f||||||||||2018-05-31 22:48:40.330104|2018-05-31 22:48:40.330104
NCT01311102|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2013-10-14||2013-12-17|2011-03-08|2011-03-09|Estimate|2013-12-17|2014-02-05|Estimate||||2013-12-17|2014-02-05|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2008|Actual|2008-12-31||Interventional||Pilot study using a population of convenience within study location.|The Impact of Pain Scores on Intrauterine Lidocaine Versus Normal Saline Infusion at the Time of IUD Placement|Double Blind, Randomized, Prospective Trial of Impact of Pain Scores on Intrauterine Lidocaine vs Normal Saline Infusion Before IUD Placement.|Completed||Phase 4|40|Actual|Women's Health Care Clinic, Torrance, California|This was a small pilot study, so may have missed small differences in pain score. Based on the results obtained, a sample size of 418 subjects would be needed to detect a statistically significant difference in the pain scores.|2|||f||||f||||||||||2018-05-31 22:48:40.41545|2018-05-31 22:48:40.41545
NCT01311089|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-08|||2015-01-26|2011-03-08|2011-03-09|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy|A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction|Completed|||169|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 22:48:40.818688|2018-05-31 22:48:40.818688
NCT01311076|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2012-02-09|2011-03-08|2011-03-09|Estimate|||||||2012-02-09|2012-02-13|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||TAK-329 Glucose Clamp Study|A Phase 1, Randomized, Placebo- and Active-Controlled, 4-Period Crossover, Proof of Concept Glucose Clamp Study to Compare the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single Doses of TAK-329 With a Single Dose of a Subcutaneously-Injected Rapid-Acting Insulin Analog in Subjects With Type 1 Diabetes Mellitus.|Completed||Phase 1|37|Actual|Takeda||4|||f||||f||||||||||2018-05-31 22:48:40.887313|2018-05-31 22:48:40.887313
NCT01311050|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-12-11|2011-03-08|2011-03-09|Estimate|||||||2011-12-11|2011-12-13|Estimate|January 2009||2009-01-31|December 2011|2011-12-31||||||||Observational|||A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer|A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer|Unknown status|Recruiting||46|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 22:48:41.041267|2018-05-31 22:48:41.041267
NCT01311037|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-12-11|2011-03-08|2011-03-09|Estimate|||||||2011-12-11|2011-12-13|Estimate|January 2009||2009-01-31|December 2011|2011-12-31||||||||Observational|||The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer|The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer A Prospective Trial|Unknown status|Recruiting||2|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 22:48:41.121172|2018-05-31 22:48:41.121172
NCT01311024|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2014-04-02||2017-09-14|2011-03-07|2011-03-09|Estimate|2014-04-02|2014-05-05|Estimate||||2017-09-14|2017-10-16|Actual|April 2011||2011-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2013|Actual|2013-06-30||Observational|FinIPcarr|These numbers include only the siblings of the infant-vaccinated FinIP children.|Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage|Indirect Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study|Active, not recruiting|||2341|Actual|National Institute for Health and Welfare, Finland|||2||f||||f||||||Samples Without DNA|"~     Nasopharyngeal and oropharyngeal swabs obtained.~   "|No||2018-05-31 22:48:41.199305|2018-05-31 22:48:41.199305
NCT01311011|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-12-11|2011-03-08|2011-03-09|Estimate|||||||2011-12-11|2011-12-13|Estimate|November 2008||2008-11-30|December 2011|2011-12-31||||||||Observational|||Study of the Clinical Efficacy of Autologous SCT in Patients With Critical Limb Ischemia|Phase II Prospective Study of the Clinical Efficacy of Autologous SCT in Patients With Critical Limb Ischemia|Unknown status|Recruiting||26|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 22:48:41.43057|2018-05-31 22:48:41.43057
NCT01310998|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2016-07-27|2011-03-07|2011-03-09|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Acute Psychological Effects of High Intensity Exercise With Schizophrenia|Acute Psychological Effects of High Intensity Exercise in Patients With Schizophrenia|Completed||N/A|60|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 22:48:41.510172|2018-05-31 22:48:41.510172
NCT01310985|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2016-02-24|2011-03-08|2011-03-09|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer|A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer|Completed|||15|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||Undecided||2018-05-31 22:48:41.584166|2018-05-31 22:48:41.584166
NCT01310972|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2016-02-24|2011-03-06|2011-03-09|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX|Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX|Completed|||6|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||Undecided||2018-05-31 22:48:41.651619|2018-05-31 22:48:41.651619
NCT01310959|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-12-11|2011-03-06|2011-03-09|Estimate|||||||2011-12-11|2011-12-13|Estimate|January 2003||2003-01-31|December 2011|2011-12-31||||||||Observational|||Establishing a Data Base for Aplastic Anemia and Other Marrow Failure Syndrome|Establishing a Data Base for Aplastic Anemia and Other Marrow Failure Syndrome|Unknown status|Recruiting||88|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 22:48:41.714259|2018-05-31 22:48:41.714259
NCT01310946|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-06|||2011-12-11|2011-03-06|2011-03-09|Estimate|||||||2011-12-11|2011-12-13|Estimate|June 2003||2003-06-30|December 2011|2011-12-31||||||||Observational|||Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology|Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology|Unknown status|Recruiting||203|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-05-31 22:48:41.771226|2018-05-31 22:48:41.771226
NCT01310933|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2012-01-31|2011-03-06|2011-03-09|Estimate|||||||2012-01-31|2012-02-02|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|February 2012|Anticipated|2012-02-29|||||Observational|||Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy|Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy|Unknown status|Recruiting||40|Anticipated|Far Eastern Memorial Hospital|||2||f||||f||||||||||2018-05-31 22:48:41.827603|2018-05-31 22:48:41.827603
NCT01310894|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-04-17|2011-03-05|2011-03-09|Estimate|||||||2016-04-17|2016-04-19|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|PCM301||Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.|A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance|Completed||Phase 3|413|Actual|Steba Biotech S.A.||2|||f||||t||||||||Yes|The data are available in case report form for each patient|2018-05-31 22:48:42.043565|2018-05-31 22:48:42.043565
NCT01310881|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-11-17|2011-03-05|2011-03-09|Estimate|||||||2011-11-17|2011-11-21|Estimate|February 2011||2011-02-28|May 2011|2011-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189|A Phase 1, Randomized, Subject Single Blinded, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of NSI-189 Phosphate in Healthy Subjects|Completed||Phase 1|35|Actual|Neuralstem Inc.||7|||f||||f||||||||||2018-05-31 22:48:42.20316|2018-05-31 22:48:42.20316
NCT01310868|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-05|2017-05-02||2017-09-06|2011-03-05|2011-03-09|Estimate|2017-05-02|2017-08-14|Actual||||2017-09-06|2017-10-05|Actual|May 2011||2011-05-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma|An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) With Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma (GALA-5 Trial)|Completed||Phase 2|59|Actual|University College, London||1|||f||||t||||||||||2018-05-31 22:48:42.29091|2018-05-31 22:48:42.29091
NCT01310855|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-05|2016-12-02||2017-05-02|2011-03-05|2011-03-09|Estimate|2016-12-02|2017-01-27|Estimate||||2017-05-02|2017-05-31|Actual|May 2011||2011-05-31|May 2017|2017-05-31|January 2014|Actual|2014-01-31|May 2013|Actual|2013-05-31||Interventional|||Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma|Multi-Center, Randomized, Double-Blind Phase II Study Comparing Cediranib (AZD2171) Plus Gefitinib (Iressa, ZD1839) With Cediranib Plus Placebo in Subjects With Recurrent/Progressive Glioblastoma (DORIC Trial)|Terminated||Phase 2|38|Actual|University College, London||2||closed to recruitment early due to AstraZeneca not developing cediranib further|f||||t||||||||||2018-05-31 22:48:42.531981|2018-05-31 22:48:42.531981
NCT01310842|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2016-10-03|2011-03-07|2011-03-09|Estimate|||||||2016-10-03|2016-10-05|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Social Determinants and Smoking Cessation|Social Determinants and Smoking Cessation|Completed|||329|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||Samples Without DNA|"~     Saliva samples at Baseline, week 12, and week 26 visits collected for cotinine tests.~   "|||2018-05-31 22:48:42.842018|2018-05-31 22:48:42.842018
NCT01310829|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2016-05-24|2011-03-08|2011-03-09|Estimate|||||||2016-05-24|2016-05-26|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Virtual Reality Intervention in Cancer Genetics|Developing Providers' Communication and Counseling Skills in Cancer Genetics Using Virtual Reality|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 22:48:42.917504|2018-05-31 22:48:42.917504
NCT01310816|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2013-12-04|2011-03-08|2011-03-09|Estimate|||||||2013-12-04|2013-12-05|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma|A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma|Completed||Phase 2|105|Actual|Infinity Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 22:48:42.975708|2018-05-31 22:48:42.975708
NCT01310803|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-10-16||2017-09-07|2011-03-08|2011-03-09|Estimate|2014-10-16|2014-10-22|Estimate||||2017-09-07|2017-10-05|Actual|May 2011||2011-05-31|September 2017|2017-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder|A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER|Terminated||Phase 3|1|Actual|Endo Pharmaceuticals|This study was terminated early. Only one subject was enrolled. No study results were generated.|2|||f||||||||||||||2018-05-31 22:48:43.188372|2018-05-31 22:48:43.188372
NCT01310790|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-03-08|2011-03-08|2011-03-09|Estimate|||||||2011-03-08|2011-03-09|Estimate|October 2006||2006-10-31|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock|Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis|Completed||Phase 4|420|Actual|Chinese Septic Shock Network|||||f||||t||||||||||2018-05-31 22:48:43.447119|2018-05-31 22:48:43.447119
NCT01310777|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2014-01-24||2014-01-24|2011-03-08|2011-03-09|Estimate|2014-01-24|2014-03-06|Estimate||||2014-01-24|2014-03-06|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||This reporting group includes all randomized subjects.|Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension|Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|771|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:48:43.531602|2018-05-31 22:48:43.531602
NCT01310764|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-28|2011-03-07|2011-03-08|Estimate|||||||2011-03-28|2011-03-29|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|July 2010|Actual|2010-07-31|November 2009|Actual|2009-11-30||Interventional|||Trabeculectomy With Subconjunctival Bevacizumab Injection|Efficacy and Safety of Trabeculectomy With Subconjunctival Bevacizumab Versus Trabeculectomy With Mitomycin C.|Completed||N/A|36|Actual|Rassoul Akram Hospital||2|||f||||t||||||||||2018-05-31 22:48:43.860139|2018-05-31 22:48:43.860139
NCT01310751|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2015-11-22|2011-03-07|2011-03-08|Estimate|||||||2015-11-22|2015-11-24|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery|Randomized Double-blind Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension (PH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Disease (CHD)|Completed||Phase 2/Phase 3|36|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 22:48:43.93492|2018-05-31 22:48:43.93492
NCT01310738|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-08-31|2011-03-07|2011-03-08|Estimate|||||||2017-08-31|2017-09-05|Actual|February 2011||2011-02-28|August 2017|2017-08-31|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|LVBrasil||Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil|Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil|Terminated||Phase 4|378|Actual|University of Brasilia||4||DSMB recommendation based on programmed interim analysis.|f||||t||||||||Undecided||2018-05-31 22:48:44.017631|2018-05-31 22:48:44.017631
NCT01310725|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2004||2004-01-31|September 2010|2010-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Evaluation of Graft Material in Coronary Artery Bypass Grafting (CABG)|Mid-term Patency of Radial Artery and No Touch Saphenous Vein as Grafts in CABG; A Randomised Controlled Trial.|Completed||N/A|108|Actual|Region Örebro County|||||f||||f||||||||||2018-05-31 22:48:44.11111|2018-05-31 22:48:44.11111
NCT01310712|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-09-21|2011-03-07|2011-03-08|Estimate|||||||2011-09-21|2011-09-22|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study|Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study.|Completed||Phase 4|50|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:48:44.185673|2018-05-31 22:48:44.185673
NCT01310699|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2017-02-21||2017-10-31|2011-03-07|2011-03-08|Estimate|2017-02-21|2017-04-06|Actual||||2017-10-31|2017-12-06|Actual|January 2013||2013-01-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|NBI||Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study|Full Inspection With Narrow Band Imaging (NBI) for Detection of Flat Lesions And Tumors During Colonoscopy- The FIND FLAT Colonoscopy Study|Completed||N/A|281|Actual|VA Palo Alto Health Care System||2|||f||||t||||||||||2018-05-31 22:48:44.263627|2018-05-31 22:48:44.263627
NCT01310686|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-11-08|2011-03-07|2011-03-08|Estimate|||||||2017-11-08|2017-11-13|Actual|April 2011||2011-04-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy|Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy|Active, not recruiting|||40|Anticipated|West Coast Retina Medical Group, Inc.|||1||f||||f||||||||||2018-05-31 22:48:44.469|2018-05-31 22:48:44.469
NCT01310673|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 1998||1998-01-31|March 2011|2011-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout|Therapy for Acute Gout: Does Initial Use of Allopurinol Effect Duration and/or Recurrence Rate of Acute Attacks|Completed||Phase 4|57|Actual|White River Junction Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 22:48:44.522385|2018-05-31 22:48:44.522385
NCT01310660|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2016-01-29|2011-03-07|2011-03-08|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2011||2011-01-31|January 2016|2016-01-31||||July 2013|Actual|2013-07-31||Observational|ELITE||Evaluation of Levator Injuries Using Transvaginal Endosonography|Evaluation of Levator Injuries Using Transvaginal Endosonography|Completed|||269|Actual|Croydon University Hospital|||1||f||||f||||||||||2018-05-31 22:48:44.585349|2018-05-31 22:48:44.585349
NCT01310647|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-02-27|2011-03-07|2011-03-08|Estimate|||||||2014-02-27|2014-02-28|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2012|Actual|2012-12-31||Interventional|FOLLPRIM||Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders|Prospective Randomized Controlled Trial of Antral Follicle Priming Prior to IVF-ICSI in Previously Diagnosed Low Responders.|Completed||Phase 2|66|Actual|Instituto de Investigacion Sanitaria La Fe||3|||f||||t||||||||||2018-05-31 22:48:44.634711|2018-05-31 22:48:44.634711
NCT01310634|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-10-24|2011-03-07|2011-03-08|Estimate|||||||2014-10-24|2014-10-28|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Epidemiology and Prevention of Anxiety and Depression in Parents of Hospitalized Neonates|Epidemiology and Prevention of Anxiety and Depression in Parents of Hospitalized Neonates|Completed||N/A|600|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 22:48:44.726841|2018-05-31 22:48:44.726841
NCT01310621|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-07-14|2011-03-07|2011-03-08|Estimate|||||||2014-07-14|2014-07-15|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|Sur-Lu-Lav||Comparison Of Surfactant Lung Lavage With Standard Care In The Treatment Of Meconium Aspiration Syndrome|Surfactant Lung Lavage Versus Standard Care In The Treatment Of Meconium Aspiration Syndrome- A Randomized Controlled Study|Completed||N/A|60|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 22:48:44.796834|2018-05-31 22:48:44.796834
NCT01310608|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2012-08-07|2011-03-07|2011-03-08|Estimate|||||||2012-08-07|2012-08-09|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Effect Study of Modified Transoesophageal Echocardiography on Cerebral Embolization After Cardiothoracic Surgery|Effect of Preoperative Imaging of the Ascending Aorta With Modified Transoesophageal Echocardiography on New Dw-MRI Lesions After Cardiac Surgery|Completed||Phase 3|32|Actual|Isala||2|||f||||t||||||||||2018-05-31 22:48:44.859903|2018-05-31 22:48:44.859903
NCT01310595|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-08-26|2011-03-07|2011-03-08|Estimate|||||||2013-08-26|2013-08-28|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Manual Therapy on Head-repositioning Accuracy and Static Postural Balance in Neck Pain Patients|To Investigate the Effectiveness of Manual Therapy on Head-repositioning Accuracy and Static Postural Balance in Patients With Non-traumatic Chronic Mechanical Neck Pain.|Completed||Phase 1|145|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 22:48:44.919904|2018-05-31 22:48:44.919904
NCT01310582|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2013-08-19||2013-11-06|2011-03-07|2011-03-08|Estimate|2013-11-06|2013-12-24|Estimate||||2013-11-06|2013-12-24|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Six patients dropped out due to physician decision.|Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females|Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females|Completed||Phase 4|57|Actual|Hahnemann University Hospital||2|||f||||f||||||||||2018-05-31 22:48:44.983201|2018-05-31 22:48:44.983201
NCT01310569|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Subcutaneous Adipose Tissue in Cases With Polycystic Ovarian Syndrome|Relationship of Subcutaneous Adipose Tissue With HOMA-IR and Plasma Adiponectin Levels in Cases With Polycystic Ovarian Syndrome|Completed|||52|Actual|Gulhane School of Medicine|||||f||||f||||||||||2018-05-31 22:48:45.225293|2018-05-31 22:48:45.225293
NCT01310556|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-06-17|2011-03-07|2011-03-08|Estimate|||||||2011-06-17|2011-06-21|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Unknown Glucose Metabolism Disorders In Patients With Coronary Artery Disease|The Relationship Between Previously Unknown Glucose Metabolism Disorders and Coronary Artery Disease in Patients Suffering From Coronary Artery Disease|Completed|||230|Actual|Gulhane School of Medicine|||1||f||||f||||||||||2018-05-31 22:48:45.273249|2018-05-31 22:48:45.273249
NCT01310543|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2016-09-13|2011-03-07|2011-03-08|Estimate|||||||2016-09-13|2016-09-14|Estimate|December 2009||2009-12-31|April 2011|2011-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Trial of the Teens and Toddlers Intervention|RCT of the Teens and Toddlers Intervention|Completed||Phase 3|449|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 22:48:45.332265|2018-05-31 22:48:45.332265
NCT01310530|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2017-09-26|2011-03-07|2011-03-08|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2011||2011-05-31|September 2017|2017-09-30|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|||Partial Breast Proton Therapy for Early Stage Breast Cancer|Phase 2 Trial of Partial Breast Proton Therapy for Early Stage Breast Cancer With Low and Intermediate Risk Factors.|Active, not recruiting||Phase 2|150|Anticipated|Loma Linda University||1|||f||||t||||||||||2018-05-31 22:48:45.395989|2018-05-31 22:48:45.395989
NCT01310517|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-10-01|2011-03-07|2011-03-08|Estimate|||||||2014-10-01|2014-10-02|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Hand Injected Ventriculography vs. Power Injected Left Ventriculography|Comparison of Very Low Contrast Volume Hand Injected Ventriculography to Standard Contrast Volume Power Injected Left Ventriculography From the Radial Artery Approach for Estimation of Left Ventricular Ejection Fraction.|Terminated|||1|Actual|Loma Linda University|||1|Study was stopped due to low enrollment.|f||||f||||||||||2018-05-31 22:48:45.457338|2018-05-31 22:48:45.457338
NCT01310504|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2012-08-16|2011-03-07|2011-03-08|Estimate|||||||2012-08-16|2012-08-17|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Use of the FAST (Focused Abdominal Scan for Trauma) Scan by Paramedics in Mass Casualty Incidents|The Use of the FAST Scan by Paramedics in Mass Casualty Incidents|Completed||N/A|19|Actual|Genesys Regional Medical Center||2|||f||||f||||||||||2018-05-31 22:48:45.50826|2018-05-31 22:48:45.50826
NCT01310491|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2014-02-14|2011-03-07|2011-03-08|Estimate|||||||2014-02-14|2014-02-17|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||RENEWING HEALTH - RegioNs of Europe WorkINg Together for HEALTH|RENEWING HEALTH Large-scale Real-life Study in Finland|Completed||N/A|595|Actual|South Karelia, Social and Health Care District||1|||f||||f||||||||||2018-05-31 22:48:45.647837|2018-05-31 22:48:45.647837
NCT01310478|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|August 2010||2010-08-31|June 2010|2010-06-30||||May 2011|Anticipated|2011-05-31||Interventional|||Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer|PhaseⅠClinical Study of Recombinant Human Endostatin in Combination With mFOLFOX6 as Initial Therapy for Patients With Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 1|15|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 22:48:45.738318|2018-05-31 22:48:45.738318
NCT01310465|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|April 2012|Anticipated|2012-04-30|December 2011|Anticipated|2011-12-31||Interventional|||The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion|The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion|Unknown status|Recruiting|Phase 4|50|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:48:45.831737|2018-05-31 22:48:45.831737
NCT01310452|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2011||2011-01-31|June 2010|2010-06-30||||||||Interventional|||Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin|A Multi-centre, Open-labeled, Randomized, Parallel Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After 26 Weeks Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily|Unknown status|Active, not recruiting|N/A|50|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 22:48:45.921082|2018-05-31 22:48:45.921082
NCT01310439|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|May 2004||2004-05-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants|A Placebo-controlled Trial of Brain Activity Changes Following Psychostimulant Medication in Adolescent Combined-subtype ADHD|Completed|||38|Actual|Hartford Hospital|||1||f||||f||||||Samples With DNA|"~     Saliva samples for genotyping~   "|||2018-05-31 22:48:46.140651|2018-05-31 22:48:46.140651
NCT01310426|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2015-07-26|2011-03-07|2011-03-08|Estimate|||||||2015-07-26|2015-07-28|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|AnaSphRF||Risk Factors for Anal Sphincter Damage During Vaginal Delivery|Risk Factors for Anal Sphincter Damage During Vaginal Delivery|Completed|||33|Actual|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 22:48:46.205037|2018-05-31 22:48:46.205037
NCT01310413|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2014-01-09|2013-08-22|2016-09-22|2011-03-07|2011-03-08|Estimate|2014-02-13|2014-03-31|Estimate|2013-08-22|2013-08-30|Estimate|2016-09-22|2016-09-23|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|July 2011|Actual|2011-07-31||Interventional|||Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age|Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age|Completed||Phase 3|842|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:48:46.395711|2018-05-31 22:48:46.395711
NCT01310400|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|2012-10-23||2014-01-07|2011-03-07|2011-03-08|Estimate|2013-03-20|2013-05-20|Estimate||||2014-01-07|2014-02-06|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children|Observer-blind, Randomized, Controlled Study to Determine the Immunogenicity and Safety of a Two-dose Regimen of Virosomal Subunit Influenza Vaccine Inflexal V in Healthy Young Children (≥6 Months to ≤35 Months) in Comparison With the Subunit Influenza Vaccine Agrippal|Completed||Phase 3|1356|Actual|Crucell Holland BV||3|||f||||f||||||||||2018-05-31 22:48:49.48893|2018-05-31 22:48:49.48893
NCT01310387|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-02-04|2011-03-07|2011-03-08|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|APM||Prospective Study of Active Pain Management in Lung Cancer Outpatients (APM)|A Randomized Prospective Controlled Study of Active Pain Management in Lung Cancer Outpatients (APM)|Completed||Phase 3|79|Actual|Chonnam National University Hospital||1|||f||||f||||||||||2018-05-31 22:48:50.863674|2018-05-31 22:48:50.863674
NCT01310374|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2013-07-09|2011-03-07|2011-03-08|Estimate|||||||2013-07-09|2013-07-10|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Observational|||Immune Response Study of Influenza Vaccine|Humoral and Cellular Immune Response Study of Influenza Vaccine|Completed|||207|Actual|Centers for Disease Control and Prevention, China|||||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 22:48:50.940146|2018-05-31 22:48:50.940146
NCT01310361|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2004||2004-01-31|January 2005|2005-01-31|March 2006||2006-03-31|||||Interventional|||Once-daily Therapy for Streptococcal Pharyngitis|Once-daily Therapy for Streptococcal Pharyngitis|Completed||Phase 1|||Azad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:48:51.001814|2018-05-31 22:48:51.001814
NCT01310348|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2012-08-12|2011-03-07|2011-03-08|Estimate|||||||2012-08-12|2012-08-14|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|EBVIMSG||Effect of Bone on Vibration-Induced Muscle Strength Gain|Effect of Bone Mineral Density on Vibration-Induced Muscle Strength Gain at The Lower Limbs|Completed||N/A|40|Actual|Bagcilar Training and Research Hospital||2|||f||||f||||||||||2018-05-31 22:48:51.112108|2018-05-31 22:48:51.112108
NCT01310335|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2016-02-23|2011-03-07|2011-03-08|Estimate|||||||2016-02-23|2016-02-25|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|WBV-SCL||Effect of Whole-Body Vibration on Plasma Sclerostin Level|Effect of Whole-Body Vibration on Plasma Sclerostin Level in Healthy Young Adult Women|Completed||N/A|15|Actual|Bagcilar Training and Research Hospital||1|||f||||f||||||||No||2018-05-31 22:48:51.257861|2018-05-31 22:48:51.257861
NCT01310322|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2015-01-13|2011-03-07|2011-03-08|Estimate|||||||2015-01-13|2015-01-14|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways|An Open, Partly Randomised, Four-way Cross-over Study in Healthy Subjects and in Patients With Mild Allergic Asthma to Investigate the Bioavailability and Basic Pharmacokinetics of a Single Dose of AZD5423 When Administered Intravenously, Orally, Inhaled Via SPIRA Nebuliser or Inhaled Via I-neb® AAD Systems|Completed||Phase 1|12|Anticipated|AstraZeneca||4|||f||||||||||||||2018-05-31 22:48:51.605503|2018-05-31 22:48:51.605503
NCT01310309|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2012-12-20|2011-03-07|2011-03-08|Estimate|||||||2012-12-20|2012-12-21|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Observational|EXecutive||EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease|EXecutive Registry: XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.|Completed|||400|Actual|Abbott Vascular|||1||f||||f||||||||||2018-05-31 22:48:51.809186|2018-05-31 22:48:51.809186
NCT01310296|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2017-10-24|2011-03-04|2011-03-08|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2011||2011-07-31|October 2017|2017-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Lofexidine ADME & Mass Balance in Volunteers|A Single-Center, Open-Label, Two-Period, Two-Treatment, Randomized Sequence Study to Determine the Mass Balance and Absolute Bioavailability of a Single Oral Dose of 14C-Labeled Lofexidine Compared to a Single Intravenous Dose of Lofexidine|Completed||Phase 1|12|Actual|US WorldMeds LLC||2|||f||||f||||||||||2018-05-31 22:48:51.965503|2018-05-31 22:48:51.965503
NCT01310283|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2012-11-09|2011-03-07|2011-03-08|Estimate|||||||2012-11-09|2012-11-14|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Caries Management by Risk Assessment in Children|Caries Management by Risk Assessment in Children|Completed||N/A|120|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 22:48:52.149977|2018-05-31 22:48:52.149977
NCT01310270|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2018-01-02|2011-03-07|2011-03-08|Estimate|||||||2018-01-02|2018-01-04|Actual|April 2011|Actual|2011-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|OMEGA-PAD||The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation|The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation|Recruiting||Phase 2|180|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:48:52.310135|2018-05-31 22:48:52.310135
NCT01310257|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-01-16|2011-03-04|2011-03-08|Estimate|||||||2014-01-16|2014-01-17|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Measures of Pain Relevant to Knee Osteoarthritis|Evaluation of Questionnaire Measures for Patients With Osteoarthritis of the Knee|Completed|||448|Actual|University of Nottingham|||1||f||||f||||||||||2018-05-31 22:48:52.445598|2018-05-31 22:48:52.445598
NCT01310244|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2015-09-21|2011-03-04|2011-03-08|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2010||2010-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Maximum Tolerated Dose Study of Belinostat (PXD-101)in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)|The Maximum Tolerated Dose and to Evaluate Safety and Efficacy of Belinostat (PXD-101) in Combination With Paclitaxel Plus Carboplatin in Chemotherapy-Naive Patients With Stage IV Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|23|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 22:48:52.631014|2018-05-31 22:48:52.631014
NCT01310231|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2018-04-05|2011-03-04|2011-03-08|Estimate|||||||2018-04-05|2018-04-06|Actual|August 22, 2011|Actual|2011-08-22|May 2017|2017-05-31|March 26, 2018|Actual|2018-03-26|July 14, 2016|Actual|2016-07-14||Interventional|||A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer|A Randomized Phase II, Double Blind Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Receiving First, Second, Third or Fourth Line Chemotherapy With Anthracycline, Taxane, Platinum, Capecitabine or Vinorelbine Based Regimens|Completed||Phase 2|40|Actual|Ozmosis Research Inc.||2|||f||||t||||||||||2018-05-31 22:48:52.775947|2018-05-31 22:48:52.775947
NCT01310218|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-03-04|2011-03-04|2011-03-08|Estimate|||||||2011-03-04|2011-03-08|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Length of Post Operative Dressing After Carpal Tunnel Release|Length of Postoperative Dressing After Mini-open Carpal Tunnel Release: A Randomized Prospective Comparison|Completed||Phase 4|96|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 22:48:52.887037|2018-05-31 22:48:52.887037
NCT01310205|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2012-03-07|2011-03-07|2011-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV|An Extension of Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Pegylated Interferon and Ribavirin After Completing Treatment in a Phase 2 Study and Have Relapsed After at Least 44 Weeks Tx With Peg-IFN and RBV.|Completed|||12|Actual|SciClone Pharmaceuticals|||2||f||||f||||||||||2018-05-31 22:48:52.969767|2018-05-31 22:48:52.969767
NCT01310192|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2015-10-01|2011-03-04|2011-03-08|Estimate|||||||2015-10-01|2015-10-05|Estimate|June 2004||2004-06-30|October 2015|2015-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography|Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography|Completed||Phase 1|20|Actual|Queen's Medical Centre||1|||f||||f||||||||||2018-05-31 22:48:53.042878|2018-05-31 22:48:53.042878
NCT01310179|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2015-04-29||2015-05-26|2011-03-04|2011-03-08|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|February 2011||2011-02-28|May 2015|2015-05-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Safety Study of Adenovirus/PNP Coupled With Fludarabine Phosphate to Treat Solid Tumors|Phase I, Open-label Study Evaluating the Safety of Escalating Doses of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally With Co-administration of Fludarabine Phosphate Intravenously) in Subjects With Advanced Solid Tumors|Completed||Phase 1|12|Actual|PNP Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 22:48:53.143783|2018-05-31 22:48:53.143783
NCT01310166|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2016-11-16|2011-03-04|2011-03-08|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Biobank||Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 4|447|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:48:53.558463|2018-05-31 22:48:53.558463
NCT01310153|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2011-03-07|2011-03-07|2011-03-08|Estimate|||||||2011-03-07|2011-03-08|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|February 2009|Actual|2009-02-28|||||Interventional|||Effect of Supine or Prone Position After Caesarean Birth|Effect of Supine or Prone Position at Delivery on Respiratory Outcomes in Full-Term Infants Following Elective Caesarean Birth|Completed||Phase 1|||Montefiore Medical Center|||||f||||||||||||||2018-05-31 22:48:53.747862|2018-05-31 22:48:53.747862
NCT01310140|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-02-10|2011-03-04|2011-03-08|Estimate|||||||2017-02-10|2017-02-13|Actual|January 2011|Actual|2011-01-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features|Comparative Risks for Insulin Resistance and Metabolic Syndrome (MS) Among Hospitalized Patients With Major Depressive Disorder With (MDpsy) or Without (MDD) Psychotic Features|Terminated|||14|Actual|Massachusetts General Hospital|||2|PI left Massachusetts General Hospital Inpatient service|f||||f||||||||||2018-05-31 22:48:53.822516|2018-05-31 22:48:53.822516
NCT01310127|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2013-04-25||2018-01-04|2011-03-07|2011-03-08|Estimate|2013-08-05|2013-09-26|Estimate||||2018-01-04|2018-01-08|Actual|November 2010||2010-11-30|August 2013|2013-08-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional||1 nepafenac patient did not use test article prior to surgery. 1 bromday patient used nsaid during study. 1 bromday patient had advanced psc cataract.|Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%|Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery|Completed||Phase 4|23|Actual|Toyos Clinic|The major limitation in the study is that it was a small pilot study so that the direct correlations of the study variable could not be evaluated. There were ethnic differences in the groups that could also influence the data.|2|||f||||f||||||||||2018-05-31 22:48:53.924535|2018-05-31 22:48:53.924535
NCT01310114|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25||2013-08-12|2018-02-27|2011-03-04|2011-03-08|Estimate||||2013-08-12|2013-08-21|Estimate|2018-02-27|2018-03-01|Actual|March 2011||2011-03-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke|A Phase 2A, Prospective, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults Following Ischemic Stroke|Terminated||Phase 2|44|Actual|Celularity Incorporated||3||Study terminated by sponsor|f||||t||||||||||2018-05-31 22:48:54.457753|2018-05-31 22:48:54.457753
NCT01310101|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-07|||2015-02-01|2011-03-07|2011-03-08|Estimate|||||||2015-02-01|2015-02-03|Estimate|April 2011||2011-04-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia|Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 2|33|Actual|Brno University Hospital||1|||f||||t||||||||||2018-05-31 22:48:54.571404|2018-05-31 22:48:54.571404
NCT01310088|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-03-10|2011-03-03|2011-03-07|Estimate|||||||2011-03-10|2011-03-11|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|AORTA||Blood Pressure and Central Vascular Stiffness in Obese Children. Relationship to Metabolic Disturbances and Subclinical Cardiovascular Damage. Effect of Weight Reduction|Blood Pressure and Central Vascular Stiffness in Obese Children. Relationship to Metabolic Disturbances and Subclinical Cardiovascular Damage. Effect of Weight Reduction|Unknown status|Recruiting|N/A|100|Anticipated|Zealand University Hospital||2|||f||||f||||||||||2018-05-31 22:48:54.686105|2018-05-31 22:48:54.686105
NCT01310075|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2017-11-13|2011-03-04|2011-03-07|Estimate|||||||2017-11-13|2017-11-17|Actual|February 2011|Actual|2011-02-28|November 2017|2017-11-30|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction|Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction: A Blinded, Prospective, Randomized, Controlled Trial|Completed||N/A|398|Anticipated|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-05-31 22:48:54.846209|2018-05-31 22:48:54.846209
NCT01310062|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2011-03-04|2011-03-04|2011-03-07|Estimate|||||||2011-03-04|2011-03-07|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|August 2012|Anticipated|2012-08-31|||||Observational|||The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer|Strategic Alliance for The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer|Unknown status|Recruiting||1600|Anticipated|Ministry of Health, Malaysia|||||f||||f||||||Samples With DNA|"~     Red blood cell and white blood cell~   "|||2018-05-31 22:48:54.924968|2018-05-31 22:48:54.924968
NCT01310049|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-11-04|2011-03-04|2011-03-07|Estimate|||||||2013-11-04|2013-11-05|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||LEO 32731 - A Study in Healthy Male Subjects|LEO 32731 - A Phase I, Single-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects|Completed||Phase 1|111|Actual|LEO Pharma||5|||f||||f||||||||||2018-05-31 22:48:55.010927|2018-05-31 22:48:55.010927
NCT01310036|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-05-16|2011-03-04|2011-03-07|Estimate|||||||2017-05-16|2017-05-18|Actual|April 30, 2011|Actual|2011-04-30|May 2017|2017-05-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|||A Study of Tarceva (Erlotinib) as First Line Therapy in Patients With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations|An Open-label Multi-center Study of Erlotinib (Tarceva®) as First Line Therapy Until and Beyond Disease Progression in NSCLC Patients Who Harbour EGFR Mutations|Completed||Phase 2|208|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:48:55.080666|2018-05-31 22:48:55.080666
NCT01310023|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2018-01-29|2011-03-04|2011-03-07|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2007||2007-03-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|SMARTT||Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women|Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women|Recruiting|||3400|Anticipated|Harvard School of Public Health|||4||f||||f||||||Samples With DNA|"~     Serum, cell pellets, meconium, saliva, hair~   "|||2018-05-31 22:48:55.206196|2018-05-31 22:48:55.206196
NCT01310010|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2015-09-28|2011-03-04|2011-03-07|Estimate|||||||2015-09-28|2015-09-29|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|DASA-TRAS||Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia|Multicenter, Non-randomized Phase II Pilot Study to Assess the Efficacy and Safety of Dasatinib After Allogeneic Stem Cell Transplantation in Patients With de Novo Philadelphia Positive (Bcr-abl +) Acute Lymphoblastic Leukemia|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Grupo Espanol de trasplantes hematopoyeticos y terapia celular||1|||f||||f||||||||||2018-05-31 22:48:55.433816|2018-05-31 22:48:55.433816
NCT01309997|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2015-09-21||2016-05-10|2011-03-04|2011-03-07|Estimate|2016-05-10|2016-06-15|Estimate||||2016-05-10|2016-06-15|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease|A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation|Completed||Phase 2|72|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||Yes|De-identified patient data and samples may be available with the appropriate approvals. Contact the PI for information.|2018-05-31 22:48:55.525763|2018-05-31 22:48:55.525763
NCT01309984|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2015-11-02|2011-03-04|2011-03-07|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure|An Open-label, Single Initial-dose, Multi-center Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure|Completed||Phase 1|10|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:48:56.316729|2018-05-31 22:48:56.316729
NCT01309971|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2014-02-14|2011-03-04|2011-03-07|Estimate|||||||2014-02-14|2014-02-19|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|December 2011|Actual|2011-12-31|March 2010|Actual|2010-03-31||Observational|||DPBRN Longitudinal Study of Questionable Occlusal Caries Lesions|Longitudinal Study of Questionable Occlusal Caries Lesions|Completed|||2624|Actual|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 22:48:56.409477|2018-05-31 22:48:56.409477
NCT01309958|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2015-08-05|2011-03-04|2011-03-07|Estimate|||||||2015-08-05|2015-08-06|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||DPBRN Development of a Patient Based Provider Intervention for Early Caries Management|Development of a Patient Based Provider Intervention for Early Caries|Completed|||334|Actual|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 22:48:56.505026|2018-05-31 22:48:56.505026
NCT01309945|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15||2015-09-23|2015-09-23|2011-03-04|2011-03-07|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression|A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients With Treatment Resistant Major Depression|Completed||Phase 2|889|Actual|Bristol-Myers Squibb||5|||f||||t||||||||||2018-05-31 22:48:56.633218|2018-05-31 22:48:56.633218
NCT01309932|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04||2015-09-23|2015-09-23|2011-03-04|2011-03-07|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|D-LITE||Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin|A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects|Completed||Phase 2|165|Actual|Bristol-Myers Squibb||7|||f||||f||||||||||2018-05-31 22:48:56.841295|2018-05-31 22:48:56.841295
NCT01309919|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2013-11-27||2015-01-22|2011-03-04|2011-03-07|Estimate|2015-01-22|2015-01-29|Estimate||||2015-01-22|2015-01-29|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Bleeding Patterns and Complications After Postpartum IUD Placement: a Pilot Study|Bleeding Patterns and Complications After Postpartum Intrauterine Device (IUD) Placement: a Pilot Study|Completed||N/A|150|Actual|Baystate Medical Center|Low rate of bleeding diary return limited our assessment of the primary outcome of bleeding/spotting days after delivery.|2|||f||||f||||||||||2018-05-31 22:48:57.032362|2018-05-31 22:48:57.032362
NCT01309906|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2012-08-10|2011-03-04|2011-03-07|Estimate|||||||2012-08-10|2012-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:48:57.29986|2018-05-31 22:48:57.29986
NCT01309893|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-11-04||2014-11-20|2011-03-04|2011-03-07|Estimate|2014-11-20|2014-11-24|Estimate||||2014-11-20|2014-11-24|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional||All eligible enrolled participants|A Study to Evaluate a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens|Completed||N/A|66|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:48:57.419612|2018-05-31 22:48:57.419612
NCT01309880|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-03-31||2015-02-13|2011-03-04|2011-03-07|Estimate|2015-02-13|2015-02-23|Estimate||||2015-02-13|2015-02-23|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional||All eligible enrolled participants|Evaluation of a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens|Completed||N/A|66|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:48:57.607905|2018-05-31 22:48:57.607905
NCT01309854|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-07-06|2011-03-04|2011-03-07|Estimate|||||||2011-07-06|2011-07-07|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects|An Open-Label, Single Center Study to Assess the Pharmacokinetics of Pioglitazone in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily|Completed||Phase 1|15|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 22:48:57.901764|2018-05-31 22:48:57.901764
NCT01309841|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-10-13||2015-05-29|2011-03-04|2011-03-07|Estimate|2015-05-29|2015-06-01|Estimate||||2015-05-29|2015-06-01|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||A total of 11 patients (4 patients each in the NKTR-118 25 mg and 12.5 mg groups and 3 patients in the placebo group) had been previously randomized within the NKTR-118 program at a different study center. These patients were excluded from the ITT and Safety analysis sets. Baseline characteristics are summarized based on the ITT analysis set.|Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)|Completed||Phase 3|652|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:48:58.094649|2018-05-31 22:48:58.094649
NCT01309828|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2013-09-28||2013-09-28|2011-03-04|2011-03-07|Estimate|2013-09-28|2013-12-13|Estimate||||2013-09-28|2013-12-13|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease|A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate Renal Impairment|Completed||Phase 3|153|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:48:59.359737|2018-05-31 22:48:59.359737
NCT01309815|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2013-01-25|2011-03-04|2011-03-07|Estimate|||||||2013-01-25|2013-01-28|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Existential Issues in Elderly People With Cancer|Existential Issues in Elderly People With Cancer in an Early Palliative Phase- a Phenomenological Hermeneutic Approach|Completed|||21|Actual|Sykehuset Innlandet HF|||1||f||||t||||||||||2018-05-31 22:49:00.271376|2018-05-31 22:49:00.271376
NCT01309802|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2016-07-28||2017-04-26|2011-03-04|2011-03-07|Estimate|2017-04-26|2017-06-02|Actual||||2017-04-26|2017-06-02|Actual|May 2011||2011-05-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|March 2015|Actual|2015-03-31||Interventional|||A Two-Part Study of BOTOX® Therapy for Ischemic Digits|A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits|Active, not recruiting||Phase 2|48|Actual|Southern Illinois University||2|||f||||t||||||||No|We will not be sharing data.|2018-05-31 22:49:00.326736|2018-05-31 22:49:00.326736
NCT01309789|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2017-06-27|2011-03-04|2011-03-07|Estimate|||||||2017-06-27|2017-06-28|Actual|February 2011||2011-02-28|June 2017|2017-06-30|February 28, 2017|Actual|2017-02-28|April 2013|Actual|2013-04-30||Interventional|||A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms|A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma|Completed||Phase 1|39|Actual|Seattle Genetics, Inc.||3|||t||||f||||||||||2018-05-31 22:49:00.97212|2018-05-31 22:49:00.97212
NCT01309776|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-01-24|2011-03-04|2011-03-07|Estimate|||||||2013-01-24|2013-01-25|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|CAMPION||Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder|Comparison of Tianeptine Versus Escitalopram for the Treatment of Depression and Cognitive Impairment in Patients With Major Depressive Disorder: A Randomized, Multicenter, Open-label Study|Completed||Phase 4|164|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 22:49:01.158683|2018-05-31 22:49:01.158683
NCT01309763|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-12-19|2011-03-04|2011-03-07|Estimate|||||||2011-12-19|2011-12-20|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|MimoVax||Safety and Tolerability of AFFITOPE AD03|A Randomized, Controlled, Parallel Group, Patient-blinded, Single-center, Phase I Pilot Study to Assess the Tolerability and Safety of Repeated Administrations of a Single-dose of AFFITOPE AD03 to Alzheimer's Disease Patients|Completed||Phase 1|28|Actual|Affiris AG||2|||f||||t||||||||||2018-05-31 22:49:01.267975|2018-05-31 22:49:01.267975
NCT01309750|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2017-01-23|2011-03-03|2011-03-07|Estimate|||||||2017-01-23|2017-01-25|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Small Bowel Transit Time in Clostridium Difficile Colitis|Small Bowel Transit Time in Clostridium Difficile Colitis|Terminated|||1|Actual|William Beaumont Hospitals|||1|logistics|f||||t||||||||||2018-05-31 22:49:01.435084|2018-05-31 22:49:01.435084
NCT01309737|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2014-07-24|2014-02-03|2014-09-18|2011-03-04|2011-03-07|Estimate|2014-09-18|2014-09-19|Estimate|2014-02-03|2014-03-06|Estimate|2014-09-18|2014-09-19|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Safety analysis set consisted of all participants who received at least 1 dose of the investigational drug (CP-690,550 or placebo).|A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis|Completed||Phase 3|960|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:49:01.674775|2018-05-31 22:49:01.674775
NCT01309724|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-03|2011-03-03|2011-03-07|Estimate|||||||2011-03-03|2011-03-07|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Hemodynamic Optimization By Non-Invasive Determination Of Cardiac Output In Critically Ill Patients|HEMODYNAMIC OPTIMIZATION BY NON-INVASIVE DETERMINATION OF CARDIAC OUTPUT IN CRITICALLY ILL PATIENTS: A RANDOMIZED, CONTROLLED TRIAL|Completed||N/A|92|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 22:49:06.813276|2018-05-31 22:49:06.813276
NCT01309711|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2018-01-10|2011-03-04|2011-03-07|Estimate|||||||2018-01-10|2018-01-12|Actual|March 30, 2011|Actual|2011-03-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|August 13, 2017|Actual|2017-08-13||Observational|MARBLE||Magnetic Resonance Biomarkers in Neonatal Encephalopathy|A Multicentre Prospective Study on Magnetic Resonance Biomarkers in Neonatal Encephalopathy|Completed|||180|Anticipated|Thayyil, Sudhin|||1||f||||f||||||Samples With DNA|"~     Blood and urine~   "|||2018-05-31 22:49:06.906088|2018-05-31 22:49:06.906088
NCT01309698|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2016-11-16|2011-03-04|2011-03-07|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2011||2011-02-28|November 2016|2016-11-30||||April 2011|Actual|2011-04-30||Interventional|||Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes|An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes|Completed||Phase 4|24|Actual|Novartis||6|||f||||||||||||||2018-05-31 22:49:06.974998|2018-05-31 22:49:06.974998
NCT01309685|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2017-10-05|2011-03-04|2011-03-07|Estimate|||||||2017-10-05|2017-10-06|Actual|February 13, 2011||2011-02-13|November 26, 2012|2012-11-26|November 26, 2014|Actual|2014-11-26|November 26, 2014|Actual|2014-11-26||Interventional|||Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment|Effect of Varenicline on a Laboratory Model of Tobacco Addiction and on Withdrawal-Induced Cognitive Impairment|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:49:07.086798|2018-05-31 22:49:07.086798
NCT01309672|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2017-03-23||2017-05-04|2011-03-04|2011-03-07|Estimate|2017-03-23|2017-05-05|Actual||||2017-05-04|2017-06-02|Actual|August 9, 2011||2011-08-09|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|November 29, 2016|Actual|2016-11-29||Interventional||One patient is excluded due to patient not receiving any protocol treatment.|S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy|Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy Phase II|Active, not recruiting||Phase 2|41|Actual|Southwest Oncology Group||1|||f||||t|t|f||||||Yes|http://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-05-31 22:49:08.125749|2018-05-31 22:49:08.125749
NCT01309659|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2014-07-30||2016-01-07|2011-03-04|2011-03-07|Estimate|2014-09-05|2014-09-08|Estimate||||2016-01-07|2016-02-05|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|February 2013|Actual|2013-02-28||Interventional|||Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia|A Randomized, Open-Label, Wait-list Control Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia and a Serum Ferritin Between 20 and 200 ng/mL|Terminated||Phase 2|19|Actual|Duke University|Small sample size.|2||Lack of Enrollment|f||||t||||||||||2018-05-31 22:49:09.047556|2018-05-31 22:49:09.047556
NCT01309646|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2013-02-21||2017-01-23|2011-03-03|2011-03-07|Estimate|2013-02-21|2013-04-02|Estimate||||2017-01-23|2017-03-06|Actual|March 2011||2011-03-31|January 2017|2017-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine|Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix™-IPV+Hib) Vaccine in Healthy Korean Infants|Completed||Phase 3|454|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:49:10.122575|2018-05-31 22:49:10.122575
NCT01309633|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2016-06-21|2011-03-04|2011-03-07|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)|Phase II Open-label Study Evaluating Two Loading Regimens of Sunitinib Alternating With Cisplatin and Gemcitabine as Systemic Therapy for Locally Advanced or Metastatic Nasopharyngeal Carcinoma|Recruiting||Phase 2|30|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 22:49:10.723596|2018-05-31 22:49:10.723596
NCT01309620|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-03|2011-03-03|2011-03-07|Estimate|||||||2011-03-03|2011-03-07|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Zinc Supplementation in Type 2 Diabetics|Does Zinc Supplementation Reduce the Extent of Oxidative Stress Damage in Diabetics? A Randomised Placebo-controlled Study.|Completed||Phase 2/Phase 3|40|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 22:49:10.866439|2018-05-31 22:49:10.866439
NCT01309607|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-10-13|2011-03-04|2011-03-07|Estimate|||||||2014-10-13|2014-10-15|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer|Phase II Open-Label Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer|Unknown status|Active, not recruiting|Phase 2|34|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 22:49:10.933391|2018-05-31 22:49:10.933391
NCT01309594|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-09-24|2011-03-03|2011-03-07|Estimate|||||||2014-09-24|2014-09-25|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|HIV-ABMi||HIV Liver Regeneration Project for HIV Patients With Cirrhosis by Autologous Bone Marrow Transplantation|A Safety and Efficacy Study of Autologous Bone Marrow Cell Infusion Therapy in HIV Infected Patients With Advanced Liver Cirrhosis|Unknown status|Enrolling by invitation|N/A|10|Anticipated|National Center for Global Health and Medicine, Japan||1|||f||||t||||||||||2018-05-31 22:49:10.998011|2018-05-31 22:49:10.998011
NCT01309581|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2012-11-07||2013-07-29|2011-03-04|2011-03-07|Estimate|2013-07-29|2013-08-30|Estimate||||2013-07-29|2013-08-30|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression|Ketamine Anesthesia to Enhance Efficacy and Tolerability of Electroconvulsive Therapy in Patients With Unipolar or Bipolar Depression|Terminated||N/A|3|Actual|Icahn School of Medicine at Mount Sinai|Early termination, limited enrollment, data analysis not done due to technical problems with measurement leading to unreliable and uninterpretable data.|2||limited enrollment|f||||t||||||||||2018-05-31 22:49:11.063602|2018-05-31 22:49:11.063602
NCT01309568|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-05-10|2011-03-03|2011-03-07|Estimate|||||||2011-05-10|2011-05-12|Estimate|February 2011||2011-02-28|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"|"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"|Completed|||2500|Actual|Quidel Corporation|||1||f||||f||||||Samples Without DNA|"~     Leftover nasal mucus placed in viral transport media will be retained after culture for~     possible RT-PCR.~   "|||2018-05-31 22:49:11.242983|2018-05-31 22:49:11.242983
NCT01309555|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2017-12-22|2011-03-03|2011-03-07|Estimate|||||||2017-12-22|2017-12-26|Actual|April 30, 2011|Actual|2011-04-30|December 2017|2017-12-31|October 31, 2016|Actual|2016-10-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS AUS||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Australia|Easypod Connect: An Australian Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|Completed|||33|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:49:11.4069|2018-05-31 22:49:11.4069
NCT01309542|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-04-22|2011-03-03|2011-03-07|Estimate|||||||2011-04-22|2011-04-26|Estimate|August 2003||2003-08-31|April 2011|2011-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder|A 10 Month Open-Label Evaluation Of The Long-Term Safety Of DVS-233 SR In Outpatients With Major Depressive Disorder.|Completed||Phase 3|1403|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:49:11.507947|2018-05-31 22:49:11.507947
NCT01309529|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2011-03-04|2011-03-04|2011-03-07|Estimate|||||||2011-03-04|2011-03-07|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|August 2011|Anticipated|2011-08-31||Observational|||Day Zero Urinary Catheter Removal in Gen Thoracic Surgery Patients|Day Zero Urinary Catheter Removal in General Thoracic Surgery Patients Receiving Thoracic Epidural Analgesia: Recatheterization Rates and Urinary Tract Infection Occurrences|Unknown status|Recruiting||45|Anticipated|Memorial Health System|||1||f||||f||||||||||2018-05-31 22:49:11.734041|2018-05-31 22:49:11.734041
NCT01309516|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-22|||2015-09-19|2011-03-04|2011-03-07|Estimate|||||||2015-09-19|2015-09-22|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Randomised Control Trial of a Complex Intervention for Postnatal Depression|Efficacy of Learning Through Play Plus Intervention to Reduce Maternal Depression for Women With Under-nourished Children: A Randomized Controlled Trial From Pakistan|Completed||Phase 2|107|Actual|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-05-31 22:49:11.804488|2018-05-31 22:49:11.804488
NCT01309503|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-03-28|2011-03-03|2011-03-07|Estimate|||||||2011-03-28|2011-03-29|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Observational|||Speech Intelligibility in Noise Using the Hearing in Noise Test (HINT)|Speech Intelligibility in Noise and Estimation of Binaural Benefits Using the Hearing in Noise Test (HINT). Studies on Normal Hearing Children and Adults, Groups of Hearing Aid Users and Cochlea Implant Users.|Unknown status|Recruiting||600|Anticipated|Oslo University Hospital|||5||f||||f||||||||||2018-05-31 22:49:11.887945|2018-05-31 22:49:11.887945
NCT01309490|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2011-03-04|2011-03-04|2011-03-07|Estimate|||||||2011-03-04|2011-03-07|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|||Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients|An Open-label, Dose Escalation Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Expressing Elevated eIF4E|Unknown status|Recruiting|Phase 1/Phase 2|37|Anticipated|Jewish General Hospital||1|||f||||f||||||||||2018-05-31 22:49:11.950385|2018-05-31 22:49:11.950385
NCT01309477|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-11-01|2011-03-04|2011-03-07|Estimate|||||||2011-11-01|2011-11-02|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)||Completed||Phase 3|20|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 22:49:12.074491|2018-05-31 22:49:12.074491
NCT01309451|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2013-11-05||2014-10-28|2011-03-04|2011-03-07|Estimate|2014-10-28|2014-10-29|Estimate||||2014-10-28|2014-10-29|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||"The unit of eyes is used to described the number of participants since some subjects had both eyes in the study and it is not feasible to separate those into their own group."|Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema|A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema|Completed||Phase 4|40|Actual|Maturi, Raj K., M.D., P.C.||2|||f||||f||||||||||2018-05-31 22:49:12.158959|2018-05-31 22:49:12.158959
NCT01309438|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-10-07|2011-03-03|2011-03-07|Estimate|||||||2014-10-07|2014-10-08|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function|An Open-Label Study to Estimate the Effect of Multiple Doses of Erythromycin on the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With Renal Impairment and Normal Renal Function|Completed||Phase 1|29|Actual|Janssen Research & Development, LLC||3|||f||||||||||||||2018-05-31 22:49:12.525272|2018-05-31 22:49:12.525272
NCT01309425|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-01-30|2011-03-03|2011-03-07|Estimate|||||||2014-01-30|2014-01-31|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|May 2011|Actual|2011-05-31|||||Interventional|||A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers|A Single-Dose, Open-Label, Randomized, Four-Way Crossover Study to Assess the Dose-Proportionality of the Pharmacokinetics of Tapentadol, Given as Tamper-Resistant Tablets, in Healthy Japanese and Korean Male Subjects|Completed||Phase 1|52|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-05-31 22:49:12.621992|2018-05-31 22:49:12.621992
NCT01309412|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-05-16|2011-03-04|2011-03-07|Estimate|||||||2014-05-16|2014-05-19|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma|A Phase 1 Study of CNTO 328 (Siltuximab) in Combination With Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1|9|Actual|Janssen Pharmaceutical K.K.||1||Protocol was stopped due to the safety issue in Global|f||||t||||||||||2018-05-31 22:49:12.680037|2018-05-31 22:49:12.680037
NCT01309399|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2016-11-22|2011-03-04|2011-03-07|Estimate|||||||2016-11-22|2016-11-23|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|November 2014|Actual|2014-11-30||Interventional|||Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur|Early Effects of PTH on the Proximal Femur|Completed||N/A|40|Actual|Health Research, Inc.||2|||f||||t||||||||||2018-05-31 22:49:12.751185|2018-05-31 22:49:12.751185
NCT01309386|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2013-02-08||2013-02-08|2011-03-03|2011-03-07|Estimate|2013-02-08|2013-03-13|Estimate||||2013-02-08|2013-03-13|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants|A Randomized, Open-Label, Parallel-Arm, Optimal Dose-Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended-Release (ER) in Japanese Subjects Treated With Around-the-Clock Opioid Analgesics for Their Moderate to Severe Chronic Malignant Tumor- Related Cancer Pain|Completed||Phase 3|100|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 22:49:12.847548|2018-05-31 22:49:12.847548
NCT01309373|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2012-02-13|2011-03-03|2011-03-07|Estimate|||||||2012-02-13|2012-02-14|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|August 2011|Actual|2011-08-31|||||Observational|||An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia|Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (REINTEGRA Study)|Completed|||1809|Actual|Janssen-Cilag, S.A.|||1||f||||f||||||||||2018-05-31 22:49:13.534152|2018-05-31 22:49:13.534152
NCT01309360|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2011-05-04||2011-07-06|2011-03-04|2011-03-07|Estimate|2011-05-31|2011-06-27|Estimate||||2011-07-06|2011-07-12|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Ultrasound-guided Axillary Plexus Block - Dose Reduction of Prilocaine|Ultrasound-guided Block of the Brachial Plexus Using Prilocaine: Effects of Local-anesthetic Dose Reduction on Parameters of Block Quality and Adverse Effects in Outpatients|Completed||Phase 4|120|Actual|Helios Research Center||3|||f||||f||||||||||2018-05-31 22:49:13.61639|2018-05-31 22:49:13.61639
NCT01309347|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2012-03-01|2011-03-04|2011-03-07|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Evaluation of the Development of an Advanced, Conformable Prosthetic Socket, Study I||Completed|||6|Actual|Infoscitex Corporation|||||f||||f||||||||||2018-05-31 22:49:13.976053|2018-05-31 22:49:13.976053
NCT01309334|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2014-08-22|2011-03-04|2011-03-07|Estimate|||||||2014-08-22|2014-08-25|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|IMAJEM||Imaging Young Myeloma (IMAgerie JEune Myélome)|Pharmacoeconomic and Clinical Prospective Comparison of PET-scan and MRI in Patients With de Novo Multiple Myeloma Less Than 65 Years of Age Treated According to IFM/DFCI 2009 Clinical Trial.|Completed||Phase 3|152|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 22:49:14.032951|2018-05-31 22:49:14.032951
NCT01309321|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2014-03-12|2011-03-03|2011-03-07|Estimate|||||||2014-03-12|2014-03-13|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Perinatal Handwashing Intervention in Bangladesh|Development and Evaluation of Perinatal Handwashing Promotion for Improved Maternal Handwashing Behavior|Completed||N/A|400|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 22:49:14.111469|2018-05-31 22:49:14.111469
NCT01309308|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|2011-03-18||2011-10-03|2011-03-04|2011-03-07|Estimate|2011-08-26|2011-10-03|Estimate||||2011-10-03|2011-10-07|Estimate|February 2011||2011-02-28|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Sweeping the Membranes, Cervical Length and Duration of Labor|The Impact of Sweeping the Membranes on Cervical Length and Labor: A Randomized Clinical Trial|Completed||N/A|150|Actual|Baskent University|Patients who did not attend the second examination, patients who did not deliver in our clinic are excluded|2|||f||||f||||||||||2018-05-31 22:49:14.205067|2018-05-31 22:49:14.205067
NCT01309295|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2016-11-01|2011-03-04|2011-03-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis|A Prospective Study Evaluating the Efficacy and Safety of Mircera in Patients With CKD in Predialysis and Dialysis.|Completed|||250|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:49:14.432225|2018-05-31 22:49:14.432225
NCT01309282|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2016-02-12||2016-08-10|2011-03-04|2011-03-07|Estimate|2016-03-29|2016-04-21|Estimate||||2016-08-10|2016-08-12|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational||Safety population included all participants who received at least one dose of study drug, whether prematurely withdrawn from the study or not and who complied with the criteria for inclusion.|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)|Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor|Completed|||9|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:49:14.510789|2018-05-31 22:49:14.510789
NCT01309269|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2015-09-02||2016-11-01|2011-03-04|2011-03-07|Estimate|2015-10-01|2015-10-29|Estimate||||2016-11-01|2016-11-02|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational||Safety Analysis Set: all participants who received at least 1 dose of methoxy polyethylene glycol-epoetin beta during the study course.|Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine|Non-interventional Study to Investigate the Long Term Effects of MIRCERA in Clinical Routine|Completed|||1083|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:49:14.830264|2018-05-31 22:49:14.830264
NCT01309256|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2013-06-01|2011-03-04|2011-03-07|Estimate|||||||2013-06-01|2013-06-04|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Multi-institutional Study on the Assessment of Robotic Surgery for Gastric Cancer||Completed|||1650|Actual|Yonsei University|||3||f||||t||||||||||2018-05-31 22:49:15.774741|2018-05-31 22:49:15.774741
NCT01309243|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2013-09-25||2015-02-03|2011-03-03|2011-03-07|Estimate|2013-09-25|2013-11-27|Estimate||||2015-02-03|2015-02-25|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|February 2014|Actual|2014-02-28|September 2012|Actual|2012-09-30||Interventional||Participants in the Safety Analysis Set (randomized and received at least 1 dose of study drug) were analyzed for baseline characteristics.|Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Completed||Phase 3|799|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 22:49:15.922996|2018-05-31 22:49:15.922996
NCT01309230|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2017-07-28|2011-03-04|2011-03-07|Estimate|||||||2017-07-28|2017-08-01|Actual|February 2011||2011-02-28|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FANG Ovarian||Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer|Open Label Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer|Active, not recruiting||Phase 2|44|Actual|Gradalis, Inc.||1|||f||||t||||||||||2018-05-31 22:49:16.940564|2018-05-31 22:49:16.940564
NCT01309217|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2014-11-17|2011-03-04|2011-03-07|Estimate|||||||2014-11-17|2014-11-18|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Dissemination of Tobacco Tactics for Hospitalized Smokers|Dissemination of Tobacco Tactics Versus 1-800-QUIT-NOW for Hospitalized Smokers|Completed||Phase 4|1528|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 22:49:17.009352|2018-05-31 22:49:17.009352
NCT01309048|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-08-28|2011-03-03|2011-03-04|Estimate|||||||2012-08-28|2012-08-29|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - A Pilot Study|Completed||Phase 1/Phase 2|10|Actual|Philips Healthcare||1|||f||||f||||||||||2018-05-31 22:49:18.587281|2018-05-31 22:49:18.587281
NCT01309204|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2014-01-24||2014-03-07|2011-03-03|2011-03-07|Estimate|2014-03-07|2014-04-07|Estimate||||2014-03-07|2014-04-07|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||This reporting group includes all subjects who received study medication, as treated.|Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension|Efficacy and Safety of Brinzolamide 10 mg/mL/Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|1184|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:49:17.17929|2018-05-31 22:49:17.17929
NCT01309191|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2014-02-25|2011-03-04|2011-03-07|Estimate|||||||2014-02-25|2014-02-27|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Microarray Analysis of Scalp Biopsies After Minoxidil Treatment|Microarray Analysis of Scalp Biopsies in Subjects With Androgenetic Alopecia Before and After the Use of Topical Minoxidil|Completed||N/A|14|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 22:49:17.435451|2018-05-31 22:49:17.435451
NCT01309178|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2011-03-04|2011-03-04|2011-03-07|Estimate|||||||2011-03-04|2011-03-07|Estimate|May 2009||2009-05-31|March 2009|2009-03-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|APA-IIb||Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo|Anti-inflammatory Pulmonal Therapy of CF Patients With Amitriptyline and Placebo - a Randomised, Double-blind, Placebo-controlled, Multicenter, Cohort - Study|Unknown status|Recruiting|Phase 2|30|Anticipated|University Children’s Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 22:49:17.536542|2018-05-31 22:49:17.536542
NCT01309165|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2014-02-11|2011-03-04|2011-03-07|Estimate|||||||2014-02-11|2014-02-13|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Exploring the Efficacy of Combined Task-Specific and Cognitive Strategy Training in Subacute Stroke|Exploring the Efficacy of Combined Task-Specific and Cognitive Strategy Training in Subacute Stroke: A Phase II Clinical Trial.|Completed||Phase 2|35|Actual|St. John's Rehab Hospital||2|||f||||f||||||||||2018-05-31 22:49:17.631543|2018-05-31 22:49:17.631543
NCT01309152|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2013-01-02|2011-03-04|2011-03-07|Estimate|||||||2013-01-02|2013-01-03|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Observational|MICK||Cefazolin Subcutaneous Microdialysis in Morbidly Obese Patients|Peri-and Postoperative Subcutaneous Adipose Tissue Cefazolin Determination Using Microdialysis in Morbidly Obese and Non-obese Patients|Completed|||16|Actual|St. Antonius Hospital|||||f||||f||||||Samples With DNA|"~     serum and microdialysis filtrate of subcutenous tissue~   "|||2018-05-31 22:49:17.708347|2018-05-31 22:49:17.708347
NCT01309139|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2013-10-31|2011-03-03|2011-03-04|Estimate|||||||2013-10-31|2013-11-01|Estimate|March 2011||2011-03-31|October 2013|2013-10-31||||June 2011|Actual|2011-06-30||Interventional|||Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers|An Open Label, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Via Respimat® B Versus the Combination of the Monoproducts of Tiotropium Via Respimat® A and BI 54903 Via Respimat® B in Healthy Volunteers|Completed||Phase 1|36|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 22:49:17.78717|2018-05-31 22:49:17.78717
NCT01309126|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2017-07-11|2011-03-03|2011-03-04|Estimate|||||||2017-07-11|2017-07-13|Actual|April 2011||2011-04-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|PRIMUS||Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer|A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination With Cetuximab (Erbitux®) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer|Terminated||Phase 3|217|Actual|Biothera||2||"Due to enrollment challenges resulting from changing treatment patterns in the use of~   cetuximab, the study has been terminated. No patients remain on study."|f||||t||||||||||2018-05-31 22:49:17.898968|2018-05-31 22:49:17.898968
NCT01309113|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2013-07-08|2011-03-03|2011-03-04|Estimate|||||||2013-07-08|2013-07-09|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|January 2012|Actual|2012-01-31||Interventional|||Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome|Double-blind Comparison of VAC BNO 1095 Film Coated Tablets With Placebo to Identify Dose Dependent Effects in Patients Suffering From Cyclic Mastodynia and Premenstrual Syndrome|Completed||Phase 3|191|Actual|Bionorica SE||3|||f||||||||||||||2018-05-31 22:49:18.117967|2018-05-31 22:49:18.117967
NCT01309100|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2014-03-27||2014-03-27|2011-03-03|2011-03-04|Estimate|2014-03-27|2014-04-29|Estimate||||2014-03-27|2014-04-29|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional||All randomized participants|Product Feasibility of a New Silicone Hydrogel Contact Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens|Completed||N/A|144|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-05-31 22:49:18.200639|2018-05-31 22:49:18.200639
NCT01309087|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-03-24|2011-03-03|2011-03-04|Estimate|||||||2014-03-24|2014-03-26|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|AEGIS||Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA|Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA|Completed|||756|Actual|Allegro Diagnostics, Corp.|||||f||||f||||||Samples With DNA|"~     Cells, Blood~   "|||2018-05-31 22:49:18.377703|2018-05-31 22:49:18.377703
NCT01309074|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-12-06|2011-03-03|2011-03-04|Estimate|||||||2012-12-06|2012-12-07|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline|Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline|Terminated||Phase 4|2|Actual|Rush University Medical Center||2||"Only two subjects were enrolled and completed the trial and enrollment of additional subjects~   was too slow. Accordingly, it was decided to terminate the study."|f||||f||||||||||2018-05-31 22:49:18.455119|2018-05-31 22:49:18.455119
NCT01309061|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-03-24|2011-03-03|2011-03-04|Estimate|||||||2014-03-24|2014-03-26|Estimate|March 2008||2008-03-31|March 2014|2014-03-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||The Effect of Human Adipose Tissue-derived MSCs in Romberg's Disease|Preliminary Investigation of the Effect of Human Adipose Tissue-derived Mesenchymal Stem Cell in Progressive Hemifacial Atrophy(Romberg's Disease)|Completed||Phase 2|5|Actual|Biostar|||||f||||f||||||||||2018-05-31 22:49:18.523521|2018-05-31 22:49:18.523521
NCT01305928|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2016-04-23|2011-02-25|2011-03-01|Estimate|||||||2016-04-23|2016-04-26|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|January 2016|Actual|2016-01-31|April 2014|Actual|2014-04-30||Interventional|||Hospitalized Smokers|Increasing Post-Discharged Follow-Up Among Hospitalized Smokers|Completed||N/A|1054|Actual|University of Kansas Medical Center||2|||f||||f||||||||Yes||2018-05-31 22:50:02.184738|2018-05-31 22:50:02.184738
NCT01309035|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2015-01-29|2011-03-02|2011-03-04|Estimate|||||||2015-01-29|2015-01-30|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Total Knee Arthroplasty - Accelerated Recovery Without Tourniquet|Total Knee Arthroplasty - Accelerated Recovery Without Tourniquet|Completed||N/A|70|Actual|Northern Orthopaedic Division, Denmark||2|||f||||t||||||||||2018-05-31 22:49:18.659161|2018-05-31 22:49:18.659161
NCT01309022|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2016-02-05|2011-03-02|2011-03-04|Estimate|||||||2016-02-05|2016-02-09|Estimate||||February 2016|2016-02-29||||||||Expanded Access|||Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)|Immunosuppressive Medications for Previous Participants in Clinical Trial NIS01 (ITN005CT, NCT00014911)|No longer available|||||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-05-31 22:49:18.71131|2018-05-31 22:49:18.71131
NCT01309009|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-11-05|2011-03-02|2011-03-04|Estimate|||||||2012-11-05|2012-11-06|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|November 2012|Actual|2012-11-30||Interventional|nocry-a||Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional Treatment|Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Efficacy and Safety of Oral Administration of Nepadutant in Infant Colic Babies Not Responder to Conventional Treatments|Withdrawn||Phase 2|0|Actual|Menarini Group||3|||f||||f||||||||||2018-05-31 22:49:18.773603|2018-05-31 22:49:18.773603
NCT01308996|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2015-03-12|2011-03-03|2011-03-04|Estimate|||||||2015-03-12|2015-03-13|Estimate|April 2012||2012-04-30|August 2012|2012-08-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation|A Prospective, Open Label, Randomized, Multicenter, Controlled Clinical Study of INFUSE® Bone Graft Used as an Alternative to Autogenous Bone Graft for Vertical Alveolar Ridge Augmentation|Withdrawn||Phase 3|0|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-05-31 22:49:18.850523|2018-05-31 22:49:18.850523
NCT01308983|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-10-22|2011-03-03|2011-03-04|Estimate|||||||2012-10-22|2012-10-23|Estimate|September 2010||2010-09-30|October 2012|2012-10-31||||December 2012|Anticipated|2012-12-31||Interventional|SAPHA||Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension||Unknown status|Recruiting|Phase 4|32|Anticipated|Augusta University||1|||f||||t||||||||||2018-05-31 22:49:18.913822|2018-05-31 22:49:18.913822
NCT01308970|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-11-12|2011-03-02|2011-03-04|Estimate|||||||2015-11-12|2015-11-13|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Quantification of Outcome Measures for Mind-body Interventions|Quantification of Outcome Measures for Mind-body Interventions|Completed||N/A|455|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 22:49:18.977054|2018-05-31 22:49:18.977054
NCT01308957|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2014-12-08|2011-03-02|2011-03-04|Estimate|||||||2014-12-08|2014-12-10|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Fish Oil and Muscle Function|Omega-3 Fatty Acids, Muscle Mass and Muscle Function|Completed||N/A|77|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 22:49:19.036292|2018-05-31 22:49:19.036292
NCT01308944|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-01-11|2011-03-02|2011-03-04|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|||Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients|Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients|Completed||Phase 1|24|Actual|Washington University School of Medicine||1|||f||||t||||||||No||2018-05-31 22:49:19.09208|2018-05-31 22:49:19.09208
NCT01308931|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-08-04|2011-03-03|2011-03-04|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels|The Effect of Tubal Ligation, Essure Placement, AND Levonorgestrel Intrauterine Device on Serum Anti-Mullerian Hormone Rates Over Time|Withdrawn|||0|Actual|Maricopa Integrated Health System|||3||f||||f||||||||||2018-05-31 22:49:19.180362|2018-05-31 22:49:19.180362
NCT01308918|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2011-06-22||2012-02-21|2011-03-02|2011-03-04|Estimate|2012-02-21|2012-03-26|Estimate||||2012-02-21|2012-03-26|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||The New GlideRite DLT Stylet®: An Observational Study|The New GlideRite DLT Stylet®: An Observational Study|Completed|||50|Actual|Laval University|||1||f||||f||||||||||2018-05-31 22:49:19.247259|2018-05-31 22:49:19.247259
NCT01308905|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-04-04|2011-03-03|2011-03-04|Estimate|||||||2017-04-04|2017-04-06|Actual|February 2011||2011-02-28|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)|Pilot Study to Determine the Utility of [18F] 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography in Monitoring Patient Response to Chemotherapy in Neuroblastoma|Recruiting||N/A|50|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 22:49:19.396792|2018-05-31 22:49:19.396792
NCT01308892|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-06-16|2011-03-03|2011-03-04|Estimate|||||||2011-06-16|2011-06-17|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CHOC||Cardiovascular Health Effects of Flavanol Rich Chocolate|Cardiovascular Health Effects of Flavanol Rich Chocolate|Completed||N/A|44|Anticipated|Wageningen University||2|||f||||f||||||||||2018-05-31 22:49:19.461539|2018-05-31 22:49:19.461539
NCT01308879|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-03|2011-03-03|2011-03-04|Estimate|||||||2011-03-03|2011-03-04|Estimate|May 2004||2004-05-31|March 2011|2011-03-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Effects of Routine Feedback to Clinicians on Youth Mental Health Outcomes: A Randomized Cluster Design|Effects of Routine Feedback to Clinicians on Youth Mental Health Outcomes: A Randomized Cluster Design|Completed||N/A|356|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 22:49:19.51704|2018-05-31 22:49:19.51704
NCT01308866|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-02|2011-03-02|2011-03-04|Estimate|||||||2011-03-02|2011-03-04|Estimate|July 2007||2007-07-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|PLEGATS||Effectiveness of a Shared Decision Aid Tool for Cardiovascular Risk Prevention in Hypercholesterolemic Patients|Effectiveness of a Shared Decision Aid Tool for Cardiovascular Risk Prevention in Hypercholesterolemic Patients|Completed||N/A|298|Actual|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 22:49:20.52415|2018-05-31 22:49:20.52415
NCT01308853|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-05-31|2011-03-03|2011-03-04|Estimate|||||||2012-05-31|2012-06-01|Estimate|March 2007||2007-03-31|February 2011|2011-02-28|May 2010|Actual|2010-05-31|February 2008|Actual|2008-02-29||Interventional|COBRA||NASHA BE for Enhancement of the Shape and Fullness of the Female Breast|An Open, Multi-center Study Evaluating Treatment Procedure, Efficacy and Safety of NASHA BE for Enhancement of the Shape and Fullness of Teh Female Breast|Completed||Phase 3|24|Actual|Q-Med AB|||||f||||f||||||||||2018-05-31 22:49:20.586972|2018-05-31 22:49:20.586972
NCT01308840|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2016-05-11||2016-07-07|2011-03-03|2011-03-04|Estimate|2016-07-07|2016-08-17|Estimate||||2016-07-07|2016-08-17|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|UGIH09067||Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer|Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer|Completed||Phase 2|31|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 22:49:20.648113|2018-05-31 22:49:20.648113
NCT01308827|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2014-03-24|2011-03-02|2011-03-04|Estimate|||||||2014-03-24|2014-03-26|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Costa Rica Epidemiological Study on S. Pneumoniae|Continuation of the Costa Rican Epidemiologic Surveillance for Invasive Pneumococcal Disease After Introduction of the Seven Valent Vaccine Into the Universal Vaccination Program|Suspended|||4000|Anticipated|Instituto de Atención Pediátrica|||1|Study recruitment was suspended due to lack of funding|f||||f|||||||"~     Bacterial isolates~   "|||2018-05-31 22:49:20.844606|2018-05-31 22:49:20.844606
NCT01308814|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2017-04-06||2017-07-19|2011-03-03|2011-03-04|Estimate|2017-07-19|2017-08-22|Actual||||2017-07-19|2017-08-22|Actual|October 2010||2010-10-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PERT|Perimenopausal women.|Perimenopausal Estrogen Replacement Therapy Study|Depression, Estrogen Replacement, and Cardiovascular Health in the Perimenopause|Completed||Phase 2/Phase 3|172|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:49:20.936208|2018-05-31 22:49:20.936208
NCT01308801|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2016-01-15|2011-03-03|2011-03-04|Estimate|||||||2016-01-15|2016-01-18|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|STIMALGI||Repetitive Transcranial Magnetic Stimulation in Fibromyalgia|Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia|Completed||N/A|42|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 22:49:21.351404|2018-05-31 22:49:21.351404
NCT01308788|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2013-09-20||2014-01-23|2011-03-03|2011-03-04|Estimate|2014-01-23|2014-01-27|Estimate||||2014-01-23|2014-01-27|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational||There will be (as shown) differences in the number of subjects based upon the time of analysis due to patient loss, data of insufficient quality at visit, or change in the drug use during period of study (patient switched off treatment by their doctor) so the number of data points varies throughout the analysis by availability.|Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow|Examination of the Effect of Aqueous Suppressant Versus Aqueous Outflow Enhancing Glaucoma Medications on Ocular Perfusion Pressure and Blood Flow: A Mechanistic Study|Completed|||35|Actual|Indiana University|Small number of subjects at final endpoint, participation number various by analysis and date||2||f||||f||||||||||2018-05-31 22:49:21.453969|2018-05-31 22:49:21.453969
NCT01308775|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-03-06|2011-03-02|2011-03-04|Estimate|||||||2015-03-06|2015-03-09|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|CC077515||Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer|A Pilot Study Comparing a Patient-Centered Symptom Reporting Follow Up Program (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer|Completed||N/A|102|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 22:49:21.849515|2018-05-31 22:49:21.849515
NCT01308762|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2011-03-30||2012-11-08|2011-03-02|2011-03-04|Estimate|2012-11-08|2012-12-06|Estimate||||2012-11-08|2012-12-06|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients|An Intra-patient Placebo-controlled, Phase I Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 (Heat-killed Mycobacterium Obuense) in Adult Melanoma Cancer Patients|Completed||Phase 1|19|Actual|Immodulon Therapeutics Ltd||1|||f||||f||||||||||2018-05-31 22:49:21.929502|2018-05-31 22:49:21.929502
NCT01308749|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2017-02-23||2017-06-15|2011-03-03|2011-03-04|Estimate|2017-06-15|2017-07-17|Actual||||2017-06-15|2017-07-17|Actual|March 2011||2011-03-31|June 2017|2017-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Oxytocin|The one participant in the oxytocin group who dropped out after 2 days is not included in the demographics or outcome analyses since no post baseline data other than AEs was obtained. This participant is included in the AE analysis.|A Study of Oxytocin in Children and Adolescents With Autistic Disorder|A Pilot Study of Oxytocin in Children and Adolescents With Autistic Disorder|Completed||Phase 2|25|Actual|University of North Carolina, Chapel Hill|This was a very small study with a very heterogeneous sample. Further the two groups included very different proportions of intellectually disabled non-verbal participants which may influence assessment of benefit.|2|||f||||f||||||||Undecided||2018-05-31 22:49:22.24097|2018-05-31 22:49:22.24097
NCT01308736|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2015-05-18||2017-07-13|2011-03-03|2011-03-04|Estimate|2015-07-22|2015-07-23|Estimate||||2017-07-13|2017-07-17|Actual|January 2011||2011-01-31|July 2017|2017-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit|Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit|Completed||N/A|73|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 22:49:22.843211|2018-05-31 22:49:22.843211
NCT01308723|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2016-11-01|2011-03-02|2011-03-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma|Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination With Sorafenib (Nexavar®), in Patients With Advanced or Metastatic and/or Unresectable Hepatocellular Carcinoma|Completed||Phase 1|6|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:49:23.095641|2018-05-31 22:49:23.095641
NCT01308710|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-01-23|2011-03-03|2011-03-04|Estimate|||||||2014-01-23|2014-01-27|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|EARLYMedit||The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia|Endothelial Assessment of Risk From Lipids in Youth: Mediterranean Diet|Completed||Phase 1|10|Actual|University of California, San Francisco|||||f||||t||||||||||2018-05-31 22:49:23.177125|2018-05-31 22:49:23.177125
NCT01308697|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-05-27|2011-03-03|2011-03-04|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Flail Chest: A Randomized Controlled Study|Operative Versus Non Operative Management of Flail Chest: A Randomized Controlled Feasibility Study|Completed||N/A|14|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:49:23.240663|2018-05-31 22:49:23.240663
NCT01308684|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2016-11-01|2011-03-02|2011-03-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma|Open-label, Combined Dose-finding (Phase I) and Efficacy-finding (Phase II) Study of RO5323441 in Combination With Bevacizumab for Patients With Recurrent Glioblastoma|Completed||Phase 1|22|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:49:23.30684|2018-05-31 22:49:23.30684
NCT01308671|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2015-06-23|2011-03-02|2011-03-04|Estimate|||||||2015-06-23|2015-06-24|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|VACL||Influence of Varenicline on the Antiplatelet Action of Clopidogrel|Influence of Varenicline on the Antiplatelet Action of Clopidogrel : the Randomized, Open-label VACL (Varenicline Clopidogrel) Study|Unknown status|Recruiting|N/A|198|Anticipated|General Hospital of Chinese Armed Police Forces||2|||f||||t||||||||||2018-05-31 22:49:23.378711|2018-05-31 22:49:23.378711
NCT01308658|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2014-02-05|2011-03-03|2011-03-04|Estimate|||||||2014-02-05|2014-02-06|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|May 2011|Actual|2011-05-31|||||Interventional|||TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions|A Phase I, Open-label, Randomized, 2-panel, 2-way Crossover Pivotal Bioequivalence Trial Between the Commercially Available 400-mg Tablet Formulation (F030) and the 800-mg Tablet Formulation of Darunavir (G002), in the Presence of Low-dose Ritonavir Under Fasted and Fed Conditions|Completed||Phase 1|128|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||||||||||||2018-05-31 22:49:23.465063|2018-05-31 22:49:23.465063
NCT01308645|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-06-08|2011-03-03|2011-03-04|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|HCC||Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma (HCC)|PhaseⅡ, Open Label, Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced or Primary Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|SBPharmaceutical IND, Co., LTD|||||f||||t||||||||||2018-05-31 22:49:23.52838|2018-05-31 22:49:23.52838
NCT01308632|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-03-02|2011-03-02|2011-03-04|Estimate|||||||2011-03-02|2011-03-04|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Metronomic Temozolamide in Patients With Recurrent Glioblastoma|PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA|Unknown status|Active, not recruiting|Phase 2/Phase 3|30|Actual|Grupo Español de Investigación en Neurooncología||1|||f||||f||||||||||2018-05-31 22:49:23.597713|2018-05-31 22:49:23.597713
NCT01308619|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2013-11-11||2014-07-08|2011-03-02|2011-03-04|Estimate|2014-07-08|2014-08-05|Estimate||||2014-07-08|2014-08-05|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo|A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules|Completed||Phase 4|170|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-05-31 22:49:23.672872|2018-05-31 22:49:23.672872
NCT01308606|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2012-10-10|2011-03-03|2011-03-04|Estimate|||||||2012-10-10|2012-10-11|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|||||Interventional|||TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study|A Phase I, Open-label, Randomized, Single-dose, 2-panel, Crossover Trial in Healthy Subjects to Assess the Relative Bioavailability of TMC435 HPMC Capsule Compared to the TMC435 Gelatin Capsule and to Assess the Effect of Different Meal Types on the Bioavailability of Both Formulations|Completed||Phase 1|48|Actual|Tibotec Pharmaceuticals, Ireland||5|||f||||||||||||||2018-05-31 22:49:23.908492|2018-05-31 22:49:23.908492
NCT01308593|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-01-03|2011-03-03|2011-03-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Brow Enhancement Study|Investigation Into Brow Aesthetics Using Botox in Conjunction With Juvederm Ultra XC as Evaluated by Patient Satisfaction|Completed||Phase 4|30|Actual|Skin Care and Laser Physicians of Beverly Hills||2|||f||||f||||||||||2018-05-31 22:49:24.055906|2018-05-31 22:49:24.055906
NCT01308580|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2016-08-18||2017-03-16|2011-03-03|2011-03-04|Estimate|2016-08-18|2016-10-11|Estimate||||2017-03-16|2017-04-17|Actual|April 2011||2011-04-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PROSELICA||Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer|Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen|Completed||Phase 3|1200|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 22:49:24.170423|2018-05-31 22:49:24.170423
NCT01308567|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|2016-09-08||2018-04-11|2011-03-03|2011-03-04|Estimate|2017-01-12|2017-03-03|Actual||||2018-04-11|2018-05-14|Actual|May 5, 2011|Actual|2011-05-05|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|September 2015|Actual|2015-09-30||Interventional|FIRSTANA||Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer|Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy|Active, not recruiting||Phase 3|1170|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 22:49:25.61063|2018-05-31 22:49:25.61063
NCT01308554|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-03-25|2011-03-02|2011-03-04|Estimate|||||||2014-03-25|2014-03-26|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pain Relieving Efficacy of TAP Block in Patients After Laparoscopic Gastric Bypass.|Analgesic Efficacy of Ultrasound-guided Single Shot Subcostal Transversus Abdominis Plane (TAP) Block After Laparoscopic Gastric Bypass.|Completed||Phase 4|80|Actual|Funch-Jensen, Peter, M.D., D.M.Sc.||2|||f||||f||||||||||2018-05-31 22:49:27.484429|2018-05-31 22:49:27.484429
NCT01308541|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2015-11-02|2011-03-03|2011-03-04|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion|A Randomized, Open-label, 3 Period Crossover Study to Characterize the Pharmacokinetics and Pharmacodynamics of LUSEDRA (Fospropofol Disodium) Injection Administered Either by Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion|Completed||Phase 1|20|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 22:49:27.549352|2018-05-31 22:49:27.549352
NCT01308528|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-07-18|2011-03-02|2011-03-04|Estimate|||||||2017-07-18|2017-07-19|Actual|February 2015|Actual|2015-02-28|July 2017|2017-07-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Prophylactic Use of Sodium Enoxaparin for Venous Thromboembolism in High-Risk Abdominal Surgery|A Non-Inferiority Study of Enoxaparin Cristalia in Relation With Enoxaparin Sanofi-Aventis for Prophylaxis Against Venous Thromboembolism in Patients With High-Risk to Develop Thromboembolic Disease Undergoing Geral Abdominal Surgery|Completed||Phase 3|243|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||2|||f||||f||||||||||2018-05-31 22:49:27.609801|2018-05-31 22:49:27.609801
NCT01308515|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-06-19|2011-03-02|2011-03-04|Estimate|||||||2017-06-19|2017-06-21|Actual|September 2010||2010-09-30|June 2017|2017-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|VGASPS||Vanguard Knee Anterior Stabilized Versus Posterior Stabilized Bearing Study|A Comparative Clinical Evaluation of the Vanguard Knee System's Anterior Stabilized & Posterior Stabilized Tibial Bearings|Withdrawn||N/A|0|Actual|Zimmer Biomet||2||Could not find interested researchers/clinicians to complete study protocol.|f||||f||||||||||2018-05-31 22:49:27.68275|2018-05-31 22:49:27.68275
NCT01308502|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-03-29|2011-03-02|2011-03-04|Estimate|||||||2012-03-29|2012-03-30|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux|A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux|Withdrawn||Phase 4|0|Actual|Children's Hospital of Philadelphia||1||Difficulty recruiting patients due to logistics|f||||f||||||||||2018-05-31 22:49:27.737375|2018-05-31 22:49:27.737375
NCT01308489|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2015-06-03|2011-03-02|2011-03-04|Estimate|||||||2015-06-03|2015-06-08|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Minimally Invasive Surgery in Treating Patients With Spinal Tumors|Comparison of Minimally Invasive Approaches of Spine Tumor Surgery|Terminated||N/A|7|Actual|City of Hope Medical Center||2||Lack of subject response|f||||t||||||||||2018-05-31 22:49:27.849519|2018-05-31 22:49:27.849519
NCT01308476|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2012-11-20||2013-01-17|2011-03-03|2011-03-04|Estimate|2012-11-20|2012-12-21|Estimate||||2013-01-17|2013-01-18|Estimate|March 2011||2011-03-31|January 2013|2013-01-31||||November 2011|Actual|2011-11-30||Observational|||SMS Reminder to Assess Adherence|Assessment if a Daily SMS (Short Message System) Reminder Improves the Adherence of COPD Patients to Therapy With Spiriva® 18 Microgram|Completed|||95|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 22:49:28.018985|2018-05-31 22:49:28.018985
NCT01308463|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2016-10-13||2017-03-20|2011-03-02|2011-03-04|Estimate|2017-03-20|2017-05-01|Actual||||2017-03-20|2017-05-01|Actual|January 2011||2011-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Discovery Elbow Long-Term Survivorship|Discovery Elbow Long-Term Survivorship Study|Terminated|||29|Actual|Zimmer Biomet|The early termination of this study lead to only a small number of consenting subjects available for analysis.|||Study terminated due to change in sponsorship|f||||f||||||||||2018-05-31 22:49:28.374043|2018-05-31 22:49:28.374043
NCT01308450|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2013-02-04||2013-11-04|2011-03-02|2011-03-04|Estimate|2013-08-26|2013-10-30|Estimate||||2013-11-04|2013-11-27|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|ADHD||Adult Normative Performance of the Quotient ADHD System|Adult Normative Performance on Quotient ADHD System - Adolescent and Adult Version (Ages 15-55 Years Old)|Completed|||300|Actual|BioBehavioral Diagnostics Company|||1||f||||f||||||||||2018-05-31 22:49:28.58313|2018-05-31 22:49:28.58313
NCT01308437|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2013-08-21|2011-03-03|2011-03-04|Estimate|||||||2013-08-21|2013-08-22|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics|An Open Label,Randomized,Comparison of the Immunogenicity and Safety of Wockhardt's Human Insulin Basal Bolus Regimen With the Novo Nordisk's Yeast Based Human Insulin Basal Bolus Regimens, Marketed in United States, in Type 1 Diabetics.|Terminated||Phase 3|134|Actual|Wockhardt||2||Business reasons|f||||f||||||||||2018-05-31 22:49:28.737742|2018-05-31 22:49:28.737742
NCT01308424|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2013-05-22||2013-08-12|2011-03-02|2011-03-04|Estimate|2013-08-12|2013-08-13|Estimate||||2013-08-12|2013-08-13|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional||Subjects randomized into the study.|Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection|A Randomized, Double-blind, Parallel, Placebo-controlled Study for the Assessment of the Safety and Efficacy of BTL-TML-HSV for the Treatment of Recurrent Symptomatic Oral Herpes Virus Infection|Completed||Phase 1/Phase 2|171|Actual|Beech Tree Labs, Inc.||2|||f||||f||||||||||2018-05-31 22:49:28.832785|2018-05-31 22:49:28.832785
NCT01308411|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-01-31|2011-03-03|2011-03-04|Estimate|||||||2014-01-31|2014-02-03|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|March 2012|Actual|2012-03-31||Interventional|PCR||Predicting Steroid Response Using Exhaled Nitric Oxide|Using Exhaled Nitric Oxide to Step Down Inhaled Corticosteroid Therapy in Asthma|Completed||N/A|191|Actual|University of Nottingham||1|||f||||f||||||||||2018-05-31 22:49:29.032859|2018-05-31 22:49:29.032859
NCT01308385|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-08-07|2011-03-03|2011-03-04|Estimate|||||||2014-08-07|2014-08-08|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Prediction and Characterization of Acute and Chronic Postoperative Pain|Prediction and Characterization of Acute and Chronic Postoperative Pain - a Longitudinal Observational Study of the Relationship Between Experimental Pain Modulation and Clinical Postoperative Pain in Patients Undergoing Minimally Invasive Repair of Pectus Excavatum|Completed|||52|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 22:49:29.099594|2018-05-31 22:49:29.099594
NCT01308372|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-11-04|2011-03-02|2011-03-04|Estimate|||||||2011-11-04|2011-11-07|Estimate|October 2011||2011-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week|Cardiovascular Risk in General Practice in France|Completed|||9246|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:49:29.204899|2018-05-31 22:49:29.204899
NCT01308359|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-03-03|2011-03-03|2011-03-04|Estimate|||||||2011-03-03|2011-03-04|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Use of Glucose and Saline for Fetal Movement Perception|Impact of Glucose Administration on Perception of Fetal Movements|Unknown status|Recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 22:49:30.256522|2018-05-31 22:49:30.256522
NCT01308346|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-05-06|2011-03-02|2011-03-04|Estimate|||||||2013-05-06|2013-05-07|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||ABSORB PHYSIOLOGY Clinical Investigation|ABSORB PHYSIOLOGY Clinical Investigation: Clinical Evaluation of the Short and Long-Term Effects of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold on Coronary Artery Blood Flow and Physiological Responsiveness|Terminated||N/A|1|Actual|Abbott Vascular||2||"Due to a challenging protocol inclusion/ exclusion criteria, only one subject was enrolled~   since the trial was initiated in June 2011."|f||||f||||||||||2018-05-31 22:49:30.389821|2018-05-31 22:49:30.389821
NCT01308333|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-01-07|2011-03-03|2011-03-04|Estimate|||||||2014-01-07|2014-01-08|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Investigation of Chronic Inflammatory Processes in Male Individuals With Hypohidrotic Ectodermal Dysplasia|Investigation of Chronic Inflammatory Processes in the Respiratory Tract and the Eyes of Male Individuals With X-linked Hypohidrotic Ectodermal Dysplasia|Completed|||38|Actual|University Hospital Erlangen|||4||f||||||||||Samples Without DNA|"~     tear fluid~   "|||2018-05-31 22:49:30.505712|2018-05-31 22:49:30.505712
NCT01308320|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-03-03|2011-03-03|2011-03-04|Estimate|||||||2011-03-03|2011-03-04|Estimate|February 2010||2010-02-28|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia|Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia|Completed||Phase 4|42|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 22:49:30.56148|2018-05-31 22:49:30.56148
NCT01308307|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-03-07|2011-03-03|2011-03-04|Estimate|||||||2011-03-07|2011-03-08|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|August 2010|Actual|2010-08-31|||||Interventional|||Is Non-cycloplegic Photorefraction Applicable for Screening Refractive Risk Factors of Amblyopia?|Is Non-cycloplegic Photorefraction Applicable for Screening Refractive Risk Factors of Amblyopia?|Completed||Phase 2|185|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||||||||||||2018-05-31 22:49:30.6392|2018-05-31 22:49:30.6392
NCT01308294|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2014-10-14|2011-03-03|2011-03-04|Estimate|||||||2014-10-14|2014-10-15|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|LAG-3/IMP321||Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients|Vaccination of Melanoma Patients (Stage II-IV) With ImmuFact IMP321, Tumor Antigenic Peptides and Montanide|Terminated||Phase 1/Phase 2|16|Actual|Centre Hospitalier Universitaire Vaudois||3||Low enrollment rate|f||||f||||||||||2018-05-31 22:49:30.70775|2018-05-31 22:49:30.70775
NCT01308281|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2016-07-25|2011-03-03|2011-03-04|Estimate|||||||2016-07-25|2016-07-27|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)|Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)|Completed||N/A|1079|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:49:30.818711|2018-05-31 22:49:30.818711
NCT01308268|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2011-03-03|2011-03-03|2011-03-04|Estimate|||||||2011-03-03|2011-03-04|Estimate|December 2010||2010-12-31|February 2011|2011-02-28|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Management of Soil-transmitted Helminthiasis and Strongyloidiasis|Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area|Unknown status|Recruiting|N/A|2000|Anticipated|Universidad Nacional de Salta|||||f||||f||||||||||2018-05-31 22:49:30.885498|2018-05-31 22:49:30.885498
NCT01308255|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2018-05-04|2011-03-03|2011-03-04|Estimate|||||||2018-05-04|2018-05-11|Actual|September 2006||2006-09-30|March 2010|2010-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|IDEA||Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)|A Multi-centre Randomised Double Blind Placebo Controlled Study Comparing Two Regimens of Combination Therapy in Early DMARD Naive Rheumatoid Arthritis.|Completed||Phase 4|112|Actual|University of Leeds||2|||f||||f||||||||||2018-05-31 22:49:30.953611|2018-05-31 22:49:30.953611
NCT01308242|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2018-04-30|2011-03-03|2011-03-04|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2011|Actual|2011-03-31|April 2018|2018-04-30|February 27, 2014|Actual|2014-02-27|February 27, 2014|Actual|2014-02-27||Interventional|||Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease|Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease|Completed||Early Phase 1|40|Actual|Milton S. Hershey Medical Center||1|||f||||f||||||||||2018-05-31 22:49:31.058366|2018-05-31 22:49:31.058366
NCT01308229|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2015-04-07|2011-03-03|2011-03-04|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|March 2015|Actual|2015-03-31|January 2011|Actual|2011-01-31||Interventional|BIPAX||Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent|Assessment of the Safety and Efficacy of the Nile PAX® Drug Eluting Coronary Bifurcation Stent System for the Treatment of Single de Novo Bifurcation Lesions in Native Coronary Arteries|Completed||N/A|102|Actual|MINVASYS||1|||f||||t||||||||||2018-05-31 22:49:31.112355|2018-05-31 22:49:31.112355
NCT01308216|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2012-04-02|2011-03-03|2011-03-04|Estimate|||||||2012-04-02|2012-04-03|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|REHELA||Transcranial Laser Therapy in the Rehabilitation of Hemiplegic Patients From Ischemic Stroke|Efficacy of Transcranial Laser Therapy for Improving Upper Extremity Functional Recovery in Hemiplegic Patients From Ischemic Stroke|Terminated||Phase 1|25|Actual|Hospital Universitario Ramon y Cajal||2||Based in the negative of patients to shave de hair.|f||||t||||||||||2018-05-31 22:49:31.179083|2018-05-31 22:49:31.179083
NCT01308203|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2015-08-17|2011-03-03|2011-03-04|Estimate|||||||2015-08-17|2015-08-19|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease|Lipid Efficacy and Effects on HDL-C Metabolism of the Extended Release Niacin/Laropiprant Combination Added to Usual Therapy in Patients With Cardiovascular Disease and Low HDL-C That Did Not Achieve the Optional Very Low LDL-C Goal|Terminated||Phase 4|32|Actual|Hospital Italiano de Buenos Aires||2||"Merck has decided to discontinue all studies with extended-release niacin/laropiprant.because~   the HPS2-THRIVE did not meet its primary endpoint"|f||||f||||||||||2018-05-31 22:49:31.241138|2018-05-31 22:49:31.241138
NCT01308190|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-03|||2015-09-09|2011-03-03|2011-03-04|Estimate|||||||2015-09-09|2015-09-10|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer|Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer|Recruiting||Phase 3|173|Anticipated|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 22:49:31.300157|2018-05-31 22:49:31.300157
NCT01308177|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection|Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 4|90|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 22:49:31.36552|2018-05-31 22:49:31.36552
NCT01308164|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2017-01-10|2011-03-02|2011-03-03|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||MD Logic Pump Advisor -Pediatric Study|Evaluation of Automated-Insulin Pump Setting Using the MD-Logic Pump Advisor -Minors Sub Study|Completed||N/A|25|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 22:49:31.572409|2018-05-31 22:49:31.572409
NCT01308151|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-12-15|2011-03-02|2011-03-03|Estimate|||||||2013-12-15|2013-12-17|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Culturally Adapted Cognitive Behavioral Therapy for Prevention of Self Harm|Culturally Adapted Manual Assisted Cognitive Behavioral Therapy for Prevention of Self Harm: A Randomized Control Trial|Completed||N/A|221|Actual|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-05-31 22:49:31.673405|2018-05-31 22:49:31.673405
NCT01308138|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2015-08-19|2011-03-02|2011-03-03|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|TRIMRIPC||Myocardial Physiology And Microanatomy In Individuals Undergoing Heart Surgery|Study of Gaining Further Understanding of the Underlying Mechanisms of Myocardial Function|Completed||N/A|60|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 22:49:31.750512|2018-05-31 22:49:31.750512
NCT01308125|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2012-04-20|2011-03-02|2011-03-03|Estimate|||||||2012-04-20|2012-04-23|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|PICSO||Safety And Feasibility Study Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention|PREPARE PICSO A Study To Evaluate The Safety And Feasibility Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention|Completed||Phase 2|10|Actual|Miracor Medical Systems|||||f||||f||||||||||2018-05-31 22:49:31.811658|2018-05-31 22:49:31.811658
NCT01308112|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-05-28|2011-03-02|2011-03-03|Estimate|||||||2013-05-28|2013-05-29|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|PIMAL||Prenatal Iron and Malaria Study|A Randomised Trial to Assess the Safety and Efficacy or Iron Supplementation in Kenyan Pregnant Women|Completed||Phase 4|470|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 22:49:31.874844|2018-05-31 22:49:31.874844
NCT01308099|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-01-16|2011-03-02|2011-03-03|Estimate|||||||2017-01-16|2017-01-18|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Assessment of Vascular Endothelial Function in Postural Tachycardia Syndrome|Assessment of Vascular Endothelial Function in Postural Tachycardia Syndrome (POTS)|Completed|||26|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||No||2018-05-31 22:49:31.943907|2018-05-31 22:49:31.943907
NCT01308086|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-08-08|2011-03-02|2011-03-03|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2010||2010-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer|A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer|Active, not recruiting||Phase 3|2000|Actual|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-05-31 22:49:32.012099|2018-05-31 22:49:32.012099
NCT01308073|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2014-12-18|2011-03-02|2011-03-03|Estimate|||||||2014-12-18|2014-12-19|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|EMIC2||Stability of Middle Molecule Clearance|Long-time Stability of Middle Molecule Clearance During CI-Ca CVVHD|Completed|||15|Actual|Heinrich-Heine University, Duesseldorf|||1||f||||f||||||||||2018-05-31 22:49:32.160698|2018-05-31 22:49:32.160698
NCT01308060|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2012-08-06|2011-03-02|2011-03-03|Estimate|||||||2012-08-06|2012-08-07|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)|A MULTI-CENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF CD07743 FOR THE IMPROVEMENT OF LATERAL CANTHAL LINES (CROW'S FEET)|Completed||Phase 3|335|Actual|Galderma R&D||2|||f||||f||||||||||2018-05-31 22:49:32.224101|2018-05-31 22:49:32.224101
NCT01308047|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-03-25|2011-03-02|2011-03-03|Estimate|||||||2014-03-25|2014-03-26|Estimate||||March 2014|2014-03-31||||||||Interventional|||Comparing Heavy Levobupivacaine With Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine.|Comparative Study of Non-inferiority Between Heavy Levobupivacaine With Enantiomeric Excess of 50% (Bupivacaine S75: R25) and Heavy Racemic Bupivacaine (Bupivacaine S50: R50) in Spinal Anesthesia for Orthopedic Procedures in the Lower Limbs.|Withdrawn||Phase 3|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||2||The Sponsor has no interest in continuing the study.|f||||f||||||||||2018-05-31 22:49:32.288448|2018-05-31 22:49:32.288448
NCT01308034|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-09-25|2011-03-02|2011-03-03|Estimate|||||||2017-09-25|2017-09-26|Actual|March 2011||2011-03-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|May 2016|Actual|2016-05-31||Interventional|||Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy|Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy|Active, not recruiting||Phase 1|18|Anticipated|Centre Leon Berard||1|||f||||t||||||||||2018-05-31 22:49:32.368507|2018-05-31 22:49:32.368507
NCT01308021|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2014-05-23|2011-03-02|2011-03-03|Estimate|||||||2014-05-23|2014-05-26|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis|Clinical Efficacy, Immunogenicity, Clinical Tolerability and Assessment of Safety of gpASIT+TM Administered Orally, According to Two Administration Schedules, for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis|Completed||Phase 2|202|Actual|BioTech Tools S.A.||3|||f||||f||||||||||2018-05-31 22:49:32.499001|2018-05-31 22:49:32.499001
NCT01308008|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-09-01|2011-03-01|2011-03-03|Estimate|||||||2016-09-01|2016-09-02|Estimate|November 2011||2011-11-30|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Home Exercise for Older Diabetics|Home Program to Enhance Mobility in Older Veteran Diabetics|Active, not recruiting||Phase 3|240|Anticipated|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 22:49:32.632235|2018-05-31 22:49:32.632235
NCT01307995|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|April 2007||2007-04-30|January 2011|2011-01-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Observational|||The Incretin Effect in Patients With Gestational Diabetes Mellitus|Observational Study to Evaluate the Reduced Incretin Effect Observed in Patients With GDM in Relation to Reversibility After a Delivery.|Completed|||20|Actual|Medical Universtity of Lodz|||2||f||||f||||||||||2018-05-31 22:49:32.70307|2018-05-31 22:49:32.70307
NCT01307982|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-10-17|2011-03-01|2011-03-03|Estimate|||||||2013-10-17|2013-10-21|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CARPNIC||Comparative Anti-Reflux Procedures in Neurologically Impaired Children|Comparative Anti-Reflux Procedures in Neurologically Impaired Children|Completed||N/A|3|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:49:32.758913|2018-05-31 22:49:32.758913
NCT01307969|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|February 2007||2007-02-28|February 2011|2011-02-28|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Formulations of Liposomal Local Anesthetics|Formulations of Liposomal Local Anesthetics for Dental Anesthesia|Completed||Phase 1|40|Actual|University of Campinas, Brazil||1|||f||||t||||||||||2018-05-31 22:49:32.827774|2018-05-31 22:49:32.827774
NCT01307956|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2018-02-11||2018-02-11|2011-03-02|2011-03-03|Estimate|2018-02-11|2018-03-13|Actual||||2018-02-11|2018-03-13|Actual|February 2011||2011-02-28|February 2018|2018-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer|A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction|Terminated||Phase 2|11|Actual|University of Nebraska||1||Drug manufacturer - Amgen requested, per DSMB observation in POWER trial.|f||||t||||||||||2018-05-31 22:49:32.92272|2018-05-31 22:49:32.92272
NCT01307943|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2013-12-09|2011-03-02|2011-03-03|Estimate|||||||2013-12-09|2013-12-10|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MBSR||Mindfulness-based Stress Reduction for Pediatric Mental Health|Mindfulness-based Stress Reduction for Pediatric Mental Health|Completed||Phase 3|85|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 22:49:33.226524|2018-05-31 22:49:33.226524
NCT01307930|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02||2014-02-04|2018-05-02|2011-03-02|2011-03-03|Estimate||||2014-05-06|2014-05-22|Estimate|2018-05-02|2018-05-04|Actual|January 2011||2011-01-31|May 2018|2018-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations|Population Pharmacokinetic Analysis of Anidulafungin in Normal, Overweight and Obese Volunteers|Completed||Phase 4|18|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||No||2018-05-31 22:49:33.312437|2018-05-31 22:49:33.312437
NCT01307917|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-12-14|2011-03-02|2011-03-03|Estimate|||||||2012-12-14|2012-12-17|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|flavonoid||Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes|Endothelial Dysfunction and the Role of Flavonoids in the Prevention of Nephropathy Among Pediatric Patients With Diabetes|Withdrawn||N/A|0|Actual|Texas Tech University Health Sciences Center||4||No funding ever received|f||||f||||||||||2018-05-31 22:49:33.378265|2018-05-31 22:49:33.378265
NCT01307904|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|Dates||The Glycemic Indices of Five Common Varieties of Dates in the Tested Among Healthy and Diabetic Subjects|The Glycemic Indices of Five Common Varieties of Dates in the Tested Among Healthy and Diabetic Subjects|Completed||Early Phase 1|23|Actual|United Arab Emirates University||2|||f||||f||||||||||2018-05-31 22:49:33.430998|2018-05-31 22:49:33.430998
NCT01307891|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2017-05-24||2017-10-24|2011-03-01|2011-03-03|Estimate|2017-08-14|2017-09-13|Actual||||2017-10-24|2017-10-26|Actual|March 2011||2011-03-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer|An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer|Completed||Phase 2|64|Actual|University of Alabama at Birmingham||2|||f||||t|t|f||||||No||2018-05-31 22:49:33.493516|2018-05-31 22:49:33.493516
NCT01307878|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-12-10|2011-03-02|2011-03-03|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction|Study of New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction|Unknown status|Recruiting|Phase 4|150|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 22:49:33.894343|2018-05-31 22:49:33.894343
NCT01307865|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-10-13|2011-03-02|2011-03-03|Estimate|||||||2013-10-13|2013-10-16|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Volume Restoration of the Aging Midface With Sculptra Aesthetic|Volume Restoration of the Aging Midface With Sculptra Aesthetic|Completed||Phase 4|15|Actual|Williams Center Plastic Surgery Specialists||1|||f||||||||||||||2018-05-31 22:49:33.962478|2018-05-31 22:49:33.962478
NCT01307852|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-04-04|2011-03-01|2011-03-03|Estimate|||||||2016-04-04|2016-04-06|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||In Vivo Dosimetry During Prostate Cancer Radiotherapy|Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy|Completed||Phase 1|7|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:49:34.049593|2018-05-31 22:49:34.049593
NCT01307839|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2012-04-11|2011-03-02|2011-03-03|Estimate|||||||2012-04-11|2012-04-12|Estimate|December 2011||2011-12-31|April 2012|2012-04-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Lidocaine Patch for Relief of Pain During Epidural Placement in Laboring Patients|A Randomized, Controlled Trial of the Lidocaine Patch for Relief of Pain During Epidural Needle Insertion in Laboring Patients|Withdrawn||N/A|0|Actual|Loma Linda University||2||Study was stopped due to non-availability of the lidocaine placebo patches.|f||||f||||||||||2018-05-31 22:49:34.113918|2018-05-31 22:49:34.113918
NCT01307826|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Massage in Treating Painful Shoulder|Comparison of the Effectiveness of Massage Based on the Tensegrity Rule and Classical Massage in Treating Painful Shoulder|Completed||N/A|||University School of Physical Education in Wroclaw||2|||f||||f||||||||||2018-05-31 22:49:34.179634|2018-05-31 22:49:34.179634
NCT01307813|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-12-12|2011-03-02|2011-03-03|Estimate|||||||2014-12-12|2014-12-16|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|Overstitch||Apollo Overstitch, a Treat and Resect Model|Evaluation of a Novel Endoscopic Suturing Device in a Treat and Resect Model|Completed||N/A|4|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-05-31 22:49:34.304904|2018-05-31 22:49:34.304904
NCT01307800|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01||2013-01-11|2013-01-11|2011-03-01|2011-03-03|Estimate||||2013-01-11|2013-01-21|Estimate|2013-01-11|2013-01-21|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of LY2140023 in Patients With Schizophrenia|A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM‑IV‑TR Schizophrenia|Terminated||Phase 3|1100|Anticipated|Eli Lilly and Company||4||"The decision to stop the trial was based on efficacy results in the overall schizophrenia~   participant population."|f||||t||||||||||2018-05-31 22:49:34.380519|2018-05-31 22:49:34.380519
NCT01307787|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|2011-03-15||2011-05-11|2011-03-02|2011-03-03|Estimate|2011-04-18|2011-05-09|Estimate||||2011-05-11|2011-05-13|Estimate|April 2005||2005-04-30|January 2011|2011-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effects of a Rehabilitation Program on Physical Performance and Disease Self-management in Rheumatoid Arthritis.|Effects of a Group-based Exercise and Educational Program on Physical Performance and Disease Self-management in Rheumatoid Arthritis: a Randomized Controlled Study|Completed||N/A|34|Actual|University Medical Center Groningen|An important limitation in our study was the low number of participants included in both groups which may have induced a lack of power.|2|||f||||f||||||||||2018-05-31 22:49:34.538586|2018-05-31 22:49:34.538586
NCT01307774|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-10-28|2011-03-02|2011-03-03|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|||Survey of Predictors of Human Papillomavirus (HPV) Vaccination Among Parents of Rural Adolescent Girls in Mysore, India|Survey of Predictors of HPV Vaccination Among Parents of Rural Adolescent Girls in Mysore, India|Unknown status|Recruiting||800|Anticipated|Public Health Research Institute, India|||||f||||f||||||||||2018-05-31 22:49:34.929739|2018-05-31 22:49:34.929739
NCT01307761|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-09-16|2011-03-02|2011-03-03|Estimate|||||||2011-09-16|2011-09-19|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|August 2013|Anticipated|2013-08-31|December 2012|Anticipated|2012-12-31||Observational|||An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules|An Easy Sonographic Scoring System for Predicting Malignant Thyroid Nodules|Unknown status|Recruiting||500|Anticipated|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 22:49:35.003096|2018-05-31 22:49:35.003096
NCT01307748|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2013-03-18|2011-03-02|2011-03-03|Estimate|||||||2013-03-18|2013-03-20|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Stress-reducing Aromatherapy|Physiologic and Expectancy Effects of Stress-reducing Aroma in Older Adults|Completed||Phase 2/Phase 3|92|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-05-31 22:49:35.062366|2018-05-31 22:49:35.062366
NCT01307735|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|July 2011|Anticipated|2011-07-31|April 2011|Anticipated|2011-04-30||Observational|mmr||International Myocarditis Registry|Prospective Assessment of the Clinical Utility of Cardiovascular Magnetic Resonance in Patients With Suspected Acute Myocarditis - A Pilot Study for Establishing an International Registry|Unknown status|Enrolling by invitation||78|Anticipated|Libin Cardiovascular Institute of Alberta|||2||f||||t||||||Samples With DNA|"~     Biopsy samples with viral or bacterial DNA~   "|||2018-05-31 22:49:35.128993|2018-05-31 22:49:35.128993
NCT01307722|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|August 2011||2011-08-31|March 2011|2011-03-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Left Atrial Distensibility Guiding Management in Advanced Chronic Heart Failure|Left Atrial Distensibility Guiding Management in Advanced Chronic Heart Failure|Unknown status|Not yet recruiting|N/A|300|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 22:49:35.192948|2018-05-31 22:49:35.192948
NCT01307709|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2012-04-25|2011-03-02|2011-03-03|Estimate|||||||2012-04-25|2012-04-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:49:35.27322|2018-05-31 22:49:35.27322
NCT01307696|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-02|||2014-04-25|2011-03-02|2011-03-03|Estimate|||||||2014-04-25|2014-04-28|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Self-Expanding Multi-Layered Partially Resorbable Lightweight Polypropylene Mesh Device (Proceed Ventral Patch® Or Pvp®) For The Treatment of Small and Medium Umbilical Ventral Hernias|Multicenter Prospective Clinical Registry To Evaluate The Safety And Efficacy Of A Self-Expanding Multi-Layered Partially Resorbable Absorbable Lightweight Polypropylene Mesh Device (Proceed Ventral Patch® Or Pvp®) For The Treatment Of Small And Medium Umbilical Ventral Hernias|Completed|||100|Actual|Algemeen Ziekenhuis Maria Middelares|||||f||||f||||||||||2018-05-31 22:49:35.326998|2018-05-31 22:49:35.326998
NCT01307683|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2015-04-03|2011-03-01|2011-03-03|Estimate|||||||2015-04-03|2015-04-06|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|MAMAS||Maternal, Adiposity, Metabolism, and Stress Study|Maternal, Adiposity, Metabolism, and Stress Study (MAMAS)|Unknown status|Active, not recruiting|N/A|202|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:49:35.395593|2018-05-31 22:49:35.395593
NCT01307657|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-06-13|2011-03-01|2011-03-03|Estimate|||||||2012-06-13|2012-06-14|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects|Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects|Completed||N/A|12|Actual|University of Nebraska||1|||f||||f||||||||||2018-05-31 22:49:35.453182|2018-05-31 22:49:35.453182
NCT01307644|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-10-17|2011-03-01|2011-03-03|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Interventional|||Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness|Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women|Completed||N/A|301|Actual|University of Nebraska||3|||f||||t||||||||No||2018-05-31 22:49:35.511026|2018-05-31 22:49:35.511026
NCT01307631|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2017-05-23||2017-08-04|2011-03-01|2011-03-03|Estimate|2017-08-04|2017-09-05|Actual||||2017-08-04|2017-09-05|Actual|March 2011|Actual|2011-03-31|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|January 2016|Actual|2016-01-31||Interventional|||Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer|A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:49:35.580734|2018-05-31 22:49:35.580734
NCT01307449|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-12-11|2011-03-01|2011-03-03|Estimate|||||||2017-12-11|2017-12-13|Actual|April 2014|Actual|2014-04-30|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Systems Biology of PNEUMOVAX®23 and PREVNAR 13®|Systems Biology of 23 Valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®)|Completed||N/A|88|Actual|Emory University||2|||f||||f||||||||Undecided||2018-05-31 22:49:38.929067|2018-05-31 22:49:38.929067
NCT01307618|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2015-12-30||2016-08-31|2011-03-01|2011-03-03|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma|A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)||2||"Due to lack of clinical efficacy and lack of drug supply, trial was closed early and~   correlative studies were not pursued further."|f||||||||||||||2018-05-31 22:49:35.911784|2018-05-31 22:49:35.911784
NCT01307605|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2018-05-07|2011-03-02|2011-03-03|Estimate|||||||2018-05-07|2018-05-08|Actual|February 9, 2011|Actual|2011-02-09|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|June 20, 2014|Actual|2014-06-20||Interventional|||Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma|Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.|Active, not recruiting||Phase 2|152|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||No||2018-05-31 22:49:36.264145|2018-05-31 22:49:36.264145
NCT01307592|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2014-01-09|2011-03-01|2011-03-03|Estimate|||||||2014-01-09|2014-01-10|Estimate|February 2011||2011-02-28|February 2011|2011-02-28||||February 2013|Anticipated|2013-02-28||Interventional|||Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma|Pilot Study of GC. (Gemcitabine-Rituximab-Oxaliplatin Combination) Given Every 14 Days With Maintenance Lenalidomide for the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 2|70|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:49:36.369447|2018-05-31 22:49:36.369447
NCT01307579|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-11-13|2011-03-01|2011-03-03|Estimate|||||||2017-11-13|2017-11-17|Actual|April 2011||2011-04-30|January 2017|2017-01-31||||June 2018|Anticipated|2018-06-30||Interventional|||Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy|A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 3|517|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 22:49:36.445164|2018-05-31 22:49:36.445164
NCT01307566|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2015-01-05|2011-03-01|2011-03-03|Estimate|||||||2015-01-05|2015-01-06|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|DM2-CPAP||Evolution With CPAP Treatment of a Cohort of Type 2 Diabetic Patients With Apnea-hypopnea Syndrome|Evolution With CPAP Treatment of a Cohort of Type 2 Diabetic Patients With Moderate to Severe Apnea-hypopnea Syndrome and Poor Glycemic Control|Completed||N/A|50|Actual|Hospital de Granollers||1|||f||||f||||||||||2018-05-31 22:49:37.620561|2018-05-31 22:49:37.620561
NCT01307553|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-03|Estimate|||||||2011-03-01|2011-03-03|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|April 2015|Anticipated|2015-04-30|October 2012|Anticipated|2012-10-31||Observational|Sleeve III||Over and Under/Aneugraft Pericardium Covered Stent Long Term Follow up Registry|OVER AND UNDER/ANEUGRAFT PERICARDIUM COVERED STENT Long Term Follow Up Registry|Unknown status|Recruiting||75|Anticipated|ITGI Medical|||1||f||||f||||||||||2018-05-31 22:49:37.694204|2018-05-31 22:49:37.694204
NCT01307540|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-03|Estimate|||||||2011-03-01|2011-03-03|Estimate|February 2007||2007-02-28|June 2010|2010-06-30||||December 2009|Actual|2009-12-31||Interventional|||Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients|Phototherapy for the Management of Oral Ulcers in Bone Marrow Recipients|Completed||N/A|20|Actual|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 22:49:37.776363|2018-05-31 22:49:37.776363
NCT01307527|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-02|2011-03-02|2011-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate||||February 2011|2011-02-28||||||||Interventional|||Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI||Unknown status|Enrolling by invitation|N/A|1|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-05-31 22:49:37.839086|2018-05-31 22:49:37.839086
NCT01307514|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2011-03-01|2011-03-01|2011-03-03|Estimate|||||||2011-03-01|2011-03-03|Estimate|November 2008||2008-11-30|September 2008|2008-09-30||||||||Observational|||Effects of Heating Massaging Vibrating Vicinity of the Insulin Delivery Site|Protocol for Evaluation of the Effects of Heating Massaging Vibrating or Application of Topical Agent on the Vicinity of the Insulin Delivery Site|Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-05-31 22:49:37.893093|2018-05-31 22:49:37.893093
NCT01307501|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-07-12|2011-03-01|2011-03-03|Estimate|||||||2017-07-12|2017-07-14|Actual|August 2011|Actual|2011-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ECLIPSE||Safety and Efficacy of Cryoablation for Metastatic Lung Tumors|Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients - Safety and Efficacy|Active, not recruiting||N/A|40|Actual|Galil Medical||1|||f||||t|f|t|f|f||||No||2018-05-31 22:49:38.061681|2018-05-31 22:49:38.061681
NCT01307488|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2015-05-08|2011-03-02|2011-03-03|Estimate|||||||2015-05-08|2015-05-12|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|April 2014|Actual|2014-04-30||Interventional|SALT||Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy|Efficacy of Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy in Patients With Viral Suppression. Randomized, Open-label 96 Weeks Non-inferiority Trial|Completed||Phase 4|286|Actual|Fundacion SEIMC-GESIDA||2|||f||||t||||||||||2018-05-31 22:49:38.161054|2018-05-31 22:49:38.161054
NCT01307475|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-27|||2017-04-02|2011-03-01|2011-03-03|Estimate|||||||2017-04-02|2017-04-04|Actual|February 2011||2011-02-28|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|FSS-QLS||Study of Quality of Life in Freeman-Sheldon Syndrome and Related Conditions|Freeman-Sheldon Syndrome Quality of Life Study (FSS-QLS): Cross-sectional Study of Concomitant Disorder-Specific Contributors to Quality of Life and Clinical Outcome|Terminated|||6|Actual|Freeman-Sheldon Research Group, Inc.|||3|Most study procedures incorporated into NCT01144741, some in NCT01306994|f||||f|f|f||||None Retained|"~     Blood samples will be taken but no retention is expected.~   "|No|Individual patient data will not be shared, due to concerns involved in masking identities of individuals with such a rare condition.|2018-05-31 22:49:38.349813|2018-05-31 22:49:38.349813
NCT01307462|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2017-01-20||2017-09-06|2011-03-01|2011-03-03|Estimate|2017-09-06|2017-10-04|Actual||||2017-09-06|2017-10-04|Actual|June 2011||2011-06-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Interventional|FAM for BOS||Targeted Therapy of Bronchiolitis Obliterans Syndrome|Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant|Completed||Phase 2|36|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||No|De-identified data are reported in aggregate.|2018-05-31 22:49:38.565819|2018-05-31 22:49:38.565819
NCT01307436|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2014-07-28|2011-03-01|2011-03-03|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines|A Phase III Randomised, Open, Controlled Study to Assess the Safety and Immunogenicity of Concomitant Administration of Virosomal Hepatitis A Vaccine (Epaxal®) With DTPaHibIPV, OPV and MMR Vaccines vs. Non-concomitant Administration in 12-15 Month Old Children. Follow-up: Serological Long-term Follow-up of Subjects for up to 42 Months, 5.5 and 7.5 Years After the Second Dose.|Completed||Phase 3|327|Actual|Crucell Holland BV||3|||f||||f||||||||||2018-05-31 22:49:39.106377|2018-05-31 22:49:39.106377
NCT01307423|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2014-05-16|2013-07-26|2017-07-21|2011-03-01|2011-03-02|Estimate|2014-07-28|2014-08-15|Estimate|2013-07-26|2013-08-02|Estimate|2017-07-21|2017-08-21|Actual|December 9, 2010|Actual|2010-12-09|July 2017|2017-07-31|August 30, 2017|Anticipated|2017-08-30|February 21, 2013|Actual|2013-02-21||Interventional|PALACE4|Full Analysis Set was defined as participants who were randomized as specified in the protocol; one participant who was randomized in error and did not receive any dose of investigational product was excluded.|Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs|Active, not recruiting||Phase 3|529|Actual|Celgene||4|||f||||f||||||||||2018-05-31 22:49:39.286631|2018-05-31 22:49:39.286631
NCT01307410|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2013-02-13|2011-03-01|2011-03-02|Estimate|||||||2013-02-13|2013-02-15|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|December 2014|Anticipated|2014-12-31|May 2014|Anticipated|2014-05-31||Observational|CCMR-3B Ext||A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China|A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China - 3B Extension A Study of China Cardiometabolic Registries (CCMR)|Unknown status|Active, not recruiting||5000|Anticipated|China Cardiometabolic Registries|||2||f||||f||||||||||2018-05-31 22:49:41.429062|2018-05-31 22:49:41.429062
NCT01307397|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2017-07-21||2017-07-21|2011-02-28|2011-03-02|Estimate|2017-07-21|2017-12-18|Actual||||2017-07-21|2017-12-18|Actual|March 1, 2011|Actual|2011-03-01|July 2017|2017-07-31|February 24, 2016|Actual|2016-02-24|February 24, 2016|Actual|2016-02-24||Interventional||The safety population included all participants who received at least one dose of study medication.|A Study of Vemurafenib in Participants With Metastatic Melanoma|An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma|Completed||Phase 3|3219|Actual|Hoffmann-La Roche||1|||f||||||f||||||||2018-05-31 22:49:41.597985|2018-05-31 22:49:41.597985
NCT01307384|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2018-01-19|2011-02-28|2011-03-02|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2012||2012-03-31|January 2017|2017-01-31|December 2024|Anticipated|2024-12-31|March 2024|Anticipated|2024-03-31||Observational|||Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) Study|Prospective Post Market Clinical Follow-Up Study of the Continuum Metal on Polyethylene Acetabular System|Active, not recruiting|||300|Anticipated|Zimmer Biomet|||1||f||||t|f|t|f|f|t|||No||2018-05-31 22:49:43.079518|2018-05-31 22:49:43.079518
NCT01307371|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-28|2011-02-28|2011-03-02|Estimate|||||||2011-02-28|2011-03-02|Estimate|March 2007||2007-03-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|March 2008|Actual|2008-03-31||Observational|||Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)|Effects and Mechanism of Autologous Bone Marrow Mononuclear Cells (BMMNC)Transplantation in Diabetic Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Who Have Undergone Percutaneous Coronary Intervention (PCI)|Unknown status|Recruiting||110|Anticipated|Xijing Hospital|||2||f||||t||||||Samples With DNA|"~     Serum, Plasma~   "|||2018-05-31 22:49:43.169058|2018-05-31 22:49:43.169058
NCT01307358|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2017-01-27|2011-03-01|2011-03-02|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PAU||A Study Comparing the Interproximal Plaque and Gingivitis Effects of Three Interdental Cleaning Modalities|A Randomized Parallel Study Comparing the Interproximal Plaque and Gingivitis Effects of Three Interdental Cleaning Modalities|Completed||N/A|80|Actual|University of North Carolina, Chapel Hill||4|||f||||f|f|f||||||||2018-05-31 22:49:43.246817|2018-05-31 22:49:43.246817
NCT01307345|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-11-17|2011-02-28|2011-03-02|Estimate|||||||2011-11-17|2011-11-21|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence|Remote Monitoring and Contingency Management Reinforcement for Alcohol Abstinence|Completed||Phase 1|30|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 22:49:43.307232|2018-05-31 22:49:43.307232
NCT01307332|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2016-05-18|2011-02-28|2011-03-02|Estimate|||||||2016-05-18|2016-05-20|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|iCAMMS-IST||Advanced MRI Measures of Repair in Alemtuzumab Treated Patients|Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients|Active, not recruiting||Phase 3|25|Anticipated|University of British Columbia||1|||f||||t||||||||||2018-05-31 22:49:43.359633|2018-05-31 22:49:43.359633
NCT01307319|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2015-02-03|2011-08-25|2015-02-03|2011-02-28|2011-03-02|Estimate|2015-02-03|2015-02-20|Estimate|2011-08-25|2011-08-29|Estimate|2015-02-03|2015-02-20|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional||Safety population: the safety population included all randomized participants who received at least one dose of randomized study medication.|Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies|Study of Two Doses of an Investigational Nasal Aerosol Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies|Completed||Phase 3|715|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 22:49:43.441723|2018-05-31 22:49:43.441723
NCT01307306|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-10-17|2011-02-28|2011-03-02|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Glucose Control in Severely Burned Patients|Glucose Control in Severely Burned Patients: Mechanisms and Therapeutic Potential|Recruiting||N/A|60|Anticipated|Sunnybrook Health Sciences Centre||3|||f||||f||||||||||2018-05-31 22:49:43.878191|2018-05-31 22:49:43.878191
NCT01307293|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2014-11-18|2011-02-28|2011-03-02|Estimate|||||||2014-11-18|2014-11-19|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Prevention of Postpartum Traumatic Stress (PTSD) in Mothers With Preterm Infants.|Randomized Controlled Trial of a Brief Cognitive Behavioral Intervention Designed to Prevent and Reduce Symptoms of Posttraumatic Stress in Mothers of Preterm Infants.|Completed||N/A|110|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 22:49:43.978476|2018-05-31 22:49:43.978476
NCT01307280|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-01-25|2011-02-28|2011-03-02|Estimate|||||||2012-01-25|2012-01-26|Estimate|August 2006||2006-08-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional|HEALTH||Weight Management Demonstration Project: HEALTH|Weight Management Demonstration Project: Healthy Eating and Active Living in TRICARE Households|Completed||N/A|2395|Actual|RTI International||3|||f||||f||||||||||2018-05-31 22:49:44.045548|2018-05-31 22:49:44.045548
NCT01307267|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2018-05-29|2011-02-28|2011-03-02|Estimate|||||||2018-05-29|2018-05-30|Actual|June 2011|Actual|2011-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|||A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab|A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)|Active, not recruiting||Phase 1|190|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:49:44.191283|2018-05-31 22:49:44.191283
NCT01307254|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-09-19|2011-03-01|2011-03-02|Estimate|||||||2012-09-19|2012-09-20|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Observational|BAFLA||Association Between Non-alcoholic Fatty Liver Disease and Iron Status|(BAFLA- Barzilai Fatty Liver and Iron Metabolism Study)|Unknown status|Recruiting||80|Anticipated|Barzilai Medical Center|||2||f||||f||||||||||2018-05-31 22:49:44.324951|2018-05-31 22:49:44.324951
NCT01307241|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-11-14|2011-02-28|2011-03-02|Estimate|||||||2013-11-14|2013-11-15|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML|Evaluation of RFC Transporter & MTHFR SNP's, as Well as hEN1 and DCK Expression as Prognostic Factors in Patients With Acute Lymphoblastic Leukemia.|Unknown status|Active, not recruiting||50|Anticipated|National Institute of Cancerología|||1||f||||f||||||Samples With DNA|"~     Blood samples.~   "|||2018-05-31 22:49:44.397601|2018-05-31 22:49:44.397601
NCT01307228|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2017-03-21|2011-03-01|2011-03-02|Estimate|||||||2017-03-21|2017-03-23|Actual|December 2010|Actual|2010-12-31|March 2017|2017-03-31|February 2013|Actual|2013-02-28|April 2011|Actual|2011-04-30||Interventional|||Effects of an Evidence Service on Health System Policymakers' Use of Research Evidence|Effects of an Evidence Service on Health System Policymakers' Use of Research Evidence|Withdrawn||N/A|0|Actual|McMaster University||2||Insufficient participants recruited for the trial|f||||f||||||||No|Not applicable - trial was terminated due to insufficient enrollment and no data was collected.|2018-05-31 22:49:44.454824|2018-05-31 22:49:44.454824
NCT01307215|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-04-23|2011-02-28|2011-03-02|Estimate|||||||2013-04-23|2013-04-24|Estimate|April 2011||2011-04-30|May 2011|2011-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||TAP Block: Does Volume Make a Difference?|Lumbar Transversus Abdominal Plane (TAP) Block: Does Volume Make a Difference?|Completed||N/A|31|Actual|McMaster University||3|||f||||f||||||||||2018-05-31 22:49:44.517163|2018-05-31 22:49:44.517163
NCT01307202|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2014-11-19|2011-03-01|2011-03-02|Estimate|||||||2014-11-19|2014-11-20|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Morphine Consumption in Joint Replacement Patients, With or Without Gabapentin Treatment|Multiple Doses of Gabapentin and Postoperative Morphine Consumption in Total Knee Arthroplasty|Completed||N/A|101|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 22:49:44.600079|2018-05-31 22:49:44.600079
NCT01307189|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-02-28|2011-02-28|2011-03-02|Estimate|||||||2011-02-28|2011-03-02|Estimate|April 2005||2005-04-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|||||Interventional|||Effects of Tiotropium on Walking Capacity in Patients With COPD|Effects of Tiotropium on Walking Capacity in Patients With COPD|Completed||Phase 4|33|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:49:44.677219|2018-05-31 22:49:44.677219
NCT01307176|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-03-31|2011-02-28|2011-03-02|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|||Exercise Training Program for Cerebellar Ataxia|Exercise Training Program for Cerebellar Ataxia|Completed||N/A|25|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||f||||||||||2018-05-31 22:49:44.748249|2018-05-31 22:49:44.748249
NCT01307163|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Systemic Variables in the Saliva of Children Undergoing Liver Transplantation|Systemic Variables in the Saliva of Children Undergoing Liver Transplantation|Unknown status|Not yet recruiting||60|Anticipated|Hadassah Medical Organization|||||f||||f||||||Samples Without DNA|"~     saliva~   "|||2018-05-31 22:49:44.818426|2018-05-31 22:49:44.818426
NCT01307150|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Observational|||Climatotherapy At The Dead Sea For Atopic Dermatitis|Evaluation of the Efficacy of Dead Sea Climatotherapy on Atopic Dermatitis Patients.|Unknown status|Not yet recruiting||50|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 22:49:44.86534|2018-05-31 22:49:44.86534
NCT01307137|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|June 2011||2011-06-30|January 2011|2011-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Peer-led and Telehealth Comparative Effectiveness Research (CER) Adoption for Diabetes Prevention and Management|Peer-lead and Telemedicine Activated Care (PACT) in Diabetes Prevention and Management|Unknown status|Not yet recruiting|N/A|85|Anticipated|South Florida Veterans Affairs Foundation for Research and Education||2|||f||||||||||||||2018-05-31 22:49:44.919123|2018-05-31 22:49:44.919123
NCT01307124|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2015-03-23|2011-02-28|2011-03-02|Estimate|||||||2015-03-23|2015-03-25|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)|A Multicenter Randomized Study to Compare the Safety and Efficacy of Low-dose Versus Standard Dose Lopinavir/Ritonavir Containing HAART Regimen in Virological Suppressed HIV-infected Thai Children|Completed||Phase 3|199|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-05-31 22:49:44.982542|2018-05-31 22:49:44.982542
NCT01307111|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2015-12-16||2016-03-09|2011-03-01|2011-03-02|Estimate|2016-03-09|2016-03-28|Estimate||||2016-03-09|2016-03-28|Estimate|February 2011||2011-02-28|February 2016|2016-02-29|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in IUD Insertion for Nulliparous Women|Completed||N/A|85|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 22:49:45.051862|2018-05-31 22:49:45.051862
NCT01305057|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-02-25|2011-02-25|2011-02-28|Estimate|||||||2011-02-25|2011-02-28|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy Test on Skin Hydration and Skin Barrier Function|Human Use Test on Skin Hydration and Skin Barrier Function|Completed||N/A|20|Actual|Cosmos Technical Center||1|||f||||t||||||||||2018-05-31 22:50:13.66596|2018-05-31 22:50:13.66596
NCT01307098|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-07-26|2011-03-01|2011-03-02|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Lysosomal Acid Lipase Deficiency|An Open Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Patients With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency|Completed||Phase 1|9|Actual|Alexion Pharmaceuticals||3|||f||||t||||||||Undecided||2018-05-31 22:49:45.27343|2018-05-31 22:49:45.27343
NCT01307085|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2013-12-11|2011-03-01|2011-03-02|Estimate|||||||2013-12-11|2013-12-12|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Remote Ischemic Preconditioning on Lung Injury After Pulmonary Resection|Effect of Remote Ischemic Preconditioning on Lung Injury in Patients Undergoing Pulmonary Resection:a Randomised Controlled Trial|Completed||N/A|108|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 22:49:45.36165|2018-05-31 22:49:45.36165
NCT01307072|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2012-07-31|2011-03-01|2011-03-02|Estimate|||||||2012-07-31|2012-08-02|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Observational|||Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy|Compliance to Ophthalmic Follow-up Examinations Affect Outcome of Vitrectomy for Proliferative Diabetic Retinopathy|Completed|||94|Actual|Kyorin University|||3||f||||f||||||||||2018-05-31 22:49:45.426951|2018-05-31 22:49:45.426951
NCT01307059|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-12-22|2011-03-01|2011-03-02|Estimate|||||||2017-12-22|2017-12-26|Actual|June 30, 2011|Actual|2011-06-30|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS SWE||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Sweden|Easypod Connect: A Swedish, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|Completed|||152|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:49:45.495672|2018-05-31 22:49:45.495672
NCT01307046|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2013-01-02||2017-03-31|2011-03-01|2011-03-02|Estimate|2013-02-19|2013-03-22|Estimate||||2017-03-31|2017-05-05|Actual|March 29, 2011|Actual|2011-03-29|March 2017|2017-03-31|February 7, 2012|Actual|2012-02-07|February 7, 2012|Actual|2012-02-07||Interventional|||MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)|A Phase III, Randomized, Active-comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954A in Japanese Patients With Essential Hypertension Uncontrolled With the High Dose of Losartan Potassium|Completed||Phase 3|336|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:49:45.57858|2018-05-31 22:49:45.57858
NCT01307033|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|2013-11-14||2017-03-31|2011-03-01|2011-03-02|Estimate|2013-11-14|2014-01-06|Estimate||||2017-03-31|2017-05-05|Actual|March 29, 2011|Actual|2011-03-29|March 2017|2017-03-31|December 4, 2012|Actual|2012-12-04|December 4, 2012|Actual|2012-12-04||Interventional|||A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)|A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]|Completed||Phase 3|278|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:49:45.765414|2018-05-31 22:49:45.765414
NCT01307020|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2012-10-11||2013-07-31|2011-03-01|2011-03-02|Estimate|2012-11-12|2012-12-10|Estimate||||2013-07-31|2013-08-12|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|DEX-TRA 02||Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain|Double-blind, Randomised, Placebo and Active Controlled, Parallel Group Study to Evaluate the Analgesic Effect of a Single Oral Administration of Four Different Combination Doses of DKP.TRIS With TRAM.HCL in Comparison With the Single Agents, on Moderate to Severe Pain Following Impacted Third Mandibular Molar Tooth Extraction|Completed||Phase 2|745|Actual|Menarini Group||10|||f||||f||||||||||2018-05-31 22:49:46.140462|2018-05-31 22:49:46.140462
NCT01307007|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2015-07-22||2018-01-19|2011-03-01|2011-03-02|Estimate|2017-06-13|2017-06-27|Actual||||2018-01-19|2018-02-16|Estimate|September 2010||2010-09-30|January 2018|2018-01-31|August 2013|Actual|2013-08-31|May 2011|Actual|2011-05-31||Interventional|||Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding|A Randomized, Controlled Study to Investigate the Safety and Explore the Mechanism of Hypophosphatemia With Intravenous Ferric Carboxymaltose (FCM) Versus Iron Dextran in Women With Iron Deficiency Secondary to Heavy Uterine Bleeding|Completed||Phase 2|69|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 22:49:46.836825|2018-05-31 22:49:46.836825
NCT01306994|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-26|||2018-03-30|2011-02-28|2011-03-02|Estimate|||||||2018-03-30|2018-04-02|Actual|March 2020|Anticipated|2020-03-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Observational|FSS-EDICT I||Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions|Freeman-Sheldon Syndrome Evaluation and Diagnosis in Clinical Settings (FSS-EDICT) I: a Case-Control, Cross-Sectional Study of Baseline and Stress Physiology Parameters|Not yet recruiting|||20|Anticipated|Freeman-Sheldon Research Group, Inc.|||2||f||||f||||||None Retained|"~     Blood samples will be taken but no retention is expected.~   "|No|We do not intend to share any individual participant data.|2018-05-31 22:49:47.094245|2018-05-31 22:49:47.094245
NCT01306981|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2013-02-19|2011-03-01|2011-03-02|Estimate|||||||2013-02-19|2013-02-20|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|RaDiVit||Ranibizumab in Diabetic Vitrectomy|A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:49:47.337034|2018-05-31 22:49:47.337034
NCT01306968|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2014-07-16||2014-08-25|2011-03-01|2011-03-02|Estimate|2014-08-25|2014-09-05|Estimate||||2014-08-25|2014-09-05|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HOPPS||Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI)|A Pilot Phase II Study of Hyperbaric Oxygen for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (HOPPS)|Completed||Phase 2|79|Actual|U.S. Army Medical Research and Materiel Command||4|||f||||f||||||||||2018-05-31 22:49:47.452839|2018-05-31 22:49:47.452839
NCT01304303|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2016-10-20|2011-02-23|2011-02-25|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination||Completed||Phase 1|30|Anticipated|Sun Pharma Advanced Research Company Limited||2|||f||||f||||||||||2018-05-31 22:50:23.198921|2018-05-31 22:50:23.198921
NCT01306955|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|February 2010||2010-02-28|March 2011|2011-03-31|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|||The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease|The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study|Unknown status|Recruiting|Phase 4|34|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:49:47.986705|2018-05-31 22:49:47.986705
NCT01306942|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2018-01-15|2011-03-01|2011-03-02|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2011|Actual|2011-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|December 2013|Actual|2013-12-31||Interventional|||Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients|A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) Patients|Active, not recruiting||Phase 1/Phase 2|37|Actual|Spanish Breast Cancer Research Group||1|||f||||f||||||||||2018-05-31 22:49:48.12884|2018-05-31 22:49:48.12884
NCT01306929|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2018-03-12|2011-03-01|2011-03-02|Estimate|||||||2018-03-12|2018-03-14|Actual|March 1, 2011|Actual|2011-03-01|March 2018|2018-03-31|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Interventional|OPEN-HART||Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease|A Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).|Completed||Phase 2|235|Actual|Teva Pharmaceutical Industries||1|||f||||t|t|f||||||||2018-05-31 22:49:48.233457|2018-05-31 22:49:48.233457
NCT01306916|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2012-07-02|2011-03-01|2011-03-02|Estimate|||||||2012-07-02|2012-07-03|Estimate|September 2004||2004-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|December 2010|Actual|2010-12-31||Observational|||Coexisting Thyroid Disease and Hyperparathyroidism|Coexisting Thyroid Disease and Hyperparathyroidism|Completed|||30|Actual|Walter Reed Army Medical Center|||1||f||||f||||||||||2018-05-31 22:49:48.293421|2018-05-31 22:49:48.293421
NCT01306903|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2013-06-03|2011-03-01|2011-03-02|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MECC||Minimal Extracorporeal Circuits (MECC) in Cardiac Surgery Procedures|Minimal Extracorporeal Circuits (MECC) in Cardiac Surgery Procedures|Completed||N/A|68|Actual|Johann Wolfgang Goethe University Hospital||3|||f||||||||||||||2018-05-31 22:49:48.436961|2018-05-31 22:49:48.436961
NCT01306890|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2017-04-21|2011-02-28|2011-03-02|Estimate|||||||2017-04-21|2017-04-24|Actual|January 27, 2011|Actual|2011-01-27|April 2017|2017-04-30|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Observational|PROCEED||A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer|A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer|Completed|||1973|Actual|Dendreon|||1||f||||f||||||||||2018-05-31 22:49:48.575511|2018-05-31 22:49:48.575511
NCT01306877|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2014-02-20||2014-10-24|2011-02-28|2011-03-02|Estimate|2014-10-24|2014-10-29|Estimate||||2014-10-24|2014-10-29|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|HEMOSTASIS||Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids|Prospective Single Blinded Randomized Controlled Trial Comparing The Covidien EEA™ Hemorrhoid and Prolapse Stapling Set With DST Series™ Technology Vs. Ethicon PPH03 In A Hemorrhoidopexy Procedure (HEMOSTASIS)|Completed||N/A|149|Actual|Medtronic - MITG||2|||f||||f||||||||||2018-05-31 22:49:49.929422|2018-05-31 22:49:49.929422
NCT01306864|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2018-02-01|2011-02-28|2011-03-02|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2011||2011-12-31|February 2018|2018-02-28|May 29, 2017|Actual|2017-05-29|April 30, 2017|Actual|2017-04-30||Interventional|HALT||Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding|Clinical Evaluation of Hemospray: Hemostasis of Active GI Luminal Tract Bleeding|Completed||N/A|67|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 22:49:50.545341|2018-05-31 22:49:50.545341
NCT01306851|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Interventional|||Prevention of Anastomotic Leak in Gastrointestinal (GI) Anastomosis With the Application of Tisseal in the Anastomotic Line|Multicenter, Randomized, Controlled, Single Blinded, Phase IV Study Comparing 2 Parallel Groups in the Evaluation of the Prevention of Anastomotic Leaks in GI High Risk Anastomosis, With or Without the Application of Fibrin Glue in the Anastomotic Line|Unknown status|Recruiting|Phase 4|200|Anticipated|Hospital General Universitario Gregorio Marañon||1|||f||||f||||||||||2018-05-31 22:49:50.685057|2018-05-31 22:49:50.685057
NCT01306838|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2017-11-02|2011-03-01|2011-03-02|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2009||2009-10-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|EMLFO||Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy|Early Supplementation of Enteral Lipid With Combination of Microlipid and Fish Oil in Infants With Enterostomy|Completed||N/A|40|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 22:49:50.778224|2018-05-31 22:49:50.778224
NCT01306825|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-06-17|2011-03-01|2011-03-02|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|DAPTO-HUS||Clinical Evaluation of Daptomycin Bone Penetration|Clinical Evaluation of Daptomycin Bone Penetration|Unknown status|Recruiting||15|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 22:49:50.874306|2018-05-31 22:49:50.874306
NCT01306812|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-08-19|2011-03-01|2011-03-02|Estimate|||||||2011-08-19|2011-08-22|Estimate|January 1998||1998-01-31|March 2011|2011-03-31||||||||Observational|SALVe||Survey of Adolescent Living in Vestmanland|Risk Factors for Alcohol Abuse and Deviant Behaviour - Biochemical and Molecular Studies in Adolescents From Swedish County|Completed|||||Uppsala University|||||f||||f||||||||||2018-05-31 22:49:50.947305|2018-05-31 22:49:50.947305
NCT01306799|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2017-03-28|2011-03-01|2011-03-02|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2010||2010-01-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|BE-CAST||To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use|Effect of Chronic Proton Pump Inhibitor Therapy on Bone Mineral Density and Bone Structure in Mid to Late Adulthood|Completed|||106|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 22:49:50.997194|2018-05-31 22:49:50.997194
NCT01306786|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-05-26|2011-03-01|2011-03-02|Estimate|||||||2015-05-26|2015-05-28|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|||Five Days Quadruple and Clarithromycin Containing Triple Therapy as Treatment for Helicobacter Pylori Eradication|Five Days Quadruple and Clarithromycin Containing Triple Therapy as Empirical First and Second-Line Treatment for Helicobacter Pylori Eradication: a Randomized Crossover Trial|Completed||N/A|800|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 22:49:51.070956|2018-05-31 22:49:51.070956
NCT01306773|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|December 2009||2009-12-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Convalescent Plasma Treatment in Severe 2009 H1N1 Infection|Convalescent Plasma Treatment in Patients With Severe 2009 H1N1 Infection: a Prospective Cohort Study|Completed||N/A|80|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:49:51.146053|2018-05-31 22:49:51.146053
NCT01306760|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-09-07|2011-03-01|2011-03-02|Estimate|||||||2016-09-07|2016-09-08|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|KANECT||The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy|The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy (ECT) for Depression: Does it Improve Treatment Outcome?|Completed||Phase 4|40|Actual|University of Aberdeen||2|||f||||f||||||||||2018-05-31 22:49:51.210801|2018-05-31 22:49:51.210801
NCT01306747|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-06-10|2011-03-01|2011-03-02|Estimate|||||||2016-06-10|2016-06-13|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|December 2015|Actual|2015-12-31|August 2012|Actual|2012-08-31||Interventional|||Stanford Chronic Pain Self-Management Programme in Danish Chronic Pain Patients|A Randomized Controlled Trial of the Stanford Chronic Pain Self-Management Programme in Danish Chronic Pain Patients|Completed||N/A|500|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:49:51.278637|2018-05-31 22:49:51.278637
NCT01306734|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-03-20|2011-03-01|2011-03-02|Estimate|||||||2012-03-20|2012-03-21|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Observational|||Hypothermia and Circulatory Arrest During Surgery on the Ascending Aorta: A Comparison Between Two Cooling Methods|Hypothermia and Circulatory Arrest During Surgery on the Ascending Aorta: A Comparison Between Two Cooling Methods|Unknown status|Recruiting||20|Anticipated|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Bloodsamples serum plasma~   "|||2018-05-31 22:49:51.430273|2018-05-31 22:49:51.430273
NCT01306721|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2013-10-12|2011-03-01|2011-03-02|Estimate|||||||2013-10-12|2013-10-16|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis|A Randomized, Double Blind, Parallel Group Study for Assessing the Efficacy and Safety of a Twice-daily Fexofenadine HCl 60 mg - Pseudoephedrine HCl 60 mg Combination or Fexofenadine HCl 60 mg - Pseudoephedrine HCl 120 mg Combination Versus Allegra® 60 mg in Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|520|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 22:49:51.570694|2018-05-31 22:49:51.570694
NCT01306708|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2012-01-27|2011-03-01|2011-03-02|Estimate|||||||2012-01-27|2012-01-31|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Amitriptyline Regarding Nimesulide in Acute Idiopathic Adhesive Capsulitis|Comparative Study Between Amitriptyline Regarding Nimesulide Associated to Nervous Blockade in the Acute Treatment of Idiopathic Adhesive Capsulitis|Completed||Phase 2|34|Actual|Universidade do Sul de Santa Catarina||1|||f||||f||||||||||2018-05-31 22:49:51.650246|2018-05-31 22:49:51.650246
NCT01306695|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2015-06-08|2011-03-01|2011-03-02|Estimate|||||||2015-06-08|2015-06-09|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|NOCIP||Northern Manhattan Caregiver Intervention Project|Comparative Effectiveness of the NYU Caregiver Intervention in Latinos in Northern Manhattan|Completed||N/A|139|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 22:49:51.717387|2018-05-31 22:49:51.717387
NCT01306682|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2013-02-06|2011-03-01|2011-03-02|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|MatfluHIVpos||Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity|Trivalent Influenza Vaccine in HIV-infected Pregnant Women and Kinetics of Transplacental Anti-influenza Antibody Transfer and Persistence in Young Infants: A Randomized Controlled Phase II Trial Evaluating Safety and Immunogenicity|Completed||Phase 2/Phase 3|194|Actual|University of Witwatersrand, South Africa||2|||f||||t||||||||||2018-05-31 22:49:51.885567|2018-05-31 22:49:51.885567
NCT01306669|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2015-01-09|2011-03-01|2011-03-02|Estimate|||||||2015-01-09|2015-01-12|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MatfluHIVneg||Influenza Vaccine Trial in HIV Uninfected Pregnant Women|Vaccination of HIV-uninfected Pregnant Women With Trivalent Influenza Vaccine in the Prevention of Influenza Illness During Early Infancy and in Mothers: Randomized Controlled Phase III Trial Evaluating Safety, Immunogenicity and Efficacy|Completed||Phase 3|2116|Actual|University of Witwatersrand, South Africa||2|||f||||t||||||||||2018-05-31 22:49:51.981439|2018-05-31 22:49:51.981439
NCT01306656|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10||2018-03-05|2018-03-15|2011-02-28|2011-03-02|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|October 2011|Actual|2011-10-31|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Vitamin D Repletion in Primary Hyperparathyroidism|Randomized Controlled Trial of Vitamin D Repletion Regimens in Primary Hyperparathyroidism|Completed||Phase 4|9|Actual|Columbia University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 22:49:52.067503|2018-05-31 22:49:52.067503
NCT01306643|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2016-08-23||2016-10-27|2011-02-28|2011-03-02|Estimate|2016-10-27|2016-12-21|Estimate||||2016-10-27|2016-12-21|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Intent-to-treat (ITT) Analysis Set: all enrolled participants who received at least 1 dose of idelalisib.|Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma|Single-agent Idelalisib for Previously Treated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events|Completed||Phase 1/Phase 2|18|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 22:49:52.179018|2018-05-31 22:49:52.179018
NCT01306630|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2014-01-23|2011-02-28|2011-03-02|Estimate|||||||2014-01-23|2014-01-27|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors|A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors|Completed||Phase 1|24|Anticipated|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:49:52.509003|2018-05-31 22:49:52.509003
NCT01306461|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2012-06-07|2011-02-28|2011-03-01|Estimate|||||||2012-06-07|2012-06-08|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations|A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those of Tafluprost and Timolol Eye Drops Given Concomitantly in Patients With Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|401|Actual|Santen Oy||2|||f||||f||||||||||2018-05-31 22:49:54.603565|2018-05-31 22:49:54.603565
NCT01306617|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2014-12-29|2012-11-16|2014-12-29|2011-02-28|2011-03-02|Estimate|2014-12-29|2015-01-08|Estimate|2012-11-16|2012-11-21|Estimate|2014-12-29|2015-01-08|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Interventional||Baseline analyses included all participants.|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|50|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 22:49:52.627495|2018-05-31 22:49:52.627495
NCT01306604|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2018-05-18|2011-03-01|2011-03-02|Estimate|||||||2018-05-18|2018-05-21|Actual|March 2011||2011-03-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|BioNPC||Biomarker for Niemann Pick Type C Disease|Biomarker for Niemann Pick Type C Disease an International, Multicenter, Epidemiological Study|Recruiting|||80|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 20ml EDTA~     and a dry blood spot filter card. To proof the correct NPC nosis in those patients where up~     to the enrollment in the study no genetic testing has been done, sequencing of NPC1 and/or~     NPC2 will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos) Gehlsheimerstr.20, 18055 Rostock (Germany)~   "|||2018-05-31 22:49:53.564929|2018-05-31 22:49:53.564929
NCT01306591|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|January 2008||2008-01-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Bevacizumab for Neovascular Age-related Macular Degeneration|Randomized Multi-center Clinical Study：Bevacizumab for Neovascular Age-related Macular Degeneration|Completed||N/A|210|Actual|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 22:49:53.706216|2018-05-31 22:49:53.706216
NCT01306578|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|January 2007||2007-01-31|February 2011|2011-02-28|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)|Comparison of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Mechanically Ventilated Children With Guillain Barre Syndrome. A Randomized Study.|Completed||N/A|41|Actual|Mansoura University Children Hospital||2|||f||||t||||||||||2018-05-31 22:49:53.77837|2018-05-31 22:49:53.77837
NCT01306565|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|January 2009||2009-01-31|November 2008|2008-11-30|January 2011|Actual|2011-01-31|June 2010|Actual|2010-06-30||Interventional|||High Dose and Low Dose of Atorvastatin in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)|Comparison Between Effect of High Dose and Low Dose of Atorvastatin in Reduction Level of CRP in Patients With Unstable Angina and NSTEMI (Non ST Elevation MI)|Completed||N/A|100|Actual|Hormozgan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 22:49:53.994693|2018-05-31 22:49:53.994693
NCT01306552|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2011-03-01|2011-03-01|2011-03-02|Estimate|||||||2011-03-01|2011-03-02|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|BEST||Evaluation of a Combined Parent-student Programme for Smoking Prevention in Berlin Schools|"BEST Prevention Study. Berlin Evaluates School Tabacco Prevention Study Evaluation of a Combined Parent-student Programme for Smoking Prevention in Berlin Schools"|Unknown status|Recruiting|N/A|3400|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 22:49:54.111777|2018-05-31 22:49:54.111777
NCT01306539|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-03-26|2011-03-01|2011-03-02|Estimate|||||||2013-03-26|2013-03-28|Estimate|July 2008||2008-07-31|March 2013|2013-03-31||||December 2014|Anticipated|2014-12-31||Interventional|||Neuropsychiatric Effects of Deep Brain Stimulation in Patients With Parkinson's Disease|Neuropsychiatric Effects of Deep Brain Stimulation in Patients With Parkinson's Disease|Unknown status|Enrolling by invitation|Phase 3|45|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 22:49:54.190191|2018-05-31 22:49:54.190191
NCT01306526|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2014-01-07|2011-03-01|2011-03-02|Estimate|||||||2014-01-07|2014-01-09|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|IDEAS-OSA||Relationship Between Obstructive Sleep Apnea and Coronary Atherosclerosis|Intravascular Ultrasound Diagnostic Evaluation of Atherosclerosis in Singapore- Obstructive Sleep Apnea (IDEAS-OSA) Study|Completed|||118|Actual|National University, Singapore|||1||f||||f||||||||||2018-05-31 22:49:54.304498|2018-05-31 22:49:54.304498
NCT01306513|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2012-11-16|2011-03-01|2011-03-02|Estimate|||||||2012-11-16|2012-11-19|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema|Effect of Autologous Bone Marrow Derived Mesenchymal Stromal Cells Prior to Lung Volume Reduction Surgery for Severe Pulmonary Emphysema- a Phase I Safety and Feasibility Study|Completed||Phase 1|10|Actual|Leiden University Medical Center||1|||f||||f||||||||||2018-05-31 22:49:54.3639|2018-05-31 22:49:54.3639
NCT01306500|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2014-08-07|2011-03-01|2011-03-02|Estimate|||||||2014-08-07|2014-08-08|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|GLAM||Effect of Gastric Lavage in Preventing Feeding Problems in Babies Born With Meconium Stained Amniotic Fluid|Effect of Gastric Lavage in Preventing Feeding Problems in Late Preterm and Term Neonates Born With Meconium Stained Amniotic Fluid : A Randomized Controlled Trial|Completed||N/A|538|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 22:49:54.428557|2018-05-31 22:49:54.428557
NCT01306487|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2012-07-31|2011-03-01|2011-03-02|Estimate|||||||2012-07-31|2012-08-02|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Observational|||Observation of Recovery of Foveal Cone Microstructures After Macular Hole Surgery|Correlation Between Visual Acuity and Recovery of Foveal Cone Microstructures After Macular Hole Surgery|Completed|||58|Actual|Kyorin University|||1||f||||f||||||||||2018-05-31 22:49:54.489579|2018-05-31 22:49:54.489579
NCT01306474|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-03-02|2011-02-28|2011-03-01|Estimate|||||||2011-03-02|2011-03-03|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|OTUP||Observation on the Treg in the Uveitis Patients|Clinical Study on the Regulatory T Cells in the Uveitis Patients Treated by Methotrexate|Completed|||30|Actual|Xijing Hospital|||2||f||||t||||||Samples Without DNA|"~     Experimental:A Drug: prednisone profess to convinced 1-1.5mg/Kg.d Experimental:B Drug:~     methotrexate profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced~     0.5-1mg/Kg.d~   "|||2018-05-31 22:49:54.549694|2018-05-31 22:49:54.549694
NCT01306435|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Low Power Laser and Exercise in Osteoarthritis of the Knee: a Randomized Clinical Trial|Effects of Low Power Laser Associated With Exercises in Osteoartite Knee: Randomized Clinical Trial, Double-blind, Controlled|Completed||Phase 2|40|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 22:49:54.749564|2018-05-31 22:49:54.749564
NCT01306422|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)|A Two Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Kinetics and Efficacy of Twice-Daily Repeat Intake of 1110 mg of Hoodia Gordonii Purified Extract (PYM50717)|Completed||N/A|64|Actual|Unilever R&D||6|||f||||f||||||||||2018-05-31 22:49:54.812914|2018-05-31 22:49:54.812914
NCT01306409|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-10-18|2011-02-28|2011-03-01|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)|Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents|Completed||Phase 4|9|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 22:49:54.890142|2018-05-31 22:49:54.890142
NCT01306396|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|April 2009||2009-04-30|February 2011|2011-02-28|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight Children|Investigation on the Preventive Effect of Reduced Fructose Consumption on the Development of Non-alcoholic Fatty Liver Disease in Children in a Long Term Study|Unknown status|Recruiting|N/A|100|Anticipated|University of Hohenheim||2|||f||||f||||||||||2018-05-31 22:49:54.94499|2018-05-31 22:49:54.94499
NCT01306383|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-11-09|2011-02-28|2011-03-01|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Interventional|SODISWATER||Solar Disinfection (SODIS) of Drinking Water for Use in Developing Countries or in Emergency Situations|Assessment of the Health Benefits Associated With Consumption of Solar Disinfection of Drinking Water by Children Under Age 5 Years, With Particular Emphasis on Dysentery and Childhood Diarrhoea|Completed||N/A|2400|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 22:49:55.010196|2018-05-31 22:49:55.010196
NCT01306370|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-08-27|2011-02-28|2011-03-01|Estimate|||||||2013-08-27|2013-08-28|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|ATRHEMOS||Fibrin Glue or Tranexamic Acid for Total Knee Arthroplasty|Prevention of Postoperative Blood Loss: Randomised Unicentric Parallel Clinical Trial That Assess the Efficacy of Fibrin Glue and Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.|Completed||Phase 3|172|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||4|||f||||f||||||||||2018-05-31 22:49:55.079396|2018-05-31 22:49:55.079396
NCT01306357|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2012-02-06|2011-02-28|2011-03-01|Estimate|||||||2012-02-06|2012-02-07|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Observational|ZOMAJET||Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device|Evaluation De L'Observance Globale Et De La Duree De Traitement Par Zomacton® Avec Le Stylo Transjecteur Zomajet® Etude Pharmaco-Epidemiologique Observationnelle Longitudinale Prospective|Completed|||87|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:49:55.240773|2018-05-31 22:49:55.240773
NCT01306344|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|March 2011|Anticipated|2011-03-31||Observational|||Qualitative Descriptive Study of the Meaning of the Ward Round|Qualitative Descriptive Study of the Meaning of the Ward Round|Unknown status|Not yet recruiting||12|Anticipated|Oslo University Hospital|||3||f||||f||||||||||2018-05-31 22:49:55.32604|2018-05-31 22:49:55.32604
NCT01306331|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28||2017-11-14|2017-11-14|2011-02-28|2011-03-01|Estimate||||2017-11-14|2017-11-17|Actual|2017-11-14|2017-11-17|Actual|April 2011||2011-04-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel|A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel|Completed||Phase 3|3389|Actual|Evofem Inc.||2|||f||||t||||||||||2018-05-31 22:49:55.383926|2018-05-31 22:49:55.383926
NCT01306318|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-11-16|2011-02-28|2011-03-01|Estimate|||||||2015-11-16|2015-11-17|Estimate|February 2011||2011-02-28|November 2015|2015-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions (Study 013-10)|A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions|Completed||N/A|24|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:49:55.489811|2018-05-31 22:49:55.489811
NCT01306305|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2012-03-01||2013-08-29|2011-02-28|2011-03-01|Estimate|2012-03-01|2012-03-29|Estimate||||2013-08-29|2013-09-09|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern Hemisphere|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations|Completed||Phase 4|110|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 22:49:55.570674|2018-05-31 22:49:55.570674
NCT01306292|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2015-02-10|2012-12-07|2016-10-25|2011-02-28|2011-03-01|Estimate|2016-01-11|2016-02-08|Estimate|2012-12-07|2012-12-11|Estimate|2016-10-25|2016-12-07|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety of SonoVue on Pulmonary Hemodynamics|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Crossover, Safety Study of the Effect of Intravenous Bolus Injections of SonoVue on Pulmonary Hemodynamics in Subjects With and Without Pulmonary Hypertension|Completed||Phase 2|36|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||Yes|Study of Lumason pulmonary hemodynamics|2018-05-31 22:49:55.864981|2018-05-31 22:49:55.864981
NCT01306279|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2016-03-17|2011-02-28|2011-03-01|Estimate|||||||2016-03-17|2016-03-21|Estimate|February 2011||2011-02-28|March 2013|2013-03-31||||August 2012|Actual|2012-08-31||Observational|||The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective|The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective|Completed|||50|Actual|Imperial College London|||1||f||||f||||||Samples Without DNA|"~     Sputum~   "|||2018-05-31 22:49:56.23094|2018-05-31 22:49:56.23094
NCT01306266|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-08-17|2011-02-28|2011-03-01|Estimate|||||||2015-08-17|2015-08-18|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|August 2011|Anticipated|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Maxalt||Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops|A Randomized, Double-blind, Placebo-controlled, Crossover Trial of Rizatriptan 10 mg Oral Disintegrating Tablet for Treatment of Acute Attacks of Chronic, Blast-induced, Post-traumatic Headache in U.S. Military Troops|Withdrawn||N/A|0|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||||2018-05-31 22:49:56.28651|2018-05-31 22:49:56.28651
NCT01306253|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2011-12-14||2013-08-29|2011-02-28|2011-03-01|Estimate|2011-12-14|2012-01-20|Estimate||||2013-08-29|2013-09-09|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2009/2010-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations|Completed||Phase 4|114|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 22:49:56.367673|2018-05-31 22:49:56.367673
NCT01306240|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2016-05-11|2011-02-28|2011-03-01|Estimate|||||||2016-05-11|2016-05-12|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ASPEN||Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation|Surfactant Treatment Compared to Nasal Continuous Positive Airway Pressure for the Management of Respiratory Distress Syndrome in the Newborn Between 35 and 41 Weeks of Gestation|Terminated||Phase 3|19|Actual|Centre Hospitalier Universitaire, Amiens||2||recruiting problems|f||||t||||||||||2018-05-31 22:49:56.617124|2018-05-31 22:49:56.617124
NCT01306227|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2016-05-13|2011-02-28|2011-03-01|Estimate|||||||2016-05-13|2016-05-16|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Interventional|||L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia|L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial|Unknown status|Active, not recruiting|Phase 3|50|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 22:49:56.674918|2018-05-31 22:49:56.674918
NCT01306214|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2014-05-16||2014-05-16|2011-02-28|2011-03-01|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Full Analysis Set (FAS): FAS included all randomised and treated patients who had a baseline HbA1c value.|Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus|A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on MDI Insulin Regimen Alone or With Metformin|Completed||Phase 3|566|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:49:56.769778|2018-05-31 22:49:56.769778
NCT01306201|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2012-05-02||2014-08-05|2011-02-28|2011-03-01|Estimate|2012-12-07|2013-01-10|Estimate||||2014-08-05|2014-08-07|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|||Novel Non-Invasive Monitoring Parameter in a Hospital Setting|A Novel Cardio-Respiratory Parameter in a Hospital Setting|Completed|||63|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-05-31 22:49:57.615254|2018-05-31 22:49:57.615254
NCT01306188|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2015-07-01|2011-02-28|2011-03-01|Estimate|||||||2015-07-01|2015-07-02|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|LYMPHOS1||Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer Patients|Study of Prognostic Value of T Cell Receptor Diversity and CD4 Lymphopenia in First Relapse Breast or Lung Cancer Patients|Completed|||179|Actual|Centre Leon Berard|||2||f||||f||||||Samples With DNA|"~     Whole blood, plasma, PBMC~   "|||2018-05-31 22:49:57.793628|2018-05-31 22:49:57.793628
NCT01306175|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2014-05-16||2014-05-16|2011-02-28|2011-03-01|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|February 2011||2011-02-28|May 2014|2014-05-31||||April 2011|Actual|2011-04-30||Interventional|||Drug Interaction Study of Digoxin and BI 10773|Relative Bioavailability of a Single Oral Dose of Digoxin (0.5 mg) When Administered Alone or in Combination With Multiple Oral Doses of BI 10773 (25 mg qd) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two-way Crossover Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:49:57.867172|2018-05-31 22:49:57.867172
NCT01306162|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2012-05-23||2014-06-03|2011-02-28|2011-03-01|Estimate|2012-06-29|2012-08-14|Estimate||||2014-06-03|2014-06-06|Estimate|February 2011||2011-02-28|April 2014|2014-04-30||||May 2011|Actual|2011-05-31||Interventional||Treated set contains of all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.|Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects|Relative Bioavailability of a Single Dose of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Dronedarone Tablet) or in Combination With 400 mg Bid Dronedarone (Tablet) at Steady State in Healthy Male and Female Volunteers (an Open Label, Randomised, Four-sequence, Two Period Cross-over, Phase I Study)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 22:49:58.070197|2018-05-31 22:49:58.070197
NCT01306149|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2017-10-24|2011-02-28|2011-03-01|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2002|Actual|2002-07-31|October 2017|2017-10-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|||Natural History of Mineral Metabolism Parameters and Protein-bound Toxins in Incident Peritoneal Dialysis Patients|Natural History of Biochemical Parameters of Mineral Metabolism and Protein-bound Uremic Retention Molecules in Incident Peritoneal Dialysis Patients: a Longitudinal Observational Study|Completed|||96|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples Without DNA|"~     whole blood, serum, urine and dialysate~   "|||2018-05-31 22:49:58.579625|2018-05-31 22:49:58.579625
NCT01306136|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|||Pilot Study of Exposure Therapy for Posttraumatic Stress Disorder|Pilot Study of Exposure Therapy for the Treatment of Puerto Ricans With Posttraumatic Stress Disorder|Completed||Phase 1|14|Actual|University of Puerto Rico||2|||f||||f||||||||||2018-05-31 22:49:58.633205|2018-05-31 22:49:58.633205
NCT01306123|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2014-10-31|2011-02-28|2011-03-01|Estimate|||||||2014-10-31|2014-11-03|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration|An Open, Randomized, Single-dose, Two-way Crossover Study to Characterize the Pharmacokinetic Properties of Cyanocobalamin When Administered as an Intranasal Spray and an Intramuscular Injection to Healthy Volunteers|Completed||Phase 1|16|Actual|Swedish Orphan Biovitrum||2|||f||||f||||||||||2018-05-31 22:49:58.692545|2018-05-31 22:49:58.692545
NCT01306110|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2016-01-07|2011-02-28|2011-03-01|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2007||2007-06-30|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|DIABSCAN||Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study|Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study|Completed|||277|Actual|Association HGE CHU Bordeaux Sud|||||f||||f||||||||||2018-05-31 22:49:58.755481|2018-05-31 22:49:58.755481
NCT01306097|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Zinc Supplementation and Severe and Recurrent Diarrhea|Evaluating the Impact of 3 Months Daily Zinc Supplementation on Incidence of Severe and Recurrent Diarrhea in 6 to 36 Months Age Children|Completed||N/A|100|Actual|Hormozgan University of Medical Sciences||1|||f||||f||||||||||2018-05-31 22:49:58.809759|2018-05-31 22:49:58.809759
NCT01306084|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-26|||2018-04-24|2011-02-26|2011-03-01|Estimate|||||||2018-04-24|2018-04-25|Actual|March 15, 2011||2011-03-15|April 5, 2018|2018-04-05||||||||Observational|||Viral Infections in Healthy and Immunocompromised Hosts|Viral Infections in Healthy and Immunocompromised Hosts|Enrolling by invitation|||129|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:49:58.879406|2018-05-31 22:49:58.879406
NCT01306058|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-26|2017-05-23||2017-12-27|2011-02-26|2011-03-01|Estimate|2017-12-27|2018-01-23|Actual||||2017-12-27|2018-01-23|Actual|February 11, 2011|Actual|2011-02-11|December 2017|2017-12-31|June 9, 2017|Actual|2017-06-09|June 1, 2016|Actual|2016-06-01||Interventional|||Sorafenib and TRC105 in Hepatocellular Cancer|A Phase I/II Study of TRC105 in Combination With Sorafenib in Hepatocellular Carcinoma (HCC)|Completed||Phase 1/Phase 2|27|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||Undecided||2018-05-31 22:49:58.981231|2018-05-31 22:49:58.981231
NCT01306045|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-26|||2018-02-07|2011-02-26|2011-03-01|Estimate|||||||2018-02-07|2018-02-08|Actual|February 26, 2011||2011-02-26|July 11, 2017|2017-07-11|December 30, 2019|Anticipated|2019-12-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies|Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies|Recruiting||Phase 2|600|Anticipated|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-05-31 22:49:59.601576|2018-05-31 22:49:59.601576
NCT01306032|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-26|2015-12-23||2017-03-16|2011-02-26|2011-03-01|Estimate|2016-04-16|2016-05-25|Estimate||||2017-03-16|2017-04-26|Actual|January 12, 2011|Actual|2011-01-12|March 2017|2017-03-31|December 15, 2016|Actual|2016-12-15|December 31, 2014|Actual|2014-12-31||Interventional||All enrolled participants.|Phase II ABT-888 With Cyclophosphamide|Phase II Randomized Trial of ABT-888 in Combination With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal, Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, or Triple-Negative Breast Cancer|Completed||Phase 2|124|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||f|t|f||||||No|Data are being shared with this CT.gov report and two peer-reviewed publications. There is no plan to share individual patient results.|2018-05-31 22:49:59.691231|2018-05-31 22:49:59.691231
NCT01306019|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-26|||2018-03-27|2011-02-26|2011-03-01|Estimate|||||||2018-03-27|2018-03-29|Actual|February 26, 2011||2011-02-26|February 15, 2018|2018-02-15|December 31, 2025|Anticipated|2025-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)|Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency|Recruiting||Phase 1/Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:50:01.082554|2018-05-31 22:50:01.082554
NCT01306006|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2014-08-06|2011-02-26|2011-03-01|Estimate|||||||2014-08-06|2014-08-07|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|MVEPI||The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age|The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age|Unknown status|Recruiting|Phase 4|3500|Anticipated|Bandim Health Project||2|||f||||||||||||||2018-05-31 22:50:01.198082|2018-05-31 22:50:01.198082
NCT01305993|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-27|2011-02-27|2011-03-01|Estimate|||||||2011-02-27|2011-03-01|Estimate|May 2011||2011-05-31|February 2011|2011-02-28||||December 2011|Anticipated|2011-12-31||Interventional|||Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer|Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Gastirc Cancer|Unknown status|Not yet recruiting|Phase 2|26|Anticipated|SBPharmaceutical IND, Co., LTD|||||f||||f||||||||||2018-05-31 22:50:01.272202|2018-05-31 22:50:01.272202
NCT01305980|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-03-03|2011-02-27|2011-03-01|Estimate|||||||2011-03-03|2011-03-04|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Colorectal Cancer|Phase Ⅱ,Open Label Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|SBPharmaceutical IND, Co., LTD|||||f||||f||||||||||2018-05-31 22:50:01.35372|2018-05-31 22:50:01.35372
NCT01305967|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-27|2011-02-27|2011-03-01|Estimate|||||||2011-02-27|2011-03-01|Estimate|January 2003||2003-01-31|February 2011|2011-02-28|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Interventional|||Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer|Phase Ⅱa,Open Label,Multicenter Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|20|Anticipated|SBPharmaceutical IND, Co., LTD|||||f||||f||||||||||2018-05-31 22:50:01.454592|2018-05-31 22:50:01.454592
NCT01305954|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-12-22|2011-02-25|2011-03-01|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2010||2010-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2013|Actual|2013-12-31||Observational|||Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients|LCCC 1027: Expression Of P16INK4a As A Predictor Of Myelosuppression In Patients With Breast Cancer|Active, not recruiting|||100|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 22:50:01.51993|2018-05-31 22:50:01.51993
NCT01305941|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2017-07-28||2017-09-14|2011-02-28|2011-03-01|Estimate|2017-09-14|2017-10-17|Actual||||2017-09-14|2017-10-17|Actual|September 2011||2011-09-30|September 2017|2017-09-30|May 4, 2019|Anticipated|2019-05-04|August 2016|Actual|2016-08-31||Interventional|||A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases|A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases|Active, not recruiting||Phase 2|32|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 22:50:01.622536|2018-05-31 22:50:01.622536
NCT01305915|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-25|2011-02-25|2011-03-01|Estimate|||||||2011-02-25|2011-03-01|Estimate|November 2007||2007-11-30|February 2011|2011-02-28|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|GBOT||Getting Back on Track: An Educational Group for Women With Breast Cancer|Getting Back on Track: A Single-session Psychoeducational Group Intervention for Women With Breast Cancer Completing Adjuvant Treatment|Completed||N/A|444|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 22:50:02.240609|2018-05-31 22:50:02.240609
NCT01305902|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2012-06-14|2011-02-28|2011-03-01|Estimate|||||||2012-06-14|2012-06-18|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Substance Use and Fitness|Substance Use and Fitness: A Pilot Study of Contingency Management in Older Adults|Completed||Phase 1|45|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 22:50:02.313577|2018-05-31 22:50:02.313577
NCT01305889|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-05-15|2011-02-28|2011-03-01|Estimate|||||||2015-05-15|2015-05-19|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor (BDNF) in Depressed Elders|The Effect of Problem Solving Therapy and Antidepressant Therapy on Cerebral Perfusion and Brain Derived Neurotropic Factor in Depressed Elders|Unknown status|Recruiting|N/A|38|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:50:02.362239|2018-05-31 22:50:02.362239
NCT01305876|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-25|2011-02-25|2011-03-01|Estimate|||||||2011-02-25|2011-03-01|Estimate|December 2008||2008-12-31|February 2011|2011-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Yoga in an Urban School for Children With Emotional Behavioral Disorders||Completed||N/A|41|Actual|Tufts Medical Center||1|||f||||||||||||||2018-05-31 22:50:02.429675|2018-05-31 22:50:02.429675
NCT01305863|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-05-01|2011-02-25|2011-03-01|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2011|Actual|2011-02-28|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|TGI-PVG-IDE||Feasibility Study of the TGI Adipose-derived Stromal Cell (ASC)-Coated ePTFE Vascular Graft|A Randomized, Controlled, Parallel Group, Blinded, Feasibility Study of the TGI Adipose-derived Stromal Cell (ASC)-Coated ePTFE Vascular Graft for Femoral-tibial Bypass Grafting.|Active, not recruiting||N/A|60|Anticipated|Tissue Genesis, LLC||2|||f||||t||||||||||2018-05-31 22:50:02.481061|2018-05-31 22:50:02.481061
NCT01305850|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2011-03-08|2011-02-28|2011-03-01|Estimate|||||||2011-03-08|2011-03-10|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|October 2011|Anticipated|2011-10-31|August 2011|Anticipated|2011-08-31||Interventional|||The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients|The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients|Unknown status|Recruiting|Phase 4|100|Anticipated|Chulalongkorn University||4|||f||||t||||||||||2018-05-31 22:50:02.541966|2018-05-31 22:50:02.541966
NCT01305837|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-07-10|2011-02-28|2011-03-01|Estimate|||||||2013-07-10|2013-07-11|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|COMTiMS||Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis|Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis|Completed||Phase 2|30|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 22:50:03.551807|2018-05-31 22:50:03.551807
NCT01305824|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16||2013-02-04|2015-04-08|2011-02-25|2011-03-01|Estimate||||2013-05-15|2013-05-23|Estimate|2015-04-08|2015-04-30|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease|Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease|Completed||Phase 2|151|Actual|Proteon Therapeutics||3|||f||||t||||||||||2018-05-31 22:50:03.639968|2018-05-31 22:50:03.639968
NCT01305811|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2014-09-29||2015-05-20|2011-02-25|2011-03-01|Estimate|2015-05-18|2015-05-21|Estimate||||2015-05-20|2015-06-15|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Acupuncture in the Treatment of Gulf War Illness|Acupuncture in the Treatment of Gulf War Illness|Completed||Phase 1/Phase 2|104|Actual|New England School of Acupuncture||2|||f||||t||||||||||2018-05-31 22:50:03.739568|2018-05-31 22:50:03.739568
NCT01305798|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2017-04-10|2011-02-25|2011-03-01|Estimate|||||||2017-04-10|2017-04-12|Actual|April 2011||2011-04-30|April 2017|2017-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening Participation|The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening Participation|Completed||N/A|11000|Actual|National Bureau of Economic Research, Inc.||3|||f||||f||||||||||2018-05-31 22:50:03.964817|2018-05-31 22:50:03.964817
NCT01305785|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-04-16|2011-02-28|2011-03-01|Estimate|||||||2013-04-16|2013-04-17|Estimate|January 1997||1997-01-31|April 2013|2013-04-30||||||||Observational|AMIS Plus||AMIS Plus - National Registry of Acute Myocardial Infarction in Switzerland|National Registry of Acute Myocardial Infarction in Switzerland|Unknown status|Recruiting||60000|Anticipated|Luzerner Kantonsspital|||||f||||f||||||||||2018-05-31 22:50:04.026094|2018-05-31 22:50:04.026094
NCT01305772|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2013-09-10||2014-08-19|2011-02-25|2011-03-01|Estimate|2014-08-19|2014-08-29|Estimate||||2014-08-19|2014-08-29|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|TOP0901||Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN|Identification of a Gene Expression Signature Profile for Panitumumab Sensitivity in Untreated Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)|Terminated||Phase 2|6|Actual|Duke University|Early termination leading to small numbers of subjects analyzed.|2||This study was terminated for low accrual.|f||||t||||||||||2018-05-31 22:50:04.201141|2018-05-31 22:50:04.201141
NCT01305759|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2017-04-17|2011-02-28|2011-03-01|Estimate|||||||2017-04-17|2017-04-18|Actual|April 2010||2010-04-30|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Observational|||Psychological, Sexually and Social Consequences of Osteoarthritis Treatment With THA or TKA and Joint Preserving Surgery|Psychological, Sexually and Social Consequences of Osteoarthritis Treatment With Total Hip or Total Knee Arthroplasties and Joint Preserving Surgery|Completed|||250|Anticipated|Hvidovre University Hospital|||3||f||||f||||||||||2018-05-31 22:50:04.552933|2018-05-31 22:50:04.552933
NCT01305746|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2014-02-11|2011-02-28|2011-03-01|Estimate|||||||2014-02-11|2014-02-13|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321|An Open-Label Long-term Safety Extension Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC)|Completed||Phase 2|382|Actual|Anthera Pharmaceuticals||3|||f||||t||||||||||2018-05-31 22:50:04.64654|2018-05-31 22:50:04.64654
NCT01305733|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2012-05-08|2011-02-28|2011-03-01|Estimate|||||||2012-05-08|2012-05-09|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|May 2012|Actual|2012-05-31||Interventional|LIA||Local Infiltration Analgesia During Total Knee Arthroplasty|Local Infiltration Analgesia During Total Knee Arthroplasty - Reduced Opiate Consumption and Faster Mobilisation Postoperatively - Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|60|Actual|Coxa, Hospital for Joint Replacement||2|||f||||t||||||||||2018-05-31 22:50:04.793747|2018-05-31 22:50:04.793747
NCT01305720|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||The Effect of Mydriatic Eye Drops on Cerebral and Mesenteric Oxygenation in Preterm Infants|The Effect of Mydriatic Eye Drops on Cerebral and Mesenteric Oxygenation in Preterm Infants|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||||f||||f||||||||||2018-05-31 22:50:04.865602|2018-05-31 22:50:04.865602
NCT01305707|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2015-08-28|2011-02-28|2011-03-01|Estimate|||||||2015-08-28|2015-08-31|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression|Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial|Terminated||Phase 4|104|Actual|Hospital Universitari de Bellvitge||2||Difficulties in recruiting|f||||f||||||||||2018-05-31 22:50:04.930115|2018-05-31 22:50:04.930115
NCT01305694|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-02-28|2011-02-28|2011-03-01|Estimate|||||||2011-02-28|2011-03-01|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|MSC||Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.|PhaseⅠ/ⅡTrial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia.|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||t||||||||||2018-05-31 22:50:05.115712|2018-05-31 22:50:05.115712
NCT01305681|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-11-02|2011-02-28|2011-03-01|Estimate|||||||2011-11-02|2011-11-03|Estimate|February 2011||2011-02-28|November 2011|2011-11-30||||December 2012|Anticipated|2012-12-31||Interventional|||Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization||Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Nationwide Children's Hospital||1|||f||||||||||||||2018-05-31 22:50:05.235316|2018-05-31 22:50:05.235316
NCT01305668|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2014-12-09|2011-02-28|2011-03-01|Estimate|||||||2014-12-09|2014-12-10|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Emphysema|Effectiveness of Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Emphysema Phenotype|Completed|||100|Actual|Villa Pineta Hospital|||2||f||||f||||||||||2018-05-31 22:50:05.30375|2018-05-31 22:50:05.30375
NCT01305655|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|2016-10-17||2016-12-10|2011-02-28|2011-03-01|Estimate|2016-12-10|2017-02-03|Estimate||||2016-12-10|2017-02-03|Estimate|July 2008||2008-07-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NOPHOCPG2||Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL|Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 3|47|Actual|Nordic Society for Pediatric Hematology and Oncology||1|||f||||t||||||||Yes|Publication in preparation in Pediatric Blood and Cancer|2018-05-31 22:50:05.381644|2018-05-31 22:50:05.381644
NCT01305642|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2016-08-08|2011-02-28|2011-03-01|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|IFO Pilot||Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study|Individualized Fortification of Breast Milk for Preterm Infants - A Pilot Study|Completed||N/A|13|Actual|McMaster Children's Hospital||1|||f||||f||||||||||2018-05-31 22:50:05.559793|2018-05-31 22:50:05.559793
NCT01305629|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2016-10-07|2011-02-28|2011-03-01|Estimate|||||||2016-10-07|2016-10-10|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional|||Intervention Targeting Substance Using Older Adults With HIV|Intervention Targeting Substance Using Older Adults With HIV|Completed||N/A|120|Actual|Hunter College of City University of New York||2|||f||||t||||||||||2018-05-31 22:50:05.624722|2018-05-31 22:50:05.624722
NCT01305616|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2011-03-25|2011-02-28|2011-03-01|Estimate|||||||2011-03-25|2011-03-28|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Effect of Yellow-Tinted Intraocular Lens on Standard Automated Perimetry (SAP) and Short-wavelength Automated Perimetry (SWAP) in Patients With and Without Glaucoma||Completed||N/A|34|Actual|Rassoul Akram Hospital||2|||f||||t||||||||||2018-05-31 22:50:05.70653|2018-05-31 22:50:05.70653
NCT01305603|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-28|||2013-04-10|2011-02-28|2011-03-01|Estimate|||||||2013-04-10|2013-04-11|Estimate|February 2011||2011-02-28|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Ultrasound-guided Dual TAP Block: Magnetic Resonance (MR) Evaluation of the Distribution of Local Anesthetic|Dual TAP Block Characteristics - Evaluation of Local Anesthetic Distribution by MR Scanning|Completed||N/A|10|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 22:50:05.788948|2018-05-31 22:50:05.788948
NCT01305590|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2018-03-30|2011-02-25|2011-02-28|Estimate|||||||2018-03-30|2018-04-03|Actual|July 2011||2011-07-31|March 2018|2018-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Understanding Medication Adherence Among HIV Patients|Understanding Medication Adherence Among HIV Patients|Completed||N/A|200|Actual|National Bureau of Economic Research, Inc.||1|||f||||f||||||||||2018-05-31 22:50:05.89054|2018-05-31 22:50:05.89054
NCT01305577|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2015-05-28||2015-06-17|2011-02-25|2011-02-28|Estimate|2015-05-28|2015-06-15|Estimate||||2015-06-17|2015-07-14|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Intent-to-treat population|Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat|Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|363|Actual|Kythera Biopharmaceuticals||3|||f||||f||||||||||2018-05-31 22:50:05.998993|2018-05-31 22:50:05.998993
NCT01305564|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2015-11-03||2016-02-29|2011-02-25|2011-02-28|Estimate|2015-11-03|2015-12-07|Estimate||||2016-02-29|2016-03-30|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional||All subjects receiving a Denali vena cava filter.|A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System|A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter|Completed||N/A|200|Actual|C. R. Bard||1|||f||||t||||||||Undecided||2018-05-31 22:50:06.626941|2018-05-31 22:50:06.626941
NCT01305551|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2014-06-04|2011-02-25|2011-02-28|Estimate|||||||2014-06-04|2014-06-05|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin Hydrochloride (HCl) XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States|Withdrawn||Phase 1|0|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 22:50:07.278639|2018-05-31 22:50:07.278639
NCT01305538|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14||2015-09-23|2015-11-06|2011-02-25|2011-02-28|Estimate||||2015-09-23|2015-10-12|Estimate|2015-11-06|2015-12-07|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Crossover Post-herpetic Neuralgia (PHN)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Cross-over Study of the Efficacy and Safety of BMS-954561 in Patients With Post-herpetic Neuralgia (PHN)|Completed||Phase 2|100|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 22:50:07.383657|2018-05-31 22:50:07.383657
NCT01305525|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-07-24|2011-02-25|2011-02-28|Estimate|||||||2015-07-24|2015-07-27|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|PAIN Registry||A Prospective Clinical Outcomes Registry|Partnership for Advancement In Neuromodulation (PAIN): A Prospective Clinical Outcomes Registry|Completed|||614|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 22:50:07.52528|2018-05-31 22:50:07.52528
NCT01305512|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2016-10-20|2011-02-25|2011-02-28|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Pharmacokinetic, Safety and Tolerability Study of SPARC1028||Completed||Phase 1|36|Actual|Sun Pharma Advanced Research Company Limited||1|||f||||f||||||||||2018-05-31 22:50:07.615064|2018-05-31 22:50:07.615064
NCT01305499|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2018-02-24|2011-02-25|2011-02-28|Estimate|||||||2018-02-24|2018-02-27|Actual|July 1, 2011|Actual|2011-07-01|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)|A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination With 5-Azacytidine (5AC, NSC 102816) in Elderly Patients With Acute Myeloid Leukemia (AML)|Recruiting||Phase 2|108|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:50:07.677066|2018-05-31 22:50:07.677066
NCT01305486|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2013-01-14|2011-02-25|2011-02-28|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|XenMatrix||A Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation|A Prospective, Multi-Center Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation|Terminated|||4|Actual|C. R. Bard|||1|Sponsor decision, not safety related.|f||||f||||||||||2018-05-31 22:50:07.7602|2018-05-31 22:50:07.7602
NCT01305473|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2012-06-12||2012-07-31|2011-02-25|2011-02-28|Estimate|2012-06-12|2012-07-18|Estimate||||2012-07-31|2012-08-01|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|Sepramesh||A Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite|A Single Arm, Single-Center, Retrospective Study With Prospective Follow-Up of Laparoscopic Ventral Hernia Repair Utilizing the Bard Sepramesh IP Composite|Completed|||90|Actual|C. R. Bard|Study was designed to use existing data. Limitations include: limited data generalizability given the retrospective, single center study design; incomplete documentation did not permit evaluation of recovery time as pre-specified secondary endpoint.||1||f||||f||||||||||2018-05-31 22:50:07.831464|2018-05-31 22:50:07.831464
NCT01305460|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-10-28|2011-02-25|2011-02-28|Estimate|||||||2015-10-28|2015-10-29|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)|A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients|Unknown status|Active, not recruiting|Phase 1/Phase 2|81|Anticipated|Groupe Francophone des Myelodysplasies||1|||f||||f||||||||||2018-05-31 22:50:08.06897|2018-05-31 22:50:08.06897
NCT01305447|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2014-12-15|2011-02-25|2011-02-28|Estimate|||||||2014-12-15|2014-12-16|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Getting Physical on Cigarettes - Smoking Cessation & Relapse Prevention|Getting Physical on Cigarettes: Exercise and Smoking Cessation - Preventing Relapse|Completed||Phase 2|413|Actual|University of Western Ontario, Canada||4|||f||||f||||||||||2018-05-31 22:50:08.16683|2018-05-31 22:50:08.16683
NCT01305434|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-02-02|2011-02-25|2011-02-28|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Mulberry Leaf Extract and Blood Glucose Control in Diabetics|Randomized Double Blind Cross Over Trial to Examine the Effect of Mulberry Leaf Extract on Post Prandial Glucose in Type 2 Diabetics|Completed||Phase 1/Phase 2|20|Actual|Craig, Nancy, M.D.||2|||f||||f||||||||||2018-05-31 22:50:08.248115|2018-05-31 22:50:08.248115
NCT01305421|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-25|2011-02-25|2011-02-28|Estimate|||||||2011-02-25|2011-02-28|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|April 2011|Anticipated|2011-04-30|March 2011|Anticipated|2011-03-31||Interventional|griptest92||Grip Test in Ventilated ICU Patients|The Role of the Grip Test in the Evaluation of Extubation Success in ICU Patients.|Unknown status|Recruiting|N/A|50|Anticipated|Centre Hospitalier Universitaire Brugmann|||||f||||f||||||||||2018-05-31 22:50:08.315031|2018-05-31 22:50:08.315031
NCT01305408|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2015-01-15|2014-05-08|2016-04-26|2011-02-25|2011-02-28|Estimate|2015-01-15|2015-01-26|Estimate|2014-05-08|2014-05-26|Estimate|2016-04-26|2016-05-26|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Randomized participants|Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|Completed||Phase 3|399|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 22:50:08.510995|2018-05-31 22:50:08.510995
NCT01305044|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2013-03-13||2015-11-09|2011-02-24|2011-02-28|Estimate|2015-11-09|2015-12-14|Estimate||||2015-11-09|2015-12-14|Estimate|December 2009||2009-12-31|November 2015|2015-11-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|HEALS||The HEALS Project - Health Education and Active Living for Surviving Seniors|Biobehavioral Effects of Tai Chi Chih Among Elderly Female Cancer Survivors|Completed||Phase 2|63|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:50:13.754825|2018-05-31 22:50:13.754825
NCT01305395|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2017-01-23|2011-02-25|2011-02-28|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|STOPCAV||Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients|Early Vs Late Sirolimus-Initiation Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||5||Due in part, to reduced transplant volume and enrollment has been difficult.|f||||t||||||||||2018-05-31 22:50:09.642493|2018-05-31 22:50:09.642493
NCT01305382|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2016-11-11|2011-02-25|2011-02-28|Estimate|||||||2016-11-11|2016-11-15|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CAVII||Noninvasive Evaluation of Cardiac Allograft Vasculopathy|Noninvasive Evaluation of Cardiac Allograft Vasculopathy in Heart Transplant Recipients II|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||3|PI left institution|f||||t||||||||||2018-05-31 22:50:09.73577|2018-05-31 22:50:09.73577
NCT01305369|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2012-03-05|2011-02-25|2011-02-28|Estimate|||||||2012-03-05|2012-03-06|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PRINA||The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma|The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma: a Pilot Randomised Controlled Trial (PRINA Study)|Completed||Phase 4|26|Actual|University of Milan|||||f||||f||||||||||2018-05-31 22:50:09.796417|2018-05-31 22:50:09.796417
NCT01305356|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2012-10-18|2011-02-25|2011-02-28|Estimate|||||||2012-10-18|2012-10-19|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions|A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions|Unknown status|Active, not recruiting|Phase 3|201|Anticipated|BioMimetic Therapeutics||2|||f||||f||||||||||2018-05-31 22:50:09.86005|2018-05-31 22:50:09.86005
NCT01305343|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-12-23|2011-02-25|2011-02-28|Estimate|||||||2015-12-23|2015-12-24|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Observational|||Neurologic Complications in Spinal Deformity Surgery|Evaluation of Neurologic Complications Associated With Surgical Correction of Adult Spinal Deformity: A Prospective, Observational, Multi-center Study|Completed|||273|Actual|AOSpine International|||1||f||||t||||||||||2018-05-31 22:50:09.953345|2018-05-31 22:50:09.953345
NCT01305330|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-05-29|2011-02-25|2011-02-28|Estimate|||||||2017-05-29|2017-05-31|Actual|August 2004||2004-08-31|May 2017|2017-05-31|January 2024|Anticipated|2024-01-31|December 2020|Anticipated|2020-12-31||Observational|||The Natural History of Small Renal Masses|Role of Active Surveillance and Identification of Prognostic Factors for Progression in Early Stage Renal Cell Carcinoma|Recruiting|||170|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||Samples With DNA|"~     Biopsy cores, nephrectomy tissue, and blood and urine will be collected~   "|No||2018-05-31 22:50:10.028395|2018-05-31 22:50:10.028395
NCT01305317|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-28|2011-02-25|2011-02-28|Estimate|||||||2011-02-28|2011-03-01|Estimate|January 2007||2007-01-31|January 2006|2006-01-31|January 2010|Actual|2010-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients|Study of Statins' Effect on Serum IgG, IgA Ang IgM Level in Chronic Hemodialysis Patients|Completed||N/A|74|Actual|Hormozgan University of Medical Sciences||1|||f||||f||||||||||2018-05-31 22:50:10.084907|2018-05-31 22:50:10.084907
NCT01305304|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2013-05-14|2011-02-25|2011-02-28|Estimate|||||||2013-05-14|2013-05-15|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|||Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology|Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology|Completed|||30|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||Samples Without DNA|"~     serum, plasma~   "|||2018-05-31 22:50:10.153573|2018-05-31 22:50:10.153573
NCT01305291|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-25|2011-02-25|2011-02-28|Estimate|||||||2011-02-25|2011-02-28|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Fibersol-2 Clinical Trials Related to Appetite|Fibersol-2 Clinical Trials Related to Appetite|Completed||N/A|20|Actual|Iowa State University||5|||f||||f||||||||||2018-05-31 22:50:10.308147|2018-05-31 22:50:10.308147
NCT01305278|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-10-25|2011-02-24|2011-02-28|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Efficacy of Balance Gaming as an Adjunct to Vestibular Rehabilitation Therapy|The Efficacy of Balance Gaming as an Adjunct to Vestibular Rehabilitation Therapy|Terminated||N/A|7|Actual|University Health Network, Toronto||3||We unfortunately experienced recruitment difficulties with this study for the past few years.|f||||f||||||||||2018-05-31 22:50:10.384998|2018-05-31 22:50:10.384998
NCT01305265|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2014-01-06||2014-01-06|2011-02-25|2011-02-28|Estimate|2014-01-06|2014-02-26|Estimate||||2014-01-06|2014-02-26|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Post-operative Sore Throat as Determined by Endotracheal Tube Inflation Technique|Post-operative Sore Throat as Determines by Endotracheal Tube Inflation Technique|Completed||N/A|141|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 22:50:10.455448|2018-05-31 22:50:10.455448
NCT01305252|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2016-11-21||2017-04-27|2011-02-24|2011-02-28|Estimate|2017-04-27|2017-06-02|Actual||||2017-04-27|2017-06-02|Actual|July 2010||2010-07-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).|CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil|Completed||Phase 4|21|Actual|Stanford University|Limitations: small,2 center study,Placebo Un-blinded,Limited event rates/Time to clinical worsening and harmonization of measures.|2|||f||||t||||||||||2018-05-31 22:50:10.662412|2018-05-31 22:50:10.662412
NCT01305239|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2012-03-08||2012-03-08|2011-02-24|2011-02-28|Estimate|2012-03-08|2012-04-10|Estimate||||2012-03-08|2012-04-10|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|ETAPE||A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients|A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients|Terminated|||398|Actual|Pfizer|Study recruitment was stopped due to difficulty enrolling the target number of participants. There were no safety concerns in the decision to terminate this study.||1|See termination reason in detailed description.|f||||f||||||||||2018-05-31 22:50:10.964811|2018-05-31 22:50:10.964811
NCT01305226|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2012-02-02|2011-02-25|2011-02-28|Estimate|||||||2012-02-02|2012-02-03|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|THR-100||A Trial Using Double-Bolus THR-100 Versus Streptokinase|A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction|Completed||Phase 3|120|Actual|Bharat Biotech International Limited||2|||f||||t||||||||||2018-05-31 22:50:11.218664|2018-05-31 22:50:11.218664
NCT01305213|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2017-06-14||2017-09-20|2011-02-25|2011-02-28|Estimate|2017-06-14|2017-07-12|Actual||||2017-09-20|2017-10-23|Actual|March 2011||2011-03-31|September 2017|2017-09-30|November 3, 2016|Actual|2016-11-03|August 2016|Actual|2016-08-31||Interventional|||Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|A Randomized Phase II Evaluation of Single-Agent Bevacizumab (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Completed||Phase 2|107|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 22:50:11.332629|2018-05-31 22:50:11.332629
NCT01305200|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2016-11-30||2017-03-28|2011-02-25|2011-02-28|Estimate|2017-03-28|2017-05-09|Actual||||2017-03-28|2017-05-09|Actual|March 2011||2011-03-31|November 2016|2016-11-30|June 30, 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant|A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation|Completed||Phase 3|226|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 22:50:12.144197|2018-05-31 22:50:12.144197
NCT01305187|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-06-17|2011-02-25|2011-02-28|Estimate|||||||2011-06-17|2011-06-20|Estimate|February 2011||2011-02-28|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3|Monocentric, Randomized, Subject and Rater Blinded Clinical Investigation to Prove the Non-inferiority of Belotero® Basic Versus Juvéderm® Ultra 3 Containing Lidocaine - After Single Injection for Correction of Nasolabial Folds (NLF)|Completed||Phase 4|40|Actual|Merz Pharmaceuticals GmbH||1|||f||||f||||||||||2018-05-31 22:50:12.643292|2018-05-31 22:50:12.643292
NCT01305174|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2016-09-29|2011-02-25|2011-02-28|Estimate|||||||2016-09-29|2016-09-30|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Iliac, Common and External (ICE) Artery Stent Trial|Balloon Expandable vs. Selfexpanding Stents to Treat Stenosis or Occlusions of Common and External Iliac Artery Disease|Terminated||Phase 4|660|Actual|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.||2||Delayed recruitment|f||||f||||||||Undecided||2018-05-31 22:50:12.700576|2018-05-31 22:50:12.700576
NCT01305161|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-08-31|2011-02-25|2011-02-28|Estimate|||||||2015-08-31|2015-09-01|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Interventional|CYPREANE||Flow Cytometry Applied to the Diagnosis of Peri-anaesthesic Reactions|Diagnostic Accuracy of Flow Cytometry Applied to the Diagnosis of Peri-anaesthesic Reactions Induced by Neuromuscular Blockers|Unknown status|Recruiting|N/A|212|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 22:50:12.853377|2018-05-31 22:50:12.853377
NCT01305148|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-08-27|2011-02-25|2011-02-28|Estimate|||||||2015-08-27|2015-08-31|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|WARFARIN||Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)|Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)|Suspended||N/A|3800|Anticipated|Iverson Genetic Diagnostics, Inc.||3||Sponsor is raising funds for the remainder of the study|f||||t||||||||||2018-05-31 22:50:12.933021|2018-05-31 22:50:12.933021
NCT01305135|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2017-06-06|2011-02-25|2011-02-28|Estimate|||||||2017-06-06|2017-06-07|Actual|December 30, 2010|Actual|2010-12-30|June 2017|2017-06-30|May 9, 2016|Actual|2016-05-09|June 2011|Actual|2011-06-30||Interventional|||Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes|A Phase I-II Study of the Efficacy and Safety of Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes|Completed||Phase 1/Phase 2|41|Actual|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||No||2018-05-31 22:50:13.094748|2018-05-31 22:50:13.094748
NCT01305122|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2018-02-27|2011-02-25|2011-02-28|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2011||2011-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma|Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study|Active, not recruiting||N/A|183|Anticipated|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 22:50:13.197574|2018-05-31 22:50:13.197574
NCT01305109|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2012-06-09|2011-02-25|2011-02-28|Estimate|||||||2012-06-09|2012-06-12|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|ROTAVAC||A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E|A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants|Unknown status|Active, not recruiting|Phase 3|6800|Anticipated|Bharat Biotech International Limited||2|||f||||t||||||||||2018-05-31 22:50:13.296471|2018-05-31 22:50:13.296471
NCT01305096|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2014-10-23|2011-02-25|2011-02-28|Estimate|||||||2014-10-23|2014-10-24|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects of Yoga on Objective and Self-reported Health Indicators Among Female and Male Individuals|Effects of Yoga on Objective and Self-reported Health Indicators Among Female and Male Individuals|Completed||N/A|44|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 22:50:13.397803|2018-05-31 22:50:13.397803
NCT01305083|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2012-05-11|2011-02-25|2011-02-28|Estimate|||||||2012-05-11|2012-05-14|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.|A Randomized, Double Blind, Placebo Controlled, Multicentric Study to Assess the Efficacy and Safety of Udenafil Tablets in Patients Suffering From Erectile Dysfunction.|Completed||Phase 3|118|Actual|Abdi Ibrahim Ilac San. ve Tic A.S.||2|||f||||f||||||||||2018-05-31 22:50:13.510701|2018-05-31 22:50:13.510701
NCT01305070|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-02-05|2011-02-25|2011-02-28|Estimate|||||||2015-02-05|2015-02-06|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|FAIR||Standard Balloon Angioplasty Versus Angioplasty With a Paclitaxel-eluting Balloon for Femoral Artery In-stent Restenosis|Femoral Artery In-Stent Restenosis (FAIR) Trial|Completed||Phase 4|118|Anticipated|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.||2|||f||||f||||||||||2018-05-31 22:50:13.586632|2018-05-31 22:50:13.586632
NCT01305031|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2014-10-25|2011-02-25|2011-02-28|Estimate|||||||2014-10-25|2014-10-28|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|||Resuscitation of Late-preterm Infants by Using Room Air or 100% Oxygen|Resuscitation of Late-preterm Infants by Using Room Air or 100% Oxygen|Completed||N/A|70|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 22:50:14.068655|2018-05-31 22:50:14.068655
NCT01305018|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-05-04|2011-02-25|2011-02-28|Estimate|||||||2011-05-04|2011-05-05|Estimate|August 2011||2011-08-31|April 2011|2011-04-30|August 2012|Anticipated|2012-08-31|January 2012|Anticipated|2012-01-31||Interventional|||Branched-chain Amino Acids Supplementation and Resistance Exercise-induced Muscle Damage and Inflammation|Effects of Leucine and Branched-chain Amino Acids (BCAA) Supplementation on Resistance Exercise-induced Muscle Damage and Inflammation: a Randomized, Double-blind, and Placebo-controlled Study|Suspended||N/A|30|Anticipated|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 22:50:14.138477|2018-05-31 22:50:14.138477
NCT01305005|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2012-07-16|2011-02-25|2011-02-28|Estimate|||||||2012-07-16|2012-07-18|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Observational|||Effect of Phacoemulsification on Ocular Blood Flow in Human|To Investigate Ocular Haemodynamics After Phacoemulsification Surgery|Completed|||58|Actual|Wenzhou Medical University|||3||f||||f||||||||||2018-05-31 22:50:14.219332|2018-05-31 22:50:14.219332
NCT01304992|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2012-11-22|2011-02-25|2011-02-28|Estimate|||||||2012-11-22|2012-11-27|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Cholesterol-lowering Effects of Lupin Protein|Effects of Lupin Protein on Lipid and Protein Metabolism in Moderate Hypercholesterolemic Subjects|Completed||N/A|66|Actual|University of Jena||3|||f||||t||||||||||2018-05-31 22:50:14.276109|2018-05-31 22:50:14.276109
NCT01304979|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2014-12-29|2011-02-24|2011-02-28|Estimate|||||||2014-12-29|2014-12-30|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Acuspine||'Acupuncture Therapy' for Pain and Function Recovery in Spine Surgery Patients|'Acupuncture Therapy' for Pain and Function Recovery in Spine Surgery Patients|Completed||N/A|114|Anticipated|Beth Israel Medical Center||3|||f||||t||||||||||2018-05-31 22:50:14.343052|2018-05-31 22:50:14.343052
NCT01304966|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|2013-04-13||2014-01-01|2011-02-25|2011-02-28|Estimate|2014-01-01|2014-02-17|Estimate||||2014-01-01|2014-02-17|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational||Children With Recurrent Respiratory Papillomatosis in Thailand|Human Papillomatosis Genotyping of Children in Thailand|Human Papillomatosis Genotyping and Severity in Patients With Recurrent Respiratory Papillomatosis of Children in Thailand|Completed|||15|Actual|Queen Sirikit National Institute of Child Health|The number of patients participating in this study was low , so additional studies should be conducted to make the research more effective.||||f||||f||||||Samples With DNA|"~     Papillomatous tissue samples taken from endoscopic biopsies will be collected by the ENT~     specialists.Samples collected from the subjects will be analyzed for HPV genotype at the Unit~     of virology and molecular, Department of pathology, Faculty of medicine Ramathibodi hospital.~   "|||2018-05-31 22:50:14.4108|2018-05-31 22:50:14.4108
NCT01304953|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-25|2011-02-25|2011-02-28|Estimate|||||||2011-02-25|2011-02-28|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Tropisetron on Postoperative Pain|Tropisetron on Postoperative Pain in Women After Gynaecological Laparoscopy|Completed||Phase 4|296|Actual|Huazhong University of Science and Technology||4|||f||||t||||||||||2018-05-31 22:50:14.560381|2018-05-31 22:50:14.560381
NCT01304940|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2017-08-29|2011-02-25|2011-02-28|Estimate|||||||2017-08-29|2017-08-31|Actual|December 2008|Actual|2008-12-31|August 2017|2017-08-31|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Observational|||Women's Post Traumatic Stress Disorder (PTSD) Research Study|The Psychophysiology and Neurobiology of PTSD Across the Menstrual Cycle|Completed|||50|Actual|VA Boston Healthcare System|||||f||||t||||||Samples Without DNA|"~     Urine, blood and saliva samples are taken. Only blood and saliva samples are retained and~     used to measure stress hormone levels.~   "|||2018-05-31 22:50:14.708647|2018-05-31 22:50:14.708647
NCT01304927|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2016-06-06|2011-02-25|2011-02-28|Estimate|||||||2016-06-06|2016-06-08|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional|||Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial|Vitamin D Supplementation and Male Infertility: The Copenhagen Bone-Gonadal Study a Double Blinded Randomized Clinical Trial|Completed||Phase 2/Phase 3|307|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 22:50:14.775714|2018-05-31 22:50:14.775714
NCT01304914|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2016-03-30|2011-02-25|2011-02-28|Estimate|||||||2016-03-30|2016-03-31|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|ORChID||Observational Research in Childhood Infectious Diseases Study|Prospective, Community-based, Longitudinal Dynamic Birth Cohort Study of Respiratory and Gastrointestinal Pathogen Identification in Brisbane Infants.|Completed|||165|Actual|Queensland Children's Medical Research Institute|||1||f||||f||||||Samples With DNA|"~     Parent-collected anterior-nasal swabs Nappy swabs~   "|||2018-05-31 22:50:14.875926|2018-05-31 22:50:14.875926
NCT01304901|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-12-17|2011-02-25|2011-02-28|Estimate|||||||2011-12-17|2011-12-20|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.|Phase 4 Study of Single Dose of Oral Montelukast When Adding to Standard Treatment in Acute Moderate to Severe Wheezing in Preschool Children.|Completed||Phase 4|80|Actual|Kecioren Education and Training Hospital||2|||f||||f||||||||||2018-05-31 22:50:14.934882|2018-05-31 22:50:14.934882
NCT01304888|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2012-07-25|2011-02-25|2011-02-28|Estimate|||||||2012-07-25|2012-07-26|Estimate|October 2003||2003-10-31|February 2011|2011-02-28|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Evaluating the Impact of the Food Support Program (Programa de Apoyo Alimentaria)|Evaluating the Impact of the Programa de Apoyo Alimentaria|Completed||N/A|6687|Actual|Instituto Nacional de Salud Publica, Mexico||4|||f||||f||||||||||2018-05-31 22:50:15.000139|2018-05-31 22:50:15.000139
NCT01304875|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2013-06-25|2011-02-25|2011-02-28|Estimate|||||||2013-06-25|2013-06-27|Estimate|April 2010||2010-04-30|June 2013|2013-06-30||||||||Observational|||Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease|Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease|Unknown status|Recruiting||20|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 22:50:15.062078|2018-05-31 22:50:15.062078
NCT01304862|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2011-02-25|2011-02-25|2011-02-28|Estimate|||||||2011-02-25|2011-02-28|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|eSMART-MH||Electronic Self-management Resource Training for Mental Health|Electronic Self-management Resource Training for Mental Health|Unknown status|Not yet recruiting|Phase 1|100|Anticipated|Case Western Reserve University||2|||f||||||||||||||2018-05-31 22:50:15.11953|2018-05-31 22:50:15.11953
NCT01304849|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-25|||2015-02-02|2011-02-25|2011-02-28|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes|Phase II Study of Interim PET-CT Scan-guided Response Adapted Therapy in Hodgkin's Lymphoma|Completed||N/A|50|Actual|Cancer Institute WIA||1|||f||||f||||||||||2018-05-31 22:50:15.239304|2018-05-31 22:50:15.239304
NCT01304836|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-08-31|2011-02-25|2011-02-28|Estimate|||||||2017-08-31|2017-09-01|Actual|January 22, 2011|Actual|2011-01-22|August 2017|2017-08-31|May 22, 2013|Actual|2013-05-22|May 22, 2013|Actual|2013-05-22||Interventional|ADVANCE||A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids|Investigating New Onset Diabetes Mellitus in Kidney Transplant Recipients Receiving an Advagraf-Based Immunosuppressive Regimen With or Without Corticosteroids - A Multicenter, Two Arm, Randomized, Open Label Clinical Study|Completed||Phase 4|1166|Actual|Astellas Pharma Inc||2|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 22:50:15.32911|2018-05-31 22:50:15.32911
NCT01304823|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2015-07-15|2011-02-24|2011-02-25|Estimate|||||||2015-07-15|2015-07-16|Estimate|June 2010||2010-06-30|July 2015|2015-07-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY|The Role of Sweet Taste Receptor Blockade on Intraduodenal Glucose- and Liquid Meal-stimulated Secretion of Satiation Peptides in Healthy Humans|Completed||Phase 1|10|Actual|University Hospital, Basel, Switzerland||5|||f||||f||||||||||2018-05-31 22:50:15.619047|2018-05-31 22:50:15.619047
NCT01304810|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2012-05-10|2011-02-24|2011-02-25|Estimate|||||||2012-05-10|2012-05-14|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation|A Phase 3, Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX™ as an Aid to Smoking Cessation|Completed|||300|Actual|Nabi Biopharmaceuticals|||2||f||||f||||||Samples Without DNA|"~     serum samples~   "|||2018-05-31 22:50:15.717857|2018-05-31 22:50:15.717857
NCT01304797|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2017-01-04|2011-02-24|2011-02-25|Estimate|||||||2017-01-04|2017-01-06|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|January 2017|Anticipated|2017-01-31|August 2016|Actual|2016-08-31||Interventional|||Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer|Active, not recruiting||Phase 1|75|Anticipated|Merrimack Pharmaceuticals||4|||f||||f||||||||||2018-05-31 22:50:15.822218|2018-05-31 22:50:15.822218
NCT01304784|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2015-12-15|2011-02-24|2011-02-25|Estimate|||||||2015-12-15|2015-12-16|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer|A Phase 1 and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors|Completed||Phase 1|100|Anticipated|Merrimack Pharmaceuticals||5|||f||||f||||||||||2018-05-31 22:50:15.920368|2018-05-31 22:50:15.920368
NCT01304771|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2012-06-19|2011-02-24|2011-02-25|Estimate|||||||2012-06-19|2012-06-20|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly|A Phase I Trial of the Safety and Efficacy of Adjuvant AKSB (Agri-King Synbiotic) Synbiotic in Patients 65 Years of Age and Older Receiving the Influenza Vaccine|Completed||Phase 1|22|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:50:16.041469|2018-05-31 22:50:16.041469
NCT01304758|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2013-08-22|2011-02-24|2011-02-25|Estimate|||||||2013-08-22|2013-08-26|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Essential Tremor|Completed||Phase 1|15|Actual|InSightec||1|||f||||f||||||||||2018-05-31 22:50:16.115836|2018-05-31 22:50:16.115836
NCT01304745|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-07-07|2011-02-24|2011-02-25|Estimate|||||||2013-07-07|2013-07-09|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|September 2013|Anticipated|2013-09-30||Interventional|||Rehabilitation of Women Following Treatment for Gynaecological Cancer; a Randomized, Controlled Study|Rehabilitation of Women Following Treatment for Gynaecological Cancer; a Randomized, Controlled Study|Unknown status|Not yet recruiting|Phase 1|130|Anticipated|Haukeland University Hospital||3|||f||||t||||||||||2018-05-31 22:50:16.185852|2018-05-31 22:50:16.185852
NCT01304732|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-03-13|2011-02-24|2011-02-25|Estimate|||||||2012-03-13|2012-03-15|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Observational|||Totally Implantable Catheters in Pediatric Hematology-oncology: a Study on Infectious Complications||Completed|||158|Actual|Grupo de Apoio ao Adolescente e a Crianca com Cancer|||||f||||f||||||||||2018-05-31 22:50:16.249406|2018-05-31 22:50:16.249406
NCT01304719|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-05-13|2011-02-24|2011-02-25|Estimate|||||||2013-05-13|2013-05-15|Estimate|October 2007||2007-10-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Computer-based Intervention to Augment Home Visitation Services: The E-Parenting Project|A Computer-based Intervention to Augment Home Visitation Services: The E-Parenting Project|Completed||N/A|413|Actual|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 22:50:16.297224|2018-05-31 22:50:16.297224
NCT01304706|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2015-04-17||2015-04-17|2011-02-24|2011-02-25|Estimate|2015-04-17|2015-05-04|Estimate||||2015-04-17|2015-05-04|Estimate|April 2011||2011-04-30|April 2015|2015-04-30||||November 2013|Actual|2013-11-30||Interventional|||Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study||Completed||Phase 3|120|Actual|Alimera Sciences||1|||f||||f||||||||||2018-05-31 22:50:16.505707|2018-05-31 22:50:16.505707
NCT01304693|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2014-04-07||2014-07-07|2011-02-24|2011-02-25|Estimate|2014-04-07|2014-05-07|Estimate||||2014-07-07|2014-07-17|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||This analysis population includes all patients who were randomized, received study drug, and completed at least 1 scheduled on-therapy study visit (ITT).|ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients|Safety and Efficacy Study of ESBA1008 Versus LUCENTIS® for the Treatment of Exudative Age-Related Macular Degeneration|Completed||Phase 1/Phase 2|376|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:50:17.045651|2018-05-31 22:50:17.045651
NCT01304680|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-11-28|2011-02-24|2011-02-25|Estimate|||||||2012-11-28|2012-11-29|Estimate|January 2011||2011-01-31|November 2012|2012-11-30||||||||Observational|||Evaluation of Fluid Resuscitation in Children With Cancer With Severe Sepsis / Septic Shock||Unknown status|Recruiting||50|Anticipated|Grupo de Apoio ao Adolescente e a Crianca com Cancer|||||f||||f||||||||||2018-05-31 22:50:18.211146|2018-05-31 22:50:18.211146
NCT01304667|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2016-05-09|2011-02-24|2011-02-25|Estimate|||||||2016-05-09|2016-05-10|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|CARE||Chemo- and Radiotherapy in Epithelial Vulvar Cancer|Chemo- and Radiotherapy in Epithelial Vulvar Cancer|Completed|||1618|Actual|AGO Study Group|||||f||||f||||||Samples Without DNA|"~     Subproject of Translational Research:~      Paraffin embedded tissue samples were collected.~   "|||2018-05-31 22:50:18.257451|2018-05-31 22:50:18.257451
NCT01304654|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-03-13|2011-02-24|2011-02-25|Estimate|||||||2013-03-13|2013-03-14|Estimate|January 2011||2011-01-31|March 2013|2013-03-31||||March 2013|Actual|2013-03-31||Observational|||ALI/ARDS in Oncologic Pediatric Patients|Practice of Mechanical Ventilation in Pediatric Oncologic Patients Diagnosed With Acute Lung Injury / Acute Respiratory Distress Syndrome|Unknown status|Active, not recruiting||29|Actual|Grupo de Apoio ao Adolescente e a Crianca com Cancer|||1||f||||f||||||||||2018-05-31 22:50:18.31024|2018-05-31 22:50:18.31024
NCT01304641|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2012-01-03||2012-03-08|2011-02-24|2011-02-25|Estimate|2012-03-08|2012-04-05|Estimate||||2012-03-08|2012-04-05|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Cardiovascular Events Based On Statin Initiation In The Elderly|Comparison Of Cardiovascular Event Rates In Elderly Patients With Newly Initiated Atorvastatin Or Simvastatin|Completed|||31603|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 22:50:18.3723|2018-05-31 22:50:18.3723
NCT01304628|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2014-12-15|2011-02-24|2011-02-25|Estimate|||||||2014-12-15|2014-12-16|Estimate||||December 2014|2014-12-31||||||||Interventional|||Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma|A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma|Withdrawn||Phase 2|0|Actual|Palatin Technologies||2||Sponsor terminated study prior to initiation.|f||||f||||||||||2018-05-31 22:50:18.77342|2018-05-31 22:50:18.77342
NCT01304615|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2018-04-03|2011-02-24|2011-02-25|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2011||2011-02-28|April 2018|2018-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|FFH||Foundations for Health|Foundations for Health: Combining Culinary Skills Training With a Lifestyle Intervention in Young Overweight Adults at Risk for Type 2 Diabetes|Completed||N/A|10|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-05-31 22:50:18.829622|2018-05-31 22:50:18.829622
NCT01304602|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-01-04|2011-02-24|2011-02-25|Estimate|||||||2017-01-04|2017-01-06|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|October 2015|Actual|2015-10-31|April 2014|Actual|2014-04-30||Interventional|||A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer|A Phase I Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer|Completed||Phase 1|20|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 22:50:18.899566|2018-05-31 22:50:18.899566
NCT01304589|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2013-12-29||2014-08-13|2011-02-24|2011-02-25|Estimate|2014-02-18|2014-04-02|Estimate||||2014-08-13|2014-08-18|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Savella in Treatment for Provoked Vestibulodynia|An Open Label Trial of Milnacipran in the Treatment of Women With Provoked Vestibulodynia|Completed||Phase 3|31|Actual|University of Tennessee||1|||f||||f||||||||||2018-05-31 22:50:18.968313|2018-05-31 22:50:18.968313
NCT01304576|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2014-09-01|2011-02-23|2011-02-25|Estimate|||||||2014-09-01|2014-09-03|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|AGNORIENT||Orientation Agnosia: Clinical and Anatomical Study|Orientation Agnosia: Neuropsychological Evaluation, Associated Symptoms, Clinical and Anatomical Correlations|Completed||N/A|34|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 22:50:20.080194|2018-05-31 22:50:20.080194
NCT01304563|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-23|2011-02-23|2011-02-25|Estimate|||||||2011-02-23|2011-02-25|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||2010/2011 Trivalent Influenza Vaccination|Safety and Efficacy of Dose Sparing Intradermal 2010/2011 Trivalent Influenza Vaccination With the Novel Microneedle Delivery Device|Completed||N/A|240|Actual|The University of Hong Kong||4|||f||||f||||||||||2018-05-31 22:50:20.204357|2018-05-31 22:50:20.204357
NCT01304550|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2017-05-24|2011-02-23|2011-02-25|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2009||2009-07-31|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Evaluation of the Accuracy of the Masimo Pulse-Hemoglobin-Meter Monitor in Surgical Patients|Evaluation of the Accuracy of the Masimo Pulse-Hemoglobin-Meter Monitor in Surgical Patients|Completed|||48|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 22:50:20.300528|2018-05-31 22:50:20.300528
NCT01304537|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2016-06-08|2011-02-24|2011-02-25|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus|Open Label, Proof of Concept, Phase I/II Study of the Safety, Tolerability and Efficacy of Intravenous Alpha-1 Antitrypsin (AAT) [Trade Name Glassia™] in Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|24|Actual|Kamada, Ltd.||3|||f||||f||||||||No||2018-05-31 22:50:20.36943|2018-05-31 22:50:20.36943
NCT01304524|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16||2018-05-23|2018-05-29|2011-02-24|2011-02-25|Estimate||||2018-05-23|2018-05-25|Actual|2018-05-29|2018-05-31|Estimate|April 2011||2011-04-30|May 2018|2018-05-31|October 2015|Actual|2015-10-31|May 2014|Actual|2014-05-31||Interventional|HPV-003||A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3|Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.|Completed||Phase 2|167|Actual|Inovio Pharmaceuticals||2|||f||||t|t|t|t|f||||||2018-05-31 22:50:20.48898|2018-05-31 22:50:20.48898
NCT01304511|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-04-28|2011-02-24|2011-02-25|Estimate|||||||2015-04-28|2015-04-29|Estimate|February 2005||2005-02-28|April 2015|2015-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®|Post-Marketing Surveillance Orgalutran (Ganirelix)®|Completed|||711|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:50:20.820715|2018-05-31 22:50:20.820715
NCT01304498|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2017-07-24||2017-07-24|2011-02-24|2011-02-25|Estimate|2017-07-24|2017-08-22|Actual||||2017-07-24|2017-08-22|Actual|February 1, 2011||2011-02-01|July 2017|2017-07-31|December 20, 2011|Actual|2011-12-20|December 20, 2011|Actual|2011-12-20||Interventional||Randomized participants|Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)|A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus (HPV) Vaccine) in Preadolescent and Adolescent Girls (9- to 15-year-old)|Completed||Phase 3|600|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:50:20.94743|2018-05-31 22:50:20.94743
NCT01304485|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2017-02-22|2011-02-24|2011-02-25|Estimate|||||||2017-02-22|2017-02-23|Actual|April 2011||2011-04-30|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma|Phase 2 Study: PET Imaging Characteristics of C11-Acetate in Patients With Prostate Carcinoma, Detection of Recurrent Disease With PSA Relapse|Recruiting||Phase 2|1500|Anticipated|Phoenix Molecular Imaging||1|||f||||f||||||||Yes|Journal Publication|2018-05-31 22:50:21.473999|2018-05-31 22:50:21.473999
NCT01304472|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-08-21|2011-02-24|2011-02-25|Estimate|||||||2011-08-21|2011-08-23|Estimate|February 2011||2011-02-28|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment|Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment|Completed||Phase 3|25|Anticipated|University of Patras||2|||f||||f||||||||||2018-05-31 22:50:21.582256|2018-05-31 22:50:21.582256
NCT01304459|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-03-21|2011-02-24|2011-02-25|Estimate|||||||2012-03-21|2012-03-23|Estimate|January 2011||2011-01-31|March 2012|2012-03-31||||||||Observational|||Vancomycin Serum Concentrations in Pediatric Oncology Patients Under Intensive Care|Vancomycin Serum Concentrations in Pediatric Oncology Patients Under Intensive Care|Unknown status|Recruiting||50|Anticipated|Grupo de Apoio ao Adolescente e a Crianca com Cancer|||||f||||f||||||||||2018-05-31 22:50:21.686255|2018-05-31 22:50:21.686255
NCT01304446|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate||||February 2011|2011-02-28||||||||Interventional|||Enteral Nutrition in Cancer Patients|Enteral Nutrition Support in Children and Adolescents With Cancer: a Non-randomized Controlled Clinical Trial|Completed||Phase 4|||Grupo de Apoio ao Adolescente e a Crianca com Cancer||1|||f||||t||||||||||2018-05-31 22:50:21.732665|2018-05-31 22:50:21.732665
NCT01304433|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-10-27|2011-02-24|2011-02-25|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Safety Profile of Hydroxyethyl Starch|Evaluation on the Safety Profile of Hydroxyethyl Starch (HES) 130/0.42|Completed|||1000|Anticipated|B. Braun Melsungen AG|||1||f||||f||||||||||2018-05-31 22:50:21.779807|2018-05-31 22:50:21.779807
NCT01304420|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-03-21|2011-02-23|2011-02-25|Estimate|||||||2012-03-21|2012-03-22|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Ultrasonography in Juvenile Idiopathic Arthritis|Changes in Joint-Cartilage as a Measure of Outcome in Juvenile Idiopathic Arthritis - Assessed by Ultrasonography and Biomarkers|Completed|||95|Actual|University of Aarhus|||||f||||f||||||Samples Without DNA|"~     Serum specimens taken for rutine markers of inflammation.~   "|||2018-05-31 22:50:21.837446|2018-05-31 22:50:21.837446
NCT01304407|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-03-25|2011-02-24|2011-02-25|Estimate|||||||2015-03-25|2015-03-27|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Calcium Absorption in Patients With Rothmund-Thomson Syndrome|Evaluation of Calcium Absorption in Patients With Rothmund-Thomson Syndrome|Unknown status|Enrolling by invitation||20|Anticipated|Baylor College of Medicine|||||f||||f||||||||||2018-05-31 22:50:21.888591|2018-05-31 22:50:21.888591
NCT01304394|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|February 2008||2008-02-29|February 2011|2011-02-28|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Safety During Use of Paediatric Triple Chamber Bag Formulas|Safety During Use of Paediatric Triple Chamber Bag Formulas, Administered IV at a Weight Dependant Dose During 5 Consecutive Days, in Paediatric Patients up to 18 Years Requiring Parenteral Nutrition.|Completed||Phase 3|161|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-05-31 22:50:22.028922|2018-05-31 22:50:22.028922
NCT01304381|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-06-16|2011-02-24|2011-02-25|Estimate|||||||2013-06-16|2013-06-18|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Integrated Cardiac Care and Palliative Homecare for Patients With Severe Heart Failure|Integrated Cardiac Care and Palliative Homecare for Patients With Severe Heart Failure|Completed||N/A|72|Actual|Umeå University||2|||f||||t||||||||||2018-05-31 22:50:22.139019|2018-05-31 22:50:22.139019
NCT01304368|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|August 2009||2009-08-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Thermotherapy on Chronic Neck Pain|Randomized Controlled Pilot Study: Effects of a Heat Pad Application in Patients With Chronic Neck Pain|Completed||N/A|50|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 22:50:22.288341|2018-05-31 22:50:22.288341
NCT01304355|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Observational|||An Assessment of Cognitive Function in Irritable Bowel Syndrome|Kynurenine Pathway Metabolites as Novel Translational Biological Markers of Irritable Bowel Syndrome: Relationship to Gastrointestinal Function, Cognition and Co-morbid Depression|Unknown status|Recruiting||85|Anticipated|University College Cork|||2||f||||t||||||Samples With DNA|"~     Plasma Serum Saliva~   "|||2018-05-31 22:50:22.377267|2018-05-31 22:50:22.377267
NCT01304342|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-08-02|2011-02-24|2011-02-25|Estimate|||||||2013-08-02|2013-08-05|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) With or Without Opioids|The Effect of Intranasal Fentanyl Versus Remifentanil Infusion on Propofol Requirements During Elective Therapeutic ERCP, as Well on the Recovery, Pain, and Early Cognitive Function: A Randomized Control Trial|Completed||N/A|180|Actual|University of Athens||3|||f||||f||||||||||2018-05-31 22:50:22.479499|2018-05-31 22:50:22.479499
NCT01304329|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|2014-05-16||2014-07-02|2011-02-24|2011-02-25|Estimate|2014-07-02|2014-07-28|Estimate||||2014-07-02|2014-07-28|Estimate|February 2011||2011-02-28|July 2014|2014-07-31||||April 2011|Actual|2011-04-30||Interventional||Treated Set: All subjects who took at least 1 dose of investigational treatment.|Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin|Relative Bioavailability of BI 10773 and Simvastatin After Single and Combined Administration - an Open-label, Randomised, Crossover Trial in Healthy Subjects|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:50:22.573141|2018-05-31 22:50:22.573141
NCT01304316|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2016-11-02|2015-05-15|2017-07-31|2011-02-23|2011-02-25|Estimate|2017-07-31|2017-08-31|Actual|2015-05-15|2015-06-08|Estimate|2017-07-31|2017-08-31|Actual|September 2010||2010-09-30|July 2017|2017-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Dose-Escalation Safety and Pharmacokinetic Study of K305|Cardiovascular Changes and Tetracaine Pharmacokinetics Following Intranasal Administration of Standard and High Doses of Kovacaine Mist (Tetracaine Hydrochloride With Oxymetazoline Hydrochloride) in Healthy Volunteers|Completed||Phase 2|12|Actual|St. Renatus, LLC||1|||f||||f||||||||Undecided||2018-05-31 22:50:22.936812|2018-05-31 22:50:22.936812
NCT01304290|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-10-24|2011-02-24|2011-02-25|Estimate|||||||2013-10-24|2013-10-25|Estimate|October 2010||2010-10-31|October 2013|2013-10-31||||January 2015|Anticipated|2015-01-31||Interventional|||Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors|Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors|Unknown status|Recruiting|N/A|20|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 22:50:23.25459|2018-05-31 22:50:23.25459
NCT01304277|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2013-12-30||2014-03-25|2011-02-23|2011-02-25|Estimate|2014-03-25|2014-04-25|Estimate||||2014-03-25|2014-04-25|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.|A Phase II Comparability Study Between Replagal® Produced From Agalsidase Alfa Manufactured by 2 Different Processes in Adult Male Patients With Fabry Disease|Completed||Phase 2|17|Actual|Shire||1|||f||||f||||||||||2018-05-31 22:50:23.33479|2018-05-31 22:50:23.33479
NCT01304264|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-01-11|2011-02-24|2011-02-25|Estimate|||||||2012-01-11|2012-01-12|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Observational|||Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients|Comparison of Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations During the Addition of Dorzolamid vs Timolol in Glaucoma Subjects Treated With Prostaglandin Analogue Monotherapy|Completed|||35|Actual|Lithuanian University of Health Sciences|||1||f||||f|||||||"~     No biospecimens will be retained~   "|||2018-05-31 22:50:23.665226|2018-05-31 22:50:23.665226
NCT01304251|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2016-01-09|2011-02-24|2011-02-25|Estimate|||||||2016-01-09|2016-01-12|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|April 2013|Actual|2013-04-30||Interventional|||Effects of Short-term Fasting on Tolerance to Chemotherapy|Effects of Short-term Fasting on Tolerance to Adjuvant Chemotherapy in Breast Cancer Patients|Completed||N/A|13|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 22:50:23.811474|2018-05-31 22:50:23.811474
NCT01304238|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2011-01-27||2017-06-06|2011-01-27|2011-02-25|Estimate|2011-01-27|2011-02-25|Estimate||||2017-06-06|2017-07-06|Actual|February 2009||2009-02-28|June 2017|2017-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II|Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht|Completed|||195|Actual|GlaxoSmithKline|Due to the retrospective nature of the data collection in this study, it is impossible to be precise about dose and frequency of dosing.||4||f||||f||||||||||2018-05-31 22:50:23.932397|2018-05-31 22:50:23.932397
NCT01304225|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|March 2013|Anticipated|2013-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser|Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser - an Anatomic and Functional Evaluation of Different Treatment Strategies|Unknown status|Recruiting|Phase 3|60|Anticipated|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 22:50:25.585862|2018-05-31 22:50:25.585862
NCT01304212|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2014-08-27|2011-02-24|2011-02-25|Estimate|||||||2014-08-27|2014-08-28|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ATR-2011||Effectiveness of Analgesia in Total Knee Arthroplasty|Comparison of the Analgesic Effect of Femoral Nerve Block, Intraarticular Infiltration or a Combination of Both in the Control of Pain in Total Knee Arthroplasty|Completed||Phase 4|137|Actual|Consorci Sanitari de Terrassa||3|||f||||f||||||||||2018-05-31 22:50:25.681474|2018-05-31 22:50:25.681474
NCT01304199|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-07-11|2011-02-24|2011-02-25|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|CANSURVIVE||Cancer Survivorship Issues: A Survey of Patients in India.AIIMS Study (CANSURVIVE)|Cancer Survivorship Issues: A Survey of Patients in India.AIIMS Study (CANSURVIVE)|Unknown status|Recruiting||200|Anticipated|All India Institute of Medical Sciences, New Delhi|||1||f||||f||||||||||2018-05-31 22:50:25.808604|2018-05-31 22:50:25.808604
NCT01304186|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-02-28|2011-02-23|2011-02-25|Estimate|||||||2013-02-28|2013-03-01|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||An Automated, Tailored Information Application for Medication Health Literacy|An Automated, Tailored Information Application for Medication Health Literacy|Completed||N/A|124|Actual|Nova Southeastern University||1|||f||||f||||||||||2018-05-31 22:50:25.894389|2018-05-31 22:50:25.894389
NCT01304173|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-02-14|2011-02-24|2011-02-25|Estimate|||||||2014-02-14|2014-02-19|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||Retrospective Chart Review of Valstar|A Retrospective Analysis to Evaluate the Effectiveness, Safety and Tolerability of Intravesical Valrubicin for the Treatment of Bladder Carcinoma in Situ in Clinical Practice|Completed|||113|Actual|Endo Pharmaceuticals|||||f||||f||||||||||2018-05-31 22:50:25.99133|2018-05-31 22:50:25.99133
NCT01304160|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2016-08-03|2011-02-24|2011-02-25|Estimate|||||||2016-08-03|2016-08-05|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer|Phase I/II Study to Investigate the Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|10|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-05-31 22:50:26.077374|2018-05-31 22:50:26.077374
NCT01304147|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2016-04-18||2016-12-16|2011-02-24|2011-02-25|Estimate|2016-12-16|2017-02-08|Estimate||||2016-12-16|2017-02-08|Estimate|October 2011||2011-10-31|December 2016|2016-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||one participant data information missing for history of Psychotherapy, and history of Failed Antidepressant Medications.|Intranasal Ketamine in Treatment-Resistant Depression|Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)|Completed||N/A|20|Actual|Icahn School of Medicine at Mount Sinai|Small sample size. Ongoing treatment with psychotropic medication allowed at stable doses makes it difficult to distinguish an intrinsic effect of ketamine from benefits resulting from the combination of ketamine with other antidepressant agents.|2|||f||||t||||||||||2018-05-31 22:50:26.209653|2018-05-31 22:50:26.209653
NCT01304134|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-08-10|2011-02-23|2011-02-25|Estimate|||||||2015-08-10|2015-08-11|Estimate|March 2010||2010-03-31|August 2015|2015-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment|A Prospective, Randomized, Blind, Multicentre, Parallel Group Study to Investigate the Efficacy and Safety of Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment|Completed||Phase 3|240|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||t||||||||||2018-05-31 22:50:26.678926|2018-05-31 22:50:26.678926
NCT01304121|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-06-15|2011-02-24|2011-02-25|Estimate|||||||2011-06-15|2011-06-16|Estimate|October 2006||2006-10-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Bioactive Glass Granules in Filling of Bone Defects|Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects|Completed||Phase 4|48|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 22:50:26.794434|2018-05-31 22:50:26.794434
NCT01304108|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Improving Venous Thromboembolism Prophylaxis|Spreading and Improving DVT Prophylaxis at Mayo Clinic (DVT-P-Spread)|Completed||Phase 4|3000|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 22:50:26.881793|2018-05-31 22:50:26.881793
NCT01304095|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2013-07-09|2011-02-24|2011-02-25|Estimate|||||||2013-07-09|2013-07-11|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|November 2013|Anticipated|2013-11-30|July 2013|Actual|2013-07-31||Interventional|REMS||Ranolazine, Ethnicity and the Metabolic Syndrome|Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study|Unknown status|Active, not recruiting|Phase 4|160|Anticipated|Atlanta Heart Specialists, LLC||2|||f||||f||||||||||2018-05-31 22:50:26.975262|2018-05-31 22:50:26.975262
NCT01304082|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2017-01-11||2017-02-28|2011-02-23|2011-02-25|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|January 2011||2011-01-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.|A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.|Terminated||N/A|29|Actual|Massachusetts General Hospital||3||Insufficient Enrollment|f||||t||||||||||2018-05-31 22:50:27.070874|2018-05-31 22:50:27.070874
NCT01304069|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-07-08|2011-02-24|2011-02-25|Estimate|||||||2011-07-08|2011-07-11|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol||Completed||Phase 1|12|Anticipated|Turku University Hospital||3|||f||||||||||||||2018-05-31 22:50:27.439434|2018-05-31 22:50:27.439434
NCT01304056|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-10-08|2011-02-24|2011-02-25|Estimate|||||||2013-10-08|2013-10-09|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||How to Study Ventilatory Physiology With the Help of Surface Electromyography (EMG) Recordings||Withdrawn|||0|Actual|Tampere University Hospital|||2|Administrative reasons|f||||f||||||||||2018-05-31 22:50:27.667909|2018-05-31 22:50:27.667909
NCT01304043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-04-19|2011-02-24|2011-02-25|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2002||2002-01-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|||||Observational|||French Observatory of Rare Malignant Tumors of the Ovary|Observatoire Francophone Des Tumeurs Malignes Rares de l'Ovaire : Protocole de Prise en Charge Chez l'Adulte (Tumeurs Germinales et Des Cordons Sexuels)|Completed|||204|Actual|ARCAGY/ GINECO GROUP|||||f||||f||||||||||2018-05-31 22:50:27.745312|2018-05-31 22:50:27.745312
NCT01304030|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-19|||2011-02-23|2011-02-23|2011-02-25|Estimate|||||||2011-02-23|2011-02-25|Estimate|February 2010||2010-02-28|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Improving Empathy and Relational Skills|Improving Empathy and Relational Skills in Resident Physicians: A Randomized Controlled Trial|Completed||N/A|99|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 22:50:27.822528|2018-05-31 22:50:27.822528
NCT01304017|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2015-06-21|2011-02-24|2011-02-25|Estimate|||||||2015-06-21|2015-06-23|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Virtual Reality Intervention for Stroke Rehabilitation|Virtual Reality Intervention for Stroke Rehabilitation|Completed||N/A|47|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 22:50:27.919032|2018-05-31 22:50:27.919032
NCT01304004|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2013-01-22|2011-02-24|2011-02-25|Estimate|||||||2013-01-22|2013-01-23|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|JIVAGO||Effect of a Drinkable Yogurt Enriched in Proteins and Fibers on Satiety|Effect of a Drinkable Yogurt Enriched in Proteins and Fibers on Satiety|Completed||N/A|40|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:50:28.007732|2018-05-31 22:50:28.007732
NCT01303991|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|March 2005||2005-03-31|February 2011|2011-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Hexvix Photodynamic Therapy in Patients With Bladder Cancer|A Phase I Feasibility Study of Hexvix Photodynamic Therapy in Patients With Intermediate or High-risk Bladder Cancer|Completed||Phase 1|17|Actual|Photocure||1|||f||||f||||||||||2018-05-31 22:50:28.097483|2018-05-31 22:50:28.097483
NCT01303978|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-09-21|2011-02-24|2011-02-25|Estimate|||||||2012-09-21|2012-09-25|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Phase II Proof-of-concept Study of APD421|Open-label, Ascending-dose, Phase II Study to Determine the Minimum Effective Dose of APD421 in the Prevention of Cisplatin-induced Nausea and Vomiting|Completed||Phase 2|51|Actual|Acacia Pharma Ltd||1|||f||||f||||||||||2018-05-31 22:50:28.1628|2018-05-31 22:50:28.1628
NCT01303965|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2018-03-12|2011-02-23|2011-02-25|Estimate|||||||2018-03-12|2018-03-14|Actual|February 7, 2011|Actual|2011-02-07|March 2018|2018-03-31|July 28, 2017|Actual|2017-07-28|September 23, 2014|Actual|2014-09-23||Interventional|||Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)|Phase I/II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy With Lenalidomide and Sirolimus in Patients With High-Risk Multiple Myeloma|Terminated||Phase 1/Phase 2|14|Actual|Indiana University||1||Slow accrual|f||||t||||||||||2018-05-31 22:50:28.242001|2018-05-31 22:50:28.242001
NCT01303952|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2017-07-17|2011-02-24|2011-02-25|Estimate|||||||2017-07-17|2017-07-19|Actual|January 2011|Actual|2011-01-31|July 2017|2017-07-31|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|DECADE||Therapy of Chronic Cold Agglutinin Disease With Eculizumab|Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab|Completed||Phase 2|13|Actual|University Hospital, Essen||1|||f||||t||||||||||2018-05-31 22:50:28.418568|2018-05-31 22:50:28.418568
NCT01303939|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-06-09|2011-02-24|2011-02-25|Estimate|||||||2015-06-09|2015-06-11|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Does Glaucoma Cause Loss of Brain Function?|Neuroimaging Brain Changes in Glaucoma|Completed|||37|Actual|Wills Eye|||2||f||||f||||||||||2018-05-31 22:50:28.525025|2018-05-31 22:50:28.525025
NCT01303757|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2016-02-08|2011-02-23|2011-02-25|Estimate|||||||2016-02-08|2016-02-09|Estimate|February 2011||2011-02-28|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FRESH Start||A Novel Diet-Phenotype Interaction Affecting Body Weight|A Novel Diet-Phenotype Interaction Affecting Body Weight|Completed||N/A|155|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 22:50:32.857685|2018-05-31 22:50:32.857685
NCT01303926|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2012-04-09|2011-02-23|2011-02-25|Estimate|||||||2012-04-09|2012-04-10|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|ERACLE||Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer|Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Cancer: a Quality of Life Oriented Phase III Trial of the GOIM|Unknown status|Active, not recruiting|Phase 3|118|Anticipated|Gruppo Oncologico Italia Meridionale||2|||f||||t||||||||||2018-05-31 22:50:28.703752|2018-05-31 22:50:28.703752
NCT01303913|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-25|2011-02-24|2011-02-25|Estimate|||||||2011-02-25|2011-02-28|Estimate|June 2010||2010-06-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|||||Observational|||Predicting Oxygen Desaturation in Chronic Obstructive Pulmonary Disease (COPD) Patients|Composite Analysis on Factors That Predict Oxygen Desaturation During Walking in COPD|Completed|||400|Actual|Villa Pineta Hospital|||2||f||||f||||||||||2018-05-31 22:50:29.034424|2018-05-31 22:50:29.034424
NCT01303900|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|January 2009||2009-01-31|February 2011|2011-02-28||||||||Observational|||Cardiovascular Disease (CVD) in Haemophilia|Cardiovascular Disease in Adult Haemophilia Patients|Unknown status|Enrolling by invitation||750|Anticipated|UMC Utrecht|||||f||||f||||||||||2018-05-31 22:50:29.122018|2018-05-31 22:50:29.122018
NCT01303887|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-05-04|2011-02-24|2011-02-25|Estimate|||||||2011-05-04|2011-05-06|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|PACIFICO||A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients|Purine-Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older Patients: a Phase III Comparison of First-line R-CVP Versus R-FC|Unknown status|Recruiting|Phase 3|680|Anticipated|University of Liverpool||2|||f||||t||||||||||2018-05-31 22:50:29.249229|2018-05-31 22:50:29.249229
NCT01303874|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|March 2011|Anticipated|2011-03-31|February 2011|Actual|2011-02-28||Interventional|EMPIRE||Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)|A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis|Unknown status|Active, not recruiting|Phase 4|112|Actual|University of Leeds||2|||f||||f||||||||||2018-05-31 22:50:29.572205|2018-05-31 22:50:29.572205
NCT01303861|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2014-07-05||2014-08-04|2011-02-23|2011-02-25|Estimate|2014-07-05|2014-08-01|Estimate||||2014-08-04|2014-08-06|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|ConNic4|Subjects who failed to respond to pre-cessation nicotine patch treatment were randomized to receive varenicline, or varenicline + bupropion. Subjects who showed reductions in ad lib smoking were randomly assigned to nicotine patch only or patch + nicotine inhaler. 22 Subjects discontinued study participation prior to being assigned to a condition.|Concurrent Bupropion / Varenicline for Smoking Cessation|Concurrent Bupropion / Varenicline for Smoking Cessation|Completed||Phase 3|702|Actual|Duke University||4|||f||||t||||||||||2018-05-31 22:50:29.714667|2018-05-31 22:50:29.714667
NCT01303848|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-05-01|2011-02-24|2011-02-25|Estimate|||||||2012-05-01|2012-05-02|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Observational|||Circadian Rhythm of Blood Lactate|Circadian Rhythm of Blood Lactate, Lipid Transferproteins and Genetic Markers (PPARs, CLOCK, Bmal1)|Completed|||30|Actual|Martin-Luther-Universität Halle-Wittenberg|||1||f||||f||||||||||2018-05-31 22:50:30.588964|2018-05-31 22:50:30.588964
NCT01303835|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2015-05-08||2015-06-25|2011-02-23|2011-02-25|Estimate|2015-06-04|2015-06-26|Estimate||||2015-06-25|2015-07-17|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|June 2014|Actual|2014-06-30||Interventional|||Low Dose Naltrexone for Glioma Patients|Effects of Low Dose Naltrexone on Quality of Life in High Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial|Completed||Phase 2|110|Actual|Duke University||2|||f||||f||||||||||2018-05-31 22:50:30.733251|2018-05-31 22:50:30.733251
NCT01303822|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-07-23|2011-02-24|2011-02-25|Estimate|||||||2013-07-23|2013-07-24|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|SASO||Mindfulness-based Stress Reduction in Cancer Treatment|Mindfulness-based Stress Reduction in Supportive Cancer Treatment: Effects of a Day-care Clinic Group Program on Psychometric Parameters in Cancer Patients (Stressbewältigung Durch Achtsamkeit in Der Supportiven Onkologischen Therapie (SASO): Auswirkung Eines Tagesklinischen Gruppenprogramms Auf Psychometrische Parameter Bei Krebspatienten)|Completed||N/A|117|Actual|Universität Duisburg-Essen||1|||f||||f||||||||||2018-05-31 22:50:31.6114|2018-05-31 22:50:31.6114
NCT01303809|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2012-05-24|2011-02-24|2011-02-25|Estimate|||||||2012-05-24|2012-05-25|Estimate|May 2011||2011-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Enhanced Recovery After Laparoscopic Sleeve Gastrectomy - a Randomised Controlled Trial|Enhanced Recovery After Laparoscopic Sleeve Gastrectomy - a Randomised Controlled Trial|Completed||N/A|106|Actual|University of Auckland, New Zealand||2|||f||||f||||||||||2018-05-31 22:50:31.812718|2018-05-31 22:50:31.812718
NCT01303796|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2015-08-17|2011-02-24|2011-02-25|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|SEAMLESS||A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia|Unknown status|Active, not recruiting|Phase 3|485|Anticipated|Cyclacel Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 22:50:32.044461|2018-05-31 22:50:32.044461
NCT01303783|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24||2015-06-05|2017-04-14|2011-02-24|2011-02-25|Estimate||||2015-06-05|2015-07-03|Estimate|2017-04-14|2017-04-18|Actual|April 2011||2011-04-30|April 2017|2017-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|DISTINCT||Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension|A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients With Essential Hypertension|Completed||Phase 2|1381|Actual|Bayer||16|||f||||f||||||||||2018-05-31 22:50:32.402229|2018-05-31 22:50:32.402229
NCT01303770|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-12-24|2011-02-24|2011-02-25|Estimate|||||||2013-12-24|2013-12-25|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis|Development and Evaluation of a Cognitive Rehabilitation Program for Persons With Multiple Sclerosis|Unknown status|Active, not recruiting|N/A|50|Anticipated|Tel Aviv University||2|||f||||||||||||||2018-05-31 22:50:32.754401|2018-05-31 22:50:32.754401
NCT01303744|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2015-10-16|2012-05-18|2015-12-02|2011-02-23|2011-02-25|Estimate|2015-12-02|2016-01-11|Estimate|2012-05-18|2012-05-30|Estimate|2015-12-02|2016-01-11|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|CT04||Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074|A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment|Completed||Phase 2|96|Actual|CERESPIR||4|||f||||t||||||||||2018-05-31 22:50:32.970142|2018-05-31 22:50:32.970142
NCT01303731|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-02-23|2011-02-23|2011-02-25|Estimate|||||||2011-02-23|2011-02-25|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Comparison of Standard and Minidose Spinal Anesthesia for Cesarean Section Operation Using Marcaine Spinal 0.5% Heavy|Phase IV, Randomized, Parallel Designed, Single Blinded Study, Comparing the Standard and Minidose Spinal Anesthesia Using Marcaine Spinal 0.5% Heavy With Addition of Fentanyl During Cesarean Section|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Bnai Zion Medical Center||2|||f||||||||||||||2018-05-31 22:50:33.60164|2018-05-31 22:50:33.60164
NCT01303718|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2015-12-11|2011-02-23|2011-02-25|Estimate|||||||2015-12-11|2015-12-15|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|INOVATE-HF||INcrease Of VAgal TonE in CHF|INcrease Of VAgal TonE in CHF (INOVATE-HF) - A Randomized Study to Establish the Safety and Efficacy of CardioFit® for the Treatment of Subjects With Heart Failure and Left Ventricular Dysfunction|Terminated||Phase 3|730|Actual|BioControl Medical||2||Futility of Primary Efficacy Endpoint|f||||t||||||||||2018-05-31 22:50:33.709249|2018-05-31 22:50:33.709249
NCT01303705|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-06-13|2011-02-24|2011-02-25|Estimate|||||||2017-06-13|2017-06-15|Actual|October 2010|Actual|2010-10-31|June 2017|2017-06-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer|Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy|Active, not recruiting||Phase 1/Phase 2|10|Actual|Providence Health & Services||3|||f||||f||||||||No||2018-05-31 22:50:34.043954|2018-05-31 22:50:34.043954
NCT01303692|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-01-13|2011-02-23|2011-02-25|Estimate|||||||2015-01-13|2015-01-14|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent|Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent|Completed|||312|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 22:50:34.149187|2018-05-31 22:50:34.149187
NCT01303679|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2018-05-17|2011-02-24|2011-02-25|Estimate|||||||2018-05-17|2018-05-18|Actual|June 2010||2010-06-30|March 2016|2016-03-31|May 2018|Actual|2018-05-31|June 2014|Actual|2014-06-30||Interventional|||1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer|Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.|Terminated||Phase 3|117|Actual|ARCAGY/ GINECO GROUP||2||Not reveal any significant difference between the 2 treatment arms|f||||t||||||||||2018-05-31 22:50:34.22942|2018-05-31 22:50:34.22942
NCT01303666|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-04-21|2011-02-24|2011-02-25|Estimate|||||||2017-04-21|2017-04-24|Actual|November 2000||2000-11-30|April 2017|2017-04-30|December 2004|Actual|2004-12-31|July 2003|Actual|2003-07-31||Interventional|||Tidal Irrigation Versus Intra-articular Steroid Injection in the Treatment of Knee Osteoarthritis|Tidal Irrigation Versus Intra-articular Steroid Injection in the Treatment of Knee Osteoarthritis|Completed||N/A|150|Actual|Portsmouth Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 22:50:34.325298|2018-05-31 22:50:34.325298
NCT01303653|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-25|2011-02-24|2011-02-25|Estimate|||||||2011-02-25|2011-02-28|Estimate|October 2010||2010-10-31|July 2010|2010-07-31||||October 2010|Anticipated|2010-10-31||Interventional|||Endoscopic Treatment of Intestinal Fistulas and Perforations|Endoscopic Treatment of Intestinal Fistulas and Perforations|Unknown status|Recruiting|Phase 1|25|Anticipated|The Oregon Clinic|||||f||||t||||||||||2018-05-31 22:50:34.406049|2018-05-31 22:50:34.406049
NCT01303640|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2015-12-09|2011-02-24|2011-02-25|Estimate|||||||2015-12-09|2015-12-10|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|NEXT||NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial|NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial|Completed||Phase 4|3235|Actual|Kyoto University, Graduate School of Medicine||2|||f||||t||||||||||2018-05-31 22:50:34.54174|2018-05-31 22:50:34.54174
NCT01303627|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|2012-01-30||2012-06-15|2011-02-24|2011-02-25|Estimate|2012-05-17|2012-06-18|Estimate||||2012-06-15|2012-06-25|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Safety of Remifentanil Infusion|The Effects of Maintenance a Remifentanil Infusion on the Hemodynamic Variables and Recovery Quality|Completed||Phase 4|42|Actual|Diskapi Teaching and Research Hospital|The limitation of our study is age and ASA status of the included patients’. The relatively older or ASA status III,IV population may interfere the effect-site concentration TCI of remifentanil|2|||f||||f||||||||||2018-05-31 22:50:34.713209|2018-05-31 22:50:34.713209
NCT01303614|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|April 2011||2011-04-30|September 2010|2010-09-30|September 2012|Anticipated|2012-09-30|April 2012|Anticipated|2012-04-30||Interventional|HSG-2010||Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysterosalpingography Practice|Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysterosalpingography Practice: a Prospective Randomized Double Blind, Placebo-controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Consorci Sanitari de Terrassa||2|||f||||f||||||||||2018-05-31 22:50:35.041754|2018-05-31 22:50:35.041754
NCT01303601|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2011-02-24|2011-02-24|2011-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|October 2010|Actual|2010-10-31|||||Interventional|||Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression|Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression: a Randomized, Double-blind, Placebo Controlled Study|Completed||Phase 4|68|Actual|China Medical University, China||2|||f||||t||||||||||2018-05-31 22:50:35.1776|2018-05-31 22:50:35.1776
NCT01303588|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-24|||2013-01-18|2011-02-24|2011-02-25|Estimate|||||||2013-01-18|2013-01-21|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|YQ-LBP||Yoga and Qigong for Elderly Patients With Chronic Low Back Pain|Yoga and Qigong for Elderly Patients With Chronic Low Back Pain|Completed||Phase 2/Phase 3|176|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 22:50:35.295519|2018-05-31 22:50:35.295519
NCT01303575|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2015-06-22|2011-02-23|2011-02-24|Estimate|||||||2015-06-22|2015-06-23|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|IYG-AI/AN||Internet-Based Sexual Health Education for Middle School Native American Youth|It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations|Completed||N/A|574|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 22:50:35.407198|2018-05-31 22:50:35.407198
NCT01303562|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2013-05-23|2011-02-23|2011-02-24|Estimate|||||||2013-05-23|2013-05-27|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|February 2013|Actual|2013-02-28|April 2011|Actual|2011-04-30||Interventional|||Clinical Assessment of Barley and Oat Phytochemicals|Clinical Assessment of Barley and Oat Phytochemicals: Acute Bioavailability, Pharmacokinetics, and Bioactivity|Completed||N/A|13|Actual|Tufts University||3|||f||||||||||||||2018-05-31 22:50:35.533604|2018-05-31 22:50:35.533604
NCT01303549|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2014-05-29|2011-02-23|2011-02-24|Estimate|||||||2014-05-29|2014-05-30|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|AVALTRA||Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients|Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients|Completed||Phase 4|61|Actual|Fundacion SEIMC-GESIDA||2|||f||||t||||||||||2018-05-31 22:50:35.624251|2018-05-31 22:50:35.624251
NCT01303536|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Ondansetron Augmentation in Treatment-resistant OCD|Ondansetron Augmentation in Treatment-resistant OCD|Completed||Phase 4|21|Actual|Institute of Neuroscience, Florence, Italy||1|||f||||t||||||||||2018-05-31 22:50:35.742483|2018-05-31 22:50:35.742483
NCT01303523|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-03-05|2011-02-23|2011-02-24|Estimate|||||||2015-03-05|2015-03-06|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Observational|M2M-Thrombose||Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort|Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort.|Completed|||1627|Actual|Floralis|||||f||||t||||||||||2018-05-31 22:50:35.858494|2018-05-31 22:50:35.858494
NCT01303510|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2011-10-10||2013-08-29|2011-02-23|2011-02-24|Estimate|2011-11-15|2011-12-19|Estimate||||2013-08-29|2013-09-09|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2008/2009-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations|Completed||Phase 4|111|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 22:50:35.971391|2018-05-31 22:50:35.971391
NCT01303497|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2017-01-11|2011-02-23|2011-02-24|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|April 2014|Actual|2014-04-30||Interventional|ANGIO-TAX+||Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas|Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, With or Without Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment.|Active, not recruiting||Phase 2|70|Anticipated|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 22:50:36.252481|2018-05-31 22:50:36.252481
NCT01303484|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2016-03-24|2011-02-23|2011-02-24|Estimate|||||||2016-03-24|2016-03-25|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|November 2012|Actual|2012-11-30||Interventional|PRIMES||The Effect of Prebiotic B-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People|A Randomised, Double-blind, Placebo Controlled Cross- Over Study to Determine the Effect of prebioticB-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People|Completed||Early Phase 1|40|Actual|Clasado||2|||f||||t||||||||||2018-05-31 22:50:36.364304|2018-05-31 22:50:36.364304
NCT01303471|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2012-05-16|2011-02-23|2011-02-24|Estimate|||||||2012-05-16|2012-05-17|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|DOLANS||Pain Assessment During General Anesthesia|Pain Assessment During General Anesthesia : DOLANS (DOULeur ANeSthesie) Study|Completed||N/A|75|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 22:50:36.451426|2018-05-31 22:50:36.451426
NCT01303458|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2017-01-04|2011-02-23|2011-02-24|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Addressing Low-Income Families' Basic Social Needs at Pediatric Visits|Addressing Low-Income Families' Basic Social Needs at Pediatric Visits: the WE CARE Project|Completed||N/A|336|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 22:50:36.687689|2018-05-31 22:50:36.687689
NCT01303445|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2012-04-24||2013-11-27|2011-02-23|2011-02-24|Estimate|2012-07-23|2012-07-24|Estimate||||2013-11-27|2013-12-24|Estimate|March 2011||2011-03-31|July 2012|2012-07-31||||April 2011|Actual|2011-04-30||Interventional|||Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers|Drug-drug Interaction Study of the Effect of Omeprazole 80 mg q.d. at Steady State on the Pharmacokinetics and Pharmacodynamics of Aggrenox® Every 12 Hours at Steady State in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover Study)|Completed||Phase 1|60|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 22:50:36.820104|2018-05-31 22:50:36.820104
NCT01303432|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2012-09-13|2011-02-23|2011-02-24|Estimate|||||||2012-09-13|2012-09-14|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Effect of Yogurts Supplemented With Mobilee on Joint Function in Healthy Individuals With Joint Discomfort|Double-blind, Placebo-controlled Nutrition Intervention Trial, to Study Efficacy and Safety of Yogurts Supplemented With Mobilee on Joint Function, Joint Structure and Quality of Life of Adults With Low Intensity Gonalgia|Completed||N/A|80|Actual|Bioiberica||2|||f||||f||||||||||2018-05-31 22:50:37.32532|2018-05-31 22:50:37.32532
NCT01303419|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-09-21|2011-02-23|2011-02-24|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2010||2010-04-30|September 2017|2017-09-30|June 30, 2012|Actual|2012-06-30|June 30, 2012|Actual|2012-06-30||Interventional|||Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer|A Multicenter, Open-Label, Crossover Trial to Assess Non-Inferiority of Dual Energy Contrast-Enhanced Digital Mammography (DE-CEDM) Compared to Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) for Identifying a Change in Patient Management in Women With Newly Diagnosed Breast Cancer|Terminated||N/A|224|Actual|GE Healthcare||2||Sponsor determined there was sufficient material collected to answer the study questions.|f||||f||||||||||2018-05-31 22:50:37.447784|2018-05-31 22:50:37.447784
NCT01303406|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2015-12-11||2016-02-10|2011-02-23|2011-02-24|Estimate|2016-02-10|2016-03-09|Estimate||||2016-02-10|2016-03-09|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PROTI||Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)|A Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study of Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone|Completed||Phase 3|29|Actual|Santhera Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:50:37.555058|2018-05-31 22:50:37.555058
NCT01303393|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|January 2007||2007-01-31|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Information Needs After Surgery for Colorectal Cancer|Information Needs After Surgery for Colorectal Cancer - From the Perspective of the Patient and Next of Kin|Completed|||100|Actual|Region Skane|||1||f||||f||||||||||2018-05-31 22:50:37.961416|2018-05-31 22:50:37.961416
NCT01303380|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2015-07-15||2015-10-13|2011-02-23|2011-02-24|Estimate|2015-08-11|2015-08-19|Estimate||||2015-10-13|2015-11-05|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The analysis was performed in the Full Analysis Set (FAS), defined as all participants who received at least one application of study treatment and had at least one post-baseline assessment for primary efficacy variable.|Canakinumab in Patients With Active Hyper-IgD Syndrome|An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS)|Completed||Phase 2|9|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:50:38.142866|2018-05-31 22:50:38.142866
NCT01303367|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-24|Estimate|||||||2011-02-22|2011-02-24|Estimate|January 2002||2002-01-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|||||Observational|||Medication Management and Care of Demented Patients With Behavioral and Psychological Symptoms of Dementia in Taiwan: A Retrospective Pilot Study|Medication Management and Care of Demented Patients With Behavioral and Psychological Symptoms of Dementia in Taiwan: A Retrospective Pilot Study|Completed|||200|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:50:39.902038|2018-05-31 22:50:39.902038
NCT01303354|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|April 2008||2008-04-30|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Lumbar Transforaminal Epidural Dexamethasone|Lumbar Transforaminal Epidural Dexamethasone: A Prospective, Randomized, Double-Blind Clinical Trial|Completed||N/A|100|Actual|Ahadian, Farshad M., M.D.||3|||f||||f||||||||||2018-05-31 22:50:39.974279|2018-05-31 22:50:39.974279
NCT01303341|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2018-05-15|2011-02-23|2011-02-24|Estimate|||||||2018-05-15|2018-05-16|Actual|February 18, 2011|Actual|2011-02-18|May 2018|2018-05-31||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma|A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma|Active, not recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 22:50:40.060399|2018-05-31 22:50:40.060399
NCT01303328|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-02-15|2011-02-23|2011-02-24|Estimate|||||||2013-02-15|2013-02-18|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|Colvir-PhaseII||Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)|A Randomized, Double-blind, Multi-centre, Placebo Controlled Phase II Clinical Study to Evaluate the Efficacy, Tolerance and Safety of an Aqueous Gel Containing an Antiviral, Directly Applied on the Cervix Exhibiting High Grade Intraepithelial Lesion.|Completed||Phase 2|200|Anticipated|Mithra Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:50:40.154504|2018-05-31 22:50:40.154504
NCT01303315|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2016-09-21|2011-02-23|2011-02-24|Estimate|||||||2016-09-21|2016-09-22|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy|TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy|Terminated||N/A|20|Actual|MetaCure (USA), Inc.||3||Company strategic decision|f||||t||||||||||2018-05-31 22:50:40.242204|2018-05-31 22:50:40.242204
NCT01303302|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2016-09-21|2011-02-23|2011-02-24|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2008||2008-04-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Crossover||The TANTALUS® II for the Treatment of Type 2 Diabetes|The TANTALUS® II for the Treatment of Type 2 Diabetes: A Single-Blind Cross-Over Study|Completed||N/A|51|Actual|MetaCure (USA), Inc.||2|||f||||t||||||||||2018-05-31 22:50:40.338909|2018-05-31 22:50:40.338909
NCT01303289|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-22|2011-02-22|2011-02-24|Estimate|||||||2011-02-22|2011-02-24|Estimate|February 2006||2006-02-28|February 2011|2011-02-28|December 2007|Actual|2007-12-31|January 2007|Actual|2007-01-31||Interventional|STDUGR||Clinical Evaluation of a Normoproteic Diet|Clinical Evaluation of a Normoproteic Diet With Ultra High Temperature Treatment|Completed||N/A|60|Actual|Vegenat, S.A.||2|||f||||f||||||||||2018-05-31 22:50:40.436094|2018-05-31 22:50:40.436094
NCT01303276|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-22|2011-02-22|2011-02-24|Estimate|||||||2011-02-22|2011-02-24|Estimate|June 2011||2011-06-30|February 2011|2011-02-28||||||||Observational|||Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)|Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion|Unknown status|Not yet recruiting||30|Anticipated|University of Toronto|||2||f||||f||||||||||2018-05-31 22:50:40.535766|2018-05-31 22:50:40.535766
NCT01303263|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-06-21|2011-02-23|2011-02-24|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||A Brief Intervention to Improve Cost-effective Resource Use Among Medicine Housestaff|A Brief Intervention to Improve Cost-effective Resource Use Among Medicine Housestaff|Completed||N/A|96|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:50:40.607328|2018-05-31 22:50:40.607328
NCT01303250|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2015-12-17|2011-02-22|2011-02-24|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|KoKris||Perioperative Colloid vs Crystalloid in Patients Undergoing Colorectal Surgery|Balanced 6 % HES 130/0.4 vs. Balanced Crystalloid-based Infusion in Patients Undergoing Colorectal Surgery|Terminated||Phase 4|31|Actual|University Hospital Muenster||2||The final decision of the review of HES-containing solution shall be awaited.|f||||f||||||||||2018-05-31 22:50:40.676159|2018-05-31 22:50:40.676159
NCT01303068|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14||2015-12-10|2016-01-12|2011-02-23|2011-02-24|Estimate||||2015-12-10|2016-01-13|Estimate|2016-01-12|2016-02-05|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF|Detection of Pseudomonas. Aeruginosa in the Airways of Patients With Cystic Fibrosis Using of Aerosolized 13C-urea|Completed||N/A|12|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 22:50:43.060571|2018-05-31 22:50:43.060571
NCT01303237|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2017-06-08|2011-02-23|2011-02-24|Estimate|||||||2017-06-08|2017-06-09|Actual|February 28, 2011|Actual|2011-02-28|June 2017|2017-06-30|August 5, 2014|Actual|2014-08-05|June 30, 2013|Actual|2013-06-30||Observational|PMS LAD SCCHN||A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA SCCHN)|Terminated|||88|Actual|Merck KGaA||||"The study was discontinued due to slow recruitment and subjects not completing follow up~   period."|f||||f||||||||||2018-05-31 22:50:40.74576|2018-05-31 22:50:40.74576
NCT01303224|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|2013-01-10||2015-09-22|2011-02-23|2011-02-24|Estimate|2013-03-21|2013-03-25|Estimate||||2015-09-22|2015-10-07|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|IRIS-2||Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)|Double-blind, Randomised, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Effect of Oral Ibodutant in Irritable Bowel Syndrome With Diarrhoea (IBS-D).|Completed||Phase 2|565|Actual|Menarini Group||4|||f||||f||||||||||2018-05-31 22:50:40.977906|2018-05-31 22:50:40.977906
NCT01303211|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-02-18|2011-02-23|2011-02-24|Estimate|||||||2013-02-18|2013-02-20|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|November 2013|Anticipated|2013-11-30|May 2013|Anticipated|2013-05-31||Observational|VES||A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger|A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger|Withdrawn|||0|Actual|London School of Hygiene and Tropical Medicine|||3|No cases on NmA meningitis were recorded following vaccination with MenAfriVac|f||||t||||||Samples Without DNA|"~     Sera samples will be separated from 5 ml blood sample obtained from cases and controls.~   "|||2018-05-31 22:50:41.723945|2018-05-31 22:50:41.723945
NCT01303198|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|June 2001||2001-06-30|February 2011|2011-02-28|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Autoset T Versus CPAP Therapy, a Comparison of Titration and Therapy|Autoset T Versus CPAP- Ein Titrations- Und Therapievergleich|Unknown status|Recruiting|Phase 3|60|Anticipated|Kaiserswerther Diakonie||2|||f||||t||||||||||2018-05-31 22:50:41.793185|2018-05-31 22:50:41.793185
NCT01303185|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2014-12-11|2011-02-23|2011-02-24|Estimate|||||||2014-12-11|2014-12-12|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Pulsed Dye Laser for the Psoriatic Nail|Pulsed Dye Laser for the Psoriatic Nail|Completed|||25|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:50:41.930239|2018-05-31 22:50:41.930239
NCT01303172|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-12-01|2011-02-23|2011-02-24|Estimate|||||||2016-12-01|2016-12-02|Estimate|June 2011||2011-06-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|February 2015|Actual|2015-02-28||Interventional|||A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer|A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer|Completed||Phase 2|110|Actual|Immodulon Therapeutics Ltd||2|||f||||t||||||||||2018-05-31 22:50:42.137716|2018-05-31 22:50:42.137716
NCT01303159|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2017-02-16||2017-04-21|2011-02-22|2011-02-24|Estimate|2017-04-21|2017-05-23|Actual||||2017-04-21|2017-05-23|Actual|March 2010||2010-03-31|April 2017|2017-04-30|January 13, 2014|Actual|2014-01-13|January 13, 2014|Actual|2014-01-13||Interventional|||Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer|Pilot Study to Assess Safety and Efficacy of an Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer|Terminated||N/A|29|Actual|Weill Medical College of Cornell University|Early study termination leading to no preliminary analyses. Total enrolled 29, only 6 subjects had follow up data of 6 months.|1||EndoHPB probe is FDA approved and considered standard of care|f||||f|f|t|f|f|f|||No|No IPD sharing|2018-05-31 22:50:42.238339|2018-05-31 22:50:42.238339
NCT01303146|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|Azylis||Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation|and Safety of METAZYM (Recombinant Human Arylsulfatase A or rhASA) for the Treatment of Patients With Late Infantile MLD Who Had Previously Hematopoietic Stem Cell Transplantation|Completed||Phase 2|1|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 22:50:42.377389|2018-05-31 22:50:42.377389
NCT01303133|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-07-27|2011-02-22|2011-02-24|Estimate|||||||2017-07-27|2017-08-01|Actual|August 2009||2009-08-31|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Natural History of Amyloid Deposition in Adults With Down Syndrome|Natural History of Amyloid Deposition in Adults With Down Syndrome|Active, not recruiting|||81|Actual|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     Trisomy 21 ApoE~   "|||2018-05-31 22:50:42.532109|2018-05-31 22:50:42.532109
NCT01303120|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-20|||2015-01-20|2011-02-23|2011-02-24|Estimate|||||||2015-01-20|2015-01-21|Estimate|May 2011||2011-05-31|February 2011|2011-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Does a Single Shot Femoral Nerve Block Alone Produce Appropriate Pain Relief?|Does a Single Shot Femoral Nerve Block Alone Produce Appropriate Pain Relief After Total Knee Arthroplasty or Should an Addition of Sciatic, Obturator and Lateral Femoral Cutaneous Nerve Blocks be Recommended?|Completed||N/A|107|Actual|Hillel Yaffe Medical Center||3|||f||||t||||||||||2018-05-31 22:50:42.592879|2018-05-31 22:50:42.592879
NCT01303107|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-03-25|2011-02-23|2011-02-24|Estimate|||||||2014-03-25|2014-03-26|Estimate||||January 2011|2011-01-31||||||||Interventional|||Comparative Mixture of Non-racemic and Racemic Enantiomers of Bupivacaine in Cesarean|A Non-Inferiority Phase 3 Comparative Study Between a Heavy Levobupivacaine in 50% Enantiomeric Excess (Bupivacaine S75:R25) and Heavy Racemic Bupivacaine for Cesarean Operation|Withdrawn||Phase 3|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||2||The Sponsor has no interest in continuing the study.|f||||f||||||||||2018-05-31 22:50:42.699564|2018-05-31 22:50:42.699564
NCT01303094|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2016-07-27|2011-02-23|2011-02-24|Estimate|||||||2016-07-27|2016-07-28|Estimate|February 2011||2011-02-28|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|December 2013|Actual|2013-12-31||Interventional|T-DIS||Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma|Phase II Randomized Trial to Evaluate Two Strategies: Continuing Versus Intermittent (Drug-holiday) Trabectedin-regimen in Patients With Advanced Soft Tissue Sarcoma Experiencing Response or Stable Disease After the Sixth Cycle|Active, not recruiting||Phase 2|53|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 22:50:42.783485|2018-05-31 22:50:42.783485
NCT01303081|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2012-08-01|2011-02-22|2011-02-24|Estimate|||||||2012-08-01|2012-08-02|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pilot Randomized Control Trial of Financial Incentives for Smoking Cessation|Financial Incentive Structures for Smoking Cessation: A Pilot Randomized Trial|Completed||N/A|63|Actual|University of Pennsylvania||5|||f||||t||||||||||2018-05-31 22:50:42.887147|2018-05-31 22:50:42.887147
NCT01303055|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Alogliptin on Pancreatic Beta Cell Function|Multicenter Trial on Effects of Alogliptin on Pancreatic Beta Cell Function|Unknown status|Recruiting|N/A|80|Anticipated|Aichi Gakuin University||2|||f||||t||||||||||2018-05-31 22:50:43.140789|2018-05-31 22:50:43.140789
NCT01303042|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy of Insulin Lispro Mix 50/50 Therapy|Multicenter Trial on Clinical Utility of Insulin Lispro Mix 50/50 T.I.D. Therapy in Patients With Type 2 Diabetes Mellitus|Unknown status|Recruiting|N/A|80|Anticipated|Aichi Gakuin University||1|||f||||t||||||||||2018-05-31 22:50:43.241387|2018-05-31 22:50:43.241387
NCT01303029|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-07-31|2011-02-23|2011-02-24|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2011||2011-02-28|July 2017|2017-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|GECA||Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer|A Phase IIb Randomized Study to Evaluate the Efficacy of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|120|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-05-31 22:50:43.359366|2018-05-31 22:50:43.359366
NCT01303016|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-03-05|2011-02-23|2011-02-24|Estimate|||||||2011-03-05|2011-03-08|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|MANI II||Improving Nutrition and Health Outcomes in Intibuca, Honduras|Improving Nutrition and Health Outcomes in Intibuca, Honduras|Unknown status|Active, not recruiting|N/A|639|Actual|Shoulder to Shoulder||2|||f||||t||||||||||2018-05-31 22:50:43.435627|2018-05-31 22:50:43.435627
NCT01303003|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-04-09|2011-02-23|2011-02-24|Estimate|||||||2015-04-09|2015-04-10|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block|Evaluation of Addition of Dexamethasone to Transversus Abdominis Plane (TAP) Peripheral Nerve Block: Does it Enhance the Quality and Duration of Analgesia?|Completed||N/A|24|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.||2|||f||||f||||||||||2018-05-31 22:50:43.496207|2018-05-31 22:50:43.496207
NCT01302990|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2013-08-15|2011-02-23|2011-02-24|Estimate|||||||2013-08-15|2013-08-16|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults|Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults|Completed||Phase 1|100|Actual|Medicago||5|||f||||t||||||||||2018-05-31 22:50:43.560051|2018-05-31 22:50:43.560051
NCT01302977|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|May 2008||2008-05-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|BRAFETO||Fetal Tracheal Occlusion in Severe Diaphragmatic Hernia: a Randomized Trial|Tracheal Occlusion Guided by Percutaneous Fetoscopy in Fetuses With Severe Isolated Congenital Diaphragmatic Hernia|Unknown status|Recruiting|Phase 2|36|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 22:50:43.642336|2018-05-31 22:50:43.642336
NCT01302964|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-08-28|2011-02-18|2011-02-24|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2010||2010-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders|Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders|Recruiting||Phase 3|30|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:50:43.762374|2018-05-31 22:50:43.762374
NCT01302951|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|July 2008||2008-07-31|February 2011|2011-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MOXI||Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.|Study on Pharmacokinetics of Moxifloxacin in Serum and Liver Tissue of Patients Undergoing Liver Resection Due to Primary or Secondary Tumor of the Liver|Completed||Phase 4|34|Actual|University Hospital, Saarland||2|||f||||f||||||||||2018-05-31 22:50:43.865362|2018-05-31 22:50:43.865362
NCT01302938|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2013-07-22||2013-07-22|2011-02-22|2011-02-24|Estimate|2013-07-22|2013-09-24|Estimate||||2013-07-22|2013-09-24|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|REMOTE||Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder|Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Center, Web-Based Phase IV Pilot Methodology Trial To Evaluate The Efficacy And Safety Of Tolterodine ER In Subjects With Overactive Bladder|Terminated||Phase 4|18|Actual|Pfizer|The study was terminated prematurely due to low participant enrollment and due to relatively small sample size; results should be interpreted with caution. Early termination of the study was not related to any safety concern.|2||"Stop date for randomization: 31/5/2012. Recruitment terminated due to lack of recruitment. No~   new safety issues were identified."|f||||f||||||||||2018-05-31 22:50:44.024912|2018-05-31 22:50:44.024912
NCT01302925|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2015-09-11|2011-02-22|2011-02-24|Estimate|||||||2015-09-11|2015-09-14|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects|PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate 0.05% and 0.015% Gel Followed by Hand Washing in Healthy Subjects.|Completed||Phase 1|100|Anticipated|Peplin||2|||f||||f||||||||||2018-05-31 22:50:45.081029|2018-05-31 22:50:45.081029
NCT01302912|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-11-03|2011-02-23|2011-02-24|Estimate|||||||2011-11-03|2011-11-04|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|May 2012|Anticipated|2012-05-31|||||Observational|||Lymphoma in the Orbit||Unknown status|Enrolling by invitation||50|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 22:50:45.162119|2018-05-31 22:50:45.162119
NCT01302899|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2012-12-21||2012-12-21|2011-02-22|2011-02-24|Estimate|2012-12-21|2013-01-30|Estimate||||2012-12-21|2013-01-30|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ARIA||To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy|A Single-blind, Double Dummy, Randomized, Multi-dose, Two Sequence, Crossover, Study to Investigate the Effects of Renin Inhibitor (Aliskiren 300 mg) on Albuminuria in Non-diabetic Nephropathy Patients Treated With Ramipril 10 mg and Volume Intervention (ARIA)|Terminated||Phase 2|8|Actual|Novartis||2||"In consequence of termination of ALTITUDE. A number of studies were continued in consultation~   with the Altitude Data Monitoring Committee."|f||||||||||||||2018-05-31 22:50:45.244692|2018-05-31 22:50:45.244692
NCT01302886|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-02-21|2011-02-22|2011-02-24|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2011||2011-05-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma|A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With Intravenous BHQ880, a Fully Human, Anti-Dickkopf1 (DKK1) Neutralizing Antibody in Previously Untreated Patients With High-risk, Smoldering Multiple Myeloma|Completed||Phase 2|41|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:50:45.7292|2018-05-31 22:50:45.7292
NCT01302873|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2017-03-20|2011-02-22|2011-02-24|Estimate|||||||2017-03-20|2017-03-22|Actual|January 2011||2011-01-31|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of BGG492 in Patients With Chronic Subjective Tinnitus|A Multicenter, Randomized, Double-blind, Placebo- Controlled, Cross-over, Proof of Concept Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 2 Weeks of BGG492 in Patients With Chronic Subjective Tinnitus|Completed||Phase 2|96|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:50:45.832164|2018-05-31 22:50:45.832164
NCT01302860|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2015-07-22||2017-02-28|2011-02-22|2011-02-24|Estimate|2015-07-22|2015-08-18|Estimate||||2017-02-28|2017-03-29|Actual|November 2010||2010-11-30|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The analysis was performed in Full analysis set population, defined as all participants who received at least one dose of study drug under this study protocol.|Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease|A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)|Completed||Phase 3|17|Actual|Novartis||1|||f||||t||||||||||2018-05-31 22:50:45.939969|2018-05-31 22:50:45.939969
NCT01302847|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2018-05-24|2011-02-22|2011-02-24|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2011||2011-03-31|May 2018|2018-05-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents|Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents|Recruiting||Phase 1/Phase 2|160|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||9|||f||||t||||||||||2018-05-31 22:50:46.19382|2018-05-31 22:50:46.19382
NCT01302834|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-05-18|2011-02-22|2011-02-24|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2011|Actual|2011-06-30|May 2017|2017-05-31||||June 2020|Anticipated|2020-06-30||Interventional|||Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer|Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer|Active, not recruiting||Phase 3|987|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 22:50:46.450378|2018-05-31 22:50:46.450378
NCT01302821|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-02-21|2011-02-22|2011-02-24|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2013|Anticipated|2013-01-31|February 2017|2017-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer|NCI 8701: A Pilot Study Utilizing C11 Alpha Methyl Tryptophan (AMT) PET Functional Imaging in Patients With Metastatic Invasive Breast Cancer Treated With 1 Methyl D Tryptophan Plus the Ad p53 DC Vaccine|Withdrawn||N/A|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 22:50:46.758807|2018-05-31 22:50:46.758807
NCT01302808|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-19|||2015-05-29|2011-02-22|2011-02-24|Estimate|||||||2015-05-29|2015-06-01|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase I/II Study of Erlotinib and Romidepsin in Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|18|Actual|University of Texas Southwestern Medical Center|||||f||||||||||||||2018-05-31 22:50:46.83252|2018-05-31 22:50:46.83252
NCT01302795|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-09-26|2011-02-23|2011-02-24|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|November 2015|Actual|2015-11-30|August 2014|Actual|2014-08-31||Interventional|||Canakinumab for Pyoderma Gangrenosum|A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum|Completed||Phase 2|5|Actual|University of Zurich||1|||f||||t||||||||Yes|The data are in the Publication Kolios et al. British Journal of Dermatology, 2015|2018-05-31 22:50:46.904213|2018-05-31 22:50:46.904213
NCT01302782|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2013-11-21|2011-02-22|2011-02-24|Estimate|||||||2013-11-21|2013-11-25|Estimate|December 2012||2012-12-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||The Effects of Normobaric Hypoxia on Blood Glucose Levels.|The Effects of Normobaric Hypoxia on Blood Glucose Levels.|Withdrawn|||0|Actual|Mike O'Callaghan Military Hospital|||||f||||f||||||||||2018-05-31 22:50:46.977325|2018-05-31 22:50:46.977325
NCT01302769|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-02-01|2011-02-23|2011-02-24|Estimate|||||||2016-02-01|2016-02-03|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Ear Acupuncture for Acute Sore Throat.|Ear Acupuncture for Acute Sore Throat. A Randomized Controlled Trial.|Completed||N/A|65|Actual|Mike O'Callaghan Military Hospital||2|||f||||f||||||||||2018-05-31 22:50:47.038393|2018-05-31 22:50:47.038393
NCT01302756|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2013-11-21|2011-02-22|2011-02-24|Estimate|||||||2013-11-21|2013-11-25|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of High Dose Folic Acid Versus Placebo on the Rate of Gestational Diabetes or Gestational Hypertension in Pregnant Women|The Effect of High Dose Folic Acid Versus Placebo on the Rate of Gestational Diabetes or Gestational Hypertension in Pregnant Women: a Randomized Controlled Trial.|Withdrawn||N/A|0|Actual|Mike O'Callaghan Military Hospital|||||f||||f||||||||||2018-05-31 22:50:47.271522|2018-05-31 22:50:47.271522
NCT01302743|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2016-12-15||2017-05-31|2011-02-22|2011-02-24|Estimate|2017-02-07|2017-03-28|Actual||||2017-05-31|2017-06-26|Actual|November 2010||2010-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.|Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin as Initial Treatment for Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.|Terminated||N/A|25|Actual|Mike O'Callaghan Military Hospital||3||lack of recruitment|f||||f||||||||No||2018-05-31 22:50:47.339747|2018-05-31 22:50:47.339747
NCT01302730|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2013-11-06|2011-02-23|2011-02-24|Estimate|||||||2013-11-06|2013-11-08|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|March 2012|Actual|2012-03-31||Observational|||Ankylosing Spondylitis and Spondyloarthritis Evaluation Tool Study|A Self-Administered Questionnaire for Early Detection of Axial Spondyloarthritis|Completed|||490|Actual|Stanford University|||||f||||f||||||||||2018-05-31 22:50:47.580119|2018-05-31 22:50:47.580119
NCT01302717|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-19|||2018-04-16|2011-02-23|2011-02-24|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2010||2010-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LVPACE||Left Ventricular Pacing to Avoid Cardiac Enlargement Study|Impact of Left Ventricular Pacing on Left Ventricular Systolic Function in High-risk Bradycardia Patients|Recruiting||N/A|98|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 22:50:47.636004|2018-05-31 22:50:47.636004
NCT01302704|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2013-11-21|2011-02-22|2011-02-24|Estimate|||||||2013-11-21|2013-11-25|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Influence of Proton Pump Inhibitors (PPI's) on Blood Levels of 25-Hydroxyvitamin D.|The Influence of Proton Pump Inhibitors (PPI's) on Blood Levels of 25-Hydroxyvitamin D.|Withdrawn|||0|Actual|Mike O'Callaghan Military Hospital|||||f||||f||||||||||2018-05-31 22:50:47.720096|2018-05-31 22:50:47.720096
NCT01302691|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2016-12-05||2016-12-05|2011-02-23|2011-02-24|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||MK-0954E Study in Participants With Hypertension (MK-0954E-357)|A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration|Completed||Phase 3|327|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:50:47.796472|2018-05-31 22:50:47.796472
NCT01302652|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2015-03-17|2011-02-23|2011-02-24|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment|Effects of Physiologic Growth Hormone Administration on Echocardiographic Parameters in Subjects With Growth Hormone Deficiency Following Cure of Acromegaly|Completed|||20|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 22:50:48.162682|2018-05-31 22:50:48.162682
NCT01302639|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2014-09-08|2011-02-22|2011-02-24|Estimate|||||||2014-09-08|2014-09-09|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Dietary Polyphenols and Lipid Oxidation|Dietary Polyphenols as Modulators of Lipid Oxidation and Mitochondrial Function in Overweight Volunteers|Completed||N/A|18|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 22:50:48.226421|2018-05-31 22:50:48.226421
NCT01302626|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-03-21|2011-02-23|2011-02-24|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2010||2010-03-31|March 2017|2017-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Observational|Radiomics||Radiomics: a Study of Outcome in Lung Cancer|Radiomics: a Prospective Study of Outcome in Lung Cancer|Completed|||216|Actual|Maastricht Radiation Oncology|||6||f||||f||||||Samples With DNA|"~     -  Lung tumor tissue~        -  Lung normal tissue~   "|||2018-05-31 22:50:48.318288|2018-05-31 22:50:48.318288
NCT01302613|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2018-02-20|2011-02-23|2011-02-24|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2011||2011-03-31|February 2018|2018-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma|A Pilot and Phase II Study of Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma|Terminated||Phase 1/Phase 2|2|Actual|University of Texas Southwestern Medical Center||1||Drug shortage|f||||t||||||||||2018-05-31 22:50:48.388292|2018-05-31 22:50:48.388292
NCT01302600|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-11-21|2011-02-18|2011-02-24|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.|Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients.|Completed||Phase 2|165|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 22:50:48.474579|2018-05-31 22:50:48.474579
NCT01302587|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-06-21|2011-02-18|2011-02-24|Estimate|||||||2012-06-21|2012-06-22|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)|A Prospective, Open Label, Assessment of [an Albuterol] Hydrofluoroalkane (HFA) Metered Dose Inhaler MDI Integrated Dose Counter|Completed|||306|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-05-31 22:50:48.62691|2018-05-31 22:50:48.62691
NCT01302574|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides|The Role of Sweet Taste Receptor Blockade on Intragastric Liquid Meal-stimulated Secretion of Satiation Peptides in Healthy Humans|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 22:50:48.721765|2018-05-31 22:50:48.721765
NCT01302561|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-08-01|2011-02-23|2011-02-24|Estimate|||||||2012-08-01|2012-08-02|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|GOS||Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season|Protocol 2: Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season|Completed||N/A|84|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:50:48.796918|2018-05-31 22:50:48.796918
NCT01302548|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2013-09-09||2014-02-28|2011-02-22|2011-02-24|Estimate|2014-02-28|2014-04-07|Estimate||||2014-02-28|2014-04-07|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect Of Wound Irrigation With Irrisept™ Delivery System On Abscess Healing In Patients Presenting To The Emergency Department|THE EFFECT OF WOUND IRRIGATION WITH IRRISEPT™ Delivery System ON ABSCESS HEALING IN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT|Terminated||N/A|33|Actual|University of Florida||2||Study did not accrue the required number of study subjects.|f||||t||||||||||2018-05-31 22:50:48.891609|2018-05-31 22:50:48.891609
NCT01302535|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-02-22|2011-02-23|2011-02-24|Estimate|||||||2012-02-22|2012-02-23|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|YHIP||The Impact of Yoga on Blood Pressure and Quality of Life in Patients With Hypertension|The Impact of Yoga on Blood Pressure and Quality of Life in Patients With Hypertension - a Randomised Controlled Trial in Primary Health Care|Completed||N/A|83|Actual|Region Skane||3|||f||||f||||||||||2018-05-31 22:50:49.118323|2018-05-31 22:50:49.118323
NCT01302522|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|September 2008||2008-09-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Mental Practice Impact on Gait and Cortical Organization in Spinal Cord Injury (SCI)|Mental Practice Impact on Gait and Cortical Organization in SCI|Completed||Phase 2|||University of Cincinnati|||||f||||t||||||||||2018-05-31 22:50:49.179539|2018-05-31 22:50:49.179539
NCT01302509|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2011-02-22|2011-02-22|2011-02-24|Estimate|||||||2011-02-22|2011-02-24|Estimate||||February 2011|2011-02-28||||||||Interventional|||Enteral Nutrition in Cancer Patient|Enteral Nutrition Support in Children and Adolescents With Cancer: a Non-randomized Controlled Clinical Trial.|Completed||Phase 4|||Grupo de Apoio ao Adolescente e a Crianca com Cancer||1|||f||||t||||||||||2018-05-31 22:50:49.222994|2018-05-31 22:50:49.222994
NCT01302496|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2017-05-23|2011-02-23|2011-02-24|Estimate|||||||2017-05-23|2017-05-24|Actual|February 2011|Actual|2011-02-28|May 2017|2017-05-31|January 2017|Actual|2017-01-31|October 2013|Actual|2013-10-31||Interventional|TriMix-Ipi||Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma|A Two-stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma|Completed||Phase 2|39|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 22:50:49.268103|2018-05-31 22:50:49.268103
NCT01302483|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2011-03-02||2015-06-16|2011-02-18|2011-02-24|Estimate|2015-06-16|2015-06-17|Estimate||||2015-06-16|2015-06-17|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia|A Phase II, Single-Center, Randomized, Double-Blind, Active-Treatment-Controlled, Parallel-Group Study of the Efficacy of Kovacaine Nasal Spray for Anesthetizing Maxillary Teeth in Healthy Dental Patients|Completed||Phase 2|45|Actual|St. Renatus, LLC|The VAS was misadministered such that even subjects with enough pain to require rescue reported essentially no pain on the global VAS. As this would exaggerate the efficacy of the study drug, these measures were not used to calculate its efficacy.|2|||f||||||||||||||2018-05-31 22:50:49.333065|2018-05-31 22:50:49.333065
NCT01302470|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2015-02-18|2011-02-23|2011-02-24|Estimate|||||||2015-02-18|2015-02-19|Estimate|February 2005||2005-02-28|February 2015|2015-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|REVERT||Comparison of Epicardial Versus Conventional Lead Placement in Cardiac Resynchronization Therapy|Randomized Study of Endovascular Versus Epicardial Lead Placement for Resynchronization Therapy|Completed||N/A|30|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||||||||||||2018-05-31 22:50:49.699842|2018-05-31 22:50:49.699842
NCT01302457|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-10-12|2011-02-18|2011-02-24|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Observational|||Oral Care Study on Burn Patients|Oral Care Study on Burn Patients|Withdrawn|||0|Actual|Saint Elizabeth Regional Medical Center|||2||f||||f||||||||||2018-05-31 22:50:49.768262|2018-05-31 22:50:49.768262
NCT01302444|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2013-06-07||2013-07-18|2011-02-23|2011-02-24|Estimate|2013-06-07|2013-07-18|Estimate||||2013-07-18|2013-07-26|Estimate|March 2011||2011-03-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|T2||Treprostinil Combined With Tadalafil for Pulmonary Hypertension|Randomized Placebo Controlled Trial of Treprostinil Infusion Combined With Oral Tadalafil or Placebo in Pulmonary Arterial Hypertension|Terminated||Phase 4|1|Actual|Rhode Island Hospital||2||One subject enrolled and completed this study. The study was stopped due to poor recruitment.|f||||t||||||||||2018-05-31 22:50:49.861282|2018-05-31 22:50:49.861282
NCT01302431|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-12-02|2011-02-23|2011-02-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Nurse-Led Manualized Telephone Support Intervention|An Exploratory Randomized Controlled Trial of a Manualized, Nurse-led, Telephone Intervention Support Service for Support Persons of People With Multiple Sclerosis|Completed||N/A|71|Actual|University of Dublin, Trinity College||2|||f||||t||||||||||2018-05-31 22:50:50.106824|2018-05-31 22:50:50.106824
NCT01302418|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2012-03-23||2017-04-03|2011-02-18|2011-02-24|Estimate|2012-05-22|2012-06-28|Estimate||||2017-04-03|2017-05-10|Actual|February 2011||2011-02-28|April 2017|2017-04-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Observational|||Collection and Testing of Respiratory Samples|Testing of Respiratory Specimens for the Validation of the QIAGEN ResPlex II Advanced Panel Test and the Artus Influenza A/B RT-PCR Test|Completed|||272|Actual|QIAGEN Gaithersburg, Inc|||1||f||||f||||||Samples With DNA|"~     Extracted nucleic acid, Residual Universal Transport Medium~   "|||2018-05-31 22:50:50.240761|2018-05-31 22:50:50.240761
NCT01302405|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-08-16|2011-02-18|2011-02-24|Estimate|||||||2017-08-16|2017-08-17|Actual|February 2011||2011-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors|A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors|Terminated||Phase 1|23|Actual|Prism Pharma Co., Ltd.||1||closing due to low enrollment, no safety issues|f||||t||||||||||2018-05-31 22:50:50.383581|2018-05-31 22:50:50.383581
NCT01302392|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2015-07-06||2017-04-28|2011-02-18|2011-02-24|Estimate|2015-07-06|2015-08-04|Estimate||||2017-04-28|2017-05-02|Actual|September 2010||2010-09-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|FOCUS||A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma|A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma|Completed||Phase 3|315|Actual|Amgen||2|||f||||t||||||||||2018-05-31 22:50:50.520583|2018-05-31 22:50:50.520583
NCT01302379|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2015-12-08|2011-02-23|2011-02-24|Estimate|||||||2015-12-08|2015-12-10|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors|Obesity-related Mechanisms and Mortality in Breast Cancer Survivors|Unknown status|Active, not recruiting|N/A|333|Actual|University of California, San Diego||4|||f||||t||||||||||2018-05-31 22:50:51.448621|2018-05-31 22:50:51.448621
NCT01302366|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2015-01-26||2015-02-11|2011-02-18|2011-02-24|Estimate|2015-02-11|2015-02-12|Estimate||||2015-02-11|2015-02-12|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma|A Phase II Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma|Terminated||Phase 2|20|Actual|New York University School of Medicine||1||due to lack of funding|f||||t||||||||||2018-05-31 22:50:51.524721|2018-05-31 22:50:51.524721
NCT01302353|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-23|2011-02-23|2011-02-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Phase I Trial of Emulsified Isoflurane|Phase I Trial of Emulsified Isoflurane in Adult Healthy Volunteers|Completed||Phase 1|78|Actual|Sichuan University||16|||f||||t||||||||||2018-05-31 22:50:51.748714|2018-05-31 22:50:51.748714
NCT01302340|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2014-01-21|2011-02-23|2011-02-24|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Delta-THC in Behavioral Disturbances in Dementia|Two Phase, Repeated Crossover Study With Dose Escalation on Delta(9)-Tetrahydrocannabinol (Delta-THC) in Behavioral Disturbances in Dementia|Completed||Phase 2|22|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 22:50:51.816448|2018-05-31 22:50:51.816448
NCT01302314|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-01-21|2011-02-23|2011-02-24|Estimate|||||||2014-01-21|2014-01-22|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Cognitive Rehabilitation in Patients With Spina Bifida|Cognitive Rehabilitation in Patients With Spina Bifida: Effects on Executive Functions, Psychological and Health Related Factors|Completed||N/A|38|Actual|Sunnaas Rehabilitation Hospital||1|||f||||f||||||||||2018-05-31 22:50:52.102646|2018-05-31 22:50:52.102646
NCT01302301|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-25|2011-02-23|2011-02-24|Estimate|||||||2011-02-25|2011-02-28|Estimate|January 2011||2011-01-31|November 2010|2010-11-30||||November 2011|Anticipated|2011-11-30||Interventional|||Endolumenal Partial Myotomy for Esophageal Motility Disorders|Endoscopic Submucosal Tunnel Dissection for Endolumenal Partial Myotomy of the Lower Esophageal Sphincter for Atypical Primary Motility Disorders Such as Achalasia and Esophageal Spasm|Unknown status|Recruiting|Phase 2|20|Anticipated|The Oregon Clinic|||||f||||t||||||||||2018-05-31 22:50:52.175534|2018-05-31 22:50:52.175534
NCT01302288|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-02-25|2011-02-23|2011-02-24|Estimate|||||||2011-02-25|2011-02-28|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||October 2012|Anticipated|2012-10-31||Interventional|||Endolumenal Partial Myotomy for the Treatment of Esophageal Achalasia|Endoscopic Submucosal Tunnel Dissection for Endolumenal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia|Unknown status|Recruiting|Phase 2|20|Anticipated|The Oregon Clinic|||||f||||t||||||||||2018-05-31 22:50:52.245393|2018-05-31 22:50:52.245393
NCT01302275|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2014-05-02|2011-02-23|2011-02-24|Estimate|||||||2014-05-02|2014-05-05|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|IMIOXC||Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain|Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain: Predictors of Response - a Randomised, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 4|117|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 22:50:52.34694|2018-05-31 22:50:52.34694
NCT01302262|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2013-03-04|2011-02-22|2011-02-24|Estimate|||||||2013-03-04|2013-03-05|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|||Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans|Does the Insula Control Smoking-induced Dopamine Release? A TMS/[11C]-PHNO Study in Humans. Part I: Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans.|Completed|||10|Actual|Centre for Addiction and Mental Health|||1||f||||f||||||Samples With DNA|"~     Whole blood (15mL)~   "|||2018-05-31 22:50:52.418936|2018-05-31 22:50:52.418936
NCT01302249|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18||2014-02-17|2014-04-18|2011-02-22|2011-02-24|Estimate||||2014-03-25|2014-04-21|Estimate|2014-04-18|2014-05-08|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||AR-12286 in Combination With Latanoprost|A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost|Completed||Phase 2|66|Actual|Aerie Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:50:52.49039|2018-05-31 22:50:52.49039
NCT01302236|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2012-07-04|2011-02-23|2011-02-24|Estimate|||||||2012-07-04|2012-07-06|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients|Effects of Eplerenone on Blood Pressure, Heart and Kidney in Elderly Hypertensive Early Stage Chronic Kidney Disease Patients|Withdrawn||Phase 4|0|Actual|Jichi Medical University||1||We could not find patients who agreed to enrolled this clinical study.|f||||f||||||||||2018-05-31 22:50:52.671108|2018-05-31 22:50:52.671108
NCT01302223|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2012-12-05|2011-02-23|2011-02-24|Estimate|||||||2012-12-05|2012-12-06|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Keratinocyte Growth Factor and Cytokines in Burns.|Keratinocyte Growth Factor, Interleukin 1 Beta, 6, 8, 10, 12 and Tumor Necrosis Factor Alpha in Burned Patients.|Completed|||8|Actual|Federal University of São Paulo|||2||f||||t||||||Samples With DNA|"~     Normal skin will be collected at first burned patient debridment and send to Cell Culture~     Laboratory to start fibroblast and queratinocyte culture.~   "|||2018-05-31 22:50:52.744374|2018-05-31 22:50:52.744374
NCT01302210|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2018-02-10|2011-02-23|2011-02-24|Estimate|||||||2018-02-10|2018-02-13|Actual|October 2010||2010-10-31|February 2018|2018-02-28|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional|DERAIL_MRSA||Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities|Detection, Education, Research and Decolonization Without Isolation in Long-term Care to Control(DERAIL)MRSA|Completed||Phase 4|22302|Actual|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||No||2018-05-31 22:50:52.820076|2018-05-31 22:50:52.820076
NCT01302197|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2018-02-12|2011-02-23|2011-02-24|Estimate|||||||2018-02-12|2018-02-13|Actual|September 2011||2011-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2017|Actual|2017-10-31||Observational|||Muscle Atrophy, Physical Performance and Glucose Tolerance Post Stroke|Muscle Atrophy, Physical Performance and Glucose Tolerance Post Stroke|Active, not recruiting|||100|Anticipated|Baltimore VA Medical Center|||||f||||t||||||Samples Without DNA|"~     Blood samples will be analyzed for metabolic biomarkers. Muscle tissue is collected for~     measurements of muscle phenotype. A urine pregnancy test is performed in women of child~     bearing age before CT imaging to exclude pregnant women due to the risk to an unborn fetus.~   "|No||2018-05-31 22:50:52.929971|2018-05-31 22:50:52.929971
NCT01302184|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-23|||2011-09-26|2011-02-23|2011-02-24|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|October 2011|Anticipated|2011-10-31|April 2011|Actual|2011-04-30||Interventional|ROLEP||Robotic Locomotor Experience Applied to Parkinson's Disease|Robotic Locomotor Experience Applied to Parkinson's Disease (ROLEP)|Unknown status|Active, not recruiting|Phase 2/Phase 3|28|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||f||||||||||2018-05-31 22:50:52.990297|2018-05-31 22:50:52.990297
NCT01302171|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2013-11-14|2011-02-22|2011-02-24|Estimate|||||||2013-11-14|2013-11-15|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|REGEN-DCM||Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy|Randomised Controlled Trial to Compare the Effects of G-CSF (Granocyte™) and Autologous Bone Marrow Progenitor Cells on Quality of Life and Left Ventricular Function in Patients With Idiopathic Dilated Cardiomyopathy|Completed||Phase 2|60|Actual|Barts & The London NHS Trust||2|||f||||t||||||||||2018-05-31 22:50:53.067503|2018-05-31 22:50:53.067503
NCT01302158|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-02-21|2011-02-21|2011-02-23|Estimate|||||||2011-02-21|2011-02-23|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Drug-drug Interaction Study With ASP1941 and Glimepiride|An Open-label, Randomized Crossover Study to Evaluate the Effect of ASP1941 on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa|Completed||Phase 1|52|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 22:50:53.157024|2018-05-31 22:50:53.157024
NCT01302145|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2017-07-26|2011-02-21|2011-02-23|Estimate|||||||2017-07-26|2017-07-28|Actual|February 25, 2009|Actual|2009-02-25|July 2017|2017-07-31|December 9, 2009|Actual|2009-12-09|December 9, 2009|Actual|2009-12-09||Interventional|||Drug to Drug Interaction Study With ASP1941 and Metformin|A Double-blind, Randomized, Placebo-controlled, Parallel Design Study, in Patients With Type 2 Diabetes Mellitus, to Investigate the Safety, Pharmacokinetics and Pharmacodynamics Interactions of Multiple Oral Doses of ASP1941 and Metformin|Completed||Phase 1|36|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:50:53.23347|2018-05-31 22:50:53.23347
NCT01302132|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-02-21|2011-02-21|2011-02-23|Estimate|||||||2011-02-21|2011-02-23|Estimate|May 2008||2008-05-31|February 2011|2011-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Mass Balance Study of ASP1941|An Open Label Study to Evaluate the Pharmacokinetics of ASP1941 After a Single Oral Dose of 14C-labeled ASP1941 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 22:50:53.308313|2018-05-31 22:50:53.308313
NCT01302119|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|2014-07-25|2012-07-26|2014-07-25|2011-02-21|2011-02-23|Estimate|2014-07-25|2014-08-15|Estimate|2012-07-26|2012-08-02|Estimate|2014-07-25|2014-08-15|Estimate|February 2011||2011-02-28|July 2014|2014-07-31||||December 2012|Actual|2012-12-31||Interventional||Analysis was performed using the intent-to-treat (ITT) population. Demographic characteristics were also analyzed using the Per Protocol (PP), Safety, and Post Study Follow Up (PSFU) populations, and were consistent with those of the ITT population. Safety analysis was performed using the Safety population.|Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail|A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults|Completed||Phase 3|604|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:50:53.37648|2018-05-31 22:50:53.37648
NCT01302106|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2013-09-30|2011-02-21|2011-02-23|Estimate|||||||2013-09-30|2013-10-01|Estimate||||September 2013|2013-09-30||||||||Interventional|CLO2009AISSM05||Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes|Phase II Study of Clofarabine in Combination With Low Dose Cytarabine for Untreated Patients With Poor Risk Myelodysplastic Syndromes|Withdrawn||Phase 2|0|Actual|Fondazione Italiana Sindromi Mielodisplastiche Onlus||1||"For increased induction mortality in older patients due to specific combinations of drugs,~   other clinical factors such as patient age and comorbidities."|f||||f||||||||||2018-05-31 22:50:53.82057|2018-05-31 22:50:53.82057
NCT01302093|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-07-06|2011-02-22|2011-02-23|Estimate|||||||2012-07-06|2012-07-10|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in Adults|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Racecadotril 100 mg FCT Versus Tiorfast® 100 mg Capsules, in Normal, Healthy, Non-Smoking Male and Female Subjects|Completed||Phase 1|40|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 22:50:53.901323|2018-05-31 22:50:53.901323
NCT01302080|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2018-05-24|2011-02-18|2011-02-23|Estimate|||||||2018-05-24|2018-05-25|Actual|April 4, 2012|Actual|2012-04-04|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|SPRITES||Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)|Sprites: Sertraline Pediatric Registry For The Evaluation Of Safety A Non-interventional, Longitudinal, Cohort Study To Evaluate The Effects Of Long-term Sertraline Treatment In Children And Adolescents|Active, not recruiting|||941|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 22:50:53.966686|2018-05-31 22:50:53.966686
NCT01302067|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2013-11-01||2014-02-25|2011-02-18|2011-02-23|Estimate|2013-11-01|2013-12-24|Estimate||||2014-02-25|2014-03-26|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||The safety analysis set included all participants who received at least 1 dose of study drug.|A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine|A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.|Completed||Phase 4|2012|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:50:54.334228|2018-05-31 22:50:54.334228
NCT01302054|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2013-02-07||2013-03-22|2011-02-18|2011-02-23|Estimate|2013-02-07|2013-03-12|Estimate||||2013-03-22|2013-04-01|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.|A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multicentre Study Of Fesoterodine 8 Mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4 Mg Extended Release (ER).|Completed||Phase 4|990|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:50:56.735753|2018-05-31 22:50:56.735753
NCT01302041|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|2016-02-16||2017-07-12|2011-02-21|2011-02-23|Estimate|2016-03-08|2016-04-06|Estimate||||2017-07-12|2017-07-13|Actual|May 6, 2011|Actual|2011-05-06|July 2017|2017-07-31|April 27, 2017|Actual|2017-04-27|July 29, 2012|Actual|2012-07-29||Interventional|||A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy|A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naïve Prostate Cancer|Completed||Phase 2|67|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 22:50:58.540159|2018-05-31 22:50:58.540159
NCT01302028|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2017-08-21|2011-02-21|2011-02-23|Estimate|||||||2017-08-21|2017-08-22|Actual|January 22, 2010|Actual|2010-01-22|August 2017|2017-08-31|June 26, 2010|Actual|2010-06-26|June 26, 2010|Actual|2010-06-26||Interventional|||Renal Impairment Study With ASP1941|An Open-label, Parallel Group Study to Assess the Effect of Different Grades of Renal Impairment in Patients With Type 2 Diabetes Mellitus on the Pharmacokinetics, Pharmacodynamics and Safety & Tolerability of ASP1941 Relative to Type 2 Diabetes Mellitus With Normal Renal Function and Healthy Volunteers|Completed||Phase 1|40|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 22:50:59.537178|2018-05-31 22:50:59.537178
NCT01302015|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-03-24|2011-02-20|2011-02-23|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2007||2007-12-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease|Completed||Phase 1/Phase 2|15|Actual|Biostar||1|||f||||f||||||||||2018-05-31 22:50:59.737979|2018-05-31 22:50:59.737979
NCT01302002|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2016-02-22|2011-02-22|2011-02-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Use of Metformin in Early Breast Cancer Patients Pre-Surgery|The Use of Metformin in Early Breast Cancer Patients Pre-Surgery: A Phase 0 Study Regarding The Biological Effect|Withdrawn||Early Phase 1|0|Actual|Instituto Nacional de Cancer, Brazil||1|||f||||t||||||||||2018-05-31 22:50:59.828221|2018-05-31 22:50:59.828221
NCT01301989|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2015-02-02|2011-02-22|2011-02-23|Estimate|||||||2015-02-02|2015-02-04|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Reducing Sleep Disparities in Minority Children|Reducing Sleep Disparities in Urban, Minority School-Aged Children|Completed||N/A|90|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 22:50:59.901726|2018-05-31 22:50:59.901726
NCT01301976|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|March 2009||2009-03-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|March 2010|Actual|2010-03-31||Observational|||Nutritional State and Intake Nutrients Assessment in Ulcerative Colitis|Nutritional State in Ulcerative Colitis Patients|Completed|||59|Actual|UPECLIN HC FM Botucatu Unesp|||||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:50:59.984912|2018-05-31 22:50:59.984912
NCT01301963|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2014-07-07||2014-07-07|2011-02-22|2011-02-23|Estimate|2014-07-07|2014-08-06|Estimate||||2014-07-07|2014-08-06|Estimate|July 2011||2011-07-31|July 2014|2014-07-31||||June 2013|Actual|2013-06-30||Interventional|||Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide|Comparison of Plerixafor and G-CSF Versus G-CSF Alone for Stem Cell Mobilization in Patients With Multiple Myeloma Previously Treated With Lenalidomide|Terminated||Phase 3|9|Actual|Case Comprehensive Cancer Center||2||Slow Accrual|f||||t||||||||||2018-05-31 22:51:00.066754|2018-05-31 22:51:00.066754
NCT01301950|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2014-06-25||2017-04-24|2011-02-22|2011-02-23|Estimate|2014-08-26|2014-09-05|Estimate||||2017-04-24|2017-06-05|Actual|May 1, 2010|Actual|2010-05-01|April 2017|2017-04-30|August 1, 2013|Actual|2013-08-01|August 1, 2013|Actual|2013-08-01||Interventional||All subjects who were consented prior to surgery were included in the analysis of baseline characteristics.|Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty|Comparison of Surgical Time and Efficiency of Total Knee Arthroplasty Using TruMatch® Personalized Solutions Compared to Conventional Total Knee Arthroplasty|Completed||N/A|30|Actual|DePuy Orthopaedics|A statistically powered sample size was not obtained; Two secondary objectives (compare costs & compare differences in OR efficiency as a function of institution type & geographic location) could not be assessed as originally intended by the protocol|2|||f||||f||||||||||2018-05-31 22:51:00.45945|2018-05-31 22:51:00.45945
NCT01301937|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-20|||2017-05-20|2011-02-22|2011-02-23|Estimate|||||||2017-05-20|2017-05-23|Actual|October 2008||2008-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Low Antimonial Dosage in American Mucosal Leishmaniasis|Phase III Clinical Trial for Mucosal or Mucocutaneous Leishmaniasis. Comparison Between the Standard and Alternative Antimonial Schemes|Recruiting||Phase 2/Phase 3|76|Anticipated|Oswaldo Cruz Foundation||2|||f||||t||||||||No||2018-05-31 22:51:00.845301|2018-05-31 22:51:00.845301
NCT01301924|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-20|||2018-05-11|2011-02-22|2011-02-23|Estimate|||||||2018-05-11|2018-05-15|Actual|October 2008||2008-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|April 2016|Actual|2016-04-30||Interventional|||Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis|Phase III Clinical Trial for American Tegumentary Leishmaniasis: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis|Completed||Phase 2/Phase 3|72|Actual|Oswaldo Cruz Foundation||2|||f||||t||||||||No||2018-05-31 22:51:00.964074|2018-05-31 22:51:00.964074
NCT01301911|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2012-12-20|2011-02-20|2011-02-23|Estimate|||||||2012-12-20|2012-12-21|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer|A Phase I Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer|Terminated||Phase 1|26|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:51:01.04522|2018-05-31 22:51:01.04522
NCT01301898|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-02-12|2011-02-22|2011-02-23|Estimate|||||||2012-02-12|2012-02-14|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients|Randomized, Single-blind, Active-controlled, Phase 1/2 Study to Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome (Mucopolysaccharidosis II) Patients|Completed||Phase 1/Phase 2|31|Actual|Green Cross Corporation||3|||f||||t||||||||||2018-05-31 22:51:01.128167|2018-05-31 22:51:01.128167
NCT01301885|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2012-06-01|2011-02-22|2011-02-23|Estimate|||||||2012-06-01|2012-06-04|Estimate|October 2005||2005-10-31|June 2012|2012-06-30||||||||Observational|ENDOMET||ENDOMET - Novel Diagnostic Tools and Treatments for Endometriosis|Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications|Unknown status|Active, not recruiting||230|Anticipated|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     serum, peritoneal fluid, endometrium tissue, healthy peritoneum, tissue of endometriosis~     (peritoneal, ovarian, deep infiltrating.~      Extracted DNA, RNA, cDNA and protein from the above samples.~   "|||2018-05-31 22:51:01.197002|2018-05-31 22:51:01.197002
NCT01301872|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2012-12-26|2011-02-18|2011-02-23|Estimate|||||||2012-12-26|2012-12-27|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effect of Mechanical Ventilation Strategy on Lung Injury in Patients With Less Severe Acute Respiratory Distress Syndrome: Targeted on RAGE|Effect of Mechanical Ventilation Strategy on Lung Injury in Patients With Less Severe Acute Respiratory Distress Syndrome: Targeted on RAGE|Unknown status|Not yet recruiting|N/A|50|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:51:01.276612|2018-05-31 22:51:01.276612
NCT01301859|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-01-12|2011-02-18|2011-02-23|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TIP||Personalized Antidepressant Adherence Strategies For Depressed Elders|Treatment Initiation and Participation Program (TIP)|Completed||N/A|231|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||Undecided||2018-05-31 22:51:01.347343|2018-05-31 22:51:01.347343
NCT01301846|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2016-08-31|2011-02-22|2011-02-23|Estimate|||||||2016-08-31|2016-09-01|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Participation of Manual Wheelchair Users in the Community|Participation of Manual Wheelchair Users in the Community: The Relationship to Wheelchair Skills Capacity|Withdrawn|||0|Actual|Nova Scotia Health Authority|||1|Need to recruit research staff|f||||f||||||||||2018-05-31 22:51:01.455387|2018-05-31 22:51:01.455387
NCT01301833|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2015-07-31||2015-10-15|2011-02-21|2011-02-23|Estimate|2015-07-31|2015-08-28|Estimate||||2015-10-15|2015-11-18|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes|Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|462|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||f||||||||||2018-05-31 22:51:01.591972|2018-05-31 22:51:01.591972
NCT01301820|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2016-03-15|2011-02-22|2011-02-23|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)|Phase II Multicentric Trial Maintenance Therapy With 6 Monthly Revlimid® Cycles Alternated With 6 Monthly Vidaza® Cycles in First CR After Induction LIA Chemotherapy for Elderly Fit Patients With Poor Prognosis Acute Myeloid Leukemia.|Completed||Phase 2|120|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||No||2018-05-31 22:51:02.735934|2018-05-31 22:51:02.735934
NCT01301807|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2018-05-21|2011-02-22|2011-02-23|Estimate|||||||2018-05-21|2018-05-23|Actual|July 2011|Actual|2011-07-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)|Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat Plus Carfilzomib in Patients With Relapsed/Refractory Myeloma|Active, not recruiting||Phase 1|63|Actual|M.D. Anderson Cancer Center||5|||f||||t|t|f||||||||2018-05-31 22:51:02.826672|2018-05-31 22:51:02.826672
NCT01301794|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-02-21|2011-02-22|2011-02-23|Estimate|||||||2013-02-21|2013-02-25|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Lovaza Mechanisms of Action|Study of the Effects of Lovaza (Omega 3 Fatty Acids) On Lipoprotein Particles and Their Transcriptional Effects|Unknown status|Recruiting|Phase 4|40|Anticipated|Brigham and Women's Hospital|||||f||||f||||||||||2018-05-31 22:51:02.979355|2018-05-31 22:51:02.979355
NCT01301781|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22||2012-09-27|2012-09-27|2011-02-22|2011-02-23|Estimate||||2012-09-27|2012-10-01|Estimate|2012-09-27|2012-10-01|Estimate|January 2011||2011-01-31|September 2012|2012-09-30||||May 2011|Actual|2011-05-31||Interventional|||BLI801 Laxative in Constipated Adults|A Pilot Efficacy Evaluation of BLI801 Laxative in Constipated Adults|Completed||Phase 2|52|Actual|Braintree Laboratories||2|||f||||f||||||||||2018-05-31 22:51:03.1078|2018-05-31 22:51:03.1078
NCT01301768|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Group Education to Improve the Iodine Nutrition in Pregnancy: Cluster Randomized Trial|Nutritional Status of Iodine in the Pregnant Population of Catalonia: a Study of Dietary Habits and Urinary Iodine|Unknown status|Recruiting|N/A|898|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 22:51:03.224281|2018-05-31 22:51:03.224281
NCT01301755|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2011-02-18|2011-02-18|2011-02-23|Estimate|||||||2011-02-18|2011-02-23|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration|Diagnosis of Invasive Pulmonary Aspergillosis by Direct Lung Tissue Aspergillus Galactomannan Antigen Detection From Aspirate by Ultrasound-guided Fine Needle Aspiration|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 22:51:03.348804|2018-05-31 22:51:03.348804
NCT01301742|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2014-05-16||2014-05-16|2011-02-22|2011-02-23|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|February 2011||2011-02-28|May 2014|2014-05-31||||May 2011|Actual|2011-05-31||Interventional|||Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers|Relative Bioavailability of Single Dose BI 10773 Co-administered With Multiple Doses of 600 mg Gemfibrozil Bid Compared to Single Dose Treatment of BI 10773 Alone in Healthy Volunteers - a Phase I, Open-label, Randomised, 2-way Crossover Trial|Completed||Phase 1|18|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:51:03.427029|2018-05-31 22:51:03.427029
NCT01301729|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2016-08-17||2016-11-02|2011-02-21|2011-02-23|Estimate|2016-11-02|2016-12-29|Estimate||||2016-11-02|2016-12-29|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Intention to treat (ITT) data set is defined as all the participants who are eligible through screening, register and enter the study.|A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment|A Multicenter, Single Arm, Open-Label PhIV Study to Investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (Neo)Adjuvant Herceptin for HER2-Positive Early Breast Cancer|Completed||Phase 4|32|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:51:03.679316|2018-05-31 22:51:03.679316
NCT01301716|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-11-01|2011-02-21|2011-02-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors|Completed||Phase 1|75|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 22:51:03.909541|2018-05-31 22:51:03.909541
NCT01301703|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|March 2011||2011-03-31|February 2010|2010-02-28|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis|The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||||2018-05-31 22:51:03.982231|2018-05-31 22:51:03.982231
NCT01301690|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-09-16|2011-02-22|2011-02-23|Estimate|||||||2011-09-16|2011-09-19|Estimate|January 2010||2010-01-31|September 2011|2011-09-30||||||||Observational|||Development of a Novel Methodology Using BMVC Staining as an Assistance to Cancer Cytological Diagnosis||Unknown status|Recruiting||100|Anticipated|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 22:51:04.043645|2018-05-31 22:51:04.043645
NCT01301677|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-06-28|2011-02-22|2011-02-23|Estimate|||||||2011-06-28|2011-06-29|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone|Double-blind, Randomised, Active (Hydrocortisone) Controlled Study of the Effect of 10% w/v Strontium Chloride Hexahydrate on Ultraviolet B Radiation (UVR) Induced Signs of Inflammation (Erythema and Pain) in Healthy Volunteers|Completed||Phase 1|47|Anticipated|X-pert Med GmbH||3|||f||||f||||||||||2018-05-31 22:51:04.098842|2018-05-31 22:51:04.098842
NCT01301664|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2013-03-06|2011-02-22|2011-02-23|Estimate|||||||2013-03-06|2013-03-07|Estimate||||March 2013|2013-03-31||||||||Expanded Access|||Cartilage Tissue Engineering||Available|||||Far Eastern Memorial Hospital|||||f||||||||||||||2018-05-31 22:51:04.158942|2018-05-31 22:51:04.158942
NCT01301651|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-10-13|2011-02-18|2011-02-23|Estimate|||||||2011-10-13|2011-10-17|Estimate|November 2007||2007-11-30|February 2011|2011-02-28|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|Parkinson||Effects of Virtual Reality Training in Patients With Parkinson's Disease|Effects of Virtual Reality Augmented Balance Training for Postural Control in Patients With Parkinson's Disease|Completed||Phase 1|42|Actual|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 22:51:04.200085|2018-05-31 22:51:04.200085
NCT01301638|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|February 2011||2011-02-28|February 2011|2011-02-28||||||||Observational|||Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections||Unknown status|Not yet recruiting||50|Anticipated|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-05-31 22:51:04.260941|2018-05-31 22:51:04.260941
NCT01301625|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2015-11-02|2011-02-21|2011-02-23|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|MitraClipANZ||MitraClip System in Australia and New Zealand|A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand|Terminated|||78|Actual|Evalve|||1||f||||t||||||||||2018-05-31 22:51:04.318555|2018-05-31 22:51:04.318555
NCT01301612|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2014-07-10|2011-02-22|2011-02-23|Estimate|||||||2014-07-10|2014-07-14|Estimate|January 2011||2011-01-31|January 2012|2012-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)|A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma|Withdrawn||Phase 2|0|Actual|Eurofarma Laboratorios S.A.||2||Regulatory requirement. A phase III study is being designed.|f||||f||||||||||2018-05-31 22:51:04.422407|2018-05-31 22:51:04.422407
NCT01301599|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2015-02-12|2011-02-22|2011-02-23|Estimate|||||||2015-02-12|2015-02-16|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)|Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia|Unknown status|Recruiting|Phase 4|315|Anticipated|Samsung Medical Center||3|||f||||t||||||||||2018-05-31 22:51:04.554796|2018-05-31 22:51:04.554796
NCT01301586|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-02-18|2011-02-18|2011-02-23|Estimate|||||||2011-02-18|2011-02-23|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||A Novel Combination Oral Agent to Treat Acne Vulgaris|A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF A NOVEL ORAL ACNE TREATMENT FOR THE TREATMENT OF ACNE VULGARIS|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Nexgen Dermatologics, Inc.||2|||f||||f||||||||||2018-05-31 22:51:04.619059|2018-05-31 22:51:04.619059
NCT01301573|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2012-02-20|2011-02-18|2011-02-23|Estimate|||||||2012-02-20|2012-02-22|Estimate|January 2011||2011-01-31|February 2012|2012-02-29||||||||Observational|||Long Term Follow-Up Study for rAAV-GAD Treated Subjects||Terminated|||40|Anticipated|Neurologix, Inc.|||1|Due to financial reasons|f||||||||||||||2018-05-31 22:51:04.690045|2018-05-31 22:51:04.690045
NCT01301560|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|June 2008||2008-06-30|February 2011|2011-02-28||||May 2013|Anticipated|2013-05-31||Interventional|||Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain Metastasis|Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 3|176|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 22:51:04.742028|2018-05-31 22:51:04.742028
NCT01301534|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-11-21|2011-02-18|2011-02-23|Estimate|||||||2013-11-21|2013-11-25|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Comparison of Methods to Improve Abdominal Aortic Aneurysm (AAA) Screening Rates in the Primary Care Setting.|Comparison of Methods to Improve Abdominal Aortic Aneurysm (AAA) Screening Rates in the Primary Care Setting.|Completed|||1700|Actual|Mike O'Callaghan Military Hospital|||4||f||||f||||||||||2018-05-31 22:51:04.859656|2018-05-31 22:51:04.859656
NCT01301521|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2018-02-07|2011-02-22|2011-02-23|Estimate|||||||2018-02-07|2018-02-08|Actual|June 11, 2013|Actual|2013-06-11|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Cinnamon||Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics|Cinnamon Trial—Assessment of the effeCt of lIfestyle iNtervention Plus Water-soluble ciNnAMon Extract On loweriNg Blood Glucose in Pre-diabetics: A Randomized, Double-blind, Multicenter, Placebo Controlled TRIAL.|Active, not recruiting||N/A|557|Anticipated|Mike O'Callaghan Military Hospital||2|||f||||f||||||||No||2018-05-31 22:51:04.917679|2018-05-31 22:51:04.917679
NCT01301508|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2017-01-11|2012-04-27|2017-01-12|2011-02-21|2011-02-23|Estimate|2017-01-12|2017-03-07|Actual|2012-04-27|2012-05-01|Estimate|2017-01-12|2017-03-07|Actual|May 2011||2011-05-31|January 2017|2017-01-31||||December 2011|Actual|2011-12-31||Interventional||Safety analysis population included all randomized participants with confirmed usage of the study medication.|Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis|A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study of the Safety and Efficacy of Topically Applied AN2898 and AN2728 in the Treatment of Patients With Mild-to-Moderate Atopic Dermatitis|Completed||Phase 2|46|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:51:04.996049|2018-05-31 22:51:04.996049
NCT01301495|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2015-06-01|2011-02-20|2011-02-23|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus|Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus|Withdrawn||Phase 2|0|Actual|Weill Medical College of Cornell University||1||No participants enrolled for more than 1 year.|f||||f||||||||||2018-05-31 22:51:05.420758|2018-05-31 22:51:05.420758
NCT01301482|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-02-01|2011-02-18|2011-02-23|Estimate|||||||2016-02-01|2016-02-03|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Ear Acupuncture for Acute Sore Throat in Patients Unable to Take Non-steroidal Anti-inflammatory Agents (NSAIDs)|Ear Acupuncture for Acute Sore Throat in Patients Unable to Take Non-steroidal Anti-inflammatory Agents (NSAIDs)|Completed||N/A|2|Actual|Mike O'Callaghan Military Hospital||2|||f||||f||||||||||2018-05-31 22:51:05.487431|2018-05-31 22:51:05.487431
NCT01300091|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2012-02-09|2011-02-18|2011-02-21|Estimate|||||||2012-02-09|2012-02-10|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Burden of Shoulder Disorders in Primary Health Care|Burden and Management of Shoulder Disorders in Primary Health Care|Unknown status|Active, not recruiting||128|Actual|Central Finland Hospital District|||||f||||t||||||||||2018-05-31 22:51:25.60126|2018-05-31 22:51:25.60126
NCT01301469|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-01-02|2011-02-22|2011-02-23|Estimate|||||||2012-01-02|2012-01-05|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparison of HES 130 in Balanced and in Unbalanced Solution|Prospective, Randomized, Double-blind, Controlled, Multicenter Study on the Efficacy and Safety of HES 130/0. 42 in a Balanced Electrolyte Solution vs a HES 130/0.4 in a Sodium Chloride Solution in Elective Surgery Patients|Completed||Phase 3|240|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-05-31 22:51:05.560809|2018-05-31 22:51:05.560809
NCT01301456|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2017-04-13||2017-07-28|2011-02-21|2011-02-23|Estimate|2017-07-28|2018-02-09|Actual||||2017-07-28|2018-02-09|Actual|March 2011|Actual|2011-03-31|July 2017|2017-07-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional||Full analysis set (FAS) included all participants who were randomized.|Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females|A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|84|Actual|Pfizer||13|||f||||f||||||||||2018-05-31 22:51:05.728703|2018-05-31 22:51:05.728703
NCT01301443|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2017-04-03|2011-02-22|2011-02-23|Estimate|||||||2017-04-03|2017-04-05|Actual|February 2011||2011-02-28|April 2017|2017-04-30|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|GEM||Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)|A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration|Completed||Phase 1|21|Actual|Oxford BioMedica||1|||f||||t||f||||||Undecided||2018-05-31 22:51:08.406735|2018-05-31 22:51:08.406735
NCT01301430|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-21|||2015-12-03|2011-02-22|2011-02-23|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ParvOryx01||Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.|Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.|Completed||Phase 1/Phase 2|18|Actual|Oryx GmbH & Co. KG||1|||f||||t||||||||||2018-05-31 22:51:08.517578|2018-05-31 22:51:08.517578
NCT01301417|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-20|||2013-06-04|2011-02-22|2011-02-23|Estimate|||||||2013-06-04|2013-06-05|Estimate|February 2011||2011-02-28|June 2013|2013-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|RETROPRESS||Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis|a RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing ™|Completed|||171|Actual|novoGI|||1||f||||f||||||||||2018-05-31 22:51:08.604896|2018-05-31 22:51:08.604896
NCT01301404|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-20|||2013-07-18|2011-02-22|2011-02-23|Estimate|||||||2013-07-18|2013-07-19|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||10% Carbohydrate Drink for Preventing Post-operative Nausea and Vomiting (PONV) After Spinal Morphine|Oral Rehydration Therapy With 10% Carbohydrate Drink for Preventing Postoperative Nausea and Vomiting (PONV) After Low Dose of Spinal Morphine in Patients Undergoing Total Knee Replacement|Completed||Phase 1|120|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 22:51:08.724219|2018-05-31 22:51:08.724219
NCT01301391|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-07-17|2011-02-22|2011-02-23|Estimate|||||||2017-07-17|2017-07-18|Actual|January 2011||2011-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy|Phase II Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy|Active, not recruiting||Phase 2|30|Actual|Tiziana Life Sciences, PLC||1|||f||||f||||||||||2018-05-31 22:51:08.889152|2018-05-31 22:51:08.889152
NCT01301378|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2016-11-20|2011-02-22|2011-02-23|Estimate|||||||2016-11-20|2016-11-22|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube|Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt|Terminated||N/A|40|Actual|Wills Eye||2||kerasys had more erosions than tutoplast|f||||t||||||||No||2018-05-31 22:51:08.977446|2018-05-31 22:51:08.977446
NCT01301365|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2011-02-20|2011-02-20|2011-02-23|Estimate|||||||2011-02-20|2011-02-23|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Observational|||Autonomic Response During Cystodistension in Patients Suspected of Having Interstitial Cystitis|Autonomic Response During Cystodistension in Patients Suspected of Having Interstitial Cystitis|Unknown status|Enrolling by invitation||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||t||||||||||2018-05-31 22:51:09.053969|2018-05-31 22:51:09.053969
NCT01301352|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2014-07-14|2011-02-22|2011-02-23|Estimate|||||||2014-07-14|2014-07-16|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|FeedNIV||Feeding Children Nasogastrically Versus Nasojejunally While Receiving Noninvasive Positive Pressure Ventilation|The Efficacy and Safety of Gastric Feeding in Critically Ill Pediatric Patients Receiving Non-invasive Positive Pressure Ventilation: A Pilot Study|Completed||N/A|30|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 22:51:09.135629|2018-05-31 22:51:09.135629
NCT01301339|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2013-11-21|2011-02-18|2011-02-23|Estimate|||||||2013-11-21|2013-11-25|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A1c FIT TEST: An Epidemiological Study Correlating Hemoglobin A1c With Results of the Air Force Physical FITness TEST.|A1c FIT TEST: An Epidemiological Study Correlating Hemoglobin A1c With Results of the Air Force Physical FITness TEST.|Completed|||535|Actual|Mike O'Callaghan Military Hospital|||1||f||||f||||||||||2018-05-31 22:51:09.241816|2018-05-31 22:51:09.241816
NCT01301326|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|RAM-SUB||Subthreshold Laser Treatment Versus Threshold Laser Treatment for Symptomatic Retinal Arterial Macroaneurysm|Pilot Randomized Clinical Trial Comparing Subthreshold Laser Treatment Versus Threshold Laser Treatment for Retinal Arterial Macroaneurysm|Completed||Phase 3|25|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-05-31 22:51:09.300781|2018-05-31 22:51:09.300781
NCT01301313|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2013-01-30|2011-02-22|2011-02-23|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children|Phase II Study to Evaluate the Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children|Terminated||Phase 2|116|Actual|Hospital Universitario Ramon y Cajal||2|||f||||t||||||||||2018-05-31 22:51:09.378089|2018-05-31 22:51:09.378089
NCT01301300|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Evaluating Central Line Hub Contamination Using a Novel Capping Device|Demonstration of Central Line Hub Contamination Reduction Using a Novel Capping Device|Unknown status|Recruiting|Phase 1/Phase 2|600|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 22:51:09.473506|2018-05-31 22:51:09.473506
NCT01301287|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|January 2010||2010-01-31|February 2011|2011-02-28||||||||Interventional|||The Effect of Chlorella on Glycemic Control of Diabetes||Unknown status|Recruiting|N/A|30|Anticipated|Cardinal Tien Hospital||1|||f||||||||||||||2018-05-31 22:51:09.552112|2018-05-31 22:51:09.552112
NCT01301274|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2011-11-16||2012-03-06|2011-02-18|2011-02-23|Estimate|2012-03-06|2012-03-07|Estimate||||2012-03-06|2012-03-07|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|NaCrICh||0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children|Randomized, Controlled, Double Blinded, Clinical Trial: 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children|Completed||N/A|66|Actual|Hospital General de Niños Pedro de Elizalde|Limitations: Antidiuretic hormone were not measured.|2|||f||||t||||||||||2018-05-31 22:51:09.648165|2018-05-31 22:51:09.648165
NCT01301261|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-06-18|2011-02-22|2011-02-23|Estimate|||||||2012-06-18|2012-06-19|Estimate|December 2010||2010-12-31|June 2012|2012-06-30||||February 2013|Anticipated|2013-02-28||Interventional|||Sugammadex: Effect on the Awareness Monitoring and Hemodynamics|The Effect of Sugammadex on Hemodynamics, Oxygenation, End-tidal CO2, Entropy and Bispectral Index Intraoperatively Without Steroid Neuromuscular Blocker|Unknown status|Recruiting|N/A|60|Anticipated|University of Athens||3|||f||||f||||||||||2018-05-31 22:51:09.988444|2018-05-31 22:51:09.988444
NCT01301248|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-05-16|2011-02-22|2011-02-23|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck|Phase II Safety and Toxicity Study of Cisplatin With or Without Cetuximab and Concomitant Radiotherapy for Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Theagenio Cancer Hospital||2|||f||||t||||||||||2018-05-31 22:51:10.087783|2018-05-31 22:51:10.087783
NCT01301235|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2012-04-27|2011-02-18|2011-02-23|Estimate|||||||2012-04-27|2012-04-30|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Observational|||Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy|Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics of the Vastus Lateralis After Sub-maximal Exercise in Patients With Mitochondrial Myopathy|Completed|||8|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 22:51:10.154848|2018-05-31 22:51:10.154848
NCT01301222|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2015-02-21|2011-02-22|2011-02-23|Estimate|||||||2015-02-21|2015-02-24|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|PD||Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas|Randomized Controlled Trial on Role of Octreotide in Preventing Pancreatic Fistula and Complications After Pancreaticoduodenectomy in Patients With Soft Pancreas|Completed||Phase 4|110|Actual|PVS Memorial Hospital||1|||f||||f||||||||||2018-05-31 22:51:10.202013|2018-05-31 22:51:10.202013
NCT01301209|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|January 2007||2007-01-31|June 2006|2006-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Recto-Anal-Repair in the Treatment of Advanced Haemorrhoidal Disease|Prospective Observational Study of Recto-Anal-Repair in the Treatment Haemorrhoidal Disease Stage III/IV|Completed|||200|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 22:51:10.265647|2018-05-31 22:51:10.265647
NCT01301196|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|STAND||Reducing Sedentary Behaviour in Young Adults at Risk of Diabetes|An Intervention to Decrease Sedentary Behaviour in Young Adults at Risk of type2 Diabetes Mellitus - Project STAND|Unknown status|Recruiting|N/A|189|Anticipated|Loughborough University||1|||f||||t||||||||||2018-05-31 22:51:10.334184|2018-05-31 22:51:10.334184
NCT01301183|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-07-26|2011-02-18|2011-02-23|Estimate|||||||2017-07-26|2017-07-28|Actual|February 2011||2011-02-28|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Anorexia Nervosa on Peak Bone Mass|Effects of Anorexia Nervosa on Peak Bone Mass|Recruiting||Phase 3|136|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 22:51:10.44157|2018-05-31 22:51:10.44157
NCT01301170|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|March 2012|Anticipated|2012-03-31|November 2011|Anticipated|2011-11-30||Interventional|||Study Evaluating the Benefit of Dry Needling for Patients With Neck Pain|The Effectiveness of Dry Needling for Patients With Neck Pain: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|66|Anticipated|Integrated Therapy Practice PC|||||f||||f||||||||||2018-05-31 22:51:10.514147|2018-05-31 22:51:10.514147
NCT01301157|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18||2015-10-12|2015-10-12|2011-02-18|2011-02-23|Estimate||||2015-10-12|2015-11-05|Estimate|2015-10-12|2015-11-05|Estimate|February 2011||2011-02-28|October 2015|2015-10-31||||January 2012|Actual|2012-01-31||Interventional|||Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients||Completed||Phase 2|294|Actual|Maruho Co., Ltd.||4|||f||||||||||||||2018-05-31 22:51:10.646304|2018-05-31 22:51:10.646304
NCT01301144|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2018-04-04|2011-02-19|2011-02-23|Estimate|||||||2018-04-04|2018-04-05|Actual|February 13, 2011||2011-02-13|March 30, 2016|2016-03-30|March 30, 2016||2016-03-30|||||Observational|||Oral Urea Breath Testing for Diagnosis and Treatment Response in Pulmonary Tuberculosis|Sensitivity and Specificity of Oral Urea Breath Testing for Presumptive Diagnosis and Treatment Response in Pulmonary Tuberculosis in Bamako, Mali|Completed|||113|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:51:10.747719|2018-05-31 22:51:10.747719
NCT01301131|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-12-29|2011-02-18|2011-02-23|Estimate|||||||2011-12-29|2012-01-02|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|VAP||Probiotics for Prevention of Ventilator-Associated Pneumonia (VAP)|Randomized Controlled Trial of Fermented Dairy Product Containing L. Casei Shirota for Prevention of Ventilator-Associated Pneumonia|Unknown status|Recruiting|Phase 4|150|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 22:51:10.807058|2018-05-31 22:51:10.807058
NCT01301118|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2012-01-07|2011-02-22|2011-02-23|Estimate|||||||2012-01-07|2012-01-10|Estimate|October 2010||2010-10-31|January 2012|2012-01-31||||||||Observational|||Graft Take and Microbiology in Burns|Split Thickness Skin Graft Take and Microbiology Evaluation in Burned Patients|Suspended|||30|Anticipated|Federal University of São Paulo||||Technical problems with protocol.|f||||t||||||||||2018-05-31 22:51:10.876218|2018-05-31 22:51:10.876218
NCT01301105|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2015-10-01|2011-02-22|2011-02-23|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||The Effects of Mindfulness Training on Pain Regulation, Negative Affect, Attention, and Social Stress|The Effects of Mindfulness Training on Pain Regulation, Negative Affect, Attention, and Social Stress.|Completed||N/A|80|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 22:51:10.927324|2018-05-31 22:51:10.927324
NCT01301092|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2014-10-03||2014-10-03|2011-02-18|2011-02-23|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.|A Study to Evaluate the Safety, Tolerability, and Absolute Bioavailability of Subcutaneous LY2189265|Completed||Phase 1|30|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 22:51:10.997253|2018-05-31 22:51:10.997253
NCT01301079|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2013-11-10||2014-11-06|2011-02-22|2011-02-23|Estimate|2014-11-06|2014-11-10|Estimate||||2014-11-06|2014-11-10|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia|Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Using Filaments, an Algometer, and Interleukins: a Double-blind, Randomized Study|Completed||Phase 3|60|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:51:11.517286|2018-05-31 22:51:11.517286
NCT01301066|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2014-02-10||2014-03-27|2011-02-22|2011-02-23|Estimate|2014-03-27|2014-04-29|Estimate||||2014-03-27|2014-04-29|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects|A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study|Completed||Phase 4|252|Actual|Kowa Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 22:51:12.372122|2018-05-31 22:51:12.372122
NCT01301053|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-01-30|2011-02-22|2011-02-23|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Pilot Study of Intensive Care Unit Continuous Glucose Monitoring|Pilot Study of Intensive Care Unit Continuous Glucose Monitoring|Unknown status|Enrolling by invitation|N/A|20|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 22:51:12.618712|2018-05-31 22:51:12.618712
NCT01301040|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-08-29|2011-02-18|2011-02-23|Estimate|||||||2013-08-29|2013-08-30|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|March 2016|Anticipated|2016-03-31|March 2013|Actual|2013-03-31||Interventional|||Early Cardiac Toxicity of Adjuvant CT in Elderly BC.|Early Detection of Chemotherapy Induced Cardiac Damage in Elderly Patients With Early Breast Cancer: a Randomized Phase II Trial Comparing (Neo) Adjuvant Epirubicin-cyclophosphamide (EC) Versus Docetaxel (Taxotere)-Cyclophosphamide (TC.)|Terminated||Phase 2|2|Actual|Jules Bordet Institute||2||Slow recruitment|f||||f||||||||||2018-05-31 22:51:12.690978|2018-05-31 22:51:12.690978
NCT01301027|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2016-08-09||2016-08-09|2011-02-22|2011-02-23|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Adipokines in Hemodialysis Patients|Effects of Pioglitazone on Adiponectin and Inflammatory Markers in Overweight or Obese Hemodialysis Patients: A Double-Blinded Randomized Controlled Trial|Completed||N/A|95|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:51:12.825599|2018-05-31 22:51:12.825599
NCT01301014|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-05-13|2011-02-18|2011-02-23|Estimate|||||||2016-05-13|2016-05-17|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Reliability and Diagnostic Accuracy of an Alternate Lachman's Test Performed in a Prone Position|Reliability and Diagnostic Accuracy of an Alternate Lachman's Test Performed in a Prone Position|Completed|||57|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-05-31 22:51:13.114773|2018-05-31 22:51:13.114773
NCT01301001|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2017-08-28|2017-05-05|2017-11-06|2011-02-22|2011-02-23|Estimate|2017-11-06|2017-11-08|Actual|2017-07-11|2017-07-13|Actual|2017-11-06|2017-11-08|Actual|August 2012||2012-08-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response|A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response|Completed||N/A|230|Actual|University of Tennessee||2|||f||||t||||||||Undecided||2018-05-31 22:51:13.168317|2018-05-31 22:51:13.168317
NCT01300988|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2016-06-02|2011-02-22|2011-02-23|Estimate|||||||2016-06-02|2016-06-03|Estimate|December 2010||2010-12-31|June 2016|2016-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose|A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals|Completed||Phase 1|18|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 22:51:13.552565|2018-05-31 22:51:13.552565
NCT01300975|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2012-07-03|2011-02-18|2011-02-23|Estimate|||||||2012-07-03|2012-07-06|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Intralesional Antimony for Bolivian Cutaneous Leishmaniasis|Short Course of Intralesional Antimony for Bolivian Cutaneous Leishmaniasis|Completed||Phase 2|90|Actual|Fundacion Nacional de Dermatologia||3|||f||||f||||||||||2018-05-31 22:51:13.705419|2018-05-31 22:51:13.705419
NCT01300962|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2017-10-09|2011-02-22|2011-02-23|Estimate|||||||2017-10-09|2017-10-10|Actual|August 2011||2011-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|February 7, 2017|Actual|2017-02-07||Interventional|||Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer|A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 1|47|Actual|UNC Lineberger Comprehensive Cancer Center||4|||f||||t||||||||||2018-05-31 22:51:13.796197|2018-05-31 22:51:13.796197
NCT01300949|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2015-01-29|2011-02-22|2011-02-23|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|SPARCS||Spaeth/Richman Contrast Sensitivity Test|Validation and Reproducibility of Spaeth/Richman Contrast Sensitivity Test|Completed|||315|Actual|Wills Eye|||||f||||f||||||||||2018-05-31 22:51:13.925634|2018-05-31 22:51:13.925634
NCT01300936|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-03-10|2011-02-22|2011-02-23|Estimate|||||||2011-03-10|2011-03-11|Estimate|March 2010||2010-03-31|March 2011|2011-03-31||||||||Observational|||Trunk Strength Study|Abdominal Wall Hernias and Abdominal Wall Function: A Quantitative Study of Trunk Strength.|Completed|||10|Anticipated|University of Kentucky|||1||f||||f||||||||||2018-05-31 22:51:14.012991|2018-05-31 22:51:14.012991
NCT01300923|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2015-07-29||2017-04-27|2011-02-18|2011-02-23|Estimate|2017-04-27|2017-04-28|Actual||||2017-04-27|2017-04-28|Actual|August 2010||2010-08-31|April 2017|2017-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Acamprosate in Youth With Fragile X Syndrome|Pilot Study of Acamprosate in Youth With Fragile X Syndrome|Completed||Phase 3|14|Actual|Indiana University|Psychophysiological measures proved non-feasible as subjects could not tolerate the procedures. The paradigms were tried on 2 subjects in the ADS arm, as data collected was not usable. Subsequently, neurobiological characterization was halted.|2|||f||||t||||||||||2018-05-31 22:51:14.083405|2018-05-31 22:51:14.083405
NCT01300910|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2012-03-15|2011-02-22|2011-02-23|Estimate|||||||2012-03-15|2012-03-16|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparison of the Shang Ring With Conventional Surgical Methods|Comparison of the Shang Ring With Conventional Surgical Methods: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|400|Anticipated|FHI 360||2|||f||||t||||||||||2018-05-31 22:51:14.414696|2018-05-31 22:51:14.414696
NCT01300897|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-01-08|2011-02-22|2011-02-23|Estimate|||||||2014-01-08|2014-01-09|Estimate|August 2005||2005-08-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Observational|Aim 2||Investigation of Cortico-Rectal Pathways in Healthy Subjects|Investigation of Cortico-Rectal Pathways in Healthy Subjects|Unknown status|Active, not recruiting||50|Anticipated|Augusta University|||1||f||||f||||||||||2018-05-31 22:51:14.573053|2018-05-31 22:51:14.573053
NCT01300884|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-03-07|2011-02-18|2011-02-23|Estimate|||||||2011-03-07|2011-03-08|Estimate|February 2008||2008-02-29|March 2011|2011-03-31||||December 2011|Anticipated|2011-12-31||Observational|||Sierra High Definition Ano-Rectal Manometry||Unknown status|Recruiting||80|Anticipated|University of Iowa|||3||f||||||||||||||2018-05-31 22:51:14.641539|2018-05-31 22:51:14.641539
NCT01300871|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2014-09-25|2011-02-22|2011-02-23|Estimate|||||||2014-09-25|2014-09-26|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|January 2012|Actual|2012-01-31|||||Observational|||Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer|Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer|Terminated|||100|Anticipated|University Health Network, Toronto|||1|Poor patient accrual|f||||f||||||||||2018-05-31 22:51:14.723098|2018-05-31 22:51:14.723098
NCT01300858|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18||2014-07-17|2015-06-15|2011-02-18|2011-02-23|Estimate||||2015-06-15|2015-07-13|Estimate|2015-06-15|2015-07-13|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients|A Phase I/II Study of the Safety and Biological Activity of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients Who Had Previously Received Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Therapy|Terminated||Phase 1/Phase 2|4|Actual|EGEN, Inc.||1||Sites could not enroll patients.|f||||t||||||||||2018-05-31 22:51:14.828654|2018-05-31 22:51:14.828654
NCT01300845|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2014-11-19|2011-02-22|2011-02-23|Estimate|||||||2014-11-19|2014-11-20|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|OXYREA||Trial Aiming at Assessing the Effect of Humidification on the Comfort of the Patient Receiving an Oxygen Therapy|Prospective, Randomized, Multi-center Trial Aiming at Assessing the Effect of Humidification on the Comfort of the Patient Receiving an Oxygen Therapy.|Completed||N/A|356|Actual|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 22:51:14.908168|2018-05-31 22:51:14.908168
NCT01300832|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-05-10|2011-02-18|2011-02-23|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The Incidence of Perioperative Deep Venous Thromboses of the Lower Extremities|The Incidence of Perioperative Deep Venous Thromboses of the Lower Extremities|Unknown status|Recruiting|N/A|1000|Anticipated|University of Chicago||1|||f||||t||||||||||2018-05-31 22:51:14.980355|2018-05-31 22:51:14.980355
NCT01300819|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2013-10-25||2014-04-09|2011-02-22|2011-02-23|Estimate|2014-04-09|2014-05-09|Estimate||||2014-04-09|2014-05-09|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional||Baseline characteristics are presented by the Randomized Set (RS), which is defined as all subjects that signed informed consent and were randomized.|Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms|Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease|Completed||Phase 4|349|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 22:51:15.107768|2018-05-31 22:51:15.107768
NCT01300806|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2013-05-20|2011-02-22|2011-02-23|Estimate|||||||2013-05-20|2013-05-22|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|SBIRT||Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting|Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting|Completed|||210|Actual|University of California, San Francisco|||2||f||||t||||||||||2018-05-31 22:51:15.852143|2018-05-31 22:51:15.852143
NCT01300793|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2012-09-24|2011-02-22|2011-02-23|Estimate|||||||2012-09-24|2012-09-26|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|July 2011|Actual|2011-07-31||Interventional|V-RICE||Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide|(RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL|Terminated||Phase 1|6|Actual|University of California, San Francisco||||closed for low accrual and no data is available.|f||||t||||||||||2018-05-31 22:51:15.911676|2018-05-31 22:51:15.911676
NCT01300780|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-08-15|2011-02-22|2011-02-23|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2010||2010-04-30|August 2017|2017-08-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching|Effect of Preoperative Use of an Anti-inflammatory on Tooth Sensitivity Caused by In-office Bleaching: A Randomized, Double-blind Clinical Trial|Completed||N/A|30|Actual|Universidade Estadual de Ponta Grossa||2|||f||||t||||||||No||2018-05-31 22:51:15.970326|2018-05-31 22:51:15.970326
NCT01300767|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2012-04-11||2012-06-26|2011-02-22|2011-02-23|Estimate|2012-04-11|2012-05-09|Estimate||||2012-06-26|2012-07-10|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Four Week Performance Comparison Between Two Commercially Available Silicone Hydrogel Lenses|4 Week Performance Comparison Between 2 Commercially Available Silicone Hydrogel Lenses|Completed||N/A|75|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:51:16.041676|2018-05-31 22:51:16.041676
NCT01300754|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|January 2006||2006-01-31|January 2011|2011-01-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Effectiveness of Dextrose Injection for Osgood-Schlatter Disease|Phase 2 Study of Dextrose Injection for Sport-Limiting Osgood Schlatter Disease in Adolescents.|Completed||Phase 1/Phase 2|54|Actual|Universidad Nacional de Rosario||3|||f||||t||||||||||2018-05-31 22:51:16.260754|2018-05-31 22:51:16.260754
NCT01300741|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2012-04-11||2012-06-26|2011-02-22|2011-02-23|Estimate|2012-04-11|2012-05-09|Estimate||||2012-06-26|2012-07-10|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||One Month Performance Comparison Between Two Commercially Available Silicone Hydrogel Lenses|One Month Performance Comparison Between 2 Commercially Available Silicone Hydrogel Lenses|Completed||N/A|75|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:51:16.326684|2018-05-31 22:51:16.326684
NCT01300728|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|2015-08-08||2016-03-01|2011-02-22|2011-02-23|Estimate|2016-03-01|2016-03-31|Estimate||||2016-03-01|2016-03-31|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2014|Actual|2014-11-30||Interventional|MCI||Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment|A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment|Unknown status|Active, not recruiting|Phase 2|52|Actual|Sutter Health||2|||f||||t||||||||||2018-05-31 22:51:16.548018|2018-05-31 22:51:16.548018
NCT01300715|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2010||2010-11-30|October 2010|2010-10-31||||May 2011|Anticipated|2011-05-31||Interventional|MBRF LBP||An Alternative Technique for Lumbar Medial Branch Radiofrequency: Comparison With the Empirical Technique||Unknown status|Recruiting|N/A|100|Anticipated|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-05-31 22:51:16.792585|2018-05-31 22:51:16.792585
NCT01300702|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-09-28|2011-02-22|2011-02-23|Estimate|||||||2011-09-28|2011-09-29|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Neuropathic in the Acute Post Operative Phase|Identification of Neuropathic Pain in the Acute Post Operative Phase Following Thoracotomy|Terminated|||0|Actual|Rigshospitalet, Denmark|||1|recruitment problems|f||||f||||||||||2018-05-31 22:51:17.780926|2018-05-31 22:51:17.780926
NCT01300689|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|July 2011||2011-07-31|February 2011|2011-02-28||||||||Observational|||Human Papillomavirus Infection and Knowledge and Attitudes About HPV Vaccines Among Men Who Have Sex With Men (MSM)||Unknown status|Not yet recruiting||3000|Anticipated|Chinese Academy of Medical Sciences|||||f||||f||||||||||2018-05-31 22:51:17.847333|2018-05-31 22:51:17.847333
NCT01300676|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|March 2009||2009-03-31|November 2007|2007-11-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||The Effects of Tualang Honey on Postmenopausal Women|The Effect of Tualang Honey and Hormonal Replacement Therapy (HRT) on Safety Profiles Among Postmenopausal Women|Completed||Phase 2/Phase 3|79|Actual|University of Science Malaysia||2|||f||||t||||||||||2018-05-31 22:51:17.91517|2018-05-31 22:51:17.91517
NCT01300663|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2011-02-22|2011-02-22|2011-02-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|WOMAN-PRO||A New Patient Reported Outcome Instrument to Assess Symptom Experience in Women With Vulvar Neoplasms (WOMAN-PRO)|Creating and Validating a Patient-reported Outcome Instrument to Assess Symptom Experience Related to Surgical Wounds in Women With Vulvar Neoplasms - A Mixed Methods Study|Unknown status|Recruiting||150|Anticipated|University of Basel|||1||f||||f||||||||||2018-05-31 22:51:17.99727|2018-05-31 22:51:17.99727
NCT01300650|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2011-12-02||2017-10-24|2011-02-17|2011-02-21|Estimate|2013-04-02|2013-05-16|Estimate||||2017-10-24|2017-11-30|Actual|February 2011||2011-02-28|October 2017|2017-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure|Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure|Completed||Phase 1/Phase 2|11|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-05-31 22:51:18.094309|2018-05-31 22:51:18.094309
NCT01300637|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|July 2011|Anticipated|2011-07-31|April 2009|Anticipated|2009-04-30||Interventional|||Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients|Prevalence of Metabolic Syndrome and Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients|Unknown status|Recruiting|N/A|60|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-05-31 22:51:18.264051|2018-05-31 22:51:18.264051
NCT01300624|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2014-07-15||2015-06-05|2011-02-17|2011-02-21|Estimate|2015-06-05|2015-06-09|Estimate||||2015-06-05|2015-06-09|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|VNeST|Number of participants was based on pilot study results and consistent with the relevant literature.|Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia|Effect Of Verb Network Strengthening Treatment on Lexical Retrieval in Aphasia|Completed||Phase 2|11|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-05-31 22:51:19.112664|2018-05-31 22:51:19.112664
NCT01300611|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2017-10-10|2011-02-17|2011-02-21|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2011||2011-01-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|USBTXA127CBT||TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation|Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation|Active, not recruiting||Phase 1|20|Anticipated|Tarix Pharmaceuticals||2|||f||||||||||||||2018-05-31 22:51:19.310901|2018-05-31 22:51:19.310901
NCT01300598|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-03-24|2011-02-17|2011-02-21|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2008||2008-12-31|March 2014|2014-03-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Degenerative Arthritis|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Degenerative Arthritis|Completed||Phase 1/Phase 2|18|Actual|Biostar|||||f||||||||||||||2018-05-31 22:51:19.382944|2018-05-31 22:51:19.382944
NCT01300585|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-05-02|2011-02-17|2011-02-21|Estimate|||||||2014-05-02|2014-05-05|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Breast MRI||MRI Evaluation of the Breast Areolar Margin and Paryenchyma|MRI Evaluation to Assess the Relationship Between the Areolar Margin and Underlying Breast Paryenchyma Attachments to the Dermis|Terminated||N/A|68|Actual|Piedmont Healthcare||1||Lack of patient population|f||||f||||||||||2018-05-31 22:51:19.446146|2018-05-31 22:51:19.446146
NCT01300572|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2018-03-19|2011-02-18|2011-02-21|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2012|Actual|2012-01-31|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|October 29, 2017|Actual|2017-10-29||Interventional|||Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome|A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 1|16|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 22:51:19.515643|2018-05-31 22:51:19.515643
NCT01300559|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2012-10-31||2013-01-03|2011-02-18|2011-02-21|Estimate|2013-01-03|2013-02-07|Estimate||||2013-01-03|2013-02-07|Estimate|April 2006||2006-04-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|September 2010|Actual|2010-09-30||Interventional|||TissueLink Study During Multi-Level Spine Surgery|Efficacy of the TissueLink Coagulation System in Reducing Hemoglobin Loss During Multi-Level Spine Surgery|Completed||Phase 4|60|Actual|Duke University|None encountered.|2|||f||||t||||||||||2018-05-31 22:51:19.756894|2018-05-31 22:51:19.756894
NCT01300546|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2013-02-01||2013-05-17|2011-02-18|2011-02-21|Estimate|2013-05-17|2013-05-21|Estimate||||2013-05-17|2013-05-21|Estimate|December 2010||2010-12-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine|TreximetTM in the Prevention and Modification of Disease Progression in Migraine|Completed||Phase 4|40|Actual|Cady, Roger, M.D.||2|||f||||f||||||||||2018-05-31 22:51:20.014749|2018-05-31 22:51:20.014749
NCT01300533|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-02-08|2011-02-18|2011-02-21|Estimate|||||||2016-02-08|2016-02-09|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|September 2013|Actual|2013-09-30||Interventional|||A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer|A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer|Completed||Phase 1|58|Actual|BIND Therapeutics|||||f||||t||||||||Yes|http://clincancerres.aacrjournals.org/content/early/2016/02/04/1078-0432.CCR-15-2548.full.pdf+html|2018-05-31 22:51:20.45525|2018-05-31 22:51:20.45525
NCT01300520|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-02-03|2011-02-18|2011-02-21|Estimate|||||||2017-02-03|2017-02-07|Estimate|March 2011|Actual|2011-03-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||The Development of a Surgical Localizing Aid Medical Device|The Development of a Surgical Localizing Aid Medical Device and the Determination and Analysis of Significant Variables|Terminated||N/A|5|Actual|Aeos Biomedical Inc.||2||Enough surgeon use to validate the usefulness of the device|f||||t||||||||||2018-05-31 22:51:20.515341|2018-05-31 22:51:20.515341
NCT01300507|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-01-17|2011-02-18|2011-02-21|Estimate|||||||2013-01-17|2013-01-18|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|March 2018|Anticipated|2018-03-31|March 2015|Anticipated|2015-03-31||Observational|PRESTIGE||PRESTIGE: PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort|PREvention of Stent Thrombosis by an Interdisciplinary Global|Unknown status|Recruiting||2000|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples With DNA|"~     Biospecimen: 1, thrombusaspiration from coronary arteries, storage and analysis at the German~     Heart Center Munich; 2, DNA-samples: storage at German Heart Center Munich, Antonius Hospital~     Nieuwegein, The Netherlands, University Hospitals Leuven Belgium and University Hospital~     Leicester, UK~   "|||2018-05-31 22:51:20.576022|2018-05-31 22:51:20.576022
NCT01300494|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Observational|BOVAS||BOVAS: Bifurcation Optimal Viewing Angle Selection Study|Bifurcation Optimal Viewing Angle Selection Study|Unknown status|Not yet recruiting||50|Anticipated|University Hospital, Gasthuisberg|||||f||||f||||||||||2018-05-31 22:51:20.632017|2018-05-31 22:51:20.632017
NCT01300468|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|April 2006||2006-04-30|February 2011|2011-02-28|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors|A Phase I Study of Oral PHA-848125AC Given Daily For 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days A Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients With Advanced/Metastatic Solid Tumors|Completed||Phase 1|38|Actual|Nerviano Medical Sciences||1|||f||||f||||||||||2018-05-31 22:51:20.667685|2018-05-31 22:51:20.667685
NCT01300455|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2014-08-19||2017-06-01|2011-02-17|2011-02-21|Estimate|2014-08-19|2014-08-29|Estimate||||2017-06-01|2017-07-02|Actual|March 19, 2011|Actual|2011-03-19|June 2017|2017-06-30|August 11, 2011|Actual|2011-08-11|August 11, 2011|Actual|2011-08-11||Interventional|||Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)|A Study to Evaluate the Effects of MK-4305 in Patients With Obstructive Sleep Apnea|Completed||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:51:20.741967|2018-05-31 22:51:20.741967
NCT01300442|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|COPD||Effects of Transcutaneous Electrical Diaphragmatic Stimulation on Respiratory Variables in COPD Patients|Fundamentation of TEDS Protocol in Healthy Subjects and Its Application in COPD Patients|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 22:51:21.191988|2018-05-31 22:51:21.191988
NCT01300429|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2018-01-19|2011-02-18|2011-02-21|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2011||2011-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus|Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus|Active, not recruiting|||30|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 22:51:21.268677|2018-05-31 22:51:21.268677
NCT01300416|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-03-23|2011-02-18|2011-02-21|Estimate|||||||2016-03-23|2016-03-24|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|PROGIS||Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms|Open, Multi-centre, Non-interventional, Observational Study to Characterize the Impact That GI Complaints Have on Patient-reported Outcomes in Patients Who Have Had a Renal Transplant. Patients Will be Evaluated at Visit 1 and Then Again After 4 (+2) Weeks (Visit 2)|Completed|||101|Actual|Novartis|||2||f||||f||||||||||2018-05-31 22:51:21.336066|2018-05-31 22:51:21.336066
NCT01300403|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Physiological Effects of Expiration With the Glottis Open in Lateral Posture (ELTGOL) and Flutter Valve in Patients With Bronchiectasis|Acute Physiological Effects of Expiration With the Glottis Open in Lateral Posture (ELTGOL) and Flutter Valve in Dynamic and Static Pulmonary Volumes of Patients With Bronchiectasis|Completed||N/A|10|Actual|Universidade Federal do Rio de Janeiro||3|||f||||f||||||||||2018-05-31 22:51:21.408103|2018-05-31 22:51:21.408103
NCT01300078|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-06-01|2011-02-17|2011-02-21|Estimate|||||||2011-06-01|2011-06-02|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||A Clinical Trial Assessing Safety of MF101 for Hot Flushes|A Phase 1 Open Label, Randomized Clinical Trial Assessing Safety of MF101 for Hot Flushes and Menopausal Symptoms in Postmenopausal Women|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Bionovo||2|||f||||t||||||||||2018-05-31 22:51:25.683721|2018-05-31 22:51:25.683721
NCT01300390|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-05-13|2011-02-18|2011-02-21|Estimate|||||||2016-05-13|2016-05-17|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|Endo-PAT||Assessment of Endothelial Function, Apolipoproteins and Adiponectin|Assessment of Endothelial Function, Apolipoproteins, and Adiponectin Levels as Markers of Cardiovascular Before and After Liver Transplantation|Completed|||150|Actual|Mayo Clinic|||1||f||||f||||||Samples Without DNA|"~     Serum samples will be retained for future liver transplant research.~   "|||2018-05-31 22:51:21.471299|2018-05-31 22:51:21.471299
NCT01300377|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2018-01-16|2011-02-18|2011-02-21|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2008||2008-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Trial Assessing The Association Between Type Of Local Anesthesia Treatment And Postoperative Pain In Patients In Having Undergone Arrhythmia Surgery|A DOUBLE-BLIND RANDOMIZED TRIAL ASSESSING THE ASSOCIATION BETWEEN TYPE OF LOCAL ANESTHESIA TREATMENT AND POSTOPERATIVE PAIN IN PATIENTS IN HAVING UNDERGONE ARRHYTHMIA SURGERY|Active, not recruiting||N/A|300|Anticipated|Baylor Research Institute||2|||f||||f||||||||||2018-05-31 22:51:21.546853|2018-05-31 22:51:21.546853
NCT01300364|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|November 2008||2008-11-30|November 2008|2008-11-30||||December 2011|Anticipated|2011-12-31||Interventional|||Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia|Double-blind Clinical Trial Controlled With Placebo of the Efficacy of Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia|Unknown status|Recruiting|Phase 4|249|Anticipated|Fundació Sant Joan de Déu||3|||f||||t||||||||||2018-05-31 22:51:21.624577|2018-05-31 22:51:21.624577
NCT01300351|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2015-03-12||2015-04-23|2011-02-18|2011-02-21|Estimate|2015-04-23|2015-04-24|Estimate||||2015-04-23|2015-04-24|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||The planned population size was 220 randomised patients and altogether 221 patients were randomised. Key demographic and baseline characteristics were balanced between the treatment groups.|Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women|A Randomised, Double-Blind, Parallel-Group, Multicentre Study Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With ER+ Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy|Completed||Phase 3|249|Actual|AstraZeneca|China CONFIRM Study was planned as a bridge study to the CONFIRM Study and therefore was not formally powered to detect a statistically significant difference between two treatment groups.|2|||f||||f||||||||||2018-05-31 22:51:21.800235|2018-05-31 22:51:21.800235
NCT01300338|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2014-03-24||2014-03-24|2011-02-17|2011-02-21|Estimate|2014-03-24|2014-04-24|Estimate||||2014-03-24|2014-04-24|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Blood Pressure Telemonitoring and Goal Blood Pressure in Diabetes|Does Home Telemonitoring Increase the Number of Diabetic Patients at Goal Blood Pressure in a Primary Care Practice?|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:51:22.338972|2018-05-31 22:51:22.338972
NCT01300325|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|November 2008||2008-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Effectiveness of Nebulized Hypertonic Saline and Epinephrine in Hospitalized Infants With Bronchiolitis|Effectiveness of Nebulized Hypertonic Saline and Epinephrine in Hospitalized Infants With Bronchiolitis|Completed||Phase 4|136|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 22:51:22.519638|2018-05-31 22:51:22.519638
NCT01300312|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-01-04|2011-02-18|2011-02-21|Estimate|||||||2013-01-04|2013-01-08|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain|Evaluation of Efficacy and Tolerability of a Fixed Dose Combination of Eperisone Hydrochloride and Diclofenac Sodium in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain: An Observer Blind, Prospective, Randomized, Controlled Study|Completed||Phase 3|239|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:51:22.666643|2018-05-31 22:51:22.666643
NCT01300299|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2018-03-01|2011-02-18|2011-02-21|Estimate|||||||2018-03-01|2018-03-05|Actual|February 2011||2011-02-28|March 2018|2018-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|STEREO||STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)|STEREOtactic Radiation and Adjuvant Chemotherapy in Lung Cancer (STEREO)|Withdrawn||N/A|0|Actual|University of Louisville||1||Unable to enroll|f||||t||||||||||2018-05-31 22:51:22.735174|2018-05-31 22:51:22.735174
NCT01300286|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|2014-01-16||2014-12-05|2011-02-17|2011-02-21|Estimate|2014-05-15|2014-06-16|Estimate||||2014-12-05|2014-12-25|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Open Label Use Of RiaStap During Aortic Reconstruction|Open Label Use Of RiaStap During Aortic Reconstruction|Completed||Phase 4|23|Actual|Duke University||1|||f||||t||||||||||2018-05-31 22:51:22.821409|2018-05-31 22:51:22.821409
NCT01300273|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-09-06|2011-02-18|2011-02-21|Estimate|||||||2011-09-06|2011-09-08|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy|Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||||2018-05-31 22:51:22.998834|2018-05-31 22:51:22.998834
NCT01300260|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2014-10-03||2014-10-03|2011-02-18|2011-02-21|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Healthy participants or participants with type 2 diabetes mellitus (T2DM) who received at least one dose of study drug (LY2189265 or Placebo).|Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose|The Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose Infusion|Completed||Phase 1|32|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:51:23.110446|2018-05-31 22:51:23.110446
NCT01300065|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2012-08-10|2011-02-17|2011-02-21|Estimate|||||||2012-08-10|2012-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:51:25.750941|2018-05-31 22:51:25.750941
NCT01299883|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2017-10-10|2011-02-17|2011-02-18|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2008||2008-08-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||West Philadelphia Consortium Randomized Control Trial|West Philadelphia Consortium to Address Disparities|Completed||N/A|543|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:51:28.762719|2018-05-31 22:51:28.762719
NCT01300247|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2016-05-18||2016-12-08|2011-02-17|2011-02-21|Estimate|2016-05-18|2016-06-24|Estimate||||2016-12-08|2017-02-02|Estimate|May 2011||2011-05-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|January 2013|Actual|2013-01-31||Interventional||Safety-Evaluable population included all participants who received any amount of study treatment.|A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)|An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 1|41|Actual|Genentech, Inc.|The interim data reported here (up to clinical cutoff date of 24 January 2013) were for participants who had completed treatment response assessment, which took place approximately 2 months after the last infusion of study treatment.|2|||f||||t||||||||No||2018-05-31 22:51:23.705986|2018-05-31 22:51:23.705986
NCT01300234|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2013-06-13||2017-08-21|2011-02-17|2011-02-21|Estimate|2013-06-13|2013-08-16|Estimate||||2017-08-21|2017-09-19|Actual|March 1, 2011||2011-03-01|January 2017|2017-01-31|December 6, 2016|Actual|2016-12-06|October 17, 2012|Actual|2012-10-17||Interventional|TDF in CHB||Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)|A Multi-centre, Double Blind, Double Dummy, Randomised, Controlled Study to Evaluate the Efficacy and Safety of TDF 300mg Once Daily (QD) Versus Adefovir Dipivoxil (ADV) 10mg QD in Chinese Subjects With CHB|Completed||Phase 3|512|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:51:24.312087|2018-05-31 22:51:24.312087
NCT01300221|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2013-09-04|2011-02-18|2011-02-21|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Observational|3DE-CHD||Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease|Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease|Withdrawn|||0|Actual|Drexel University|||5|Study did not receive IRB approval.|f||||f||||||||||2018-05-31 22:51:24.80979|2018-05-31 22:51:24.80979
NCT01300208|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18||2013-09-25|2016-04-26|2011-02-17|2011-02-21|Estimate||||2013-09-25|2013-10-25|Estimate|2016-04-26|2016-05-25|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus|A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus|Completed||Phase 2|48|Actual|Celgene Corporation||3|||f||||t||||||||||2018-05-31 22:51:24.876543|2018-05-31 22:51:24.876543
NCT01300195|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-09-27|2011-02-18|2011-02-21|Estimate|||||||2011-09-27|2011-09-28|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|April 2013|Anticipated|2013-04-30|November 2012|Anticipated|2012-11-30||Observational|||Prediction of Persistent Postsurgical Pain After Video-assisted Thoracic Surgery (VATS)|Factors Predicting Persistent Post-surgical Pain After Video-assisted Thoracic Surgery (VATS)|Unknown status|Recruiting||200|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     whole blood used to detect genetic polymorphism~   "|||2018-05-31 22:51:24.982334|2018-05-31 22:51:24.982334
NCT01300182|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-02-12|2011-02-18|2011-02-21|Estimate|||||||2013-02-12|2013-02-13|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|WBVT||The Effect of Early WBVT on Neuromuscular Control After ACLR|The Effect of Early Whole-Body Vibration Therapy on Neuromuscular Control After Anterior Cruciate Ligament Reconstruction|Completed||N/A|48|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 22:51:25.048158|2018-05-31 22:51:25.048158
NCT01300169|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2017-05-27|2011-02-18|2011-02-21|Estimate|||||||2017-05-27|2017-05-31|Actual|March 2011||2011-03-31|May 2017|2017-05-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|OWL||Operation Worth Living Project With Suicidal Soldiers at Ft. Stewart|A Randomized Clinical Trial of the Collaborative Assessment and Management of Suicidality Versus Enhanced Care as Usual for Suicidal Soldiers|Completed||N/A|150|Actual|The Catholic University of America||2|||f||||t||||||||Undecided||2018-05-31 22:51:25.117819|2018-05-31 22:51:25.117819
NCT01300156|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)|A Multicenter Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Patients With Refractory or Relapsed Hodgkin's Lymphoma (HL)|Unknown status|Recruiting|Phase 2|37|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 22:51:25.203424|2018-05-31 22:51:25.203424
NCT01300143|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2017-07-03|2011-02-18|2011-02-21|Estimate|||||||2017-07-03|2017-07-05|Actual|June 2011|Actual|2011-06-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|TACERTE||Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma|Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma|Active, not recruiting||Phase 2|126|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 22:51:25.295223|2018-05-31 22:51:25.295223
NCT01300130|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|June 1995||1995-06-30|February 2011|2011-02-28|March 1998|Actual|1998-03-31|March 1998|Actual|1998-03-31||Interventional|||Investigations on Improving Docosahexaenoic and Arachidonic Acid Content in Preterm Infant Formula|Investigations on Improving Docosahexaenoic and Arachidonic Acid Content in Preterm Infant Formula|Completed||N/A|66|Actual|Ludwig-Maximilians - University of Munich||4|||f||||f||||||||||2018-05-31 22:51:25.388983|2018-05-31 22:51:25.388983
NCT01300117|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-12-28|2011-02-18|2011-02-21|Estimate|||||||2011-12-28|2011-12-29|Estimate|October 2010||2010-10-31|December 2011|2011-12-31||||||||Observational|||Influence of Extracorporeal Circulation During Cardiac Surgery on the Development of Postoperative Thrombotic Thrombocytopenic Purpura (TTP)|Influence of Extracorporeal Circulation During Cardiac Surgery on the Development of Postoperative TTP|Unknown status|Recruiting||70|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||||||2018-05-31 22:51:25.456607|2018-05-31 22:51:25.456607
NCT01300104|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2015-02-18|2011-02-18|2011-02-21|Estimate|||||||2015-02-18|2015-02-19|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Feasibility Study on a Nordic Lifestyle Intervention Trial Among Men With Prostate Cancer|Feasibility Study on a Nordic Lifestyle Intervention Trial Investigating the Effect of Vigorous Activity and Intake of Whole Grain Rye on Cancer Progression, Insulin Sensitivity and Inflammation Among Men With Early Stage Prostate Cancer.|Completed||N/A|24|Actual|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 22:51:25.523426|2018-05-31 22:51:25.523426
NCT01300052|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2017-01-12|2011-10-12|2017-03-17|2011-02-17|2011-02-21|Estimate|2017-01-12|2017-03-07|Actual|2011-10-20|2011-10-26|Estimate|2017-03-17|2017-04-17|Actual|January 26, 2011|Actual|2011-01-26|March 2017|2017-03-31|June 6, 2011|Actual|2011-06-06|June 6, 2011|Actual|2011-06-06||Interventional||The Intent-to-Treat (ITT) population included all randomized participants who received the study medication.|AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis|A Multicenter, Randomized, Double-Blind, 12-Week Study Of The Safety And Efficacy Of AN2728 Versus AN2728 Vehicle In The Treatment Of Patients With Mild-To-Moderate Plaque-Type Psoriasis|Completed||Phase 2|68|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:51:25.7907|2018-05-31 22:51:25.7907
NCT01300039|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-18|2011-02-18|2011-02-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|January 2003||2003-01-31|February 2011|2011-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter Formigenes|Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter Formigenes|Completed|||50|Actual|VA New York Harbor Healthcare System|||2||f||||f||||||||||2018-05-31 22:51:26.16877|2018-05-31 22:51:26.16877
NCT01300026|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-02-08|2011-02-17|2011-02-21|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 2011||2011-04-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2013|Actual|2013-10-31||Interventional|||AMG 319 Lymphoid Malignancy FIH|A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies|Completed||Phase 1|28|Actual|Amgen||2|||f||||||||||||||2018-05-31 22:51:26.223556|2018-05-31 22:51:26.223556
NCT01300013|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17||2014-01-15|2014-03-24|2011-02-17|2011-02-21|Estimate||||2014-01-15|2014-02-12|Estimate|2014-03-24|2014-04-21|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure|Completed||Phase 2|614|Actual|Amgen||2|||f||||t||||||||||2018-05-31 22:51:26.334697|2018-05-31 22:51:26.334697
NCT01300000|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2017-03-27|2011-02-17|2011-02-21|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2010|Actual|2010-03-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|September 2014|Actual|2014-09-30||Interventional|||Effects of Early Nutrition on Growth|Effects of Early Nutrient Intake on Growth and Body Composition|Completed||N/A|649|Actual|Abbott Nutrition||3|||f||||t||||||||Undecided||2018-05-31 22:51:26.750149|2018-05-31 22:51:26.750149
NCT01299987|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2016-01-18|2011-02-18|2011-02-21|Estimate|||||||2016-01-18|2016-01-20|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|November 2025|Anticipated|2025-11-30|November 2017|Anticipated|2017-11-30||Interventional|TARGIT-E||Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer|TARGIT-E(Elderly) Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer|Active, not recruiting||Phase 2|265|Anticipated|Universitätsmedizin Mannheim||1|||f||||t||||||||||2018-05-31 22:51:26.846012|2018-05-31 22:51:26.846012
NCT01299974|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2015-12-22|2011-02-18|2011-02-21|Estimate|||||||2015-12-22|2015-12-23|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PARIS||Project PARIS: Parents and Residents in Session|Project PARIS: Parents and Residents in Session|Completed||N/A|83|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 22:51:26.979365|2018-05-31 22:51:26.979365
NCT01299961|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|2015-01-06||2015-05-15|2011-02-18|2011-02-21|Estimate|2015-01-20|2015-01-30|Estimate||||2015-05-15|2015-06-10|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2013|Actual|2013-02-28||Interventional|||Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis|Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis|Completed||Phase 3|25|Actual|University of California, Los Angeles|This is a very small open-label study of 25 patients on a FDA approved drug, where efficacy (by standard validated measures) and safety were not the primary end points.|1|||f||||f||||||||||2018-05-31 22:51:27.222987|2018-05-31 22:51:27.222987
NCT01299948|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2013-03-21|2011-02-18|2011-02-21|Estimate|||||||2013-03-21|2013-03-22|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|March 2011|Actual|2011-03-31||Interventional|ProCort1||Progression of HIV-Disease Under Low Dose Corticosteroids|A Phase II Clinical Trial to Assess Risk and Benefit of Oral Low Dose Prednisolone for HIV Infected People Prior to the Commencement of Antiretroviral Treatment|Completed||Phase 2|326|Actual|Medical Mission Institute, Germany||2|||f||||t||||||||||2018-05-31 22:51:27.761805|2018-05-31 22:51:27.761805
NCT01299935|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2011-02-23|2011-02-18|2011-02-21|Estimate|||||||2011-02-23|2011-02-24|Estimate|January 1998||1998-01-31|February 2011|2011-02-28|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||A Randomized Controlled Trial of Stress Reduction on Cardiovascular Morbidity and Mortality in African Americans|Stress Reduction and Cardiovascular Disease Morbidity and Mortality|Completed||Phase 2|201|Actual|Maharishi University of Management||2|||f||||t||||||||||2018-05-31 22:51:27.90171|2018-05-31 22:51:27.90171
NCT01299922|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-18|||2015-02-26|2011-02-18|2011-02-21|Estimate|||||||2015-02-26|2015-02-27|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|October 2014|Anticipated|2014-10-31|March 2014|Anticipated|2014-03-31||Interventional|Csa-LES||Clinical Trial Treatment in Lupus Nephritis|Phase III, Open, Randomized, Parallel-group Clinical Trial, to Evaluate the Efficacy and Safety of Treatment With Prednisone, Cyclosporine, Mycophenolic Acid Versus Prednisone and Mycophenolic Acid in Lupus Nephritis Type III-IV-V.|Withdrawn||Phase 3|0|Actual|Hospital Universitario Fundación Alcorcón||2||IT was impossible to find patients|f||||t||||||||||2018-05-31 22:51:28.000562|2018-05-31 22:51:28.000562
NCT01299909|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2014-05-17||2017-10-23|2011-02-17|2011-02-18|Estimate|2016-12-07|2017-02-01|Estimate||||2017-10-23|2017-11-29|Actual|March 2011||2011-03-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MTS2|This is based on enrollment - it was the number randomized. The Quitline group was a non-randomized, treatment as usual group.|Study Two on the Effectiveness of Mindfulness Training for Smokers|Study Two for Development of Novel Behavioral Intervention Mindfulness Training for Smokers|Completed||N/A|175|Actual|University of Wisconsin, Madison||3|||f||||t||||||||Yes|Data will be available after June 2014 from Principal Investigator James Davis, MD, who is now at Duke University (james.m.davis@duke.edu).|2018-05-31 22:51:28.168545|2018-05-31 22:51:28.168545
NCT01299896|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2016-01-21||2016-02-23|2011-02-17|2011-02-18|Estimate|2016-01-26|2016-02-24|Estimate||||2016-02-23|2016-03-22|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|CTQ||Connect to Quit for Smoking|Connect to Quit: Coordinated Care for Smoking Cessation Among Low Income Veterans|Completed||N/A|633|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 22:51:28.563347|2018-05-31 22:51:28.563347
NCT01299870|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-02-13|2011-02-17|2011-02-18|Estimate|||||||2012-02-13|2012-02-14|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Catamenial Epilepsy Treatment|Keishibukuryogan (Japanese Herbal Supplement) for the Adjunctive Treatment of Catamenial Epilepsy in Adult: Safety Study|Unknown status|Recruiting|Phase 2|17|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 22:51:28.827904|2018-05-31 22:51:28.827904
NCT01299857|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2012-09-12|2011-02-17|2011-02-18|Estimate|||||||2012-09-12|2012-09-13|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|Suiviritux||Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab|EVALUATION CLINIQUE ET BIOLOGIQUE A LONG TERME DES PATIENTS ATTEINTS DE FORMES SEVERES DE PEMPHIGUS TRAITES PAR LE RITUXIMAB|Completed||Phase 3|22|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-05-31 22:51:28.907905|2018-05-31 22:51:28.907905
NCT01299844|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|December 2006||2006-12-31|February 2011|2011-02-28|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|DIALBEST||Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic, and Health Outcomes Among Latinos|Impact of Type 2 Diabetes Peer Counseling on Behavioral, Metabolic, and Health Outcomes Among Latinos|Completed||N/A|208|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 22:51:28.962679|2018-05-31 22:51:28.962679
NCT01299831|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-05-23|2011-02-17|2011-02-18|Estimate|||||||2014-05-23|2014-05-26|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Relationship Between Body Composition and Growth Hormone, SIRT Signaling, Protein Turnover and Insulin Sensitivity|THE RELATIONSHIP BETWEEN BODY COMPOSITION AND GROWTH HORMONE, SIRT SIGNALING, PROTEIN TURNOVER AND INSULIN SENSITIVITY. Studies of Signaling Pathways in Fat and Muscle, and Turnover of Protein, Sugar and Fat After Stimulation With Growth Hormone and During Fasting in Lean and Obese Subjects|Completed||N/A|19|Actual|University of Aarhus||4|||f||||f||||||||||2018-05-31 22:51:29.070021|2018-05-31 22:51:29.070021
NCT01299818|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Assessment of Central Pain in Patients Who Undergo Spinal Surgery and Influence in Surgery Outcome|Assessment of Central Pain in Patients Who Undergo Spinal Surgery and Influence in Surgery Outcome|Unknown status|Not yet recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||||||2018-05-31 22:51:29.132676|2018-05-31 22:51:29.132676
NCT01299805|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2013-01-07||2013-10-24|2011-02-17|2011-02-18|Estimate|2013-10-24|2013-12-13|Estimate||||2013-10-24|2013-12-13|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults|A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Effects of Oral Administration of Lu AA21004 20 mg on the Concentrations of Selected Neurotransmitters in Healthy Male Subjects|Completed||Phase 1|17|Actual|Takeda||2|||f||||f||||||||||2018-05-31 22:51:29.219089|2018-05-31 22:51:29.219089
NCT01299792|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2016-11-21|2011-02-16|2011-02-18|Estimate|||||||2016-11-21|2016-11-22|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction|Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Due to Spinal Cord Injury|Completed|||60|Actual|Swiss Paraplegic Centre Nottwil|||1||f||||f||||||||||2018-05-31 22:51:29.78316|2018-05-31 22:51:29.78316
NCT01299779|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2013-06-04|2011-02-17|2011-02-18|Estimate|||||||2013-06-04|2013-06-05|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Incidence of Hyponatremia in PEG-SD Compared to PEG-ELS|The Incidence of Hyponatremia With Two Commonly Prescribed Purgatives for Colonoscopy-Polyethylene Glycol 3350 With a Sports Drink (PEG-SD) Compared to Polyethylene Glycol 3350 With Electrolyte Solution (PEG-ELS)|Completed||N/A|460|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 22:51:29.837391|2018-05-31 22:51:29.837391
NCT01299766|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2018-01-16|2011-02-17|2011-02-18|Estimate|||||||2018-01-16|2018-01-18|Actual|June 21, 2011|Actual|2011-06-21|January 2018|2018-01-31|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional|||Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment|Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment|Completed||Phase 3|200|Anticipated|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 22:51:29.902988|2018-05-31 22:51:29.902988
NCT01299753|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-04-25|2011-02-17|2011-02-18|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2011||2011-02-28|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Catecholamine Blockade Post-burn|Clinical and Molecular Effects of Catecholamine Blockade Post-burn|Recruiting||N/A|80|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:51:29.978582|2018-05-31 22:51:29.978582
NCT01299740|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-13|||2011-03-27|2011-02-17|2011-02-18|Estimate|||||||2011-03-27|2011-03-29|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|||Skills Group for Children With Emotional Dysregulation and Their Parents|Dialectical Behavioral Therapy (DBT) Based Skills Group for Children With Emotional Dysregulation and Their Parents|Unknown status|Recruiting|N/A|20|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 22:51:30.073292|2018-05-31 22:51:30.073292
NCT01299727|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-06-06|2011-02-17|2011-02-18|Estimate|||||||2017-06-06|2017-06-07|Actual|February 1, 2011||2011-02-01|June 2017|2017-06-30|October 29, 2021|Anticipated|2021-10-29|October 29, 2021|Anticipated|2021-10-29||Interventional|||Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)|An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)|Active, not recruiting||Phase 1/Phase 2|12|Actual|Shire||3|||f||||f||||||||||2018-05-31 22:51:30.159001|2018-05-31 22:51:30.159001
NCT01299714|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2018-04-23|2011-02-16|2011-02-18|Estimate|||||||2018-04-23|2018-04-25|Actual|February 2011||2011-02-28|April 2018|2018-04-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Observational|||Community Awareness, Resources and Education (CARE II): Project 3|Community Awareness, Resources and Education (CARE II): Project 3|Completed|||191|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||Samples With DNA|"~     serum, Pap specimen, cervical specimen for HPV analysis, oral rinse specimen, saliva specimen~   "|||2018-05-31 22:51:30.226346|2018-05-31 22:51:30.226346
NCT01299207|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2016-01-05|2011-02-16|2011-02-18|Estimate|||||||2016-01-05|2016-01-07|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Observational|||PITT PCI Xience Registry|PITT PCI Xience Registry: A Prospective Evaluation of Dual Antiplatelet Therapy Compliance and Outcomes After Treatment With the Xience Stent|Completed|||2506|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 22:51:42.68484|2018-05-31 22:51:42.68484
NCT01299701|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-02-13|2011-02-16|2011-02-18|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2008||2008-12-31|February 2017|2017-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors|An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Excretion (ADME) of ASA404 After a Single Intravenous Infusion of 3000 mg [14C]ASA404 in Patients With Advanced Solid Tumor Malignancies|Terminated||Phase 1|7|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:51:30.282003|2018-05-31 22:51:30.282003
NCT01299688|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2018-01-15|2011-02-17|2011-02-18|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2010|Actual|2010-03-31|January 2018|2018-01-31|March 11, 2013|Actual|2013-03-11|March 11, 2013|Actual|2013-03-11||Observational|||HER2 Circulating Tumor Cells in Gastric Cancer|HER2 Circulating Tumor Cells in Gastric Cancer|Completed|||135|Actual|Samsung Medical Center|||||f||||f||||||Samples Without DNA|"~     blood, circulating tumor cell~   "|||2018-05-31 22:51:30.332864|2018-05-31 22:51:30.332864
NCT01299675|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2018-04-26|2011-02-17|2011-02-18|Estimate|||||||2018-04-26|2018-04-27|Actual|February 8, 2011|Actual|2011-02-08|April 2018|2018-04-30|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Observational|||SureScan Post-Approval Study||Completed|||2483|Actual|Medtronic|||2||f||||f||||||||||2018-05-31 22:51:30.388851|2018-05-31 22:51:30.388851
NCT01299662|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2012-08-10|2011-02-17|2011-02-18|Estimate|||||||2012-08-10|2012-08-13|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers|An Open Label Study to Evaluate Innate Immune Responses Induced by a Pattern Recognition Receptor Agonist, Poly-ICLC (Hiltonol), in Healthy Volunteers|Completed||Phase 1|6|Actual|Rockefeller University||1|||f||||f||||||||||2018-05-31 22:51:31.452565|2018-05-31 22:51:31.452565
NCT01299649|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|DEF-418||Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®|A Retrospective Observational Database Study To Compare In-Hospital All-Cause Mortality in Critically Ill Patients Undergoing Echocardiography With or Without DEFINITY®|Completed|||4300000|Actual|Lantheus Medical Imaging|||2||f||||f||||||||||2018-05-31 22:51:31.523953|2018-05-31 22:51:31.523953
NCT01299636|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-10-30|2011-02-17|2011-02-18|Estimate|||||||2015-10-30|2015-11-02|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of PM060184 in Patients With Advanced Solid Tumors|Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors|Completed||Phase 1|60|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 22:51:31.573587|2018-05-31 22:51:31.573587
NCT01299623|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-08-17|2011-02-17|2011-02-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Breast Cancer Prevention Education|Disseminating Breast Cancer Prevention to African American Women|Completed||N/A|366|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 22:51:31.641088|2018-05-31 22:51:31.641088
NCT01299610|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2017-05-19|2012-02-16|2017-10-17|2011-02-17|2011-02-18|Estimate|2017-05-19|2017-10-16|Actual|2012-02-16|2012-02-20|Estimate|2017-10-17|2017-11-17|Actual|December 1, 2010||2010-12-01|May 2017|2017-05-31|April 14, 2011|Actual|2011-04-14|March 1, 2011|Actual|2011-03-01||Interventional|||A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo|A Randomised, Double-blind, Placebo-controlled Study of Topical GW870086X Formulation in Subjects With Moderate or Severe Atopic Dermatitis|Completed||Phase 2|25|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:51:31.781624|2018-05-31 22:51:31.781624
NCT01299597|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-07-19|2011-02-17|2011-02-18|Estimate|||||||2017-07-19|2017-07-21|Actual|January 18, 2010|Actual|2010-01-18|July 2017|2017-07-31|February 26, 2010|Actual|2010-02-26|February 26, 2010|Actual|2010-02-26||Interventional|||A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.|A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:51:32.811625|2018-05-31 22:51:32.811625
NCT01299584|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2011-03-24||2017-06-06|2011-02-17|2011-02-18|Estimate|2011-03-24|2011-04-18|Estimate||||2017-06-06|2017-07-06|Actual|September 2005||2005-09-30|June 2017|2017-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||ULTIVA Post Marketing Surveillance|A Post Marketing Surveillance to Monitor the Safety of ULTIVA (Remifentanil) Adminstered in Korean Subjects According to the Prescribing Information|Completed|||775|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:51:32.932448|2018-05-31 22:51:32.932448
NCT01299571|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2011-03-24||2017-06-06|2011-02-17|2011-02-18|Estimate|2011-03-24|2011-04-18|Estimate||||2017-06-06|2017-07-05|Actual|December 2004||2004-12-31|June 2017|2017-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|AVO PMS||AVODART(Dutasteride) Post-marketing Surveillance(PMS)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVODART(Dutasteride) Administered in Korean BPH(Benign Prostatic Hyperplasia) Patients According to the Prescribing Information|Completed|||3977|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:51:33.156685|2018-05-31 22:51:33.156685
NCT01299558|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2017-06-09|2011-02-17|2011-02-18|Estimate|||||||2017-06-09|2017-06-12|Actual|May 17, 2010|Actual|2010-05-17|June 2017|2017-06-30|July 15, 2010|Actual|2010-07-15|July 15, 2010|Actual|2010-07-15||Interventional|||Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects|An Open-label, Non-randomised, Three-way Crossover, Single Dose Study to Determine the Absolute Bioavailability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder, in Healthy Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:51:33.751961|2018-05-31 22:51:33.751961
NCT01299220|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-01-14|2011-02-16|2011-02-18|Estimate|||||||2013-01-14|2013-01-16|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)|Pilot Study of Acitretin for Treatment of Erlotinib-induced Skin Rash|Withdrawn||Phase 4|0|Actual|University of Pittsburgh||||Unable to enroll subjects by sponsor deadline|f||||t||||||||||2018-05-31 22:51:42.619842|2018-05-31 22:51:42.619842
NCT01299545|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2013-01-31|2011-02-16|2011-02-18|Estimate|||||||2013-01-31|2013-02-01|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|PRINT||Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy|Validation Study of RA-INF-Dx as a Multigene Molecular Test Intended to Aid in the Identification of Patients With Rheumatoid Arthritis Who Are Unlikely to Show an Initial Response to Infliximab and Methotrexate Combination Therapy|Terminated|||123|Actual|TcLand Expression S.A.|||1|Recruitment difficulties|f||||f||||||Samples With DNA|"~     Whole blood sampling in Paxgene tubes (DNA, RNA) Whole blood sampling in EDTA tubes~   "|||2018-05-31 22:51:33.933861|2018-05-31 22:51:33.933861
NCT01299532|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2013-11-08|2011-02-16|2011-02-18|Estimate|||||||2013-11-08|2013-11-11|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|October 2013|Actual|2013-10-31|June 2010|Actual|2010-06-30||Interventional|COBRA||Macrolane VRF30 for Enhancement of Shape and Fullness of Female Breast|An Open, Multi-center Study Evaluating Efficacy and Safety of Macrolane VRF30 for Enhancement of the Shape and Fullness of the Female Breast|Completed||Phase 4|71|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 22:51:34.056554|2018-05-31 22:51:34.056554
NCT01299519|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-06-30|2011-02-17|2011-02-18|Estimate|||||||2017-06-30|2017-07-05|Actual|February 2011||2011-02-28|June 2017|2017-06-30|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Interventional|PWL||Progressive Weight Loss and Metabolic Health|Progressive Weight Loss and Metabolic Health|Completed||N/A|59|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 22:51:34.192051|2018-05-31 22:51:34.192051
NCT01299506|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-01-19|2011-02-17|2011-02-18|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide|An Observational, Multicenter, Open-label Study of the Management of Patients With Advanced Soft Tissue Sarcoma After Failure of Anthracyclines and/or Ifosfamide or Patients Unsuited to Receive These Drugs|Completed|||102|Actual|PharmaMar|||2||f||||f||||||||||2018-05-31 22:51:34.32675|2018-05-31 22:51:34.32675
NCT01299493|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-09-07|2011-02-17|2011-02-18|Estimate|||||||2017-09-07|2017-09-08|Actual|June 19, 2012|Actual|2012-06-19|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Systems Intervention to Promote Colorectal Cancer (CRC) Screening|Systems Intervention to Promote Colorectal Cancer Screening/ Program for the Elimination of Cancer Disparities|Recruiting||N/A|3186|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 22:51:34.463137|2018-05-31 22:51:34.463137
NCT01299480|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2014-11-21||2015-06-02|2011-02-16|2011-02-18|Estimate|2015-06-02|2015-06-04|Estimate||||2015-06-02|2015-06-04|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years|A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged ≥11 To <19 Years|Completed||Phase 2|1714|Actual|Pfizer||5|||f||||t||||||||||2018-05-31 22:51:34.679424|2018-05-31 22:51:34.679424
NCT01299467|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-11-30|2011-02-16|2011-02-18|Estimate|||||||2011-11-30|2011-12-02|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge|A Randomized, Double-Blind, Third Party Open, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Duration Of Action Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects|Withdrawn||Phase 1|0|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 22:51:36.42017|2018-05-31 22:51:36.42017
NCT01299454|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2015-08-04||2015-09-29|2011-02-16|2011-02-18|Estimate|2015-08-04|2015-09-03|Estimate||||2015-09-29|2015-10-20|Estimate|December 2010||2010-12-31|September 2015|2015-09-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects|A Single-dose, Open-label, Parallel Group, Matched Study Evaluating the Pharmacokinetics of Oral OPC-34712 Tablet in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects|Completed||Phase 1|45|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||||||||||||2018-05-31 22:51:36.577162|2018-05-31 22:51:36.577162
NCT01299441|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2017-03-22|2011-02-17|2011-02-18|Estimate|||||||2017-03-22|2017-03-24|Actual|February 2011|Actual|2011-02-28|March 2017|2017-03-31|October 2016|Actual|2016-10-31|December 2013|Actual|2013-12-31||Observational|||Endotracheal Cardiac Output Monitor (ECOM) for Patients Undergoing Liver Transplantation|Noninvasive ECOM Monitoring of Hemodynamic Parameters During Liver Transplantation|Terminated|||40|Actual|Mayo Clinic|||1|unable to complete statistical analysis|f||||||||||||||2018-05-31 22:51:37.740962|2018-05-31 22:51:37.740962
NCT01299428|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|August 2011|Anticipated|2011-08-31|May 2011|Anticipated|2011-05-31||Interventional|||Evaluation of the Cerebral Oxygenation With Near Infrared Spectrophotometry (NIRS) at the Hypernatremic Dehydration in Newborn||Unknown status|Recruiting|N/A|2|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||1|||f||||f||||||||||2018-05-31 22:51:37.791354|2018-05-31 22:51:37.791354
NCT01299415|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-08-31|2011-02-16|2011-02-18|Estimate|||||||2011-08-31|2011-09-02|Estimate|August 2009||2009-08-31|August 2011|2011-08-31||||September 2010|Actual|2010-09-30||Interventional|||Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor|A Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effects of Fluvoxamine on the Pharmacokinetics of ASA404 in Adult Patients With Solid Tumor Malignancies|Terminated||Phase 1|17|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:51:37.848003|2018-05-31 22:51:37.848003
NCT01299402|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2012-09-30|2011-02-16|2011-02-18|Estimate|||||||2012-09-30|2012-10-02|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||A Study on the Effects of Soulera Herbal Blend Intake on Chronic Stress in Healthy Adults|A Pilot Double-Blind Crossover Study on the Effects of Soulera Herbal Blend Intake on Chronic Stress and Its Biomarkers in Healthy Adults|Terminated||Phase 1|64|Actual|NEMA Research, Inc.||2||Financial Reasons|f||||f||||||||||2018-05-31 22:51:37.908311|2018-05-31 22:51:37.908311
NCT01299389|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-03-04||2013-06-13|2011-02-17|2011-02-18|Estimate|2013-06-13|2013-06-17|Estimate||||2013-06-13|2013-06-17|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Safety analysis set included all randomly assigned participants who received at least 1 injection of double-blind study drug.|An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia|Completed||Phase 3|323|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 22:51:38.016153|2018-05-31 22:51:38.016153
NCT01299376|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2016-12-01||2016-12-01|2011-02-16|2011-02-18|Estimate|2016-12-01|2017-01-26|Estimate||||2016-12-01|2017-01-26|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|November 2011|Actual|2011-11-30||Interventional|||MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)|A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] and an Open-label, Long-term Clinical Trial to Study the Safety of MK-0954E|Completed||Phase 3|286|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:51:39.659484|2018-05-31 22:51:39.659484
NCT01299363|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-04-07|2011-02-17|2011-02-18|Estimate|||||||2015-04-07|2015-04-09|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|DDS||Dilators for Dyspareunia Prevention|Vaginal Dilators for Prevention of De Novo Dyspareunia After Prolapse Surgery: A Randomized Controlled Trial|Completed||Phase 4|60|Actual|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 22:51:40.046193|2018-05-31 22:51:40.046193
NCT01299350|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-04-09|2011-02-17|2011-02-18|Estimate|||||||2014-04-09|2014-04-10|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Nt-proBNP Versus Clinical Guided Discharge in Acute Heart Failure|Randomized Comparison Between Nt-proBNP or Clinical Guided Discharges in Patients Hospitalized With Acute Heart Failure|Completed||Phase 4|125|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 22:51:40.103321|2018-05-31 22:51:40.103321
NCT01299337|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2012-05-10|2011-02-16|2011-02-18|Estimate|||||||2012-05-10|2012-05-11|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|T3ECT||Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)|Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)|Completed|||29|Actual|Mayo Clinic|||1||f||||t||||||Samples With DNA|"~     Thyroid measures at time of sustained response will include free T3, free T4, and TSH. All~     draws will be done before ECT treatment. An additional free T3 will be obtained at the second~     visit that confirms sustained response. The mean free T3 will be used as the outcome measure.~     If a suppressed TSH is found, a TSH be repeated 1 week later. At the beginning of the study~     30 mL of blood will be drawn and a portion of the collected blood sample will undergo DNA~     extraction. The extracted DNA will undergo genetic analysis. The remainder owill be~     immortalized and stored for future study. Blood will be drawn into 1 10-mL EDTA tube and 2~     10-mL Heparin tubes . Samples will be stored at Mayo Clinic BAP Lab for subsequent DNA~     extraction, analysis, and storage.~   "|||2018-05-31 22:51:40.158122|2018-05-31 22:51:40.158122
NCT01299324|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2014-08-18|2011-02-17|2011-02-18|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure|Feasibility Study of Retrograde Delivery of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Patients Diagnosed With Congestive Heart Failure (CHF)|Completed||Phase 1|30|Actual|Harvest Technologies||2|||f||||t||||||||||2018-05-31 22:51:40.375326|2018-05-31 22:51:40.375326
NCT01299311|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2012-07-09|2011-02-16|2011-02-18|Estimate|||||||2012-07-09|2012-07-10|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||NEAT and Insulin Sensitivity|The Effect of Activity on Insulin Sensitivity and Lipid Metabolism in Sedentary, Overweight People.|Completed||N/A|18|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 22:51:40.449379|2018-05-31 22:51:40.449379
NCT01299298|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-08-01|2011-02-17|2011-02-18|Estimate|||||||2016-08-01|2016-08-03|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects|Completed||Phase 1|20|Actual|Kastle Therapeutics, LLC||2|||f||||t||||||||||2018-05-31 22:51:40.519042|2018-05-31 22:51:40.519042
NCT01299285|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2017-03-10||2017-05-15|2011-02-16|2011-02-18|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-08|Actual|February 2011||2011-02-28|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects|Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects|Completed||Phase 1|6|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:51:40.598717|2018-05-31 22:51:40.598717
NCT01299272|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2018-02-17|2014-04-14|2018-03-16|2011-02-16|2011-02-18|Estimate|2018-03-16|2018-04-17|Actual|2014-04-14|2014-05-06|Estimate|2018-03-16|2018-04-17|Actual|May 2011||2011-05-31|March 2018|2018-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All enrolled participants.|A Study in Prevention of Re-emergence of Depression Symptoms|LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder|Completed||Phase 3|1249|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:51:40.955726|2018-05-31 22:51:40.955726
NCT01299259|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2014-10-27|2011-02-17|2011-02-18|Estimate|||||||2014-10-27|2014-10-28|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease|Improving Primary Care Follow-up for Adolescents With PID: A Randomized Controlled Trial Using Text Message Reminders|Completed||N/A|95|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 22:51:42.362426|2018-05-31 22:51:42.362426
NCT01299246|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|July 2013|Anticipated|2013-07-31|November 2012|Anticipated|2012-11-30||Interventional|||The Effectiveness of Improving Self-care After Counseling for the Diabetics Mellitus Foots Around Chiayi Region|The Effectiveness of Improving Self-care and Health Status After Promoting Counseling for the Diabetics Mellitus Patients With DM Foots Around Yunlin and Chiayi Region|Unknown status|Active, not recruiting|Phase 1/Phase 2|386|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 22:51:42.430409|2018-05-31 22:51:42.430409
NCT01299233|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2015-01-05|2011-02-17|2011-02-18|Estimate|||||||2015-01-05|2015-01-06|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Reproducibility of RNFL Circle Scans With ART-Function of Heidelberg Spectralis SD-OCT Software Version 5.3|Reproducibility of RNFL Circle Scans With ART-Function of Heidelberg Spectralis SD-OCT Software Version 5.3|Unknown status|Enrolling by invitation||100|Anticipated|University of Zurich|||2||f||||f||||||||||2018-05-31 22:51:42.558978|2018-05-31 22:51:42.558978
NCT01299194|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2017-05-02|2011-02-16|2011-02-18|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2010||2010-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|June 2015|Actual|2015-06-30||Interventional|||Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa|A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in Patients With Pseudomonas Aeruginosa|Completed||Phase 4|32|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 22:51:42.747055|2018-05-31 22:51:42.747055
NCT01299181|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2013-08-27|2011-02-17|2011-02-18|Estimate|||||||2013-08-27|2013-08-28|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis|A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis|Completed||Phase 4|60|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 22:51:42.820473|2018-05-31 22:51:42.820473
NCT01299168|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2018-05-28|2011-02-16|2011-02-18|Estimate|||||||2018-05-28|2018-05-30|Actual|May 2011||2011-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation|Multi-centric Observational Study to Analyse the Diagnostic Molecular Features in the Clinical Setting of Kidney Allograft Biopsies|Recruiting|||500|Anticipated|University of Alberta|||1||f||||f||||||Samples Without DNA|"~     Needle kidney biopsy core as per local standard of care~   "|No||2018-05-31 22:51:42.896705|2018-05-31 22:51:42.896705
NCT01299155|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2012-10-22|2011-02-17|2011-02-18|Estimate|||||||2012-10-22|2012-10-23|Estimate|March 2011||2011-03-31|October 2011|2011-10-31||||September 2011|Actual|2011-09-30||Interventional|||A Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses|A Randomized, Pilot Study, Subject Masked Comparison of Visual Function After Bilateral Implantation of Presbyopia Correcting Intraocular Lenses (IOLs)|Completed||N/A|24|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:51:42.998579|2018-05-31 22:51:42.998579
NCT01299142|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-02-16|2011-02-16|2011-02-18|Estimate|||||||2011-02-16|2011-02-18|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Interventional|||Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)|Phase I Study of Human Monoclonal Antibody (FGI-101-1A6) in Normal Healthy Volunteers|Unknown status|Recruiting|Phase 1|48|Anticipated|Functional Genetics Inc.||2|||f||||t||||||||||2018-05-31 22:51:43.067085|2018-05-31 22:51:43.067085
NCT01299129|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-12-24|2011-02-17|2011-02-18|Estimate|||||||2011-12-24|2011-12-29|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Functional and Morphologic Aspects of Intravitreal Triamcinolone for Uveitis-associated Cystoid Macular Edema|Functional and Morphologic Aspects of Intravitreal Triamcinolone for Uveitis-associated Cystoid Macular Edema|Completed|||30|Actual|Medical University of Vienna|||||f||||||||||||||2018-05-31 22:51:43.129128|2018-05-31 22:51:43.129128
NCT01299116|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2017-11-14||2018-01-31|2011-02-16|2011-02-18|Estimate|2018-01-25|2018-01-26|Actual||||2018-01-31|2018-02-28|Actual|December 2011|Actual|2011-12-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|LARC||Long-Acting Reversible Contraception|Long-Acting Reversible Contraception: New Research to Reduce Unintended Pregnancy|Completed||Phase 4|916|Actual|FHI 360||3|||f||||f|t|f|||f|||No||2018-05-31 22:51:43.183328|2018-05-31 22:51:43.183328
NCT01299103|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2014-11-10||2016-03-28|2011-02-16|2011-02-18|Estimate|2016-03-28|2016-04-15|Estimate||||2016-03-28|2016-04-15|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial Wrinkles|A Prospective, Randomized, Open-Label, 3-Arm Parallel Study Comparing the Safety and Efficacy of Single Therapy Versus Double and Triple Therapy Using the Surgitron® Dual RF™ S5 With the Pellevé™ Wrinkle Treatment Handpiece and Pellevé™ Treatment Gel for the Treatment of Moderate Facial Wrinkles in Fitzpatrick Skin Types I - IV|Completed||N/A|40|Actual|Ellman International||3|||f||||f||||||||||2018-05-31 22:51:43.454209|2018-05-31 22:51:43.454209
NCT01299090|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2014-11-09||2016-03-28|2011-02-16|2011-02-18|Estimate|2014-11-14|2014-11-21|Estimate||||2016-03-28|2016-04-27|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Prospective Pellevé™ Neck Wrinkle Study|Prospective Pellevé™ Neck Wrinkle Study|Completed||N/A|49|Actual|Ellman International||1|||f||||f||||||||No||2018-05-31 22:51:43.681216|2018-05-31 22:51:43.681216
NCT01299077|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2011-08-16||2011-12-21|2011-02-17|2011-02-18|Estimate|2011-10-20|2011-11-28|Estimate||||2011-12-21|2011-12-28|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|||Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China|A Retrospective Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar Disc Degenerative Disease in China|Completed|||478|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 22:51:43.971518|2018-05-31 22:51:43.971518
NCT01299064|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-10-28|2011-02-17|2011-02-18|Estimate|||||||2014-10-28|2014-10-29|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2011|Actual|2011-07-31||Observational|||Transcultural Mindfulness Assessment: A Mixed Methods Analysis|Transcultural Mindfulness Assessment: A Mixed Methods Analysis|Completed|||46|Actual|Pacific University|||1||f||||f||||||||||2018-05-31 22:51:44.160229|2018-05-31 22:51:44.160229
NCT01299051|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-03-07|2011-02-16|2011-02-18|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|October 2014|Actual|2014-10-31||Interventional|||Steps to Health: Targeting Obesity in the Health Care Workplace|Steps to Health: Targeting Obesity in the Health Care Workplace|Completed||N/A|550|Actual|Duke University||3|||f||||t||||||||||2018-05-31 22:51:44.210812|2018-05-31 22:51:44.210812
NCT01299038|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2018-02-05|2011-02-16|2011-02-18|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2010||2010-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer|A Multi-dose Phase II Trial of Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer|Active, not recruiting||Phase 2|20|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 22:51:44.283415|2018-05-31 22:51:44.283415
NCT01299025|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2015-03-25||2015-04-07|2011-02-17|2011-02-18|Estimate|2015-04-07|2015-04-24|Estimate||||2015-04-07|2015-04-24|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit|Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit|Completed||N/A|84|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 22:51:44.363225|2018-05-31 22:51:44.363225
NCT01299012|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2017-02-08|2011-02-17|2011-02-18|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2010||2010-10-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|||Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus|Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus, a Retrospective Chart Review|Completed|||30|Actual|University at Buffalo|||||f||||f||||||||||2018-05-31 22:51:44.654152|2018-05-31 22:51:44.654152
NCT01298999|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2017-12-08|2011-02-17|2011-02-18|Estimate|||||||2017-12-08|2017-12-12|Actual|June 2010||2010-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus|Randomized Placebo-Controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus|Active, not recruiting||Phase 2|20|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 22:51:44.712741|2018-05-31 22:51:44.712741
NCT01298986|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2015-03-26|2011-02-17|2011-02-18|Estimate|||||||2015-03-26|2015-03-27|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AF||Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management|Atrial Fibrillation Ablation The Hybrid Approach Versus Traditional Management|Withdrawn||Early Phase 1|0|Actual|Inova Health Care Services||4||No subjects were ever enrolled.|f||||f||||||||||2018-05-31 22:51:44.792455|2018-05-31 22:51:44.792455
NCT01298973|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2012-01-13|2011-02-17|2011-02-18|Estimate|||||||2012-01-13|2012-01-18|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions|Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions|Completed||Phase 4|50|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-05-31 22:51:44.858122|2018-05-31 22:51:44.858122
NCT01298960|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2015-06-30|2011-02-17|2011-02-18|Estimate|||||||2015-06-30|2015-07-01|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|June 2013||2013-06-30|June 2013||2013-06-30||Interventional|FUNDEX001||Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients|Phase II Randomized Study of Cotreatment With Growth Hormone in a Long GnRH Agonist Protocol in Women With Previous Poor Ovarian Response|Suspended||Phase 2|52|Anticipated|Institut Universitari Dexeus||2|||f||||f||||||||||2018-05-31 22:51:44.916713|2018-05-31 22:51:44.916713
NCT01298947|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-18|2011-02-17|2011-02-18|Estimate|||||||2011-02-18|2011-02-21|Estimate|April 2011||2011-04-30|February 2011|2011-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|PHOTOPAC||Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions|Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in Instent Femoro-popliteal Obstructions|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Herz-Zentrums Bad Krozingen||2|||f||||t||||||||||2018-05-31 22:51:44.981857|2018-05-31 22:51:44.981857
NCT01298934|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2015-03-05|2011-02-17|2011-02-18|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||LBH589 (Panobinostat) for the Treatment of Myelofibrosis|A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients With Primary Myelofibrosis (PMF) and Post-polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)|Unknown status|Active, not recruiting|Phase 1/Phase 2|22|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 22:51:45.036404|2018-05-31 22:51:45.036404
NCT01298921|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-03-15|2011-02-16|2011-02-18|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache|A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache|Unknown status|Recruiting|Phase 1|12|Anticipated|Geisinger Clinic||2|||f||||f||||||||||2018-05-31 22:51:45.102019|2018-05-31 22:51:45.102019
NCT01298908|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2016-01-06|2011-02-17|2011-02-18|Estimate|||||||2016-01-06|2016-01-08|Estimate|October 2007||2007-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Treatments in Venous Insufficiency|The Utility of Novel Ambulatory Treatment Techniques in Venous Insufficiency|Completed||N/A|231|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 22:51:45.170206|2018-05-31 22:51:45.170206
NCT01298895|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome|Optical Low Coherence Reflectometry Enables Preoperative Detection of Zonular Weakness in Pseudoexfoliation Syndrome|Completed|||224|Actual|General Hospital Sveti Duh|||2||f||||f||||||||||2018-05-31 22:51:45.241645|2018-05-31 22:51:45.241645
NCT01298882|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-02-16|2011-02-16|2011-02-18|Estimate|||||||2011-02-16|2011-02-18|Estimate||||January 2011|2011-01-31||||||||Interventional|||Diacerein on Insulin Secretion in Diabetes|Effect of Diacerein on Insulin Secretion in Patients With Type 2 Diabetes Mellitus and Overweight or Obesity|Completed||Phase 2|||Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 22:51:45.323611|2018-05-31 22:51:45.323611
NCT01298869|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2014-01-27|2011-02-16|2011-02-18|Estimate|||||||2014-01-27|2014-01-29|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|||The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients|The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in CKD Patients|Unknown status|Recruiting||60|Anticipated|Chulalongkorn University|||1||f||||f||||||||||2018-05-31 22:51:45.381809|2018-05-31 22:51:45.381809
NCT01298856|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-08|||2011-02-16|2011-02-16|2011-02-18|Estimate|||||||2011-02-16|2011-02-18|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|CAI||The Effect of Hydrotherapy and Land-based Rehabilitation Program Combined With Ankle Taping in Athletes With Chronic Ankle Instability|The Effect of Hydrotherapy and Land-based Rehabilitation Program Combined With Ankle Taping on Ankle Functional Ability and Re-injury Rate in Athletes With Chronic Ankle Instability|Completed||N/A|50|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 22:51:45.451453|2018-05-31 22:51:45.451453
NCT01298843|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2014-05-13|2011-02-16|2011-02-18|Estimate|||||||2014-05-13|2014-05-14|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital|Pharmacokinetics of a Single Dose of Ceftaroline Fosamil in Children Ages Birth to Younger Than 12 Years With Suspected or Confirmed Infection|Completed||Phase 4|53|Actual|Forest Laboratories||1|||f||||t||||||||||2018-05-31 22:51:45.510427|2018-05-31 22:51:45.510427
NCT01298830|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-03-25|2011-02-16|2011-02-18|Estimate|||||||2013-03-25|2013-03-26|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage|GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage|Terminated||Phase 1/Phase 2|11|Actual|CellMed AG, a subsidiary of BTG plc.||1||"Need for improvement of study medication. Safety data collected sufficient. No further gain in~   knowledge expected."|f||||t||||||||||2018-05-31 22:51:45.584002|2018-05-31 22:51:45.584002
NCT01298817|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2017-03-07|2011-02-17|2011-02-18|Estimate|||||||2017-03-07|2017-03-10|Actual|March 2011||2011-03-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SILVER||Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat|Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat and Associated Cardio-metabolic Risk in Obese, Older Adults: A Feasibility Study|Completed||N/A|24|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 22:51:45.650182|2018-05-31 22:51:45.650182
NCT01298804|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-08-08|2011-02-17|2011-02-18|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Preventing Maternal Depression In Head Start|Preventing Maternal Depression In Head Start|Completed||N/A|230|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 22:51:45.710909|2018-05-31 22:51:45.710909
NCT01298791|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-10-07|2011-02-17|2011-02-18|Estimate|||||||2016-10-07|2016-10-10|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|August 2011|Actual|2011-08-31|June 2011|Anticipated|2011-06-30||Interventional|||The Impact Of Physician Communication On Family Inpatient Experience|The Impact Of Physician Communication On Family Inpatient Experience|Withdrawn||N/A|0|Actual|Boston Medical Center||2||Inability to recruit participants|f||||f||||||||||2018-05-31 22:51:45.772423|2018-05-31 22:51:45.772423
NCT01298778|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2015-08-31||2017-11-06|2011-02-17|2011-02-18|Estimate|2017-05-10|2017-06-09|Actual||||2017-11-06|2017-11-08|Actual|August 2010||2010-08-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||High Pain Intervention in Cesarean Sections|Improving Pain Relief For Those Who Need It Most After Cesarean Delivery|Completed||N/A|69|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 22:51:45.832504|2018-05-31 22:51:45.832504
NCT01298765|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-01-12|2011-02-16|2011-02-18|Estimate|||||||2017-01-12|2017-01-13|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain|A 52-Week, Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain|Completed||Phase 3|434|Actual|BioDelivery Sciences International||1|||f||||f||||||||||2018-05-31 22:51:46.257809|2018-05-31 22:51:46.257809
NCT01298752|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16||2013-02-13|2013-11-22|2011-02-16|2011-02-18|Estimate||||2013-02-13|2013-02-15|Estimate|2013-11-22|2013-12-17|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery|The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery|Terminated||Phase 3|142|Actual|Bausch & Lomb Incorporated||2||"Recruiting or enrolling participants has halted prematurely and will not resume; participants~   are no longer being examined or treated."|f||||f||||||||||2018-05-31 22:51:46.359584|2018-05-31 22:51:46.359584
NCT01298739|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-10-24|2011-02-16|2011-02-18|Estimate|||||||2011-10-24|2011-10-25|Estimate|February 2011||2011-02-28|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Asthma Control Study 2011|Asthma Control Study 2011|Completed|||1524|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:51:46.432584|2018-05-31 22:51:46.432584
NCT01298726|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Pharmaceutical Care in Type 2 Diabetes|Pharmaceutical Care Program for Users of Brazilian Public Health Care System With Type 2 Diabetes Mellitus: Randomized Controlled Clinical Trial|Completed||N/A|100|Actual|Universidade Federal de Ouro Preto||2|||f||||f||||||||||2018-05-31 22:51:46.609579|2018-05-31 22:51:46.609579
NCT01298713|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-03-14|2011-02-16|2011-02-18|Estimate|||||||2017-03-14|2017-03-15|Actual|March 2008|Actual|2008-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2011|Actual|2011-06-30||Interventional|||Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer|Phase 2 Study Assessing the Tolerance and Efficacy of Tamoxifen Alone Versus the Association Tamoxifen-RAD001 (Everolimus) in Patients With Anti-aromatase Resistant Breast Metastatic Cancer|Active, not recruiting||Phase 2|111|Actual|ARCAGY/ GINECO GROUP||2|||f||||f||||||||||2018-05-31 22:51:46.691237|2018-05-31 22:51:46.691237
NCT01298700|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-12-08|2011-02-16|2011-02-18|Estimate|||||||2016-12-08|2016-12-12|Estimate|April 2011||2011-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|A 2-year, Multicenter, Double-masked, Randomized, Parallel Study of the Safety of LUMIGAN® 0.1 mg/mL Compared With LUMIGAN® 0.3 mg/mL in Patients With Glaucoma or Ocular Hypertension|Completed||Phase 4|807|Actual|Allergan||2|||f||||f||||||||||2018-05-31 22:51:46.776792|2018-05-31 22:51:46.776792
NCT01298687|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16||2014-07-28|2017-05-03|2011-02-16|2011-02-18|Estimate||||2014-07-28|2014-07-31|Estimate|2017-05-03|2017-05-05|Actual|February 2011||2011-02-28|July 2014|2014-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Divided Dose of TRAVATAN®||Completed||Phase 2|67|Actual|Alcon Research||6|||f||||f||||||||||2018-05-31 22:51:46.948846|2018-05-31 22:51:46.948846
NCT01298674|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-01-04|2011-02-17|2011-02-18|Estimate|||||||2017-01-04|2017-01-05|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Epidemiological Study of the Prevalence of Age-Related Macular Degeneration in Portugal|Epidemiological Study of the Prevalence of Age-Related Macular Degeneration in Portugal|Completed|||6023|Actual|Association for Innovation and Biomedical Research on Light and Image|||||f||||f||||||||||2018-05-31 22:51:47.020723|2018-05-31 22:51:47.020723
NCT01298505|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|June 2010||2010-06-30|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects|A Phase 1 Double-Blind (3rd Party Open), Randomized, Placebo-Controlled Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects.|Terminated||Phase 1|0|Actual|Pfizer||3||This study was stopped due to lack of evidence for clinical efficacy.|f||||f||||||||||2018-05-31 22:51:54.97743|2018-05-31 22:51:54.97743
NCT01298661|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|2013-04-16||2013-10-31|2011-02-17|2011-02-18|Estimate|2013-07-30|2013-09-13|Estimate||||2013-10-31|2013-11-26|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||"In the group of health young subjects there were a loss of 2 individuals who did not completed the evaluations.~In the group of COPD patients there was a loss of 2 patients who did not completed the evaluations."|Reliability, Sensitivity and Validity of the 6 Minute Step Test in Chronic Obstructive Pulmonary Disease (COPD) Patients|Evaluation of Reliability, Sensitivity and Validity of the Six Minute Step Test in Patients With Chronic Obstructive Pulmonary Disease and Its Relation With Predictors Markers of Risk of Death|Completed||N/A|91|Actual|Universidade Federal de Sao Carlos|The enrolled patient's and subject's numbers were smaller than the estimated for healthy elders and different COPD groups, because of the low acceptance of a three days evaluation protocol. So COPD patients were analyzed in a single group.|3|||f||||f||||||||||2018-05-31 22:51:47.1163|2018-05-31 22:51:47.1163
NCT01298648|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2014-01-31||2014-03-19|2011-02-16|2011-02-18|Estimate|2014-01-31|2014-03-18|Estimate||||2014-03-19|2014-04-15|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational||Safety analysis set: Excluding 21 patients who were transferred to other institutions during the surveillance period and 2 patients who made no visit after the first administration, 1693 patients were included in the safety analysis set.|Special Investigation in Patients With Crohn's Disease (All Patients Investigation)|Special Investigation (All Cases Investigation in Patients With Crohn's Disease)|Completed|||1716|Actual|AbbVie|||1||f||||||||||||||2018-05-31 22:51:47.785546|2018-05-31 22:51:47.785546
NCT01298635|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2011-02-17|2011-02-17|2011-02-18|Estimate|||||||2011-02-17|2011-02-18|Estimate|January 2005||2005-01-31|November 2004|2004-11-30|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Interventional|||Comparison of Phacotrabeculectomy and Trabeculectomy in the Treatment of Primary Angle-closure Glaucoma (PACG)|Comparison of Combined Phacotrabeculectomy and Trabeculectomy Only in the Treatment of Primary Angle-closure Glaucoma|Completed||N/A|31|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:51:50.684882|2018-05-31 22:51:50.684882
NCT01298622|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-17|||2014-03-19|2011-02-17|2011-02-18|Estimate|||||||2014-03-19|2014-03-21|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Imaging Genetic Study of the Core Family of Obsessive-compulsive Disorder (OCD) Patient|The Study of Structural and Functional Brain Abnormalities and the Association With the Genetic Polymorphism in the Core Family of OCD Patient|Unknown status|Recruiting||100|Anticipated|Kunming Medical University|||3||f||||t||||||Samples With DNA|"~     perapheral blood DNA of all participants~   "|||2018-05-31 22:51:50.859713|2018-05-31 22:51:50.859713
NCT01298609|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2014-05-22|2011-02-16|2011-02-17|Estimate|||||||2014-05-22|2014-05-26|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia|A Randomized Controlled Pilot Study to Examine the Efficacy of Greater Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia|Completed||N/A|40|Actual|St. Jude Medical||3|||f||||f||||||||||2018-05-31 22:51:50.928167|2018-05-31 22:51:50.928167
NCT01298596|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2017-05-02|2011-02-16|2011-02-17|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2011|Actual|2011-06-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|PHE-LEEP||Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women|Impact of Cryotherapy Versus Loop Electrosurgical Excision Procedure (LEEP) on Recurrence of Cervical Intraepithelial Neoplasia and HIV-1 Cervical Shedding Among HIV-positive Women|Completed||N/A|400|Actual|University of Washington||2|||f||||t||||||||No||2018-05-31 22:51:50.998969|2018-05-31 22:51:50.998969
NCT01298583|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-01-09|2011-02-16|2011-02-17|Estimate|||||||2012-01-09|2012-01-10|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|January 2008|Actual|2008-01-31||Interventional|||Ankle Tracking Training in Stroke|Ankle Tracking Training in Stroke|Completed||Phase 1|16|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 22:51:51.079467|2018-05-31 22:51:51.079467
NCT01298570|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2017-11-20||2018-01-29|2011-02-16|2011-02-17|Estimate|2018-01-29|2018-02-28|Actual||||2018-01-29|2018-02-28|Actual|April 7, 2011|Actual|2011-04-07|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|November 15, 2016|Actual|2016-11-15||Interventional|||Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer|Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|181|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 22:51:51.176838|2018-05-31 22:51:51.176838
NCT01298557|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2013-04-29|2011-02-16|2011-02-17|Estimate|||||||2013-04-29|2013-05-01|Estimate|February 2007||2007-02-28|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|Dana-REAC||MEG and DTI of Neural Function and Connectivity in Traumatic Brain Injury|Magnetoencephalography and High-Field Diffusion Tensor Magnetic Resonance Imaging of Neural Function and Connectivity in Traumatic Brain Injury|Completed|||69|Actual|University of California, San Francisco|||2||f||||t||||||||||2018-05-31 22:51:52.145107|2018-05-31 22:51:52.145107
NCT01298544|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2012-02-13||2012-02-13|2011-02-16|2011-02-17|Estimate|2012-02-13|2012-03-16|Estimate||||2012-02-13|2012-03-16|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers|A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518|Completed||Phase 4|335|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:51:52.234019|2018-05-31 22:51:52.234019
NCT01298531|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2014-01-09||2014-07-28|2011-02-16|2011-02-17|Estimate|2014-07-28|2014-07-29|Estimate||||2014-07-28|2014-07-29|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|SPARSE||A Study to Evaluate the NSAIDS Sparing Effect of Etanercept in Subjects With Axial Spondyloarthritis|A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis|Completed||Phase 4|90|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:51:52.686488|2018-05-31 22:51:52.686488
NCT01298518|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2012-10-05||2012-10-05|2011-02-16|2011-02-17|Estimate|2012-10-05|2012-11-06|Estimate||||2012-10-05|2012-11-06|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients|A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Efficacy And Safety Of 4-Week Administration Of Multiple Oral Doses Of PF-04620110 In Type 2 Diabetes Mellitus Subjects With Insufficient Glycemic Control On Metformin|Completed||Phase 1|48|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:51:54.419789|2018-05-31 22:51:54.419789
NCT01298492|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2017-07-26||2017-07-28|2011-02-16|2011-02-17|Estimate|2017-07-28|2017-08-31|Actual||||2017-07-28|2017-08-31|Actual|July 1, 2011|Actual|2011-07-01|July 2017|2017-07-31|July 27, 2016|Actual|2016-07-27|July 27, 2016|Actual|2016-07-27||Interventional|OPERA II|The modified intent-to-treat (mITT) population included all enrolled participants who received at least 1 dose of investigational product.|A Study To Monitor Long-Term Treatment With PF-00547659|A Multicenter Open-label Extension Study To Assess Long-term Safety Of PF-00547659 In Subjects With Crohn's Disease OPERA II|Completed||Phase 2|268|Actual|Shire||1|||f||||t||||||||||2018-05-31 22:51:55.14711|2018-05-31 22:51:55.14711
NCT01298479|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Sayana-Uniject Volumetric Delivery|Quantitative Determination of the Volume of Suspension Delivered Via the Uniject Delivery System Following Simulated Subcutaneous Injection by Healthcare Professionals Into a Synthetic Subcutaneous Injection Training Device|Completed|||25|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 22:51:55.644867|2018-05-31 22:51:55.644867
NCT01298466|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-04-17|2011-02-16|2011-02-17|Estimate|||||||2012-04-17|2012-04-19|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|PINPOINT||Primary Care Identification Of Patients With Chronic Neuropathic Low Back Pain Study|Open-Labeled European Study To Support The Early Identification Of Patients With Chronic Neuropathic Low Back Pain In Primary Care And To Assess The Effectiveness And Tolerability Of Pregabalin In This Population|Withdrawn||Phase 4|0|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:51:55.927758|2018-05-31 22:51:55.927758
NCT01298440|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|January 2008||2008-01-31|February 2011|2011-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Bevacizumab Effect on Blood Velocity|The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization|Completed|||12|Actual|Optical Imaging, Ltd.|||||f||||t||||||||||2018-05-31 22:51:56.194338|2018-05-31 22:51:56.194338
NCT01298414|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-05-17|2011-02-16|2011-02-17|Estimate|||||||2016-05-17|2016-05-19|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia|Pediatric Myeloid Leukemia-Specific miRNA Expression Profiles Induced by the Leukemic Stem Cell Niche|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Bone Marrow~   "|||2018-05-31 22:51:56.421657|2018-05-31 22:51:56.421657
NCT01298401|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2015-11-14|2011-02-16|2011-02-17|Estimate|||||||2015-11-14|2015-11-17|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas|A Phase I Study of Induction AMG 479 and Gemcitabine, Followed by AMG 479, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer|Completed||Phase 1|8|Actual|Radiation Therapy Oncology Group||6|||f||||t||||||||||2018-05-31 22:51:56.641638|2018-05-31 22:51:56.641638
NCT01298388|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-09-15|2011-02-16|2011-02-17|Estimate|||||||2011-09-15|2011-09-16|Estimate|July 2011||2011-07-31|September 2011|2011-09-30||||March 2013|Anticipated|2013-03-31||Observational|||Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998|Assessment of the Long Term Outcome of Childhood ALL Patients Enrolled in EORTC Children's Leukemia Group Trials Between 1971 and 1998|Unknown status|Not yet recruiting||3138|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:51:56.936701|2018-05-31 22:51:56.936701
NCT01298375|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-07-18|2011-02-16|2011-02-17|Estimate|||||||2012-07-18|2012-07-19|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|MetPhe||Metabolic Phenotyping in Humans|Metabolic Characterization of Type 2 Diabetic, Obese, Lean Sedentary and Endurance Trained Individuals in Vivo, ex Vivo and in Vitro|Unknown status|Recruiting||132|Anticipated|Maastricht University Medical Center|||||f||||t||||||Samples With DNA|"~     DNA, RNA, tissue, primary myoblasts, mitochondria~   "|||2018-05-31 22:51:57.159436|2018-05-31 22:51:57.159436
NCT01298362|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2016-06-20||2016-07-31|2011-02-16|2011-02-17|Estimate|2016-07-31|2016-09-20|Estimate||||2016-07-31|2016-09-20|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|POCHARBI|This analysis is based on the 209 patients having full data (i.e. BMD measurements at baseline and at 12 months) however, their proﬁle is similar to the proﬁle of the whole sample of 290 patients originally enrolled.|Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer|Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer in Real World Clinical Settings in Greece|Completed|||290|Actual|Hellenic Breast Surgeons Society|||2||f||||t||||||||||2018-05-31 22:51:57.432743|2018-05-31 22:51:57.432743
NCT01298349|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Perception Processing in Schizophrenia Patients and Normal Population|Perception Processing in Schizophrenia Patients and Normal Population.|Unknown status|Not yet recruiting||200|Anticipated|HaEmek Medical Center, Israel|||2||f||||t||||||||||2018-05-31 22:51:59.026125|2018-05-31 22:51:59.026125
NCT01298336|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-01-30|2011-02-16|2011-02-17|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|CAMOMY||Treatment of Mycobacterium Xenopi Pulmonary Infection|Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi|Recruiting||Phase 3|92|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 22:51:59.335728|2018-05-31 22:51:59.335728
NCT01298323|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|2014-04-25|2011-03-28|2017-11-02|2011-02-16|2011-02-17|Estimate|2014-11-17|2014-11-24|Estimate|2011-04-12|2011-04-25|Estimate|2017-11-02|2017-12-07|Actual|February 25, 2011|Actual|2011-02-25|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|April 2013|Actual|2013-04-30||Interventional|88|Of 103 patients randomized to vandetanib 300 mg+outreach arm, all except 1 patient took part in outreach program . This patient was withdrawn due to eligibility criteria failure and could not be contacted successfully. Hence the results have been summarized under vandetanib 300 mg for safety summaries.|Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment|A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib|Active, not recruiting||Phase 3|205|Actual|Sanofi||2|||f||||||||||||||2018-05-31 22:52:00.245977|2018-05-31 22:52:00.245977
NCT01298310|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2012-05-21|2011-02-16|2011-02-17|Estimate|||||||2012-05-21|2012-05-22|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)|A Randomised, Double-blind, Placebo-controlled, Three-way Cross-over Single Center Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)|Completed||Early Phase 1|27|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:52:01.992662|2018-05-31 22:52:01.992662
NCT01298297|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2012-12-06|2011-02-15|2011-02-17|Estimate|||||||2012-12-06|2012-12-10|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy of Buprenorphine for Treatment of Acute Pain|Comparison of Sublingual Buprenorphine With Intravenous Morphine Sulfate in Treatment of Acute Pain Due to Long Bone Fracture|Completed||Phase 4|80|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 22:52:02.28061|2018-05-31 22:52:02.28061
NCT01298284|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-06-14|2011-02-16|2011-02-17|Estimate|||||||2011-06-14|2011-06-15|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|June 2010|Actual|2010-06-30||Interventional|||A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol|Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial|Unknown status|Recruiting|Phase 4|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 22:52:02.366165|2018-05-31 22:52:02.366165
NCT01298271|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-06-14|2011-02-16|2011-02-17|Estimate|||||||2011-06-14|2011-06-15|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Interventional|||Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker|A Randomized Trial of GVS Alone vs. Nadolol|Unknown status|Recruiting|Phase 4|120|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 22:52:02.456793|2018-05-31 22:52:02.456793
NCT01298258|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure|Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor|Unknown status|Recruiting|N/A|120|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 22:52:02.548201|2018-05-31 22:52:02.548201
NCT01298245|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-12-05|2011-02-16|2011-02-17|Estimate|||||||2011-12-05|2011-12-06|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Observational|DMR-1||Genetic Association of Diabetic Retinopathy-1|Genetic Association Studies of Diabetic Retinopathy (1): Vanguard Phase|Unknown status|Recruiting||200|Anticipated|Taipei Veterans General Hospital, Taiwan|||2||f||||f||||||Samples With DNA|"~     The participants will receive fasting blood sampling for the measurements of glucose, HbA1c,~     lipid profile, and biochemistry. An additional 10 ml blood sample will be taken for DNA~     extraction from buffy coat. Early morning urine samples will also be collected for evaluation~     of overt proteinuria by a dipstick method.~   "|||2018-05-31 22:52:02.627386|2018-05-31 22:52:02.627386
NCT01298232|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||One-year Outcomes of Electromechanical Activation Time (EMAT)-Guided vs. Symptom-guided Heart Failure Therapy in Acute Heart Failure Syndrome (AHFS) Patients||Unknown status|Recruiting|N/A|200|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 22:52:02.730965|2018-05-31 22:52:02.730965
NCT01298219|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20||2013-02-01|2013-02-01|2011-02-15|2011-02-17|Estimate||||2013-02-01|2013-02-05|Estimate|2013-02-01|2013-02-05|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)|A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction|Completed||Phase 3|447|Actual|Sucampo Pharma Americas, LLC||2|||f||||f||||||||||2018-05-31 22:52:02.850478|2018-05-31 22:52:02.850478
NCT01298206|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-11-20|2011-02-16|2011-02-17|Estimate|||||||2013-11-20|2013-11-21|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon|Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon|Completed|||129|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||Samples With DNA|"~     Specimens collected from cases(ie positive for pandemic influenza by RT PCR) will be~     processed in order to isolate and characterize the viruses causing infection.~   "|||2018-05-31 22:52:03.144467|2018-05-31 22:52:03.144467
NCT01298193|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2015-05-18|2011-02-15|2011-02-17|Estimate|||||||2015-05-18|2015-05-19|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|April 2014|Actual|2014-04-30|March 2013|Actual|2013-03-31||Interventional|||Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients|A Prospective, Open Label, Non-comparative Trial to Determine the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients|Completed||Phase 4|212|Actual|Spanish Breast Cancer Research Group||1|||f||||f||||||||||2018-05-31 22:52:03.251829|2018-05-31 22:52:03.251829
NCT01298180|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2015-05-26|2011-02-16|2011-02-17|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?|Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?|Completed||Phase 4|111|Actual|University Hospital, Toulouse||5|||f||||f||||||||||2018-05-31 22:52:03.357938|2018-05-31 22:52:03.357938
NCT01298167|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2012-09-10||2012-10-10|2011-02-15|2011-02-17|Estimate|2012-10-10|2012-11-09|Estimate||||2012-10-10|2012-11-09|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery|Fast Absorbing Gut Suture Versus Cyanoacrylate Tissue Adhesive in the Epidermal Closure of Linear Repairs Following Mohs Micrographic Surgery|Completed||N/A|14|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:52:03.544214|2018-05-31 22:52:03.544214
NCT01298154|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2011-05-04|2011-02-15|2011-02-17|Estimate|||||||2011-05-04|2011-05-05|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Effects of Intact and Hydrolyzed Pea Protein on Food Intake, Glycemic Response and Subjective Appetite|The Effects of Intact and Hydrolyzed Yellow Pea Protein on Food Intake, Glycemic Response, and Subjective Appetite in Healthy Young Men.|Completed||Phase 1|26|Anticipated|University of Toronto||5|||f||||f||||||||||2018-05-31 22:52:03.713555|2018-05-31 22:52:03.713555
NCT01298141|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2018-05-16|2011-02-16|2011-02-17|Estimate|||||||2018-05-16|2018-05-21|Actual|August 10, 2011|Actual|2011-08-10|May 2018|2018-05-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|||A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease|A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease|Completed||Phase 3|171|Actual|Shire||1|||f||||t||||||||||2018-05-31 22:52:03.789006|2018-05-31 22:52:03.789006
NCT01298128|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2011-08-17||2012-10-01|2011-02-16|2011-02-17|Estimate|2012-06-13|2012-07-17|Estimate||||2012-10-01|2012-10-05|Estimate|February 2006||2006-02-28|October 2012|2012-10-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment|A Randomized Controlled Trial of NuvaRing® Versus Combined Oral Contraceptive Pills for Pre-treatment in In-Vitro Fertilization (IVF) Cycles|Terminated||N/A|70|Actual|University of Toronto|early termination due to poor recruitment|2|||f||||f||||||||||2018-05-31 22:52:03.863475|2018-05-31 22:52:03.863475
NCT01298115|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-15|2011-02-15|2011-02-17|Estimate|||||||2011-02-15|2011-02-17|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|PINOT||Patient INformation About Options for Treatment - PINOT|Patient Information About Options for Treatment of Stage 5 Chronic Kidney Disease|Completed|||721|Actual|University of Sydney|||1||f||||f||||||||||2018-05-31 22:52:04.037079|2018-05-31 22:52:04.037079
NCT01298102|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients|Safety and Efficacy of Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Transplant and Dialyzed Patients: a Prospective Cohort Study.|Completed||Phase 4|185|Actual|Erasme University Hospital||1|||f||||t||||||||||2018-05-31 22:52:04.099604|2018-05-31 22:52:04.099604
NCT01298089|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-02-17|2011-02-16|2011-02-17|Estimate|||||||2011-02-17|2011-02-18|Estimate|February 2006||2006-02-28|February 2011|2011-02-28|February 2009|Actual|2009-02-28|February 2007|Actual|2007-02-28||Observational|||A Study of Flap Thickness Results Using the Carriazo Pendular Microkeratome - 130 Micrometers Head.|LASIK Flap Thickness Predictability With the Carriazo Pendular Microkeratome|Completed|||131|Actual|Democritus University of Thrace|||||f||||||||||||||2018-05-31 22:52:04.162493|2018-05-31 22:52:04.162493
NCT01298076|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2015-06-02|2011-02-15|2011-02-17|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema|A Multicentre Randomised Clinical Trial of Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema|Completed||Phase 2|61|Actual|University of Sydney||2|||f||||f||||||||||2018-05-31 22:52:04.209126|2018-05-31 22:52:04.209126
NCT01298063|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2013-08-08||2013-12-05|2011-02-16|2011-02-17|Estimate|2013-08-08|2013-10-17|Estimate||||2013-12-05|2013-12-31|Estimate|February 2011||2011-02-28|August 2013|2013-08-31||||January 2012|Actual|2012-01-31||Interventional|||Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib|Pharmacokinetics, Safety and Tolerability of Different Oral Doses of Afatinib, in Subjects With Mild to Moderate Hepatic Impairment Compared to Healthy Subjects - a Phase I, Single-dose, Open-label, Dose-escalation Study in a Matched Group Design|Completed||Phase 1|35|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:52:04.30966|2018-05-31 22:52:04.30966
NCT01298050|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-08-03|2011-02-16|2011-02-17|Estimate|||||||2011-08-03|2011-08-04|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Observational|SEAC||Refractory IHCA and OHCA Treated With ECMO|Refractory In and Out of Hospital Cardiac Arrest Treated With Extracorporeal Membrane Oxygenation. Observational, Single Centre, Prospective Study.|Unknown status|Recruiting||40|Anticipated|University of Milano Bicocca|||1||f||||f||||||||||2018-05-31 22:52:04.634678|2018-05-31 22:52:04.634678
NCT01298037|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-08-21|2011-02-16|2011-02-17|Estimate|||||||2017-08-21|2017-08-23|Actual|February 2011||2011-02-28|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B|HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B|Active, not recruiting|||201|Actual|University of Pennsylvania|||||f||||t||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 22:52:04.705852|2018-05-31 22:52:04.705852
NCT01298024|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2013-04-05|2011-02-16|2011-02-17|Estimate|||||||2013-04-05|2013-04-08|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|NEMEX-ATR||A Pilot Study on Exercise After Achilles Tendon Rupture|NEMEX-ATR: A Randomized Pilot Study on Early Neuromuscular Exercise in Non-surgically Treated Achilles Tendon Rupture|Completed||Phase 2|30|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 22:52:05.779022|2018-05-31 22:52:05.779022
NCT01298011|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-06-15|2011-02-15|2011-02-17|Estimate|||||||2015-06-15|2015-06-17|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|December 2013|Actual|2013-12-31||Interventional|||Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer|A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer|Completed||Phase 2|25|Actual|Pancreatic Cancer Research Team||1|||f||||f||||||||||2018-05-31 22:52:05.866739|2018-05-31 22:52:05.866739
NCT01297998|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2017-11-13|2011-02-15|2011-02-17|Estimate|||||||2017-11-13|2017-11-17|Actual|January 2011||2011-01-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy|A Phase I Study of Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin in Patients With Biliary Tract Cancer Undergoing Curative Resection Without Major Hepatectomy|Completed||Phase 1|24|Actual|Kansai Hepatobiliary Oncology Group||1|||f||||t||||||||||2018-05-31 22:52:05.944456|2018-05-31 22:52:05.944456
NCT01297985|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|January 2006||2006-01-31|February 2011|2011-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|BRIDGES||A Randomized Controlled Trial of Mental Health Peer-Led Education|Efficacy of Peer-Led Education in Improving Mental Health Recovery Outcomes in Tennessee|Completed||Phase 2|428|Actual|University of Illinois at Chicago|||||f||||f||||||||||2018-05-31 22:52:06.017904|2018-05-31 22:52:06.017904
NCT01297972|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2014-02-02|2011-02-16|2011-02-17|Estimate|||||||2014-02-02|2014-02-04|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia|Bone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic Anemia|Completed||Phase 1/Phase 2|9|Actual|University of Sao Paulo|||||f||||t||||||||||2018-05-31 22:52:06.081368|2018-05-31 22:52:06.081368
NCT01297959|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2015-09-15|2011-02-15|2011-02-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|October 2015|Anticipated|2015-10-31||Interventional|Triple IN||Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery|Phase 3 Study of the Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections Among Colorectal Surgery Patients (Triple IN Study-INhibition of INcisional INfections)|Unknown status|Active, not recruiting|Phase 3|1350|Anticipated|Excited States, LLC||2|||f||||t||||||||||2018-05-31 22:52:06.153271|2018-05-31 22:52:06.153271
NCT01297946|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2012-04-20|2011-02-16|2011-02-17|Estimate|||||||2012-04-20|2012-04-23|Estimate||||January 2012|2012-01-31||||||||Interventional|CLASS-01||Closed-loop Control of Glucose Levels in the Context of Exercise in Adults With Type-1 Diabetes|An Open-label, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Dual-hormone Closed-loop Strategy as Compared to Conventional CSII Therapy in Regulating Glucose Levels in Adults With Type-1 Diabetes in the Context of Exercise|Completed||Phase 1/Phase 2|15|Anticipated|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 22:52:06.375822|2018-05-31 22:52:06.375822
NCT01297933|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2018-05-02|2011-02-15|2011-02-17|Estimate|||||||2018-05-02|2018-05-03|Actual||||May 2018|2018-05-31||||||||Expanded Access|Omegaven||Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease|Intravenous Omega-3 Fatty Acid (Omegaven) for Pediatric Patients With Total Parenteral Nutrition Associated Liver Dysfunction|Available|||||Children's Hospital of Philadelphia|||||||||||||||||||2018-05-31 22:52:06.457507|2018-05-31 22:52:06.457507
NCT01297920|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2013-05-17||2013-05-17|2011-02-16|2011-02-17|Estimate|2013-05-17|2013-07-04|Estimate||||2013-05-17|2013-07-04|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||This reporting group includes all randomized subjects, as treated.|Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%|A Three-Month, Randomized, Double-Masked, Parallel-Group Study With a Planned Three-Month Safety Extension of the Efficacy and Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension|Completed||Phase 3|1062|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:52:06.545634|2018-05-31 22:52:06.545634
NCT01297907|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|May 2008||2008-05-31|October 2007|2007-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Bronchial Hyperreactivity in Children With Crohn Disease||Completed|||47|Actual|Rambam Health Care Campus|||2||f||||t||||||||||2018-05-31 22:52:06.911217|2018-05-31 22:52:06.911217
NCT01297894|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-12-24|2011-02-16|2011-02-17|Estimate|||||||2011-12-24|2011-12-29|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii|Colistin Plus Fosfomycin in Multi-Drug Resistant Acinetobacter Baumannii|Unknown status|Recruiting|Phase 3|92|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 22:52:06.986747|2018-05-31 22:52:06.986747
NCT01297881|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2013-03-04|2011-02-16|2011-02-17|Estimate|||||||2013-03-04|2013-03-05|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|BPFS||Belgian Pulmonary Function Study|Belgian Pulmonary Function Study : the Belgian Thoracic Society|Completed|||1000|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-05-31 22:52:07.06515|2018-05-31 22:52:07.06515
NCT01297868|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate||||February 2011|2011-02-28||||||||Observational|||Impact of Exercise on Retinal Microvascular Regulation Measured by Dynamic Vessel Analysis in Healthy Individuals||Completed|||||University Medicine Greifswald|||1||f||||f||||||||||2018-05-31 22:52:07.136341|2018-05-31 22:52:07.136341
NCT01297855|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2011-12-29|2011-02-15|2011-02-17|Estimate|||||||2011-12-29|2012-01-02|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|August 2012|Anticipated|2012-08-31|May 2012|Anticipated|2012-05-31||Interventional|||Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii|Randomized Controlled Trial of Colistin Versus Colistin Plus Rifampicin in MDR P.Aeruginosa and A.Baumanii|Unknown status|Recruiting|Phase 3|130|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 22:52:07.207478|2018-05-31 22:52:07.207478
NCT01297842|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-12-29|2011-02-16|2011-02-17|Estimate|||||||2011-12-29|2012-01-02|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|August 2013|Anticipated|2013-08-31|April 2013|Anticipated|2013-04-30||Interventional|||Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections|An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections|Unknown status|Recruiting|Phase 4|100|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 22:52:07.271502|2018-05-31 22:52:07.271502
NCT01297829|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-12-12|2011-02-16|2011-02-17|Estimate|||||||2014-12-12|2014-12-16|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|March 2015|Anticipated|2015-03-31|August 2013|Actual|2013-08-31||Interventional|||Does Preoperative Caldolor Decrease the Requirement for Postoperative Narcotics|Does Preoperative Caldolor Decrease the Requirement for Postoperative Narcotics in Patients Undergoing Laparoscopic or Open Inguinal and/or Umbilical Hernia Repair? A Randomized, Double-Blind, Prospective Trial|Unknown status|Active, not recruiting|Phase 3|51|Actual|St. Barnabas Medical Center||2|||f||||f||||||||||2018-05-31 22:52:07.437061|2018-05-31 22:52:07.437061
NCT01297816|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|April 2011|Anticipated|2011-04-30|December 2010|Anticipated|2010-12-31||Interventional|minocyclin &RD||Evaluation of Neuroprotective Effect of Minocycline|Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery|Unknown status|Recruiting|Phase 2|||Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:52:07.515298|2018-05-31 22:52:07.515298
NCT01297803|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-02-16|2011-02-16|2011-02-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Comparison of Two Method Antimetabolites Application on Corneal Function in Trabeculectomy Surgery|Corneal Endothelial Cell Loss Following Trabeculectomy With mitomycin_c Application Before Versus After Sclera Flap Dissection|Unknown status|Recruiting|Phase 2|||Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:52:07.59693|2018-05-31 22:52:07.59693
NCT01297790|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-09-15|2011-02-16|2011-02-17|Estimate|||||||2011-09-15|2011-09-16|Estimate|November 2009||2009-11-30|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Cough Responses to Tussive Agents in Health and Disease|Cough Responses to Tussive Agents in Health and Disease|Completed|||102|Actual|Manchester University NHS Foundation Trust|||5||f||||f||||||Samples Without DNA|"~     Sputum.~   "|||2018-05-31 22:52:07.681086|2018-05-31 22:52:07.681086
NCT01297777|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-08-26|2011-02-16|2011-02-17|Estimate|||||||2016-08-26|2016-08-29|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Imatinib in KIT-negative Systemic Mastocytosis|Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations|Completed||Phase 4|10|Actual|Hospital Virgen de la Salud||1|||f||||f||||||||No||2018-05-31 22:52:07.777762|2018-05-31 22:52:07.777762
NCT01297764|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2015-08-20|2011-02-16|2011-02-17|Estimate|||||||2015-08-20|2015-08-21|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|QUAD||A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 22:52:07.870438|2018-05-31 22:52:07.870438
NCT01297751|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-01-23|2011-02-16|2011-02-17|Estimate|||||||2012-01-23|2012-01-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:52:07.952309|2018-05-31 22:52:07.952309
NCT01297738|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2013-01-23|2011-02-16|2011-02-17|Estimate|||||||2013-01-23|2013-01-24|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|DISAB||Diet, Insulin Sensitivity And the Brain|The Effect of Dietary Patterns and Diet Composition on Insulin Sensitivity and Cerebral Dopamine- and Serotonin Transporters|Completed||N/A|39|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||5|||f||||f||||||||||2018-05-31 22:52:07.994226|2018-05-31 22:52:07.994226
NCT01297725|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-10-18|2011-02-16|2011-02-17|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Sharp Versus Blunt Fascial Incision at Caesarean Section|Sharp Versus Blunt Fascial Incision at Caesarean Section: A Prospective Randomized Double-blinded Case-Control Study With the Case as it's Own Control.|Completed||N/A|30|Anticipated|Holbaek Sygehus||2|||f||||f||||||||||2018-05-31 22:52:08.093617|2018-05-31 22:52:08.093617
NCT01297712|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-06-01|2011-02-15|2011-02-17|Estimate|||||||2015-06-01|2015-06-02|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|||Endoscopic Assessment of Polyp Histology|On-Site Endoscopic Prediction of Polyp Histology During Screening Colonoscopy|Terminated||N/A|1069|Actual|Universitätsklinikum Hamburg-Eppendorf||2||enrollment terminated, analysis ongoing|f||||f||||||||||2018-05-31 22:52:08.173408|2018-05-31 22:52:08.173408
NCT01297699|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-01-19|2011-02-16|2011-02-17|Estimate|||||||2016-01-19|2016-01-20|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|GRC||Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)|Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.|Completed||Phase 3|32|Actual|Hospital Clinico Universitario de Santiago||2|||f||||f||||||||||2018-05-31 22:52:08.250279|2018-05-31 22:52:08.250279
NCT01297686|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-03-20|2011-02-15|2011-02-17|Estimate|||||||2013-03-20|2013-03-22|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Exercise Versus Corticosteroid Randomized Clinical Trial for Plantar Fasciitis|A Clinical Trial of a Multi-Element Exercise Program for Plantar Fasciopathy in Workers Required to Stand for Prolonged Periods of Time|Completed||Phase 2/Phase 3|56|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:52:08.336791|2018-05-31 22:52:08.336791
NCT01297673|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-12-15|2011-02-16|2011-02-17|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Reflux in Spinal Cord Injury Patients With Neurogenic Lower Urinary Tract Dysfunction|Vesico-ureteral Reflux in a Contemporary Series of Spinal Cord Injury Patients With Neurogenic Lower Urinary Tract Dysfunction|Completed|||120|Actual|Balgrist University Hospital|||1||f||||f||||||||||2018-05-31 22:52:08.41468|2018-05-31 22:52:08.41468
NCT01297660|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-12-15|2011-02-16|2011-02-17|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Neuro-urological Outcome After Spinal Cord Injury||Completed|||55|Actual|Balgrist University Hospital|||1||f||||f||||||||||2018-05-31 22:52:08.479804|2018-05-31 22:52:08.479804
NCT01297647|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2016-12-15|2011-02-16|2011-02-17|Estimate|||||||2016-12-15|2016-12-16|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Incidence of Urinary Tract Infection After Urodynamic Investigation|Incidence of Urinary Tract Infection and Germ Identification After Urodynamic Investigation in Patients With Spinal Cord Injury|Completed||N/A|317|Actual|Balgrist University Hospital||1|||f||||f||||||||||2018-05-31 22:52:08.553172|2018-05-31 22:52:08.553172
NCT01297634|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2011-11-22|2011-02-16|2011-02-17|Estimate|||||||2011-11-22|2011-11-23|Estimate|May 2011||2011-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle|Phase IV Study of Radial Diffusion of the Botulinum Toxin Type A: Electromyographic Evaluation of the Frontal Muscle.|Completed||Phase 4|64|Actual|Ivo Pitanguy Institute||3|||f||||t||||||||||2018-05-31 22:52:08.61247|2018-05-31 22:52:08.61247
NCT01297621|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-16|||2013-07-05|2011-02-16|2011-02-17|Estimate|||||||2013-07-05|2013-07-09|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Physical Activity and Sexuality After Reduction Mammaplasty|Satisfaction, Physical Activity and Sexuality Outcomes in Breast Reduction Patients|Completed||N/A|60|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 22:52:08.674613|2018-05-31 22:52:08.674613
NCT01297608|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-12-11|2011-02-15|2011-02-17|Estimate|||||||2013-12-11|2013-12-12|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Interventional|||A Double Blinded Study to Examine the Effect of Coated Suppositories on Fecal Incontinence in Patients With Spinal Cord Injury||Withdrawn||Phase 2|0|Actual|RDD Pharma Ltd||2|||f||||f||||||||||2018-05-31 22:52:08.746282|2018-05-31 22:52:08.746282
NCT01297595|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2012-01-05||2012-02-15|2011-02-15|2011-02-17|Estimate|2012-01-05|2012-02-08|Estimate||||2012-02-15|2012-02-16|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule|A Phase 1, Open-Label, Single Dose, Randomized, Cross-Over Relative Bioavailability Study Comparing An Oral Liquid Formulation To A Formulated Capsule Of Crizotinib (PF 02341066) In Healthy Volunteers|Completed||Phase 1|22|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:52:08.816351|2018-05-31 22:52:08.816351
NCT01297582|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-06-12|2011-02-15|2011-02-17|Estimate|||||||2012-06-12|2012-06-14|Estimate|January 2011||2011-01-31|June 2012|2012-06-30||||June 2011|Actual|2011-06-30||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, Single-Dose Escalation and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects|Completed||Phase 1|56|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 22:52:09.29755|2018-05-31 22:52:09.29755
NCT01297569|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-02-20|2011-02-15|2011-02-16|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2011||2011-01-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|OPTIMAL||"Ranibizumab Treat and Extend in Diabetic Macular Edma"|"An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized Treat and Extend Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema"|Completed||Phase 4|7|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:52:09.365074|2018-05-31 22:52:09.365074
NCT01297556|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-15|2011-02-15|2011-02-16|Estimate|||||||2011-02-15|2011-02-16|Estimate|April 2011||2011-04-30|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|IBS||Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.|Examining Patient Attributes To Determine Optimal Treatment Outcome in Irritable Bowel Syndrome.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Michigan Gastroenterology Institute||2|||f||||t||||||||||2018-05-31 22:52:09.455998|2018-05-31 22:52:09.455998
NCT01297543|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11||2016-05-10|2016-06-29|2011-02-15|2011-02-16|Estimate||||2016-05-10|2016-06-03|Estimate|2016-06-29|2016-07-01|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia|A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia|Completed||Phase 1/Phase 2|45|Actual|Cellerant Therapeutics||10|||f||||f||||||||||2018-05-31 22:52:09.644654|2018-05-31 22:52:09.644654
NCT01297530|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-07-28|2011-02-15|2011-02-16|Estimate|||||||2013-07-28|2013-07-30|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY87-2243 Given Once Daily in Subjects With Advanced Malignancies|Terminated||Phase 1|5|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:52:09.810028|2018-05-31 22:52:09.810028
NCT01297517|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2013-03-27|2012-07-17|2013-05-14|2011-02-15|2011-02-16|Estimate|2013-03-27|2013-05-13|Estimate|2012-07-17|2012-07-25|Estimate|2013-05-14|2013-05-21|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||This reporting group includes all participants randomized to study drug, as treated.|Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%|Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension|Completed||Phase 3|1001|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:52:09.90601|2018-05-31 22:52:09.90601
NCT01297504|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2014-08-22||2014-09-19|2011-02-15|2011-02-16|Estimate|2014-08-22|2014-09-03|Estimate||||2014-09-19|2014-10-01|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational||Participants Studied|A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America|A One-Year Observational Study of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America|Completed|||464|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:52:10.333475|2018-05-31 22:52:10.333475
NCT01297491|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|2015-10-30||2016-03-10|2011-02-15|2011-02-16|Estimate|2015-12-31|2016-02-02|Estimate||||2016-03-10|2016-03-11|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BASALT-1|Analysis set Stage 1 includes all patients who were enrolled during Stage 1 after meeting eligibility criteria and who have received at least one dose of study drug.|Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer|An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway|Completed||Phase 2|63|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:52:11.008633|2018-05-31 22:52:11.008633
NCT01297465|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2013-10-23||2014-01-10|2011-02-15|2011-02-16|Estimate|2014-01-10|2014-02-24|Estimate||||2014-01-10|2014-02-24|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PERSIST|Safety Population included all the randomized participants who had received at least 1 dose of Pergoveris® or Gonal-f®.|PERgoveriS In Stratified Treatment for Assisted Reproductive Technique|A Phase IIIB, Multicentre, Multinational, Randomized, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® Day 1 to Day 5 Followed by Pergoveris® Starting Day 6 to Pergoveris® Starting Day 1 in Women Between 36 and 40 Years of Age Undergoing Assisted Reproductive Technique (ART)|Completed||Phase 3|202|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 22:52:11.914469|2018-05-31 22:52:11.914469
NCT01297452|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-03-30|2011-02-15|2011-02-16|Estimate|||||||2017-03-30|2017-03-31|Actual|February 15, 2011|Actual|2011-02-15|March 2017|2017-03-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors|A Phase I Study of BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors|Completed||Phase 1|45|Actual|Memorial Sloan Kettering Cancer Center||4|||f||||t||||||||||2018-05-31 22:52:12.634691|2018-05-31 22:52:12.634691
NCT01297439|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-04-29|2011-02-15|2011-02-16|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|CONTRADYS||"New Prophylactic Maneuver: the Pushing Maneuver, Aiming to Reduce the Risk for Shoulder Dystocia"|"CONTRADYS : A Randomized Controlled Trial of a New Prophylactic Maneuver, the Pushing Maneuver, Aiming to Reduce the Risk for Shoulder Dystocia"|Terminated||N/A|1538|Actual|Assistance Publique - Hôpitaux de Paris||2||the study stopped due to the lack of inclusion.|f||||f||||||||||2018-05-31 22:52:12.781204|2018-05-31 22:52:12.781204
NCT01297426|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-12-23|2011-02-15|2011-02-16|Estimate|||||||2015-12-23|2015-12-24|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|Leptin signali||Leptin Signaling in Lean and Obese Humans|Leptin Signaling in Humans|Withdrawn|||0|Actual|VA Office of Research and Development|||1|funding expired|f||||f||||||||||2018-05-31 22:52:12.851537|2018-05-31 22:52:12.851537
NCT01297257|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2013-11-20||2014-01-21|2011-02-15|2011-02-16|Estimate|2014-01-21|2014-03-06|Estimate||||2014-01-21|2014-03-06|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Observational|DELIVER||DELIVER Study: DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER Stenting||Completed|||7845|Actual|Medtronic Vascular|||||f||||f||||||||||2018-05-31 22:52:16.646393|2018-05-31 22:52:16.646393
NCT01297413|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-04-16|2011-02-14|2011-02-16|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2011||2011-02-28|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Interventional|||A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke|A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke|Active, not recruiting||Phase 1/Phase 2|38|Actual|Stemedica Cell Technologies, Inc.||1|||f||||t||||||||||2018-05-31 22:52:12.903668|2018-05-31 22:52:12.903668
NCT01297400|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2018-04-16|2011-02-15|2011-02-16|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2, 2019|Anticipated|2019-01-02|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Clinical Study of the Efficacy and Safety of MEBO® Wound Ointment in Subjects With Partial Thickness Burns|A Phase II, Randomized, Controlled, Single-Center Pilot Study of the Efficacy and Safety of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Partial Thickness Burns|Not yet recruiting||Phase 2|14|Anticipated|Skingenix, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 22:52:13.015463|2018-05-31 22:52:13.015463
NCT01297387|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-18|2011-02-15|2011-02-16|Estimate|||||||2011-02-18|2011-02-21|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|December 2009|Actual|2009-12-31|||||Observational|||Feasibility of Peripheral Angioplasty in Type D TASCII Lesions|An Observational, Prospective Study Evaluating Feasibility of Peripheral Angioplasty in Diabetic Patients With Critical Limb Ischemia in C and D Obstructions of Transatlantic Inter-Society Consensus (TASC II).|Completed|||344|Actual|IRCCS Multimedica|||1||f||||f||||||||||2018-05-31 22:52:13.129915|2018-05-31 22:52:13.129915
NCT01297374|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-15|2011-02-15|2011-02-16|Estimate|||||||2011-02-15|2011-02-16|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|AMO||Effect of Three Non-drug Intervention in Treatment of Children With Overweight|EFFECT OF THREE NON-DRUG INTERVENTION IN TREATMENT OF CHILDREN WITH OVERWEIGHT|Unknown status|Active, not recruiting|N/A|90|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||||||||||||2018-05-31 22:52:13.208035|2018-05-31 22:52:13.208035
NCT01297361|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-02|||2013-04-22|2011-02-15|2011-02-16|Estimate|||||||2013-04-22|2013-04-23|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||The Association Between Religious Origin and Age, and Vitamin B12 and Folic Acid Plasma Levels in Non Jewish Population in Western Galilee||Completed||N/A|90|Actual|Meir Medical Center||1|||f||||f||||||||||2018-05-31 22:52:13.300468|2018-05-31 22:52:13.300468
NCT01297348|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2013-04-02||2013-06-27|2011-02-14|2011-02-16|Estimate|2013-04-02|2013-05-27|Estimate||||2013-06-27|2013-07-17|Estimate|July 2007||2007-07-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Study Of Lybrel In Relation To Venous Thromboembolism|Postmarketing Study Of Lybrel In Relation To Venous Thromboembolism|Completed|||598682|Actual|Pfizer|Data for DVT, PE and CVST were not reported separately as the 3 were components of the primary endpoint VTE and not separate endpoints.||2||f||||f||||||||||2018-05-31 22:52:13.368773|2018-05-31 22:52:13.368773
NCT01297335|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2015-07-27||2016-09-01|2011-02-15|2011-02-16|Estimate|2015-11-30|2016-01-01|Estimate||||2016-09-01|2016-10-19|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Intrathecal Clonidine in Hypertensive Subjects With Poorly Controlled Blood Pressure|Hemodynamic Effect of Intrathecal Clonidine in Hypertensive Subjects: A Pilot Study to Assess Its Effectiveness in Hypertensive Subjects With Poor Blood Pressure Control (Phase II)|Completed||Phase 2|10|Actual|The Center for Clinical Research, Winston-Salem, NC|This study was limited by small sample size, and lack of control group.|1|||f||||t||||||||No|no individual's data will be shared with anyone other than the members of the study staff, and the confidentiality will be maintained in accordance with HIPAA rules.|2018-05-31 22:52:13.800036|2018-05-31 22:52:13.800036
NCT01297322|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2014-09-30||2014-09-30|2011-02-15|2011-02-16|Estimate|2014-09-30|2014-10-03|Estimate||||2014-09-30|2014-10-03|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|RESPECT||RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)|A Multi-Center, Prospective, Randomized, Controlled, Trial to Evaluate the Safety and Efficacy of the Cardiva VASCADE™ Vascular Closure System (VCS) vs. Manual Compression for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures|Completed||N/A|420|Actual|Cardiva Medical, Inc.||2|||f||||t||||||||||2018-05-31 22:52:14.094924|2018-05-31 22:52:14.094924
NCT01297309|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2017-02-01|2011-02-14|2011-02-16|Estimate|||||||2017-02-01|2017-02-03|Estimate|April 2011||2011-04-30|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)|A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)|Active, not recruiting||Phase 3|50|Anticipated|Shire||1|||f||||f||||||||||2018-05-31 22:52:14.483914|2018-05-31 22:52:14.483914
NCT01297296|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-06-21|2011-02-15|2011-02-16|Estimate|||||||2017-06-21|2017-06-22|Actual|July 2011||2011-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2014|Actual|2014-06-30||Observational|PARACHUTEIII||A Multinational Trial to Evaluate the Longterm Safety of the Parachute Implant System|PARACHUTE III: A Multinational Trial to Evaluate the Longterm Safety of the Parachute System|Terminated|||54|Actual|CardioKinetix, Inc|||||f||||f||||||||||2018-05-31 22:52:14.775589|2018-05-31 22:52:14.775589
NCT01297283|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2013-12-23||2017-02-14|2011-02-15|2011-02-16|Estimate|2014-02-14|2014-04-01|Estimate||||2017-02-14|2017-03-21|Actual|July 2010|Actual|2010-07-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|LECG||Leadless Electrocardiogram (ECG) Evaluation Study|Leadless ECG Evaluation Study - Prospectively, Randomized, Cross-over, Multi-center, Interventional, Post-market Release Study to Evaluate the LECG System.|Completed||N/A|195|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||No|No sharing|2018-05-31 22:52:15.13093|2018-05-31 22:52:15.13093
NCT01297270|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2015-07-03|2014-05-06|2015-08-18|2011-02-15|2011-02-16|Estimate|2015-08-18|2015-09-18|Estimate|2014-05-06|2014-05-21|Estimate|2015-08-18|2015-09-18|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Full analysis set (FAS) included all randomized patients who were dispensed study medication and were documented to have taken at least one dose.|Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)|A Phase III, Randomized, Double Blind and Placebo Controlled Study of Once Daily BI 201335 120 mg for 24 Weeks and BI 201335 240 mg for 12 Weeks in Combination With Pegylated Interferon Alpha and Ribavirin in Treatment Naive Patients With Genotype 1 Chronic Hepatitis C Infection.|Completed||Phase 3|658|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 22:52:15.6114|2018-05-31 22:52:15.6114
NCT01297244|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-11-04|2011-02-15|2011-02-16|Estimate|||||||2013-11-04|2013-11-05|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma|A Phase 2 and Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma|Completed||Phase 2|105|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:52:16.757223|2018-05-31 22:52:16.757223
NCT01297231|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2012-11-12|2011-02-14|2011-02-16|Estimate|||||||2012-11-12|2012-11-14|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI|Prospective Analysis of Changes in Background Parenchymal Enhancement (BPE) and Amount of Fibroglandular Tissue on Breast MRI in Early Stage Breast Cancer Patients on Tamoxifen|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center|||1|Lack of funding|f||||||||||Samples With DNA|"~     blood or saliva~   "|||2018-05-31 22:52:16.968232|2018-05-31 22:52:16.968232
NCT01297218|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-04-19|2011-02-15|2011-02-16|Estimate|||||||2012-04-19|2012-04-23|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||The Safety and The Efficacy Evaluation of NEUROSTEM®-AD in Patients With Alzheimer's Disease|Open-Label, Single-Center, Phase 1 Clinical Trial to Evaluate the Safety and the Efficacy of NEUROTSTEM®-AD in Patients With Dementia of the Alzheimer's Type|Completed||Phase 1|9|Actual|Medipost Co Ltd.||1|||f||||t||||||||||2018-05-31 22:52:17.030553|2018-05-31 22:52:17.030553
NCT01297205|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2014-04-03|2011-02-15|2011-02-16|Estimate|||||||2014-04-03|2014-04-07|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy Evaluation of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia|Open Label, Single-Center, Phase 1 Clinical Study to Evaluate the Safety and the Efficacy of PNEUMOSTEM® Treatment in Premature Infants With Bronchopulmonary Dysplasia|Completed||Phase 1|9|Actual|Medipost Co Ltd.||1|||f||||t||||||||||2018-05-31 22:52:17.09845|2018-05-31 22:52:17.09845
NCT01297192|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-07-25|2011-02-15|2011-02-16|Estimate|||||||2013-07-25|2013-07-29|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously|An Open-label, One-sequence, Two-arm Study to Evaluate the Effect of Steady State Concentrations of Mirabegron on the Pharmacokinetics of Solifenacin and to Evaluate the Effect of Steady State Concentrations of Solifenacin on the Pharmacokinetics of Mirabegron in Healthy Young Male and Female Subjects|Completed||Phase 1|41|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:52:17.163836|2018-05-31 22:52:17.163836
NCT01297179|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2013-07-01|2011-02-15|2011-02-16|Estimate|||||||2013-07-01|2013-07-03|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill|A Double-blind Two-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics (PK) of an Ethinyl Estradiol and Levonorgestrel Containing Combined Oral Contraceptive (COC)|Completed||Phase 1|30|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 22:52:17.319763|2018-05-31 22:52:17.319763
NCT01297166|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-10-24|2011-02-15|2011-02-16|Estimate|||||||2013-10-24|2013-10-25|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris|A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris.|Completed||Phase 1|25|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 22:52:17.458571|2018-05-31 22:52:17.458571
NCT01297153|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-06-30|2011-02-15|2011-02-16|Estimate|||||||2011-06-30|2011-07-01|Estimate|May 2003||2003-05-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||Aphakia Versus Pseudophakia in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery|Aphakia vs Pseudophakia - Randomized Clinical Trial in Children Under 2 Years Undergoing Bilateral Congenital Cataract Surgery|Completed||Phase 4|100|Anticipated|Iladevi Cataract and IOL Research Center||2|||f||||t||||||||||2018-05-31 22:52:17.524698|2018-05-31 22:52:17.524698
NCT01297140|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2014-10-02|2011-02-15|2011-02-16|Estimate|||||||2014-10-02|2014-10-03|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|July 2015|Anticipated|2015-07-31||Interventional|PACO||"The PACO Study (Personnalité Alzheimer COmportement)"|The Role of Personality in the Occurrence of Behavioural Disorders in Patients Suffering From Alzheimer Disease|Unknown status|Recruiting|N/A|252|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 22:52:17.666173|2018-05-31 22:52:17.666173
NCT01297127|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2016-11-01|2011-02-15|2011-02-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection|Prospective Multicentre Noninterventional Observational Study on Predictors of Treatment Response in a Cohort of Treatment naïve HIV-infected Patients Treated With Saquinavir (PROSPECTOR)|Completed|||151|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:52:17.737696|2018-05-31 22:52:17.737696
NCT01297114|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2017-10-30|2011-02-15|2011-02-16|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2011||2011-03-31|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Observational|||Imaging of Cognition, Learning, and Memory in Aging|Imaging of Cognition, Learning, and Memory in Aging|Completed|||294|Actual|Columbia University|||2||f||||f||||||Samples With DNA|"~     Whole blood (frozen)~   "|Yes|De-identified data could be shared based on NIH regulations|2018-05-31 22:52:17.801731|2018-05-31 22:52:17.801731
NCT01297101|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-15|2011-02-15|2011-02-16|Estimate|||||||2011-02-15|2011-02-16|Estimate||||January 2011|2011-01-31||||||||Expanded Access|||Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy|A National, Multi Center, Randomized, Open-label, Phase II Trial of Tarceva Versus Combination of Gemcitabine Plus Cisplatin as Neoadjuvant Treatment in Stage IIIA-N1,N2 NSCLC With Activating EGFR Mutation in Exon 19 or 21|Temporarily not available|||||Shanghai Chest Hospital|||||f||||||||||||||2018-05-31 22:52:17.861424|2018-05-31 22:52:17.861424
NCT01297088|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-01-18|2011-02-14|2011-02-16|Estimate|||||||2013-01-18|2013-01-21|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.|Open-label, Single Center Study of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 18 µg Mass Dose) for Evaluation of Biodistribution in Pathological Tissue in Patients With Cancer or Inflammation|Completed||Phase 1|24|Actual|Piramal Imaging SA||1|||f||||f||||||||||2018-05-31 22:52:17.910293|2018-05-31 22:52:17.910293
NCT01297075|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2014-05-22|2011-02-15|2011-02-16|Estimate|||||||2014-05-22|2014-05-23|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|Output||Outreach Visits to Optimize Chronic Care Management in General Practice: A Cluster Randomized Trial|Outreach Visits to Optimize Chronic Care Management in General Practice: A Cluster Randomized Trial|Completed||N/A|189|Actual|Research Unit Of General Practice, Copenhagen||2|||f||||f||||||||||2018-05-31 22:52:17.976523|2018-05-31 22:52:17.976523
NCT01297062|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2012-04-27||2015-03-24|2011-02-14|2011-02-16|Estimate|2012-04-27|2012-05-31|Estimate||||2015-03-24|2015-04-14|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects|A Randomized, Phase 1, Three-Period, Placebo- and Positive-Controlled, Double-Blind, Crossover Study to Assess the Electrophysiological Effects of Exenatide at Therapeutic and Supratherapeutic Concentrations on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects|Completed||Phase 1|94|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 22:52:18.078142|2018-05-31 22:52:18.078142
NCT01297049|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2014-12-02|2011-02-15|2011-02-16|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|I-care||I-care: Stimulating Self-management in Patients With Type 2-diabetes|I-care: Stimulating Self-management in Patients With Type 2-diabetes Through Web-based Situational Feedback. A Pilot Study.|Unknown status|Active, not recruiting|N/A|15|Actual|Oslo and Akershus University College of Applied Sciences||1|||f||||t||||||||||2018-05-31 22:52:18.466171|2018-05-31 22:52:18.466171
NCT01297036|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-15|2011-02-15|2011-02-16|Estimate|||||||2011-02-15|2011-02-16|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Pharmacokinetic Comparisons of Two Donepezil Formulations|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Donepezil Between Two Donepezil Products, Aricept® Tablet and Neuropezil ODT, in Healthy Subjects|Completed||Phase 1|22|Actual|Korea University Anam Hospital||2|||f||||f||||||||||2018-05-31 22:52:18.535736|2018-05-31 22:52:18.535736
NCT01297023|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2012-11-06|2011-02-15|2011-02-16|Estimate|||||||2012-11-06|2012-11-07|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Human Intervention Study With Calcium Phosphate and Vitamin D|The Effect of Vitamin D3 Alone and in Combination With Calcium Phosphate on Bone Metabolism in Healthy Adults|Completed||N/A|60|Actual|University of Jena||4|||f||||t||||||||||2018-05-31 22:52:18.598934|2018-05-31 22:52:18.598934
NCT01297010|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-08-02|2011-02-15|2011-02-16|Estimate|||||||2011-08-02|2011-08-03|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|vomiting||Dexamethasone Compared to Ondansetron and Dexamethasone for Prophylaxis of Postoperative Vomiting in Children|Dexamethasone Compared to Ondansetron and Dexamethasone for Prophylaxis of Postoperative Vomiting in Children Undergoing Ambulatory Surgery: Clinical Trial Randomized, Double Blind, Placebo-controlled|Completed||Phase 3|134|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-05-31 22:52:18.655784|2018-05-31 22:52:18.655784
NCT01296997|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2012-11-06|2011-02-15|2011-02-16|Estimate|||||||2012-11-06|2012-11-07|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Calcium Phosphate and Incretins|Influence of a Calcium Phosphate Supplementation on the Secretion of Incretins in Humans.|Completed||N/A|10|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 22:52:18.711519|2018-05-31 22:52:18.711519
NCT01296984|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2014-11-17|2011-02-15|2011-02-16|Estimate|||||||2014-11-17|2014-11-19|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|APER||Oncological and Functional Result of AbdominoPerineal Extra Levator Resection for Distal Rectal Cancer|A Registry Based Study of Clinical Results and of Health and Wellbeing in Patients After Abdominoperineal Resection for Rectal Cancer|Completed|||1319|Actual|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||||2018-05-31 22:52:18.767546|2018-05-31 22:52:18.767546
NCT01296971|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2016-11-01|2011-02-15|2011-02-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)|Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon Alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER Study)|Withdrawn||Phase 3|0|Actual|Hoffmann-La Roche||3||study was not started due to an administrative reason on the part of the local Health Authority|f||||||||||||||2018-05-31 22:52:18.819967|2018-05-31 22:52:18.819967
NCT01296958|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2014-10-22|2011-02-15|2011-02-16|Estimate|||||||2014-10-22|2014-10-24|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Targeted Screening for Taenia Solium Tapeworms|Targeted Screening for Taenia Solium Tapeworms|Completed||N/A|1811|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 22:52:18.874154|2018-05-31 22:52:18.874154
NCT01296945|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2012-03-28|2011-02-15|2011-02-16|Estimate|||||||2012-03-28|2012-03-30|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Nutrition Knowledge for Spanish-speaking Parents|Nutrition Knowledge for Spanish-speaking Parents: Evaluation of Paper Handouts, Computer Modules and Web Modules|Completed||N/A|160|Anticipated|Johns Hopkins University||4|||f||||f||||||||||2018-05-31 22:52:18.930228|2018-05-31 22:52:18.930228
NCT01296932|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2017-08-16|2011-02-15|2011-02-16|Estimate|||||||2017-08-16|2017-08-17|Actual|February 11, 2011|Actual|2011-02-11|August 2017|2017-08-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)|A Phase I, Open, Dose Escalation Trial With BI 836826 in Patients With Advanced Chronic Lymphocytic Leukaemia|Completed||Phase 1|37|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 22:52:19.094864|2018-05-31 22:52:19.094864
NCT01296919|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-09-11|2011-02-15|2011-02-16|Estimate|||||||2011-09-11|2011-09-13|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|July 2010|Actual|2010-07-31||Observational|||The Clinical Significance of the Uncinate Process Histopathology in Chronic Rhinosinusitis|New Insights on the Clinical Significance of the Uncinate Process Histopathology in Patients With Chronic Rhinosinusitis|Unknown status|Recruiting||30|Anticipated|Assuta Hospital Systems|||1||f||||t||||||Samples Without DNA|"~     Pathologic uncinate process tissue~   "|||2018-05-31 22:52:19.164125|2018-05-31 22:52:19.164125
NCT01296906|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-06-19|2011-02-14|2011-02-16|Estimate|||||||2013-06-19|2013-06-21|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|December 2010|Actual|2010-12-31||Interventional|||Population Versus Practice-based Interventions to Increase Immunizations|Population Versus Practice-based Interventions to Increase Immunizations|Completed||N/A|31567|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 22:52:19.223111|2018-05-31 22:52:19.223111
NCT01296893|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-06-05|2011-02-15|2011-02-16|Estimate|||||||2016-06-05|2016-06-07|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|February 2014|Actual|2014-02-28||Interventional|chemobrain||Can Exercise Improve Cancer Associated Cognitive Dysfunction?|Can Exercise Improve Cancer Associated Cognitive Dysfunction?|Completed||Phase 2|31|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 22:52:19.294298|2018-05-31 22:52:19.294298
NCT01296880|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-12-23|2011-02-15|2011-02-16|Estimate|||||||2015-12-23|2015-12-24|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy|Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy|Completed|||60|Actual|State University of New York - Downstate Medical Center|||2||f||||f||||||||||2018-05-31 22:52:19.353245|2018-05-31 22:52:19.353245
NCT01296867|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2011-02-15|2011-02-15|2011-02-16|Estimate|||||||2011-02-15|2011-02-16|Estimate|March 2006||2006-03-31|February 2011|2011-02-28|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Observational|||Corneal Asphericity Adjustment (Q Adjustment) in Myopic and Hyperopic Patients Undergoing Refractive Correction With Excimer Laser||Completed|||36|Actual|Democritus University of Thrace|||||f||||f||||||||||2018-05-31 22:52:19.406403|2018-05-31 22:52:19.406403
NCT01296854|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2015-03-24|2011-02-15|2011-02-16|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|BPCeaux||The Effect of Spa Treatment on Chronic Obstructive Pulmonary Disease|The Effect of Spa Treatment on Chronic Obstructive Pulmonary Disease|Terminated||N/A|39|Actual|Centre Hospitalier Universitaire de Nīmes||2||The feasability of inclusions has proven very low.|f||||t||||||||||2018-05-31 22:52:19.448852|2018-05-31 22:52:19.448852
NCT01296841|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2012-01-15||2017-01-17|2011-02-15|2011-02-16|Estimate|2013-01-06|2013-02-07|Estimate||||2017-01-17|2017-03-03|Actual|October 2009||2009-10-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care|A Randomized Controlled Pilot: Use of Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care|Completed||Phase 2|34|Actual|VA Palo Alto Health Care System||2|||f||||t||||||||||2018-05-31 22:52:19.601675|2018-05-31 22:52:19.601675
NCT01296828|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-15|2011-02-15|2011-02-16|Estimate|||||||2011-02-15|2011-02-16|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|May 2011|Anticipated|2011-05-31|November 2010|Actual|2010-11-30||Observational|||Lips and Tongue of Mouth Breathing Children|Posture, Tone and Mobility of Lips and Tongue of Mouth Breathing Children|Unknown status|Enrolling by invitation||40|Actual|Pontificia Universidade Catolica de Sao Paulo|||1||f||||t||||||||||2018-05-31 22:52:19.870597|2018-05-31 22:52:19.870597
NCT01296815|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|2014-10-30||2015-07-22|2011-02-15|2011-02-16|Estimate|2015-07-22|2015-07-27|Estimate||||2015-07-22|2015-07-27|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity|Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity|Completed||Phase 2|14|Actual|Centro de Investigación en. Enfermedades Infecciosas, Mexico||2|||f||||f||||||||||2018-05-31 22:52:19.934499|2018-05-31 22:52:19.934499
NCT01296802|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-12-14|2011-02-14|2011-02-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|April 2006||2006-04-30|December 2011|2011-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|DEXFEN_PET||Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging|"Investigation of Serotonin Neurotransmission in Ecstasy Users Employing Combined Dexfenfluramine Challenge and Positron Emission Tomography: a Functional Probe to Assess MDMA Neurotoxicity"|Completed||N/A|50|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 22:52:20.150402|2018-05-31 22:52:20.150402
NCT01296789|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-07-27|2011-02-14|2011-02-15|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparison of a Tissue Perfusion Guided Hemodynamic Protocol With a Standard Hemodynamic Protocol in Septic Shock Patients|Comparison of a Tissue Perfusion Guided Hemodynamic Protocol With a Conventional Hemodynamic Protocol in Septic Shock Patients: a Prospective, Randomised, Controlled Study|Terminated||N/A|40|Actual|University Hospital Inselspital, Berne||2||Problems implementing the trial|f||||f||||||||||2018-05-31 22:52:20.233188|2018-05-31 22:52:20.233188
NCT01296776|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-12-01|2011-02-14|2011-02-15|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Electromyostimulation on Bone|Effects of Whole-Body Electromyostimulation on Osteoporosis and Sarcopenia in Independently Living, Frail Elderly Females|Completed||Phase 3|78|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 22:52:20.312744|2018-05-31 22:52:20.312744
NCT01296763|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2015-12-04||2016-02-19|2011-02-14|2011-02-15|Estimate|2016-02-19|2016-03-22|Estimate||||2016-02-19|2016-03-22|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2014|Actual|2014-01-31||Interventional||Subject with advanced pancreatic cancer|Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer|A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer|Completed||Phase 1|18|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The P.I. and Astrazeneca decided not to move forward with the Phase II part of the study. Therefore the arms of Irinotecan, Cisplatin, Mitomycin C with Olaparib versus Irinotecan, Cisplatin, Mitomycin C without Olaparib will not be compared.|1|||f||||t||||||||||2018-05-31 22:52:20.421866|2018-05-31 22:52:20.421866
NCT01296750|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2014-07-21|2011-02-14|2011-02-15|Estimate|||||||2014-07-21|2014-07-22|Estimate|June 2011||2011-06-30|February 2011|2011-02-28|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|Co_Leap||Late Compared to Early Physiotherapy Following Knee Dislocation|A Randomized Clinical Trial Comparing Late Versus Early Physiotherapy Start Times Following Multi Ligament Reconstruction for Knee Dislocation (Co-LEAP)|Unknown status|Recruiting|Phase 3|70|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 22:52:20.984337|2018-05-31 22:52:20.984337
NCT01296737|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-08-07|2011-02-14|2011-02-15|Estimate|||||||2011-08-07|2011-08-09|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Observational|||Validation of Quantitative Ventricular Function Imaging Single Photon Emission Tomography (Spect)Using the D-SPECT Cardiac Camera|Validation of Quantitative Ventricular Function Imaging|Completed|||50|Anticipated|Spectrum Dynamics|||||f||||t||||||||||2018-05-31 22:52:21.036538|2018-05-31 22:52:21.036538
NCT01296724|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-11-25|2011-02-14|2011-02-15|Estimate|||||||2013-11-25|2013-11-26|Estimate|February 2011||2011-02-28|November 2013|2013-11-30||||July 2013|Actual|2013-07-31||Interventional|||PREMAPIV : Intravesical Pressure Variation at Different Bladder Instillation Volumes in Newborn Children|PREMAPIV : Intravesical Pressure Variation at Different Bladder Instillation Volumes in Newborn Children|Completed||N/A|54|Actual|Rennes University Hospital||2|||f||||||||||||||2018-05-31 22:52:21.074093|2018-05-31 22:52:21.074093
NCT01296711|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14||2013-06-03|2014-08-26|2011-02-14|2011-02-15|Estimate||||2013-06-03|2013-06-11|Estimate|2014-08-26|2014-08-27|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056|A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056|Completed||Phase 2|190|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 22:52:21.132048|2018-05-31 22:52:21.132048
NCT01296698|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2012-03-29||2012-03-29|2011-02-14|2011-02-15|Estimate|2012-03-29|2012-04-23|Estimate||||2012-03-29|2012-04-23|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week Trial to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers in a Naturalistic Environment|Terminated||Phase 3|257|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|Summary tabulations are not available for the primary and some secondary outcome measures because the study was terminated early due to a technical issue (randomization error).|2||Study terminated due to a technical issue (randomization error).|f||||f||||||||||2018-05-31 22:52:21.413542|2018-05-31 22:52:21.413542
NCT01296685|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-05-31|2011-02-14|2011-02-15|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2011||2011-03-31|February 2011|2011-02-28||||||||Observational|||Clinical Evaluation of Air Handling in Baby fx Oxygenator With Integrated Arterial Filter Versus Baby rx Oxygenator With Non Integrated Arterial Line Filter|Clinical Evaluation of Air Handling in Baby fx Oxygenator With Integrated Arterial Filter Versus Baby rx Oxygenator With Non Integrated Arterial Line Filter|Unknown status|Not yet recruiting||40|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||t||||||||||2018-05-31 22:52:21.92287|2018-05-31 22:52:21.92287
NCT01296672|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2017-06-26||2017-09-07|2011-02-14|2011-02-15|Estimate|2017-08-07|2017-09-08|Actual||||2017-09-07|2017-10-06|Actual|February 2011||2011-02-28|March 2017|2017-03-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer|Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test|Completed||Phase 4|383|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 22:52:21.965703|2018-05-31 22:52:21.965703
NCT01296659|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2012-07-11|2011-02-14|2011-02-15|Estimate|||||||2012-07-11|2012-07-12|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma|Phase Ib Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Patients With Advanced Unresectable Soft Tissue Sarcoma|Withdrawn||Phase 1|0|Actual|The University of Texas Health Science Center at San Antonio||2||Principal Investigator left institution.|f||||t||||||||||2018-05-31 22:52:22.289481|2018-05-31 22:52:22.289481
NCT01296646|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2013-08-12||2013-10-29|2011-02-14|2011-02-15|Estimate|2013-10-29|2013-11-25|Estimate||||2013-10-29|2013-11-25|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SweetNal||Sweet Preference and Alcohol Craving|Sweet Preference and Alcohol Craving Predict Naltrexone Response in Alcoholism|Completed||Phase 2|80|Actual|University of North Carolina, Chapel Hill||4|||f||||t||||||||||2018-05-31 22:52:23.203402|2018-05-31 22:52:23.203402
NCT01296633|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2016-08-07|2011-02-14|2011-02-15|Estimate|||||||2016-08-07|2016-08-09|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Medtable: An Electronic Medical Record (EMR) Strategy to Promote Patient Medication Understanding and Use|Medtable: An Electronic Medical Record (EMR) Strategy to Promote Patient Medication Understanding and Use|Completed||N/A|674|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||||2018-05-31 22:52:23.40904|2018-05-31 22:52:23.40904
NCT01296620|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2012-07-25|2011-02-14|2011-02-15|Estimate|||||||2012-07-25|2012-07-26|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Ulimorelin Study of Efficacy and Safety (ULISES 008)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection|Completed||Phase 3|330|Actual|Tranzyme, Inc.||3|||f||||||||||||||2018-05-31 22:52:23.507286|2018-05-31 22:52:23.507286
NCT01296607|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-08-31|2011-02-14|2011-02-15|Estimate|||||||2011-08-31|2011-09-02|Estimate|February 2011||2011-02-28|August 2011|2011-08-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers - Protocol 4|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-05-31 22:52:23.630046|2018-05-31 22:52:23.630046
NCT01296594|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-07-23|2011-02-14|2011-02-15|Estimate|||||||2013-07-23|2013-07-24|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Improving Antihypertensive Medication Adherence|Improving Antihypertensive Medication Adherence|Completed||Phase 1|30|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 22:52:24.464674|2018-05-31 22:52:24.464674
NCT01296581|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2017-11-21|2011-02-14|2011-02-15|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2011||2011-02-28|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety Study of X-82 in Patients With Advanced Solid Tumors|Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors|Completed||Phase 1|52|Actual|Tyrogenex||1|||f||||f||||||||||2018-05-31 22:52:24.523406|2018-05-31 22:52:24.523406
NCT01296568|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2012-04-26|2011-02-14|2011-02-15|Estimate|||||||2012-04-26|2012-04-27|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors|Disposition of [14C]LY2603618 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumors|Completed||Phase 1|12|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:52:24.579072|2018-05-31 22:52:24.579072
NCT01296555|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2018-05-30|2011-02-14|2011-02-15|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 16, 2011|Actual|2011-03-16|May 2018|2018-05-31|November 23, 2022|Anticipated|2022-11-23|November 23, 2022|Anticipated|2022-11-23||Interventional|||A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer|An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer|Recruiting||Phase 1|724|Anticipated|Genentech, Inc.||6|||f|||||t|f||||||||2018-05-31 22:52:24.670412|2018-05-31 22:52:24.670412
NCT01296542|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-07-11|2011-02-14|2011-02-15|Estimate|||||||2011-07-11|2011-07-13|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Observational|||A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery|A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification|Unknown status|Recruiting||60|Anticipated|Bucci Laser Vision Institute|||2||f||||t||||||||||2018-05-31 22:52:24.897261|2018-05-31 22:52:24.897261
NCT01296529|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-12-11|2011-02-14|2011-02-15|Estimate|||||||2012-12-11|2012-12-12|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Observational|||Study on Immunopathogenesis in HIV and Hepatitis C Coinfection|A Pilot Study on Immunopathogenesis in HIV and Hepatitis C Coinfection|Completed|||59|Actual|Rush University Medical Center|||4||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 22:52:24.9717|2018-05-31 22:52:24.9717
NCT01296516|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2018-05-23|2011-02-14|2011-02-15|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2011||2011-02-28|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|PRIDE||Postpartum Weight Loss and Exercise (PRIDE)|Early Postpartum Treatment of Gestational Diabetes With Weight Loss and Exercise|Completed||N/A|7|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 22:52:25.058543|2018-05-31 22:52:25.058543
NCT01296503|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-02-14|2011-02-14|2011-02-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|October 2003||2003-10-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|July 2008|Actual|2008-07-31||Interventional|||Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma|Thalidomide Plus Dexamethasone as Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: a Multicenter Phase 3 Randomized Trial|Completed||Phase 3|213|Actual|Grupo de Estudos Multicentricos em Onco-Hematologia||2|||f||||t||||||||||2018-05-31 22:52:25.139871|2018-05-31 22:52:25.139871
NCT01296490|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-12-31|2011-02-13|2011-02-15|Estimate|||||||2013-12-31|2014-01-01|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Physical Fitness Effect on the Different Oxidative Stress Measurements|Assessing Physical Fitness Effect on the Different Oxidative Stress Measurements, at Rest and After Acute Exercise|Completed||N/A|32|Actual|Wingate Institute||1|||f||||f||||||||||2018-05-31 22:52:25.224391|2018-05-31 22:52:25.224391
NCT01296477|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2016-01-04|2011-02-14|2011-02-15|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|AIQ||To Evaluate the Use of ASTHMA IQ in a Primary Care Setting|Examination of ASTHMA IQ to Improve Patient Outcomes in a Primary Care Setting|Completed|||375|Actual|American Academy of Family Physicians|||2||f||||||||||||||2018-05-31 22:52:25.300116|2018-05-31 22:52:25.300116
NCT01296464|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-09-09|2011-02-14|2011-02-15|Estimate|||||||2011-09-09|2011-09-12|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PARTEST||Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens|Duration of Motor Response After Administration of Experimental Levodopa/Carbidopa/Entacapone Treatment Regimens Compared to Standard Treatment (Stalevo®);a Randomised,Double-blind,Crossover,Multicentre,Single Dose Study in Patients With Parkinson?s Disease and Wearing-off Symptoms|Completed||Phase 2|27|Anticipated|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 22:52:25.358962|2018-05-31 22:52:25.358962
NCT01296451|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-04-24|2011-02-14|2011-02-15|Estimate|||||||2016-04-24|2016-04-26|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study of a New MVA Vaccine for Hepatitis C Virus|A Phase I Study to Assess the Safety and Immunogenicity of AdCh3NSmut and MVA-NSmut in Healthy Volunteers and Patients With Hepatitis C Virus Infection|Completed||Phase 1|55|Actual|ReiThera Srl||10|||f||||t||||||||||2018-05-31 22:52:25.433618|2018-05-31 22:52:25.433618
NCT01296438|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2015-02-20|2011-02-14|2011-02-15|Estimate|||||||2015-02-20|2015-02-23|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1|A Randomised Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Type 1 Diabetes|Completed||Phase 1|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:52:25.513464|2018-05-31 22:52:25.513464
NCT01296425|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2017-12-22|2011-02-14|2011-02-15|Estimate|||||||2017-12-22|2017-12-26|Actual|July 31, 2011|Actual|2011-07-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS AUT||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Austria|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Austria|Completed|||50|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 22:52:25.575508|2018-05-31 22:52:25.575508
NCT01296412|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2013-02-05||2017-05-09|2011-02-14|2011-02-15|Estimate|2013-02-05|2013-03-15|Estimate||||2017-05-09|2017-06-09|Actual|March 11, 2011|Actual|2011-03-11|May 2017|2017-05-31|February 29, 2012|Actual|2012-02-29|February 29, 2012|Actual|2012-02-29||Interventional|||Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)|A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|653|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:52:25.65388|2018-05-31 22:52:25.65388
NCT01296399|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-13|||2011-02-14|2011-02-14|2011-02-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|January 2000||2000-01-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||In-stent Restenosis in Patients With Patent Previous Bare Metal Stent|The Rate of In-stent Restenosis Within Bare Metal Stents as Compared to Drug Eluting Stents in Patients With Patent Previously Deployed Bare Metal Stent|Completed|||300|Actual|Rambam Health Care Campus|||2||f||||f||||||||||2018-05-31 22:52:26.066639|2018-05-31 22:52:26.066639
NCT01296386|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-09-24|2011-02-14|2011-02-15|Estimate|||||||2014-09-24|2014-09-25|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84|An Open-label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC84, a New Vaccine Against Clostridium Difficile, in Healthy Subjects|Completed||Phase 1|82|Actual|Valneva Austria GmbH||4|||f||||t||||||||||2018-05-31 22:52:26.193394|2018-05-31 22:52:26.193394
NCT01296373|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-13|||2013-12-17|2011-02-14|2011-02-15|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Observational|RESTORE||A Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection|An Observational Study to Explore Reconstitution of Immunity in Patients With Advanced HIV-1-infection Commencing Combination Antiretroviral Therapy (HIVNAT 136 RESTORE Study:Thailand)|Completed|||53|Actual|Kirby Institute|||1||f||||f||||||Samples With DNA|"~     serum, plasma, PBMC and DNA will be stored for 10 years total.~   "|||2018-05-31 22:52:26.268583|2018-05-31 22:52:26.268583
NCT01296360|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2014-12-10||2014-12-10|2011-02-14|2011-02-15|Estimate|2014-12-10|2014-12-19|Estimate||||2014-12-10|2014-12-19|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|November 2011|Actual|2011-11-30||Interventional||Safety Population: subjects who entered into the study and were randomized|Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country|Long-Term Immunity and Safety With or Without a Booster Dose Following Primary Vaccination With the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population in a JEV-Endemic Country. Open-Label, Randomized, Phase 3 Study|Completed||Phase 3|300|Actual|Valneva Austria GmbH||2|||f||||f||||||||||2018-05-31 22:52:26.349701|2018-05-31 22:52:26.349701
NCT01296347|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2016-12-07||2017-03-03|2011-02-14|2011-02-15|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|April 2011||2011-04-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Low Dose Peri-operative IV Ketamine for Chronic Post-surgery Pain Prevention|A Double-blind, Randomised Placebo-controlled Trial to Determine Whether Low-dose Intravenous Ketamine Peri-operatively Can Prevent Chronic Post-surgical Pain, in Patients Undergoing Thoracotomy or Video Assisted Thoracic Surgery (VATS)|Completed||Phase 4|104|Actual|Imperial College Healthcare NHS Trust||2|||f||||t||||||||Undecided||2018-05-31 22:52:26.602755|2018-05-31 22:52:26.602755
NCT01296334|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2016-11-23|2011-02-14|2011-02-15|Estimate|||||||2016-11-23|2016-11-28|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|PASORII||Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine|Analgesic and Antihyperalgesic Effects of Morphine and Buprenorphine Following an Experimental Inflammatory Injury in Volunteers.|Completed||N/A|34|Actual|University of Copenhagen||5|||f||||t||||||||||2018-05-31 22:52:26.846616|2018-05-31 22:52:26.846616
NCT01296321|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-02-15|2011-02-14|2011-02-15|Estimate|||||||2011-02-15|2011-02-16|Estimate|February 2010||2010-02-28|February 2011|2011-02-28|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|NOVA III||Tailored Internet-administrated Treatment of Panic Symptoms - A Randomised Controlled Trial|Tailored Internet-administrated Treatment of Panic Symptoms - A Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|57|Actual|Linkoeping University||2|||f||||||||||||||2018-05-31 22:52:26.925279|2018-05-31 22:52:26.925279
NCT01296308|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2012-07-16|2011-02-14|2011-02-15|Estimate|||||||2012-07-16|2012-07-17|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|CIT-DN||Complementary and Integrative Therapy for Diabetic Neuropathy|Effectiveness of a Complementary and Integrative Therapy in Diabetic Neuropathy Patients.|Completed|||6|Actual|Universität Duisburg-Essen|||1||f||||t||||||||||2018-05-31 22:52:27.012954|2018-05-31 22:52:27.012954
NCT01296295|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2011-02-13|2011-02-13|2011-02-15|Estimate|||||||2011-02-13|2011-02-15|Estimate|January 2005||2005-01-31|February 2011|2011-02-28|March 2011|Anticipated|2011-03-31|December 2010|Actual|2010-12-31||Interventional|ESPIROTAB||Effectiveness of Regular Reporting of Spirometric Results on Smoking Quit Rate.|Effectiveness of Regular Reporting of Spirometric Results Combined With a Smoking Cessation Advice by a Primary Care Physician on Smoking Quit Rate in Adult Smokers: a Randomized Controlled Trial.|Unknown status|Active, not recruiting|N/A|466|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 22:52:27.080963|2018-05-31 22:52:27.080963
NCT01296282|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-13|||2011-02-13|2011-02-13|2011-02-15|Estimate|||||||2011-02-13|2011-02-15|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Comparison Between Internal and External Chest Impedance Measurement||Unknown status|Not yet recruiting||50|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 22:52:27.145699|2018-05-31 22:52:27.145699
NCT01296269|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2011-04-07|2011-02-14|2011-02-15|Estimate|||||||2011-04-07|2011-04-08|Estimate|April 2011||2011-04-30|April 2011|2011-04-30||||May 2012|Anticipated|2012-05-31||Interventional|||Effects of Intranasal Oxytocin and Vasopressin on Social Behavior|Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls|Unknown status|Recruiting|N/A|150|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 22:52:27.201445|2018-05-31 22:52:27.201445
NCT01296256|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-13|||2016-02-15|2011-02-14|2011-02-15|Estimate|||||||2016-02-15|2016-02-17|Estimate|May 2011||2011-05-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BeEAM2010-01||Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL).|Bendamustine, Cytarabine, Etoposide and Melphalan as Conditioning for Autologous Stem Cell Transplant in Patients With Aggressive Non Hodgkin's Lymphoma.|Completed||Phase 2|60|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||||2018-05-31 22:52:27.277702|2018-05-31 22:52:27.277702
NCT01296243|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2012-07-20|2011-02-14|2011-02-15|Estimate|||||||2012-07-20|2012-07-24|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|February 2015|Anticipated|2015-02-28|August 2012|Anticipated|2012-08-31||Interventional|||Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer|A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer|Unknown status|Recruiting|Phase 2|57|Anticipated|Genta Incorporated||1|||f||||f||||||||||2018-05-31 22:52:27.365314|2018-05-31 22:52:27.365314
NCT01296230|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-05-23|2011-02-14|2011-02-15|Estimate|||||||2013-05-23|2013-05-24|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Varicocelectomy: Can Sex-hormones Predict Improvements in Semen Quality?|Varicocelectomy: Can Sex-hormones Predict Improvements in Semen Quality?|Terminated||N/A|3|Actual|Copenhagen University Hospital at Herlev||1||Failure to recruit participants|f||||f||||||||||2018-05-31 22:52:27.517135|2018-05-31 22:52:27.517135
NCT01296217|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-03-03|2011-02-14|2011-02-15|Estimate|||||||2011-03-03|2011-03-04|Estimate||||February 2011|2011-02-28||||||||Interventional|||Sentinel Lymph Node Detection in Prostate Surgery by Laparoscopy|"Evaluation of the Sentinel Lymph Node Technic of the Prostate by Laparoscopy"|Completed||N/A|24|Anticipated|Centre René Gauducheau||1|||f||||f||||||||||2018-05-31 22:52:27.575939|2018-05-31 22:52:27.575939
NCT01296204|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-03-21|2011-02-14|2011-02-15|Estimate|||||||2011-03-21|2011-03-22|Estimate||||February 2011|2011-02-28||||||||Interventional|BB4||Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131|Phase I of Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131|Completed||Phase 1|33||Centre René Gauducheau||1|||f||||f||||||||||2018-05-31 22:52:27.632659|2018-05-31 22:52:27.632659
NCT01296191|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-07-11|2011-02-14|2011-02-15|Estimate|||||||2011-07-11|2011-07-13|Estimate|May 2011||2011-05-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification|Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification|Unknown status|Recruiting|Phase 4|120|Anticipated|Bucci Laser Vision Institute||2|||f||||f||||||||||2018-05-31 22:52:27.703619|2018-05-31 22:52:27.703619
NCT01296178|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2017-10-25|2011-02-14|2011-02-15|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2010||2010-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years|PROTOCOL FOR First Line TREATMENT ADAPTED TO RISK of Acute Myeloblastic Leukemia in Patients LESS THAN OR EQUAL TO 65 YEARS|Recruiting||N/A|200|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-05-31 22:52:27.794677|2018-05-31 22:52:27.794677
NCT01296165|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2014-12-01|2011-02-14|2011-02-15|Estimate|||||||2014-12-01|2014-12-03|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||International Travel and the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli|The Importance of International Travel in the Spread of Extended-spectrum Beta-lactamase-producing Escherichia Coli|Completed|||173|Actual|University of Calgary|||1||f||||t||||||Samples With DNA|"~     Stool specimens~   "|||2018-05-31 22:52:27.871225|2018-05-31 22:52:27.871225
NCT01296152|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2015-09-28||2015-11-18|2011-02-14|2011-02-15|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||All participants enrolled.|Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women|An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/Ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women|Completed||Phase 2|25|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-05-31 22:52:27.974747|2018-05-31 22:52:27.974747
NCT01296139|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-12|||2018-02-13|2011-02-12|2011-02-15|Estimate|||||||2018-02-13|2018-02-14|Actual|January 26, 2011||2011-01-26|March 19, 2015|2015-03-19|March 19, 2015|Actual|2015-03-19|March 19, 2015|Actual|2015-03-19||Interventional|||Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer|Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer|Completed||Phase 1|21|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:52:28.427301|2018-05-31 22:52:28.427301
NCT01296126|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-12|||2018-05-23|2011-02-12|2011-02-15|Estimate|||||||2018-05-23|2018-05-24|Actual|January 26, 2011||2011-01-26|February 3, 2014|2014-02-03|February 3, 2014||2014-02-03|||||Observational|||Structural and Functional Neuroimaging Studies of Combat Veterans|Structural and Functional Neuroimaging Studies of Combat Veterans|Completed|||81|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:52:28.496713|2018-05-31 22:52:28.496713
NCT01296113|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2017-09-19|2011-02-12|2011-02-15|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2011||2011-05-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|January 2016|Actual|2016-01-31||Interventional|CHIVA||Chemotherapy for Lung Cancer in HIV-positive Patients|Phase II Trial Evaluating the Efficacy and Safety of Carboplatin Plus Pemetrexed in Human Immunodeficiency Virus Positive (HIV+) Patients With Stage III (Not Amenable to Radiation or Inoperable) or Stage IV Nonsquamous Non Small Cell Lung Cancer|Completed||Phase 2|62|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||1|||f||||f||||||||||2018-05-31 22:52:28.562747|2018-05-31 22:52:28.562747
NCT01296100|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-12|||2016-07-25|2011-02-14|2011-02-15|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2011||2011-02-28|July 2016|2016-07-31|March 2015|Actual|2015-03-31|January 2013|Actual|2013-01-31||Interventional|DEMOJUAN||DEMOJUAN- DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia|DEMOnstration Area for Primary Prevention of Type 2 Diabetes, JUAN Mina and Barranquilla, Colombia|Completed||N/A|730|Actual|Centro de Investigacion Sanitaria||2|||f||||f||||||||Yes|The study group is ready to share the data in de-identified format once the main results have been reported or in case any journal may ask for the data to run a check.|2018-05-31 22:52:28.687741|2018-05-31 22:52:28.687741
NCT01296087|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11||2012-07-13|2013-09-03|2011-02-11|2011-02-15|Estimate||||2012-07-13|2012-07-23|Estimate|2013-09-03|2013-09-13|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||TC-6987 for the Treatment of Mild to Moderate Asthma|A Phase II Multicenter, Randomized, Double-Blind,Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma|Completed||Phase 2|203|Actual|Targacept Inc.||2|||f||||f||||||||||2018-05-31 22:52:28.768685|2018-05-31 22:52:28.768685
NCT01296074|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2017-10-17|2011-02-14|2011-02-15|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2011|Actual|2011-03-31|October 2017|2017-10-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|||Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response|The Perioperative Effect of Corticosteroid Prophylaxis on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response|Completed||N/A|30|Actual|Beijing Anzhen Hospital||1|||f||||t||||||||||2018-05-31 22:52:28.853135|2018-05-31 22:52:28.853135
NCT01296061|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2016-10-25|2011-02-14|2011-02-15|Estimate|||||||2016-10-25|2016-10-27|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|October 2016|Actual|2016-10-31||Observational|||Kidney Transplant Failure|Effect of Immunosuppressive Medication Use on Patient Outcomes Following Kidney Transplantation Failure|Terminated|||270|Actual|Ottawa Hospital Research Institute|||1|Funding ended.|f||||f||||||Samples Without DNA|"~     Class I and II HLA antibodies~   "|||2018-05-31 22:52:28.913983|2018-05-31 22:52:28.913983
NCT01296048|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-12|||2011-12-22|2011-02-12|2011-02-15|Estimate|||||||2011-12-22|2011-12-23|Estimate|November 2010||2010-11-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|GBA||Clinical Test for Transtek Glass Body Analyzer|Verify the Functions and Efficiency of Transtek Glass Body Analyzer, GBF-830, GBF-835, GBF-950, SA-15|Completed|||74|Actual|BTS International|||1||f||||f||||||||||2018-05-31 22:52:28.970435|2018-05-31 22:52:28.970435
NCT01296035|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2014-08-19||2015-07-28|2011-02-11|2011-02-15|Estimate|2015-07-28|2015-08-25|Estimate||||2015-07-28|2015-08-25|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|PanGem||Panitumumab and Gemcitabine in Relapsed Ovarian Cancer|A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.|Terminated||Phase 2|8|Actual|Women and Infants Hospital of Rhode Island|This study was terminated prematurely due to poor accrual. The outcome measures could not be analyzed due to the small number or participants.|1||Newer technologies available; poor accrual to study.|f||||t||||||||||2018-05-31 22:52:29.032206|2018-05-31 22:52:29.032206
NCT01296022|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-04-09|2011-02-14|2011-02-15|Estimate|||||||2018-04-09|2018-04-10|Actual|February 2011|Actual|2011-02-28|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PRAETORIAN||A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy|Randomized Trial to Study the Efficacy and Adverse Effects of the Subcutaneous and Transvenous Implantable Cardioverter Defibrillator (ICD) in Patients With a Class I or IIa Indication for ICD Without an Indication for Pacing|Active, not recruiting||N/A|850|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 22:52:29.251786|2018-05-31 22:52:29.251786
NCT01296009|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-02-14|2011-02-14|2011-02-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Effect of Traditional Chinese Medicine (TCM) on Embryo Implantation in In-vitro Fertilization (IVF) Patients|Effect of Traditional Chinese Medicine (TCM) on Embryo Implantation in In-vitro Fertilization (IVF) Patients|Unknown status|Recruiting|Phase 1|300|Anticipated|Wuhan University||1|||f||||t||||||||||2018-05-31 22:52:29.378554|2018-05-31 22:52:29.378554
NCT01295970|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2013-06-11|2011-02-11|2011-02-15|Estimate|||||||2013-06-11|2013-06-13|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|September 2018|Anticipated|2018-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Surgery Versus Radiosurgery for the Treatment of Single Brain Metastases|Feasibility of a Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Single Brain Metastases|Withdrawn||N/A|0|Actual|University Health Network, Toronto||2||Recruitment challenges|f||||t||||||||||2018-05-31 22:52:29.455741|2018-05-31 22:52:29.455741
NCT01295957|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-02-14|2011-02-14|2011-02-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||Alzheimer's Disease Reminiscence Quality of Life|Phase 4 Study of a Reminiscence Program to Improve Quality of Life of Alzheimer's Disease Long Term Care Residents Using a Randomized Controlled Trial|Completed||Phase 4|135|Actual|Universidad Nacional de Rosario||3|||f||||f||||||||||2018-05-31 22:52:29.531467|2018-05-31 22:52:29.531467
NCT01295944|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2017-11-22|2011-02-14|2011-02-15|Estimate|||||||2017-11-22|2017-11-24|Actual|October 21, 2015||2015-10-21|November 16, 2017|2017-11-16|July 1, 2020|Anticipated|2020-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Carboplatin and Bevacizumab for Recurrent Ependymoma|Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial|Recruiting||Phase 2|35|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:52:29.601389|2018-05-31 22:52:29.601389
NCT01295931|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2015-10-05|2011-02-11|2011-02-15|Estimate|||||||2015-10-05|2015-10-07|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Nuclear and Near-Infrared (NIR) Imaging in Melanoma|Diagnostic Nodal Staging for Melanoma With Nuclear and Near-Infrared (NIR) Molecular Optical Imaging|Completed||Phase 1|20|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:52:29.677665|2018-05-31 22:52:29.677665
NCT01295918|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-09-07|2011-02-14|2011-02-15|Estimate|||||||2013-09-07|2013-09-10|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|AADreuter||Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children|Efficacy of the Probiotic Lactobacillus Reuteri in Prevention of Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children and Adolescents|Completed||Phase 3|100|Actual|St Marina University Hospital, Varna, Bulgaria||2|||f||||t||||||||||2018-05-31 22:52:29.752084|2018-05-31 22:52:29.752084
NCT01295905|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|2012-04-18||2012-06-26|2011-02-11|2011-02-15|Estimate|2012-05-18|2012-06-20|Estimate||||2012-06-26|2012-07-10|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Prospective Study of an Investigational Daily Disposable Contact Lens||Completed||N/A|90|Actual|Alcon Research||2|||f||||||||||||||2018-05-31 22:52:29.832242|2018-05-31 22:52:29.832242
NCT01295892|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2013-04-17|2011-02-14|2011-02-15|Estimate|||||||2013-04-17|2013-04-18|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Chronic Effects of Estrogen in Microcirculation|Chronic Effects of Estrogen in Microcirculation and Insulin Resistance in Postmenopausal Obese Women|Completed||Phase 4|44|Actual|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 22:52:30.020089|2018-05-31 22:52:30.020089
NCT01295879|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2012-09-10||2012-09-10|2011-02-14|2011-02-15|Estimate|2012-09-10|2012-10-23|Estimate||||2012-09-10|2012-10-23|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Vitamin D Repletion in Stone Formers With Hypercalciuria|Effect of Ergocalciferol Repletion on Urine Calcium Among Stone Formers With Vitamin D Deficiency and Hypercalciuria|Completed||Phase 4|30|Actual|New York Presbyterian Hospital||1|||f||||f||||||||||2018-05-31 22:52:30.09371|2018-05-31 22:52:30.09371
NCT01295866|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-14|2011-02-14|2011-02-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Observational|||Evaluation Effects of Nasal Nitric Oxide Measurements Are Associated With Atopy Status in Chronic Nasal Inflammation||Completed|||131|Actual|Beijing Tongren Hospital|||1||f||||t||||||||||2018-05-31 22:52:30.233962|2018-05-31 22:52:30.233962
NCT01295853|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-02-14|2011-02-14|2011-02-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||T3 Versus T4 Sympathicotomy for Treatment of Primary Palmar Hyperhidrosis|T3 Versus T4 Sympathicotomy for Treatment of Primary Palmar Hyperhidrosis: a Prospective Randomized Study|Completed||N/A|136|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 22:52:30.309434|2018-05-31 22:52:30.309434
NCT01295840|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2014-06-06||2015-03-05|2011-02-10|2011-02-15|Estimate|2015-03-05|2015-03-06|Estimate||||2015-03-05|2015-03-06|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|QUARTO||Quartet Lead and Resynchronization Therapy Options|QUARTET LEAD AND RESYNCHRONIZATION THERAPY OPTIONS To Investigate the Stimulatory Possibilities Offered by the Different Configurations Available for the Quartet Lead and Their Effect on Haemodynamic and Clinical Response.|Completed||Phase 4|51|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 22:52:30.396022|2018-05-31 22:52:30.396022
NCT01295827|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-03-15|2011-02-14|2011-02-15|Estimate|||||||2018-03-15|2018-03-16|Actual|March 4, 2011|Actual|2011-03-04|March 2018|2018-03-31|October 8, 2018|Anticipated|2018-10-08|July 2, 2018|Anticipated|2018-07-02||Interventional|KEYNOTE-001||Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)|Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)|Active, not recruiting||Phase 1|1260|Actual|Merck Sharp & Dohme Corp.||12|||f||||f|t|f||||||||2018-05-31 22:52:30.625803|2018-05-31 22:52:30.625803
NCT01295814|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|2013-07-20||2015-07-12|2011-02-14|2011-02-15|Estimate|2015-07-12|2015-07-16|Estimate||||2015-07-12|2015-07-16|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Efficacy Study of Adalimumab to Treat Interstitial Cystitis|An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC)|Completed||Phase 3|43|Actual|ICStudy, LLC||2|||f||||t||||||||||2018-05-31 22:52:30.725237|2018-05-31 22:52:30.725237
NCT01295801|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2011-02-14|2011-02-14|2011-02-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|September 2011|Anticipated|2011-09-30|July 2011|Anticipated|2011-07-31||Observational|||Vitamin B6 on Relieving Linezolid-associated Cytopenias|The Effects and Mechanism of Vitamin B6 on Relieving Linezolid-associated Cytopenias|Unknown status|Recruiting||80|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||||||2018-05-31 22:52:31.001282|2018-05-31 22:52:31.001282
NCT01295788|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-14|||2017-07-11|2011-02-14|2011-02-15|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2011|Actual|2011-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|June 2014|Actual|2014-06-30||Interventional|||Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial)|Simultaneous vs Delayed Initiation of REAL-Time Continuous Glucose Monitoring in Children and Adolescents With Type 1 Diabetes Starting Insulin Pump Therapy|Active, not recruiting||N/A|144|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||Undecided||2018-05-31 22:52:31.055513|2018-05-31 22:52:31.055513
NCT01295775|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2012-11-05|2011-02-14|2011-02-15|Estimate|||||||2012-11-05|2012-11-06|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|DRESS||Diabetic Retinopathy Sulodexide Study|A Multicentre, Double-Blind, Randomised, Placebo Controlled Study of the Activity of Sulodexide in Diabetic Patients With Mild to Moderate Non-Proliferative Retinopathy|Completed||Phase 2|127|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 22:52:31.122979|2018-05-31 22:52:31.122979
NCT01295762|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2017-01-31|2011-02-11|2011-02-14|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2011|Actual|2011-05-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|March 2017|Anticipated|2017-03-31||Interventional|Immuneuro||Immunomonitoring of Children With Neuroblastoma|Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies|Active, not recruiting||N/A|35|Actual|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 22:52:31.183479|2018-05-31 22:52:31.183479
NCT01295749|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-07-02|2011-02-11|2011-02-14|Estimate|||||||2012-07-02|2012-07-03|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|FLOWERS||Effects of Laryngeal Tube Ventilation on no Flow Time During Out of Hospital Cardiac Arrest|Reduction of no Flow Time During Out of Hospital Cardiac Arrest by Using Laryngeal Tube for Airway Management by Nurses.|Completed||Phase 3|84|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 22:52:31.246048|2018-05-31 22:52:31.246048
NCT01295736|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2014-01-31|2011-02-11|2011-02-14|Estimate|||||||2014-01-31|2014-02-03|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SEDUCE||Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY|Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study|Completed||Phase 3|84|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 22:52:31.421918|2018-05-31 22:52:31.421918
NCT01295723|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-09-17|2011-02-11|2011-02-14|Estimate|||||||2012-09-17|2012-09-19|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|December 2021|Anticipated|2021-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)|Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)|Recruiting||N/A|200|Anticipated|St. Joseph Hospital of Orange||1|||f||||t||||||||||2018-05-31 22:52:31.555798|2018-05-31 22:52:31.555798
NCT01295710|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-05-13|2011-02-11|2011-02-14|Estimate|||||||2016-05-13|2016-05-16|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)|Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors|Unknown status|Active, not recruiting|Phase 3|260|Actual|Neovii Biotech||2|||f||||t||||||||||2018-05-31 22:52:31.690968|2018-05-31 22:52:31.690968
NCT01295697|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2012-03-07|2011-02-11|2011-02-14|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Study of EZN-2208 Pediatric Patients With Solid Tumors|A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors|Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Anticipated|Enzon Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:52:31.879787|2018-05-31 22:52:31.879787
NCT01295684|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cranberry Juice and Cardiovascular Disease|The Influence Of Cranberry Juice On Risk Factors For Cardiovascular Disease|Completed||N/A|60|Anticipated|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 22:52:31.970792|2018-05-31 22:52:31.970792
NCT01295671|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|2017-10-19||2018-02-27|2011-02-11|2011-02-14|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|February 2011||2011-02-28|February 2018|2018-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BASH III||Beverages and Societal Health|Sugar Sweetened Beverages And Cardiovascular Disease Risk|Completed||N/A|203|Actual|Boston Children’s Hospital||3|||f||||f||||||||No||2018-05-31 22:52:32.077047|2018-05-31 22:52:32.077047
NCT01295658|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2018-01-26|2011-02-11|2011-02-14|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2010|Actual|2010-05-31|January 2018|2018-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Cancer Survivor Registry: The Breast Cancer M.A.P. (Mind Affects the Physical) Project|Cancer Survivor Registry: The Breast Cancer M.A.P. (Mind Affects the Physical) Project|Completed|||3729|Actual|Cancer Support Community, Research and Training Institute, Philadelphia|||1||f||||f||||||||||2018-05-31 22:52:32.68991|2018-05-31 22:52:32.68991
NCT01295645|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-05-22|2011-02-11|2011-02-14|Estimate|||||||2018-05-22|2018-05-24|Actual|March 2011|Actual|2011-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis|A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:52:32.75183|2018-05-31 22:52:32.75183
NCT01295632|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-08-26|2011-02-11|2011-02-14|Estimate|||||||2015-08-26|2015-08-27|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)|Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer|Completed||Phase 1|65|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 22:52:32.827519|2018-05-31 22:52:32.827519
NCT01295619|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-11-25|2011-02-11|2011-02-14|Estimate|||||||2016-11-25|2016-11-28|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy|A Prospective, Open, Multi-center, Single-arm Study of the Performance and Safety of I-020805 in the Prevention of Cerebrospinal Fluid Leakage Following Elective Cranial Surgery|Completed||N/A|41|Actual|Kuros Biosurgery AG||1|||f||||f||||||||No||2018-05-31 22:52:32.903086|2018-05-31 22:52:32.903086
NCT01295606|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-12-12|2011-02-11|2011-02-14|Estimate|||||||2011-12-12|2011-12-13|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Cefazolin Pharmacokinetics: Elimination Clearance in Neonates|Cefazolin Pharmacokinetics: Elimination Clearance in Neonates|Completed||Phase 4|40|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:52:32.981994|2018-05-31 22:52:32.981994
NCT01295593|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2012-06-06|2011-02-11|2011-02-14|Estimate|||||||2012-06-06|2012-06-07|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)|Phase I-II Study of Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia (CLL) Patients|Unknown status|Recruiting|Phase 1/Phase 2|33|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 22:52:33.084044|2018-05-31 22:52:33.084044
NCT01295580|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2013-07-22|2011-02-11|2011-02-14|Estimate|||||||2013-07-22|2013-07-23|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|||Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis|Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis|Completed||Phase 3|350|Actual|Bioventus LLC||2|||f||||f||||||||||2018-05-31 22:52:33.165427|2018-05-31 22:52:33.165427
NCT01295567|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2013-01-08|2011-02-11|2011-02-14|Estimate|||||||2013-01-08|2013-01-10|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Interventional|||Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective Coronary Artery Bypass Grafting (CABG)?|Can Dipyridamole Induce Protection Against Ischemia and Reperfusion Injury in Patients Undergoing Elective CABG?|Completed||Phase 4|95|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 22:52:33.280225|2018-05-31 22:52:33.280225
NCT01295554|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-02-10|2011-02-11|2011-02-14|Estimate|||||||2012-02-10|2012-02-13|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|AngioIRMNative||Comparative Study of Non-enhanced Versus Contrast Enhanced MR Angiography in Peripheral Arterial Disease on a 3T MR Scanner.|Comparative Study of Non-enhanced Versus Contrast Enhanced MR Angiography in Peripheral Arterial Disease on a 3T MR Scanner.|Completed|||22|Actual|Rennes University Hospital|||1||f||||f||||||||||2018-05-31 22:52:33.350012|2018-05-31 22:52:33.350012
NCT01295541|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Early Progressive Mobility in the CVICU: Assessing Current Status|Early Progressive Mobility in the CVICU: Assessing Current Status|Completed|||10|Actual|Hill-Rom|||1||f||||f||||||||||2018-05-31 22:52:33.40767|2018-05-31 22:52:33.40767
NCT01295528|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Observational|BPM||Clinical Study of Blood Pressure Monitor in Conformance With the ANSI/AAMI SP10 Standard|Verify the functionS of BPM TMB-986 to Comply With ANSI/AAMI SP10|Completed|||95|Actual|BTS International|||1||f||||f||||||||||2018-05-31 22:52:33.464353|2018-05-31 22:52:33.464353
NCT01295515|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2017-10-18|2011-02-11|2011-02-14|Estimate|||||||2017-10-18|2017-10-19|Actual|February 11, 2011||2011-02-11|July 12, 2017|2017-07-12|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy|Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy|Completed||Phase 1/Phase 2|25|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:52:33.581914|2018-05-31 22:52:33.581914
NCT01295502|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2017-05-03|2011-02-11|2011-02-14|Estimate|||||||2017-05-03|2017-05-08|Actual|April 2011||2011-04-30|May 2017|2017-05-31||||December 2019|Anticipated|2019-12-31||Interventional|||Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer|A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes|Active, not recruiting||Phase 1|45|Anticipated|Gynecologic Oncology Group||1|||f||||||||||||||2018-05-31 22:52:33.650977|2018-05-31 22:52:33.650977
NCT01295489|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2018-05-21|2011-02-11|2011-02-14|Estimate|||||||2018-05-21|2018-05-22|Actual|March 2011||2011-03-31|May 2018|2018-05-31||||January 2018|Actual|2018-01-31||Observational|||Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma|Completed|||39|Anticipated|Gynecologic Oncology Group|||2||f||||||||||||||2018-05-31 22:52:33.786472|2018-05-31 22:52:33.786472
NCT01295476|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2016-05-16|2011-02-11|2011-02-14|Estimate|||||||2016-05-16|2016-05-18|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia|Biological Correlates With T-cell Acute Lymphoblastic Leukemia (T-ALL) Gene Expression and Clinical Outcome|Completed|||135|Anticipated|Children's Oncology Group|||||f||||||||||Samples With DNA|"~     Bone Marrow~   "|||2018-05-31 22:52:34.78|2018-05-31 22:52:34.78
NCT01295463|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2013-08-09|2011-02-11|2011-02-14|Estimate|||||||2013-08-09|2013-08-12|Estimate|December 2010||2010-12-31|February 2011|2011-02-28||||June 2012|Anticipated|2012-06-30||Observational|||Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer|Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center|Unknown status|Recruiting||96|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:52:34.850149|2018-05-31 22:52:34.850149
NCT01295450|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|April 2011||2011-04-30|February 2011|2011-02-28|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Study to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex|A Clinical Multicenter, Phase III, Randomized, Double-blind, Prospectively to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex in Stimulating the Appetite|Unknown status|Not yet recruiting|Phase 3|74|Anticipated|MDCPharma Produtos Farmaceuticos LTDA||2|||f||||t||||||||||2018-05-31 22:52:34.930261|2018-05-31 22:52:34.930261
NCT01295437|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|March 2003||2003-03-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2005|Actual|2005-01-31||Interventional|Lichtenstein||Comparison of Three Meshes in Lichtenstein Hernia Repair|A Single-surgeon Randomized Study Comparing Three Composite Meshes on Chronic Pain After Lichtenstein Hernia Repair in Local Anesthesia|Completed||N/A|300|Actual|Kuopio University Hospital||3|||f||||t||||||||||2018-05-31 22:52:35.00972|2018-05-31 22:52:35.00972
NCT01295424|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-01-30|2011-02-11|2011-02-14|Estimate|||||||2015-01-30|2015-02-02|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|FINNRESUSCI||Epidemiology and Cost-effectiveness of Out-Of-Hospital Cardiac Arrest in Finland|FinnResusci: Epidemiology and Cost-effectiveness of Out-Of-Hospital Cardiac Arrest in Finland|Completed|||2600|Actual|Kuopio University Hospital|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 22:52:35.078056|2018-05-31 22:52:35.078056
NCT01295411|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-04-27|2011-02-11|2011-02-14|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|September 2015|Anticipated|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia|Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia|Unknown status|Active, not recruiting|N/A|100|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:52:35.150688|2018-05-31 22:52:35.150688
NCT01295398|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2014-08-28|2011-02-11|2011-02-14|Estimate|||||||2014-08-28|2014-08-29|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|November 2014|Anticipated|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Influence of the Nebulizer on the Clinical Efficacy of Hypertonic Saline 3% in Children Aged Less Than 18 Months and Hospitalized With Acute Viral Bronchiolitis|Influence of the Nebulizer on the Clinical Efficacy of Hypertonic Saline 3% in Children Aged Less Than 18 Months and Hospitalized With Acute Viral Bronchiolitis|Unknown status|Active, not recruiting|N/A|168|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 22:52:35.229422|2018-05-31 22:52:35.229422
NCT01295385|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2015-04-20|2011-02-11|2011-02-14|Estimate|||||||2015-04-20|2015-04-22|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy|Contribution Of Nuclear Magnetic Resonance Imaging In The Study Of Diabetic Cardiomyopathy|Unknown status|Recruiting|N/A|25|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 22:52:35.380485|2018-05-31 22:52:35.380485
NCT01295372|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-11-07|2011-02-11|2011-02-14|Estimate|||||||2016-11-07|2016-11-08|Estimate|April 2011||2011-04-30|November 2016|2016-11-30||||October 2012|Actual|2012-10-31||Interventional|||Safety and Efficacy of Zicronapine in Patients With Schizophrenia|A 6-month, Randomised, Double-blind, Parallel-group, Risperidone-controlled, Fixed-dose Study Evaluating the Safety and Efficacy of Zicronapine in Patients With Schizophrenia|Completed||Phase 3|160|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 22:52:35.466082|2018-05-31 22:52:35.466082
NCT01295359|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-03-18|2011-02-11|2011-02-14|Estimate|||||||2011-03-18|2011-03-21|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Impact of a Hospital Physical Therapy Program on Chronic Obstructive Pulmonary Disease (COPD) Patients|Impact of a Hospital Physical Therapy Program on Exacerbated Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 22:52:35.609723|2018-05-31 22:52:35.609723
NCT01295346|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2017-08-07|2011-02-11|2011-02-14|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2011||2011-01-31|August 2017|2017-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Biomarkers of Mild and Moderate Traumatic Brain Injury|Biomarkers of Mild and Moderate Traumatic Brain Injury|Completed|||290|Actual|Banyan Biomarkers, Inc|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 22:52:35.722262|2018-05-31 22:52:35.722262
NCT01295333|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-04-20|2011-02-11|2011-02-14|Estimate|||||||2015-04-20|2015-04-22|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance|Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance|Completed||Phase 3|200|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 22:52:35.820512|2018-05-31 22:52:35.820512
NCT01295320|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|2017-05-11||2017-10-23|2011-02-11|2011-02-14|Estimate|2017-05-11|2017-10-05|Actual||||2017-10-23|2017-11-27|Actual|February 28, 2011|Actual|2011-02-28|October 2017|2017-10-31|June 20, 2013|Actual|2013-06-20|June 20, 2013|Actual|2013-06-20||Interventional|||Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects|Long Term Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Subjects|Completed||Phase 2|129|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:52:35.911686|2018-05-31 22:52:35.911686
NCT01295307|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2015-10-06|2011-02-11|2011-02-14|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|BRIDGE||Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 2|86|Actual|Technische Universität Dresden||1|||f||||||||||||||2018-05-31 22:52:36.168997|2018-05-31 22:52:36.168997
NCT01295294|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2014-11-02|2011-02-11|2011-02-14|Estimate|||||||2014-11-02|2014-11-04|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)|International, Prospective, Double-blind, 3-arm Comparative, Randomized, Placebo-controlled Phase IV Study on the Effect of Counseling and Either Tranexamic Acid or Mefenamic Acid or Placebo, on the Management of Bleeding/Spotting in Women Using the Levonorgestrel-releasing Intrauterine System (MIRENA) for Contraception.|Completed||Phase 4|187|Actual|Bayer||3|||f||||f||||||||||2018-05-31 22:52:36.250733|2018-05-31 22:52:36.250733
NCT01295281|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2013-11-22||2014-01-15|2011-02-11|2011-02-14|Estimate|2014-01-15|2014-03-03|Estimate||||2014-01-15|2014-03-03|Estimate|March 2011||2011-03-31|January 2014|2014-01-31||||May 2011|Actual|2011-05-31||Interventional|||Evaluation of a New Catheter Material for Intermittent Catheterization|A Prospective, Randomized, Cross-over Study - Evaluation of a New Catheter Material for Intermittent Catheterization|Completed||N/A|107|Actual|Wellspect HealthCare||2|||f||||f||||||||||2018-05-31 22:52:36.432732|2018-05-31 22:52:36.432732
NCT01295268|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-01-23|2011-02-10|2011-02-14|Estimate|||||||2017-01-23|2017-01-25|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study of Emu Oil vs. Placebo for Vulvar Pain in Women.|The Efficacy of Emu Oil vs. Placebo in Minimizing Vulvar Pain Levels in Women--A Randomized, Double Blinded, Placebo-Controlled Trial.|Terminated||N/A|1|Actual|William Beaumont Hospitals||2||enrollment volume due to placebo arm of trial|f||||f||||||||||2018-05-31 22:52:36.685636|2018-05-31 22:52:36.685636
NCT01295255|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|February 2009||2009-02-28|January 2011|2011-01-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|||Interaction Effect of Asthma and Aeroallergen Category on the Psychological Status in Allergic Rhinitis Patients||Completed|||524|Actual|Beijing Tongren Hospital|||||f||||||||||||||2018-05-31 22:52:36.75566|2018-05-31 22:52:36.75566
NCT01295242|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2013-11-15|2011-02-11|2011-02-14|Estimate|||||||2013-11-15|2013-11-19|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|WHIM||Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)|Natural History of HPV Infections in Mid-Adult Women|Completed|||409|Actual|University of Washington|||||f||||f||||||Samples With DNA|"~     Self-collected vaginal samples for HPV testing. Self-collected oral samples for HPV testing.~     Serum samples for HPV antibody testing.~   "|||2018-05-31 22:52:36.811107|2018-05-31 22:52:36.811107
NCT01295229|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2016-03-29|2011-02-11|2011-02-14|Estimate|||||||2016-03-29|2016-03-31|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2012|Actual|2012-06-30||Interventional|CROSSROADS||Calorie Reduction Or Surgery: Seeking Remission for Obesity And Diabetes|Feasibility, Efficacy, and Mechanisms of Surgical vs Medical Diabetes Treatment|Completed||N/A|43|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 22:52:36.876264|2018-05-31 22:52:36.876264
NCT01295216|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|2016-06-01||2017-03-20|2011-02-11|2011-02-14|Estimate|2017-03-20|2017-03-21|Actual||||2017-03-20|2017-03-21|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings|Mobile Health to Prevent Progression of Pre-hypertension in Latin American Urban Settings|Terminated||N/A|637|Actual|Institute of Nutrition of Central America and Panama||2||No significant change for the primary objective at 12 months|f||||f||||||||||2018-05-31 22:52:36.987483|2018-05-31 22:52:36.987483
NCT01295203|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Internet-based Physical Activity Intervention|Internet-based Physical Activity Intervention|Completed||Phase 3|12287|Actual|University of Southern Denmark||1|||f||||f||||||||||2018-05-31 22:52:37.348007|2018-05-31 22:52:37.348007
NCT01295190|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2014-05-21|2011-02-11|2011-02-14|Estimate|||||||2014-05-21|2014-05-22|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|PRISKIKO||Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass|Substitution of Propofol by Sevoflurane During Pediatric Cardiopulmonary Bypass: Effect on Metabolic Acidosis and Clinical Outcome|Completed|||200|Actual|University of Schleswig-Holstein|||2||f||||f||||||||||2018-05-31 22:52:37.433791|2018-05-31 22:52:37.433791
NCT01295177|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2011-02-10|2011-02-10|2011-02-14|Estimate|||||||2011-02-10|2011-02-14|Estimate|January 2004||2004-01-31|February 2011|2011-02-28|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|insulin||Topic Insulin Accelerates Wound Healing in Diabetes|Topic Insulin Accelerates Wound in Diabetes|Completed||Phase 1/Phase 2|22|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 22:52:37.54473|2018-05-31 22:52:37.54473
NCT01295164|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2017-03-01|2011-02-10|2011-02-14|Estimate|||||||2017-03-01|2017-03-03|Actual|October 2011||2011-10-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|VOPTICA||Measurement of High Order Aberrations in Late Stages Keratoconus|Feasibility of Measurement of High Order Aberrations in Late Stages Keratoconus by Using an Adaptive Optics Visual Simulator AOVIS-I|Terminated||N/A|28|Actual|University Hospital, Toulouse||4||Lack of recruitment|f||||f||||||||No||2018-05-31 22:52:37.686553|2018-05-31 22:52:37.686553
NCT01295151|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2016-11-01|2011-02-11|2011-02-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SWITCH||SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.|Randomised-controlled Trial of Switching to Alternative Tumour-necrosis Factor (TNF)-Blocking Drugs or Abatacept or Rituximab in Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug|Completed||Phase 4|122|Actual|University of Leeds||3|||f||||t||||||||||2018-05-31 22:52:37.779596|2018-05-31 22:52:37.779596
NCT01295138|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2011-02-22|2011-02-11|2011-02-14|Estimate|||||||2011-02-22|2011-02-23|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|July 2012|Anticipated|2012-07-31|February 2012|Anticipated|2012-02-29||Interventional|||Pilot Study of the Effect of Lactulose on Post Caesarean Section Constipation|Pilot Study of the Effect of Lactulose on Post Caesarean Section Constipation|Unknown status|Not yet recruiting|N/A|30|Anticipated|NHS Fife||2|||f||||f||||||||||2018-05-31 22:52:37.875877|2018-05-31 22:52:37.875877
NCT01295125|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-06-25|2011-02-11|2011-02-14|Estimate|||||||2012-06-25|2012-06-27|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|Davol||Comparative Study of Biologic Mesh Versus Repair With Component Separation.|Randomized Control Trial of Biologic Mesh (XenMATRIXTM) vs. Component Separation Alone in Contaminated Ventral Hernia Repair:a Pilot Study|Completed||Phase 4|9|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 22:52:37.997651|2018-05-31 22:52:37.997651
NCT01295112|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2017-08-03||2017-09-17|2011-02-11|2011-02-14|Estimate|2017-09-17|2017-10-18|Actual||||2017-09-17|2017-10-18|Actual|May 2011||2011-05-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion|Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion|Completed||Phase 2/Phase 3|68|Actual|Texas Retina Associates|Limitations of this study included the relatively small size of 68 eyes, however statistical analyses were robust,.|2|||f||||f||||||||||2018-05-31 22:52:38.108922|2018-05-31 22:52:38.108922
NCT01295099|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|January 2015|Anticipated|2015-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Keloid Scarring: Treatment and Pathophysiology|Keloid Scarring:A Randomized Clinical and Laboratory Based Study on the Treatment and Differentiation Factors of the Local Disease|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Queen Mary University of London||3|||f||||t||||||||||2018-05-31 22:52:38.654609|2018-05-31 22:52:38.654609
NCT01295086|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2015-01-20|2011-02-11|2011-02-14|Estimate|||||||2015-01-20|2015-01-21|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|January 2018|Anticipated|2018-01-31|November 2014|Actual|2014-11-30||Interventional|||Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer|Dose Determination of Taxotere®, Eloxatin® and Xeloda® (TEX)in Combination With Herceptin® as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV)|Unknown status|Recruiting|N/A|15|Anticipated|Odense University Hospital||1|||f||||f||||||||||2018-05-31 22:52:38.772302|2018-05-31 22:52:38.772302
NCT01295073|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-05-03|2011-02-10|2011-02-14|Estimate|||||||2018-05-03|2018-05-09|Actual||||May 2018|2018-05-31||||||||Interventional|||Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus|Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus|Withdrawn||Phase 2|0|Actual|University of British Columbia||2||appropriate study medication supply could not be identified|f||||f||||||||||2018-05-31 22:52:38.928425|2018-05-31 22:52:38.928425
NCT01295060|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10||2013-09-09|2013-09-17|2011-02-10|2011-02-14|Estimate||||2013-09-17|2013-09-20|Estimate|2013-09-17|2013-09-20|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly|PHASE IIIB, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AN 84-MG OCTREOTIDE SUBCUTANEOUS HYDROGEL IMPLANT IN SUBJECTS WITH ACROMEGALY|Terminated||Phase 3|12|Actual|Endo Pharmaceuticals||1||Program was terminated for business reasons|f||||f||||||||||2018-05-31 22:52:39.042028|2018-05-31 22:52:39.042028
NCT01295047|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|July 2006||2006-07-31|January 2006|2006-01-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Medical Therapies in Marfan Syndrome.|Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial|Completed||Phase 4|18|Actual|Cardiff University||3|||f||||t||||||||||2018-05-31 22:52:39.282618|2018-05-31 22:52:39.282618
NCT01295034|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2017-03-06||2017-03-06|2011-02-11|2011-02-14|Estimate|2017-03-06|2017-04-17|Actual||||2017-03-06|2017-04-17|Actual|March 2011||2011-03-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Vitamin D Supplements for HIV-positive Patients on cART|Vitamin D Supplements for HIV-positive Patients on cART|Completed||N/A|62|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||Undecided||2018-05-31 22:52:39.479172|2018-05-31 22:52:39.479172
NCT01295021|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-06-07|2011-02-10|2011-02-14|Estimate|||||||2013-06-07|2013-06-10|Estimate|February 2011||2011-02-28|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|SORT||The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.|A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.|Completed|||1514|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:52:39.89484|2018-05-31 22:52:39.89484
NCT01295008|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2016-01-12|2011-02-11|2011-02-14|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Androgenetic Alopecia in Fabry Disease|Androgenetic Alopecia in Fabry Disease|Completed|||107|Actual|Baylor Research Institute|||2||f||||f||||||||||2018-05-31 22:52:40.148095|2018-05-31 22:52:40.148095
NCT01294995|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ESTCTFLC||Effect of Short-term Chinese Tea-flavor Liquor Consumption|Phase 1 Study of Chinese Tea-flavor Liquor|Completed||Phase 1|45|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 22:52:40.261672|2018-05-31 22:52:40.261672
NCT01294982|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2013-01-22|2011-02-11|2011-02-14|Estimate|||||||2013-01-22|2013-01-23|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency|Phase II, Randomized, Double-blind, Placebo-controlled Trial of the AOBO-001 for the Treatment of Overactive Bladder With Symptoms of Urge Urinary Incontinence and Frequency|Completed||Phase 2|66|Actual|American Oriental Bioengineering, Inc.||3|||f||||f||||||||||2018-05-31 22:52:40.412584|2018-05-31 22:52:40.412584
NCT01294969|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2016-12-15|2011-02-11|2011-02-14|Estimate|||||||2016-12-15|2016-12-16|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Patient Perception Study for AL-4943A||Completed||Phase 4|47|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:52:40.548094|2018-05-31 22:52:40.548094
NCT01294956|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2016-11-17|2011-02-11|2011-02-14|Estimate|||||||2016-11-17|2016-11-18|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Clinical Evaluation of an Investigational Lubricant Eye Gel (FID 115958D)||Completed||N/A|147|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:52:40.624586|2018-05-31 22:52:40.624586
NCT01294943|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2012-08-14|2011-02-11|2011-02-14|Estimate|||||||2012-08-14|2012-08-15|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Observational|||Evaluating the Effectiveness of the Tongue Cleaner in Critical Patients|Evaluating the Effectiveness of the Tongue Cleaner in Patients Wholly or Partially Dependent Care|Completed|||50|Actual|University of Sao Paulo|||1||f||||t||||||Samples Without DNA|"~     tongue biofilm~   "|||2018-05-31 22:52:40.718574|2018-05-31 22:52:40.718574
NCT01294930|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2013-02-20|2011-02-11|2011-02-14|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|IOPC||Indicators of Operative and Postoperative Complications in Patients Operated for Hip Fracture|Indicators of Operative and Postoperative Complications in Patients Operated for Hip Fracture|Completed|||45|Actual|University Hospital, Linkoeping|||1||f||||f||||||None Retained|"~     Urine~   "|||2018-05-31 22:52:40.77701|2018-05-31 22:52:40.77701
NCT01294917|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2012-02-15||2017-01-20|2011-02-10|2011-02-14|Estimate|2012-04-12|2012-05-14|Estimate||||2017-01-20|2017-03-06|Actual|February 2011||2011-02-28|January 2017|2017-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of a New Abbott Medical Optics (AMO) Multi-Purpose Solution (MPS) to Existing Contact Lens Regimens|Comparison of a New AMO MPS to Existing Contact Lens Regimens|Completed||N/A|40|Actual|Abbott Medical Optics||3|||f||||f||||||||||2018-05-31 22:52:40.866017|2018-05-31 22:52:40.866017
NCT01294904|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|August 2016|Anticipated|2016-08-31|May 2014|Anticipated|2014-05-31||Observational|||Mechanisms of Infertility and Hormonal Changes in Patients With Chronic Kidney Disease|Studies of Infertility in Patients With Chronic Kidney Disease|Unknown status|Enrolling by invitation||100|Anticipated|Lund University|||4||f||||f||||||Samples Without DNA|"~     Samples are stored at SUS, Malmö, Sweden~   "|||2018-05-31 22:52:41.038201|2018-05-31 22:52:41.038201
NCT01294891|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2014-10-27|2011-02-11|2011-02-14|Estimate|||||||2014-10-27|2014-10-28|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease|Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease|Completed|||6|Actual|Oregon Health and Science University|||3||f||||t||||||||||2018-05-31 22:52:41.131937|2018-05-31 22:52:41.131937
NCT01294878|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|IComaliz||Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome|Explorative Study on the Use of Omalizumab in Patients Suffering From Interstitial Cystitis/Painful Bladder Syndrome|Completed||Phase 3|3|Actual|IRCCS Policlinico S. Matteo||1|||f||||t||||||||||2018-05-31 22:52:41.239489|2018-05-31 22:52:41.239489
NCT01294865|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-02-11|2011-02-11|2011-02-14|Estimate|||||||2011-02-11|2011-02-14|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Observational|suPAR||Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis|The Plasma Levels of suPAR in Late-onset Neonatal Sepsis|Unknown status|Active, not recruiting||120|Anticipated|Ankara University|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:52:41.326999|2018-05-31 22:52:41.326999
NCT01294852|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2011-06-21|2011-02-11|2011-02-14|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|||Comparison of Two Strategies for Surfactant Prophylaxis in Premature Infants|A Randomized Trial: Comparison of Two Strategies for Surfactant Prophylaxis in Premature Infants|Unknown status|Recruiting|N/A|100|Anticipated|Ankara University||2|||f||||f||||||||||2018-05-31 22:52:41.40671|2018-05-31 22:52:41.40671
NCT01294839|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2016-07-28|2011-02-10|2011-02-14|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RVOTCARE||Right Ventricular Outflow Tract Study|Right Ventricular Outflow Tract Septal Pacing for Cardiac Dysfunction Prevention Evaluation|Completed||N/A|380|Actual|St. Jude Medical||3|||f||||t||||||||||2018-05-31 22:52:41.658832|2018-05-31 22:52:41.658832
NCT01294826|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2015-06-04|2011-02-10|2011-02-14|Estimate|||||||2015-06-04|2015-06-08|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer|Phase IB With Expansion of Patients at the MTD Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer|Completed||Phase 1|20|Actual|Swedish Medical Center||1|||f||||f||||||||||2018-05-31 22:52:41.72407|2018-05-31 22:52:41.72407
NCT01294813|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-02-15|2011-02-10|2011-02-14|Estimate|||||||2011-02-15|2011-02-16|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|Broncho-EIT||Bronchoscopy and Electric Impedance Tomography (EIT) Pilot Study|Bronchoscopy and Electric Impedance Tomography to Investigate the Influence of Bronchoscopy on Pulmonary Regional Ventilation Measurements by Electric Impedance Tomography (EIT)|Unknown status|Recruiting|N/A|20|Anticipated|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 22:52:41.812845|2018-05-31 22:52:41.812845
NCT01294800|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2016-08-18||2016-11-03|2011-02-10|2011-02-14|Estimate|2016-08-18|2016-10-11|Estimate||||2016-11-03|2016-12-21|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All Randomized Participants|A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)|A Phase 2, 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Preladenant in Japanese Subjects With Moderate to Severe Parkinson's Disease. (Phase 2; Protocol No. P06402)|Completed||Phase 2|450|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-05-31 22:52:41.908701|2018-05-31 22:52:41.908701
NCT01294787|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2012-11-29||2013-03-19|2011-02-10|2011-02-11|Estimate|2013-03-19|2013-03-20|Estimate||||2013-03-19|2013-03-20|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|BRIGHT||Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.|Completed||Phase 3|85|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:52:42.589875|2018-05-31 22:52:42.589875
NCT01294774|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-03-20|2011-02-10|2011-02-11|Estimate|||||||2017-03-20|2017-03-22|Actual|February 2011||2011-02-28|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus|A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus|Completed||Phase 2|10|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:52:43.264|2018-05-31 22:52:43.264
NCT01294761|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2015-03-27|2011-02-10|2011-02-11|Estimate|||||||2015-03-27|2015-03-30|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|December 2013|Actual|2013-12-31|February 2012|Actual|2012-02-29||Interventional|SPARE||Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir|Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function|Completed||N/A|59|Actual|National Center for Global Health and Medicine, Japan||2|||f||||t||||||||||2018-05-31 22:52:43.364103|2018-05-31 22:52:43.364103
NCT01294748|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2014-02-06||2016-12-15|2011-02-10|2011-02-11|Estimate|2014-02-06|2014-03-26|Estimate||||2016-12-15|2017-02-08|Estimate|February 2011||2011-02-28|December 2016|2016-12-31|August 2016|Actual|2016-08-31|June 2012|Actual|2012-06-30||Interventional|DESSOLVE-II||Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease|Clinical Investigation of a DES (MiStent™ System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in Native Coronary Arteries.|Completed||Phase 2|184|Actual|Micell Technologies||2|||f||||t||||||||No||2018-05-31 22:52:43.474649|2018-05-31 22:52:43.474649
NCT01294735|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2012-08-14|2011-02-10|2011-02-11|Estimate|||||||2012-08-14|2012-08-15|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)|A Phase I Study of MK-4827 in Combination With Temozolomide in Patients With Advanced Cancer|Completed||Phase 1|19|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 22:52:44.017497|2018-05-31 22:52:44.017497
NCT01294722|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-03-18|2011-02-10|2011-02-11|Estimate|||||||2013-03-18|2013-03-19|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti‐Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea|The Prevalence of Out-patients With Rheumatoid Arthritis Fulfilling the Indication for Anti-tumor Necrosis Factor(TNFa) Therapy in General Hospital Setting in Korea: a Multi-center, Non-interventional, Observational Study|Completed|||1700|Actual|Janssen Korea, Ltd., Korea|||||f||||f||||||||||2018-05-31 22:52:44.0756|2018-05-31 22:52:44.0756
NCT01294709|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2014-09-03||2017-04-06|2011-02-10|2011-02-11|Estimate|2014-09-03|2014-09-10|Estimate||||2017-04-06|2017-05-12|Actual|February 12, 2008|Actual|2008-02-12|April 2017|2017-04-30|March 13, 2009|Actual|2009-03-13|February 28, 2009|Actual|2009-02-28||Interventional||All enrolled participants who received at least one dose of study drug.|A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)|A Double-Blind, Randomized, Placebo-Controlled, 2-Period Crossover Study to Assess the Safety, Tolerability, and Effects of MK-0974 on Exercise Tolerance in Patients With Stable Angina|Completed||Phase 1|64|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:52:44.138386|2018-05-31 22:52:44.138386
NCT01294696|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2014-01-21||2017-03-07|2011-02-10|2011-02-11|Estimate|2014-01-21|2014-03-04|Estimate||||2017-03-07|2017-04-04|Actual|October 2010||2010-10-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|SORT||Survey of Osteoarthritis Real World Therapies (MK-0663-140)|Survey of Osteoarthritis Real World Therapies (SORT)|Completed|||1261|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:52:44.47685|2018-05-31 22:52:44.47685
NCT01294683|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2016-06-09||2017-03-06|2011-02-10|2011-02-11|Estimate|2016-10-20|2016-12-13|Estimate||||2017-03-06|2017-04-04|Actual|February 2011||2011-02-28|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)|A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|Terminated||Phase 3|977|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:52:44.922143|2018-05-31 22:52:44.922143
NCT01294670|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2018-02-23|2011-02-10|2011-02-11|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2011|Actual|2011-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors|A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors|Active, not recruiting||Phase 1/Phase 2|27|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:52:45.577023|2018-05-31 22:52:45.577023
NCT01294657|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-02-15|2011-02-10|2011-02-11|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2011|Actual|2011-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Obesity: Cancer Risk Among African Americans|Obesity: Cancer Risk Among African Americans-Developing Interventions Through Community Collaboration|Active, not recruiting|||300|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||Samples Without DNA|"~     16 saliva samples to be collected for hormone testing.~   "|||2018-05-31 22:52:45.686779|2018-05-31 22:52:45.686779
NCT01294644|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2015-05-28||2015-05-28|2011-02-10|2011-02-11|Estimate|2015-05-28|2015-06-12|Estimate||||2015-05-28|2015-06-12|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Safety analysis set|Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat|Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|360|Actual|Kythera Biopharmaceuticals||3|||f||||f||||||||||2018-05-31 22:52:45.811461|2018-05-31 22:52:45.811461
NCT01294631|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2012-10-13|2011-02-10|2011-02-11|Estimate|||||||2012-10-13|2012-10-16|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers|An Open-Label, Two-Period, Fixed-Sequence Study to Explore the Effects of Multiple Doses of Hydrochlorothiazide on the Pharmacodynamics, Pharmacokinetics, and Safety of Multiple Doses of Canagliflozin in Healthy Subjects|Completed||Phase 1|30|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 22:52:46.403912|2018-05-31 22:52:46.403912
NCT01294618|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2014-08-25|2011-02-10|2011-02-11|Estimate|||||||2014-08-25|2014-08-26|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|September 2013|Actual|2013-09-30|March 2011|Actual|2011-03-31||Interventional|NILOPEG||Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia|"Phase II Multicenter Study Evaluating the Efficacy and the Safety of a Combination of Nilotinib Plus Pegylated Interferon Alpha 2a for de Novo Chronic Phase Chronic Myelogenous Leukemia Patients"|Completed||Phase 2|60|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 22:52:46.47131|2018-05-31 22:52:46.47131
NCT01294605|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2016-09-14|2011-02-10|2011-02-11|Estimate|||||||2016-09-14|2016-09-15|Estimate|April 2003||2003-04-30|September 2016|2016-09-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)|Double-blind, Randomized, Phase III Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of Three Consecutive Doses of dTpa, or of dTpa-IPV Followed by Two Doses of Td Vaccine , and Compared to Three Consecutive Doses of Td Vaccine Administered to Healthy Adults in a 0,1,6-month Schedule|Completed||Phase 4|460|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:52:46.541351|2018-05-31 22:52:46.541351
NCT01293838|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-02-10|2011-02-10|2011-02-11|Estimate|||||||2011-02-10|2011-02-11|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|CAP-E||Cipralex® for Anxiety Disorders in Adolescents|Cipralex® for Anxiety Disorders in Adolescents: Clinical and Physiological Changes Associated With Open Label, Flexible-dose Treatment|Unknown status|Recruiting|Phase 1|30|Anticipated|University of Ottawa|||||f||||t||||||||||2018-05-31 22:53:00.789927|2018-05-31 22:53:00.789927
NCT01294592|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2014-05-15||2016-10-24|2011-02-10|2011-02-11|Estimate|2014-05-15|2014-06-16|Estimate||||2016-10-24|2016-12-05|Estimate|December 2010||2010-12-31|October 2016|2016-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CONDUCT||Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement|Comparative Efficacy of Dutasteride Plus Tamulsoin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice With Step-up Therapy to Tamsulosin in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement.|Completed||Phase 4|742|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 22:52:46.689055|2018-05-31 22:52:46.689055
NCT01294579|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-03-17|2011-02-10|2011-02-11|Estimate|||||||2017-03-17|2017-03-20|Actual|May 17, 2011|Actual|2011-05-17|March 2017|2017-03-31|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|||Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)|A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) Which Has Relapsed After Rituximab or a Rituximab Containing Therapy|Completed||Phase 2|53|Actual|Novartis||1|||f||||f||||||||||2018-05-31 22:52:47.901601|2018-05-31 22:52:47.901601
NCT01294566|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-06-27|2011-02-10|2011-02-11|Estimate|||||||2017-06-27|2017-06-28|Actual|November 29, 2010|Actual|2010-11-29|June 2017|2017-06-30|March 23, 2011|Actual|2011-03-23|March 23, 2011|Actual|2011-03-23||Interventional|||FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers|A Randomized, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Asian Adult Subjects|Completed||Phase 1|17|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:52:48.067487|2018-05-31 22:52:48.067487
NCT01294553|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2011-02-17||2017-06-07|2011-02-10|2011-02-11|Estimate|2011-02-17|2011-03-15|Estimate||||2017-06-07|2017-07-07|Actual|June 2004||2004-06-30|February 2011|2011-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|AVANDAMETPMS||An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of Avandamet® Administered in Korean Diabetic Patients According to the Prescribing Information|Completed|||717|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 22:52:48.186167|2018-05-31 22:52:48.186167
NCT01294540|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-08-28|2011-02-10|2011-02-11|Estimate|||||||2013-08-28|2013-08-29|Estimate|December 2010||2010-12-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Doses of E2609 in Healthy Subjects and an Elderly Cohort|Completed||Phase 1|73|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 22:52:48.393972|2018-05-31 22:52:48.393972
NCT01294527|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2017-02-06|2011-02-10|2011-02-11|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2011||2011-02-28|February 2017|2017-02-28|October 2016|Actual|2016-10-31|April 2012|Actual|2012-04-30||Interventional|WiSE-CRT||Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy|Multicenter, Prospective Evaluation of Performance, Safety, and Surveillance of the WiCS-LV System in Patients Indicated for Cardiac Resynchronization Therapy|Completed||N/A|17|Actual|EBR Systems, Inc.||1|||f||||t||||||||||2018-05-31 22:52:48.464264|2018-05-31 22:52:48.464264
NCT01294514|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2012-05-02||2014-08-05|2011-02-10|2011-02-11|Estimate|2012-12-07|2013-01-10|Estimate||||2014-08-05|2014-08-07|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Observational||Healthy volunteers|Novel Non-Invasive Monitoring Parameter in Healthy Volunteers|Novel Cardio-Respiratory Parameter in Healthy Volunteers|Completed|||27|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-05-31 22:52:48.563927|2018-05-31 22:52:48.563927
NCT01294501|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2015-04-23|2011-02-10|2011-02-11|Estimate|||||||2015-04-23|2015-04-24|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Decreasing Medication Errors by Caregivers Using a Health Literacy Intervention|Decreasing Medication Errors by Caregivers Using a Health Literacy Intervention|Terminated||N/A|132|Actual|Columbia University||1||PI left the institution|f||||f||||||||||2018-05-31 22:52:48.699768|2018-05-31 22:52:48.699768
NCT01294488|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-05-07|2011-02-10|2011-02-11|Estimate|||||||2013-05-07|2013-05-08|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Using Technology to Augment the Implementation and Effectiveness of PCIT|Using Technology to Augment the Implementation and Effectiveness of PCIT|Completed||Phase 2|317|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 22:52:48.755715|2018-05-31 22:52:48.755715
NCT01294475|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-05-07|2011-02-10|2011-02-11|Estimate|||||||2013-05-07|2013-05-09|Estimate|May 2007||2007-05-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Preventing Child Maltreatment Through A Cellular-Phone Technology-Based Parenting Program|Preventing Child Maltreatment Through A Cellular-Phone Technology-Based Parenting Program|Completed||Phase 1/Phase 2|371|Actual|Centers for Disease Control and Prevention||1|||f||||t||||||||||2018-05-31 22:52:48.842468|2018-05-31 22:52:48.842468
NCT01294462|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2013-07-10|2011-02-23|2014-06-18|2011-02-10|2011-02-11|Estimate|2014-03-31|2014-05-02|Estimate|2011-03-15|2011-03-25|Estimate|2014-06-18|2014-06-27|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||One discontinued patient (due to withdrawal of consent) in Ticagrelor (AZD6140) group did not agree to disclose any data. Thus the number of baseline participants in Ticagrelor (AZD6140) group is 400 instead of 401 that is the number of participants who started the first period.|Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)|A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned|Completed||Phase 3|801|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 22:52:48.929875|2018-05-31 22:52:48.929875
NCT01293266|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-03-10|2011-02-09|2011-02-10|Estimate|||||||2011-03-10|2011-03-11|Estimate|June 2009||2009-06-30|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|PRISCATHLAB||Effect of Propofol and Sevoflurane on Lactate During Anesthesia for Pediatric Heart Catheterisation|Effect of Propofol and Sevoflurane on Base Excess, pH and Lactate in Pediatric Heart Catheterisation|Completed||N/A|40|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 22:53:05.292309|2018-05-31 22:53:05.292309
NCT01294449|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2014-08-25||2014-12-03|2011-02-10|2011-02-11|Estimate|2014-12-03|2014-12-04|Estimate||||2014-12-03|2014-12-04|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|MADIT-CRT PAR|All subjects enrolled into the Reigstry were previous participants in the MADIT-CRT trial, the baseline characteristics did not pertain to the entry into the Registry.|Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry|Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry|Completed|||394|Actual|Boston Scientific Corporation|||2||f||||f||||||||||2018-05-31 22:52:50.515076|2018-05-31 22:52:50.515076
NCT01294436|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2013-07-10||2013-11-22|2011-02-10|2011-02-11|Estimate|2013-07-10|2013-09-16|Estimate||||2013-11-22|2013-12-17|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||The safety analysis set included all subjects who received at least one dose of study medication and who provided any safety records.|Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus|A Long Term Open Label Study to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy or Combination Therapies With Anti-diabetic Drugs in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 3|728|Actual|AstraZeneca|In the efficacy analysis, for participants who did not complete 52-week treatment period LOCF (last observation carried forward) was used.|1|||f||||||||||||||2018-05-31 22:52:51.066199|2018-05-31 22:52:51.066199
NCT01294423|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2013-01-30|2011-05-09|2014-07-17|2011-02-10|2011-02-11|Estimate|2013-07-19|2013-08-23|Estimate|2011-05-09|2011-05-13|Estimate|2014-07-17|2014-07-24|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus|A 24-week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 3|261|Actual|AstraZeneca|For participants who did not complete 24 weeks LOCF (last observation carried forward) was used. Only values prior to rescue medication were used for outcome measures except for total body weight which was evaluated regardless of rescue.|3|||f||||f||||||||||2018-05-31 22:52:51.656289|2018-05-31 22:52:51.656289
NCT01294410|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2015-06-24|2011-02-10|2011-02-11|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis|A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With BMS-936557 in Subjects With Active Ulcerative Colitis (UC)|Completed||Phase 2|305|Actual|Bristol-Myers Squibb||5|||f||||t||||||||||2018-05-31 22:52:52.110144|2018-05-31 22:52:52.110144
NCT01294397|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2016-12-14||2017-04-05|2011-02-10|2011-02-11|Estimate|2017-04-05|2017-06-20|Actual||||2017-04-05|2017-06-20|Actual|March 2011||2011-03-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Denosumab on the Pharmacokinetics of Etanercept|The Effects of Denosumab on the Pharmacokinetics of Etanercept in Postmenopausal Women With Low Bone Mineral Density and Rheumatoid Arthritis|Terminated||Phase 1|19|Actual|Amgen||1||Lack of enrollment.|f||||||||||||||2018-05-31 22:52:52.393068|2018-05-31 22:52:52.393068
NCT01294384|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2013-09-24||2013-09-24|2011-02-10|2011-02-11|Estimate|2013-09-24|2013-11-25|Estimate||||2013-09-24|2013-11-25|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease||Completed||Phase 3|305|Actual|Allergan||3|||f||||f||||||||||2018-05-31 22:52:52.731259|2018-05-31 22:52:52.731259
NCT01294371|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2013-05-10||2013-05-10|2011-02-10|2011-02-11|Estimate|2013-05-10|2013-07-22|Estimate||||2013-05-10|2013-07-22|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin)|Prospective, Multi-Center, Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Gonadoliberin Agonist Lucrin Depot.|Completed|||391|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:52:53.208436|2018-05-31 22:52:53.208436
NCT01294358|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-10-05|2011-02-10|2011-02-11|Estimate|||||||2017-10-05|2017-10-06|Actual|January 26, 2011||2011-01-26|August 20, 2015|2015-08-20|July 23, 2014|Actual|2014-07-23|July 23, 2014|Actual|2014-07-23||Interventional|||Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial|Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial|Completed||Phase 1|7|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:52:53.472631|2018-05-31 22:52:53.472631
NCT01294345|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-03-27|2011-02-10|2011-02-11|Estimate|||||||2018-03-27|2018-03-29|Actual|February 10, 2011||2011-02-10|October 4, 2017|2017-10-04||||||||Observational|||Personalized Genomic Research|Personalized Genomic Research|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:52:53.552399|2018-05-31 22:52:53.552399
NCT01294332|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-05-18|2011-02-10|2011-02-11|Estimate|||||||2018-05-18|2018-05-21|Actual|May 26, 2011||2011-05-26|October 2, 2017|2017-10-02|February 11, 2014|Actual|2014-02-11|December 31, 2013|Actual|2013-12-31||Interventional|||Effect of Aerobic Exercise Training on Cardiorespiratory Function in Patients With Traumatic Brain Injury|Effect of Aerobic Exercise Training on Cardiorespiratory Function in Patients With Traumatic Brain Injury|Completed||Phase 1/Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:52:53.634936|2018-05-31 22:52:53.634936
NCT01294319|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2017-08-11||2017-10-19|2011-02-10|2011-02-11|Estimate|2017-10-19|2017-11-21|Actual||||2017-10-19|2017-11-21|Actual|January 24, 2011||2011-01-24|October 2017|2017-10-31|August 10, 2016|Actual|2016-08-10|August 10, 2016|Actual|2016-08-10||Interventional|||Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men|Evaluation of Cortisol Resistance in Young Sedentary and Endurance-trained Men and Elderly Sedentary Men|Completed||Phase 2|51|Actual|National Institutes of Health Clinical Center (CC)||8|||f||||f|t|f||||||No||2018-05-31 22:52:53.714871|2018-05-31 22:52:53.714871
NCT01293825|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2013-12-28||2014-12-08|2011-02-10|2011-02-11|Estimate|2014-03-19|2014-04-22|Estimate||||2014-12-08|2014-12-30|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Zip Ad||Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)|Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder|Completed||Phase 4|30|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-05-31 22:53:00.903086|2018-05-31 22:53:00.903086
NCT01294306|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2016-08-23||2016-10-18|2011-02-10|2011-02-11|Estimate|2016-08-23|2016-10-17|Estimate||||2016-10-18|2016-11-29|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy|Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 22:52:54.369611|2018-05-31 22:52:54.369611
NCT01294293|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2014-12-23|2011-02-10|2011-02-11|Estimate|||||||2014-12-23|2014-12-25|Estimate|March 2011||2011-03-31|December 2014|2014-12-31||||July 2014|Actual|2014-07-31||Interventional|||TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|A Phase I Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD; NSC# 712227) or in Combination With Weekly Pactilaxel (NSC #673089) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 1|20|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-05-31 22:52:55.64882|2018-05-31 22:52:55.64882
NCT01294280|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-08-07|2011-02-10|2011-02-11|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2008||2008-07-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy|Participation in the Lung Adjuvant Cisplatin Evaluation Biological Program (LACE-BIO). A Study of Prognostic and Predictive Markers in Early Stage Non-Small Cell Lung Cancer|Recruiting|||1606|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 22:52:55.754234|2018-05-31 22:52:55.754234
NCT01294267|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2017-04-18||2018-01-17|2011-02-09|2011-02-11|Estimate|2018-01-17|2018-02-14|Actual||||2018-01-17|2018-02-14|Actual|September 2010||2010-09-30|January 2018|2018-01-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|PERMIT1||Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation|PERcutaneous heModynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation|Completed||N/A|20|Actual|Icahn School of Medicine at Mount Sinai|The lack of a control group precludes drawing definitive conclusions between the lack of either statistically or clinically significant changes in perioperative markers of end-organ perfusion/function and the use of a pLVAD.|1|||f||||t||||||||No||2018-05-31 22:52:55.862927|2018-05-31 22:52:55.862927
NCT01294254|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2015-04-02|2011-02-10|2011-02-11|Estimate|||||||2015-04-02|2015-04-03|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|OleoSplit||Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites|Open, Prospective, Controlled, Randomised, Multicenter Phase II Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites|Completed||Phase 2|24|Actual|Amryt Pharma||2|||f||||f||||||||||2018-05-31 22:52:56.074749|2018-05-31 22:52:56.074749
NCT01294241|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2016-10-22||2017-05-27|2011-02-10|2011-02-11|Estimate|2017-05-27|2018-01-23|Actual||||2017-05-27|2018-01-23|Actual|November 2010||2010-11-30|May 2017|2017-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||As 2 participants received 2 cycles of treatment each, 12 wounds were treated with study medication.|Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)|Open, Prospective, Controlled Case Series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare® Versus Non-adhesive Wound Dressing Alone in Accelerating the Epithelialization of Skin Lesions of Patients With Epidermolysis Bullosa Hereditaria|Completed||Phase 2|10|Actual|Amryt Pharma|Small sample size, subjects with dystrophic Epidermolysis bullosa only, difficult wound size analysis at fixed study days due to several episodes of re-trauma in both intervention and control wounds|2|||f||||f||||||||No||2018-05-31 22:52:56.16323|2018-05-31 22:52:56.16323
NCT01294228|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2016-08-26||2016-12-09|2011-02-10|2011-02-11|Estimate|2016-12-09|2017-02-02|Estimate||||2016-12-09|2017-02-02|Estimate|March 2011||2011-03-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|April 2013|Actual|2013-04-30||Observational|REAL-ICU|Participants whom received an adjudicated diagnosis of either AKI or non-AKI.|Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU|Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU|Completed|||1001|Actual|Biosite|||||f||||f||||||Samples Without DNA|"~     Plasma Urine~   "|No||2018-05-31 22:52:56.370607|2018-05-31 22:52:56.370607
NCT01294215|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2014-06-20|2011-02-10|2011-02-11|Estimate|||||||2014-06-20|2014-06-23|Estimate|February 2011||2011-02-28|June 2014|2014-06-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||High Dose BAYA1040_Nifedipine: a Long Term Combination Study|A Multicenter, Open Label, Long Term Study of Oral BAYA1040_CR 80 mg (40 mg Bid) in Combination With Other Antihypertensives for 52 Weeks in Patients With Essential Hypertension|Completed||Phase 3|72|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:52:56.580154|2018-05-31 22:52:56.580154
NCT01294202|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10||2016-01-08|2016-01-08|2011-02-10|2011-02-11|Estimate||||2016-01-08|2016-02-05|Estimate|2016-01-08|2016-02-05|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|April 2013|Actual|2013-04-30||Interventional|||A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST|An Open-Label, Randomised, Multi-Centre, Phase II Study to Investigate the Safety and Efficacy of AT13387, Either as Monotherapy or in Combination With Imatinib, in Patients With Unresectable and/or Metastatic Malignant GIST Whose Tumour Has Progressed Following Treatment With a Maximum of Three Tyrosine Kinase Inhibitors|Completed||Phase 2|26|Actual|Astex Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:52:56.652021|2018-05-31 22:52:56.652021
NCT01294189|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-02-10|2011-02-10|2011-02-11|Estimate|||||||2011-02-10|2011-02-11|Estimate|August 2008||2008-08-31|January 2011|2011-01-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Observational|||Advance Directives and End-of-life Decision Making in Intensive Care Medicine in Germany|The Impact of Instituting a Law for Advance Directives on End-of-life Decision Making in Intensive Care Medicine in Germany|Completed|||224|Actual|Charite University, Berlin, Germany|||1||f||||||||||||||2018-05-31 22:52:56.735514|2018-05-31 22:52:56.735514
NCT01294176|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2015-02-02|2011-02-10|2011-02-11|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Lipoic Acid as a Treatment for Acute Optic Neuritis|Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study|Unknown status|Recruiting|Phase 1|54|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:52:56.79142|2018-05-31 22:52:56.79142
NCT01294163|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2015-11-06||2015-12-18|2011-02-10|2011-02-11|Estimate|2015-12-18|2015-12-21|Estimate||||2015-12-18|2015-12-21|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Full Analysis Set (FAS): randomised and treated patients|Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery|Efficacy and Safety of Xenon Anaesthesia Compared to Sevoflurane Anaesthesia and Total Intravenous Anaesthesia for On-pump Coronary Artery Bypass Graft Surgery: a Randomised, Three-arm, Single-blind, International Study|Completed||Phase 3|509|Actual|Air Liquide Santé International||3|||f||||f||||||||||2018-05-31 22:52:56.886772|2018-05-31 22:52:56.886772
NCT01294150|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2014-04-01||2018-01-17|2011-02-10|2011-02-11|Estimate|2015-07-15|2015-08-13|Estimate||||2018-01-17|2018-02-14|Actual|February 2011||2011-02-28|January 2018|2018-01-31|July 5, 2017|Actual|2017-07-05|February 2013|Actual|2013-02-28||Interventional|LIFT||The Safety and Effectiveness of UroLift: LIFT Pivotal Study|Luminal Improvement Following Prostatic Tissue Approximation for the Treatment of Lower Urinary Tract Symptoms|Completed||N/A|206|Actual|NeoTract, Inc.||3|||f||||t||||||||No||2018-05-31 22:52:57.683084|2018-05-31 22:52:57.683084
NCT01294137|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-05-07|2011-02-10|2011-02-11|Estimate|||||||2013-05-07|2013-05-09|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SAFE||Sleep Apnea in Frail Elderly|Accuracy of Pulse Oximetry to Detect Sleep Apnea in Frail Hospitalized Patients|Completed||N/A|80|Actual|AGIR à Dom||1|||f||||t||||||||||2018-05-31 22:52:58.367446|2018-05-31 22:52:58.367446
NCT01294124|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2014-12-08|2011-02-10|2011-02-11|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2015||2015-03-31|December 2014|2014-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Investigating the Neurobiology of Tinnitus|Investigating The Neurobiology of Tinnitus|Not yet recruiting|||300|Anticipated|Washington University School of Medicine|||2||f||||t||||||||||2018-05-31 22:52:58.444575|2018-05-31 22:52:58.444575
NCT01294111|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2018-05-02|2011-02-10|2011-02-11|Estimate|||||||2018-05-02|2018-05-08|Actual|November 2010||2010-11-30|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|March 2012|Actual|2012-03-31||Interventional|||Tai Chi Training for Elderly People With Chronic Heart Failure||Completed||N/A|45|Actual|Umeå University||2|||f||||||||||||||2018-05-31 22:52:58.517206|2018-05-31 22:52:58.517206
NCT01294098|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2018-02-26||2018-03-28|2011-02-09|2011-02-11|Estimate|2018-03-28|2018-03-30|Actual||||2018-03-28|2018-03-30|Actual|February 2011|Actual|2011-02-28|March 2018|2018-03-31|October 8, 2014|Actual|2014-10-08|October 8, 2013|Actual|2013-10-08||Interventional|||Efficacy Study of Femoral Nerve Block in Children With a Femur Fracture|Examining the Efficacy of Femoral Nerve Block in Children With a Femoral Shaft Fracture|Terminated||N/A|2|Actual|Washington University School of Medicine||3||Patients were not willing to be randomized and therefore recruitment could not continue.|f||||t||||||||||2018-05-31 22:52:58.60488|2018-05-31 22:52:58.60488
NCT01294085|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-11-24|2011-02-09|2011-02-11|Estimate|||||||2011-11-24|2011-11-28|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Observational|||Case Series Study of Biliary Tract Cancer Patients in Japan|Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer|Completed|||300|Actual|Kansai Hepatobiliary Oncology Group|||||f||||t||||||||||2018-05-31 22:52:58.908512|2018-05-31 22:52:58.908512
NCT01294072|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-03-01|2011-02-09|2011-02-11|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|||Study Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Colon Cancer Tissue|Phase I Clinical Trial Investigating the Ability of Plant Exosomes to Deliver Curcumin to Normal and Malignant Colon Tissue|Active, not recruiting||Phase 1|7|Actual|James Graham Brown Cancer Center||3|||f||||t||||||||||2018-05-31 22:52:58.98553|2018-05-31 22:52:58.98553
NCT01294059|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2014-07-29|2011-02-09|2011-02-11|Estimate|||||||2014-07-29|2014-07-31|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients|Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients|Completed||Phase 1|51|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 22:52:59.062775|2018-05-31 22:52:59.062775
NCT01294046|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2017-01-18||2017-04-13|2011-02-09|2011-02-11|Estimate|2017-01-18|2017-03-07|Actual||||2017-04-13|2017-04-14|Actual|March 2011||2011-03-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||no subjects had data collected, 3 were enrolled, but did not have data collected or analyzed.|Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches|Electrical Stimulation of the Sphenopalatine Ganglion for the Treatment of Migraine Headaches|Completed||N/A|3|Actual|The Cleveland Clinic||1|||f||||t||||||||No||2018-05-31 22:52:59.138742|2018-05-31 22:52:59.138742
NCT01294033|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-03-15|2011-02-10|2011-02-11|Estimate|||||||2017-03-15|2017-03-16|Actual|August 2009||2009-08-31|March 2017|2017-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease|Effect of Therapeutic Hyperoxia on Maximal Oxygen Consumption and Perioperative Risk Stratification in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|20|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 22:52:59.307329|2018-05-31 22:52:59.307329
NCT01294020|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-12-05|2011-02-09|2011-02-11|Estimate|||||||2017-12-05|2017-12-07|Actual|May 25, 2011|Actual|2011-05-25|December 2017|2017-12-31|May 2026|Anticipated|2026-05-31|October 25, 2015|Actual|2015-10-25||Interventional|||Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®|A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up|Active, not recruiting||Phase 2|81|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 22:52:59.374217|2018-05-31 22:52:59.374217
NCT01294007|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-01-15|2011-02-09|2011-02-11|Estimate|||||||2016-01-15|2016-01-20|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)|A Radiographic Analysis Using PureGen Osteoprogenitor Cell Allograft Versus Autologous Bone in Posterolateral Fusion in a Side-by-Side Comparison in the Same Patient (PLF)|Terminated||N/A|1|Actual|Alphatec Spine, Inc.||2||Product no longer on the market|f||||||||||||||2018-05-31 22:52:59.566502|2018-05-31 22:52:59.566502
NCT01293812|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2015-12-21|2011-02-10|2011-02-11|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Effect on Pain of Oral Sucrose Versus Placebo in Children 1 to 3 Months Old Needing Venipuncture|A Randomized Double-blind Trial Comparing the Effect on Pain of an Oral Sucrose Solution Versus Placebo in Children 1 to 3 Months Old Needing Venipuncture|Completed||Phase 4|82|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 22:53:01.13521|2018-05-31 22:53:01.13521
NCT01293994|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-11-18|2011-02-10|2011-02-11|Estimate|||||||2016-11-18|2016-11-22|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Study of Genetic Variation Influencing Pain and Response to Opioid Medications|A Study of Genetic Variation Influencing Pain and Response to Opioid Medications in Patients With Chronic Pain|Withdrawn|||0|Actual|Stanford University||||Do not have necessary resources to continue|f||||f||||||Samples With DNA|"~     Saliva biospecimen collection will be performed via mail or in person. The PI will send~     participants a letter informing them of the opportunity to participate in a study of genetic~     variation influencing pain and opioid responsiveness phenotypes. If participants agree to~     provide a saliva biospecimen and to participate in the study, an informed consent letter and~     an Oragene™ DNA Self-Collection Kit, in disk format OG-250 (DNA Genotek, Inc., Ottawa,~     Ontario, Canada) will be sent to the participant by the PI. According to the manufacturer~     instructions, participants will provide a 2 ml saliva sample, which will be preserved using~     the reagents provided within the Oragene™ kit. Saliva samples are considered stable at room~     temperature for 5 years by Oragene™.~   "|No||2018-05-31 22:52:59.626902|2018-05-31 22:52:59.626902
NCT01293981|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-01-15|2011-02-10|2011-02-11|Estimate|||||||2016-01-15|2016-01-20|Estimate|February 2011||2011-02-28|January 2016|2016-01-31||||January 2012|Actual|2012-01-31||Observational|||Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)|Radiographic and Clinical Outcomes of PureGen Osteoprogenitor Cell Allograft in Posterior Lumbar and Transforaminal Interbody Fusion Procedures|Terminated|||6|Actual|Alphatec Spine, Inc.|||1|Product no longer on the market|f||||||||||||||2018-05-31 22:52:59.682847|2018-05-31 22:52:59.682847
NCT01293968|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2011-05-05||2012-05-16|2011-02-10|2011-02-11|Estimate|2012-05-16|2012-06-20|Estimate||||2012-05-16|2012-06-20|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||"Therapeutic Effects of Ibuprofen, Diphenhydramine and Aluminium MgS on Recurrent Aphthous Stomatitis"|"Therapeutic Effects of Ibuprofen, Diphenhydramine and Aluminium MgS on Recurrent Aphthous Stomatitis"|Completed||Phase 2|37|Actual|Qazvin University Of Medical Sciences|Small number of population. Studying just one concentration of Ibuprofen. Lack of a placebo.|2|||f||||t||||||||||2018-05-31 22:52:59.751152|2018-05-31 22:52:59.751152
NCT01293955|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2015-04-23|2011-02-09|2011-02-11|Estimate|||||||2015-04-23|2015-04-24|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|Joins_Carp_Ⅳ||Assessment of Protective Effect of JOINS on Cartilage in Knee Osteoarthritis|A Randomized, Double Blinded, Parallel Group, Placebo-controlled Clinical Trial to Assess the Protective Effect of JOINS on Cartilage in Knee Osteoarthritis|Completed||Phase 4|76|Actual|SK Chemicals Co.,Ltd.||2|||f||||f||||||||||2018-05-31 22:52:59.954977|2018-05-31 22:52:59.954977
NCT01293942|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-06-04|2011-02-09|2011-02-11|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||IXO+A in mCRC With Liver-only Metastases|A Single-arm Phase II Downsizing Study of Irinotecan, Capecitabine and Oxaliplatin (IXO) and Bevacizumab as First-line Treatment to Assess Conversion to Resectability of Liver-only Metastases in Colorectal Cancer Patients With Initially Unresectable Metastases|Withdrawn||Phase 2|0|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 22:53:00.041233|2018-05-31 22:53:00.041233
NCT01293929|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-03-03|2011-02-10|2011-02-11|Estimate|||||||2011-03-03|2011-03-04|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Association of Circulating Chemerin Levels and Arterial Stiffness||Unknown status|Recruiting||120|Anticipated|Korea University|||2||f||||t||||||||||2018-05-31 22:53:00.133494|2018-05-31 22:53:00.133494
NCT01293916|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-04-03|2011-02-10|2011-02-11|Estimate|||||||2013-04-03|2013-04-05|Estimate|June 2006||2006-06-30|April 2013|2013-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Spica Casting in Pediatric Femur Fractures: Study of Single Leg Versus Double Leg Spica Casts|Spica Casting in Pediatric Femur Fractures: A Prospective Randomized Controlled Study of Single Leg vs Double Leg Spica Casts|Completed||N/A|52|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 22:53:00.191087|2018-05-31 22:53:00.191087
NCT01293903|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-08-26|2011-02-10|2011-02-11|Estimate|||||||2017-08-26|2017-08-29|Actual|January 2012||2012-01-31|August 2017|2017-08-31|September 30, 2016|Actual|2016-09-30|December 31, 2015|Actual|2015-12-31||Interventional|QLQX-DCM||Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy|A Multi-center, Randomized, Double, Placebo-controlled, Parallel Group Study of Improving Heart Function and Immunoregulation Effects of Qiliqiangxin Capsule in Patients With Dilated Cardiomyopathy|Completed||Phase 4|374|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 22:53:00.269168|2018-05-31 22:53:00.269168
NCT01293890|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-07-29|2011-02-10|2011-02-11|Estimate|||||||2013-07-29|2013-07-30|Estimate|March 2011||2011-03-31|July 2013|2013-07-31||||September 2014|Anticipated|2014-09-30||Observational|AMICE||Adherence to Medication and Its Impact on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: The AMICE Prospective Study|Adherence to Medication and Its Impact on COPD Exacerbations: The AMICE Prospective Study|Unknown status|Recruiting||100|Anticipated|Katholieke Universiteit Leuven|||1||f||||f||||||Samples With DNA|"~     blood urine~   "|||2018-05-31 22:53:00.352935|2018-05-31 22:53:00.352935
NCT01293877|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-02-10|2011-02-10|2011-02-11|Estimate|||||||2011-02-10|2011-02-11|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|LGP||Laparoscopic Gastric Plication Compared With Laparoscopic Sleeve Gastrectomy|Laparoscopic Gastric Plication for Treatment of Morbid Obesity|Unknown status|Not yet recruiting|N/A|200|Anticipated|Bikkur Holim Hospital||2|||f||||f||||||||||2018-05-31 22:53:00.423325|2018-05-31 22:53:00.423325
NCT01293864|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2017-11-02|2011-02-10|2011-02-11|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2007||2007-04-30|December 2015|2015-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Structural Analysis of Human Tissue|Structural Analysis of Human Tissue|Terminated|||35|Actual|Wake Forest University Health Sciences||||This is not a clinical trials study|f||||f||||||Samples Without DNA|"~     Abdominal tissue~   "|||2018-05-31 22:53:00.501582|2018-05-31 22:53:00.501582
NCT01293851|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2018-05-18|2011-02-10|2011-02-11|Estimate|||||||2018-05-18|2018-05-21|Actual|December 22, 2010||2010-12-22|November 13, 2012|2012-11-13|November 13, 2012||2012-11-13|||||Observational|||Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage|Characterization of the Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Peripheral Neuropathy Progression|Terminated|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:53:00.565218|2018-05-31 22:53:00.565218
NCT01291654|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2012-12-18|2011-02-07|2011-02-08|Estimate|||||||2012-12-18|2012-12-19|Estimate|April 2012||2012-04-30|December 2012|2012-12-31||||December 2014|Anticipated|2014-12-31||Interventional|||Paracetamol and Patent Ductus Arteriosus (PDA)|Paracetamol in the Treatment of Patent Ductus Arteriosus in the Premature Neonate|Unknown status|Recruiting|Phase 2|80|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 22:53:30.679329|2018-05-31 22:53:30.679329
NCT01293799|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2018-04-27|2011-02-10|2011-02-11|Estimate|||||||2018-04-27|2018-04-30|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PEPS||Prevention of Peritonitis in Peritoneal Dialysis|Prevention of Peritonitis in Patients With Peritoneal Dialysis - Effects of Regular Follow-up of Patients´ Theoretical Knowledge and Practical Skills With Focus on Infection Prophylaxis|Completed||N/A|713|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 22:53:01.200309|2018-05-31 22:53:01.200309
NCT01293786|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-05-25|2011-02-10|2011-02-11|Estimate|||||||2011-05-25|2011-05-26|Estimate|February 2011||2011-02-28|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Serum Magnesium and Vascular Calcification|Comparison of Vascular Calcification Between Kidney Transplant Recipients and Predialysis Chronic Kidney Disease and Its Association With Serum Magnesium|Completed|||400|Anticipated|Ramathibodi Hospital|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:53:01.270944|2018-05-31 22:53:01.270944
NCT01293773|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2014-11-06|2011-02-10|2011-02-11|Estimate|||||||2014-11-06|2014-11-07|Estimate|October 2010||2010-10-31|August 2011|2011-08-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|OCELOT||Outcome of Second Generation Drug-eLuting Stents in Patients With Diabetes Mellitus|Outcome of seCond Generation Drug-ELuting Stents in Patients With Diabetes Mellitus: cOmparison of Three differenT Drug Regimens|Withdrawn||Phase 4|0|Actual|Policlinico Casilino ASL RMB||3|||f||||t||||||||||2018-05-31 22:53:01.401117|2018-05-31 22:53:01.401117
NCT01293760|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2012-05-08|2011-02-10|2011-02-11|Estimate|||||||2012-05-08|2012-05-10|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Immediate Post-placental Insertion of the Copper T 380A After Cesarean Delivery Versus 6 Week Post-cesarean Insertion|Immediate Post-placental Insertion of the Copper T 380A After Cesarean Delivery Versus 6 Week Post-cesarean Insertion: A Pilot Randomized Controlled Trial|Completed||N/A|68|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-05-31 22:53:01.482467|2018-05-31 22:53:01.482467
NCT01293747|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-10-12|2011-02-10|2011-02-11|Estimate|||||||2011-10-12|2011-10-13|Estimate|February 2011||2011-02-28|October 2011|2011-10-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetics of Injectable Estradiol and Progesterone Microspheres Suspension|Multiple-dose Pharmacokinetic Study of Two Aqueous Suspensions of Estradiol and Progesterone Microspheres (1 mg/20 mg & 0.5 mg/15 mg) for Intramuscular Administration, in Postmenopausal Volunteers.|Completed||Phase 1|30|Anticipated|Productos Científicos S. A. de C. V.||2|||f||||f||||||||||2018-05-31 22:53:01.5639|2018-05-31 22:53:01.5639
NCT01293734|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2011-02-10|2011-02-10|2011-02-11|Estimate|||||||2011-02-10|2011-02-11|Estimate|December 2008||2008-12-31|January 2011|2011-01-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Research on Traditional Chinese Medicine (TCM) Clinical Treatment of the Acute Episode of Bronchial Asthma.||Completed||Phase 2|360|Actual|Liaoning University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 22:53:01.63419|2018-05-31 22:53:01.63419
NCT01293721|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2012-05-22|2011-02-10|2011-02-11|Estimate|||||||2012-05-22|2012-05-23|Estimate|November 2011||2011-11-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of Low-Magnitude, High-Frequency Vibration Treatment on Osteoporotic Hip Fracture Healing|Prospective Randomized Controlled Trial of the Efficacy of Low-Magnitude, High-Frequency Vibration Treatment on Osteoporotic Hip Fracture Healing|Completed||Phase 2/Phase 3|72|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 22:53:01.702489|2018-05-31 22:53:01.702489
NCT01293708|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|||2013-02-19|2011-02-10|2011-02-11|Estimate|||||||2013-02-19|2013-02-20|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2011|Actual|2011-02-28||Observational|Realistic 80||Realities, Expectations and Attitudes to Life Support Technologies in Intensive Care for Octogenarians:|Realities, Expectations and Attitudes to Life Support Technologies in Intensive Care for Octogenarians:|Completed|||610|Actual|Clinical Evaluation Research Unit at Kingston General Hospital|||1||f||||f||||||||||2018-05-31 22:53:01.774183|2018-05-31 22:53:01.774183
NCT01293695|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-10|2015-01-28||2016-07-18|2011-02-10|2011-02-11|Estimate|2015-08-18|2015-09-17|Estimate||||2016-07-18|2016-08-16|Estimate|September 2007||2007-09-30|July 2016|2016-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial|Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial|Completed||N/A|187|Actual|Baylor University|"limitations: results may not generalize to all women with hot flashes~some hot flashes occur at other times than during the climacteric~self-selection bias (predispositions to mind-body therapy)~population was largely caucasian"|2|||f||||t||||||||No||2018-05-31 22:53:01.909293|2018-05-31 22:53:01.909293
NCT01293682|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2018-04-26|2011-02-09|2011-02-10|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2010||2010-11-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of High Dose Calcitriol in Breast Cancer Patients|A Pilot Study of the Effects of High-Dose Oral Calcitriol in Breast Cancer Patients Prior to Surgery|Active, not recruiting||Phase 2|12|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 22:53:02.404286|2018-05-31 22:53:02.404286
NCT01293669|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09||2012-07-13|2013-09-03|2011-02-09|2011-02-10|Estimate||||2012-07-13|2012-07-23|Estimate|2013-09-03|2013-09-13|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus|Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|440|Actual|Targacept Inc.||2|||f||||f||||||||||2018-05-31 22:53:02.470447|2018-05-31 22:53:02.470447
NCT01293656|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-06-01|2011-02-09|2011-02-10|Estimate|||||||2015-06-01|2015-06-02|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166)|Cross-sectional Study of Inflammatory Bowel Disease Severity and Treatment Patterns in Eastern Europe, Middle East, and North Africa. (P08166)|Withdrawn|||0|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:53:02.5519|2018-05-31 22:53:02.5519
NCT01293643|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-08-07|2011-02-09|2011-02-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)|A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated|Completed||Phase 3|99|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:53:02.60427|2018-05-31 22:53:02.60427
NCT01293630|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2015-10-29|2011-02-09|2011-02-10|Estimate|||||||2015-10-29|2015-10-30|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors|An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Paclitaxel and Carboplatin Every 3 Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|18|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:53:02.662433|2018-05-31 22:53:02.662433
NCT01293617|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-07-15|2011-02-09|2011-02-10|Estimate|||||||2011-07-15|2011-07-18|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Blackberry Intake and Biomarkers of Cancer Risk|Blackberry Intake and Biomarkers of Cancer Risk|Completed||N/A|52|Anticipated|USDA Beltsville Human Nutrition Research Center||2|||f||||||||||||||2018-05-31 22:53:02.729389|2018-05-31 22:53:02.729389
NCT01293604|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-10-13|2011-02-09|2011-02-10|Estimate|||||||2011-10-13|2011-10-14|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease||Completed||N/A|69|Anticipated|USDA Beltsville Human Nutrition Research Center||3|||f||||t||||||||||2018-05-31 22:53:02.7951|2018-05-31 22:53:02.7951
NCT01293591|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2017-06-01|2011-02-09|2011-02-10|Estimate|||||||2017-06-01|2017-06-02|Actual|July 2010||2010-07-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Garlic Intake And Biomarkers Of Cancer Risk|Garlic Intake And Biomarkers Of Cancer Risk|Completed||N/A|18|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 22:53:02.85395|2018-05-31 22:53:02.85395
NCT01293578|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-03-18|2011-02-09|2011-02-10|Estimate|||||||2016-03-18|2016-03-21|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TRICEP||Study to Test Use of a Decision Aid in a Clinical Visit to Help Patients Choose a Diabetes Medication|Translating Information on Comparative Effectiveness Into Practice (TRICEP)|Completed||N/A|550|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:53:03.051979|2018-05-31 22:53:03.051979
NCT01293565|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2012-06-26|2011-02-09|2011-02-10|Estimate|||||||2012-06-26|2012-06-28|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Observational|||Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia|Completed|||27|Actual|Edimer Pharmaceuticals|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 22:53:03.124855|2018-05-31 22:53:03.124855
NCT01293552|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09||2013-06-21|2013-06-28|2011-02-09|2011-02-10|Estimate||||2013-06-21|2013-07-01|Estimate|2013-06-28|2013-07-04|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Clinical Trial To Evaluate ANT-1207 In Subjects With Acne|Clinical Trial To Evaluate Botulinum Neurotoxin Type A (ANT-1207) In Subjects With Acne|Completed||Phase 2|72|Actual|Anterios Inc.||5|||f||||t||||||||||2018-05-31 22:53:03.230369|2018-05-31 22:53:03.230369
NCT01293539|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2017-06-22||2017-07-28|2011-02-09|2011-02-10|Estimate|2017-06-22|2017-07-21|Actual||||2017-07-28|2017-08-28|Actual|March 2011||2011-03-31|July 2017|2017-07-31|August 2021|Anticipated|2021-08-31|August 2016|Actual|2016-08-31||Interventional|||Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma|Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma|Terminated||Phase 2|10|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||IAC is now recognized as part of standard of care treatment options in the US.|f||||t||||||||||2018-05-31 22:53:03.31697|2018-05-31 22:53:03.31697
NCT01293526|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2017-11-16|2011-02-09|2011-02-10|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2011|Actual|2011-02-28|November 2017|2017-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SonR Access||Acute Optimization of Cardiac Resynchronization Therapy (CRT)Using Echocardiography and SonR|Acute Optimization of Cardiac Resynchronization Therapy (CRT) Using Echocardiography and SonR|Completed||N/A|39|Actual|Piedmont Healthcare||3|||f||||f||||||||||2018-05-31 22:53:03.495289|2018-05-31 22:53:03.495289
NCT01293513|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-02-09|2011-02-09|2011-02-10|Estimate|||||||2011-02-09|2011-02-10|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Structured Treatment Interruption (STI) in Acute/Primary HIV|Structured Treatment Interruption (STI) in Acute/Primary HIV|Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 22:53:03.629137|2018-05-31 22:53:03.629137
NCT01293500|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2016-05-03|2011-02-09|2011-02-10|Estimate|||||||2016-05-03|2016-05-05|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|GRIPIT||Goal-directed Resuscitative Interventions During Pediatric Inter-facility Transport (The GRIPIT Trial)|Goal-directed Resuscitative Interventions During Pediatric Inter-facility Transport (The GRIPIT Trial)|Terminated||N/A|230|Actual|Arkansas Children's Hospital Research Institute|||||f||||t||||||||||2018-05-31 22:53:03.682466|2018-05-31 22:53:03.682466
NCT01293487|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2012-06-20|2011-02-09|2011-02-10|Estimate|||||||2012-06-20|2012-06-22|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.|A Phase I Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of RN564 In Women With Osteopenia And In Healthy Men|Completed||Phase 1|68|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:53:03.744675|2018-05-31 22:53:03.744675
NCT01293474|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-01-05|2011-02-09|2011-02-10|Estimate|||||||2015-01-05|2015-01-06|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Choroidal Thickness in Glaucoma Patients and Healthy Controls||Unknown status|Enrolling by invitation||200|Anticipated|University of Zurich|||2||f||||||||||||||2018-05-31 22:53:03.825978|2018-05-31 22:53:03.825978
NCT01293461|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08||2013-02-25|2013-02-25|2011-02-09|2011-02-10|Estimate||||2013-02-25|2013-03-01|Estimate|2013-02-25|2013-03-01|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes|A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|72|Actual|Cebix Incorporated||2|||f||||f||||||||||2018-05-31 22:53:03.900483|2018-05-31 22:53:03.900483
NCT01293448|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2018-01-23|2011-02-09|2011-02-10|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2010||2010-12-31|January 2018|2018-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium|Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium|Completed||Phase 1|21|Actual|C2 Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 22:53:03.983951|2018-05-31 22:53:03.983951
NCT01293435|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2012-09-06|2011-02-09|2011-02-10|Estimate|||||||2012-09-06|2012-09-07|Estimate|March 2011||2011-03-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|REACH||Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections|Observational Study to Assess Clinical Management Patterns in Patients With Hospitalised Community-Acquired Pneumonia (CAP) or Complicated Skin and Skin Structure Infections (cSSSI)|Completed|||4035|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:53:04.097652|2018-05-31 22:53:04.097652
NCT01293422|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2012-09-07|2011-02-09|2011-02-10|Estimate|||||||2012-09-07|2012-09-10|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Rifa-2||Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis|PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon|Completed||Phase 4|12|Actual|University of Oulu||1|||f||||f||||||||||2018-05-31 22:53:04.353783|2018-05-31 22:53:04.353783
NCT01293409|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-05-30|2011-02-09|2011-02-10|Estimate|||||||2011-05-30|2011-06-01|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Bright Light Therapy in Seasonal Affective Disorder (SAD)|Transcranial Brain-Targeted Bright Light Treatment Via Ear Canals in Seasonal Affective Disorder (SAD) - a Randomized Placebo Controlled Dose Finding Study|Completed||N/A|90|Anticipated|University of Oulu||3|||f||||t||||||||||2018-05-31 22:53:04.423908|2018-05-31 22:53:04.423908
NCT01293396|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-09-22|2011-02-09|2011-02-10|Estimate|||||||2011-09-22|2011-09-23|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|HUCKEPACK2||Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids|Comparison of the Impact of Biphasic Insulin Aspart 30(BiAsp30), Biphasic Insulin Aspart 70 (BiAsp 70) and Insulin Aspart on Postprandial Glucose and Lipid Metabolism During Two Consecutive Meals in Type 2 Diabetics.|Completed||Phase 4|20|Actual|Medical University of Graz||3|||f||||f||||||||||2018-05-31 22:53:04.503324|2018-05-31 22:53:04.503324
NCT01293383|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-03-25|2011-02-09|2011-02-10|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects|A Phase 1 Study Evaluating the Safety of LEO 90105 and Its Vehicle, After Multiple Administration on Intact Skin of Healthy Japanese Male Subjects. A Single Centre, Prospective, Randomised, Double-blinded, Vehicle-controlled Clinical Study|Completed||Phase 1|12|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 22:53:04.575591|2018-05-31 22:53:04.575591
NCT01293370|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2013-07-01|2011-02-09|2011-02-10|Estimate|||||||2013-07-01|2013-07-02|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|IVRMH||Important Factors in Integration of Vocational Rehabilitation in Mental Health|Important Factors in Integration of Vocational Rehabilitation in Mental Health|Completed|||10|Actual|University Hospital of North Norway|||1||f||||t||||||||||2018-05-31 22:53:04.632478|2018-05-31 22:53:04.632478
NCT01293357|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-03-25|2011-02-09|2011-02-10|Estimate|||||||2015-03-25|2015-03-26|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects|A Phase 1 Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects A Single Centre, Randomised, Controlled, Investigator Blinded Study With Intra-individual Comparison of the Active Formulation and Its Components|Completed||Phase 1|20|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 22:53:04.697758|2018-05-31 22:53:04.697758
NCT01293344|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-10-05|2011-02-09|2011-02-10|Estimate|||||||2011-10-05|2011-10-07|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|ALIMED||Effects of the Mediterranean Diet on Cardiovascular Risk Profile in Men and Women|Gender Differences in Response to the Mediterranean Diet|Completed||N/A|70|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:53:04.755296|2018-05-31 22:53:04.755296
NCT01293331|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-06-16|2011-02-09|2011-02-10|Estimate|||||||2015-06-16|2015-06-17|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Observational|||Study of Febrile Illness for Dengue-Endemic Areas in Latin America|Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Latin America|Completed|||3000|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 22:53:04.840415|2018-05-31 22:53:04.840415
NCT01293318|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-10-24|2011-02-09|2011-02-10|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|November 2015|Actual|2015-11-30||Observational|COPA||Study of Copeptin as a Diagnostic Marker for Acute Pancreatitis|Copeptin Pancreatitis Trial|Completed|||150|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 22:53:04.920968|2018-05-31 22:53:04.920968
NCT01293305|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-02-09|2011-02-09|2011-02-10|Estimate|||||||2011-02-09|2011-02-10|Estimate|November 2011||2011-11-30|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Study With Chondroitin Sulfate and Glucosamine Sulfate (in Dosage Capsule and Sachet) in Treating Osteoarthritis|Randomized Evaluation Of Not Less Medical Association Chondroitin Sulfate Plus Glucosamine Sulfate (In Powder Dosage Forms And Oral Capsule), Manufactured By The Geolab Pharmaceutical Industry Ltd, Compared To The Drug Condroflex® (Powder And Oral Capsule), Manufactured In The Laboratory Zodiac, The Treatment Of Osteoarthritis.|Unknown status|Not yet recruiting|Phase 3|320|Anticipated|Azidus Brasil||4|||f||||t||||||||||2018-05-31 22:53:04.990331|2018-05-31 22:53:04.990331
NCT01293292|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2017-05-04|2011-02-09|2011-02-10|Estimate|||||||2017-05-04|2017-05-08|Actual|January 2011||2011-01-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Forsteo||Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action|Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action. A Two-year Open-label Single-arm Study of Teriparatide in Secondary Care|Completed||Phase 4|19|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 22:53:05.162882|2018-05-31 22:53:05.162882
NCT01293279|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-10-06|2011-02-09|2011-02-10|Estimate|||||||2011-10-06|2011-10-07|Estimate|February 2011||2011-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|HCV||HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China|HCV Viral Genotyping Distribution and Genetic Variation in IL28B Distributions Among the Han Ethnic Chinese in China|Completed|||997|Anticipated|Peking University People's Hospital|||1||f||||t||||||Samples With DNA|"~     By having the approvals from the EC and China National Human Genetic Resource Management~     Office (under China Ministry of Health) and having the patient informed consent, blood~     samples of all recruited patients will be retained under the proper conditions in Peking~     University People's Hospital, Beijing, China~   "|||2018-05-31 22:53:05.230066|2018-05-31 22:53:05.230066
NCT01293253|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-10-28|2011-02-09|2011-02-10|Estimate|||||||2011-10-28|2011-10-31|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|IRMA||Effect of Daily Stair Walking on Cardiovascular Health|Danish: Integreret Motion på Arbejdspladsen (IRMA) English: Implementation of Exercise at the Workplace|Completed||N/A|150|Anticipated|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 22:53:05.363718|2018-05-31 22:53:05.363718
NCT01293240|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2012-05-01||2012-06-26|2011-02-09|2011-02-10|Estimate|2012-05-01|2012-06-01|Estimate||||2012-06-26|2012-07-10|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Prospective Study of Lens Performance of a Monthly Replacement Lens at Two Weeks and Four Weeks|Prospective Study of Lens Performance of a Monthly Replacement Lens at Two Weeks and Four Weeks|Completed||N/A|117|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:53:05.438463|2018-05-31 22:53:05.438463
NCT01293227|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2012-01-23|2011-02-09|2011-02-10|Estimate|||||||2012-01-23|2012-01-24|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||WRx Distal Radius Wrist Fracture Study|The Effect of Intramedullary Locked Nail Versus Volar Locked Plating in the Treatment of Extra-articular and Minimally Displaced Intra-articular Distal Radius Fractures: A Prospective Randomized Trial.|Terminated||N/A|6|Actual|Mayo Clinic||||Funding was withdrawn due to inadequete enrollment.|f||||f||||||||||2018-05-31 22:53:05.633154|2018-05-31 22:53:05.633154
NCT01293214|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2017-12-07|2011-02-09|2011-02-10|Estimate|||||||2017-12-07|2017-12-11|Actual|February 2010|Actual|2010-02-28|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Vascularized Composite Allotransplantation for Multiple Extremity Amputations|Vascularized Composite Allotransplantation for Multiple Extremity Amputations|Recruiting||N/A|10|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 22:53:05.750989|2018-05-31 22:53:05.750989
NCT01293201|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-08-31|2011-02-09|2011-02-10|Estimate|||||||2011-08-31|2011-09-02|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Trial of STAHIST in Seasonal Allergic Rhinitis|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of STAHIST in Adult and Adolescent Subjects With a History of Seasonal Allergic Rhinitis|Completed||Phase 3|290|Actual|Magna Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 22:53:05.848375|2018-05-31 22:53:05.848375
NCT01293188|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-03-06|2011-02-09|2011-02-10|Estimate|||||||2015-03-06|2015-03-09|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|ARVA||Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement|Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement|Completed|||434|Actual|French Cardiology Society|||1||f||||f||||||||||2018-05-31 22:53:05.970567|2018-05-31 22:53:05.970567
NCT01293175|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2013-07-11|2011-02-09|2011-02-10|Estimate|||||||2013-07-11|2013-07-12|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Whole Grain Polyphenol Bioavailability and Effects on Health|Whole Grain Polyphenol Bioavailability and Effects on Inflammatory, Oxidative and Hormonal Status|Completed||N/A|80|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 22:53:06.086795|2018-05-31 22:53:06.086795
NCT01293162|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2016-02-02|2011-02-09|2011-02-10|Estimate|||||||2016-02-02|2016-02-03|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|ARMOPREVCVR||The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk|Study on the Role of a Combination of Nutraceuticals (Armolipid Prev) With an Effect on Blood Pressure and Lipids in the Control of Cardiovascular Risk|Completed|||150|Actual|Federico II University|||1||f||||t||||||||||2018-05-31 22:53:06.185645|2018-05-31 22:53:06.185645
NCT01293149|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-05-06|2011-02-09|2011-02-10|Estimate|||||||2015-05-06|2015-05-08|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Clonidine in Femoral Nerve Block Surgery in Children|The Effects of Clonidine on Postoperative Analgesia After Single Shot Femoral Nerve Block Following Arthroscopic Knee Surgery in Children|Withdrawn||Phase 2|0|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 22:53:06.272058|2018-05-31 22:53:06.272058
NCT01293136|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2012-01-27|2011-02-09|2011-02-10|Estimate|||||||2012-01-27|2012-01-31|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Retrospective Femoral Nerve Block Study||Completed|||400|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 22:53:06.365192|2018-05-31 22:53:06.365192
NCT01293123|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-06-04|2011-02-09|2011-02-10|Estimate|||||||2015-06-04|2015-06-08|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals|Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals|Terminated||N/A|3|Actual|University of California, San Diego||2||Did not meet enrollment goals|f||||t||||||||||2018-05-31 22:53:06.458847|2018-05-31 22:53:06.458847
NCT01293110|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2017-12-18|2011-02-09|2011-02-10|Estimate|||||||2017-12-18|2017-12-20|Actual|January 2010||2010-01-31|December 2017|2017-12-31|January 2030|Anticipated|2030-01-31|January 2030|Anticipated|2030-01-31||Observational|||Lower Urinary Tract Dysfunction Database|Database of Patients With Lower Urinary Tract Dysfunction Treated at the University of Zürich|Recruiting|||7000|Anticipated|Balgrist University Hospital|||||f||||f||||||||No||2018-05-31 22:53:06.543431|2018-05-31 22:53:06.543431
NCT01293097|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2013-04-28|2011-02-09|2011-02-10|Estimate|||||||2013-04-28|2013-04-30|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ISCAP||Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI|Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention(PCI)|Completed||Phase 4|2884|Actual|Peking University First Hospital||2|||f||||t||||||||||2018-05-31 22:53:06.62202|2018-05-31 22:53:06.62202
NCT01293084|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2015-09-10||2015-09-10|2011-02-09|2011-02-10|Estimate|2015-09-10|2015-09-22|Estimate||||2015-09-10|2015-09-22|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Hypertonic Saline and Mucociliary Clearance in Children|Acute Inhalation of Hypertonic Saline Does Not Improve Mucociliary Clearance in All Children With Cystic Fibrosis|Completed||Phase 2|17|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:53:06.718399|2018-05-31 22:53:06.718399
NCT01293071|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-11-30|2011-02-09|2011-02-10|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|SATURN||Effect of Antibiotic Rotation in the ICU on the Prevalence of Antibiotic Resistant Gram-negative Colonisation|"The SATURN Consortium, Impact of Specific Antibiotic Therapies on the Prevalence of hUman Host ResistaNt Bacteria. Workpackage 2: The SATURN ICU-trial."|Completed||Phase 4|10000|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 22:53:06.890214|2018-05-31 22:53:06.890214
NCT01293058|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-02-09|2011-02-09|2011-02-10|Estimate|||||||2011-02-09|2011-02-10|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose|Study of Routs of Naloxone Administration for Opioid Overdosed Patients|Completed||Phase 2|100|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:53:06.970105|2018-05-31 22:53:06.970105
NCT01293045|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2014-04-08|2011-02-08|2011-02-10|Estimate|||||||2014-04-08|2014-04-09|Estimate|June 2010||2010-06-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Biological Bone Markers and Hydrolyzed Collagen Supplement in Menopausal Healthy Women|Study of Change in Biological Markers of Bone Metabolism Following Consumption of Hydrolyzed Collagen for 3 Months in Healthy, Non-osteoporotic, Menopausal Women.|Completed||Phase 1|44|Actual|Nealth Sarl||2|||f||||f||||||||||2018-05-31 22:53:07.05114|2018-05-31 22:53:07.05114
NCT01293032|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2016-04-05||2016-06-01|2011-02-09|2011-02-10|Estimate|2016-06-01|2016-07-12|Estimate||||2016-06-01|2016-07-12|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|||Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer|Choosing Neoadjuvant Chemotherapy Versus Hormonal Therapy for Breast Cancer Based on Gene Expression Profile|Completed||N/A|59|Actual|Virginia Commonwealth University||4|||f||||t||||||||Yes||2018-05-31 22:53:07.151616|2018-05-31 22:53:07.151616
NCT01293019|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2012-11-16|2011-02-09|2011-02-10|Estimate|||||||2012-11-16|2012-11-19|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|MUCOSTEO||Osteopathic Treatment in Adult Patients With Cystic Fibrosis|Impact of an Osteopathic Manipulative Treatment on Pain of Adult Patients With Cystic Fibrosis - a Pilot Study|Completed||Phase 3|32|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 22:53:07.692626|2018-05-31 22:53:07.692626
NCT01293006|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|2014-08-19||2017-06-01|2011-02-09|2011-02-10|Estimate|2014-09-08|2014-09-10|Estimate||||2017-06-01|2017-07-02|Actual|March 25, 2011|Actual|2011-03-25|June 2017|2017-06-30|February 22, 2012|Actual|2012-02-22|January 20, 2012|Actual|2012-01-20||Interventional|||Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)|A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:53:07.791751|2018-05-31 22:53:07.791751
NCT01292993|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-03-29|2011-02-09|2011-02-10|Estimate|||||||2011-03-29|2011-03-30|Estimate|February 2011||2011-02-28|March 2011|2011-03-31||||March 2011|Actual|2011-03-31||Interventional|||A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects|A Phase 1, Randomized, Open-Label, 3-Period, 3-Treatment, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of LX4211 and Metformin in Healthy Subjects|Completed||Phase 1|18|Anticipated|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 22:53:08.222148|2018-05-31 22:53:08.222148
NCT01292980|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-02-10|2011-02-09|2011-02-10|Estimate|||||||2011-02-10|2011-02-11|Estimate|August 2010||2010-08-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Air Fluidized Therapy (AFT) in Patients With Suspected Deep Tissue Injury (sDTI)|Air Fluidized Therapy Use in Patients Who Present With Suspected Deep Tissue Injury - a Case Series|Completed|||5|Actual|Hill-Rom|||||f||||f||||||||||2018-05-31 22:53:08.29675|2018-05-31 22:53:08.29675
NCT01292967|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-02-09|2011-02-09|2011-02-10|Estimate|||||||2011-02-09|2011-02-10|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Influence of Sugar on the Bioavailability of Cocoa Flavanols|The Influence of Maltitol on the Absorption and Metabolism of Flavanols From Chocolate|Completed||N/A|15|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 22:53:08.352461|2018-05-31 22:53:08.352461
NCT01292954|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-02-09|2011-02-09|2011-02-10|Estimate|||||||2011-02-09|2011-02-10|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Effect of Blueberries on Vascular Function in Healthy Men|Effects of Blueberries on Vascular Function and Blood Pressure in Healthy Men|Completed||N/A|10|Actual|University of Reading||4|||f||||t||||||||||2018-05-31 22:53:08.426844|2018-05-31 22:53:08.426844
NCT01292941|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-08-06|2011-02-09|2011-02-10|Estimate|||||||2015-08-06|2015-08-07|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers|Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers|Withdrawn||Phase 1|0|Actual|Coloplast A/S||4||Product development project closed prematurely|f||||f||||||||||2018-05-31 22:53:08.48737|2018-05-31 22:53:08.48737
NCT01292928|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|2015-08-14||2017-01-25|2011-02-09|2011-02-10|Estimate|2015-12-15|2016-01-20|Estimate||||2017-01-25|2017-03-08|Actual|April 2011||2011-04-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|July 2014|Actual|2014-07-31||Interventional|||SuperNOVA Clinical Stenting Trial|Stenting of the Superficial Femoral (SFA) and Proximal Popliteal Arteries (PPA) With the Boston Scientific INNOVA Self-Expanding Bare Metal Stent System|Completed||N/A|299|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 22:53:08.589725|2018-05-31 22:53:08.589725
NCT01292915|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2014-05-15|2011-02-09|2011-02-10|Estimate|||||||2014-05-15|2014-05-16|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|NIS-PUB||Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients|Survey of Non-Variceal Upper Gastro Intestinal Bleeding in Vietnamese Patients|Completed|||1044|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:53:10.245444|2018-05-31 22:53:10.245444
NCT01292902|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-02-09|2011-02-09|2011-02-10|Estimate|||||||2011-02-09|2011-02-10|Estimate|July 2010||2010-07-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Regional Distribution of Ventilation in Patients With Chronic Heart Failure||Completed||N/A|31|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 22:53:10.407991|2018-05-31 22:53:10.407991
NCT01292889|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2016-01-05|2011-02-09|2011-02-10|Estimate|||||||2016-01-05|2016-01-07|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|Season605||Study of Genes in Relation to Seasonal Affective Disorder and Major Depressive Disorder|Gene Polymorphisms in Mood Disorders|Completed|||30|Actual|University of Pittsburgh|||4||f||||f||||||Samples With DNA|"~     Saliva samples for DNA collection~   "|No|Summary data will be provided upon request to collaborators.|2018-05-31 22:53:10.486948|2018-05-31 22:53:10.486948
NCT01292876|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|2016-07-27||2017-07-13|2011-02-08|2011-02-10|Estimate|2017-07-13|2017-08-14|Actual||||2017-07-13|2017-08-14|Actual|December 2010||2010-12-31|July 2017|2017-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MTURR||Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)|Musculotendinous Tissue Unit Repair and Reinforcement (MTURR) With the Use of Biologic Scaffolds for Patients Suffering From Severe Skeletal Muscle Injury|Completed||N/A|17|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 22:53:10.581474|2018-05-31 22:53:10.581474
NCT01292863|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-02-01|2011-02-08|2011-02-10|Estimate|||||||2013-02-01|2013-02-04|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|May 2012|Anticipated|2012-05-31|February 2012|Anticipated|2012-02-29||Interventional|Delflex||The Impact of Delflex on Mesothelial Cell Viability and Peritoneal Transport|The Impact of a Biocompatible Peritoneal Dialysis Solution (Delflex Neutral pH) on Mesothelial Cell Viability and Peritoneal Transport|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2||Study was modified to in vitro design and no longer involves participants|f||||f||||||||||2018-05-31 22:53:10.775625|2018-05-31 22:53:10.775625
NCT01292850|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-02-09|2011-02-09|2011-02-10|Estimate|||||||2011-02-09|2011-02-10|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Skin Sterility After Ethyl-Chloride Spray|Skin Sterility After Ethyl-Chloride Spray|Completed|||15|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||||||2018-05-31 22:53:10.873303|2018-05-31 22:53:10.873303
NCT01292837|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|2014-06-03||2015-04-27|2011-02-08|2011-02-10|Estimate|2014-07-21|2014-08-12|Estimate||||2015-04-27|2015-05-15|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||The Baseline Analysis Population refers to the Safety Set. The Safety Set was a subset of the Enrolled Set and consisted of all subjects taking at least 1 dose of the study medication.|A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures|An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Levetiracetam in Japanese Patients (≥4 to <16 Years) With Uncontrolled Generalized Tonic-clonic (GTC) Seizures Despite Treatment With 1 or 2 Antiepileptic Drug(s)|Completed||Phase 3|13|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 22:53:10.98117|2018-05-31 22:53:10.98117
NCT01292824|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-12-01|2011-02-09|2011-02-10|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|ITX5061||Pilot Study of Hepatitis C Virus Entry Inhibitor (ITX 5061) in Liver Transplant Recipients|Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection|Completed||Phase 1|24|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 22:53:11.258414|2018-05-31 22:53:11.258414
NCT01292811|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2016-09-27|2011-02-09|2011-02-10|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|MCRCT||Restoration of Upper Limb Function in Individuals With Sub-Acute Spinal Cord Injury|Restoration of Upper Limb Function in Individuals With Sub-Acute Spinal Cord Injury|Active, not recruiting||Phase 3|25|Actual|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-05-31 22:53:11.341334|2018-05-31 22:53:11.341334
NCT01292798|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2016-01-27||2016-03-23|2011-02-09|2011-02-10|Estimate|2016-03-23|2016-04-22|Estimate||||2016-03-23|2016-04-22|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|REEF||Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab|Open Label, Phase I/II, Residual Edema Evaluation With 0.5mg and 2.0mg Ranibizumab Formulations (REEF)|Completed||Phase 1/Phase 2|43|Actual|California Retina Consultants||1|||f||||f||||||||||2018-05-31 22:53:11.425401|2018-05-31 22:53:11.425401
NCT01292785|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2015-04-08|2011-02-09|2011-02-10|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity|Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity: A Longitudinal Study Using 7 Tesla Ultrahigh-field Magnetic Resonance Imaging|Completed|||80|Actual|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 22:53:11.564937|2018-05-31 22:53:11.564937
NCT01292772|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-09-23|2011-02-09|2011-02-10|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2010||2010-12-31|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Observational|||The Effects of Radiation in Reconstructed Breasts|The Effects of Radiation Therapy on the Reconstructed Breast: An Evaluation Using MR Imaging|Recruiting|||20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 22:53:11.70853|2018-05-31 22:53:11.70853
NCT01292759|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-09|||2011-02-14|2011-02-09|2011-02-10|Estimate|||||||2011-02-14|2011-02-15|Estimate|July 2010||2010-07-31|July 2010|2010-07-31||||||||Observational|||Non-invasive Assessment of Arterial Blood Pressure and Functional Hemodynamic Parameters|An Evaluation of a New, Non-invasive Monitoring Device in Major Abdominal Surgery Patients|Unknown status|Recruiting||24|Anticipated|Johannes Gutenberg University Mainz|||||f||||f||||||||||2018-05-31 22:53:11.78041|2018-05-31 22:53:11.78041
NCT01292746|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|2015-07-09||2015-11-07|2011-02-08|2011-02-09|Estimate|2015-11-07|2015-12-11|Estimate||||2015-11-07|2015-12-11|Estimate|February 2011||2011-02-28|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study of the Effect of Low Level Laser Light on Hair Growth on the Female Human Scalp|An Evaluation of the Effect of the Erchonia ML Scanner (MLS) on the Treatment of Androgenic Alopecia in Females|Terminated||N/A|14|Actual|Erchonia Corporation||1||Recruitment and subject study compliance was difficult|f||||f||||||||||2018-05-31 22:53:11.837356|2018-05-31 22:53:11.837356
NCT01292733|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2016-01-15|2011-02-08|2011-02-09|Estimate|||||||2016-01-15|2016-01-20|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|OCEDP||Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer|Ovarian Cancer Early Detection Screening Program|Terminated||Early Phase 1|534|Actual|Swedish Medical Center||1||Closed per local IRB due to advancements in standard ovarian cancer screening.|f||||f||||||||||2018-05-31 22:53:12.035526|2018-05-31 22:53:12.035526
NCT01292720|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-05-23|2011-02-08|2011-02-09|Estimate|||||||2014-05-23|2014-05-28|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|VITD-HI||Vitamin D Supplementation in Chronic Stable Heart Failure|Vitamin D Supplementation in Chronic Stable Heart Failure: a Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 3|29|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 22:53:12.11018|2018-05-31 22:53:12.11018
NCT01292707|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2014-11-18|2011-02-08|2011-02-09|Estimate|||||||2014-11-18|2014-11-19|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|TACT||A Cluster-randomised Trial of Interventions to Improve Antimalarial Prescribing With Malaria Tests|A Cluster-randomised Trial of Health Worker and Community Interventions to Improve Adherence to National Guidelines for the Use of ACTs in Tanzania|Completed||N/A|1152|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-05-31 22:53:12.21142|2018-05-31 22:53:12.21142
NCT01292694|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2018-01-23|2011-02-08|2011-02-09|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2011|Actual|2011-03-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure|Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure|Terminated||Phase 1|12|Actual|Vanderbilt University Medical Center||3||Could not enroll enough participants, and lost funding.|f||||f||||||||||2018-05-31 22:53:12.300972|2018-05-31 22:53:12.300972
NCT01292681|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-09-07|2011-02-08|2011-02-09|Estimate|||||||2011-09-07|2011-09-08|Estimate|August 2009||2009-08-31|September 2011|2011-09-30||||January 2012|Anticipated|2012-01-31||Interventional|||Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer|Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer|Unknown status|Recruiting|N/A|60|Anticipated|Radboud University||1|||f||||f||||||||||2018-05-31 22:53:12.389117|2018-05-31 22:53:12.389117
NCT01292668|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2014-09-26|2011-02-08|2011-02-09|Estimate|||||||2014-09-26|2014-09-29|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|July 2012|Actual|2012-07-31||Interventional|||Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer|A Phase I Study for Superficial Basal Cell Carcinoma to Determine the Irradiance - Dependent Pain Threshold for Methylaminolevulinate (MAL)/PDT.|Completed||Phase 1|21|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 22:53:12.471274|2018-05-31 22:53:12.471274
NCT01292655|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-10-16|2011-02-08|2011-02-09|Estimate|||||||2017-10-16|2017-10-18|Actual|March 3, 2011|Actual|2011-03-03|October 2017|2017-10-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors|Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors|Completed||Phase 1|94|Actual|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 22:53:12.563994|2018-05-31 22:53:12.563994
NCT01292642|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|2013-06-25||2013-08-13|2011-02-08|2011-02-09|Estimate|2013-08-13|2013-08-14|Estimate||||2013-08-13|2013-08-14|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CBT-MJ-NIC||Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence|Cognitive Behavioral Therapy and the Nicotine Transdermal Patch for Cannabis Dependence and Nicotine Dependence|Completed||Phase 2|12|Actual|Mclean Hospital|slightly more than one‐third of participants did not complete treatment. The small sample size and relatively high proportion of treatment non‐completers may limit our interpretation of the results.|1|||f||||f||||||||||2018-05-31 22:53:12.659038|2018-05-31 22:53:12.659038
NCT01292629|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2015-02-11||2015-03-18|2011-02-04|2011-02-09|Estimate|2015-03-18|2015-03-20|Estimate||||2015-03-18|2015-03-20|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Comparison of the Hoya Surgical Optics (HSO) iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.|Comparison of the HSO iSert 251 Posterior Chamber Aspheric Aphakic Intraocular Lens to Historical / Literature Controls.|Completed||N/A|125|Actual|Hoya Surgical Optics, Inc.||1|||f||||f||||||||||2018-05-31 22:53:12.874978|2018-05-31 22:53:12.874978
NCT01292616|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2012-02-23|2011-02-08|2011-02-09|Estimate|||||||2012-02-23|2012-02-24|Estimate|October 2011||2011-10-31|February 2012|2012-02-29|October 2012|Anticipated|2012-10-31|||||Observational|||Effect of TNF-Inhibition Combined With Conventional DMARDs on Cervical Pannus in Patients With RA and Cervical Spine Involvement||Unknown status|Recruiting||15|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 22:53:13.057822|2018-05-31 22:53:13.057822
NCT01292603|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|2015-09-23||2017-12-15|2011-02-08|2011-02-09|Estimate|2015-11-10|2015-12-15|Estimate||||2017-12-15|2017-12-18|Actual|April 18, 2011|Actual|2011-04-18|December 2017|2017-12-31|November 17, 2017|Actual|2017-11-17|May 7, 2014|Actual|2014-05-07||Interventional||Safety Analysis Population (SAP): all participants who received at least one dose of study medication whether prematurely withdrawn or not. In Part 2 two participants randomized to the rituximab SC 1600 mg arm were included in Rituximab IV 500 mg/m^2 arm as they received only the first cycle of rituximab IV 375 mg/m^2.|A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia|An Adaptive, Comparative, Randomized, Parallel-group, Multi Center, Phase Ib Study of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With Chemotherapy (Fludarabine and Cyclophosphamide), in Patients With Previously Untreated CLL|Completed||Phase 1|240|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:53:13.221925|2018-05-31 22:53:13.221925
NCT01292590|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2017-04-25|2011-02-08|2011-02-09|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2010||2010-09-30|April 2017|2017-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Dietary Fat on Glycemic Control in Type 1 Diabetes|Use of Closed Loop Control to Examine the Effect of Changes in Dietary Fat Intake on Insulin Requirements and Glucose Control|Completed||N/A|10|Actual|Joslin Diabetes Center||1|||f||||f||||||||||2018-05-31 22:53:15.328741|2018-05-31 22:53:15.328741
NCT01292577|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-05-25|2011-02-08|2011-02-09|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2010||2010-09-30|May 2017|2017-05-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia|Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia|Completed||Phase 1/Phase 2|33|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:53:15.389393|2018-05-31 22:53:15.389393
NCT01292564|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2014-05-08|2011-02-08|2011-02-09|Estimate|||||||2014-05-08|2014-05-09|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study to See How Low Level Laser Light Affects Subcutaneous Fat Around the Hips and Waist|An Evaluation of the Effect of the Erchonia ML Scanner (MLS) as Applied to Body Contouring of the Waist and Hips on Fat Emulsification Pilot Study.|Withdrawn||N/A|0|Actual|Erchonia Corporation||2||Insufficient resources at test site for recruitment.|f||||f||||||||||2018-05-31 22:53:15.559482|2018-05-31 22:53:15.559482
NCT01292551|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-04-18|2011-02-08|2011-02-09|Estimate|||||||2013-04-18|2013-04-19|Estimate|February 2011||2011-02-28|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|TEMPO||Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.|Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test|Completed||Phase 2|75|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 22:53:15.63184|2018-05-31 22:53:15.63184
NCT01292538|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|2014-04-01||2014-05-07|2011-02-08|2011-02-09|Estimate|2014-05-07|2014-06-03|Estimate||||2014-05-07|2014-06-03|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of the Effectiveness of Green Diode Laser Light on Body Shaping|A Double-blind, Placebo-controlled Randomized Evaluation of the Effect of the Erchonia Scanner Device (GLS) Green Diode on Body Contouring of the Waist, Hips and Thighs|Completed||N/A|67|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-05-31 22:53:15.707654|2018-05-31 22:53:15.707654
NCT01292343|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2015-10-26|2011-02-07|2011-02-09|Estimate|||||||2015-10-26|2015-10-28|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Triclosan Toothpaste and Third Molar Surgery|Effect of a Triclosan Containing Dentifrice on Oral Bacteria and Postoperative Complications Following Third Molar Surgery|Completed||N/A|141|Actual|University of Rochester|||||f||||f||||||||||2018-05-31 22:53:18.193867|2018-05-31 22:53:18.193867
NCT01292525|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2016-03-22|2011-02-08|2011-02-09|Estimate|||||||2016-03-22|2016-03-23|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Protocol Calcineurin Inhibitor (CNI) Weaning|Prospective, Multicenter, Randomized, Double-blind, Controlled Parallel Group Study Designed to Assess the Risk-benefit Balance of the Gradual Withdrawal of a Calcineurin Inhibitor (Tacrolimus) in Renal Transplant Patients Over 4 Years and Clinically Selected|Terminated||Phase 3|16|Actual|Nantes University Hospital||2||Difficulties of recruitment|f||||t||||||||||2018-05-31 22:53:15.910864|2018-05-31 22:53:15.910864
NCT01292512|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2012-03-09|2011-02-08|2011-02-09|Estimate|||||||2012-03-09|2012-03-12|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Bereavement Management - Description, Assessment and Care|Bereavement Management. Description, Assessment and Care. A Randomized Controlled Study.|Completed||N/A|402|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:53:15.979717|2018-05-31 22:53:15.979717
NCT01292499|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-02-08|2011-02-08|2011-02-09|Estimate|||||||2011-02-08|2011-02-09|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|||Italian Network for the Improvement of Compliance in Depression|Italian Network for the Improvement of Compliance in Depression|Unknown status|Recruiting|N/A|1264|Anticipated|Ospedale Amedeo di Savoia||4|||f||||t||||||||||2018-05-31 22:53:16.046704|2018-05-31 22:53:16.046704
NCT01292486|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2012-09-14||2013-04-24|2011-02-08|2011-02-09|Estimate|2013-04-24|2013-05-01|Estimate||||2013-04-24|2013-05-01|Estimate|February 2011||2011-02-28|April 2013|2013-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure|Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Multiple Myeloma Patients|Completed||N/A|32|Actual|Terumo BCT||1|||f||||f||||||||||2018-05-31 22:53:16.123393|2018-05-31 22:53:16.123393
NCT01292473|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2013-06-17||2013-10-09|2011-02-08|2011-02-09|Estimate|2013-06-17|2013-09-02|Estimate||||2013-10-09|2013-10-11|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.|A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)|A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1)|Completed||Phase 3|323|Actual|Genentech, Inc.||4|||f||||f||||||||||2018-05-31 22:53:16.377502|2018-05-31 22:53:16.377502
NCT01292460|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-03-12|2011-02-08|2011-02-09|Estimate|||||||2013-03-12|2013-03-13|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies|A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those Given Individually in Patients With Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|600|Anticipated|Santen Oy||4|||f||||f||||||||||2018-05-31 22:53:17.273459|2018-05-31 22:53:17.273459
NCT01292447|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2013-12-06|2011-02-08|2011-02-09|Estimate|||||||2013-12-06|2013-12-10|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Trial of 2% Lidocaine Gel for Intrauterine Device (IUD) Insertion|A Randomized Controlled Trial of 2% Lidocaine Gel for IUD Insertion|Completed||N/A|150|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 22:53:17.395031|2018-05-31 22:53:17.395031
NCT01292434|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-03-08|2011-02-07|2011-02-09|Estimate|||||||2016-03-08|2016-03-10|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|LIITB||Lunch is in the Bag: Helping Parents Increase Fruit, Vegetables, and Whole Grains in Preschool Sack Lunches|Lunch in the Bag: Packing More Fruit, Vegetables, Grain in Preschool Sack Lunches|Completed||Phase 1|1266|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||No||2018-05-31 22:53:17.484588|2018-05-31 22:53:17.484588
NCT01292421|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-01-29|2011-02-08|2011-02-09|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2013||2013-02-28|January 2013|2013-01-31||||December 2013|Anticipated|2013-12-31||Interventional|||Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination|Pilot Study Testing the Immunogenic Efficacy of an Edible Vaccine for Hepatitis B in Healthy Volunteers|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||4|||f||||t||||||||||2018-05-31 22:53:17.634028|2018-05-31 22:53:17.634028
NCT01292408|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-01-19|2011-02-08|2011-02-09|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2011||2011-01-31|January 2012|2012-01-31||||January 2012|Anticipated|2012-01-31||Interventional|||Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients|Autophagy Inhibition Using Hydrochloroquine in Breast Cancer Patients:a Pilot Study|Unknown status|Recruiting|Phase 2|20|Anticipated|Radboud University||1|||f||||t||||||||||2018-05-31 22:53:17.727253|2018-05-31 22:53:17.727253
NCT01292395|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2017-08-10|2011-02-07|2011-02-09|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2010||2010-09-30|August 2017|2017-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency|The Musculoskeletal Response to Energy Deficit: Defining Optimal Protein Intake|Completed||N/A|42|Actual|United States Army Research Institute of Environmental Medicine||3|||f||||f||||||||||2018-05-31 22:53:17.815338|2018-05-31 22:53:17.815338
NCT01292382|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2011-04-20|2011-02-08|2011-02-09|Estimate|||||||2011-04-20|2011-04-21|Estimate|November 2010||2010-11-30|August 2010|2010-08-31|July 2012|Anticipated|2012-07-31|November 2010|Actual|2010-11-30||Interventional|TMSMemOld||Effects of rTMS on the Cognition of Elderly With Mild Memory Complaints|Effects of rTMS on the Cognition of Elderly With Cognitive Impairment no Dementia ( CIND )|Unknown status|Recruiting|N/A|34|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 22:53:17.894091|2018-05-31 22:53:17.894091
NCT01292369|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2011-08-17|2011-02-08|2011-02-09|Estimate|||||||2011-08-17|2011-08-18|Estimate|February 2011||2011-02-28|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study|Observational Study Aimed to Characterize a System for Breast and Colon Cancer Diagnosis by Breath Testing - NaNose Study|Unknown status|Recruiting||560|Anticipated|Rambam Health Care Campus|||4||f||||f||||||Samples Without DNA|"~     Breath samples~   "|||2018-05-31 22:53:18.036946|2018-05-31 22:53:18.036946
NCT01292356|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2017-04-04|2011-02-08|2011-02-09|Estimate|||||||2017-04-04|2017-04-05|Actual|December 20, 2010|Actual|2010-12-20|April 2017|2017-04-30|March 3, 2016|Actual|2016-03-03|March 3, 2016|Actual|2016-03-03||Interventional|||Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response||Completed||Phase 2|28|Actual|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 22:53:18.13331|2018-05-31 22:53:18.13331
NCT01292330|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2011-02-08|2011-02-08|2011-02-09|Estimate|||||||2011-02-08|2011-02-09|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|November 2011|Anticipated|2011-11-30|September 2011|Anticipated|2011-09-30||Interventional|||A Clinical Study to Evaluate the Clinical Outcomes of Hepatectomy With Nutritional Risk After Preoperative Nutritional Support|A Clinical Study to Evaluate the Clinical Outcomes of Hepatectomy With Nutritional Risk After Preoperative Nutritional Support|Unknown status|Recruiting|N/A|60|Anticipated|Peking Union Medical College Hospital|||||f||||f||||||||||2018-05-31 22:53:18.275117|2018-05-31 22:53:18.275117
NCT01292317|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2016-03-16|2011-02-08|2011-02-09|Estimate|||||||2016-03-16|2016-03-18|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Neutrophil Gelatinase-associated Lipocalin (NGAL) and Contrast Media Induced Nephropathy|Early Detection and Intervention of Acute Contrast Media Induced Nephropathy Using Neutrophil Gelatinase-associated Lipocalin (NGAL) May Improve Renal Outcome: A Study in Patients Undergoing Intra-arterial Angiography.|Completed||N/A|819|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 22:53:18.340082|2018-05-31 22:53:18.340082
NCT01292304|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2015-05-28||2015-06-30|2011-02-07|2011-02-09|Estimate|2015-06-30|2015-07-27|Estimate||||2015-06-30|2015-07-27|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Tolvaptan for Ascites in Cirrhotic Patients|Single Center, Open Labeled Pilot Study Evaluating the Safety and Efficacy of Tolvaptan in Patients With Cirrhotic Ascites|Completed||Phase 4|10|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 22:53:18.429354|2018-05-31 22:53:18.429354
NCT01292291|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-08-06|2011-02-08|2011-02-09|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 2011||2011-04-30|September 2011|2011-09-30||||April 2013|Anticipated|2013-04-30||Interventional|||MRI in Diagnosing Prostate Cancer|PROMIS - Prostate MRI Imaging Study - Evaluation of Multi-Parametric Magnetic Resonance Imaging in the Diagnosis and Characterization of Prostate Cancer|Unknown status|Not yet recruiting|N/A|714|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 22:53:18.656158|2018-05-31 22:53:18.656158
NCT01292278|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2014-12-04|2011-02-08|2011-02-09|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2006||2006-01-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|August 2015|Anticipated|2015-08-31||Observational|||Constitution of Cerebrospinal Fluid and Blood Database/Specimen in Acute Stage of Subarachnoid Hemorrhage (aSAH) Patients|The Possible Role of Neuropeptide Y After Spontaneous Subarachnoid Hemorrhage|Unknown status|Recruiting||90|Anticipated|University of Regensburg|||2||f||||t||||||Samples Without DNA|"~     cerebrospinal fluid / serum~   "|||2018-05-31 22:53:18.733823|2018-05-31 22:53:18.733823
NCT01292265|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2012-10-26||2012-10-26|2011-02-08|2011-02-09|Estimate|2012-10-26|2012-12-05|Estimate||||2012-10-26|2012-12-05|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SWIFT||A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)|A Phase 3b, Open Label, Multicenter, Exploratory Study to Assess Changes in Joint Inflammation Using Ultrasonography in Subjects With Rheumatoid Arthritis Treated for 12 Weeks With Certolizumab Pegol|Terminated||Phase 3|3|Actual|UCB Pharma||1||Termination of study due to low enrollment. There were no safety issues.|f||||f||||||||||2018-05-31 22:53:18.815736|2018-05-31 22:53:18.815736
NCT01292252|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2015-12-02|2011-02-07|2011-02-09|Estimate|||||||2015-12-02|2015-12-04|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Use of Forteo (Teriparatide) in Posterolateral Lumbar Spine Fusion|Assessment of the Efficacy of Forteo (Teriparatide) in Patients Undergoing Posterolateral Lumbar Spinal Fusion|Unknown status|Recruiting|N/A|90|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 22:53:18.991112|2018-05-31 22:53:18.991112
NCT01292239|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2013-10-15|2013-04-23|2013-12-16|2011-02-08|2011-02-09|Estimate|2013-10-15|2013-12-09|Estimate|2013-04-23|2013-05-01|Estimate|2013-12-16|2014-01-17|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients|A Phase III, Randomized, Double-blind, Placebo-controlled Trial in Japan to Investigate the Efficacy and Safety of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naive, Genotype 1, Hepatitis C-infected Subjects|Completed||Phase 3|183|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 22:53:19.104415|2018-05-31 22:53:19.104415
NCT01292226|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2014-10-03||2016-04-08|2011-02-08|2011-02-09|Estimate|2015-02-23|2015-03-02|Estimate||||2016-04-08|2016-05-12|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||All enrolled participants.|A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).|Relationships Between Pharmacokinetic and Pharmacodynamic Strategies for Assessment of the Risks for Acute Rejection and Side Effects of Mycophenolate Mofetil|Completed||Phase 2|45|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:53:19.859847|2018-05-31 22:53:19.859847
NCT01292213|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2014-09-04|2011-02-08|2011-02-09|Estimate|||||||2014-09-04|2014-09-08|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom|Identification and Characterisation of Bacteria Causing Chronic Cough Among Children in the United Kingdom|Terminated|||19|Actual|GlaxoSmithKline|||2|"• Long delay due to challenges with sample analysis at local labs; • Low recruitment of case~   and control subjects; • Constant staff turn-over in the sites."|f||||||||||Samples With DNA|"~     Cough swab, oropharyngeal swab, nasopharyngeal swabs, blood and bronchoscopy/ bronchoalveolar~     lavage samples.~   "|||2018-05-31 22:53:21.140018|2018-05-31 22:53:21.140018
NCT01292200|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2017-06-29|2011-02-08|2011-02-09|Estimate|||||||2017-06-29|2017-07-02|Actual|July 2010||2010-07-31|July 2016|2016-07-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Breast Health in Chinese American Women|A RCT to Promote Mammography Adherence Among Chinese Immigrant Women|Completed||N/A|954|Actual|Georgetown University||2|||f||||f||||||||Undecided||2018-05-31 22:53:21.31106|2018-05-31 22:53:21.31106
NCT01292187|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2013-07-11||2014-09-05|2011-02-07|2011-02-09|Estimate|2014-09-05|2014-09-12|Estimate||||2014-09-05|2014-09-12|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional||Baseline Lumbar Spine BMD (Bone Mineral Density) T-scores, plasma CTx-1 (collagen type 1 C telopeptide), , FRAX scores, age, race and body weight were compared between the two treatment arms and were found to have similar means, respectively.|A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis|A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture|Completed||Phase 2|129|Actual|Tarsa Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 22:53:22.474547|2018-05-31 22:53:22.474547
NCT01292174|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2012-12-17|2011-02-08|2011-02-09|Estimate|||||||2012-12-17|2012-12-18|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|TMB-108||Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers|A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Ibalizumab in HIV-Negative, At-Risk Volunteers|Completed||Phase 1|25|Actual|TaiMed Biologics Inc.||3|||f||||t||||||||||2018-05-31 22:53:23.64209|2018-05-31 22:53:23.64209
NCT01292161|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-02-08|2011-02-08|2011-02-09|Estimate|||||||2011-02-08|2011-02-09|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C|Study of Silymarin for Improving Hepatitis C|Completed||Phase 2|55|Actual|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:53:23.74713|2018-05-31 22:53:23.74713
NCT01292148|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2015-07-17|2011-02-07|2011-02-09|Estimate|||||||2015-07-17|2015-07-21|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Observational|TH||Measurement of Core Temperatures During Therapeutic Hypothermia|Core Temperature Measurement in Therapeutic Hypothermia: Tympanic Membrane, Bladder and Rectal Versus Pulmonary Artery Methods|Completed|||20|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 22:53:23.897499|2018-05-31 22:53:23.897499
NCT01292135|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2014-02-28||2014-07-17|2011-02-08|2011-02-09|Estimate|2014-07-17|2014-07-24|Estimate||||2014-07-17|2014-07-24|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)|A Phase 1b, Multicenter, Open-label, Parallel-group Safety Study of a Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI 32765, in Combination With Chemotherapy in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Completed||Phase 1|33|Actual|Pharmacyclics LLC.||2|||f||||f||||||||||2018-05-31 22:53:23.963782|2018-05-31 22:53:23.963782
NCT01292122|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2012-12-19|2011-02-08|2011-02-09|Estimate|||||||2012-12-19|2012-12-20|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds|A Single-Center, Prospective, Randomized Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds|Terminated||N/A|3|Actual|Organogenesis||1|||f||||f||||||||||2018-05-31 22:53:24.737655|2018-05-31 22:53:24.737655
NCT01292109|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2012-02-08|2011-02-08|2011-02-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Observational|||A Study of PICOPREP in Patients Needed to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery.|Compliance and Efficacy in the Use of PICOPREP for Bowel Cleansing|Completed|||252|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 22:53:24.877607|2018-05-31 22:53:24.877607
NCT01292096|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2016-02-29|2011-02-07|2011-02-09|Estimate|||||||2016-02-29|2016-03-02|Estimate|August 2007||2007-08-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Intervening With and Improving Care for Patients at Risk for Frequent Hospital Admissions|Intervening With and Improving Care for Patients at Risk for Frequent Hospital Admissions|Completed||Phase 1|19|Actual|New York University School of Medicine|||||f||||f||||||||||2018-05-31 22:53:24.973261|2018-05-31 22:53:24.973261
NCT01292083|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-02-05|2011-02-07|2011-02-09|Estimate|||||||2014-02-05|2014-02-06|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery|A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression in Triple Negative Invasive Breast Cancer|Withdrawn||N/A|0|Actual|University of Southern California||1||No accrual last 2 years|f||||t||||||||||2018-05-31 22:53:25.050208|2018-05-31 22:53:25.050208
NCT01292070|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2014-01-06||2014-01-06|2011-02-08|2011-02-09|Estimate|2014-01-06|2014-02-20|Estimate||||2014-01-06|2014-02-20|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Intent-to-treat|Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy|A Dose-Escalating Phase 0 Study to Evaluate the Safety and Local Cutaneous Reactivity of Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD) in Cat-allergic Healthy Volunteers|Terminated||Early Phase 1|4|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The experimental protein (human Fcgamma1-Fel d1 fusion protein) & control protein (standardized cat hair allergenic extract) elicited comparable reactivity in the first four participants dosed and consequently the trial was discontinued for futility|1||Futility|f||||t||||||||||2018-05-31 22:53:25.161509|2018-05-31 22:53:25.161509
NCT01292057|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2017-06-08||2017-07-07|2011-02-08|2011-02-09|Estimate|2017-06-08|2017-07-07|Actual||||2017-07-07|2017-08-08|Actual|February 2011||2011-02-28|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Aripiprazole Effects on Alcohol Drinking and Craving|Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication|Completed||Phase 3|99|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 22:53:25.509555|2018-05-31 22:53:25.509555
NCT01292044|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2015-03-26|2011-02-08|2011-02-09|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Role of Elastography in the Diagnosis of Thyroid Nodules|The Role of Elastography in the Diagnosis of Thyroid Nodules|Completed||N/A|188|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 22:53:25.892972|2018-05-31 22:53:25.892972
NCT01292031|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2016-02-02|2011-02-08|2011-02-09|Estimate|||||||2016-02-02|2016-02-03|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MagicBullet||Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)|Randomized, Open Label, Multicenter, Non-inferiority Trial to Compare Safety and Efficacy of Colistin vs. Meropenem in VAP Caused by CR-GNB|Completed||Phase 3|232|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||t||||||||||2018-05-31 22:53:25.982094|2018-05-31 22:53:25.982094
NCT01292018|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2013-02-20|2011-02-08|2011-02-09|Estimate|||||||2013-02-20|2013-02-21|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|February 2012|Actual|2012-02-29|||||Observational|SOLID||Management of Dyslipidemia in Adult Type 2 Diabetes Patients in India|A Non Interventional, Cross Sectional, Epidemiological Study on the Management of Dyslipidemia in Type 2 DM Adult Patients in India|Completed|||5400|Actual|AstraZeneca|||||f||||f||||||Samples Without DNA|"~     Lipid profile ( Low Density Lipoproteins(LDL), High Density Lipoprotein (HDL), Triglycerides~     & Total cholesterol) Blood Glucose Measurements (Fasting Plasma Glucose)~   "|||2018-05-31 22:53:26.136244|2018-05-31 22:53:26.136244
NCT01292005|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2013-09-23||2016-09-14|2011-02-08|2011-02-09|Estimate|2013-10-23|2013-12-13|Estimate||||2016-09-14|2016-10-25|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pentoxifylline Treatment of Acute Pancreatitis|Pentoxifylline Treatment in Acute Pancreatitis; A Double-Blind Placebo-Controlled Randomized Trial|Completed||Early Phase 1|28|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:53:26.219121|2018-05-31 22:53:26.219121
NCT01291992|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2018-03-09|2011-02-08|2011-02-09|Estimate|||||||2018-03-09|2018-03-13|Actual|September 2010|Actual|2010-09-30|March 2018|2018-03-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Observational|||Seizures After Cardiac Surgery -- A Study With Continuous EEG Monitoring|Seizures After Cardiac Surgery -- A Prospective Study With Continuous EEG Monitoring|Completed|||100|Actual|Lawson Health Research Institute|||1||f||||f||||||||||2018-05-31 22:53:26.891435|2018-05-31 22:53:26.891435
NCT01291979|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-02-08|2011-02-08|2011-02-09|Estimate|||||||2011-02-08|2011-02-09|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||The Effect of Intravenous Lidocaine on Pain After Tonsillectomy|Intravenous Lidocaine for Effective Pain Relief After Tonsillectomy: a Prospective, Randomized, Double-blind, Placebo-controlled Study|Unknown status|Not yet recruiting|Phase 4|62|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||f||||||||||2018-05-31 22:53:26.989411|2018-05-31 22:53:26.989411
NCT01291966|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-02-08|2011-02-08|2011-02-09|Estimate|||||||2011-02-08|2011-02-09|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|||||Interventional|ATEM-AP||Efficacy of a Intervention to Reduce Medication Errors and Improve Adherence|Efficacy of a Intervention to Reduce Medication Errors and Therapeutic Failure in Patients Over 65 Years Polypharmacy|Completed||N/A|154|Actual|Hospital Universitario Reina Sofia de Cordoba||1|||f||||f||||||||||2018-05-31 22:53:27.07122|2018-05-31 22:53:27.07122
NCT01291953|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2015-08-17|2011-02-08|2011-02-09|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|FAMDAP||Effectiveness of Early Detection of Atrial Fibrillation|Effectiveness of Early Detection of Atrial Fibrillation in People 65 Years or More bt Physicians and Nurse in Primary Care|Completed||N/A|6990|Actual|Hospital Universitario Reina Sofia de Cordoba||2|||f||||f||||||||||2018-05-31 22:53:27.145242|2018-05-31 22:53:27.145242
NCT01291940|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2013-06-19|2011-02-08|2011-02-09|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|EES||The Effects of Emollient Therapy on the Skin Barrier|The Effects of Emollient Therapy on the Skin Barrier Function|Unknown status|Recruiting|N/A|190|Anticipated|Oregon Health and Science University||3|||f||||t||||||||||2018-05-31 22:53:27.199535|2018-05-31 22:53:27.199535
NCT01291927|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2011-02-08|2011-02-08|2011-02-09|Estimate|||||||2011-02-08|2011-02-09|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Pancreas-sparing Duodenectomy Versus Pancreatoduodenectomy for Early-stage Periampullary Carcinoma|Comparison of Pancreas-sparing Duodenectomy With Pancreatoduodenectomy for Early-stage Periampullary Carcinoma:A Prospective Non-Randomized Trial|Unknown status|Recruiting|N/A|120|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 22:53:27.2825|2018-05-31 22:53:27.2825
NCT01291914|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04||2013-02-22|2013-02-22|2011-02-07|2011-02-09|Estimate||||2013-02-22|2013-02-28|Estimate|2013-02-22|2013-02-28|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized,Placebo-Controlled, Two-Phase Study (a Single Ascending Dose Phase Followed by a Proof of Concept Phase) to Assess the Safety, Efficacy and Pharmacokinetics of FX005 for the Treatment of Pain in Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|140|Actual|Flexion Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 22:53:27.394601|2018-05-31 22:53:27.394601
NCT01291901|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04||2014-07-28|2014-07-28|2011-02-08|2011-02-09|Estimate||||2014-07-28|2014-08-08|Estimate|2014-07-28|2014-08-08|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Interventional|||NP2 Enkephalin For Treatment of Intractable Cancer Pain|A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy|Completed||Phase 2|33|Actual|Diamyd Inc||2|||f||||f||||||||||2018-05-31 22:53:27.551656|2018-05-31 22:53:27.551656
NCT01291888|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2015-08-04|2011-02-08|2011-02-09|Estimate|||||||2015-08-04|2015-08-05|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease|Efficacy and Tolerability of Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease: A Single-center Randomized Trial.|Completed|||50|Actual|University of Michigan|||||f||||f||||||Samples Without DNA|"~     A total of 30 ml blood (CBC with differential and platelets-3ml, comprehensive panel-5-7ml,~     biomarkers-20ml) will be drawn by venipuncture typically from the antecubital vein at~     baseline visit (30ml), and week 6-study midpoint (30ml) and end of study (30ml). At the~     screening visit only 10ml blood will be required (CBC and Comprehensive Panel).~   "|||2018-05-31 22:53:27.771401|2018-05-31 22:53:27.771401
NCT01291875|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2014-02-10|2011-02-08|2011-02-09|Estimate|||||||2014-02-10|2014-02-12|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Periodontal Treatment and Metabolic Control in Type 2 Diabetic Patients||Unknown status|Recruiting|N/A|732|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:53:27.838676|2018-05-31 22:53:27.838676
NCT01291862|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2012-01-31|2011-02-08|2011-02-09|Estimate|||||||2012-01-31|2012-02-02|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion|Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion|Unknown status|Recruiting|N/A|30|Anticipated|Yonsei University|||||f||||f||||||||||2018-05-31 22:53:27.912852|2018-05-31 22:53:27.912852
NCT01291849|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-08|2011-02-08|2011-02-09|Estimate|||||||2011-02-08|2011-02-09|Estimate|March 2010||2010-03-31|January 2011|2011-01-31|May 2010|Actual|2010-05-31|||||Interventional|||The Effect-site Concentration of Remifentanil for Preventing Cough During Emergence From Balanced Anesthesia for Nasal Surgery||Completed||Phase 4|24|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 22:53:27.990767|2018-05-31 22:53:27.990767
NCT01291836|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2016-01-05||2017-08-05|2011-02-08|2011-02-09|Estimate|2017-08-05|2018-02-19|Actual||||2017-08-05|2018-02-19|Actual|December 2010||2010-12-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|October 2013|Actual|2013-10-31||Observational|AKINESIS|ED presentation with symptoms of Heart Failure.|Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study|Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)|Completed|||930|Actual|Alere San Diego|||||f||||t||||||Samples Without DNA|"~     Urine Samples, Plasma Samples~   "|||2018-05-31 22:53:28.089233|2018-05-31 22:53:28.089233
NCT01291823|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|December 2010||2010-12-31|February 2011|2011-02-28|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer|A Phase II Study of Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal|Unknown status|Recruiting|Phase 2|70|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 22:53:28.277147|2018-05-31 22:53:28.277147
NCT01291810|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2014-09-17|2011-02-07|2011-02-08|Estimate|||||||2014-09-17|2014-09-18|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|May 2014|Actual|2014-05-31|October 2012|Actual|2012-10-31||Interventional|||Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety and Immunogenicity of Neovacs' TNFα-Kinoid in Adult Subjects With Crohn's Disease|Completed||Phase 2|66|Actual|Neovacs||2|||f||||t||||||||||2018-05-31 22:53:28.363709|2018-05-31 22:53:28.363709
NCT01291797|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2011-08-17|2011-02-07|2011-02-08|Estimate|||||||2011-08-17|2011-08-19|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease|Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease|Terminated|||4|Actual|Icahn School of Medicine at Mount Sinai|||1|due to inability to recruit sufficient sample size in reasonable time frame.|f||||f||||||||||2018-05-31 22:53:28.486145|2018-05-31 22:53:28.486145
NCT01291784|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2013-07-31||2014-11-21|2011-02-07|2011-02-08|Estimate|2014-08-13|2014-08-28|Estimate||||2014-11-21|2014-12-08|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||patients with intermediate -1 or higher primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF). Patients were eligible if they had documented BMF of MF-2 or higher as assessed by the European consensus grading score and grade 3 or higher by modified Bauermeister scale.|Anti-TGF-beta Therapy in Patients With Myelofibrosis|Phase I Study of GC1008 in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera/Essential Thrombocythemia Related Myelofibrosis (Post-PV/ET MF)|Terminated||Phase 1|3|Actual|Icahn School of Medicine at Mount Sinai|"Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.~Limited patient data (2 evaluable patients), a dose accumulation ratio cannot be determined."|1||"Early termination when the drug was no longer made available by the pharmaceutical company due~   to unanticipated management and administrative decisions."|f||||t||||||||||2018-05-31 22:53:28.552451|2018-05-31 22:53:28.552451
NCT01291771|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2015-01-15|2011-02-07|2011-02-08|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|MICROCARD||Myocardial Microvascular Disease in ESRD|Detection and Outcomes of Myocardial Microvascular Disease in Patients With End Stage Renal Disease|Terminated||N/A|30|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 22:53:29.772824|2018-05-31 22:53:29.772824
NCT01291758|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2014-02-24|2011-02-07|2011-02-08|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Exercise in Gulf War Illness (GWI)||Completed|||50|Actual|Georgetown University|||2||f||||t||||||Samples With DNA|"~     Plasma, serum, urine, cerebrospinal fluid (CSF), and buccal swab samples retained for testing~     as described in protocol.~   "|||2018-05-31 22:53:29.845908|2018-05-31 22:53:29.845908
NCT01291745|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|September 2015|Anticipated|2015-09-30|September 2013|Anticipated|2013-09-30||Observational|O-MDS-Protocol||Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES|Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES|Unknown status|Recruiting||200|Anticipated|Fondazione Amelia Scorza Onlus|||1||f||||f||||||Samples With DNA|"~     bone marrow and buccal cell samples~   "|||2018-05-31 22:53:29.930735|2018-05-31 22:53:29.930735
NCT01291732|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2013-10-31|2011-02-07|2011-02-08|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 2011||2011-02-28|October 2013|2013-10-31||||April 2011|Actual|2011-04-30||Interventional|||Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (12.5 mg, 50 mg, 200 mg) of BI 135585 XX (Tablet) in Chinese and Japanese Healthy Male Volunteers (Randomised, Double-blind,Placebo-controlled Within Dose Groups)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:53:30.073746|2018-05-31 22:53:30.073746
NCT01291719|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-05|||2018-01-08|2011-02-07|2011-02-08|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2008||2008-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Insulin Balanced Infusion System|Insulin Balanced Infusion System Control of Glucose|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Admetsys Corporation||1|||f||||t||||||||Undecided||2018-05-31 22:53:30.135466|2018-05-31 22:53:30.135466
NCT01291706|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2014-04-25|2011-02-07|2011-02-08|Estimate|||||||2014-04-25|2014-04-28|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|TCD||Transcranial Doppler on Admission of Patients With Mild to Moderate Traumatic Brain Injury|Prospective, Multicentre, Observational Study|Completed|||369|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 22:53:30.313222|2018-05-31 22:53:30.313222
NCT01291693|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2015-12-01|2011-02-07|2011-02-08|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PECO||Testing Delivery Channels of Brief Motivational Alcohol Intervention|Testing Delivery Channels of Brief Motivational Alcohol Intervention Among General Hospital Inpatients With Risky Drinking: Personal Counseling Versus Computer-generated Feedback Letters|Completed||Phase 2/Phase 3|975|Actual|University Medicine Greifswald||3|||f||||f||||||||||2018-05-31 22:53:30.423703|2018-05-31 22:53:30.423703
NCT01291680|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Observational|||Assessment of Central Pain in the Peripartum Period|Assessment of Central Pain in the Peripartum Period|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 22:53:30.530424|2018-05-31 22:53:30.530424
NCT01291667|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|May 2009||2009-05-31|February 2011|2011-02-28||||||||Observational|HOPES||Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE|A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab( Cipterbin®) Plus vinorelbinE Simultaneously or Sequencely|Completed|||330|Anticipated|Shanghai CP Guojian Pharmaceutical Co.,Ltd.|||||f||||t||||||||||2018-05-31 22:53:30.621923|2018-05-31 22:53:30.621923
NCT01291641|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-04-25|2011-02-06|2011-02-08|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2011||2011-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|IMPACTonIMT||Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy|Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study|Completed||Phase 4|342|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 22:53:30.780635|2018-05-31 22:53:30.780635
NCT01291628|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2012-01-18|2011-02-07|2011-02-08|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Prevention of Capecitabine Induced Hand and Foot Syndrome|A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome|Unknown status|Not yet recruiting|N/A|10|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 22:53:30.902858|2018-05-31 22:53:30.902858
NCT01291615|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2014-10-21|2011-02-06|2011-02-08|Estimate|||||||2014-10-21|2014-10-23|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer|Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer|Completed||Phase 1|6|Actual|Kansai Hepatobiliary Oncology Group||2|||f||||t||||||||||2018-05-31 22:53:31.013185|2018-05-31 22:53:31.013185
NCT01291602|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-06|||2017-08-31|2011-02-07|2011-02-08|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2011||2011-02-28|August 2017|2017-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects|Completed||Phase 1|15|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 22:53:31.090597|2018-05-31 22:53:31.090597
NCT01291589|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-08-08|2011-02-07|2011-02-08|Estimate|||||||2016-08-08|2016-08-09|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|ENGAGE||HIV Prevention in Very High Risk Men Who Have Sex With Men|HIV Prevention in Very High Risk Men Who Have Sex With Men|Completed||Phase 1|14|Actual|Fenway Community Health||1|||f||||t||||||||||2018-05-31 22:53:31.162595|2018-05-31 22:53:31.162595
NCT01291576|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-06-13|2011-02-07|2011-02-08|Estimate|||||||2017-06-13|2017-06-14|Actual|March 2011||2011-03-31|June 2017|2017-06-30|September 2023|Anticipated|2023-09-30|September 2013|Actual|2013-09-30||Interventional|ENDORE||Functional Outcomes of Surgical Management of Deep Endometriosis Infiltrating the Rectum|Randomized Trial Comparing Digestive and Urinary Dysfunction Secondary to 2 Surgical Techniques Used in the Management of Deep Endometriosis Infiltrating the Rectum: Colorectal Resection and Rectal Nodules Excision (ENDORE)|Active, not recruiting||N/A|60|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 22:53:31.251358|2018-05-31 22:53:31.251358
NCT01291563|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2012-11-05|2011-02-05|2011-02-08|Estimate|||||||2012-11-05|2012-11-06|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|April 2011|Actual|2011-04-30|||||Interventional|||TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions|A Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group Trial to Evaluate the Effect of Single-dose TMC207 on the QT/QTc Interval in Healthy Subjects|Completed||Phase 1|88|Actual|Tibotec BVBA||4|||f||||||||||||||2018-05-31 22:53:31.323485|2018-05-31 22:53:31.323485
NCT01291550|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||||||Observational|||Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples||Unknown status|Recruiting||300|Anticipated|Rambam Health Care Campus|||3||f||||f||||||||||2018-05-31 22:53:31.421954|2018-05-31 22:53:31.421954
NCT01291537|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2016-10-10|2011-02-07|2011-02-08|Estimate|||||||2016-10-10|2016-10-11|Estimate|November 2011||2011-11-30|October 2016|2016-10-31||||March 2016|Actual|2016-03-31||Interventional|||Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients||Completed||Phase 2|56|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 22:53:31.567046|2018-05-31 22:53:31.567046
NCT01291524|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-05-13|2011-02-07|2011-02-08|Estimate|||||||2011-05-13|2011-05-16|Estimate|February 2011||2011-02-28|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Evaluate The Effects Of Caloric Content And Time Of Dosing On The Pharmacokinetics Of Pregabalin Controlled Release Formulation As Compared To The Immediate Release Formulation|Completed||Phase 1|24|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:53:31.660586|2018-05-31 22:53:31.660586
NCT01291511|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-06-10|2011-02-05|2011-02-08|Estimate|||||||2016-06-10|2016-06-13|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|REPRIEVE||Relapse Prevention Study in Patients With Schizophrenia|A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension|Completed||Phase 3|303|Actual|Vanda Pharmaceuticals||2|||f||||||||||||||2018-05-31 22:53:31.826564|2018-05-31 22:53:31.826564
NCT01291498|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2013-06-27||2017-11-07|2011-02-07|2011-02-08|Estimate|2014-05-22|2014-06-25|Estimate||||2017-11-07|2017-12-18|Actual|April 2011||2011-04-30|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma|High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma|Terminated||N/A|1|Actual|Oxford University Hospitals NHS Trust||1||The manufacturer is not currently supporting research in this indication.|f||||f||||||||||2018-05-31 22:53:32.059322|2018-05-31 22:53:32.059322
NCT01291485|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-10-09|2011-02-07|2011-02-08|Estimate|||||||2012-10-09|2012-10-10|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Electronic Intervention for HIV Medication Adherence|Randomized Clinical Trial Examining the Efficacy of an Electronic Intervention for HIV Medication Adherence|Completed||N/A|97|Actual|Oklahoma State University Center for Health Sciences||2|||f||||t||||||||||2018-05-31 22:53:32.249553|2018-05-31 22:53:32.249553
NCT01291472|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-12-12|2011-02-07|2011-02-08|Estimate|||||||2011-12-12|2011-12-13|Estimate|June 2011||2011-06-30|February 2011|2011-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Disposition of Intravenous Ketorolac|Disposition of Intravenous Ketorolac After Cesarean Section|Completed||Phase 4|42|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 22:53:32.440148|2018-05-31 22:53:32.440148
NCT01291459|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2015-12-29|2011-02-07|2011-02-08|Estimate|||||||2015-12-29|2015-12-30|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|NNNB||Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients|Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Association Pour la Recherche en Infectiologie||1|||f||||t||||||||||2018-05-31 22:53:32.524938|2018-05-31 22:53:32.524938
NCT01291446|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2012-03-22|2011-02-07|2011-02-08|Estimate|||||||2012-03-22|2012-03-23|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Effect of Diet on Intestinal Gas Production and Evacuation in Healthy Subjects and Flatulent Patients|Objective Markers Flatulence: Determination of Gas Production and Evacuation in Response to Dietary Manipulations|Completed||N/A|50|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f||||||||||2018-05-31 22:53:32.622043|2018-05-31 22:53:32.622043
NCT01291433|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2017-12-07|2011-02-07|2011-02-08|Estimate|||||||2017-12-07|2017-12-08|Actual|March 2011||2011-03-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|PENTOCLO||Trial of Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy|Randomized Clinical Trial Evaluating Combined Pentoxifylline-tocopherol-clodronate vs Placebo in Radiation-induced Brachial Plexopathy: the PENTOCLO Trial|Completed||Phase 3|59|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:53:32.695826|2018-05-31 22:53:32.695826
NCT01291420|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2013-07-11|2011-02-07|2011-02-08|Estimate|||||||2013-07-11|2013-07-12|Estimate|February 2011||2011-02-28|July 2013|2013-07-31||||February 2014|Anticipated|2014-02-28||Interventional|||Dendritic Cell Vaccination for Patients With Solid Tumors|Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study|Unknown status|Enrolling by invitation|Phase 1/Phase 2|10|Anticipated|University Hospital, Antwerp|||||f||||f||||||||||2018-05-31 22:53:32.787142|2018-05-31 22:53:32.787142
NCT01291407|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2013-09-17|2011-02-07|2011-02-08|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer|A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer|Completed||Phase 1|27|Actual|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:53:32.86073|2018-05-31 22:53:32.86073
NCT01291394|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-12-22|2011-02-07|2011-02-08|Estimate|||||||2017-12-22|2017-12-26|Actual|January 31, 2011|Actual|2011-01-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS FRA||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|Completed|||223|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 22:53:32.9432|2018-05-31 22:53:32.9432
NCT01291381|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Interventional|||Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children|Regulatory T Cells in the Response to SIT in Allergic Rhinitis.|Completed||N/A|50|Actual|Beijing Tongren Hospital||2|||f||||t||||||||||2018-05-31 22:53:33.011951|2018-05-31 22:53:33.011951
NCT01291368|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-10-19|2011-02-07|2011-02-08|Estimate|||||||2012-10-19|2012-10-22|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care|Does Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care?|Completed|||248|Actual|University of Aarhus|||||f||||t||||||||||2018-05-31 22:53:33.090527|2018-05-31 22:53:33.090527
NCT01291355|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2014-11-11|2011-02-07|2011-02-08|Estimate|||||||2014-11-11|2014-11-13|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Maternal Positioning and Occipitoposterior Fetal Position|Maternal Positioning to Correct Occipitoposterior Fetal Position in Labor: A Randomized Controlled Trial|Completed||N/A|438|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 22:53:33.147156|2018-05-31 22:53:33.147156
NCT01291342|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-05|||2013-02-05|2011-02-05|2011-02-08|Estimate|||||||2013-02-05|2013-02-06|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|DIP||Detection and Identification of Preeclampsia Via Volatile Biomarkers|Detection and Identification of Preeclampsia Via Volatile Biomarkers|Completed|||90|Anticipated|The Nazareth Hospital, Israel|||3||f||||t||||||Samples Without DNA|"~     Breath Serum~   "|||2018-05-31 22:53:33.21107|2018-05-31 22:53:33.21107
NCT01291329|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2015-02-12|2011-02-07|2011-02-08|Estimate|||||||2015-02-12|2015-02-13|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|WJ-MSC-AMI||Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)|Phase 2 Study of Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With ST-segment Elevation Acute Myocardial Infarction (AMI)|Completed||Phase 2|160|Anticipated|Navy General Hospital, Beijing||1|||f||||t||||||||||2018-05-31 22:53:33.262462|2018-05-31 22:53:33.262462
NCT01291316|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-12-13|2011-02-07|2011-02-08|Estimate|||||||2011-12-13|2011-12-14|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation||Completed||Phase 1/Phase 2|25|Actual|University Hospital, Geneva||3|||f||||f||||||||||2018-05-31 22:53:33.402067|2018-05-31 22:53:33.402067
NCT01291303|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|NIMV01AECB||Optimization of Ventilator Setting for Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Optimization of Ventilator Setting by Flow and Pressure Curves Analysis During Noninvasive Ventilation for Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Completed||N/A|70|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 22:53:33.483986|2018-05-31 22:53:33.483986
NCT01291290|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2013-03-13|2011-02-07|2011-02-08|Estimate|||||||2013-03-13|2013-03-14|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Interventional|rAAA||START - Early Thrombocyte Administration to Patients With Ruptured Abdominal Aortic Aneurism|Thrombocyte Administration Versus no Thrombocytes to Patients With Ruptured Abdominal Aortic Aneurism Before Transport to Hospital With Vascular Surgical Department|Unknown status|Recruiting|N/A|420|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 22:53:33.59703|2018-05-31 22:53:33.59703
NCT01291277|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2016-10-25||2016-12-23|2011-02-04|2011-02-08|Estimate|2016-10-31|2016-12-26|Estimate||||2016-12-23|2017-02-13|Actual|August 2008||2008-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Time Interval for Endoscopic Variceal Ligation|Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices|Completed||Phase 4|90|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 22:53:33.694769|2018-05-31 22:53:33.694769
NCT01291264|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2014-01-21||2014-01-21|2011-02-04|2011-02-08|Estimate|2014-01-21|2014-03-04|Estimate||||2014-01-21|2014-03-04|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational||Men who have sex with men|Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]|Evaluation of Abbott RealTime CT/NG for the Detection of Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] From the Pharynx, Rectum & Urethra of Men Who Have Sex With Men [MSM]|Terminated|||260|Actual|University of California, San Francisco|Our limitations are small number of subjects enrolled due to early termination of the study and we had no pharyngeal CT infections.|||Abbott Molecular stopped funding of study|f||||f||||||Samples With DNA|"~     clinician-collected rectal and pharyngeal swabs along with FCUs~   "|||2018-05-31 22:53:33.933555|2018-05-31 22:53:33.933555
NCT01291251|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2012-04-23|2011-02-07|2011-02-08|Estimate|||||||2012-04-23|2012-04-24|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|February 2012|Actual|2012-02-29|December 2010|Actual|2010-12-31||Observational|||Compliance With Antibiotic Treatment in General Practice|Compliance With Antibiotic Treatment in General Practice|Completed|||270|Actual|Norwegian Medical Association|||||f||||f||||||||||2018-05-31 22:53:34.094403|2018-05-31 22:53:34.094403
NCT01291238|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|March 2004||2004-03-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2007|Actual|2007-06-30||Interventional|||School Intervention With Daily Physical Activity and Healthy Food for Students With an Intellectual Disability.|Lifestyle Related Health and Health Promoting Activities for Youths With Intellectual Disabilities|Completed||N/A|145|Actual|Karolinska Institutet||1|||f||||t||||||||||2018-05-31 22:53:34.167936|2018-05-31 22:53:34.167936
NCT01291225|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|2016-01-31||2016-03-02|2011-02-07|2011-02-08|Estimate|2016-03-02|2016-04-01|Estimate||||2016-03-02|2016-04-01|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SPARK||Safe Play Areas for Ross County Kids Project|Safe Play Areas for Ross County Kids Project|Completed||N/A|311|Actual|Nationwide Children's Hospital||2|||f||||f||||||||No||2018-05-31 22:53:34.260868|2018-05-31 22:53:34.260868
NCT01291212|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|||Efficacy of Luteinizing Hormone (LH) Activity in Low Responder Patients With Transdermal Testosterone|Efficacy of LH Activity in Low Responder Patients With Transdermal Testosterone: a Randomised Controlled Study.|Unknown status|Active, not recruiting|N/A|104|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 22:53:34.530362|2018-05-31 22:53:34.530362
NCT01291199|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-07|2011-02-07|2011-02-08|Estimate|||||||2011-02-07|2011-02-08|Estimate|November 2006||2006-11-30|January 2011|2011-01-31|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Interventional|||Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome|Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome|Completed||Phase 2/Phase 3|57|Actual|University of Cologne||2|||f||||t||||||||||2018-05-31 22:53:34.612593|2018-05-31 22:53:34.612593
NCT01291186|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-08-02|2011-02-07|2011-02-08|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Body-mass Index (BMI) on Median Effective Dose of Intrathecal Hyperbaric Bupivacaine|The Effect of BMI on Median Effective Dose (ED50) of Intrathecal Hyperbaric Bupivacaine for Total Knee Replacement Arthroplasty|Completed||N/A|108|Actual|Seoul Medical Center||12|||f||||f||||||||||2018-05-31 22:53:34.690119|2018-05-31 22:53:34.690119
NCT01291173|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2012-10-26||2014-12-22|2011-02-04|2011-02-08|Estimate|2012-11-28|2012-12-31|Estimate||||2014-12-22|2015-01-12|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|BED|Safety Analysis Set defined as all randomized subjects who had taken at least 1 dose of investigational product and who had at least 1 follow-up safety assessment completed. One subject in the Placebo group did not have a post-baseline safety assessment and was excluded from the safety population (n=259).|Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder|Completed||Phase 2|271|Actual|Shire|External investigation at a site was initiated for reasons unrelated to the study. Lacking information on the investigation, it was deemed prudent to exclude data from subjects enrolled at site (n=11) from the primary analyses of efficacy and safety.|4|||f||||f||||||||||2018-05-31 22:53:34.866117|2018-05-31 22:53:34.866117
NCT01291160|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2014-04-11||2014-04-11|2011-02-07|2011-02-08|Estimate|2014-04-11|2014-05-13|Estimate||||2014-04-11|2014-05-13|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers|A Prospective, Randomized Blinded Multicenter, Parallel Study Comparing Transdermal, Continuous Oxygen Delivery to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers|Completed||Phase 2/Phase 3|130|Actual|Neogenix, LLC dba Ogenix||2|||f||||t||||||||||2018-05-31 22:53:35.904326|2018-05-31 22:53:35.904326
NCT01291147|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2013-11-12|2011-02-07|2011-02-08|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Interventional|||Local Anaesthetic Infusion For Laparoscopic Hysterectomy|Local Anaesthetic Infusion For Laparoscopic Hysterectomy: A Randomised Controlled Trial|Completed||Phase 4|60|Actual|Ashford and St. Peter's Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 22:53:36.217241|2018-05-31 22:53:36.217241
NCT01285037|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2018-02-19|2011-01-26|2011-01-27|Estimate|||||||2018-02-19|2018-02-20|Actual|September 9, 2009|Actual|2009-09-09|February 2018|2018-02-28|September 11, 2017|Actual|2017-09-11|July 21, 2017|Actual|2017-07-21||Interventional|||A Study of LY2801653 in Advanced Cancer|A Phase 1 Study of LY2801653 in Patients With Advanced Cancer|Completed||Phase 1|190|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:55:40.741245|2018-05-31 22:55:40.741245
NCT01291134|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2013-12-31|2011-02-07|2011-02-08|Estimate|||||||2013-12-31|2014-01-03|Estimate|February 2011||2011-02-28|December 2013|2013-12-31||||||||Observational|||PureGen: A Radiographic Analysis of Rate and Quality of Fusion in Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF)|PureGen Osteoprogenitor Cell Allograft: A Radiographic Analysis of Rate and Quality of Fusion in Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF)|Terminated|||50|Anticipated|Alphatec Spine, Inc.|||1|PureGen was taken off of the market|f||||||||||||||2018-05-31 22:53:36.300437|2018-05-31 22:53:36.300437
NCT01291121|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2015-01-21|2011-02-07|2011-02-08|Estimate|||||||2015-01-21|2015-01-26|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion|Intravitreal Administration of Ranibizumab Combined With Intravitreous Injection of Expansile Gas and Induction of Posterior Vitreous Detachment in Treatment of Exudative AMD With Posterior VMA: a Pilot, Open Label, Comparative Study|Completed||N/A|30|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 22:53:36.377334|2018-05-31 22:53:36.377334
NCT01291108|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2013-08-13|2012-10-17|2013-11-04|2011-02-04|2011-02-08|Estimate|2013-11-04|2013-11-06|Estimate|2012-10-17|2012-10-23|Estimate|2013-11-04|2013-11-06|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 2|125|Actual|Allergan||6|||f||||f||||||||||2018-05-31 22:53:36.490304|2018-05-31 22:53:36.490304
NCT01291095|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-07|||2011-03-03|2011-02-07|2011-02-08|Estimate|||||||2011-03-03|2011-03-04|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma|Phase II Randomized Controlled Trial of Accelerated Fractionation Radiotherapy (6 Fractions Per Week) Versus Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 2|80|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 22:53:36.942136|2018-05-31 22:53:36.942136
NCT01291082|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-01-26|2011-02-04|2011-02-07|Estimate|||||||2013-01-26|2013-01-29|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|August 2013|Anticipated|2013-08-31|April 2013|Anticipated|2013-04-30||Observational|METAMARBO||Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo)|Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)|Unknown status|Recruiting||50|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 22:53:37.039492|2018-05-31 22:53:37.039492
NCT01291069|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2017-04-14|2011-02-04|2011-02-07|Estimate|||||||2017-04-14|2017-04-17|Actual|September 2011||2011-09-30|April 2017|2017-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients|Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients|Completed||Phase 1|20|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:53:37.124749|2018-05-31 22:53:37.124749
NCT01291056|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2015-06-19||2016-05-19|2011-02-04|2011-02-07|Estimate|2016-05-19|2016-06-28|Estimate||||2016-05-19|2016-06-28|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation|Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation: A Double-blind, Placebo-controlled, Crossover Study|Completed||N/A|20|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 22:53:37.216553|2018-05-31 22:53:37.216553
NCT01291043|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2012-11-14|2011-02-04|2011-02-07|Estimate|||||||2012-11-14|2012-11-15|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy of Shiatsu in Individuals With Fibromyalgia: a Randomized Clinical Trial|Efficacy of Shiatsu in Pain, Flexibility, Sleep, Anxiety and Quality of Life in Individuals With Fibromyalgia: a Randomized Clinical Trial|Completed||N/A|34|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 22:53:37.487171|2018-05-31 22:53:37.487171
NCT01291030|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2017-01-16|2011-02-04|2011-02-07|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Impact of Magnesium Supplementation on Insulin Resistance and Secretion in Renal Transplant Recipients|The Impact of Magnesium Supplementation on Insulin Resistance and Secretion in Renal Transplant Recipients|Completed||N/A|70|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-05-31 22:53:37.608145|2018-05-31 22:53:37.608145
NCT01291017|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2015-03-12||2016-04-08|2011-02-04|2011-02-07|Estimate|2015-05-04|2015-05-21|Estimate||||2016-04-08|2016-05-13|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|||Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.|A Phase II Clinical Trail of the Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Previously Treated, Advanced NSCLC Patients With Wildtype Retinoblastoma Protein (RB) and Inactive Cyclin Dependent Kinase (CDK)N2a|Completed||Phase 2|19|Actual|University of Florida||1|||f||||t||||||||||2018-05-31 22:53:37.732706|2018-05-31 22:53:37.732706
NCT01291004|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2013-08-20|2011-02-04|2011-02-07|Estimate|||||||2013-08-20|2013-08-21|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives|A Multicenter, Open-label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins|Completed||Phase 1|206|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 22:53:38.053758|2018-05-31 22:53:38.053758
NCT01290991|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2012-08-20|2011-02-04|2011-02-07|Estimate|||||||2012-08-20|2012-08-21|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Evaluate the Safety of Augment™ Bone Graft|A Pilot Study to Augment™ Bone Graft Plus Evaluate the Safety of Allograft for Treatment of Osteochondral Defects (OCD) of the Knee|Completed||N/A|1|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 22:53:38.189868|2018-05-31 22:53:38.189868
NCT01290978|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2013-01-29||2013-04-16|2011-02-04|2011-02-07|Estimate|2013-01-29|2013-03-05|Estimate||||2013-04-16|2013-04-24|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||A sample size of 18 subjects and 18 drape samples per subject was determined to provide 80% power to detect a difference of 20% for the drape by prep comparison. A minimum of 20 subjects was used to account for the uncertainty in variability.|Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin|Prospective, Randomized Comparison of Two Presurgical Skin Antiseptic Preparations and Resultant Surgical Incise Drape Adhesion to Skin|Completed||Phase 4|22|Actual|3M|All 22 subjects enrolled completed the study|2|||f||||f||||||||||2018-05-31 22:53:38.283495|2018-05-31 22:53:38.283495
NCT01290965|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2014-11-05|2011-02-04|2011-02-07|Estimate|||||||2014-11-05|2014-11-06|Estimate|April 2007||2007-04-30|February 2011|2011-02-28|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients|A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Effect of Treatment With SCY 635 on Plasma HCV RNA Following 15 Days of Oral Administration in Adult Patients With Chronic Hepatitis C Infection|Completed||Phase 1|57|Actual|Scynexis, Inc.||7|||f||||f||||||||||2018-05-31 22:53:38.436466|2018-05-31 22:53:38.436466
NCT01290952|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2016-03-16||2016-09-29|2011-02-04|2011-02-07|Estimate|2016-09-29|2016-11-21|Estimate||||2016-09-29|2016-11-21|Estimate|September 2006||2006-09-30|September 2016|2016-09-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|On-Off||On Versus Off Pump Myocardial Revascularization Study|ON Pump vs OFF Pump Myocardial Revascularization in High Risk Patients: a Randomized Study|Completed||Phase 4|411|Actual|Medtronic Italia||2|||f||||f||||||||No|The main manuscript with the results of the primary endpoint analysis was published in December 2011.There are no plans to make individual partecipant data available|2018-05-31 22:53:38.604589|2018-05-31 22:53:38.604589
NCT01290939|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2018-02-19|2011-02-04|2011-02-07|Estimate|||||||2018-02-19|2018-02-21|Estimate|October 2011||2011-10-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|October 2015|Actual|2015-10-31||Interventional|||Bevacizumab and Lomustine for Recurrent GBM|Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma|Active, not recruiting||Phase 3|433|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||No||2018-05-31 22:53:38.914747|2018-05-31 22:53:38.914747
NCT01290926|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2016-02-23|2011-02-04|2011-02-07|Estimate|||||||2016-02-23|2016-02-24|Estimate|February 2011||2011-02-28|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|SoMore||Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer|Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer|Completed||Phase 2|97|Actual|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 22:53:39.002182|2018-05-31 22:53:39.002182
NCT01290913|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2015-02-04||2015-03-18|2011-02-04|2011-02-07|Estimate|2015-02-04|2015-02-20|Estimate||||2015-03-18|2015-04-07|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Xolair Enhances Oral Desensitization in Peanut Allergic Patients|Xolair Enhances Oral Desensitization in Peanut Allergic Patients|Completed||Phase 1/Phase 2|13|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 22:53:39.08603|2018-05-31 22:53:39.08603
NCT01290900|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2017-08-31|2011-02-04|2011-02-07|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2011||2011-02-28|August 2017|2017-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers|Completed||Phase 1|54|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:53:39.262764|2018-05-31 22:53:39.262764
NCT01290887|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2016-03-23|2015-10-21|2016-04-28|2011-02-04|2011-02-07|Estimate|2016-04-28|2016-06-06|Estimate|2015-10-21|2015-11-02|Estimate|2016-04-28|2016-06-06|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Enrolled participants|Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma|An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma|Terminated||Phase 3|1052|Actual|Teva Pharmaceutical Industries||1||Business decision|f||||t||||||||||2018-05-31 22:53:39.423513|2018-05-31 22:53:39.423513
NCT01290874|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2017-03-06||2018-03-28|2011-02-04|2011-02-07|Estimate|2018-03-28|2018-03-30|Actual||||2018-03-28|2018-03-30|Actual|March 30, 2011||2011-03-30|March 2018|2018-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|BELT||Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)|Blacks and Exacerbations on LABA vs. Tiotropium (BELT)|Completed||Phase 3|1070|Actual|Brigham and Women's Hospital||2|||f||||t||||||||Undecided||2018-05-31 22:53:41.314576|2018-05-31 22:53:41.314576
NCT01290861|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2012-08-02|2011-02-04|2011-02-07|Estimate|||||||2012-08-02|2012-08-03|Estimate|February 2011||2011-02-28|August 2012|2012-08-31||||||||Observational|CAB||Cognitive Assessment Battery (CAB) Beta Study|Cognitive Assessment Battery (CAB)Beta Study|Completed|||255|Actual|CHDI Foundation, Inc.|||3||f||||f||||||||||2018-05-31 22:53:42.026876|2018-05-31 22:53:42.026876
NCT01290848|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-08-25|2011-02-04|2011-02-07|Estimate|||||||2013-08-25|2013-08-27|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|April 2012|Actual|2012-04-30|July 2011|Actual|2011-07-31||Interventional|TIME||A Health Promotion Campaign Targeting Caregivers of Young Children|Take TIME for Your Child's Health: A Health Promotion Campaign Targeting Caregivers of Young Children|Completed||Phase 2|1374|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 22:53:42.105798|2018-05-31 22:53:42.105798
NCT01290835|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2016-10-04|2011-02-04|2011-02-07|Estimate|||||||2016-10-04|2016-10-05|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|June 2019|Anticipated|2019-06-30||Interventional|CKPBI||Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer|Conformal Partial Breast Irradiation With CyberKnife After Resection for Early Stage Breast Cancer|Active, not recruiting||Phase 1/Phase 2|20|Actual|Essentia Health||1|||f||||f||||||||||2018-05-31 22:53:42.166866|2018-05-31 22:53:42.166866
NCT01290822|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2016-05-26||2016-08-25|2011-02-04|2011-02-07|Estimate|2016-07-05|2016-08-15|Estimate||||2016-08-25|2016-10-06|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|BiBET||Optimized Biventricular Pacing Allograft Recipients|Optimized Biventricular Pacing in Allograft Recipients|Terminated||Phase 1/Phase 2|12|Actual|Columbia University||2||Slow accrual and anticipated loss of funding|f||||f||||||||Undecided||2018-05-31 22:53:42.307183|2018-05-31 22:53:42.307183
NCT01290809|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2015-10-13|2011-02-04|2011-02-07|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Observational|||Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) Patients|Cognitive Sequelae of Prophylactic Cranial Irradiation in Non-small Cell Lung Cancer Patients|Completed|||170|Anticipated|Maastricht Radiation Oncology|||2||f||||t||||||||||2018-05-31 22:53:42.676378|2018-05-31 22:53:42.676378
NCT01290796|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2014-04-10||2017-02-07|2011-02-04|2011-02-07|Estimate|2014-04-10|2014-05-12|Estimate||||2017-02-07|2017-03-27|Actual|January 2011||2011-01-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|June 2013|Actual|2013-06-30||Interventional|CEASe||Clinical Evaluation of Ajust™ in Stress Urinary Incontinence|Clinical Evaluation of Ajust™ in Stress Urinary Incontinence (CEASe)|Completed||N/A|153|Actual|C. R. Bard||1|||f||||f||||||||No||2018-05-31 22:53:42.777434|2018-05-31 22:53:42.777434
NCT01290783|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2015-04-28|2011-02-04|2011-02-07|Estimate|||||||2015-04-28|2015-04-29|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|October 2014|Actual|2014-10-31||Interventional|FOLF(HA)iri||Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC|Randomized Double-blind Phase III Trial of FOLF(HA)Iri vs FOLFIRI for Second or Third Line Therapy in Irinotecan-naïve Patients With Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 3|390|Anticipated|Alchemia Oncology||2|||f||||t||||||||||2018-05-31 22:53:43.083787|2018-05-31 22:53:43.083787
NCT01290770|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2014-09-26|2011-02-04|2011-02-07|Estimate|||||||2014-09-26|2014-09-29|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Observational|||Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina|Search a Correlation Between Lipoprotein(a) Rate and TFPI(Tissue Factor Pathway Inhibitor)Activity in Obese Patients With Chest Pain Like Angina|Terminated|||40|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     whole blood and serum~   "|||2018-05-31 22:53:43.228274|2018-05-31 22:53:43.228274
NCT01290757|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2012-04-18||2014-05-08|2011-02-04|2011-02-07|Estimate|2012-05-29|2012-06-29|Estimate||||2014-05-08|2014-05-19|Estimate|January 2011||2011-01-31|December 2013|2013-12-31||||April 2011|Actual|2011-04-30||Interventional||Treated set includes all patients who received at least one study treatment.|Bioequivalence of Two Different Capsule Types of Dabigatran|Bioequivalence of Two Different Capsule Types of 150 mg Dabigatran Etexilate Made From Two Different Drug Product Batches, Following Oral Administration in Healthy Male and Female Volunteers (Open-label, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)|Completed||Phase 1|180|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:53:43.306615|2018-05-31 22:53:43.306615
NCT01290744|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2015-06-03|2011-02-03|2011-02-07|Estimate|||||||2015-06-03|2015-06-04|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy|Effect of Additional Clofazimine on ENL Reactions in Leprosy|Completed||Phase 4|100|Actual|Leonard Wood Memorial||2|||f||||f||||||||||2018-05-31 22:53:43.590963|2018-05-31 22:53:43.590963
NCT01290731|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2013-10-17|2013-05-02|2013-12-16|2011-02-03|2011-02-07|Estimate|2013-12-16|2014-02-04|Estimate|2013-05-02|2013-05-10|Estimate|2013-12-16|2014-02-04|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy|A Phase III, Open-label Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Genotype 1, Hepatitis C-infected Subjects Who Relapsed After Previous IFN-based Therapy|Completed||Phase 3|49|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 22:53:43.715553|2018-05-31 22:53:43.715553
NCT01290718|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2014-12-03||2014-12-15|2011-02-04|2011-02-07|Estimate|2014-12-15|2014-12-17|Estimate||||2014-12-15|2014-12-17|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All randomized participants|A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.|Study of Trastuzumab Combined With Capecitabine on HER2-positive Metastatic Breast Cancer Patients Pretreated With Trastuzumab and Taxanes or HER2- Positive Breast Cancer Patients Relapsed From (Neo)Adjuvant Therapy of Trastuzumab and Taxanes|Terminated||Phase 2|4|Actual|Hoffmann-La Roche||1||Slow recruitment|f||||||||||||||2018-05-31 22:53:44.085972|2018-05-31 22:53:44.085972
NCT01290705|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2016-02-17|2011-02-04|2011-02-07|Estimate|||||||2016-02-17|2016-02-18|Estimate|November 2007||2007-11-30|February 2016|2016-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Dosage-dependence of Graded Exercise Therapy in Patients With Patellofemoral Pain Syndrome.|Dosage-dependence of Graded Exercise Therapy in Patients With Patellofemoral Pain Syndrome. A Randomized Controlled Clinical Trial.|Completed||N/A|40|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||Undecided||2018-05-31 22:53:44.263337|2018-05-31 22:53:44.263337
NCT01290692|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-10-21|2011-02-04|2011-02-07|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma|Phase 2 Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma|Completed||Phase 2|86|Actual|TVAX Biomedical||1|||f||||f||||||||||2018-05-31 22:53:44.326683|2018-05-31 22:53:44.326683
NCT01290679|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2014-02-03||2014-06-10|2011-02-03|2011-02-07|Estimate|2014-06-10|2014-06-13|Estimate||||2014-06-10|2014-06-13|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|QUEST-2||An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys®) and Ribavirin (Copegus®) or Peginterferon α-2b (PegIntron®) and Ribavirin (Rebetol®) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects|Completed||Phase 3|393|Actual|Janssen R&D Ireland||2|||f||||t||||||||||2018-05-31 22:53:44.480698|2018-05-31 22:53:44.480698
NCT01290666|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2015-11-09||2016-11-15|2011-02-04|2011-02-07|Estimate|2016-11-15|2017-01-13|Estimate||||2016-11-15|2017-01-13|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Observational|||Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair|Multicenter,Prospective, Observational Study of GORE® BIO-A® Fistula Plug for Use in Anal Fistula Repair|Terminated|||93|Actual|W.L.Gore & Associates|||1|Sufficient patient population achieved; decision not due to product complaints.|f||||f||||||||No||2018-05-31 22:53:45.904281|2018-05-31 22:53:45.904281
NCT01290653|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2014-05-13|2011-02-04|2011-02-07|Estimate|||||||2014-05-13|2014-05-14|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|DNJ||Dry Needling Versus Strain-counterstrain on the Upper Trapezius|Dry Needling Versus Strain Counterstrain Technique: Pilot Study Comparing Effects Over the Upper Trapezius Myofascial Trigger Point|Completed||N/A|39|Actual|Cardenal Herrera University||3|||f||||t||||||||||2018-05-31 22:53:46.141268|2018-05-31 22:53:46.141268
NCT01290640|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2013-03-18||2014-01-21|2011-02-03|2011-02-07|Estimate|2014-01-21|2014-03-07|Estimate||||2014-01-21|2014-03-07|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|February 2013|Actual|2013-02-28|September 2011|Actual|2011-09-30||Observational|PFC & TC3||Comparison of Kinematics for Subjects Implanted With a PFC Sigma Rotating Platform or Fixed Bearing TC3 Prosthesis|In Vivo Comparison of Kinematics for Subjects Implanted With a Press Fit Condylar Sigma Rotating Platform or Fixed Bearing Total Condylar III Prothesis|Completed|||22|Actual|The University of Tennessee, Knoxville|No limitations were encountered.||2||f||||f||||||||||2018-05-31 22:53:46.235974|2018-05-31 22:53:46.235974
NCT01290627|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2013-05-17||2014-01-21|2011-02-04|2011-02-07|Estimate|2013-11-25|2014-01-13|Estimate||||2014-01-21|2014-02-17|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|Patella||In Vivo Determination of 3D Patellofemoral Mechanics|In Vivo Determination of 3D Patellofemoral Mechanics|Completed|||30|Actual|The University of Tennessee, Knoxville|No adverse effects, events or unexpected risks occurred The sample size per group was small Age of the TKA groups were matched, the age of the normal subjects were not Cartilage thickness for normals had to be assumed as MRIs could not be obtained||3||f||||f||||||||||2018-05-31 22:53:46.798393|2018-05-31 22:53:46.798393
NCT01290614|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|2015-05-19||2015-06-16|2011-02-04|2011-02-07|Estimate|2015-06-16|2015-07-13|Estimate||||2015-06-16|2015-07-13|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)|A Chronic Care Model Based QI Program to Improve the Care of Patients With CKD|Completed||Phase 4|2199|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 22:53:47.451493|2018-05-31 22:53:47.451493
NCT01290601|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2017-03-17||2018-01-29|2011-02-03|2011-02-07|Estimate|2017-06-14|2018-01-25|Actual||||2018-01-29|2018-02-23|Actual|September 15, 2003||2003-09-15|January 2018|2018-01-31|January 10, 2005|Actual|2005-01-10|January 10, 2005|Actual|2005-01-10||Interventional|||Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults|A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults|Terminated||Phase 2|70|Actual|U.S. Army Medical Research and Materiel Command|IDMC determined that Cohort 1 failed to meet specified endpoint for d28 cure rate; Cohort 2 wasn't initiated and follow-up in Cohort 1 should be completed according to protocol. Following last subjects last visit for Cohort 1 study was terminated.|4||Failure to meet pre-specified endpoint for the day 28 cure rate|f||||t|t|f||||||No||2018-05-31 22:53:47.843275|2018-05-31 22:53:47.843275
NCT01290588|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-09-12|2011-02-04|2011-02-07|Estimate|||||||2017-09-12|2017-09-14|Actual|June 2013|Actual|2013-06-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Aqueous Humor Dynamics and Biometric Parameters in Eyes of Children|Aqueous Humor Dynamics and Biometric Parameters in Eyes of Children|Recruiting|||144|Anticipated|University of Nebraska|||4||f||||f||||||||Undecided|Data Sharing plan is yet to be finalized.|2018-05-31 22:53:48.929375|2018-05-31 22:53:48.929375
NCT01290575|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2012-03-26|2011-02-04|2011-02-07|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes Treated With Metformin Monotherapy.|Completed||Phase 1|67|Actual|Bristol-Myers Squibb||9|||f||||f||||||||||2018-05-31 22:53:49.221735|2018-05-31 22:53:49.221735
NCT01290562|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-05-02|2011-02-03|2011-02-07|Estimate|||||||2017-05-02|2017-05-03|Actual|June 2011||2011-06-30|May 2017|2017-05-31|April 27, 2017|Actual|2017-04-27|December 2015|Actual|2015-12-31||Interventional|||Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases (Spine SBRT)|A University of Toronto Phase II Study to Determine Efficacy of Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases|Completed||Phase 2|90|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 22:53:49.320908|2018-05-31 22:53:49.320908
NCT01290549|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-06-14|2011-02-04|2011-02-07|Estimate|||||||2017-06-14|2017-06-16|Actual|March 22, 2011|Actual|2011-03-22|June 2017|2017-06-30|November 18, 2014|Actual|2014-11-18|June 29, 2012|Actual|2012-06-29||Interventional|||A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma|An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics Of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma|Completed||Phase 1|95|Actual|Genentech, Inc.||2|||f|||||t|f||||||||2018-05-31 22:53:49.529171|2018-05-31 22:53:49.529171
NCT01290536|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2014-05-10||2014-12-11|2011-02-03|2011-02-07|Estimate|2014-12-11|2014-12-22|Estimate||||2014-12-11|2014-12-22|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||per protocol|Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases|Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Metastatic Liver Disease From Primary Colorectal, Neuroendocrine, Cholangiocarcinoma, Melanoma, and Breast Cancers Refractory to Chemotherapy: A Pilot Study|Completed||Phase 2|42|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 22:53:49.795423|2018-05-31 22:53:49.795423
NCT01290523|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2015-07-28||2015-07-28|2011-02-03|2011-02-07|Estimate|2015-07-28|2015-08-25|Estimate||||2015-07-28|2015-08-25|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma|Safety Profile Assessment of TheraSphere® Yttrium-90 Glass Microspheres Used for Treatment of Hepatocellular Carcinoma: A Pilot Study|Terminated||Phase 2|14|Actual|University of California, San Francisco||1||Off study clinical use of Y90 glass microspheres (TheraSphere)|f||||t||||||||||2018-05-31 22:53:50.000774|2018-05-31 22:53:50.000774
NCT01290510|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2011-09-21|2011-02-03|2011-02-07|Estimate|||||||2011-09-21|2011-09-22|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Hyaluronan in the Treatment of Painful Tendinopathy|Hyaluronan in the Treatment of Painful Tendinopathy|Completed||N/A|35|Actual|TRB Chemedica AG||1|||f||||f||||||||||2018-05-31 22:53:50.200124|2018-05-31 22:53:50.200124
NCT01290328|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2014-02-26|2011-02-04|2011-02-07|Estimate|||||||2014-02-26|2014-02-27|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation|Epoetin Alfa in the Treatment of Post-Transplant Anemia: A Randomized Controlled Trial|Terminated||N/A|100|Anticipated|Mehrotra, Anita, M.D.||2||low enrollment, termination of funding|f||||t||||||||||2018-05-31 22:53:52.374614|2018-05-31 22:53:52.374614
NCT01290497|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-02-28|2011-02-04|2011-02-07|Estimate|||||||2014-02-28|2014-03-03|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of 3 Different Dosage Regimens of Hyaluronic Acid in Patients With Knee Osteoarthritis (OA)|Pilot, Unicentre, Randomized, Parallel, Controlled Study to Evaluate the Efficacy and Safety of Three Different Intraarticular Dosage Regimens of Adant® in Patients With Osteoarthritis of the Knee|Completed||Phase 4|45|Actual|Tedec-Meiji Farma, S.A.||3|||f||||f||||||||||2018-05-31 22:53:50.277286|2018-05-31 22:53:50.277286
NCT01290484|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2014-05-13||2015-05-22|2011-02-04|2011-02-07|Estimate|2014-05-13|2014-06-12|Estimate||||2015-05-22|2015-06-19|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional||Based on funding|A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations|An Investigational Pilot Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations|Completed||Phase 1/Phase 2|7|Actual|Stanford University|Baseline MRI examinations were performed within 6 months prior to commencement of sildenafil; several subjects took sildenafil for more than 20 weeks due to MRI scheduling and personal accommodations|1|||f||||t||||||||||2018-05-31 22:53:50.365277|2018-05-31 22:53:50.365277
NCT01290471|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-05-16|2011-02-03|2011-02-07|Estimate|||||||2014-05-16|2014-05-19|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors|Phase 1, Open Label Study to Assess the Safety and Tolerability of U3 1565 in Subjects With Advanced Solid Malignant Tumors|Completed||Phase 1|36|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 22:53:50.581068|2018-05-31 22:53:50.581068
NCT01290458|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2011-02-04|2011-02-04|2011-02-07|Estimate|||||||2011-02-04|2011-02-07|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||The Effect of Antioxidant Vitamin Supplementation on Muscle Performance and Redox Status After Eccentric Training|The Effect of Antioxidant Vitamin Supplementation on Muscle Performance and Redox Status After Eccentric Training|Completed||N/A|28|Actual|University of Thessaly||2|||f||||t||||||||||2018-05-31 22:53:50.651251|2018-05-31 22:53:50.651251
NCT01290445|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2016-06-30|2011-02-03|2011-02-07|Estimate|||||||2016-06-30|2016-07-04|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Varenicline Pregnancy Cohort Study|Varenicline Pregnancy Cohort Study Protocol Chantix (Registered)/Champix-(Registered) (Varenicline Tartrate)|Completed|||1|Actual|Pfizer|||3||f||||f||||||||||2018-05-31 22:53:50.751439|2018-05-31 22:53:50.751439
NCT01290432|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2012-05-24|2011-02-03|2011-02-07|Estimate|||||||2012-05-24|2012-05-25|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women|The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women|Completed||N/A|15|Actual|Palm Beach Center for Reproductive Medicine||1|||f||||t||||||||||2018-05-31 22:53:50.848972|2018-05-31 22:53:50.848972
NCT01290419|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2012-03-06|2011-02-03|2011-02-07|Estimate|||||||2012-03-06|2012-03-08|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine|A Phase 1 Randomized, Observer-Blinded,Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus F Protein Particle Vaccine in Healthy Adults|Completed||Phase 1|150|Actual|Novavax||7|||f||||t||||||||||2018-05-31 22:53:51.039204|2018-05-31 22:53:51.039204
NCT01290406|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2012-06-20|2011-02-04|2011-02-07|Estimate|||||||2012-06-20|2012-06-21|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|December 2017|Anticipated|2017-12-31|September 2014|Anticipated|2014-09-30||Interventional|||BEZ235 Trial in Patients With Advanced Endometrial Carcinoma|A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma|Withdrawn||Phase 2|0|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:53:51.208659|2018-05-31 22:53:51.208659
NCT01290393|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-05-02|2011-02-03|2011-02-07|Estimate|||||||2013-05-02|2013-05-06|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada|Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada|Terminated|||2|Actual|GlaxoSmithKline|||2|"Low accrual of subjects primarily attributable to the low uptake of Cervarix in the US and~   Canada in women aged 15 to 25 years of age."|f||||||||||||||2018-05-31 22:53:51.362245|2018-05-31 22:53:51.362245
NCT01290380|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-08-31|2011-02-04|2011-02-07|Estimate|||||||2011-08-31|2011-09-02|Estimate|February 2010||2010-02-28|August 2011|2011-08-31||||November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies|An Open-label, Multi-center Study to Evaluate the Effects of ASA404 Alone and in Combination With Taxane-based Chemotherapy on the Pharmacokinetics of Simvastatin, Caffeine, Omeprazole, and Diclofenac in Patients With Advanced Solid Tumor Malignancies|Terminated||Phase 1|54|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:53:51.606869|2018-05-31 22:53:51.606869
NCT01290367|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-10-12|2011-02-03|2011-02-07|Estimate|||||||2016-10-12|2016-10-14|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain|A Prospective, Double Blind, Controlled Study Evaluating Safety and Preliminary Efficacy of a Single Injection of Adult Mesenchymal Precursor Cells (MPCs) Combined With Hyaluronan in Subjects With Chronic Discogenic Lumbar Back Pain|Completed||Phase 2|100|Actual|Mesoblast, Ltd.||4|||f||||t||||||||||2018-05-31 22:53:51.68534|2018-05-31 22:53:51.68534
NCT01290354|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-11-08|2011-02-03|2011-02-07|Estimate|||||||2017-11-08|2017-11-13|Actual|September 12, 2011|Actual|2011-09-12|November 2017|2017-11-30|March 18, 2013|Actual|2013-03-18|March 18, 2013|Actual|2013-03-18||Interventional|||Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer|An Open-label Positron Emission Tomography Study to Investigate and Quantify Brain and Tumour Penetration of [11C]Lapatinib in Subjects With HER2-overexpressing Breast Cancer|Completed||Phase 1|10|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:53:51.803172|2018-05-31 22:53:51.803172
NCT01290341|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2013-07-26|2013-04-15|2013-07-26|2011-02-03|2011-02-07|Estimate|2013-07-26|2013-09-26|Estimate|2013-04-15|2013-04-23|Estimate|2013-07-26|2013-09-26|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|NAFT-600|The Safety Evaluation Set (SES) which is the population of subjects who receive at least one dose of study medication is used.|Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|Completed||Phase 3|860|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 22:53:51.923843|2018-05-31 22:53:51.923843
NCT01290315|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2015-06-11||2018-02-02|2011-02-03|2011-02-07|Estimate|2018-02-02|2018-02-08|Actual||||2018-02-02|2018-02-08|Actual|August 2009|Actual|2009-08-31|February 2018|2018-02-28|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|||Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women|A Randomized, Controlled Study to Investigate the Safety and Oxidative Stress Potential of Intravenous Ferric Carboxymaltose (FCM) vs. IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women|Completed||Phase 2|49|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 22:53:52.527766|2018-05-31 22:53:52.527766
NCT01290302|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2018-01-22|2011-02-03|2011-02-07|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2010||2010-10-31|January 2018|2018-01-31||||December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia|Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia|Completed||Phase 1|36|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:53:53.073752|2018-05-31 22:53:53.073752
NCT01290289|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2011-02-04|2011-02-04|2011-02-07|Estimate|||||||2011-02-04|2011-02-07|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Analgesia in Labor, a Prospective Parallel Study to Compare Regional Analgesia and Intravenous (IV) Pethidine Analgesia|Analgesia in Labor, a Prospective Parallel Single Blind Study to Compare Regional Analgesia (Combined Spinal Epidural Analgesia (CSE), Epidural Analgesia (E)) and Intravenous (IV) Pethidine Analgesia|Completed||N/A|60|Actual|Cairo University||1|||f||||f||||||||||2018-05-31 22:53:53.158091|2018-05-31 22:53:53.158091
NCT01290276|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2014-07-31|2011-02-03|2011-02-04|Estimate|||||||2014-07-31|2014-08-01|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation|Phase Ia/Ib Study of Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation|Completed||Phase 1|6|Actual|Duke University||2|||f||||f||||||||||2018-05-31 22:53:53.237456|2018-05-31 22:53:53.237456
NCT01290263|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|2017-01-17||2017-06-04|2011-02-03|2011-02-04|Estimate|2017-04-20|2017-05-25|Actual||||2017-06-04|2017-07-02|Actual|December 2010||2010-12-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|July 2015|Actual|2015-07-31||Interventional|||Amgen 386 for Recurrent Glioblastoma|Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma|Completed||Phase 1/Phase 2|48|Actual|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 22:53:53.373263|2018-05-31 22:53:53.373263
NCT01290250|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2013-03-14|2011-02-03|2011-02-04|Estimate|||||||2013-03-14|2013-03-15|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|BIONAOS||Evaluation of a New Orange-Based Beverage Enriched With Polyphenols in Adult Humans|Evaluation of a New Orange-Based Beverage Enriched With Polyphenols (Whole Press) on Features of Metabolic Syndrome and Cardiovascular Risk Factors Related to Inflammation and Antioxidant Defense System in Adult Humans|Completed||N/A|210|Actual|The Coca-Cola Company||2|||f||||t||||||||||2018-05-31 22:53:54.18756|2018-05-31 22:53:54.18756
NCT01290237|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2017-04-15||2018-03-04|2011-02-03|2011-02-04|Estimate|2018-02-02|2018-03-05|Actual||||2018-03-04|2018-03-29|Actual|February 2011||2011-02-28|March 2018|2018-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Use of a Loading Dose of Vancomycin in Pediatric Dosing|The Use of a Loading Dose of Intravenous Vancomycin Will Achieve Therapeutic Concentration Earlier Than Conventional Pediatric Dosing: A Randomized Controlled Trial|Terminated||N/A|59|Actual|Boston Children’s Hospital|"trial underpowered to detect an increase of ≥40% in concentrations (small sample size)~more cases excluded in the high-dose group than in reference group (possible analysis bias)~increase in red man syndrome in the high-dose group"|2||PI leaving institution, slow enrollment|f||||f||||||||||2018-05-31 22:53:54.286344|2018-05-31 22:53:54.286344
NCT01290224|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2013-11-11||2014-01-16|2011-02-03|2011-02-04|Estimate|2014-01-16|2014-03-05|Estimate||||2014-01-16|2014-03-05|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||MC5-A Scrambler Therapy in Reducing Peripheral Neuropathy Caused by Chemotherapy|Scrambler Therapy for the Treatment of Chemotherapy Induced Peripheral Neuropathy: An Evaluation of a Sham Procedure and Phase II Trial|Completed||Phase 2|10|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 22:53:54.52991|2018-05-31 22:53:54.52991
NCT01290211|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2011-06-27|2011-02-03|2011-02-04|Estimate|||||||2011-06-27|2011-06-29|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Open-Label, Fixed-Sequence Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Completed||Phase 1|28|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 22:53:54.858296|2018-05-31 22:53:54.858296
NCT01290198|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2012-09-04|2011-02-03|2011-02-04|Estimate|||||||2012-09-04|2012-09-05|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|EETY||Role of Epoxy-eicosatrienoic Acids in Post-occlusive Hyperemia and Thermal Hyperemia|Role of Epoxy-eicosatrienoic Acids in Post-occlusive Hyperemia and Thermal Hyperemia|Completed||N/A|20|Actual|University Hospital, Grenoble||4|||f||||t||||||||||2018-05-31 22:53:54.934708|2018-05-31 22:53:54.934708
NCT01290185|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-06-26|2011-02-03|2011-02-04|Estimate|||||||2012-06-26|2012-06-28|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Coiled Catheters for Regional Anesthesia|Improving the Success Rate of Continuous Peripheral Nerve Blocks Using a Novel Coiled Catheter|Completed||N/A|152|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:53:55.026102|2018-05-31 22:53:55.026102
NCT01290172|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2014-11-27|2011-02-03|2011-02-04|Estimate|||||||2014-11-27|2014-12-02|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.|A Single-center, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.|Completed||Phase 1|33|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:53:55.105383|2018-05-31 22:53:55.105383
NCT01290159|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-12-18|2011-02-03|2011-02-04|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Observational|||The Development Of A Novel Biomarker For Early Identification Of The Individual's State Of Tolerance To Heat|Preliminary Study of Identifying the Tolerance to Heat by a Novel Biomarker of Oxidative Stress|Completed|||10|Actual|Sheba Medical Center|||3||f||||f||||||||||2018-05-31 22:53:55.207533|2018-05-31 22:53:55.207533
NCT01290146|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-04-07|2011-02-03|2011-02-04|Estimate|||||||2017-04-07|2017-04-10|Actual|February 2011|Actual|2011-02-28|April 2017|2017-04-30|March 2017|Actual|2017-03-31|June 2015|Actual|2015-06-30||Interventional|ELEVATE||ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE|Early Use of Levosimendan Compared to Usual Care in Advanced Chronic Heart Failure (ACHF)|Terminated||Phase 3|13|Actual|Niguarda Hospital||2||Due to lack of enrollment|f||||f||||||||||2018-05-31 22:53:55.335331|2018-05-31 22:53:55.335331
NCT01290133|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-10-11|2011-02-03|2011-02-04|Estimate|||||||2011-10-11|2011-10-13|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV)|A Phase I, Randomized, Placebo-Controlled, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of the Captisol™ Formulation of Vestipitant (GW597599) in Healthy Adult Subjects|Completed||Phase 1|55|Actual|Accenture||2|||f||||f||||||||||2018-05-31 22:53:55.46754|2018-05-31 22:53:55.46754
NCT01290120|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-09-15|2011-02-03|2011-02-04|Estimate|||||||2014-09-15|2014-09-16|Estimate|November 2002||2002-11-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma|Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma|Completed||Phase 2|182|Actual|Northern Italy Leukemia Group|||||f||||f||||||||||2018-05-31 22:53:55.609211|2018-05-31 22:53:55.609211
NCT01290107|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2016-05-17|2011-02-03|2011-02-04|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|January 2015|Actual|2015-01-31||Observational|||Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia|MLL Rearrangements in Acute Myeloid Leukemia: A Pilot Project to Expand and Study MLL-ENL in NOD SCID Gamma Mice|Completed|||9|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Bone Marrow~   "|||2018-05-31 22:53:55.6873|2018-05-31 22:53:55.6873
NCT01290094|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2015-07-17||2015-07-17|2011-02-03|2011-02-04|Estimate|2015-07-17|2015-08-13|Estimate||||2015-07-17|2015-08-13|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Intent-to-treat (ITT) population included participants who received at least 1 dose of study medication and at least 1 efficacy measurement was performed. One participant who was enrolled in the study initially, withdrew informed consent and was excluded from ITT population.|A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis|Interventional, Single Arm, Open Label Study of the Efficacy, Safety and Compliance to the Treatment With Intravenous (IV) Ibandronate (Bonviva®) in the Postmenopausal Osteoporosis Treatment of Bisphosphonates naïve Patients in Daily Practice|Completed||Phase 3|41|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:53:55.751369|2018-05-31 22:53:55.751369
NCT01290081|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2011-02-03|2011-02-03|2011-02-04|Estimate|||||||2011-02-03|2011-02-04|Estimate|October 2007||2007-10-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|TBIDU||Enhanced Tuberculosis Case Detection Among Substitution Treatment Patients|Prevalence of Latent Tuberculosis and Enhanced Tuberculosis Case Detection Among Injecting Drug Users Receiving Methadone Substitution Treatment|Completed||N/A|112|Actual|National Institute for Health Development, Estonia||2|||f||||||||||||||2018-05-31 22:53:55.964038|2018-05-31 22:53:55.964038
NCT01290068|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2017-01-13||2017-03-09|2011-02-03|2011-02-04|Estimate|2017-01-13|2017-03-06|Actual||||2017-03-09|2017-04-07|Actual|April 2011||2011-04-30|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||This analysis population includes all randomized participants to whom the randomized IOL was presented and/or implanted during the first eye surgery (from a try to a full success), as randomized.|Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses|Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof® ReSTOR IOL Implantation Compared to Monofocal IOL Implantation|Completed||N/A|208|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 22:53:56.044752|2018-05-31 22:53:56.044752
NCT01290055|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2017-09-20|2011-02-03|2011-02-04|Estimate|||||||2017-09-20|2017-09-25|Actual|February 2011||2011-02-28|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Turnover of Antigen Specific Lymphocytes After Immunization With the Yellow Fever Vaccine|Turnover of Antigen Specific Lymphocytes After Immunization With the 17D Yellow Fever Vaccine|Recruiting||N/A|40|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 22:53:56.370835|2018-05-31 22:53:56.370835
NCT01290042|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-03-12|2011-02-03|2011-02-04|Estimate|||||||2015-03-12|2015-03-17|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.|A Phase 1, Randomized, Double-Blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects, in Subjects With Active Ulcerative Colitis, and in Subjects With Active Crohn's Disease.|Completed||Phase 1|43|Actual|Amgen||2|||f||||||||||||||2018-05-31 22:53:56.446214|2018-05-31 22:53:56.446214
NCT01290029|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2016-08-09||2016-10-26|2011-02-03|2011-02-04|Estimate|2016-10-26|2016-12-19|Estimate||||2016-10-26|2016-12-19|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional||All enrolled participants|Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease|An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to Less Than 6 Years With Chronic Kidney Disease Receiving Dialysis|Completed||Phase 1|14|Actual|Amgen||1|||f||||f||||||||||2018-05-31 22:53:56.528403|2018-05-31 22:53:56.528403
NCT01290016|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2015-04-07|2011-02-03|2011-02-04|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MYLIFE||Youth Lifestyle Intervention With Food and Exercise|MY LIFE Study - McGill Youth Lifestyle Intervention With Food and Exercise Study|Completed||N/A|132|Actual|McGill University||5|||f||||f||||||||||2018-05-31 22:53:56.83349|2018-05-31 22:53:56.83349
NCT01290003|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2015-09-26|2011-02-03|2011-02-04|Estimate|||||||2015-09-26|2015-09-29|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|AbProM||Role of Antibiotics in Preventing Infection in Babies Born Through Meconium Stained Liquor|Role of Prophylactic Antibiotics in Preventing Neonatal Sepsis in Neonates Born Through Meconium Stained Amniotic Fluid - A Randomized Controlled Trial|Completed||N/A|250|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 22:53:56.929265|2018-05-31 22:53:56.929265
NCT01289665|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-07-19|2011-02-03|2011-02-04|Estimate|||||||2011-07-19|2011-07-21|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effect of Lubricating Gel on Patient Comfort During Speculum Insertion.|The Effect of Lubricating Gel on Patient Comfort During Speculum Insertion.|Completed||N/A|120|Anticipated|Florida Hospital||2|||f||||f||||||||||2018-05-31 22:54:08.862234|2018-05-31 22:54:08.862234
NCT01289990|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2014-05-16||2014-07-14|2011-02-03|2011-02-04|Estimate|2014-07-14|2014-07-15|Estimate||||2014-07-14|2014-07-15|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Full Analysis Set (FAS): which contained all randomised patients who received at least 1 dose of study drug and had a baseline HbA1c assessment, irrespective of participation in the extension trial.|Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes|A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23|Completed||Phase 3|2705|Actual|Boehringer Ingelheim||13|||f||||||||||||||2018-05-31 22:53:57.266115|2018-05-31 22:53:57.266115
NCT01289977|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2018-02-15|2011-02-03|2011-02-04|Estimate|||||||2018-02-15|2018-02-19|Actual|October 2010||2010-10-31|February 2018|2018-02-28|April 15, 2016|Actual|2016-04-15|April 2016|Actual|2016-04-30||Observational|||Immune Responses After Human Subject Challenge With Sand Fly Bites|Immune Responses After Human Subject Challenge With Sand Fly Bites: Exploratory Study for Selection of Potential Leishmania Vaccine Antigen Candidates|Completed|||68|Actual|Uniformed Services University of the Health Sciences|||2||f||||t||||||Samples With DNA|"~     Plasma and white blood cells will be retained.~   "|||2018-05-31 22:54:04.429368|2018-05-31 22:54:04.429368
NCT01289964|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-08-18|2011-02-03|2011-02-04|Estimate|||||||2011-08-18|2011-08-19|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|TS||The Effect of 5 Times Dry Cupping in the Treatment of Chronic Neck Pain|Randomised Controlled Pilot Study: the Effect of Dry Cupping on Pain and Sensory Thresholds in the Treatment of Chronic Non Specific Neck Pain|Completed||N/A|50|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 22:54:04.483851|2018-05-31 22:54:04.483851
NCT01289951|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2013-01-31|2011-02-03|2011-02-04|Estimate|||||||2013-01-31|2013-02-01|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|LIVERAL||Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis|Phase I, Open Label, Unicentric Study of Multiple-dose Pharmacokinetics of Raltegravir in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus With and Without Advanced (Child-Pugh C) Hepatic Cirrhosis.|Completed||Phase 1|10|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f||||||||||2018-05-31 22:54:04.580907|2018-05-31 22:54:04.580907
NCT01289938|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2016-05-12|2011-02-03|2011-02-04|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2009||2009-07-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MalD||Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine|Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine|Terminated||Phase 1|49|Actual|University Hospital Tuebingen||2||"To unsuccessful recruitment of rare UM-genotype. All other planned genotype groups are~   completed (EM, IM and PM)."|f||||f||||||||||2018-05-31 22:54:04.661671|2018-05-31 22:54:04.661671
NCT01289925|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2018-04-05|2011-02-03|2011-02-04|Estimate|||||||2018-04-05|2018-04-09|Actual|February 2006|Actual|2006-02-28|April 2018|2018-04-30|January 20, 2012|Actual|2012-01-20|January 20, 2012|Actual|2012-01-20||Interventional|||Effect of Selenium Intervention on Inflammation in Older Adults|Antioxidant Nutrient Inflammation Interventions in Older Adults|Terminated||N/A|182|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 22:54:04.743151|2018-05-31 22:54:04.743151
NCT01289912|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2016-12-03||2018-01-24|2011-02-03|2011-02-04|Estimate|2018-01-24|2018-01-25|Actual||||2018-01-24|2018-01-25|Actual|January 2011||2011-01-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TSC||Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)|Randomized Double-Blind Phase 2 Trial Of RAD001 For Neurocognition In Individuals With Tuberous Sclerosis Complex|Completed||Phase 2|52|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 22:54:04.865474|2018-05-31 22:54:04.865474
NCT01289899|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-02-03|2011-02-03|2011-02-04|Estimate|||||||2011-02-03|2011-02-04|Estimate|January 2004||2004-01-31|February 2011|2011-02-28|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects|BR-A-657, A Phase 1, Double-blind, Placebo-controlled, Ascending Multiple Oral Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects|Completed||Phase 1|16|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 22:54:05.551649|2018-05-31 22:54:05.551649
NCT01289886|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-02-03|2011-02-03|2011-02-04|Estimate|||||||2011-02-03|2011-02-04|Estimate|September 2003||2003-09-30|January 2011|2011-01-31|December 2003|Actual|2003-12-31|November 2003|Actual|2003-11-30||Interventional|||Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects|BR-A-657, A Phase 1, Double-blind, Placebo-controlled, Ascending Single Oral Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects Incorporating a Comparison of Fed/Fasted Pharmacokinetics|Completed||Phase 1|40|Actual|Boryung Pharmaceutical Co., Ltd||5|||f||||t||||||||||2018-05-31 22:54:05.609596|2018-05-31 22:54:05.609596
NCT01289873|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2013-09-09|2011-02-03|2011-02-04|Estimate|||||||2013-09-09|2013-09-10|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|HOP-IN||Prevalence, Persistence, and Risk Factors for Oral Human Papillomavirus (HPV) Infections in College Women|Prevalence, Persistence, and Risk Factors for Oral HPV Infections in College Women|Completed|||1036|Actual|University of Florida|||||f||||f||||||||||2018-05-31 22:54:05.685342|2018-05-31 22:54:05.685342
NCT01289860|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2013-02-20|2011-02-03|2011-02-04|Estimate|||||||2013-02-20|2013-02-21|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Investigating the Acute Effects of Flavonoids in Blueberries on Cognitive Function.|A Controlled, Cross-over, Acute Intervention Study Investigating the Cognitive and Neuronal Effects of Flavonoids in Blueberries.|Completed||N/A|47|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 22:54:05.737008|2018-05-31 22:54:05.737008
NCT01289847|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2014-12-08||2014-12-15|2011-02-03|2011-02-04|Estimate|2014-12-15|2014-12-23|Estimate||||2014-12-15|2014-12-23|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency|A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents|Completed||Phase 4|25|Actual|Bio Products Laboratory||1|||f||||f||||||||||2018-05-31 22:54:05.826209|2018-05-31 22:54:05.826209
NCT01289483|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-04-17|2011-02-02|2011-02-03|Estimate|||||||2017-04-17|2017-04-18|Actual|February 2011||2011-02-28|April 2017|2017-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Fospropofol for Sedation During Elective Awake Intubation||Withdrawn||N/A|0|Actual|The Cleveland Clinic||4||sponsor has decided not to support this study.|f||||f||||||||||2018-05-31 22:54:12.887755|2018-05-31 22:54:12.887755
NCT01289834|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2014-10-21|2011-02-02|2011-02-04|Estimate|||||||2014-10-21|2014-10-22|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||A Migration and Bone Density Study Comparing Hi-Fatigue Bone Cement and Palacos Bone Cement|A Migration (RSA) and Bone Density (DEXA) Study Comparing Hi-Fatigue Bone Cement and Palacos Bone Cement in Fixation of a Smooth vs. a Fine-blasted Femoral Stem. A Prospective Randomized Study on Primary Total Hip Arthroplasty.|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:54:06.223188|2018-05-31 22:54:06.223188
NCT01289821|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|2013-04-09||2017-03-13|2011-02-03|2011-02-04|Estimate|2013-07-29|2013-09-04|Estimate||||2017-03-13|2017-03-15|Actual|February 2011||2011-02-28|March 2017|2017-03-31|June 2014|Actual|2014-06-30|March 2012|Actual|2012-03-31||Interventional|||First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib|An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib|Completed||Phase 2|54|Actual|Bayer||1|||f||||t||||||||||2018-05-31 22:54:06.332916|2018-05-31 22:54:06.332916
NCT01289808|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2012-01-06|2011-02-03|2011-02-04|Estimate|||||||2012-01-06|2012-01-09|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Reduced Infant Response To A Routine Care Procedure After Glucose 25% Analgesia|Reduced Infant Response To A Routine Care Procedure After Glucose 25% Analgesia|Terminated||N/A|180|Actual|The Baruch Padeh Medical Center, Poriya||1||changes were made to the which needed an entireley new submission|f||||f||||||||||2018-05-31 22:54:06.745906|2018-05-31 22:54:06.745906
NCT01289795|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2011-02-03|2011-02-03|2011-02-04|Estimate|||||||2011-02-03|2011-02-04|Estimate|July 2010||2010-07-31|January 2011|2011-01-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Observational|EPCAS||Endothelial Function and Progenitor Cells in Acute Ischemic Stroke|Endothelial Function and Progenitor Cells in Acute Ischemic Stroke|Unknown status|Recruiting||30|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||Samples Without DNA|"~     whole blood, serum, PBMC, plasma~   "|||2018-05-31 22:54:06.806945|2018-05-31 22:54:06.806945
NCT01289782|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2014-01-27||2014-05-20|2011-02-03|2011-02-04|Estimate|2014-05-20|2014-06-04|Estimate||||2014-05-20|2014-06-04|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|QUEST-1||An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinfected Subjects|Completed||Phase 3|395|Actual|Janssen R&D Ireland||2|||f||||t||||||||||2018-05-31 22:54:06.950235|2018-05-31 22:54:06.950235
NCT01289769|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-12-14|2011-02-03|2011-02-04|Estimate|||||||2011-12-14|2011-12-15|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effect of Dexmedetomidine on Hemodynamic Response During Double Lumen Endotracheal Intubation|The Effect of Prophylactic Dexmedetomidine on Hemodynamic Disturbances During Double Lumen Endotracheal Intubation. A Double-blinded, Randomized, Placebo-Controlled Trial.|Completed||Phase 2|60|Actual|Chiang Mai University||2|||f||||f||||||||||2018-05-31 22:54:08.004232|2018-05-31 22:54:08.004232
NCT01289756|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2015-02-23|2011-02-03|2011-02-04|Estimate|||||||2015-02-23|2015-02-24|Estimate|December 2009||2009-12-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene|Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene|Completed||Phase 1|20|Actual|Robert Bosch Gesellschaft für Medizinische Forschung mbH||4|||f||||f||||||||||2018-05-31 22:54:08.137676|2018-05-31 22:54:08.137676
NCT01289743|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-03|2011-02-03|2011-02-04|Estimate|||||||2011-02-03|2011-02-04|Estimate|February 2002||2002-02-28|February 2002|2002-02-28|May 2012|Anticipated|2012-05-31|September 2003|Actual|2003-09-30||Interventional|Enbrel_AS-2||Etanercept (Enbrel) in Ankylosing Spondylitis|An Open-label Study of Etanercept (Enbrel) Efficacy in Ankylosing Spondylitis|Unknown status|Active, not recruiting|Phase 2|24|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 22:54:08.24063|2018-05-31 22:54:08.24063
NCT01289730|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-03|2011-02-03|2011-02-04|Estimate|||||||2011-02-03|2011-02-04|Estimate|February 2002||2002-02-28|February 2002|2002-02-28|May 2012|Anticipated|2012-05-31|September 2003|Actual|2003-09-30||Interventional|Enbrel_uSpA-2||Etanercept (Enbrel) in Undifferentiated Spondyloarthritis|An Open-label Study of Etanercept (Enbrel) Efficacy in Undifferentiated Spondyloarthritis|Unknown status|Active, not recruiting|Phase 2|8|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 22:54:08.318761|2018-05-31 22:54:08.318761
NCT01289717|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2017-08-10|2011-02-02|2011-02-04|Estimate|||||||2017-08-10|2017-08-14|Actual|March 2011||2011-03-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|PROGENI-KI||Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients|Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients - Transplant Proteogenomics|Completed|||307|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     Samples of blood, urine, and tissue~   "|||2018-05-31 22:54:08.390473|2018-05-31 22:54:08.390473
NCT01289704|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-02-03|2011-02-03|2011-02-04|Estimate|||||||2011-02-03|2011-02-04|Estimate|February 2011||2011-02-28|October 2010|2010-10-31|January 2012|Anticipated|2012-01-31|October 2011|Anticipated|2011-10-31||Interventional|TreSPE||Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A)|A Multicenter Study to Evaluate the Effects on Charcot−Marie−Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program.|Unknown status|Not yet recruiting|Phase 2/Phase 3|92|Anticipated|University of Genova||2|||f||||f||||||||||2018-05-31 22:54:08.466679|2018-05-31 22:54:08.466679
NCT01289691|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-02|2011-02-02|2011-02-04|Estimate|||||||2011-02-02|2011-02-04|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Atelectasis After Pulmonary Lobectomy: The Effect Of Air During One-Lung Ventilation (OLV) On Postoperative Atelectasis|Atelectasis After Pulmonary Lobectomy: The Effect Of Air During One-Lung Ventilation (OLV) On Postoperative Atelectasis.|Unknown status|Recruiting|N/A|70|Anticipated|London Health Sciences Centre||2|||f||||f||||||||||2018-05-31 22:54:08.647031|2018-05-31 22:54:08.647031
NCT01289678|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2017-03-06|2011-02-03|2011-02-04|Estimate|||||||2017-03-06|2017-03-08|Actual|July 2006||2006-07-31|March 2017|2017-03-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia|Phase II Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia|Terminated||Phase 2|13|Actual|Leo W. Jenkins Cancer Center||1||Unable to meet accrual goals|f||||t||||||||||2018-05-31 22:54:08.784098|2018-05-31 22:54:08.784098
NCT01289652|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-03|||2014-04-22|2011-02-03|2011-02-04|Estimate|||||||2014-04-22|2014-04-23|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|April 2017|Anticipated|2017-04-30|May 2016|Anticipated|2016-05-31||Observational|PROBE-C||The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals|PRospective OBservational Evaluation of the Natural History and Treatment of Acute HCV in HIV-positive Individuals: The PROBE-C Study|Unknown status|Recruiting||600|Anticipated|Istituto Superiore di Sanità|||2||f||||t||||||Samples With DNA|"~     For phylogenetic analysis HCV RNA detection will be performed.~   "|||2018-05-31 22:54:08.95466|2018-05-31 22:54:08.95466
NCT01289639|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2014-10-01||2017-07-14|2011-02-03|2011-02-04|Estimate|2014-10-10|2014-10-20|Estimate||||2017-07-14|2017-08-17|Actual|October 2005||2005-10-31|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional||Subjects recruited with known NAFLD or NASH.|Insulin Resistance in Non-alcoholic Fatty Liver Disease|Insulin Resistance in Non-alcoholic Fatty Liver Disease (Protocol Drug Change From Project Career Development Award (CDA)-2-044-08S)|Terminated||N/A|11|Actual|VA Office of Research and Development|Due to low enrollment, the study was stopped prematurely. Due to the low number of subjects enrolled, statistical analysis was not possible on the intervention study.|3||Low recruitment in intervention study. Baseline data published.|f||||f||||||||||2018-05-31 22:54:09.061568|2018-05-31 22:54:09.061568
NCT01289626|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-05-19|2011-02-03|2011-02-04|Estimate|||||||2014-05-19|2014-05-20|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy of Lanthanum Carbonate in Calciphylaxis|Evaluation of Efficacy of Lanthanum Carbonate (Fosrenol) in Patients With Calciphylaxis|Completed||Phase 1|12|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-05-31 22:54:09.729012|2018-05-31 22:54:09.729012
NCT01289613|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-05-21|2011-02-02|2011-02-04|Estimate|||||||2014-05-21|2014-05-22|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|||Clinically Relevant Asymmetry of Bispectral Index|Clinically Relevant Asymmetry of Bispectral Index During Anesthesia for ENT Surgery in Adults and Children|Completed|||88|Actual|University of Schleswig-Holstein|||2||f||||f||||||||||2018-05-31 22:54:09.846968|2018-05-31 22:54:09.846968
NCT01289600|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-06-09|2011-02-02|2011-02-04|Estimate|||||||2015-06-09|2015-06-10|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Mechanical Ventilation and Respiratory Muscle Work of Breathing in Acute Respiratory Distress Syndrome (ARDS) Patients|The Role of Diaphragm Electromyography (EMG) Guided Mechanical Ventilation on Respiratory Physiology in Mechanically Ventilated Patients With Acute Respiratory Distress Syndrome (ARDS)|Completed||N/A|12|Actual|University Medical Center Nijmegen||4|||f||||t||||||||||2018-05-31 22:54:09.919566|2018-05-31 22:54:09.919566
NCT01289587|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2016-05-10|2011-02-03|2011-02-04|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|December 2012|Actual|2012-12-31||Interventional|DIAfit||Promoting Physical Activity in Patients With Type 2 Diabetes (DIAfit)|Efficacy and Feasibility of a Program to Promote Physical Activity in Patients With Type 2 Diabetes (DIAfit)|Unknown status|Active, not recruiting|N/A|120|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 22:54:10.183282|2018-05-31 22:54:10.183282
NCT01289574|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2014-06-27||2014-07-29|2011-02-02|2011-02-03|Estimate|2014-06-27|2014-07-25|Estimate||||2014-07-29|2014-08-01|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional||Randomized subjects|Topical ASC-J9 Cream for Acne|Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Safety and Efficacy of 0.1% and 0.025% ASC-J9 Creams Applied Topically Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris|Completed||Phase 2|181|Actual|AndroScience Corp||3|||f||||f||||||||||2018-05-31 22:54:10.292264|2018-05-31 22:54:10.292264
NCT01289561|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-02-23|2011-02-02|2011-02-03|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Combined Effects of Alcohol and Caffeine|Combined Effects of Alcohol and Caffeine|Completed||Phase 1|20|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 22:54:11.132176|2018-05-31 22:54:11.132176
NCT01289548|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2012-09-05||2013-07-08|2011-02-02|2011-02-03|Estimate|2013-07-08|2013-09-10|Estimate||||2013-07-08|2013-09-10|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation|Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation|Completed||N/A|120|Actual|Huazhong University of Science and Technology|The trial was conducted only in our hospital and had a relatively small sample size because of the scarcity of relative living donor renal transplantation compared to other surgeries.|3|||f||||f||||||||||2018-05-31 22:54:11.239551|2018-05-31 22:54:11.239551
NCT01289535|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-12-29|2011-02-02|2011-02-03|Estimate|||||||2011-12-29|2011-12-30|Estimate|November 2010||2010-11-30|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|Expand IDWP21||Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years|Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years|Unknown status|Recruiting|Phase 4|750|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 22:54:11.919828|2018-05-31 22:54:11.919828
NCT01289522|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2017-02-23||2017-04-07|2011-02-02|2011-02-03|Estimate|2017-02-23|2017-04-07|Actual||||2017-04-07|2017-05-15|Actual|September 2009||2009-09-30|October 2016|2016-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|TPEx||Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Study of Cetuximab, Docetaxel and Cisplatin as First-line Treatment in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinomas - GORTEC 2008-03 TPEx|Completed||Phase 2|54|Actual|Groupe Oncologie Radiotherapie Tete et Cou||1|||f||||f||||||||||2018-05-31 22:54:12.183851|2018-05-31 22:54:12.183851
NCT01289509|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2013-10-31|2011-02-02|2011-02-03|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects|A Randomized, Open-Label, 4-Way Crossover Replicate Design Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects|Completed||Phase 1|42|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:54:12.609068|2018-05-31 22:54:12.609068
NCT01289496|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2014-02-24|2011-02-02|2011-02-03|Estimate|||||||2014-02-24|2014-02-26|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Ribavirin Dose Optimization for the Treatment of Hepatitis C|Ribavirin Dose Optimization for the Treatment of Hepatitis C: A Pilot Study|Completed||Phase 2|13|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-05-31 22:54:12.694268|2018-05-31 22:54:12.694268
NCT01289470|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-05-18|2011-02-02|2011-02-03|Estimate|||||||2012-05-18|2012-05-21|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Clinical Assessment of Nonin 7600 Near Infrared Spectroscopy (NIRS) Tissue Oximetry During Cardiovascular Surgery|Clinical Assessment of Nonin 7600 Near Infrared Spectroscopy (NIRS) Tissue Oximetry During Cardiovascular Surgery|Completed|||50|Actual|Nonin Medical, Inc|||||f||||f||||||||||2018-05-31 22:54:13.058673|2018-05-31 22:54:13.058673
NCT01289457|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2017-06-29|2011-02-02|2011-02-03|Estimate|||||||2017-06-29|2017-07-02|Actual|February 2, 2011|Actual|2011-02-02|June 2017|2017-06-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome|Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome|Completed||Phase 1/Phase 2|286|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 22:54:13.206608|2018-05-31 22:54:13.206608
NCT01289444|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-08-31|2011-02-02|2011-02-03|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2011|Actual|2011-07-31|August 2017|2017-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|FACE||Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle|Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle|Completed||N/A|216|Actual|Children's Research Institute||2|||f||||t||||||||Yes|De-identified participant data will be shared upon request to the PI after the close of the study.|2018-05-31 22:54:13.352263|2018-05-31 22:54:13.352263
NCT01289431|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01||2012-02-28|2013-11-22|2011-02-02|2011-02-03|Estimate||||2012-05-03|2012-05-07|Estimate|2013-11-22|2013-12-17|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis|Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).|Completed||Phase 2|251|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 22:54:13.561237|2018-05-31 22:54:13.561237
NCT01289418|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|2012-07-09||2012-08-15|2011-02-02|2011-02-03|Estimate|2012-07-09|2012-08-14|Estimate||||2012-08-15|2012-08-21|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Surveillance for Adverse Events Following Pandemic H1N1 Immunization|Short and Long-Term Electronic Surveillance of a Large Number of Healthcare Workers Following Administration of an Adjuvanted Ph1n1 Vaccine|Completed|||6525|Actual|PHAC/CIHR Influenza Research Network|Only 52% answered the 3 surveys. We don't know why 48% didn't complete the 3 surveys (were they too sick or not motivated).We didn't have a group of comparable unvaccinated individuals (to estimate the risks attributable to the vaccine).||3||f||||f||||||||||2018-05-31 22:54:13.697194|2018-05-31 22:54:13.697194
NCT01289405|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2014-02-05|2011-02-02|2011-02-03|Estimate|||||||2014-02-05|2014-02-06|Estimate|October 2010||2010-10-31|February 2014|2014-02-28||||December 2011|Actual|2011-12-31||Interventional|||Phonoaudiologic Therapy Adjunct to Treatment on Patients With Obstructive Sleep Apnea|Phonoaudiologic Therapy as an Adjunct to the Continuous Positive Airway Pressure Treatment on Patients With Obstructive Sleep Apnea Syndrome|Completed||N/A|80|Actual|Associação Fundo de Incentivo à Pesquisa||2|||f||||t||||||||||2018-05-31 22:54:14.108198|2018-05-31 22:54:14.108198
NCT01289392|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2013-01-28||2013-04-25|2011-02-02|2011-02-03|Estimate|2013-03-04|2013-04-12|Estimate||||2013-04-25|2013-05-03|Estimate|October 2010||2010-10-31|March 2013|2013-03-31||||January 2013|Actual|2013-01-31||Interventional|||Continuous Positive Airway Pressure (CPAP), Oral Appliance and Physical Exercise in the Obstructive Sleep Apnea|Effects of the Treatment With Continuous Positive Airway Pressure (CPAP) and Oral Appliance, Associated or Not Associated With Physical Exercise, in the Obstructive Sleep Apnea|Completed||N/A|25|Actual|Associação Fundo de Incentivo à Pesquisa||3|||f||||t||||||||||2018-05-31 22:54:14.286663|2018-05-31 22:54:14.286663
NCT01289379|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2011-02-02|2011-02-02|2011-02-03|Estimate|||||||2011-02-02|2011-02-03|Estimate||||February 2011|2011-02-28||||||||Interventional|HFJV||The Effect of High Frequency Jet Ventilation (HFJV)During Laparoscopic Operations|The Effect of High Frequency Jet Ventilation (HFJV)on Pneumoperitoneum Induced Cardiovascular Changes, During Laparoscopic Surgery.|Completed||N/A|||Western Galilee Hospital-Nahariya||1|||f||||f||||||||||2018-05-31 22:54:14.615425|2018-05-31 22:54:14.615425
NCT01289366|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-08-10|2011-02-02|2011-02-03|Estimate|||||||2011-08-10|2011-08-11|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Inflammatory Bowel Disease (IBD)|Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Patients With Inflammatory Bowel Disease|Completed|||40|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||t||||||||||2018-05-31 22:54:14.684525|2018-05-31 22:54:14.684525
NCT01289353|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2018-01-24|2011-02-02|2011-02-03|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2010||2010-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer|Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks)|Active, not recruiting||Phase 1/Phase 2|39|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 22:54:14.760049|2018-05-31 22:54:14.760049
NCT01289340|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-02|2011-02-02|2011-02-03|Estimate|||||||2011-02-02|2011-02-03|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Observational|||Wound Healing and Pain Management in Partial Thickness Burns|Pain Management and Wound Healing in Partial Thickness Burn: Comparative, Post Marketing, Observational Trail Comparing Advanced Foam Dressings to Conventional Treatment.|Unknown status|Not yet recruiting||100|Anticipated|Rabin Medical Center|||3||f||||t||||||||||2018-05-31 22:54:14.853333|2018-05-31 22:54:14.853333
NCT01289327|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|||2011-02-02|2011-02-02|2011-02-03|Estimate|||||||2011-02-02|2011-02-03|Estimate|April 2010||2010-04-30|December 2010|2010-12-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Propofol Versus Midazolam+Alfentanil for Sedation During Bronchoscopy: Comparison by Cutaneous Carbon Dioxide Tension|Propofol Versus Midazolam Plus Alfentanil for Sedation During Flexible Bronchoscopy: Respiratory Depression Comparison Inspected by Cutaneous Carbon Dioxide Tension Level|Completed||N/A|115|Actual|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 22:54:14.953217|2018-05-31 22:54:14.953217
NCT01289314|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-09|2011-02-02|2011-02-03|Estimate|||||||2011-02-09|2011-02-10|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy|A Comparison of Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy.|Unknown status|Recruiting|N/A|62|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:54:15.031157|2018-05-31 22:54:15.031157
NCT01289301|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-02|2011-02-02|2011-02-03|Estimate|||||||2011-02-02|2011-02-03|Estimate|October 2011||2011-10-31|October 2010|2010-10-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|BKVIRUS||Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant|Polyomavirus BK Nephropathy After Renal Transplantation: Randomized Clinical Trial to Demonstrate That Switching to mTOR Inhibitor is More Effective Than a Reduction of Immunosuppressive Therapy|Not yet recruiting||Phase 4|124|Anticipated|Hannover Medical School||2|||f||||t||||||||||2018-05-31 22:54:15.116486|2018-05-31 22:54:15.116486
NCT01289288|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2013-05-20|2011-02-02|2011-02-03|Estimate|||||||2013-05-20|2013-05-21|Estimate|July 2007||2007-07-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CRC||A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese|A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese|Completed||Phase 1/Phase 2|480|Actual|Georgetown University||2|||f||||t||||||||||2018-05-31 22:54:15.204963|2018-05-31 22:54:15.204963
NCT01289275|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2017-10-26||2017-10-31|2011-02-02|2011-02-03|Estimate|2017-10-31|2017-11-29|Actual||||2017-10-31|2017-11-29|Actual|August 2011||2011-08-31|October 2017|2017-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Smoking Cessation in Hospitalized Smokers|Smoking Cessation in Hospitalized Smokers|Completed||Phase 4|1270|Actual|University of California, San Diego||4|||f||||t||||||||No||2018-05-31 22:54:15.291166|2018-05-31 22:54:15.291166
NCT01289262|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2016-01-20|2011-02-02|2011-02-03|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Long Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure|Long Term Comparison of Double Layer Continuously Locked Closure of Uterine Incision in Cesarean Section Versus Double Layer Purse String Closure (Turan Technique): A Prospective Randomized Study|Completed||N/A|100|Actual|Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi||2|||f||||t||||||||||2018-05-31 22:54:16.811943|2018-05-31 22:54:16.811943
NCT01289249|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2014-11-05|2011-02-02|2011-02-03|Estimate|||||||2014-11-05|2014-11-06|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet|Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet|Completed|||10|Actual|Oslo University Hospital|||1||f||||f||||||Samples Without DNA|"~     Two blood samples are taken from each included patient. (Each 2 ml heparin full blood).~   "|||2018-05-31 22:54:17.097676|2018-05-31 22:54:17.097676
NCT01289236|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2012-08-07|2011-02-02|2011-02-03|Estimate|||||||2012-08-07|2012-08-09|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||"MILNACIPRAN in Subjects With Chronic Shoulder Pain"|"An Exploratory, Randomized, Single Blinded, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of MILNACIPRAN in Subjects With Chronic Shoulder Pain"|Completed||Phase 4|40|Actual|Delray Research Associates||3|||f||||f||||||||||2018-05-31 22:54:17.350964|2018-05-31 22:54:17.350964
NCT01289223|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2018-04-25|2011-02-02|2011-02-03|Estimate|||||||2018-04-25|2018-04-26|Actual|February 2011||2011-02-28|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ROBIN||A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.|A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab|Recruiting||Phase 3|125|Anticipated|Mundipharma Research Limited||2|||f||||t||||||||||2018-05-31 22:54:17.684713|2018-05-31 22:54:17.684713
NCT01289210|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2014-05-28||2014-09-29|2011-02-02|2011-02-03|Estimate|2014-09-29|2014-10-06|Estimate||||2014-09-29|2014-10-06|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Interventional|||VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas|A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas|Terminated||Phase 1/Phase 2|2|Actual|VentiRx Pharmaceuticals Inc.|Due to slow enrollment, the study was closed by the sponsor. 2 participants were enrolled. 1 participant was analyzed for the primary outcome measure (tumor response) and 2 participants were analyzed for safety and toxicity.|1||The study was stopped due to slow rate of recruitment.|f||||t||||||||||2018-05-31 22:54:18.049898|2018-05-31 22:54:18.049898
NCT01289197|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-01-08|2011-02-02|2011-02-03|Estimate|||||||2016-01-08|2016-01-11|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Health Promotion in Early Adolescence: Sleep, Activity, and Emotion Regulation|Health Promotion in Early Adolescence: Sleep, Activity, and Emotion Regulation|Completed||N/A|324|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:54:18.630545|2018-05-31 22:54:18.630545
NCT01289184|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-02|2011-02-02|2011-02-03|Estimate|||||||2011-02-02|2011-02-03|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Observational|||Air Quality Monitoring and Health Surveillance of Workers in the Photocopier Units|Air Quality Monitoring and Health Surveillance of Workers in the Photocopier Units|Unknown status|Recruiting||200|Anticipated|Avinashilingam Deemed University|||5||f||||f||||||||||2018-05-31 22:54:18.924757|2018-05-31 22:54:18.924757
NCT01289171|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-02-01|2011-02-01|2011-02-03|Estimate|||||||2011-02-01|2011-02-03|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|October 2010|Actual|2010-10-31|June 2009|Actual|2009-06-30||Interventional|||Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients|Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients: Prospective Treatment Trial With Topical Glycolic Acid and HPV Genotype Characterization|Completed||N/A|38|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 22:54:19.141645|2018-05-31 22:54:19.141645
NCT01289158|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-07|2011-02-02|2011-02-03|Estimate|||||||2011-02-07|2011-02-08|Estimate|February 2011||2011-02-28|October 2010|2010-10-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Combined Malonic and Methylmalonic Aciduria (CMAMMA): Gene Identification and Outcome Study||Unknown status|Recruiting||6|Anticipated|McGill University Health Center|||1||f||||f||||||Samples With DNA|"~     1. A 5 cc sample of blood from a vein in EDTA tube for DNA testing~        2. A 5 cc sample of urine sample to measure the levels of MA and MMA~        3. An additional 5 cc (1 tsp) of blood sample will be collected from the parents for DNA~          testing~   "|||2018-05-31 22:54:19.395812|2018-05-31 22:54:19.395812
NCT01289145|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2012-11-13|2011-02-02|2011-02-03|Estimate|||||||2012-11-13|2012-11-15|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|STEPS||Stage-based Exercise Promotion Study|Stage-based Exercise Promotion Study|Completed||N/A|500|Anticipated|Freie Universität Berlin||1|||f||||t||||||||||2018-05-31 22:54:19.455476|2018-05-31 22:54:19.455476
NCT01289132|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-01|2011-02-01|2011-02-03|Estimate|||||||2011-02-01|2011-02-03|Estimate|July 2007||2007-07-31|February 2011|2011-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-536 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension|Completed||Phase 2|926|Actual|Takeda||7|||f||||f||||||||||2018-05-31 22:54:19.525988|2018-05-31 22:54:19.525988
NCT01289119|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2013-02-17||2013-02-17|2011-02-01|2011-02-03|Estimate|2013-02-17|2013-03-22|Estimate||||2013-02-17|2013-03-22|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes|An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Determine the Efficacy and Safety of SYR-322 When Used in Subjects With Type 2 Diabetes|Completed||Phase 3|506|Actual|Takeda||6|||f||||f||||||||||2018-05-31 22:54:19.688195|2018-05-31 22:54:19.688195
NCT01289106|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-02|2011-02-02|2011-02-03|Estimate|||||||2011-02-02|2011-02-03|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|April 2012|Anticipated|2012-04-30|October 2011|Anticipated|2011-10-31||Interventional|||Modified Dose and Schedule of Recombinant Hepatitis B Vaccination in HIV-infected Adult Subjects|Open-Label, Randomized Controlled Trial Comparing Three Strategies of Hepatitis B Vaccination in HIV-1-Infected Patients With CD4 Cell Counts Above 200 permm3 and Suppressed Viral Load|Unknown status|Recruiting|Phase 3|132|Anticipated|Chiang Mai University||3|||f||||f||||||||||2018-05-31 22:54:22.969086|2018-05-31 22:54:22.969086
NCT01289093|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2017-01-30|2011-02-02|2011-02-03|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|life-in||Quality of Life After Laparoscopic Inguinal- Incisional and Umbilical Herniotomy.|Quality of Life After Laparoscopic Inguinal- Incisional- and Umbilical Herniotomy.|Completed|||140|Actual|Zealand University Hospital|||4||f||||t||||||||||2018-05-31 22:54:23.105339|2018-05-31 22:54:23.105339
NCT01289080|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2015-08-04||2015-09-29|2011-02-01|2011-02-03|Estimate|2015-09-29|2015-10-29|Estimate||||2015-09-29|2015-10-29|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects|A Single-dose, Open-label, Parallel-group, Matched Trial Evaluating the Pharmacokinetics of Oral OPC-34712 Tablets in Subjects With Normal Renal Function and Renally Impaired Subjects|Completed||Phase 1|19|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 22:54:24.102912|2018-05-31 22:54:24.102912
NCT01289067|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2017-01-10||2018-01-16|2011-02-02|2011-02-03|Estimate|2018-01-16|2018-02-13|Actual||||2018-01-16|2018-02-13|Actual|December 2010||2010-12-31|January 2018|2018-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||"Utilizing A Genomic Sig for BRCAness to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca"|"Predicting Response to Platinum Chemotherapy in Metastatic Castration Resistant Prostate Ca(mCRPC)Using a Genomic Signature for BRCAness: A Phase II Prospective Open Label Clinical Trial of Satraplatin in Men With mCRPC Who Have Progressed on Docetaxel"|Completed||Phase 2|13|Actual|Icahn School of Medicine at Mount Sinai|limitation include low sample size|1|||f||||t||||||||||2018-05-31 22:54:24.588562|2018-05-31 22:54:24.588562
NCT01289054|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2015-04-14|2011-02-02|2011-02-03|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||A Global Imatinib and Nilotinib Pregnancy Exposure Registry|A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS)|Completed|||4|Actual|Novartis|||2||f||||||||||||||2018-05-31 22:54:24.894348|2018-05-31 22:54:24.894348
NCT01289041|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2015-03-30||2015-03-30|2011-02-02|2011-02-03|Estimate|2015-03-30|2015-04-10|Estimate||||2015-03-30|2015-04-10|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||BKM120 as Second-line Therapy for Advanced Endometrial Cancer|A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma|Completed||Phase 2|71|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:54:25.105662|2018-05-31 22:54:25.105662
NCT01289028|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|2016-02-24||2016-11-15|2011-02-02|2011-02-03|Estimate|2016-09-14|2016-11-01|Estimate||||2016-11-15|2017-01-02|Estimate|November 2008||2008-11-30|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.|An Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.|Completed||Phase 3|125|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:54:25.638443|2018-05-31 22:54:25.638443
NCT01289015|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2013-07-26|2013-04-15|2013-07-26|2011-02-02|2011-02-03|Estimate|2013-07-26|2013-09-26|Estimate|2013-04-15|2013-04-23|Estimate|2013-07-26|2013-09-26|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|NAFT-600|The Safety Evaluation Set (SES) which is the population of subjects who received at least one dose of study medication was used.|Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis|Completed||Phase 3|855|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 22:54:26.025025|2018-05-31 22:54:26.025025
NCT01289002|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2014-09-06|2011-02-02|2011-02-03|Estimate|||||||2014-09-06|2014-09-09|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|September 2012|Actual|2012-09-30||Observational|eBMX-PMR||e-BioMatrix PostMarket Registry|A Postmarket Registry of the BioMatrix™ and BioMatrix Flex™ Drug Eluting Stents.|Unknown status|Active, not recruiting||4000|Anticipated|Biosensors Europe SA|||||f||||t||||||||||2018-05-31 22:54:26.465819|2018-05-31 22:54:26.465819
NCT01288989|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2014-08-07|2011-02-01|2011-02-03|Estimate|||||||2014-08-07|2014-08-08|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors|Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:54:26.631024|2018-05-31 22:54:26.631024
NCT01288976|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2016-11-03||2018-03-12|2011-02-02|2011-02-03|Estimate|2017-05-18|2017-12-18|Actual||||2018-03-12|2018-04-06|Actual|October 2008||2008-10-31|March 2018|2018-03-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Observational|ACCESS-EU||ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe|ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe|Completed|||721|Actual|Evalve|||3||f||||f||||||||||2018-05-31 22:54:26.779048|2018-05-31 22:54:26.779048
NCT01288963|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2018-01-31|2011-02-02|2011-02-03|Estimate|||||||2018-01-31|2018-02-01|Actual|February 2010||2010-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|June 2019|Anticipated|2019-06-30||Observational|||"IL-2 SELECT Tissue Collection Protocol in Patients With Advanced Melanoma"|"The High-Dose Aldesleukin (IL-2) SELECT Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma"|Active, not recruiting|||153|Anticipated|Dana-Farber Cancer Institute|||1||f||||t||||||Samples With DNA|"~     tumor tissue, blood~   "|||2018-05-31 22:54:27.688087|2018-05-31 22:54:27.688087
NCT01288950|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2012-08-20|2011-02-02|2011-02-03|Estimate|||||||2012-08-20|2012-08-22|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|BCG-25-D||Vitamin D Supplementation Enhances Immune Response to Bacille-Calmette-Guerin (BCG) Vaccination in Infants|Vitamin D Supplementation Enhances Immune Response to BCG Vaccination in Infants|Completed||N/A|49|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 22:54:27.748024|2018-05-31 22:54:27.748024
NCT01288937|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-12-21|2011-02-02|2011-02-03|Estimate|||||||2016-12-21|2016-12-23|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain|A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain|Terminated||N/A|6|Actual|Columbia University||2||Poor recruitment|f||||f||||||||Yes||2018-05-31 22:54:27.813711|2018-05-31 22:54:27.813711
NCT01288924|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-12-05|2011-02-01|2011-02-03|Estimate|||||||2016-12-05|2016-12-06|Estimate|February 2011||2011-02-28|December 2016|2016-12-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Can Parecoxib Reduce Post-operative Ipsilateral Shoulder Pain?|Can Preemptive Analgesia With Parecoxib Reduce Post-operative Ipsilateral Shoulder Pain? A Double-blinded, Randomized, Placebo-controlled Trial.|Completed||Phase 2|160|Actual|Chiang Mai University||2|||f||||f||||||||No||2018-05-31 22:54:27.955652|2018-05-31 22:54:27.955652
NCT01288911|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2015-10-15||2017-12-04|2011-02-01|2011-02-03|Estimate|2015-10-29|2015-12-03|Estimate||||2017-12-04|2017-12-28|Actual|March 2, 2011|Actual|2011-03-02|December 2017|2017-12-31|November 8, 2017|Actual|2017-11-08|October 19, 2014|Actual|2014-10-19||Interventional|||A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer|A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer|Completed||Phase 2|375|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 22:54:28.07894|2018-05-31 22:54:28.07894
NCT01288898|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-01|2011-02-01|2011-02-03|Estimate|||||||2011-02-01|2011-02-03|Estimate|May 2007||2007-05-31|February 2011|2011-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941|A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of ASP1941 and to Explore the Effect of ASP1941 on Urine and Blood Glucose Levels in Healthy Subjects|Completed||Phase 1|48|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 22:54:28.95512|2018-05-31 22:54:28.95512
NCT01288885|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-01|2011-02-01|2011-02-03|Estimate|||||||2011-02-01|2011-02-03|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects|A Double-blind, Placebo-controlled, Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food-effect of Single Oral Doses of ASP1941 in Healthy Male Subjects|Completed||Phase 1|76|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 22:54:29.009561|2018-05-31 22:54:29.009561
NCT01288872|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2013-09-26|2011-02-02|2011-02-03|Estimate|||||||2013-09-26|2013-09-30|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Praziquantel-Pharmacokinetic Study|Praziquantel Pharmacokinetics in Pregnancy and During Lactation|Completed||Phase 1|47|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-05-31 22:54:29.066328|2018-05-31 22:54:29.066328
NCT01288859|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2011-07-25||2012-07-31|2011-02-02|2011-02-03|Estimate|2012-07-31|2012-08-01|Estimate||||2012-07-31|2012-08-01|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Physiological Effects of New Polyphenol-enriched Foods in Humans|Physiological Effects of New Polyphenol-enriched Foods in Healthy Humans|Completed||N/A|10|Actual|Federico II University||6|||f||||t||||||||||2018-05-31 22:54:29.150142|2018-05-31 22:54:29.150142
NCT01288846|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-02|||2011-02-03|2011-02-02|2011-02-03|Estimate|||||||2011-02-03|2011-02-04|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|March 2011|Anticipated|2011-03-31||Observational|||Medication List in and Out of Hospital|Communication About Medication Through the Medication List Coming Into the Hospital With the Patient, Being Changed in the Hospital and Then Returning With the Patient to the Community.|Unknown status|Not yet recruiting||30|Anticipated|University of Oslo|||1||f||||t||||||||||2018-05-31 22:54:29.495676|2018-05-31 22:54:29.495676
NCT01288833|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2017-01-17||2018-03-28|2011-02-01|2011-02-02|Estimate|2018-03-28|2018-04-30|Actual||||2018-03-28|2018-04-30|Actual|March 2011||2011-03-31|March 2018|2018-03-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|VALID||Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study|Real Time Colorectal Polyp Diagnosis in Colorectal Cancer Screening Using Close Focus High Definition Narrow Band Imaging Colonoscopy Compared to Conventional Histopathology Diagnosis - the VALID (Veterans Affairs Lesion Interpretation and Diagnosis) Colonoscopy Study|Completed||N/A|558|Actual|VA Palo Alto Health Care System||2|||f||||t||||||||No||2018-05-31 22:54:29.575185|2018-05-31 22:54:29.575185
NCT01288820|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2013-08-28|2011-02-01|2011-02-02|Estimate|||||||2013-08-28|2013-08-29|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|ACTPQ||Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria|Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup|Completed||Phase 3|331|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 22:54:29.809727|2018-05-31 22:54:29.809727
NCT01288807|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-10-24|2011-02-01|2011-02-02|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2011||2011-02-28|June 2013|2013-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|Forest||Effect of Milnacipran on Pain in Fibromyalgia|Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study|Completed||Phase 4|10|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 22:54:29.876087|2018-05-31 22:54:29.876087
NCT01287819|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-10-17|2011-01-31|2011-02-01|Estimate|||||||2012-10-17|2012-10-19|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Observational|fMRI||Apolipoprotein E Gene and Functional MRI|Polymorphisms of Apolipoprotein E Gene and the Presentation of Resting-state Functional MRI|Unknown status|Recruiting||200|Anticipated|Taipei Medical University Shuang Ho Hospital|||1||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-05-31 22:54:44.663206|2018-05-31 22:54:44.663206
NCT01288794|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2017-01-19|2011-02-01|2011-02-02|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|November 2014|Actual|2014-11-30||Interventional|ANSWER||Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis|The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial|Completed||Phase 4|431|Actual|University of Bologna||2|||f||||t||||||||||2018-05-31 22:54:30.028227|2018-05-31 22:54:30.028227
NCT01288781|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2011-11-24||2012-02-06|2011-01-31|2011-02-02|Estimate|2011-11-24|2011-12-26|Estimate||||2012-02-06|2012-02-07|Estimate|July 2011||2011-07-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Intracranial Pressure in Experimental Models of Headache|Intracranial Pressure in Experimental Models of Headache|Completed||N/A|23|Actual|Bangor University|Acetazolamide did not reduce high altitude headache as expected. Nevertheless the relationship between optic nerve sheath diameter and headache could still be determined by completing other analyses.|2|||f||||f||||||||||2018-05-31 22:54:30.177234|2018-05-31 22:54:30.177234
NCT01288768|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2013-05-02|2011-02-01|2011-02-02|Estimate|||||||2013-05-02|2013-05-03|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Is a Knee Arthroscopy of Any Benefit for the Middleaged Patient With Meniscal Symptoms?|Is a Knee Arthroscopy of Any Benefit for the Middleaged Patient With Meniscal Symptoms?|Completed||N/A|150|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 22:54:30.551321|2018-05-31 22:54:30.551321
NCT01288755|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-06-23|2011-02-01|2011-02-02|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2011||2011-02-28|June 2011|2011-06-30|May 2011|Actual|2011-05-31|||||Interventional|||TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir|A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC278 25 mg q.d. and Raltegravir 400 mg b.i.d.|Completed||Phase 1|24|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||||||||||||2018-05-31 22:54:30.632795|2018-05-31 22:54:30.632795
NCT01288742|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-11-29|2011-02-01|2011-02-02|Estimate|||||||2012-11-29|2012-11-30|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin|A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Transporter Substrates, Digoxin and Rosuvastatin|Completed||Phase 1|33|Actual|Tibotec Pharmaceuticals, Ireland||5|||f||||||||||||||2018-05-31 22:54:30.704395|2018-05-31 22:54:30.704395
NCT01288729|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2015-10-28||2017-01-06|2011-02-01|2011-02-02|Estimate|2017-01-06|2017-02-27|Actual||||2017-01-06|2017-02-27|Actual|January 2011||2011-01-31|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter|Duration of Infusion Set Function: A Study Comparing the Quick-Set Teflon Catheter vs Sure-T Steel Infusion Set Catheter|Completed||N/A|20|Actual|Stanford University|This was a single center study with 20 subjects enrolled in a cross-over study. A larger study would make results more robust. In addition, if each subject had worn each infusion set 3 to 6 times, it would make the study more robust.|2|||f||||t||||||||No||2018-05-31 22:54:30.783341|2018-05-31 22:54:30.783341
NCT01288716|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2013-07-30|2011-02-01|2011-02-02|Estimate|||||||2013-07-30|2013-07-31|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders|Completed||Phase 2|150|Actual|Seaside Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 22:54:30.965702|2018-05-31 22:54:30.965702
NCT01288703|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2014-05-27|2011-02-01|2011-02-02|Estimate|||||||2014-05-27|2014-05-28|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Observational|CAT||Computerized-Adaptive Testing: Feasibility In Women With Pelvic Floor Disorders (CAT)|Computerized-Adaptive Testing: Feasibility In Women With Pelvic Floor Disorders|Completed|||20|Actual|Women and Infants Hospital of Rhode Island|||||f||||f||||||||||2018-05-31 22:54:31.05277|2018-05-31 22:54:31.05277
NCT01288690|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2013-06-13|2011-02-01|2011-02-02|Estimate|||||||2013-06-13|2013-06-17|Estimate|December 2010||2010-12-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Stress Reduction in Middle Eastern Refugees|Stress Reduction in Middle Eastern Refugees|Completed||Phase 2|63|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 22:54:31.12226|2018-05-31 22:54:31.12226
NCT01288677|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2013-03-19|2011-02-01|2011-02-02|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||TMC649128HPC1001 - First In-human Trial to Examine Safety, Tolerability, and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses of TMC649128 in Healthy Volunteers|Phase I, First In-human, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability, and Blood and Plasma Pharmacokinetics of Increasing Single Oral Doses of TMC649128|Completed||Phase 1|54|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||||||||||||2018-05-31 22:54:31.19231|2018-05-31 22:54:31.19231
NCT01288664|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2014-02-10|2011-02-01|2011-02-02|Estimate|||||||2014-02-10|2014-02-12|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis||Withdrawn||Phase 3|0|Actual|Sun Yat-sen University||1||sponsor withdraw from this study|f||||t||||||||||2018-05-31 22:54:31.270557|2018-05-31 22:54:31.270557
NCT01288651|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-01|2011-02-01|2011-02-02|Estimate|||||||2011-02-01|2011-02-02|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Iron Deficiency In Pulmonary Hypertension|Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension|Unknown status|Recruiting|Phase 4|30|Anticipated|VU University Medical Center|||||f||||f||||||||||2018-05-31 22:54:31.339283|2018-05-31 22:54:31.339283
NCT01288638|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-10-13|2011-02-01|2011-02-02|Estimate|||||||2017-10-13|2017-10-17|Actual|January 2011||2011-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Lifestyle Intervention for Polycystic Ovary Syndrome: Pulse-Based Diet and Exercise|A Lifestyle Intervention for Women With Polycystic Ovary Syndrome: The Role of a Pulse-Based Diet and Aerobic Exercise on Infertility Measures and Metabolic Syndrome Risk|Completed||N/A|95|Actual|University of Saskatchewan||2|||f||||t||||||||||2018-05-31 22:54:31.40142|2018-05-31 22:54:31.40142
NCT01288625|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2012-10-12|2011-02-01|2011-02-02|Estimate|||||||2012-10-12|2012-10-15|Estimate|March 2011||2011-03-31|October 2012|2012-10-31||||December 2011|Actual|2011-12-31||Interventional|||Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine|Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine|Suspended||Phase 4|150|Anticipated|Sun Pharmaceutical Industries Limited||3||There were IP availability issues due to which the study could not be started.|f||||f||||||||||2018-05-31 22:54:31.462693|2018-05-31 22:54:31.462693
NCT01288612|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2014-12-23||2014-12-23|2011-02-01|2011-02-02|Estimate|2014-12-23|2015-01-07|Estimate||||2014-12-23|2015-01-07|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|challenge||Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus|Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus|Completed||N/A|459|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 22:54:31.560574|2018-05-31 22:54:31.560574
NCT01288599|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-06-29|2011-02-01|2011-02-02|Estimate|||||||2012-06-29|2012-07-03|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Single Versus Conventional Laparoscopy for Benign Adnexal Disease|Single Port Laparoscopy Versus Conventional Laparoscopy for Benign Adnexal Disease - A Randomized Controlled Trial.|Completed||Phase 3|40|Actual|Sorlandet Hospital HF||2|||f||||t||||||||||2018-05-31 22:54:32.178281|2018-05-31 22:54:32.178281
NCT01288586|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-03-24|2011-02-01|2011-02-02|Estimate|||||||2017-03-24|2017-03-27|Actual|October 5, 2009|Actual|2009-10-05|March 2017|2017-03-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Observational|STAR 8||Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients|Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of Scandinavian Total Ankle Replacement (STAR) Ankle Among Continued Access Study Patients|Completed|||87|Actual|Stryker Trauma GmbH|||1||f||||f||||||||||2018-05-31 22:54:32.254101|2018-05-31 22:54:32.254101
NCT01288573|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-05-15|2011-02-01|2011-02-02|Estimate|||||||2017-05-15|2017-05-16|Actual|March 3, 2014||2014-03-03|May 2017|2017-05-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone|A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants.|Completed||Phase 1/Phase 2|46|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 22:54:32.331025|2018-05-31 22:54:32.331025
NCT01288560|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2018-05-28|2011-01-31|2011-02-02|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2011||2011-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|AIMI-HF||IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF)|Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) Project I-A of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)|Recruiting||Phase 4|1511|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 22:54:32.44765|2018-05-31 22:54:32.44765
NCT01288547|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-02-22|2011-01-31|2011-02-02|Estimate|||||||2012-02-22|2012-02-23|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Effects of Theobromine and Caffeine on Mood, Cognition and Blood Pressure|Temporal Change of Mood and Cognition in Healthy Subjects After Consumption of Theobromine and/ or Caffeine|Completed||N/A|24|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 22:54:32.691547|2018-05-31 22:54:32.691547
NCT01288534|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2016-04-29||2017-09-21|2011-02-01|2011-02-02|Estimate|2016-04-29|2016-06-09|Estimate||||2017-09-21|2017-10-24|Actual|January 2011||2011-01-31|September 2017|2017-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Hypofractionated Stereotactic Body Radiation Therapy (SBRT)|A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion|Completed||Phase 2|68|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 22:54:32.797567|2018-05-31 22:54:32.797567
NCT01288521|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2017-03-31||2018-02-22|2011-01-31|2011-02-02|Estimate|2018-02-22|2018-03-09|Actual||||2018-02-22|2018-03-09|Actual|October 2008||2008-10-31|February 2018|2018-02-28|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients|Utilizing Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients|Completed||Phase 4|8|Actual|University of Iowa|Early termination leading to small numbers of subjects analyzed.|2|||f||||t||||||||No||2018-05-31 22:54:33.0813|2018-05-31 22:54:33.0813
NCT01288508|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-09-16|2011-02-01|2011-02-02|Estimate|||||||2014-09-16|2014-09-17|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Investigation of Supra Fiber in the Treatment of Adults With Constipation|Investigation of Supra Fiber in the Treatment of Adults With Constipation-A Double-blind Randomized Controlled Trial|Completed||N/A|89|Actual|Augusta University||2|||f||||||||||||||2018-05-31 22:54:33.353466|2018-05-31 22:54:33.353466
NCT01288495|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2014-09-16|2011-01-31|2011-02-02|Estimate|||||||2014-09-16|2014-09-17|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Long Term Fructose|Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance: a Double-blind, Randomized Crossover Study|Terminated||N/A|15|Actual|Augusta University||2||PI moved institutions and changed study protocol|f||||||||||||||2018-05-31 22:54:33.428832|2018-05-31 22:54:33.428832
NCT01288482|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2014-05-12|2011-02-01|2011-02-02|Estimate|||||||2014-05-12|2014-05-13|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||AeroEclipse II Agreement|Use of the AeroEclipse II Breath Actuated Nebulizer for the Delivery of Methacholine Chloride Bronchoprovocation Agent: A Pilot Study.|Completed||Phase 4|32|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 22:54:33.516175|2018-05-31 22:54:33.516175
NCT01288469|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2015-08-21|2012-12-12|2015-08-21|2011-02-01|2011-02-02|Estimate|2015-08-21|2015-09-24|Estimate|2012-12-12|2012-12-17|Estimate|2015-08-21|2015-09-24|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed Dose/Dose Regimen, Multicenter Study Evaluating the Efficacy and Safety of SAR236553 When Co-administered With 80 mg of Atorvastatin Over 8 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL (≥2.59 mmol/L) on Atorvastatin 10 mg|Completed||Phase 2|92|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 22:54:33.627967|2018-05-31 22:54:33.627967
NCT01288456|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-05-25|2011-02-01|2011-02-02|Estimate|||||||2012-05-25|2012-05-28|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Observational|||Study to Evaluate Novel Gastric Space Occupying Device|A Single Centre 30-day Observational Non-randomised Study to Evaluate Preliminary Safety and Efficacy of a Novel Gastric Space Occupying Device as an Aid for Weight Loss|Completed|||10|Actual|Obalon Therapeutics, Inc.|||||f||||f||||||||||2018-05-31 22:54:34.104177|2018-05-31 22:54:34.104177
NCT01288443|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2015-08-21|2012-12-12|2015-08-21|2011-02-01|2011-02-02|Estimate|2015-08-21|2015-09-24|Estimate|2012-12-12|2012-12-17|Estimate|2015-08-21|2015-09-24|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Randomized population.|Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of Five Doses and Two Dose Regimens of SAR236553 Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL (≥ 2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy|Completed||Phase 2|183|Actual|Sanofi||6|||f||||t||||||||||2018-05-31 22:54:34.204846|2018-05-31 22:54:34.204846
NCT01288430|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2015-03-02|2011-02-01|2011-02-02|Estimate|||||||2015-03-02|2015-03-03|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study of DS-2248, in Subjects With Advanced Solid Tumors|A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors|Terminated||Phase 1|60|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 22:54:35.226858|2018-05-31 22:54:35.226858
NCT01288417|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-07-23|2011-02-01|2011-02-02|Estimate|||||||2012-07-23|2012-07-24|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|OPAL||Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir|Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir|Completed||Phase 1|24|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 22:54:35.33493|2018-05-31 22:54:35.33493
NCT01288404|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-01|2011-02-01|2011-02-02|Estimate|||||||2011-02-01|2011-02-02|Estimate|January 2008||2008-01-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium|A Pilot Study of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium|Completed||N/A|80|Actual|Ramathibodi Hospital||4|||f||||f||||||||||2018-05-31 22:54:35.549992|2018-05-31 22:54:35.549992
NCT01288391|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2016-05-12|2011-02-01|2011-02-02|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients|An Open Non-randomised Dose Escalation Trial Investigating the Safety and Pharmacokinetics of Single Intravenous Administrations of NNC128-0000-2011 in Patients With Haemophilia A or B|Completed||Phase 1|15|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:54:35.825933|2018-05-31 22:54:35.825933
NCT01288378|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2017-12-12|2011-02-01|2011-02-02|Estimate|||||||2017-12-12|2017-12-13|Actual|March 2012||2012-03-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Empirical Versus Preemptive Antifungal Therapy|Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups|Active, not recruiting||Phase 3|556|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 22:54:35.936388|2018-05-31 22:54:35.936388
NCT01288365|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-03-16|2011-02-01|2011-02-02|Estimate|||||||2012-03-16|2012-03-19|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||The Impact of Exercise Training on Functional Capacity in Heart Failure|Impact of Exercise Training on Functional Capacity in Heart Failure Patients With Preserved Ejection Fraction.|Unknown status|Recruiting|N/A|80|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 22:54:36.035489|2018-05-31 22:54:36.035489
NCT01288352|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2017-02-03|2011-02-01|2011-02-02|Estimate|||||||2017-02-03|2017-02-06|Estimate|February 2011||2011-02-28|February 2017|2017-02-28|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|EAST||Early Treatment of Atrial Fibrillation for Stroke Prevention Trial|Early Therapy of Atrial Fibrillation for Stroke Prevention Trial (EAST).|Active, not recruiting||Phase 4|2789|Actual|Atrial Fibrillation Network||2|||f||||t||||||||Undecided||2018-05-31 22:54:37.091013|2018-05-31 22:54:37.091013
NCT01288339|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|||2018-05-11|2011-02-01|2011-02-02|Estimate|||||||2018-05-11|2018-05-16|Actual|November 8, 2010|Actual|2010-11-08|May 2018|2018-05-31|February 13, 2015|Actual|2015-02-13|February 13, 2015|Actual|2015-02-13||Interventional|PULSE||Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer|An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy|Completed||Phase 2|78|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||2|||f||||f||||||||||2018-05-31 22:54:37.235098|2018-05-31 22:54:37.235098
NCT01288326|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-01-25|2011-02-01|2011-02-02|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|ROOTS||Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes Mellitus|Completed|||254|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:54:37.373303|2018-05-31 22:54:37.373303
NCT01288313|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2014-08-19|2011-01-31|2011-02-02|Estimate|||||||2014-08-19|2014-08-20|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Oméga 3||Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Human Milk Composition of Lactating Women|Effect of N-3 Polyunsaturated Fatty Acids Supplementation on the Human Milk Composition of Lactating Women: Nutritional Intervention With Rapeseed Oil and n-3 Margarine Compared to Standard Olive Oil|Completed||N/A|82|Actual|University Hospital, Bordeaux||4|||f||||f||||||||||2018-05-31 22:54:37.493464|2018-05-31 22:54:37.493464
NCT01288300|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2013-09-23|2011-01-31|2011-02-02|Estimate|||||||2013-09-23|2013-09-24|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Health and Faith (Salud y Fe): Community-Based Diabetes Pilot Intervention|Health and Faith (Salud y Fe): Community-Based Diabetes Pilot Intervention|Completed||N/A|100|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 22:54:37.673799|2018-05-31 22:54:37.673799
NCT01288287|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2015-09-29||2016-08-05|2011-01-31|2011-02-02|Estimate|2016-05-17|2016-06-27|Estimate||||2016-08-05|2016-09-16|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|RA-PROACTIVE|Baseline characteristics refer to the Safety Set, consisting of all patients entered into the study who took at least one dose of Certolizumab Pegol.|Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients|A Prospective, Multicentre, Non-interventional, Observational, Cohort Study to Evaluate the Long Term Clinical, Patient Reported and Health Care Resource Utilization Effects of an Early Response to Certolizumab Pegol (Cimzia®) in Rheumatoid Arthritis Patients in Daily Clinical Practice in the United Kingdom and Eire.|Completed|||149|Actual|UCB Pharma|||2||f||||f||||||||||2018-05-31 22:54:37.793678|2018-05-31 22:54:37.793678
NCT01288274|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-01-31|2011-01-31|2011-02-02|Estimate|||||||2011-01-31|2011-02-02|Estimate|June 2008||2008-06-30|May 2010|2010-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CBDDMPA||Community Based Distribution of Injectable Contraceptives in Tigray, Ethiopia|Safety and Feasibility of Community Based DMPA Provision in Tigray, Ethiopia|Completed||N/A|1062|Actual|University of California, Berkeley||2|||f||||f||||||||||2018-05-31 22:54:38.154593|2018-05-31 22:54:38.154593
NCT01288261|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2016-04-20|2011-01-31|2011-02-02|Estimate|||||||2016-04-20|2016-04-21|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|May 2013|Actual|2013-05-31||Interventional|||Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer|A Phase I Trial of Weekly Paclitaxel in Combination With Bavituximab in Patients With Her-2 Negative Metastatic Breast Cancer|Completed||Phase 1|14|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 22:54:38.252041|2018-05-31 22:54:38.252041
NCT01288248|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-07-25|2011-01-31|2011-02-02|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Noninferiority Clinical Trial With Laryngeal Mask and Endotracheal Tube|The Risk of Laryngospasm in Children is Similar to the Use of the Laryngeal Mask and the Endotracheal Tube in Children 2 Years to 14 Years: Clinical Trial Randomized Noninferiority|Unknown status|Active, not recruiting|Phase 3|338|Anticipated|Universidad de Antioquia||2|||f||||t||||||||||2018-05-31 22:54:38.342609|2018-05-31 22:54:38.342609
NCT01288235|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2018-05-03|2011-02-01|2011-02-02|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2011||2011-01-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation|A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes|Active, not recruiting||Phase 2|100|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:54:38.436809|2018-05-31 22:54:38.436809
NCT01288222|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2017-12-03|2011-02-01|2011-02-02|Estimate|||||||2017-12-03|2017-12-05|Actual|June 2011||2011-06-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Selecting a Favorable KIR Donor in Unrelated HCT for AML|KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor|Active, not recruiting||N/A|506|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 22:54:38.538184|2018-05-31 22:54:38.538184
NCT01288209|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|2013-10-15|2013-04-23|2013-12-18|2011-02-01|2011-02-02|Estimate|2013-12-18|2014-01-24|Estimate|2013-04-23|2013-05-01|Estimate|2013-12-18|2014-01-24|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy|A Phase III, Randomized, Open-label, Two-arm Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Hepatitis C, Genotype 1-Infected Subjects Who Failed to Respond to Previous IFN-based Therapy|Completed||Phase 3|106|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 22:54:38.677389|2018-05-31 22:54:38.677389
NCT01288196|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2013-01-25|2011-02-01|2011-02-02|Estimate|||||||2013-01-25|2013-01-28|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CNTO 6785 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects|Completed||Phase 1|32|Actual|Janssen-Cilag International NV||6|||f||||||||||||||2018-05-31 22:54:39.41403|2018-05-31 22:54:39.41403
NCT01288183|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2018-01-24|2011-02-01|2011-02-02|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2011||2011-01-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Anodal Transcranial Direct Current Stimulation (tDCS) in the Treatment of Tobacco Addiction|Behavioral Impact of Prefrontal Anodal Transcranial Direct Current Stimulation on Smokers|Completed||N/A|38|Actual|Hôpital le Vinatier||2|||f||||f||||||||||2018-05-31 22:54:39.51873|2018-05-31 22:54:39.51873
NCT01288170|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2011-02-01|2011-02-01|2011-02-02|Estimate|||||||2011-02-01|2011-02-02|Estimate|February 2010||2010-02-28|February 2011|2011-02-28||||July 2010|Anticipated|2010-07-31||Interventional|||Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®|Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®|Unknown status|Recruiting|N/A|12|Anticipated|Erempharma||2|||f||||f||||||||||2018-05-31 22:54:39.607109|2018-05-31 22:54:39.607109
NCT01288157|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-05-26|2011-02-01|2011-02-02|Estimate|||||||2014-05-26|2014-05-28|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects|A Randomized, Open-label Study to Evaluate the Pharmacokinetics of a Single Subcutaneous Administration of 50 mg or 100 mg Golimumab in a Pre-filled Syringe Formulation to Healthy Male Chinese Subjects|Completed||Phase 1|24|Actual|Centocor, Inc.||2|||f||||||||||||||2018-05-31 22:54:39.70584|2018-05-31 22:54:39.70584
NCT01288144|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-02-03|2011-02-01|2011-02-02|Estimate|||||||2012-02-03|2012-02-06|Estimate|July 2007||2007-07-31|February 2012|2012-02-29||||November 2011|Actual|2011-11-30||Interventional|||Clinical Decision Support for Women With a History of Gestational Diabetes|Clinical Decision Support for Women With a History of Gestational Diabetes|Completed||N/A|1000|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 22:54:39.808228|2018-05-31 22:54:39.808228
NCT01287962|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2013-12-05|2011-01-31|2011-02-02|Estimate|||||||2013-12-05|2013-12-09|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|March 2014|Anticipated|2014-03-31|April 2013|Actual|2013-04-30||Interventional|||Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer|Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer:a Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study|Unknown status|Active, not recruiting|Phase 3|480|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:54:41.872736|2018-05-31 22:54:41.872736
NCT01288131|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-01|||2014-01-27|2011-02-01|2011-02-02|Estimate|||||||2014-01-27|2014-01-29|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment|Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone|Terminated||Phase 3|8|Actual|Chulalongkorn University||2||"We observed >90 % efficacy in cyclophosphamide and Prednisolone group for treatment of~   anti-i-HuEpo associated PRCA"|f||||f||||||||||2018-05-31 22:54:39.872443|2018-05-31 22:54:39.872443
NCT01288105|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-12-27|2011-01-31|2011-02-02|Estimate|||||||2011-12-27|2011-12-28|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|||Use of Optical Coherence Tomography to Determine the Optimal Management of Patients With Drug-eluting Stents Who Need Non-cardiac Surgery|Use of Optical Coherence Tomography to Determine the Optimal Management of Patients With Drug-eluting Stents Who Need Non-cardiac Surgery|Terminated||Phase 4|107|Anticipated|North Texas Veterans Healthcare System||1|||f||||f||||||||||2018-05-31 22:54:39.998128|2018-05-31 22:54:39.998128
NCT01288092|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-06-05|2011-01-31|2011-02-02|Estimate|||||||2012-06-05|2012-06-07|Estimate|March 2012||2012-03-31|June 2012|2012-06-30||||September 2015|Anticipated|2015-09-30||Interventional|||BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer|A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer, With or Without PI3K Activated Pathway|Withdrawn||Phase 2|0|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:54:40.072962|2018-05-31 22:54:40.072962
NCT01288079|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2012-08-07||2012-11-14|2011-02-01|2011-02-02|Estimate|2012-09-27|2012-10-29|Estimate||||2012-11-14|2012-11-20|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy|Terminated||Phase 2|145|Actual|AstraZeneca|The study was terminated early and thus only a fraction of the planned number of patients were randomized and many did not complete the study. As a consequence the possibility of interpreting efficacy over an 8 week period is considerably reduced.|4|||f||||f||||||||||2018-05-31 22:54:40.200158|2018-05-31 22:54:40.200158
NCT01288066|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2018-04-26|2011-02-01|2011-02-02|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2011||2011-09-30|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|December 2021|Anticipated|2021-12-31||Interventional|Epoca H vs T||"Effectiveness of Hemi- Versus Total Shoulder Arthroplasty Using Implants of the Epoca System"|A Randomized Multicenter Study Comparing the Effectiveness of Hemi- Versus Total Shoulder Arthroplasty in Patients With a Degenerative Joint Disease|Active, not recruiting||N/A|76|Actual|AO Clinical Investigation and Documentation||2|||f||||f||||||||||2018-05-31 22:54:41.042131|2018-05-31 22:54:41.042131
NCT01288053|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2016-07-11|2011-02-01|2011-02-02|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease|Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease|Terminated||Phase 1/Phase 2|9|Actual|Northwestern University||1||No participant enrolled more than two years. No plan to continue study.|f||||f||||||||No||2018-05-31 22:54:41.13906|2018-05-31 22:54:41.13906
NCT01288040|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2015-03-31|2011-02-01|2011-02-02|Estimate|||||||2015-03-31|2015-04-01|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Locomotor Training for Neurological Disease|Locomotor Training for Neurological Disease|Completed||Phase 1|92|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||f||||||||||2018-05-31 22:54:41.229225|2018-05-31 22:54:41.229225
NCT01288027|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2014-11-24||2014-12-04|2011-01-31|2011-02-02|Estimate|2014-11-24|2014-12-02|Estimate||||2014-12-04|2014-12-19|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||FAS population included all participants who received at least one complete infusion of alglucosidase alfa.|Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa|A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa|Completed||Phase 4|16|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 22:54:41.34379|2018-05-31 22:54:41.34379
NCT01288014|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-07-18|2011-02-01|2011-02-02|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2011||2011-01-31|July 2017|2017-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Cytokine Production and Immunity to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine|Relationship of Cytokine Production and Immune Responses to Varicella Zoster Virus (VZV) in Elderly Recipients of Zoster Vaccine|Completed|||26|Actual|Columbia University|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 22:54:41.601654|2018-05-31 22:54:41.601654
NCT01288001|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-11-20|2011-01-31|2011-02-02|Estimate|||||||2012-11-20|2012-11-21|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|||Study of Evaluating the Duration of Efficacy of One Intra Articular Injection of Sodium Hyaluronate 2.0% in Patients With Painful Osteoarthritis of the Knee|A Pilot, Open, Randomised, Controlled, add-on Study Evaluating the Duration of Efficacy of One Intra Articular Injection of Sodium Hyaluronate 2.0% in Patients With Painful Osteoarthritis of the Knee|Completed||Phase 2|20|Actual|TRB Chemedica||1|||f||||||||||||||2018-05-31 22:54:41.659561|2018-05-31 22:54:41.659561
NCT01287988|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-01-12|2011-02-01|2011-02-02|Estimate|||||||2017-01-12|2017-01-13|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies|Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies.|Completed|||24|Actual|ThromboGenics|||2||f||||f||||||||||2018-05-31 22:54:41.712449|2018-05-31 22:54:41.712449
NCT01287975|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2018-02-23|2011-01-31|2011-02-02|Estimate|||||||2018-02-23|2018-02-27|Actual|January 2011||2011-01-31|February 2018|2018-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ARTS-BCI||Brain Computer Interface (BCI) Technology for Stroke Hand Rehabilitation|ARTS-BCI: Advanced Brain Computer Interface (BCI) Technology for Wrist and Hand Rehabilitation After Stroke|Completed||N/A|21|Actual|Tan Tock Seng Hospital||3|||f||||f||||||||||2018-05-31 22:54:41.790051|2018-05-31 22:54:41.790051
NCT01287949|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-09-08|2011-01-31|2011-02-02|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2011|Actual|2011-01-31|September 2017|2017-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older|An Open-label, Multicentre Study to Evaluate the Immunogenicity and Safety of One Dose of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older Without a Previous Diphtheria- and Tetanus-containing Booster Within the Last 20 Years|Completed||Phase 3|342|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:54:41.942333|2018-05-31 22:54:41.942333
NCT01287936|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2016-12-19|2011-01-31|2011-02-02|Estimate|||||||2016-12-19|2016-12-21|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of Modified Stem Cells in Stable Ischemic Stroke|A Phase 1/2A Study of the Safety and Efficacy of Modified Stromal Cells (SB623) in Patients With Stable Ischemic Stroke|Completed||Phase 1/Phase 2|18|Actual|SanBio, Inc.||1|||f||||t||||||||||2018-05-31 22:54:42.027803|2018-05-31 22:54:42.027803
NCT01287923|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2018-04-06|2011-02-01|2011-02-02|Estimate|||||||2018-04-06|2018-04-10|Actual|February 21, 2011|Actual|2011-02-21|April 2018|2018-04-30|September 1, 2017|Actual|2017-09-01|June 8, 2017|Actual|2017-06-08||Observational|BMS-LyTrans||Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans|Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans|Completed|||326|Actual|Rennes University Hospital|||4||f||||f||||||Samples With DNA|"~     For this study, 4 newly included cohorts are necesseray :~        -  100 new DLBCL patients are necessary. The blood will be taken at the diagnosis for DLBCL~          patients included 075-GOELAMS trial or 075-like patient.~        -  100 healthy blood donors. This cohort of matched for sex & gender will be constituted at~          the EFS (French Blood Bank) of Rennes.~        -  100 septic patients included at the Rennes University Hospital.~        -  100 075-like DLBCL patients in completed remission.~      This project will also used already available blood collections: 2) Mantle cell lymphoma, 3)~     localized DLBCL and septic shock. Paraffin blocks of patient 075-trial DLBCLs are in the~     GOELAMSthèque bank localized in the Pathology Department Hôtel Dieu, Paris supervised by Pr~     Diane Damotte. Tissue Microarrays and complete paraffin blocks as well as some -80° tumors~     are already available.~   "|||2018-05-31 22:54:42.094598|2018-05-31 22:54:42.094598
NCT01287910|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2013-09-04|2011-02-01|2011-02-02|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|Amsterdam||Transmyocardial Laser Revascularization and Cardiovascular Magnetic Resonance Imaging|Effect of Transmyocardial Laser Revascularization on Myocardial Perfusion and Left Ventricular Structure by Cardiovascular Magnetic Resonance Imaging and Dynamic Volumetric Computed Tomography|Terminated||N/A|2|Actual|Piedmont Healthcare||1||Lack of patient population|f||||f||||||||||2018-05-31 22:54:42.172947|2018-05-31 22:54:42.172947
NCT01287897|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2015-09-14||2015-12-14|2011-01-31|2011-02-02|Estimate|2015-12-14|2016-01-21|Estimate||||2015-12-14|2016-01-21|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|ANDANTE|Baseline characteristics were summarized for the safety analysis set (SAS), which consisted of all participants who received at least 1 dose of study drug.|A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy|A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Crohn's Disease Who Are Anti-tnf Inadequate Responders (Andante)|Completed||Phase 2|250|Actual|Pfizer|Enrollment into the 200 mg arm was halted on 14 August 2013 before reaching the planned sample size due to safety findings in NCT01405196. Hence the 200 mg vs placebo comparisons were excluded from the primary analyses and reported separately.|3|||f||||t||||||||||2018-05-31 22:54:42.406184|2018-05-31 22:54:42.406184
NCT01287884|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-11-07|2011-01-31|2011-02-02|Estimate|||||||2012-11-07|2012-11-09|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Correlation of Arterial Blood Gas (ABG) and Venous Blood Gas (VBG) in the Undifferentiated Critically Ill Patient|Correlation of Arterial Blood Gas (ABG) and Venous Blood Gas (VBG) in the Undifferentiated Critically Ill Patient|Completed||N/A|156|Actual|Christiana Care Health Services||1|||f||||f||||||||||2018-05-31 22:54:44.083507|2018-05-31 22:54:44.083507
NCT01287871|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2012-10-12|2011-01-31|2011-02-02|Estimate|||||||2012-10-12|2012-10-15|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer|Addressing Stigma in Screening and Diagnostic Delay for Cervical Cancer|Completed|||332|Actual|City of Hope Medical Center|||1||f||||t||||||||||2018-05-31 22:54:44.134397|2018-05-31 22:54:44.134397
NCT01287858|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2015-10-29|2011-01-31|2011-02-02|Estimate|||||||2015-10-29|2015-11-02|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects|A Phase 1, Randomized, Double Blind, Placebo Controlled, Sequential, Ascending Single-Dose and Multiple-Dose First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC430 in Healthy Subjects|Completed||Phase 1|88|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 22:54:44.181829|2018-05-31 22:54:44.181829
NCT01287845|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2013-01-18|2011-02-01|2011-02-02|Estimate|||||||2013-01-18|2013-01-21|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers|Open-label, Multi Center PET/CT Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 18F Labeled PET Tracer BAY1075553 Following a Single Intravenous Administration of 300 MBq in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers.|Completed||Phase 1|14|Actual|Piramal Imaging SA||2|||f||||f||||||||||2018-05-31 22:54:44.260356|2018-05-31 22:54:44.260356
NCT01287832|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2013-12-02||2014-01-16|2011-01-31|2011-02-01|Estimate|2013-12-02|2014-01-17|Estimate||||2014-01-16|2014-02-10|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)||Terminated||Phase 4|11|Actual|St. John Health System, Michigan||2||Low patient enrollment|f||||t||||||||||2018-05-31 22:54:44.330153|2018-05-31 22:54:44.330153
NCT01287806|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-31|2011-01-31|2011-02-01|Estimate|||||||2011-01-31|2011-02-01|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Ulinastatin in Inhalation Lung Injury|Multicenter,Randomized,Parallel Assignment,Blank Control Study of Ulinastatin in Inhalation Lung Injury|Unknown status|Not yet recruiting|Phase 2|120|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 22:54:44.733582|2018-05-31 22:54:44.733582
NCT01287793|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-05-23|2011-01-31|2011-02-01|Estimate|||||||2011-05-23|2011-05-24|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects|Randomized, 4-Way, Crossover Single Dose, Placebo And Active Controlled Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects|Completed||Phase 1|48|Anticipated|Pfizer||4|||f||||f||||||||||2018-05-31 22:54:44.812624|2018-05-31 22:54:44.812624
NCT01287780|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-08-15|2011-01-31|2011-02-01|Estimate|||||||2013-08-15|2013-08-16|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Local Gentamicin Application to Reduce Postoperative Infection Rate|Local Gentamicin Application to Reduce Postoperative Infection Rate in Hemiarthroplasty After Fracture of the Proximal Femur: a Randomized Controlled Trial|Completed||Phase 3|800|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 22:54:44.899589|2018-05-31 22:54:44.899589
NCT01287767|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2015-10-06|2011-01-31|2011-02-01|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2013|Actual|2013-01-31||Interventional|DIF2||A Support Program for Carers of Persons With Dementia|A Support Program for Carers of Persons With Dementia - a 24 Months RCT|Completed||N/A|230|Actual|Norwegian Centre for Ageing and Health||2|||f||||t||||||||||2018-05-31 22:54:44.976643|2018-05-31 22:54:44.976643
NCT01287754|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2015-05-06||2015-06-01|2011-01-31|2011-02-01|Estimate|2015-06-01|2015-06-02|Estimate||||2015-06-01|2015-06-02|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All erlotinib-treated participants who received at least one dose of erlotinib, in addition to all enrolled untreated patients, were included in the analysis.|A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations|A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor|Completed||Phase 4|24|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 22:54:45.118589|2018-05-31 22:54:45.118589
NCT01287741|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|2017-04-07||2018-05-09|2011-01-31|2011-02-01|Estimate|2017-08-15|2017-08-17|Actual||||2018-05-09|2018-05-11|Actual|July 31, 2011|Actual|2011-07-31|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|April 29, 2016|Actual|2016-04-29||Interventional||The intent-to-treat (ITT) population included all randomized participants.|A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)|A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 3|1418|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:54:45.448735|2018-05-31 22:54:45.448735
NCT01287728|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2017-01-12|2011-01-31|2011-02-01|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy|The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy|Completed||Phase 3|182|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:54:47.161755|2018-05-31 22:54:47.161755
NCT01287715|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-01-31|2011-01-31|2011-02-01|Estimate|||||||2011-01-31|2011-02-01|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|ABC-STOP||Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis|When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis|Unknown status|Recruiting|Phase 4|50|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 22:54:47.351613|2018-05-31 22:54:47.351613
NCT01287702|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-02-28|2011-01-31|2011-02-01|Estimate|||||||2011-02-28|2011-03-02|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Interventional|||Early Feeding Following Ligation of Acute Bleeding Varices|The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices|Unknown status|Recruiting|Phase 4|120|Anticipated|E-DA Hospital||2|||f||||t||||||||||2018-05-31 22:54:47.464241|2018-05-31 22:54:47.464241
NCT01287689|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-07-31|2011-01-31|2011-02-01|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2010|Actual|2010-07-31|July 2017|2017-07-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|5 Years|Observational [Patient Registry]|SIGNS||Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study|An Open, Uncontrolled, Non-interventional Observational Cohort Outcome Study of Immunoglobulins in 3 Indications: Primary and Secondary Immunodeficiencies and Neurological Auto-immune Diseases|Completed|||685|Actual|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 22:54:47.540426|2018-05-31 22:54:47.540426
NCT01287663|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2014-08-28|2011-01-31|2011-02-01|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|ERPOUPER||Effectiveness of Permethrin Impregnated Underwear in Preventing Louse Proliferation in Infected Homeless|Effectiveness of Permethrin Impregnated Underwear in Preventing Louse Proliferation in Infected Homeless|Terminated||N/A|125|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 22:54:47.627195|2018-05-31 22:54:47.627195
NCT01287637|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2016-01-16|2011-01-31|2011-02-01|Estimate|||||||2016-01-16|2016-01-20|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|EASY||Early Closure of Temporary Ileostomy|Early Closure of Temporary Ileostomy- a Randomized Clinical Trial|Completed||N/A|89|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 22:54:47.698652|2018-05-31 22:54:47.698652
NCT01287624|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2015-03-19|2011-01-31|2011-02-01|Estimate|||||||2015-03-19|2015-03-23|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|TNBC||Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)|A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer|Completed||Phase 3|240|Actual|Fudan University||2|||f||||f||||||||||2018-05-31 22:54:47.76346|2018-05-31 22:54:47.76346
NCT01287611|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2014-07-07||2015-04-08|2011-01-31|2011-02-01|Estimate|2014-08-28|2014-08-29|Estimate||||2015-04-08|2015-04-29|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Short Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure|Short Term Comparison of Double Layer Continuously Locked Closure of Uterine Incision in Cesarean Section Versus Double Layer Purse String Closure (Turan Technique): A Prospective Randomized Study|Completed||N/A|168|Actual|Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi|The present trial is a single-center study. The similar results should be supported in a multicenter study. Another limitation of this study is the more than 25% overall rate of loss to follow-up.|2|||f||||t||||||||||2018-05-31 22:54:47.892718|2018-05-31 22:54:47.892718
NCT01287598|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2018-05-07|2011-01-31|2011-02-01|Estimate|||||||2018-05-07|2018-05-08|Actual|August 2, 2011|Actual|2011-08-02|May 2018|2018-05-31|January 29, 2019|Anticipated|2019-01-29|December 31, 2018|Anticipated|2018-12-31||Interventional|||BAY73-4506 Probe Substrate Study|A Phase I, Non-randomized Open-label Study to Evaluate the Effect of BAY73-4506 (Regorafenib) on Probe Substrates of CYP 2C9 (Warfarin), 2C19 (Omeprazole) and 3A4 (Midazolam) in a Cocktail Approach (Group A) and on a Probe Substrate of CYP 2C8 (Rosiglitazone, Group B) in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|40|Actual|Bayer||2|||f||||f|t|f||||||||2018-05-31 22:54:48.109092|2018-05-31 22:54:48.109092
NCT01287585|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25||2016-08-10|2016-08-24|2011-01-31|2011-02-01|Estimate||||2016-08-24|2016-08-26|Estimate|2016-08-24|2016-08-26|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|ADI-PEG 20||Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy|A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy|Completed||Phase 3|636|Actual|Polaris Group||2|||f||||t||||||||||2018-05-31 22:54:48.189251|2018-05-31 22:54:48.189251
NCT01287572|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-31|2011-01-31|2011-02-01|Estimate|||||||2011-01-31|2011-02-01|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|August 2012|Anticipated|2012-08-31|February 2012|Anticipated|2012-02-29||Observational|||Efficiency of Ventilation During Conscious Sedation in the Pediatric Intensive Care Unit|Efficiency of Ventilation During Conscious Sedation of Pediatric Patients Undergoing Minor Procedures in the Pediatric Intensive Care Unit|Unknown status|Not yet recruiting||80|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 22:54:48.330631|2018-05-31 22:54:48.330631
NCT01287559|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|||2011-01-31|2011-01-31|2011-02-01|Estimate|||||||2011-01-31|2011-02-01|Estimate|March 2011||2011-03-31|January 2011|2011-01-31||||December 2011|Anticipated|2011-12-31||Observational|||Monitoring Necrotizing Enterocolitis in Premature Infants|Monitoring Necrotizing Enterocolitis in Premature Infants Using Depth-Resolved Broad Spectrum NIRS|Unknown status|Not yet recruiting||100|Anticipated|Spectros Corporation|||2||f||||t||||||||||2018-05-31 22:54:48.384727|2018-05-31 22:54:48.384727
NCT01287546|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-02-14|2011-01-31|2011-02-01|Estimate|||||||2017-02-14|2017-02-15|Actual|April 13, 2010|Actual|2010-04-13|February 2017|2017-02-28|October 26, 2016|Actual|2016-10-26|January 8, 2015|Actual|2015-01-08||Interventional|||A Study of LY2875358 in Participants With Advanced Cancer|A Phase 1 Study of LY2875358 in Patients With Advanced Cancer|Completed||Phase 1|117|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 22:54:48.450056|2018-05-31 22:54:48.450056
NCT01287533|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|||2014-11-18|2011-01-30|2011-02-01|Estimate|||||||2014-11-18|2014-11-19|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids|Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids|Completed||Phase 4|167|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:54:48.528769|2018-05-31 22:54:48.528769
NCT01287520|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2011-06-19|2011-01-31|2011-02-01|Estimate|||||||2011-06-19|2011-06-21|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of LY2090314 in Patients With Advanced or Metastatic Cancer|Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin|Completed||Phase 1|41|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:54:48.595344|2018-05-31 22:54:48.595344
NCT01287507|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2014-08-25|2011-01-31|2011-02-01|Estimate|||||||2014-08-25|2014-08-26|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Lactoferrin Prophylaxis in VLBW and Regulator T-cells|Oral Lactoferrin Prophylaxis to Prevent Sepsis and Necrotising Enterocolitis of Very Low Birth Weight Neonates in Neonatal Intensive Care Unit and Effect on T-regulatory Cells.|Completed||N/A|60|Actual|Ankara University||2|||f||||f||||||||||2018-05-31 22:54:48.660496|2018-05-31 22:54:48.660496
NCT01287494|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-01-28|2011-01-28|2011-02-01|Estimate|||||||2011-01-28|2011-02-01|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|July 2014|Anticipated|2014-07-31|February 2014|Anticipated|2014-02-28||Interventional|DCM||Depression Care Management for Depressed Elders in China Primary Care|Collaborative Care for Depressed Elders in China|Unknown status|Recruiting|Phase 4|320|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 22:54:48.896433|2018-05-31 22:54:48.896433
NCT01287481|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-03-15|2011-01-28|2011-02-01|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pain and Stress Management for Fibromyalgia|Emotional Exposure and Cognitive Behavioral Therapies for Fibromyalgia|Completed||Phase 2|230|Actual|Wayne State University||3|||f||||f||||||||||2018-05-31 22:54:48.977386|2018-05-31 22:54:48.977386
NCT01287468|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2011-01-31|2011-01-31|2011-02-01|Estimate|||||||2011-01-31|2011-02-01|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|December 2014|Anticipated|2014-12-31|||||Observational|||Academia Sinica Investigator Award 2010|Academia Sinica Investigator Award 2010|Unknown status|Active, not recruiting||415|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:54:49.056162|2018-05-31 22:54:49.056162
NCT01287455|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|||2013-06-12|2011-01-31|2011-02-01|Estimate|||||||2013-06-12|2013-06-13|Estimate|February 2011||2011-02-28|June 2013|2013-06-30|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|||The Effect of Vitamin D Replacement on Airway Reactivity, Allergy and Inflammatory Mediators in Exhaled Breath Condensate in Vitamin D Deficient Asthmatic Children||Completed||N/A|83|Actual|Rambam Health Care Campus||2|||f||||||||||||||2018-05-31 22:54:49.112416|2018-05-31 22:54:49.112416
NCT01287442|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2011-11-03|2011-01-28|2011-02-01|Estimate|||||||2011-11-03|2011-11-04|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|December 2010||2010-12-31|||||Observational|||"Evaluation of Filtering Blebs Using the Wuerzburg Bleb Classification Score Compared to Other Clinical Findings, e.g. the Intraocular Pressure (IOP)"||Completed|||100|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 22:54:49.180263|2018-05-31 22:54:49.180263
NCT01287429|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2012-11-19|2011-01-28|2011-02-01|Estimate|||||||2012-11-19|2012-11-20|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Lung Ultrasound for Acute Dyspnea in Emergency Department|Lung Ultrasound for Acute Dyspnea in Emergency Department - Prospective Multicenter Study on Accuracy, Reproducibility, and Diagnostic Impact of Lung Ultrasound in the Evaluation of Patients With Dyspnea in the Emergency Department|Completed|||1005|Actual|University of Turin, Italy|||1||f||||f||||||||||2018-05-31 22:54:49.243019|2018-05-31 22:54:49.243019
NCT01287416|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2013-11-07||2014-04-09|2011-01-28|2011-02-01|Estimate|2014-04-09|2014-05-13|Estimate||||2014-04-09|2014-05-13|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||The number of baseline participants reflects the number of participants that showed up on the day of training, as that was our first point of contact and the time point at which the baseline questionnaire was given. This is different than the number of people that we invited to participate in the study.|Circle of Life. Improving Capacity of Swampy Cree Community Members to Recognize People at Risk for Suicide|Circle of Life.Improving Capacity of Swampy Cree Community Members to Recognize People at Risk for Suicide: A Randomized Controlled Pilot Study|Completed||N/A|55|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 22:54:49.420957|2018-05-31 22:54:49.420957
NCT01287403|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|2013-04-09||2013-07-11|2011-01-31|2011-02-01|Estimate|2013-07-11|2013-08-14|Estimate||||2013-07-11|2013-08-14|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional||All subjects were recruited within the staff of the Nestlé Research Center between February and June 2011.|Response of Alkylresorcinols to Different Cereals|Response of Alkylresorcinols and Other Biomarkers to Different Cereals|Completed||N/A|14|Actual|Nestlé||6|||f||||f||||||||||2018-05-31 22:54:50.256669|2018-05-31 22:54:50.256669
NCT01287390|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2016-01-26|2011-01-31|2011-02-01|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck|Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck: a Multicenter, Two-arm, Randomized Phase II Trial.|Completed||Phase 2|100|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:54:50.737152|2018-05-31 22:54:50.737152
NCT01287377|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-11-07|2011-01-28|2011-02-01|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2010|Actual|2010-11-30|November 2017|2017-11-30|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|||Smoking Cessation With the Nicotine Patch: A Pilot Study of Patch Messaging|Smoking Cessation With the Nicotine Patch: A Pilot Study of Patch Messaging|Completed||Phase 3|243|Actual|University of California, San Diego||3|||f||||f||||||||No||2018-05-31 22:54:50.838257|2018-05-31 22:54:50.838257
NCT01287364|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2012-05-01||2012-10-31|2011-01-28|2011-02-01|Estimate|2012-09-28|2012-10-31|Estimate||||2012-10-31|2012-11-02|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis|Psychometric Evaluation of a Novel Questionnaire Designed to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids Administered Via HFA Aerosol or Aqueous Suspension Used for the Treatment of Allergic Rhinitis|Completed||Phase 3|185|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 22:54:50.944042|2018-05-31 22:54:50.944042
NCT01287351|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2013-08-02|2011-01-28|2011-02-01|Estimate|||||||2013-08-02|2013-08-05|Estimate|January 2004||2004-01-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|December 2008|Actual|2008-12-31||Observational|USQvarAsthma||Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study|Retrospective, Real-life Observational Evaluation of the Effectiveness and Cost-effectiveness of Extra-fine Hydrofluoroalkane (HFA) Beclometasone (BDP) Compared With Fluticasone Propionate (FP) in the Management of Asthma in a Representative Population in the United States (US)|Completed|||82903|Actual|Research in Real-Life Ltd|||4||f||||f||||||||||2018-05-31 22:54:51.999492|2018-05-31 22:54:51.999492
NCT01287338|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2013-09-16|2011-01-31|2011-02-01|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.|A Randomized, Double-Masked, Placebo-Controlled, Proof of Concept Study to Evaluate the Short-term Safety and Efficacy of the QLT Proprietary Olopatadine Punctal Plug Delivery System in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.|Terminated||Phase 2|143|Actual|Mati Therapeutics Inc.||2||Lack of definitive clinical results.|f||||f||||||||||2018-05-31 22:54:52.094913|2018-05-31 22:54:52.094913
NCT01287325|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-28|2011-01-28|2011-02-01|Estimate|||||||2011-01-28|2011-02-01|Estimate|September 2003||2003-09-30|January 2011|2011-01-31||||April 2004|Actual|2004-04-30||Interventional|||Efficacy of DNK333 in Patients With COPD and Cough|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Clinical Efficacy, Tolerability and Safety of Two Weeks Treatment With DNK333 100 mg Bid in Patients With COPD and Cough.|Completed||Phase 1/Phase 2|28|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:54:52.195091|2018-05-31 22:54:52.195091
NCT01287312|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-01-31|2011-01-31|2011-02-01|Estimate|||||||2011-01-31|2011-02-01|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Trichloroacetic Acid for Endoscopic Tracho-esophageal Fistula Repair|Trichloroacetic Acid for Endoscopic Tracho-esophageal Fistula Repair|Unknown status|Recruiting|N/A|20|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 22:54:52.275773|2018-05-31 22:54:52.275773
NCT01287299|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|||2011-01-30|2011-01-30|2011-02-01|Estimate|||||||2011-01-30|2011-02-01|Estimate|July 2005||2005-07-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|PANS||Glycemic Load, Metabolism & Obesity in Pregnancy|Dietary Glycemic Load & Metabolism in Obese Pregnant Women|Completed||N/A|64|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||||2018-05-31 22:54:52.353113|2018-05-31 22:54:52.353113
NCT01287286|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|||2011-02-06|2011-01-31|2011-02-01|Estimate|||||||2011-02-06|2011-02-08|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|May 2012|Anticipated|2012-05-31|April 2011|Anticipated|2011-04-30||Interventional|||Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy|Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy— a Double Blinded, Randomized, Placebo-controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|64|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 22:54:52.452213|2018-05-31 22:54:52.452213
NCT01287273|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-12-05|2011-01-31|2011-02-01|Estimate|||||||2013-12-05|2013-12-06|Estimate|April 2011||2011-04-30|December 2013|2013-12-31||||February 2014|Anticipated|2014-02-28||Observational|IVF-2010||The Impact of Early Embryos Incubation on Pregnancy Rate in IVF|The Impact of Early Embryos Incubation on Pregnancy Rate in IVF|Unknown status|Recruiting||660|Anticipated|Carmel Medical Center|||2||f||||f||||||||||2018-05-31 22:54:52.606535|2018-05-31 22:54:52.606535
NCT01287260|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-30|||2014-01-28|2011-01-30|2011-02-01|Estimate|||||||2014-01-28|2014-01-29|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||High Dose BAYA1040_Nifedipine: a Dose-comparative Study|A Multicenter, Double-blind, Parallel-group Comparative Study Between Oral BAYA1040_CR 80 mg and 40 mg for 8 Weeks in Patients With Essential Hypertension for Whom Oral BAYA1040_CR 40 mg is Insufficient|Completed||Phase 3|352|Actual|Bayer||2|||f||||f||||||||||2018-05-31 22:54:52.687016|2018-05-31 22:54:52.687016
NCT01287247|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2015-04-09|2011-01-31|2011-02-01|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|XCiDaBLE||Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States|Prospective, Observational Trial Evaluating Xeomin®(incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States|Completed|||688|Actual|Merz North America, Inc.|||2||f||||f||||||||||2018-05-31 22:54:53.041626|2018-05-31 22:54:53.041626
NCT01287234|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2012-12-18|2011-01-29|2011-02-01|Estimate|||||||2012-12-18|2012-12-20|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SonR Pilot||Atrio-Ventricular (AV) Delay Optimization Using Echocardiography Versus the SonR Signal|Atrio-Ventricular Delay Optimization in Patients Implanted With a Cardiac Resynchronization Device Using Echocardiography Versus the SonR Signal: A Pilot Study|Completed||N/A|15|Actual|Piedmont Healthcare||1|||f||||f||||||||||2018-05-31 22:54:53.216603|2018-05-31 22:54:53.216603
NCT01287221|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2013-07-02||2014-02-11|2011-01-28|2011-02-01|Estimate|2014-02-11|2014-03-28|Estimate||||2014-02-11|2014-03-28|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|MSA||Study of Rifampicin in Multiple System Atrophy|Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy|Terminated||Phase 3|100|Actual|Mayo Clinic|The study was terminated early; the Data Safety and Monitoring Board recommended stopping the study after an interim analysis of the primary endpoint revealed that futility criteria were met.|2||"DSMB recommended stopping the study after an interim analysis of the primary endpoint revealed~   that futility criteria were met."|f||||t||||||||||2018-05-31 22:54:53.313843|2018-05-31 22:54:53.313843
NCT01287208|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2012-10-31||2017-12-04|2011-01-28|2011-02-01|Estimate|2012-10-31|2012-11-29|Estimate||||2017-12-04|2017-12-07|Actual|October 2010|Actual|2010-10-31|December 2017|2017-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents|Be Fit in Residency: a Randomized Controlled Trial of an Activity Device Among Medicine Residents|Completed||N/A|104|Actual|Massachusetts General Hospital|"Wearing the device may have increased steps in both groups and decreased ability to see a difference.~Unable to collect some secondary outcomes due to logistical issues with obtaining this data without an applications program interface (API)."|2|||f||||f||||||||||2018-05-31 22:54:53.891403|2018-05-31 22:54:53.891403
NCT01287195|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2017-04-11||2017-06-12|2011-01-28|2011-02-01|Estimate|2017-06-12|2017-06-14|Actual||||2017-06-12|2017-06-14|Actual|April 7, 2009|Actual|2009-04-07|April 2017|2017-04-30|May 2, 2013|Actual|2013-05-02|May 2, 2013|Actual|2013-05-02||Interventional||All participants enrolled in the study.|Oral OKT3 for the Treatment of Active Ulcerative Colitis|Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis|Completed||Phase 1/Phase 2|6|Actual|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 22:54:54.307463|2018-05-31 22:54:54.307463
NCT01287182|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-29|||2013-05-18|2011-01-31|2011-02-01|Estimate|||||||2013-05-18|2013-05-21|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis|Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis|Completed||Phase 3|100|Actual|Omicron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:54:54.621645|2018-05-31 22:54:54.621645
NCT01287169|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-29|||2018-02-13|2011-01-29|2011-02-01|Estimate|||||||2018-02-13|2018-02-14|Actual|January 10, 2011||2011-01-10|December 4, 2012|2012-12-04|December 4, 2012||2012-12-04|||||Observational|||BPA Biomonitoring Study in Cashiers|BPA Biomonitoring Study in Cashiers|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:54:54.675709|2018-05-31 22:54:54.675709
NCT01287156|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-29|||2017-10-18|2011-01-29|2011-02-01|Estimate|||||||2017-10-18|2017-10-19|Actual|January 29, 2011||2011-01-29|August 11, 2017|2017-08-11||||||||Observational|||Evaluation and Diagnosis of Potential Research Subjects With Traumatic Brain Injury|Evaluation and Diagnosis of Potential Research Subjects With Traumatic Brain Injury (TBI)|Recruiting|||2500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:54:54.719746|2018-05-31 22:54:54.719746
NCT01287143|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-29|||2017-10-05|2011-01-29|2011-02-01|Estimate|||||||2017-10-05|2017-10-06|Actual|January 13, 2011||2011-01-13|August 9, 2017|2017-08-09|August 9, 2017||2017-08-09|||||Observational|||Quantifying and Understanding the Signs and Symptoms of Fever|Beyond Intuition: Quantifying and Understanding the Signs and Symptoms of Fever|Terminated|||99|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:54:54.78962|2018-05-31 22:54:54.78962
NCT01287130|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-29|||2018-02-13|2011-01-29|2011-02-01|Estimate|||||||2018-02-13|2018-02-14|Actual|January 7, 2011||2011-01-07|February 5, 2016|2016-02-05|August 27, 2013|Actual|2013-08-27|August 27, 2013|Actual|2013-08-27||Interventional|||AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer|A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:54:54.972395|2018-05-31 22:54:54.972395
NCT01287117|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-08-13||2013-11-04|2011-01-28|2011-02-01|Estimate|2013-08-13|2013-10-18|Estimate||||2013-11-04|2013-11-27|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Modified intent-to-treat (mITT) population: All participants randomized in the study who received at least 1 dose of study drug. 1 participant (randomized to omalizumab 75 mg) did not receive study drug and was not included in the mITT population.|A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)|Completed||Phase 3|319|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 22:54:55.094142|2018-05-31 22:54:55.094142
NCT01286948|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-08-11|2011-01-28|2011-01-31|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2011||2011-01-31|August 2017|2017-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Prevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG|A Randomized, Cross-over, Clinical Trial to Assess the Prevention of Ovulation Achieved by Single Intra-vaginal Administration of 0.75 mg Levonorgestrel (LNG) Gel (Levogel) as Compared to 1.5 mg Oral LNG|Completed||Phase 1|20|Actual|Population Council||2|||f||||t||||||||||2018-05-31 22:54:59.346281|2018-05-31 22:54:59.346281
NCT01287104|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-29|||2018-05-11|2011-01-29|2011-02-01|Estimate|||||||2018-05-11|2018-05-14|Actual|January 29, 2011||2011-01-29|November 6, 2017|2017-11-06|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias|A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Hematologic Malignancies|Active, not recruiting||Phase 1|34|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:54:56.091832|2018-05-31 22:54:56.091832
NCT01287091|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-08-19|2011-01-28|2011-02-01|Estimate|||||||2011-08-19|2011-08-23|Estimate|October 2010||2010-10-31|August 2011|2011-08-31||||||||Interventional|||A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet|An Open-Label, 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet|Completed||Phase 1|46|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 22:54:56.210325|2018-05-31 22:54:56.210325
NCT01287078|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-29|||2018-03-27|2011-01-29|2011-02-01|Estimate|||||||2018-03-27|2018-03-29|Actual|January 29, 2011||2011-01-29|February 5, 2018|2018-02-05|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans|Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans|Active, not recruiting||Phase 2|23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:54:56.295218|2018-05-31 22:54:56.295218
NCT01287065|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-06-06||2016-11-23|2011-01-28|2011-02-01|Estimate|2013-06-06|2013-08-09|Estimate||||2016-11-23|2017-01-11|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function|A Randomised, Repeat-dose, Placebo-controlled, Double-blind Study to Evaluate and Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder, When Administered Either in the Morning or in the Evening, in Male and Female Asthmatic Subjects|Completed||Phase 2|26|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:54:56.398936|2018-05-31 22:54:56.398936
NCT01287052|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2015-07-29|2011-01-31|2011-02-01|Estimate|||||||2015-07-29|2015-07-30|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Nitrous Oxide for Acute Migraine Pain in the Emergency Room (ED)|Nitrous Oxide for Acute Pediatric Migraine Pain Management in the Emergency Room|Completed||N/A|30|Anticipated|Children's Hospitals and Clinics of Minnesota||1|||f||||f||||||||||2018-05-31 22:54:56.734444|2018-05-31 22:54:56.734444
NCT01287039|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2016-03-23|2015-09-23|2016-05-26|2011-01-28|2011-02-01|Estimate|2016-05-26|2016-06-27|Estimate|2015-09-23|2015-10-02|Estimate|2016-05-26|2016-06-27|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional||Randomized set|A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma|A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma|Completed||Phase 3|489|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-05-31 22:54:56.842593|2018-05-31 22:54:56.842593
NCT01287026|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2018-05-16|2011-01-31|2011-02-01|Estimate|||||||2018-05-16|2018-05-17|Actual|January 25, 2011||2011-01-25|November 22, 2017|2017-11-22|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||Real-time MRI Right Heart Catheterization Using Passive Catheters|Real-Time MRI Right Heart Catheterization Using Passive Catheters|Recruiting||Phase 1|150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:54:57.820613|2018-05-31 22:54:57.820613
NCT01287013|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2016-08-04||2017-12-04|2011-01-31|2011-02-01|Estimate|2017-12-04|2018-01-05|Actual||||2017-12-04|2018-01-05|Actual|January 2011||2011-01-31|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparing Xperguide vs. Conventional Methods During Percutaneous Image Guided Procedures|Prospective Randomized Trial Comparing Navigation With Xperguide vs. Conventional Methods During Percutaneous Image Guided Procedures|Terminated||N/A|87|Actual|National Institutes of Health Clinical Center (CC)||2||Investigator left NIH|f||||t|f|t|f|f|f|||No||2018-05-31 22:54:57.888368|2018-05-31 22:54:57.888368
NCT01287000|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2018-04-04|2011-01-31|2011-02-01|Estimate|||||||2018-04-04|2018-04-05|Actual|March 1, 2011||2011-03-01|November 14, 2017|2017-11-14||||||||Observational|||Gulf Long-Term Follow-Up Study|Gulf Long-Term Follow-Up Study|Active, not recruiting|||32658|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:54:58.146849|2018-05-31 22:54:58.146849
NCT01286987|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-07-28|2011-01-28|2011-02-01|Estimate|||||||2017-07-28|2017-08-01|Actual|January 3, 2011|Actual|2011-01-03|July 2017|2017-07-31|January 30, 2017|Actual|2017-01-30|March 31, 2015|Actual|2015-03-31||Interventional|||Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors|A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors|Completed||Phase 1|113|Actual|Pfizer||1|||f||||||||||||||2018-05-31 22:54:59.115278|2018-05-31 22:54:59.115278
NCT01286974|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2012-09-19|2011-01-28|2011-02-01|Estimate|||||||2012-09-19|2012-09-21|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.|Disposition of [14C]ABT-869 in Patients With Solid Tumors Following a Single Oral Dose Administration|Terminated||Phase 1|3|Actual|Abbott||2||Terminated early, Sponsor Decision|f||||f||||||||||2018-05-31 22:54:59.22794|2018-05-31 22:54:59.22794
NCT01286961|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-31|||2011-10-04|2011-01-31|2011-02-01|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Observational|TOSP||The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy|The Interval Between the Time of Second PEG Dose and the Start of the Colonoscopy|Completed|||360|Anticipated|Inje University|||1||f||||t||||||||||2018-05-31 22:54:59.285824|2018-05-31 22:54:59.285824
NCT01284660|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2013-12-18|2011-01-26|2011-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Docosahexaenoic Acid (DHA) Effects on Cognitive Function, Craving and Psychosocial Factors in Heavy Cigarette Smokers||Completed||N/A|51|Actual|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 22:55:44.237262|2018-05-31 22:55:44.237262
NCT01286935|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-01-28|2011-01-28|2011-01-31|Estimate|||||||2011-01-28|2011-01-31|Estimate|August 2007||2007-08-31|January 2011|2011-01-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD|A Phase III, Double-blind, Placebo-controlled, 18-mon Ext Study Long-term Efficacy & Safety of 50 & 100mg/Day Doses of Safinamide, as add-on Therapy, in Idiopathic PD Pts With Motor Fluctuations, Treated With Levodopa, Who May be Receiving DA, and/or Anticholinergic|Completed||Phase 3|544|Actual|Newron Pharmaceuticals SPA||3|||f||||t||||||||||2018-05-31 22:54:59.410037|2018-05-31 22:54:59.410037
NCT01286922|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2013-05-23|2011-01-28|2011-01-31|Estimate|||||||2013-05-23|2013-05-27|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ISAIC||The Insulin Sensitivity Using Aerobic Interval Conditioning|The Insulin Sensitivity Using Aerobic Interval Conditioning|Completed||Phase 1|42|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-05-31 22:54:59.475792|2018-05-31 22:54:59.475792
NCT01286909|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2011-02-09|2011-01-28|2011-01-31|Estimate|||||||2011-02-09|2011-02-10|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|LaFlavon||Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)|Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)|Unknown status|Recruiting|Phase 3|40|Anticipated|Omicron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 22:54:59.678368|2018-05-31 22:54:59.678368
NCT01286896|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-10-07|2011-01-28|2011-01-31|Estimate|||||||2011-10-07|2011-10-10|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors|Use of Individual PK-guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|30|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 22:54:59.764267|2018-05-31 22:54:59.764267
NCT01286883|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-01-26|2011-01-28|2011-01-31|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2011|Actual|2011-02-28|January 2017|2017-01-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Observational|||Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells|Prevalence of Stem Cell and Prognostic Markers in Circulating Tumor Cells of Patients With Metastatic Colorectal Cancer Undergoing Chemotherapy|Completed|||33|Actual|Milton S. Hershey Medical Center|||1||f||||t||||||Samples With DNA|"~     Blood will be drawn at 7 different time intervals to analyze CSC and other prognostic markers~     on circulating tumor cells.~   "|Undecided|To evaluate if data is valuable|2018-05-31 22:54:59.845093|2018-05-31 22:54:59.845093
NCT01286870|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-10-26|2011-01-28|2011-01-31|Estimate|||||||2015-10-26|2015-10-28|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Becker Continued Access Study|Continued Access Study of the Mentor Becker Expander/Breast Implant|Terminated||Phase 3|11|Actual|Mentor Worldwide, LLC||1||Sponsor terminated|f||||f||||||||||2018-05-31 22:54:59.912713|2018-05-31 22:54:59.912713
NCT01286857|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2011-07-15|2011-01-28|2011-01-31|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||An Investigation to Evaluate the Function of a New Silicon Cover Film and an On-top Suction Device to be Used in a NPWT System in the Treatment of Acute and Chronic Wounds|A Prospective, Open, Non-controlled Proof-of-concept Investigation to Evaluate the Function of a New Silicon Cover Film and an On-top Suction Device to be Used in a NPWT System in the Treatment of Acute and Chronic Wounds|Completed||Phase 2/Phase 3|15|Anticipated|Molnlycke Health Care AB|||||f||||f||||||||||2018-05-31 22:54:59.981512|2018-05-31 22:54:59.981512
NCT01286844|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-06-06|2011-01-27|2011-01-31|Estimate|||||||2017-06-06|2017-06-07|Actual|November 2010||2010-11-30|June 2017|2017-06-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||GSK2190915 Pediatric Study|An Open Label, Dose Escalation Study to Examine the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of Single and Repeat Oral Doses of GSK2190915 in Children Aged From 1 to 11 Years With Asthma|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:55:00.047326|2018-05-31 22:55:00.047326
NCT01286831|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2017-06-16|2011-01-27|2011-01-31|Estimate|||||||2017-06-16|2017-06-20|Actual|May 18, 2010|Actual|2010-05-18|June 2017|2017-06-30|July 9, 2010|Actual|2010-07-09|July 9, 2010|Actual|2010-07-09||Interventional|||A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.|An Open-label, Single-arm Study to Determine the Excretionbalance and Metabolic Disposition of [14C]GW642444administered as a Single Dose of an Oral Solution to Healthy Malevolunteers|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:55:00.121347|2018-05-31 22:55:00.121347
NCT01286818|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2014-05-16||2014-10-03|2011-01-28|2011-01-31|Estimate|2014-10-03|2014-10-06|Estimate||||2014-10-03|2014-10-06|Estimate|February 2011||2011-02-28|October 2014|2014-10-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional||Safety population: Participants who received any quantity of study medication.|A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)|A Phase 1b Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine|Completed||Phase 1|6|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 22:55:00.24145|2018-05-31 22:55:00.24145
NCT01286805|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2012-07-23||2013-05-01|2011-01-28|2011-01-31|Estimate|2013-05-01|2013-06-05|Estimate||||2013-05-01|2013-06-05|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|LPB Hip Scope||Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial|Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial|Completed||Phase 4|83|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 22:55:00.505092|2018-05-31 22:55:00.505092
NCT01286792|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2015-03-17|2011-01-28|2011-01-31|Estimate|||||||2015-03-17|2015-03-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:55:00.818187|2018-05-31 22:55:00.818187
NCT01286779|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-10-19|2011-01-28|2011-01-31|Estimate|||||||2017-10-19|2017-10-23|Actual|April 12, 2011|Actual|2011-04-12|September 2017|2017-09-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||BAX 326 (rFIX) Continuation Study|BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study|Completed||Phase 3|117|Actual|Shire||1|||f||||t||||||||||2018-05-31 22:55:00.860792|2018-05-31 22:55:00.860792
NCT01286766|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2014-03-04|2011-01-28|2011-01-31|Estimate|||||||2014-03-04|2014-03-05|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma|A Randomized Phase II Trial of Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma|Completed||Phase 2|6|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:55:00.988999|2018-05-31 22:55:00.988999
NCT01286753|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2016-07-22||2016-07-22|2011-01-28|2011-01-31|Estimate|2016-07-22|2016-09-07|Estimate||||2016-07-22|2016-09-07|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional||Intent-to-Treat population, defined as all enrolled participants.|A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation|An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine|Completed||Phase 2|51|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 22:55:01.109209|2018-05-31 22:55:01.109209
NCT01286740|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-03-08|2012-12-12|2013-04-19|2011-01-27|2011-01-31|Estimate|2013-03-08|2013-04-19|Estimate|2012-12-13|2012-12-18|Estimate|2013-04-19|2013-04-26|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Interventional||Safety Analysis Set: participants who enrolled and received at least one dose of study drug|Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR|A Phase 2B Open Label Pilot Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV 1 Infected Subjects|Completed||Phase 2|50|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 22:55:01.781859|2018-05-31 22:55:01.781859
NCT01286727|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-05-04|2011-01-28|2011-01-31|Estimate|||||||2015-05-04|2015-05-05|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|February 2016|Anticipated|2016-02-29|January 2015|Actual|2015-01-31||Interventional|||Study to Improve Renal Function After Kidney Transplantation|Multicenter Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation and at Risk for Dialysis|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Angion Biomedica Corp||2|||f||||t||||||||||2018-05-31 22:55:02.108011|2018-05-31 22:55:02.108011
NCT01286714|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2014-08-28|2011-01-28|2011-01-31|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Assessment of Fistula Closure by OTSC Clip After Bariatric Surgery|Assessment of Fistula Closure by OTSC Clip After Bariatric Surgery|Completed||N/A|15|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:55:02.179711|2018-05-31 22:55:02.179711
NCT01286701|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-01-10|2011-01-28|2011-01-31|Estimate|||||||2012-01-10|2012-01-11|Estimate|January 2002||2002-01-31|January 2011|2011-01-31|March 2002|Actual|2002-03-31|February 2002|Actual|2002-02-28||Interventional|||Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fed Conditions|Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fed Conditions|Completed||Phase 1|18|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:55:02.325556|2018-05-31 22:55:02.325556
NCT01286688|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-01-10|2011-01-28|2011-01-31|Estimate|||||||2012-01-10|2012-01-11|Estimate|January 2002||2002-01-31|January 2011|2011-01-31|March 2002|Actual|2002-03-31|February 2002|Actual|2002-02-28||Interventional|||Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Under Fasting Conditions|Randomized, 2-way Crossover Bioequivalence Study of Terbinafine Hydrochloride Tablets, 250 mg and Lamisil® 250 mg Tablets in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 22:55:02.392107|2018-05-31 22:55:02.392107
NCT01286675|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2018-01-17|2011-01-28|2011-01-31|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Eltrombopag Plus Granulocyte Colony-stimulating Factor (G-CSF) on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant (ASCT)|A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation|Active, not recruiting||Early Phase 1|19|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 22:55:02.471346|2018-05-31 22:55:02.471346
NCT01286662|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-27|2011-01-27|2011-01-31|Estimate|||||||2011-01-27|2011-01-31|Estimate|January 1978||1978-01-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome|In Modern Era, Recurrent Desmoids Determine Outcome in Patients With Gardner Syndrome: A Cohort Study of Three Generations of an Adenomatous Polyposis Coli (APC-) Mutation-Positive Family Across 30 Years|Completed|||105|Actual|Triemli Hospital|||||f||||f||||||||||2018-05-31 22:55:02.551559|2018-05-31 22:55:02.551559
NCT01286649|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2017-03-06|2011-01-27|2011-01-31|Estimate|||||||2017-03-06|2017-03-08|Actual|December 2010||2010-12-31|March 2017|2017-03-31|February 23, 2017|Actual|2017-02-23|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia|Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia.|Completed||Phase 1/Phase 2|19|Actual|RepliCel Life Sciences, Inc.||1|||f||||f||||||||||2018-05-31 22:55:02.616254|2018-05-31 22:55:02.616254
NCT01286636|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2016-01-12|2011-01-28|2011-01-31|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Artificial Neural Network Directed Therapy of Severe Obstructive Sleep Apnea|Artificial Neural Network Directed Therapy of Severe Obstructive Sleep Apnea|Withdrawn||Phase 3|0|Actual|State University of New York at Buffalo||2|||f||||f||||||||||2018-05-31 22:55:02.706334|2018-05-31 22:55:02.706334
NCT01286623|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-06-26|2011-01-27|2011-01-31|Estimate|||||||2017-06-26|2017-06-27|Actual|April 1, 2011|Actual|2011-04-01|June 2017|2017-06-30|June 6, 2013|Actual|2013-06-06|June 6, 2013|Actual|2013-06-06||Observational|SSAT041||The Pharmacology/Aging Clinic|Study Title: The Pharmacology/Aging Clinic: Clinical Routine Monitoring of HIV-infected Patients Over 50 Year of Age.|Completed|||75|Actual|St Stephens Aids Trust|||||f||||f||||||||||2018-05-31 22:55:02.773763|2018-05-31 22:55:02.773763
NCT01286610|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2017-02-07|2011-01-28|2011-01-31|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2011||2011-02-28|February 2017|2017-02-28|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|VTICU||Applicability and Safety of Vibration Therapy in Intensive Care Unit (ICU) Patients|Application of Vibration Therapy as a Measure of Muscle Activation in ICU Patients and Its Effect on Hemodynamics, Intracranial Pressure as Well as Energy Metabolism|Completed||N/A|20|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 22:55:02.832189|2018-05-31 22:55:02.832189
NCT01286597|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-07-07|2011-01-27|2011-01-31|Estimate|||||||2012-07-07|2012-07-10|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Effects of Lactose Intolerance on Gastrointestinal Function and Symptoms in a Chinese Population|The Effects of Lactose Intolerance on Gastrointestinal Function and Symptoms in a Chinese Population|Unknown status|Recruiting|N/A|3000|Anticipated|Sir Run Run Shaw Hospital||1|||f||||t||||||||||2018-05-31 22:55:02.905273|2018-05-31 22:55:02.905273
NCT01286584|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2015-02-03|2011-01-28|2011-01-31|Estimate|||||||2015-02-03|2015-02-05|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ViRT||Varenicline in Drug Treatment|Smoking Cessation in a Drug Treatment Program: A Randomized Trial of Varenicline Versus Placebo.|Completed||Phase 4|33|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 22:55:03.011314|2018-05-31 22:55:03.011314
NCT01286571|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2013-10-31|2011-01-28|2011-01-31|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2011||2011-01-31|October 2013|2013-10-31||||March 2011|Actual|2011-03-31||Interventional|||Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food|Bioavailability and Pharmacokinetics of 50 mg BI 135585 XX Administered as Tablet With and Without Food to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)|Completed||Phase 1|14|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:55:03.111086|2018-05-31 22:55:03.111086
NCT01286558|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|2012-09-20||2014-06-17|2011-01-28|2011-01-31|Estimate|2012-09-20|2012-10-22|Estimate||||2014-06-17|2014-06-27|Estimate|January 2011||2011-01-31|January 2014|2014-01-31||||September 2011|Actual|2011-09-30||Interventional|||Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg Plus Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination in Patients With Hypertension|Completed||Phase 3|225|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:55:03.270158|2018-05-31 22:55:03.270158
NCT01286545|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-01-27|2011-01-27|2011-01-31|Estimate|||||||2011-01-27|2011-01-31|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Observational|EASIC registry||European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study|European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study|Unknown status|Not yet recruiting||100|Anticipated|Rheumazentrum Ruhrgebiet|||1||f||||f||||||||||2018-05-31 22:55:04.057773|2018-05-31 22:55:04.057773
NCT01286532|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-28|||2013-01-31|2011-01-28|2011-01-31|Estimate|||||||2013-01-31|2013-02-01|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Asthma in Children|A Six-month Non-interventional Prospective Study of Various Controller Therapies for Moderate Persistent and Severe Persistent Asthma in Children in Real Life Outpatient Clinical Practice|Completed|||283|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:55:04.331204|2018-05-31 22:55:04.331204
NCT01286519|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2017-09-13|2011-01-28|2011-01-31|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2010||2010-07-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Pharmacokinetics of Off Label Pediatric Medications|Pharmacokinetics of Off Label Pediatric Medications|Recruiting|||400|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 22:55:04.448028|2018-05-31 22:55:04.448028
NCT01286506|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2016-08-29|2011-01-27|2011-01-31|Estimate|||||||2016-08-29|2016-08-31|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Observational Study of Blood Pressure Measurements and Continuous Dialysis|Observational Study Evaluating the Hemodynamic Relationship Between Volume Removal and Pulse Pressure Variation During Renal Replacement Therapy|Terminated|||7|Actual|University of Chicago|||2||f||||f||||||||||2018-05-31 22:55:04.536087|2018-05-31 22:55:04.536087
NCT01286493|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2014-04-21||2015-10-19|2011-01-27|2011-01-31|Estimate|2014-05-18|2014-06-04|Estimate||||2015-10-19|2015-11-18|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Preliminary study|Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination|Immune Response After Booster Vaccination in HIV - Infected Patients Who Ever Received Rabies Primary Vaccination|Completed||N/A|33|Actual|Queen Saovabha Memorial Institute|Small sample size heterogeneous characteristics of participants Use only CD4+ T lymphocyte counts as the only immunologic surrogate marker|1|||f||||t||||||||||2018-05-31 22:55:04.588719|2018-05-31 22:55:04.588719
NCT01286480|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2016-12-13||2017-06-23|2011-01-27|2011-01-31|Estimate|2017-06-23|2017-06-26|Actual||||2017-06-23|2017-06-26|Actual|January 2011||2011-01-31|June 2017|2017-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|CHAPTER|We enrolled 66 participants. 5 intervention participants and 3 usual care participants withdrew their participation from the study before any study measures were completed.|Congenital Heart Adolescents: Program of Transition Evaluation Research|Evaluation of Novel Transition Interventions for Youth With Congenital Heart Disease|Completed||N/A|66|Actual|University of Alberta|"single centre trial~most interventions were conducted by a single nurse~assessed self-management behaviours based on self-report~long-term follow-up and attendance in an adult cardiac clinic were not assessed"|2|||f||||f|f|f||||||No||2018-05-31 22:55:04.713424|2018-05-31 22:55:04.713424
NCT01286467|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-06-05|2011-01-27|2011-01-31|Estimate|||||||2013-06-05|2013-06-06|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||A Study Of PF-04449913 Administered Alone In Select Solid Tumors|A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Solid Tumors|Completed||Phase 1|23|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:55:05.017703|2018-05-31 22:55:05.017703
NCT01286454|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2011-12-01||2012-01-24|2011-01-28|2011-01-31|Estimate|2011-12-01|2012-01-09|Estimate||||2012-01-24|2012-01-26|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||This Is A Study Of Bioavailability And Food Effect For Fesoterodine.|An Open-Label, Single-Dose, Randomized, Cross-Over Study To Estimate The Bioavailability And Food Effect Of 4 Mg Fesoterodine Extended Release Beads-In-Capsule Formulations Compared To Commercial Tablet Formulation In Healthy Volunteers|Completed||Phase 1|20|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 22:55:05.164001|2018-05-31 22:55:05.164001
NCT01286441|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27||2015-06-08|2017-10-31|2011-01-27|2011-01-31|Estimate||||2015-06-08|2015-07-07|Estimate|2017-10-31|2017-11-06|Actual|November 2012||2012-11-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts|A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose-ranging, Efficacy and Safety Trial of a New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts (Verruca Vulgaris)|Completed||Phase 2|176|Actual|ViroXis Corporation||4|||f||||f||||||||||2018-05-31 22:55:05.875069|2018-05-31 22:55:05.875069
NCT01286428|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2012-03-12|2011-01-27|2011-01-31|Estimate|||||||2012-03-12|2012-03-14|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Completed|||30|Actual|Pathfinder Therapeutics|||||f||||t||||||||||2018-05-31 22:55:05.964529|2018-05-31 22:55:05.964529
NCT01286415|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-03-22|2011-01-27|2011-01-31|Estimate|||||||2017-03-22|2017-03-27|Actual|September 2008||2008-09-30|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Group Cognitive Processing Therapy for Combat-related Posttraumatic Stress Disorder (PTSD)|Group Cognitive Processing Therapy for Combat-related PTSD|Completed||N/A|108|Actual|VA Boston Healthcare System||2|||f||||t||||||||||2018-05-31 22:55:06.05583|2018-05-31 22:55:06.05583
NCT01286402|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2015-06-30||2016-01-05|2011-01-27|2011-01-31|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy|Double-blind, Placebo-Controlled Pilot Study of Bupropion to Promote Smoking Cessation During Pregnancy|Completed||Phase 2|11|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 22:55:06.14364|2018-05-31 22:55:06.14364
NCT01286389|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2014-11-04|2011-01-27|2011-01-31|Estimate|||||||2014-11-04|2014-11-05|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|May 2013|Actual|2013-05-31||Interventional|||Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition|Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition|Completed||N/A|80|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 22:55:06.420372|2018-05-31 22:55:06.420372
NCT01286376|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-28|2011-01-28|2011-01-31|Estimate|||||||2011-01-28|2011-01-31|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|August 2011|Anticipated|2011-08-31|March 2011|Anticipated|2011-03-31||Interventional|COSI||Evaluating the Effectiveness of LACTOFOS in Constipated Patients|Randomized, Double Blind, Comparative LACTOFOS With Placebo in Constipation Patients.|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:55:06.495368|2018-05-31 22:55:06.495368
NCT01286363|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-28|2011-01-28|2011-01-31|Estimate|||||||2011-01-28|2011-01-31|Estimate|September 2006||2006-09-30|January 2011|2011-01-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Observational|||Facial Patterns and Masticatory Symmetries|Preferred Chewing Side, Symmetry of Bite Force and Occlusal Contact Area of Subjects With Different Craniofacial Vertical Dimensions|Completed|||86|Actual|University of Campinas, Brazil|||3||f||||f||||||||||2018-05-31 22:55:06.573239|2018-05-31 22:55:06.573239
NCT01286350|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2018-02-08|2011-01-27|2011-01-31|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2014||2014-05-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|FL3X||FL3X Study: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes (FL3X)|FL3X: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes|Completed||N/A|258|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:55:06.662049|2018-05-31 22:55:06.662049
NCT01286337|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-28|2011-01-28|2011-01-31|Estimate|||||||2011-01-28|2011-01-31|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Interventional|||Axillary Lymphadenectomy. A Randomized Trial Comparing Bipolar Vessel Sealing To Conventional Technique|Axillary Lymphadenectomy. A Randomized Trial Comparing Bipolar Vessel Sealing To Conventional Technique|Completed||Phase 3|116|Actual|University of Milano Bicocca||2|||f||||f||||||||||2018-05-31 22:55:06.740295|2018-05-31 22:55:06.740295
NCT01286324|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2013-01-21||2017-10-06|2011-01-27|2011-01-31|Estimate|2013-06-24|2013-07-30|Estimate||||2017-10-06|2017-11-07|Actual|July 2008||2008-07-31|October 2017|2017-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Chamomile for Chronic Primary Insomnia|A Pilot Grant to Examine the Feasibility, Efficacy and Tolerability of a Standardized Chamomile Extract in Treating Chronic Primary Insomnia|Completed||Phase 2|34|Actual|University of Michigan|Used subjective sleep measures. We did not assess the characteristics of participants' sleep difficulties and these sleep issues may be important considering the age-range of individuals included in the study|2|||f||||f||||||||||2018-05-31 22:55:06.818851|2018-05-31 22:55:06.818851
NCT01286311|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-05-13||2015-01-27|2011-01-27|2011-01-31|Estimate|2015-01-27|2015-02-09|Estimate||||2015-01-27|2015-02-09|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||218 patients (of the 14 physician randomized to the intervention) and 217 patients (of the 15 physician randomized to the intervention) participated in the study.|Tailored Communication to Reduce Cardiovascular Risk|Tailored Communication to Reduce Cardiovascular Risk|Completed||N/A|464|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 22:55:07.148779|2018-05-31 22:55:07.148779
NCT01286298|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-01-27|2011-01-27|2011-01-31|Estimate|||||||2011-01-27|2011-01-31|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Interventional|||Diode Laser in Gingival Enlargement Related to Orthodontics|The Clinical Application of Diode Laser in Gingival Enlargement Related to Orthodontics|Unknown status|Recruiting|N/A|20|Anticipated|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 22:55:07.505556|2018-05-31 22:55:07.505556
NCT01286285|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-27|2011-01-27|2011-01-31|Estimate|||||||2011-01-27|2011-01-31|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|March 2012|Anticipated|2012-03-31|||||Observational|||Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria|An Active, Epidemiological Surveillance Study on Influenza-related Hospitalizations to Intensive Care Units and Fatalities in Paediatric Hospitals in Bavaria Covering the Influenza Seasons 2010/2011 and 2011/2012|Unknown status|Enrolling by invitation||1140|Anticipated|University Children's Hospital, Wuerzburg|||||f||||f||||||Samples With DNA|"~     Naso-pharyngeal swab, if not available nasal wash or other respiratory secretion (only if~     collected routinely by the hospital)~   "|||2018-05-31 22:55:07.626264|2018-05-31 22:55:07.626264
NCT01285583|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2016-11-21|2011-01-27|2011-01-28|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Extension Study of TRO19622 in ALS|An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole|Completed||Phase 2/Phase 3|271|Actual|Hoffmann-La Roche||1|||f||||t||||||||||2018-05-31 22:55:20.951531|2018-05-31 22:55:20.951531
NCT01286272|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2018-04-17|2011-01-27|2011-01-31|Estimate|||||||2018-04-17|2018-04-18|Actual|April 8, 2011|Actual|2011-04-08|April 2018|2018-04-30|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|||Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma|A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma|Completed||Phase 2|135|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 22:55:07.719746|2018-05-31 22:55:07.719746
NCT01286259|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2014-10-28|2011-01-28|2011-01-31|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals|Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals|Completed||N/A|16|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 22:55:07.912246|2018-05-31 22:55:07.912246
NCT01286246|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-01-07|2011-01-27|2011-01-31|Estimate|||||||2015-01-07|2015-01-08|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PROTO||Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor|Pilot Randomized Controlled Trial of Vaginal Progesterone to Prevent Preterm Birth in Women With Threatened Preterm Labor|Terminated||Phase 4|34|Actual|University of Calgary||2||Trial investigators were unable to recruit the estimated sample|f||||f||||||||||2018-05-31 22:55:08.00906|2018-05-31 22:55:08.00906
NCT01286233|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-09-08|2011-01-27|2011-01-31|Estimate|||||||2015-09-08|2015-09-09|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32|Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer|Unknown status|Active, not recruiting||394|Actual|NSABP Foundation Inc|||2||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 22:55:08.118521|2018-05-31 22:55:08.118521
NCT01286220|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-28|2011-01-28|2011-01-31|Estimate|||||||2011-01-28|2011-01-31|Estimate|December 2010||2010-12-31|January 2011|2011-01-31||||||||Interventional|||Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis|A Randomized, Controlled, Evaluator-blinded Study to Evaluate the Efficacy of Dilute Bleach Baths on Skin Disease Control in Pediatric Patients With Atopic Dermatitis|Unknown status|Recruiting|N/A|40|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 22:55:08.768348|2018-05-31 22:55:08.768348
NCT01286207|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2011-05-20||2015-02-13|2011-01-27|2011-01-31|Estimate|2011-05-20|2011-06-10|Estimate||||2015-02-13|2015-03-04|Estimate|March 1995||1995-03-31|February 2015|2015-02-28|May 1997|Actual|1997-05-31|May 1997|Actual|1997-05-31||Interventional|||Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)|Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Protocols 022, 025, 029)|Completed||Phase 3|1959|Actual|Merck Sharp & Dohme Corp.||3|||||||f||||||||||2018-05-31 22:55:08.885174|2018-05-31 22:55:08.885174
NCT01286194|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-28|2011-01-28|2011-01-31|Estimate|||||||2011-01-28|2011-01-31|Estimate|April 2006||2006-04-30|January 2006|2006-01-31|January 2007||2007-01-31|||||Observational|||A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms|A Multi-Center, Open-Label, All-Comers, Single Group Observational Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC )Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms|Completed|||1500|Anticipated|Eisai Inc.|||1||||||||||||||||2018-05-31 22:55:09.367396|2018-05-31 22:55:09.367396
NCT01286181|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2013-04-01|2011-01-27|2011-01-31|Estimate|||||||2013-04-01|2013-04-04|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Device-guided Breathing for Shortness of Breath in COPD|Device-guided Slow Breathing in COPD Patients With Clinically Significant Dyspnea: Phase 2|Completed||N/A|11|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 22:55:09.456086|2018-05-31 22:55:09.456086
NCT01286168|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2014-10-13||2014-12-03|2011-01-27|2011-01-31|Estimate|2014-10-13|2014-10-20|Estimate||||2014-12-03|2014-12-19|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||This number includes all subjects who started study therapy.|Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction|Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction|Completed||Phase 2|110|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:55:09.537549|2018-05-31 22:55:09.537549
NCT01286155|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2013-05-03|2011-01-27|2011-01-31|Estimate|||||||2013-05-03|2013-05-06|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Epidemiology of Barrett's Esophagus: A Population Based Study|Epidemiology of Barrett's Esophagus: A Population Based Study|Completed|||534|Actual|Mayo Clinic|||3||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 22:55:10.035901|2018-05-31 22:55:10.035901
NCT01286142|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-10-13|2011-01-27|2011-01-31|Estimate|||||||2011-10-13|2011-10-17|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Observational|||Oseltamivir Infant Influenza Safety Study|A Prospective, Observational Safety Study in Children <= 24 Months of Age Receiving Oseltamivir for the Treatment or Prophylaxis of Influenza Infection|Completed|||900|Anticipated|Charite University, Berlin, Germany|||3||f||||f||||||||||2018-05-31 22:55:10.100997|2018-05-31 22:55:10.100997
NCT01286129|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2012-03-29||2013-05-24|2011-01-27|2011-01-31|Estimate|2013-05-24|2013-07-01|Estimate||||2013-05-24|2013-07-01|Estimate|November 2005||2005-11-30|May 2013|2013-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Nasal Allergen Challenge in Rhinitic Subjects|Comparative Responses to Nasal Allergen Challenge in Allergic Rhinitic Subjects With or Without Asthma|Completed||N/A|45|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:55:10.177778|2018-05-31 22:55:10.177778
NCT01286116|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-06-21|2011-01-28|2011-01-31|Estimate|||||||2017-06-21|2017-06-23|Actual|May 2011||2011-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|January 2013|Actual|2013-01-31||Interventional|PARACHUTE||A Multinational Trial To Evaluate The Parachute Implant System|A MULTINATIONAL TRIAL TO EVALUATE THE PARACHUTE IMPLANT SYSTEM: PARACHUTE PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE|Terminated||Phase 3|59|Actual|CardioKinetix, Inc||1||Company closed|f||||f||||||||||2018-05-31 22:55:10.385947|2018-05-31 22:55:10.385947
NCT01285934|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-08-19|2011-01-27|2011-01-28|Estimate|||||||2015-08-19|2015-08-21|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Hematopoietic Stem Cell Support Versus Insulin in T1D|A Trial of High Dose Immunosuppression and Autologous Hematopoietic Stem Cell Support Versus Intensive Insulin Therapy in Adults With Early Onset Type I Diabetes Mellitus|Withdrawn||Phase 1/Phase 2|0|Actual|Northwestern University||2||No participant enrolled|f||||t||||||||||2018-05-31 22:55:12.69282|2018-05-31 22:55:12.69282
NCT01286103|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2012-03-12|2011-01-27|2011-01-31|Estimate|||||||2012-03-12|2012-03-13|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|||||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers|An Open-Label, Multiple-Dose Study to Assess the Steady-State Pharmacokinetics, Pharmacodynamics and Safety of Once-Daily Versus Twice-Daily Dosing With Canagliflozin in Healthy Subjects|Completed||Phase 1|34|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 22:55:10.535487|2018-05-31 22:55:10.535487
NCT01286090|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-01-27|2011-01-27|2011-01-31|Estimate|||||||2011-01-27|2011-01-31|Estimate|July 2003||2003-07-31|January 2011|2011-01-31|October 2003|Actual|2003-10-31|||||Interventional|||An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus|Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus|Terminated||Phase 4|4|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Sponsor request|f||||f||||||||||2018-05-31 22:55:10.618577|2018-05-31 22:55:10.618577
NCT01286077|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-11-07||2016-04-26|2011-01-27|2011-01-31|Estimate|2013-11-07|2013-12-30|Estimate||||2016-04-26|2016-05-30|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|April 2014|Actual|2014-04-30|November 2012|Actual|2012-11-30||Interventional|||Velcade Consolidation Bone Study|A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease|Completed||Phase 2|106|Actual|Janssen-Cilag International NV||2|||f||||f||||||||||2018-05-31 22:55:10.729548|2018-05-31 22:55:10.729548
NCT01286064|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-01-28|2011-01-28|2011-01-31|Estimate|||||||2011-01-28|2011-01-31|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|April 2011|Anticipated|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Colorectal Cancer Detection by Means of Optical Fluoroscopy|Role of Natural Fluorescence of Human Blood Plasma in Patients With Colorectal Cancer.|Unknown status|Recruiting|N/A|200|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||t||||||||||2018-05-31 22:55:11.242948|2018-05-31 22:55:11.242948
NCT01286051|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-03-19|2011-01-27|2011-01-31|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles|Efficacy of Single Dose Ganirelix in Gonadotropin Ovulation Induction Cycles|Completed||N/A|80|Actual|Houston Fertility Institute||2|||f||||f||||||||||2018-05-31 22:55:11.323129|2018-05-31 22:55:11.323129
NCT01286038|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2018-02-26|2011-01-28|2011-01-31|Estimate|||||||2018-02-26|2018-02-28|Actual|March 21, 2011|Actual|2011-03-21|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia|A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Who Progressed or Are Resistant to Hypomethylating Agents|Active, not recruiting||Phase 1/Phase 2|37|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 22:55:11.415722|2018-05-31 22:55:11.415722
NCT01286025|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-01-27|2011-01-27|2011-01-31|Estimate|||||||2011-01-27|2011-01-31|Estimate|February 2008||2008-02-29|January 2011|2011-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Comparing the Effect of Video-cases and Text-cases on Medical Students' Learning in Tutorial|A Randomized Crossover Study to Compare the Critical Thinking of Medical Students When Using Video-based or Written Cases|Completed||N/A|28|Actual|Harvard University Faculty of Medicine||2|||f||||f||||||||||2018-05-31 22:55:11.500524|2018-05-31 22:55:11.500524
NCT01286012|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2014-02-03||2017-09-26|2011-01-27|2011-01-31|Estimate|2014-02-03|2014-03-26|Estimate||||2017-09-26|2017-10-27|Actual|January 2011||2011-01-31|September 2017|2017-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PRIME|Safety Population: Subjects who received any amount of study drug, including those who receive the wrong treatment.|Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients|Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate: The PRIME Study|Completed||Phase 2|108|Actual|Rockwell Medical Technologies, Inc.||2|||f||||f||||||||||2018-05-31 22:55:11.608127|2018-05-31 22:55:11.608127
NCT01285999|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-01-30|2011-01-28|2011-01-31|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|April 2014|Anticipated|2014-04-30|March 2013|Anticipated|2013-03-31||Interventional|PLATINUM China||A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion|PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion|Unknown status|Active, not recruiting|N/A|500|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 22:55:12.100471|2018-05-31 22:55:12.100471
NCT01285986|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-01-27|2011-01-27|2011-01-28|Estimate|||||||2011-01-27|2011-01-28|Estimate|January 1995||1995-01-31|January 2011|2011-01-31|June 1998|Actual|1998-06-30|June 1998|Actual|1998-06-30||Interventional|SCAMICOS||Scandinavian Miller Collar Study|Scandinavian Miller Collar Study|Completed||N/A|352|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 22:55:12.183699|2018-05-31 22:55:12.183699
NCT01285973|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-08-11|2011-01-27|2011-01-28|Estimate|||||||2015-08-11|2015-08-13|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Evaluation of Integra® Artificial Dermis for the Treatment of Leg Ulcers||Completed|||30|Actual|Integra LifeSciences Services|||||f||||f||||||||||2018-05-31 22:55:12.359651|2018-05-31 22:55:12.359651
NCT01285960|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2016-04-12|2011-01-27|2011-01-28|Estimate|||||||2016-04-12|2016-04-13|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids|A Clinical Study to Evaluate Safety of the ExAblate Model 2100 Type 1.1 System (ExAblate 2100/2000 UF V2 System) in the Treatment of Symptomatic Uterine Fibroids|Completed||N/A|106|Actual|InSightec||1|||f||||f||||||||||2018-05-31 22:55:12.42124|2018-05-31 22:55:12.42124
NCT01285947|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-09-03||2016-12-05|2011-01-27|2011-01-28|Estimate|2013-12-17|2014-02-05|Estimate||||2016-12-05|2017-02-01|Estimate|February 2011||2011-02-28|December 2016|2016-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparing the Pain Experience Between Patients Who Have and Who Have Not Undergone Dermatologic Procedures|A Pilot Study of 20 Subjects: Pain Experience in Naive vs. Non-naive Subjects Undergoing Energy-based Dermatologic Procedures|Completed||N/A|20|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 22:55:12.504837|2018-05-31 22:55:12.504837
NCT01285921|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-11-03|2011-01-27|2011-01-28|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2011||2011-02-28|November 2017|2017-11-30|October 2017|Actual|2017-10-31|November 2016|Actual|2016-11-30||Interventional|HIPPOCAMPE||Functional Link Between Hippocampal and Vestibular Systems: a Pilot Study in Epilepsy Surgery|Functional Link Between Hippocampal and Vestibular Systems: a Pilot Study in Epilepsy Surgery Principal Investigator: Elizabeth VITTE|Completed||N/A|22|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 22:55:12.759247|2018-05-31 22:55:12.759247
NCT01285908|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2013-09-24||2014-09-23|2011-01-27|2011-01-28|Estimate|2014-02-25|2014-03-26|Estimate||||2014-09-23|2014-10-10|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Baseline characteristics are included for all subjects meeting eligibility criteria.|Intravenous Norepinephrine for Orthostatic Hypotension|Safety and Efficacy of Intravenous Norepinephrine for Orthostatic Hypotension|Completed||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||t||||||||||2018-05-31 22:55:12.829653|2018-05-31 22:55:12.829653
NCT01285895|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-04-14|2011-01-27|2011-01-28|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Needs in Education for Pulmonary or Cardiopulmonary Transplanted Cystic Fibrosis Patients|Assessing of the Educational Needs of Patients Who Received a Lung Transplantation or a Simultaneous Heart-lung Transplantation for Mucoviscidosis|Completed|||60|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 22:55:13.330338|2018-05-31 22:55:13.330338
NCT01285882|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2015-04-14|2011-01-27|2011-01-28|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Representations of Transplantation in Patients and in Health Care Professionals|Representations of Transplantation in Patients With Mucoviscidosis, in Their Assistants and in Their Medical Persons|Completed|||14|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 22:55:13.389648|2018-05-31 22:55:13.389648
NCT01285869|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2017-08-10|2011-01-27|2011-01-28|Estimate|||||||2017-08-10|2017-08-11|Actual|November 2010||2010-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|IMIEPAP||Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia|Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia: a Prospective Randomized Controlled Trial.|Active, not recruiting||N/A|314|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 22:55:13.452611|2018-05-31 22:55:13.452611
NCT01285856|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2014-08-28|2011-01-27|2011-01-28|Estimate|||||||2014-08-28|2014-08-29|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications|Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications|Unknown status|Recruiting|N/A|220|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 22:55:13.530944|2018-05-31 22:55:13.530944
NCT01285843|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2014-08-27||2016-08-26|2011-01-27|2011-01-28|Estimate|2014-09-09|2014-09-15|Estimate||||2016-08-26|2016-10-20|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component|Periprosthetic Bone Mineral Density After Total Hip Arthroplasty Performed Through a Minimally Invasive Anterior Approach (AMIS) With Either an AMIStem or a Quadra Femoral Component.|Completed||N/A|40|Actual|Medacta International SA||2|||f||||||||||||||2018-05-31 22:55:13.614405|2018-05-31 22:55:13.614405
NCT01285830|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2014-03-19|2011-01-27|2011-01-28|Estimate|||||||2014-03-19|2014-03-20|Estimate|February 2001||2001-02-28|January 2011|2011-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Primary Prevention of Allergic Disease in Early Child by Lactobacillus Reuteri|Primary Prevention of Allergic Disease in Early Child by Lactobacillus Reuteri|Completed||Phase 2|232|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 22:55:13.850127|2018-05-31 22:55:13.850127
NCT01285817|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2015-10-22|2011-01-27|2011-01-28|Estimate|||||||2015-10-22|2015-10-23|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Interventional|SFCE METRO 01||A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.|A Phase II Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing Solid Tumours.|Unknown status|Recruiting|Phase 2|90|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:55:13.929243|2018-05-31 22:55:13.929243
NCT01285804|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-01-27|2011-01-27|2011-01-28|Estimate|||||||2012-01-27|2012-01-31|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Impact of Using a Cuffed Endotracheal Tube on Limiting the Risk of Airway Fire||Completed||N/A|200|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 22:55:13.989447|2018-05-31 22:55:13.989447
NCT01285791|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2016-02-18||2016-02-18|2011-01-27|2011-01-28|Estimate|2016-02-18|2016-03-16|Estimate||||2016-02-18|2016-03-16|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Sonographic Evaluation of Visceral Fat After Bariatric Surgery|Sonographic Evaluation of Visceral and Subcutaneous Fat in Morbidly Obese Patients Before and After 3 Different Types of Bariatric Surgery.|Completed|||39|Actual|Hadassah Medical Organization|||3||f||||f||||||||No|not planning on sharing data|2018-05-31 22:55:14.042515|2018-05-31 22:55:14.042515
NCT01285778|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2018-05-11|2011-01-27|2011-01-28|Estimate|||||||2018-05-11|2018-05-16|Actual|October 2010|Actual|2010-10-31|May 2018|2018-05-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|VITAL||Vectibix for the Treatment of Anal Cancer|Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma|Completed||Phase 2|58|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f||||||||||2018-05-31 22:55:14.592759|2018-05-31 22:55:14.592759
NCT01285596|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2013-07-01|2011-01-27|2011-01-28|Estimate|||||||2013-07-01|2013-07-03|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex|An Open-label, Randomized, 2-way Crossover Study to Evaluate the Pharmacokinetics of Mirabegron and Its Metabolites in Healthy Young and Elderly Male and Female Subjects|Completed||Phase 1|75|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 22:55:20.778445|2018-05-31 22:55:20.778445
NCT01285765|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2018-03-05|2011-01-27|2011-01-28|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2010|Actual|2010-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients|Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+|Active, not recruiting||Phase 3|650|Anticipated|The Lymphoma Academic Research Organisation||2|||f||||t|f|f||||||No||2018-05-31 22:55:14.928667|2018-05-31 22:55:14.928667
NCT01285752|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2016-07-21|2011-01-27|2011-01-28|Estimate|||||||2016-07-21|2016-07-25|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)||Completed||Phase 2|240|Anticipated|Asahi Kasei Pharma Corporation||3|||f||||||||||||||2018-05-31 22:55:15.390608|2018-05-31 22:55:15.390608
NCT01285739|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|||2011-11-10|2011-01-27|2011-01-28|Estimate|||||||2011-11-10|2011-11-11|Estimate|January 2002||2002-01-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Tracheostomized COPD Patients and Non Invasive Mechanical Ventilation|Eight-year Follow up in Tracheostomized COPD Patients Undergoing Domiciliary Non Invasive Mechanical Ventilation.|Unknown status|Active, not recruiting||247|Actual|Fondazione Salvatore Maugeri|||2||f||||t||||||Samples Without DNA|"~     whole blood, tracheobronchial aspirate (TBA)~   "|||2018-05-31 22:55:15.654226|2018-05-31 22:55:15.654226
NCT01285726|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2016-04-29|2011-01-27|2011-01-28|Estimate|||||||2016-04-29|2016-05-02|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|IPOD-PD||Initiative for Patient Outcomes in Dialysis - Peritoneal Dialysis (PD) (IPOD-PD Study)|Initiative for Patient Outcomes in Dialysis - PD (IPOD-PD Study)|Completed|||1092|Actual|Fresenius Medical Care Deutschland GmbH|||||f||||f||||||||||2018-05-31 22:55:15.868708|2018-05-31 22:55:15.868708
NCT01285713|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2012-12-14||2018-01-09|2011-01-27|2011-01-28|Estimate|2012-12-14|2013-01-23|Estimate||||2018-01-09|2018-01-11|Actual|September 2010||2010-09-30|January 2018|2018-01-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||IV Glucose for Dehydration Treatment|Effects of Glucose Containing Fluid in the Treatment of Acute Dehydration|Completed||Phase 2|83|Actual|Children's Hospital of Philadelphia|Single center study Small sample size Enrollment available 16 hours/day Evaluated one dextrose load of 500mg/kg|2|||f||||f||||||||||2018-05-31 22:55:16.255734|2018-05-31 22:55:16.255734
NCT01285700|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2012-09-25|2011-01-26|2011-01-28|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|November 2012|Anticipated|2012-11-30|January 2012|Actual|2012-01-31||Interventional|||Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis|A Single Center, Randomized, Open-label, Multiple-dose Study of the Efficacy and Long-term Safety of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.|Unknown status|Active, not recruiting|Phase 2|10|Actual|Zymenex A/S||2|||f||||f||||||||||2018-05-31 22:55:16.667209|2018-05-31 22:55:16.667209
NCT01285687|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-23|||2015-06-30|2011-01-26|2011-01-28|Estimate|||||||2015-06-30|2015-07-01|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Acupuncture for Post-tonsillectomy Pain Control in Children|Acupuncture for Post-tonsillectomy Pain Control in Children: a Single-blinded, Randomized, Controlled Study|Completed||N/A|60|Actual|Ziv Hospital||2|||f||||t||||||||||2018-05-31 22:55:16.796171|2018-05-31 22:55:16.796171
NCT01285674|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-23|||2011-01-27|2011-01-27|2011-01-28|Estimate|||||||2011-01-27|2011-01-28|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.|INTRATYMPANIC STEROID TREATMENT FOR THE PREVENTION OF INNER EAR TOXICITY ASSOCIATED WITH SYSTEMIC TREATMENT WITH CISPLATIN.|Unknown status|Not yet recruiting|N/A|20|Anticipated|Ziv Hospital||1|||f||||t||||||||||2018-05-31 22:55:16.92455|2018-05-31 22:55:16.92455
NCT01285661|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2016-07-17|2011-01-26|2011-01-28|Estimate|||||||2016-07-17|2016-07-19|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|MORGAGNI||Optimal Duration of Anticoagulation in Deep Venous Thrombosis|Identification of the Optimal Duration of Anticoagulation in Patients With Deep Venous Thrombosis of the Lower Extremities With the Use of Residual Vein Thrombosis in Combination With D-Dimer|Completed||Phase 3|584|Actual|University of Padova||1|||f||||t||||||||||2018-05-31 22:55:17.030269|2018-05-31 22:55:17.030269
NCT01285648|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-26|2011-01-26|2011-01-28|Estimate|||||||2011-01-26|2011-01-28|Estimate|November 2007||2007-11-30|January 2011|2011-01-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|CPAP||Study of CPAP as Intervention After Lung Resection|APPLICATION OF CONTINUOUS POSITIVE AIRWAY PRESSURE IN POSTOPERATIVE OF LUNG RESECTION|Completed||N/A|40|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 22:55:17.128792|2018-05-31 22:55:17.128792
NCT01285635|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2015-01-20||2016-03-03|2011-01-26|2011-01-28|Estimate|2015-06-26|2015-07-23|Estimate||||2016-03-03|2016-03-31|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|December 2012|Actual|2012-12-31||Interventional|||A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck|A Phase II of AT-101 in Combination With Docetaxel in Patients With Recurrent, Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Terminated||Phase 2|35|Actual|University of Michigan Cancer Center||3||drug is no longer manufactured|f||||t||||||||||2018-05-31 22:55:17.25078|2018-05-31 22:55:17.25078
NCT01285622|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2017-06-27|2011-01-26|2011-01-28|Estimate|||||||2017-06-27|2017-06-28|Actual|January 2011||2011-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Plethysmography Variability Index as an Indicator of Adequacy of Preload|Cardiac Output Changes and Evaluation of Plethysmography Variability Index (PVI) as an Indicator of Adequacy of Preload in Women Undergoing Robotic Surgery|Suspended|||40|Anticipated|University of Louisville|||1|Unable to receive funding|f||||f||||||||||2018-05-31 22:55:18.071105|2018-05-31 22:55:18.071105
NCT01285609|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2016-05-16||2017-11-16|2011-01-27|2011-01-28|Estimate|2016-05-16|2016-06-23|Estimate||||2017-11-16|2017-12-13|Actual|January 16, 2011|Actual|2011-01-16|November 2017|2017-11-30|August 22, 2017|Actual|2017-08-22|June 9, 2015|Actual|2015-06-09||Interventional||Randomized Participants Who Received at Least One Dose of Blinded Study Therapy|Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin|Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|1289|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 22:55:18.223583|2018-05-31 22:55:18.223583
NCT01285570|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-07-25|2011-01-27|2011-01-28|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ULISES||Ulimorelin Study of Efficacy and Safety (ULISES 007)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection|Completed||Phase 3|332|Actual|Tranzyme, Inc.||3|||f||||||||||||||2018-05-31 22:55:21.051957|2018-05-31 22:55:21.051957
NCT01285557|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2016-10-19|2011-01-26|2011-01-28|Estimate|||||||2016-10-19|2016-10-21|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|DIGEST||Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial|An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy|Active, not recruiting||Phase 3|500|Anticipated|Taiho Oncology, Inc.||2|||f||||t||||||||||2018-05-31 22:55:21.191872|2018-05-31 22:55:21.191872
NCT01285544|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2013-12-15|2011-01-26|2011-01-28|Estimate|||||||2013-12-15|2013-12-17|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia|Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial|Completed||Phase 4|289|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 22:55:21.378102|2018-05-31 22:55:21.378102
NCT01285531|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2011-02-15|2011-01-26|2011-01-28|Estimate|||||||2011-02-15|2011-02-17|Estimate|January 2011||2011-01-31|February 2011|2011-02-28||||January 2012|Anticipated|2012-01-31||Interventional|||Pediatric Lumbar Puncture Success Using the COMPASS|"Institutional Review Board Application #13373, Entitled A Randomized Clinical Trial of Pediatric Lumbar Puncture Success Using The Compass, a Compact Quantitative Pressure Transducer"|Unknown status|Recruiting|N/A|60|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 22:55:21.446674|2018-05-31 22:55:21.446674
NCT01285518|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2014-12-18||2016-09-27|2011-01-26|2011-01-28|Estimate|2016-09-27|2016-11-18|Estimate||||2016-09-27|2016-11-18|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Safety analysis population included all participants who received at least 1 dose of study medication.|Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes|A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of Pf-05231023 In Adult Subjects With Type 2 Diabetes|Completed||Phase 1|84|Actual|Pfizer|Results for C0 and Vss was included as secondary endpoints as per change in the planned analysis.|2|||f||||f||||||||||2018-05-31 22:55:21.690297|2018-05-31 22:55:21.690297
NCT01285505|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-04-07|2011-01-26|2011-01-28|Estimate|||||||2011-04-07|2011-04-08|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation|Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To An Alprazolam Sublingual Tablet|Withdrawn||Phase 1|26|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:55:25.067493|2018-05-31 22:55:25.067493
NCT01285492|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2013-09-04||2013-12-03|2011-01-26|2011-01-28|Estimate|2013-09-04|2013-11-07|Estimate||||2013-12-03|2013-12-27|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of QVA149 (110 Mcg Indacaterol / 50 Mcg Glycopyrrolate o.d.) Using Tiotropium (18 Mcg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|160|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:55:25.390401|2018-05-31 22:55:25.390401
NCT01285479|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-07-30|2011-01-26|2011-01-28|Estimate|||||||2017-07-30|2017-08-01|Actual|October 15, 2011|Actual|2011-10-15|July 2017|2017-07-31|September 25, 2023|Anticipated|2023-09-25|September 25, 2023|Anticipated|2023-09-25||Observational|||Pregnancy Registry Trial|The Multi-National Pregnancy Fingolimod Exposure Registry in Multiple Sclerosis (Epidemiological Study Protocol FTY720D2404)|Recruiting|||500|Anticipated|Novartis|||1||f||||||||||||||2018-05-31 22:55:26.628238|2018-05-31 22:55:26.628238
NCT01285466|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-02-13|2011-01-27|2011-01-28|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2011||2011-01-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab|A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer|Completed||Phase 1|110|Actual|Novartis||4|||f||||||||||||||2018-05-31 22:55:26.74887|2018-05-31 22:55:26.74887
NCT01285453|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-11-26|2011-01-26|2011-01-28|Estimate|||||||2012-11-26|2012-11-27|Estimate|March 2009||2009-03-31|November 2012|2012-11-30||||December 2009|Actual|2009-12-31||Interventional|||Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors|A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors|Completed||Phase 1|9|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:55:26.820833|2018-05-31 22:55:26.820833
NCT01285440|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2017-11-07|2011-01-26|2011-01-28|Estimate|||||||2017-11-07|2017-11-09|Actual|March 2010||2010-03-31|November 2017|2017-11-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|Lowdoseprebx||Use of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions|Determination of the Sensitivity of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions|Completed|||150|Anticipated|Mayo Clinic|||1||f||||t||||||||||2018-05-31 22:55:26.882282|2018-05-31 22:55:26.882282
NCT01285427|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2013-05-08||2014-04-15|2011-01-26|2011-01-28|Estimate|2014-04-15|2014-04-17|Estimate||||2014-04-15|2014-04-17|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Clinical Protocol SeCore, uTYPE and 3500 Dx System|SeCore Sequencing Kit and 3500xl Dx Genetic Analyzer Clinical Performance Testing vs. SSP UniTray|Completed|||300|Actual|Life Technologies Corporation|||1||f||||f||||||Samples With DNA|"~     DNA isolated from whole blood samples~   "|||2018-05-31 22:55:26.941363|2018-05-31 22:55:26.941363
NCT01285414|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-04-10|2011-01-26|2011-01-28|Estimate|||||||2012-04-10|2012-04-11|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase 2 Study of Verubulin With Radiation Therapy and Temozolomide in Subjects Newly Diagnosed With Glioblastoma Multiforme|Completed||Phase 2|5|Actual|Myrexis Inc.||2|||f||||t||||||||||2018-05-31 22:55:27.217567|2018-05-31 22:55:27.217567
NCT01285401|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2016-05-31||2016-10-07|2011-01-26|2011-01-28|Estimate|2016-05-31|2016-07-11|Estimate||||2016-10-07|2016-11-28|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|SOLAR|Baseline analysis set included all randomized subjects.|Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment|A Three Arm, Randomized, Double Blind, Placebo Controlled, Multicenter, Phase II Study to Evaluate the Efficacy of Vigantol® Oil as Add on Therapy in Subjects With Relapsing Remitting Multiple Sclerosis Receiving Treatment With 44mg Tiw of Rebif®|Completed||Phase 2|260|Actual|Merck KGaA||3|||f||||t||||||||||2018-05-31 22:55:27.356952|2018-05-31 22:55:27.356952
NCT01285388|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2017-12-19|2011-01-26|2011-01-28|Estimate|||||||2017-12-19|2017-12-21|Actual|July 2010||2010-07-31|December 2017|2017-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers|A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects|Completed||Phase 1|50|Actual|Yungjin Pharm. Co., Ltd.||6|||f||||t||||||||||2018-05-31 22:55:28.611862|2018-05-31 22:55:28.611862
NCT01285375|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-26|2011-01-26|2011-01-28|Estimate|||||||2011-01-26|2011-01-28|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution||Unknown status|Recruiting|Phase 1|20|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 22:55:28.717646|2018-05-31 22:55:28.717646
NCT01285362|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2015-03-05|2011-01-27|2011-01-28|Estimate|||||||2015-03-05|2015-03-09|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study|Fish Oil for the Treatment of Nonalcoholic Fatty Liver Disease in Children|Completed||N/A|8|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 22:55:28.952256|2018-05-31 22:55:28.952256
NCT01285349|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-01-26|2011-01-26|2011-01-28|Estimate|||||||2011-01-26|2011-01-28|Estimate|November 2005||2005-11-30|January 2011|2011-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|Connect II||HIV/STI Prevention for Drug-Involved Couples|HIV/STI Prevention for Drug-Involved Couples|Completed||Phase 2|564|Actual|Columbia University||3|||f||||f||||||||||2018-05-31 22:55:29.201099|2018-05-31 22:55:29.201099
NCT01285336|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-27|2011-01-27|2011-01-28|Estimate|||||||2011-01-27|2011-01-28|Estimate|August 2010||2010-08-31|January 2012|2012-01-31||||||||Interventional|||The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis|The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis.|Completed||N/A|||China Medical University Hospital||1|||f||||||||||||||2018-05-31 22:55:29.267738|2018-05-31 22:55:29.267738
NCT01285323|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2016-03-23|2015-09-24|2016-05-26|2011-01-26|2011-01-28|Estimate|2016-05-26|2016-06-27|Estimate|2015-09-24|2015-10-02|Estimate|2016-05-26|2016-06-27|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Randomized participants|A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma|A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma|Completed||Phase 3|464|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 22:55:29.378221|2018-05-31 22:55:29.378221
NCT01285310|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2014-04-22|2013-05-28|2017-09-18|2011-01-26|2011-01-28|Estimate|2014-07-24|2014-08-15|Estimate|2013-05-28|2013-06-06|Estimate|2017-09-18|2017-10-19|Actual|December 9, 2010|Actual|2010-12-09|September 2017|2017-09-30|September 10, 2012|Actual|2012-09-10|February 21, 2012|Actual|2012-02-21||Interventional||Full Analysis Set (FAS) The FAS consisted of all participants who were randomized as specified per protocol during the placebo controlled period.|Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study, To Compare the Efficacy and Safety of Two Doses of Apremilast (CC-10004) in Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|Terminated||Phase 2|237|Actual|Celgene|The study was terminated before the 2–year time point was reached due to lack of clinical efficacy.|3||Study is terminated due to lack of efficacy|f||||t||||||||||2018-05-31 22:55:30.692158|2018-05-31 22:55:30.692158
NCT01285297|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2015-08-18|2011-01-26|2011-01-28|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PHOENIX||Safety Study of Transmyocardial Revascularization (TMR) With Bone Marrow Aspirate (BMAC) for Angina Reduction|A Prospective, Multicenter, Single Arm Study of Transmyocardial Revascularization (TMR) Plus Bone Marrow Aspirate Concentrated (BMAC) Using the Cardiogenesis PHOENIX Combination Handpiece Delivery System|Terminated||N/A|7|Actual|Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.||1|||f||||t||||||||||2018-05-31 22:55:33.220516|2018-05-31 22:55:33.220516
NCT01285284|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-08-08|2011-01-26|2011-01-27|Estimate|||||||2011-08-08|2011-08-09|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|EMOC||Effect of Music Over the Tolerance to Colonoscopy.|The Effect of Music Over the Tolerance to Colonoscopy ¿Does it Reduce the Discomfort, the Anxiety and the Need of Sedation? Multicentric Randomized Controlled Trial.|Unknown status|Recruiting|Phase 4|300|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 22:55:33.288643|2018-05-31 22:55:33.288643
NCT01285271|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-10-05|2011-01-26|2011-01-27|Estimate|||||||2011-10-05|2011-10-06|Estimate|May 2011||2011-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|CArDiAX||A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon|The Safety and Feasibility of Delivering Xenon to Patients Before and After Coronary Artery Bypass Graft Implantation: a Pilot Study|Completed||Phase 3|30|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 22:55:33.37914|2018-05-31 22:55:33.37914
NCT01285258|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|March 2004||2004-03-31|March 2004|2004-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Emergency Peripartum Hysterectomy: A Prospective Study in Iran|Study of Peripartum Hysterectomy for Maternal Hemorrhage|Completed||Phase 2|41|Actual|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:55:33.449346|2018-05-31 22:55:33.449346
NCT01285245|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2011-04-13|2011-01-26|2011-01-27|Estimate|||||||2011-04-13|2011-04-14|Estimate|April 2011||2011-04-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus|Effect of Interleukin-1 Receptor Antagonist on Insulin Sensitivity in Type 1 Diabetes Mellitus.|Unknown status|Recruiting|Phase 2|16|Anticipated|Radboud University||1|||f||||f||||||||||2018-05-31 22:55:33.561915|2018-05-31 22:55:33.561915
NCT01285232|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2012-03-23|2011-01-26|2011-01-27|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Anakinra on Insulin Secretion|The Effect of Interleukin-1 Receptor Antagonist on Insulin Secretion in Subjects With Beta Cell Dysfunction|Unknown status|Active, not recruiting|N/A|16|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 22:55:33.638647|2018-05-31 22:55:33.638647
NCT01285219|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|January 2006||2006-01-31|January 2011|2011-01-31|December 2008|Actual|2008-12-31|May 2007|Actual|2007-05-31||Interventional|||A Study Comparing Pegylated Filgrastim and Filgrastim in Support for Chemotherapy|A Multicenter, Randomized, Cross-over Phase 3 Comparing Preventive Pegylated Filgrastim and Filgrastim in Cancer Patients Receiving Myelosuppressive Chemotherapy|Completed||Phase 3|337|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:55:33.744987|2018-05-31 22:55:33.744987
NCT01285206|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|December 2010||2010-12-31|September 2010|2010-09-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Carbon Polymer Blankets to Prevent Incidence Of Peri-Operative Hypothermia (IPH) in the DSU|A Study To Determine Whether Carbon Polymer Blankets Can Reduce The During And After Short, Day Operations|Unknown status|Recruiting|N/A|70|Anticipated|Brighton and Sussex University Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 22:55:33.825517|2018-05-31 22:55:33.825517
NCT01285193|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|June 2011||2011-06-30|January 2011|2011-01-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Treating Hypertension With Breath Control|A Randomized Controlled Trial to Treat Hypertension by Regularising and Slowing Breathing|Unknown status|Not yet recruiting|N/A|84|Anticipated|Penang Hospital, Malaysia||1|||f||||f||||||||||2018-05-31 22:55:33.917701|2018-05-31 22:55:33.917701
NCT01285180|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-10-27|2011-01-26|2011-01-27|Estimate|||||||2016-10-27|2016-10-28|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|DINO||Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe COPD|Daxas in COPD Therapy|Completed|||5472|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:55:34.162981|2018-05-31 22:55:34.162981
NCT01285167|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-10-27|2011-01-26|2011-01-27|Estimate|||||||2016-10-27|2016-10-31|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|DACOTA||Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)|Daxas for COPD Therapy (DACOTA)|Completed|||3645|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:55:37.754503|2018-05-31 22:55:37.754503
NCT01285154|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-04-21|2011-01-26|2011-01-27|Estimate|||||||2011-04-21|2011-04-22|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Observational|||Modified Triple Osteotomy for Acetabular Dysplasia|Modified Triple Osteotomy for Acetabular Dysplasia - A Modified Technique for Better Femoral Head Medialization and Coverage|Unknown status|Recruiting||2|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 22:55:39.77506|2018-05-31 22:55:39.77506
NCT01285141|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-12-04|2011-01-26|2011-01-27|Estimate|||||||2012-12-04|2012-12-05|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|TL01||Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine|Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Three Cervico-vaginal Topical Immunisations With a Fixed Dose of HIV CN54gp140 Glycoprotein-hsp70 Conjugate Vaccine|Completed||Phase 1|8|Actual|St George's, University of London||1|||f||||f||||||||||2018-05-31 22:55:39.83951|2018-05-31 22:55:39.83951
NCT01285115|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|December 2008||2008-12-31|October 2010|2010-10-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form|Phase 3 The Comparative Clinical Study of Gamisoyosan on Anxiety of Generalized Anxiety Disorder According to Dosage Form : A Randomized, Double Blind, Parallel-controlled Trial|Completed||Phase 3|147|Actual|Korea Health Industry Development Institute||3|||f||||t||||||||||2018-05-31 22:55:39.911119|2018-05-31 22:55:39.911119
NCT01285102|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2015-09-10|2011-01-26|2011-01-27|Estimate|||||||2015-09-10|2015-09-11|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional|||Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer|Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease|Terminated||Phase 2|4|Actual|Fox Chase Cancer Center||1||This study was closed early by the DSMB due to increased toxicity.|f||||f||||||||||2018-05-31 22:55:40.00224|2018-05-31 22:55:40.00224
NCT01285089|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-01-29|2011-01-26|2011-01-27|Estimate|||||||2014-01-29|2014-01-30|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|ACQUI-7||Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia|Prospective French Study on ACQUIred Haemophilia Treatment With Recombinant Factor VIIa (NovoSeven®) A Prospective Observational Study on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for the Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia|Completed|||21|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 22:55:40.09309|2018-05-31 22:55:40.09309
NCT01285076|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2013-12-19||2015-01-29|2011-01-26|2011-01-27|Estimate|2014-02-24|2014-03-24|Estimate||||2015-01-29|2015-02-16|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|NEEDS||Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)|Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects (NEEDS Study)|Completed|||834|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:55:40.174942|2018-05-31 22:55:40.174942
NCT01285063|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2013-02-20|2011-01-26|2011-01-27|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|||Intervention Study for Overweight and Obese Kindergarten Children|Combined Physical Activity and Diet Intervention for the Treatment of Overweight and Obesity in Kindergarten Children|Withdrawn||N/A|0|Actual|Meir Medical Center||1||We were not successful in raising money for this project|f||||f||||||||||2018-05-31 22:55:40.530308|2018-05-31 22:55:40.530308
NCT01285050|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2016-08-15||2016-10-06|2011-01-26|2011-01-27|Estimate|2016-10-06|2016-11-29|Estimate||||2016-10-06|2016-11-29|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds|Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy|Completed||Phase 4|20|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 22:55:40.603465|2018-05-31 22:55:40.603465
NCT01285024|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2016-02-19||2017-03-13|2011-01-26|2011-01-27|Estimate|2016-03-17|2016-04-18|Estimate||||2017-03-13|2017-04-11|Actual|December 2010||2010-12-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty|A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty|Completed||N/A|109|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 22:55:40.822846|2018-05-31 22:55:40.822846
NCT01285011|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-09-10|2011-01-26|2011-01-27|Estimate|||||||2014-09-10|2014-09-11|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|||Short Term Follow-up of Patient Implanted With the Proximal Interphalangeal Implant|Short Term Follow-up of Patient Implanted With the Proximal Interphalangeal|Completed|||156|Actual|Integra LifeSciences Services|||1||f||||f||||||||||2018-05-31 22:55:41.028382|2018-05-31 22:55:41.028382
NCT01284998|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-09-10|2011-01-26|2011-01-27|Estimate|||||||2014-09-10|2014-09-11|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Short Term Follow-up of Patent Implanted With the B-BOP Lock Plate|Short Term Follow-up of Patent Implanted With the B-BOP Lock Plate|Completed|||85|Actual|Integra LifeSciences Services|||1||f||||f||||||||||2018-05-31 22:55:41.134867|2018-05-31 22:55:41.134867
NCT01284985|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-09-10|2011-01-26|2011-01-27|Estimate|||||||2014-09-10|2014-09-11|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Short Term Follow-up of Patient Implanted With the Metatarso-Phalangeal Prosthesis METIS®|Short Term Follow-up of Patient Implanted With the Metatarso-Phalangeal Prosthesis METIS®|Completed|||60|Actual|Integra LifeSciences Services|||1||f||||f||||||||||2018-05-31 22:55:41.211829|2018-05-31 22:55:41.211829
NCT01284972|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-10-09|2011-01-26|2011-01-27|Estimate|||||||2012-10-09|2012-10-10|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||HINTEGRA Total Ankle Prosthesis Follow-up|Short to Mid Term Follow-up of Patient Implanted With the HINTEGRA® Total Ankle Prosthesis|Completed|||225|Actual|Integra LifeSciences Services|||1||f||||f||||||||||2018-05-31 22:55:41.274436|2018-05-31 22:55:41.274436
NCT01284959|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2012-02-29||2012-09-21|2011-01-26|2011-01-27|Estimate|2012-09-21|2012-10-23|Estimate||||2012-09-21|2012-10-23|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Different Safety Profile of Risperidone and Paliperidone Extended-release|Different Safety Profile of Risperidone and Paliperidone Extended-release: a Double-blind, Placebo-controlled Trial With Healthy Volunteers|Completed||Phase 4|34|Actual|Chonbuk National University Hospital|The sample size was small, which presents higher risk of a type II error. The time of assessment after administering placebo or risperidone was noon to 2 PM, which may have contributed to the increased reports of sedation|3|||f||||f||||||||||2018-05-31 22:55:41.353656|2018-05-31 22:55:41.353656
NCT01284946|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda|A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload|Unknown status|Recruiting|Phase 2|45|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 22:55:41.859362|2018-05-31 22:55:41.859362
NCT01284933|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-08-28|2011-01-26|2011-01-27|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2011|Actual|2011-02-28|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|CAPIAS||Carotid Plaque Imaging in Acute Stroke|Carotid Plaque Imaging in Acute Stroke|Recruiting|||300|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, RNA~   "|||2018-05-31 22:55:42.010317|2018-05-31 22:55:42.010317
NCT01284920|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2016-01-29|2011-01-26|2011-01-27|Estimate|||||||2016-01-29|2016-02-01|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients|A Phase I/II, Open-Label, Uncontrolled, Dose-Escalation Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer|Completed||Phase 1/Phase 2|47|Actual|Astellas Pharma Inc||4|||f||||t||||||||Undecided||2018-05-31 22:55:42.093395|2018-05-31 22:55:42.093395
NCT01284907|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2014-12-16|2011-01-26|2011-01-27|Estimate|||||||2014-12-16|2014-12-17|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Vit D to Treat Asthma in Children: a Randomized, Double-blind, Placebo-controlled Trial|Vit D to Treat Asthma in Children: a Randomized, Double-blind, Placebo-controlled Trial|Withdrawn||N/A|0|Actual|United Arab Emirates University||2||No Participants|f||||t||||||||||2018-05-31 22:55:42.242134|2018-05-31 22:55:42.242134
NCT01284894|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-01-14|2011-01-26|2011-01-27|Estimate|||||||2014-01-14|2014-01-15|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Esophageal High Resolution Manometry and Dysphagia|Diagnostic Yield of Esophageal High Resolution Manometry in Patients With Unexplained Dysphagia|Completed||N/A|247|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 22:55:42.380873|2018-05-31 22:55:42.380873
NCT01284881|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-01-31|2011-01-26|2011-01-27|Estimate|||||||2012-01-31|2012-02-02|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Observational|||Self-Reported Versus Objective Measured Compliance With Oral Appliance Therapy for Obstructive Sleep Apnea Hypopnea Syndrome|Self-Reported vs Objective Measured Compliance With Oral Appliance Therapy for Obstructive Sleep Apnea Hypopnea Syndrome|Completed|||50|Actual|University Hospital, Antwerp|||1||f||||f||||||||||2018-05-31 22:55:42.500349|2018-05-31 22:55:42.500349
NCT01284868|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-23|||2013-07-01|2011-01-26|2011-01-27|Estimate|||||||2013-07-01|2013-07-03|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.|An Exploratory Study Into the Mechanism of Mirabegron-induced Cardiovascular Effects in Healthy Male Subjects.|Completed||Phase 1|12|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:55:42.627904|2018-05-31 22:55:42.627904
NCT01284855|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2017-02-06|2011-01-26|2011-01-27|Estimate|||||||2017-02-06|2017-02-07|Estimate|April 2011||2011-04-30|February 2017|2017-02-28|March 20, 2013|Actual|2013-03-20|October 15, 2012|Actual|2012-10-15||Interventional|||Comparison of Two Dose Regimens of Snake Antivenom for the Treatment of Snake Bites Envenoming in Nepal|A Randomized, Double-blind, Clinical Trial of Two Dose Regimens of VINS Polyvalent Antivenom (ATC J06AA03) for the Treatment of Snake Bites With Neurotoxic Envenoming in Nepal|Completed||Phase 2|250|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 22:55:42.7297|2018-05-31 22:55:42.7297
NCT01284842|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|CAFIS||Call- Associated Acute Fatigue in Surgical Residency|Call-associated Acute Fatigue in Surgical Residency- Subjective Perception or Objective Fact?|Completed|||38|Actual|Philipps University Marburg Medical Center|||||f||||f||||||||||2018-05-31 22:55:42.885498|2018-05-31 22:55:42.885498
NCT01284829|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2015-09-29|2011-01-26|2011-01-27|Estimate|||||||2015-09-29|2015-10-01|Estimate|February 2011||2011-02-28|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Diagnosis of Indeterminate Adrenal Tumors on Conventional Imaging: A French Prospective Multicentric Study|Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Diagnosis of Indeterminate Adrenal Tumors on Conventional Imaging: A French Prospective Multicentric Study|Unknown status|Active, not recruiting|N/A|165|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:55:43.016812|2018-05-31 22:55:43.016812
NCT01284816|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2015-07-23|2011-01-26|2011-01-27|Estimate|||||||2015-07-23|2015-07-24|Estimate|September 2010||2010-09-30|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||Impact of Bariatric Surgery on Epicardial Adipose Tissue and on Myocardial Function|Impact of Bariatric Surgery on Epicardial Adipose Tissue and on Myocardial Function|Completed||N/A|44|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:55:43.337711|2018-05-31 22:55:43.337711
NCT01284803|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2015-04-20|2011-01-26|2011-01-27|Estimate|||||||2015-04-20|2015-04-21|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Feasibility and Acceptability of an Educational Intervention to Improve the Management of Depression in Primary Care.|Feasibility and Acceptability of an Educational Intervention to Improve the Management of Depression in Primary Care|Completed||N/A|50|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:55:43.448695|2018-05-31 22:55:43.448695
NCT01284790|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-08-29|2011-01-26|2011-01-27|Estimate|||||||2014-08-29|2014-09-01|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pitch and Loudness Perception by Cochlear Implant Listeners: Psychophysics and Objective Measures|Pitch and Loudness Perception by Cochlear Implant Listeners: Psychophysics and Objective Measures|Terminated||N/A|1|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 22:55:43.575041|2018-05-31 22:55:43.575041
NCT01284777|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2014-08-28|2011-01-26|2011-01-27|Estimate|||||||2014-08-28|2014-08-29|Estimate|May 2010||2010-05-31|August 2014|2014-08-31||||May 2012|Actual|2012-05-31||Observational|||Nuclear Matrix and Cancer: Proteomic and Genomic Analyses Using Microarray in Cells Obtained Via Thoracocentesis||Completed|||27|Actual|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||||2018-05-31 22:55:43.641206|2018-05-31 22:55:43.641206
NCT01284764|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2011-10-04|2011-01-26|2011-01-27|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|SMW||Efficacy Study of a Low Volume of Water Intake and Mosapride for Endoscopy in Patients With Subtotal Gastrectomy|Efficacy of a Low Volume of Water Intake and Mosapride for Endoscopy Preparation in Gastric Cancer Patients With Subtotal Gastrectomy: A Randomized Controlled Trial|Completed||Phase 3|144|Anticipated|Inje University||2|||f||||f||||||||||2018-05-31 22:55:43.703719|2018-05-31 22:55:43.703719
NCT01284751|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-05-11|2011-01-26|2011-01-27|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients|The Use of Major Depression Inventory (MDI) in Measuring Preoperative Depressive Symptoms in Breast Cancer Patients|Completed|||21|Actual|Herlev Hospital|||1||f||||f||||||||||2018-05-31 22:55:43.768381|2018-05-31 22:55:43.768381
NCT01284738|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-08-28|2011-01-26|2011-01-27|Estimate|||||||2014-08-28|2014-08-29|Estimate|March 2010||2010-03-31|August 2014|2014-08-31||||February 2014|Actual|2014-02-28||Interventional|||Beta-thalassemia and Microparticles|Beta-thalassemia and Microparticles|Completed||N/A|33|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 22:55:43.825942|2018-05-31 22:55:43.825942
NCT01284725|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-08-29|2011-01-26|2011-01-27|Estimate|||||||2014-08-29|2014-09-01|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Interventional|WIN-Lupus||Weaning of Immunosuppression in Nephritis of Lupus|Weaning of Immunosuppression in Nephritis of Lupus|Unknown status|Recruiting|Phase 3|200|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 22:55:43.884551|2018-05-31 22:55:43.884551
NCT01284712|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-09-29|2011-01-26|2011-01-27|Estimate|||||||2015-09-29|2015-10-01|Estimate|July 2009||2009-07-31|September 2015|2015-09-30||||July 2013|Actual|2013-07-31||Observational|||Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)||Unknown status|Active, not recruiting||27|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 22:55:43.954692|2018-05-31 22:55:43.954692
NCT01284699|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-08-28|2011-01-26|2011-01-27|Estimate|||||||2014-08-28|2014-08-29|Estimate|April 2010||2010-04-30|August 2014|2014-08-31||||April 2015|Anticipated|2015-04-30||Interventional|||Evaluation of the Safety and Efficacy of Bilateral Subthalamic Nucleus (SNT) Radiosurgery in Idiopathic Severe Parkinson's Disease Fulfilling Inclusion Criteria for STN Deep Brain Stimulation and Presenting With a Contraindication to Intracerebral Electrode Implantation.|Evaluation of the Safety and Efficacy of Bilateral Subthalamic Nucleus (SNT) Radiosurgery in Idiopathic Severe Parkinson's Disease Fulfilling Inclusion Criteria for STN Deep Brain Stimulation and Presenting With a Contraindication to Intracerebral Electrode Implantation.|Unknown status|Recruiting|N/A|20|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 22:55:44.026144|2018-05-31 22:55:44.026144
NCT01284686|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-08-28|2011-01-26|2011-01-27|Estimate|||||||2014-08-28|2014-08-29|Estimate|September 2010||2010-09-30|August 2014|2014-08-31||||March 2014|Actual|2014-03-31||Interventional|||Pathophysiology of Neuronal Oscillations Within Subthalamo-cortical Loops in Parkinson's Disease|Pathophysiology of Neuronal Oscillations Within Subthalamo-cortical Loops in Parkinson's Disease|Unknown status|Active, not recruiting|N/A|20|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 22:55:44.09093|2018-05-31 22:55:44.09093
NCT01284673|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2016-08-02|2011-01-26|2011-01-27|Estimate|||||||2016-08-02|2016-08-03|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|NEOCORD||Characterization of the Cord Blood Stem Cell in Situation of Neonatal Asphyxia|Characterization of the Cord Blood Stem Cell in Situation of Neonatal Asphyxia|Completed||N/A|10|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 22:55:44.175988|2018-05-31 22:55:44.175988
NCT01284647|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-01-13|2011-01-26|2011-01-27|Estimate|||||||2014-01-13|2014-01-14|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|||A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis|A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis|Completed||Phase 4|156|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 22:55:44.287147|2018-05-31 22:55:44.287147
NCT01284634|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|2013-12-03||2014-09-09|2011-01-26|2011-01-27|Estimate|2013-12-03|2014-01-20|Estimate||||2014-09-09|2014-09-18|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Study to Assess the Effect of Cannabidiol on Liver Fat Levels in Subjects With Fatty Liver Disease.|A Randomised, Partially-blind, Placebo-controlled, Pilot, Dose-ranging Study to Assess the Effect of Cannabidiol on Liver Fat Levels in Subjects With Fatty Liver Disease|Completed||Phase 2|25|Actual|GW Research Ltd||3|||f||||f||||||||||2018-05-31 22:55:44.50958|2018-05-31 22:55:44.50958
NCT01284621|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2014-05-16||2014-06-23|2011-01-26|2011-01-27|Estimate|2014-06-23|2014-07-22|Estimate||||2014-06-23|2014-07-22|Estimate|January 2011||2011-01-31|June 2014|2014-06-30||||March 2011|Actual|2011-03-31||Interventional|||Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers|Relative Bioavailability of Multiple Oral Doses of BI 10773 (25 mg) and Ramipril (5 mg) Administered Together Compared to Multiple Oral Doses of BI 10773 (25 mg) Alone and Ramipril (5 mg) Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Three Way Crossover, Clinical Phase I Study)|Completed||Phase 1|23|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:55:46.446116|2018-05-31 22:55:46.446116
NCT01284608|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-12-21|2011-01-26|2011-01-27|Estimate|||||||2012-12-21|2012-12-24|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|UROCOR||Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)|Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)|Completed|||197|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:55:47.002717|2018-05-31 22:55:47.002717
NCT01284595|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2014-08-12|2011-01-26|2011-01-27|Estimate|||||||2014-08-12|2014-08-13|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931|[14C] AZD8931 - A Phase I, Open Label Study of the Absorption, Metabolism, Excretion, and Pharmacokinetics Following a Single Oral Dose to Healthy Male Subjects|Completed||Phase 1|6|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-05-31 22:55:47.115092|2018-05-31 22:55:47.115092
NCT01284582|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2012-10-04|2011-01-26|2011-01-27|Estimate|||||||2012-10-04|2012-10-05|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)|Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP), in Healthy Male Subjects With High Density Lipoprotein Cholesterol (HDLc) Blood Concentrations Equal or Below 80 mg/dl|Completed||Phase 1|36|Actual|Affiris AG||3|||f||||t||||||||||2018-05-31 22:55:47.180328|2018-05-31 22:55:47.180328
NCT01284569|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2013-02-26|2011-01-26|2011-01-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|March 2011||2011-03-31|December 2012|2012-12-31||||October 2012|Actual|2012-10-31||Interventional|||Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients|A Phase I/II, Randomised, Double-Blind, Placebo Controlled Study, Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Single and Multiple Intravenous Doses of ALX-0061 in Patients With RA|Completed||Phase 1/Phase 2|65|Actual|Ablynx||2|||f||||t||||||||||2018-05-31 22:55:47.250872|2018-05-31 22:55:47.250872
NCT01284556|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2017-11-09|2011-01-26|2011-01-27|Estimate|||||||2017-11-09|2017-11-14|Actual|November 2010||2010-11-30|November 2017|2017-11-30|April 2016|Actual|2016-04-30|January 2013|Actual|2013-01-31||Interventional|||Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures|An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Phenobarbital as Adjunctive Therapy in Participants (> or = 17 to 70 Years Old) With Partial Onset Seizures|Completed||Phase 3|314|Actual|West-Ward Pharmaceutical||3|||f||||t||||||||||2018-05-31 22:55:47.355004|2018-05-31 22:55:47.355004
NCT01284543|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-25|2011-01-25|2011-01-27|Estimate|||||||2011-01-25|2011-01-27|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||January 2012|Anticipated|2012-01-31||Interventional|||Study Comparing Tan EndoGlide With the Busin Glide for Insertion of the Donor Graft in DSAEK|Randomized Prospective Study Comparing Tan EndoGlide With the Busin Glide for Insertion of the Donor Graft in Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|Unknown status|Recruiting|N/A|42|Anticipated|University Health Network, Toronto||2|||f||||||||||||||2018-05-31 22:55:47.439446|2018-05-31 22:55:47.439446
NCT01284530|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25||2013-05-22|2016-05-12|2011-01-25|2011-01-27|Estimate||||2013-06-04|2013-06-12|Estimate|2016-05-12|2016-06-02|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy|Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy|Completed||Phase 1/Phase 2|30|Actual|Supernus Pharmaceuticals, Inc.||4|||f||||||||||||||2018-05-31 22:55:47.5292|2018-05-31 22:55:47.5292
NCT01284517|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2013-08-07||2013-10-31|2011-01-25|2011-01-27|Estimate|2013-08-07|2013-10-14|Estimate||||2013-10-31|2013-11-26|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PREVAIL3|This is the full analysis set (intent-to-treat population)|Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression|A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.|Completed||Phase 3|356|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 22:55:47.622475|2018-05-31 22:55:47.622475
NCT01284504|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2016-10-15||2018-02-19|2011-01-26|2011-01-27|Estimate|2016-10-15|2016-12-08|Estimate||||2018-02-19|2018-03-16|Actual|January 2011||2011-01-31|February 2018|2018-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer|The Effect Of Celecoxib On The Perioperative Inflammatory Response In Colon Cancer Patients - A Double-Blind Placebo-Controlled Trial|Terminated||N/A|1|Actual|Stanford University||2||low accrual rate; the only participant withdrew after signing consent|f||||t||||||||No||2018-05-31 22:55:48.140353|2018-05-31 22:55:48.140353
NCT01284491|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2012-11-29||2013-01-03|2011-01-26|2011-01-27|Estimate|2012-11-29|2013-01-03|Estimate||||2013-01-03|2013-01-08|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PRECISE||A Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0|A Prospective, Randomized, Controlled Study to Evaluate Cutaneous Scar Quality Following Bilateral Breast Reduction With the PEAK PlasmaBlade 4.0|Terminated||N/A|13|Actual|Medtronic Surgical Technologies|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.|2||Termination due to acquisition of PEAK Surgical by Medtronic|f||||f||||||||||2018-05-31 22:55:48.343467|2018-05-31 22:55:48.343467
NCT01284478|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2012-10-03|2011-01-25|2011-01-27|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery|Phase 2 Study of Ozurdex for Combined Pseudophakic Cystoid Macula Edema and Diabetic Macula Edema After Cataract Surgery|Completed||Phase 2|6|Actual|Northern California Retina Vitreous Associates||1|||f||||f||||||||||2018-05-31 22:55:48.460631|2018-05-31 22:55:48.460631
NCT01284465|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2015-04-06|2011-01-25|2011-01-27|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Type 2 Diabetes Self-management Intervention for Low-income Women|A Comprehensive Approach to Type 2 Diabetes Self-management for Low-income Women|Completed||N/A|56|Actual|Meharry Medical College||2|||f||||f||||||||||2018-05-31 22:55:48.527948|2018-05-31 22:55:48.527948
NCT01284452|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-04-17|2011-01-26|2011-01-27|Estimate|||||||2015-04-17|2015-04-20|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy of Hydrocortisone in Treatment of Severe Sepsis/Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Efficacy of Moderate Dose Hydrocortisone in Treatment of Severe Sepsis and Septic Shock Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome: A Randomized Controlled Trial|Completed||N/A|197|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 22:55:48.589978|2018-05-31 22:55:48.589978
NCT01284439|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-26|2011-01-26|2011-01-27|Estimate|||||||2011-01-26|2011-01-27|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|February 2012|Anticipated|2012-02-29|January 2012|Anticipated|2012-01-31||Interventional|||Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma|Effect of Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% in the Treatment of Ocular Surface Disease in Glaucoma Patients|Unknown status|Recruiting|N/A|120|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 22:55:48.662104|2018-05-31 22:55:48.662104
NCT01284426|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2015-08-21||2015-12-30|2011-01-25|2011-01-27|Estimate|2015-12-30|2016-02-01|Estimate||||2015-12-30|2016-02-01|Estimate|March 2003||2003-03-31|December 2015|2015-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|NHCU|Remission period, chronic urticaria|Natural History of Chronic Urticaria|The Natural History of Chronic Urticaria in Childhood: A Prospective Study|Completed|||94|Actual|Mahidol University|This study did not perform basophil histamine releasing assay to identify the existence of functional autoantibodies, since there was no available laboratory to do this test.||1||f||||f||||||||||2018-05-31 22:55:48.781545|2018-05-31 22:55:48.781545
NCT01284413|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2014-06-29|2011-01-25|2011-01-27|Estimate|||||||2014-06-29|2014-07-01|Estimate|December 2010||2010-12-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|||Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer|Phase I/II Study of Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer|Completed||Phase 1/Phase 2|68|Actual|Kansai Hepatobiliary Oncology Group||1|||f||||t||||||||||2018-05-31 22:55:48.889323|2018-05-31 22:55:48.889323
NCT01284400|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-05-31|2011-01-26|2011-01-27|Estimate|||||||2011-05-31|2011-06-02|Estimate|January 2007||2007-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Home-based Disease Management Program to Improve Clinical Outcomes in Patients With Heart Failure|The Japanese Heart Failure Outpatients Disease Management and Cardiac Evaluation (J-HOMECARE)|Completed||Phase 3|156|Anticipated|Japanese Heart Failure Outpatient Disease Management Evaluation Investigators||2|||f||||t||||||||||2018-05-31 22:55:48.961845|2018-05-31 22:55:48.961845
NCT01284387|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20||2014-12-11|2014-12-11|2011-01-25|2011-01-27|Estimate||||2014-12-11|2015-01-05|Estimate|2014-12-11|2015-01-05|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|ACCTION||Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease|A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|126|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||3|||f||||t||||||||||2018-05-31 22:55:49.015939|2018-05-31 22:55:49.015939
NCT01284374|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2012-12-13|2011-01-25|2011-01-27|Estimate|||||||2012-12-13|2012-12-17|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Parent-son-provider Decision-making About HPV Vaccination|An Investigation of Parent-son-provider Decision-making About HPV Vaccination|Completed|||62|Actual|Indiana University|||3||f||||f||||||||||2018-05-31 22:55:49.099103|2018-05-31 22:55:49.099103
NCT01284361|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2013-12-02||2016-12-02|2011-01-25|2011-01-27|Estimate|2016-10-10|2016-12-01|Estimate||||2016-12-02|2017-02-01|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Each subject was given 10 Control catheters and 10 Test catheters to be used consecutively until all 20 catheters were used. Subjects used either the Test catheters (A) first and then the Control catheters (B) or vice versa. Subjects completed questionnaire after using each catheter and a preference questionnaire after all catheters were used.|Comparison of Two Intermittent Urinary Catheters|User Preference Study to Compare a 40cm Intermittent Catheter to a 30cm Intermittent Catheter|Completed||N/A|91|Actual|Hollister Incorporated|Male catheter users only in USA only.|2|||f||||f||||||||Yes|Published in Spinal Cord (2013) 51, 772-775|2018-05-31 22:55:49.22841|2018-05-31 22:55:49.22841
NCT01284348|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17||2014-08-21|2017-11-14|2011-01-25|2011-01-27|Estimate||||2014-08-27|2014-08-29|Estimate|2017-11-14|2017-11-17|Actual|January 2011||2011-01-31|November 2017|2017-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer|An Open-Label Randomized, Phase 2A, Dose-ranging Study of Sotatercept (ACE-011) for Chemotherapy-Induced Anemia in Subjects With Advanced or Metastatic Solid Tumors Treated With Platinum-Based Chemotherapeutic Regimens|Terminated||Phase 2|25|Actual|Celgene||2||Persistent low enrollment made study continuation no longer feasible|f||||t||||||||||2018-05-31 22:55:49.461467|2018-05-31 22:55:49.461467
NCT01284335|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2016-08-25|2011-01-26|2011-01-27|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|October 2012|Actual|2012-10-31||Interventional|||A Safety Study in Patients With Advanced Solid Tumors|A Phase 1 Multicenter, Dose-escalation Study of LY573636-Sodium in Combination With 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients With Advanced Solid Tumors|Completed||Phase 1|234|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 22:55:49.631088|2018-05-31 22:55:49.631088
NCT01284322|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2014-07-15|2011-01-26|2011-01-27|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Interventional|||Fresolimumab In Systemic Sclerosis|OPEN LABEL TRIAL OF ANTI-TGF-BETA MAB, FRESOLIMUMAB, IN SYSTEMIC SCLEROSIS - A PHASE ONE BIOMARKER TRIAL|Completed||Phase 1|18|Actual|Boston University||1|||f||||t||||||||||2018-05-31 22:55:49.77094|2018-05-31 22:55:49.77094
NCT01284309|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-12-10|2011-01-25|2011-01-27|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects|A Phase 1b, Randomized, Double-Masked, Parallel Group, Placebo Controlled Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects|Completed||Phase 1|321|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:55:49.840779|2018-05-31 22:55:49.840779
NCT01284296|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2012-04-03||2012-05-18|2011-01-25|2011-01-26|Estimate|2012-04-03|2012-04-04|Estimate||||2012-05-18|2012-05-28|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Three Methods of Hemoglobin Monitoring|Comparison of Three Methods of Hemoglobin Monitoring in Patients Undergoing Spine or Hip Surgery|Completed||N/A|20|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 22:55:49.927776|2018-05-31 22:55:49.927776
NCT01284283|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2018-04-05|2011-01-25|2011-01-26|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2009||2009-11-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|STAR 2 PAS||2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use|2-Year Post-Approval Study to Investigate the STAR Ankle Under Actual Conditions of Use|Recruiting||N/A|98|Anticipated|Stryker Trauma GmbH||1|||f||||f|f|t|f|f||||No||2018-05-31 22:55:50.084788|2018-05-31 22:55:50.084788
NCT01284270|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2013-09-04|2011-01-25|2011-01-26|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2011||2011-01-31|June 2011|2011-06-30||||January 2013|Anticipated|2013-01-31||Interventional|Hawaii||Lipid Rich Necrotic Core Lesion Detected by Cardiac Magnetic Resonance Imaging (CMR)|High Amount of Lipid Rich Necrotic Core Lesion Identified by Pre-interventional Intravascular Ultrasound (IVUS) is Associated With High Rate of Delayed Hyper-enhancement as Detected by Contrast-enhanced Cardiac Magnetic Resonance Imaging|Withdrawn||N/A|0|Actual|Piedmont Healthcare||1||Study not to be initiated|f||||f||||||||||2018-05-31 22:55:50.187741|2018-05-31 22:55:50.187741
NCT01284257|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2017-02-23|2011-01-25|2011-01-26|Estimate|||||||2017-02-23|2017-02-27|Actual|June 2007|Actual|2007-06-30|February 2017|2017-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|MORE registry||Observational Registry Study of Renal Transplant Patients|A Phase IV, Non-interventional, Multi-center, Open-label, Prospective, Observational Study of the Safety, Effectiveness, Tolerability and Compliance of Immunosuppressive Regimens Using Mycophenolic Acid to Treat de Novo Renal Transplant Patients in Routine Clinical Practice|Withdrawn|||0|Actual|Novartis|||2||f||||f||||||||||2018-05-31 22:55:50.259352|2018-05-31 22:55:50.259352
NCT01284244|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2016-12-17||2017-02-12|2011-01-25|2011-01-26|Estimate|2017-02-12|2017-03-31|Actual||||2017-02-12|2017-03-31|Actual|January 2011||2011-01-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|SURE||A Randomized Controlled Trial of the Uresta Continence Pessary|A Randomized Controlled Trial of the Uresta Continence Pessary; Short-term Uresta Efficacy Study (SURE Study)|Completed||N/A|36|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:55:50.33959|2018-05-31 22:55:50.33959
NCT01284231|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-03-02|2011-01-25|2011-01-26|Estimate|||||||2015-03-02|2015-03-03|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas|A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas|Completed||Phase 1|78|Actual|MedImmune LLC||4|||f||||f||||||||||2018-05-31 22:55:50.518857|2018-05-31 22:55:50.518857
NCT01284218|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-11-07|2011-01-25|2011-01-26|Estimate|||||||2013-11-07|2013-11-08|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)|Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)|Completed|||23514|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||5||f||||f||||||||||2018-05-31 22:55:50.769425|2018-05-31 22:55:50.769425
NCT01284205|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2014-08-28|2011-01-25|2011-01-26|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|February 2017|Anticipated|2017-02-28|February 2014|Anticipated|2014-02-28||Interventional|||First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC|Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression|Withdrawn||Phase 3|0|Actual|Bioniche Life Sciences Inc.||2||This indication is not being pursued at this point in time.|t||||t||||||||||2018-05-31 22:55:50.822554|2018-05-31 22:55:50.822554
NCT01284192|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2016-06-27|2011-01-25|2011-01-26|Estimate|||||||2016-06-27|2016-06-28|Estimate|December 2010||2010-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|February 2014|Actual|2014-02-28||Interventional|||Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)|A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects With Advanced Malignancies|Completed||Phase 1|46|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 22:55:50.892709|2018-05-31 22:55:50.892709
NCT01284179|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2016-12-19|2011-01-25|2011-01-26|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2011||2011-02-28|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study|Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study|Terminated||N/A|8|Actual|University of North Carolina, Chapel Hill||2||Unable to enroll|f||||t||||||||||2018-05-31 22:55:50.954476|2018-05-31 22:55:50.954476
NCT01284166|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-07-17|2011-01-25|2011-01-26|Estimate|||||||2013-07-17|2013-07-18|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension||Withdrawn||Phase 3|0|Actual|Allergan||1||"Study was never initiated due to company decision. No study subjects were ever enrolled or~   treated."|f||||f||||||||||2018-05-31 22:55:51.01315|2018-05-31 22:55:51.01315
NCT01284153|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-02-03|2011-01-25|2011-01-26|Estimate|||||||2011-02-03|2011-02-04|Estimate|January 2011||2011-01-31|February 2011|2011-02-28||||||||Observational|||Potential Benefits of Radiotherapy in Prone Position for Breast Cancer Patients: a Planning Study|A Comparison of Three Radiotherapy Techniques for Breast Cancer: a Planning Study|Unknown status|Recruiting||30|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 22:55:51.069669|2018-05-31 22:55:51.069669
NCT01284140|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2018-03-23||2018-05-03|2011-01-25|2011-01-26|Estimate|2018-05-03|2018-05-07|Actual||||2018-05-03|2018-05-07|Actual|January 2011||2011-01-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||Subjects with 24-hour urinary 6-sulfatoxymelatonin profiles from both Day 1 and Day 3 were analyzed (11 subjects out of a total of 22). One of the remaining subjects had an unevaluable profile from Day 1. The remaining subjects died or had their urinary catheter removed prior to Day 3.|Improving the Sleep and Circadian Rhythms of Mechanically Ventilated Patients|Improving the Sleep and Circadian Rhythms of Mechanically Ventilated Patients|Completed||N/A|24|Actual|University of Iowa|Lower dose light intervention received by one subject; the study design resulted in significant attrition, limiting the number of evaluable patients; baseline differences in the timing of maximal melatonin excretion may have influenced the results.|2|||f||||t||||||||Undecided||2018-05-31 22:55:52.134346|2018-05-31 22:55:52.134346
NCT01284127|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2018-01-08|2011-01-25|2011-01-26|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2012||2012-03-31|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Observational|||Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis|Phase IV Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis|Completed|||38|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 22:55:52.621705|2018-05-31 22:55:52.621705
NCT01284114|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2012-07-05||2012-09-19|2011-01-25|2011-01-26|Estimate|2012-09-19|2012-10-22|Estimate||||2012-09-19|2012-10-22|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients|Effects of Aliskiren on Blood Pressure, Heart and Kidney in Elderly Hypertensive Chronic Kidney Disease Patients|Completed||Phase 4|23|Actual|Jichi Medical University||1|||f||||f||||||||||2018-05-31 22:55:52.728097|2018-05-31 22:55:52.728097
NCT01284101|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-25|2011-01-25|2011-01-26|Estimate|||||||2011-01-25|2011-01-26|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||January 2012|Anticipated|2012-01-31||Interventional|||Prospective Randomized Study Comparing Endothelial Cell Loss Using the Tan EndoGlide With Forceps for Insertion of the Donor Graft in DSAEK|Prospective Randomized Study Comparing Endothelial Cell Loss Using the Tan EndoGlide With Forceps for Insertion of the Donor Graft in DSAEK|Unknown status|Recruiting|N/A|42|Anticipated|University Health Network, Toronto||2|||f||||||||||||||2018-05-31 22:55:52.969474|2018-05-31 22:55:52.969474
NCT01284088|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2012-03-14|2011-01-25|2011-01-26|Estimate|||||||2012-03-14|2012-03-15|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Setting|A Prospective, Randomized, Open Label, Trial Comparing the PrePex™ Device to Surgical Circumcision for Rapid Scale Up of Male Circumcision in Resource Limited Settings|Completed||N/A|217|Actual|Ministry of Health, Rwanda||2|||f||||t||||||||||2018-05-31 22:55:53.15343|2018-05-31 22:55:53.15343
NCT01284075|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2014-08-21|2011-01-25|2011-01-26|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery|The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery|Terminated||N/A|10|Actual|University of Minnesota - Clinical and Translational Science Institute||3||Low accrual|f||||f||||||||||2018-05-31 22:55:53.338953|2018-05-31 22:55:53.338953
NCT01284062|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2014-11-10|2013-05-23|2014-11-10|2011-01-25|2011-01-26|Estimate|2014-11-10|2014-11-18|Estimate|2013-05-23|2013-06-05|Estimate|2014-11-10|2014-11-18|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Analysis population included all randomized participants.|Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients|A Phase 2a, Randomized, Double-blind, Sponsor Unblinded, Placebo-controlled, Multiple Dose Study To Evaluate The Pharmacodynamics, Pharmacokinetics And Safety Of Anrukinzumab In Subjects With Active Ulcerative Colitis|Completed||Phase 2|84|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:55:53.554928|2018-05-31 22:55:53.554928
NCT01284049|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2016-03-29|2011-01-25|2011-01-26|Estimate|||||||2016-03-29|2016-03-30|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Interventional|MEGANORM||Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease|Study in Adults on HPN Who Have Developed PNALD Comparing Equivalent Doses of Two Lipid Emulsions: OMEGAVEN 10%®, Enriched in n-3 EFA, and a Standard Lipid Emulsion, Intralipid 20%® Not Enriched in n-3 EFA + Vitamin E Supplement|Completed||N/A|31|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:55:55.056466|2018-05-31 22:55:55.056466
NCT01284036|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2013-01-30|2011-01-25|2011-01-26|Estimate|||||||2013-01-30|2013-01-31|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|FIH||A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects|Ascending Single Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of PF-05230905 Administered Subcutaneously Or Intravenously To Healthy Subjects|Completed||Phase 1|63|Actual|Ablynx||1|||f||||f||||||||||2018-05-31 22:55:55.1339|2018-05-31 22:55:55.1339
NCT01284023|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2017-03-15|2011-01-25|2011-01-26|Estimate|||||||2017-03-15|2017-03-17|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|August 2011|Actual|2011-08-31||Observational|||Use of Near Infrared Spectroscopy to Detect Muscle Perfusion in the Lower Extremity of Uninjured Subjects|Use of Near Infrared Spectroscopy to Detect Muscle Perfusion in the Lower Extremity of Uninjured Subjects|Active, not recruiting|||42|Anticipated|J&M Shuler|||1||f||||f||||||||||2018-05-31 22:55:55.243817|2018-05-31 22:55:55.243817
NCT01284010|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2017-08-07|2011-01-25|2011-01-26|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2011||2011-02-28|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia|Genome-Wide Analysis of Genetic Alterations in Adult Acute Lymphoblastic Leukemia|Active, not recruiting|||200|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-05-31 22:55:55.307601|2018-05-31 22:55:55.307601
NCT01283997|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2018-01-08|2011-01-25|2011-01-26|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2011|Actual|2011-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Prevention of Treatment Induced Neuropathy in Multiple Myeloma|A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma|Active, not recruiting||Phase 2|142|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 22:55:55.385978|2018-05-31 22:55:55.385978
NCT01283984|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-08-17|2011-01-25|2011-01-26|Estimate|||||||2011-08-17|2011-08-18|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||AZD2115 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD2115 After Single Ascending Doses in Healthy Male Subjects|Completed||Phase 1|96|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 22:55:55.468811|2018-05-31 22:55:55.468811
NCT01283971|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|2013-10-07||2014-01-09|2011-01-25|2011-01-26|Estimate|2014-01-09|2014-02-10|Estimate||||2014-01-09|2014-02-10|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor|A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor|Terminated||Phase 4|96|Actual|Hoffmann-La Roche|Data interpretation was limited by the very small sample size (enrollment 1/7 of planned sample size; not powered for formal statistical analysis) and the open-label observation (study un-blinded following protocol amendment to terminate enrollment).|2||The study was closed due to the slow enrollment rate.|f||||||||||||||2018-05-31 22:55:55.620433|2018-05-31 22:55:55.620433
NCT01283958|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-25|2011-01-25|2011-01-26|Estimate|||||||2011-01-25|2011-01-26|Estimate|September 2007||2007-09-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|||||Observational|||The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome|Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome|Completed|||12|Actual|Gachon University Gil Medical Center|||||f||||||||||||||2018-05-31 22:55:56.423234|2018-05-31 22:55:56.423234
NCT01283945|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2018-04-10|2011-01-25|2011-01-26|Estimate|||||||2018-04-10|2018-04-12|Actual|July 2010||2010-07-31|April 2018|2018-04-30|May 4, 2017|Actual|2017-05-04|September 2016|Actual|2016-09-30||Interventional|||Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors|An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours|Completed||Phase 1/Phase 2|134|Actual|Servier||1|||f||||f||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 22:55:56.489604|2018-05-31 22:55:56.489604
NCT01283932|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-25|2011-01-25|2011-01-26|Estimate|||||||2011-01-25|2011-01-26|Estimate|October 2004||2004-10-31|January 2011|2011-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fed Condition|A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed Release Tablets (Wyeth Laboratories, USA) in Healthy, Adult, Human Subjects Under Fed Conditions.|Completed||Phase 1|52|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:55:56.579482|2018-05-31 22:55:56.579482
NCT01283919|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-25|2011-01-25|2011-01-26|Estimate|||||||2011-01-25|2011-01-26|Estimate|October 2004||2004-10-31|January 2011|2011-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Bioequivalence Study of Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition|A Randomized, Two-treatment, Two-period, Two-sequence,Single Dose, Crossover Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets (Dr. Reddy's Laboratories Ltd, India) to be Compared With Protonix® 40 mg (Pantoprazole Sodium) Delayed Release Tablets (Wyeth Laboratories, USA) in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|42|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:55:56.649321|2018-05-31 22:55:56.649321
NCT01283906|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-09-10|2011-01-25|2011-01-26|Estimate|||||||2013-09-10|2013-09-12|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|MuGard||A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients|A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck|Completed||Phase 4|120|Anticipated|Access Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 22:55:56.73974|2018-05-31 22:55:56.73974
NCT01283893|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2013-06-01|2011-01-25|2011-01-26|Estimate|||||||2013-06-01|2013-06-04|Estimate|December 2010||2010-12-31|June 2013|2013-06-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Standardization of D2 Lymphadenectomy and Surgical Quality Control: KLASS-02-QC|Standardization of D2 Lymphadenectomy and Surgical Quality Control for KLASS-02 Trial: KLASS-02-QC|Unknown status|Recruiting||160|Anticipated|Yonsei University|||2||f||||t||||||||||2018-05-31 22:55:56.839321|2018-05-31 22:55:56.839321
NCT01283880|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2012-05-29|2011-01-25|2011-01-26|Estimate|||||||2012-05-29|2012-05-30|Estimate|May 2012||2012-05-31|January 2011|2011-01-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Renal Tubular Acidosis in Incident Renal Transplant Recipients|Renal Tubular Acidosis in Incident Renal Transplant Recipients|Unknown status|Recruiting||50|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 22:55:56.937182|2018-05-31 22:55:56.937182
NCT01283867|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2011-01-25|2011-01-25|2011-01-26|Estimate|||||||2011-01-25|2011-01-26|Estimate|November 2007||2007-11-30|January 2011|2011-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet of Dr. Reddy's Laboratories Limited Comparing With That of Cellcept 500 mg Tablet of Roche Laboratories in Healthy, Adult,Human, Male Subjects Under Non-fasting Conditions.|Completed||Phase 1|92|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:55:57.012964|2018-05-31 22:55:57.012964
NCT01283854|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2015-02-27|2011-01-25|2011-01-26|Estimate|||||||2015-02-27|2015-03-02|Estimate|June 2011||2011-06-30|November 2014|2014-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Cycle Study: a Study of the Effectiveness of Cycling Exercise in Breaking the Cycle of Pregnancy Diabetes|Preventing Gestational Diabetes Mellitus Using a Home-based Supervised Exercise Program During Pregnancy|Completed||N/A|172|Actual|The University of Western Australia||2|||f||||t||||||||||2018-05-31 22:55:57.084116|2018-05-31 22:55:57.084116
NCT01283841|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-25|2011-01-25|2011-01-26|Estimate|||||||2011-01-25|2011-01-26|Estimate|November 2007||2007-11-30|January 2011|2011-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Four-period, Two Sequence, Single Dose, Replicate, Crossover, Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablet of Dr. Reddy's Laboratories Limited Comparing With That of Cellcept 500 mg Tablet of Roche Laboratories in Healthy, Adult,Human, Male Subjects Under Fasting Conditions.|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:55:57.176571|2018-05-31 22:55:57.176571
NCT01283828|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-10-04|2011-01-25|2011-01-26|Estimate|||||||2013-10-04|2013-10-07|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age in the United States|Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age in the United States|Completed|||4977|Actual|Gynuity Health Projects|||||f||||t||||||Samples With DNA|"~     Vaginal and rectal swabs~   "|||2018-05-31 22:55:57.258619|2018-05-31 22:55:57.258619
NCT01283815|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2014-09-21|2011-01-25|2011-01-26|Estimate|||||||2014-09-21|2014-09-23|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Laparoscopic Management of Periappendicular Abscess|Laparoscopic Management of Periappendicular Abscess - Randomized Controlled Trial|Completed||Phase 2|60|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 22:55:57.333159|2018-05-31 22:55:57.333159
NCT01283802|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-25|2011-01-25|2011-01-26|Estimate|||||||2011-01-25|2011-01-26|Estimate|June 2004||2004-06-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|||||Observational|IOCUS||Intraoperative Cholangio-Ultrasound in Resective Liver Surgery|More Than 400 Hepatectomies Without Intraoperative Cholangiography: Prospective Validation of the Role of Ultrasound|Completed|||448|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 22:55:57.402153|2018-05-31 22:55:57.402153
NCT01283789|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2017-02-06|2011-01-25|2011-01-26|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2011||2011-02-28|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|April 2016|Actual|2016-04-30||Interventional|||Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer|Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer|Active, not recruiting||Phase 2|23|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 22:55:57.475341|2018-05-31 22:55:57.475341
NCT01283776|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2014-06-08|2011-01-25|2011-01-26|Estimate|||||||2014-06-08|2014-06-10|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|OCTET-CY||Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation|A Phase II Study to Investigate the Efficacy of Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation|Completed||Phase 2|11|Actual|University of Cologne||1|||f||||f||||||||||2018-05-31 22:55:57.550187|2018-05-31 22:55:57.550187
NCT01283763|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-10-30|2011-01-25|2011-01-26|Estimate|||||||2016-10-30|2016-11-01|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|ITIC2||Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia|ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial|Terminated||Phase 3|95|Actual|Medical University of Vienna||2||poor recruitment|f||||t||||||||||2018-05-31 22:55:57.628729|2018-05-31 22:55:57.628729
NCT01283750|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2014-06-11|2011-01-25|2011-01-26|Estimate|||||||2014-06-11|2014-06-12|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Maximizing Independence at Home (MIND at Home)|Maximizing Independence at Home (MIND at Home): Dementia Care at Home Study|Completed||Phase 2/Phase 3|303|Actual|Johns Hopkins University||1|||f||||||||||||||2018-05-31 22:55:57.698324|2018-05-31 22:55:57.698324
NCT01283737|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2012-06-25|2011-01-25|2011-01-26|Estimate|||||||2012-06-25|2012-06-26|Estimate||||June 2012|2012-06-30||||||||Interventional|||Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD)|A Randomized, Subject-blind, Controlled Pilot Trial to Evaluate the Effectiveness and Safety of the Use of Demineralized Bone Matrix (DBX®) Versus Mosaicplasty in the Treatment of Late-Stage Osteochondritis Dissecans (OCD) of the Knee in Patients With a Mature Skeleton|Withdrawn||Phase 4|0|Actual|Synthes GmbH||2|||f||||f||||||||||2018-05-31 22:55:57.854779|2018-05-31 22:55:57.854779
NCT01283724|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2015-08-12|2011-01-25|2011-01-26|Estimate|||||||2015-08-12|2015-08-13|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|March 2013|Actual|2013-03-31||Interventional|VISADO||Visanne Study to Assess Safety in Adolescents|A Multi-center, Open Label, Single-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of 2 mg Dienogest Tablets for the Treatment of Endometriosis in Adolescents Over a Treatment Period of 52 Weeks|Completed||Phase 2|111|Actual|Bayer||1|||f||||f||||||||||2018-05-31 22:55:57.990446|2018-05-31 22:55:57.990446
NCT01283711|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-05-16|2011-01-25|2011-01-26|Estimate|||||||2013-05-16|2013-05-17|Estimate|March 2011||2011-03-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Safety and Efficacy of the Apollo™ System for Treatment of Wrinkles and Rhytides|Evaluation of Safety and Efficacy of the Apollo™ System for Treatment of Wrinkles and Rhytides|Completed||N/A|37|Actual|Pollogen||1|||f||||f||||||||||2018-05-31 22:55:58.114586|2018-05-31 22:55:58.114586
NCT01283698|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2015-05-28|2011-01-25|2011-01-26|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Clinical Trial to Investigate Efficacy of LAS41004 in Psoriasis|An Investigator-blind, Controlled Study to Assess the Efficacy of Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test|Completed||Phase 2|20|Anticipated|Almirall, S.A.||5|||f||||f||||||||||2018-05-31 22:55:58.18477|2018-05-31 22:55:58.18477
NCT01283685|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2012-07-10|2011-01-24|2011-01-26|Estimate|||||||2012-07-10|2012-07-11|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Breathing Helium-Hyperoxia During Exercise in Patients With Chronic Obstructive Pulmonary Disease|Does Breathing Helium-Hyperoxia Increase the Tolerance of One-Legged Exercise in Ventilatory Limited Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|15|Actual|West Park Healthcare Centre|||||f||||f||||||||||2018-05-31 22:55:58.258004|2018-05-31 22:55:58.258004
NCT01283672|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-07-15|2011-01-24|2011-01-26|Estimate|||||||2011-07-15|2011-07-18|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Acute Heart Health Benefits of Whole Grain Barley and Oats in Healthy Men and Women||Completed||N/A|18|Anticipated|USDA Beltsville Human Nutrition Research Center|||||f||||t||||||||||2018-05-31 22:55:58.331487|2018-05-31 22:55:58.331487
NCT01283659|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2018-05-28|2011-01-24|2011-01-26|Estimate|||||||2018-05-28|2018-05-30|Actual|February 2011||2011-02-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|CTA-HF||IMAGE-HF Project I-C: Computed Tomographic Coronary Angiography for Heart Failure Patients|Computed Tomographic Coronary Angiography for Heart Failure Patients (CTA -HF) Project I-C of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)|Active, not recruiting||N/A|253|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 22:55:58.393451|2018-05-31 22:55:58.393451
NCT01283646|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-25|||2013-03-01|2011-01-25|2011-01-26|Estimate|||||||2013-03-01|2013-03-04|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|Inappetence||Efficacy and Tolerability of Apevitin BC Comparing to Vitamin Complex in Stimulating the Appetite|Multicenter Clinical Study, Phase III, Randomized, Double-blind, of Prospectively Evaluate the Effectiveness and Tolerability of Apevitin BC Comparing to Vitamin Complex in Appetite Stimulation|Completed||Phase 3|51|Actual|EMS||2|||f||||t||||||||||2018-05-31 22:55:58.513417|2018-05-31 22:55:58.513417
NCT01283633|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-03-09|2011-01-25|2011-01-26|Estimate|||||||2012-03-09|2012-03-12|Estimate|February 2011||2011-02-28|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Investigation of the Use of Remote Presence Robots in Delivery of Neuromodulation|Investigation of the Use of Remote Presence Robots in the Administration of Neuromodulation Treatment|Completed||Phase 4|30|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 22:55:58.588132|2018-05-31 22:55:58.588132
NCT01283620|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2015-05-06|2011-01-25|2011-01-26|Estimate|||||||2015-05-06|2015-05-07|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Atlantic Canada Modified Constraint Induced Movement Therapy Trial|Atlantic Canada Modified Constraint Induced Movement Therapy Trial|Completed||N/A|14|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 22:55:58.662578|2018-05-31 22:55:58.662578
NCT01283607|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2013-11-14|2011-01-24|2011-01-26|Estimate|||||||2013-11-14|2013-11-18|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||E-health Cognitive Behavioral Therapy in Women Treated by in Vitro Fertilization (IVF)|Treatment of Depression and Anxiety by an E-health Cognitive Behavioral Therapy (Digicoach) in Women Treated by in Vitro Fertilization (IVF)|Completed||N/A|120|Actual|University Medical Center Nijmegen||2|||f||||t||||||||||2018-05-31 22:55:58.735484|2018-05-31 22:55:58.735484
NCT01283594|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24||2014-01-21|2017-08-03|2011-01-24|2011-01-26|Estimate||||2014-01-21|2014-02-14|Estimate|2017-08-03|2017-08-08|Actual|March 2011||2011-03-31|May 2014|2014-05-31||||October 2012|Actual|2012-10-31||Interventional|||Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off|A Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of SYN115 as Adjunctive Therapy in Levodopa-treated Parkinson's Subjects With End of Dose Wearing Off|Completed||Phase 2/Phase 3|420|Actual|Biotie Therapies Inc.||5|||f||||f||||||||||2018-05-31 22:55:58.824373|2018-05-31 22:55:58.824373
NCT01283581|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2013-08-23||2013-10-29|2011-01-25|2011-01-26|Estimate|2013-08-23|2013-10-29|Estimate||||2013-10-29|2013-11-21|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||ITT (intent-to-treat) population, defined as all subjects who were randomized.|A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections|A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid|Completed||Phase 2|256|Actual|Melinta Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 22:55:59.031112|2018-05-31 22:55:59.031112
NCT01283568|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-11-25|2011-01-25|2011-01-26|Estimate|||||||2011-11-25|2011-11-29|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Observational|GH||Safety and Efficacy Study of Gamaline+Hipericin in PMS|Phase IV Study of Combined GAMALINE and HIPERICIN for Treating Pre-Menstrual Syndrome and Vasomotor Symptoms|Unknown status|Recruiting||240|Anticipated|Phytopharm Consulting Brazil|||4||f||||t||||||||||2018-05-31 22:55:59.631248|2018-05-31 22:55:59.631248
NCT01283555|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2012-02-16||2012-07-10|2011-01-24|2011-01-26|Estimate|2012-05-21|2012-06-22|Estimate||||2012-07-10|2012-07-16|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparative Safety Study of Two Vaginal Applicators With Tenofovir|Comparative Safety Study of Pre-Filled Plastic and User-Filled Paper Vaginal Applicators With Candidate Microbicide, Tenofovir|Completed||N/A|25|Actual|PATH|Due to an error in the interpretation of the user instructions and resulting depth of plunger insertion into the barrel by the participants, the dose delivery data for the prefilled applicator were not valid.|2|||f||||f||||||||||2018-05-31 22:55:59.721104|2018-05-31 22:55:59.721104
NCT01283542|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2018-05-10|2011-01-25|2011-01-26|Estimate|||||||2018-05-10|2018-05-16|Actual|November 26, 2012|Actual|2012-11-26|May 2018|2018-05-31|May 5, 2016|Actual|2016-05-05|May 5, 2016|Actual|2016-05-05||Interventional|Passion I||Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.|An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma|Completed||Phase 2|20|Actual|Novartis||1|||f|||||f|f||||||Undecided||2018-05-31 22:56:00.218176|2018-05-31 22:56:00.218176
NCT01283529|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2016-08-29|2011-01-25|2011-01-26|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|February 2014|Actual|2014-02-28||Observational|||Reference Values for Pulse Induced Continuous Cardiac Output (PiCCO) Variables in Children|Reference Values for Cardiac Output and Blood Volume Variables in Children With Normal Cardiac Function Measured Under General Anesthesia.|Completed|||31|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 22:56:00.309464|2018-05-31 22:56:00.309464
NCT01283516|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2014-05-29||2017-02-07|2011-01-24|2011-01-26|Estimate|2014-07-18|2014-08-11|Estimate||||2017-02-07|2017-03-16|Actual|January 2011||2011-01-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|October 2013|Actual|2013-10-31||Interventional||Full Analysis Set (FAS) consisted of all patients (including NSCLC and non-NSCLC) who received at least one dose of LDK378. Patients were classified according to the intended treatment dose group.|A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase|A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)|Completed||Phase 1|304|Actual|Novartis||3|||f||||f||||||||||2018-05-31 22:56:00.466281|2018-05-31 22:56:00.466281
NCT01283503|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-04-20|2011-01-24|2011-01-26|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2009||2009-10-31|April 2016|2016-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors|A Phase I Study of BKM120, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|15|Actual|Novartis||1|||f||||f||||||||||2018-05-31 22:56:04.901138|2018-05-31 22:56:04.901138
NCT01283490|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2016-11-18|2011-01-24|2011-01-26|Estimate|||||||2016-11-18|2016-11-21|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Sonophoresis on Topical Anesthesia: A Pilot Study|The Effect of Sonophoresis on Topical Anesthesia: a Clinical Trial|Completed||Phase 1|50|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 22:56:05.15903|2018-05-31 22:56:05.15903
NCT01283477|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2012-03-26|2011-01-25|2011-01-26|Estimate|||||||2012-03-26|2012-03-27|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery|Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery|Completed||N/A|44|Actual|Letterkenny General Hospital||2|||f||||f||||||||||2018-05-31 22:56:06.168036|2018-05-31 22:56:06.168036
NCT01283464|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2013-04-12||2016-03-07|2011-01-24|2011-01-26|Estimate|2013-07-19|2013-08-20|Estimate||||2016-03-07|2016-04-04|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles|Double-blinded, Single-center, Parallel-arm Comparison Study of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage|Completed||Phase 2|24|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 22:56:06.280248|2018-05-31 22:56:06.280248
NCT01283451|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2015-09-04|2011-01-25|2011-01-26|Estimate|||||||2015-09-04|2015-09-09|Estimate|January 2010||2010-01-31|September 2015|2015-09-30||||December 2016|Anticipated|2016-12-31||Observational|||Ability of Near Infrared Spectroscopy to Isolate Compartments of the Extremity|Ability of Near Infrared Spectroscopy to Isolate Compartments of the Extremity|Unknown status|Active, not recruiting||63|Anticipated|J&M Shuler|||1||f||||f||||||||||2018-05-31 22:56:06.666008|2018-05-31 22:56:06.666008
NCT01283438|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2018-03-06|2011-01-25|2011-01-26|Estimate|||||||2018-03-06|2018-03-07|Actual|December 17, 2010|Actual|2010-12-17|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2016|Actual|2016-10-31||Interventional|||A Prospective, Randomized, Multicenter Study to Demonstrate the Superiority of the Barricaid to Discectomy for Primary Lumbar Disc Herniation|A Prospective, Randomized, Multicenter Study to Demonstrate the Superiority of the Barricaid to Discectomy for Primary Lumbar Disc Herniation|Active, not recruiting||Phase 4|550|Anticipated|Intrinsic Therapeutics||2|||f||||t||||||||||2018-05-31 22:56:06.741824|2018-05-31 22:56:06.741824
NCT01283425|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-09-03|2011-01-25|2011-01-26|Estimate|||||||2014-09-03|2014-09-04|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Daily Life||Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions|An Open-label, Randomized, Two-period Crossover Study to Evaluate the Safety Use of the InsuPatch Device in Daily Life Conditions.|Completed||Phase 4|147|Actual|Insuline Medical Ltd.||2|||f||||f||||||||||2018-05-31 22:56:07.008751|2018-05-31 22:56:07.008751
NCT01283412|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2013-11-19|2011-01-24|2011-01-26|Estimate|||||||2013-11-19|2013-11-20|Estimate|June 2013||2013-06-30|November 2013|2013-11-30||||June 2014|Anticipated|2014-06-30||Interventional|||Dexmedetomidine on Postoperative Delirium and Quality of Recovery in Geriatric Patients|Intraoperative Application of Dexmedetomidine on the Incidence of Postoperative Delirium and Quality of Recovery in Geriatric Patients Undergoing Major Surgery|Unknown status|Recruiting|Phase 3|500|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 22:56:07.257099|2018-05-31 22:56:07.257099
NCT01283399|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2016-11-01|2011-01-25|2011-01-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis|A Non-interventional Multicenter Study of MabThera® (Rituximab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis|Completed|||79|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:56:07.56328|2018-05-31 22:56:07.56328
NCT01283386|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2016-11-01|2011-01-24|2011-01-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status|Prospective Randomized Study to Compare Efficacy and Safety of RFC-lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-line Therapy in Patients With B-cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status|Completed||Phase 4|18|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:56:08.04376|2018-05-31 22:56:08.04376
NCT01283373|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-10-03|2011-01-24|2011-01-26|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 1|84|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:56:08.666151|2018-05-31 22:56:08.666151
NCT01283360|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2015-05-27|2011-01-24|2011-01-26|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Project Gel||Microbicide Safety and Acceptability in Young Men|Microbicide Safety and Acceptability in Young Men|Completed||Phase 1|249|Actual|CONRAD||2|||f||||t||||||||||2018-05-31 22:56:08.780831|2018-05-31 22:56:08.780831
NCT01283347|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-12-25|2011-01-24|2011-01-26|Estimate|||||||2012-12-25|2012-12-27|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|8F-DTBZ||18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging|Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging|Completed||Phase 2|100|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 22:56:08.941502|2018-05-31 22:56:08.941502
NCT01283009|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2017-04-24|2011-01-24|2011-01-25|Estimate|||||||2017-04-24|2017-04-26|Actual|January 9, 2012|Actual|2012-01-09|April 2017|2017-04-30|August 31, 2016|Actual|2016-08-31|July 31, 2016|Actual|2016-07-31||Interventional|ESCAPe||Extended Steroid in CAP(e)|CSP #574 - Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans With Severe Community-Acquired Pneumonia|Completed||Phase 3|586|Actual|VA Office of Research and Development||2|||f||||t||||||||Undecided||2018-05-31 22:56:30.623627|2018-05-31 22:56:30.623627
NCT01283334|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2014-11-17||2014-11-26|2011-01-24|2011-01-25|Estimate|2014-11-26|2014-12-04|Estimate||||2014-11-26|2014-12-04|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer|A Phase I/IIB Study of Combination Weekly Carboplatin, Cetuximab and Dose Escalation of RAD001 in Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 1/Phase 2|20|Actual|Emory University|Limitations of this analysis include the small sample size in this phase 1b study, a patient population with mixed primary sites of disease, and variable doses of everolimus.|1|||f||||t||||||||||2018-05-31 22:56:09.045206|2018-05-31 22:56:09.045206
NCT01283321|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2015-01-20||2015-02-02|2011-01-24|2011-01-25|Estimate|2015-02-02|2015-02-16|Estimate||||2015-02-02|2015-02-16|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|RiaCT|20 subjects were randomized after the screening visit/labs|RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery|RiaSTAP vs. Conventional Transfusion for Patients Undergoing Valve Replacement Surgery: RiaCT|Terminated||Phase 2|26|Actual|Emory University|Early termination leading to small number of subjects analyzed|2||Insufficient funding to complete total projected enrollment|f||||t||||||||||2018-05-31 22:56:09.59895|2018-05-31 22:56:09.59895
NCT01283308|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2016-10-27|2011-01-24|2011-01-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|D-CLIP||A Randomized Trial of Diabetes Prevention Through Lifestyle Change in India|The Diabetes Community Lifestyle Improvement Program (D-CLIP): A Translation Randomized Trial of a Culturally Specific Lifestyle Intervention for Diabetes Prevention in India|Completed||N/A|599|Actual|Emory University||2|||f||||f||||||||||2018-05-31 22:56:09.90738|2018-05-31 22:56:09.90738
NCT01283295|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-08-03|2011-01-24|2011-01-25|Estimate|||||||2017-08-03|2017-08-04|Actual|November 2007||2007-11-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|IMP||Immune Monitoring and Assay Development in Organ Transplant Recipients|Immune Monitoring and Assay Development in Organ Transplant Recipients|Recruiting|||5000|Anticipated|Emory University|||6||f||||f||||||Samples With DNA|"~     PBMCs, serum, urine, kidney and liver biopsy samples, broncheolar lavage fluid~   "|||2018-05-31 22:56:10.098994|2018-05-31 22:56:10.098994
NCT01283282|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2015-03-06||2015-04-15|2011-01-24|2011-01-25|Estimate|2015-04-15|2015-05-01|Estimate||||2015-04-15|2015-05-01|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|APECS|41 subjects completed the entire study.|Investigation of the Athero-Protective Effects of Clopidogrel|Phase 4 Study of Clopidogrel in Patients With Stable Coronary Artery Disease to Determine Effects on Vascular Function, Biomarkers and Endothelial Progrenitor Cells|Completed||Phase 4|48|Actual|Emory University|Limited sample size|2|||f||||f||||||||||2018-05-31 22:56:11.378011|2018-05-31 22:56:11.378011
NCT01283269|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2014-12-03|2011-01-24|2011-01-25|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional|||A Rehabilitation Intervention for Amnestic Mild Cognitive Impairment|A Multicenter Rehabilitation Intervention for Amnestic Mild Cognitive Impairment|Completed||N/A|128|Actual|Emory University||1|||f||||f||||||||||2018-05-31 22:56:12.053469|2018-05-31 22:56:12.053469
NCT01283256|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2014-01-23|2011-01-24|2011-01-25|Estimate|||||||2014-01-23|2014-01-27|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Observational|||A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.|Evaluation of Safety and Efficacy of Zonisamide in Adult Patients With Partial, Generalized and Combined Seizures: An Open Labeled, Non-comparative, Observational Study|Completed|||655|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 22:56:12.797221|2018-05-31 22:56:12.797221
NCT01283243|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2012-02-01|2011-01-24|2011-01-25|Estimate|||||||2012-02-01|2012-02-02|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients|Prospective Study for Assessment of Normal Value of Acoustic Radiation Force Impulse (ARFI) Elastography in HIV Patients Without Abnormal Liver Function and Chronic Liver Disease|Unknown status|Recruiting||100|Anticipated|Yonsei University|||1||f||||t||||||||||2018-05-31 22:56:13.89278|2018-05-31 22:56:13.89278
NCT01283230|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2012-02-01|2011-01-24|2011-01-25|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Evaluation of Liver Fibrosis Staging With Acoustic Radiation Force Impulse Elastography|Prospective Cohort Study for Evaluation of Liver Fibrosis Staging With Acoustic Radiation Force Impulse Elastography in Patients With Chronic Liver Disease and Healthy Liver/Kidney Donors|Completed|||150|Actual|Yonsei University|||2||f||||t||||||||||2018-05-31 22:56:14.518955|2018-05-31 22:56:14.518955
NCT01283217|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2013-06-01|2011-01-24|2011-01-25|Estimate|||||||2013-06-01|2013-06-04|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer|A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0)|Unknown status|Recruiting|Phase 3|166|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 22:56:15.408821|2018-05-31 22:56:15.408821
NCT01283204|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2016-03-03|2011-01-24|2011-01-25|Estimate|||||||2016-03-03|2016-03-07|Estimate|February 2010||2010-02-28|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer|Randomized Phase II Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|228|Anticipated|Yonsei University||4|||f||||f||||||||||2018-05-31 22:56:15.980468|2018-05-31 22:56:15.980468
NCT01283191|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2014-12-16|2011-01-24|2011-01-25|Estimate|||||||2014-12-16|2014-12-18|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Behavioral Incentives to Increase Exercise in Cocaine Dependent Women|Using Behavioral Incentives to Promote Exercise Compliance in Cocaine Dependent Women|Completed||N/A|26|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 22:56:16.419251|2018-05-31 22:56:16.419251
NCT01283022|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2014-01-24|2012-07-16|2014-03-10|2011-01-24|2011-01-25|Estimate|2014-03-10|2014-04-14|Estimate|2012-07-16|2012-07-25|Estimate|2014-03-10|2014-04-14|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)|A Multicenter, Open-Label, Phase II Study of the 200 mcg Misoprostol Vaginal Insert (MVI 200) to Obtain Pharmacokinetics in Women at Term Gestation (The MVI-PK Study)|Completed||Phase 2|24|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:56:29.498208|2018-05-31 22:56:29.498208
NCT01283178|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2016-10-27|2011-01-24|2011-01-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC|A Phase I Dose Escalation Trial: Concurrent Intensity-Modulated Radiotherapy (IMRT) and Chemotherapy With Molecular Image-Guided Adaptive Radiation Therapy (IGART) for Advanced Head and Neck Squamous Cell Carcinomas (HNSCC)|Terminated||Phase 1|3|Actual|Virginia Commonwealth University||1||"The study was terminated. The data analysis was futile with only 3 accruals. PI opted to~   terminate with IRB and withdraw FDA IND."|f||||t||||||||No|The data analysis was futile with only 3 accruals. PI opted to terminate with the IRB and withdraw the FDA IND.|2018-05-31 22:56:16.577024|2018-05-31 22:56:16.577024
NCT01283165|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-11-09|2011-01-24|2011-01-25|Estimate|||||||2011-11-09|2011-11-10|Estimate|April 2003||2003-04-30|January 2003|2003-01-31|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Observational|Zimworms||Worm Infestation and Child Health in Zimbabwe|Analysis on the Burden of Helminths-plasmodium Polyparasitism, Impact on Anaemia and Effects of Integrated School Based Parasite Control and Health Education in Zimbabwe|Completed|||1303|Actual|University of Zimbabwe|||1||f||||t||||||||||2018-05-31 22:56:17.379084|2018-05-31 22:56:17.379084
NCT01283152|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2014-12-09||2014-12-09|2011-01-24|2011-01-25|Estimate|2014-12-09|2014-12-11|Estimate||||2014-12-09|2014-12-11|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PSE||Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.|Randomized Controlled Trial Evaluating the Efficacy of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) in Patients With Hepatic Encephalopathy.|Completed||N/A|50|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 22:56:18.344574|2018-05-31 22:56:18.344574
NCT01283139|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2016-06-01||2018-03-23|2011-01-24|2011-01-25|Estimate|2016-06-01|2016-07-11|Estimate||||2018-03-23|2018-04-19|Actual|March 31, 2011|Actual|2011-03-31|March 2018|2018-03-31|April 17, 2014|Actual|2014-04-17|November 14, 2013|Actual|2013-11-14||Interventional||Intent-to-treat (ITT) population included all participants who were randomized into the study.|A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus|A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus|Completed||Phase 2|834|Actual|MedImmune LLC||4|||f||||t||||||||||2018-05-31 22:56:20.700257|2018-05-31 22:56:20.700257
NCT01283126|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-05-04|2011-01-24|2011-01-25|Estimate|||||||2017-05-04|2017-05-09|Actual|January 2011|Actual|2011-01-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery|Blood/Interstitial Glucose Measurements and Cognitive Function During Hypoglycemia and Recovery|Completed||N/A|20|Actual|Joslin Diabetes Center||1|||f||||f||||||||No||2018-05-31 22:56:25.505334|2018-05-31 22:56:25.505334
NCT01283113|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-02-28|2011-01-24|2011-01-25|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2010||2010-08-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method|Evaluation of Intra-Abdominal Fat Contents in Patients With Type 2 Diabetes Using a Novel Non-Invasive Method of Bioelectric Impedance|Completed|||110|Actual|Joslin Diabetes Center|||||f||||f||||||||||2018-05-31 22:56:25.622877|2018-05-31 22:56:25.622877
NCT01283100|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-12-22|2011-01-22|2011-01-25|Estimate|||||||2014-12-22|2014-12-24|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|June 2011|Anticipated|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.|A Phase 1, Open Label, Single Sequence, Two-Way Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1379572 Pharmacokinetics in Healthy Adult Subjects|Withdrawn||Phase 1|0|Actual|ViiV Healthcare||3||"In a Phase II study in HIV-infected patients there were a number of seizures, although exact~   causality could not be assessed phase 1 activity was terminated."|f||||f||||||||||2018-05-31 22:56:25.913422|2018-05-31 22:56:25.913422
NCT01283087|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2017-11-23|2011-01-24|2011-01-25|Estimate|||||||2017-11-23|2017-11-27|Actual|January 2011||2011-01-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Spinal Anesthesia Using Lidocaine and Sufentanil and (Transient Neurological Symptoms) TNS|Spinal Anesthesia Using Lidocaine and Sufentanil and TNS (=Transient Neurological Symptoms)|Completed|||168|Actual|Vestre Viken Ringerike Sykehus|||||f||||f||||||||||2018-05-31 22:56:26.033268|2018-05-31 22:56:26.033268
NCT01283074|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2016-11-01|2011-01-24|2011-01-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)|Prognostic Factors of Long-term Response to Treatment With Pegylated Interferon Alfa-2a in Patients With HbeAg-negative Chronic Hepatitis B. (Perseas)|Completed|||107|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:56:26.588497|2018-05-31 22:56:26.588497
NCT01283061|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-25|2011-01-24|2011-01-25|Estimate|||||||2011-01-25|2011-01-26|Estimate|December 2007||2007-12-31|January 2011|2011-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioavailability Study Of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of 'ACCOLATE' Tablets 20 mg of Astrazeneca Pharmaceuticals, USA In Healthy Adult Human Subjects Under Fasting Conditions.|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 22:56:27.1397|2018-05-31 22:56:27.1397
NCT01283048|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2016-09-19|2011-01-24|2011-01-25|Estimate|||||||2016-09-19|2016-09-21|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma|A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies|Completed||Phase 1|32|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 22:56:27.866439|2018-05-31 22:56:27.866439
NCT01283035|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2016-02-16||2016-05-16|2011-01-24|2011-01-25|Estimate|2016-05-16|2016-06-24|Estimate||||2016-05-16|2016-06-24|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase II Study of MK-2206 in the Treatment of Recurrent High-Grade Serous Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed||Phase 2|6|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:56:28.111051|2018-05-31 22:56:28.111051
NCT01282996|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-10-04|2011-01-24|2011-01-25|Estimate|||||||2012-10-04|2012-10-05|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Intraoperative Protective Ventilation in Abdominal Surgery (IMPROVE Study)|Intraoperative Lung Protective Ventilation in Abdominal Surgery: A Randomized Controlled Study|Completed||Phase 4|400|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:56:31.292973|2018-05-31 22:56:31.292973
NCT01282983|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|September 2011|Anticipated|2011-09-30|February 2011|Anticipated|2011-02-28||Interventional|||Study of Digestive Tolerance of Orange Juice With Fibers|Study of Digestive Tolerance of Orange Juice With Fibers|Unknown status|Recruiting|Phase 1|200|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 22:56:31.937238|2018-05-31 22:56:31.937238
NCT01282970|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2014-11-18|2011-01-24|2011-01-25|Estimate|||||||2014-11-18|2014-11-19|Estimate|February 2011||2011-02-28|November 2014|2014-11-30||||July 2011|Actual|2011-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (5 to 100 mg q.d. for 14 Days) of BI 135585 XX in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)|Completed||Phase 1|72|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:56:32.12748|2018-05-31 22:56:32.12748
NCT01282957|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2016-08-24|2011-01-21|2011-01-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Way to Health, Healthy Measures|Financial Incentives for Home-based Health Management: A Pilot Randomized Trial|Completed||N/A|75|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 22:56:32.344269|2018-05-31 22:56:32.344269
NCT01282944|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-03-04|2011-01-24|2011-01-25|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Encouraging Walking in Older Adults|Encouraging Walking in Older Adults|Completed||N/A|92|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 22:56:32.847914|2018-05-31 22:56:32.847914
NCT01282931|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-10-09|2011-01-24|2011-01-25|Estimate|||||||2011-10-09|2011-10-12|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer|Development and Implementation of a Patient-reported Outcome Questionnaire to Assess the Value of Progression-free Survival for Women With Metastatic Breast Cancer.|Completed|||200|Anticipated|Health Outcomes Solutions|||||f||||f||||||||||2018-05-31 22:56:33.255251|2018-05-31 22:56:33.255251
NCT01282918|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-06-22|2011-01-24|2011-01-25|Estimate|||||||2015-06-22|2015-06-23|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||NORDIC ICD (Cardioverter Defibrillator Implantation) Trial|NO Regular Defibrillation Testing In Cardioverter Defibrillator Implantation (NORDIC ICD) Trial|Completed||N/A|1077|Actual|Biotronik SE & Co. KG||2|||f||||t||||||||||2018-05-31 22:56:34.277397|2018-05-31 22:56:34.277397
NCT01282905|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-25|2011-01-24|2011-01-25|Estimate|||||||2011-01-25|2011-01-26|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|||||Observational|||Hydrogen Sulfide Detoxification and Butyrate Metabolism in Ulcerative Colitis|Impact of the Mucosal Detoxification Mechanism of Hydrogen Sulphide on the Oxidation Pathway of Butyrate in Ulcerative Colitis|Completed|||106|Actual|Katholieke Universiteit Leuven|||2||f||||f||||||Samples With DNA|"~     colon tissue~   "|||2018-05-31 22:56:35.027963|2018-05-31 22:56:35.027963
NCT01282892|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|February 2009||2009-02-28|January 2011|2011-01-31|December 2010|Anticipated|2010-12-31|November 2009|Actual|2009-11-30||Observational|||Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis|Visceral Abdominal Fat, Non Alcoholic Fatty Liver Diseases and Asymptomatic Coronary Atherosclerosis|Unknown status|Active, not recruiting||150|Anticipated|Ziv Hospital|||2||f||||f||||||||||2018-05-31 22:56:35.232926|2018-05-31 22:56:35.232926
NCT01282879|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-23|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|December 2009||2009-12-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ITRAG||Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients|Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation|Terminated||Phase 4|36|Actual|Samsung Medical Center||1||In interim analysis, this study met the primary hypothesis.|f||||t||||||||||2018-05-31 22:56:35.616017|2018-05-31 22:56:35.616017
NCT01282866|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|2014-01-06||2016-09-06|2011-01-23|2011-01-25|Estimate|2014-02-20|2014-04-03|Estimate||||2016-09-06|2016-10-21|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||The power calculation proposed a sample of 35 participants to be sufficient to obtain qualitative assessment of hair removal, as well as the qualitative assessment of treatment time and pain experienced during treatment with the LightSheer Duet HS handpiece.|Hair Count Reduction Verification Study With the LightSheer Duet HS Handpiece|Hair Count Reduction Verification Study With the LightSheer Duet HS Handpiece|Completed||N/A|35|Actual|Lumenis Ltd.||1|||f||||||||||||||2018-05-31 22:56:35.908231|2018-05-31 22:56:35.908231
NCT01282853|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-23|||2015-08-28|2011-01-23|2011-01-25|Estimate|||||||2015-08-28|2015-08-31|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Peptic Ulcer Bleeding|The Influence of Biopsy Number and Site on the Sensitivity of Rapid Urease Test for Diagnosis of H. Pylori Infection in Patients With Bleeding Gastroduodenal Ulcer|Completed||N/A|116|Actual|Far Eastern Memorial Hospital||3|||f||||f||||||||||2018-05-31 22:56:36.752684|2018-05-31 22:56:36.752684
NCT01282840|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-23|||2016-09-04|2011-01-23|2011-01-25|Estimate|||||||2016-09-04|2016-09-07|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.||Recruiting||N/A|300|Anticipated|Far Eastern Memorial Hospital||1|||f||||||||||||||2018-05-31 22:56:37.406421|2018-05-31 22:56:37.406421
NCT01282827|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-01-25|2011-01-24|2011-01-25|Estimate|||||||2011-01-25|2011-01-26|Estimate|November 2006||2006-11-30|January 2011|2011-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Paraorbital-Occipital Electric Stimulation in Patients With Optic Neuropathy (BCT_optnerve)|Paraorbital-occipital Alternating Electric Current Stimulation in Patients With Optic Neuropathy|Completed||Phase 2/Phase 3|40|Actual|University of Magdeburg||2|||f||||f||||||||||2018-05-31 22:56:37.902671|2018-05-31 22:56:37.902671
NCT01282814|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2011-02-11||2011-02-11|2011-01-24|2011-01-25|Estimate|2011-02-11|2011-03-08|Estimate||||2011-02-11|2011-03-08|Estimate|February 2003||2003-02-28|February 2011|2011-02-28|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study|Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as the Content of 1 x 150 mg Extended-Release Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-05-31 22:56:38.076269|2018-05-31 22:56:38.076269
NCT01282801|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|2011-02-11||2011-02-11|2011-01-24|2011-01-25|Estimate|2011-02-11|2011-03-08|Estimate||||2011-02-11|2011-03-08|Estimate|September 2002||2002-09-30|February 2011|2011-02-28|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsules in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|18|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-05-31 22:56:40.374046|2018-05-31 22:56:40.374046
NCT01282788|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2013-12-05|2011-01-24|2011-01-25|Estimate|||||||2013-12-05|2013-12-09|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|CAT02||Efficacy of Caterpillar Cereal for Complementary Feeding in the Democratic Republic of Congo|A Novel Sustainable Complementary Feeding Product for Infants and Young Children in the Democratic Republic of Congo: Caterpillar Cereal|Completed||N/A|222|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 22:56:42.501904|2018-05-31 22:56:42.501904
NCT01282775|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-21|2011-01-21|2011-01-25|Estimate|||||||2011-01-21|2011-01-25|Estimate|September 2005||2005-09-30|January 2011|2011-01-31|March 2007|Actual|2007-03-31|November 2006|Actual|2006-11-30||Interventional|||Interventions to Control Obesity in Community Colleges (CDC WAY to Health)|Interventions to Control Obesity in Community Colleges|Completed||Early Phase 1|1029|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 22:56:43.239533|2018-05-31 22:56:43.239533
NCT01282762|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2018-02-27|2011-01-21|2011-01-25|Estimate|||||||2018-02-27|2018-03-01|Actual|December 2010||2010-12-31|February 2018|2018-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease|An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV™ Compared With Engerix-B® in Adults With Chronic Kidney Disease Who Have Previously Received At Least One Hepatitis B Vaccine Series|Completed|||147|Actual|Dynavax Technologies Corporation|||||f||||f||||||Samples Without DNA|"~     Serum retained during study duration for additional testing if indicated~   "|Undecided|No Changes to status a/o 3/2017|2018-05-31 22:56:43.457779|2018-05-31 22:56:43.457779
NCT01282749|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-05-27|2011-01-21|2011-01-25|Estimate|||||||2014-05-27|2014-05-28|Estimate|October 2002||2002-10-31|May 2014|2014-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effectiveness of SisterTalk Hartford for Weight Loss Among African-American Women|The Hospitals-Churches Partnership for Health Project: SisterTalk Hartford|Completed||N/A|322|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 22:56:43.525508|2018-05-31 22:56:43.525508
NCT01282736|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-05-13|2011-01-24|2011-01-25|Estimate|||||||2013-05-13|2013-05-15|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|May 2015|Anticipated|2015-05-31|September 2014|Anticipated|2014-09-30||Interventional|||Guided Self-Help for Binge Eating Disorder|Comparison of Integrative Response Therapy and Cognitive Behavioral Therapy Guided Self-Help for Binge Eating Disorder|Unknown status|Active, not recruiting|N/A|100|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 22:56:43.585615|2018-05-31 22:56:43.585615
NCT01282723|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2011-01-24||2011-02-16|2011-01-21|2011-01-25|Estimate|2011-02-16|2011-03-15|Estimate||||2011-02-16|2011-03-15|Estimate|August 2008||2008-08-31|February 2011|2011-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring Patients by Practicing Clinicians|Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring Patients by Practicing Clinicians|Completed|||20|Actual|Reproductive Research Technologies, LP|||1||f||||||||||||||2018-05-31 22:56:43.673209|2018-05-31 22:56:43.673209
NCT01282710|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2011-01-24||2011-02-16|2011-01-21|2011-01-25|Estimate|2011-02-16|2011-03-15|Estimate||||2011-02-16|2011-03-15|Estimate|August 2008||2008-08-31|February 2011|2011-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Comparison of SureCALL® EMG Labor Monitor® and Tocodynamometer to Intrauterine Pressure Catheter Measurement (IUPC) Measurement in Pregnant Women|Comparison of SureCALL® EMG Labor Monitor® and Tocodynamometer to Intrauterine Pressure Catheter Measurement in Pregnant Women|Completed|||20|Actual|Reproductive Research Technologies, LP|||1||f||||||||||||||2018-05-31 22:56:43.852841|2018-05-31 22:56:43.852841
NCT01282697|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|August 2014|Anticipated|2014-08-31|March 2013|Anticipated|2013-03-31||Interventional|RAPIRI||Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors|Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors|Unknown status|Not yet recruiting|Phase 1|33|Anticipated|University Hospital, Strasbourg, France||1|||f||||t||||||||||2018-05-31 22:56:44.555206|2018-05-31 22:56:44.555206
NCT01282684|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-03-26|2011-01-24|2011-01-25|Estimate|||||||2015-03-26|2015-03-30|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers|A Phase 1 First in Human Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Plexxikon||7|||f||||f||||||||||2018-05-31 22:56:44.76585|2018-05-31 22:56:44.76585
NCT01282671|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2014-06-04|2011-01-24|2011-01-25|Estimate|||||||2014-06-04|2014-06-05|Estimate|September 2007||2007-09-30|June 2014|2014-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Deep Breathing Exercises Two Months After Cardiac Surgery|Effects of Deep Breathing Exercises Two Months After Cardiac Surgery|Completed||Phase 2|357|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 22:56:44.840055|2018-05-31 22:56:44.840055
NCT01282658|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-02-16|2011-01-24|2011-01-25|Estimate|||||||2011-02-16|2011-02-17|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Observational|PSIFL||Pharmacogenomics Study of CPT-11 as the First-line Chemotherapy for mCRC|Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC|Unknown status|Recruiting||200|Anticipated|Huazhong University of Science and Technology|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 22:56:45.000795|2018-05-31 22:56:45.000795
NCT01282645|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2013-03-21|2011-01-24|2011-01-25|Estimate|||||||2013-03-21|2013-03-22|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Case Series to Evaluate Patient Specific Implants (PSI) in Polyether Ether Ketone (PEEK) Performance After 2 Years|A Retrospective Case Series to Evaluate the Long Term Outcome of the Use of Synthes Patient Specific Implants (PSI®) Made of Polyether Ether Ketone (PEEK) for the Treatment of Cranial Defects in Patients With a Mature Skeleton|Withdrawn|||0|Actual|Synthes GmbH|||1||f||||f||||||||||2018-05-31 22:56:45.08631|2018-05-31 22:56:45.08631
NCT01282632|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|August 2002||2002-08-31|September 2010|2010-09-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression|A Double Blind Pilot Trial to Evaluate Efficacy Trends and Safety of Risperidone and Olanzapine as add-on Therapy to Serotonin Type Antidepressants in Subjects With Treatment Resistant Depression (TRD)|Completed||Phase 1/Phase 2|42|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 22:56:45.32096|2018-05-31 22:56:45.32096
NCT01282619|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|May 2010||2010-05-31|January 2011|2011-01-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease|A Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Study to Evaluate the Safety and Efficacy of Huperzine A Sustained-Release Tablets in Patients With Mild to Moderate Alzheimer's Disease|Unknown status|Recruiting|Phase 2/Phase 3|390|Anticipated|Shandong Luye Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-05-31 22:56:45.473093|2018-05-31 22:56:45.473093
NCT01282606|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24||2012-07-12|2013-09-05|2011-01-24|2011-01-25|Estimate||||2012-07-25|2012-08-02|Estimate|2013-09-05|2013-09-16|Estimate|December 2007||2007-12-31|September 2013|2013-09-30||||August 2012|Actual|2012-08-31||Interventional|||Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation|An Open Label, Non-randomized Dose-escalation Study to Assess Safety and Tolerability of SI-6603 in Patients With Lumbar Disc Herniation (Phase II Study)|Completed||Phase 2|18|Actual|Seikagaku Corporation||3|||f||||t||||||||||2018-05-31 22:56:45.731161|2018-05-31 22:56:45.731161
NCT01282593|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2017-01-16|2011-01-24|2011-01-25|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|LAL TEL/ALM1||Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).|Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).|Recruiting||N/A|50|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 22:56:45.80857|2018-05-31 22:56:45.80857
NCT01282580|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2015-10-24|2011-01-24|2011-01-25|Estimate|||||||2015-10-24|2015-10-27|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|December 2012|Actual|2012-12-31||Interventional|||Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention|Omega 3 Fatty Acids and Breast Cancer Prevention: Protective Benefits of Increased Fish Consumption|Completed||Phase 1|25|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 22:56:45.932955|2018-05-31 22:56:45.932955
NCT01282567|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-02-02|2011-01-24|2011-01-25|Estimate|||||||2012-02-02|2012-02-03|Estimate|May 2011||2011-05-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study for the Artificial Pancreas Project : Determination of a Tuning Strategy of Metabolic Profiles|Preliminary Study for the Artificial Pancreas Project : Determination of a Tuning Strategy of Metabolic Profiles|Completed||N/A|3|Actual|Rennes University Hospital||1|||f||||||||||||||2018-05-31 22:56:46.013809|2018-05-31 22:56:46.013809
NCT01282554|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2014-01-03|2011-01-24|2011-01-25|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|EMS-Dialyse||Evaluation of Electrostimulation Program During Dialysis Sessions in Chronic Renal Failure Patients|Evaluation of Electrostimulation Program During Dialysis Sessions in Chronic Renal Failure Patients|Completed||N/A|68|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 22:56:46.10445|2018-05-31 22:56:46.10445
NCT01282541|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2012-09-11|2011-01-24|2011-01-25|Estimate|||||||2012-09-11|2012-09-12|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora|Determination of the Optimum Delivery Route for the Intraglandular Administration of Botulinum Toxin A in Patients With Refractory Epiphora|Completed||Phase 2|26|Actual|Merbs, Shannath, M.D., Ph.D.||2|||f||||t||||||||||2018-05-31 22:56:46.262105|2018-05-31 22:56:46.262105
NCT01282528|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|September 2010||2010-09-30|January 2011|2011-01-31||||||||Interventional|ULTRA||Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis|Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis|Unknown status|Recruiting|Phase 4|85|Anticipated|Peking Union Medical College Hospital|||||f||||t||||||||||2018-05-31 22:56:46.467256|2018-05-31 22:56:46.467256
NCT01282515|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2012-08-23|2011-01-24|2011-01-25|Estimate|||||||2012-08-23|2012-08-24|Estimate|August 2011||2011-08-31|August 2012|2012-08-31||||April 2013|Anticipated|2013-04-30||Interventional|||Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT|A Study of Topical Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) and a Phase III Comparative Treatment Study of HAL PDT in Female Genital Erosive Lichen Planus (GELP)|Unknown status|Active, not recruiting|Phase 2/Phase 3|48|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:56:46.582091|2018-05-31 22:56:46.582091
NCT01282502|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2017-12-20|2011-01-21|2011-01-25|Estimate|||||||2017-12-20|2017-12-21|Actual|August 2011||2011-08-31|December 2017|2017-12-31|March 2022|Anticipated|2022-03-31|March 2015|Actual|2015-03-31||Interventional|||Midostaurin (PKC412) for Locally Advanced Rectal Cancer|Phase I Study of Chemoradiation With Midostaurin (PKC412) For Locally Advanced Rectal Cancer|Active, not recruiting||Phase 1|19|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:56:46.674292|2018-05-31 22:56:46.674292
NCT01282489|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2015-05-19|2011-01-24|2011-01-25|Estimate|||||||2015-05-19|2015-05-20|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Evaluation of Methods to Asses Visual Prosthesis Systems Using Sighted Volunteers and Visual Reality Simulator|Evaluation of Methods to Asses Visual Prosthesis Systems Using Sighted Volunteers and Visual Reality Simulator|Unknown status|Recruiting||50|Anticipated|Meir Medical Center|||||f||||||||||||||2018-05-31 22:56:46.771534|2018-05-31 22:56:46.771534
NCT01282476|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2017-02-14||2017-04-03|2011-01-24|2011-01-25|Estimate|2017-02-14|2017-03-31|Actual||||2017-04-03|2017-05-09|Actual|June 2011|Actual|2011-06-30|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional|||Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma|Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma|Terminated||Phase 2|18|Actual|Massachusetts General Hospital||1||slow accrual|f||||t||||||||||2018-05-31 22:56:46.858784|2018-05-31 22:56:46.858784
NCT01282463|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21||2015-05-08|2015-05-08|2011-01-21|2011-01-25|Estimate||||2015-05-08|2015-05-25|Estimate|2015-05-08|2015-05-25|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma|An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy|Completed||Phase 2|148|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 22:56:47.59629|2018-05-31 22:56:47.59629
NCT01282450|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-07-18|2011-01-24|2011-01-25|Estimate|||||||2011-07-18|2011-07-19|Estimate|May 2006||2006-05-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)|Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC).|Completed||Phase 2|60|Anticipated|Maastricht Radiation Oncology||1|||f||||f||||||||||2018-05-31 22:56:47.828349|2018-05-31 22:56:47.828349
NCT01282437|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-24|||2015-04-09|2011-01-24|2011-01-25|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|NVALT11||Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC|Prophylactic Cranial Irradiation (PCI) Versus Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer; A Phase III Randomized Study.|Completed||Phase 3|315|Actual|Maastricht Radiation Oncology||2|||f||||f||||||||||2018-05-31 22:56:47.948563|2018-05-31 22:56:47.948563
NCT01282424|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2014-08-22|2014-03-20|2018-04-13|2011-01-24|2011-01-25|Estimate|2014-08-22|2014-09-04|Estimate|2014-03-20|2014-04-16|Estimate|2018-04-13|2018-05-15|Actual|March 4, 2011|Actual|2011-03-04|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|June 25, 2013|Actual|2013-06-25||Interventional|DELTA|ITT Analysis Set: Enrolled participants who received at least one dose of study drug|Efficacy and Safety Study of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma|A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents|Active, not recruiting||Phase 2|125|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 22:56:48.090241|2018-05-31 22:56:48.090241
NCT01282411|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-07-26|2011-01-21|2011-01-25|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2010||2010-02-28|July 2016|2016-07-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Observational|||Anatomic Outcomes Following Ozurdex Injections|Anatomic Outcomes Following Ozurdex Injection|Completed|||10|Actual|Barnes Retina Institute|||||f||||t||||||||||2018-05-31 22:56:48.927375|2018-05-31 22:56:48.927375
NCT01282398|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|April 2015|Anticipated|2015-04-30|April 2012|Anticipated|2012-04-30||Interventional|SIMPRO||Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis|Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 22:56:48.982333|2018-05-31 22:56:48.982333
NCT01282385|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2011-01-24|2011-01-24|2011-01-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|SIMBETA||Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension|Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 22:56:49.066486|2018-05-31 22:56:49.066486
NCT01282372|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2015-07-28||2015-10-08|2011-01-24|2011-01-25|Estimate|2015-07-28|2015-08-26|Estimate||||2015-10-08|2015-11-09|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab|A 2-year HRQL Observational Study Evaluating the Effect of Treatment With Adalimumab on Work Productivity and Sleep in Patients With Rheumatic Diseases in Greece|Completed|||500|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:56:49.240809|2018-05-31 22:56:49.240809
NCT01282359|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2015-09-15|2011-01-24|2011-01-25|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|PROMETEO||Efficacy of a Minimal Intervention Educational Program in the Asthma Control and Exacerbations Prevention|Efficacy of a Minimal Intervention Educational Program in the Asthma Control and Exacerbations Prevention|Completed||Phase 4|250|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||3|||f||||t||||||||||2018-05-31 22:56:49.807505|2018-05-31 22:56:49.807505
NCT01282346|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05||2017-02-20|2017-02-20|2011-01-22|2011-01-25|Estimate||||2017-02-20|2017-02-23|Actual|2017-02-20|2017-02-23|Actual|January 2011||2011-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||SOLX Gold Shunt for Refractory Glaucoma|Clinical Evaluation of the SOLX Gold Shunt for the Reduction of Intraocular Pressure (IOP) in Refractory Glaucoma|Completed||N/A|116|Actual|SOLX, Inc.||1|||f||||||||||||||2018-05-31 22:56:49.890307|2018-05-31 22:56:49.890307
NCT01282333|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-22|||2013-07-01|2011-01-22|2011-01-25|Estimate|||||||2013-07-01|2013-07-02|Estimate|January 2011||2011-01-31|July 2013|2013-07-31||||February 2013|Actual|2013-02-28||Interventional|||Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer|Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer|Terminated||Phase 1|44|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:56:49.974861|2018-05-31 22:56:49.974861
NCT01282320|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2013-07-01|2011-01-21|2011-01-24|Estimate|||||||2013-07-01|2013-07-02|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|March 2012|Actual|2012-03-31||Interventional|WHAT||WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women|WHAT - Effectiveness of Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women. A Randomized Controlled Pragmatic Pilot Study|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 22:56:50.212435|2018-05-31 22:56:50.212435
NCT01282008|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2018-04-04|2011-01-21|2011-01-24|Estimate|||||||2018-04-04|2018-04-05|Actual|January 21, 2011||2011-01-21|January 26, 2018|2018-01-26||||||||Observational|||Message Testing for Tobacco-Related Corrective Statements|Message Testing for Tobacco-Related Corrective Statements|Completed|||627|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:56:55.762444|2018-05-31 22:56:55.762444
NCT01282307|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2012-08-13|2011-01-21|2011-01-24|Estimate|||||||2012-08-13|2012-08-14|Estimate|February 2008||2008-02-29|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|GEBRCT||Improving Insight in Patients Diagnosed With Schizophrenia|Meaningful Change With the Method Guided Self-Determination - a Randomised Controlled Study for Patients Diagnosed With Schizophrenia.|Completed||N/A|101|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:56:50.300457|2018-05-31 22:56:50.300457
NCT01282294|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2015-01-27||2015-02-25|2011-01-21|2011-01-24|Estimate|2015-01-27|2015-02-11|Estimate||||2015-02-25|2015-03-17|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational||The baseline analysis population consistes of patients with an open or closed tibia fracture who were treated with the ETN PROtect.|Clinical Follow-up to Evaluate the Clinical Usefulness of Gentamicin-coated Titanium Nails in Tibia Fractures|Prospective Open Label Post Market Clinical Follow-up to Evaluate the Clinical Usefulness of the Operative Stabilization of Closed and Open Fractures of the Tibia Using Gentamicin - Coated Titanium Nails|Completed|||100|Actual|Synthes GmbH|||1||f||||f||||||||||2018-05-31 22:56:50.448614|2018-05-31 22:56:50.448614
NCT01282281|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-01-16|2011-01-21|2011-01-24|Estimate|||||||2014-01-16|2014-01-17|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Observational|||Prospective Metabolic Monitoring of Youth and Adults With Bipolar Disorder|Prospective Metabolic Monitoring of Youth and Adults With Bipolar Disorder.|Completed|||13|Actual|Sunnybrook Health Sciences Centre|||1||f||||t||||||||||2018-05-31 22:56:51.05054|2018-05-31 22:56:51.05054
NCT01282268|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2013-07-30|2011-01-21|2011-01-24|Estimate|||||||2013-07-30|2013-07-31|Estimate|May 2011||2011-05-31|July 2013|2013-07-31||||December 2012|Actual|2012-12-31||Interventional|Harbor-A||Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome|Completed||Phase 3|125|Actual|Seaside Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 22:56:51.100167|2018-05-31 22:56:51.100167
NCT01282255|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21||2012-05-10|2017-02-08|2011-01-21|2011-01-24|Estimate||||2012-05-10|2012-05-15|Estimate|2017-02-08|2017-02-09|Estimate|February 2011||2011-02-28|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis|A Randomised, Double Blind, Placebo-controlled, Multiple Dose Trial of Anti-IL-20 (109-0012) in Subjects With Rheumatoid Arthritis|Completed||Phase 2|67|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:56:51.180112|2018-05-31 22:56:51.180112
NCT01282242|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2017-02-27||2017-05-24|2011-01-21|2011-01-24|Estimate|2017-02-27|2017-04-11|Actual||||2017-05-24|2017-06-15|Actual|January 2011||2011-01-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|MR WITNESS|Analysis population consists of all subjects enrolled who suffered an unwitnessed stroke and qualified per AHA guidelines to receive IV tPA within a window of 3-4.5 hours since symptom discovery and whose signal intensity ratio (SIR) on MRI was <1.15 for primary arm and <1.25 for secondary arm.|A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients|MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients|Completed||Phase 2|88|Actual|Massachusetts General Hospital|This was a single arm open label trial. Genetech provided alteplase free of charge for this NINDS sponsored study.|1|||f||||t||||||||No||2018-05-31 22:56:52.237578|2018-05-31 22:56:52.237578
NCT01282229|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2015-06-18||2015-09-15|2011-01-21|2011-01-24|Estimate|2015-09-15|2015-10-14|Estimate||||2015-09-15|2015-10-14|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|LANAP|Data are for number of quadrants|Study to Compare Laser Assisted New Attachment Procedure (LANAP) to Traditional Treatments of Chronic Periodontitis|A Multi-Center Single Blind Study of the Laser Assisted New Attachment Procedure Compared to Scaling and Root Planing Alone, Modified Widman Flap Surgery, and Coronal Debridement Alone in the Treatment of Chronic Periodontitis|Completed||N/A|59|Actual|Institute for Advanced Laser Dentistry||4|||f||||f||||||||||2018-05-31 22:56:52.683259|2018-05-31 22:56:52.683259
NCT01282216|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-10-14|2011-01-21|2011-01-24|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide|Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant (BMT) With High-dose Post Transplantation Cyclophosphamide.|Completed||N/A|61|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 22:56:53.147807|2018-05-31 22:56:53.147807
NCT01282203|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2012-11-30||2013-01-28|2011-01-21|2011-01-24|Estimate|2013-01-02|2013-01-07|Estimate||||2013-01-28|2013-03-04|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|SEVOPROTECTION||Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevorane in Adult Patients Required General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on Cardiovascular System in Common Clinical Practice|Evaluation of VIMA With SEVOrane in Adult Patients Required General Anesthesia fOr Surgery in TErms of Quality of Anesthesia and Its Influence on Cardiovascular sysTem In commON Clinical Practice (SEVOPROTECTION)|Completed|||1122|Actual|AbbVie|Troponin T and CK-MB values were not collected in the study, therefore no conclusions can be made regarding the influence of volatile induction and maintenance anesthesia with Sevorane on myocardial ischemia markers.||1||f||||||||||||||2018-05-31 22:56:53.251659|2018-05-31 22:56:53.251659
NCT01282190|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2015-08-17|2011-01-21|2011-01-24|Estimate|||||||2015-08-17|2015-08-18|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Dislip-EM||Effectiveness of Motivational Interview in Patients With Dyslipidemia|Effectiveness of Motivational Interview in Patients With Dyslipidemia Treated in Primary Care Consultations (Dislip-EM Study)|Completed||N/A|207|Actual|Hospital Universitario Reina Sofia de Cordoba||1|||f||||t||||||||||2018-05-31 22:56:53.672383|2018-05-31 22:56:53.672383
NCT01282177|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2017-01-17|2011-01-21|2011-01-24|Estimate|||||||2017-01-17|2017-01-19|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|||Influenza Vaccine Safety and Effectiveness in Healthcare Providers|Monitoring Seasonal and Pandemic Vaccine Safety and Effectiveness in Healthcare Providers:A Prospective Cohort Study|Completed|||1143|Actual|Dalhousie University|||||f||||f||||||||||2018-05-31 22:56:53.727903|2018-05-31 22:56:53.727903
NCT01281995|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2018-03-27|2011-01-21|2011-01-24|Estimate|||||||2018-03-27|2018-03-29|Actual|January 21, 2011||2011-01-21|October 20, 2017|2017-10-20||||||||Observational|||Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers|Effects of Systemically Administered Hydrocortisone on the Human Immunome in Healthy Volunteers|Completed|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:56:55.80915|2018-05-31 22:56:55.80915
NCT01282164|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2016-12-27||2017-05-15|2011-01-21|2011-01-24|Estimate|2017-02-20|2017-04-05|Actual||||2017-05-15|2017-05-17|Actual|January 2011||2011-01-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|GST|One patient did not achieve hypoglycemia during the insulin tolerance test|The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis|The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis|Completed||N/A|43|Actual|The Cleveland Clinic|This includes the relatively small number of subjects, and that the majority of patients had growth hormone deficiency (GHD), so a larger study assessing adults with mild hypothalamic-pituitary disease and possible but unconfirmed GHD is required.|2|||f||||f||||||||No||2018-05-31 22:56:53.79378|2018-05-31 22:56:53.79378
NCT01282151|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2015-07-13|2011-01-21|2011-01-24|Estimate|||||||2015-07-13|2015-07-14|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|TRAIL||TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer|A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer|Terminated||Phase 3|148|Actual|Chonnam National University Hospital||2||Difficulty in recruitment due to approval of maintenance pemetrexed treatment|f||||t||||||||||2018-05-31 22:56:54.328918|2018-05-31 22:56:54.328918
NCT01282138|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2012-06-20||2012-12-16|2011-01-21|2011-01-24|Estimate|2012-06-20|2012-07-25|Estimate||||2012-12-16|2012-12-18|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Assessment of Alcon's Ocular Image Quantification System|A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC)|Completed||Phase 4|13|Actual|Alcon Research|This was a pilot study with a small number of subjects not adequately powered to detect treatment differences.|2|||f||||f||||||||||2018-05-31 22:56:54.51936|2018-05-31 22:56:54.51936
NCT01282125|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2017-03-10|2011-01-21|2011-01-24|Estimate|||||||2017-03-10|2017-03-13|Actual|December 2010|Actual|2010-12-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Nasal Obstruction in Sleep Apnea Patients Compared to the General Population|A Comparative Study of Nasal Obstruction in a Sleep Apnea Population Compared to the General Population|Completed|||217|Actual|Norwegian University of Science and Technology|||2||f||||f|f|f||||||||2018-05-31 22:56:54.722657|2018-05-31 22:56:54.722657
NCT01282112|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-06-25|2011-01-21|2011-01-24|Estimate|||||||2014-06-25|2014-06-26|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Sedation for Brainstem Evoked Auditory Response (BEAR) Testing Using Intravenous Pentobarbital|Sedation for Brainstem Evoked Auditory Response (BEAR) Testing Using Intravenous Pentobarbital - A Retrospective Study|Completed|||416|Actual|Akron Children's Hospital|||||f||||f||||||||||2018-05-31 22:56:54.792524|2018-05-31 22:56:54.792524
NCT01282099|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-06-24|2011-01-21|2011-01-24|Estimate|||||||2014-06-24|2014-06-26|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||A Critical Appraisal of the Role of Near Infrared Spectroscopy (NIRS) in the Pediatric Intensive Care Unit (PICU)|Is There a Canary in the PICU? A Critical Appraisal of the Role of Near Infrared Spectroscopy (NIRS) in the Pediatric Intensive Care Unit (PICU)|Completed|||22|Actual|Akron Children's Hospital|||2||f||||f||||||||||2018-05-31 22:56:54.860566|2018-05-31 22:56:54.860566
NCT01282086|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2012-12-07||2013-01-04|2011-01-21|2011-01-24|Estimate|2013-01-04|2013-02-04|Estimate||||2013-01-04|2013-02-04|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|SEVOPROTECTION||Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevorane in Adult Patients Requiring General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on the Cardiovascular System in Common Clinical Practice|Evaluation of VIMA With Sevorane in Adult Patients Required General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on Cardiovascular System in Common Clinical Practice (SEVOPROTECTION)|Completed|||1365|Actual|AbbVie|The data on troponin T values were not collected in the study and CK-MB was detected in a small number of patients, therefore no conclusions can be made regarding the influence of VIMA with Sevorane on myocardial ischemia markers.||1||f||||||||||||||2018-05-31 22:56:54.953622|2018-05-31 22:56:54.953622
NCT01282073|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2015-04-09|2011-01-21|2011-01-24|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|MMFPRIMER||Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy|A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy|Unknown status|Recruiting|Phase 3|62|Anticipated|Kyungpook National University||2|||f||||t||||||||||2018-05-31 22:56:55.274947|2018-05-31 22:56:55.274947
NCT01282060|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2017-01-09|2011-01-21|2011-01-24|Estimate|||||||2017-01-09|2017-01-10|Estimate|March 2009||2009-03-31|January 2017|2017-01-31|September 2021|Anticipated|2021-09-30|April 2016|Actual|2016-04-30||Observational|||Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients|Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients|Active, not recruiting|||986|Actual|Association Pour la Recherche en Diabetologie et en Geriatrie|||||f||||t||||||||No||2018-05-31 22:56:55.424227|2018-05-31 22:56:55.424227
NCT01282047|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2014-07-31|2011-01-21|2011-01-24|Estimate|||||||2014-07-31|2014-08-01|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|LENAKAP||Lenalidomide in Kaposi Disease Associated With HIV Infection|Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Lenalidomide in Kaposi Disease Associated With HIV Infection (ANRS 154/LENAKAP)|Terminated||Phase 2|12|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 22:56:55.502699|2018-05-31 22:56:55.502699
NCT01282034|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-08-04|2011-01-21|2011-01-24|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Study for the Treatment of Knee Chondral and Osteochondral Lesions|Multicenter Randomized Controlled Trial for the Treatment of Knee Chondral and Osteochondral Lesions: Marrow Stimulation Techniques vs MaioRegen|Completed||Phase 4|145|Actual|Fin-Ceramica Faenza Spa||2|||f||||f||||||||||2018-05-31 22:56:55.614834|2018-05-31 22:56:55.614834
NCT01282021|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2018-05-23|2011-01-21|2011-01-24|Estimate|||||||2018-05-23|2018-05-24|Actual|January 10, 2011||2011-01-10|November 16, 2017|2017-11-16||||||||Observational|||Molecular Immunohematology in Ethiopian Sub-Populations|Molecular Immunohematology in Ethiopian Sub-Populations|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:56:55.709181|2018-05-31 22:56:55.709181
NCT01281982|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2018-02-13|2011-01-21|2011-01-24|Estimate|||||||2018-02-13|2018-02-14|Actual|January 13, 2011||2011-01-13|September 24, 2012|2012-09-24|September 24, 2012||2012-09-24|||||Observational|||(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas|(11C)N-Desmethyl-Loperamide as a Marker of P-Glycoprotein Function in Patients With Gliomas|Terminated|||2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:56:55.861995|2018-05-31 22:56:55.861995
NCT01281969|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2016-08-31|2011-01-21|2011-01-24|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)|A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)|Unknown status|Active, not recruiting|Phase 3|48|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:56:55.914185|2018-05-31 22:56:55.914185
NCT01281956|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2018-02-13|2011-01-21|2011-01-24|Estimate|||||||2018-02-13|2018-02-14|Actual|January 7, 2011||2011-01-07|October 5, 2017|2017-10-05|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||PRX-00023 Therapy in Localization-Related Epilepsy|A Phase II Clinical Trial of PRX-00023 Therapy in Localization-Related Epilepsy|Terminated||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 22:56:56.116686|2018-05-31 22:56:56.116686
NCT01281943|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2013-07-02|2011-01-21|2011-01-24|Estimate|||||||2013-07-02|2013-07-04|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|May 2014|Anticipated|2014-05-31|July 2012|Anticipated|2012-07-31||Interventional|||Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer|Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1||Doxil Shortage|f||||f||||||||||2018-05-31 22:56:56.184079|2018-05-31 22:56:56.184079
NCT01281930|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Abscess Packing Versus Wick Placement After Incision and Drainage|Abscess Packing Versus Wick Placement After Incision and Drainage|Unknown status|Recruiting|N/A|160|Anticipated|Washington University School of Medicine||2|||f||||||||||||||2018-05-31 22:56:56.246103|2018-05-31 22:56:56.246103
NCT01281917|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2017-06-20||2017-07-21|2011-01-21|2011-01-24|Estimate|2017-07-21|2017-08-21|Actual||||2017-07-21|2017-08-21|Actual|February 2011||2011-02-28|July 2017|2017-07-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional||The study enrolled patients with relapsed and refractory B-cell non-Hodgkin lymphoma.|Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|Completed||Phase 2|40|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 22:56:56.334543|2018-05-31 22:56:56.334543
NCT01281904|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2015-08-05|2011-01-20|2011-01-24|Estimate|||||||2015-08-05|2015-08-06|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AcuCrft||Acupressure for Persistent Cancer Related Fatigue|Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors|Completed||Phase 2/Phase 3|288|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 22:56:56.75768|2018-05-31 22:56:56.75768
NCT01281891|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-09-11|2011-01-20|2011-01-24|Estimate|||||||2012-09-11|2012-09-12|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|HÖFTPLASTIK||Postoperative Pain Relief Following Total Hip Arthroplasty. A Comparison Between Intrathecal Morphine (IM) and Local Infiltration Analgesia (LIA)|Postoperative Pain Relief Following Total Hip Arthroplasty. A Comparison Between Intrathecal Morphine (IM) and Local Infiltration Analgesia (LIA)|Unknown status|Recruiting|Phase 4|80|Anticipated|Region Örebro County||2|||f||||t||||||||||2018-05-31 22:56:56.857547|2018-05-31 22:56:56.857547
NCT01281878|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-10-26|2011-01-21|2011-01-24|Estimate|||||||2012-10-26|2012-10-29|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PHOX-B6-Pilot||Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate|PILOTSTUDIE ZUR PYRIDOXALPHOSPHATTHERAPIE BEI PATIENTEN MIT PRIMÄRER HYPEROXALURIE TYP I (PHOX-B6-PILOT) Pilot Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate|Completed||Phase 2|12|Actual|University of Cologne||1|||f||||f||||||||||2018-05-31 22:56:56.951586|2018-05-31 22:56:56.951586
NCT01281865|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|2014-10-03||2014-10-03|2011-01-21|2011-01-24|Estimate|2014-10-03|2014-10-08|Estimate||||2014-10-03|2014-10-08|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma|A Phase 1b/2 Study of Imatinib in Combination With Everolimus in Synovial Sarcoma|Completed||Phase 1/Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:56:57.025799|2018-05-31 22:56:57.025799
NCT01281852|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2017-08-08|2011-01-21|2011-01-24|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2011||2011-03-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix|Completed||Phase 1|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:56:57.304509|2018-05-31 22:56:57.304509
NCT01281839|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2014-02-03||2014-03-26|2011-01-21|2011-01-24|Estimate|2014-03-26|2014-04-23|Estimate||||2014-03-26|2014-04-23|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PROMISE||An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects Who Relapsed After Previous Interferon-based Therapy|Completed||Phase 3|394|Actual|Janssen R&D Ireland||2|||f||||t||||||||||2018-05-31 22:56:57.480245|2018-05-31 22:56:57.480245
NCT01281826|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-02-09|2011-01-21|2011-01-24|Estimate|||||||2011-02-09|2011-02-11|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Dual-energy CT in Detecting Bone Marrow Edema of Vertebral Compression Fractures|Use of Dual-energy CT in Detecting Bone Marrow Edema of Vertebral Compression Fractures|Unknown status|Recruiting||70|Anticipated|National Cheng-Kung University Hospital|||||f||||t||||||||||2018-05-31 22:56:58.598978|2018-05-31 22:56:58.598978
NCT01281813|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2018-02-27|2011-01-20|2011-01-24|Estimate|||||||2018-02-27|2018-02-28|Actual|August 8, 2011|Actual|2011-08-08|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV|Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above|Active, not recruiting||Phase 3|133|Actual|Janssen Sciences Ireland UC||10|||f||||f||f||||||||2018-05-31 22:56:58.666959|2018-05-31 22:56:58.666959
NCT01281800|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-01-21|2011-01-21|2011-01-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|August 2008||2008-08-31|January 2011|2011-01-31||||August 2014|Anticipated|2014-08-31||Interventional|AGILI||Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma|Cisplatin With Either Alimta or Gemcitabine in Long Infusion for Mesothelioma: A Randomised Phase II Trial (AGILI Trial)|Unknown status|Recruiting|Phase 2|72|Anticipated|Institute of Oncology Ljubljana||2|||f||||||||||||||2018-05-31 22:56:58.825965|2018-05-31 22:56:58.825965
NCT01281787|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2014-06-17|2011-01-21|2011-01-24|Estimate|||||||2014-06-17|2014-06-18|Estimate|April 2008||2008-04-30|June 2014|2014-06-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|PRESAGE||PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer|Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer|Completed||Phase 3|320|Actual|European Institute of Oncology||3|||f||||f||||||||||2018-05-31 22:56:58.911664|2018-05-31 22:56:58.911664
NCT01281774|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2012-03-06|2011-01-21|2011-01-24|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers|An Adaptive, Phase I, Randomised, Placebo-controlled, Sponsor-unblinded, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous CSL112 in Healthy Volunteers|Completed||Phase 1|36|Actual|CSL Limited||2|||f||||t||||||||||2018-05-31 22:56:58.997971|2018-05-31 22:56:58.997971
NCT01281761|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2013-06-12|2011-01-21|2011-01-24|Estimate|||||||2013-06-12|2013-06-14|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)|Phase II Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer Patients Who Have Failed Irinotecan and Oxaliplatin-based Chemotherapy|Completed||Phase 2|52|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 22:56:59.06713|2018-05-31 22:56:59.06713
NCT01281748|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-21|2011-01-21|2011-01-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|July 2005||2005-07-31|May 2005|2005-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Evaluation Of The Efficacy Of Corticosteroids In Patients With An Acute Exacerbation Of Chronic Obstructive Pulmonary Disease Receiving Ventilator Support||Terminated||Phase 4|83|Actual|Hospital Universitario Getafe||2||Low rate of enrollment|f||||||||||||||2018-05-31 22:56:59.206771|2018-05-31 22:56:59.206771
NCT01281735|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2017-10-10|2011-01-20|2011-01-24|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2011||2011-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|ICMLPed||International Chronic Myeloid Leukemia Pediatric Study|INTERNATIONAL STUDY of Chronic Myeloid Leukaemia (CML) Treatment and Outcomes in Children and Adolescents|Recruiting|||750|Anticipated|Poitiers University Hospital|||||f||||t||||||||||2018-05-31 22:56:59.311591|2018-05-31 22:56:59.311591
NCT01281722|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-21|2011-01-21|2011-01-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|July 2019|Anticipated|2019-07-31|July 2014|Anticipated|2014-07-31||Observational|||Role of SLURP-1 in Melanoma and Melanoma Stem Cells||Recruiting|||150|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples With DNA|"~     serum, DNA, tissue~   "|||2018-05-31 22:56:59.449211|2018-05-31 22:56:59.449211
NCT01281709|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|April 2011|Anticipated|2011-04-30|March 2011|Anticipated|2011-03-31||Observational|||Primary Care Physician's Wishes and Influencing Factors Toward Provision of Integrated Health Care|Primary Care Physician's Wishes and Influencing Factors Toward Provision of Integrated Health Care|Unknown status|Enrolling by invitation||350|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 22:56:59.515131|2018-05-31 22:56:59.515131
NCT01281696|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|||2013-10-15|2011-01-21|2011-01-24|Estimate|||||||2013-10-15|2013-10-16|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis|A Phase II Study of Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis|Completed||Phase 2|40|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 22:56:59.581491|2018-05-31 22:56:59.581491
NCT01281683|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||||||Observational|||Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy|Dynamic Contrast-enhanced Magnetic Resonance Imaging in Evaluation of Liver Functional Status and Treatment Efficacy in Patients With Hepatocellular Carcinoma After Locoregional Therapy|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 22:56:59.654573|2018-05-31 22:56:59.654573
NCT01281670|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||The Effects of Combining Whole Body Vibration Training With Plyometric Jumping on the Neuromuscular Adaptations of Human Triceps Surae Muscles|The Effects of Combining Whole Body Vibration Training With Plyometric Jumping on the Neuromuscular Adaptations of Human Triceps Surae Muscles|Unknown status|Recruiting|N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 22:56:59.722145|2018-05-31 22:56:59.722145
NCT01281657|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-09-05|2011-01-21|2011-01-24|Estimate|||||||2012-09-05|2012-09-06|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program|A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program|Completed|||64|Actual|Novartis|||1||f||||||||||||||2018-05-31 22:56:59.832442|2018-05-31 22:56:59.832442
NCT01281644|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2014-08-14||2014-10-15|2011-01-21|2011-01-24|Estimate|2014-10-15|2014-10-20|Estimate||||2014-10-15|2014-10-20|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|KP||Treatment of Keratosis Pilaris With 810 nm Diode Laser|Treatment of Keratosis Pilaris With 810 nm Diode Laser|Completed||N/A|23|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 22:57:00.056612|2018-05-31 22:57:00.056612
NCT01281631|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17||2012-11-20|2012-11-20|2011-01-21|2011-01-24|Estimate||||2012-11-20|2012-11-22|Estimate|2012-11-20|2012-11-22|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|136|Actual|Neuraltus Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 22:57:00.236435|2018-05-31 22:57:00.236435
NCT01281618|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2013-05-03|2011-01-20|2011-01-24|Estimate|||||||2013-05-03|2013-05-06|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|CR20||Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus|Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus|Completed|||48|Actual|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     Tissue specimens from Barrett's esophagus~   "|||2018-05-31 22:57:00.312284|2018-05-31 22:57:00.312284
NCT01281605|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2016-03-15|2011-01-20|2011-01-24|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of Two Titration Programs of Adding Insulin Detemir to OADs in Poorly Controlled Type 2 Diabetes|Comparison of Two Titration Programs of Adding Insulin Detemir to Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes Patients|Unknown status|Recruiting|Phase 4|200|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:57:00.460073|2018-05-31 22:57:00.460073
NCT01281592|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2014-02-21|2011-01-20|2011-01-24|Estimate|||||||2014-02-21|2014-02-25|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours|Open-Label, Phase 1 Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours|Completed||Phase 1|36|Actual|Aptose Biosciences Inc.||1|||f||||||||||||||2018-05-31 22:57:00.58192|2018-05-31 22:57:00.58192
NCT01281579|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-11-29|2011-01-20|2011-01-24|Estimate|||||||2012-11-29|2012-11-30|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers|An Open-Label, Randomized, Parallel-Group, Single-Center Study to Evaluate the Single and Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Healthy Subjects|Completed||Phase 1|27|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||||||||||||2018-05-31 22:57:00.695418|2018-05-31 22:57:00.695418
NCT01281566|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|March 2003||2003-03-31|January 2011|2011-01-31|July 2003|Actual|2003-07-31|||||Interventional|||A Study of Cisapride in Premature Infants With Feeding Problems|Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of R051619 (Cisapride Oral Suspension 0.2mg/kg q.i.d) for the Treatment of Feeding Intolerance in Premature Infants|Terminated||Phase 4|8|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Sponsor request|f||||f||||||||||2018-05-31 22:57:00.811486|2018-05-31 22:57:00.811486
NCT01281553|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|September 2003||2003-09-30|January 2011|2011-01-31|October 2003|Actual|2003-10-31|||||Interventional|||A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease|Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of R051619 (Cisapride Oral Suspension 0.2 mg/kg q.i.d.) for the Treatment of Symptomatic Gastro-Oesophageal Reflux Disease (GORD) in Infants and Children|Terminated||Phase 4|6|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Sponsor request|f||||f||||||||||2018-05-31 22:57:00.92196|2018-05-31 22:57:00.92196
NCT01281540|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|May 2003||2003-05-31|January 2011|2011-01-31|November 2003|Actual|2003-11-30|||||Interventional|||An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options|Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options|Terminated||Phase 4|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Sponsor request|f||||f||||||||||2018-05-31 22:57:00.984785|2018-05-31 22:57:00.984785
NCT01281527|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2014-03-06|2011-01-20|2011-01-24|Estimate|||||||2014-03-06|2014-03-10|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|PALMFlexS||Paliperidone Palmitate Flexible Dosing in Schizophrenia|A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics|Completed||Phase 3|1044|Actual|Janssen-Cilag International NV||1|||f||||f||||||||||2018-05-31 22:57:01.097367|2018-05-31 22:57:01.097367
NCT01281514|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-02-23|2011-01-20|2011-01-24|Estimate|||||||2018-02-23|2018-02-27|Actual|December 14, 2010|Actual|2010-12-14|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE|Active, not recruiting||Phase 1|21|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 22:57:01.597289|2018-05-31 22:57:01.597289
NCT01281501|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2012-04-08||2013-09-09|2011-01-20|2011-01-24|Estimate|2012-06-20|2012-07-27|Estimate||||2013-09-09|2013-09-18|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole|A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain|Completed||Phase 4|87|Actual|Chulalongkorn University|1. This was a small, single-centered study. 2. Exaggerated self-evaluation of the patients' pain score and the physician’s expectation of a “good outcome” may also have biased the report. 3. The short-term recurrence of the pain was not studied.|2|||f||||f||||||||||2018-05-31 22:57:01.693778|2018-05-31 22:57:01.693778
NCT01281488|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2017-10-11|2011-01-20|2011-01-24|Estimate|||||||2017-10-11|2017-10-13|Actual|October 20, 2011||2011-10-20|October 2017|2017-10-31|October 9, 2017|Actual|2017-10-09|October 9, 2017|Actual|2017-10-09||Interventional|||Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors|A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors|Completed||Phase 1|28|Actual|City of Hope Medical Center||5|||f||||t||||||||||2018-05-31 22:57:02.033383|2018-05-31 22:57:02.033383
NCT01281475|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2016-08-06||2017-12-12|2011-01-21|2011-01-24|Estimate|2016-11-16|2017-01-13|Estimate||||2017-12-12|2018-01-09|Actual|January 2011||2011-01-31|December 2017|2017-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Only participants who completed the study were analyzed. Therefore all numbers in the Results section refer to the participants who completed the study.|A Trial of Levodopa in Angelman Syndrome|A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome|Completed||Phase 2/Phase 3|67|Actual|Boston Children’s Hospital||2|||f||||t||||||||Undecided||2018-05-31 22:57:02.15559|2018-05-31 22:57:02.15559
NCT01281462|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13||2013-06-10|2014-01-02|2011-01-20|2011-01-24|Estimate||||2013-06-10|2013-06-18|Estimate|2014-01-02|2014-02-03|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections|A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection|Completed||Phase 2|217|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 22:57:02.521809|2018-05-31 22:57:02.521809
NCT01281436|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-20|2011-01-20|2011-01-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|||Health Information Technology to Support Clinical Decision Making in Obesity Care|Health Information Technology to Support Clinical Decision Making in Obesity Care|Unknown status|Recruiting|N/A|24|Anticipated|Arizona State University||2|||f||||t||||||||||2018-05-31 22:57:02.670617|2018-05-31 22:57:02.670617
NCT01281410|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-06-30|2011-01-21|2011-01-24|Estimate|||||||2011-06-30|2011-07-04|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Inspiratory Muscle Training in Patients Receiving Allogenic Stem Cell Transplantation|Effectiveness of an Inspiratory Muscle Training in Patients Receiving Allogenic Stem Cell Transplantation|Unknown status|Recruiting|N/A|106|Anticipated|Elisabethinen Hospital||2|||f||||t||||||||||2018-05-31 22:57:02.810086|2018-05-31 22:57:02.810086
NCT01281397|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-12-01|2011-01-20|2011-01-21|Estimate|||||||2014-12-01|2014-12-03|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Bleeding Prediction in Patients Following Cardiac Surgery Using Whole Blood Aggregometry and Thromboelastometry|Bleeding Prediction in Patients Undergoing Cardiac Surgery Using Whole Blood Impedance Aggregometry and Rotational Thromboelastometry|Terminated|||148|Actual|University of Zagreb|||1|"After 148 patients enrolled, interim analysis revealed positive results in regard to primary~   hypothesis."|f||||t||||||||||2018-05-31 22:57:02.963726|2018-05-31 22:57:02.963726
NCT01281384|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2018-05-28|2011-01-20|2011-01-21|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2011||2011-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|OUTSMART||Routine vs Selective Cardiac Magnetic Resonance in Non-Ischemic Heart Failure|Routine vs Selective Cardiac Magnetic Resonance in Non-Ischemic Heart Failure (OUTSMART-HF) Project I-B of Imaging Modalities to Assist With Guiding Therapy and the Evaluation of Patients With Heart Failure (IMAGE-HF)|Active, not recruiting||N/A|518|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 22:57:03.053599|2018-05-31 22:57:03.053599
NCT01281371|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2013-06-26|2011-01-20|2011-01-21|Estimate|||||||2013-06-26|2013-06-27|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan|Clinical Devolution of a Medication Change at Patients With Mono- or Combination Therapy With Sitaxentan to a Regime Without Sitaxentan.|Completed|||9|Actual|Heidelberg University|||||f||||f||||||Samples With DNA|"~     only remaining blood of the security laboratory for analysis of plasma concentrations of~     drugs~   "|||2018-05-31 22:57:03.166994|2018-05-31 22:57:03.166994
NCT01281358|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2015-12-01|2011-01-20|2011-01-21|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|HOP-ON||Helping Our Premature Infants ON to Better Motor Skills (HOP-ON)|Development and Evaluation of a Parenting Intervention to Promote Development in Infants Born Very Premature|Completed||N/A|160|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 22:57:03.246381|2018-05-31 22:57:03.246381
NCT01281345|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2014-11-18|2011-01-20|2011-01-21|Estimate|||||||2014-11-18|2014-11-19|Estimate|April 2011||2011-04-30|January 2011|2011-01-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|||SIHAM Candidemia Network:An Observational Study|A Multicenter Observational Study of Candidemia Among ICU Patients in India|Completed|||1400|Actual|Society of Indian Human & Animal Mycologist|||||f||||f||||||Samples With DNA|"~     Candida isolates~   "|||2018-05-31 22:57:03.335168|2018-05-31 22:57:03.335168
NCT01281332|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2015-09-09|2011-01-20|2011-01-21|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Mechanical Device for the Relief of Hot Flashes|Evaluation of a Novel Mechanical Device for Relief of Menopausal Vasomotor Symptoms.|Completed||Phase 2|40|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 22:57:03.399425|2018-05-31 22:57:03.399425
NCT01281319|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-21|Estimate|||||||2011-01-20|2011-01-21|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Evaluation of a Serology Diagnostic Kit for the Detection of Genital Mycoplasma in Pregnancy|Evaluation of a Diagnostic Kit for the Detection of Serum Antibodies Anti Genital Mycoplasma in High Risk Pregnant Women|Unknown status|Recruiting||300|Anticipated|Promyco Diagnostics|||3||f||||f||||||Samples With DNA|"~     Cervix swab, amniotic fluid and serum samples~   "|||2018-05-31 22:57:03.480747|2018-05-31 22:57:03.480747
NCT01281306|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2015-07-21|2013-01-02|2015-12-22|2011-01-20|2011-01-21|Estimate|2015-07-21|2015-08-18|Estimate|2013-01-02|2013-01-04|Estimate|2015-12-22|2016-01-29|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension|Completed||Phase 2|910|Actual|Novartis||7|||f||||||||||||||2018-05-31 22:57:03.59903|2018-05-31 22:57:03.59903
NCT01281293|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2017-12-14|2011-01-20|2011-01-21|Estimate|||||||2017-12-14|2017-12-18|Actual|January 2011|Actual|2011-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|V-COMPAS||Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated|A Post Market, Long Term, Prospective, Observational, Multi-site Outcome Study to Follow the Clinical Course and Seizure Reduction of Patients With Refractory Seizures Who Are Being Treated With Adjunctive VNS Therapy.|Active, not recruiting|||124|Actual|LivaNova|||||f||||f||||||||||2018-05-31 22:57:04.912662|2018-05-31 22:57:04.912662
NCT01281280|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-10-14|2011-01-20|2011-01-21|Estimate|||||||2014-10-14|2014-10-16|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Observational|PuLsE 2||PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1|A Post-Market, Open Observational Long-term Effectiveness Follow-up Study of Participants With Drug-resistant Epilepsy With Partial-onset Seizures Previously Enrolled in a Randomized Controlled Trial (E-100: PuLsE) Comparing Best Medical Practice With or w/o Adjunctive Vagus Nerve Stimulation Therapy|Completed|||81|Actual|Cyberonics, Inc.|||2||f||||f||||||||||2018-05-31 22:57:04.993143|2018-05-31 22:57:04.993143
NCT01281267|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2017-03-20|2011-01-20|2011-01-21|Estimate|||||||2017-03-20|2017-03-22|Actual|September 2009||2009-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Face Transplantation for Treatment of Severe Facial Deformity|Transplantation of Allograft Face or Facial Subunit for Treatment of Severe Facial Deformation|Recruiting||N/A|10|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 22:57:05.084315|2018-05-31 22:57:05.084315
NCT01281254|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20||2015-04-23|2017-11-27|2011-01-20|2011-01-21|Estimate||||2015-04-23|2015-05-12|Estimate|2017-11-27|2017-12-02|Actual|April 18, 2011|Actual|2011-04-18|November 2017|2017-11-30|April 19, 2017|Actual|2017-04-19|August 29, 2014|Actual|2014-08-29||Interventional|||AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)|A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Terminated||Phase 3|223|Actual|Amgen||2||"Closure of long term follow up (LTFU) and study earlier than previously outlined in the~   protocol as no beneficial information gained from continuing LTFU."|f||||t||||||||||2018-05-31 22:57:05.258411|2018-05-31 22:57:05.258411
NCT01281241|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-21|Estimate|||||||2011-01-20|2011-01-21|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Observational|||Study on Mechanical and Electrical Alternans|The Connection Between Mechanical Alternans Measured by Pressure-Volume (PV) Loop Catheter in Patients With Ischemic Heart Failure and the Occurrence of Microvolt T Wave Alternans (MTWA)|Unknown status|Active, not recruiting||10|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||t||||||||||2018-05-31 22:57:05.449137|2018-05-31 22:57:05.449137
NCT01281228|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2015-06-02|2011-01-20|2011-01-21|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|Braini-Ex||The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes|The Effect of GLP-1 Receptor Activation on Central Reward and Satiety Circuits in Response to Food Stimuli in Obesity and Diabetes|Completed||N/A|48|Actual|VU University Medical Center||3|||f||||f||||||||||2018-05-31 22:57:05.515149|2018-05-31 22:57:05.515149
NCT01281215|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-10-31|2011-01-20|2011-01-21|Estimate|||||||2012-10-31|2012-11-01|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Education Interventions Model for Rational Drug Use (RDU)|Education Interventions Model for Rational Drug Use|Completed||N/A|120|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:57:05.591252|2018-05-31 22:57:05.591252
NCT01281202|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2016-02-02||2016-05-16|2011-01-20|2011-01-21|Estimate|2016-02-19|2016-02-23|Estimate||||2016-05-16|2016-05-18|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Vigabatrin for the Treatment of Cocaine Dependency|Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study|Completed||Phase 2/Phase 3|207|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||Yes||2018-05-31 22:57:05.665922|2018-05-31 22:57:05.665922
NCT01281189|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20||2014-11-24|2017-12-13|2011-01-20|2011-01-21|Estimate||||2014-11-24|2014-12-11|Estimate|2017-12-13|2017-12-15|Actual|March 2011||2011-03-31|December 2017|2017-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|EMPOWER||Phase 3 Study of Dexpramipexole in ALS|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis|Completed||Phase 3|943|Actual|Knopp Biosciences||2|||f||||t||||||||||2018-05-31 22:57:05.99913|2018-05-31 22:57:05.99913
NCT01281176|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2018-05-23|2011-01-20|2011-01-21|Estimate|||||||2018-05-23|2018-05-24|Actual|February 9, 2011|Actual|2011-02-09|May 2018|2018-05-31||||April 30, 2014|Actual|2014-04-30||Interventional|||High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors|Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study|Active, not recruiting||Phase 1|20|Actual|National Cancer Institute (NCI)||6|||f||||t||||||||||2018-05-31 22:57:06.284653|2018-05-31 22:57:06.284653
NCT01281163|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2015-08-26|2011-01-20|2011-01-21|Estimate|||||||2015-08-26|2015-08-27|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer|A Phase 1b Dose-Escalation Study of the AKT Inhibitor MK-2206 (NSC# 749607) Plus Lapatinib (NSC# 727989) Administered in Patients With HER2 Positive Metastatic Breast Cancer|Terminated||Phase 1|4|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:57:06.456866|2018-05-31 22:57:06.456866
NCT01281150|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2015-05-22|2011-01-20|2011-01-21|Estimate|||||||2015-05-22|2015-05-25|Estimate|January 2011||2011-01-31|May 2015|2015-05-31||||April 2015|Actual|2015-04-30||Interventional|||Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors|Completed||Phase 1|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:57:06.555441|2018-05-31 22:57:06.555441
NCT01281137|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2017-08-08|2011-01-20|2011-01-21|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2011|Actual|2011-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|SOLE-EST||Study of Changes in Estrogen Levels and Grip Strength in Postmenopausal Women Who Have Received 4 to 6 Years of Hormone Therapy for Breast Cancer and Are Currently Receiving Letrozole on Clinical Trial IBCSG-35-07|SOLE Estrogen Substudy (SOLE-EST) - Investigating Changes in Estrogen Levels and Grip Strength for Patients Participating in the SOLE Trial|Active, not recruiting|||104|Actual|International Breast Cancer Study Group|||||f||||t||||||Samples With DNA|"~     Serum, whole blood,~   "|||2018-05-31 22:57:06.641699|2018-05-31 22:57:06.641699
NCT01281124|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2013-05-15||2018-05-23|2011-01-20|2011-01-21|Estimate|2013-09-05|2013-09-13|Estimate||||2018-05-23|2018-05-24|Actual|January 12, 2011|Actual|2011-01-12|May 2018|2018-05-31||||April 15, 2011|Actual|2011-04-15||Interventional|||Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer|Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC|Active, not recruiting||Phase 2|1|Actual|National Cancer Institute (NCI)|Due to low enrollment of this trial all outcomes were not assessed.|1|||f||||||||||||||2018-05-31 22:57:06.713447|2018-05-31 22:57:06.713447
NCT01281111|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-11-17|2011-01-20|2011-01-21|Estimate|||||||2011-11-17|2011-11-18|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|109HV106||Alternate Dosing Regimens of BG00012 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of BG00012 Administered With and Without 325 mg Aspirin in Healthy Adult Volunteers|Completed||Phase 1|56|Actual|Biogen||5|||f||||f||||||||||2018-05-31 22:57:06.930255|2018-05-31 22:57:06.930255
NCT01281098|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2015-03-18|2011-01-20|2011-01-21|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.|Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy (PDR).|Completed||Phase 2|22|Actual|Association for Innovation and Biomedical Research on Light and Image||2|||f||||f||||||||||2018-05-31 22:57:07.012084|2018-05-31 22:57:07.012084
NCT01281085|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-04-13|2011-01-20|2011-01-21|Estimate|||||||2011-04-13|2011-04-14|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Validation of a Score for Shoulder Function Evaluation Based on Movement Analysis|Validation of a Kinematic Functional Shoulder Score Including Only Essential Movements: a Pilot Study|Completed|||16|Actual|Haute Ecole Cantonale Vaudoise de Santé|||1||f||||f||||||||||2018-05-31 22:57:07.102215|2018-05-31 22:57:07.102215
NCT01281072|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2011-01-20|2011-01-20|2011-01-21|Estimate|||||||2011-01-20|2011-01-21|Estimate||||January 2011|2011-01-31||||||||Interventional|||Study To Evaluate Long Term Treatment Effect Of Diapep277® In Patients Who Have Completed Study 901 And Study 910** (Extension To 901)||Unknown status|Not yet recruiting|Phase 3|||Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 22:57:07.175116|2018-05-31 22:57:07.175116
NCT01281059|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-08-27|2011-01-20|2011-01-21|Estimate|||||||2012-08-27|2012-08-28|Estimate|January 2011||2011-01-31|August 2011|2011-08-31||||||||Interventional|||Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test||Unknown status|Active, not recruiting|N/A|||Hadassah Medical Organization|||||f||||t||||||||||2018-05-31 22:57:07.231379|2018-05-31 22:57:07.231379
NCT01281033|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2013-07-31|2011-01-20|2011-01-21|Estimate|||||||2013-07-31|2013-08-01|Estimate|December 2010||2010-12-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|SMART||CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial|CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial|Completed||Phase 4|80|Actual|Careggi Hospital||2|||f||||t||||||||||2018-05-31 22:57:07.293675|2018-05-31 22:57:07.293675
NCT01281020|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2014-05-09|2011-01-20|2011-01-21|Estimate|||||||2014-05-09|2014-05-12|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|||Adherence With Fixed Versus Unfixed Glaucoma Therapy|A 3-month, Observational Study Investigating With Electronic Monitoring the Level of Adherence and Treatment Satisfaction With Latanoprost/Timolol Fixed Combination Versus Unfixed Therapy in Open-angle Glaucoma|Completed|||132|Actual|Aristotle University Of Thessaloniki|||2||f||||f||||||||||2018-05-31 22:57:07.370558|2018-05-31 22:57:07.370558
NCT01281007|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2015-05-29||2015-07-03|2011-01-20|2011-01-21|Estimate|2015-07-03|2015-07-07|Estimate||||2015-07-03|2015-07-07|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes|A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes|Completed||Phase 3|150|Actual|EMS||2|||f||||t||||||||||2018-05-31 22:57:07.445082|2018-05-31 22:57:07.445082
NCT01280994|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2018-04-18|2011-01-20|2011-01-21|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2011||2011-01-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Hyperpolarized 129Xe MRI for Imaging Pulmonary Function|Hyperpolarized 129Xe MR Imaging of the Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease|Recruiting||Phase 1|160|Anticipated|Duke University|||||f||||f||||||||||2018-05-31 22:57:07.653876|2018-05-31 22:57:07.653876
NCT01280981|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2011-05-03||2011-06-28|2011-01-19|2011-01-21|Estimate|2011-06-28|2011-07-26|Estimate||||2011-06-28|2011-07-26|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding|A Multi-center, Open Label Extension Study to Evaluate the Safety of an Oral Dose of Tranexamic Acid (XP12B) Administered Three Times Daily During Menstruation for the Treatment of Menorrhagia|Completed||Phase 3|288|Actual|Ferring Pharmaceuticals||1|||f||||t||||||||||2018-05-31 22:57:07.77431|2018-05-31 22:57:07.77431
NCT01280968|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2013-10-29||2014-01-29|2011-01-20|2011-01-21|Estimate|2013-10-29|2013-12-18|Estimate||||2014-01-29|2014-03-05|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional|PETNic002||Improving the Efficacy of Anti-Nicotine Immunotherapy|Improving the Efficacy of Anti-Nicotine Immunotherapy|Completed||Phase 2|52|Actual|Duke University||2|||f||||t||||||||||2018-05-31 22:57:08.379613|2018-05-31 22:57:08.379613
NCT01280955|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2015-09-27||2017-03-24|2011-01-20|2011-01-21|Estimate|2015-10-26|2015-11-26|Estimate||||2017-03-24|2017-04-25|Actual|December 2011|Actual|2011-12-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional||Baseline includes transplant recipients only and excludes 1 patient who withdrew from the study.|Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant|A Phase I/II Study: Enhancing Donor Hematopoietic Cell Engraftment With Plerixafor in Myeloablative Allogeneic Hematopoietic Cell Transplantation|Completed||Phase 1/Phase 2|41|Actual|Duke University|Study was limited to recipients of matched adult donor grafts|1|||f||||t||||||||||2018-05-31 22:57:08.756656|2018-05-31 22:57:08.756656
NCT01280942|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2014-05-27||2018-02-07|2011-01-20|2011-01-21|Estimate|2018-02-07|2018-02-14|Actual||||2018-02-07|2018-02-14|Actual|January 2011||2011-01-31|February 2018|2018-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Early Warning System for Clinical Deterioration on General Hospital Wards|Early Warning System for Clinical Deterioration on General Hospital Wards.|Completed||N/A|20031|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 22:57:09.131563|2018-05-31 22:57:09.131563
NCT01280747|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-06-06|2011-01-19|2011-01-21|Estimate|||||||2012-06-06|2012-06-07|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study|Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study|Terminated|||42|Actual|Pfizer|||4|See termination reason in detailed description.|f||||f||||||||||2018-05-31 22:57:12.918844|2018-05-31 22:57:12.918844
NCT01280929|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2015-10-07|2011-01-20|2011-01-21|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy|Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy (Ranibizumab 0.5 mg Intravitreal Injections) Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP (Monotherapy) in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy|Completed||Phase 2|54|Actual|Association for Innovation and Biomedical Research on Light and Image||3|||f||||f||||||||||2018-05-31 22:57:09.355094|2018-05-31 22:57:09.355094
NCT01280916|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2012-09-12|2011-01-19|2011-01-21|Estimate|||||||2012-09-12|2012-09-14|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Interventional|||Mindful Awareness in Body-Oriented Therapy for Women's Substance Abuse Treatment|Mindful Awareness in Body-Oriented Therapy for Women's Substance Abuse Treatment|Completed||Phase 1|46|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 22:57:10.393089|2018-05-31 22:57:10.393089
NCT01280903|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2016-12-13||2018-01-02|2011-01-19|2011-01-21|Estimate|2018-01-02|2018-01-31|Actual||||2018-01-02|2018-01-31|Actual|January 2012||2012-01-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|STAR||Staying Active With Arthritis: RCT of Physical Activity for Older Adults With Osteoarthritis and Hypertension|Promoting Physical Activity in Older Adults With Comorbidity|Completed||N/A|182|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 22:57:10.538688|2018-05-31 22:57:10.538688
NCT01280890|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-06-11|2011-01-20|2011-01-21|Estimate|||||||2012-06-11|2012-06-12|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Person- Centred Care Among Nursing Home Patients With Dementia|Person-centred Care and Dementia Care Mapping Among Nursing Home Patients - a 10 Months Randomised Controlled Intervention Study|Completed||N/A|624|Actual|Norwegian Centre for Ageing and Health||3|||f||||t||||||||||2018-05-31 22:57:11.957968|2018-05-31 22:57:11.957968
NCT01280877|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2017-01-27|2011-01-19|2011-01-21|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2010||2010-12-31|January 2017|2017-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)|Multicenter Study of Paraorbital-Occipital Alternating Current Stimulation Therapy in Patients With Optic Neuropathy|Completed||N/A|90|Actual|University of Magdeburg||2|||f||||f|f|f||||||Undecided||2018-05-31 22:57:12.034756|2018-05-31 22:57:12.034756
NCT01280864|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-04-18|2011-01-19|2011-01-21|Estimate|||||||2012-04-18|2012-04-20|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||MAPP Investigation of Pelvic Floor-Brain Neurobiologic Axis in IC/IBS and IBS|Investigation of Pelvic Floor-Brain Neurobiologic Axis in IC/IBS and IBS|Terminated|||36|Actual|University of Iowa|||3|the study PI left the university of iowa|f||||||||||||||2018-05-31 22:57:12.114843|2018-05-31 22:57:12.114843
NCT01280851|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-01-13|2011-01-20|2011-01-21|Estimate|||||||2012-01-13|2012-01-18|Estimate|September 2011||2011-09-30|January 2012|2012-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Living Renal Donor MRI Study|Comprehensive Morphological and Functional Assessment of Living Renal Donor With Magnetic Resonance Imaging With Comparison to Computed Tomographic Angiography and Renal Scintigraphy|Withdrawn||N/A|0|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 22:57:12.198431|2018-05-31 22:57:12.198431
NCT01280838|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2015-05-26|2011-01-19|2011-01-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico|Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico|Completed||N/A|400|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 22:57:12.259129|2018-05-31 22:57:12.259129
NCT01280825|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2018-01-09|2011-01-19|2011-01-21|Estimate|||||||2018-01-09|2018-01-11|Actual|January 14, 2011|Actual|2011-01-14|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing|The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing|Recruiting|||1200|Anticipated|University of Chicago|||1||f||||f||||||Samples With DNA|"~     Whole blood and DNA~   "|||2018-05-31 22:57:12.329788|2018-05-31 22:57:12.329788
NCT01280812|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2015-05-26|2011-01-20|2011-01-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2011||2011-02-28|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Applying Mobile Persuasive Technologies to Increase Physical Activity in Women|Applying Mobile Persuasive Technologies to Increase Physical Activity in Women|Completed||N/A|210|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 22:57:12.385296|2018-05-31 22:57:12.385296
NCT01280799|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-05-16|2011-01-19|2011-01-21|Estimate|||||||2014-05-16|2014-05-19|Estimate|May 2009||2009-05-31|May 2014|2014-05-31||||May 2012|Actual|2012-05-31||Interventional|||Family Treatment for Adolescents With Anorexia Nervosa|Acceptance Based Separated Family Treatment for Adolescents With Anorexia Nervosa|Completed||Phase 1|26|Actual|Towson University||1|||f||||t||||||||||2018-05-31 22:57:12.570146|2018-05-31 22:57:12.570146
NCT01280786|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2014-01-31|2011-01-19|2011-01-21|Estimate|||||||2014-01-31|2014-02-03|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-05-31 22:57:12.65129|2018-05-31 22:57:12.65129
NCT01280773|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2016-08-02|2011-01-19|2011-01-21|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of NAVA on Duration of Weaning in Difficult to Wean Patients|Department of Critical Care Medicine, Nanjing Zhong-Da Hospital, Southeast University School of Medicine, China; Department of Critical Care Medicine St. Michaels's Hospital, University of Toronto, Canada|Completed||N/A|91|Actual|Southeast University, China||2|||f||||t||||||||||2018-05-31 22:57:12.75469|2018-05-31 22:57:12.75469
NCT01280760|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2013-12-18|2011-01-19|2011-01-21|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Observational|NAVA-NIV||Impact of Neurally Adjusted Ventilator Assist (NAVA) Mode on Patient Ventilator Asynchrony Using Non-invasive Ventilation (NAVA-NIV)|Impact of Neurally Adjusted Ventilator Assist (NAVA) Mode on Patient Ventilator Asynchrony Using Non-invasive Ventilation (NAVA-NIV)|Completed|||16|Actual|Pierre and Marie Curie University|||1||f||||f||||||||||2018-05-31 22:57:12.853771|2018-05-31 22:57:12.853771
NCT01280734|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-12-11|2011-01-20|2011-01-21|Estimate|||||||2011-12-11|2011-12-13|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects|Randomised, Double-blind, 3-way Crossover, Single Dose, Placebo-controlled Study Investigating the Effect on Postural Instability of Melatonin and Zolpidem in Healthy Adult Subjects Aged of 55 to 64 Years.|Completed||Phase 4|26|Actual|Neurim Pharmaceuticals Ltd.||3|||f||||t||||||||||2018-05-31 22:57:13.039504|2018-05-31 22:57:13.039504
NCT01280721|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-10-16|2011-01-19|2011-01-21|Estimate|||||||2015-10-16|2015-10-19|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]|A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]|Completed||Phase 3|135|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 22:57:13.118244|2018-05-31 22:57:13.118244
NCT01280708|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-09-06|2011-01-20|2011-01-21|Estimate|||||||2011-09-06|2011-09-07|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Protocol DIVAT-Uro|Establishment of a National Thematic Network in Urology for the Extension of the Cohort DIVAT (Données Informatisées et Validées en Transplantation) in Surgical Parameters of Renal and Pancreatic Transplant Patients : An Innovative Tool for the Promotion of Epidemiological Studies, Identification of Risk Factors and Good Practices in the Domain of Transplant Surgery|Unknown status|Recruiting||2000|Anticipated|Nantes University Hospital|||1||f||||t||||||||||2018-05-31 22:57:13.188239|2018-05-31 22:57:13.188239
NCT01280695|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2013-10-30||2014-03-17|2011-01-20|2011-01-21|Estimate|2013-10-30|2013-12-20|Estimate||||2014-03-17|2014-04-14|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients|A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients|Completed||Phase 2|129|Actual|Metabolic Solutions Development Company||5|||f||||f||||||||||2018-05-31 22:57:13.269463|2018-05-31 22:57:13.269463
NCT01280682|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2011-01-19|2011-01-19|2011-01-21|Estimate|||||||2011-01-19|2011-01-21|Estimate|July 2010||2010-07-31|April 2010|2010-04-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes|Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes|Unknown status|Recruiting|Phase 4|50|Anticipated|Nanjing Medical University||1|||f||||t||||||||||2018-05-31 22:57:13.847654|2018-05-31 22:57:13.847654
NCT01280669|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2017-08-03|2011-01-20|2011-01-21|Estimate|||||||2017-08-03|2017-08-07|Actual|March 2011||2011-03-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|SAVE-2||Intravitreal Sirolimus as Therapeutic Approach to Uveitis|Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis|Recruiting||Phase 2|30|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 22:57:13.933215|2018-05-31 22:57:13.933215
NCT01280656|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2016-08-02||2016-10-06|2011-01-20|2011-01-21|Estimate|2016-08-02|2016-09-26|Estimate||||2016-10-06|2016-11-29|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|June 2013|Actual|2013-06-30|November 2012|Actual|2012-11-30||Observational|||A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)|Retrospective Study to Evaluate the Impact of Using Interferon (Pegylated or Not) in the Treatment of Patients With Chronic Hepatitis C in Brazil (DECISION)|Completed|||660|Actual|Hoffmann-La Roche|||3||f||||||||||||||2018-05-31 22:57:14.046083|2018-05-31 22:57:14.046083
NCT01280643|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2015-09-10|2011-01-20|2011-01-21|Estimate|||||||2015-09-10|2015-09-11|Estimate|March 2010||2010-03-31|September 2015|2015-09-30||||December 2012|Actual|2012-12-31||Interventional|||Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|An Exploratory Study of Chemotherapy for Metastatic Colorectal Cancer Based Upon Thymidine Phosphorylase Expression, KRAS and BRAF Mutation Status, and ERCC1 Expression|Completed||N/A|11|Actual|Fox Chase Cancer Center||9|||f||||t||||||||||2018-05-31 22:57:14.861272|2018-05-31 22:57:14.861272
NCT01280630|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2012-01-31|2011-01-20|2011-01-21|Estimate|||||||2012-01-31|2012-02-01|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|TRACE||Multicentre Retrospective Study to Understand Anti-thrombotic Treatment Patterns and Outcomes of Acute Coronary Syndrome (ACS) Patients|A Multicentre Retrospective Study to Understand Anti-thrombotic Treatment Patterns and Outcomes of Acute Coronary Syndrome (ACS) Patients in India|Completed|||500|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:57:15.05017|2018-05-31 22:57:15.05017
NCT01280617|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-05-28|2011-01-20|2011-01-21|Estimate|||||||2014-05-28|2014-05-29|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Low Dose Thymoglobin in Renal Transplant Patients|Low Dose Thymoglobulin As Induction Agent on Prednisone-Free Regimens of Renal Transplant Recipients|Completed||N/A|58|Actual|Lahey Clinic||2|||f||||f||||||||||2018-05-31 22:57:15.116599|2018-05-31 22:57:15.116599
NCT01280604|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2014-10-14||2015-06-04|2011-01-19|2011-01-21|Estimate|2015-06-04|2015-06-08|Estimate||||2015-06-04|2015-06-08|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy|Effects of Fenofibrate 160mg to 54mg Conversion on Triglyceride Levels in Patients on Statin Therapy|Completed||N/A|66|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 22:57:15.228937|2018-05-31 22:57:15.228937
NCT01280591|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|2014-01-24|2012-05-23|2015-05-13|2011-01-20|2011-01-21|Estimate|2014-05-16|2014-06-17|Estimate|2012-05-23|2012-05-31|Estimate|2015-05-13|2015-06-08|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|Morpheus II||Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain|A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep|Completed||Phase 3|712|Actual|Bayer||4|||f||||f||||||||||2018-05-31 22:57:15.687905|2018-05-31 22:57:15.687905
NCT01280578|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2017-06-26|2011-01-19|2011-01-21|Estimate|||||||2017-06-26|2017-06-27|Actual|February 1, 2011|Actual|2011-02-01|June 2017|2017-06-30|June 1, 2012|Actual|2012-06-01|June 1, 2012|Actual|2012-06-01||Observational|||The Coherex FlatStent™ EF PFO Migraine Registry|The Coherex PFO Migraine Registry|Terminated|||3|Actual|Coherex Medical||||Lack of enrollment|f||||t||||||||||2018-05-31 22:57:16.710645|2018-05-31 22:57:16.710645
NCT01280565|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2015-10-07|2011-01-19|2011-01-21|Estimate|||||||2015-10-07|2015-10-08|Estimate|January 2011||2011-01-31|October 2015|2015-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit|A Prospective, Multicenter, Randomized, Open-label, Activecontrolled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Dacarbazine in the Treatment of Patients With Non-resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-kit|Unknown status|Recruiting|Phase 3|200|Anticipated|AB Science||2|||f||||t||||||||||2018-05-31 22:57:16.754681|2018-05-31 22:57:16.754681
NCT01280552|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2014-10-02||2017-02-10|2011-01-19|2011-01-20|Estimate|2014-10-02|2014-10-07|Estimate||||2017-02-10|2017-03-20|Actual|January 2011||2011-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)|A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation|Completed||Phase 2|124|Actual|ImmunoCellular Therapeutics, Ltd.||2|||f||||t||||||||||2018-05-31 22:57:16.844262|2018-05-31 22:57:16.844262
NCT01280539|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-09-04|2011-01-19|2011-01-20|Estimate|||||||2012-09-04|2012-09-05|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Multiple Sclerosis||Completed||N/A|20|Anticipated|Hasselt University||2|||f||||t||||||||||2018-05-31 22:57:17.217809|2018-05-31 22:57:17.217809
NCT01280526|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2014-05-21|2011-01-19|2011-01-20|Estimate|||||||2014-05-21|2014-05-22|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|November 2012|Actual|2012-11-30||Interventional|Ro-CHOP||A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas|A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax®) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas|Completed||Phase 1/Phase 2|37|Actual|The Lymphoma Academic Research Organisation||4|||f||||t||||||||||2018-05-31 22:57:17.282764|2018-05-31 22:57:17.282764
NCT01280513|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-08-01|2011-01-19|2011-01-20|Estimate|||||||2012-08-01|2012-08-02|Estimate|October 2009||2009-10-31|August 2012|2012-08-31||||June 2010|Actual|2010-06-30||Interventional|||Effect of Increased Protein Intake on Colonic Metabolism|Influence of a Protein Diet on the Colonic Metabolism and Phosphorus Housekeeping in Healthy Volunteers.|Completed||N/A|20|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 22:57:17.371188|2018-05-31 22:57:17.371188
NCT01280500|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2018-02-04|2011-01-19|2011-01-20|Estimate|||||||2018-02-04|2018-02-06|Actual|March 2011||2011-03-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN|Accelerating Implementation of Comparative Effectiveness Findings on Clinical and Delivery Systems by Leveraging AHRQ Networks|Completed||N/A|1040|Actual|Carolinas Healthcare System||5|||f||||t||||||||||2018-05-31 22:57:17.436644|2018-05-31 22:57:17.436644
NCT01280487|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-01-15|2011-01-19|2011-01-20|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||A Safety Study of Oral ZSTK474 in Patients With Cancer|A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies|Completed||Phase 1|39|Actual|Zenyaku Kogyo Co., Ltd.||1|||f||||t||||||||||2018-05-31 22:57:17.527995|2018-05-31 22:57:17.527995
NCT01280474|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|August 2013|Anticipated|2013-08-31|||||Observational|||Effects of Maternal Depressive Symptomatology on Pregnancy Outcomes and Newborn Development --- How is Paternal Psychopathology Involved?|Effects of Maternal Depressive Symptomatology on Pregnancy Outcomes and Newborn Development --- How is Paternal Psychopathology Involved?|Unknown status|Active, not recruiting||300|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:57:17.620642|2018-05-31 22:57:17.620642
NCT01280461|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|July 2010||2010-07-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|||||Observational|||An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia|An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia|Unknown status|Enrolling by invitation||142|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||t||||||||||2018-05-31 22:57:17.676527|2018-05-31 22:57:17.676527
NCT01280448|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|September 2013|Anticipated|2013-09-30|||||Observational|||The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism|The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism|Unknown status|Active, not recruiting||600|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||Samples With DNA|"~     genes~   "|||2018-05-31 22:57:17.741141|2018-05-31 22:57:17.741141
NCT01280435|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|||||Observational|||Islide-Establishing a Clinical Dermatopathology Online Discourse System|Islide-Establishing a Clinical Dermatopathology Online Discourse System|Completed|||80|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:57:17.798804|2018-05-31 22:57:17.798804
NCT01280422|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|August 2010|Actual|2010-08-31|||||Observational|||Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database|Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database|Completed|||67128927|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:57:17.856245|2018-05-31 22:57:17.856245
NCT01280409|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2015-12-03|2011-01-19|2011-01-20|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|||Metformin Postpartum for GDM RCT for Reduced Weight Retention|The Effects of Metformin on Retained Postpartum Weight in Women With Gestational Diabetes: A Randomized, Placebo-Controlled Trial|Completed||Phase 4|114|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 22:57:17.901195|2018-05-31 22:57:17.901195
NCT01280396|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2018-04-30|2011-01-19|2011-01-20|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2010||2010-11-30|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|||Metabolic Side-effects for Second-generation Antipsychotics|Metabolic Side-effects in Patients Receiving Clozapine and Second-generation Antipsychotics in an Outpatient Clinic|Completed|||241|Actual|The University of Hong Kong|||1||f||||||||||||||2018-05-31 22:57:17.979194|2018-05-31 22:57:17.979194
NCT01280383|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-07-22|2011-01-19|2011-01-20|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Non-invasive Neurally Adjusted Ventilatory Assist|Non-invasive Neurally Adjusted Ventilatory Assist (niNAVA) After Extubation: Proposal for a Crossover-randomized Feasibility Trial|Withdrawn||Phase 1|0|Actual|University Hospital Inselspital, Berne||1||Study does not meet the new legal requirements set forth in the Human Research Act|f||||f||||||||||2018-05-31 22:57:18.043977|2018-05-31 22:57:18.043977
NCT01280370|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2018-03-26|2011-01-19|2011-01-20|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2010||2010-09-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|IHR_SALTC||Prospective Evaluation of Laparoscopic and Open Incisional Hernia Repair: a Multicenter Cohort Study|Prospective Evaluation of Laparoscopic and Open Hernia Repair: a Multicenter Cohort Study|Active, not recruiting|||371|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 22:57:18.11331|2018-05-31 22:57:18.11331
NCT01280357|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|2011-08-11||2013-03-20|2011-01-19|2011-01-20|Estimate|2013-03-20|2013-03-21|Estimate||||2013-03-20|2013-03-21|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Accuracy and Reliability of Fetal Heart Rate and Uterine Contraction Monitoring Method|Study to Determine Substantial Equivalence of Electrohysterography (EHG) Monitoring to Tocodynanometer Monitoring|Completed||N/A|60|Actual|Monica Healthcare Ltd||2|||f||||f||||||||||2018-05-31 22:57:18.193765|2018-05-31 22:57:18.193765
NCT01280344|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13||2013-08-30|2017-04-12|2011-01-19|2011-01-20|Estimate||||2013-08-30|2013-09-13|Estimate|2017-04-12|2017-04-13|Actual|April 2011|Actual|2011-04-30|April 2017|2017-04-30|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function|Phase II Double-Blind Placebo-Controlled Dose Finding Study to Evaluate Safety/Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection w/Primary Anastomosis|Completed||Phase 2|320|Actual|Helsinn Therapeutics (U.S.), Inc||4|||f||||f||||||||||2018-05-31 22:57:18.502595|2018-05-31 22:57:18.502595
NCT01280331|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18||2012-05-15|2012-05-15|2011-01-18|2011-01-20|Estimate||||2012-05-15|2012-05-17|Estimate|2012-05-15|2012-05-17|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients|A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Effects of Q8003 to the Morphine-Equivalent Doses of Oxycodone and of Morphine on the Opioid-Related Adverse Events of Moderate to Severe Nausea, Emesis, and Dizziness in Subjects With Acute Moderate-to-Severe Postoperative Pain Following Bunionectomy Surgery|Completed||Phase 3|375|Actual|QRxPharma Inc.||3|||f||||f||||||||||2018-05-31 22:57:18.647584|2018-05-31 22:57:18.647584
NCT01280318|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-11-13|2011-01-19|2011-01-20|Estimate|||||||2012-11-13|2012-11-14|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|HNSCC||Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery|Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery|Completed||Phase 1/Phase 2|60|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||f||||||||||2018-05-31 22:57:18.724167|2018-05-31 22:57:18.724167
NCT01280305|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|RAL-S-01||Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder|A Randomized Trial Administering Raloxifene vs Placebo as add-on to Antipsychotics in Post Menopausal Patients With Schizophrenia or Schizoaffective Disorder|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 22:57:18.79209|2018-05-31 22:57:18.79209
NCT01280292|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-02-02|2011-01-19|2011-01-20|Estimate|||||||2011-02-02|2011-02-03|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|July 2013|Anticipated|2013-07-31|February 2013|Anticipated|2013-02-28||Interventional|||Central Hypothyroidism, a Novel Laboratory Measurement|Central Hypothyroidism,a New Laboratory Approach for Hormone Measurement|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 22:57:18.97199|2018-05-31 22:57:18.97199
NCT01280279|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|May 2009||2009-05-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Observational|||Necessity for Repetitive Education of Behavioral Modification|Short-term Effects of Systematized Behavioral Modification Program (SBMP) for Nocturia: A Prospective Study|Completed|||104|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 22:57:19.027057|2018-05-31 22:57:19.027057
NCT01280266|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|2012-07-04||2012-12-07|2011-01-19|2011-01-20|Estimate|2012-12-07|2012-12-11|Estimate||||2012-12-07|2012-12-11|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon|Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial|Completed||Phase 2/Phase 3|29|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 22:57:19.097574|2018-05-31 22:57:19.097574
NCT01280253|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2016-11-11|2011-01-19|2011-01-20|Estimate|||||||2016-11-11|2016-11-15|Estimate|January 2011||2011-01-31|November 2016|2016-11-30||||August 2014|Actual|2014-08-31||Observational|||Preoperative Biochemical Predictors of Outcome in Patients With Hip Fracture|Can Biochemical Tests Predict Outcome in Patients With Hip Fracture?|Completed|||999|Actual|Region Skane|||||f||||t||||||Samples Without DNA|"~     Litium-heparin plasma EDTA plasma~   "|Yes|Upon reasonable request|2018-05-31 22:57:19.546915|2018-05-31 22:57:19.546915
NCT01280240|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2013-06-03|2011-01-19|2011-01-20|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|PK-CIA-06||Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA).|Completed||Phase 1|11|Actual|Pharmacosmos A/S||2|||f||||t||||||||||2018-05-31 22:57:19.619931|2018-05-31 22:57:19.619931
NCT01280227|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2017-04-05|2011-01-19|2011-01-20|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2005||2005-01-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|October 2010|Actual|2010-10-31||Interventional|SiSom||Supporting Patient Provider Communication in Paediatric Care|Supporting Patient Provider Communication for Children With Cancer and Congenital Heart Disease|Completed||N/A|144|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:57:19.702701|2018-05-31 22:57:19.702701
NCT01280214|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-15|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Local Triamcinolone Injection in Active Thyroid Orbitopathy|Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy|Unknown status|Not yet recruiting|N/A|30|Anticipated|HaEmek Medical Center, Israel||1|||f||||t||||||||||2018-05-31 22:57:19.793796|2018-05-31 22:57:19.793796
NCT01280201|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2016-08-17|2011-01-19|2011-01-20|Estimate|||||||2016-08-17|2016-08-18|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|April 2013|Actual|2013-04-30||Interventional|||Pazopanib as Single Agent in Advanced NETs|A Phase II, Open Label, Uncontrolled and Multicenter Trial of Pazopanib Given as a Single Agent in Patients With Progressive Advanced/Metastatic Neuroendocrine Tumors (NET): a Search for Activity, Safety, and Predictive Biomarkers|Completed||Phase 2|44|Actual|Grupo Espanol de Tumores Neuroendocrinos||1|||f||||f||||||||||2018-05-31 22:57:19.878193|2018-05-31 22:57:19.878193
NCT01280188|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2012-08-10|2011-01-19|2011-01-20|Estimate|||||||2012-08-10|2012-08-13|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).|Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese Patients|Completed||Phase 3|20|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 22:57:19.986094|2018-05-31 22:57:19.986094
NCT01280175|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2016-12-15|2011-01-19|2011-01-20|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2006||2006-12-31|December 2016|2016-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Foster With or Without Charcoal Block or Aerochamber Plus|Pharmacokinetics and Lung Bioavailability of BDP/Formoterol HFA Fixed Combination After Single Administration in 12 Healthy Volunteers Using the Standard Actuator With or Without Charcoal Block or the Aerochamber Spacer.|Completed||Phase 1|13|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 22:57:20.065443|2018-05-31 22:57:20.065443
NCT01280162|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-10-18|2011-01-19|2011-01-20|Estimate|||||||2014-10-18|2014-10-21|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|February 2011|Actual|2011-02-28||Interventional|||Malaria Active Epidemiology and Treatment Study|An Active Malaria Epidemiology Cohort Study With Evaluation of a 2 Day Versus 3 Day Treatment Regimen of DHA-Piperaquine for Patients With Uncomplicated Malaria|Completed||N/A|222|Actual|Armed Forces Research Institute of Medical Sciences, Thailand||2|||f||||f||||||||||2018-05-31 22:57:20.133872|2018-05-31 22:57:20.133872
NCT01280149|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2017-04-05|2011-01-18|2011-01-20|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2011||2011-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Reduction of IgE Antibody in Human Allergic Subjects|Reduction of IgE Antibody in Human Allergic Subjects|Active, not recruiting||Phase 1|60|Anticipated|Northwestern University||6|||f||||f||||||||No||2018-05-31 22:57:20.208839|2018-05-31 22:57:20.208839
NCT01280136|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2014-06-12|2011-01-18|2011-01-20|Estimate|||||||2014-06-12|2014-06-13|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Web-Based Middle School HIV Prevention Curricula: Aspiring for Reach and Impact|Web-Based Middle School HIV Prevention Curricula: Aspiring for Reach and Impact|Completed||N/A|1700|Actual|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 22:57:20.288986|2018-05-31 22:57:20.288986
NCT01280123|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2015-08-13||2015-09-15|2011-01-18|2011-01-20|Estimate|2015-09-15|2015-10-14|Estimate||||2015-09-15|2015-10-14|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Pioglitazone in Early Parkinson's Disease|A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study of Pioglitazone in Early Parkinson's Disease|Completed||Phase 2|210|Actual|University of Rochester||3|||f||||t||||||||||2018-05-31 22:57:20.371121|2018-05-31 22:57:20.371121
NCT01280110|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2012-06-07||2012-07-12|2011-01-18|2011-01-20|Estimate|2012-06-07|2012-07-12|Estimate||||2012-07-12|2012-07-18|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients|The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients|Completed||Phase 4|44|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 22:57:21.027535|2018-05-31 22:57:21.027535
NCT01280097|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-07-13|2011-01-19|2011-01-20|Estimate|||||||2015-07-13|2015-07-15|Estimate|December 2010||2010-12-31|July 2015|2015-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|SID||Study of Sleep and Delirium in the Intensive Care Unit (ICU)|Sleep Disruption and ICU Delirium: Delirium Assessment and Monitoring Combined With the Evaluation of Sleep Using the Sedline Brain Function Monitor.|Completed|||57|Actual|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Blood will be collected as part of the study. It will be used to measure circadian markers~     that will include core body temperature, cortisol and melatonin rhythms. If subjects agree,~     some will be stored in a bank for future research.~   "|||2018-05-31 22:57:21.282038|2018-05-31 22:57:21.282038
NCT01280084|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-02-10|2011-01-19|2011-01-20|Estimate|||||||2012-02-10|2012-02-14|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|LAMB||Labour Analgesia and Movement in Babies|The Effect of Labour Analgesia on Babies' Movements After Birth: An Actigraphic Study|Completed|||40|Actual|University of British Columbia|||4||f||||t||||||||||2018-05-31 22:57:21.355165|2018-05-31 22:57:21.355165
NCT01280071|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate||||January 2011|2011-01-31||||||||Interventional|||Adenosine Activity in Producing Venoarteriolar Reflexes||Unknown status|Not yet recruiting|N/A|||Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||||2018-05-31 22:57:21.514446|2018-05-31 22:57:21.514446
NCT01280058|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2018-01-10||2018-02-08|2011-01-18|2011-01-20|Estimate|2018-01-10|2018-02-07|Actual||||2018-02-08|2018-03-09|Actual|December 2010|Actual|2010-12-31|February 2018|2018-02-28|January 20, 2016|Actual|2016-01-20|January 19, 2016|Actual|2016-01-19||Interventional|||Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer|A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer|Completed||Phase 2|73|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 22:57:21.626423|2018-05-31 22:57:21.626423
NCT01280045|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-05-29|2011-01-19|2011-01-20|Estimate|||||||2012-05-29|2012-05-31|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|January 2015|Anticipated|2015-01-31|May 2013|Anticipated|2013-05-31||Interventional|||Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy|Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns|Unknown status|Recruiting|Phase 3|50|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 22:57:22.308594|2018-05-31 22:57:22.308594
NCT01280032|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2013-11-12|2011-01-19|2011-01-20|Estimate|||||||2013-11-12|2013-11-13|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Kypho-IORT||Kypho-IORT: Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases|Kypho-IORT: Phase II Study for Dose Escalation of Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases|Completed||Phase 2|18|Anticipated|Universitätsmedizin Mannheim||1|||f||||f||||||||||2018-05-31 22:57:22.421771|2018-05-31 22:57:22.421771
NCT01280019|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|May 2012|Anticipated|2012-05-31|December 2011|Anticipated|2011-12-31||Interventional|||FRC Guided Therapy in Acute Respiratory Failure|Functional Residual Capacity Guided Alveolar Recruitment Strategy in Patients With Acute Respiratory Failure After Cardiac Surgery|Unknown status|Recruiting|Phase 4|20|Anticipated|University of Luebeck||2|||f||||f||||||||||2018-05-31 22:57:22.495531|2018-05-31 22:57:22.495531
NCT01280006|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-12-02|2011-01-19|2011-01-20|Estimate|||||||2011-12-02|2011-12-05|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans|Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans|Completed||Phase 1/Phase 2|12|Actual|University of Calgary|||||f||||t||||||||||2018-05-31 22:57:22.582442|2018-05-31 22:57:22.582442
NCT01279993|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-19|2011-01-19|2011-01-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Orthoptic Changes Following Photorefractive Keratectomy|Orthoptic Changes Following Photorefractive Keratectomy|Completed||Phase 3|||Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:57:22.662064|2018-05-31 22:57:22.662064
NCT01279980|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-02-17|2011-01-19|2011-01-20|Estimate|||||||2011-02-17|2011-02-18|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Clinical Trial Comparing Epidurals and Local Anaesthetic Wound Catheters in Patients Having Bowel Surgery|Continuous Wound Infiltration With Local Anaesthetic vs. Epidurals in an Enhanced Recovery Protocol: A Randomised Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|Scarborough General Hospital||2|||f||||t||||||||||2018-05-31 22:57:22.726952|2018-05-31 22:57:22.726952
NCT01279967|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-11-19|2011-01-19|2011-01-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|ADAM||A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma|A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma|Unknown status|Active, not recruiting|Phase 2|70|Actual|Barts & The London NHS Trust||2|||f||||f||||||||||2018-05-31 22:57:22.816538|2018-05-31 22:57:22.816538
NCT01279954|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2016-07-07|2011-01-19|2011-01-20|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2012||2012-01-31|July 2016|2016-07-31||||June 2017|Anticipated|2017-06-30||Interventional|||Abatacept in the Treatment of Uveitis|An Openlabel, Phase II Trial of Abatacept (Orencia) in the Treatment of Refractory Non-infectious Uveitis.|Active, not recruiting||Phase 2|10|Actual|Oregon Health and Science University||3|||f||||||||||||||2018-05-31 22:57:22.912118|2018-05-31 22:57:22.912118
NCT01279941|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2015-10-28|2011-01-19|2011-01-20|Estimate|||||||2015-10-28|2015-10-30|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SHIELD||Safety & Health Improvement: Enhancing Law Enforcement Departments|Safety & Health Improvement: Enhancing Law Enforcement Departments|Completed||N/A|489|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 22:57:22.98763|2018-05-31 22:57:22.98763
NCT01279928|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2011-01-24|2011-01-19|2011-01-20|Estimate|||||||2011-01-24|2011-01-25|Estimate|March 2010||2010-03-31|January 2011|2011-01-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|DIVIDEND||Detection of Vascular Injury in Diabetes Through Eye and Nailfold Data (DIVIDEND) - A Pilot Study|Detection of Vascular Injury in Diabetes Through Eye and Nailfold Data (DIVIDEND) - A Pilot Study|Completed|||26|Actual|John Hunter Hospital|||1||f||||f||||||||||2018-05-31 22:57:23.11602|2018-05-31 22:57:23.11602
NCT01279915|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-20|Estimate|||||||2011-01-18|2011-01-20|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects|Phase I Study of ASP0456 - A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Non-elderly Healthy Male Subjects|Completed||Phase 1|32|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 22:57:23.176363|2018-05-31 22:57:23.176363
NCT01279902|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2016-07-25|2011-01-19|2011-01-20|Estimate|||||||2016-07-25|2016-07-26|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|August 2016|Anticipated|2016-08-31||Interventional|||Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL|Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised Stage I or II CD20+ Diffuse Large B-cell Lymphoma|Active, not recruiting||Phase 2|32|Actual|Asan Medical Center||1|||f||||f||||||||No||2018-05-31 22:57:23.23771|2018-05-31 22:57:23.23771
NCT01279889|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-02-10|2011-01-18|2011-01-19|Estimate|||||||2012-02-10|2012-02-14|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Predicting Hypotension Related to Spinal Anesthesia|Predicting Hypotension Resistant to Phenylephrine (PE) Infusion in Elective Cesarean Delivery (CD)|Completed|||47|Actual|University of British Columbia|||1||f||||t||||||||||2018-05-31 22:57:23.302877|2018-05-31 22:57:23.302877
NCT01279876|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-08-12|2011-01-18|2011-01-19|Estimate|||||||2015-08-12|2015-08-14|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Melatonin in Relapsing-Remitting Multiple Sclerosis Patients|Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients|Completed||Phase 2|25|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:57:23.363379|2018-05-31 22:57:23.363379
NCT01279863|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-08-11|2011-01-18|2011-01-19|Estimate|||||||2011-08-11|2011-08-12|Estimate|February 2011||2011-02-28|May 2010|2010-05-31|February 2012|Anticipated|2012-02-29|August 2011|Anticipated|2011-08-31||Observational|VRI||VRI in Children With Acute Respiratory Symptoms.|Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms.|Unknown status|Not yet recruiting||80|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-05-31 22:57:23.420521|2018-05-31 22:57:23.420521
NCT01279850|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2017-11-27|2011-01-18|2011-01-19|Estimate|||||||2017-11-27|2017-11-29|Actual|August 29, 2011|Actual|2011-08-29|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|RAINBOW-L||Safety And Efficacy In Long Term Use Of Lyrica (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Long Term Use Of Lyrica(Regulatory Post Marketing Commitment Plan)|Completed|||891|Actual|Pfizer|||1||f||||f|t|f||||||||2018-05-31 22:57:23.47161|2018-05-31 22:57:23.47161
NCT01279837|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-01-04|2011-01-18|2011-01-19|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2006||2006-06-30|January 2011|2011-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Pharyngocise Dose Response Study|Muscle Preservation and Swallow Function Following Radiotherapy: A Dose Response Study|Completed||Phase 2/Phase 3|130|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 22:57:23.609033|2018-05-31 22:57:23.609033
NCT01279824|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-01-04|2011-01-18|2011-01-19|Estimate|||||||2012-01-04|2012-01-05|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|ANSRS||Adjunctive Neuromuscular Electrical Stimulation for the Rehabilitation of Swallowing|A Randomized Controlled Trial of NMES vs. Traditional Dysphagia Therapy After Stroke|Completed||Phase 2/Phase 3|53|Actual|University of Florida||3|||f||||t||||||||||2018-05-31 22:57:23.705939|2018-05-31 22:57:23.705939
NCT01279811|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2017-10-24|2011-01-18|2011-01-19|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2011||2011-01-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|CAMPER||The Canadian Multicentre CSF Monitoring and Biomarker Study|The Canadian Multicentre CSF Monitoring and Biomarker Study|Recruiting||N/A|100|Anticipated|University of British Columbia||1|||f||||t||||||||||2018-05-31 22:57:23.819662|2018-05-31 22:57:23.819662
NCT01279798|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2011-02-25|2011-01-18|2011-01-19|Estimate|||||||2011-02-25|2011-03-01|Estimate||||January 2011|2011-01-31||||||||Expanded Access|||Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)|Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.|No longer available|||||NovaRx Corporation|||||||||||||||||||2018-05-31 22:57:23.931379|2018-05-31 22:57:23.931379
NCT01279785|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-11-23|2011-01-18|2011-01-19|Estimate|||||||2015-11-23|2015-11-25|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy|A Phase 1 Pilot Study of 123I-MIP-1072 Single Photon Emission Computed Tomography (SPECT)/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy|Withdrawn|||0|Actual|Molecular Insight Pharmaceuticals, Inc.|||1|Similar study to be completd once kit for new formulation becomes available.|f||||f||||||||||2018-05-31 22:57:23.983409|2018-05-31 22:57:23.983409
NCT01279772|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2017-03-10|2011-01-18|2011-01-19|Estimate|||||||2017-03-10|2017-03-13|Actual|October 2011||2011-10-31|July 2012|2012-07-31||||||||Observational|IELSG33||This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas|A Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas Treated With R-CHOP With or Without Radiotherapy|Terminated|||1|Actual|International Extranodal Lymphoma Study Group (IELSG)||||due to slow accrual (only 1 patient entered)|f||||f||||||||||2018-05-31 22:57:24.047842|2018-05-31 22:57:24.047842
NCT01279759|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2013-01-17|2011-01-18|2011-01-19|Estimate|||||||2013-01-17|2013-01-18|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Follow up of Patients Operated With Anterior Cruciate Ligament Reconstruction|Pre- and Post Operative Predictive Factors for Function 6 Months After Anterior Cruciate Ligament Reconstruction|Unknown status|Recruiting||35|Anticipated|Haraldsplass Deaconess Hospital|||||f||||f||||||||||2018-05-31 22:57:24.105231|2018-05-31 22:57:24.105231
NCT01279746|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2015-06-21|2011-01-18|2011-01-19|Estimate|||||||2015-06-21|2015-06-23|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia|The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia|Completed|||100|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-05-31 22:57:24.187975|2018-05-31 22:57:24.187975
NCT01279733|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-08-21|2011-01-18|2011-01-19|Estimate|||||||2012-08-21|2012-08-22|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|Microarray||Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis|Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis|Completed|||4450|Actual|Columbia University|||1||f||||f||||||Samples With DNA|"~     -  Additional 15 ml of amniotic fluid (minimum 10 ml) for amniocentesis~        -  Blood sample (10 ml) from each parent will be obtained in case of a need to test for~          suspected familial copy number variants (CNVs) or discrepant results, and also to~          evaluate for maternal cell contamination (patient's blood sample).~        -  10 ml of amniotic fluid with suspended cells, (minimum 7 ml)~        -  5 mg of villi (minimum of 2mg)~   "|||2018-05-31 22:57:24.24084|2018-05-31 22:57:24.24084
NCT01279720|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-09-11|2011-01-18|2011-01-19|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2003||2003-10-31|September 2015|2015-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Gene Therapy ADA Deficiency|Phase I Gene Therapy Protocol for Adenosine Deaminase Deficiency|Completed||Phase 1/Phase 2|8|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||||||||||||2018-05-31 22:57:24.298166|2018-05-31 22:57:24.298166
NCT01279707|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-07-11|2011-01-18|2011-01-19|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|MARALL||Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)|Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent or Refractory B-precursor Acute Lymphoblastic Leukaemia (ALL)|Unknown status|Active, not recruiting|Phase 1/Phase 2|55|Anticipated|Queen Mary University of London||3|||f||||t||||||||||2018-05-31 22:57:24.364132|2018-05-31 22:57:24.364132
NCT01279694|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2016-04-12|2011-01-18|2011-01-19|Estimate|||||||2016-04-12|2016-04-13|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CARMYSAP||Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)|Phase I/II Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma.|Completed||Phase 1/Phase 2|72|Actual|Nantes University Hospital|||||f||||||||||||||2018-05-31 22:57:24.439824|2018-05-31 22:57:24.439824
NCT01279681|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2017-02-23||2017-11-06|2011-01-18|2011-01-19|Estimate|2017-11-06|2017-12-08|Actual||||2017-11-06|2017-12-08|Actual|January 2011||2011-01-31|November 2017|2017-11-30|November 1, 2014|Actual|2014-11-01|November 2014|Actual|2014-11-30||Interventional|||Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer|Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer|Terminated||Phase 3|32|Actual|Alliance for Clinical Trials in Oncology||2||Slow accrual|f||||t||||||||||2018-05-31 22:57:24.513431|2018-05-31 22:57:24.513431
NCT01279668|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2012-10-08|2011-01-17|2011-01-19|Estimate|||||||2012-10-08|2012-10-10|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|MAC||Montelukast for Persistent Cough in Young People and Adults|A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care|Unknown status|Active, not recruiting|Phase 4|276|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 22:57:26.12948|2018-05-31 22:57:26.12948
NCT01279655|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-09-11|2011-01-18|2011-01-19|Estimate|||||||2012-09-11|2012-09-12|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|May 2013|Anticipated|2013-05-31|December 2011|Actual|2011-12-31||Interventional|||Motor Training and White Matter in Multiple Sclerosis (MS)|The Influence of a tDCS Combined Long-term Motor Training Program on Structural White Matter Changes in the Brain, Functionality and Psychological Outcome Measures in Multiple Sclerosis.|Terminated||N/A|60|Actual|Hasselt University||3|||f||||t||||||||||2018-05-31 22:57:26.256157|2018-05-31 22:57:26.256157
NCT01279642|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Placement of Peripherally Inserted Central Venous Catheters (PICC) in Children Guided by Ultrasound|The Use of Doppler Vascular Ultrasound by Nurses During the Placement of Peripherally Inserted Central Venous Catheters in Children: Clinical, Randomized and Controlled Trial.|Completed||N/A|42|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 22:57:26.350565|2018-05-31 22:57:26.350565
NCT01279629|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-06-17|2011-01-18|2011-01-19|Estimate|||||||2011-06-17|2011-06-20|Estimate|February 2011||2011-02-28|January 2011|2011-01-31||||||||Observational|MED||Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis|Open Clinical Study, Comparing Non-inferiority for Efficacy of the Drug Tazarotene 0.1% Versus the Comparator Drug Calcipotriol 0.005% in the Treatment of Chronic Plaque Psoriasis|Suspended|||50|Anticipated|Glenmark Farmacêutica Ltda|||2||f||||t||||||||||2018-05-31 22:57:26.593537|2018-05-31 22:57:26.593537
NCT01279616|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2018-02-28|2011-01-18|2011-01-19|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2010||2010-09-30|February 2018|2018-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease|A Pilot Study of an Immunosuppressive and Myeloablative Preparative Regimen for Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for Severe Sickle Cell Disease|Terminated||Phase 2|4|Actual|Nationwide Children's Hospital||1||PI moving to a different institution.|f||||t||||||||||2018-05-31 22:57:26.74751|2018-05-31 22:57:26.74751
NCT01279603|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2014-09-18|2011-01-18|2011-01-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas|A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GO-203-2c Given Intravenously Daily X21 Repeated Every 28 Days in Patients With Advanced Solid Tumors Including Lymphomas|Completed||Phase 1|23|Actual|Genus Oncology, LLC||1|||f||||||||||||||2018-05-31 22:57:26.850319|2018-05-31 22:57:26.850319
NCT01279590|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18||2011-12-19|2011-12-19|2011-01-18|2011-01-19|Estimate||||2011-12-19|2011-12-22|Estimate|2011-12-19|2011-12-22|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)|A Double-blind, Randomized, Placebo-controlled and Active-comparator-controlled Phase 2b Study to Evaluate Statin-associated Myalgia Incidence, Lipid Profile Effect, and Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients With Primary Hypercholesterolemia, Fredrickson IIa or IIb, Who Have Discontinued Two or More Prior Statin Therapies Due to Statin-associated Myalgia|Completed||Phase 2|282|Actual|Furiex Pharmaceuticals, Inc||3|||f||||f||||||||||2018-05-31 22:57:26.934089|2018-05-31 22:57:26.934089
NCT01279577|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-02-09|2011-01-18|2011-01-19|Estimate|||||||2015-02-09|2015-02-10|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|TRUST-2||Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease|Double-blind, Randomised, Placebo-controlled, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Three Different Dosages of Oral Trichuris Suis Ova (TSO) Suspension in Active Crohn's Disease|Completed||Phase 2|254|Actual|Dr. Falk Pharma GmbH||4|||f||||t||||||||||2018-05-31 22:57:27.172589|2018-05-31 22:57:27.172589
NCT01279564|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2014-11-04||2016-06-27|2011-01-18|2011-01-19|Estimate|2014-11-04|2014-11-11|Estimate||||2016-06-27|2016-07-27|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison Between Etview Tracheoscopic Ventilation Tube - TVT to Standard Endotracheal Intubation|Comparison Between Etview Tracheoscopic Ventilation Tube - TVT to Standard Endotracheal Intubation During Regular and Difficult Intubation|Completed||N/A|72|Actual|Rambam Health Care Campus||2|||f||||t||||||||Undecided||2018-05-31 22:57:27.290225|2018-05-31 22:57:27.290225
NCT01279551|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-24|2011-01-18|2011-01-19|Estimate|||||||2011-01-24|2011-01-25|Estimate|January 2004||2004-01-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|TAGASH||Topical Application of GTN 0.4% in the Treatment of Anismus Following Stapled Haemorrhoidopexy|Topical Application of GTN 0.4% in the Treatment of Anismus Following Stapled Haemorrhoidopexy|Completed||Phase 2/Phase 3|40|Actual|University of Roma La Sapienza||2|||f||||||||||||||2018-05-31 22:57:27.794831|2018-05-31 22:57:27.794831
NCT01279538|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-02-08|2011-01-18|2011-01-19|Estimate|||||||2012-02-08|2012-02-10|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation|A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety, and Tolerability Study of ASKP1240 in de Novo Kidney Transplantation|Completed||Phase 1|46|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 22:57:27.947374|2018-05-31 22:57:27.947374
NCT01279525|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|||||Interventional|EPICA||Intervention to Reduce Falls Incidence|EFFECTIVENESS OF A MULTIFACTORIAL INTERVENTION PROGRAM TO REDUCE FALLS INCIDENCE AMONG COMMUNITY-LIVING ELDERLY PEOPLE|Completed||N/A|404|Actual|Andalusian Regional Ministry of Health||1|||f||||f||||||||||2018-05-31 22:57:28.204752|2018-05-31 22:57:28.204752
NCT01279512|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2012-01-05|2011-01-18|2011-01-19|Estimate|||||||2012-01-05|2012-01-06|Estimate|December 2006||2006-12-31|August 2006|2006-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Metformin Versus Acarbose Treatment in Infertile Overweight Women With Polycystic Ovary Syndrome (PCOS)|Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial|Completed||Phase 4|50|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 22:57:28.269349|2018-05-31 22:57:28.269349
NCT01279499|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-19|2011-01-18|2011-01-19|Estimate|||||||2011-01-19|2011-01-20|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients|Propofol Versus Sevoflurane as Sole Anesthetic Agent in Gastric By-Pass Surgery for Morbid Obesity: A Prospective Randomized Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|University of Patras||4|||f||||||||||||||2018-05-31 22:57:28.443299|2018-05-31 22:57:28.443299
NCT01279486|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|||2011-09-27|2011-01-17|2011-01-19|Estimate|||||||2011-09-27|2011-09-28|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Clearblue Home Pregnancy Test Consumer Study|Clearblue Home Pregnancy Test Consumer Study|Completed|||120|Anticipated|SPD Development Company Limited|||||f||||f||||||Samples Without DNA|"~     Urine samples~   "|||2018-05-31 22:57:28.580729|2018-05-31 22:57:28.580729
NCT01279473|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2011-08-22|2011-01-18|2011-01-19|Estimate|||||||2011-08-22|2011-08-24|Estimate|August 2005||2005-08-31|August 2011|2011-08-31||||December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)|A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ALL (Philadelphia Positive Acute Lymphocytic Leukemia)(Extension Study)|Completed||Phase 1/Phase 2|42|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:57:28.669477|2018-05-31 22:57:28.669477
NCT01279460|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-01-17|2011-01-17|2011-01-19|Estimate|||||||2011-01-17|2011-01-19|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Aortic Stiffness in Chronic Kidney Disease Stage 2 to 4|Evaluation of Aortic Stiffness in CKD II to IV|Completed|||167|Actual|Technische Universität München|||1||f||||f||||||||||2018-05-31 22:57:29.057539|2018-05-31 22:57:29.057539
NCT01279447|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2013-12-05||2014-04-14|2011-01-18|2011-01-19|Estimate|2014-04-14|2014-05-12|Estimate||||2014-04-14|2014-05-12|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Both groups statistically similar|Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control|Infrapatellar Nerve Block for Post-operative Analgesia for Knee Arthroscopy|Completed||Phase 4|68|Actual|Northwestern University|outpatient nature and self reporting of outcome measures|2|||f||||f||||||||||2018-05-31 22:57:29.146388|2018-05-31 22:57:29.146388
NCT01279434|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-25|||2015-05-27|2011-01-15|2011-01-19|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|||Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial|Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial|Withdrawn||N/A|0|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 22:57:30.091772|2018-05-31 22:57:30.091772
NCT01279421|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2017-08-28|2011-01-18|2011-01-19|Estimate|||||||2017-08-28|2017-08-30|Actual|November 2010||2010-11-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|June 2016|Actual|2016-06-30||Interventional|Encuentro||High Risk Crack Use Settings and HIV in El Salvador|High Risk Crack Use Settings and HIV in El Salvador|Active, not recruiting||N/A|4382|Actual|Medical College of Wisconsin||2|||f||||t||||||||||2018-05-31 22:57:30.182275|2018-05-31 22:57:30.182275
NCT01279408|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2016-12-28|2011-01-18|2011-01-19|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)|Prospective Observational Study Of Patients With Asymptomatic Centrally Located Advanced NSCLC Who Are Not Suitable For Curative Treatment|Recruiting|||120|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 22:57:30.261189|2018-05-31 22:57:30.261189
NCT01279395|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2018-04-30|2011-01-14|2011-01-19|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2010||2010-11-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Anti-inflammatory Agents and Cholesterol Metabolism|Impact of Anti-inflammatory Agents on Cholesterol Metabolism and Atherogenic Potency of Patient Plasma|Recruiting|||60|Anticipated|Winthrop University Hospital|||3||f||||f||||||||||2018-05-31 22:57:30.331323|2018-05-31 22:57:30.331323
NCT01279382|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|January 2002||2002-01-31|January 2011|2011-01-31|January 2006||2006-01-31|||||Interventional|||Effect of Hypnotherapy in Irritable Bowel Syndrome (IBS)|Effectiviteit Van Hypnotherapie Bij Prikkelbare Darmsyndroom (Effectiveness of Hypnotherapy in Irritable Bowel Syndrome)|Completed||N/A|112|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 22:57:30.432347|2018-05-31 22:57:30.432347
NCT01279369|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2018-05-01|2011-01-18|2011-01-19|Estimate|||||||2018-05-01|2018-05-07|Actual|October 2009||2009-10-31|May 2018|2018-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta|The Use of Fetal Fibronectin (fFN) in Predicting Preterm Delivery Due to Abruptio Placenta in Patients With Minor Maternal Trauma.|Terminated|||3|Actual|Winthrop University Hospital||||Quantitative assessment of fFN only able to be performed at one laboratory.|f||||t||||||Samples Without DNA|"~     Fetal fibronectin~   "|||2018-05-31 22:57:30.561499|2018-05-31 22:57:30.561499
NCT01279356|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-01-27|2011-01-18|2011-01-19|Estimate|||||||2011-01-27|2011-01-28|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|August 2012|Anticipated|2012-08-31|February 2012|Anticipated|2012-02-29||Observational|||Volatile Organic Compounds (VOCs) and Liver Diseases|Analysis of Volatile Organic Compounds in Exhaled Air as a Non-invasive Biomarker for Liver Diseases|Unknown status|Not yet recruiting||160|Anticipated|Maastricht University Medical Center|||1||f||||f||||||Samples With DNA|"~     The following biospecimens will be collected: exhaled air and plasma/serum~   "|||2018-05-31 22:57:30.831506|2018-05-31 22:57:30.831506
NCT01279343|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-08-02|2011-01-14|2011-01-19|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|||Cervical Foley Plus Vaginal Misoprostol for Labor Induction|Cervical Foley Plus Vaginal Misoprostol Versus Vaginal Misoprostol for Cervical Ripening and Labor Induction: A Randomized Trial|Unknown status|Recruiting|N/A|122|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 22:57:31.053874|2018-05-31 22:57:31.053874
NCT01279330|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|Pagedocc2||Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?|Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? A Cluster Randomised Controlled Study.|Unknown status|Recruiting|N/A|1569|Anticipated|University of Paris 5 - Rene Descartes||2|||f||||f||||||||||2018-05-31 22:57:31.152442|2018-05-31 22:57:31.152442
NCT01279317|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2011-07-20||2011-08-25|2011-01-17|2011-01-19|Estimate|2011-08-25|2011-10-03|Estimate||||2011-08-25|2011-10-03|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vinegar Co-ingestion in Type 2 Diabetes|The Effect of Vinegar Co-ingestion on Postprandial Glucose Control in Type 2 Diabetes Patients|Completed||N/A|12|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 22:57:31.23038|2018-05-31 22:57:31.23038
NCT01279304|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2014-02-27|2011-01-18|2011-01-19|Estimate|||||||2014-02-27|2014-02-28|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|RAPCHEM||Radiotherapy After Primary Chemotherapy for Breastcancer|Radiotherapy After Primary CHEMotherapy for cT1-2cN1M0 Breast Cancer.: a Multicentre Prospective Registration Study.|Unknown status|Recruiting||710|Anticipated|Maastricht Radiation Oncology|||3||f||||f||||||||||2018-05-31 22:57:31.459019|2018-05-31 22:57:31.459019
NCT01279291|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-03-05|2011-01-17|2011-01-19|Estimate|||||||2013-03-05|2013-03-06|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer|Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer|Terminated||Phase 1|22|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||4||"The study was stopped due to the inability to determine an acceptable dose with the potential~   for further study"|f||||f||||||||||2018-05-31 22:57:31.678353|2018-05-31 22:57:31.678353
NCT01279278|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|Pagedocc1||Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?|Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? A Cluster Randomised Controlled Study.|Unknown status|Recruiting|N/A|2700|Anticipated|University of Paris 5 - Rene Descartes||2|||f||||t||||||||||2018-05-31 22:57:31.79553|2018-05-31 22:57:31.79553
NCT01279265|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2015-06-11||2015-10-07|2011-01-14|2011-01-19|Estimate|2015-10-07|2015-11-11|Estimate||||2015-10-07|2015-11-11|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|LGG||Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic|Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Crying, Intestinal Microbiota, and Intestinal Inflammation in Infants With Colic|Completed||N/A|30|Actual|The University of Texas Health Science Center, Houston|75% of eligible babies either declined to enter the study or dropped out.|2|||f||||t||||||||||2018-05-31 22:57:31.951373|2018-05-31 22:57:31.951373
NCT01279252|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2015-09-01|2011-01-17|2011-01-19|Estimate|||||||2015-09-01|2015-09-02|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|January 2015|Actual|2015-01-31||Interventional|CLEAR||CLL Empirical Antibiotic Regimen|A Phase II Trial of Broad Spectrum Antibiotic Therapy for Early Stage, Non-progressive Chronic Lymphocytic Leukaemia Without Adverse Prognostic Factors|Unknown status|Active, not recruiting|Phase 2|71|Anticipated|King's College Hospital NHS Trust||1|||f||||f||||||||||2018-05-31 22:57:32.385457|2018-05-31 22:57:32.385457
NCT01279239|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-07-26|2011-01-14|2011-01-19|Estimate|||||||2011-07-26|2011-07-27|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Metabonomics Fingerprinting of Multiple Trauma|Establishing 1H Nuclear Magnetic Resonance (NMR) Based Metabonomics Fingerprinting Profile for Severe Poly Trauma Patients|Completed|||40|Actual|Sichuan Academy of Medical Sciences|||2||f||||f||||||Samples Without DNA|"~     Plasma from peripheral blood.~   "|||2018-05-31 22:57:32.470323|2018-05-31 22:57:32.470323
NCT01279226|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-11-30|2011-01-14|2011-01-19|Estimate|||||||2012-11-30|2012-12-03|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Investigation of Radiofrequency Device for Treatment of Wrinkles and Rhytides|Radiofrequency Magnetic Induction Device for Use in Dermatologic Procedures for the Non-Invasive Treatment of Wrinkles and Rhytides|Completed||N/A|40|Actual|Rocky Mountain Biosystems, Inc.|||||f||||t||||||||||2018-05-31 22:57:32.548118|2018-05-31 22:57:32.548118
NCT01279213|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia|Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study|Completed||Phase 4|70|Actual|Universidad Nacional de Rosario||2|||f||||f||||||||||2018-05-31 22:57:32.626332|2018-05-31 22:57:32.626332
NCT01279200|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2014-12-18||2015-01-05|2011-01-18|2011-01-19|Estimate|2015-01-05|2015-01-06|Estimate||||2015-01-05|2015-01-06|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Use of High Cost Monitoring During Letrozole Ovulation Induction|Use of High Cost Monitoring During Letrozole Ovulation Induction and Effect on Pregnancy Rates - A Pilot Study|Completed||Phase 4|21|Actual|University of Michigan|The original intent was to study 400 women, but due to recruiting and time restraints, final enrollment was only 21. Therefore, statistical analyses of the results were eliminated, as well as some additional outcome measures originally planned for.|2|||f||||f||||||||||2018-05-31 22:57:32.71282|2018-05-31 22:57:32.71282
NCT01279187|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2017-06-28||2018-01-31|2011-01-18|2011-01-19|Estimate|2018-01-31|2018-02-07|Actual||||2018-01-31|2018-02-07|Actual|February 2011||2011-02-28|January 2018|2018-01-31|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|||The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone|The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone|Terminated||Phase 2|27|Actual|University of Michigan||2||Study was terminated due to patient complications unrelated to study drugs|f||||f||||||||No||2018-05-31 22:57:33.282867|2018-05-31 22:57:33.282867
NCT01279174|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-12-08|2011-01-18|2011-01-19|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Galileo-Hip Whole Body Vibration /Conventional Physiotherapy /Coxarthrosis|Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Coxarthrosis: a Randomized, Controlled Study|Completed||Phase 4|40|Actual|University of Cologne||2|||f||||f||||||||||2018-05-31 22:57:33.673286|2018-05-31 22:57:33.673286
NCT01279161|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2014-12-01|2011-01-18|2011-01-19|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|FTO_T1DM||The Role of FTO Gene Polymorphism and Insulin Preparation in Obesity in Children With Type 1 Diabetes Mellitus|The Role of FTO Gene Polymorphism and Insulin Preparation in Overweight/Obesity in Children With Type 1 Diabetes Mellitus|Completed|||2000|Actual|University of Bialystok|||2||f||||t||||||Samples With DNA|"~     Small amount of peripheral blood for isolation of DNA for assessment of FTO polymorphism.~   "|||2018-05-31 22:57:33.832023|2018-05-31 22:57:33.832023
NCT01279148|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2013-11-28|2011-01-18|2011-01-19|Estimate|||||||2013-11-28|2013-12-02|Estimate|April 2014||2014-04-30|November 2013|2013-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Electromagnetic Tracking of Devices During Interventional Procedures|Electromagnetic Tracking of Devices During Interventional Procedures|Unknown status|Not yet recruiting||20|Anticipated|Philips Healthcare|||2||f||||f||||||Samples Without DNA|"~     Liver Biopsy analyzed as per standard of care~   "|||2018-05-31 22:57:34.013555|2018-05-31 22:57:34.013555
NCT01279135|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|February 2018|Anticipated|2018-02-28|February 2016|Anticipated|2016-02-29||Interventional|PARCER||Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix|Phase III Randomized Trial of Image Guided Intensity Modulated Radiotherapy (IG-IMRT) and Conventional Radiotherapy for Late Toxicity Reduction After Postoperative Radiotherapy in Ca Cervix.|Unknown status|Recruiting|Phase 3|240|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||||2018-05-31 22:57:34.179562|2018-05-31 22:57:34.179562
NCT01279122|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-02-16|2011-01-18|2011-01-19|Estimate|||||||2011-02-16|2011-02-17|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses|Evaluation of Visual Outcomes of Monovision Patients Bilaterally Implanted With Nanoflex Intraocular Lenses|Unknown status|Recruiting|Phase 4|100|Anticipated|Innovative Medical||1|||f||||f||||||||||2018-05-31 22:57:34.335466|2018-05-31 22:57:34.335466
NCT01279109|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2017-01-13||2017-11-02|2011-01-17|2011-01-19|Estimate|2017-03-14|2017-04-25|Actual||||2017-11-02|2017-12-07|Actual|January 2011||2011-01-31|April 2017|2017-04-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Interventional|||Starting Pediatric Obesity Prevention in Pregnancy|Starting Pediatric Obesity Prevention in Pregnancy|Completed||N/A|147|Actual|Wake Forest University Health Sciences|Pilot study; Low session attendance; Missing data from medical record abstractions; Loss to follow-up, possibly due to not requiring participants to attend two baseline visits prior to randomization; Generalizability may be limited to Latina women|2|||f||||t||||||||Yes|"An individual participant data set (The Madre Sana Data Set) and codebook are publically available and can be downloaded at:~http://www.insna.org/connections/v35/v35_2_6.html Citation: Gesell SB, Tesdahl E. Data Exchange Network: The Madre Sana data set. Connections 2016, 35 (2), 62-65."|2018-05-31 22:57:34.426164|2018-05-31 22:57:34.426164
NCT01279096|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2014-12-08|2011-01-17|2011-01-19|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|Vandevol||Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia|A Phase I Dose Escalation Study of Clofarabine Given in Combination With Multi-agent Therapy for Remission Induction in Pediatric Patients With Acute Lymphoblastic Leukemia in First Relapse or Refractory to First Line Therapy -|Completed||Phase 1|20|Actual|University Hospital, Lille|||||f||||t||||||||||2018-05-31 22:57:35.093616|2018-05-31 22:57:35.093616
NCT01279083|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-12-14|2011-01-18|2011-01-19|Estimate|||||||2012-12-14|2012-12-17|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension|A Phase I/II Dose Escalation Safety and Efficacy Trial of DE-112 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 1/Phase 2|147|Actual|Santen Inc.||6|||f||||f||||||||||2018-05-31 22:57:35.162195|2018-05-31 22:57:35.162195
NCT01279070|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|2011-11-16||2013-08-14|2011-01-18|2011-01-19|Estimate|2013-07-12|2013-08-15|Estimate||||2013-08-14|2013-08-23|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|March 2011|Actual|2011-03-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia|Efficacy of Repyflec Cognitive Remediation Group Training in Cognition, Functional Outcomes and Psychiatric Symptoms of Outpatients With Schizophrenia.|Completed||Phase 4|62|Actual|Fundació Sant Joan de Déu|It would be useful to widen the assessment of cognitive measures and negative symptoms. Metacognition has not been appropriately studied.|2|||f||||f||||||||||2018-05-31 22:57:35.261468|2018-05-31 22:57:35.261468
NCT01279057|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17||2012-08-10|2017-03-27|2011-01-18|2011-01-19|Estimate||||2012-12-14|2012-12-19|Estimate|2017-03-27|2017-03-28|Actual|December 2010|Actual|2010-12-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Fluticasone Furoate Nasal Spray (Lek Pharmaceuticals) With Veramyst® Nasal Spray (GlaxoSmithKline) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|Completed||Phase 3|962|Actual|Sandoz||3|||f||||||||||||||2018-05-31 22:57:35.757549|2018-05-31 22:57:35.757549
NCT01279044|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|2014-03-18||2014-09-30|2011-01-18|2011-01-19|Estimate|2014-09-30|2014-10-07|Estimate||||2014-09-30|2014-10-07|Estimate|September 2007||2007-09-30|September 2014|2014-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||There were no significant differences between the two study arms on baseline demographics, HIV testing, and substance use. The mean age was 33.6 years; 49% were white and 51% non-white including 26% Latino/Hispanic, 11% Asian and Pacific Islander, 10% black/African American, and 6% mixed/other race.|Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)|Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM): Adaptation of the Personalized Cognitive Counseling (PCC) Intervention|Completed||Phase 1/Phase 2|385|Actual|San Francisco Department of Public Health|Self-report data subject to recall bias Sample is San Francisco SUMSM; may not be generalizable to other locations 42% screened as substance-dependent per SDS Inclusion of dependent MSM reduced ability to detect significant intervention effects|2|||f||||f||||||||||2018-05-31 22:57:35.848293|2018-05-31 22:57:35.848293
NCT01279031|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-01-13|2011-01-18|2011-01-19|Estimate|||||||2012-01-13|2012-01-18|Estimate|October 2011||2011-10-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial|Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial|Completed||Phase 4|25|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-05-31 22:57:36.536229|2018-05-31 22:57:36.536229
NCT01279018|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|October 2010||2010-10-31|June 2010|2010-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Persistent Pain After Breast Cancer Treatment With Docetaxel|Persistent Pain After Breast Cancer Treatment With Docetaxel|Completed|||2490|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 22:57:36.625153|2018-05-31 22:57:36.625153
NCT01279005|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|July 2011|Anticipated|2011-07-31|April 2011|Anticipated|2011-04-30||Observational|MSM HIV||Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV|Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV - Focus Groups, Observational Study|Unknown status|Not yet recruiting||50|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 22:57:36.695932|2018-05-31 22:57:36.695932
NCT01278992|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-02-14|2011-01-17|2011-01-19|Estimate|||||||2011-02-14|2011-02-15|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Rhodiola Rosea for Mental and Physical Fatigue|A Randomized Trial of Rhodiola Rosea for Mental and Physical Fatigue in Nurses|Unknown status|Enrolling by invitation|Phase 2|90|Anticipated|Government of Alberta|||||f||||t||||||||||2018-05-31 22:57:36.757649|2018-05-31 22:57:36.757649
NCT01278979|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-05-20|2011-01-17|2011-01-19|Estimate|||||||2013-05-20|2013-05-21|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|June 2012|Actual|2012-06-30||Interventional|||Diagnosing Perineal Tears, Does Different Assessment Methods Affect the Midwife's Clinical Judgement of Perineal Tears?|Diagnosing Perineal Tears. Consistency in Midwifes Clinical Judgement When Assessing Perineal Tears Using Two Different Assessment Methods.|Completed||N/A|400|Actual|Ostfold Hospital Trust||2|||f||||t||||||||||2018-05-31 22:57:36.905947|2018-05-31 22:57:36.905947
NCT01278966|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2011-01-17|2011-01-17|2011-01-19|Estimate|||||||2011-01-17|2011-01-19|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Modified Atkins Diet in Children and Adolescents With Drug-resistant Epilepsy|Modified Atkins Diet in Children and Adolescents With Drug-resistant Epilepsy - a Prospective Pilot Trial|Completed||N/A|21|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 22:57:37.071475|2018-05-31 22:57:37.071475
NCT01278953|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2016-01-07||2016-02-05|2011-01-17|2011-01-19|Estimate|2016-01-07|2016-02-08|Estimate||||2016-02-05|2016-03-08|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|June 2013|Actual|2013-06-30||Interventional|TOCCASTAR||TOCCASTAR - TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation|A Prospective, Randomized, Multicenter, Interventional Study to Evaluate the Safety and Effectiveness of the TactiCath Percutaneous Ablation Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Using Contact Force Assisted Radiofrequency Ablation|Completed||N/A|295|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 22:57:37.169989|2018-05-31 22:57:37.169989
NCT01278940|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2016-08-12|2011-01-18|2011-01-19|Estimate|||||||2016-08-12|2016-08-15|Estimate|March 2002||2002-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|February 2006|Actual|2006-02-28||Interventional|||Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma|Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma|Completed||Phase 1/Phase 2|31|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 22:57:37.566407|2018-05-31 22:57:37.566407
NCT01278927|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2014-11-24||2018-03-20|2011-01-17|2011-01-19|Estimate|2015-11-16|2015-12-17|Estimate||||2018-03-20|2018-04-18|Actual|January 2011||2011-01-31|March 2018|2018-03-31|November 2014|Actual|2014-11-30|January 2013|Actual|2013-01-31||Interventional|||Exercise and Stress Management Post Autologous and Allogeneic Transplant (BMT CTN 0902)|A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients (BMT CTN #0902)|Completed||N/A|711|Actual|Medical College of Wisconsin||4|||f||||t||||||||Yes|Results will be published in a manuscript|2018-05-31 22:57:37.670819|2018-05-31 22:57:37.670819
NCT01278914|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2011-07-21|2011-01-18|2011-01-19|Estimate|||||||2011-07-21|2011-07-22|Estimate||||July 2011|2011-07-31||||||||Interventional|||Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer|Phase I/II Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer|Completed||Phase 1/Phase 2|||Oslo University Hospital|||||f||||f||||||||||2018-05-31 22:57:38.526158|2018-05-31 22:57:38.526158
NCT01278901|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|February 2011||2011-02-28|January 2011|2011-01-31||||February 2012|Anticipated|2012-02-29||Observational|||The Effect of PPI Therapy on the Result of Helicobacter Pylori Diagnostic Tests||Unknown status|Not yet recruiting||30|Anticipated|Rabin Medical Center|||1||f||||f||||||||||2018-05-31 22:57:38.571008|2018-05-31 22:57:38.571008
NCT01278888|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2014-01-02|2011-01-18|2011-01-19|Estimate|||||||2014-01-02|2014-01-03|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|PLEACE||Minimally Invasive or Open Surgery for Lung Cancer: Pain, Quality of Life and Economy.|Minimally Invasive or Open Surgery for Lung Cancer: Pain, Quality of Life and Economy.|Unknown status|Recruiting|N/A|500|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 22:57:38.650376|2018-05-31 22:57:38.650376
NCT01278875|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2014-06-20|2011-01-18|2011-01-19|Estimate|||||||2014-06-20|2014-06-23|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|HDL_ACS||Function of High Density Lipoproteins in Acute Coronary Syndromes|High Density Lipoprotein Function in Acute Coronary Syndromes|Unknown status|Recruiting||65|Anticipated|McGill University Health Center|||3||f||||f||||||Samples Without DNA|"~     Serum Plasma HDL isolated by ultracentrifugation~   "|||2018-05-31 22:57:38.77113|2018-05-31 22:57:38.77113
NCT01278862|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2015-01-22|2011-01-18|2011-01-19|Estimate|||||||2015-01-22|2015-01-26|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Clinical Evaluation of Lava Digital Veneer System (DVS) Crowns|Clinical Evaluation of Lava Digital Veneer System (DVS) Crowns|Terminated||N/A|75|Actual|3M||2||product no longer on market|f||||f||||||||||2018-05-31 22:57:38.828576|2018-05-31 22:57:38.828576
NCT01278849|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2012-11-26|2011-01-17|2011-01-19|Estimate|||||||2012-11-26|2012-11-27|Estimate|January 2010||2010-01-31|November 2012|2012-11-30||||November 2010|Actual|2010-11-30||Interventional|||An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function|A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of ASA404 in Adult Cancer Patients With Impaired Hepatic Function and With Normal Hepatic Function|Terminated||Phase 1|5|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:57:38.908051|2018-05-31 22:57:38.908051
NCT01278836|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-26|2011-01-18|2011-01-19|Estimate|||||||2011-01-26|2011-01-27|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Fasciocutaneous Flaps for Leg Defects|Study of Fasciocutaneous Flaps for Treatment of Leg Defects|Completed||Phase 2|23|Actual|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 22:57:39.067227|2018-05-31 22:57:39.067227
NCT01278823|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|||2018-03-07|2011-01-17|2011-01-19|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2011||2011-01-31|March 2018|2018-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|STAMPEDEII||Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes|Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes|Completed||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 22:57:39.18004|2018-05-31 22:57:39.18004
NCT01278810|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-27|2011-01-18|2011-01-19|Estimate|||||||2011-01-27|2011-01-28|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients|A Phase I ,Single Center, Open-labeling, Single and Dose-escalating Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Novel ERa36 Modifier Icaritin in Advanced Breast Patients|Unknown status|Recruiting|Phase 1|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 22:57:39.292467|2018-05-31 22:57:39.292467
NCT01278797|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-17|2012-02-13||2014-02-28|2011-01-17|2011-01-19|Estimate|2012-02-13|2012-03-16|Estimate||||2014-02-28|2014-03-28|Estimate|January 2011||2011-01-31|February 2014|2014-02-28||||February 2011|Actual|2011-02-28||Interventional|||Telmisartan and Amlodipine Versus Monocomponent Tablets|A Single-Dose, Comparative Bioavailability Study of Telmisartan/Amlodipine 80 mg/10 mg Tablets Versus Micardis 80 mg Tablets With Norvasc 10 mg Tablets Under Fasting Conditions|Completed||Phase 1|28|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:57:39.414504|2018-05-31 22:57:39.414504
NCT01278784|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-12-07|2011-01-18|2011-01-19|Estimate|||||||2012-12-07|2012-12-10|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers|Local Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers|Completed||Phase 1|24|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 22:57:39.607289|2018-05-31 22:57:39.607289
NCT01278771|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|||2011-01-19|2011-01-18|2011-01-19|Estimate|||||||2011-01-19|2011-01-20|Estimate|March 2011||2011-03-31|October 2010|2010-10-31||||||||Observational|CHD||Coronary Anomalies in Congenital Heart Disease|Coronary Anomalies in Congenital Heart Disease|Unknown status|Not yet recruiting||1200|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 22:57:39.692204|2018-05-31 22:57:39.692204
NCT01278758|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|||2012-11-26|2011-01-16|2011-01-19|Estimate|||||||2012-11-26|2012-11-27|Estimate|March 2010||2010-03-31|November 2012|2012-11-30||||November 2010|Actual|2010-11-30||Interventional|||A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function|A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function|Terminated||Phase 1|7|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:57:39.738148|2018-05-31 22:57:39.738148
NCT01278745|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|2016-12-01||2017-02-28|2011-01-16|2011-01-19|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|September 2011||2011-09-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Randomized participants|Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation|Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11)|Terminated||Phase 2|362|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study was terminated with 163 participants randomized, well short of the study's goal of 300 randomized participants.|2||Due to inability to meet accrual goals within the funding period|f||||t||||||||||2018-05-31 22:57:39.862309|2018-05-31 22:57:39.862309
NCT01278732|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-03-31|2011-01-18|2011-01-19|Estimate|||||||2015-03-31|2015-04-03|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mass|Central Blood Pressure Over 24 Hours (ABPM) and Left Ventricular Mas|Completed|||350|Actual|Klinikum Wels-Grieskirchen|||1||f||||f||||||||||2018-05-31 22:57:41.081008|2018-05-31 22:57:41.081008
NCT01278719|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-04-20|2011-01-18|2011-01-19|Estimate|||||||2012-04-20|2012-04-23|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|ACAAGSONP||The Factors Associated With the Formation of Nasal polyp-a Case Control and Descriptive Study|'The Factors Associated With the Formation of Nasal Polyp'|Unknown status|Recruiting||180|Anticipated|Karnataka Institute of Medical Sciences|||4||f||||t||||||||||2018-05-31 22:57:41.161511|2018-05-31 22:57:41.161511
NCT01278706|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-25|2011-01-18|2011-01-19|Estimate|||||||2011-01-25|2011-01-26|Estimate|January 2011||2011-01-31|December 2010|2010-12-31||||January 2013|Anticipated|2013-01-31||Interventional|||Endometrial Biopsy Protocol for In Vitro Fertilization (IVF)|Comparing Timing and Number of Endometrial Biopsies in IVF Treatment and Identifying Biochemical Markers to Predict Endometrial Receptivity|Unknown status|Not yet recruiting|N/A|200|Anticipated|Kaplan Medical Center||4|||f||||t||||||||||2018-05-31 22:57:41.245379|2018-05-31 22:57:41.245379
NCT01278693|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effect of Oral L-carnitine Supplement on Lipid Profile, Anemia, and Quality of Life of Patients|Study of Treatment of Dyslipidemia for Hemodialysis|Completed||Phase 2|54|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:57:41.357412|2018-05-31 22:57:41.357412
NCT01278680|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-08-17|2011-01-18|2011-01-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Incentives for Moving||Withdrawn||N/A|0|Actual|Harvard University||3||"Enrollment has not begun; study suspended indefinitely due to change in management at company~   where we were going to conduct the study."|f||||t||||||||||2018-05-31 22:57:41.541689|2018-05-31 22:57:41.541689
NCT01277796|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate||||January 2011|2011-01-31||||||||Expanded Access|HECT||Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis|Pilot Study of Thermotherapy Treatment for Cutaneous Leishmaniasis in Peru With the HECT-CL Device|Available|||||Universidad Peruana Cayetano Heredia|||||f||||||||||||||2018-05-31 22:57:53.008657|2018-05-31 22:57:53.008657
NCT01278667|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|||2011-01-23|2011-01-18|2011-01-19|Estimate|||||||2011-01-23|2011-01-25|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Observational|||Methylphenidate and the Relations Between Emotional Processing and Social Functioning Among Children With ADHD|Difficulties in Emotional Processing, the Influence of Methylphenidate on This Processing and the Relations Between Emotional Processing and Social Functioning Among Children With ADHD|Unknown status|Recruiting||80|Anticipated|Bnai Zion Medical Center|||||f||||f||||||||||2018-05-31 22:57:41.60257|2018-05-31 22:57:41.60257
NCT01278654|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2012-03-15|2011-01-18|2011-01-19|Estimate|||||||2012-03-15|2012-03-19|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Lottery Incentives for Moving||Completed||N/A|212|Actual|Harvard University||2|||f||||t||||||||||2018-05-31 22:57:41.658806|2018-05-31 22:57:41.658806
NCT01278641|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|January 2008||2008-01-31|April 2008|2008-04-30|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Men With Fibromyalgia or Chronic Widespread Pain - Effect of Exercise on Symptoms and Body Functions|Men With Fibromyalgia or Chronic Widespread Pain - Effect of Exercise on Symptoms and Body Functions|Completed||N/A|44|Actual|Göteborg University||3|||f||||f||||||||||2018-05-31 22:57:41.713204|2018-05-31 22:57:41.713204
NCT01278628|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2016-08-08|2011-01-18|2011-01-19|Estimate|||||||2016-08-08|2016-08-10|Estimate|August 2009||2009-08-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||SUMCO Metabolic Syndrome Project||Completed||Phase 1|114|Actual|Fukuoka University||1|||f||||t||||||||||2018-05-31 22:57:41.772653|2018-05-31 22:57:41.772653
NCT01278615|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-15|2015-09-04||2016-01-04|2011-01-15|2011-01-19|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Terminated||Phase 2|16|Actual|National Cancer Institute (NCI)||1||Closed Prematurely.|f||||t||||||||||2018-05-31 22:57:41.844638|2018-05-31 22:57:41.844638
NCT01278602|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2013-03-02|2011-01-18|2011-01-19|Estimate|||||||2013-03-02|2013-03-05|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma|A Multi-center Phase II Study of R-ESHAP Followed by Autologous Transplantation as Salvage Treatment for Patients With Refractory or Relapsed Diffuse Large B-cell Lymphoma.|Unknown status|Recruiting|Phase 2|50|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 22:57:42.237215|2018-05-31 22:57:42.237215
NCT01278589|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-10-27|2011-01-18|2011-01-19|Estimate|||||||2011-10-27|2011-10-28|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Antioxidative Effect of Plantago Asiatica L. Extract|Acute Effect of Plantago Asiatica L. Extract on Antioxidative Biomarkers in Subjects With Mild Hyperlipidemia: A Pilot Study|Completed||N/A|40|Anticipated|Ewha Womans University||4|||f||||f||||||||||2018-05-31 22:57:42.337434|2018-05-31 22:57:42.337434
NCT01278576|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-05-14|2011-01-18|2011-01-19|Estimate|||||||2012-05-14|2012-05-15|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|BTX-A||Botulinum Toxin A Adult Gastrocnemius Muscle Study|An Efficacy Comparison of Botulinum Toxin A Injection Into Two Different Sites in Gastrocnemius Muscle for the Treatment of Spastic Patients, Randomized Controlled Trial|Completed||Phase 4|40|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 22:57:42.528234|2018-05-31 22:57:42.528234
NCT01278563|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2011-01-18|2011-01-18|2011-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||A Trial to Investigate the Impact of a Low Glycemic Index (GI) Diet on Body Mass Index and Obesity Related Cardiovascular and Hormonal Factors in Chinese Adolescents|A Randomized Controlled Trial to Investigate the Impact of a Low Glycemic Index (GI) Diet on Body Mass Index and Obesity Related Cardiovascular and Hormonal Factors in Chinese Adolescents|Unknown status|Not yet recruiting|N/A|280|Anticipated|Chinese University of Hong Kong|||||f||||f||||||||||2018-05-31 22:57:42.64934|2018-05-31 22:57:42.64934
NCT01278550|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2015-08-10|2011-01-18|2011-01-19|Estimate|||||||2015-08-10|2015-08-13|Estimate|January 1995||1995-01-31|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Prevention of Recurrent Ulcer Bleeding in High-risk Users of Low-dose Aspirin|Prevention of Recurrent Ulcer Bleeding in High-risk Users of Low-dose Aspirin (NSAID#2NANC Study)|Completed|||503|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 22:57:42.73115|2018-05-31 22:57:42.73115
NCT01278537|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2014-03-13|2011-01-18|2011-01-19|Estimate|||||||2014-03-13|2014-03-14|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|PERATECS||Patient Empowerment and Risk-assessed Treatment to Improve Outcome in the Elderly After Onco-surgery|Patient Empowerment and Risk-assessed Treatment to Improve Outcome in the Elderly After Gastrointestinal, Thoracical or Urogenital Cancer Surgery.|Completed||N/A|690|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 22:57:42.826237|2018-05-31 22:57:42.826237
NCT01278524|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2013-08-09|2011-01-18|2011-01-19|Estimate|||||||2013-08-09|2013-08-13|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|IMPROVE-ICU||International Multicenter Study One Day Prevalence Observational Study for Delirium on ICU|International Multicenter Study One Day Prevalence Observational Study for Delirium on ICU|Completed|||1002|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 22:57:42.925863|2018-05-31 22:57:42.925863
NCT01278511|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-01-26|2011-01-18|2011-01-19|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2011||2011-01-31|January 2016|2016-01-31||||||||Interventional|||Prospective Pilot Study Validating the Canadian C-Spine Rule Pre-hospital|A Prospective Pilot Study Validating the Canadian C-Spine Rule in a Pre-hospital Setting|Withdrawn||N/A|0|Actual|Katholieke Universiteit Leuven||1||Not feasible|f||||f||||||||||2018-05-31 22:57:43.051126|2018-05-31 22:57:43.051126
NCT01278498|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-18|||2014-10-08|2011-01-18|2011-01-19|Estimate|||||||2014-10-08|2014-10-09|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|EMOTION||The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients|A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life|Unknown status|Active, not recruiting|Phase 4|444|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 22:57:43.131625|2018-05-31 22:57:43.131625
NCT01278485|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2013-05-14||2015-07-17|2011-01-18|2011-01-19|Estimate|2013-08-22|2013-08-26|Estimate||||2015-07-17|2015-07-28|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|NEEDS||Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)|Naturalistic Evaluation of Hypoglycemic Events in Diabetic Subjects|Completed|||726|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 22:57:43.357115|2018-05-31 22:57:43.357115
NCT01278472|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Cosmesis and Body Image After Single Port or 4-Port Laparoscopic Cholecystectomy|Cosmesis and Body Image After Single Port Laparoscopic or Conventional Laparoscopic Cholecystectomy: A Double Blinded Randomised Controlled Trial|Unknown status|Recruiting|N/A|110|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 22:57:43.730057|2018-05-31 22:57:43.730057
NCT01278459|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2015-05-29|2011-01-14|2011-01-17|Estimate|||||||2015-05-29|2015-06-01|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|PVS3||Can Atorvastatin Improve Vascular Function in Women With a History of Preeclampsia?|Can Atorvastatin Improve Vascular Function in Women With a History of Preeclampsia? A Randomised, Double-blinded, Placebo-controlled Crossover Trial of Atorvastatin in Women With a History of Preeclampsia.|Completed||Phase 3|11|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 22:57:43.807047|2018-05-31 22:57:43.807047
NCT01278446|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-11-01|2011-01-14|2011-01-17|Estimate|||||||2013-11-01|2013-11-04|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Extensively Hydrolyzed Formula: Hypoallergenicity|Evaluation of Hypoallergenicity of a 100% Whey, Extensively Hydrolyzed Infant Formula|Completed||N/A|||Nestlé||2|||f||||f||||||||||2018-05-31 22:57:43.88643|2018-05-31 22:57:43.88643
NCT01278433|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-03-28|2011-01-14|2011-01-17|Estimate|||||||2013-03-28|2013-03-29|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China|Large Scale Safety Study of IMOVAX Polio in Selected Cities in China, an Observational Post Marketing Study|Completed||Phase 4|5007|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 22:57:43.993777|2018-05-31 22:57:43.993777
NCT01278420|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2012-06-13|2011-01-14|2011-01-17|Estimate|||||||2012-06-13|2012-06-14|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL|AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL|Unknown status|Recruiting|Phase 4|60|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-05-31 22:57:44.129678|2018-05-31 22:57:44.129678
NCT01278407|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|2015-10-27||2015-12-30|2011-01-14|2011-01-17|Estimate|2015-10-27|2015-11-30|Estimate||||2015-12-30|2016-02-02|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional||The data is based on Full Analysis Set, defined as all the randomized patients who received the study drug at least once and had valid efficacy assessment data at more than one point.|A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase|Completed||Phase 3|142|Actual|Eisai Inc.||5|||f||||||||||||||2018-05-31 22:57:44.290975|2018-05-31 22:57:44.290975
NCT01278394|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|2014-07-25|2014-01-18|2017-09-13|2011-01-14|2011-01-17|Estimate|2014-07-25|2014-08-15|Estimate|2011-02-09|2011-02-14|Estimate|2017-09-13|2017-10-16|Actual|March 2007||2007-03-31|September 2017|2017-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||All analyses were performed using the intent-to-treat (ITT) population.|Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail|An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail|Completed||Phase 2|29|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 22:57:44.884081|2018-05-31 22:57:44.884081
NCT01278381|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2002||2002-01-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Prognostic Score To Predict Major Complications After Pancreaticoduodenectomy|A PROGNOSTIC SCORE TO PREDICT MAJOR COMPLICATIONS AFTER PANCREATICODUODENECTOMY.|Completed|||700|Actual|Università Vita-Salute San Raffaele|||1||f||||f||||||||||2018-05-31 22:57:45.173777|2018-05-31 22:57:45.173777
NCT01278368|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-12-21|2011-01-14|2011-01-17|Estimate|||||||2012-12-21|2012-12-24|Estimate|January 2003||2003-01-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection|PREOPERATIVE CHEMOTHERAPY DOES NOT ADVERSELY AFFECT SHORT-TERM OUTCOME AFTER PANCREATIC RESECTION.|Completed||N/A|150|Actual|Università Vita-Salute San Raffaele||2|||f||||f||||||||||2018-05-31 22:57:45.23087|2018-05-31 22:57:45.23087
NCT01278355|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-12-02|2011-01-14|2011-01-17|Estimate|||||||2013-12-02|2013-12-03|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Assessing the Feasibility of Integrating Ear Acupuncture Into the Aeromedical Evacuation System From RAB to AAFB|The Feasibility of Integrating Ear Acupuncture for Pain in Patients Being Transported Via the Aeromedical Evacuation System From Ramstein Air Base to Andrews AFB, Maryland USA: An Observational Study|Completed|||40|Anticipated|Samueli Institute for Information Biology|||1||f||||||||||||||2018-05-31 22:57:45.314527|2018-05-31 22:57:45.314527
NCT01278342|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|2011-01-22||2017-02-28|2011-01-14|2011-01-17|Estimate|2011-01-22|2011-02-17|Estimate||||2017-02-28|2017-03-03|Actual|September 2006||2006-09-30|February 2017|2017-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|HOSCAR||Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients|An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventional Regimen|Completed||Phase 4|70|Actual|Novartis||3|||f||||||||||||||2018-05-31 22:57:45.399528|2018-05-31 22:57:45.399528
NCT01278329|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2003||2003-01-31|December 2010|2010-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|PEXMUSIC||Maternal Music Exposure During Pregnancy Influences Neonatal Behaviour|Effect of Maternal Ante-natal Music Exposure on Neonatal Behavior Measured Using Brazelton Neonatal Behavioral Scale: A Randomized Open-label Study|Completed||Phase 4|339|Actual|NSCB Medical College||2|||f||||t||||||||||2018-05-31 22:57:46.5726|2018-05-31 22:57:46.5726
NCT01278316|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2018-03-20|2011-01-14|2011-01-17|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2011||2011-01-31|March 2018|2018-03-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Rural Veterans With Post-traumatic Stress Disorder (PTSD) And Comorbid Mild Traumatic Brain Injury (TBI): A Feasibility Study|Remote Administration Of Cognitive Training Tasks In Rural Veterans With PTSD And Comorbid Mild TBI: A Feasibility Study|Completed||N/A|16|Actual|Michael Debakey Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 22:57:46.686431|2018-05-31 22:57:46.686431
NCT01278303|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2015-04-08||2016-02-15|2011-01-14|2011-01-17|Estimate|2016-02-15|2016-03-14|Estimate||||2016-02-15|2016-03-14|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|COASTII||Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta|Covered Cheatham Platinum Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta|Completed||Phase 2|82|Actual|Johns Hopkins University||1|||f||||t||||||||No|Individual patient data is confidential and not shared.|2018-05-31 22:57:46.785706|2018-05-31 22:57:46.785706
NCT01278290|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|July 2010||2010-07-31|December 2010|2010-12-31|October 2011|Anticipated|2011-10-31|April 2011|Anticipated|2011-04-30||Interventional|||Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls|Triptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls.|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Hospital de Niños R. Gutierrez de Buenos Aires||2|||f||||t||||||||||2018-05-31 22:57:46.982477|2018-05-31 22:57:46.982477
NCT01278277|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2017-07-18|2011-01-14|2011-01-17|Estimate|||||||2017-07-18|2017-07-19|Actual|February 2011||2011-02-28|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|STARSAF02||Saffron Supplementation in Stargardt's Disease|A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 22:57:47.065029|2018-05-31 22:57:47.065029
NCT01278264|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-04-26|2011-01-14|2011-01-17|Estimate|||||||2011-04-26|2011-04-27|Estimate|June 2011||2011-06-30|February 2011|2011-02-28|August 2012|Anticipated|2012-08-31|May 2012|Anticipated|2012-05-31||Interventional|TAPA||Transversus Abdominis Plane Blocks With Abdominoplasty|Transversus Abdominis Plane Blocks in Patients Scheduled for an Abdominoplasty. A Prospective, Randomized, Double Blind, Comparison Between the Posterior Approach and Placebo.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Clinique Saint-Jean, Bruxelles||2|||f||||f||||||||||2018-05-31 22:57:47.932021|2018-05-31 22:57:47.932021
NCT01278251|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate||||January 2011|2011-01-31||||||||Observational|||Functional Review of Distal Biceps Re-Insertion||Completed|||||West Penn Allegheny Health System|||1||f||||||||||||||2018-05-31 22:57:48.039073|2018-05-31 22:57:48.039073
NCT01278238|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-01-09|2011-01-14|2011-01-17|Estimate|||||||2013-01-09|2013-01-11|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Optimization of Hemodynamic Conditions During Caesarean Section Under Spinal Anaesthesia|Hemodynamic Effect of Prophylactic Phenylephrine Versus Lower Limb Compression in Women During Caesarean Section Under Spinal Anaesthesia|Completed||N/A|120|Actual|Anestesiavdelingen Baerum Sykehus||3|||f||||f||||||||||2018-05-31 22:57:48.108806|2018-05-31 22:57:48.108806
NCT01278225|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2018-03-27|2011-01-14|2011-01-17|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2011|Actual|2011-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain|Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain|Active, not recruiting|||80|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 22:57:48.174687|2018-05-31 22:57:48.174687
NCT01278212|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-01-15|2011-01-14|2011-01-17|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2011||2011-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer|A Phase II Study of Accelerated Hypofractionated Radiotherapy (AHF-RT) After Breast Conserving Surgery (BCS) in Medically Underserved Patients|Active, not recruiting||Phase 2|155|Actual|University of Louisville||1|||f||||t||||||||||2018-05-31 22:57:48.266536|2018-05-31 22:57:48.266536
NCT01278199|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2017-03-21|2011-01-14|2011-01-17|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2011|Actual|2011-11-30|March 2017|2017-03-31|February 27, 2017|Actual|2017-02-27|December 27, 2016|Actual|2016-12-27||Interventional|ARTEMHYS||Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance|A Multicentric Randomized Trial Comparing the Bronchial Artery Embolization Combined With Medical Measures and the Medical Measures Alone in the Treatment of Non-severe Acute Hemoptysis of Mild-to-moderate Abundance|Completed||N/A|73|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 22:57:48.343688|2018-05-31 22:57:48.343688
NCT01278186|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-07-16|2011-01-14|2011-01-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|BABILON||Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions|Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)|Unknown status|Active, not recruiting|Phase 4|190|Anticipated|B.Braun Surgical SA||2|||f||||||||||||||2018-05-31 22:57:48.438722|2018-05-31 22:57:48.438722
NCT01278173|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|2016-04-28||2016-04-28|2011-01-14|2011-01-17|Estimate|2016-04-28|2016-06-07|Estimate||||2016-04-28|2016-06-07|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||All patients who took at least one dose of IMP.|A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)|A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)|Completed||Phase 4|65|Actual|Lundbeck LLC||1|||f||||f||||||||||2018-05-31 22:57:48.658413|2018-05-31 22:57:48.658413
NCT01278160|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|2012-09-14||2014-10-16|2011-01-14|2011-01-17|Estimate|2012-09-14|2012-10-18|Estimate||||2014-10-16|2014-10-27|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756|An Extension Trial of BIAsp-3756, Explorative Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens on the Effect of Glycaemic Control in Chinese Type 2 Diabetes Patients|Completed||Phase 4|179|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:57:49.002329|2018-05-31 22:57:49.002329
NCT01278147|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|May 2007||2007-05-31|January 2011|2011-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Cancer Fatigue Education Program|Development and Implementation of a Cancer Fatigue Education Program|Completed||N/A|200|Actual|Institut de Cancérologie de la Loire||2|||f||||f||||||||||2018-05-31 22:57:49.452931|2018-05-31 22:57:49.452931
NCT01278134|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14||2016-07-20|2016-11-01|2011-01-14|2011-01-17|Estimate||||2016-07-20|2016-07-22|Estimate|2016-11-01|2016-11-02|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)|INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment With a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir Boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) With or Without Copegus® in Interferon Naïve HCV Genotype 1 Infected Patients|Completed||Phase 2|170|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 22:57:49.52782|2018-05-31 22:57:49.52782
NCT01278121|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2017-01-16|2011-01-14|2011-01-17|Estimate|||||||2017-01-16|2017-01-18|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Study of the Potential of a Macronutrient Balanced Normocaloric Diet to Treat Lifestyle Diseases|Food and Health; Testing of the Anti-Inflammatory Potential of a Macronutrient Balanced Normocaloric Diet|Completed||N/A|28|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-05-31 22:57:49.727481|2018-05-31 22:57:49.727481
NCT01278108|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-10-17|2011-01-14|2011-01-17|Estimate|||||||2011-10-17|2011-10-18|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||First-in-Human Single Ascending and Multiple Dose of GLPG0778|Double-blind, Placebo-controlled, Dose-ranging Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Oral Doses, and Multiple Oral Doses of GLPG0778 in Healthy Subjects.|Completed||Phase 1|40|Anticipated|Galapagos NV||4|||f||||f||||||||||2018-05-31 22:57:49.811252|2018-05-31 22:57:49.811252
NCT01278095|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-03-23|2011-01-14|2011-01-17|Estimate|||||||2011-03-23|2011-03-24|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Oral Bioavailability of GLPG0555 in Different Solid Formulations|A Randomized, Open Label, 3-way Crossover Study to Compare the Oral Bioavailability of GLPG0555 After Single-dose Intake in Healthy Subjects as a Solid Dispersion Formulation, With and Without Food, Relative to a Nanosuspension Formulation|Completed||Phase 1|12|Actual|Galapagos NV||3|||f||||f||||||||||2018-05-31 22:57:49.881914|2018-05-31 22:57:49.881914
NCT01278082|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2016-01-20|2011-01-14|2011-01-17|Estimate|||||||2016-01-20|2016-01-21|Estimate|April 2008||2008-04-30|January 2016|2016-01-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|SCCMS||SOIBD Collagenous Colitis Maintenance Study|Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules Versus Placebo for Maintenance of Remission in Patients With Collagenous Colitis|Completed||Phase 3|92|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-05-31 22:57:49.95425|2018-05-31 22:57:49.95425
NCT01278069|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-09-16|2011-01-14|2011-01-17|Estimate|||||||2013-09-16|2013-09-18|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PETAML||PET-CT in AML for Detection of Extramedullary AML Manifestations|PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations|Completed|||93|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-05-31 22:57:50.037151|2018-05-31 22:57:50.037151
NCT01278056|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-07-19|2011-01-14|2011-01-17|Estimate|||||||2012-07-19|2012-07-20|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|DEFINE||The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis|The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial|Completed||Phase 1/Phase 2|5|Actual|Crolll Gmbh||1|||f||||t||||||||||2018-05-31 22:57:50.089553|2018-05-31 22:57:50.089553
NCT01278043|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2016-08-24|2011-01-13|2011-01-17|Estimate|||||||2016-08-24|2016-08-26|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ARIVE-PCI||Antiplatelet Response, Interval Variability & Events in Percutaneous Coronary Intervention (ARIVE-PCI) Registry|Incidence, Predictors and Impact of Response Variability to Oral Dual Antiplatelet Therapy, as Measured by Point-of-care Platelet Aggregometry, Following Percutaneous Coronary Intervention|Active, not recruiting|||100|Anticipated|University of Chicago|||||f||||f||||||||||2018-05-31 22:57:50.200074|2018-05-31 22:57:50.200074
NCT01278030|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2013-06-04||2013-10-21|2011-01-13|2011-01-17|Estimate|2013-10-21|2013-12-09|Estimate||||2013-10-21|2013-12-09|Estimate|August 2010||2010-08-31|October 2013|2013-10-31||||June 2012|Actual|2012-06-30||Interventional|ENVISION||Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates|Real Time 3-Dimensional Echocardiography for Left Ventricular Lead Site Selection to Reduce Cardiac Resynchronization Therapy Non-Responder Rates (ENVISION)|Completed||N/A|78|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 22:57:50.275508|2018-05-31 22:57:50.275508
NCT01278017|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|August 2010||2010-08-31|November 2010|2010-11-30|July 2012|Anticipated|2012-07-31|June 2011|Anticipated|2011-06-30||Interventional|||The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis|The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis|Unknown status|Recruiting|Phase 4|200|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 22:57:50.533064|2018-05-31 22:57:50.533064
NCT01278004|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-05-25|2011-01-14|2011-01-17|Estimate|||||||2016-05-25|2016-05-26|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CINE-E||Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study)|A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy|Completed||Phase 2|15|Actual|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 22:57:50.68922|2018-05-31 22:57:50.68922
NCT01277991|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-04-06|2011-01-13|2011-01-17|Estimate|||||||2011-04-06|2011-04-07|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550|Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2-period, Crossover, Bioequivalence Study Comparing Phase 2b 1 Mg And 5 Mg Tablet Formulations Of Cp-690,550 Under Fasted Conditions|Completed||Phase 1|30|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 22:57:50.776482|2018-05-31 22:57:50.776482
NCT01277978|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2008||2008-01-31|January 2011|2011-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Haemodynamic Effects of Oxytocin and Carbetocin|Haemodynamic Assessment at Primary Caesarean Section After Administration of Carbetocin Versus Oxytocin: a Doubleblind Randomized Trail|Completed|||84|Actual|Medical University of Graz|||2||f||||f||||||||||2018-05-31 22:57:50.907446|2018-05-31 22:57:50.907446
NCT01277965|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-04-19|2011-01-14|2011-01-17|Estimate|||||||2013-04-19|2013-04-22|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|DIABRASPORT||Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity|Use of a CMGS to Validate Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Treated With Subcutaneous Continuous Insulin Infusion and Practicing Physical Activity|Completed||N/A|20|Anticipated|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||5|||f||||t||||||||||2018-05-31 22:57:50.989031|2018-05-31 22:57:50.989031
NCT01277952|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-03-28|2011-01-13|2011-01-17|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2011||2011-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Deep Brain Stimulation for Traumatic Brain Injury|Deep Brain Stimulation for Treatment of Severe Disability From Traumatic Brain Injury|Completed||N/A|4|Actual|Ohio State University||1|||f||||t||||||||No||2018-05-31 22:57:51.096077|2018-05-31 22:57:51.096077
NCT01277939|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2013-08-29|2011-01-14|2011-01-17|Estimate|||||||2013-08-29|2013-09-02|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|CPT||CPT for Offenders With SUD|Computerized Psychosocial Treatment for Offenders With Substance Use Disorders|Completed||N/A|376|Actual|National Development and Research Institutes, Inc.||2|||f||||t||||||||||2018-05-31 22:57:51.168805|2018-05-31 22:57:51.168805
NCT01277926|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2012-12-05|2011-01-14|2011-01-17|Estimate|||||||2012-12-05|2012-12-06|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer|Patterns of Care in Hormone-Receptor Positive, Advanced Breast Cancer in Brazil: A Prospective, Observational Study|Terminated|||7|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:57:51.27632|2018-05-31 22:57:51.27632
NCT01277913|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-11-03|2011-01-14|2011-01-17|Estimate|||||||2013-11-03|2013-11-05|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effect of Supplementation With Two Different Doses of Vitamin D on Bone Mineral Density, Vitamin D Levels and Hand Grip Strength in Children With Diabetes Mellitus Type 1|The Effect of Supplementation With Two Different Doses of Vitamin D (500 IU vs 1000IU)on Bone Mineral Density, Serum 25 Hydroxyvitamin D and Hand Grip Strength in Children With Diabetes Mellitus Type 1 - a Randomized Controlled Trial.|Completed||Phase 4|60|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 22:57:51.366144|2018-05-31 22:57:51.366144
NCT01277900|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2013|Anticipated|2013-12-31|January 2012|Anticipated|2012-01-31||Observational|ADSMT-1||Efficacy and Safety Study of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) to Treat Type 2 Diabetes Mellitus|Efficacy and Safety Study of LRYGB to Treat Type 2 Diabetes Mellitus|Unknown status|Not yet recruiting||500|Anticipated|Asia Metabolic Surgery Research Group|||1||f||||t||||||Samples Without DNA|"~     Blood and urine~   "|||2018-05-31 22:57:51.460619|2018-05-31 22:57:51.460619
NCT01277887|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2017-04-21||2017-12-20|2011-01-13|2011-01-17|Estimate|2017-12-20|2017-12-21|Actual||||2017-12-20|2017-12-21|Actual|December 2010||2010-12-31|December 2017|2017-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Smoking Cessation for Smokers With Sleep Problems|Smoking Cessation for Smokers With Sleep Problems|Completed||N/A|19|Actual|Yale University||2|||f||||t||||||||||2018-05-31 22:57:51.536123|2018-05-31 22:57:51.536123
NCT01277874|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-03-09|2011-01-13|2011-01-17|Estimate|||||||2017-03-09|2017-03-13|Actual|December 2014||2014-12-31|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Oscillatory Versus Non-Oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support|Oscillatory Versus Non-Oscillatory Nasal Continuous Airway Pressure Neonatal Respiratory Support|Withdrawn||N/A|0|Actual|University of Utah||2||PI has left Institution|f||||f||||||||||2018-05-31 22:57:51.958289|2018-05-31 22:57:51.958289
NCT01277861|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2012-02-16||2013-03-14|2011-01-13|2011-01-17|Estimate|2013-03-14|2013-03-15|Estimate||||2013-03-14|2013-03-15|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment|Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment|Completed||Phase 4|100|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 22:57:52.041667|2018-05-31 22:57:52.041667
NCT01277848|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-10-24|2011-01-13|2011-01-17|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2009||2009-05-31|October 2017|2017-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||PLAC1 in Reproduction|PLAC1 in Reproduction|Completed|||500|Actual|University of South Florida|||||f||||t||||||||||2018-05-31 22:57:52.314671|2018-05-31 22:57:52.314671
NCT01277835|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2014-12-01|2011-01-14|2011-01-17|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Intravenous Lidocaine Infusion During Video-assisted Thoracic Procedures for Improved Pain Control|Intravenous Lidocaine Infusion During VATS Procedures Reduces Postoperative Analgesic Requirements|Completed||N/A|48|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 22:57:52.368094|2018-05-31 22:57:52.368094
NCT01277822|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2014-03-24||2017-03-30|2011-01-14|2011-01-17|Estimate|2014-03-24|2014-04-24|Estimate||||2017-03-30|2017-05-03|Actual|May 30, 2011|Actual|2011-05-30|March 2017|2017-03-31|April 22, 2013|Actual|2013-04-22|April 22, 2013|Actual|2013-04-22||Interventional|||Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)|The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlodipine 5 mg Monotherapy|Completed||Phase 4|334|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 22:57:52.469174|2018-05-31 22:57:52.469174
NCT01277809|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-06-21|2011-01-13|2011-01-17|Estimate|||||||2017-06-21|2017-06-23|Actual|December 2010||2010-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of a Walking Program on Balance, Falls and Well Being in Individuals Residing in Long-term Care|Community Alliance for Quality of Life in Long Term Care: The Effects of a Walking Program on Balance, Falls and Well Being in Individuals Residing in Long-term Care|Active, not recruiting||N/A|179|Anticipated|University of Saskatchewan||3|||f||||f||||||||||2018-05-31 22:57:52.916783|2018-05-31 22:57:52.916783
NCT01277783|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-06-18|2011-01-14|2011-01-17|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|April 2014|Anticipated|2014-04-30||Interventional|ALSYNC||ALternate Site Cardiac ReSYNChronization (ALSYNC) Study|ALternate Site Cardiac ReSYNChronization Study|Unknown status|Enrolling by invitation|N/A|130|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||||f||||t||||||||||2018-05-31 22:57:53.10102|2018-05-31 22:57:53.10102
NCT01277770|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2017-10-24|2011-01-13|2011-01-17|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2009||2009-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Studies of Kidney Transplant Outcome|Studies of Kidney Transplant Outcome|Active, not recruiting|||7500|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||||2018-05-31 22:57:53.186882|2018-05-31 22:57:53.186882
NCT01277757|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2015-10-14||2016-11-21|2011-01-13|2011-01-17|Estimate|2016-01-13|2016-02-12|Estimate||||2016-11-21|2017-01-13|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Two participants were not treated.|Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer|Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:57:53.288631|2018-05-31 22:57:53.288631
NCT01277744|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-02-19|2011-01-13|2011-01-17|Estimate|||||||2018-02-19|2018-02-21|Estimate|May 9, 2011|Actual|2011-05-09|February 2018|2018-02-28|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Interventional|||Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor|A Phase II Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor and Other Non-Carcinomas|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 22:57:53.562212|2018-05-31 22:57:53.562212
NCT01277731|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2012-11-18|2011-01-14|2011-01-17|Estimate|||||||2012-11-18|2012-11-20|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Methylprednisolone Replacement for Dexamethasone-induced Hiccup|Pilot Study of Methylprednisolone Replacement for Dexamethasone-induced Hiuup Patients|Withdrawn||N/A|0|Actual|Gyeongsang National University Hospital||1|||f||||f||||||||||2018-05-31 22:57:53.626771|2018-05-31 22:57:53.626771
NCT01277718|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2016-05-27||2017-04-04|2011-01-13|2011-01-17|Estimate|2016-05-27|2016-07-07|Estimate||||2017-04-04|2017-05-10|Actual|January 2011||2011-01-31|April 2017|2017-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||All enrolled participants|A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants|A Phase 1, Open-Label, 3-Period, Randomized, Crossover Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of GDC-0973 in Healthy Subjects|Completed||Phase 1|20|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 22:57:53.694503|2018-05-31 22:57:53.694503
NCT01277705|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-09-06|2011-01-13|2011-01-17|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2002||2002-01-31|September 2016|2016-09-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®|Assess Immunogenicity, Reactogenicity of GSK Biologicals'-dTpa-IPV Vaccine Versus dTpa & IPV Vaccines Administered Separately & Compared With Aventis Pasteur MSD's Td-IPV Vaccine When Administered to Healthy Adolescents & Adults|Completed||Phase 3|806|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:57:54.208383|2018-05-31 22:57:54.208383
NCT01277692|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-06-27|2011-01-13|2011-01-17|Estimate|||||||2017-06-27|2017-06-28|Actual|November 3, 2010|Actual|2010-11-03|June 2017|2017-06-30|May 9, 2011|Actual|2011-05-09|May 9, 2011|Actual|2011-05-09||Interventional|||A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.|A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Subjects|Completed||Phase 1|58|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 22:57:54.320087|2018-05-31 22:57:54.320087
NCT01277679|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2014-05-29|2011-01-13|2011-01-17|Estimate|||||||2014-05-29|2014-06-02|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunteers and in Patients With Cardiac Failure|An Evaluation of MRI Measures of Lung Water Increases With Postural Changes in Healthy Subjects and in Patients With Cardiac Failure: A Methods Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:57:54.469768|2018-05-31 22:57:54.469768
NCT01277666|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2017-07-05|2014-01-09|2017-08-21|2011-01-13|2011-01-17|Estimate|2017-08-21|2017-09-19|Actual|2014-01-09|2014-02-07|Estimate|2017-08-21|2017-09-19|Actual|December 20, 2010|Actual|2010-12-20|July 2017|2017-07-31|July 11, 2013|Actual|2013-07-11|July 11, 2013|Actual|2013-07-11||Interventional|SHIELD-1||A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease|A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease|Completed||Phase 3|608|Actual|GlaxoSmithKline||3|||f||||t||||||||||2018-05-31 22:57:54.59376|2018-05-31 22:57:54.59376
NCT01277653|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Observational|||Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma|Prospective, Randomized Study of PIVKA-II and AFP Measurement Every 3 Months Compared to AFP Every 6 Months in Surveillance Program for Early Detection of Hepatocellular Carcinoma|Unknown status|Recruiting||1000|Anticipated|Yonsei University|||2||f||||t||||||||||2018-05-31 22:57:55.75709|2018-05-31 22:57:55.75709
NCT01277640|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-09-05|2011-01-14|2011-01-17|Estimate|||||||2017-09-05|2017-09-08|Actual|March 2011||2011-03-31|September 2017|2017-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures|Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures|Completed||Phase 1|48|Actual|International Partnership for Microbicides, Inc.||3|||f||||t||||||||||2018-05-31 22:57:55.902767|2018-05-31 22:57:55.902767
NCT01277627|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2011||2011-01-31|December 2010|2010-12-31||||July 2012|Anticipated|2012-07-31||Interventional|HELICON||Influence of Nevirapine on HCV Viral Load|Influence of Nevirapine on HCV Viral Load Among HIV/HCV-coinfected Patients|Unknown status|Not yet recruiting|N/A|60|Anticipated|Valme University Hospital||2|||f||||f||||||||||2018-05-31 22:57:55.975799|2018-05-31 22:57:55.975799
NCT01277614|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Therapeutic Lifestyle Modifications to Reduce Burden of Chronic Disease|A Randomized Control Trial for the Implementation of Lifestyle Modifications to Reduce the Burden of Chronic Disease Among University Staff|Completed||N/A|144|Actual|The University of The West Indies||2|||f||||t||||||||||2018-05-31 22:57:56.04184|2018-05-31 22:57:56.04184
NCT01277601|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2015-08-10||2016-07-15|2011-01-14|2011-01-17|Estimate|2015-08-10|2015-09-09|Estimate||||2016-07-15|2016-08-26|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional||"Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants were analyzed by actual treatment received.~11 participants were never dosed are not included in the Safety Analysis Set due to the following reasons for discontinuation: 7 = Subject Never Dosed with Study Drug; 4 = Withdrawal by Subject."|Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B|A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys®) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)|Completed||Phase 4|751|Actual|Gilead Sciences||4|||f||||f||||||||||2018-05-31 22:57:56.192637|2018-05-31 22:57:56.192637
NCT01277588|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2012-01-16|2011-01-14|2011-01-17|Estimate|||||||2012-01-16|2012-01-18|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Evaluation of the Physicians and Patients Experience of Fetal Scalp Sampling||Completed|||51|Actual|Uppsala University Hospital|||2||f||||f||||||||||2018-05-31 22:57:58.395284|2018-05-31 22:57:58.395284
NCT01277575|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2013-12-18|2011-01-14|2011-01-17|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia|Multicenter Study of Non-invasive Repetitive Paraorbital Alternating Current Stimulation of the Brain: Therapy for Aphasy|Terminated||Phase 3|30|Anticipated|University of Magdeburg||2||recruitment efforts did not result in a sufficient number of patients|f||||f||||||||||2018-05-31 22:57:58.46073|2018-05-31 22:57:58.46073
NCT01277562|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2015-06-03|2011-01-14|2011-01-17|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer|Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer|Completed|||56|Actual|City of Hope Medical Center|||2||f||||t||||||||||2018-05-31 22:57:58.53015|2018-05-31 22:57:58.53015
NCT01277549|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2012-09-11||2013-05-02|2011-01-13|2011-01-17|Estimate|2013-05-02|2013-05-03|Estimate||||2013-05-02|2013-05-03|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational||Data is given only for subjects who completed the study. Reasons why subjects did not complete the study are given above in Participant Flow.|Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors|Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors|Completed|||71|Actual|Terumo BCT|||2||f||||f||||||||||2018-05-31 22:57:58.603464|2018-05-31 22:57:58.603464
NCT01277536|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2014-03-17|2011-01-14|2011-01-17|Estimate|||||||2014-03-17|2014-03-18|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland|Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland (ESTIMATE): Evaluation of a Prediction Rule|Completed|||1478|Actual|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 22:57:58.850926|2018-05-31 22:57:58.850926
NCT01277523|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2014-10-14||2014-10-14|2011-01-13|2011-01-17|Estimate|2014-10-14|2014-10-20|Estimate||||2014-10-14|2014-10-20|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Treated set which included all randomised patients who were dispensed and received, at least one documented dose of trial medication.|Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma|Completed||Phase 3|392|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:57:58.950968|2018-05-31 22:57:58.950968
NCT01277510|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2015-04-29||2015-06-12|2011-01-13|2011-01-17|Estimate|2015-04-29|2015-05-15|Estimate||||2015-06-12|2015-07-10|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pediatric Chronic Kidney Disease Safety and Efficacy|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis|Terminated||Phase 3|43|Actual|Amgen|The study was terminated early with a smaller sample size. However, the study was still sufficiently powered for the double-blind phase. The data collected in the open-label phase is very sparse.|2||"Study was suspended in agreement between sponsor and FDA due to concerns about the study design~   after a fatality had occurred in the presence of hypocalcemia."|f||||t||||||||||2018-05-31 22:58:00.683389|2018-05-31 22:58:00.683389
NCT01277497|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2016-01-13|2011-01-13|2011-01-17|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4|A Randomized Study on the Effects of Sevelamer Carbonate Versus Calcium Acetate on Biomarkers of Vascular Calcification, Inflammation, and Endothelial Dysfunction in Chronic Kidney Disease Stages 3 and 4|Terminated||Phase 4|30|Actual|Albany College of Pharmacy and Health Sciences||2||low enrollment|f||||f||||||||||2018-05-31 22:58:02.166117|2018-05-31 22:58:02.166117
NCT01277484|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2015-11-18|2011-01-14|2011-01-17|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|September 2014|Actual|2014-09-30||Interventional|PODAC||Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML|Single Arm, Open Label, Phase I Study for Dose and Schedule Finding of Decitabine in Patients With Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation|Unknown status|Active, not recruiting|Phase 1|19|Actual|Seoul St. Mary's Hospital||1|||f||||f||||||||||2018-05-31 22:58:02.234278|2018-05-31 22:58:02.234278
NCT01277471|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-04-04|2011-01-14|2011-01-17|Estimate|||||||2012-04-04|2012-04-06|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Frequency||Effect of Meal Frequency on Insulin Resistance in Subjects With Type 2 Diabetes|Effect of Meal Frequency on Insulin Resistance, Insulin Secretion, and Hepatic Fat Content in Subjects With Type 2 Diabetes|Completed||N/A|54|Actual|Institute for Clinical and Experimental Medicine||2|||f||||t||||||||||2018-05-31 22:58:02.302755|2018-05-31 22:58:02.302755
NCT01277458|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2011-01-14|2011-01-14|2011-01-17|Estimate|||||||2011-01-14|2011-01-17|Estimate|June 2011||2011-06-30|December 2010|2010-12-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Ethnicity Data in HIV Positive Men Who Have Sex With Men|Accuracy of Ethnicity Recording in MSM Patients With HIV of Non-White Ethnicity in London|Unknown status|Not yet recruiting||400|Anticipated|Public Health England|||1||f||||f||||||||||2018-05-31 22:58:02.369852|2018-05-31 22:58:02.369852
NCT01277445|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2015-03-09|2011-01-14|2011-01-17|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Fructan Prebiotics on the Intestinal Microbiota|Evaluation of the Effects of Fructan Prebiotics on the Intestinal Microbiota in Humans: Human Clinical Feeding Trial.|Completed||N/A|28|Actual|Guelph Food Research Centre||2|||f||||f||||||||||2018-05-31 22:58:02.425186|2018-05-31 22:58:02.425186
NCT01277432|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2015-08-20|2011-01-14|2011-01-17|Estimate|||||||2015-08-20|2015-08-24|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|DD2||Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)|A Multicentre Study to Investigate the Prevalence and Factors Associated With Depression in Chinese Patients With Type 2 Diabetes|Completed|||3218|Actual|Chinese University of Hong Kong|||2||f||||t||||||||||2018-05-31 22:58:02.582812|2018-05-31 22:58:02.582812
NCT01277419|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-14|||2017-03-11|2011-01-14|2011-01-17|Estimate|||||||2017-03-11|2017-03-14|Actual|July 2000||2000-07-31|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|GESPIC||German Spondyloarthritis Inception Cohort|German Spondyloarthritis Inception Cohort|Recruiting|||1000|Anticipated|Charite University, Berlin, Germany|||4||f||||||||||||||2018-05-31 22:58:02.689576|2018-05-31 22:58:02.689576
NCT01277406|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-03-31|2011-01-13|2011-01-14|Estimate|||||||2015-03-31|2015-04-01|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2013|Actual|2013-02-28||Interventional|SHORE||4SC-201 (Resminostat) in Advanced Colorectal Carcinoma|A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Resminostat (4SC-201) in Combination With a Second-line Treatment in Patients With K-ras Mutated Advanced Colorectal Carcinoma|Completed||Phase 1/Phase 2|17|Actual|4SC AG||2|||f||||t||||||||||2018-05-31 22:58:02.769383|2018-05-31 22:58:02.769383
NCT01277393|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-01-12|2011-01-12|2011-01-14|Estimate|||||||2011-01-12|2011-01-14|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|March 2011|Anticipated|2011-03-31|||||Observational|||Care of Critically Ill Patients Enteral Nutrition Guidelines for the Implementation of the Effectiveness of the Intervention|Care of Critically Ill Patients Enteral Nutrition Guidelines for the Implementation of the Effectiveness of the Intervention|Unknown status|Active, not recruiting||100|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 22:58:02.862726|2018-05-31 22:58:02.862726
NCT01277380|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-01-13|2011-01-13|2011-01-14|Estimate|||||||2011-01-13|2011-01-14|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|August 2011|Anticipated|2011-08-31|||||Observational|||Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR|Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR|Unknown status|Enrolling by invitation||100|Anticipated|Taipei Medical University WanFang Hospital|||3||f||||f||||||||||2018-05-31 22:58:02.956763|2018-05-31 22:58:02.956763
NCT01277367|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2016-08-17|2011-01-12|2011-01-14|Estimate|||||||2016-08-17|2016-08-19|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Vitality Health Incentives for Physical Activity|A Prospective, Randomized Clinical Trial Comparing the Effectiveness of Different Types of Incentives in Increasing Physical Activity Behavior on the Vitality Health Promotion Programme|Withdrawn||Phase 3|0|Actual|University of Pennsylvania||6|||f||||f||||||||||2018-05-31 22:58:03.066439|2018-05-31 22:58:03.066439
NCT01277354|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2015-09-28||2017-03-20|2011-01-12|2011-01-14|Estimate|2016-06-24|2016-08-08|Estimate||||2017-03-20|2017-04-17|Actual|April 2010||2010-04-30|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effectiveness of Cognitive Processing Therapy in Pregnant Women With a History of Pregnancy Loss/Complication|Effectiveness of Cognitive Processing Therapy in Reducing Post-traumatic Symptoms and Enhancing Birth Outcomes in Pregnant Women With a Previous Pregnancy Loss or Complication|Terminated||N/A|2|Actual|University of Pennsylvania|The limitations of this trial include an insufficient number of subjects enrolled which prohibits our ability to analyze the data in any meaningful fashion.|2||Loss of funding|f||||f||||||||No||2018-05-31 22:58:03.153463|2018-05-31 22:58:03.153463
NCT01277341|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07||2013-01-03|2013-12-04|2011-01-13|2011-01-14|Estimate||||2013-01-03|2013-01-08|Estimate|2013-12-04|2013-12-30|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy of Bepotastine in the Treatment of Seasonal Allergic Rhinitis||Completed||Phase 2|600|Actual|Bausch & Lomb Incorporated||4|||f||||t||||||||||2018-05-31 22:58:03.402435|2018-05-31 22:58:03.402435
NCT01277328|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-09-14|2011-01-13|2011-01-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis|Tocilizumab (RoActemra) poST Marketing Observational Study in DMARD-IR Patients to Assess Efficacy and Safety in routiNE Clinical Practice - STONE|Terminated|||95|Actual|Hoffmann-La Roche|||1|Contract terminated with Site Management Organization|f||||||||||||||2018-05-31 22:58:03.466425|2018-05-31 22:58:03.466425
NCT01277315|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-02-25|2011-01-13|2011-01-14|Estimate|||||||2011-02-25|2011-02-28|Estimate|February 2011||2011-02-28|January 2011|2011-01-31||||June 2012|Anticipated|2012-06-30||Interventional|||Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis|Open Safety and Tolerability Trial to Evaluate a Subcutaneous Injection Solution of 100 mg of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis|Unknown status|Recruiting|Phase 2|20|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 22:58:03.522022|2018-05-31 22:58:03.522022
NCT01277302|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2013-10-17||2014-03-27|2011-01-13|2011-01-14|Estimate|2014-03-27|2014-04-23|Estimate||||2014-03-27|2014-04-23|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Intent-to-treat population: All enrolled participants who received at least 1 ranibizumab injection in the study.|A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion|A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion|Completed||Phase 4|202|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 22:58:03.635603|2018-05-31 22:58:03.635603
NCT01277289|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-09-18|2011-01-13|2011-01-14|Estimate|||||||2012-09-18|2012-09-19|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|Crodex||Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease|Multicenter, Randomized, Double-blind, Parallel-group Study of Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease|Terminated||Phase 3|51|Actual|Erydel||2||due to the big difficulty to enrol suitable patients|f||||f||||||||||2018-05-31 22:58:04.396549|2018-05-31 22:58:04.396549
NCT01277276|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-02-08|2011-01-13|2011-01-14|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2008||2008-11-30|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Study of Chemotherapy Side Effects in Cancer Patients: Non-invasive Optical Measurements of the Brain|Study of Chemotherapy Side Effects in Cancer Patients: Non-invasive Optical Measurements of the Brain|Withdrawn|||0|Actual|University of California, Irvine|||1|no participant enrolled|f||||f||||||||||2018-05-31 22:58:04.481137|2018-05-31 22:58:04.481137
NCT01277263|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-08-29|2011-01-13|2011-01-14|Estimate|||||||2017-08-29|2017-08-31|Actual|December 2010||2010-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging|Predicting Pathological Response Within the 1st Week of Neoadjuvant Chemotherapy Using Functional Parameters Measured With Diffuse Optical Spectroscopic Imaging|Withdrawn|||0|Actual|University of California, Irvine||||Not a Clinical Trial study|f||||t||||||Samples Without DNA|"~     C-Protein serum~   "|||2018-05-31 22:58:04.599109|2018-05-31 22:58:04.599109
NCT01277250|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2015-06-17|2011-01-13|2011-01-14|Estimate|||||||2015-06-17|2015-06-19|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient|Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient|Completed||Phase 4|1548|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 22:58:04.716965|2018-05-31 22:58:04.716965
NCT01277237|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2014-01-22|2011-01-13|2011-01-14|Estimate|||||||2014-01-22|2014-01-23|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease|The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease|Completed||Phase 3|50|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 22:58:04.814378|2018-05-31 22:58:04.814378
NCT01277224|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2013-05-24|2011-01-13|2011-01-14|Estimate|||||||2013-05-24|2013-05-27|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Movi2||Effectiveness of a Physical Activity Intervention on the Obesity of Schoolchildren|Effectiveness of a Leisure Time Physical Activity Intervention on the Overweight and the Obesity in Schoolchildren. The Cuenca's Study|Completed||N/A|1200|Actual|University of Castilla-La Mancha||2|||f||||t||||||||||2018-05-31 22:58:04.894632|2018-05-31 22:58:04.894632
NCT01277211|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2014-09-08||2017-06-01|2011-01-12|2011-01-14|Estimate|2014-09-08|2014-09-15|Estimate||||2017-06-01|2017-07-02|Actual|September 19, 2011|Actual|2011-09-19|June 2017|2017-06-30|September 18, 2013|Actual|2013-09-18|September 18, 2013|Actual|2013-09-18||Interventional||All Subjects Treated (AST) group, which consisted of all randomized participants who used at least one ring/pill.|A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)|A Randomized, Open-Label, Controlled, Multi-Center Trial to Evaluate the Contraceptive Efficacy, Cycle Control, Safety and Acceptability of NuvaRing® (SCH 900702) in Chinese Women|Completed||Phase 3|983|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 22:58:04.984138|2018-05-31 22:58:04.984138
NCT01277198|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-01-13|2011-01-13|2011-01-14|Estimate|||||||2011-01-13|2011-01-14|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Role of Flexible Cystoscopy in Laparoscopic Stone Surgery|The Role of Flexible Cystoscopy in Laparoscopic Stone Surgery: a Single Surgeon Experience|Completed|||80|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 22:58:05.430507|2018-05-31 22:58:05.430507
NCT01277185|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-05-03|2011-01-13|2011-01-14|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2010||2010-04-30|May 2018|2018-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Calcium Metabolism in Mexican American Adolescents|Calcium Metabolism in Mexican American Adolescents|Completed||N/A|45|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 22:58:05.487769|2018-05-31 22:58:05.487769
NCT01277172|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-08|||2011-01-12|2011-01-12|2011-01-14|Estimate|||||||2011-01-12|2011-01-14|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|TREND||TREatment of degeNerative and Neoplastic Diseases With Rituximab|Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients|Unknown status|Recruiting|Phase 2/Phase 3|54|Anticipated|Probiomed S.A. de C.V.||4|||f||||t||||||||||2018-05-31 22:58:05.609454|2018-05-31 22:58:05.609454
NCT01277159|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2017-03-27||2018-02-15|2011-01-13|2011-01-14|Estimate|2017-08-01|2017-08-31|Actual||||2018-02-15|2018-02-19|Actual|October 2010||2010-10-31|February 2018|2018-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine|Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine|Completed||N/A|108|Actual|Hospital for Special Surgery, New York||5|||f||||f||||||||No||2018-05-31 22:58:05.690975|2018-05-31 22:58:05.690975
NCT01277146|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2016-09-16|2011-01-12|2011-01-14|Estimate|||||||2016-09-16|2016-09-20|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors|Completed||Phase 1|42|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 22:58:05.925007|2018-05-31 22:58:05.925007
NCT01277133|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-11-01|2011-01-13|2011-01-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)|The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With Metastatic Breast Cancer Treated With First Line Regimens Based On AvaStin|Terminated|||83|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:58:05.985469|2018-05-31 22:58:05.985469
NCT01277120|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-09-14|2011-01-13|2011-01-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Colorectal Cancer (CRONOS 1)|The Correlation Between the Moment of Bevacizumab theRapy initiatiOn and the Efficacy in patieNt With cOlorectal Cancer Treated With AvaStin Based First Line Regimens (CRONOS 1)|Terminated|||174|Actual|Hoffmann-La Roche|||1|Contract terminated with Site Management Organization|f||||||||||||||2018-05-31 22:58:06.037753|2018-05-31 22:58:06.037753
NCT01277107|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2014-12-18|2011-01-13|2011-01-14|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia|Double Blind, Polysomnographic, Two-Way Crossover Study To Compere The Efficacy Of Gastric Retentive Zaleplon (Zaleplon AP) To Placebo In Subjects With Insomnia Characterized By Both Difficulty In Falling Asleep And Staying Asleep|Completed||Phase 2|83|Actual|Intec Pharma Ltd.||2|||f||||t||||||||||2018-05-31 22:58:06.192873|2018-05-31 22:58:06.192873
NCT01277094|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-11-01|2011-01-13|2011-01-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease|Multi-center, Double-blind, Randomized, Placebo-controlled Study of Selective 11 Beta-HSD1 Inhibition With RO5093151 for 12 Weeks to Investigate Efficacy, Safety and Pharmacokinetics of RO5093151 in Non-alcoholic Fatty Liver Disease and Its Metabolic Consequences.|Completed||Phase 1|82|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 22:58:06.267232|2018-05-31 22:58:06.267232
NCT01277081|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2013-06-27||2015-02-02|2011-01-13|2011-01-14|Estimate|2015-02-02|2015-02-18|Estimate||||2015-02-02|2015-02-18|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Paracetamol on the Common Cold|To Assess the Subjective Effect of Two Paracetamol Preparations on the Feeling of Breathing in Subjects With the Common Cold.|Completed||Phase 2|200|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 22:58:06.381026|2018-05-31 22:58:06.381026
NCT01277068|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2015-08-21|2011-01-13|2011-01-14|Estimate|||||||2015-08-21|2015-08-24|Estimate|September 2010||2010-09-30|August 2015|2015-08-31||||September 2014|Actual|2014-09-30||Interventional|||Effects of Various Bariatric Surgical Procedures on Intestinal Triglyceride-rich-lipoprotein (TRL) Metabolism in Obese Patients|Effects of Various Bariatric Surgical Procedures on Intestinal Triglyceride-rich-lipoprotein (TRL) Metabolism in Obese Patients|Completed||N/A|36|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 22:58:06.710935|2018-05-31 22:58:06.710935
NCT01277055|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-01-13|2011-01-13|2011-01-14|Estimate|||||||2011-01-13|2011-01-14|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||||||Observational|Vision MRT||MRI Perfusion Imaging at 3Tx Compared to Invasive FFR Measurements|MRI Perfusion Imaging at 3T With TX Parallel RF Technology to Identify Myocardial Ischemia Compared to Invasive FFR Measurements|Unknown status|Recruiting||150|Anticipated|Heart Center Bogenhausen|||||f||||f||||||||||2018-05-31 22:58:06.777114|2018-05-31 22:58:06.777114
NCT01277042|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|2012-09-06||2016-08-29|2011-01-13|2011-01-14|Estimate|2013-10-04|2013-12-03|Estimate||||2016-08-29|2016-10-07|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)|Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects|Completed||Phase 3|1212|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 22:58:06.865362|2018-05-31 22:58:06.865362
NCT01277029|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2016-09-04|2011-01-13|2011-01-14|Estimate|||||||2016-09-04|2016-09-07|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Study of Psychiatric Aspects in Women With Lower Urinary Tract Symptoms||Recruiting|||500|Anticipated|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 22:58:07.405238|2018-05-31 22:58:07.405238
NCT01277016|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2017-03-09|2011-01-13|2011-01-14|Estimate|||||||2017-03-09|2017-03-10|Actual|January 2011||2011-01-31|August 2016|2016-08-31|July 31, 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|EMN-03||A Trial for Systemic Light-chain (AL) Amyloidosis|A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis|Completed||Phase 3|110|Actual|European Myeloma Network||2|||f||||t||||||||||2018-05-31 22:58:07.472351|2018-05-31 22:58:07.472351
NCT01277003|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-01-18|2011-01-13|2011-01-14|Estimate|||||||2011-01-18|2011-01-19|Estimate|December 2010||2010-12-31|November 2010|2010-11-30||||February 2011|Anticipated|2011-02-28||Interventional|||To Investigate the Therapeutic Effect of Aculife Magnetic Therapist on Carpal Tunnel Syndrome|To Investigate the Therapeutic Effect of Aculife Magnetic Therapist on Carpal Tunnel Syndrome|Unknown status|Recruiting|N/A|30|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 22:58:07.558211|2018-05-31 22:58:07.558211
NCT01276990|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2012-02-08|2011-01-13|2011-01-14|Estimate|||||||2012-02-08|2012-02-09|Estimate|January 2011||2011-01-31|February 2012|2012-02-29||||September 2012|Anticipated|2012-09-30||Interventional|||Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.|Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 ZW (Powder in Bottle Formulation) at 12.5 mg q24h, 12.5 mg q12h, 12.5 mg q8h, 25 mg q12h, 25 mg q8h, 50 mg q12h, 37.5 mg q8h and 50 mg q8h Dose Levels for 10 Days in Healthy Male Volunteers (Randomized, Double-blind Placebo-controlled Within Dose Groups)|Withdrawn||Phase 1|0|Actual|Boehringer Ingelheim||9|||f||||||||||||||2018-05-31 22:58:07.658968|2018-05-31 22:58:07.658968
NCT01276977|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-13|2011-01-13|2011-01-14|Estimate|||||||2011-01-13|2011-01-14|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine|Zolmitriptan Nasal Spray VS Eletriptan in the Acute Treatment of Migraine|Completed||N/A|80|Actual|California Medical Clinic for Headache||2|||f||||f||||||||||2018-05-31 22:58:07.801723|2018-05-31 22:58:07.801723
NCT01276964|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-07-13|2011-01-13|2011-01-14|Estimate|||||||2012-07-13|2012-07-16|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|MEVA-1||Protocol for the Determination of Menstrual Losses in Healthy Women With Apparently Normal Cycles|Protocol for the Determination of Menstrual Losses Using a System for the Quantitative Determination of Menses (Quantitative Evaluation of Menses [QUEM] Method) and Its Application to Healthy Women With Apparently Normal Cycles|Unknown status|Recruiting||150|Anticipated|University of L'Aquila|||1||f||||t||||||Samples With DNA|"~     Soiled oads and tampons, vacuum sealed are retained till their evaluation, they will be~     appropiately discharged after their analysis~   "|||2018-05-31 22:58:07.891338|2018-05-31 22:58:07.891338
NCT01276951|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-01-23|2011-01-13|2011-01-14|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2008||2008-12-31|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Controlled Clinical Trial to Determine the Effective Dose of Cocoa in Lowering Blood Pressure|Controlled Clinical Trial of the Effect of Cocoa Consumption in Lowering Blood Pressure and in the Modulation of Endothelial Inflammation in Hypertensive Patients Assigned to an Entity Health Promoting.|Completed||N/A|125|Actual|Universidad de Antioquia||5|||f||||f|f|f||||||No||2018-05-31 22:58:07.958999|2018-05-31 22:58:07.958999
NCT01276938|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2017-05-23|2011-01-13|2011-01-14|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2009||2009-04-30|September 2010|2010-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Exclusive Intraoperative Radiation Therapy for Breast Cancer|Tolerance Evaluation of Exclusive Intraoperative Radiation Therapy at Different Doses for Breast Cancer Conservative Treatment|Completed||Phase 2/Phase 3|40|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||t||||||||||2018-05-31 22:58:08.065119|2018-05-31 22:58:08.065119
NCT01276925|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2015-10-21|2011-01-13|2011-01-14|Estimate|||||||2015-10-21|2015-10-23|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|THAMBUS||Total Hip Arthroplasty: Multiple Blocks by UltraSound|The Effect of Ultrasound Guided Blockade of the Femoral Nerve, the Anterior Division of the Obturator Nerve, and the Lateral Femoral Cutaneous Nerve on Postoperative Pain, Morphine Consumption, and Mobilization After Total Hip Arthroplasty.|Unknown status|Recruiting|N/A|81|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 22:58:08.157629|2018-05-31 22:58:08.157629
NCT01276912|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-13|||2011-01-13|2011-01-13|2011-01-14|Estimate|||||||2011-01-13|2011-01-14|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|STOP-GO||Study TO Prevent Diabetes With Short-term Insulin Glargine Only|A Multicenter, Randomized, Controlled Trial to Prevent Diabetes With Short-term Insulin Glargine Treatment or Lifestyle Intervention|Unknown status|Recruiting|N/A|2420|Anticipated|Beijing Tongren Hospital|||||f||||t||||||||||2018-05-31 22:58:08.273635|2018-05-31 22:58:08.273635
NCT01276899|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2012-11-28|2011-01-12|2011-01-13|Estimate|||||||2012-11-28|2012-11-29|Estimate|September 2010||2010-09-30|November 2012|2012-11-30||||||||Observational|||Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients|Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients|Unknown status|Recruiting||80|Anticipated|Jewish General Hospital|||2||f||||f||||||Samples With DNA|"~     Tumor samples from the primary breast tumor or metastatic lesions will be obtained by needle~     core biopsy. In the neoadjuvant setting, samples will be also collected at the time of~     surgery. To obtain sufficient material for tissue banking, four needle core biopsies will be~     removed from the same neoplastic lesion. Two of the biospecimens will be snap frozen for~     phosphoprotein preservation, one will be placed in RNAlater for nucleic acid preservation and~     the other one will be placed in formalin for FFPE. Additionally, blood samples will be~     collected at different time points during treatment.~   "|||2018-05-31 22:58:08.333297|2018-05-31 22:58:08.333297
NCT01276886|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-01-21|2011-01-12|2011-01-13|Estimate|||||||2011-01-21|2011-01-24|Estimate|January 1996||1996-01-31|December 2010|2010-12-31|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Observational|GISDIC||Italian Study Group on Complicated Diverticulosis|Italian Study Group on Complicated Diverticulosis: The Natural History of Left-sided Acute Diverticulitis|Completed|||||Gruppo Italiano per lo Studio della Diverticolite Complicata|||1||f||||t||||||||||2018-05-31 22:58:08.436182|2018-05-31 22:58:08.436182
NCT01276873|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-12|2011-01-12|2011-01-13|Estimate|||||||2011-01-12|2011-01-13|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Clinical Variations and Pain Assessment in Newborns Submitted to Intratracheal Aspiration With Open and Closed System|Clinical Variations and Pain Assessment in Newborns Submitted to Intratracheal Aspiration With Open and Closed System.|Completed||N/A|13|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 22:58:08.491255|2018-05-31 22:58:08.491255
NCT01276860|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-01-31|2011-01-12|2011-01-13|Estimate|||||||2018-01-31|2018-02-01|Actual|May 2010||2010-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PVT||The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea|The Use of Psychomotor Vigilance Testing in the Assessment of Pediatric Obstructive Sleep Apnea|Active, not recruiting||N/A|110|Anticipated|University of Arkansas|||||f||||t||||||||||2018-05-31 22:58:08.552334|2018-05-31 22:58:08.552334
NCT01276847|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2012-11-19||2015-01-13|2011-01-12|2011-01-13|Estimate|2013-01-24|2013-02-28|Estimate||||2015-01-13|2015-01-26|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)|A Clinical Trial to Assess the Effects of Ustekinumab and Etanercept on Skin and Blood Biomarkers of Psoriasis in Patients With Moderate to Severe Disease|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 22:58:08.651785|2018-05-31 22:58:08.651785
NCT01276834|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-08-04|2011-01-12|2011-01-13|Estimate|||||||2017-08-04|2017-08-07|Actual|September 2010||2010-09-30|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|NOCTX-2||Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation|Randomised Comparison of Two Different Immunosuppressive Regimens on Progression of Arteriosclerosis in Renal Transplant Patients.|Terminated||Phase 4|13|Actual|Dianet Dialysis Centers||2||insufficient patients enrolled|f||||f||||||||||2018-05-31 22:58:08.980669|2018-05-31 22:58:08.980669
NCT01276821|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2012-09-11||2013-04-23|2011-01-12|2011-01-13|Estimate|2013-04-23|2013-05-31|Estimate||||2013-04-23|2013-05-31|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Bronchiolitis.|Efficacy of Nebulised Hypertonic Saline (3%) Among Children With Mild to Moderately Severe Bronchiolitis - A Double Blind Randomized Controlled Trial.|Completed||Phase 4|100|Actual|Tribhuvan University Teaching Hospital, Institute Of Medicine.||2|||f||||t||||||||||2018-05-31 22:58:09.069242|2018-05-31 22:58:09.069242
NCT01276808|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2014-08-19|2011-01-12|2011-01-13|Estimate|||||||2014-08-19|2014-08-20|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|MAGNA||Magnetic Navigation for Contrast and Radiation Reduction|Reduction in Contrast Volume and Radiation With Magnetic Navigation: a Prospective Randomised Trial|Unknown status|Recruiting|N/A|300|Anticipated|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||||2018-05-31 22:58:09.640988|2018-05-31 22:58:09.640988
NCT01276795|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-01-12|2011-01-12|2011-01-13|Estimate|||||||2011-01-12|2011-01-13|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients|Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients|Completed||N/A|13|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 22:58:09.745248|2018-05-31 22:58:09.745248
NCT01276782|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2015-09-09|2011-01-12|2011-01-13|Estimate|||||||2015-09-09|2015-09-10|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Levothyroxine in Pregnant SLE Patients|Pilot Double-Blind Placebo Controlled Trial of Levothyroxine in Pregnant Systemic Lupus Erythematosus (SLE) Patients With Autoimmune Thyroid Disease|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||1||Withdraw the study because further analysis showed that it would be futile.|f||||t||||||||||2018-05-31 22:58:09.819707|2018-05-31 22:58:09.819707
NCT01276769|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2011-11-15|2011-01-12|2011-01-13|Estimate|||||||2011-11-15|2011-11-16|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer|Phase IIb Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Epirubicin as Neoadjuvant Treatment in Locally Advanced Triple-negative Breast Cancer|Unknown status|Recruiting|Phase 2|80|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:58:09.900023|2018-05-31 22:58:09.900023
NCT01276756|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2013-01-30||2013-03-19|2011-01-12|2011-01-13|Estimate|2013-03-19|2013-05-03|Estimate||||2013-03-19|2013-05-03|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)|Randomized Study for the Assessment of Nitazoxanide in the Treatment of Chronic Hepatitis C Genotype 4|Completed||Phase 2/Phase 3|100|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 22:58:10.007233|2018-05-31 22:58:10.007233
NCT01276743|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2014-02-27|2011-01-12|2011-01-13|Estimate|||||||2014-02-27|2014-02-28|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|February 2013|Actual|2013-02-28|July 2011|Actual|2011-07-31||Observational|||Study of PTPN22 C1858T Polymorphism in Children and Adolescents of Greek Origin With T1DM|Study of Protein Tyrosine Phosphatase Non-receptor Type 22 (PTPN22) C1858T Polymorphism in Children and Adolescents of Greek Origin With Type 1 Diabetes Mellitus (T1DM)|Completed|||200|Actual|Aristotle University Of Thessaloniki|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 22:58:10.339399|2018-05-31 22:58:10.339399
NCT01276730|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2017-12-27|2011-01-12|2011-01-13|Estimate|||||||2017-12-27|2017-12-29|Actual|October 2007||2007-10-31|December 2017|2017-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Advanced Cervical Cancer Trial in India|A Pilot Phase II Two-Arm, Randomized Clinical Trial of Concomitant Immunotherapy (With Interferon-Alpha and Retinoic Acid) and Radiation Therapy for the Treatment of Advanced Cervical Cancer in India|Completed||Phase 2|209|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 22:58:10.404272|2018-05-31 22:58:10.404272
NCT01276717|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2015-12-02|2011-01-12|2011-01-13|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|July 2013|Actual|2013-07-31||Interventional|||Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma|Phase I Trial of Carfilzomib (PR-171) in Combination With Vorinostat (SAHA) in Patients With Relapsed/Refractory B-Cell Lymphomas|Completed||Phase 1|20|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 22:58:10.50127|2018-05-31 22:58:10.50127
NCT01276704|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2018-01-15|2011-01-12|2011-01-13|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2011|Actual|2011-01-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer|Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer|Completed||Phase 2|179|Actual|University of Kansas Medical Center||2|||f||||t||||||||No|Global results will be published.|2018-05-31 22:58:10.577719|2018-05-31 22:58:10.577719
NCT01276691|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2014-05-19|2011-01-12|2011-01-13|Estimate|||||||2014-05-19|2014-05-21|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting|Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting|Completed||Phase 4|24|Actual|University of Illinois at Urbana-Champaign||4|||f||||f||||||||||2018-05-31 22:58:10.679933|2018-05-31 22:58:10.679933
NCT01276678|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-11-05|2011-01-12|2011-01-13|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|MAGMA||Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis|Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis (The MAGMA STUDY)|Unknown status|Recruiting||1300|Anticipated|LifeBridge Health|||2||f||||f||||||Samples With DNA|"~     Biomarker Analysis by Multi-Analyte Profiling Genetic Testing-GWAS and CYP2C19 genotyping~     Comprehensive Lipoprotein Cholesterol Profile Platelet aggregation and~     Thrombelastography-Clot characteristics and antiplatelet response Urinary~     11-dehydrothromboxane~   "|||2018-05-31 22:58:10.757403|2018-05-31 22:58:10.757403
NCT01276665|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2012-12-17|2011-01-12|2011-01-13|Estimate|||||||2012-12-17|2012-12-18|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Perioperative Outcome in Patients Undergoing Radical Cystectomy|Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Blood Loss and Perioperative Outcome in Patients Undergoing Open Radical Cystectomy|Completed||N/A|190|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 22:58:10.824044|2018-05-31 22:58:10.824044
NCT01276652|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2016-12-29||2017-07-25|2011-01-12|2011-01-13|Estimate|2017-07-25|2017-09-26|Actual||||2017-07-25|2017-09-26|Actual|November 2001||2001-11-30|July 2017|2017-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Sleep and Circadian Rhythms in Mechanically Ventilated Patients|Sleep and Circadian Rhythms in Mechanically Ventilated Patients: a Feasibility and Mechanistic Study.|Completed||N/A|25|Actual|University of Iowa|Logistical issues related to the performance of continuous bedside polysomnography may vary from institution to institution, thereby limiting the generalizability of our results where the primary outcome measure is concerned.|3|||f||||t||||||||No|As this is a pilot study, there are no plans to share IPD.|2018-05-31 22:58:10.895006|2018-05-31 22:58:10.895006
NCT01276639|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2014-07-24|2014-02-03|2014-09-18|2011-01-12|2011-01-13|Estimate|2014-09-18|2014-09-19|Estimate|2014-02-03|2014-03-06|Estimate|2014-09-18|2014-09-19|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Safety analysis set included all participants who received at least 1 dose of investigational drug (CP-690,550 or placebo).|A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis|Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis|Completed||Phase 3|901|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 22:58:11.417702|2018-05-31 22:58:11.417702
NCT01276626|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2014-08-04|2011-01-12|2011-01-13|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome|Pilot Study of Probiotic Bifidobacterium Longum (B. Longum) on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome (IBS).|Completed||Phase 1/Phase 2|40|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 22:58:17.254863|2018-05-31 22:58:17.254863
NCT01276613|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-07-06|2011-01-12|2011-01-13|Estimate|||||||2017-07-06|2017-07-11|Actual|January 2011|Actual|2011-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas|Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas|Active, not recruiting||N/A|18|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 22:58:17.458155|2018-05-31 22:58:17.458155
NCT01276600|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-11-29|2011-01-12|2011-01-13|Estimate|||||||2011-11-29|2011-11-30|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|HPTN066||Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers|Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers|Completed||Phase 1|32|Actual|HIV Prevention Trials Network||4|||f||||t||||||||||2018-05-31 22:58:17.634073|2018-05-31 22:58:17.634073
NCT01276587|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12||2015-02-04|2018-03-21|2011-01-12|2011-01-13|Estimate||||2015-04-15|2015-05-06|Estimate|2018-03-21|2018-03-23|Actual|January 2011||2011-01-31|March 2018|2018-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of Vitamin D in Children With Sickle Cell Disease|Pilot Study of Vitamin D Therapy to Prevent Respiratory Complications in Children With Sickle Cell Disease|Completed||Phase 1/Phase 2|4|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 22:58:17.738444|2018-05-31 22:58:17.738444
NCT01276574|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2018-05-04|2011-01-12|2011-01-13|Estimate|||||||2018-05-04|2018-05-07|Actual|October 2009||2009-10-31|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|Mupet||Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT|Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Positron Emission Tomography/Computed Tomography)|Active, not recruiting|||150|Anticipated|Turku University Hospital|||||f||||f||||||Samples With DNA|"~     tumour samples, whole blood and serum samples~   "|||2018-05-31 22:58:17.80637|2018-05-31 22:58:17.80637
NCT01276561|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-02-01|2011-01-12|2011-01-13|Estimate|||||||2017-02-01|2017-02-03|Estimate|October 2009||2009-10-31|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|October 2016|Actual|2016-10-31||Interventional|||Single Incision Versus Standard Laparoscopic Splenectomy|Single Incision Versus Standard Laparoscopic Splenectomy|Withdrawn||N/A|0|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||No||2018-05-31 22:58:17.865405|2018-05-31 22:58:17.865405
NCT01276548|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-05-08|2011-01-12|2011-01-13|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2009||2009-10-31|May 2017|2017-05-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|GPMOC202||A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer||Completed||Phase 2|102|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||t||||||||||2018-05-31 22:58:17.954075|2018-05-31 22:58:17.954075
NCT01276535|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2013-04-12||2015-11-07|2011-01-12|2011-01-13|Estimate|2015-11-07|2015-12-11|Estimate||||2015-11-07|2015-12-11|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of the Use of Low Level Laser Therapy to Reduce Acne|A Pilot Study to Evaluate the Efficacy of Low-level Laser Therapy in Reducing Blemishes by Quantifying a Decrease in Signs of Blemishes, Both Non-inflammatory and Inflammatory|Completed||N/A|12|Actual|Erchonia Corporation||1|||f||||f||||||||||2018-05-31 22:58:18.015478|2018-05-31 22:58:18.015478
NCT01276522|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2012-05-23|2011-01-12|2011-01-13|Estimate|||||||2012-05-23|2012-05-24|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety of Canakinumab in Schnitzler Syndrome|Efficacy and Safety of Canakinumab in Schnitzler Syndrome|Completed||Phase 2|8|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 22:58:18.168899|2018-05-31 22:58:18.168899
NCT01276509|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2016-10-05|2015-02-08|2017-04-13|2011-01-12|2011-01-13|Estimate|2017-03-02|2017-04-13|Actual|2015-02-08|2015-02-25|Estimate|2017-04-13|2017-04-17|Actual|April 6, 2011|Actual|2011-04-06|April 2017|2017-04-30|October 9, 2015|Actual|2015-10-09|February 7, 2014|Actual|2014-02-07||Interventional|OPERA||Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease|A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)|Completed||Phase 2|265|Actual|Shire||4|||f||||t||||||||||2018-05-31 22:58:18.437927|2018-05-31 22:58:18.437927
NCT01276496|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2016-03-14|2011-01-12|2011-01-13|Estimate|||||||2016-03-14|2016-03-15|Estimate|December 2010||2010-12-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Interventional|||Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery|A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies|Completed||Phase 1|13|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:58:19.545405|2018-05-31 22:58:19.545405
NCT01276483|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-06-21|2011-01-12|2011-01-13|Estimate|||||||2017-06-21|2017-06-22|Actual|February 2011||2011-02-28|June 2017|2017-06-30|June 21, 2017|Actual|2017-06-21|June 2017|Actual|2017-06-30||Observational|||Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients|Treatment Response Evaluation in Patients With Gastrointestinal Stromal Tumor Using PET/CT and DW MRI|Completed|||40|Actual|Oslo University Hospital|||||f||||f||||||||||2018-05-31 22:58:19.650747|2018-05-31 22:58:19.650747
NCT01276470|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-02-13|2011-01-12|2011-01-13|Estimate|||||||2018-02-13|2018-02-14|Actual|January 12, 2011||2011-01-12|February 8, 2018|2018-02-08||||||||Observational|||Environmental Risk Factors for the Anti-synthetase Syndrome|Environmental Risk Factors for the Anti-Synthetase Syndrome|Recruiting|||450|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:58:19.701052|2018-05-31 22:58:19.701052
NCT01276457|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2011-01-25||2011-05-17|2011-01-12|2011-01-13|Estimate|2011-03-22|2011-04-19|Estimate||||2011-05-17|2011-05-20|Estimate|May 2006||2006-05-31|May 2011|2011-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|EVEREST||Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients|An 18 Month Extension to the Multicenter, Randomized, Open-label Trial (NCT00170885) to Evaluate the Safety, Tolerability, and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de Novo Renal Transplant Recipients|Completed||Phase 3|223|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:58:19.791762|2018-05-31 22:58:19.791762
NCT01276444|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-12|2011-01-12|2011-01-13|Estimate|||||||2011-01-12|2011-01-13|Estimate|January 2008||2008-01-31|January 2011|2011-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Comparison of Goal-directed Algorithms of Hemodynamic Therapy After Combined Valve Repair|Comparison of Goal-directed Algorithms of Hemodynamic Therapy After Combined Valve Repair: a Randomized Clinical Trial|Completed||N/A|43|Actual|Northern State Medical University||2|||f||||f||||||||||2018-05-31 22:58:20.53246|2018-05-31 22:58:20.53246
NCT01276431|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2014-02-05|2011-01-12|2011-01-13|Estimate|||||||2014-02-05|2014-02-06|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Norspan Efficacy and Safety Among Elderly Subjects||Completed||Phase 4|102|Actual|Mundipharma AB||1|||f||||||||||||||2018-05-31 22:58:20.616517|2018-05-31 22:58:20.616517
NCT01276418|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2016-09-06|2011-01-12|2011-01-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||ENT FiberLase CO2 Study|ENT FiberLase CO2 Study|Completed||N/A|49|Actual|Lumenis Ltd.||1|||f||||||||||||||2018-05-31 22:58:20.675058|2018-05-31 22:58:20.675058
NCT01276405|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2016-11-01|2011-01-12|2011-01-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)|The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)|Terminated|||123|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 22:58:20.796962|2018-05-31 22:58:20.796962
NCT01276392|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2015-08-19|2011-01-12|2011-01-13|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|February 2015|Anticipated|2015-02-28|November 2014|Anticipated|2014-11-30||Observational|||Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy|Platelet Function, Whole Blood Coagulation and Fibrinolysis During Continuous Renal Replacement Therapy - a Comparison of Citrate and Heparin Anticoagulation|Withdrawn|||0|Actual|Heinrich-Heine University, Duesseldorf|||2|A main person involved left the site|f||||f||||||||||2018-05-31 22:58:20.852206|2018-05-31 22:58:20.852206
NCT01276379|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2018-05-09|2011-01-12|2011-01-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2011||2011-01-31|May 2018|2018-05-31|December 21, 2017|Actual|2017-12-21|March 15, 2017|Actual|2017-03-15||Interventional|POSIBA||Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab|Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment|Completed||Phase 2|221|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||t||||||||||2018-05-31 22:58:20.91255|2018-05-31 22:58:20.91255
NCT01276366|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2011-06-21|2011-01-12|2011-01-13|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2010||2010-01-31|December 2009|2009-12-31||||September 2011|Anticipated|2011-09-30||Interventional|APIP||Amphia Premature Infant Pain Study|Amphia Premature Infant Pain Study; Breast Milk vs Sucrose|Unknown status|Active, not recruiting|N/A|75|Anticipated|Amphia Hospital||3|||f||||f||||||||||2018-05-31 22:58:21.03149|2018-05-31 22:58:21.03149
NCT01276353|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2014-02-24||2014-08-05|2011-01-12|2011-01-13|Estimate|2014-07-07|2014-08-01|Estimate||||2014-08-05|2014-08-08|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia|A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia|Completed||Phase 2|45|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 22:58:21.130487|2018-05-31 22:58:21.130487
NCT01276340|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-05-16|2011-01-12|2011-01-13|Estimate|||||||2012-05-16|2012-05-17|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Observational|||Prospective Evaluation of Keat Electrostimulator in the Auto-reeducation of Female Urinary Incontinence|Prospective Evaluation of Keat Electrostimulator in the Auto-reeducation|Completed|||450|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||t||||||||||2018-05-31 22:58:21.405827|2018-05-31 22:58:21.405827
NCT01276327|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2014-03-12||2014-06-03|2011-01-12|2011-01-13|Estimate|2014-03-12|2014-04-17|Estimate||||2014-06-03|2014-06-09|Estimate|January 2011||2011-01-31|March 2014|2014-03-31||||May 2011|Actual|2011-05-31||Interventional||TS - The treated set included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.|Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin 5 mg / Pioglitazone 30 mg Compared With Its Mono-components in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Replicate Design Study With Two Treatments in Four Crossover Periods)|Completed||Phase 1|64|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 22:58:21.488649|2018-05-31 22:58:21.488649
NCT01276314|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-05|2017-11-03||2017-12-17|2011-01-11|2011-01-13|Estimate|2017-12-17|2017-12-19|Actual||||2017-12-17|2017-12-19|Actual|January 2009||2009-01-31|December 2014|2014-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||A total of 135 SCAR patients (including 91 SJS/TEN cases and 44 DRESS cases) were enrolled to analyze.|Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions|Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR)|Completed||N/A|135|Actual|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||||2018-05-31 22:58:21.787392|2018-05-31 22:58:21.787392
NCT01276301|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2014-05-16||2014-05-16|2011-01-12|2011-01-13|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|January 2011||2011-01-31|May 2014|2014-05-31||||February 2011|Actual|2011-02-28||Interventional|||DDI Between BI Empagliflozin (10773) and Verapamil|Relative Bioavailability of BI 10773 Given Alone and Together With Verapamil - an Open-label, Randomised, Crossover Trial in Healthy Subjects|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 22:58:22.119754|2018-05-31 22:58:22.119754
NCT01276288|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|2014-05-16||2014-08-05|2011-01-12|2011-01-13|Estimate|2014-07-10|2014-08-06|Estimate||||2014-08-05|2014-09-03|Estimate|January 2011||2011-01-31|August 2014|2014-08-31||||June 2011|Actual|2011-06-30||Interventional||Treated set (TS) that includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes|Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between 25 mg BI 10773 and 25 mg Hydrochlorothiazide or 5 mg Torasemide Under Steady State Conditions in Patients With Type 2 Diabetes Mellitus in an Open-label, Randomised, Cross-over Trial|Completed||Phase 1|23|Actual|Boehringer Ingelheim|"Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information"|5|||f||||||||||||||2018-05-31 22:58:22.557715|2018-05-31 22:58:22.557715
NCT01276275|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2016-03-30|2011-01-12|2011-01-13|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel|A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in National Swedish Registries|Completed|||7200|Actual|AstraZeneca|||3||f||||f||||||||||2018-05-31 22:58:23.689972|2018-05-31 22:58:23.689972
NCT01276262|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2012-02-17|2011-01-12|2011-01-13|Estimate|||||||2012-02-17|2012-02-20|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects|A Single-blind, Placebo-controlled, 2-period, Fixed Sequence Study to Determine the Effects of Coadministration of Fostamatinib 100 mg Twice Daily on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects|Completed||Phase 1|22|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 22:58:23.765493|2018-05-31 22:58:23.765493
NCT01276249|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2015-07-14|2011-01-11|2011-01-13|Estimate|||||||2015-07-14|2015-07-15|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|March 2018|Anticipated|2018-03-31|April 2015|Actual|2015-04-30||Observational|||The STAPLE International Post-Market Registry|The STAPLE-International Post-Market Registry|Unknown status|Active, not recruiting||100|Anticipated|Aptus Endosystems|||1||f||||f||||||||||2018-05-31 22:58:23.870847|2018-05-31 22:58:23.870847
NCT01276236|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2014-07-23|2011-01-11|2011-01-13|Estimate|||||||2014-07-23|2014-07-24|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|April 2015|Anticipated|2015-04-30|January 2015|Anticipated|2015-01-31||Interventional|||Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)|Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)|Unknown status|Enrolling by invitation|N/A|10|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 22:58:23.971436|2018-05-31 22:58:23.971436
NCT01276223|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2013-01-31||2013-03-08|2011-01-12|2011-01-13|Estimate|2013-03-08|2013-03-11|Estimate||||2013-03-08|2013-03-11|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients|A Multi-Center, Randomized, Double-Masked Evaluation of Anti-Inflammatory Treatment in Patients With Dry Eye|Completed||Phase 2|722|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 22:58:24.070758|2018-05-31 22:58:24.070758
NCT01276210|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-07-14|2011-01-11|2011-01-13|Estimate|||||||2017-07-14|2017-07-17|Actual|February 2011||2011-02-28|July 2017|2017-07-31|June 2017|Actual|2017-06-30|July 2015|Actual|2015-07-31||Interventional|||Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases|A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases|Completed||Phase 1|23|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 22:58:24.367043|2018-05-31 22:58:24.367043
NCT01276197|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2016-06-16||2016-10-21|2011-01-12|2011-01-13|Estimate|2016-08-05|2016-09-30|Estimate||||2016-10-21|2016-12-02|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional|||Using Stories to Address Disparities in Hypertension|Using Stories to Address Disparities in Hypertension|Completed||N/A|618|Actual|VA Office of Research and Development|Our multi-site trial was limited by challenges in recruitment (lower enrollment at one site) that resulted in overall recruitment lower than planned. Further, we did have some loss to follow-up.|2|||f||||t||||||||Yes|We plan to report on our primary outcome|2018-05-31 22:58:24.443428|2018-05-31 22:58:24.443428
NCT01276184|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-12|2011-01-12|2011-01-13|Estimate|||||||2011-01-12|2011-01-13|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|January 2013|Anticipated|2013-01-31|July 2012|Anticipated|2012-07-31||Interventional|||Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil|A Randomized, Controlled Trial to Compare the Effectiveness of SMS Text Message Reminders Compared to Usual Care to Increase Adherence to the Gardasil Vaccine Dosing Schedule (GCC 1063GCC).|Unknown status|Not yet recruiting|N/A|200|Anticipated|University of Maryland||2|||f||||f||||||||||2018-05-31 22:58:24.710595|2018-05-31 22:58:24.710595
NCT01276171|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2017-01-12||2017-04-10|2011-01-11|2011-01-13|Estimate|2017-04-10|2017-06-26|Actual||||2017-04-10|2017-06-26|Actual|February 2010||2010-02-28|April 2017|2017-04-30|April 2015|Actual|2015-04-30|December 2011|Actual|2011-12-31||Interventional|||Ultrasound-image Guided Versus Doppler Guided Versus Palpation Technique for Arterial Cannulation in Adults|Ultrasound-image Guided Versus Doppler Guided Versus Palpation Technique for Arterial Cannulation in Adults|Completed||N/A|749|Actual|University of Iowa||3|||f||||t||||||||No|We are not planning on sharing IPD.|2018-05-31 22:58:24.85729|2018-05-31 22:58:24.85729
NCT01276158|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-03-09|2011-01-11|2011-01-13|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2011|Actual|2011-05-31|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pediatric Radial Arterial Cannulation|Ultrasound-image Versus Doppler-guided Radial Artery Cannulation in Infants and Small Children|Completed||N/A|104|Actual|University of Iowa||2|||f||||t||||||||No||2018-05-31 22:58:25.086672|2018-05-31 22:58:25.086672
NCT01276145|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2018-01-16|2011-01-11|2011-01-13|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2010||2010-09-30|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Prevalence Of Internal Pudendal Artery Disease In Patients With Erectile Dysfunction Undergoing Diagnostic Coronary Angiography|Prevalence Of Internal Pudendal Artery Disease In Patients With Erectile Dysfunction Undergoing Diagnostic Coronary Angiography|Completed|||1|Actual|University of Chicago|||||f||||f||||||||||2018-05-31 22:58:25.156119|2018-05-31 22:58:25.156119
NCT01276132|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2016-08-23|2011-01-12|2011-01-13|Estimate|||||||2016-08-23|2016-08-24|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Patient Satisfaction and Safety Outcomes After Enrollment in a Same-Day (SD) Percutaneous Coronary Intervention Program|Patient Satisfaction and Safety Outcomes After Enrollment in a Same-Day (SD) Percutaneous Coronary Intervention Program|Recruiting|||250|Anticipated|University of Chicago|||2||f||||f||||||||||2018-05-31 22:58:25.211958|2018-05-31 22:58:25.211958
NCT01276119|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-03-21|2011-01-12|2011-01-13|Estimate|||||||2012-03-21|2012-03-22|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, Single-dose, Dose-escalating Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CDP6038 in Healthy Male Subjects|Completed||Phase 1|67|Actual|UCB Pharma||14|||f||||f||||||||||2018-05-31 22:58:25.259609|2018-05-31 22:58:25.259609
NCT01276106|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2014-11-07||2018-04-24|2011-01-12|2011-01-13|Estimate|2014-11-17|2014-11-18|Estimate||||2018-04-24|2018-05-22|Actual|January 2011||2011-01-31|April 2018|2018-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional||Baseline was defined as the last measurement obtained on or before the first dose of the study medication.|Study of AC-201 in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of AC-201 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|259|Actual|TWi Biotechnology, Inc.||4|||f||||f||||||||||2018-05-31 22:58:25.46909|2018-05-31 22:58:25.46909
NCT01276093|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2015-12-28|2011-01-11|2011-01-13|Estimate|||||||2015-12-28|2015-12-30|Estimate|July 2011||2011-07-31|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|December 2015|Actual|2015-12-31||Interventional|PAVANE||Pulmonary Vein Ablation Versus Amiodarone in the Elderly|Pulmonary Vein Ablation Versus Amiodarone in the Elderly|Terminated||N/A|59|Actual|St. Jude Medical||2||DSMB recommendation; enrollment too slow|f||||t||||||||||2018-05-31 22:58:25.868786|2018-05-31 22:58:25.868786
NCT01276080|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-07-08|2011-01-11|2011-01-13|Estimate|||||||2012-07-08|2012-07-10|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fed Conditions|A Study to Evaluate A Study to Evaluate the Relative Bioavailability of Donepezil Hydrochloride 10 mg Tablets (OHM Laboratories, Inc., USA) Compared to ARICEPT® (Donepezil Hydrochloride)10 mg Tablets (Eisai Inc.) in Healthy Volunteers Under Non-Fasted Conditions|Completed||Phase 1|36|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 22:58:25.935226|2018-05-31 22:58:25.935226
NCT01276067|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-07-19|2011-01-11|2011-01-13|Estimate|||||||2012-07-19|2012-07-20|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Bioequivalence Study of Donepezil Hydrochloride 10 mg Tablets Under Fasting Conditions|A Study to Evaluate the Relative Bioavailability of Donepezil Hydrochloride 10 mg Tablets (OHM Laboratories, Inc., USA) Compared to ARICEPT® (Donepezil Hydrochloride) 10 mg Tablets (Eisai Inc.) in Healthy Volunteers Under Fasted Conditions.|Completed||Phase 1|32|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 22:58:25.991041|2018-05-31 22:58:25.991041
NCT01276054|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2014-07-01||2014-07-01|2011-01-11|2011-01-13|Estimate|2014-07-01|2014-08-01|Estimate||||2014-07-01|2014-08-01|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.|Reducing the Incidence and Severity of Arm Lymphedema With Axillary Reverse Mapping and Implementation of a Lymphedema Screening and Intervention Program|Terminated||Phase 2|4|Actual|University of Southern California|Study terminated early due to P.I. moving to another institution.|2||P.I. left|f||||t||||||||||2018-05-31 22:58:26.128401|2018-05-31 22:58:26.128401
NCT01276041|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2018-01-26|2011-01-11|2011-01-13|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2011|Actual|2011-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer|Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer|Active, not recruiting||Phase 2|69|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:58:26.686798|2018-05-31 22:58:26.686798
NCT01276028|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-11-02|2011-01-12|2011-01-13|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2011||2011-04-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|AIM||Acupuncture in Menopause|Acupuncture for Vasomotor Symptoms|Completed||N/A|209|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 22:58:26.79058|2018-05-31 22:58:26.79058
NCT01276015|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-18|2011-01-12|2011-01-13|Estimate|||||||2011-01-18|2011-01-19|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy|SPREAD AND EFFECTIVENESS OF BOTULINUM NEUROTOXIN A IN SPASTIC EQUINUS IN CEREBRAL PALSY:SHORT-TERM STUDY|Completed||Phase 4|18|Actual|Universita di Verona||1|||f||||t||||||||||2018-05-31 22:58:26.863521|2018-05-31 22:58:26.863521
NCT01276002|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2015-12-04|2011-01-12|2011-01-13|Estimate|||||||2015-12-04|2015-12-07|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|Disduct||Evaluation of Pancreatic Duct Stenting in Patients With Pancreatic Pseudocysts.|Randomized Multicenter Study on Pancreatic Duct Stenting in Disrupted or Obstructed Ducts in Context With Endoscopic Treatment of Pancreatic Pseudocysts.|Unknown status|Recruiting|N/A|120|Anticipated|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 22:58:27.022869|2018-05-31 22:58:27.022869
NCT01275989|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-01-12|2011-01-12|2011-01-13|Estimate|||||||2011-01-12|2011-01-13|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|EAEIRTSOSAA||Ear Acupuncture Effectiveness In Reducing The Signs And Symptoms Of Stress And Anxiety|EAR ACUPUNCTURE EFFECTIVENESS IN REDUCING THE SIGNS AND SYMPTOMS OF STRESS AND ANXIETY|Terminated||N/A|56|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 22:58:27.093474|2018-05-31 22:58:27.093474
NCT01275976|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2015-02-03|2011-01-12|2011-01-13|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|CAESAR||Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture|Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture|Terminated||Phase 3|11|Actual|UMC Utrecht||2||Futility and limited feasibility|f||||t||||||||||2018-05-31 22:58:27.145783|2018-05-31 22:58:27.145783
NCT01275963|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2016-11-05|2011-01-12|2011-01-13|Estimate|||||||2016-11-05|2016-11-08|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|LAX||New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function|New Echocardiographic Parameters for Assessment of Longitudinal Left Ventricular Function|Completed|||400|Actual|Heidelberg University|||8||f||||f||||||||||2018-05-31 22:58:27.216395|2018-05-31 22:58:27.216395
NCT01274390|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2017-02-01|2011-01-09|2011-01-11|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|RECAP||Impact of Blood Storage Duration on Physiologic Measures|Impact of Blood Storage Duration on Physiologic Measures: RECESS Ancillary Physiologic Study (RECAP)|Completed|||390|Anticipated|Duke University|||2||f||||t||||||||||2018-05-31 22:58:49.990135|2018-05-31 22:58:49.990135
NCT01275950|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2011-01-12|2011-01-12|2011-01-13|Estimate|||||||2011-01-12|2011-01-13|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||A Study to Evaluate the Impact of Direct and Surrogate Advertising and Compliance With the Bill With the Respect to Sale of Tobacco Products Around Educational Institutes|An Intervention Study To Evaluate The Impact Of Direct and Surrogate Advertising And Compliance With The Bill With The Respect To Sale Of Tobacco Products Around Educational Institutes|Unknown status|Recruiting|N/A|480|Anticipated|Tata Memorial Hospital|||||f||||t||||||||||2018-05-31 22:58:27.281419|2018-05-31 22:58:27.281419
NCT01275937|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-08-11|2011-01-12|2011-01-13|Estimate|||||||2011-08-11|2011-08-12|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy|A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding|Unknown status|Recruiting|Phase 4|65|Anticipated|Taipei Medical University||2|||f||||f||||||||||2018-05-31 22:58:27.376379|2018-05-31 22:58:27.376379
NCT01275924|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2018-04-17|2011-01-12|2011-01-13|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2011||2011-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|March 2015|Actual|2015-03-31||Interventional|TIGHTROPE-SS||Tightrope or Screw Fixation of Acute Tibiofibular Syndesmotic Injury|Tightrope or Screw Fixation of Acute Tibiofibular Syndesmotic Injury. Randomised Controlled Trial.|Completed||N/A|97|Actual|Sykehuset Asker og Baerum||2|||f||||f||||||||||2018-05-31 22:58:27.457011|2018-05-31 22:58:27.457011
NCT01275911|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2013-03-25|2011-01-12|2011-01-13|Estimate|||||||2013-03-25|2013-03-27|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Non-opioid Analgesia for Fast-track Surgery|Fast-track Laparoscopic Surgery. The Effect of Anesthetic Technique|Completed||N/A|40|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 22:58:27.531763|2018-05-31 22:58:27.531763
NCT01275898|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-08-04|2011-01-12|2011-01-13|Estimate|||||||2011-08-04|2011-08-05|Estimate|April 2010||2010-04-30|March 2010|2010-03-31||||||||Observational|||Comparison of INVOS and FORE SIGHT Cerebral Oximeter|Assessing Cerebral Oxygenation During Different Surgical Procedures - Comparison of INVOS and ForeSight Cerebral Oximeter|Unknown status|Recruiting||35|Anticipated|Johannes Gutenberg University Mainz|||4||f||||f||||||||||2018-05-31 22:58:27.605362|2018-05-31 22:58:27.605362
NCT01275885|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-07-15|2011-01-12|2011-01-13|Estimate|||||||2011-07-15|2011-07-18|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|VIDI-P||Vitamin D Intervention in Infants - Pilot|Vitamin D Intervention in Infants - Pilot|Completed||Phase 4|113|Actual|Helsinki University Central Hospital||3|||f||||||||||||||2018-05-31 22:58:27.647675|2018-05-31 22:58:27.647675
NCT01275872|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-10-31|2011-01-12|2011-01-13|Estimate|||||||2011-10-31|2011-11-01|Estimate|April 2010||2010-04-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Guided Imagery and Progressive Muscle Relaxation as a Means to Improve the Psychological Well-being and the Quality of Life for Patients With Breast and Prostate Cancer|A Randomized Clinical Trial on the Effect of Guided Imagery and Progressive Muscle Relaxation for the Management of Pain, Stress, Anxiety and Depression as a Means to Improve the Psychological Well-being and the Quality of Life for Patients With Breast and Prostate Cancer|Completed||N/A|200|Anticipated|Cyprus University of Technology||1|||f||||t||||||||||2018-05-31 22:58:27.707955|2018-05-31 22:58:27.707955
NCT01275859|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-08-26|2011-01-12|2011-01-13|Estimate|||||||2017-08-26|2017-08-29|Actual|September 2010||2010-09-30|August 2017|2017-08-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|Neo-All-In||Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer|Neoadjuvant Letrozole and Lapatinib in Postmenopausal Women With ER and Her2 Positive Breast Cancer|Completed||Phase 2|25|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:58:27.765831|2018-05-31 22:58:27.765831
NCT01275846|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2011-01-12|2011-01-12|2011-01-13|Estimate|||||||2011-01-12|2011-01-13|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Interventional|||Deployment of American Heart Association Heart Failure Protocols and Content Within the Intel® Health Guide System|Study for Deployment of American Heart Association Heart Failure Protocols and Educational Content Within the Intel® Health Guide System With a Congestive Heart Failure Cohort|Unknown status|Active, not recruiting|N/A|26|Actual|American Heart Association||1|||f||||f||||||||||2018-05-31 22:58:27.851479|2018-05-31 22:58:27.851479
NCT01275833|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-02|2017-04-10||2017-06-22|2011-01-11|2011-01-12|Estimate|2017-06-22|2017-06-26|Actual||||2017-06-22|2017-06-26|Actual|July 2011||2011-07-31|June 2017|2017-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|RESTORE-AV||Restoration of Atrioventricular Synchrony Trial|Restoration of Atrioventricular Synchrony Trial|Terminated||N/A|2|Actual|Boston Scientific Corporation|Early termination leading to small number of patients analyzed. As the study was stopped early, the primary objective is underpowered.|2||Difficult subject recruitment|f||||f||||||||No||2018-05-31 22:58:27.916114|2018-05-31 22:58:27.916114
NCT01275820|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||A Study to Evaluate Glucose and Insulin Response to Nutralin|A Study to Evaluate Glucose and Insulin Response to Nutralin|Completed|||10|Actual|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 22:58:28.240745|2018-05-31 22:58:28.240745
NCT01275807|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2015-09-21|2011-01-11|2011-01-12|Estimate|||||||2015-09-21|2015-09-22|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|AcCliMaT||Effectiveness and Safety of Acupuncture for Climacteric Syndrome in Patients With Breast Cancer|Acupuncture as an Integrated Intervention for the Control of Symptoms of Climacteric Syndrome in Patients Affected by Breast Cancer|Completed||Phase 4|190|Actual|Azienda Usl di Bologna||2|||f||||f||||||||||2018-05-31 22:58:28.309024|2018-05-31 22:58:28.309024
NCT01275794|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2012-06-01|2011-01-11|2011-01-12|Estimate|||||||2012-06-01|2012-06-04|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage|Screening Epidemiological Program on Compensation Evaluation of DM Type 2 Patients on OAD Monotherapy and Physicians Satisfaction of Their Usage|Completed|||1849|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:58:28.391085|2018-05-31 22:58:28.391085
NCT01275274|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2017-02-17|2011-01-10|2011-01-12|Estimate|||||||2017-02-17|2017-02-23|Actual|January 2012||2012-01-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens|Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens|Withdrawn||Phase 2|0|Actual|University of North Carolina, Chapel Hill||2||no subject enrolled in nearly 2 years|f||||f||||||||No|no data obtained.|2018-05-31 22:58:37.366834|2018-05-31 22:58:37.366834
NCT01275781|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-01-28|2011-01-11|2011-01-12|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion|A Phase 1, Open-Label, Non-randomized, Single-Center Study to Assess Distribution, Metabolism and Excretion After [14C]-Labelled Intravenous Administration of AZD9742 as a 2-hour Infusion to Healthy Male Volunteers|Withdrawn||Phase 1|0|Actual|AstraZeneca||1||Withdrawn due to the local Radiation Safety Committee refusing to approve it.|f||||f||||||||||2018-05-31 22:58:28.473023|2018-05-31 22:58:28.473023
NCT01275768|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-13|2011-01-11|2011-01-12|Estimate|||||||2011-01-13|2011-01-14|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|||Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice|A Double Blind, Randomized Controlled Prospective Trial of Endo-biliary Radio-frequency Ablation for Maintenance of Metal Stent Patency in Patients With Malignant Obstructive Jaundice|Unknown status|Active, not recruiting|Phase 1/Phase 2|100|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t||||||||||2018-05-31 22:58:28.541314|2018-05-31 22:58:28.541314
NCT01275755|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2015-04-21||2016-01-05|2011-01-11|2011-01-12|Estimate|2015-06-04|2015-06-08|Estimate||||2016-01-05|2016-02-03|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All participants who received at least 1 dose of study drug|Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain|Completed||Phase 2|81|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 22:58:28.612958|2018-05-31 22:58:28.612958
NCT01275742|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2017-08-09|2011-01-11|2011-01-12|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2011|Actual|2011-01-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|HOPE-HF||Helping Others Toward Positive Emotions in People With Heart Failure|Testing a Brief Cognitive Therapy Intervention for Depressive Symptoms in Patients With Heart Failure|Completed||N/A|180|Anticipated|University of Kentucky||1|||f||||f||||||||||2018-05-31 22:58:28.804005|2018-05-31 22:58:28.804005
NCT01275729|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2018-01-16|2011-01-11|2011-01-12|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2010||2010-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury|The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury|Recruiting||N/A|200|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 22:58:28.935078|2018-05-31 22:58:28.935078
NCT01275716|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2016-08-23|2011-01-11|2011-01-12|Estimate|||||||2016-08-23|2016-08-24|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications. Is a Picture Really Worth a Thousand Words?|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications. Is a Picture Really Worth a Thousand Words?|Recruiting||N/A|120|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 22:58:29.015878|2018-05-31 22:58:29.015878
NCT01275703|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-12-21|2011-01-11|2011-01-12|Estimate|||||||2015-12-21|2015-12-23|Estimate|May 2010||2010-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing|Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Exercise Testing|Withdrawn|||0|Actual|University of Chicago|||1|The PI left this institution, and the study was closed.|f||||f||||||||||2018-05-31 22:58:29.097556|2018-05-31 22:58:29.097556
NCT01275690|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2017-01-09|2011-01-11|2011-01-12|Estimate|||||||2017-01-09|2017-01-11|Estimate|May 2010||2010-05-31|January 2017|2017-01-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing|Noninvasive Cardiac Output Measurements in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization With Acute Vasodilator Testing|Withdrawn|||0|Actual|University of Chicago|||1|The PI closed this study and went to another institution.|f||||f||||||||||2018-05-31 22:58:29.147644|2018-05-31 22:58:29.147644
NCT01275677|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2018-05-24|2011-01-11|2011-01-12|Estimate|||||||2018-05-24|2018-05-25|Actual|January 6, 2011|Actual|2011-01-06|May 2018|2018-05-31||||July 31, 2017|Actual|2017-07-31||Interventional|||Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer|A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer|Active, not recruiting||Phase 3|3296|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-05-31 22:58:30.24178|2018-05-31 22:58:30.24178
NCT01275664|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2017-10-10||2018-04-24|2011-01-11|2011-01-12|Estimate|2018-03-16|2018-04-12|Actual||||2018-04-24|2018-05-22|Actual|June 2011||2011-06-30|May 2017|2017-05-31||||May 2014|Actual|2014-05-31||Interventional||Eligible and treated patients|Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer|Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy|Terminated||N/A|4|Actual|Gynecologic Oncology Group||1||Study terminated due to no patient population available|f||||||||||||||2018-05-31 22:58:33.113298|2018-05-31 22:58:33.113298
NCT01275651|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-08-07|2011-01-11|2011-01-12|Estimate|||||||2017-08-07|2017-08-08|Actual|December 2010||2010-12-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole|Androgen Receptor (AR) Activity in Castration-Resistant Prostate Cancer (CRPC) and Response to Ketoconazole|Active, not recruiting|||48|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue, bone marrow, and blood~   "|||2018-05-31 22:58:33.365696|2018-05-31 22:58:33.365696
NCT01275638|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|April 2005||2005-04-30|April 2005|2005-04-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Moderate-Dose Steroid Therapy in Sepsis|The Effect of Moderate-Dose Steroid Therapy in Sepsis: A Placebo-Controlled, Randomized Study|Completed||Phase 4|55|Actual|TC Erciyes University||1|||f||||t||||||||||2018-05-31 22:58:33.424075|2018-05-31 22:58:33.424075
NCT01275625|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2013-09-23||2014-01-13|2011-01-11|2011-01-12|Estimate|2014-01-13|2014-03-03|Estimate||||2014-01-13|2014-03-03|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|July 2013|Actual|2013-07-31|October 2012|Actual|2012-10-31||Interventional|||Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia|A Multicenter, Open Label Study Of Maraviroc, Zidovudine And Lamivudine Twice Daily For The Treatment Of Antiretroviral Naïve HIV-Infected Patients With R5 HIV-1 In Russia|Completed||Phase 4|98|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 22:58:33.503958|2018-05-31 22:58:33.503958
NCT01275612|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2018-03-20|2011-01-11|2011-01-12|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2010|Actual|2010-11-30|March 2018|2018-03-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|CIS/MSC08||Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers|Ex-Vivo Expanded Mesenchymal Stem Cells To Repair The Kidney And Improve Function In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers|Withdrawn||Phase 1|0|Actual|Mario Negri Institute for Pharmacological Research||1||"Patients evaluated so far could not be enrolled because they did not meet the primary criterion~   of acute renal failure provided by the study protocol"|f||||f||||||||||2018-05-31 22:58:33.935271|2018-05-31 22:58:33.935271
NCT01275599|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-06-07|2011-01-11|2011-01-12|Estimate|||||||2011-06-07|2011-06-08|Estimate|January 2011||2011-01-31|June 2011|2011-06-30||||April 2011|Actual|2011-04-30||Interventional|||Drug-Drug Interaction Study Between Telaprevir and Buprenorphine|A Phase 1, Open-Label, Single-Sequence Study to Examine the Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy|Completed||Phase 1|16|Anticipated|Vertex Pharmaceuticals Incorporated||1|||f||||f||||||||||2018-05-31 22:58:34.010748|2018-05-31 22:58:34.010748
NCT01275586|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2016-10-27||2017-04-11|2011-01-11|2011-01-12|Estimate|2017-04-11|2017-04-12|Actual||||2017-04-11|2017-04-12|Actual|January 2011||2011-01-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|Pilot Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|Completed||Early Phase 1|6|Actual|Indiana University||1|||f||||t||||||||No||2018-05-31 22:58:34.12351|2018-05-31 22:58:34.12351
NCT01275573|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2013-06-18|2011-01-11|2011-01-12|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|rTMS||Evaluation of the Effect of Repetitive Transcranial Magnetic Stimulation in Pain Perception in Parkinson's Disease|High Frequency rTMS (Repetitive Transcranial Magnetic Stimulation) Effect Applied on Primary Cortical Motor, on Nociceptive Perception Thresholds in Parkinson's Disease Patients: a Physiopathology Study|Completed||Phase 2|30|Actual|University Hospital, Toulouse||3|||f||||t||||||||||2018-05-31 22:58:34.401581|2018-05-31 22:58:34.401581
NCT01275560|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2015-06-02|2011-01-11|2011-01-12|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Does the Negativation of the Glucose Hydrogen Breath Test Come Along With a Reduction of the Symptoms of Gaz Incontinence ?||Completed||Phase 3|16|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 22:58:34.468099|2018-05-31 22:58:34.468099
NCT01275547|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-01-28|2011-01-11|2011-01-12|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|NASKEMI||The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam|The Analgesic Effect of Combined Treatment With Intranasal S-Ketamine and Intranasal Midazolam Compared With Morphine Patient Controlled Analgesia in Spinal Surgery Patients|Completed||Phase 2/Phase 3|22|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 22:58:34.526171|2018-05-31 22:58:34.526171
NCT01275534|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-01-16|2011-01-11|2011-01-12|Estimate|||||||2013-01-16|2013-01-17|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|PROVIVO||Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation|Patient Reported Outcomes in View of Symptom Experience of Late Effects and Self-management After Haematopoietic Stem Cell Transplantation - A Mixed Methods Study|Completed|||375|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 22:58:34.608357|2018-05-31 22:58:34.608357
NCT01275521|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-08-22|2011-01-11|2011-01-12|Estimate|||||||2017-08-22|2017-08-23|Actual|January 10, 2011|Actual|2011-01-10|August 2017|2017-08-31|April 28, 2015|Actual|2015-04-28|April 28, 2015|Actual|2015-04-28||Interventional|PROTOX||A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy|Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.|Completed||Phase 3|127|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 22:58:34.684991|2018-05-31 22:58:34.684991
NCT01275508|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-09-13|2011-01-11|2011-01-12|Estimate|||||||2012-09-13|2012-09-14|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|FA-Crohn||Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut|Prospective, Monocentric, Open-label, Clinical Phase 1 Study to Demonstrate the Safety and Tolerability of FITC-Adalimumab After Single Topical Administration to the Intestinal Mucosa During Endomicroscopy in Patients With Crohn's Disease|Completed||Phase 1/Phase 2|25|Actual|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-05-31 22:58:34.772654|2018-05-31 22:58:34.772654
NCT01275495|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-03-30|2011-01-11|2011-01-12|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TASKII||Telephone Assessment and Skill-Building Intervention for Stroke Caregivers|Telephone Assessment and Skill-Building Intervention for Stroke Caregivers|Completed||Phase 3|254|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 22:58:34.921412|2018-05-31 22:58:34.921412
NCT01275482|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-04-06|2011-01-11|2011-01-12|Estimate|||||||2011-04-06|2011-04-07|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effectiveness of Transverse Friction Massage in Latent Myofascial Trigger Points in Anterior Deltoid Muscle|Effectiveness of Transverse Friction Massage Causing or Not Local Twitch Response in Anterior Deltoid Muscle Latent Myofascial Trigger Points|Completed||Early Phase 1|40|Anticipated|University of Castilla-La Mancha||2|||f||||f||||||||||2018-05-31 22:58:35.000168|2018-05-31 22:58:35.000168
NCT01275469|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.|A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80 mg) Orally Administered Once Daily for 35 Days in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. A Double Blind, Parallel Group, Placebo-controlled and Randomized Study.|Completed||Phase 2|47|Actual|Genfit||2|||f||||f||||||||||2018-05-31 22:58:35.063052|2018-05-31 22:58:35.063052
NCT01275456|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-07-04|2011-01-11|2011-01-12|Estimate|||||||2011-07-04|2011-07-06|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Validation of an Environmental Exposure Chamber for Inhalation Studies With House Dust Mite Allergen in Patients With Allergic Rhinitis|Validation of an Environmental Exposure Chamber for Inhalation Studies With House Dust Mite Allergen in Patients With Allergic Rhinitis|Completed||N/A|18|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||t||||||||||2018-05-31 22:58:35.155832|2018-05-31 22:58:35.155832
NCT01275443|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-06-23|2011-01-11|2011-01-12|Estimate|||||||2017-06-23|2017-06-26|Actual|January 2011||2011-01-31|June 2017|2017-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.|A Pharmacokinetic Evaluation of the Exposure and Distribution of TMC278LA for Use as Pre-exposure Prophylaxis, in Plasma and Genital Tract / Rectal Compartments, Following a Single Intramuscular Dose at Different Doses in HIV-negative Healthy Volunteers.|Completed||Phase 1|66|Actual|St Stephens Aids Trust||4|||f||||f||||||||||2018-05-31 22:58:35.229132|2018-05-31 22:58:35.229132
NCT01275430|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2014-07-10||2016-11-14|2011-01-11|2011-01-12|Estimate|2016-05-25|2016-07-04|Estimate||||2016-11-14|2016-11-16|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|STAT-PICC|Subjects undergoing PICC placement for long term IV therapy|Assessment of the Precision of the Sherlock 3CG Tip Positioning System|A Study to Assess the Precision of the Sherlock 3CG Tip Positioning System as a Tool to Guide Peripherally Inserted Central Catheter Placement|Terminated||N/A|27|Actual|C. R. Bard||2||Phase I completed. Phase II is cancelled.|f||||f||||||||No|Phase I was feasibility and wasn't powered. Phase II was powered, but cancelled due to slow enrollment during Phase I.|2018-05-31 22:58:35.365752|2018-05-31 22:58:35.365752
NCT01275417|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-09-23|2011-01-11|2011-01-12|Estimate|||||||2011-09-23|2011-09-26|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|BCSM||Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head|Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head|Completed|||160|Actual|China Medical University Hospital|||2||f||||t||||||||||2018-05-31 22:58:35.583878|2018-05-31 22:58:35.583878
NCT01275404|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-10-03|2011-01-11|2011-01-12|Estimate|||||||2017-10-03|2017-10-04|Actual|December 2010||2010-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ACT-ED||Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program|ACT-ED: Acceptance and Commitment Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program|Active, not recruiting||N/A|110|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 22:58:35.638462|2018-05-31 22:58:35.638462
NCT01275391|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2016-10-06|2011-01-11|2011-01-12|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|September 2013|Anticipated|2013-09-30|May 2013|Anticipated|2013-05-31||Interventional|||cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use|cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use|Withdrawn||Phase 1/Phase 2|0|Actual|Boston Children’s Hospital||4||This project was not funded.|f||||f||||||||No||2018-05-31 22:58:35.700323|2018-05-31 22:58:35.700323
NCT01275378|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-10-07|2011-01-11|2011-01-12|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Comparative Effectiveness Research for Two Medical Home Models for Attention Deficit Hyperactivity Disorder|COMPARATIVE EFFECTIVENESS RESEARCH FOR TWO MEDICAL HOME MODELS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER|Completed||N/A|156|Anticipated|Boston Medical Center||2|||f||||f||||||||||2018-05-31 22:58:35.77777|2018-05-31 22:58:35.77777
NCT01275365|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|2018-01-19||2018-01-19|2011-01-11|2011-01-12|Estimate|2018-01-19|2018-02-16|Estimate||||2018-01-19|2018-02-16|Estimate|May 2011||2011-05-31|January 2018|2018-01-31|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|OPTIMen||Optimizing Protein Intake in Older Americans With Mobility Limitations|Optimizing Protein Intake in Older Americans With Mobility Limitations|Completed||Phase 3|92|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 22:58:35.877296|2018-05-31 22:58:35.877296
NCT01275352|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-06-01|2011-01-11|2011-01-12|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression|A Randomized, Double Blind Pilot Study Evaluating CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression in Caucasian Hypertensive Patients Treated With Eplerenone|Withdrawn||Phase 4|0|Actual|Washington University School of Medicine||4||Lack of funding|f||||t||||||||||2018-05-31 22:58:36.445663|2018-05-31 22:58:36.445663
NCT01275339|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2015-12-08|2011-01-10|2011-01-12|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ASPEN||Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study|Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study|Unknown status|Recruiting|Phase 4|56|Anticipated|Washington University School of Medicine||4|||f||||t||||||||||2018-05-31 22:58:36.522611|2018-05-31 22:58:36.522611
NCT01275326|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-21|2011-01-11|2011-01-12|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|||||Observational|||Indoor Air Quality and Infectious Aerosols in Health Care Facilities|Indoor Air Quality and Infectious Aerosols in Health Care Facilities|Completed|||120|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:58:36.598183|2018-05-31 22:58:36.598183
NCT01275313|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2017-05-23||2017-05-23|2011-01-11|2011-01-12|Estimate|2017-05-23|2017-06-09|Actual||||2017-05-23|2017-06-09|Actual|April 2011||2011-04-30|May 2017|2017-05-31|June 5, 2015|Actual|2015-06-05|June 5, 2015|Actual|2015-06-05||Interventional|RCT-WC2||Wheeled Mobility for Preventing Pressure Ulcers|RCT on Wheeled Mobility for Preventing Pressure Ulcers|Completed||N/A|258|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 22:58:36.65472|2018-05-31 22:58:36.65472
NCT01275300|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-05-14|2011-01-10|2011-01-12|Estimate|||||||2013-05-14|2013-05-15|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|Niacin||Biosynthesis of PGD2 in Vivo|A Pilot Study to Measure Plasma and Urinary Prostaglandin D2 Metabolites Evoked by Niacin|Completed||Phase 4|22|Actual|University of Pennsylvania||5|||f||||t||||||||||2018-05-31 22:58:37.102329|2018-05-31 22:58:37.102329
NCT01275287|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-02-17|2011-01-11|2011-01-12|Estimate|||||||2017-02-17|2017-02-23|Actual|May 2011||2011-05-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab|Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis|Withdrawn||Phase 2|0|Actual|University of North Carolina, Chapel Hill||2||the study failed to enroll any patient and sponsor wished to stop.|f||||f||||||||No|no plan too share data|2018-05-31 22:58:37.29499|2018-05-31 22:58:37.29499
NCT01275261|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-11-13|2011-01-10|2011-01-12|Estimate|||||||2012-11-13|2012-11-14|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pilot Study of Avoidance of Bladder Catheters in Stroke Patients to Avoid Urinary Tract Infections|Pilot Randomized Trial of a Nursing Protocol to Avoid Bladder Catheterization in Patients With Stroke|Terminated||Phase 2|5|Actual|University of California, San Francisco||2||Investigator no longer at institution-no data analyzed|f||||f||||||||||2018-05-31 22:58:37.459411|2018-05-31 22:58:37.459411
NCT01275248|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2013-01-16|2011-01-10|2011-01-12|Estimate|||||||2013-01-16|2013-01-18|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Who Have Not Adequately Responded To Treatment With A Serotonin Reuptake Inhibitor|Terminated||Phase 2|130|Actual|Transcept Pharmaceuticals||3||lack of efficacy|f||||t||||||||||2018-05-31 22:58:37.573734|2018-05-31 22:58:37.573734
NCT01275235|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2016-04-01|2011-01-11|2011-01-12|Estimate|||||||2016-04-01|2016-04-05|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|T2DM||Exposure to Type II Diabetes for Two Siblings With the Same Parents|Metabolic Traits of Adult Sib-pairs Discordant for Intrauterine Diabetes Exposure.|Terminated|||10|Actual|Pennington Biomedical Research Center|||1|We were unable to recruit enough sibling pairs in a timely manner.|f||||f||||||Samples Without DNA|"~     Whole blood, urine and muscle cell.~   "|||2018-05-31 22:58:37.685469|2018-05-31 22:58:37.685469
NCT01275222|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2016-08-04|2011-01-11|2011-01-12|Estimate|||||||2016-08-04|2016-08-08|Estimate|November 2002||2002-11-30|August 2016|2016-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors|A Phase I-II, Open-label Study of RAD001 in Combination With Glivec®/Gleevec™ (Imatinib) in Patients With Glivec/Gleevec-refractory/Resistant Gastrointestinal Stromal Tumors.|Completed||Phase 1/Phase 2|120|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:58:37.808686|2018-05-31 22:58:37.808686
NCT01275209|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-12-03|2011-01-11|2011-01-12|Estimate|||||||2012-12-03|2012-12-05|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|LIFT||Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma|A Phase Ib, Multicenter, Open-label Study of HCD122 Administered Intravenously in Combination With Bendamustine in Patients With CD40+ Follicular Lymphoma Who Are Refractory to Rituximab|Completed||Phase 1|1|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:58:37.986693|2018-05-31 22:58:37.986693
NCT01275196|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2015-09-16||2016-03-10|2011-01-10|2011-01-12|Estimate|2015-11-04|2015-12-09|Estimate||||2016-03-10|2016-04-08|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients|ENESTChina: A Phase III Multi-center, Open-label, Randomized Study of Nilotinib Versus Imatinib in Chinese Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Completed||Phase 3|267|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:58:38.125029|2018-05-31 22:58:38.125029
NCT01275183|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2015-06-16|2011-01-10|2011-01-12|Estimate|||||||2015-06-16|2015-06-18|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck|A Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of the Head and Neck|Completed||Early Phase 1|5|Actual|New Mexico Cancer Care Alliance||1|||f||||t||||||||||2018-05-31 22:58:38.825836|2018-05-31 22:58:38.825836
NCT01275170|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-10-16|2011-01-10|2011-01-12|Estimate|||||||2015-10-16|2015-10-19|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005 AM1)|A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Subjects With Impaired Renal Function|Completed||Phase 1|49|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 22:58:38.956752|2018-05-31 22:58:38.956752
NCT01275157|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-04-14|2011-01-10|2011-01-12|Estimate|||||||2011-04-14|2011-04-15|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects|Disposition of [14C]-LY2452473 Following Oral Administration in Healthy Human Subjects|Completed||Phase 1|6|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 22:58:39.073688|2018-05-31 22:58:39.073688
NCT01275144|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-04-14|2011-01-10|2011-01-12|Estimate|||||||2011-04-14|2011-04-15|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of the Effect of LY2216684 on Lorazepam|Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Lorazepam in Healthy Subjects|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 22:58:39.143981|2018-05-31 22:58:39.143981
NCT01275131|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2014-06-26||2014-06-26|2011-01-10|2011-01-12|Estimate|2014-06-26|2014-07-25|Estimate||||2014-06-26|2014-07-25|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||All participants who received at least one dose of study drug.|Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)|Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20)|Completed||Phase 1|45|Actual|Halozyme Therapeutics||4|||f||||f||||||||||2018-05-31 22:58:39.265491|2018-05-31 22:58:39.265491
NCT01275118|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2014-02-26|2011-01-11|2011-01-12|Estimate|||||||2014-02-26|2014-02-28|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of Postoperative Visual Acuity and Spectacle Independence Between the Tecnis Multifocal Intraoculer Lens (IOL) and the Crystalens Accommodating IOL|Comparative Study of Photopic and Mesopic Distance, Intermediate and Near Visual Acuity, and Spectacle Independence With Bilateral Implantation of the Tecnis Multifocal (TMF) Intraocular Lens or Crystalens AO (CAO) Intraocular Lens|Completed||Phase 4|26|Actual|Drs. Fine, Hoffman and Packer, LLC|||||f||||f||||||||||2018-05-31 22:58:40.022608|2018-05-31 22:58:40.022608
NCT01274403|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate||||December 2010|2010-12-31||||||||Interventional|||A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma||Completed||Phase 2|130|Actual|Gruppo Italiano Studio Linfomi||2|||f||||f||||||||||2018-05-31 22:58:49.929261|2018-05-31 22:58:49.929261
NCT01275105|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10||2012-02-24|2012-03-02|2011-01-11|2011-01-12|Estimate||||2012-03-01|2012-03-05|Estimate|2012-03-02|2012-03-06|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)|A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)|Completed||Phase 2|68|Actual|Eye Therapies, LLC||4|||f||||f||||||||||2018-05-31 22:58:40.162561|2018-05-31 22:58:40.162561
NCT01275092|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2012-08-09||2013-08-06|2011-01-10|2011-01-12|Estimate|2013-08-06|2013-08-08|Estimate||||2013-08-06|2013-08-08|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|PRECISE||Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)|CorPath® PRECISE Percutaneous Robotically-Enhanced Coronary Intervention Study (PRECISE)|Completed||Phase 2|164|Actual|Corindus Inc.||1|||f||||t||||||||||2018-05-31 22:58:40.255531|2018-05-31 22:58:40.255531
NCT01275079|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Change of Nasalance After Tonsillectomy in Thai Adult|Change of Nasalance After Tonsillectomy in Thai Adult|Unknown status|Recruiting||30|Anticipated|Chulalongkorn University|||||f||||f||||||Samples Without DNA|"~     Rt. and Lt.tonsil~   "|||2018-05-31 22:58:40.535209|2018-05-31 22:58:40.535209
NCT01275066|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2014-03-11|2013-08-02|2014-06-06|2011-01-11|2011-01-12|Estimate|2014-03-11|2014-04-15|Estimate|2013-08-02|2013-08-09|Estimate|2014-06-06|2014-07-07|Estimate|February 2011||2011-02-28|June 2014|2014-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|Completed||Phase 3|177|Actual|BioMarin Pharmaceutical||3|||f||||t||||||||||2018-05-31 22:58:40.646685|2018-05-31 22:58:40.646685
NCT01275053|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2017-01-06||2017-09-15|2011-01-10|2011-01-12|Estimate|2017-04-24|2017-08-03|Actual||||2017-09-15|2017-10-17|Actual|July 2002||2002-07-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|December 2013|Actual|2013-12-31||Interventional|||In Vivo Leptin Signaling in Humans After Acute Leptin Administration|In Vivo Leptin Signaling in Humans After Acute Leptin Administration|Completed||Phase 1|12|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||No||2018-05-31 22:58:41.814461|2018-05-31 22:58:41.814461
NCT01275040|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-03-23|2011-01-11|2011-01-12|Estimate|||||||2011-03-23|2011-03-24|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Interventional|CCMSD||The Efficacy of Specialist Collaboration and Mobile Screening for Improving the Management of Diabetes|The Efficacy of Primary and Tertiary Specialist Care Collaboration and Mobile Complications Screening for Improving the Management of Diabetes at Primary Health Care Level in Tshwane District - A Cluster Randomized Trial|Unknown status|Enrolling by invitation|N/A|600|Anticipated|University of Pretoria||2|||f||||t||||||||||2018-05-31 22:58:42.009446|2018-05-31 22:58:42.009446
NCT01275027|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-04-21|2011-01-11|2011-01-12|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin|A Phase II, Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin|Withdrawn||Phase 2|0|Actual|Avera McKennan Hospital & University Health Center||2||Sponsor recalled the study|f||||t||||||||||2018-05-31 22:58:42.089466|2018-05-31 22:58:42.089466
NCT01275014|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Corticosteroids as Additive in Temporomandibular Joint (TMJ) Arthrocentesis|Corticosteroids as Additive in Arthrocentesis of the Temporomandibular Joint: Double Blind, Randomised Controlled Trial of Effectiveness.|Unknown status|Active, not recruiting|Phase 4|28|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 22:58:42.163345|2018-05-31 22:58:42.163345
NCT01275001|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-10-04|2011-01-11|2011-01-12|Estimate|||||||2011-10-04|2011-10-06|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Effects of Music Intervention on the Brain Development of Preschool Children|Effects of Music Intervention on the Brain Development of Preschool Children|Completed|||34|Actual|Avera McKennan Hospital & University Health Center|||2||f||||t||||||||||2018-05-31 22:58:42.240723|2018-05-31 22:58:42.240723
NCT01274988|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2014-04-14|2011-01-11|2011-01-12|Estimate|||||||2014-04-14|2014-04-16|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Deep Brain Stimulation of Nucleus Accumbens to Prevent Opiate Relapse|Deep Brain Stimulation of Nucleus Accumbens as a New Treatment to Prevent Relapse for Opiate Addicts|Unknown status|Recruiting|N/A|20|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 22:58:42.306995|2018-05-31 22:58:42.306995
NCT01274975|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-03-24|2011-01-11|2011-01-12|Estimate|||||||2014-03-24|2014-03-26|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|MSC||Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.|Safety of Autologous Adipose Derived Mesenchymal Stem Cells in Patients With Spinal Cord Injury|Completed||Phase 1|8|Actual|Biostar|||||f||||||||||||||2018-05-31 22:58:42.390831|2018-05-31 22:58:42.390831
NCT01274962|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2018-01-31|2011-01-11|2011-01-12|Estimate|||||||2018-01-31|2018-02-01|Actual|November 2009||2009-11-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer|An Adaptative Randomized Phase II Study on the Timing of FOLFOX for Patients With Operable Stage III Rectal Cancer|Active, not recruiting||Phase 2|180|Actual|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||||||||||||2018-05-31 22:58:42.522458|2018-05-31 22:58:42.522458
NCT01274949|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2011-09-13|2011-01-09|2011-01-12|Estimate|||||||2011-09-13|2011-09-14|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|LI-ESWT||The Effect of Low Intensity Shockwave Therapy for ED in Post Radical Prostatectomy Patients Who Didn't Respond to PDE5i|The Effect of Low Intensity Shock Wave Therapy in Post Radical Prostatectomy Severe ED Patients Not Responding to Oral Medication|Completed||Phase 3|20|Anticipated|Rambam Health Care Campus||1|||f||||t||||||||||2018-05-31 22:58:42.612088|2018-05-31 22:58:42.612088
NCT01274936|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2014-11-11|2011-01-11|2011-01-12|Estimate|||||||2014-11-11|2014-11-13|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|February 2015|Anticipated|2015-02-28||Interventional|||Qishe Pill for Cervical Radiculopathy|Effectiveness of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy: a Randomized, Double-blind, Placebo-controlled, Multicentre Trial|Unknown status|Recruiting|Phase 2|240|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 22:58:42.714482|2018-05-31 22:58:42.714482
NCT01274923|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2011-05-17|2011-01-09|2011-01-12|Estimate|||||||2011-05-17|2011-05-18|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|LI-ESWT||Double Blind Placebo Controlled Study on the Effect of Extracorporal Shock Wave Therapy on Erectile Dysfunction in PDE5i Responders|The Effect of Low Intensity Shock Wave Therapy on Erectile Dysfunction in Patients Responding to PDE5i's|Unknown status|Recruiting|Phase 3|20|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:58:42.792457|2018-05-31 22:58:42.792457
NCT01274910|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2013-11-21|2011-01-11|2011-01-12|Estimate|||||||2013-11-21|2013-11-25|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|EFOPaKR-01||Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial|Effect of Fish Oil on Surgery Pain After Knee Replacement Patients: Randomized, Prospective, Double Blind, Placebo Control Trial|Unknown status|Recruiting|N/A|60|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 22:58:42.87484|2018-05-31 22:58:42.87484
NCT01274897|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|2012-03-13||2012-09-17|2011-01-11|2011-01-12|Estimate|2012-09-17|2012-10-16|Estimate||||2012-09-17|2012-10-16|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea|A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea|Completed||Phase 3|450|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:58:42.96283|2018-05-31 22:58:42.96283
NCT01274884|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2014-11-17|2011-01-11|2011-01-12|Estimate|||||||2014-11-17|2014-11-19|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Tightrope Fixation of Acromioclavicular Joint Dislocation - a Prospective Series|Prospective Series of Acute Acromioclavicular Dislocations Grade III+. Arthroscopic Fixation With Tightrope (R).|Completed||N/A|25|Actual|Sykehuset Asker og Baerum||1|||f||||f||||||||||2018-05-31 22:58:43.34555|2018-05-31 22:58:43.34555
NCT01274871|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|December 2009||2009-12-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Observational|||Sensory Changes From Chest Drains|Late Sensory Changes From Chest Drain Insertion During Thoracotomy|Completed|||21|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 22:58:43.411412|2018-05-31 22:58:43.411412
NCT01274858|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-09-27|2011-01-11|2011-01-12|Estimate|||||||2011-09-27|2011-09-28|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Sensory Mapping and Thermal Thresholds After Thoracic Surgery|Sensory Mapping and Thermal Thresholds After Thoracic Surgery|Completed|||12|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 22:58:43.472699|2018-05-31 22:58:43.472699
NCT01274845|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Use of Heliox in the Management of Neonates With Meconium Aspiration Syndrome|Use of Heliox in the Management of Neonates With Meconium Aspiration Syndrome|Completed||N/A|8|Actual|Poznan University of Medical Sciences||1|||f||||f||||||||||2018-05-31 22:58:43.531065|2018-05-31 22:58:43.531065
NCT01274832|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2011-01-13|2011-01-11|2011-01-12|Estimate|||||||2011-01-13|2011-01-14|Estimate|February 2011||2011-02-28|October 2008|2008-10-31|September 2014|Anticipated|2014-09-30|April 2013|Anticipated|2013-04-30||Observational|DeBraStE||Prospective Study to Compare Results of STN-DBS Between Early Treated and Late-treated PD Patient|Prospective Study to Compare the Impact on Motor, Neuropsychological, Psychiatric Outcomes and Quality of Life of STN-DBS Between Early Treated and Late-treated PD Patients.|Unknown status|Not yet recruiting||40|Anticipated|A.O. Ospedale Papa Giovanni XXIII|||2||f||||f||||||||||2018-05-31 22:58:43.585624|2018-05-31 22:58:43.585624
NCT01274819|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2013-10-14|2011-01-11|2011-01-12|Estimate|||||||2013-10-14|2013-10-16|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|DLA||Dynamic Light Application to Prevent ICU Acquired Delirium|Dynamic Light Application to Prevent ICU Acquired Delirium|Completed||N/A|1000|Actual|Jeroen Bosch Ziekenhuis||2|||f||||f||||||||||2018-05-31 22:58:43.674962|2018-05-31 22:58:43.674962
NCT01274806|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2011-01-11|2011-01-11|2011-01-12|Estimate|||||||2011-01-11|2011-01-12|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|TAKE-CARE||Take-Care Program: Effectiveness of a Physical Therapy Program on Cancer Related Symptoms|TAKE-CARE: EFFECTIVENESS OF A PHYSICAL THERAPY COMBINING CORE STABILITY EXERCISE AND MASSAGE IN CANCER RELATED SYMPTOMS|Completed||N/A|78|Actual|Instituto de Salud Carlos III||2|||f||||t||||||||||2018-05-31 22:58:43.757433|2018-05-31 22:58:43.757433
NCT01274793|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2015-03-17|2011-01-11|2011-01-12|Estimate|||||||2015-03-17|2015-03-19|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy|Multicentre Randomized Controlled Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy|Unknown status|Recruiting|Phase 1|240|Anticipated|Huazhong University of Science and Technology||3|||f||||t||||||||||2018-05-31 22:58:43.824761|2018-05-31 22:58:43.824761
NCT01274780|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2014-12-15|2011-01-11|2011-01-12|Estimate|||||||2014-12-15|2014-12-16|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|May 2013|Actual|2013-05-31||Interventional|||Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients||Completed||Phase 4|180|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 22:58:43.898|2018-05-31 22:58:43.898
NCT01274767|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-11|||2017-04-21|2011-01-11|2011-01-12|Estimate|||||||2017-04-21|2017-04-24|Actual|January 1995||1995-01-31|April 2017|2017-04-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Observational|3NANC||Prevention of Recurrent Ulcer Bleeding in High-risk Aspirin Users Who Are Not Infected With Helicobacter Pylori|Prevention of Recurrent Ulcer Bleeding in High-risk Aspirin Users Who Are Not Infected With Helicobacter Pylori: A Prospective Cohort Study (NSAID#3NANC Study)|Completed|||467|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 22:58:43.953761|2018-05-31 22:58:43.953761
NCT01274754|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-12-01|2011-01-11|2011-01-12|Estimate|||||||2014-12-01|2014-12-03|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Observational|||Neuroprotection With Erythromycin in Cardiac Surgery|Perioperative Administration of Erythromycin and Brain Protection|Completed|||40|Actual|AHEPA University Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be taken from all patients for the detection of tau protein, IL-1 and~     IL-6,~        1. preoperatively~        2. 12 hours after surgery~        3. the 6th day after surgery~   "|||2018-05-31 22:58:44.003281|2018-05-31 22:58:44.003281
NCT01274741|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2017-02-20|2011-01-10|2011-01-11|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2011||2011-01-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of Treatment for Posttraumatic Stress Disorder and Substance Use|Pilot Study of an Integrated Exposure-Based Model for Posttraumatic Stress Disorder and Substance Use Disorder|Completed||N/A|52|Actual|VA Boston Healthcare System||2|||f||||t||||||||No||2018-05-31 22:58:44.058666|2018-05-31 22:58:44.058666
NCT01274728|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2010||2010-11-30|January 2011|2011-01-31||||||||Observational|PAPPA-pilot||PAclitaxel-eluting Balloon in Primary PCI in Amsterdam; Pilot Study|Pilot Study on PAclitaxel-eluting Balloon in Primary PCI in Amsterdam. A Clinical Evaluation, to Study the Feasibility and Safety of a Paclitaxel-eluting Balloon in Primary Percutaneous Coronary Intervention for Acute ST-elevation Myocardial Infarction.|Unknown status|Recruiting||100|Anticipated|Onze Lieve Vrouwe Gasthuis|||1||f||||t||||||Samples Without DNA|"~     Biochemistry, haematology~   "|||2018-05-31 22:58:44.140497|2018-05-31 22:58:44.140497
NCT01274715|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2012-10-25||2014-04-07|2011-01-10|2011-01-11|Estimate|2014-04-07|2014-05-08|Estimate||||2014-04-07|2014-05-08|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|HOPE||HOPE Pilot for Veterans With Complex Diabetes|Behavioral Health Coaching for Rural Veterans With Diabetes and Depression|Completed||N/A|12|Actual|Michael Debakey Veterans Affairs Medical Center|A very small sample was collected, and there was not a control group to compare to our intervention group.|1|||f||||f||||||||||2018-05-31 22:58:45.162397|2018-05-31 22:58:45.162397
NCT01274702|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2018-03-19|2011-01-10|2011-01-11|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2010||2010-05-31|December 2017|2017-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|VISION||Visual Reconstitution Therapy After Optic Neuritis|Visual Reconstitution Therapy After Optic Neuritis|Completed||Phase 2|25|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:58:45.312874|2018-05-31 22:58:45.312874
NCT01274689|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|May 1997||1997-05-31|June 2008|2008-06-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Observational|||External Lid Loading for the Temporary Treatment of the Paresis of the M. Orbicularis Oculi: a Clinical Note|External Lid Loading for the Temporary Treatment of the Paresis of the M. Orbicularis Oculi: a Clinical Note|Completed|||152|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-05-31 22:58:45.376429|2018-05-31 22:58:45.376429
NCT01274676|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|MOMA||"Carotid Stenting in Patients With High Risk Carotid Stenosis (Soft Plaque)"|Randomized Trial of Proximal-versus Distal Cerebral Protection on Micro Embolization During Carotid Artery Stenting in Patients With High Risk Lipid Palque|Completed||N/A|53|Actual|Centro Cardiologico Monzino||2|||f||||t||||||||||2018-05-31 22:58:45.457997|2018-05-31 22:58:45.457997
NCT01274663|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-10-07|2011-01-10|2011-01-11|Estimate|||||||2011-10-07|2011-10-12|Estimate|November 2010||2010-11-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study Of PF-05175157 In Healthy Volunteers|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-05175157 After Administration Of Single Escalating Oral Doses Under Fasted And Fed Conditions In Healthy Volunteers|Completed||Phase 1|63|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 22:58:45.64323|2018-05-31 22:58:45.64323
NCT01274650|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2016-10-12|2011-01-10|2011-01-11|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Correlation Between Wound Volume and Depth of Decubitus Ulcers And Resting Energy Expenditure|Correlation Between Wound Volume and Depth of Decubitus Ulcers And Resting Energy Expenditure|Completed||N/A|25|Actual|Saint Elizabeth Regional Medical Center||1|||f||||f||||||||||2018-05-31 22:58:45.750727|2018-05-31 22:58:45.750727
NCT01274637|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2017-01-10||2017-07-05|2011-01-10|2011-01-11|Estimate|2017-07-05|2017-08-01|Actual||||2017-07-05|2017-08-01|Actual|March 2011||2011-03-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PROSPER||PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot|Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism|Completed||Phase 3|62|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 22:58:45.910651|2018-05-31 22:58:45.910651
NCT01274624|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-02-08|2011-01-10|2011-01-11|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2010||2010-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer|A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer|Active, not recruiting||Phase 1|32|Anticipated|Oncolytics Biotech|||||f||||f||||||||||2018-05-31 22:58:46.318426|2018-05-31 22:58:46.318426
NCT01274611|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2013-07-18||2014-08-12|2011-01-10|2011-01-11|Estimate|2013-12-17|2014-02-03|Estimate||||2014-08-12|2014-08-15|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||This was a parallel-group randomized control trial with allocation ratio 1:1, using random block size of 2. The unit of randomization was the individual axilla.|Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)|Comparing the Efficacy Between Suction-Curettage and Botox Injections in the Treatment of Axillary Hyperhidrosis|Completed||N/A|20|Actual|Northwestern University|There was a the lack of long-term assessment of comparative effectiveness. It is uncertain whether suction-curettage removes the eccrine sweat glands or mainly the apocrine glands.|2|||f||||t||||||||||2018-05-31 22:58:46.409284|2018-05-31 22:58:46.409284
NCT01274598|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2017-01-10|2011-01-10|2011-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2010||2010-12-31|January 2017|2017-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects|Open Label Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects|Completed||Phase 1|15|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 22:58:46.57838|2018-05-31 22:58:46.57838
NCT01274585|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2013-12-30||2017-12-05|2011-01-10|2011-01-11|Estimate|2013-12-30|2014-02-13|Estimate||||2017-12-05|2018-01-05|Actual|January 2011||2011-01-31|December 2017|2017-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence|Does Percutaneous Tibial Nerve Stimulation (PTNS) Improve Outcomes in Patients Presenting With Fecal Incontinence|Terminated||N/A|5|Actual|Massachusetts General Hospital||2||Study was terminated due to low recruitment rates|f||||t||||||||||2018-05-31 22:58:46.753174|2018-05-31 22:58:46.753174
NCT01274572|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-04-06|2011-01-10|2011-01-11|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|June 2011|Actual|2011-06-30|January 2011|Anticipated|2011-01-31||Observational|||Blood for Immune Response to Provenge® in HRPC|Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients|Withdrawn|||0|Actual|Mary Crowley Medical Research Center||||Drug became available with insurance reimbursement|f||||f||||||||||2018-05-31 22:58:47.151541|2018-05-31 22:58:47.151541
NCT01274559|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2014-01-30||2017-02-24|2011-01-10|2011-01-11|Estimate|2014-01-30|2014-03-14|Estimate||||2017-02-24|2017-03-28|Actual|March 2011||2011-03-31|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia|Terminated||Phase 3|1173|Actual|Merck Sharp & Dohme Corp.|MK-0524A-133 was stopped prior to completion. Raw individual efficacy data were obtained but none of planned efficacy outcomes were summarized or analyzed. Only safety data were summarized.|2||"In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a~   significant increase in incidence of some types of non-fatal SAEs"|f||||f||||||||||2018-05-31 22:58:47.272121|2018-05-31 22:58:47.272121
NCT01274546|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-08-06|2011-01-10|2011-01-11|Estimate|||||||2012-08-06|2012-08-07|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|||Long Term Foundation Knee Study|A Long-term, Multicenter Follow Up Study of the Cruciate-retaining Foundation Knee System|Completed|||43|Actual|Encore Medical, L.P.|||2||f||||f||||||||||2018-05-31 22:58:48.204013|2018-05-31 22:58:48.204013
NCT01274533|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2016-03-23||2016-04-21|2011-01-10|2011-01-11|Estimate|2016-03-23|2016-04-22|Estimate||||2016-04-21|2016-05-23|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Lenalidomide in HTLV-1 Adult T-Cell Leukemia|A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma|Completed||Phase 2|4|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 22:58:48.326394|2018-05-31 22:58:48.326394
NCT01274520|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2014-07-22|2011-01-10|2011-01-11|Estimate|||||||2014-07-22|2014-07-23|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|HMP2||Hypothermic Machine Preservation-Phase 2|Hypothermic Machine Preservation of Extended Criteria Liver Allografts for Transplantation|Completed||Phase 2|24|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 22:58:48.649033|2018-05-31 22:58:48.649033
NCT01274507|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2016-12-19|2011-01-10|2011-01-11|Estimate|||||||2016-12-19|2016-12-20|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease|A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease|Completed||Early Phase 1|328|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 22:58:48.745122|2018-05-31 22:58:48.745122
NCT01274494|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2013-09-10|2011-01-10|2011-01-11|Estimate|||||||2013-09-10|2013-09-11|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication|COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication|Completed|||1501|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 22:58:48.895491|2018-05-31 22:58:48.895491
NCT01274481|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-08-08|2011-01-10|2011-01-11|Estimate|||||||2012-08-08|2012-08-10|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Iloprost Effects on Gas Exchange and Pulmonary Mechanics|Effect of Iloprost on Gas Exchange and Pulmonary Mechanics in Patients With Pulmonary Hypertension and ARDS/ALI|Completed||Phase 1|20|Actual|University of Oklahoma||1|||f||||t||||||||||2018-05-31 22:58:48.97488|2018-05-31 22:58:48.97488
NCT01274468|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2012-08-08|2011-01-10|2011-01-11|Estimate|||||||2012-08-08|2012-08-10|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Tumor Markers in Lung Cancer|Tumor Markers in Lung Cancer|Completed|||10|Actual|University of Oklahoma|||||f||||f||||||Samples Without DNA|"~     Lung biopsy~   "|||2018-05-31 22:58:49.310432|2018-05-31 22:58:49.310432
NCT01274455|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2016-03-11|2011-01-10|2011-01-11|Estimate|||||||2016-03-11|2016-03-14|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|TherGAP||Gene Therapy of Pancreatic Ductal Adenocarcinoma|PILOT STUDY OF GENE THERAPY FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA WITH INTRATUMOURAL INJECTION OF JetPEI/DNA COMPLEXES WITH ANTITUMOURAL EFFECT AND CHEMOSENSITIZING ACTIVITY FOR GEMCITABINE|Completed||Phase 1|22|Actual|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 22:58:49.409292|2018-05-31 22:58:49.409292
NCT01274442|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2015-06-02|2011-01-10|2011-01-11|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Polymorphism||Impact of Genetic Polymorphisms on Dental Implant Loss|A Case-control Study on the Impact of Genetic Polymorphisms on Dental Implant Loss.|Unknown status|Recruiting|N/A|68|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 22:58:49.5153|2018-05-31 22:58:49.5153
NCT01274429|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|2017-01-21||2018-02-27|2011-01-10|2011-01-11|Estimate|2017-01-21|2017-03-10|Actual||||2018-02-27|2018-03-27|Actual|December 2010||2010-12-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults|Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults|Terminated||Phase 1/Phase 2|5|Actual|University of North Carolina, Chapel Hill|Early termination due to lack of funding prior to any subjects reaching the primary endpoint.|1||Lack of funding|f||||t||||||||No||2018-05-31 22:58:49.666058|2018-05-31 22:58:49.666058
NCT01274416|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2013-08-12|2011-01-10|2011-01-11|Estimate|||||||2013-08-12|2013-08-14|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|ASFT||Acceptance-Based Separated Family Treatment for Adolescent Anorexia Nervosa|Acceptance-Based Separated Family Treatment for Adolescent Anorexia Nervosa|Completed||N/A|75|Actual|Duke University|||||f||||t||||||||||2018-05-31 22:58:49.853039|2018-05-31 22:58:49.853039
NCT01274377|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2017-06-02|2011-01-10|2011-01-11|Estimate|||||||2017-06-02|2017-06-05|Actual|February 2011||2011-02-28|June 2017|2017-06-30|October 5, 2015|Actual|2015-10-05|February 23, 2015|Actual|2015-02-23||Interventional|||Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT|A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation|Terminated||Phase 1|5|Actual|Duke University||2|||f||||t||||||||||2018-05-31 22:58:50.143966|2018-05-31 22:58:50.143966
NCT01274364|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2015-03-04|2011-01-10|2011-01-11|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|China-JD||Establishing a Diabetes Registry Using the JADE-DIAMOND Electronic Portal (CN001)|China-JD Program: A Multi-centre Demonstration Project to Evaluate the Effectiveness and Acceptability of the Joint Asia Diabetes Evaluation (JADE) and DIAbetes MONitoring Database (DIAMOND) Programs in Asian Type 2 Diabetic Patients|Completed||N/A|3586|Actual|Asia Diabetes Foundation||2|||f||||t||||||||||2018-05-31 22:58:50.221349|2018-05-31 22:58:50.221349
NCT01274351|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2017-12-01|2011-01-10|2011-01-11|Estimate|||||||2017-12-01|2017-12-05|Actual|January 25, 2011|Actual|2011-01-25|December 2017|2017-12-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|A Phase II Multi-center, Open-label, Non-randomized Study of Nilotinib as First Line Treatment in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Active, not recruiting||Phase 2|112|Actual|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 22:58:50.297437|2018-05-31 22:58:50.297437
NCT01274338|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-08|||2018-05-24|2011-01-08|2011-01-11|Estimate|||||||2018-05-24|2018-05-25|Actual|May 25, 2011|Actual|2011-05-25|May 2018|2018-05-31||||May 1, 2020|Anticipated|2020-05-01||Interventional|||Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery|A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma|Active, not recruiting||Phase 3|1500|Anticipated|National Cancer Institute (NCI)||6|||f||||t||||||||||2018-05-31 22:58:50.50739|2018-05-31 22:58:50.50739
NCT01274325|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2013-09-09|2011-01-10|2011-01-11|Estimate|||||||2013-09-09|2013-09-11|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma|Comparison of Anti-inflammatory Effects of Seroflo 125 Inhaler With Seretide Evohaler(25/125) in Patients With Asthma|Completed||Phase 3|51|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 22:58:51.986852|2018-05-31 22:58:51.986852
NCT01274312|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-05-09|2011-01-10|2011-01-11|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Colorectal Transport|Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Colorectal Transport|Completed||N/A|10|Actual|University of Aarhus|||||f||||t||||||||||2018-05-31 22:58:52.082334|2018-05-31 22:58:52.082334
NCT01274299|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-01-09|2011-01-09|2011-01-11|Estimate|||||||2011-01-09|2011-01-11|Estimate|November 2010||2010-11-30|January 2011|2011-01-31|November 2012|Anticipated|2012-11-30|||||Observational|||Measurements of Facial Dimensions in Infants and Toddlers 0-4 Years of Age|Facial Dimensions in Infants and Toddlers|Unknown status|Recruiting||300|Anticipated|Ziv Hospital|||1||f||||f||||||||||2018-05-31 22:58:52.183472|2018-05-31 22:58:52.183472
NCT01274286|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2011-01-09|2011-01-09|2011-01-11|Estimate|||||||2011-01-09|2011-01-11|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|||||Observational|||Evaluation of the Effectiveness of the New Hospital Accreditation|Evaluation of the Effectiveness of the New Hospital Accreditation|Completed|||0|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 22:58:52.267194|2018-05-31 22:58:52.267194
NCT01274273|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2014-12-01|2011-01-10|2011-01-11|Estimate|||||||2014-12-01|2014-12-02|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer|A Randomized Phase II Trial of IL-2/IFN-α Plus Bevacizumab Versus IL-2/IFN-α in Metastatic Renal Cell Carcinoma (mRCC) - Danish Renal Cancer Group (DARENCA) Study-1|Unknown status|Active, not recruiting|Phase 2|118|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 22:58:52.330018|2018-05-31 22:58:52.330018
NCT01274260|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-09|||2014-05-23|2011-01-10|2011-01-11|Estimate|||||||2014-05-23|2014-05-28|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|January 2014|Actual|2014-01-31||Interventional|SPALIT||Trial of Steroids in Pediatric Acute Lung Injury/ARDS|Steroids in Pediatric Acute Lung Injury/ARDS Trial: A Blinded, Placebo-controlled, Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 22:58:52.446437|2018-05-31 22:58:52.446437
NCT01274247|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-08-01|2011-01-10|2011-01-11|Estimate|||||||2012-08-01|2012-08-02|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Use of Topical Benzocaine for Analgesia in Lingual Frenotomy of the Newborn|Time of Cry After Lingual Frenotomy in Infants With Lingual Frenulum and Breastfeeding Difficulties, With or Without Use of Topical Benzocaine Analgesia|Terminated||Phase 1/Phase 2|21|Actual|Tel-Aviv Sourasky Medical Center||2||"The study ethics committee recommended concluding the study for longer crying time with~   benzocaine and very short crying time in all participants."|f||||f||||||||||2018-05-31 22:58:52.531274|2018-05-31 22:58:52.531274
NCT01274234|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-02-27|2011-01-09|2011-01-11|Estimate|||||||2013-02-27|2013-02-28|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EGO-COMBO||OCT Evaluation of Healing of COMBO Stent|Evaluation of Neointimal Healing of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: the EGO-COMBO Pilot Study|Completed||Phase 1/Phase 2|61|Actual|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 22:58:52.605443|2018-05-31 22:58:52.605443
NCT01274221|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-01-18|2011-01-10|2011-01-11|Estimate|||||||2012-01-18|2012-01-20|Estimate|February 2011||2011-02-28|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 3b, Randomized, Double-blind, Multicenter, Placebo Controlled, Dose Optimization, Crossover, Analog Classroom, Safety and Efficacy Study of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD))|Withdrawn||Phase 3|0|Actual|Shire||2||Cancellation was not safety related but a shift in study priorities for Shire.|f||||f||||||||||2018-05-31 22:58:52.693512|2018-05-31 22:58:52.693512
NCT01274208|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2014-11-18|2011-01-10|2011-01-11|Estimate|||||||2014-11-18|2014-11-19|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Observational|||Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C|Enhanced HCV Nonstructural Protein 3 (NS3) -Specific T Cell Proliferation,Interferon γ (IFNγ) and Interleukin-10 (IL-10) Secreting Clones, and Peripheral Blood Natural Killers T Cells ( NKT Cells) in Patients With Type I Gaucher Disease Infected With HCV : An Advantage in Anti Hepatitis Immunity?|Unknown status|Recruiting||80|Anticipated|Shaare Zedek Medical Center|||1||f||||f||||||||||2018-05-31 22:58:52.760689|2018-05-31 22:58:52.760689
NCT01274195|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2013-11-17|2011-01-10|2011-01-11|Estimate|||||||2013-11-17|2013-11-19|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML|Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML|Unknown status|Recruiting|Phase 2|27|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 22:58:52.848099|2018-05-31 22:58:52.848099
NCT01274182|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2017-11-09|2016-12-14|2018-01-23|2011-01-10|2011-01-11|Estimate|2018-01-23|2018-01-24|Actual|2016-12-14|2016-12-15|Estimate|2018-01-23|2018-01-24|Actual|January 2011||2011-01-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|January 2016|Actual|2016-01-31||Interventional||Full Analysis Set|GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy|A Randomized, Double-blind, Controlled Study to Evaluate PK, PD, Safety and Efficacy of GP2013 and Rituximab in Patients With Rheumatoid Arthritis Refractory or Intolerant to Standard DMARDs and up to Three Anti-TNF Therapies.|Completed||Phase 1/Phase 2|312|Actual|Sandoz||3|||f||||t||||||||||2018-05-31 22:58:53.021054|2018-05-31 22:58:53.021054
NCT01274169|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|March 2008||2008-03-31|February 2008|2008-02-29|March 2010||2010-03-31|||||Observational|||Measurment of GFR by Nasal Sensors||Completed|||||Rambam Health Care Campus|||||f||||||||||||||2018-05-31 22:58:54.499832|2018-05-31 22:58:54.499832
NCT01274156|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|LI-ESWT||Double Blind Placebo Controlled Study on the Effect of Extracorporal Shock Wave Therapy on Erectile Dysfunction|The Effect of Low Intensity Shock Wave Therapy on Erectile Dysfunction in Patients Responding to PDE5i's|Completed||Phase 3|60|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 22:58:54.560979|2018-05-31 22:58:54.560979
NCT01274143|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2016-04-06|2011-01-07|2011-01-11|Estimate|||||||2016-04-06|2016-04-08|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Family CARE||Family Colorectal Cancer Awareness and Risk Education Project (Family CARE Project)|Impact of Remote Familial Colorectal Cancer Assessment and Counseling|Completed||N/A|496|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 22:58:54.64142|2018-05-31 22:58:54.64142
NCT01274130|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-05-10|2011-01-10|2011-01-11|Estimate|||||||2012-05-10|2012-05-11|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Investigatory Study of Metformin's Pharmacokinetics, Pharmacodynamics and Drug Drug Interactions Classifying the Group by MATE1 Genotype in Healthy Volunteers|Investigatory Study of Metformin's Pharmacokinetics, Pharmacodynamics and Drug Drug Interactions Classifying the Group by MATE1 Genotype in Healthy Volunteers|Completed||N/A|30|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 22:58:54.717317|2018-05-31 22:58:54.717317
NCT01274117|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2017-10-24|2011-01-10|2011-01-11|Estimate|||||||2017-10-24|2017-10-25|Actual|December 2010||2010-12-31|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Trial Comparing One-stage With Two-stage Basilic Vein Transposition|Randomized Trial Comparing Transposition of the Basilic Vein, for Vascular Access, Performed in One-stage Versus Two-stages|Terminated||N/A|16|Actual|University of Patras||2||"PRIMARY EFFICACY OUTCOME MEASURE (MATURATION) WAS SIGNIFICANT, IN FAVOR OF THE TW0-STAGE~   PROCEDURE"|f||||f||||||||||2018-05-31 22:58:54.774943|2018-05-31 22:58:54.774943
NCT01274104|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2015-04-21|2011-01-07|2011-01-11|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia|A Pilot Study on the Effect of Vitamin D Treatment in Patients With Statin-Associated Myalgia|Withdrawn||Phase 1|0|Actual|Avera McKennan Hospital & University Health Center||2||PI resigned.|f||||t||||||||||2018-05-31 22:58:54.832292|2018-05-31 22:58:54.832292
NCT01274091|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-04-16|2011-01-10|2011-01-11|Estimate|||||||2012-04-16|2012-04-17|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|Genediet||Gene - Diet Interactions|Gene-diet Interactions|Completed||N/A|30|Actual|University of Eastern Finland||2|||f||||f||||||||||2018-05-31 22:58:55.798752|2018-05-31 22:58:55.798752
NCT01274078|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2012-07-26|2011-01-10|2011-01-11|Estimate|||||||2012-07-26|2012-07-27|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Exercise With or Without Blueberries on Cardiovascular Risk Markers|Effects of Exercise With or Without Blueberries on Cardiovascular Risk Markers|Completed||N/A|32|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 22:58:55.878733|2018-05-31 22:58:55.878733
NCT01274065|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2015-01-13|2011-01-07|2011-01-11|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Outcomes|Developing an Interdisciplinary Pharmacogenomic Treatment Approach to Reduce Medication Burden and Improve Subject Outcomes|Completed|||38|Actual|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples With DNA|"~     saliva~   "|||2018-05-31 22:58:55.942158|2018-05-31 22:58:55.942158
NCT01274052|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Study of Postprandial Incretin Response in Women With Gestational Diabetes|Reduced Postprandial GLP-1 Response in Gestational Diabetes Mellitus: a Fully Reversible Phenomenon|Completed|||19|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||f||||||Samples Without DNA|"~     Blood Plasma~   "|||2018-05-31 22:58:56.032281|2018-05-31 22:58:56.032281
NCT01274039|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2013-04-12|2011-01-10|2011-01-11|Estimate|||||||2013-04-12|2013-04-15|Estimate|February 2009||2009-02-28|April 2013|2013-04-30|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Observational|||Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide|Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide. A Possible Pretreatment for Trabeculectomy Surgery.|Completed|||||University of Cologne|||1||f||||f||||||||||2018-05-31 22:58:56.098199|2018-05-31 22:58:56.098199
NCT01274026|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|January 2012|Anticipated|2012-01-31|August 2011|Anticipated|2011-08-31||Interventional|IST||Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders|"Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression in PKU Nonresponders to Kuvan® (Sapropterin Dihydrochloride)"|Unknown status|Recruiting|N/A|30|Anticipated|Tulane University School of Medicine|||||f||||f||||||||||2018-05-31 22:58:56.173174|2018-05-31 22:58:56.173174
NCT01274013|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2017-06-26|2011-01-07|2011-01-11|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2009||2009-10-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers|A Pilot Study on Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers|Suspended|||100|Anticipated|Avera McKennan Hospital & University Health Center|||2|Non Hep C study arm has been completed, Hep C study arm has not been completed.|f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 22:58:56.254551|2018-05-31 22:58:56.254551
NCT01274000|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2015-10-09|2011-01-07|2011-01-11|Estimate|||||||2015-10-09|2015-10-12|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients|Phase II Study of YM060 - Double-blind, Parallel-group Comparative Study in Patients (Female) With Diarrhea-predominant Irritable Bowel Syndrome|Completed||Phase 2|409|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 22:58:56.32249|2018-05-31 22:58:56.32249
NCT01273987|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study||Unknown status|Enrolling by invitation|Phase 2/Phase 3|70|Anticipated|Southwest Hospital, China||1|||f||||f||||||||||2018-05-31 22:58:56.50714|2018-05-31 22:58:56.50714
NCT01273974|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients|The Comparison of Serum Antibody Response to Standard Intramuscular and Half Dose Intradermal Influenza Vaccine in Hemodialysis Patients in Shiraz City in 1388.|Completed||Phase 2/Phase 3|130|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:58:56.583155|2018-05-31 22:58:56.583155
NCT01273961|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-02-08|2011-01-07|2011-01-11|Estimate|||||||2012-02-08|2012-02-09|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|||Study of Radiofrequency Device for Use in Non-Invasive Cosmetic Procedures|Radiofrequency Magnetic Induction Device for Use in Non-Invasive Body Contouring|Completed||N/A|20|Actual|Rocky Mountain Biosystems, Inc.|||||f||||f||||||||||2018-05-31 22:58:56.658881|2018-05-31 22:58:56.658881
NCT01273948|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-02-02|2011-01-10|2011-01-11|Estimate|||||||2012-02-02|2012-02-06|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection|A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection|Completed||Phase 1/Phase 2|66|Actual|Peregrine Pharmaceuticals||3|||f||||f||||||||||2018-05-31 22:58:56.720541|2018-05-31 22:58:56.720541
NCT01273935|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2010|Actual|2010-12-31|||||Observational|||Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke|Dose-Dependent Effect of Early Antiplatelet Therapy in Acute Ischemic Stroke|Completed|||400|Actual|Ruhr University of Bochum|||2||f||||f||||||||||2018-05-31 22:58:56.853276|2018-05-31 22:58:56.853276
NCT01273922|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-05-21|2011-01-07|2011-01-11|Estimate|||||||2012-05-21|2012-05-22|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida|Phase I Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections, Administered Intramuscular to Healthy Adults|Completed||Phase 1|40|Actual|NovaDigm Therapeutics, Inc.||2|||f||||||||||||||2018-05-31 22:58:56.970353|2018-05-31 22:58:56.970353
NCT01273909|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2014-06-04|2011-01-10|2011-01-11|Estimate|||||||2014-06-04|2014-06-06|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment|Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment|Unknown status|Enrolling by invitation||1000|Anticipated|The National Institute of Lymphology|||2||f||||f||||||||||2018-05-31 22:58:57.058723|2018-05-31 22:58:57.058723
NCT01273896|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2015-10-19||2015-10-19|2011-01-07|2011-01-11|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer|A Phase 2 Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer|Completed||Phase 2|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 22:58:57.153048|2018-05-31 22:58:57.153048
NCT01273883|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2015-01-07||2015-04-09|2011-01-10|2011-01-11|Estimate|2015-01-07|2015-01-14|Estimate||||2015-04-09|2015-04-30|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Trial of Magnesium Dependent Tinnitus|A Phase III Trial of Magnesium Dependent Tinnitus|Completed||Phase 3|38|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 22:58:57.338605|2018-05-31 22:58:57.338605
NCT01273870|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2011-02-01|2011-01-10|2011-01-11|Estimate|||||||2011-02-01|2011-02-02|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|||Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers|Post Marketing Surveillance Investigating Blood Compatibility Characteristics of Baxter Xenium+, Fresenius FX and Gambro Polyflux Dialyzers|Completed|||8|Actual|Praxisverbund Dialyse und Apherese|||||f||||f||||||||||2018-05-31 22:58:57.568916|2018-05-31 22:58:57.568916
NCT01273857|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2015-04-21||2015-06-12|2011-01-10|2011-01-11|Estimate|2015-06-12|2015-06-15|Estimate||||2015-06-12|2015-06-15|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|TICAP||Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single Ventricle Physiology|Phase I Study of Cardiac Progenitor Cell Therapy in Patients With Single Ventricle Physiology|Completed||Phase 1|14|Actual|Okayama University||2|||f||||t||||||||||2018-05-31 22:58:57.63129|2018-05-31 22:58:57.63129
NCT01273844|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2017-04-05|2011-01-10|2011-01-11|Estimate|||||||2017-04-05|2017-04-07|Actual|March 1, 2011|Actual|2011-03-01|April 2017|2017-04-30|May 12, 2016|Actual|2016-05-12|May 12, 2016|Actual|2016-05-12||Interventional|||Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)|Study of the Combination of Bortezomib and Dexamethasone Followed by HSCT in AL|Completed||N/A|21|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-05-31 22:58:57.96601|2018-05-31 22:58:57.96601
NCT01273831|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|||2011-01-10|2011-01-10|2011-01-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia|Study of Effects of Cisatracurium and Atracurium on Intraocular Pressure|Completed||Phase 2|90|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 22:58:58.060568|2018-05-31 22:58:58.060568
NCT01273818|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-10|2013-12-09||2014-12-17|2011-01-10|2011-01-11|Estimate|2014-12-17|2014-12-29|Estimate||||2014-12-17|2014-12-29|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||300 consequtive patients were diveded into three groups randomly, but during follow-up period since 24 patients used any kind of antibiotics for reasons other than postoperative complications, only 276 patients were analyzed.|Effectiveness of Topical Antibiotic Prophylaxis in Inguinal Hernia Repair|Is Topical Antibiotic Prophylaxis Effective in Lichtenstein Hernia Repair: a Comparison Study|Completed||Phase 4|276|Actual|Diskapi Teaching and Research Hospital||3|||f||||t||||||||||2018-05-31 22:58:58.184796|2018-05-31 22:58:58.184796
NCT01273805|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2017-04-11||2017-05-19|2011-01-07|2011-01-11|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|January 2011|Actual|2011-01-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional||The analysis dataset is comprised of all enrolled patients.|Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer|Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|20|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 22:58:58.513754|2018-05-31 22:58:58.513754
NCT01273792|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2018-01-24|2011-01-10|2011-01-11|Estimate|||||||2018-01-24|2018-01-25|Actual|May 2010||2010-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Investigation of Biomarkers in Susac Syndrome|Investigation of Relevant Biomarkers in Patients With Susac Syndrome|Recruiting|||30|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||Samples Without DNA|"~     Blood samples (serum, Blood cells)~   "|||2018-05-31 22:58:59.007292|2018-05-31 22:58:59.007292
NCT01273779|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-02-02|2011-01-10|2011-01-11|Estimate|||||||2012-02-02|2012-02-03|Estimate|June 2011||2011-06-30|February 2012|2012-02-29|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|OASIS||Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis|OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis|Suspended||Phase 2/Phase 3|1280|Anticipated|Agennix||2||Data Safety Monitoring Board recommendation|f||||t||||||||||2018-05-31 22:58:59.099107|2018-05-31 22:58:59.099107
NCT01273766|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2013-06-20||2017-12-22|2011-01-07|2011-01-10|Estimate|2013-11-05|2013-11-27|Estimate||||2017-12-22|2018-01-23|Actual|January 2011||2011-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|March 2012|Actual|2012-03-31||Interventional|||Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies|Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload|Completed||Phase 2|16|Actual|Wake Forest University Health Sciences|adverse events were only tracked on Arm I|3|||f||||t|t|f||||||||2018-05-31 22:58:59.328224|2018-05-31 22:58:59.328224
NCT01273753|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-12-01|2011-01-07|2011-01-10|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Intradialytic Exercise as Assessed by Bioimpedance Analysis and Blood Volume Monitoring|Using Bioimpedance Analysis and Blood Volume Monitoring to Assess the Impact of Intradialytic Exercise|Completed||N/A|17|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 22:59:00.253849|2018-05-31 22:59:00.253849
NCT01273740|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|January 1995||1995-01-31|January 2011|2011-01-31|June 1998|Actual|1998-06-30|June 1998|Actual|1998-06-30||Interventional|SWEXSUS||Swedish External Support Study|Swedish External Support Study is Randomized Trial of the Effect of External Support of PTFE-grafts for Bypass to Below Knee Arteries.|Completed||N/A|334|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 22:59:00.362611|2018-05-31 22:59:00.362611
NCT01273727|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2015-05-12|2011-01-07|2011-01-10|Estimate|||||||2015-05-12|2015-05-13|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Ozurdex for Macular Edema Post Membrane Peeling|Ozurdex in Treatment of Macular Edema Post Membrane Peeling|Completed||Phase 2/Phase 3|35|Actual|Retina Specialists, PC||3|||f||||t||||||||||2018-05-31 22:59:00.465319|2018-05-31 22:59:00.465319
NCT01273714|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|January 1999||1999-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2004|Actual|2004-12-31||Interventional|||Subtotal Versus Total Thyroidectomy for Benign Goiter|Subtotal Versus Total Thyroidectomy for Benign Thyroid Disease - a Prospective Case-control Surgical Outcome Study.|Completed||N/A|8006|Actual|Jagiellonian University||2|||f||||t||||||||||2018-05-31 22:59:00.54348|2018-05-31 22:59:00.54348
NCT01273701|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-10|Estimate|||||||2011-01-06|2011-01-10|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence|Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence|Unknown status|Not yet recruiting|N/A|60|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 22:59:00.618895|2018-05-31 22:59:00.618895
NCT01273688|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|EpiFlex||Eccentric Training With or Without Elbow Brace for Epicondylitis|Eccentric Training With Our Without Elbow Brace for Epicondylitis - a Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 3|90|Anticipated|Hannover Medical School||2|||f||||f||||||||||2018-05-31 22:59:00.707378|2018-05-31 22:59:00.707378
NCT01273675|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||||||Observational|||An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy|An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy|Unknown status|Active, not recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples Without DNA|"~     Serum and Urine~   "|||2018-05-31 22:59:00.818079|2018-05-31 22:59:00.818079
NCT01273662|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-02-07|2011-01-06|2011-01-10|Estimate|||||||2017-02-07|2017-02-09|Estimate|April 2011|Actual|2011-04-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma|Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma|Completed||Phase 2|45|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 22:59:00.865007|2018-05-31 22:59:00.865007
NCT01273649|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-05-27|2011-01-07|2011-01-10|Estimate|||||||2014-05-27|2014-05-29|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Therapeutic Effects of Cryotherapy on Arthrogenic Muscle Inhibition in Patients With Cruciate Ligament Reconstruction|Therapeutic Effects of Cryotherapy and Transcutaneous Nerves Stimulation on Arthrogenic Muscle Inhibition in Patients With Anterior Cruciate Ligament Reconstruction|Unknown status|Recruiting|N/A|30|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 22:59:00.939701|2018-05-31 22:59:00.939701
NCT01273636|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-01-06|2011-01-06|2011-01-10|Estimate|||||||2011-01-06|2011-01-10|Estimate|January 2005||2005-01-31|December 2010|2010-12-31|June 2011|Anticipated|2011-06-30|January 2006|Anticipated|2006-01-31||Observational|||Risk Factors for Concurrent Endometrial Carcinoma in Patients With a Curettage Diagnosis of Endometrial Hyperplasia|Concurrent Endometrial Cancer With Endometrial Hyperplasia or Endometrial Intraepithelial Neoplasia - Focus on Risk Factors Analysis|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 22:59:01.014462|2018-05-31 22:59:01.014462
NCT01273623|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2015-04-16||2015-10-19|2011-01-07|2011-01-10|Estimate|2015-04-16|2015-05-04|Estimate||||2015-10-19|2015-11-18|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Jetstream G3™ Calcium Study|A Prospective, Single-Arm Study to Evaluate the Effects of the Jetstream G3 System on Calcified Peripheral Vascular Lesions|Completed||Phase 4|55|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 22:59:01.11207|2018-05-31 22:59:01.11207
NCT01273610|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2018-02-16|2011-01-07|2011-01-10|Estimate|||||||2018-02-16|2018-02-19|Actual|April 2011||2011-04-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer|Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 2|40|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 22:59:01.338992|2018-05-31 22:59:01.338992
NCT01273597|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2012-11-21||2013-01-11|2011-01-07|2011-01-10|Estimate|2012-11-21|2012-12-21|Estimate||||2013-01-11|2013-01-18|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands|Post-marketing Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Paricalcitol i.v. in the Treatment of Chronic Kidney Disease (CKD) 5 Stage Patients With (Severe) Secondary Hyperparathyroidism in Hungary|Completed|||60|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:59:01.442646|2018-05-31 22:59:01.442646
NCT01273584|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2016-01-21|2011-01-07|2011-01-10|Estimate|||||||2016-01-21|2016-01-22|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|MOP||Metformin in Obese Non-diabetic Pregnant Women|Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?|Completed||Phase 2/Phase 3|450|Actual|Epsom and St Helier University Hospitals NHS Trust||2|||f||||t||||||||No||2018-05-31 22:59:01.906061|2018-05-31 22:59:01.906061
NCT01273571|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2013-07-26|2011-01-07|2011-01-10|Estimate|||||||2013-07-26|2013-07-29|Estimate|December 2010||2010-12-31|July 2013|2013-07-31|February 2011|Actual|2011-02-28|||||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers|An Open-Label, Fixed Sequence Study to Investigate the Potential for Pharmacokinetic and Pharmacodynamic Interaction Between Single-Dose Metformin and Multiple-Dose Canagliflozin in Healthy Subjects|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 22:59:02.117273|2018-05-31 22:59:02.117273
NCT01273558|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2013-04-19|2011-01-07|2011-01-10|Estimate|||||||2013-04-19|2013-04-22|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|||||Interventional|||A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus|An Open-Label Study to Compare Two Methods for Determining the Renal Threshold for Glucose in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|28|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 22:59:02.178282|2018-05-31 22:59:02.178282
NCT01273545|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2014-04-07|2011-01-07|2011-01-10|Estimate|||||||2014-04-07|2014-04-08|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|||||Observational|||PRILIGY Usage Patterns in Selected Populations|PRILIGY Usage Patterns in Selected Populations|Completed|||3000|Actual|Janssen Research & Development, LLC|||1||f||||f||||||||||2018-05-31 22:59:02.484351|2018-05-31 22:59:02.484351
NCT01273532|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-03-12|2011-01-07|2011-01-10|Estimate|||||||2012-03-12|2012-03-13|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|||||Interventional|||A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 50-mg Extended-Release, Tamper-Resistant Formulation (TRF) Tablets Relative to One 100-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects|Completed||Phase 1|30|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 22:59:02.63999|2018-05-31 22:59:02.63999
NCT01273519|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2014-01-09||2014-02-25|2011-01-07|2011-01-10|Estimate|2014-01-09|2014-02-24|Estimate||||2014-02-25|2014-03-26|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab|Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab|Completed|||155|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 22:59:02.885489|2018-05-31 22:59:02.885489
NCT01273350|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2014-07-30|2011-01-07|2011-01-10|Estimate|||||||2014-07-30|2014-07-31|Estimate|October 2004||2004-10-31|July 2014|2014-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Prospective, Non-Randomized, Evaluation of Low-Risk Patients Undergoing Carotid Stenting With ANgiomax (Bivalirudin)|Physician I.D.E. G#040160; Low Risk Carotid Stenting Study Using Bivalirudin at PinnacleHealth Hospitals and Holy Spirit Hospital|Unknown status|Recruiting|N/A|154|Anticipated|SPSI d.b.a Capital Cardiovascular Associates||1|||f||||t||||||||||2018-05-31 22:59:04.863386|2018-05-31 22:59:04.863386
NCT01273506|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-03-12|2011-01-07|2011-01-10|Estimate|||||||2012-03-12|2012-03-13|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|||||Interventional|||A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 25-mg Extended-Release Tamper-Resistant Formulation (TRF) Tablets Relative to One 50-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects|Completed||Phase 1|30|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 22:59:03.866814|2018-05-31 22:59:03.866814
NCT01273493|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2016-02-12|2011-01-07|2011-01-10|Estimate|||||||2016-02-12|2016-02-15|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction|An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction|Completed||Phase 1|15|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 22:59:03.942284|2018-05-31 22:59:03.942284
NCT01273480|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2014-11-24|2011-01-07|2011-01-10|Estimate|||||||2014-11-24|2014-11-25|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies|An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 22:59:04.043831|2018-05-31 22:59:04.043831
NCT01273467|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2014-03-16|2011-01-07|2011-01-10|Estimate|||||||2014-03-16|2014-03-18|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|||||Interventional|||A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)|A Randomized, Double-Blind, Placebo-Controlled Ascending Single-Dose Study of the Intravenous Infusion of CNTO 0007 in Subjects Who Have Experienced Ischemic Cerebral Infarction|Completed||Phase 1|13|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 22:59:04.135552|2018-05-31 22:59:04.135552
NCT01273454|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2013-09-03|2011-01-07|2011-01-10|Estimate|||||||2013-09-03|2013-09-04|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||An Observational Study to Investigate Clinical Usefulness of OROS Hydromorphone in Korean Cancer Patients|An Open-label, Multi-center, Non-interventional Study to Investigate Clinical Usefulness of Hydromorphone OROS in Korean Cancer Patients|Completed|||648|Actual|Janssen Korea, Ltd., Korea|||1||f||||||||||||||2018-05-31 22:59:04.208702|2018-05-31 22:59:04.208702
NCT01273441|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-12-05|2011-01-07|2011-01-10|Estimate|||||||2011-12-05|2011-12-06|Estimate|December 2010||2010-12-31|December 2011|2011-12-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|||Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice|Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice|Unknown status|Recruiting|Phase 4|400|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||2|||f||||f||||||||||2018-05-31 22:59:04.280782|2018-05-31 22:59:04.280782
NCT01273428|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2012-09-10|2011-01-07|2011-01-10|Estimate|||||||2012-09-10|2012-09-12|Estimate||||January 2011|2011-01-31|November 2011|Anticipated|2011-11-30|June 2011|Anticipated|2011-06-30||Interventional|||HP011-101, HP828-101, and Standard Care for Pressure Ulcers|Comparison of HP011-101, HP828-101, and Standard Care in the Management of Stage I-II Pressure Ulcers in Patients With Spinal Cord Injury|Withdrawn||Phase 2|0|Actual|Healthpoint||3||The device test article is no longer available|f||||f||||||||||2018-05-31 22:59:04.396429|2018-05-31 22:59:04.396429
NCT01273415|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-04-27|2011-01-07|2011-01-10|Estimate|||||||2017-04-27|2017-05-01|Actual|August 2010|Actual|2010-08-31|April 2017|2017-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer|Usefulness of Ki67 Proliferative Index to Predict Recurrence and Benefit From Adjuvant Chemotherapy in Hormone Receptor (HR)-Positive Breast Cancer|Completed|||1070|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 22:59:04.457266|2018-05-31 22:59:04.457266
NCT01273402|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-09-24|2011-01-07|2011-01-10|Estimate|||||||2012-09-24|2012-09-25|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|August 2018|Anticipated|2018-08-31|February 2013|Anticipated|2013-02-28||Interventional|||Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer|Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide|Terminated||Phase 1|30|Anticipated|Immunomedics, Inc.||1||A new study is being designed. No patients were enrolled.|f||||f||||||||||2018-05-31 22:59:04.517277|2018-05-31 22:59:04.517277
NCT01273389|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07||2014-07-14|2016-02-25|2011-01-07|2011-01-10|Estimate||||2014-07-14|2014-07-16|Estimate|2016-02-25|2016-03-24|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment With CNTO 136 Administered Intravenously in Subjects With Active Lupus Nephritis|Completed||Phase 2|25|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 22:59:04.593387|2018-05-31 22:59:04.593387
NCT01273376|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2013-11-18|2011-01-06|2011-01-10|Estimate|||||||2013-11-18|2013-11-19|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|MDD||Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study of RX-10100 in Subjects With Major Depressive Disorder.|Completed||Phase 2|314|Actual|Rexahn Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 22:59:04.700151|2018-05-31 22:59:04.700151
NCT01273363|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-02-27|2011-01-07|2011-01-10|Estimate|||||||2012-02-27|2012-02-28|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|NIKA||Non-interventional Retrospective Multicenter Study of Patients With Bronchial Asthma During a Routine Visit to Out of Patients' Clinics|Non-interventional Retrospective Multicenter Study of Patients With Bronchial Asthma During a Routine Visit to Out of Patients' Clinics|Completed|||1000|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 22:59:04.806992|2018-05-31 22:59:04.806992
NCT01272986|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-03-06|2011-01-07|2011-01-10|Estimate|||||||2011-03-06|2011-03-08|Estimate|January 2011||2011-01-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|OP512011||Trial of Screening for ALOA-IgG AtheroAbzyme Test|Trial of Screening for ALOA-IgG AtheroAbzyme Test Comparing Healthy,Asymptomatic Myocardial Ischemic and Acute Coronary Syndrome Patients|Completed||Phase 3|100|Anticipated|Omicron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 22:59:09.161565|2018-05-31 22:59:09.161565
NCT01273337|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-01-14|2011-01-07|2011-01-10|Estimate|||||||2014-01-14|2014-01-16|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|July 2014|Anticipated|2014-07-31||Interventional|||Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects|A Phase 2 Randomized, Controlled Study With a Phase 1 Safety Cohort Testing ALD-401 Derived From Autologous Bone Marrow Delivered Via Intracarotid Infusion in Subjects With Ischemic Stroke With Blinded Assessments|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Aldagen||2|||f||||t||||||||||2018-05-31 22:59:04.937294|2018-05-31 22:59:04.937294
NCT01273324|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-01-30|2011-01-07|2011-01-10|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2011||2011-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2016|Actual|2016-07-31||Observational|||Radiostereometric Analysis (RSA) and DEXA to Evaluate Fixation and Wear of the Restoration ADM Acetabular System|Prospective Clinical Study Using Radiostereometric Analysis (RSA) and DEXA to Evaluate Fixation and Wear of the Restoration ADM Acetabular System|Active, not recruiting|||30|Anticipated|Dalhousie University|||1||f||||f||||||||||2018-05-31 22:59:05.011511|2018-05-31 22:59:05.011511
NCT01273311|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-04-04|2011-01-07|2011-01-10|Estimate|||||||2018-04-04|2018-04-05|Actual|December 22, 2010||2010-12-22|February 18, 2014|2014-02-18|February 18, 2014||2014-02-18|||||Observational|||CARDIA Brain MRI Substudy|Contribution of Diabetes and Its Causes to Signs of Brain Aging in a Young-to-Middle Age Cohort|Completed|||719|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:59:05.15368|2018-05-31 22:59:05.15368
NCT01273298|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2011-06-22|2011-01-07|2011-01-10|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2008||2008-06-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Effects of Cardioselective β-blockers on Dynamic Hyperinflation in COPD|Effects of Cardioselective Beta-blockers on Dynamic Hyperinflation in Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|27|Actual|Laval University||2|||f||||f||||||||||2018-05-31 22:59:05.219985|2018-05-31 22:59:05.219985
NCT01273285|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|April 2009||2009-04-30|January 2011|2011-01-31||||March 2010|Actual|2010-03-31||Interventional|||Reproducibility of Nerve Fiber Layer Thickness Measurements in Patients With Glaucoma and Healthy Controls Using Spectral-Domain and Time-Domain OCT||Terminated||Phase 4|50|Actual|University of Zurich|||||f||||||||||||||2018-05-31 22:59:05.30496|2018-05-31 22:59:05.30496
NCT01273272|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2017-11-01|2011-01-07|2011-01-10|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2011||2011-02-28|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|CBTAC||Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers|Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial|Completed||Phase 2|50|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 22:59:05.362449|2018-05-31 22:59:05.362449
NCT01273259|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||March 2011|Anticipated|2011-03-31||Interventional|||Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults|Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults. Phase 2 Trial|Unknown status|Not yet recruiting|Phase 2|8|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 22:59:05.455991|2018-05-31 22:59:05.455991
NCT01273246|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-07-21|2011-01-07|2011-01-10|Estimate|||||||2011-07-21|2011-07-25|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children|A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children.|Completed||Phase 1|132|Actual|Sinovac Biotech Co., Ltd||10|||f||||t||||||||||2018-05-31 22:59:05.545577|2018-05-31 22:59:05.545577
NCT01273233|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2013-03-13|2011-01-07|2011-01-10|Estimate|||||||2013-03-13|2013-03-15|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults|A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults|Completed||Phase 1|36|Actual|Sinovac Biotech Co., Ltd||4|||f||||t||||||||||2018-05-31 22:59:05.629353|2018-05-31 22:59:05.629353
NCT01273220|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-05-18|2011-01-07|2011-01-10|Estimate|||||||2018-05-18|2018-05-21|Actual|January 7, 2011||2011-01-07|August 10, 2017|2017-08-10||||||||Observational|||National Epidemiologic Survey on Alcohol and Related Conditions-III|National Epidemiologic Survey on Alcohol and Related Conditions -III|Completed|||36309|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:59:05.717215|2018-05-31 22:59:05.717215
NCT01273207|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-05-26|2011-01-07|2011-01-10|Estimate|||||||2018-05-26|2018-05-30|Actual|February 1, 2011||2011-02-01|May 21, 2018|2018-05-21|June 30, 2025|Anticipated|2025-06-30|June 30, 2025|Anticipated|2025-06-30||Interventional|||Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans|Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans|Recruiting||Phase 2|78|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:59:05.785094|2018-05-31 22:59:05.785094
NCT01273194|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2017-10-05|2011-01-07|2011-01-10|Estimate|||||||2017-10-05|2017-10-06|Actual|December 20, 2010||2010-12-20|September 8, 2015|2015-09-08|September 8, 2015||2015-09-08|||||Observational|||Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents|Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents|Completed|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:59:05.869764|2018-05-31 22:59:05.869764
NCT01273181|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2013-02-14||2015-10-06|2011-01-07|2011-01-10|Estimate|2013-02-14|2013-03-27|Estimate||||2015-10-06|2015-10-28|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes|Phase I/II Study of Metastatic Cancer That Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes|Terminated||Phase 1/Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||t||||||||||2018-05-31 22:59:05.955226|2018-05-31 22:59:05.955226
NCT01273168|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-05-17|2011-01-07|2011-01-10|Estimate|||||||2018-05-17|2018-05-18|Actual|January 7, 2011||2011-01-07|March 19, 2018|2018-03-19|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Endoxifen in Adults With Hormone Receptor Positive Solid Tumors|Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors|Active, not recruiting||Phase 1|40|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:59:06.598751|2018-05-31 22:59:06.598751
NCT01273155|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-04-04|2011-01-07|2011-01-10|Estimate|||||||2018-04-04|2018-04-05|Actual|January 10, 2011||2011-01-10|January 3, 2018|2018-01-03|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction|A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction|Completed||Phase 1|72|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 22:59:06.680432|2018-05-31 22:59:06.680432
NCT01273142|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Observational|||Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection|A Prospective, Open-label 96-week Observational Pilot Study to Compare the Safety of Efavirenz Versus Nevirapine (Each in Combination With Zidovudine and Lamivudine or Tenofovir and Lamivudine) in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection.|Unknown status|Not yet recruiting||100|Anticipated|Henan Provincial Hospital|||||f||||f||||||||||2018-05-31 22:59:06.751803|2018-05-31 22:59:06.751803
NCT01273129|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-04-03|2011-01-07|2011-01-10|Estimate|||||||2018-04-03|2018-04-04|Actual|December 7, 2010||2010-12-07|April 2, 2018|2018-04-02||||||||Observational|||Surgery as a Treatment for Medically Intractable Epilepsy|Surgery as a Treatment for Medically Intractable Epilepsy|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:59:06.797086|2018-05-31 22:59:06.797086
NCT01273116|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-01-21|2011-01-07|2011-01-10|Estimate|||||||2013-01-21|2013-01-23|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|CWSInHosp||In Hospital Care and Welfare Standard|Towards an In Hospital CARE AND WELFARE STANDARD for Frail Elderly|Completed||N/A|404|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 22:59:06.85326|2018-05-31 22:59:06.85326
NCT01273103|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-05-15|2011-01-06|2011-01-10|Estimate|||||||2014-05-15|2014-05-19|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|February 2011|Anticipated|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects|An Open Label, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 200 mg, Administered as an Oral Suspension to Healthy Adult Subjects|Withdrawn||Phase 1|0|Actual|ViiV Healthcare||1||GSK2248761 development program is on clinical hold.|f||||f||||||||||2018-05-31 22:59:06.934702|2018-05-31 22:59:06.934702
NCT01273090|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2014-01-29|2011-01-07|2011-01-10|Estimate|||||||2014-01-29|2014-01-30|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma|A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children With Refractory or Recurrent Solid Tumors and Lymphomas|Completed||Phase 1|34|Actual|Children's Oncology Group||1|||f||||||||||||||2018-05-31 22:59:07.006642|2018-05-31 22:59:07.006642
NCT01273077|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Observational|||Evaluation of Universal Rotavirus Vaccination Program|Evaluation of Universal Rotavirus Vaccination Program|Unknown status|Recruiting||10000|Anticipated|Dalhousie University|||6||f||||f||||||||||2018-05-31 22:59:07.100126|2018-05-31 22:59:07.100126
NCT01273064|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2012-03-29||2012-06-04|2011-01-07|2011-01-10|Estimate|2012-04-26|2012-05-30|Estimate||||2012-06-04|2012-06-11|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders|Terminated||Phase 2|114|Actual|Conatus Pharmaceuticals Inc.|This study was terminated early after 3 reports of hyperbilirubinemia occurred(2 on 60mg bid and 1 on 30mg bid of CTS 1027). Two incidents were reported as part of an SAE. The risk/benefit ratio did not warrant further continuation of the study.|4||Risk-benefit ratio|f||||t||||||||||2018-05-31 22:59:07.193477|2018-05-31 22:59:07.193477
NCT01273051|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-04-13|2011-01-07|2011-01-10|Estimate|||||||2017-04-13|2017-04-14|Actual|November 2010||2010-11-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2012|Actual|2012-08-31||Interventional|CARTS||Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer|CHEMORADIOTHERAPY FOR RECTAL CANCER IN THE DISTAL RECTUM FOLLOWED BY ORGANSPARING TRANSANAL ENDOSCOPIC MICROSURGERY: CARTS Study CApecitabine, Radiotherapy and Tem Surgery. A PHASE II, FEASIBILITY TRIAL|Completed||Phase 2|55|Actual|Radboud University|||||f||||t||||||||||2018-05-31 22:59:08.545818|2018-05-31 22:59:08.545818
NCT01273038|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2012-01-09||2013-02-22|2011-01-07|2011-01-10|Estimate|2013-02-22|2013-04-01|Estimate||||2013-02-22|2013-04-01|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Clinical Investigation for New Filter to Ostomy Bags|Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags|Completed||N/A|20|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 22:59:08.636353|2018-05-31 22:59:08.636353
NCT01273025|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|LimePKphase1||Lime Powder Regimen in Healthy Volunteers|Medicinal Effect of Lime Powder Regimen in HK-2 Cell Exposed to Lithogenic Crystals and Its Citraturic and Antioxidative Responses in Healthy Volunteers|Unknown status|Enrolling by invitation|Phase 1|15|Actual|Chulalongkorn University|||||f||||t||||||||||2018-05-31 22:59:08.813627|2018-05-31 22:59:08.813627
NCT01273012|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-07-28|2011-01-07|2011-01-10|Estimate|||||||2011-07-28|2011-08-01|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|infloran||Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital|Cost-effectiveness of Infloran (TM) in Treating Acute Childhood Diarrhea in Phramongkutklao Hospital|Unknown status|Recruiting|N/A|128|Anticipated|Phramongkutklao College of Medicine and Hospital||2|||f||||f||||||||||2018-05-31 22:59:08.872564|2018-05-31 22:59:08.872564
NCT01272999|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2014-09-10|2011-01-07|2011-01-10|Estimate|||||||2014-09-10|2014-09-12|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Impact of Prevnar 13 on Ear Infections in Children|Postmarketing Observational Study Of The Impact Of Prevnar 13 (Pneumococcal 13 Valent Conjugate Vaccine) On Otitis Media In Children|Completed|||391|Actual|Pfizer|||1||f||||f||||||None Retained|"~     Microbiology samples (middle ear fluid) taken by treating physicians in standard course of~     care for ear infections.~   "|||2018-05-31 22:59:09.062175|2018-05-31 22:59:09.062175
NCT01272973|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2015-02-20|2011-01-07|2011-01-10|Estimate|||||||2015-02-20|2015-02-23|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects|Completed||Phase 1|96|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 22:59:09.229766|2018-05-31 22:59:09.229766
NCT01272960|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2016-05-16||2017-10-24|2011-01-07|2011-01-10|Estimate|2017-10-24|2017-12-02|Actual||||2017-10-24|2017-12-02|Actual|October 2010||2010-10-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MISTIC||Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial|Randomized, Open-label, Controlled Trial of Immediate Postpartum Versus Interval Insertion of Mirena to Increase the Usage at 6 Months After Delivery|Completed||N/A|53|Actual|Washington University School of Medicine|Inability to recruit and randomize our target sample size, to detect rare adverse events that may be associated with immediate insertion, women randomized to immediate insertion were more likely to return for their 6-month string check visit.|2|||f||||f||||||||||2018-05-31 22:59:09.32055|2018-05-31 22:59:09.32055
NCT01272947|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2012-07-17||2012-12-06|2011-01-07|2011-01-10|Estimate|2012-12-06|2013-01-10|Estimate||||2012-12-06|2013-01-10|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects With Acute Blunt Soft Tissue Injuries/Contusions of the Limbs|Completed||Phase 3|204|Actual|Novartis||2|||f||||f||||||||||2018-05-31 22:59:09.603388|2018-05-31 22:59:09.603388
NCT01272934|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2012-08-07||2013-01-15|2011-01-07|2011-01-10|Estimate|2012-12-06|2013-01-15|Estimate||||2013-01-15|2013-01-24|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain|Completed||Phase 3|205|Actual|Novartis||2|||f||||||||||||||2018-05-31 22:59:09.8267|2018-05-31 22:59:09.8267
NCT01272921|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2013-09-30||2017-03-08|2011-01-07|2011-01-10|Estimate|2014-02-04|2014-03-21|Estimate||||2017-03-08|2017-04-06|Actual|November 2010||2010-11-30|March 2017|2017-03-31||||August 2012|Actual|2012-08-31||Interventional|||The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block|A Dose Response Study for Duration of Analgesia Using Bupivacaine and Ropivacaine for Infragluteal Parabiceps Sciatic Block|Completed||Phase 4|142|Actual|Northwestern University|We used 5-mL increments of local anesthetic w/epinephrine between 5-30 mL which may have prevented from identifying more precisely the volume at which onset/duration were similar.|2|||f||||f||||||||||2018-05-31 22:59:10.029353|2018-05-31 22:59:10.029353
NCT01272908|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2014-05-12||2017-07-06|2011-01-07|2011-01-10|Estimate|2014-07-08|2014-08-05|Estimate||||2017-07-06|2017-08-15|Actual|July 18, 2006|Actual|2006-07-18|June 2017|2017-06-30|March 12, 2009|Actual|2009-03-12|March 12, 2009|Actual|2009-03-12||Interventional||Intent-to-Treat (ITT) Population: all participants who recieved any amount of infused medication whether or not they completed any further assessment.|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)|Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)|Completed||Phase 3|120|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-05-31 22:59:10.309733|2018-05-31 22:59:10.309733
NCT01272895|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-02-27|2011-01-07|2011-01-10|Estimate|||||||2013-02-27|2013-02-28|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|EGO||OCT Evaluation of Early Healing of EPC Capturing (GENOUS) Stent (EGO Study)|Evaluation of Endothelial Progenitor Cell (EPC) Capturing (GENOUS) Stent After Coronary Stenting Utilizing Optical Coherence Tomography (OCT): the EGO Study|Completed||Phase 4|53|Actual|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 22:59:11.156126|2018-05-31 22:59:11.156126
NCT01272882|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2012-10-31||2017-04-27|2011-01-07|2011-01-10|Estimate|2012-12-04|2013-01-07|Estimate||||2017-04-27|2017-05-25|Actual|May 2010||2010-05-31|April 2017|2017-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Electrical Impedance Tomography (EIT) Monitoring in Adults With ALI or ARDS|Electrical Impedance Tomography (EIT) Monitoring: A Pilot Comparison to Standard of Care Assessments in Adults With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)|Completed||N/A|13|Actual|Christiana Care Health Services||1|||f||||f||||||||No|IPD data will not be shared|2018-05-31 22:59:11.234327|2018-05-31 22:59:11.234327
NCT01272869|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2012-01-09||2012-11-29|2011-01-07|2011-01-10|Estimate|2012-11-29|2012-12-31|Estimate||||2012-11-29|2012-12-31|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags|Clinical Investigation of Filter Improvement for New Filter to Ostomy Bags|Completed||N/A|20|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 22:59:11.382736|2018-05-31 22:59:11.382736
NCT01272856|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-08-03|2011-01-07|2011-01-10|Estimate|||||||2012-08-03|2012-08-07|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study on the Safety of Abatacept in Relapsing Polychondritis|An Open-Label, Single-Center, Phase I Study on the Safety of Abatacept in Relapsing Polychondritis|Completed||Phase 1|4|Actual|Benaroya Research Institute||1|||f||||f||||||||||2018-05-31 22:59:11.562484|2018-05-31 22:59:11.562484
NCT01272843|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|January 2015|Anticipated|2015-01-31|March 2014|Anticipated|2014-03-31||Observational|||Physiological Magnetic Resonance Imaging (MRI) to Improve Carotid Endarterectomy Outcomes||Unknown status|Not yet recruiting||50|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||t||||||||||2018-05-31 22:59:11.627202|2018-05-31 22:59:11.627202
NCT01272830|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2017-07-19||2018-01-29|2011-01-06|2011-01-10|Estimate|2018-01-29|2018-01-31|Actual||||2018-01-29|2018-01-31|Actual|October 2010||2010-10-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|Apatone-B||Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements|A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties|Completed||Phase 2|57|Actual|IC-MedTech Corporation|limited accrual due to meeting stringent study inclusion/exclusion criteria.Stringent inclusion/exclusion created to allow SEB analyses w/o interference or artifacts,& not due to study drug issues,interaction or limitations.|2|||f||||t||||||||No||2018-05-31 22:59:11.702329|2018-05-31 22:59:11.702329
NCT01272817|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2013-12-05|2011-01-07|2011-01-10|Estimate|||||||2013-12-05|2013-12-06|Estimate|October 2001||2001-10-31|December 2013|2013-12-31||||January 2015|Anticipated|2015-01-31||Interventional|Mini-allo||Nonmyeloablative Allogeneic Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation|Unknown status|Recruiting|N/A|50|Anticipated|Scripps Health||2|||f||||f||||||||||2018-05-31 22:59:12.092036|2018-05-31 22:59:12.092036
NCT01272804|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2016-12-06||2016-12-06|2011-01-06|2011-01-10|Estimate|2016-12-06|2017-02-01|Estimate||||2016-12-06|2017-02-01|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Safety analysis set included all participants who received at least 1 dose of study medication.|Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes|A Phase 1 Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-04937319 In Adult Patients With Type 2 Diabetes Mellitus (t2dm)|Completed||Phase 1|61|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:59:12.224434|2018-05-31 22:59:12.224434
NCT01272791|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03||2017-04-18|2017-04-18|2011-01-07|2011-01-10|Estimate||||2017-04-18|2017-04-19|Actual|2017-04-18|2017-04-19|Actual|January 2011||2011-01-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer|A Randomized, Open-Label, Phase 2 Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer|Completed||Phase 2|70|Actual|Peregrine Pharmaceuticals||2|||f||||f||||||||||2018-05-31 22:59:13.601925|2018-05-31 22:59:13.601925
NCT01272778|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-07|2011-01-07|2011-01-10|Estimate|||||||2011-01-07|2011-01-10|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)|Acute Effect of Four Doses of Lorazepam on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction™ Test|Unknown status|Recruiting|N/A|16|Anticipated|Orasi Medical, Inc.||5|||f||||f||||||||||2018-05-31 22:59:13.700358|2018-05-31 22:59:13.700358
NCT01272765|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-05-31|2011-01-06|2011-01-10|Estimate|||||||2012-05-31|2012-06-01|Estimate|March 2012||2012-03-31|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Anti-psychotic Medication (Stable Dose) Weight Loss Study|Surveillance Study of Weight Response and Body Composition in Subjects Taking a Stable Dose of Risperdal, Seroquel, and/or Zyprexa for Greater Than 3 Months in Combination With 500 mg IHBG-10 TID|Withdrawn||Phase 2|0|Actual|Avera McKennan Hospital & University Health Center||4||Study did not get started.|f||||t||||||||||2018-05-31 22:59:13.767708|2018-05-31 22:59:13.767708
NCT01272752|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-05-31|2011-01-06|2011-01-10|Estimate|||||||2012-05-31|2012-06-01|Estimate|April 2013||2013-04-30|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Anti-psychotic Medication (New Use) Weight Loss Study|Surveillance Study of Weight Response and Body Composition in Subjects Who Are First-Time Users (Less Than 3 Months) of the Following Medications: Risperdal, Seroquel, and/or Zyprexa, in Combination With 500 mg IHBG-10 TID|Withdrawn||Phase 2|0|Actual|Avera McKennan Hospital & University Health Center||2||Study did not get started.|f||||t||||||||||2018-05-31 22:59:13.835591|2018-05-31 22:59:13.835591
NCT01272739|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-10-04|2011-01-06|2011-01-10|Estimate|||||||2011-10-04|2011-10-06|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Randomized Study to Evaluate the Effect of an Investigational Product on Weight Loss and Body Composition|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of IHBG-10 on Weight Loss and Body Composition|Completed||Phase 2|10|Actual|Avera McKennan Hospital & University Health Center||2|||f||||t||||||||||2018-05-31 22:59:13.906392|2018-05-31 22:59:13.906392
NCT01272726|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-05-31|2011-01-07|2011-01-10|Estimate|||||||2012-05-31|2012-06-01|Estimate|March 2009||2009-03-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Influence of Education on Acceptance of Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Among Women|Influence of Education on Acceptance of Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Among Women|Completed|||60|Actual|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples With DNA|"~     saliva~   "|||2018-05-31 22:59:14.051922|2018-05-31 22:59:14.051922
NCT01272713|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2014-05-06|2011-01-07|2011-01-10|Estimate|||||||2014-05-06|2014-05-07|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|August 2014|Anticipated|2014-08-31|January 2014|Actual|2014-01-31||Interventional|AVOID||Air Verses Oxygen In myocarDial Infarction Study|A Randomised Controlled Trial of Oxygen Therapy in Acute Myocardial Infarction (AVOID - Air Verses Oxygen In myocarDial Infarction Study)|Unknown status|Active, not recruiting|N/A|638|Actual|Bayside Health||2|||f||||t||||||||||2018-05-31 22:59:14.120739|2018-05-31 22:59:14.120739
NCT01272700|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-02-02|2011-01-07|2011-01-10|Estimate|||||||2012-02-02|2012-02-03|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effect of Pressure Controlled Ventilation on the Pulmonary Mechanics in Prone Position Using the Wilson Frame: A Comparison With Volume Controlled Ventilation|The Effect of Pressure Controlled Ventilation on the Pulmonary Mechanics in Prone Position Using the Wilson Frame: A Comparison With Volume Controlled Ventilation|Completed||N/A|40|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 22:59:14.214803|2018-05-31 22:59:14.214803
NCT01272687|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2018-05-18|2011-01-07|2011-01-10|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2011|Actual|2011-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PadGau||Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation|Epidemiological Study to Determine Mutations in the Gaucher Gene in Patients With Idiopathic Parkinson's Disease for Phenotype-genotype Correlation|Recruiting|||1500|Anticipated|University of Rostock|||1||f||||t||||||||||2018-05-31 22:59:14.287084|2018-05-31 22:59:14.287084
NCT01272674|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2015-06-01|2011-01-07|2011-01-10|Estimate|||||||2015-06-01|2015-06-02|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Adiponectin and Circulating Progenitor Cells (CPC) Function|Adiponectin Promotes the Migration of Circulating Progenitor Cells Through p38-mediated Induction of the CXCR4 Receptor|Completed||Phase 1|20|Actual|University of Leipzig||3|||f||||f||||||||||2018-05-31 22:59:14.396291|2018-05-31 22:59:14.396291
NCT01272661|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|2014-03-25||2014-12-11|2011-01-07|2011-01-10|Estimate|2014-04-27|2014-05-28|Estimate||||2014-12-11|2015-01-05|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|BFS||Breast for Success: A Family-Centered Intervention in Support of Breastfeeding Among High-risk Low-income Mothers|Breast for Success: A Family-Centered Intervention in Support of Breastfeeding Among High-risk Low-income Mothers in Cleveland|Completed||N/A|1296|Actual|University Hospitals Cleveland Medical Center||3|||f||||t||||||||||2018-05-31 22:59:14.46117|2018-05-31 22:59:14.46117
NCT01272648|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-01-28|2011-01-07|2011-01-10|Estimate|||||||2013-01-28|2013-01-29|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|RePCa||Rehabilitation After Radiotherapy for Prostate Cancer|Rehabilitation and Coping of Effects After Curative Radiotherapy for Prostate|Completed||Phase 2/Phase 3|161|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 22:59:14.763|2018-05-31 22:59:14.763
NCT01272635|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|2016-03-11||2016-11-01|2011-01-07|2011-01-10|Estimate|2016-11-01|2016-12-28|Estimate||||2016-11-01|2016-12-28|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|APRIL - OCELOT||Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.|Azithromycin for Preventing the Development of Upper Respiratory Tract Illness Into Lower Respiratory Tract Symptoms in Children and Oral Corticosteroids for Treating Episodes of Significant Lower Respiratory Tract Symptoms in Children|Completed||Phase 3|607|Actual|Milton S. Hershey Medical Center||4|||f||||t||||||||||2018-05-31 22:59:14.840907|2018-05-31 22:59:14.840907
NCT01272622|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2016-09-15|2011-01-07|2011-01-10|Estimate|||||||2016-09-15|2016-09-16|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|||Prospective Study of Children and Adolescents With Craniopharyngioma|KRANIOPHARYNGEOM 2007 - Multicenter Prospective Study of Children and Adolescents With Craniopharyngioma|Recruiting||N/A|120|Anticipated|Klinikum Oldenburg gGmbH||2|||f||||t||||||||||2018-05-31 22:59:15.310091|2018-05-31 22:59:15.310091
NCT01272609|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2012-03-23|2011-01-07|2011-01-10|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|May 2012|Anticipated|2012-05-31|January 2011|Actual|2011-01-31||Interventional|||Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel|Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel|Unknown status|Recruiting|Phase 3|44|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 22:59:15.392322|2018-05-31 22:59:15.392322
NCT01272596|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-07|||2017-12-21|2011-01-07|2011-01-10|Estimate|||||||2017-12-21|2017-12-22|Actual|December 2009||2009-12-31|December 2017|2017-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis|Evaluation of Low Contrast Sloan Visual Charts as Method for the Assessment of Disease Progression in Multiple Sclerosis|Completed|||100|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 22:59:15.495447|2018-05-31 22:59:15.495447
NCT01272583|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2013-10-15||2014-02-14|2011-01-07|2011-01-10|Estimate|2013-12-31|2014-02-17|Estimate||||2014-02-14|2014-03-14|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|DARE||Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery|Effects of 6 Weeks Treatment With a Dipeptidyl Peptidase 4 Inhibitor on Counterregulatory and Incretin Hormones During Acute Hypoglycaemia in Patients With Type 1 Diabetes: a Randomized Double Blind Placebo-controlled Cross-over Study|Completed||N/A|16|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 22:59:15.674966|2018-05-31 22:59:15.674966
NCT01272570|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2015-05-26|2011-01-06|2011-01-07|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors|Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors: The Role of Aromatase Inhibitors|Completed|||58|Actual|University of Michigan|||2||f||||f||||||Samples Without DNA|"~     whole saliva~   "|||2018-05-31 22:59:16.539439|2018-05-31 22:59:16.539439
NCT01272557|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-03-31|2011-01-06|2011-01-07|Estimate|||||||2014-03-31|2014-04-01|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|SoraDox||Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial|Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial|Unknown status|Active, not recruiting|Phase 2|170|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 22:59:16.799572|2018-05-31 22:59:16.799572
NCT01272544|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Oral Health of Individuals Who Attended a Mother-child Dental Care Program - Longitudinal Study|Oral Health of Individuals Who Attended a Mother-child Dental Care Program - Longitudinal Study|Completed|||278|Actual|Universidade Federal do Piauí|||2||f||||f||||||||||2018-05-31 22:59:16.889628|2018-05-31 22:59:16.889628
NCT01272531|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-04-09|2011-01-06|2011-01-07|Estimate|||||||2012-04-09|2012-04-10|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|January 2016|Anticipated|2016-01-31|January 2013|Anticipated|2013-01-31||Observational|||Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)|Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)|Unknown status|Recruiting||880|Anticipated|University of California, San Diego|||2||f||||t||||||Samples With DNA|"~     DNA from patients with bipolar disorder~   "|||2018-05-31 22:59:16.995269|2018-05-31 22:59:16.995269
NCT01272518|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-07-11|2011-01-06|2011-01-07|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2011||2011-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Assessment of Cardiac Autonomic Behavior in Patients With Mood Disorders|Assessment of Cardiac Autonomic Behavior in Patients With Mood Disorders With a Focus on the Chaos Theory|Recruiting|||20|Anticipated|Sao Jose do Rio Preto Medical School|||||f||||t||||||||||2018-05-31 22:59:17.113745|2018-05-31 22:59:17.113745
NCT01272505|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate||||April 2010|2010-04-30||||||||Interventional|SILS||Conventional SILS vs Harmonic Scalpel SILS||Unknown status|Recruiting|N/A|137|Anticipated|Mansoura University||2|||f||||||||||||||2018-05-31 22:59:17.178681|2018-05-31 22:59:17.178681
NCT01272492|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Infant Nutrition: Evaluation of an Educational Touchscreen Computer Program|Infant Nutrition: Evaluation of an Educational Touchscreen Computer Program for Use in a Spanish-speaking Population of Caregivers of Young Children (APA Phase II)|Completed||N/A|||Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:59:17.23802|2018-05-31 22:59:17.23802
NCT01272479|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C|Comparison of Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With and Without Chronic Hepatitis C|Completed|||80|Actual|Istanbul University|||3||f||||t||||||||||2018-05-31 22:59:17.293372|2018-05-31 22:59:17.293372
NCT01272466|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|February 2010||2010-02-28|May 2009|2009-05-31||||February 2012|Anticipated|2012-02-29||Interventional|||Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma|Vaccination With Peptides Derived From Anti-apoptotic Proteins From the Bcl-2 Family, Administered in Combination With Montanide ISA-51 in Relation to Treatment With Proteasome Inhibitors in Patients With Relapsed Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Herlev Hospital||1|||f||||f||||||||||2018-05-31 22:59:17.351466|2018-05-31 22:59:17.351466
NCT01272453|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-05-29|2011-01-06|2011-01-07|Estimate|||||||2014-05-29|2014-05-30|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|CTDOSE||Computed Tomography Dose Reduction Using Sequential or Fast Pitch Sprial Technique|Computed Tomography Dose Reduction Using Sequential or Fast Pitch Sprial Technique Employed in Cardiothoracic Imaging|Completed|||2640|Actual|William Beaumont Hospitals|||2||f||||f||||||||||2018-05-31 22:59:17.419048|2018-05-31 22:59:17.419048
NCT01272440|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-11-12|2011-01-06|2011-01-07|Estimate|||||||2013-11-12|2013-11-13|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia|PEG-asparaginase Treatment in the NOPHO ALL-2008 Protocol: Antibody Formation, Pharmacokinetics, Pharmacodynamics and Side Effects.|Unknown status|Recruiting||200|Anticipated|Aarhus University Hospital|||||f||||t||||||Samples With DNA|"~     Blood, Cerebrospinal fluid~   "|||2018-05-31 22:59:17.480768|2018-05-31 22:59:17.480768
NCT01272427|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2013-02-13|2011-01-06|2011-01-07|Estimate|||||||2013-02-13|2013-02-15|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Glucose, Whey Protein and Time to the Next Meal on Mealtime Food Intake in Children|The Effect of Glucose, Whey Protein and Time to the Next Meal on Food Intake and Subjective Appetite in Normal Weight and Overweight/Obese Children|Completed||N/A|36|Actual|University of Toronto||6|||f||||f||||||||||2018-05-31 22:59:17.537283|2018-05-31 22:59:17.537283
NCT01272414|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2015-06-02|2011-01-06|2011-01-07|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|February 2012|Actual|2012-02-29|January 2012|Anticipated|2012-01-31||Interventional|||Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction||Withdrawn||Phase 4|0|Actual|University of Toronto||2||lack of funding|f||||||||||||||2018-05-31 22:59:17.603239|2018-05-31 22:59:17.603239
NCT01272401|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2017-02-21|2011-01-06|2011-01-07|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2010||2010-06-30|February 2017|2017-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Quality of Life in Breast Cancer Patients and Survivors|Determinants and Correlates of Physical Activity in Breast Cancer Survivors|Completed|||500|Actual|University of Illinois at Urbana-Champaign|||1||f||||f|f|f||||||No||2018-05-31 22:59:17.67232|2018-05-31 22:59:17.67232
NCT01272388|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-12-18|2011-01-06|2011-01-07|Estimate|||||||2012-12-18|2012-12-20|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|ASPEN-AVR||Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study|Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study|Terminated||Phase 4|1|Actual|Washington University School of Medicine||2||"We designed a different pilot trial based on data obtained after this study started - the 2~   studies were too overlapping to continue both."|f||||t||||||||||2018-05-31 22:59:17.728113|2018-05-31 22:59:17.728113
NCT01272375|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-05-11|2011-01-06|2011-01-07|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers|Completed||Phase 1|48|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 22:59:17.800473|2018-05-31 22:59:17.800473
NCT01272362|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2016-11-14|2011-01-06|2011-01-07|Estimate|||||||2016-11-14|2016-11-16|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|REVERBREZ||To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol|Study of the Predictive Value of Airway Obstruction Reversibility on the Effectiveness of Indacaterol (Onbrez® Breezhaler ®) 150 mcg Once Daily in Patients With Moderate to Severe COPD|Completed||Phase 4|625|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:59:17.876394|2018-05-31 22:59:17.876394
NCT01272349|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2013-11-20|2011-01-06|2011-01-07|Estimate|||||||2013-11-20|2013-11-21|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Intermittent Hypoxia Elicits Prolonged Restoration of Motor Function in Human SCI|Intermittent Hypoxia Elicits Prolonged Restoration of Motor Function in Human SCI|Completed||Phase 1|19|Actual|Emory University||2|||f||||t||||||||||2018-05-31 22:59:18.106828|2018-05-31 22:59:18.106828
NCT01272336|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2016-01-23|2011-01-06|2011-01-07|Estimate|||||||2016-01-23|2016-01-26|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|August 2013|Actual|2013-08-31||Interventional|||Study Effects of Intermittent Hypoxia on Restoring Hand Function Following SCI|Intermittent Hypoxia Promotes Restoration of Hand Function Following SCI|Completed||Phase 1|53|Actual|Emory University||2|||f||||f||||||||||2018-05-31 22:59:18.182524|2018-05-31 22:59:18.182524
NCT01272323|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-05-19|2011-01-06|2011-01-07|Estimate|||||||2011-05-19|2011-05-20|Estimate|February 2011||2011-02-28|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Cat-PAD Follow on Study|An Optional 1 Year Follow up Study to Evaluate the Continued Efficacy of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber|Completed|||170|Anticipated|Circassia Limited|||3||f||||f||||||||||2018-05-31 22:59:18.255084|2018-05-31 22:59:18.255084
NCT01272310|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|July 2013|Anticipated|2013-07-31|January 2012|Anticipated|2012-01-31||Interventional|||Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.|A Phase I/II, Open Clinical Trial to Assess the Safety, Tolerability and Efficacy of a Fixed Dose Combination Therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN Alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infected Subjects Who Failed to Respond Following a Course of Peg-IFN and RBV Therapy (SoC).|Unknown status|Not yet recruiting|Phase 1/Phase 2|36|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 22:59:18.403126|2018-05-31 22:59:18.403126
NCT01269879|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|VIBES||VIBration Training in EpicondylitiS|Vibration Training in Epicondylitis - a Randomized Trial|Unknown status|Not yet recruiting|Phase 3|70|Anticipated|Hannover Medical School||2|||f||||f||||||||||2018-05-31 23:00:34.981176|2018-05-31 23:00:34.981176
NCT01272297|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-12-18|2011-01-06|2011-01-07|Estimate|||||||2012-12-18|2012-12-19|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|LI-ESWT||The Effect of Low Intensity Shock Wave Therapy for ED in PDE5i Non Responders|The Effect of Low Intensity Shock Wave Therapy in Severe ED Patients Not Responding to Oral Medication|Completed||Phase 3|29|Actual|Rambam Health Care Campus||1|||f||||t||||||||||2018-05-31 22:59:18.47167|2018-05-31 22:59:18.47167
NCT01272284|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2013-09-27||2014-06-19|2011-01-05|2011-01-07|Estimate|2013-09-27|2013-11-28|Estimate||||2014-06-19|2014-06-20|Estimate|December 2010||2010-12-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|July 2012|Actual|2012-07-31||Interventional|||The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study|The Altis® Single Incision Sling System for Female Stress Urinary Incontinence Study|Completed||N/A|113|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 22:59:18.560606|2018-05-31 22:59:18.560606
NCT01272271|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|February 2008||2008-02-29|January 2011|2011-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Safety of Overnight Corneal Reshaping Lenses|Postmarket Study of the Safety of Overnight Corneal Reshaping Lenses|Completed|||1317|Actual|Ohio State University|||2||f||||f||||||||||2018-05-31 22:59:18.78553|2018-05-31 22:59:18.78553
NCT01272258|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2017-01-31|2011-01-06|2011-01-07|Estimate|||||||2017-01-31|2017-02-02|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Observed Systemic, Long-Acting, Anti-HIV Treatment With a Monoclonal Anti CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-Infected Injection Drug Users With Viral Rebound and Documented Poor Adherence to the Previous Antiretroviral Regimen|Withdrawn||Phase 2|0|Actual|CytoDyn, Inc.||2||Lack of enrollment|f||||f||||||||||2018-05-31 22:59:18.83886|2018-05-31 22:59:18.83886
NCT01272245|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2018-03-19||2018-04-30|2011-01-06|2011-01-07|Estimate|2018-04-30|2018-05-30|Actual||||2018-04-30|2018-05-30|Actual|July 2011||2011-07-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 2|36|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 22:59:18.963204|2018-05-31 22:59:18.963204
NCT01272232|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2015-01-22|2014-01-24|2017-12-06|2011-01-06|2011-01-07|Estimate|2015-01-22|2015-02-09|Estimate|2014-01-24|2014-02-24|Estimate|2017-12-06|2017-12-29|Actual|June 1, 2011|Actual|2011-06-01|December 2017|2017-12-31|January 25, 2013|Actual|2013-01-25|January 1, 2013|Actual|2013-01-01||Interventional|||Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes|Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period|Completed||Phase 3|846|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 22:59:19.307791|2018-05-31 22:59:19.307791
NCT01272219|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2015-01-22|2014-03-04|2017-12-20|2011-01-06|2011-01-07|Estimate|2015-01-22|2015-02-09|Estimate|2014-03-12|2014-04-09|Estimate|2017-12-20|2018-01-19|Actual|June 1, 2011|Actual|2011-06-01|December 2017|2017-12-31|March 2, 2015|Actual|2015-03-02|March 18, 2013|Actual|2013-03-18||Interventional|||Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes|Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation|Completed||Phase 3|3731|Actual|Novo Nordisk A/S||5|||f||||f|t|f||||||||2018-05-31 22:59:20.925304|2018-05-31 22:59:20.925304
NCT01272206|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2014-08-19|2011-01-06|2011-01-07|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects|A Single-centre, Randomised, Double-blind, Single Dose, Cross-over Trial Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021, Following Intravenous Administration in Healthy Male Subjects|Completed||Phase 1|12|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:59:24.367283|2018-05-31 22:59:24.367283
NCT01272193|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2015-10-21|2012-01-17|2017-02-09|2011-01-06|2011-01-07|Estimate|2015-10-21|2015-11-23|Estimate|2012-01-17|2012-01-19|Estimate|2017-02-09|2017-03-17|Actual|January 2011||2011-01-31|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|BOOST™||Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™: JAPAN)|Completed||Phase 3|296|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 22:59:24.446383|2018-05-31 22:59:24.446383
NCT01272180|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2014-01-31||2014-09-19|2011-01-06|2011-01-07|Estimate|2014-09-19|2014-09-26|Estimate||||2014-09-19|2014-09-26|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional||Anaysis was done on the All Enrolled Population, ie, all subjects who signed an informed consent/assent, undergone screening procedure(s) and were randomized.|Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults|Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB With OMV + MenACWY Combination Vaccination Formulations|Completed||Phase 2|484|Actual|Novartis||4|||f||||||||||||||2018-05-31 22:59:24.848299|2018-05-31 22:59:24.848299
NCT01272167|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2014-07-04|2011-01-06|2011-01-07|Estimate|||||||2014-07-04|2014-07-08|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of a Long-term Grapefruit Juice Consumption on Vascular Protection and Bone Metabolism|Effects of a Long-term and Regular Grapefruit Juice Consumption on Vascular Protection and Bone Metabolism : a Cross-over Designed Study to Determine the Specific Role of Naringin|Completed||N/A|52|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 22:59:25.689764|2018-05-31 22:59:25.689764
NCT01272154|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-01-27|2011-01-06|2011-01-07|Estimate|||||||2012-01-27|2012-01-31|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|CERDYS||Cerebellum and Cortical Plasticity: the Case of Dystonia|Cerebellum and Cortical Plasticity: the Case of Dystonia|Unknown status|Recruiting|N/A|120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||t||||||||||2018-05-31 22:59:25.739801|2018-05-31 22:59:25.739801
NCT01272141|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2014-09-03||2014-09-11|2011-01-06|2011-01-07|Estimate|2014-09-03|2014-09-10|Estimate||||2014-09-11|2014-09-22|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer|Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer|Terminated||Phase 2|5|Actual|Emory University||1||Slow accrual, Funding stopped|f||||t||||||||||2018-05-31 22:59:25.818955|2018-05-31 22:59:25.818955
NCT01272128|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2015-10-16|2011-01-06|2011-01-07|Estimate|||||||2015-10-16|2015-10-20|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Observational|AVAIL||Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study|A Multicenter, Prospective Non-interventional Study to Evaluate the Quality of Life in Belgian Patients With CIS or RRMS in Whom Interferon Beta-1a IM Treatment Has Been Initiated|Completed|||100|Actual|Biogen|||||f||||f||||||||||2018-05-31 22:59:25.958763|2018-05-31 22:59:25.958763
NCT01272115|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2012-05-01|2011-01-05|2011-01-07|Estimate|||||||2012-05-01|2012-05-02|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|IHCM||Integrative Health Care Model for Climacteric Stage Women|Integrative Health Care Model for Climacteric Stage Women|Completed||N/A|380|Actual|Coordinación de Investigación en Salud, Mexico|||||f||||t||||||||||2018-05-31 22:59:26.051654|2018-05-31 22:59:26.051654
NCT01272102|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-06-24|2011-01-06|2011-01-07|Estimate|||||||2013-06-24|2013-06-25|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma|Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma|Completed|||119|Actual|Carl Zeiss Meditec, Inc.|||1||f||||t||||||||||2018-05-31 22:59:26.109212|2018-05-31 22:59:26.109212
NCT01272089|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-09-16|2011-01-06|2011-01-07|Estimate|||||||2012-09-16|2012-09-18|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis|A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis|Completed||Phase 4|300|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 22:59:26.177971|2018-05-31 22:59:26.177971
NCT01272076|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2013-06-24||2013-12-17|2011-01-06|2011-01-07|Estimate|2013-09-09|2013-11-14|Estimate||||2013-12-17|2014-01-20|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)|Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)|Completed|||85|Actual|Carl Zeiss Meditec, Inc.|No adverse event were found or reported for this study.||1||f||||t||||||||||2018-05-31 22:59:26.266139|2018-05-31 22:59:26.266139
NCT01272063|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-06-24|2011-01-06|2011-01-07|Estimate|||||||2013-06-24|2013-06-25|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography|Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography|Completed|||91|Actual|Carl Zeiss Meditec, Inc.|||1||f||||t||||||||||2018-05-31 22:59:26.400929|2018-05-31 22:59:26.400929
NCT01272050|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-09-28|2011-01-06|2011-01-07|Estimate|||||||2017-09-28|2017-10-02|Actual|January 6, 2011|Actual|2011-01-06|September 2017|2017-09-30|December 2025|Anticipated|2025-12-31|July 29, 2016|Actual|2016-07-29||Interventional|||Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery|Dose Intensified Salvage Radiotherapy in Biochemically Relapsed Prostate Cancer Without Macroscopic Disease. A Randomized Phase III Trial.|Active, not recruiting||Phase 3|350|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||No||2018-05-31 22:59:26.477085|2018-05-31 22:59:26.477085
NCT01272037|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2018-05-24|2011-01-06|2011-01-07|Estimate|||||||2018-05-24|2018-05-25|Actual|January 15, 2011|Actual|2011-01-15|March 2018|2018-03-31||||February 1, 2022|Anticipated|2022-02-01||Interventional|||Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer|A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer|Active, not recruiting||Phase 3|10000|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 22:59:26.876342|2018-05-31 22:59:26.876342
NCT01272024|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2016-06-13|2011-01-06|2011-01-07|Estimate|||||||2016-06-13|2016-06-15|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|TEAMS||An Intervention to Improve Outcomes in Patients With Advanced Cancer|An Intervention to Improve Outcomes in Patients With Advanced Cancer|Completed||Phase 3|146|Actual|Yale University||2|||f||||f||||||||||2018-05-31 22:59:29.45418|2018-05-31 22:59:29.45418
NCT01272011|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2015-12-18||2016-02-26|2011-01-05|2011-01-07|Estimate|2016-02-26|2016-03-29|Estimate||||2016-02-26|2016-03-29|Estimate|May 2010||2010-05-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Breathing and Walking Treatments on Recovery Post-Spinal Cord Injury|Intermittent Hypoxia and Locomotor Training: Effects Following SCI|Completed||N/A|16|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-05-31 22:59:29.522667|2018-05-31 22:59:29.522667
NCT01271998|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2017-08-30|2011-01-05|2011-01-07|Estimate|||||||2017-08-30|2017-08-31|Actual|December 8, 2010|Actual|2010-12-08|August 2017|2017-08-31|January 3, 2011|Actual|2011-01-03|January 3, 2011|Actual|2011-01-03||Interventional|||Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg|Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg TR-701 Free Acid in Healthy Volunteers|Completed||Phase 1|20|Actual|Trius Therapeutics LLC||1|||f||||f||||||||||2018-05-31 22:59:29.826229|2018-05-31 22:59:29.826229
NCT01271985|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2014-05-06|2011-01-05|2011-01-07|Estimate|||||||2014-05-06|2014-05-08|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PolyIran||Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill|Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians|Unknown status|Active, not recruiting|Phase 3|7000|Anticipated|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-05-31 22:59:29.888475|2018-05-31 22:59:29.888475
NCT01271972|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2015-06-12|2011-01-06|2011-01-07|Estimate|||||||2015-06-12|2015-06-16|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Study of Nesvacumab (REGN910/ SAR307746)|A Phase 1 Study of REGN910 Administered Every 2 Weeks in Patients With Advanced Solid Malignancies|Completed||Phase 1|53|Actual|Regeneron Pharmaceuticals||7|||f||||t||||||||||2018-05-31 22:59:29.965436|2018-05-31 22:59:29.965436
NCT01271959|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-10-04|2011-01-06|2011-01-07|Estimate|||||||2012-10-04|2012-10-05|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study|A Multicenter, Post-Market Follow-up Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study|Terminated|||167|Actual|Precision Therapeutics|||||f||||f||||||Samples With DNA|"~     DNA, RNA, and proteomic research will be conducted on excess tissue cells.~   "|||2018-05-31 22:59:30.136784|2018-05-31 22:59:30.136784
NCT01271946|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2012-10-26||2013-01-23|2011-01-05|2011-01-07|Estimate|2012-12-07|2013-01-17|Estimate||||2013-01-23|2013-01-31|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|RECITAL||A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access System|A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access System|Completed||N/A|351|Actual|Arstasis, Inc.||1|||f||||f||||||||||2018-05-31 22:59:30.232439|2018-05-31 22:59:30.232439
NCT01271933|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05||2013-08-30|2013-09-23|2011-01-05|2011-01-07|Estimate||||2013-08-30|2013-09-13|Estimate|2013-09-23|2013-10-01|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients|A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Fibromyalgia (Protocol A0081245)|Completed||Phase 3|777|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:59:30.491632|2018-05-31 22:59:30.491632
NCT01271920|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2017-02-21|2011-01-05|2011-01-07|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2010||2010-09-30|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab|A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen|Completed||Phase 2|45|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:59:30.619681|2018-05-31 22:59:30.619681
NCT01271907|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2012-11-07||2017-07-03|2011-01-06|2011-01-07|Estimate|2012-12-12|2012-12-13|Estimate||||2017-07-03|2017-08-01|Actual|April 15, 2011|Actual|2011-04-15|July 2017|2017-07-31|December 8, 2011|Actual|2011-12-08|December 8, 2011|Actual|2011-12-08||Interventional|||Drosophila-generated CTL|Phase II Study of Metastatic Melanoma Using a Nonmyeloablative Lymphodepleting Regimen Followed by Melanoma-Reactive T-Cells Sensitized in Vitro With Peptide-Pulsed Drosophila Cells|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||3||Study was terminated due to withdrawal of CRADA partner.|f||||f|t|f||||||No||2018-05-31 22:59:30.69725|2018-05-31 22:59:30.69725
NCT01271894|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-05-10|2011-01-05|2011-01-07|Estimate|||||||2013-05-10|2013-05-13|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)|The Intensive Pharmacokinetics Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks|Completed||Phase 3|40|Actual|Kirby Institute||2|||f||||f||||||||||2018-05-31 22:59:31.835277|2018-05-31 22:59:31.835277
NCT01271881|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|October 2010||2010-10-31|January 2011|2011-01-31||||October 2011|Anticipated|2011-10-31||Interventional|||Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins|Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins|Unknown status|Recruiting|N/A|140|Anticipated|American Access Care||2|||f||||t||||||||||2018-05-31 22:59:31.920487|2018-05-31 22:59:31.920487
NCT01271868|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-06-26|2011-01-06|2011-01-07|Estimate|||||||2017-06-26|2017-06-28|Actual|November 2010|Actual|2010-11-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B|Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B|Completed||Phase 3|22|Anticipated|Aptevo Therapeutics||2|||f||||t||||||||||2018-05-31 22:59:32.00175|2018-05-31 22:59:32.00175
NCT01271855|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2018-01-08||2018-02-05|2011-01-06|2011-01-07|Estimate|2018-01-08|2018-02-06|Actual||||2018-02-05|2018-03-07|Actual|July 22, 2009|Actual|2009-07-22|February 2018|2018-02-28|September 29, 2011|Actual|2011-09-29|September 29, 2011|Actual|2011-09-29||Interventional|CRAMPS||Assessing Maternal Post-partum Pain With Suppositories|CRAMPS Trial: Controlled Randomized Trial Assessing Maternal Post-partum Pain With Suppositories|Completed||Phase 4|100|Actual|Loyola University|There are no limitations or caveats to report|2|||f||||f|t|f|||f|||No|There is no plan to share individual participant data.|2018-05-31 22:59:32.091276|2018-05-31 22:59:32.091276
NCT01271842|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2012-12-27|2011-01-06|2011-01-07|Estimate|||||||2012-12-27|2012-12-28|Estimate|October 2010||2010-10-31|December 2012|2012-12-31||||||||Observational|RESPIFLU||Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study|Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study|Completed|||38|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||||||2018-05-31 22:59:32.449624|2018-05-31 22:59:32.449624
NCT01271829|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2014-03-17|2011-01-05|2011-01-07|Estimate|||||||2014-03-17|2014-03-18|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Incorporating Avocados in Meals|Incorporating Avocados in Meals: Effect on Glycemic Index, Insulin Response, Satiety and Satiety-related Gastrointestinal Peptides in Humans|Completed||N/A|30|Actual|Loma Linda University||3|||f||||t||||||||||2018-05-31 22:59:32.597175|2018-05-31 22:59:32.597175
NCT01271816|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2014-01-02|2011-01-06|2011-01-07|Estimate|||||||2014-01-02|2014-01-03|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|PREPARE||Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Patients|Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic ARVC Patients|Terminated|||100|Anticipated|Lawson Health Research Institute|||1|inadequate recruitment|f||||t||||||||||2018-05-31 22:59:32.674371|2018-05-31 22:59:32.674371
NCT01271673|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Observational|||Cohort Study to Assess the Level of Compliance in Undertaking Breast Self Examination Among Women Attending Preventive Oncology Clinic|A Short Duration Pilot Cohort Study to Assess the Level of Compliance in Undertaking Breast Self Examination (BSE) Among Women Attending Preventive Oncology Clinic|Unknown status|Recruiting||100|Anticipated|Tata Memorial Hospital|||1||f||||||||||||||2018-05-31 22:59:40.233032|2018-05-31 22:59:40.233032
NCT01271803|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2016-05-11||2018-04-05|2011-01-05|2011-01-07|Estimate|2016-05-11|2016-06-17|Estimate||||2018-04-05|2018-04-09|Actual|February 17, 2011|Actual|2011-02-17|April 2018|2018-04-30|June 29, 2018|Anticipated|2018-06-29|October 1, 2013|Actual|2013-10-01||Interventional||All treated participants|A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma|A Phase IB, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Vemurafenib in Combination With GDC-0973 (Cobimetinib) When Administered in BRAFV600E Mutation-Positive Patients Previously Treated (But Without Prior Exposure to BRAF or MEK Inhibitor Therapy) or Previously Untreated for Locally Advanced/Unresectable or Metastatic Melanoma or Those Who Have Progressed After Treatment With Vemurafenib|Active, not recruiting||Phase 1|131|Actual|Hoffmann-La Roche||12|||f||||||||||||||2018-05-31 22:59:32.939873|2018-05-31 22:59:32.939873
NCT01271790|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05||2013-11-27|2014-01-08|2011-01-06|2011-01-07|Estimate||||2013-11-27|2013-12-24|Estimate|2014-01-08|2014-02-06|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140|Completed||Phase 2|245|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 22:59:37.342141|2018-05-31 22:59:37.342141
NCT01271777|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2012-09-21|2011-01-06|2011-01-07|Estimate|||||||2012-09-21|2012-09-24|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity|A Pilot Study to Evaluate the Efficacy of GFT505 (80mg) Orally Administered Once Daily for 8 Weeks on Insulin Sensitivity Using a Glucose Clamp Technique and Safety in Male Patients With Insulin Resistance and Abdominal Obesity. A Multicentre, Randomised, Single Blind, Placebo-Controlled, Cross Over Study.|Completed||Phase 2|22|Actual|Genfit||2|||f||||f||||||||||2018-05-31 22:59:37.590033|2018-05-31 22:59:37.590033
NCT01271764|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-09-25|2011-01-06|2011-01-07|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||The Association of G9a Protein and Outcome of Patients With Endometrial Cancer||Completed||N/A|97|Actual|Far Eastern Memorial Hospital||1|||f||||||||||||||2018-05-31 22:59:37.654562|2018-05-31 22:59:37.654562
NCT01271751|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity|A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 28 Days in Atherogenic Dyslipidaemic Patients With Abdominal Obesity. A Double Blind, Placebo-controlled and Randomized Study.|Completed||Phase 2|96|Actual|Genfit||2|||f||||f||||||||||2018-05-31 22:59:38.04371|2018-05-31 22:59:38.04371
NCT01271738|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-08-13|2011-01-06|2011-01-07|Estimate|||||||2015-08-13|2015-08-17|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer|Measuring the Effect of Additional Tumor Cavity Margins Excision at the Time of Breast Conserving Surgery for Stage 0, I, II, and III Breast Cancer Patients on Re-excision Rate, Cosmetic Results and Total Costs|Completed||N/A|79|Actual|Emory University||2|||f||||t||||||||||2018-05-31 22:59:38.175997|2018-05-31 22:59:38.175997
NCT01271725|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-09-21|2011-01-06|2011-01-07|Estimate|||||||2017-09-21|2017-09-25|Actual|May 24, 2011|Actual|2011-05-24|September 2017|2017-09-30|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures|LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting|Completed||Phase 2|74|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 22:59:38.267877|2018-05-31 22:59:38.267877
NCT01271712|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2013-05-24|2013-01-30|2018-05-10|2011-01-06|2011-01-07|Estimate|2013-08-21|2013-10-25|Estimate|2013-01-30|2013-02-01|Estimate|2018-05-10|2018-05-15|Actual|January 4, 2011|Actual|2011-01-04|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|January 26, 2012|Actual|2012-01-26||Interventional|GRID||Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)|A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib|Active, not recruiting||Phase 3|199|Actual|Bayer|Overall survival results are confounded by the fact that 85% of the participants initially randomized to placebo switched to open-label regorafenib.|2|||f||||t|t|f||||||||2018-05-31 22:59:38.492944|2018-05-31 22:59:38.492944
NCT01271699|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2017-02-16|2011-01-06|2011-01-07|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2011||2011-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis|Multiple Sclerosis and Fabry Disease: Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis - an Epidemiological Study|Completed|||250|Actual|University of Rostock|||1||f||||t||||||Samples With DNA|"~     Fabry diagnostic will be done centrally: blood samples will be stored for analysis of~     a-galactosidase in blood, Gb3 as well as lyso-Gb3. In all cases direct analysis of the gene~     will be done, especially in females where due to the Lyonisation effect a-galactosidase~     activity might be normal in blood although the patient might suffer from Fabry disease.~   "|Undecided||2018-05-31 22:59:39.954713|2018-05-31 22:59:39.954713
NCT01271686|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|2013-12-17||2014-05-19|2011-01-06|2011-01-07|Estimate|2014-05-19|2014-06-19|Estimate||||2014-05-19|2014-06-19|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||24-hour IOP-lowering Effect of 0.01% Bimatoprost|24-hour IOP-lowering Effect of 0.01% Bimatoprost|Completed||Phase 4|16|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 22:59:40.068827|2018-05-31 22:59:40.068827
NCT01271491|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-01-31|2011-01-05|2011-01-06|Estimate|||||||2017-01-31|2017-02-02|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Observational|||The Genetics of Respiratory Failure in Bronchiolitis|The Genetics of Respiratory Failure in Bronchiolitis|Active, not recruiting|||174|Actual|Connecticut Children's Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Saliva and blood~   "|No||2018-05-31 22:59:41.366831|2018-05-31 22:59:41.366831
NCT01271660|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2018-04-23|2011-01-06|2011-01-07|Estimate|||||||2018-04-23|2018-04-24|Actual|July 2011|Actual|2011-07-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Interventional|||A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis|A Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy and Safety of 6-week Treatment of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis|Completed||Phase 3|60|Actual|Seoul National University Boramae Hospital||2|||f||||f||||||||Undecided||2018-05-31 22:59:40.300009|2018-05-31 22:59:40.300009
NCT01271647|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-07-26|2011-01-06|2011-01-07|Estimate|||||||2011-07-26|2011-07-28|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|CYYTO||Classic Yin and Yang Tonic Formula for Osteopenia|Randomized Controlled Trial of Classic Yin and Yang Tonic Formula in Osteopenia|Unknown status|Recruiting|N/A|200|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 22:59:40.361115|2018-05-31 22:59:40.361115
NCT01271634|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-07-22|2011-01-06|2011-01-07|Estimate|||||||2011-07-22|2011-07-25|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Observe Abnormal Potential From the Offending Vessel to the Facial Muscles of HFS Patients|Observation of the Abnormal Potential From the Offending Vessel to the Facial Muscles of Hemifacial Spasm Patients|Unknown status|Enrolling by invitation||20|Anticipated|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||||2018-05-31 22:59:40.500345|2018-05-31 22:59:40.500345
NCT01271621|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||Influence of Glidescope Assisted Endotracheal Intubation on Intraocular Presure||Unknown status|Recruiting|Phase 4|50|Anticipated|King Khaled Eye Specialist Hospital||2|||f||||t||||||||||2018-05-31 22:59:40.55644|2018-05-31 22:59:40.55644
NCT01271608|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-06|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Study to Evaluate the Need of Needle Change for Application of Intramuscular, Subcutaneous and Intradermal Injection.|Intramuscular and Subcutaneous Injections: is it Necessary to Have Needles Exchanged?|Completed||N/A|1240|Actual|Hospital M'Boi Mirim|||||f||||t||||||||||2018-05-31 22:59:40.624051|2018-05-31 22:59:40.624051
NCT01271595|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2011-01-06|2011-01-06|2011-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|May 2011|Anticipated|2011-05-31|April 2010|Actual|2010-04-30||Interventional|AUTO-ACUSAR||AUTO-ACUSAR - Effects of Acupuncture on the Autonomic Nervous System in Seasonal Allergic Rhinitis Patients|Acupuncture in Seasonal Allergic Rhinitis- Effects on the Autonomic Nervous System (AUTO-ACUSAR)- an Explorative Substudy of ACUSAR|Unknown status|Active, not recruiting|N/A|60|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:59:40.680867|2018-05-31 22:59:40.680867
NCT01271582|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2018-01-09|2011-01-06|2011-01-07|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2009||2009-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2014|Actual|2014-06-30||Interventional|||Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients|Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients With Advanced Colorectal or Gastric Cancer Treated With FOLFIRI Regimen|Active, not recruiting||Phase 4|1500|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 22:59:40.756661|2018-05-31 22:59:40.756661
NCT01271569|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||A Study to Assess the Efficacy and Safety of Fospropofol Disodium|A Phase 1,Open, Dose-escalation Study to Assess the Efficacy and Safety of Fospropofol Disodium Injection in Healthy Volunteers|Completed||Phase 1|80|Actual|West China Hospital||1|||f||||t||||||||||2018-05-31 22:59:40.82478|2018-05-31 22:59:40.82478
NCT01271556|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|SALM1||Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients|Salmeterol Improves Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients|Completed||N/A|20|Actual|University of Milan||4|||f||||f||||||||||2018-05-31 22:59:40.882197|2018-05-31 22:59:40.882197
NCT01271543|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2013-01-31||2016-03-17|2011-01-05|2011-01-06|Estimate|2013-11-12|2013-12-30|Estimate||||2016-03-17|2016-04-15|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional||Sample size of 30 patient for each group was calculated based on previous publications (2,3) to obtain of power of 80% and alfa of 0.05 to detect a 20 bpm for heart rate and 20 mmHg for blood pressure difference for paired hemodynamic data.|Comparing Hemodynamic Changes for Intubation With Shikani Intubating Stylet and Macintosh Laryngoscope||Completed||Phase 4|60|Actual|Milton S. Hershey Medical Center|NO adverse events|2|||f||||f||||||||||2018-05-31 22:59:40.966915|2018-05-31 22:59:40.966915
NCT01271530|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2013-09-18|2011-01-05|2011-01-06|Estimate|||||||2013-09-18|2013-09-19|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Arm Cycling to Improve Fitness in Polio Survivors|The Impact of an Arm Ergometry Training Programme on Cardiovascular Fitness, Energy Cost of Walking and Fatigue in Prior Polio Patients|Completed||N/A|55|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 22:59:41.155088|2018-05-31 22:59:41.155088
NCT01271517|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|September 2005||2005-09-30|January 2011|2011-01-31||||March 2011|Anticipated|2011-03-31||Interventional|BAS||Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis|Effects of New Longacting Insulin Analogs on Metabolic Control, Endogenous Insulin Production, GH/IGF-I Axis and Quality of Life - Comparison of NPH, Glargine Och Detemir Insulin From the Debut of Type 1 Diabetes Mellitus in Adolescents|Unknown status|Active, not recruiting|Phase 4|120|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 22:59:41.217131|2018-05-31 22:59:41.217131
NCT01271504|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2017-08-25|2011-01-05|2011-01-06|Estimate|||||||2017-08-25|2017-08-28|Actual|April 2011||2011-04-30|August 2017|2017-08-31|June 23, 2015|Actual|2015-06-23|June 23, 2015|Actual|2015-06-23||Interventional|||E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|102|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 22:59:41.28079|2018-05-31 22:59:41.28079
NCT01270113|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate||||December 2010|2010-12-31||||||||Interventional|||Improving Methadone Maintenance Treatment Compliance and Outcomes in China|Improving Methadone Maintenance Treatment Compliance and Outcomes in China|Completed||N/A|||University of California, Los Angeles|||||f||||f||||||||||2018-05-31 23:00:31.845396|2018-05-31 23:00:31.845396
NCT01271478|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-02-12|2011-01-05|2011-01-06|Estimate|||||||2013-02-12|2013-02-13|Estimate|August 2009||2009-08-31|February 2013|2013-02-28||||December 2010|Actual|2010-12-31||Interventional|||Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients|Effect of Telmisartan and Captopril on Systemic Inflammation of Patients on Hemodialysis|Completed||Phase 4|60|Actual|Coordinación de Investigación en Salud, Mexico||4|||f||||f||||||||||2018-05-31 22:59:41.418998|2018-05-31 22:59:41.418998
NCT01271465|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2018-03-26|2011-01-05|2011-01-06|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2010|Actual|2010-09-30|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Analysis of Donor Biopsy Tissue Samples at the Time of Kidney Transplant|mRNA and microRNA Profiles in Renal Transplant at the Time of Organ Reperfusion|Recruiting|||120|Anticipated|Weill Medical College of Cornell University|||||f||||||||||Samples With DNA|"~     Blood, urine, and kidney tissue will be analyzed for mRNA and microRNA expression of~     pro-inflammatory genes.~   "|Undecided||2018-05-31 22:59:41.487117|2018-05-31 22:59:41.487117
NCT01271452|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2011-12-09||2011-12-09|2011-01-05|2011-01-06|Estimate|2011-12-09|2012-01-16|Estimate||||2011-12-09|2012-01-16|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines||Completed||Phase 4|224|Actual|Allergan||2|||f||||f||||||||||2018-05-31 22:59:41.732857|2018-05-31 22:59:41.732857
NCT01271439|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-08-10|2011-01-05|2011-01-06|Estimate|||||||2013-08-10|2013-08-13|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|REPLACE||Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma|A Phase II Study of Neoadjuvant Chemotherapy + IMRT Combined With Cetuximab in Advanced T Stage of Nasopharyngeal Carcinoma|Completed||Phase 2|60|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 22:59:41.961398|2018-05-31 22:59:41.961398
NCT01271426|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs|Association of Complement Factor H and ARMS2 Genotypes With Response of Polypoidal Choroidal Vasculopathy to Intravitreal Ranibizumab|Completed|||74|Actual|Nihon University|||||f||||||||||Samples With DNA|"~     white blood cell~   "|||2018-05-31 22:59:42.031986|2018-05-31 22:59:42.031986
NCT01271413|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2013-11-23||2014-03-25|2011-01-05|2011-01-06|Estimate|2014-01-20|2014-03-07|Estimate||||2014-03-25|2014-04-16|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Cognitive Stimulation|Effects of Cognitive Training in Methadone Maintenance Patients|Completed||Phase 2|134|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 22:59:42.085273|2018-05-31 22:59:42.085273
NCT01271400|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-09-06|2011-01-05|2011-01-06|Estimate|||||||2011-09-06|2011-09-08|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|Freezing||LANDA Embryo Freezing Technique.|Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates|Unknown status|Active, not recruiting||20|Anticipated|West Coast Fertility Centers|||||f||||t||||||||||2018-05-31 22:59:42.314641|2018-05-31 22:59:42.314641
NCT01271387|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2014-02-14|2011-01-05|2011-01-06|Estimate|||||||2014-02-14|2014-02-17|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment|An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon With That in Matched Healthy Control Subjects|Completed||Phase 1|29|Actual|Vanda Pharmaceuticals||3|||f||||f||||||||||2018-05-31 22:59:42.376712|2018-05-31 22:59:42.376712
NCT01271374|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-05-04|2011-01-05|2011-01-06|Estimate|||||||2011-05-04|2011-05-05|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|AMORE||Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome|Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|InVasc Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 22:59:42.446941|2018-05-31 22:59:42.446941
NCT01271361|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-12-06|2011-01-05|2011-01-06|Estimate|||||||2012-12-06|2012-12-07|Estimate|November 2010||2010-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|September 2011|Actual|2011-09-30||Interventional|TROFI||Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients|Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients: an Optical Frequency Domain Imaging (OFDI) Study|Completed||Phase 1/Phase 2|140|Actual|Terumo Europe N.V.||2|||f||||t||||||||||2018-05-31 22:59:42.530653|2018-05-31 22:59:42.530653
NCT01271348|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-10-31|2011-01-05|2011-01-06|Estimate|||||||2011-10-31|2011-11-01|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise|Multiple-dose, Randomized, Double Blinded, Placebo-controlled, Cross Over Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise|Completed||Phase 1|50|Anticipated|X-pert Med GmbH||2|||f||||||||||||||2018-05-31 22:59:42.637659|2018-05-31 22:59:42.637659
NCT01271335|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2012-03-22|2011-01-05|2011-01-06|Estimate|||||||2012-03-22|2012-03-23|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Collagenase Total Occlusion-1 Trial|Collagenase Total Occlusion-1 Trial|Completed||Phase 1|28|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 22:59:42.725351|2018-05-31 22:59:42.725351
NCT01271322|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2013-04-10|2011-01-05|2011-01-06|Estimate|||||||2013-04-10|2013-04-11|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|HICON||Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG)|Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric Junction During Neoadjuvant Treatment: HICON Trial|Terminated||Phase 2|||National Center for Tumor Diseases, Heidelberg|||||f||||f||||||||||2018-05-31 22:59:42.803879|2018-05-31 22:59:42.803879
NCT01271309|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-08-07|2011-01-05|2011-01-06|Estimate|||||||2013-08-07|2013-08-09|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|August 2008|Actual|2008-08-31||Observational|||Stem Cell Migratory Activity: Prognostic Marker in Myocardial Ischemia|Migratory and Angiogenic Dysfunction of Circulating CD133 Stem Cells: a New Prognostic Marker in Myocardial Ischemia.|Completed|||170|Actual|IRCCS Multimedica|||1||f||||f||||||||||2018-05-31 22:59:42.866411|2018-05-31 22:59:42.866411
NCT01271296|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2011-01-13|2011-01-05|2011-01-06|Estimate|||||||2011-01-13|2011-01-17|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease|Use of Liquorice and Grapefruit in Patients With Addison's Disease|Completed||N/A|17|Actual|Haukeland University Hospital||3|||f||||f||||||||||2018-05-31 22:59:42.925677|2018-05-31 22:59:42.925677
NCT01271283|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2015-06-03|2011-01-05|2011-01-06|Estimate|||||||2015-06-03|2015-06-04|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia|Lenalidomide for the Treatment of CLL Patients With High-Risk Disease|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 22:59:43.035949|2018-05-31 22:59:43.035949
NCT01271270|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2017-10-05|2011-01-05|2011-01-06|Estimate|||||||2017-10-05|2017-10-06|Actual|December 20, 2010||2010-12-20|September 20, 2012|2012-09-20|September 20, 2012|Actual|2012-09-20|September 20, 2012|Actual|2012-09-20||Interventional|||Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration|A Phase I Unmasked Study to Investigate the Safety and Tolerability of Subconjunctival Injections of Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 22:59:43.101605|2018-05-31 22:59:43.101605
NCT01271257|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2016-01-27|2011-01-05|2011-01-06|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetics of Misoprostol With Titrated Oral Administration|Phase 1 Study of Titrated Oral Misoprostol|Completed||Phase 1|10|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 22:59:43.152815|2018-05-31 22:59:43.152815
NCT01271244|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|2014-10-02||2014-10-02|2011-01-05|2011-01-06|Estimate|2014-10-02|2014-10-07|Estimate||||2014-10-02|2014-10-07|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder|Effects of Escitalopram on Autonomic Reactivity in Post Traumatic Stress Disorder Among Veterans of Operation Enduring Freedom and Iraqi Freedom (OEF/OIF)|Completed||Phase 4|11|Actual|VA Nebraska Western Iowa Health Care System|Due to small number of subjects recruited in major depression groupwe are unable to compare to the PTSD group.|2|||f||||f||||||||||2018-05-31 22:59:43.228223|2018-05-31 22:59:43.228223
NCT01271231|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-05-28|2011-01-05|2011-01-06|Estimate|||||||2013-05-28|2013-05-29|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Study on Periodontal Treatment in Diabetic Patients|Effects of Periodontal Treatment on Clinical Parameters and Glucose Metabolism in Diabetic Patients|Completed||N/A|90|Actual|Universidad de Antioquia||3|||f||||||||||||||2018-05-31 22:59:43.409452|2018-05-31 22:59:43.409452
NCT01271218|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|November 2005||2005-11-30|January 2011|2011-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program|Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program: a Randomized Placebo Controlled Clinical Trial|Completed||Phase 4|36|Actual|Texas A&M University||2|||f||||f||||||||||2018-05-31 22:59:43.476181|2018-05-31 22:59:43.476181
NCT01271205|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|January 2011||2011-01-31|December 2010|2010-12-31||||||||Observational|||Red Cell Distribution Width and Mortality in Adult Pneumonia Patients||Unknown status|Not yet recruiting||2000|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-05-31 22:59:43.541402|2018-05-31 22:59:43.541402
NCT01271192|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2020|Anticipated|2020-12-31|December 2015|Anticipated|2015-12-31||Interventional|NARC||Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer|A Randomized Multicenter Clinical Trial of Direct Surgical Resection Compared to Neoadjuvant Followed by Surgical Resection in Treating Patients With Operable Local Recurrent Carcinoma Of The Rectum|Recruiting||N/A|360|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 22:59:43.587958|2018-05-31 22:59:43.587958
NCT01271179|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|July 2004||2004-07-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of Sequential Perfusion of Liver Grafts to Prevent Nonanastomotic Biliary Strictures After Liver Transplantation|Study of Sequential Perfusion of Liver Grafts With Low-viscosity and High-viscosity Preservation Solutions to Decrease the Incidence of Nonanastomotic Biliary Strictures After Liver Transplantation|Completed||N/A|141|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 22:59:43.951387|2018-05-31 22:59:43.951387
NCT01271166|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|October 2007||2007-10-31|January 2011|2011-01-31||||August 2009|Actual|2009-08-31||Interventional|||Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer||Terminated||Phase 1|10|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:59:44.051117|2018-05-31 22:59:44.051117
NCT01271153|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2015-06-25|2011-01-05|2011-01-06|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients|Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients.|Completed||N/A|20|Actual|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 22:59:44.13167|2018-05-31 22:59:44.13167
NCT01271140|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-11-11|2011-01-05|2011-01-06|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||High Dose Insulin Therapy to Improve Liver Function|High Dose Insulin Therapy to Improve Liver Function in Patients With HCV Liver Cirrhosis|Unknown status|Active, not recruiting|N/A|5|Anticipated|McGill University Health Center||1|||f||||t||||||||||2018-05-31 22:59:44.227608|2018-05-31 22:59:44.227608
NCT01271127|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-06-11|2011-01-05|2011-01-06|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SCAR||Screening for Coronary Artery Disease After Mediastinal Irradiation|Screening for Coronary Artery Disease After Mediastinal Irradiation in Hodgkin Lymphoma Survivors|Completed||N/A|50|Actual|Leiden University Medical Center|||||f||||f||||||||||2018-05-31 22:59:44.299484|2018-05-31 22:59:44.299484
NCT01270100|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate||||December 2010|2010-12-31||||||||Interventional|||Recovery Management Intervention in China|Reducing HIV/AIDS and Drug Abuse Among Heroin Addicts Released From Compulsory Rehabilitation in China|Completed||N/A|||University of California, Los Angeles||1|||f||||||||||||||2018-05-31 23:00:33.054466|2018-05-31 23:00:33.054466
NCT01271114|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2014-03-07|2011-01-05|2011-01-06|Estimate|||||||2014-03-07|2014-03-10|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|HYSATESS-p||Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension|Hypertonic Saline and Terlipressin Linked To an Early Goal-Driven Protocol for Septic Shock or Sepsis-Associated Hypotension: A Pilot Trial (HYSATESS)|Terminated||Phase 3|21|Actual|Hospital General de Ciudad Real||2||Low recruitment rate|f||||t||||||||||2018-05-31 22:59:44.369795|2018-05-31 22:59:44.369795
NCT01271101|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-01-05|2011-01-05|2011-01-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|March 2011|Anticipated|2011-03-31||Observational|EASY-CHINA||The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome|The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome|Unknown status|Recruiting||1800|Anticipated|Fudan University|||1||f||||t||||||||||2018-05-31 22:59:44.449594|2018-05-31 22:59:44.449594
NCT01271088|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2011-11-15|2011-01-05|2011-01-06|Estimate|||||||2011-11-15|2011-11-16|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Protective Effect of N-acetylcysteine Against From Ototoxicity|Phase 3 Study of Protective Effect of N-acetylcysteine Against From Ototoxicity|Completed||Phase 2/Phase 3|60|Actual|TC Erciyes University||2|||f||||t||||||||||2018-05-31 22:59:44.51776|2018-05-31 22:59:44.51776
NCT01271075|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2012-05-30|2011-01-05|2011-01-06|Estimate|||||||2012-05-30|2012-05-31|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|BUCUM||Bilastine Updosing - Characterization of Underlying Mechanisms|Double-blind, Triple Cross-over, Placebo-controlled Study to Assess the Efficacy, Mechanisms, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Cold Contact Urticaria (CCU)|Completed||Phase 2/Phase 3|20|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 22:59:44.593228|2018-05-31 22:59:44.593228
NCT01271062|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-05|||2013-03-06|2011-01-05|2011-01-06|Estimate|||||||2013-03-06|2013-03-07|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Restoration of Beta Cell Function and Cardiovascular Parameters in Relation to Adipoinsular and Enteroinsular Axes After Gastric Bypass Surgery|Restoration of Beta Cell Function and Cardiovascular Parameters in Relation to Adipoinsular and Enteroinsular Axes After Gastric Bypass Surgery in Severely Obese Patients With Type 2 Diabetes|Completed||N/A|55|Actual|Cantonal Hospital of St. Gallen||4|||f||||t||||||||||2018-05-31 22:59:44.66851|2018-05-31 22:59:44.66851
NCT01271049|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2012-12-11|2011-01-04|2011-01-06|Estimate|||||||2012-12-11|2012-12-12|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths|A Double-blind, Randomized, Controlled Evaluation of the Tolerability of a Proprietary Oil Blend in Adults Residing in Areas Endemic for Helminth Infections.|Terminated||N/A|45|Actual|Mondelēz International, Inc.||2||Due to a business decision to stop the project, the study was terminated early.|f||||f||||||||||2018-05-31 22:59:44.738687|2018-05-31 22:59:44.738687
NCT01271036|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2013-04-26||2014-01-30|2011-01-05|2011-01-06|Estimate|2014-01-30|2014-03-04|Estimate||||2014-01-30|2014-03-04|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||Full Analysis Set|Safety Study of a Sensitive Sensual Touch and Personal Lubricant|A Single-Center, Medically Supervised, Safety Evaluation Study of a Sensitive Sensual Touch and Personal Lubricant Product in Couples|Completed||N/A|124|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-05-31 22:59:44.818948|2018-05-31 22:59:44.818948
NCT01271023|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2016-09-07|2011-01-05|2011-01-06|Estimate|||||||2016-09-07|2016-09-09|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|CTR||Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System|Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System|Completed||Phase 1|57|Actual|Jaeb Center for Health Research||1|||f||||t||||||||||2018-05-31 22:59:45.185717|2018-05-31 22:59:45.185717
NCT01271010|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2017-08-22||2017-08-22|2011-01-04|2011-01-06|Estimate|2017-08-22|2018-03-20|Actual||||2017-08-22|2018-03-20|Actual|June 17, 2011|Actual|2011-06-17|August 2017|2017-08-31|May 4, 2016|Actual|2016-05-04|May 4, 2016|Actual|2016-05-04||Interventional||All enrolled participants.|A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status|Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status|Terminated||Phase 4|89|Actual|Hoffmann-La Roche||1|||f||||f|f|f||||||||2018-05-31 22:59:45.297258|2018-05-31 22:59:45.297258
NCT01270997|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-02|||2014-07-13|2011-01-04|2011-01-06|Estimate|||||||2014-07-13|2014-07-15|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Randomized Double-blind Parallel Trial to Evaluate Equivalence in Efficacy and Safety of HD203 and Enbrel in RA Patients|A Multicenter Randomized Double-blind Active-controlled Parallel Group Phase Ⅲ Trial to Evaluate the Equivalence in Efficacy and Safety of HD203 and Enbrel in Combination With Methotrexate in Patients With Rheumatoid Arthritis|Completed||Phase 3|294|Actual|Hanwha Chemical||2|||f||||f||||||||||2018-05-31 22:59:45.508211|2018-05-31 22:59:45.508211
NCT01270984|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2012-10-30|2011-01-05|2011-01-06|Estimate|||||||2012-10-30|2012-10-31|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Imatinib||Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects|Completed||Phase 1|30|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 22:59:45.566057|2018-05-31 22:59:45.566057
NCT01270971|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2014-07-25|2012-07-26|2014-07-25|2011-01-04|2011-01-06|Estimate|2014-07-25|2014-08-15|Estimate|2012-07-26|2012-08-02|Estimate|2014-07-25|2014-08-15|Estimate|December 2010||2010-12-31|July 2014|2014-07-31||||November 2012|Actual|2012-11-30||Interventional||Analysis was performed using the intent-to-treat (ITT) population. Demographic characteristics were also analyzed using the Per Protocol (PP), Safety, and Post Study Follow Up (PSFU) populations, and were consistent with those of the ITT population. Safety analysis was performed using the Safety population.|Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail|A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults|Completed||Phase 3|594|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 22:59:45.64607|2018-05-31 22:59:45.64607
NCT01270958|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2010-10-28||2014-08-04|2010-12-09|2011-01-05|Estimate|2010-12-09|2011-01-05|Estimate||||2014-08-04|2014-08-06|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|AVY-REG00108VN||A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis|A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis (PAR)|Completed||Phase 4|60|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 22:59:46.976566|2018-05-31 22:59:46.976566
NCT01270945|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04||2014-06-05|2014-06-20|2011-01-04|2011-01-05|Estimate||||2014-06-05|2014-06-18|Estimate|2014-06-20|2014-06-24|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.|Phase II Open Label,Randomized Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody(CV-18C3)in Reducing Restenosis in Patients Undergoing Percutaneous Femoro-popliteal Revascularization.|Completed||Phase 2|43|Actual|XBiotech, Inc.||2|||f||||f||||||||||2018-05-31 22:59:47.471116|2018-05-31 22:59:47.471116
NCT01270932|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-12-27|2011-01-04|2011-01-05|Estimate|||||||2017-12-27|2017-12-29|Actual|November 2010||2010-11-30|December 2017|2017-12-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients|An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal Failure|Completed||Phase 2|28|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 22:59:47.553445|2018-05-31 22:59:47.553445
NCT01270919|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2014-05-22||2014-05-22|2011-01-04|2011-01-05|Estimate|2014-05-22|2014-06-24|Estimate||||2014-05-22|2014-06-24|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Prospective, Post-market, Multi-center Feasibility Study of the BioDuct® Meniscal Repair Device|This Study Will be a Prospective, Non-randomized Evaluation of the Change Between Preoperative and Postoperative Outcomes for Those Who Receive the BioDuct® Device Meniscal Repair Device.|Terminated||N/A|1|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-05-31 22:59:47.653024|2018-05-31 22:59:47.653024
NCT01270906|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|December 2003||2003-12-31|January 2011|2011-01-31||||October 2006|Actual|2006-10-31||Interventional|||Safety of CHIR-258 (TKI258) in Advanced Solid Tumors|A Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodyniamics of CHIR-258 in Subjects With Advanced Solid Tumor Malignancies|Terminated||Phase 1|35|Actual|Novartis||1|||f||||||||||||||2018-05-31 22:59:47.778026|2018-05-31 22:59:47.778026
NCT01270893|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2012-08-01|2011-01-04|2011-01-05|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2011||2011-01-31|August 2012|2012-08-31||||||||Interventional|||Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)|A Two-Arm Study of Preoperative Nilotinib for Patients With Resectable or Potentially Resectable Gastrointestinal Stromal Tumor (GIST)|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2||No particapnt recruitment.|f||||f||||||||||2018-05-31 22:59:47.865825|2018-05-31 22:59:47.865825
NCT01270880|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2015-04-01||2015-04-01|2011-01-04|2011-01-05|Estimate|2015-04-01|2015-04-14|Estimate||||2015-04-01|2015-04-14|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Phase II Trial of STA-9090 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Based Chemotherapy|Completed||Phase 2|18|Actual|Barbara Ann Karmanos Cancer Institute|Small sample size.|1|||f||||t||||||||||2018-05-31 22:59:48.012383|2018-05-31 22:59:48.012383
NCT01270867|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2013-11-20||2015-07-13|2011-01-04|2011-01-05|Estimate|2014-01-09|2014-02-27|Estimate||||2015-07-13|2015-08-03|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|TREVO2||Randomized Trial Evaluating Performance of the Trevo Retriever Versus the Merci Retriever in Acute Ischemic Stroke|Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO 2)|Completed||N/A|178|Actual|Stryker Neurovascular||2|||f||||t||||||||||2018-05-31 22:59:48.318507|2018-05-31 22:59:48.318507
NCT01270854|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2017-05-25|2011-01-04|2011-01-05|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2011||2011-02-28|May 2017|2017-05-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients|Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients|Completed||N/A|46|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 22:59:49.069656|2018-05-31 22:59:49.069656
NCT01270841|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2014-06-18||2014-06-27|2011-01-04|2011-01-05|Estimate|2014-06-27|2014-07-28|Estimate||||2014-06-27|2014-07-28|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Safety population|Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism|A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism|Completed||Phase 2|83|Actual|Repros Therapeutics Inc.||4|||f||||f||||||||||2018-05-31 22:59:49.310094|2018-05-31 22:59:49.310094
NCT01270828|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2015-10-01||2015-12-08|2011-01-04|2011-01-05|Estimate|2015-12-08|2016-01-13|Estimate||||2015-12-08|2016-01-13|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional||Baseline analysis population description consisted of all participants randomized to the DB phase who received at least 1 dose of study medication in the DB phase (full analysis set).|Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia|A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)|Completed||Phase 3|806|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 22:59:50.535373|2018-05-31 22:59:50.535373
NCT01270815|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-05-12|2011-01-04|2011-01-05|Estimate|||||||2011-05-12|2011-05-13|Estimate|March 2011||2011-03-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following Various Sized Lunches As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Pregabalin Controlled Release Formulation Administered At Lunch Following Various Caloric Intakes As Compared To The Immediate Release Formulation|Completed||Phase 1|28|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 22:59:54.661518|2018-05-31 22:59:54.661518
NCT01270802|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2013-08-14||2013-11-24|2011-01-04|2011-01-05|Estimate|2013-08-14|2013-10-24|Estimate||||2013-11-24|2013-12-18|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|||Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients|A Randomized Controlled Pilot Trial Comparing Continued Antiretroviral Therapy With Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) With Switch to Tenofovir/Emtricitabine/Raltegravir (TDF/FTC/RAL) on Changes in Endothelial Function and Markers of Bone Metabolism|Completed||Phase 4|30|Actual|Indiana University|The study was open-label. Correction for multiple testing was not performed, so apparently significant results may be falsely positive.|2|||f||||t||||||||||2018-05-31 22:59:54.829958|2018-05-31 22:59:54.829958
NCT01270789|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2014-09-10|2011-01-04|2011-01-05|Estimate|||||||2014-09-10|2014-09-12|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|LIBRA||LIraglutide and Beta-cell RepAir (LIBRA) Study|A Randomized Controlled Study Assessing the Effect of Liraglutide on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes Mellitus: The LIraglutide and Beta-cell RepAir (LIBRA) Study|Completed||Phase 3|63|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:59:56.879633|2018-05-31 22:59:56.879633
NCT01270776|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2013-05-13|2011-01-04|2011-01-05|Estimate|||||||2013-05-13|2013-05-14|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Efficacy Study Comparing 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine|Comparison of 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine for Skin Antisepsis Prior to Venepuncture in Very Low Birth Weight Infants: A Planned Non-inferiority Trial|Unknown status|Recruiting|N/A|462|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 22:59:57.07804|2018-05-31 22:59:57.07804
NCT01270763|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2015-03-17|2011-01-04|2011-01-05|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Gene x Behavior Interaction in the Look AHEAD Study|Gene x Behavior Interaction in the Look AHEAD Study|Completed|||4108|Actual|The Miriam Hospital|||1||f||||t||||||Samples With DNA|"~     DNA obtained as part of the parent study~   "|||2018-05-31 22:59:57.216663|2018-05-31 22:59:57.216663
NCT01270750|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-27|2011-01-04|2011-01-05|Estimate|||||||2011-01-27|2011-01-28|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|BOSMIVAR||Bosentan for Severe Mitral Valve Dysfunction|Pilot Trial of Bosentan for Secondary Pulmonary Hypertension Due to Severe Mitral Valve Dysfunction|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|General Hospital of Chalkida|||||f||||f||||||||||2018-05-31 22:59:57.346133|2018-05-31 22:59:57.346133
NCT01270737|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|March 2011||2011-03-31|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Whole Soy and Daidzein on Reduction of Blood Pressure in Postmenopausal Chinese Women|A Double-blind Randomized Controlled Trial on Whole Soy and Daidzein Supplementation on Reduction of Blood Pressure in Prehypertensive Postmenopausal Chinese Women|Unknown status|Not yet recruiting|N/A|270|Anticipated|Chinese University of Hong Kong||3|||f||||t||||||||||2018-05-31 22:59:57.49494|2018-05-31 22:59:57.49494
NCT01270724|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2018-02-26|2011-01-04|2011-01-05|Estimate|||||||2018-02-26|2018-02-27|Actual|August 2010||2010-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic Stem Cell Rescue (AuHSCR) for Patients With Recurrent or Progressive Intracranial Germ Cell Tumors|Recruiting||Phase 2|28|Anticipated|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 22:59:57.574218|2018-05-31 22:59:57.574218
NCT01270711|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2014-02-06||2014-04-14|2011-01-04|2011-01-05|Estimate|2014-02-06|2014-03-24|Estimate||||2014-04-14|2014-05-02|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|SUCRE|Study population included all participants who were treated with cabergoline, registered in one of the databases and those recruited from specialized clinical centers in Italy for Parkinson&#8217;s disease during the study period.|Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)|Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)|Completed|||22014|Actual|Pfizer|Results not reported for Year 2012 (Year 7) since several databases did not contribute data for Year 7 and amount of person-time of follow-up dropped in all databases. Designation of primary and secondary endpoints was based on study team's input.||1||f||||f||||||||||2018-05-31 22:59:57.838204|2018-05-31 22:59:57.838204
NCT01270698|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-01-14|2011-01-04|2011-01-05|Estimate|||||||2015-01-14|2015-01-15|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer|A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Colorectal Cancer.|Completed||Phase 1|26|Actual|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 23:00:02.80818|2018-05-31 23:00:02.80818
NCT01270685|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2015-06-25|2011-01-04|2011-01-05|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|August 2011|Anticipated|2011-08-31|April 2011|Anticipated|2011-04-30||Observational|||2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies|2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies|Withdrawn|||0|Actual|VA Office of Research and Development|||4|Not a Clinical Trial requirement per VA HSR&D|f||||f||||||||||2018-05-31 23:00:03.160395|2018-05-31 23:00:03.160395
NCT01270672|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2016-01-20|2011-01-04|2011-01-05|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)|"Effects of Carvedilol on the Cardiovascular and Subjective Response to MDMA (3,4-Methylenedioxymethamphetamine, Ecstasy)"|Completed||N/A|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 23:00:03.413766|2018-05-31 23:00:03.413766
NCT01270659|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2017-04-06||2017-05-19|2011-01-04|2011-01-05|Estimate|2017-05-19|2017-06-20|Actual||||2017-05-19|2017-06-20|Actual|May 2011||2011-05-31|May 2017|2017-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|FAIRTOP II||Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury|Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial|Completed||Phase 3|60|Actual|University of Oklahoma||4|||f||||t||||||||||2018-05-31 23:00:03.614726|2018-05-31 23:00:03.614726
NCT01269892|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Early Administration of Lactose-free Milk in Children Presenting With Acute Diarrhea|Study of Nutritional Regime for Acute Diarrhea|Completed||Phase 2|74|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:00:34.82335|2018-05-31 23:00:34.82335
NCT01270646|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2015-03-05|2011-01-04|2011-01-05|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|CARTO-CRT||Impact of Intraventricular Electrical Activation in Resynchronization Therapy|Study of the Role of Intraventricular Electrical Activation in the Treatment of Congestive Heart Failure by Cardiac Resynchronization Therapy: Invasive Evaluation and Validation of Non-Invasive Strategy Using CardioInsight ®|Completed||Phase 2|18|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 23:00:05.243717|2018-05-31 23:00:05.243717
NCT01270633|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2017-11-30|2011-01-04|2011-01-05|Estimate|||||||2017-11-30|2017-12-02|Actual|December 2010||2010-12-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study With Primatrix Dermal Repair Scaffold For The Treatment Of Diabetic Foot Ulcers|A Multi-Center, Prospective, Randomized Study With Primatrix Dermal Repair Scaffold For The Treatment Of Diabetic Foot Ulcers|Terminated||N/A|30|Actual|Integra LifeSciences Corporation||2||Business Decision|f||||f||||||||||2018-05-31 23:00:05.486494|2018-05-31 23:00:05.486494
NCT01270620|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2015-07-18||2015-10-01|2011-01-04|2011-01-05|Estimate|2015-08-13|2015-09-16|Estimate||||2015-10-01|2015-10-22|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement|Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement: A Pilot Assessment of Short-term and Long-term Differences in Outcome|Completed||Phase 4|100|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 23:00:05.748917|2018-05-31 23:00:05.748917
NCT01270607|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2013-05-22|2011-01-04|2011-01-05|Estimate|||||||2013-05-22|2013-05-23|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|August 2012|Actual|2012-08-31|December 2010|Actual|2010-12-31||Interventional|||Acupuncture and Pain Processing|Acupuncture and Pain Processing|Completed||N/A|10|Actual|Stanford University||1|||f||||||||||||||2018-05-31 23:00:07.387962|2018-05-31 23:00:07.387962
NCT01270594|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-05-26|2011-01-03|2011-01-05|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|||A Pilot Study to Evaluate a Telepharmacy Intervention to Improve Inhaler Adherence in Veterans With COPD|A Pilot Study to Evaluate a Telepharmacy Intervention to Improve Inhaler Adherence in Veterans With COPD|Completed||Phase 2|97|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 23:00:07.756283|2018-05-31 23:00:07.756283
NCT01270581|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2015-12-04||2016-12-23|2011-01-03|2011-01-05|Estimate|2016-12-23|2017-02-16|Actual||||2016-12-23|2017-02-16|Actual|July 2010||2010-07-31|December 2016|2016-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation|High Flow Nasal Cannula vs Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation|Terminated||N/A|7|Actual|Icahn School of Medicine at Mount Sinai|low enrollment, data not analyzed - too small for any meaningful interpretation|2||lack of sufficient enrollment|f||||t||||||||||2018-05-31 23:00:08.115404|2018-05-31 23:00:08.115404
NCT01270568|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-20|2011-01-03|2011-01-05|Estimate|||||||2011-01-20|2011-01-21|Estimate|March 2010||2010-03-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Mind-body Interventions in Cardiac Patients||Completed||N/A|60|Anticipated|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 23:00:09.176093|2018-05-31 23:00:09.176093
NCT01270555|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2011-01-07||2013-03-04|2011-01-03|2011-01-05|Estimate|2011-01-31|2011-02-25|Estimate||||2013-03-04|2013-03-08|Estimate|May 1999||1999-05-31|March 2013|2013-03-31||||July 2001|Actual|2001-07-31||Interventional|||Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults|Efficacy Of Bupropion SR For Attention Deficit Hyperactivity Disorder (ADHD) In Adults With Recent Past or Current Substance Use Disorders|Completed||N/A|32|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 23:00:09.499287|2018-05-31 23:00:09.499287
NCT01270542|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2014-05-19||2017-07-14|2011-01-03|2011-01-05|Estimate|2017-07-14|2017-08-17|Actual||||2017-07-14|2017-08-17|Actual|June 2009||2009-06-30|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|PDR||Avastin for PDR (Proliferative Diabetic Retinopathy)|Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management|Completed||N/A|20|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 23:00:10.363493|2018-05-31 23:00:10.363493
NCT01270529|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2016-05-12||2016-06-22|2011-01-04|2011-01-05|Estimate|2016-06-22|2016-08-04|Estimate||||2016-06-22|2016-08-04|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|March 2014|Actual|2014-03-31|June 2012|Actual|2012-06-30||Interventional|||Pedometers to Assess and Increase Physical Activity Among Children With Chronic Kidney Disease|Pedometers to Assess and Increase Physical Activity Among Children With Chronic Kidney Disease|Completed||N/A|44|Actual|University of California, San Francisco||3|||f||||||||||||||2018-05-31 23:00:11.625003|2018-05-31 23:00:11.625003
NCT01270516|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2018-05-04|2011-01-04|2011-01-05|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2014||2014-01-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of EPA and HMB on Strength in ICU Patients|Effect of EPA and HMB on Diaphragm and Limb Muscle Strength in Mechanically Ventilated Patients|Recruiting||N/A|80|Anticipated|University of Kentucky||4|||f||||t||||||||||2018-05-31 23:00:15.755716|2018-05-31 23:00:15.755716
NCT01270503|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|2014-10-31||2014-10-31|2011-01-04|2011-01-05|Estimate|2014-10-31|2014-11-14|Estimate||||2014-10-31|2014-11-14|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional||Safety analysis set|Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines|Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines|Completed||Phase 4|538|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 23:00:16.396302|2018-05-31 23:00:16.396302
NCT01270490|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2012-02-13|2011-01-04|2011-01-05|Estimate|||||||2012-02-13|2012-02-14|Estimate|January 2011||2011-01-31|February 2012|2012-02-29||||January 2013|Anticipated|2013-01-31||Interventional|||Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia|A Multicentre, Prospective, Randomized Open-label Pilot Study to Assess the Feasibility and Preliminary Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia|Unknown status|Recruiting|Phase 3|20|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 23:00:18.648619|2018-05-31 23:00:18.648619
NCT01270477|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-04-18|2011-01-04|2011-01-05|Estimate|||||||2011-04-18|2011-04-19|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|October 2012|Anticipated|2012-10-31|May 2012|Anticipated|2012-05-31||Interventional|FROST||Hyperbaric Oxygen Treatment as Adjuvant Treatment for Frost Injury|Study of the Possible Improvement in Level of Sequela and Amputation/Amputation Level After Frost Injury by the Adjuvant Treatment of Hyperbaric Oxygen.|Unknown status|Recruiting|N/A|20|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 23:00:19.662872|2018-05-31 23:00:19.662872
NCT01270464|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|2016-03-23|2014-05-08|2016-04-28|2011-01-03|2011-01-05|Estimate|2016-04-28|2016-06-06|Estimate|2014-05-08|2014-05-26|Estimate|2016-04-28|2016-06-06|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Randomized population|A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma|A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma|Completed||Phase 3|315|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-05-31 23:00:20.742959|2018-05-31 23:00:20.742959
NCT01270451|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2014-10-22|2011-01-04|2011-01-05|Estimate|||||||2014-10-22|2014-10-23|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Guidance in Diet and Physical Activity for Prevention of Weight Gain After Gastric Bypass Surgery|Guidance in Diet and Physical Activity for Prevention of Weight Gain After Gastric Bypass Surgery.|Completed||N/A|165|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 23:00:25.243182|2018-05-31 23:00:25.243182
NCT01270438|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2017-04-03|2011-01-04|2011-01-05|Estimate|||||||2017-04-03|2017-04-04|Actual|December 2010|Actual|2010-12-31|April 2017|2017-04-30|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|||Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer|A Phase 2 Study of RO4929097 (NSC 749225) in Combination With FOLFOX Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Alone for the First-Line Treatment of Patients With Metastatic Colorectal Cancer (NCI #8467)|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:00:25.609396|2018-05-31 23:00:25.609396
NCT01270425|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2013-02-27|2011-01-04|2011-01-05|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Observational|||Sonographic and Laboratory Evaluation of the Thyroid Gland in Patients With Systemic Sclerosis|Sonographic Characterization of the Thyroid Gland in Patients With Systemic Sclerosis With and Without Hashimoto Thyroiditis|Completed|||60|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:00:26.080646|2018-05-31 23:00:26.080646
NCT01270412|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2011-07-16|2011-01-04|2011-01-05|Estimate|||||||2011-07-16|2011-07-19|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|PRP||Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis|Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis - A Randomized-Double-Blind Trial|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 23:00:26.374811|2018-05-31 23:00:26.374811
NCT01270399|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2012-10-29|2011-01-04|2011-01-05|Estimate|||||||2012-10-29|2012-10-30|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer|Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer|Unknown status|Recruiting||20|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 23:00:26.596602|2018-05-31 23:00:26.596602
NCT01270386|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2012-02-09|2011-01-04|2011-01-05|Estimate|||||||2012-02-09|2012-02-10|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer|A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Study of Apatinib as Third Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer|Completed||Phase 2|136|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 23:00:26.667086|2018-05-31 23:00:26.667086
NCT01270373|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2017-11-15|2011-01-04|2011-01-05|Estimate|||||||2017-11-15|2017-11-17|Actual|August 2010||2010-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|NeoSAMBA||NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?|Randomized Phase II Trial of the Sequences of Anthracyline and Taxane in Locally Advanced Breast Cancer|Active, not recruiting||Phase 2|112|Anticipated|Instituto Nacional de Cancer, Brazil||2|||f||||f||||||||||2018-05-31 23:00:26.909977|2018-05-31 23:00:26.909977
NCT01270360|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2015-06-12|2011-01-04|2011-01-05|Estimate|||||||2015-06-12|2015-06-15|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|VATNIMAD||Validation of an Alternative Biological Test to Increase the Detection Sensitivity of a Colon Tumour|Validation of a Non Invasive methylateDNA Test for te Diagnosis of Colorectal Tumour in Asymptomatic Individuals|Completed|||502|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Blood, Serum Urine, Stools Tissues~   "|||2018-05-31 23:00:27.039329|2018-05-31 23:00:27.039329
NCT01270347|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03||2018-01-17|2018-01-17|2011-01-04|2011-01-05|Estimate||||2018-01-17|2018-01-19|Actual|2018-01-17|2018-01-19|Actual|January 2011||2011-01-31|January 2018|2018-01-31|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|TIS||Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients|Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients|Completed||Phase 3|267|Actual|Horizon Pharma USA, Inc.||2|||f||||t||||||||||2018-05-31 23:00:27.346087|2018-05-31 23:00:27.346087
NCT01270334|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|February 2011||2011-02-28|January 2011|2011-01-31||||||||Observational|||Effect of Vaginal PH on Treatment Effectiveness With Misoprostol for First Trimester Missed Abortions|Effect of Vaginal PH on Treatment Effectiveness With Misoprostol for First Trimester Missed Abortions|Unknown status|Not yet recruiting||400|Anticipated|HaEmek Medical Center, Israel|||2||f||||t||||||||||2018-05-31 23:00:27.998388|2018-05-31 23:00:27.998388
NCT01270321|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2018-04-23|2011-01-04|2011-01-05|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2010||2010-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer|A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer|Active, not recruiting||Phase 2|42|Actual|Emory University||3|||f||||t||||||||||2018-05-31 23:00:28.127505|2018-05-31 23:00:28.127505
NCT01270308|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|December 2008||2008-12-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions|Open Label, Randomized, Two-treatment, Three-period, Three-sequence, Partial Replicate Oral Bioequivalence Study of Lansoprazole 30 mg DR Capsules of Dr.Reddy's Laboratories Limited, India Comparing With That of PREVACID® (Containing Lansoprazole) 30 mg DR Capsules of TAP Pharmaceuticals Inc. USA, in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:00:28.341918|2018-05-31 23:00:28.341918
NCT01270295|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2013-03-12|2011-01-04|2011-01-05|Estimate|||||||2013-03-12|2013-03-13|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|SoLiRAGE||Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLiRAGE).|Soluble Forms and Ligands of the Receptor for Advanced Glycation End Products (RAGE) in the Pulmonary Edema Fluid and Plasma From ICU Patients With ALI/ARDS : an Observational Prospective Study.|Completed|||60|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:00:28.432034|2018-05-31 23:00:28.432034
NCT01270282|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30||2014-06-24|2015-01-13|2011-01-04|2011-01-05|Estimate||||2015-01-13|2015-01-26|Estimate|2015-01-13|2015-01-26|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TACTT1||Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus|Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus|Completed||Phase 2|82|Actual|Auris Medical, Inc.||2|||f||||||||||||||2018-05-31 23:00:28.653044|2018-05-31 23:00:28.653044
NCT01270269|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2017-03-01|2011-01-04|2011-01-05|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2011||2011-02-28|March 2017|2017-03-31|June 2014|Actual|2014-06-30|March 2013|Actual|2013-03-31||Interventional|ACT-ICU||ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit|ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit|Completed||N/A|87|Actual|Vanderbilt University Medical Center||3|||f||||f||||||||||2018-05-31 23:00:28.961675|2018-05-31 23:00:28.961675
NCT01270256|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2014-06-16||2014-07-17|2011-01-04|2011-01-05|Estimate|2014-06-16|2014-07-16|Estimate||||2014-07-17|2014-07-25|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||NasoNeb Delivery of an Intranasal Steroid|Evaluation of NasoNeb™ Delivery of an Intranasal Steroid in the Treatment of Perennial Allergic Rhinitis|Completed||Phase 4|41|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 23:00:29.105271|2018-05-31 23:00:29.105271
NCT01270243|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-19|2011-01-04|2011-01-05|Estimate|||||||2011-01-19|2011-01-21|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Observational|||Bacterial Microbiota In The Tonsils Of Children|Bacterial Microbiota In The Tonsils Of Children Undergoing Adenotonsillectomy And Normal Controls|Unknown status|Recruiting||30|Anticipated|University of Chicago|||3||f||||t||||||||||2018-05-31 23:00:29.603986|2018-05-31 23:00:29.603986
NCT01270230|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2016-10-25|2011-01-03|2011-01-05|Estimate|||||||2016-10-25|2016-10-27|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|August 2016|Actual|2016-08-31|February 2015|Actual|2015-02-28||Interventional|||A Randomized Controlled Trial of the Bruthas Project|A Randomized Controlled Trial of the Bruthas Project|Completed||Phase 2|396|Actual|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 23:00:29.69361|2018-05-31 23:00:29.69361
NCT01270217|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2017-07-06|2011-01-03|2011-01-05|Estimate|||||||2017-07-06|2017-07-11|Actual|December 2010|Actual|2010-12-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Behavior and Driving Safety Study II|Behavior and Driving Safety Study II|Completed||N/A|200|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 23:00:29.799856|2018-05-31 23:00:29.799856
NCT01270204|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-05-25|2011-01-03|2011-01-05|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2011||2011-01-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||The Effect of Food Taste, Temperature, and Viscosity on Swallowing Efficiency|The Effect of Food Taste, Temperature, and Viscosity on Swallowing Efficiency|Completed|||1|Actual|University of California, Davis|||2||f||||f||||||||||2018-05-31 23:00:30.036629|2018-05-31 23:00:30.036629
NCT01270191|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-06-26|2011-01-03|2011-01-05|Estimate|||||||2013-06-26|2013-06-27|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients|The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients|Unknown status|Recruiting|Phase 4|160|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 23:00:30.311709|2018-05-31 23:00:30.311709
NCT01270178|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||||||Observational|||Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy|Prospective Trial of Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy|Unknown status|Not yet recruiting||420|Anticipated|Taipei Veterans General Hospital, Taiwan|||1||f||||f||||||||||2018-05-31 23:00:30.425583|2018-05-31 23:00:30.425583
NCT01270165|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2012-01-31|2011-01-04|2011-01-05|Estimate|||||||2012-01-31|2012-02-02|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis B|Antiviral Efficacy of Continuing Lamivudine Plus Adefovir or Switching to Telbivudine Plus Adefovir in HBeAg-positive Lamivudine-refractory Chronic Hepatitis B Patients Who Have Suboptimal Response to Lamivudine Plus Adefovir for at Least 12 Months|Unknown status|Recruiting|Phase 3|110|Anticipated|Yonsei University|||||f||||t||||||||||2018-05-31 23:00:30.504825|2018-05-31 23:00:30.504825
NCT01270152|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter|Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter.|Completed||Phase 2|21|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 23:00:30.581965|2018-05-31 23:00:30.581965
NCT01270139|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|2012-07-26||2017-08-29|2011-01-04|2011-01-05|Estimate|2012-07-26|2012-08-30|Estimate||||2017-08-29|2017-09-08|Actual|April 1, 2007|Actual|2007-04-01|August 2017|2017-08-31|August 1, 2016|Actual|2016-08-01|April 1, 2009|Actual|2009-04-01||Interventional|NANOM-FIM||Plasmonic Nanophotothermal Therapy of Atherosclerosis|Plasmonic Photothermal Therapy of Flow-Limiting Atherosclerotic Lesions With Silica-Gold Nanoparticles: a First-in-Man Study|Completed||N/A|180|Actual|Ural Medical University|The study was launched as a PROBE trial. But randomization was broken because of the specific study design, where procedures differ significantly, and impossibility to calculate sample size due to absolute novelty of the technology.|3|||f||||t|f|f||||||Yes|The raw data will be partially shared (a Protocol for NANOM-FIM trial and related DREAM project; raw data with atomic force microscopy and scanning electron microscopy) in Mendeley Datasets and ResearchGate without any additional dissemination.|2018-05-31 23:00:30.688362|2018-05-31 23:00:30.688362
NCT01270126|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2013-06-19||2013-09-04|2011-01-04|2011-01-05|Estimate|2013-06-20|2013-09-04|Estimate||||2013-09-04|2013-09-16|Estimate|November 2006||2006-11-30|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|SCT_optnerve||Trial of Alternating Current Stimulation in Optic Neuropathy|Treatment of Patients With Optic Neuropathy Using Transorbital Alternating Current Stimulation - a Randomized Trial|Completed||Phase 2|22|Actual|University of Magdeburg||2|||f||||f||||||||||2018-05-31 23:00:31.611195|2018-05-31 23:00:31.611195
NCT01270087|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|May 2005||2005-05-31|January 2007|2007-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.|The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.|Completed||Phase 4|14|Actual|Skane University Hospital||1|||f||||t||||||||||2018-05-31 23:00:33.131388|2018-05-31 23:00:33.131388
NCT01270074|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2016-04-28|2011-01-04|2011-01-05|Estimate|||||||2016-04-28|2016-04-29|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|COMBATCF||Prevention of Bronchiectasis in Infants With Cystic Fibrosis|A Phase 3 Multi-centre Randomised Placebo-controlled Study of Azithromycin in the Primary Prevention of Radiologically-defined Bronchiectasis in Infants With Cystic Fibrosis.|Recruiting||Phase 3|130|Anticipated|Queensland Children's Medical Research Institute||2|||f||||t||||||||Undecided||2018-05-31 23:00:33.219454|2018-05-31 23:00:33.219454
NCT01270061|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-05-07|2011-01-04|2011-01-05|Estimate|||||||2015-05-07|2015-05-08|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Project Wellness: Increasing HIV Testing Among West African Immigrants|Project Wellness: Increasing HIV Testing Among West African Immigrants|Withdrawn||N/A|0|Actual|North Bronx Healthcare Network||2||We did not receive proper funding to complete this study|f||||f||||||||||2018-05-31 23:00:33.337987|2018-05-31 23:00:33.337987
NCT01270048|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||The Effect of Bunsimgieum on the Chest Discomfort of Hwa-byung's Major Symptom|The Effect of Bunsimgi-eum(Fenxinqiyin) on the Chest Discomfort of Hwa-byung's Major Symptom : Randomized, Double-blinded, Placebo-control Trial|Completed||Phase 3|144|Actual|Korea Health Industry Development Institute||2|||f||||t||||||||||2018-05-31 23:00:33.416253|2018-05-31 23:00:33.416253
NCT01270035|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-06-23|2011-01-04|2011-01-05|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2011||2011-01-31|December 2010|2010-12-31||||January 2014|Anticipated|2014-01-31||Interventional|||Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate||Unknown status|Recruiting|Phase 4|40|Anticipated|Keio University||1|||f||||||||||||||2018-05-31 23:00:33.479496|2018-05-31 23:00:33.479496
NCT01270022|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2004||2004-01-31|January 2011|2011-01-31|July 2010|Actual|2010-07-31|April 2006|Actual|2006-04-30||Interventional|||Development, Implementation and Evaluation of the Impact of a Guideline in Clinical Practise for Cardiovascular Risk|Development, Implementation and Evaluation of the Impact of a Guideline in Clinical Practise for Cardiovascular Risk.|Completed||N/A|||Gerencia De Atencion Primaria Area 2 De Madrid||2|||f||||||||||||||2018-05-31 23:00:33.548649|2018-05-31 23:00:33.548649
NCT01270009|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2012-05-15|2011-01-04|2011-01-05|Estimate|||||||2012-05-15|2012-05-16|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||Role of BCL-B in Multiple Myeloma|Implication of the Antiapoptotic Protein BCL-B in the Pathogenesis of Multiple Myeloma|Unknown status|Recruiting||60|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-05-31 23:00:33.709008|2018-05-31 23:00:33.709008
NCT01269996|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-04|||2015-08-21|2011-01-04|2011-01-05|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Interventional|JUBILEE||JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients|JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients|Completed||Phase 4|71|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:00:33.811511|2018-05-31 23:00:33.811511
NCT01269983|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-04|2011-01-04|2011-01-05|Estimate|||||||2011-01-04|2011-01-05|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Effectiveness of Fascial Manipulation for Chronic Low Back Pain|Effectiveness of Fascial Manipulation for Chronic Low Back Pain. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|University of Bologna||2|||f||||f||||||||||2018-05-31 23:00:33.897129|2018-05-31 23:00:33.897129
NCT01269970|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|January 2004||2004-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|July 2008|Actual|2008-07-31||Observational|||Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy|Early Metabolic Response Evaluation With 18-FDG PET-CT in Esophageal Cancer Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy|Completed|||||Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 23:00:33.999779|2018-05-31 23:00:33.999779
NCT01269957|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|November 2009||2009-11-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Observational|||Halitosis and Mouth Breathing in Children|Halitosis and Mouth Breathing in Children|Completed|||55|Actual|University of Nove de Julho|||2||f||||t||||||||||2018-05-31 23:00:34.066772|2018-05-31 23:00:34.066772
NCT01269944|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2017-11-01|2011-01-03|2011-01-04|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2007||2007-07-31|November 2017|2017-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Effects of Osteotomies Around the Knee on Cartilage Glycosaminoglycan Content Using dGEMRIC Non-invasive Imaging|Effects of Osteotomies Around the Knee on Cartilage Glycosaminoglycan Content Using dGEMRIC Non-invasive Imaging, a Pilot Study|Completed|||10|Actual|UMC Utrecht|||1||f||||t||||||||||2018-05-31 23:00:34.134334|2018-05-31 23:00:34.134334
NCT01269931|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Evaluation of Clinical Endobronchial Ultrasound Skills Following Clinical Versus Simulation Training.|Evaluation of Clinical Endobronchial Ultrasound Skills Following Clinical Versus Simulation Training.|Completed|||24|Actual|University of Calgary|||2||f||||t||||||||||2018-05-31 23:00:34.215866|2018-05-31 23:00:34.215866
NCT01269918|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2016-06-06||2016-10-26|2011-01-03|2011-01-04|Estimate|2016-10-26|2016-12-20|Estimate||||2016-10-26|2016-12-20|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|RemivsDex||A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain|A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain|Completed||N/A|142|Actual|The Cleveland Clinic||2|||f||||t||||||||Undecided||2018-05-31 23:00:34.333547|2018-05-31 23:00:34.333547
NCT01269905|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate||||January 2005|2005-01-31||||||||Observational|||Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management||Completed|||||Johann Wolfgang Goethe University Hospital|||3||f||||||||||||||2018-05-31 23:00:34.785771|2018-05-31 23:00:34.785771
NCT01269866|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-02-04|2011-01-03|2011-01-04|Estimate|||||||2013-02-04|2013-02-05|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus|Duloxetine (Cymbalta) in the Reduction of Pain Severity in Patient With Systemic Lupus Erythematosus: A Pilot Study|Completed||N/A|26|Actual|Brain Resource Center||1|||f||||f||||||||||2018-05-31 23:00:35.07111|2018-05-31 23:00:35.07111
NCT01269853|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-11-29|2011-01-03|2011-01-04|Estimate|||||||2017-11-29|2017-12-02|Actual|October 2010||2010-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA|Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.|Recruiting||Phase 1/Phase 2|54|Anticipated|Northwell Health||2|||f||||f||||||||||2018-05-31 23:00:35.177228|2018-05-31 23:00:35.177228
NCT01269840|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2014-10-05|2011-01-03|2011-01-04|Estimate|||||||2014-10-05|2014-10-07|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|June 2012|Actual|2012-06-30||Observational|||Comparison of Two Radial Head Implants|Comparison of Monopolar In-Growth and Loose Bipolar Radial Head Implants in the Treatment of Irreparable Radial Head Fractures|Completed|||41|Actual|Northwestern University|||||f||||t||||||||||2018-05-31 23:00:35.269404|2018-05-31 23:00:35.269404
NCT01269827|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|January 2006||2006-01-31|January 2011|2011-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pentoxifylline and Systemic Inflammation in Hemodialysis Patients|Randomized, Double-Blinded, Controlled Clinical Trial of the Effect Pentoxifylline vs Placebo on the Serum Concentrations of TNF-a, IL-6 and CRP of Patients in Hemodialysis|Completed||Phase 4|36|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 23:00:35.330699|2018-05-31 23:00:35.330699
NCT01269814|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2012-10-16|2011-01-03|2011-01-04|Estimate|||||||2012-10-16|2012-10-17|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Observational|||The Impact of Rockall Risk Scoring System on Management of Upper Gastrointestinal System Bleeding|The Impact of Rockall Risk Scoring System on Timing of Endoscopy, Length of Hospital Stay, Morbidity and Mortality in Patients With Upper Gastrointestinal System Bleeding|Unknown status|Recruiting||100|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||1||f||||t||||||||||2018-05-31 23:00:35.415513|2018-05-31 23:00:35.415513
NCT01269801|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-02|2014-07-11||2014-12-12|2011-01-03|2011-01-04|Estimate|2014-12-12|2014-12-16|Estimate||||2014-12-12|2014-12-16|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|JUVE_BTX|Baseline analysis stratified by treatment group (per sequence).|Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds|A Phase IV Prospective, Open Label, Randomized, Crossover Study Evaluating BOTOX Cosmetic for Injection and JUVEDERM Injectable Gel for the Treatment of Moderate to Severe Facial Wrinkles and Folds|Completed||Phase 4|156|Actual|AboutSkin Dermatology and DermSurgery, PC||2|||f||||t||||||||||2018-05-31 23:00:35.498445|2018-05-31 23:00:35.498445
NCT01269788|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2012-03-05|2011-01-02|2011-01-04|Estimate|||||||2012-03-05|2012-03-06|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial|Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial|Completed||Phase 2/Phase 3|144|Actual|Tehran University of Medical Sciences||6|||f||||f||||||||||2018-05-31 23:00:35.728083|2018-05-31 23:00:35.728083
NCT01269775|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-02|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Face to Face Lecture, Interactive Internet Based and Computer Based Teaching|Comparison of Face to Face Lecture Based, Interactive Internet Based and Computer Based Teaching Regarding Students' Knowledge Achievement and Satisfaction: A Randomized Controlled Trial|Completed||Early Phase 1|84||Tehran University of Medical Sciences||3|||f||||f||||||||||2018-05-31 23:00:35.8094|2018-05-31 23:00:35.8094
NCT01269762|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2012-01-02|2011-01-02|2011-01-04|Estimate|||||||2012-01-02|2012-01-05|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules|Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules|Completed||Phase 4|14|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 23:00:35.863674|2018-05-31 23:00:35.863674
NCT01269749|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2017-08-03||2017-10-05|2011-01-03|2011-01-04|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|October 2010||2010-10-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||This was a pediatric study. All participants were <18yrs of age. Due to the low number of participants enrolled the data was not sufficient to analyze.|Radioactive Iodide Therapy for Pediatric Graves' Disease|Radioactive Iodide Therapy for Pediatric Graves' Disease|Completed||Phase 2|19|Actual|University of Florida||2|||f||||f|t|f||||||||2018-05-31 23:00:35.943363|2018-05-31 23:00:35.943363
NCT01269736|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2017-06-01||2017-08-28|2011-01-03|2011-01-04|Estimate|2017-08-28|2017-08-31|Actual||||2017-08-28|2017-08-31|Actual|August 2008||2008-08-31|June 2017|2017-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PULSE||Implementation of Practice Standards for ECG Monitoring|Implementation of Practice Standards for ECG Monitoring|Completed||N/A|92057|Actual|Yale University||2|||f||||t|f|f||||||No||2018-05-31 23:00:36.178444|2018-05-31 23:00:36.178444
NCT01269723|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2014-01-28|2011-01-03|2011-01-04|Estimate|||||||2014-01-28|2014-01-29|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers|Effects of Sulforaphane (SFN)on Innate Immune Responses to Live Attenuated Influenza Virus in Smokers and Nonsmokers|Completed||N/A|51|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:00:36.58308|2018-05-31 23:00:36.58308
NCT01269554|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-13|||2014-03-10|2011-01-03|2011-01-04|Estimate|||||||2014-03-10|2014-03-11|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|May 2013|Actual|2013-05-31||Observational|||Etiology of Diarrhea in Guinea-Bissau and in Finland|Etiology of Diarrhea in Guinea-Bissau and in Finland|Unknown status|Active, not recruiting||800|Anticipated|Bandim Health Project|||8||f||||f||||||Samples Without DNA|"~     Faecea samples are collected for analysis of patogens~   "|||2018-05-31 23:00:37.833321|2018-05-31 23:00:37.833321
NCT01269372|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2014-08-03|2010-12-31|2011-01-04|Estimate|||||||2014-08-03|2014-08-05|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon|Evaluation of Capsule Endoscopy With PillCam® Colon 2 in Visualization of the Colon|Completed||N/A|30|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-05-31 23:00:39.039664|2018-05-31 23:00:39.039664
NCT01269710|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2012-11-08||2013-01-18|2011-01-03|2011-01-04|Estimate|2013-01-18|2013-02-22|Estimate||||2013-01-18|2013-02-22|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|SATIETY||Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study|Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study|Completed|||4|Actual|University of North Carolina, Chapel Hill|This study only enrolled 4 subjects, thus, sample size was a significant limitation. Further, since only a single subject completed to Week 52, it is difficult to determine treatment indication effectiveness with second generation antipsychotics.||||f||||f||||||Samples Without DNA|"~     fasting glucose, lipid profile, insulin, leptin, prolactin, AST, ALT, CRP, adiponectin,~     ghrelin, cortisol, and relevant cytokines or peptide hormones (e.g., NP-Y, resistin,~     TNF-alpha, IL-1b, IL-2, IL-6, IL-8, IL-12, IL-18), sex hormones (e.g., testosterone,~     dehydroepiandrosterone, estrogen, luteinizing hormone, follicle stimulating hormone, and sex~     hormone binding globulin), and SGAP level (not baseline), to assure compliance. TSH and CBC~     will be measured at baseline only.~      Each subject will be asked to provide an additional 16 ml blood sample (approximately 1~     tablespoon) for DNA collection and genotyping.~   "|||2018-05-31 23:00:36.658723|2018-05-31 23:00:36.658723
NCT01269697|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-05-17|2011-01-03|2011-01-04|Estimate|||||||2013-05-17|2013-05-20|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|LIMPIA||Lutein Influence on Macula of Persons Issued From Amd Parents|Lutein Influence on Macula of Persons Issued From Amd Parents|Completed||Phase 3|120|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 23:00:36.904174|2018-05-31 23:00:36.904174
NCT01269684|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2017-02-23|2011-01-03|2011-01-04|Estimate|||||||2017-02-23|2017-02-24|Actual|August 2008|Actual|2008-08-31|February 2017|2017-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|HERMES||Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients|A 6-Month Open Pilot Study to Investigate the Safety and Tolerability of Immediate Conversion From Calcineurin Inhibitor Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients|Withdrawn||Phase 4|0|Actual|Novartis||1||No patient has never been included in the trial|f||||||||||||||2018-05-31 23:00:36.996041|2018-05-31 23:00:36.996041
NCT01269671|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-08-21|2011-01-03|2011-01-04|Estimate|||||||2015-08-21|2015-08-24|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|FAP||Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain|Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain|Withdrawn||Phase 1|0|Actual|Medical College of Wisconsin||2||PI has left institution|f||||t||||||||||2018-05-31 23:00:37.082171|2018-05-31 23:00:37.082171
NCT01269658|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21||2011-07-06|2013-10-29|2011-01-03|2011-01-04|Estimate||||2011-07-06|2011-07-14|Estimate|2013-10-29|2013-11-21|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)|A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis|Terminated||Phase 2|40|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-05-31 23:00:37.17298|2018-05-31 23:00:37.17298
NCT01269645|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2016-06-06|2011-01-03|2011-01-04|Estimate|||||||2016-06-06|2016-06-08|Estimate|July 2009||2009-07-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|September 2011|Actual|2011-09-30||Interventional|FACT||Facts and Attitudes About Clinical Trials|Evaluating Educational Materials About Cancer Clinical Trials|Completed||N/A|471|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 23:00:37.247752|2018-05-31 23:00:37.247752
NCT01269632|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-01-09|2011-01-03|2011-01-04|Estimate|||||||2017-01-09|2017-01-10|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CO19 COVERTE||Cohort of Young Adults Infected With HIV Since Birth or During Childhood|Long Term Evaluation of Young Adults Born to HIV-infected Mothers. A Cohort of Young Adults Infected With HIV Since Birth or During Childhood|Active, not recruiting||N/A|469|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||f||||||||||2018-05-31 23:00:37.347718|2018-05-31 23:00:37.347718
NCT01269619|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-02|||2011-01-02|2011-01-02|2011-01-04|Estimate|||||||2011-01-02|2011-01-04|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Comparative Study of Static and Dynamic Back Supports for Lower Back Pain|Comparative Study of Static and Dynamic Back Supports for Lower Back Pain|Unknown status|Not yet recruiting|N/A|20|Anticipated|Wolfson Medical Center||2|||f||||t||||||||||2018-05-31 23:00:37.443334|2018-05-31 23:00:37.443334
NCT01269606|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2014-06-13|2011-01-03|2011-01-04|Estimate|||||||2014-06-13|2014-06-16|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes|A Trial Comparing the Pharmacokinetic Properties of Insulin Aspart With Fast-acting Insulin Human Following Intravenous Infusion or Intramuscular Injection in Japanese Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|13|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 23:00:37.509392|2018-05-31 23:00:37.509392
NCT01269593|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2018-01-12|2011-01-03|2011-01-04|Estimate|||||||2018-01-12|2018-01-17|Actual|December 2010|Actual|2010-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study|PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study|Recruiting||Early Phase 1|67|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:00:37.586732|2018-05-31 23:00:37.586732
NCT01269580|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-08-07|2011-01-03|2011-01-04|Estimate|||||||2013-08-07|2013-08-09|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|June 2013|Actual|2013-06-30||Observational|||Diabetic Foot and Vascular Progenitor Cells|The Diabetic Foot: Relevance of Vascular Progenitor Cells as a Prognostic Marker of Cardiovascular Mortality, Restenosis, and Atherosclerotic Disease Progression in Treated Limb.|Unknown status|Active, not recruiting||122|Actual|IRCCS Multimedica|||2||f||||f||||||||||2018-05-31 23:00:37.663652|2018-05-31 23:00:37.663652
NCT01269567|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-07-22|2011-01-03|2011-01-04|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|GRECCAR 5||Drainage After Rectal Excision for Rectal Cancer|Randomized Trial Comparing Drainage Versus no Drainage Following Rectal Excision With Low Anastomosis for Rectal Cancer|Completed||Phase 3|494|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 23:00:37.728441|2018-05-31 23:00:37.728441
NCT01269541|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2017-08-21|2011-01-03|2011-01-04|Estimate|||||||2017-08-21|2017-08-22|Actual|March 1, 2011|Actual|2011-03-01|May 2015|2015-05-31|May 1, 2015|Actual|2015-05-01|May 1, 2015|Actual|2015-05-01||Interventional|MESS||MESS-study MRSA Eradication Study Skåne|MESS- MRSA Eradication Study Skåne. A Comparison Between Systemic Antibiotic Treatment in Combination With Topical Mupirocintreatment With Only Topical Mupiroicintreatment to Eradicate MRSA in Throat Carriers|Completed||N/A|69|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 23:00:37.910505|2018-05-31 23:00:37.910505
NCT01269528|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-11-08|2011-01-03|2011-01-04|Estimate|||||||2015-11-08|2015-11-10|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation|Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation|Completed|||42|Actual|Rambam Health Care Campus|||2||f||||t||||||Samples Without DNA|"~     Whole blood for complete blood count , IGE and cytokines.~   "|||2018-05-31 23:00:37.985746|2018-05-31 23:00:37.985746
NCT01269515|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2017-05-29|2011-01-03|2011-01-04|Estimate|||||||2017-05-29|2017-05-31|Actual|October 2010||2010-10-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|OUSCOX2||Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients|Optional Immunomodulating Therapy and Improved Vaccination Responses by Adjuvant Administration of a Cyclooxygenase Type 2 Inhibitor in Antiretroviral naïve HIV-infected Patients and Patients on ART|Completed||Phase 2|60|Actual|Oslo University Hospital||6|||f||||f||||||||No||2018-05-31 23:00:38.07205|2018-05-31 23:00:38.07205
NCT01269502|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2014-09-18|2011-01-03|2011-01-04|Estimate|||||||2014-09-18|2014-09-19|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Prevention of Secondary Foot Ulcers in Patients With Diabetes Using Systematic Measuring of Skin Temperature.|Prevention of Secondary Foot Ulcers in Patients With Diabetes. Will People With Diabetes Who Have Had a Foot Ulcer be Able to Prevent Secondary Ulcers by Systematically Measuring Their Skin Temperature?|Completed||N/A|41|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:00:38.152637|2018-05-31 23:00:38.152637
NCT01269489|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-01|||2012-03-23|2011-01-03|2011-01-04|Estimate|||||||2012-03-23|2012-03-26|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Health-related Quality of Life in General Slovenian Population|Health-related Quality of Life in General Slovenian Poplation Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality-of-Life Questionnaire QLQ-C30|Unknown status|Recruiting||600|Anticipated|Institute of Oncology Ljubljana|||1||f||||f||||||||||2018-05-31 23:00:38.213435|2018-05-31 23:00:38.213435
NCT01269476|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2010-12-31|2010-12-31|2011-01-04|Estimate|||||||2010-12-31|2011-01-04|Estimate|December 2009||2009-12-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers|Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers|Completed||Phase 1|27|Actual|SeneXta Therapeutics SA||2|||f||||f||||||||||2018-05-31 23:00:38.290399|2018-05-31 23:00:38.290399
NCT01269463|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-31|||2013-01-22|2010-12-31|2011-01-04|Estimate|||||||2013-01-22|2013-01-24|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|||Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting|A Randomized, Double-Blind Study of the Time Course of Response to Biphentin Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom Setting|Completed||Phase 3|27|Actual|Rhodes Pharmaceuticals, L.P.||2|||f||||f||||||||||2018-05-31 23:00:38.350679|2018-05-31 23:00:38.350679
NCT01269450|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2018-01-20|2011-01-03|2011-01-04|Estimate|||||||2018-01-20|2018-01-23|Actual|December 2010||2010-12-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31||Interventional|||Progesterone and Second Trimester Bleeding|The Impact of Progesterone on the Risk of Preterm Birth Among Women With Second Trimester Bleeding. A Double Blind Placebo Controlled Trial|Terminated||N/A|128|Actual|HaEmek Medical Center, Israel||2||Slow recruitment|f||||t||||||||||2018-05-31 23:00:38.431959|2018-05-31 23:00:38.431959
NCT01269437|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-31|||2011-08-22|2011-01-03|2011-01-04|Estimate|||||||2011-08-22|2011-08-23|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma|Open-label, Randomized, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Budesonide Novolizer Dry Powder Inhaler Compared With Budesonide Turbuhaler Dry Powder Inhaler in Chinese Mild to Moderate Asthma Patients|Unknown status|Recruiting|Phase 2/Phase 3|332|Anticipated|NovaMed Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 23:00:38.510406|2018-05-31 23:00:38.510406
NCT01269424|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-31|||2016-12-20|2010-12-31|2011-01-04|Estimate|||||||2016-12-20|2016-12-22|Estimate|December 2010||2010-12-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma|O6-Benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140KMGMT+ Hematopoietic Progenitors to Protect Hematopoiesis|Suspended||Phase 1|14|Anticipated|Case Comprehensive Cancer Center||3||Revisions due - Enroll to cohort 2|f||||t||||||||||2018-05-31 23:00:38.627147|2018-05-31 23:00:38.627147
NCT01269411|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-31|||2013-02-06|2010-12-31|2011-01-04|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2011||2011-07-31|February 2013|2013-02-28||||February 2012|Actual|2012-02-29||Interventional|||RO4929097 in Treating Patients With Recurrent Invasive Gliomas|"Phase I Pharmacodynamic and High Content Study of the Gamma-Secretase Inhibitor RO4929097 in Patients With Recurrent Malignant Gliomas (MGs) Targeting p75NTR to Inhibit Brain Tumor Initiating Cells (BTICs) and Recurrent Invasive Gliomas"|Terminated||Phase 1|22|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-05-31 23:00:38.786216|2018-05-31 23:00:38.786216
NCT01269398|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-03-21|2011-01-03|2011-01-04|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31||||August 2014|Anticipated|2014-08-31||Interventional|||GO-LIF With Percutaneous Facet Fusion|Achieving Solide Fusion, Comibing the GO-LIF Procedure for Spinal Fixation and Stabilization With Percutaneous Posetrior Facets Fusion.|Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 23:00:38.860186|2018-05-31 23:00:38.860186
NCT01269385|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2016-04-19|2011-01-03|2011-01-04|Estimate|||||||2016-04-19|2016-04-21|Estimate|January 2011||2011-01-31|June 2015|2015-06-30||||June 2014|Actual|2014-06-30||Interventional|||Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia|Early Treatment of High Risk Chronic Lymphocytic Leukemia With Alemtuzumab, Rituximab, and PGG Beta-Glucan: A Phase I/II Trial|Unknown status|Active, not recruiting|Phase 1/Phase 2|55|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 23:00:38.925042|2018-05-31 23:00:38.925042
NCT01269346|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-31|2016-10-26||2017-02-10|2011-01-03|2011-01-04|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|December 2010||2010-12-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|March 2013|Actual|2013-03-31||Interventional||Full analysis set (FAS) included all participants who received at least one dose of study drug.|Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer|A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer|Completed||Phase 2|52|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 23:00:39.222701|2018-05-31 23:00:39.222701
NCT01269333|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-08-18|2011-01-03|2011-01-04|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2011||2011-01-31|August 2015|2015-08-31||||July 2012|Actual|2012-07-31||Interventional|||Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel|Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel. a Randomized, Double-blind Placebo Controlled, Crossover Trial|Completed||Phase 1|15|Actual|Hadassah Medical Organization||3|||f||||||||||||||2018-05-31 23:00:39.65133|2018-05-31 23:00:39.65133
NCT01269320|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2012-08-27|2011-01-03|2011-01-04|Estimate|||||||2012-08-27|2012-08-28|Estimate|January 2012||2012-01-31|August 2011|2011-08-31||||||||Interventional|||Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease||Withdrawn||Phase 4|0|Actual|Hadassah Medical Organization||||Sponsors decision|f||||t||||||||||2018-05-31 23:00:39.719865|2018-05-31 23:00:39.719865
NCT01269307|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2014-12-11|2011-01-03|2011-01-04|Estimate|||||||2014-12-11|2014-12-12|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Combination Ketamine and Propofol vs Propofol for Emergency Department Sedation: A Prospective Randomized Trial|Combination Ketamine and Propofol vs Propofol for Emergency Department Sedation: A Prospective Randomized Trial|Completed||N/A|99|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 23:00:39.778501|2018-05-31 23:00:39.778501
NCT01269294|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2013-05-03|2010-12-30|2011-01-04|Estimate|||||||2013-05-03|2013-05-06|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers|A Double-blind, Double-dummy, Randomized, 4-period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of TMC435 on the QTc Interval in Healthy Subjects|Completed||Phase 1|60|Actual|Tibotec Pharmaceuticals, Ireland||7|||f||||t||||||||||2018-05-31 23:00:39.868467|2018-05-31 23:00:39.868467
NCT01269281|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|July 2005||2005-07-31|October 2005|2005-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions|Open Label, Randomized, Two Way Crossover, Comparative Evaluation of Relative Bioavailabilities of Two Formulations of Sumatriptan Succinate Tablets 100 mg (Dr. Reddy's Laboratories Limited, India)With the Reference Formulation Imitrex Tablets 100 mg (Glaxosmilthkine) in Healthy Adult Subjects Under Fed Conditions.|Completed||Phase 1|50|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:00:39.962214|2018-05-31 23:00:39.962214
NCT01269268|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2014-02-04|2011-01-03|2011-01-04|Estimate|||||||2014-02-04|2014-02-05|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis|Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis|Unknown status|Recruiting||260|Anticipated|Yonsei University|||2||f||||f||||||Samples Without DNA|"~     peripheral blood and serum will be retained~   "|||2018-05-31 23:00:40.039732|2018-05-31 23:00:40.039732
NCT01269255|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2013-06-01|2011-01-03|2011-01-04|Estimate|||||||2013-06-01|2013-06-04|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer|A Phase I Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer|Completed||Phase 1|6|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 23:00:40.095461|2018-05-31 23:00:40.095461
NCT01269242|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2016-08-04|2011-01-03|2011-01-04|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||The Effects of Bindarit in Preventing Stent Restenosis|A Pilot Study to Evaluate the Efficacy and Safety of Different Bindarit Dosages in Preventing Stent Restenosis|Completed||Phase 2|148|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||3|||f||||f||||||||||2018-05-31 23:00:40.162852|2018-05-31 23:00:40.162852
NCT01269229|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2016-09-05|2011-01-03|2011-01-04|Estimate|||||||2016-09-05|2016-09-07|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis|A Phase 2 Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis|Completed||Phase 2|32|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 23:00:40.24142|2018-05-31 23:00:40.24142
NCT01269216|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-01-26|2011-01-03|2011-01-04|Estimate|||||||2015-01-26|2015-01-28|Estimate|October 2008||2008-10-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer|A Randomized Phase II Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer|Completed||Phase 2|136|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:00:40.303202|2018-05-31 23:00:40.303202
NCT01269203|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2012-09-05|2010-12-30|2011-01-04|Estimate|||||||2012-09-05|2012-09-07|Estimate|October 2012||2012-10-31|September 2012|2012-09-30||||October 2015|Anticipated|2015-10-31||Interventional|||Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients|A Phase II Randomized Study of the Efficacy of Curcumin for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 23:00:40.370705|2018-05-31 23:00:40.370705
NCT01269190|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2018-01-02|2010-12-30|2011-01-04|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2010|Actual|2010-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Proflavine: A Feasibility Study for In Vivo Imaging of Oral Neoplasia|Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study|Recruiting||N/A|275|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:00:40.45035|2018-05-31 23:00:40.45035
NCT01269177|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|May 2009||2009-05-31|October 2010|2010-10-31||||||||Observational|ACPE||Mortality and Risk Factors in Patients With Acute Cardiogenic Pulmonary Edema: a Multicentric, Observational, Prospective Study|Mortality and Risk Factors in Patients With Acute Cardiogenic Pulmonary Edema: a Multicentric, Observational, Prospective Study|Unknown status|Recruiting||1000|Anticipated|University of Milan|||1||f||||||||||||||2018-05-31 23:00:40.549342|2018-05-31 23:00:40.549342
NCT01269164|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2017-05-26|2011-01-03|2011-01-04|Estimate|||||||2017-05-26|2017-05-31|Actual|July 2010||2010-07-31|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Interventional|||Face Transplantation Clinical Trial|Protocol for Composite Facial Allograft Transplant|Recruiting||N/A|2|Anticipated|The Cleveland Clinic||1|||f||||t||||||||Undecided||2018-05-31 23:00:40.624511|2018-05-31 23:00:40.624511
NCT01269151|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2015-04-07|2011-01-03|2011-01-04|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|March 2013|Actual|2013-03-31||Interventional|LucERG||Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD|A Prospective, Non-randomized, Mono-center, Cohort Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections on Retinal Function in Patients With Wet Age-related Macular Degeneration During Twelve Month|Completed||N/A|20|Actual|University of Luebeck||1|||f||||t||||||||||2018-05-31 23:00:40.695757|2018-05-31 23:00:40.695757
NCT01269138|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2012-11-26|2011-01-03|2011-01-04|Estimate|||||||2012-11-26|2012-11-27|Estimate|January 2007||2007-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|||||Observational|STER||Treatment of Inherited Factor VII Deficiency|Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study|Completed|||223|Actual|University of L'Aquila|||1||f||||t||||||Samples Without DNA|"~     Plasma for Factor VII inhibitor assay is stored and sent to a Central Laboratory for the~     inhibitor determination. Samples are discharged after the inhibitor determination~   "|||2018-05-31 23:00:40.761786|2018-05-31 23:00:40.761786
NCT01269125|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|2012-06-29||2013-07-23|2011-01-03|2011-01-04|Estimate|2013-06-18|2013-07-24|Estimate||||2013-07-23|2013-07-30|Estimate|May 2004||2004-05-31|July 2013|2013-07-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.|Ultralong Administration of GnRH-a Before in Vitro Fertilization Improves Fertilization Rate But Not Pregnancy Rate in Women With Endometriosis. A Prospective, Randomized, Controlled Trial.|Completed||N/A|180|Actual|University of Ioannina||3|||f||||f||||||||||2018-05-31 23:00:40.841897|2018-05-31 23:00:40.841897
NCT01269112|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2016-05-12|2011-01-03|2011-01-04|Estimate|||||||2016-05-12|2016-05-13|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy|Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Renal Failure: a Randomized Controlled Trial|Completed||Phase 4|103|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 23:00:41.165414|2018-05-31 23:00:41.165414
NCT01269099|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Hypokalemia and Intravenous Patient Controlled Analgesia|Hypokalemia and Intravenous Patient Controlled Analgesia|Completed||N/A|50|Actual|Seoul Medical Center||2|||f||||f||||||||||2018-05-31 23:00:41.313851|2018-05-31 23:00:41.313851
NCT01269086|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2011-05-26|2011-01-03|2011-01-04|Estimate|||||||2011-05-26|2011-05-27|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Family Preventive Visits to Detect Risk Factors in the Family|Family Preventive Visits to Detect Risk Factors in the Family|Completed||N/A|300|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 23:00:41.403557|2018-05-31 23:00:41.403557
NCT01269073|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-27|2011-01-03|2011-01-04|Estimate|||||||2011-01-27|2011-01-28|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Comparison Of The Berlin Questionnaire To The Portland Sleep Quiz|Comparison Of The Berlin Questionnaire To The Portland Sleep Quiz In Identification Of Patients At Risk For Obstructive Sleep Apnea|Unknown status|Enrolling by invitation||400|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-05-31 23:00:41.482816|2018-05-31 23:00:41.482816
NCT01269060|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2012-08-02|2011-01-03|2011-01-04|Estimate|||||||2012-08-02|2012-08-06|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy of Single Incision (Embryonic NOTES) Laparoscopic Colorectal Surgery|Phase 2 Study of Efficacy of Single Incision (Embryonic NOTES) Laparoscopic Colorectal Surgery|Completed||Phase 2|48|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 23:00:41.559649|2018-05-31 23:00:41.559649
NCT01269047|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|2017-05-09||2018-03-13|2011-01-03|2011-01-04|Estimate|2018-02-06|2018-02-08|Actual||||2018-03-13|2018-04-12|Actual|August 2009||2009-08-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia|Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia|Completed||Phase 4|37|Actual|Albert Einstein College of Medicine, Inc.||3|||f||||t||||||||||2018-05-31 23:00:41.658576|2018-05-31 23:00:41.658576
NCT01269034|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2018-02-06|2011-01-03|2011-01-04|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2010||2010-12-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||New Onset Type 1 Diabetes: Role of Exenatide|New Onset Type 1 Diabetes: Role of Exenatide|Recruiting||Phase 4|20|Anticipated|Albert Einstein College of Medicine, Inc.||4|||f||||t||||||||||2018-05-31 23:00:42.062967|2018-05-31 23:00:42.062967
NCT01269021|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2016-03-15|2011-01-03|2011-01-04|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)|Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.|Completed||N/A|176|Actual|Nanjing University School of Medicine||2|||f||||t||||||||||2018-05-31 23:00:42.17816|2018-05-31 23:00:42.17816
NCT01269008|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2018-02-16|2011-01-03|2011-01-04|Estimate|||||||2018-02-16|2018-02-20|Estimate|December 2010||2010-12-31|February 2018|2018-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Closedloop||Closed Loop System With Pramlintide Versus Exenatide|CLOSED LOOP SYSTEM IN TYPE 1 DIABETES MANAGEMENT COMPARISON WITH PRAMLINTIDE Vs EXENATIDE|Completed||Phase 1|13|Actual|Albert Einstein College of Medicine, Inc.|||||f||||f||||||||||2018-05-31 23:00:42.274387|2018-05-31 23:00:42.274387
NCT01268449|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2010-12-29|2010-12-29|2010-12-30|Estimate|||||||2010-12-29|2010-12-30|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Evaluation of Low Dose Laser in Treatment of Tinnitus|Phase 1 Evaluation of Low Dose Laser in Treatment of Tinnitus|Completed||Phase 2|66|Actual|Islamic Azad University of Mashhad||2|||f||||t||||||||||2018-05-31 23:00:47.688564|2018-05-31 23:00:47.688564
NCT01268995|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|||||Interventional|ISINODAT||Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation|A Randomized, Prospective Trial to Evaluate the Effect of Conversion From Tacrolimus to Cyclosporine A After Early Initiation of Insulin Therapy in Patients With New-onset Diabetes Mellitus After Kidney Transplantation|Terminated||Phase 2|32|Anticipated|Medical University of Vienna||2||It was impossible to recruit the scheduled number of patients|f||||t||||||||||2018-05-31 23:00:42.343715|2018-05-31 23:00:42.343715
NCT01268982|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Socket Preservation Procedure on Dimensional Changes of the Ridge, and Its Efficacy.|Dimensional Changes of the Alveolar Ridge Contour After Socket Preservation, Stability of Implants Placed, and Histological Evaluation of Newly Formed Bone at These Sites.|Completed||Phase 2|32|Actual|Mashhad University of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:00:42.42049|2018-05-31 23:00:42.42049
NCT01268969|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|PND||Comparison Between Two Different Technique in Treatment of Chronic Pilonidal Disease|A Prospective Randomized Trial-comparing Excision and Limberg Flap Closure Versus Karydakis Flap Reconstruction for Treatment of Sacrococcygeal Pilonidal Disease|Completed||N/A|120|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 23:00:42.490309|2018-05-31 23:00:42.490309
NCT01268956|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-01-03|2011-01-03|2011-01-04|Estimate|||||||2011-01-03|2011-01-04|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Observational|||Circulating Lymphatic Progenitor Cell and Lymph Node Metastasis|Correlation of Circulating Lymphatic Progenitor Cells With Lymph Node Metastasis in Ovarian Cancer Patients|Unknown status|Not yet recruiting||60|Anticipated|Hospital Universitari de Bellvitge|||2||f||||f||||||Samples Without DNA|"~     blood serum~   "|||2018-05-31 23:00:42.57294|2018-05-31 23:00:42.57294
NCT01268943|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2015-03-05||2015-03-17|2011-01-03|2011-01-04|Estimate|2015-03-05|2015-03-17|Estimate||||2015-03-17|2015-04-06|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients|Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer|Completed||Phase 1|18|Actual|Chinese Academy of Medical Sciences||4|||f||||f||||||||||2018-05-31 23:00:42.651495|2018-05-31 23:00:42.651495
NCT01268930|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-03|||2011-06-21|2011-01-03|2011-01-04|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Comparison of Hemostatic Matrix and Bipolar Coagulation in Surgical Treatment of Endometriomas||Completed||N/A|30|Actual|Ankara University||2|||f||||t||||||||||2018-05-31 23:00:42.999182|2018-05-31 23:00:42.999182
NCT01268917|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2010-12-30|2010-12-30|2010-12-31|Estimate|||||||2010-12-30|2010-12-31|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||March 2011|Anticipated|2011-03-31||Interventional|||The Effects of Preoperative Aspirin on Graft Patency and Cardiac Events in Off-pump Coronary Artery Bypass||Unknown status|Recruiting|Phase 3|200|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 23:00:43.072789|2018-05-31 23:00:43.072789
NCT01268904|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2010-12-30|2010-12-30|2010-12-31|Estimate|||||||2010-12-30|2010-12-31|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Observational|||Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures||Unknown status|Not yet recruiting||50|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-05-31 23:00:43.135634|2018-05-31 23:00:43.135634
NCT01268891|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|2013-06-28||2013-10-07|2010-12-30|2010-12-31|Estimate|2013-10-07|2013-12-03|Estimate||||2013-10-07|2013-12-03|Estimate|January 2011||2011-01-31|October 2013|2013-10-31||||June 2012|Actual|2012-06-30||Interventional||"Age and Gender: all-patients-treated set (APTS) – all patients in the APRS who took at least one dose of investigational medicinal product (IMP).~Study-specific Characteristics: full-analysis set (FAS) – all patients in the APTS who had at least one valid post-baseline assessment of total daily OFF time (at least one valid post-baseline diary)."|Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in Korea|Completed||Phase 3|132|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 23:00:43.203776|2018-05-31 23:00:43.203776
NCT01268878|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2014-01-02|2010-12-30|2010-12-31|Estimate|||||||2014-01-02|2014-01-03|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|OTOHTPF||Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol|Hematologic Toxicity Observation of the TPF Medical Protocol. Description of the Impact of Febrile Neutropenia in Patients Who Receive the Chemotherapy of the TPF Medical Protocol in Head and Neck Cell Carcinoma|Completed|||130|Actual|Groupe Oncologie Radiotherapie Tete et Cou|||||f||||f||||||||||2018-05-31 23:00:43.488608|2018-05-31 23:00:43.488608
NCT01268865|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2011-06-02|2010-12-30|2010-12-31|Estimate|||||||2011-06-02|2011-06-03|Estimate|December 2010||2010-12-31|June 2011|2011-06-30||||||||Observational|ARFI||Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis|Clinical Application of Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis in HBV and HCV-infected Patients|Unknown status|Recruiting||200|Anticipated|China Medical University Hospital|||2||f||||t||||||||||2018-05-31 23:00:43.562313|2018-05-31 23:00:43.562313
NCT01268852|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2017-02-16|2010-12-30|2010-12-31|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2011||2011-01-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effectiveness of Insignia ™ Versus Standard Orthodontic Treatment With Damon Q Brackets|Effectiveness of Insignia ™ Versus Standard Orthodontic Treatment With Damon Q Brackets|Completed||N/A|180|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 23:00:43.615582|2018-05-31 23:00:43.615582
NCT01268839|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2013-09-02|2010-12-30|2010-12-31|Estimate|||||||2013-09-02|2013-09-04|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers|A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Subjects|Completed||Phase 1|20|Actual|Tibotec, Inc||1|||f||||||||||||||2018-05-31 23:00:43.672929|2018-05-31 23:00:43.672929
NCT01268826|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2011-01-21|2010-12-30|2010-12-31|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|DESHYDRAT||DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children|DESHYDRAT : Assessment of the Prevalence of Dehydration Among 9 to 11 Year-old Children.|Completed|||500|Anticipated|Rennes University Hospital|||1||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 23:00:43.726284|2018-05-31 23:00:43.726284
NCT01268813|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2010-12-30|2010-12-30|2010-12-31|Estimate|||||||2010-12-30|2010-12-31|Estimate|February 2011||2011-02-28|November 2010|2010-11-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Personalized Medicine for Diabetes Prediction and Prevention of Complications|Personalized Medicine in Diabetes Using a Nanotechnology Platform|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 23:00:43.775009|2018-05-31 23:00:43.775009
NCT01268800|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2014-05-05|2010-12-30|2010-12-31|Estimate|||||||2014-05-05|2014-05-06|Estimate|February 2011||2011-02-28|May 2014|2014-05-31||||August 2014|Anticipated|2014-08-31||Observational|||Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy|Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy, a Sensitive Method for Identifying Resistant AML Clones|Unknown status|Recruiting||50|Anticipated|Rambam Health Care Campus|||1||f||||f||||||Samples With DNA|"~     Blood bone marrow and buccal smear~   "|||2018-05-31 23:00:43.842535|2018-05-31 23:00:43.842535
NCT01268787|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2015-04-15|2010-12-30|2010-12-31|Estimate|||||||2015-04-15|2015-04-16|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine|A Phase I, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine Administrated With Adjuvant AlPO4 in Health Volunteers|Completed||Phase 1|60|Actual|National Health Research Institutes, Taiwan||2|||f||||t||||||||||2018-05-31 23:00:44.766569|2018-05-31 23:00:44.766569
NCT01268774|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2013-04-17|2010-12-30|2010-12-31|Estimate|||||||2013-04-17|2013-04-18|Estimate|February 2009||2009-02-28|April 2013|2013-04-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Observational|||Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.|Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide|Completed|||529|Actual|LEO Pharma|||||f||||t||||||||||2018-05-31 23:00:44.838784|2018-05-31 23:00:44.838784
NCT01268761|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2013-09-18|2010-12-30|2010-12-31|Estimate|||||||2013-09-18|2013-09-19|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome|Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome|Completed||Phase 3|100|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 23:00:44.88181|2018-05-31 23:00:44.88181
NCT01268748|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-12-30|2010-12-30|2010-12-31|Estimate|||||||2010-12-30|2010-12-31|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Interventional|UMBI-CHOL||Single Port Versus Four Ports Laparoscopic Cholecystectomy and Early Postoperative Pain|Efficacy of Transumbilical Versus Standard Laparoscopic Cholecystectomy on Postoperative Pain|Unknown status|Recruiting|N/A|120|Anticipated|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 23:00:44.954497|2018-05-31 23:00:44.954497
NCT01268735|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2010-12-30|2010-12-30|2010-12-31|Estimate|||||||2010-12-30|2010-12-31|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|LIPCOF||The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye|The Effect of Ocular Surface Lubricant Eyedrops on Lid Parallel Conjunctival Folds (LIPCOF) and Other Signs and Symptoms of Dysfunctional Tear Syndrome|Completed||Phase 4|229|Actual|University of Zagreb||1|||f||||f||||||||||2018-05-31 23:00:45.077035|2018-05-31 23:00:45.077035
NCT01268722|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-04-05|2010-12-30|2010-12-31|Estimate|||||||2012-04-05|2012-04-06|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2016|Anticipated|2016-12-31|December 2013|Anticipated|2013-12-31||Interventional|FACTORY||Balloon Angioplasty Versus Primary Stenting for the Treatment of Femoropopliteal Artery Chronic Total Occlusions|Balloon Angioplasty Versus Self-expanding Stent for Recanalization of Chronic Total Occlusions of the Femoral Artery|Unknown status|Recruiting|Phase 3|150|Anticipated|University of Patras||2|||f||||t||||||||||2018-05-31 23:00:45.145312|2018-05-31 23:00:45.145312
NCT01268709|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2010-12-30|2010-12-30|2010-12-31|Estimate|||||||2010-12-30|2010-12-31|Estimate||||December 2010|2010-12-31||||||||Interventional|||Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome||Completed||Phase 2|||Qom University of Medical Sciences||3|||f||||t||||||||||2018-05-31 23:00:45.247705|2018-05-31 23:00:45.247705
NCT01268696|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-07-20|2010-12-30|2010-12-31|Estimate|||||||2011-07-20|2011-07-22|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|January 2015|Anticipated|2015-01-31|August 2011|Anticipated|2011-08-31||Observational|GENMetS||Genetic Assessment of the Patients With Metabolic Syndrome|Genetic Assessment of the Patients With Metabolic Syndrome in Polish Population|Unknown status|Active, not recruiting||300|Anticipated|Medical Universtity of Lodz|||2||f||||t||||||Samples With DNA|"~     the blood samples taken into EDTA~   "|||2018-05-31 23:00:45.384909|2018-05-31 23:00:45.384909
NCT01268683|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|2014-03-11||2014-05-14|2010-12-30|2010-12-31|Estimate|2014-05-14|2014-06-06|Estimate||||2014-05-14|2014-06-06|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|June 2012|Actual|2012-06-30||Interventional|GAMES-PILOT||Glyburide Advantage in Malignant Edema and Stroke Pilot|A Multi-center, Prospective, Open Label, Phase IIa Trial of RP-1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Experience Clinically Significant Brain Swelling.|Completed||Phase 1/Phase 2|10|Actual|Remedy Pharmaceuticals, Inc.|The trial was a single arm; there is thus no placebo to compare RP-1127 to.|1|||f||||t||||||||||2018-05-31 23:00:45.460425|2018-05-31 23:00:45.460425
NCT01268670|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2013-07-30|2010-12-29|2010-12-31|Estimate|||||||2013-07-30|2013-07-31|Estimate|July 2012||2012-07-31|July 2013|2013-07-31||||July 2013|Anticipated|2013-07-31||Interventional|||The Addition of Oral Analgesics to LET During Laceration Repair|Adjunctive Oral Analgesia for Laceration Repair: Assessing Pain in a Pediatric Emergency Department|Suspended||N/A|150|Anticipated|Children's Hospitals and Clinics of Minnesota||3||This study is currently suspended due to transition of the investigator.|f||||||||||||||2018-05-31 23:00:45.705131|2018-05-31 23:00:45.705131
NCT01268657|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2016-08-13|2010-12-29|2010-12-31|Estimate|||||||2016-08-13|2016-08-16|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Intervention for Anxiety After Falls|Intervention for Disabling Anxiety in Older Adults Injured by Falls|Completed||Phase 1|23|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-05-31 23:00:45.780295|2018-05-31 23:00:45.780295
NCT01268644|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2016-05-02|2010-12-30|2010-12-31|Estimate|||||||2016-05-02|2016-05-04|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|August 2014|Actual|2014-08-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Metreleptin in Type 1 Diabetes Mellitus|Open Label Single Center Pilot Study to Study Teh Effects of Metreleptin Administration in Patients With Type 1 Diabetes Mellitus ( T1DM ).|Terminated||Phase 1|7|Actual|University of Texas Southwestern Medical Center||1||Sponsor request|f||||t||||||||||2018-05-31 23:00:45.859322|2018-05-31 23:00:45.859322
NCT01268631|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2010-12-30|2010-12-30|2010-12-31|Estimate|||||||2010-12-30|2010-12-31|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|MTF||Mechanism-based Choice of Therapy: Can Treatments Success in Fibromyalgia Patients be Coupled to Psychophysical Pain Modulation Profile?|Mechanism-based Choice of Therapy: Can Treatments Success in Fibromyalgia Patients be Coupled to Psychophysical Pain Modulation Profile?|Unknown status|Not yet recruiting|N/A|150|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 23:00:45.926501|2018-05-31 23:00:45.926501
NCT01268618|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-07-20|2010-12-30|2010-12-31|Estimate|||||||2011-07-20|2011-07-21|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia|A Double-blind, Randomized, Placebo-controlled, Dual-center Study on the Effect of Healthy Trinity (Retail Label)/Trenev Trio (Professional Label) on Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) and Functional Dyspepsia|Terminated||Phase 2/Phase 3|120|Anticipated|Sprim Advanced Life Sciences||2|||f||||f||||||||||2018-05-31 23:00:45.999841|2018-05-31 23:00:45.999841
NCT01268605|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2014-09-18|2010-12-29|2010-12-31|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|POH RCERT||Postoperative Hypersensitivity Randomized Comparative Effectiveness Research Trial|Resin Based Composite Occlusal Restoration Postoperative Hypersensitivity: Randomized Comparative Effectiveness Research Trial|Completed||Phase 3|341|Actual|Pearl Network||2|||f||||t||||||||||2018-05-31 23:00:46.086488|2018-05-31 23:00:46.086488
NCT01268592|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2013-04-22|2010-12-29|2010-12-31|Estimate|||||||2013-04-22|2013-04-23|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Fertility Preservation in Female Cancer Patients|Vitrification of Oocytes From Female Cancer Patients to Preserve Their Fertility Potential|Terminated||N/A|16|Actual|Northwell Health||1||Study technique has been declared part of standard care|f||||f||||||||||2018-05-31 23:00:46.203828|2018-05-31 23:00:46.203828
NCT01268579|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2018-01-02|2010-12-29|2010-12-31|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2010||2010-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma|A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma|Active, not recruiting||N/A|7|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:00:46.342455|2018-05-31 23:00:46.342455
NCT01268566|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|2016-12-21|2016-05-20|2017-02-21|2010-12-29|2010-12-31|Estimate|2017-02-21|2017-04-06|Actual|2016-06-02|2016-06-07|Estimate|2017-02-21|2017-04-06|Actual|January 2011||2011-01-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme|A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme|Completed||Phase 2|62|Actual|MedImmune LLC||1|||f||||f||||||||||2018-05-31 23:00:46.451838|2018-05-31 23:00:46.451838
NCT01268553|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|2017-06-06||2017-08-31|2010-12-30|2010-12-31|Estimate|2017-08-31|2017-09-01|Actual||||2017-08-31|2017-09-01|Actual|August 2010||2010-08-31|August 2017|2017-08-31|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Interventional|||Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication|Transition From Parenteral Prostanoids to Inhaled Treprostinil|Completed||Phase 4|6|Actual|Los Angeles Biomedical Research Institute||1|||f||||f||||||||||2018-05-31 23:00:46.829542|2018-05-31 23:00:46.829542
NCT01268540|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2015-02-04|2010-12-29|2010-12-31|Estimate|||||||2015-02-04|2015-02-06|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|COAST||Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses|Comparison of Aspheric Toric & Non-toric Aphakic Intraocular Lenses|Completed||N/A|235|Actual|Hoya Surgical Optics, Inc.||4|||f||||f||||||||||2018-05-31 23:00:47.031106|2018-05-31 23:00:47.031106
NCT01268527|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15||2013-05-21|2017-04-25|2010-12-29|2010-12-31|Estimate||||2013-05-21|2013-05-29|Estimate|2017-04-25|2017-04-26|Actual|March 2010||2010-03-31|April 2017|2017-04-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris|A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris|Completed||Phase 2|30|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:00:47.117784|2018-05-31 23:00:47.117784
NCT01268514|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2017-02-13|2010-12-29|2010-12-31|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2011||2011-02-28|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Observational|ENHANCE||ENHANCE: A Prospective EvaluatioN of Permacol™ in tHe Repair of Complex AbdomiNal Wall CasEs|ENHANCE: A Prospective Long-term EvaluatioN of the Use of Permacol™ Biological Implant in tHe Repair of Complex AbdomiNal Wall CasEs|Active, not recruiting|||200|Anticipated|Medtronic - MITG|||||f||||f||||||||||2018-05-31 23:00:47.213045|2018-05-31 23:00:47.213045
NCT01268501|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|2012-01-13||2012-06-26|2010-12-29|2010-12-31|Estimate|2012-02-06|2012-02-09|Estimate||||2012-06-26|2012-06-29|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Assessment of a Multifocal Contact Lens for People Who Use Reading Glasses Only|Clinical Assessment of a New Multifocal Contact Lens With Emmetropic Presbyopes|Completed||N/A|103|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:00:47.295518|2018-05-31 23:00:47.295518
NCT01268488|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|2012-09-14||2016-09-28|2010-12-29|2010-12-31|Estimate|2012-09-14|2012-10-16|Estimate||||2016-09-28|2016-11-03|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting|Clinical Trial Protocol for NINJA 2 System With CONTOUR Sensor|Completed||N/A|98|Actual|Ascensia Diabetes Care|It was decided that this investigational BG monitoring system would not be part of a regulatory submission. It will not proceed to market.|1|||f||||f||||||||||2018-05-31 23:00:47.411873|2018-05-31 23:00:47.411873
NCT01268475|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-12-29|2010-12-29|2010-12-30|Estimate|||||||2010-12-29|2010-12-30|Estimate|March 2009||2009-03-31|November 2010|2010-11-30||||||||Observational|||Exercise Capacity in Bronchiectasis Resection|Impact of Pulmonary Resection on Exercise Capacity in Patients With Bronchiectasis|Unknown status|Recruiting||30|Anticipated|University of Sao Paulo|||||f||||t||||||||||2018-05-31 23:00:47.566375|2018-05-31 23:00:47.566375
NCT01268436|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2014-03-20|2010-12-29|2010-12-30|Estimate|||||||2014-03-20|2014-03-24|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|Cohort Dental||Cohort Comparison of Dental Nerve Block With Other Forms of Analgesia in Alleviating the Pain of Toothache|Cohort Comparison of Dental Nerve Block With Other Forms of Analgesia in Alleviating the Pain of Toothache|Completed|||64|Actual|Albany Medical College|||2||f||||f||||||||||2018-05-31 23:00:47.830187|2018-05-31 23:00:47.830187
NCT01268423|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2011-01-04|2010-12-29|2010-12-30|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Interventional|||Early Percutaneous Tracheostomy and Swallowing Dysfunction|Impact of Early Percutaneous Tracheostomy on the Incidence of Swallowing Dysfunction in Critically Ill Patients on Mechanical Ventilation. A Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|120|Anticipated|University of Chile||2|||f||||t||||||||||2018-05-31 23:00:47.959837|2018-05-31 23:00:47.959837
NCT01268410|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2012-09-19|2010-12-29|2010-12-30|Estimate|||||||2012-09-19|2012-09-20|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Observational|ERICC||Epidemiology of Respiratory Insufficiency in Critical Care|Epidemiological Study of Patients With Acute Respiratory Failure Admitted to Brazilian Intensive Care Units|Completed|||773|Actual|Hospital Sirio-Libanes|||1||f||||t||||||||||2018-05-31 23:00:48.063316|2018-05-31 23:00:48.063316
NCT01268397|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2016-03-08|2010-12-29|2010-12-30|Estimate|||||||2016-03-08|2016-03-09|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Unstable Dorsally Displaced Fractures of the Distal Radius in the Elderly|Unstable Dorsally Displaced Fractures of the Distal Radius in the Elderly. A Randomized Comparison Between Operative Fixation and Plaster Cast Treatment.|Recruiting||N/A|80|Anticipated|Danderyd Hospital||2|||f||||f||||||||Undecided||2018-05-31 23:00:48.129656|2018-05-31 23:00:48.129656
NCT01268384|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2011-12-05|2010-12-29|2010-12-30|Estimate|||||||2011-12-05|2011-12-06|Estimate|April 2006||2006-04-30|December 2011|2011-12-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|||Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer|Phase II Study of Fixed Dose Rate Gemcitabine Plus Capecitabine in Locally Advanced Pancreatic Cancer|Completed||Phase 2|43|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 23:00:48.216075|2018-05-31 23:00:48.216075
NCT01268371|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2014-02-11|2010-12-29|2010-12-30|Estimate|||||||2014-02-11|2014-02-12|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|BESS||Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents|Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents|Unknown status|Active, not recruiting|Phase 4|1462|Anticipated|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 23:00:48.288751|2018-05-31 23:00:48.288751
NCT01268358|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2017-03-28|2010-12-29|2010-12-30|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2010||2010-10-31|March 2017|2017-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis|A Single Center, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) for the Treatment of Patients With Alpha-mannosidosis.|Completed||Phase 1|10|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||t||||||||||2018-05-31 23:00:48.391793|2018-05-31 23:00:48.391793
NCT01268345|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-29|||2010-12-29|2010-12-29|2010-12-30|Estimate|||||||2010-12-29|2010-12-30|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||AST Clinical Investigation||Completed||N/A|63|Actual|Andon Medical Co.,Ltd||2|||f||||f||||||||||2018-05-31 23:00:48.461997|2018-05-31 23:00:48.461997
NCT01268332|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2017-08-11|2010-12-29|2010-12-30|Estimate|||||||2017-08-11|2017-08-15|Actual|May 2011||2011-05-31|August 2017|2017-08-31|March 7, 2013|Actual|2013-03-07|September 2012|Actual|2012-09-30||Interventional|MTN-005||Safety and Adherence of a Non-medicated Intravaginal Ring (IVR)|Expanded Safety and Adherence Study of a Non-medicated Intravaginal Ring|Completed||Phase 2|195|Actual|Population Council||2|||f||||t||||||||||2018-05-31 23:00:48.523324|2018-05-31 23:00:48.523324
NCT01268319|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2017-06-08|2010-12-29|2010-12-30|Estimate|||||||2017-06-08|2017-06-12|Actual|May 2011|Actual|2011-05-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|September 2014|Actual|2014-09-30||Interventional|CANARY||CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow|A Randomized Pilot Trial of the Use of a Distal Protection Device to Prevent Peri-procedural MI During Dilation of Coronary Stenoses Caused by Plaques With Large Lipid Cores|Terminated||N/A|85|Actual|InfraReDx||3|||f||||t||||||||||2018-05-31 23:00:48.596527|2018-05-31 23:00:48.596527
NCT01268306|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2012-08-18||2016-08-18|2010-12-29|2010-12-30|Estimate|2016-08-18|2016-08-22|Estimate||||2016-08-18|2016-08-22|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses|A Single-site, Open-Label Prospective Evaluation of Biocompatibility and Corneal Staining Associated With Use of Bausch & Lomb (B+L) BioTrue Contact Lens Multi-purpose Solution (MPS) and B+L PureVision Contact Lenses.|Completed||Phase 4|8|Actual|Epstein, Arthur B., OD, FAAO|Pilot study with insignificant subject population for statistical analysis|1|||f||||f||||||||||2018-05-31 23:00:48.697251|2018-05-31 23:00:48.697251
NCT01268293|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2015-02-21||2016-08-29|2010-12-29|2010-12-30|Estimate|2015-02-21|2015-03-06|Estimate||||2016-08-29|2016-10-07|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|April 2013|Actual|2013-04-30|December 2011|Actual|2011-12-31||Interventional|||A Study of E7080 in Subjects With Solid Tumor|A Phase 1 Study of E7080 in Subjects With Solid Tumor|Completed||Phase 1|9|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 23:00:48.868997|2018-05-31 23:00:48.868997
NCT01268280|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-09-16|2010-12-29|2010-12-30|Estimate|||||||2013-09-16|2013-09-17|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis|A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy|Terminated||Phase 2|32|Actual|Cytokinetics||1||Closed after complete treatment of 32 patients after 21 months' recruitment.|f||||t||||||||||2018-05-31 23:00:49.056677|2018-05-31 23:00:49.056677
NCT01268267|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2012-04-27||2016-01-29|2010-12-28|2010-12-30|Estimate|2012-04-27|2012-05-31|Estimate||||2016-01-29|2016-02-29|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting|Clinical Trial Protocol for Ninja 2 System With TATSU Sensor|Completed||N/A|94|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 23:00:49.158384|2018-05-31 23:00:49.158384
NCT01268254|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|April 2011|Anticipated|2011-04-30|March 2011|Anticipated|2011-03-31||Observational|||Red Wine and Ageing and Atherosclerosis|The Red Wine Project: a Study of Ageing Indexes and Prevalence of Atherosclerosis in Regular Red Wine Consumers Versus Abstainers|Unknown status|Recruiting||200|Anticipated|University of Sao Paulo|||1||f||||f||||||Samples With DNA|"~     total blood sample~   "|||2018-05-31 23:00:49.3169|2018-05-31 23:00:49.3169
NCT01268241|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2016-04-12|2010-12-28|2010-12-29|Estimate|||||||2016-04-12|2016-04-13|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|SWITCH||The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease|International Observational Retrospective Case Review of Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Males and Females With Anderson-Fabry Disease|Completed|||200|Actual|University of Rostock|||1||f||||t||||||Samples With DNA|"~     Plasma and urine GB3 and lyso-GB3 and agalsidase antibodies will be analyzed in central~     laboratories, there is consent for extra blood samples to be taken (at the time of the switch~     and after 6, 12 and 24 months)~   "|Undecided||2018-05-31 23:00:49.370377|2018-05-31 23:00:49.370377
NCT01268228|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-10-14|2010-12-28|2010-12-29|Estimate|||||||2013-10-14|2013-10-16|Estimate|December 2011||2011-12-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|COSIBRIA&CO||Intracoronary Electrocardiogram (ECG) and Myonecrosis After Bifurcation Stenting|COronary SIde Branch Residual IschemiA and COllateralization Assessment Study (COSIBRIA & Co Study)|Completed|||131|Actual|University National Heart Hospital|||2||f||||t||||||||||2018-05-31 23:00:49.44424|2018-05-31 23:00:49.44424
NCT01268215|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|December 2013|Anticipated|2013-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.|The Effect of Endotracheal Instillation of Surfactant With and Without Budesonide on the Development of Bronchopulmonary Dysplasia in Ventilator-dependent, Extremely Low Birth Weight Infants: A Pilot Study|Unknown status|Recruiting|Phase 2|45|Anticipated|East Carolina University||3|||f||||t||||||||||2018-05-31 23:00:49.494174|2018-05-31 23:00:49.494174
NCT01268202|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2016-06-09|2010-12-28|2010-12-29|Estimate|||||||2016-06-09|2016-06-10|Estimate|December 2010||2010-12-31|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|PRAVACUR||Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis|Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis|Recruiting||Phase 2|55|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 23:00:49.565081|2018-05-31 23:00:49.565081
NCT01268189|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2013-12-10||2015-09-08|2010-12-28|2010-12-29|Estimate|2015-09-08|2015-10-09|Estimate||||2015-09-08|2015-10-09|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Subjects serve as their own control as experimental and standard of care dressings applied to 2 different donor sites. Total of 17 participants completed, with 34 donor sites.|Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds|Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds|Completed||N/A|20|Actual|United States Army Institute of Surgical Research||1|||f||||f||||||||||2018-05-31 23:00:49.637369|2018-05-31 23:00:49.637369
NCT01268176|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-05-09|2010-12-28|2010-12-29|Estimate|||||||2013-05-09|2013-05-13|Estimate|December 2010||2010-12-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Effect of a Meal on Vitamin D Absorption|Meal Effects on the 25OHD3 Response to Supplemental Vitamin D3|Completed||Phase 1|62|Actual|Tufts University||3|||f||||f||||||||||2018-05-31 23:00:49.902162|2018-05-31 23:00:49.902162
NCT01268163|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2017-03-16|2010-12-28|2010-12-29|Estimate|||||||2017-03-16|2017-03-20|Actual|August 2007||2007-08-31|July 2015|2015-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer|A Phase 1, Double-blinded, Randomised, Multi-centre, Three-period, Three-treatment, Crossover Study to Compare the Intravenous Pharmacokinetic and Safety Characteristics of European Taxotere® and American Taxotere® With Hospira Docetaxel Injection Administered at a Therapeutic Dose in Cancer Patients.|Completed||Phase 1|32|Actual|Hospira, now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-05-31 23:00:49.98815|2018-05-31 23:00:49.98815
NCT01268150|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2016-05-11||2016-06-28|2010-12-28|2010-12-29|Estimate|2016-06-28|2016-08-09|Estimate||||2016-06-28|2016-08-09|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|August 2013|Actual|2013-08-31|March 2012|Actual|2012-03-31||Interventional||Full analysis set included all participants who received at least one dose of study drug.|A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer|A Phase 2, Multicenter, Single-Arm Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer|Completed||Phase 2|56|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 23:00:50.101732|2018-05-31 23:00:50.101732
NCT01268137|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|January 2008||2008-01-31|December 2010|2010-12-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||DBS in Treatment Resistant Major Depression|DEEP BRAIN STIMULATION IN TREATMENT RESISTANT MAJOR DEPRESSION. Controlled and Crossed Study on Efficacy and Safety.|Unknown status|Active, not recruiting|Phase 3|8|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 23:00:50.565187|2018-05-31 23:00:50.565187
NCT01268124|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|December 2008||2008-12-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HTC-867 Administered Orally to Healthy Japanese Male Subjects|Completed||Phase 1|56|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-05-31 23:00:50.633575|2018-05-31 23:00:50.633575
NCT01268111|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2013-01-04||2015-05-11|2010-12-28|2010-12-29|Estimate|2013-04-18|2013-05-24|Estimate||||2015-05-11|2015-06-08|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Vitamin D Replacement on Insulin Sensitivity|Effect of Vitamin D Supplementation on Insulin Sensitivity and Retinol-binding Protein 4 Levels in Subjects With Vitamin D Deficiency|Completed||Phase 1|12|Actual|Texas Tech University Health Sciences Center||2|||f||||f||||||||||2018-05-31 23:00:50.703405|2018-05-31 23:00:50.703405
NCT01268098|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2015-02-20|2012-09-21|2015-11-10|2010-12-28|2010-12-29|Estimate|2015-02-20|2015-03-06|Estimate|2012-09-21|2012-10-01|Estimate|2015-11-10|2015-12-08|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)|A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism|Completed||Phase 3|42|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:00:50.924425|2018-05-31 23:00:50.924425
NCT01268085|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Radiation Safety Alert|Radiation Safety Alert- A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|2200|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 23:00:51.228496|2018-05-31 23:00:51.228496
NCT01268072|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-02-18|2010-12-28|2010-12-29|Estimate|||||||2013-02-18|2013-02-20|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|||A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease|A Prospective Observational Study to Evaluate Biomarkers in Acute Exacerbations in Chronic Obstructive Pulmonary Disease|Terminated|||61|Actual|MedImmune LLC|||2|"Study was completed with 69 subjects enrolled due to difficult enrolment and adequate biomarker~   data was avaible with 69 subjects in the study."|f||||f||||||Samples Without DNA|"~     Symptom, physiological data, blood, and sputum.~   "|||2018-05-31 23:00:51.295785|2018-05-31 23:00:51.295785
NCT01268059|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2014-03-05|2010-12-28|2010-12-29|Estimate|||||||2014-03-05|2014-03-06|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer|A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|123|Actual|MedImmune LLC||3|||f||||f||||||||||2018-05-31 23:00:51.371067|2018-05-31 23:00:51.371067
NCT01268046|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2017-03-17|2010-12-28|2010-12-29|Estimate|||||||2017-03-17|2017-03-21|Actual|November 2009|Actual|2009-11-30|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Aging and Estrogen on Memory and Cognition|Effects of Aging and Estrogen on Cortical Function|Active, not recruiting||Phase 4|60|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||f|||Yes|De-identified information will be made available on request to the PI once the primary data analysis has been published.|2018-05-31 23:00:51.472879|2018-05-31 23:00:51.472879
NCT01268033|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-03-20|2010-12-28|2010-12-29|Estimate|||||||2015-03-20|2015-03-23|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|NEPHRUTIX||Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood|A Prospective, Randomized, Double Blind, Placebo-controlled Phase II/III Study Evaluating the Efficacy of Rituximab in the Prevention of Relapse of Calcineurin Inhibitors Dependent Idiopathic Nephrotic Syndrome of Childhood|Completed||Phase 2/Phase 3|26|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 23:00:51.55044|2018-05-31 23:00:51.55044
NCT01268020|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-11-08|2010-12-28|2010-12-29|Estimate|||||||2013-11-08|2013-11-11|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|FMH3||Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC|An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate [18F]-FMH3 by Positron Emission Tomography (PET) for Quantization of the Receptor Histamine-3 in Human|Completed||Early Phase 1|5|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-05-31 23:00:51.639945|2018-05-31 23:00:51.639945
NCT01268007|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-01-20|2010-12-28|2010-12-29|Estimate|||||||2011-01-20|2011-01-24|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Heartbeat Sensitivity Calibration Using the ECG Accessory|This is an Observational, Un-blinded, Non-significant Risk, Non-interventional Study Designed to Collect ECG Data on at Least One Subject Out of a Pool of up to Three (3) Healthy Male Subjects at One Clinical Site (Clinical Trials of Texas).|Completed|||1|Anticipated|Cyberonics, Inc.|||1||f||||t||||||||||2018-05-31 23:00:51.69678|2018-05-31 23:00:51.69678
NCT01267994|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2014-09-16||2017-12-12|2010-12-28|2010-12-29|Estimate|2015-03-23|2015-04-06|Estimate||||2017-12-12|2018-01-10|Actual|June 2011||2011-06-30|December 2017|2017-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Corticosteroid-resistant AIED patients.|A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease|A Phase I/II Open-label Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease|Completed||Phase 1/Phase 2|13|Actual|Northwell Health||1|||f||||t||||||||||2018-05-31 23:00:51.748472|2018-05-31 23:00:51.748472
NCT01267981|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2016-06-06|2010-12-28|2010-12-29|Estimate|||||||2016-06-06|2016-06-07|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PREPINTEST||Efficacy of Small Bowel Preparation in Capsule Endoscopy|Impact of Small Bowel Preparation Using Polyethylene Glycol for Endoscopic Video-capsule (EVC)Exploration in Unexplained Gastrointestinal Bleedings|Completed||Phase 3|858|Actual|University Hospital, Brest||3|||f||||f||||||||||2018-05-31 23:00:52.034122|2018-05-31 23:00:52.034122
NCT01267968|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-07-05|2010-12-23|2010-12-29|Estimate|||||||2017-07-05|2017-07-07|Actual|January 11, 2011|Actual|2011-01-11|July 2017|2017-07-31|March 16, 2011|Actual|2011-03-16|March 16, 2011|Actual|2011-03-16||Interventional|||An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects|An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects|Completed||Phase 1|25|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:00:52.127655|2018-05-31 23:00:52.127655
NCT01267955|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2018-05-23|2010-12-28|2010-12-29|Estimate|||||||2018-05-23|2018-05-24|Actual|December 21, 2010|Actual|2010-12-21|May 2018|2018-05-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Vismodegib in Treating Patients With Advanced Chondrosarcomas|A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas|Active, not recruiting||Phase 2|45|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 23:00:52.208618|2018-05-31 23:00:52.208618
NCT01267760|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-07-06|2010-12-27|2010-12-28|Estimate|||||||2013-07-06|2013-07-09|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|MHD||Clinical and Biochemical Effects of Multipass Hemodialysis|Clinical and Biochemical Effects of Multipass Hemodialysis|Completed||Phase 2|12|Actual|Herlev Hospital||1|||f||||f||||||||||2018-05-31 23:00:53.436462|2018-05-31 23:00:53.436462
NCT01267942|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.|Single Intraoperative Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Full Oral Course in Prevention of Post Adenotonsillectomy Morbidity:A Randomised Clinical Trial.|Completed||N/A|126|Actual|University of Nairobi||2|||f||||t||||||||||2018-05-31 23:00:52.286164|2018-05-31 23:00:52.286164
NCT01267929|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|2012-03-05||2017-11-10|2010-12-28|2010-12-29|Estimate|2014-01-17|2014-02-17|Estimate||||2017-11-10|2017-12-18|Actual|September 2009||2009-09-30|November 2017|2017-11-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Mirror Neurons Stimulation on Motor Skill Rehabilitation in Children With Cerebral Palsy||Completed||N/A|30|Actual|Thammasat University|This Video Compact Disc (VCD) program was applicable for children with cerebral palsy with spastic diplegia who had high GMFCS level (1-3). Generalized the results to children with other types of cerebral palsy with different severity are limited.|2|||f||||t||||||||||2018-05-31 23:00:52.361895|2018-05-31 23:00:52.361895
NCT01267916|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2012-01-29|2010-12-28|2010-12-29|Estimate|||||||2012-01-29|2012-01-31|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Intrinsic PEEP During Mechanical Ventilation of Patients With Obesity|Intrinsic PEEP During Mechanical Ventilation of Patients With Obesity. Influence of Low Respiratory Rate With Unchanged Minute Volume.|Completed||N/A|20|Actual|Seoul Medical Center||6|||f||||f||||||||||2018-05-31 23:00:52.565772|2018-05-31 23:00:52.565772
NCT01267903|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-06-09|2010-12-28|2010-12-29|Estimate|||||||2011-06-09|2011-06-10|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children|A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children|Completed||Phase 1|100|Actual|Jiangsu Province Centers for Disease Control and Prevention||5|||f||||t||||||||||2018-05-31 23:00:52.651838|2018-05-31 23:00:52.651838
NCT01267890|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|July 2011|Anticipated|2011-07-31|May 2011|Anticipated|2011-05-31||Observational|||The Conflicts of Ethics and Law on Patient's Surrogate|Health Service Administration China Medical University (Chih-Jaan Tai)|Unknown status|Recruiting||120|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 23:00:52.715527|2018-05-31 23:00:52.715527
NCT01267877|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-01-04|2010-12-28|2010-12-29|Estimate|||||||2017-01-04|2017-01-05|Estimate|March 2010||2010-03-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Patient Perception of Mammogram Guidelines|Patient Perception of Mammogram Guidelines|Completed||N/A|247|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 23:00:52.760791|2018-05-31 23:00:52.760791
NCT01267864|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-10-27|2010-12-28|2010-12-29|Estimate|||||||2012-10-27|2012-10-30|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||A Randomized Trial of Valproate Versus Ketorolac Versus Metoclopramide for Acute Migraine|IV Valproate for Acute Migraine. A Randomized Comparison Versus IV Metoclopramide and IV Ketorolac|Unknown status|Recruiting|Phase 4|330|Anticipated|Montefiore Medical Center||3|||f||||t||||||||||2018-05-31 23:00:52.831372|2018-05-31 23:00:52.831372
NCT01267851|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2011-02-14|2010-12-28|2010-12-29|Estimate|||||||2011-02-14|2011-02-15|Estimate|January 1999||1999-01-31|December 2010|2010-12-31||||||||Observational|||Clinical Database and Biobank of Patients With Gynecologic Neoplasms|A Large Multicentre Clinical Database and Biobank of Patients With Gynecologic Neoplasms|Unknown status|Recruiting||||Huazhong University of Science and Technology|||||f||||t||||||||||2018-05-31 23:00:52.926272|2018-05-31 23:00:52.926272
NCT01267838|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2016-09-04|2010-12-28|2010-12-29|Estimate|||||||2016-09-04|2016-09-07|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|BBK2||Culotte Technique Versus TAP Stunting for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents|Randomised Comparison of T-stenting Versus Culotte Technique for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents.|Completed||Phase 4|300|Actual|Heart Center Bad Krozingen||2|||f||||f||||||||No||2018-05-31 23:00:52.992347|2018-05-31 23:00:52.992347
NCT01267825|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2018-04-16|2010-12-27|2010-12-29|Estimate|||||||2018-04-16|2018-04-18|Actual|September 1, 2010|Actual|2010-09-01|April 2018|2018-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||CT Guided Injection for Low Back Radiculopathy: A Randomized Clinical Trial|A Randomized Trial of CT-guided Perineural Injection With a Corticosteroid Plus a Long Acting Local Anesthetic Versus Standard Medical Management in Patients With Acute Lumbar Radiculopathy and a Corresponding Disc Herniation|Terminated||Phase 4|1|Actual|Montefiore Medical Center||2||Slow enrollment|f||||f||||||||||2018-05-31 23:00:53.073697|2018-05-31 23:00:53.073697
NCT01267812|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2018-03-06|2010-12-27|2010-12-29|Estimate|||||||2018-03-06|2018-03-07|Actual|August 26, 2011||2011-08-26|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation|A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation|Active, not recruiting||Phase 2|36|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:00:53.148546|2018-05-31 23:00:53.148546
NCT01267799|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2017-06-28|2010-12-28|2010-12-29|Estimate|||||||2017-06-28|2017-06-29|Actual|July 2011|Actual|2011-07-31|June 2017|2017-06-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Observational|||Health Status of Workers in Photocopier Units|Correlation Between Pulmonary Function and Selected Serum/Sputum Biomarkers of Pulmonary Damage Among Workers in Photocopier Units|Completed|||160|Actual|Avinashilingam Deemed University|||2||f||||f||||||||||2018-05-31 23:00:53.253146|2018-05-31 23:00:53.253146
NCT01267786|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2010-12-28|2010-12-28|2010-12-29|Estimate|||||||2010-12-28|2010-12-29|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||December 2011|Anticipated|2011-12-31||Interventional|||The Effect of Volatile Anesthetics Sevoflurane and Desflurane on Liver, Renal and Cardiovascular Systems During Liver Surgery|The Effect of Volatile Anesthetics Sevoflurane and Desflurane on Liver, Renal and Cardiovascular Systems During Liver Surgery|Unknown status|Recruiting|Phase 4|40|Anticipated|Aretaieio Hospital||2|||f||||t||||||||||2018-05-31 23:00:53.305999|2018-05-31 23:00:53.305999
NCT01267773|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2013-03-20|2010-12-28|2010-12-29|Estimate|||||||2013-03-20|2013-03-21|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Treatment of Conduct Problems and Depression|Treatment of Youth Comorbid Conduct Problems and Depression|Unknown status|Recruiting|Phase 1|30|Anticipated|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 23:00:53.375786|2018-05-31 23:00:53.375786
NCT01267747|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2014-03-26|2010-12-27|2010-12-28|Estimate|||||||2014-03-26|2014-03-27|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Observational|PAPPHY||Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation|Prospective Assessment of The Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation|Unknown status|Recruiting||1000|Anticipated|University Hospital Padova|||1||f||||t||||||Samples With DNA|"~     Venous blood will be withdrawn to measure~        -  levels of ions (sodium, potassium, magnesium), creatinine, proBNP, and TSH in the serum,~          and~        -  percent HbA1c levels, plasma aldosterone concentration (PAC), renin concentrations (DRA)~          and renin activity (PRA) in the plasma.~      A venous blood specimen will be used to separate buffy coat for downstream identification of~     SNP associated with primary aldosteronism and development of atrial flutter or fibrillation.~      Urine specimens will be collected to measure microalbuminuria.~   "|||2018-05-31 23:00:53.499408|2018-05-31 23:00:53.499408
NCT01267734|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2013-12-15|2010-12-27|2010-12-28|Estimate|||||||2013-12-15|2013-12-17|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|December 2011|Actual|2011-12-31||Interventional|HOST-ASSURE||Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen|Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease|Unknown status|Recruiting|Phase 4|3750|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 23:00:53.578478|2018-05-31 23:00:53.578478
NCT01267721|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2014-10-07|2010-12-27|2010-12-28|Estimate|||||||2014-10-07|2014-10-08|Estimate|January 2011||2011-01-31|October 2014|2014-10-31||||December 2012|Actual|2012-12-31||Observational|||Macrophage Migration Inhibitory Factor (MIF)- Cardiac Surgery|Macrophage Migration Inhibitory Factor (MIF) as a Marker of Perioperative Inflammatory Reaction During Heart Surgery|Completed|||100|Actual|RWTH Aachen University|||1||f||||f||||||Samples Without DNA|"~     inflammatory markers (different)~   "|||2018-05-31 23:00:53.665784|2018-05-31 23:00:53.665784
NCT01267708|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|November 2010||2010-11-30|November 2010|2010-11-30||||||||Observational|||Platelet Function in Patients Undergoing PCI||Unknown status|Recruiting||1500|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 23:00:53.723013|2018-05-31 23:00:53.723013
NCT01267695|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2015-02-02|2010-12-27|2010-12-28|Estimate|||||||2015-02-02|2015-02-03|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor|Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor|Completed||Phase 2|20|Actual|Peking University|||||f||||t||||||||||2018-05-31 23:00:53.772535|2018-05-31 23:00:53.772535
NCT01267682|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2016-09-26|2010-12-27|2010-12-28|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Cognitive Intervention For Delirium in Dementia|Reserve For Delirium Superimposed On Dementia (DSD)|Completed||Phase 2|283|Actual|Penn State University||2|||f||||t||||||||||2018-05-31 23:00:53.867878|2018-05-31 23:00:53.867878
NCT01267669|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|November 2005||2005-11-30|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|AVB-EVL+S||A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding|A Double Blind Randomized Placebo-Controlled Trial of Somatostatin in Association With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding|Completed||N/A|61|Actual|Govind Ballabh Pant Hospital||2|||f||||f||||||||||2018-05-31 23:00:53.95312|2018-05-31 23:00:53.95312
NCT01267656|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2012-08-10|2010-12-27|2010-12-28|Estimate|||||||2012-08-10|2012-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:00:54.018956|2018-05-31 23:00:54.018956
NCT01267643|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2018-01-24|2010-12-27|2010-12-28|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2011||2011-05-31|January 2018|2018-01-31|April 16, 2013|Actual|2013-04-16|December 16, 2011|Actual|2011-12-16||Interventional|||Alefacept in Patients With Relapsed/Refractory Aplastic Anemia|A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia|Terminated||Phase 1|4|Actual|The Cleveland Clinic||1||Study drug not available at this time|f||||t||||||||||2018-05-31 23:00:54.0648|2018-05-31 23:00:54.0648
NCT01267630|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2011-06-22|2010-12-27|2010-12-28|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||The Validity of the Thai Version of the Confusion Assessment Method|The Validity and Reliability of Thai Version of the Confusion Assessment Method for the Intensive Care Unit (CAM -ICU)|Unknown status|Enrolling by invitation||70|Anticipated|Chiang Mai University|||1||f||||f||||||||||2018-05-31 23:00:54.13636|2018-05-31 23:00:54.13636
NCT01267617|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|November 2010||2010-11-30|December 2010|2010-12-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Measuring Cardiovascular Stress in Patients on Hemodialysis|Measuring Cardiovascular Stress in Patients on Hemodialysis|Unknown status|Enrolling by invitation||60|Anticipated|West Penn Allegheny Health System|||1||f||||f||||||||||2018-05-31 23:00:54.206297|2018-05-31 23:00:54.206297
NCT01267604|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||||||Interventional|||Ovarian Stimulation: Inositol and Melatonin|Improving Oocyte Retrieval Using a Combined Therapy of Recombinant Follicle Stimulating Hormone (rFSH) and Inositol and Melatonin|Unknown status|Recruiting|Phase 4|150|Anticipated|AGUNCO Obstetrics and Gynecology Centre||2|||f||||f||||||||||2018-05-31 23:00:54.258683|2018-05-31 23:00:54.258683
NCT01267591|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|January 2009||2009-01-31|January 2009|2009-01-31||||||||Observational|||Peripheral Artery Tonometry in Children With Type 1 Diabetes and Obese Children|Peripheral Artery Tonometry in Children With Type 1 Diabetes and Obese Children.|Unknown status|Recruiting||70|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||t||||||||||2018-05-31 23:00:54.462711|2018-05-31 23:00:54.462711
NCT01267578|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|April 2010||2010-04-30|December 2010|2010-12-31|May 2012|Anticipated|2012-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)|Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens (STF-II) for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 2|60|Anticipated|University of Yamanashi||1|||f||||t||||||||||2018-05-31 23:00:54.591089|2018-05-31 23:00:54.591089
NCT01267565|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2015-06-09|2010-12-27|2010-12-28|Estimate|||||||2015-06-09|2015-06-10|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|June 2012|Actual|2012-06-30|April 2011|Actual|2011-04-30||Interventional|||Tracheal Dosage of Amylase : a New Surrogate for Microaspirations in Ventilated ICU Patients||Completed||N/A|40|Actual|Université Victor Segalen Bordeaux 2||2|||f||||f||||||||||2018-05-31 23:00:54.686279|2018-05-31 23:00:54.686279
NCT01267552|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|July 2000||2000-07-31|July 2010|2010-07-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer|Randomized Clinical Trial of Axillary Lymphadenectomy Without Drainage for Breast Cancer Treatment|Completed||Phase 2/Phase 3|240|Actual|Universidade Federal de Goias||2|||f||||f||||||||||2018-05-31 23:00:54.76377|2018-05-31 23:00:54.76377
NCT01267539|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|April 2008||2008-04-30|January 2008|2008-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Suan Tsao Jen Tang for Treating Menopause With Sleep Problem: a Clinical Observation||Completed|||67|Actual|Taipei City Hospital|||||f||||t||||||||||2018-05-31 23:00:54.8727|2018-05-31 23:00:54.8727
NCT01267526|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2017-12-22|2010-12-27|2010-12-28|Estimate|||||||2017-12-22|2017-12-26|Actual|May 31, 2011|Actual|2011-05-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS CAN||A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment|"Easypod™ Connect Registry: A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of SAIZEN® in Pediatric Subjects Using Easypod™ Auto-injector"|Completed|||205|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:00:54.947993|2018-05-31 23:00:54.947993
NCT01267513|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2012-03-16|2010-12-27|2010-12-28|Estimate|||||||2012-03-16|2012-03-19|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|LIFEBEAM||Ambulatory Measurements of Physiological Parameters|Noninvasive Ambulatory Measurements of Physiological Parameters Using a DLS-based Sensor|Unknown status|Recruiting||200|Anticipated|Meir Medical Center|||2||f||||t||||||||||2018-05-31 23:00:55.051279|2018-05-31 23:00:55.051279
NCT01267500|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2015-11-23|2010-12-27|2010-12-28|Estimate|||||||2015-11-23|2015-11-24|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia|Randomized Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia|Terminated||Phase 2|60|Actual|Singapore National Eye Centre||1||Difficulty to keep children in randomly assigned groups.|f||||||||||||||2018-05-31 23:00:55.124579|2018-05-31 23:00:55.124579
NCT01267487|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|July 2009||2009-07-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Interventional|||Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass|Phase 4 Study of Fixed-dose and Titration Schemes of Heparin and Protamine in Cardiopulmonary Bypass Cardiac Surgeries : Evaluation of Post-operatory Blood Loss and Transfusion Requirements|Completed||Phase 4|240|Actual|SANE-Society of Anesthesiology||4|||f||||t||||||||||2018-05-31 23:00:55.190726|2018-05-31 23:00:55.190726
NCT01267474|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|March 2007||2007-03-31|November 2010|2010-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Reducing the Use of Sugar by School Lunch Cooks in Public Schools|Reducing the Use and the Consumption of Sugar by School Lunch Cooks in Public Schools: a Cluster Randomized Trial|Completed||Phase 3|95|Actual|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 23:00:55.283571|2018-05-31 23:00:55.283571
NCT01267461|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2012-08-09|2010-12-27|2010-12-28|Estimate|||||||2012-08-09|2012-08-10|Estimate||||August 2012|2012-08-31||||||||Expanded Access|||Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells||Available|||||Meir Medical Center|||||f||||||||||||||2018-05-31 23:00:55.354876|2018-05-31 23:00:55.354876
NCT01267448|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2011-04-15|2010-12-27|2010-12-28|Estimate|||||||2011-04-15|2011-04-18|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia|A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia|Unknown status|Recruiting|Phase 4|100|Anticipated|John H. Stroger Hospital||2|||f||||t||||||||||2018-05-31 23:00:55.408043|2018-05-31 23:00:55.408043
NCT01267435|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of Tibial and Femoral Tunnel Position After Arthroscopic Reconstruction of the Anterior Cruciate Ligament|Study of Evaluation of Tibial and Femoral Tunnel Position After ACL Reconstruction|Completed||Phase 2|40|Actual|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:00:55.509963|2018-05-31 23:00:55.509963
NCT01267422|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|2015-05-21||2018-01-07|2010-12-27|2010-12-28|Estimate|2016-03-29|2016-05-02|Estimate||||2018-01-07|2018-01-31|Actual|April 2011||2011-04-30|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|rAAV2-ND4||Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)|Safety and Efficacy Study of a Single Intravitreal Injection of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy|Completed||N/A|9|Actual|Huazhong University of Science and Technology|Early termination leading to small numbers of subjects analyzed.|1|||f||||t||||||||No||2018-05-31 23:00:55.609129|2018-05-31 23:00:55.609129
NCT01267409|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2012-01-12|2010-12-27|2010-12-28|Estimate|||||||2012-01-12|2012-01-13|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Mapping and Manipulating the Emotional Territories of the Basal Ganglia in PD Patients|Mapping and Manipulating the Emotional Territories of the Subthalamic (STN) Area in Deep Brain Stimulation (DBS) Treated Parkinson Patients|Unknown status|Recruiting|N/A|20|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 23:00:55.906202|2018-05-31 23:00:55.906202
NCT01267396|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2012-01-10|2010-12-27|2010-12-28|Estimate|||||||2012-01-10|2012-01-11|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions|Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fasting Conditions in Healthy Human Adult Subjects.|Completed||Phase 1|32|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:00:55.978384|2018-05-31 23:00:55.978384
NCT01267383|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2012-01-10|2010-12-27|2010-12-28|Estimate|||||||2012-01-10|2012-01-11|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg in Fed Conditions|Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation ZOLOFT® 100 mg Tablet (Pfizer, USA)Under Fed Conditions in Healthy Human Adult Subjects.|Completed||Phase 1|32|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:00:56.044646|2018-05-31 23:00:56.044646
NCT01267370|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-27|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|January 2002||2002-01-31|October 2003|2003-10-31|October 2003|Actual|2003-10-31|December 2002|Actual|2002-12-31||Interventional|SOYFIBER||Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial|Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial|Completed||Phase 4|30|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 23:00:56.107204|2018-05-31 23:00:56.107204
NCT01267357|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-26|2010-12-26|2010-12-28|Estimate|||||||2010-12-26|2010-12-28|Estimate|July 2010||2010-07-31|November 2010|2010-11-30||||November 2010|Actual|2010-11-30||Observational|||P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer|Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance|Completed|||62|Actual|Rambam Health Care Campus|||2||f||||f||||||Samples With DNA|"~     Existing paraffin pathology blocks in hospital's library were used. Remainder of material was~     returned to the library.~      No identifying features were retained or attached to specimens.~   "|||2018-05-31 23:00:56.176572|2018-05-31 23:00:56.176572
NCT01267344|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2016-05-03|2010-12-27|2010-12-28|Estimate|||||||2016-05-03|2016-05-04|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|May 2015|Actual|2015-05-31|December 2013|Actual|2013-12-31||Interventional|BTC||A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC|A Randomized Phase II Study of Gemcitabine Plus Oxaliplatin (GEMOX) With or Without Cetuximab in Locally Advanced and Metastatic Biliary Tract Cancer (BTC)|Completed||Phase 2|122|Actual|National Health Research Institutes, Taiwan||2|||f||||t||||||||||2018-05-31 23:00:56.231222|2018-05-31 23:00:56.231222
NCT01267331|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2011-01-11|2010-12-27|2010-12-28|Estimate|||||||2011-01-11|2011-01-12|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Cell Therapy in Patients With Chronic Ischemic Heart Disease Undergoing Cardiac Surgery|A Prospective,Randomized, Placebo-Controlled Study of Intramyocardial Injection of Autologous Bone-Marrow Mononuclear Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 23:00:56.305109|2018-05-31 23:00:56.305109
NCT01267318|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-26|||2012-07-04|2010-12-27|2010-12-28|Estimate|||||||2012-07-04|2012-07-06|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Evaluation of Gastric Juice Samples During Standard Gastroscopy Procedure||Terminated|||5|Actual|Given Imaging Ltd.||||"Sponsor decided to terminate the entire project, and therefore there was no use for the samples~   collected in the study."|f||||f||||||Samples With DNA|"~     Gastric juices content suctioned from patients routinely during the course of Gastroscopy.~   "|||2018-05-31 23:00:56.377708|2018-05-31 23:00:56.377708
NCT01267305|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-25|||2014-04-28|2010-12-25|2010-12-28|Estimate|||||||2014-04-28|2014-04-29|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery|The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery|Completed||N/A|362|Actual|Shanghai Zhongshan Hospital||6|||f||||f||||||||||2018-05-31 23:00:56.425432|2018-05-31 23:00:56.425432
NCT01267292|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|2017-02-16||2017-05-03|2010-12-24|2010-12-28|Estimate|2017-05-03|2017-05-04|Actual||||2017-05-03|2017-05-04|Actual|March 2011||2011-03-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Psychopharmacology for Cocaine Dependence - Buspirone|Psychopharmacology of Novel Medications for Cocaine Dependence - Buspirone|Completed||Phase 2|50|Actual|The University of Texas Health Science Center, Houston||2|||f||||t|t|f|||f|||||2018-05-31 23:00:56.546105|2018-05-31 23:00:56.546105
NCT01267279|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|||2015-01-21|2010-12-27|2010-12-28|Estimate|||||||2015-01-21|2015-01-26|Estimate|January 2005||2005-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty|Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty|Completed||Phase 4|66|Actual|Spokane Joint Replacement Center||2|||f||||f||||||||||2018-05-31 23:00:56.981584|2018-05-31 23:00:56.981584
NCT01267266|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|2015-01-30||2015-03-18|2010-12-24|2010-12-28|Estimate|2015-03-18|2015-04-01|Estimate||||2015-03-18|2015-04-01|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|November 2013|Actual|2013-11-30|September 2012|Actual|2012-09-30||Interventional||Patients entering lead-in phase.|Saracatinib in Treating Patients With Prostate Cancer|A Randomized Discontinuation Phase 2 Study of AZD0530 as a Metastasis Inhibitor in Castrate Resistant Prostate Cancer|Terminated||Phase 2|31|Actual|National Cancer Institute (NCI)||2||Per protocol, study was terminated due to low rate of randomized patients.|f||||||||||||||2018-05-31 23:00:57.043776|2018-05-31 23:00:57.043776
NCT01267253|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|2016-11-04||2017-08-23|2010-12-24|2010-12-28|Estimate|2016-11-04|2017-01-04|Estimate||||2017-08-23|2017-09-21|Actual|April 4, 2011|Actual|2011-04-04|August 2017|2017-08-31||||October 4, 2015|Actual|2015-10-04||Interventional||Eligible and treated participants|Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)|Active, not recruiting||Phase 2|31|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 23:00:58.249775|2018-05-31 23:00:58.249775
NCT01267240|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-24|2016-12-02||2017-03-03|2010-12-24|2010-12-28|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|December 2010||2010-12-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|June 2015|Actual|2015-06-30||Interventional|||Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase II Study of Vorinostat and Capecitabine in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) and Nasopharyngeal Carcinoma (NPC)|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)|Early termination due to lack of activity of study drug.|1||Study treatment did not show clinical activity.|f||||t||||||||No||2018-05-31 23:00:58.748088|2018-05-31 23:00:58.748088
NCT01267227|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2013-03-19||2017-12-11|2010-12-23|2010-12-28|Estimate|2013-03-19|2013-05-03|Estimate||||2017-12-11|2018-01-10|Actual|December 2010||2010-12-31|December 2017|2017-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress|Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress|Completed||Phase 2/Phase 3|80|Actual|University of Mississippi Medical Center||4|||f||||f||||||||||2018-05-31 23:00:59.077526|2018-05-31 23:00:59.077526
NCT01267214|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2012-11-20|2010-12-27|2010-12-28|Estimate|||||||2012-11-20|2012-11-21|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|July 2011|Actual|2011-07-31|February 2010|Actual|2010-02-28||Interventional|||The Efficacy and Safety of Intraarticular Sodium Hyaluronate (Hyalgan) After Proximal Tibial Osteotomy in Treatment of Knee Osteoarthritis Patients||Completed||Phase 2|40|Actual|TRB Chemedica||2|||f||||||||||||||2018-05-31 23:00:59.383427|2018-05-31 23:00:59.383427
NCT01267201|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|2012-05-24||2012-05-24|2010-12-23|2010-12-28|Estimate|2012-05-24|2012-06-28|Estimate||||2012-05-24|2012-06-28|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form|A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, Crossover Bioavailability Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/Ml to Methylprednisolone 32 Mg Tablet Under Fasted Conditions|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:00:59.461591|2018-05-31 23:00:59.461591
NCT01267188|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2011-04-18|2010-12-23|2010-12-28|Estimate|||||||2011-04-18|2011-04-20|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia|A Phase 2, Open-Label, Dose Titration Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 2|10|Anticipated|Neurocrine Biosciences||1|||f||||f||||||||||2018-05-31 23:00:59.728399|2018-05-31 23:00:59.728399
NCT01267175|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|2011-01-21||2011-02-16|2010-12-27|2010-12-28|Estimate|2011-01-21|2011-02-14|Estimate||||2011-02-16|2011-02-18|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|X54User||United Kingdom User Evaluation, MiniMed Paradigm® X54 System|United Kingdom User Evaluation, MiniMed Paradigm® X54 System|Completed||Phase 4|31|Actual|Medtronic Diabetes||1|||f||||f||||||||||2018-05-31 23:00:59.883296|2018-05-31 23:00:59.883296
NCT01267162|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2016-03-14|2010-12-27|2010-12-28|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Long-term Study on Anti-HBV Effect of Tenofovir and Resistance Surveillance in Asian-American Adult Patients|Long-term Observational Study on Anti-HBV Effect of Tenofovir Disoproxil Fumarate (TDF) and Resistance Surveillance in Asian-American Adult Patients Formerly Participating Gilead 123 Studies|Completed|||31|Actual|Medical Procare PLLC|||1||f||||t||||||||||2018-05-31 23:01:00.029725|2018-05-31 23:01:00.029725
NCT01267149|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-27|2010-12-27|2010-12-28|Estimate|||||||2010-12-27|2010-12-28|Estimate|August 2010||2010-08-31|December 2010|2010-12-31||||||||Observational|||A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines|Phase 4 Study - A Clinical Study Evaluaing the Efficacy, Safety, and Patient Satisfaction of Injectable Hylaronic Acid With 0.3% Lidocain Hydrochloride, Prevelle Silk, for Superficial, Vertical Perioral Lines and Superficial, Horizontal, Lateral Canthal Lines|Unknown status|Recruiting||13|Anticipated|Goldman, Butterwick, Fitzpatrick and Groff|||||f||||t||||||||||2018-05-31 23:01:00.099682|2018-05-31 23:01:00.099682
NCT01267136|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|2013-12-19||2014-03-11|2010-12-23|2010-12-28|Estimate|2014-03-11|2014-04-17|Estimate||||2014-03-11|2014-04-17|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy|A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy|Completed||Phase 4|84|Actual|Children's Hospitals and Clinics of Minnesota|There was insufficient power to detect differences in safety.|2|||f||||f||||||||||2018-05-31 23:01:00.18516|2018-05-31 23:01:00.18516
NCT01267123|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2016-09-30|2010-12-23|2010-12-24|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||The Value of the Trendelenburg Position During Routine Colonoscopy: A Pilot Study.|The Value of the Trendelenburg Position During Routine Colonoscopy: A Pilot Study.|Completed||N/A|66|Actual|University of Missouri-Columbia||2|||f||||f||||||||Undecided||2018-05-31 23:01:00.494441|2018-05-31 23:01:00.494441
NCT01267110|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2015-09-15|2010-12-23|2010-12-24|Estimate|||||||2015-09-15|2015-09-16|Estimate|September 2010||2010-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Engaging Diverse Underserved Communities to Bridge the Mammography Divide|Engaging Diverse Underserved Communities to Bridge the Mammography Divide|Completed||N/A|261|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 23:01:00.563464|2018-05-31 23:01:00.563464
NCT01267097|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2014-02-19|2010-12-23|2010-12-24|Estimate|||||||2014-02-19|2014-02-20|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|PAC||The PAC Study: Parents as Agents of Change in Pediatric Weight Management|The PAC Study: Parents as Agents of Change in Pediatric Weight Management|Completed||N/A|63|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 23:01:00.640292|2018-05-31 23:01:00.640292
NCT01267084|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2015-10-12|2010-12-23|2010-12-24|Estimate|||||||2015-10-12|2015-10-14|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies|An Open-Label, Multicenter Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies|Completed||Phase 1/Phase 2|12|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 23:01:00.716678|2018-05-31 23:01:00.716678
NCT01267071|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2017-06-07|2010-12-23|2010-12-24|Estimate|||||||2017-06-07|2017-06-09|Actual|June 14, 2010|Actual|2010-06-14|June 2017|2017-06-30|September 1, 2010|Actual|2010-09-01|September 1, 2010|Actual|2010-09-01||Interventional|||A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers|A Single Dose, Open Label, Nonrandomized, Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers|Completed||Phase 1|8|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:01:00.796538|2018-05-31 23:01:00.796538
NCT01267058|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|September 1997||1997-09-30|December 2010|2010-12-31|February 1998|Actual|1998-02-28|February 1998|Actual|1998-02-28||Interventional|||Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults|Single-blind, Clinical Study of the Immunogenicity and Reactogenicity of SB Biologicals' dTpa, pa Vaccines and a Td Vaccine, Given as a Booster Dose to Healthy Adults, From the Age of 18 Years Onwards|Completed||Phase 3|550|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 23:01:00.89206|2018-05-31 23:01:00.89206
NCT01267045|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|2014-11-04||2015-07-20|2010-12-23|2010-12-24|Estimate|2014-12-15|2014-12-17|Estimate||||2015-07-20|2015-08-07|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|December 2012|Actual|2012-12-31||Interventional|||Mindfulness-Based Stress Reduction for Gulf War Syndrome|A Randomized Controlled Trial of a Mindfulness Based Intervention for Gulf War Syndrome|Completed||N/A|55|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:01:01.001297|2018-05-31 23:01:01.001297
NCT01267032|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2014-12-01|2010-12-23|2010-12-24|Estimate|||||||2014-12-01|2014-12-02|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ISCWCBTI||Helping Veterans Quit Smoking by Improving Their Sleep|Improving Smoking Cessation Outcomes in PTSD With CBT for Insomnia|Terminated||Phase 2|142|Actual|VA Office of Research and Development||2||Terminated after two years by CSRD|f||||t||||||||||2018-05-31 23:01:01.720345|2018-05-31 23:01:01.720345
NCT01267019|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|2016-11-15||2017-01-24|2010-12-23|2010-12-24|Estimate|2017-01-24|2017-03-15|Actual||||2017-01-24|2017-03-15|Actual|February 2011||2011-02-28|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ASCI||Social Cognition Intervention|Augmenting Social Cognitive Intervention for Veterans With Schizophrenia|Completed||N/A|153|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-05-31 23:01:01.798603|2018-05-31 23:01:01.798603
NCT01267006|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-07-05|2010-12-23|2010-12-24|Estimate|||||||2017-07-05|2017-07-07|Actual|November 5, 2010|Actual|2010-11-05|July 2017|2017-07-31|January 27, 2011|Actual|2011-01-27|January 27, 2011|Actual|2011-01-27||Interventional|||Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old|A Randomized Cross-over Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Twice Daily Oral Administration of GSK1325756, Compared to Placebo, in Healthy Subjects; and the Pharmacokinetic Profile of Twice Daily Oral Administration of GSK1325756 in Healthy Fed and Fasted Elderly Subjects|Completed||Phase 1|40|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:01:02.194284|2018-05-31 23:01:02.194284
NCT01266993|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16||2014-05-29|2017-06-13|2010-12-23|2010-12-24|Estimate||||2014-05-29|2014-06-02|Estimate|2017-06-13|2017-06-20|Actual|January 3, 2011|Actual|2011-01-03|June 2017|2017-06-30|May 17, 2014|Actual|2014-05-17|March 31, 2014|Actual|2014-03-31||Interventional|||Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children|Persistence of Antibodies After Vaccination With a Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children and Safety and Immunogenicity of a Booster Dose at 68 Months Post-primary Vaccination|Completed||Phase 3|207|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 23:01:02.330278|2018-05-31 23:01:02.330278
NCT01266980|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-08-01|2010-12-23|2010-12-24|Estimate|||||||2017-08-01|2017-08-03|Actual|November 18, 2010|Actual|2010-11-18|August 2017|2017-08-31|March 22, 2011|Actual|2011-03-22|March 22, 2011|Actual|2011-03-22||Interventional|||A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.|An Open-label, Non-randomized Pharmacokinetic and Safety Study of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Renal Impairment.|Completed||Phase 1|18|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:01:02.487399|2018-05-31 23:01:02.487399
NCT01266967|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2013-06-24|2012-06-07|2014-04-24|2010-12-23|2010-12-24|Estimate|2014-01-16|2014-03-05|Estimate|2012-06-07|2012-06-11|Estimate|2014-04-24|2014-05-08|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|Break MB||A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain|BRF113929: An Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain|Completed||Phase 2|172|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-05-31 23:01:02.668198|2018-05-31 23:01:02.668198
NCT01266954|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2017-11-07|2010-12-23|2010-12-24|Estimate|||||||2017-11-07|2017-11-09|Actual|June 1, 2010|Actual|2010-06-01|November 2017|2017-11-30|September 1, 2011|Actual|2011-09-01|September 1, 2011|Actual|2011-09-01||Interventional|||An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer|An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 23:01:03.806546|2018-05-31 23:01:03.806546
NCT01266941|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-07-18|2010-12-23|2010-12-24|Estimate|||||||2017-07-18|2017-07-21|Actual|October 18, 2010|Actual|2010-10-18|July 2017|2017-07-31|July 15, 2011|Actual|2011-07-15|July 15, 2011|Actual|2011-07-15||Interventional|||A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.|An Open-label, Non-randomized, Pharmacokinetic and Safety Study of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment|Completed||Phase 1|35|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:01:03.875307|2018-05-31 23:01:03.875307
NCT01266928|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-02-06|2010-12-23|2010-12-24|Estimate|||||||2012-02-06|2012-02-07|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study||Completed||Phase 3|244|Actual|Erzincan Military Hospital||2|||f||||t||||||||||2018-05-31 23:01:03.958811|2018-05-31 23:01:03.958811
NCT01266915|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-10-24|2010-12-23|2010-12-24|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2009||2009-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Cutaneous Lupus Registry|Molecular Studies on Cutaneous Lupus|Recruiting|||500|Anticipated|University of Texas Southwestern Medical Center|||4||f||||f||||||||||2018-05-31 23:01:04.009794|2018-05-31 23:01:04.009794
NCT01266902|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2018-02-27|2010-12-23|2010-12-24|Estimate|||||||2018-02-27|2018-02-28|Actual|February 25, 2011|Actual|2011-02-25|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1|An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278|Active, not recruiting||Phase 3|483|Actual|Janssen R&D Ireland||1|||f||||f||f||||||||2018-05-31 23:01:04.071746|2018-05-31 23:01:04.071746
NCT01266889|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|May 2011|Anticipated|2011-05-31|March 2011|Anticipated|2011-03-31||Observational|||Measurement of Cerebral Oxygenation Using NIRS Method in the Preterm Infants With Intracranial Haemorrhagia||Unknown status|Recruiting||20|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||1||f||||t||||||||||2018-05-31 23:01:04.340777|2018-05-31 23:01:04.340777
NCT01266876|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|2015-08-20|2011-04-19|2015-08-20|2010-12-23|2010-12-24|Estimate|2015-08-20|2015-09-22|Estimate|2011-04-19|2011-04-28|Estimate|2015-08-20|2015-09-22|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of REGN727 in Patients With Heterozygous Familial Hypercholesterolemia|Completed||Phase 2|77|Actual|Regeneron Pharmaceuticals||5|||f||||t||||||||||2018-05-31 23:01:04.469218|2018-05-31 23:01:04.469218
NCT01266863|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2015-06-09|2010-12-23|2010-12-24|Estimate|||||||2015-06-09|2015-06-10|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||E Test Strips Applied to Bronchoalveolar Lavage for Suspicion of Hospital-acquired Pneumonia to Accelerate Antibiogram Analysis.||Completed||N/A|30|Actual|Université Victor Segalen Bordeaux 2||1|||f||||f||||||||||2018-05-31 23:01:05.73783|2018-05-31 23:01:05.73783
NCT01266850|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|2014-10-09||2014-10-23|2010-12-23|2010-12-24|Estimate|2014-10-23|2014-10-28|Estimate||||2014-10-23|2014-10-28|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional||Population for baseline analysis includes all participants who were enrolled, randomized, and received at least the first vaccination.|Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules|Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®|Completed||Phase 4|1384|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-05-31 23:01:05.845704|2018-05-31 23:01:05.845704
NCT01266837|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-11-10|2010-12-23|2010-12-24|Estimate|||||||2017-11-10|2017-11-14|Actual|March 2011||2011-03-31|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|September 26, 2017|Actual|2017-09-26||Interventional|MARC-2||Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)|An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy|Completed||Phase 4|64|Actual|iOMEDICO AG||1|||f||||f||||||||No||2018-05-31 23:01:06.848746|2018-05-31 23:01:06.848746
NCT01266824|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2012-12-10||2013-02-15|2010-12-23|2010-12-24|Estimate|2013-02-15|2013-03-19|Estimate||||2013-02-15|2013-03-19|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Proparacaine and Mydriatic Eye Drops|Randomized Control Trial of the Effects of Proparacaine on the Pain Response to Mydriatic Eye Drops|Terminated||N/A|5|Actual|Children's Hospital of Philadelphia|Enrollment for the randomized controlled study above was poor and the study was terminated without patient analysis. An observational study of the pain response to mydriatic eye drops without use of Proparacaine was completed in place of this trial.|2||Recruitment for the study has been terminated due to poor enrollment|f||||t||||||||||2018-05-31 23:01:06.916979|2018-05-31 23:01:06.916979
NCT01266811|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2013-01-25|2010-12-23|2010-12-24|Estimate|||||||2013-01-25|2013-01-28|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|April 2014|Anticipated|2014-04-30||Interventional|||A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma|Withdrawn||Phase 3|0|Actual|Centocor, Inc.||2||"Study canceled based on results of different study with similar hypothesis, investigational~   agent, & patient"|f||||t||||||||||2018-05-31 23:01:07.209831|2018-05-31 23:01:07.209831
NCT01266798|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2014-12-02|2010-12-23|2010-12-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2011||2011-03-31|December 2010|2010-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PREP||Effects of a Patient Directed Web-portal to Improve Health Literacy Skills|Effects of a Patient Directed Web-portal to Improve Health Literacy Skills|Completed||N/A|96|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||||||||||||2018-05-31 23:01:07.365826|2018-05-31 23:01:07.365826
NCT01266785|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2011-07-20|2010-12-23|2010-12-24|Estimate|||||||2011-07-20|2011-07-22|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Infliximab, Regulatory T Cells, IL2 and Crohn's Disease|Analysis of Relationship Between Infliximab Treatment Response, Regulatory T Cells, and Interleukin-2 in Crohn's Disease|Unknown status|Recruiting|N/A|20|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-05-31 23:01:07.429299|2018-05-31 23:01:07.429299
NCT01266772|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2013-02-06|2010-12-23|2010-12-24|Estimate|||||||2013-02-06|2013-02-07|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effect of Montelukast in Asthma in Children|The Effect of Montelukast on Anti-inflammatory Treatment and Asthma Exacerbation Prevention in Children Sensitive to Dust Mites.|Unknown status|Recruiting|Phase 3|160|Anticipated|Medical Universtity of Lodz||2|||f||||t||||||||||2018-05-31 23:01:07.499764|2018-05-31 23:01:07.499764
NCT01266759|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Combined Contraceptive Vaginal Ring(NuvaRing)in Women With Idiopathic Menorrhagia|Combined Contraceptive Vaginal Ring or Norethisterone for Treatment of Idiopathic Menorrhagia|Completed||N/A|95|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 23:01:07.589965|2018-05-31 23:01:07.589965
NCT01266746|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-12-31|2010-12-23|2010-12-24|Estimate|||||||2012-12-31|2013-01-03|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Optical Coherence Tomography in Gas-filled Eyes|Clinical Observation of Postoperative Status of Macular Hole in Gas-filled Eyes by Spectral Domain-optical Coherence Tomography|Completed|||37|Actual|Kyorin University|||3||f||||f||||||||||2018-05-31 23:01:07.66213|2018-05-31 23:01:07.66213
NCT01266733|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2015-06-17|2010-12-23|2010-12-24|Estimate|||||||2015-06-17|2015-06-18|Estimate|February 2007||2007-02-28|December 2010|2010-12-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment|Improvement of the Health-related Quality of Life of Patients With Fibromyalgia Using Multidisciplinary Treatment|Completed||Phase 2|153|Actual|Hospital Galdakao-Usansolo||2|||f||||t||||||||||2018-05-31 23:01:07.729565|2018-05-31 23:01:07.729565
NCT01266720|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|March 2012|Anticipated|2012-03-31|March 2010|Actual|2010-03-31||Interventional|||HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)|Phase 1 Study of HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1|6|Actual|Fukushima Medical University||1|||f||||t||||||||||2018-05-31 23:01:07.802134|2018-05-31 23:01:07.802134
NCT01266707|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|March 2013|Anticipated|2013-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma|Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1|9|Anticipated|Fukushima Medical University||1|||f||||t||||||||||2018-05-31 23:01:07.884555|2018-05-31 23:01:07.884555
NCT01266694|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2014-01-13|2010-12-23|2010-12-24|Estimate|||||||2014-01-13|2014-01-14|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|POPE2||Cochicine Treatment for Post- Operative Pericardial Effusion|Cochicine Treatment for Post- Operative Pericardial Effusion: The POPE 2 Study A Multicenter, Double-blind, Randomized Trial|Completed||Phase 4|199|Actual|French Cardiology Society||2|||f||||f||||||||||2018-05-31 23:01:07.983321|2018-05-31 23:01:07.983321
NCT01266681|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|March 2011||2011-03-31|November 2010|2010-11-30||||May 2012|Anticipated|2012-05-31||Interventional|ACDC||Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm|Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus|Unknown status|Not yet recruiting|N/A|100|Anticipated|Eastbourne General Hospital||2|||f||||t||||||||||2018-05-31 23:01:08.087828|2018-05-31 23:01:08.087828
NCT01266668|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2011-11-28|2010-12-23|2010-12-24|Estimate|||||||2011-11-28|2011-11-29|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Observational|||The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)|Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma in Patients Treated With R-CHOP; Consortium for Improving Survival of Lymphoma (CISL) Study|Completed|||100|Actual|Chonbuk National University Hospital|||2||f||||f||||||||||2018-05-31 23:01:08.158572|2018-05-31 23:01:08.158572
NCT01266655|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2014-09-04|2010-12-23|2010-12-24|Estimate|||||||2014-09-04|2014-09-05|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|BACLAD||Baclofen for the Treatment of Alcohol Dependence|Baclofen for the Treatment of Alcohol Dependence - BACLAD|Completed||Phase 2/Phase 3|56|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:01:08.21866|2018-05-31 23:01:08.21866
NCT01266642|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2018-04-23|2010-12-23|2010-12-24|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2011|Actual|2011-02-28|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer|Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer|Active, not recruiting||Phase 2|288|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 23:01:08.276186|2018-05-31 23:01:08.276186
NCT01266629|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2011-01-10|2010-12-23|2010-12-24|Estimate|||||||2011-01-10|2011-01-11|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Observational|||The Clinical Utility of Fecal Caprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy|The Clinical Utility of Fecal Calprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy: A Prospective Study|Unknown status|Recruiting||40|Anticipated|Shaare Zedek Medical Center|||1||f||||f||||||||||2018-05-31 23:01:08.510473|2018-05-31 23:01:08.510473
NCT01266616|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2015-11-24|2010-12-23|2010-12-24|Estimate|||||||2015-11-24|2015-11-25|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|||Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults|A Phase I Randomized, Partially Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a Cytokine Enhanced HIV-1 Multi-Antigen (HIV MAG) pDNA Vaccine Delivered Intramuscularly Followed by in Vivo Electroporation (IM/EP) or Intramuscularly in HIV-1 Infected Adults Receiving ART|Completed||Phase 1|62|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||10|||f||||t||||||||||2018-05-31 23:01:08.582813|2018-05-31 23:01:08.582813
NCT01266603|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-09-14|2010-12-23|2010-12-24|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2012|Actual|2012-02-29|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI|A Phase II Trial of High Dose Interleukin-2 (HDIL-2) With Recombinant MAGE-A3 Protein Combined With Adjuvant System AS15 (recMAGE-A3 + AS15) in Patients With Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:01:08.67907|2018-05-31 23:01:08.67907
NCT01266590|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2011-04-15|2010-12-20|2010-12-24|Estimate|||||||2011-04-15|2011-04-18|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of LY2216684 and Digoxin in Healthy Subjects|Effect of LY2216684 on the Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|30|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:01:08.757182|2018-05-31 23:01:08.757182
NCT01266577|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2018-03-27|2010-12-23|2010-12-24|Estimate|||||||2018-03-27|2018-03-29|Actual|December 23, 2010||2010-12-23|March 14, 2018|2018-03-14||||||||Observational|||Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle|Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:01:08.824677|2018-05-31 23:01:08.824677
NCT01266564|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-08-10|2010-12-20|2010-12-24|Estimate|||||||2017-08-10|2017-08-11|Actual|September 3, 2010|Actual|2010-09-03|August 2017|2017-08-31|July 10, 2015|Actual|2015-07-10|July 10, 2015|Actual|2015-07-10||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Colorectal Cancer|A Non-interventional Multicenter Study of First-line Avastin® (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer|Completed|||205|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:01:08.890313|2018-05-31 23:01:08.890313
NCT01266551|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-21|2010-12-21|2010-12-24|Estimate|||||||2010-12-21|2010-12-24|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|August 2010||2010-08-31|August 2010||2010-08-31||Interventional|||Car Safety Seat and Gastroesophageal Reflux Disease|The Car Safety Seat; Cause of Increased Gastroesophageal Reflux Disease in Infants?|Terminated||N/A|||University Hospital, Antwerp||1||Intended number of patients reached|f||||f||||||||||2018-05-31 23:01:09.016862|2018-05-31 23:01:09.016862
NCT01266538|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|IBD||Inflammatory Bowel Disease(IBD)Database|Epidemiologic, Clinical, Endoscopic and Histological Database of Patients With Inflammatory Bowel Disease (IBD)|Not yet recruiting|||2500|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||f||||||Samples Without DNA|"~     blood serum, gastrointestinal biopsies, fecal samples~   "|||2018-05-31 23:01:09.075323|2018-05-31 23:01:09.075323
NCT01266525|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23||2016-02-12|2016-02-12|2010-12-23|2010-12-24|Estimate||||2016-02-12|2016-03-14|Estimate|2016-02-12|2016-03-14|Estimate|February 2011||2011-02-28|February 2016|2016-02-29|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy|Completed||Phase 2|291|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 23:01:09.171947|2018-05-31 23:01:09.171947
NCT01266512|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2014-07-15|2010-12-23|2010-12-24|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|C-CRISP||Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer|Phase II Study of Concurrent Chemoradiotherapy Using IMRT (With Single Photon Emission Computed Tomography/SPECT-CT to Define Functional Lung Volume and Positron Emission Tomography/PET to Define Gross Tumour Volume/GTV) and Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer (NSCLC)|Completed||Phase 2|34|Actual|Sanofi||1|||f||||||||||||||2018-05-31 23:01:09.356662|2018-05-31 23:01:09.356662
NCT01266499|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-04-26|2010-12-23|2010-12-24|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2009||2009-07-31|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).|A Randomized Open Label Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).|Completed||N/A|200|Actual|Rambam Health Care Campus||4|||f||||f||||||||||2018-05-31 23:01:09.436442|2018-05-31 23:01:09.436442
NCT01266486|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2014-07-01|2010-12-23|2010-12-24|Estimate|||||||2014-07-01|2014-07-02|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Metformin on Breast Cancer Metabolism|A Phase 2 Single Arm Study to Examine the Effects of Metformin on Cancer Metabolism in Patients With Early Stage Breast Cancer Receiving Neoadjuvant Chemotherapy|Completed||Phase 2|41|Actual|Oxford University Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 23:01:09.521133|2018-05-31 23:01:09.521133
NCT01266473|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2013-01-10|2010-12-23|2010-12-24|Estimate|||||||2013-01-10|2013-01-11|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study of Individualized Physiotherapy for Airway Clearance in Cystic Fibrosis.|Efficacy Study of Physiotherapy for Airway Clearance in Cystic Fibrosis. Randomized Controlled Trials in Single Subjects (N of 1 RCT`s).|Completed||N/A|6|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 23:01:09.605128|2018-05-31 23:01:09.605128
NCT01266460|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-08-23|2010-12-23|2010-12-24|Estimate|||||||2017-08-23|2017-08-24|Actual|May 23, 2011|Actual|2011-05-23|August 2017|2017-08-31||||October 2, 2018|Anticipated|2018-10-02||Interventional|||Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix|Active, not recruiting||Phase 2|67|Anticipated|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 23:01:09.672178|2018-05-31 23:01:09.672178
NCT01266447|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|2016-12-07||2017-06-15|2010-12-23|2010-12-24|Estimate|2016-12-07|2017-02-01|Estimate||||2017-06-15|2017-07-12|Actual|February 2011||2011-02-28|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Eligible and treated patients|Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix|Completed||Phase 2|27|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:01:09.803357|2018-05-31 23:01:09.803357
NCT01266434|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2016-03-15|2010-12-23|2010-12-24|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|Simvastatin||The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma|The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma|Completed||Phase 3|44|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 23:01:10.243121|2018-05-31 23:01:10.243121
NCT01266421|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2018-01-24|2010-12-23|2010-12-24|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2010||2010-12-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Observational|||Visanne Post-approval Observational Study (VIPOS)|International Active Surveillance Study of Medication Used for the Treatment of Endometriosis: Visanne Post-approval Observational Study|Active, not recruiting|||28400|Actual|Center for Epidemiology and Health Research, Germany|||2||f||||t||||||||||2018-05-31 23:01:10.298597|2018-05-31 23:01:10.298597
NCT01266408|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2017-05-18|2010-12-23|2010-12-24|Estimate|||||||2017-05-18|2017-05-19|Actual|October 2010||2010-10-31|May 2017|2017-05-31|December 2025|Anticipated|2025-12-31|November 2025|Anticipated|2025-11-30||Observational|||INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)|International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study|Recruiting|||80000|Anticipated|Center for Epidemiology and Health Research, Germany|||3||f||||t||||||||||2018-05-31 23:01:10.347756|2018-05-31 23:01:10.347756
NCT01266395|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2011-08-08|2010-12-23|2010-12-24|Estimate|||||||2011-08-08|2011-08-09|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|||||Observational|IMPAEPOC||Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)|Impact of Morning Symptoms in Clinical Control of COPD|Completed|||1268|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:01:10.41143|2018-05-31 23:01:10.41143
NCT01266369|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-23|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|February 2007||2007-02-28|December 2010|2010-12-31|May 2010|Actual|2010-05-31|November 2007|Actual|2007-11-30||Interventional|||Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation|A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open-label, 2-parallel Group, Phase IIa Study to Compare Efficacy and Safety of AB1010 at 3 or 6 mg/kg/Day in Treatment of Patients With Mastocytosis With Handicap and Bearing Activating Point Mutations in the Phosphotransferase Domain of c-Kit Such as the Main Mutation Asp-816-Val (D816V)|Completed||Phase 2|21|Actual|AB Science||2|||f||||f||||||||||2018-05-31 23:01:10.67228|2018-05-31 23:01:10.67228
NCT01266356|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-22|2010-12-22|2010-12-24|Estimate|||||||2010-12-22|2010-12-24|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|August 2012|Anticipated|2012-08-31|||||Observational|||A TMU/NIH Integrated Research Project Translation of Basic Research to Clinical Diagnosis and Treatment of Mild Traumatic Brain Injury (mTBI)|A TMU/NIH Integrated Research Project Translation of Basic Research to Clinical Diagnosis and Treatment of Mild Traumatic Brain Injury (mTBI)|Unknown status|Enrolling by invitation||500|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 23:01:10.721376|2018-05-31 23:01:10.721376
NCT01266343|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|January 2007||2007-01-31|December 2010|2010-12-31|December 2009|Actual|2009-12-31|||||Observational|||Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma|Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma|Completed|||60|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 23:01:10.767382|2018-05-31 23:01:10.767382
NCT01266330|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-22|2010-12-22|2010-12-24|Estimate|||||||2010-12-22|2010-12-24|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|January 2010|Actual|2010-01-31|April 2009|Actual|2009-04-30||Interventional|||Dairy Attenuation of Metabolic Disease|Dairy Attenuation of Oxidative and Inflammatory Stress in Metabolic Syndrome|Completed||N/A|40|Actual|University of Tennessee||2|||f||||f||||||||||2018-05-31 23:01:10.824285|2018-05-31 23:01:10.824285
NCT01266317|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2017-12-31||2018-02-14|2010-12-22|2010-12-24|Estimate|2017-12-31|2018-01-24|Actual||||2018-02-14|2018-03-14|Actual|March 2011||2011-03-31|February 2018|2018-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations|Open-Label, Feasibility Study of Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids in Patients With Acute Idiopathic Pulmonary Fibrosis Exacerbations|Completed||Phase 1/Phase 2|9|Actual|University of Pittsburgh|This was a pilot, open-label trial of an unprecedented regimen for a highly lethal disease and, as such, included only small numbers of subjects and historical controls.|1|||f||||t||||||||||2018-05-31 23:01:10.964135|2018-05-31 23:01:10.964135
NCT01266304|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-02-08|2010-12-22|2010-12-24|Estimate|||||||2017-02-08|2017-02-10|Actual|January 2011||2011-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|HEAL||The Healing Context in Complementary and Alternative Medicine (CAM): Instrument Development and Initial Validation|The Healing Context in CAM: Instrument Development and Initial Validation|Completed|||72|Actual|University of Pittsburgh|||1||f||||t||||||||||2018-05-31 23:01:11.173803|2018-05-31 23:01:11.173803
NCT01266291|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2017-04-19||2017-06-12|2010-12-23|2010-12-24|Estimate|2017-06-12|2017-07-12|Actual||||2017-06-12|2017-07-12|Actual|August 2010||2010-08-31|June 2017|2017-06-30|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|STARS||Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients|Sabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability Study|Terminated||Phase 4|1|Actual|University of Pennsylvania|The study was terminated due to insufficient enrollment; 98 potentially eligible patients were pre-screened and only one enrolled. The study was not terminated due to concerns regarding safety or efficacy.|1||"Was not possible to enroll sufficient number of subjects to draw any worthwhile conclusions~   from the study."|f||||t||||||||||2018-05-31 23:01:11.269806|2018-05-31 23:01:11.269806
NCT01266278|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-06-22|2010-12-22|2010-12-24|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Analysis of Sport Specific Adaptations of the Shoulder in Adolescent Elite Handball Players and the Influence of the Preventive Use of Tape on These Outcome Measurements.|Analysis of Sport Specific Adaptations of the Shoulder in Adolescent Elite Handball Players and the Influence of the Preventive Use of Tape on Shoulder Strength, Mobility, the Position of the Scapula and the Size of the Subacromial Space.|Completed||N/A|30|Anticipated|University Ghent||1|||f||||f||||||||||2018-05-31 23:01:11.495683|2018-05-31 23:01:11.495683
NCT01266265|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2015-12-15||2016-01-20|2010-12-23|2010-12-24|Estimate|2016-01-20|2016-02-17|Estimate||||2016-01-20|2016-02-17|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|Aspire||Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies|A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution|Completed|||1333|Actual|United Therapeutics|||2||f||||f||||||||||2018-05-31 23:01:11.636165|2018-05-31 23:01:11.636165
NCT01266252|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2018-05-04|2010-12-22|2010-12-24|Estimate|||||||2018-05-04|2018-05-11|Actual|July 28, 2011|Actual|2011-07-28|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|April 20, 2017|Actual|2017-04-20||Interventional|NEODEX||Dexmedetomidine in Mechanically Ventilated Neonates With Single-Organ Respiratory Failure.|Dexmedetomidine Pharmacokinetics - Pharmacodynamics in Mechanically Ventilated Neonates With Single-organ Respiratory Failure (NEODEX).|Completed||Phase 3|35|Actual|University Hospital, Ghent||1|||f||||t||||||||||2018-05-31 23:01:12.362521|2018-05-31 23:01:12.362521
NCT01266239|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-23|2010-12-23|2010-12-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|July 2010||2010-07-31|December 2010|2010-12-31|July 2015|Anticipated|2015-07-31|July 2012|Anticipated|2012-07-31||Interventional|J-REVERSE||Comparison Between Everolimus-eluting Stent (EES) and Sirolimus-eluting Stent (SES) in the Bifurcation Lesion|Japanese Registry Study in Comparison Between Everolimus-eluting Stent and Sirolimus-eluting Stent for the Bifurcation Lesion|Unknown status|Recruiting|N/A|300|Anticipated|Shin Yukuhashi Hospital||4|||f||||t||||||||||2018-05-31 23:01:12.429865|2018-05-31 23:01:12.429865
NCT01266226|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2015-05-19|2010-12-23|2010-12-24|Estimate|||||||2015-05-19|2015-05-20|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of ACP on Surgical Repair of Rotator Cuff Tears|Effect of Autologous Plasma (ACP) on Surgical Repair of Rotator Cuff Tears|Completed||N/A|129|Actual|Schulthess Klinik||2|||f||||t||||||||||2018-05-31 23:01:12.613189|2018-05-31 23:01:12.613189
NCT01266213|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2017-04-27|2010-12-22|2010-12-24|Estimate|||||||2017-04-27|2017-05-01|Actual|December 2010||2010-12-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|FLAG||Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women|Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman|Active, not recruiting||Phase 2|147|Anticipated|Samsung Medical Center||3|||f||||t||||||||||2018-05-31 23:01:12.689099|2018-05-31 23:01:12.689099
NCT01266200|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2012-11-26|2010-12-22|2010-12-24|Estimate|||||||2012-11-26|2012-11-27|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|MicroSpine||Identification of Microcirculation and Inflammation After Posterior Stabilization of the Spine|Identification of Cutaneous and Muscular Microcirculation and Inflammatory Response After Posterior Stabilization of the Spine|Completed||N/A|40|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 23:01:12.772981|2018-05-31 23:01:12.772981
NCT01266187|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2015-09-21|2010-12-22|2010-12-24|Estimate|||||||2015-09-21|2015-09-22|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study)|Perioperative Chemotherapy With FOLFOX Plus Cetuximab Versus Adjuvant FOLFOX Plus Cetuximab for Patients With Resectable Liver Metastases of Colorectal Carcinoma|Terminated||N/A|16|Actual|RWTH Aachen University||2||Recruitment difficulities|f||||f||||||||||2018-05-31 23:01:12.83839|2018-05-31 23:01:12.83839
NCT01266174|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2015-04-13|2010-12-22|2010-12-24|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults|Randomized, Double-blind, Parallel Trial Comparing the Effects of Eltoprazine (Adjunct to Anti-psychotics) With Placebo in Adults With Schizophrenia, in Improving One or More Dimensions of Cognitive Impairment Associated With Schizophrenia|Completed||Phase 2|31|Actual|Amarantus BioScience Holdings, Inc.||2|||f||||t||||||||||2018-05-31 23:01:12.912259|2018-05-31 23:01:12.912259
NCT01266161|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22||2012-04-19|2012-04-19|2010-12-22|2010-12-24|Estimate||||2012-04-19|2012-04-24|Estimate|2012-04-19|2012-04-24|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Multiple Dose Dental Pain Study Of Ibuprofen Extended Release|A Multiple Dose Dental Pain Study Of An Ibuprofen 600 Mg Extended Release Caplet|Completed||Phase 3|139|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:01:12.995198|2018-05-31 23:01:12.995198
NCT01266148|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2014-04-11||2015-05-15|2010-12-22|2010-12-24|Estimate|2014-04-11|2014-05-13|Estimate||||2015-05-15|2015-06-10|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SCHEDULE||SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance|SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early CNI Avoidance|Completed||Phase 4|115|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:01:13.115008|2018-05-31 23:01:13.115008
NCT01266135|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2015-04-14|2010-12-22|2010-12-24|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPF|Terminated||Phase 2|40|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:01:13.634131|2018-05-31 23:01:13.634131
NCT01266122|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2014-08-04||2015-05-14|2010-12-22|2010-12-24|Estimate|2015-05-14|2015-06-01|Estimate||||2015-05-14|2015-06-01|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Addressing Psychosocial Needs and HIV Risk in Indian MSM|Addressing Psychosocial Needs and HIV Risk in Indian MSM|Completed||N/A|96|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:01:14.682972|2018-05-31 23:01:14.682972
NCT01266109|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-06-17|2010-12-22|2010-12-24|Estimate|||||||2013-06-17|2013-06-18|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Enhancing Juvenile Drug Court Outcomes With Evidence-Based Practices|Enhancing Juvenile Drug Court Outcomes With Evidence-Based Practices|Completed||Phase 2|172|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 23:01:14.881576|2018-05-31 23:01:14.881576
NCT01266096|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2017-10-23|2010-12-22|2010-12-24|Estimate|||||||2017-10-23|2017-10-25|Actual|January 2011||2011-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study|PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study|Active, not recruiting||N/A|10|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:01:14.945994|2018-05-31 23:01:14.945994
NCT01266083|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2018-02-23|2010-12-22|2010-12-24|Estimate|||||||2018-02-23|2018-02-26|Actual|December 2010|Actual|2010-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)|Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting||Phase 2|29|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:01:15.011233|2018-05-31 23:01:15.011233
NCT01266070|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2016-12-21||2016-12-21|2010-12-22|2010-12-24|Estimate|2016-12-21|2017-02-13|Actual||||2016-12-21|2017-02-13|Actual|November 2012||2012-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||TKI 258 in Von Hippel-Lindau Syndrome (VHL)|A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome|Terminated||Phase 2|6|Actual|M.D. Anderson Cancer Center||1||Trial met toxicity stopping rule|f||||f||||||||||2018-05-31 23:01:15.093916|2018-05-31 23:01:15.093916
NCT01266057|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-07-12|2010-12-22|2010-12-24|Estimate|||||||2017-07-12|2017-07-14|Actual|April 28, 2011|Actual|2011-04-28|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer|A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|143|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 23:01:15.418063|2018-05-31 23:01:15.418063
NCT01266044|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-09-19|2010-12-22|2010-12-24|Estimate|||||||2017-09-19|2017-09-21|Actual|December 2011|Actual|2011-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia|Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia|Active, not recruiting||Phase 3|435|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 23:01:15.515425|2018-05-31 23:01:15.515425
NCT01266031|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2016-03-15||2017-02-21|2010-12-22|2010-12-24|Estimate|2016-08-02|2016-09-23|Estimate||||2017-02-21|2017-03-24|Actual|July 12, 2011|Actual|2011-07-12|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|June 30, 2015|Actual|2015-06-30||Interventional|||Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma|Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma|Completed||Phase 1/Phase 2|96|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||t|||No||2018-05-31 23:01:15.668194|2018-05-31 23:01:15.668194
NCT01266018|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2016-11-30||2017-05-10|2010-12-23|2010-12-24|Estimate|2017-05-10|2017-06-06|Actual||||2017-05-10|2017-06-06|Actual|January 2011||2011-01-31|May 2017|2017-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||All enrolled subjects|Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer|Phase II Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer|Terminated||Phase 2|22|Actual|Ludwig Institute for Cancer Research|The study was terminated early due to lack of efficacy and slow enrollment; therefore, only 22 of the planned 45 subjects were enrolled, treated, and evaluated for study endpoints.|2||Lack of efficacy in Cohort 2; slow enrollment in Cohort 1|f||||f||||||||Yes||2018-05-31 23:01:16.57641|2018-05-31 23:01:16.57641
NCT01266005|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2014-12-16|2010-12-22|2010-12-24|Estimate|||||||2014-12-16|2014-12-18|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients|A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients|Terminated||Phase 4|75|Anticipated|Bukwang Pharmaceutical||2|||f||||||||||||||2018-05-31 23:01:17.054746|2018-05-31 23:01:17.054746
NCT01265992|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2013-11-08||2014-01-22|2010-12-22|2010-12-24|Estimate|2014-01-22|2014-02-19|Estimate||||2014-01-22|2014-02-19|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|CAPITOL|Full analysis set, defined as all included participants who received at least 1 dose of paricalcitol capsules.|Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis|Post Marketing Observational Study to Assess Patient Management Practices and Quality of Life With the Capsules Form of Paricalcitol in the Treatment of SHPT in Stage 3 - 5 Chronic Kidney Disease Patients Not Yet on Dialysis Under Conditions of Usual Clinical Care (CAPITOL)|Completed|||50|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:01:17.166634|2018-05-31 23:01:17.166634
NCT01265979|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2015-04-09|2010-12-22|2010-12-23|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib|Whole Body Diffusion-weighted MRI (WB-DWI) for Early Prediction and Evaluation of Therapy Response in Patients With Advanced Metastatic Gastrointestinal Stromal Tumors (GIST) Treated With Regorafenib.|Completed|||5|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 23:01:17.554655|2018-05-31 23:01:17.554655
NCT01265966|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2012-12-08||2013-03-08|2010-12-22|2010-12-23|Estimate|2013-03-08|2013-03-11|Estimate||||2013-03-08|2013-03-11|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Cortisol Response to Moderate and Deep Sedation in Children|Characterization of the Normal Cortisol Response to Moderate and Deep Sedation in Adrenally Sufficient Children|Completed|||149|Actual|Tripler Army Medical Center|There is concern that the presence of a cortisol response is merely a biochemical phenomena and not of clinical importance for minor surgeries/mild stress.||2||f||||t||||||None Retained|"~     This is an observational study measuring salivary cortisol levels. No interventions will done~     based on these measurements during the study. Specimens will be disposed off at the end of~     the study.~   "|||2018-05-31 23:01:17.630267|2018-05-31 23:01:17.630267
NCT01265953|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2017-05-12||2017-06-16|2010-12-22|2010-12-23|Estimate|2017-06-16|2017-07-14|Actual||||2017-06-16|2017-07-14|Actual|July 2011||2011-07-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|PBroC||Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation|Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation|Completed||N/A|98|Actual|Portland VA Medical Center||2|||f||||t||||||||||2018-05-31 23:01:17.863214|2018-05-31 23:01:17.863214
NCT01265940|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2012-10-09|2010-12-22|2010-12-23|Estimate|||||||2012-10-09|2012-10-10|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Pazopanib and Vinflunine in Urothelial Cancer of the Bladder|Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment|Completed||Phase 1/Phase 2|5|Actual|Lukas-Krankenhaus GmbH||1|||f||||f||||||||||2018-05-31 23:01:18.170105|2018-05-31 23:01:18.170105
NCT01265927|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2015-10-26|2010-12-22|2010-12-23|Estimate|||||||2015-10-26|2015-10-27|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|August 2012|Actual|2012-08-31||Interventional|||A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer|A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer|Completed||Phase 1|10|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 23:01:18.245344|2018-05-31 23:01:18.245344
NCT01265914|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2012-03-23|2010-12-22|2010-12-23|Estimate|||||||2012-03-23|2012-03-26|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine|A Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of an Influenza A Vaccine (FP-01.1)|Completed||Phase 1|49|Actual|Immune Targeting Systems Ltd||2|||f||||t||||||||||2018-05-31 23:01:18.36631|2018-05-31 23:01:18.36631
NCT01265901|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22||2017-09-25|2017-10-04|2010-12-22|2010-12-23|Estimate||||2017-09-28|2017-10-04|Actual|2017-10-04|2017-10-12|Actual|December 2010||2010-12-31|September 2017|2017-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma|A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma|Completed||Phase 3|339|Actual|immatics Biotechnologies GmbH||2|||f||||t||||||||||2018-05-31 23:01:18.454808|2018-05-31 23:01:18.454808
NCT01265888|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2016-09-16|2010-12-22|2010-12-23|Estimate|||||||2016-09-16|2016-09-19|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PHiano||Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.|A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl.|Completed||Phase 2|31|Actual|Geno LLC||3|||f||||f||||||||Yes||2018-05-31 23:01:18.82742|2018-05-31 23:01:18.82742
NCT01265875|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2013-07-29||2016-03-08|2010-12-22|2010-12-23|Estimate|2016-02-26|2016-03-01|Estimate||||2016-03-08|2016-03-09|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Secretin Infusion for Pain Due to Chronic Pancreatitis|Secretin Infusion for Pain Due to Chronic Pancreatitis|Completed||Phase 1/Phase 2|12|Actual|ChiRhoClin, Inc.||1|||f||||t||||||||||2018-05-31 23:01:18.938636|2018-05-31 23:01:18.938636
NCT01265862|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2012-08-22|2010-12-22|2010-12-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Does the Use of the GlideRite® Endotracheal Tube in Combination With the I-gel® Improve Intubation Success Rate?|Comparison of LMA-Fastrach® and I-gel® for Tracheal Intubation: Does the Use of the GlideRite® Endotracheal Tube in Combination With the I-gel® Improve Success Rate?|Completed||N/A|120|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 23:01:19.181606|2018-05-31 23:01:19.181606
NCT01265849|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-12-06|2010-12-22|2010-12-23|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2010||2010-12-31|July 2017|2017-07-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|IT-MATTERS||Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity|Phase III Study of LI [Multikine®] Plus SOC (Surgery + Radiotherapy or Surgery + Concurrent Radiochemotherapy) in Subjects With Advanced Primary Squamous Cell Carcinoma of the Oral Cavity/Soft Palate vs. SOC Only|Completed||Phase 3|928|Anticipated|CEL-SCI Corporation||3|||f||||t||||||||No|There is no plan|2018-05-31 23:01:19.281991|2018-05-31 23:01:19.281991
NCT01265836|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-04-11|2010-12-22|2010-12-23|Estimate|||||||2011-04-11|2011-04-12|Estimate|March 2011||2011-03-31|April 2011|2011-04-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|DEMAND||Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes|Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes|Withdrawn|||1064|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:01:19.494062|2018-05-31 23:01:19.494062
NCT01265823|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2013-02-01||2013-02-01|2010-12-22|2010-12-23|Estimate|2013-02-01|2013-03-11|Estimate||||2013-02-01|2013-03-11|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis|Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 4|150|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:01:19.591273|2018-05-31 23:01:19.591273
NCT01265810|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2017-11-08|2010-12-21|2010-12-23|Estimate|||||||2017-11-08|2017-11-13|Actual|November 2011|Actual|2011-11-30|November 2017|2017-11-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|COMTT||Caphosol in Oral Mucositis Due to Targeted Therapy|Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy|Completed||Phase 3|64|Actual|Impaqtt Foundation||2|||f||||f||||||||||2018-05-31 23:01:20.010553|2018-05-31 23:01:20.010553
NCT01265797|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2013-08-07||2015-02-02|2010-12-21|2010-12-23|Estimate|2015-02-02|2015-02-10|Estimate||||2015-02-02|2015-02-10|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional||The overall number of baseline participants used for analysis is the number completing the blinded period from the run-in period, and differs from the number of participants started in the Participant Flow Module due to drop-out and other causes listed in the participant flow module.|Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches|Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches|Completed||N/A|68|Actual|University of Toledo Health Science Campus|Recall bias in completing survey instruments. Incomplete diary data with regards to headache symptoms, acute medication use and relief limited analysis for other proposed secondary outcomes.Higher than anticipated drop-out rate.|2|||f||||f||||||||||2018-05-31 23:01:20.162095|2018-05-31 23:01:20.162095
NCT01265784|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2015-08-04||2015-08-04|2010-12-22|2010-12-23|Estimate|2015-08-04|2015-09-04|Estimate||||2015-08-04|2015-09-04|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||All randomized participants.|Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections|A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety, and PK of 2 Dose Regimens of TP-434 Compared With Ertapenem in Adult Community-Acquired Complicated Intra-abdominal Infections|Completed||Phase 2|143|Actual|Tetraphase Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 23:01:20.709221|2018-05-31 23:01:20.709221
NCT01265771|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2011-12-02|2010-12-22|2010-12-23|Estimate|||||||2011-12-02|2011-12-05|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|TELEMARC2||Optimizing Diagnostics Of Arrhythmia Events In Children Using Intelligent Telemetric Solutions|Optimizing Diagnostics And Therapy Of Arrhythmia And Syncope Events Using Intelligent Telemetric Solutions. Diagnostics Of Arrhythmia In Children|Unknown status|Recruiting|N/A|400|Anticipated|Institute of Cardiology, Warsaw, Poland||3|||f||||f||||||||||2018-05-31 23:01:21.648536|2018-05-31 23:01:21.648536
NCT01265758|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2013-02-18|2010-12-22|2010-12-23|Estimate|||||||2013-02-18|2013-02-20|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|TELEMARC1||Telemetric Arrhythmia Diagnosis in Adults|OPTIMIZING DIAGNOSTICS AND THERAPY OF ARRHYTHMIA AND SYNCOPE EVENTS USING INTELLIGENT TELEMETRIC SOLUTIONS - Evaluation of Arrhythmia Diagnostics in Adults|Unknown status|Recruiting|N/A|360|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-05-31 23:01:21.745549|2018-05-31 23:01:21.745549
NCT01265745|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2013-12-06|2010-12-21|2010-12-23|Estimate|||||||2013-12-06|2013-12-09|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects|A Phase I, Double-blind, Randomized, Placebo Controlled, Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) as a 120 Minute Infusion in Healthy, Normal Subjects|Completed||Phase 1|28|Actual|PharmAthene, Inc.||2|||f||||t||||||||||2018-05-31 23:01:21.841381|2018-05-31 23:01:21.841381
NCT01265732|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2015-10-15|2010-12-21|2010-12-23|Estimate|||||||2015-10-15|2015-10-16|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers|An Open Label, Randomized 3-Way Crossover Single Dose Study To Compare The Pharmacokinetics And Relative Bioavailability Of PF-04191834 Using An Oral Wet-Milled Suspension Formulation Versus An Oral Single Dose Dispersion Formulation Under Fasted Conditions In Healthy Volunteers|Withdrawn||Phase 1|0|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:01:21.909612|2018-05-31 23:01:21.909612
NCT01265719|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2016-05-11|2010-12-21|2010-12-23|Estimate|||||||2016-05-11|2016-05-13|Estimate|December 2010||2010-12-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|LYNX||Long-Term Non-Interventional Latanoprost Study|A Prospective, Non-interventional, Longitudinal Cohort Study To Evaluate The Long-term Safety Of Latanoprost Treatment In Pediatric Populations|Completed|||178|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 23:01:21.988864|2018-05-31 23:01:21.988864
NCT01265706|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2014-12-12|2010-12-22|2010-12-23|Estimate|||||||2014-12-12|2014-12-15|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||Livalo Acute Myocardial Infarction Study (LAMIS)|1-year, Prospective, Randomized, Open-label, Parallel Group Observational Study to Evaluate the Safety and Efficacy of 4mg/Day of Pitavastatin Versus 2mg/Day of Pitavastatin in Acute Myocardial Infarction(AMI)|Completed|||1000|Anticipated|JW Pharmaceutical|||||f||||f||||||||||2018-05-31 23:01:22.125432|2018-05-31 23:01:22.125432
NCT01265693|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-07-20|2010-12-22|2010-12-23|Estimate|||||||2016-07-20|2016-07-21|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|HLIPT2010||The Effect of Antiviral Therapy With Pegylated Interferon-alpha on Auditory Disability|The Effect of Antiviral Therapy With Pegylated Interferon-alpha for Chronic Hepatitis C and B on Auditory Disability: A Prospective Study|Completed|||100|Actual|Carmel Medical Center|||||f||||f||||||||No||2018-05-31 23:01:22.174325|2018-05-31 23:01:22.174325
NCT01265680|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2013-04-05|2010-12-22|2010-12-23|Estimate|||||||2013-04-05|2013-04-08|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|SHOT||Blood Sparing Strategies: Single Shot High Dose Erythropoietin Two Days Before Heart Surgery|Single High Dose Erythropoietin Obviates Transfusions: an Independent, Blinded, Prospective Randomized Study in Heart Surgery Population.|Completed||N/A|600|Actual|Cardiochirurgia E.H.||2|||f||||t||||||||||2018-05-31 23:01:22.250082|2018-05-31 23:01:22.250082
NCT01265667|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2017-06-01||2017-08-20|2010-12-22|2010-12-23|Estimate|2017-08-20|2017-09-20|Actual||||2017-08-20|2017-09-20|Actual|July 2011||2011-07-31|July 2017|2017-07-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Trial of CF101 to Treat Patients With Psoriasis|A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 2/Phase 3|293|Actual|Can-Fite BioPharma||2|||f||||t||||||||||2018-05-31 23:01:22.365348|2018-05-31 23:01:22.365348
NCT01265654|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2011-11-22|2010-12-22|2010-12-23|Estimate|||||||2011-11-22|2011-11-23|Estimate|January 2011||2011-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|HOT ABC||Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer|Reasons for Changing HOrmonal Therapy of Advanced Breast Cancer|Completed|||234|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 23:01:22.663206|2018-05-31 23:01:22.663206
NCT01265641|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2011-06-27|2010-12-22|2010-12-23|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||To Investigate the Effects of AZD1981 on the QT Interval|A Single-centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four-period Crossover Study in Healthy Male Volunteers, to Assess the Effect on QT/QTc Interval of Single Oral Doses of AZD1981 (200 mg and 2000 mg) Using Moxifloxacin (Avelox®) as a Positive Control|Completed||Phase 1|44|Anticipated|AstraZeneca||4|||f||||||||||||||2018-05-31 23:01:22.762698|2018-05-31 23:01:22.762698
NCT01265628|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2012-01-25|2010-12-22|2010-12-23|Estimate|||||||2012-01-25|2012-01-26|Estimate|November 2010||2010-11-30|January 2012|2012-01-31||||August 2011|Actual|2011-08-31||Observational|ValGATE||Validation of the GATE Software|Validation of the GATE Software for Static Visual Field Examinations|Completed|||30|Actual|University Hospital Tuebingen|||3||f||||f||||||||||2018-05-31 23:01:22.84814|2018-05-31 23:01:22.84814
NCT01265615|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|2010-12-27||2015-05-14|2010-12-22|2010-12-23|Estimate|2011-05-23|2011-06-21|Estimate||||2015-05-14|2015-06-09|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients|Phase 4 Study of Paricalcitol and Calcitriol for Reparative Management of Chronic Allograft Dysfunction and Renocardiac Syndrome in Vitamin D Insufficient Renal Transplant Recipients|Completed||Phase 4|109|Actual|Ural Medical University||4|||f||||t||||||||||2018-05-31 23:01:22.942913|2018-05-31 23:01:22.942913
NCT01265602|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2012-07-23|2010-12-22|2010-12-23|Estimate|||||||2012-07-23|2012-07-24|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis|Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis|Completed||Phase 3|889|Actual|Almirall, S.A.||3|||f||||||||||||||2018-05-31 23:01:23.718146|2018-05-31 23:01:23.718146
NCT01265589|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-07-25|2010-12-22|2010-12-23|Estimate|||||||2011-07-25|2011-07-26|Estimate|January 2012||2012-01-31|November 2010|2010-11-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|RDS||Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome|Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 23:01:23.811607|2018-05-31 23:01:23.811607
NCT01265576|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2015-12-08|2010-12-22|2010-12-23|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|February 2014|Actual|2014-02-28||Interventional|||Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)|A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia|Unknown status|Active, not recruiting|Phase 2|20|Actual|Vicus Therapeutics||2|||f||||t||||||||||2018-05-31 23:01:23.919134|2018-05-31 23:01:23.919134
NCT01265563|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2017-01-27||2017-03-31|2010-12-21|2010-12-23|Estimate|2017-03-21|2017-03-31|Actual||||2017-03-31|2017-05-09|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|February 2015|Actual|2015-02-28||Interventional|CGDN||N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy|Correction of Glutathione Deficiency for Treatment of Diabetic Nephropathy|Completed||Phase 2|108|Actual|VA Office of Research and Development||5|||f||||t||||||||Undecided||2018-05-31 23:01:24.029062|2018-05-31 23:01:24.029062
NCT01265550|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2017-12-21||2018-02-22|2010-12-22|2010-12-23|Estimate|2018-02-22|2018-02-26|Actual||||2018-02-22|2018-02-26|Actual|August 13, 2012|Actual|2012-08-13|February 2018|2018-02-28|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|||A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors|CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors|Completed||Phase 3|78|Actual|VA Office of Research and Development||3|||f||||t||||||||No||2018-05-31 23:01:24.650532|2018-05-31 23:01:24.650532
NCT01265537|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2016-06-28|2010-12-22|2010-12-23|Estimate|||||||2016-06-28|2016-06-29|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Astellas||A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf|A Prospective, Open Label, Pilot Study Comparing the Use of Low-target Advagraf With Rabbit Antithymocyte Globulin Induction Versus Conventional Target Advagraf With Basiliximab Induction in a Steroid-avoidance Immunosuppressive Protocol for de Novo Renal Transplant Recipients|Recruiting||N/A|30|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:01:25.497429|2018-05-31 23:01:25.497429
NCT01265524|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2013-01-03||2013-03-12|2010-12-21|2010-12-23|Estimate|2013-03-12|2013-03-13|Estimate||||2013-03-12|2013-03-13|Estimate|April 2011||2011-04-30|March 2013|2013-03-31||||November 2011|Actual|2011-11-30||Interventional|||Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease|A Phase 2, Randomized, Double-Blind, Multi-center Study Comparing CLP Versus Placebo in Heart Failure Patients With Chronic Kidney Disease|Completed||Phase 2|113|Actual|Sorbent Therapeutics||2|||f||||f||||||||||2018-05-31 23:01:25.590928|2018-05-31 23:01:25.590928
NCT01265511|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2014-10-22||2017-07-18|2010-12-22|2010-12-23|Estimate|2017-07-18|2017-08-18|Actual||||2017-07-18|2017-08-18|Actual|November 2010||2010-11-30|July 2017|2017-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of SCY-635, Pegasys and Copegus in Hepatitis C|A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection|Completed||Phase 2|10|Actual|Scynexis, Inc.||2|||f||||f||||||||||2018-05-31 23:01:25.984142|2018-05-31 23:01:25.984142
NCT01265498|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2015-06-26||2018-03-12|2010-12-21|2010-12-23|Estimate|2015-07-27|2015-08-21|Estimate||||2018-03-12|2018-04-06|Actual|March 2011||2011-03-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|FLINT||The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)|The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial|Completed||Phase 2|283|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-05-31 23:01:26.403421|2018-05-31 23:01:26.403421
NCT01265485|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-08-21|2010-12-22|2010-12-23|Estimate|||||||2011-08-21|2011-08-23|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||An Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects|An Open Label Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects|Completed||Phase 1/Phase 2|6|Anticipated|RDD Pharma Ltd||1|||f||||f||||||||||2018-05-31 23:01:27.937233|2018-05-31 23:01:27.937233
NCT01265472|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-22|2010-12-22|2010-12-23|Estimate|||||||2010-12-22|2010-12-23|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Observational|||Comparison of Translocator Protein Expression and Binding Activity in Normal Tissue Versus Non Melanotic Malignancy|Comparison of the Expression Level of Translocator Protein (TSPO) and Binding Activity in Normal Cutaneous Tissue Versus Non Melanotic Cutaneous Malignancy.|Unknown status|Not yet recruiting||100|Anticipated|Rambam Health Care Campus|||||f||||f||||||Samples Without DNA|"~     Specimens of normal skin, squamous cell carcinoma or basal cell carcinoma~   "|||2018-05-31 23:01:27.989518|2018-05-31 23:01:27.989518
NCT01265459|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2013-12-03||2014-03-17|2010-12-22|2010-12-23|Estimate|2013-12-03|2014-01-20|Estimate||||2014-03-17|2014-04-14|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Different Volumes of Durolane in Knee OA|Double-Blind, Randomized Study of Three Different Volumes of Durolane in Subjects With Osteoarthritis of the Knee|Completed||Phase 2|68|Actual|Q-Med AB||3|||f||||f||||||||||2018-05-31 23:01:28.049831|2018-05-31 23:01:28.049831
NCT01265446|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2012-03-29||2013-04-17|2010-12-22|2010-12-23|Estimate|2012-06-19|2012-07-26|Estimate||||2013-04-17|2013-04-24|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.|A Randomized, Double-blind, Parallel Group, Single-dose Study of the Efficacy of Lidocaine 8 mg + Cetylpyridinium Chloride (CPC) 2 mg Fixed Combination Lozenges on Sore Throat Pain Intensity Compared to Lozenges Containing Lidocaine 1 mg and CPC 2 mg in Subjects With Sore Throat Due to Upper Respiratory Tract Infection.|Completed||Phase 3|250|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:01:28.353309|2018-05-31 23:01:28.353309
NCT01265433|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2018-01-23|2010-12-22|2010-12-23|Estimate|||||||2018-01-23|2018-01-25|Actual|December 21, 2010|Actual|2010-12-21|January 2017|2017-01-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy|Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy|Completed||Phase 2|31|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-05-31 23:01:28.545082|2018-05-31 23:01:28.545082
NCT01265420|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2015-03-28||2015-04-08|2010-12-22|2010-12-23|Estimate|2015-03-28|2015-04-09|Estimate||||2015-04-08|2015-04-30|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb|The Efficacy and Safety of Xiaflex Injections for the Treatment of Thumb Cords in Dupuytren's Contractures|Completed||Phase 4|7|Actual|Indiana Hand to Shoulder Center|1 patient was seen at Day 10, but not at day 30. At Day 10, patient met the primary endpoint|1|||f||||f||||||||||2018-05-31 23:01:28.649021|2018-05-31 23:01:28.649021
NCT01265407|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2018-04-04|2010-12-22|2010-12-23|Estimate|||||||2018-04-04|2018-04-05|Actual|December 22, 2010||2010-12-22|March 7, 2018|2018-03-07||||||||Observational|||Malaria Surveillance in Rakai, Uganda|Malaria Surveillance in Rakai, Uganda|Completed|||1650|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:01:28.761207|2018-05-31 23:01:28.761207
NCT01265394|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2013-03-27||2013-06-21|2010-12-21|2010-12-23|Estimate|2013-05-14|2013-06-21|Estimate||||2013-06-21|2013-07-02|Estimate|December 2010||2010-12-31|June 2013|2013-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional||This is the number of participants that completed.|Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects|A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40|Completed||Phase 3|218|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 23:01:28.880369|2018-05-31 23:01:28.880369
NCT01265381|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2018-04-04|2010-12-22|2010-12-23|Estimate|||||||2018-04-04|2018-04-05|Actual|December 22, 2010||2010-12-22|March 13, 2018|2018-03-13||||||||Observational|||Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study|Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study|Completed|||673|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:01:29.41524|2018-05-31 23:01:29.41524
NCT01265368|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-03-22|2010-12-22|2010-12-23|Estimate|||||||2017-03-22|2017-03-23|Actual|December 2010||2010-12-31|March 2016|2016-03-31|August 2018|Anticipated|2018-08-31|August 2013|Actual|2013-08-31||Interventional|ASET||A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)|A Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination With a DNA-based Double Stem Loop Immunomodulator in Patients With Advanced Renal Cell Carcinoma (ASET Study)|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Mologen AG||1|||f||||t||||||||||2018-05-31 23:01:29.536164|2018-05-31 23:01:29.536164
NCT01265355|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2015-02-03|2010-12-22|2010-12-23|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement|Community Based Prophylaxis for Rotavirus Gastroenteritis in Children by an Anti-rotavirus Protein Based Food Supplement|Completed||Phase 2/Phase 3|330|Actual|Christian Medical College, Vellore, India||2|||f||||t||||||||||2018-05-31 23:01:29.666194|2018-05-31 23:01:29.666194
NCT01265342|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2014-03-10|2010-12-22|2010-12-23|Estimate|||||||2014-03-10|2014-03-11|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|ENBe||Efficacy of Nebulised Beclometasone in Viral Wheezing Prophylaxis|Efficacy Of Nebulised Beclometasone Versus Placebo In Preventing Viral Wheezing In Pre-School Children|Completed||Phase 4|576|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t||||||||||2018-05-31 23:01:29.784525|2018-05-31 23:01:29.784525
NCT01265329|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2014-08-04|2010-12-22|2010-12-23|Estimate|||||||2014-08-04|2014-08-05|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MACS||Methods for Objective Selection of Competent Sperm||Completed||N/A|237|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 23:01:29.993375|2018-05-31 23:01:29.993375
NCT01265316|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2014-02-05|2010-12-22|2010-12-23|Estimate|||||||2014-02-05|2014-02-06|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Observational|PediQ-CPR||Measurement of the Quality of Pediatric CPR|Pediatric CPR Quality: Quantitative Measurement of Pediatric Cardiopulmonary Resuscitation (CPR) Quality During In-Hospital Cardiac Arrest|Completed|||4|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-05-31 23:01:30.108749|2018-05-31 23:01:30.108749
NCT01265303|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2013-05-06|2010-12-22|2010-12-23|Estimate|||||||2013-05-06|2013-05-07|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|TELEMARC 4||Telemetric Arrhythmia and Syncope Diagnosis - Evaluation of Arrhythmia Treatment Efficacy|OPTIMIZING DIAGNOSTICS AND THERAPY OF ARRHYTHMIA AND SYNCOPE EVENTS USING INTELLIGENT TELEMETRIC SOLUTIONS - Evaluation of Arrhythmia Treatment Efficacy|Unknown status|Recruiting|N/A|360|Anticipated|Institute of Cardiology, Warsaw, Poland||3|||f||||f||||||||||2018-05-31 23:01:30.204942|2018-05-31 23:01:30.204942
NCT01265290|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2011-12-02|2010-12-22|2010-12-23|Estimate|||||||2011-12-02|2011-12-05|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|TELEMARC3||Optimizing Diagnostics Of Syncope Events Using Intelligent Telemetric Solutions.|Optimizing Diagnostics And Therapy Of Arrhythmia And Syncope Events Using Intelligent Telemetric Solutions. Diagnostics Of Syncope In Children.|Unknown status|Recruiting|N/A|640|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-05-31 23:01:30.653498|2018-05-31 23:01:30.653498
NCT01265277|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-06-30|2010-12-21|2010-12-23|Estimate|||||||2017-06-30|2017-07-02|Actual|July 2009|Actual|2009-07-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Changes in Sleep Patterns and Stress in Infants Entering Child Care|Changes in Sleep Patterns and Stress in Infants Entering Child Care: Implications for SIDS Risk|Enrolling by invitation|||20|Actual|University of Virginia|||2||f||||f||||||Samples Without DNA|"~     urine samples from both mom and baby~   "|||2018-05-31 23:01:31.318431|2018-05-31 23:01:31.318431
NCT01265264|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20||2013-10-04|2013-10-28|2010-12-22|2010-12-23|Estimate||||2013-10-04|2013-10-28|Estimate|2013-10-28|2013-11-20|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Interventional|||Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol|A Randomized, Double-Blind, Dose-Response Study of the Safety and Efficacy of Oral Ulodesine Added to Allopurinol in Subjects With Gout Who Have Not Adequately Responded to Allopurinol Monotherapy|Completed||Phase 2|279|Actual|BioCryst Pharmaceuticals||5|||f||||t||||||||||2018-05-31 23:01:31.502513|2018-05-31 23:01:31.502513
NCT01265251|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-22|2010-12-22|2010-12-23|Estimate|||||||2010-12-22|2010-12-23|Estimate|August 2007||2007-08-31|December 2010|2010-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Computerized Neuropsychology in Idiopathic Normal Pressure Hydrocephalus (INPH)|Evaluation of a Computerised Neuropsychological Test Battery for Idiopathic Normal Pressure Hydrocephalus (INPH)|Completed|||97|Actual|Umeå University|||3||f||||f||||||||||2018-05-31 23:01:32.761258|2018-05-31 23:01:32.761258
NCT01265238|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2014-12-31|2010-12-22|2010-12-23|Estimate|||||||2014-12-31|2015-01-01|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|March 2012|Actual|2012-03-31||Observational|||Neuro-orthopaedic Surgery in the Treatment of the Spastic Equinovarus Foot|Study of the Efficacy and Safety of the Neuro-orthopaedic Surgery in the Treatment of the Spastic Equinovarus Foot With ICF Assessment|Completed|||22|Actual|University Hospital of Mont-Godinne|||||f||||f||||||||||2018-05-31 23:01:32.906379|2018-05-31 23:01:32.906379
NCT01265225|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2013-12-22|2010-12-22|2010-12-23|Estimate|||||||2013-12-22|2013-12-24|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Observational|||Prognostic Value of Stem Cell Related Markers|Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II|Withdrawn|||0|Actual|The Baruch Padeh Medical Center, Poriya||||no finance|f||||t||||||||||2018-05-31 23:01:32.997627|2018-05-31 23:01:32.997627
NCT01265212|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-06-28|2010-12-22|2010-12-23|Estimate|||||||2017-06-28|2017-07-02|Actual|September 2010||2010-09-30|June 2017|2017-06-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Prevalence of Human Papillomavirus in Men Living in the Northern Plains|Prevalence of Human Papillomavirus in Men Living in the Northern Plains|Completed|||110|Actual|Sanford Health|||||f||||f||||||Samples With DNA|"~     Epithelial skin swabs collected for the purpose of HPV DNA detection. DNA extraction and HPV~     testing will be performed.~   "|||2018-05-31 23:01:33.066581|2018-05-31 23:01:33.066581
NCT01264198|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2014-03-26|2010-12-20|2010-12-21|Estimate|||||||2014-03-26|2014-03-27|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||The Role of Resistance Training in Non Alcoholic Fatty Liver Disease|The Role of Resistance Training in Non Alcoholic Fatty Liver Disease|Completed||N/A|82|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 23:01:48.388696|2018-05-31 23:01:48.388696
NCT01265199|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2013-01-21|2010-12-22|2010-12-23|Estimate|||||||2013-01-21|2013-01-23|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)|Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk, Acute Myelogenous Leukemia (AML)|Terminated||Phase 1|29|Actual|Ascenta Therapeutics||||Study was terminated before a MTD was determined for administrative reasons|f||||f||||||||||2018-05-31 23:01:33.207709|2018-05-31 23:01:33.207709
NCT01265186|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-22|2010-12-22|2010-12-23|Estimate|||||||2010-12-22|2010-12-23|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Evaluation of Sedation in Newborns|Evaluation of Sedation in Newborns - a Prospective, Controlled, Observer Blinded Clinical Trial in 67 Patients|Unknown status|Recruiting||67|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 23:01:33.33004|2018-05-31 23:01:33.33004
NCT01265173|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2017-08-21|2010-12-22|2010-12-23|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2007||2007-04-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC|Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis|Completed||Phase 4|261|Actual|Korea University||3|||f||||t||||||||||2018-05-31 23:01:33.439444|2018-05-31 23:01:33.439444
NCT01265160|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-22|||2010-12-22|2010-12-22|2010-12-23|Estimate|||||||2010-12-22|2010-12-23|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Observational|JZF||Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)|Jiangzhuo Prescription ，Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)|Unknown status|Recruiting||240|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|||3||f||||t||||||||||2018-05-31 23:01:33.528461|2018-05-31 23:01:33.528461
NCT01265147|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-01-19|2010-12-22|2010-12-23|Estimate|||||||2011-01-19|2011-01-20|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|December 2017|Anticipated|2017-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma|Phase II Study to Evaluate Efficacy and Safety of Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Patients With Nasopharyngeal Carcinoma|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||f||||||||||2018-05-31 23:01:33.66227|2018-05-31 23:01:33.66227
NCT01265134|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-31|2010-12-21|2010-12-22|Estimate|||||||2010-12-31|2011-01-03|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|August 2011|Anticipated|2011-08-31|||||Observational|||Efficacy of Arch Insoles in the Dynamic Postural Control for the Elderly|Efficacy of Arch Insoles in the Dynamic Postural Control for the Elderly|Unknown status|Active, not recruiting||60|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 23:01:34.180783|2018-05-31 23:01:34.180783
NCT01265121|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-21|2010-12-21|2010-12-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.|Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.|Unknown status|Active, not recruiting|N/A|12|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 23:01:34.79817|2018-05-31 23:01:34.79817
NCT01265108|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2015-07-27|2010-12-21|2010-12-22|Estimate|||||||2015-07-27|2015-07-29|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Effects of Iron on Exercise Capacity During Hypoxia|Effects of Intravenous Iron Supplementation on Exercise Capacity During Sustained Alveolar Hypoxia in Healthy Humans.|Completed||Phase 1|12|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 23:01:34.904695|2018-05-31 23:01:34.904695
NCT01265095|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2012-08-28|2010-12-21|2010-12-22|Estimate|||||||2012-08-28|2012-08-30|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Establish Quantitative PCR to Measure Bacteria Load of the VRE Bacteremia|Establish Quantitative PCR to Measure Bacteria Load of the VRE Bacteremia|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 23:01:35.054576|2018-05-31 23:01:35.054576
NCT01265082|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-21|2010-12-21|2010-12-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||||||Observational|||Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission|Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission|Unknown status|Active, not recruiting||40|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 23:01:35.244432|2018-05-31 23:01:35.244432
NCT01265069|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2013-05-31|2010-12-21|2010-12-22|Estimate|||||||2013-05-31|2013-06-03|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy|Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy|Unknown status|Recruiting|Phase 4|204|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 23:01:35.439299|2018-05-31 23:01:35.439299
NCT01265056|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2013-01-22||2018-01-22|2010-12-21|2010-12-22|Estimate|2013-01-22|2013-02-26|Estimate||||2018-01-22|2018-01-23|Actual|February 2010|Actual|2010-02-28|December 2017|2017-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Effect of Neurontin on Pain Management in the Acutely Burned Patient|The Effect of Neurontin on Pain Management in the Acutely Burned Patient|Completed||N/A|53|Actual|University of Iowa||2|||f||||f||||||||Yes|Researchers can contact me (lucy-wibbenmeyer@uiowa.edu) for study protocol or statistical plan.|2018-05-31 23:01:35.614609|2018-05-31 23:01:35.614609
NCT01265043|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2015-06-09|2010-12-21|2010-12-22|Estimate|||||||2015-06-09|2015-06-11|Estimate|July 2008||2008-07-31|June 2015|2015-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Randomized Clinical Trial of Oral Health Promotion Interventions Among Patients After Stroke|A Randomized Clinical Trial of Oral Health Promotion Interventions Among Patients Following Stroke|Completed||Phase 4|102|Actual|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 23:01:36.331402|2018-05-31 23:01:36.331402
NCT01263626|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2015-06-05|2010-12-20|2010-12-21|Estimate|||||||2015-06-05|2015-06-08|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|January 2012|Actual|2012-01-31||Observational|||Cough Monitoring Study|Monitoring Cough Device - Step 1 and 2|Completed|||33|Actual|Vanderbilt University|||2||f||||f||||||||||2018-05-31 23:01:57.477237|2018-05-31 23:01:57.477237
NCT01265030|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2017-04-05|2010-12-21|2010-12-22|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2014||2014-02-28|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis|A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis|Recruiting||Phase 1/Phase 2|15|Anticipated|Maine Medical Center||1|||f||||t||||||||||2018-05-31 23:01:36.452438|2018-05-31 23:01:36.452438
NCT01265017|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2018-04-16|2010-12-21|2010-12-22|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2012||2012-07-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes|Single-center, Double-masked, Placebo-controlled Parallel-group Study of Pregnancy-related Hormones Estradiol and Medroxyprogesterone, in Conjunction With Hydrocortisone and Growth Hormone to Stimulate C-peptide Secretion in Women With T1DM|Withdrawn||Phase 1|0|Actual|Sansum Diabetes Research Institute||2||Insufficient funding|f||||f||||||||||2018-05-31 23:01:36.936883|2018-05-31 23:01:36.936883
NCT01265004|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-11-26|2010-12-21|2010-12-22|Estimate|||||||2012-11-26|2012-11-27|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|MicroASR||Identification of Microcirculation After Surgical Treatment of Rupture of the Achilles Tendon|Evaluation of Microcirculation in Skin and Tendon After Surgical Treatment of Acute Rupture of the Achilles Tendon With Stitches or Fibrin-glue|Completed|||20|Actual|RWTH Aachen University|||3||f||||f||||||||||2018-05-31 23:01:37.355475|2018-05-31 23:01:37.355475
NCT01264991|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2017-10-23|2010-12-21|2010-12-22|Estimate|||||||2017-10-23|2017-10-24|Actual|February 21, 2011|Actual|2011-02-21|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SLAMSHAM||The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients|The Benefit of Arthroscopic Partial Meniscectomy in Middle-Aged Patients - A Double-Blinded Randomized Placebo (Sham) Controlled Multi-Centre Trial|Terminated||N/A|41|Actual|Slagelse Hospital||2||"Recruitment stalled. Study terminated before inclusion of sufficient number of participants~   included"|f||||f||||||||||2018-05-31 23:01:37.450588|2018-05-31 23:01:37.450588
NCT01264978|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-21|2010-12-21|2010-12-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|COPD||Evaluation of Utility Quadriceps Magnetic Stimulation in COPD (Chronic Obstructive Pulmonary Disease) Patients After Hospital Exacerbation|Evaluation of Utility Quadriceps Magnetic Stimulation in COPD (Chronic Obstructive Pulmonary Disease) Patients After Hospital Exacerbation|Unknown status|Not yet recruiting|Phase 3|32|Anticipated|Hospital de Cruces||1|||f||||t||||||||||2018-05-31 23:01:37.526642|2018-05-31 23:01:37.526642
NCT01264965|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2014-11-12|2010-12-21|2010-12-22|Estimate|||||||2014-11-12|2014-11-14|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Non-cancer Pain and Cognitive Impairment: A Disabling Relationship|Opioids Versus Extra Strength Acetaminophen for the Management of Moderate Persistent Non-cancer Pain|Terminated||Phase 4|25|Actual|University of Chicago||2||recruitment problems|f||||f||||||||||2018-05-31 23:01:37.62766|2018-05-31 23:01:37.62766
NCT01264952|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2014-12-19||2014-12-19|2010-12-21|2010-12-22|Estimate|2014-12-19|2015-01-01|Estimate||||2014-12-19|2015-01-01|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Interventional|ECTJ||Treatment of Liver Metastases With Electrochemotherapy|Treatment of Liver Metastases With Electrochemotherapy|Completed||Phase 1/Phase 2|16|Actual|Institute of Oncology Ljubljana|||||f||||t||||||||||2018-05-31 23:01:37.70138|2018-05-31 23:01:37.70138
NCT01264939|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2013-09-23||2013-09-23|2010-12-20|2010-12-22|Estimate|2013-09-23|2013-11-26|Estimate||||2013-09-23|2013-11-26|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Modified intent-to-treat (mITT) population: All randomized participants who received at least 1 dose of study drug. One participant (randomized to placebo) did not receive study drug and was not included in the mITT population.|A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists|Completed||Phase 3|336|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:01:39.344502|2018-05-31 23:01:39.344502
NCT01264926|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-03-21|2010-12-21|2010-12-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|February 2012||2012-02-29|March 2013|2013-03-31||||March 2015|Anticipated|2015-03-31||Observational|||Evaluation of the Difference in the Acromion Humerus Gap at Sitting,Lying||Unknown status|Active, not recruiting||||Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 23:01:40.693248|2018-05-31 23:01:40.693248
NCT01264913|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2016-09-29|2010-12-20|2010-12-22|Estimate|||||||2016-09-29|2016-10-03|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|SW||Cardiometabolic Risk of Shiftwork|Cardiometabolic Risk of ShiftWork: Sleep Loss vs.Circadian Disruption|Terminated|||64|Actual|University of Chicago|||2|impossible to retain participants in 3-year longitudinal study|f||||t||||||||||2018-05-31 23:01:40.761252|2018-05-31 23:01:40.761252
NCT01264900|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2016-03-03|2010-12-20|2010-12-22|Estimate|||||||2016-03-03|2016-03-04|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Cognitive Behavioral Aggression Treatment|Cognitive Behavioral Aggression Treatment: Effects on Brain and Behavior|Completed||Phase 2|120|Actual|Temple University||2|||f||||t||||||||||2018-05-31 23:01:40.843991|2018-05-31 23:01:40.843991
NCT01264887|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2015-04-30||2015-06-01|2010-12-21|2010-12-22|Estimate|2015-06-01|2015-06-22|Estimate||||2015-06-01|2015-06-22|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Tapentadol in Chronic Malignant Tumour Related Pain|Open-label, Single-arm, Flexible Dosing, Phase III Trial, With Oral Tapentadol Prolonged Release (PR) in Subjects With Chronic Malignant Tumor-related Pain Who Have Completed the Maintenance Period of the KF5503/15 Trial.|Terminated||Phase 3|31|Actual|Grünenthal GmbH|The trial was stopped for administrative reasons. Three years after trial initiation 2 participants were in the trial and to permit analysis and reporting the sponsor decided to terminate the trial.|1||Administrative reasons|f||||f||||||||||2018-05-31 23:01:40.948076|2018-05-31 23:01:40.948076
NCT01264874|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2018-01-30|2010-12-21|2010-12-22|Estimate|||||||2018-01-30|2018-01-31|Actual|May 2010||2010-05-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|MelaViD||MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients|Phase III, Randomized, Double Blind Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients|Terminated||Phase 3|150|Actual|European Institute of Oncology||2||poor accrual rate|f||||f||||||||||2018-05-31 23:01:41.564171|2018-05-31 23:01:41.564171
NCT01264861|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-09-15|2010-12-20|2010-12-22|Estimate|||||||2017-09-15|2017-09-18|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|January 24, 2012|Actual|2012-01-24|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging|"Open-Label Escalating Dose Study Using [123|]ß-CIT SPECT Single Photon Emission Computerized Tomography (SPECT) to Evaluate Dopamine and Serotonin Transporter Occupancy by Safinamide in Parkinson Disease Patients"|Terminated||Phase 2|5|Actual|Newron Pharmaceuticals SPA||1||"The Dopamine transporter brain imaging trial is terminated due to a company decision to return~   all rights for Safinamide back to Newron Pharmaceuticals"|f||||f||||||||||2018-05-31 23:01:41.686325|2018-05-31 23:01:41.686325
NCT01264848|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2015-02-09|2010-12-21|2010-12-22|Estimate|||||||2015-02-09|2015-02-10|Estimate|March 2010||2010-03-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|October 2010|Actual|2010-10-31||Interventional|||Endovascular Treatment for Chronic Cerebrospinal Venous Insufficiency (CCSVI)|Endovascular Correction of Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Evaluation of Influence of These Treatments on the Symptoms of Multiple Sclerosis|Completed||Phase 1/Phase 2|100|Actual|Euromedic Specialist Clinics, Poland||1|||f||||f||||||||||2018-05-31 23:01:41.768346|2018-05-31 23:01:41.768346
NCT01264835|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2011-11-28||2012-02-01|2010-12-20|2010-12-22|Estimate|2012-02-01|2012-03-02|Estimate||||2012-02-01|2012-03-02|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Assessment of a Slotted Anoscope That Facilitates Hemorrhoidectomy||Terminated||N/A|2|Actual|Ethicon Endo-Surgery|No analyses are being reported for the primary outcome measure as this trial was terminated early. The procedure was only performed with the slotted anoscope in 1 subject. No assessment or analysis of primary or secondary objectives was performed.|||Slow Enrollment|f||||f||||||||||2018-05-31 23:01:41.872643|2018-05-31 23:01:41.872643
NCT01264822|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-02-23|2010-12-21|2010-12-22|Estimate|||||||2017-02-23|2017-02-27|Actual|January 13, 2011|Actual|2011-01-13|January 2017|2017-01-31|November 17, 2016|Actual|2016-11-17|February 29, 2016|Actual|2016-02-29||Observational|||Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori|Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori|Completed|||108|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 23:01:42.008781|2018-05-31 23:01:42.008781
NCT01264809|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2010-12-21|2010-12-21|2010-12-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|March 2011||2011-03-31|December 2010|2010-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|APDT 2||Exercise Consultation for Type 2 Diabetes Patients in Real Life|Does Exercise Consultation Have a Realistic Chance of Increasing the Physical Activity Level of Type 2 Diabetes Patients in Real Life?|Unknown status|Not yet recruiting|N/A|80|Anticipated|University Hospital Center of Martinique||2|||f||||t||||||||||2018-05-31 23:01:42.1115|2018-05-31 23:01:42.1115
NCT01264796|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-03-06|2010-12-21|2010-12-22|Estimate|||||||2017-03-06|2017-03-08|Actual|November 2009||2009-11-30|March 2012|2012-03-31|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||Community-Based Diabetes Care for Korean American Immigrants|Community-Based Diabetes Care for Korean American Immigrants|Completed||N/A|250|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 23:01:42.221225|2018-05-31 23:01:42.221225
NCT01264783|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2011-09-30|2010-12-21|2010-12-22|Estimate|||||||2011-09-30|2011-10-04|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Tolerability of RNS60 Given by IV to Healthy Subjects|Phase I, Double-blind, Randomized, Placebo-controlled, Single-center Study to Assess the Safety and Tolerability of RNS60 Administered Intravenously to Healthy Subjects|Completed||Phase 1|12|Actual|Revalesio Corporation||2|||f||||f||||||||||2018-05-31 23:01:42.294172|2018-05-31 23:01:42.294172
NCT01264770|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2013-11-22||2014-04-03|2010-12-21|2010-12-22|Estimate|2014-04-03|2014-05-06|Estimate||||2014-04-03|2014-05-06|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|OSKIRA -4||Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)|(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis|Terminated||Phase 2|644|Actual|AstraZeneca||5||"AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to~   Rigel Pharmaceuticals."|f||||t||||||||||2018-05-31 23:01:42.557996|2018-05-31 23:01:42.557996
NCT01264757|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2016-02-04|2010-12-20|2010-12-22|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|STEPS||Steps Toward Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population|Steps Toward Adapting Physical Activity Guidelines for the Lower Mississippi Delta Population|Completed||Early Phase 1|43|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 23:01:43.931679|2018-05-31 23:01:43.931679
NCT01264744|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-22|2010-12-21|2010-12-22|Estimate|||||||2010-12-22|2010-12-23|Estimate|November 2009||2009-11-30|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Detection of Chromosomal Aberrations in Urine Samples Using Fluorescent in Situ Hybridization (FISH) (UroVysion Test)|Concordance Study for Detection of Chromosomal Aberrations Using FISH in Urine Samples Sections|Completed|||174|Actual|Applied Spectral Imaging Ltd.|||||f||||f||||||Samples Without DNA|"~     Urine samples~   "|||2018-05-31 23:01:43.985951|2018-05-31 23:01:43.985951
NCT01264731|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2016-12-15|2010-12-20|2010-12-22|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MEL53||Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma|Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma|Completed||Phase 1|4|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 23:01:44.118275|2018-05-31 23:01:44.118275
NCT01264718|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2015-05-27|2010-12-21|2010-12-22|Estimate|||||||2015-05-27|2015-05-28|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Randomized Trial of Effects of Parent Mentors on Insuring Minority Children|A Randomized Trial of Effects of Parent Mentors on Insuring Minority Children|Unknown status|Active, not recruiting|N/A|300|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 23:01:44.190172|2018-05-31 23:01:44.190172
NCT01264705|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-05-31|2010-12-21|2010-12-22|Estimate|||||||2016-05-31|2016-06-01|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer|A Phase I/II Study of Bavituximab and Sorafenib In Patients With Advanced Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|56|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 23:01:44.2564|2018-05-31 23:01:44.2564
NCT01264692|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-06-12|2010-12-21|2010-12-22|Estimate|||||||2012-06-12|2012-06-13|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|REDUCE-1||Essential Hypertension|A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 2|196|Actual|Actelion||3|||f||||f||||||||||2018-05-31 23:01:44.317722|2018-05-31 23:01:44.317722
NCT01264679|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2017-08-10||2017-10-03|2010-12-21|2010-12-22|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|December 27, 2011|Actual|2011-12-27|October 2017|2017-10-31|April 24, 2015|Actual|2015-04-24|April 24, 2015|Actual|2015-04-24||Interventional||The Safety Population included all randomized participants who had received at least 1 dose of study drug.|A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease|An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease|Terminated||Phase 3|8|Actual|AMAG Pharmaceuticals, Inc.|While sample data were collected, it was not run through any analysis to obtain the necessary outcome measure data. As such, summary of the data set is not possible.|1||"Several factors contributed to significant challenges in enrollment and led the Sponsor to~   discontinue the AMAG-FER-CKD-253 study as designed."|f||||t|t|f||||||||2018-05-31 23:01:44.410596|2018-05-31 23:01:44.410596
NCT01264666|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-21|2010-12-21|2010-12-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|TFL||Postprandial Effect of Chinese Tea Flavor Liquor on Selected CVD Risk Factors|Phase I Study of Chinese Tea Flavor Liquor on Human Health|Completed||Phase 1|16|Actual|Zhejiang University||3|||f||||t||||||||||2018-05-31 23:01:44.621989|2018-05-31 23:01:44.621989
NCT01264653|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-07-04|2010-12-21|2010-12-22|Estimate|||||||2012-07-04|2012-07-06|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery|Study of Intracameral Adrenaline for Pupil Dilation Without Topical Mydriatics in Refractive Cataract Surgery|Completed||N/A|60|Actual|Wenzhou Medical University||1|||f||||t||||||||||2018-05-31 23:01:44.68429|2018-05-31 23:01:44.68429
NCT01264640|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2010-12-21|2010-12-21|2010-12-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|March 2011|Anticipated|2011-03-31|February 2011|Anticipated|2011-02-28||Interventional|||Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma|The Impact of Aspirin and Clopidogrel on Brain-derived Neurotrophic Factor (BDNF) Concentrations in Human Serum and Plasma|Unknown status|Active, not recruiting|N/A|25|Anticipated|University of Rostock||1|||f||||f||||||||||2018-05-31 23:01:44.747927|2018-05-31 23:01:44.747927
NCT01264627|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2018-05-03|2010-12-21|2010-12-22|Estimate|||||||2018-05-03|2018-05-09|Actual|February 1, 2011|Actual|2011-02-01|May 2018|2018-05-31|August 31, 2017|Actual|2017-08-31|July 31, 2017|Actual|2017-07-31||Interventional|||A New Translational Tool for Studying the Role of Breathing in Meditation|Project Inspire: A New Translational Tool for Studying the Role of Breathing in Meditation|Completed||N/A|99|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:01:44.816419|2018-05-31 23:01:44.816419
NCT01264614|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2014-12-02||2015-03-09|2010-12-21|2010-12-22|Estimate|2015-03-09|2015-03-11|Estimate||||2015-03-09|2015-03-11|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||13 early dementia participants and 9 normative older adult participants.|Effects of Strengthening Exercise on the Brain for Early Dementia and Normative Older Adults|Neuropsychological and Neuroimaging Effects of Strengthening Exercise for Early Dementia and Normative Older Adults|Completed||N/A|22|Actual|Union College, New York||2|||f||||f||||||||||2018-05-31 23:01:44.887278|2018-05-31 23:01:44.887278
NCT01264601|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|2017-07-31||2017-09-25|2010-12-21|2010-12-22|Estimate|2017-09-25|2017-10-26|Actual||||2017-09-25|2017-10-26|Actual|October 2010||2010-10-31|September 2017|2017-09-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|SAFE||Safe Administration of Flu Vaccine to Egg Allergic Children|Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg|Completed||N/A|31|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 23:01:45.186816|2018-05-31 23:01:45.186816
NCT01264588|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2010-12-20|2010-12-20|2010-12-22|Estimate|||||||2010-12-20|2010-12-22|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|TOPCGP-2008||The Effects of Topical Calcium Glycerophosphate on Surgical Wound Healing and Residual Scarring|A Randomized, Single Blind, Comparative, Controlled Study On The Effects Of Topical Calcium Glycerophosphate On Surgical Wound Healing And Residual Scarring In Bilateral Total Knee Arthroplasty Patients|Completed||N/A|20|Actual|AkPharma Inc.||2|||f||||t||||||||||2018-05-31 23:01:45.621162|2018-05-31 23:01:45.621162
NCT01264575|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-01-29|2010-12-21|2010-12-22|Estimate|||||||2012-01-29|2012-01-31|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty|ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty|Completed||N/A|162|Actual|Seoul Medical Center||12|||f||||f||||||||||2018-05-31 23:01:45.687288|2018-05-31 23:01:45.687288
NCT01264562|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2016-05-01|2010-12-21|2010-12-22|Estimate|||||||2016-05-01|2016-05-03|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|Cognicares||Cognition in Breast Cancer Patients: The Impact of Cancer-related Stress|Cognition in Breast Cancer Patients: The Impact of Cancer-related Stress|Completed|||254|Actual|Ludwig-Maximilians - University of Munich|||3||f||||f||||||Samples Without DNA|"~     Saliva~   "|||2018-05-31 23:01:45.779648|2018-05-31 23:01:45.779648
NCT01264549|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-21|||2018-02-01|2010-12-21|2010-12-22|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2010||2010-12-31|February 2018|2018-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|STRAWINSKI||Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)|Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients|Completed||N/A|230|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:01:45.847133|2018-05-31 23:01:45.847133
NCT01264536|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-09-07|2010-12-20|2010-12-21|Estimate|||||||2012-09-07|2012-09-10|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|NEOLACTO||Pilot Study: Lactoferrin for Prevention of Neonatal Sepsis|Pilot Study: Lactoferrin for Prevention of Neonatal Sepsis|Completed||Phase 2|190|Actual|Universidad Peruana Cayetano Heredia||2|||f||||t||||||||||2018-05-31 23:01:45.921035|2018-05-31 23:01:45.921035
NCT01264523|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-09-07|2010-12-20|2010-12-21|Estimate|||||||2012-09-07|2012-09-10|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients|Short-term Effect of the Intake of Moderately High-protein, Low-glycemic Load Products on Anthropometrical, Glucose Metabolism and Lipid Metabolism Biomarkers, in Type-2 Diabetes Patients|Completed||N/A|17|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||||f||||||||||||||2018-05-31 23:01:46.035691|2018-05-31 23:01:46.035691
NCT01264510|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-12-04|2010-12-20|2010-12-21|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|Baha||Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha)|The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 23:01:46.10314|2018-05-31 23:01:46.10314
NCT01264497|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2010-12-20|2010-12-20|2010-12-21|Estimate|||||||2010-12-20|2010-12-21|Estimate|February 2002||2002-02-28|December 2010|2010-12-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes|A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus|Completed||Phase 2|55|Actual|Theratechnologies|||||f||||f||||||||||2018-05-31 23:01:46.219304|2018-05-31 23:01:46.219304
NCT01264484|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-03-29|2010-12-20|2010-12-21|Estimate|||||||2017-03-29|2017-03-30|Actual|December 2010||2010-12-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||ADVANTAGE® Prosthetic Heart Valve Long-term Follow-up Trial|ADVANTAGE Prosthetic Heart Valve Long Term Follow Up|Terminated|||212|Actual|Medtronic Cardiovascular|||1|The primary objective was considered sufficient for follow-up.|f||||f||||||||||2018-05-31 23:01:46.274179|2018-05-31 23:01:46.274179
NCT01264471|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2015-04-10|2010-12-20|2010-12-21|Estimate|||||||2015-04-10|2015-04-13|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Mechanisms of Mitochondrial Defects in Gulf War Syndrome|Mechanisms of Mitochondrial Defects in Gulf War Syndrome|Completed|||26|Actual|Medical Neurogenetics, LLC|||1||f||||t||||||Samples With DNA|"~     whole blood and tissue~   "|||2018-05-31 23:01:46.347705|2018-05-31 23:01:46.347705
NCT01264458|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-10-12|2010-12-20|2010-12-21|Estimate|||||||2017-10-12|2017-10-16|Actual|January 2011||2011-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2017|Actual|2017-01-31||Observational|||Microvesicle Production After Acute Trauma and Its Clinical Impact on Venothromboembolism|Microvesicle Production After Acute Trauma and Its Clinical Impact on Venothromboembolism|Active, not recruiting|||2720|Anticipated|Mayo Clinic|||2||f||||f||||||||||2018-05-31 23:01:46.421314|2018-05-31 23:01:46.421314
NCT01264445|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2013-02-08|2010-12-20|2010-12-21|Estimate|||||||2013-02-08|2013-02-11|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines|A Phase I Double-blinded, Placebo-controlled, Randomized Trial in HIV-uninfected, Healthy Adult Volunteers to Evaluate the Safety and Immunogenicity of an Adjuvanted GSK HIV Vaccine Administered With Ad35-GRIN Investigational Vaccine|Completed||Phase 1|147|Actual|International AIDS Vaccine Initiative||4|||f||||t||||||||||2018-05-31 23:01:46.475807|2018-05-31 23:01:46.475807
NCT01264432|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-11-20|2010-12-20|2010-12-21|Estimate|||||||2017-11-20|2017-11-21|Actual|January 1, 2011|Actual|2011-01-01|November 2017|2017-11-30|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer|A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-Abdominal Disease|Completed||Phase 1|34|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:01:46.572374|2018-05-31 23:01:46.572374
NCT01264419|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-06-12|2010-12-20|2010-12-21|Estimate|||||||2017-06-12|2017-06-14|Actual|March 2009||2009-03-31|June 2017|2017-06-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Silk Road Medical First in Man Study - Neuroprotection During Carotid Stenting and Angioplasty||Completed||Phase 3|75|Actual|Silk Road Medical||1|||f||||f||||||||||2018-05-31 23:01:46.672238|2018-05-31 23:01:46.672238
NCT01264406|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2016-02-03|2010-12-20|2010-12-21|Estimate|||||||2016-02-03|2016-02-04|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Observational|E-MECHANIC||The Comparison of Energy in Take and Body Weight EXERCISE|Examination of Mechanisms (E-MECHANIC) of Exercise-induced Weight Compensation|Completed|||198|Actual|Pennington Biomedical Research Center|||3||f||||f||||||||||2018-05-31 23:01:46.73575|2018-05-31 23:01:46.73575
NCT01264393|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2013-04-23|2010-12-20|2010-12-21|Estimate|||||||2013-04-23|2013-04-24|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SHARE||State-wide Health Approach to Increase Reach and Effectiveness: Study 1|Using a State-Wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies|Completed||Phase 3|500|Actual|The Miriam Hospital||3|||f||||t||||||||||2018-05-31 23:01:46.800038|2018-05-31 23:01:46.800038
NCT01264380|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|2015-07-29||2016-11-01|2010-12-20|2010-12-21|Estimate|2015-11-16|2015-12-17|Estimate||||2016-11-01|2016-11-02|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All participants who received at least 1 dose of vemurafenib.|A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma|A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients|Completed||Phase 1|16|Actual|Hoffmann-La Roche|Results for OS was not reported due to change in planned analysis.|3|||f||||||||||||||2018-05-31 23:01:46.894512|2018-05-31 23:01:46.894512
NCT01264367|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2014-12-17|2010-12-19|2010-12-21|Estimate|||||||2014-12-17|2014-12-18|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)|A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)|Completed||Phase 4|60|Anticipated|Bukwang Pharmaceutical||2|||f||||f||||||||||2018-05-31 23:01:47.494836|2018-05-31 23:01:47.494836
NCT01264354|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2014-12-16|2010-12-19|2010-12-21|Estimate|||||||2014-12-16|2014-12-18|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Interventional|||An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B|An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B|Completed||Phase 4|60|Anticipated|Bukwang Pharmaceutical||3|||f||||f||||||||||2018-05-31 23:01:47.562849|2018-05-31 23:01:47.562849
NCT01264341|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-02-13|2010-12-20|2010-12-21|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2010||2010-12-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma|Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer|Terminated||Phase 2|39|Actual|Hellenic Cooperative Oncology Group||1||"Based on the developments in the treatment of recurrent metastatic renal cancer, the study~   treatment is no longer considered to be the best treatment option"|f||||f||||||||||2018-05-31 23:01:47.633199|2018-05-31 23:01:47.633199
NCT01264328|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-20|2010-12-20|2010-12-21|Estimate|||||||2010-12-20|2010-12-21|Estimate|December 2010||2010-12-31|April 2010|2010-04-30|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|VECTITAX||Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer|"Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer"|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Grupo Español de Tratamiento de Tumores de Cabeza y Cuello||1|||f||||f||||||||||2018-05-31 23:01:47.704146|2018-05-31 23:01:47.704146
NCT01264315|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2017-09-05|2010-12-20|2010-12-21|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2008||2008-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant|Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant|Recruiting||Phase 2|53|Anticipated|Fondazione Neoplasie Sangue Onlus||1|||f||||t||||||||||2018-05-31 23:01:47.772388|2018-05-31 23:01:47.772388
NCT01264302|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2010-12-20|2010-12-20|2010-12-21|Estimate|||||||2010-12-20|2010-12-21|Estimate|November 2006||2006-11-30|December 2006|2006-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions|A Randomized, Single-dose, Two-treatment, Two-way, Crossover Bioequivalence Study of Finasteride 5 mg Tablets (Dr. Reddy's Laboratories Limited) With the Reference Formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.) Under Fed Conditions in Healthy Adult Male Subjects.|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:01:47.836956|2018-05-31 23:01:47.836956
NCT01264289|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2010-12-20|2010-12-20|2010-12-21|Estimate|||||||2010-12-20|2010-12-21|Estimate|November 2006||2006-11-30|December 2006|2006-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions|A Randomized, Single-dose, Two-treatment, Two-way, Crossover Bioequivalence Study of Finasteride 5 mg Tablets (Dr. Reddy's Laboratories Limited) With the Reference Formulation PROSCAR® 5 mg Tablet (Merck & Co., Inc.) Under Fasting Conditions in Healthy Adult Male Subjects.|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:01:47.893566|2018-05-31 23:01:47.893566
NCT01264276|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2015-02-03|2010-12-20|2010-12-21|Estimate|||||||2015-02-03|2015-02-04|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Observational|e-ROP||Telemedicine Approaches to Evaluating Acute-phase ROP|Telemedicine Approaches to Evaluating Acute-phase ROP|Completed|||269|Actual|Children's Hospital of Philadelphia|||||f||||t||||||||||2018-05-31 23:01:47.957791|2018-05-31 23:01:47.957791
NCT01264263|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2012-03-12|2010-12-20|2010-12-21|Estimate|||||||2012-03-12|2012-03-13|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|ALTO||Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes|Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes|Completed|||181|Actual|AstraZeneca|||1||f||||f||||||Samples Without DNA|"~     Whole blood and serum, urine~   "|||2018-05-31 23:01:48.042507|2018-05-31 23:01:48.042507
NCT01264250|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-05-23|2010-12-20|2010-12-21|Estimate|||||||2011-05-23|2011-05-24|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers|A Phase I, Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Subjects|Completed||Phase 1|48|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:01:48.109342|2018-05-31 23:01:48.109342
NCT01264237|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2011-03-22|2010-12-20|2010-12-21|Estimate|||||||2011-03-22|2011-03-23|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|April 2012|Anticipated|2012-04-30|August 2011|Anticipated|2011-08-31||Interventional|||Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain|An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain|Unknown status|Recruiting|Phase 4|120|Anticipated|Analgesic Solutions||2|||f||||t||||||||||2018-05-31 23:01:48.167222|2018-05-31 23:01:48.167222
NCT01264224|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2014-01-19|2010-12-20|2010-12-21|Estimate|||||||2014-01-19|2014-01-22|Estimate|December 2010||2010-12-31|January 2014|2014-01-31||||June 2012|Actual|2012-06-30||Interventional|||PAC-14028 in Healthy Male Volunteers|A Dose-block Randomized, Double-blind, Placebo-controlled Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of PAC-14028 After Oral Administration in Healthy Male Volunteers.|Completed||Phase 1|60|Actual|Amorepacific Corporation||1|||f||||f||||||||||2018-05-31 23:01:48.270604|2018-05-31 23:01:48.270604
NCT01264211|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2015-11-03|2010-12-20|2010-12-21|Estimate|||||||2015-11-03|2015-11-05|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|June 2012|Actual|2012-06-30||Interventional|||Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)|A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study|Completed||Phase 2|40|Actual|TRB Chemedica||2|||f||||t||||||||||2018-05-31 23:01:48.334341|2018-05-31 23:01:48.334341
NCT01264185|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2014-08-18|2010-12-20|2010-12-21|Estimate|||||||2014-08-18|2014-08-19|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|HPTN063||Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings|Preparing for International Prevention Trials Involving HIV-Infected Individuals in Care Settings|Completed|||751|Actual|HIV Prevention Trials Network|||2||f||||f||||||Samples With DNA|"~     Blood, genital fluids~   "|||2018-05-31 23:01:48.529186|2018-05-31 23:01:48.529186
NCT01264172|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2012-11-26|2010-12-20|2010-12-21|Estimate|||||||2012-11-26|2012-11-27|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|MicroProxFem||Identification of Microcirculation and Inflammation After Minimal-invasive Osteosynthesis of the Proximal Femur|Identification of the Cutaneous and Muscular Microcirculation and Inflammatory Response After Minimal-invasive Osteosynthesis of the Proximal Femur|Completed||N/A|50|Actual|RWTH Aachen University||3|||f||||f||||||||||2018-05-31 23:01:48.594077|2018-05-31 23:01:48.594077
NCT01264159|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-05-31|2010-12-20|2010-12-21|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|||Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients||Terminated||N/A|70|Actual|Hillel Yaffe Medical Center||2||The principle investigator decided to change the protocol|f||||||||||||||2018-05-31 23:01:48.691909|2018-05-31 23:01:48.691909
NCT01264146|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2012-11-26|2010-12-19|2010-12-21|Estimate|||||||2012-11-26|2012-11-27|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|HOCIF||Hyperbaric Oxygen Therapy in Calcaneal Intraarticular Fractures: Can it Decrease the Soft-tissue Complication Rate?|Hyperbaric Oxygen Therapy in Calcaneal Intraarticular Fractures: Can it Decrease the Soft-tissue Complication Rate?|Completed||N/A|20|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 23:01:48.763127|2018-05-31 23:01:48.763127
NCT01264133|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2014-12-16|2010-12-20|2010-12-21|Estimate|||||||2014-12-16|2014-12-18|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|June 2013|Actual|2013-06-30||Interventional|||A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B|An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B|Terminated||Phase 4|200|Anticipated|Bukwang Pharmaceutical|||||f||||f||||||||||2018-05-31 23:01:48.959387|2018-05-31 23:01:48.959387
NCT01264120|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2014-01-23|2010-12-20|2010-12-21|Estimate|||||||2014-01-23|2014-01-24|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Interventional|||The Impact of a Bariatric Rehabilitation Service on Patient Outcomes|The Impact of a Bariatric Rehabilitation Service on Weight Loss and Psychological Adjustment.|Unknown status|Enrolling by invitation|N/A|290|Anticipated|University of Surrey||2|||f||||f||||||||||2018-05-31 23:01:49.077117|2018-05-31 23:01:49.077117
NCT01264107|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2012-07-24|2010-12-20|2010-12-21|Estimate|||||||2012-07-24|2012-07-26|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Observational|||An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine|An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine|Completed|||37|Actual|Bukwang Pharmaceutical|||||f||||f||||||||||2018-05-31 23:01:49.164197|2018-05-31 23:01:49.164197
NCT01264094|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-19|||2015-07-20|2010-12-20|2010-12-21|Estimate|||||||2015-07-20|2015-07-22|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period|A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period|Terminated||Phase 4|200|Anticipated|Bukwang Pharmaceutical||||Enrollment|f||||f||||||||||2018-05-31 23:01:49.226499|2018-05-31 23:01:49.226499
NCT01264081|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-18|2015-03-10||2017-07-10|2010-12-18|2010-12-21|Estimate|2015-03-10|2015-03-19|Estimate||||2017-07-10|2017-08-09|Actual|May 20, 2011|Actual|2011-05-20|July 2017|2017-07-31|November 22, 2013|Actual|2013-11-22|November 22, 2013|Actual|2013-11-22||Interventional|||Lapatinib in Stage IV Melanoma With ERBB4 Mutations|A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations|Terminated||Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)||1||Protocol would not be able to reach stated accrual.|f||||f|t|f||||||No||2018-05-31 23:01:49.301957|2018-05-31 23:01:49.301957
NCT01264068|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2010-12-20|2010-12-20|2010-12-21|Estimate|||||||2010-12-20|2010-12-21|Estimate|August 2008||2008-08-31|March 2008|2008-03-31|December 2009|Anticipated|2009-12-31|April 2009|Anticipated|2009-04-30||Interventional|||The Influence of Chinese Medicine on Metabolomics in Menopausal or Postpartum Women||Unknown status|Recruiting|Phase 3|60|Anticipated|Taipei City Hospital||3|||f||||||||||||||2018-05-31 23:01:49.515084|2018-05-31 23:01:49.515084
NCT01264055|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-18|||2018-05-22|2010-12-18|2010-12-21|Estimate|||||||2018-05-22|2018-05-23|Actual|December 18, 2010||2010-12-18|May 16, 2018|2018-05-16||||||||Observational|||Cross-sectional Characterization of Idiopathic Bronchiectasis|Cross-Sectional Characterization of Idiopathic Bronchiectasis|Completed|||275|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:01:49.593739|2018-05-31 23:01:49.593739
NCT01264042|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2013-10-11|2010-12-20|2010-12-21|Estimate|||||||2013-10-11|2013-10-14|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|NTBI_pw||Iron Supplementation During Pregnancy and Non-Transferrin-Bound Iron (NTBI)|Iron Supplementation During Pregnancy and Non-Transferrin-Bound Iron (NTBI)|Completed||N/A|30|Actual|Swiss Federal Institute of Technology||1|||f||||t||||||||||2018-05-31 23:01:49.675949|2018-05-31 23:01:49.675949
NCT01264029|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-18|||2018-05-17|2010-12-18|2010-12-21|Estimate|||||||2018-05-17|2018-05-18|Actual|December 9, 2010||2010-12-09|November 5, 2012|2012-11-05|November 5, 2012|Actual|2012-11-05|November 5, 2012|Actual|2012-11-05||Interventional|||Efficacy of Mindful Tai Chi on Obese or Overweight Adults: A Randomized Controlled Clinical Trial|Efficacy of Mindful Tai Chi Intervention on Obese and Overweight Adults: A Randomized Controlled Clinical Trial|Terminated||Phase 2|25|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 23:01:49.742058|2018-05-31 23:01:49.742058
NCT01264016|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-18|2012-04-04||2016-01-29|2010-12-18|2010-12-21|Estimate|2012-04-04|2012-05-01|Estimate||||2016-01-29|2016-02-29|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Performance of a New Glucose Meter System|Performance of the TATSU/Tradewind Blood Glucose Monitoring System|Completed||N/A|96|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 23:01:49.83566|2018-05-31 23:01:49.83566
NCT01264003|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2010-12-20|2010-12-20|2010-12-21|Estimate|||||||2010-12-20|2010-12-21|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Antibiotic Prophylaxis in Mesh Repair of Inguinal Hernias|Single Dose Antibiotic Prophylaxis in Lihtenstein Repair for Primary Inguinal Hernias|Completed||Phase 4|200|Actual|Diskapi Teaching and Research Hospital||1|||f||||f||||||||||2018-05-31 23:01:50.003552|2018-05-31 23:01:50.003552
NCT01263990|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2013-08-08|2010-12-20|2010-12-21|Estimate|||||||2013-08-08|2013-08-12|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|May 2012|Actual|2012-05-31||Interventional|VaSNex||Validation of Stroke Volume Measurement by a New Noninvasive Hemodynamic Monitoring System (NexFin)in Comparison to Different Invasive Procedures as Picco2, FloTrac and TEE|Prospective, Monocentric Pilot Study for the Validation of Stroke Volume by Use of NexFin in Comparison to Different Hemodynamic Monitoring Procedures (Picco2, FloTrac and TEE)|Completed||N/A|20|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 23:01:50.057774|2018-05-31 23:01:50.057774
NCT01263977|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2014-06-05|2010-12-20|2010-12-21|Estimate|||||||2014-06-05|2014-06-06|Estimate|December 2010||2010-12-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|THEMIS||Thermodilution - Controlled Management of Volume Therapy in Septic Shock|A Randomized Mono-center Study Looking at the Effect of Thermodilution Controlled Therapy for Volume Optimization on the Duration of Septic Shock in Patients With Septic Shock|Completed||N/A|60|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:01:50.120267|2018-05-31 23:01:50.120267
NCT01263964|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2014-07-18|2010-12-20|2010-12-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|TRELAS||Troponin Elevation in Acute Ischemic Stroke (TRELAS)|Troponin Elevation in Acute Ischemic Stroke (TRELAS) - a Prospective Study on the Frequency and Correlation to Coronary Artery Disease and to Stroke Localisation|Completed|||58|Actual|Charite University, Berlin, Germany|||2||f||||f||||||Samples Without DNA|"~     Biomarkers indicating myocardial or neuronal damage~   "|||2018-05-31 23:01:50.182463|2018-05-31 23:01:50.182463
NCT01263951|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2015-12-14|2010-12-17|2010-12-21|Estimate|||||||2015-12-14|2015-12-15|Estimate|November 2010||2010-11-30|December 2015|2015-12-31||||November 2014|Actual|2014-11-30||Interventional|||Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone|A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 23:01:50.246836|2018-05-31 23:01:50.246836
NCT01263938|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-12-08|2010-12-20|2010-12-21|Estimate|||||||2017-12-08|2017-12-12|Actual|September 2011||2011-09-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Modulation of Monocyte Activation by Atorvastatin in HIV Infection|Pilot Study to Evaluate Effects of Atorvastatin on Monocyte Activation in HAART-treated HIV Infected Individuals|Completed||Phase 4|5|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 23:01:50.316098|2018-05-31 23:01:50.316098
NCT01263925|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2012-04-17||2014-10-17|2010-12-17|2010-12-21|Estimate|2012-05-25|2012-06-29|Estimate||||2014-10-17|2014-10-27|Estimate|April 2001||2001-04-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Prostaglandin E1 in Outpatients With Intermittent Claudication|Intravenous Prostaglandin E1 Treatment in Outpatients With Intermittent Claudication|Completed||Phase 3|561|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 23:01:50.407091|2018-05-31 23:01:50.407091
NCT01263912|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-11-29|2010-12-20|2010-12-21|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2010||2010-12-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|August 2015|Actual|2015-08-31||Interventional|||Essential Fatty Acid Nutrition For 1-2 Yr-Olds|Essential Fatty Acid Nutrition in Infants 1 to 2 Years-of-Age|Completed||N/A|133|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 23:01:51.041378|2018-05-31 23:01:51.041378
NCT01263899|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2012-04-19|2010-12-17|2010-12-21|Estimate|||||||2012-04-19|2012-04-20|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies|A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies|Completed||Phase 2|28|Actual|S*BIO||1|||f||||f||||||||||2018-05-31 23:01:51.105045|2018-05-31 23:01:51.105045
NCT01263886|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14||2015-11-18|2015-11-18|2010-12-17|2010-12-21|Estimate||||2015-11-18|2015-12-21|Estimate|2015-11-18|2015-12-21|Estimate|February 2011||2011-02-28|November 2015|2015-11-30|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|DISRUPT||Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer|A Multinational, Randomized, Double Blind, Controlled Phase II Trial of Ombrabulin With Taxane and Platinum Combination Administered Every Three Weeks, in First Line Treatment of Patients Metastatic Non-small Cell Lung Cancer|Completed||Phase 2|176|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:01:52.079218|2018-05-31 23:01:52.079218
NCT01263873|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2011-05-26||2014-12-02|2010-12-20|2010-12-21|Estimate|2011-11-14|2011-12-19|Estimate||||2014-12-02|2014-12-17|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ETT||Examining the Ease of Intubation Using the Parker Flex-Tip® or a Standard Endotracheal Tube|Examining the Ease of Intubation Using the Parker Flex-Tip® or a Standard Mallinckrodt® Endotracheal When Using the Glidescope®|Completed||N/A|60|Actual|University Hospitals Cleveland Medical Center|Limitations of this study included an un-blinded use of ETTs|2|||f||||t||||||||||2018-05-31 23:01:52.194946|2018-05-31 23:01:52.194946
NCT01263860|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2014-11-14|2010-12-20|2010-12-21|Estimate|||||||2014-11-14|2014-11-18|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients|A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus|Completed||Phase 3|242|Actual|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 23:01:52.386274|2018-05-31 23:01:52.386274
NCT01263847|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2018-05-03|2010-12-17|2010-12-21|Estimate|||||||2018-05-03|2018-05-09|Actual|June 2009|Actual|2009-06-30|May 2018|2018-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|Friesland||Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls|The Effect of Galactooligosaccharide (GOS) Supplementation on Calcium Absorption and Retention in Female Adolescent Girls|Completed||Early Phase 1|31|Actual|Purdue University||3|||f||||f||||||||||2018-05-31 23:01:52.456054|2018-05-31 23:01:52.456054
NCT01263834|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2014-01-30|2010-12-20|2010-12-21|Estimate|||||||2014-01-30|2014-01-31|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Bevacizumab||Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome|The Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|39|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 23:01:52.607805|2018-05-31 23:01:52.607805
NCT01263821|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-08-03|2010-12-17|2010-12-21|Estimate|||||||2017-08-03|2017-08-04|Actual|August 2009||2009-08-31|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Image Guided Therapy in the Treatment of Gliomas|Image Guided Adaptive Multi-modality Therapy in the Treatment of Gliomas|Terminated||N/A|15|Actual|New York University School of Medicine||1||Lack of enrollment|f||||t|f|f||||||||2018-05-31 23:01:52.688402|2018-05-31 23:01:52.688402
NCT01263808|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2010-12-20|2010-12-20|2010-12-21|Estimate|||||||2010-12-20|2010-12-21|Estimate|April 2008||2008-04-30|December 2010|2010-12-31||||August 2008|Actual|2008-08-31||Interventional|||Cardiac Safety of Indacaterol|A Randomized, Multiple-dose, Placebo- and Positive-controlled Parallel Group Study to Evaluate the Effects of Indacaterol on Cardiac Safety in Healthy Subjects|Completed||Phase 1|404|Actual|Novartis||5|||f||||||||||||||2018-05-31 23:01:52.782181|2018-05-31 23:01:52.782181
NCT01263782|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-09-14|2010-12-20|2010-12-21|Estimate|||||||2017-09-14|2017-09-15|Actual|May 17, 2011|Actual|2011-05-17|September 2017|2017-09-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer|BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting|Completed||Phase 2|64|Actual|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 23:01:52.861732|2018-05-31 23:01:52.861732
NCT01263769|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2018-01-09|2010-12-20|2010-12-21|Estimate|||||||2018-01-09|2018-01-11|Actual|February 2011|Actual|2011-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)|A Phase II Clinical Trial Examining the Impact Of Neoadjuvant Axitinib On Primary Tumor Response In Patients With Locally Advanced Clear Cell Renal Cell Carcinoma|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:01:52.95377|2018-05-31 23:01:52.95377
NCT01263756|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-12-06|2010-12-20|2010-12-21|Estimate|||||||2011-12-06|2011-12-08|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Autism Spectrum Disorders (ASD) Driving Study|A Study of the Driving Performance of Individuals With Autism Spectrum Disorders|Completed|||10|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 23:01:53.038631|2018-05-31 23:01:53.038631
NCT01263743|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2016-04-18|2010-12-20|2010-12-21|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Relaxation Response Training to Treat Hypertension|Relaxation Response Training to Treat Hypertension: Effects on Blood Pressure, Biomarkers, and Endothelial Function|Completed||N/A|58|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 23:01:53.09715|2018-05-31 23:01:53.09715
NCT01263730|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-04-18|2010-12-17|2010-12-21|Estimate|||||||2012-04-18|2012-04-19|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Tai Chi Training for Treating Depressed Chinese Americans|Tai Chi Training for Treating Depressed Chinese Americans|Completed||N/A|38|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:01:53.163155|2018-05-31 23:01:53.163155
NCT01263717|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2014-09-08||2017-09-28|2010-12-20|2010-12-21|Estimate|2014-10-10|2014-10-13|Estimate||||2017-09-28|2017-10-30|Actual|December 2010||2010-12-31|September 2017|2017-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Growth Hormone Releasing Hormone in HIV|Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV Lipodystrophy|Completed||N/A|54|Actual|Massachusetts General Hospital|Please note that we intended to collect and analyze data on PAI1 and tPA but we did not have sufficient funds to do this.|2|||f||||t||||||||||2018-05-31 23:01:53.254775|2018-05-31 23:01:53.254775
NCT01263704|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2018-03-19||2018-04-18|2010-12-17|2010-12-21|Estimate|2018-04-18|2018-04-23|Actual||||2018-04-18|2018-04-23|Actual|July 17, 2011|Actual|2011-07-17|April 2018|2018-04-30|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional||Intent-to-Treat (ITT) population included all enrolled participants.|A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia|A Phase II, Multicenter, Single Arm Study to Determine the Efficacy and Safety of Low Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab as Primary Therapy in Elderly Untreated Patients (>/=65 Years Old) With Chronic Lymphocytic Leukemia|Completed||Phase 2|42|Actual|Hoffmann-La Roche||1|||f|||||t|f|||t|||||2018-05-31 23:01:53.588833|2018-05-31 23:01:53.588833
NCT01263691|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2014-01-17||2014-08-01|2010-12-20|2010-12-21|Estimate|2014-08-01|2014-08-20|Estimate||||2014-08-01|2014-08-20|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults|A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults|Completed||Phase 1|105|Actual|Emergent BioSolutions||6|||f||||t||||||||||2018-05-31 23:01:54.171627|2018-05-31 23:01:54.171627
NCT01263678|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2013-08-01|2010-12-20|2010-12-21|Estimate|||||||2013-08-01|2013-08-05|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SST HCoach RCT||Helping Patients With Spinal Stenosis Make a Treatment Decision: A Randomized Study Assessing The Benefits of Health Coaching||Completed||N/A|199|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 23:01:56.927651|2018-05-31 23:01:56.927651
NCT01263665|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2014-01-13||2015-11-18|2010-12-20|2010-12-21|Estimate|2014-01-13|2014-02-24|Estimate||||2015-11-18|2015-12-17|Estimate|December 2010||2010-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|August 2012|Actual|2012-08-31||Interventional||Patients with de novo and/or restenotic lesions (post PTA) of the SFA, with a total lesion length of ≥ 20 cm based on visual estimate|Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis|Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface to Treat de Novo and/or Restenotic Lesions of the Superficial Femoral Artery (SFA)|Completed||N/A|71|Actual|W.L.Gore & Associates||1|||f||||f||||||||||2018-05-31 23:01:57.012266|2018-05-31 23:01:57.012266
NCT01263652|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-12-16|2010-12-16|2010-12-21|Estimate|||||||2010-12-16|2010-12-21|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients|The Relationship Between Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine Patients|Unknown status|Not yet recruiting|N/A|200|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-05-31 23:01:57.198942|2018-05-31 23:01:57.198942
NCT01263639|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2013-11-11||2014-06-30|2010-12-20|2010-12-21|Estimate|2014-06-30|2014-07-28|Estimate||||2014-06-30|2014-07-28|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Improving Patient Satisfaction Improving Patient Satisfaction|Improving Patient Satisfaction in the Orthopaedic Trauma Population|Completed||N/A|228|Actual|Vanderbilt University|No adverse events. Limitations included poor patient follow-up due to poor patient participation with telephone call surveys.|2|||f||||t||||||||||2018-05-31 23:01:57.289697|2018-05-31 23:01:57.289697
NCT01263613|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2014-04-04|2010-12-17|2010-12-20|Estimate|||||||2014-04-04|2014-04-08|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer|Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer|Completed||Early Phase 1|6|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 23:01:57.529472|2018-05-31 23:01:57.529472
NCT01263600|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2018-01-11|2010-12-17|2010-12-20|Estimate|||||||2018-01-11|2018-01-16|Actual|December 2010||2010-12-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|||Hepatitis B Research Network Pediatric Cohort Study (HBRN)|Cohort Hepatitis B Virus (HBV) Pediatric Protocol|Active, not recruiting|||463|Actual|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Liver biopsy tissue, blood (serum, plasma, and DNA)~   "|No||2018-05-31 23:01:57.585772|2018-05-31 23:01:57.585772
NCT01263587|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-09-26|2010-12-17|2010-12-20|Estimate|||||||2017-09-26|2017-09-28|Actual|December 2010||2010-12-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|HBRN||Hepatitis B Research Network Adult Cohort Study|Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study)|Recruiting|||2500|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Liver biopsy tissue, blood (serum, plasma, and DNA)~   "|No||2018-05-31 23:01:57.746487|2018-05-31 23:01:57.746487
NCT01263574|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-06-20|2010-12-17|2010-12-20|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2011|Anticipated|2011-02-28|June 2017|2017-06-30|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome|Trial of Ethanol Lock Therapy to Prevent Catheter Associated Blood Stream Infections|Withdrawn||Phase 2|0|Actual|Boston Children’s Hospital||2||No participants. IND denied by FDA.|f||||t||||||||No||2018-05-31 23:01:57.858451|2018-05-31 23:01:57.858451
NCT01263561|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2014-12-01||2014-12-07|2010-12-17|2010-12-20|Estimate|2014-12-07|2014-12-09|Estimate||||2014-12-07|2014-12-09|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Prospective Randomized Study Comparing Ex-PRESS to Trabeculectomy|Prospective Randomized Study Comparing Ex-PRESS to Trabeculectomy|Completed||N/A|64|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 23:01:57.930288|2018-05-31 23:01:57.930288
NCT01263548|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-05-31|2010-12-17|2010-12-20|Estimate|||||||2012-05-31|2012-06-01|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder||Completed|||45|Actual|University Health Network, Toronto|||1||f||||||||||||||2018-05-31 23:01:58.180093|2018-05-31 23:01:58.180093
NCT01263535|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-08-27|2010-12-17|2010-12-20|Estimate|||||||2012-08-27|2012-08-28|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Use of an Ocular Telemetry Sensor in Tafluprost Treated Patients|Circadian Continuous Intraocular Pressure Monitoring With SENSIMED Triggerfish® Ocular Telemetry Sensor in Patients on Tafluprost Treatment|Terminated||Phase 4|15|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 23:01:58.238704|2018-05-31 23:01:58.238704
NCT01263522|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2018-05-04|2010-12-17|2010-12-20|Estimate|||||||2018-05-04|2018-05-10|Estimate|December 2010|Actual|2010-12-31|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SAusE||Optimization of Preventive Effects of Physical Training|"Optimization of Preventive Effects of Physical Training Saarländische Ausdauer-Etappe (SAusE)"|Completed||N/A|266|Actual|Saarland University||4|||f|||||f|f||||||||2018-05-31 23:01:58.288027|2018-05-31 23:01:58.288027
NCT01263509|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2011-06-08||2012-02-01|2010-12-17|2010-12-20|Estimate|2011-07-28|2011-08-29|Estimate||||2012-02-01|2012-02-03|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan|A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2/Phase 3|179|Actual|Takeda||2|||f||||f||||||||||2018-05-31 23:01:58.413061|2018-05-31 23:01:58.413061
NCT01263496|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2011-06-08||2012-02-01|2010-12-17|2010-12-20|Estimate|2011-06-08|2011-07-07|Estimate||||2012-02-01|2012-02-03|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan|A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan.|Completed||Phase 2|438|Actual|Takeda||5|||f||||f||||||||||2018-05-31 23:01:59.812456|2018-05-31 23:01:59.812456
NCT01263483|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2011-06-08||2012-02-01|2010-12-17|2010-12-20|Estimate|2011-06-08|2011-07-11|Estimate||||2012-02-01|2012-02-03|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan|A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2/Phase 3|230|Actual|Takeda||3|||f||||f||||||||||2018-05-31 23:02:02.823374|2018-05-31 23:02:02.823374
NCT01263470|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2011-06-08||2012-02-01|2010-12-17|2010-12-20|Estimate|2011-06-08|2011-07-06|Estimate||||2012-02-01|2012-02-03|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan|A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan|Completed||Phase 2|480|Actual|Takeda||6|||f||||f||||||||||2018-05-31 23:02:03.6264|2018-05-31 23:02:03.6264
NCT01263457|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-12-22|2010-12-17|2010-12-20|Estimate|||||||2017-12-22|2017-12-26|Actual|November 30, 2010|Actual|2010-11-30|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS UK||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|Completed|||191|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:02:05.059652|2018-05-31 23:02:05.059652
NCT01263288|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2013-06-21|2010-12-17|2010-12-20|Estimate|||||||2013-06-21|2013-06-24|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||Effect of Vitamin D Supplementation on Muscular Strength, Musculoskeletal Pain and Headache|Effect of Vitamin D Supplementation on Muscular Strength, Musculoskeletal Pain and Headache in Immigrants Living in Norway. Randomized, Double Blinded, Placebo Controlled Study|Completed||Phase 4|251|Actual|University of Oslo||3|||f||||t||||||||||2018-05-31 23:02:06.647589|2018-05-31 23:02:06.647589
NCT01263444|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|2014-04-23||2014-05-18|2010-12-17|2010-12-20|Estimate|2014-04-23|2014-05-19|Estimate||||2014-05-18|2014-05-20|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||This analysis population includes all enrolled participants.|Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy|Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (AZARGA®) to Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy|Completed||Phase 4|47|Actual|Alcon Research|A single-arm, non-randomized study somewhat limits interpretation of efficacy results. A 3-month duration does not allow for long-term safety conclusions; however, data obtained at V2 and V3 did not vary much, indicating a steady state at Month 1.|1|||f||||f||||||||||2018-05-31 23:02:05.13118|2018-05-31 23:02:05.13118
NCT01263431|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2015-01-21|2010-12-17|2010-12-20|Estimate|||||||2015-01-21|2015-01-22|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Comparison Between Excisional Hemorrhoidectomy and Haemorrhoidal Dearterialisation With Anopexy|Prospective Randomized Trial on Surgical Treatment of Grade 3 Hemorrhoids: Hemorrhoidectomy Versus Doppler-guided Transanal Haemorrhoidal Dearterialisation and Anopexy|Completed||Phase 4|50|Actual|Scientific Institute San Raffaele||2|||f||||t||||||||||2018-05-31 23:02:05.329935|2018-05-31 23:02:05.329935
NCT01263418|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2015-10-08|2010-12-17|2010-12-20|Estimate|||||||2015-10-08|2015-10-12|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas|A Phase II Trial Of Ofatumumab In Older (≥70 Years) Patients With Previously Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas|Withdrawn||Phase 2|0|Actual|UNC Lineberger Comprehensive Cancer Center||1||No patients enrolled and funding has been withdrawn.|f||||t||||||||||2018-05-31 23:02:05.565555|2018-05-31 23:02:05.565555
NCT01263405|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-02-08|2010-12-17|2010-12-20|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2010||2010-12-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging|Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging|Completed|||3|Actual|University of California, Irvine|||2||f||||t||||||||||2018-05-31 23:02:05.651955|2018-05-31 23:02:05.651955
NCT01263392|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-06-19|2010-12-17|2010-12-20|Estimate|||||||2013-06-19|2013-06-20|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparing Urinary Tract Infections in Children With Spina Bifida Using Two Types of Catheters for Catheterization|A Comparison of the Incidence of Symptomatic Urinary Tract Infections in Children With Spina Bifida Using Hydrophilic or Non-hydrophilic Polyvinyl Chloride Catheters for Clean Intermittent Catheterization: a Randomized Cross Over Trial|Completed||N/A|46|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 23:02:05.72385|2018-05-31 23:02:05.72385
NCT01263379|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2018-01-18|2010-12-17|2010-12-20|Estimate|||||||2018-01-18|2018-01-23|Actual|October 5, 2010|Actual|2010-10-05|January 2018|2018-01-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa|A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Stanford University||1|||f||||t|t|f||||||Yes|Results will be submitted to scientific journals for publication and presented at scientific meetings.|2018-05-31 23:02:05.804996|2018-05-31 23:02:05.804996
NCT01263366|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-04-17|2010-12-17|2010-12-20|Estimate|||||||2013-04-17|2013-04-19|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients|Exploratory Study of Topical Norepinephrine in Post-Surgical Breast Cancer Patients Receiving Radiotherapy|Terminated||Phase 1|10|Actual|ProCertus BioPharm, Inc||1||Enrollment issues|f||||f||||||||||2018-05-31 23:02:05.87926|2018-05-31 23:02:05.87926
NCT01263353|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2016-04-20|2010-12-17|2010-12-20|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|COOPERATE-1||Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs|An Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study|Completed||Phase 1|36|Actual|Novartis||6|||f||||||||||||||2018-05-31 23:02:05.954341|2018-05-31 23:02:05.954341
NCT01263340|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-12-04|2010-12-17|2010-12-20|Estimate|||||||2013-12-04|2013-12-05|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|CoCO||Characterisation of People With COPD|Observational, Multi-centre, Retrospective Cohort Study to Evaluate Prevalence, Incidence, Severity, Co-morbidities and Burden of Disease in Patients With a Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) by Close Scrutiny of the Patient Journey|Completed|||10000|Anticipated|National Services for Health Improvement Ltd|||1||f||||t||||||||||2018-05-31 23:02:06.034545|2018-05-31 23:02:06.034545
NCT01263327|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2014-02-20|2010-12-17|2010-12-20|Estimate|||||||2014-02-20|2014-02-24|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine|An Open-Label, Single-dose, Non-Randomized, Safety and Tolerability Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 55 Years|Completed||Phase 1|38|Actual|Xiamen University||1|||f||||f||||||||||2018-05-31 23:02:06.172144|2018-05-31 23:02:06.172144
NCT01263314|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2015-10-30|2010-12-17|2010-12-20|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Safety, Tolerability and Pharmacokinetics of MK-8266 in Elderly Subjects With High Blood Pressure (MK-8266-003 AM1)|A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8266 in Elderly Subjects With Hypertension|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 23:02:06.246239|2018-05-31 23:02:06.246239
NCT01263301|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2011-07-09||2013-02-03|2010-12-17|2010-12-20|Estimate|2012-12-27|2013-02-01|Estimate||||2013-02-03|2013-02-12|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||11 hemodialytic patients particitated the study, only 2 shows SSS in carotid duplex. We analysed these 2 patients only.|Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm|Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm|Completed||N/A|16|Actual|Mennonite Christian Hospital|the number of the study is small, no standard technique for measurement of blood flow of vascular access|2|||f||||f||||||||||2018-05-31 23:02:06.356326|2018-05-31 23:02:06.356326
NCT01263275|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2015-09-15|2010-12-17|2010-12-20|Estimate|||||||2015-09-15|2015-09-17|Estimate|December 2010||2010-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Trial of Transcranial Direct Current Stimulation (tDCS) for Depression|Open Pilot Trial of Transcranial Direct Current Stimulation (tDCS) for Depression.|Completed||Phase 2|3|Actual|The University of New South Wales||1|||f||||f||||||||||2018-05-31 23:02:06.740021|2018-05-31 23:02:06.740021
NCT01263262|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-10-23|2010-12-17|2010-12-20|Estimate|||||||2013-10-23|2013-10-24|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||A Comparison of Infection Rates Between Two Surgical Sites|A Comparative Assessment Between Two Surgical Sites of the Rate of Corneal Toxicity and Ototoxicity With the Use of Povidone-iodine Versus Chlorhexidine-alcohol for Facial Lesions Treated With Mohs Micrographic Surgery|Completed|||600|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 23:02:06.810771|2018-05-31 23:02:06.810771
NCT01263249|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-06-13|2010-12-17|2010-12-20|Estimate|||||||2011-06-13|2011-06-14|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Effects of Catheter Tip Location Relative to the Femoral Nerve on Sensory and Motor Function|Continuous Femoral Nerve Blocks: Effects of Catheter Tip Location Relative to the Femoral Nerve on Sensory and Motor Function|Completed||Phase 4|19|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 23:02:06.87452|2018-05-31 23:02:06.87452
NCT01263236|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-02-01|2010-12-17|2010-12-20|Estimate|||||||2017-02-01|2017-02-03|Estimate|December 2010||2010-12-31|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of LY2940094 in Major Depressive Disorder|A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of LY2940094 in Healthy Male Subjects|Completed||Phase 1|66|Actual|BlackThorn Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 23:02:06.940732|2018-05-31 23:02:06.940732
NCT01263223|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-04-01|2010-12-16|2010-12-20|Estimate|||||||2011-04-01|2011-04-04|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors|Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors|Completed||Phase 1|0|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:02:07.017638|2018-05-31 23:02:07.017638
NCT01263210|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2010-12-17|2010-12-17|2010-12-20|Estimate|||||||2010-12-17|2010-12-20|Estimate|March 2003||2003-03-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Pneumococcal Vaccination of Otitis-prone Children|Conjugate Pneumococcal Vaccination - a Randomized Study in Young Otitis-prone Children|Completed||N/A|109|Actual|Lund University Hospital||2|||f||||t||||||||||2018-05-31 23:02:07.105725|2018-05-31 23:02:07.105725
NCT01263197|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-04-15|2010-12-16|2010-12-20|Estimate|||||||2011-04-15|2011-04-18|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of LY2216684 in Healthy Subjects Receiving Albuterol or Propanolol|Effect of LY2216684 on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Albuterol or Propranolol|Completed||Phase 1|48|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 23:02:07.182325|2018-05-31 23:02:07.182325
NCT01263184|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2010-12-28|2010-12-17|2010-12-20|Estimate|||||||2010-12-28|2010-12-29|Estimate|November 2009||2009-11-30|November 2010|2010-11-30||||||||Observational|Sodisow||Symptoms of Degeneration in Shoulder of Wheelchair-users|Längsschnittstudie Zur Belastungsinduzierten Anpassung, Schädigung Oder Degeneration Der Schulter Bei Rollstuhlathleten/-Innen|Unknown status|Recruiting||60|Anticipated|Hannover Medical School|||3||f||||||||||||||2018-05-31 23:02:07.271937|2018-05-31 23:02:07.271937
NCT01263171|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2016-09-20|2010-12-17|2010-12-20|Estimate|||||||2016-09-20|2016-09-21|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|COPERNICUS||Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery|A Stratified Phase II Study of Neoadjuvant Chemotherapy Given Before SCPRT as Treatment for Patients With MRI-Staged Operable Rectal Cancer at High Risk of Metastatic Relapse|Completed||Phase 2|60|Actual|Cardiff University||1|||f||||t||||||||Undecided||2018-05-31 23:02:07.351602|2018-05-31 23:02:07.351602
NCT01263158|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2015-08-10|2010-12-17|2010-12-20|Estimate|||||||2015-08-10|2015-08-11|Estimate|October 1998||1998-10-31|August 2015|2015-08-31|December 2003|Actual|2003-12-31|||||Interventional|||Labour Augmentation by Means of Oxytocin - Obstetric Outcome and Women's Experiences||Completed||N/A|2072|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 23:02:07.436981|2018-05-31 23:02:07.436981
NCT01263145|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2017-08-24|2010-12-17|2010-12-20|Estimate|||||||2017-08-24|2017-08-25|Actual|January 5, 2011|Actual|2011-01-05|August 2017|2017-08-31|October 19, 2012|Actual|2012-10-19|October 19, 2012|Actual|2012-10-19||Interventional|||MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer|Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer|Completed||Phase 1|34|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:02:07.500781|2018-05-31 23:02:07.500781
NCT01263132|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2011-09-19||2014-01-20|2010-12-17|2010-12-20|Estimate|2011-09-19|2011-10-27|Estimate||||2014-01-20|2014-02-13|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|M-F0434||Neuropathic Pain Management|Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study|Completed||Phase 3|104|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:02:07.595468|2018-05-31 23:02:07.595468
NCT01263119|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-04-18|2010-12-16|2010-12-20|Estimate|||||||2011-04-18|2011-04-19|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of LY2216684 and Warfarin in Healthy Subjects|Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects|Completed||Phase 1|18|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:02:07.860124|2018-05-31 23:02:07.860124
NCT01263106|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-03-15|2010-12-16|2010-12-20|Estimate|||||||2011-03-15|2011-03-17|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of LY2216684 and Theophylline in Healthy Subjects|Effect of LY2216684 on the Pharmacokinetics of Theophylline in Healthy Subjects|Completed||Phase 1|21|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:02:08.087558|2018-05-31 23:02:08.087558
NCT01262768|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2014-02-19|2010-12-16|2010-12-17|Estimate|||||||2014-02-19|2014-02-20|Estimate|April 2010||2010-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|PSMA||Efficacy of Portion Size Measurement Aids|Exploring the Accuracy and Acceptability of Portion Size Measurement Aids in Parents of Overweight Children|Completed||N/A|36|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 23:02:19.773277|2018-05-31 23:02:19.773277
NCT01263093|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-05-04|2010-12-17|2010-12-20|Estimate|||||||2011-05-04|2011-05-05|Estimate|December 2010||2010-12-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel|Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of R-130964, the Active Metabolite of Clopidogrel, in Healthy Subjects|Completed||Phase 1|47|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:02:08.179231|2018-05-31 23:02:08.179231
NCT01263080|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2016-08-01|2010-12-17|2010-12-20|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RECOVERY2||Evaluation of Mirtazapine and Folic Acid for Schizophrenia:|Multicentre Randomised Double-blind, Placebo-controlled 2x2 Factorial Trial Investigating the Effects of Adding Mirtazapine and Folic Acid to Existing Therapy for Patients With Schizophrenia|Completed||Phase 4|333|Actual|Capital Medical University||4|||f||||t||||||||Undecided||2018-05-31 23:02:08.257953|2018-05-31 23:02:08.257953
NCT01263067|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-01-13|2010-12-17|2010-12-20|Estimate|||||||2015-01-13|2015-01-14|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|||Lifespan Integration for Posttraumatic Stress Disorder From an Auto Accident|Lifespan Integration Therapy for Posttraumatic Stress Disorder of Adults Involved in an Auto Accident|Completed||N/A|6|Actual|Argosy University||2|||f||||t||||||||||2018-05-31 23:02:08.341538|2018-05-31 23:02:08.341538
NCT01263054|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2016-01-13||2017-07-21|2010-12-16|2010-12-20|Estimate|2016-02-11|2016-03-09|Estimate||||2017-07-21|2017-08-21|Actual|December 2010||2010-12-31|March 2015|2015-03-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|COLD||Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain|A Prospective, Randomized, Multi-Center, Open-Label Clinical Trial Comparing Disc Biacuplasty With Medical Management for Discogenic Lumbar Back Pain|Completed||N/A|67|Actual|Halyard Health||2|||f||||f||||||||||2018-05-31 23:02:08.436834|2018-05-31 23:02:08.436834
NCT01263041|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2014-04-14|2010-12-17|2010-12-20|Estimate|||||||2014-04-14|2014-04-15|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|preterm||Effect of L-arginine and Glutamine on Preterm|Effect of Early Enteral Supplementation of L-arginine and Glutamine on Preterm Neonate|Completed||Phase 2/Phase 3|75|Actual|Ain Shams University||3|||f||||t||||||||||2018-05-31 23:02:08.801549|2018-05-31 23:02:08.801549
NCT01263028|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2012-08-21||2015-03-10|2010-12-16|2010-12-20|Estimate|2012-08-21|2012-09-20|Estimate||||2015-03-10|2015-03-30|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|EASY||Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose|Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose|Terminated||N/A|6|Actual|Kaiser Permanente|Study terminated due to insufficient enrollment numbers.|1||"Strong enrollment efforts resulted in few eligible subjects and high screen failures due to CKD~   patients with higher vitamin D levels than anticipated."|f||||f||||||||||2018-05-31 23:02:08.878976|2018-05-31 23:02:08.878976
NCT01263015|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2013-08-15|2012-11-15|2018-03-08|2010-12-16|2010-12-20|Estimate|2014-05-29|2014-07-02|Estimate|2012-11-15|2012-11-21|Estimate|2018-03-08|2018-04-04|Actual|February 1, 2011||2011-02-01|March 2018|2018-03-31|December 3, 2015|Actual|2015-12-03|May 14, 2012|Actual|2012-05-14||Interventional|||A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)|A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|Completed||Phase 3|844|Actual|ViiV Healthcare||2|||f||||t||||||||||2018-05-31 23:02:09.05593|2018-05-31 23:02:09.05593
NCT01263002|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-17|||2014-12-16|2010-12-17|2010-12-20|Estimate|||||||2014-12-16|2014-12-18|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC|An Open Study to Evaluate the Efficacy, Safety and Sustained Effect of Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With Chronic Hepatitis B Associated Hepatocellular Carcinoma|Completed||Phase 4|33|Anticipated|Bukwang Pharmaceutical|||||f||||||||||||||2018-05-31 23:02:11.993623|2018-05-31 23:02:11.993623
NCT01262989|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2011-03-03||2017-07-05|2010-12-16|2010-12-20|Estimate|2011-03-03|2011-03-31|Estimate||||2017-07-05|2017-08-14|Actual|January 4, 2010|Actual|2010-01-04|July 2017|2017-07-31|January 26, 2010|Actual|2010-01-26|January 26, 2010|Actual|2010-01-26||Interventional|||SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin|Randomized, Two-period, Cross-over, Bioequivalence Study on Tamsulosin Hydrochloride 0,4 mg Prolonged Release Hard Gelatin Capsule Versus SECOTEX® (Tamsulosin Hydrochloride) 0,4 mg Prolonged Release Hard Gelatin Capsule (Boehringer Ingelheim) in Healthy Male Volunteers Under Fasting Conditions.|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:02:12.070464|2018-05-31 23:02:12.070464
NCT01262976|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16||2013-04-11|2016-12-05|2010-12-16|2010-12-20|Estimate||||2013-04-11|2013-04-18|Estimate|2016-12-05|2016-12-06|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|July 2012|Actual|2012-07-31||Interventional|||Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults|Safety and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to HIV-positive Adults Living in a Tuberculosis Endemic Region|Completed||Phase 2|240|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 23:02:12.310117|2018-05-31 23:02:12.310117
NCT01262963|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-11-08|2010-12-16|2010-12-20|Estimate|||||||2017-11-08|2017-11-13|Actual|January 26, 2011|Actual|2011-01-26|November 2017|2017-11-30|April 8, 2011|Actual|2011-04-08|April 8, 2011|Actual|2011-04-08||Interventional|||An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors|An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects With BRAF Mutant Solid Tumors|Completed||Phase 1|4|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:02:12.423157|2018-05-31 23:02:12.423157
NCT01262950|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2010-12-17|2010-12-17|2010-12-20|Estimate|||||||2010-12-17|2010-12-20|Estimate||||October 2010|2010-10-31||||||||Expanded Access|||Development of a Fall Prevention and Fall Detection System for Ambulatory Rehabilitation of Parkinson's Patients||Temporarily not available|||||Far Eastern Memorial Hospital|||||f||||||||||||||2018-05-31 23:02:12.492983|2018-05-31 23:02:12.492983
NCT01262937|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2018-02-21|2010-12-17|2010-12-20|Estimate|||||||2018-02-21|2018-02-26|Actual|July 2009|Actual|2009-07-31|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||A Study to Examine the Human Gastrointestinal Tract Using the Confocal Endomicroscope|A Pilot Study to Examine the Human Gastrointestinal Tract Using the Confocal Endomicroscope|Terminated|||106|Actual|Yale University|||2||f||||f||||||||||2018-05-31 23:02:12.533238|2018-05-31 23:02:12.533238
NCT01262924|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2010-12-16|2010-12-16|2010-12-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|October 1997||1997-10-31|December 2010|2010-12-31|December 1998|Actual|1998-12-31|December 1998|Actual|1998-12-31||Interventional|||Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine|A Phase III, Blinded, Randomised, Monocentre, Comparative Clinical Study of the Immunogenicity, Reactogenicity and Safety of a Single Booster Dose of SB Biologicals' Candidate dTpa and pa Vaccines and SB Biologicals' Licensed Td Vaccine in Healthy Adults Aged ≥18 Years|Completed||Phase 3|116|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 23:02:12.605785|2018-05-31 23:02:12.605785
NCT01262911|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-08-02|2010-12-16|2010-12-17|Estimate|||||||2017-08-02|2017-08-04|Actual|February 17, 2011|Actual|2011-02-17|August 2017|2017-08-31|April 26, 2011|Actual|2011-04-26|April 26, 2011|Actual|2011-04-26||Interventional|||Effect of SRT2379 on Endotoxin-Induced Inflammation|A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects|Completed||Phase 1|17|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:02:12.683823|2018-05-31 23:02:12.683823
NCT01262898|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2017-09-14|2015-04-27|2017-10-16|2010-12-16|2010-12-17|Estimate|2017-09-14|2017-10-13|Actual|2015-04-27|2015-05-13|Estimate|2017-10-16|2017-11-17|Actual|May 3, 2011|Actual|2011-05-03|September 2017|2017-09-30|February 26, 2013|Actual|2013-02-26|February 26, 2013|Actual|2013-02-26||Interventional|||Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis|A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis|Completed||Phase 2|79|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 23:02:12.890681|2018-05-31 23:02:12.890681
NCT01262885|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-06-27|2010-12-16|2010-12-17|Estimate|||||||2017-06-27|2017-06-28|Actual|October 7, 2010|Actual|2010-10-07|June 2017|2017-06-30|August 25, 2011|Actual|2011-08-25|August 25, 2011|Actual|2011-08-25||Interventional|||A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects|A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects|Completed||Phase 1|84|Actual|GlaxoSmithKline||8|||f||||f||||||||||2018-05-31 23:02:14.777116|2018-05-31 23:02:14.777116
NCT01262872|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2014-03-13|2013-04-11|2017-05-15|2010-12-16|2010-12-17|Estimate|2014-03-13|2014-04-21|Estimate|2013-04-11|2013-04-18|Estimate|2017-05-15|2017-06-08|Actual|February 9, 2011||2011-02-09|March 2017|2017-03-31|March 18, 2013|Actual|2013-03-18|March 18, 2013|Actual|2013-03-18||Interventional|||Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants|Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Years in The Gambia|Completed||Phase 2|1320|Actual|GlaxoSmithKline||8|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:02:15.147112|2018-05-31 23:02:15.147112
NCT01262859|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2014-01-10|2010-12-16|2010-12-17|Estimate|||||||2014-01-10|2014-01-13|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pilot Study for Locally Advanced Head and Neck Cancer|Pilot Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||1||PI relocated to another institution. No subjects went on treatment.|f||||t||||||||||2018-05-31 23:02:18.836774|2018-05-31 23:02:18.836774
NCT01262846|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2016-12-08||2017-03-01|2010-12-16|2010-12-17|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|November 2010||2010-11-30|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals|Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals|Completed||Phase 4|195|Actual|University of Pennsylvania|Caution The trial was not powered to determine clinical efficacy or to detect differences in the occurrence of less common adverse events.|2|||f||||f||||||||||2018-05-31 23:02:18.903457|2018-05-31 23:02:18.903457
NCT01262833|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2014-03-13|2010-12-16|2010-12-17|Estimate|||||||2014-03-13|2014-03-14|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|INDEED||Pudendal Assessment in Erectile Dysfunction|A Cohort Study of the Functional Significance of Internal Pudendal Artery Stenoses in Patients With Erectile Dysfunction|Terminated|||10|Actual|University of Pennsylvania|||2|data suggesting pudendal artery stenosis rarely being cause of ED|f||||t||||||||||2018-05-31 23:02:19.246514|2018-05-31 23:02:19.246514
NCT01262820|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2016-07-28||2017-01-23|2010-12-16|2010-12-17|Estimate|2016-07-28|2016-09-16|Estimate||||2017-01-23|2017-03-07|Actual|December 2010||2010-12-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|LCCC0921||Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab|A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab|Completed||Phase 2|15|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:02:19.313538|2018-05-31 23:02:19.313538
NCT01262807|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-06-05|2010-12-16|2010-12-17|Estimate|||||||2015-06-05|2015-06-08|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Reducing Range of Motion Deficits Post Radial Fracture|Reducing Range of Motion Deficits With In-cast Exercises: A Randomized Controlled Trial|Completed||N/A|70|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 23:02:19.592925|2018-05-31 23:02:19.592925
NCT01262794|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-09-26|2010-12-16|2010-12-17|Estimate|||||||2011-09-26|2011-09-27|Estimate|November 2010||2010-11-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects|A Phase 1, Randomized, Double-blind, Placebo Controlled, Single-center, Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of CDP6038 Administered Subcutaneously to Healthy Japanese Males|Completed||Phase 1|20|Actual|UCB Pharma||5|||f||||f||||||||||2018-05-31 23:02:19.651768|2018-05-31 23:02:19.651768
NCT01262781|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2014-04-09|2010-12-16|2010-12-17|Estimate|||||||2014-04-09|2014-04-10|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Observational|FLAB||Is Fructose Linked to Adiposity in Babies?|Is Fructose Linked to Adiposity in Babies?|Completed|||40|Actual|University of California, San Francisco|||||f||||f||||||||||2018-05-31 23:02:19.71598|2018-05-31 23:02:19.71598
NCT01262755|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2015-04-16||2015-04-16|2010-12-16|2010-12-17|Estimate|2015-04-16|2015-05-04|Estimate||||2015-04-16|2015-05-04|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|TRIAGE|450 African Americans living around Temple Hospital|Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology|Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology|Completed|||450|Actual|Temple University|||1||f||||f||||||||||2018-05-31 23:02:19.837484|2018-05-31 23:02:19.837484
NCT01262742|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-09-02|2010-12-16|2010-12-17|Estimate|||||||2011-09-02|2011-09-05|Estimate|November 2010||2010-11-30|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Carbetocin at Elective Cesarean Delivery|Carbetocin at Elective Cesarean Delivery: A Dose Finding Study|Completed||N/A|80|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||5|||f||||f||||||||||2018-05-31 23:02:19.990347|2018-05-31 23:02:19.990347
NCT01262729|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2015-09-22|2010-12-16|2010-12-17|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|10-015||Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation|Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation|Terminated||Phase 2|5|Actual|RWTH Aachen University||2||Feasibility and Recruitment problems|f||||f||||||||||2018-05-31 23:02:20.075607|2018-05-31 23:02:20.075607
NCT01262716|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2011-10-24|2010-12-16|2010-12-17|Estimate|||||||2011-10-24|2011-10-25|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer|A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer|Completed|||3|Anticipated|Rogers Sciences Inc.|||||f||||t||||||||||2018-05-31 23:02:20.150563|2018-05-31 23:02:20.150563
NCT01262703|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-04-26|2010-12-16|2010-12-17|Estimate|||||||2017-04-26|2017-04-27|Actual|December 2011|Actual|2011-12-31|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2013|Actual|2013-10-31||Interventional|RESTORE||Safety Study of a Bioresorbable Coronary Stent|Pilot Study of the ReZolve™ Sirolimus-Eluting Bioresorbable Coronary Stent|Active, not recruiting||N/A|49|Actual|REVA Medical, Inc.||1|||f||||t||||||||||2018-05-31 23:02:20.19986|2018-05-31 23:02:20.19986
NCT01262690|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2011-10-11|2010-12-16|2010-12-17|Estimate|||||||2011-10-11|2011-10-12|Estimate|November 2010||2010-11-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin|A Phase 1 Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05230901 Administered Subcutaneously To Healthy Subjects|Terminated||Phase 1|44|Actual|Pfizer||1||"The study was terminated on 21-Sept-2011 due to the emergent safety concern of sensory~   symptoms."|f||||f||||||||||2018-05-31 23:02:20.440758|2018-05-31 23:02:20.440758
NCT01262677|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16||2013-09-13|2013-09-13|2010-12-16|2010-12-17|Estimate||||2013-09-13|2013-09-19|Estimate|2013-09-13|2013-09-19|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Once-A-Day Pregabalin For Partial Seizures|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial Of Pregabalin Controlled Release Formulation As Adjunctive Therapy In Adults With Partial Onset Seizures - Protocol A0081194|Completed||Phase 3|334|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 23:02:20.546162|2018-05-31 23:02:20.546162
NCT01262664|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2018-02-15|2010-12-16|2010-12-17|Estimate|||||||2018-02-15|2018-02-19|Actual|May 24, 2012|Actual|2012-05-24|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity|A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity|Active, not recruiting||Phase 1|4|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:02:20.745283|2018-05-31 23:02:20.745283
NCT01262651|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2018-03-23|2016-06-24|2018-03-23|2010-12-16|2010-12-17|Estimate|2018-03-23|2018-04-23|Actual|2016-07-04|2016-07-06|Estimate|2018-03-23|2018-04-23|Actual|November 25, 2010|Actual|2010-11-25|March 2018|2018-03-31|July 2, 2015|Actual|2015-07-02|July 2, 2015|Actual|2015-07-02||Interventional||Safety population included all participants who received at least one infusion of study drug.|Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer|A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy|Completed||Phase 3|397|Actual|GW Pharmaceuticals Ltd.||2|||f||||t||||||||||2018-05-31 23:02:20.913194|2018-05-31 23:02:20.913194
NCT01262638|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16||2015-08-13|2015-08-27|2010-12-16|2010-12-17|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.|Completed||Phase 2|177|Actual|Esperion Therapeutics||8|||f||||f||||||||||2018-05-31 23:02:21.488519|2018-05-31 23:02:21.488519
NCT01262625|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2014-10-27|2010-12-15|2010-12-17|Estimate|||||||2014-10-27|2014-10-28|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|RESCUE||Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations|ACRIN 4701 RESCUE: Randomized Evaluation of Patients With Stable Angina Comparing Utilization of Diagnostic Examinations|Terminated||Phase 3|1050|Actual|American College of Radiology Imaging Network||2||Funding timeline completed|f||||t||||||||||2018-05-31 23:02:21.56543|2018-05-31 23:02:21.56543
NCT01262612|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-07-12|2010-12-16|2010-12-17|Estimate|||||||2013-07-12|2013-07-15|Estimate|April 2010||2010-04-30|July 2013|2013-07-31||||December 2011|Actual|2011-12-31||Interventional|||Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion|A Phase II Study of Cediranib as Palliative Treatment in Patients With Symptomatic Malignant Ascites or Pleural Effusion|Terminated||Phase 2|12|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 23:02:21.647938|2018-05-31 23:02:21.647938
NCT01262599|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2015-05-12||2016-07-26|2010-12-16|2010-12-17|Estimate|2015-08-04|2015-08-10|Estimate||||2016-07-26|2016-09-02|Estimate|February 2010||2010-02-28|July 2016|2016-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Use of Pulsed Electromagnetic Fields (PEMF) After Breast Reconstruction Surgery|Effect of Pulsed Electromagnetic Fields on Postoperative Recovery After TRAM Flap Breast Reconstruction|Completed||Phase 4|32|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 23:02:21.72077|2018-05-31 23:02:21.72077
NCT01262586|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2016-11-16|2010-12-16|2010-12-17|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.|Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device|Completed||Phase 3|24|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:02:21.944561|2018-05-31 23:02:21.944561
NCT01262573|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2015-04-27||2016-11-28|2010-12-15|2010-12-17|Estimate|2015-04-27|2015-05-12|Estimate||||2016-11-28|2017-01-16|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Barbed Suture vs Smooth Suture for Vaginal Cuff Closure|Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial|Completed||Phase 4|64|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:02:22.011653|2018-05-31 23:02:22.011653
NCT01262560|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2016-12-13||2017-08-29|2010-12-16|2010-12-17|Estimate|2017-08-29|2017-08-31|Actual||||2017-08-29|2017-08-31|Actual|February 2012||2012-02-29|August 2017|2017-08-31|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional||All eligible patients|Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer|Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer|Completed||Phase 2|163|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-05-31 23:02:22.406268|2018-05-31 23:02:22.406268
NCT01262547|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|2014-06-18||2014-10-30|2010-12-16|2010-12-17|Estimate|2014-10-30|2014-10-31|Estimate||||2014-10-30|2014-10-31|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A New Micrografting Technique for Vitiligo|A Randomized Controlled Pilot Study to Examine the Use of Micrografting, Using a Novel Grafting Technique for the Repigmentation of Vitiligo|Terminated||Phase 2|3|Actual|Massachusetts General Hospital|Early termination of study leading to small number of subjects analyzed.|3||The study sponsor was acquired by a company that focuses on chronic wounds.|f||||f||||||||||2018-05-31 23:02:23.559829|2018-05-31 23:02:23.559829
NCT01262534|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-05-03|2010-12-16|2010-12-17|Estimate|||||||2013-05-03|2013-05-06|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.|Observational Epidemiological Registry to Assess the Clinical Profile in Patients With Moderate to Severe Psoriasis in Spain|Completed|||1042|Actual|Janssen-Cilag, S.A.|||3||f||||||||||||||2018-05-31 23:02:23.800398|2018-05-31 23:02:23.800398
NCT01262521|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2013-11-07|2010-12-16|2010-12-17|Estimate|||||||2013-11-07|2013-11-08|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Dietary Nitrate and Cardiovascular Health|Physiological Effects of Oral Nitrate on Vascular Function|Completed||N/A|20|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 23:02:23.895969|2018-05-31 23:02:23.895969
NCT01262508|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2016-02-18|2010-12-16|2010-12-17|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Development of Algorithms to Predict Hemodynamic Instability|Development of Algorithms to Detect and Predict Hemodynamic Instability in Patients at Risk|Completed|||60|Actual|Heinrich-Heine University, Duesseldorf|||1||f||||f||||||||||2018-05-31 23:02:24.046684|2018-05-31 23:02:24.046684
NCT01262495|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2010-12-16|2010-12-16|2010-12-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Testicular Tissue Viability After Cryopreservation||Unknown status|Not yet recruiting|N/A|5|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-05-31 23:02:24.191849|2018-05-31 23:02:24.191849
NCT01262482|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2012-11-08|2010-12-16|2010-12-17|Estimate|||||||2012-11-08|2012-11-09|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment|A Phase 2 Trial of Oxaliplatin and Sorafenib Combination in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Relapsed After a Cisplatin Based Treatment|Completed||Phase 2|41|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f||||||||||2018-05-31 23:02:24.440181|2018-05-31 23:02:24.440181
NCT01262469|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2014-12-14|2010-12-16|2010-12-17|Estimate|||||||2014-12-14|2014-12-16|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|December 2011|Actual|2011-12-31||Interventional|GERICO09||Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.|PHASE II STUDY Evaluating the Toxicity and Activity of the Combination Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over With Metastatic Breast Cancer Over Expressing HER2|Completed||Phase 2|4|Actual|UNICANCER||1|||f||||f||||||||||2018-05-31 23:02:24.515297|2018-05-31 23:02:24.515297
NCT01262456|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2015-06-18|2012-04-26|2015-09-16|2010-12-16|2010-12-17|Estimate|2015-09-16|2015-10-15|Estimate|2012-04-26|2012-04-27|Estimate|2015-09-16|2015-10-15|Estimate|February 2011||2011-02-28|September 2015|2015-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Demographic data offered from the Full Analysis Set population.|Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablets for the Treatment of Nocturia in Adult Males|Completed||Phase 3|395|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-05-31 23:02:24.626301|2018-05-31 23:02:24.626301
NCT01262443|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2016-09-30|2010-12-16|2010-12-17|Estimate|||||||2016-09-30|2016-10-03|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Efficacy of Transcatheter Radiofrequency Ablation of Atrial Flutter With Standard Irrigated Catheter With Flexible Tip|Prospective Study to Evaluate the Acute and 6-month Efficacy of Transcatheter Radiofrequency Ablation of Common Atrial Flutter With a Standard Irrigated Catheter With Flexible Tip.|Completed||N/A|30|Actual|Ettore Sansavini Health Science Foundation||1|||f||||t||||||||No||2018-05-31 23:02:25.402158|2018-05-31 23:02:25.402158
NCT01262430|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2018-03-28|2010-12-16|2010-12-17|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2011||2011-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2015|Actual|2015-08-31||Interventional|||Application of Radiostereometric Analysis (RSA) to Triathlon Knee Components Inserted Using the OtisMed Custom-fit Total Knee Replacement System|Randomized Control Trial Using RSA to Compare the OtisMed Customfit Total Knee Replacement Procedure With Computer Assisted Surgery|Active, not recruiting||N/A|52|Actual|Dalhousie University||2|||f||||f||||||||||2018-05-31 23:02:25.460867|2018-05-31 23:02:25.460867
NCT01262417|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-16|2010-12-16|2010-12-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|July 2008||2008-07-31|May 2010|2010-05-31||||November 2010|Actual|2010-11-30||Interventional|SEPRAC2T||Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation|Evaluationof the Efficiency of a Resorbable Barrier Membrane for the Prevention of Abdominal and Peri-hepatic Adhesion in Patients With Colorectal Cancer Requiring Two-stage Surgery for the Resection of Hepatic Metastases|Completed||Phase 2|60|Actual|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 23:02:25.526022|2018-05-31 23:02:25.526022
NCT01262404|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2010-12-16|2010-12-16|2010-12-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Observational|calm||Imaging Cerebral and Sub-cerebral Correlates of Meditative States|Imaging Cerebral and Sub-cerebral Correlates of Meditative States|Unknown status|Recruiting||58|Anticipated|Boston University|||1||f||||t||||||||||2018-05-31 23:02:25.611154|2018-05-31 23:02:25.611154
NCT01262391|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-08-31|2010-12-16|2010-12-17|Estimate|||||||2011-08-31|2011-09-02|Estimate|October 2010||2010-10-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents|A Multicenter, Open-label, Single Ascending Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Patients Aged 5 to 17 Years (Inclusive) With Overactive Bladder (OAB)|Completed||Phase 1|42|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 23:02:25.660583|2018-05-31 23:02:25.660583
NCT01262378|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2018-04-05|2010-12-16|2010-12-17|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2009||2009-02-28|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Harmonic vs HF Knife in Patients Requiring Abdominal Surgery|Clinical Outcome of the Seroma Amount Using the Harmonic vs the HF Knife for Surgery According to Lockwood and Abdominoplastic Surgery: A Prospective Controlled Study|Completed||N/A|22|Actual|Asklepios proresearch||2|||f||||f||||||||||2018-05-31 23:02:25.729243|2018-05-31 23:02:25.729243
NCT01262365|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14||2016-01-12|2016-01-12|2010-12-15|2010-12-17|Estimate||||2016-01-12|2016-02-05|Estimate|2016-01-12|2016-02-05|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|EMBODY 1||Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease|Completed||Phase 3|793|Actual|UCB Pharma||3|||f||||t||||||||||2018-05-31 23:02:25.793581|2018-05-31 23:02:25.793581
NCT01262352|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2012-10-31||2013-02-04|2010-12-15|2010-12-17|Estimate|2012-12-18|2013-01-30|Estimate||||2013-02-04|2013-02-11|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of VX-770 on Lung Clearance Index in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 >90% Predicted|Completed||Phase 2|21|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 23:02:27.057987|2018-05-31 23:02:27.057987
NCT01262339|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2014-12-04||2015-01-13|2010-12-15|2010-12-17|Estimate|2015-01-13|2015-01-26|Estimate||||2015-01-13|2015-01-26|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|||BTX-A Treatment for Palmar Hyperhidrosis|Randomized, Single-blind Comparison of Botulinum Toxin Treatment for Palmar Hyperhidrosis Via Iontophoresis Versus Intradermal Injection|Terminated||Phase 2/Phase 3|2|Actual|University of Wisconsin, Madison||1||low enrollment; principal investigator left sponsoring institution|f||||t||||||||||2018-05-31 23:02:28.792034|2018-05-31 23:02:28.792034
NCT01262326|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-16|2010-12-16|2010-12-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|January 2005||2005-01-31|December 2010|2010-12-31||||December 2011|Anticipated|2011-12-31||Interventional|||Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production||Unknown status|Enrolling by invitation|N/A|80|Anticipated|University of Texas Southwestern Medical Center||2|||f||||||||||||||2018-05-31 23:02:29.14591|2018-05-31 23:02:29.14591
NCT01262313|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-09-24|2010-12-15|2010-12-17|Estimate|||||||2013-09-24|2013-09-26|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Healthy Creations: Community Based Lifestyle Intervention Validation|Healthy Creations: Community Based Lifestyle Intervention Validation|Completed||N/A|46|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 23:02:29.207571|2018-05-31 23:02:29.207571
NCT01262300|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2017-11-29|2010-12-15|2010-12-17|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2010||2010-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2014|Actual|2014-11-30||Interventional|||Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents|Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Nursing Home Residents|Active, not recruiting||Phase 1|33|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 23:02:29.268182|2018-05-31 23:02:29.268182
NCT01262287|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2016-12-17||2017-02-09|2010-12-16|2010-12-17|Estimate|2016-12-17|2017-02-10|Actual||||2017-02-09|2017-03-20|Actual|January 2011||2011-01-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Dutasteride for the Reduction of Alcohol Use in Male Drinkers|Placebo Controlled Pilot Study of Dutasteride for the Reduction of Alcohol Use in Male Drinkers|Completed||Phase 4|47|Actual|UConn Health|28% of participants were abstinent for the entire 8-week medication treatment period which reduced ability to detect the hypothesized treatment effects of dutasteride related to alcohol's acute effects on neuroactive steroid production.|2|||f||||f||||||||No||2018-05-31 23:02:29.345955|2018-05-31 23:02:29.345955
NCT01262274|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-05-19|2010-12-16|2010-12-17|Estimate|||||||2015-05-19|2015-05-21|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|Neo-ACET BC||Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer|Randomized Phase II Trial of Anastrozole in Combination With/Without Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Primary Breast Cancer|Terminated||Phase 2|57|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2||Due to an adverse event revelation.|f||||t||||||||||2018-05-31 23:02:29.733576|2018-05-31 23:02:29.733576
NCT01262261|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15||2012-10-24|2017-06-12|2010-12-16|2010-12-17|Estimate||||2012-10-24|2012-10-30|Estimate|2017-06-12|2017-06-14|Actual|November 2010||2010-11-30|June 2017|2017-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Re-Treatment Study of Probuphine in Opioid Addiction|A Phase 3, Six-Month, Open-Label, Re-Treatment Study of Probuphine in Opioid Addiction|Completed||Phase 3|85|Actual|Braeburn Pharmaceuticals||1|||f||||t||||||||||2018-05-31 23:02:29.800983|2018-05-31 23:02:29.800983
NCT01262248|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2011-06-15|2010-12-15|2010-12-17|Estimate|||||||2011-06-15|2011-06-16|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Observational|||Computer-based Classification of Colorectal Polyps Using Narrow-band Imaging|Computer-based Classification of Small Colorectal Polyps|Completed|||434|Actual|Tischendorf, Jens, M.D.|||1||f||||f||||||||||2018-05-31 23:02:29.893202|2018-05-31 23:02:29.893202
NCT01262235|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-08-27|2010-12-16|2010-12-17|Estimate|||||||2015-08-27|2015-08-28|Estimate|December 2010||2010-12-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients|A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|68|Actual|Arbutus Biopharma Corporation||1|||f||||t||||||||||2018-05-31 23:02:29.950222|2018-05-31 23:02:29.950222
NCT01262222|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2017-09-07|2010-12-16|2010-12-17|Estimate|||||||2017-09-07|2017-09-08|Actual|December 2010||2010-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events|Endothelial Dysfunction in Patients Undergoing Major Cancer Surgery: Incidence and Predictive Value for Postoperative Cardiac Events|Active, not recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     blood draw~   "|||2018-05-31 23:02:30.030057|2018-05-31 23:02:30.030057
NCT01262209|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2016-09-07|2010-12-15|2010-12-17|Estimate|||||||2016-09-07|2016-09-09|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|LOVIT||Clinical Effectiveness of Low Vision Rehabilitation in Glaucoma Patients|Clinical Effectiveness of Low Vision Rehabilitation in Glaucoma Patients With Moderate or Severe Vision Loss|Completed||N/A|16|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 23:02:30.089616|2018-05-31 23:02:30.089616
NCT01262196|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-08-20|2010-12-16|2010-12-17|Estimate|||||||2013-08-20|2013-08-22|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients|A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of MP4OX Treatment, in Addition to Standard Treatment, in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock|Completed||Phase 2|348|Actual|Sangart||2|||f||||t||||||||||2018-05-31 23:02:30.185134|2018-05-31 23:02:30.185134
NCT01262183|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-05-10|2010-12-15|2010-12-17|Estimate|||||||2012-05-10|2012-05-11|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|April 2012|Actual|2012-04-30||Interventional|PANORAMIC||Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus|A Randomised Phase II Study of Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus|Terminated||Phase 2|4|Actual|Radboud University||2||low recruitment numbers|f||||t||||||||||2018-05-31 23:02:30.351229|2018-05-31 23:02:30.351229
NCT01262170|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-10-29|2010-12-16|2010-12-17|Estimate|||||||2015-10-29|2015-10-30|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers|A Randomized, Double-Blind, Active-Controlled, Crossover, Pilot Study to Evaluate the Safety and Efficacy of CigRx™ Lozenge, a Non-Nicotine Non-Tobacco Dietary Supplement, in Daily Smokers in Temporarily Reducing the Desire to Smoke|Completed||Phase 1|109|Actual|Rock Creek Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:02:30.438721|2018-05-31 23:02:30.438721
NCT01262157|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-11|||2011-05-18|2010-12-15|2010-12-17|Estimate|||||||2011-05-18|2011-05-19|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Interventional|LI-ESWT||Low Intensity ShockWave Therapy for ED in Non Responders to PDE5i - a Double Blind Placebo Controlled Study|A Clinical Randomized Double Blind Placebo Controlled Study on the Effect of Low Intensity Shock Wave Therapy for Erectile Dysfunction in a Group of Patients Not Responding to Oral Therapy|Unknown status|Recruiting|Phase 3|60|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 23:02:30.513534|2018-05-31 23:02:30.513534
NCT01262144|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-12-15|2010-12-15|2010-12-17|Estimate|||||||2010-12-15|2010-12-17|Estimate|August 2010||2010-08-31|November 2010|2010-11-30||||||||Observational|||SUV Max as Predictor of Outcome in Cervical Cancer|A Study to Evaluate the Value of SUV-Max in PET-FDG in Predicting Outcome of Surgery Vis a Vis Need for Radiotherapy|Completed|||50|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 23:02:30.592139|2018-05-31 23:02:30.592139
NCT01262131|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2011-05-13||2011-06-06|2010-12-16|2010-12-17|Estimate|2011-06-06|2011-07-01|Estimate||||2011-06-06|2011-07-01|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Evaluation of Magnetic Fields to Treat Fibromyalgia|A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Fibromyalgia: Pilot Study Protocol|Completed||Phase 2|13|Actual|pico-tesla Magnetic Therapies, LLC||3|||f||||f||||||||||2018-05-31 23:02:30.655735|2018-05-31 23:02:30.655735
NCT01262118|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2012-12-17||2012-12-17|2010-12-15|2010-12-17|Estimate|2012-12-17|2013-01-23|Estimate||||2012-12-17|2013-01-23|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis|An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis|Completed||Phase 1|69|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:02:30.876282|2018-05-31 23:02:30.876282
NCT01262105|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2012-03-14||2012-04-09|2010-12-15|2010-12-17|Estimate|2012-03-14|2012-04-09|Estimate||||2012-04-09|2012-04-11|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Device to Reduce Surgery Site Contamination - Spine|Reduction of Airborne Microbes in the Surgical Field During Spine Procedures Using Directed Local Airflow|Completed||N/A|23|Actual|Nimbic Systems, LLC||2|||f||||||||||||||2018-05-31 23:02:31.660474|2018-05-31 23:02:31.660474
NCT01262092|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2013-02-04||2013-06-19|2010-12-15|2010-12-17|Estimate|2013-06-19|2013-06-21|Estimate||||2013-06-19|2013-06-21|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|Detox|analysis was based on those starting the buprenorphine detox except for one subject in the gabapentin arm (evidence of noncompliance with medication procedures and diversion)|Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals|Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals|Completed||Phase 2|30|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 23:02:31.968733|2018-05-31 23:02:31.968733
NCT01262079|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2011-08-11|2010-12-15|2010-12-17|Estimate|||||||2011-08-11|2011-08-15|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|||Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.|Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.|Completed|||180|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||9||f||||f||||||Samples With DNA|"~     Serum Plasma PBMC Whole-blood~   "|||2018-05-31 23:02:32.47486|2018-05-31 23:02:32.47486
NCT01262066|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2016-07-28|2010-12-15|2010-12-17|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2002||2002-09-30|November 2010|2010-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|Lifeskills BP||Effects of Lifeskills Workshop on BP in Hypertensive Employees|RCT of LifeSkills Workshop on BP in Hypertensive Employees|Completed||Phase 2|181|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-05-31 23:02:32.596604|2018-05-31 23:02:32.596604
NCT01262053|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-24|2010-12-15|2010-12-17|Estimate|||||||2010-12-24|2010-12-27|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Investigating Wrong-Patient Computerized Physician Order Entry (CPOE) Errors|Investigating Wrong-Patient CPOE Errors|Unknown status|Active, not recruiting|N/A|5000|Anticipated|Montefiore Medical Center||3|||f||||t||||||||||2018-05-31 23:02:32.669475|2018-05-31 23:02:32.669475
NCT01262040|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2018-05-04|2010-12-16|2010-12-17|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2010|Actual|2010-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive|Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive|Active, not recruiting||N/A|154|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:02:32.863758|2018-05-31 23:02:32.863758
NCT01262027|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2016-12-08||2017-05-23|2010-12-15|2010-12-17|Estimate|2016-12-08|2017-02-02|Estimate||||2017-05-23|2017-06-15|Actual|January 27, 2012|Actual|2012-01-27|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2015|Actual|2015-11-30||Interventional|||TKI258 for Metastatic Inflammatory Breast Cancer Patients|A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients With Stage IV HER2-negative Inflammatory Breast Cancer (IBC) and Local or Distant Relapse|Active, not recruiting||Phase 2|22|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:02:32.991646|2018-05-31 23:02:32.991646
NCT01262014|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2016-08-10|2010-12-16|2010-12-17|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|February 2014|Actual|2014-02-28||Interventional|||Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer|Phase II, Multicenter, Prospective, Single Arm, Open Labeled Clinical Trial Investigating Pazopanib, a Multi-targeted Tyrosine Kinase Inhibitor (TKI) of VEGFR-1, -2, -3, PDGFR-α and -β and c-Kit in Patients With Platinum-resistant Advanced Ovarian Cancer.|Completed||Phase 2|28|Actual|Grupo Español de Investigación en Cáncer de Ovario||1|||f||||f||||||||||2018-05-31 23:02:33.607695|2018-05-31 23:02:33.607695
NCT01262001|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2017-08-03|2010-12-15|2010-12-17|Estimate|||||||2017-08-03|2017-08-04|Actual|March 2011||2011-03-31|August 2017|2017-08-31|June 21, 2017|Actual|2017-06-21|June 26, 2014|Actual|2014-06-26||Interventional|FGCL-3019-049||Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis|A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|90|Actual|FibroGen|||||f||||f||||||||||2018-05-31 23:02:33.816341|2018-05-31 23:02:33.816341
NCT01261988|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-16|2010-12-15|2010-12-17|Estimate|||||||2010-12-16|2010-12-20|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Assess the Safety and Adhesive Performance of the VIPER System When Compared to Esteem™|A Single Center, Feasibility Study Using Healthy Volunteers to Assess the Safety and Adhesive Performance of the VIPER System When Compared to the Esteem™ Cut to Fit One Piece Closed End Pouch|Completed||Phase 1|10|Anticipated|ConvaTec Inc.|||||f||||f||||||||||2018-05-31 23:02:34.216576|2018-05-31 23:02:34.216576
NCT01261975|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2011-09-21||2012-01-24|2010-12-16|2010-12-17|Estimate|2012-01-24|2012-02-27|Estimate||||2012-01-24|2012-02-27|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System|Co-Axial Micro-incision Cataract Surgery(C-MICS) Versus Standard Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System|Completed||Phase 4|36|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:02:34.314615|2018-05-31 23:02:34.314615
NCT01261962|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2010-12-16|2010-12-16|2010-12-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|August 2013|Anticipated|2013-08-31|December 2011|Anticipated|2011-12-31||Interventional|||Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer|Modulation of Immune Response by Oral Zinc Supplementation in Adjuvant Chemotherapy for Colon Cancer: a Study of Global Gene Expression and Function of Humoral Immunity and Neutrophils|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 23:02:34.827631|2018-05-31 23:02:34.827631
NCT01261949|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2016-01-07|2010-12-16|2010-12-17|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Combined Low Frequency Frontal and Temporal rTMS Treatment in Chronic Tinnitus|Effectiveness of Low Frequency Combined Frontal and Temporal Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Chronic Tinnitus|Completed||N/A|50|Actual|University of Regensburg||2|||f||||f||||||||||2018-05-31 23:02:35.068967|2018-05-31 23:02:35.068967
NCT01261936|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2010-12-16|2010-12-16|2010-12-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|||||Observational|MEVA-3||Evaluation of Menses in Congenital Bleeding Disorders|Protocol for the Determination of Menstrual Blood Losses in Women Affected by Congenital Bleeding Disorders|Unknown status|Recruiting||30|Anticipated|University of L'Aquila|||1||f||||f||||||Samples With DNA|"~     Vacuum sealed soiled pads and tampons, will be weighted and than opportunely discarghed~   "|||2018-05-31 23:02:35.381334|2018-05-31 23:02:35.381334
NCT01261923|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-01-26|2010-12-16|2010-12-17|Estimate|||||||2013-01-26|2013-01-29|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease|Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients|Completed||Phase 1/Phase 2|16|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 23:02:35.635728|2018-05-31 23:02:35.635728
NCT01253395|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|April 2006||2006-04-30|December 2010|2010-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Exercise for Fibromyalgia|Randomized Equivalency Trial of Strength Compared to Aerobic Exercise on Pain Severity in Adults With Fibromyalgia|Completed||N/A|72|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 23:05:06.861462|2018-05-31 23:05:06.861462
NCT01261910|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2014-07-25|2010-12-16|2010-12-17|Estimate|||||||2014-07-25|2014-07-28|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Enhancing Education Regarding Living Donor Transplant Among Kidney Transplant Candidates|Enhancing Education Regarding Living Donor Transplant Among Kidney Transplant Candidates|Completed||N/A|500|Actual|St. Barnabas Medical Center||2|||f||||f||||||||||2018-05-31 23:02:35.72785|2018-05-31 23:02:35.72785
NCT01261897|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2011-10-03|2010-12-16|2010-12-17|Estimate|||||||2011-10-03|2011-10-04|Estimate|January 2011||2011-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Total Knee Arthroplasty|The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Total Knee Arthroplasty|Completed||Phase 4|40|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 23:02:35.799951|2018-05-31 23:02:35.799951
NCT01261884|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2015-01-15|2010-12-16|2010-12-17|Estimate|||||||2015-01-15|2015-01-16|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||Exercise in Pregnancy for Reduction of Blood Pressure in Obese Patients|Exercise Intervention in Pregnancy for Reduction of Blood Pressure in Obese Gravidas|Completed||N/A|66|Anticipated|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 23:02:35.928072|2018-05-31 23:02:35.928072
NCT01261871|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2016-08-17|2010-12-16|2010-12-17|Estimate|||||||2016-08-17|2016-08-19|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning|Intraocular Pressure During Robotic Prostatectomy, Laparoscopic Surgery, and Open Exploratory Laparotomy|Completed|||60|Actual|United States Naval Medical Center, San Diego|||1||f||||t||||||||No||2018-05-31 23:02:36.001281|2018-05-31 23:02:36.001281
NCT01261858|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-22|2010-12-16|2010-12-17|Estimate|||||||2010-12-22|2010-12-23|Estimate|February 2011||2011-02-28|November 2010|2010-11-30|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Sternal Closure With Biologic Bone Cement in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|Reinforced Sternal Closure Using Osteoconductive Biologic Bone Cement (Kryptonite) in Patients Undergoing Coronary Artery Bypass Grafting|Unknown status|Not yet recruiting|Phase 4|64|Anticipated|National University Heart Centre, Singapore||2|||f||||f||||||||||2018-05-31 23:02:36.06019|2018-05-31 23:02:36.06019
NCT01261845|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2015-04-17|2010-12-16|2010-12-17|Estimate|||||||2015-04-17|2015-04-20|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|March 2013|Actual|2013-03-31|October 2011|Actual|2011-10-31||Observational|ECOHCARE||Ecology of Medical Care - Utilisation of Health Care in Austria|Ecology of Medical Care - Utilisation of Health Care in Austria|Completed|||3500|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 23:02:36.143693|2018-05-31 23:02:36.143693
NCT01261832|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-16|||2017-08-15|2010-12-16|2010-12-17|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2011|Actual|2011-07-31|August 2017|2017-08-31|July 13, 2018|Anticipated|2018-07-13|July 2018|Anticipated|2018-07-31||Interventional|SILOAM||Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients|Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent|Recruiting||Phase 4|951|Anticipated|Korea University Guro Hospital||3|||f||||t||||||||||2018-05-31 23:02:36.220456|2018-05-31 23:02:36.220456
NCT01261819|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2010-12-20|2010-12-16|2010-12-17|Estimate|||||||2010-12-20|2010-12-21|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||"Laparoscopic Cystoscopy Versus Traditional Cystoscopy"|"Laparoscopic Cystoscopy Versus Traditional Cystoscopy in Patients Undergoing Minimally Invasive Hysterectomy: A Prospective Comparison Study"|Completed||N/A|68|Actual|Florida Hospital||2|||f||||f||||||||||2018-05-31 23:02:36.347862|2018-05-31 23:02:36.347862
NCT01261806|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2016-12-19|2010-12-15|2010-12-16|Estimate|||||||2016-12-19|2016-12-20|Estimate|April 2010||2010-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mental Health Services for Toddlers in Foster Care|Mental Health Services for Toddlers in Foster Care|Completed||Phase 1|220|Actual|University of Delaware||2|||f||||t||||||||No||2018-05-31 23:02:36.415101|2018-05-31 23:02:36.415101
NCT01261793|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14||2016-01-12|2016-01-12|2010-12-15|2010-12-16|Estimate||||2016-01-12|2016-02-05|Estimate|2016-01-12|2016-02-05|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|EMBODY 2||Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease|Completed||Phase 3|792|Actual|UCB Pharma||3|||f||||t||||||||||2018-05-31 23:02:36.555187|2018-05-31 23:02:36.555187
NCT01261780|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2017-06-20||2017-10-06|2010-12-15|2010-12-16|Estimate|2017-10-06|2017-11-06|Actual||||2017-10-06|2017-11-06|Actual|April 2011||2011-04-30|October 2017|2017-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||MC-5A for Chemotherapy Induced Peripheral Neuropathy|Treatment of Painful Chemotherapy -Induced Peripheral Neuropathy With the MC-5A Pain Therapy Medical Device, a Randomized, Double-Blind, Sham-Controlled Clinical Trial|Completed||Phase 2|14|Actual|University of Wisconsin, Madison|The small sample size is subject to type II error. The estimated effect size for MC5A is high: the company estimates 100% of patients will respond. Thus our power calculations suggested a small sample could still detect a difference.|2|||f||||t||||||||||2018-05-31 23:02:36.88487|2018-05-31 23:02:36.88487
NCT01261767|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-02-08|2010-12-15|2010-12-16|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 2008||2008-04-30|February 2017|2017-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects|A Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Trial of Anti-IL-20 (109-0012) 100 mg/Vial in Psoriatic Subjects, Followed by an Expansion Phase|Terminated||Phase 1|55|Actual|Novo Nordisk A/S||2||"Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns~   were present"|f||||f||||||||||2018-05-31 23:02:37.367171|2018-05-31 23:02:37.367171
NCT01261754|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2015-11-23|2010-12-15|2010-12-16|Estimate|||||||2015-11-23|2015-11-25|Estimate|December 2010||2010-12-31|November 2015|2015-11-30||||February 2012|Actual|2012-02-29||Interventional|||A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers|A Phase I Study of the PK, Tissue Distribution and Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen, 99mTc-MIP-1404 and 99mTc-MIP-1405, in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers|Completed||Phase 1|16|Actual|Molecular Insight Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 23:02:37.448844|2018-05-31 23:02:37.448844
NCT01261741|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-11-26|2010-12-15|2010-12-16|Estimate|||||||2013-11-26|2013-11-27|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems|Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of 10mg Memantine in the Treatment of Memory, Concentration or Attention Problems in the Absence of Dementia|Completed||Phase 2|299|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-05-31 23:02:37.511418|2018-05-31 23:02:37.511418
NCT01261728|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2018-01-02|2010-12-15|2010-12-16|Estimate|||||||2018-01-02|2018-01-04|Actual|December 14, 2010|Actual|2010-12-14|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma|Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma|Recruiting||Phase 2|54|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:02:37.717316|2018-05-31 23:02:37.717316
NCT01261715|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-15|2010-12-15|2010-12-16|Estimate|||||||2010-12-15|2010-12-16|Estimate|January 2011||2011-01-31|October 2010|2010-10-31||||February 2012|Anticipated|2012-02-29||Interventional|||Staples Versus Dermabond for Closure of the Skin After Cesarean Section|Staples Versus Dermabond for Closure of the Skin After Cesarean Section|Unknown status|Enrolling by invitation|Phase 4|50|Actual|Meir Medical Center||1|||f||||f||||||||||2018-05-31 23:02:37.826719|2018-05-31 23:02:37.826719
NCT01261702|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-02-14|2010-12-15|2010-12-16|Estimate|||||||2013-02-14|2013-02-18|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Magnesium Infusion for Pain Relief After Thoracotomy. A Randomized Controlled Trial.|Intravenous Magnesium Infusion for Pain Relief After Thoracotomy. A Randomized Controlled Trial.|Terminated||Phase 4|32|Actual|Mahidol University||2||not include patient anymore|f||||f||||||||||2018-05-31 23:02:37.891665|2018-05-31 23:02:37.891665
NCT01261689|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2013-11-26|2010-12-15|2010-12-16|Estimate|||||||2013-11-26|2013-11-27|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|TREAT||The Randomised Epidural Analgesia in Term Delivering Women Trial (TREAT)|The Randomised Epidural Analgesia in Term Delivering Women Trial|Completed||N/A|488|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 23:02:37.968579|2018-05-31 23:02:37.968579
NCT01261676|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-10-29|2010-12-15|2010-12-16|Estimate|||||||2012-10-29|2012-10-30|Estimate|December 2010||2010-12-31|October 2012|2012-10-31||||October 2013|Anticipated|2013-10-31||Observational|SIMPLE||Current Dutch Practice on Caesarean Sections: Identification of Barriers and Facilitators for Optimal Care|Current Dutch Practice on Caesarean Sections: Identification of Barriers and Facilitators for Optimal Care.|Unknown status|Enrolling by invitation||1000|Anticipated|Maastricht University Medical Center|||2||f||||||||||||||2018-05-31 23:02:38.090559|2018-05-31 23:02:38.090559
NCT01261663|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2013-11-04|2010-12-15|2010-12-16|Estimate|||||||2013-11-04|2013-11-06|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|June 2014||2014-06-30|November 2013|Actual|2013-11-30||Observational|ACTICLAN||Impact of the Time of Oral Nutritional Supplements (ONS) Consumption on Daily Alimentary Intakes of Malnourished Elderly|Impact of the Time of Oral Nutritional Supplements (ONS) Consumption on Daily Alimentary Intakes of Malnourished Elderly Subjects Hospitalized in Long Term Care Unit (LTCU)|Completed|||48|Anticipated|University Hospital, Limoges|||1||f||||f||||||||||2018-05-31 23:02:38.186968|2018-05-31 23:02:38.186968
NCT01261650|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2014-07-02|2010-12-15|2010-12-16|Estimate|||||||2014-07-02|2014-07-03|Estimate|December 2010||2010-12-31|July 2014|2014-07-31||||||||Interventional|||Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome|Influence of Transcranial Direct Current Stimulation of the Primary Motor Cortex on Pain Sensation in Patients Suffering From Fibromyalgia Syndrome|Terminated||Phase 4|50|Anticipated|Karl Landsteiner Institute of Remobilization and Functional Health||2||There could not be enough patients recruited|f||||t||||||||||2018-05-31 23:02:38.263943|2018-05-31 23:02:38.263943
NCT01261637|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-05-22|2010-12-15|2010-12-16|Estimate|||||||2013-05-22|2013-05-23|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Abdominal Wall Local Anesthesia to Maximize Postoperative Pain Control After Cesarean Delivery|Ultrasound Guided 0.25% Ropivacaine Transversus Abdominis Plane Block in Addition to Intrathecal Morphine and Multimodal Analgesia for the Management of Postoperative Pain Among Women Undergoing Cesarean Delivery.|Completed||Phase 4|86|Actual|IWK Health Centre||2|||f||||t||||||||||2018-05-31 23:02:38.349874|2018-05-31 23:02:38.349874
NCT01261624|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2014-01-14||2014-03-11|2010-12-15|2010-12-16|Estimate|2014-03-11|2014-04-16|Estimate||||2014-03-11|2014-04-16|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis|A Multicenter, Open Label, Dose Finding Study to Evaluate Efficacy and Safety of Givinostat Administered in Two Different Doses in Patients With Poly JIA Not Adequately Responding to the Standard Treatment.|Terminated||Phase 2|16|Actual|Italfarmaco||2||"The primary reason for the decision to discontinue the study is lack of enrolment; this~   decision is not related to any tolerability concerns with Givinostat"|f||||f||||||||||2018-05-31 23:02:38.45482|2018-05-31 23:02:38.45482
NCT01261611|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2014-02-27|2010-12-15|2010-12-16|Estimate|||||||2014-02-27|2014-02-28|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia|A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short Term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport® and Dysport RU®) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport RU® Following Repeated Treatments of Subjects With Cervical Dystonia|Completed||Phase 3|333|Actual|Ipsen||3|||f||||f||||||||||2018-05-31 23:02:39.138623|2018-05-31 23:02:39.138623
NCT01261598|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2016-10-14|2010-12-15|2010-12-16|Estimate|||||||2016-10-14|2016-10-17|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|RTEP2||Predictive Value of FDG-TEP During Radiotherapy or Chemo-radiotherapy in Patients With NCSC on the One-year Survival|Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival|Completed||N/A|98|Actual|Centre Henri Becquerel||2|||f||||t||||||||No||2018-05-31 23:02:39.285105|2018-05-31 23:02:39.285105
NCT01261039|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-03-15|2010-12-15|2010-12-16|Estimate|||||||2012-03-15|2012-03-16|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Production of Vitamin D Metabolites by UV-radiation From Solar Bed|Production of Vitamin D Metabolites by UV-radiation From Solar Bed|Completed||N/A|20|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 23:02:47.258139|2018-05-31 23:02:47.258139
NCT01261585|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-15|2010-12-15|2010-12-16|Estimate|||||||2010-12-15|2010-12-16|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|RTEP4||Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT|Study of the Modification of the Fixation of FDG, F-Miso and FLT Measured in PET/CT at Patients Before and in the Course of Exclusive Radiotherapy or Concomitant Radiochemotherapy for Primitive Bronchial Cancer|Completed|||5|Actual|Centre Henri Becquerel|||||f||||t||||||||||2018-05-31 23:02:39.345862|2018-05-31 23:02:39.345862
NCT01261572|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2013-07-08|2010-12-15|2010-12-16|Estimate|||||||2013-07-08|2013-07-10|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study to Find Maintenance Dose for Periodic Administration of ASP3550|Phase II Study of ASP3550 - A Maintenance-dose Finding Study for Periodic Dosage Regimen in Patients With Prostate Cancer -|Completed||Phase 2|155|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-05-31 23:02:39.399138|2018-05-31 23:02:39.399138
NCT01261559|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2013-06-18||2017-11-01|2010-12-14|2010-12-16|Estimate|2013-08-30|2013-11-05|Estimate||||2017-11-01|2017-12-06|Actual|December 2010||2010-12-31|November 2017|2017-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Chrysalis||Breast Displacement and CT Radiation Dose|Effect of Displacement During Computed Tomography on Breast Radiation Dose and Image Quality|Completed||N/A|72|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:02:39.474474|2018-05-31 23:02:39.474474
NCT01261546|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-05-29|2010-12-15|2010-12-16|Estimate|||||||2015-05-29|2015-06-01|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CORTEEC||Clinical Trial Corticoids For Empyema And Pleural Effusion In Children|MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN|Completed||Phase 2|60|Actual|Hospital Infanta Sofia||2|||f||||t||||||||||2018-05-31 23:02:39.690879|2018-05-31 23:02:39.690879
NCT01261533|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-05-22|2010-12-15|2010-12-16|Estimate|||||||2013-05-22|2013-05-23|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment|The Multi-center Exploratory Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment|Unknown status|Recruiting|Phase 1|122|Anticipated|GuangZhou WeiShiBo Biotechnology Co., ltd||1|||f||||t||||||||||2018-05-31 23:02:39.759029|2018-05-31 23:02:39.759029
NCT01261520|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-04-23|2010-12-15|2010-12-16|Estimate|||||||2012-04-23|2012-04-24|Estimate|July 2005||2005-07-31|April 2012|2012-04-30||||August 2009|Actual|2009-08-31||Interventional|||Chinese Women and Mammography Screening|Promoting Adherence to Mammography Use in Chinese Women|Completed||Phase 3|671|Actual|Georgetown University||1|||f||||f||||||||||2018-05-31 23:02:39.833611|2018-05-31 23:02:39.833611
NCT01261507|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2013-04-05||2015-11-04|2010-12-15|2010-12-16|Estimate|2014-06-18|2014-07-17|Estimate||||2015-11-04|2015-12-01|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Reader Study of DeltaView™ Chest Radiograph Software|Reader Study to Demonstrate That Use of DeltaView™ is Superior to the Use Standard Prior and Current Antero/Posterior (AP/PA) X-ray Image Pair|Completed|||15|Actual|Georgetown University|The main limitation is that the experimental format for this study is similar to, but not identical to the clinical pattern of practice in that more data is recorded during the study than would normally be gathered in clinical practice||||f||||f||||||||||2018-05-31 23:02:39.973259|2018-05-31 23:02:39.973259
NCT01261494|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-07-12|2010-12-15|2010-12-16|Estimate|||||||2011-07-12|2011-07-13|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus|A Pilot Study to Evaluate the Efficacy and Safety of GFT505 (80mg) Orally Administered Once Daily for 12 Weeks in Patients With Type 2 Diabetes Mellitus. A Multicentre, Randomised, Double Blind, Placebo-Controlled Study.|Completed||Phase 2|97|Actual|Genfit||2|||f||||f||||||||||2018-05-31 23:02:40.151926|2018-05-31 23:02:40.151926
NCT01261481|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-12-06|2010-12-14|2010-12-16|Estimate|||||||2012-12-06|2012-12-07|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact|Comparison of the Relative Oral Bioavailability of Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact|Completed||Phase 1|29|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 23:02:40.256271|2018-05-31 23:02:40.256271
NCT01261468|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-03-14|2010-12-15|2010-12-16|Estimate|||||||2012-03-14|2012-03-15|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Treatment With Spinal Cord Stimulation: Effect on Sensory Parameters|Treatment With Spinal Cord Stimulation: Effect on Sensory Parameters|Completed||N/A|15|Actual|Danish Pain Research Center||2|||f||||t||||||||||2018-05-31 23:02:40.332332|2018-05-31 23:02:40.332332
NCT01261455|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-12-14|2010-12-14|2010-12-16|Estimate|||||||2010-12-14|2010-12-16|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia|Prospective Randomized Pilot Study Comparing the Surgical Times Between Inferior Versus Superior Conjunctival Autografts for Primary Pterygia|Unknown status|Recruiting|N/A|40|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 23:02:40.403953|2018-05-31 23:02:40.403953
NCT01261442|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-04-25|2010-12-14|2010-12-16|Estimate|||||||2012-04-25|2012-04-26|Estimate|January 2011||2011-01-31|June 2010|2010-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Can Ultrasound Detect Diabetic Peripheral Neuropathy?|Can Ultrasound Detect Diabetic Peripheral Neuropathy?|Completed|||100|Actual|University Health Network, Toronto|||2||f||||t||||||||||2018-05-31 23:02:40.48543|2018-05-31 23:02:40.48543
NCT01261429|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2013-04-15|2010-12-15|2010-12-16|Estimate|||||||2013-04-15|2013-04-16|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)|Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)|Completed||Phase 2|50|Actual|Centre Leon Berard||1|||f||||t||||||||||2018-05-31 23:02:40.557936|2018-05-31 23:02:40.557936
NCT01261416|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-15|2010-12-15|2010-12-16|Estimate|||||||2010-12-15|2010-12-16|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Pharmacokinetics of Levetiracetam (Keppra) in Neonates|Pharmacokinetics and Safety of IV Levetiracetam (Keppra) in Full Term and Preterm Neonates|Completed|||18|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-05-31 23:02:40.68337|2018-05-31 23:02:40.68337
NCT01261403|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15||2013-08-13|2018-02-28|2010-12-15|2010-12-16|Estimate||||2013-08-13|2013-08-22|Estimate|2018-02-28|2018-03-02|Actual|December 2010||2010-12-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|February 2012|Actual|2012-02-29||Interventional|||Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis|A Phase 2, Randomized, Double- Blind, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Active Rheumatoid Arthritis|Terminated||Phase 2|26|Actual|Celularity Incorporated||3||Enrollment terminated pending additional Phase 1 data|f||||t||||||||||2018-05-31 23:02:40.75326|2018-05-31 23:02:40.75326
NCT01261390|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2015-08-19||2017-04-18|2010-12-15|2010-12-16|Estimate|2017-04-18|2017-05-30|Actual||||2017-04-18|2017-05-30|Actual|March 2011||2011-03-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BestAIR|If were not able to collect data from a participant (24-hour blood pressure monitor, echocardiogram, questionnaires, etc), we did not included them in the Baseline Analysis for that measure. This will result in different n-values for each arm.|Sleep Apnea Intervention for Cardiovascular Disease Reduction|A Planning Study: Sleep Apnea Intervention for Cardiovascular Disease Reduction|Completed||N/A|169|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 23:02:40.901489|2018-05-31 23:02:40.901489
NCT01261377|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2017-01-11|2010-12-15|2010-12-16|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)|Comparison of Effects of Bi-level Positive Airway Pressure Therapy and Nocturnal Oxygen Therapy on Right and Left Ventricular Hemodynamics in Overlap Syndrome (Co-existent Chronic Obstructive Airway Disease and Obstructive Sleep Apnea)|Withdrawn||Phase 1/Phase 2|0|Actual|Brigham and Women's Hospital||3||the fellow interested in this project left the institution|f||||t||||||||No|nothing to include|2018-05-31 23:02:42.751845|2018-05-31 23:02:42.751845
NCT01261364|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2015-12-02|2010-12-15|2010-12-16|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||Pharmacogenetic-Directed Treatment for Major Depression|The Evaluation of the Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting:A Randomized Double Blind Pilot Study|Completed||N/A|50|Actual|Assurex Health Inc.||2|||f||||t||||||||||2018-05-31 23:02:42.811697|2018-05-31 23:02:42.811697
NCT01261351|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2014-12-17|2010-12-14|2010-12-16|Estimate|||||||2014-12-17|2014-12-18|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|PRESTIGE||Study of Coagulation Activation Markers and Pre Eclampsia|Coagulation Activation Markers and Pre Eclampsia : Correlation With Complications|Completed|||300|Actual|University Hospital, Lille|||||f||||t||||||Samples With DNA|"~     -  Maternal blood and urine~        -  cord blood~   "|||2018-05-31 23:02:42.958304|2018-05-31 23:02:42.958304
NCT01261338|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-10-22|2010-12-15|2010-12-16|Estimate|||||||2012-10-22|2012-10-23|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|October 2012|Anticipated|2012-10-31|April 2012|Actual|2012-04-30||Interventional|PCBs||Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama|Intervention to Reduce Body Burdens of PCBs in Residents of Anniston, Alabama|Unknown status|Active, not recruiting|N/A|28|Anticipated|University of Cincinnati||1|||f||||f||||||||||2018-05-31 23:02:43.04656|2018-05-31 23:02:43.04656
NCT01261325|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2016-03-14|2015-04-27|2018-04-23|2010-12-15|2010-12-16|Estimate|2016-07-04|2016-08-15|Estimate|2015-04-27|2015-05-15|Estimate|2018-04-23|2018-05-22|Actual|December 2010||2010-12-31|December 2017|2017-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|BRITE|Baseline Characteristics consist of the Randomized Set (RS). The RS includes all subjects that were randomized.|Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures|Completed||Phase 3|768|Actual|UCB Pharma||3|||f||||f||||||||||2018-05-31 23:02:43.211802|2018-05-31 23:02:43.211802
NCT01261312|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2017-12-22|2010-12-15|2010-12-16|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2010||2010-12-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)|A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)|Active, not recruiting||Phase 1/Phase 2|300|Anticipated|Astex Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:02:44.176635|2018-05-31 23:02:44.176635
NCT01261299|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2018-01-05|2010-12-15|2010-12-16|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2010|Actual|2010-12-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer|A Phase 0 Clinical Trial of Microdosing Carboplatin and Molecular Profiling for Chemoresistance|Terminated||Early Phase 1|21|Actual|University of California, Davis||1||Contract ended|f||||t|t|f||||||||2018-05-31 23:02:44.264766|2018-05-31 23:02:44.264766
NCT01261286|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-14|2010-12-14|2010-12-16|Estimate|||||||2010-12-14|2010-12-16|Estimate||||December 2010|2010-12-31||||||||Interventional|||Drug-Disease Interaction in Crohn's Disease|Pharmacodynamics and Pharmacokinetics of Verapamil in Crohn's Disease Patients|Completed||Phase 1|||University of Alberta|||||f||||f||||||||||2018-05-31 23:02:44.326083|2018-05-31 23:02:44.326083
NCT01261273|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2016-07-03|2010-12-14|2010-12-16|Estimate|||||||2016-07-03|2016-07-06|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|e-NOBORI||e-NOBORI Observational Registry of Nobori DES|Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients|Active, not recruiting|||18000|Actual|Terumo Europe N.V.|||14||f||||t||||||||||2018-05-31 23:02:44.425291|2018-05-31 23:02:44.425291
NCT01261260|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-14|2010-12-14|2010-12-16|Estimate|||||||2010-12-14|2010-12-16|Estimate|November 2006||2006-11-30|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Uridine-GABA||Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers|The Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers|Completed||Phase 1|33|Actual|Mclean Hospital||1|||f||||f||||||||||2018-05-31 23:02:44.77755|2018-05-31 23:02:44.77755
NCT01261247|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2018-04-19||2018-04-19|2010-12-14|2010-12-16|Estimate|2018-04-19|2018-05-17|Actual||||2018-04-19|2018-05-17|Actual|January 2011||2011-01-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|May 9, 2016|Actual|2016-05-09||Interventional||Baseline characteristics are summarized for patients who completed the study.|Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|Active, not recruiting||Phase 2|41|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 23:02:45.817108|2018-05-31 23:02:45.817108
NCT01261234|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-11|||2018-03-05|2010-12-15|2010-12-16|Estimate|||||||2018-03-05|2018-03-07|Actual|December 2010|Actual|2010-12-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2017|Actual|2017-03-31||Interventional|CAS-CARE||Carotid Artery Stenting With Cilostazol Addition for Restenosis|Effect of Cilostazol on In-stent Restenosis After Carotid Artery Stenting; Multi-center, Prospective, Randomized, Open-label Blind-endpoint Trial|Active, not recruiting||Phase 4|900|Anticipated|Kobe City General Hospital||2|||f||||t||||||||||2018-05-31 23:02:46.067086|2018-05-31 23:02:46.067086
NCT01261221|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-05-21|2010-12-15|2010-12-16|Estimate|||||||2012-05-21|2012-05-23|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans||Completed|||137|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||t||||||||||2018-05-31 23:02:46.139591|2018-05-31 23:02:46.139591
NCT01261208|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2017-02-28|2010-12-14|2010-12-16|Estimate|||||||2017-02-28|2017-03-03|Actual|May 2010||2010-05-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|May 2010|Actual|2010-05-31||Observational|||The Study of the Prevalence of Helicobacter Pylori Infection Among HIV/AIDS Cohort|The Study of the Prevalence of Helicobacter Pylori Infection Among HIV/AIDS Cohort|Recruiting|||200|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-05-31 23:02:46.185447|2018-05-31 23:02:46.185447
NCT01261195|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-08-16|2010-12-14|2010-12-16|Estimate|||||||2011-08-16|2011-08-17|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Establishment of Vascular Permeability Model for Research Purpose by Human Umbilical Vascular Endothelial Cells|Establishment of Vascular Permeability Model for Research Purpose by Human|Unknown status|Recruiting||60|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||t||||||Samples With DNA|"~     the umbilical cord~   "|||2018-05-31 23:02:46.251289|2018-05-31 23:02:46.251289
NCT01261182|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-14|2010-12-14|2010-12-16|Estimate|||||||2010-12-14|2010-12-16|Estimate||||December 2010|2010-12-31||||||||Interventional|||Targeting School Feeding Programs at Vulnerable Sub-Groups|Study of School Feeding Programs' Impact on Anemia Status in Pre-adolescent Girls and Other Vulnerable Household Members in a Cluster-Randomized Trial in Uganda|Completed||N/A|2083|Actual|International Food Policy Research Institute||3|||f||||f||||||||||2018-05-31 23:02:46.398006|2018-05-31 23:02:46.398006
NCT01261169|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-14|2010-12-14|2010-12-16|Estimate|||||||2010-12-14|2010-12-16|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|||||Observational|||Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study|Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study|Unknown status|Recruiting||40|Anticipated|Genovate Biotechnology Co., Ltd.,|||1||f||||f||||||||||2018-05-31 23:02:46.473299|2018-05-31 23:02:46.473299
NCT01261156|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2014-07-10|2010-12-14|2010-12-16|Estimate|||||||2014-07-10|2014-07-11|Estimate|October 2010||2010-10-31|July 2014|2014-07-31||||December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects|An Open-label, Single-Sequence Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/A5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and Its Metabolites in Healthy Subjects|Completed||Phase 1|24|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 23:02:46.545139|2018-05-31 23:02:46.545139
NCT01261143|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2012-04-24|2010-12-14|2010-12-16|Estimate|||||||2012-04-24|2012-04-25|Estimate|August 2010||2010-08-31|October 2011|2011-10-31||||April 2012|Actual|2012-04-30||Interventional|||Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy|Phase III Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy|Completed||Phase 3|164|Anticipated|Bukwang Pharmaceutical||2|||f||||||||||||||2018-05-31 23:02:46.614172|2018-05-31 23:02:46.614172
NCT01261130|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-05-30|2010-12-15|2010-12-16|Estimate|||||||2017-05-30|2017-05-31|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults|Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With or Without GLA-AF in Brazilian Adults|Completed||Phase 1|102|Actual|Baylor College of Medicine||13|||f||||t||||||||||2018-05-31 23:02:46.687949|2018-05-31 23:02:46.687949
NCT01261117|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-08-08|2010-12-15|2010-12-16|Estimate|||||||2011-08-08|2011-08-09|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants|Oral Versus Intravenous Ibuprofen Treatment|Completed||N/A|70|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 23:02:46.789278|2018-05-31 23:02:46.789278
NCT01261104|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-15|2010-12-15|2010-12-16|Estimate|||||||2010-12-15|2010-12-16|Estimate|April 2010||2010-04-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||Relationship Between Hearing Thresholds, Handicap and Time for Treatment-seeking|Relationship Between Hearing Thresholds, Handicap and Time for Treatment-seeking in a Public Hearing Healthcare Service|Completed|||||University of Sao Paulo|||2||f||||t||||||||||2018-05-31 23:02:46.865246|2018-05-31 23:02:46.865246
NCT01261091|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2014-04-23|2010-12-15|2010-12-16|Estimate|||||||2014-04-23|2014-04-24|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|SETPOINT||Early Tracheostomy in Ventilated Stroke Patients|Stroke-Related Early Tracheostomy vs. Prolonged Orotracheal Intubation in Neurocritical Care Trial|Completed||N/A|60|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 23:02:46.922778|2018-05-31 23:02:46.922778
NCT01261078|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2011-07-19|2010-12-15|2010-12-16|Estimate|||||||2011-07-19|2011-07-20|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Bupivacaine Dose Sparing Effect of Intrathecal Epinephrine|The Bupivacaine Dose Sparing Effect of Intrathecal Epinephrine for Spinal Anesthesia in Total Knee Replacement Arthroplasty|Completed||N/A|75|Anticipated|Seoul Medical Center||5|||f||||f||||||||||2018-05-31 23:02:46.992613|2018-05-31 23:02:46.992613
NCT01261065|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-15|2010-12-15|2010-12-16|Estimate|||||||2010-12-15|2010-12-16|Estimate|December 2001||2001-12-31|December 2010|2010-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure|Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure|Completed||Phase 4|55|Actual|Michael Debakey Veterans Affairs Medical Center|||||f||||f||||||||||2018-05-31 23:02:47.060836|2018-05-31 23:02:47.060836
NCT01261052|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2012-10-02||2012-11-29|2010-12-15|2010-12-16|Estimate|2012-10-30|2012-11-29|Estimate||||2012-11-29|2012-12-03|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Real-time Adaptation to Changes in Insulin Sensitivity|Sensor-Controlled Insulin and Glucagon Delivery in Subjects With Type 1 Diabetes: Real-time Adaptation to Changes in Insulin Sensitivity|Completed||Phase 2|14|Actual|Legacy Health System||2|||f||||f||||||||||2018-05-31 23:02:47.129536|2018-05-31 23:02:47.129536
NCT01261026|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2010-12-15|2010-12-15|2010-12-16|Estimate|||||||2010-12-15|2010-12-16|Estimate||||December 2007|2007-12-31||||||||Observational|UNIFESP||Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?|Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?|Completed|||||Federal University of São Paulo|||2||f||||||||||||||2018-05-31 23:02:47.310082|2018-05-31 23:02:47.310082
NCT01261013|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-23|2010-12-15|2010-12-16|Estimate|||||||2010-12-23|2010-12-27|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|March 2010||2010-03-31|||||Observational|||Intrastromal Corneal Ring Segment Implantation in 219 Keratoconic Eyes at Different Stages|Intrastromal Corneal Ring Segment Implantation in 219 Keratoconic Eyes at Different Stages|Completed|||219|Actual|Fernandez-Vega Ophthalmological Institute|||3||f||||t||||||||||2018-05-31 23:02:47.386732|2018-05-31 23:02:47.386732
NCT01261000|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|2017-04-18||2017-07-23|2010-12-15|2010-12-16|Estimate|2017-07-23|2017-08-22|Actual||||2017-07-23|2017-08-22|Actual|November 2010||2010-11-30|July 2017|2017-07-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Tissue Biomarker for Pegvisomant Action|Tissue Biomarker for Pegvisomant Action|Completed||N/A|8|Actual|Cedars-Sinai Medical Center|Small sample size due to rare patient population|1|||f||||f||||||||||2018-05-31 23:02:47.497927|2018-05-31 23:02:47.497927
NCT01260987|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2015-07-29|2010-12-15|2010-12-16|Estimate|||||||2015-07-29|2015-07-30|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Fractional CO2 Laser Assisted Photodynamic Therapy|Conventional Versus Fractional CO2 Laser Assisted Photodynamic Therapy for Basal Call Carcinomas and Actinic Keratoses|Completed||Phase 2/Phase 3|47|Actual|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 23:02:47.628944|2018-05-31 23:02:47.628944
NCT01260974|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-15|||2012-07-17|2010-12-15|2010-12-16|Estimate|||||||2012-07-17|2012-07-18|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|CPHRLTX||Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients|Pilot Study: Efficacy of Caspofungin for Antifungal Prophylaxis for Selected High Risk Liver Transplant Patients|Unknown status|Recruiting|Phase 2|38|Anticipated|Azienda Ospedaliera di Padova||1|||f||||t||||||||||2018-05-31 23:02:47.720609|2018-05-31 23:02:47.720609
NCT01260961|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2016-11-28|2010-12-14|2010-12-15|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|November 2013|Actual|2013-11-30||Interventional|||Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial|Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial|Active, not recruiting||N/A|132|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 23:02:47.842447|2018-05-31 23:02:47.842447
NCT01260948|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2011-01-24||2011-01-24|2010-12-14|2010-12-15|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|April 2006||2006-04-30|January 2011|2011-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions.|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:02:47.928706|2018-05-31 23:02:47.928706
NCT01260935|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-01-16|2010-12-14|2010-12-15|Estimate|||||||2012-01-16|2012-01-18|Estimate|November 2002||2002-11-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures|A Prospective Randomized Single-Blinded Multi-Institutional Study Comparing the Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures|Completed||N/A|121|Actual|Swedish Medical Center||2|||f||||f||||||||||2018-05-31 23:02:48.208533|2018-05-31 23:02:48.208533
NCT01260922|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2011-01-24||2011-01-24|2010-12-14|2010-12-15|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|April 2006||2006-04-30|January 2011|2011-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.|A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:02:48.2915|2018-05-31 23:02:48.2915
NCT01260909|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-11-29|2010-12-14|2010-12-15|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2014||2014-01-31|November 2017|2017-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Real-Time MV/kV Image Guided Radiation Therapy|Real-Time MV/kV Image Guided Radiation Therapy|Withdrawn|||0|Actual|Stanford University|||1|Business decision|f||||t||||||||||2018-05-31 23:02:48.545759|2018-05-31 23:02:48.545759
NCT01260896|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2011-01-24||2011-01-24|2010-12-14|2010-12-15|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|September 2002||2002-09-30|January 2011|2011-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsule in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:02:48.616564|2018-05-31 23:02:48.616564
NCT01260883|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2011-07-20||2013-06-04|2010-12-14|2010-12-15|Estimate|2012-08-07|2012-08-08|Estimate||||2013-06-04|2013-06-13|Estimate|May 2000||2000-05-31|June 2013|2013-06-30|December 2010|Actual|2010-12-31|March 2008|Actual|2008-03-31||Interventional|||Ketorolac in Postoperative Infants: Pharmacokinetics and Safety|Ketorolac in Postoperative Infants: Pharmacokinetics and Safety|Completed||Phase 3|77|Actual|Seattle Children's Hospital||3|||f||||t||||||||||2018-05-31 23:02:48.908345|2018-05-31 23:02:48.908345
NCT01260870|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13||2015-06-05|2015-06-05|2010-12-14|2010-12-15|Estimate||||2015-06-05|2015-07-03|Estimate|2015-06-05|2015-07-03|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)|European Study of POBA Versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia|Terminated||Phase 2|44|Actual|Bayer||2||Bayer terminated the program and sold the IP to Medronic|f||||t||||||||||2018-05-31 23:02:49.293455|2018-05-31 23:02:49.293455
NCT01260857|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2013-05-13|2010-12-14|2010-12-15|Estimate|||||||2013-05-13|2013-05-14|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension|An Open Label, Observational, Post Marketing Surveillance Study To Assess The Safety And Efficacy Of The Spironolactone Plus Hydroflumethiazide (Aldazide) In The Treatment Of Filipino Patients With Stage 1 To 2 Hypertension|Withdrawn|||0|Actual|Pfizer|||||f||||f||||||||||2018-05-31 23:02:49.429905|2018-05-31 23:02:49.429905
NCT01260844|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-10-19|2010-12-14|2010-12-15|Estimate|||||||2011-10-19|2011-10-21|Estimate|April 2011||2011-04-30|May 2011|2011-05-31||||||||Interventional|||Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.|An Open-Label Study to Evaluate the Effect of a Single Dose of Briakinumab on the Pharmacokinetics of Single Doses of Caffeine, Tolbutamide, Omeprazole, Metroprolol, and Midazolam in Subjects With Moderate to Severe Psoriasis|Withdrawn||Phase 1|12|Anticipated|Abbott||1||Study stopped|f||||f||||||||||2018-05-31 23:02:49.497132|2018-05-31 23:02:49.497132
NCT01260831|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-06-20|2010-12-14|2010-12-15|Estimate|||||||2017-06-20|2017-06-21|Actual|January 2011||2011-01-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EPOCH||Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)|Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH): a Cluster Randomized Trial of the Bedside Paediatric Early Warning System|Completed||Phase 2|144539|Actual|The Hospital for Sick Children||2|||f||||t||||||||No||2018-05-31 23:02:49.574379|2018-05-31 23:02:49.574379
NCT01260818|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-11-30|2010-12-14|2010-12-15|Estimate|||||||2011-11-30|2011-12-01|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||December 2011|Anticipated|2011-12-31||Interventional|||Topical Application of Tranexamic Acid Reduces Postoperative Blood Loss in Total Hip Arthroplasty|Prospective Randomized Trial Comparing Topical Tranexamic Acid Plus Standard Of Care Versus Standard Of Care For The Reduction Of Blood Loss Following Primary Total Hip Arthroplasty Surgery|Unknown status|Recruiting|N/A|100|Anticipated|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 23:02:49.681971|2018-05-31 23:02:49.681971
NCT01260805|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-02-18|2010-12-14|2010-12-15|Estimate|||||||2011-02-18|2011-02-21|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.|A Phase I, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Bioequivalence Of Ethinylestradiol + Gestodene - Harmonet 0,02mg + 0,075mg (Laboratórios Pfizer Ltda.) In The Sugar Coated Tablets Form, Versus Femiane® 0,02mg + 0,075mg (Schering Do Brasil Química E Farmacêutica Ltda.), In The Sugar Coated Tablets Form, Under Fasted Conditions In Female And Healthy Volunteers.|Completed||Phase 1|32|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 23:02:49.766249|2018-05-31 23:02:49.766249
NCT01260792|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-03-23|2010-12-14|2010-12-15|Estimate|||||||2012-03-23|2012-03-26|Estimate|February 2010||2010-02-28|September 2009|2009-09-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Observational|ChiP-ARD||Children and Parents With ADHD and Related Disorders|Validation and Norms for Attention Deficit/Hyperactivity Disorder Scales in Children and Adults. Description of Associated Factors.|Completed|||2600|Actual|Centre Hospitalier Universitaire de Nice|||2||f||||f||||||||||2018-05-31 23:02:49.848937|2018-05-31 23:02:49.848937
NCT01260779|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2016-07-08|2010-12-13|2010-12-15|Estimate|||||||2016-07-08|2016-07-11|Estimate||||July 2016|2016-07-31||||||||Expanded Access|||Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors|Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration|No longer available|||||Provectus Pharmaceuticals|||||||||||||||||||2018-05-31 23:02:49.9074|2018-05-31 23:02:49.9074
NCT01260766|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-16|2010-12-14|2010-12-15|Estimate|||||||2010-12-16|2010-12-17|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Acne Treatment With Active Oplon's Patches - 15-18 Years Old|Phase II- Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Oplon-Pure Science Ltd.||2|||f||||t||||||||||2018-05-31 23:02:49.960071|2018-05-31 23:02:49.960071
NCT01260753|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-04-14|2010-12-14|2010-12-15|Estimate|||||||2011-04-14|2011-04-15|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge|Double Blind Randomised Placebo and Active Controlled, Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge to Allergic Patients Otherwise Healthy|Completed||Phase 2|24|Anticipated|Palau Pharma S.A.||3|||f||||||||||||||2018-05-31 23:02:50.034086|2018-05-31 23:02:50.034086
NCT01260740|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-10-05|2010-12-14|2010-12-15|Estimate|||||||2017-10-05|2017-10-06|Actual|December 7, 2010||2010-12-07|June 23, 2017|2017-06-23|June 23, 2017||2017-06-23|||||Observational|||The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans|The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans|Terminated|||174|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:02:50.102108|2018-05-31 23:02:50.102108
NCT01260727|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2015-08-27|2010-12-14|2010-12-15|Estimate|||||||2015-08-27|2015-08-28|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Interventional|||Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults|A Phase I Study of the Safety and Immunogenicity of PENNVAX-G DNA (ENV & GAG) Administered by Intramuscular Biojector 2000 or CELLECTRA Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 ENV/CM240 GAG/POL) Boost in Healthy, HIV Uninfected Adults|Completed||Phase 1|92|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 23:02:50.161387|2018-05-31 23:02:50.161387
NCT01260714|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2015-08-18|2010-12-14|2010-12-15|Estimate|||||||2015-08-18|2015-08-20|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia|A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥ 60 With Poor Prognosis Acute Myeloid Leukemia (AML)|Terminated||Phase 1|13|Actual|National Cancer Institute (NCI)||1||Inadequate accrual rate|f||||t||||||||||2018-05-31 23:02:50.245101|2018-05-31 23:02:50.245101
NCT01260701|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2014-07-07||2015-12-14|2010-12-14|2010-12-15|Estimate|2014-07-07|2014-08-04|Estimate||||2015-12-14|2016-01-18|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Interventional||Eligible patients who began protocol therapy.|Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer|A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer|Completed||Phase 2|75|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:02:50.379752|2018-05-31 23:02:50.379752
NCT01260532|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-13|2010-12-13|2010-12-15|Estimate|||||||2010-12-13|2010-12-15|Estimate|July 2009||2009-07-31|December 2010|2010-12-31|June 2019|Anticipated|2019-06-30|||||Observational|||The Association of Costimulatory Molecules and PPAR-polymorphisms With Autoimmune Thyroid Disease in Taiwan|The Association of Costimulatory Molecules and PPAR-polymorphisms With Autoimmune Thyroid Disease in Taiwan|Enrolling by invitation|||300|Anticipated|Taipei Medical University WanFang Hospital|||3||f||||f||||||||||2018-05-31 23:02:54.139178|2018-05-31 23:02:54.139178
NCT01260688|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|2013-10-07||2018-04-17|2010-12-14|2010-12-15|Estimate|2013-10-07|2013-12-05|Estimate||||2018-04-17|2018-05-16|Actual|October 2010||2010-10-31|April 2018|2018-04-30|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional|||Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel|A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)|Clinical development discontinuation of Cediranib leading to small numbers of subjects analyzed.|2|||f||||f||||||||||2018-05-31 23:02:51.073114|2018-05-31 23:02:51.073114
NCT01260675|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-06-21|2010-12-14|2010-12-15|Estimate|||||||2017-06-21|2017-06-23|Actual|December 2010||2010-12-31|June 2017|2017-06-30|January 31, 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone|A Study to Assess the Pharmacokinetic Profile of an Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8mg/2mg Capsules Relative to the Pharmacokinetic Profile of Suboxone® (Buprenorphine HCl/Naloxone HCl 8mg/2mg Sublingual Tablets).|Completed|||12|Actual|NanoSHIFT LLC|||2||f||||f||||||||||2018-05-31 23:02:51.795836|2018-05-31 23:02:51.795836
NCT01260662|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|2015-04-10||2015-06-15|2010-12-14|2010-12-15|Estimate|2015-04-10|2015-04-29|Estimate||||2015-06-15|2015-07-14|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Baseline Participants include any individual who received drug and underwent procedural sedation.|Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation|Randomized Blinded Three Arm Trial of Propofol, 1:1 Combination of Propofol and Ketamine, and 4:1 Combination of Propofol and Ketamine for Procedural Sedation in the Emergency Department|Completed||Phase 4|271|Actual|Minneapolis Medical Research Foundation||3|||f||||f||||||||||2018-05-31 23:02:51.882612|2018-05-31 23:02:51.882612
NCT01260649|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2017-03-03||2017-04-18|2010-12-14|2010-12-15|Estimate|2017-03-03|2017-04-14|Actual||||2017-04-18|2017-05-22|Actual|November 1, 2010|Actual|2010-11-01|April 2017|2017-04-30|November 1, 2012|Actual|2012-11-01|October 26, 2012|Actual|2012-10-26||Interventional|||N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression||Terminated||Phase 4|17|Actual|Massachusetts General Hospital||2||lack of funding to cover staff salary (clinician and research coordinator)|f||||f||||||||||2018-05-31 23:02:52.138782|2018-05-31 23:02:52.138782
NCT01260636|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2012-01-04|2010-12-13|2010-12-15|Estimate|||||||2012-01-04|2012-01-05|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|VALUE||Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries|A Phase III, Comparative Multi-center Randomized Double-blind, Crossover Study of the Safety, Tolerability and Diagnostic Efficacy of Gadobenate Dimeglumine and Gadopentetate Dimeglumine in Magnetic Resonance Angiography of the Carotid, Renal/Abdominal and Peripheral Arteries|Completed||Phase 3|120|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-05-31 23:02:52.365554|2018-05-31 23:02:52.365554
NCT01260623|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-08-25|2010-12-14|2010-12-15|Estimate|||||||2017-08-25|2017-08-28|Actual|September 9, 2009|Actual|2009-09-09|August 2017|2017-08-31|May 31, 2013|Actual|2013-05-31|May 31, 2013|Actual|2013-05-31||Observational|||Pilot Study of How Children With Asthma Exacerbations Metabolize Prednisone|In Vivo Prednisolone/Prednisone Pharmacokinetic Pilot Study in Children With Asthma Exacerbations|Completed|||20|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-05-31 23:02:52.418599|2018-05-31 23:02:52.418599
NCT01260610|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2015-06-15|2010-12-14|2010-12-15|Estimate|||||||2015-06-15|2015-06-16|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients|An Exploratory, Randomized, Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug Alone in HBeAg Negative Chronic Hepatitis B Patients|Withdrawn||N/A|0|Actual|Institute of Liver and Biliary Sciences, India||3||lack of funds|f||||f||||||||||2018-05-31 23:02:52.471821|2018-05-31 23:02:52.471821
NCT01260597|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2015-08-10|2010-12-14|2010-12-15|Estimate|||||||2015-08-10|2015-08-11|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||Tobacco Quit Line Re-enrollments for the Underserved|Re-engagement in Evidence-based Quit Line Treatment for Low Income Smokers|Completed||N/A|2985|Actual|Alere Wellbeing||2|||f||||f||||||||||2018-05-31 23:02:52.530507|2018-05-31 23:02:52.530507
NCT01260584|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|2012-09-19||2012-11-12|2010-12-14|2010-12-15|Estimate|2012-11-12|2012-12-12|Estimate||||2012-11-12|2012-12-12|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease|The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease|Completed||Phase 4|110|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 23:02:52.686462|2018-05-31 23:02:52.686462
NCT01260571|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-14|2010-12-14|2010-12-15|Estimate|||||||2010-12-14|2010-12-15|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)|Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples)|Unknown status|Not yet recruiting|Phase 4|62|Anticipated|Zurita Laboratorio Farmaceutico Ltda.||1|||f||||f||||||||||2018-05-31 23:02:53.875146|2018-05-31 23:02:53.875146
NCT01260558|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-05-07|2010-12-14|2010-12-15|Estimate|||||||2012-05-07|2012-05-08|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|PPS/PFS-OCT||Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography|Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term|Unknown status|Recruiting|Phase 4|20|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:02:53.989031|2018-05-31 23:02:53.989031
NCT01260545|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2012-10-17|2010-12-13|2010-12-15|Estimate|||||||2012-10-17|2012-10-19|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies|Phase I Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies|Completed||Phase 1|14|Actual|XBiotech, Inc.||1|||f||||||||||||||2018-05-31 23:02:54.082128|2018-05-31 23:02:54.082128
NCT01249040|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate||||September 2004|2004-09-30||||||||Interventional|||The Study of Different Treatment Programs for Patients With Frozen Shoulder|The Study of Different Treatment Programs for Patients With Frozen Shoulder|Unknown status|Recruiting|N/A|30|Anticipated|China Medical University Hospital|||||f||||||||||||||2018-05-31 23:06:47.828765|2018-05-31 23:06:47.828765
NCT01260519|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-12-14|2010-12-14|2010-12-15|Estimate|||||||2010-12-14|2010-12-15|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coronary Angiography|Efficacy of a Single Dose Intravenous Heparin During Diagnostic Angiography in Reducing Sheath-clot Formation: A Randomized Controlled Trial|Completed||Phase 3|304|Actual|Prince Sultan Cardiac Center, Adult Cardiology Department.||1|||f||||f||||||||||2018-05-31 23:02:54.225173|2018-05-31 23:02:54.225173
NCT01260506|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2015-10-14|2010-12-14|2010-12-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|December 2010||2010-12-31|October 2015|2015-10-31||||December 2015|Anticipated|2015-12-31||Interventional|||Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme||Unknown status|Active, not recruiting|Phase 1/Phase 2|75|Anticipated|Vascular Biogenics Ltd. operating as VBL Therapeutics||1|||f||||t||||||||||2018-05-31 23:02:54.28235|2018-05-31 23:02:54.28235
NCT01260493|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2014-01-22||2014-06-11|2010-12-13|2010-12-15|Estimate|2014-06-11|2014-07-15|Estimate||||2014-06-11|2014-07-15|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|October 2011|Actual|2011-10-31|June 2010|Actual|2010-06-30||Interventional|||Continuum of Care for Frail Elderly People|Continuum of Care, From the Emergency Ward to Living at Home - Implementation and Evaluation of an Intervention for Frail Elderly People|Completed||N/A|181|Actual|Vardalinstitutet The Swedish Institute for Health Sciences||2|||f||||f||||||||||2018-05-31 23:02:54.349846|2018-05-31 23:02:54.349846
NCT01260480|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-16|2010-12-14|2010-12-15|Estimate|||||||2010-12-16|2010-12-17|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||February 2012|Anticipated|2012-02-29||Interventional|||An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation|A Prospective, Multicenter Study, to Evaluate the Efficacy and Safety of [18F]-ML-10, a Positron Emission Tomography (PET) Imaging Radiotracer, in Early Detection of Response of Non-Hematological Tumors to Concurrent Chemoradiotherapy|Unknown status|Recruiting|Phase 2|60|Anticipated|Aposense Ltd.||1|||f||||f||||||||||2018-05-31 23:02:54.546374|2018-05-31 23:02:54.546374
NCT01260467|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2015-06-19||2015-11-06|2010-12-13|2010-12-15|Estimate|2015-11-06|2015-12-10|Estimate||||2015-11-06|2015-12-10|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Memantine for Recurrent Glioblastoma|A Phase II Study of Memantine in the Treatment of Recurrent Glioblastoma|Terminated||Phase 2|4|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 23:02:54.643218|2018-05-31 23:02:54.643218
NCT01260454|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2016-01-22||2016-03-22|2010-12-13|2010-12-15|Estimate|2016-01-22|2016-02-22|Estimate||||2016-03-22|2016-04-21|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain|The Qutenza® Patch for Disabling Treprostinil Infusion Site Pain|Completed||Phase 2|6|Actual|University of Rochester||1|||f||||f||||||||||2018-05-31 23:02:54.820163|2018-05-31 23:02:54.820163
NCT01260441|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2015-11-20|2010-12-13|2010-12-15|Estimate|||||||2015-11-20|2015-11-24|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||An In-Hospital Family Member Cardiopulmonary Resuscitation (CPR) Education Program|CPR Education of Patient Family Members Using CPR Anytime Training Program|Completed||Phase 1|500|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 23:02:55.143398|2018-05-31 23:02:55.143398
NCT01260428|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-02-27|2010-12-14|2010-12-15|Estimate|||||||2012-02-27|2012-02-28|Estimate|February 2011||2011-02-28|February 2012|2012-02-29||||||||Observational|hypex||Effects of Expiratory Pressure on Arterial Oxygenation During Hypoxia|Arterial Oxygenation During Hypoxia : Effects of an Added Expiratory Resistance|Unknown status|Recruiting||20|Anticipated|AGIR à Dom|||1||f||||f||||||||||2018-05-31 23:02:55.219372|2018-05-31 23:02:55.219372
NCT01260415|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2015-07-06|2010-12-13|2010-12-15|Estimate|||||||2015-07-06|2015-07-07|Estimate|August 2010||2010-08-31|July 2015|2015-07-31||||June 2013|Actual|2013-06-30||Interventional|||A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases|A Phase II Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases|Completed||Phase 2|59|Anticipated|University Health Network, Toronto|||||f||||t||||||||||2018-05-31 23:02:55.316359|2018-05-31 23:02:55.316359
NCT01260402|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2014-08-20|2010-12-13|2010-12-15|Estimate|||||||2014-08-20|2014-08-21|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|EPI-ENDO||Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure.|Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure.|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 23:02:55.397759|2018-05-31 23:02:55.397759
NCT01260389|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2012-05-11|2010-12-13|2010-12-15|Estimate|||||||2012-05-11|2012-05-14|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|PHARMACOP||Pharmaceutical Care for Chronic Obstructive Pulmonary Disease (COPD) Study.|Pharmaceutical Care for COPD Study|Completed||N/A|734|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:02:55.572336|2018-05-31 23:02:55.572336
NCT01260376|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2012-09-17|2010-12-13|2010-12-15|Estimate|||||||2012-09-17|2012-09-18|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise|Effect of Pharmacological Anti-lipolysis on FFA and VLDL-TG Metabolism Before and During Exercise|Completed||N/A|9|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:02:55.642757|2018-05-31 23:02:55.642757
NCT01260363|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-05-01|2010-12-13|2010-12-15|Estimate|||||||2012-05-01|2012-05-02|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Infiltration Analgesia With Femoral Nerve Block After Hamstrings Anterior Cruciate Ligament Reconstruction|Pain Treatment After Anterior Cruciate Ligament Reconstruction|Completed||Phase 4|60|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:02:55.711009|2018-05-31 23:02:55.711009
NCT01260350|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|2014-11-07|2014-05-28|2014-11-07|2010-12-13|2010-12-15|Estimate|2014-11-07|2014-11-17|Estimate|2014-05-28|2014-06-02|Estimate|2014-11-07|2014-11-17|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study medication.|Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3|A Multi-center, Open-Labeled Exploratory Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 400 mg and Ribavirin for 12 Weeks With and Without Pegylated Interferon in Treatment-Naïve Patients With Chronic HCV Infection Genotype 2 or Genotype 3|Completed||Phase 2|292|Actual|Gilead Sciences||22|||f||||f||||||||||2018-05-31 23:02:55.930386|2018-05-31 23:02:55.930386
NCT01260337|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-06-28|2010-12-13|2010-12-15|Estimate|||||||2013-06-28|2013-07-01|Estimate|March 2010||2010-03-31|September 2010|2010-09-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study|The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study|Completed||N/A|100|Actual|Temple University||2|||f||||f||||||||||2018-05-31 23:03:04.473762|2018-05-31 23:03:04.473762
NCT01260324|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2011-03-16||2011-08-17|2010-12-13|2010-12-15|Estimate|2011-03-16|2011-04-25|Estimate||||2011-08-17|2011-08-19|Estimate|August 2008||2008-08-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|The Detection and Epidemiology of NAION in a Commercially Insured Population in the United States.|Completed|||21283|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 23:03:04.64025|2018-05-31 23:03:04.64025
NCT01260311|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2014-09-04||2014-09-04|2010-12-13|2010-12-15|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-04|2014-09-11|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder|Post Marketing Surveillance To Assess The Safety And Efficacy Of Fesoterodine (Toviaz) On Filipino Patients Diagnosed With Over-Active Bladder|Completed|||508|Actual|Pfizer|The implementation of Protocol Amendment 1 led to removal of all primary efficacy outcome measures, therefore the efficacy outcome measures were not investigated or reported.||1||f||||f||||||||||2018-05-31 23:03:05.472438|2018-05-31 23:03:05.472438
NCT01260298|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-03-09|2010-12-14|2010-12-15|Estimate|||||||2011-03-09|2011-03-11|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Protocol To Evaluate Patient Measurements After Ultrasonic Treatment|Protocol To Evaluate Patient Measurements After Ultrasonic Treatment.|Completed|||12|Anticipated|Sound Surgical Technologies, LLC.|||1||f||||f||||||||||2018-05-31 23:03:05.727276|2018-05-31 23:03:05.727276
NCT01260285|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2011-11-02|2010-12-13|2010-12-15|Estimate|||||||2011-11-02|2011-11-04|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Safety of Vardenafil in Patients Undergoing Cardiac Surgery|The Safety of Vardenafil in Patients Undergoing Cardiac Surgery|Completed||Phase 1|10|Actual|McGuire Research Institute||1|||f||||f||||||||||2018-05-31 23:03:05.806357|2018-05-31 23:03:05.806357
NCT01260272|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|2012-08-29||2014-04-03|2010-12-14|2010-12-15|Estimate|2012-10-03|2012-11-01|Estimate||||2014-04-03|2014-04-29|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects|A Randomized, Unblinded, Single Research Site, Comparator Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects|Completed||N/A|49|Actual|Louisville Metabolic and Atherosclerosis Research Center|This was a single research site pilot study, which would benefit from a larger study, or at least, a similar confirmatory study.|2|||f||||f||||||||||2018-05-31 23:03:05.898414|2018-05-31 23:03:05.898414
NCT01260259|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2013-09-16|2010-12-13|2010-12-15|Estimate|||||||2013-09-16|2013-09-18|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SCRIPT||Seattle Cardiorenal Remote Ischemic Preconditioning Trial|Effect of Remote Ischemic Preconditioning in Children Undergoing Cardiac Surgery|Completed||N/A|90|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 23:03:06.6666|2018-05-31 23:03:06.6666
NCT01260246|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-03-13|2010-12-14|2010-12-15|Estimate|||||||2017-03-13|2017-03-14|Actual|December 2010||2010-12-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes|Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes.|Terminated||N/A|12|Actual|Lawson Health Research Institute||2||Slow recruitment|f||||f||||||||||2018-05-31 23:03:06.753528|2018-05-31 23:03:06.753528
NCT01260233|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2013-08-22|2010-12-13|2010-12-15|Estimate|||||||2013-08-22|2013-08-26|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2012|Actual|2012-05-31||Interventional|||Effect of a Perioperative Smoking Cessation Program on Smoking Cessation/Reduction and Perioperative Complications|The Effect of a Perioperative Smoking Cessation Program on Rates of Smoking Cessation/Reduction and Perioperative Complications: a Randomized Clinical Trial.|Completed||N/A|168|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:03:06.837823|2018-05-31 23:03:06.837823
NCT01260220|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-08-25|2010-12-13|2010-12-15|Estimate|||||||2017-08-25|2017-08-28|Actual|November 12, 2009|Actual|2009-11-12|August 2017|2017-08-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|CABLE||Randomized Trial of Segmental Versus Circumferential Antral Ablation in Paroxysmal Atrial Fibrillation|Randomized Trial of Segmental Versus Circumferential Antral Ablation in Paroxysmal Atrial Fibrillation|Completed||N/A|120|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 23:03:06.928642|2018-05-31 23:03:06.928642
NCT01260207|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-08-25|2010-12-13|2010-12-15|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2010|Actual|2010-01-31|March 2017|2017-03-31|December 15, 2014|Actual|2014-12-15|December 15, 2014|Actual|2014-12-15||Interventional|IVR-ACS BPG||Using IVR to Maintain ACS Patients on Best Practice Guidelines|Using Interactive Voice Response to Improve Disease Management and Compliance With Acute Coronary Syndrome Best Practice Guidelines|Terminated||Phase 3|654|Actual|Lawson Health Research Institute||2||Terminated due to unachievable sample size and lack of resource availability|f||||f||||||||||2018-05-31 23:03:07.020486|2018-05-31 23:03:07.020486
NCT01260194|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|2016-02-15||2016-11-01|2010-12-13|2010-12-15|Estimate|2016-02-15|2016-03-14|Estimate||||2016-11-01|2016-11-02|Estimate|June 2011||2011-06-30|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Intent-to-treat (ITT) population included all participants who received at least 1 dose of study drug and did not report any major protocol violation.|A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer|An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer|Terminated||Phase 4|4|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:03:07.194736|2018-05-31 23:03:07.194736
NCT01260181|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2018-02-02|2010-12-13|2010-12-15|Estimate|||||||2018-02-02|2018-02-05|Actual|March 31, 2011|Actual|2011-03-31|February 2018|2018-02-28|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations|Phase II, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor|Completed||Phase 2|30|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:03:07.445832|2018-05-31 23:03:07.445832
NCT01260168|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-05-12|2010-12-13|2010-12-15|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies|Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies|Completed|||435|Actual|Exact Sciences Corporation|||1||f||||f||||||Samples With DNA|"~     Residual specimens and histopathology tissue slides or blocks will be stored for up to 10~     years in the Sponsor's on-site bio-repository or similar commercial bio-repository contracted~     by the Sponsor.~   "|||2018-05-31 23:03:07.547503|2018-05-31 23:03:07.547503
NCT01260155|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2013-10-31|2010-12-13|2010-12-15|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects|A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects|Completed||Phase 1|16|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 23:03:07.66437|2018-05-31 23:03:07.66437
NCT01260142|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|2016-11-30||2016-11-30|2010-12-13|2010-12-15|Estimate|2016-11-30|2017-01-27|Estimate||||2016-11-30|2017-01-27|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion|A Randomized, Open-Label, Single-Bolus, 2-Period, Multi-Dose Level, 3 Cohort Crossover Design, Pharmacokinetic/Pharmacodynamic Study of Lusedra (Fospropofol Disodium) Injection Compared With Propofol Injectable Emulsion|Completed||Phase 4|36|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 23:03:07.765973|2018-05-31 23:03:07.765973
NCT01260129|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-03-28|2010-12-14|2010-12-15|Estimate|||||||2012-03-28|2012-03-30|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Interventional|||Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH|Safety and Efficacy of 8mg Once-daily Versus 4mg Twice-daily Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH ; 12-week, Double-blind, Randomized, Comparison, Multi-center Study|Completed||Phase 4|424|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-05-31 23:03:08.430269|2018-05-31 23:03:08.430269
NCT01260116|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-14|2010-12-14|2010-12-15|Estimate|||||||2010-12-14|2010-12-15|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|March 2012|Anticipated|2012-03-31|October 2011|Anticipated|2011-10-31||Observational|||Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With Schizophrenia|Efficacy and Safety of Ziprasidone in the Treatment of Depressive Symptoms in Patients With Schizophrenia：an 8-week Open-label Study|Unknown status|Not yet recruiting||120|Anticipated|Wuhan University|||1||f||||t||||||||||2018-05-31 23:03:08.517878|2018-05-31 23:03:08.517878
NCT01260103|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-07-24|2010-12-13|2010-12-15|Estimate|||||||2017-07-24|2017-07-26|Actual|December 2011||2011-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma|A Randomized Phase 3 Study of Antineoplastons A10 and AS2-1 vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma After Carboplatin or Cisplatin Therapy|Withdrawn||Phase 3|0|Actual|Burzynski Research Institute||2||Withdrawn: study halted prematurely, prior to enrollment of first participant|f||||f||||||||No||2018-05-31 23:03:08.577592|2018-05-31 23:03:08.577592
NCT01260090|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-08-09|2010-12-14|2010-12-15|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Interventional|||Vagus Nerve Stimulation to Augment Recovery From Minimally Conscious or Persistently Vegetative States After Traumatic Brain Injury|Vagus Nerve Stimulation to Augment Recovery From Minimally Conscious or Persistently Vegetative States After Traumatic Brain Injury|Unknown status|Recruiting|Phase 3|12|Anticipated|VA New York Harbor Healthcare System||2|||f||||||||||||||2018-05-31 23:03:08.681371|2018-05-31 23:03:08.681371
NCT01260077|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-14|2010-12-14|2010-12-15|Estimate|||||||2010-12-14|2010-12-15|Estimate||||February 2009|2009-02-28||||||||Observational|||Steady State Vestibular Evoked Myogenic Potentials|Steady State Vestibular Evoked Myogenic Potentials|Completed|||||Universidade Estadual de Ciências da Saúde de Alagoas|||1||f||||t||||||||||2018-05-31 23:03:08.766454|2018-05-31 23:03:08.766454
NCT01260064|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-05-25|2010-12-13|2010-12-15|Estimate|||||||2011-05-25|2011-05-26|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Open Appendectomy Versus Laparoscopic Appendectomy|The Outcomes of Various Appendectomy Techniques in a High-volume Center.|Completed||N/A|150|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital||3|||f||||t||||||||||2018-05-31 23:03:08.843679|2018-05-31 23:03:08.843679
NCT01260051|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2010-12-16|2010-12-14|2010-12-15|Estimate|||||||2010-12-16|2010-12-17|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Observational|||Intrapartum Epidural Fentanyl/Bupivacaine Analgesia, Infant Feeding Behavior, & Breast-Feeding Outcomes|Intrapartum Epidural Fentanyl/Bupivacaine Analgesia, Infant Feeding Behavior, & Breast-Feeding Outcomes|Completed|||310|Actual|University Hospitals Cleveland Medical Center|||2||f||||f||||||||||2018-05-31 23:03:09.085439|2018-05-31 23:03:09.085439
NCT01260038|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2012-01-17|2010-12-14|2010-12-15|Estimate|||||||2012-01-17|2012-01-18|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|HERMES||Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.|Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.|Completed|||107|Actual|University Hospital, Antwerp|||||f||||f||||||None Retained|"~     At diagnosis a tumor sample is collected for histological evaluation, this sample will be~     used for the biomarker analysis.~   "|||2018-05-31 23:03:09.151134|2018-05-31 23:03:09.151134
NCT01260025|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2012-02-14|2010-12-14|2010-12-15|Estimate|||||||2012-02-14|2012-02-16|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor|Dose Escalation Study of Tolerability and Pharmacokinetics of PEDylated Recombinant Human Endostatin(M2ES)in the Treatment of Advanced Solid Tumor|Completed||Phase 1|20|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 23:03:09.228334|2018-05-31 23:03:09.228334
NCT01260012|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-14|2010-12-14|2010-12-15|Estimate|||||||2010-12-14|2010-12-15|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|December 2015|Anticipated|2015-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis|Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver.|Unknown status|Recruiting|N/A|414|Anticipated|Addis Ababa University||3|||f||||f||||||||||2018-05-31 23:03:09.305407|2018-05-31 23:03:09.305407
NCT01259999|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2011-06-30|2010-12-14|2010-12-15|Estimate|||||||2011-06-30|2011-07-01|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Energy Dense Formula to People Living in Old Peoples Home|Distribution of an Energy Rich Formula at Medication Rounds to Individuals Living in Old Peoples Home - Effects on Energy Intake Compared to Standard Nutritional Treatment|Completed||N/A|32|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 23:03:09.405933|2018-05-31 23:03:09.405933
NCT01259986|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2012-09-26|2010-12-14|2010-12-15|Estimate|||||||2012-09-26|2012-09-27|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|June 2011|Actual|2011-06-30||Interventional|||Treatment of Vitiligo With Low-energy Visible Light Laser|Treatment of Recalcitrant Forms of Vitiligo With a Low-energy 635 nm Visible Light Laser|Terminated||N/A|3|Actual|Henry Ford Health System||1||3 patients enrolled, no meaningful repigmentation observed. Recruitment halted.|f||||t||||||||||2018-05-31 23:03:09.481657|2018-05-31 23:03:09.481657
NCT01259973|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-04-15|2010-12-14|2010-12-15|Estimate|||||||2011-04-15|2011-04-18|Estimate|February 2011||2011-02-28|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|APSEP||Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers|Phase I Clinical Trial. Study of the Impact of Pharmacogenetic Markers in Predicting the Appearance of Extrapyramidal Symptomatology After the Treatment With Typical vs. Atypical Antipsychotics, in Healthy Volunteers|Unknown status|Enrolling by invitation|Phase 1|24|Anticipated|Hospital Clinic of Barcelona||3|||f||||f||||||||||2018-05-31 23:03:09.553658|2018-05-31 23:03:09.553658
NCT01259960|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2017-09-21|2010-12-14|2010-12-15|Estimate|||||||2017-09-21|2017-09-25|Actual|February 2011||2011-02-28|September 2017|2017-09-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease. A Prospective Long-term Evaluation|Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease. A Prospective Long-term Evaluation.|Completed|||187|Actual|General Hospital Amstetten|||3||f||||f||||||||||2018-05-31 23:03:09.76266|2018-05-31 23:03:09.76266
NCT01259947|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2016-01-26|2010-12-14|2010-12-15|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2006||2006-07-31|January 2016|2016-01-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||Lippia Alba for Migraine Prophylaxis and Treatment|Chemical Composition and Therapeutic Effects of Lippia Alba (Mill.) N. E. Brown Leaves Ethanolic Extract in Patients With Migraine|Completed||Phase 2|60|Actual|Casa Espirita Terra de Ismael||1|||f||||t||||||||||2018-05-31 23:03:09.824829|2018-05-31 23:03:09.824829
NCT01259934|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|November 1996||1996-11-30|December 2010|2010-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Nordic Adjuvant IFN Melanoma Trial|Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma|Completed||Phase 3|855|Actual|Karolinska Institutet||3|||f||||t||||||||||2018-05-31 23:03:09.892897|2018-05-31 23:03:09.892897
NCT01259921|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-06-27|2010-12-13|2010-12-14|Estimate|||||||2011-06-27|2011-06-29|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||EEG Biofeedback in the Treatment of Chronic Treatment-Resistant PTSD|Application of Neurofeedback as a Mechanism of Affect Regulation Treatment of Adults With Complex Adaptation to Chronic Interpersonal Trauma Exposure|Unknown status|Active, not recruiting|N/A|100|Anticipated|Justice Resource Institute||1|||f||||f||||||||||2018-05-31 23:03:09.97849|2018-05-31 23:03:09.97849
NCT01259908|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2018-04-06|2010-12-13|2010-12-14|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2010||2010-09-30|April 2018|2018-04-30|May 2023|Anticipated|2023-05-31|May 2015|Actual|2015-05-31||Observational|LAS||Laparoscopic Surgical Treatment of Aorto-iliac Occlusive Disease|Laparoscopic Aortic Surgery: Norwegian Experiance|Active, not recruiting|||80|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 23:03:10.063256|2018-05-31 23:03:10.063256
NCT01259895|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2014-08-14|2010-12-13|2010-12-14|Estimate|||||||2014-08-14|2014-08-18|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Observational|||Effects of Time of Sleep Restriction in Obesity|Effect os Sleep Restriction on Control of Food Intake and Metabolism of Obese Subjects|Completed|||20|Actual|Federal University of São Paulo|||2||f||||||||||||||2018-05-31 23:03:10.136898|2018-05-31 23:03:10.136898
NCT01259882|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-01-31|2010-12-13|2010-12-14|Estimate|||||||2012-01-31|2012-02-02|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Single Dose Escalation Study In Healthy Volunteers To Determine The Pharmacokinetics, Safety And Tolerability Of PF-05089771 In Healthy Volunteers|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration, Pharmacokinetics And Exploratory Pharmacodynamics Of PF-05089771 In Healthy Volunteers|Completed||Phase 1|61|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 23:03:10.210998|2018-05-31 23:03:10.210998
NCT01259869|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-04-10|2010-12-13|2010-12-14|Estimate|||||||2015-04-10|2015-04-13|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression|A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression|Completed||Phase 2|34|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-05-31 23:03:10.300906|2018-05-31 23:03:10.300906
NCT01259856|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2018-01-22|2010-12-13|2010-12-14|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2011||2011-09-30|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)|Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)|Completed||Phase 3|168|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 23:03:10.380859|2018-05-31 23:03:10.380859
NCT01259843|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2012-06-13|2010-12-13|2010-12-14|Estimate|||||||2012-06-13|2012-06-14|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ONSAA||French National Observatory of Aortic Syndromes|French National Observatory of Aortic Syndromes|Completed|||280|Actual|French Cardiology Society|||1||f||||f||||||||||2018-05-31 23:03:10.502434|2018-05-31 23:03:10.502434
NCT01259830|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2014-05-22|2010-12-13|2010-12-14|Estimate|||||||2014-05-22|2014-05-23|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery|A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery|Terminated||Phase 4|81|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:03:10.55618|2018-05-31 23:03:10.55618
NCT01259817|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2017-01-10|2010-12-13|2010-12-14|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)|Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis|Completed||Phase 2|135|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 23:03:10.640994|2018-05-31 23:03:10.640994
NCT01259804|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2015-01-13|2010-12-13|2010-12-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|STOP||Study of Tolerance to Oral Peanut|Efficacy and Safety of High-dose Peanut Oral Immunotherapy With Factors Predicting Outcome|Completed||Phase 1|22|Actual|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 23:03:10.752451|2018-05-31 23:03:10.752451
NCT01259791|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-03-13|2010-12-13|2010-12-14|Estimate|||||||2017-03-13|2017-03-15|Actual|September 2010||2010-09-30|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design|Evaluation of Patients With Statin Myopathy Using an N of 1 Trial Design|Completed||N/A|10|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:03:10.813719|2018-05-31 23:03:10.813719
NCT01259778|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2017-12-22|2010-12-13|2010-12-14|Estimate|||||||2017-12-22|2017-12-26|Actual|February 28, 2011|Actual|2011-02-28|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS KOR||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea|Easypod Connect: A National, Multicentre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment|Completed|||224|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:03:10.871519|2018-05-31 23:03:10.871519
NCT01259765|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-08-08|2010-12-13|2010-12-14|Estimate|||||||2011-08-08|2011-08-09|Estimate|January 2006||2006-01-31|February 2006|2006-02-28|November 2009|Actual|2009-11-30|September 2008|Actual|2008-09-30||Interventional|||Llama Antibody, Rotavirus Diarrhoea, Children|Safety and Tolerability of a Novel Llama-derived Anti-rotavirus VHH Fragment in Human Volunteers (Part-I), and Its Effect on Severity and Duration of Rotavirus Diarrhoea in Children (Part II). (This Registration Only Covers Part II)|Completed||Phase 2|176|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 23:03:10.933637|2018-05-31 23:03:10.933637
NCT01259752|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2012-07-30|2010-12-13|2010-12-14|Estimate|||||||2012-07-30|2012-07-31|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CASED||Compression Stockings in Ankle Sprain|Prospective Randomized Study of Compression Stockings in Ankle Sprain in Adults|Completed||Phase 3|130|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:03:11.004012|2018-05-31 23:03:11.004012
NCT01259739|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2013-11-07|2010-12-13|2010-12-14|Estimate|||||||2013-11-07|2013-11-08|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Cocoa Flavanols and Exercise Capacity|The Impact of Dietary Cocoa Flavanols on Cardio-pulmonary Exercise Capacity in Human.|Completed||N/A|13|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 23:03:11.088381|2018-05-31 23:03:11.088381
NCT01259726|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2015-01-20||2015-02-11|2010-12-10|2010-12-14|Estimate|2015-02-11|2015-02-12|Estimate||||2015-02-11|2015-02-12|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional||Intent-to-Treat-Safety (ITT-S) population was defined as all randomized participants who received at least 1 dose of study drug.|Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI|Completed||Phase 2|173|Actual|Shire||4|||f||||t||||||||||2018-05-31 23:03:11.176098|2018-05-31 23:03:11.176098
NCT01259713|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2015-03-25||2015-04-17|2010-12-13|2010-12-14|Estimate|2015-03-25|2015-04-06|Estimate||||2015-04-17|2015-05-07|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|AmBiGuard|Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.|Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 3|355|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 23:03:11.980161|2018-05-31 23:03:11.980161
NCT01259700|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2016-02-15|2010-12-13|2010-12-14|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|December 2012|Actual|2012-12-31||Interventional|||High Cardiovascular Risk Management and Salt Reduction in Rural Villages in China|China Rural Health Initiative: High Cardiovascular Risk Management and Salt Reduction in Rural Villages in China -- Two Parallel Large Cluster Randomized Controlled Trials|Completed||N/A|120|Actual|The George Institute for Global Health, China||4|||f||||t||||||||||2018-05-31 23:03:13.039171|2018-05-31 23:03:13.039171
NCT01259687|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2013-11-23|2010-12-13|2010-12-14|Estimate|||||||2013-11-23|2013-11-26|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|PuTT-NICOM||Pulse Transit Time in Anesthetized Patients: Blood Pressure or Cardiac Output as Measured With NICOM Monitor|Pulse Transit Time in Anesthetized Ventilated Patients: Affect of Blood Pressure or Cardiac Output as Measured With NICOM Monitor|Completed|||63|Actual|Carmel Medical Center|||1||f||||f||||||||||2018-05-31 23:03:13.122679|2018-05-31 23:03:13.122679
NCT01259674|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2014-12-01|2010-12-13|2010-12-14|Estimate|||||||2014-12-01|2014-12-02|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ABOMEG||Evaluation of the Efficacy and Tolerability of ABO/MEG-B-09 in Children With Acute Cough|Randomized, Single-center, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Tolerability of ABO/MEG-B-09 in Pediatric Cough|Completed||Phase 3|102|Actual|Aboca Spa Societa' Agricola||2|||f||||f||||||||||2018-05-31 23:03:13.184779|2018-05-31 23:03:13.184779
NCT01259661|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-12|2010-12-12|2010-12-14|Estimate|||||||2010-12-12|2010-12-14|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Physical Activity and Metabolic Risk Factors in Postmenopausal Women|Physical Activity and Metabolic Risk Factors in Postmenopausal Women|Unknown status|Recruiting|N/A|50|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-05-31 23:03:13.247949|2018-05-31 23:03:13.247949
NCT01259648|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2016-03-18|2010-12-13|2010-12-14|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects|Randomized Study Evaluating the Efficacy and Safety of Remifentanil in a Rapid Sequence Induction for Fragile Subjects|Completed||Phase 4|75|Actual|Centre Hospitalier Universitaire de Nīmes||3|||f||||f||||||||Yes|Data available upon request.|2018-05-31 23:03:13.309399|2018-05-31 23:03:13.309399
NCT01259635|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-12-12|2010-12-12|2010-12-14|Estimate|||||||2010-12-12|2010-12-14|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Biofeedback to Ameliorate Freezing of Gait|Biofeedback-based Motor Learning to Ameliorate Freezing of Gait|Unknown status|Not yet recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 23:03:13.369811|2018-05-31 23:03:13.369811
NCT01259622|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-12|||2011-05-13|2010-12-13|2010-12-14|Estimate|||||||2011-05-13|2011-05-16|Estimate|February 2011||2011-02-28|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|TUNDRA-AF||Effects of Intravenous K201 on the Restoration of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation|A mulTi-center, Randomized, doUble-bliNded, Placebo-controlled Dose-escalating Study of the Effects of K201 on the RestorAtion of Sinus Rhythm in Subjects With Symptomatic Atrial Fibrillation of Recent Onset|Terminated||Phase 2|80|Anticipated|Sequel Pharmaceuticals, Inc||2|||f||||t||||||||||2018-05-31 23:03:13.583295|2018-05-31 23:03:13.583295
NCT01259609|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy||Completed||N/A|82|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 23:03:13.668259|2018-05-31 23:03:13.668259
NCT01259596|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2016-01-07||2017-11-06|2010-12-13|2010-12-14|Estimate|2017-08-01|2017-10-03|Actual||||2017-11-06|2017-12-08|Actual|January 2011||2011-01-31|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)|A Randomized Controlled Trial (RCT)of Cognitive Behavioral Therapy-Telephone (CBT-T) for Late-Life Generalized Anxiety Disorder (GAD)|Completed||N/A|141|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 23:03:13.754383|2018-05-31 23:03:13.754383
NCT01259583|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2013-03-12|2010-12-13|2010-12-14|Estimate|||||||2013-03-12|2013-03-13|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Carbon Dioxide Insufflation (CO2) and Warm Water Infusion (WWI) Versus Standard Air Insufflation (AI) for Unsedated Colonoscopy||Completed||N/A|341|Actual|Valduce Hospital||2|||f||||||||||||||2018-05-31 23:03:14.094778|2018-05-31 23:03:14.094778
NCT01259570|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-12|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|May 2012|Anticipated|2012-05-31|December 2011|Anticipated|2011-12-31||Interventional|||Bioavailability of Vitamin D Encapsulated in Casein Micelles, Compared to Its Bioavailability in the Milk-fat, or in a Synthetic Emulsifier Currently Used for Supplementation and Enrichment||Unknown status|Not yet recruiting|N/A|120|Anticipated|Rambam Health Care Campus||4|||f||||f||||||||||2018-05-31 23:03:14.15422|2018-05-31 23:03:14.15422
NCT01259557|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2012-04-24|2010-12-12|2010-12-14|Estimate|||||||2012-04-24|2012-04-25|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm|Multi-center, Phase Ⅳ, Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® in Subjects With Essential Blepharospasm|Completed||Phase 4|110|Actual|Medy-Tox||1|||f||||f||||||||||2018-05-31 23:03:14.208772|2018-05-31 23:03:14.208772
NCT01259544|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-12|||2012-02-15|2010-12-13|2010-12-14|Estimate|||||||2012-02-15|2012-02-16|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency||Completed||Phase 2|33|Actual|Exalenz Bioscience LTD.||2|||f||||t||||||||||2018-05-31 23:03:14.267049|2018-05-31 23:03:14.267049
NCT01259531|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2012-03-28|2010-12-13|2010-12-14|Estimate|||||||2012-03-28|2012-03-30|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|STRONG||Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)|A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia|Completed||Phase 4|100|Actual|JW Pharmaceutical||1|||f||||f||||||||||2018-05-31 23:03:14.32395|2018-05-31 23:03:14.32395
NCT01259518|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2011-06-06|2010-12-11|2010-12-14|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|January 2012|Anticipated|2012-01-31|September 2011|Anticipated|2011-09-30||Interventional|||Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas|A Phase I Dose Escalation Study on the Tolerability and Activity of TriN 2755 in Patients With Advanced Solid Tumors and Sarcomas Using Two Different Dosage Regimens|Unknown status|Recruiting|Phase 1|48|Anticipated|Trin Therapeutics GmbH||2|||f||||t||||||||||2018-05-31 23:03:14.390069|2018-05-31 23:03:14.390069
NCT01259505|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-11|||2014-11-13|2010-12-13|2010-12-14|Estimate|||||||2014-11-13|2014-11-17|Estimate|December 2009||2009-12-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|June 2012|Actual|2012-06-30||Interventional|||Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer|Phase I Study of Multiple-Vaccine Therapy Using Epitope Peptides Restricted to HLA-A*2402 in Treating Patients With Refractory Breast Cancer|Completed||Phase 1|10|Actual|Tokyo Medical University||1|||f||||t||||||||||2018-05-31 23:03:14.508219|2018-05-31 23:03:14.508219
NCT01259492|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-11|2013-08-06||2014-09-29|2010-12-11|2010-12-14|Estimate|2014-03-27|2014-04-29|Estimate||||2014-09-29|2014-10-07|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)|A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD|Completed||Phase 3|725|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:03:14.642213|2018-05-31 23:03:14.642213
NCT01259479|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-11|||2017-10-05|2010-12-11|2010-12-14|Estimate|||||||2017-10-05|2017-10-06|Actual|December 3, 2010||2010-12-03|May 29, 2015|2015-05-29|May 29, 2015|Actual|2015-05-29|August 1, 2013|Actual|2013-08-01||Interventional|||Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors|A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 23:03:16.524291|2018-05-31 23:03:16.524291
NCT01259466|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2015-07-16||2015-08-27|2010-12-10|2010-12-14|Estimate|2015-08-27|2015-09-28|Estimate||||2015-08-27|2015-09-28|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers|Internet-Administered Smoking Cessation Treatment for Overweight and Obese Smokers|Completed||N/A|54|Actual|Yale University||2|||f||||f||||||||||2018-05-31 23:03:16.606343|2018-05-31 23:03:16.606343
NCT01259453|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|May 2003||2003-05-31|December 2010|2010-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|HVS||Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules|Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules|Completed||Phase 4|595|Actual|Yale University||2|||f||||t||||||||||2018-05-31 23:03:16.840962|2018-05-31 23:03:16.840962
NCT01259440|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2015-02-20||2015-10-05|2010-12-10|2010-12-14|Estimate|2015-10-05|2015-11-04|Estimate||||2015-10-05|2015-11-04|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Using Telemedicine to Improve Veteran Sleep Apnea Care|Using Telemedicine to Improve Veteran Sleep Apnea Care|Completed||Phase 1/Phase 2|23|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:03:16.925469|2018-05-31 23:03:16.925469
NCT01259427|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2015-10-28||2016-02-05|2010-12-13|2010-12-14|Estimate|2015-12-18|2016-01-28|Estimate||||2016-02-05|2016-03-08|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|ESS||Reducing Internalized Stigma in People With Serious Mental Illness|Reducing Internalized Stigma In People With Serious Mental Illness|Completed||Phase 2|252|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:03:17.123032|2018-05-31 23:03:17.123032
NCT01259414|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2016-11-01|2010-12-13|2010-12-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma|Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma|Recruiting||Phase 3|812|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:03:17.386286|2018-05-31 23:03:17.386286
NCT01259401|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2014-12-17||2015-01-06|2010-12-10|2010-12-14|Estimate|2014-12-17|2014-12-30|Estimate||||2015-01-06|2015-01-15|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HERO-ADHC||Treating Sleep Problems in VA Adult Day Health Care|Treating Sleep Problems in VA Adult Day Health Care|Completed||N/A|72|Actual|VA Office of Research and Development|Small sample size; predominantly male study sample|2|||f||||f||||||||||2018-05-31 23:03:17.473069|2018-05-31 23:03:17.473069
NCT01259388|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2016-03-30|2010-12-10|2010-12-14|Estimate|||||||2016-03-30|2016-03-31|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||A Pilot Study of Lithium in Progressive Multiple Sclerosis|A Pilot Trial of Lithium in Progressive Multiple Sclerosis|Completed||Phase 1/Phase 2|20|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:03:17.770716|2018-05-31 23:03:17.770716
NCT01259375|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2016-09-29||2017-03-03|2010-12-13|2010-12-14|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|September 2011||2011-09-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ARSARC-PI-0010||Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma|A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma|Completed||Phase 2|24|Actual|University of Utah||1|||f||||f||||||||No||2018-05-31 23:03:17.854382|2018-05-31 23:03:17.854382
NCT01259362|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-21|2010-12-13|2010-12-14|Estimate|||||||2010-12-21|2010-12-22|Estimate|March 2010||2010-03-31|September 2010|2010-09-30|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|TMSCOCDEPEND||Effects of Repeated Transcranial Magnetic Stimulation (rTMS) on the Treatment of Cocaine Addicted Patients|Efeitos da Estimulacao Magnetica Transcrania de Repeticao ( EMTr) no Tratamento da Dependencia ao Uso de Cocaina|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 23:03:18.104454|2018-05-31 23:03:18.104454
NCT01259349|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-14|2010-12-13|2010-12-14|Estimate|||||||2010-12-14|2010-12-15|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|April 2012|Anticipated|2012-04-30|April 2011|Anticipated|2011-04-30||Interventional|OCTOPUS||Effect of Minimising Ultrasound Power to 1% During Cataract Surgery on Corneal Endothelium.|Standard Coaxial Microincision Cataract Surgery Versus Coaxial Microincision Cataract Surgery Using 1% Ultrasound in Immature Senile Cataract :a Corneal Endothelium Study|Unknown status|Recruiting|Phase 3|72|Anticipated|Dr. Ram Manohar Lohia Hospital||2|||f||||t||||||||||2018-05-31 23:03:18.194288|2018-05-31 23:03:18.194288
NCT01259336|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-02-18|2010-12-13|2010-12-14|Estimate|||||||2012-02-18|2012-02-22|Estimate|July 2010||2010-07-31|November 2010|2010-11-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|ITRACONASP||Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis|A RANDOMIZED CONTROLLED STUDY OF ITRACONAZOLE IN CHRONIC CAVITARY PULMONARY ASPERGILLOSIS|Completed||Phase 4|31|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 23:03:18.283615|2018-05-31 23:03:18.283615
NCT01259323|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2012-10-02|2010-12-10|2010-12-14|Estimate|||||||2012-10-02|2012-10-04|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Extrinsic Atopic Dermatitis|Completed||Phase 1|30|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 23:03:18.361834|2018-05-31 23:03:18.361834
NCT01259310|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2016-03-04|2010-12-13|2010-12-14|Estimate|||||||2016-03-04|2016-03-07|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|WEPOD||Women With Epilepsy: Pregnancy Outcomes and Deliveries|Women With Epilepsy: Pregnancy Outcomes and Deliveries|Completed|||199|Actual|New York University School of Medicine|||2||f||||f||||||||||2018-05-31 23:03:18.454651|2018-05-31 23:03:18.454651
NCT01259115|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2011-01-07||2014-05-08|2010-12-10|2010-12-13|Estimate|2011-01-07|2011-01-26|Estimate||||2014-05-08|2014-05-19|Estimate|October 2002||2002-10-31|May 2014|2014-05-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole|A Single Center, Randomized, Double-Blind, Crossover Study to Assess Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of BTDS and Ketoconazole, Used As a CYP3A4 Inhibitor, in Healthy Subjects|Completed||Phase 1|20|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:03:24.361433|2018-05-31 23:03:24.361433
NCT01259297|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2013-12-18||2014-02-27|2010-12-13|2010-12-14|Estimate|2014-02-27|2014-04-08|Estimate||||2014-02-27|2014-04-08|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|APOLLO|Full analysis Set (FAS): All randomized patients, regardless of receiving study medication.|A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People|A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People|Terminated||Phase 3|2336|Actual|Novartis|Due to early termination, 1759 patients were randomized as against 11,000. Only 25 primary endpoints had accrued during median follow-up of 209 days as against planned 2000 in 5 years. These low numbers significantly limit interpretation of results.|8||Terminated early in agreement with Health Authorities for feasibility reasons|f||||||||||||||2018-05-31 23:03:18.596031|2018-05-31 23:03:18.596031
NCT01259284|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2012-04-24||2012-07-31|2010-12-13|2010-12-14|Estimate|2012-06-28|2012-08-01|Estimate||||2012-07-31|2012-08-07|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer|A Double Blinded, Randomized Study Comparing the Effectiveness of Fish Oil Supplements, Oral Statins, and Placebo in Reducing the Incidence of Atrial Fibrillation Following a Lung Resection in Patients With Lung Cancer|Terminated||Phase 2/Phase 3|2|Actual|M.D. Anderson Cancer Center||3||Terminated due to low accrual.|f||||t||||||||||2018-05-31 23:03:20.43633|2018-05-31 23:03:20.43633
NCT01259271|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2011-03-16|2010-12-13|2010-12-14|Estimate|||||||2011-03-16|2011-03-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:03:20.802802|2018-05-31 23:03:20.802802
NCT01259258|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|varicocele||Dye Assisted Lymphatic Sparing Subinguinal Varicocelectomy|Dye Assisted Lymphatic Sparing Varicocelectomy,Prospective Randomized Study|Completed||Phase 2|80|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 23:03:20.835957|2018-05-31 23:03:20.835957
NCT01259245|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2012-10-02||2013-03-02|2010-12-13|2010-12-14|Estimate|2013-03-02|2013-03-05|Estimate||||2013-03-02|2013-03-05|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|COPD||Effectiveness of Incorporating Tai Chi in Pulmonary Rehabilitation Program for Chronic Obstructive Pulmonary Disease Patients in Primary Health Care|Effectiveness of Incorporating Tai Chi in Pulmonary Rehabilitation Program for COPD Patients in Primary Health Care|Completed||N/A|192|Actual|Kwong Wah Hospital|There was high attrition rate of 28% which further contributed to our small sample size with wide 95% confidence interval of several outcome variables results.|2|||f||||t||||||||||2018-05-31 23:03:20.980982|2018-05-31 23:03:20.980982
NCT01259232|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2014-03-19|2010-12-13|2010-12-14|Estimate|||||||2014-03-19|2014-03-21|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||The Imaging Genetic Study of Schizophrenia and Family||Unknown status|Recruiting||100|Anticipated|Kunming Medical University|||3||f||||t||||||||||2018-05-31 23:03:22.368318|2018-05-31 23:03:22.368318
NCT01259219|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|November 2010||2010-11-30|December 2010|2010-12-31|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Interventional|RBT||Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra|Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra|Unknown status|Recruiting|Phase 1|40|Anticipated|Harriet Shezi Children's Clinic||1|||f||||t||||||||||2018-05-31 23:03:22.474164|2018-05-31 23:03:22.474164
NCT01259206|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-06-17|2010-12-13|2010-12-14|Estimate|||||||2011-06-17|2011-06-21|Estimate|February 2009||2009-02-28|October 2008|2008-10-31|March 2009|Actual|2009-03-31|||||Observational|No acronym||Plantar Faciitis and Diabetes Mellitus|Increased Calcaneal Spur Incidence in Patients With Obesity and Type 2 Diabetes Mellitus|Completed|||93|Actual|Gulhane School of Medicine|||2||f||||t||||||||||2018-05-31 23:03:22.614567|2018-05-31 23:03:22.614567
NCT01259193|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2011-04-13|2010-12-13|2010-12-14|Estimate|||||||2011-04-13|2011-04-14|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC|Phase II Study of Sorafenib and Zoledronic Acid in Advanced HCC|Unknown status|Recruiting|Phase 2|50|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 23:03:22.683767|2018-05-31 23:03:22.683767
NCT01259180|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis|Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis : A Preliminary Study|Unknown status|Not yet recruiting|N/A|30|Anticipated|East West Neo Medical Center||3|||f||||f||||||||||2018-05-31 23:03:23.417759|2018-05-31 23:03:23.417759
NCT01259167|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|JOBA-Loba||JOBA & Chronic LOw BAck Pain JOBA® & Chronic LOw BAck Pain JOBA® & Chronic LOw BAck Pain JOBA® & Chronic LOw BAck Pain|JOBA & Chronic LOw BAck Pain|Unknown status|Enrolling by invitation||50|Anticipated|Catholic University of the Sacred Heart|||3||f||||t||||||||||2018-05-31 23:03:23.702896|2018-05-31 23:03:23.702896
NCT01259154|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2010-12-13|2010-12-13|2010-12-14|Estimate|||||||2010-12-13|2010-12-14|Estimate||||December 2010|2010-12-31||||||||Observational|||Combined RF Surgery of the Tongue Base and Uvulopalatopharyngoplasty (UPPP) for Obstructive Sleep Apnea|Combined Bipolar Radiofrequency Surgery of the Tongue Base and Uvulopalatopharyngoplasty for Obstructive Sleep Apnea|Completed|||||Charles University, Czech Republic|||2||f||||t||||||||||2018-05-31 23:03:23.873311|2018-05-31 23:03:23.873311
NCT01259141|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-13|||2015-07-25|2010-12-13|2010-12-14|Estimate|||||||2015-07-25|2015-07-28|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Optimization of Mycoplasm Pneumonia Antibiotic Therapy|The Optimization of Mycoplasm Pneumonia Antibiotic Therapy: Multi-centre, Prospective, Randomized Controlled Study|Completed||N/A|208|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 23:03:23.983987|2018-05-31 23:03:23.983987
NCT01259128|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22||2013-12-19|2014-04-24|2010-12-10|2010-12-13|Estimate||||2014-01-27|2014-02-28|Estimate|2014-04-24|2014-05-13|Estimate|April 2010||2010-04-30|April 2014|2014-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia|A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (≥ 75 Years Old) With Nocturia|Completed||Phase 3|32|Actual|Serenity Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:03:24.095815|2018-05-31 23:03:24.095815
NCT01259102|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2011-01-13||2012-08-27|2010-12-10|2010-12-13|Estimate|2011-01-13|2011-02-07|Estimate||||2012-08-27|2012-09-03|Estimate|November 2000||2000-11-30|August 2012|2012-08-31|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods|A Parallel Open-Label Study to Examine Plasma Concentrations of Buprenorphine Following Reapplication of 10-mg Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods in Healthy Subjects|Completed||Phase 1|70|Actual|Purdue Pharma LP||5|||f||||f||||||||||2018-05-31 23:03:25.871195|2018-05-31 23:03:25.871195
NCT01259089|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2018-01-09|2010-12-10|2010-12-13|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer|"A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors"|Active, not recruiting||Phase 1/Phase 2|43|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 23:03:28.080406|2018-05-31 23:03:28.080406
NCT01259076|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2015-04-09|2010-12-10|2010-12-13|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer|Effect of Weight Loss on Breast Density Using Both Digital Mammography and Breast MRI|Terminated|||43|Actual|Northwestern University|||2|Study was closed early due to slow accrual.|f||||t||||||||||2018-05-31 23:03:28.287306|2018-05-31 23:03:28.287306
NCT01259063|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2017-12-06||2018-02-13|2010-12-10|2010-12-13|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|December 2010|Actual|2010-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder|Phase I/II Study of RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder|Completed||Phase 1/Phase 2|33|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:03:28.508525|2018-05-31 23:03:28.508525
NCT01259050|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2012-03-09|2010-12-10|2010-12-13|Estimate|||||||2012-03-09|2012-03-12|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Safety Study of High Doses of Zinc in ALS Patients|Phase 1 Open Label Study of Zinc Therapy in ALS Patients|Completed||Phase 1/Phase 2|10|Anticipated|Phoenix Neurological Associates, LTD||1|||f||||t||||||||||2018-05-31 23:03:30.514864|2018-05-31 23:03:30.514864
NCT01259037|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2017-10-31|2010-12-10|2010-12-13|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2009||2009-01-31|October 2017|2017-10-31|October 29, 2017|Actual|2017-10-29|June 30, 2011|Actual|2011-06-30||Observational|||A Study of Ultrasonography With Elastography in Skin Neoplasms||Completed|||30|Actual|Wayne State University|||||f||||||||||Samples With DNA|"~     Skin biopsies of lesions imaged with ultrasound are processed for routine histology and~     retained.~   "|||2018-05-31 23:03:30.796809|2018-05-31 23:03:30.796809
NCT01259024|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2017-06-01||2018-04-12|2010-12-10|2010-12-13|Estimate|2017-06-01|2017-06-23|Actual||||2018-04-12|2018-05-15|Actual|December 2011||2011-12-31|April 2018|2018-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead|Hepatic Arterial Embolization of Hepatocellular Carcinoma With a Doxorubicin Eluting Bead|Terminated||N/A|1|Actual|Washington University School of Medicine|Overall limitation was related to not reaching the target number of participants needed to achieve target power and statistically reliable results due to denial of CMS reimbursement. Majority of this patient population is covered by CMS services.|1||inability to obtain CMS approval|f||||t||||||||Undecided||2018-05-31 23:03:30.876517|2018-05-31 23:03:30.876517
NCT01259011|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2016-09-29||2017-07-28|2010-12-10|2010-12-13|Estimate|2017-07-28|2017-09-25|Actual||||2017-07-28|2017-09-25|Actual|March 2010||2010-03-31|July 2017|2017-07-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|SPIRIT||A Representational Intervention to Promote Preparation for End-of-life Decision Making|A Randomized Controlled Trial of SPIRIT: A Representational Intervention to Promote Preparation for End-of-Life Decision Making|Completed||N/A|210|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||Undecided||2018-05-31 23:03:31.114347|2018-05-31 23:03:31.114347
NCT01258998|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2015-10-09||2015-10-09|2010-12-10|2010-12-13|Estimate|2015-10-09|2015-11-10|Estimate||||2015-10-09|2015-11-10|Estimate|December 2010||2010-12-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma|Phase II Study of MK-2206 in Patients With Relapsed Lymphoma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:03:32.461727|2018-05-31 23:03:32.461727
NCT01258985|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2015-11-04||2016-06-23|2010-12-10|2010-12-13|Estimate|2016-06-23|2016-08-04|Estimate||||2016-06-23|2016-08-04|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|TCPT||Tai Chi and Physical Therapy for Knee Osteoarthritis|Tai Chi and Physical Therapy for Knee Osteoarthritis|Completed||N/A|204|Actual|Tufts Medical Center||2|||f||||t||||||||Yes|De-identified participant data will be made available upon request.|2018-05-31 23:03:32.857869|2018-05-31 23:03:32.857869
NCT01258972|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2016-10-17|2010-12-10|2010-12-13|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|October 2016|Actual|2016-10-31|November 2014|Actual|2014-11-30||Interventional|TRYTON||Prospective, Single Blind, Rand Controlled Study to Evaluate the Safety & Effectness of Tryton Side Branch Stent Used With DES Treatmt of de Novo Bifurcation Lesions in MB & SB in Native Coronaries|TRYTON PIVOTAL IDE Coronary Bifurcation Extended Access Study|Completed||N/A|133|Actual|Tryton Medical, Inc.||2|||f||||t||||||||Undecided||2018-05-31 23:03:33.571933|2018-05-31 23:03:33.571933
NCT01258959|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2011-06-08|2010-12-10|2010-12-13|Estimate|||||||2011-06-08|2011-06-09|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||"Anaesthesia for Ophthalmic Surgery: How Retro is the Peribulbar Block?"|"Anaesthesia for Ophthalmic Surgery: How Retro is the Peribulbar Block?"|Completed|||100|Anticipated|Sunnybrook Health Sciences Centre|||1||f||||f||||||||||2018-05-31 23:03:33.679587|2018-05-31 23:03:33.679587
NCT01258946|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2011-06-10|2010-12-10|2010-12-13|Estimate|||||||2011-06-10|2011-06-13|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Observational|||Epicardial Adipose Tissue Thickness in Polycystic Ovary Syndrome (PCOS)|The Relationship Between Epicardial Adipose Tissue Thickness, Insulin Resistance and Plasma Adiponectin Concentrations In Patients With Polycystic Ovary Syndrome|Completed|||45|Actual|Gulhane School of Medicine|||||f||||t||||||||||2018-05-31 23:03:33.736155|2018-05-31 23:03:33.736155
NCT01258465|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|January 2005||2005-01-31|December 2010|2010-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Research in Autism: Parent Intervention|Research in Autism: Parent Intervention|Completed||N/A|39|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 23:03:44.752429|2018-05-31 23:03:44.752429
NCT01258933|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2017-09-13|2010-12-10|2010-12-13|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2011|Actual|2011-07-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy|Ofatumumab for Residual Disease and Maintenance Following Chemotherapy or Chemoimmunotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Active, not recruiting||Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:03:33.82422|2018-05-31 23:03:33.82422
NCT01258920|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2014-06-23|2010-12-10|2010-12-13|Estimate|||||||2014-06-23|2014-06-24|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia|A Long-Term, Open-Label Study of Flexibly Dosed Paliperidone Palmitate Long-Acting Intramuscular Injection in Japanese Patients With Schizophrenia|Completed||Phase 3|201|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 23:03:33.914486|2018-05-31 23:03:33.914486
NCT01258907|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10||2013-08-20|2016-11-01|2010-12-10|2010-12-13|Estimate||||2013-08-20|2013-08-28|Estimate|2016-11-01|2016-11-02|Estimate|March 2010||2010-03-31|November 2016|2016-11-30||||July 2012|Actual|2012-07-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)|A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER - Goal of Oxidized Ldl and Activated Macrophage Inhibition by Exposure to a Recombinant Antibody)|Completed||Phase 2|147|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:03:34.044212|2018-05-31 23:03:34.044212
NCT01258894|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-12-21|2010-12-10|2010-12-13|Estimate|||||||2010-12-21|2010-12-22|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||Investigation of Human Alpha-fetoprotein Genes|Investigation of Human Alpha-fetoprotein Genes|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     10c.c Whole Blood~   "|||2018-05-31 23:03:34.141284|2018-05-31 23:03:34.141284
NCT01258881|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|April 2010||2010-04-30|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Retrospective Study of Ovarian Cancer Patients With Brain Metastasis|Retrospective Study of Ovarian Cancer Patients With Brain Metastasis|Unknown status|Recruiting||70|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 23:03:34.211686|2018-05-31 23:03:34.211686
NCT01258868|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2018-05-23|2010-12-10|2010-12-13|Estimate|||||||2018-05-23|2018-05-24|Actual|December 1, 2010||2010-12-01|August 17, 2016|2016-08-17|June 13, 2016|Actual|2016-06-13|June 13, 2016|Actual|2016-06-13||Interventional|||Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas|Epigenetically-Modified Autologous Tumor Cell Vaccines With ISCOMATRIX(TM) Adjuvant and Oral Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas|Terminated||Phase 1|44|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 23:03:34.286271|2018-05-31 23:03:34.286271
NCT01258855|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2018-04-02|2010-12-10|2010-12-13|Estimate|||||||2018-04-02|2018-04-03|Actual|January 18, 2011|Actual|2011-01-18|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Study of Sequential Biotherapy With Aflibercept and High Dose IL-2 Versus High Dose IL-2 Alone in Patients With Inoperable Stage III or Stage IV Melanoma: Efficacy and Biomarker Study|Completed||Phase 2|84|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 23:03:34.364766|2018-05-31 23:03:34.364766
NCT01258842|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Bifidobacterium Lactis HN019 Supplementation for Prevention of Influenza Infection in Healthy Adults|Double-blind, Randomized, Placebo-controlled Trial of the Effects of Prophylactic Bifidobacterium Lactis HN019 Supplementation on the Incidence of Influenza Infection in Healthy Adults|Unknown status|Recruiting|Phase 3|426|Anticipated|Fonterra Research Centre||2|||f||||f||||||||||2018-05-31 23:03:34.507721|2018-05-31 23:03:34.507721
NCT01258829|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2015-06-29|2010-12-10|2010-12-13|Estimate|||||||2015-06-29|2015-06-30|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|BRAVO||British Randomised Controlled Trial of Atrioventricular (AV) and Interventricular (VV) Optimisation (BRAVO)|British Randomised Controlled Trial of AV and VV Optimisation (BRAVO): Randomised Clinical Trial of the Effects of Non-invasive Haemodynamic Optimisation of Cardiac Resynchronisation Devices on Exercise Capacity|Completed||N/A|403|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 23:03:34.601426|2018-05-31 23:03:34.601426
NCT01258816|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2013-09-20|2010-12-10|2010-12-13|Estimate|||||||2013-09-20|2013-09-23|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)|A Phase I Study of the Human Pharmacokinetics and Cardiac Safety of Elacytarabine|Completed||Phase 1|43|Actual|Clavis Pharma|||||f||||f||||||||||2018-05-31 23:03:34.663621|2018-05-31 23:03:34.663621
NCT01258803|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2012-10-01||2017-03-17|2010-12-09|2010-12-13|Estimate|2013-05-20|2013-07-18|Estimate||||2017-03-17|2017-04-14|Actual|December 2010||2010-12-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)|A Randomized, Evaluator-Blind, Crossover, Single Dose Study of the Bronchodilator Effect of Formoterol Fumarate in Combination With Mometasone Furoate Metered Dose Inhaler Delivered With and Without a Spacer Versus Placebo and Foradil® Aerolizer® in Children With Persistent Asthma (Protocol No. P06476)|Completed||Phase 2|92|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:03:34.771145|2018-05-31 23:03:34.771145
NCT01258790|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2014-03-25||2014-05-30|2010-12-10|2010-12-13|Estimate|2014-05-30|2014-07-01|Estimate||||2014-05-30|2014-07-01|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Repetitive Transcranial Magnetic Stimulation to Reduce Tics|Using Transcranial Magnetic Stimulation to Reduce Tics|Completed||N/A|12|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 23:03:35.397421|2018-05-31 23:03:35.397421
NCT01258777|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2013-09-03|2010-12-10|2010-12-13|Estimate|||||||2013-09-03|2013-09-04|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|April 2011|Actual|2011-04-30|||||Interventional|||A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects|A Phase I Study to Evaluate the Safety and Pharmacokinetics of CNTO 148 Following Single Subcutaneous Administration to Healthy Japanese and Caucasian Subjects|Completed||Phase 1|49|Actual|Centocor, Inc.||2|||f||||f||||||||||2018-05-31 23:03:35.657592|2018-05-31 23:03:35.657592
NCT01258764|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-05-19|2010-12-10|2010-12-13|Estimate|||||||2015-05-19|2015-05-20|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|1HAT||Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril|Series of Single Patient Trials Comparing the Efficacy Between the Most Commonly Prescribed Thiazide Diuretic in the US, Hydrochlorothiazide, and Lisinopril for the Treatment of Stage 1 Hypertension.|Completed||N/A|2|Actual|Scripps Translational Science Institute||2|||f||||f||||||||||2018-05-31 23:03:35.835015|2018-05-31 23:03:35.835015
NCT01258751|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2011-07-05|2010-12-09|2010-12-13|Estimate|||||||2011-07-05|2011-07-06|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers|A Phase 1, Open-Label Study To Evaluate 5-Ht6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11c]PF-04171252 Following Single Oral Dose Administration Of PF-05212377 (Sam-760) In Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:03:35.927347|2018-05-31 23:03:35.927347
NCT01258738|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2013-11-11||2015-09-14|2010-12-09|2010-12-13|Estimate|2015-09-14|2015-10-19|Estimate||||2015-09-14|2015-10-19|Estimate|February 2011||2011-02-28|September 2015|2015-09-30|October 2014|Actual|2014-10-31|November 2012|Actual|2012-11-30||Interventional|EMBARK|The safety analysis set for the double blind period was defined as all randomized participants who took at least one dose of study medication. A total of 224 of the 225 randomized participants received study medication (1 subject randomized to the placebo group did not receive study medication).|Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes|A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etanercept On A Background Nsaid In The Treatment Of Adult Subjects With Non Radiographic Axial Spondyloarthritis With A 92 Week Open Label Extension|Completed||Phase 3|225|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:03:36.287548|2018-05-31 23:03:36.287548
NCT01258725|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|December 2012|Anticipated|2012-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Alterations of the Uteroplacental and Fetal Pulmonary Circulation Following Amnioinfusion|Alterations of the Uteroplacental and Fetal Pulmonary Circulation in Patients With Severe Idiopathic Oligohydramnios Following Amnioinfusion Therapy in a Longitudinal Study|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|Szeged University||1|||f||||f||||||||||2018-05-31 23:03:40.537136|2018-05-31 23:03:40.537136
NCT01258712|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-12-12|2010-12-10|2010-12-13|Estimate|||||||2012-12-12|2012-12-13|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients|Randomized, Placebo-controlled Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients|Completed||Phase 3|86|Actual|Chugai Pharma Taiwan||2|||f||||f||||||||||2018-05-31 23:03:40.634241|2018-05-31 23:03:40.634241
NCT01258699|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|August 2009||2009-08-31|December 2010|2010-12-31||||||||Interventional|||A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects|A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects|Completed||Phase 1|30|Anticipated|Bukwang Pharmaceutical||3|||f||||||||||||||2018-05-31 23:03:40.708137|2018-05-31 23:03:40.708137
NCT01258686|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2013-11-22|2010-12-10|2010-12-13|Estimate|||||||2013-11-22|2013-11-25|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|November 2012|Actual|2012-11-30||Interventional|||Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy|A Double-blind Phase III Study With Silymarin in the Patients Infected With HCV Who Failed Conventional Antiviral Therapy|Completed||Phase 3|53|Actual|Bukwang Pharmaceutical||2|||f||||f||||||||||2018-05-31 23:03:40.761315|2018-05-31 23:03:40.761315
NCT01258673|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2012-01-02|2010-12-10|2010-12-13|Estimate|||||||2012-01-02|2012-01-05|Estimate|November 2010||2010-11-30|December 2010|2010-12-31||||December 2011|Actual|2011-12-31||Interventional|||A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy|A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)|Completed||Phase 3|263|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 23:03:40.823441|2018-05-31 23:03:40.823441
NCT01258660|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2011-04-19||2013-09-15|2010-12-10|2010-12-13|Estimate|2011-04-19|2011-05-13|Estimate||||2013-09-15|2013-09-20|Estimate|December 2006||2006-12-31|September 2013|2013-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate|A Randomized, Double-blind, Double-dummy, 2-parallel Arms Clinical Trial to Assess the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and to Compare the Profile of Circulating Folate Metabolites During 24 Weeks of Treatment With an Oral Contraceptive Containing Ethinylestradiol, Drospirenone and L-5-methyltetrahydrofolate (SH T04532A and SH T04532C) or Yasmin (SH T04532D and SH T04532PC) Co-administered With Folic Acid (SH K04532B) Followed by 20 Weeks of Open-label Treatment With Yasmin Only (Folate Elimination Phase) in Women Seeking Contraception|Completed||Phase 1|172|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:03:40.904167|2018-05-31 23:03:40.904167
NCT01258647|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2011-08-26|2010-12-10|2010-12-13|Estimate|||||||2011-08-26|2011-08-30|Estimate|October 2010||2010-10-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CAT01||Acceptability of a Cereal for Complementary Feeding of Infants and Young Children Made From Caterpillars|Caterpillar Cereal: Maternal and Infant Acceptability|Completed||N/A|40|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 23:03:42.649976|2018-05-31 23:03:42.649976
NCT01258634|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-12-09|2010-12-09|2010-12-13|Estimate|||||||2013-12-09|2013-12-10|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response|A Pilot Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response|Terminated||Phase 1|2|Actual|University of Chicago||1||PI no longer affiliated with institution; only 2 subjects enrolled|f||||f||||||||||2018-05-31 23:03:42.726279|2018-05-31 23:03:42.726279
NCT01258621|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Learning Curve for Laparoscopic Distal Pancreatectomy|Learning Curve for Laparoscopic Distal Pancreatectomy in a High-volume Hospital|Completed||N/A|30|Actual|Università Vita-Salute San Raffaele||1|||f||||f||||||||||2018-05-31 23:03:42.808947|2018-05-31 23:03:42.808947
NCT01258608|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07||2014-07-10|2018-02-14|2010-12-09|2010-12-13|Estimate||||2014-07-10|2014-07-14|Estimate|2018-02-14|2018-02-16|Estimate|February 8, 2011|Actual|2011-02-08|February 2018|2018-02-28|November 29, 2017|Actual|2017-11-29|May 31, 2013|Actual|2013-05-31||Interventional|||Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma|A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma|Completed||Phase 2|101|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:03:42.984958|2018-05-31 23:03:42.984958
NCT01258595|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2011-09-19||2016-04-12|2010-12-10|2010-12-13|Estimate|2011-09-19|2011-10-27|Estimate||||2016-04-12|2016-05-16|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age|Safety and Immunogenicity of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age|Completed||Phase 2|300|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:03:43.209439|2018-05-31 23:03:43.209439
NCT01258582|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2012-05-03||2012-06-10|2010-12-10|2010-12-13|Estimate|2012-05-03|2012-06-05|Estimate||||2012-06-10|2012-06-13|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|USHER||Two Approaches to Routine HIV Testing in a Hospital Emergency Department|Optimizing Strategies for Universal HIV Testing (The USHER Trial): Phase II|Completed||N/A|1651|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:03:43.602453|2018-05-31 23:03:43.602453
NCT01258569|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-08-24|2010-12-10|2010-12-13|Estimate|||||||2015-08-24|2015-08-26|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Entereg Laparoscopic Colon Resection Study|Entereg Laparoscopic Colon Resection Study|Completed||Phase 2|135|Actual|Hartford Hospital||2|||f||||f||||||||||2018-05-31 23:03:43.958066|2018-05-31 23:03:43.958066
NCT01258556|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|June 2010||2010-06-30|December 2010|2010-12-31||||July 2010|Actual|2010-07-31||Interventional|||The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis||Completed||Phase 2/Phase 3|150|Anticipated|Lawson Health Research Institute||2|||f||||||||||||||2018-05-31 23:03:44.027467|2018-05-31 23:03:44.027467
NCT01258543|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2011-06-09|2010-12-10|2010-12-13|Estimate|||||||2011-06-09|2011-06-13|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Osteopathic Evaluation on Patients With Non-specific Back Pain: An Inter-examiner Reliability Study|Osteopathic Evaluation on Patients With Non-specific Back Pain: An Observational Inter-examiner Reliability Study|Completed|||20|Actual|Kirnan, Jaime|||1||f||||t||||||||||2018-05-31 23:03:44.0948|2018-05-31 23:03:44.0948
NCT01258530|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-06-06|2010-12-09|2010-12-13|Estimate|||||||2017-06-06|2017-06-07|Actual|December 20, 2010|Actual|2010-12-20|June 2017|2017-06-30|February 3, 2011|Actual|2011-02-03|February 3, 2011|Actual|2011-02-03||Interventional|||A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers|A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:03:44.174819|2018-05-31 23:03:44.174819
NCT01258517|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2016-09-01|2010-12-10|2010-12-13|Estimate|||||||2016-09-01|2016-09-05|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||The Effect of Surfactant Administration on Cerebral Oxygenation|The Effect of the Type and the Method of Surfactant Administration on Oxygenation in Preterm Infants: a Near Infrared Spectroscopy Study|Suspended|||40|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||1|principle investigator moved to an another hospital|f||||f||||||||||2018-05-31 23:03:44.265486|2018-05-31 23:03:44.265486
NCT01258504|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|2014-07-09||2017-05-03|2010-12-10|2010-12-13|Estimate|2015-05-29|2015-06-02|Estimate||||2017-05-03|2017-05-31|Actual|January 2011||2011-01-31|May 2017|2017-05-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Observational|||Influence of CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Bosentan|Influence of Cytochrome P450 3A4 (CYP3A4)-Induction by St. John's Wort (SJW) on the Steady State Pharmacokinetics of Bosentan|Completed|||13|Actual|Heidelberg University|Interindividual changes of the interaction were large suggesting that close monitoring of bosentan effects is advisable because in a sizeable fraction of volunteers the exposure to bosentan was reduced.||2||f||||f||||||||||2018-05-31 23:03:44.420636|2018-05-31 23:03:44.420636
NCT01258491|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|May 2005||2005-05-31|December 2005|2005-12-31|December 2005|Actual|2005-12-31|November 2005|Actual|2005-11-30||Interventional|||Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects|Double-blind, Randomized, Placebo-controlled, Single-center, 2 Treatment, 3-way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects|Completed||Phase 1|18|Actual|Heidelberg University|||||f||||||||||||||2018-05-31 23:03:44.624321|2018-05-31 23:03:44.624321
NCT01258478|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|LCRS||Lung Cancer Rehabilitation Study|Short-Term Pre-operative Rehabilitation for Patients With Lung Cancer: A Randomized Trial.|Unknown status|Recruiting|N/A|390|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 23:03:44.671849|2018-05-31 23:03:44.671849
NCT01258452|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-02-09|2010-12-09|2010-12-13|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|CT03||Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects|Randomized, Balanced, Single Dose, Cross-Over Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects|Completed||Phase 1|12|Actual|CERESPIR||2|||f||||f||||||||||2018-05-31 23:03:44.823621|2018-05-31 23:03:44.823621
NCT01258439|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-01-08|2010-12-10|2010-12-13|Estimate|||||||2015-01-08|2015-01-12|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ROaR+||Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.|Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir-boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)-Naive Adults or Adults Recommencing ART.|Completed||Phase 4|25|Actual|St Vincent's Hospital, Sydney||2|||f||||t||||||||||2018-05-31 23:03:44.887947|2018-05-31 23:03:44.887947
NCT01258426|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2010-12-10|2010-12-10|2010-12-13|Estimate|||||||2010-12-10|2010-12-13|Estimate||||December 2010|2010-12-31||||||||Observational|||Human Selenoprotein P Concentration With Glucose Tolerance Status|Human Selenoprotein P Concentration With Glucose Tolerance Status|Completed|||||Korea University|||1||f||||f||||||||||2018-05-31 23:03:44.958853|2018-05-31 23:03:44.958853
NCT01258413|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-22|2010-12-10|2010-12-13|Estimate|||||||2010-12-22|2010-12-24|Estimate|November 1999||1999-11-30|November 2010|2010-11-30|February 2009|Actual|2009-02-28|February 2004|Actual|2004-02-29||Interventional|||Laparoscopic vs Abdominal Radical Hysterectomy In Patients With Early Cervical Cancer|Laparoscopic vs Abdominal Radical Hysterectomy With Pelvic Lymphadenectomy in Patients With Early Cervical Cancer: A Randomized Clinical Trial|Completed||Phase 3|30|Actual|Hospital Nossa Senhora da Conceicao||2|||f||||f||||||||||2018-05-31 23:03:44.996597|2018-05-31 23:03:44.996597
NCT01258400|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2011-11-15|2010-12-09|2010-12-13|Estimate|||||||2011-11-15|2011-11-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:03:45.070183|2018-05-31 23:03:45.070183
NCT01258387|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2014-04-15||2014-06-30|2010-12-09|2010-12-13|Estimate|2014-06-30|2014-07-01|Estimate||||2014-06-30|2014-07-01|Estimate|December 2010||2010-12-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|GGF2-1101-1|Safety Population. Consists of all patients who took one of the double-blind investigational drugs.|Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure|A Phase 1, Double-Blind, Placebo-Controlled Study of Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure|Completed||Phase 1|40|Actual|Acorda Therapeutics||1|||f||||t||||||||||2018-05-31 23:03:45.144975|2018-05-31 23:03:45.144975
NCT01258374|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2015-09-01|2010-12-10|2010-12-13|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Observational|RALDAR||Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.|Dual Therapy With Raltegravir 400 mg BID and Darunavir/Ritonavir 800/100 mg QD in HIV Infected Patients Failing to Nucleoside Reverse Transcriptase Inhibitors Based Regimens|Completed|||15|Actual|Hospital Clinic of Barcelona|||1||f||||f||||||||||2018-05-31 23:03:46.230076|2018-05-31 23:03:46.230076
NCT01258361|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-10|||2015-03-25|2010-12-10|2010-12-13|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Echocardiographic Assessment of Volume Variation Secondary to Preoperative Fasting|Echocardiographic Assessment of Volume Variation Secondary to Preoperative Fasting|Completed|||100|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 23:03:46.289419|2018-05-31 23:03:46.289419
NCT01258348|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-04-13|2010-12-09|2010-12-10|Estimate|||||||2012-04-13|2012-04-17|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Phase 1b Trial in Patients With Renal Cell Cancer|A Phase 1b Study of LY573636-sodium in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Cancer|Completed||Phase 1|35|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:03:46.344261|2018-05-31 23:03:46.344261
NCT01258335|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2011-11-21|2010-12-09|2010-12-10|Estimate|||||||2011-11-21|2011-11-22|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|Omega 3||Omega-3-fatty Acids on Age-related Macular|Short Term Ocular Safety Assessment of High Dose Omega-3 Supplementation for Age-Related Macular Degeneration.|Completed||N/A|25|Actual|Mid Atlantic Retina||2|||f||||f||||||||||2018-05-31 23:03:46.408145|2018-05-31 23:03:46.408145
NCT01258322|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|January 2008||2008-01-31|March 2007|2007-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients|Twelve Weeks of Pioglitazone Therapy Significantly Attenuates Dysmetabolism and Reduces Inflammation in Prevalent Peritoneal Dialysis Patients. A Randomized, Cross-over Trial.|Completed||N/A|70|Actual|Huashan Hospital||1|||f||||t||||||||||2018-05-31 23:03:46.555275|2018-05-31 23:03:46.555275
NCT01258309|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2012-01-24|2010-12-09|2010-12-10|Estimate|||||||2012-01-24|2012-01-25|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis||Completed||Phase 3|129|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:03:46.632745|2018-05-31 23:03:46.632745
NCT01258296|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|February 2003||2003-02-28|December 2010|2010-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|Fentanyl Patch||Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction|Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction|Completed||Phase 4|60|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:03:46.704034|2018-05-31 23:03:46.704034
NCT01258283|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2017-02-02|2010-12-09|2010-12-10|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Observational|||PET / CT With 18F-FDG: Does it Optimize the I 123-MIBG Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator?|PET / CT With 18F-FDG (18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography): Does it Optimize the I 123-MIBG (Iodine 123 Metaiodobenzylguanidine) Imaging Results in the Search for Discriminating Factors for the Implementation of an Implantable Defibrillator for Primary Prevention in Patients With Heart Failure of Ischemic Origin?|Terminated|||6|Actual|Centre Hospitalier Universitaire de Nīmes|||1|Inclusion rate too slow / infeasible.|f||||f||||||||||2018-05-31 23:03:46.790457|2018-05-31 23:03:46.790457
NCT01258270|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2013-06-06|2010-12-09|2010-12-10|Estimate|||||||2013-06-06|2013-06-10|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Patient Satisfaction With AQUACEL® Ag Surgical Dressing Compared to Standard Surgical Dressing|Efficacy and Patient Satisfaction With AQUACEL® Ag Surgical Dressing Compared to Standard Surgical Dressing. A Prospective, Randomized Study in Primary Total Joint Arthroplasty.|Completed||N/A|300|Actual|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 23:03:46.859872|2018-05-31 23:03:46.859872
NCT01258257|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2017-02-02|2010-12-09|2010-12-10|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2011||2011-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|EARLYDRAIN||EARLYdrain - Outcome After Early Lumbar CSF-drainage in Aneurysmal SAH|EARLYdrain - Prospective Outcome Study of Early Lumbar Drainage in Aneurysmal Subarachnoid Hemorrhage|Completed||Phase 3|300|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||Yes|Full anonymized data is planned to be shared among collaborators.|2018-05-31 23:03:46.931266|2018-05-31 23:03:46.931266
NCT01258244|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2018-01-22|2010-12-09|2010-12-10|Estimate|||||||2018-01-22|2018-01-25|Actual|December 7, 2010|Actual|2010-12-07|January 2018|2018-01-31|February 25, 2015|Actual|2015-02-25|February 25, 2015|Actual|2015-02-25||Observational|||Arizona Prehospital CPR Quality Improvement Project|Arizona Prehospital CPR Quality Improvement Project|Completed|||101|Actual|Maricopa Integrated Health System|||1||f||||f||||||||||2018-05-31 23:03:47.017812|2018-05-31 23:03:47.017812
NCT01258231|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2017-10-02|2010-12-09|2010-12-10|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2000||2000-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|CABGGenomics||Identification of Genomic Predictors of Adverse Events After Cardiac Surgery|Identification of Genomic Predictors of Adverse Events After Cardiac Surgery|Recruiting|||4000|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||Samples With DNA|"~     DNA, buffy coat, plasma, serum and urine~   "|||2018-05-31 23:03:47.117326|2018-05-31 23:03:47.117326
NCT01258218|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2012-06-05|2010-12-09|2010-12-10|Estimate|||||||2012-06-05|2012-06-06|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Accent MRI Pacemaker and Tendril MRI Lead New Technology Assessment|Accent MRI Pacemaker and Tendril MRI Lead New Technology Assessment|Completed|||78|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 23:03:47.194143|2018-05-31 23:03:47.194143
NCT01258205|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2017-05-18|2010-12-09|2010-12-10|Estimate|||||||2017-05-18|2017-05-19|Actual|February 28, 2011|Actual|2011-02-28|May 2017|2017-05-31|February 18, 2015|Actual|2015-02-18|February 18, 2015|Actual|2015-02-18||Interventional|||Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease, and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease|Completed||Phase 1|48|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:03:47.250658|2018-05-31 23:03:47.250658
NCT01258192|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2014-07-28|2010-12-09|2010-12-10|Estimate|||||||2014-07-28|2014-07-29|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|nabPCESCC||Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients|Multicenter,Phase ⅡStudy of Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Squamous Cell Carcinoma Patients|Completed||Phase 2|35|Actual|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 23:03:47.34554|2018-05-31 23:03:47.34554
NCT01258179|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2018-05-14|2010-12-09|2010-12-10|Estimate|||||||2018-05-14|2018-05-17|Actual|February 2011|Actual|2011-02-28|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Peri-operative Expression Analysis of Pancreatic Stone Protein in a Surgical Study Population|Peri-operative Expression Analysis of Pancreatic Stone Protein and Pancreatitis-associated Protein in a Surgical Study Population|Terminated|||30|Actual|University of Zurich|||2|low recruitment|f||||t||||||Samples With DNA|"~     Venous blood samples~   "|||2018-05-31 23:03:47.426439|2018-05-31 23:03:47.426439
NCT01258166|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2012-02-02|2010-12-09|2010-12-10|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2005||2005-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Traumatic Ulnar Translocation of the Carpus|Traumatic Ulnar Translocation of the Carpus: Early Diagnosis and Treatment|Completed|||10|Actual|Northwestern University|||1||f||||||||||||||2018-05-31 23:03:47.788252|2018-05-31 23:03:47.788252
NCT01258153|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2015-05-04||2015-05-26|2010-12-09|2010-12-10|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|no-cry|113 : ITT - defined as the safety population randomised with at least 24h diary recording post 1st dose of study treatment|Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic|Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Administration of Nepadutant in Infant Colic|Completed||Phase 2|115|Actual|Menarini Group||3|||f||||f||||||||||2018-05-31 23:03:47.873833|2018-05-31 23:03:47.873833
NCT01258140|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-01-21|2010-12-09|2010-12-10|Estimate|||||||2013-01-21|2013-01-23|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|REDOPED||Detection of Pulmonary Embolism With Low-dose CT Pulmonary Angiography|Detection of Pulmonary Embolism With CT Pulmonary Angiography Using Reduced Contrast Medium and Radiation Dose: Comparison of 100 kVp and 80 kVp Protocols|Completed||N/A|504|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 23:03:48.318143|2018-05-31 23:03:48.318143
NCT01258127|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|August 2015|Anticipated|2015-08-31|August 2012|Anticipated|2012-08-31||Observational|||Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)|Adjuvant Chemotherapy of Pemetrexed/Carboplatin Compared With Vinorelbine/Carboplatin in Patients With Completely Resected NSCLC|Unknown status|Recruiting||134|Anticipated|Shanghai Nancy Medical Sci-Tech Co. Ltd|||2||f||||t||||||||||2018-05-31 23:03:48.383099|2018-05-31 23:03:48.383099
NCT01258114|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|MAATHERMES||Maâthermes: Spa Treatment for Overweight and Obesity|Maâthermes a Randomised Controlled Trial of Spa Treatment of Overweight and Obesity|Completed||Phase 3|400|Actual|Association Francaise pour la Recherche Thermale||2|||f||||f||||||||||2018-05-31 23:03:48.511442|2018-05-31 23:03:48.511442
NCT01257945|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2012-10-01|2010-12-08|2010-12-10|Estimate|||||||2012-10-01|2012-10-02|Estimate|April 2003||2003-04-30|October 2012|2012-10-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Exercise for People With Parkinson's Disease|Exercise, Physical Function, and Parkinson's Disease|Completed||Phase 2|163|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 23:03:51.464044|2018-05-31 23:03:51.464044
NCT01258101|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2016-01-05||2016-05-30|2010-12-09|2010-12-10|Estimate|2016-05-30|2016-07-11|Estimate||||2016-05-30|2016-07-11|Estimate|May 2003||2003-05-31|May 2016|2016-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3|Randomized, Multicenter Study to Compare the Efficacy of Pegylated Interferon Alfa (PEG-IFN) in Combination With Two Different Doses of Ribavirin in Patients With Chronic Hepatitis C and Subtype 2/3|Completed||Phase 4|395|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:03:48.661616|2018-05-31 23:03:48.661616
NCT01258088|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2018-02-16|2010-12-09|2010-12-10|Estimate|||||||2018-02-16|2018-02-20|Actual|November 30, 2010|Actual|2010-11-30|February 2018|2018-02-28|December 31, 2010|Actual|2010-12-31|December 31, 2010|Actual|2010-12-31||Interventional|AN2728-PSR-104||Safety Study of Ointment for the Treatment of Plaque-type Psoriasis|A Randomized, Double-blind, Vehicle-controlled, Multiple Cohort Study To Determine The Safety, Tolerability, And Pharmacokinetic Profile Of An2728 Ointment B, 2% In Healthy Volunteers And Patients With Mild-to-moderate Plaque-type Psoriasis|Completed||Phase 1|16|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 23:03:49.916278|2018-05-31 23:03:49.916278
NCT01258075|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2017-12-22|2010-12-09|2010-12-10|Estimate|||||||2017-12-22|2017-12-27|Actual|November 2010||2010-11-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|WELKid DM||Colesevelam Pediatric Type 2 Diabetes Mellitus Study|Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects With Type 2 Diabetes Mellitus|Recruiting||Phase 4|230|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 23:03:50.097947|2018-05-31 23:03:50.097947
NCT01258062|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2017-02-01|2010-12-09|2010-12-10|Estimate|||||||2017-02-01|2017-02-02|Estimate|September 2010||2010-09-30|February 2017|2017-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults|Phase 1, Double Blind, Randomized, Placebo Controlled Study to Assess Safety and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults.|Completed||Phase 1|7|Actual|Ology Bioservices||2|||f||||f||||||||||2018-05-31 23:03:50.204439|2018-05-31 23:03:50.204439
NCT01258049|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2013-09-13||2014-01-27|2010-12-09|2010-12-10|Estimate|2014-01-27|2014-02-28|Estimate||||2014-01-27|2014-02-28|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Superiority of ArTiMist Versus Quinine in Children With Severe Malaria|A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.|Completed||Phase 3|151|Actual|Proto Pharma Ltd||2|||f||||t||||||||||2018-05-31 23:03:50.299185|2018-05-31 23:03:50.299185
NCT01258036|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2012-09-27|2010-12-09|2010-12-10|Estimate|||||||2012-09-27|2012-09-28|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Observational|MODAM||Mother Daughter Bone Microarchitecture|Rôle de la Microarchitecture Osseuse Dans le déterminisme héréditaire de la fragilité Osseuse|Unknown status|Recruiting||1040|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||t||||||Samples With DNA|"~     serum plasma urine whole blood for DNA extraction~   "|||2018-05-31 23:03:50.920709|2018-05-31 23:03:50.920709
NCT01258023|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-04-13|2010-12-09|2010-12-10|Estimate|||||||2012-04-13|2012-04-16|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|Fluad Tx||Seasonal Flu Vaccine in Adult Transplant Recipients|A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine Including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers|Completed||Phase 2|122|Actual|HepNet Study House, German Liverfoundation||1|||f||||t||||||||||2018-05-31 23:03:51.010019|2018-05-31 23:03:51.010019
NCT01258010|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2014-04-30|2010-12-09|2010-12-10|Estimate|||||||2014-04-30|2014-05-01|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery|Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery|Completed||N/A|99|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 23:03:51.072156|2018-05-31 23:03:51.072156
NCT01257997|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2018-01-25|2010-12-09|2010-12-10|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2010||2010-12-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Quantification of Human Adipogenesis|Quantification of Human Adipogenesis|Completed|||20|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||Samples Without DNA|"~     Fat biopsy. Oral mucosal smear. White blood cells.~   "|||2018-05-31 23:03:51.13966|2018-05-31 23:03:51.13966
NCT01257984|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2014-10-27|2010-12-09|2010-12-10|Estimate|||||||2014-10-27|2014-10-28|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function|A Multicenter, Open-label, Randomized, Controlled, Two-arm Study to Assess Compliance With Daily Tablet Intake of Women on Treatment With the Oral Contraceptive SH T00186D/BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function Over 12 Months|Completed||Phase 3|508|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:03:51.198834|2018-05-31 23:03:51.198834
NCT01257971|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-03-19|2010-12-09|2010-12-10|Estimate|||||||2012-03-19|2012-03-20|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Non-interventional Study (NIS) to Assess Reaching of Cholesterol Target Values in Patients Treated With HMG-CoA Reductase Inhibitors|Non-interventional Study to Assess Reaching of Cholesterol Target Values in Patients Treated With 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) Reductase Inhibitors in Croatia|Completed|||1868|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:03:51.307052|2018-05-31 23:03:51.307052
NCT01257958|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2015-10-01|2010-12-08|2010-12-10|Estimate|||||||2015-10-01|2015-10-05|Estimate|February 1998||1998-02-28|December 2010|2010-12-31|June 2000|Actual|2000-06-30|February 2000|Actual|2000-02-29||Interventional|||Vitamin D Pilot Study in Patients With Multiple Sclerosis|Vitamin D Pilot Study in Patients With Multiple Sclerosis|Completed||Phase 1|||University of Wisconsin, Madison||1|||||||f||||||||||2018-05-31 23:03:51.395301|2018-05-31 23:03:51.395301
NCT01257932|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2018-02-02|2010-12-09|2010-12-10|Estimate|||||||2018-02-02|2018-02-06|Actual|December 2010||2010-12-31|February 2018|2018-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging|Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging|Withdrawn|||0|Actual|University of California, Irvine|||1|"According to the NIH definition of clinical trial studies, this study does not meet requirement~   to be a clinical trial study."|f||||t||||||||||2018-05-31 23:03:51.531379|2018-05-31 23:03:51.531379
NCT01257919|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2014-02-19|2010-12-09|2010-12-10|Estimate|||||||2014-02-19|2014-02-21|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea|Investigator-blinded, Randomized, Cross-over, Multiple Dose Phase I Study on Safety and Pharmacokinetics of Topically Applied Azelaic Acid Foam, 15% Compared to Azelaic Acid Gel, 15% in Subjects With Papulopustular Rosacea|Completed||Phase 1|21|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:03:51.595159|2018-05-31 23:03:51.595159
NCT01257906|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo|A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING CLINDAMYCIN PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL (ACTAVIS MID-ATLANTIC LLC) TO ZIANA® (CLINDAMYCIN PHOSPHATE 1.2% AND TRETINOIN 0.025%) GEL (MEDICIS, THE DERMATOLOGY COMPANY®) AND BOTH ACTIVE TREATMENTS TO CLINDAMYCIN PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL PLACEBO (ACTAVIS MID-ATLANTIC LLC) IN THE TREATMENT OF MILD TO SEVERE ACNE VULGARIS|Completed||N/A|1225|Actual|Actavis Mid-Atlantic LLC||3|||f||||f||||||||||2018-05-31 23:03:51.825405|2018-05-31 23:03:51.825405
NCT01257893|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2013-05-29|2010-12-08|2010-12-10|Estimate|||||||2013-05-29|2013-05-31|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|ARWM||Aspirin Resistance in Women With Migraine|Aspirin Resistance in Women With Migraine|Withdrawn||N/A|0|Actual|Swedish Medical Center||2|||f||||f||||||||||2018-05-31 23:03:51.921418|2018-05-31 23:03:51.921418
NCT01257880|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2011-07-20||2011-09-21|2010-12-08|2010-12-10|Estimate|2011-08-16|2011-09-21|Estimate||||2011-09-21|2011-09-27|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|CAMP||Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)|Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)|Completed|||31|Actual|Swedish Medical Center|Subjects were recruited from a headache clinic and had a high degree of migraine burden; thus, the sample may not accurately represent the general migraine population. The number of men in the sample was insufficient to test sex differences.||2||f||||f||||||||||2018-05-31 23:03:52.00854|2018-05-31 23:03:52.00854
NCT01257867|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-11-07|2010-12-09|2010-12-10|Estimate|||||||2012-11-07|2012-11-09|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Lithia Water Study: Effects of Lithia Water on BDNF and Oxidative Stress Markers in Healthy Male Participants|Lithia Water Study: Effects of Lithia Water on BDNF and Oxidative Stress Markers in Healthy Male Participants|Terminated||N/A|5|Actual|University of British Columbia||2||This study was terminated by the Principal Investigator|f||||f||||||||||2018-05-31 23:03:52.216701|2018-05-31 23:03:52.216701
NCT01257854|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2017-12-14|2010-12-08|2010-12-10|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2008||2008-02-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Polymorphisms and Busulfan Pharmacokinetic Study|Polymorphisms and Busulfan Pharmacokinetic Study in Pediatric Transplnatation|Active, not recruiting|||200|Anticipated|University Hospital, Geneva|||1||f||||f||||||Samples With DNA|"~     DNA from each patient are kept. Plasma from some centers are kept~   "|||2018-05-31 23:03:52.281977|2018-05-31 23:03:52.281977
NCT01257841|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|November 2002||2002-11-30|December 2010|2010-12-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects|Effects of Four-day Fast on Gut-derived Hormones and Inflammatory Markers in Healthy, Normal-weight Women.|Completed||N/A|20|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:03:52.405846|2018-05-31 23:03:52.405846
NCT01257828|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-23|||2018-04-16|2010-12-08|2010-12-10|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2011||2011-12-31|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|CSM-Protect||Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)|Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study|Active, not recruiting||Phase 3|270|Anticipated|AOSpine North America Research Network||2|||f||||f||||||||||2018-05-31 23:03:52.478764|2018-05-31 23:03:52.478764
NCT01257815|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2014-09-29|2010-12-09|2010-12-10|Estimate|||||||2014-09-29|2014-09-30|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|RELIGHT||Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment|Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema.|Completed||Phase 4|111|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:03:52.575678|2018-05-31 23:03:52.575678
NCT01257802|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|2017-04-14||2017-05-23|2010-12-09|2010-12-10|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|May 2011||2011-05-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|LUPRON|Because only 14 people randomized, baseline data is provided for those for whom relevant outcome measures were achieved.|GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases|GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases|Terminated||Phase 3|14|Actual|University of Michigan||2|||f||||t||||||||No||2018-05-31 23:03:52.67124|2018-05-31 23:03:52.67124
NCT01257789|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Observational|||Eliminating Learning Curve Related Morbidity in Fast Track Laparoscopic Roux-en-Y Gastric Bypass|Structured Bariatric Fellowship Programme Moelholm Private Hospital - Denmark. Learning Laparoscopic RY - Gastric Bypass One Way to do it|Completed|||300|Actual|Private Hospital Moelholm|||1||f||||f||||||||||2018-05-31 23:03:52.982246|2018-05-31 23:03:52.982246
NCT01257776|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-08-04|2010-12-09|2010-12-10|Estimate|||||||2015-08-04|2015-08-05|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|July 2015|Actual|2015-07-31|February 2013|Actual|2013-02-28||Interventional|||Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients|Using Mesenchymal Stem Cells From Adipose Tissue (CeTMAd) as Cell Regeneration Therapy in Chronic Ischemic Syndrome of Lower Limbs in Diabetic Patients|Completed||Phase 1/Phase 2|33|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||3|||f||||t||||||||||2018-05-31 23:03:53.05471|2018-05-31 23:03:53.05471
NCT01257763|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-09-14|2010-12-09|2010-12-10|Estimate|||||||2012-09-14|2012-09-17|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Tolerability Study of the Application of a 3M Microstructure Transdermal System|Tolerability Study of the Application of a 3M Microstructure Transdermal System by Finger Pressure to the Face in Healthy Subjects Stratified by Age and Fitzpatrick Skin Type|Completed||Phase 1|54|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 23:03:53.125681|2018-05-31 23:03:53.125681
NCT01257750|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2012-10-05||2017-12-19|2010-12-08|2010-12-10|Estimate|2012-10-05|2012-11-06|Estimate||||2017-12-19|2018-01-18|Actual|November 2010||2010-11-30|December 2017|2017-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Treatment of Corneal Neovascularization With Topical Pazopanib|Safety and Efficacy of Topical Pazopanib in Treatment of Corneal Neovascularization|Completed||Phase 1/Phase 2|20|Actual|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||||2018-05-31 23:03:53.198759|2018-05-31 23:03:53.198759
NCT01257737|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2018-02-16||2018-04-04|2010-12-09|2010-12-10|Estimate|2018-04-04|2018-05-04|Actual||||2018-04-04|2018-05-04|Actual|October 4, 2010|Actual|2010-10-04|April 2018|2018-04-30|February 16, 2017|Actual|2017-02-16|February 16, 2017|Actual|2017-02-16||Interventional||Safety Population: All participants who received any amount of study medication|To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)|Long Term Use of HPN-100 in Urea Cycle Disorders|Completed||Phase 4|88|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||f|t|f||||||Undecided||2018-05-31 23:03:53.438843|2018-05-31 23:03:53.438843
NCT01257724|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2011-12-14|2010-12-09|2010-12-10|Estimate|||||||2011-12-14|2011-12-15|Estimate|March 2011||2011-03-31|December 2011|2011-12-31|January 2013|Anticipated|2013-01-31|September 2012|Anticipated|2012-09-30||Interventional|||Effects of an Evidence Service on Community-based AIDS Service Organizations' Use of Research Evidence|Effects of an Evidence Service on Community-based AIDS Service Organizations' Use of Research Evidence: A Protocol for a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|58|Actual|Ontario HIV Treatment Network||2|||f||||f||||||||||2018-05-31 23:03:54.342793|2018-05-31 23:03:54.342793
NCT01257711|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2012-04-13|2010-12-09|2010-12-10|Estimate|||||||2012-04-13|2012-04-16|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|December 2016|Anticipated|2016-12-31|October 2014|Anticipated|2014-10-31||Interventional|SCAR||A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer|A Prospective Randomised Study Comparing Billroth II With Roux-en-Y Reconstruction After Radical Distal Subtotal Gastrectomy for Gastric Cancer|Unknown status|Recruiting|N/A|160|Anticipated|National Healthcare Group, Singapore||1|||f||||f||||||||||2018-05-31 23:03:54.409131|2018-05-31 23:03:54.409131
NCT01257698|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-02-08|2010-12-09|2010-12-10|Estimate|||||||2012-02-08|2012-02-09|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy|A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy|Completed||N/A|21|Actual|Mid Atlantic Retina||2|||f||||f||||||||||2018-05-31 23:03:54.494874|2018-05-31 23:03:54.494874
NCT01257685|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2010-12-09|2010-12-09|2010-12-10|Estimate|||||||2010-12-09|2010-12-10|Estimate|September 2007||2007-09-30|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Selenoprotein P and Non-alcoholic Fatty Liver Disease|Selenoprotein P and Non-alcoholic Fatty Liver Disease|Completed|||120|Actual|Korea University|||2||f||||f||||||||||2018-05-31 23:03:54.560231|2018-05-31 23:03:54.560231
NCT01257672|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2014-04-17|2010-12-09|2010-12-10|Estimate|||||||2014-04-17|2014-04-21|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Symptomatic Treatment of Acute Gastroenteritis|Oral Ondansetron vs Domperidone for Symptomatic Treatment of Vomiting During Acute Gastroenteritis in Children: Multicentre Randomized Controlled Trial|Completed||Phase 3|356|Actual|IRCCS Burlo Garofolo||3|||f||||t||||||||||2018-05-31 23:03:54.613145|2018-05-31 23:03:54.613145
NCT01257659|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-10-30|2010-12-09|2010-12-10|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RectoVerso||STARR Trans-anal Resection Versus Vaginal Rectocele Repair Using Elevate: Effects on Defecatory Function|STARR Type Trans-anal Resection Versus Vaginal Rectocele Repair Using a Posterier Elevate Prothesis: a Randomized, Multicentric, Prospective Study on Defecatory Function|Terminated||N/A|4|Actual|Centre Hospitalier Universitaire de Nīmes||2||Unable to find enough patients who accept randomization of surgical procedures.|f||||f||||||||||2018-05-31 23:03:54.754665|2018-05-31 23:03:54.754665
NCT01257646|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-03-24|2010-12-09|2010-12-10|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|MASEA||Observation of the Gait Cycle in Patients With Hemiplegia in Order to Improve the Triggering of Functional Electrical Stimulation|Observation of the Gait Cycle in Patients With Hemiplegia in Order to Improve the Triggering of Functional Electrical Stimulation|Completed|||20|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 23:03:54.85498|2018-05-31 23:03:54.85498
NCT01257633|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-09|||2015-03-26|2010-12-09|2010-12-10|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Observational|||Surgical Treatment of Early Stage Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance|Observational Study on Surgical Treatment of Early Stage (T1-T2) Glotto-supraglottic Laryngeal Cancer Via Transoral Resection With Robotic Assistance|Completed|||54|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 23:03:54.926227|2018-05-31 23:03:54.926227
NCT01257620|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-02-10|2010-12-08|2010-12-10|Estimate|||||||2012-02-10|2012-02-13|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|Celiac||Clinical Trial on the Effects of Bifidobacterium Infantis in Active Celiac Disease|Exploratory, Randomized, Double-blind, Placebo-Controlled Study on the Effects of Bifidobacterium Infantis in Active Celiac Disease|Completed||N/A|22|Actual|Bai, Julio M.D.||2|||f||||t||||||||||2018-05-31 23:03:55.008399|2018-05-31 23:03:55.008399
NCT01241851|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Effect of Acute Exercise on Cognitive Functions||Unknown status|Not yet recruiting|Early Phase 1|40|Anticipated|Hillel Yaffe Medical Center||3|||f||||t||||||||||2018-05-31 23:08:39.149068|2018-05-31 23:08:39.149068
NCT01257607|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2012-10-22|2010-12-08|2010-12-09|Estimate|||||||2012-10-22|2012-10-23|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye|A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model|Completed||Phase 2|150|Actual|Mimetogen Pharmaceuticals USA, Inc.||3|||f||||t||||||||||2018-05-31 23:03:55.103626|2018-05-31 23:03:55.103626
NCT01257594|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2016-09-07|2010-12-08|2010-12-09|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas|Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation|Active, not recruiting||N/A|22|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 23:03:55.195227|2018-05-31 23:03:55.195227
NCT01257581|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2014-03-10||2014-12-03|2010-12-08|2010-12-09|Estimate|2014-12-03|2014-12-04|Estimate||||2014-12-03|2014-12-04|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|SDALS-001|Efficacy outcomes are adjusted for baseline differences in time from symptom onset to diagnosis, site of symptom onset, and VC.|Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|Phase 2 Selection Trial of High Dosage Creatine and Two Dosages of Tamoxifen in Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|60|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 23:03:55.338449|2018-05-31 23:03:55.338449
NCT01257568|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2018-02-15|2010-12-08|2010-12-09|Estimate|||||||2018-02-15|2018-02-19|Actual|November 2010||2010-11-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|June 6, 2017|Actual|2017-06-06||Interventional|||Rejuvenate Modular Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Rejuvenate® Modular Hip System|Active, not recruiting||N/A|44|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-05-31 23:03:56.14978|2018-05-31 23:03:56.14978
NCT01257555|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-03-22|2010-12-08|2010-12-09|Estimate|||||||2012-03-22|2012-03-26|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Evaluation of a Photopneumatic System for the Treatment of Acne||Completed|||24|Anticipated|Valeant Pharmaceuticals|||1||f||||t||||||||||2018-05-31 23:03:56.209357|2018-05-31 23:03:56.209357
NCT01257542|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2012-08-21|2012-02-15|2012-08-21|2010-12-08|2010-12-09|Estimate|2012-08-21|2012-09-20|Estimate|2012-02-28|2012-03-01|Estimate|2012-08-21|2012-09-20|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Acute Cough Study In Children|A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose, Pilot Study To Evaluate Efficacy Of Dextromethorphan Hydrobromide On Acute Cough In A Pediatric Population|Terminated||Phase 4|140|Actual|Pfizer|Due to methodological issues during study conduct, the study was terminated after only less than 50% of the targeted enrollment was achieved.|2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:03:56.275022|2018-05-31 23:03:56.275022
NCT01257529|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2011-06-06|2010-12-08|2010-12-09|Estimate|||||||2011-06-06|2011-06-07|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Evaluate The Effects Of A Low, Medium And High Fat Evening Meal On The Pharmacokinetics Of Pregabalin Controlled Release Formulation As Compared To The Immediate Release Formulation|Completed||Phase 1|28|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:03:56.717168|2018-05-31 23:03:56.717168
NCT01257516|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2011-03-17|2010-12-08|2010-12-09|Estimate|||||||2011-03-17|2011-03-18|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers|An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of 660 Mg (2 X 330 Mg Tablets) Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 300 Mg Of The Immediate Release Formulation Administered Twice Daily|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:03:56.794956|2018-05-31 23:03:56.794956
NCT01257503|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2014-12-09||2014-12-31|2010-12-08|2010-12-09|Estimate|2014-12-18|2015-01-02|Estimate||||2014-12-31|2015-01-14|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional||Eligible patients enrolled. Age data were analyzed on 127 participants in the placebo group since exact data were missing for 2 participants|Homeopathic Cold Remedy for Children Study|Randomized Controlled Trial of a Homeopathic Cold Remedy for Children|Completed||N/A|263|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:03:56.887088|2018-05-31 23:03:56.887088
NCT01257490|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-04-17|2010-12-08|2010-12-09|Estimate|||||||2017-04-17|2017-04-18|Actual|October 2009||2009-10-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Integrated Smoking Cessation Treatment for Low Income Community Corrections|Integrated Smoking Cessation Treatment for Low Income Community Corrections|Completed||N/A|689|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 23:03:57.241243|2018-05-31 23:03:57.241243
NCT01257477|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2013-04-01|2010-12-08|2010-12-09|Estimate|||||||2013-04-01|2013-04-04|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|RELIANCE||LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|Research Study to Evaluate LOTRONEX® in Severe IBS-D: Analysis of Current Clinical Practice Environment|Completed|||400|Anticipated|Prometheus Laboratories|||||f||||f||||||||||2018-05-31 23:03:57.302196|2018-05-31 23:03:57.302196
NCT01257464|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-03-05|2010-12-08|2010-12-09|Estimate|||||||2014-03-05|2014-03-06|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Sitagliptin in Cystic Fibrosis-Related Diabetes|The Effects of the DPPIV Inhibitor Sitagliptin in Cystic Fibrosis-related Diabetes|Terminated||Phase 2|3|Actual|University of British Columbia||2||Lack of recruitment|f||||f||||||||||2018-05-31 23:03:58.283375|2018-05-31 23:03:58.283375
NCT01257451|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-12-14|2010-12-08|2010-12-09|Estimate|||||||2012-12-14|2012-12-18|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents)|Completed||Phase 3|431|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:03:58.368651|2018-05-31 23:03:58.368651
NCT01257438|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2015-07-22||2016-11-09|2010-12-08|2010-12-09|Estimate|2016-11-09|2017-01-09|Estimate||||2016-11-09|2017-01-09|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|November 2013|Actual|2013-11-30||Interventional|RESCUE|275 subjects were enrolled but, the primary effectiveness endpoint was statistically tested with 220 subjects.|FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis|Prospective, Multi-Center, Randomized, Concurrently-Controlled Study of the FLUENCY® PLUS Endovascular Stent Graft in the Treatment of In-stent Restenosis in the Arteriovenous (AV) Access Venous Outflow Circuit (RESCUE)|Completed||N/A|275|Actual|C. R. Bard||2|||f||||t||||||||No||2018-05-31 23:03:58.504773|2018-05-31 23:03:58.504773
NCT01257425|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2013-09-27||2014-04-30|2010-12-08|2010-12-09|Estimate|2014-04-30|2014-05-26|Estimate||||2014-04-30|2014-05-26|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|PAMIS|Analysed from intent-to-treat (ITT) population comprised of 103 patients (SC: 52 and IM: 51 patients).|Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg|A Phase II, Multicentre, Open, Prospective, Randomised, Parallel-Group, Pharmacodynamic Equivalence Study on Intramuscular Versus Subcutaneous Applications of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Patients With Advanced Prostate Cancer|Completed||Phase 2|109|Actual|Ipsen||2|||f||||f||||||||||2018-05-31 23:03:59.598968|2018-05-31 23:03:59.598968
NCT01257412|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-02-29|2010-12-08|2010-12-09|Estimate|||||||2012-02-29|2012-03-01|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone|A 24-week National Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Trial in India to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone.|Suspended||Phase 3|375|Anticipated|AstraZeneca||3||FSI delayed until 15 January 2013|f||||f||||||||||2018-05-31 23:04:00.087994|2018-05-31 23:04:00.087994
NCT01257399|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2013-04-03|2010-12-08|2010-12-09|Estimate|||||||2013-04-03|2013-04-04|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase|Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase|Completed||Phase 3|251|Actual|Tillotts Pharma AG||2|||f||||f||||||||||2018-05-31 23:04:00.259829|2018-05-31 23:04:00.259829
NCT01257386|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2013-04-03|2010-12-08|2010-12-09|Estimate|||||||2013-04-03|2013-04-04|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis|Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis|Completed||Phase 3|251|Actual|Tillotts Pharma AG||2|||f||||f||||||||||2018-05-31 23:04:00.340186|2018-05-31 23:04:00.340186
NCT01257373|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-28|2010-12-08|2010-12-09|Estimate|||||||2010-12-28|2010-12-30|Estimate|April 2010||2010-04-30|November 2009|2009-11-30|April 2013|Anticipated|2013-04-30|April 2011|Anticipated|2011-04-30||Observational|||Efficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in Diabetes|Efficacy and Safety of Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent in Treatment of Complex Coronary Lesions in Diabetes|Unknown status|Recruiting||1300|Anticipated|Xijing Hospital|||1||f||||t||||||||||2018-05-31 23:04:00.411454|2018-05-31 23:04:00.411454
NCT01257360|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-01-12|2010-12-08|2010-12-09|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|January 2016|Actual|2016-01-31||Interventional|NEO-RIT||Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)|NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)|Unknown status|Active, not recruiting|Phase 2|59|Actual|WiSP Wissenschaftlicher Service Pharma GmbH|||||f||||t||||||||||2018-05-31 23:04:00.498091|2018-05-31 23:04:00.498091
NCT01257347|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2016-07-25||2017-02-15|2010-12-08|2010-12-09|Estimate|2017-02-15|2017-04-05|Actual||||2017-02-15|2017-04-05|Actual|January 2011||2011-01-31|February 2017|2017-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MATCH|12 usual care clinicians had visits with 35 patients; 12 intervention clinicians has visits with 65 patients. 'Participant' in this study could mean a clinician or a patient.|Measuring Adherence to Control Hypertension|Uncontrolled Hypertension: The Role of Medication Adherence and Clinical Inertia|Completed||N/A|124|Actual|Columbia University||2|||f||||t||||||||No||2018-05-31 23:04:00.593952|2018-05-31 23:04:00.593952
NCT01257334|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|July 2012|Anticipated|2012-07-31|September 2011|Anticipated|2011-09-30||Interventional|||Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea|Unknown status|Enrolling by invitation|Phase 3|1390|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||t||||||||||2018-05-31 23:04:01.04909|2018-05-31 23:04:01.04909
NCT01257321|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate||||December 2010|2010-12-31||||||||Observational|||Risk Stratification of Post Tonsillectomy Respiratory Complications in the Pediatric Population||Unknown status|Not yet recruiting||200|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 23:04:01.113199|2018-05-31 23:04:01.113199
NCT01257308|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|August 2013|Anticipated|2013-08-31|||||Observational|||Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients|Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients|Unknown status|Enrolling by invitation||100|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:04:01.178023|2018-05-31 23:04:01.178023
NCT01257295|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2011-12-23|2010-12-08|2010-12-09|Estimate|||||||2011-12-23|2011-12-26|Estimate|December 2010||2010-12-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ProVe||Properties of Dietary Fibre and Energy Intake|Properties of Dietary Fibre and Energy Intake: an Intervention to Study the Effect of Physicochemical Properties of Dietary Fibre on Energy Intake and Underlying Mechanisms|Completed||N/A|29|Actual|Wageningen University||6|||f||||f||||||||||2018-05-31 23:04:01.230284|2018-05-31 23:04:01.230284
NCT01241357|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2016-09-20|2010-11-15|2010-11-16|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Observational|||High-Tc Susceptometer to Monitor Transfusional Iron Overload|High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device)|Completed|||99|Actual|Columbia University|||1||f||||f||||||||||2018-05-31 23:08:53.046495|2018-05-31 23:08:53.046495
NCT01257282|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|September 2007||2007-09-30|December 2010|2010-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|PUMI||Prevalence and Prognostic Value of Unrecognized Myocardial Injury in Stable Coronary Artery Disease (PUMI)|Prevalence and Prognostic Value of Unrecognised Myocardial Injury in Stable Coronary Artery Disease (PUMI)- a Multicenter, Observational Cohort Study.|Unknown status|Recruiting||275|Anticipated|Uppsala University|||||f||||f||||||Samples With DNA|"~     Plasma samples for biochemical markers. Whole blood samples for extraction of DNA for genetic~     analysis.~   "|||2018-05-31 23:04:01.301713|2018-05-31 23:04:01.301713
NCT01257269|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2018-02-12|2010-12-08|2010-12-09|Estimate|||||||2018-02-12|2018-02-13|Actual|October 2006||2006-10-31|February 2018|2018-02-28|October 2030|Anticipated|2030-10-31|October 2030|Anticipated|2030-10-31||Observational|TTP registry||Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)|Thrombotic Thrombocytopenic Purpura Registry - A Prospective Observational Study for Patients Suffering From Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)|Recruiting|||180|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||Samples With DNA|"~     Whole blood and plasma~   "|||2018-05-31 23:04:01.380419|2018-05-31 23:04:01.380419
NCT01257256|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Observational|HSA-246||Investigating the Relationships Among Illness Cognition, Social Support, Stress, and Emotional Reactions of Infertile Patients|Health Service Administration China Medical University|Unknown status|Recruiting||1|Anticipated|China Medical University Hospital|||1||f||||t||||||||||2018-05-31 23:04:01.575638|2018-05-31 23:04:01.575638
NCT01257243|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2013-02-26|2010-12-08|2010-12-09|Estimate|||||||2013-02-26|2013-02-27|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|||Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment|Multicentric, Randomized, Open-label Trial to Evaluate the Superiority of Fixed Dose Combination of Oxomemazine, Guaifenesin and Potassium Iodate to Guaifenesin Monotherapy in Acute Cough Treatment|Unknown status|Recruiting|Phase 3|120|Anticipated|EMS||2|||f||||f||||||||||2018-05-31 23:04:01.636792|2018-05-31 23:04:01.636792
NCT01257230|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2014-06-12||2014-08-27|2010-12-08|2010-12-09|Estimate|2014-08-07|2014-08-08|Estimate||||2014-08-27|2014-09-05|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Treated set which included all randomised patients who were dispensed trial medication and received at least one documented dose of trial medication.|Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma|A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma.|Completed||Phase 3|398|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:04:01.761546|2018-05-31 23:04:01.761546
NCT01257217|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2017-01-13||2017-03-09|2010-12-08|2010-12-09|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|November 2010||2010-11-30|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||This analysis population includes all randomized participants who received IOLs without major deviations and/or surgical complications (efficacy population).|A Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting Intraocular Lenses (IOLs)|A Randomized, Subject-Masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting IOLs|Completed||N/A|31|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:04:02.507114|2018-05-31 23:04:02.507114
NCT01257204|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2015-08-05||2015-11-10|2010-12-08|2010-12-09|Estimate|2015-11-10|2015-12-14|Estimate||||2015-11-10|2015-12-14|Estimate|December 2010||2010-12-31|November 2015|2015-11-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional||All participants who received at least 1 dose of study drug.|Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection|A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 Infection|Completed||Phase 2|196|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 23:04:02.8504|2018-05-31 23:04:02.8504
NCT01257191|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2017-01-09|2010-12-07|2010-12-09|Estimate|||||||2017-01-09|2017-01-11|Estimate|April 2010||2010-04-30|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Compare the Effects of Different Sized Particles on Cells in the Nose|Cellular Inflammation Characterization of Nasal Challenges With Fine and Ultrafine Particles|Completed||Phase 1|25|Actual|University of California, Los Angeles||5|||f||||t||||||||||2018-05-31 23:04:03.856453|2018-05-31 23:04:03.856453
NCT01257178|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-06-02|2010-12-07|2010-12-09|Estimate|||||||2011-06-02|2011-06-03|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment|A Single Dose Pharmacokinetics Study of LY2624803 in Subjects With Hepatic Impairment|Terminated||Phase 1|0|Actual|Eli Lilly and Company||4||Trial was Terminated prior to subjects receiving study drug; no trial results|f||||f||||||||||2018-05-31 23:04:03.947814|2018-05-31 23:04:03.947814
NCT01257165|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2013-12-12|2010-12-08|2010-12-09|Estimate|||||||2013-12-12|2013-12-13|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Driving Simulator Performance After Intake of Zopiclone Sleeping Pills|Driving Simulator Performance Related to Serum Concentrations of the Benzodiazepine-like Hypnotic Zopiclone|Withdrawn||N/A|0|Actual|St. Olavs Hospital||4|||f||||f||||||||||2018-05-31 23:04:04.021872|2018-05-31 23:04:04.021872
NCT01257152|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2016-04-18|2010-12-08|2010-12-09|Estimate|||||||2016-04-18|2016-04-20|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy|Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy|Completed|||754|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 23:04:04.12505|2018-05-31 23:04:04.12505
NCT01257139|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2015-04-01|2010-12-08|2010-12-09|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ESOGIA||"Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a Classical Strategy of Treatment Allocation, With anOptimized Strategy Allocating the Same Treatments"||Completed||Phase 3|490|Actual|Rennes University Hospital||2|||f||||||||||||||2018-05-31 23:04:04.200597|2018-05-31 23:04:04.200597
NCT01257126|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2012-04-25|2010-12-08|2010-12-09|Estimate|||||||2012-04-25|2012-04-26|Estimate|April 2011||2011-04-30|April 2012|2012-04-30||||December 2011|Anticipated|2011-12-31||Interventional|||Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection|Efficacy of Diclofenac Potassium Versus Nimesulide in the Treatment of Fever and Pain in Children Aged 3 to 7 Years With Community Acquired, Non-complicated, Upper Respiratory Tract Infection|Withdrawn||Phase 4|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:04:04.323505|2018-05-31 23:04:04.323505
NCT01257113|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2015-06-22|2010-12-08|2010-12-09|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Supervised Exercise Therapy vs Home Exercises for Patients With Subacromial Impingement|Is Supervised Exercise Therapy a Better Option Than Home Exercises for Patients With Subacromial Impingement When Looking at Pain and Function?|Completed||N/A|46|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 23:04:04.388867|2018-05-31 23:04:04.388867
NCT01257100|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2018-05-23|2010-12-08|2010-12-09|Estimate|||||||2018-05-23|2018-05-24|Actual|December 8, 2010||2010-12-08|July 6, 2017|2017-07-06||||||||Observational|||Environmental and Genetic Determinants of NPC|Environmental and Genetic Determinants of NPC|Completed|||3500|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:04:04.462141|2018-05-31 23:04:04.462141
NCT01257087|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2016-11-01|2010-12-08|2010-12-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|GLUCOSURG1||Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery|Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery.|Completed||N/A|20|Actual|Imperial College London||2|||f||||t||||||||No||2018-05-31 23:04:04.529938|2018-05-31 23:04:04.529938
NCT01257074|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-03-01|2010-12-08|2010-12-09|Estimate|||||||2013-03-01|2013-03-04|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis|A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis.|Completed||Phase 3|76|Actual|EMS||2|||f||||f||||||||||2018-05-31 23:04:04.601626|2018-05-31 23:04:04.601626
NCT01257061|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2013-03-01|2010-12-08|2010-12-09|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment|Unicentric Comparing Effectiveness Superiority of to Clemastine Fumarate 1, 0 mg/g + Dexamethasone 0, 5 mg/g to Dexchlorpheniramine Maleate 10 mg/g in Eczema Treatment.|Unknown status|Recruiting|Phase 3|30|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 23:04:04.679137|2018-05-31 23:04:04.679137
NCT01257048|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2012-08-31|2010-12-08|2010-12-09|Estimate|||||||2012-08-31|2012-09-03|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler|An Open, Randomised, Parallel Group Multi-centre, Methodology Study, Evaluating the Sensitivity of Oxygen-Enhanced Magnetic Resonance Imaging (OE-MRI) in Detecting and Comparing Response to 8 Weeks Treatment With Budesonide/Formoterol Turbuhaler® (320/9 µg Bid) and Formoterol Turbuhaler® (9 µg Bid) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Early Phase 1|34|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 23:04:04.786219|2018-05-31 23:04:04.786219
NCT01257035|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2013-06-14|2010-12-08|2010-12-09|Estimate|||||||2013-06-14|2013-06-17|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Observational|FAZA||Predictive Value of 18F-FAZA in Rectum Cancer|The Predictive Value of 18F-FAZA-PET/CT in Neoadjuvant Radiation for Patients With Locally Advanced Rectum Cancer|Terminated|||21|Actual|Vejle Hospital|||1|"The logistics of this trial (incl. supply of tracer) in connection with the patients' treatment~   course caused the inclusion rate to be very slow."|f||||f||||||||||2018-05-31 23:04:04.852491|2018-05-31 23:04:04.852491
NCT01257022|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2014-03-04|2010-12-08|2010-12-09|Estimate|||||||2014-03-04|2014-03-05|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Familias Unidas: Preventing Drug Abuse and HIV in Hispanic First Offenders|Preventing Drug Abuse and HIV in Hispanic First Offenders|Completed||Phase 2|242|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 23:04:04.96365|2018-05-31 23:04:04.96365
NCT01257009|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|August 2009||2009-08-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Atorvastatin and Sympathetic Activity in Chronic Kidney Disease|Atorvastatin Reduces Sympathetic Activity in Patients With Chronic Kidney Disease|Completed||Phase 4|10||UMC Utrecht||2|||f||||t||||||||||2018-05-31 23:04:05.030358|2018-05-31 23:04:05.030358
NCT01256996|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|January 2012|Anticipated|2012-01-31|April 2011|Anticipated|2011-04-30||Interventional|||Therapy of Peri-implantitis: Scaling Versus Low Abrasive Powder|A Randomized Multicenter Study in the Therapy of Periimplantitis: Scaling Versus Low Abrasive Powder|Unknown status|Enrolling by invitation|Phase 2|40|Anticipated|Heidelberg University||1|||f||||||||||||||2018-05-31 23:04:05.095788|2018-05-31 23:04:05.095788
NCT01256983|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|2013-09-26||2014-01-29|2010-12-08|2010-12-09|Estimate|2013-12-10|2014-01-28|Estimate||||2014-01-29|2014-03-03|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|SleepTx-1||Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation|Daily Light Intervention in Renal Transplant Recipients Having a Sleep-Wake Dysregulation|Completed||Early Phase 1|30|Actual|University of Basel|The study was very long and burdensome for the participants, a full powered study should be shorter.|2|||f||||t||||||||||2018-05-31 23:04:05.159293|2018-05-31 23:04:05.159293
NCT01256970|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2013-09-10|2010-12-08|2010-12-09|Estimate|||||||2013-09-10|2013-09-11|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||The Study of Polycystic Ovary Syndrome (PCOS) and Questionnaire|The Study of Polycystic Ovary Syndrome (PCOS) and Questionnaire|Completed|||306|Actual|Taipei Medical University WanFang Hospital|||2||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 23:04:05.356285|2018-05-31 23:04:05.356285
NCT01256957|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2016-12-01|2010-12-08|2010-12-09|Estimate|||||||2016-12-01|2016-12-05|Estimate|November 2008||2008-11-30|December 2010|2010-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|WEST||Effect of HEPA Air Filters on Subclinical Markers of Cardiovascular Health|Assessing the Impact of Wood Stove Interventions on Air Quality|Completed||N/A|56|Actual|Simon Fraser University||2|||f||||f||||||||||2018-05-31 23:04:05.429735|2018-05-31 23:04:05.429735
NCT01256944|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2013-11-28||2015-12-08|2010-12-08|2010-12-09|Estimate|2015-12-08|2016-01-13|Estimate||||2015-12-08|2016-01-13|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||To Study Polycystic Ovary Syndrome in Taiwanese Women|To Study Polycystic Ovary Syndrome in Taiwanese Women|Completed|||290|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 23:04:05.5051|2018-05-31 23:04:05.5051
NCT01256931|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||||||Observational|||Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients.|Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients.|Unknown status|Recruiting||110|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||||2018-05-31 23:04:05.82165|2018-05-31 23:04:05.82165
NCT01256918|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2011-02-24||2012-07-07|2010-12-08|2010-12-09|Estimate|2012-07-07|2012-08-16|Estimate||||2012-07-07|2012-08-16|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|CALIBCHOP||Study of Phacodepth Required for Safe and Effective Chop During Phacoemulsification for Cataract.|Evaluation of Phacodepth Required to Achieve Full Thickness Nuclear Crack in Various Grades of Cataract and to Determine the Correlation Between the Two.|Completed|||200|Actual|Dr. Ram Manohar Lohia Hospital|first time use of callibrated phacotip to measure phacotip penetration during vertical chop during phacoemulsification , hence no pre existing results to compare with.||||f||||t||||||||||2018-05-31 23:04:05.900754|2018-05-31 23:04:05.900754
NCT01256905|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|December 2010||2010-12-31|April 2010|2010-04-30||||April 2011|Anticipated|2011-04-30||Interventional|Armodafinil||Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies|Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies|Unknown status|Recruiting|N/A|20|Anticipated|New York University|||||f||||f||||||||||2018-05-31 23:04:06.107101|2018-05-31 23:04:06.107101
NCT01256892|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-09|2010-12-08|2010-12-09|Estimate|||||||2010-12-09|2010-12-10|Estimate||||December 2010|2010-12-31||||||||Interventional|||Insulin Dependent Gestational Diabetes Mellitus: Randomized Trial of Induction of Labour at 38 and 40 Weeks of Gestation||Completed||N/A|||Medical University of Vienna|||||f||||f||||||||||2018-05-31 23:04:06.181952|2018-05-31 23:04:06.181952
NCT01256879|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-11-21|2010-12-07|2010-12-09|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|||Cimetidine Biowaivers|Evaluation of Excipient Effects on Biopharmaceuticals Classification System (BCS) Class 3 Drug Cimetidine|Unknown status|Recruiting|Phase 1|24|Anticipated|University of Maryland||4|||f||||t||||||||||2018-05-31 23:04:06.231308|2018-05-31 23:04:06.231308
NCT01256866|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2010-12-08|2010-12-08|2010-12-09|Estimate|||||||2010-12-08|2010-12-09|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|June 2012|Anticipated|2012-06-30|October 2011|Anticipated|2011-10-31||Interventional|||Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine|Sedation of Mechanically Ventilated Critically Ill Patients: Midazolam Versus Dexmedetomidine|Unknown status|Recruiting|Phase 4|146|Anticipated|Hospital Sao Domingos||2|||f||||t||||||||||2018-05-31 23:04:06.316535|2018-05-31 23:04:06.316535
NCT01256853|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2011-12-21|2010-12-08|2010-12-09|Estimate|||||||2011-12-21|2011-12-22|Estimate|September 2006||2006-09-30|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Modified Vaccinia Ankara (MVA) Vaccine Study|A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens|Completed||Phase 1|18|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 23:04:06.386256|2018-05-31 23:04:06.386256
NCT01256840|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2017-05-12||2017-10-09|2010-12-07|2010-12-09|Estimate|2017-10-09|2017-10-13|Actual||||2017-10-09|2017-10-13|Actual|December 2010||2010-12-31|October 2017|2017-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|CRONA||Long-term Caloric Restriction and Cellular Aging Markers|Caloric Restriction With Optimal Nutrition and Aging Study|Completed|||71|Actual|University of California, San Francisco|||3||f||||f||||||Samples With DNA|"~     Whole blood, serum.~   "|||2018-05-31 23:04:06.461637|2018-05-31 23:04:06.461637
NCT01256827|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2013-11-12|2010-12-07|2010-12-09|Estimate|||||||2013-11-12|2013-11-14|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Observational|SEVEN UP||Seven Year Update of Macular Degeneration Patients|Seven Year Observational Update of Macular Degeneration Patients Post-MARINA/ANCHOR and HORIZON Trials (SEVEN UP Study)|Completed|||65|Actual|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     blood samples will be drawn~   "|||2018-05-31 23:04:06.778478|2018-05-31 23:04:06.778478
NCT01256814|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-08|||2011-08-29|2010-12-08|2010-12-09|Estimate|||||||2011-08-29|2011-08-30|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|||||Interventional|||Study of SystemCHANGE-HIV|SystemCHANGE-HIV: A Pilot Study Exploring the Effect of a Systems-based Intervention to Increase Physical Activity, Sleep Behavior, and Mental Wellness|Completed||N/A|43|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 23:04:06.850608|2018-05-31 23:04:06.850608
NCT01256801|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-07-27|2010-12-08|2010-12-09|Estimate|||||||2015-07-27|2015-07-29|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Observational|GMPE||Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion|Gene Expression Profiling of Breast Cancer Cells in Pleural Effusion Prodict the Response of Malignant Pleural Effusion to Immunotherapy|Completed|||36|Actual|Beijing Cancer Hospital|||1||f||||t||||||Samples Without DNA|"~     The cancer cells are taken from the malignant pleural effusion of breast cancer patiets.~   "|||2018-05-31 23:04:06.910944|2018-05-31 23:04:06.910944
NCT01256788|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-07-23|2010-12-07|2010-12-09|Estimate|||||||2015-07-23|2015-07-24|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Post-op Treatment With Hyaluronic Acid Injections|Prospective Randomized Study Evaluating Clinical Effectiveness of Post-op Treatment With Hyaluronic Acid Injections in Degenerative Joint Disease & Meniscal Tears|Terminated||Phase 4|33|Actual|The Hawkins Foundation||2||Insurance now covers post-op HA injections, drastically decreasing enrollment.|f||||t||||||||||2018-05-31 23:04:06.974897|2018-05-31 23:04:06.974897
NCT01256775|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-01-18|2010-12-07|2010-12-09|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2003||2003-09-30|January 2011|2011-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)|A Multicenter, Double-blind, Randomized, Parallel Group Study to Assess the Effect of NCX4016 vs Placebo on Walking Distance in Patients With Peripheral Arterial Occlusive Disease at Leriche-Fontaine Stage II|Completed||Phase 2|442|Actual|NicOx Research Institute S.r.l.||2|||f||||t||||||||||2018-05-31 23:04:07.06598|2018-05-31 23:04:07.06598
NCT01256762|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02||2015-03-13|2015-12-22|2010-12-07|2010-12-09|Estimate||||2015-03-13|2015-04-02|Estimate|2015-12-22|2016-01-26|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer|A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer|Completed||Phase 2|166|Actual|Geron Corporation||2|||f||||f||||||||||2018-05-31 23:04:07.197384|2018-05-31 23:04:07.197384
NCT01256749|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-09-08|2010-12-08|2010-12-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A Comparative Study of Global 12 Lead Electroencephalogram to Frontal SedlineTM Electroencephalogram|A Comparative Study of Global 12 Lead Electroencephalogram to Frontal SedlineTM Electroencephalogram Monitoring for the Evaluation of Intraoperative Burst Suppression During Elective Craniotomy or Transphenoidal Pituitary Resection|Completed|||31|Actual|Loma Linda University|||||f||||f||||||||||2018-05-31 23:04:07.413069|2018-05-31 23:04:07.413069
NCT01256736|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-11-18|2010-12-07|2010-12-09|Estimate|||||||2013-11-18|2013-11-20|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|December 2011|Actual|2011-12-31||Interventional|||To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis|Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study|Completed||Phase 3|89|Actual|JW Pharmaceutical||1|||f||||t||||||||||2018-05-31 23:04:07.467963|2018-05-31 23:04:07.467963
NCT01256723|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2017-01-26|2010-12-08|2010-12-09|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2015|Actual|2015-05-31||Observational|J-LESSON||Japan Unprotected Left Main Coronary Artery Disease Percutaneous Coronary Intervention (PCI) Strategy On New Generation Stents|Multicenter Prospective Registry of PCI With a New Generation Everolimus- Eluting Stent for Unprotected Left Main Coronary Artery Disease|Active, not recruiting|||441|Actual|Associations for Establishment of Evidence in Interventions|||1||f||||t||||||||||2018-05-31 23:04:07.531776|2018-05-31 23:04:07.531776
NCT01256710|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2018-04-18|2010-12-07|2010-12-08|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2011||2011-01-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Trifecta Durability Study|Trifecta Durability Study|Active, not recruiting|||1231|Actual|St. Jude Medical|||1||f||||f||||||||No||2018-05-31 23:04:07.598377|2018-05-31 23:04:07.598377
NCT01256697|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-12-19|2010-12-07|2010-12-08|Estimate|||||||2013-12-19|2013-12-20|Estimate|August 2008||2008-08-31|December 2013|2013-12-31|January 2011|Actual|2011-01-31|April 2009|Actual|2009-04-30||Interventional|||The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa|The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella|Completed||N/A|34|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:04:07.657557|2018-05-31 23:04:07.657557
NCT01256684|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2017-03-14|2013-05-01|2017-05-31|2010-12-07|2010-12-08|Estimate|2017-03-14|2017-04-25|Actual|2013-05-01|2013-05-09|Estimate|2017-05-31|2017-06-26|Actual|December 2010||2010-12-31|May 2017|2017-05-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional||Baseline Analysis Population corresponds to the Safety Population which includes all subjects who received any amount of DHEA or placebo, and who have any safety information available.|DHEA Against Vaginal Atrophy - 3-Month Efficacy Study|DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA)|Completed||Phase 3|255|Actual|EndoCeutics Inc.||3|||f||||t||||||||||2018-05-31 23:04:07.746666|2018-05-31 23:04:07.746666
NCT01256671|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2017-03-16|2013-05-01|2017-09-15|2010-12-07|2010-12-08|Estimate|2017-09-15|2017-10-18|Actual|2013-05-01|2013-05-09|Estimate|2017-09-15|2017-10-18|Actual|December 2010||2010-12-31|September 2017|2017-09-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional||Baseline Analysis Population corresponds to the Safety Population which includes all subjects who received any amount of DHEA, and who have any safety information available.|DHEA Against Vaginal Atrophy - Safety Study of 12 Months|DHEA Against Vaginal Atrophy - Safety Study of 12 Months|Completed||Phase 3|530|Actual|EndoCeutics Inc.||1|||f||||t||||||||||2018-05-31 23:04:08.311082|2018-05-31 23:04:08.311082
NCT01256658|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2013-07-23||2014-01-14|2010-12-07|2010-12-08|Estimate|2013-11-22|2013-11-25|Estimate||||2014-01-14|2014-02-10|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)|A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemether-lumefantrine (Coartem® / Coartem® Dispersible)|Completed||Phase 4|14075|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:04:08.741441|2018-05-31 23:04:08.741441
NCT01256645|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|WTT||Transfusion Strategies in Weaning Patients|Liberal Versus Restrictive Transfusion Management in Patients Being Weaned From Prolonged Mechanical Ventilation|Unknown status|Recruiting|Phase 4|120|Anticipated|Krankenhaus Kloster Grafschaft||2|||f||||f||||||||||2018-05-31 23:04:09.70792|2018-05-31 23:04:09.70792
NCT01256632|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-06-26|2010-12-07|2010-12-08|Estimate|||||||2012-06-26|2012-06-28|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|PVD||Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy|Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy|Completed||N/A|40|Actual|Vision Research Foundation||2|||f||||f||||||||||2018-05-31 23:04:09.78802|2018-05-31 23:04:09.78802
NCT01256619|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|September 2010||2010-09-30|December 2010|2010-12-31||||September 2010|Anticipated|2010-09-30||Interventional|||Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health||Unknown status|Recruiting|Phase 2|61|Anticipated|Tehran University of Medical Sciences||1|||f||||f||||||||||2018-05-31 23:04:09.887093|2018-05-31 23:04:09.887093
NCT01256606|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2013-01-08|2010-12-07|2010-12-08|Estimate|||||||2013-01-08|2013-01-10|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Prenatal Test for Fetal Aneuploidy Detection|Investigational Study of a Prenatal Diagnostic Test for Fetal Aneuploidy|Completed|||4000|Actual|Roche Sequencing Solutions|||2||f||||f||||||||||2018-05-31 23:04:09.946324|2018-05-31 23:04:09.946324
NCT01256593|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2017-11-27|2010-12-07|2010-12-08|Estimate|||||||2017-11-27|2017-11-29|Actual|February 5, 2011|Actual|2011-02-05|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|RAINBOW||Safety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Lyrica(Regulatory Post Marketing Commitment Plan)|Completed|||3827|Actual|Pfizer|||1||f||||f|t|f||||||||2018-05-31 23:04:10.073493|2018-05-31 23:04:10.073493
NCT01256580|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-01-13|2010-12-07|2010-12-08|Estimate|||||||2014-01-13|2014-01-14|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Interventional|CNV||Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD|Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration|Withdrawn||N/A|0|Actual|Massachusetts Eye and Ear Infirmary||2||Lack of eligible subjects.|f||||f||||||||||2018-05-31 23:04:10.15028|2018-05-31 23:04:10.15028
NCT01256567|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2014-05-16||2014-05-16|2010-12-07|2010-12-08|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer|A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 1|7|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 23:04:10.251003|2018-05-31 23:04:10.251003
NCT01256554|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2018-01-31|2010-12-07|2010-12-08|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2010|Actual|2010-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression|Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management of Patients With Inoperable, Previously Irradiated Metastatic Epidural Spinal Cord Compression (MESCC)|Active, not recruiting||Phase 1|36|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:04:10.590127|2018-05-31 23:04:10.590127
NCT01256541|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-10-05|2010-12-07|2010-12-08|Estimate|||||||2011-10-05|2011-10-06|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Kristalose as Bowel Evacuant Prior to Colonoscopy|A Single Center, Open-Label, Pilot Study to Determine the Safety, Efficacy, and Patient Preference of Kristalose as a Bowel Evacuant Prior to Colonoscopy|Completed||Phase 1|20|Anticipated|Benaroya Research Institute||1|||f||||f||||||||||2018-05-31 23:04:10.694413|2018-05-31 23:04:10.694413
NCT01256528|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2016-07-14|2010-12-07|2010-12-08|Estimate|||||||2016-07-14|2016-07-15|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Delayed-Delayed Breast Reconstruction|A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients With Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy|Completed||N/A|40|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:04:10.770404|2018-05-31 23:04:10.770404
NCT01256515|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2013-05-28|2010-12-07|2010-12-08|Estimate|||||||2013-05-28|2013-05-29|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Interventional|||Health Management Training to Enhance Influenza Vaccine Immunogenicity|Health Management Training to Enhance Influenza Vaccine Immunogenicity|Completed||N/A|40|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:04:10.843231|2018-05-31 23:04:10.843231
NCT01256502|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2013-12-18||2017-10-05|2010-12-07|2010-12-08|Estimate|2014-04-16|2014-05-16|Estimate||||2017-10-05|2017-11-06|Actual|October 2010||2010-10-31|October 2017|2017-10-31|April 2014|Actual|2014-04-30|October 2012|Actual|2012-10-31||Interventional||Subjects implanted with SERI® during their Stage I breast reconstruction surgery|The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction Surgery||Completed||N/A|160|Actual|Sofregen Medical, Inc.|None to report.|1|||f||||||||||||||2018-05-31 23:04:10.941841|2018-05-31 23:04:10.941841
NCT01256489|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2015-11-03|2010-12-07|2010-12-08|Estimate|||||||2015-11-03|2015-11-04|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)|Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis|Withdrawn||Phase 1/Phase 2|0|Actual|Massachusetts Eye and Ear Infirmary||1||"Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (~3 in~   1 million). No eligible subjects have been identified."|f||||t||||||||||2018-05-31 23:04:11.217924|2018-05-31 23:04:11.217924
NCT01256476|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2012-04-03||2012-05-02|2010-12-07|2010-12-08|Estimate|2012-04-03|2012-04-30|Estimate||||2012-05-02|2012-05-08|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PREVAIL-US||Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia|A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA|Completed||Phase 4|328|Actual|Kowa Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 23:04:11.311691|2018-05-31 23:04:11.311691
NCT01256463|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2016-12-30|2010-12-07|2010-12-08|Estimate|||||||2016-12-30|2017-01-02|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional|||HIV Prevention for PLHIV: Evaluation of an Intervention Toolkit for HIV Care & Treatment Settings|HIV Prevention for People Living With HIV/AIDS: Evaluation of an Intervention Toolkit for HIV Care and Treatment Settings|Completed||N/A|3548|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 23:04:11.577302|2018-05-31 23:04:11.577302
NCT01256450|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2015-11-04|2015-02-24|2017-01-12|2010-12-07|2010-12-08|Estimate|2015-11-04|2015-12-08|Estimate|2015-02-24|2015-03-17|Estimate|2017-01-12|2017-02-27|Actual|November 2010||2010-11-30|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Analysis based on Randomized population; all subjects who were randomized into the double-blind period, even if study drug was not taken in the period|Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain|A 12-Week, Placebo Controlled, Double Blind, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Buprenorphine HCl Buccal Film in Subjects With Moderate to Severe Chronic Low Back Pain|Completed||Phase 3|334|Actual|BioDelivery Sciences International||2|||f||||f||||||||||2018-05-31 23:04:11.682853|2018-05-31 23:04:11.682853
NCT01256437|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2017-05-07|2010-12-07|2010-12-08|Estimate|||||||2017-05-07|2017-05-09|Actual|January 2011||2011-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|EGFR'I||Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash|Double Blind Placebo Controlled Trial, for Evaluating Preventive Therapy With Either Oint Threolone Versus Synthomycine Versus Aqua Cream, for EGFR'I Induced Acneiform Rash|Completed||Phase 2|90|Actual|Rabin Medical Center||3|||f||||f||||||||Yes||2018-05-31 23:04:12.114948|2018-05-31 23:04:12.114948
NCT01256424|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2014-08-06||2016-04-08|2010-12-07|2010-12-08|Estimate|2014-08-06|2014-08-21|Estimate||||2016-04-08|2016-05-16|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia|A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2)|Completed||Phase 2|262|Actual|Photocure||4|||f||||f||||||||||2018-05-31 23:04:12.188423|2018-05-31 23:04:12.188423
NCT01256411|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2015-07-21||2015-09-22|2010-12-07|2010-12-08|Estimate|2015-09-22|2015-10-21|Estimate||||2015-09-22|2015-10-21|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension|An Open-label, Long-term Extension Study to Evaluate the Safety, Tolerability and Efficacy of 12 Months of LCZ696 Treatment in Patients With Essential Hypertension|Completed||Phase 2|341|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:04:12.632098|2018-05-31 23:04:12.632098
NCT01256398|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2018-05-24|2010-12-07|2010-12-08|Estimate|||||||2018-05-24|2018-05-25|Actual|December 14, 2010|Actual|2010-12-14|May 2018|2018-05-31||||November 14, 2017|Actual|2017-11-14||Interventional|||Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase II Study of Dasatinib (Sprycel&#174;) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults &gt;/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG|Active, not recruiting||Phase 2|66|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:04:13.100297|2018-05-31 23:04:13.100297
NCT01256385|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2016-10-04||2017-02-23|2010-12-07|2010-12-08|Estimate|2016-12-09|2017-02-06|Estimate||||2017-02-23|2017-03-27|Actual|November 2010||2010-11-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MAESTRO HN|Three patients from each treatment arm did not start treatment and are considered non-evaluable.|Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy|A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy|Completed||Phase 2|86|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:04:14.360521|2018-05-31 23:04:14.360521
NCT01256372|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-05|||2012-03-14|2010-12-07|2010-12-08|Estimate|||||||2012-03-14|2012-03-15|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery|An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery|Completed||Phase 2|77|Actual|Action Pharma A/S||3|||f||||t||||||||||2018-05-31 23:04:15.126027|2018-05-31 23:04:15.126027
NCT01256359|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2018-05-03|2010-12-06|2010-12-08|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2010||2010-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2012|Actual|2012-10-31||Interventional|DOC-MEK||Docetaxel With or Without AZD6244 in Melanoma|A Double Blind Randomised Phase 2 Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma|Active, not recruiting||Phase 2|80|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 23:04:15.20181|2018-05-31 23:04:15.20181
NCT01256346|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2014-12-01|2010-12-07|2010-12-08|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Electrocardiography Versus Pulse Oximetry for Newborn Heart Rate Determination|A Comparison of Electrocardiography Versus Pulse Oximetry for Determination of Initial Heart Rate in Preterm Newborns: A Pilot Study.|Withdrawn|||0|Actual|University of Oklahoma|||1|Study completed by another institution prior to enrollment of first subject.|f||||f||||||||||2018-05-31 23:04:15.267231|2018-05-31 23:04:15.267231
NCT01256333|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-07-02|2010-12-07|2010-12-08|Estimate|||||||2013-07-02|2013-07-03|Estimate|January 2011||2011-01-31|July 2013|2013-07-31||||||||Observational|OPTIPEP||Optimization of Arterial Oxygen Transport by Positive End-expiratory Pressure Variation in Acute Respiratory Distress Syndrome|Optimization of Arterial Oxygen Transport by Positive End-expiratory Pressure Variation in Acute Respiratory Distress Syndrome|Completed|||12|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 23:04:15.332558|2018-05-31 23:04:15.332558
NCT01256320|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2017-05-01|2010-12-06|2010-12-08|Estimate|||||||2017-05-01|2017-05-04|Actual|June 2010||2010-06-30|May 2017|2017-05-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Egg Study With Peripheral Arterial Disease|The Impact of Egg Consumption on Indices of Vascular Health in Individuals With Peripheral Arterial Disease|Completed||N/A|60|Actual|University of Manitoba||3|||f||||f||||||||||2018-05-31 23:04:15.390961|2018-05-31 23:04:15.390961
NCT01256307|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2014-12-03|2010-12-06|2010-12-08|Estimate|||||||2014-12-03|2014-12-04|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|REEVASAS||Effects of an Individualized Training Program on Severity Markers of Obstructives Sleep Apnea/Hypopnea Syndrome (OSAS)|Effects of an Individualized Training Program on Severity Markers of Obstructives Sleep Apnea/Hypopnea Syndrome (OSAS)|Completed||N/A|68|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 23:04:15.467945|2018-05-31 23:04:15.467945
NCT01256294|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2012-05-21||2012-05-21|2010-12-07|2010-12-08|Estimate|2012-05-21|2012-06-21|Estimate||||2012-05-21|2012-06-21|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients|A Prospective, Multi-center, Open-label, Randomized, Two Period, Two Sequence, Crossover Study to Compare the Steady State Pharmacokinetics of Generic Tacrolimus (Sandoz) to Prograf in Stable Renal Transplant Patients|Completed||Phase 4|71|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:04:15.556562|2018-05-31 23:04:15.556562
NCT01256281|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2013-12-02||2015-04-06|2010-12-07|2010-12-08|Estimate|2015-04-06|2015-04-23|Estimate||||2015-04-06|2015-04-23|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|RESCUED||Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency Department: Phase I|RESCUED: Phase I: Regional Anesthesia for Sickle Cell Crisis Using Ultrasound in The Emergency|Terminated||Phase 1|2|Actual|Icahn School of Medicine at Mount Sinai|study was terminated due to lack of resources. no data analysis for this study.|1||lack of resources|f||||t||||||||||2018-05-31 23:04:15.894715|2018-05-31 23:04:15.894715
NCT01256268|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-08-29|2010-12-07|2010-12-08|Estimate|||||||2017-08-29|2017-08-30|Actual|June 13, 2011|Actual|2011-06-13|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|February 3, 2016|Actual|2016-02-03||Interventional|||Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids|Phase 1A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers|Completed||Phase 1|24|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-05-31 23:04:16.017378|2018-05-31 23:04:16.017378
NCT01256255|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-05-26|2010-12-07|2010-12-08|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|May 2015|Actual|2015-05-31||Observational|||Influenza Virus - A Multicenter Registry|INFLUENZA VIRUS INFECTIONS IN TRANSPLANT RECIPIENTS: A MULTICENTER REGISTRY|Unknown status|Active, not recruiting||300|Anticipated|University of Alberta|||1||f||||f||||||Samples Without DNA|"~     serum and nasal swabs~   "|||2018-05-31 23:04:16.104605|2018-05-31 23:04:16.104605
NCT01256242|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2011-05-27|2010-12-07|2010-12-08|Estimate|||||||2011-05-27|2011-05-30|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Pilot Study of Augment Rotator Cuff for Surgical Treatment of Full Thickness Rotator Cuff Tears|A Single Blinded, Multi-center, Randomized, Controlled, Pilot Study to Evaluate the Safety and Performance of Augment™ Rotator Cuff for Primary Surgical Treatment of Full Thickness Rotator Cuff Tears|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|BioMimetic Therapeutics||2|||f||||f||||||||||2018-05-31 23:04:16.164765|2018-05-31 23:04:16.164765
NCT01256229|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2016-11-11|2010-12-06|2010-12-08|Estimate|||||||2016-11-11|2016-11-15|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Outcomes In Children With Developmental Delay And Deafness|OUTCOMES IN CHILDREN WITH DEVELOPMENTAL DELAY AND DEAFNESS: A PROSPECTIVE, RANDOMIZED TRIAL|Completed||Phase 1|303|Actual|Stanford University||3|||f||||||||||||||2018-05-31 23:04:16.240124|2018-05-31 23:04:16.240124
NCT01256216|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2017-06-16|2010-12-07|2010-12-08|Estimate|||||||2017-06-16|2017-06-19|Actual|September 2010||2010-09-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Signature Versus Computer Assisted Surgery Study|A Comparison of Signature Custom Cutting Guides and Computer Assisted Surgery Techniques With the Vanguard Knee System|Completed||N/A|60|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-05-31 23:04:16.334295|2018-05-31 23:04:16.334295
NCT01256203|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2014-02-28|2010-12-07|2010-12-08|Estimate|||||||2014-02-28|2014-03-04|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light|Prospective, Randomized, Controlled, Partially Blinded, Skin Photobiological Clinical Study of the Efficacy and Safety of a Sunscreen Product as Skin Protector Against Porfimer Sodium-induced Phototoxicity to Visible Light|Withdrawn||Phase 2|0|Actual|Pinnacle Biologics Inc.||1||Sponsor cancelled the study|f||||f||||||||||2018-05-31 23:04:16.399127|2018-05-31 23:04:16.399127
NCT01256190|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2013-04-11||2016-07-22|2010-12-07|2010-12-08|Estimate|2014-04-14|2014-05-15|Estimate||||2016-07-22|2016-08-22|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||A Study of Fibrocaps in Liver Surgery in the Netherlands|A Phase 2, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety and Study of Topical Fibrocaps™ and Gelatin Sponge in Surgical Hemostasis in the Netherlands|Completed||Phase 2|56|Actual|Mallinckrodt||2|||f||||t||||||||||2018-05-31 23:04:16.484448|2018-05-31 23:04:16.484448
NCT01256177|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2013-10-31||2016-03-18|2010-12-07|2010-12-08|Estimate|2016-01-04|2016-02-03|Estimate||||2016-03-18|2016-04-15|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Full Analysis Set (FAS) Of the 148 patients randomized to each group, 1 in each group did not receive treatament. In addition, there were 15 patients (7 placebo; 8 quetiapine XR) for which no MADRS data were collected. All 17 patients are included in the Reason Not Completed Section above.|Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression|A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression|Completed||Phase 3|361|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:04:16.89117|2018-05-31 23:04:16.89117
NCT01256164|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2013-04-11||2017-08-14|2010-12-07|2010-12-08|Estimate|2013-10-21|2013-11-11|Estimate||||2017-08-14|2017-09-13|Actual|December 2010||2010-12-31|August 2017|2017-08-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||U.S. Study of Fibrocaps in Surgical Hemostasis|A U.S. Phase 2, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Fibrocaps™ and Gelatin Sponge (USP) in Surgical Hemostasis|Completed||N/A|70|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 23:04:17.430263|2018-05-31 23:04:17.430263
NCT01256151|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-05-24|2010-12-06|2010-12-08|Estimate|||||||2011-05-24|2011-05-26|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet|Open-label, Randomized, Single-Dose, 2 Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet|Completed||Phase 1|28|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:04:17.782288|2018-05-31 23:04:17.782288
NCT01256138|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||||||Observational|||Allogene MSCs Transplantation in Liver for Patients With Chronic Liver Diseases Through Portal Vein by Ultrasound Guiding||Unknown status|Recruiting||60|Anticipated|Sun Yat-sen University|||2||f||||t||||||||||2018-05-31 23:04:17.851755|2018-05-31 23:04:17.851755
NCT01256125|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||||||Observational|||Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.|Therapeutic Effects of Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.|Unknown status|Recruiting||60|Anticipated|Sun Yat-sen University|||2||f||||t||||||||||2018-05-31 23:04:17.913277|2018-05-31 23:04:17.913277
NCT01256112|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2017-10-16|2010-12-06|2010-12-08|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2006||2006-09-30|October 2017|2017-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Parent Supported Weight Reduction in Down Syndrome|Parent Supported Weight Reduction in Down Syndrome|Completed||N/A|21|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f|f|f||||||||2018-05-31 23:04:17.978489|2018-05-31 23:04:17.978489
NCT01256099|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2015-04-01|2010-12-07|2010-12-08|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|IpsyInsomni||Internet-CBT for Insomnia|Guided Internet-treatment for Insomnia. Treatment Effects, Health Economics and Interaction With Depression|Completed||N/A|191|Actual|Karolinska Institutet||4|||f||||f||||||||||2018-05-31 23:04:18.065732|2018-05-31 23:04:18.065732
NCT01255566|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-04-23|2010-12-06|2010-12-07|Estimate|||||||2013-04-23|2013-04-24|Estimate|August 2009||2009-08-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Observational|||Medical Therapy Versus Sinus Surgery for Chronic Rhinosinusitis: A Prospective, Multi-institutional Study|A Comparison of Medical Therapy to Medical Therapy Plus Endoscopic Sinus Surgery in Patients With Chronic Rhinosinusitis|Completed|||186|Actual|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 23:04:26.47867|2018-05-31 23:04:26.47867
NCT01256086|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2012-07-26||2012-08-13|2010-12-07|2010-12-08|Estimate|2012-08-13|2012-09-12|Estimate||||2012-08-13|2012-09-12|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg|Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg in Patients With Stable Asthma Using Bronchoprovocation With Methacholine as a Bioassay Randomized, Double-blind, Four-period, Four-sequence Cross-over Trial|Completed||Phase 2|44|Actual|MEDA Pharma GmbH & Co. KG||4|||f||||f||||||||||2018-05-31 23:04:18.157311|2018-05-31 23:04:18.157311
NCT01256073|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2014-02-27|2010-12-07|2010-12-08|Estimate|||||||2014-02-27|2014-02-28|Estimate|February 2007||2007-02-28|February 2014|2014-02-28|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia|An Open-label, Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia|Completed||Phase 1|21|Actual|Innate Pharma||1|||f||||f||||||||||2018-05-31 23:04:18.479126|2018-05-31 23:04:18.479126
NCT01256060|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2015-01-13||2016-07-12|2010-12-07|2010-12-08|Estimate|2015-04-13|2015-04-15|Estimate||||2016-07-12|2016-08-12|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Intranasal Oxytocin for the Treatment of Children and Adolescents With ASD (OXY)|Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)|Completed||Phase 2|15|Actual|Anagnostou, Evdokia, M.D.|The sample size is too small to view both safety and efficacy data. The design did not exceed the commonly used 24 IU / dose, so it is not clear that higher doses would not confer benefit. In the absence of placebo, adverse events may be inflated.|1|||f||||t||||||||||2018-05-31 23:04:18.568342|2018-05-31 23:04:18.568342
NCT01256047|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2014-01-28|2010-12-07|2010-12-08|Estimate|||||||2014-01-28|2014-01-29|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy|Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy|Unknown status|Recruiting|Phase 4|40|Anticipated|Chiba University||2|||f||||f||||||||||2018-05-31 23:04:18.778225|2018-05-31 23:04:18.778225
NCT01256034|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|2012-09-24||2012-09-24|2010-12-07|2010-12-08|Estimate|2012-09-24|2012-10-23|Estimate||||2012-09-24|2012-10-23|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|EPIPD||Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy|Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy|Completed||Phase 4|50|Actual|Chiba University||2|||f||||f||||||||||2018-05-31 23:04:18.853862|2018-05-31 23:04:18.853862
NCT01256021|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|July 2011|Anticipated|2011-07-31|April 2011|Anticipated|2011-04-30||Interventional|||The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy|Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy|Unknown status|Recruiting|Phase 4|212|Anticipated|Medy-Tox||1|||f||||f||||||||||2018-05-31 23:04:19.049132|2018-05-31 23:04:19.049132
NCT01256008|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2015-01-29||2015-04-09|2010-12-07|2010-12-08|Estimate|2015-03-26|2015-04-10|Estimate||||2015-04-09|2015-05-01|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Intervention Study of Depression in Breast Cancer Patients|Early Identification and Early Warning of Psychological Problems in Breast Cancer Patients, and Intervention Study Using Cognitive Behavioral Therapy on Depression in Breast Cancer Patients|Completed||N/A|392|Actual|Wenzhou Medical University||3|||f||||t||||||||||2018-05-31 23:04:19.135653|2018-05-31 23:04:19.135653
NCT01255995|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-11-15|2010-12-07|2010-12-08|Estimate|||||||2012-11-15|2012-11-16|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|May 2022|Anticipated|2022-05-31|December 2021|Anticipated|2021-12-31||Observational|PXF||Natural History of IOL in Pseudo Exfoliation Syndrome|The Natural History of Artificial Intraocular Lenses (IOL) in Eyes With Exfoliation Syndrome|Active, not recruiting|||1500|Anticipated|Aurolab|||2||f||||t||||||||||2018-05-31 23:04:19.426557|2018-05-31 23:04:19.426557
NCT01255982|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2012-10-25|2010-12-07|2010-12-08|Estimate|||||||2012-10-25|2012-10-26|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Observational|||Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up|Functional Assessment of Patients With Acute Bipolar Depression After 8 Months of Follow-up|Completed|||249|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:04:19.488026|2018-05-31 23:04:19.488026
NCT01255969|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2016-08-03|2010-12-07|2010-12-08|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|February 2014|Actual|2014-02-28||Interventional|EXCITE||EXerCise Introduction To Enhance Performance in Dialysis(EXCITE)|EXerCise Introduction To Enhance Performance in Dialysis: the EXCITE Study|Completed||Phase 4|500|Actual|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||t||||||||||2018-05-31 23:04:19.677209|2018-05-31 23:04:19.677209
NCT01255956|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-01-24|2010-12-07|2010-12-08|Estimate|||||||2011-01-24|2011-01-25|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|ISRII||Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)|Efficacy Evaluation of In-bare Metal Stent Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter. Study With Intravascular Ultrasound and Optical Coherence Tomography|Unknown status|Recruiting|Phase 3|200|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 23:04:19.759669|2018-05-31 23:04:19.759669
NCT01255943|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2017-03-28|2010-12-07|2010-12-08|Estimate|||||||2017-03-28|2017-03-29|Actual|July 2010||2010-07-31|March 2017|2017-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices|Testing Spread and Implementation of Novel MRSA-Reducing Practices|Completed|||175|Actual|Maine Medical Center Research Institute|||1||f||||t||||||||||2018-05-31 23:04:19.847514|2018-05-31 23:04:19.847514
NCT01255930|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|January 2011|Anticipated|2011-01-31|||||Observational|||Evaluation of Placenta Maturity by the Sonographic Textures|Evaluation of Placenta Maturity by the Sonographic Textures|Unknown status|Recruiting||150|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:04:19.910713|2018-05-31 23:04:19.910713
NCT01255917|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2016-03-03|2010-12-07|2010-12-08|Estimate|||||||2016-03-03|2016-03-07|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Nerve Growth Factor in Chronic Pancreatitis|Nerve Growth Factor in Chronic Pancreatitis|Completed|||38|Actual|Virginia Commonwealth University|||1||f||||f||||||Samples Without DNA|"~     Pancreatic fluid obtained by duodenal aspiration~   "|||2018-05-31 23:04:19.964182|2018-05-31 23:04:19.964182
NCT01255904|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2016-01-25||2016-04-12|2010-12-07|2010-12-08|Estimate|2016-01-25|2016-02-22|Estimate||||2016-04-12|2016-05-16|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Trial Of Oral Chloral Hydrate Versus Intranasal Dexmedetomidine For Sedated Abr Exams|A RANDOMIZED CONTROLLED TRIAL OF ORAL CHLORAL HYDRATE VERSUS INTRANASAL DEXMEDETOMIDINE FOR SEDATED ABR EXAMS.|Completed||Phase 4|90|Actual|Baylor College of Medicine|This study was not designed to detect small differences in rare adverse and the overall safety of either medication cannot be assessed based on these results alone.|2|||f||||t||||||||||2018-05-31 23:04:20.041624|2018-05-31 23:04:20.041624
NCT01255891|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|January 2010||2010-01-31|August 2009|2009-08-31|January 2015|Anticipated|2015-01-31|August 2014|Anticipated|2014-08-31||Interventional|||Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate|A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate|Unknown status|Recruiting|Phase 2|46|Anticipated|McGill University||1|||f||||f||||||||||2018-05-31 23:04:20.23504|2018-05-31 23:04:20.23504
NCT01255878|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism|The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial|Completed||N/A|20|Actual|Mashhad University of Medical Sciences||2|||f||||||||||||||2018-05-31 23:04:20.321176|2018-05-31 23:04:20.321176
NCT01255865|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-06-30|2010-12-06|2010-12-08|Estimate|||||||2011-06-30|2011-07-01|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||Comparison Study of Core Temperature Thermometry Systems|Deep Tissue Thermometry 510(k) Premarket Notification Trial|Unknown status|Enrolling by invitation||120|Anticipated|Arizant Healthcare|||7||f||||f||||||||||2018-05-31 23:04:20.396474|2018-05-31 23:04:20.396474
NCT01255852|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2015-09-01|2010-12-07|2010-12-08|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|APORIAS||Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting|Phase 4 of Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting|Completed||Phase 4|100|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 23:04:20.456676|2018-05-31 23:04:20.456676
NCT01255839|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-07|2010-12-07|2010-12-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|December 2002||2002-12-31|January 2002|2002-01-31|December 2010|Actual|2010-12-31|September 2005|Actual|2005-09-30||Interventional|||The Balloon Project for Birth Induction|A Prospective Multi-centre Randomised Comparison on Induction of Labour With Double-balloon Installation Device Versus Prostaglandin E2 Minprostin|Completed||Phase 4|825|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 23:04:20.528988|2018-05-31 23:04:20.528988
NCT01255826|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-07|||2017-08-30|2010-12-07|2010-12-08|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2012||2012-01-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Ventilatory Management of the Preterm Neonate in the Delivery Room|Ventilatory Management of the Preterm Neonate in the Delivery Room.|Completed||Phase 2|112|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 23:04:20.586045|2018-05-31 23:04:20.586045
NCT01255813|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2015-12-28|2010-12-06|2010-12-07|Estimate|||||||2015-12-28|2015-12-29|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache|Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache|Completed||N/A|43|Actual|Autonomic Technologies, Inc.||3|||f||||t||||||||||2018-05-31 23:04:20.659368|2018-05-31 23:04:20.659368
NCT01255800|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2014-01-29|2010-12-06|2010-12-07|Estimate|||||||2014-01-29|2014-01-31|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer|A Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer: a Rational Anti-Cancer Stem Cell Combination.|Completed||Phase 1|9|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 23:04:20.730477|2018-05-31 23:04:20.730477
NCT01255787|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2013-10-25||2013-10-25|2010-12-06|2010-12-07|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder|A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder|Completed||Phase 2/Phase 3|600|Actual|Takeda||4|||f||||f||||||||||2018-05-31 23:04:20.822767|2018-05-31 23:04:20.822767
NCT01255774|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-04|||2011-12-02|2010-12-06|2010-12-07|Estimate|||||||2011-12-02|2011-12-05|Estimate|June 2007||2007-06-30|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|FVF4193s||Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy|Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter|Unknown status|Recruiting|Phase 3|20|Anticipated|The New York Eye & Ear Infirmary||1|||f||||f||||||||||2018-05-31 23:04:21.817431|2018-05-31 23:04:21.817431
NCT01255761|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2013-10-07||2018-03-08|2010-12-06|2010-12-07|Estimate|2014-02-04|2014-03-07|Estimate||||2018-03-08|2018-04-04|Estimate|November 2010||2010-11-30|March 2018|2018-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|PREDICT|The Baseline Characteristics consists of the Safety Set (SS). SS consists of all subjects that received at least 1 dose of study medication.|A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects|Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia|Completed||Phase 4|736|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 23:04:21.926163|2018-05-31 23:04:21.926163
NCT01255748|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2018-01-16|2010-12-06|2010-12-07|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2009||2009-06-30|January 2018|2018-01-31||||June 2029|Anticipated|2029-06-30|30 Years|Observational [Patient Registry]|||Registry Study for Radiation Therapy Outcomes|Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Radiation Therapy|Recruiting|||20000|Anticipated|Proton Collaborative Group|||1||f||||f||||||||||2018-05-31 23:04:23.196714|2018-05-31 23:04:23.196714
NCT01255735|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2016-12-01|2010-12-06|2010-12-07|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2015|Actual|2015-10-31||Observational|||Randomized Controlled Trial of Voice on Children With Vocal Nodules|Randomized Controlled Trial of Voice on Children With Vocal Nodules|Completed|||114|Actual|Massachusetts Eye and Ear Infirmary|||1||f||||t||||||||||2018-05-31 23:04:23.297914|2018-05-31 23:04:23.297914
NCT01255722|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2015-08-27||2015-11-12|2010-12-06|2010-12-07|Estimate|2015-11-12|2015-12-16|Estimate||||2015-11-12|2015-12-16|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|X-ACT|All included patients set: all included patients, even those who have withdrew prior to contrast injection.|Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography|Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (X-ACT Study)|Completed||Phase 4|468|Actual|Guerbet|The main limitation of the study is the absence of gold standard such as conventional angiography to confirm the readers’ assessments. Diagnostic accuracy could therefore not be compared.|3|||f||||t||||||||||2018-05-31 23:04:23.387394|2018-05-31 23:04:23.387394
NCT01255709|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03||2016-02-18|2016-02-18|2010-12-06|2010-12-07|Estimate||||2016-02-18|2016-03-17|Estimate|2016-02-18|2016-03-17|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS|CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers|Completed||Phase 2|24|Actual|Amphastar Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 23:04:23.832025|2018-05-31 23:04:23.832025
NCT01255696|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03||2012-07-13|2012-07-30|2010-12-06|2010-12-07|Estimate||||2012-07-30|2012-08-06|Estimate|2012-07-30|2012-08-06|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease|A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac Disease|Completed||Phase 2|61|Actual|Alvine Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 23:04:23.947642|2018-05-31 23:04:23.947642
NCT01255683|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-04-21|2010-12-06|2010-12-07|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Oral Steroid Treatment for Chronic Rhinosinusitis|Single-arm Clinical Evaluation of Oral Steroid Treatment for Chronic Rhinosinusitis|Withdrawn|||0|Actual|Oregon Health and Science University|||1|Lack of proposed funding.|f||||f||||||||||2018-05-31 23:04:24.011789|2018-05-31 23:04:24.011789
NCT01255670|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-04-08|2010-12-06|2010-12-07|Estimate|||||||2011-04-08|2011-04-11|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Penicillin and Metronidazole in Treatment of Peritonsillar Abscess|Penicillin and Metronidazole in Treatment of Peritonsillar Abscess - Prospective, Double-blind, Randomized, Placebo-controlled Study|Completed||N/A|200|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 23:04:24.065856|2018-05-31 23:04:24.065856
NCT01255657|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-11-17|2010-12-06|2010-12-07|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2010||2010-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of ABT-806 in Subjects With Advanced Solid Tumor Types|A Phase 1 Study of ABT-806 in Subjects With Advanced Solid Tumor Types Likely to Either Overexpress Wild-Type Epidermal Growth Factor Receptor (EGFR) or to Express Variant III Mutant EGFR|Completed||Phase 1|49|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:04:24.129427|2018-05-31 23:04:24.129427
NCT01255644|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-07-20|2010-12-06|2010-12-07|Estimate|||||||2015-07-20|2015-07-21|Estimate|December 2010||2010-12-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|VGCV-CLL||Antiviral Treatment of Chronic Lymphocytic Leukemia|Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study|Completed||Phase 4|20|Anticipated|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 23:04:24.190692|2018-05-31 23:04:24.190692
NCT01255631|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2015-02-05||2015-09-15|2010-12-06|2010-12-07|Estimate|2015-09-15|2015-10-16|Estimate||||2015-09-15|2015-10-16|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Baseline analysis population was determined by the patients who completed the study (7 total patients: 4 Sham and 3 active PEMF)|Pulsed Electromagnetic Fields (PEMF) and Post-Axillary Surgery Morbidity|Use of Pulsed Electromagnetic Fields in Reducing Arm and Shoulder Complaints in Breast Cancer Patients After Lymph Node Dissection|Terminated||Phase 4|22|Actual|Columbia University|Early termination leading to small numbers of subjects analyzed|2||Poor enrollment|f||||t||||||||||2018-05-31 23:04:24.254004|2018-05-31 23:04:24.254004
NCT01255618|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Observational|||The Measurement Of Cerebral Oxygenisation With NIRS Method İn Polycythaemic Infants Might Add A Criterion To Indicate PPET?||Unknown status|Recruiting||40|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||1||f||||t||||||None Retained|"~     blood~   "|||2018-05-31 23:04:25.38008|2018-05-31 23:04:25.38008
NCT01255605|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-06-15|2010-12-06|2010-12-07|Estimate|||||||2012-06-15|2012-06-18|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|||||Observational|||Impact of IPT With Sulfadoxin Pyrimetamin on Pregnant Women and Their Babies Outcomes in Peri-urban Areas of Bobo-Dioulasso(Burkina Faso)|Impact of Intermittent Preventive Treatment (IPT) With Sulfadoxine-pyrimethamine (SP) on the Morbidities Associated With Malaria in Pregnant Women and Newborns in Peri-urban Areas of Bobo-Dioulasso, 5 Years After Its Adoption by the National Program for Fight Against Malaria in Burkina Faso.|Completed|||772|Actual|Université Polytechnique de Bobo-Dioulasso|||||f||||t||||||Samples With DNA|"~     The investigators make thick and thin blood smear and collect a few drops of blood on the 3MM~     paper Whatmann Schleicher-Schuell.~   "|||2018-05-31 23:04:25.464506|2018-05-31 23:04:25.464506
NCT01255592|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2015-06-25||2015-09-07|2010-12-06|2010-12-07|Estimate|2015-09-07|2015-10-08|Estimate||||2015-09-07|2015-10-08|Estimate|February 2011||2011-02-28|September 2015|2015-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|STRATUS||Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis|A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis|Completed||Phase 2|83|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 23:04:25.587836|2018-05-31 23:04:25.587836
NCT01255579|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|July 2007||2007-07-31|December 2008|2008-12-31||||December 2008|Actual|2008-12-31||Interventional|FORTINO||Effects on Small Airways of Two Long-term Extrafine Treatments in Asthma|Effects on Small Airways Obstruction of Two Long-term Treatments With Extrafine Beclomethasone/Formoterol vs Fluticasone/Salmeterol in Asthma|Completed||Phase 4|10|Actual|Università degli Studi di Brescia||2|||f||||f||||||||||2018-05-31 23:04:26.414813|2018-05-31 23:04:26.414813
NCT01255397|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|January 2011||2011-01-31|December 2010|2010-12-31||||||||Interventional|||Proposed Research Protocol For Male Infertility|Proposed Research Protocol For Male Infertility|Unknown status|Not yet recruiting|N/A|50|Anticipated|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-05-31 23:04:28.19948|2018-05-31 23:04:28.19948
NCT01255553|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-03-03|2010-12-06|2010-12-07|Estimate|||||||2014-03-03|2014-03-04|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Partial Breast Irradiation in a Low-risk Population Screened With MRI|Image Guided Partial Breast Irradiation (PBL) In A Low-Risk Population Screened With Magnetic Resonance Imaging (MRI)|Withdrawn||N/A|0|Actual|University of Chicago||||No patients enrolled.|f||||f||||||||||2018-05-31 23:04:26.67432|2018-05-31 23:04:26.67432
NCT01255540|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-10-21|2010-12-06|2010-12-07|Estimate|||||||2015-10-21|2015-10-22|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||After Eighty Study|A Randomised Prospective Study of an Invasive Strategy Versus Medical Therapy in Patients Over 80 Years With Non ST-Elevation Myocardial Infarction (NSTEMI) or Unstable Angina Pectoris (UAP)|Active, not recruiting|||492|Anticipated|Oslo University Hospital|||||f||||t||||||||||2018-05-31 23:04:26.721263|2018-05-31 23:04:26.721263
NCT01255527|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-06-01|2010-12-06|2010-12-07|Estimate|||||||2013-06-01|2013-06-04|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study|A Phase 1/2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study|Unknown status|Recruiting|Phase 1/Phase 2|53|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 23:04:26.775787|2018-05-31 23:04:26.775787
NCT01255514|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2017-11-26|2010-12-06|2010-12-07|Estimate|||||||2017-11-26|2017-11-28|Actual|October 30, 2008|Actual|2008-10-30|November 2017|2017-11-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma|Sequential High-dose Dexamethasone and Response Adopted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Multicenter Phase 2 Study|Completed||Phase 2|30|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:04:26.851555|2018-05-31 23:04:26.851555
NCT01255501|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate||||December 2010|2010-12-31||||||||Interventional|||First in Human Study of NI-0701 in Healthy Volunteers|A First in Man Randomized Placebo Controlled Study of Single Ascending Intravenous Doses of NI-0701 in Healthy Volunteers|Completed||Phase 1|||NovImmune SA||2|||f||||||||||||||2018-05-31 23:04:26.910806|2018-05-31 23:04:26.910806
NCT01255488|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Interventional|||Research Abstract Usefulness in Clinical Decision-making|Family Nurse Practitioner Perception of Journal Abstract Usefulness in Clinical Decision-making: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|50|Anticipated|Uniformed Services University of the Health Sciences||2|||f||||f||||||||||2018-05-31 23:04:27.050343|2018-05-31 23:04:27.050343
NCT01255475|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2014-06-06|2010-12-06|2010-12-07|Estimate|||||||2014-06-06|2014-06-10|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|REPIC||Blood Pressure Reduction in Heart Failure|Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2/Phase 3|21|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:04:27.12922|2018-05-31 23:04:27.12922
NCT01255462|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-04-30|2010-12-06|2010-12-07|Estimate|||||||2012-04-30|2012-05-01|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration|A Multicenter, Open Label, Single Ascending Dose Study to Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration|Completed||Phase 1|24|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:04:27.206667|2018-05-31 23:04:27.206667
NCT01255449|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2012-09-18||2012-12-22|2010-12-06|2010-12-07|Estimate|2012-12-22|2013-01-31|Estimate||||2012-12-22|2013-01-31|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|FOT-BOS||Respiratory Impedance and Obliterative Bronchiolitis|Predictive Value of Within-breath Respiratory Input Impedance in the Early Diagnosis of Obliterative Bronchiolitis After Allogeneic Hematopoietic Stem Cell Transplantation|Completed||N/A|26|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||1|||f||||t||||||||||2018-05-31 23:04:27.297517|2018-05-31 23:04:27.297517
NCT01255436|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2012-08-31||2017-01-06|2010-12-06|2010-12-07|Estimate|2012-08-31|2012-10-02|Estimate||||2017-01-06|2017-02-23|Actual|January 2011||2011-01-31|January 2017|2017-01-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Effectiveness of SMS Text Reminders to Improve Blood Pressure Among Patients With Hypertension|Effectiveness of SMS Text Reminders to Improve Blood Pressure Among Patients With Hypertension at a General Medicine Outpatient Clinic in a Tertiary Center in Manila, Philippines: A Randomized Controlled Trial|Completed||N/A|700|Actual|University of the Philippines|Strong conclusions cannot be made because of the high attrition rate at the end of the study.|2|||f||||t||||||||No||2018-05-31 23:04:27.463939|2018-05-31 23:04:27.463939
NCT01255423|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2012-06-08||2012-09-03|2010-12-06|2010-12-07|Estimate|2012-09-03|2012-10-04|Estimate||||2012-09-03|2012-10-04|Estimate|November 2010||2010-11-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain|Completed||Phase 3|206|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:04:27.849744|2018-05-31 23:04:27.849744
NCT01255410|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2015-12-14|2010-12-06|2010-12-07|Estimate|||||||2015-12-14|2015-12-15|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Metapneumovirus Vaccine, rHMPV-Pa Lot HMPV #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HMPV-Seropositive Children 12 to 59 Months of Age, and HMPV-Seronegative Infants and Children 6 to 59 Months of Age|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||t||||||||||2018-05-31 23:04:28.131081|2018-05-31 23:04:28.131081
NCT01255384|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||||||Observational|||Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes|Possible Epigenetic Changes in Offspring of Women With Pregestational and Gestational Diabetes: Molecular Studies of the Placenta and Cord Blood and Possible Correlation to Postnatal Development.|Unknown status|Not yet recruiting||300|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples Without DNA|"~     Placental biopsy cord bloos Saliva~   "|||2018-05-31 23:04:28.244178|2018-05-31 23:04:28.244178
NCT01255371|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-11-07|2010-12-06|2010-12-07|Estimate|||||||2012-11-07|2012-11-08|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|May 2013|Anticipated|2013-05-31||Interventional|ALISA||A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir|A Multicenter Phase III Trial of Second-line Antiretroviral Treatment Strategies in African Adults (Tanzania Ans South Africa) Using Atazanavir or Lopinavir/Ritonavir|Withdrawn||Phase 3|0|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2||drug procurement issues|f||||t||||||||||2018-05-31 23:04:28.305662|2018-05-31 23:04:28.305662
NCT01255358|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-12-27|2010-12-06|2010-12-07|Estimate|||||||2011-12-27|2011-12-29|Estimate|February 2011||2011-02-28|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|IEDAT01||Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients|Evaluations of Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Ataxia Teleangiectasia Patients|Completed||Phase 2|22|Actual|Erydel||1|||f||||f||||||||||2018-05-31 23:04:28.369233|2018-05-31 23:04:28.369233
NCT01255345|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-06-23|2010-12-06|2010-12-07|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|December 2012|Anticipated|2012-12-31|||||Observational|Female CPP||Female Chronic Pelvic Pain|Female Chronic Pelvic Pain: Prevalence, Risk Factors and Clinical Characteristics With Particular Reference to the Pelvic Musculature|Unknown status|Recruiting||2500|Anticipated|Copenhagen University Hospital at Herlev|||1||f||||t||||||||||2018-05-31 23:04:28.443213|2018-05-31 23:04:28.443213
NCT01255332|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Observational|HpyloriITP||Helicobacter Pylori Immune Thrombocytopenic Purpura|Efficacy of Helicobacter Pylori Eradication for the 1st Line Treatment of Immune Thrombocytopenic Purpura (ITP) Patients With Moderate Thrombocytopenia|Unknown status|Recruiting||26|Anticipated|Cooperative Study Group A for Hematology|||1||f||||t||||||||||2018-05-31 23:04:28.498637|2018-05-31 23:04:28.498637
NCT01255319|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|November 2010||2010-11-30|December 2010|2010-12-31|November 2014|Anticipated|2014-11-30|November 2012|Anticipated|2012-11-30||Observational|CyFluATG||Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS)|Conditioning With Cyclophosphamide, Fludarabine and Antithymocyte Globulin for Allogeneic Hematopoietic Cell Transplantation in Lower Risk Myelodysplastic Syndrome|Unknown status|Recruiting||15|Anticipated|Cooperative Study Group A for Hematology|||||f||||f||||||||||2018-05-31 23:04:28.646785|2018-05-31 23:04:28.646785
NCT01255306|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2011-12-18||2012-03-22|2010-12-06|2010-12-07|Estimate|2011-12-18|2012-01-24|Estimate||||2012-03-22|2012-03-23|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy|The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy|Completed|||60|Actual|"University Hospital Sestre Milosrdnice"|||2||f||||t||||||||||2018-05-31 23:04:28.722898|2018-05-31 23:04:28.722898
NCT01255293|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-06-13|2010-12-06|2010-12-07|Estimate|||||||2013-06-13|2013-06-14|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments|A Prospective, Randomized Study Comparing 1000 Centistoke and 5000 Centistoke Silicone Oil Tamponade for Repair of Proliferative Vitreoretinopathy Retinal Detachments and Diabetic Tractional Retinal Detachments|Completed||N/A|15|Actual|Mid Atlantic Retina||2|||f||||f||||||||||2018-05-31 23:04:29.013543|2018-05-31 23:04:29.013543
NCT01255280|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2012-05-31|2010-12-06|2010-12-07|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2011||2011-01-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Behavioral Activation and HIV Risk Reduction for Men Who Have Sex With Men With Crystal Meth Abuse|Behavioral Activation and HIV Risk Reduction for MSM With Crystal Methamphetamine Abuse|Unknown status|Recruiting|Phase 1|50|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:04:29.197977|2018-05-31 23:04:29.197977
NCT01255267|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate||||December 2010|2010-12-31||||||||Observational|||The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients|The Correlation Between Genetic Polymorphism, Platelet Activity, , Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients|Unknown status|Recruiting||||China Medical University Hospital|||3||f||||t||||||||||2018-05-31 23:04:29.276439|2018-05-31 23:04:29.276439
NCT01255254|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||The Effect of Oral Hygiene and Full Mouth Scaling on Metabolic Control in Patients With Type II Diabetes||Unknown status|Recruiting|Phase 1|40|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 23:04:29.333151|2018-05-31 23:04:29.333151
NCT01255241|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-07-28|2010-12-06|2010-12-07|Estimate|||||||2011-07-28|2011-07-29|Estimate|February 2011||2011-02-28|July 2011|2011-07-31|August 2014|Anticipated|2014-08-31|||||Observational|LLD||The Effect of Lower Limb Deformities (LLD) on Children's Gait and on Energy Expenditure|The Effect of Lower Limb Deformities (LLD) on Children's Gait and on Energy Expenditure|Unknown status|Recruiting||30|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 23:04:29.398198|2018-05-31 23:04:29.398198
NCT01255228|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-12-05|2010-12-05|2010-12-07|Estimate|||||||2010-12-05|2010-12-07|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Interventional|||Effect of Low Glycemic Index Diet on Body Composition and Mechanism of Obese Women|Effect of Low Glycemic Index Diet on Body Composition and Mechanism of Obese|Unknown status|Active, not recruiting|N/A|20|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-05-31 23:04:29.474512|2018-05-31 23:04:29.474512
NCT01211496|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-10-03|2010-09-28|2010-09-29|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2004||2004-06-30|October 2016|2016-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Velocity Training in Functionally Limited Elderly|High Velocity Resistance Training in Older Men and Women|Completed||N/A|52|Actual|University of Missouri-Columbia||3|||f||||f||||||||No||2018-05-31 23:18:44.368383|2018-05-31 23:18:44.368383
NCT01255215|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-05|||2014-02-19|2010-12-05|2010-12-07|Estimate|||||||2014-02-19|2014-02-20|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial|Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial|Completed||Phase 1/Phase 2|180|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 23:04:29.541|2018-05-31 23:04:29.541
NCT01255202|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-05|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|April 2011|Anticipated|2011-04-30||Observational|||The Prediction of Preeclampsia/Toxemia in Twin Pregnancy|Prospective Longitudenal Study in the Prediction of Preeclampsia/Toxemia in Twin Pregnancy|Unknown status|Recruiting||200|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 23:04:29.613661|2018-05-31 23:04:29.613661
NCT01255189|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2011-08-05|2010-12-06|2010-12-07|Estimate|||||||2011-08-05|2011-08-09|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Measurement of the Effect of Positional Changes on Cerebral Oxygenation in Preterm Infants|Measurement of the Effect of Positional Changes on Cerebral Oxygenation in Preterm Infants: A Near Infrared Spectroscopy Study|Completed||Phase 4|30|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||1|||f||||f||||||||||2018-05-31 23:04:29.684325|2018-05-31 23:04:29.684325
NCT01255176|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-06-18|2010-12-06|2010-12-07|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2010||2010-01-31|December 2010|2010-12-31||||December 2011|Actual|2011-12-31||Interventional|RTAC||Rebalancing Thoraco Abdominal Heart Disease in Infants (RTAC)|Evaluation of the Effects of Physical Therapy Method of Restoring Cardiac Thoracic Abdominal Infants|Completed||N/A|60|Actual|University of the State of Santa Catarina||3|||f||||t||||||||||2018-05-31 23:04:29.747077|2018-05-31 23:04:29.747077
NCT01255163|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-04|2017-11-08||2018-01-23|2010-12-04|2010-12-07|Estimate|2018-01-23|2018-02-21|Estimate||||2018-01-23|2018-02-21|Estimate|November 21, 2010||2010-11-21|January 2018|2018-01-31|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Interventional||The baseline analysis population includes 27 participants who underwent randomization and received at least one dose of experimental medication. Of those 27, we have at least one outcome measure (i.e. at least the 6 months follow-up data point) for 21 participants. Of those 21, 18 completed the study (i.e. reached 18 months).|A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease|A Pilot Study of Exendin-4 in Alzheimer s Disease|Terminated||Phase 2|57|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated after AstraZeneca withdrew support. Early termination lead to small number of subjects analyzed.|2||AstraZeneca withdrew support for the study.|f||||t|t|f|||f|||||2018-05-31 23:04:29.837439|2018-05-31 23:04:29.837439
NCT01255150|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-04|||2018-05-12|2010-12-04|2010-12-07|Estimate|||||||2018-05-12|2018-05-15|Actual|December 1, 2010||2010-12-01|April 29, 2015|2015-04-29|April 29, 2015||2015-04-29|||||Observational|||Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer|Frequency of Epidermal Growth Factor Receptor Mutations in Latinos/Hispanics With Non-Small Lung Cancer|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:04:30.399829|2018-05-31 23:04:30.399829
NCT01255137|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-04|2013-03-07||2013-04-25|2010-12-04|2010-12-07|Estimate|2013-04-25|2013-06-27|Estimate||||2013-04-25|2013-06-27|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer|Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer|Completed||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-05-31 23:04:30.479753|2018-05-31 23:04:30.479753
NCT01255124|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-04|||2011-09-12|2010-12-06|2010-12-07|Estimate|||||||2011-09-12|2011-09-14|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children|Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children|Completed|||1297|Actual|Jiangsu Province Centers for Disease Control and Prevention|||1||f||||f||||||Samples Without DNA|"~     Umbilical cord blood serum and blood serum, Nasopharyngeal swabs, rectal swab~   "|||2018-05-31 23:04:30.715188|2018-05-31 23:04:30.715188
NCT01255111|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-04|||2011-06-22|2010-12-04|2010-12-07|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|||||Observational|ROOMILA||Adaptation to Nocturnal Noninvasive Ventilation in Patients With Chronic Respiratory Failure (ROOMILA)|Adaptation to Nocturnal Noninvasive Ventilation in Patients With Chronic Respiratory Failure|Completed|||10|Anticipated|Groupe de Recherche sur le Handicap Respiratoire|||||f||||f||||||||||2018-05-31 23:04:30.849598|2018-05-31 23:04:30.849598
NCT01255098|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2010-12-03|2010-12-03|2010-12-07|Estimate|||||||2010-12-03|2010-12-07|Estimate|November 2009||2009-11-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|||||Observational|||A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood Culture|A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood Culture|Completed|||300|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 23:04:30.909704|2018-05-31 23:04:30.909704
NCT01255085|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2012-06-14|2010-12-03|2010-12-07|Estimate|||||||2012-06-14|2012-06-15|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Interventional|||Yellow Pea Protein and Fibre and Short Term Food Intake|The Effect of Yellow Pea Protein and Fiber on Short Term Food Intake, Subjective Appetite and Glycemic Response in Healthy Young Males|Completed||N/A|20|Actual|University of Toronto||5|||f||||||||||||||2018-05-31 23:04:30.966814|2018-05-31 23:04:30.966814
NCT01255072|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-06-29|2010-12-06|2010-12-07|Estimate|||||||2011-06-29|2011-06-30|Estimate|August 2009||2009-08-31|May 2007|2007-05-31|December 2011|Anticipated|2011-12-31|September 2009|Actual|2009-09-30||Interventional|||rTMS in Elderly Depressed:Neuronavegated Study|Repetitive Transcranial Magnetic Stimulation in Elderly Depressed: Neuronavegated Study|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 23:04:31.040334|2018-05-31 23:04:31.040334
NCT01255059|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-05|||2015-12-21|2010-12-05|2010-12-07|Estimate|||||||2015-12-21|2015-12-22|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||GWAS Research of Lung Cancer in Tianjin|GWAS Research of Lung Cancer by Department of Epidemiology and Biostatistics in Tianjin Medical University Cancer Institute and Hospital|Unknown status|Recruiting||500|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||2||f||||t||||||Samples With DNA|"~     Peripheral blood sample (10 ml) was collected from each study subject. Buffy coats were~     isolated and frozen for DNA extraction.~   "|||2018-05-31 23:04:31.114282|2018-05-31 23:04:31.114282
NCT01255046|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2014-08-19|2010-12-05|2010-12-07|Estimate|||||||2014-08-19|2014-08-20|Estimate|December 2015||2015-12-31|August 2014|2014-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||Study of STA-1 as an Add-on Treatment to Donepezil|A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease|Not yet recruiting||Phase 2|136|Anticipated|Sinphar Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 23:04:31.233193|2018-05-31 23:04:31.233193
NCT01255033|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-05|||2016-09-22|2010-12-05|2010-12-07|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Oxygen Peripheral Saturations and Lung Surgery|Evaluation of the Continuous Measurement of Tissular (StO2) and Cerebral (ScO2) Oxygenation During Lung Surgery and During the 6 First Postoperative Hours (Prospective Monocentric Study).|Completed|||47|Actual|Hopital Foch|||1||f||||f||||||||||2018-05-31 23:04:31.321647|2018-05-31 23:04:31.321647
NCT01255020|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2015-05-20|2010-12-06|2010-12-07|Estimate|||||||2015-05-20|2015-05-22|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Renal Protective Effects of Restricted Protein Dietary With α-keto Acid in CAPD Patients|Safety and Efficacy Evaluation of Restricted Protein Dietary Supplemented With α-keto Acid on Protecting Residual Renal Function in CAPD Patients——A Prospective, Double Blind Randomized, Parallel Control, Multi-center Clinical Trial|Completed||N/A|160|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:04:31.389765|2018-05-31 23:04:31.389765
NCT01255007|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2015-01-06|2010-12-06|2010-12-07|Estimate|||||||2015-01-06|2015-01-07|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases|Prospective Comparison of 3T Gd-EOB-DTPA-enhanced MRI, Diffusion Weighted MR Imaging and MDCT of Colorectal Liver Metastases for Preoperative Detection and Assessment of Treatment Response Following Chemotherapy Treatment|Completed||N/A|50|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:04:31.458766|2018-05-31 23:04:31.458766
NCT01254994|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Interventional|||The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure|A Prospective Open Label Control Study to Evaluate the Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure|Completed||Phase 2|108|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:04:31.532066|2018-05-31 23:04:31.532066
NCT01254981|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2013-08-28|2010-12-06|2010-12-07|Estimate|||||||2013-08-28|2013-08-29|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|SORT-OUT V||SORT-OUT V - Randomised Clinical Comparative Study of the Nobori and the Cypher Stent.|Randomized Clinical Comparative Study of the Nobori and the Cypher Stents in Unselected Subjects With Ischemic Heart Disease|Completed||Phase 4|2504|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 23:04:31.605393|2018-05-31 23:04:31.605393
NCT01254968|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Observational|||Influence of Direction of Movement While Walking|Influence of Direction of Movement While Walking Upon the Blood Flow Rate Through Brain, Examined by Transcranial Doppler Sonography in Young Healthy Subjects.|Completed|||1|Actual|Medical University of Silesia|||2||f||||t||||||||||2018-05-31 23:04:31.748633|2018-05-31 23:04:31.748633
NCT01254955|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-01-13|2010-12-06|2010-12-07|Estimate|||||||2012-01-13|2012-01-16|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Observational|||Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients|Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients|Completed|||||Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||||2018-05-31 23:04:31.806079|2018-05-31 23:04:31.806079
NCT01254942|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-05-13|2010-12-03|2010-12-07|Estimate|||||||2017-05-13|2017-05-16|Actual|December 2010||2010-12-31|May 2017|2017-05-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Mobilizing Evidence Into Action to Improve Outcomes of Vulnerable Seniors|Mobilizing Evidence Into Action to Improve Outcomes of Vulnerable Seniors|Completed||N/A|62|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 23:04:31.880789|2018-05-31 23:04:31.880789
NCT01254929|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2017-10-06|2010-12-06|2010-12-07|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2010|Actual|2010-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2014|Actual|2014-02-28||Observational|||F-18 PET Bone Scans Versus Tc-99m Bone Scans for the Diagnosis of Bone Metastases|18F-Fluoride PET Bone Scans Versus Traditional 99mTc-MDP Gamma Camera Bone Scans for the Diagnosis of Bone Metastases: a Blinded, Prospective Trial|Active, not recruiting|||300|Anticipated|Seattle Nuclear Medicine|||2||f||||f||||||||||2018-05-31 23:04:31.961419|2018-05-31 23:04:31.961419
NCT01254916|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-05-06|2010-12-06|2010-12-07|Estimate|||||||2012-05-06|2012-05-08|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||The Sinonasal Outcome Test - 22, Validated for Danish Patients|The Sinonasal Outcome Test - 22, Validated for Danish Patients|Completed|||44|Actual|Odense University Hospital|||1||f||||||||||||||2018-05-31 23:04:32.038989|2018-05-31 23:04:32.038989
NCT01254903|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2018-01-31|2010-12-03|2010-12-07|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2010|Actual|2010-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC)|Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC)|Active, not recruiting||Phase 1|36|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:04:32.087232|2018-05-31 23:04:32.087232
NCT01254890|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2016-03-31||2016-03-31|2010-12-03|2010-12-07|Estimate|2016-03-31|2016-05-06|Estimate||||2016-03-31|2016-05-06|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome|Phase I/II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227)|Completed||Phase 1/Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:04:32.162872|2018-05-31 23:04:32.162872
NCT01211301|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2013-06-17|2010-09-28|2010-09-29|Estimate|||||||2013-06-17|2013-06-19|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|February 2012|Actual|2012-02-29||Interventional|||Medifast 5 & 1 Plan|Randomized Controlled Trial of the Medifast 5 & 1 Plan|Completed||N/A|120|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 23:18:46.055031|2018-05-31 23:18:46.055031
NCT01254877|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|2018-01-29||2018-03-15|2010-12-06|2010-12-07|Estimate|2018-03-15|2018-04-17|Actual||||2018-03-15|2018-04-17|Actual|December 2010||2010-12-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons|Ondansetron Pharmacotherapy for Hazardous Drinking in HIV+, African-American Women|Completed||Phase 2|357|Actual|Johns Hopkins University|Drinking data are based on patient self-report.|3|||f||||t||||||||Undecided||2018-05-31 23:04:32.440015|2018-05-31 23:04:32.440015
NCT01254864|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2018-04-25|2010-12-03|2010-12-07|Estimate|||||||2018-04-25|2018-04-27|Actual|March 2011|Actual|2011-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies|Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies|Active, not recruiting||Phase 2|180|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 23:04:32.796295|2018-05-31 23:04:32.796295
NCT01254851|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2012-04-24||2015-06-15|2010-12-03|2010-12-07|Estimate|2015-06-15|2015-07-08|Estimate||||2015-06-15|2015-07-08|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|POWER||Post Operative Walking Enhancements for Recovery (POWER) Trial|Post Operative Walking Enhancements for Recovery (POWER) Trial|Completed||N/A|146|Actual|Loyola University|Difficulty ensuring that encouragement was given, as we did not quantify the frequency of encouragement by the health care team. Loss of data due to loss of pedometers|2|||f||||f||||||||||2018-05-31 23:04:32.873985|2018-05-31 23:04:32.873985
NCT01254838|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-06|2010-12-06|2010-12-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma||Completed||Phase 1|||Iwate Medical University|||||f||||t||||||||||2018-05-31 23:04:33.066308|2018-05-31 23:04:33.066308
NCT01254825|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2012-09-09|2010-12-06|2010-12-07|Estimate|||||||2012-09-09|2012-09-11|Estimate|November 2010||2010-11-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy|The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy|Completed||Phase 4|72|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 23:04:33.118169|2018-05-31 23:04:33.118169
NCT01254812|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-09-22|2010-12-06|2010-12-07|Estimate|||||||2011-09-22|2011-09-23|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Does the Application of a Bilateral-dual Transverse Abdominal Plane (TAP)Block Have an Influence on Lung Function?|Changes on Pulmonary Function After Application of a Bilateral-dual TAP-block|Completed|||12|Actual|Bispebjerg Hospital|||2||f||||t||||||||||2018-05-31 23:04:33.178135|2018-05-31 23:04:33.178135
NCT01254799|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2011-11-25|2010-12-06|2010-12-07|Estimate|||||||2011-11-25|2011-11-28|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|DOX-DMPA||Doxycycline in Treatment of Bleeding With Depot Medroxyprogesterone Acetate (DMPA)|Doxycycline in Treatment of Bleeding With DMPA: a Double Blinded Randomized Controlled Trial|Completed||Phase 3|68|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 23:04:33.231066|2018-05-31 23:04:33.231066
NCT01254786|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-12-06|2010-12-03|2010-12-07|Estimate|||||||2010-12-06|2010-12-08|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Non-dependent HFPPV Versus CPAP for Video-assisted Thoracoscopy|Comparative Study of the Non-dependent Continuous Positive Pressure Ventilation and High Frequency Positive Pressure Ventilation During One-lung Ventilation for Thoracoscopy|Completed||Phase 2|30|Actual|King Faisal University||2|||f||||t||||||||||2018-05-31 23:04:33.288955|2018-05-31 23:04:33.288955
NCT01254773|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03||2014-02-26|2014-04-21|2010-12-03|2010-12-07|Estimate||||2014-02-26|2014-03-26|Estimate|2014-04-21|2014-05-09|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|SUMMIT AD||Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|146|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||4|||f||||t||||||||||2018-05-31 23:04:33.438504|2018-05-31 23:04:33.438504
NCT01254760|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2012-01-17||2012-06-26|2010-12-03|2010-12-07|Estimate|2012-01-17|2012-02-17|Estimate||||2012-06-26|2012-07-10|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Comparison of Two Multifocal Contact Lenses Worn on a Daily Disposable Basis||Completed||N/A|79|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:04:33.573061|2018-05-31 23:04:33.573061
NCT01254747|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2012-04-18||2012-06-26|2010-12-03|2010-12-07|Estimate|2012-04-18|2012-05-17|Estimate||||2012-06-26|2012-07-10|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Evaluation of an Investigational Soft Contact Lens||Completed||N/A|130|Actual|Alcon Research||4|||f||||f||||||||||2018-05-31 23:04:33.822291|2018-05-31 23:04:33.822291
NCT01254734|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2014-11-07|2010-12-03|2010-12-07|Estimate|||||||2014-11-07|2014-11-10|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer|Outcomes in Transoral Robotic Microsurgery for Head and Neck Tumors|Terminated||N/A|7|Actual|City of Hope Medical Center||1||The study will be rewritten as a data registry study|f||||t||||||||||2018-05-31 23:04:34.278597|2018-05-31 23:04:34.278597
NCT01254721|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2013-10-22||2014-04-09|2010-12-06|2010-12-07|Estimate|2014-04-09|2014-05-08|Estimate||||2014-04-09|2014-05-08|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|STAR||A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study|A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative, Phase 4 Study|Terminated||Phase 4|131|Actual|AstraZeneca||2||Difficulty of recruitment.|f||||f||||||||||2018-05-31 23:04:34.41178|2018-05-31 23:04:34.41178
NCT01254708|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-10-18|2010-12-03|2010-12-06|Estimate|||||||2011-10-18|2011-10-19|Estimate|January 2012||2012-01-31|October 2011|2011-10-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients|A Pilot Study to Determine the Safety and Clinical Efficacy of Once-Weekly Inhaled AmBisome for the Prevention of Aspergillus Colonization in Lung Transplant Recipients|Suspended||Phase 2|4|Anticipated|University Health Network, Toronto||2||Study has been placed on hold due to unavailability of funding.|f||||||||||||||2018-05-31 23:04:34.762784|2018-05-31 23:04:34.762784
NCT01254695|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-11-09|2010-12-03|2010-12-06|Estimate|||||||2011-11-09|2011-11-10|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Improving the Efficacy of Sacral Nerve Stimulation for Fecal Incontinence by Alteration of Stimulation Parameters|Improving the Efficacy of Sacral Nerve Stimulation for Fecal Incontinence by Alteration of Stimulation Parameters|Completed||N/A|15|Actual|University of Aarhus||5|||f||||t||||||||||2018-05-31 23:04:34.859376|2018-05-31 23:04:34.859376
NCT01254682|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-09-27|2010-12-03|2010-12-06|Estimate|||||||2011-09-27|2011-09-28|Estimate|January 2007||2007-01-31|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Intra-articular Hyaluronan Substitution in Arthroscopy of the Wrist|Intra-articular Hyaluronan Substitution in Arthroscopy of the Wrist|Completed||N/A|140|Actual|TRB Chemedica AG||2|||f||||f||||||||||2018-05-31 23:04:34.944303|2018-05-31 23:04:34.944303
NCT01254669|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2014-07-31||2017-04-11|2010-12-03|2010-12-06|Estimate|2014-10-22|2014-10-24|Estimate||||2017-04-11|2017-05-19|Actual|January 2011||2011-01-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|HPV||An Intervention Study To Improve Human PapillomaVirus ( HPV) Immunization in Haitian and African American Girls|A Randomized Clinical Trial To Improve HPV Immunization in Haitian and African American Girls|Completed||N/A|200|Actual|Boston Medical Center|Limitations:small sample,Enrolling only mothers, of daughters who are African-American and Haitians lead to longer recruitment time/non-generalizable data. Future studies should include heterogeneous ethnicities,fathers, sons, and any legal guardian.|2|||f||||f|f|f||||||No||2018-05-31 23:04:35.031224|2018-05-31 23:04:35.031224
NCT01254656|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2014-01-21||2014-05-27|2010-12-03|2010-12-06|Estimate|2014-05-27|2014-06-09|Estimate||||2014-05-27|2014-06-09|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022|A Long Term Open-Label Extension Study Of Lersivirine For The Treatment Of HIV-1 Infection|Terminated||Phase 2|108|Actual|Pfizer|The study was terminated on 29 Jan 13 due to termination of lersivirine development program. All participants were enrolled from study A5271015 except one from A5271022. Above summarized outcome measures included participants enrolled from A5271015.|6||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:04:35.518401|2018-05-31 23:04:35.518401
NCT01254643|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2014-12-12||2017-02-17|2010-12-03|2010-12-06|Estimate|2014-12-12|2014-12-22|Estimate||||2017-02-17|2017-03-22|Actual|January 2011||2011-01-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).|A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls|Completed||Phase 3|100|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:04:36.337077|2018-05-31 23:04:36.337077
NCT01254630|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2018-03-14||2018-03-14|2010-12-03|2010-12-06|Estimate|2018-03-14|2018-04-13|Actual||||2018-03-14|2018-04-13|Actual|June 24, 2011|Actual|2011-06-24|March 2018|2018-03-31|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional||All randomized participants included in study analyses. Twenty randomized participants were not included in baseline analyses: 19 participants from a single site identified to have major Good Clinical Practice compliance issues and 1 participant that was not vaccinated.|A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)|A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy|Completed||Phase 3|5305|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-05-31 23:04:37.592807|2018-05-31 23:04:37.592807
NCT01254617|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2018-05-23|2010-12-03|2010-12-06|Estimate|||||||2018-05-23|2018-05-24|Actual|February 10, 2011|Actual|2011-02-10|May 2018|2018-05-31||||January 29, 2014|Actual|2014-01-29||Interventional|ADCC||Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer|Enhancement of Cetuximab-Induced Antibody-Dependent Cellular Cytotoxicity (ADCC) With Lenalidomide in Advanced Solid Tumors: A Phase I/IB Study|Active, not recruiting||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:04:43.563607|2018-05-31 23:04:43.563607
NCT01254604|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2014-04-09||2017-05-29|2010-12-03|2010-12-06|Estimate|2014-04-09|2014-05-09|Estimate||||2017-05-29|2017-06-21|Actual|December 1, 2011|Actual|2011-12-01|May 2017|2017-05-31|May 9, 2013|Actual|2013-05-09|May 9, 2013|Actual|2013-05-09||Interventional||All Participants as Treated (APaT) population: All randomized participants who received at least one dose of study drug|Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)|A Phase III, Randomized, Active Comparator-Controlled, Four-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma or Ocular Hypertension in India|Completed||Phase 3|190|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:04:43.676769|2018-05-31 23:04:43.676769
NCT01254591|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2013-08-23|2010-12-03|2010-12-06|Estimate|||||||2013-08-23|2013-08-26|Estimate|November 2006||2006-11-30|December 2010|2010-12-31||||August 2013|Anticipated|2013-08-31||Interventional|||Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer|Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation|Unknown status|Recruiting|N/A|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:04:43.922397|2018-05-31 23:04:43.922397
NCT01254578|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2017-09-22|2010-12-03|2010-12-06|Estimate|||||||2017-09-22|2017-09-25|Actual|November 24, 2010|Actual|2010-11-24|September 2017|2017-09-30|November 9, 2012|Actual|2012-11-09|November 9, 2012|Actual|2012-11-09||Interventional|||Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers|A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies|Completed||Phase 1|17|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:04:44.007466|2018-05-31 23:04:44.007466
NCT01254565|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2017-03-01|2015-07-08|2017-03-01|2010-12-03|2010-12-06|Estimate|2017-03-01|2017-04-13|Actual|2015-07-08|2015-07-30|Estimate|2017-03-01|2017-04-13|Actual|February 20, 2011||2011-02-20|March 2017|2017-03-31|August 24, 2011|Actual|2011-08-24|July 2011|Actual|2011-07-31||Interventional||All randomized participants who received at least one 1 dose of investigational product (the modified intent-to-treat [mITT] population)|Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism|A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism|Completed||Phase 2|87|Actual|KAI Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 23:04:44.140742|2018-05-31 23:04:44.140742
NCT01254552|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2018-03-05|2010-12-03|2010-12-06|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2010|Actual|2010-08-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|September 2011|Actual|2011-09-30||Interventional|ACCREDIT||Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis|Assessment With Cardiac Computed Tomography Angiography (CCTA) and Magnetic Resonance Imaging (MRI) in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis|Active, not recruiting||Phase 4|351|Actual|Guerbet||1|||f||||t||||||||||2018-05-31 23:04:45.399394|2018-05-31 23:04:45.399394
NCT01254539|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2017-03-29|2010-12-03|2010-12-06|Estimate|||||||2017-03-29|2017-03-30|Actual|October 2010||2010-10-31|November 2015|2015-11-30|November 20, 2015|Actual|2015-11-20|November 20, 2015|Actual|2015-11-20||Interventional|||Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)|Phase I/II Clinical Trial on The Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis (Extension CMN/ELA)|Completed||Phase 1/Phase 2|63|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||3|||f||||t||||||||||2018-05-31 23:04:45.462427|2018-05-31 23:04:45.462427
NCT01254526|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-11-01|2010-12-03|2010-12-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|April 2013|Actual|2013-04-30|July 2012|Actual|2012-07-31||Interventional|||Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 1|52|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:04:45.539563|2018-05-31 23:04:45.539563
NCT01254513|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2013-01-29|2010-12-03|2010-12-06|Estimate|||||||2013-01-29|2013-01-30|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|November 2016|Anticipated|2016-11-30|November 2013|Anticipated|2013-11-30||Interventional|GERICO10||Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients|"Randomized Phase II Study Evaluating the Feasibility of a Chemotherapy With Docetaxel-Prednisone in a Weekly Schedule or Every 3 Weeks, for Castration-resistant Metastatic Prostate Cancer Elderly Patients (>=75), Vulnerable or Frail , as Defined by the Criteria of the International Society of Geriatric Oncology (SIOG)"|Unknown status|Recruiting|Phase 2|144|Anticipated|UNICANCER||2|||f||||f||||||||||2018-05-31 23:04:45.647361|2018-05-31 23:04:45.647361
NCT01254500|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|September 2010||2010-09-30|December 2010|2010-12-31||||September 2011|Anticipated|2011-09-30||Observational|||To Investigate the Event Related Potentials (ERPs) of Patients With Brain Lesions||Unknown status|Recruiting||90|Anticipated|China Medical University Hospital|||3||f||||||||||||||2018-05-31 23:04:45.823779|2018-05-31 23:04:45.823779
NCT01254487|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2014-09-06|2010-12-03|2010-12-06|Estimate|||||||2014-09-06|2014-09-09|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|September 2012|Actual|2012-09-30||Observational|||e-BioMatrix PostMarket Surveillance Registry|A Postmarket Surveillance Registry of the BioMatrix Drug-eluting Stent|Unknown status|Active, not recruiting||1121|Actual|Biosensors Europe SA|||||f||||t||||||||||2018-05-31 23:04:45.885712|2018-05-31 23:04:45.885712
NCT01254474|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2013-04-24|2010-12-03|2010-12-06|Estimate|||||||2013-04-24|2013-04-25|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|January 2014|Anticipated|2014-01-31|June 2013|Anticipated|2013-06-30||Interventional|EvaMAP||Evaluation of Depolarization and Repolarisation Activity During Cardiac Arrhythmia Using a Novel Monophasic Action Potential Catheter|Evaluation of Depolarization and Repolarisation Activity During Cardiac Arrhythmia Using a Novel Monophasic Action Potential Catheter|Suspended||N/A|150|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 23:04:46.245095|2018-05-31 23:04:46.245095
NCT01254461|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2011-04-28|2010-12-03|2010-12-06|Estimate|||||||2011-04-28|2011-04-29|Estimate|February 2011||2011-02-28|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Drug-Drug Interaction Study Between AZD1981 and Pravastatin to Study the Effect of AZD1981 on the Kinetics of Pravastatin|A Phase I, Open Label, Randomised, Parallel Group Study of Repeated Oral Doses of AZD1981 (100 mg Twice Daily and 400 mg Twice Daily Via Tablet) for Eight Days and Single Doses of Pravastatin (Pravachol® Tablet 40 mg) to Evaluate the Pharmacokinetic Interaction of AZD1981 and Pravastatin in Healthy Male Volunteers|Completed||Phase 1|30|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 23:04:46.421815|2018-05-31 23:04:46.421815
NCT01254448|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2013-09-03|2010-12-03|2010-12-06|Estimate|||||||2013-09-03|2013-09-04|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease|Two-Part, Sequential Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TC-5619-238 in Elderly Subjects With and Without Alzheimer's Disease|Completed||Phase 1|38|Actual|Targacept Inc.||2|||f||||f||||||||||2018-05-31 23:04:46.539717|2018-05-31 23:04:46.539717
NCT01254435|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|May 2009||2009-05-31|March 2009|2009-03-31|September 2010|Actual|2010-09-30|August 2009|Actual|2009-08-31||Interventional|||Positioning During Colonoscopy|Does Patient Position During Extubation at Colonoscopy Influence the Quality of Mucosal Visualisation?|Completed||Early Phase 1|41|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 23:04:46.620689|2018-05-31 23:04:46.620689
NCT01254422|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2014-09-18|2010-12-03|2010-12-06|Estimate|||||||2014-09-18|2014-09-19|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia|Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia|Completed||Phase 3|250|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 23:04:46.984131|2018-05-31 23:04:46.984131
NCT01209923|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-09-24|2010-09-24|2010-09-27|Estimate|||||||2010-09-24|2010-09-27|Estimate|May 2007||2007-05-31|July 2010|2010-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Validation of the Stayhealthy BC1 Body Comp Analyzer|Validation of the BC1 Bioelectrical Impedance Body Comp Analyzer|Completed||N/A|180|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 23:19:06.05918|2018-05-31 23:19:06.05918
NCT01254409|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2014-04-11||2016-05-17|2010-12-03|2010-12-06|Estimate|2014-10-24|2014-11-03|Estimate||||2016-05-17|2016-06-22|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PRM151F-12GL|All subjects enrolled in study|A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Masked, Sponsor-Unmasked, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRM-151 Administered Intravenously to Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 1|21|Actual|Promedior, Inc.||2|||f||||f||||||||||2018-05-31 23:04:47.239813|2018-05-31 23:04:47.239813
NCT01254396|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2012-01-07||2012-01-07|2010-12-03|2010-12-06|Estimate|2012-01-07|2012-02-08|Estimate||||2012-01-07|2012-02-08|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.|An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered Without Water Under Fed Compared To Fasted Conditions|Completed||Phase 1|12|Actual|Pfizer|AUC (0-t) was the intended primary outcome measure.|2|||f||||f||||||||||2018-05-31 23:04:48.237794|2018-05-31 23:04:48.237794
NCT01254383|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2011-06-07|2010-12-03|2010-12-06|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.|An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of Sildenafil Following Fasted Administration Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered With Or Without Water Relative To Viagra® Oral Tablet With Water|Completed||Phase 1|36|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:04:48.433878|2018-05-31 23:04:48.433878
NCT01254370|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29||2015-06-05|2016-05-26|2010-12-03|2010-12-06|Estimate||||2015-06-05|2015-07-03|Estimate|2016-05-26|2016-06-06|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease|A Phase 2, Randomized Study Evaluating the Safety and Efficacy of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® in Subjects With Glaucoma or Ocular Hypertension and Ocular Surface Disease|Completed||Phase 2|105|Actual|Santen SAS||2|||f||||||||||||||2018-05-31 23:04:48.496994|2018-05-31 23:04:48.496994
NCT01254357|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2015-10-05|2010-12-03|2010-12-06|Estimate|||||||2015-10-05|2015-10-06|Estimate|December 2011||2011-12-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Observational|YA||Burn Outcomes in Young Adult Burn Survivors|Burn Outcomes in Young Adult Burn Survivors- A Multicenter Outcomes Study|Completed|||15|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 23:04:48.604479|2018-05-31 23:04:48.604479
NCT01254344|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2012-10-16||2017-02-17|2010-12-03|2010-12-06|Estimate|2012-10-16|2012-11-16|Estimate||||2017-02-17|2017-03-22|Actual|December 2010||2010-12-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Ceftriaxone Sodium/Metronidazole for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery in Chinese Adults|Completed||Phase 3|599|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:04:48.739998|2018-05-31 23:04:48.739998
NCT01254331|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2015-02-10||2015-02-10|2010-12-03|2010-12-06|Estimate|2015-02-10|2015-02-26|Estimate||||2015-02-10|2015-02-26|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Safety population: All participants who received at least one dose of medication and for whom at least one post baseline safety measurement was available.|An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment|Open Label, Multicenter, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs|Completed||Phase 3|51|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:04:49.197628|2018-05-31 23:04:49.197628
NCT01254318|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2016-09-13||2016-09-13|2010-12-03|2010-12-06|Estimate|2016-09-13|2016-11-02|Estimate||||2016-09-13|2016-11-02|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|TRAFIC||Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)|Temporal Realistic Assessment of the Fungal Infection Incidence Across Canada for High Risk Subjects With Hematological Disease (TRAFIC)|Completed|||130|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:04:49.815051|2018-05-31 23:04:49.815051
NCT01254305|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2013-08-22|2012-07-25|2014-08-05|2010-12-03|2010-12-06|Estimate|2014-08-05|2014-08-06|Estimate|2012-07-25|2012-08-02|Estimate|2014-08-05|2014-08-06|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||A total of 262 patients were randomized to receive double-blind treatment. The Baseline Participant population is based on the 251 randomized patients received at least 1 dose of double-blind treatment (Safety Population).|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder|A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder|Completed||Phase 2|262|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 23:04:49.972471|2018-05-31 23:04:49.972471
NCT01254292|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2014-01-07||2017-08-24|2010-12-03|2010-12-06|Estimate|2014-03-31|2014-04-07|Estimate||||2017-08-24|2017-09-25|Actual|January 6, 2011|Actual|2011-01-06|August 2017|2017-08-31|May 28, 2014|Actual|2014-05-28|January 8, 2013|Actual|2013-01-08||Interventional|||LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study|Multicenter, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 12 µg LNG/Day Initial in Vitro Release Rate (LCS12) in Comparison to a Combined Oral Contraceptive Containing 30 µg Ethinyl Estradiol and 3 mg Drospirenone (Yasmin®) in Young Women (18-29 Years) Over 18 Months of Use|Completed||Phase 3|567|Actual|Bayer||2|||f||||f|t|f||||||||2018-05-31 23:04:50.588946|2018-05-31 23:04:50.588946
NCT01254123|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|November 2009||2009-11-30|January 2010|2010-01-31||||||||Interventional|EXAMI||Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)|Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)|Unknown status|Recruiting|Phase 3|40|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-05-31 23:04:53.970982|2018-05-31 23:04:53.970982
NCT01254279|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2015-01-19|2010-12-02|2010-12-06|Estimate|||||||2015-01-19|2015-01-21|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen|Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients|Completed||Phase 3|984|Actual|Sanofi||1|||f||||||||||||||2018-05-31 23:04:51.892556|2018-05-31 23:04:51.892556
NCT01254266|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2011-07-24|2010-12-02|2010-12-06|Estimate|||||||2011-07-24|2011-07-26|Estimate|December 2010||2010-12-31|May 2010|2010-05-31|September 2014|Anticipated|2014-09-30|June 2013|Anticipated|2013-06-30||Interventional|||The Efficacy of an Inpatient Program for Long-term Weight Maintenance in Children and Adolescents With Morbid Obesity|Morbid Obesity in Children and Adolescents : Does Inpatient Treatment in a Psychosomatic Unit Increases the Chance for a Long-term Weight Maintenance?|Unknown status|Recruiting|N/A|30|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 23:04:52.270896|2018-05-31 23:04:52.270896
NCT01254253|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2011-11-21|2010-12-03|2010-12-06|Estimate|||||||2011-11-21|2011-11-22|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|November 2011|Anticipated|2011-11-30|March 2010|Actual|2010-03-31||Interventional|||Functional and Clinical Benefits of PCI in Patients With CTO|Multimodality Imaging Evaluation of Functional and Clinical Benefits of Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Lesion|Unknown status|Recruiting|N/A|150|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 23:04:52.368792|2018-05-31 23:04:52.368792
NCT01254240|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2016-05-10|2010-12-03|2010-12-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2010||2010-12-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PRUVAB||Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases|Randomized Double-blind Phase 2 Study of Impact of Ultraviolet A (UVA) on Pruritus During Ultraviolet A/B (UVA/B) Phototherapy of Inflammatory Dermatoses|Completed||Phase 2|80|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 23:04:52.453442|2018-05-31 23:04:52.453442
NCT01254227|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2014-11-03|2010-12-03|2010-12-06|Estimate|||||||2014-11-03|2014-11-05|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|HYPERION||Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload|Phase II, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Patients With Severe Cardiac Iron Overload Due to Chronic Blood Transfusion (HYPERION)|Completed||Phase 2|60|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:04:52.526659|2018-05-31 23:04:52.526659
NCT01254214|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2016-06-21||2016-09-13|2010-12-03|2010-12-06|Estimate|2016-09-13|2016-10-31|Estimate||||2016-09-13|2016-10-31|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|August 2015|Actual|2015-08-31|June 2014|Actual|2014-06-30||Interventional|||Journeys to Wellness: A Transplant Candidate Study|Mindfulness for Symptom Reduction: A Transplant Candidate Study in Program Grant Studies of Organ Transplantation in Animals and Man 2P01 DK013083|Completed||Phase 3|63|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||Undecided||2018-05-31 23:04:52.622049|2018-05-31 23:04:52.622049
NCT01254201|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2017-03-13|2010-12-03|2010-12-06|Estimate|||||||2017-03-13|2017-03-15|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Pathogenesis of Idiopathic Dry Eyes|The Pathogenesis of Idiopathic Dry Eyes|Completed|||90|Actual|University of Michigan|||3||f||||f||||||||No||2018-05-31 23:04:52.930222|2018-05-31 23:04:52.930222
NCT01254188|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2015-11-02||2016-02-03|2010-12-03|2010-12-06|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ENESTxtnd|Newly diagnosed CML-CP patients not previously treated with imatinib and diagnosed within 6 months of study entry, except for hydroxyurea, and/or anagrelide . In emergent cases where the patient requires disease management Gleevec/Glivec at any dose may be prescribed to the patient for no longer than 2 weeks in duration|Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients|Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase|Completed||Phase 3|421|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:04:53.015251|2018-05-31 23:04:53.015251
NCT01254175|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-12-02|2010-12-02|2010-12-06|Estimate|||||||2014-12-02|2014-12-03|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children|Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 23:04:53.656072|2018-05-31 23:04:53.656072
NCT01254162|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-09-11|2010-12-02|2010-12-06|Estimate|||||||2014-09-11|2014-09-12|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers|A 4-Week, Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Potential of Topically Applied 0.75% (w/w) MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers|Completed||Phase 2|135|Actual|Mimetica Pty Limited||1|||f||||t||||||||||2018-05-31 23:04:53.728321|2018-05-31 23:04:53.728321
NCT01254149|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-06-13|2010-12-03|2010-12-06|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic|Intraocular Pressure Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic|Completed|||43|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 23:04:53.783477|2018-05-31 23:04:53.783477
NCT01254136|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01||2010-12-13|2012-01-20|2010-12-02|2010-12-06|Estimate||||2010-12-13|2010-12-16|Estimate|2012-01-20|2012-01-25|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer|A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.|Terminated||Phase 1/Phase 2|20|Anticipated|Incyte Corporation||1||Incyte has suspended development of the compound.|f||||f||||||||||2018-05-31 23:04:53.882923|2018-05-31 23:04:53.882923
NCT01254110|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2013-10-15|2010-12-02|2010-12-06|Estimate|||||||2013-10-15|2013-10-16|Estimate|April 2009||2009-04-30|October 2013|2013-10-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Observational|Intesmetapro||Amino Acid and Intestinal Protein Metabolism : Working Study|Physiological Study on Glutamine and Leucine Effects on Intestinal Protein Metabolism|Completed|||36|Actual|University Hospital, Rouen|||3||f||||f||||||Samples Without DNA|"~     whole blood duodenal tissue~   "|||2018-05-31 23:04:54.061429|2018-05-31 23:04:54.061429
NCT01254097|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2015-09-23|2010-12-03|2010-12-06|Estimate|||||||2015-09-23|2015-09-25|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|July 2011|Actual|2011-07-31||Interventional|||Probiotics in Primary Care|Feasibility Study of Probiotics in Primary Care|Completed||N/A|51|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 23:04:55.434167|2018-05-31 23:04:55.434167
NCT01254084|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Effect of Gynostemma Pentaphyllum Tea in Insulin Sensitivity in Type 2 Diabetic Patients|Gynostemma Pentaphyllum Tea Improves Insulin Sensitivity in Type 2 Diabetic Patients|Completed||Phase 1/Phase 2|16|Actual|Hanoi Medical University||2|||f||||t||||||||||2018-05-31 23:04:55.504144|2018-05-31 23:04:55.504144
NCT01254071|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-06-09|2010-12-02|2010-12-06|Estimate|||||||2017-06-09|2017-06-12|Actual|September 10, 2010|Actual|2010-09-10|June 2017|2017-06-30|December 21, 2010|Actual|2010-12-21|December 21, 2010|Actual|2010-12-21||Interventional|ARI114694||A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.|An Open-label, Randomized, Single Dose, Two-Period Crossover Study to Determine the Bioavailability of a Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg Capsules and Tamsulosin Hydrochloride 0.2mg|Completed||Phase 1|86|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:04:55.584249|2018-05-31 23:04:55.584249
NCT01254058|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-07-27|2010-12-03|2010-12-06|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2010||2010-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Saccadic Eye Movements Are Impaired In Glaucoma|Novel Vision Testing Paradigms for Patients With Glaucoma|Enrolling by invitation|||40|Actual|St. Michael's Hospital, Toronto|||2||f||||f||||||||||2018-05-31 23:04:55.687694|2018-05-31 23:04:55.687694
NCT01254045|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2011-08-03||2014-08-28|2010-12-03|2010-12-06|Estimate|2014-08-28|2014-08-29|Estimate||||2014-08-28|2014-08-29|Estimate|February 2007||2007-02-28|August 2014|2014-08-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional||Ten enrolled. One not randomized because on antipsychotic mediation at baseline. Nine started and one lost to follow-up after baseline. Eight participants were included in data analysis. Each participant received a dose of either 24IU oxytocin, 48IU oxytocin or placebo at each of 3 visits, spaced 1 wk apart, to the lab (i.e., baseline, wk 2, wk 3).|Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome|Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome|Completed||Phase 2|10|Actual|Stanford University||6|||f||||f||||||||||2018-05-31 23:04:55.771065|2018-05-31 23:04:55.771065
NCT01254032|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2016-08-17|2010-12-02|2010-12-06|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|PACE||Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD|A 24 Week Study to Evaluate the Predictive Ability of the COPD Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With Chronic Obstructive Pulmonary Disease|Completed|||70|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:04:56.084933|2018-05-31 23:04:56.084933
NCT01254019|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2017-09-21|2010-12-02|2010-12-06|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2, 2010|Actual|2010-12-02|September 2017|2017-09-30|June 28, 2013|Actual|2013-06-28|June 28, 2013|Actual|2013-06-28||Interventional|DMD114044||A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy|Completed||Phase 3|186|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 23:04:57.055983|2018-05-31 23:04:57.055983
NCT01254006|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate||||August 2009|2009-08-31||||||||Interventional|||Retinal Nerve Fibres Layers Thickness Study in Glaucomatous Patients||Completed||N/A|||University of Roma La Sapienza|||||f||||||||||||||2018-05-31 23:04:57.196156|2018-05-31 23:04:57.196156
NCT01253993|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|April 2006||2006-04-30|December 2010|2010-12-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Observational|||Impaired Decision-making in Adolescents|Impaired Decision-making in Adolescents: A Vulnerability Factor for the Development of Substance Use and Abuse.|Completed|||152|Actual|UMC Utrecht|||||f||||t||||||||||2018-05-31 23:04:57.258096|2018-05-31 23:04:57.258096
NCT01253980|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|2013-05-06||2015-10-07|2010-12-03|2010-12-06|Estimate|2013-05-06|2013-06-26|Estimate||||2015-10-07|2015-11-09|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children|The Efficacy of Prophylactic Antibiotics in the Management of Pneumonitis Following Paraffin (Kerosene) Ingestion in Children|Completed||N/A|74|Actual|University of Cape Town|Early termination leading to small number of participants. Some patients did not attend follow-up and were only contacted by phone, therefore clinical data not available for all participants at follow-up.|2|||f||||t||||||||||2018-05-31 23:04:57.324327|2018-05-31 23:04:57.324327
NCT01253967|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2015-04-09|2010-12-02|2010-12-06|Estimate|||||||2015-04-09|2015-04-13|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in Children < 5 Years of Age in Romania|Hospital-based Surveillance to Estimate the Disease Burden of Rotavirus Gastroenteritis in Children < 5 Years of Age in Romania|Completed|||1234|Actual|GlaxoSmithKline|||3||f||||||||||Samples Without DNA|"~     Stool samples~   "|||2018-05-31 23:04:57.630261|2018-05-31 23:04:57.630261
NCT01253954|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Observational|china-scan||A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China|Epidemiology of Invasive Candida Infections in Critically Ill Patients: A Multicenter, Prospective, Observational Study in China|Unknown status|Recruiting||300|Anticipated|Southeast University, China|||1||f||||f||||||||||2018-05-31 23:04:57.750296|2018-05-31 23:04:57.750296
NCT01253941|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2013-09-11|2010-12-03|2010-12-06|Estimate|||||||2013-09-11|2013-09-13|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Mud Bath Therapy in Chronic Obstructive Pulmonary Disease|Effects of Mud Bath Therapy in Chronic Obstructive Pulmonary Disease|Completed||N/A|42|Actual|Fondazione Salvatore Maugeri||2|||f||||t||||||||||2018-05-31 23:04:57.823036|2018-05-31 23:04:57.823036
NCT01253928|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-03|||2010-12-03|2010-12-03|2010-12-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|March 2007||2007-03-31|February 2007|2007-02-28||||June 2011|Anticipated|2011-06-30||Interventional|||Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD|Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals|Unknown status|Recruiting|Phase 4|16|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||||||||||||2018-05-31 23:04:57.91575|2018-05-31 23:04:57.91575
NCT01253915|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2013-10-30|2010-12-03|2010-12-06|Estimate|||||||2013-10-30|2013-10-31|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine|Terminated||Phase 2|35|Actual|Capnia, Inc.||2||Low enrollment and lack of funding for study|f||||f||||||||||2018-05-31 23:04:58.008242|2018-05-31 23:04:58.008242
NCT01253902|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2012-10-08||2012-10-08|2010-12-03|2010-12-06|Estimate|2012-10-08|2012-11-07|Estimate||||2012-10-08|2012-11-07|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 4|164|Actual|Allergan||3|||f||||f||||||||||2018-05-31 23:04:58.115294|2018-05-31 23:04:58.115294
NCT01253889|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-02-20|2010-12-03|2010-12-06|Estimate|||||||2017-02-20|2017-02-23|Actual|December 2010||2010-12-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Sweetheart Study: Oral Glucose for Reducing Stress During Echocardiographic Assessment in Infants in the NICU|Glucose 25% and Facilitated Tucking for Reducing Procedural Stress During Neonatologist-performed Cardiac Echocardiography in Infants in the NICU|Completed||Phase 4|104|Actual|Children's & Women's Health Centre of British Columbia||4|||f||||f||||||||||2018-05-31 23:04:58.401594|2018-05-31 23:04:58.401594
NCT01253876|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Effect of Soymilk Replacement on Anthropometric and Blood Pressure Value||Completed||Phase 4|||Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:04:58.486492|2018-05-31 23:04:58.486492
NCT01253863|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|August 2006||2006-08-31|August 2006|2006-08-31|September 2009|Actual|2009-09-30|May 2008|Actual|2008-05-31||Interventional|||Diagnostic Accuracy of the Preoperative Clinical Examination in Upper Limb Injuries|Study of Accuracy of Preoperative Examination in Penetrating Wound|Completed||Phase 2|250|Actual|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:04:58.549543|2018-05-31 23:04:58.549543
NCT01253850|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-04-13|2010-12-02|2010-12-03|Estimate|||||||2017-04-13|2017-04-17|Actual|August 2010||2010-08-31|April 2017|2017-04-30|March 6, 2013|Actual|2013-03-06|July 2011|Actual|2011-07-31||Observational|||Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I|Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I|Completed|||31|Actual|Fenway Community Health|||||f||||t||||||||No||2018-05-31 23:04:58.633149|2018-05-31 23:04:58.633149
NCT01253837|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2011-09-22|2010-12-02|2010-12-03|Estimate|||||||2011-09-22|2011-09-23|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||L19TNFα in Patients With Advanced Solid Tumors|Phase I/II Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|34|Anticipated|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:04:58.702652|2018-05-31 23:04:58.702652
NCT01253824|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2014-04-10||2014-05-15|2010-12-02|2010-12-03|Estimate|2014-05-15|2014-06-17|Estimate||||2014-05-15|2014-06-17|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||All subjects were included for safety and pharmacodynamics analysis.|Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers|Pharmacodynamics of NPC-01( 1mg Norethisterone and 0.02mg Ethinyl Estradiol) and IKH-01( 1mg Norethisterone and 0.035mg Ethinyl Estradiol); Effect of NPC-01 and IKH-01 on Serum Concentrations of Estradiol, Progesterone, FSH and LH.|Completed||Phase 3|14|Actual|Nobelpharma||2|||f||||f||||||||||2018-05-31 23:04:58.884658|2018-05-31 23:04:58.884658
NCT01253811|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2016-03-29||2016-05-18|2010-12-02|2010-12-03|Estimate|2016-05-18|2016-06-24|Estimate||||2016-05-18|2016-06-24|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|mentor™5|The safety analysis set (SAS) included all patients exposed to trial drug (rFXIII).|Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency|A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency. Safety Extension Trial to F13CD-3760|Completed||Phase 3|6|Actual|Novo Nordisk A/S|Limitations of the trial included the small number of subjects analysed and the sensitivity of the Berichrom® FXIII activity assay. However, congenital FXIII deficiency is a rare disease and there were no bleeds requiring haemostatic treatment.|1|||f||||f||||||||||2018-05-31 23:04:59.213746|2018-05-31 23:04:59.213746
NCT01253798|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-09-19|2010-12-02|2010-12-03|Estimate|||||||2012-09-19|2012-09-20|Estimate|November 2010||2010-11-30|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Group Exercise After Hip Replacement Surgery|What Type of Group Exercise Should be Chosen for Osteoarthritis Patients in the Rehabilitation Phase Following Hip Replacement Surgery?|Terminated||N/A|19|Actual|Norwegian University of Science and Technology||2||recruitement unsuccessful|f||||f||||||||||2018-05-31 23:04:59.815652|2018-05-31 23:04:59.815652
NCT01253785|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Observational|||Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia|Completed|||10|Actual|SterilMed, Inc.|||||f||||f||||||||||2018-05-31 23:04:59.885343|2018-05-31 23:04:59.885343
NCT01253772|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia in Neonates|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia in Neonates|Completed|||4|Actual|SterilMed, Inc.|||||f||||f||||||||||2018-05-31 23:04:59.9352|2018-05-31 23:04:59.9352
NCT01253759|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-05-01|2010-12-02|2010-12-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Observational|||Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma|10 Years Report of Combined Simultaneous Transpupillary Thermotherapy and ICG-based Photodynamic Therapy for Choroidal Melanoma|Completed|||46|Actual|New England Retina Associates|||1||f||||f||||||||||2018-05-31 23:05:00.003309|2018-05-31 23:05:00.003309
NCT01253746|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|April 2009||2009-04-30|December 2010|2010-12-31||||||||Observational|NTD||Genetics of Neural Tube Defects|Genetics of Neural Tubes Defects|Unknown status|Recruiting||6000|Anticipated|John P. Hussman Institute for Human Genomics|||||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 23:05:00.080156|2018-05-31 23:05:00.080156
NCT01253733|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2016-01-25|2010-12-02|2010-12-03|Estimate|||||||2016-01-25|2016-01-26|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||MD2Me - Texting to Promote Chronic Disease Management|TAHLC - Texting to Promote Adolescent Health Liaisons and Chronic Disease Management|Completed||N/A|81|Actual|Huang, Jeannie, M.D.||2|||f||||t||||||||||2018-05-31 23:05:00.146083|2018-05-31 23:05:00.146083
NCT01253720|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-01-25|2010-12-02|2010-12-03|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||PACE CALL: Weight Loss Study for Childhood Leukemia Survivors|PACE CALL: A Tailored Weight Management Program for Childhood ALL Survivors|Completed||N/A|38|Actual|Huang, Jeannie, M.D.||2|||f||||||||||||||2018-05-31 23:05:00.228926|2018-05-31 23:05:00.228926
NCT01253707|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2016-12-22|2010-12-02|2010-12-03|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2010||2010-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2015|Actual|2015-10-31||Interventional|||A Study of AMG 337 in Subjects With Advanced Solid Tumors|A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|111|Actual|Amgen||1|||f||||||||||||||2018-05-31 23:05:00.304348|2018-05-31 23:05:00.304348
NCT01253694|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2013-05-01|2010-12-02|2010-12-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|||Ranibizumab as a Rescue Therapy for Diabetic Macular Edema|Ranibizumab in Residual Diabetic Macular Edema Following Previous Intravitreal Bevacizumab Therapy|Withdrawn||Phase 2|0|Actual|New England Retina Associates||2|||f||||t||||||||||2018-05-31 23:05:00.473547|2018-05-31 23:05:00.473547
NCT01253681|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2015-10-13|2010-12-02|2010-12-03|Estimate|||||||2015-10-13|2015-10-14|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|October 2012|Actual|2012-10-31||Interventional|||Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer|A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers|Completed||Phase 1|27|Actual|Amgen||1|||f||||f||||||||||2018-05-31 23:05:00.553772|2018-05-31 23:05:00.553772
NCT01253668|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2015-12-14|2010-12-02|2010-12-03|Estimate|||||||2015-12-14|2015-12-15|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Brivanib Metastatic Renal Cell Carcinoma|Brivanib (BMS-582664, Brivanib Alaninate) in Treatment of Refractory Metastatic Renal Cell Carcinoma - A Phase II Pharmacodynamic and Baseline Biomarker Study|Completed||Phase 2|10|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 23:05:00.646461|2018-05-31 23:05:00.646461
NCT01253655|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-04-26|2010-12-02|2010-12-03|Estimate|||||||2011-04-26|2011-04-28|Estimate|November 2010||2010-11-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|3193A1-1103||To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers|A Phase 1, Open-Label Study To Evaluate 5-HT6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]PF-04171252 Following Single Oral Dose Administration Of PF-05212365 (SAM-531) In Healthy Subjects|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:05:00.739681|2018-05-31 23:05:00.739681
NCT01253642|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2017-09-14||2017-12-07|2010-12-02|2010-12-03|Estimate|2017-12-07|2017-12-11|Actual||||2017-12-07|2017-12-11|Actual|July 12, 2010||2010-07-12|December 2017|2017-12-31|September 15, 2017|Actual|2017-09-15|September 15, 2016|Actual|2016-09-15||Interventional||11 subjects received combination therapy|Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel|A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy|Terminated||Phase 2|11|Actual|OHSU Knight Cancer Institute|Early termination leading to small numbers of subjects analyzed; overall morbidity of patient population prohibited long term treatment or follow-up.|1||low enrollment|f||||t||||||||||2018-05-31 23:05:00.849669|2018-05-31 23:05:00.849669
NCT01253629|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02||2016-03-22|2016-03-22|2010-12-02|2010-12-03|Estimate||||2016-03-22|2016-04-25|Estimate|2016-03-22|2016-04-25|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate AFQ056 in Adult Patients With Fragile X Syndrome|Completed||Phase 2|175|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:05:01.25874|2018-05-31 23:05:01.25874
NCT01253616|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-02-16|2010-12-02|2010-12-03|Estimate|||||||2017-02-16|2017-02-17|Actual|December 2010||2010-12-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Proof-of-Concept Study Assessing VNS Paired With Tones for Tinnitus|A Proof-of-Concept Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus|Completed||N/A|10|Actual|MicroTransponder Inc.||1|||f||||f||||||||||2018-05-31 23:05:01.45349|2018-05-31 23:05:01.45349
NCT01253603|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01||2013-10-29|2013-10-29|2010-12-01|2010-12-03|Estimate||||2013-10-29|2013-11-21|Estimate|2013-10-29|2013-11-21|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy, Safety, and Pharmacokinetics of QAW039|A Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Pharmacokinetics of QAW039 in Steroid-free Patients With Mild to Moderate Persistent Asthma|Completed||Phase 2|170|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:05:01.569907|2018-05-31 23:05:01.569907
NCT01253590|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2015-03-04|2010-12-02|2010-12-03|Estimate|||||||2015-03-04|2015-03-06|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation|Feasibility of Remote Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation|Terminated|||5|Actual|Memorial Sloan Kettering Cancer Center|||1|Lack of accrual|f||||||||||||||2018-05-31 23:05:01.736947|2018-05-31 23:05:01.736947
NCT01253577|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2012-12-11||2015-05-26|2010-12-02|2010-12-03|Estimate|2015-03-30|2015-04-13|Estimate||||2015-05-26|2015-06-22|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|ADVANCE II||A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis|A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis|Completed||Phase 3|105|Actual|Intersect ENT||2|||f||||||||||||||2018-05-31 23:05:01.985235|2018-05-31 23:05:01.985235
NCT01253564|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2015-07-13||2017-06-26|2010-12-02|2010-12-03|Estimate|2015-07-13|2015-08-07|Estimate||||2017-06-26|2017-07-31|Actual|November 22, 2010|Actual|2010-11-22|June 2017|2017-06-30|March 14, 2012|Actual|2012-03-14|March 14, 2012|Actual|2012-03-14||Interventional||Safety population: All participants who received at least one dose of study medication.|A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases|An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases|Completed||Phase 2|24|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:05:02.476967|2018-05-31 23:05:02.476967
NCT01253551|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-10-13|2010-12-02|2010-12-03|Estimate|||||||2012-10-13|2012-10-16|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|April 2011|Actual|2011-04-30|||||Interventional|||VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir|A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state|Completed||Phase 1|21|Actual|Tibotec BVBA||2|||f||||||||||||||2018-05-31 23:05:02.890091|2018-05-31 23:05:02.890091
NCT01253525|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2014-05-16||2014-05-16|2010-12-02|2010-12-03|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||All enrolled participants|Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas|A Phase 1b Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas|Completed||Phase 1|6|Actual|Eli Lilly and Company|Cycle 3 and beyond pharmacokinetic sampling was collected per the protocol-defined limited sampling schedule.|1|||f||||f||||||||||2018-05-31 23:05:03.163682|2018-05-31 23:05:03.163682
NCT01253512|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|March 2011||2011-03-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Study to Assess the Safety and Efficacy of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)|Double Blind, Placebo Controlled, Escalating Single-dose, Pilot Study to Assess the Safety of THR-18 When Administered to Patients Suffering Acute Ischemic Stroke and Treated With Tissue Plasminogen Activator (tPA)|Unknown status|Not yet recruiting|Phase 1/Phase 2|22|Anticipated|Thrombotech Ltd.||3|||f||||t||||||||||2018-05-31 23:05:03.811458|2018-05-31 23:05:03.811458
NCT01253499|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-16|2010-12-02|2010-12-03|Estimate|||||||2010-12-16|2010-12-17|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Multiple Dose Study of TRx0037|A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers|Completed||Phase 1|31|Actual|TauRx Therapeutics Ltd||1|||||||||||||||||2018-05-31 23:05:03.971107|2018-05-31 23:05:03.971107
NCT01253486|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2013-09-23|2010-12-02|2010-12-03|Estimate|||||||2013-09-23|2013-09-25|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|WrittenHeart||Expressive Writing for Heart Healing|Use of Expressive Writing in the Cardiac Rehabilitation of Obese In-patients With Ischemic Heart Disease (IHD)|Completed||N/A|100|Actual|Istituto Auxologico Italiano||4|||f||||f||||||||||2018-05-31 23:05:04.085611|2018-05-31 23:05:04.085611
NCT01253473|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2017-03-27|2010-12-01|2010-12-03|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2012|Actual|2012-04-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|SACOPD||Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)|"COPDGene Ancillary Proposal: Symbicort Intervention in Airway Predominant"|Completed||Phase 4|46|Actual|National Jewish Health||3|||f||||t||||||||No||2018-05-31 23:05:04.204354|2018-05-31 23:05:04.204354
NCT01253460|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-04-05|2010-12-01|2010-12-03|Estimate|||||||2018-04-05|2018-04-09|Actual|July 20, 2011|Actual|2011-07-20|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|||Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)|A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH|Terminated||Phase 2|19|Actual|M.D. Anderson Cancer Center||1||Accrual not met|f||||f|t|f||||||||2018-05-31 23:05:04.33256|2018-05-31 23:05:04.33256
NCT01253447|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2014-12-23||2014-12-23|2010-12-02|2010-12-03|Estimate|2014-12-23|2015-01-07|Estimate||||2014-12-23|2015-01-07|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:05:04.455527|2018-05-31 23:05:04.455527
NCT01253434|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2013-05-13|2010-12-02|2010-12-03|Estimate|||||||2013-05-13|2013-05-14|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||E2022 Patch Formulation Single Dose Phase I Study|E2022 Patch Formulation Single Dose Phase I Study|Completed||Phase 1|80|Actual|Eisai Inc.||5|||f||||||||||||||2018-05-31 23:05:04.791486|2018-05-31 23:05:04.791486
NCT01253421|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2017-05-02||2018-04-25|2010-12-01|2010-12-03|Estimate|2017-12-19|2018-01-18|Actual||||2018-04-25|2018-04-27|Actual|February 2012||2012-02-29|April 2018|2018-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effects of Dopamine on Reward Processing|The Effects of Dopamine on Reward Processing|Completed||Phase 1|159|Actual|Mclean Hospital|The choice of a 50-mg dose of amisulpride was based on animal work showing low doses potentiate striatal dopamine release, have strong hedonic effects, and increase the incentive value of environmental cues. Higher doses may have different results.|4|||f||||f|t|f||||||No||2018-05-31 23:05:04.992669|2018-05-31 23:05:04.992669
NCT01253408|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2013-02-04||2013-03-22|2010-12-01|2010-12-03|Estimate|2013-03-22|2013-05-07|Estimate||||2013-03-22|2013-05-07|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)|Study of the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Irritable Bowel Syndrome|Completed||Phase 2|36|Actual|Mayo Clinic|This study included assessment of only four doses of dronabinol over 2 days.|3|||f||||f||||||||||2018-05-31 23:05:06.502047|2018-05-31 23:05:06.502047
NCT01253382|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2018-01-22|2010-12-02|2010-12-03|Estimate|||||||2018-01-22|2018-01-24|Actual|June 1, 2012||2012-06-01|January 2018|2018-01-31||||April 1, 2015|Anticipated|2015-04-01||Interventional|||Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema|A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema (HAE)|Withdrawn||Phase 2/Phase 3|0|Actual|Shire||2|||f||||t||||||||||2018-05-31 23:05:07.013082|2018-05-31 23:05:07.013082
NCT01253369|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2015-12-08||2018-01-29|2010-12-02|2010-12-03|Estimate|2015-12-08|2016-01-12|Estimate||||2018-01-29|2018-02-23|Actual|June 2010||2010-06-30|January 2018|2018-01-31|December 2014|Actual|2014-12-31|September 2012|Actual|2012-09-30||Interventional|||Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer|A Phase II Study of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)|Completed||Phase 2|33|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 23:05:07.084147|2018-05-31 23:05:07.084147
NCT01253356|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-01-05|2010-12-02|2010-12-03|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|February 2012|Anticipated|2012-02-29|January 2012|Anticipated|2012-01-31||Interventional|ACTIONS||ACTIONS - Aortic Counterpulsation to Improve Outcomes in Noncardiac Surgery|A Multicenter, Randomized, Controlled Pilot Study of Intra-Aortic Balloon Counterpulsation to Prevent Perioperative Cardiac Events in High-Risk Cardiac Patients Undergoing Noncardiac Surgery|Terminated||Phase 4|1|Actual|Datascope Corp.||2||Only 1 patient recruited and deemed ineligible.|f||||t||||||||||2018-05-31 23:05:07.347512|2018-05-31 23:05:07.347512
NCT01253343|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2012-11-19||2013-05-23|2010-12-02|2010-12-03|Estimate|2013-05-23|2013-08-28|Estimate||||2013-05-23|2013-08-28|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Pediatric Aggression and Violence|Salivary Hormones and Pediatric Aggression and Violence: A Feasibility Study|Completed|||17|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples Without DNA|"~     Saliva specimens will be retained for future research use for particpants who have given~     proper consent.~   "|||2018-05-31 23:05:07.439122|2018-05-31 23:05:07.439122
NCT01253330|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2016-02-11|2010-12-02|2010-12-03|Estimate|||||||2016-02-11|2016-02-12|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Usage, Usability & Effect on Adherence and Clinical Outcomes of Text Message Reminders for Adolescents With Asthma|Study of the Usage, Usability, Acceptability, and Effect on Adherence and Clinical Outcomes of a Web Based Text Messaging System for Adolescents With Asthma- Phase 2|Completed||N/A|61|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 23:05:07.867026|2018-05-31 23:05:07.867026
NCT01253317|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2014-05-13||2017-06-20|2010-12-02|2010-12-03|Estimate|2017-06-20|2017-06-22|Actual||||2017-06-20|2017-06-22|Actual|December 2010||2010-12-31|June 2017|2017-06-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional||Twelve girls with MECP2 mutations participated in the 4-week MAD period; ten of them continued and completed the subsequent 20-week OLE. Nine subjects met full diagnostic criteria for RTT, all of whom continued in the OLE.|Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)|Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With IGF-1|Completed||Phase 1|12|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 23:05:07.993403|2018-05-31 23:05:07.993403
NCT01253304|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2014-10-03||2014-10-03|2010-12-01|2010-12-03|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Participants who received at least one dose of study drug (LY2189265).|A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment|A Single Dose Pharmacokinetic Study of LY2189265 in Subjects With Varying Degrees of Hepatic Impairment|Completed||Phase 1|26|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 23:05:08.344652|2018-05-31 23:05:08.344652
NCT01253291|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2014-04-30|2010-12-01|2010-12-03|Estimate|||||||2014-04-30|2014-05-02|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||A Study of Japanese Rheumatoid Arthritis Patients|An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate|Completed||Phase 1|32|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:05:09.260438|2018-05-31 23:05:09.260438
NCT01253278|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2011-06-09|2010-12-01|2010-12-03|Estimate|||||||2011-06-09|2011-06-10|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Oral Doses of LY2393910 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|38|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 23:05:09.355101|2018-05-31 23:05:09.355101
NCT01253265|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2016-04-20||2016-04-20|2010-12-01|2010-12-03|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study in Rheumatoid Arthritis|Multiple-Dose, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate Treatment|Completed||Phase 1|32|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 23:05:09.455826|2018-05-31 23:05:09.455826
NCT01253252|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2017-07-27|2010-12-02|2010-12-03|Estimate|||||||2017-07-27|2017-07-28|Actual|August 2009|Actual|2009-08-31|July 2017|2017-07-31||||August 2009|Actual|2009-08-31||Interventional|AAAendo||Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms (AAA) Metabolic Activity|Endoprosthesis Treatment Effects on Human Abdominal Aorta Aneurysms(AAA)Metabolic Activity|Completed||N/A|45|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-05-31 23:05:10.648678|2018-05-31 23:05:10.648678
NCT01253239|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2016-07-18|2010-12-02|2010-12-03|Estimate|||||||2016-07-18|2016-07-20|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation the TECNIS IOL in Both Eyes VS the ReZoom IOL in One and TECNIS IOL in the Opposite|A Retrospective Evaluation Comparing Post Operative Visual Outcomes in Patients Implanted With the TECNIS IOL in Both Eyes Versus the ReZoom IOL in One Eye and TECNIS IOL in the Opposite Eye|Completed|||175|Actual|Bucci Laser Vision Institute|||2||f||||f||||||||Undecided||2018-05-31 23:05:10.760015|2018-05-31 23:05:10.760015
NCT01253226|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2011-09-16|2010-12-01|2010-12-03|Estimate|||||||2011-09-16|2011-09-20|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study for Japanese Patients With Rheumatoid Arthritis|Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate|Completed||Phase 1|32|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 23:05:11.051357|2018-05-31 23:05:11.051357
NCT01253213|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2013-04-23|2010-12-02|2010-12-03|Estimate|||||||2013-04-23|2013-04-24|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||BR55 in Prostate Cancer: an Exploratory Clinical Trial|Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2|Completed||Early Phase 1|26|Actual|Bracco Diagnostics, Inc||1|||f||||f||||||||||2018-05-31 23:05:11.258596|2018-05-31 23:05:11.258596
NCT01253200|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|2017-03-09||2018-02-15|2010-12-02|2010-12-03|Estimate|2018-01-18|2018-02-15|Actual||||2018-02-15|2018-03-19|Actual|January 2011||2011-01-31|February 2018|2018-02-28|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|BLOCk-CTI||Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter|Clinical Evaluation of the Blazer® Open-Irrigated Radiofrequency Ablation Catheter for the Treatment of Type 1 Atrial Flutter|Completed||N/A|302|Actual|Boston Scientific Corporation|Two interim study suspensions occurred during enrollment that did not impact the integrity of the data and subsequent analyses.|2|||f||||f|f|t|f|f||||No||2018-05-31 23:05:11.359345|2018-05-31 23:05:11.359345
NCT01253187|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2010-12-09||2013-08-01|2010-12-02|2010-12-03|Estimate|2011-04-18|2011-05-09|Estimate||||2013-08-01|2013-08-07|Estimate|October 2006||2006-10-31|August 2013|2013-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)|Open-label, Randomized, Three-fold Crossover Study to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.02 mg Ethinylestradiol (EE) and 3 mg Drospirenone (DRSP) Without [SH T00186D] and With [SH T04532B] 0.451 mg L-mefolinate (Metafolin), and to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.451 mg L-mefolinate (Metafolin) Without [SH T04532C] and With 0.02 mg EE/ 3 mg DRSP [SH T04532B] in 42 Healthy Young Women|Completed||Phase 1|44|Actual|Bayer||3|||f||||f||||||||||2018-05-31 23:05:12.375321|2018-05-31 23:05:12.375321
NCT01253174|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2010-12-09||2013-08-01|2010-12-02|2010-12-03|Estimate|2011-04-18|2011-05-09|Estimate||||2013-08-01|2013-08-07|Estimate|August 2006||2006-08-31|August 2013|2013-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)|Open-label, Randomized, Three-fold Crossover Study to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.03 mg Ethinylestradiol (EE) and 3 mg Drospirenone (DRSP) Without [SH T470FA] and With [SH T04532A] 0.451 mg Metafolin®, and to Investigate the Bioequivalence of Two Different Tablet Formulations Containing 0.451 mg Metafolin® Without [SH T04532C] and With 0.03 mg EE/ 3 mg DRSP [SH T04532A] in 42 Healthy Young Women|Completed||Phase 1|48|Actual|Bayer||3|||f||||f||||||||||2018-05-31 23:05:13.395412|2018-05-31 23:05:13.395412
NCT01253161|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2018-01-09|2010-12-01|2010-12-03|Estimate|||||||2018-01-09|2018-01-11|Actual|January 24, 2011|Actual|2011-01-24|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)|Phase II Study of Pasireotide LAR in Patients With Metastatic Neuroendocrine Carcinomas|Active, not recruiting||Phase 2|29|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t|t|f||||||||2018-05-31 23:05:14.15832|2018-05-31 23:05:14.15832
NCT01253148|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2016-07-18||2017-02-17|2010-12-02|2010-12-03|Estimate|2016-08-26|2016-10-19|Estimate||||2017-02-17|2017-03-22|Actual|January 2011||2011-01-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||All participants|Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma|Phase II Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres As First-Line Treatment For Cholangiocarcinoma|Completed||N/A|25|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 23:05:14.345297|2018-05-31 23:05:14.345297
NCT01253135|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2015-12-17||2015-12-17|2010-12-01|2010-12-03|Estimate|2015-12-17|2015-12-21|Estimate||||2015-12-17|2015-12-21|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional||There were 40 participants in the entire study. Only 25 participants in the amended protocol|Study to Determine if Fibrin Affects the Ability of a Wound to Heal|An Open-label, Randomized, Evaluator-Blinded Study of the Effect of Polymerized Fibrin Applied Topically Once Per Week, on Healing of Induced Thermal Wounds, Versus Weekly Application of White Petrolatum|Completed||Phase 1|40|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 23:05:14.814857|2018-05-31 23:05:14.814857
NCT01253122|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Comparative Bioavailability in Healthy Elderly Volunteers|Comparative Bioavailability of TRx0037 and TRx0014 in Healthy Elderly Volunteers|Completed||Phase 1|24|Actual|TauRx Therapeutics Ltd||2|||f||||f||||||||||2018-05-31 23:05:15.144176|2018-05-31 23:05:15.144176
NCT01253109|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-01-23|2010-12-02|2010-12-03|Estimate|||||||2012-01-23|2012-01-24|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Continuous Intraocular Pressure (IOP) Monitoring in Pigmentary Dispersion Syndrome and Pigmentary Glaucoma Patients|Detection of Induced IOP Fluctuations by SENSIMED Triggerfish® in Pigmentary Syndrome and Glaucoma Patients|Terminated|||15|Anticipated|Sensimed AG|||1|"Law agreement between Triggerfish signal and GAT IOP during both sessions. However, an increase~   in the Triggerfish signal was observed during jogging phase."|f||||f||||||||||2018-05-31 23:05:15.304484|2018-05-31 23:05:15.304484
NCT01253096|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-11-19|2010-12-02|2010-12-03|Estimate|||||||2014-11-19|2014-11-20|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Intratumoral Application of L19IL2 in Patients With Malignant Melanoma|A Phase II Study of Intratumoral Application of L19IL2 in Patients With Stage III/IV Melanoma.|Completed||Phase 2|25|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:05:15.369372|2018-05-31 23:05:15.369372
NCT01253083|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2018-05-23|2010-12-02|2010-12-03|Estimate|||||||2018-05-23|2018-05-24|Actual|November 15, 2010||2010-11-15|April 14, 2016|2016-04-14|June 6, 2014|Actual|2014-06-06|June 6, 2014|Actual|2014-06-06||Interventional|||Mobility Training to Improve Motor Behavior in Toddlers With or at Risk for Cerebral Palsy: A Pilot Study|Mobility Training to Improve Motor Behavior in Toddlers With or at Risk for Cerebral Palsy - A Pilot Study|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:05:15.519014|2018-05-31 23:05:15.519014
NCT01252563|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2014-01-09|2010-12-01|2010-12-03|Estimate|||||||2014-01-09|2014-01-13|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|ENTER10||Amlodipine 10mg Drug Use Investigation|Enhanced Dose Norvasc Treatment For Essential Hypertension In Realworld (Norvasc®10mg Drug Use Investigation)|Completed|||14141|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:05:24.260443|2018-05-31 23:05:24.260443
NCT01253070|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|2016-01-13||2018-05-07|2010-12-02|2010-12-03|Estimate|2016-01-13|2016-02-11|Estimate||||2018-05-07|2018-05-08|Actual|April 1, 2011|Actual|2011-04-01|March 2018|2018-03-31||||October 31, 2014|Actual|2014-10-31||Interventional|||Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study Incorporating Sorafenib (NSC 724772) Into the Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia|Active, not recruiting||Phase 2|54|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:05:15.612977|2018-05-31 23:05:15.612977
NCT01253057|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-01|2010-12-01|2010-12-03|Estimate|||||||2010-12-01|2010-12-03|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|||||Observational|||A Research on the Hospital Pollution Control and Hygine Intervention of Chemotherapy Drugs Exposure|A Research on the Hospital Pollution Control and Hygine Intervention of Chemotherapy Drugs Exposure|Unknown status|Active, not recruiting||200|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 23:05:17.35552|2018-05-31 23:05:17.35552
NCT01253044|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2015-06-30||2015-09-18|2010-12-01|2010-12-03|Estimate|2015-09-18|2015-10-19|Estimate||||2015-09-18|2015-10-19|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Acceptance and Commitment Therapy (ACT) for OEF/OIF Veterans|Initial Randomized Controlled Trial of Acceptance and Commitment Therapy (ACT) for Distress and Impairment in OEF/OIF Veterans|Completed||N/A|160|Actual|Veterans Medical Research Foundation||2|||f||||t||||||||||2018-05-31 23:05:17.547292|2018-05-31 23:05:17.547292
NCT01253031|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-12-21|2010-12-02|2010-12-03|Estimate|||||||2015-12-21|2015-12-23|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Working Memory Changes With Aging and Hearing Loss|Effects of Aging and Hearing Loss During Rapid Sound Processing|Completed|||63|Actual|VA Office of Research and Development|||3||f||||t||||||||||2018-05-31 23:05:17.92082|2018-05-31 23:05:17.92082
NCT01253018|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2015-12-01||2016-02-01|2010-12-01|2010-12-03|Estimate|2015-12-01|2016-01-07|Estimate||||2016-02-01|2016-03-01|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SRT3|Age, gender, race/ethnicity, type of stroke.|Evaluation of Robot Assisted Neuro-Rehabilitation|Evaluation of Robot Assisted Neuro-rehabilitation|Completed||Phase 1/Phase 2|59|Actual|VA Office of Research and Development|The amount of change on our primary outcome measure (FM) for this population of stroke survivors with moderated to severe upper extremity motor impairment was less than predicted (4 points vs. 8) resulting in the study groups being underpowered.|2|||f||||t||||||||||2018-05-31 23:05:18.04204|2018-05-31 23:05:18.04204
NCT01253005|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2012-11-13|2010-12-02|2010-12-03|Estimate|||||||2012-11-13|2012-11-14|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Effect of Physical Properties of Lipid Emulsions on Gastrointestinal Function|The Effect of Physical Properties of Lipid Emulsions on Gastrointestinal Motility and Transit, Hormonal Feedback, Visceral Sensation and Satiety in Healthy Volunteers|Completed||N/A|18|Actual|University of Zurich|||||f||||||||||||||2018-05-31 23:05:18.398256|2018-05-31 23:05:18.398256
NCT01252992|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-27|||2017-04-13|2010-12-02|2010-12-03|Estimate|||||||2017-04-13|2017-04-14|Actual|March 14, 2011||2011-03-14|April 2017|2017-04-30|February 21, 2018|Anticipated|2018-02-21|February 21, 2018|Anticipated|2018-02-21||Observational|PARATB||Paradoxical Reactions in Non Immuno-compromized Patients With Extrapulmonary Tuberculosis|Paradoxical Reactions During Anti-mycobacterial Treatment of Extrapulmonary Tuberculosis in Non Immuno-compromized Patients : Clinical, Radiological et Immunological|Active, not recruiting|||200|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Blood samples (immunologic test), DNA, RNA, Biopsy~   "|||2018-05-31 23:05:18.466322|2018-05-31 23:05:18.466322
NCT01252979|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2012-02-03|2010-12-01|2010-12-03|Estimate|||||||2012-02-03|2012-02-06|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Ketones & Mitochondrial Heteroplasmy|Ketones & Mitochondrial Heteroplasmy|Completed||Early Phase 1|13|Actual|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 23:05:18.548733|2018-05-31 23:05:18.548733
NCT01252966|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2016-09-07||2017-01-12|2010-12-01|2010-12-03|Estimate|2016-11-04|2017-01-02|Estimate||||2017-01-12|2017-01-16|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Cognitive Training for Nicotine Dependence|Cognitive Training for Nicotine Dependence|Completed||N/A|213|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:05:18.648949|2018-05-31 23:05:18.648949
NCT01252953|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2018-02-01||2018-04-06|2010-12-01|2010-12-03|Estimate|2018-04-06|2018-05-04|Actual||||2018-04-06|2018-05-04|Actual|June 2011||2011-06-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|January 31, 2017|Actual|2017-01-31||Interventional|REVEAL||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification|REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease|Active, not recruiting||Phase 3|30449|Actual|University of Oxford||2|||f||||t||||||||Yes|Proposals for substudies must be approved by the Steering Committee. Procedures for accessing the data for this study are available on: https://www.ndph.ox.ac.uk/about/data-access-policy.|2018-05-31 23:05:19.132127|2018-05-31 23:05:19.132127
NCT01252940|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2013-03-08||2015-10-27|2010-12-02|2010-12-03|Estimate|2013-03-08|2013-04-19|Estimate||||2015-10-27|2015-12-04|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|January 2012|Actual|2012-01-31||Interventional||Safety Analysis Set: participants who were randomized and received at least one dose of study drug|Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF|A Phase 3 Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients|Completed||Phase 3|482|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 23:05:20.183598|2018-05-31 23:05:20.183598
NCT01252927|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2016-10-19|2010-12-02|2010-12-03|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of a Gatekeeper Training Program|Evaluation of a Gatekeeper Training Program as Suicide Intervention Training for Medical Students|Active, not recruiting||N/A|110|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 23:05:21.246816|2018-05-31 23:05:21.246816
NCT01252576|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2011-06-21|2010-12-02|2010-12-03|Estimate|||||||2011-06-21|2011-06-22|Estimate|December 2010||2010-12-31|June 2011|2011-06-30||||June 2011|Actual|2011-06-30||Observational|||Linguistic and Cultural Validation in Italian of Female Sexual Function Index (FSFI) Questionnaire|Linguistic and Cultural Validation in Italian of Female Sexual Function Index Questionnaire (FSFI)|Unknown status|Active, not recruiting||300|Anticipated|Club Italiano Femminile di Urologia|||1||f||||f||||||||||2018-05-31 23:05:24.19773|2018-05-31 23:05:24.19773
NCT01252914|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-12-14|2010-12-02|2010-12-03|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2010|Actual|2010-12-31|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent|A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent|Active, not recruiting||Phase 4|80|Anticipated|Glaukos Corporation||1|||f||||f||||||||||2018-05-31 23:05:21.317827|2018-05-31 23:05:21.317827
NCT01252901|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-05-27|2010-12-02|2010-12-03|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Observational|||Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases|Registry for Patients With WT1 Mutation Associated Diseases|Completed|||52|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-05-31 23:05:21.386544|2018-05-31 23:05:21.386544
NCT01252888|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-12-14|2010-12-02|2010-12-03|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2010|Actual|2010-12-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents|A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents|Completed||Phase 4|40|Anticipated|Glaukos Corporation||1|||f||||f||||||||||2018-05-31 23:05:21.45949|2018-05-31 23:05:21.45949
NCT01252875|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2018-04-25|2010-12-02|2010-12-03|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2010|Actual|2010-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TST||Treat Stroke to Target|EVALUATION OF TWO SECONDARY CARE STRATEGIES AFTER STROKE OR TRANSIENT ISCHEMIC ATTACK (TIA): ACHEIVED TARGET LDL-C TO 100 mg/dL (+/- 10,mg/dL) OR LESS THAN 70 mg/dL.|Recruiting||N/A|3760|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 23:05:21.528549|2018-05-31 23:05:21.528549
NCT01252862|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-12-14|2010-12-02|2010-12-03|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2010|Actual|2010-12-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents|A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents|Completed||Phase 4|40|Anticipated|Glaukos Corporation||1|||f||||f||||||||||2018-05-31 23:05:21.62122|2018-05-31 23:05:21.62122
NCT01252849|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-03-07|2010-12-02|2010-12-03|Estimate|||||||2018-03-07|2018-03-09|Actual|December 2010||2010-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects|A Prospective, Randomized, Controlled Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications, Implanted With One, Two, or Three Trabecular Micro-Bypass Stents|Active, not recruiting||N/A|120|Anticipated|Glaukos Corporation||3|||f||||f||||||||||2018-05-31 23:05:21.702297|2018-05-31 23:05:21.702297
NCT01252836|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-12-14|2010-12-02|2010-12-03|Estimate|||||||2016-12-14|2016-12-15|Estimate|September 2010||2010-09-30|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study Evaluating AWBAT-D Versus the Standard of Care of Split-thickness Skin Graft Donor Sites|Randomized, Prospective, Pilot Study Evaluating a Temporary Skin Substitute (AWBAT-D) Versus the Standard of Care in the Postoperative Treatment of Split-thickness Skin Graft Donor Sites|Withdrawn||Phase 4|0|Actual|Georgetown University||2||P.I decided to prematurely end this study.|f||||t||||||||No|Data was not collected for use in future research and will not be shared.|2018-05-31 23:05:21.773701|2018-05-31 23:05:21.773701
NCT01252823|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-11-23|2010-12-02|2010-12-03|Estimate|||||||2017-11-23|2017-11-27|Actual|December 28, 2010|Actual|2010-12-28|November 2017|2017-11-30|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|RYTHMODIAL||Implantable Loop Recorder in Hemodialysis Patients|Identification and Prevention of Sudden Cardiac Death Causes in Hemodialysis Patients|Completed||N/A|72|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 23:05:21.840317|2018-05-31 23:05:21.840317
NCT01252810|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2014-02-06||2014-05-01|2010-12-01|2010-12-03|Estimate|2014-04-02|2014-05-02|Estimate||||2014-05-01|2014-05-15|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure|A Phase 2, Double-Blind, Randomized, Safety Study of GE-145 320 mg I/mL Injection Versus Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Artery Catheterization Procedure|Completed||Phase 2|284|Actual|GE Healthcare||2|||f||||t||||||||||2018-05-31 23:05:21.947221|2018-05-31 23:05:21.947221
NCT01252797|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2018-05-10|2010-12-02|2010-12-03|Estimate|||||||2018-05-10|2018-05-14|Actual|October 2010||2010-10-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|November 2016|Actual|2016-11-30||Interventional|RAD 1002||Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)|RAD 1002: Phase I Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases|Completed||Phase 1|20|Actual|University of Alabama at Birmingham||2|||f||||t|f|t|f||f|||||2018-05-31 23:05:22.338938|2018-05-31 23:05:22.338938
NCT01252784|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-01|2010-12-01|2010-12-03|Estimate|||||||2010-12-01|2010-12-03|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|October 2014|Anticipated|2014-10-31|October 2012|Anticipated|2012-10-31||Observational|RICandDLI||Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation|Reduced-intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Followed by Prophylactic Dose-escalating Donor Lymphocyte Infusions in Higher Risk Myelodysplastic Syndrome|Unknown status|Recruiting||20|Anticipated|Cooperative Study Group A for Hematology|||||f||||f||||||None Retained|"~     This clinical trial will use busulfan, fludarabine, thymoglobulin and methylprednisolone for~     conditioning therapy, and cyclosporine and methotrexate for prevention of GVHD. All drugs had~     been previously accepted for administration to human in respective indication and there is no~     need to further evaluate the efficacy and the safety of each drug separately. Dose-escalating~     DLI is also widely accepted procedure after allogeneic HCT.~   "|||2018-05-31 23:05:22.426292|2018-05-31 23:05:22.426292
NCT01252771|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2014-08-14|2010-12-02|2010-12-03|Estimate|||||||2014-08-14|2014-08-18|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|PKM2||Phosphate Kinetic Modeling 2|Phosphate Kinetic Modeling 2|Completed||Phase 4|81|Actual|Fresenius Medical Care North America||1|||f||||f||||||||||2018-05-31 23:05:22.500196|2018-05-31 23:05:22.500196
NCT01198964|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2017-05-24|2010-09-08|2010-09-10|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2010||2010-09-30|May 2017|2017-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Observational|BCI||Optimization of Human Cortical Stimulation|U.S.-German Collaboration: Optimization of Human Cortical Stimulation|Recruiting|||8|Anticipated|University of Washington|||1||f||||f||||||||||2018-05-31 23:22:10.843275|2018-05-31 23:22:10.843275
NCT01252758|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-03-09|2010-12-01|2010-12-03|Estimate|||||||2018-03-09|2018-03-13|Actual|November 2012||2012-11-30|March 2018|2018-03-31|October 2015|Actual|2015-10-31|April 2013|Anticipated|2013-04-30||Interventional|||Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma|A Phase II Study to Assess the Efficacy and Safety of a Single Inhaled Dose of Albuterol Sulfate Dry Powder Via the Trivair Deposition System Versus Albuterol Sulfate HFA pMDI in Patients With Intermittent or Persistent Mild Asthma|Withdrawn||Phase 2|0|Actual|Acerus Pharmaceuticals Corporation||6|||f||||f||||||||||2018-05-31 23:05:22.579483|2018-05-31 23:05:22.579483
NCT01252745|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2018-02-15||2018-04-25|2010-12-01|2010-12-03|Estimate|2018-03-27|2018-04-26|Actual||||2018-04-25|2018-05-23|Actual|August 2010||2010-08-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Efficacy of an Intranasal Testosterone Product|An Open Label, Randomized, Balanced, Three Treatment, Parallel Design, Pharmacokinetic Study of Intranasal TBS-1 Administration to Hypogonadal Men|Completed||Phase 2|22|Actual|Acerus Pharmaceuticals Corporation||3|||f||||f||||||||||2018-05-31 23:05:22.674513|2018-05-31 23:05:22.674513
NCT01252732|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2013-06-25|2010-12-01|2010-12-03|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 2010||2010-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SOLO II||Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection|A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)|Completed||Phase 3|1019|Actual|The Medicines Company||2|||f||||t||||||||||2018-05-31 23:05:23.079776|2018-05-31 23:05:23.079776
NCT01252719|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2012-11-09|2010-12-01|2010-12-03|Estimate|||||||2012-11-09|2012-11-14|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|SOLO I||Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection|A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I)|Completed||Phase 3|960|Actual|The Medicines Company||2|||f||||t||||||||||2018-05-31 23:05:23.238542|2018-05-31 23:05:23.238542
NCT01252706|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-01|2010-12-01|2010-12-03|Estimate|||||||2010-12-01|2010-12-03|Estimate|March 2011||2011-03-31|November 2010|2010-11-30|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|||Estimation of Alcohol, Substance and Cigarettes Exposure Among Pregnant Women in the Israeli Periphery and Center, and the Contribution of Brief Intervention||Unknown status|Not yet recruiting|N/A|10000|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:05:23.313895|2018-05-31 23:05:23.313895
NCT01252693|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-06-02|2010-12-01|2010-12-03|Estimate|||||||2015-06-02|2015-06-04|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer|Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer|Completed||Phase 2|203|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 23:05:23.381515|2018-05-31 23:05:23.381515
NCT01252680|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2013-03-13|2010-12-01|2010-12-03|Estimate|||||||2013-03-13|2013-03-15|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Immunogenicity and Interchangeability of Two Inactivated Hepatitis A Vaccines|A Randomized, Double-blind Clinical Trial of Two Inactivated Hepatitis A Vaccines in Healthy Children|Completed||Phase 4|303|Actual|Sinovac Biotech Co., Ltd||4|||f||||f||||||||||2018-05-31 23:05:23.459701|2018-05-31 23:05:23.459701
NCT01252667|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2018-03-29|2010-12-02|2010-12-03|Estimate|||||||2018-03-29|2018-04-02|Actual|January 25, 2011|Actual|2011-01-25|March 2018|2018-03-31||||January 25, 2019|Anticipated|2019-01-25||Interventional|||Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant|A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML|Active, not recruiting||Phase 2|44|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 23:05:23.544578|2018-05-31 23:05:23.544578
NCT01252654|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2016-07-19|2010-12-01|2010-12-03|Estimate|||||||2016-07-19|2016-07-20|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Observational|||Comparison of Intralase and Visumax Femtosecond Laser for Laser In Situ Keratomileusis||Completed|||45|Actual|Singapore Eye Research Institute|||2||f||||t||||||||||2018-05-31 23:05:23.650914|2018-05-31 23:05:23.650914
NCT01252641|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29||2015-05-18|2015-05-18|2010-12-01|2010-12-03|Estimate||||2015-05-18|2015-06-11|Estimate|2015-05-18|2015-06-11|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects|A Phase 1/2, Open Label, Single Infusion Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases (SB-728-T) in HIV Infected Subjects|Completed||Phase 1/Phase 2|21|Actual|Sangamo Therapeutics||1|||f||||f||||||||||2018-05-31 23:05:23.713532|2018-05-31 23:05:23.713532
NCT01252628|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01||2015-04-30|2018-05-14|2010-12-01|2010-12-03|Estimate||||2015-04-30|2015-05-19|Estimate|2018-05-14|2018-05-16|Actual|December 2010||2010-12-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Phase 1 and 2 Study of PX-866 and Cetuximab|Phase 1/2 Study of PX-866 and Cetuximab|Completed||Phase 1/Phase 2|178|Actual|Seattle Genetics, Inc.||4|||f||||t||||||||||2018-05-31 23:05:23.785913|2018-05-31 23:05:23.785913
NCT01252615|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2016-10-24|2010-11-30|2010-12-03|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|P+P||Patient and Partner Intervention After an Implantable Cardioverter Defibrillator (ICD)|Patient and Intimate Partner Intervention to Improve Outcomes After an ICD|Completed||Phase 2|301|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:05:23.938429|2018-05-31 23:05:23.938429
NCT01252602|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2014-10-16|2010-12-02|2010-12-03|Estimate|||||||2014-10-16|2014-10-20|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Prenatal Depression and Failure to Breastfeed|Prospective Study of Maternal Prenatal Depression as a Risk Factor for Failure to Breastfeed|Withdrawn|||0|Actual|Oklahoma State University Center for Health Sciences|||2||f||||t||||||||||2018-05-31 23:05:24.015657|2018-05-31 23:05:24.015657
NCT01252589|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2016-09-13|2010-12-02|2010-12-03|Estimate|||||||2016-09-13|2016-09-14|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Patient Reported Outcomes in Chronic Myeloid Leukemia|Patient Reported Outcomes in Chronic Myeloid Leukemia. GIMEMA QoL - CML0310.|Completed|||480|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||||2018-05-31 23:05:24.105761|2018-05-31 23:05:24.105761
NCT01252550|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-11-17|2010-12-02|2010-12-03|Estimate|||||||2014-11-17|2014-11-18|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|MOSAIC||Effects of Activia in IBS|Association Between GI Microbiota, Low-grade Inflammation and Classical Pathophysiological Factors in Patients With Irritable Bowel Syndrome (IBS) and Effect of the Consumption of Activia on GI Symptoms Provoked by a Lactulose Challenge Test in IBS Patients|Completed||N/A|100|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 23:05:24.340523|2018-05-31 23:05:24.340523
NCT01252537|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-04-21|2010-12-02|2010-12-03|Estimate|||||||2014-04-21|2014-04-23|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|March 2012|Actual|2012-03-31||Observational|||Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia|Assessment of Immunosuppression in HIV-infected Patients With Tuberculosis With Access to Antiretroviral Therapy in Primary Health Care Centres in Ethiopia - Clinical and Immunological Markers and Associations With Treatment Outcome|Completed|||1200|Actual|Lund University|||1||f||||f||||||Samples Without DNA|"~     Aliquoted plasma will be collected from consenting participants and stored at -80 C for~     analysis of potential prognostic markers reflecting immune activation and inflammation~     status.~   "|||2018-05-31 23:05:24.438595|2018-05-31 23:05:24.438595
NCT01252524|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2012-08-31|2010-12-02|2010-12-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study|Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study|Completed||N/A|48|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 23:05:24.504017|2018-05-31 23:05:24.504017
NCT01252511|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-01-13|2010-12-02|2010-12-03|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|August 2014|Actual|2014-08-31||Interventional|||Determinants of Fat Malabsorption After Roux-en-Y Gastric Bypass|Surgical Treatment of Severe Obesity by Roux-en-Y Gastric Bypass: a Randomized Prospective Study on the Effect of Reciprocal Changes in Y-limb Lengths on Intestinal Absorption of Dietary Fat, Protein and Carbohydrate.|Unknown status|Active, not recruiting|N/A|20|Anticipated|Baylor Research Institute||2|||f||||f||||||||||2018-05-31 23:05:24.578325|2018-05-31 23:05:24.578325
NCT01252498|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-02-03|2010-12-02|2010-12-03|Estimate|||||||2014-02-03|2014-02-04|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis|A Pilot Study to Evaluate the Role of Cyclooxygenase Pathway in Radiation Therapy and Chemoradiation Therapy Induced Mucositis in Head and Neck Cancer Patients|Completed|||9|Actual|University of Vermont|||1||f||||f||||||None Retained|"~     Saliva will be collected at 4 time points before, during, immediately after, and several~     weeks after radiotherapy for head and neck cancer.~   "|||2018-05-31 23:05:24.646613|2018-05-31 23:05:24.646613
NCT01252485|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-08-10|2010-12-02|2010-12-03|Estimate|||||||2017-08-10|2017-08-14|Actual|July 2010||2010-07-31|August 2017|2017-08-31||||||||Observational|AMLSG BiO||Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project|Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project|Recruiting|||||University of Ulm|||||f||||f||||||||||2018-05-31 23:05:24.728942|2018-05-31 23:05:24.728942
NCT01252472|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2015-04-24|2010-12-02|2010-12-03|Estimate|||||||2015-04-24|2015-04-28|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Flomax Study for Floppy Iris Syndrome|Diagnostic Imaging for Intraoperative Floppy Iris Syndrome|Completed|||36|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 23:05:24.933987|2018-05-31 23:05:24.933987
NCT01252459|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-15|2010-12-02|2010-12-03|Estimate|||||||2010-12-15|2010-12-16|Estimate|July 2011||2011-07-31|December 2010|2010-12-31|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|GLIAA||Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme|Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|University Hospital Freiburg||2|||f||||t||||||||||2018-05-31 23:05:25.039134|2018-05-31 23:05:25.039134
NCT01252446|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|September 2008||2008-09-30|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|June 2010|Actual|2010-06-30||Observational|NF ADHD||Children With ADHD Symptoms: Comorbid Conditions, Cognitive and Social Performance|Children With ADHD Symptoms: Comorbid Conditions, Cognitive and Social Performance|Unknown status|Recruiting||187|Anticipated|University of Bergen|||1||f||||t||||||||||2018-05-31 23:05:25.128924|2018-05-31 23:05:25.128924
NCT01252433|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2012-03-15|2010-12-02|2010-12-03|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Children's Intake of Foods Reduced in Energy Density|Children's Intake of Foods Reduced in Energy Density|Completed||N/A|49|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 23:05:25.258511|2018-05-31 23:05:25.258511
NCT01252420|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-12-03|2010-12-02|2010-12-03|Estimate|||||||2010-12-03|2010-12-06|Estimate|November 2010||2010-11-30|July 2010|2010-07-31|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Interventional|TWISTER||Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis|Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER)|Unknown status|Recruiting|Phase 4|330|Anticipated|Monash Medical Centre|||||f||||f||||||||||2018-05-31 23:05:25.327553|2018-05-31 23:05:25.327553
NCT01252407|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2012-08-01|2010-12-02|2010-12-03|Estimate|||||||2012-08-01|2012-08-02|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|TensIC||Acute Effect of Transcutaneous Electrical Nerve Stimulation in Heart Failure|Acute Effect of Transcutaneous Electrical Nerve Stimulation on the Sympathetic and Parasympathetic Systems in Individuals With Heart Failure|Unknown status|Active, not recruiting|N/A|30|Anticipated|Federal University of Health Science of Porto Alegre||1|||f||||t||||||||||2018-05-31 23:05:25.427032|2018-05-31 23:05:25.427032
NCT01252394|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2010-12-02|2010-12-02|2010-12-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Correspondence of ScO2 and Cardiac Output in Hemodialysis|ScO2 and Cardiac Output - Correspondence Study in Hemodialysis Patients|Unknown status|Recruiting||37|Anticipated|Danish State Hospital|||1||f||||f||||||||||2018-05-31 23:05:25.511544|2018-05-31 23:05:25.511544
NCT01252381|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2017-07-03|2010-12-02|2010-12-03|Estimate|||||||2017-07-03|2017-07-05|Actual|November 2010||2010-11-30|July 2017|2017-07-31|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|||Supplementary Intake of Vitamin D During 12 Weeks Strength Training in Younger and Older People|The Importance of Supplementary Intake of Vitamin D on the Efficacy of 12 Weeks of Strength Training in Both Vitamin D Sufficient Younger and Older People|Completed||N/A|40|Actual|Bispebjerg Hospital||2|||f||||||||||||||2018-05-31 23:05:25.583572|2018-05-31 23:05:25.583572
NCT01252368|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-11-28|2010-12-02|2010-12-03|Estimate|||||||2012-11-28|2012-11-29|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|||||Observational|||Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)|Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)|Completed|||48|Actual|University of Zurich|||2||f||||||||||||||2018-05-31 23:05:25.665582|2018-05-31 23:05:25.665582
NCT01252355|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2014-04-23||2014-05-30|2010-12-02|2010-12-03|Estimate|2014-04-23|2014-05-22|Estimate||||2014-05-30|2014-06-09|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|TERACLES|Randomized population: all randomized participants according to the treatment group to which they were assigned.|Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta|A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta|Terminated||Phase 3|534|Actual|Sanofi|The early termination of study with reduced sample size and participant follow-up impacts the power and interpretability, and limits the ability to assess the overall benefit/risk of adjunctive therapy. Termination was not due to any safety concerns.|3||Sponsor decision to prematurely stop the study, not linked to any safety concern.|f||||t||||||||||2018-05-31 23:05:25.809796|2018-05-31 23:05:25.809796
NCT01252342|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-01-09|2010-11-30|2010-12-02|Estimate|||||||2012-01-09|2012-01-11|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?|Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?|Withdrawn||Phase 4|0|Actual|University of Saskatchewan||2||"Proposed doses were too large, bolus oxytocin may cause cases of arrythmias, and some even~   advocate slowing down the infusion rates that are currently used."|f||||||||||||||2018-05-31 23:05:26.850847|2018-05-31 23:05:26.850847
NCT01252329|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2017-10-21|2010-11-30|2010-12-02|Estimate|||||||2017-10-21|2017-10-24|Actual|April 2011||2011-04-30|October 2017|2017-10-31|July 14, 2014|Actual|2014-07-14|July 14, 2014|Actual|2014-07-14||Interventional|||Comparison of Elective Lymph Node Treatment Versus Clinical Observation in the Absence of Palpable Lymph Nodes for High Risk Skin Squamous Cell Carcinoma (SCC)|High Risk Cutaneous Squamous Cell Carcinoma Treated With Mohs Surgery Randomized to Elective Management of the Draining Lymph Nodes vs. Periodic Clinical Nodal Observation|Terminated||N/A|29|Actual|University of Pittsburgh||2||insufficient recruitment|f||||t||||||||||2018-05-31 23:05:26.913683|2018-05-31 23:05:26.913683
NCT01252316|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2015-12-01|2010-11-30|2010-12-02|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Cardiopulmonary Resuscitation (CPR) Dissemination Study Using Nurses and Volunteers|An In-Hospital VSI CPR Dissemination Study Using Nurses and Volunteers|Completed||Phase 1/Phase 2|500|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 23:05:26.98812|2018-05-31 23:05:26.98812
NCT01252303|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2011-06-22|2010-12-01|2010-12-02|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Effect of Nutrisystem Meal Provision on Weight|The Effect of a Behavioral Weight Loss Program With Nutrisystem Meal Provision on Change in Weight, Fasting Blood Glucose, Cholesterol, and Blood Pressure Over 12 Weeks.|Completed||N/A|50|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 23:05:27.192873|2018-05-31 23:05:27.192873
NCT01252290|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2016-05-03||2016-10-25|2010-11-30|2010-12-02|Estimate|2016-10-25|2016-12-16|Estimate||||2016-10-25|2016-12-16|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Breast Cancer Risk Biomarkers in Postmenopausal Women|Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids|Completed||Phase 2|35|Actual|University of Kansas Medical Center||1|||f||||t||||||||No|Summary results for the cohort have been published.|2018-05-31 23:05:27.303517|2018-05-31 23:05:27.303517
NCT01252277|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2015-12-14||2016-06-10|2010-11-30|2010-12-02|Estimate|2016-06-10|2016-07-21|Estimate||||2016-06-10|2016-07-21|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Breast Cancer Risk Biomarkers in Premenopausal Women|Modulation of Breast Cancer Risk Biomarkers in Premenopausal Women by High Dose Omega-3 Fatty Acids|Completed||Phase 2|36|Actual|University of Kansas Medical Center||1|||f||||f||||||||No||2018-05-31 23:05:27.597703|2018-05-31 23:05:27.597703
NCT01252264|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2018-05-01|2010-11-30|2010-12-02|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2010|Actual|2010-11-30|May 2018|2018-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||FaceBase Biorepository|FaceBase Biorepository|Completed|||5000|Actual|University of Iowa|||2||f||||t||||||Samples With DNA|"~     -  A biological sample will be obtained by a blood draw. In adults, we will obtain a blood~          sample of 1-2 tablespoons (10-30 mL). For children, the amount will be smaller depending~          on their weight: 1 mL per kg to a maximum of 30 mL.~        -  If a blood draw is refused, DNA can be taken from a cheek swab, spit sample or~          fingerstick.~        -  If a participant is having surgery for a medical reason, we may request a tissue sample~          (for example: skin, bone, or muscle). If there were to be extra tissue, amniotic fluid,~          other biological samples available from a procedure performed for clinical indications,~          we may request a sample.~   "|No||2018-05-31 23:05:28.876382|2018-05-31 23:05:28.876382
NCT01252251|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2017-05-15||2017-07-06|2010-12-01|2010-12-02|Estimate|2017-07-06|2017-08-01|Actual||||2017-07-06|2017-08-01|Actual|November 2010||2010-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma|A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma|Completed||Phase 2|14|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:05:29.023054|2018-05-31 23:05:29.023054
NCT01252069|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2016-01-12|2010-12-01|2010-12-02|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)|A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding|Completed||Phase 3|132|Actual|PregLem SA||2|||f||||t||||||||||2018-05-31 23:05:32.675501|2018-05-31 23:05:32.675501
NCT01252238|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2013-06-24||2018-01-18|2010-12-01|2010-12-02|Estimate|2013-06-24|2013-09-05|Estimate||||2018-01-18|2018-02-13|Actual|June 2010||2010-06-30|January 2018|2018-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance|Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance|Terminated||N/A|24|Actual|Brigham and Women's Hospital|No conclusions can be drawn from study due to very low sample size. The sponsor terminated the study after a separate study reported adverse events in a diabetic population who had taken both valsartan and aliskiren.|3||Study sponsor terminated study due to AE's reported with valsartan and aliskiren|f||||||||||||||2018-05-31 23:05:29.326765|2018-05-31 23:05:29.326765
NCT01252225|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-09-15|2010-11-30|2010-12-02|Estimate|||||||2011-09-15|2011-09-16|Estimate|February 2011||2011-02-28|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Lidocaine: Effect of Lidocaine in Chronic Cough|Effect of Lidocaine and Its Delivery in Patients With Chronic Cough|Completed||Phase 4|30|Anticipated|Manchester University NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 23:05:29.804647|2018-05-31 23:05:29.804647
NCT01252212|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2013-11-18|2010-11-30|2010-12-02|Estimate|||||||2013-11-18|2013-11-20|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|AIM||Adherence, Improvement Measure (AIM) System|Adherence, Improvement Measure (AIM) System; Challenge Topic: 10-MH-101|Completed||Phase 3|99|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:05:29.911751|2018-05-31 23:05:29.911751
NCT01252199|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2013-04-23|2010-12-01|2010-12-02|Estimate|||||||2013-04-23|2013-04-25|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2|A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (cαStx1) and 2 (cαStx2) Administered Concomitantly to Children With Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Diarrhea (SHIGATEC Trial)|Completed||Phase 2|45|Actual|Thallion Pharmaceuticals||2|||f||||t||||||||||2018-05-31 23:05:30.005862|2018-05-31 23:05:30.005862
NCT01252186|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2015-02-27|2013-05-02|2015-02-27|2010-11-30|2010-12-02|Estimate|2015-02-27|2015-03-13|Estimate|2013-05-02|2013-05-10|Estimate|2015-02-27|2015-03-13|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||The intent-to-treat (ITT) population included all randomized and treated participants who had both baseline and at least one post-baseline measurement of prothrombin fragment 1+2 (F1+2).|A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women|A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-Day Extended Cycle Oral Contraceptive Regimen, Compared to Two 28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy Women.|Completed||Phase 2|265|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 23:05:30.281554|2018-05-31 23:05:30.281554
NCT01252173|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-04-20|2010-12-01|2010-12-02|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||Measurement Of Endotracheal Tube Cuff Pressure In Emergency Department Patients|MEASUREMENT OF ENDOTRACHEAL TUBE CUFF PRESSURE IN EMERGENCY DEPARTMENT PATIENTS|Withdrawn|||0|Actual|Beth Israel Medical Center|||||f||||||||||||||2018-05-31 23:05:31.224054|2018-05-31 23:05:31.224054
NCT01252160|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-04-18|2010-12-01|2010-12-02|Estimate|||||||2018-04-18|2018-04-19|Actual|October 28, 2010|Actual|2010-10-28|April 2018|2018-04-30|September 26, 2013|Actual|2013-09-26|September 26, 2013|Actual|2013-09-26||Interventional|STRIDE||Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage|A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain|Completed||Phase 4|306|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 23:05:31.385629|2018-05-31 23:05:31.385629
NCT01252147|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2011-11-30||2012-08-24|2010-12-01|2010-12-02|Estimate|2012-08-24|2012-09-28|Estimate||||2012-08-24|2012-09-28|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Inter-rater and Intra-rater Reliability Study of the Global Eyelash Assessment Scale for Assessment of Overall Eyelash Prominence||Completed|||68|Actual|Allergan|||||f||||f||||||||||2018-05-31 23:05:31.654558|2018-05-31 23:05:31.654558
NCT01252134|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2012-05-08||2012-05-08|2010-12-01|2010-12-02|Estimate|2012-05-08|2012-06-11|Estimate||||2012-05-08|2012-06-11|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SILVER||Evaluation of Silicone Hydrogel Lens Wettability With Marketed Lens Care Solutions|The Evaluation of Silicone Hydrogel Lens Wettability With Marketed Lens Care Solutions|Completed||N/A|22|Actual|Alcon Research||6|||f||||f||||||||||2018-05-31 23:05:31.899342|2018-05-31 23:05:31.899342
NCT01252121|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-10-26|2010-12-01|2010-12-02|Estimate|||||||2012-10-26|2012-10-30|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline||Completed||N/A|27|Actual|Alcon Research||6|||f||||f||||||||||2018-05-31 23:05:32.1876|2018-05-31 23:05:32.1876
NCT01252108|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2015-11-16|2010-12-01|2010-12-02|Estimate|||||||2015-11-16|2015-11-17|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers|Phase 2A Open-label Study to Evaluate Safety, Tolerability, and Antimicrobial Activity of Single, Daily Doses of SQ109 in Urea Breath Test Positive Volunteers|Withdrawn||Phase 2|0|Actual|Sequella, Inc.||1||lack of funding|f||||f||||||||||2018-05-31 23:05:32.287145|2018-05-31 23:05:32.287145
NCT01252095|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2012-05-21||2017-10-05|2010-12-01|2010-12-02|Estimate|2012-06-26|2012-08-02|Estimate||||2017-10-05|2017-10-09|Actual|January 2011||2011-01-31|October 2017|2017-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours|An Open-label, Single Centre Phase I Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours|Terminated||Phase 1|4|Actual|Zucero Pty Ltd|Early termination due to unexpected injection site reactions leading to small numbers of subjects analyzed. An MTD could not be determined for this study.|1||Unexpected injection site reactions.|f||||t||||||||||2018-05-31 23:05:32.364552|2018-05-31 23:05:32.364552
NCT01252082|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-04-07|2010-12-01|2010-12-02|Estimate|||||||2015-04-07|2015-04-08|Estimate|June 2007||2007-06-30|April 2015|2015-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Non-surgical Periodontal Therapy Effects Metabolic Control in Diabetics|Evaluation of Effect of Nonsurgical Periodontal Therapy on Metabolic Control in Patients With Type II Diabetes|Completed||Phase 2|40|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:05:32.588676|2018-05-31 23:05:32.588676
NCT01252056|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-05-07|2010-12-01|2010-12-02|Estimate|||||||2013-05-07|2013-05-08|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy|A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy|Completed||Phase 4|353|Actual|Otsuka Beijing Research Institute||3|||f||||f||||||||||2018-05-31 23:05:32.762184|2018-05-31 23:05:32.762184
NCT01252043|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-11-30|2010-11-30|2010-12-02|Estimate|||||||2010-11-30|2010-12-02|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Observational|||Retrospective Review of CT and MR in Pediatric Patients With Cholestasis|Retrospective Review of Computed Tomography and Magnetic Resonance Images in Pediatric Patients With Cholestasis|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||3||f||||t||||||||||2018-05-31 23:05:32.829528|2018-05-31 23:05:32.829528
NCT01252030|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-08-15|2010-12-01|2010-12-02|Estimate|||||||2016-08-15|2016-08-17|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TeleRehabII||Telemonitoring During Phase 2-3 Cardiac Rehabilitation|Impact of Telemonitoring Intervention on Physical Activity, CVD Risk Factors, During Phase 2-3 Cardiac Rehabilitation|Completed||Phase 2|80|Actual|Jessa Hospital||2|||f||||t||||||||||2018-05-31 23:05:32.897323|2018-05-31 23:05:32.897323
NCT01252017|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2012-12-26|2010-11-30|2010-12-02|Estimate|||||||2012-12-26|2012-12-27|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|November 2013|Anticipated|2013-11-30||Interventional|||Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation|Cytomegalovirus (CMV) Reactivation in Post-allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) Patients: Salvage and Prophylactic Treatments of Nilotinib|Unknown status|Recruiting|Phase 2|36|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 23:05:32.957067|2018-05-31 23:05:32.957067
NCT01252004|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-11-21|2010-12-01|2010-12-02|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2010||2010-11-30|November 2017|2017-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|OFSETT||French Observatory Syndromes Tako-Tsubo|French Observatory Syndromes Tako-Tsubo|Completed|||121|Actual|French Cardiology Society|||1||f||||f||||||||||2018-05-31 23:05:33.026639|2018-05-31 23:05:33.026639
NCT01251991|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2014-01-28|2010-12-01|2010-12-02|Estimate|||||||2014-01-28|2014-01-29|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ProFi||Cholesterol Lowering Treatment With Psyllium Husks and Isolated Soy Protein in Hypercholesterolemia|Additive Cholesterol Lowering Effect by Concomitant Treatment With Psyllium Husks and Isolated Soy Protein in Addition to Heart-healthy Diet in Hypercholesterolemia|Completed||Phase 4|41|Actual|Aalborg Universitetshospital||4|||f||||f||||||||||2018-05-31 23:05:33.080762|2018-05-31 23:05:33.080762
NCT01251978|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2016-10-17||2016-10-17|2010-12-01|2010-12-02|Estimate|2016-10-17|2016-10-19|Estimate||||2016-10-17|2016-10-19|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)|Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma|Completed||Phase 2|10|Actual|New England Retina Associates||2|||f||||t||||||||||2018-05-31 23:05:33.25204|2018-05-31 23:05:33.25204
NCT01251965|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2015-10-14|2010-12-01|2010-12-02|Estimate|||||||2015-10-14|2015-10-16|Estimate|December 2010||2010-12-31|October 2015|2015-10-31||||October 2015|Actual|2015-10-31||Interventional|||Phase l/II Study of Ruxolitinib for Acute Leukemia|A Phase I/II Study to Determine the Safety and Efficacy of Ruxolitinib, a JAK1/JAK2 Inhibitor, in Subjects With Relapsed or Refractory Acute Leukemia|Completed||Phase 1/Phase 2|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:05:33.518842|2018-05-31 23:05:33.518842
NCT01251952|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2013-10-25||2017-05-26|2010-11-30|2010-12-02|Estimate|2013-10-25|2013-12-16|Estimate||||2017-05-26|2017-06-20|Actual|November 2010||2010-11-30|May 2017|2017-05-31|May 2013|Actual|2013-05-31|July 2011|Actual|2011-07-31||Interventional|||Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation|Phase I Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation.|Terminated||Phase 1|2|Actual|Barbara Ann Karmanos Cancer Institute|Analysis was not completed due to the small number of patients accrued and drugs were unavailable.|1||Drug unavailable|f||||t||||||||||2018-05-31 23:05:33.618413|2018-05-31 23:05:33.618413
NCT01251939|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-08-19|2010-12-01|2010-12-02|Estimate|||||||2012-08-19|2012-08-21|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Observational|||Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious|Observational Study of Near Infrared Spectroscopy to Monitor Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious in Preterm Infants|Completed|||30|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital|||2||f||||t||||||||||2018-05-31 23:05:33.795493|2018-05-31 23:05:33.795493
NCT01251926|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-02-27|2010-12-01|2010-12-02|Estimate|||||||2018-02-27|2018-02-28|Actual|November 15, 2010||2010-11-15|May 2, 2014|2014-05-02|April 23, 2014|Actual|2014-04-23|||||Interventional|||EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors|Pilot Study of Weekly EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors|Completed||Phase 1|12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:05:33.864203|2018-05-31 23:05:33.864203
NCT01251913|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-10-05|2010-12-01|2010-12-02|Estimate|||||||2017-10-05|2017-10-06|Actual|November 12, 2010||2010-11-12|April 29, 2015|2015-04-29|April 29, 2015||2015-04-29|||||Observational|||A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes|A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes|Terminated|||7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:05:33.92919|2018-05-31 23:05:33.92919
NCT01251900|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-01-25|2010-12-01|2010-12-02|Estimate|||||||2018-01-25|2018-01-26|Actual|November 12, 2010||2010-11-12|January 16, 2018|2018-01-16||||||||Observational|||BRCA Mutations in Latinas|BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:05:33.996479|2018-05-31 23:05:33.996479
NCT01251887|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-03-27|2010-12-01|2010-12-02|Estimate|||||||2018-03-27|2018-03-29|Actual|November 12, 2010||2010-11-12|March 9, 2018|2018-03-09|July 31, 2022|Anticipated|2022-07-31|June 1, 2020|Anticipated|2020-06-01||Interventional|||Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition|Dietary Linoleic Acid Regulation of Omega-3HUFA Metabolism: Satiety and Body Composition Among Overweight Female Subjects|Recruiting||N/A|180|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:05:34.063754|2018-05-31 23:05:34.063754
NCT01251874|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-04-20|2010-12-01|2010-12-02|Estimate|||||||2018-04-20|2018-04-23|Actual|November 16, 2010|Actual|2010-11-16|April 2018|2018-04-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer|A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer|Completed||Phase 1|44|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:05:34.161217|2018-05-31 23:05:34.161217
NCT01251861|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-04-26|2010-12-01|2010-12-02|Estimate|||||||2018-04-26|2018-04-27|Actual|December 23, 2010|Actual|2010-12-23|February 2018|2018-02-28||||April 30, 2018|Anticipated|2018-04-30||Interventional|||Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer|Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy|Active, not recruiting||Phase 2|104|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:05:34.305529|2018-05-31 23:05:34.305529
NCT01251848|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-03-04|2010-12-01|2010-12-02|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Drug Interaction Between Ritonavir And Sitaxsentan|A Phase 1, Open Label, Randomized, Multiple Dose Study To Assess The Two-Way Drug Interaction Between Sitaxsentan And Low Dose Ritonavir In Healthy Subjects|Withdrawn||Phase 1|0|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:05:34.616311|2018-05-31 23:05:34.616311
NCT01251835|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2015-03-04|2010-12-01|2010-12-02|Estimate|||||||2015-03-04|2015-03-05|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan|A Phase 1, Open Label, Fixed Sequence Design, Multiple Dose Study To Assess The Effect Of Rifampin On The Pharmacokinetics Of Sitaxsentan In Healthy Subjects|Withdrawn||Phase 1|0|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:05:34.684714|2018-05-31 23:05:34.684714
NCT01251822|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-08-30|2010-12-01|2010-12-02|Estimate|||||||2012-08-30|2012-08-31|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation|Double-dummy, Double-blind, Randomised, Parallel Group, Controlled Comparative Study of Polyethylene Glycol (PEG)Plus Electrolytes Versus Prucalopride in Females With Chronic Constipation Who Failed Adequate Relief With Laxatives|Completed||Phase 3|240|Actual|Norgine||2|||f||||f||||||||||2018-05-31 23:05:34.741472|2018-05-31 23:05:34.741472
NCT01251809|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2013-05-17|2010-12-01|2010-12-02|Estimate|||||||2013-05-17|2013-05-20|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia|A Randomized, Multi-centre, Parallel-group, Open Label, Oncaspar® Controlled Dose Ranging Trial of Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukaemia|Terminated||Phase 1/Phase 2|56|Anticipated|medac GmbH||4|||f||||t||||||||||2018-05-31 23:05:34.805135|2018-05-31 23:05:34.805135
NCT01251796|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2017-03-14|2010-12-01|2010-12-02|Estimate|||||||2017-03-14|2017-03-15|Actual|December 2010|Actual|2010-12-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of ARQ 197 in Combination With Erlotinib|A Phase I Study of ARQ 197 in Combination With Erlotinib in CYP2C19 Poor Metabolizer Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer|Completed||Phase 1|9|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-05-31 23:05:34.992037|2018-05-31 23:05:34.992037
NCT01251783|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-01|2010-12-01|2010-12-02|Estimate|||||||2010-12-01|2010-12-02|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||A Prebiotic Agave Derivated Metlin & Metlos in Infant Formula|Double Blind, Randomized, Controlled Clinical Trial for Evaluate The Efficiency and Safety of a Fiber System From Agave, With Prebiotic Action, Metlin® and Metlos®, Incorporated to an Infant Formula for Term Newborn Babies|Completed||Phase 3|600|Actual|National Institute of Pediatrics, Mexico||6|||f||||t||||||||||2018-05-31 23:05:35.050934|2018-05-31 23:05:35.050934
NCT01251770|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2011-12-13||2017-01-17|2010-12-01|2010-12-02|Estimate|2011-12-20|2012-01-25|Estimate||||2017-01-17|2017-03-03|Actual|December 2010||2010-12-31|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|surgical-Na||Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children|Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children|Completed||Phase 3|78|Actual|Hospital General de Niños Pedro de Elizalde||2|||f||||t||||||||||2018-05-31 23:05:35.138503|2018-05-31 23:05:35.138503
NCT01251757|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2016-07-25||2017-02-01|2010-11-30|2010-12-02|Estimate|2016-12-07|2017-02-01|Estimate||||2017-02-01|2017-03-13|Actual|August 2011||2011-08-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|PATIENT|All randomized participants|Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies|Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)|Completed||N/A|21752|Actual|Kaiser Permanente||3|||f||||t||||||||No|At the request of AHRQ we did not create a formal public data release.|2018-05-31 23:05:35.474459|2018-05-31 23:05:35.474459
NCT01251744|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2017-05-26|2010-12-01|2010-12-02|Estimate|||||||2017-05-26|2017-05-30|Actual|December 9, 2010|Actual|2010-12-09|May 2017|2017-05-31|June 17, 2015|Actual|2015-06-17|November 6, 2013|Actual|2013-11-06||Interventional|||Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus|Study of Maternal-foetal Cytomegalovirus (CMV) Transmission|Completed||N/A|159|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 23:05:36.358838|2018-05-31 23:05:36.358838
NCT01251731|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-04-04|2010-12-01|2010-12-02|Estimate|||||||2012-04-04|2012-04-06|Estimate|July 2010||2010-07-31|April 2012|2012-04-30||||January 2011|Actual|2011-01-31||Interventional|||Single and Multiple Dose Asian Bridging Study|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Single-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of 10, 40, and 80 mg E5501 Followed by a Selected Dose for Multiple Dosing Administered to Healthy Japanese, Chinese, and Caucasian Subjects|Completed||Phase 1|36|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 23:05:36.497153|2018-05-31 23:05:36.497153
NCT01251718|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-02-23|2010-12-01|2010-12-02|Estimate|||||||2017-02-23|2017-02-27|Actual|December 1, 2010|Actual|2010-12-01|January 2017|2017-01-31|February 18, 2016|Actual|2016-02-18|October 14, 2015|Actual|2015-10-14||Observational|||Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease|Post-marketing Surveillance of Donepezil Hydrochloride- Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Disease|Completed|||894|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 23:05:36.602143|2018-05-31 23:05:36.602143
NCT01251705|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-01|2010-12-01|2010-12-02|Estimate|||||||2010-12-01|2010-12-02|Estimate|November 2010||2010-11-30|December 2010|2010-12-31|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Observational|||Comparation of Different Devices to Measure Corneal Thickness|Comparation of Different Devices to Measure Corneal Thickness|Unknown status|Recruiting||70|Anticipated|Technische Universität Dresden|||||f||||f||||||||||2018-05-31 23:05:36.84986|2018-05-31 23:05:36.84986
NCT01251692|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-12-01|2010-12-01|2010-12-02|Estimate|||||||2010-12-01|2010-12-02|Estimate|January 1996||1996-01-31|November 2010|2010-11-30|January 2010|Actual|2010-01-31|January 2000|Actual|2000-01-31||Interventional|PTK x CE||Phototherapeutic Keratectomy (PTK) on Recurrent Corneal Erosions|Ten-year Results of Phototherapeutic Keratectomy on Recurrent Corneal Erosions|Completed||Phase 4|26|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-05-31 23:05:36.934128|2018-05-31 23:05:36.934128
NCT01251679|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2012-09-10|2010-12-01|2010-12-02|Estimate|||||||2012-09-10|2012-09-11|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|HITS||Household Influenza Transmission Study|Study to Assess Effectiveness of Nonpharmaceutical Interventions (Handwashing, Face Mask Use) to Prevent Influenza Transmission in Households|Unknown status|Active, not recruiting|N/A|2920|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 23:05:36.980568|2018-05-31 23:05:36.980568
NCT01251666|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-08-31|2010-12-01|2010-12-02|Estimate|||||||2012-08-31|2012-09-03|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|HeMO||Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening|Comparison of Performances of Two Automated Immunochemical Faecal Occult Blood Tests in Colorectal Cancer Screening, in Reference to Usual Care Guaiac Test|Completed||Phase 3|19797|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 23:05:37.086471|2018-05-31 23:05:37.086471
NCT01251653|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2016-04-22||2016-04-22|2010-12-01|2010-12-02|Estimate|2016-04-22|2016-05-30|Estimate||||2016-04-22|2016-05-30|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational||Treated Set (TS): The Treated Set consists of all patients who received at least one application of the trial drug.|A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel|A Phase I Dose Escalation Trial of Once Daily Oral Treatment Using Afatinib (BIBW2992) Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors.|Completed|||94|Actual|Boehringer Ingelheim|||2||f||||||||||Samples Without DNA|"~     Pharmacokinetic samples~   "|||2018-05-31 23:05:37.45362|2018-05-31 23:05:37.45362
NCT01251640|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2015-07-01|2010-12-01|2010-12-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|BAGPAC||Combination With Gemcitabine in Advanced Pancreatic Cancer|A Multi-center, Phase I/II Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|90|Actual|Bayer||1|||f||||t||||||||||2018-05-31 23:05:42.302987|2018-05-31 23:05:42.302987
NCT01251627|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2018-02-27|2010-12-01|2010-12-02|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2010||2010-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|December 2011|Actual|2011-12-31||Interventional|DECI2009||Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia|A Phase II Multicenter Open-label Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia|Active, not recruiting||Phase 2|41|Anticipated|Fondazione Italiana Sindromi Mielodisplastiche Onlus||1|||f||||f||||||||||2018-05-31 23:05:43.054532|2018-05-31 23:05:43.054532
NCT01251614|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|2016-12-16||2017-08-25|2010-12-01|2010-12-02|Estimate|2017-02-17|2017-04-04|Actual||||2017-08-25|2017-09-25|Actual|December 2010||2010-12-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|December 2013|Actual|2013-12-31||Interventional||Intent-to-treat population included all randomized participants|A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate|A Multicenter, Randomized, Double-dummy, Double-blind Study Evaluating Two Doses of Adalimumab Versus Methotrexate (MTX) in Pediatric Subjects With Chronic Plaque Psoriasis (Ps)|Completed||Phase 3|114|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 23:05:43.466605|2018-05-31 23:05:43.466605
NCT01251601|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-01-31|2010-12-01|2010-12-02|Estimate|||||||2012-01-31|2012-02-02|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||The Effect of Pregnancy on the PK of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters|The Effect of Pregnancy on the Pharmacokinetics of Isentress®: A Longitudinal Investigation in the Second and Third Trimesters|Withdrawn|||0|Actual|University of North Carolina, Chapel Hill|||1|Withdrawn due to inability to recruit eligible participants|f||||f||||||||||2018-05-31 23:05:48.214532|2018-05-31 23:05:48.214532
NCT01251588|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2017-01-12||2017-06-16|2010-11-30|2010-12-02|Estimate|2017-03-15|2017-04-27|Actual||||2017-06-16|2017-07-13|Actual|December 2010||2010-12-31|June 2017|2017-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|Extension|The patients who did not elect to participate in the Extension study differed in their degree of response in SUMMIT relative to those who elected to participate in the Extension (ie, loss of higher-responding MACI patients and lower-responding microfracture patients).|Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee|An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea|Completed|||128|Actual|Vericel Corporation|Potential problems that may be observed with elective participation in extension studies were observed in the SUMMIT Extension. Thus, the value of inferential testing that compares treatment groups without accounting for missing data is limited.||2||f||||f||||||||No||2018-05-31 23:05:48.653348|2018-05-31 23:05:48.653348
NCT01251575|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2017-10-30|2010-12-01|2010-12-02|Estimate|||||||2017-10-30|2017-11-01|Actual|December 1, 2010|Actual|2010-12-01|October 2017|2017-10-31||||November 30, 2018|Anticipated|2018-11-30||Interventional|||Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant|A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-center Trial|Recruiting||Phase 2|80|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 23:05:49.527505|2018-05-31 23:05:49.527505
NCT01250873|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-01-27|2010-11-29|2010-12-01|Estimate|||||||2011-01-27|2011-01-28|Estimate|November 2010||2010-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline|LY2216684 and Sertraline Pharmacokinetic Interaction Study in Healthy Subjects|Completed||Phase 1|0|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:06:20.759705|2018-05-31 23:06:20.759705
NCT01251562|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2014-05-15|2010-11-30|2010-12-02|Estimate|||||||2014-05-15|2014-05-16|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|May 2014|Anticipated|2014-05-31|August 2012|Actual|2012-08-31||Interventional|||Safety Study of Sterile Compound c31510 for Injection to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound c31510 for Injection Administered Intravenously to Subjects With Solid Tumors|Suspended||Phase 1|63|Anticipated|Berg, LLC||1||Interim Analysis|f||||||||||||||2018-05-31 23:05:49.724961|2018-05-31 23:05:49.724961
NCT01251549|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-28|||2016-10-04|2010-11-30|2010-12-02|Estimate|||||||2016-10-04|2016-10-05|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO)|Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO)|Completed||N/A|32|Actual|ReWalk Robotics, Inc.||1|||f||||f||||||||||2018-05-31 23:05:50.065227|2018-05-31 23:05:50.065227
NCT01251536|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-05-02|2010-12-01|2010-12-02|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2010|Actual|2010-12-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|June 2016|Actual|2016-06-30||Interventional|Everest2||Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer|A Two Arm Phase II Study of FOLFIRI in Combination With Standard or Escalating Dose of Cetuximab as First Line Treatment of K-Ras Wild Type Metastatic Colorectal Cancer: Everest 2|Active, not recruiting||Phase 2|375|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||No||2018-05-31 23:05:50.348676|2018-05-31 23:05:50.348676
NCT01251523|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2017-03-13|2010-12-01|2010-12-02|Estimate|||||||2017-03-13|2017-03-15|Actual|November 2010||2010-11-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Improving Asthma Outcomes Through Cultural Competence Training for Physicians|Improving Asthma Outcomes Through Cultural Competence Training for Physicians|Completed||N/A|1176|Actual|University of Michigan||3|||f||||t||||||||||2018-05-31 23:05:50.510966|2018-05-31 23:05:50.510966
NCT01251510|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2013-01-22|2010-12-01|2010-12-02|Estimate|||||||2013-01-22|2013-01-23|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Bile Acid-induced GLP-secretion. A Study in Cholecystectomized Subjects|Bile Acid-induced GLP-secretion. A Study in Cholecystectomized Subjects|Completed|||20|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 23:05:50.715098|2018-05-31 23:05:50.715098
NCT01251497|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2010-12-01|2010-12-01|2010-12-02|Estimate|||||||2010-12-01|2010-12-02|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|Yo Puedo||¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos|¡Si, Yo Puedo Control Mi Diabetes!: A Diabetes Self-management Education Program for Hispanic/Latinos|Completed||Early Phase 1|||Texas AgriLife Extension Service|||||f||||f||||||||||2018-05-31 23:05:50.8225|2018-05-31 23:05:50.8225
NCT01251484|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2012-10-03|2010-12-01|2010-12-02|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||BIBF 1120 in Recurrent Glioblastoma Multiforme|Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme|Completed||Phase 2|25|Actual|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 23:05:51.044834|2018-05-31 23:05:51.044834
NCT01251471|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-10-28|2010-12-01|2010-12-02|Estimate|||||||2016-10-28|2016-10-31|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|||Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response|Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response|Completed||Phase 4|26|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 23:05:51.324931|2018-05-31 23:05:51.324931
NCT01251458|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-09-27|2010-12-01|2010-12-02|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Hepatocellular Carcinoma (HCC)_Torisel_|Phase I/II Study of Temsirolimus (Torisel®) as Novel Therapeutic Drug for Patients With Unresectable Hepatocellular Carcinoma (HCC)- A Correlative Study With Stathmin Over-expression|Completed||Phase 1/Phase 2|46|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 23:05:51.527988|2018-05-31 23:05:51.527988
NCT01251432|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2016-11-02|2010-12-01|2010-12-02|Estimate|||||||2016-11-02|2016-11-04|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Risk Factors and Potential Causes of Eustachian Tube Dysfunction in Adults|Risk Factors and Potential Causes of Eustachian Tube Dysfunction in Adults With Clinically Diagnosed Chronic Otitis Media With Effusion and/or Eustachian Tube Dysfunction|Completed|||30|Actual|University of Pittsburgh|||2||f||||f||||||||||2018-05-31 23:05:51.656859|2018-05-31 23:05:51.656859
NCT01251419|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-05-16|2010-11-30|2010-12-01|Estimate|||||||2012-05-16|2012-05-18|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Impact of Social Proximity on Conversion to Generic Prescription Medications|The Impact of Social Proximity on Conversion to Generic Prescription Medications|Completed||N/A|10000|Actual|National Bureau of Economic Research, Inc.||3|||f||||f||||||||||2018-05-31 23:05:51.726741|2018-05-31 23:05:51.726741
NCT01251406|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-08-04|2010-11-30|2010-12-01|Estimate|||||||2014-08-04|2014-08-06|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|December 2012|Actual|2012-12-31||Interventional|ZS-01-210||Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure|A Randomized, Parallel, Placebo-controlled, Double-blind Phase IIa Study of Efficacy and Safety of Recombinant Human Neuregulin-1 (Neucardin) in Subjects With Stable Chronic Heart Failure|Completed||Phase 2|120|Anticipated|Zensun Sci. & Tech. Co., Ltd.||3|||f||||t||||||||||2018-05-31 23:05:51.943696|2018-05-31 23:05:51.943696
NCT01251393|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-11-23|2010-11-30|2010-12-01|Estimate|||||||2012-11-23|2012-11-27|Estimate|May 2011||2011-05-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional|||Cocaine/Crack and Reduction of Compulsion With Biperiden|Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden|Completed||Phase 3|60|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 23:05:52.280871|2018-05-31 23:05:52.280871
NCT01251380|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|2016-08-30|2015-05-07|2017-04-27|2010-11-30|2010-12-01|Estimate|2017-04-27|2017-06-01|Actual|2015-05-07|2015-05-25|Estimate|2017-04-27|2017-06-01|Actual|October 2011||2011-10-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Dysport® Pediatric Lower Limb Spasticity Follow-on Study|A Phase III, Prospective, Multicentre, Open Label, Extension Study Assessing the Long Term Safety and Efficacy of Repeated Treatment With DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy|Completed||Phase 3|216|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 23:05:52.447221|2018-05-31 23:05:52.447221
NCT01249950|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2013-11-08|2010-11-26|2010-11-30|Estimate|||||||2013-11-08|2013-11-11|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|December 2011|Actual|2011-12-31||Observational|||Study on the Appropriateness of Bariatric Surgery in Adolescents|Study on the Appropriateness of Bariatric Surgery in Adolescents|Terminated|||10|Actual|University Hospital, Toulouse|||1||f||||f||||||||||2018-05-31 23:06:35.68917|2018-05-31 23:06:35.68917
NCT01251367|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|2017-07-03|2015-04-28|2017-11-08|2010-11-30|2010-12-01|Estimate|2017-11-08|2017-11-09|Actual|2015-04-28|2015-05-15|Estimate|2017-11-08|2017-11-09|Actual|June 2011||2011-06-30|November 2017|2017-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||The summary of baseline characteristics presented are from subjects completing Study 140 who were selected by the investigator for entry into Study 142 and received at least one injection of study treatment in this open label extension study.|Dysport® Adult Lower Limb Spasticity Follow-on Study|A Phase III, Prospective, Multicentre, Open Label, Extension Study, to Assess the Long Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Lower Limb Spasticity in Adult Subjects With Spastic Hemiparesis Due to Stroke or Traumatic Brain Injury|Completed||Phase 3|352|Actual|Ipsen|Data is summarised according to total dose received at each corresponding cycle (i.e. including 1000 U and 1500 U Dysport® in lower limb during all cycles, as well as 1000 U in lower limb + 500 U Dysport® in upper limb during Cycles 3 and 4).|1|||f||||f||||||||||2018-05-31 23:05:54.731576|2018-05-31 23:05:54.731576
NCT01251354|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2015-08-06||2015-09-23|2010-11-30|2010-12-01|Estimate|2015-08-06|2015-09-02|Estimate||||2015-09-23|2015-10-19|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy|A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.|Terminated||Phase 2|6|Actual|Ipsen|Study terminated due to poor enrollment|1||"The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the~   primary endpoint will not be reached."|f||||||||||||||2018-05-31 23:06:00.635988|2018-05-31 23:06:00.635988
NCT01251341|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2014-12-04|2010-11-30|2010-12-01|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|CALM||The Compassion and Attention Longitudinal Meditation Study|Mechanisms of Meditation|Completed||N/A|226|Actual|University of Arizona||3|||f||||t||||||||||2018-05-31 23:06:02.118231|2018-05-31 23:06:02.118231
NCT01251328|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2015-02-09|2010-11-30|2010-12-01|Estimate|||||||2015-02-09|2015-02-10|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|INSERT||Near INfrared Spectroscopy in Aortic valvE ReplacemenT|Near Infrared Spectroscopy in Aortic Valve Replacement|Completed||N/A|62|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:06:02.418003|2018-05-31 23:06:02.418003
NCT01251315|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2013-07-15||2014-03-17|2010-11-30|2010-12-01|Estimate|2014-01-29|2014-03-17|Estimate||||2014-03-17|2014-04-14|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels|PILOT: The Effects of Short Term Administration of a Novel Glutathione Precursor (FT061452), on Serum and Intracellular Glutathione Levels|Completed||Phase 1|24|Actual|Charles Drew University of Medicine and Science||6|||f||||t||||||||||2018-05-31 23:06:02.812292|2018-05-31 23:06:02.812292
NCT01251302|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2018-02-21|2010-11-30|2010-12-01|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2010||2010-11-30|February 2018|2018-02-28|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Observational|IMPACT-CARD||Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern|Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern|Completed|||171|Actual|CardioDx|||2||f||||f||||||None Retained|"~     PaxGene tube for RNA collected~   "|||2018-05-31 23:06:05.999535|2018-05-31 23:06:05.999535
NCT01251289|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-06-08|2010-11-30|2010-12-01|Estimate|||||||2012-06-08|2012-06-11|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||The Prevalence of Group B Streptococcus Positive Pregnant Patients in an Inner City Tertiary Care Center|The Prevalence of Group B Streptococcus Positive Pregnant Patients in an Inner City Tertiary Care Center|Completed|||628|Actual|St. Michael's Hospital, Toronto|||||f||||||||||||||2018-05-31 23:06:14.183581|2018-05-31 23:06:14.183581
NCT01251276|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2017-07-26||2018-04-10|2010-11-30|2010-12-01|Estimate|2017-07-26|2017-08-28|Actual||||2018-04-10|2018-04-11|Actual|November 30, 2010|Actual|2010-11-30|April 2018|2018-04-30|April 12, 2011|Actual|2011-04-12|April 12, 2011|Actual|2011-04-12||Interventional||All enrolled and vaccinated participants|Hepatitis B Challenge Dose in Adults (V232-059-10)|A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥50 Years Old) Vaccinated With a Primary Series of an Hepatitis B Vaccine|Completed||Phase 3|204|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f|||t|||||2018-05-31 23:06:15.520895|2018-05-31 23:06:15.520895
NCT01251263|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|Estradiol/MAM||Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.|Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.|Unknown status|Recruiting|Phase 4|40|Anticipated|Scott and White Hospital & Clinic||2|||f||||f||||||||||2018-05-31 23:06:16.043157|2018-05-31 23:06:16.043157
NCT01251250|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2014-01-10|2010-11-30|2010-12-01|Estimate|||||||2014-01-10|2014-01-13|Estimate|December 2010||2010-12-31|January 2014|2014-01-31||||July 2011|Actual|2011-07-31||Interventional|||Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia|Phase I Clinical Trial of Neem Leaf Extract for the Treatment of Chronic Lymphocytic Leukemia|Withdrawn||Phase 1|0|Actual|Roswell Park Cancer Institute||1||lost sponsor support|f||||t||||||||||2018-05-31 23:06:16.130946|2018-05-31 23:06:16.130946
NCT01251237|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study to Assess the Tolerability, Safety and Efficacy of an Adapted Gut Cleansing Solution in Routine Colon Cleansing Prior to Colonoscopies|Open Study to Assess the Tolerability, Safety and Efficacy of an Adapted 2 Litre Gut Cleansing Solution (NRL0706) in Routine Colon Cleansing Prior to Colonoscopies for Colon Tumour Screening.|Completed||Phase 2|120|Actual|Norgine||1|||f||||f||||||||||2018-05-31 23:06:16.34574|2018-05-31 23:06:16.34574
NCT01251224|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2017-03-15|2010-11-30|2010-12-01|Estimate|||||||2017-03-15|2017-03-16|Actual|November 2010||2010-11-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MAAIT||Mouse Allergen and Asthma Intervention Trial|Mouse Allergen and Asthma Intervention Trial|Completed||Phase 3|361|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 23:06:16.426151|2018-05-31 23:06:16.426151
NCT01250691|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|August 2010|Actual|2010-08-31|July 2008|Actual|2008-07-31||Observational|||Effects of Isolated Rooms on the Prevalence of Hospital Acquired Pneumonia in a Respiratory ICU|Epidemiologic Study of Hospital Acquired Pneumonia in a Respiratory ICU|Completed|||532|Actual|Eskisehir Osmangazi University|||3||f||||t||||||||||2018-05-31 23:06:26.231753|2018-05-31 23:06:26.231753
NCT01251211|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2016-03-10|2010-11-30|2010-12-01|Estimate|||||||2016-03-10|2016-03-11|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Botulinum Toxin in Peripheral Neuropathic Pain|Randomized Double Blind Placebo Controlled Multicenter Study of the Efficacy and Safety of Repeated Administrations of Botulinum Toxin Type A (Botox) in the Treatment of Peripheral Neuropathic Pain|Completed||Phase 4|66|Actual|Hospital Ambroise Paré Paris||2|||f||||f||||||||No||2018-05-31 23:06:16.495188|2018-05-31 23:06:16.495188
NCT01251198|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-06-13|2010-11-30|2010-12-01|Estimate|||||||2012-06-13|2012-06-14|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|SFL||Stent For Life Observatory|Stent For Life Observatory|Completed|||460|Actual|French Cardiology Society|||1||f||||f||||||||||2018-05-31 23:06:16.57448|2018-05-31 23:06:16.57448
NCT01251185|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2013-02-17|2010-11-30|2010-12-01|Estimate|||||||2013-02-17|2013-02-20|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Extracorporeal Shockwave Myocardial Revascularization (ESMR) Therapy For The Treatment of Chronic Heart Failure|Extracorporeal Shockwave Myocardial Revascularization(ESMR)Therapy For The Treatment of Chronic Heart Failure.|Completed||Phase 1|9|Actual|Medispec||1|||f||||f||||||||||2018-05-31 23:06:16.666103|2018-05-31 23:06:16.666103
NCT01251172|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2017-09-27|2010-11-30|2010-12-01|Estimate|||||||2017-09-27|2017-09-28|Actual|December 2010||2010-12-31|September 2017|2017-09-30||||July 2012|Actual|2012-07-31||Interventional|||RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase II Study of RO4929097 to Eradicate Residual Disease in Patients With Multiple Myeloma Post Single Autologous Stem Cell Transplant|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1||Lack of Drug Supply|f||||||||||||||2018-05-31 23:06:16.737529|2018-05-31 23:06:16.737529
NCT01251159|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2017-05-16|2010-11-30|2010-12-01|Estimate|||||||2017-05-16|2017-05-17|Actual|May 15, 2009|Actual|2009-05-15|May 2017|2017-05-31|June 15, 2009|Actual|2009-06-15|June 15, 2009|Actual|2009-06-15||Observational|||Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia|Somatic Mutations in Stem and Progenitor Cells in AML|Completed|||30|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:06:16.850408|2018-05-31 23:06:16.850408
NCT01251146|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2012-11-01||2017-01-25|2010-11-30|2010-12-01|Estimate|2012-11-01|2012-11-30|Estimate||||2017-01-25|2017-03-08|Actual|November 2010||2010-11-30|January 2017|2017-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension|Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Patients With Essential Hypertension|Completed||Phase 4|177|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 23:06:16.960848|2018-05-31 23:06:16.960848
NCT01251133|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study|A Phase III Study to Assess Immunogenicity and Safety of 4th LBVH0101 Vaccination Compared With 4th Hiberix™ Vaccination in Healthy Toddlers Who Completed Primary Vaccination in LG-VHCL002 Study|Completed||Phase 3|122|Actual|LG Life Sciences||2|||f||||t||||||||||2018-05-31 23:06:17.332033|2018-05-31 23:06:17.332033
NCT01251120|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2014-11-03||2014-11-06|2010-11-30|2010-12-01|Estimate|2014-11-06|2014-11-11|Estimate||||2014-11-06|2014-11-11|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Due to limited number of participants (n=2) the study was prematurely terminated.|A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis|A Pragmatic, Randomized, Parallel Group Study of the Effect on Disease Remission, Work Productivity and Tolerability of Tocilizumab in Combination With DMARDs and Individually Designed Best Practice DMARD Therapy in Patients With Early, Moderate to Severe Rheumatoid Arthritis|Terminated||Phase 4|2|Actual|Hoffmann-La Roche||2||The study was stopped prematurely due to lack of enrollment.|f||||||||||||||2018-05-31 23:06:17.433658|2018-05-31 23:06:17.433658
NCT01251107|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2015-08-11|2010-11-30|2010-12-01|Estimate|||||||2015-08-11|2015-08-13|Estimate|March 2000||2000-03-31|February 2011|2011-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma|Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL)|Completed||Phase 3|331|Actual|Fondazione Michelangelo||2|||f||||f||||||||||2018-05-31 23:06:17.704356|2018-05-31 23:06:17.704356
NCT01251094|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2012-02-13|2010-11-30|2010-12-01|Estimate|||||||2012-02-13|2012-02-14|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Dementia Registry for Parkinson's Disease||Completed|||30|Actual|China Medical University Hospital|||||f||||||||||||||2018-05-31 23:06:17.802735|2018-05-31 23:06:17.802735
NCT01251081|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||Effect of the Intensity of Continuous Renal Replacement Therapy|Effect of the Intensity of Continuous Renal Replacement Therapy in Patients With Sepsis and Acute Kidney Injury: Single-center Randomized Clinical Trial|Completed||N/A|280|Actual|Zhejiang University||2|||f||||f||||||||||2018-05-31 23:06:17.850239|2018-05-31 23:06:17.850239
NCT01251068|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-12-06|2010-11-30|2010-12-01|Estimate|||||||2010-12-06|2010-12-07|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Measurement of Cerebral and Peripheric Tissue Oxygenation in Anemic Preterm Infants Who Underwent Blood Transfusion|Measurement of Cerebral and Peripheric Tissue Oxygenation in Anemic Preterm Infants Who Underwent Blood Transfusion:A Near Infrared Spectroscopy Study.|Unknown status|Recruiting|N/A|40|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||1|||f||||t||||||||||2018-05-31 23:06:17.946002|2018-05-31 23:06:17.946002
NCT01251055|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2013-10-27|2010-11-30|2010-12-01|Estimate|||||||2013-10-27|2013-10-29|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||GlyT-1 Inhibitor Treatment for Refractory Schizophrenia|GlyT-1 Inhibitor Treatment for Refractory Schizophrenia and Its Effects on NMDA Modulation|Completed||Phase 2|40|Actual|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 23:06:18.059065|2018-05-31 23:06:18.059065
NCT01251042|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2013-03-12||2013-04-29|2010-11-30|2010-12-01|Estimate|2013-03-12|2013-04-24|Estimate||||2013-04-29|2013-05-06|Estimate|October 2010||2010-10-31|April 2013|2013-04-30||||December 2011|Actual|2011-12-31||Interventional|||Comparison Between Return and Wastage of Your Own Blood, Collected During Spinal Surgery, for Verification of Safety When Returning Blood|A Prospective, Randomized, Controlled Study on Intra-operative Autologous Transfusion With the Sangvia® Blood Salvage System in Spinal Surgery|Completed||N/A|51|Actual|Wellspect HealthCare||2|||f||||f||||||||||2018-05-31 23:06:18.14502|2018-05-31 23:06:18.14502
NCT01251029|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|January 2014|Anticipated|2014-01-31|September 2013|Anticipated|2013-09-30||Interventional|||Effect of N-acetylcysteine on Renal Functioning of Chronic Kidney Diseases(CKD) Patients After General Anesthesia|Ability of N-acetylcysteine to Prevent Deterioration in Renal Functioning in CKD Patients Undergoing Major Surgery Under General Anesthesia|Unknown status|Not yet recruiting|Phase 1|||Assaf-Harofeh Medical Center||1|||f||||||||||||||2018-05-31 23:06:18.92615|2018-05-31 23:06:18.92615
NCT01251016|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2015-12-05|2010-11-30|2010-12-01|Estimate|||||||2015-12-05|2015-12-08|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Observational|||Effect of Bariatric Surgery on Gut Hormones Production and Cure of Type 2 Diabetes Mellitus|Changes in Gene Expression of Intestinal Tissue From Type 2 Diabetes Patients Submitted to Roux-en-Y Gastric Bypass|Unknown status|Recruiting||30|Anticipated|University of Sao Paulo|||||f||||t||||||||||2018-05-31 23:06:19.009876|2018-05-31 23:06:19.009876
NCT01251003|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2015-12-09|2010-11-30|2010-12-01|Estimate|||||||2015-12-09|2015-12-10|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|December 2014|Anticipated|2014-12-31||Interventional|||Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury|Safety of Autologous Human Umbilical Cord Blood Treatment for Traumatic Brain in Children|Withdrawn||Phase 1/Phase 2|0|Actual|The University of Texas Health Science Center, Houston||||"Unable to identify eligible subjects with traumatic brain injury who also have banked umbilical~   cord blood at CBR."|f||||t||||||||||2018-05-31 23:06:19.08451|2018-05-31 23:06:19.08451
NCT01250990|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2016-05-17||2016-06-24|2010-11-30|2010-12-01|Estimate|2016-05-17|2016-06-24|Estimate||||2016-06-24|2016-07-28|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ENTHRALL||Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis|A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Effects Of Niacin On Reverse Cholesterol Transport As Measured Using [1,2-3H]-Cholesterol (3H-cholesterol) in Healthy Volunteers.|Completed||N/A|22|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 23:06:19.146903|2018-05-31 23:06:19.146903
NCT01250977|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2012-07-16|2010-11-30|2010-12-01|Estimate|||||||2012-07-16|2012-07-17|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Donepexil on Smoking|The Effect of Acetylcholinesterase Inhibitors on Smoking Behavior|Completed||Phase 2|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania||4|||f||||t||||||||||2018-05-31 23:06:19.426009|2018-05-31 23:06:19.426009
NCT01250964|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Endothelial Cell Loss and Induced Astigmatism After Wound-directed and Wound-assisted IOL Injection|Endothelial Cell Loss and Surgically Induced Astigmatism After 2.2 mm Wound Assisted vs 2.4 mm Wound-Directed Clear Corneal Incisions for Intraocular Lens Insertion During Cataract Surgery|Completed||N/A|72|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:06:19.54492|2018-05-31 23:06:19.54492
NCT01250951|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2016-12-08|2010-11-29|2010-12-01|Estimate|||||||2016-12-08|2016-12-12|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.|1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.|Completed||Phase 4|111|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:06:19.640235|2018-05-31 23:06:19.640235
NCT01250938|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2017-07-11|2010-11-30|2010-12-01|Estimate|||||||2017-07-11|2017-07-14|Actual|July 2009||2009-07-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ESI-CO||Effectiveness of Early Intervention in an Underserved Population|2/2-Effects of Parent-Implemented Intervention for Toddlers With Autism Spectrum|Active, not recruiting||N/A|44|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||Yes|"Data are maintained by Florida Statue University, the data coordinating center for this collaborative project. We have shared deidentified study data by depositing it in the NIH National Database for Autism Research (NDAR).~We have a long-standing commitment to making our data available to other investigators. As part of our previous work with NIMH (e.g. NIMH Collaborative RO1 MH089390) and others (e.g. Simons Simplex Collection), our data collection methods and data structures have been designed with NDAR's data-sharing protocol in mind (we collect information necessary to generate the Global Unique Identifier). Our study uses standardized assessments and all data are maintained in a secure database."|2018-05-31 23:06:19.731181|2018-05-31 23:06:19.731181
NCT01250925|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2013-04-24||2016-11-11|2010-11-30|2010-12-01|Estimate|2016-11-11|2017-01-10|Estimate||||2016-11-11|2017-01-10|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|||Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface|Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study|Completed||Phase 4|94|Actual|Massachusetts Eye and Ear Infirmary||3|||f||||f||||||||No||2018-05-31 23:06:19.843082|2018-05-31 23:06:19.843082
NCT01250912|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2018-04-04|2010-11-30|2010-12-01|Estimate|||||||2018-04-04|2018-04-06|Actual|March 2010||2010-03-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Imaging With a Radio Tracer to Guide VT Ablations|Three Dimension Neuron Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Ventricular Tachycardia Ablations|Completed||N/A|20|Actual|University of Maryland||1|||f||||t||||||||||2018-05-31 23:06:20.455068|2018-05-31 23:06:20.455068
NCT01250899|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|2014-08-25||2014-11-24|2010-11-30|2010-12-01|Estimate|2014-08-25|2014-09-05|Estimate||||2014-11-24|2014-11-25|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||HIV-infected men and women with HIV-1 RNA <200 copies/mL on stable ART and daily vitamin D <400IU were enrolled|Vitamin D in HIV-Infected Patients on HAART|Vitamin D, Immune Activation, and Metabolic Abnormalities in HIV-Infected Patients on Antiretroviral Therapy|Completed||N/A|122|Actual|University of California, Los Angeles|This trial was prospective, but open label and not randomized. However, randomization to placebo would not have been clinically appropriate.|2|||f||||f||||||||||2018-05-31 23:06:20.53806|2018-05-31 23:06:20.53806
NCT01250886|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2016-03-14|2010-11-29|2010-12-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Acid-base Balance in Patients Undergoing Colonoscopy|Intravenous Fluid Administration in Patients Undergoing Colonoscopy: Double Blind, Randomised Clinical Trial of Underlying Acid-base Derangement|Unknown status|Enrolling by invitation|Phase 1|90|Anticipated|Mahidol University||3|||f||||t||||||||||2018-05-31 23:06:20.699295|2018-05-31 23:06:20.699295
NCT01250860|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Short-term Effects of the Simultaneous Use of Two Physiotherapeutic Methods in the Treatment of Adolescent Idiopathic Scoliosis - Pilot Study|Short-term Effects of the Simultaneous Use of Two Physiotherapeutic Methods in the Treatment of Adolescent Idiopathic Scoliosis - Pilot Study|Completed||N/A|42|Actual|Medical University of Silesia||2|||f||||t||||||||||2018-05-31 23:06:20.892252|2018-05-31 23:06:20.892252
NCT01250847|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-08-18|2010-11-30|2010-12-01|Estimate|||||||2011-08-18|2011-08-19|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|ES-ARMS||Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)|Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)|Unknown status|Recruiting|Phase 4|83|Anticipated|Severance Hospital||3|||f||||t||||||||||2018-05-31 23:06:21.02271|2018-05-31 23:06:21.02271
NCT01250834|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2014-10-03||2014-10-03|2010-11-29|2010-12-01|Estimate|2014-10-03|2014-10-08|Estimate||||2014-10-03|2014-10-08|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||LY2189265 and Atorvastatin Interaction Study|Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects|Completed||Phase 1|27|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:06:21.230981|2018-05-31 23:06:21.230981
NCT01250821|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2013-04-18|2010-11-30|2010-12-01|Estimate|||||||2013-04-18|2013-04-19|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility|Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility|Completed||Phase 4|75|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 23:06:21.641754|2018-05-31 23:06:21.641754
NCT01250808|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate||||November 2010|2010-11-30||||||||Expanded Access|||Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy||Available|||||Peking University|||||f||||||||||||||2018-05-31 23:06:21.71552|2018-05-31 23:06:21.71552
NCT01250795|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2016-05-10|2010-11-30|2010-12-01|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults|A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years|Completed||Phase 1|100|Actual|Fraunhofer, Center for Molecular Biotechnology||5|||f||||t||||||||Undecided||2018-05-31 23:06:21.942747|2018-05-31 23:06:21.942747
NCT01250782|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|GluTrac||Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.|Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.|Unknown status|Recruiting|Phase 2|150|Anticipated|Hospital Universitari Son Dureta||2|||f||||t||||||||||2018-05-31 23:06:22.008127|2018-05-31 23:06:22.008127
NCT01250769|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2012-05-31||2012-08-21|2010-11-29|2010-12-01|Estimate|2012-08-21|2012-09-19|Estimate||||2012-08-21|2012-09-19|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Evaluating the Effect of Tooth Cleaning Devices on Oral Health|Evaluating the Effect of a Novel Interproximal Cleaning Device on Oral Health|Completed||N/A|170|Actual|Philips Oral Healthcare||4|||f||||f||||||||||2018-05-31 23:06:22.08477|2018-05-31 23:06:22.08477
NCT01250756|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2013-01-22||2013-01-22|2010-11-29|2010-12-01|Estimate|2013-01-22|2013-02-26|Estimate||||2013-01-22|2013-02-26|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.|A Phase 4, Randomized, Open-label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan.|Completed||Phase 4|321|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:06:22.441746|2018-05-31 23:06:22.441746
NCT01250743|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-02-17|2010-11-30|2010-12-01|Estimate|||||||2011-02-17|2011-02-18|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C|An Open-Label Pilot Study of the Safety, Tolerability and Anti-Viral Activity of High Dose Intravenous Ascorbic Acid in Patients Chronically Infected With Hepatitis C Virus Genotype 1, Who Have Failed Prior Therapy With Interferon-alpha and Ribavirin|Terminated||N/A|10|Anticipated|Health Innovations, Frontier Research Institute||1|||f||||f||||||||||2018-05-31 23:06:25.289978|2018-05-31 23:06:25.289978
NCT01250730|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2011-10-20||2011-10-20|2010-11-29|2010-12-01|Estimate|2011-10-20|2011-11-29|Estimate||||2011-10-20|2011-11-29|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066|A Phase 1, Open Label, Dose Escalation, Single Oral Dose Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066|Completed||Phase 1|18|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:06:25.384222|2018-05-31 23:06:25.384222
NCT01250717|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2013-07-01||2013-12-16|2010-11-29|2010-12-01|Estimate|2013-12-16|2014-02-04|Estimate||||2013-12-16|2014-02-04|Estimate|January 2001||2001-01-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer|Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer|Completed||Phase 2|28|Actual|Dana-Farber Cancer Institute|Although this study has the longest median follow-up periods reported (80 months or 6.6 years), the overall number of participants is too few to make strong judgements about efficacy|1|||f||||t||||||||||2018-05-31 23:06:25.976313|2018-05-31 23:06:25.976313
NCT01250704|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-12-01|Estimate|||||||2010-11-29|2010-12-01|Estimate|April 2010||2010-04-30|November 2010|2010-11-30||||March 2011|Anticipated|2011-03-31||Observational|||Inherited Myokymia: A Clinical and Genetic Study of a Family|Inherited Myokymia: A Clinical and Genetic Study of a Family|Unknown status|Recruiting||18|Anticipated|China Medical University Hospital|||||f||||t||||||Samples With DNA|"~     Genomic DNA was extracted from each patient's peripheral blood leukocytes using Genomaker DNA~     extraction kit (Blossom, Taipei, Taiwan). The complete KCNA1 coding region, including the~     intron/exon boundaries, was amplified according to the procedure reported by Imbrici et al~   "|||2018-05-31 23:06:26.170154|2018-05-31 23:06:26.170154
NCT01250678|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Observational|||Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab|Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab|Unknown status|Not yet recruiting||50|Anticipated|Cantonal Hospital of St. Gallen|||2||f||||f||||||||||2018-05-31 23:06:26.296771|2018-05-31 23:06:26.296771
NCT01250665|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Multiple Sclerosis|Cohort Study Comparing Corpus Callosum Atrophy as a Marker of Later Development of Cognitive Impairment in Patients With Early and Remitting Relapsing Multiple Sclerosis|Unknown status|Not yet recruiting||65|Anticipated|Cantonal Hospital of St. Gallen|||2||f||||f||||||||||2018-05-31 23:06:26.367036|2018-05-31 23:06:26.367036
NCT01250652|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2013-07-15|2010-11-30|2010-12-01|Estimate|||||||2013-07-15|2013-07-17|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|LevoHydroxy||Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses|Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study|Completed||Phase 4|24|Actual|Association Asthma, Bulgaria||2|||f||||t||||||||||2018-05-31 23:06:26.426392|2018-05-31 23:06:26.426392
NCT01250639|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|August 2010||2010-08-31|November 2010|2010-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|T2D2||Type 2 Diabetes Mellitus Collaborative Genetic Study on Non-aboriginal Taiwanese|Type 2 Diabetes Mellitus Collaborative Genetic Study Room|Unknown status|Recruiting||5000|Anticipated|China Medical University Hospital|||||f||||t||||||Samples With DNA|"~     serum,urine~   "|||2018-05-31 23:06:26.497345|2018-05-31 23:06:26.497345
NCT01250626|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-30|2010-11-30|2010-12-01|Estimate|||||||2010-11-30|2010-12-01|Estimate|August 2010||2010-08-31|August 2010|2010-08-31||||||||Observational|||Establish the Caring Model of Children With Chronic Kidney Disease and End-stage Renal Disease: To Set up Childhood Glomerular Filtration Rate (GFR) Formula in Taiwan||Unknown status|Active, not recruiting||80|Actual|China Medical University Hospital|||1||f||||||||||||||2018-05-31 23:06:26.552267|2018-05-31 23:06:26.552267
NCT01250613|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-12-01|Estimate|||||||2010-11-29|2010-12-01|Estimate|June 2010||2010-06-30|November 2010|2010-11-30||||||||Observational|||Genomic Study of Congenital Malformation|Genomic Study of Congenital Malformation|Unknown status|Recruiting||900|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 23:06:26.708015|2018-05-31 23:06:26.708015
NCT01250600|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-29|2010-11-29|2010-12-01|Estimate|||||||2010-11-29|2010-12-01|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Effects of Intelligent Tele-Cardiopulmonary Exercise System on Rehabilitation for Patients With Myocardial Infarction|Application of Intelligent Wireless and Portable Tele-Cardiopulmonary Exercise System on Rehabilitation for Patients With Myocardial Infarction|Unknown status|Not yet recruiting|N/A|80|Anticipated|China Medical University Hospital||2|||f||||||||||||||2018-05-31 23:06:26.764501|2018-05-31 23:06:26.764501
NCT01250587|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-09-20|2010-11-30|2010-12-01|Estimate|||||||2012-09-20|2012-09-24|Estimate|November 2010||2010-11-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea|A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PDC31 in Patients With Primary Dysmenorrhea|Completed||Phase 1|24|Actual|PDC Biotech GmbH||1|||f||||t||||||||||2018-05-31 23:06:26.832351|2018-05-31 23:06:26.832351
NCT01250574|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-30|||2016-06-24|2010-11-30|2010-12-01|Estimate|||||||2016-06-24|2016-06-27|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2014|Actual|2014-06-30||Observational|||Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections||Active, not recruiting|||173|Actual|University Hospital, Akershus|||2||f||||f||||||||||2018-05-31 23:06:26.893398|2018-05-31 23:06:26.893398
NCT01250561|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-12-01|Estimate|||||||2010-11-29|2010-12-01|Estimate|February 2002||2002-02-28|November 2010|2010-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Reduction of Postherpetic Neuralgia in Herpes Zoster||Completed||N/A|133|Actual|Center for Clinical Studies, Texas|||||f||||t||||||||||2018-05-31 23:06:26.951926|2018-05-31 23:06:26.951926
NCT01250548|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2014-09-02|2010-11-29|2010-12-01|Estimate|||||||2014-09-02|2014-09-03|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)|The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment|Completed||Phase 2|34|Actual|Baylor Research Institute||2|||f||||t||||||||||2018-05-31 23:06:27.010299|2018-05-31 23:06:27.010299
NCT01250535|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2013-01-17|2010-11-29|2010-11-30|Estimate|||||||2013-01-17|2013-01-21|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Human Cytochrome P450 4F Enzymes and Drug Interactions|Human Cytochrome P450 4F Enzymes and Drug Interactions|Completed||Phase 1|19|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:06:27.092306|2018-05-31 23:06:27.092306
NCT01250509|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2012-05-29||2013-01-16|2010-11-29|2010-11-30|Estimate|2013-01-16|2013-02-18|Estimate||||2013-01-16|2013-02-18|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|July 2008|Actual|2008-07-31|October 2007|Actual|2007-10-31||Interventional|CALMM||Craving and Lifestyle Management Through Mindfulness Study|Effects of Stress Reduction on Eating, Fat Distribution, and Cell Aging Among Overweight Women|Completed||Phase 2|53|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:06:27.23665|2018-05-31 23:06:27.23665
NCT01250496|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-11-27|2010-11-29|2010-11-30|Estimate|||||||2012-11-27|2012-11-28|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ASSUAGE||Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging|Attenuation of the Side Effect Profile of Regadenoson: A Randomized Double-Blind Placebo Controlled Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging.|Completed||Phase 4|248|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 23:06:27.474954|2018-05-31 23:06:27.474954
NCT01250483|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-11-27|2010-11-27|2010-11-30|Estimate|||||||2010-11-27|2010-11-30|Estimate|January 2001||2001-01-31|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Effects of Alpha Blockers on Prostate-specific Antigen (PSA) Change in Men With Lower Urinary Tract Symptoms (LUTS)||Completed|||174|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 23:06:27.561861|2018-05-31 23:06:27.561861
NCT01250470|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2017-02-24|2010-11-29|2010-11-30|Estimate|||||||2017-02-24|2017-02-27|Actual|September 5, 2012|Actual|2012-09-05|February 2017|2017-02-28|May 29, 2014|Actual|2014-05-29|May 29, 2014|Actual|2014-05-29||Interventional|||Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma|Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Survivin-Positive Malignant Gliomas|Completed||Phase 1|9|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 23:06:27.623933|2018-05-31 23:06:27.623933
NCT01250457|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-10-29|2010-11-29|2010-11-30|Estimate|||||||2012-10-29|2012-10-30|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Topical Timolol for the Treatment of Benign Vascular Periocular Lesions|Topical Timolol for the Treatment of Benign Vascular Periocular Lesions|Withdrawn||Phase 4|0|Actual|Loyola University||1||Unknown, PI has left the institution. There was no enrollment.|f||||f||||||||||2018-05-31 23:06:27.705969|2018-05-31 23:06:27.705969
NCT01250444|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|March 2009||2009-03-31|October 2010|2010-10-31||||July 2010|Actual|2010-07-31||Interventional|TREMVEN||Effects of Inspiratory Muscle Training on Cardiovascular Function in Hypertension.|Inspiratory Muscle Training: Effects on Blood Pressure, Heart Rate Variability and Functional Capacity in Hypertensive Patients.|Unknown status|Active, not recruiting|N/A|14|Anticipated|Federal University of Health Science of Porto Alegre||1|||f||||t||||||||||2018-05-31 23:06:27.767814|2018-05-31 23:06:27.767814
NCT01250431|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2018-04-23|2010-11-29|2010-11-30|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2010|Actual|2010-11-30|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Gene Expression Correlates of Post-Traumatic Stress Disorder (PTSD) Symptom Change After EFT (Emotional Freedom Techniques)|Gene Expression Correlates of PTSD Symptom Change After EFT (Emotional Freedom Techniques): A Randomized Controlled Trial|Completed||Early Phase 1|18|Actual|Soul Medicine Institute||2|||f||||f||||||||||2018-05-31 23:06:27.834159|2018-05-31 23:06:27.834159
NCT01250418|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2014-07-23||2014-08-18|2010-11-29|2010-11-30|Estimate|2014-08-18|2014-08-28|Estimate||||2014-08-18|2014-08-28|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||SNAP VS BIS(OAA/S) Scale During a Sedation Regimen With and Without Ketamine|A Comparison Between the Correlation of the Bispectral Index Versus Snap Index With the Observer's Assessment of Alertness and Sedation (OAA/S) Scale During a Sedation Regimen With and Without Ketamine|Terminated||N/A|25|Actual|Northwestern University||2||Monitor manufacturer stopped marketing plan for the product.|f||||f||||||||||2018-05-31 23:06:27.904635|2018-05-31 23:06:27.904635
NCT01250405|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2014-04-04|2010-11-29|2010-11-30|Estimate|||||||2014-04-04|2014-04-07|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ECIRA||Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients|Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients|Completed||Phase 4|23|Actual|Laval University||2|||f||||f||||||||||2018-05-31 23:06:28.16534|2018-05-31 23:06:28.16534
NCT01250392|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-05-16|2010-11-29|2010-11-30|Estimate|||||||2012-05-16|2012-05-18|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Effect of Active Choice on Nurse Visit Participation|The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening and Nurse Visit Participation|Completed||N/A|3500|Actual|National Bureau of Economic Research, Inc.||2|||f||||t||||||||||2018-05-31 23:06:28.219776|2018-05-31 23:06:28.219776
NCT01250379|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|2015-06-05||2016-01-12|2010-11-26|2010-11-30|Estimate|2015-06-05|2015-06-30|Estimate||||2016-01-12|2016-02-11|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|March 2015|Actual|2015-03-31|December 2013|Actual|2013-12-31||Interventional||Intent-to-treat (ITT) population: all randomized participants.|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)|A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizumab in Combination With Chemotherapy for Patients With Locally Recurrent or Metastatic Breast Cancer After First-line Chemotherapy and Bevacizumab Treatment|Completed||Phase 3|494|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:06:28.375413|2018-05-31 23:06:28.375413
NCT01250366|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-07-11|2010-11-29|2010-11-30|Estimate|||||||2012-07-11|2012-07-12|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects|A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects|Completed||Phase 1|70|Actual|Bristol-Myers Squibb||7|||f||||t||||||||||2018-05-31 23:06:30.330463|2018-05-31 23:06:30.330463
NCT01250353|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|June 2006||2006-06-30|December 2009|2009-12-31|July 2009|Actual|2009-07-31|June 2007|Actual|2007-06-30||Interventional|||The Use of Natural Latex Biomembrane in Ocular Surface Reconstruction|The Use of Natural Latex Biomembrane in Ocular Surface Reconstruction and Pterygium|Completed||Phase 2|127|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:06:30.505375|2018-05-31 23:06:30.505375
NCT01250340|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-11-27|2010-11-29|2010-11-30|Estimate|||||||2012-11-27|2012-11-28|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|January 2011|Actual|2011-01-31||Interventional|||Type 2 Diabetes Mellitus and Atherosclerosis|Type 2 Diabetes Mellitus: Role of Inflammation and Innate Immunity in The Pathogenesis of Endothelial Dysfunction and Atherosclerosis|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 23:06:30.583376|2018-05-31 23:06:30.583376
NCT01250327|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-27|||2017-10-16|2010-11-29|2010-11-30|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2009||2009-03-31|October 2017|2017-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|REVALV||Medico-economic Evaluation of a Non-chirurgical Pulmonary Valve Replacement (REVALV)|Medico-economic Evaluation of a Non-chirurgical Pulmonary Valve Replacement for the Treatment of Lesions of the Ventricular Outflow Tract.|Completed||N/A|93|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 23:06:30.673104|2018-05-31 23:06:30.673104
NCT01250314|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-27|||2012-07-01|2010-11-27|2010-11-30|Estimate|||||||2012-07-01|2012-07-03|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|OSTEHOM||Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density|Radiological, Biological, Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density|Completed||N/A|79|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:06:30.746753|2018-05-31 23:06:30.746753
NCT01250301|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-07-16|2010-11-29|2010-11-30|Estimate|||||||2012-07-16|2012-07-17|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|Denic||De-nicotinised Cigarettes Study|Complementing Current NHS Stop Smoking Service Treatments for Smokers With Behavioural Replacement: The Role of De-nicotinised Cigarettes|Completed||N/A|200|Actual|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 23:06:30.812244|2018-05-31 23:06:30.812244
NCT01250288|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-12-20|2010-11-29|2010-11-30|Estimate|||||||2012-12-20|2012-12-24|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Observational|||Usage of Health Information Exchange (HIE) Technologies|Patient Adoption and Use of Health Information Exchange (HIE) Technologies|Completed|||7800|Anticipated|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-05-31 23:06:30.88472|2018-05-31 23:06:30.88472
NCT01250275|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2013-03-25|2010-11-29|2010-11-30|Estimate|||||||2013-03-25|2013-03-27|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease|Effects of Canola Oil on Blood Vessel Function in Peripheral Arterial Disease (PAD)|Completed||N/A|53|Actual|University of Manitoba||7|||f||||f||||||||||2018-05-31 23:06:31.017532|2018-05-31 23:06:31.017532
NCT01250262|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2014-02-12|2010-11-29|2010-11-30|Estimate|||||||2014-02-12|2014-02-14|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Resistance Exercise Effects on Fear Avoidance and Physical Function in Obese Older Adults With Low Back Pain|Resistance Exercise Effects on Fear Avoidance Beliefs and Physical Function in Obese, Older Adults With Chronic Low Back Pain|Completed||N/A|72|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 23:06:31.114237|2018-05-31 23:06:31.114237
NCT01250249|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.|A Randomized, Open Label, Single-period, Single-treatment, Controlled Multi Center Phase Iii Study of Comparing Safety and Reactogenecity of Lyophilized BCG Vaccine ip (0.1 mg in 0.1 ml) of Green Signal Bio Pharma Private Limited India With BCG Vaccine (0.1 mg in 0.1 ml) of Serum Institute of India Limited (SIIL),India in 120 Healthy Children.|Completed||Phase 3|120|Actual|Green Signal Biopharma Private Limited||1|||f||||t||||||||||2018-05-31 23:06:31.188234|2018-05-31 23:06:31.188234
NCT01250236|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-12-02|2010-11-29|2010-11-30|Estimate|||||||2010-12-02|2010-12-03|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Effect of Brimonidine on Corneal Thickness|Effect of Brimonidine on Corneal Thickness|Unknown status|Recruiting||10|Anticipated|Augenarztpraxis Breisach|||2||f||||f||||||||||2018-05-31 23:06:31.248142|2018-05-31 23:06:31.248142
NCT01250223|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2016-01-05|2010-11-29|2010-11-30|Estimate|||||||2016-01-05|2016-01-06|Estimate|February 2003||2003-02-28|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|May 2008|Actual|2008-05-31||Observational|||Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)|F2-PROTOCOL: Prospective Collection of Data of Possible Prognostic Relevance in Patients With Follicular Lymphoma|Unknown status|Active, not recruiting||1093|Actual|Associazione Angela Serra per la ricerca sul cancro|||||f||||f||||||Samples Without DNA|"~     Formalin-fixed tissue for central diagnostic pathology review~   "|||2018-05-31 23:06:31.332683|2018-05-31 23:06:31.332683
NCT01250210|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration|Evaluation of Pharmacodynamic Effects on Ovulation Suppression and Cycle Control of Three Agile Contraceptive Patches Containing Different Doses of Ethinyl Estradiol(EE)During Three Cycles of Administration|Completed||Phase 2|123|Actual|Agile Therapeutics||3|||f||||f||||||||||2018-05-31 23:06:31.468667|2018-05-31 23:06:31.468667
NCT01250197|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-12-20|2010-11-29|2010-11-30|Estimate|||||||2010-12-20|2010-12-22|Estimate|November 2010||2010-11-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Formulation Comparison in Normal Volunteers|A Double-masked, Crossover Study Assessing the Ocular and Systemic Safety and Systemic Absorption of Two Formulations of 0.5% AR-12286 Ophthalmic Solution in Normal Volunteers|Completed||Phase 1|18|Anticipated|Aerie Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:06:31.580501|2018-05-31 23:06:31.580501
NCT01250184|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-27|2014-09-27||2014-10-04|2010-11-27|2010-11-30|Estimate|2014-10-04|2014-10-10|Estimate||||2014-10-04|2014-10-10|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional||"This was calculated with the software Sample Size Javeriana University it was took in to account a error type I of 0.05, type II of 0.2, number of measurements before randomization = 1, after performing the randomization = 2, correlation between measurements of 0.6, clinically important difference of 0.35, for a number of patients = 45 each"|Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.|Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial.|Completed||Phase 4|127|Actual|Grupo Rehabilitacion en Salud|The therapists were not the same throughout the investigation, however all were standardized to interventions; especilaistas doctors who applied the injections were different. No specific measure of patient-centered operation is used.|3|||f||||f||||||||||2018-05-31 23:06:31.657823|2018-05-31 23:06:31.657823
NCT01250171|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2012-09-11||2012-12-04|2010-11-29|2010-11-30|Estimate|2012-12-04|2013-01-07|Estimate||||2012-12-04|2013-01-07|Estimate|November 2010||2010-11-30|December 2012|2012-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients|A Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Intravenous Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Syndrome|Completed||Phase 2|72|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:06:32.263432|2018-05-31 23:06:32.263432
NCT01250158|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2013-03-28|2010-11-29|2010-11-30|Estimate|||||||2013-03-28|2013-03-29|Estimate|September 2010||2010-09-30|March 2013|2013-03-31||||January 2014|Anticipated|2014-01-31||Interventional|PILP FiM||Liver-PILP First-in-Man|First In-vivo Trial of the Liver Percutaneous Isolated Localized Perfusion (PILP) Set for the Treatment of Liver Metastases|Unknown status|Recruiting|N/A|6|Anticipated|Medical Device Works NV SA||1|||f||||t||||||||||2018-05-31 23:06:32.67834|2018-05-31 23:06:32.67834
NCT01250145|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2012-09-21||2012-09-21|2010-11-29|2010-11-30|Estimate|2012-09-21|2012-10-23|Estimate||||2012-09-21|2012-10-23|Estimate|November 2010||2010-11-30|September 2012|2012-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women|A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women|Completed||Phase 1|251|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:06:32.782077|2018-05-31 23:06:32.782077
NCT01250132|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2017-08-17|2010-11-29|2010-11-30|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2010|Actual|2010-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|Endoc-TC||Ante-hypophyseal Dysfunctions in Children Following Moderate to Severe Traumatic Brain Injuries|Are Ante-hypophyseal Dysfunctions in the Acute Phase of Moderate to Severe Traumatic Brain Injury Predictive of Long-term Ante-hypophyseal Sequelae in Children?|Active, not recruiting||N/A|110|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 23:06:33.252196|2018-05-31 23:06:33.252196
NCT01250119|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2015-08-28||2016-02-16|2010-11-29|2010-11-30|Estimate|2015-08-28|2015-10-05|Estimate||||2016-02-16|2016-03-14|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Diagnostic population: All participants newly diagnosed with recurrent or metastatic NSCLC who entered the study and signed the consent form were included in this population.|A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.|Assess the Incidence of Mutations in the Tyrosine Kinase Domain of the Endothelial Growth Factor Receptor in UK Patients With Newly Diagnosed Metastatic or Recurrent Non-small Cell Lung Cancer and to Investigate the Quality of Life of These Patients Undergoing First-line Therapy With Erlotinib.|Completed||Phase 2|688|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:06:33.457243|2018-05-31 23:06:33.457243
NCT01250106|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2011-07-28|2010-11-29|2010-11-30|Estimate|||||||2011-07-28|2011-07-29|Estimate|November 2010||2010-11-30|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications|Phase I Study of Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|German Diabetes Center||2|||f||||f||||||||||2018-05-31 23:06:34.606029|2018-05-31 23:06:34.606029
NCT01250093|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|March 2008||2008-03-31|October 2008|2008-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||"Acupuncture Compared With Sham Acupuncture for Treatment of Chronic Neck Myofascial Pain"||Completed||N/A|||China Medical University Hospital|||||f||||||||||||||2018-05-31 23:06:34.692543|2018-05-31 23:06:34.692543
NCT01250080|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2007||2007-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Gutamine Administration in the Innate Immune System Response in ICU Patients.||Completed||N/A|43|Actual|Hospital Universitari Son Dureta||2|||f||||||||||||||2018-05-31 23:06:34.737277|2018-05-31 23:06:34.737277
NCT01250067|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-26|2010-11-26|2010-11-30|Estimate|||||||2010-11-26|2010-11-30|Estimate|August 2003||2003-08-31|September 2005|2005-09-30||||||||Interventional|||Motor-related Cortical Potential in Patients With Essential Tremor||Completed||N/A|||China Medical University Hospital|||||f||||||||||||||2018-05-31 23:06:34.799896|2018-05-31 23:06:34.799896
NCT01250054|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|2011-07-19||2012-06-26|2010-11-29|2010-11-30|Estimate|2011-07-19|2011-08-12|Estimate||||2012-06-26|2012-06-29|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Comparison of Two Multifocal Contact Lenses||Completed||N/A|17|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:06:34.867109|2018-05-31 23:06:34.867109
NCT01250041|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|||Continuous Saphenous Block Versus Continuous Femoral Block for Total Knee Arthroplasty|Continuous Saphenous Block Vs. Continuous Femoral Block for Total Knee Arthroplasty: Prospective, Randomized, Double Blind Study.|Unknown status|Not yet recruiting|N/A|40|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:06:34.987571|2018-05-31 23:06:34.987571
NCT01250015|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Does Numerical And Pictorial Information On Risk And Benefit Affects The Uptake Of Colorectal Cancer Screening?|THE RESULTS OF A RANDOMISED CONTROLLED QUESTIONNAIRE-BASED TRIAL ON WHETHER PROVISION OF NUMERICAL AND PICTORIAL INFORMATION ON RISK AND BENEFIT AFFECTS THE UPTAKE OF COLORECTAL CANCER SCREENING?|Completed|||400|Actual|County Durham and Darlington NHS Foundation Trust|||2||f||||t||||||||||2018-05-31 23:06:35.061418|2018-05-31 23:06:35.061418
NCT01250002|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-27|2012-03-05||2014-06-25|2010-11-29|2010-11-30|Estimate|2013-06-19|2013-06-21|Estimate||||2014-06-25|2014-06-26|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Lidocaine and Outpatient Gynecologic Laparoscopy|The Effect of Perioperative Systemic Lidocaine on Quality of Recovery After Outpatient Gynecologic Laparoscopy|Completed||N/A|70|Actual|Northwestern University|Quality of recovery (QOR-40) instrument validation was performed in the in-patient setting and formal validation for the outpatient setting is still lacking.|2|||f||||f||||||||||2018-05-31 23:06:35.124363|2018-05-31 23:06:35.124363
NCT01249989|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2017-06-08|2010-11-27|2010-11-30|Estimate|||||||2017-06-08|2017-06-12|Actual|November 2011||2011-11-30|June 2017|2017-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MBC2||Make Better Choices|Make Better Choices (MBC) - Multiple Behavior Change in Diet and Activity|Completed||N/A|212|Actual|Northwestern University||3|||f||||t|f|f||||||No||2018-05-31 23:06:35.33999|2018-05-31 23:06:35.33999
NCT01249976|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-27|||2012-07-25|2010-11-27|2010-11-30|Estimate|||||||2012-07-25|2012-07-26|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Incat||Recent Techniques for Diagnosing Central Venous Catheter-related Bloodstream Infections in Children|Evaluation of Recent Techniques for Diagnosing Central Venous Catheter-related Bloodstream Infections in Critically Ill Children|Completed||N/A|148|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:06:35.409997|2018-05-31 23:06:35.409997
NCT01249963|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2012-06-21|2010-11-26|2010-11-30|Estimate|||||||2012-06-21|2012-06-22|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Enteral Nutrition Product in Mild Acute Pancreatitis|Evaluation of Oral Enteral Nutrition Supplement in Patients With Mild Acute Pancreatitis|Unknown status|Recruiting|N/A|40|Anticipated|Vegenat, S.A.||2|||f||||f||||||||||2018-05-31 23:06:35.603641|2018-05-31 23:06:35.603641
NCT01249937|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2011-02-08|2010-11-26|2010-11-30|Estimate|||||||2011-02-08|2011-02-09|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Interventional|STAR||Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab|Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab|Unknown status|Recruiting|Phase 2|30|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:06:35.757246|2018-05-31 23:06:35.757246
NCT01249924|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2013-12-17|2010-11-26|2010-11-30|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effectiveness of Perioperative CPAP to Reduce Obstructive Sleep Apnea Related Adverse Events|The Effectiveness of Perioperative CPAP to Reduce the Occurrence of Sleep Apnea Related Adverse Events in Surgical Patients With Obstructive Sleep Apnea|Completed||N/A|120|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:06:35.853067|2018-05-31 23:06:35.853067
NCT01249911|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-28|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Lactobacillus Reuteri DSM 17938 and Prevention of Respiratory and Gastrointestinal Infections in Mexican Infants|Efficacy & Cost-Effectiveness of Lactobacillus Reuteri DSM 17938 Administration to Prevent the Risk of Respiratory or Gastrointestinal Infections in Child Day Care Centers: A Randomized, Double Blind, Placebo Control Trial (RDDCT).|Unknown status|Not yet recruiting|Phase 3|269|Anticipated|National Institute of Pediatrics, Mexico||2|||f||||t||||||||||2018-05-31 23:06:35.926371|2018-05-31 23:06:35.926371
NCT01249898|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-28|||2014-03-03|2010-11-29|2010-11-30|Estimate|||||||2014-03-03|2014-03-04|Estimate||||February 2014|2014-02-28||||||||Observational|||The Treatment and Intra-operative Imaging of Scaphoid Fracture Reduction and Fixation||Unknown status|Recruiting||||Hadassah Medical Organization|||||f||||||||||||||2018-05-31 23:06:35.99509|2018-05-31 23:06:35.99509
NCT01249885|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-28|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Observational|||Implications of Pacifier Use in Israeli Children|Observational Study - Pacifier Use in Israeli Children|Unknown status|Not yet recruiting||400|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 23:06:36.050056|2018-05-31 23:06:36.050056
NCT01249872|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2013-03-31||2013-06-18|2010-11-29|2010-11-30|Estimate|2013-06-18|2013-07-24|Estimate||||2013-06-18|2013-07-24|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens|Postoperative Thoracic Epidural Analgesia in Super Obese Patients (~BMI 60 kg m-2) Undergoing Open Weight Loss Surgery :Does the Addition of Morphine to 0.1% and 0.2% Levobupivacaine Affect Postoperative Pain Relief, Perioperative Lung Function, Return of Normal Gastrointestinal Mobility and Ambulation?|Completed||Phase 2/Phase 3|96|Actual|University of Patras|"Patients in groups A and D did not receive epidural morphine intraoperatively.~We excluded patients aged > 50 yr as increasing the age of morbidly obese patients, might have increased the risk of perioperative complications"|6|||f||||f||||||||||2018-05-31 23:06:36.129798|2018-05-31 23:06:36.129798
NCT01249859|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2014-12-08|2010-11-29|2010-11-30|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|ADCI001||Prognosis of Signet Ring Cells in Upper Digestive Neoplasms|Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas?|Completed|||2500|Actual|University Hospital, Lille|||2||f||||t||||||||||2018-05-31 23:06:36.789281|2018-05-31 23:06:36.789281
NCT01249846|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-28|||2013-01-16|2010-11-29|2010-11-30|Estimate|||||||2013-01-16|2013-01-17|Estimate|December 2010||2010-12-31|January 2013|2013-01-31||||||||Interventional|||The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis|The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis|Completed||Phase 3|||Dexcel Pharma Technologies Ltd.||2|||f||||f||||||||||2018-05-31 23:06:37.9055|2018-05-31 23:06:37.9055
NCT01249833|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|2016-11-22||2017-01-18|2010-11-26|2010-11-30|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|November 2010||2010-11-30|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|FOCUS||Effect of Oseltamivir on Cognitive Function in Subjects With Influenza|Randomised, Open-label, Multi-Centre, Phase IV Study Assessing the Effect of Oseltamivir Treatment on Cognitive Function in Subjects With Confirmed Influenza Virus Infection|Completed||Phase 4|122|Actual|Trial Management Group Inc.||2|||f||||f||||||||Undecided||2018-05-31 23:06:37.991338|2018-05-31 23:06:37.991338
NCT01249820|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-01-31|2010-11-26|2010-11-30|Estimate|||||||2013-01-31|2013-02-01|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ANIDULAPK||Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease|Pharmacokinetics of Anidulafungin Given Intravenously as Antifungal Prophylaxis to Recipients of an Allogeneic Haematopoietic Stem Cell Transplant Following Myeloablative Chemotherapy or Patients Receiving Intensive Chemotherapy for AML-MDS|Completed||Phase 2|26|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 23:06:38.516868|2018-05-31 23:06:38.516868
NCT01249807|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|October 2010||2010-10-31|November 2010|2010-11-30||||October 2010|Anticipated|2010-10-31||Observational|||Taiwanese People's Willingness to Participate in Cancer Screening: Colon, Oral Cavity, Breast, and Cervical Cancer Screening||Unknown status|Active, not recruiting||100|Anticipated|China Medical University Hospital|||1||f||||t||||||||||2018-05-31 23:06:38.590557|2018-05-31 23:06:38.590557
NCT01249794|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2018-03-20|2010-11-29|2010-11-30|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2010||2010-09-30|March 2018|2018-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CPAP-CCH||Non Invasive Ventilation After Cardiac Surgery|Effectiveness of Continuous Positive Airway Pressure Outside the Intensive Care Unit After Cardiac Surgery|Completed||N/A|||Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-05-31 23:06:38.732521|2018-05-31 23:06:38.732521
NCT01249781|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-26|2010-11-26|2010-11-30|Estimate|||||||2010-11-26|2010-11-30|Estimate|September 2010||2010-09-30|November 2010|2010-11-30||||||||Observational|||The Related Factors With Resilience in Caregivers Whose Child With Leukemia||Unknown status|Enrolling by invitation||50|Anticipated|China Medical University Hospital|||1||f||||||||||||||2018-05-31 23:06:38.808657|2018-05-31 23:06:38.808657
NCT01249586|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|ELBPS||E-learning: Teaching of Blindness Prevention|E-learning as a Complement to Traditional Teaching of Blindness Prevention|Completed||Phase 3|||Clinica Oftamologica Zona Sul||1|||f||||f||||||||||2018-05-31 23:06:40.902094|2018-05-31 23:06:40.902094
NCT01249768|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2016-03-30|2010-11-26|2010-11-30|Estimate|||||||2016-03-30|2016-03-31|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Observational|PADDO||Parkinson's Disease, Diagnostic Observations (PADDO)|Observational Study Assessing the Diagnostic Contribution of 3-Tesla MRI, CSF Analysis and a Second Opinion in a Specialized Movement Disorder Centre, in Differentiating Between Parkinson's Disease and Atypical Parkinsonism|Recruiting|||150|Anticipated|Radboud University|||1||f||||f||||||Samples With DNA|"~     Whole blood, cerebrospinal fluids~   "|||2018-05-31 23:06:38.8627|2018-05-31 23:06:38.8627
NCT01249755|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2012-08-09|2010-11-26|2010-11-30|Estimate|||||||2012-08-09|2012-08-10|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Observational|||International Validation of a Delirium Prediction Model for ICU Patients|International Validation of a Delirium Prediction Model for ICU Patients (PRE-DELIRIC) in ICUs; a Multicentre Trial.|Completed|||2000|Actual|Radboud University|||1||f||||f||||||||||2018-05-31 23:06:38.92558|2018-05-31 23:06:38.92558
NCT01249742|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-26|2010-11-26|2010-11-30|Estimate|||||||2010-11-26|2010-11-30|Estimate|February 2009||2009-02-28|November 2010|2010-11-30|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|||Sugarsquare. Focus on the Adolescent: Digital Treatment of Type 1 Diabetes Through the Internet|Sugarsquare. Focus on the Adolescent: Digital Treatment of Type 1 Diabetes Through the Internet|Completed||N/A|65|Actual|Radboud University|||||f||||f||||||||||2018-05-31 23:06:38.984354|2018-05-31 23:06:38.984354
NCT01249729|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2010-11-26|2010-11-26|2010-11-30|Estimate|||||||2010-11-26|2010-11-30|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|September 2009|Anticipated|2009-09-30|||||Observational|||3D Reconstructed Image Processin by Computer Proram From MRI Data|3D Reconstructed Image Processin by Computer Proram|Unknown status|Not yet recruiting||100|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 23:06:39.044062|2018-05-31 23:06:39.044062
NCT01249716|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2012-03-27|2010-11-29|2010-11-30|Estimate|||||||2012-03-27|2012-03-29|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|OHE||Follow-up Home Visits With Nutrition|Follow-up Home Visits With Nutrition (OHE)|Completed||N/A|152|Actual|University of Copenhagen|||||f||||t||||||||||2018-05-31 23:06:39.098642|2018-05-31 23:06:39.098642
NCT01249703|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2020|Anticipated|2020-01-31|October 2010|Actual|2010-10-31||Observational|||The Early Diagnosis and Warning Role of Erectile Dysfunction|The Early Diagnosis and Warning Role of Erectile Dysfunction:a Multi-institutional Clinical Study.|Recruiting|||150000|Anticipated|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 23:06:39.165019|2018-05-31 23:06:39.165019
NCT01249690|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|June 2014|Anticipated|2014-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma|Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes|Unknown status|Recruiting|Phase 4|100|Anticipated|Second Military Medical University||2|||f||||t||||||||||2018-05-31 23:06:39.23755|2018-05-31 23:06:39.23755
NCT01249677|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2009||2009-01-31|October 2008|2008-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes|Chronic Reduction of Fasting Gylcaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes|Completed||Phase 4|14|Actual|Ruhr University of Bochum||1|||f||||f||||||||||2018-05-31 23:06:39.320299|2018-05-31 23:06:39.320299
NCT01249664|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|2014-02-16||2014-04-17|2010-11-26|2010-11-30|Estimate|2014-02-16|2014-04-01|Estimate||||2014-04-17|2014-05-05|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|Myrror||VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)|A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia|Completed||Phase 3|122|Actual|Bayer||2|||f||||t||||||||||2018-05-31 23:06:39.443762|2018-05-31 23:06:39.443762
NCT01249651|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|2012-06-08||2012-10-01|2010-11-29|2010-11-30|Estimate|2012-10-01|2012-10-31|Estimate||||2012-10-01|2012-10-31|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole|An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole.|Completed||Phase 4|101|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 23:06:40.328633|2018-05-31 23:06:40.328633
NCT01249638|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2011-03-11|2010-11-29|2010-11-30|Estimate|||||||2011-03-11|2011-03-14|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|December 2016|Anticipated|2016-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC|Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 3|516|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 23:06:40.529181|2018-05-31 23:06:40.529181
NCT01249625|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2018-03-01|2010-11-29|2010-11-30|Estimate|||||||2018-03-01|2018-03-05|Actual|December 2010||2010-12-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ResPECT||The Respiratory Protection Effectiveness Clinical Trial|Incidence of Respiratory Illness in Outpatient Healthcare Workers Who Wear Respirators or Medical Masks While Caring for Patients|Active, not recruiting||N/A|1600|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 23:06:40.633737|2018-05-31 23:06:40.633737
NCT01249612|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2012-07-18|2010-11-29|2010-11-30|Estimate|||||||2012-07-18|2012-07-19|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|IS||Knee Joint Icing and Knee-extension Strength|No Effect of Knee Joint Icing on Knee-extension Strength After Total Knee Arthroplasty. A Randomized Cross-over Study|Terminated||Phase 1|20|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 23:06:40.75876|2018-05-31 23:06:40.75876
NCT01249599|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-12-10|2010-11-29|2010-11-30|Estimate|||||||2012-12-10|2012-12-11|Estimate|November 2010||2010-11-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Stress-induced Vascular Dysfunction: Evaluation of Endothelial Function in a Cohort of Patients With Takotsubo Syndrome|Stress-induced Vascular Dysfunction: Evaluation of Endothelial Function in a Cohort of Patients With Takotsubo Syndrome|Completed|||44|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 23:06:40.834153|2018-05-31 23:06:40.834153
NCT01249573|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-06-09|2010-11-25|2010-11-30|Estimate|||||||2011-06-09|2011-06-10|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||The Effect of Fascia Therapy and Transcutaneous Fibrolysis on Acute Ankle Sprain|The Effect of Fascia Therapy and Transcutaneous Fibrolysis on Acute Ankle Sprain in Young Adults.|Completed||N/A|60|Anticipated|University Ghent||3|||f||||f||||||||||2018-05-31 23:06:40.957074|2018-05-31 23:06:40.957074
NCT01249560|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2011||2011-01-31|December 2009|2009-12-31|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Observational|||Impact of Raltegravir on the Viral Reservoirs|Impact of Raltegravir on the Viral Reservoirs|Unknown status|Not yet recruiting||20|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||||||2018-05-31 23:06:41.058034|2018-05-31 23:06:41.058034
NCT01249547|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2017-04-24|2010-11-29|2010-11-30|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2010||2010-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Nasopharyngeal Carcinoma (NPC) Axitinib|Phase 2 Study of Axitinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|37|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 23:06:41.125565|2018-05-31 23:06:41.125565
NCT01249534|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-12-09|2010-11-29|2010-11-30|Estimate|||||||2010-12-09|2010-12-10|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Diagnostic Value of C-reactive Protein for Detection of Postoperative Inflammatory Complications After Gastroesophageal Cancer Surgery||Completed|||200|Anticipated|Cantonal Hospital of St. Gallen|||1||f||||f||||||||||2018-05-31 23:06:41.196916|2018-05-31 23:06:41.196916
NCT01249521|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-29|||2010-11-29|2010-11-29|2010-11-30|Estimate|||||||2010-11-29|2010-11-30|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|November 2012|Anticipated|2012-11-30|November 2011|Anticipated|2011-11-30||Interventional|Vengeance||Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer|Open Label Phase II Study Evaluating the Combination of Bevacizumab and AMG386 Without Chemotherapy as First Line Treatment of Advanced Colorectal Cancer|Unknown status|Recruiting|Phase 2|40|Anticipated|Austin Health|||||f||||t||||||||||2018-05-31 23:06:41.252152|2018-05-31 23:06:41.252152
NCT01249508|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-12-21|2010-11-26|2010-11-29|Estimate|||||||2010-12-21|2010-12-22|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Nutrition Labeling Program to Promote Healthy Dietary Patterns|A University Canteen-based Labeling Program to Promote Healthy Dietary Patterns|Completed||N/A|474|Actual|University Ghent||1|||f||||f||||||||||2018-05-31 23:06:41.317209|2018-05-31 23:06:41.317209
NCT01249495|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-12-09|2010-11-26|2010-11-29|Estimate|||||||2010-12-09|2010-12-10|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|November 2013|Anticipated|2013-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Treatment of Chronic Leg Ulcer in Outpatient's Department and i Primary Care - Wound Size and Inflammation|Treatment of Chronic Legg Ulcer in Outpatient's Department and i Primary Care - Wound Size and Inflammation|Unknown status|Recruiting|N/A|50|Anticipated|Oslo University Hospital|||||f||||f||||||||||2018-05-31 23:06:41.457752|2018-05-31 23:06:41.457752
NCT01249482|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-12-10|2010-11-25|2010-11-29|Estimate|||||||2010-12-10|2010-12-13|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|August 2012|Anticipated|2012-08-31|||||Observational|||Symptom Assessment for GERD Patients Receiving H. Pylori Eradication|Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 23:06:41.533471|2018-05-31 23:06:41.533471
NCT01249469|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-11-25|2010-11-25|2010-11-29|Estimate|||||||2010-11-25|2010-11-29|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011|Evaluate the Lightening Effect of the Whitening Cosmetic Product BEX-2011 on Solar Lentigines by Harmonic Generation Microscopy|Unknown status|Recruiting|N/A|40|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 23:06:41.603474|2018-05-31 23:06:41.603474
NCT01249456|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2015-06-24|2010-11-26|2010-11-29|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2006||2006-05-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients|An Observational, Multicenter Study on the Safety and Efficacy of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients Who Completed Adjuvant Tamoxifen or Toremifen Treatment|Completed|||392|Actual|Novartis|||1||f||||||||||||||2018-05-31 23:06:41.679316|2018-05-31 23:06:41.679316
NCT01249443|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2017-12-19|2010-11-25|2010-11-29|Estimate|||||||2017-12-19|2017-12-21|Actual|November 2013|Actual|2013-11-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|May 2016|Actual|2016-05-31||Interventional|||Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection|A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection|Terminated||Phase 1|17|Actual|AIDS Malignancy Consortium||1||Inadequate accrual rate|f||||f|t|f|||f|||||2018-05-31 23:06:41.735697|2018-05-31 23:06:41.735697
NCT01249430|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2017-09-20|2010-11-25|2010-11-29|Estimate|||||||2017-09-20|2017-09-21|Actual|January 20, 2011|Actual|2011-01-20|September 2017|2017-09-30|May 24, 2013|Actual|2013-05-24|May 24, 2013|Actual|2013-05-24||Interventional|||Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:06:41.843823|2018-05-31 23:06:41.843823
NCT01249417|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|2016-08-30|2015-05-07|2016-12-08|2010-11-25|2010-11-29|Estimate|2016-12-08|2017-02-03|Estimate|2015-05-07|2015-05-25|Estimate|2016-12-08|2017-02-03|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional||Baseline characteristic values were based on the ITT population, defined as all randomised subjects who received at least one injection of study treatment and who had a MAS score in the GSC assessed both at baseline and at Week 4.|Dysport® Pediatric Lower Limb Spasticity Study|A Phase III, Multicentre, Double Blind, Prospective, Randomised, Placebo Controlled Study Assessing the Efficacy and Safety of DYSPORT® Used in the Treatment of Lower Limb Spasticity in Children With Dynamic Equinus Foot Deformity Due to Cerebral Palsy|Completed||Phase 3|241|Actual|Ipsen||3|||f||||f||||||||||2018-05-31 23:06:41.977796|2018-05-31 23:06:41.977796
NCT01249079|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-30|2010-11-26|2010-11-29|Estimate|||||||2010-11-30|2010-12-01|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||December 2013|Anticipated|2013-12-31||Observational|||Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan|Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan|Unknown status|Recruiting||600|Anticipated|China Medical University Hospital|||1||f||||||||||||||2018-05-31 23:06:47.671043|2018-05-31 23:06:47.671043
NCT01249404|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|2017-07-03|2015-05-07|2017-11-08|2010-11-25|2010-11-29|Estimate|2017-09-14|2017-10-17|Actual|2015-05-07|2015-05-25|Estimate|2017-11-08|2017-12-11|Actual|March 2011||2011-03-31|November 2017|2017-11-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional||The ITT population included all randomised subjects who received at least 1 injection of study medication and who had a Modified Ashworth Scale (MAS) score in the gastrocnemius-soleus (GSC) assessed at baseline (pre-treatment) and at Week 4.|Dysport® Adult Lower Limb Spasticity Study|A Phase III, Multicentre, Double-blind, Prospective, Randomized, Placebo-controlled Study, Assessing the Efficacy and Safety of Dysport® Used for the Treatment of Lower-limb Spasticity in Adult Subjects With Hemiparesis Due to Stroke or Traumatic Brain Injury|Completed||Phase 3|388|Actual|Ipsen||3|||f||||t||||||||||2018-05-31 23:06:42.754403|2018-05-31 23:06:42.754403
NCT01249391|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2016-02-15|2010-11-26|2010-11-29|Estimate|||||||2016-02-15|2016-02-17|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|SPLINTOA||Splinting to Treat Hand Osteoarthritis|Splinting to Treat Interphalangeal Joint Deformity in Hand Osteoarthritis(Splint OA Study)|Completed||Phase 2|45|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 23:06:43.902|2018-05-31 23:06:43.902
NCT01249378|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|LIPINFLOX||Metabolic Impact of Fat Digestion|Metabolic Impact of the Digestion of Fat in Emulsified vs Non-emulsified Form in Lean or Obese Volunteers|Unknown status|Recruiting|N/A|20|Anticipated|Hospices Civils de Lyon||3|||f||||t||||||||||2018-05-31 23:06:43.972247|2018-05-31 23:06:43.972247
NCT01249365|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2017-03-02|2010-11-26|2010-11-29|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2011||2011-01-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study|Completed||Phase 3|199|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 23:06:44.044738|2018-05-31 23:06:44.044738
NCT01249352|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2014-01-03|2010-11-26|2010-11-29|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|NICE||A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer|A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer|Completed||Phase 2/Phase 3|104|Actual|Eurofarma Laboratorios S.A.||2|||f||||f||||||||||2018-05-31 23:06:44.137006|2018-05-31 23:06:44.137006
NCT01249339|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|May 2004||2004-05-31|November 2010|2010-11-30|April 2005|Actual|2005-04-30|August 2004|Actual|2004-08-31||Interventional|SMWS03||In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus|In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Four Brands of Swedish 'Snus' in Regular Snus Users|Completed||Phase 1|32|Actual|Contract Research Organization el AB||4|||f||||f||||||||||2018-05-31 23:06:44.239965|2018-05-31 23:06:44.239965
NCT01249326|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-07-13|2010-11-25|2010-11-29|Estimate|||||||2012-07-13|2012-07-16|Estimate|December 2010||2010-12-31|July 2012|2012-07-31|June 2016|Anticipated|2016-06-30|December 2013|Anticipated|2013-12-31||Interventional|BIBOP||"Protein Need and Interest of  Quick Proteins  to the Obese Subject Operated by Bariatric Surgery (BIBOP)"|"Protein Need and Interest of  Quick Proteins  to the Obese Subject Operated by Bariatric Surgery (BIBOP)"|Unknown status|Recruiting|N/A|70|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:06:44.323271|2018-05-31 23:06:44.323271
NCT01249313|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2011-06-22|2010-11-26|2010-11-29|Estimate|||||||2011-06-22|2011-06-27|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|April 2012|Anticipated|2012-04-30||Observational|||Risk Factor and Outcome of Candidemia||Unknown status|Not yet recruiting||1000|Anticipated|China Medical University Hospital|||||f||||||||||||||2018-05-31 23:06:44.389608|2018-05-31 23:06:44.389608
NCT01249300|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|December 2010||2010-12-31|November 2010|2010-11-30||||||||Observational|||Comparison of Ultrasound and Videofluoroscopic Imaging Techniques in Diagnosing Dysphagia in Stroke Patients|Comparison of Ultrasound and Videofluoroscopic Imaging Techniques in Diagnosing Dysphagia in Stroke Patients|Unknown status|Not yet recruiting||30|Anticipated|China Medical University Hospital|||1||f||||||||||||||2018-05-31 23:06:44.433376|2018-05-31 23:06:44.433376
NCT01249287|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-25|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|April 2009||2009-04-30|November 2010|2010-11-30||||||||Observational|||FMRI in Monitoring Intracerebral Stem Cell Implantation for Chronic Stroke Patients||Unknown status|Active, not recruiting||30|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 23:06:44.494662|2018-05-31 23:06:44.494662
NCT01249274|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2016-01-05||2017-02-24|2010-11-24|2010-11-29|Estimate|2016-10-19|2016-12-12|Estimate||||2017-02-24|2017-03-28|Actual|February 2011|Actual|2011-02-28|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||All 25 in each study group were included in intention-to-treat and safety analyses.|Progesterone for Postpartum Cocaine Relapse|Progesterone for Postpartum Cocaine Relapse|Completed||N/A|50|Actual|Yale University|Women seen only once per week leading to reliance on self-reports more than urine, results of which differed; post-partum women with cocaine use disorder have other issues affecting likelihood of cocaine use; missed visits may have biased results.|2|||f||||t||||||||Yes|Data request should be made to the PI|2018-05-31 23:06:44.561752|2018-05-31 23:06:44.561752
NCT01249261|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2011-07-14||2011-10-27|2010-11-24|2010-11-29|Estimate|2011-09-15|2011-10-26|Estimate||||2011-10-27|2011-11-02|Estimate|October 2001||2001-10-31|October 2011|2011-10-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover|A 1-year, Risedronate-free, Multicenter, Outpatient, Phase IIIb Extension Study to Assess Bone Turnover Recovery in Women With Postmenopausal Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, and RVE1998080 (no NCT Study Numbers)|Completed||Phase 3|61|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 23:06:45.352784|2018-05-31 23:06:45.352784
NCT01249248|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2012-04-10|2010-11-26|2010-11-29|Estimate|||||||2012-04-10|2012-04-12|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|November 2010|Actual|2010-11-30||Observational|PACA||PD2i Analysis of Heart Rate Variability in Competitive Sports|PD2i Analysis of Heart Rate Variability in Competitive Sports|Completed|||90|Actual|University of Mississippi Medical Center|||8||f||||t||||||||||2018-05-31 23:06:45.890673|2018-05-31 23:06:45.890673
NCT01249066|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||||||Observational|||Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma|Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma|Unknown status|Recruiting||100|Anticipated|China Medical University Hospital|||||f||||f||||||||||2018-05-31 23:06:47.73156|2018-05-31 23:06:47.73156
NCT01249235|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-24|2010-11-24|2010-11-29|Estimate|||||||2010-11-24|2010-11-29|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery|Prospective Randomized Controlled Trial Comparing Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery|Unknown status|Recruiting|N/A|60|Anticipated|University Health Network, Toronto||2|||f||||||||||||||2018-05-31 23:06:45.953368|2018-05-31 23:06:45.953368
NCT01249222|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasmapheresis|Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasma Therapeutic Exchange|Unknown status|Recruiting|N/A|27|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:06:46.022822|2018-05-31 23:06:46.022822
NCT01249209|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-26|2010-11-26|2010-11-29|Estimate|||||||2010-11-26|2010-11-29|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Outpatient Treatment of Patients With Morbid Obesity - a Two-year Follow up|Qualitative Retrospective Study Where the Intervention Consisted of Group Therapy and Individual Interviews Over a Two-year Period|Completed||N/A|69|Actual|Sykehuset Innlandet HF||1|||f||||f||||||||||2018-05-31 23:06:46.106625|2018-05-31 23:06:46.106625
NCT01249196|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2013-11-25|2010-11-24|2010-11-29|Estimate|||||||2013-11-25|2013-11-26|Estimate|May 2010||2010-05-31|November 2010|2010-11-30||||August 2013|Actual|2013-08-31||Interventional|||A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease||Completed||Phase 3|256|Anticipated|SK Chemicals Co.,Ltd.||4|||f||||||||||||||2018-05-31 23:06:46.164805|2018-05-31 23:06:46.164805
NCT01249183|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2017-09-08|2010-11-24|2010-11-29|Estimate|||||||2017-09-08|2017-09-11|Actual|October 2010||2010-10-31|September 2017|2017-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old|An Open-label, Randomised, Multicentre Study to Evaluate the Immunogenicity and Safety of a Booster Dose of Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Adsorbed Vaccine (REPEVAX) Administered Concomitantly Versus Non-concomitantly With an Influenza Vaccine (VAXIGRIP) to Subjects of 60 Years of Age and Older|Completed||Phase 3|954|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:06:46.235729|2018-05-31 23:06:46.235729
NCT01249170|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2013-11-15|2010-11-26|2010-11-29|Estimate|||||||2013-11-15|2013-11-19|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows|Communication Skills Training and Competency Assessment for Pulmonary and Critical Care Medicine Fellows|Completed||N/A|16|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 23:06:46.346404|2018-05-31 23:06:46.346404
NCT01249157|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2015-10-17||2015-11-19|2010-11-24|2010-11-29|Estimate|2015-11-19|2015-12-24|Estimate||||2015-11-19|2015-12-24|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||The first 5 patients who consent to the study will be intended for training purposes only.|Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast|Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast|Terminated||N/A|6|Actual|Memorial Sloan Kettering Cancer Center|The first 5 patients who consent to the study were used for training purposes only.|1||Lack of accrual|f||||||||||||||2018-05-31 23:06:46.416067|2018-05-31 23:06:46.416067
NCT01249144|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2014-03-17|2010-11-24|2010-11-29|Estimate|||||||2014-03-17|2014-03-18|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Visual and Refractive Outcomes After Implantation of Aspheric IOLs With Different Dioptric Increments and Manufacturing|A Randomized Fellow-eye Controlled Clinical Trial to Compare the Visual and Refractive Outcomes Between Two Aspheric IOLs With Different Dioptric Increments and Manufacturing Tolerances in Patients Undergoing Bilateral Cataract Surgery|Terminated||Phase 4|75|Actual|Lenstec Incorporated||2|||f||||f||||||||||2018-05-31 23:06:46.547657|2018-05-31 23:06:46.547657
NCT01249131|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2016-06-07||2017-07-06|2010-11-24|2010-11-29|Estimate|2016-06-07|2016-07-18|Estimate||||2017-07-06|2017-08-15|Actual|December 1, 2010|Actual|2010-12-01|June 2017|2017-06-30|January 10, 2011|Actual|2011-01-10|January 10, 2011|Actual|2011-01-10||Interventional||All enrolled participants|A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants|A Phase I, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of GDC-0973 in Healthy Subjects|Completed||Phase 1|20|Actual|Genentech, Inc.||6|||f||||||||||||||2018-05-31 23:06:46.635812|2018-05-31 23:06:46.635812
NCT01249118|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2016-09-06||2017-04-04|2010-11-24|2010-11-29|Estimate|2016-12-12|2017-02-06|Estimate||||2017-04-04|2017-05-10|Actual|November 2010||2010-11-30|April 2017|2017-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||Safety population included participants who received study drug and had at least 1 post-dose safety assessment for Part 1 and the participants who were randomized, received study drug, and had at least 1 post-dose safety assessment for Part 2.|An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)|A Phase 1, Single Dose, Randomized, Cross-over Absolute Bioavailability Study in Healthy Subjects Comparing Oral to Intravenous Administration of GDC-0973|Completed||Phase 1|13|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:06:47.11453|2018-05-31 23:06:47.11453
NCT01249105|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2016-03-09|2010-11-26|2010-11-29|Estimate|||||||2016-03-09|2016-03-10|Estimate||||March 2016|2016-03-31||||||||Interventional|||MK-2206 for Recurrent Malignant Glioma|A Phase II Study of MK-2206 for Recurrent Malignant Glioma|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||2||"Merck (supplier of study drug & funding) has undergone a large reprioritization, in which they~   had to terminate many oncology trials, including this one."|f||||t||||||||||2018-05-31 23:06:47.443029|2018-05-31 23:06:47.443029
NCT01249092|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2013-07-31||2013-10-16|2010-11-26|2010-11-29|Estimate|2013-10-16|2013-12-09|Estimate||||2013-10-16|2013-12-09|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|||Pentoxifylline for Primary Biliary Cirrhosis|A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis|Completed||Phase 2|20|Actual|The Cleveland Clinic|Our study was a small open label pilot completed with no technical problems. The information generated will be useful in designing future larger studies. The main limitation is that PBC is a rare disease which resulted in prolonged enrollment phase.|1|||f||||t||||||||||2018-05-31 23:06:47.512093|2018-05-31 23:06:47.512093
NCT01249027|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2015-10-11|2010-11-26|2010-11-29|Estimate|||||||2015-10-11|2015-10-14|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|XV CHINA SAS||XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study|XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study|Unknown status|Active, not recruiting||2605|Actual|Abbott Vascular|||1||f||||f||||||||||2018-05-31 23:06:47.886699|2018-05-31 23:06:47.886699
NCT01249014|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2015-05-18|2010-11-24|2010-11-25|Estimate|||||||2015-05-18|2015-05-20|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Temperature Study in Cesarean Section|Study Using Fluid Warming and Forced Air Warming Immediately Prior to and During Elective Cesarean Section|Unknown status|Recruiting|N/A|45|Anticipated|Stanford University||3|||f||||f||||||||||2018-05-31 23:06:47.980781|2018-05-31 23:06:47.980781
NCT01249001|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2017-04-18|2010-11-24|2010-11-25|Estimate|||||||2017-04-18|2017-04-19|Actual|October 2010|Actual|2010-10-31|April 2017|2017-04-30|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents|Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents|Terminated||Phase 2|4|Actual|The Hospital for Sick Children||2||lack of eligible participants to enrol|f||||f||||||||||2018-05-31 23:06:48.158952|2018-05-31 23:06:48.158952
NCT01248988|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2017-01-12|2010-11-24|2010-11-25|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2010||2010-12-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea|Safety of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal-protein D-diphtheria Toxoid-tetanus Toxoid Conjugate (10PN-PD-DiT) Vaccine, Synflorix When Administered According to the Approved Prescribing Information in Korea|Completed|||622|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 23:06:48.244924|2018-05-31 23:06:48.244924
NCT01248975|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24||2012-04-12|2016-11-23|2010-11-24|2010-11-25|Estimate||||2012-04-12|2012-04-16|Estimate|2016-11-23|2016-11-25|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID|Completed||Phase 2|145|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:06:48.326395|2018-05-31 23:06:48.326395
NCT01248962|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2017-06-15|2010-11-24|2010-11-25|Estimate|||||||2017-06-15|2017-06-16|Actual|November 2010|Actual|2010-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer|Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in theTreatment of Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer|Active, not recruiting||Phase 2|148|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-05-31 23:06:48.474711|2018-05-31 23:06:48.474711
NCT01248949|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2016-12-02||2017-02-09|2010-11-24|2010-11-25|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|October 2010||2010-10-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional||Safety population included all participants who receive any treatment with MEDI3617.|A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors|Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|162|Actual|MedImmune LLC||5|||f||||f||||||||||2018-05-31 23:06:48.65258|2018-05-31 23:06:48.65258
NCT01248936|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2016-01-13||2016-07-12|2010-11-24|2010-11-25|Estimate|2016-01-13|2016-02-11|Estimate||||2016-07-12|2016-08-12|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Safety population included all the participants who received at least one dose, or a partial dose of vemurafenib. Three participants who were enrolled did not receive vemurafenib hence not included in safety population.|A Study of RO5185426 in Patients With Metastatic Melanoma|A SINGLE ARM, OPEN LABEL, EXPANDED ACCESS STUDY OF RG7204 IN PREVIOUSLY TREATED PATIENTS WITH METASTATIC MELANOMA|Completed||Phase 2|374|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:06:50.885903|2018-05-31 23:06:50.885903
NCT01248923|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2016-04-21|2010-11-24|2010-11-25|Estimate|||||||2016-04-21|2016-04-22|Estimate|December 2010||2010-12-31|April 2016|2016-04-30||||March 2016|Actual|2016-03-31||Interventional|||A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma||Completed||Phase 1|55|Actual|Array BioPharma||3|||f||||||||||||||2018-05-31 23:06:52.230635|2018-05-31 23:06:52.230635
NCT01248910|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|December 2008||2008-12-31|October 2010|2010-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|SASES||Health Benefits of Alpine Skiing for the Elderly|SASES: SAlzburg Skiing in the Elderly Study: Health Benefits of Alpine Skiing for the Elderly|Completed||N/A|||University of Salzburg||2|||f||||f||||||||||2018-05-31 23:06:52.322782|2018-05-31 23:06:52.322782
NCT01248897|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2018-05-17|2010-11-24|2010-11-25|Estimate|||||||2018-05-17|2018-05-21|Actual|August 17, 2010||2010-08-17|May 2018|2018-05-31|September 5, 2014|Actual|2014-09-05|December 1, 2013|Actual|2013-12-01||Observational|BioPATH||Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib|A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy|Completed|||158|Actual|GlaxoSmithKline|||1||f||||f||||||Samples With DNA|"~     Tumor tissues~   "|||2018-05-31 23:06:52.383594|2018-05-31 23:06:52.383594
NCT01248884|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2014-05-08|2012-07-23|2014-07-03|2010-11-24|2010-11-25|Estimate|2014-05-08|2014-06-06|Estimate|2012-07-23|2012-07-31|Estimate|2014-07-03|2014-07-16|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)|Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination|Completed||Phase 2|721|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 23:06:52.560778|2018-05-31 23:06:52.560778
NCT01248871|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2012-12-18|2010-11-24|2010-11-25|Estimate|||||||2012-12-18|2012-12-19|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail"|"Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail"|Completed||N/A|120|Actual|University Medical Center Groningen||3|||f||||f||||||||||2018-05-31 23:06:53.372046|2018-05-31 23:06:53.372046
NCT01248858|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2017-05-05|2010-11-24|2010-11-25|Estimate|||||||2017-05-05|2017-05-09|Actual|December 3, 2010|Actual|2010-12-03|May 2017|2017-05-31|April 23, 2015|Actual|2015-04-23|January 30, 2014|Actual|2014-01-30||Interventional|||Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.|A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.|Terminated||Phase 1|69|Actual|GlaxoSmithKline||1||The reason for termination was lack of tolerability and efficacy of the combination treatment|f||||f||||||||||2018-05-31 23:06:53.444576|2018-05-31 23:06:53.444576
NCT01248845|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2017-05-04|2010-11-24|2010-11-25|Estimate|||||||2017-05-04|2017-05-08|Actual|August 2010||2010-08-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparative Effects on Diaphragmatic Electrical Activity and Respiratory Pattern of Various Levels of Assistance|Comparative Effects on Diaphragmatic Electrical Activity and Respiratory Pattern of Various Levels of Assistance in Pressure Support and in Neurally Adjusted Ventilatory Assist|Terminated||N/A|2|Actual|University of Lausanne Hospitals||||Difficulties to enroll patients|f||||f||||||||||2018-05-31 23:06:53.546939|2018-05-31 23:06:53.546939
NCT01248832|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2013-12-10|2010-11-24|2010-11-25|Estimate|||||||2013-12-10|2013-12-11|Estimate|August 2004||2004-08-31|December 2013|2013-12-31|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|||Smokers' Quitline for Asian Language Speakers|Smokers' Quitline for Asian Language Speakers|Completed||Phase 3|2277|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 23:06:53.607802|2018-05-31 23:06:53.607802
NCT01248819|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Local Anesthetic Nebulization and Instillation for Pain Control After Laparoscopic Surgery|Double Blind Randomized Phase III Controlled Trial Comparing the Effect of Intraperitoneal Nebulization of Ropivacaine With Intraperitoneal Instillation of Ropivacaine on Pain Control After Laparoscopic Cholecystectomy|Completed||Phase 3|60|Actual|San Gerardo Hospital||2|||f||||f||||||||||2018-05-31 23:06:53.689994|2018-05-31 23:06:53.689994
NCT01248806|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2016-08-09|2010-11-24|2010-11-25|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2004||2004-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Observational|COSMOS||Continuous Observation of Smoking Subject|Validation of Low-dose Spiral CT for Early Diagnosis of Lung Cancer in a High Risk Population|Active, not recruiting|||5203|Actual|European Institute of Oncology|||1||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 23:06:53.767774|2018-05-31 23:06:53.767774
NCT01248793|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2012-05-25||2013-03-14|2010-11-24|2010-11-25|Estimate|2012-05-25|2012-06-28|Estimate||||2013-03-14|2013-03-20|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Ankylosing Spondylitis|Completed||Phase 3|213|Actual|Centocor, Inc.||2|||f||||f||||||||||2018-05-31 23:06:53.972326|2018-05-31 23:06:53.972326
NCT01248780|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2012-10-05||2013-08-12|2010-11-24|2010-11-25|Estimate|2013-05-24|2013-07-01|Estimate||||2013-08-12|2013-09-06|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|July 2012|Actual|2012-07-31|October 2011|Actual|2011-10-31||Interventional|||Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 3|264|Actual|Centocor, Inc.||2|||f||||f||||||||||2018-05-31 23:06:54.418419|2018-05-31 23:06:54.418419
NCT01248767|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2014-01-07|2010-11-24|2010-11-25|Estimate|||||||2014-01-07|2014-01-08|Estimate|September 2008||2008-09-30|January 2014|2014-01-31||||||||Observational|||"A Prospective Clinical Study of a Cohort of Pathological or at Risk Gamblers Seeking Treatment"|"A Prospective Clinical Study of a Cohort of Pathological or at Risk Gamblers Seeking Treatment in the University Hospital of Nantes"|Unknown status|Recruiting||||Nantes University Hospital|||||f||||f||||||||||2018-05-31 23:06:54.728519|2018-05-31 23:06:54.728519
NCT01248754|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2016-10-18|2010-11-24|2010-11-25|Estimate|||||||2016-10-18|2016-10-20|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Positron Emission Tomography (PET) With 3,4-dihydroxy-6-18F-fluoro-L-enylalanine (18F-FDOPA) Study|A Phase II Study Using 18F-FDOPA Positron Emission Tomography Imaging for Neurosurgery and Assessment of Surgical Resection|Completed||Phase 2|20|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 23:06:54.786602|2018-05-31 23:06:54.786602
NCT01248741|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2013-02-08|2010-11-24|2010-11-25|Estimate|||||||2013-02-08|2013-02-12|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|Vitesse||CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse|High Dose Rate (HDR)Prostate Brachytherapy With Vitesse tm|Completed||Phase 2|25|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 23:06:54.858278|2018-05-31 23:06:54.858278
NCT01248728|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2015-12-16||2016-04-12|2010-11-24|2010-11-25|Estimate|2016-04-12|2016-05-18|Estimate||||2016-04-12|2016-05-18|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Omega-3 Fatty Acids For Treatment Of Young Children With Autism (OMG)|A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids in the Treatment of Young Children With Autism|Completed||Phase 2|38|Actual|Anagnostou, Evdokia, M.D.||2|||f||||f||||||||||2018-05-31 23:06:54.947163|2018-05-31 23:06:54.947163
NCT01248715|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2017-08-07||2017-10-03|2010-11-23|2010-11-25|Estimate|2017-08-07|2017-09-06|Actual||||2017-10-03|2017-11-06|Actual|November 2010||2010-11-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|RETOS||Rapid Empiric Treatment With Oseltamivir Study (RETOS)|Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)|Completed||Phase 4|1107|Actual|University of Louisville|The primary limitation of our study that we were not able to reach the number of patients that were estimated in the sample size calculation.|2|||f||||t||||||||||2018-05-31 23:06:55.344921|2018-05-31 23:06:55.344921
NCT01248702|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-03-06|2010-11-23|2010-11-25|Estimate|||||||2012-03-06|2012-03-07|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|CAPTURE||A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy|A Critical Pathway for Implantable Cardioverter-Defibrillators in Patients With Ischemic Cardiomyopathy|Unknown status|Not yet recruiting|N/A|600|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:06:55.634143|2018-05-31 23:06:55.634143
NCT01248689|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-23|2010-11-23|2010-11-25|Estimate|||||||2010-11-23|2010-11-25|Estimate|February 2011||2011-02-28|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Effect of Sevoflurane Concentration on Intraocular Pressure in Surgical Children With Healthy Eyes|The Effect of Different Concentrations of Sevoflorane on Intraocular Pressure in Children Undergoing Ocular Surgery Under General Anesthesia|Unknown status|Not yet recruiting|N/A|21|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-05-31 23:06:55.705515|2018-05-31 23:06:55.705515
NCT01248676|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2011-08-15|2010-11-23|2010-11-25|Estimate|||||||2011-08-15|2011-08-16|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||An Evaluation of the Usability and Usefulness of a Multi-language Online Patient Education Module|An Evaluation of the Usability and Usefulness of a Multi-language Online Patient Education Module: A Pilot Study|Completed||N/A|10|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-05-31 23:06:55.77311|2018-05-31 23:06:55.77311
NCT01248663|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|August 2010|Actual|2010-08-31|November 2009|Actual|2009-11-30||Interventional|||Reconstruction Method and Delayed Gastric Emptying After Pancreatic Surgery|Influence of the Reconstruction Method on the Incidence of Delayed Gastric Emptying After Pylorus Preserving Pancreaticoduodenectomy. A Prospective, Randomized Trial.|Completed||N/A|64|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 23:06:55.821723|2018-05-31 23:06:55.821723
NCT01248650|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|TRK-820||Safety Study of TRK-820 for Patient With Hemodialysis|A Clinical Study to Investigate Pharmacokinetics and Safety of Single-Dose TRK-820 Soft Capsule in Patient With Hemodialysis|Completed||Phase 1|16|Actual|SK Chemicals Co.,Ltd.||2|||f||||f||||||||||2018-05-31 23:06:56.013614|2018-05-31 23:06:56.013614
NCT01248637|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2017-11-09|2010-11-24|2010-11-25|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2010||2010-10-31|November 2017|2017-11-30||||January 2018|Anticipated|2018-01-31||Observational|||Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole|A Clinical Trial of Intratumoral Hypoxia and Its Biologic Correlates in Patients Undergoing Surgical Resection of Localized Pancreatic Cancer, Using Pre-operative Administration of the Hypoxia Marker Pimonidazole.|Active, not recruiting|||200|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Pancreatic Tumor biopsy and blood samples.~   "|||2018-05-31 23:06:56.082874|2018-05-31 23:06:56.082874
NCT01248624|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-08-31|2010-11-24|2010-11-25|Estimate|||||||2017-08-31|2017-09-05|Actual|December 2006||2006-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2011|Actual|2011-06-30||Interventional|||Randomized Controlled Trial of Early Palliative Care for Patients With Advanced Cancer|Early Specialized Palliative Care Team Intervention for Patients With Metastatic Cancer: A Cluster Randomized Trial|Active, not recruiting||N/A|461|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 23:06:56.156566|2018-05-31 23:06:56.156566
NCT01248611|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2014-05-09|2010-11-24|2010-11-25|Estimate|||||||2014-05-09|2014-05-12|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|NFCP1-2010||Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer|Nasal Fentanyl for Patient Controlled Treatment of Pain in Cancer An Open Label Prospective Phase I b Study|Completed||Phase 1/Phase 2|10|Actual|St. Olavs Hospital||1|||f||||f||||||||||2018-05-31 23:06:56.22922|2018-05-31 23:06:56.22922
NCT01248598|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||||||Observational|||The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis||Unknown status|Recruiting||10|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 23:06:56.317849|2018-05-31 23:06:56.317849
NCT01248585|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2015-11-27|2010-11-24|2010-11-25|Estimate|||||||2015-11-27|2015-11-30|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|||Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases|A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases|Completed||Phase 3|298|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 23:06:56.386163|2018-05-31 23:06:56.386163
NCT01248572|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2014-03-17|2010-11-24|2010-11-25|Estimate|||||||2014-03-17|2014-03-18|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Evaluation of Effective Lens Position With a Uniplanar Bi-aspheric IOL|Evaluation of Lens Effective Position, Stability and Prediction With a 12mm Uniplanar, Biaspheric Intraocular Lens|Completed||Phase 4|40|Actual|Lenstec Incorporated||1|||f||||f||||||||||2018-05-31 23:06:56.516693|2018-05-31 23:06:56.516693
NCT01248546|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2013-02-04|2010-11-24|2010-11-25|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|September 2015|Anticipated|2015-09-30|December 2012|Actual|2012-12-31||Observational|DBT||Tomosynthesis in the Oslo Breast Cancer Screening Program|Digital Breast Tomosynthesis in the Oslo Mammography Screening Program|Unknown status|Active, not recruiting||25000|Anticipated|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 23:06:56.595983|2018-05-31 23:06:56.595983
NCT01248533|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2016-03-29|2010-11-24|2010-11-25|Estimate|||||||2016-03-29|2016-03-30|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|December 2029|Anticipated|2029-12-31|December 2029|Anticipated|2029-12-31||Observational|AAAscreening||Screening for Abdominal Aortic Aneurysm in 65 Year Old Males in Oslo|Screening for Abdominal Aortic Aneurysm|Enrolling by invitation|||7500|Actual|Oslo University Hospital|||||f||||f||||||||Yes|All data are entered into the Electronic Patient Journal of Oslo University Hospital (DIPS)|2018-05-31 23:06:56.661584|2018-05-31 23:06:56.661584
NCT01248520|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2017-07-20|2010-11-23|2010-11-25|Estimate|||||||2017-07-20|2017-07-24|Actual|September 2010||2010-09-30|July 2017|2017-07-31|April 2014|Actual|2014-04-30|May 2012|Actual|2012-05-31||Interventional|||Influenza and Text Messaging in Pregnancy|Text Messaging For Preventative Health During Pregnancy; Improving Influenza Vaccination Rates In Pregnancy: A Randomized Controlled Trial of Text Messaging to Increase Vaccine Uptake|Completed||N/A|216|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 23:06:56.711435|2018-05-31 23:06:56.711435
NCT01248507|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2016-10-27|2010-11-24|2010-11-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations|Comparative Evaluation of COPD Specific Quality of Life Assessment Questionnaires (the COPD Assessment Test, the Clinical COPD Questionnaire, the COPD Severity Score and the Airways Questionnaire 20 as Predictive Tools for Risk of Acute COPD Exacerbations|Completed|||634|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:06:56.782396|2018-05-31 23:06:56.782396
NCT01248494|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2016-07-22|2010-11-23|2010-11-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|December 2012|Actual|2012-12-31||Interventional|||PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer|A Phase Ib Trial of BKM120 (a PI3K Inhibitor) or BEZ235 (a PI3K/mTOR Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer|Completed||Phase 1|72|Actual|Vanderbilt-Ingram Cancer Center||3|||f||||t||||||||||2018-05-31 23:06:56.845919|2018-05-31 23:06:56.845919
NCT01248481|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2013-06-19|2010-11-24|2010-11-25|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|July 2012|Actual|2012-07-31|||||Observational|||GlucoFriend-evaluation the Effectiveness of Glucobay When Combined With a Basal Insulin|Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress|Completed|||539|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:06:56.970702|2018-05-31 23:06:56.970702
NCT01248468|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2012-03-22||2012-06-22|2010-11-24|2010-11-25|Estimate|2012-06-22|2012-07-30|Estimate||||2012-06-22|2012-07-30|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine|A Multi-center, Randomized, Double-blind, Parallel-group Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine.|Completed||Phase 4|752|Actual|Novartis||3|||f||||f||||||||||2018-05-31 23:06:57.088279|2018-05-31 23:06:57.088279
NCT01248455|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2015-04-29||2018-01-16|2010-11-24|2010-11-25|Estimate|2015-04-29|2015-05-15|Estimate||||2018-01-16|2018-02-20|Actual|November 1, 2010|Actual|2010-11-01|January 2018|2018-01-31|April 2015|Actual|2015-04-30|May 1, 2014|Actual|2014-05-01||Interventional|||A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma|A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM)|Terminated||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)|Study stopped after the first stage due to lack of patients meeting the defined primary objective (50% decline in M-protein). The study did not continue to the second stage of enrollment due to lack of efficacy as defined by our criteria.|1||Lack of patients meeting the defined primary obj. (50% decline in M-protein).|f||||t|t|f||||||No||2018-05-31 23:06:57.516234|2018-05-31 23:06:57.516234
NCT01248442|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2012-02-08|2010-11-24|2010-11-25|Estimate|||||||2012-02-08|2012-02-09|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Immune and Metabolic Effects of Vitamin D Supplementation in Healthy Humans|Placebo Controlled Study to Assess the Effects of Vitamin D Supplementation on Parameters of the Immune, Endocrine and Metabolic System in Healthy Women and Men.|Completed||Phase 4|60|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 23:06:57.767571|2018-05-31 23:06:57.767571
NCT01248429|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2012-06-06|2010-11-24|2010-11-25|Estimate|||||||2012-06-06|2012-06-07|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|TKI-CPK-1003||Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases|National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)|Completed|||154|Actual|Centre Oscar Lambret|||1||f||||f||||||||||2018-05-31 23:06:57.839897|2018-05-31 23:06:57.839897
NCT01248416|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-09-22|2010-11-23|2010-11-25|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ThrasherAI||Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature|A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature|Completed||Phase 3|77|Actual|Nemours Children's Clinic||3|||f||||t||||||||||2018-05-31 23:06:57.924504|2018-05-31 23:06:57.924504
NCT01248403|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2017-03-06|2010-11-24|2010-11-25|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2011||2011-10-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|AIO-STO-0111||A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy|A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen|Active, not recruiting||Phase 3|300|Actual|Krankenhaus Nordwest||2|||f||||t||||||||||2018-05-31 23:06:58.00539|2018-05-31 23:06:58.00539
NCT01248390|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-06-19|2010-11-24|2010-11-25|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2010||2010-08-31|June 2017|2017-06-30|October 3, 2016|Actual|2016-10-03|May 2014|Actual|2014-05-31||Interventional|||"Interactive Metronome Technology for Blast-Related Traumatic Brain Injury"|"A Randomized, Controlled, Trial of Interactive Metronome Technology for Remediation of Cognitive Difficulties Following Blast-Related Traumatic Brain Injury"|Completed||N/A|48|Actual|The Defense and Veterans Brain Injury Center||2|||f||||f||||||||||2018-05-31 23:06:58.07851|2018-05-31 23:06:58.07851
NCT01248377|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2011-10-09|2010-11-24|2010-11-25|Estimate|||||||2011-10-09|2011-10-12|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Skin Testing and ELISPOT Assay in Patients With a History of Non-Immediate Reactions to Cephalosporins|The Results of Skin Testing and The Detection of Cytokine Secretion From Drug Specific Peripheral Blood Mononuclear Cells Using ELISPOT Assay in the Diagnosis of Nonimmediate Reactions to Cephalosporins|Completed|||28|Actual|Chulalongkorn University|||1||f||||t||||||Samples Without DNA|"~     PBMCs and serum will be collected for further analysis, if indicated~   "|||2018-05-31 23:06:58.164828|2018-05-31 23:06:58.164828
NCT01248364|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2014-08-29|2014-04-28|2014-08-29|2010-11-24|2010-11-25|Estimate|2014-08-29|2014-09-09|Estimate|2014-04-28|2014-05-14|Estimate|2014-08-29|2014-09-09|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Treated set which included all patients/healthy subjects treated with at least one dose of empagliflozin.|A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects|An Open-label, Phase II Study to Determine Acute (After the First Dose Administration) and Chronic (After 28 Days of Treatment) Effects of the Sodium-glucose Co-transporter-2 (SGLT-2) Inhibitor Empagliflozin (BI 10773) (25 mg Once Daily) on Pre and Postprandial Glucose Homeostasis in Patients With IGT and, Type 2 Diabetes Mellitus and Healthy Subjects|Completed||Phase 2|91|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:06:58.326985|2018-05-31 23:06:58.326985
NCT01248351|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2011-04-27|2010-11-23|2010-11-25|Estimate|||||||2011-04-27|2011-04-28|Estimate|November 2010||2010-11-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Reversibility of Dual Antiplatelet Therapy by Platelets|Reversibility of Dual Antiplatelet Therapy by Platelets.Phase II Study|Completed||Phase 2|6|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 23:06:58.918545|2018-05-31 23:06:58.918545
NCT01248338|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|March 2006||2006-03-31|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|NEMENDAS||Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function|Comparison the Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function and Large Artery Stiffness|Completed||Phase 4|80|Actual|Berlin-Chemie AG Menarini Group||2|||f||||f||||||||||2018-05-31 23:06:59.001835|2018-05-31 23:06:59.001835
NCT01248325|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-25|Estimate|||||||2010-11-23|2010-11-25|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||A Study of Luffa Operculate Nasal Solution 5mg/mL Compared With Saline (NaCl 09%) for the Relief of Nasal Obstruction|Clinical Trial Unicenter, Phase III, Randomized, Double-blind, Comparative to Evaluate the Efficacy, Tolerability and Superiority of Luffa Operculate Nasal Solution 5mg/mL Compared With Saline Solution in the Relief of Nasal Obstruction.|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Zurita Laboratorio Farmaceutico Ltda.||2|||f||||f||||||||||2018-05-31 23:06:59.085129|2018-05-31 23:06:59.085129
NCT01248312|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-08-17|2010-11-23|2010-11-25|Estimate|||||||2012-08-17|2012-08-20|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Incidence of Hypercapnea in Morbidly Obese Post-Surgical Bariatric Patients Using the Sen Tec Transcutaneous PCO2 Monitor|Estimation of the Incidence of Hypercapnea in Morbidly Obese Post-Surgical Patients Using the Sen Tec Transcutaneous PCO2 Monitor|Completed|||22|Actual|William Beaumont Hospitals|||2||f||||t||||||||||2018-05-31 23:06:59.163485|2018-05-31 23:06:59.163485
NCT01248299|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2016-05-23|2010-11-24|2010-11-25|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|January 2015|Actual|2015-01-31||Interventional|E-DIS||Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.|A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable Toxicity After a 6-weeks Chemotherapy Course .|Unknown status|Active, not recruiting|Phase 2|105|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 23:06:59.22809|2018-05-31 23:06:59.22809
NCT01248286|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2013-10-21|2010-11-23|2010-11-25|Estimate|||||||2013-10-21|2013-10-22|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes|Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes|Completed||N/A|100|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 23:06:59.329579|2018-05-31 23:06:59.329579
NCT01248273|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-03-13|2010-11-23|2010-11-25|Estimate|||||||2017-03-13|2017-03-14|Actual|November 2010|Actual|2010-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission|Phase I Trial of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission|Completed||Phase 1|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:06:59.411196|2018-05-31 23:06:59.411196
NCT01248260|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2015-12-03|2010-11-23|2010-11-25|Estimate|||||||2015-12-03|2015-12-04|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Preventing Fetal Body and Brain Size Reduction in Low-income Smoking Mothers: A Randomized Clinical Trial|Preventing Fetal Body and Brain Size Reduction in Low-income Smoking Mothers: A Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|450|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 23:06:59.484259|2018-05-31 23:06:59.484259
NCT01248247|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2018-03-16|2010-11-23|2010-11-25|Estimate|||||||2018-03-16|2018-03-20|Actual|June 2011|Actual|2011-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|334|Actual|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 23:06:59.55105|2018-05-31 23:06:59.55105
NCT01248234|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2012-07-12|2010-11-24|2010-11-25|Estimate|||||||2012-07-12|2012-07-16|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone?|Does Administration of Etomidate and Propofol if the Anesthetic Induction of the Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngosacopy, When Compared to Propofol or Etomidate Alone?|Withdrawn||Phase 3|0|Actual|University of Mississippi Medical Center||3||Did not begin|f||||f||||||||||2018-05-31 23:06:59.638035|2018-05-31 23:06:59.638035
NCT01248221|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2013-02-13||2013-02-13|2010-11-24|2010-11-25|Estimate|2013-02-13|2013-03-18|Estimate||||2013-02-13|2013-03-18|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Carbon-13 (13C)-Spirulina Platensis Gastric Emptying Breath Test (GEBT)|[13C]-Spirulina Platensis GEBT - Dual-Label Validation Study|Completed||N/A|30|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:06:59.713449|2018-05-31 23:06:59.713449
NCT01248208|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|FluEMIST||FluMist in Egg Allergic Patients|Flu Vaccine in Egg-allergic Patients Minimizing Injections Safety Trial|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-05-31 23:06:59.955832|2018-05-31 23:06:59.955832
NCT01248195|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2018-05-14|2010-11-24|2010-11-25|Estimate|||||||2018-05-14|2018-05-15|Actual|May 2011||2011-05-31|May 2018|2018-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|OPTIMISE||Optimization of Treatment and Management of Schizophrenia in Europe|Optimization of Treatment and Management of Schizophrenia in Europe|Completed||Phase 4|479|Actual|UMC Utrecht||6|||f||||t||||||||||2018-05-31 23:07:00.0528|2018-05-31 23:07:00.0528
NCT01248182|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2012-04-05|2010-11-24|2010-11-25|Estimate|||||||2012-04-05|2012-04-06|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Bone to Skin Thickness Study: Obese Versus Normal Population|Bone to Skin Thickness Study: Obese Versus Normal Population|Terminated|||21|Actual|University of Mississippi Medical Center||||Study was terminated by investigator|f||||f||||||||||2018-05-31 23:07:00.19743|2018-05-31 23:07:00.19743
NCT01248169|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2013-12-11|2010-11-24|2010-11-25|Estimate|||||||2013-12-11|2013-12-12|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Observational|ICASH||Impedance Cardiographic (ICG) Assessment of Pregnant Women With Severe Hypertension to Assess Impact of Standard Therapy|Impedance Cardiographic Assessment of Gravidas With Severe Hypertension (ICASH)to Assess Impact of Standard Therapy on Hemodynamic Parameters - A Pilot Study|Completed|||30|Actual|University of Mississippi Medical Center|||2||f||||f||||||Samples Without DNA|"~     One tube of blood~   "|||2018-05-31 23:07:00.260778|2018-05-31 23:07:00.260778
NCT01248156|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2013-12-11|2010-11-24|2010-11-25|Estimate|||||||2013-12-11|2013-12-12|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Observational|||The Maintenance of Human Atrial Fibrillation|The Maintenance of Human Atrial Fibrillation|Unknown status|Recruiting||86|Anticipated|University of California, San Diego|||2||f||||t||||||||||2018-05-31 23:07:00.325667|2018-05-31 23:07:00.325667
NCT01248143|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2014-11-14|2010-11-24|2010-11-25|Estimate|||||||2014-11-14|2014-11-17|Estimate|November 2010||2010-11-30|November 2014|2014-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases|Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases|Completed||Phase 2/Phase 3|300|Actual|Touro College||2|||f||||f||||||||||2018-05-31 23:07:00.408754|2018-05-31 23:07:00.408754
NCT01248130|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2014-09-15||2017-10-05|2010-11-23|2010-11-25|Estimate|2014-09-15|2014-09-22|Estimate||||2017-10-05|2017-11-06|Actual|November 2009||2009-11-30|October 2017|2017-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders|Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders|Terminated||Phase 2|7|Actual|Massachusetts General Hospital|This study was terminated early due to a change in the research priorities of the Principal Investigator in combination with low subject interest. Therefore, no data was analyzed.|2||"Due to a change in the research priorities of the principal investigator in combination with~   low subject interest."|f||||f||||||||||2018-05-31 23:07:00.497124|2018-05-31 23:07:00.497124
NCT01248117|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|PEARL2||Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy|Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab (2.0mg) Prospectively|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Retina Consultants of Hawaii||2|||f||||||||||||||2018-05-31 23:07:00.789369|2018-05-31 23:07:00.789369
NCT01248104|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-04-21|2010-11-24|2010-11-25|Estimate|||||||2014-04-21|2014-04-23|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|February 2015|Anticipated|2015-02-28|March 2013|Actual|2013-03-31||Interventional|||Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery|Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery|Unknown status|Active, not recruiting|N/A|100|Anticipated|Loma Linda University||2|||f||||f||||||||||2018-05-31 23:07:00.910869|2018-05-31 23:07:00.910869
NCT01248091|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2012-09-12|2010-11-24|2010-11-25|Estimate|||||||2012-09-12|2012-09-14|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effect of Nitroprusside on Intrauterine Device (IUD) Insertion|The Effect of Nitroprusside on the IUD Insertion Experience in Nulliparous Women: a Pilot Study|Completed||N/A|24|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 23:07:01.078246|2018-05-31 23:07:01.078246
NCT01248078|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|March 2004||2004-03-31|November 2010|2010-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Antibiotic Prophylaxis Before Surgery Versus After Cord Clamping in Elective Cesarean Delivery - a Double-blind, Prospective, Randomized Placebo-controlled Trial||Completed||N/A|1112|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 23:07:01.168473|2018-05-31 23:07:01.168473
NCT01248065|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|2014-06-18||2014-07-23|2010-11-24|2010-11-25|Estimate|2014-07-23|2014-08-13|Estimate||||2014-07-23|2014-08-13|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|VIDA||Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma|Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma|Completed||Phase 3|408|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 23:07:01.284022|2018-05-31 23:07:01.284022
NCT01248052|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2011-06-24|2010-11-23|2010-11-25|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY2979165 in Healthy Subjects|Completed||Phase 1|25|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 23:07:01.835114|2018-05-31 23:07:01.835114
NCT01248039|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-24|||2012-07-18|2010-11-24|2010-11-25|Estimate|||||||2012-07-18|2012-07-19|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Preoperative Pain, Function, and Activity for Total Hip and Knee Arthroplasty Patients|The Influence of Preoperative Pain, Function, and Activity on Time to Fulfill Discharge Criteria for Total Hip and Knee Arthroplasty Patients|Completed|||100|Anticipated|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 23:07:01.936086|2018-05-31 23:07:01.936086
NCT01248026|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-01-22|2010-11-24|2010-11-25|Estimate|||||||2013-01-22|2013-01-23|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|BMILK||Impact of Buttermilk on Cholesterol Concentration and Homeostasis|Impact of Buttermilk on Cholesterol Concentration and Homeostasis|Completed||N/A|42|Actual|Laval University||2|||f||||f||||||||||2018-05-31 23:07:02.021074|2018-05-31 23:07:02.021074
NCT01248013|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2010-11-24||2011-01-05|2010-11-24|2010-11-25|Estimate|2011-01-05|2011-01-06|Estimate||||2011-01-05|2011-01-06|Estimate|September 2005||2005-09-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Irritable Bowel Syndrome Hypnotherapy|Outcome Effectiveness Predictors of Irritable Bowel Syndrome Hypnotherapy|Completed||N/A|89|Actual|Mind-Body Digestive Center|Subjects who dropped out did so for reasons of inconvenience of scheduling attendance.||||f||||f||||||||||2018-05-31 23:07:02.110195|2018-05-31 23:07:02.110195
NCT01248000|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-24|2010-11-24|2010-11-25|Estimate|||||||2010-11-24|2010-11-25|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|May 2010|Actual|2010-05-31|||||Observational|||The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy|"The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the Real World: a Population Based Study From Northern Italy"|Completed|||136|Actual|Gruppo Italiano Studio Linfomi|||1||f||||f||||||||||2018-05-31 23:07:02.27779|2018-05-31 23:07:02.27779
NCT01247987|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2015-04-30|2010-11-24|2010-11-25|Estimate|||||||2015-04-30|2015-05-01|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Comparison of Transfers of Thawed Blastocysts Versus Blastocysts Derived From Thawed Bipronuclear Oocytes|Comparison of Transfers of Thawed Blastocysts Versus Blastocysts Derived From Thawed Bipronuclear Oocytes|Completed||N/A|140|Actual|Fertility Center of Las Vegas||2|||f||||f||||||||||2018-05-31 23:07:02.357978|2018-05-31 23:07:02.357978
NCT01247974|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2014-02-13||2017-06-28|2010-11-23|2010-11-25|Estimate|2015-08-13|2015-09-16|Estimate||||2017-06-28|2017-07-02|Actual|December 2010||2010-12-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation Of New Onset Postoperative Atrial Fibrillation|Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM® for Pericardial Closure|Completed||N/A|439|Actual|Aziyo Biologics, Inc.||2|||f||||t||||||||||2018-05-31 23:07:02.445442|2018-05-31 23:07:02.445442
NCT01247961|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2016-12-08|2010-11-23|2010-11-25|Estimate|||||||2016-12-08|2016-12-12|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Early Treatment With Dexamethasone in Mild Acute Pancreatitis|Intravenous Dexamethasone for the Early Treatment of Mild Acute Pancreatitis: A Double-Blind, Randomized, Placebo Controlled Trial|Withdrawn||Phase 2|0|Actual|Brigham and Women's Hospital||2||Investigator left institution|f||||t||||||||||2018-05-31 23:07:02.758062|2018-05-31 23:07:02.758062
NCT01247948|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-12-09|2010-11-24|2010-11-25|Estimate|||||||2010-12-09|2010-12-10|Estimate|February 2011||2011-02-28|November 2010|2010-11-30|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|J0001I41||Evaluating the Accuracy of Navigation Assisted Pedicle Screw Placement of Spine Surgery|A Multi-center Randomized Controlled Trial Evaluating the Accuracy of Navigation Assisted Pedicle Screw Placement of Spine Surgery|Unknown status|Not yet recruiting|N/A|656|Anticipated|Beijing Jishuitan Hospital||1|||f||||t||||||||||2018-05-31 23:07:02.860507|2018-05-31 23:07:02.860507
NCT01247935|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2011-07-11|2010-11-24|2010-11-25|Estimate|||||||2011-07-11|2011-07-12|Estimate|November 2010||2010-11-30|June 2010|2010-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Electroacupuncture and Trancutaneous Electrical Nervous Stimulation (TENS) for Colonoscopy Analgesia|Electroacupuncture and Trancutaneous Electrical Nervous Stimulation Analgesia for Colonoscopy: a Prospective, Randomized, Controlled Study|Completed||N/A|60|Actual|Azienda Per I Servizi Sanitari N. 2 Isontina||3|||f||||f||||||||||2018-05-31 23:07:02.935478|2018-05-31 23:07:02.935478
NCT01247922|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2015-10-26||2015-12-07|2010-11-24|2010-11-25|Estimate|2015-12-07|2016-01-11|Estimate||||2015-12-07|2016-01-11|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205|Open-label, Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205|Terminated||Phase 2|4|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|1||"In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety~   concerns. As a result, the companion trial, OSI-774-206 has been stopped"|f||||t||||||||||2018-05-31 23:07:03.062428|2018-05-31 23:07:03.062428
NCT01247909|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2016-10-24|2010-11-24|2010-11-25|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|Infaseme||Infant Severe Sepsis and Bacterial Meningitis in Malawi|An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi|Completed||Phase 4|351|Actual|University of Malawi College of Medicine||2|||f||||t||||||||||2018-05-31 23:07:03.382273|2018-05-31 23:07:03.382273
NCT01247896|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2011-07-05|2010-11-23|2010-11-24|Estimate|||||||2011-07-05|2011-07-06|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Single Dose Escalation Study of PF-05190457 in Healthy Volunteers|A Phase 1 Placebo-controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of PF-05190457 Under Fasted and Fed Conditions in Healthy Adult Subjects|Completed||Phase 1|26|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 23:07:03.460312|2018-05-31 23:07:03.460312
NCT01247883|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-01-31|2010-11-23|2010-11-24|Estimate|||||||2011-01-31|2011-02-02|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers|A Two Period, 2 Sequence Crossover To Establish The Relative Bioavailability Of A Single Pf-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers|Completed||Phase 1|13|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:07:03.558123|2018-05-31 23:07:03.558123
NCT01247870|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2015-05-06|2010-11-23|2010-11-24|Estimate|||||||2015-05-06|2015-05-07|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Metformin in Chronic Obstructive Pulmonary Disease|A Randomised, Double-blind, Placebo-controlled Trial of Metformin in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations: a Pilot Study|Completed||Phase 4|52|Actual|St George's, University of London||2|||f||||f||||||||||2018-05-31 23:07:03.653371|2018-05-31 23:07:03.653371
NCT01247857|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Local Anesthetic Nebulization for Pain Control After Laparoscopic Cholecystectomy|Double Blind Randomized Phase III Controlled Trial Comparing the Effect of Preoperative and Postoperative Nebulization of Ropivacaine on Pain Control After Laparoscopic Cholecystectomy|Completed||Phase 3|90|Actual|San Gerardo Hospital||3|||f||||f||||||||||2018-05-31 23:07:03.746134|2018-05-31 23:07:03.746134
NCT01247844|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2015-03-04|2010-11-23|2010-11-24|Estimate|||||||2015-03-04|2015-03-06|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment|Evaluation of Healing at Three Time Intervals and Potential for Spontaneous Detachment|Completed||N/A|50|Actual|FHI 360||3|||f||||f||||||||||2018-05-31 23:07:03.813567|2018-05-31 23:07:03.813567
NCT01247831|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2017-02-06|2010-11-23|2010-11-24|Estimate|||||||2017-02-06|2017-02-08|Estimate|November 2010||2010-11-30|February 2017|2017-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SLT/ORA||The Effect of Selective Laser Trabeculoplasty (SLT) on Ocular Rigidity|The Effect of Selective Laser Trabeculoplasty (SLT) on Ocular Rigidity|Completed||N/A|150|Actual|Technische Universität Dresden||1|||f||||f||||||||||2018-05-31 23:07:04.89537|2018-05-31 23:07:04.89537
NCT01247818|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2012-09-27|2010-11-23|2010-11-24|Estimate|||||||2012-09-27|2012-09-28|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||Randomized Study of PH-10 for Psoriasis|A Phase 2 Dose-Randomized, Vehicle-Controlled Study of PH-10-Aqueous Hydrogel for the Treatment of Plaque Psoriasis|Completed||Phase 2|99|Actual|Provectus Pharmaceuticals||4|||f||||f||||||||||2018-05-31 23:07:04.97685|2018-05-31 23:07:04.97685
NCT01247805|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2011-02-10|2010-11-23|2010-11-24|Estimate|||||||2011-02-10|2011-02-11|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions|A Pivotal Randomised, Open-Label 3-Way Crossover Study To Demonstrate Bioequivalence Of The Sildenafil Citrate Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil Citrate 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions|Completed||Phase 1|42|Anticipated|Pfizer||3|||f||||f||||||||||2018-05-31 23:07:05.049312|2018-05-31 23:07:05.049312
NCT01247792|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2017-08-08|2010-11-23|2010-11-24|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2010||2010-08-31|August 2017|2017-08-31|September 30, 2014|Actual|2014-09-30|September 30, 2014|Actual|2014-09-30||Interventional|EIDECS||End-of-life Decision-making in Patients With Sepsis-related Organ Failure|A Time-series Intervention Analysis of End-of-life Decision-making in Patients With Sepsis-related Organ Failure|Completed||N/A|174|Actual|Center for Sepsis Control and Care, Germany||2|||f||||f||||||||||2018-05-31 23:07:05.143201|2018-05-31 23:07:05.143201
NCT01247779|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2017-07-19|2010-11-23|2010-11-24|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2010|Actual|2010-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|May 2016|Actual|2016-05-31||Interventional|ROBO-GYN||Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy|Assessment of Perioperative Morbidity in Gyneco-oncology According to the Surgical Approach : Coelioscopy Versus Robot-assisted Coelioscopy|Active, not recruiting||N/A|386|Actual|Centre Oscar Lambret||2|||f||||t|f|f||||||No||2018-05-31 23:07:05.248178|2018-05-31 23:07:05.248178
NCT01247766|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2018-03-26|2010-11-23|2010-11-24|Estimate|||||||2018-03-26|2018-03-29|Actual|December 31, 2010|Actual|2010-12-31|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Safety Study of Abatacept to Treat Rheumatoid Arthritis|Post-marketing Observational Study Assessing the Long-term Safety of Abatacept Using a Population-based Cohort of Rheumatoid Arthritis Patients in the Province of British Columbia|Active, not recruiting|||8000|Anticipated|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 23:07:05.353054|2018-05-31 23:07:05.353054
NCT01247753|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-05-19|2010-11-22|2010-11-24|Estimate|||||||2017-05-19|2017-05-23|Actual|March 1, 2011|Actual|2011-03-01|May 2017|2017-05-31|March 1, 2012|Actual|2012-03-01|March 1, 2012|Actual|2012-03-01||Interventional|WENDY||Walking Exercise and Nutrition to Reduce Diabetes Risk for You (WENDY)|Stepping Up to Health - Walking Exercise and Nutrition to Reduce Diabetes Risk for You (WENDY)|Completed||N/A|60|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 23:07:05.411804|2018-05-31 23:07:05.411804
NCT01247740|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2012-01-09|2010-11-23|2010-11-24|Estimate|||||||2012-01-09|2012-01-10|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Three-chamber-bag Versus Compounded Bag|A Prospective, Controlled, Randomized, Blinded, Parallel Group Multicentre Study on the Safety and Efficacy of a Convenience Three-chamber Bag for Parenteral Nutrition in Post-operative Patients After Abdominal Surgery Versus a Compounded Monobag|Completed||Phase 3|240|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-05-31 23:07:05.573283|2018-05-31 23:07:05.573283
NCT01247727|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-04-21|2010-11-23|2010-11-24|Estimate|||||||2011-04-21|2011-04-22|Estimate|July 2011||2011-07-31|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Heart Rate Variability in Extracorporeal Membrane Oxygenation (ECMO) Patients|Clinical Application of Multimodal Physiological Signal Analysis in Critical Ill Patients Depending on Extracorporeal Membrane Oxygenation|Unknown status|Not yet recruiting||40|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 23:07:05.651315|2018-05-31 23:07:05.651315
NCT01247714|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2014-12-09|2010-11-23|2010-11-24|Estimate|||||||2014-12-09|2014-12-10|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|May 2015|Anticipated|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Evaluation of a Specific Enteral Diet for Diabetics|Clinical Evaluation of a Specific Enteral Diet for Diabetics.A Randomised Cross-Over Study|Unknown status|Active, not recruiting|N/A|43|Actual|Vegenat, S.A.||2|||f||||f||||||||||2018-05-31 23:07:05.727688|2018-05-31 23:07:05.727688
NCT01247701|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2018-01-19|2010-11-23|2010-11-24|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2010||2010-11-30|January 2018|2018-01-31|November 2027|Anticipated|2027-11-30|November 2024|Anticipated|2024-11-30||Interventional|UCAML||Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies|Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML)|Recruiting||N/A|20|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 23:07:05.844416|2018-05-31 23:07:05.844416
NCT01247688|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2013-12-11|2010-11-23|2010-11-24|Estimate|||||||2013-12-11|2013-12-12|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|UCALL||Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies|Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies (UCALL)|Withdrawn||N/A|0|Actual|Baylor College of Medicine||1||This study was withdrawn due to low accrual.|f||||t||||||||||2018-05-31 23:07:05.955659|2018-05-31 23:07:05.955659
NCT01247675|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2016-11-03||2017-01-20|2010-11-23|2010-11-24|Estimate|2017-01-20|2017-03-09|Actual||||2017-01-20|2017-03-09|Actual|November 2010||2010-11-30|January 2017|2017-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency|A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients With Growth Hormone Deficiency|Completed||Phase 2|37|Actual|Ascendis Pharma A/S||4|||f||||f||||||||No||2018-05-31 23:07:06.078269|2018-05-31 23:07:06.078269
NCT01247662|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-11-14|2010-11-23|2010-11-24|Estimate|||||||2012-11-14|2012-11-15|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|||||Observational|||Psychometric Studies of the Chinese Versions of the SRS, CAST, and AQ|Psychometric Studies of the Chinese Versions of the Social Responsiveness Scale, the Childhood Asperger's Syndrome Test, and the Autism Spectrum Quotient|Completed|||2460|Actual|National Taiwan University Hospital|||3||f||||t||||||||||2018-05-31 23:07:06.538688|2018-05-31 23:07:06.538688
NCT01183507|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2016-09-29|2010-08-16|2010-08-17|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2012|Actual|2012-08-31||Interventional|TSE||Task Specific Exercise for the Prevention of Disability|Task Specific Exercise for the Pre-Clinically Disabled|Completed||Phase 1|71|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 23:27:40.850942|2018-05-31 23:27:40.850942
NCT01247649|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|||2012-11-18|2010-11-23|2010-11-24|Estimate|||||||2012-11-18|2012-11-20|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Assessing Continuous Non- Invasive Blood Glucose Sensor- Physical Logic AG|Assessing Continuous Non- Invasive Blood Glucose Sensor- Physical Logic AG|Terminated||N/A|4|Actual|Rabin Medical Center||1||sponsor decision|f||||f||||||||||2018-05-31 23:07:06.594917|2018-05-31 23:07:06.594917
NCT01247636|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Home-Exercise vs General Physical Activity: Effect on Health-related Quality of Life|Effect of Progressive Home-Exercise on Health-related Quality of Life, Balance and Mobility in Older People Discharge From an Outpatient Geriatric Clinic.|Completed||Phase 2|110|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 23:07:06.658062|2018-05-31 23:07:06.658062
NCT01247623|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2014-11-04|2010-11-23|2010-11-24|Estimate|||||||2014-11-04|2014-11-05|Estimate|January 2005||2005-01-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma|Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma|Completed||Phase 1/Phase 2|||Oslo University Hospital|||||f||||f||||||||||2018-05-31 23:07:06.727958|2018-05-31 23:07:06.727958
NCT01247610|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-11-14|2010-11-22|2010-11-24|Estimate|||||||2012-11-14|2012-11-15|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|December 2015|Anticipated|2015-12-31|||||Observational|||Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder|Adult Outcome of Children With Attention-deficit/Hyperactivity Disorder|Unknown status|Recruiting||390|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-05-31 23:07:06.77684|2018-05-31 23:07:06.77684
NCT01247597|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2018-05-12|2010-11-23|2010-11-24|Estimate|||||||2018-05-12|2018-05-15|Actual|November 23, 2010||2010-11-23|December 26, 2017|2017-12-26||||||||Observational|||DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study|DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:07:06.922389|2018-05-31 23:07:06.922389
NCT01247584|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2016-05-17|2010-11-23|2010-11-24|Estimate|||||||2016-05-17|2016-05-19|Estimate|November 2010||2010-11-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia|Telomere Length and Telomerase Mutations in Pediatric Acute Myeloid Leukemia|Completed|||234|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     bone marrow~   "|||2018-05-31 23:07:07.012107|2018-05-31 23:07:07.012107
NCT01247571|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2017-02-10||2017-07-31|2010-11-23|2010-11-24|Estimate|2017-06-28|2017-07-27|Actual||||2017-07-31|2017-08-29|Actual|January 2011||2011-01-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Eligible and treated patients|Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:07:07.114075|2018-05-31 23:07:07.114075
NCT01247558|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-07-23|2010-11-23|2010-11-24|Estimate|||||||2012-07-23|2012-07-25|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy|Administrative Claims Analysis of Metanx® in Diabetic Peripheral Neuropathy|Completed|||500|Anticipated|Pamlab, Inc.|||2||f||||f||||||||||2018-05-31 23:07:07.49829|2018-05-31 23:07:07.49829
NCT01247545|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2015-05-28|2010-11-23|2010-11-24|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ERICCA||Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery|Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in Coronary Artery Bypass Graft Surgery|Completed||Phase 3|1612|Actual|University College, London||2|||f||||t||||||||||2018-05-31 23:07:07.597692|2018-05-31 23:07:07.597692
NCT01247532|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-29|2010-11-23|2010-11-24|Estimate|||||||2010-11-29|2010-11-30|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pilot Study of Mindfulness-Based Stress Reduction for Patients With Persistent Cancer-Related Fatigue|Pilot Study of Mindfulness-Based Stress Reduction for Patients With Persistent Cancer-Related Fatigue|Completed||Phase 1|35|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 23:07:07.725442|2018-05-31 23:07:07.725442
NCT01247519|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|July 2010|Actual|2010-07-31||Interventional|||The Effects of Post-hospitalization Telehealth Care in the Patients Who Admitted Via Emergency Department|The Effects of Post-hospitalization Telehealth Care in the Patients Who Admitted Via Emergency Department|Unknown status|Recruiting|N/A|500|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 23:07:07.796465|2018-05-31 23:07:07.796465
NCT01247506|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-24|Estimate|||||||2010-11-22|2010-11-24|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Different Genetic Features Associated With Hepatic Carcinogenesis|Identification of Survival-related microRNAs in Hepatocellular Carcinoma|Unknown status|Recruiting||160|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples With DNA|"~     HCC tissues and paired nontumor tissues~   "|||2018-05-31 23:07:07.90336|2018-05-31 23:07:07.90336
NCT01247493|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Interventional|m-FLAI||Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)|Multicenter, Phase 2 Clinical Trial Evaluating the Efficacy and Tolerability of Induction and Consolidation Chemotherapy Comprising Fludarabine, Cytarabine, and Attenuated-dose Idarubicin in Elderly Patients With AML(Acute Myeloid Leukemia)|Completed||Phase 2|108|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 23:07:07.99774|2018-05-31 23:07:07.99774
NCT01247480|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2014-01-21|2010-11-22|2010-11-24|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|December 2014||2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer||Unknown status|Active, not recruiting||||National University Hospital, Singapore|||1||f||||f||||||||||2018-05-31 23:07:08.085486|2018-05-31 23:07:08.085486
NCT01247467|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2014-01-21|2010-11-23|2010-11-24|Estimate|||||||2014-01-21|2014-01-22|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Breast Tumor - a Pilot Study||Unknown status|Active, not recruiting||10|Anticipated|National University Hospital, Singapore|||1||f||||f||||||||||2018-05-31 23:07:08.151162|2018-05-31 23:07:08.151162
NCT01247454|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2016-12-02|2010-11-23|2010-11-24|Estimate|||||||2016-12-02|2016-12-06|Estimate|July 2009||2009-07-31|December 2016|2016-12-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|MM||Medication Management and Culture of Safety|Risk Informed Intervention Development and Implementation of Safe Ambulatory Care|Completed||N/A|7000|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 23:07:08.223989|2018-05-31 23:07:08.223989
NCT01247441|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2014-01-13|2010-11-22|2010-11-24|Estimate|||||||2014-01-13|2014-01-14|Estimate||||January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Observational|||Breast Cancer Registry - National University Health System, Singapore||Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 23:07:08.295747|2018-05-31 23:07:08.295747
NCT01247428|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2013-12-19||2016-12-15|2010-11-23|2010-11-24|Estimate|2014-06-10|2014-06-12|Estimate||||2016-12-15|2016-12-19|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|March 2016|Actual|2016-03-31|September 2012|Actual|2012-09-30||Interventional|DESSOLVE-I|Patients with symptomatic ischemic heart disease due to discrete de novo lesions < 20 mm in length in the native coronary arteries with reference vessel diameters between 2.5 mm and 3.5 mm.|First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease|A First-In-Human Trial of a New Novel DES (MiStent System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in the Native Coronary Arteries|Completed||Phase 2|30|Actual|Micell Technologies||1|||f||||t||||||||No||2018-05-31 23:07:08.376075|2018-05-31 23:07:08.376075
NCT01247415|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-07-03|2010-11-23|2010-11-24|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|March 2011|Actual|2011-03-31||Observational|||Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine|Clinical Investigation of Anaphylaxis, Allergic-like Reactions and Oculo-Respiratory Syndrome (ORS) Following Administration of an Adjuvanted Vaccine Against H1N1 Pandemic Influenza|Unknown status|Active, not recruiting||138|Actual|PHAC/CIHR Influenza Research Network|||4||f||||f||||||Samples With DNA|"~     whole blood,PBMC and serum~   "|||2018-05-31 23:07:08.920092|2018-05-31 23:07:08.920092
NCT01247402|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-12-08|2010-11-23|2010-11-24|Estimate|||||||2010-12-08|2010-12-09|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|PACUBA 1||Paclitaxel Balloon Versus Standard Balloon in In-stent Restenoses of the Superficial Femoral Artery (PACUBA I Trial)|A Monocenter Randomized Clinical Trial of PAClitaxel drUg-eluting BAlloon Versus Standard Percutaneous Transluminal Angioplasty to Reduce Restenosis in Patients With In-stent Stenoses in the Superficial Femoral and Proximal Popliteal Artery|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 23:07:09.03995|2018-05-31 23:07:09.03995
NCT01247389|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2016-09-16|2010-11-23|2010-11-24|Estimate|||||||2016-09-16|2016-09-19|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Incisional Hernia After Midline Versus Transverse Extraction Incision in Laparoscopic Colectomy|Incisional Hernia After Midline Versus Transverse Extraction Incision in Laparoscopic Colectomy: A Pilot Randomized Trial|Recruiting||N/A|50|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:07:09.206201|2018-05-31 23:07:09.206201
NCT01247376|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Temperature Sensitive Release of PGE2 and Diminished Energy Requirements in Synovial Tissue With Postoperative Cryotherapy - A Prospective Randomised Study After Knee Arthroscopy|Temperature Sensitive Release of PGE2 and Diminished Energy Requirements in Synovial Tissue With Postoperative Cryotherapy - A Prospective Randomised Study After Knee Arthroscopy|Completed||N/A|40|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 23:07:09.338301|2018-05-31 23:07:09.338301
NCT01247363|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-04-01|2010-11-22|2010-11-24|Estimate|||||||2011-04-01|2011-04-04|Estimate|November 2010||2010-11-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of LY2608204 in Patients With Type 2 Diabetes|Safety and Tolerability of Multiple Ascending Doses of LY2608204 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|20|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:07:09.424504|2018-05-31 23:07:09.424504
NCT01247350|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2017-03-10||2017-09-06|2010-11-22|2010-11-24|Estimate|2017-09-06|2018-04-13|Actual||||2017-09-06|2018-04-13|Actual|November 2010||2010-11-30|September 2017|2017-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of LY3009104(Baricitinib) for Healthy Subjects|A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Japanese Healthy Subjects|Completed||Phase 1|34|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 23:07:09.531085|2018-05-31 23:07:09.531085
NCT01247337|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2014-03-20|2010-11-23|2010-11-24|Estimate|||||||2014-03-20|2014-03-21|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma|Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Gemcitabine and Capecitabine in Combination With Cetuximab in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma. A Phase II Trial.|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Herlev Hospital||1|||f||||t||||||||||2018-05-31 23:07:10.296202|2018-05-31 23:07:10.296202
NCT01247324|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|2017-03-30|2016-10-10|2018-05-23|2010-11-23|2010-11-24|Estimate|2017-07-17|2017-07-18|Actual|2016-10-10|2016-10-12|Estimate|2018-05-23|2018-05-25|Actual|August 31, 2011|Actual|2011-08-31|May 2018|2018-05-31|November 20, 2019|Anticipated|2019-11-20|April 2, 2015|Actual|2015-04-02||Interventional||Intent-to-treat (ITT) population included all randomized participants in the study.|A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis|A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif®) in Patients With Relapsing Multiple Sclerosis|Active, not recruiting||Phase 3|821|Actual|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 23:07:10.460011|2018-05-31 23:07:10.460011
NCT01247311|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2017-06-13|2010-11-22|2010-11-24|Estimate|||||||2017-06-13|2017-06-15|Actual|November 2010||2010-11-30|June 2017|2017-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Vitamin D and the Health of Blood Vessels in Kidney Disease|The Impact of Vitamin D Supplementation on Vascular Stiffness and Blood Pressure in Chronic Kidney Disease Patients|Completed||N/A|129|Actual|University of British Columbia||3|||f||||t||||||||||2018-05-31 23:07:11.773352|2018-05-31 23:07:11.773352
NCT01247298|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2016-12-28||2017-07-13|2010-11-22|2010-11-24|Estimate|2017-04-04|2017-06-19|Actual||||2017-07-13|2017-08-21|Actual|October 2010||2010-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|RAD 0902||A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma|RAD 0902: A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma|Completed||Early Phase 1|17|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 23:07:11.920369|2018-05-31 23:07:11.920369
NCT01247285|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2011-01-24||2011-01-24|2010-11-22|2010-11-24|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|May 2001||2001-05-31|January 2011|2011-01-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions|A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:07:12.284024|2018-05-31 23:07:12.284024
NCT01247272|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2011-01-24||2011-01-24|2010-11-22|2010-11-24|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|May 2001||2001-05-31|January 2011|2011-01-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions|A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:07:12.840327|2018-05-31 23:07:12.840327
NCT01247259|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-22|2010-11-22|2010-11-24|Estimate|||||||2010-11-22|2010-11-24|Estimate|November 2007||2007-11-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Interventional|||Efficacy of Sublingual Immunotherapy in Polysensitized Allergic Rhinitis Patients|Efficacy of Sublingual Immunotherapy With House Dust Mite Extract in Poly-allergen-sensitized Allergic Rhinitis Patients|Completed||N/A|134|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:07:13.450929|2018-05-31 23:07:13.450929
NCT01247246|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-05-22|2010-11-22|2010-11-24|Estimate|||||||2014-05-22|2014-05-26|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer|A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|SciClone Pharmaceuticals||4|||f||||f||||||||||2018-05-31 23:07:13.555116|2018-05-31 23:07:13.555116
NCT01247233|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2017-05-03|2010-11-23|2010-11-24|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2010||2010-12-31|May 2017|2017-05-31|October 2025|Anticipated|2025-10-31|October 2020|Anticipated|2020-10-31||Interventional|SHARE||Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI)for Breast Cancer|Phase III Multicentric Trial Comparing Accelerated Partial Breast Irradiation (APBI) Versus Standard or Hypofractionated Whole Breast Irradiation in Low Risk of Local Recurrence of Breast Cancer|Active, not recruiting||Phase 3|1006|Actual|UNICANCER||2|||f||||t||||||||||2018-05-31 23:07:13.720787|2018-05-31 23:07:13.720787
NCT01247220|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2014-10-01||2014-10-03|2010-11-22|2010-11-24|Estimate|2014-10-03|2014-10-06|Estimate||||2014-10-03|2014-10-06|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Revolution||REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study|REVOLUTIONARY: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by Ultra Widefield angIOgraphy in combiNAtion With Ranibizumab Study Phase II|Completed||Phase 2|12|Actual|Retina Associates of Florida, P.A.|small study size|2|||f||||t||||||||||2018-05-31 23:07:14.024499|2018-05-31 23:07:14.024499
NCT01247207|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2018-04-25|2010-11-23|2010-11-24|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2010|Actual|2010-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Ataluren for Previously Treated Patients With nmDBMD in the US|An Open-label, Safety Study for Previously Treated Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy|Enrolling by invitation||Phase 3|110|Anticipated|PTC Therapeutics||1|||f||||f||||||||No||2018-05-31 23:07:14.661992|2018-05-31 23:07:14.661992
NCT01247194|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-02-01|2010-11-22|2010-11-24|Estimate|||||||2012-02-01|2012-02-03|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1|A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection|Completed||Phase 1|24|Actual|Presidio Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 23:07:14.822783|2018-05-31 23:07:14.822783
NCT01247181|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-09-07|2010-11-23|2010-11-24|Estimate|||||||2011-09-07|2011-09-08|Estimate|November 2010||2010-11-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CAMPS||Cameroon Mobile Phone SMS Trial|Improving Adherence to HAART Using Mobile Phone Text Messages|Completed||N/A|200|Actual|Yaounde Central Hospital||2|||f||||t||||||||||2018-05-31 23:07:14.974654|2018-05-31 23:07:14.974654
NCT01247168|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2012-06-05|2010-11-23|2010-11-24|Estimate|||||||2012-06-05|2012-06-06|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||An Open-Label, Dose-Escalation Study of AZD2461|An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors|Completed||Phase 1|75|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 23:07:15.093494|2018-05-31 23:07:15.093494
NCT01247155|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate||||April 2009|2009-04-30||||||||Observational|||First Postoperative Day Review After Uneventful Phacoemulsification||Completed|||||Veroia General Hospital|||2||f||||||||||||||2018-05-31 23:07:15.19193|2018-05-31 23:07:15.19193
NCT01247142|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2014-07-04|2010-11-23|2010-11-24|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis||Completed|||24|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples Without DNA|"~     exhaled breath condensate~   "|||2018-05-31 23:07:15.285949|2018-05-31 23:07:15.285949
NCT01247129|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Delaying the Superficial Inferior Epigastric Artery (SIEA) Flap and Determining the Change in SIEA Diameter and Blood Flow|Delaying the Superficial Inferior Epigastric Artery (SIEA) Flap: A Solution to the Problem of the Small Caliber of the Donor Artery|Completed||Phase 2|26|Actual|University Medical Centre Ljubljana||1|||f||||f||||||||||2018-05-31 23:07:15.397259|2018-05-31 23:07:15.397259
NCT01247116|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|December 2009||2009-12-31|November 2010|2010-11-30||||December 2012|Anticipated|2012-12-31||Observational|||First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension|First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study|Unknown status|Recruiting||15|Anticipated|University of Calgary|||||f||||f||||||||||2018-05-31 23:07:15.50144|2018-05-31 23:07:15.50144
NCT01247103|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-30|2010-11-23|2010-11-24|Estimate|||||||2010-11-30|2010-12-01|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects|A Phase 1, Single-centre Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Dose, Parallel-group Study to Determine the Safety, Tolerability, and Pharmacokinetics of AZD4316 in Healthy Volunteers|Withdrawn||Phase 1|128|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 23:07:15.6903|2018-05-31 23:07:15.6903
NCT01247090|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2011-04-04||2018-02-07|2010-11-23|2010-11-24|Estimate|2011-04-04|2011-04-28|Estimate||||2018-02-07|2018-02-08|Actual|October 2010||2010-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease|Pilot Study of the Effect of Intradialytic Vasopressin Infusion on Chronic Blood Pressure Control in Hypertensive Patients With End Stage Renal Disease: A Program to Develop a Decisive, Randomized Controlled Trial|Recruiting||Phase 2|36|Anticipated|Columbia University||3|||f||||t||||||||No||2018-05-31 23:07:15.771006|2018-05-31 23:07:15.771006
NCT01247077|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2015-03-30|2010-11-23|2010-11-24|Estimate|||||||2015-03-30|2015-03-31|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?|Neuropsychologic and Immunological Evaluation in Treatment of Thyroid Diseases. Is Selenium Efficient?|Completed||Phase 2|44|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 23:07:16.279601|2018-05-31 23:07:16.279601
NCT01247064|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2014-03-14||2014-07-31|2010-11-22|2010-11-24|Estimate|2014-07-31|2014-08-19|Estimate||||2014-07-31|2014-08-19|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Hypertonic Saline for Acute Bronchiolitis|Nebulized Hypertonic Saline for Acute Bronchiolitis in the Emergency Department|Completed||Phase 4|62|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 23:07:16.465707|2018-05-31 23:07:16.465707
NCT01247051|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2011-08-26|2010-11-23|2010-11-24|Estimate|||||||2011-08-26|2011-08-29|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of Two Different Heart-lung Machine Filling Methods: Precoating Versus Colloidal Fluids||Completed||N/A|90|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 23:07:18.534663|2018-05-31 23:07:18.534663
NCT01247038|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-06-19|2010-11-23|2010-11-24|Estimate|||||||2017-06-19|2017-06-21|Actual|January 2011||2011-01-31|June 2017|2017-06-30|July 10, 2015|Actual|2015-07-10|July 10, 2015|Actual|2015-07-10||Interventional|MagnumCRCT||A Multicentre Trial to Compare Two Articulating Bearing Surfaces as Used in Cementless Primary Hip Arthroplasty|A Multicentre Prospective Randomised Control Trial to Compare Two Articulating Bearing Surfaces, Ceramic on Metal and Metal on Metal Large Diameter Femoral Heads, as Used in Cementless Primary Hip Arthroplasty|Terminated||N/A|130|Actual|Zimmer Biomet||2||Biomet's focus has changed and we no longer expect further developments|f||||f||||||||No||2018-05-31 23:07:18.603438|2018-05-31 23:07:18.603438
NCT01247025|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-03-21|2010-11-22|2010-11-24|Estimate|||||||2014-03-21|2014-03-26|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|August 2011|Anticipated|2011-08-31|April 2011|Actual|2011-04-30||Observational|||Prolonged Grief and Suicide Among Veterans|Examining Prolonged Grief Disorder and Its Relationship to Self-Directed Violence Among Veterans|Withdrawn|||0|Actual|VA Eastern Colorado Health Care System|||1|Study should not have been listed on ClinicalTrials.gov|f||||f||||||||||2018-05-31 23:07:18.723228|2018-05-31 23:07:18.723228
NCT01247012|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2011-09-06|2010-11-23|2010-11-24|Estimate|||||||2011-09-06|2011-09-07|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|MILOve||Minimization of IntraLipid Versus Omegaven|A Randomized Controlled Trial of Minimization of Intralipid Versus Omegaven for the Treatment of Severe Cholestasis- A Pilot Trial|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Children's & Women's Health Centre of British Columbia||2|||f||||t||||||||||2018-05-31 23:07:18.837334|2018-05-31 23:07:18.837334
NCT01246999|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2015-09-24||2016-11-10|2010-11-23|2010-11-24|Estimate|2016-08-25|2016-10-19|Estimate||||2016-11-10|2016-12-29|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional||Baseline characteristics were confined to the children enrolled in the second year only. In the second year randomization was confined to the two groups of greatest interest: 1) LAIV IN twice and 2) IIV IM followed by LAIV IN.|Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children|Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated Seasonal (A/California/7/2009-like, A/Perth/16/2009-like, and B/Brisbane/60/2008-like (B/Victoria Lineage) Influenza Vaccines in Children|Completed||Phase 4|34|Actual|University of Rochester||4|||f||||f||||||||||2018-05-31 23:07:18.939445|2018-05-31 23:07:18.939445
NCT01246986|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2018-05-29|2010-11-23|2010-11-24|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 2011||2011-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of LY2157299 in Participants With Hepatocellular Carcinoma|Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma|Active, not recruiting||Phase 2|235|Anticipated|Eli Lilly and Company||6|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:07:19.437803|2018-05-31 23:07:19.437803
NCT01246973|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2016-01-05||2016-02-08|2010-11-22|2010-11-24|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|February 2011||2011-02-28|February 2016|2016-02-29|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Oral Curcumin for Radiation Dermatitis|Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients|Completed||Phase 2/Phase 3|686|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 23:07:19.556818|2018-05-31 23:07:19.556818
NCT01246271|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|February 2008||2008-02-29|January 2008|2008-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Sub Urethral Sling With or With Out Anterior Repair|a Retrospective Cohort Recognize the Out Comes of SUS With or Without Anterior Vaginal Repair|Completed|||98|Actual|Tabriz University|||2||f||||t||||||||||2018-05-31 23:07:27.881418|2018-05-31 23:07:27.881418
NCT01246960|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2014-10-03|2014-04-25|2014-10-03|2010-11-23|2010-11-24|Estimate|2014-10-03|2014-10-08|Estimate|2014-04-25|2014-05-13|Estimate|2014-10-03|2014-10-08|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional||Intent-to-Treat (ITT) Population: all randomized participants.|A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer|Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach|Completed||Phase 2|168|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:07:19.97603|2018-05-31 23:07:19.97603
NCT01246947|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-06-30|2010-11-23|2010-11-24|Estimate|||||||2017-06-30|2017-07-02|Actual|September 2010|Actual|2010-09-30|June 2017|2017-06-30|February 2017|Actual|2017-02-28|June 2016|Actual|2016-06-30||Interventional|||Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation|A Prospective Randomized Trial of Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Mitral Operation|Completed||N/A|57|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 23:07:21.030226|2018-05-31 23:07:21.030226
NCT01246934|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Segment Transport Versus Acute Shortening In The Treatment of Tibial Pseudarthroses With Bone Loss||Completed||N/A|22|Actual|Bezmialem Vakif University||1|||f||||f||||||||||2018-05-31 23:07:21.099755|2018-05-31 23:07:21.099755
NCT01246921|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-23|||2010-11-23|2010-11-23|2010-11-24|Estimate|||||||2010-11-23|2010-11-24|Estimate|September 2009||2009-09-30|June 2009|2009-06-30||||August 2011|Anticipated|2011-08-31||Interventional|||Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo|Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial|Unknown status|Recruiting|Phase 4|50|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||||||||||||2018-05-31 23:07:21.152305|2018-05-31 23:07:21.152305
NCT01246908|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-07-08|2010-11-22|2010-11-24|Estimate|||||||2012-07-08|2012-07-10|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|CX157-201||Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression|Completed||Phase 2|360|Actual|CeNeRx BioPharma Inc.||2|||f||||f||||||||||2018-05-31 23:07:21.236173|2018-05-31 23:07:21.236173
NCT01246895|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2016-01-07||2017-06-06|2010-11-22|2010-11-24|Estimate|2017-06-06|2018-01-24|Actual||||2017-06-06|2018-01-24|Actual|March 2011||2011-03-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational||Sample size determination for the 1-year trial was previously reported. All treated participants who enrolled in the extension study were included in the efficacy analyses, which were performed according to a preapproved statistical analysis plan.|Follow-Up Study Evaluating The Long Term Safety and Efficacy of BST-CarGel and Microfracture Repair of the Knee|Follow-up Study Evaluating The Long-Term Safety and Efficacy of BST-CarGel® and Microfracture In Repair of Focal Articular Cartilage Lesions on The Femoral Condyle (Extension Study of Protocols CG-CIP01-P & CG-CIP02-P)|Completed|||67|Actual|Piramal Healthcare Canada Ltd|Since the sample size was not predetermined, the statistical methods were used in a conditional fashion such that those that were determined to be invalid or inappropriate upon data review were discarded or replaced by more appropriate analyses.||2||f||||f||||||||No|Not planned|2018-05-31 23:07:21.360999|2018-05-31 23:07:21.360999
NCT01246882|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-05-08|2010-11-22|2010-11-23|Estimate|||||||2017-05-08|2017-05-10|Actual|January 2011||2011-01-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SIRRACT||Stroke Inpatient Rehabilitation Reinforcement of ACTivity|Stroke Inpatient Rehabilitation Reinforcement of ACTivty: An International Multisite Clinical Trial|Completed||Phase 2|140|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:07:21.704281|2018-05-31 23:07:21.704281
NCT01246869|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2017-09-26|2010-11-22|2010-11-23|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2011||2011-08-31|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water|Assessment of Primary and Metastatic Brain Tumor Hypoxia With 18F-Fluoromisonidazole, [18F]Fluoro-2-deoxy-D-glucose (FDG) and [15O]Water (H215O)|Recruiting|||30|Anticipated|University of Utah|||||f||||t||||||||||2018-05-31 23:07:21.824867|2018-05-31 23:07:21.824867
NCT01246856|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-09-09|2010-11-22|2010-11-23|Estimate|||||||2011-09-09|2011-09-12|Estimate|November 2010||2010-11-30|September 2011|2011-09-30||||October 2011|Anticipated|2011-10-31||Observational|TOXTAC||MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study|MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC)|Unknown status|Recruiting||150|Anticipated|Radboud University|||||f||||||||||||||2018-05-31 23:07:21.893281|2018-05-31 23:07:21.893281
NCT01246843|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-11-01|2010-11-22|2010-11-23|Estimate|||||||2011-11-01|2011-11-02|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib|Evaluation of Cognitive Function of Patients Treated With Sunitinib or Sorafenib|Completed|||50|Anticipated|Radboud University|||2||f||||f||||||||||2018-05-31 23:07:21.954925|2018-05-31 23:07:21.954925
NCT01246830|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-12-02|2010-11-22|2010-11-23|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2012||2012-01-31|September 2010|2010-09-30|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Observational|||The Use of 2D and 3D Imaging Modalities and Its Influence on Diagnosis and Treatment Planning in Orthodontics|The Use of 2D and 3D Imaging Modalities and Its Influence on Diagnosis and Treatment Planning in Orthodontics|Completed|||32|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 23:07:22.016042|2018-05-31 23:07:22.016042
NCT01246817|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-04-10|2010-11-22|2010-11-23|Estimate|||||||2012-04-10|2012-04-11|Estimate|August 2009||2009-08-31|April 2012|2012-04-30||||August 2012|Anticipated|2012-08-31||Interventional|||Temsirolimus-RCC-imaging|Evaluation of the Activity of Temsirolimus With FDG-PET and FLT-PET in Patients With Renal Cell Cancer|Unknown status|Recruiting|Phase 2|51|Anticipated|Radboud University|||||f||||t||||||||||2018-05-31 23:07:23.156691|2018-05-31 23:07:23.156691
NCT01246804|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-11-26|2010-11-22|2010-11-23|Estimate|||||||2012-11-26|2012-11-27|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|GINGER||The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)|The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)|Completed||Phase 1|18|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 23:07:23.233114|2018-05-31 23:07:23.233114
NCT01246791|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2014-04-10||2014-05-15|2010-11-22|2010-11-23|Estimate|2014-05-15|2014-06-17|Estimate||||2014-05-15|2014-06-17|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers|A Single Dose Pharmacokinetics Study of NPC-01 (1mg Norethisterone and 0.02mg Ethynyl Estradiol) in Healthy Female Volunteers|Completed||Phase 3|12|Actual|Nobelpharma||1|||f||||f||||||||||2018-05-31 23:07:23.326265|2018-05-31 23:07:23.326265
NCT01246778|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-04-30|2010-11-22|2010-11-23|Estimate|||||||2014-04-30|2014-05-01|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|SCAR||Sunitinib and Atrial Trabeculae Contractility|The Influence of Sunitinib on Contractility of Human Atrial Trabeculae|Completed|||20|Actual|Radboud University|||2||f||||f||||||None Retained|"~     Atrial tissue~   "|||2018-05-31 23:07:23.537575|2018-05-31 23:07:23.537575
NCT01246765|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2018-05-01|2010-11-22|2010-11-23|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2008||2008-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|15 Months|Observational [Patient Registry]|||National Pregnancy Registry for Atypical Antipsychotics|National Pregnancy Registry for Atypical Antipsychotics|Recruiting|||800|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 23:07:23.605335|2018-05-31 23:07:23.605335
NCT01246752|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-12-02|2010-11-22|2010-11-23|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AML||Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR|Randomised Trial on Allogeneic Haematopoietic Stem Cell Transplantation in Patients Under the Age of 60 Years With Acute Myeloid Leukemia of Intermediate Risk in First Complete Remission and a Matched Sibling or Unrelated Donor (ETAL-1)|Unknown status|Recruiting|Phase 3|356|Anticipated|University Hospital Carl Gustav Carus||2|||f||||t||||||||||2018-05-31 23:07:23.797485|2018-05-31 23:07:23.797485
NCT01246739|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2018-01-11|2010-11-22|2010-11-23|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2011||2011-06-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|AUSC||Adrenalectomy Versus Follow-up in Patients With Subclinical Cushings Syndrome|Adrenalectomy Versus Follow-up in Patients With Mild Hypercortisolism: a Prospective Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Region Skane||2|||f||||f||||||||||2018-05-31 23:07:24.042087|2018-05-31 23:07:24.042087
NCT01246726|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2016-11-14|2010-11-22|2010-11-23|Estimate|||||||2016-11-14|2016-11-15|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|MOSS||Multiple Oncological Serial Scans Study|The Tumour Bed as Target for Breast Irradiation Following Breast Conserving Surgery|Terminated||N/A|9|Actual|University Hospitals Bristol NHS Foundation Trust||||MRI scanner de-commissioned and there was no suitable alternative.|f||||f||||||||||2018-05-31 23:07:24.149949|2018-05-31 23:07:24.149949
NCT01246713|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2013-02-18||2017-03-28|2010-11-22|2010-11-23|Estimate|2013-03-26|2013-05-08|Estimate||||2017-03-28|2017-05-08|Actual|December 2010||2010-12-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|May 2011|Actual|2011-05-31||Interventional|||Effect on Acetaminophen Metabolism by Liquid Formulations|Effect on Acetaminophen Metabolism by Liquid Formulations: Do Excipients in Liquid Formulation Prevent Production of Toxic Metabolites?|Completed||N/A|15|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 23:07:24.232427|2018-05-31 23:07:24.232427
NCT01246700|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Sensory Attention Focused Exercise in Parkinson's Disease|Sensory Attention Focused Exercise in Parkinson's Disease: A Randomized Double-Crossover Trial.|Unknown status|Active, not recruiting|N/A|76|Actual|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||2|||f||||f||||||||||2018-05-31 23:07:24.415465|2018-05-31 23:07:24.415465
NCT01246687|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2017-12-24|2010-11-22|2010-11-23|Estimate|||||||2017-12-24|2017-12-27|Actual|March 2010|Actual|2010-03-31|December 2017|2017-12-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|myDIDeA||Web-based Dietary Intervention for Diabetic Patients|Dietary Intervention Among Patients With Type 2 Diabetes Mellitus: An e-Approach|Completed||N/A|134|Actual|Monash University||2|||f||||||||||||||2018-05-31 23:07:24.490318|2018-05-31 23:07:24.490318
NCT01246674|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-07-18|2010-11-22|2010-11-23|Estimate|||||||2012-07-18|2012-07-19|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|THA||Thigh Swelling, Hip-muscle Strength, and Functional Performance Following Total Hip Arthroplasty|Thigh Swelling, Hip-muscle Strength, and Functional Performance Following Total Hip Arthroplasty Monitored Pre-operatively, on the Day of Discharge, and One Week Post-surgery|Completed|||30|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 23:07:24.557082|2018-05-31 23:07:24.557082
NCT01246661|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|November 2010|Anticipated|2010-11-30|April 2010|Actual|2010-04-30||Observational|||MilkScreen™ Home Test for Alcohol in Breast Milk Clinical Study|MilkScreen™ Home Test for Alcohol in Breast Milk Clinical Study|Unknown status|Active, not recruiting||50|Anticipated|UpSpring Baby, Ltd.|||||f||||t||||||||||2018-05-31 23:07:24.609568|2018-05-31 23:07:24.609568
NCT01246648|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-08-06|2010-11-22|2010-11-23|Estimate|||||||2012-08-06|2012-08-07|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|January 2013|Anticipated|2013-01-31|February 2011|Actual|2011-02-28||Interventional|||Chronic Presence of Epstein Barr Virus in Sulcular and Junctional Epithelial Tissue From Gingiva is Associated With Severe Periodontitis||Unknown status|Recruiting|N/A|6|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 23:07:24.660455|2018-05-31 23:07:24.660455
NCT01246635|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-14|||2015-03-27|2010-11-22|2010-11-23|Estimate|||||||2015-03-27|2015-03-30|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|November 2011|Actual|2011-11-30||Interventional|||Smith & Nephew's European Trufit Study|A Prospective, Multi-Center, Randomized, Single-Blind, Controlled Study Comparing the Trufit CB (Cartilage Bone) Implant to Microfracture for the Treatment of Patients With Single, Isolated Defects of the Knee|Completed||Phase 4|153|Actual|Smith & Nephew, Inc.||3|||f||||t||||||||||2018-05-31 23:07:24.748603|2018-05-31 23:07:24.748603
NCT01246622|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2018-03-28|2010-11-22|2010-11-23|Estimate|||||||2018-03-28|2018-03-29|Actual|February 7, 2011|Actual|2011-02-07|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2014|Actual|2014-05-01||Interventional|||Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of Cytarabine and Lenalidomide in Relapsed or Refractory Acute Myeloid Leukemia Patients|Active, not recruiting||Phase 1|32|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 23:07:24.914128|2018-05-31 23:07:24.914128
NCT01246609|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2015-09-07|2010-11-22|2010-11-23|Estimate|||||||2015-09-07|2015-09-09|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||The Effect of Irrigation Solution Volume on Electrolytes and Acid-Base Balance|The Effect of Irrigation Solution Volume on Electrolytes and Acid-Base Balance in Patients Undergoing Percutaneous Lithotripsy|Terminated|||1|Actual|Rambam Health Care Campus||||the doctor who ran this study, left|f||||f||||||||||2018-05-31 23:07:25.034305|2018-05-31 23:07:25.034305
NCT01246596|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-12-17|2010-11-22|2010-11-23|Estimate|||||||2012-12-17|2012-12-18|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|January 2014|Anticipated|2014-01-31|June 2011|Actual|2011-06-30||Interventional|||Chronic Presence of Epstein Barr Virus in Epithelial Cells From Gingiva is Associated With Periodontitis||Unknown status|Recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 23:07:25.088663|2018-05-31 23:07:25.088663
NCT01246583|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22||2013-04-09|2013-04-09|2010-11-22|2010-11-23|Estimate||||2013-04-09|2013-04-16|Estimate|2013-04-09|2013-04-16|Estimate|February 2011||2011-02-28|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||CP-690-550 Ointment For Chronic Plaque Psoriasis|A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild To Moderate Chronic Plaque Psoriasis|Completed||Phase 2|71|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:07:25.176778|2018-05-31 23:07:25.176778
NCT01246570|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2014-09-24|2010-11-22|2010-11-23|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|April 2013|Actual|2013-04-30||Interventional|||Exercise Training Adherence After Cardiac Rehabilitation in Coronary Heart Disease Patients|Supported Home-based Exercise Training Versus Usual Care After Cardiac Rehabilitation. A Randomized Controlled Study|Completed||N/A|48|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 23:07:25.291734|2018-05-31 23:07:25.291734
NCT01246557|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2014-04-03|2010-11-22|2010-11-23|Estimate|||||||2014-04-03|2014-04-04|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|LENDEX-LLC-09||Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment|Open Label Multi-center Pilot Phase I/II Non-controlled Clinical Trial to Assess Safety and Efficieecy of the Lenalidomide and Dexamethasone Association in Patients With Chronic Relapse or Treatment Resistant Lymphatic Leukemia Following Treatment Containing Fludarabine.|Completed||Phase 1/Phase 2|20|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||||f||||t||||||||||2018-05-31 23:07:25.386973|2018-05-31 23:07:25.386973
NCT01246544|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-09-07|2010-11-22|2010-11-23|Estimate|||||||2011-09-07|2011-09-08|Estimate|November 2010||2010-11-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|Patient Safety||Helsinki Declaration on Patient Safety|Helsinki Declaration on Patient Safety|Completed|||28|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 23:07:25.483919|2018-05-31 23:07:25.483919
NCT01246531|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|January 2008||2008-01-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Metabolic Assessment of Aging Men With Urinary Lithiasis|Clinical Investigation of Aging Men With Renal Stones: The Role of Bone Demineralization (Metabolic and Hormonal Assessment)|Completed|||42|Actual|University of Sao Paulo General Hospital|||2||f||||t||||||||||2018-05-31 23:07:25.547446|2018-05-31 23:07:25.547446
NCT01246518|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2012-10-24|2010-11-22|2010-11-23|Estimate|||||||2012-10-24|2012-10-25|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis|An Open, Multi-centre Trial Comparing the Efficacy and Safety of Two Different Treatment Regimens of Topical MOB015 Treatment of Distal Subungual Onychomycosis (DSO)|Completed||Phase 2|250|Anticipated|Moberg Pharma AB||2|||f||||f||||||||||2018-05-31 23:07:25.616436|2018-05-31 23:07:25.616436
NCT01246505|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2012-07-11|2010-11-22|2010-11-23|Estimate|||||||2012-07-11|2012-07-12|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|PFAST-CTOs||Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions|Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions|Completed||Phase 3|105|Actual|BridgePoint Medical|||||f||||t||||||||||2018-05-31 23:07:25.683837|2018-05-31 23:07:25.683837
NCT01246492|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-05-17|2010-11-22|2010-11-23|Estimate|||||||2012-05-17|2012-05-18|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||The Effect of Artificial Sweeteners on Blood Glucose Response|The Effect of Artificial Sweeteners on Blood Glucose Response|Withdrawn||N/A|0|Actual|Northumbria University||4|||f||||f||||||||||2018-05-31 23:07:25.752845|2018-05-31 23:07:25.752845
NCT01246479|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2015-04-13||2015-04-13|2010-11-22|2010-11-23|Estimate|2015-04-13|2015-04-29|Estimate||||2015-04-13|2015-04-29|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|October 2012|Actual|2012-10-31||Interventional|||Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study|Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study|Completed||Phase 3|23|Actual|Valneva Austria GmbH||1|||f||||f||||||||||2018-05-31 23:07:25.829351|2018-05-31 23:07:25.829351
NCT01246466|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22||2014-04-15|2016-01-29|2010-11-22|2010-11-23|Estimate||||2014-06-16|2014-06-19|Estimate|2016-01-29|2016-02-29|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|DEEP||Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study|Feasibility Trial of a Hybrid Approach for Treatment of Patients With Persistent or Longstanding Persistent Atrial Fibrillation With Radiofrequency Ablation|Completed||Phase 1/Phase 2|24|Actual|AtriCure, Inc.||1|||f||||t||||||||||2018-05-31 23:07:25.983861|2018-05-31 23:07:25.983861
NCT01246453|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2011-07-15|2010-11-22|2010-11-23|Estimate|||||||2011-07-15|2011-07-18|Estimate|December 2003||2003-12-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema|A Prospective, Randomized, Double Blind, Controlled Trial to Evaluate Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Pleural Empyema|Completed||Phase 4|204|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 23:07:26.055762|2018-05-31 23:07:26.055762
NCT01160705|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2017-05-23|2010-07-09|2010-07-12|Estimate|||||||2017-05-23|2017-05-24|Actual|November 2009||2009-11-30|May 2017|2017-05-31||||December 2017|Anticipated|2017-12-31||Observational|||Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2|Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer|Active, not recruiting|||43|Actual|Cancer Trials Ireland|||||f||||||||||||||2018-05-31 23:35:51.303449|2018-05-31 23:35:51.303449
NCT01246440|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2016-08-09|2010-11-22|2010-11-23|Estimate|||||||2016-08-09|2016-08-11|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission|A Phase II of Intraperitoneal Catumaxomab as a Consolidation Therapy in Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma in Second or Third Complete Clinical Disease Remission|Completed||Phase 2|39|Actual|Grupo Español de Investigación en Cáncer de Ovario||1|||f||||f||||||||||2018-05-31 23:07:26.12727|2018-05-31 23:07:26.12727
NCT01246427|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2016-09-13|2010-11-22|2010-11-23|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|HBC||Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer|Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy|Completed||Phase 3|138|Actual|Centre Leon Berard||2|||f||||f||||||||||2018-05-31 23:07:26.220328|2018-05-31 23:07:26.220328
NCT01246414|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|January 2010||2010-01-31|November 2010|2010-11-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|||Inflammatory Markers in Exhaled Breath Condensates From Asthmatic Patients|Inflammatory Markers in Exhaled Breath Condensates From Asthmatic Patients|Completed|||38|Actual|Chulalongkorn University|||3||f||||f||||||Samples Without DNA|"~     Exhaled breathe condensates~   "|||2018-05-31 23:07:26.302635|2018-05-31 23:07:26.302635
NCT01246401|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2017-02-27||2017-06-14|2010-11-22|2010-11-23|Estimate|2017-06-14|2017-07-17|Actual||||2017-06-14|2017-07-17|Actual|March 2011||2011-03-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|NewHope||Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations|Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations|Completed||Phase 1/Phase 2|151|Actual|Yale University||2|||f||||t||||||||Yes|Data has been shared with the National Institute on Drug Abuse as a site in the data harmonization project associated with Seek, Test, Treat and Retain for Criminal Justice Populations.|2018-05-31 23:07:26.456133|2018-05-31 23:07:26.456133
NCT01246388|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-31|||2014-10-19|2010-11-21|2010-11-23|Estimate|||||||2014-10-19|2014-10-21|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy|Evaluation of Fibrosis and Steatosis in Patients With Chronic Hepatopathy: Non-invasive Imaging and Serum Markers vs. Liver Biopsy|Unknown status|Active, not recruiting||50|Anticipated|Tischendorf, Jens, M.D.|||1||f||||f||||||Samples Without DNA|"~     Blood Serum~   "|||2018-05-31 23:07:26.991059|2018-05-31 23:07:26.991059
NCT01246375|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|||2010-11-24|2010-11-22|2010-11-23|Estimate|||||||2010-11-24|2010-11-25|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids|Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids|Unknown status|Not yet recruiting|N/A|20|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:07:27.073541|2018-05-31 23:07:27.073541
NCT01246362|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|||2017-02-08|2010-11-22|2010-11-23|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2011||2011-07-31|February 2017|2017-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty|A Randomized Controlled Trial to Study the Efficacy of Pre-emptive Etoricoxib in Reducing Postoperative Pain and Improving Functional Outcome in Total Knee Arthroplasty|Completed||Phase 2|65|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 23:07:27.137799|2018-05-31 23:07:27.137799
NCT01246349|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2014-01-17||2017-11-13|2010-11-22|2010-11-23|Estimate|2014-03-15|2014-04-21|Estimate||||2017-11-13|2017-11-17|Actual|September 2010||2010-09-30|November 2017|2017-11-30|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Motivational Interviewing for Weight Loss|Motivational Interviewing as an Intervention to Increase Adolescent Self-Efficacy and Promote Weight Loss|Completed||N/A|40|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:07:27.220855|2018-05-31 23:07:27.220855
NCT01246336|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|||2017-10-30|2010-11-22|2010-11-23|Estimate|||||||2017-10-30|2017-10-31|Actual|August 2009||2009-08-31|October 2017|2017-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Exploratory Study Using Nanotechnology to Detect Biomarkers of Parkinson's Disease From Exhaled Breath|Exploratory Study to Detect Volatile Biomarkers of Idiopathic Parkinson's Disease and Parkinsonism From Exhaled Breath Using a Nanomedical Artificial Olfactory System.|Completed|||41|Actual|Rambam Health Care Campus|||2||f||||f||||||Samples Without DNA|"~     Exhaled breath~   "|||2018-05-31 23:07:27.499682|2018-05-31 23:07:27.499682
NCT01246323|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-14|||2011-08-04|2010-11-21|2010-11-23|Estimate|||||||2011-08-04|2011-08-05|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Combined Anesthesia for Laparoscopy Surgery in Gynecology|Combined General and Spinal Anesthesia vs. General Anesthesia for Pain Relief During Laparoscopy Gynecological Surgery|Unknown status|Recruiting|N/A|40|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 23:07:27.564|2018-05-31 23:07:27.564
NCT01246310|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2011-06-23|2010-11-22|2010-11-23|Estimate|||||||2011-06-23|2011-06-27|Estimate|November 2010||2010-11-30|June 2011|2011-06-30||||December 2011|Anticipated|2011-12-31||Interventional|||Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients|Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients.|Unknown status|Recruiting|Phase 4|60|Anticipated|AGUNCO Obstetrics and Gynecology Centre||2|||f||||f||||||||||2018-05-31 23:07:27.648941|2018-05-31 23:07:27.648941
NCT01246297|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2016-05-12|2010-11-22|2010-11-23|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Effect of Pulmonary Rehabilitation in Lung Cancer Survivors|A Pilot Study of Early Outpatient Pulmonary Rehabilitation Following Thoracic Surgery for Lung Cancer|Completed||N/A|30|Actual|Imperial College Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 23:07:27.733075|2018-05-31 23:07:27.733075
NCT01246284|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2015-06-03|2010-11-19|2010-11-23|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata|Efficacy and Safety of Different Concentrations of Intralesional Triamcinolone Acetonide in Alopecia Areata: A Prospective, Randomized, Double-blind, Placebo-controlled Study|Completed||N/A|5|Actual|University of British Columbia||4|||f||||f||||||||||2018-05-31 23:07:27.806619|2018-05-31 23:07:27.806619
NCT01246258|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|2015-10-05||2016-03-08|2010-11-22|2010-11-23|Estimate|2016-03-08|2016-04-06|Estimate||||2016-03-08|2016-04-06|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Otolith Function in Patients With Primary Ciliary Dyskinesia|Otolith Function in Patients With Primary Ciliary Dyskinesia: a Pilot Study|Completed|||5|Actual|Imperial College Healthcare NHS Trust|||1||f||||t||||||||||2018-05-31 23:07:27.945359|2018-05-31 23:07:27.945359
NCT01246245|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|December 2010||2010-12-31|July 2010|2010-07-31||||||||Observational|||Nursing Care Management of External Fixation in Hospitalization: Pin Site Infection Incidence||Unknown status|Not yet recruiting||100|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-05-31 23:07:28.098868|2018-05-31 23:07:28.098868
NCT01246232|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2015-03-31|2010-11-22|2010-11-23|Estimate|||||||2015-03-31|2015-04-01|Estimate|September 2011||2011-09-30|September 2011|2011-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|AMICUS||Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia|Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia|Completed||Phase 4|69|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 23:07:28.144642|2018-05-31 23:07:28.144642
NCT01246219|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2017-12-18|2010-11-22|2010-11-23|Estimate|||||||2017-12-18|2017-12-20|Actual|October 2011|Actual|2011-10-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Short Stature Related Distress|The Influence of Growth Hormone (GH) Therapy on Short Stature Related Distress a Prospective Randomized Controlled Trial|Completed||Phase 4|60|Actual|Rabin Medical Center||3|||f||||f||||||||||2018-05-31 23:07:28.211082|2018-05-31 23:07:28.211082
NCT01246206|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-21|2015-01-28||2017-05-26|2010-11-22|2010-11-23|Estimate|2017-05-26|2017-06-01|Actual||||2017-05-26|2017-06-01|Actual|November 2010||2010-11-30|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT|A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation|Completed||Phase 2|21|Actual|Barbara Ann Karmanos Cancer Institute|The small number of patients makes the data hard to interpret.|1|||f||||t||||||||||2018-05-31 23:07:28.282785|2018-05-31 23:07:28.282785
NCT01246193|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2011-01-17|2010-11-21|2010-11-23|Estimate|||||||2011-01-17|2011-01-19|Estimate|November 2010||2010-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||CKD-828(80/2.5mg) Pharmacokinetic Study|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 80mg and S-Amlodipine 2.5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers|Completed||Phase 1|65|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 23:07:28.625533|2018-05-31 23:07:28.625533
NCT01246180|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-07-27|2010-11-22|2010-11-23|Estimate|||||||2011-07-27|2011-07-28|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Microcirculation & ASICs|Study of the Cutaneous Microcirculation: ASIC Involvement.|Completed||N/A|20|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 23:07:28.712092|2018-05-31 23:07:28.712092
NCT01246167|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2018-05-07|2010-11-22|2010-11-23|Estimate|||||||2018-05-07|2018-05-14|Actual|January 2011||2011-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|April 2016|Actual|2016-04-30||Interventional|TPHF||Treatment of Proximal Humeral Fractures|An International, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Conservative, Plate Fixation and Prosthesis in Treatment of Displaced 2, 3, and 4 Part Fractures of Proximal Humerus of 60 Years and Older Patients|Recruiting||N/A|290|Anticipated|Tampere University Hospital||3|||f||||t||||||||||2018-05-31 23:07:28.779315|2018-05-31 23:07:28.779315
NCT01246154|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|January 2011|Anticipated|2011-01-31|November 2010|Actual|2010-11-30||Observational|||An Evaluation of Exercise Tolerance in Asthmatic Patients||Unknown status|Not yet recruiting||15|Anticipated|Physio Care|||1||f||||t||||||||||2018-05-31 23:07:28.88674|2018-05-31 23:07:28.88674
NCT01246141|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-20|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|January 1998||1998-01-31|January 1998|1998-01-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Observational|||The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease|The Institute of Cardiovascular Surgery|Completed|||68|Actual|Xijing Hospital|||2||f||||t||||||||||2018-05-31 23:07:28.955358|2018-05-31 23:07:28.955358
NCT01246128|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-20|||2017-06-30|2010-11-20|2010-11-23|Estimate|||||||2017-06-30|2017-07-02|Actual|October 31, 2010||2010-10-31|July 12, 2011|2011-07-12|July 12, 2011||2011-07-12|||||Observational|||Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics|PET Assay of Acetylcholine Beta2* Nicotinic Receptor Density in Smoking and Non-Smoking Schizophrenics|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:07:29.028329|2018-05-31 23:07:29.028329
NCT01246115|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:07:29.088824|2018-05-31 23:07:29.088824
NCT01246102|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-20|||2018-02-13|2010-11-20|2010-11-23|Estimate|||||||2018-02-13|2018-02-14|Actual|November 19, 2010||2010-11-19|October 27, 2017|2017-10-27|October 27, 2017|Actual|2017-10-27|December 30, 2013|Actual|2013-12-30||Interventional|||AT13387 in Adults With Refractory Solid Tumors|Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors|Completed||Phase 1|31|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 23:07:29.129966|2018-05-31 23:07:29.129966
NCT01246089|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-20|||2013-12-31|2010-11-22|2010-11-23|Estimate|||||||2013-12-31|2014-01-01|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||Ranibizumab for Myopic Neovascularization|Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization|Unknown status|Active, not recruiting|Phase 4|20|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-05-31 23:07:29.202128|2018-05-31 23:07:29.202128
NCT01246076|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2015-08-26||2015-11-30|2010-11-22|2010-11-23|Estimate|2015-11-30|2016-01-05|Estimate||||2015-11-30|2016-01-05|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|May 2014|Actual|2014-05-31||Interventional|||Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents|Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents|Completed||Phase 2|24|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 23:07:29.287526|2018-05-31 23:07:29.287526
NCT01245894|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on the Coronary Microcirculation|Completed||Phase 4|87|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 23:07:30.890769|2018-05-31 23:07:30.890769
NCT01246063|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2018-04-23|2010-11-22|2010-11-23|Estimate|||||||2018-04-23|2018-04-24|Actual|May 14, 2012|Actual|2012-05-14|April 2018|2018-04-30|March 23, 2018|Actual|2018-03-23|December 28, 2017|Actual|2017-12-28||Interventional|||Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|40|Actual|Washington University School of Medicine||3|||f||||t|t|f||||||No||2018-05-31 23:07:29.627806|2018-05-31 23:07:29.627806
NCT01246050|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2014-02-06|2010-11-22|2010-11-23|Estimate|||||||2014-02-06|2014-02-10|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||"Developing a Hub and Satellite Heart Failure Provider's Network: A New Model of Community Based Outpatient Clinic (CBOC) Providers Study"|Developing a Hub and Satellite Heart Failure Providers Network|Completed||N/A|7|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:07:29.72315|2018-05-31 23:07:29.72315
NCT01246037|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2014-01-13|2010-11-22|2010-11-23|Estimate|||||||2014-01-13|2014-01-14|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Beta-blockers in i-PAH|Beta-blocker Therapy in Idiopathic Pulmonary Arterial Hypertension|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 23:07:29.806396|2018-05-31 23:07:29.806396
NCT01246024|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|February 2011||2011-02-28|November 2010|2010-11-30|April 2013|Anticipated|2013-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Influence of Hypoxia on Electroretingraphy (ERG) Measurements||Unknown status|Not yet recruiting|N/A|30|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 23:07:29.891035|2018-05-31 23:07:29.891035
NCT01246011|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2012-01-03||2017-10-16|2010-11-19|2010-11-23|Estimate|2012-03-09|2012-03-12|Estimate||||2017-10-16|2017-11-17|Actual|November 2010||2010-11-30|October 2017|2017-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion|Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion|Terminated||Phase 4|9|Actual|Massachusetts General Hospital|The study was ended early due to slow enrollment and results will not be analyzed. The 4 subjects who completed the study were all in the same arm of the study.|3||Enrollment was too slow.|f||||t||||||||||2018-05-31 23:07:29.963452|2018-05-31 23:07:29.963452
NCT01245998|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2018-05-01|2010-11-22|2010-11-23|Estimate|||||||2018-05-01|2018-05-04|Actual|December 1, 2010|Actual|2010-12-01|May 2018|2018-05-31|January 1, 2014|Actual|2014-01-01|December 3, 2012|Actual|2012-12-03||Interventional|REVETR||Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis|Prospective, Randomized, Double-blinded Trial of the Efficacy and Safety of Different Doses and Duration of Low Molecular Weight Heparin (Dalteparin) in Superficial Vein Thrombosis|Completed||Phase 4|68|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 23:07:30.216002|2018-05-31 23:07:30.216002
NCT01245985|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2013-04-23|2010-11-22|2010-11-23|Estimate|||||||2013-04-23|2013-04-24|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|November 2013|Anticipated|2013-11-30|November 2012|Actual|2012-11-30||Interventional|TPF-C-HIT||TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors|Induction Chemotherapy With TPF Followed by Radioimmunotherapy With Cetuximab and Intensity Modulated Radiotherapy (IMRT) Plus Carbon Ion Boost for Locally Advanced Tumors of the Oro-, Hypopharynx and Larynx: TPF-C-HIT|Terminated||Phase 2|8|Actual|Heidelberg University||1||slow recruitment (only 8 patients recruited and treated until 12/2012)|f||||t||||||||||2018-05-31 23:07:30.291562|2018-05-31 23:07:30.291562
NCT01245972|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-12-01|2010-11-22|2010-11-23|Estimate|||||||2014-12-01|2014-12-03|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PDLNMSC||Pilot Study of PDL to Treat BCC and SCCIS|A Pilot Study to Examine the Effectiveness of 595nM Pulsed Dye Lasers in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma in Situ|Completed||N/A|20|Actual|University of California, San Diego||3|||f||||f||||||||||2018-05-31 23:07:30.352709|2018-05-31 23:07:30.352709
NCT01245959|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-02-12|2010-11-22|2010-11-23|Estimate|||||||2014-02-12|2014-02-13|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting|Phase 3|476|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:07:30.404723|2018-05-31 23:07:30.404723
NCT01245946|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2011-05-31|2010-11-22|2010-11-23|Estimate|||||||2011-05-31|2011-06-01|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris|Efficacy Comparison Study of Topical Aminolaevulinic Acid-Photodynamic Therapy Versus Adapalene Gel 0.1% Plus Doxycycline for Treatment of Moderate Acne Vulgaris. Randomized, Simple Blind, Controlled Trial.|Completed||Phase 2|46|Actual|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 23:07:30.484847|2018-05-31 23:07:30.484847
NCT01245933|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2018-04-10|2010-11-22|2010-11-23|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2010||2010-11-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|December 2013|Actual|2013-12-31||Observational|COSYCONET||Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in Patients With COPD|Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD|Active, not recruiting|||2741|Actual|Philipps University Marburg Medical Center|||||f||||t||||||Samples With DNA|"~     blood urine sputum~   "|||2018-05-31 23:07:30.555069|2018-05-31 23:07:30.555069
NCT01245920|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2012-08-28|2010-11-19|2010-11-23|Estimate|||||||2012-08-28|2012-08-30|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Effects of Bone Graft Placement at Implant Installation on Buccal Plate Stability|Effects of Bone Graft Placement at Implant Installation on Buccal Plate Stability: A Randomized Controlled Clinical Trial|Withdrawn||N/A|0|Actual|Creighton University||2||Inadequate number of patients whou could meet inclusion criteria.|f||||t||||||||||2018-05-31 23:07:30.720156|2018-05-31 23:07:30.720156
NCT01245907|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2014-04-24|2010-11-22|2010-11-23|Estimate|||||||2014-04-24|2014-04-25|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|CARIN||Climacteric Therapy With Applied Relaxation Using InterNet|Climacteric Therapy With Applied Relaxation Using InterNet - CARIN Study|Terminated||N/A|46|Actual|Ostergotland County Council, Sweden||2||Unacceptable high drop-out rate.|f||||f||||||||||2018-05-31 23:07:30.801026|2018-05-31 23:07:30.801026
NCT01245881|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|March 2008||2008-03-31|November 2010|2010-11-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Fractional Photothermolysis for Treating Melasma|A Multicenter Study of Fractional Photothermolysis in the Treatment of Melasma|Completed||N/A|51|Actual|Laserklinik Karlsruhe||2|||f||||||||||||||2018-05-31 23:07:30.975956|2018-05-31 23:07:30.975956
NCT01245868|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-05-07|2010-11-22|2010-11-23|Estimate|||||||2015-05-07|2015-05-08|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Spinal Anaesthesia for Knee Arthroscopy: Does Lignocaine Shorten the Effect of Bupivacaine|Spinal Anaesthesia for Knee Arthroscopy: Does Lignocaine Shorten the Effect of Bupivacaine?|Completed||Phase 4|60|Actual|Frederikssunds Hospital, Denmark||2|||f||||t||||||||||2018-05-31 23:07:31.061394|2018-05-31 23:07:31.061394
NCT01245855|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|PGEACS||Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention|Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 23:07:31.157938|2018-05-31 23:07:31.157938
NCT01245842|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2013-10-27|2010-11-22|2010-11-23|Estimate|||||||2013-10-27|2013-10-29|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||The Hand Osteoarthritis Exercise Trial|Osteoarthritis Care in Primary Health: Hand Exercises and Telephone Counselling for Hand OA - a Randomized Controlled Trial|Completed||N/A|130|Actual|Diakonhjemmet Hospital||2|||f||||||||||||||2018-05-31 23:07:31.257378|2018-05-31 23:07:31.257378
NCT01245829|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|February 2011||2011-02-28|November 2010|2010-11-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||A Randomized Trial Comparing Matt and Antimicrobial Cellomed Laminates|Bacterial Contamination of Critical Care Observation Charts: a Randomized Trial Comparing Matt and Antimicrobial Cellomed Laminates.|Unknown status|Not yet recruiting|N/A|200|Anticipated|County Durham and Darlington NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 23:07:31.342291|2018-05-31 23:07:31.342291
NCT01245816|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2015-04-23|2010-11-22|2010-11-23|Estimate|||||||2015-04-23|2015-04-24|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|||A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)|A Randomized Phase III Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)|Withdrawn||Phase 3|0|Actual|Cancer Prevention Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 23:07:31.42679|2018-05-31 23:07:31.42679
NCT01245803|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2010-11-22|2010-11-22|2010-11-23|Estimate|||||||2010-11-22|2010-11-23|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|AVATAR||Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS|Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome|Unknown status|Recruiting|Phase 4|400|Anticipated|Beijing Anzhen Hospital||2|||f||||||||||||||2018-05-31 23:07:31.501337|2018-05-31 23:07:31.501337
NCT01245790|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2011-06-15|2010-11-22|2010-11-23|Estimate|||||||2011-06-15|2011-06-16|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of Fostamatinib in Subjects With Impaired Kidney Function|An Open-label, Phase I Study to Assess the Pharmacokinetics of R406 in Subjects With Renal Impairment Compared to Healthy Subjects Following Administration of a Single Dose of Fostamatinib 150 mg|Completed||Phase 1|24|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 23:07:31.586501|2018-05-31 23:07:31.586501
NCT01245777|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2014-12-04|2010-11-19|2010-11-22|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy|Exploratory Study of the Efficacy, Practicability and Safety of Intravenous Iron Supplementation Therapy in Moderate to Severe Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy|Completed||Phase 4|15|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 23:07:31.683815|2018-05-31 23:07:31.683815
NCT01245764|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2014-02-04||2017-03-23|2010-11-19|2010-11-22|Estimate|2014-05-01|2014-06-03|Estimate||||2017-03-23|2017-04-21|Actual|March 21, 2011|Actual|2011-03-21|March 2017|2017-03-31|April 15, 2013|Actual|2013-04-15|April 15, 2013|Actual|2013-04-15||Interventional|||GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)|Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa|Completed||Phase 3|250|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:07:31.794484|2018-05-31 23:07:31.794484
NCT01245751|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2013-04-10||2017-03-15|2010-11-19|2010-11-22|Estimate|2013-04-10|2013-05-29|Estimate||||2017-03-15|2017-04-12|Actual|April 2011||2011-04-30|March 2017|2017-03-31|May 2015|Actual|2015-05-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)|Safety, Tolerability and Immunogenicity of a Booster Dose of ZOSTAVAX™ Administered ≥10 Years After a First Dose Compared With a First Dose of ZOSTAVAX™|Completed||Phase 3|600|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:07:32.340135|2018-05-31 23:07:32.340135
NCT01245738|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2014-08-08||2017-01-30|2010-11-19|2010-11-22|Estimate|2014-08-08|2014-08-22|Estimate||||2017-01-30|2017-03-10|Actual|August 2010||2010-08-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|REMAINS|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.|Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)|Dyslipidemia: REsidual and Mixed Abnormalities IN Spite of Statin Therapy: The Dyslipidemia REMAINS Study: A Multicenter, Prospective, Observational Study of Lipid Profiles and Treatment Patterns at Presentation and After 12 Weeks of Statin Therapy Among Indian Adults Presenting With First Coronary Event|Completed|||635|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:07:32.962404|2018-05-31 23:07:32.962404
NCT01245725|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2018-03-09|2010-11-19|2010-11-22|Estimate|||||||2018-03-09|2018-03-13|Actual||||March 2018|2018-03-31||||||||Interventional|ATLAST-PCI||Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention|A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention|Withdrawn||Phase 3|0|Actual|Medicure||2||Study was not initiated, change in clinical development|f||||f||||||||||2018-05-31 23:07:33.169681|2018-05-31 23:07:33.169681
NCT01245712|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2018-03-26|2010-11-19|2010-11-22|Estimate|||||||2018-03-26|2018-03-27|Actual|November 15, 2010|Actual|2010-11-15|March 2018|2018-03-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2021|Anticipated|2021-11-01||Interventional|||Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation|Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation|Recruiting||Phase 2|200|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:07:33.228188|2018-05-31 23:07:33.228188
NCT01245699|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2015-11-17|2010-11-19|2010-11-22|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Observational|||MIHS Emergency Department CPR Quality Improvement Project|MIHS Emergency Department CPR Quality Improvement Project|Recruiting|||150|Anticipated|Maricopa Integrated Health System|||||f||||f||||||||||2018-05-31 23:07:33.343901|2018-05-31 23:07:33.343901
NCT01245686|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2013-02-05|2010-11-19|2010-11-22|Estimate|||||||2013-02-05|2013-02-06|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk|A Combined Lifestyle and Medication Intervention to Reduce CVD Risk|Completed||N/A|489|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 23:07:33.42092|2018-05-31 23:07:33.42092
NCT01245673|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2017-12-18|2010-11-19|2010-11-22|Estimate|||||||2017-12-18|2017-12-20|Actual|April 2011||2011-04-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma|Phase II Combination Immunotherapy After ASCT for Advanced Myeloma to Study MAGE-A3 Immunizations With Hiltonol® (Poly-ICLC) Plus Transfer of Vaccine-Primed Autologous T Cells Followed by Lenalidomide Maintenance|Active, not recruiting||Phase 2|28|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 23:07:34.626257|2018-05-31 23:07:34.626257
NCT01245660|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-01-10|2010-11-19|2010-11-22|Estimate|||||||2013-01-10|2013-01-11|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|LAPAINBLAD||A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy|Pilot Study of Lapatinib (Tyverb®) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy|Terminated||Early Phase 1|3|Actual|University Hospital, Bordeaux||1||The rythm of enrollment was not compatible with the objective of recruitement in the research.|f||||t||||||||||2018-05-31 23:07:34.7128|2018-05-31 23:07:34.7128
NCT01245647|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2013-08-27||2018-04-04|2010-11-19|2010-11-22|Estimate|2014-01-10|2014-02-27|Estimate||||2018-04-04|2018-05-07|Actual|November 2010||2010-11-30|April 2018|2018-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|WHAT-IF||Will Having Alcohol Treatment Improve Functioning?|Pharmacotherapy for Hazardous Drinking in HIV Infected Women: Randomized Trial|Completed||Phase 2|19|Actual|University of Florida|Sample size was very small, and 3 participants did not return for any follow-up visits; 15 completed through the Month 4 assessment, and 12 completed through Month 7. Therefore, our ability to draw conclusions based on this sample is limited.|2|||f||||f||||||||||2018-05-31 23:07:34.815757|2018-05-31 23:07:34.815757
NCT01245634|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19||2016-09-01|2016-11-01|2010-11-19|2010-11-22|Estimate||||2016-09-01|2016-09-02|Estimate|2016-11-01|2016-11-02|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|Study Assessing 20 mg/kg Dose of the Recombinant Human Monoclonal Antibody Against P-selectin in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|Completed||Phase 2|384|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:07:35.486424|2018-05-31 23:07:35.486424
NCT01245621|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-01-02|2010-11-19|2010-11-22|Estimate|||||||2014-01-02|2014-01-03|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ENABLE III||Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)|Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes|Completed||N/A|360|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 23:07:35.858883|2018-05-31 23:07:35.858883
NCT01245608|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2018-03-03|2010-11-19|2010-11-22|Estimate|||||||2018-03-03|2018-03-06|Actual|October 2011|Actual|2011-10-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|January 2018|Actual|2018-01-31||Interventional|PolyIran-L||Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.|Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.|Active, not recruiting||Phase 3|2400|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 23:07:36.243423|2018-05-31 23:07:36.243423
NCT01245595|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2015-03-31||2015-06-03|2010-11-19|2010-11-22|Estimate|2015-06-03|2015-06-08|Estimate||||2015-06-03|2015-06-08|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|KIDPROAM||Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery|A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass|Completed||N/A|144|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 23:07:36.370063|2018-05-31 23:07:36.370063
NCT01245582|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2011-11-08|2010-11-19|2010-11-22|Estimate|||||||2011-11-08|2011-11-09|Estimate|July 2011||2011-07-31|November 2011|2011-11-30|August 2015|Anticipated|2015-08-31|February 2014|Anticipated|2014-02-28||Interventional|SECOX||Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients|A Randomized Phase III Study of Oxaliplatin (Eloxatin) and Capecitabine on Top of Sorafenib Versus Sorafenib Alone as First-line Palliative Treatment in Advanced Hepatocellular Carcinoma Patients|Withdrawn||Phase 3|0|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 23:07:36.863977|2018-05-31 23:07:36.863977
NCT01245569|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2017-03-28|2010-11-19|2010-11-22|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2011||2011-04-30|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|FUTURE||A Study in Patients With Chronic Obstructive Pulmonary Disease|A 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Seretide® 500/50 (Fluticasone 500 µg Plus Salmeterol 50 µg/Actuation), 1 Inhalation b.i.d., in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|373|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 23:07:36.961211|2018-05-31 23:07:36.961211
NCT01245556|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2013-06-11|2010-11-19|2010-11-22|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma|A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma|Completed||Phase 1|8|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 23:07:37.145135|2018-05-31 23:07:37.145135
NCT01245543|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2015-10-29|2010-11-19|2010-11-22|Estimate|||||||2015-10-29|2015-11-02|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors|Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|Daiichi Sankyo, Inc.||2||Clinical investigations have been discontinued and transfer to BMS 3/24/2015|f||||f||||||||||2018-05-31 23:07:37.234335|2018-05-31 23:07:37.234335
NCT01245530|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-06-09|2010-11-18|2010-11-22|Estimate|||||||2011-06-09|2011-06-13|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia|Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study|Completed||Phase 3|280|Actual|Whanin Pharmaceutical Company||2|||f||||t||||||||||2018-05-31 23:07:37.324254|2018-05-31 23:07:37.324254
NCT01245517|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-18|2010-11-18|2010-11-22|Estimate|||||||2010-11-18|2010-11-22|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient|The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient|Unknown status|Recruiting|N/A|60|Anticipated|Taipei Medical University WanFang Hospital||1|||f||||t||||||||||2018-05-31 23:07:37.418218|2018-05-31 23:07:37.418218
NCT01245504|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2014-04-24|2010-11-19|2010-11-22|Estimate|||||||2014-04-24|2014-04-25|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Assessment of Socket Shapes Made by Central Fabrication Facilities|Clinical Evaluation of an Algorithm to Assess Sockets Made by Central Fabrication Facilities|Completed|||24|Actual|University of Washington|||1||f||||f||||||||||2018-05-31 23:07:37.547483|2018-05-31 23:07:37.547483
NCT01245491|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2011-01-13|2010-11-19|2010-11-22|Estimate|||||||2011-01-13|2011-01-14|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effects of Vibration on Hypoxia|The Effects of Vibration on Hypoxia|Completed||N/A|13|Actual|Institute of Aviation Medicine, Oslo, Norway|||||f||||f||||||||||2018-05-31 23:07:37.682778|2018-05-31 23:07:37.682778
NCT01245478|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2013-04-30|2010-11-19|2010-11-22|Estimate|||||||2013-04-30|2013-05-01|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||DePuy Revision TKA Implant 5yr Survivorship|Clinical Outcome and 5-year Implant Survival Rate Among Adult Revision Total Knee Arthroplasty Patients With DePuy Implant Components|Withdrawn|||0|Actual|The New England Baptist Hospital||||"Retrospective record review only (no subject enrollment). Contract never executed between~   Sponsor and Site."|f||||f||||||||||2018-05-31 23:07:37.771613|2018-05-31 23:07:37.771613
NCT01245465|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-22|2010-11-19|2010-11-22|Estimate|||||||2010-11-22|2010-11-23|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|CUPE-1||Profermin® in Active Ulcerative Colitis|Safety and Efficacy of Profermin® to Induce Remission in Patients With Ulcerative Colitis|Completed||Phase 1/Phase 2|39|Actual|Nordisk Rebalance A/S||1|||f||||f||||||||||2018-05-31 23:07:37.90656|2018-05-31 23:07:37.90656
NCT01245452|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2013-10-30|2010-11-19|2010-11-22|Estimate|||||||2013-10-30|2013-10-31|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TOMERA||Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate|Comparative Study of the Clinical Response and Cardiorespiratory Endurance in Early Rheumatoid Arthritis Patients Treated With Tocilizumab or Methotrexate Addendum Protocol : Global Gene Expression Profiles in Synovial Biopsies|Completed||N/A|30|Actual|Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 23:07:38.04623|2018-05-31 23:07:38.04623
NCT01245439|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2015-10-05||2015-10-05|2010-11-19|2010-11-22|Estimate|2015-10-05|2015-11-03|Estimate||||2015-10-05|2015-11-03|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Intent-to-treat (ITT) population consisted of all participants included in the study who received at least one dose of study medication.|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis|Local Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD|Completed||Phase 3|65|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:07:38.230121|2018-05-31 23:07:38.230121
NCT01245426|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2016-11-30|2010-11-19|2010-11-22|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)|A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to Determine the Efficacy and Dose Response of Repeat Inhaled Doses of GW870086X on FEV1 in Adults With Persistent Asthma|Completed||Phase 2|136|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:07:39.32075|2018-05-31 23:07:39.32075
NCT01245413|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2012-01-09||2012-11-29|2010-11-19|2010-11-22|Estimate|2012-11-29|2013-01-01|Estimate||||2012-11-29|2013-01-01|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Controlled Randomized Study With Athena Base Plate Versus SenSura Base Plate on Perspiring Skin|Controlled Randomized Study With a New Base Plate Versus SenSura Base Plate on Perspiring Skin|Completed||N/A|32|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 23:07:39.564854|2018-05-31 23:07:39.564854
NCT01245400|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2014-03-11|2010-11-19|2010-11-22|Estimate|||||||2014-03-11|2014-03-13|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|April 2017|Anticipated|2017-04-30|April 2014|Anticipated|2014-04-30||Interventional|Z-Lig||Safety and Efficacy Study of the Z-Lig Medical Device Compared to Allograft|A Prospective, Randomized, Double-Blind, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the Z-Lig Medical Device Compared to Allograft for the Reconstruction of Ruptured Anterior Cruciate Ligaments|Unknown status|Active, not recruiting|N/A|60|Anticipated|Aperion Biologics, Inc.||2|||f||||f||||||||||2018-05-31 23:07:39.812413|2018-05-31 23:07:39.812413
NCT01240096|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|September 2006||2006-09-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|||||Interventional|||Mirtazapine Versus Placebo in Functional Dyspepsia|Phase 4 Study of Mirtazapine in Functional Dyspepsia Patients With Weight Loss|Unknown status|Recruiting|Phase 4|35|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 23:09:21.044979|2018-05-31 23:09:21.044979
NCT01245387|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2010-12-21||2011-01-12|2010-11-19|2010-11-22|Estimate|2010-12-21|2011-01-07|Estimate||||2011-01-12|2011-01-13|Estimate|August 2006||2006-08-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|MACULA||Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration|Long-Term Non-Interventional Study (AB Study) To Investigate The Efficacy And Safety Of Macugen® In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice|Completed|||1001|Actual|Pfizer|Time to first AE not estimated due to insufficient number of events. Visit numbers for NEI-VFQ-25 deviated from numbering used in other analyses; it represents the sequence number of questionaries administered (Visit 1=first assessment, etc.).||1||f||||f||||||||||2018-05-31 23:07:40.036511|2018-05-31 23:07:40.036511
NCT01245374|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2012-04-18||2017-01-12|2010-11-19|2010-11-22|Estimate|2012-05-22|2012-06-25|Estimate||||2017-01-12|2017-02-27|Actual|November 2010||2010-11-30|January 2017|2017-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents|Assessment of the Ease of Use of Norditropin NordiFlex® Relative to the One of the Device Previously Used by Patients or Parents|Completed||Phase 4|103|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 23:07:41.046864|2018-05-31 23:07:41.046864
NCT01245361|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2013-10-30|2010-11-19|2010-11-22|Estimate|||||||2013-10-30|2013-10-31|Estimate|November 2007||2007-11-30|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|UA-IFX||A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit|"A Comparative Study Of A 6-Month Infliximab (Remicade®) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis (RA) : Clinical, Radiological (MRI) And Synovial Benefit P1200/001."|Completed||N/A|30|Actual|Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 23:07:41.545182|2018-05-31 23:07:41.545182
NCT01245348|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-02-22|2010-11-18|2010-11-22|Estimate|||||||2013-02-22|2013-02-25|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|REST||Relative Effectiveness of Schizophrenia Therapy Study|Relative Effectiveness of Schizophrenia Therapy (REST) Study|Completed|||1110|Actual|Medco Health Solutions, Inc.|||2||f||||f||||||Samples With DNA|"~     One milliliter of saliva will be self collected by study subjects for genetic testing.~   "|||2018-05-31 23:07:41.611569|2018-05-31 23:07:41.611569
NCT01245335|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2015-12-14|2010-11-19|2010-11-22|Estimate|||||||2015-12-14|2015-12-15|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)|Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease|Completed||Phase 3|97|Actual|Harvest Technologies||2|||f||||t||||||||||2018-05-31 23:07:41.699796|2018-05-31 23:07:41.699796
NCT01245322|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2014-11-06|2010-11-19|2010-11-22|Estimate|||||||2014-11-06|2014-11-10|Estimate|January 2007||2007-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Treatment of Bacterial Vaginosis Combined With Human Lactobacilli|Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses|Completed||Phase 4|75|Anticipated|Skaraborg Hospital||1|||f||||f||||||||||2018-05-31 23:07:41.915147|2018-05-31 23:07:41.915147
NCT01245309|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2014-01-14|2010-11-19|2010-11-22|Estimate|||||||2014-01-14|2014-01-15|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ESICOHF||Endometrial Scratching Prior to Controlled Ovarian Stimulation (COH) in Women Undergoing In-vitro Fertilization With Previous IVF Failure|Endometrial Injury Prior to Controlled Ovarian Stimulation (COH) in Women Undergoing In-vitro Fertilization in Women With Previous IVF Failure.|Completed||Early Phase 1|500|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 23:07:41.990984|2018-05-31 23:07:41.990984
NCT01245296|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2014-08-19|2010-11-19|2010-11-22|Estimate|||||||2014-08-19|2014-08-20|Estimate|April 2008||2008-04-30|August 2014|2014-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Early Versus Delayed Cord Clamping at Term: Outcomes in Swedish Infants|Early Versus Delayed Cord Clamping at Term: Outcomes in Swedish Infants|Completed||N/A|392|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 23:07:42.063553|2018-05-31 23:07:42.063553
NCT01245283|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2014-07-02||2014-11-19|2010-11-19|2010-11-22|Estimate|2014-10-01|2014-10-08|Estimate||||2014-11-19|2014-12-05|Estimate|November 2010||2010-11-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Resistance Exercise and Knee Osteoarthritis Pain, Functional Impairment and Cartilage Turnover|Comparative Resistance Exercise Effect on Knee Osteoarthritis Pain, Functional Impairment and Cartilage Turnover|Completed||N/A|90|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 23:07:42.201253|2018-05-31 23:07:42.201253
NCT01245270|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2013-08-23||2017-05-23|2010-11-19|2010-11-22|Estimate|2014-08-13|2014-08-15|Estimate||||2017-05-23|2017-06-20|Actual|September 2010||2010-09-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Single Supplement of a Standardised Bilberry Extract Modifies Glycaemic Response|A Single Supplement of a Standardised Bilberry Extract (36% (w/w) Anthocyanins) Modifies Glycaemic Response in Persons With Type 2 Diabetes Controlled by Diet and Lifestyle.|Completed||N/A|8|Actual|University of Aberdeen||2|||f||||t||||||||Undecided||2018-05-31 23:07:42.684182|2018-05-31 23:07:42.684182
NCT01245257|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2016-09-09|2010-11-19|2010-11-22|Estimate|||||||2016-09-09|2016-09-12|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis|Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis|Completed|||50|Anticipated|University of Aarhus|||1||f||||f||||||Samples Without DNA|"~     Serum, plasma, urine~   "|||2018-05-31 23:07:42.92876|2018-05-31 23:07:42.92876
NCT01245244|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2012-09-20|2010-11-19|2010-11-22|Estimate|||||||2012-09-20|2012-09-21|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Mor2010||Morphine Modulation of The Brain's Pain Matrix|Morphine Modulation of The Brain's Pain Matrix|Completed||Phase 4|40|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:07:42.997609|2018-05-31 23:07:42.997609
NCT01245231|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2016-05-17|2010-11-19|2010-11-22|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2010||2010-05-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia|Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML-II|Completed|||150|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:07:43.088604|2018-05-31 23:07:43.088604
NCT01239225|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-07|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|September 2009||2009-09-30|October 2010|2010-10-31||||March 2010|Actual|2010-03-31||Interventional|||Prevalence of Abdominal Aortic Aneurysm in Patients Undergoing Coronary Angiography||Completed||Phase 4|200|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 23:09:33.842095|2018-05-31 23:09:33.842095
NCT01245205|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2014-10-22|2010-11-19|2010-11-22|Estimate|||||||2014-10-22|2014-10-23|Estimate|November 2010||2010-11-30|October 2014|2014-10-31||||August 2014|Actual|2014-08-31||Interventional|||Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer|A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-Expansion in Advanced HER2+ Breast Cancer|Completed||Phase 1|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:07:43.152364|2018-05-31 23:07:43.152364
NCT01245179|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2018-05-29|2010-11-19|2010-11-22|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 2010||2010-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|LBH589||Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease|Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell Disease|Active, not recruiting||Phase 1|27|Anticipated|Augusta University||1|||f||||t||||||||||2018-05-31 23:07:43.246169|2018-05-31 23:07:43.246169
NCT01245166|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-19|2010-11-19|2010-11-22|Estimate|||||||2010-11-19|2010-11-22|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus||Unknown status|Recruiting|Phase 3|220|Anticipated|Lotus Pharmaceutical||2|||f||||t||||||||||2018-05-31 23:07:43.327531|2018-05-31 23:07:43.327531
NCT01245153|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2016-01-31|2010-11-19|2010-11-22|Estimate|||||||2016-01-31|2016-02-02|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Rectal Balloon Training in Female Urinary Incontinence|Phase 2B Study of Rectal Ballooning Training in Female Urinary Incontinence|Completed||Phase 2|28|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 23:07:43.393376|2018-05-31 23:07:43.393376
NCT01245140|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2016-12-07||2017-11-27|2010-11-19|2010-11-22|Estimate|2017-02-17|2017-04-04|Actual||||2017-11-27|2017-12-21|Actual|April 26, 2011|Actual|2011-04-26|November 2017|2017-11-30|April 16, 2014|Actual|2014-04-16|March 12, 2014|Actual|2014-03-12||Interventional|||Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis|Efficacy of Oral Alitretinoin Treatment in Patients With Palmo-plantar Pustulosis (PPP) Inadequately Responding to Standard Topical Treatment|Completed||Phase 2|33|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:07:43.519305|2018-05-31 23:07:43.519305
NCT01245127|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2012-06-14|2010-11-19|2010-11-22|Estimate|||||||2012-06-14|2012-06-15|Estimate|May 2011||2011-05-31|November 2010|2010-11-30|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|||Ilaris (Canakinumab) in the Schnitzler Syndrome|Ilaris (Canakinumab) in the Schnitzler Syndrome. A Case Series.|Completed||Phase 2|1|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 23:07:44.4454|2018-05-31 23:07:44.4454
NCT01245114|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-12-02|2010-11-19|2010-11-22|Estimate|||||||2010-12-02|2010-12-03|Estimate||||July 2010|2010-07-31|December 2010|Actual|2010-12-31|||||Observational|THAO||Tübingen High Altitude Ophthalmology Study|Tübingen High Altitude Ophthalmology Study (THAO)|Completed|||||University Hospital Tuebingen|||||f||||f||||||||||2018-05-31 23:07:44.52699|2018-05-31 23:07:44.52699
NCT01245101|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|2016-03-24||2016-10-28|2010-11-19|2010-11-22|Estimate|2016-10-28|2016-12-23|Estimate||||2016-10-28|2016-12-23|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Addition of Raltegravir to Established Antiretroviral Suppressive Therapy|A Prospective, Open-Label, Double-Arm, Crossover, Single-Center Pilot Study to Evaluate the Addition of Raltegravir to Established Suppressive Antiretroviral Therapy While Monitoring Changes in Markers of Immune Activation Among HIV-1 Infected Individuals Without Adequate Immune Restoration|Terminated||Phase 4|15|Actual|University of Miami|Only 11 of 12 patients completed week 40 and were analyzed as per protocol. In view of poor enrollment and a simple analysis of the limited amount of data that failed to support our hypothesis, the study was terminated early.|2||Poor enrollment.|f||||f||||||||||2018-05-31 23:07:44.589014|2018-05-31 23:07:44.589014
NCT01245088|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2012-08-29|2010-11-19|2010-11-22|Estimate|||||||2012-08-29|2012-08-31|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|May 2012|Anticipated|2012-05-31|March 2012|Anticipated|2012-03-31||Interventional|||Chondroitin Sulfate for Crohn's Disease|A Pilot Study of Chondroitin Sulfate (CS) for the Treatment of Mild to Moderate Crohn's Disease|Withdrawn||Phase 1/Phase 2|0|Actual|University Hospitals Cleveland Medical Center||1||Sponsor withdrew support after no patients enrolled|f||||f||||||||||2018-05-31 23:07:44.785443|2018-05-31 23:07:44.785443
NCT01245075|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2016-12-06|2010-11-19|2010-11-22|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|NASA||Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction|Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction|Recruiting||Early Phase 1|10|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 23:07:44.991616|2018-05-31 23:07:44.991616
NCT01245062|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2013-02-14||2018-03-09|2010-11-18|2010-11-22|Estimate|2013-02-14|2013-03-15|Estimate||||2018-03-09|2018-04-05|Actual|November 22, 2010|Actual|2010-11-22|January 2018|2018-01-31|December 16, 2016|Actual|2016-12-16|October 26, 2011|Actual|2011-10-26||Interventional|||GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma|A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma|Completed||Phase 3|322|Actual|GlaxoSmithKline||3|||f||||t|t|f||||||||2018-05-31 23:07:45.332227|2018-05-31 23:07:45.332227
NCT01245049|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2017-02-24|2012-07-26|2017-04-12|2010-11-18|2010-11-22|Estimate|2017-04-12|2017-07-05|Actual|2012-07-26|2012-08-03|Estimate|2017-04-12|2017-07-05|Actual|April 1, 2011||2011-04-01|February 2017|2017-02-28|April 2, 2012|Actual|2012-04-02|March 27, 2012|Actual|2012-03-27||Interventional|||Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children|Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 3 and 4-year-old Children|Completed||Phase 3|387|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 23:07:46.525848|2018-05-31 23:07:46.525848
NCT01245036|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-05-13|2010-11-19|2010-11-22|Estimate|||||||2013-05-13|2013-05-15|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Antituberculous Therapy in Management of Sarcoidosis|Rifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled Trial|Completed||N/A|100|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||t||||||||||2018-05-31 23:07:47.238225|2018-05-31 23:07:47.238225
NCT01160510|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-04-04|2010-07-09|2010-07-12|Estimate|||||||2018-04-04|2018-04-05|Actual|June 24, 2010||2010-06-24|January 26, 2018|2018-01-26||||||||Observational|||Genetics of Mammographic Appearances and Patterns (The GenMap Study)|Genetics of Mammographic Appearances and Patterns (The GenMap Study)|Completed|||106|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:35:53.543166|2018-05-31 23:35:53.543166
NCT01245023|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2012-12-31|2010-11-19|2010-11-22|Estimate|||||||2012-12-31|2013-01-03|Estimate|January 2014||2014-01-31|December 2012|2012-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Adhesiolysis in Chronic Abdominal Pain|Laparoscopic Adhesiolysis in Treatment of Chronic Abdominal Pain - a Prospective Randomized Trial|Withdrawn||N/A|0|Actual|North Karelia Central Hospital||2||lack of funding|f||||f||||||||||2018-05-31 23:07:47.303851|2018-05-31 23:07:47.303851
NCT01245010|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-10-10|2010-11-19|2010-11-22|Estimate|||||||2011-10-10|2011-10-12|Estimate|April 2009||2009-04-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Water Beverage Intervention Trial for Reducing Risk Factors of Metabolic Syndrome in Young Mexican Free Living Women|Randomized Controlled Trial of a Water Beverage Intervention Trial for Reducing Risk Factors of Metabolic Syndrome in Young Mexican Free Living Women|Completed||N/A|240|Actual|Mexican National Institute of Public Health||2|||f||||t||||||||||2018-05-31 23:07:47.37086|2018-05-31 23:07:47.37086
NCT01244997|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-19|2010-11-19|2010-11-22|Estimate|||||||2010-11-19|2010-11-22|Estimate|November 2003||2003-11-30|November 2010|2010-11-30|May 2009|Actual|2009-05-31|April 2008|Actual|2008-04-30||Interventional|||Evaluation of Implants Placed Immediately or Delayed Into Extraction Sites|Prospective Evaluation of Immediate Temporized Implants|Completed||Phase 3|75|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f||||||||||2018-05-31 23:07:47.518182|2018-05-31 23:07:47.518182
NCT01244984|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2013-06-06||2016-11-23|2010-11-18|2010-11-22|Estimate|2013-06-06|2013-08-09|Estimate||||2016-11-23|2017-01-11|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma|A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and FF Inhalation Powder in Japanese Subjects With Asthma|Completed||Phase 3|243|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:07:47.636847|2018-05-31 23:07:47.636847
NCT01244971|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-19|||2010-11-19|2010-11-19|2010-11-22|Estimate|||||||2010-11-19|2010-11-22|Estimate|January 2004||2004-01-31|December 2003|2003-12-31||||June 2004|Actual|2004-06-30||Interventional|||Exercise and Acarbose in Type 2 Diabetes|Effect of Exercise Training - Alone or in Combination With Acarbose - on Clinical and Metabolic Factors, and Studies of Cellular and Moleculargenetic Factors, in Type 2 Diabetes.|Completed||Phase 4|62|Actual|Karolinska Institutet||3|||f||||||||||||||2018-05-31 23:07:49.12106|2018-05-31 23:07:49.12106
NCT01244958|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-03-23|2010-11-19|2010-11-22|Estimate|||||||2016-03-23|2016-03-24|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis|Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis - a Multicenter Randomised Double-blind Clinical Trial|Completed||Phase 3|156|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-05-31 23:07:49.309038|2018-05-31 23:07:49.309038
NCT01244945|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-03-26|2010-11-19|2010-11-22|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|LRFC||Lactobacillus Reuteri DSM 17938 in Functional Constipation|Effect of Lactobacillus Reuteri DSM 17938 on Gut Motility in Patients With Functional Constipation|Completed||Phase 4|72|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||2|||f||||f||||||||||2018-05-31 23:07:49.442591|2018-05-31 23:07:49.442591
NCT01244932|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-05-08|2010-11-19|2010-11-22|Estimate|||||||2012-05-08|2012-05-10|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Minimum Effective Volume of Local Anesthetic Using Ultrasound for Brachial Plexus Block|Determination of the Minimum Effective Volume of Local Anesthetic Using Ultrasound Guidance for Interscalene Brachial Plexus Block|Completed||Phase 2|33|Anticipated|Federal University of São Paulo|||||f||||f||||||||||2018-05-31 23:07:49.503453|2018-05-31 23:07:49.503453
NCT01244906|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2015-01-29||2015-04-09|2010-11-18|2010-11-19|Estimate|2015-03-13|2015-03-17|Estimate||||2015-04-09|2015-05-01|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant|A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|26|Actual|Northside Hospital, Inc.||1|||f||||f||||||||||2018-05-31 23:07:49.600232|2018-05-31 23:07:49.600232
NCT01244893|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2013-08-29||2017-08-31|2010-11-18|2010-11-19|Estimate|2013-12-16|2014-02-03|Estimate||||2017-08-31|2017-09-01|Actual|October 2010||2010-10-31|August 2017|2017-08-31||||November 2010|Actual|2010-11-30||Interventional||44 persons enrolled, 42 completed as cohort, 2 dropped due to: 1 non-trial related adverse event, and 1 protocol deviation|Study of ACUVUE® ADVANCE® PLUS Contact Lenses.||Completed||N/A|44|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-05-31 23:07:50.147815|2018-05-31 23:07:50.147815
NCT01244880|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2014-03-19|2010-11-18|2010-11-19|Estimate|||||||2014-03-19|2014-03-21|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects|Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 2-Way, 4-Period Crossover Study To Assess Effects Of PF-02545920 On Ketamine-Induced Aberrant Prefrontal Response To Associative Learning In Healthy Subjects|Terminated||Phase 1|4|Actual|Pfizer||4||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:07:50.366078|2018-05-31 23:07:50.366078
NCT01244867|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-07-30|2010-11-18|2010-11-19|Estimate|||||||2012-07-30|2012-07-31|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine|A Phase 2, Randomized, Observer-blind, Single Center, Dose-Ranging Study to Evaluate the Immunogenicity Safety and Tolerability of the H5 VLP Influenza Vaccine With or Without Alhydrogel in Healthy Adults 18-60 Years of Age.|Completed||Phase 2|255|Actual|Medicago||5|||f||||t||||||||||2018-05-31 23:07:50.466689|2018-05-31 23:07:50.466689
NCT01244854|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2017-06-02|2010-11-18|2010-11-19|Estimate|||||||2017-06-02|2017-06-06|Actual|October 1, 2010|Actual|2010-10-01|June 2017|2017-06-30|March 6, 2015|Actual|2015-03-06|August 13, 2012|Actual|2012-08-13||Interventional|||Life Goals Behavioral Change to Improve Outcomes for Veterans With Serious Mental Illness|Life Goals Behavioral Change to Improve Outcomes for Veterans With SMI|Completed||N/A|55|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-05-31 23:07:50.546957|2018-05-31 23:07:50.546957
NCT01150188|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2016-10-25|2010-06-23|2010-06-24|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effects of Amino Acids on Regional Lipid Metabolism|Effects of Amino Acids on Regional Lipid Metabolism|Completed||N/A|125|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 23:38:58.970637|2018-05-31 23:38:58.970637
NCT01244841|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-05-07|2010-11-18|2010-11-19|Estimate|||||||2013-05-07|2013-05-09|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|INUT||Effects on Health Status in Patients Early Discharged After Primary Percutaneous Coronary Intervention (PCI)|The Effect on 30 Day Health Status After Early Discharge in Patient With ST Elevation Myocardial Infarction Treated With Primary PCI|Completed||N/A|140|Actual|Helse Stavanger HF||2|||f||||f||||||||||2018-05-31 23:07:50.616722|2018-05-31 23:07:50.616722
NCT01244828|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2015-07-30||2015-07-30|2010-11-18|2010-11-19|Estimate|2015-07-30|2015-08-26|Estimate||||2015-07-30|2015-08-26|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)|Long-term Study of Asenapine in Subjects With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (Protocol P06238)|Completed||Phase 3|157|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 23:07:50.710999|2018-05-31 23:07:50.710999
NCT01244815|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2014-08-21||2017-06-01|2010-11-18|2010-11-19|Estimate|2014-08-21|2014-09-04|Estimate||||2017-06-01|2017-07-02|Actual|June 16, 2011|Actual|2011-06-16|June 2017|2017-06-30|September 17, 2013|Actual|2013-09-17|August 28, 2013|Actual|2013-08-28||Interventional||The population consisted of all randomized participants who received at least one dose of study drug.|Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)|Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P06107)|Completed||Phase 3|404|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:07:51.018618|2018-05-31 23:07:51.018618
NCT01244802|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2017-09-20|2010-11-18|2010-11-19|Estimate|||||||2017-09-20|2017-09-25|Actual|November 2010||2010-11-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Immune Responses to Yellow Fever Vaccine|Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination|Recruiting|||150|Anticipated|Emory University|||2||f||||f|f|f||||Samples With DNA|"~     Blood~   "|||2018-05-31 23:07:52.095648|2018-05-31 23:07:52.095648
NCT01244789|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2018-02-01|2010-11-18|2010-11-19|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2011|Actual|2011-12-31|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer|A Phase II Randomized Trial of Postoperative Chemotherapy or no Further Treatment for Patients With Node-negative Stage I-II Intermediate or High Risk Endometrial Cancer|Recruiting||Phase 2|240|Anticipated|Danish Gynecological Cancer Group||2|||f||||t||||||||||2018-05-31 23:07:52.153516|2018-05-31 23:07:52.153516
NCT01244776|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2011-05-05|2010-11-18|2010-11-19|Estimate|||||||2011-05-05|2011-05-06|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer|Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer|Unknown status|Recruiting|N/A|100|Anticipated|Shaanxi Aierfu Activtissue Engineering||1|||f||||t||||||||||2018-05-31 23:07:52.23035|2018-05-31 23:07:52.23035
NCT01244763|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2013-01-28|2010-11-18|2010-11-19|Estimate|||||||2013-01-28|2013-01-30|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of FG-4592 in Non-Dialysis Chronic Kidney Disease Patients With Anemia||Completed||Phase 2|145|Actual|FibroGen||1|||f||||t||||||||||2018-05-31 23:07:52.300234|2018-05-31 23:07:52.300234
NCT01244750|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2018-01-19|2010-11-18|2010-11-19|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2, 2010|Actual|2010-12-02|January 2018|2018-01-31|August 30, 2020|Anticipated|2020-08-30|January 30, 2020|Anticipated|2020-01-30||Observational|SIMPLICITY||Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting|Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)|Active, not recruiting|||1494|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 23:07:52.404151|2018-05-31 23:07:52.404151
NCT01244737|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2018-04-12|2010-11-18|2010-11-19|Estimate|||||||2018-04-12|2018-04-17|Actual|October 2010|Actual|2010-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||FLT-PET Imaging of Brain Tumors in Children|Phase 2 Study of [18F]FLT for PET Imaging of Brain Tumors in Children|Enrolling by invitation||Phase 2|75|Anticipated|Boston Children’s Hospital||3|||f||||f|t|f||||||Undecided|No current plans to share individual participant data|2018-05-31 23:07:55.074482|2018-05-31 23:07:55.074482
NCT01244724|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2014-12-24||2015-07-29|2010-11-18|2010-11-19|Estimate|2015-07-29|2015-08-03|Estimate||||2015-07-29|2015-08-03|Estimate|October 2007||2007-10-31|July 2015|2015-07-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Lexapro for Major Depression in Patients With Epilepsy|Lexapro for Major Depression in Patients With Epilepsy|Terminated||Phase 4|26|Actual|Weill Medical College of Cornell University||1||Unable to recruit targeted #|f||||f||||||||||2018-05-31 23:07:55.379872|2018-05-31 23:07:55.379872
NCT01244711|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2014-12-18||2015-03-17|2010-11-18|2010-11-19|Estimate|2015-03-04|2015-03-06|Estimate||||2015-03-17|2015-04-03|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines|An Open-label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines in Treatment-refractory Patients With Unipolar Depression or Generalized Anxiety Disorder and Chronic Benzodiazepine Use|Terminated||Phase 4|1|Actual|Weill Medical College of Cornell University||1||Terminated: recruiting or enrolling participants has halted prematurely|f||||f||||||||||2018-05-31 23:07:55.831457|2018-05-31 23:07:55.831457
NCT01244698|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2014-05-12|2010-11-18|2010-11-19|Estimate|||||||2014-05-12|2014-05-13|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction|Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction|Completed||Phase 4|132|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 23:07:56.419793|2018-05-31 23:07:56.419793
NCT01244685|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-10-03|2010-11-18|2010-11-19|Estimate|||||||2012-10-03|2012-10-05|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Trial With Deltex Cardio in Elective Bowel Resection Patients|Randomized Controlled Trial With Deltex CardioQ in Elective Bowel Resection Patients|Completed||N/A|58|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 23:07:56.665504|2018-05-31 23:07:56.665504
NCT01230593|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2017-02-17|2010-10-28|2010-10-29|Estimate|||||||2017-02-17|2017-02-23|Actual|November 2010||2010-11-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Chalazion Conservative Treatment Trial|A 5-year Multicenter Prospective Randomized Trial Comparing Three Conservative Chalazion Treatments|Completed||N/A|150|Actual|McMaster University||3|||f||||f||||||||||2018-05-31 23:12:05.420323|2018-05-31 23:12:05.420323
NCT01244672|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-10-03|2010-11-18|2010-11-19|Estimate|||||||2012-10-03|2012-10-05|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|THD||Trans-anal Hemorrhoidal Dearterialization (THD) vs. Hemorrhoidectomy|Trans-anal Hemorrhoidal Dearterialization (THD) vs. Hemorrhoidectomy for 3rd and 4th Degree Hemorrhoids in at Least Three Quadrants: A Prospective Randomized Control Pilot Study.|Completed||N/A|40|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 23:07:56.787774|2018-05-31 23:07:56.787774
NCT01244659|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-03-01|2010-11-18|2010-11-19|Estimate|||||||2013-03-01|2013-03-04|Estimate|May 2014||2014-05-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment|An Open Randomized Non-inferiority Study to Compare Safety and Efficacy of Immunosuppressive Regiments Using Tacrolimus From EMS and Prograf® in Post Renal Transplanted Patients|Suspended||Phase 3|60|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2018-05-31 23:07:56.885106|2018-05-31 23:07:56.885106
NCT01244646|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-12-05|2010-11-18|2010-11-19|Estimate|||||||2012-12-05|2012-12-06|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.|Perceived Hypoglycemia- and Weight-related Quality of Life of Patients With Sulfonylurea Derivate-treated Diabetes Mellitus Type 2, a Non-interventional Study.|Terminated|||48|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:07:56.999451|2018-05-31 23:07:56.999451
NCT01244633|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2015-03-12||2015-08-27|2010-11-18|2010-11-19|Estimate|2015-08-27|2015-09-29|Estimate||||2015-08-27|2015-09-29|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Ecopipam Treatment of Tourette Syndrome|Ecopipam Treatment of Tourette Syndrome|Completed||Phase 1/Phase 2|18|Actual|Psyadon Pharma|This was an open label study with no placebo control|1|||f||||t||||||||||2018-05-31 23:07:57.192436|2018-05-31 23:07:57.192436
NCT01244620|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2012-01-18||2012-01-18|2010-11-18|2010-11-19|Estimate|2012-01-18|2012-02-22|Estimate||||2012-01-18|2012-02-22|Estimate|November 2010||2010-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses|A Phase 1, Open Label, Randomized, Four Period, Crossover, Multiple Dose Study To Assess The Pharmacokinetic Interaction Between Sitaxsentan and Tadalafil and The Effect Of Sildenafil On Sitaxsentan PK In Healthy Subjects|Terminated||Phase 1|16|Actual|Pfizer|Study endpoints were not analyzed due to early termination.|4||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,~   specifically new emerging evidence of hepatic injury."|f||||f||||||||||2018-05-31 23:07:57.417656|2018-05-31 23:07:57.417656
NCT01244607|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate||||November 2010|2010-11-30||||||||Interventional|||NI-0801 in Allergic Contact Dermatitis|A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis|Completed||Phase 1|22|Actual|NovImmune SA||2|||f||||f||||||||||2018-05-31 23:07:57.763861|2018-05-31 23:07:57.763861
NCT01244594|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-01-07|2010-11-18|2010-11-19|Estimate|||||||2014-01-07|2014-01-08|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Effects of Two Functional Electrical Stimulation Cycling Paradigms|The Effects of Two Functional Electrical Stimulation Cycling Paradigms|Completed||Phase 2/Phase 3|17|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 23:07:57.825042|2018-05-31 23:07:57.825042
NCT01244581|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-06-19|2010-11-18|2010-11-19|Estimate|||||||2012-06-19|2012-06-20|Estimate|September 1999||1999-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry|Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry|Completed||Phase 3|84|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 23:07:58.023405|2018-05-31 23:07:58.023405
NCT01244568|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-12-19|2010-11-18|2010-11-19|Estimate|||||||2014-12-19|2014-12-23|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2|Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment- Study 2|Completed||N/A|218|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:07:58.206378|2018-05-31 23:07:58.206378
NCT01244555|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2015-11-30|2010-11-18|2010-11-19|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional|||Muscle Treatment for Management of Pain & Disability in Tension-type Headache|Muscle Treatment for Management of Pain & Disability in Tension-type Headache|Completed||Phase 2|69|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 23:07:58.333934|2018-05-31 23:07:58.333934
NCT01244542|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2017-10-04|2010-11-18|2010-11-19|Estimate|||||||2017-10-04|2017-10-05|Actual|August 2011|Actual|2011-08-31|September 2017|2017-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pain and Schizophrenia|Pain and Schizophrenia|Terminated||N/A|83|Actual|University Hospital, Strasbourg, France||2||recruitment difficulties|f||||f||||||||||2018-05-31 23:07:58.429578|2018-05-31 23:07:58.429578
NCT01244529|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2011-12-19||2017-08-31|2010-11-17|2010-11-19|Estimate|2011-12-19|2012-01-24|Estimate||||2017-08-31|2017-09-29|Actual|September 1, 2010|Actual|2010-09-01|August 2017|2017-08-31|November 1, 2010|Actual|2010-11-01|November 1, 2010|Actual|2010-11-01||Interventional||All enrolled subjects.|Comparison of Lens Fit and Lens Power of a New Contact Lens to Two Marketed Contact Lenses in a Population of Soft Contact Lens Wearers||Completed||N/A|41|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||f||||||||||2018-05-31 23:07:58.526303|2018-05-31 23:07:58.526303
NCT01244516|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2011-11-29||2018-04-09|2010-11-17|2010-11-19|Estimate|2011-12-19|2012-01-24|Estimate||||2018-04-09|2018-05-08|Actual|September 1, 2010|Actual|2010-09-01|April 2018|2018-04-30|November 1, 2010|Actual|2010-11-01|November 1, 2010|Actual|2010-11-01||Interventional||Population consists of those subjects who were enrolled and randomly assigned to a treatment arm AND who completed the study per protocol.|Multi-Center 2-Week Clinical Evaluation of Three Silicone Hydrogel Contact Lenses||Completed||N/A|540|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f||||||||||2018-05-31 23:07:58.847281|2018-05-31 23:07:58.847281
NCT01244503|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2014-08-07||2015-07-27|2010-11-18|2010-11-19|Estimate|2015-07-27|2015-07-28|Estimate||||2015-07-27|2015-07-28|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional||Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.|Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)|Prediction of Severity of Liver Disease in Patients With Suspected Nonalcoholic Fatty Liver Disease (NAFLD) by 13C Octanoate Breath Test (OBT)|Terminated||Phase 2|61|Actual|Virginia Commonwealth University||1||Budgetary Issues|f||||f||||||||||2018-05-31 23:07:59.240771|2018-05-31 23:07:59.240771
NCT01244490|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2014-05-09||2015-02-04|2010-11-18|2010-11-19|Estimate|2014-06-09|2014-07-14|Estimate||||2015-02-04|2015-02-24|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Safety Population defined as all randomized subjects who took at least 1 dose of investigational product. One subject did not receive investigational product, therefore n = 337.|Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|338|Actual|Shire||3|||f||||t||||||||||2018-05-31 23:07:59.560013|2018-05-31 23:07:59.560013
NCT01244477|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2014-11-13||2018-02-12|2010-11-18|2010-11-19|Estimate|2014-11-24|2014-12-02|Estimate||||2018-02-12|2018-03-12|Actual|May 16, 2011|Actual|2011-05-16|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|May 31, 2013|Actual|2013-05-31||Interventional|||Neuroimaging the Impact of Treatment on Neural Substrates of Trust in Post-Traumatic Stress Disorder (PTSD)|Neuroimaging the Impact of Treatment on Neural Substrates of Trust in PTSD|Active, not recruiting||N/A|61|Actual|VA Office of Research and Development|This is a pilot study based on a small sample of Veterans with PTSD.|2|||f||||f|f|f|||f|||No||2018-05-31 23:08:00.967111|2018-05-31 23:08:00.967111
NCT01244464|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-08-02|2010-11-18|2010-11-19|Estimate|||||||2012-08-02|2012-08-03|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||A Study of the Safety of IMOVAX Polio™ in China|Safety Study of IMOVAX Polio™ in Selected Cities in China, an Observational Post Marketing Study|Completed||Phase 4|800|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:08:01.38482|2018-05-31 23:08:01.38482
NCT01244451|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2015-01-29|2010-11-18|2010-11-19|Estimate|||||||2015-01-29|2015-01-30|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|BendOfa||GIMEMA CLL0809 Study (BendOfa)|A Single-Arm Multi-Center Trial of Bendamustine Given With Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL). EudraCT Number 2009-017663-42. GIMEMA CLL0809 Protocol|Completed||Phase 2|49|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-05-31 23:08:01.497082|2018-05-31 23:08:01.497082
NCT01244438|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-03-08|2010-11-18|2010-11-19|Estimate|||||||2012-03-08|2012-03-12|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Study of FP-1039 in Subjects With Endometrial Cancers|An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations|Withdrawn||Phase 2|0|Actual|Five Prime Therapeutics, Inc.||1||"Study FP1039-002 was not feasible. The original assumption was at least 5% of patients screened~   would qualify, but after screening 70 patients, none qualified."|f||||t||||||||||2018-05-31 23:08:01.632654|2018-05-31 23:08:01.632654
NCT01244425|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|2013-01-09||2013-02-19|2010-11-18|2010-11-19|Estimate|2013-01-09|2013-02-12|Estimate||||2013-02-19|2013-02-20|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection|A Randomized, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fibrin Sealant VH S/D 500 S-apr (Tisseel) for Hemostasis in Subjects Undergoing Hepatic Resection|Completed||Phase 2|70|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 23:08:01.728473|2018-05-31 23:08:01.728473
NCT01244412|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2013-06-05||2015-05-15|2010-11-18|2010-11-19|Estimate|2015-05-15|2015-06-02|Estimate||||2015-05-15|2015-06-02|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Assessment of Prototype Hand-held Fundus Camera|Assessment of Prototype Hand-held Fundus Camera|Terminated|||1|Actual|University of Rochester|It was determined that the project should stop in order for more technical changes to be made on the prototype|||"The PI wanted to make additional changes to the hand held camera therefore he terminated the~   study rather than continue with an outdated camera design."|f||||f||||||||||2018-05-31 23:08:02.1932|2018-05-31 23:08:02.1932
NCT01244399|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-01-11|2010-11-18|2010-11-19|Estimate|||||||2012-01-11|2012-01-12|Estimate|November 2010||2010-11-30|June 2011|2011-06-30||||||||Observational|||"Influence of Espresso on Adsorption of Myo-inositol"|"Influence of Espresso on Adsorption of Orally Administrated Myo-inositol in Humans"|Completed|||12|Anticipated|AGUNCO Obstetrics and Gynecology Centre|||||f||||||||||||||2018-05-31 23:08:02.385628|2018-05-31 23:08:02.385628
NCT01244386|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|June 2010||2010-06-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Low-dose CT Using Iterative Reconstruction in Patients With Inflammatory Bowel Disease||Unknown status|Recruiting||250|Anticipated|University College Cork|||1||f||||f||||||||||2018-05-31 23:08:02.476301|2018-05-31 23:08:02.476301
NCT01244373|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|Qu01||A Prospective Observational Case Series of a Four-ring-haptic Acrylic One-piece IOL|"Observational Case Series of the Implantation of Intraocular Lens QUATRIX® Aspheric Evolutive Pre-loaded."|Completed|||9|Actual|General Hospital Linz|||1||f||||f||||||||||2018-05-31 23:08:02.598124|2018-05-31 23:08:02.598124
NCT01244360|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2011-06-01|2010-11-18|2010-11-19|Estimate|||||||2011-06-01|2011-06-02|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|MUresv||The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance|The Effects of Resveratrol Supplementation on Measurements of Health and Human Performance|Unknown status|Active, not recruiting|N/A|44|Actual|Marywood University||2|||f||||f||||||||||2018-05-31 23:08:02.739374|2018-05-31 23:08:02.739374
NCT01244347|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2015-01-13|2010-11-18|2010-11-19|Estimate|||||||2015-01-13|2015-01-14|Estimate|July 2009||2009-07-31|January 2015|2015-01-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Folic Acid Dosage and Malformations Reduction|Randomized Clinical Trial to Evaluate the Efficacy of High Dose of Folic Acid to Prevent the Occurrence of Congenital Malformations|Unknown status|Active, not recruiting|Phase 3|5000|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||t||||||||||2018-05-31 23:08:02.914183|2018-05-31 23:08:02.914183
NCT01244334|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-08-06|2010-11-18|2010-11-19|Estimate|||||||2012-08-06|2012-08-08|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.|A Randomized, Masked Multi-center Safety & Efficacy Study of the Effects of Preoperative & Postoperative Cataract Surgery Use of Difluprednate Ophthalmic Emulsion, 0.05% Compared to Prednisolone Acetate Ophthalmic Suspension 1% on Visual Acuity & Corneal Edema.|Completed||Phase 4|52|Actual|Cincinnati Eye Institute Northern Kentucky||2|||f||||t||||||||||2018-05-31 23:08:03.566022|2018-05-31 23:08:03.566022
NCT01244321|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2015-01-28|2010-11-18|2010-11-19|Estimate|||||||2015-01-28|2015-01-29|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|COVADIS||COVADIS Pilot Trial: COseal in Ventricular Assist DevIceS|A Controlled, Single-Center Clinical Pilot Study to Evaluate the Performance of CoSeal as a Barrier for Adhesion Prevention in Patients Submitted to Ventricular Assist Device VAD)|Unknown status|Recruiting||30|Anticipated|German Heart Institute|||2||f||||f||||||||||2018-05-31 23:08:03.683383|2018-05-31 23:08:03.683383
NCT01244308|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2013-07-26|2010-11-18|2010-11-19|Estimate|||||||2013-07-26|2013-07-29|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|August 2011|Actual|2011-08-31|September 2009|Actual|2009-09-30||Observational|Efface||Effectiveness and Reliability of VectSelect™ Feature for Avoidance of Phrenic Nerve Stimulation in Cardiac Resynchronisation Therapy (CRT) Patients|Effectiveness and Reliability of VectSelect™ Feature for Avoidance of Phrenic Nerve Stimulation in CRT Patients|Completed|||132|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 23:08:03.773528|2018-05-31 23:08:03.773528
NCT01244295|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2014-01-15|2010-11-18|2010-11-19|Estimate|||||||2014-01-15|2014-01-16|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|CGTOA||Study of Interpersonal Therapy and Complicated Grief Treatment in Adults 50 Years and Older|Complicated Grief Treatment in Older Adults|Completed||N/A|151|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 23:08:03.859215|2018-05-31 23:08:03.859215
NCT01244282|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2016-06-09|2010-11-18|2010-11-19|Estimate|||||||2016-06-09|2016-06-10|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||A Study of Two Methodologies for Measuring Blood Flow in the Brain in Response to Non-Drug Stimuli (P08085/MK-0000-180)|A Pilot Clinical Trial to Study Arterial Spin Labeling and USPIO-enhanced MRI Methodologies for Measuring Hemodynamic Responses to Non-Drug Stimuli in Healthy Subjects|Completed||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 23:08:03.953565|2018-05-31 23:08:03.953565
NCT01244269|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-10-19|2010-11-18|2010-11-19|Estimate|||||||2012-10-19|2012-10-22|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.|Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease.|Terminated||Phase 4|6|Actual|Laval University||4||"Inadequate enrolment, protocol too challenging for participants, lack of observable benefit~   after analysis of 6 patients."|f||||||||||||||2018-05-31 23:08:04.010649|2018-05-31 23:08:04.010649
NCT01244256|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|September 2007|Anticipated|2007-09-30|August 2007|Anticipated|2007-08-31||Interventional|acne||Evaluation of Efficacy and Comparative Isolation of the Association Beclomethasone Clotrimzaol + + Gentamicin in Patients With Acne Contaminated|Isolation and Comparative Efficacy of the Combination of beclometasona0, 025% + Gentamicin 0.1% + Clotrimazole 1% Topical Dermatological Cream of GLENMARK PHARMACEUTICALS, in Patients Infected With Acne|Suspended||Phase 2/Phase 3|80|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-05-31 23:08:04.117926|2018-05-31 23:08:04.117926
NCT01244243|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2014-12-12||2016-08-16|2010-11-17|2010-11-19|Estimate|2015-05-22|2015-05-27|Estimate||||2016-08-16|2016-08-18|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Robot3||Robot-Assisted Hand Motor Therapy for Subjects With Hemiparetic Stroke|Robot-Assisted Hand Motor Therapy for Subjects With Hemiparetic Stroke|Completed||Phase 2|41|Actual|University of California, Irvine||1|||f||||f||||||||||2018-05-31 23:08:04.255949|2018-05-31 23:08:04.255949
NCT01244230|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-10-12|2010-11-17|2010-11-19|Estimate|||||||2013-10-12|2013-10-16|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)|An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Atopic Dermatitis|Completed||Phase 2/Phase 3|100|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 23:08:04.600175|2018-05-31 23:08:04.600175
NCT01244217|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-10-12|2010-11-17|2010-11-19|Estimate|||||||2013-10-12|2013-10-16|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)|An Open-label, Uncontrolled 4-week Study to Assess the Safety, Efficacy and Pharmacokinetics of Allegra® (Dry Syrup Formulation) 15 mg or 30 mg Twice Daily in Pediatric Patients With Perennial Allergic Rhinitis|Completed||Phase 2/Phase 3|100|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 23:08:04.771856|2018-05-31 23:08:04.771856
NCT01244204|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-08-01|2010-11-18|2010-11-19|Estimate|||||||2012-08-01|2012-08-03|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|||Role of Vitamin D in Innate Immunity to Tuberculosis|Vitamin D Supplementations as Adjunct to Anti-tuberculosis Drugs in Mongolia|Completed||N/A|120|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 23:08:04.875106|2018-05-31 23:08:04.875106
NCT01244191|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17||2015-10-22|2017-05-08|2010-11-18|2010-11-19|Estimate||||2015-10-22|2015-11-16|Estimate|2017-05-08|2017-05-09|Actual|November 2010||2010-11-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|August 2013|Actual|2013-08-31||Interventional|||Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 3|1048|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||||2018-05-31 23:08:04.979711|2018-05-31 23:08:04.979711
NCT01244178|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-10-24|2010-11-18|2010-11-19|Estimate|||||||2013-10-24|2013-10-25|Estimate|November 2010||2010-11-30|October 2013|2013-10-31||||December 2013|Anticipated|2013-12-31||Interventional|||Hyperinsulinemic Therapy in Sepsis|Hyperinsulinemic Therapy in Sepsis|Unknown status|Active, not recruiting|N/A|15|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-05-31 23:08:05.591626|2018-05-31 23:08:05.591626
NCT01244165|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|January 2002||2002-01-31|November 2010|2010-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study of Cytrix Use in Pelvic Floor Prolapse Treatment|Clinical Investigation of Fetal Bovine Dermis Material (Cytrix) for Use in the Treatment of Pelvic Floor Prolapse|Completed||Phase 4|45|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 23:08:05.673307|2018-05-31 23:08:05.673307
NCT01238510|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2013-04-22|2010-11-09|2010-11-10|Estimate|||||||2013-04-22|2013-04-23|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PROTECT-SB||Comparison Between Provisional Versus Routine Kissing Balloon Technique After Main Vessel Crossover Stenting for Bifurcated Lesions.||Completed||Phase 4|120|Actual|Saiseikai Yokohama City Eastern Hospital||2|||f||||||||||||||2018-05-31 23:09:49.91678|2018-05-31 23:09:49.91678
NCT01244152|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|LIFE||Self-Management in African Americans With Diabetes and Hypertension|Lifestyle Improvement Through Food and Exercise (LIFE): Self-Management in African Americans With Diabetes and Hypertension|Completed||Phase 2|59|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 23:08:05.750706|2018-05-31 23:08:05.750706
NCT01244139|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2017-01-05|2010-11-18|2010-11-19|Estimate|||||||2017-01-05|2017-01-09|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety Study of BIIB033 in Subjects With Multiple Sclerosis|A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis|Completed||Phase 1|47|Actual|Biogen||2|||f||||t||||||||||2018-05-31 23:08:05.81411|2018-05-31 23:08:05.81411
NCT01244126|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2013-08-09||2016-02-03|2010-11-18|2010-11-19|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy|Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes|Completed||Phase 4|171|Actual|Baylor College of Medicine|This study used an objective pain scale where the minimum clinically important difference in scores is unknown. The study did not use a group receiving no active treatment as this was unethical. We also did not measure blood levels of opioids.|3|||f||||f||||||||||2018-05-31 23:08:05.917909|2018-05-31 23:08:05.917909
NCT01244113|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|July 2010||2010-07-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Optimal Dose of Propofol for Induction of Deep Sedation for Brain MRI Scanning in Children With Cerebral Palsy|Optimal Dose of Propofol for Induction of Deep Sedation for Brain MRI Scanning in Children With Cerebral Palsy|Completed||N/A|20|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 23:08:06.321282|2018-05-31 23:08:06.321282
NCT01244100|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2010-12-10|2010-11-17|2010-11-19|Estimate|||||||2010-12-10|2010-12-13|Estimate|October 2010||2010-10-31|December 2010|2010-12-31||||December 2010|Actual|2010-12-31||Interventional|||Food-Effect Pharmacokinetic Study of PL2200||Completed||Phase 1|20|Anticipated|PLx Pharma||1|||f||||||||||||||2018-05-31 23:08:06.384571|2018-05-31 23:08:06.384571
NCT01244087|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2013-06-13|2010-11-18|2010-11-19|Estimate|||||||2013-06-13|2013-06-14|Estimate|December 2010||2010-12-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|December 2011|Actual|2011-12-31||Observational|||Pilot Clinical Trial (Phase II) of Inquiry-based Stress Reduction (IBSR) Program for Survivors of Breast Cancer|Pilot Clinical Trial (Phase II) of Inquiry-based Stress Reduction (IBSR) Program for Survivors of Breast Cancer|Completed|||30|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:08:06.45921|2018-05-31 23:08:06.45921
NCT01244074|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate||||February 2010|2010-02-28||||||||Interventional|||Visual Rehabilitation of Patients With Myopic Maculopathy||Completed||N/A|||University of Roma La Sapienza||1|||f||||||||||||||2018-05-31 23:08:06.532065|2018-05-31 23:08:06.532065
NCT01244061|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2013-10-30||2014-05-20|2010-11-18|2010-11-19|Estimate|2014-05-20|2014-06-09|Estimate||||2014-05-20|2014-06-09|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider|A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline|Completed||Phase 4|498|Actual|Pfizer|One SAE, exposure via semen, was not included under the Adverse Events since this event was considered to be experienced by a non-study participant, who was the study participant's partner. This event was coded as nonserious in the safety database.|2|||f||||t||||||||||2018-05-31 23:08:06.620962|2018-05-31 23:08:06.620962
NCT01244048|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2012-03-06|2010-11-18|2010-11-19|Estimate|||||||2012-03-06|2012-03-07|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Intervention With n3 LC-PUFA-supplemented Yogurt|Intervention With n3 LC-PUFA-supplemented Yogurt: Effects on Cardiovascular Risk Factors and Inflammatory Biomarkers|Completed||N/A|53|Actual|University of Jena|||||f||||t||||||||||2018-05-31 23:08:06.988849|2018-05-31 23:08:06.988849
NCT01244035|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2015-10-30|2010-11-18|2010-11-19|Estimate|||||||2015-10-30|2015-11-02|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008 AM1)(COMPLETED)|Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Different Dosing Regimens of MK-8266 or Placebo in Subjects With Hypertension|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||12|||f||||f||||||||||2018-05-31 23:08:07.039726|2018-05-31 23:08:07.039726
NCT01244022|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2013-07-15|2010-11-18|2010-11-19|Estimate|||||||2013-07-15|2013-07-16|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Cytokine Changes After Colorectal Cancer Resection|Postoperative Serum Cytokine Changes After Radical Resection of Colorectal Cancer|Completed|||28|Actual|University Hospital Dubrava|||1||f||||f||||||Samples Without DNA|"~     For each patient, serum samples will be stored at -80°C for later determining of serum~     cytokine levels~   "|||2018-05-31 23:08:07.129912|2018-05-31 23:08:07.129912
NCT01244009|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2016-11-03|2010-11-17|2010-11-19|Estimate|||||||2016-11-03|2016-11-07|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)|A Phase II Efficacy Study of MK-4827 in Patients With Mantle Cell Lymphoma|Withdrawn||Phase 2|0|Actual|Tesaro, Inc.||1||Sponsor decision|f||||f||||||||||2018-05-31 23:08:07.263674|2018-05-31 23:08:07.263674
NCT01243996|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant|High-dose Ibuprofen for Patent Ductus Arteriosus in Extremely Preterm Infants: a Randomized Controlled Study|Completed||Phase 2/Phase 3|70|Actual|University of Florence||1|||f||||f||||||||||2018-05-31 23:08:07.325978|2018-05-31 23:08:07.325978
NCT01243632|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-17|2010-11-17|2010-11-18|Estimate|||||||2010-11-17|2010-11-18|Estimate|December 2002||2002-12-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment|A Phase II Trial of Low-dose Gemcitabine in Prolonged Infusion and Cisplatin in Treatment of Malignant Pleural Mesothelioma|Completed||Phase 2|78|Actual|Institute of Oncology Ljubljana|||||f||||||||||||||2018-05-31 23:08:13.972544|2018-05-31 23:08:13.972544
NCT01243983|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2013-01-08|2010-11-18|2010-11-19|Estimate|||||||2013-01-08|2013-01-10|Estimate|February 2011||2011-02-28|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis|A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects With Active Noninfectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye|Completed||Phase 3|155|Actual|Lux Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 23:08:07.40353|2018-05-31 23:08:07.40353
NCT01243970|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2016-10-25|2010-11-18|2010-11-19|Estimate|||||||2016-10-25|2016-10-26|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Ephedrine vs Phenylephrine - ECG Changes|Randomised, Double-blind, Phase IV Study to Compare the Incidence of ECG Changes During Elective Caesarean Section Under Spinal Anaesthesia When Using Phenylephrine or Ephedrine Infusion to Maintain Baseline Systolic Blood Pressure|Terminated||Phase 4|29|Actual|University College London Hospitals||2||Change in clinical practice since the start of the trial in 2011 (phenylephrine superior)|f||||t||||||||||2018-05-31 23:08:07.531336|2018-05-31 23:08:07.531336
NCT01243957|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2011-01-20|2010-11-17|2010-11-19|Estimate|||||||2011-01-20|2011-01-21|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.|LY2216684 and Fluoxetine Pharmacokinetic Interaction Study in Healthy Subjects|Completed||Phase 1|0|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:08:07.596292|2018-05-31 23:08:07.596292
NCT01243944|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2014-12-22|2010-12-13|2018-03-08|2010-11-18|2010-11-19|Estimate|2015-02-19|2015-03-06|Estimate|2010-12-13|2010-12-16|Estimate|2018-03-08|2018-04-04|Actual|October 2010||2010-10-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|January 2014|Actual|2014-01-31||Interventional||All enrolled participants, regardless treated or not.|Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)|Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)|Active, not recruiting||Phase 3|222|Actual|Incyte Corporation||2|||t||||||||||||||2018-05-31 23:08:07.756498|2018-05-31 23:08:07.756498
NCT01243931|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2018-04-04|2010-11-18|2010-11-19|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2011||2011-06-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy|Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy|Recruiting||N/A|80|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 23:08:08.586476|2018-05-31 23:08:08.586476
NCT01243918|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2013-10-04|2010-11-18|2010-11-19|Estimate|||||||2013-10-04|2013-10-07|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|OPTI O2||Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure|Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure|Terminated||N/A|16|Actual|Nantes University Hospital||4||Difficulty of recruitment|f||||f||||||||||2018-05-31 23:08:08.669332|2018-05-31 23:08:08.669332
NCT01243905|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-01-18|2010-11-18|2010-11-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Group Psychoeducational Program for Mothers of Children With High Functional Pervasive Developmental Disorders|Group Psychoeducational Program for Mothers of Preschool Children With High Functional Pervasive Developmental Disorders: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|74|Anticipated|Nagoya City University||2|||f||||f||||||||||2018-05-31 23:08:08.764738|2018-05-31 23:08:08.764738
NCT01243892|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2016-10-07||2016-10-07|2010-11-18|2010-11-19|Estimate|2016-10-07|2016-12-01|Estimate||||2016-10-07|2016-12-01|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational||Study population included all enrolled somatropin-naive pre-pubertal participants with growth hormone deficiency or ISS.|A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device|A Phase IV, Open Label, Multicenter, Case-controlled Study of Growth in Patients Using the Nutropin AQ® Nuspin®|Terminated|||18|Actual|Genentech, Inc.|The study was terminated prematurely due to slow enrollment.||2|The study was closed due to the slow enrollment rate.|f||||||||||||||2018-05-31 23:08:08.867071|2018-05-31 23:08:08.867071
NCT01243879|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate||||November 2010|2010-11-30||||||||Interventional|||The Effect of Food Stimuli on the Calorie Restriction Response in Healthy Subjects|The Effect of Food Stimuli on the Calorie Restriction Response in Healthy Subjects|Completed||N/A|||Leiden University Medical Center||2|||f||||||||||||||2018-05-31 23:08:09.063365|2018-05-31 23:08:09.063365
NCT01243866|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|February 2007||2007-02-28|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of Dental Treatment on Children's Growth|Effect of Dental Treatment on Children's Growth|Completed||Phase 1/Phase 2|86|Actual|King Fahad Armed Forces Hospital||2|||f||||t||||||||||2018-05-31 23:08:09.107203|2018-05-31 23:08:09.107203
NCT01243853|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2011-01-14|2010-11-18|2010-11-19|Estimate|||||||2011-01-14|2011-01-17|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|ALFA||Alpha-galactosidase Enzyme and Irritable Bowel Syndrome|Alpha-galactosidase Enzyme and Irritable Bowel Syndrome|Unknown status|Recruiting|N/A|150|Anticipated|Verman Oy Ab||2|||f||||f||||||||||2018-05-31 23:08:09.231294|2018-05-31 23:08:09.231294
NCT01243840|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-01-23|2010-11-18|2010-11-19|Estimate|||||||2012-01-23|2012-01-25|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|June 2019|Anticipated|2019-06-30|June 2014|Anticipated|2014-06-30||Observational|J-CARP||Japan Central Aortic Pressure Prospective Study|Central Blood Pressure Follow-up Study in Japanese|Recruiting|||3000|Anticipated|Jichi Medical University|||||f||||f||||||||||2018-05-31 23:08:09.304044|2018-05-31 23:08:09.304044
NCT01243827|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-07-18|2010-11-18|2010-11-19|Estimate|||||||2012-07-18|2012-07-19|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study|Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study|Unknown status|Recruiting|Phase 4|200|Anticipated|Jichi Medical University||2|||f||||t||||||||||2018-05-31 23:08:09.37565|2018-05-31 23:08:09.37565
NCT01242241|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Propofol in Obese Children|Propofol in Obese Children|Unknown status|Recruiting|N/A|80|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 23:08:35.436679|2018-05-31 23:08:35.436679
NCT01243814|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2012-03-19|2010-11-18|2010-11-19|Estimate|||||||2012-03-19|2012-03-20|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Double-blind RCT of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle|A Double-blind, Randomized, Placebo-controlled Study of the Relative Efficacy of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle|Completed||N/A|69|Actual|Henry DeGroot, M.D.||2|||f||||f||||||||||2018-05-31 23:08:09.442834|2018-05-31 23:08:09.442834
NCT01243801|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2015-03-20|2010-11-18|2010-11-19|Estimate|||||||2015-03-20|2015-03-23|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Prevention of Persistent Postsurgical Pain After Thoracotomy|Phase 4 Study of Prevention of Persistent Postsurgical Pain After Thoracotomy Using Ketamine|Completed||Phase 4|104|Actual|Hospital Clinic of Barcelona||3|||f||||f||||||||||2018-05-31 23:08:09.538559|2018-05-31 23:08:09.538559
NCT01243788|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-18|||2010-11-18|2010-11-18|2010-11-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|July 2009||2009-07-31|October 2008|2008-10-31|October 2011|Anticipated|2011-10-31|February 2011|Anticipated|2011-02-28||Interventional|||The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD|Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Ipratropium/Albuterolin Chinese Patients With Moderate-to-severe COPD.|Unknown status|Recruiting|Phase 4|450|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 23:08:09.629395|2018-05-31 23:08:09.629395
NCT01243775|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2015-07-19||2015-07-20|2010-11-18|2010-11-19|Estimate|2015-07-20|2015-08-17|Estimate||||2015-07-20|2015-08-17|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|BELOXAN||BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC|Phase II Trial of First Line Docetaxel and Oxaliplatin in Stage IV or Relapsed Non-Small Cell Lung Cancer|Completed||Phase 2|33|Actual|Chonnam National University Hospital||1|||f||||t||||||||||2018-05-31 23:08:09.750851|2018-05-31 23:08:09.750851
NCT01243762|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2017-06-13||2018-04-10|2010-11-17|2010-11-19|Estimate|2017-06-13|2017-10-30|Actual||||2018-04-10|2018-04-11|Actual|November 22, 2010|Actual|2010-11-22|April 2018|2018-04-30|March 25, 2013|Actual|2013-03-25|December 4, 2012|Actual|2012-12-04||Interventional||Total number of participants for each dose combination for the overall study|A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)|Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer|Terminated||Phase 1|47|Actual|Merck Sharp & Dohme Corp.|The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.|7||"The study was terminated for business reasons and not due to any safety or efficacy concerns~   related to dalotuzumab."|f||||f|t|f||||||||2018-05-31 23:08:10.017841|2018-05-31 23:08:10.017841
NCT01243749|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2018-04-04|2010-11-17|2010-11-18|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2010|Actual|2010-12-31|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|April 2013|Actual|2013-04-30||Observational|R-C Registry||RESOLUTE China Registry:|Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Real-World Patient Population in China|Completed|||1800|Actual|Medtronic Vascular|||||f||||t||||||||||2018-05-31 23:08:12.612677|2018-05-31 23:08:12.612677
NCT01243736|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2016-01-19|2010-11-17|2010-11-18|Estimate|||||||2016-01-19|2016-01-20|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|CEPREP||Assessment of Combined Bowel Preparation for Capsule Endoscopy Study|Assessment of Combined Bowel Preparation for Capsule Endoscopy Study|Completed||Phase 1|50|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 23:08:12.693311|2018-05-31 23:08:12.693311
NCT01243723|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-03-18|2010-11-17|2010-11-18|Estimate|||||||2014-03-18|2014-03-19|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|EDUCDYS||Study Assessing the Efficacy of Eductyl® for the Treatment of Patients With Dyschesia|Étude Comparative, randomisée, Double-insu, en Groupes parallèles évaluant l'efficacité d'Eductyl® Versus Placebo Chez Des Patients Souffrant d'Une dyschésie|Completed||Phase 4|306|Actual|Laboratoires Techni Pharma||2|||f||||t||||||||||2018-05-31 23:08:12.861519|2018-05-31 23:08:12.861519
NCT01243710|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2013-08-14|2010-11-17|2010-11-18|Estimate|||||||2013-08-14|2013-08-15|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Taurolidine in Haemodialysis Catheter Related Bacteraemia|A Randomised Controlled Trial of Taurolidine With Heparin for Prevention of Recurrence of Catheter Related Bacteraemia in Haemodialysis Patients.|Completed||Phase 4|27|Actual|Imperial College Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 23:08:12.933258|2018-05-31 23:08:12.933258
NCT01243697|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2013-11-13|2010-11-17|2010-11-18|Estimate|||||||2013-11-13|2013-11-14|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|RESPIRONDINE||Assessment of Desogestrel in Ondine Syndrome|Assessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine Syndrome|Completed||Phase 2/Phase 3|6|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 23:08:13.011141|2018-05-31 23:08:13.011141
NCT01243684|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2015-10-18|2010-11-17|2010-11-18|Estimate|||||||2015-10-18|2015-10-20|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|January 2014|Actual|2014-01-31|June 2012|Actual|2012-06-30||Interventional|Tractocervical||A Magnetic Resonance Imaging Study of Patients With Cervical Spondylosis|Structural Spinal Cord Integrity in Patients With Cervical Spondylosis in Relation to Clinical Status|Completed||N/A|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:08:13.088339|2018-05-31 23:08:13.088339
NCT01243671|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2013-03-26||2014-06-27|2010-11-17|2010-11-18|Estimate|2013-03-26|2013-05-15|Estimate||||2014-06-27|2014-07-25|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|March 2012|Actual|2012-03-31||Interventional|||A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease|A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease|Completed||Phase 3|20|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:08:13.214521|2018-05-31 23:08:13.214521
NCT01243658|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2017-12-20|2010-11-17|2010-11-18|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2011||2011-01-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||"The Effects of Oxytocin on Patients With Borderline Personality Disorder"|"The Effects of Oxytocin on Patients With Borderline Personality Disorder"|Recruiting||N/A|150|Anticipated|University of Freiburg||2|||f||||t||||||||||2018-05-31 23:08:13.853724|2018-05-31 23:08:13.853724
NCT01243645|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-17|2010-11-17|2010-11-18|Estimate|||||||2010-11-17|2010-11-18|Estimate||||September 2010|2010-09-30||||||||Interventional|||MP-1 Biofeedback: Pattern Stimulus Versus Audio-feedback in AMD|MP-1 Biofeedback: Pattern Stimulus Versus Audio-feedback in Age Related Macular Degeneration (AMD)|Completed||N/A|||University of Roma La Sapienza|||||f||||f||||||||||2018-05-31 23:08:13.924829|2018-05-31 23:08:13.924829
NCT01243619|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2015-02-18||2017-04-12|2010-11-17|2010-11-18|Estimate|2015-02-18|2015-03-05|Estimate||||2017-04-12|2017-05-17|Actual|August 2010||2010-08-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer|3'-Deoxy-3'(18) F-Fluorothymidine Positron Emission Tomography/Computed Tomography (PET/CT) for Initial Staging, Radiotherapy Target Definition, and Assessment of Response to Therapy in Patients With Esophageal Cancer: A Pilot Study|Completed||N/A|5|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 23:08:14.041174|2018-05-31 23:08:14.041174
NCT01243606|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2017-10-06|2010-11-17|2010-11-18|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2010||2010-12-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders|Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders|Completed||N/A|250|Actual|Boston University Charles River Campus||3|||f||||t||||||||Undecided||2018-05-31 23:08:14.250462|2018-05-31 23:08:14.250462
NCT01243593|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2015-05-29|2010-11-17|2010-11-18|Estimate|||||||2015-05-29|2015-06-02|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Transversus Abdominis Plane Block in Children Undergoing Open Pyeloplasty Surgery|Transversus Abdominis Plane Block in Children Undergoing Open Pyeloplasty Surgery|Completed||Phase 2|32|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:08:14.339179|2018-05-31 23:08:14.339179
NCT01243580|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2017-07-21||2017-12-21|2010-11-17|2010-11-18|Estimate|2017-07-25|2017-12-19|Actual||||2017-12-21|2018-01-23|Actual|August 2009||2009-08-31|December 2017|2017-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol|An Open-Label Study to Evaluate Pharmacokinetic Profile of Agile TCDS AG200-15 and to Compare Exposure to Ethinyl Estradiol to Oral Contraceptive (Orthocyclen®) in Healthy Female Volunteers|Completed||Phase 1|36|Actual|Agile Therapeutics||2|||f||||f||||||||||2018-05-31 23:08:14.450104|2018-05-31 23:08:14.450104
NCT01243567|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2013-01-22||2013-01-22|2010-11-17|2010-11-18|Estimate|2013-01-22|2013-02-26|Estimate||||2013-01-22|2013-02-26|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated||Completed||Phase 4|81|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:08:14.931871|2018-05-31 23:08:14.931871
NCT01243554|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2018-01-11|2010-11-17|2010-11-18|Estimate|||||||2018-01-11|2018-01-12|Actual|September 2010||2010-09-30|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Exercise Training in Pregnancy for Obese Mothers|Exercise Training in Pregnancy. Good for the Mother - Good for the Child?|Completed||N/A|91|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 23:08:15.189902|2018-05-31 23:08:15.189902
NCT01243541|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2018-01-09|2010-11-17|2010-11-18|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2010||2010-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel|Cold Therapy to Prevent Paclitaxel-Induced Peripheral Neuropathy and Cutaneous Toxicity|Active, not recruiting||N/A|66|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 23:08:15.291205|2018-05-31 23:08:15.291205
NCT01243528|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-12-12|2010-11-17|2010-11-18|Estimate|||||||2014-12-12|2014-12-15|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|Malnutrition||Observational Study at the Influence of Malnutrition on Infections|Prospective, Non-interventional Observational Study at the Influence of Malnutrition on Nosocomial Infections in Patients During Early Neurological Rehabilitation|Completed|||100|Actual|Schoen Clinic Bad Aibling|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:08:15.377172|2018-05-31 23:08:15.377172
NCT01243515|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2013-02-07|2010-11-17|2010-11-18|Estimate|||||||2013-02-07|2013-02-08|Estimate||||February 2013|2013-02-28||||||||Observational|||Comparison of a Non-Invasive Central Venous Pressure Device and Physical Examination in Patients With Chronic Kidney Disease|Clinical Validation of a Non-Invasive Central Venous Pressure Device in Comparison With Physical Examination in Patients With Chronic Kidney Disease and Healthy Volunteers|Withdrawn|||0|Actual|Mespere Lifesciences Inc.|||2||f||||f||||||||||2018-05-31 23:08:15.438737|2018-05-31 23:08:15.438737
NCT01243502|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-17|2010-11-17|2010-11-18|Estimate|||||||2010-11-17|2010-11-18|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers|A Multiple Dose, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Topically Administered CT327 in Healthy Male Volunteers|Completed||Phase 1|16|Actual|Creabilis SA||2|||f||||f||||||||||2018-05-31 23:08:15.517642|2018-05-31 23:08:15.517642
NCT01243489|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-07-14|2010-11-17|2010-11-18|Estimate|||||||2014-07-14|2014-07-15|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|Crescendo||Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation|CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy|Unknown status|Active, not recruiting|Phase 4|200|Anticipated|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||2|||f||||f||||||||||2018-05-31 23:08:15.572526|2018-05-31 23:08:15.572526
NCT01243476|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2018-04-25|2010-11-17|2010-11-18|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2010||2010-01-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|SINTRA-REV||Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome|Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.|Active, not recruiting||Phase 3|61|Actual|Fundación General de la Universidad de Salamanca||2|||f||||f||||||||||2018-05-31 23:08:15.766626|2018-05-31 23:08:15.766626
NCT01243463|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2011-07-20|2010-11-17|2010-11-18|Estimate|||||||2011-07-20|2011-07-21|Estimate|February 2010||2010-02-28|July 2011|2011-07-31||||||||Observational|BAROSA||Bariatric Surgery and Obstructive Sleep Apnea|Effects of Bariatric Surgery on Obstructive Sleep Apnea|Completed|||20|Anticipated|Summa Health System|||||f||||f||||||||||2018-05-31 23:08:15.875145|2018-05-31 23:08:15.875145
NCT01241877|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2011-04-19|2010-11-15|2010-11-16|Estimate|||||||2011-04-19|2011-04-20|Estimate|November 2010||2010-11-30|April 2011|2011-04-30||||June 2011|Anticipated|2011-06-30||Interventional|||Astaxanthin Supplementation in Cyclists||Unknown status|Recruiting|N/A|24|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 23:08:38.983807|2018-05-31 23:08:38.983807
NCT01243450|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2014-09-07||2014-11-17|2010-11-17|2010-11-18|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-17|2014-11-18|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||number of acne lesions by counting|Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo|Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo|Completed||Phase 3|958|Actual|Spear Pharmaceuticals||3|||f||||t||||||||||2018-05-31 23:08:15.996419|2018-05-31 23:08:15.996419
NCT01243437|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-09-10|2010-11-17|2010-11-18|Estimate|||||||2012-09-10|2012-09-11|Estimate|December 2010||2010-12-31|September 2012|2012-09-30||||June 2013|Anticipated|2013-06-30||Interventional|||A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans|A Randomized, Non-inferiority, Active Controlled Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin Versus Doxycycline in the Treatment of Plague in Humans|Unknown status|Recruiting|Phase 2|200|Anticipated|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 23:08:16.233461|2018-05-31 23:08:16.233461
NCT01243424|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2018-05-17|2010-11-17|2010-11-18|Estimate|||||||2018-05-17|2018-05-21|Actual|October 26, 2010|Actual|2010-10-26|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes|A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.|Active, not recruiting||Phase 3|6072|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:08:16.427867|2018-05-31 23:08:16.427867
NCT01243411|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2015-02-04||2017-09-07|2010-11-17|2010-11-18|Estimate|2015-03-31|2015-04-15|Estimate||||2017-09-07|2017-10-05|Actual|November 2010||2010-11-30|September 2017|2017-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of AA4500 in Men With Peyronie's Disease|A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease|Completed||Phase 3|348|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:08:17.478259|2018-05-31 23:08:17.478259
NCT01243398|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-11-28|2010-11-17|2010-11-18|Estimate|||||||2012-11-28|2012-11-29|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy|Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gefitinib (Iressa®) Versus Placebo in Esophageal Cancer Progressing After Chemotherapy|Completed||Phase 3|450|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 23:08:17.773874|2018-05-31 23:08:17.773874
NCT01243385|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2017-11-07|2010-11-17|2010-11-18|Estimate|||||||2017-11-07|2017-11-08|Actual|November 16, 2010|Actual|2010-11-16|November 2017|2017-11-30|December 2032|Anticipated|2032-12-31|April 17, 2012|Actual|2012-04-17||Interventional|||Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer|Metformin in Castration Resistant Prostate Cancer. A Multicenter Phase II Trial.|Active, not recruiting||Phase 2|44|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||No||2018-05-31 23:08:17.94231|2018-05-31 23:08:17.94231
NCT01243372|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2017-08-07|2010-11-17|2010-11-18|Estimate|||||||2017-08-07|2017-08-08|Actual|November 2009||2009-11-30|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer|Evaluating BRAF Mutations as Predictors of Efficacy in Cetuximab-Treated Colorectal Cancer Patients: A Retrospective Study of Tissues From CALGB / SWOG|Active, not recruiting|||1142|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:08:18.037016|2018-05-31 23:08:18.037016
NCT01243359|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-04-01|2010-11-17|2010-11-18|Estimate|||||||2014-04-01|2014-04-02|Estimate|October 2010||2010-10-31|October 2013|2013-10-31||||February 2014|Actual|2014-02-28||Interventional|||Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies|Phase I Pharmacodynamic Trial of Sequential Sunitinib With Bevacizumab in Patients With Renal Cell Carcinoma and Other Advanced Solid Malignancies|Completed||Phase 1|6|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:08:18.106985|2018-05-31 23:08:18.106985
NCT01243346|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-11-04|2010-11-17|2010-11-18|Estimate|||||||2014-11-04|2014-11-06|Estimate|April 2011||2011-04-30|November 2014|2014-11-30||||July 2014|Actual|2014-07-31||Interventional|||Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene|Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions, Including the D842V Mutation, in the PDGFRA Gene|Completed||Phase 2|20|Actual|Arog Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:08:18.205088|2018-05-31 23:08:18.205088
NCT01243333|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2018-04-20|2010-11-16|2010-11-18|Estimate|||||||2018-04-20|2018-04-23|Actual|January 26, 2011|Actual|2011-01-26|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 6, 2018|Actual|2018-03-06||Interventional|||Multi-Tracer Positron Emission Tomography in Patients With Solid Tumors|Multi-tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents|Active, not recruiting||N/A|26|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 23:08:18.2788|2018-05-31 23:08:18.2788
NCT01243320|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2015-06-04||2015-07-28|2010-11-17|2010-11-18|Estimate|2015-07-28|2015-08-25|Estimate||||2015-07-28|2015-08-25|Estimate|December 2010||2010-12-31|July 2015|2015-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||In Vivo Assessment of Silver Biomaterial Nano-Toxicity|In Vivo Assessment of Silver Biomaterial Nano-Toxicity|Completed||Phase 1/Phase 2|36|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 23:08:18.38354|2018-05-31 23:08:18.38354
NCT01243307|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2011-06-06|2010-11-17|2010-11-18|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers|A Phase I, Single-centre, Multiple-dose, Placebo-controlled Crossover Study to Investigate the Pharmacodynamic Effects of CT327 (0.1% Topical Cream) on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers|Completed||Phase 1|24|Anticipated|Creabilis SA||2|||f||||f||||||||||2018-05-31 23:08:19.058318|2018-05-31 23:08:19.058318
NCT01243294|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2011-02-17||2011-10-04|2010-11-17|2010-11-18|Estimate|2011-05-23|2011-06-22|Estimate||||2011-10-04|2011-10-07|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study Evaluating a New Ostomy Appliance With Regard to Leakage, Handling and Comfort|Cross-over, Open Label Study Evaluating a New Ostomy Appliance With Regard to Leakage, Handling and Comfort|Completed||Phase 2/Phase 3|56|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 23:08:19.135844|2018-05-31 23:08:19.135844
NCT01243281|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2011-06-26|2010-11-17|2010-11-18|Estimate|||||||2011-06-26|2011-06-28|Estimate|March 2011||2011-03-31|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Interventional|||Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B|A Randomized Design Study to Compare the Efficacy of Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B: Role of Host and Viral Factors Associated With Treatment Response|Unknown status|Recruiting|N/A|126|Anticipated|Chulalongkorn University||1|||f||||t||||||||||2018-05-31 23:08:19.348334|2018-05-31 23:08:19.348334
NCT01243268|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2016-09-15|2010-11-17|2010-11-18|Estimate|||||||2016-09-15|2016-09-16|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy|A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy|Completed|||612|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:08:19.443797|2018-05-31 23:08:19.443797
NCT01243255|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-04-03|2010-11-17|2010-11-18|Estimate|||||||2012-04-03|2012-04-04|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|CEPHEUS||Polish Survey on the Efficacy of the Hypercholesterolemia Treatment|Centralized Pan-European Survey on the Undertreatment of Hypercholesterolemia. Polish Survey on the Efficacy of the Hypercholesterolemia Treatment|Completed|||1500|Actual|AstraZeneca|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:08:19.55669|2018-05-31 23:08:19.55669
NCT01243242|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2011-10-30||2012-04-17|2010-11-17|2010-11-18|Estimate|2012-03-26|2012-04-18|Estimate||||2012-04-17|2012-04-20|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)|Randomized, Double-blind, Placebo-controlled, Multi-center Study Designed to Evaluate the Efficacy, Safety and Tolerability of Metadoxine Extended Release in Adults With Attention Deficit Hyperactive Disorder|Completed||Phase 2|120|Actual|Alcobra Ltd.||2|||f||||f||||||||||2018-05-31 23:08:19.617032|2018-05-31 23:08:19.617032
NCT01243229|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2018-04-11|2010-11-17|2010-11-18|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2010||2010-10-31|October 2017|2017-10-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Genetic Analysis of Congenital Diaphragmatic Disorders|Genetic Analysis of Congenital Diaphragmatic Disorders|Recruiting|||400|Anticipated|University of Utah|||||f||||f||||||Samples With DNA|"~     Blood or buccal swabs~   "|||2018-05-31 23:08:19.876187|2018-05-31 23:08:19.876187
NCT01243216|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2016-09-29|2010-11-17|2010-11-18|Estimate|||||||2016-09-29|2016-09-30|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Does Ultrasound of the Spine Improve Labor Epidurals/Spinal Anesthesia in Obstetric Patients?|The Utility of Pre-procedure Ultrasound for Neuraxial Analgesia/Anesthesia in Obstetric Patients|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||2||Lack of personnel/research time|f||||t||||||||No||2018-05-31 23:08:19.928313|2018-05-31 23:08:19.928313
NCT01243203|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2017-05-04|2010-11-17|2010-11-18|Estimate|||||||2017-05-04|2017-05-08|Actual|November 2007||2007-11-30|November 2013|2013-11-30|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Smoking Cessation Program in the Preadmission Clinic: The Use of a Teachable Moment||Completed||N/A|300|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 23:08:19.991781|2018-05-31 23:08:19.991781
NCT01243190|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2017-09-22|2010-11-17|2010-11-18|Estimate|||||||2017-09-22|2017-09-26|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Active, not recruiting||Phase 2|44|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:08:20.041355|2018-05-31 23:08:20.041355
NCT01243177|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2016-01-25||2017-10-25|2010-11-16|2010-11-18|Estimate|2016-01-25|2016-02-23|Estimate||||2017-10-25|2017-10-26|Actual|April 2011||2011-04-30|October 2017|2017-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|SP0993|Baseline Characteristics refer to the Safety Analysis Set which is defined as all randomized subjects who took at least 1 dose of study medication and is identical with the Full Analysis Set.|Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older|A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.|Completed||Phase 3|888|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 23:08:20.280995|2018-05-31 23:08:20.280995
NCT01243164|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2018-05-25|2010-11-17|2010-11-18|Estimate|||||||2018-05-25|2018-05-30|Actual|November 2010||2010-11-30|May 2018|2018-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy of Wheelchair Skills Training on Confidence Using a Manual Wheelchair|Efficacy of the Wheelchair Skills Training Program for Improving Confidence With Using a Manual Wheelchair in Younger and Older Able-bodied Adults: A Pilot RCT|Completed||N/A|20|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 23:08:21.11868|2018-05-31 23:08:21.11868
NCT01243151|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-07-09|2010-11-16|2010-11-18|Estimate|||||||2012-07-09|2012-07-10|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of PF-04950615 (RN316) In Healthy Adult Subjects With Hypercholesterolemia|Completed||Phase 1|68|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 23:08:21.194046|2018-05-31 23:08:21.194046
NCT01243138|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2012-06-25|2010-11-16|2010-11-18|Estimate|||||||2012-06-25|2012-06-27|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|ACE||Africa and Middle East Cardiovascular Epidemiological Study|Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region|Completed|||4386|Actual|Pfizer|||||f||||f||||||None Retained|"~     Whole Blood~   "|||2018-05-31 23:08:21.30479|2018-05-31 23:08:21.30479
NCT01230398|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2014-09-26|2010-10-27|2010-10-29|Estimate|||||||2014-09-26|2014-09-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:12:07.570632|2018-05-31 23:12:07.570632
NCT01243125|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15||2014-08-04|2014-08-04|2010-11-16|2010-11-18|Estimate||||2014-08-04|2014-08-07|Estimate|2014-08-04|2014-08-07|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation|A Multicenter, Double-blind, Crossover Design, Pilot Study to Evaluate the Effect of NVC-422 Catheter Irrigation on Urinary Catheter Patency|Completed||Phase 2|67|Actual|NovaBay Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:08:21.454205|2018-05-31 23:08:21.454205
NCT01243112|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|2011-09-15||2011-10-25|2010-11-17|2010-11-18|Estimate|2011-10-25|2011-12-02|Estimate||||2011-10-25|2011-12-02|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|CA||Effectiveness Study of Different Local Anesthetic Mixtures|Onset and Duration of Effect of Lidocaine, Bupivacaine, and Lidocaine/Bupivacaine Mixture With Epinephrine.|Completed||Phase 4|25|Actual|Scott and White Hospital & Clinic||4|||f||||f||||||||||2018-05-31 23:08:21.534474|2018-05-31 23:08:21.534474
NCT01243099|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-07-22|2010-11-17|2010-11-18|Estimate|||||||2013-07-22|2013-07-23|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Observational|DESERT||Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions|Des Re-Endothelization for In-StEnt ResTenosis. The DESERT Study|Completed|||31|Actual|S.M. Misericordia Hospital|||2||f||||f||||||||||2018-05-31 23:08:21.695353|2018-05-31 23:08:21.695353
NCT01243086|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2018-04-05|2010-11-16|2010-11-18|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2011||2011-03-31|April 2015|2015-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|STAR||OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab|OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab|Completed||Phase 2|10|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 23:08:21.748056|2018-05-31 23:08:21.748056
NCT01243073|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11||2015-04-14|2015-12-22|2010-11-16|2010-11-18|Estimate||||2015-04-14|2015-04-20|Estimate|2015-12-22|2016-01-26|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|October 2013|Actual|2013-10-31||Interventional|ET/PV||Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera|A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy|Completed||Phase 2|20|Actual|Geron Corporation||1|||f||||f||||||||||2018-05-31 23:08:21.837028|2018-05-31 23:08:21.837028
NCT01243060|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2014-10-02|2010-11-17|2010-11-18|Estimate|||||||2014-10-02|2014-10-06|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance|Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance|Completed||N/A|203|Actual|Northern California Institute of Research and Education||4|||f||||t||||||||||2018-05-31 23:08:21.904197|2018-05-31 23:08:21.904197
NCT01243047|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2012-11-20|2010-11-17|2010-11-18|Estimate|||||||2012-11-20|2012-11-22|Estimate|September 2007||2007-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Intermittent Versus Continuous Tarceva Study|Intermittent Versus Continuous Erlotinib With Concomitant Modified 'Xelox' (q3W) in First-line Treatment of Metastatic Colorectal Cancer|Completed||Phase 2|60|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:08:21.975934|2018-05-31 23:08:21.975934
NCT01243034|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-17|2010-11-17|2010-11-18|Estimate|||||||2010-11-17|2010-11-18|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Observational|||Waist Circumference Measurements in Schizophrenic Patients|Variability of Waist Circumference Measurements at 3 Sites and Its Relationship With Cardiovascular Risk Factors in Patients With Schizophrenia|Unknown status|Not yet recruiting||80|Anticipated|Changhua Christian Hospital|||||f||||f||||||||||2018-05-31 23:08:22.051131|2018-05-31 23:08:22.051131
NCT01243021|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-17|||2010-11-17|2010-11-17|2010-11-18|Estimate|||||||2010-11-17|2010-11-18|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Validation of an Early Warning Score Based Triage System in the Emergency Department|Nurse Administered Early Warning Score System Can be Used for Emergency Department Triage|Completed|||300|Actual|Bispebjerg Hospital|||||f||||f||||||||||2018-05-31 23:08:22.102809|2018-05-31 23:08:22.102809
NCT01243008|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2010-11-18|2010-11-16|2010-11-17|Estimate|||||||2010-11-18|2010-11-19|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|IXO-01||Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation|A Single Centre, Randomized, Investigator Blinded, Placebo-controlled Ascending Dose Study to Assess the Local Safety, the Skin and Plasma Concentration of Azithromycin Dermal Formulation During Repeated Applications on the Skin of Healthy Volunteers|Completed||Phase 1/Phase 2|32|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 23:08:22.4712|2018-05-31 23:08:22.4712
NCT01242995|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-05-06|2010-11-16|2010-11-17|Estimate|||||||2015-05-06|2015-05-07|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Endoscopic Retrograde Cholangiopancreatography (ERCP) With Cholangiopancreatoscopy Using a Thin Scope|Prospective Evaluation of the Clinical Utility of the Thin Scope/Anchoring Balloon Cholangiopancreatoscopy System for Disorders fo the Pancreatobiliary System|Withdrawn|||0|Actual|University of Florida|||1|The device was withdrawn from clinical use|f||||f||||||||||2018-05-31 23:08:22.573666|2018-05-31 23:08:22.573666
NCT01242982|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-04-07|2010-11-16|2010-11-17|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Subcapital and Shaft Fractures of the 5. Metacarpal|Prospective Randomised Study of Subcapital and Shaft Fractures of the 5. Metacarpal. Comparison Conservative Treatment and Operation|Terminated||N/A|39|Actual|St. Olavs Hospital||2||problems to include patients, patients not showing up at check-up|f||||t||||||||||2018-05-31 23:08:22.725408|2018-05-31 23:08:22.725408
NCT01242956|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-09-22|2010-11-16|2010-11-17|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||Video-based Training for Rehabilitation of Upper Limb Functions After Stroke|Video-based Training for Rehabilitation of Upper Limb Functions After Stroke: a New Treatment Exploiting the Mirror Neuron System|Terminated||Phase 2|100|Actual|RWTH Aachen University||2||Problem to recruit sufficient patient number|f||||t||||||||||2018-05-31 23:08:22.936377|2018-05-31 23:08:22.936377
NCT01242943|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2011-11-21|2010-11-16|2010-11-17|Estimate|||||||2011-11-21|2011-11-22|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Radioimmunotherapy With 131I-L19SIP in Patients With Cancer|A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER|Terminated||Phase 1/Phase 2|34|Actual|Philogen S.p.A.||1||"With the determination of the RD and a well established understanding of the safety and~   tolerability profile, the main endpoints of the study have been met."|f||||f||||||||||2018-05-31 23:08:23.087331|2018-05-31 23:08:23.087331
NCT01242930|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16||2016-02-08|2016-04-13|2010-11-16|2010-11-17|Estimate||||2016-03-14|2016-04-13|Estimate|2016-04-13|2016-05-12|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma|A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma|Completed||Phase 2|13|Actual|Geron Corporation||2|||f||||f||||||||||2018-05-31 23:08:23.204561|2018-05-31 23:08:23.204561
NCT01242917|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-02-08|2010-11-16|2010-11-17|Estimate|||||||2012-02-08|2012-02-09|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CARAT-2||A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy|Completed||Phase 2|159|Actual|ChemoCentryx||3|||f||||t||||||||||2018-05-31 23:08:23.297918|2018-05-31 23:08:23.297918
NCT01242904|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2017-08-25|2010-11-16|2010-11-17|Estimate|||||||2017-08-25|2017-08-28|Actual|September 30, 2010|Actual|2010-09-30|August 2017|2017-08-31|February 28, 2015|Actual|2015-02-28|February 28, 2015|Actual|2015-02-28||Interventional|||Use of a Bimodal Solution for Peritoneal Dialysis|Randomized Controlled Trial of Bimodal Solution for Peritoneal Dialysis: 24-Hour UF Efficiency Using Bimodal PD Solutions During the Long Dwell|Completed||Phase 2|36|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:08:23.634824|2018-05-31 23:08:23.634824
NCT01242891|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2012-03-02|2010-11-16|2010-11-17|Estimate|||||||2012-03-02|2012-03-06|Estimate||||March 2012|2012-03-31||||||||Expanded Access|CAP||Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device Under a Continued Access Protocol|A Prospective, Multi-center, Single Arm Study to Assess the Safety and Probable Benefit of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device (EXCOR® Pediatric)Under a Continued Access Protocol.|Approved for marketing|||||Berlin Heart, Inc|||||||||||||||||||2018-05-31 23:08:23.775351|2018-05-31 23:08:23.775351
NCT01242878|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-17|2010-11-16|2010-11-17|Estimate|||||||2010-11-17|2010-11-18|Estimate|December 2010||2010-12-31|November 2010|2010-11-30||||||||Observational|MACS||MACS Study - Microparticles and Coagulation in Sickle Cell Disease|MACS Study - Microparticles and Coagulation in Sickle Cell Disease: An Observational Study to Measure the Levels of Circulating Microvesicles and Coagulation Activation Parameters in Patients With Sickle Cell Disease in the in- and Out-patient Setting.|Unknown status|Not yet recruiting||360|Anticipated|University College, London|||2||f||||f||||||Samples Without DNA|"~     plasma will be retained following appropriate informed written consent for further ethically~     approved studies as stipulated on the consent forms~   "|||2018-05-31 23:08:23.925384|2018-05-31 23:08:23.925384
NCT01242865|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2013-04-24|2010-11-16|2010-11-17|Estimate|||||||2013-04-24|2013-04-26|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Self Help Intervention to Decrease Stress|Self Help Intervention to Decrease Stress: A Pilot Trial|Completed||N/A|33|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 23:08:24.086543|2018-05-31 23:08:24.086543
NCT01242852|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-06-03|2010-11-16|2010-11-17|Estimate|||||||2015-06-03|2015-06-04|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|inSIGHT||SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle|SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle|Completed||Phase 4|750|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 23:08:24.186151|2018-05-31 23:08:24.186151
NCT01242839|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2016-05-04|2010-11-16|2010-11-17|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|UNICOL||Randomized Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing|Randomized Multicentric Double Blinded Study Evaluating CACICOL20 Efficiency Versus Placebo Corneal Chronic Ulcers Healing|Completed||N/A|139|Actual|Organ, Tissue, Regeneration, Repair and Replacement||3|||f||||f||||||||||2018-05-31 23:08:24.570705|2018-05-31 23:08:24.570705
NCT01242826|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-05-28|2010-11-16|2010-11-17|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2011||2011-02-28|May 2015|2015-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects|A Trial Investigating the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 (BIAsp 50) in Healthy Chinese Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 23:08:24.832598|2018-05-31 23:08:24.832598
NCT01242813|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2015-11-02||2016-01-05|2010-11-16|2010-11-17|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||The analysis was performed on Safety Set (SAF) defined as all participants who received at least one application of study treatment and had least one post-baseline safety assessment.|Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).|An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).|Completed||Phase 2|20|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:08:25.027536|2018-05-31 23:08:25.027536
NCT01242800|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2017-12-12|2010-11-16|2010-11-17|Estimate|||||||2017-12-12|2017-12-14|Actual|February 8, 2011|Actual|2011-02-08|December 2017|2017-12-31|June 30, 2027|Anticipated|2027-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer|A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 3|391|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-05-31 23:08:25.969442|2018-05-31 23:08:25.969442
NCT01242787|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2012-04-13|2010-11-16|2010-11-17|Estimate|||||||2012-04-13|2012-04-16|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|LB80380||Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B|A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Completed LG-BVCL007 Study|Unknown status|Active, not recruiting|Phase 2|115|Anticipated|LG Life Sciences||2|||f||||f||||||||||2018-05-31 23:08:27.693334|2018-05-31 23:08:27.693334
NCT01241864|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2018-05-16|2010-11-15|2010-11-16|Estimate|||||||2018-05-16|2018-05-21|Actual|December 2010||2010-12-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Islet Transplantation in Type 1 Diabetic Kidney Allograft|Islet Transplantation in Type 1 Diabetic Kidney Allograft|Active, not recruiting||Phase 2|2|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 23:08:39.06807|2018-05-31 23:08:39.06807
NCT01242774|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-17|||2015-05-05|2010-11-16|2010-11-17|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)|A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)|Completed||Phase 1|46|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:08:27.802009|2018-05-31 23:08:27.802009
NCT01242761|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-16|2010-11-16|2010-11-17|Estimate|||||||2010-11-16|2010-11-17|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Ultrasound as a Diagnostic Tool for Rotator Cuff Tears|Ultrasound as a Diagnostic Tool for Rotator Cuff Tears: Accuracy of Results From the Community Versus Results From a Hospital-based Ultrasound Service and Surgical Findings|Unknown status|Not yet recruiting||50|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 23:08:27.909565|2018-05-31 23:08:27.909565
NCT01242748|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2015-02-26|2012-12-20|2015-05-13|2010-11-16|2010-11-17|Estimate|2015-05-13|2015-06-03|Estimate|2012-12-20|2012-12-28|Estimate|2015-05-13|2015-06-03|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional||CS35A Full Analysis Set|A Degarelix Trial in Patients With Prostate Cancer|An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy|Terminated||Phase 3|288|Actual|Ferring Pharmaceuticals||2||"Inadequate recruitment resulting in a too low patient number for collection of long term~   efficacy data."|f||||t||||||||||2018-05-31 23:08:28.0408|2018-05-31 23:08:28.0408
NCT01242735|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-07-21|2010-11-16|2010-11-17|Estimate|||||||2015-07-21|2015-07-22|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Exercise and Health Intervention for Patients With Obsessive Compulsive Disorder (OCD)|Testing the Efficacy of an Exercise Intervention for Patients With OCD|Completed||Phase 2|56|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 23:08:29.920079|2018-05-31 23:08:29.920079
NCT01242722|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2012-10-02|2010-11-16|2010-11-17|Estimate|||||||2012-10-02|2012-10-03|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|ELEVATE 2||Evaluation of Left Ventricular Autothreshold, Phase Two|Evaluation of Left Ventricular Autothreshold, Phase Two|Completed|||100|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 23:08:30.005737|2018-05-31 23:08:30.005737
NCT01242696|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2017-02-02|2010-11-16|2010-11-17|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2010||2010-11-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|March 2013|Actual|2013-03-31||Observational|TE-Prove||TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove)|PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the TAXUS® Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice|Completed|||1014|Actual|Boston Scientific Corporation|||1||f||||f||||||||No|Primary endpoint data presented at TCT 2014.|2018-05-31 23:08:30.094462|2018-05-31 23:08:30.094462
NCT01242683|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-05-29|2010-11-16|2010-11-17|Estimate|||||||2014-05-29|2014-06-02|Estimate|May 2008||2008-05-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|VAFO||Vivamos Activos Fair Oaks Program for Weight Loss in Low Income Latinos|Case-Management & Environmental Support to Sustain Weight Loss & Reduce CHD Risk|Completed||Phase 2|207|Actual|Stanford University||3|||f||||t||||||||||2018-05-31 23:08:30.275649|2018-05-31 23:08:30.275649
NCT01242670|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2015-10-07|2010-11-16|2010-11-17|Estimate|||||||2015-10-07|2015-10-09|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Ross River Virus (RRV) Vaccine Study|A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older|Completed||Phase 3|1968|Actual|Ology Bioservices||1|||f||||t||||||||||2018-05-31 23:08:30.369237|2018-05-31 23:08:30.369237
NCT01242657|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2017-10-31|2010-11-15|2010-11-17|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2006||2006-10-31|October 2017|2017-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Quit and Fit: Teen Smoking Cessation|Quit and Fit: Exploring the Effects of Physical Activity on Teen Smoking Cessation|Completed||N/A|236|Actual|West Virginia University||3|||f||||f||||||||No||2018-05-31 23:08:30.474547|2018-05-31 23:08:30.474547
NCT01242644|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2013-06-26|2010-11-15|2010-11-17|Estimate|||||||2013-06-26|2013-06-28|Estimate|October 2006||2006-10-31|June 2013|2013-06-30|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Interventional|||Comparison of a Pain Pump Versus Injectable Medication for Analgesia in Knee Arthroscopy|Comparison of a Pain Pump Versus Injectable Medication for Analgesia in Knee Arthroscopy|Completed||Phase 2|49|Actual|University of South Alabama||3|||f||||f||||||||||2018-05-31 23:08:30.55324|2018-05-31 23:08:30.55324
NCT01242631|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-02-24|2010-11-16|2010-11-17|Estimate|||||||2015-02-24|2015-02-25|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|RADIT||Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer|A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer|Completed||Phase 2|25|Actual|Hannover Medical School||1|||f||||f||||||||||2018-05-31 23:08:30.628405|2018-05-31 23:08:30.628405
NCT01242618|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2014-08-19|2010-11-16|2010-11-17|Estimate|||||||2014-08-19|2014-08-20|Estimate|October 2010||2010-10-31|August 2014|2014-08-31||||February 2013|Actual|2013-02-28||Interventional|||Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule|Tissue Engineered Nasal Cartilage for Reconstruction of the Alar Lobule Following Resection of a Non Melanoma Skin Cancer- a Phase I Clinical Trial.|Completed||Phase 1|5|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-05-31 23:08:30.819999|2018-05-31 23:08:30.819999
NCT01242605|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2016-05-11|2010-11-16|2010-11-17|Estimate|||||||2016-05-11|2016-05-13|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|May 2016|Actual|2016-05-31|March 2013|Actual|2013-03-31||Interventional|ABC-04||ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer|ABC-04 a Phase 1B Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer|Completed||Phase 1|13|Actual|University College, London||1|||f||||t||||||||Undecided||2018-05-31 23:08:30.900035|2018-05-31 23:08:30.900035
NCT01242592|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-16|2010-11-16|2010-11-17|Estimate|||||||2010-11-16|2010-11-17|Estimate|February 2005||2005-02-28|November 2010|2010-11-30|June 2008||2008-06-30|||||Interventional|||Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis|Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis: Randomized Placebo Controlled Trial|Completed||Phase 2|56|Actual|NMP Medical Research Institute||2|||f||||t||||||||||2018-05-31 23:08:30.975291|2018-05-31 23:08:30.975291
NCT01242579|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2011-09-08|2010-11-16|2010-11-17|Estimate|||||||2011-09-08|2011-09-09|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium|A Double-Blind, Randomised, Placebo-Controlled Phase I Trial to Compare the Pharmacokinetics of Maraviroc and Dapivirine Following Application of Maraviroc Vaginal Vaginal Gel, 0.1% 2.5g, Dapivirine Vaginal Gel, 0.05%, 2.5g and Maraviroc 0.1% + Dapivirine 0.05% Vaginal Gel, 2.5g Formulations, and to Assess Their Safety as Compared to the Matching Placebo Vaginal Gel, 2.5g in Healthy, HIV-Negative Women|Withdrawn||Phase 1|0|Actual|International Partnership for Microbicides, Inc.||4||"In order to focus efforts on the combination ring formulation, IPM decided not to move forward~   with this trial."|f||||t||||||||||2018-05-31 23:08:31.042853|2018-05-31 23:08:31.042853
NCT01242566|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-16|2010-11-16|2010-11-17|Estimate|||||||2010-11-16|2010-11-17|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|TAG||Temozolomide in Elderly Patients With KPS < 70|Phase II Trial of Temozolomide in Elderly Patients With Glioblastoma and Poor Performance Status (KPS<70).|Completed||Phase 2|70|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:08:31.117289|2018-05-31 23:08:31.117289
NCT01242553|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2017-09-26|2010-11-16|2010-11-17|Estimate|||||||2017-09-26|2017-09-28|Actual|October 2009||2009-10-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Clinical Validation Study for iVue|Clinical Validation Study for iVue|Completed|||48|Actual|Optovue|||4||f||||f||||||||||2018-05-31 23:08:31.221477|2018-05-31 23:08:31.221477
NCT01242540|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2017-06-22|2010-11-16|2010-11-17|Estimate|||||||2017-06-22|2017-06-26|Actual|November 2010||2010-11-30|June 2017|2017-06-30|October 2016|Actual|2016-10-31|June 2011|Actual|2011-06-30||Observational|||Brain Activation During Accommodation to Painful Stimulation With FMRI|Brain Activation During Accommodation to Painful Stimulation With Functional Imaging of Pain|Completed|||15|Actual|University of Pittsburgh|||||f||||t||||||||||2018-05-31 23:08:31.320417|2018-05-31 23:08:31.320417
NCT01242527|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2013-06-26||2016-06-24|2010-11-15|2010-11-17|Estimate|2013-06-27|2013-09-06|Estimate||||2016-06-24|2016-08-04|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|EVOLVE||Epanova® for Lowering Very High Triglycerides|Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia|Completed||Phase 2/Phase 3|399|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:08:31.418433|2018-05-31 23:08:31.418433
NCT01242514|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2013-12-18||2014-02-25|2010-11-16|2010-11-17|Estimate|2014-02-25|2014-04-04|Estimate||||2014-02-25|2014-04-04|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|OSKIRA-X||Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)|(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis|Terminated||Phase 3|1917|Actual|AstraZeneca||3||"AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to~   Rigel Pharmaceuticals."|f||||f||||||||||2018-05-31 23:08:31.982281|2018-05-31 23:08:31.982281
NCT01242501|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-16|2010-11-16|2010-11-17|Estimate|||||||2010-11-16|2010-11-17|Estimate|August 2005||2005-08-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Brief HIV Prevention Counseling for STI Patients in South Africa|Randomized Trial of a Brief HIV Risk Reduction Counseling Intervention for Sexually Transmitted Infections Clinic Patients in Cape Town, South Africa|Completed||Phase 2|617|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 23:08:33.521502|2018-05-31 23:08:33.521502
NCT01242488|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15||2013-01-25|2014-08-26|2010-11-16|2010-11-17|Estimate||||2013-01-25|2013-01-29|Estimate|2014-08-26|2014-08-27|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy|Randomized, Double-blind, Placebo-controlled, Dose Ranging Study With an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects With Rheumatoid Arthritis Having Previously Failed TNF-blocker Therapy|Completed||Phase 2|221|Actual|UCB Pharma||9|||f||||t||||||||||2018-05-31 23:08:33.635232|2018-05-31 23:08:33.635232
NCT01242475|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2013-01-18|2010-11-16|2010-11-17|Estimate|||||||2013-01-18|2013-01-21|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|TESEC-03||A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG|A Phase IIa Specificity Trial of the Diagnostic Agent C-Tb, When Given Intradermally by the Mantoux Technique to Healthy Volunteers Previously Vaccinated With BCG|Completed||Phase 2|151|Actual|Statens Serum Institut||2|||f||||f||||||||||2018-05-31 23:08:33.915567|2018-05-31 23:08:33.915567
NCT01242462|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-05-29|2010-11-16|2010-11-17|Estimate|||||||2014-05-29|2014-06-02|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|August 2012|Actual|2012-08-31||Interventional|||Feasibility of Mid-frequency Ventilation in Newborns With RDS: Randomized Crossover Pilot Trial|Feasibility of Mid-frequency Ventilation in Newborn Infants With Respiratory Distress Syndrome (RDS): Crossover Pilot Trial|Completed||Phase 1/Phase 2|12|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 23:08:34.003169|2018-05-31 23:08:34.003169
NCT01242449|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-05-20|2010-11-16|2010-11-17|Estimate|||||||2015-05-20|2015-05-21|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2012|Actual|2012-10-31||Interventional|OVINTRA||Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer|A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer|Completed||Phase 2|10|Actual|Vejle Hospital|||||f||||t||||||||||2018-05-31 23:08:34.083345|2018-05-31 23:08:34.083345
NCT01242436|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2015-04-09|2010-11-16|2010-11-17|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis|Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis|Completed||N/A|50|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 23:08:34.15375|2018-05-31 23:08:34.15375
NCT01242423|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-17|2010-11-16|2010-11-17|Estimate|||||||2010-11-17|2010-11-18|Estimate|November 2006||2006-11-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Healing of Burns and the Effect of Shockwave Therapy on the Recovery of Skin Grafts|Accelerated Healing of Second Degree Burns and the Effect of Musculoskeletal Shockwave Therapy on the Recovery of Skin Graft Donor Sites|Completed||Phase 2/Phase 3|100|Actual|Unfallkrankenhaus Berlin||3|||f||||f||||||||||2018-05-31 23:08:34.218021|2018-05-31 23:08:34.218021
NCT01242410|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2015-05-09|2010-11-15|2010-11-17|Estimate|||||||2015-05-09|2015-05-12|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PECEP-TWINS||Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix in Twins|Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix in Twins|Completed||Phase 4|137|Actual|Maternal-Infantil Vall d´Hebron Hospital||2|||f||||t||||||||||2018-05-31 23:08:34.284696|2018-05-31 23:08:34.284696
NCT01242397|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-12-01|2010-11-16|2010-11-17|Estimate|||||||2010-12-01|2010-12-02|Estimate|January 2011||2011-01-31|November 2009|2009-11-30|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|MiRBi||Mitral Insufficiency Reduction With Biventricular Pacing|Prospective.Randomized, Blinded, Crossover Chronic IDE Study of the Effects of Pacing on Mitral Regurgitation in Patients Without Standard Indications for Cardiac Resynchronization Therapy|Unknown status|Not yet recruiting|Phase 1|50|Anticipated|Trinity Medical Center, Illinois||2|||f||||t||||||||||2018-05-31 23:08:34.349141|2018-05-31 23:08:34.349141
NCT01242384|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-09-18|2010-11-15|2010-11-17|Estimate|||||||2016-09-18|2016-09-20|Estimate|June 2008||2008-06-30|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PECEP-RETARD||Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women After Threatened Preterm Labor(PECEP-RETARD)|Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women After Threatened Preterm Labor|Completed||Phase 4|500|Actual|Maternal-Infantil Vall d´Hebron Hospital||2|||f||||t||||||||||2018-05-31 23:08:34.40721|2018-05-31 23:08:34.40721
NCT01242371|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|2013-08-29||2014-01-07|2010-11-16|2010-11-17|Estimate|2013-08-29|2013-11-14|Estimate||||2014-01-07|2014-02-06|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia|A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia|Completed||N/A|65|Actual|Sheppard Pratt Health System|Did not perform more detailed measures of gastrointestinal functioning or obtain a more complete history of participants’ gastrointestinal symptoms and associated treatment|2|||f||||t||||||||||2018-05-31 23:08:34.477421|2018-05-31 23:08:34.477421
NCT01242358|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2011-11-20|2010-11-16|2010-11-17|Estimate|||||||2011-11-20|2011-11-22|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|PEG||Capnography During Percutaneous Endoscopic Gastrostomy (PEG)|Clinical Value of Advanced Patient Monitoring Using Capnography With Analysis of the Integrated Pulmonary Index During Percutaneous Endoscopic Gastrostomy.|Unknown status|Recruiting|Phase 3|170|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 23:08:34.702323|2018-05-31 23:08:34.702323
NCT01242345|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2011-11-20|2010-11-16|2010-11-17|Estimate|||||||2011-11-20|2011-11-22|Estimate|June 2010||2010-06-30|November 2010|2010-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Capnography During Upper GI Endoscopy|Clinical Value of Advanced Patient Monitoring With Capnography and Analysis of the Integrated Pulmonary Index During Interventional Upper Gastrointestinale Endoscopy|Completed||Phase 3|170|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 23:08:34.77482|2018-05-31 23:08:34.77482
NCT01242332|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-16|2010-11-16|2010-11-17|Estimate|||||||2010-11-16|2010-11-17|Estimate|August 2009||2009-08-31|May 2009|2009-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Perioperative Administration of Pregabalin in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction|Perioperative Administration of Pregabalin in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction: Does it Help to Relieve Postoperative Pain?|Completed||Phase 4|60|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 23:08:34.839854|2018-05-31 23:08:34.839854
NCT01242319|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-16|2010-11-16|2010-11-17|Estimate|||||||2010-11-16|2010-11-17|Estimate|September 2002||2002-09-30|September 2002|2002-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice|Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice|Completed|||5218|Actual|Memorial Hospital of Rhode Island|||2||f||||t||||||||||2018-05-31 23:08:34.915867|2018-05-31 23:08:34.915867
NCT01242306|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2010-11-16|2010-11-16|2010-11-17|Estimate|||||||2010-11-16|2010-11-17|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|CREDENTIAL||Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions|Head-to-Head Comparison of Endothelial Dysfunction (Bare Metal Stent vs Sirolimus Eluting Stent) in the Same Patient With Multiple Coronary Artery Lesions|Completed||Phase 1/Phase 2|25|Actual|Azienda Ospedaliera San Camillo Forlanini||2|||f||||t||||||||||2018-05-31 23:08:35.106165|2018-05-31 23:08:35.106165
NCT01242293|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2016-02-20|2010-11-15|2010-11-17|Estimate|||||||2016-02-20|2016-02-23|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Intrapartum Hydration||Completed||N/A|300|Actual|HaEmek Medical Center, Israel||3|||f||||t||||||||||2018-05-31 23:08:35.17439|2018-05-31 23:08:35.17439
NCT01242280|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2015-02-04|2010-11-16|2010-11-17|Estimate|||||||2015-02-04|2015-02-05|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding.|Esophageal Stent is More Effective Than Tamponade Controlling Refractory Esophageal Variceal Bleeding: a Randomized Controlled Trial|Completed||Phase 3|28|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 23:08:35.240957|2018-05-31 23:08:35.240957
NCT01242267|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2017-08-08|2010-11-15|2010-11-16|Estimate|||||||2017-08-08|2017-08-10|Actual|May 11, 2010|Actual|2010-05-11|August 2017|2017-08-31|January 20, 2016|Actual|2016-01-20|January 20, 2016|Actual|2016-01-20||Interventional|Thal/Mel/Vel||Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT|A Phase I/II Study of Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Advanced Multiple Myeloma|Completed||Phase 1/Phase 2|29|Actual|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 23:08:35.310151|2018-05-31 23:08:35.310151
NCT01242254|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2014-03-25|2010-11-15|2010-11-16|Estimate|||||||2014-03-25|2014-03-27|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|March 2010|Actual|2010-03-31||Interventional|HOPE||A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD|An Open Label, Multicenter, Randomized, Uncontrolled Study Assessing the Safety and Efficacy of KH902 in Patients With Choroidal Neovascularization Due to Neovascular Age-related Macular Degeneration(HOPE Study)|Completed||Phase 1/Phase 2|36|Actual|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||f||||||||||2018-05-31 23:08:35.372904|2018-05-31 23:08:35.372904
NCT01242228|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2016-01-18|2010-11-15|2010-11-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients|A Phase 3, Open-Label, Non-comparative Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Combination With an DPP-4 Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With a DPP-4 Inhibitor Alone.|Completed||Phase 3|106|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 23:08:35.51694|2018-05-31 23:08:35.51694
NCT01242215|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2016-01-18|2010-11-15|2010-11-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients|A Phase 3, Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone|Completed||Phase 3|243|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 23:08:35.655798|2018-05-31 23:08:35.655798
NCT01242202|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2016-01-18|2010-11-15|2010-11-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients|A Phase 3, Open-Label, Non-comparative Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Combination With an α-Glucosidase Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With an α-glucosidase Inhibitor Alone.|Completed||Phase 3|113|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 23:08:35.735556|2018-05-31 23:08:35.735556
NCT01242176|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2014-05-16||2014-05-16|2010-11-15|2010-11-16|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|November 2010||2010-11-30|May 2014|2014-05-31||||December 2010|Actual|2010-12-31||Interventional|||Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers|Relative Bioavailability of 25 mg BI 10773 (Final Formulation) Compared to 25 mg BI 10773 XX (Trial Formulation 2) Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:08:35.823857|2018-05-31 23:08:35.823857
NCT01242163|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-14|||2010-11-22|2010-11-15|2010-11-16|Estimate|||||||2010-11-22|2010-11-23|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|December 2012|Anticipated|2012-12-31|||||Observational|||Application of Chemical Sensors for Diagnosis of Inflammatory Bowel Diseases and Irritable Bowel Syndrome by Respiratory Samples|Application of Chemical Sensors for Diagnosis of Inflammatory Bowel Diseases and Irritable Bowel Syndrome by Respiratory Samples|Unknown status|Not yet recruiting||200|Anticipated|Rambam Health Care Campus|||||f||||f||||||Samples Without DNA|"~     Experiated lung air~   "|||2018-05-31 23:08:36.036998|2018-05-31 23:08:36.036998
NCT01242150|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-14|||2014-01-21|2010-11-15|2010-11-16|Estimate|||||||2014-01-21|2014-01-22|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|NCPAP||Noninvasive Continuous Positive Airway Pressure (NCPAP) in Children|Noninvasive Continuous Positive Airway Pressure by Helmet or Facial Mask in Children: a Multicenter Randomized Controlled Study|Completed||Phase 3|60|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||t||||||||||2018-05-31 23:08:36.087556|2018-05-31 23:08:36.087556
NCT01242137|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-14|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|October 2009||2009-10-31|October 2010|2010-10-31||||||||Observational|||Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide||Unknown status|Recruiting||30|Anticipated|Assaf-Harofeh Medical Center|||3||f||||||||||||||2018-05-31 23:08:36.16199|2018-05-31 23:08:36.16199
NCT01242124|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-13|||2015-12-21|2010-11-15|2010-11-16|Estimate|||||||2015-12-21|2015-12-22|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy|Randomized Study of Intrathoracic Side-to-side Stapled Esophagogastric Anastomosis Versus Circular-Stapled Technique in Ivor-Lewis Oesophagectomy|Unknown status|Active, not recruiting|Phase 2/Phase 3|40|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f||||||||||2018-05-31 23:08:36.235518|2018-05-31 23:08:36.235518
NCT01242111|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2015-07-10||2015-08-28|2010-11-13|2010-11-16|Estimate|2015-08-28|2015-09-30|Estimate||||2015-08-28|2015-09-30|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|Terminated||Phase 1/Phase 2|20|Actual|BioMarin Pharmaceutical||1|||f||||f||||||||||2018-05-31 23:08:36.341341|2018-05-31 23:08:36.341341
NCT01242098|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2012-06-07|2010-11-15|2010-11-16|Estimate|||||||2012-06-07|2012-06-08|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|Fos/Ser_switch||Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management|Retrospective, Real-life Observational, Matched Cohort Evaluation of the Effectiveness of BDP/FOR (Fostair® 100/6) and FP/SAL (Seretide® 125) in Patients Switching From Seretide to Fostair in UK Primary Care Asthma Management|Completed|||137|Actual|Research in Real-Life Ltd|||2||f||||t||||||||||2018-05-31 23:08:36.91522|2018-05-31 23:08:36.91522
NCT01242085|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2013-02-19||2013-05-09|2010-11-15|2010-11-16|Estimate|2013-03-26|2013-05-08|Estimate||||2013-05-09|2013-05-14|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Interventional|||Preoperative Alignment of Total Knee Replacement|Alignment of Total Knee Components Using Standard or Custom Instrumentation|Completed||Phase 3|64|Actual|VA Palo Alto Health Care System|none except small sample sizes|2|||f||||f||||||||||2018-05-31 23:08:36.986089|2018-05-31 23:08:36.986089
NCT01242072|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2012-07-17|2010-11-15|2010-11-16|Estimate|||||||2012-07-17|2012-07-18|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies|A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|Ziopharm||1|||f||||f||||||||||2018-05-31 23:08:37.202529|2018-05-31 23:08:37.202529
NCT01242059|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2012-06-13|2010-11-12|2010-11-16|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Yellow Pea Fractions and Short-term Food Intake, Subjective Appetite and Glycemic Response|Effect of Yellow Pea Fractions on Short-term Food Intake at 120 Minutes, Subjective Appetite and Glycemic Response in Young Adult Males|Completed||N/A|20|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 23:08:37.258582|2018-05-31 23:08:37.258582
NCT01242046|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2015-05-26|2010-11-15|2010-11-16|Estimate|||||||2015-05-26|2015-05-27|Estimate||||May 2015|2015-05-31||||||||Interventional|||Effects of Caffeine on Women's Sexual Arousal|The Effects of Caffeine on Female Genital Arousal|Withdrawn||N/A|0|Actual|University of Texas at Austin||2||Key personnel were reassigned to different project|f||||f||||||||||2018-05-31 23:08:37.425047|2018-05-31 23:08:37.425047
NCT01242033|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-12-03|2010-11-12|2010-11-16|Estimate|||||||2010-12-03|2010-12-06|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Acute Red Raspberry Consumption on Post-prandial Oxidative Stress|An Acute Intervention Study Investigating the Effect of Red Raspberry Consumption on Post-prandial Oxidative Stress|Completed||N/A|8|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 23:08:37.488329|2018-05-31 23:08:37.488329
NCT01242020|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2017-07-13||2017-08-10|2010-11-12|2010-11-16|Estimate|2017-07-13|2017-08-10|Actual||||2017-08-10|2017-08-11|Actual|January 2011|Actual|2011-01-31|August 2017|2017-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|MARS||Microvascular Flow Assessment Repeatability Study: The MARS Study|Microvascular Flow Assessment of the Periadventitial Adipose Tissue, Subcutaneous Adipose Tissue and Skeletal Muscle Using Contrast Enhanced Ultrasound (CEU); A Repeatability Study|Terminated||N/A|6|Actual|University of Pennsylvania|Early termination (not feasible with available equipment) leading to small number of subjects analyzed.|2||"Unable to reliably reproduce, visualize, or quantify microvascular flow in the subcutaneous~   tissue, the skeletal muscle or peri-adventitia"|f||||f||||||||||2018-05-31 23:08:37.56879|2018-05-31 23:08:37.56879
NCT01242007|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients|Lung Function Impairment and Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients|Completed||N/A|58|Actual|University of Nancy|||||f||||t||||||||||2018-05-31 23:08:37.79158|2018-05-31 23:08:37.79158
NCT01241994|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate||||January 2004|2004-01-31||||||||Interventional|||Automatic Adaptive System Dialysis (AASD)|Automatic Adaptive System Dialysis (AASD) for Dialysis Related Hypotension and Intolerance: a Prospective Long-term Multicenter Study|Completed||N/A|||St. Orsola Hospital||2|||f||||f||||||||||2018-05-31 23:08:37.844405|2018-05-31 23:08:37.844405
NCT01241981|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2018-05-07|2010-11-15|2010-11-16|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2011||2011-03-31|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|December 21, 2016|Actual|2016-12-21||Observational|||Digital Breast Tomosynthesis in Younger Symptomatic Women|Digital Breast Tomosynthesis (DBT): Sensitivity for Cancer and Accuracy in Assessing Extent of Malignant Disease in Symptomatic Women Below 60 With Clinical or Ultrasound Signs Compatible With Malignancy|Completed|||446|Actual|NHS Tayside|||1||f||||f||||||||||2018-05-31 23:08:37.896442|2018-05-31 23:08:37.896442
NCT01241968|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-02-17|2010-11-15|2010-11-16|Estimate|||||||2013-02-17|2013-02-20|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|August 2012|Actual|2012-08-31||Interventional|||Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease|Randomized, Placebo Controlled, Double Blind Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Medispec||2|||f||||f||||||||||2018-05-31 23:08:37.948972|2018-05-31 23:08:37.948972
NCT01241955|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2011-04-04|2010-11-15|2010-11-16|Estimate|||||||2011-04-04|2011-04-05|Estimate|February 2011||2011-02-28|April 2011|2011-04-30||||February 2012|Anticipated|2012-02-29||Interventional|||Temporal Intervention Trial of a CPR Video in the ICU|A Temporal Intervention Trial of a CPR Video in the ICU|Unknown status|Recruiting|N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:08:38.112609|2018-05-31 23:08:38.112609
NCT01241942|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2017-02-02|2010-11-15|2010-11-16|Estimate|||||||2017-02-02|2017-02-06|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability|Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability|Terminated||N/A|103|Actual|University of North Carolina, Chapel Hill||2||Funding exhausted.|f||||t|f|t|f|||||No||2018-05-31 23:08:38.195571|2018-05-31 23:08:38.195571
NCT01241929|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-07-09|2010-11-15|2010-11-16|Estimate|||||||2012-07-09|2012-07-10|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Using Videos in Advance Care Planning for Patients With Advanced Cancer|A Pilot Study of Using Video Images in Advance Care Planning in Patients With Advanced Cancer|Completed||N/A|150|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:08:38.304672|2018-05-31 23:08:38.304672
NCT01241916|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2012-04-16||2012-05-30|2010-11-15|2010-11-16|Estimate|2012-05-30|2012-07-03|Estimate||||2012-05-30|2012-07-03|Estimate|August 2003||2003-08-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||A Prospective Randomized Trial of Static-Progressive Versus Dynamic Splinting for Post-Traumatic Elbow Stiffness|A Prospective Randomized Trial of Static-Progressive Versus Dynamic Splinting for Post-Traumatic Elbow Stiffness|Completed||N/A|66|Actual|Massachusetts General Hospital|Evaluation of <80% of enrolled patients at planned follow-up times; musculoskeletal injury patients are difficult to maintain in protocol. Some violations where enrollment/evaluation points were slightly outside the planned range of acceptable times.|2|||f||||t||||||||||2018-05-31 23:08:38.392147|2018-05-31 23:08:38.392147
NCT01241903|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2014-05-21||2017-02-26|2010-11-15|2010-11-16|Estimate|2014-05-21|2014-06-24|Estimate||||2017-02-26|2017-03-28|Actual|June 2011||2011-06-30|February 2017|2017-02-28|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions|Early Use of Rosuvastatin (Crestor) in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions|Completed||Phase 1|54|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 23:08:38.649648|2018-05-31 23:08:38.649648
NCT01241890|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2015-07-16|2010-11-15|2010-11-16|Estimate|||||||2015-07-16|2015-07-17|Estimate|October 2011||2011-10-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Observational|PREVEC||Prevention of CF Exacerbation in Childhood: PREVEC Study|Prevention of CF Exacerbation in Childhood (PREVEC): Early Recognition of Inflammation by Non-invasive Biomarkers in Exhaled Breath (Condensate)|Completed|||49|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 23:08:38.920846|2018-05-31 23:08:38.920846
NCT01241838|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-08-03|2010-11-15|2010-11-16|Estimate|||||||2012-08-03|2012-08-06|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect of Heart Rate on Cardiac Index in Patients With Left Ventricular Hypertrophy|The Effect of Heart Rate on Cardiac Index in Patients With Left Ventricular Hypertrophy|Terminated||N/A|11|Actual|University of Aarhus||2||Insufficient no of patients eligible for enrollment.|f||||f||||||||||2018-05-31 23:08:39.226909|2018-05-31 23:08:39.226909
NCT01241825|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2014-09-26|2010-11-15|2010-11-16|Estimate|||||||2014-09-26|2014-09-30|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Chewing Gum on Small Bowel Transit Time|The Effect of Chewing Gum on Small Bowel Transit Time: a Prospective Randomized Trial.|Completed||N/A|122|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:08:39.285588|2018-05-31 23:08:39.285588
NCT01241812|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2017-10-10|2010-11-15|2010-11-16|Estimate|||||||2017-10-10|2017-10-12|Actual|October 2010||2010-10-31|October 2017|2017-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Biomarkers and Knee Osteoarthritis|Biomarkers and Knee Osteoarthritis: Associations With Joint Load and Effects of Exercise|Completed||N/A|17|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:08:39.338346|2018-05-31 23:08:39.338346
NCT01241799|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-11-22|2010-11-12|2010-11-16|Estimate|||||||2010-11-22|2010-11-24|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Yield of Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS-FNA) With and Without the Use of a Stylet in the Biopsy Needle|A Prospective, Single Blinded, Randomized, Controlled Study to Compare the Yield of Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS-FNA) With and Without the Use of a Stylet in the Biopsy Needle|Completed||N/A|72|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 23:08:39.397115|2018-05-31 23:08:39.397115
NCT01241786|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2012-11-07|2010-11-15|2010-11-16|Estimate|||||||2012-11-07|2012-11-08|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL|A Phase II, Single Arm Study Examining the Combination of Lenalidomide and Azacitidine (RA-CLL) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)|Terminated||Phase 2|28|Anticipated|Hackensack University Medical Center||||anticipated results not seen and population not seen|f||||t||||||||||2018-05-31 23:08:39.453721|2018-05-31 23:08:39.453721
NCT01241773|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-11-07|2010-11-12|2010-11-16|Estimate|||||||2012-11-07|2012-11-08|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir|A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, Efavirenz and Raltegravir, at Steady State|Completed||Phase 1|48|Actual|Tibotec Pharmaceuticals, Ireland||6|||f||||||||||||||2018-05-31 23:08:39.561057|2018-05-31 23:08:39.561057
NCT01241760|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2013-09-23||2014-05-14|2010-11-12|2010-11-16|Estimate|2014-05-14|2014-06-04|Estimate||||2014-05-14|2014-06-04|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection|A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection|Completed||Phase 3|744|Actual|Janssen Infectious Diseases BVBA||2|||f||||t||||||||||2018-05-31 23:08:39.661148|2018-05-31 23:08:39.661148
NCT01241747|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2018-02-07|2010-11-15|2010-11-16|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2009||2009-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Exercise for Women With Peripheral Arterial Disease|Exercise for Women With Peripheral Arterial Disease|Recruiting||N/A|74|Anticipated|University of Oklahoma||2|||f||||f||||||||||2018-05-31 23:08:40.438812|2018-05-31 23:08:40.438812
NCT01241734|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-02-02|2010-11-15|2010-11-16|Estimate|||||||2014-02-02|2014-02-04|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|RICER||Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL|Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)|Unknown status|Active, not recruiting|Phase 1/Phase 2|67|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 23:08:40.52511|2018-05-31 23:08:40.52511
NCT01241721|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2016-11-16|2010-11-12|2010-11-16|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer|Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer|Completed||N/A|34|Actual|Swedish Medical Center||1|||f||||f||||||||||2018-05-31 23:08:40.594356|2018-05-31 23:08:40.594356
NCT01241708|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2017-08-08|2010-11-15|2010-11-16|Estimate|||||||2017-08-08|2017-08-09|Actual|April 8, 2010|Actual|2010-04-08|August 2017|2017-08-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|(Mel/MelVel)||Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma|Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma|Recruiting||Phase 3|142|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 23:08:40.666864|2018-05-31 23:08:40.666864
NCT01241695|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2012-06-29|2010-11-15|2010-11-16|Estimate|||||||2012-06-29|2012-07-02|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety, Acceptability and Efficacy of a Long-term Intervention With a Diabetes-specific Low-carbohydrate, High-mono-unsaturated Fatty Acid Containing Oral Nutritional Supplement on Glycaemic Control in Type 2 Diabetic Patients||Completed||N/A|40|Actual|Fresenius Kabi||2|||f||||f||||||||||2018-05-31 23:08:40.759487|2018-05-31 23:08:40.759487
NCT01241682|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2014-02-26|2010-11-15|2010-11-16|Estimate|||||||2014-02-26|2014-02-27|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|PMR-MM-002||Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma|Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma|Completed||Phase 1|10|Actual|Erasmus Medical Center||1|||f||||t||||||||||2018-05-31 23:08:41.794709|2018-05-31 23:08:41.794709
NCT01241669|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2014-07-10|2010-11-15|2010-11-16|Estimate|||||||2014-07-10|2014-07-11|Estimate|October 2010||2010-10-31|July 2014|2014-07-31||||August 2011|Actual|2011-08-31||Interventional|||Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity|A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Multiple Doses of E5555 on the Pharmacokinetics of Metformin (a Substrate for OCT2 Transporter) and on Renal Function in Healthy Subjects|Completed||Phase 1|104|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:08:41.87367|2018-05-31 23:08:41.87367
NCT01241656|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-06-21|2010-11-15|2010-11-16|Estimate|||||||2013-06-21|2013-06-25|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1|Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment (DESI)- Study 1|Completed||N/A|2521|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-05-31 23:08:41.940485|2018-05-31 23:08:41.940485
NCT01241643|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-07-24|2010-11-15|2010-11-16|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Inspire 3||Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders|A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in HIV-infected Patients With CD4 Counts Remaining Between 101-350 Cells/µL After at Least 2 Years of HAART and Plasma HIV RNA < 50 Copies/mL for 18 Months.|Terminated||Phase 2|92|Actual|Cytheris SA||2||"Terminated [CYTHERISSA filed for banckcuptcy in June 2013.Subjects treated by CYT107 were~   followed up for at the least 3 months.]"|f||||t||||||||||2018-05-31 23:08:42.011647|2018-05-31 23:08:42.011647
NCT01241630|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-05-09|2010-11-15|2010-11-16|Estimate|||||||2014-05-09|2014-05-12|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Clinical Outcome|Somato-sensory Reflex Arch in Spinal Cord Injury - Effect on Clinical Outcome|Completed||N/A|10|Actual|University of Aarhus|||||f||||t||||||||||2018-05-31 23:08:42.076426|2018-05-31 23:08:42.076426
NCT01241617|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2012-01-22|2010-11-15|2010-11-16|Estimate|||||||2012-01-22|2012-01-24|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||ENDO GIA Stapler With Duet Tissue Reinforcement System (TRS) Used in Pulmonary Resections|Randomized Trial Between Buttressed and Non Buttressed Stapling in Pulmonary Lobectomy|Terminated||N/A|100|Actual|Medtronic - MITG||2||"Covidien is conducting a voluntary recall of DuetTRS™ use in the thoracic cavity. IFU is~   revised to contraindicate use in adult and pediatric thoracic surgeries"|f||||f||||||||||2018-05-31 23:08:42.139311|2018-05-31 23:08:42.139311
NCT01241604|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-11-12|2010-11-12|2010-11-16|Estimate|||||||2010-11-12|2010-11-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:08:42.207118|2018-05-31 23:08:42.207118
NCT01241591|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2014-01-27||2014-05-08|2010-11-12|2010-11-16|Estimate|2014-04-04|2014-05-07|Estimate||||2014-05-08|2014-05-19|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Full Analysis Set (FAS): included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550, etanercept, or placebo).|A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP- 690,550 And 1 Subcutaneous Dose Of Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis|Completed||Phase 3|1101|Actual|Pfizer|Clinical interpretation regarding sub-phenotypes of psoriasis (e.g., scalp psoriasis) should not be made based on the reported assessments by body regions. For example, the body region of head does not reflect solely scalp psoriasis.|4|||f||||t||||||||||2018-05-31 23:08:42.506908|2018-05-31 23:08:42.506908
NCT01241578|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2015-04-06|2010-11-15|2010-11-16|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Improving Behavioral Weight Loss Via Electronic Handheld Device|Improving Behavioral Weight Loss Via Electronic Handheld Device|Completed||N/A|20|Actual|The Miriam Hospital||1|||f||||f||||||||||2018-05-31 23:08:45.582433|2018-05-31 23:08:45.582433
NCT01241565|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2014-03-31||2014-06-03|2010-11-15|2010-11-16|Estimate|2014-06-03|2014-07-03|Estimate||||2014-06-03|2014-07-03|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||128 subjects were screened for enrollment. 50 subjects were consented, enrolled and treated. There were 78 screen failures. 3 subjects were excluded from analysis, leaving 47 eligible subjects.|ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection|A Prospective, Multi-Center Evaluation of the ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection|Completed||N/A|50|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 23:08:45.656649|2018-05-31 23:08:45.656649
NCT01241552|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2016-10-24||2017-02-28|2010-11-12|2010-11-16|Estimate|2016-10-24|2016-12-15|Estimate||||2017-02-28|2017-03-29|Actual|October 2011||2011-10-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MODIFY I||A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)|Completed||Phase 3|1452|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:08:45.948993|2018-05-31 23:08:45.948993
NCT01241539|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|2012-05-10||2014-02-24|2010-11-15|2010-11-16|Estimate|2012-06-21|2012-07-27|Estimate||||2014-02-24|2014-04-07|Estimate|November 2010||2010-11-30|February 2014|2014-02-28||||May 2011|Actual|2011-05-31||Interventional||Treated set (TS) included all 7 subjects who were dispensed trial medication and were documented to have taken at least 1 dose of investigational treatment.|Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis|Open Label, Non Randomized, Multiple Dose Phase I Study to Investigate the Elimination, Pharmacokinetics, Pharmacodynamics and Safety of Dabigatran Etexilate (Pradaxa) Under Steady State Conditions Before, During and After Haemodialysis in Patients With End Stage Renal Disease (ESRD) Undergoing Regular Haemodialysis|Completed||Phase 1|7|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:08:48.325212|2018-05-31 23:08:48.325212
NCT01241526|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2016-01-13|2010-11-15|2010-11-16|Estimate|||||||2016-01-13|2016-01-14|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|COMET||The COPD Patient Management European Trial (COMET)|An International Phase IV Randomised Trial for Medical and Medico-economic Evaluations of Home-based Disease Management Program in Patients With Gold III/IV Chronic Obstructive Pulmonary Disease.|Completed||Phase 4|346|Actual|Air Liquide Santé International||2|||f||||t||||||||||2018-05-31 23:08:49.210514|2018-05-31 23:08:49.210514
NCT01241513|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2012-10-22||2016-05-17|2010-11-15|2010-11-16|Estimate|2016-05-17|2016-05-18|Estimate||||2016-05-17|2016-05-18|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Induced Changes in Ventilatory Responsiveness and Altitude Exposure|Modulation of Oxygen Sensor Reactivity to Mimic Altitude Acclimatization|Terminated||Phase 4|21|Actual|United States Army Research Institute of Environmental Medicine|Study terminated due to results of preliminary analyses.|2||Results of preliminary analyses showed no reason to continue the study|f||||t||||||||||2018-05-31 23:08:49.462649|2018-05-31 23:08:49.462649
NCT01241500|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2018-03-26|2010-11-15|2010-11-16|Estimate|||||||2018-03-26|2018-03-27|Actual|November 2010||2010-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|ONTIME||Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts|Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine|Active, not recruiting||Phase 3|299|Actual|Onconova Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 23:08:49.734531|2018-05-31 23:08:49.734531
NCT01241487|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2017-02-21|2010-11-15|2010-11-16|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2009||2009-02-28|February 2017|2017-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy|An 8 Weeks Open Label National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy|Completed||Phase 4|150|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 23:08:49.998743|2018-05-31 23:08:49.998743
NCT01241474|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2012-08-06|2010-11-12|2010-11-16|Estimate|||||||2012-08-06|2012-08-07|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Fish Oil on Insulin Sensitivity|Chronic Long-chain n-3 PUFA Supplement and Insulin Action in Human Subjects With Impaired Glucose Regulation|Completed||N/A|34|Actual|University of Aberdeen||2|||f||||t||||||||||2018-05-31 23:08:50.140603|2018-05-31 23:08:50.140603
NCT01241461|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2011-11-17|2010-11-15|2010-11-16|Estimate|||||||2011-11-17|2011-11-21|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of LY2584702 in Solid Tumors|A Phase 1 Study of LY2584702 in Japanese Patients With Solid Tumors|Completed||Phase 1|15|Anticipated|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 23:08:50.339029|2018-05-31 23:08:50.339029
NCT01241448|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2018-03-24|2012-05-24|2018-03-24|2010-11-12|2010-11-16|Estimate|2018-03-24|2018-04-24|Actual|2012-05-24|2012-06-01|Estimate|2018-03-24|2018-04-24|Actual|January 2011||2011-01-31|March 2018|2018-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional||Baseline data is provided for all randomized participants excluding the 9 participants from a single site where data integrity issues were identified (Intent-to-treat population).|A Study of LY2409021 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of LY2409021 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|263|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 23:08:50.485979|2018-05-31 23:08:50.485979
NCT01241435|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2011-05-04|2010-11-12|2010-11-16|Estimate|||||||2011-05-04|2011-05-05|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of LY2216684 in Subjects With Impaired Hepatic Function|The Effect of Impaired Hepatic Function on the Pharmacokinetics of LY2216684|Completed||Phase 1|36|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:08:52.134289|2018-05-31 23:08:52.134289
NCT01241422|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2015-12-18|2010-11-12|2010-11-16|Estimate|||||||2015-12-18|2015-12-21|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model|A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model|Completed||Phase 2|22|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||t||||||||||2018-05-31 23:08:52.221146|2018-05-31 23:08:52.221146
NCT01241409|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-10-28|2010-11-12|2010-11-16|Estimate|||||||2012-10-28|2012-10-30|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers|Pivotal Study to Assess the Bioequivalence of the To-be-Marketed Sprinkle Capsule Formulation and the Phase 3 Sprinkle Capsule Formulation of Rabeprazole Sodium in Fasted Condition and to Assess the Effect of Food on the To-be-Marketed Formulation in Healthy Adult Subjects|Completed||Phase 1|78|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||6|||f||||||||||||||2018-05-31 23:08:52.322419|2018-05-31 23:08:52.322419
NCT01241396|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2016-06-17|2010-11-12|2010-11-16|Estimate|||||||2016-06-17|2016-06-20|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure|An Observational Study of the Treatment of Multiple Myeloma in Routine Clinical Practice|Completed|||2396|Actual|Janssen Pharmaceutica N.V., Belgium|||1||f||||f||||||||||2018-05-31 23:08:52.450456|2018-05-31 23:08:52.450456
NCT01241383|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2016-07-05|2010-11-15|2010-11-16|Estimate|||||||2016-07-05|2016-07-06|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|ScS-REINBO||Effect of Bosentan in Scleroderma Renal Crisis|Effect of Bosentan in the Course of Scleroderma Renal Crisis|Completed||Phase 2|16|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:08:52.813167|2018-05-31 23:08:52.813167
NCT01241370|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Observational|||Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects|Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects|Completed|||78|Actual|ELAB-Logistics|||3||f||||f||||||||||2018-05-31 23:08:52.88659|2018-05-31 23:08:52.88659
NCT01241344|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2013-10-31|2010-11-15|2010-11-16|Estimate|||||||2013-10-31|2013-11-04|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Adv||The Adv Halt Trial|A Randomized, Placebo-Controlled Multi-Site Phase 2 Study Evaluation the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation in Adults and Children|Completed||Phase 2|52|Actual|Chimerix||2|||f||||||||||||||2018-05-31 23:08:53.164979|2018-05-31 23:08:53.164979
NCT01241331|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11||2012-09-27|2012-09-27|2010-11-15|2010-11-16|Estimate||||2012-09-27|2012-10-01|Estimate|2012-09-27|2012-10-01|Estimate|November 2010||2010-11-30|September 2012|2012-09-30||||April 2011|Actual|2011-04-30||Interventional|||BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris|A Randomized, Controlled Evaluation of the Safety and Efficacy of a Topical Treatment for Moderate-Severe Facial Acne Vulgaris|Completed||Phase 2|233|Actual|Braintree Laboratories||2|||f||||f||||||||||2018-05-31 23:08:53.256289|2018-05-31 23:08:53.256289
NCT01241318|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2015-01-28|2010-11-12|2010-11-16|Estimate|||||||2015-01-28|2015-01-29|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ZamCAT||Zambia Chlorhexidine Application Trial|Impact of Chlorhexidine Cord Cleansing for Prevention of Neonatal Mortality in Zambia|Completed||Phase 2/Phase 3|77535|Actual|Boston University||2|||f||||t||||||||||2018-05-31 23:08:53.401433|2018-05-31 23:08:53.401433
NCT01241305|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2018-04-23|2010-11-15|2010-11-16|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2010||2010-10-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||One-Time DNA Study for Vasculitis|VCRC Genetic Repository One-Time DNA Protocol|Recruiting|||1300|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Two 10 ml tubes of blood will be collected for DNA extraction.~   "|||2018-05-31 23:08:53.496692|2018-05-31 23:08:53.496692
NCT01241292|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2015-12-16||2018-01-19|2010-11-12|2010-11-16|Estimate|2015-12-16|2016-01-22|Estimate||||2018-01-19|2018-02-15|Actual|January 14, 2011|Actual|2011-01-14|January 2018|2018-01-31|January 16, 2017|Actual|2017-01-16|February 14, 2014|Actual|2014-02-14||Interventional||All participants who received at least one dose of study drug were summarized.|Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone|Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan|Completed||Phase 1|7|Actual|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 23:08:53.773191|2018-05-31 23:08:53.773191
NCT01241279|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2013-05-17||2014-11-25|2010-11-12|2010-11-16|Estimate|2014-11-25|2014-11-26|Estimate||||2014-11-25|2014-11-26|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses|A Two Arm Prospective, Randomized, Double-Masked Clinical Evaluation of Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric Lenses|Terminated||Phase 4|6|Actual|Bausch & Lomb Incorporated|Study terminated early due to lack of enrollment|2||Terminated due to low enrollment|f||||f||||||||||2018-05-31 23:08:54.479805|2018-05-31 23:08:54.479805
NCT01241266|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2011-12-29|2010-11-12|2010-11-16|Estimate|||||||2011-12-29|2011-12-30|Estimate|November 2010||2010-11-30|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|PUB||China Survey of Peptic Ulcer Bleeding|China Survey of Peptic Ulcer Bleeding|Completed|||1044|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:08:54.646679|2018-05-31 23:08:54.646679
NCT01241253|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2018-01-08|2010-11-12|2010-11-16|Estimate|||||||2018-01-08|2018-01-10|Actual|November 2009||2009-11-30|January 2018|2018-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Glycemic Response of Bean-and-rice Meals in Type 2 Diabetes Mellitus|Glycemic Response of Bean-and-rice Meals in Persons With Type 2 Diabetes Mellitus|Completed||Phase 2|17|Actual|Arizona State University||1|||f||||f||||||||||2018-05-31 23:08:54.728383|2018-05-31 23:08:54.728383
NCT01241240|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2014-09-04||2014-09-04|2010-11-12|2010-11-16|Estimate|2014-09-04|2014-09-10|Estimate||||2014-09-04|2014-09-10|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|192|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:08:55.011575|2018-05-31 23:08:55.011575
NCT01241227|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|April 2003||2003-04-30|November 2010|2010-11-30|February 2009|Actual|2009-02-28|||||Observational|PVTE||Prognosis Value of Transient Elastography and Non-invasive Markers of Fibrosis in Patients With Chronic Liver Disease|Prognosis Value of Transient Elastography and Non-invasive Markers of Fibrosis in Patients With Chronic Liver Disease. A Prospective Follow-up of 4,935 Person-years|Completed|||1830|Actual|Association HGE CHU Bordeaux Sud|||1||f||||t||||||||||2018-05-31 23:08:55.240872|2018-05-31 23:08:55.240872
NCT01241214|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12||2012-01-06|2012-01-06|2010-11-15|2010-11-16|Estimate||||2012-01-06|2012-01-11|Estimate|2012-01-06|2012-01-11|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SAR||Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis|A Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group, Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis|Completed||Phase 2|579|Actual|Actelion||6|||f||||f||||||||||2018-05-31 23:08:55.331256|2018-05-31 23:08:55.331256
NCT01241201|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2011-07-20|2010-11-15|2010-11-16|Estimate|||||||2011-07-20|2011-07-21|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Intestinal Barrier Function and Probiotics.|A Study Proposal to Investigate the Sequels of Mucosal Inflammation Caused by ETEC Infection - the Effects of Probiotics.|Completed||N/A|32|Actual|TNO||1|||f||||f||||||||||2018-05-31 23:08:55.415584|2018-05-31 23:08:55.415584
NCT01241188|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2015-04-16|2010-11-15|2010-11-16|Estimate|||||||2015-04-16|2015-04-17|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TESEC-04||A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)|A Phase IIb Sensitivity Trial of the Diagnostic Agent C-Tb, When Given Intradermally by the Mantoux Technique to Adult Patients Recently Diagnosed With Active TB|Completed||Phase 2|253|Actual|Statens Serum Institut||2|||f||||t||||||||||2018-05-31 23:08:55.488356|2018-05-31 23:08:55.488356
NCT01241175|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate||||March 2009|2009-03-31||||||||Interventional|||The Effect of Intravenous Magnesium Sulfate on Intraocular Pressure Following Tracheal Intubation||Completed||Phase 3|||Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-05-31 23:08:55.561932|2018-05-31 23:08:55.561932
NCT01241162|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2017-05-08|2010-11-15|2010-11-16|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2010||2010-08-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma|A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed Neuroblastoma and Sarcoma.|Completed||Phase 1|19|Actual|University of Louisville||1|||f||||t||||||||||2018-05-31 23:08:55.707192|2018-05-31 23:08:55.707192
NCT01241149|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|November 2010||2010-11-30|November 2010|2010-11-30||||November 2013|Anticipated|2013-11-30||Interventional|||Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery|Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery.|Unknown status|Recruiting|N/A|32|Anticipated|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-05-31 23:08:55.790529|2018-05-31 23:08:55.790529
NCT01241136|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|November 2010||2010-11-30|November 2010|2010-11-30||||December 2014|Anticipated|2014-12-31||Interventional|||Open Wide Excision Versus Minimal Surgery for Pilonidal Disease|Open Wide Excision Versus Minimal Surgery for Pilonidal Disease: A Randomized Control Trial Evaluating for Early Recurrence and Patient Satisfaction|Unknown status|Recruiting|N/A|106|Anticipated|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-05-31 23:08:55.867727|2018-05-31 23:08:55.867727
NCT01241123|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|November 2010||2010-11-30|November 2010|2010-11-30||||December 2012|Anticipated|2012-12-31||Interventional|||The Influence of Ambulation on the Return of Bowel Function After Colorectal Surgery|The Influence of Ambulation on the Return of Bowel Function After Colorectal Surgery: Traditional Care Versus Early Mobilization Protocol|Unknown status|Recruiting|N/A|98|Anticipated|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-05-31 23:08:55.952061|2018-05-31 23:08:55.952061
NCT01241110|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|CTO||To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment|Phase 4 Study of Azitromicin in the Treatment of PID|Completed||Phase 4|100|Actual|Guilan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:08:56.028622|2018-05-31 23:08:56.028622
NCT01241097|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Pleiotropism of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe|Comparison of the Effect on Endothelial Function of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe|Unknown status|Recruiting|N/A|60|Anticipated|Federal University of Bahia||1|||f||||t||||||||||2018-05-31 23:08:56.102479|2018-05-31 23:08:56.102479
NCT01241084|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2011-09-29|2010-11-15|2010-11-16|Estimate|||||||2011-09-29|2011-10-03|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on Asthmatic Children|Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on the Airways Allergic Inflammation of Asthmatic Children|Completed||N/A|50|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 23:08:56.179287|2018-05-31 23:08:56.179287
NCT01241071|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2017-08-07|2010-11-15|2010-11-16|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2011||2011-01-31|August 2017|2017-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Myofascial Release on Pain, Disability and Electromyography of Erector Spinae in Chronic Low Back Pain|Effects of a Myofascial Release Protocol on Pain, Disability and Activation Pattern of Erector Spinae in Patients With Chronic Low Back Pain|Completed||N/A|54|Actual|Cardenal Herrera University||2|||f||||f||||||||||2018-05-31 23:08:56.245393|2018-05-31 23:08:56.245393
NCT01241058|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2016-01-17|2010-11-15|2010-11-16|Estimate|||||||2016-01-17|2016-01-20|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|Belcro||Registry of Pediatric Patients Diagnosed With Crohn's Disease in Belgium|Belgian Registry of Pediatric Crohn's Disease|Completed|||257|Actual|Belgian Society for Pediatric Gastroentrology Hepatology and Nutrition|||||f||||f||||||||||2018-05-31 23:08:56.315596|2018-05-31 23:08:56.315596
NCT01241045|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Observational|||Study of Effect of Vaginal ph and Acidification of Vaginal Misoprostol on Its Efficacy for Induction of Midtrimester Abortion|EFFECT OF VAGINAL Ph AND ACIDIFICATION OF VAGINAL MISOPROSTOL ON ITS EFFICACY FOR INDUCTION OF MID-TRIMESTERIC ABORTION|Unknown status|Not yet recruiting||100|Anticipated|Ain Shams University|||1||f||||t||||||||||2018-05-31 23:08:56.367828|2018-05-31 23:08:56.367828
NCT01241032|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2010-11-15|2010-11-15|2010-11-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|June 2006||2006-06-30|November 2010|2010-11-30||||February 2007|Actual|2007-02-28||Interventional|DA8159_DIA_I||Phase I Study to Investigate the Alcohol Interaction of DA8159|A Randomized, Open, Crossover Clinical Study to Investigate the Effects of Alcohol on the Pharmacokinetics of Udenafil Tablet in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:08:56.42181|2018-05-31 23:08:56.42181
NCT01241019|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2013-12-12|2010-11-15|2010-11-16|Estimate|||||||2013-12-12|2013-12-13|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|NeoNATI||Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia|Safety and Efficacy of Oral Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia: a Pilot Study of the Neonatal Neuroprotection of Asphyxiated Tuscan Infants (NeoNATI) Network|Completed||Phase 2|64|Actual|Azienda Ospedaliero, Universitaria Meyer||2|||f||||f||||||||||2018-05-31 23:08:56.485358|2018-05-31 23:08:56.485358
NCT01241006|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2016-01-05|2010-11-15|2010-11-16|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma|A Randomized Double-Blind Controlled Trial of Single Oral Dose Dexamethasone Versus Five Days of Oral Prednisone in Acute Mild to Moderate Adult Asthma|Completed||Phase 4|376|Actual|Alameda County Medical Center||2|||f||||t||||||||||2018-05-31 23:08:56.564261|2018-05-31 23:08:56.564261
NCT01240993|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2016-11-04|2010-11-12|2010-11-15|Estimate|||||||2016-11-04|2016-11-08|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers|Fostering Mothers' Emotionally-Responsive Parenting|Completed||N/A|100|Actual|Yale University||2|||f||||t||||||||No||2018-05-31 23:08:56.633118|2018-05-31 23:08:56.633118
NCT01240980|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2012-03-14|2010-11-12|2010-11-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)|A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|104|Actual|Bristol-Myers Squibb||12|||f||||f||||||||||2018-05-31 23:08:56.723175|2018-05-31 23:08:56.723175
NCT01240967|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2014-03-14|2010-11-12|2010-11-15|Estimate|||||||2014-03-14|2014-03-17|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function|An Open-Label, Multi-Center, Phase I Study To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 (S-Mecamylamine) in Subjects With Renal Impairment With Subjects With Normal Renal Function|Completed||Phase 1|40|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 23:08:56.825557|2018-05-31 23:08:56.825557
NCT01240954|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2011-08-26|2010-11-12|2010-11-15|Estimate|||||||2011-08-26|2011-08-29|Estimate|December 2010||2010-12-31|August 2011|2011-08-31||||||||Interventional|||Comparison of Different Up-dosing Schedules With Osiris||Terminated||Phase 2|210|Anticipated|ALK-Abelló A/S||3||CA approval not obtained|f||||||||||||||2018-05-31 23:08:56.889993|2018-05-31 23:08:56.889993
NCT01240941|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2013-08-18|2010-11-12|2010-11-15|Estimate|||||||2013-08-18|2013-08-20|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer|Phase II Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor Positive Breast Cancer|Withdrawn||Phase 2|0|Actual|Vanderbilt-Ingram Cancer Center||1||Funding was not available|f||||t||||||||||2018-05-31 23:08:56.955035|2018-05-31 23:08:56.955035
NCT01240928|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2013-08-18|2010-11-12|2010-11-15|Estimate|||||||2013-08-18|2013-08-20|Estimate||||August 2013|2013-08-31||||||||Interventional|||MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer|A Phase Ib Trial of MK-2206 (an AKT Inhibitor) in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer|Withdrawn||Phase 1|0|Actual|Vanderbilt-Ingram Cancer Center||1||Funding not available, study did not open to accrual and will not open in future|f||||t||||||||||2018-05-31 23:08:57.016084|2018-05-31 23:08:57.016084
NCT01240915|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2015-11-20||2016-01-26|2010-11-10|2010-11-15|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The safety analysis set consisted of all participants who received at least 1 dose of study medication.|A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis|A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis|Completed||Phase 2|105|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 23:08:57.312207|2018-05-31 23:08:57.312207
NCT01240902|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2015-03-06||2018-05-07|2010-11-12|2010-11-15|Estimate|2015-05-20|2015-06-08|Estimate||||2018-05-07|2018-05-09|Actual|November 2010||2010-11-30|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2014|Actual|2014-08-31||Interventional||Participant Population= As Treated (AT) cohort. The AT cohort consisted of all Intent to Treat (ITT) subjects with an attempted implant procedure.|Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement|Medtronic CoreValve® U.S. Pivotal Trial|Active, not recruiting||N/A|1453|Actual|Medtronic Cardiovascular||4|||f||||t||||||||||2018-05-31 23:09:00.352877|2018-05-31 23:09:00.352877
NCT01240889|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-10-08|2010-11-10|2010-11-15|Estimate|||||||2012-10-08|2012-10-10|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Roche||Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*|Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*|Completed||N/A|60|Actual|Creighton University||2|||f||||f||||||||||2018-05-31 23:09:04.745939|2018-05-31 23:09:04.745939
NCT01240876|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10||2014-05-08|2016-07-19|2010-11-10|2010-11-15|Estimate||||2014-05-08|2014-05-26|Estimate|2016-07-19|2016-07-21|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation|A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study to Evaluate the Safety and Efficacy of CEP-37247 Administered at Single Doses of 0.5, 1, 3, 6, or 12 mg by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation|Completed||Phase 1/Phase 2|98|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-05-31 23:09:04.828521|2018-05-31 23:09:04.828521
NCT01240863|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2017-02-19|2013-05-02|2017-06-02|2010-11-12|2010-11-15|Estimate|2017-06-02|2017-06-05|Actual|2013-05-02|2013-05-10|Estimate|2017-06-02|2017-06-05|Actual|November 2010||2010-11-30|June 2017|2017-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Randomized participants|Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time|A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time|Completed||Phase 3|391|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 23:09:05.1211|2018-05-31 23:09:05.1211
NCT01240850|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|December 2013|Anticipated|2013-12-31|May 2012|Anticipated|2012-05-31||Interventional|FIPREDEX||Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial|Medical Therapy in Idiopathic Retroperitoneal Fibrosis: a Multicenter, Randomized, Controlled Trial of Prednisone vs Low-dose Prednisone Plus Methotrexate|Unknown status|Recruiting|Phase 3|200|Anticipated|University of Parma||2|||f||||f||||||||||2018-05-31 23:09:07.321682|2018-05-31 23:09:07.321682
NCT01240837|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2012-03-09|2010-11-12|2010-11-15|Estimate|||||||2012-03-09|2012-03-12|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|LIPS||Effect of Palm Sugar on Blood Glucose Concentrations|Investigation of the Glycaemic Index of Arenga Pinnata Palm Sugar|Completed||N/A|21|Actual|Wageningen University||3|||f||||f||||||||||2018-05-31 23:09:07.402702|2018-05-31 23:09:07.402702
NCT01240824|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2014-04-10|2010-11-12|2010-11-15|Estimate|||||||2014-04-10|2014-04-14|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|BCG||Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer|A Phase I Trial to Determine the Safety, Tolerability and Maximum Tolerated Intravesical Dose of Aminophylline With BCG in Patients With Non-invasive Bladder Cancer|Completed||Early Phase 1|3|Actual|University of Virginia||1|||f||||t||||||||||2018-05-31 23:09:07.486556|2018-05-31 23:09:07.486556
NCT01240811|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2013-01-15||2017-11-29|2010-11-12|2010-11-15|Estimate|2013-06-17|2013-07-22|Estimate||||2017-11-29|2017-12-26|Actual|November 2010||2010-11-30|November 2017|2017-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|CHIC||Study of Immune Cell Changes in the Genital Tract 2 Months After Initiation of an IUD for Contraception|Impact of Intrauterine Contraception on the Immune Environment of the Female Genital Tract|Completed||N/A|42|Actual|University of Pittsburgh|We identified a need for methods optimization prior to proceeding with a large definitive study to determine contraceptive hormone induced changes in genital tract immune cell populations.|3|||f||||f||||||||||2018-05-31 23:09:07.587389|2018-05-31 23:09:07.587389
NCT01240798|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2010-11-22|2010-11-12|2010-11-15|Estimate|||||||2010-11-22|2010-11-23|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Depression and Anxiety in the Aetiology and Prognosis of Specific Cardiovascular Disease Syndromes: a CALIBER Study|Depression and Anxiety in the Aetiology and Prognosis of Specific Cardiovascular Disease Syndromes: a CALIBER Study Using Linked GPRD-MINAP-HES Data|Unknown status|Active, not recruiting||0|Actual|University College, London|||1||f||||t||||||||||2018-05-31 23:09:07.909434|2018-05-31 23:09:07.909434
NCT01240785|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2013-12-04||2014-11-21|2010-11-11|2010-11-15|Estimate|2014-11-21|2014-11-24|Estimate||||2014-11-21|2014-11-24|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|December 2012|Actual|2012-12-31|January 2011|Actual|2011-01-31||Interventional|||Metformin Versus Insulin in Gestational Diabetes|Metformin Versus Insulin in Gestational Diabetes. A Randomized Controlled Single Center Trial.|Completed||Phase 4|221|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 23:09:07.986678|2018-05-31 23:09:07.986678
NCT01240772|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2014-08-22|2010-11-12|2010-11-15|Estimate|||||||2014-08-22|2014-08-25|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|April 2013|Actual|2013-04-30||Interventional|LIGALONGO||Randomized Controlled Trial Comparing Transanal Doppler-guided Arterial Ligation With Mucopexy and Stapled Haemorrhoidopexy|Cost-effectiveness of New Surgical Treatments for Haemorrhoidal Disease - Randomized Controlled Trial Comparing Transanal Doppler-guided Arterial Ligation With Mucopexy and Stapled Haemorrhoidopexy (Longo's Technique)|Completed||Phase 3|407|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 23:09:08.331495|2018-05-31 23:09:08.331495
NCT01240759|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11||2018-04-26|2018-05-10|2010-11-12|2010-11-15|Estimate||||2018-04-26|2018-04-27|Actual|2018-05-10|2018-05-15|Actual|October 2010||2010-10-31|May 2018|2018-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy|A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy|Completed||Phase 2|218|Actual|Shionogi Inc.||4|||f||||t||||||||||2018-05-31 23:09:08.431788|2018-05-31 23:09:08.431788
NCT01240746|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2013-07-03|2012-03-29|2015-06-16|2010-11-11|2010-11-15|Estimate|2013-12-12|2014-01-14|Estimate|2012-03-29|2012-04-02|Estimate|2015-06-16|2015-07-14|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Study of Quadrivalent Influenza Vaccine Among Children|Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine|Completed||Phase 3|4363|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 23:09:08.679534|2018-05-31 23:09:08.679534
NCT01240733|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:09:10.981256|2018-05-31 23:09:10.981256
NCT01240720|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2014-02-24|2010-11-12|2010-11-15|Estimate|||||||2014-02-24|2014-02-25|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|November 2011|Actual|2011-11-30||Interventional|||A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer|A Phase I/II Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer|Completed||Phase 1/Phase 2|65|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:09:11.023547|2018-05-31 23:09:11.023547
NCT01240707|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-09-26|2010-11-12|2010-11-15|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pathophysiologic Changes in the Respiratory System After Fire Smoke Inhalation|Pathophysiologic Changes in the Respiratory System After Fire Smoke Inhalation|Completed||N/A|40|Actual|Oslo University Hospital||1|||f||||f||||||||Undecided||2018-05-31 23:09:11.904628|2018-05-31 23:09:11.904628
NCT01240694|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15||2013-09-09|2016-07-19|2010-11-12|2010-11-15|Estimate||||2013-09-09|2013-09-17|Estimate|2016-07-19|2016-07-21|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus|An Open-Label Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus|Terminated||Phase 3|136|Actual|Teva Pharmaceutical Industries||1||Business Decision; there were no safety issues|f||||||||||||||2018-05-31 23:09:12.091348|2018-05-31 23:09:12.091348
NCT01240681|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2015-03-10|2010-11-11|2010-11-15|Estimate|||||||2015-03-10|2015-03-11|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|IMPACT||Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|A Pilot Study of Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|Completed||N/A|32|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||t||||||||||2018-05-31 23:09:12.991195|2018-05-31 23:09:12.991195
NCT01240668|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2015-05-13|2010-11-12|2010-11-15|Estimate|||||||2015-05-13|2015-05-15|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|HN Registry||Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia|An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized With Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization|Completed|||5028|Actual|Otsuka America Pharmaceutical|||1||f||||f||||||||||2018-05-31 23:09:13.697721|2018-05-31 23:09:13.697721
NCT01240655|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-09-01|2010-11-12|2010-11-15|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2011||2011-04-30|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors|A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|76|Actual|Novartis||1|||f||||f||||||||||2018-05-31 23:09:14.099398|2018-05-31 23:09:14.099398
NCT01240642|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2012-11-26|2010-11-12|2010-11-15|Estimate|||||||2012-11-26|2012-11-27|Estimate|January 2010||2010-01-31|November 2012|2012-11-30||||December 2010|Actual|2010-12-31||Interventional|||An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404|A Multi-center, Open-label, Dose-escalation Study in Patients With Advanced Cacner to Determine the Effect of the ASA404 Infusion Rate and Co-administration With the Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokinetics of Free and Total ASA404|Terminated||Phase 1|27|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:09:14.281956|2018-05-31 23:09:14.281956
NCT01240629|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-07-05|2010-11-11|2010-11-15|Estimate|||||||2017-07-05|2017-07-11|Actual|November 2, 2010|Actual|2010-11-02|July 2017|2017-07-31|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer|Completed||Phase 1/Phase 2|43|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 23:09:14.439359|2018-05-31 23:09:14.439359
NCT01240616|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2018-04-04|2010-11-11|2010-11-15|Estimate|||||||2018-04-04|2018-04-05|Actual|October 24, 2010||2010-10-24|December 24, 2014|2014-12-24|December 24, 2014||2014-12-24|||||Observational|||Nicotinic Modulation of the Default Network of Resting Brain Function|Nicotinic Modulation of the Default Network of Resting Brain Function|Completed|||43|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:09:14.624289|2018-05-31 23:09:14.624289
NCT01240603|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2018-04-04|2010-11-11|2010-11-15|Estimate|||||||2018-04-04|2018-04-05|Actual|October 24, 2010||2010-10-24|September 11, 2013|2013-09-11|September 11, 2013||2013-09-11|||||Observational|||Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia|Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia|Completed|||415|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:09:14.700647|2018-05-31 23:09:14.700647
NCT01240590|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2015-10-26||2017-02-27|2010-11-11|2010-11-15|Estimate|2015-11-27|2015-12-31|Estimate||||2017-02-27|2017-04-10|Actual|January 26, 2011|Actual|2011-01-26|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|August 31, 2015|Actual|2015-08-31||Interventional|||A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)|A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)|Completed||Phase 1/Phase 2|27|Actual|National Institutes of Health Clinical Center (CC)|The phase II portion was not completed because it was impossible to recruit.|5|||f||||f|t|f||||||No||2018-05-31 23:09:14.798311|2018-05-31 23:09:14.798311
NCT01240577|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2017-10-05|2010-11-11|2010-11-15|Estimate|||||||2017-10-05|2017-10-06|Actual|October 26, 2010||2010-10-26|February 26, 2013|2013-02-26|July 30, 2012|Actual|2012-07-30|July 30, 2012|Actual|2012-07-30||Interventional|||An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas|An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:09:16.214021|2018-05-31 23:09:16.214021
NCT01240551|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|2014-12-15||2017-10-02|2010-11-11|2010-11-15|Estimate|2014-12-15|2014-12-24|Estimate||||2017-10-02|2017-11-06|Actual|November 30, 2010|Actual|2010-11-30|October 2017|2017-10-31|May 31, 2013|Actual|2013-05-31|May 31, 2013|Actual|2013-05-31||Interventional|||F-18 Sodium Fluoride in Prostate Cancer|A Pilot Study of F-18 Sodium Fluoride PET/CT for Metastatic Burden Qualification in Prostate Cancer|Completed||Phase 2|60|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f||||||Yes|Anonymized patient images and associated Prostate Specific-Antigen (PSA) and Gleason Scores.|2018-05-31 23:09:16.312827|2018-05-31 23:09:16.312827
NCT01240538|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2014-05-09|2010-11-11|2010-11-15|Estimate|||||||2014-05-09|2014-05-13|Estimate|December 2010||2010-12-31|January 2014|2014-01-31||||April 2014|Actual|2014-04-30||Interventional|||Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors|A Phase 1 Dose Escalation Study of Reolysin, a Replication Competent Reovirus, in Pediatric Patients With Relapsed or Refractory Solid Tumors|Completed||Phase 1|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:09:16.729529|2018-05-31 23:09:16.729529
NCT01240525|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2018-01-24|2010-11-11|2010-11-15|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2011|Actual|2011-11-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|ProT4||Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers|Multicenter Randomized Phase II Study to Evaluate the Efficacy of Prophylactic Transfer of CD4 Lymphocytes After T-cell Depleted Reduced Intensity HLA-Identical Sibling Transplantation for Haematological Cancers|Recruiting||Phase 2|68|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 23:09:17.067228|2018-05-31 23:09:17.067228
NCT01240512|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11||2017-03-08|2017-03-08|2010-11-11|2010-11-15|Estimate||||2017-03-08|2017-03-09|Actual|2017-03-08|2017-03-09|Actual|December 2010||2010-12-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|DAYLIGHT||DAYLIGHT: Vitamin D Therapy in Individuals at High Risk of Hypertension|Daylight: The Effect of Vitamin D Supplementation on Blood Pressure in Vitamin D Deficient Individuals With Pre-Hypertension|Completed||N/A|534|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:09:17.218414|2018-05-31 23:09:17.218414
NCT01240499|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2011-10-05|2010-11-12|2010-11-15|Estimate|||||||2011-10-05|2011-10-07|Estimate|September 2003||2003-09-30|October 2011|2011-10-31|September 2008|Actual|2008-09-30|September 2006|Actual|2006-09-30||Interventional|CHOIX||Effects of a Health-At-Every-Size Approach on Weight Management in Premenopausal Overweight Women|Intervention s'Inspirant du Nouveau Paradigme en matière de Gestion de Poids Chez Des Femmes préménopausées présentant un Surplus de Poids|Completed||N/A|144|Actual|Laval University||3|||f||||f||||||||||2018-05-31 23:09:17.297084|2018-05-31 23:09:17.297084
NCT01240486|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2014-05-16|2010-11-12|2010-11-15|Estimate|||||||2014-05-16|2014-05-19|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Observational|||IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int'l Sites|IMPAACT P1073: Study Of Immune Reconstitution Inflammatory Syndrome (IRIS) For International Sites Initiating Highly Active Antiretroviral Therapy (HAART) In Infants And Children < 72 Months Of Age|Completed|||207|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||||f||||f||||||||||2018-05-31 23:09:17.417711|2018-05-31 23:09:17.417711
NCT01240473|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-07|||2018-03-15|2010-11-12|2010-11-15|Estimate|||||||2018-03-15|2018-03-16|Actual|April 2007||2007-04-30|November 2010|2010-11-30|July 2009|Actual|2009-07-31|March 2008|Actual|2008-03-31||Interventional|||A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh|A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh|Completed||N/A|200|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||t||||||||||2018-05-31 23:09:17.562309|2018-05-31 23:09:17.562309
NCT01240460|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2012-07-26|2010-11-12|2010-11-15|Estimate|||||||2012-07-26|2012-07-27|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection|An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection|Completed||Phase 1|40|Actual|Sanofi||3|||f||||||||||||||2018-05-31 23:09:17.6822|2018-05-31 23:09:17.6822
NCT01240447|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2014-07-09|2010-11-12|2010-11-15|Estimate|||||||2014-07-09|2014-07-10|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|August 2012|Actual|2012-08-31||Interventional|||Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients|A Prospective, Randomised, Open Label Phase II Study of Active Specific Immunotherapy With Racotumomab Versus Support Treatment in Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|7|Actual|Laboratorio Elea S.A.C.I.F. y A.||2|||f||||f||||||||||2018-05-31 23:09:17.820576|2018-05-31 23:09:17.820576
NCT01240434|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Randomized Prospective Trial on the Occurrence of Laparoscopic Trocar Site Hernias|Estudio Prospectivo Aleatorizado Simple Ciego Sobre la Incidencia de Hernias Incisionales en Los Orificios de Los trócares de Laparoscopia: Cierre aponeurótico Superficial Frente a cicatrización aponeurótica Sin Cierre|Completed||N/A|195|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 23:09:17.948666|2018-05-31 23:09:17.948666
NCT01240421|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2015-05-21|2010-11-12|2010-11-15|Estimate|||||||2015-05-21|2015-05-22|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|November 2014|Anticipated|2014-11-30|March 2015|Anticipated|2015-03-31||Expanded Access|||An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory|An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory|Approved for marketing|||||Eisai Inc.|||||||||||||||||||2018-05-31 23:09:18.070667|2018-05-31 23:09:18.070667
NCT01240408|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2015-03-03|2010-11-11|2010-11-15|Estimate|||||||2015-03-03|2015-03-04|Estimate|July 2010||2010-07-31|November 2013|2013-11-30||||November 2011|Actual|2011-11-30||Interventional|||E7080 Food Effect Study in Healthy Subjects|E7080 Food Effect Study in Healthy Subjects|Completed||Phase 1|16|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 23:09:18.180984|2018-05-31 23:09:18.180984
NCT01240395|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2014-02-17|2010-11-12|2010-11-15|Estimate|||||||2014-02-17|2014-02-19|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Mindfulness-based Cognitive Therapy for Individuals With Multiple Chemical Sensitivity||Completed||N/A|82|Anticipated|The Danish Research Centre for Chemical Sensitivities||2|||f||||||||||||||2018-05-31 23:09:18.268016|2018-05-31 23:09:18.268016
NCT01240382|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2014-05-23||2014-08-08|2010-11-12|2010-11-15|Estimate|2014-07-16|2014-08-08|Estimate||||2014-08-08|2014-08-13|Estimate||||August 2014|2014-08-31||||February 2008|Actual|2008-02-29||Interventional|||Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye|Double-masked Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Multi-center Study, in Comparison to 0.1% Sodium Hyaluronate Ophthalmic Solution) - Phase III Confirmatory Study -|Completed||Phase 3|332|Actual|Santen Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 23:09:18.377836|2018-05-31 23:09:18.377836
NCT01240369|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-11|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|October 2010||2010-10-31|November 2010|2010-11-30||||||||Observational|||Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma||Unknown status|Active, not recruiting||250|Anticipated|China Medical University Hospital|||4||f||||t||||||||||2018-05-31 23:09:18.663918|2018-05-31 23:09:18.663918
NCT01240356|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2014-01-27||2016-05-17|2010-11-12|2010-11-15|Estimate|2016-05-17|2016-05-23|Estimate||||2016-05-17|2016-05-23|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CLOTBUST-HF||CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial|Combined Lysis of Thrombus in Brain Ischemia With Transcranial Ultrasound and Systemic T-PA-Hands-Free. A Phase I/II Pilot Safety Trial|Completed||Phase 1/Phase 2|35|Actual|The University of Texas Health Science Center, Houston|The last phase (Phase II: 3-6 hour non-lytic patients who presented between 3-6 hours and with evidence of mismatch on neuroimaging), was not completed. This portion of the study was not started as new published evidence suggested little value.|2|||f||||t||||||||||2018-05-31 23:09:18.748648|2018-05-31 23:09:18.748648
NCT01240343|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2018-01-10|2010-11-10|2010-11-15|Estimate|||||||2018-01-10|2018-01-11|Actual|June 2009||2009-06-30|January 2018|2018-01-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Observational|BioBank||Creation of the Biobank Related to Eye Disease|Creation of the Biobank Related to Eye Disease|Completed|||669|Actual|William Beaumont Hospitals|||||f||||f||||||Samples With DNA|"~     blood, urine other body fluids (i.e. vitreous)~   "|No|No plan to share at this time|2018-05-31 23:09:19.1068|2018-05-31 23:09:19.1068
NCT01240330|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2010-11-22||2011-03-02|2010-11-10|2010-11-15|Estimate|2011-01-24|2011-02-21|Estimate||||2011-03-02|2011-03-03|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Vasculaire Compression System Increases Flow Velocity in the Femoral Vein|Evaluation of the Effect of the Vasculaire Compression System on Flow Velocity in the Femoral Vein|Completed||N/A|33|Actual|Venous Health Systems, Inc.|||||f||||f||||||||||2018-05-31 23:09:19.167698|2018-05-31 23:09:19.167698
NCT01240317|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2017-06-22|2010-11-12|2010-11-15|Estimate|||||||2017-06-22|2017-06-26|Actual|December 2010||2010-12-31|June 2017|2017-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||eVent in the Human Patient Simulator|eVENT: An Expert System for Detecting Critical Events During Anesthesia (Human Patient Simulator Study)|Completed|||36|Actual|University of British Columbia|||||f||||t||||||||||2018-05-31 23:09:19.320969|2018-05-31 23:09:19.320969
NCT01240304|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2018-04-11|2010-11-10|2010-11-15|Estimate|||||||2018-04-11|2018-04-12|Actual|November 2010||2010-11-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas|A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemotherapy With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas|Active, not recruiting||Phase 2|20|Anticipated|University of Arkansas||1|||f||||f||||||||||2018-05-31 23:09:19.365383|2018-05-31 23:09:19.365383
NCT01240291|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-05-22|2010-11-10|2010-11-15|Estimate|||||||2012-05-22|2012-05-24|Estimate|March 2011||2011-03-31|May 2012|2012-05-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|GLINT||The Clinical Role of Intravenous Glutamine in Trauma Patients Receiving Enteral Nutrition|Effect of Intravenous GLutamine Supplementation IN Trauma Patients Receiving Enteral Nutrition Study Protocol (GLINT Study): A Prospective, Blinded, Randomized, Placebo-controlled Clinical Trial|Unknown status|Recruiting|Phase 3|88|Anticipated|Royal Brisbane and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:09:19.43527|2018-05-31 23:09:19.43527
NCT01240278|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2017-10-12|2010-11-10|2010-11-15|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2010||2010-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Histology of Functional Density in Postmenopausal Breast|Pilot Study to Examine Histological Characteristics of Mammographic Density With Molecular Breast Imaging: Part 1 - Postmenopausal Women|Enrolling by invitation|||20|Anticipated|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     core biopsy samples of dense breast tissue~   "|||2018-05-31 23:09:19.566749|2018-05-31 23:09:19.566749
NCT01240265|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2013-04-26|2010-11-10|2010-11-15|Estimate|||||||2013-04-26|2013-04-30|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Vitamin D Supplementation in Breastfeeding Women|Maternal Oral Vitamin D Supplementation Via Daily or Monthly Regimens and the Effect on Levels of Vitamin D in Human Milk and Infant Serum|Completed||Phase 2/Phase 3|80|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:09:19.616961|2018-05-31 23:09:19.616961
NCT01240252|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2013-06-03|2010-11-10|2010-11-15|Estimate|||||||2013-06-03|2013-06-05|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance|Molecular Regulation of Muscle Glucose Metabolism in Man, Protocol 4|Completed||Phase 1|14|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 23:09:19.699315|2018-05-31 23:09:19.699315
NCT01240239|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-11-28|2010-11-12|2010-11-15|Estimate|||||||2016-11-28|2016-11-29|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Comparison of Telemedicine Evaluation to Standard Evaluation Methods for Pre-Anesthesia Consultation|Comparison of Telemedicine Evaluation to Standard Evaluation Methods for Pre-Anesthesia Consultation|Completed|||200|Actual|Loma Linda University|||3||f||||f||||||||||2018-05-31 23:09:19.805984|2018-05-31 23:09:19.805984
NCT01240226|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2017-03-02|2010-11-10|2010-11-15|Estimate|||||||2017-03-02|2017-03-03|Actual|November 2010||2010-11-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet|An Open-Label, 2-Part Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet|Completed||Phase 1|22|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:09:19.866433|2018-05-31 23:09:19.866433
NCT01240213|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2013-08-05|2010-11-10|2010-11-15|Estimate|||||||2013-08-05|2013-08-07|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|ViDA||Vitamin D, Diet and Activity Study|Vitamin D, Weight Loss, and Breast Cancer Biomarkers|Completed||N/A|218|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 23:09:19.929665|2018-05-31 23:09:19.929665
NCT01240200|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2013-12-17||2014-10-29|2010-11-10|2010-11-15|Estimate|2014-10-28|2014-10-30|Estimate||||2014-10-29|2014-11-05|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional||Forty-six subjects completed trial (23 in Pen to Vial group and 23 in Vial to Pen group) and had complete data for this analysis.|Satisfaction of Treatment Among Elderly Patients With Insulin Therapy|Satisfaction of Treatment Among Elderly Patients With Insulin Therapy Using Pens for a Basal Insulin Treatment (STEP IT UP a BIT)|Completed||Phase 4|56|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:09:20.124762|2018-05-31 23:09:20.124762
NCT01240187|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2013-05-13|2010-11-10|2010-11-15|Estimate|||||||2013-05-13|2013-05-14|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects|A Randomized, Open-label, Crossover Study to Demonstrate Bioequivalence Between 6 x2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects|Completed||Phase 1|22|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:09:20.369554|2018-05-31 23:09:20.369554
NCT01240174|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2017-01-30|2010-11-10|2010-11-15|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis|Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis|Completed||N/A|400|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 23:09:20.435186|2018-05-31 23:09:20.435186
NCT01240161|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2017-08-28|2010-11-10|2010-11-15|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2009||2009-12-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Personalized Translational Platform for Biomarker Discovery in Brain Tumors|Personalized Translational Platform for Biomarker Discovery in Brain Tumors|Completed|||37|Actual|Brigham and Women's Hospital|||1||f||||f||||||||||2018-05-31 23:09:20.505373|2018-05-31 23:09:20.505373
NCT01240148|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2011-04-11|2010-11-10|2010-11-15|Estimate|||||||2011-04-11|2011-04-12|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy Volunteers|Completed||Phase 1|26|Actual|AstraZeneca||5|||f||||||||||||||2018-05-31 23:09:20.57275|2018-05-31 23:09:20.57275
NCT01240135|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2012-06-08||2012-06-08|2010-11-10|2010-11-15|Estimate|2012-06-08|2012-07-12|Estimate||||2012-06-08|2012-07-12|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Performance of a Silicone Hydrogel Lens With Use of FID 114675A|Clinical Performance of a Marketed Silicone Hydrogel Contact Lens When Used With Silicone Hydrogel MPDS FID 114675A|Completed||N/A|89|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:09:20.644577|2018-05-31 23:09:20.644577
NCT01240122|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2012-02-15||2018-01-10|2010-11-10|2010-11-15|Estimate|2012-06-07|2012-06-11|Estimate||||2018-01-10|2018-02-06|Actual|August 2010||2010-08-31|January 2018|2018-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Short-Term Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions||Completed||N/A|30|Actual|Abbott Medical Optics||2|||f||||||||||||||2018-05-31 23:09:20.813043|2018-05-31 23:09:20.813043
NCT01240109|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2011-05-12|2010-11-12|2010-11-15|Estimate|||||||2011-05-12|2011-05-13|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Effect of Remifentanil on Cough During Emergence From General Anesthesia : Trial to Compare Between Sevoflurane Anesthesia and Propofol Anesthesia|Effect of Remifentanil on Cough During Emergence From General Anesthesia : Randomized Trial to Comparison Between Sevoflurane Anesthesia and Propofol Anesthesia|Completed||Phase 4|70|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:09:20.96744|2018-05-31 23:09:20.96744
NCT01240083|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2013-10-14|2010-11-12|2010-11-15|Estimate|||||||2013-10-14|2013-10-16|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Effectiveness of Theta-burst Stimulation (TBS) in Patients With Major Depression|Effectiveness of Theta-burst Stimulation (TBS) Versus Tonic High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)in Patients With Major Depression|Completed||N/A|61|Actual|University of Regensburg||3|||f||||f||||||||||2018-05-31 23:09:21.122369|2018-05-31 23:09:21.122369
NCT01240070|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2011-08-11|2010-11-12|2010-11-15|Estimate|||||||2011-08-11|2011-08-12|Estimate|January 2002||2002-01-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|MINDIT||Multifactorial Intervention in Type 2 Diabetes - Italy|Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 4|1461|Actual|University of Parma||2|||f||||t||||||||||2018-05-31 23:09:21.214372|2018-05-31 23:09:21.214372
NCT01240057|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2018-05-25|2010-11-12|2010-11-15|Estimate|||||||2018-05-25|2018-05-30|Actual|November 2011||2011-11-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|November 2020|Anticipated|2020-11-30||Interventional|TOTAL||Tracheal Occlusion To Accelerate Lung Growth (TOTAL) Trial for Severe Pulmonary Hypoplasia|Randomized Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) Versus Expectant Management During Pregnancy in Fetuses With Left Sided and Isolated Congenital Diaphragma Hernia and Severe Pulmonary Hypoplasia.|Recruiting||Phase 2/Phase 3|116|Anticipated|University Hospital, Gasthuisberg||2|||f||||t||||||||||2018-05-31 23:09:22.332222|2018-05-31 23:09:22.332222
NCT01240044|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2013-06-18|2010-11-12|2010-11-15|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2010||2010-07-31|October 2010|2010-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Respiratory Therapy and Newborn Pain: Comparison Between Techniques|Study of Respiratory Therapy and Newborn Pain That Made a Comparison Between Physiotherapeutical Techniques|Completed||N/A|60|Actual|University of the State of Santa Catarina||3|||f||||t||||||||||2018-05-31 23:09:22.471652|2018-05-31 23:09:22.471652
NCT01240031|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Effect of Energy- and Protein-rich Foods on Physiological Functions and Quality of Life in Undernourished Patients|Framework for Developing Appetising, Energy- and Protein-rich Foods for Patients at Nutritional Risk: Effect on Physiological Functions and Quality of Life|Unknown status|Recruiting|N/A|80|Anticipated|University of Copenhagen|||||f||||||||||||||2018-05-31 23:09:22.534918|2018-05-31 23:09:22.534918
NCT01240018|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-06-14|2010-11-12|2010-11-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|September 2009||2009-09-30|June 2012|2012-06-30||||June 2011|Actual|2011-06-30||Interventional|ProSat||ProSat - Long Term Effect of Probiotics on Satiety|Probiotics and Satiety - Acute Effects and Persistence of Acute Effects|Completed||N/A|66|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 23:09:22.605464|2018-05-31 23:09:22.605464
NCT01240005|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|September 2013|Anticipated|2013-09-30|December 2012|Anticipated|2012-12-31||Interventional|||Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma|A Phase I/II Evaluation of Cytokine Induced Killer Cells Stimulated by DC(DCIK) Immunotherapy in Patients With Renal Cell Carcinoma|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Qingdao University||1|||f||||f||||||||||2018-05-31 23:09:22.670948|2018-05-31 23:09:22.670948
NCT01239992|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|2013-12-02||2014-03-12|2010-11-12|2010-11-15|Estimate|2014-03-12|2014-04-10|Estimate||||2014-03-12|2014-04-10|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia|Effect of Niacin/Laropiprant on Postprandial Lipoprotein and Glucose Metabolism in Patients With Severe Dyslipoproteinemia|Terminated||Phase 4|12|Actual|Ludwig-Maximilians - University of Munich||1||negative endpoint study resulting in withdrawal of study drug|f||||f||||||||||2018-05-31 23:09:22.753313|2018-05-31 23:09:22.753313
NCT01239979|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-12-21|2010-11-12|2010-11-15|Estimate|||||||2010-12-21|2010-12-22|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Observational|||Plasma Myeloperoxidase Levels in Patients With Coronary Artery Disease|Evaluation of the Association Between Myeloperoxidase Levels and Cardiovascular Risk Factors in Patients With Coronary Artery Disease|Completed|||150|Actual|Isfahan University of Medical Sciences|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:09:23.674463|2018-05-31 23:09:23.674463
NCT01239966|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2016-02-21|2010-11-12|2010-11-15|Estimate|||||||2016-02-21|2016-02-23|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|PARSA||Pulmonary And Renal Support During Acute Respiratory Distress Syndrome|Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With the Acute Respiratory Distress Syndrome and Acute Renal Failure|Completed||Phase 3|11|Actual|Hôpital Européen Marseille|||||f||||f||||||||No||2018-05-31 23:09:23.733414|2018-05-31 23:09:23.733414
NCT01239953|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2012-02-24|2010-11-12|2010-11-15|Estimate|||||||2012-02-24|2012-02-27|Estimate|January 2010||2010-01-31|February 2012|2012-02-29||||July 2012|Anticipated|2012-07-31||Interventional|RIBS V||RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)|RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 4|190|Actual|Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular||2|||f||||t||||||||||2018-05-31 23:09:23.82237|2018-05-31 23:09:23.82237
NCT01239940|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2011-06-23|2010-11-12|2010-11-15|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2010||2010-01-31|November 2010|2010-11-30||||July 2012|Anticipated|2012-07-31||Interventional|RIBS IV||RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)|RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|310|Anticipated|Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular||2|||f||||t||||||||||2018-05-31 23:09:23.976655|2018-05-31 23:09:23.976655
NCT01239927|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2010-11-12|2010-11-12|2010-11-15|Estimate|||||||2010-11-12|2010-11-15|Estimate|January 2000||2000-01-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Hartmann vs R/A in Peritonitis by Perforated Diverticulitis|Hartmann vs Resection With Anastomosis and Diverting Stoma for Peritonitis Caused by Perforated Left-sided Colon Diverticulitis: a Multicenter Prospective Randomized Study.|Completed||Phase 2/Phase 3|100|Actual|Ente Ospedaliero Ospedali Galliera|||||f||||t||||||||||2018-05-31 23:09:24.26029|2018-05-31 23:09:24.26029
NCT01239914|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2012-08-24|2010-11-12|2010-11-15|Estimate|||||||2012-08-24|2012-08-27|Estimate|January 2005||2005-01-31|July 2010|2010-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|COACT||CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)|CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)|Unknown status|Recruiting||11000|Anticipated|The Catholic University of Korea|||||f||||t||||||Samples With DNA|"~     Whole blood, serum and DNA~   "|||2018-05-31 23:09:24.336166|2018-05-31 23:09:24.336166
NCT01239901|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-12|||2017-03-24|2010-11-12|2010-11-15|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2009||2009-12-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Iron Mediated Vascular Disease in Sickle Cell Anemia Patients|Iron-mediated Vascular Disease in Sickle Cell Disease.|Active, not recruiting|||150|Anticipated|Children's Hospital Los Angeles|||||f||||t||||||Samples With DNA|"~     Red Blood Cells (RBCs), Peripheral Blood Mononuclear Cells (PBMCs), Plasma, Serum, and Urine~   "|No||2018-05-31 23:09:24.434762|2018-05-31 23:09:24.434762
NCT01239888|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2012-01-15|2010-11-12|2010-11-15|Estimate|||||||2012-01-15|2012-01-18|Estimate|January 2012||2012-01-31|January 2012|2012-01-31||||November 2012|Anticipated|2012-11-30||Interventional|||Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study|Phase IB Study of Efficacy and Safety of Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression|Unknown status|Recruiting|Phase 1|15|Anticipated|The Alfred||3|||f||||f||||||||||2018-05-31 23:09:24.512152|2018-05-31 23:09:24.512152
NCT01239875|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2017-03-21|2010-11-10|2010-11-11|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2010|Actual|2010-11-30|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma|"LS1081, A Pilot Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation or Intradermally for Patients With B-Cell Non-Hodgkin's Lymphoma"|Terminated||N/A|16|Actual|Mayo Clinic||2||Lack of funding|f||||t||||||||||2018-05-31 23:09:24.619214|2018-05-31 23:09:24.619214
NCT01239862|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2015-05-26|2010-11-10|2010-11-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|May 2011|Actual|2011-05-31||Interventional|SilicStemCell||Safety of Stem Cells Intrabronchial Instillation for Silicosis|Phase-1 Study of Autologous Bone Marrow Cells Intrabronchial Instillation for Patients Silicosis|Completed||Phase 1|5|Actual|Universidade Federal do Rio de Janeiro||1|||f||||t||||||||||2018-05-31 23:09:24.716272|2018-05-31 23:09:24.716272
NCT01239849|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-12|2010-11-10|2010-11-11|Estimate|||||||2010-11-12|2010-11-15|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|||Korean AMADEUS Study|A Multicenter, Eight Weeks Treatment, Single Step Titration, Open Label Study Assessing the Percentage of Korean Diabetic Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Dose 10mg, 20mg, 40mg|Unknown status|Recruiting|Phase 4|500|Anticipated|The Catholic University of Korea|||||f||||t||||||||||2018-05-31 23:09:24.787282|2018-05-31 23:09:24.787282
NCT01239836|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2013-05-14|2010-11-10|2010-11-11|Estimate|||||||2013-05-14|2013-05-15|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effectiveness of Continence Promotion Interventions Among Community-dwelling Older Women|Self-management, Constructivism or Both as Knowledge Transfer Strategies for Reducing the Cost and Impact of Urinary Incontinence Among Community-dwelling Senior Women in the United Kingdom|Completed||N/A|259|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||4|||f||||f||||||||||2018-05-31 23:09:24.86925|2018-05-31 23:09:24.86925
NCT01239823|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-04-07|2010-11-10|2010-11-11|Estimate|||||||2011-04-07|2011-04-11|Estimate|November 2010||2010-11-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Platform Exercise Training|Platform Exercise Training for Women at Risk for Knee Osteoarthritis|Completed||N/A|50|Anticipated|University of Iowa||2|||f||||f||||||||||2018-05-31 23:09:24.959734|2018-05-31 23:09:24.959734
NCT01239810|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-12-08|2010-11-10|2010-11-11|Estimate|||||||2010-12-08|2010-12-09|Estimate|June 2005||2005-06-30|December 2010|2010-12-31|December 2008|Actual|2008-12-31|November 2006|Actual|2006-11-30||Observational|Ostenil||Intra-articular Hyaluronic Acid in Mild to Moderate Knee Osteoarthritis|Effect of Intra-articular Hyaluronic Acid on Articular Cartilage Morphology and Composition in Mild to Moderate Knee Osteoarthritis|Completed|||34|Actual|Technische Universität München|||2||f||||f||||||||||2018-05-31 23:09:25.029573|2018-05-31 23:09:25.029573
NCT01239797|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2016-08-04||2017-09-20|2010-11-10|2010-11-11|Estimate|2017-01-04|2017-01-05|Estimate||||2017-09-20|2017-09-26|Actual|March 28, 2011|Actual|2011-03-28|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|September 2, 2014|Actual|2014-09-02||Interventional|ELOQUENT - 2|Randomized: all participants randomized to any treatment group|Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma|Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)|Active, not recruiting||Phase 3|761|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 23:09:25.362002|2018-05-31 23:09:25.362002
NCT01239784|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2013-08-25|2010-11-10|2010-11-11|Estimate|||||||2013-08-25|2013-08-27|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Neurodevelopmental Rehabilitation for Toddlers With Complex Heart Defects|Neurodevelopmental Rehabilitation for Toddlers With Complex Heart Defects|Completed||Phase 2|20|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 23:09:27.149031|2018-05-31 23:09:27.149031
NCT01239771|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-06-27|2010-11-10|2010-11-11|Estimate|||||||2012-06-27|2012-06-28|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects|A Phase I, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of TC-5214 Given as Multiple Ascending Oral Doses in Medically Stable Elderly Subjects|Completed||Phase 1|32|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:09:27.229734|2018-05-31 23:09:27.229734
NCT01239758|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01||2013-01-24|2013-01-30|2010-11-10|2010-11-11|Estimate||||2013-01-30|2013-02-01|Estimate|2013-01-30|2013-02-01|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 2|11|Actual|Acceleron Pharma, Inc.||3||This study was terminated based on preliminary safety data.|f||||t||||||||||2018-05-31 23:09:27.305298|2018-05-31 23:09:27.305298
NCT01238497|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2017-04-11|2010-11-09|2010-11-10|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2010|Actual|2010-09-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|August 2014|Actual|2014-08-31||Observational|||SOURCE XT REGISTRY|Edwards SAPIEN™ Aortic Bioprosthesis Multi-Region Outcome Registry XT|Active, not recruiting|||2954|Actual|Edwards Lifesciences|||3||f||||t||||||||||2018-05-31 23:09:50.118548|2018-05-31 23:09:50.118548
NCT01239745|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2012-10-11||2012-10-11|2010-11-10|2010-11-11|Estimate|2012-10-11|2012-10-31|Estimate||||2012-10-11|2012-10-31|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer|A Non-Interventional Study With Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy|Terminated|||46|Actual|Pfizer|The study was prematurely discontinued, therefore not all data was analyzed.||1|See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:09:27.403921|2018-05-31 23:09:27.403921
NCT01239732|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2016-03-17||2016-05-03|2010-11-10|2010-11-11|Estimate|2016-05-03|2016-06-10|Estimate||||2016-05-03|2016-06-10|Estimate|December 2010||2010-12-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety population: included all participants who received at least one dose of study medication.|A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer|Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma|Completed||Phase 3|1021|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:09:27.798531|2018-05-31 23:09:27.798531
NCT01239719|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-01-27|2010-11-10|2010-11-11|Estimate|||||||2011-01-27|2011-01-28|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Randomized Study for Effectiveness and Safety Evaluation of Dexamethasone 0.5 mg + Fumarate Clemastine 1 mg Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis||Unknown status|Not yet recruiting|Phase 3|96|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 23:09:28.820189|2018-05-31 23:09:28.820189
NCT01239706|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|November 2010||2010-11-30|February 2010|2010-02-28|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1|A Phase IIa, Single Centre, Open Label Study to Characterize the Safety of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1|Unknown status|Recruiting|Phase 2|10|Anticipated|University of Calgary||1|||f||||t||||||||||2018-05-31 23:09:28.888231|2018-05-31 23:09:28.888231
NCT01239693|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-05-11|2010-11-10|2010-11-11|Estimate|||||||2016-05-11|2016-05-13|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|iLiNS-DYAD-M||Supplementing Maternal and Infant Diet With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS)|A Research Plan for a Randomised, Single-blind, Parallel Group Controlled Trial in Rural Malawi, Testing the Health Effects of Supplementing Maternal Diet During Pregnancy and Lactation and Infant Diet From 6 to 18 Months of Age With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS)|Completed||Phase 3|1391|Actual|University of Tampere||3|||f||||t||||||||||2018-05-31 23:09:28.970636|2018-05-31 23:09:28.970636
NCT01239680|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2013-12-30||2014-05-14|2010-11-10|2010-11-11|Estimate|2014-05-14|2014-06-17|Estimate||||2014-05-14|2014-06-17|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy|Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy.|Completed||N/A|5|Actual|University of Missouri, Kansas City|Many subjects excluded due to being unstable after initial resuscitation, having altered mental status, inability to speak English, <21 years of age, or blood alcohol in excess of 80mg/dl. No waiver of consent.|2|||f||||f||||||||||2018-05-31 23:09:29.07432|2018-05-31 23:09:29.07432
NCT01239667|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|February 2012|Anticipated|2012-02-29|May 2011|Anticipated|2011-05-31||Interventional|||Rehabilitative Care to Patients With Heart Failure|Rehabilitative Care to Patients With Heart Failure|Unknown status|Recruiting|N/A|194|Anticipated|University College Sjælland||1|||f||||t||||||||||2018-05-31 23:09:29.307065|2018-05-31 23:09:29.307065
NCT01239654|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2012-05-22|2010-11-10|2010-11-11|Estimate|||||||2012-05-22|2012-05-23|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|APICE-OCT||Activity of Platelets After Inhibition and Cardiovascular Events Optical Coherence Tomography Study|Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study|Completed||Phase 3|60|Actual|IRCCS San Raffaele||2|||f||||t||||||||||2018-05-31 23:09:29.386598|2018-05-31 23:09:29.386598
NCT01239641|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-12|2010-11-10|2010-11-11|Estimate|||||||2010-11-12|2010-11-15|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Interventional|||High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids|Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study|Unknown status|Recruiting|Phase 4|220|Anticipated|Chongqing Medical University|||||f||||t||||||||||2018-05-31 23:09:29.469599|2018-05-31 23:09:29.469599
NCT01239628|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-02-26|2010-11-10|2010-11-11|Estimate|||||||2016-02-26|2016-02-29|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|DECIDE||A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke|A National, Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities up to 3 Years Follow up of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity Post-CVA (Cerebrovascular Accident)|Terminated|||45|Actual|Ipsen||||Participant enrolment was lower than expected|f||||f||||||||||2018-05-31 23:09:29.555535|2018-05-31 23:09:29.555535
NCT01239615|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2015-10-12|2010-11-10|2010-11-11|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Test-retest Stability of MR-parameters. A Neuroimaging Pilot-study in Healthy Volunteers|Test-retest Stability of MR-parameters. A Neuroimaging Pilot-study in Healthy Volunteer|Withdrawn|||0|Actual|Aarhus University Hospital|||1||f||||f||||||||||2018-05-31 23:09:29.685017|2018-05-31 23:09:29.685017
NCT01239602|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|||The Variation of Movement Related Cortical Potential, Cortico-cortical Inhibition, and Motor Evoked Potential in Intracerebral Implantation of Antologous Peripheral Blood Stem Cells(CD34)in Old Ischemic Stroke||Unknown status|Recruiting||36|Anticipated|China Medical University Hospital|||3||f||||||||||||||2018-05-31 23:09:29.73433|2018-05-31 23:09:29.73433
NCT01239589|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2011-03-28|2010-11-10|2010-11-11|Estimate|||||||2011-03-28|2011-03-29|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes|European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes Treated With Immediate Release Quetiapine or Extended Release Quetiapine|Completed|||1280|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:09:29.827618|2018-05-31 23:09:29.827618
NCT01239576|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-06-15|2010-11-10|2010-11-11|Estimate|||||||2017-06-15|2017-06-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:09:29.989144|2018-05-31 23:09:29.989144
NCT01239563|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|May 2016|Anticipated|2016-05-31|May 2012|Anticipated|2012-05-31||Interventional|TIKT||Thymoglobulin Induction in Kidney Transplant Recipients|THYMOGLOBULIN INDUCTION AND STEROID-FREE IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION FROM DECEASED DONORS AFTER CARDIAC DEATH-AN OPEN LABEL RANDOMISED CONTROLLED TRIAL TO EVALUATE THE ROLE OF THYMOGLOBULIN AS INDUCTION IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTS FROM DECEASED DONORS AFTER CARDIAC DEATH|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 23:09:30.026216|2018-05-31 23:09:30.026216
NCT01239550|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2018-04-23|2010-11-10|2010-11-11|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2011||2011-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|IDIOM||Insulin Detemir in Obesity Management|"Making an ObeseBrain(and Body)Lean: Insulin Detemir,Monoamines,and Reward"|Active, not recruiting||N/A|240|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 23:09:30.107522|2018-05-31 23:09:30.107522
NCT01239537|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2017-12-07|2010-11-10|2010-11-11|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2010||2010-11-30|December 2017|2017-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Swine Flu (Influenza A H1N1) Follow on Vaccine Study|A Multi-centre, Open-label, Clinical, Phase 4 Trial, Following on From a Head-to-head Comparison Study of Two H1N1 Influenza Vaccines in Children, to Compare Firstly, the Persistence of Antibody Against the A/California/7/2009 (H1N1) Virus and Secondly the Immunogenicity and Reactogenicity of One Dose of a Non-adjuvanted Trivalent Seasonal Influenza Vaccine, in Children Who Had Received a Two-dose Immunisation Regimen of Celvapan or Pandemrix.|Completed|||560|Anticipated|University of Oxford|||2||f||||t||||||||||2018-05-31 23:09:30.336282|2018-05-31 23:09:30.336282
NCT01239524|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate||||November 2010|2010-11-30||||||||Interventional|||The Significance of Latissimus Dorsi Flap Innervation in Delayed Breast Reconstruction|The Significance of Latissimus Dorsi Flap Innervation in Delayed Breast Reconstruction|Completed||Phase 3|28|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 23:09:30.420317|2018-05-31 23:09:30.420317
NCT01239511|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2014-08-13||2014-08-13|2010-11-10|2010-11-11|Estimate|2014-08-13|2014-08-27|Estimate||||2014-08-13|2014-08-27|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||For subjects without the primary efficacy variable due to early discontinuaton and those with protocol violation were excluded from the analysis group.|Phase IIb Study of STA-2 in Patients With Chronic Stable Angina|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Dose-Response and Safety of STA-2 in Patients With Chronic Stable Angina|Completed||Phase 2|186|Actual|Sinphar Pharmaceutical Co., Ltd||4|||f||||t||||||||||2018-05-31 23:09:30.489808|2018-05-31 23:09:30.489808
NCT01239498|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-08-07|2010-11-10|2010-11-11|Estimate|||||||2011-08-07|2011-08-09|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Saline Injection - Assisted Anesthesia in Eyelid Surgery|Saline Injection - Assisted Anesthesia in Eyelid Surgery|Unknown status|Recruiting|Phase 4|60|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:09:30.829779|2018-05-31 23:09:30.829779
NCT01239485|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2013-11-17|2010-11-10|2010-11-11|Estimate|||||||2013-11-17|2013-11-19|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents|Phase I Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents|Unknown status|Recruiting|Phase 1|18|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 23:09:30.906739|2018-05-31 23:09:30.906739
NCT01239472|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2012-06-05|2010-11-10|2010-11-11|Estimate|||||||2012-06-05|2012-06-06|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|November 2013|Anticipated|2013-11-30|June 2013|Anticipated|2013-06-30||Interventional|||Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant|Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant|Unknown status|Recruiting|Phase 4|30|Anticipated|Santa Casa de Misericórdia de Belo Horizonte||2|||f||||f||||||||||2018-05-31 23:09:31.033511|2018-05-31 23:09:31.033511
NCT01239459|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2012-02-28|2010-11-10|2010-11-11|Estimate|||||||2012-02-28|2012-03-01|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment|An Open-label Pharmacokinetic and Tolerability Study of Teriflunomide Given as a Single 14 mg Dose in Subjects With Severe Renal Impairment, and in Matched Subjects With Normal Renal Function|Completed||Phase 1|16|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:09:31.11601|2018-05-31 23:09:31.11601
NCT01239446|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|January 2011||2011-01-31|November 2010|2010-11-30||||January 2012|Anticipated|2012-01-31||Interventional|||Hybrid SPECT/CTCA for the Assessment of the Presence and Hemodynamic Significance of CAD in Asymptomatic Patients.|Hybrid Single-Photon Emission Computed Tomography/Computed Tomography Coronary Angiography for the Assessment of the Presence and Hemodynamic Significance of CAD in Asymptomatic Patients After Mediastinal Irradiation for Hodgkin Lymphoma.|Unknown status|Not yet recruiting|N/A|100|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 23:09:31.190751|2018-05-31 23:09:31.190751
NCT01239433|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-09-26|2010-11-10|2010-11-11|Estimate|||||||2016-09-26|2016-09-27|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Pathophysiologic Changes in the Respiratory System During Therapeutic Interventions|Pathophysiologic Changes in the Respiratory System During Therapeutic Interventions|Completed|||25|Actual|Oslo University Hospital|||1||f||||f||||||||Undecided||2018-05-31 23:09:31.258021|2018-05-31 23:09:31.258021
NCT01238484|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2013-07-10|2010-11-09|2010-11-10|Estimate|||||||2013-07-10|2013-07-11|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Ankle Equinus Contracture Treated With Dynamic Splinting|Ankle Equinus Contracture Treated With Dynamic Splinting in a Randomized, Controlled Trial|Terminated||N/A|15|Actual|Dynasplint Systems, Inc.||2||Centers could not meet enrollment goals|f||||f||||||||||2018-05-31 23:09:50.401563|2018-05-31 23:09:50.401563
NCT01239420|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-09-26|2010-11-10|2010-11-11|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Observational|NORCAST||Norwegian Cardio-Respiratory Arrest Study|Norwegian Cardio-Respiratory Arrest Study (NORCAST)|Recruiting|||261|Anticipated|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     Serum, plasma, blood (PaxGene). For future identification of biochemical markers in~     prognostication after cardiorespiratory arrest. For future identification of biochemical~     markers for cardiac arrest (primarily serum, but also on mRNA-level).~   "|Undecided||2018-05-31 23:09:31.320527|2018-05-31 23:09:31.320527
NCT01239407|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2014-10-29|2010-11-10|2010-11-11|Estimate|||||||2014-10-29|2014-10-30|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|CFP||Culturally-focused Consultation for Asian Americans and Latino Americans|Culturally Focused Psychiatric Consultation Service for Asian American and Latino American Primary Care Patients With Depression|Completed||N/A|122|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:09:31.386705|2018-05-31 23:09:31.386705
NCT01239394|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2017-01-25||2017-09-18|2010-11-10|2010-11-11|Estimate|2017-01-26|2017-03-17|Actual||||2017-09-18|2017-10-18|Actual|December 2010|Actual|2010-12-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2013|Actual|2013-03-31||Interventional|||Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma|Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma|Completed||Phase 2|43|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:09:31.467379|2018-05-31 23:09:31.467379
NCT01239381|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2017-03-24||2017-10-03|2010-11-10|2010-11-11|Estimate|2017-06-14|2017-07-13|Actual||||2017-10-03|2017-11-06|Actual|June 2010||2010-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|January 2016|Actual|2016-01-31||Interventional||Patients that were registered but did not start study therapy were not included in the analysis.|Individualized Stereotactic Body Radiotherapy of Liver Metastases|Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases|Completed||N/A|92|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:09:31.751635|2018-05-31 23:09:31.751635
NCT01239368|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2018-05-05|2010-11-10|2010-11-11|Estimate|||||||2018-05-05|2018-05-08|Actual|November 10, 2010||2010-11-10|December 27, 2017|2017-12-27|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma|Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy|Completed||Phase 1/Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 23:09:32.070381|2018-05-31 23:09:32.070381
NCT01239355|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2015-06-10||2015-09-03|2010-11-10|2010-11-11|Estimate|2015-09-03|2015-10-05|Estimate||||2015-09-03|2015-10-05|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy|A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy|Terminated||Phase 2|15|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results|1||Early termination for discouraging results|f||||||||||||||2018-05-31 23:09:32.152711|2018-05-31 23:09:32.152711
NCT01239342|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2017-03-22||2017-05-10|2010-11-10|2010-11-11|Estimate|2017-05-10|2017-06-07|Actual||||2017-05-10|2017-06-07|Actual|January 27, 2011|Actual|2011-01-27|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|March 31, 2016|Actual|2016-03-31||Interventional|||Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer|A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma|Active, not recruiting||Phase 2|43|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:09:32.556356|2018-05-31 23:09:32.556356
NCT01239329|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2011-02-16|2010-11-10|2010-11-11|Estimate|||||||2011-02-16|2011-02-17|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Malnutrition in People With Complex Multiple Disabilities|Understanding of Malnutrition in People With Complex Multiple Disabilities|Unknown status|Recruiting||125|Anticipated|Maastricht University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Blood as well as urine samples will be collected. Urine samples are important concerning~     measurement of body composition according to the Deuterium dilution method. A blood sample~     will be collected for measurement of nutrients.~   "|||2018-05-31 23:09:33.1653|2018-05-31 23:09:33.1653
NCT01239316|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|2015-12-10||2015-12-10|2010-11-10|2010-11-11|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|August 2015|Actual|2015-08-31|June 2014|Actual|2014-06-30||Interventional|||Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma|A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:09:33.296876|2018-05-31 23:09:33.296876
NCT01239303|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2011-11-07|2010-11-10|2010-11-11|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|February 2012|Anticipated|2012-02-29|January 2012|Anticipated|2012-01-31||Interventional|||Effects of Citrulline on Gut Functioning During Excercise|Effects of Citrulline on Gut Functioning During Excercise|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 23:09:33.58411|2018-05-31 23:09:33.58411
NCT01239277|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2011-09-13|2010-11-10|2010-11-11|Estimate|||||||2011-09-13|2011-09-14|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Combined Nutrient Intake and Muscle Protein Synthesis|Combined Nutrient Intake and Muscle Protein Synthesis|Completed||N/A|48|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 23:09:33.650591|2018-05-31 23:09:33.650591
NCT01239251|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2015-03-04|2010-11-10|2010-11-11|Estimate|||||||2015-03-04|2015-03-06|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Observational|||GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy|Feasibility of Using the GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy|Terminated|||8|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 23:09:33.723257|2018-05-31 23:09:33.723257
NCT01239238|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2013-11-14|2010-11-10|2010-11-11|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|RASTER||Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study|Reduction of Asthma Exacerbation Rate in Children by Non-invasive Monitoring of Inflammatory Markers in Exhaled Breath (Condensate): the RASTER Study|Completed|||102|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 23:09:33.783361|2018-05-31 23:09:33.783361
NCT01239212|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2014-02-26||2015-08-05|2010-11-10|2010-11-11|Estimate|2014-08-27|2014-09-08|Estimate||||2015-08-05|2015-08-07|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dosing of Levetiracetam (Keppra) in Neonates|Pharmacokinetics and Safety of 50 mg/kg IV Levetiracetam (Keppra) in Full Term and Preterm Neonates|Completed||Phase 1/Phase 2|7|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||||||2018-05-31 23:09:33.900949|2018-05-31 23:09:33.900949
NCT01239199|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2014-02-26|2010-11-10|2010-11-11|Estimate|||||||2014-02-26|2014-02-27|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|NOnourisson||Is the Exhaled Nitric Oxide in Infants a Predictive Marker of Asthma ?|Is the Exhaled Nitric Oxide in Infants a Predictive Marker of Asthma?|Completed||N/A|86|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:09:34.031436|2018-05-31 23:09:34.031436
NCT01239186|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2013-08-06|2010-11-10|2010-11-11|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|September 2011|Actual|2011-09-30||Observational|METHYLHOMME||Identification and Characterization of the Methylation Abnormalities on Whole Genome Among Infertile Men|Identification and Characterization of the Methylation Abnormalities on Whole Genome Among Infertile Men|Completed|||49|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Sample of sperm collected by automasturbation~   "|||2018-05-31 23:09:34.132853|2018-05-31 23:09:34.132853
NCT01239173|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-07-25|2010-11-10|2010-11-11|Estimate|||||||2012-07-25|2012-07-26|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|VIVITRAU||Emotional Memory Reactivation in Posttraumatic Stress Disorder|Reliving the Traumatic Event in Posttraumatic Stress Disorder: An Emotional Memory Reactivation Pathology? An fMRI Study|Terminated||Phase 3|5|Actual|Assistance Publique - Hôpitaux de Paris||4||Study stopped by promoter for lack of inclusion|f||||t||||||||||2018-05-31 23:09:34.205292|2018-05-31 23:09:34.205292
NCT01239160|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2018-01-25|2010-11-10|2010-11-11|Estimate|||||||2018-01-25|2018-01-26|Actual|November 2010||2010-11-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|ACE||Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphedema|At Home Evaluation of Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphoedema(ACE: At Home Compression Evaluation)|Recruiting||N/A|262|Anticipated|Centre for Research & Implementation of Clinical Practice||2|||f||||t||||||||||2018-05-31 23:09:34.28754|2018-05-31 23:09:34.28754
NCT01239147|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2013-04-26|2010-11-10|2010-11-11|Estimate|||||||2013-04-26|2013-04-29|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Whole Grain on Weight Maintenance|Effect of Whole Grain Inclusion in the Diet on Abdominal Fat Regain After a Weight Loss Diet|Completed||Phase 3|186|Actual|Cereal Partners Worldwide||2|||f||||t||||||||||2018-05-31 23:09:34.383505|2018-05-31 23:09:34.383505
NCT01239134|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-03-01|2010-11-09|2010-11-11|Estimate|||||||2017-03-01|2017-03-03|Actual|October 2010||2010-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|TRX518-001||Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors|Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose|Recruiting||Phase 1|71|Anticipated|Leap Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 23:09:34.445954|2018-05-31 23:09:34.445954
NCT01239121|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2016-03-16||2016-07-14|2010-11-10|2010-11-11|Estimate|2016-03-16|2016-04-21|Estimate||||2016-07-14|2016-08-15|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Regional Data Exchange to Improve Medication Safety|Implementing a Regional Data Exchange Tool to Improve Medication Use and Safety|Completed||N/A|402|Actual|VA Office of Research and Development|In the HIE-enhanced medication reconciliation intervention arm, the Health Information Exchange (HIE) capabilities were reduced from what was planned, limiting the potency of the intervention relative to control.|3|||f||||f||||||||No||2018-05-31 23:09:34.533372|2018-05-31 23:09:34.533372
NCT01239108|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2012-09-06|2010-11-09|2010-11-11|Estimate|||||||2012-09-06|2012-09-07|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias|A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias|Withdrawn||Phase 1|0|Actual|Astex Pharmaceuticals||||"The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe~   to continue clinical development of this molecule."|f||||||||||||||2018-05-31 23:09:35.285185|2018-05-31 23:09:35.285185
NCT01239095|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-06-02|2010-11-09|2010-11-11|Estimate|||||||2017-06-02|2017-06-06|Actual|July 2011||2011-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection|Perioperative Administration of Oral Green Tea Extract/Milk Thistle Extract to Colorectal Cancer Patients Undergoing Colorectal Cancer Resection, a Phase 1 Study|Recruiting||Phase 1|30|Anticipated|St. Luke's-Roosevelt Hospital Center||1|||f||||f||||||||No||2018-05-31 23:09:35.338691|2018-05-31 23:09:35.338691
NCT01239082|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2018-01-10|2010-11-10|2010-11-11|Estimate|||||||2018-01-10|2018-01-12|Actual|April 30, 2012|Actual|2012-04-30|January 2018|2018-01-31|September 29, 2028|Anticipated|2028-09-29|September 29, 2028|Anticipated|2028-09-29||Interventional|CONFIRM||Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)|CSP #577 - Colonoscopy vs. Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer|Active, not recruiting||N/A|50000|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 23:09:35.411003|2018-05-31 23:09:35.411003
NCT01239069|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2014-05-19|2010-11-09|2010-11-11|Estimate|||||||2014-05-19|2014-05-21|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease|A Phase II, Prospective, Randomized, Observer-masked, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of Two Concentrations Compared to Placebo for the Treatment of Dry Eye Disease|Completed||Phase 2|140|Actual|Santen Inc.||3|||f||||||||||||||2018-05-31 23:09:35.677346|2018-05-31 23:09:35.677346
NCT01239056|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2015-07-24||2015-08-21|2010-11-09|2010-11-11|Estimate|2015-07-24|2015-08-21|Estimate||||2015-08-21|2015-09-07|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Evaluation of Pancreatic Pseudocyst Drainage With a Metal Stent|Prospective Evaluation of the Clinical Utility of Pseudocyst Drainage With Metal Stent|Completed|||22|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 23:09:35.773694|2018-05-31 23:09:35.773694
NCT01239043|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2012-05-14||2012-06-18|2010-11-09|2010-11-11|Estimate|2012-05-14|2012-06-19|Estimate||||2012-06-18|2012-06-25|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|April 2011|Actual|2011-04-30||Interventional|||Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination|Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29|Completed||Phase 2|139|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:09:35.953122|2018-05-31 23:09:35.953122
NCT01239030|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2013-01-22|2010-11-09|2010-11-11|Estimate|||||||2013-01-22|2013-01-24|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD|A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|236|Actual|Rhodes Pharmaceuticals, L.P.||5|||f||||f||||||||||2018-05-31 23:09:36.551499|2018-05-31 23:09:36.551499
NCT01239017|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2015-03-16|2010-11-09|2010-11-11|Estimate|||||||2015-03-16|2015-03-18|Estimate||||March 2015|2015-03-31||||||||Interventional|||A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee|A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Single Dose Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee|Withdrawn||Phase 2|0|Actual|Regeneron Pharmaceuticals||5|||f||||t||||||||||2018-05-31 23:09:36.716009|2018-05-31 23:09:36.716009
NCT01239004|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2012-01-05|2010-11-09|2010-11-11|Estimate|||||||2012-01-05|2012-01-06|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|CERTAIN||Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy|A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia|Completed||Phase 4|140|Actual|Radiant Research||2|||f||||f||||||||||2018-05-31 23:09:36.830502|2018-05-31 23:09:36.830502
NCT01238991|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2014-12-12||2014-12-12|2010-11-09|2010-11-11|Estimate|2014-12-12|2014-12-22|Estimate||||2014-12-12|2014-12-22|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease|A Phase Iia, Multicenter, Treatment Assigned, Open-label, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease|Terminated||Phase 2|53|Actual|Pfizer|Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.|3|||f||||t||||||||||2018-05-31 23:09:37.025143|2018-05-31 23:09:37.025143
NCT01238978|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-02-21|2010-11-09|2010-11-11|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2010||2010-10-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|GLYCEMIA||Phase 4 Study in the Elderly Patients With T2DM|A Multicenter, Prospective, Randomized, Open-label, Parallel Group Study to Investigate the Clinical Benefit on Hypoglycemia Frequency of 24 Weeks Treatment With Galvus Versus Usual Care (Any OAD of Another Class Added to Metformin Within SmPc) in Older Patients With Type 2 Diabetes Insufficiently Controlled by Metformin Monotherapy.|Completed||Phase 4|46|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:09:38.961965|2018-05-31 23:09:38.961965
NCT01238965|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2015-05-26|2010-11-09|2010-11-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy|Phase I Clinical Trial With LBH589 and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU Based Chemotherapy|Terminated||Phase 1|7|Actual|University of Southern California||1||Adverse Events|f||||t||||||||||2018-05-31 23:09:39.078823|2018-05-31 23:09:39.078823
NCT01238952|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-11-12|2010-11-09|2010-11-11|Estimate|||||||2014-11-12|2014-11-13|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|November 2010|Actual|2010-11-30||Interventional|||Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer|A Phase I Study of NK012 in Combination With Carboplatin in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Triple Negative Metastatic Breast Cancer|Completed||Phase 1|4|Actual|Nippon Kayaku Co.,Ltd.|||||f||||||||||||||2018-05-31 23:09:39.186088|2018-05-31 23:09:39.186088
NCT01238939|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-11-12|2010-11-09|2010-11-11|Estimate|||||||2014-11-12|2014-11-13|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer|A Phase I Study of NK012 in Combination With Infusional 5-fluorouracil and Leucovorin in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Colorectal Cancer|Completed||Phase 1|35|Anticipated|Nippon Kayaku Co.,Ltd.||1|||f||||||||||||||2018-05-31 23:09:39.249646|2018-05-31 23:09:39.249646
NCT01238926|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Vitamin B6, B12, Folic Acid and Exercise in Parkinson's Disease|Effects of Vitamin Supplementation and Strength Training in Parkinson's Disease|Unknown status|Active, not recruiting|N/A|40|Anticipated|New York Institute of Technology||4|||f||||f||||||||||2018-05-31 23:09:39.314091|2018-05-31 23:09:39.314091
NCT01238913|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2015-09-29|2010-11-09|2010-11-11|Estimate|||||||2015-09-29|2015-10-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Use of Metal Stents on Benign Esophageal Lesions|Prospective Evaluation of the Clinical Utility of the Endoscopic Placement of Mental Stent for Benign Esophageal Lesions|Withdrawn|||0|Actual|University of Florida|||1|No one met the inclusion/exclusion criteria|f||||f||||||||||2018-05-31 23:09:39.405604|2018-05-31 23:09:39.405604
NCT01238900|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2015-06-29||2015-08-31|2010-11-09|2010-11-11|Estimate|2015-08-31|2015-10-02|Estimate||||2015-08-31|2015-10-02|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Evaluation of the Use of Metal Stents as Part of the Treatment of Benign Biliary Strictures|Prospective Evaluation of the Clinical Utility of Placement of Metal Stent for Benign Biliary Strictures|Completed|||23|Actual|University of Florida|Fifty-six percent of our patients had prior therapy for their benign biliary stricture; therefore they were not treatment naive. High prevalence of CP-related strictures which are known to be more difficult to treat.||1||f||||f||||||||||2018-05-31 23:09:39.456147|2018-05-31 23:09:39.456147
NCT01238887|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2014-03-27|2010-11-09|2010-11-11|Estimate|||||||2014-03-27|2014-03-31|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress|Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress|Terminated||Phase 1/Phase 2|17|Actual|University of Florida||3||Some capsules used in this study were been found to be cracked and leaking.|f||||t||||||||||2018-05-31 23:09:39.626993|2018-05-31 23:09:39.626993
NCT01238874|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2011-03-28|2010-11-09|2010-11-11|Estimate|||||||2011-03-28|2011-03-29|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|LatAmCRT||Latin America Cardiac Resynchronization Therapy Study|Latin America Cardiac Resynchronization Therapy Study|Unknown status|Enrolling by invitation|Phase 4|200|Anticipated|Medtronic Latin America||1|||f||||||||||||||2018-05-31 23:09:39.709806|2018-05-31 23:09:39.709806
NCT01238861|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2016-05-31||2016-09-28|2010-11-09|2010-11-11|Estimate|2016-09-28|2016-11-17|Estimate||||2016-09-28|2016-11-17|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional||The modified intent-to-treat (mITT) population included all randomized participants who received any dose of investigational product.|Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma|A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma|Completed||Phase 2|964|Actual|MedImmune LLC||6|||f||||f||||||||||2018-05-31 23:09:40.888604|2018-05-31 23:09:40.888604
NCT01238848|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2012-07-16||2016-12-20|2010-11-10|2010-11-11|Estimate|2012-07-16|2012-08-17|Estimate||||2016-12-20|2017-02-10|Actual|December 2010||2010-12-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|Hypertonic||Efficacy of Nebulized Hypertonic Saline in the Treatment of Acute Bronchiolitis|A Randomized Controlled Trial to Evaluate Efficacy of Nebulized Hypertonic Saline vs. Normal Saline in the Treatment of Hospitalized Children With Bronchiolitis|Completed||N/A|82|Actual|Hospital General de Niños Pedro de Elizalde|The initially estimated sample size was not achieved|2|||f||||t||||||||||2018-05-31 23:09:42.843501|2018-05-31 23:09:42.843501
NCT01238835|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-02-07|2010-11-09|2010-11-11|Estimate|||||||2017-02-07|2017-02-09|Estimate|September 2009|Actual|2009-09-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|February 2011|Actual|2011-02-28||Interventional|PREVAIL-TA||Placement of Aortic Balloon Expandable Transcatheter Valves Trial (TransApical)|Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (TransApical)|Completed||N/A|218|Actual|Edwards Lifesciences||1|||f||||t|f|t|f|f||||No||2018-05-31 23:09:43.856417|2018-05-31 23:09:43.856417
NCT01238822|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2011-07-14||2012-04-02|2010-11-10|2010-11-11|Estimate|2012-04-02|2012-04-04|Estimate||||2012-04-02|2012-04-04|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Response Variability in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Response Variability in Children With ADHD|Completed||Phase 4|96|Actual|Children's Hospital Medical Center, Cincinnati||4|||f||||f||||||||||2018-05-31 23:09:44.124086|2018-05-31 23:09:44.124086
NCT01238809|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2011-06-06|2010-11-09|2010-11-11|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France|Gastroprotective Agent Utilization and Compliance in Patients > 60 Years Taking Low-dose Aspirin in France|Withdrawn|||7300|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:09:44.570119|2018-05-31 23:09:44.570119
NCT01238796|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2012-02-06|2010-11-09|2010-11-11|Estimate|||||||2012-02-06|2012-02-08|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin|A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin|Completed||Phase 1|45|Actual|Theravance Biopharma Antibiotics, Inc.||3|||f||||f||||||||||2018-05-31 23:09:44.737532|2018-05-31 23:09:44.737532
NCT01238783|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2011-11-29|2010-11-09|2010-11-11|Estimate|||||||2011-11-29|2011-12-01|Estimate|January 2011||2011-01-31|November 2011|2011-11-30||||December 2011|Anticipated|2011-12-31||Interventional|||Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis||Withdrawn||Phase 2|0|Actual|Alcon Research||4|||f||||f||||||||||2018-05-31 23:09:44.927702|2018-05-31 23:09:44.927702
NCT01238770|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-02-08|2010-11-10|2010-11-11|Estimate|||||||2016-02-08|2016-02-10|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer|A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer|Completed||Phase 1/Phase 2|10|Actual|University Hospital Heidelberg||1|||f||||t||||||||||2018-05-31 23:09:45.085252|2018-05-31 23:09:45.085252
NCT01238757|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-09-12|2010-11-10|2010-11-11|Estimate|||||||2016-09-12|2016-09-14|Estimate|June 2010||2010-06-30|September 2016|2016-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|NavPed-NI||Patient-ventilator Asynchrony During Mechanical Non-Invasive Assisted-ventilation in Pediatric Patients (NavPed-NI)|Patient-ventilator Asynchrony During Mechanical Non-Invasive Assisted-ventilation in Pediatric Patients|Completed||N/A|7|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 23:09:45.204857|2018-05-31 23:09:45.204857
NCT01238744|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|December 2010|Anticipated|2010-12-31|August 2010|Actual|2010-08-31||Interventional|MUCISAT||Flaxseed Mucilage and Satiety|Effect of Flaxseed Mucilage Drinks and Tablets on Satiety and Energy Intake|Unknown status|Active, not recruiting|N/A|45|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 23:09:45.328254|2018-05-31 23:09:45.328254
NCT01238731|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|March 2012|Anticipated|2012-03-31|January 2011|Anticipated|2011-01-31||Observational|SALT||Persistent Pulmonary Artery Hypertension After Valve Replacement|Persistence of Severe Pulmonary Artery Hypertension in Patients After vaLve replacemenT|Unknown status|Not yet recruiting||300|Anticipated|University Hospital, Bonn|||1||f||||f||||||||||2018-05-31 23:09:45.409088|2018-05-31 23:09:45.409088
NCT01238718|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-08-23|2010-11-10|2010-11-11|Estimate|||||||2011-08-23|2011-08-24|Estimate|October 2008||2008-10-31|November 2010|2010-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Use of Lidocaine in Rapid Sequence Induction|Impact of Lidocaine on Anesthetic Depth During Rapid Sequence Induction|Completed||N/A|76|Anticipated|University of Athens||2|||f||||||||||||||2018-05-31 23:09:45.55915|2018-05-31 23:09:45.55915
NCT01238705|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-11-10|2010-11-10|2010-11-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Interventional|||Combined Antihypertensive Therapy and Sexual Dysfunction|Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension|Unknown status|Recruiting|Phase 4|280|Anticipated|LanZhou University||2|||f||||t||||||||||2018-05-31 23:09:45.733927|2018-05-31 23:09:45.733927
NCT01238692|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-10|||2016-12-02|2010-11-10|2010-11-11|Estimate|||||||2016-12-02|2016-12-06|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)|A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma|Active, not recruiting||Phase 2|42|Actual|Jewish General Hospital||2|||f||||t||||||||||2018-05-31 23:09:45.8624|2018-05-31 23:09:45.8624
NCT01238679|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-04-11|2010-11-09|2010-11-10|Estimate|||||||2012-04-11|2012-04-13|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Multiple Dose Tolerance Study For PF-04958242|A Phase I, Randomized, Subject And Investigator-Blind, Sponsor Open, Multiple Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Healthy Adult Volunteers|Terminated||Phase 1|20|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:09:46.166879|2018-05-31 23:09:46.166879
NCT01238666|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2012-03-12|2010-11-09|2010-11-10|Estimate|||||||2012-03-12|2012-03-14|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures|Completed|||27|Actual|Pathfinder Therapeutics|||||f||||t||||||||||2018-05-31 23:09:46.314786|2018-05-31 23:09:46.314786
NCT01238653|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2012-08-07|2010-11-09|2010-11-10|Estimate|||||||2012-08-07|2012-08-08|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Terminated|||8|Actual|Pathfinder Therapeutics||||Slow enrollment with limited population for study parameters.|f||||t||||||||||2018-05-31 23:09:46.46203|2018-05-31 23:09:46.46203
NCT01238640|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2011-03-11||2012-07-06|2010-11-09|2010-11-10|Estimate|2011-03-11|2011-04-08|Estimate||||2012-07-06|2012-07-13|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab|Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab. A Study in Healthy Smokers|Completed||N/A|84|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 23:09:46.592018|2018-05-31 23:09:46.592018
NCT01238627|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2012-07-06|2010-11-09|2010-11-10|Estimate|||||||2012-07-06|2012-07-10|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg|Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg - A Study in Healthy Smokers|Completed||N/A|40|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||||2018-05-31 23:09:47.124457|2018-05-31 23:09:47.124457
NCT01238614|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|October 2007||2007-10-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|July 2009|Actual|2009-07-31||Interventional|||Universal Screening for Maternal Depression With the CHICA System|Universal Screening for Maternal Depression With the CHICA System|Completed||N/A|3250|Actual|Indiana University||3|||f||||f||||||||||2018-05-31 23:09:47.238507|2018-05-31 23:09:47.238507
NCT01238601|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-10|2010-11-09|2010-11-10|Estimate|||||||2010-11-10|2010-11-11|Estimate|July 2007||2007-07-31|November 2010|2010-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Upright Magnetic Resonance Imaging (MRI) Study - Breast Implant Shell Geometry and Edge Scalloping|Breast Implant Shell Geometry and Edge Scalloping: A Study Using the Upright MRI Machine|Completed|||18|Actual|Ideal Implant Incorporated|||||f||||||||||||||2018-05-31 23:09:47.419982|2018-05-31 23:09:47.419982
NCT01238588|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2017-05-26||2017-07-03|2010-11-09|2010-11-10|Estimate|2017-05-26|2017-06-21|Actual||||2017-07-03|2017-07-31|Actual|June 10, 2011|Actual|2011-06-10|July 2017|2017-07-31|April 8, 2016|Actual|2016-04-08|April 8, 2016|Actual|2016-04-08||Interventional|||The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan|The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan|Terminated||N/A|24|Actual|Brigham and Women's Hospital|Enrollment was much slower than anticipated due to logistical reasons, study at the direction of funding source terminated early and therefore none of the collected samples were analyzed.|1||The study stopped due to lack of funding.|f||||f||||||||||2018-05-31 23:09:47.487417|2018-05-31 23:09:47.487417
NCT01238575|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2015-04-30||2015-10-30|2010-11-09|2010-11-10|Estimate|2015-10-30|2015-12-07|Estimate||||2015-10-30|2015-12-07|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder|Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder|Completed||Phase 4|62|Actual|Yale University||2|||f||||t||||||||||2018-05-31 23:09:48.093503|2018-05-31 23:09:48.093503
NCT01238562|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2013-01-31|2010-11-08|2010-11-10|Estimate|||||||2013-01-31|2013-02-04|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|Filgrastim||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients|A Randomized, Open-label, Single-dose, Dose-escalation, Self-controlled Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YPEG-Filgrastim in Cancer Patients Receiving Chemotherapy|Completed||Phase 1|30|Actual|Xiamen Amoytop Biotech Co., Ltd.||5|||f||||t||||||||||2018-05-31 23:09:49.157091|2018-05-31 23:09:49.157091
NCT01238549|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-08-17|2010-11-08|2010-11-10|Estimate|||||||2016-08-17|2016-08-18|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Observational|||Extending Veteran Participation in the Validation of the Spinal Cord Injury-Quality Of Life/Computerized Adaptive Test (SCI-QOL/CAT)|Extending Veteran Participation in the Validation of the SCI-QOL/CAT|Active, not recruiting|||400|Anticipated|VA Office of Research and Development|||1||f||||f||||||||Undecided||2018-05-31 23:09:49.366651|2018-05-31 23:09:49.366651
NCT01238536|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2016-05-11||2017-11-15|2010-11-09|2010-11-10|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|April 2011||2011-04-30|November 2017|2017-11-30|September 2015|Actual|2015-09-30|August 2013|Actual|2013-08-31||Interventional|LESS||Lumbar Epidural Steroid Injections for Spinal Stenosis Multicenter Randomized, Controlled Trial (LESS Trial)|Multicenter Randomized Controlled Trial of Epidural Steroid Injections for Spinal Stenosis in Persons 50 and Older|Completed||Phase 4|400|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 23:09:49.509014|2018-05-31 23:09:49.509014
NCT01238523|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-08-14|2010-11-09|2010-11-10|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2007||2007-05-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of Tibial Shaft Fractures in Children|Early Weight-Bearing in the Closed Treatment of Tibial Shaft Fractures in Children|Completed||N/A|81|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:09:49.847994|2018-05-31 23:09:49.847994
NCT01238471|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2014-05-12||2014-06-12|2010-11-09|2010-11-10|Estimate|2014-05-12|2014-06-10|Estimate||||2014-06-12|2014-06-26|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study|Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study.|Completed||Phase 1/Phase 2|20|Actual|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 23:09:50.491902|2018-05-31 23:09:50.491902
NCT01238458|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-09-27|2010-11-09|2010-11-10|Estimate|||||||2012-09-27|2012-09-28|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|November 2011|Actual|2011-11-30||Interventional|[18F]AV-45||Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers|Phase II Study for Amyloid Binding Imaging Study of [18F]AV-45 in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Healthy Volunteers|Unknown status|Enrolling by invitation|Phase 2|150|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 23:09:50.744057|2018-05-31 23:09:50.744057
NCT01238445|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-01-31|2010-11-09|2010-11-10|Estimate|||||||2017-01-31|2017-02-02|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Assessing Response to Albuterol in Bronchiolitis|Assessing Response to Albuterol in Bronchiolitis|Completed|||29|Actual|Connecticut Children's Medical Center|||||f||||f|f|f||||||No||2018-05-31 23:09:50.806412|2018-05-31 23:09:50.806412
NCT01238432|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-01-31|2010-11-09|2010-11-10|Estimate|||||||2017-01-31|2017-02-02|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||The Genetics of Severe Asthma in Children|The Genetics of Severe Asthma in Children|Recruiting|||200|Anticipated|Connecticut Children's Medical Center|||3||f||||f|f|f||||Samples With DNA|"~     saliva and blood~   "|No||2018-05-31 23:09:50.869391|2018-05-31 23:09:50.869391
NCT01238419|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2011-09-02|2010-11-09|2010-11-10|Estimate|||||||2011-09-02|2011-09-05|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Physiotulle vs Urgotul in the Treatment of Leg Ulcer|Clinical Assessment of Physiotulle Dressing Compared to Urgotul Dressing in the Treatment of Leg Ulcer|Completed||Phase 4|188|Anticipated|Coloplast A/S||2|||f||||f||||||||||2018-05-31 23:09:50.954192|2018-05-31 23:09:50.954192
NCT01238406|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-01-10|2010-11-09|2010-11-10|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Overnight MD-Logic|Multicenter, Prospective, Open Label, Cross Over, Pilot Trial to Evaluate Blood Glucose Control Overnight Under Closed-loop Insulin Delivery With MD Logic Artificial Pancreas (MDLAP)System in Patients With Type 1 Diabetes|Completed||N/A|151|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 23:09:51.075437|2018-05-31 23:09:51.075437
NCT01238393|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2016-01-12|2010-11-09|2010-11-10|Estimate|||||||2016-01-12|2016-01-13|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|LERM||Treatment of Epiretinal Membranes With Ranibizumab|A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study|Completed||N/A|11|Actual|Queen's University||1|||f||||t||||||||||2018-05-31 23:09:51.170324|2018-05-31 23:09:51.170324
NCT01238380|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2014-04-02|2010-11-09|2010-11-10|Estimate|||||||2014-04-02|2014-04-04|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|UNITED||Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes|Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes|Completed|||1916|Actual|NIHR Exeter Clinical Research Facility|||1||f||||t||||||Samples With DNA|"~     Samples with DNA and plasma samples.~   "|||2018-05-31 23:09:51.236833|2018-05-31 23:09:51.236833
NCT01238367|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-02-09|2010-11-09|2010-11-10|Estimate|||||||2017-02-09|2017-02-10|Actual|November 2010||2010-11-30|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543|Multi-centre, Open-label, Non-randomised Single Dose Trial Investigating the Pharmacokinetics of N8 in Japanese Subjects With Haemophilia A|Completed||Phase 1|6|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 23:09:51.327682|2018-05-31 23:09:51.327682
NCT01238354|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2016-06-14|2010-11-09|2010-11-10|Estimate|||||||2016-06-14|2016-06-16|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Family & Friends - the Significance of a Significant Other in Treatment|Conservative Treatment of Obesity at Røros Rehabilitation Centre - A Randomised Trial|Completed||N/A|80|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||Undecided||2018-05-31 23:09:51.404014|2018-05-31 23:09:51.404014
NCT01238341|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2015-09-02||2015-10-02|2010-11-09|2010-11-10|Estimate|2015-09-02|2015-10-05|Estimate||||2015-10-02|2015-10-23|Estimate|June 2007||2007-06-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy|Prospective Evaluation of Clinical Utility of Endoscopic Retrograde Cholangiopancreatography (ERCP) With Overtube in Patients With Altered Gastric Anatomy|Completed|||7|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 23:09:51.478686|2018-05-31 23:09:51.478686
NCT01238328|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2012-05-31|2010-11-08|2010-11-10|Estimate|||||||2012-05-31|2012-06-04|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis|Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:09:51.65335|2018-05-31 23:09:51.65335
NCT01238315|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2015-01-13|2010-11-08|2010-11-10|Estimate|||||||2015-01-13|2015-01-15|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis|A Phase Ib Study of the Safety and Preliminary Efficacy of Allogeneic Intracerebral Human Central Nervous System Stem Cell Transplantation in Subjects With Non-Refractory Infantile and Late Infantile Neuronal Ceroid Lipofuscinosis|Withdrawn||Phase 1|0|Actual|StemCells, Inc.||1||Lack of timely patient accrual|f||||t||||||||||2018-05-31 23:09:51.739555|2018-05-31 23:09:51.739555
NCT01238302|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-02-23|2010-11-08|2010-11-10|Estimate|||||||2017-02-23|2017-02-27|Actual|July 2009|Actual|2009-07-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma(PRP) in Large to Massive Tears|Arthroscopic Rotator Cuff Repair With Platelet-Rich Plasma(PRP) in Large to Massive Tears : A Randomized Controlled Trial|Completed||N/A|48|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:09:51.808459|2018-05-31 23:09:51.808459
NCT01238289|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-01-05|2010-11-09|2010-11-10|Estimate|||||||2011-01-05|2011-01-06|Estimate|September 2006||2006-09-30|November 2010|2010-11-30|February 2010|Actual|2010-02-28|March 2009|Actual|2009-03-31||Interventional|||Randomized Trial of Peer Led Education-Project Dulce|Peer-Led Diabetes Education Programs in High Risk Mexican Americans Evaluates Glycemic Control Compared to Standard Approaches: A Project Dulce™ Promotora Randomized Trial|Completed||N/A|207|Actual|Scripps Whittier Diabetes Institute||2|||f||||t||||||||||2018-05-31 23:09:51.881405|2018-05-31 23:09:51.881405
NCT01238276|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-08-14|2010-11-08|2010-11-10|Estimate|||||||2016-08-14|2016-08-16|Estimate|January 2014||2014-01-31|August 2016|2016-08-31||||December 2015|Anticipated|2015-12-31||Expanded Access|DAD||Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion|Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion|Temporarily not available|||||Sonescence, Inc.|||||||||||||||||||2018-05-31 23:09:51.961129|2018-05-31 23:09:51.961129
NCT01238263|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|||Autologous Serum Skin Testing in Patients With Atopic Dermatitis Autologous Serum Skin Testing in Patients With Atopic Dermatitis||Completed|||90|Actual|Yuzuncu Yıl University|||||f||||t||||||||||2018-05-31 23:09:52.034526|2018-05-31 23:09:52.034526
NCT01238250|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2017-12-19|2010-11-09|2010-11-10|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2010||2010-10-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Online Study of Individuals With Genetic Changes and Features of Autism: Simons Variation in Individuals Project (Simons VIP)|Online Study of Individuals With Genetic Changes and Features of Autism: Simons Variation in Individuals Project (Simons VIP Phase 2)|Recruiting|||5000|Anticipated|Simons VIP Connect|||5||f||||f||||||Samples With DNA|"~     Whole blood will be collected for the purposes of DNA analysis and for some participants to~     establish a cell line that can be used for research-related purposes.~   "|Yes|Identifiers will be removed from data which will be stored in a secure database; qualified researchers can request access through the Simons Foundation Autism Research Initiative (www.SFARI.org)|2018-05-31 23:09:52.077354|2018-05-31 23:09:52.077354
NCT01238237|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-01-30|2010-11-09|2010-11-10|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA|Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma|Completed||Phase 1|15|Actual|Northwell Health||1|||f||||f||||||||||2018-05-31 23:09:52.24682|2018-05-31 23:09:52.24682
NCT01238224|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-06-18|2010-11-09|2010-11-10|Estimate|||||||2015-06-18|2015-06-19|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes|The Effect of Selective PDE-5 Inhibition on Capillary Recruitment, Glucose Uptake and Endothelial Function Following a Mixed Meal in Patients With Type 2 Diabetes Patients.|Terminated||Phase 1|22|Actual|Vastra Gotaland Region||2||Durability of study medications could not be guaranteed after the expire date.|f||||f||||||||||2018-05-31 23:09:52.315417|2018-05-31 23:09:52.315417
NCT01238211|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|2014-07-21||2018-05-24|2010-11-09|2010-11-10|Estimate|2014-07-21|2014-08-12|Estimate||||2018-05-24|2018-05-25|Actual|December 14, 2010|Actual|2010-12-14|May 2018|2018-05-31||||July 17, 2015|Actual|2015-07-17||Interventional|||Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|61|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:09:52.445314|2018-05-31 23:09:52.445314
NCT01238185|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2013-08-09|2010-11-09|2010-11-10|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Aspirin Mouthwash in Treating Patients With Oral Leukoplakia|Oral Topical Cyclooxygenase Inhibitor (Aspirin) Mouthwash for Treatment of Oral Dysplasia|Completed||Phase 1|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:09:53.348764|2018-05-31 23:09:53.348764
NCT01238172|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2018-01-23|2010-11-09|2010-11-10|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2011||2011-01-31|January 2018|2018-01-31||||April 2018|Anticipated|2018-04-30||Interventional|||Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance|The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance|Active, not recruiting||Phase 3|464|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 23:09:53.481826|2018-05-31 23:09:53.481826
NCT01238159|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-03-01|2010-11-09|2010-11-10|Estimate|||||||2015-03-01|2015-03-03|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma|Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by MIDLE (Methotrexate, Ifosfamide, Dexamethasone, L-asparaginase, Etoposide) Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma|Completed||Phase 2|30|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 23:09:53.958169|2018-05-31 23:09:53.958169
NCT01238146|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2013-06-05|2010-11-09|2010-11-10|Estimate|||||||2013-06-05|2013-06-06|Estimate|October 2010||2010-10-31|June 2013|2013-06-30||||April 2012|Actual|2012-04-30||Interventional|||Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|National Cancer Institute (NCI)||2||No patients accrued.|f||||t||||||||||2018-05-31 23:09:54.096258|2018-05-31 23:09:54.096258
NCT01238133|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2015-09-03|2010-11-09|2010-11-10|Estimate|||||||2015-09-03|2015-09-04|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|August 2015|Actual|2015-08-31|January 2014|Actual|2014-01-31||Interventional|||Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer|A Phase 1 Study of Neoadjuvant Chemotherapy With the Gamma Secretase Inhibitor RO4929097 in Combination With Paclitaxel and Carboplatin in Patients With Clinical Stage II-III Triple Negative Breast Cancer|Terminated||Phase 1|14|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:09:54.173254|2018-05-31 23:09:54.173254
NCT01149317|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-01-27|2010-06-22|2010-06-23|Estimate|||||||2012-01-27|2012-01-31|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ADDOPT||Acupuncture for Chronic Pain|Acupuncture to Decrease Disparities in Outcomes of Pain Treatment|Completed||N/A|235|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||f||||||||||2018-05-31 23:39:30.9737|2018-05-31 23:39:30.9737
NCT01238120|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2018-04-25|2010-11-09|2010-11-10|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2010||2010-11-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients|A Phase II Study of the Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients Undergoing Chemotherapy|Recruiting||Phase 2|116|Anticipated|University of Rochester||4|||f||||t||||||||No|Overall study results will be presented to participants, faculty and staff at the University of Rochester Medical Center. tudy results will be presented at professional meetings and published|2018-05-31 23:09:54.281908|2018-05-31 23:09:54.281908
NCT01238107|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2014-09-09|2010-11-09|2010-11-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Clinical Study With MT-102 in Subjects With Cancer Cachexia|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate Doses of MT-102 in Subjects With Cachexia Related to Stage III and IV Non-small Cell Lung Cancer and Colorectal Cancer|Completed||Phase 2|87|Actual|PsiOxus Therapeutics Ltd||3|||f||||t||||||||||2018-05-31 23:09:54.36149|2018-05-31 23:09:54.36149
NCT01238094|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2013-06-13|2010-11-09|2010-11-10|Estimate|||||||2013-06-13|2013-06-14|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|May 2014|Anticipated|2014-05-31|November 2013|Anticipated|2013-11-30||Interventional|||Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer|Placebo-controlled, Double-blinded Phase III Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 3|258|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 23:09:54.445403|2018-05-31 23:09:54.445403
NCT01238081|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2012-05-31|2010-11-09|2010-11-10|Estimate|||||||2012-05-31|2012-06-01|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults|The Role of Respiratory Viruses in Exacerbations of Cystic Fibrosis in Adults.|Completed|||100|Actual|Manchester University NHS Foundation Trust|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:09:54.508012|2018-05-31 23:09:54.508012
NCT01238068|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Comparison of the Results of Treatment by Gamma Nail Versus Dynamic Hip Screw for Unstable Intertrochanteric Hip Fractures||Unknown status|Not yet recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-05-31 23:09:54.566559|2018-05-31 23:09:54.566559
NCT01238055|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2013-04-08|2010-11-09|2010-11-10|Estimate|||||||2013-04-08|2013-04-09|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer|Randomized Phase II Trial of Sunitinib and Docetaxel in Advanced Gastric Cancer Patients Who Had Prior Chemotherapy With Fluoropyrimidine and Platinum|Completed||Phase 2|116|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 23:09:55.542722|2018-05-31 23:09:55.542722
NCT01238042|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2014-12-01|2010-11-09|2010-11-10|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2003||2003-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2004|Actual|2004-10-31||Interventional|||Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus|A Pilot Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus|Completed||Phase 1|18|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 23:09:55.613728|2018-05-31 23:09:55.613728
NCT01238029|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-11-20|2010-11-09|2010-11-10|Estimate|||||||2014-11-20|2014-11-21|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CELAVIE||Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer|Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab|Terminated||Phase 1|12|Actual|Sponsor GmbH||1||new methods of treatment, no more patients appilicable for study|f||||t||||||||||2018-05-31 23:09:55.686613|2018-05-31 23:09:55.686613
NCT01238016|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-08-16|2010-11-09|2010-11-10|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional|Pilot||Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - a Pilot Study|Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - a Pilot Study - A One Month Non-controlled Observational Study|Terminated||N/A|16|Actual|UNEEG Medical A/S||1||Replaced by new study|f||||f||||||||||2018-05-31 23:09:55.794302|2018-05-31 23:09:55.794302
NCT01238003|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Clinical Relevance of Anti-Neutrophil Cytoplasm Antibody (ANCA)in Hospitalized Patients||Unknown status|Not yet recruiting||380|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-05-31 23:09:55.853253|2018-05-31 23:09:55.853253
NCT01237990|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2012-01-19|2010-11-08|2010-11-10|Estimate|||||||2012-01-19|2012-01-20|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|Completed|||20|Actual|Pathfinder Therapeutics|||||f||||t||||||||||2018-05-31 23:09:55.918548|2018-05-31 23:09:55.918548
NCT01237977|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2012-04-24|2010-11-08|2010-11-10|Estimate|||||||2012-04-24|2012-04-25|Estimate|November 2009||2009-11-30|April 2012|2012-04-30||||September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines|"Double-blind, Randomized, Active Drug Comparative, Parallel Designed, Multi-center,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® Versus Botox® in the Treatment of Glabellar Lines"|Completed||Phase 3|314|Actual|Medy-Tox||2|||f||||f||||||||||2018-05-31 23:09:55.995477|2018-05-31 23:09:55.995477
NCT01237964|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|March 2011||2011-03-31|November 2010|2010-11-30|August 2011|Anticipated|2011-08-31|April 2011|Anticipated|2011-04-30||Interventional|||Injectable Collagenase For Burns' Associated Contracture|Phase 2 Of Injectable Collagenase (Xiaflex) For Burns' Associated Contracture|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 23:09:56.187599|2018-05-31 23:09:56.187599
NCT01237756|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|September 2008||2008-09-30|June 2008|2008-06-30|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Electrical Impedance Tomography for Endotracheal Tube Placement|Electrical Impedance Tomography for Endotracheal Tube Placement in Pediatric Patients|Completed||N/A|18|Actual|University Hospital Freiburg||1|||f||||f||||||||||2018-05-31 23:09:57.733633|2018-05-31 23:09:57.733633
NCT01237951|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-09-22|2010-11-08|2010-11-10|Estimate|||||||2017-09-22|2017-09-25|Actual|November 8, 2010|Actual|2010-11-08|September 2017|2017-09-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma|High-dose Gemcitabine, Busulfan and Melphalan With Autologous Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma|Completed||Phase 2|75|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:09:56.309257|2018-05-31 23:09:56.309257
NCT01237938|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-04-02|2010-11-09|2010-11-10|Estimate|||||||2014-04-02|2014-04-03|Estimate|March 2006||2006-03-31|April 2014|2014-04-30||||October 2008|Actual|2008-10-31||Interventional|||Effect of a Low Glycemic Index Diet on Breast Density|Pilot Study of the Effect of a Low Glycemic Index Diet on Breast Density (Diet and Breast Health Study )|Terminated||N/A|46|Actual|Roswell Park Cancer Institute||1||test|f||||t||||||||||2018-05-31 23:09:56.414586|2018-05-31 23:09:56.414586
NCT01237925|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-10|Estimate|||||||2010-11-08|2010-11-10|Estimate||||November 2010|2010-11-30||||||||Interventional|||Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Gel) in the Relief of Sunburn Related Symptoms|Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Gel) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Mild to Moderate Sunburn Related Symptoms|Unknown status|Not yet recruiting|Phase 3|124|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||||||||||||2018-05-31 23:09:56.4865|2018-05-31 23:09:56.4865
NCT01237912|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|April 2005||2005-04-30|November 2010|2010-11-30|December 2006|Actual|2006-12-31|May 2006|Actual|2006-05-31||Observational|||European Exposure Study|A European, Multi-centre Study to Determine the Exposure of Adult Smokers and Non-smokers to Cigarette Smoke Constituents|Completed|||1667|Actual|Philip Morris Products S.A.|||||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 23:09:56.571839|2018-05-31 23:09:56.571839
NCT01237899|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-03-15|2010-11-09|2010-11-10|Estimate|||||||2011-03-15|2011-03-17|Estimate|October 2010||2010-10-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance|Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance After Multiple Oral Dosing of LY2623091 in Healthy Volunteers|Completed||Phase 1|32|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 23:09:56.636806|2018-05-31 23:09:56.636806
NCT01237886|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2017-07-05|2010-11-09|2010-11-10|Estimate|||||||2017-07-05|2017-07-07|Actual|November 2009||2009-11-30|July 2017|2017-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|WAVE||Weaning And Variability Evaluation|Weaning And Variability Evaluation|Completed|||660|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 23:09:56.733282|2018-05-31 23:09:56.733282
NCT01237873|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-02-21|2010-11-09|2010-11-10|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2011||2011-01-31|February 2017|2017-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension|A Open-label, 52 Week, Extension to an 8-week, Double Blind, Multicenter, 6-arm, Placebo-controlled, Parallel Group Study to Evaluate the Long Term Safety of SPA100 (Aliskiren/Amlodipine)|Completed||Phase 3|150|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:09:56.811711|2018-05-31 23:09:56.811711
NCT01237860|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-11-14|2010-11-08|2010-11-10|Estimate|||||||2011-11-14|2011-11-16|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|L300Plus||Evaluation of the Safety and Performance of the NESS L300 Plus System|Evaluation of the Safety and Performance of the NESS L300 Plus System|Completed||Phase 3|45|Anticipated|Bioness Inc|||||f||||f||||||||||2018-05-31 23:09:56.8955|2018-05-31 23:09:56.8955
NCT01237847|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|July 2010||2010-07-31|November 2010|2010-11-30|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Interventional|PHONE||A Brief Intervention to Improve Adherence in Teens With Inflammatory Bowel Disease|A Brief Intervention to Improve Adherence in Teens With Inflammatory Bowel Disease|Unknown status|Active, not recruiting|N/A|90|Anticipated|Rosalind Franklin University of Medicine and Science||3|||f||||f||||||||||2018-05-31 23:09:56.99057|2018-05-31 23:09:56.99057
NCT01237834|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2014-10-28|2010-11-09|2010-11-10|Estimate|||||||2014-10-28|2014-10-30|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Physiological Responses in Tobacco Chippers|Physiological Responses in Tobacco Chippers (Non Nicotine-dependent Light Smokers)|Completed|||178|Actual|Oregon Health and Science University|||3||f||||f||||||||||2018-05-31 23:09:57.059393|2018-05-31 23:09:57.059393
NCT01237821|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2014-03-24|2010-11-09|2010-11-10|Estimate|||||||2014-03-24|2014-03-26|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Comparing OTC Acne Treatment to Prescription Regimen|A MULTI-CENTER, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TWO ACNE CREAMS IN SUBJECTS WITH MILD TO MODERATE ACNE VULGARIS|Completed||N/A|80|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 23:09:57.115329|2018-05-31 23:09:57.115329
NCT01237808|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2018-02-27|2010-11-09|2010-11-10|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2011||2011-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation|Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation|Active, not recruiting||Phase 3|144|Actual|University of Ulm||2|||f||||t||||||||||2018-05-31 23:09:57.200272|2018-05-31 23:09:57.200272
NCT01237795|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2014-07-24|2010-11-09|2010-11-10|Estimate|||||||2014-07-24|2014-07-28|Estimate|February 2008||2008-02-29|July 2014|2014-07-31|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Experimental Denture Pastes|A Randomized Trial of Experimental Dentifrices for Cleaning Dentures|Completed||N/A|36|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 23:09:57.441915|2018-05-31 23:09:57.441915
NCT01237782|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2014-07-24|2010-11-09|2010-11-10|Estimate|||||||2014-07-24|2014-07-28|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy of a Propolis-based Denture Cleanser|Efficacy of a Propolis Solution for Cleaning Complete Dentures: a Randomized Crossover Trial|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:09:57.526022|2018-05-31 23:09:57.526022
NCT01237769|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2011-08-17|2010-11-09|2010-11-10|Estimate|||||||2011-08-17|2011-08-18|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome|Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Ioannina||2|||f||||f||||||||||2018-05-31 23:09:57.618096|2018-05-31 23:09:57.618096
NCT01237743|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2011-03-14|2010-11-09|2010-11-10|Estimate|||||||2011-03-14|2011-03-15|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Microembolic Signals and Serum Markers of Neuronal Damage During Transcatheter Aortic Valve Implantation.|Transcranial Doppler Microembolic Signals and Serum Markers of Neuronal Damage During Transcatheter Aortic Valve Implantation|Completed|||21|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||Samples Without DNA|"~     Serum levels of S-100β Determined by an electrochemoluminescence immunoassay using the~     Modular system and the S100β reagent kit (Roche Diagnostics, Basel, Switzerland).~   "|||2018-05-31 23:09:57.833699|2018-05-31 23:09:57.833699
NCT01237730|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2010-11-09|2010-11-09|2010-11-10|Estimate|||||||2010-11-09|2010-11-10|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|PEG||Tailored Antibiotics Prophylaxis for Percutaneous Endoscopic Gastrostomy|Impact of Oropharyngeal Microorganism Colonization on the Peristomal Infection After Percutaneous Endoscopic Gastrostomy and the Effect of Tailored Antibiotics Prophylaxis|Unknown status|Recruiting|N/A|100|Anticipated|National Cheng Kung University||2|||f||||f||||||||||2018-05-31 23:09:57.917788|2018-05-31 23:09:57.917788
NCT01237717|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-09|||2013-01-21|2010-11-09|2010-11-10|Estimate|||||||2013-01-21|2013-01-23|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Relationship of Urine Sodium Excretion to Central Blood Pressure and Aortic Pulse Wave Velocity|Relationship of Urine Sodium Excretion to Central Blood Pressure and Aortic Pulse Wave Velocity|Completed|||200|Actual|DongGuk University|||2||f||||f||||||Samples With DNA|"~     Serum, Plasma, and DNA sample (whole blood)~   "|||2018-05-31 23:09:58.00891|2018-05-31 23:09:58.00891
NCT01237704|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-02-24|2010-11-09|2010-11-10|Estimate|||||||2013-02-24|2013-02-26|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy|Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy: a Randomised-controlled Trial|Unknown status|Recruiting|N/A|160|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:09:58.110423|2018-05-31 23:09:58.110423
NCT01237691|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2018-04-06|2010-11-08|2010-11-09|Estimate|||||||2018-04-06|2018-04-10|Actual|November 2010|Actual|2010-11-30|April 2018|2018-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||An Evaluation of California's Experiment With HOPE|Phase 1 Study of California's HOPE Experiment|Completed||N/A|105|Anticipated|Pepperdine University||2|||f||||t||||||||||2018-05-31 23:09:58.192575|2018-05-31 23:09:58.192575
NCT01237678|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2016-04-01||2017-12-19|2010-11-08|2010-11-09|Estimate|2017-12-19|2018-01-18|Actual||||2017-12-19|2018-01-18|Actual|November 2010||2010-11-30|December 2017|2017-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer|A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|181|Actual|ImmunoGen, Inc.||2||Study was stopped early due to lack of efficacy signal and safety concerns|f||||t||||||||||2018-05-31 23:09:58.342514|2018-05-31 23:09:58.342514
NCT01237665|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-10-12|2010-11-08|2010-11-09|Estimate|||||||2012-10-12|2012-10-15|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|December 2017|Anticipated|2017-12-31|December 2012|Anticipated|2012-12-31||Interventional|IXOr||IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer|A Phase II Trial of Neoadjuvant IXO Regimen (Irinotecan, Capecitabine [Xeloda], Oxaliplatin) Followed by Combined Modality Capecitabine and Radiation for Locally Resectable Advanced Rectal Cancer|Unknown status|Active, not recruiting|Phase 2|15|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 23:10:00.066784|2018-05-31 23:10:00.066784
NCT01237652|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|November 2006||2006-11-30|November 2010|2010-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|PROMISE||Perioperative Myocardial Ischemia in Isolated Systolic Hypertension|Perioperative Myocardial Ischemia in Isolated Systolic Hypertension (PROMISE)|Completed|||312|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-05-31 23:10:00.255145|2018-05-31 23:10:00.255145
NCT01237639|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2016-10-11|2010-11-08|2010-11-09|Estimate|||||||2016-10-11|2016-10-12|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|TRIST||Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation|Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation: The TRIST Study|Completed||Phase 3|300|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 23:10:00.359575|2018-05-31 23:10:00.359575
NCT01237626|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-04-03|2010-11-08|2010-11-09|Estimate|||||||2017-04-03|2017-04-05|Actual|October 2008||2008-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CANDRIVE||CIHR Team in Driving in Older Persons|The CIHR Team in Driving in Older Persons (Candrive II) Research Program|Enrolling by invitation|||932|Actual|Ottawa Hospital Research Institute|||||f||||t||||||||||2018-05-31 23:10:00.484941|2018-05-31 23:10:00.484941
NCT01237613|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2015-05-08||2015-06-29|2010-11-08|2010-11-09|Estimate|2015-05-08|2015-05-27|Estimate||||2015-06-29|2015-07-22|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Prospective Study on Artelon® Tissue Reinforcement in Repair of Chronic Ruptures and Re-ruptures of the Achilles Tendon|Prospective Study on Artelon® Tissue Reinforcement in Repair of Chronic Ruptures and Re-ruptures of the Achilles Tendon|Terminated||N/A|4|Actual|Orthopedic Foot and Ankle Center, Ohio|The sample size is small due to the study being terminated early because of sponsor bankrupty,|1||Sponsoring company declared bankrupty|f||||f||||||||||2018-05-31 23:10:00.62453|2018-05-31 23:10:00.62453
NCT01237600|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-12-05|2010-11-08|2010-11-09|Estimate|||||||2011-12-05|2011-12-07|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction|Efficacy of Cultivated Corneal Epithelial Stem Cell for Ocular Surface Reconstruction|Completed||Phase 2/Phase 3|19|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 23:10:00.900057|2018-05-31 23:10:00.900057
NCT01237418|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-11-21|2010-11-08|2010-11-09|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2010||2010-10-31|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Observational|FAST-MI 2010||French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010|French Registry of Acute Coronary Syndrome With or Without ST Elevation 2010|Active, not recruiting|||3700|Anticipated|French Cardiology Society|||1||f||||t||||||Samples With DNA|"~     When normal blood test done at the patient's admission into ISB, an additional quantity of 60~     ml of blood will be drawn up for building a DNAthèque (15 ml) and a serum bank (45 ml) on~     only markers related to atherosclerotic disease~   "|||2018-05-31 23:10:02.47525|2018-05-31 23:10:02.47525
NCT01237587|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2018-01-18|2010-11-08|2010-11-09|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2011||2011-03-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|May 2017|Actual|2017-05-31||Interventional|||A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome|Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome|Completed||Phase 3|184|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:10:00.977289|2018-05-31 23:10:00.977289
NCT01237574|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2017-09-05|2010-11-08|2010-11-09|Estimate|||||||2017-09-05|2017-09-08|Actual|November 1, 2011|Actual|2011-11-01|September 2017|2017-09-30|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Observational|CALMET||Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease|Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease|Active, not recruiting|||527|Actual|University Hospital, Bordeaux|||1||f||||f||||||Samples With DNA|"~     -  serum~        -  plasma (DNA)~   "|||2018-05-31 23:10:01.151085|2018-05-31 23:10:01.151085
NCT01237561|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-03-31|2010-11-08|2010-11-09|Estimate|||||||2017-03-31|2017-04-04|Actual|October 2010|Actual|2010-10-31|March 2017|2017-03-31|October 25, 2013|Actual|2013-10-25|October 25, 2013|Actual|2013-10-25||Interventional|LungAge||Translating The GOLD COPD Guidelines Into Primary Care Practice|Translating The GOLD COPD Guidelines Into Primary Care Practice|Completed||N/A|3593|Actual|Memorial Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 23:10:01.311114|2018-05-31 23:10:01.311114
NCT01237548|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2013-06-10|2010-11-08|2010-11-09|Estimate|||||||2013-06-10|2013-06-11|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|||The Evaluation of the Acute Effect of Water-Pipe Smoking on the Endothelial Function and the Respiratory System||Completed|||62|Actual|Rambam Health Care Campus|||1||f||||t||||||||||2018-05-31 23:10:01.425869|2018-05-31 23:10:01.425869
NCT01237535|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|November 2011||2011-11-30|November 2010|2010-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates|Luteal Phase Support With Progesterone vs Estrogen and Progesterone on Pregnancy Rates in Ovarian Stimulation and Intrauterine Insemination Cycles: a Prospective Randomized Study|Unknown status|Not yet recruiting|Phase 4|400|Anticipated|Rabin Medical Center||3|||f||||f||||||||||2018-05-31 23:10:01.521467|2018-05-31 23:10:01.521467
NCT01237522|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-12-28|2010-11-08|2010-11-09|Estimate|||||||2010-12-28|2010-12-29|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers|A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers.|Completed||Phase 4|50|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 23:10:01.747652|2018-05-31 23:10:01.747652
NCT01237509|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2015-03-19|2010-11-08|2010-11-09|Estimate|||||||2015-03-19|2015-03-20|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Observational|sleep||EEG Changes of type1 Diabetes During Sleep -Insulin Induced Hypoglycemia|Registration of EEG Changes During Sleep Associated With Insulin Induced Hypoglycemia in Type 1 Diabetic|Completed|||10|Actual|UNEEG Medical A/S|||1||f||||f||||||||||2018-05-31 23:10:01.8339|2018-05-31 23:10:01.8339
NCT01237496|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-11-01|2010-11-08|2010-11-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2005||2005-07-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253|Longitudinal Analysis of HBV-specific T Cell Responses in Patients With HBeAg-negative Chronic Hepatitis B (CHB) Treated With Pegylated Interferon Alfa-2a (40 KD) (Pegasys - RO258310). Immunology Sub-study of ML18253|Completed||Phase 3|17|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:10:01.90827|2018-05-31 23:10:01.90827
NCT01237483|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2017-10-25|2010-11-08|2010-11-09|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2010|Actual|2010-10-31|October 2017|2017-10-31|July 5, 2016|Actual|2016-07-05|July 2016|Actual|2016-07-31||Interventional|||Reirradiation and Erbitux in the HNSCC|A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|50|Actual|Groupe Oncologie Radiotherapie Tete et Cou||1|||f||||t||||||||||2018-05-31 23:10:02.075216|2018-05-31 23:10:02.075216
NCT01237470|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|January 2005||2005-01-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|DESLICH||The Desarda and Lichtenstein Techniques in Inguinal Hernia Treatment.|The Desarda and Lichtenstein Techniques in Primary Hernia Treatment in Adult Males: Randomised, Multicenter, Blinded Study.|Terminated||N/A|2009|Actual|Nicolaus Copernicus University||2||protocol completed|f||||t||||||||||2018-05-31 23:10:02.16691|2018-05-31 23:10:02.16691
NCT01237457|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2015-08-03|2010-11-08|2010-11-09|Estimate|||||||2015-08-03|2015-08-05|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms|177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Excel Diagnostics and Nuclear Oncology Center||1|||f||||t||||||||||2018-05-31 23:10:02.26004|2018-05-31 23:10:02.26004
NCT01237444|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2012-06-08|2010-11-08|2010-11-09|Estimate|||||||2012-06-08|2012-06-12|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|GARDEL||Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.|A Phase 3, Randomized, Open Label, Controlled Study of Lopinavir/Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.|Completed||Phase 3|417|Actual|The Huesped Foundation||2|||f||||t||||||||||2018-05-31 23:10:02.343534|2018-05-31 23:10:02.343534
NCT01237431|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-02-22|2010-11-08|2010-11-09|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2009||2009-11-30|August 2009|2009-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|HEP-Reflex||Importance of Liver Innervation for the Osmopressor Response in Humans|Importance of Liver Innervation for the Osmopressor Response in Humans|Completed||N/A|40|Actual|Hannover Medical School||2|||f||||f||||||||||2018-05-31 23:10:02.415983|2018-05-31 23:10:02.415983
NCT01237405|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2012-11-26|2010-11-08|2010-11-09|Estimate|||||||2012-11-26|2012-11-27|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Observational|||A Study of FolateScan in Patients With Knee Osteoarthritis|Study of 99mTc-EC20 Imaging (FolateScan) in Participants With Knee Osteoarthritis|Completed|||25|Actual|Duke University|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, urine, synovial fluid~   "|||2018-05-31 23:10:02.601296|2018-05-31 23:10:02.601296
NCT01237392|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-07-22|2010-11-08|2010-11-09|Estimate|||||||2014-07-22|2014-07-24|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Ultrasonic Wound Debridement vs. Standard Sharp Debridement|Ultrasonic Surgical Wound Debridement vs. Standard Sharp Debridement In the Treatment of Chronic Wounds: A Single Center, Randomized, Parallel, Clinical Outcome Trial|Completed||N/A|75|Actual|Calvary Hospital, Bronx, NY||2|||f||||f||||||||||2018-05-31 23:10:02.774789|2018-05-31 23:10:02.774789
NCT01237379|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2014-12-19|2010-11-05|2010-11-09|Estimate|||||||2014-12-19|2014-12-23|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Peroxisomal Defects and Familial Risk for Bipolar Disorder|Peroxisomal Defects and Familial Risk for Bipolar Disorder|Completed|||80|Actual|University of Cincinnati|||4||f||||f||||||None Retained|"~     Laboratory methods: The gas chromatography procedure used to determine red blood cell fatty~     acid composition. Briefly, total fatty acid composition will be determined. Indices of~     peroxisome function, including (1) plasma very long chain fatty acids concentrations, (2)~     plasma bile acid C27 intermediate concentrations, (3) plasma pipecolic acid concentrations,~     and (4) RBC plasmalogen concentrations, will be determined by liquid chromatography tandem~     mass spectrometry and gas chromatography. Plasma cytokine and C-Reactive Protein~     (CRP)concentrations will be determined. All blood analyses will be performed by a technician~     blinded to diagnostic group identity.~   "|||2018-05-31 23:10:02.938061|2018-05-31 23:10:02.938061
NCT01237366|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2014-10-23|2010-11-05|2010-11-09|Estimate|||||||2014-10-23|2014-10-27|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|January 2013|Actual|2013-01-31||Interventional|STAR||Study Targeting Affect Regulation|A Pilot RCT of Expressive Writing With HIV-Positive Methamphetamine Users|Completed||Phase 1/Phase 2|56|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:10:03.28407|2018-05-31 23:10:03.28407
NCT01237353|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2013-05-14||2013-05-14|2010-11-08|2010-11-09|Estimate|2013-05-14|2013-07-02|Estimate||||2013-05-14|2013-07-02|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers|Pilot Study Evaluating Gastric Re-acidification Using Betaine Hydrochloride in Healthy Volunteers With Pharmacologically Induced Hypochlorhydria|Completed||N/A|6|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:10:03.468336|2018-05-31 23:10:03.468336
NCT01237340|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2012-09-11||2013-08-04|2010-11-08|2010-11-09|Estimate|2012-09-11|2012-10-11|Estimate||||2013-08-04|2013-08-07|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study|A Phase IIIb, Open-label, Single-arm, Multicenter Study to Assess the Immunogenicity of the Recombinant-Human Growth Hormone (r-hGH) Liquid Multidose Formulation (Saizen® Solution for Injection) When Administered to Male and Female Adults With Documented Growth Hormone Deficiency (GHD)|Terminated||Phase 3|59|Actual|EMD Serono||1||"The Sponsor voluntarily terminated this trial because compliance to strict Good Clinical~   Practice (GCP) requirements was not ensured - No safety concerns"|f||||f||||||||||2018-05-31 23:10:03.904|2018-05-31 23:10:03.904
NCT01237327|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2010-12-07||2011-05-03|2010-11-05|2010-11-09|Estimate|2011-02-17|2011-03-14|Estimate||||2011-05-03|2011-05-06|Estimate|November 2001||2001-11-30|May 2011|2011-05-31|December 2009|Actual|2009-12-31|December 2007|Actual|2007-12-31||Interventional|||Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer|Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study|Completed||Phase 3|84|Actual|Pfizer|At the time of study completion in 2007, via protocol amendment participants still on treatment were allowed to continue treatment, being monitored for Serious Adverse Events (SAE) only. The final participant discontinued in 2009.|2|||f||||f||||||||||2018-05-31 23:10:04.488521|2018-05-31 23:10:04.488521
NCT01237314|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2015-11-30|2010-11-08|2010-11-09|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|REACT2||The Impact of Food on Blood Sugar in People With Type 2 Diabetes|Evaluation of the Glycemic Impact of Food in Patients With Type 2 Diabetes Taking Glargine and/or Exenatide|Completed|||46|Actual|HealthPartners Institute|||3||f||||f||||||||||2018-05-31 23:10:05.214717|2018-05-31 23:10:05.214717
NCT01237301|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2013-08-30||2015-11-30|2010-11-05|2010-11-09|Estimate|2013-11-14|2014-01-06|Estimate||||2015-11-30|2015-12-29|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|REACT3||Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes|Comparison of Clinical Decisions and Outcomes Employing a Treat to Target Design for Subjects With Type 2 Diabetes Randomized to Either SMBG or CGM|Completed||N/A|124|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 23:10:05.388899|2018-05-31 23:10:05.388899
NCT01237288|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-07|||2013-09-30|2010-11-08|2010-11-09|Estimate|||||||2013-09-30|2013-10-01|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets|Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets|Completed||Phase 3|16|Actual|Zeria Pharmaceutical||1|||f||||f||||||||||2018-05-31 23:10:05.829973|2018-05-31 23:10:05.829973
NCT01237275|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2015-12-30|2010-11-07|2010-11-09|Estimate|||||||2015-12-30|2015-12-31|Estimate|October 1999||1999-10-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2003|Actual|2003-12-31||Interventional|||Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients|Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients|Unknown status|Active, not recruiting|N/A|300|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 23:10:05.963118|2018-05-31 23:10:05.963118
NCT01237262|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|November 2010||2010-11-30|November 2010|2010-11-30||||November 2010|Actual|2010-11-30||Interventional|ELIDACE||Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy|Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|University of Padova||1|||f||||t||||||||||2018-05-31 23:10:06.053293|2018-05-31 23:10:06.053293
NCT01237249|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-01-16|2010-11-07|2010-11-09|Estimate|||||||2017-01-16|2017-01-18|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|May 2016|Actual|2016-05-31|August 2014|Actual|2014-08-31||Interventional|||Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone|A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone (Rd).|Completed||Phase 2|250|Actual|PETHEMA Foundation||2|||f||||t||||||||||2018-05-31 23:10:06.181303|2018-05-31 23:10:06.181303
NCT01237236|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2018-03-02|2010-11-08|2010-11-09|Estimate|||||||2018-03-02|2018-03-06|Actual|December 21, 2010|Actual|2010-12-21|March 2018|2018-03-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.|A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|156|Actual|Novartis||1|||f||||f||||||||No||2018-05-31 23:10:06.410802|2018-05-31 23:10:06.410802
NCT01237223|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2012-05-11||2012-05-11|2010-11-05|2010-11-09|Estimate|2012-05-11|2012-06-13|Estimate||||2012-05-11|2012-06-13|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension|An 8-week Double-blind, Multicenter, Randomized, 6-arm, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren and Amlodipine) in Patients With Essential Hypertension|Completed||Phase 3|1342|Actual|Novartis||6|||f||||f||||||||||2018-05-31 23:10:06.670137|2018-05-31 23:10:06.670137
NCT01237210|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2018-02-09|2010-11-08|2010-11-09|Estimate|||||||2018-02-09|2018-02-12|Actual|February 2010||2010-02-28|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||7T MRS in Parkinson's Disease|Magnetic Resonance Spectroscopy of Parkinson's Disease at 7 Tesla|Recruiting|||26|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 23:10:07.776701|2018-05-31 23:10:07.776701
NCT01237197|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2013-09-10||2014-09-04|2010-11-08|2010-11-09|Estimate|2014-09-04|2014-09-12|Estimate||||2014-09-04|2014-09-12|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Exenatide in Extreme Pediatric Obesity|Exenatide in Extreme Pediatric Obesity|Completed||Phase 2|26|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 23:10:07.918808|2018-05-31 23:10:07.918808
NCT01237184|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2017-05-30|2010-11-08|2010-11-09|Estimate|||||||2017-05-30|2017-05-31|Actual|September 2010||2010-09-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Initial Stability of Posterior Maxillary Implants With Bicortical Fixation|Comparison of Initial Implant Stability of Posterior Maxillary Implants With Bicortical Fixation to Implants Engaging Only the Alveolar Crest|Active, not recruiting|||45|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||||No||2018-05-31 23:10:08.286012|2018-05-31 23:10:08.286012
NCT01237171|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer|Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC|Unknown status|Recruiting||40|Anticipated|IsoRay Medical, Inc.|||1||f||||f||||||||||2018-05-31 23:10:08.354091|2018-05-31 23:10:08.354091
NCT01237158|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-08-15|2010-11-08|2010-11-09|Estimate|||||||2011-08-15|2011-08-16|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||October 2012|Anticipated|2012-10-31||Observational|SPECGENE||Genetic Association Study Between GAD1 and Reelin Polymorphisms and GABA/Glutamate MRS in Bipolar Disorder Type 1 and Healthy Controls: SPECGENE PROJECT|Genetic Association Study Between GAD1 and Reelin Polymorphisms and GABA/Glutamate MRS in Bipolar Disorder Type 1 and Healthy Controls: SPECGENE PROJECT|Unknown status|Recruiting||140|Anticipated|University of Sao Paulo|||2||f||||t||||||||||2018-05-31 23:10:08.44181|2018-05-31 23:10:08.44181
NCT01237145|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-07|||2018-01-17|2010-11-08|2010-11-09|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2011||2011-09-30|January 2018|2018-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|BIRD||Bronchoalveolar Immune Response Determination|Study to Determine the Immune Response From Broncho-alveolar Cells Against Pigeon Specific Antigens|Completed|||10|Actual|Bossink, A.W.J.|||2||f||||f||||||Samples Without DNA|"~     Cells obtained from Broncho alveolar lavage and blood collection~   "|||2018-05-31 23:10:08.521928|2018-05-31 23:10:08.521928
NCT01237132|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate||||December 2009|2009-12-31||||||||Observational|||East-West Hepatocellular Carcinoma Study Group|EAST-WEST HEPATOCELLULAR CARCINOMA STUDY GROUP|Completed|||||University of Milan|||||f||||f||||||||||2018-05-31 23:10:08.590053|2018-05-31 23:10:08.590053
NCT01237119|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-03-22|2010-11-08|2010-11-09|Estimate|||||||2016-03-22|2016-03-23|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|LEAN||Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis|48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes|Completed||Phase 2|52|Actual|University of Birmingham||2|||f||||t||||||||||2018-05-31 23:10:08.656442|2018-05-31 23:10:08.656442
NCT01237106|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2015-12-01|2010-11-08|2010-11-09|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|November 2012|Actual|2012-11-30|February 2012|Actual|2012-02-29||Interventional|||In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS)|In Vitro Maturation for Polycystic Ovary Syndrome (PCOS)- A Pilot Study|Completed||N/A|10|Actual|University Reproductive Associates||1|||f||||f||||||||||2018-05-31 23:10:08.738418|2018-05-31 23:10:08.738418
NCT01237093|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-06|||2018-05-23|2010-11-06|2010-11-09|Estimate|||||||2018-05-23|2018-05-24|Actual|October 24, 2010||2010-10-24|April 20, 2018|2018-04-20||||||||Observational|||Developing Biomarkers of Dietary Intake|Developing Biomarkers of Dietary Intake|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:10:08.8564|2018-05-31 23:10:08.8564
NCT01237080|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2012-10-29||2013-01-17|2010-11-08|2010-11-09|Estimate|2013-01-17|2013-02-20|Estimate||||2013-01-17|2013-02-20|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Intubation of Morbidly Obese Patients. A Clinical Trial, Comparing Glide Scope ® With Fastrach TM|Intubation of Morbidly Obese Patients. A Randomized Clinical Trial, Comparing GlideScope ® With Fastrach TM.|Completed||N/A|100|Actual|Glostrup University Hospital, Copenhagen|Acta Anaesthesiol Scand 2012; 56: 755–761|2|||f||||f||||||||||2018-05-31 23:10:08.947609|2018-05-31 23:10:08.947609
NCT01237067|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-06|||2018-01-18|2010-11-06|2010-11-09|Estimate|||||||2018-01-18|2018-01-19|Actual|November 15, 2010||2010-11-15|January 16, 2018|2018-01-16|February 3, 2017|Actual|2017-02-03|November 16, 2014|Actual|2014-11-16||Interventional|||Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers|A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers|Completed||Phase 1|77|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 23:10:09.260616|2018-05-31 23:10:09.260616
NCT01237054|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-06|2014-12-18||2017-07-07|2010-11-06|2010-11-09|Estimate|2015-01-08|2015-01-16|Estimate||||2017-07-07|2017-08-14|Actual|October 17, 2010|Actual|2010-10-17|July 2017|2017-07-31|August 9, 2011|Actual|2011-08-09|August 9, 2011|Actual|2011-08-09||Interventional|||Imaging in MGUS, SMM and MM|A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM)|Completed||Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-05-31 23:10:09.376637|2018-05-31 23:10:09.376637
NCT01237041|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-06|||2018-05-16|2010-11-06|2010-11-09|Estimate|||||||2018-05-16|2018-05-17|Actual|January 1, 2011||2011-01-01|December 13, 2017|2017-12-13|December 13, 2017|Actual|2017-12-13|October 17, 2017|Actual|2017-10-17||Interventional|||Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children|Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children|Terminated||Phase 1/Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 23:10:09.765132|2018-05-31 23:10:09.765132
NCT01237028|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-09-05|2010-11-08|2010-11-09|Estimate|||||||2016-09-05|2016-09-07|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers|Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers|Completed||N/A|168|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:10:10.872074|2018-05-31 23:10:10.872074
NCT01237015|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-01-25|2010-11-08|2010-11-09|Estimate|||||||2011-01-25|2011-01-26|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Effect of Nasal Continuous Positive Airway Pressure (CPAP) on Oral Feeding in Human Neonates|Effect of Nasal Continuous Positive Airway Pressure (CPAP) on Sucking, Swallowing and Coordination of Breathing and Swallowing During Oral Feeding in Human Neonates|Unknown status|Recruiting|N/A|10|Anticipated|Université de Sherbrooke|||||f||||t||||||||||2018-05-31 23:10:10.949277|2018-05-31 23:10:10.949277
NCT01237002|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|January 2005||2005-01-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Pringle Time Exceeding 120 Min in Liver Resection|Safety of Intermittent Pringle Maneuver Cumulative Time Exceeding 120 Min in Liver Resection|Completed|||189|Actual|University of Milan|||2||f||||f||||||||||2018-05-31 23:10:11.00965|2018-05-31 23:10:11.00965
NCT01236989|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ARversusNAR||Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC|Anatomical Liver Resection by Means of Ultrasound-guided Vessel Compression Versus Non-anatomical Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|120|Anticipated|University of Milan||2|||f||||t||||||||||2018-05-31 23:10:11.072051|2018-05-31 23:10:11.072051
NCT01236976|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-08-04|2010-11-08|2010-11-09|Estimate|||||||2011-08-04|2011-08-05|Estimate|December 2010||2010-12-31|August 2010|2010-08-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|SCIPA Full-On||SCIPA Full-On :Intensive Exercise Program After Spinal Cord Injury|SCIPA Full-On :Intensive Exercise Program After Spinal Cord Injury|Unknown status|Recruiting|Phase 3|188|Anticipated|University of Melbourne||2|||f||||t||||||||||2018-05-31 23:10:11.168152|2018-05-31 23:10:11.168152
NCT01236963|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-09|2010-11-08|2010-11-09|Estimate|||||||2010-11-09|2010-11-10|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|||Essential Oils Mouthrinse and Dental Floss, Comparison of Efficacy on Interproximal Gingivitis and Dental Plaque Accumulation|Comparison of Efficacy on Interproximal Gingivitis and Dental Plaque Accumulation of an Essential Oils Mouthrinse and Dental Floss.|Completed||N/A|60|Actual|University of Lisbon||2|||f||||f||||||||||2018-05-31 23:10:11.291948|2018-05-31 23:10:11.291948
NCT01236950|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-09|2010-11-08|2010-11-09|Estimate|||||||2010-11-09|2010-11-10|Estimate|April 2007||2007-04-30|July 2010|2010-07-31|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|||Study of an Essential Oil and a Delmopinol Mouthrinse Effect on Dental Plaque Accumulation Index, Gingivitis Index and on Streptococcus Mutans, Lactobacillus, Aerobic and Anaerobic Oral Bacteria Colony Counts.|Study of an Essential Oil and a Delmopinol Mouthrinse Effect on Dental Plaque Accumulation Index, Gingivitis Index and on Streptococcus Mutans, Lactobacillus, Aerobic and Anaerobic Oral Bacteria Colony Counts.|Completed||N/A|90|Actual|University of Lisbon||3|||f||||f||||||||||2018-05-31 23:10:11.374307|2018-05-31 23:10:11.374307
NCT01236937|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Interventional|GENCTBIOPSY||Respiration Gated Laser Guided CT Lung Nodule Biopsy|Respiration Gated Laser Guided CT Lung Nodule Biopsy|Unknown status|Recruiting|N/A|400|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 23:10:11.605511|2018-05-31 23:10:11.605511
NCT01236924|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|January 2011||2011-01-31|November 2010|2010-11-30||||||||Interventional|||Effectiveness of Global Postural Reeducation in Patients With Chronic Symptomatic Lumbar Disc Herniation|Effectiveness of Global Postural Reeducation in Patients With Chronic Symptomatic Lumbar Disc Herniation|Unknown status|Active, not recruiting|Phase 1|||Universidade Gama Filho||1|||f||||t||||||||||2018-05-31 23:10:11.695998|2018-05-31 23:10:11.695998
NCT01236911|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|November 2012|Anticipated|2012-11-30|September 2012|Anticipated|2012-09-30||Observational|||Prognosis Association of Hypocalcemia on Moderate-severe TBI, COHORTE STUDY||Unknown status|Recruiting||20|Anticipated|Universidad Autonoma de San Luis Potosí|||1||f||||f||||||||||2018-05-31 23:10:11.761624|2018-05-31 23:10:11.761624
NCT01236898|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-09-07|2010-11-08|2010-11-09|Estimate|||||||2011-09-07|2011-09-08|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Pharmacokinetic Study on N-acetylneuraminic Acid|Pharmacokinetic Study on N-acetylneuraminic Acid in Patients With Distal Myopathy With Rimmed Vacuoles (DMRV) - Hereditary Inclusion Body Myopathy (hIBM)|Completed||Phase 1|6|Actual|Tohoku University||1|||f||||t||||||||||2018-05-31 23:10:11.849599|2018-05-31 23:10:11.849599
NCT01236885|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2015-04-21|2010-11-05|2010-11-09|Estimate|||||||2015-04-21|2015-04-23|Estimate|December 2012||2012-12-31|April 2015|2015-04-30||||February 2015|Actual|2015-02-28||Interventional|||Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant|Use of a Computer-Guided Glucose Management System for Patients Undergoing Blood and Marrow Transplants (BMT)|Completed||N/A|19|Actual|Fred Hutchinson Cancer Research Center||1|||f||||||||||||||2018-05-31 23:10:11.936272|2018-05-31 23:10:11.936272
NCT01236872|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-08-04|2010-11-08|2010-11-09|Estimate|||||||2011-08-04|2011-08-08|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Acute Effect of Beetroot Juice in Normal and Hypertensive Subjects|The Acute Effect of Beetroot Juice on Circulating Nitrate and Nitrite Levels and Blood Pressure in Normotensives and Hypertensives|Completed||N/A|15|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 23:10:12.048298|2018-05-31 23:10:12.048298
NCT01236859|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2013-10-08|2010-11-08|2010-11-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus|Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus After Orthopedics Surgery|Completed||N/A|180|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 23:10:12.131633|2018-05-31 23:10:12.131633
NCT01236846|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-04-25|2010-11-08|2010-11-09|Estimate|||||||2012-04-25|2012-04-26|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Vitamin D Receptor Polymorphisms and Efficacy of Vitamin D-Fortified Yogurt Drink in Patients With Type 2 Diabetes|Determination of VDR Single Nucleotide Polymorphisms (SNPs ) and Their Rols in Efficacy of Vitamin D-fortified Yogurt Drink on the Metabolic-, Inflammatory - and Oxidative Stress Parameters in Type 2 Diabetic Patients|Completed||N/A|180|Actual|National Nutrition and Food Technology Institute||4|||f||||t||||||||||2018-05-31 23:10:12.216278|2018-05-31 23:10:12.216278
NCT01236833|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-08-02|2010-11-08|2010-11-09|Estimate|||||||2011-08-02|2011-08-04|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|LR||Lactated Ringer's Solution in Neonates With Feeding Intolerance|Enteral Administration of Lactated Ringer's Solution in Neonates With Feeding Intolerance, a Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 23:10:12.294124|2018-05-31 23:10:12.294124
NCT01236820|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|September 2010||2010-09-30|November 2010|2010-11-30||||||||Observational|L5||A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients|L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients|Unknown status|Recruiting||48|Anticipated|China Medical University Hospital|||3||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 23:10:12.368352|2018-05-31 23:10:12.368352
NCT01236807|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-12-26|2010-11-08|2010-11-09|Estimate|||||||2016-12-26|2016-12-28|Estimate|December 2010||2010-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||MR INFORM - MR Perfusion Imaging to Guide Management of Patients With Stable Coronary Artery Disease|MR INFORM - a Randomized Non-inferiority Multicenter Trial Comparing MR Perfusion Imaging and Fractional Flow Reserve (FFR) to Guide Management of Patients With Stable Coronary Artery Disease|Completed||N/A|915|Actual|King's College London||2|||f||||t||||||||||2018-05-31 23:10:12.435752|2018-05-31 23:10:12.435752
NCT01236794|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-01-25|2010-11-05|2010-11-09|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|August 2016|Actual|2016-08-31||Interventional|ELSC||Community-Based Participatory Research to Improve Health and Quality of Life of Latino Youth: Every Little Step Counts|Community-Based Participatory Research to Improve Health and Quality of Life of Latino Youth: Every Little Step Counts|Unknown status|Active, not recruiting|N/A|60|Anticipated|Arizona State University||1|||f||||t||||||||No||2018-05-31 23:10:12.506487|2018-05-31 23:10:12.506487
NCT01236781|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2012-03-13|2010-11-08|2010-11-09|Estimate|||||||2012-03-13|2012-03-14|Estimate|December 2010||2010-12-31|March 2012|2012-03-31||||June 2012|Anticipated|2012-06-30||Interventional|||Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates|Comparison of Full-Field Digital Mammography With Digital Breast Tomosynthesis Image Acquisition in Relation to Screening Call-Back Rate|Unknown status|Active, not recruiting|Phase 2/Phase 3|550|Anticipated|American College of Radiology Imaging Network||2|||f||||t||||||||||2018-05-31 23:10:12.570288|2018-05-31 23:10:12.570288
NCT01236768|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2017-07-20|2012-07-10|2017-08-17|2010-11-05|2010-11-09|Estimate|2017-08-17|2017-09-15|Actual|2013-01-28|2013-01-30|Estimate|2017-08-17|2017-09-15|Actual|October 2010||2010-10-31|August 2017|2017-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|ATI-CL13|Safety Population (number of subjects that received drug)|Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm|An Open-Label, Randomized, Phase 3 Study of the Contraceptive Efficacy and Safety of Agile Transdermal Contraceptive Delivery System in Comparison to an Oral Contraceptive (OC) Containing 150 mcg LNG and 30 mcg EE|Completed||Phase 3|407|Actual|Agile Therapeutics||2|||f||||f||||||||||2018-05-31 23:10:12.774853|2018-05-31 23:10:12.774853
NCT01236755|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2016-02-18|2010-11-08|2010-11-09|Estimate|||||||2016-02-18|2016-02-22|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|DOEE2||Discontinuation of Lens Wear in New Ortho-k Children (DOEE2)|Discontinuation of Orthokeratology on Eyeball Elongation (DOEE) Study. (2) Discontinuation of Lens Wear in New Ortho-k Children|Completed||N/A|90|Actual|The Hong Kong Polytechnic University||1|||f||||f||||||||||2018-05-31 23:10:13.150862|2018-05-31 23:10:13.150862
NCT01236742|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|2017-06-13||2017-11-09|2010-11-08|2010-11-09|Estimate|2017-06-20|2017-11-08|Actual||||2017-11-09|2017-12-18|Actual|July 2010||2010-07-31|November 2017|2017-11-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|DOEE1||Discontinuation of Orthokeratology on Eyeball Elongation in Myopic Children|Discontinuation of Orthokeratology on Eyeball Elongation (DOEE) Study. (1) Discontinuation of Lens Wear in Existing Ortho-k Children|Completed||N/A|53|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 23:10:13.25327|2018-05-31 23:10:13.25327
NCT01236729|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2018-02-27|2010-11-08|2010-11-09|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2009||2009-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2013|Actual|2013-06-30||Observational|||Disability and Self-rated Health Following Primary Knee Replacement|The Effects of Primary Knee Replacement for Osteoarthritis on Disability in Activities of Daily Living and Self-rated Health in Older People|Active, not recruiting|||460|Actual|Coxa, Hospital for Joint Replacement|||1||f||||f||||||||||2018-05-31 23:10:13.595304|2018-05-31 23:10:13.595304
NCT01236222|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2011-08-08|2010-11-05|2010-11-08|Estimate|||||||2011-08-08|2011-08-09|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Health Effects of Commuter Cycling|Health Effects of Commuter Cycling|Completed||N/A|60|Anticipated|University of Southern Denmark||2|||f||||||||||||||2018-05-31 23:10:21.940545|2018-05-31 23:10:21.940545
NCT01236716|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2014-08-04|2010-11-08|2010-11-09|Estimate|||||||2014-08-04|2014-08-06|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|C-TONG1002||Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung|A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung|Completed||Phase 2|126|Actual|Chinese Society of Lung Cancer||2|||f||||t||||||||||2018-05-31 23:10:13.667076|2018-05-31 23:10:13.667076
NCT01236703|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2012-01-03|2010-11-08|2010-11-09|Estimate|||||||2012-01-03|2012-01-05|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Observational|||Hematological Infection Score Compared to the Hospital Standard for Diagnosis of SIRS or Sepsis on ICU|Hematological Infection Profile (ICIS/ICPS) Compared to Actual Best Hospital Practice for Differentiation of SIRS and Sepsis and Management of Antiinfective Therapy in ICU Patients|Completed|||207|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 23:10:13.746136|2018-05-31 23:10:13.746136
NCT01236690|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-06-27|2010-11-08|2010-11-09|Estimate|||||||2011-06-27|2011-06-28|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy|The Clinical Research of the Intermediate and Advanced Hepatoma Treated by Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy|Unknown status|Recruiting|Phase 2|284|Anticipated|Changhai Hospital|||||f||||t||||||||||2018-05-31 23:10:13.815936|2018-05-31 23:10:13.815936
NCT01236677|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-12-13|2010-11-08|2010-11-09|Estimate|||||||2010-12-13|2010-12-14|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing|The Establishment and Improvement of Community Acquired Pneumonia Monitoring and Disposal Network in Beijing|Unknown status|Recruiting||1100|Anticipated|Capital Medical University|||1||f||||t||||||Samples With DNA|"~     sputum,serum,and throat swabs~   "|||2018-05-31 23:10:13.893599|2018-05-31 23:10:13.893599
NCT01236664|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2011-10-11|2010-11-08|2010-11-09|Estimate|||||||2011-10-11|2011-10-12|Estimate|January 2012||2012-01-31|October 2011|2011-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||An Evaluation of the Memory at Work Program|An Evaluation of the Memory at Work Program|Withdrawn||N/A|0|Actual|Baycrest||2||The sponsor is no longer developing this program and therefore has withdrawn the funding.|f||||f||||||||||2018-05-31 23:10:13.963848|2018-05-31 23:10:13.963848
NCT01236651|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-08|||2010-11-08|2010-11-08|2010-11-09|Estimate|||||||2010-11-08|2010-11-09|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|September 2011|Anticipated|2011-09-30|April 2011|Anticipated|2011-04-30||Interventional|||Meperidine Versus Drotaverine Regarding the Effect on the Duration of the First Stage of Labor in Full Term Primigravidae|Comparison Between Meperidine and Drotaverine Regarding the Effect on the Duration of the First Stage of Labor in Full Term Primigravidae|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 23:10:14.031078|2018-05-31 23:10:14.031078
NCT01236638|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05||2014-05-30|2014-07-11|2010-11-05|2010-11-08|Estimate||||2014-05-30|2014-06-17|Estimate|2014-07-11|2014-07-15|Estimate|November 2010||2010-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)|A Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability & Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis|Completed||Phase 2|120|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 23:10:14.09478|2018-05-31 23:10:14.09478
NCT01236625|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2012-11-01|2010-11-05|2010-11-08|Estimate|||||||2012-11-01|2012-11-02|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|LAPAD||The Effect of Adhesiolysis During Elective Abdominal Surgery on Per- and Postoperative Complication, Quality of Life and Socioeconomic Costs|A Prospective Study on the Effect of Adhesiolysis During Elective Laparotomy or Laparoscopy on Per- and Postoperative Complication, Quality of Life and Socioeconomic Costs|Completed|||752|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 23:10:14.164775|2018-05-31 23:10:14.164775
NCT01236612|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2014-01-20|2010-11-05|2010-11-08|Estimate|||||||2014-01-20|2014-01-22|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EHMI9||Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Completed||N/A|25|Actual|Radboud University||4|||f||||t||||||||||2018-05-31 23:10:14.239722|2018-05-31 23:10:14.239722
NCT01236599|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2010-11-05|2010-11-05|2010-11-08|Estimate|||||||2010-11-05|2010-11-09|Estimate|August 2009||2009-08-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Thermoregulation in the Preterm Infant|Comparison of Polyethylene Wrap With and Without Previous Drying in Preterm Infants: A Randomized Clinical Trial.|Completed||N/A|90|Actual|Instituto Mexicano del Seguro Social||3|||f||||t||||||||||2018-05-31 23:10:14.321182|2018-05-31 23:10:14.321182
NCT01236586|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2017-06-30|2010-11-05|2010-11-08|Estimate|||||||2017-06-30|2017-07-02|Actual|October 8, 2010||2010-10-08|April 13, 2011|2011-04-13|April 13, 2011|Actual|2011-04-13|April 13, 2011|Actual|2011-04-13||Interventional|||RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia|A Phase 1/2 Study of RO4929097, An Oral Small Molecule Inhibitor of Gamma-Secretase, in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:10:14.473295|2018-05-31 23:10:14.473295
NCT01236573|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2015-08-20||2015-10-26|2010-11-05|2010-11-08|Estimate|2015-09-24|2015-10-26|Estimate||||2015-10-26|2015-11-26|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes|Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12|Terminated||Phase 1/Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)|Due to the unexpected toxicities, likely attributable to the tumor infiltrating lymphocytes (TIL) transduced with IL-12, and low percentage of durable responses, we decided to close this study.|11||Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.|f||||t||||||||||2018-05-31 23:10:14.601002|2018-05-31 23:10:14.601002
NCT01140087|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2017-08-16|2010-06-07|2010-06-09|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2010||2010-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Face Transplantation|Maxillofacial Composite Tissue Allograft Transplantation: Face Transplant|Recruiting||N/A|5|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 23:42:18.224949|2018-05-31 23:42:18.224949
NCT01236560|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2017-10-11|2010-11-05|2010-11-08|Estimate|||||||2017-10-11|2017-10-12|Actual|November 15, 2010|Actual|2010-11-15|October 2017|2017-10-31|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Interventional|||Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma|A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas|Completed||Phase 2/Phase 3|101|Actual|National Cancer Institute (NCI)||5|||f||||||||||||||2018-05-31 23:10:16.959635|2018-05-31 23:10:16.959635
NCT01236547|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2018-05-24|2010-11-05|2010-11-08|Estimate|||||||2018-05-24|2018-05-25|Actual|October 28, 2010|Actual|2010-10-28|May 2018|2018-05-31||||October 7, 2018|Anticipated|2018-10-07||Interventional|||Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer|A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer|Active, not recruiting||Phase 2|121|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 23:10:17.345096|2018-05-31 23:10:17.345096
NCT01236534|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2013-01-31||2015-11-06|2010-11-05|2010-11-08|Estimate|2015-11-06|2015-12-10|Estimate||||2015-11-06|2015-12-10|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Lubiprostone in Patients With Multiple Sclerosis Associated Constipation|Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation|Completed||Phase 4|21|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 23:10:17.580726|2018-05-31 23:10:17.580726
NCT01236521|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2016-02-16|2010-11-05|2010-11-08|Estimate|||||||2016-02-16|2016-02-18|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CAMEO||Care Management for the Effective Use of Opioids|Care Management for the Effective Use of Opioids (CAMEO)|Completed||N/A|261|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 23:10:18.06447|2018-05-31 23:10:18.06447
NCT01236508|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2017-04-21|2010-11-05|2010-11-08|Estimate|||||||2017-04-21|2017-04-24|Actual|November 2010||2010-11-30|April 2017|2017-04-30|October 27, 2016|Actual|2016-10-27|October 27, 2016|Actual|2016-10-27||Interventional|||Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease|Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease|Terminated||Phase 4|50|Anticipated|Ottawa Heart Institute Research Corporation||1||difficulties recruiting this population for study population|f||||f||||||||||2018-05-31 23:10:18.161939|2018-05-31 23:10:18.161939
NCT01236495|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2012-03-11|2010-11-05|2010-11-08|Estimate|||||||2012-03-11|2012-03-13|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|pain||Comparison for Pethidine Requirement in Patients Received Spinal Morphine 0.2 and 0.3 mg for Post Lobectomy Analgesia|Comparison for Pethidine Requirement in Patients Received Spinal Morphine 0.2 and 0.3 Milligram for Post Lobectomy (Lung) Analgesia|Completed||Phase 4|40|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 23:10:18.237422|2018-05-31 23:10:18.237422
NCT01236482|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2010-11-05|2010-11-05|2010-11-08|Estimate|||||||2010-11-05|2010-11-08|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Oxytocin in Cesarean Delivery|Comparing Oxytocin and Oxytocin-ergometrine Combinations for Increasing Uterine Tone in Cesarean Delivery: a Pharmacokinetic-pharmacodynamic Study.|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 23:10:18.316276|2018-05-31 23:10:18.316276
NCT01236469|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2015-08-17|2010-11-05|2010-11-08|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|February 2012|Actual|2012-02-29|May 2011|Actual|2011-05-31||Observational|SGAV||CryoValve® SG Aortic Human Heart Valve Combination Study|CryoValve® SG Aortic Human Heart Valve Combination Retrospective/Prospective, Multi-Center, Cohort Study|Completed|||50|Actual|CryoLife, Inc.|||1||f||||f||||||||||2018-05-31 23:10:18.409481|2018-05-31 23:10:18.409481
NCT01236456|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2011-08-11|2010-11-05|2010-11-08|Estimate|||||||2011-08-11|2011-08-12|Estimate|October 2003||2003-10-31|August 2011|2011-08-31|November 2006|Anticipated|2006-11-30|||||Interventional|||High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy|A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy|Withdrawn||Phase 2|25|Anticipated|Stony Brook University||||I am relocating to Johns Hopkins Medical Center|f||||||||||||||2018-05-31 23:10:18.493704|2018-05-31 23:10:18.493704
NCT01236443|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-01-10|2010-11-05|2010-11-08|Estimate|||||||2014-01-10|2014-01-13|Estimate|August 2000||2000-08-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|May 2003|Actual|2003-05-31||Interventional|||Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus|A Phase I/II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for the Treatment of High Grade Dysplasia, Carcinoma-in-situ and Early Adenocarcinoma in Barrett's Esophagus|Completed||Phase 1|18|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 23:10:18.616415|2018-05-31 23:10:18.616415
NCT01236430|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2014-12-30|2010-11-05|2010-11-08|Estimate|||||||2014-12-30|2014-12-31|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)|A Study to Evaluate the Definitive Bioequivalence of SCH 900068 With Marketed Products (Protocol No. P07551)|Completed||Phase 1|200|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:10:18.693708|2018-05-31 23:10:18.693708
NCT01236417|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2012-04-12|2010-11-05|2010-11-08|Estimate|||||||2012-04-12|2012-04-13|Estimate|March 2010||2010-03-31|April 2012|2012-04-30||||March 2012|Actual|2012-03-31||Interventional|||Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia|Exercise Intervention in Breast Cancer Patients With Treatment-Induced Arthralgia|Completed||N/A|27|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 23:10:18.775322|2018-05-31 23:10:18.775322
NCT01236404|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05||2013-05-06|2013-05-13|2010-11-05|2010-11-08|Estimate||||2013-05-13|2013-05-21|Estimate|2013-05-13|2013-05-21|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus|Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1/Phase 2|80|Actual|PhaseBio Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 23:10:18.835507|2018-05-31 23:10:18.835507
NCT01236391|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2015-02-12||2015-08-24|2010-11-05|2010-11-08|Estimate|2015-03-04|2015-03-13|Estimate||||2015-08-24|2015-08-28|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PCYC-1104-CA|One hundred fifteen subjects were enrolled and 111 subjects received at least 1 dose of ibrutinib and constitute the all treated population and the safety analysis set.|Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)|Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma|Completed||Phase 2|115|Actual|Pharmacyclics LLC.||1|||f||||f||||||||||2018-05-31 23:10:18.982769|2018-05-31 23:10:18.982769
NCT01236378|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2012-01-30||2012-02-29|2010-11-05|2010-11-08|Estimate|2012-01-30|2012-02-29|Estimate||||2012-02-29|2012-03-01|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients|An Open-Label, Non-Randomized Study To Evaluate The Steady-State Pharmacokinetics Of Sirolimus Tablets In Chinese Patients With Stable Renal Allografts|Completed||Phase 1|24|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:10:19.691217|2018-05-31 23:10:19.691217
NCT01236365|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2014-12-29||2015-05-21|2010-11-05|2010-11-08|Estimate|2015-05-18|2015-05-21|Estimate||||2015-05-21|2015-06-18|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|October 2013|Actual|2013-10-31||Interventional|||Statins in Children With Type 1 Diabetes and Hypercholesterolemia|Statins in Children With Type 1 Diabetes: Effects on Metabolism, Inflammation and Endothelial Function|Completed||Phase 3|42|Actual|Nemours Children's Clinic||2|||f||||t||||||||||2018-05-31 23:10:20.029847|2018-05-31 23:10:20.029847
NCT01236352|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05||2017-03-22|2017-03-22|2010-11-05|2010-11-08|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|April 2011||2011-04-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Multiple Ascending Dose of BMS-911543|A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis|Completed||Phase 1/Phase 2|84|Actual|Bristol-Myers Squibb||12|||f||||f||||||||||2018-05-31 23:10:20.36086|2018-05-31 23:10:20.36086
NCT01236339|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2014-01-31||2014-05-01|2010-11-05|2010-11-08|Estimate|2014-05-01|2014-06-03|Estimate||||2014-05-01|2014-06-03|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Patients who have cirrhosis of the liver with portal hypertension and difficult to treat ascites|Early TIPS for Ascites Study|The GORE® VIATORR® TIPS Endoprosthesis Versus Large-Volume Paracentesis for the Treatment of Ascites in Patients With Portal Hypertension|Terminated||N/A|26|Actual|W.L.Gore & Associates|Early termination due to very low enrollment.No subjects completed 24 month follow-up,sample size too small for adequate statistical analysis.Collected Adverse Events limited to hospitalizations and Liver Disease Complications as defined in protocol.|2||Slow enrollment|f||||t||||||||||2018-05-31 23:10:20.488436|2018-05-31 23:10:20.488436
NCT01236326|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2015-07-29||2015-07-29|2010-11-05|2010-11-08|Estimate|2015-07-29|2015-08-26|Estimate||||2015-07-29|2015-08-26|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Conventional Laparoscopic Versus Laparoendoscopic Single Site Donor Nephrectomy in Living Donor Kidney Transplantation|A Randomized, Prospective, Parallel Group Study of Conventional Laparoscopic Donor Nephrectomy (LDN) Versus Laparoendoscopic Single Site Donor Nephrectomy (LESS-DN) in Living Donor Kidney Transplantation|Completed||N/A|105|Actual|Weill Medical College of Cornell University|Inability to secure complete data on the donor questionnaires (25% of subjects did not return 2-month questionnaire); no validated tool available to assess donor recovery and satisfaction; clinical donor follow-up was suboptimal.|2|||f||||f||||||||||2018-05-31 23:10:20.88621|2018-05-31 23:10:20.88621
NCT01236313|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2016-02-16|2010-11-04|2010-11-08|Estimate|||||||2016-02-16|2016-02-18|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Aortic Wall and Left Ventricular Mechanics: Echocardiographic and Hemodynamic Analysis|Aortic Wall and Left Ventricular Mechanics: Echocardiographic and Hemodynamic Analysis|Terminated|||51|Actual|Weill Medical College of Cornell University|||1|Insufficient recruitment to complete study|f||||f||||||||No|No plan to share IPD|2018-05-31 23:10:21.258882|2018-05-31 23:10:21.258882
NCT01236300|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2015-02-12||2016-05-06|2010-11-05|2010-11-08|Estimate|2015-03-17|2015-03-31|Estimate||||2016-05-06|2016-06-08|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|INSPECT||In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors|In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors|Completed||N/A|66|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 23:10:21.33828|2018-05-31 23:10:21.33828
NCT01236287|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2018-02-26|2010-11-05|2010-11-08|Estimate|||||||2018-02-26|2018-02-28|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Special Access for the Use of Voclosporin for Kidney Transplantation|Special Access for the Use of Voclosporin for Kidney Transplantation|Available|||||Weill Medical College of Cornell University|||||||||||||||||||2018-05-31 23:10:21.488056|2018-05-31 23:10:21.488056
NCT01236274|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2010-11-05|2010-11-05|2010-11-08|Estimate|||||||2010-11-05|2010-11-08|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Risk of Myocardial Infarction in Users of Antipsychotic Agents|The Risk of Myocardial Infarction in Users of Antipsychotic Agents: a CALIBER Study|Unknown status|Active, not recruiting||90000|Anticipated|London School of Hygiene and Tropical Medicine|||3||f||||t||||||||||2018-05-31 23:10:21.540994|2018-05-31 23:10:21.540994
NCT01236261|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2013-04-22|2010-11-05|2010-11-08|Estimate|||||||2013-04-22|2013-04-23|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|CANDIPOP||Prospective Population Study on Candidemia in Spain|Prospective Population Study on Candidemia in Spain (Estudio Poblacional Prospectivo Sobre Candidemia en España)|Completed|||730|Actual|Fundacion SEIMC-GESIDA|||1||f||||t||||||Samples Without DNA|"~     Fungal strains obtained from blood cultures.~   "|||2018-05-31 23:10:21.623115|2018-05-31 23:10:21.623115
NCT01236248|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2017-07-14|2010-11-05|2010-11-08|Estimate|||||||2017-07-14|2017-07-18|Actual|December 2004||2004-12-31|July 2017|2017-07-31|October 4, 2012|Actual|2012-10-04|March 2010|Actual|2010-03-31||Interventional|||Drug Abuse Prevention Among Girls Through a Mother-Daughter Intervention|Drug Abuse Prevention Among Girls Through a Mother-Daughter Intervention|Completed||N/A|916|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 23:10:21.737334|2018-05-31 23:10:21.737334
NCT01236235|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2013-09-04|2010-11-05|2010-11-08|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|REMAIN||Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting|A Non Comparative Observational Study to Describe the Duration and Outcome of Treatment in Therapy naïve HIV Positive Patients Initiated on Atazanavir (ATV)/ Ritonavir (RTV)-Based Highly Active Antiretroviral Therapy (HAART) Regimens|Completed|||525|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 23:10:21.818668|2018-05-31 23:10:21.818668
NCT01236209|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2017-05-05|2010-11-05|2010-11-08|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2009||2009-03-31|May 2017|2017-05-31|January 2013|Actual|2013-01-31|July 2010|Actual|2010-07-31||Interventional|||Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback|Stimulating Self Management in Patients With Fibromyalgia Through Web-based Situational Feedback|Completed||N/A|140|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||t||||||||||2018-05-31 23:10:21.999125|2018-05-31 23:10:21.999125
NCT01236196|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2014-12-05||2014-12-12|2010-11-05|2010-11-08|Estimate|2014-12-12|2014-12-23|Estimate||||2014-12-12|2014-12-23|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||OEF/OIF/OND military veterans with chronic pain|Telephone Cognitive Behavior Therapy for OEF Veterans With Pain|Telephone Cognitive Behavior Therapy for OEF Veterans With Pain|Completed||N/A|41|Actual|VA Office of Research and Development|The fact that this study was conducted in northern California may have posed some threat to external validity when applying these findings to the nationwise VA system.|2|||f||||t||||||||||2018-05-31 23:10:22.101652|2018-05-31 23:10:22.101652
NCT01236183|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2011-07-21|2010-11-04|2010-11-08|Estimate|||||||2011-07-21|2011-07-22|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Evaluation of Learning Curve of Manual Skills in Anesthesia Residents|Evaluation of Learning Curve of Manual Skills in Anesthesia Residents|Completed|||24|Anticipated|Mahidol University|||||f||||f||||||||||2018-05-31 23:10:22.434463|2018-05-31 23:10:22.434463
NCT01236170|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2014-12-03||2015-02-05|2010-11-05|2010-11-08|Estimate|2014-12-17|2014-12-31|Estimate||||2015-02-05|2015-02-25|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||Understanding Quality and Equity in Wheelchairs for Veterans|Understanding Quality and Equity in Wheelchairs for Veterans|Completed|||497|Actual|VA Office of Research and Development|||1||f||||t||||||||||2018-05-31 23:10:22.650533|2018-05-31 23:10:22.650533
NCT01236157|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-11-21|2010-11-05|2010-11-08|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2009||2009-11-30|November 2017|2017-11-30|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Observational|DOLORES||"Monitoring of Nontraumatic Chest Pain Borne by the Department of Emergency Help Medicalized (SAMU)"|"Monitoring of Nontraumatic Chest Pain Borne by the Department of Emergency Help Medicalized (SAMU)"|Completed|||1816|Actual|French Cardiology Society|||1||f||||t||||||||||2018-05-31 23:10:23.013023|2018-05-31 23:10:23.013023
NCT01236144|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2014-06-10|2010-11-05|2010-11-08|Estimate|||||||2014-06-10|2014-06-11|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|AML18 Pilot||A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.|An NCRI Acute Myeloid Leukaemia Working Group Pilot Trial Under the Auspices of the Cardiff Experimental Cancer Medicine Centre to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.|Completed||Phase 1/Phase 2|113|Actual|Cardiff University||3|||f||||t||||||||||2018-05-31 23:10:23.327342|2018-05-31 23:10:23.327342
NCT01236131|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2016-08-15|2010-11-05|2010-11-08|Estimate|||||||2016-08-15|2016-08-17|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||The Role of Novel Organisms in Acute Endometritis|Characterization of Novel Organisms in the Genital Tract of Women With PID and Determination of Their Association With Endometritis.|Completed|||480|Actual|University of Pittsburgh|||1||f||||f||||||Samples With DNA|"~     Endometrial biopsy specimens and isolates may be retained and stored in various registries~     such as:~        1. Human Microbiome Project~        2. J Craig Venture Institute~        3. PathoGene~        4. American Type Culture Collection~        5. CGS MindTouch Wiki hosted on Amazon's Elastic Compute Cloud~          (http://www.amazon.com/gp/browse.html?node-3435361)52 and will utilize MindTouch's~          Amazon Machine Image of their Wiki platform for rapid deployment~   "|||2018-05-31 23:10:23.67018|2018-05-31 23:10:23.67018
NCT01236118|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2016-04-20||2016-04-20|2010-11-04|2010-11-08|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||All enrolled participants.|A Study of LY2439821 in Rheumatoid Arthritis|An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients With Rheumatoid Arthritis on Concomitant Methotrexate|Completed||Phase 1|28|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:10:23.999971|2018-05-31 23:10:23.999971
NCT01236105|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2011-11-17||2011-11-17|2010-11-04|2010-11-08|Estimate|2011-11-17|2011-12-22|Estimate||||2011-11-17|2011-12-22|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject|Evaluation of the Impact of Activated Charcoal and Time of Dose on the Absorption of LY2624803 in Healthy Subjects|Completed||Phase 1|21|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:10:26.120907|2018-05-31 23:10:26.120907
NCT01236092|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2015-04-07|2010-11-05|2010-11-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Low Back Study to Compare Traditional Physical Therapy With Combined Therapy Protocol|Clinical Study Comparing Traditional Physical Therapy and Alternate Therapy in Patients With Lumbar Radiculitis and Radiculopathy Secondary to Neural Compression.|Terminated||N/A|36|Anticipated|Michael Wilson & Associates Health Care Consulting, LLC||||Inadequate patient enrollment|f||||t||||||||||2018-05-31 23:10:27.172047|2018-05-31 23:10:27.172047
NCT01236079|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2016-08-29|2010-11-04|2010-11-08|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|November 2013|Actual|2013-11-30||Interventional|I-TSAR||Cessation Service Use and Effectiveness for Hospitalized Smokers|Inpatient Technology-Supported Assisted Referral|Completed||N/A|900|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 23:10:27.379284|2018-05-31 23:10:27.379284
NCT01236066|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-06-06|2010-11-04|2010-11-08|Estimate|||||||2017-06-06|2017-06-07|Actual|October 2010||2010-10-31|June 2017|2017-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia|A Study on the Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 23:10:27.507192|2018-05-31 23:10:27.507192
NCT01236053|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2011-07-01||2017-06-06|2010-11-04|2010-11-08|Estimate|2011-07-07|2011-08-04|Estimate||||2017-06-06|2017-07-06|Actual|June 2010||2010-06-30|June 2017|2017-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Cancer in Patients With Gabapentin (GPRD)|Risk of Cancer in Patients Exposed to Gabapentin in the GPRD|Completed|||2323608|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:10:27.998619|2018-05-31 23:10:27.998619
NCT01236040|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-05-09|2010-11-04|2010-11-08|Estimate|||||||2017-05-09|2017-05-10|Actual|November 29, 2010|Actual|2010-11-29|May 2017|2017-05-31|August 20, 2012|Actual|2012-08-20|September 6, 2011|Actual|2011-09-06||Interventional|||Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old|Immunogenicity and Safety Study of GSK Biologicals' Cell Culture Derived Pandemic Influenza Vaccines GSK2590066A and GSK2592984A Administered to Healthy Adults 18 - 49 Years Old|Completed||Phase 1|521|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:10:36.182523|2018-05-31 23:10:36.182523
NCT01236027|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-12-15|2010-11-05|2010-11-08|Estimate|||||||2017-12-15|2017-12-19|Actual|November 2010||2010-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Specimen Collection Study for Development and Validation of Laboratory Procedures|Collection of Biological Specimens for Development and Validation of Laboratory Procedures to Support Future Clinical Research Studies|Recruiting|||220|Anticipated|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 23:10:36.288784|2018-05-31 23:10:36.288784
NCT01236014|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-06-06|2010-11-04|2010-11-08|Estimate|||||||2017-06-06|2017-06-07|Actual|August 2009||2009-08-31|June 2017|2017-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Indirect Comparison Between Eltrombopag & Romiplostim|Indirect Comparison of Efficacy of Treatments for Idiopathic Immune Thrombocytopenic Purpura - Review of Platelet Responses and Bleeding Events|Completed|||1|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 23:10:36.357863|2018-05-31 23:10:36.357863
NCT01236001|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|2013-05-13||2013-08-06|2010-11-05|2010-11-08|Estimate|2013-08-06|2013-08-08|Estimate||||2013-08-06|2013-08-08|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||"The Safety Set (SS) consists of all enrolled subjects who received at least one dose of VIMPAT® (before or during the study).~The SS was used to analyze demographic data and baseline characteristics."|Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older|Multi-center, Observational, Drug-utilization Study in Belgium to Evaluate the Use of VIMPAT® in Clinical Practice as Adjunctive Treatment of Partial Onset Epilepsy in Subjects Aged 16 and Older.|Completed|||192|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 23:10:36.429505|2018-05-31 23:10:36.429505
NCT01235988|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-06-06|2010-11-04|2010-11-08|Estimate|||||||2017-06-06|2017-06-07|Actual|August 2009||2009-08-31|June 2017|2017-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Meta-analysis - Eltrombopag|Systematic Review of the Clinical and Cost Effectiveness of Treatments for Idiopathic (Immune) Thrombocytopenic Purpura (ITP): Direct Meta Analysis|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 23:10:37.012611|2018-05-31 23:10:37.012611
NCT01235975|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2017-03-20|2012-07-23|2017-03-20|2010-11-04|2010-11-08|Estimate|2017-03-20|2017-04-28|Actual|2012-07-23|2012-07-31|Estimate|2017-03-20|2017-04-28|Actual|November 2010||2010-11-30|October 2016|2016-10-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years|Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older|Completed||Phase 3|440|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:10:37.119934|2018-05-31 23:10:37.119934
NCT01235962|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14||2017-01-26|2018-03-28|2010-11-04|2010-11-08|Estimate||||2017-01-26|2017-01-27|Estimate|2018-03-28|2018-03-30|Actual|December 1, 2010|Actual|2010-12-01|March 2018|2018-03-31|April 15, 2019|Anticipated|2019-04-15|October 15, 2015|Actual|2015-10-15||Interventional|PROTECT||A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)|A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy|Active, not recruiting||Phase 3|1540|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 23:10:37.684469|2018-05-31 23:10:37.684469
NCT01235949|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04||2013-04-11|2017-04-20|2010-11-04|2010-11-08|Estimate||||2013-04-11|2013-04-18|Estimate|2017-04-20|2017-04-24|Actual|November 12, 2010||2010-11-12|April 2017|2017-04-30|December 8, 2012|Actual|2012-12-08|March 28, 2012|Actual|2012-03-28||Interventional|||Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment|Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines|Completed||Phase 4|850|Actual|GlaxoSmithKline||18|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:10:38.415391|2018-05-31 23:10:38.415391
NCT01235936|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05||2012-09-14|2012-09-27|2010-11-05|2010-11-08|Estimate||||2012-09-27|2012-10-01|Estimate|2012-09-27|2012-10-01|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia|Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4|Completed||Phase 2|10|Actual|Akebia Therapeutics||1|||f||||f||||||||||2018-05-31 23:10:38.640196|2018-05-31 23:10:38.640196
NCT01235923|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2012-11-29||2013-06-19|2010-11-05|2010-11-08|Estimate|2013-06-19|2013-07-29|Estimate||||2013-06-19|2013-07-29|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants|A Randomized, Masked Study of Weekly Erythropoietin Dosing in Preterm Infants|Completed||Phase 2|20|Actual|University of New Mexico|pilot study with only 20 infants evaluated|2|||f||||f||||||||||2018-05-31 23:10:38.727409|2018-05-31 23:10:38.727409
NCT01235572|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2015-02-05|2010-11-04|2010-11-05|Estimate|||||||2015-02-05|2015-02-06|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy|Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML|Completed||Phase 2|200|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 23:10:45.251723|2018-05-31 23:10:45.251723
NCT01235910|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2014-12-10||2017-10-27|2010-11-04|2010-11-08|Estimate|2015-07-21|2015-08-18|Estimate||||2017-10-27|2017-12-04|Actual|May 2011||2011-05-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation|Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation|Terminated||Phase 4|1|Actual|University of Colorado, Denver|The study was stopped due to difficulty finding patients who met the strict inclusion/exclusion criteria. Only one patient was started on study drug.|1||Study was stopped early due to difficulty finding patients who met I/E criteria.|f||||f||||||||||2018-05-31 23:10:39.053687|2018-05-31 23:10:39.053687
NCT01235897|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2013-07-29||2014-03-27|2010-11-04|2010-11-08|Estimate|2013-10-21|2013-11-19|Estimate||||2014-03-27|2014-04-17|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Interventional||all subjects receiving study treatment were included in study analysis|MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies|A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab|Completed||Phase 1|17|Actual|University of California, San Francisco|MTD was defined as a dose resulting in 3 or fewer DLTs in 11 patients, plus a cohort of 4 patients by a modified TPI dose escalation method. Based on interim toxicity data from other studies, study dose did not exceed 135mg weekly.|1|||f||||t||||||||||2018-05-31 23:10:39.220183|2018-05-31 23:10:39.220183
NCT01235884|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2013-02-04|2010-11-05|2010-11-08|Estimate|||||||2013-02-04|2013-02-05|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|October 2011|Actual|2011-10-31||Interventional|||Prevention of the Minor Digestive Disorders by Lactobacillus Reuteri Supplementation|Prevention of the Minor Digestive Disorders by Lactobacillus Reuteri Supplementation.|Completed||N/A|492|Actual|University of Bari||2|||f||||t||||||||||2018-05-31 23:10:39.42817|2018-05-31 23:10:39.42817
NCT01235871|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-04-19|2010-11-05|2010-11-08|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Single and Multiple-Dose Study of SB1578|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB1578 When Administered Orally to Healthy Adult Subjects With One Single-Dose Group Crossing Over to Assess Food Effect|Completed||Phase 1|40|Actual|S*BIO||2|||f||||f||||||||||2018-05-31 23:10:39.501988|2018-05-31 23:10:39.501988
NCT01235858|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2012-04-03|2010-11-05|2010-11-08|Estimate|||||||2012-04-03|2012-04-04|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|EAS||Aseptic Techniques During Epidural Analgesia in the Labor Floor|Responding to the ASRA (American Society of Regional Anesthesia) Challenge - Should Gowning be the Standard of Practice for Epidural Anesthesia: A Randomized Control Trial|Completed||N/A|240|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||t||||||||||2018-05-31 23:10:39.569033|2018-05-31 23:10:39.569033
NCT01235845|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2010-12-02|2010-11-05|2010-11-08|Estimate|||||||2010-12-02|2010-12-03|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|September 2013|Anticipated|2013-09-30|December 2012|Anticipated|2012-12-31||Interventional|||Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma|A Phase I/II Clinical Trial Evaluating DC Activated Cytokine-induced Killer Cell(DCIK) Combined With DC Treatment for Glioma|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Qingdao University||1|||f||||f||||||||||2018-05-31 23:10:39.6484|2018-05-31 23:10:39.6484
NCT01235832|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2015-04-27|2010-11-05|2010-11-08|Estimate|||||||2015-04-27|2015-04-28|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors|The Effect of One Avocado Per Day on Established and Emerging Cardiovascular Disease (CVD) Risk Factors|Completed||N/A|54|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 23:10:39.717579|2018-05-31 23:10:39.717579
NCT01235819|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2016-07-26|2010-11-05|2010-11-08|Estimate|||||||2016-07-26|2016-07-27|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus|Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus|Completed||Phase 4|20|Actual|Command Hospital, India||3|||f||||f||||||||No|Not permitted|2018-05-31 23:10:39.791862|2018-05-31 23:10:39.791862
NCT01235806|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2015-09-29|2010-11-05|2010-11-08|Estimate|||||||2015-09-29|2015-09-30|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|March 2012|Actual|2012-03-31|March 2009|Actual|2009-03-31||Interventional|||Contribution of ESAOTE™ Low Field MRI for Diagnosis of Scaphoid Fractures|Contribution of ESAOTE™ Low Field MRI for Diagnosis of Scaphoid Fractures.|Completed||N/A|36|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 23:10:39.855174|2018-05-31 23:10:39.855174
NCT01235793|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2018-01-11|2010-11-05|2010-11-08|Estimate|||||||2018-01-11|2018-01-16|Actual|October 14, 2010|Actual|2010-10-14|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|DRBEAT||The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma|A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma|Recruiting||Phase 2|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 23:10:39.914236|2018-05-31 23:10:39.914236
NCT01235780|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2010-11-05|2010-11-05|2010-11-08|Estimate|||||||2010-11-05|2010-11-08|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|July 2010|Actual|2010-07-31|||||Observational|||Factors Affecting Corneal Hysteresis in Taiwanese|Factors Affecting Corneal Hysteresis in Taiwanese|Completed|||83|Actual|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-05-31 23:10:39.998388|2018-05-31 23:10:39.998388
NCT01235767|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2016-08-04|2010-11-05|2010-11-08|Estimate|||||||2016-08-04|2016-08-08|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|VACVINA||Animal Source Food Supplement and Pregnancy in Vietnam|Effect of Animal Source Food Supplement Prior to and During Pregnancy on Birth Weight and Prematurity in Rural Vietnam|Completed||N/A|291|Actual|Children's Hospital & Research Center Oakland||3|||f||||t||||||||No||2018-05-31 23:10:40.035661|2018-05-31 23:10:40.035661
NCT01235754|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04||2013-01-04|2013-01-04|2010-11-05|2010-11-08|Estimate||||2013-01-04|2013-01-10|Estimate|2013-01-04|2013-01-10|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)|A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women|Completed||Phase 3|626|Actual|BioSante Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:10:40.214882|2018-05-31 23:10:40.214882
NCT01235741|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2013-08-12||2015-03-26|2010-11-04|2010-11-08|Estimate|2013-11-14|2013-12-09|Estimate||||2015-03-26|2015-04-15|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Baseline for all participants (213) was baseline at enrollment (Day 1 of Lead-in period); baseline for participants who were randomized to treatment before study was terminated was Day 1 of randomization (last measurement before first dose of assigned drug).|A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects|A Randomized, Double-Blind, Placebo-Controled, Multicenter Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects Following A Low‑Calorie Diet Lead-In|Terminated||Phase 2|213|Actual|AstraZeneca||2||"Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro~   assay in 2 participants."|f||||f||||||||||2018-05-31 23:10:40.405654|2018-05-31 23:10:40.405654
NCT01235728|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2014-05-13||2017-03-09|2010-11-04|2010-11-05|Estimate|2014-05-13|2014-06-11|Estimate||||2017-03-09|2017-04-07|Actual|November 2010||2010-11-30|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)|A Double Blind, Active-Comparator-, and Vehicle-Controlled, Multiple-Dose Study to Evaluate the Efficacy and Pharmacokinetics of MK-0873 in Patients With Plaque Psoriasis|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 23:10:40.989382|2018-05-31 23:10:40.989382
NCT01235715|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2013-01-31||2013-08-22|2010-11-04|2010-11-05|Estimate|2013-08-22|2013-10-29|Estimate||||2013-08-22|2013-10-29|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery|The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery|Completed||Phase 4|200|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 23:10:41.247078|2018-05-31 23:10:41.247078
NCT01235702|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|September 2002||2002-09-30|March 2003|2003-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Metro Atlanta Heart Disease Study - II (MAHDS II)|Multiple CVD Risk Reduction in Adult African-Americans: A Pilot Study|Completed||Phase 1|210|Actual|Morehouse School of Medicine|||||f||||f||||||||||2018-05-31 23:10:41.687837|2018-05-31 23:10:41.687837
NCT01235689|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2017-10-30||2017-12-15|2010-11-04|2010-11-05|Estimate|2017-12-05|2017-12-07|Actual||||2017-12-15|2018-01-16|Actual|February 11, 2011|Actual|2011-02-11|December 2017|2017-12-31|January 3, 2017|Actual|2017-01-03|November 3, 2016|Actual|2016-11-03||Interventional|CALM||Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease|An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects With Moderate to Severe Crohn's Disease|Completed||Phase 3|252|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 23:10:41.803978|2018-05-31 23:10:41.803978
NCT01235676|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2013-03-18|2010-11-04|2010-11-05|Estimate|||||||2013-03-18|2013-03-20|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Tissue Composition of Newborn Infants of Obese and Lean Mothers|Is it Possible to Reduce the Number of Macrosomic Infants With Abundant Fat Tissue by Lifestyle Intervention During Pregnancy ?|Completed||N/A|270|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 23:10:42.865829|2018-05-31 23:10:42.865829
NCT01235663|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2015-03-17|2010-11-04|2010-11-05|Estimate|||||||2015-03-17|2015-03-19|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Minimizing the Risk for Obesity During Infancy by Extensive Advisory Service|Does Advisory Support to Prolong the Breast-feeding Period Reduce the Risk for Obesity and Metabolic Dysfunction in Infants of Obese Mothers ?|Completed||N/A|226|Actual|Hvidovre University Hospital||1|||f||||f||||||||||2018-05-31 23:10:42.928689|2018-05-31 23:10:42.928689
NCT01235650|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2012-01-27|2010-11-04|2010-11-05|Estimate|||||||2012-01-27|2012-01-31|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care|Prevalence of Inadvertent Hyperventilation During Intraoperative Anesthetic Care|Completed|||160|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 23:10:42.978212|2018-05-31 23:10:42.978212
NCT01235637|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2012-07-03|2010-11-04|2010-11-05|Estimate|||||||2012-07-03|2012-07-04|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|DOLOREAPEDIA||Alfentanil Versus Sufentanil for Pain in Children During for Tracheal Suction|Efficacy of Alfentanyl Versus Sufentanyl in Children for Pain During Treatment by Tracheal Suction in an Intensive Care Unit.|Completed||Phase 3|40|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 23:10:43.043668|2018-05-31 23:10:43.043668
NCT01235624|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2013-11-05|2010-11-04|2010-11-05|Estimate|||||||2013-11-05|2013-11-06|Estimate|March 2009||2009-03-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes|Autosomal Dominant Retinitis Pigmentosa: Prevalence of Known Genes Identification of New Loci / Genes|Completed||N/A|1161|Actual|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 23:10:43.112686|2018-05-31 23:10:43.112686
NCT01235598|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2013-09-26||2014-02-07|2010-11-04|2010-11-05|Estimate|2013-12-16|2014-02-05|Estimate||||2014-02-07|2014-03-12|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|MARVELOUS|The Baseline characteristics refer to the Safety Set (SS) population. The Safety Population includes all subjects enrolled who received at least 1 injection of study treatment.|Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)|A 16-week Double-blind, Placebo-controlled (for Initial 2 Weeks) Randomized Period, Followed by a 24-week Open-label Extension to Assess Magnetic Resonance Image (MRI) - Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)|Completed||Phase 3|41|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 23:10:43.192106|2018-05-31 23:10:43.192106
NCT01235585|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22||2016-07-08|2016-11-01|2010-11-04|2010-11-05|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)|Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.|Completed||Phase 3|597|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:10:44.909923|2018-05-31 23:10:44.909923
NCT01230008|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|June 2002||2002-06-30|June 2009|2009-06-30|December 2009|Actual|2009-12-31|June 2007|Actual|2007-06-30||Observational|pml||Radiotherapy in Primary Mediastinal Lymphoma|Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP|Completed|||198|Actual|Instituto Mexicano del Seguro Social|||3||f||||f||||||||||2018-05-31 23:12:10.610549|2018-05-31 23:12:10.610549
NCT01235559|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22||2016-07-06|2016-11-01|2010-11-04|2010-11-05|Estimate||||2016-07-06|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)|Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.|Completed||Phase 3|604|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:10:45.3752|2018-05-31 23:10:45.3752
NCT01235546|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2017-03-13||2017-06-29|2010-11-04|2010-11-05|Estimate|2017-06-29|2017-07-28|Actual||||2017-06-29|2017-07-28|Actual|May 2011||2011-05-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|C/SOAP||Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection|Cesarean Section Optimal Antibiotic Prophylaxis Trial|Completed||N/A|2013|Actual|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 23:10:45.643871|2018-05-31 23:10:45.643871
NCT01235533|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Fish Oil Supplementation in Late-life Depression|The Assessment for the Effects of Health Products on Depression and Cognitive Function:Fish Oil in Patients With Late-life Depression|Completed||N/A|89|Actual|Taipei City Psychiatric Center, Taiwan||2|||f||||f||||||||||2018-05-31 23:10:45.965754|2018-05-31 23:10:45.965754
NCT01235520|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-06-01|2010-11-04|2010-11-05|Estimate|||||||2015-06-01|2015-06-02|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)|Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.|Completed||Phase 3|595|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:10:46.15486|2018-05-31 23:10:46.15486
NCT01235507|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2014-10-13||2014-11-03|2010-11-04|2010-11-05|Estimate|2014-10-13|2014-10-20|Estimate||||2014-11-03|2014-11-07|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Intent-to-Treat (ITT) Population: all participants enrolled in the study who completed the baseline visit and received at least 1 dose of study medication.|A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)|Actemra - Local Bosnian Open, Multicentric, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis After Inadequate Response to DMARDs|Completed||Phase 3|71|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:10:46.439126|2018-05-31 23:10:46.439126
NCT01235494|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-05-04|2010-11-04|2010-11-05|Estimate|||||||2017-05-04|2017-05-05|Actual|July 2010|Actual|2010-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Development of New MRI Pulse Sequences for Probing Lung Function in Volunteers With Hyperpolarised 3He Gas|Development of New MRI Pulse Sequences for Probing Lung Function in Volunteers With Hyperpolarised 3He Gas|Recruiting||Phase 1|20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 23:10:46.92956|2018-05-31 23:10:46.92956
NCT01235481|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2015-05-12|2010-11-04|2010-11-05|Estimate|||||||2015-05-12|2015-05-13|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Validation of an Exercise DVD for Maintenance After Pulmonary Rehabilitation.|Validation of an Exercise DVD for Maintenance After 12-week Outpatient Pulmonary Rehabilitation Program: a Randomized Clinical Trial.|Completed||Phase 3|90|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 23:10:46.988422|2018-05-31 23:10:46.988422
NCT01235468|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-12-01|2010-11-04|2010-11-05|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)|Allogenic Transplantation of Ex-vivo Expanded CB Progenitors for Haematological Disorders|Withdrawn||Phase 1|0|Actual|Sheba Medical Center||1||loss of support|f||||f||||||||||2018-05-31 23:10:47.117187|2018-05-31 23:10:47.117187
NCT01235455|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2012-10-30|2010-11-04|2010-11-05|Estimate|||||||2012-10-30|2012-11-01|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|May 2011|Actual|2011-05-31|||||Observational|POR-BetaPlus||Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors|Portuguese BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis (MS) After Conversion to Betaferon by Using Elements of the BetaPlus Program|Completed|||10|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:10:47.265173|2018-05-31 23:10:47.265173
NCT01235442|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2013-05-15||2014-07-18|2010-11-04|2010-11-05|Estimate|2013-08-27|2013-10-31|Estimate||||2014-07-18|2014-07-25|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis|A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|592|Actual|Amgen||2|||f||||f||||||||||2018-05-31 23:10:47.388203|2018-05-31 23:10:47.388203
NCT01235429|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2013-11-12|2010-11-03|2010-11-05|Estimate|||||||2013-11-12|2013-11-14|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Partners in Care Diabetes Self-management Intervention|Specific Aim 3: Partners in Care Randomized Controlled Trial|Completed||N/A|100|Anticipated|University of Hawaii||2|||f||||t||||||||||2018-05-31 23:10:48.584206|2018-05-31 23:10:48.584206
NCT01235416|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2011-01-20|2010-11-04|2010-11-05|Estimate|||||||2011-01-20|2011-01-21|Estimate|September 2005||2005-09-30|January 2011|2011-01-31|February 2010|Actual|2010-02-28|April 2008|Actual|2008-04-30||Interventional|||A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors|A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors|Completed||Phase 1|57|Actual|Amgen||3|||f||||||||||||||2018-05-31 23:10:48.669922|2018-05-31 23:10:48.669922
NCT01233700|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2014-12-02|2010-11-02|2010-11-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Brief Intervention to Prevent Poor Psychosocial Outcomes in Living Donors|Brief Nursing Intervention to Prevent Poor Psychosocial Outcomes in Living Donors|Completed||Phase 2|113|Actual|University of Pittsburgh||3|||f||||f||||||||||2018-05-31 23:11:11.172509|2018-05-31 23:11:11.172509
NCT01235403|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2012-12-18||2018-03-14|2010-11-04|2010-11-05|Estimate|2012-12-18|2013-01-24|Estimate||||2018-03-14|2018-05-21|Actual|June 2010||2010-06-30|March 2018|2018-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SELF||Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure|A Multicenter, Open Label Study to Evaluate the Tolerability, Safety and Efficacy of Lacosamide (200mg - 400mg/Day) as add-on Therapy for Patients With Partial Onset Epilepsy Using a Flexible Dose-escalation Schedule and Individualized Maintenance Doses|Completed||Phase 4|100|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 23:10:48.802572|2018-05-31 23:10:48.802572
NCT01235390|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-11-01|2010-11-03|2010-11-05|Estimate|||||||2013-11-01|2013-11-04|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effects of the Consumption of California Walnuts on Cardiovascular Health|Effects of California Walnuts on Vascular Function and Immune Health in Postmenopausal Women|Completed||Phase 1|36|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 23:10:49.145551|2018-05-31 23:10:49.145551
NCT01235377|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|2014-11-17||2014-11-17|2010-11-04|2010-11-05|Estimate|2014-11-17|2014-11-25|Estimate||||2014-11-17|2014-11-25|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional||patients of the 18 providers|Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study|Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study|Completed||Phase 4|20|Actual|VA Pharmacy Benefits Management Strategic Healthcare Group||2|||f||||f||||||||||2018-05-31 23:10:49.22724|2018-05-31 23:10:49.22724
NCT01235364|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2011-08-10|2010-11-04|2010-11-05|Estimate|||||||2011-08-10|2011-08-11|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Assessment of Pain With Insertion of the Foley Catheter for Induction of Labour||Completed||N/A|42|Actual|Uppsala University Hospital||2|||f||||f||||||||||2018-05-31 23:10:49.462195|2018-05-31 23:10:49.462195
NCT01235351|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-10-04|2010-11-03|2010-11-05|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2010||2010-10-31|October 2011|2011-10-31||||October 2011|Anticipated|2011-10-31||Interventional|ELEVATE-TIMI56||Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56|Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56|Unknown status|Active, not recruiting|Phase 2|275|Anticipated|The TIMI Study Group||4|||f||||t||||||||||2018-05-31 23:10:49.579703|2018-05-31 23:10:49.579703
NCT01235338|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2011-11-04||2013-03-27|2010-11-03|2010-11-05|Estimate|2011-11-04|2011-12-08|Estimate||||2013-03-27|2013-04-04|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers|A Phase 1, Open-label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR, Administered Alone and in Combination in Healthy Adult Subjects|Completed||Phase 1|80|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:10:49.718914|2018-05-31 23:10:49.718914
NCT01235325|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-05|2010-11-04|2010-11-05|Estimate|||||||2010-11-05|2010-11-09|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients|The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease|Completed||Phase 4|70|Actual|University College Cork||2|||f||||t||||||||||2018-05-31 23:10:50.592334|2018-05-31 23:10:50.592334
NCT01235312|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2011-06-21|2010-11-04|2010-11-05|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Microcirculatory Mapping of the Aging Hand and Foot||Completed|||120|Anticipated|Hannover Medical School|||3||f||||||||||||||2018-05-31 23:10:50.660507|2018-05-31 23:10:50.660507
NCT01235299|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2017-02-23|2010-11-04|2010-11-05|Estimate|||||||2017-02-23|2017-02-27|Actual|September 2010||2010-09-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Free Flap Microcirculatory Monitoring Correlates to Free Flap Temperature Assessment|Free Flap Microcirculatory Monitoring Correlates to Free Flap Temperature Assessment|Completed|||54|Actual|Hannover Medical School|||3||f||||f||||||||||2018-05-31 23:10:50.711681|2018-05-31 23:10:50.711681
NCT01235286|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|RIPC||Cutaneous Remote Ischemic Preconditioning in Plastic Surgery|Effects of Remote Ischemic Preconditioning in Cutaneous Microcirculation of Anterolateral Thigh Flaps|Completed||N/A|27|Actual|Hannover Medical School||1|||f||||f||||||||||2018-05-31 23:10:50.757002|2018-05-31 23:10:50.757002
NCT01235273|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2014-02-18|2010-11-04|2010-11-05|Estimate|||||||2014-02-18|2014-02-20|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|TOSCA2||Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study.|Phase 2 Study of Growth Hormone Administration in Patients With Chronic Heart Failure and Low IGF-1 Levels|Suspended||Phase 2|100|Anticipated|Federico II University||2||insufficient enrollment|f||||f||||||||||2018-05-31 23:10:50.811314|2018-05-31 23:10:50.811314
NCT01235260|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2016-07-15|2010-11-04|2010-11-05|Estimate|||||||2016-07-15|2016-07-19|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes|A Study of Cancer Risk Associated With Becaplermin Use in Veteran Diabetes Patients Served by the U.S. Veterans Health Administration|Completed|||||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||2||f||||||||||||||2018-05-31 23:10:50.867547|2018-05-31 23:10:50.867547
NCT01235247|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2011-07-28|2010-11-04|2010-11-05|Estimate|||||||2011-07-28|2011-07-29|Estimate|February 2011||2011-02-28|September 2007|2007-09-30|March 2012|Anticipated|2012-03-31|October 2011|Anticipated|2011-10-31||Interventional|||Decision Support AMPATH|Electronic Medical Records to Improve Patient & Public Health in Rural Kenya|Unknown status|Recruiting|N/A|||Indiana University||1|||f||||f||||||||||2018-05-31 23:10:50.933272|2018-05-31 23:10:50.933272
NCT01235234|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2015-02-22||2015-03-10|2010-11-04|2010-11-05|Estimate|2015-03-10|2015-03-11|Estimate||||2015-03-10|2015-03-11|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Trial of CF101 to Treat Patients With Dry Eye Disease|A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease|Completed||Phase 3|236|Actual|Can-Fite BioPharma||3|||f||||f||||||||||2018-05-31 23:10:51.023063|2018-05-31 23:10:51.023063
NCT01234740|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2018-04-12|2010-11-03|2010-11-04|Estimate|||||||2018-04-12|2018-04-17|Actual|December 2010||2010-12-31|April 2018|2018-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases|BAFETINIB-P1-GBM-01: A Pilot Study Using Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Bafetinib in Patients With Recurrent Brain Tumors|Completed||Phase 1|7|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:10:56.081707|2018-05-31 23:10:56.081707
NCT01235221|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2014-07-03|2010-11-04|2010-11-05|Estimate|||||||2014-07-03|2014-07-04|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.|Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials|Completed||Phase 3|38|Actual|Biogen||1|||f||||f||||||||||2018-05-31 23:10:51.457048|2018-05-31 23:10:51.457048
NCT01235208|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2012-08-14|2010-11-04|2010-11-05|Estimate|||||||2012-08-14|2012-08-15|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||"The Effect of the Treatment Program Dr. Fedon Lindbergs Vektcoach on Body Weight and Composition and Hormonal Profile"|The Effect of a Low Carbohydrate Low Energy Ketogenic Diet Followed by Progressively Increased Intake of Low Glycemic Foods Over 7 Months on Weight and Body Composition and Hormonal Profile|Completed||N/A|44|Actual|Eurodiet Scandinavia AS||1|||f||||f||||||||||2018-05-31 23:10:51.532598|2018-05-31 23:10:51.532598
NCT01235195|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2011-11-21||2012-05-17|2010-11-03|2010-11-05|Estimate|2012-04-10|2012-05-07|Estimate||||2012-05-17|2012-05-23|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioequivalence Study Comparing Sertraline Hydrochloride 50 mg Film-Coated Tablets To Sertraline Hydrochloride 50 mg Hard Capsules Under Fasted Conditions|Completed||Phase 1|30|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:10:51.607011|2018-05-31 23:10:51.607011
NCT01235182|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Observational|||Ultrasound in Acute Dyspnea in the Field|Combination of Lung Ultrasound(a Comet-tail Sign) and N-terminal Pro-brain Natriuretic Paptide in Differentiating Acute Dyspnea in Prehospital Emergency Setting|Completed|||248|Actual|University Clinical Centre, Maribor|||1||f||||f||||||||||2018-05-31 23:10:51.913708|2018-05-31 23:10:51.913708
NCT01235169|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2013-03-21|2010-11-04|2010-11-05|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31||||March 2015|Anticipated|2015-03-31||Interventional|||Evaluation of the Proximal Femoral Nail Antirotation With Cement Augmentation in Osteoporotic Femoral Neck Fractures||Unknown status|Not yet recruiting|Phase 1/Phase 2|||Hadassah Medical Organization||1|||f||||||||||||||2018-05-31 23:10:52.011474|2018-05-31 23:10:52.011474
NCT01235156|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|November 2010||2010-11-30|November 2010|2010-11-30||||||||Observational|||Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions|A Single-dose, Open Labeled, Multicenter Phase IIa Clinical Study on the Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions|Unknown status|Recruiting||36|Anticipated|Jiangsu Furui Pharmaceuticals Co., Ltd|||||f||||t||||||||||2018-05-31 23:10:52.144217|2018-05-31 23:10:52.144217
NCT01235143|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2013-10-08|2010-11-04|2010-11-05|Estimate|||||||2013-10-08|2013-10-09|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Emergence Agitation Between Sevoflurane and Desflurane in Pediatric|Comparison the Incidence of Emergence Agitation Between Sevoflurane and Desflurane After Pediatric Urologic Surgery|Completed||N/A|136|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 23:10:52.212674|2018-05-31 23:10:52.212674
NCT01235130|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2016-05-12|2010-11-04|2010-11-05|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|AFFORD||Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation|Phase 3 A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Long-chain N-3 Polyunsaturated Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation|Completed||Phase 3|337|Actual|Montreal Heart Institute||2|||f||||t||||||||Undecided||2018-05-31 23:10:52.299245|2018-05-31 23:10:52.299245
NCT01235117|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2013-08-23|2010-11-04|2010-11-05|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2010||2010-01-31|November 2010|2010-11-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia|A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML)|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:10:52.374852|2018-05-31 23:10:52.374852
NCT01235104|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|January 2001||2001-01-31|January 2001|2001-01-31|October 2010|Anticipated|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Impact of Total Nephrectomy on Patients With Kidney Stone|Impact of Total Nephrectomy on Patients With Kidney Stone|Unknown status|Active, not recruiting||500|Anticipated|University of Sao Paulo General Hospital|||1||f||||f||||||||||2018-05-31 23:10:52.445704|2018-05-31 23:10:52.445704
NCT01235091|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|August 2000||2000-08-31|November 2010|2010-11-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|WTW||Prevention of HIV and STDs in Drug Using Women|Prevention of HIV and STDs in Drug Using Women|Completed||N/A|501|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 23:10:52.501202|2018-05-31 23:10:52.501202
NCT01235078|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-06-28|2010-11-04|2010-11-05|Estimate|||||||2012-06-28|2012-07-02|Estimate|April 2010||2010-04-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Observation of Intraosseous Vascular Access in the Emergency Department|An Observational Study of Intraosseous Vascular Access Compared to Central Venous Catheters in the Emergency Department|Completed|||105|Actual|Vidacare Corporation|||1||f||||f||||||||||2018-05-31 23:10:52.581549|2018-05-31 23:10:52.581549
NCT01235065|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2017-09-25|2010-11-03|2010-11-05|Estimate|||||||2017-09-25|2017-09-27|Actual|July 2008||2008-07-31|September 2017|2017-09-30|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|||GlideScope Versus Direct Laryngoscope for Emergency Intubation|GlideScope vs. Direct Laryngoscope for Emergency Intubation|Completed||N/A|658|Actual|University of Maryland||2|||f||||t||||||||No|None exists|2018-05-31 23:10:52.667744|2018-05-31 23:10:52.667744
NCT01235052|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2017-08-08|2010-11-04|2010-11-05|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2009||2009-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MISORL||Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer|Prognostic Evaluation of Fluor 18 Labelled FLUROMISONIDAZOLE (18F-FMISO) Positon Emission Tomography-Computed Tomography (PET-CT) in Head and Neck Squamous Cell Carcinomas|Completed||N/A|16|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 23:10:52.766997|2018-05-31 23:10:52.766997
NCT01235039|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02||2015-07-28|2015-07-28|2010-11-03|2010-11-05|Estimate||||2015-07-28|2015-07-29|Estimate|2015-07-28|2015-07-29|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus|A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|43|Actual|Biodel||3|||f||||f||||||||||2018-05-31 23:10:52.857524|2018-05-31 23:10:52.857524
NCT01235026|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-12-16|2010-11-04|2010-11-05|Estimate|||||||2010-12-16|2010-12-17|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|||Synbiotics and Low Grade Inflammation in Obese Subjects|Impact of the Administration of a Synbiotic on Low Grade Inflammation in Obese Subjects|Unknown status|Recruiting|N/A|44|Anticipated|University of Chile||2|||f||||t||||||||||2018-05-31 23:10:52.933755|2018-05-31 23:10:52.933755
NCT01235013|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-18|2010-11-04|2010-11-05|Estimate|||||||2010-11-18|2010-11-19|Estimate||||October 2010|2010-10-31||||||||Interventional|DIS-MVC||Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3|Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 23:10:53.029852|2018-05-31 23:10:53.029852
NCT01235000|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-04|||2010-11-04|2010-11-04|2010-11-05|Estimate|||||||2010-11-04|2010-11-05|Estimate|October 2010||2010-10-31|November 2010|2010-11-30||||||||Observational|TITRE IIB||TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost|TITRE IIB Follow-Up: TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost|Unknown status|Enrolling by invitation||30|Anticipated|British Columbia Centre for Disease Control|||1||f||||f||||||||||2018-05-31 23:10:53.09994|2018-05-31 23:10:53.09994
NCT01234987|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2011-10-27|2010-11-03|2010-11-04|Estimate|||||||2011-10-27|2011-10-28|Estimate||||December 2010|2010-12-31||||||||Observational|||Diagnosis of Cancer Using Breath Samples|Diagnosis of Cancer Using Breath Samples|Completed|||||Technion, Israel Institute of Technology|||3||f||||||||||||||2018-05-31 23:10:53.171872|2018-05-31 23:10:53.171872
NCT01234974|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2013-01-08|2010-11-03|2010-11-04|Estimate|||||||2013-01-08|2013-01-10|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus|Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma|Withdrawn||Phase 2|0|Actual|Milton S. Hershey Medical Center||1||Study never undertaken|f||||t||||||||||2018-05-31 23:10:53.220719|2018-05-31 23:10:53.220719
NCT01234961|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-11-13|2010-11-03|2010-11-04|Estimate|||||||2012-11-13|2012-11-14|Estimate|September 2007||2007-09-30|November 2012|2012-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Outcome Study of the ReDO Intervention for Women With Stress-related Disorders|Outcomes of the Work Rehabilitation Method Redesigning Daily Occupations (ReDO) - a Quasi-experimental Study Among Women With Stress-related Disorders|Completed||N/A|84|Actual|Lund University||2|||f||||f||||||||||2018-05-31 23:10:53.300835|2018-05-31 23:10:53.300835
NCT01234948|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|September 2009|Actual|2009-09-30|January 2009|Actual|2009-01-31||Observational|||Oral Malodour and Periodontal Disease-related Parameters|Oral Malodour and Periodontal Disease-related Parameters. Clinical and Real-time PCR Findings|Completed|||78|Actual|Aristotle University Of Thessaloniki|||3||f||||f||||||Samples With DNA|"~     The tongue coating was collected with repeated strokes under relative pressure, using a~     sterile plastic microbiology loop of 10μl capacity from the terminal sulcus to the apex of~     the tongue. Samples were stored on ice in 1.5ml sterile Eppendorf tubes containing 0.4ml~     purified H2O. After vortex mixing for 30 seconds to evenly disperse the material the samples~     were stored at -70oC until required. The laboratory analysis was performed blind. Once thawed~     the tongue specimen was vortex mixed for 30 seconds and an aliquot was taken for subsequent~     use in the real-time PCR analysis. Lysates of samples were prepared by boiling the aliquot~     for 10 minutes after puncturing the cap with a fine sterile needle to prevent pressure build~     up.~   "|||2018-05-31 23:10:53.375697|2018-05-31 23:10:53.375697
NCT01234935|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2018-01-05|2010-11-03|2010-11-04|Estimate|||||||2018-01-05|2018-01-09|Actual|January 13, 2011|Actual|2011-01-13|January 2018|2018-01-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery|A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma|Completed||Phase 2|8|Actual|Translational Oncology Research International||2|||f||||t||||||||||2018-05-31 23:10:53.455866|2018-05-31 23:10:53.455866
NCT01234922|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2014-12-09||2017-12-21|2010-11-03|2010-11-04|Estimate|2014-12-09|2014-12-15|Estimate||||2017-12-21|2018-01-23|Actual|February 2011||2011-02-28|December 2014|2014-12-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors|A Phase II Study of the Effect of ACE Inhibitors on Pro-Angiogenic Hormones in Cancer Patients With Hypertension|Terminated||Phase 2|6|Actual|Wake Forest University Health Sciences||4||slow accrual|f||||f|t|f||||||||2018-05-31 23:10:53.565504|2018-05-31 23:10:53.565504
NCT01234909|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2015-05-28|2010-11-03|2010-11-04|Estimate|||||||2015-05-28|2015-06-01|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Observational|||Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis|The Atopic Dermatitis Clinic as an Entry Point for Community Outreach in Asthma, Missed Immunizations, and Vitamin D Deficiency|Terminated|||98|Actual|Medical College of Wisconsin|||1|Not meeting enrollment goals.|f||||f||||||||||2018-05-31 23:10:54.112698|2018-05-31 23:10:54.112698
NCT01234896|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-07-06|2010-11-03|2010-11-04|Estimate|||||||2012-07-06|2012-07-10|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products|Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products. A Study in Healthy Smokers.|Completed||N/A|44|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||||2018-05-31 23:10:54.292024|2018-05-31 23:10:54.292024
NCT01234883|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2014-02-28||2018-03-28|2010-11-03|2010-11-04|Estimate|2014-02-28|2014-04-07|Estimate||||2018-03-28|2018-04-26|Actual|June 2011||2011-06-30|March 2018|2018-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||The ITT population was all subjects who were randomized to receive study treatment. Baseline characteristics include data from participants in the ITT population.|Intravenous (IV) Solutions for Dehydration in Children With Gastroenteritis|A Double-Blind, Randomized, Comparative Efficacy and Safety Trial of Intravenous Solutions for the Treatment of Moderate to Severe Dehydration in Children With Acute Gastroenteritis|Terminated||Phase 4|100|Actual|Baxter Healthcare Corporation|Early termination of study due to low enrollment.|2||Insufficient enrollment|f||||f||||||||||2018-05-31 23:10:54.375325|2018-05-31 23:10:54.375325
NCT01234870|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2014-09-02||2014-09-25|2010-11-03|2010-11-04|Estimate|2014-09-25|2014-09-26|Estimate||||2014-09-25|2014-09-26|Estimate|June 2010||2010-06-30|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||All 40 patients were successfully scanned per the imaging protocol and all images collected were of diagnostic quality and successfully processed. Age, gender, race, ethnicity and BMI were collected on all 40 patients and all have been included in the analyses.|Comprehensive Evaluation of Ischemic Heart Disease Using MRI|Comprehensive Evaluation of Ischemic Heart Disease Using MRI|Completed||Phase 2/Phase 3|40|Actual|Northwestern University|The small number of subjects results in reduced statistical power; The cohort was selected from patients at a single medical center, potentially reducing generalizability; Variability in patient behavior during MR scans may affect analyses|1|||f||||t||||||||||2018-05-31 23:10:54.738844|2018-05-31 23:10:54.738844
NCT01234857|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2017-05-29|2010-11-03|2010-11-04|Estimate|||||||2017-05-29|2017-05-31|Actual|September 17, 2010|Actual|2010-09-17|May 2017|2017-05-31|October 15, 2013|Actual|2013-10-15|October 15, 2013|Actual|2013-10-15||Interventional|||A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)|A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients|Completed||Phase 2|115|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-05-31 23:10:54.982236|2018-05-31 23:10:54.982236
NCT01234844|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2011-08-27|2010-11-03|2010-11-04|Estimate|||||||2011-08-27|2011-08-30|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||"The Relationship Between Pet Therapy and Well-being in Geriatric Rehabilitation In-patients"|"The Relationship Between Pet Therapy and Well Being in Geriatric Rehabilitation In-patients"|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 23:10:55.077778|2018-05-31 23:10:55.077778
NCT01234831|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2012-10-02||2017-09-29|2010-11-03|2010-11-04|Estimate|2012-11-01|2012-11-30|Estimate||||2017-09-29|2017-10-31|Actual|December 2010||2010-12-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|September 2011|Actual|2011-09-30||Interventional|||A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients|A Novel Approach to MRSA Screening of Colonized Patients and Impact on Hospital Resource Allocation and Patient Care|Completed||N/A|463|Actual|Massachusetts General Hospital|This study was conducted at a single tertiary academic center and in the absence of any national guidelines, we implemented the local standard of care for discontinuation of CP, the components of which are found in variable combinations nationally.|2|||f||||f||||||||||2018-05-31 23:10:55.186409|2018-05-31 23:10:55.186409
NCT01234818|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-11-08|2010-11-03|2010-11-04|Estimate|||||||2012-11-08|2012-11-12|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|KGOG2006||Management of Endometrial Hyperplasia With a LNG-IUS: Multicenter Study: KGOG2006|Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System:Single Arm, Prospective Multicenter Study: Korean Gynecologic Oncology Group Study (KGOG2006)|Unknown status|Recruiting|Phase 2|80|Anticipated|Korean Gynecologic Oncology Group||1|||f||||f||||||||||2018-05-31 23:10:55.468203|2018-05-31 23:10:55.468203
NCT01234805|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2017-07-27|2010-11-03|2010-11-04|Estimate|||||||2017-07-27|2017-08-01|Actual|December 2010||2010-12-31|September 2012|2012-09-30||||September 2012|Actual|2012-09-30||Interventional|||Yoga Therapy in Treating Patients With Malignant Brain Tumors|Yoga and Brain Cancer: A Feasibility Study|Terminated||N/A|9|Actual|Wake Forest University Health Sciences||1||Slow Accruals|f||||f|f|f||||||||2018-05-31 23:10:55.570301|2018-05-31 23:10:55.570301
NCT01234792|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-07-06|2010-11-03|2010-11-04|Estimate|||||||2012-07-06|2012-07-10|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Single-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.|Single-Dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products - A Study in Healthy Smokers|Completed||N/A|24|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 23:10:55.658902|2018-05-31 23:10:55.658902
NCT01234779|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03||2013-10-07|2016-11-01|2010-11-03|2010-11-04|Estimate||||2013-10-07|2013-10-30|Estimate|2016-11-01|2016-11-02|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia|A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia|Completed||Phase 2|301|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:10:55.761488|2018-05-31 23:10:55.761488
NCT01234766|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2018-04-13||2018-04-13|2010-11-03|2010-11-04|Estimate|2018-04-13|2018-05-14|Actual||||2018-04-13|2018-05-14|Actual|October 2010||2010-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2014|Actual|2014-06-30||Interventional|Fol-BRITe||Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma|A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study)|Active, not recruiting||Phase 2|39|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 23:10:55.90212|2018-05-31 23:10:55.90212
NCT01234753|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Follow up of Adults With Congenitally Malformed Hearts With Focus on Computer-Based Education and Psychosocial Support|Follow up of Adults With Congenitally Malformed Hearts With Focus on Computer-Based Education and Psychosocial Support|Completed||N/A|114|Actual|University Hospital, Linkoeping||1|||f||||f||||||||||2018-05-31 23:10:56.036451|2018-05-31 23:10:56.036451
NCT01231958|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2018-05-01|2010-10-29|2010-11-01|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2004||2004-06-30|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|October 2009|Actual|2009-10-31||Observational|BPRHS||Boston Puerto Rican Health Study|The Boston Puerto Rican Health Study: Center for Population Health and Health Disparities|Completed|||1650|Actual|University of Massachusetts, Lowell|||||f||||f||||||Samples With DNA|"~     blood, urine, saliva~   "|||2018-05-31 23:11:35.695057|2018-05-31 23:11:35.695057
NCT01234727|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2011-07-04|2010-11-03|2010-11-04|Estimate|||||||2011-07-04|2011-07-06|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes|Multicentre Performance Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes Randomised to Multiple Devices|Completed|||501|Actual|Abbott Diabetes Care|||1||f||||f||||||||||2018-05-31 23:10:56.162683|2018-05-31 23:10:56.162683
NCT01234714|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2011-11-11||2012-02-07|2010-11-03|2010-11-04|Estimate|2012-02-07|2012-02-08|Estimate||||2012-02-07|2012-02-08|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Observational|MRsteatosis||Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications|Liver Fat Quantification by Magnetic Resonance Imaging (MRI): A Novel Tool for Prediction of Postoperative Complications After Major Liver Resection?|Completed|||84|Actual|University of Zurich|||1||f||||t||||||||||2018-05-31 23:10:56.222462|2018-05-31 23:10:56.222462
NCT01234701|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-05-25|2010-11-03|2010-11-04|Estimate|||||||2012-05-25|2012-05-28|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|MRevaluation||Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI)|Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI) in Non-Cirrhotic Patients - A Double Blind International Multicenter Study|Completed|||108|Actual|University of Zurich|||1||f||||t||||||||||2018-05-31 23:10:56.416161|2018-05-31 23:10:56.416161
NCT01234688|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects of Aerobic Training in End Stage Renal Disease Patients|Effects of Aerobic Training During Hemodialysis on Exercise Tolerance in End Stage Renal Disease Patients|Completed||N/A|28|Actual|Federal University of Juiz de Fora||2|||f||||t||||||||||2018-05-31 23:10:56.517855|2018-05-31 23:10:56.517855
NCT01234675|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2015-02-05||2015-07-21|2010-11-03|2010-11-04|Estimate|2015-07-21|2015-07-22|Estimate||||2015-07-21|2015-07-22|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia|The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia|Completed||Phase 4|19|Actual|Cleveland Sleep Research Center|A well-established adaptation and re-adaptation to laboratory effects may have compromised our results. Other study biases include biases inherent in the crossover design, and a small sample size.|2|||f||||t||||||||||2018-05-31 23:10:56.59245|2018-05-31 23:10:56.59245
NCT01234662|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-05-31|2010-11-03|2010-11-04|Estimate|||||||2012-05-31|2012-06-01|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|April 2012|Actual|2012-04-30||Interventional|CESAR||Influence of Surgical Regional Anesthesia on Postoperative Pain|Combined Spinal Epidural Anesthesia (CSE) vs Spinal Anesthesia for Elective Cesarean Sections. Influence of Surgical Regional Anesthesia on Postoperative Pain|Unknown status|Active, not recruiting|N/A|171|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 23:10:56.880053|2018-05-31 23:10:56.880053
NCT01234649|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2018-03-21|2010-11-03|2010-11-04|Estimate|||||||2018-03-21|2018-03-22|Actual|August 11, 2011|Actual|2011-08-11|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)|Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)|Active, not recruiting||Phase 3|150|Actual|Woman's||2|||f||||t||||||||No||2018-05-31 23:10:57.844608|2018-05-31 23:10:57.844608
NCT01234636|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-11-12|2010-11-03|2010-11-04|Estimate|||||||2015-11-12|2015-11-13|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CLASS||Conjugated Linoleic Acid Supplementation Study|Effects of cis9,trans11 Conjugated Linoleic Acid on Platelet Function, Markers of Haemostasis and Inflammation on Humans|Completed||N/A|50|Actual|University of Aberdeen||2|||f||||f||||||||||2018-05-31 23:10:57.964198|2018-05-31 23:10:57.964198
NCT01234623|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-05-25|2010-11-03|2010-11-04|Estimate|||||||2011-05-25|2011-05-26|Estimate|February 2010||2010-02-28|April 2011|2011-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Cord Blood Serum in the Treatment of Ocular Surface Diseases|Pilot Phase. Cord Blood Serum in the Treatment of Ocular Surface Diseases|Completed|||30|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||1||f||||t||||||||||2018-05-31 23:10:58.049761|2018-05-31 23:10:58.049761
NCT01234610|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2017-12-18|2010-11-03|2010-11-04|Estimate|||||||2017-12-18|2017-12-20|Actual|January 2010||2010-01-31|December 2017|2017-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Feasibility Study of Exercise Training for Abdominal Aortic Aneurysm Disease|Exercise Therapy for Abdominal Aortic Aneurysm Disease: a Feasibility Study|Completed||N/A|60|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 23:10:58.123385|2018-05-31 23:10:58.123385
NCT01234597|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2016-07-12|2010-11-03|2010-11-04|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SeLan||Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day|A Comparative Study to Evaluate the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 DM Patients Uncontrolled With a Basal Insulin or Premix Once a Day|Completed||Phase 4|219|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:10:58.198612|2018-05-31 23:10:58.198612
NCT01234584|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-12-07|2010-11-03|2010-11-04|Estimate|||||||2010-12-07|2010-12-08|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||June 2011|Anticipated|2011-06-30||Interventional|||Soft and Hard Tissue Changes Around the New Lance® Implants Using Traditional and Switch Platform Abutments||Unknown status|Recruiting|N/A|45|Anticipated|Rambam Health Care Campus||2|||f||||||||||||||2018-05-31 23:10:58.286401|2018-05-31 23:10:58.286401
NCT01234571|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|November 2010||2010-11-30|October 2010|2010-10-31||||||||Observational|||Impact of Hemo-dialysis Therapy on Blood Levels of Treprostenil in End Stage Renal Disease Patients With Pulmonary Hypertension||Unknown status|Not yet recruiting||5|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 23:10:58.353959|2018-05-31 23:10:58.353959
NCT01234558|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2012-09-10|2010-11-03|2010-11-04|Estimate|||||||2012-09-10|2012-09-12|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression|Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder|Completed||Phase 2|115|Actual|Naurex, Inc||4|||f||||f||||||||||2018-05-31 23:10:58.489565|2018-05-31 23:10:58.489565
NCT01234545|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2014-11-13|2010-11-03|2010-11-04|Estimate|||||||2014-11-13|2014-11-14|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors|A Prospective Observational Study on the Home Treatment of Haemarthrosis With rFVIIa (Activated Recombinant Factor VII) in Haemophilia A and B Patients With Inhibitors|Completed|||35|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 23:10:58.591285|2018-05-31 23:10:58.591285
NCT01234532|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2017-10-02|2010-11-03|2010-11-04|Estimate|||||||2017-10-02|2017-10-04|Actual|October 2010||2010-10-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery|GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response|Terminated||Phase 2|5|Actual|University of Maryland||1||low accrual|f||||||||||||||2018-05-31 23:10:58.682176|2018-05-31 23:10:58.682176
NCT01234519|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02||2018-02-20|2018-03-13|2010-11-02|2010-11-04|Estimate||||2018-02-20|2018-02-21|Estimate|2018-03-13|2018-03-15|Actual|November 2010||2010-11-30|March 2013|2013-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy|A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy|Terminated||Phase 1/Phase 2|12|Actual|AEterna Zentaris||5||Poor recruitment|f||||t||||||||||2018-05-31 23:10:58.768739|2018-05-31 23:10:58.768739
NCT01234506|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-07-30|2010-11-03|2010-11-04|Estimate|||||||2013-07-30|2013-08-01|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Oxi-Stress||Oxidative Stress and Nutritional Supplementation Intervention Study|Community Alliance for Quality of Life in Long Term Care: Oxidative Stress and Nutritional Supplementation Intervention Study|Completed||Phase 2|21|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 23:10:58.864347|2018-05-31 23:10:58.864347
NCT01234493|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-05-13|2010-11-03|2010-11-04|Estimate|||||||2016-05-13|2016-05-16|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Syndesmotic Injury and Fixation in Supination-External (SE) Ankle Fractures|Syndesmotic Injury and Fixation in SE Ankle Fractures: A Prospective Randomized Study|Completed||N/A|140|Actual|University of Oulu||2|||f||||t||||||||No||2018-05-31 23:10:58.953192|2018-05-31 23:10:58.953192
NCT01234480|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2015-02-13|2010-11-02|2010-11-04|Estimate|||||||2015-02-13|2015-02-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:10:59.033546|2018-05-31 23:10:59.033546
NCT01234467|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2017-02-17||2017-04-28|2010-11-02|2010-11-04|Estimate|2017-03-14|2017-04-26|Actual||||2017-04-28|2017-05-24|Actual|March 2011|Actual|2011-03-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|December 2013|Actual|2013-12-31||Interventional|||Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma|A Phase II Trial of Bendamustine in Combination With Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma|Completed||Phase 2|23|Actual|UNC Lineberger Comprehensive Cancer Center|The planned interim analysis was designed for futility (if ORR is less than 13/23 patients). It passed the futility criteria, but based on the survival rate at the time of interim analysis, the investigators decided to terminate the trial.|1|||f||||t||||||||||2018-05-31 23:10:59.104268|2018-05-31 23:10:59.104268
NCT01234454|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-04-01|2010-11-02|2010-11-04|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2002||2002-01-31|November 2010|2010-11-30|December 2007|Actual|2007-12-31|June 2005|Actual|2005-06-30||Interventional|||Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI|Risperidone Effects On Frontal And Temporal Cortical Function In Schizophrenia Patients Undergoing FMRI Cognitive Task Performance|Completed||N/A|34|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 23:10:59.48801|2018-05-31 23:10:59.48801
NCT01234441|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-12-01|2010-11-02|2010-11-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|February 2016|Anticipated|2016-02-29||Interventional|IHOPE||Intra Hemodialytic Oral Protein and Exercise (IHOPE)|Intradialytic Protein Supplementation & Exercise Training in Dialysis Patients.|Unknown status|Active, not recruiting|N/A|150|Anticipated|University of Illinois at Urbana-Champaign||3|||f||||t||||||||||2018-05-31 23:10:59.69515|2018-05-31 23:10:59.69515
NCT01234428|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2010-11-02|2010-11-02|2010-11-04|Estimate|||||||2010-11-02|2010-11-04|Estimate|June 1998||1998-06-30|November 2010|2010-11-30|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||Esophageal Dysmotility and Dilatation After Laparoscopic Gastric Banding|Esophageal Dysmotility Disorders Following Laparoscopic Gastric Banding - An Underestimated Complication.|Completed||N/A|167|Actual|Spital STS AG||1|||f||||f||||||||||2018-05-31 23:10:59.784363|2018-05-31 23:10:59.784363
NCT01234415|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-03-17|2010-11-02|2010-11-04|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|NASEPT||Bone Substitute in the Multi Traumatized Nasal Septum Reconstruction|Multicentric Pilot, Clinical Study of a Bone Substitute Safety and Efficacy in the Multi Traumatized Nasal Septum Reconstruction|Completed||Phase 2|26|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 23:10:59.908429|2018-05-31 23:10:59.908429
NCT01234402|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03||2014-09-29|2017-09-25|2010-11-03|2010-11-04|Estimate||||2014-09-29|2014-10-08|Estimate|2017-09-25|2017-10-02|Actual|March 2011||2011-03-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|October 2013|Actual|2013-10-31||Interventional|||Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients|An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy|Completed||Phase 2|153|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:11:00.010138|2018-05-31 23:11:00.010138
NCT01234389|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-01-23|2010-11-02|2010-11-04|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Immediate Detection of Helicobacter Infection With a New Electrochemical System.|Immediate Detection of Helicobacter Infection With a New Electrochemical System|Unknown status|Recruiting|N/A|120|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 23:11:00.157099|2018-05-31 23:11:00.157099
NCT01228955|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-04-05|2010-10-26|2010-10-27|Estimate|||||||2017-04-05|2017-04-06|Actual|February 2010||2010-02-28|April 2017|2017-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Yoga Intervention for Cancer Survivors|Yoga Intervention for Cancer Survivors|Completed|||48|Actual|Vanderbilt University Medical Center|||1||f||||t||||||||No||2018-05-31 23:12:31.299438|2018-05-31 23:12:31.299438
NCT01234376|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-01-23|2010-11-02|2010-11-04|Estimate|||||||2013-01-23|2013-01-24|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|||Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis|Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis|Unknown status|Recruiting||45|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-05-31 23:11:00.2456|2018-05-31 23:11:00.2456
NCT01234363|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-09-18|2010-11-03|2010-11-04|Estimate|||||||2013-09-18|2013-09-19|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|GREFE||Renal Allograft : Evaluation of Parenchymal Fibrosis by Elastography|Evaluation of the Potential of Elastography for Noninvasive Assessment of Fibrosis in Kidney Transplant|Unknown status|Recruiting|N/A|60|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 23:11:00.357856|2018-05-31 23:11:00.357856
NCT01234350|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2018-04-12|2010-11-03|2010-11-04|Estimate|||||||2018-04-12|2018-04-13|Actual|January 2011||2011-01-31|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Observational|||Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer|A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With Firmagon (Degarelix) on a GnRH Agonist|Completed|||1511|Actual|Ferring Pharmaceuticals|||2||f||||t||||||||||2018-05-31 23:11:00.477882|2018-05-31 23:11:00.477882
NCT01234337|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2015-05-10||2017-11-14|2010-11-03|2010-11-04|Estimate|2015-08-04|2015-09-03|Estimate||||2017-11-14|2017-12-12|Actual|February 21, 2011|Actual|2011-02-21|November 2017|2017-11-30|October 20, 2017|Actual|2017-10-20|May 12, 2014|Actual|2014-05-12||Interventional|||Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer|A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer|Completed||Phase 3|537|Actual|Bayer|Results of exploratory analysis of biomarkers are anticipated in the month of February, 2016.|2|||f||||t|t|f||||||||2018-05-31 23:11:00.824631|2018-05-31 23:11:00.824631
NCT01234324|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2018-01-19|2010-11-03|2010-11-04|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2010|Actual|2010-10-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|NEOPECX||ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction|An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.|Completed||Phase 2|171|Actual|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 23:11:02.216694|2018-05-31 23:11:02.216694
NCT01234311|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01||2015-10-02|2015-10-02|2010-11-03|2010-11-04|Estimate||||2015-10-02|2015-10-21|Estimate|2015-10-02|2015-10-21|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer|Completed||Phase 3|1245|Actual|Active Biotech AB||2|||f||||t||||||||||2018-05-31 23:11:02.317917|2018-05-31 23:11:02.317917
NCT01234298|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2012-03-13|2010-11-02|2010-11-04|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2012||2012-01-31|September 2011|2011-09-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|NSS||SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia|A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Low- and High-dose Range Groups of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia|Withdrawn||Phase 3|0|Actual|Shire||3||Study was discontinued due to non-safety related business prioritization decisions|f||||||||||||||2018-05-31 23:11:02.781529|2018-05-31 23:11:02.781529
NCT01234285|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2014-05-19|2010-11-03|2010-11-04|Estimate|||||||2014-05-19|2014-05-20|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|October 2013|Anticipated|2013-10-31|April 2013|Anticipated|2013-04-30||Interventional|||Safety of Heparin in Patients With Septic Shock|Safety of Heparin Anticoagulation for Prevention of Death in Patients With Septic Shock.|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver||4||Sara Cheng, MD has left the Univ. of Colorado and the study has been closed.|f||||t||||||||||2018-05-31 23:11:02.854661|2018-05-31 23:11:02.854661
NCT01234272|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2011-08-15|2010-11-03|2010-11-04|Estimate|||||||2011-08-15|2011-08-16|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-|Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-|Completed||Phase 4|59|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:11:02.96971|2018-05-31 23:11:02.96971
NCT01234259|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2017-03-27|2010-11-03|2010-11-04|Estimate|||||||2017-03-27|2017-03-28|Actual|December 2010||2010-12-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment|Evaluation of Safety and Efficacy of Using Venus Freeze™ (MP)2 V2 System for Wrinkles Rhytides and Cellulite Treatment - a Pilot Study|Completed||N/A|60|Actual|Venus Concept||2|||f||||f||||||||||2018-05-31 23:11:03.084088|2018-05-31 23:11:03.084088
NCT01234246|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|March 2010||2010-03-31|August 2010|2010-08-31|March 2014|Anticipated|2014-03-31|||||Observational|||Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners.|Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners.|Unknown status|Recruiting||1200|Anticipated|University of Tilburg|||2||f||||f||||||||||2018-05-31 23:11:03.172373|2018-05-31 23:11:03.172373
NCT01234233|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2016-05-12|2010-11-03|2010-11-04|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|THER4-1||Effects of Preoperative Warming of Patients on Postoperative Hypothermia and Shivering|Effects of Preoperative Warming of Patients on Postoperative Hypothermia and Shivering.|Completed||N/A|400|Actual|University of Schleswig-Holstein||4|||f||||f||||||||||2018-05-31 23:11:03.266496|2018-05-31 23:11:03.266496
NCT01234220|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-01-14|2010-11-03|2010-11-04|Estimate|||||||2013-01-14|2013-01-15|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Observational|AVIS||Adrenal Vein Sampling International Study (AVIS Study)|Multicenter Study on Use and Interpretation of Adrenal Vein Sampling|Completed|||2604|Actual|University Hospital Padova|||1||f||||t||||||||||2018-05-31 23:11:03.358237|2018-05-31 23:11:03.358237
NCT01234207|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2013-06-27||2017-04-17|2010-11-03|2010-11-04|Estimate|2017-04-17|2017-04-18|Actual||||2017-04-17|2017-04-18|Actual|February 2009||2009-02-28|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|CZV_PAL1||Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle|Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle|Completed||N/A|95|Actual|University of California, Berkeley|Possibility of insufficient head immobilization during off-axis VA measurement on left side only for some subjects. May explain difference of off-axis VA results between right and left sides.|2|||f||||f||||||||||2018-05-31 23:11:03.459311|2018-05-31 23:11:03.459311
NCT01234194|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Composite Variability Index and Propofol Remifentanil Anesthesia|Changes in the Composite Variability Index in Response to Different Remifentanil Concentrations and Standardized Painful Stimuli.|Completed||N/A|24|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 23:11:03.759881|2018-05-31 23:11:03.759881
NCT01234181|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|CSHSBMMCTTHD||Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Transplantation to Treat Heart Diseases|Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Intracoronary Transplantation in Myocardial Infarction and Other Heart Diseases.|Unknown status|Not yet recruiting|N/A|100|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t||||||||||2018-05-31 23:11:03.825483|2018-05-31 23:11:03.825483
NCT01234168|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-01-30|2010-11-03|2010-11-04|Estimate|||||||2017-01-30|2017-02-01|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|SYMNET||A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea|An International, Cross Sectional, Non-interventional, Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea|Completed|||340|Actual|Ipsen|||||f||||f||||||||||2018-05-31 23:11:03.895042|2018-05-31 23:11:03.895042
NCT01234155|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2014-12-02|2010-11-03|2010-11-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2012|Actual|2012-11-30||Interventional|||Exercise Training and Type 2 Diabetes||Completed||N/A|32|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 23:11:04.089669|2018-05-31 23:11:04.089669
NCT01234142|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-10-13|2010-11-02|2010-11-04|Estimate|||||||2011-10-13|2011-10-14|Estimate|November 2010||2010-11-30|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study Evaluating the Absorption Of Varenicline Through The Skin Following Once Daily Application Of A Patch For 14 Days|A Phase 1, Investigator And Subject Blind (Sponsor Open), Randomized, Placebo Controlled, Parallel Cohort, Escalating Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of A Varenicline Transdermal Delivery System In Adult Smokers|Completed||Phase 1|45|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:11:04.155811|2018-05-31 23:11:04.155811
NCT01234129|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|||2010-11-03|2010-11-03|2010-11-04|Estimate|||||||2010-11-03|2010-11-04|Estimate|June 2002||2002-06-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma|Results of Phase III Study to Assess if Zoledronic Acid Have Antumor Activity in Multiple Myeloma|Completed|||320|Actual|Instituto Mexicano del Seguro Social|||3||f||||f||||||||||2018-05-31 23:11:04.221584|2018-05-31 23:11:04.221584
NCT01234116|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-09-26|2010-11-03|2010-11-04|Estimate|||||||2013-09-26|2013-09-27|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PEP||Post-Exposure Prophylaxis in Health Care Workers|A Prospective, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Raltegravir + Truvada Versus Kaletra + Truvada, for Post-exposure Prophylaxis in Health Care Workers|Completed||Phase 4|16|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 23:11:04.281646|2018-05-31 23:11:04.281646
NCT01234103|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-03|2017-08-22||2017-08-24|2010-11-03|2010-11-04|Estimate|2017-08-24|2017-08-25|Actual||||2017-08-24|2017-08-25|Actual|September 2010||2010-09-30|August 2017|2017-08-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Preventing Health Damaging Behaviors in Male and Female Army Recruits|Preventing Health Damaging Behaviors in Male and Female Army Recruits|Terminated||N/A|933|Actual|United States Department of Defense||2||Due to lack of continue funding|f||||t||||||||No||2018-05-31 23:11:04.352589|2018-05-31 23:11:04.352589
NCT01234090|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2016-06-14|2010-11-02|2010-11-04|Estimate|||||||2016-06-14|2016-06-15|Estimate|June 2010||2010-06-30|June 2016|2016-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Living With Aphasia: An International Study|Living With Aphasia: An International Study|Terminated|||15|Actual|New York University School of Medicine|||1|Funding stopped|f||||t||||||||||2018-05-31 23:11:04.9143|2018-05-31 23:11:04.9143
NCT01234077|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-03-27|2010-11-03|2010-11-04|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2010||2010-03-31|March 2017|2017-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study Comparing In-laboratory Polysomnography Electrocardiogram (PSG ECG) to Simultaneously Recorded In-laboratory ECG on the CPC M1 Device|A Single Blind Randomized Study Comparing In-laboratory Polysomnography Electrocardiogram to Simultaneously Recorded In-laboratory Electrocardiogram on the CPC M1 Device and Compared to Home Recorded Electrocardiogram With the CPC M1 Device.|Completed||N/A|50|Actual|National Jewish Health||1|||f||||f||||||||||2018-05-31 23:11:04.984279|2018-05-31 23:11:04.984279
NCT01234064|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-01-16|2010-11-03|2010-11-04|Estimate|||||||2012-01-16|2012-01-18|Estimate|November 2010||2010-11-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Graduated Compression Stockings (GCS) Pilot Substudy|Graduated Compression Stockings (GCS) for Prevention of Venous Thromboembolism in Patients Who Have Major Surgery: Pilot Study Assessing Feasibility of Adding This Evaluation to the PeriOperative ISchemic Evaluation-2 Trial (POISE-2 Trial)|Completed||Phase 3|50|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 23:11:05.058281|2018-05-31 23:11:05.058281
NCT01234051|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2011-12-09|2010-11-02|2010-11-04|Estimate|||||||2011-12-09|2011-12-12|Estimate|November 2010||2010-11-30|November 2010|2010-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer|Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer|Unknown status|Recruiting|Phase 2|53|Anticipated|Korean South West Oncology Group||1|||f||||f||||||||||2018-05-31 23:11:05.144907|2018-05-31 23:11:05.144907
NCT01234038|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-11-01|2010-11-03|2010-11-04|Estimate|||||||2012-11-01|2012-11-05|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|March 2015|Anticipated|2015-03-31|September 2013|Anticipated|2013-09-30||Interventional|NSCLC||Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel|A Phase 1b/2 Study of Carboplatin-Paclitaxel, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Stage IV Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|112|Anticipated|Ionis Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 23:11:05.256421|2018-05-31 23:11:05.256421
NCT01234025|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-11-01|2010-11-03|2010-11-04|Estimate|||||||2012-11-01|2012-11-05|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|March 2015|Anticipated|2015-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)|A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|112|Anticipated|Ionis Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 23:11:05.380088|2018-05-31 23:11:05.380088
NCT01234012|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-03-09|2010-11-03|2010-11-04|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1|A Phase I Study of Therapeutic Cancer Vaccine IMF-001 in Patients With Malignancies Expressing NY-ESO-1|Completed||Phase 1|23|Actual|ImmunoFrontier, Inc.||1|||f||||f||||||||||2018-05-31 23:11:05.50034|2018-05-31 23:11:05.50034
NCT01233999|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2013-07-17||2014-03-15|2010-11-03|2010-11-04|Estimate|2014-03-15|2014-04-21|Estimate||||2014-03-15|2014-04-21|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Botulinum Toxin in the Treatment of Raynaud's|Botulinum Toxin in the Treatment of Raynaud's|Completed||N/A|10|Actual|Emory University|Pilot study with limited numbers to analyze|1|||f||||t||||||||||2018-05-31 23:11:05.574232|2018-05-31 23:11:05.574232
NCT01233986|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-10-04|2010-11-02|2010-11-04|Estimate|||||||2011-10-04|2011-10-05|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|October 2011|Anticipated|2011-10-31|March 2011|Actual|2011-03-31||Observational|||Association of Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)|Prospective, Matched Case Control, Multicenter, Observational Study for the Association of Serum Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)|Unknown status|Recruiting||112|Anticipated|Hallym University Medical Center|||2||f||||t||||||Samples Without DNA|"~     Serum level of apolipoprotein B-48~   "|||2018-05-31 23:11:05.698392|2018-05-31 23:11:05.698392
NCT01233973|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-04-28|2010-11-03|2010-11-04|Estimate|||||||2012-04-28|2012-05-01|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Using Videos to Improve Understanding of the Delivery of End-of-life Medical Care in Non-hospital Settings||Completed||N/A|101|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:11:05.765488|2018-05-31 23:11:05.765488
NCT01233960|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2017-12-07|2010-11-02|2010-11-03|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2010||2010-09-30|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease|A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease|Active, not recruiting||Phase 3|120|Anticipated|Mesoblast, Ltd.||1|||f||||f||||||||||2018-05-31 23:11:05.833762|2018-05-31 23:11:05.833762
NCT01233947|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-01-06|2010-11-02|2010-11-03|Estimate|||||||2012-01-06|2012-01-09|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Study of AFP464 +/- Faslodex in ER + Breast Cancer|A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy|Terminated||Phase 2|7|Actual|Tigris Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:11:05.937729|2018-05-31 23:11:05.937729
NCT01233934|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2010-11-02|2010-11-02|2010-11-03|Estimate|||||||2010-11-02|2010-11-03|Estimate|February 2011||2011-02-28|November 2010|2010-11-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites||Unknown status|Not yet recruiting|Phase 3|90|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||t||||||||||2018-05-31 23:11:05.998986|2018-05-31 23:11:05.998986
NCT01233921|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2013-12-20||2014-02-19|2010-11-02|2010-11-03|Estimate|2014-02-19|2014-04-02|Estimate||||2014-02-19|2014-04-02|Estimate|September 2010||2010-09-30|February 2014|2014-02-28||||July 2012|Actual|2012-07-31||Interventional|||Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer|A Preliminary Study to Evaluate the Effects of Palifermin in Patients at Risk of Chronic Graft-versus-host Disease|Completed||N/A|6|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 23:11:06.064296|2018-05-31 23:11:06.064296
NCT01233908|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2010-11-02|2010-11-02|2010-11-03|Estimate|||||||2010-11-02|2010-11-03|Estimate|January 2010||2010-01-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Diagnosis of Posttraumatic Stress Disorder Following Primary Rhegmatogenous Retinal Detachment|Diagnosis of Posttraumatic Stress Disorder Following Primary Rhegmatogenous Retinal Detachment|Completed|||547|Actual|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 23:11:06.295421|2018-05-31 23:11:06.295421
NCT01233895|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-11-02|2010-11-02|2010-11-03|Estimate|||||||2010-11-02|2010-11-03|Estimate|September 2006||2006-09-30|October 2010|2010-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma|Open Label Study of the Anti Insulin-like Growth Factor 1 Receptor (IGF-1R) Monoclonal Antibody, AVE1642, as Single Agent (Dose Escalation, Part 1) and in Combination With Velcade® (Combination, Part 2) in Patients With Recurrent, Refractory Multiple Myeloma (MM)|Completed||Phase 1|26|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:11:06.363349|2018-05-31 23:11:06.363349
NCT01233882|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-06-29|2010-11-02|2010-11-03|Estimate|||||||2012-06-29|2012-07-03|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bosutinib In Subjects With Renal Impairment|An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults|Completed||Phase 1|34|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:11:06.426349|2018-05-31 23:11:06.426349
NCT01233713|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-05-25|2010-11-02|2010-11-03|Estimate|||||||2012-05-25|2012-05-28|Estimate|May 2006||2006-05-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ColonPerfRCT||Hartmann's Versus Primary Anastomosis in Left-sided Colon Perforation|Hartmann's Versus Primary Anastomosis in Left-sided Colon Perforation - A Prospective Randomized Multicenter Trial|Completed||Phase 2/Phase 3|62|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 23:11:11.091419|2018-05-31 23:11:11.091419
NCT01233869|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2015-08-26||2016-02-10|2010-11-02|2010-11-03|Estimate|2015-09-29|2015-10-28|Estimate||||2016-02-10|2016-03-11|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional||The safety population included all participants who received at least 1 dose of study medication.|Bosutinib For Autosomal Dominant Polycystic Kidney Disease|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Clinical Activity And Pharmacokinetics Of Bosutinib (PF-05208763) Versus Placebo In Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Completed||Phase 2|172|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 23:11:06.67269|2018-05-31 23:11:06.67269
NCT01233856|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-08-25|2010-11-02|2010-11-03|Estimate|||||||2011-08-25|2011-08-26|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Omega-3 Fatty Acids as an Adjunctive Therapy for Treatment in Attention-Deficit Hyperactivity Disorder (ADHD)|Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD|Unknown status|Recruiting|N/A|30|Anticipated|Maimonides Medical Center||2|||f||||||||||||||2018-05-31 23:11:08.21809|2018-05-31 23:11:08.21809
NCT01233843|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2017-10-25|2010-11-02|2010-11-03|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2009||2009-05-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|2007/02||Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.|A Phase III Randomized Multicenter Study,Comparing an Induction Chemotherapy Followed by Irradiation and Concurrent Erbitux Versus Chemoradiotherapy for Patients With Locoregional Advanced Head and Neck Cancers|Active, not recruiting||Phase 3|370|Actual|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||||2018-05-31 23:11:08.34293|2018-05-31 23:11:08.34293
NCT01233830|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2011-04-11|2010-11-02|2010-11-03|Estimate|||||||2011-04-11|2011-04-12|Estimate|November 2010||2010-11-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers|A Phase I, Single Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Administration of Multiple Ascending Doses for 12 Days in Young and Elderly Healthy Japanese Volunteers|Completed||Phase 1|19|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:11:08.452821|2018-05-31 23:11:08.452821
NCT01233817|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2012-12-05||2017-05-15|2010-11-01|2010-11-03|Estimate|2013-02-05|2013-03-12|Estimate||||2017-05-15|2017-06-14|Actual|June 2010|Actual|2010-06-30|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Progressive Strength Training in Spinal Muscular Atrophy|Pilot Study of Progressive Strength Training in Spinal Muscular Atrophy|Completed||N/A|12|Actual|University of Utah|This was a pilot study with only one arm, the treatment arm. This is an inherent limitation.|1|||f||||t||||||||||2018-05-31 23:11:08.516195|2018-05-31 23:11:08.516195
NCT01233804|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2018-05-29|2010-11-01|2010-11-03|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 2010||2010-11-30|May 2018|2018-05-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Opting In vs Opting Out|Opting In vs Opting Out: Impact on Influenza Vaccination in Pregnant Women|Completed||N/A|280|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:11:08.941397|2018-05-31 23:11:08.941397
NCT01233791|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-07-09|2010-11-02|2010-11-03|Estimate|||||||2015-07-09|2015-07-10|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Diazepam Vaginal Suppositories for High Tone Pelvic Floor Dysfunction.|Diazepam Vaginal Suppositories as a Treatment Option for High Tone PElvic Floor Dysfunction: A Randomized Controlled Trial.|Completed||N/A|48|Actual|TriHealth Inc.||2|||f||||t||||||||||2018-05-31 23:11:09.06542|2018-05-31 23:11:09.06542
NCT01233778|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2013-03-14|2010-11-02|2010-11-03|Estimate|||||||2013-03-14|2013-03-15|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|COMIT||Canola Oil Multicentre Intervention Trial (COMIT)|Canola and Flax Oils in Modulation of Vascular Function and Biomarkers of Cardiovascular Disease Risk|Completed||N/A|43|Actual|Penn State University||5|||f||||f||||||||||2018-05-31 23:11:09.215634|2018-05-31 23:11:09.215634
NCT01233765|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2017-02-13|2010-11-02|2010-11-03|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2011||2011-09-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Analysis of Neutrophil Response in Chronic Periodontitis|Analysis of Neutrophil Response in Chronic Periodontitis (Including the Project Entitled 'Pro-Inflammatory Cytokine Production by Neutrophils in Periodontitis Patients')|Completed|||40|Anticipated|Birmingham Community Healthcare NHS|||2||f||||f||||||||||2018-05-31 23:11:09.319237|2018-05-31 23:11:09.319237
NCT01233752|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-07-18|2010-11-02|2010-11-03|Estimate|||||||2013-07-18|2013-07-19|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|PCA-Gene||Association Between Clinical Effect of Morphine With PCA After Surgery and Pharmacogenetics|Association Between Clinical Effect of Morphine in Patients With PCA After Major Surgery and Pharmacogenetics: Prospective Observational Clinical Study.|Completed|||224|Actual|IRCCS Policlinico S. Matteo|||2||f||||t||||||Samples With DNA|"~     genes OPRM1, COMT, UGTs, ESR1~   "|||2018-05-31 23:11:09.477665|2018-05-31 23:11:09.477665
NCT01233739|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-02-21|2010-11-02|2010-11-03|Estimate|||||||2013-02-21|2013-02-22|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis.|Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Measurement With Sensory and Quantitive Functional Tests and Concordance Analysis With Subjective Scales of Pain.|Unknown status|Recruiting|Phase 4|108|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 23:11:09.599434|2018-05-31 23:11:09.599434
NCT01233726|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2015-12-18||2016-07-20|2010-11-02|2010-11-03|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Age ≥18 years, ICU stay ≤48 hours upon randomization to EN formula, mechanical ventilation, EN indicated for an expected time ≥5 days. Patients were also required to meet American Diabetes Association criteria for diabetes/hyperglycemia (baseline blood glucose >126 mg/dL after fasting or>200 mg/dL otherwise) in the first 48 h of ICU admission.|Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia|Effects of a Complete Diet Rich in Monounsaturated Fatty Acids and Slow Absorption Carbohydrate Administration in Critically Ill Patients With Stress Hyperglycemia. Open Study, Blind Randomised, Multicenter and Controlled.|Completed||N/A|159|Actual|Vegenat, S.A.|No overall limitations and caveats have been observed and/or registered related with the products intake during the clinical trial period.|3|||f||||f||||||||Undecided||2018-05-31 23:11:09.706253|2018-05-31 23:11:09.706253
NCT01231945|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-06-30|2010-10-29|2010-11-01|Estimate|||||||2017-06-30|2017-07-02|Actual|October 11, 2010||2010-10-11|December 20, 2010|2010-12-20|December 20, 2010||2010-12-20|||||Observational|||Low-Cost Molecular Cervical Cancer Screening Study|Low-Cost Molecular Cervical Cancer Screening Study|Completed|||7500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:11:36.158304|2018-05-31 23:11:36.158304
NCT01233687|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2016-01-12||2017-06-20|2010-11-02|2010-11-03|Estimate|2016-07-20|2016-09-01|Estimate||||2017-06-20|2017-06-22|Actual|August 2011||2011-08-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer|A Phase I/II Trial of AMG 102 and Erlotinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|49|Actual|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 23:11:12.391758|2018-05-31 23:11:12.391758
NCT01233674|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-01-04|2010-11-02|2010-11-03|Estimate|||||||2016-01-04|2016-01-05|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Examination of Left Atrial Fibrosis Using MRI|Examination of Left Atrial Fibrosis Using MRI|Withdrawn|||0|Actual|University of Pittsburgh|||1||f||||||||||||||2018-05-31 23:11:12.636133|2018-05-31 23:11:12.636133
NCT01233661|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-01-04|2010-11-02|2010-11-03|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SAVD||Short Atrioventricular Delay Pacing|Short Atrioventricular Delay Pacing|Withdrawn||N/A|0|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 23:11:12.695869|2018-05-31 23:11:12.695869
NCT01233648|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-01-04|2010-11-02|2010-11-03|Estimate|||||||2016-01-04|2016-01-05|Estimate|June 2006||2006-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)|Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)|Completed||Phase 4|52|Actual|University of Pittsburgh||2|||f||||||||||||||2018-05-31 23:11:12.775342|2018-05-31 23:11:12.775342
NCT01233635|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-01-04|2010-11-02|2010-11-03|Estimate|||||||2016-01-04|2016-01-05|Estimate|November 2005||2005-11-30|January 2016|2016-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)|Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)|Terminated||Phase 4|228|Anticipated|University of Pittsburgh||3||inadequate enrollment rate|f||||||||||||||2018-05-31 23:11:12.894438|2018-05-31 23:11:12.894438
NCT01233622|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2017-02-21|2010-11-02|2010-11-03|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2010||2010-10-31|February 2017|2017-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|Vildagliptin||Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride|A Multi-center, Randomized, Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin 50 mg Bid as add-on Therapy to Metformin Plus Glimepiride in Patients With Type 2 Diabetes|Completed||Phase 3|317|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:11:12.979525|2018-05-31 23:11:12.979525
NCT01233609|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2017-08-17||2017-10-24|2010-11-02|2010-11-03|Estimate|2017-10-24|2017-12-02|Actual||||2017-10-24|2017-12-02|Actual|November 2010||2010-11-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VPA||Trial of Oral Valproic Acid for Retinitis Pigmentosa|A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa|Completed||Phase 2|90|Actual|Foundation Fighting Blindness Clinical Research Institute||2|||f||||t||||||||||2018-05-31 23:11:13.273831|2018-05-31 23:11:13.273831
NCT01233596|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-03-03|2010-11-02|2010-11-03|Estimate|||||||2015-03-03|2015-03-04|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|MCI_vs_BCI||Monocanalicular Versus Bicanalicular Intubation in the Treatment of Congenital Nasolacrimal Duct Obstruction|Monocanalicular Versus Bicanalicular Intubation in the Treatment of Congenital Nasolacrimal Duct Obstruction|Completed||Phase 3|70|Actual|University Hospital Ostrava||2|||f||||t||||||||||2018-05-31 23:11:14.028975|2018-05-31 23:11:14.028975
NCT01233583|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-12-02|2010-11-02|2010-11-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Regulatory T-cells in Psoriasis Patients as Targets for Therapy|Enumeration and Functional Evaluation of Regulatory T-cells in Psoriasis Patients Before and After Treatment With: Calcipotriol/Betamethasone, Acitretin, Narrow-Band UVB and Anti-TNF Alpha Therapy (Etanercept, Adalimumab and Infliximab)|Completed|||38|Actual|University of Aberdeen|||4||f||||t||||||Samples Without DNA|"~     Whole Blood Skin biopsy~   "|||2018-05-31 23:11:14.09622|2018-05-31 23:11:14.09622
NCT01233570|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2010-11-02|2010-11-02|2010-11-03|Estimate|||||||2010-11-02|2010-11-03|Estimate||||November 2010|2010-11-30||||||||Interventional|||Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease|Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease|Completed||Phase 2|20|Actual|University of Aberdeen||1|||f||||f||||||||||2018-05-31 23:11:14.206529|2018-05-31 23:11:14.206529
NCT01233557|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2015-11-04|2010-11-02|2010-11-03|Estimate|||||||2015-11-04|2015-11-05|Estimate|September 2010||2010-09-30|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Biomarkers of Bone Resorption in Metastatic Prostate Cancer|Measurement of Biomarkers of Bone Resorption in Patients With Hormone Sensitive Bone Metastases From Prostate Cancer Treated With Antiandrogen Therapy and Bisphosphonates|Completed|||40|Actual|University of Aberdeen|||1||f||||f||||||||||2018-05-31 23:11:14.285964|2018-05-31 23:11:14.285964
NCT01233544|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2016-05-11|2010-11-02|2010-11-03|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|RAS01||Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases|The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial|Terminated||Phase 3|300|Anticipated|University of Aarhus||2||Insufficient recruitment|f||||f||||||||||2018-05-31 23:11:14.33566|2018-05-31 23:11:14.33566
NCT01233531|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2016-01-20|2010-11-02|2010-11-03|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Cash Transfer for the Prevention of HIV in Young South African Women|Effects of Cash Transfer for the Prevention of HIV in Young South African Women|Completed||Phase 3|2537|Actual|HIV Prevention Trials Network||2|||f||||t||||||||||2018-05-31 23:11:14.506581|2018-05-31 23:11:14.506581
NCT01233518|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2015-08-17|2010-11-01|2010-11-03|Estimate|||||||2015-08-17|2015-08-19|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|DeFACTO||Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography|Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography|Completed||N/A|285|Actual|HeartFlow, Inc.||1|||f||||t||||||||||2018-05-31 23:11:14.601721|2018-05-31 23:11:14.601721
NCT01233505|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-04-01|2010-11-02|2010-11-03|Estimate|||||||2014-04-01|2014-04-02|Estimate|October 2010||2010-10-31|October 2013|2013-10-31||||October 2013|Actual|2013-10-31||Interventional|||Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors|Terminated||Phase 1|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:11:14.712429|2018-05-31 23:11:14.712429
NCT01233492|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-10-07|2010-11-02|2010-11-03|Estimate|||||||2013-10-07|2013-10-08|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme|A Cancer Research UK Pharmacokinetic Study of BPA in Patients With High Grade Glioma to Optimize Uptake Parameters for Clinical Trials of BNCT|Terminated||Phase 1|36|Anticipated|Cancer Research UK||||Sponsor Decision|f||||||||||||||2018-05-31 23:11:14.813421|2018-05-31 23:11:14.813421
NCT01233479|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-10-19|2010-11-02|2010-11-03|Estimate|||||||2012-10-19|2012-10-23|Estimate|May 2010||2010-05-31|October 2012|2012-10-31||||July 2011|Anticipated|2011-07-31||Interventional|||Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy|Immunologic Profile of Patients With Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy|Withdrawn||N/A|0|Actual|Pediatric Brain Tumor Consortium||||"This non-therapeutic study was registered in error. The PRS team doesn't delete studies once~   registered, so they recommended changing the status to Withdrawn"|f||||||||||||||2018-05-31 23:11:14.892043|2018-05-31 23:11:14.892043
NCT01233453|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2014-01-29|2010-11-02|2010-11-03|Estimate|||||||2014-01-29|2014-01-30|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|May 2012|Actual|2012-05-31||Interventional|COMPARE-II||Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent|Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study|Unknown status|Active, not recruiting|Phase 4|2700|Anticipated|Maasstad Hospital||2|||f||||t||||||||||2018-05-31 23:11:15.007637|2018-05-31 23:11:15.007637
NCT01233440|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2012-01-26|2010-11-02|2010-11-03|Estimate|||||||2012-01-26|2012-01-31|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B|An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B|Completed||Phase 1|25|Actual|CSL Behring||3|||f||||t||||||||||2018-05-31 23:11:15.105239|2018-05-31 23:11:15.105239
NCT01233427|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-08-22|2010-11-02|2010-11-03|Estimate|||||||2014-08-22|2014-08-25|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Observational|||Infant Feeding Study.09-68|The Infant Feeding Experience of New Mothers - a Descriptive Pilot Study.|Completed|||24|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-05-31 23:11:15.216571|2018-05-31 23:11:15.216571
NCT01233414|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2016-04-07|2010-11-01|2010-11-03|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|RUBI||Randomized Trial of Parent Training for Young Children With Autism|Randomized Trial of Parent Training for Young Children With Autism|Completed||N/A|180|Actual|Yale University||2|||f||||t||||||||||2018-05-31 23:11:15.282835|2018-05-31 23:11:15.282835
NCT01233401|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-07-26|2010-11-01|2010-11-03|Estimate|||||||2011-07-26|2011-07-28|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Tdap Vaccination for Infant Caregivers|Tdap Vaccination for Infant Caregivers in the Pediatric Office|Completed|||102|Actual|Yale University|||2||f||||f||||||||||2018-05-31 23:11:15.377601|2018-05-31 23:11:15.377601
NCT01233388|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2012-06-08|2010-11-01|2010-11-03|Estimate|||||||2012-06-08|2012-06-12|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Real-time Influenza Vaccine Surveillance|Real-time Influenza Vaccine Surveillance: FLUNET|Completed|||400|Actual|Columbia University|||1||f||||f||||||||||2018-05-31 23:11:15.450342|2018-05-31 23:11:15.450342
NCT01233375|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26||2014-08-28|2014-12-09|2010-11-01|2010-11-03|Estimate||||2014-12-09|2014-12-31|Estimate|2014-12-09|2014-12-31|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma|A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-1.01 for Infusion as Second-Line Therapy for Gemcitabine- Refractory Patients With Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression|Completed||Phase 2|19|Actual|Clovis Oncology, Inc.||1|||f||||f||||||||||2018-05-31 23:11:15.530902|2018-05-31 23:11:15.530902
NCT01233362|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2013-09-24|2010-11-02|2010-11-03|Estimate|||||||2013-09-24|2013-09-25|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of Alternative Vaccination Schedule of Oral Cholera Vaccine|A Randomized Controlled Trial To Evaluate the Immunogenicity of Two Doses of the Modified Killed Whole-Cell Oral Cholera Vaccine Under Two Alternative Vaccination Schedules.|Completed||Phase 2|386|Actual|International Vaccine Institute||6|||f||||f||||||||||2018-05-31 23:11:15.637757|2018-05-31 23:11:15.637757
NCT01233349|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-10-12|2010-11-02|2010-11-03|Estimate|||||||2011-10-12|2011-10-13|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of Litramine in Overweight and Obese Subjects|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of LitramineTM in Reducing Body Weight in Overweight and Obese Subjects|Completed||Phase 3|125|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 23:11:15.72596|2018-05-31 23:11:15.72596
NCT01233336|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2013-02-04|2010-11-02|2010-11-03|Estimate|||||||2013-02-04|2013-02-05|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Hepatocyte Growth Factor (HGF) Concentration in Myocardial Infarction|Hepatocyte Growth Factor as an Early Marker of Myocardial Injury and Prognostic Factor of Cardiovascular Events in Log-term Follow up in Patients With Acute Coronary Syndrome|Completed|||45|Actual|Institute of Cardiology, Warsaw, Poland|||||f||||f||||||Samples Without DNA|"~     plasma for HGF concentration~   "|||2018-05-31 23:11:15.788311|2018-05-31 23:11:15.788311
NCT01233323|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2017-02-02|2010-11-02|2010-11-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2010||2010-02-28|February 2017|2017-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|DETECT PS||Detection of Phrenic Nerve Stimulation Using Sensors' Signals|Detection of Phrenic Nerve Stimulation Using Accelerometer and Electrogram Signals Study|Completed|||60|Actual|Boston Scientific Corporation|||1||f||||||||||||||2018-05-31 23:11:15.939402|2018-05-31 23:11:15.939402
NCT01233310|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-08-22|2010-11-02|2010-11-03|Estimate|||||||2012-08-22|2012-08-23|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|SBC-CD||Evaluation of Small Bowel Colon Capsule for Bowel Visualization in Crohn's Disease Patients|Evaluation of Small Bowel Colon Capsule for Bowel Visualization in Crohn's Disease Patients|Completed|||26|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-05-31 23:11:16.009375|2018-05-31 23:11:16.009375
NCT01233297|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2017-03-08|2010-11-02|2010-11-03|Estimate|||||||2017-03-08|2017-03-09|Actual|November 2010||2010-11-30|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|AB-studie||Antibiotic Treatment of Recurrent Episodes of Asthma in Children|Antibiotic Treatment of Recurrent Episode of Asthma in Children - a Randomised, Case-controlled Study Within the COPSAC2010 Cohort (Asthma Begins in Childhood)|Active, not recruiting||Phase 2|70|Anticipated|Copenhagen Studies on Asthma in Childhood||2|||f||||t||||||||||2018-05-31 23:11:16.081741|2018-05-31 23:11:16.081741
NCT01233284|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2012-12-14||2013-11-27|2010-11-02|2010-11-03|Estimate|2012-12-14|2013-01-21|Estimate||||2013-11-27|2013-12-24|Estimate|November 2010||2010-11-30|September 2013|2013-09-30||||January 2012|Actual|2012-01-31||Interventional|||Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.|A Phase II Randomised, Double-blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Three Doses of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (1.25, 2.5 and 5.0 Mcg Once Daily) Versus Placebo in Patients With Moderate Persistent Asthma.|Completed||Phase 2|149|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:11:16.220689|2018-05-31 23:11:16.220689
NCT01233271|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-06-08|2010-11-02|2010-11-03|Estimate|||||||2011-06-08|2011-06-09|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|DELIOS 02||Feasibility of Blood Glucose Control With the Space TGC System in Postoperative Cardiac Surgery Patients in the ICU|Single-centre, Open Study to Investigate the Feasibility of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) Over an Extended Glucose Control Range (4.4 to 8.3 mmol/L) for a Maximum of 48 Hours in Postoperative Cardiac Surgery Patients in the ICU|Completed||N/A|10|Anticipated|B. Braun Melsungen AG||1|||f||||f||||||||||2018-05-31 23:11:17.156396|2018-05-31 23:11:17.156396
NCT01233258|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2013-10-30||2016-10-14|2010-11-02|2010-11-03|Estimate|2014-01-13|2014-02-11|Estimate||||2016-10-14|2016-11-28|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Leopold II||A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A|A Phase II/III, Randomized, Cross-over, Open-label Trial to Demonstrate Superiority of Prophylaxis Over On-demand Therapy in Previously Treated Subjects With Severe Hemophilia A Treated With Plasma Protein-free Recombinant FVIII Formulated With Sucrose (BAY 81-8973)|Completed||Phase 3|80|Actual|Bayer||6|||f||||t||||||||||2018-05-31 23:11:17.25395|2018-05-31 23:11:17.25395
NCT01233245|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-11-14|2010-11-02|2010-11-03|Estimate|||||||2012-11-14|2012-11-15|Estimate|April 2004||2004-04-30|November 2012|2012-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program|BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program|Completed|||1077|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:11:17.696044|2018-05-31 23:11:17.696044
NCT01233232|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|2015-04-30||2015-08-27|2010-11-02|2010-11-03|Estimate|2015-04-30|2015-05-19|Estimate||||2015-08-27|2015-09-17|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|CIRRUS||A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 2|109|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 23:11:17.824183|2018-05-31 23:11:17.824183
NCT01233219|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2017-03-01|2010-11-02|2010-11-03|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2010||2010-11-30|March 2017|2017-03-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||Association Between Clinical Effect of Continuous Morphine Administration After Surgery and Pharmacogenetics|Association Between Clinical Effect of Continuous Morphine Administration in Patients After Major Surgery and Pharmacogenetics: Perspective Observational Clinical Study|Withdrawn|||0|Actual|IRCCS Policlinico S. Matteo|||2||f||||t||||||Samples With DNA|"~     genes OPRM1, COMT, UGTs, ESR1~   "|||2018-05-31 23:11:18.464344|2018-05-31 23:11:18.464344
NCT01233206|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2011-06-09|2010-11-02|2010-11-03|Estimate|||||||2011-06-09|2011-06-10|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles|Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization|Completed||Phase 4|120|Actual|University Magna Graecia||2|||f||||t||||||||||2018-05-31 23:11:18.548015|2018-05-31 23:11:18.548015
NCT01233193|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2016-05-05|2010-11-02|2010-11-03|Estimate|||||||2016-05-05|2016-05-06|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|AFenPA||The Effect of Pharmacist Intervention on Blood Pressure Control|Pharmacist Intervention Effect on the Medication Adherence and Blood Pressure Control in Treated Patients|Unknown status|Active, not recruiting|N/A|140|Anticipated|Universidad de Granada||2|||f||||f||||||||||2018-05-31 23:11:18.632457|2018-05-31 23:11:18.632457
NCT01233180|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-02-22|2010-11-02|2010-11-03|Estimate|||||||2011-02-22|2011-02-23|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effects of Gua Sha and Thermotherapy on Chronic Neck Pain|Randomized Controlled Trial Comparing Gua Sha Massage and Thermotherapy for Chronic Neck Pain: Effects on Pain Intensity, Haptic Perception and Body Image.|Completed||N/A|50|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 23:11:18.710798|2018-05-31 23:11:18.710798
NCT01233167|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-07-19|2010-11-02|2010-11-03|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2011||2011-08-31|October 2010|2010-10-31|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|EASTS||Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation|Benefits and Risks Evaluation of Different Anti-platelet Strategies Beyond a 12-month Period Inpatients Receiving Sirolimus Drug-eluting Stent Implantation|Unknown status|Not yet recruiting|N/A|5232|Anticipated|Sir Run Run Shaw Hospital||3|||f||||t||||||||||2018-05-31 23:11:18.776444|2018-05-31 23:11:18.776444
NCT01233154|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2014-03-04|2010-11-02|2010-11-03|Estimate|||||||2014-03-04|2014-03-05|Estimate|October 2007||2007-10-31|March 2014|2014-03-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Effect of a L. Paracasei Strain on Grass Pollen Allergic Rhinitis Subjects||Completed||N/A|30|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 23:11:18.852991|2018-05-31 23:11:18.852991
NCT01233141|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-02|||2011-07-27|2010-11-02|2010-11-03|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 2011||2011-01-31|November 2010|2010-11-30||||||||Observational|||Viennese Registry on Patients With Chronic Critical Limb Ischemia|Phase IV Hospital Based Registry to Explore the Outcome of Chronic Critical Limb Ischemia|Unknown status|Recruiting||400|Anticipated|Medical University of Vienna|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, urine~   "|||2018-05-31 23:11:18.913137|2018-05-31 23:11:18.913137
NCT01233128|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-04-06|2010-11-02|2010-11-03|Estimate|||||||2012-04-06|2012-04-09|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy|Association of Vascular Endothelial Growth Factor and LOC387715/HTRA1 Polymorphisms With the Response to Intravitreal Ranibizumab Injections in Polypoidal Choroidal Vasculopathy|Completed|||121|Actual|Kyungpook National University|||1||f||||t||||||Samples With DNA|"~     Genomic DNA was extracted from peripheral blood with the Qiagen QIAamp Blood Kit (Qiagen,~     Valencia, CA).~   "|||2018-05-31 23:11:18.977628|2018-05-31 23:11:18.977628
NCT01233115|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-08-28|2010-11-02|2010-11-03|Estimate|||||||2011-08-28|2011-08-30|Estimate|October 2010||2010-10-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||LOC387715/HTRA1 and the Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy|LOC387715/HTRA1 Variants and the Response to Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy|Completed|||70|Actual|Kyungpook National University|||1||f||||t||||||Samples With DNA|"~     Genomic DNA was extracted from peripheral blood. The two SNPs (rs10490924 in the LOC387715~     locus and rs11200638 in HTRA1 gene) were analyzed by LC480 Real time PCR (Roche, Basel,~     Switzerland) at D&P Biotech (Daegu, Korea).~   "|||2018-05-31 23:11:19.03667|2018-05-31 23:11:19.03667
NCT01233102|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2016-02-19|2010-11-02|2010-11-03|Estimate|||||||2016-02-19|2016-02-22|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mesenchymal Stem Cells Treat Liver Cirrhosis|Umbilical Cord Mesenchymal Stem Cell Transfusion in Patients With Severe Liver Cirrhosis|Suspended||Phase 1/Phase 2|200|Anticipated|Chinese Academy of Sciences||2|||f||||t||||||||||2018-05-31 23:11:19.102495|2018-05-31 23:11:19.102495
NCT01233089|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2016-11-17|2010-11-01|2010-11-03|Estimate|||||||2016-11-17|2016-11-21|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|COPPER||Fitting Children With Contact Lenses|Quality of Life and Ease of Fit, Fitting Children With Contact Lenses|Completed||N/A|194|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 23:11:19.180983|2018-05-31 23:11:19.180983
NCT01233076|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2011-08-05||2012-06-26|2010-11-01|2010-11-03|Estimate|2011-08-05|2011-09-08|Estimate||||2012-06-26|2012-07-10|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Clinical Comparison of Two Daily Disposable Contact Lenses in a Population of Daily Disposable Contact Lens Wearers||Completed||N/A|60|Actual|Alcon Research||2|||f||||||||||||||2018-05-31 23:11:19.262297|2018-05-31 23:11:19.262297
NCT01233063|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2014-08-28|2010-11-01|2010-11-03|Estimate|||||||2014-08-28|2014-08-29|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ALIVE||Diet and Activity Promotion Among Older Working Adults|Diet and Activity Promotion Among Older Working Adults|Completed||N/A|610|Actual|Berkeley Analytics, Inc.||3|||f||||f||||||||||2018-05-31 23:11:19.396934|2018-05-31 23:11:19.396934
NCT01233050|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2017-03-20||2018-03-02|2010-11-01|2010-11-02|Estimate|2017-08-01|2017-09-05|Actual||||2018-03-02|2018-03-06|Actual|December 2010||2010-12-31|March 2018|2018-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||"Chlorhexidine-Alcohol arm - 8 participants were excluded after treatment administered due to inclusion/exclusion criteria~Iodine Povacrylex-Alcohol Arm - 6 participants were excluded after treatment administered due to inclusion/exclusion criteria"|Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery|A Randomized Double-Blind Study of 2% Chlorhexidine Gluconate / 70% Isopropyl Alcohol vs Iodine Povacrylex [0.7% Available Iodine] / 74% Isopropyl Alcohol for Perioperative Skin Preparation in Open Elective Colorectal Surgery|Completed||N/A|802|Actual|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 23:11:19.470819|2018-05-31 23:11:19.470819
NCT01233037|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2016-08-03|2010-11-01|2010-11-02|Estimate|||||||2016-08-03|2016-08-05|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Observational|EFECT-LVAD||Markers of Endothelial Function and Exercise CapaciTy in Patients With Left Ventricular Assist Devices (EFECT LVAD)|Observational Study Assessing Markers of Endothelial Function and Exercise CapaciTy in Patients With Left Ventricular Assist Devices|Completed|||20|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples With DNA|"~     Some of the blood collected at each visit will stored by the investigator for up to 5 years.~     Samples will be kept in our laboratory for up to 5 years as plasma, after which they will be~     destroyed. Samples will be identified only by a code number, only the principal investigator~     and his research staff will have access to the code. The results of the future tests will not~     be communicated to subjects in this study.~      The samples are stored in the form of plasma from Peripheral blood for additional markers of~     endothelial function (Soluble thrombomodulin, IL-6, etc.)~   "|||2018-05-31 23:11:19.749337|2018-05-31 23:11:19.749337
NCT01233024|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2012-03-28|2010-11-01|2010-11-02|Estimate|||||||2012-03-28|2012-03-29|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Satiety Response of Four Dietary Fibers|Satiety Response of Fructo-oligosaccharide (FOS), Inulin, Soluble Corn Fiber (SCF), and Resistant Starch (RS) in Overweight Woman and Relationship to Fermentation|Completed||Early Phase 1|20|Actual|University of Minnesota - Clinical and Translational Science Institute||5|||f||||f||||||||||2018-05-31 23:11:19.803664|2018-05-31 23:11:19.803664
NCT01233011|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2017-06-22|2010-11-01|2010-11-02|Estimate|||||||2017-06-22|2017-06-26|Actual|December 2010||2010-12-31|June 2017|2017-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Evaluation of the Intubating Laryngeal Airway in Children|Evaluation of the Intubating Laryngeal Airway in Children - Phase 3|Completed|||120|Actual|University of British Columbia|||||f||||t||||||None Retained|"~     No biospecimens.~   "|||2018-05-31 23:11:19.974089|2018-05-31 23:11:19.974089
NCT01232998|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|June 2008||2008-06-30|April 2008|2008-04-30||||||||Observational|||Emergency Department Patient Satisfaction Survey in the Imam Reza Hospital , Tabriz ,Iran, 2008||Completed|||504|Actual|Tabriz University|||3||f||||t||||||||||2018-05-31 23:11:20.041463|2018-05-31 23:11:20.041463
NCT01228448|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2018-03-06|2010-10-25|2010-10-26|Estimate|||||||2018-03-06|2018-03-08|Actual|October 2010||2010-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||In-Room PET in Proton Radiation Therapy|Pilot Study of In-Room PET in Proton Radiation Therapy|Recruiting||N/A|39|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:12:40.501993|2018-05-31 23:12:40.501993
NCT01232985|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2012-05-29|2010-11-01|2010-11-02|Estimate|||||||2012-05-29|2012-05-30|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults|An Open-Label Pilot Study to Determine the Efficacy and Tolerability of a Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis With Associated Pruritus in Adults|Completed||Phase 2|17|Actual|Oculus Innovative Sciences, Inc.||1|||f||||f||||||||||2018-05-31 23:11:20.128129|2018-05-31 23:11:20.128129
NCT01232972|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2013-04-22|2010-11-01|2010-11-02|Estimate|||||||2013-04-22|2013-04-23|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|egg freezing||Oocyte Cryopreservation|Oocyte Cryopreservation|Terminated||N/A|23|Actual|Northwell Health||1||Study technique has been declared part of standard care|f||||f||||||||||2018-05-31 23:11:20.203989|2018-05-31 23:11:20.203989
NCT01232959|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2016-01-12|2010-11-01|2010-11-02|Estimate|||||||2016-01-12|2016-01-13|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TVC||Feasibility of Transvaginal Cholecystectomy|Feasibility of Transvaginal Cholecystectomy|Withdrawn||N/A|0|Actual|Mayo Clinic||1||Subjects not interested|f||||t||||||||||2018-05-31 23:11:20.274847|2018-05-31 23:11:20.274847
NCT01232946|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2017-10-23|2010-11-01|2010-11-02|Estimate|||||||2017-10-23|2017-10-25|Actual|January 2012||2012-01-31|October 2017|2017-10-31|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|||Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake|Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake|Completed||N/A|26|Actual|Indiana University||3|||f||||t||||||||No||2018-05-31 23:11:20.344087|2018-05-31 23:11:20.344087
NCT01232933|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|June 2010||2010-06-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Use of the VasoNova VPS System During PICC Placement in an Algorithm Confirmation Study Using Fluoroscopy|Use of the VasoNova VPS System During PICC Placement in an Algorithm Confirmation Study Using Fluoroscopy|Completed||N/A|83|Actual|VasoNova, Inc.||1|||f||||f||||||||||2018-05-31 23:11:20.434321|2018-05-31 23:11:20.434321
NCT01232920|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2015-12-01||2016-06-07|2010-11-01|2010-11-02|Estimate|2015-12-01|2016-01-05|Estimate||||2016-06-07|2016-07-15|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|FAST||First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial|First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial|Completed||Phase 3|80|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:11:20.500332|2018-05-31 23:11:20.500332
NCT01232907|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-10-06|2010-11-01|2010-11-02|Estimate|||||||2014-10-06|2014-10-08|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effects of L-carnitine on Fatigue in Spinal Cord Injury|The Effects of L-carnitine on Fatigue in Spinal Cord Injury|Completed||Phase 2|2|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 23:11:20.765696|2018-05-31 23:11:20.765696
NCT01232894|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2013-05-21||2013-11-18|2010-11-01|2010-11-02|Estimate|2013-11-18|2013-11-19|Estimate||||2013-11-18|2013-11-19|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|MOVE-ON||12-week Open-label Evaluation of Efficacy and Safety of Indacaterol|A 12 Week, Multi-center, Randomized, Open Label Study, eValuating the Efficacy and Safety of Treatment Regimens That Include ONbrez (Indacaterol) in Patients With Moderate to Severe COPD (MOVE-ON Study)|Completed||Phase 3|90|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:11:20.85001|2018-05-31 23:11:20.85001
NCT01232881|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-04-27|2010-11-01|2010-11-02|Estimate|||||||2011-04-27|2011-04-28|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study|Terminated|||27|Actual|Hoosier Cancer Research Network|||1|funding terminated|f||||t||||||Samples Without DNA|"~     Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed~     paraffin embedded tissue block.~      Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after~     the last dose of lonafarnib.~   "|||2018-05-31 23:11:21.064544|2018-05-31 23:11:21.064544
NCT01232868|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-23|2015-09-21|2012-10-09|2015-10-27|2010-11-01|2010-11-02|Estimate|2015-10-27|2015-11-30|Estimate|2012-10-09|2012-10-11|Estimate|2015-10-27|2015-11-30|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||All subjects received a single dose of the trivalent Influenza vaccine (TIV).|Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly|Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly|Completed||N/A|66|Actual|Emory University|Long period of time required for detailed analysis of gene expressions in different participants|2|||f||||f||||||||||2018-05-31 23:11:21.152696|2018-05-31 23:11:21.152696
NCT01232855|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-30|||2015-09-30|2010-10-30|2010-11-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia|Regulation of S100A10 by the PML-RAR-alpha Oncoprotein|Completed|||10|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:11:21.480171|2018-05-31 23:11:21.480171
NCT01232842|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-30|||2016-07-07|2010-10-30|2010-11-02|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2010||2010-10-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia|Assessment of Stem Cell Heterogeneity in AML in Co-Culture Systems Using X Chromosome Inactivation Patterns|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:11:21.546705|2018-05-31 23:11:21.546705
NCT01232829|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-30|2014-11-19||2014-11-19|2010-10-30|2010-11-02|Estimate|2014-11-19|2014-11-26|Estimate||||2014-11-19|2014-11-26|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|July 2012|Actual|2012-07-31||Interventional||A patient that is alive at 6 months is considered a treatment success. The largest success proportion where the proposed treatment was considered ineffective was 15% and the smallest was 35%. This MinMax design used 32 patients to test the null hypothesis that the true success proportion in a given patient population is at most 15%.|Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer|A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer|Completed||Phase 2|18|Actual|National Cancer Institute (NCI)|The study met criteria to accrue 32 subjects but only 18 were enrolled. It was decided to stop further enrollment after RO4929097 was discontinued by the sponsor and was no longer a development candidate.|1|||f||||t||||||||||2018-05-31 23:11:21.624533|2018-05-31 23:11:21.624533
NCT01232816|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-30|||2016-09-12|2010-11-01|2010-11-02|Estimate|||||||2016-09-12|2016-09-14|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Role of T Helper 17 and Regulatory T Cells in Delayed Graft Function|Can T Helper 17 and Regulatory T Cells Explain the Pathophysiology of Delayed Graft Function in Renal Transplant Recipients?|Active, not recruiting|||50|Anticipated|McGill University Health Center|||2||f||||f||||||Samples Without DNA|"~     Urine Kidney biopsy Kidney preservation fluid~   "|No|There is no plan to make the experimental data available to participants. Their clinical data, however, is available to them through their treating physician.|2018-05-31 23:11:21.816379|2018-05-31 23:11:21.816379
NCT01232803|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2013-03-19|2010-11-01|2010-11-02|Estimate|||||||2013-03-19|2013-03-20|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Rectal Safety and Acceptability Study of Tenofovir 1% Gel|A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel|Completed||Phase 1|65|Actual|CONRAD||4|||f||||t||||||||||2018-05-31 23:11:21.868243|2018-05-31 23:11:21.868243
NCT01232790|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2013-01-24||2015-11-04|2010-10-29|2010-11-02|Estimate|2014-03-10|2014-04-16|Estimate||||2015-11-04|2015-12-01|Estimate|February 2010||2010-02-28|November 2015|2015-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|NAC||A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia|A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia|Completed||N/A|28|Actual|Yale University||2|||f||||f||||||||||2018-05-31 23:11:21.964328|2018-05-31 23:11:21.964328
NCT01232777|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2013-10-16|2010-10-29|2010-11-02|Estimate|||||||2013-10-16|2013-10-17|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|July 2018|Anticipated|2018-07-31|April 2015|Anticipated|2015-04-30||Interventional|BLOCK-ROP||Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)|Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)|Withdrawn||Phase 2|0|Actual|Vision Research Foundation||3||Lack of funding|f||||t||||||||||2018-05-31 23:11:22.383989|2018-05-31 23:11:22.383989
NCT01232764|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2012-09-27|2010-11-01|2010-11-02|Estimate|||||||2012-09-27|2012-09-28|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PUMTT||Pressure Ulcer Multi-disciplinary Teams Via Telemedicine (PUMTT): A Trial in Long Term Care|Pressure Ulcer Multi-disciplinary Teams Via Telemedicine (PUMTT): A Cluster Pragmatic Randomised Controlled Trial in Long Term Care|Completed||Phase 3|137|Actual|University of Toronto||1|||f||||t||||||||||2018-05-31 23:11:22.472621|2018-05-31 23:11:22.472621
NCT01232751|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-01-09|2010-11-01|2010-11-02|Estimate|||||||2012-01-09|2012-01-10|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ISO||Effects of Isoflavones on Gene-expression|The Effect of Isoflavone Supplement Intake on Gene-expression in Postmenopausal Women|Completed||N/A|30|Actual|Wageningen University|||||f||||f||||||||||2018-05-31 23:11:22.616217|2018-05-31 23:11:22.616217
NCT01232738|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2016-11-16||2018-04-17|2010-10-29|2010-11-02|Estimate|2018-04-17|2018-05-18|Actual||||2018-04-17|2018-05-18|Actual|December 2011||2011-12-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Multi-Center Controlled Screening Trial of Safety and Efficacy of Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|36|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 23:11:22.729593|2018-05-31 23:11:22.729593
NCT01232725|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-08-03|2010-11-01|2010-11-02|Estimate|||||||2017-08-03|2017-08-04|Actual|August 2009||2009-08-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional|||Donor Human Milk and Neurodevelopmental Outcomes in Very Low Birthweight (VLBW) Infants|Clinical Epidemiologic and Biologic Studies of Donor Human Milk and Breastfeeding|Completed||N/A|121|Actual|University of Iowa||2|||f||||t||||||||Yes|Contact PI to discuss data sharing|2018-05-31 23:11:23.044222|2018-05-31 23:11:23.044222
NCT01232712|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2013-08-06|2010-11-01|2010-11-02|Estimate|||||||2013-08-06|2013-08-09|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies|A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies|Completed||Phase 1/Phase 2|15|Actual|Vaxil Therapeutics Ltd.||1|||f||||f||||||||||2018-05-31 23:11:23.146682|2018-05-31 23:11:23.146682
NCT01232699|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2014-05-15|2010-11-01|2010-11-02|Estimate|||||||2014-05-15|2014-05-16|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|iReach2||Internet Obesity Treatment Enhanced With Motivational Interviewing|Internet Obesity Treatment Enhanced With Motivational Interviewing|Completed||Early Phase 1|495|Actual|University of Vermont||3|||f||||t||||||||||2018-05-31 23:11:23.235248|2018-05-31 23:11:23.235248
NCT01232686|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-02-15|2010-11-01|2010-11-02|Estimate|||||||2017-02-15|2017-02-16|Actual|October 2010||2010-10-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Snow||Snow Disease Surveillance System Study|Snow Disease Surveillance System Study|Completed||N/A|200|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 23:11:23.343839|2018-05-31 23:11:23.343839
NCT01232673|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2013-03-21|2010-11-01|2010-11-02|Estimate|||||||2013-03-21|2013-03-22|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Autologous Bone Marrow Stem Cell Transfer in Patients With Chronical Critical Limb Ischemia and Diabetic Foot|Autologous Bone Marrow Stem Cell Transfer in Patients With Chronical Critical Limb Ischemia and Diabetic Foot|Completed||Phase 2|96|Actual|University Hospital Ostrava||2|||f||||t||||||||||2018-05-31 23:11:23.413599|2018-05-31 23:11:23.413599
NCT01232660|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-02-10|2010-11-01|2010-11-02|Estimate|||||||2014-02-10|2014-02-11|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|SSAT039||Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)|The Immunological Impact of Adding Hydroxychloroquine in Patients With Discordant CD4+ Cell Responses to Suppressive HAART: A Phase I Pilot Study.|Unknown status|Recruiting|Phase 1|12|Anticipated|St Stephens Aids Trust||2|||f||||f||||||||||2018-05-31 23:11:23.486137|2018-05-31 23:11:23.486137
NCT01232647|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2017-07-31|2010-11-01|2010-11-02|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|VITKANDOP||Vitamin K as Additive Treatment in Osteoporosis|The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis|Recruiting||Phase 2/Phase 3|105|Anticipated|Guy's and St Thomas' NHS Foundation Trust||3|||f||||f||||||||Undecided||2018-05-31 23:11:23.578159|2018-05-31 23:11:23.578159
NCT01139541|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2015-08-17|2010-06-07|2010-06-08|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Testing Strategies for Increasing Exercise|Testing Strategies for Increasing Exercise|Completed||N/A|224|Actual|Harvard University||4|||f||||t||||||||||2018-05-31 23:42:29.433751|2018-05-31 23:42:29.433751
NCT01232634|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2016-11-08|2010-11-01|2010-11-02|Estimate|||||||2016-11-08|2016-11-09|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Observational|||Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles|External Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles. MRI Correlation.|Completed|||57|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 23:11:23.674529|2018-05-31 23:11:23.674529
NCT01232621|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-01-04|2010-11-01|2010-11-02|Estimate|||||||2013-01-04|2013-01-07|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Approach Study|A Randomized Pilot Study of Different Methods of Approaching Substitute Decision Makers Regarding Research Participation in the Intensive Care Unit: The Approach Study|Completed||Phase 2|138|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 23:11:23.745527|2018-05-31 23:11:23.745527
NCT01232608|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2013-04-04|2010-11-01|2010-11-02|Estimate|||||||2013-04-04|2013-04-05|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EXCADI||Exercise Training in Patients With Coronary Heart Disease and Type 2 Diabetes|Exercise Training in Patients With Coronary Heart Disease and Type 2 Diabetes|Completed||N/A|137|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 23:11:23.830132|2018-05-31 23:11:23.830132
NCT01232595|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2015-03-24|2010-11-01|2010-11-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections|Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections|Completed||Phase 2|109|Actual|Novartis||6|||f||||f||||||||||2018-05-31 23:11:23.917342|2018-05-31 23:11:23.917342
NCT01232582|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-02-19|2010-11-01|2010-11-02|Estimate|||||||2012-02-19|2012-02-22|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety and Efficacy of MRgFUS for the Treatment of Low Back Pain|Safety and Efficacy of ExAblate MR Guided Focused Ultrasound for the Treatment of Low Back Pain Related to Facet Joint Osteoarthritis|Completed||Phase 2|50|Anticipated|InSightec|||||f||||f||||||||||2018-05-31 23:11:24.029409|2018-05-31 23:11:24.029409
NCT01232569|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2013-04-18||2015-07-07|2010-11-01|2010-11-02|Estimate|2013-08-20|2013-10-23|Estimate||||2015-07-07|2015-07-29|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|May 2012|Actual|2012-05-31||Interventional||Baseline Characteristics are reported for the safety population which included all patients who received at least 1 dose of study drug and had at least 1 post-dose safety assessment. One patient who received tocilizumab had no post-baseline safety data and was excluded from the safety population.|A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis|Completed||Phase 3|656|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:11:24.162385|2018-05-31 23:11:24.162385
NCT01232556|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27||2014-05-29|2014-05-29|2010-10-29|2010-11-02|Estimate||||2014-05-29|2014-06-02|Estimate|2014-05-29|2014-06-02|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy|An Open-Label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin Administered In Combination With Rituximab Compared To Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates For Intensive High-Dose Chemotherapy|Terminated||Phase 3|340|Actual|Pfizer||2||"The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety~   issues were identified."|f||||t||||||||||2018-05-31 23:11:25.1023|2018-05-31 23:11:25.1023
NCT01232543|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28||2012-04-09|2012-04-09|2010-11-01|2010-11-02|Estimate||||2012-04-09|2012-04-11|Estimate|2012-04-09|2012-04-11|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|0405-01-04||Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis|An Open-Label Evaluation of the Adrenal Suppression Potential of Product 0405 in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects|Completed||Phase 2|114|Actual|Fougera Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 23:11:26.288015|2018-05-31 23:11:26.288015
NCT01232530|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2015-07-29|2010-11-01|2010-11-02|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2010||2010-06-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|PVACT||Pharmacovigilance for ACTs in Africa|Pharmacovigilance for Artemisinin-based Combination Treatments in Africa|Completed|||3176|Actual|Centre Muraz|||4||f||||f||||||Samples With DNA|"~     Blood spot on filter paper for PCR analysis~   "|||2018-05-31 23:11:26.441298|2018-05-31 23:11:26.441298
NCT01232517|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2015-04-29|2010-10-29|2010-11-02|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||NeuroVision® Dynamic Screw Test Study|A Prospective Evaluation of the Dynamic Function of the NeuroVision® System for the Placement of Lumbar Pedicle Screws|Completed|||60|Actual|NuVasive|||||f||||f||||||||||2018-05-31 23:11:26.508627|2018-05-31 23:11:26.508627
NCT01232504|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2014-01-26||2014-10-27|2010-10-31|2010-11-02|Estimate|2014-10-22|2014-10-27|Estimate||||2014-10-27|2014-11-04|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT|Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial|Completed||Phase 4|206|Actual|Xiamen Amoytop Biotech Co., Ltd.|The limitations of the current study included the lack of blinding and placebo group.|3|||f||||t||||||||||2018-05-31 23:11:26.595955|2018-05-31 23:11:26.595955
NCT01232309|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-30|||2012-10-22|2010-10-30|2010-11-02|Estimate|||||||2012-10-22|2012-10-23|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)|Completed||N/A|135|Actual|Stratum Nutrition||4|||f||||t||||||||||2018-05-31 23:11:30.130956|2018-05-31 23:11:30.130956
NCT01232491|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2012-11-14||2017-03-28|2010-10-29|2010-11-02|Estimate|2012-11-14|2012-12-11|Estimate||||2017-03-28|2017-05-01|Actual|October 29, 2010|Actual|2010-10-29|March 2017|2017-03-31|November 14, 2011|Actual|2011-11-14|November 1, 2011|Actual|2011-11-01||Interventional|DIET™||Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes|A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin (Levemir DIET)|Completed||Phase 4|611|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:11:27.113104|2018-05-31 23:11:27.113104
NCT01232478|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2015-03-30|2010-10-29|2010-11-02|Estimate|||||||2015-03-30|2015-03-31|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|iCARE||I Change Adherence & Raise Expectations|I Change Adherence & Raise Expectations|Completed||Phase 3|641|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:11:27.896151|2018-05-31 23:11:27.896151
NCT01232465|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2014-01-21||2014-03-14|2010-10-29|2010-11-02|Estimate|2014-01-21|2014-03-06|Estimate||||2014-03-14|2014-04-11|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Observational|TBA on IVF||Impact of Sperm DNA Integrity on In Vitro Cycles|Impact of Sperm DNA Integrity on In Vitro Cycles|Completed|||420|Actual|Northwell Health|||2||f||||f||||||Samples Without DNA|"~     slide smears will be kept to observe overall DNA integrity of sperm sample~   "|||2018-05-31 23:11:28.014861|2018-05-31 23:11:28.014861
NCT01232452|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28||2013-04-30|2016-07-18|2010-11-01|2010-11-02|Estimate||||2013-04-30|2013-05-08|Estimate|2016-07-18|2016-07-20|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2013|Actual|2013-01-31||Interventional|||A Study in Non-Small Cell Lung Cancer|An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Carcinoma|Completed||Phase 2|168|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 23:11:28.299252|2018-05-31 23:11:28.299252
NCT01232439|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-05-05|2010-11-01|2010-11-02|Estimate|||||||2011-05-05|2011-05-09|Estimate|December 2010||2010-12-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Brain Receptor Occupancy in Healthy Subjects|Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects|Completed||Phase 1|13|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:11:28.547389|2018-05-31 23:11:28.547389
NCT01232426|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-31|||2012-08-17|2010-11-01|2010-11-02|Estimate|||||||2012-08-17|2012-08-20|Estimate|March 2011||2011-03-31|August 2012|2012-08-31||||January 2014|Anticipated|2014-01-31||Interventional|||A Randomized Controlled Trial of the Treatment of Mallet Fractures|A Randomized Controlled Trial of the Treatment of Mallet Fractures: Conservative Versus Operative Using One Meniscus Arrow®|Unknown status|Recruiting|N/A|84|Anticipated|Conmed Linvatec Benelux||2|||f||||f||||||||||2018-05-31 23:11:28.648835|2018-05-31 23:11:28.648835
NCT01232413|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2011-02-24|2010-11-01|2010-11-02|Estimate|||||||2011-02-24|2011-02-28|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Effect of Repeat Oral Doses of ASP1941 on Cardiac Repolarization in Healthy Male and Female Adult Subjects|Completed||Phase 1|88|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 23:11:28.765967|2018-05-31 23:11:28.765967
NCT01232400|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2015-01-07|2010-11-01|2010-11-02|Estimate|||||||2015-01-07|2015-01-08|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|August 2016|Anticipated|2016-08-31|July 2015|Anticipated|2015-07-31||Interventional|ABASH||Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage|Adrenergic Blockade After Subarachnoid Hemorrhage|Withdrawn||N/A|0|Actual|University of Michigan||2||Funding withdrawn. Design not feasible.|f||||t||||||||||2018-05-31 23:11:28.856492|2018-05-31 23:11:28.856492
NCT01232387|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2013-09-19|2010-11-01|2010-11-02|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|June 2012|Actual|2012-06-30||Observational|||Identification of Early Predictors of Fetomaternal Hemorrhage|Identification of Early Predictors of Fetomaternal Hemorrhage And Development Of An Automated Screening Strategy For At-Risk Pregnancies|Completed|||39|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||Samples Without DNA|"~     Whole blood, placenta~   "|||2018-05-31 23:11:28.96875|2018-05-31 23:11:28.96875
NCT01232374|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2015-08-19|2010-11-01|2010-11-02|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Interventional|||Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma|A Clinical Study of Nimotuzumab in Combination With Concurrent Chemotherapy and Radiation for Patients With Local Advanced Esophageal Squamous Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|144|Anticipated|Biotech Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 23:11:29.046614|2018-05-31 23:11:29.046614
NCT01232361|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-01-19|2010-10-29|2010-11-02|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|IMPAACT P1080||IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents|IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents|Completed|||127|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||2||f||||f||||||Samples With DNA|"~     Non-viable PBMC pellets for DNA genotypic analysis~   "|||2018-05-31 23:11:29.307733|2018-05-31 23:11:29.307733
NCT01232348|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-31|||2011-12-06|2010-10-31|2010-11-02|Estimate|||||||2011-12-06|2011-12-07|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|SURE||Symbicort Turbuhaler 30/60 Clinical Experience Investigation|Symbicort Turbuhaler 30/60 Clinical Experience Investigation|Completed|||3643|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:11:29.572255|2018-05-31 23:11:29.572255
NCT01232335|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-31|||2013-05-28|2010-10-31|2010-11-02|Estimate|||||||2013-05-28|2013-05-29|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|ENSURE||Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation|Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation for Long-term Use|Completed|||1500|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:11:29.743232|2018-05-31 23:11:29.743232
NCT01232322|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-31|||2013-01-23|2010-11-01|2010-11-02|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2006||2006-10-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation|Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation for Long-term Use in Pediatrics|Completed|||633|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:11:29.968903|2018-05-31 23:11:29.968903
NCT01232296|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2015-03-26||2015-11-02|2010-11-01|2010-11-02|Estimate|2015-11-02|2015-12-04|Estimate||||2015-11-02|2015-12-04|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment|An Open-label, Randomized, Multi-center, Phase II Study to Compare the Safety and Efficacy of TKI258 Versus Sorafenib as First-line Treatment in Adult Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 2|162|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:11:30.437682|2018-05-31 23:11:30.437682
NCT01232283|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2014-10-22|2013-05-24|2017-11-30|2010-11-01|2010-11-02|Estimate|2014-11-03|2014-11-05|Estimate|2013-05-24|2013-06-05|Estimate|2017-11-30|2018-01-04|Actual|November 22, 2010|Actual|2010-11-22|November 2017|2017-11-30|November 30, 2016|Actual|2016-11-30|March 15, 2012|Actual|2012-03-15||Interventional|ESTEEM 2|The full analysis set (FAS) consisted of all participants who were randomized as specified in the protocol. Those who were randomized in error and did not receive any dose of Investigational product (IP) were excluded from FAS. Participants were included in the treatment group to which they were randomized APR 30 BID or placebo for the FAS.|Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|413|Actual|Celgene||2|||f||||f||||||||||2018-05-31 23:11:31.279121|2018-05-31 23:11:31.279121
NCT01232270|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2013-03-04|2010-11-01|2010-11-02|Estimate|||||||2013-03-04|2013-03-06|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Optimal Effect Site Concentration of Propofol for Conscious Sedation in Elderly Male Patients Undergoing Urologic Surgery Under Spinal Anesthesia With or Without Intrathecal Fentanyl|The Optimal Effect Site Concentration of Propofol for Conscious Sedation in Elderly Male Patients Undergoing Urologic Surgery Under Spinal Anesthesia With or Without Intrathecal Fentanyl|Completed||N/A|43|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:11:32.563612|2018-05-31 23:11:32.563612
NCT01232257|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-10-25|2010-11-01|2010-11-02|Estimate|||||||2012-10-25|2012-10-26|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD)|Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease|Completed||Phase 3|28|Actual|UMC Utrecht||4|||f||||f||||||||||2018-05-31 23:11:32.655722|2018-05-31 23:11:32.655722
NCT01232244|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2013-12-09|2010-11-01|2010-11-02|Estimate|||||||2013-12-09|2013-12-10|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.||Completed|||15|Actual|University Hospital, Gentofte, Copenhagen|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 23:11:32.752473|2018-05-31 23:11:32.752473
NCT01232231|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2013-02-14|2010-11-01|2010-11-02|Estimate|||||||2013-02-14|2013-02-15|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|||Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting|Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus in the Outpatient Setting: a Randomized Controlled Study|Completed||N/A|15|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 23:11:32.846871|2018-05-31 23:11:32.846871
NCT01232218|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-07-26|2010-11-01|2010-11-02|Estimate|||||||2012-07-26|2012-07-27|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|TPHSP||Treatment Protocol for Hemiplegic Shoulder Pain|Effectiveness of a Three-Dimensional Scapular-Humeral Mobilization Technique on Hemiplegic Shoulder Pain|Completed||N/A|20|Actual|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-05-31 23:11:32.946919|2018-05-31 23:11:32.946919
NCT01232205|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|2010-11-02||2010-11-02|2010-11-01|2010-11-02|Estimate|2010-11-02|2010-12-02|Estimate||||2010-11-02|2010-12-02|Estimate|June 2001||2001-06-30|December 2009|2009-12-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|ASIP1||Antioxidant Supplementation in Pregnant Women|Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status|Completed||Phase 2/Phase 3|168|Actual|Showa University||2|||f||||f||||||||||2018-05-31 23:11:33.046422|2018-05-31 23:11:33.046422
NCT01232192|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Interventional|AACP||Study of Antenatal Model to Prevent Preterm Delivery|Study of Antenatal Model to Prevent Preterm Delivery: Early Detection and Treatment of Bacterial Vaginosis|Unknown status|Recruiting|N/A|220|Anticipated|Showa University||2|||f||||f||||||||||2018-05-31 23:11:33.248496|2018-05-31 23:11:33.248496
NCT01232179|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|PDR||Comparison of Two Laser Therapy Methods for PDR|Comparison Between Result and Side Effects of Treatment of Prolifrative Diabetic Retinopaty by Conventional and Extended Targeted Pan Retinal Photocoagolation|Unknown status|Recruiting|Phase 2|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 23:11:33.326329|2018-05-31 23:11:33.326329
NCT01232166|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|March 2004||2004-03-31|October 2010|2010-10-31|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||Which is the Best Bedside Test to Detect Endobronchial Intubation?|Endotracheal Tube Insertion Depth Better Detects Endobronchial Intubation Than Bilateral Auscultation or Observation of Chest Movements - a Prospective Randomised Trial|Completed||N/A|160|Actual|Medical University of Vienna||8|||f||||||||||||||2018-05-31 23:11:33.410338|2018-05-31 23:11:33.410338
NCT01232153|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2018-03-29|2010-11-01|2010-11-02|Estimate|||||||2018-03-29|2018-03-30|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|PREOXY||Preoxygenation Before Prehospital Tracheal Intubation With NIV Versus Balloon|Preoxygenation Before Prehospital Tracheal Intubation With NIV Versus Balloon. A Multicenter Randomized Controlled Trial in Mobile Medical Emergency Rescue Service|Active, not recruiting||N/A|230|Anticipated|Hopital of Melun||2|||f||||t|f|f||||||Undecided||2018-05-31 23:11:33.48116|2018-05-31 23:11:33.48116
NCT01232140|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2012-03-21|2010-11-01|2010-11-02|Estimate|||||||2012-03-21|2012-03-22|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|CATCH||CRP-guided Antibiotic Treatment in COPD Exacerbations Admitted to the Hospital|CRP-guided Antibiotic Treatment in Patients Hospitalized With Acute Exacerbations of COPD Patients. A Randomized Controlled Intervention Trial.|Unknown status|Recruiting|N/A|220|Anticipated|Medical Center Alkmaar||2|||f||||f||||||||||2018-05-31 23:11:33.547076|2018-05-31 23:11:33.547076
NCT01232127|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2012-07-23||2012-08-27|2010-11-01|2010-11-02|Estimate|2012-07-25|2012-08-28|Estimate||||2012-08-27|2012-08-31|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection|Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine on the Pharmacokinetics of Atazanavir in HIV-Infected Subjects Receiving Atazanavir With Ritonavir and Tenofovir|Completed||Phase 4|25|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 23:11:33.667172|2018-05-31 23:11:33.667172
NCT01232114|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2010|Anticipated|2010-10-31|October 2010|Actual|2010-10-31||Observational|SMT||Safety Study of a Chinese Herbal Formula Simotang Oral Liquid for the Treatment of Functional Dyspepsia|Phase 2 Study of of a Chinese Herbal Formula Simotang Oral Liquid for the Treatment of Functional Dyspepsia|Unknown status|Recruiting||400|Anticipated|Hunan University of Traditional Chinese Medicine|||||f||||t||||||||||2018-05-31 23:11:34.072353|2018-05-31 23:11:34.072353
NCT01232101|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Covered or Uncovered Bile Duct Stents|Covered and Uncovered Self Expandable Metallic Stents Are Equally Efficacious in Bile Duct Strictures. Results of a Randomized Study.|Completed||N/A|71|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 23:11:34.218445|2018-05-31 23:11:34.218445
NCT01232088|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2015-10-30|2010-11-01|2010-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Observational|||Questionnaire of the Section Perioperative Intensive Care of the European Society of Intensive Care Medicine (ESICM) on Standardized Drug Labelling|Questionnaire of the Section Perioperative Intensive Care of the European Society of Intensive Care Medicine (ESICM) on Standardized Drug Labelling|Completed|||482|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 23:11:34.287789|2018-05-31 23:11:34.287789
NCT01232075|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-07-11|2010-11-01|2010-11-02|Estimate|||||||2011-07-11|2011-07-12|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination|Extended Letrozole Regimen Versus Clomiphene Citrate for Superovulation in Patients With Unexplained Infertility Undergoing Intrauterine Insemination|Completed||Phase 2|214|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 23:11:34.358662|2018-05-31 23:11:34.358662
NCT01232062|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2015-07-22|2010-11-01|2010-11-02|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|October 2013|Actual|2013-10-31|May 2011|Actual|2011-05-31||Observational|DC-CIK||Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients|Study of High-dose Chemotherapy Combined With Adoptive Cellular Therapy With Dentritic and Cytokine-induced Killer Cells in Triple Negative Breast Cancer Patients|Completed|||46|Actual|Beijing Cancer Hospital|||||f||||t||||||None Retained|"~     about 4ml peripheral vein blood，paraffin section on metastatic tissue，~   "|||2018-05-31 23:11:34.448157|2018-05-31 23:11:34.448157
NCT01232049|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2011-06-24|2010-11-01|2010-11-02|Estimate|||||||2011-06-24|2011-06-27|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||March 2011|Actual|2011-03-31||Interventional|||Drug Interaction and Safety Between Pitavastatin and Valsartan (CWP-PTV-101)|A Randomized, Open-label, Multiple Dose, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety Between Pitavastatin and Valsartan in Healthy Male Subjects|Completed||Phase 1|24|Anticipated|Asan Medical Center||3|||f||||||||||||||2018-05-31 23:11:34.5089|2018-05-31 23:11:34.5089
NCT01232036|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018|A Clinical Trial to Compare the Pharmacokinetic and Pharmacodynamic Characteristics and Safety After Oral Administration of Glucophage With Those After Oral Administration of HL-018 in Healthy Male Volunteers|Completed||Phase 1|28|Actual|Asan Medical Center||3|||f||||f||||||||||2018-05-31 23:11:34.582746|2018-05-31 23:11:34.582746
NCT01232023|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-11-09|2010-11-01|2010-11-02|Estimate|||||||2010-11-09|2010-11-10|Estimate|January 2010||2010-01-31|October 2010|2010-10-31||||December 2010|Anticipated|2010-12-31||Interventional|||Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent|Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent|Unknown status|Recruiting|Phase 1|12|Anticipated|Asan Medical Center||4|||f||||f||||||||||2018-05-31 23:11:34.688533|2018-05-31 23:11:34.688533
NCT01232010|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2015-01-13|2010-11-01|2010-11-02|Estimate|||||||2015-01-13|2015-01-15|Estimate|November 2009||2009-11-30|January 2015|2015-01-31||||December 2011|Actual|2011-12-31||Interventional|SK3530_RI_I||Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal Impaired Male Patients|Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients|Completed||Phase 1|12|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:11:34.761566|2018-05-31 23:11:34.761566
NCT01231997|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2010-11-01|2010-11-01|2010-11-02|Estimate|||||||2010-11-01|2010-11-02|Estimate|November 2009||2009-11-30|October 2010|2010-10-31||||November 2010|Actual|2010-11-30||Interventional|DA8159_RI_I||Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients|Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients|Completed||Phase 1|27|Anticipated|Asan Medical Center||4|||f||||f||||||||||2018-05-31 23:11:34.861361|2018-05-31 23:11:34.861361
NCT01231984|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2013-10-24||2014-05-27|2010-11-01|2010-11-02|Estimate|2014-05-27|2014-06-27|Estimate||||2014-05-27|2014-06-27|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Baseline characteristics are presented for the population of subjects (274) that completed the wash-in period and were randomized into the study arms.|Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles|Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fine™ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fine™ Short 8mm x 31G Pen Needle or the BD Ultra Fine™ 12.7mm x 29G Pen Needle|Completed||N/A|293|Actual|Becton, Dickinson and Company||2|||f||||f||||||||||2018-05-31 23:11:34.945541|2018-05-31 23:11:34.945541
NCT01231971|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2017-11-17|2010-10-29|2010-11-01|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2011||2011-01-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|ADNI2||Alzheimer's Disease Neuroimaging Initiative 2|Alzheimer's Disease Neuroimaging Initiative 2|Active, not recruiting|||650|Anticipated|University of Southern California|||5||f||||t||||||Samples With DNA|"~     blood, urine, cerebrospinal fluid~   "|||2018-05-31 23:11:35.519347|2018-05-31 23:11:35.519347
NCT01231932|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2018-05-22|2010-10-29|2010-11-01|Estimate|||||||2018-05-22|2018-05-23|Actual|October 29, 2010||2010-10-29|May 4, 2018|2018-05-04||||||||Observational|||Investigating Molecular-Genetic Correlates of Fatigue Experienced by Cancer Patients Receiving Treatment|Investigating Molecular-Genetic Correlates of Fatigue Experienced by Cancer Patients Receiving Treatment|Recruiting|||206|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:11:36.225462|2018-05-31 23:11:36.225462
NCT01231919|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-04-28|2010-10-29|2010-11-01|Estimate|||||||2014-04-28|2014-04-29|Estimate|January 2011||2011-01-31|April 2013|2013-04-30||||April 2013|Actual|2013-04-30||Interventional|||MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia|A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:11:36.317451|2018-05-31 23:11:36.317451
NCT01231906|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2018-02-09|2010-10-29|2010-11-01|Estimate|||||||2018-02-09|2018-02-12|Actual|November 2010||2010-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma|A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma|Active, not recruiting||Phase 3|693|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 23:11:36.533677|2018-05-31 23:11:36.533677
NCT01231893|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|May 2008||2008-05-31|October 2010|2010-10-31||||||||Interventional|||Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury|Transplantation of Autologous Olfactory Ensheathing Cells for Treatment of Complete Human Spinal Cord Injuries- a Phase I Clinical Trial.|Unknown status|Recruiting|Phase 1|10|Anticipated|Wroclaw Medical University||2|||f||||f||||||||||2018-05-31 23:11:36.954688|2018-05-31 23:11:36.954688
NCT01231880|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2013-05-22|2010-10-29|2010-11-01|Estimate|||||||2013-05-22|2013-05-23|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SBMC||School Based Malaria Control in Ugandan Schoolchildren|School-based Malaria Control: Impact of Intermittent Preventive Treatment on Malaria Morbidity and Cognitive Function in Ugandan School Children|Completed||Phase 3|740|Actual|Makerere University||3|||f||||t||||||||||2018-05-31 23:11:37.030759|2018-05-31 23:11:37.030759
NCT01231867|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2015-05-01|2010-10-29|2010-11-01|Estimate|||||||2015-05-01|2015-05-04|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Cohort Study of Clopidogrel and Proton Pump Inhibitors|Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study|Completed|||24471|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-05-31 23:11:37.10962|2018-05-31 23:11:37.10962
NCT01231854|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-06-02|2010-10-29|2010-11-01|Estimate|||||||2014-06-02|2014-06-03|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|TocyDD||Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.|Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis. A Randomized Controlled Investigator-initiated Double-blind Trial.|Terminated||Phase 4|15|Actual|Technische Universität Dresden||2||"delayed start of the trial, both treatment options already have market authorizations, study~   medication expired"|f||||f||||||||||2018-05-31 23:11:37.17836|2018-05-31 23:11:37.17836
NCT01231841|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|2012-01-31||2018-01-25|2010-10-29|2010-11-01|Estimate|2012-02-08|2012-03-09|Estimate||||2018-01-25|2018-02-22|Actual|March 2005||2005-03-31|January 2018|2018-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia|Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA)|Completed||Phase 2|20|Actual|The Cleveland Clinic||1|||f||||t||||||||||2018-05-31 23:11:37.2452|2018-05-31 23:11:37.2452
NCT01231828|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-02-26|2010-10-29|2010-11-01|Estimate|||||||2013-02-26|2013-02-27|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|AutoSop-Foie||Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.|Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. Impact of Lactulose and Carnitine Treatment.|Completed||N/A|55|Actual|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 23:11:37.416508|2018-05-31 23:11:37.416508
NCT01231815|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-04-08|2010-10-29|2010-11-01|Estimate|||||||2014-04-08|2014-04-09|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|RECOPE||Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner|Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner|Unknown status|Recruiting|N/A|30|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 23:11:37.480255|2018-05-31 23:11:37.480255
NCT01231802|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2012-07-16|2010-10-29|2010-11-01|Estimate|||||||2012-07-16|2012-07-17|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|January 2013|Anticipated|2013-01-31|August 2012|Anticipated|2012-08-31||Interventional|||Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer|A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|140|Anticipated|Adherex Technologies, Inc.||2|||f||||f||||||||||2018-05-31 23:11:37.555605|2018-05-31 23:11:37.555605
NCT01231789|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-08-19|2010-10-29|2010-11-01|Estimate|||||||2012-08-19|2012-08-21|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||The Neuroprotection of Remote Ischemic Preconditioning (RIPC) on Cardiac Surgery in Multicenter|The Neuroprotection of Remote Ischemic Preconditioning on Cardiac Surgery in Multicenter|Unknown status|Recruiting|N/A|150|Anticipated|Xijing Hospital||2|||f||||f||||||||||2018-05-31 23:11:37.630139|2018-05-31 23:11:37.630139
NCT01231776|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2011-02-21|2010-10-29|2010-11-01|Estimate|||||||2011-02-21|2011-02-23|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|February 2011|Anticipated|2011-02-28|January 2011|Anticipated|2011-01-31||Interventional|||Acupuncture Improves Sleep in Patients Undergoing Cardiopulmonary Bypass|Study of Acupuncture of Traditional Chinese Medicine|Unknown status|Recruiting|N/A|60|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 23:11:37.696436|2018-05-31 23:11:37.696436
NCT01231763|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2011-02-08|2010-10-29|2010-11-01|Estimate|||||||2011-02-08|2011-02-09|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|FACE||Acceptability Study of Vaginal Films for HIV Prevention|Film Acceptability Characterization and Evaluation|Completed|||84|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 23:11:38.676482|2018-05-31 23:11:38.676482
NCT01231750|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2013-06-25||2015-06-23|2010-10-29|2010-11-01|Estimate|2015-06-23|2015-06-25|Estimate||||2015-06-23|2015-06-25|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|TOPCAP||Efficacy of Topical Capsaicin Cream for Stable Angina|A Randomized, Placebo-Controlled, Cross-Over Study to Assess the Safety and Efficacy of TOPical CAPsaicin With Stable Angina (TOPCAP)|Terminated||Phase 3|7|Actual|University of Cincinnati||2||Unable to identify study population to achieve number expected|f||||t||||||||||2018-05-31 23:11:38.775817|2018-05-31 23:11:38.775817
NCT01231737|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|November 2010||2010-11-30|October 2009|2009-10-31|February 2012|Anticipated|2012-02-29|February 2011|Anticipated|2011-02-28||Interventional|||Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)|Efficacy of Prulifloxacin vs Phosphomycin in the Prophylasy of Urinary Tract Infection|Unknown status|Enrolling by invitation|Phase 2|96|Anticipated|University Of Perugia||1|||f||||t||||||||||2018-05-31 23:11:38.994952|2018-05-31 23:11:38.994952
NCT01231724|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-05-30|2010-10-28|2010-11-01|Estimate|||||||2013-05-30|2013-06-03|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|April 2012|Anticipated|2012-04-30|February 2012|Anticipated|2012-02-29||Interventional|||Topical Allstate and Nasal Allergen Challenge|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical Allstate in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (CETALY0001)|Withdrawn||Phase 3|0|Actual|University of Chicago||2||study halted prematurely, prior to enrollment of first participant|f||||f||||||||||2018-05-31 23:11:39.063831|2018-05-31 23:11:39.063831
NCT01231711|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention|Improving Quality-of-life and Depressive Symptoms for OEF/OIF Combat Veterans: Assessing the Benefits of Interactive, Internet-based Psychotherapy and Peer-to-peer Support|Completed||Phase 1|50|Actual|Prevail Health Solutions, LLC||1|||f||||f||||||||||2018-05-31 23:11:39.130078|2018-05-31 23:11:39.130078
NCT01231698|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2013-01-23|2010-10-29|2010-11-01|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Heart Rate Control With Esmolol in Septic Shock|Strict Heart Rate Control With Esmolol in Septic Shock: a Randomized, Controlled, Clinical Pilot Study|Completed||Phase 2|154|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 23:11:39.201008|2018-05-31 23:11:39.201008
NCT01231685|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2016-09-20|2010-10-29|2010-11-01|Estimate|||||||2016-09-20|2016-09-21|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection|A Randomized Prospective Open Label Study of Switching to Raltegravir Based ART Compared to Maintaining Ritonavir Boosted PI-based ART on Liver Fibrosis Progression in HIV-HCV Coinfected Patients|Completed||Phase 2|9|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 23:11:39.316607|2018-05-31 23:11:39.316607
NCT01231672|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2015-03-26|2010-10-29|2010-11-01|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|SEPSICOAG||Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients With Septic Shock|Evaluation and Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients Entering Intensive Care Units for Septic Shock|Completed|||780|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 23:11:39.467832|2018-05-31 23:11:39.467832
NCT01231659|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2018-05-11|2010-10-29|2010-11-01|Estimate|||||||2018-05-11|2018-05-14|Actual|August 9, 2011|Actual|2011-08-09|May 2018|2018-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|Phase II Open Label Study of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic, Estrogen Receptor Positive Breast Cancer, After Failure of Tamoxifen and/or Anastrozole and/or Letrozole and/or Fulvestrant and/or Exemestane|Completed||Phase 4|72|Actual|Novartis||1|||f|||||f|f||||||No||2018-05-31 23:11:39.557989|2018-05-31 23:11:39.557989
NCT01231646|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2015-08-24||2015-10-23|2010-10-28|2010-11-01|Estimate|2015-09-23|2015-10-23|Estimate||||2015-10-23|2015-11-20|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|April 2013|Actual|2013-04-30||Observational|||Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?|Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?|Completed|||38|Actual|Northwell Health|||2||f||||f||||||||||2018-05-31 23:11:39.654723|2018-05-31 23:11:39.654723
NCT01231633|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2017-08-22||2018-03-05|2010-10-29|2010-11-01|Estimate|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|September 2010||2010-09-30|March 2018|2018-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)|Comparative Study of Initial Ozurdex (Dexamethasone Implant) Versus Avastin (Bevacizumab) in the Treatment of Macular Edema Following Central Retinal Vein Occlusion (CRVO)|Completed||N/A|27|Actual|Long Island Vitreoretinal Consultants||2|||f||||f||||||||||2018-05-31 23:11:39.879858|2018-05-31 23:11:39.879858
NCT01231620|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2017-04-11|2015-12-10|2018-03-08|2010-10-28|2010-11-01|Estimate|2017-10-17|2017-11-20|Actual|2015-12-10|2016-01-12|Estimate|2018-03-08|2018-03-12|Actual|January 15, 2011|Actual|2011-01-15|March 2018|2018-03-31|March 18, 2015|Actual|2015-03-18|March 18, 2015|Actual|2015-03-18||Interventional|ZORO||A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza|A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza|Completed||Phase 3|626|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:11:40.349665|2018-05-31 23:11:40.349665
NCT01231607|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2012-08-30||2016-11-21|2010-10-28|2010-11-01|Estimate|2012-08-30|2012-10-04|Estimate||||2016-11-21|2017-01-11|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia|A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia|Completed||Phase 3|917|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:11:43.257394|2018-05-31 23:11:43.257394
NCT01231594|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2018-01-10|2010-10-28|2010-11-01|Estimate|||||||2018-01-10|2018-01-12|Actual|November 5, 2010||2010-11-05|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors|A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors|Active, not recruiting||Phase 1|221|Actual|Novartis||3|||f||||f|t|f||||||No||2018-05-31 23:11:44.614004|2018-05-31 23:11:44.614004
NCT01231581|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2013-06-20||2013-07-25|2010-10-28|2010-11-01|Estimate|2013-07-25|2013-09-26|Estimate||||2013-07-25|2013-09-26|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|April 2012|Actual|2012-04-30||Interventional|||Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer|A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK Inhibitor GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Subjects With Metastatic Pancreatic Cancer|Completed||Phase 2|160|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 23:11:44.73865|2018-05-31 23:11:44.73865
NCT01231568|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2017-11-10|2010-10-28|2010-11-01|Estimate|||||||2017-11-10|2017-11-14|Actual|October 21, 2010|Actual|2010-10-21|November 2017|2017-11-30|May 13, 2011|Actual|2011-05-13|May 13, 2011|Actual|2011-05-13||Interventional|||An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor|An Open-Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation-Positive Tumor|Completed||Phase 1|28|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 23:11:45.498728|2018-05-31 23:11:45.498728
NCT01231555|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2017-08-28|2012-04-26|2017-10-16|2010-10-28|2010-11-01|Estimate|2017-10-16|2017-11-17|Actual|2012-04-26|2012-04-30|Estimate|2017-10-16|2017-11-17|Actual|November 18, 2010|Actual|2010-11-18|August 2017|2017-08-31|July 4, 2011|Actual|2011-07-04|July 4, 2011|Actual|2011-07-04||Interventional|SIGNET||Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)|Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 Administered With Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|Terminated||Phase 2|23|Actual|ViiV Healthcare||3|||f||||t||||||||||2018-05-31 23:11:45.621287|2018-05-31 23:11:45.621287
NCT01231542|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-06-06|2010-10-28|2010-11-01|Estimate|||||||2017-06-06|2017-06-08|Actual|May 2011||2011-05-31|June 2017|2017-06-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers|Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers|Completed||Phase 1|27|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 23:11:46.176807|2018-05-31 23:11:46.176807
NCT01231529|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2011-07-26|2010-10-28|2010-11-01|Estimate|||||||2011-07-26|2011-07-27|Estimate|November 2010||2010-11-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||GSK1349572 Hepatic Impairment Study|A Phase I, Open-Label, Parallel-Group, Two-Part, Adaptive Study to Evaluate the Pharmacokinetics and Safety of GSK1349572 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (ING113097)|Completed||Phase 1|16|Actual|ViiV Healthcare||4|||f||||f||||||||||2018-05-31 23:11:46.337586|2018-05-31 23:11:46.337586
NCT01231516|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2013-08-15||2018-05-14|2010-10-28|2010-11-01|Estimate|2013-12-12|2014-01-31|Estimate||||2018-05-14|2018-05-16|Actual|October 26, 2010|Actual|2010-10-26|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|February 4, 2013|Actual|2013-02-04||Interventional|SAILING||A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults|A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults|Active, not recruiting||Phase 3|724|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 23:11:46.446201|2018-05-31 23:11:46.446201
NCT01231503|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2015-05-04||2018-03-14|2010-10-28|2010-11-01|Estimate|2015-05-04|2015-05-20|Estimate||||2018-03-14|2018-04-11|Actual|January 13, 2011|Actual|2011-01-13|March 2018|2018-03-31|December 23, 2014|Actual|2014-12-23|April 30, 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants|Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine 257049 When Administered on Different Schedules to Infants in Africa|Completed||Phase 2|480|Actual|GlaxoSmithKline||8|||f||||t||||||||||2018-05-31 23:11:47.915419|2018-05-31 23:11:47.915419
NCT01231490|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2011-01-27|2010-10-28|2010-11-01|Estimate|||||||2011-01-27|2011-01-31|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Acute Osteoarthritis Experimental Model Study.|A Double Blind, Randomised, Placebo Controlled Methodological Cross-over Study to Investigate the Senstivity of a Novel Study Design and Endpoints to Treatment Effects of Naproxen in Osteoarthritis|Completed||Phase 2|53|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:11:50.465037|2018-05-31 23:11:50.465037
NCT01231477|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Observational|||Cytokines and Sevoflurane During Surgery|Effects of Inhalation Anaesthesia With Sevoflurane on Cytokine Response in Patients Submitted to Otorhinolaryngological Surgery|Completed|||30|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||t||||||||||2018-05-31 23:11:50.561414|2018-05-31 23:11:50.561414
NCT01231464|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2011-01-22||2017-06-06|2010-10-28|2010-11-01|Estimate|2011-01-22|2011-02-04|Estimate||||2017-06-06|2017-07-06|Actual|September 2009||2009-09-30|June 2017|2017-06-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis|Completed||Phase 3|365|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 23:11:50.65044|2018-05-31 23:11:50.65044
NCT01231451|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-11-25|2010-10-29|2010-11-01|Estimate|||||||2010-11-25|2010-11-29|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Depot Contraception With and Without Lopinavir/Ritonavir|The Pharmacokinetics of Depot Medroxyprogesterone Acetate (DMPA) in the Absence and Presence of Lopinavir/Ritonavir in HIV-1 Infected Women|Withdrawn||Phase 1|10|Anticipated|St Stephens Aids Trust||1||Ethics board said the study could not be fully justified.|f||||f||||||||||2018-05-31 23:11:50.889142|2018-05-31 23:11:50.889142
NCT01231438|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2012-11-08|2010-10-29|2010-11-01|Estimate|||||||2012-11-08|2012-11-09|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.|An Open, Randomized, Crossover Phase 2 Pilot Study of Treatment of Stage 3B Renal Failure With Active Vitamin D or a Phosphate Binder to Evaluate the Effect on the FGF23 and PTH Levels.|Completed||Phase 2|21|Actual|Helse Stavanger HF||2|||f||||f||||||||||2018-05-31 23:11:50.951664|2018-05-31 23:11:50.951664
NCT01231425|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2011-11-07|2010-10-28|2010-11-01|Estimate|||||||2011-11-07|2011-11-08|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|October 2012|Anticipated|2012-10-31|June 2012|Anticipated|2012-06-30||Observational|PUCTURE-CV||Prospective Study of Clinical Utility of Acupuncture in Back Pain|Prospective Epidemiological Study To Evaluate The Clinical Utility Of Acupuncture In The Treatment Of Back Pain (Study PUCTURE-CV)|Unknown status|Active, not recruiting||102|Anticipated|Group G-6|||2||f||||f||||||||||2018-05-31 23:11:51.021164|2018-05-31 23:11:51.021164
NCT01231412|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2017-11-01||2018-02-13|2010-10-28|2010-11-01|Estimate|2017-11-01|2017-12-04|Actual||||2018-02-13|2018-03-13|Actual|November 2010||2010-11-30|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|October 8, 2016|Actual|2016-10-08||Interventional|||Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant|A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial|Completed||Phase 3|174|Actual|Fred Hutchinson Cancer Research Center||3|||f||||t||||||||||2018-05-31 23:11:51.093726|2018-05-31 23:11:51.093726
NCT01231399|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2017-04-26||2017-04-26|2010-10-28|2010-11-01|Estimate|2017-04-26|2017-05-31|Actual||||2017-04-26|2017-05-31|Actual|February 2012||2012-02-29|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer|Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma|Completed||Phase 1/Phase 2|6|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:11:51.527449|2018-05-31 23:11:51.527449
NCT01231386|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2017-08-18|2010-10-29|2010-11-01|Estimate|||||||2017-08-18|2017-08-22|Actual|November 2009||2009-11-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer|MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer|Recruiting|||165|Anticipated|City of Hope Medical Center|||||f||||t||||||Samples With DNA|"~     Tissue and Blood Procurement. Breast cancer tissues from core biopsies (as available,~     preferably fresh frozen or RNA-later preserved, but in case of lack of availability,~     formalin-fixed paraffin-embedded [FFPE] core or tissue samples) which have been collected or~     will be collected under IRB#05091 or 05015.~   "|||2018-05-31 23:11:52.045104|2018-05-31 23:11:52.045104
NCT01231373|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2013-12-20|2013-07-23|2015-02-19|2010-10-28|2010-11-01|Estimate|2014-02-19|2014-04-02|Estimate|2013-11-13|2013-12-06|Estimate|2015-02-19|2015-03-12|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|September 2011|Actual|2011-09-30||Interventional|VANISH-2|Patients receiving blinded treatment|Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence|"A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence VANISH-2"|Completed||Phase 3|235|Actual|BTG International Inc.||4|||f||||t||||||||||2018-05-31 23:11:52.155781|2018-05-31 23:11:52.155781
NCT01231360|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-02-20|2010-10-28|2010-11-01|Estimate|||||||2013-02-20|2013-02-22|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease (PAD)|The Effect of Exercise Training on Skeletal Muscle Metabolism in Peripheral Artery Disease|Unknown status|Recruiting|N/A|75|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:11:53.254035|2018-05-31 23:11:53.254035
NCT01231347|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14||2014-02-21|2016-10-26|2010-10-28|2010-11-01|Estimate||||2014-03-28|2014-04-25|Estimate|2016-10-26|2016-10-27|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GAMMA||QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas|Terminated||Phase 3|800|Actual|NantCell, Inc.||3||Planned independent DMC Interim review: ended for futility w/no safety concerns|f||||t||||||||||2018-05-31 23:11:53.363999|2018-05-31 23:11:53.363999
NCT01231334|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2012-06-25||2012-06-25|2010-10-29|2010-11-01|Estimate|2012-06-25|2012-07-27|Estimate||||2012-06-25|2012-07-27|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne||Completed||Phase 4|286|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:11:54.559929|2018-05-31 23:11:54.559929
NCT01231321|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2011-02-25||2011-04-20|2010-10-29|2010-11-01|Estimate|2011-02-25|2011-03-24|Estimate||||2011-04-20|2011-04-26|Estimate|December 2007||2007-12-31|April 2011|2011-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis|An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira®) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|100|Actual|Abbott||1|||f||||t||||||||||2018-05-31 23:11:55.628514|2018-05-31 23:11:55.628514
NCT01231308|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2012-12-20|2010-10-29|2010-11-01|Estimate|||||||2012-12-20|2012-12-24|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Roux-en-Y-Gastric Bypass vs. Lifestyle Modification and Medical Therapy in the Treatment of Type 2 Diabetes|Roux-en-Y-Gastric Bypass (RYGB) Versus Lifestyle Modification Plus Medical Therapy in the Treatment of Type 2 Diabetes in Overweight-to-Moderately Obese Patients: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|50|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-05-31 23:11:56.14799|2018-05-31 23:11:56.14799
NCT01231113|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2016-02-23|2010-10-29|2010-11-01|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|DHAPPQ/MIP||Efficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in Ghana|Efficacy, Safety and Tolerability of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Falciparum Malaria in Pregnancy: an Open-label, Randomised Controlled, Non-inferiority Trial|Completed||Phase 3|417|Actual|Kwame Nkrumah University of Science and Technology||2|||f||||t||||||||||2018-05-31 23:11:57.980181|2018-05-31 23:11:57.980181
NCT01231295|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-01-31|2010-10-29|2010-11-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|ISALP||Isotopic Imaging for Prodromal Alzheimer's Disease|Evaluating the Performance of Isotopic Brain Imaging of Glucose Metabolism Via PET (18F-FDG) and Perfusion SPECT (99mTc-ECD) for the Diagnosis of Prodromal Stage Alzheimer's Disease|Completed|||143|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||Samples With DNA|"~     3 x 10ml of blood and 3 ml lumbar puncture for Abeta1-40, A1beta-42, Abetan-40, Abetan-42,~     sAPPalpha, Tau, pTau, and DNA extraction for the ApoE4 gene~   "|||2018-05-31 23:11:56.352316|2018-05-31 23:11:56.352316
NCT01231282|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-01-02|2010-10-29|2010-11-01|Estimate|||||||2017-01-02|2017-01-04|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|April 2013|Actual|2013-04-30|October 2011|Actual|2011-10-31||Interventional|||Technique Optimization With Whole-body Diffusion-weighted MRI|Technique Optimization and Anatomy of the Human Body With Whole-body Diffusion-weighted MRI: Study With Healthy Volunteers|Completed||N/A|30|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 23:11:56.474016|2018-05-31 23:11:56.474016
NCT01231269|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-01-02|2010-10-29|2010-11-01|Estimate|||||||2017-01-02|2017-01-04|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma|Whole-body Diffusion-weighted Magnetic Resonance Imaging for Staging and Treatment Prediction of Lymphoma|Unknown status|Active, not recruiting|N/A|100|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 23:11:56.536082|2018-05-31 23:11:56.536082
NCT01231256|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2018-05-01|2010-10-29|2010-11-01|Estimate|||||||2018-05-01|2018-05-02|Actual|February 1998||1998-02-28|May 2018|2018-05-31|December 2015|Actual|2015-12-31|November 2001|Actual|2001-11-30||Interventional|||Preventive Health Consultations With Young Adults With Multiple Problems|A Study on Preventive Health Consultations in General Practice With Young Adults With Multiple Problems; a Randomised Controlled Study|Completed||N/A|495|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 23:11:56.601079|2018-05-31 23:11:56.601079
NCT01231243|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2011-12-05|2010-10-29|2010-11-01|Estimate|||||||2011-12-05|2011-12-06|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Clinical Effectiveness of In-office Bleaching Activated With a LED/Laser Device|Color Change and Sensitivity Level for In-office Bleaching With and Without a LED/Laser Device|Completed||Phase 4|60|Actual|Universidade Estadual de Ponta Grossa||4|||f||||f||||||||||2018-05-31 23:11:56.679817|2018-05-31 23:11:56.679817
NCT01231230|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2014-03-24||2016-05-27|2010-10-29|2010-11-01|Estimate|2014-12-03|2014-12-10|Estimate||||2016-05-27|2016-06-30|Estimate|May 2007||2007-05-31|May 2016|2016-05-31|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional||Fourteen lifetime nonsmokers with a physician diagnosis of asthma were recruited for the study. All but one of the subjects were using an ICS/LABA combination preparation regularly, and all used a short-acting b2-adrenergic agonist as rescue medication. All subjects had to have a prebronchodilator FEV1 of 60% to 85% predicted .|Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway|Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway|Completed||N/A|14|Actual|University of Miami||4|||f||||f||||||||No||2018-05-31 23:11:56.762809|2018-05-31 23:11:56.762809
NCT01231217|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|October 2010||2010-10-31|May 2010|2010-05-31||||||||Interventional|||Green Tea in Crohn's Disease||Unknown status|Recruiting|N/A|80|Anticipated|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 23:11:56.943708|2018-05-31 23:11:56.943708
NCT01231204|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2016-04-07|2010-10-29|2010-11-01|Estimate|||||||2016-04-07|2016-04-11|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|November 2012|Actual|2012-11-30||Interventional|||Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks|Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks|Completed||Phase 4|60|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 23:11:57.028748|2018-05-31 23:11:57.028748
NCT01231191|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2012-03-06|2010-10-29|2010-11-01|Estimate|||||||2012-03-06|2012-03-08|Estimate||||March 2012|2012-03-31||||||||Interventional|Cadence||A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures|Withdrawn||Phase 4|0|Actual|University of California, San Diego||2||study not funded|f||||f||||||||||2018-05-31 23:11:57.263133|2018-05-31 23:11:57.263133
NCT01231178|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ALGOBES||The Effect of an Alginate Based Beverage on Weight Loss|Alginate Fibers Effect on Body Weight and Risk Markers for Type 2 Diabetes and Cardiovascular Disease.|Completed||N/A|96|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 23:11:57.355665|2018-05-31 23:11:57.355665
NCT01231165|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2012-06-08|2010-10-29|2010-11-01|Estimate|||||||2012-06-08|2012-06-11|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|February 2011|Actual|2011-02-28|May 2010|Actual|2010-05-31||Interventional|||Treatment of Coronary Heart Disease With Amiloride|Comparative Randomized Single-blind Trial of Amiloride in Coronary Heart Disease|Completed||Phase 2/Phase 3|70|Actual|University of Carabobo||2|||f||||f||||||||||2018-05-31 23:11:57.434659|2018-05-31 23:11:57.434659
NCT01231152|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2012-05-24|2010-10-29|2010-11-01|Estimate|||||||2012-05-24|2012-05-25|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||The Impact of Obesity on Children and Adolescents.|The Relation of Obesity With Metabolic Disorders, Inflammation Markers and Arterial Blood Pressure With Preclinical Target-organ Damage in Children and Young Adolescents.|Unknown status|Recruiting||80|Anticipated|University of Athens|||||f||||f||||||||||2018-05-31 23:11:57.527049|2018-05-31 23:11:57.527049
NCT01231139|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-10-26|2010-10-29|2010-11-01|Estimate|||||||2014-10-26|2014-10-28|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|PARITY||The Paracetamol AfteR Traumatic Brain InjurY Study|A Multi-centre Phase 2b Randomised Controlled Trial Investigating the Efficacy and Safety of Intravenous Paracetamol in Reducing Core Body Temperature After Traumatic Brain Injury|Completed||Phase 2|41|Actual|South East Sydney and Illawarra Area Health Service||2|||f||||t||||||||||2018-05-31 23:11:57.671588|2018-05-31 23:11:57.671588
NCT01231126|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-11-15|2010-10-29|2010-11-01|Estimate|||||||2010-11-15|2010-11-16|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation the Blood Loss in Pregnancies With Misoprostol-induced Labour|Evaluation the Blood Loss in Pregnancies With Misoprostol-induced Labour|Completed||Phase 4|161|Actual|Maternidade Escola Assis Chateaubriand||4|||f||||t||||||||||2018-05-31 23:11:57.875399|2018-05-31 23:11:57.875399
NCT01231100|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2015-08-31|2010-10-29|2010-11-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Hand-carried Ultrasound Echocardiography in the Hospital|Effects of Hand-carried Ultrasound Echocardiography by Hospitalists Among Inpatients Referred for Standard Echocardiography: a Randomized Trial|Completed||N/A|453|Actual|John H. Stroger Hospital||2|||f||||f||||||||||2018-05-31 23:11:58.136347|2018-05-31 23:11:58.136347
NCT01231087|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|January 2008||2008-01-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|January 2008|Actual|2008-01-31||Observational|||Energy Expenditure Pre and Post Bariatric Surgery|Energy Expenditure in Patients Pre and Post Bariatric Surgery|Completed|||32|Actual|Gastrocirurgia, Brazil|||||f||||f||||||||||2018-05-31 23:11:58.193536|2018-05-31 23:11:58.193536
NCT01231074|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|May 2011|Anticipated|2011-05-31|February 2011|Anticipated|2011-02-28||Interventional|GFMS||Reducing Antipsychotic-Induced Weight Gain in Children With Metformin|Reducing Antipsychotic-Induced Weight Gain in Children With Metformin|Unknown status|Recruiting|Phase 1|96|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 23:11:58.245065|2018-05-31 23:11:58.245065
NCT01231061|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2014-07-23|2010-10-29|2010-11-01|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 2010||2010-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Spinal met_radiosurgery/SBRT Study|Randomized Phase II Study of Image-Guided Radiosurgery / SBRT for Localized Spine Metastasis|Completed||Phase 2|1|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:11:58.379814|2018-05-31 23:11:58.379814
NCT01231035|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2011-07-22|2010-10-29|2010-11-01|Estimate|||||||2011-07-22|2011-07-25|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|RECLOSE2-ACS||REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)|REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry|Completed|||1789|Actual|Careggi Hospital|||||f||||t||||||||||2018-05-31 23:11:58.459718|2018-05-31 23:11:58.459718
NCT01231022|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2015-07-27|2010-10-29|2010-11-01|Estimate|||||||2015-07-27|2015-07-29|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2011|Actual|2011-06-30||Observational|MBC||Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)|Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer|Completed|||52|Actual|Beijing Cancer Hospital|||||f||||t||||||None Retained|"~     patients' blood sample~   "|||2018-05-31 23:11:58.542544|2018-05-31 23:11:58.542544
NCT01231009|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2010-10-29|2010-10-29|2010-11-01|Estimate|||||||2010-10-29|2010-11-01|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis|The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis: a Prospective Randomized Controlled Clinical Trial|Unknown status|Recruiting|Early Phase 1|40|Anticipated|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-05-31 23:11:58.62843|2018-05-31 23:11:58.62843
NCT01230996|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-08-30|2010-10-28|2010-10-29|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2010|Actual|2010-07-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|DEPICT||Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer|A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer|Active, not recruiting||Phase 1/Phase 2|22|Actual|Barts & The London NHS Trust||1|||f||||t||||||||||2018-05-31 23:11:58.698387|2018-05-31 23:11:58.698387
NCT01230983|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-06-04|2010-10-28|2010-10-29|Estimate|||||||2013-06-04|2013-06-06|Estimate|June 1996||1996-06-30|June 2013|2013-06-30|October 2004|Actual|2004-10-31|September 2001|Actual|2001-09-30||Interventional|T-Cell #4||Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma|Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study|Completed||Phase 3|573|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-05-31 23:11:58.789422|2018-05-31 23:11:58.789422
NCT01230970|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2013-10-10|2010-10-28|2010-10-29|Estimate|||||||2013-10-10|2013-10-11|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer|A Phase II, Open-label, Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 Administered for 14 Days Prior to Surgery to Postmenopausal Women With Newly Diagnosed Primary Invasive Oestrogen Receptor Positive Breast Cancer|Terminated||Phase 2|2|Actual|Ipsen||1||"The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the~   primary endpoint will not be reached."|f||||f||||||||||2018-05-31 23:11:59.011979|2018-05-31 23:11:59.011979
NCT01230957|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28||2013-12-03|2018-02-05|2010-10-28|2010-10-29|Estimate||||2013-12-03|2013-12-27|Estimate|2018-02-05|2018-02-09|Actual|October 2010||2010-10-31|February 2018|2018-02-28|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults|Safety and Immunogenicity of Different Formulations of a Clostridium Difficile Toxoid Vaccine Administered at Three Different Schedules in Adults Aged 40 to 75 Years at Risk of C. Difficile Infection|Completed||Phase 2|650|Actual|Sanofi||7|||f||||f||||||||||2018-05-31 23:11:59.106395|2018-05-31 23:11:59.106395
NCT01230944|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2010-10-28|2010-10-28|2010-10-29|Estimate|||||||2010-10-28|2010-10-29|Estimate|December 2004||2004-12-31|October 2010|2010-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Conventional Nissen Fundoplication Versus Laparoscopic Nissen Fundoplication|Conventional Nissen Fundoplication vs. Laparoscopic Nissen Fundoplication: a Prospective Randomized Study, Long-term Follow-up|Completed||N/A|110|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 23:11:59.223|2018-05-31 23:11:59.223
NCT01230931|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-06-12|2010-10-28|2010-10-29|Estimate|||||||2012-06-12|2012-06-14|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel)|Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat|Unknown status|Recruiting|Phase 4|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:11:59.283773|2018-05-31 23:11:59.283773
NCT01230762|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2011-05-18|2010-10-28|2010-10-29|Estimate|||||||2011-05-18|2011-05-19|Estimate||||January 2011|2011-01-31|April 2005|Actual|2005-04-30|||||Interventional|||An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation|An Open Label Study of the Long-term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation|Completed||Phase 3|1774|Actual|Alza Corporation, DE, USA||1|||f||||||||||||||2018-05-31 23:12:02.604081|2018-05-31 23:12:02.604081
NCT01230918|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-04-21|2010-10-28|2010-10-29|Estimate|||||||2017-04-21|2017-04-24|Actual|May 2011||2011-05-31|April 2017|2017-04-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|SCAR||Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis|Technetium-NC100692 SCintigraphy to Detect avB3 Integrin Expression as a mARker of Fibrosis in Hypertrophic Cardiomyopathy and Acute Coronary Syndrome: the SCAR Study|Terminated||Phase 2|120|Anticipated|Ottawa Heart Institute Research Corporation||1||Costs of study procedures has changed and escalated and became prohibitive.|f||||f||||||||||2018-05-31 23:11:59.394442|2018-05-31 23:11:59.394442
NCT01230905|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-04-21|2010-10-28|2010-10-29|Estimate|||||||2017-04-21|2017-04-24|Actual|July 2008||2008-07-31|April 2017|2017-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|AST||Study to Monitor the Effects of Androgen Suppression Treatment on the Heart|Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve?|Completed||Phase 4|181|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 23:11:59.464659|2018-05-31 23:11:59.464659
NCT01230892|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2015-02-12||2015-02-12|2010-10-28|2010-10-29|Estimate|2015-02-12|2015-02-27|Estimate||||2015-02-12|2015-02-27|Estimate|February 2010||2010-02-28|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||4 subjects either withdrew or were lost to follow-up and not included in analysis population. Additionally, one subject in the Atenolol arm was removed from analysis population due to IVUS occurring in the incorrect artery.|Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques|The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease|Completed||Phase 4|29|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:11:59.601238|2018-05-31 23:11:59.601238
NCT01230879|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2017-06-06|2010-10-28|2010-10-29|Estimate|||||||2017-06-06|2017-06-07|Actual|July 15, 2009||2009-07-15|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Ageing on Airway Remodeling|Study of Bronchoalveolar Lung Remodeling in Subjects From 60 Years Free of Progressive Lung Disease: Structure-function Analysis|Terminated||N/A|101|Actual|University Hospital, Montpellier||3|||f||||t||||||||||2018-05-31 23:11:59.85785|2018-05-31 23:11:59.85785
NCT01230866|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2018-01-16|2010-10-28|2010-10-29|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2010||2010-11-30|January 2018|2018-01-31||||December 2020|Anticipated|2020-12-31||Interventional|||Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer|A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate|Recruiting||Phase 3|150|Anticipated|Proton Collaborative Group||2|||f||||t||||||||||2018-05-31 23:12:00.093486|2018-05-31 23:12:00.093486
NCT01230853|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2013-05-20|2010-10-28|2010-10-29|Estimate|||||||2013-05-20|2013-05-22|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study|A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease|Completed||Phase 1|80|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 23:12:00.250594|2018-05-31 23:12:00.250594
NCT01230840|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2010-10-28|2010-10-28|2010-10-29|Estimate|||||||2010-10-28|2010-10-29|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|Benefiber||Effect of Wheat Dextrin on Calcium and Magnesium Absorption|Effect of Wheat Dextrin on Calcium and Magnesium Absorption|Completed||Phase 4|40|Actual|Creighton University||2|||f||||f||||||||||2018-05-31 23:12:00.343644|2018-05-31 23:12:00.343644
NCT01230827|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2014-09-23||2016-03-31|2010-10-28|2010-10-29|Estimate|2014-09-23|2014-09-29|Estimate||||2016-03-31|2016-04-04|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional|||A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)|A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy|Terminated||Phase 3|173|Actual|Janssen Research & Development, LLC||2||Trial has failed to meet primary - and major secondary endpoints|f||||t||||||||||2018-05-31 23:12:00.4488|2018-05-31 23:12:00.4488
NCT01230814|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2014-08-14||2014-09-26|2010-10-28|2010-10-29|Estimate|2014-09-25|2014-09-26|Estimate||||2014-09-26|2014-10-06|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All randomized participants.|Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women|A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women|Completed||Phase 2|234|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 23:12:01.593022|2018-05-31 23:12:01.593022
NCT01230801|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2015-05-15|2010-10-28|2010-10-29|Estimate|||||||2015-05-15|2015-05-19|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|March 2013|Actual|2013-03-31||Interventional|||Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease|A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant Human GAA) in Patients With Late-onset Pompe Disease|Completed||Phase 1/Phase 2|30|Actual|BioMarin Pharmaceutical||1|||f||||f||||||||||2018-05-31 23:12:02.040444|2018-05-31 23:12:02.040444
NCT01230788|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-23|2014-07-30||2014-11-26|2010-10-28|2010-10-29|Estimate|2014-07-30|2014-08-18|Estimate||||2014-11-26|2014-12-01|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Rituximab|no patients were analyzed due to early termination of study|Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia|A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)|Terminated||N/A|1|Actual|Emory University|The one subject was enrolled became a screen failure as she started a prohibited medication prior to going on study.|1||Lack of enrollment|f||||t||||||||||2018-05-31 23:12:02.117154|2018-05-31 23:12:02.117154
NCT01230775|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2016-05-25|2010-10-28|2010-10-29|Estimate|||||||2016-05-25|2016-05-26|Estimate|December 2010||2010-12-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|ARETA||"Anagrelide Retard vs. Placebo: Efficacy and Safety in At-risk Patients With Essential Thrombocythaemia"|"A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of Anagrelide Retard Versus Placebo in at Risk Subjects With Essential Thrombocythaemia"|Completed||Phase 3|146|Actual|AOP Orphan Pharmaceuticals AG||2|||f||||t||||||||||2018-05-31 23:12:02.425698|2018-05-31 23:12:02.425698
NCT01230749|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2013-03-18|2012-06-08|2013-10-17|2010-10-28|2010-10-29|Estimate|2013-10-17|2013-12-11|Estimate|2012-06-08|2012-06-11|Estimate|2013-10-17|2013-12-11|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Randomized, Placebo- and Active Comparator-Controlled, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of JNJ-41443532 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|89|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-05-31 23:12:02.743803|2018-05-31 23:12:02.743803
NCT01230736|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2016-11-18|2010-10-28|2010-10-29|Estimate|||||||2016-11-18|2016-11-21|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy of Changing to DuoTrav From Prior Therapy|Assessing the Safety and Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients Uncontrolled on Bimatoprost 0.03%/Timolol 0.5% Therapy (Fixed or Unfixed)|Completed||Phase 4|105|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:12:03.390287|2018-05-31 23:12:03.390287
NCT01230723|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-05-07|2010-10-28|2010-10-29|Estimate|||||||2012-05-07|2012-05-08|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|December 2011|Actual|2011-12-31||Interventional|ZES/EES-OCT||Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography|RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:12:03.46071|2018-05-31 23:12:03.46071
NCT01230710|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|2015-02-05||2015-03-24|2010-10-28|2010-10-29|Estimate|2015-03-24|2015-03-30|Estimate||||2015-03-24|2015-03-30|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression|A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy|Completed||Phase 4|51|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:12:03.534164|2018-05-31 23:12:03.534164
NCT01230697|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-10-28|2010-10-28|2010-10-29|Estimate|||||||2010-10-28|2010-10-29|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|September 2011|Anticipated|2011-09-30|August 2010|Actual|2010-08-31||Observational|SORHORM||Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)|Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib. Multicenter Cohort Study|Unknown status|Recruiting||60|Anticipated|University of Turin, Italy|||1||f||||t||||||Samples Without DNA|"~     Serum analites involved in phosphate homeostasis~   "|||2018-05-31 23:12:04.727573|2018-05-31 23:12:04.727573
NCT01230684|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-10-24|2010-10-28|2010-10-29|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2010||2010-12-31|October 2017|2017-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair|Comparison of Contrast Enhanced Ultrasound and the Gold Standard Computed Tomographic Angiography in Detection of Endoleak Following Endovascular Abdominal Aortic Aneurysm Repair.|Terminated||N/A|4|Actual|University of Michigan||1||Due to low enrollment|f||||f||||||||||2018-05-31 23:12:04.804471|2018-05-31 23:12:04.804471
NCT01230671|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2013-10-24|2010-10-28|2010-10-29|Estimate|||||||2013-10-24|2013-10-25|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Physical and Psychological Benefits of Yoga and Breast Cancer|The Physical and Psychological Benefits of Yoga in Patients With Breast Cancer: A Feasibility Study|Completed||Phase 1|80|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:12:04.879878|2018-05-31 23:12:04.879878
NCT01230658|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2012-11-05|2010-10-28|2010-10-29|Estimate|||||||2012-11-05|2012-11-06|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|||Prophylactic Enoxaparin Dosing in Roux-en-Y Gastric Bypass Surgery Patients at St. Vincent Carmel|Prophylactic Enoxaparin Dosing in Roux-en-Y Gastric Bypass Surgery Patients at the St. Vincent Carmel Bariatric Center of Excellence|Completed|||51|Actual|St. Vincent Carmel Hospital|||||f||||f||||||||||2018-05-31 23:12:04.950017|2018-05-31 23:12:04.950017
NCT01230645|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2011-02-10|2010-10-28|2010-10-29|Estimate|||||||2011-02-10|2011-02-11|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||RV568 - Viral Challenge With RSV|A Randomized, Single-blind, Placebo-controlled, Parallel Group Study to Investigate the Effects of Intranasal RV568 (400μg) Administered Twice Daily to Adult Male Volunteers Experimentally Inoculated With Live Respiratory Syncytial Virus|Completed||Phase 1|42|Actual|Respivert Ltd||2|||f||||f||||||||||2018-05-31 23:12:05.008831|2018-05-31 23:12:05.008831
NCT01230632|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-12-07|2010-10-28|2010-10-29|Estimate|||||||2013-12-07|2013-12-10|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|IMPART||Metabolic Phenotyping of Individuals Born Following Assisted Reproduction Techniques|Metabolic Phenotyping of Individuals Born Following Assisted Reproduction|Completed||N/A|34|Actual|University of Adelaide||1|||f||||t||||||||||2018-05-31 23:12:05.12082|2018-05-31 23:12:05.12082
NCT01230619|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-12-03|2010-10-28|2010-10-29|Estimate|||||||2010-12-03|2010-12-06|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis|A Two Day, Randomised, Single Blind, Parallel Group Trial of Repeat Doses of Intranasal RV568 in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|75|Actual|Respivert Ltd||2|||f||||f||||||||||2018-05-31 23:12:05.188988|2018-05-31 23:12:05.188988
NCT01230606|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2011-07-26|2010-10-27|2010-10-29|Estimate|||||||2011-07-26|2011-07-28|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|ABCD-PCI||Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention|Ambulatory Closure Device Percutaneous Intervention: a Multi-Center Randomized Trial Evaluating Patient Satisfaction, Safety, and Cost Effectiveness of Ambulatory PCI in the Current Era|Completed|||303|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||t||||||||||2018-05-31 23:12:05.252175|2018-05-31 23:12:05.252175
NCT01230580|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2012-10-09|2010-10-28|2010-10-29|Estimate|||||||2012-10-09|2012-10-10|Estimate|November 2008||2008-11-30|October 2010|2010-10-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|PIVOT||Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)|A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART|Unknown status|Active, not recruiting|Phase 4|587|Actual|Medical Research Council||2|||f||||t||||||||||2018-05-31 23:12:05.531863|2018-05-31 23:12:05.531863
NCT01230567|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-04-09|2010-10-28|2010-10-29|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Observational|||Comparison Between the Histological and Clinical Diagnosis of Non Healing Wounds|Comparison Between the Histological and Clinical Diagnosis of Non Healing Wounds|Completed|||41|Actual|Carmel Medical Center|||||f||||t||||||||||2018-05-31 23:12:05.617198|2018-05-31 23:12:05.617198
NCT01230554|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2014-02-12|2010-10-28|2010-10-29|Estimate|||||||2014-02-12|2014-02-14|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Product Performance of a Daily Disposable Contact Lens|A Study to Assess the Product Performance of a Daily Disposable Contact Lens|Completed||N/A|212|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 23:12:05.695664|2018-05-31 23:12:05.695664
NCT01230541|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2011-11-29|2010-10-27|2010-10-29|Estimate|||||||2011-11-29|2011-11-30|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effect of Udenafil on Spermatogenesis|Effect of Udenafil on Spermatogenesis: A Double-blind, Randomized, Placebo-controlled, Parallel-group Study|Completed||Phase 1|239|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 23:12:05.770822|2018-05-31 23:12:05.770822
NCT01230528|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-28|2010-10-28|2010-10-29|Estimate|||||||2010-10-28|2010-10-29|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Observational|RT||Childhood Reactive Thrombocytosis|Childhood Reactive Thrombocytosis (RT)|Completed|||||Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:12:05.885139|2018-05-31 23:12:05.885139
NCT01230515|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2012-09-07|2010-10-27|2010-10-29|Estimate|||||||2012-09-07|2012-09-10|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Observational|||Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol||Completed|||65|Actual|Vanderbilt-Ingram Cancer Center|||4||f||||f||||||||||2018-05-31 23:12:05.950107|2018-05-31 23:12:05.950107
NCT01230502|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2014-02-24||2014-04-04|2010-10-27|2010-10-29|Estimate|2014-04-04|2014-05-07|Estimate||||2014-04-04|2014-05-07|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation|Donor Specific Regulation (DSR) Guided Tacrolimus Withdrawal to Myfortic Monotherapy in Liver Transplantation|Terminated||N/A|11|Actual|University of Wisconsin, Madison||3||insufficient study population to meet study objective|f||||t||||||||||2018-05-31 23:12:06.033369|2018-05-31 23:12:06.033369
NCT01230489|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2018-01-04|2010-10-27|2010-10-29|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2011|Actual|2011-01-31|January 2018|2018-01-31|November 28, 2016|Actual|2016-11-28|November 28, 2016|Actual|2016-11-28||Interventional|||"The Efficacy of MediHoney to Facilitate Catheter Exit-Site Surgical Wound Healing"|"The Efficacy of MediHoney to Facilitate Catheter Exit-Site Surgical Wound Healing and Prevention of Wound Bacterial Colonization: A Randomized, Open-label, Controlled, Clinical Trial"|Completed||N/A|13|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 23:12:06.274746|2018-05-31 23:12:06.274746
NCT01230476|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2017-05-19|2010-10-27|2010-10-29|Estimate|||||||2017-05-19|2017-05-23|Actual|May 2010||2010-05-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|May 2013|Actual|2013-05-31||Interventional|||Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma|Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma|Terminated||Phase 2|3|Actual|University of Malaya||1|||f||||f||||||||||2018-05-31 23:12:06.355129|2018-05-31 23:12:06.355129
NCT01230463|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-27|2010-10-27|2010-10-29|Estimate|||||||2010-10-27|2010-10-29|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Study of Whether 15 mg Dose of Ketorolac IV is as Effective as a 30 mg Dose.|Intraoperative Ketorolac Dose of 15 mg Versus the Standard 30 mg on Early Postoperative Pain After Spine Surgery: A Randomised, Blinded, Non-Inferiority Trial|Unknown status|Recruiting|N/A|50|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 23:12:06.418233|2018-05-31 23:12:06.418233
NCT01230450|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2013-01-23|2010-10-27|2010-10-29|Estimate|||||||2013-01-23|2013-01-24|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|SITOT||Feasibility of Comparing Two Surgical Treatment of Female Urodynamic Stress|Feasibility of Comparing Two Surgical Treatment of Female Urodynamic Stress Incontinence (SITOT)|Completed||Phase 1|137|Actual|University of Aberdeen||2|||f||||t||||||||||2018-05-31 23:12:06.490139|2018-05-31 23:12:06.490139
NCT01230437|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-28|2010-10-28|2010-10-29|Estimate|||||||2010-10-28|2010-10-29|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Montelukast and Nasal Epithelial Cell Inflammatory Responses in Asthma and Rhinitis|The Effect of Montelukast on Inflammatory Responses of Nasal Epithelial Cells Cultured From Patients With Asthma, With and Without Concomitant Allergic Rhinitis|Unknown status|Not yet recruiting||40|Anticipated|University of Aberdeen|||1||f||||t||||||||||2018-05-31 23:12:06.57956|2018-05-31 23:12:06.57956
NCT01230424|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2016-09-28||2017-06-30|2010-10-27|2010-10-29|Estimate|2017-06-30|2017-07-31|Actual||||2017-06-30|2017-07-31|Actual|March 2011||2011-03-31|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Steroid Injections in a Knee With Osteoarthritis|Effect of Intra-articular Steroids on Structural Progression of Knee OA: A Randomized Controlled Trial|Completed||Phase 4|140|Actual|Tufts Medical Center|Plan for interim analysis was eliminated with the support of the DSMB because of feasibility issues for completing cartilage measurements contemporaneously and because early trial cessation would preclude analysis of informative secondary outcomes.|2|||f||||t||||||||No||2018-05-31 23:12:06.76854|2018-05-31 23:12:06.76854
NCT01230411|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2016-06-13|2010-10-27|2010-10-29|Estimate|||||||2016-06-13|2016-06-14|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack|A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack|Recruiting||Phase 4|120|Anticipated|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 23:12:07.492571|2018-05-31 23:12:07.492571
NCT01230385|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2011-05-16|2010-10-27|2010-10-29|Estimate|||||||2011-05-16|2011-05-17|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects|Randomized, Open-Label, Parallel Group Study To Investigate The Safety And Tolerability Of Multiple Dose Lersivirine (Proposed Phase 3 Formulation) For 21 Days In Healthy Subjects|Completed||Phase 1|75|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 23:12:07.605686|2018-05-31 23:12:07.605686
NCT01230359|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2011-07-18|2010-10-27|2010-10-29|Estimate|||||||2011-07-18|2011-07-19|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Early Nutritional Intervention in Patients With Autism Spectrum Disorders|EARLY NUTRITIONAL INTERVENTION IN PATIENTS WITH AUTISM SPECTRUM DISORDERS|Completed||N/A|40|Actual|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 23:12:07.676133|2018-05-31 23:12:07.676133
NCT01230346|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2018-05-04|2010-10-27|2010-10-29|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2, 2010||2010-12-02|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer|Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas|Active, not recruiting||N/A|475|Anticipated|City of Hope Medical Center||3|||f||||t||||||||||2018-05-31 23:12:07.744775|2018-05-31 23:12:07.744775
NCT01230320|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2016-08-09|2010-10-28|2010-10-29|Estimate|||||||2016-08-09|2016-08-11|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|July 2012|Actual|2012-07-31||Interventional|||Simplified vs. Conventional Methods for Complete Denture Fabrication|Simplified vs. Conventional Methods for the Fabrication of Complete Dentures in a Public Health Setting|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:12:07.825191|2018-05-31 23:12:07.825191
NCT01230307|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2016-09-28||2016-09-28|2010-10-28|2010-10-29|Estimate|2016-09-28|2016-11-18|Estimate||||2016-09-28|2016-11-18|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|DELIGHTFUL||Vitamin D Supplementation for Treatment of Heart Failure|D suppLementation In HearT FaiLure (DELIGHTFUL)|Terminated||Phase 4|28|Actual|University of Michigan|Only a fraction of the original goal of enrollment was met. Therefore, analysis of comparative results was not done. No conclusions of any kind can be made from analyzing the data with the number of patients completing the trial (6 vs 4 patients).|2||Unable to recruit sufficient number of patients.|f||||f||||||||||2018-05-31 23:12:07.915043|2018-05-31 23:12:07.915043
NCT01230294|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2016-11-05|2010-10-28|2010-10-29|Estimate|||||||2016-11-05|2016-11-08|Estimate|October 2010||2010-10-31|November 2016|2016-11-30||||December 2015|Actual|2015-12-31||Observational|NEW-RV||New Echocardiographic Methods for Right Ventricular Function.|Evaluation of New Echocardiographic Methods for Measurement of Right Ventricular Function.|Active, not recruiting|||150|Anticipated|Heidelberg University|||3||f||||t||||||||||2018-05-31 23:12:08.286829|2018-05-31 23:12:08.286829
NCT01230281|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-12-13|2010-10-28|2010-10-29|Estimate|||||||2010-12-13|2010-12-14|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|C3G||A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Black Bean Seed Coat Extract|A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Black Bean Seed Coat Extract|Completed||N/A|12|Anticipated|Seoul St. Mary's Hospital||1|||f||||f||||||||||2018-05-31 23:12:08.384041|2018-05-31 23:12:08.384041
NCT01230268|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-12-13|2010-10-28|2010-10-29|Estimate|||||||2010-12-13|2010-12-14|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|C3G||A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Mulberry Fruit Extract|A Study to Evaluate Pharmacokinetics of C3G and to Estimate Antioxidative Markers After Repeated Administration of Mulberry Fruit Extract|Completed||N/A|12|Anticipated|Seoul St. Mary's Hospital||1|||f||||f||||||||||2018-05-31 23:12:08.469417|2018-05-31 23:12:08.469417
NCT01230255|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2010-10-28|2010-10-28|2010-10-29|Estimate|||||||2010-10-28|2010-10-29|Estimate|January 2007||2007-01-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Percutaneous Catheter Decompression in the Treatment of Elevated Intra-abdominal Pressure|Percutaneous Catheter Decompression in the Treatment of Elevated Intra-abdominal Pressure|Completed||Phase 3|62|Actual|Orlando Regional Medical Center||2|||f||||t||||||||||2018-05-31 23:12:08.540325|2018-05-31 23:12:08.540325
NCT01230242|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2011-08-01|2010-10-28|2010-10-29|Estimate|||||||2011-08-01|2011-08-02|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Postplacental Mirena IUD Insertion and Estimating Expulsion Rates.|Experimental Study Examining Mirena IUD Insertion and Estimating Rates of Expulsion Immediately After Placental Delivery.|Suspended||Phase 4|81|Anticipated|Maine Medical Center Research Institute||||Suspended to determine if Mirena device could be charged to patient insurance|f||||t||||||||||2018-05-31 23:12:08.611078|2018-05-31 23:12:08.611078
NCT01230229|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2017-08-22|2010-10-28|2010-10-29|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2010|Actual|2010-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Primary Stenting vs Conservative Treatment in Claudicants - a Study on Quality of Life|Primary Stenting vs Conservative Treatment in Claudicants - a Study on Quality of Life|Completed||N/A|100|Actual|Lund University||2|||f||||f||||||||||2018-05-31 23:12:08.673856|2018-05-31 23:12:08.673856
NCT01230216|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2016-01-07|2010-10-28|2010-10-29|Estimate|||||||2016-01-07|2016-01-11|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|PREVUS||Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound|Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound|Terminated||Phase 4|8|Actual|Kyoto University, Graduate School of Medicine||2||Slow patients enrollment|f||||t||||||||||2018-05-31 23:12:08.759696|2018-05-31 23:12:08.759696
NCT01230203|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2010-10-28|2010-10-28|2010-10-29|Estimate|||||||2010-10-28|2010-10-29|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|April 2013|Anticipated|2013-04-30|November 2012|Anticipated|2012-11-30||Interventional|ESSEA||Computed Tomography Scan Versus Color Duplex Ultrasound for Surveillance of Endovascular Repair of Abdominal Aortic Aneurysm. A Prospective Multicenter Study|Computed Tomography Scan Versus Color Duplex Ultrasound for Surveillance of Endovascular Repair of Abdominal Aortic Aneurysm. A Prospective Multicenter Study|Unknown status|Recruiting|N/A|1000|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 23:12:08.847729|2018-05-31 23:12:08.847729
NCT01226901|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-06-26|2010-10-21|2010-10-22|Estimate|||||||2012-06-26|2012-06-28|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|November 2011|Actual|2011-11-30|February 2011|Actual|2011-02-28||Interventional|||A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)|A Phase I Study of MK-4827 in Patients With Solid Tumor|Terminated||Phase 1|3|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-05-31 23:13:21.193591|2018-05-31 23:13:21.193591
NCT01230190|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2016-01-11|2010-10-28|2010-10-29|Estimate|||||||2016-01-11|2016-01-12|Estimate|March 2011||2011-03-31|March 2011|2011-03-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|BAMBOO||Management of Eczema by Specific Probiotic Strains|Beyond Conventional Treatment of Atopic Eczema in Infants: Management By Specific prObiOtic Strains|Withdrawn||Phase 3|0|Actual|Agentschap NL||2||Because of safety issues/support concerning the multispecies probiotic mixture|f||||t||||||||||2018-05-31 23:12:08.986988|2018-05-31 23:12:08.986988
NCT01230177|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2014-03-27||2017-01-03|2010-10-27|2010-10-28|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|May 2011||2011-05-31|January 2017|2017-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)|Enbrel Qw Special Investigation (Regulatory Post Marketing Commitment Plan)|Completed|||3|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:12:09.075023|2018-05-31 23:12:09.075023
NCT01230164|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2011-12-19|2010-10-27|2010-10-28|Estimate|||||||2011-12-19|2011-12-21|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Comparison of Four Different Aberrometers for Evaluation of Higher Order Visual Aberrations|Comparison of Four Different Aberrometers for Evaluation of Higher Order Visual Aberrations|Completed|||21|Actual|Massachusetts Eye and Ear Infirmary|||||f||||f||||||||||2018-05-31 23:12:09.227598|2018-05-31 23:12:09.227598
NCT01230151|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2011-02-17|2010-10-27|2010-10-28|Estimate|||||||2011-02-17|2011-02-18|Estimate|December 2010||2010-12-31|February 2011|2011-02-28||||December 2011|Anticipated|2011-12-31||Interventional|SAGE||Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease|Sustained Affect of GUIDE (SAGE):A Software Evaluation Study|Withdrawn||N/A|80|Anticipated|Intelect Medical, Inc.||2||Sponsor (Intelect Medical, Inc.) was acquired by Boston Scientific and study was canceled.|f||||f||||||||||2018-05-31 23:12:09.388868|2018-05-31 23:12:09.388868
NCT01230138|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2012-12-09|2010-10-27|2010-10-28|Estimate|||||||2012-12-09|2012-12-11|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis|A Randomised, Double Blind, Placebo Controlled Efficacy and Safety Trial of Different Doses/Dose Regimens of FP187 Compared to Placebo in Moderate to Severe Plaque Psoriasis (Pivotal Registration Study)|Completed||Phase 2|252|Actual|Forward-Pharma GmbH||5|||f||||f||||||||||2018-05-31 23:12:09.46551|2018-05-31 23:12:09.46551
NCT01230125|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25||2012-08-17|2013-11-22|2010-10-27|2010-10-28|Estimate||||2012-08-17|2012-08-24|Estimate|2013-11-22|2013-12-17|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery|Study to Assess the Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery|Completed||Phase 3|250|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:12:09.550687|2018-05-31 23:12:09.550687
NCT01230112|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2013-07-29|2010-10-27|2010-10-28|Estimate|||||||2013-07-29|2013-07-30|Estimate|December 2009||2009-12-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||The Role of ITGAM in Systemic Lupus Erythematosus|TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus|Completed|||40|Actual|Northwell Health|||||f||||f||||||Samples With DNA|"~     Blood and DNA will be collected and retained~   "|||2018-05-31 23:12:09.624981|2018-05-31 23:12:09.624981
NCT01230099|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-10-28|2010-10-27|2010-10-28|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Informing Decisions in Chronic Critical Illness: A Randomized Control Trial (RCT)|Informing Decisions in Chronic Critical Illness: A Randomized Control Trial (RCT)|Completed||N/A|622|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 23:12:09.680982|2018-05-31 23:12:09.680982
NCT01230086|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2017-04-10|2010-10-27|2010-10-28|Estimate|||||||2017-04-10|2017-04-12|Actual|August 2010||2010-08-31|April 2017|2017-04-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|Trop-Shock||Trop-Shock DFT-testing Versus None|hs Troponin Release in Relation to Different ICD-Implantation Procedures|Completed||Phase 4|195|Actual|Deutsches Herzzentrum Muenchen||3|||f||||f||||||||||2018-05-31 23:12:09.75828|2018-05-31 23:12:09.75828
NCT01230073|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2018-05-23|2010-10-27|2010-10-28|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2011||2011-02-28|May 2018|2018-05-31|December 2017|Actual|2017-12-31|July 2014|Actual|2014-07-31||Interventional|SAN REMO 2||Treatment Satisfaction in Implantable Cardioverter Defibrillator Recipients|Treatment Satisfaction With Remote Monitoring in Implantable Cardioverter Defibrillator Recipients|Completed||Phase 4|120|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:12:09.820535|2018-05-31 23:12:09.820535
NCT01230060|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2013-05-16||2013-08-09|2010-10-27|2010-10-28|Estimate|2013-08-09|2013-08-22|Estimate||||2013-08-09|2013-08-22|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional||All implanted eyes|One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction|A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of a Bausch + Lomb One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction|Completed||Phase 3|122|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 23:12:09.939553|2018-05-31 23:12:09.939553
NCT01230047|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2011|Anticipated|2011-10-31|January 2011|Anticipated|2011-01-31||Interventional|||Mindfulness and Lifestyle Interventions for Depression and Anxiety: A Pilot Study|Evaluation of a Psychoeducational Intervention Teaching Mindfulness and Lifestyle Interventions for Clinical Depression and Anxiety (A Pilot Study)|Unknown status|Active, not recruiting|N/A|30|Anticipated|Arizona State University||2|||f||||f||||||||||2018-05-31 23:12:10.069823|2018-05-31 23:12:10.069823
NCT01230034|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria|Randomized, Controlled, PROBE Trial, Evaluating the Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic Patients and Mild to Moderate Hypertension With Microalbuminuria|Unknown status|Recruiting|Phase 3|206|Anticipated|University of Pavia||2|||f||||t||||||||||2018-05-31 23:12:10.157064|2018-05-31 23:12:10.157064
NCT01230021|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2014-01-22|2012-05-10|2017-01-10|2010-10-27|2010-10-28|Estimate|2014-06-11|2014-06-12|Estimate|2012-05-10|2012-05-15|Estimate|2017-01-10|2017-02-24|Actual|November 2010||2010-11-30|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|mentor™4||Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency|A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to Less Than 6 Years Old) Subjects With Congenital FXIII A-subunit Deficiency|Completed||Phase 3|6|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 23:12:10.263042|2018-05-31 23:12:10.263042
NCT01229995|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|May 2009||2009-05-31|October 2010|2010-10-31||||||||Interventional|||Randomized Controlled Clinical Trial of CAD/CAM and Conventionally Fabricated Singl Implant Abutments.|A Comparison of Zirconia CAD/CAM and Conventionally Fabricated Single Implant Abutments and Restorations in the Esthetic Zone: a Randomized Controlled Clinical Trial.|Unknown status|Active, not recruiting|N/A|30|Actual|Harvard School of Dental Medicine||1|||f||||t||||||||||2018-05-31 23:12:10.68255|2018-05-31 23:12:10.68255
NCT01229982|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27||2013-09-16|2013-09-16|2010-10-27|2010-10-28|Estimate||||2013-09-16|2013-09-19|Estimate|2013-09-16|2013-09-19|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma|A Phase 2 Study Evaluating Safety and Efficacy of the Latanoprost Punctal Plug Delivery System (L PPDS)in Subjects With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG)|Completed||Phase 2|121|Actual|Mati Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 23:12:10.745687|2018-05-31 23:12:10.745687
NCT01229969|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2013-01-23|2010-10-27|2010-10-28|Estimate|||||||2013-01-23|2013-01-24|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|WiiFit||A Pilot Study of the Wii Fit as a Low-Cost Virtual Reality System to Evaluate Balance Ability in Older Adults|A Pilot Study of the Wii Fit as a Low-Cost Virtual Reality System to Evaluate Balance Ability in Older Adults|Completed||N/A|20|Actual|Atlanta VA Medical Center||2|||f||||f||||||||||2018-05-31 23:12:10.802382|2018-05-31 23:12:10.802382
NCT01229956|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2016-05-17|2010-10-27|2010-10-28|Estimate|||||||2016-05-17|2016-05-19|Estimate|November 2010||2010-11-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia|Promoter Methylation in MLL-Rearranged Childhood AML|Completed|||32|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:12:10.864105|2018-05-31 23:12:10.864105
NCT01229943|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2016-01-13||2018-04-26|2010-10-27|2010-10-28|Estimate|2016-01-13|2016-02-11|Estimate||||2018-04-26|2018-04-27|Actual|October 15, 2010|Actual|2010-10-15|January 2018|2018-01-31||||September 1, 2014|Actual|2014-09-01||Interventional|||Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery|Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors|Active, not recruiting||Phase 2|150|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 23:12:11.032728|2018-05-31 23:12:11.032728
NCT01229930|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2013-08-23|2010-10-27|2010-10-28|Estimate|||||||2013-08-23|2013-08-26|Estimate|June 2010||2010-06-30|October 2010|2010-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery|CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer|Completed||Phase 2|130|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:12:12.906925|2018-05-31 23:12:12.906925
NCT01229917|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2011-07-06|2010-10-26|2010-10-28|Estimate|||||||2011-07-06|2011-07-07|Estimate||||July 2011|2011-07-31||||||||Interventional|||Rhinovirus Study With Lactobacillus Rhamnosus GG||Completed||Phase 4|||Valio Ltd|||||f||||||||||||||2018-05-31 23:12:12.964785|2018-05-31 23:12:12.964785
NCT01229904|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-04-06|2010-10-26|2010-10-28|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy|Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy|Completed||N/A|40|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-05-31 23:12:13.011428|2018-05-31 23:12:13.011428
NCT01229891|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|2011-11-06||2011-12-10|2010-10-27|2010-10-28|Estimate|2011-12-10|2012-01-16|Estimate||||2011-12-10|2012-01-16|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink in Diabetic Patients|Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink on Glycemic, Metabolic, Inflammatory, Immunity and Oxidative Stress Markers in Type 2 Diabetes|Completed||Phase 2|90|Actual|National Nutrition and Food Technology Institute||3|||f||||t||||||||||2018-05-31 23:12:13.085189|2018-05-31 23:12:13.085189
NCT01229878|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2018-03-05|2010-10-26|2010-10-28|Estimate|||||||2018-03-05|2018-03-06|Actual|December 1, 2011|Actual|2011-12-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|January 1, 2019|Anticipated|2019-01-01||Interventional|||Vitamin D Supplementation in Kidney Disease|Vitamin D Supplementation on Physical and Cognitive Function-Pilot Study|Recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 23:12:13.576902|2018-05-31 23:12:13.576902
NCT01229865|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-03-26|2010-10-26|2010-10-28|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer||Unknown status|Active, not recruiting|Phase 2|29|Actual|Vascular Biogenics Ltd. operating as VBL Therapeutics||1|||f||||t||||||||||2018-05-31 23:12:13.652089|2018-05-31 23:12:13.652089
NCT01229852|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2014-05-15|2010-10-27|2010-10-28|Estimate|||||||2014-05-15|2014-05-19|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Treatment of Fibromyalgia Using Deep Shaped-Field Transcranial Magnetic Stimulation a Clinical Feasibility Study|Treatment of Fibromyalgia Using Deep Shaped-Field (DSF) Transcranial Magnetic Stimulation (TMS): A Clinical Feasibility Study|Completed||N/A|35|Actual|Cervel Neurotech, Inc.||1|||f||||f||||||||||2018-05-31 23:12:13.70816|2018-05-31 23:12:13.70816
NCT01229839|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2016-12-06|2010-10-27|2010-10-28|Estimate|||||||2016-12-06|2016-12-07|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC|Chemoembolization of Unresectable Hepatocellular Carcinoma With or Without Mixing the Chemotherapy With Lipiodol: Effectiveness and Safety. A Prospective and Randomized Clinical Trial.|Recruiting||Phase 3|668|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:12:13.766402|2018-05-31 23:12:13.766402
NCT01229826|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-09-01|2010-10-27|2010-10-28|Estimate|||||||2015-09-01|2015-09-02|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|MRE||Magnetic Resonance Elastography (MRE) of Uterine Fibroids|Magnetic Resonance Elastography (MRE) of Uterine Fibroids|Completed|||134|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 23:12:13.851952|2018-05-31 23:12:13.851952
NCT01226238|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-06-25|2010-10-21|2010-10-22|Estimate|||||||2014-06-25|2014-06-26|Estimate|October 2010||2010-10-31|June 2014|2014-06-30||||June 2011|Actual|2011-06-30||Interventional|||Online Self-help for Depressed Patients Awaiting Psychotherapy||Terminated||N/A|230|Actual|University of Luebeck||2|||f||||||||||||||2018-05-31 23:13:52.640018|2018-05-31 23:13:52.640018
NCT01229813|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2015-04-10|2010-10-27|2010-10-28|Estimate|||||||2015-04-10|2015-04-13|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ACT2||Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.||Completed||Phase 3|233|Actual|Lund University Hospital||4|||f||||f||||||||||2018-05-31 23:12:13.971051|2018-05-31 23:12:13.971051
NCT01229800|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|SPEN||Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial|Efficacy, Safety and Tolerability of Split-dose of PEG Compared With NaP Solution for Colonoscopy Preparation: A Randomized, Controlled Trial|Completed||Phase 3|207|Actual|Inje University||2|||f||||t||||||||||2018-05-31 23:12:14.094246|2018-05-31 23:12:14.094246
NCT01229787|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|||||Observational|||The Relation Between Obesity, Adipose Tissue Content of Fatty Acids and Systemic and Airway Inflammation|The Relation Between Obesity, Adipose Tissue Content of Fatty Acids and Systemic and Airway Inflammation|Completed|||5384|Actual|Cyprus International Institute for Environment and Public Health|||||f||||t||||||||||2018-05-31 23:12:14.175435|2018-05-31 23:12:14.175435
NCT01229774|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2014-09-12|2010-10-27|2010-10-28|Estimate|||||||2014-09-12|2014-09-15|Estimate|February 2011||2011-02-28|September 2010|2010-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty|Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty, a Prospective, Double Blind, Phase III Study|Completed||Phase 3|100|Actual|University of Regensburg||2|||f||||f||||||||||2018-05-31 23:12:14.243746|2018-05-31 23:12:14.243746
NCT01229761|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2017-03-09|2010-10-26|2010-10-28|Estimate|||||||2017-03-09|2017-03-10|Actual|May 2011||2011-05-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|March 2015|Actual|2015-03-31||Interventional|Mpepu||Study to Improve Survival Among HIV-Exposed Infants in Botswana|A Randomized Study of Cotrimoxazole Prophylaxis and Longer Breastfeeding Duration to Improve Survival Among HIV-Exposed Infants in Botswana|Active, not recruiting||Phase 2|3724|Anticipated|Harvard School of Public Health||4|||f||||t||||||||||2018-05-31 23:12:14.330051|2018-05-31 23:12:14.330051
NCT01229748|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-04-29|2010-10-27|2010-10-28|Estimate|||||||2015-04-29|2015-05-01|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Family Intervention for Teen Drinking in the ER|Family Intervention for Teen Drinking and Alcohol-Related Crises in the ER|Completed||N/A|104|Actual|University of Miami||3|||f||||f||||||||||2018-05-31 23:12:14.419356|2018-05-31 23:12:14.419356
NCT01229735|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|2015-11-09||2017-07-06|2010-10-27|2010-10-28|Estimate|2016-01-13|2016-02-12|Estimate||||2017-07-06|2017-08-15|Actual|November 2010||2010-11-30|July 2017|2017-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The Baseline Characteristics refers to the Safety Set which consists of all subjects who were randomized and received at least 1 dose of trial medication.|Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures|A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures|Completed||Phase 4|343|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 23:12:14.507581|2018-05-31 23:12:14.507581
NCT01229722|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|2014-02-10||2014-07-22|2010-10-27|2010-10-28|Estimate|2014-07-22|2014-08-11|Estimate||||2014-07-22|2014-08-11|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ARemind||ARemind: A Personalized System to Remind for Adherence|ARemind: A Personalized System to Remind for Adherence|Completed||N/A|70|Actual|Dimagi Inc.||2|||f||||t||||||||||2018-05-31 23:12:14.923003|2018-05-31 23:12:14.923003
NCT01229709|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2014-10-26|2010-10-26|2010-10-28|Estimate|||||||2014-10-26|2014-10-28|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|MBTR||Mindfulness Based Tinnitus Reduction (MBTR): A Symptom Perception Shift Program|Phase 2 Mindfulness Based Tinnitus Reduction (MBTR) Study: A Symptom Perception Shift Program|Completed||Phase 2|10|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:12:15.099025|2018-05-31 23:12:15.099025
NCT01229696|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2016-04-07|2010-10-27|2010-10-28|Estimate|||||||2016-04-07|2016-04-11|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Continuous Popliteal Nerve Blocks: Effect of Perineural Catheter Tip Location Relative to the Sciatic Nerve Bifurcation on Postoperative Analgesia|Continuous Popliteal Nerve Blocks: Effect of Perineural Catheter Tip Location Relative to the Sciatic Nerve Bifurcation on Postoperative Analgesia|Completed||Phase 4|150|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 23:12:15.1819|2018-05-31 23:12:15.1819
NCT01229683|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2012-03-06|2010-10-27|2010-10-28|Estimate|||||||2012-03-06|2012-03-08|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Observational|||Effects of Interscalene Brachial Plexus Nerve Blocks on the Hand and Forearm|Effects of Interscalene Brachial Plexus Nerve Blocks on the Hand and Forearm|Completed|||62|Actual|University of California, San Diego|||1||f||||f||||||||||2018-05-31 23:12:15.252076|2018-05-31 23:12:15.252076
NCT01229670|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|July 2010||2010-07-31|October 2010|2010-10-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Effects of Aerobic Interval and Continuous Exercise Trainings in Patients With Chronic Heart Failure|Effects of Aerobic Interval and Continuous Exercise Trainings on Cardiovascular Hemorheological Characteristics and Atherothrombosis/Angiogenesis-related Variables in Patients With Chronic Heart Failure|Unknown status|Recruiting|N/A|90|Anticipated|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 23:12:15.323034|2018-05-31 23:12:15.323034
NCT01229657|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-27|||2010-10-27|2010-10-27|2010-10-28|Estimate|||||||2010-10-27|2010-10-28|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Evaluation of Anatomic and Visual Outcomes of Initially Closed Macular Holes|Study of the Anatomic and Visual Outcomes in Patients With Initially Closed Macular Holes After Vitreoretinal Surgery|Completed|||79|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 23:12:15.399332|2018-05-31 23:12:15.399332
NCT01229644|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2012-11-26|2010-10-27|2010-10-28|Estimate|||||||2012-11-26|2012-11-27|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas|A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas|Terminated||Phase 2|70|Anticipated|Arog Pharmaceuticals, Inc.||3|||f||||||||||||||2018-05-31 23:12:15.449876|2018-05-31 23:12:15.449876
NCT01229631|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2017-02-13|2010-10-27|2010-10-28|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2010||2010-12-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|December 2014|Actual|2014-12-31||Interventional|ENURGISE||The Effect of Daily Dietary Intake of Dried Juice Concentrates of Fruit, Vegetables and Berries Upon Outcomes of Chronic Periodontitis|The Effect of Daily Dietary Intake of Dried Juice Concentrates of Fruit, Vegetables and Berries (Juice Plus+) Upon Periodontal Outcomes in Chronic Periodontitis: A Multicentre Randomised Controlled Trial|Active, not recruiting||N/A|90|Anticipated|Birmingham Community Healthcare NHS||2|||f||||f||||||||||2018-05-31 23:12:15.657187|2018-05-31 23:12:15.657187
NCT01229618|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2015-10-01|2010-10-26|2010-10-28|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|November 2011|Actual|2011-11-30||Interventional|||Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer|A Phase 1 Ascending-dose Study to Assess the Safety and Tolerability and Imaging Potential of Hyperpolarized Pyruvate (13C) Injection in Subjects With Prostate Cancer|Completed||Phase 1|31|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 23:12:15.725896|2018-05-31 23:12:15.725896
NCT01229605|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-12-08|2010-10-27|2010-10-28|Estimate|||||||2011-12-08|2011-12-12|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer|Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer, A Collaborative Trial|Withdrawn||Phase 2|0|Actual|Tufts Medical Center||1||Study was not a good fit for the patient population seen at this hospital.|f||||f||||||||||2018-05-31 23:12:15.792953|2018-05-31 23:12:15.792953
NCT01229592|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-07-16|2010-10-27|2010-10-28|Estimate|||||||2012-07-16|2012-07-17|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Ethanol in the Prevention of Central Venous Catheter Infections|Clinical Study of Ethanol Lock-therapy in the Prevention of Non-tunnelled, Short Term Central Venous Catheter Associated Infections|Terminated||N/A|200|Actual|Hospital General Universitario Gregorio Marañon||2||"The non significative reduction of CRBSI adverse events,the need for a high frecuency of~   catheter manipulations"|f||||f||||||||||2018-05-31 23:12:15.853875|2018-05-31 23:12:15.853875
NCT01229579|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2011-03-31|2010-10-27|2010-10-28|Estimate|||||||2011-03-31|2011-04-01|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan|Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan: a Randomized, Controlled Trial|Completed||N/A|320|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-05-31 23:12:15.920924|2018-05-31 23:12:15.920924
NCT01229566|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-11-23|2010-10-26|2010-10-27|Estimate|||||||2011-11-23|2011-11-24|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia|Unknown status|Active, not recruiting|Phase 3|240|Anticipated|Trygg Pharma, Inc.||3|||f||||f||||||||||2018-05-31 23:12:15.987973|2018-05-31 23:12:15.987973
NCT01229553|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-06-10|2010-10-26|2010-10-27|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients|Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients at the CF Center at SUNY Upstate Medical University, Syracuse, NY.|Withdrawn||N/A|0|Actual|State University of New York - Upstate Medical University||1||protocol was never implemented as procedures became standard of care|f||||f||||||||||2018-05-31 23:12:16.058999|2018-05-31 23:12:16.058999
NCT01229540|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate||||September 2008|2008-09-30||||||||Interventional|||Clinical Research on Retinal Neovascularization of Diabetic Retinopathy||Terminated||N/A|||Tianjin Medical University||1|||f||||||||||||||2018-05-31 23:12:16.146967|2018-05-31 23:12:16.146967
NCT01229527|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|2011-09-19||2012-01-02|2010-10-26|2010-10-27|Estimate|2012-01-02|2012-02-01|Estimate||||2012-01-02|2012-02-01|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison Between Two Different Dosages of Remifentanil During Colonoscopy|Comparison Between Two Different Dosages of Remifentanil Administered by PCSA (Patient Controlled Sedation and Analgesia) and Meperidine During Colonoscopy: A Randomized Double-Blind Trial|Completed||Phase 4|90|Actual|Ospedale San Raffaele||3|||f||||||||||||||2018-05-31 23:12:16.3172|2018-05-31 23:12:16.3172
NCT01229514|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2012-08-01|2010-10-26|2010-10-27|Estimate|||||||2012-08-01|2012-08-02|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Functional Magnetic Resonance Imaging (fMRI) Findings in Children With Early Exposure to General Anesthesia|A Comparison of Functional Magnetic Resonance Imaging (fMRI) Findings in Children With and Without a History of Early Exposure to General Anesthetics|Completed|||30|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 23:12:17.664848|2018-05-31 23:12:17.664848
NCT01229501|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2016-06-22|2010-10-26|2010-10-27|Estimate|||||||2016-06-22|2016-06-24|Estimate|March 2010||2010-03-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Fat Biology, Sleep Disorders, and Cardiovascular Disease|Fat Biology, Sleep Disorders, and Cardiovascular Disease|Completed|||14|Actual|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     Serum and plasma.~   "|||2018-05-31 23:12:18.079274|2018-05-31 23:12:18.079274
NCT01229488|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-03-25|2010-10-26|2010-10-27|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||System for Ocular Oxygen Measurement||Withdrawn||N/A|0|Actual|Indiana University||1||I withdrew from this study|f||||f||||||||||2018-05-31 23:12:18.607215|2018-05-31 23:12:18.607215
NCT01229475|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2013-02-28|2010-10-26|2010-10-27|Estimate|||||||2013-02-28|2013-03-01|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|REDO-AF||Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation|Stepwise Approach Versus Linear Ablation for Repeat Procedure in Patients With Recurrence of Persistent Atrial Fibrillation|Unknown status|Recruiting|N/A|130|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:12:18.843171|2018-05-31 23:12:18.843171
NCT01229462|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|2012-08-15||2012-08-15|2010-10-26|2010-10-27|Estimate|2012-08-15|2012-09-14|Estimate||||2012-08-15|2012-09-14|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension||Completed||N/A|238|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:12:19.355735|2018-05-31 23:12:19.355735
NCT01229449|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study|A Double-blind, Parallel-group, Placebo-controlled, Randomised, Single Dose Study to Compare Ibuprofen + Acetaminophen; Ibuprofen + Codeine (Nurofen Plus®) and Acetaminophen + Codeine (Panadeine® Extra) in Postoperative Dental Pain.|Completed||Phase 3|678|Actual|Reckitt Benckiser LLC||5|||f||||f||||||||||2018-05-31 23:12:19.581533|2018-05-31 23:12:19.581533
NCT01229436|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|2013-10-29||2014-01-29|2010-10-26|2010-10-27|Estimate|2014-01-29|2014-03-17|Estimate||||2014-01-29|2014-03-17|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|POINT X||Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)|Prospective Open-Label Investigation Of The Non-surgical Treatment With Collagenase Clostridium Histolyticum (Xiapex)|Completed||Phase 3|254|Actual|Pfizer|Results were not reported for fifth injection as no finger received 5 injections.Results are reported for 'number of days of concomitant pain medication' as 'amount of pain medication' was interpreted as total number of days with pain medication use.|1|||f||||f||||||||||2018-05-31 23:12:19.799287|2018-05-31 23:12:19.799287
NCT01229423|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2011-12-16||2011-12-16|2010-10-26|2010-10-27|Estimate|2011-12-16|2012-01-23|Estimate||||2011-12-16|2012-01-23|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects||Completed||Phase 4|62|Actual|Allergan||1|||f||||f||||||||||2018-05-31 23:12:21.399475|2018-05-31 23:12:21.399475
NCT01229410|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2013-03-13||2013-07-02|2010-10-26|2010-10-27|Estimate|2013-07-02|2013-08-05|Estimate||||2013-07-02|2013-08-05|Estimate|December 2010||2010-12-31|July 2013|2013-07-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy||Completed||Phase 1|24|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:12:21.672813|2018-05-31 23:12:21.672813
NCT01229397|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2012-10-23||2014-01-07|2010-10-26|2010-10-27|Estimate|2013-03-20|2013-05-20|Estimate||||2014-01-07|2014-02-06|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V|A Phase III Open, Randomized, Parallel, Multi-center Study in Children Aged 6 - 35 Months to Compare the Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V Administered According to a 0/4 Week Schedule|Completed||Phase 3|205|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 23:12:22.066721|2018-05-31 23:12:22.066721
NCT01229384|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2012-06-08|2010-10-26|2010-10-27|Estimate|||||||2012-06-08|2012-06-11|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|BPAP||Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions|Randomized Controlled Trial Comparing Standard Versus Positive Pressure Nebulization in Infants With Bronchiolitis to Reduce Hospital Admissions|Unknown status|Recruiting|N/A|200|Anticipated|Phoenix Children's Hospital||2|||f||||t||||||||||2018-05-31 23:12:22.426809|2018-05-31 23:12:22.426809
NCT01229371|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2012-10-23||2013-08-29|2010-10-26|2010-10-27|Estimate|2013-02-15|2013-03-22|Estimate||||2013-08-29|2013-09-09|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers|Randomized, Parallel-group, Double-blind Multi-center Phase III Study to Assess the Immunogenicity and Safety of the 2010/2011-season Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers, in Elderly and Young Adults|Completed||Phase 3|440|Actual|Crucell Holland BV||4|||f||||f||||||||||2018-05-31 23:12:22.530746|2018-05-31 23:12:22.530746
NCT01229358|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2016-01-11|2010-10-26|2010-10-27|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Interventional|SILVER||Clinical Trial of a Silver Eluting Dressing System|Prospective, Randomized Clinical Trial of a Silver Eluting Dressing System for Prevention of Lower Extremity Revascularization Wound Complications|Completed||Phase 4|500|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:12:23.011137|2018-05-31 23:12:23.011137
NCT01229345|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2012-05-02|2010-10-26|2010-10-27|Estimate|||||||2012-05-02|2012-05-04|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Exercise With or Without Breakfast, on Metabolism, Appetite and Cognition|The Interactive Effect of Breakfast Consumption and Exercise on Metabolism, Appetite and Cognitive Function|Completed||N/A|12|Actual|Northumbria University||4|||f||||||||||||||2018-05-31 23:12:23.083632|2018-05-31 23:12:23.083632
NCT01229332|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2011-12-04|2010-10-26|2010-10-27|Estimate|||||||2011-12-04|2011-12-06|Estimate|January 2011||2011-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients|A Phase I/II, Single-center, Randomized, Cross-over, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Administration of Subcutaneous Continuously-delivered Carbidopa Solution (ND0611) on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations|Completed||Phase 1/Phase 2|24|Actual|NeuroDerm Ltd.||2|||f||||||||||||||2018-05-31 23:12:23.244185|2018-05-31 23:12:23.244185
NCT01229319|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2011-06-21|2010-10-26|2010-10-27|Estimate|||||||2011-06-21|2011-06-22|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses|An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms|Unknown status|Recruiting|Phase 4|20|Anticipated|Frankel, Amylynne, M.D.||2|||f||||t||||||||||2018-05-31 23:12:23.306257|2018-05-31 23:12:23.306257
NCT01229306|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2013-05-02|2010-10-26|2010-10-27|Estimate|||||||2013-05-02|2013-05-03|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|January 2014|Anticipated|2014-01-31|July 2013|Anticipated|2013-07-31||Interventional|||Repeat Ablation Procedure in Patients With Relapse of Atrial Fibrillation|Repeat Ablation Procedure in Patients With Relapse of Paroxysmal Atrial Fibrillation Using Reisolation of Pulmonary Vein Versus Reisolation of Pulmonary Vein With Additional Anterior Line|Unknown status|Recruiting|N/A|108|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:12:23.379332|2018-05-31 23:12:23.379332
NCT01229293|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-09-21|2010-10-26|2010-10-27|Estimate|||||||2012-09-21|2012-09-25|Estimate|February 2007||2007-02-28|September 2012|2012-09-30|November 2011|Actual|2011-11-30|March 2010|Actual|2010-03-31||Interventional|RTHA and THA||Gait Analysis and Neuromuscular Function After Primary Total Hip Replacement|The Effect of Implant Design on Postoperative Mechanical Muscle Function Recovery and Gait in Hip Replacement Patients: A Randomized Clinical Trail|Completed||Phase 2|39|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 23:12:23.44352|2018-05-31 23:12:23.44352
NCT01229280|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|February 2011|Anticipated|2011-02-28|January 2011|Anticipated|2011-01-31||Interventional|||Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.|Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Center for Clinical Pharmacology Research Bdbeq S.A.||2|||f||||f||||||||||2018-05-31 23:12:23.545779|2018-05-31 23:12:23.545779
NCT01229267|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2016-07-27|2010-10-26|2010-10-27|Estimate|||||||2016-07-27|2016-07-28|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM4)|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)|Completed||Phase 3|1257|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 23:12:23.734536|2018-05-31 23:12:23.734536
NCT01229254|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2017-07-21|2016-11-30|2017-09-13|2010-10-25|2010-10-27|Estimate|2017-09-13|2017-09-18|Actual|2017-07-13|2017-07-17|Actual|2017-09-13|2017-09-18|Actual|September 2010||2010-09-30|July 2017|2017-07-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional||All enrolled patients who took at least 1 dose of study medication|Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter|A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter|Completed||Phase 2|189|Actual|Portola Pharmaceuticals||3|||f||||f||||||||||2018-05-31 23:12:23.856734|2018-05-31 23:12:23.856734
NCT01229241|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-01-19|2010-10-26|2010-10-27|Estimate|||||||2012-01-19|2012-01-20|Estimate|July 2005||2005-07-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|LEVOROPI||Assessment of Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion|Prospective Randomized Double-blinded Study of Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion|Completed||Phase 4|181|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 23:12:24.209463|2018-05-31 23:12:24.209463
NCT01229228|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2011-11-22||2012-05-15|2010-10-26|2010-10-27|Estimate|2012-03-01|2012-03-29|Estimate||||2012-05-15|2012-05-22|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study of Naproxen Capsules to Treat Dental Pain|A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Naproxen [Test] Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars|Completed||Phase 2|254|Actual|Iroko Pharmaceuticals, LLC||5|||f||||f||||||||||2018-05-31 23:12:24.278581|2018-05-31 23:12:24.278581
NCT01229215|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25||2016-08-10|2016-11-01|2010-10-25|2010-10-27|Estimate||||2016-08-10|2016-08-12|Estimate|2016-11-01|2016-11-02|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy|A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy|Completed||Phase 2|143|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:12:24.601183|2018-05-31 23:12:24.601183
NCT01229202|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2011-06-29|2010-10-25|2010-10-27|Estimate|||||||2011-06-29|2011-07-01|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery|Use of Vascular Endothelial Growth Factor Inhibitor, Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery|Unknown status|Recruiting|Phase 4|60|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 23:12:25.626007|2018-05-31 23:12:25.626007
NCT01229189|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2012-03-07|2010-10-26|2010-10-27|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of the Effectiveness of Vitamin D Supplementation to Pregnant Women and Their Infants in Pakistan.|Evaluation of the Effectiveness of Vitamin D Supplementation to Pregnant Women and Their Infants in Pakistan|Completed||N/A|460|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 23:12:25.723337|2018-05-31 23:12:25.723337
NCT01229176|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2014-03-05||2014-04-11|2010-10-26|2010-10-27|Estimate|2014-03-05|2014-04-10|Estimate||||2014-04-11|2014-05-01|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||All enrolled Set|Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants|A Phase 2a, Randomized, Controlled, Observer Blind, Age De-Escalation, Multicenter and Multinational Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants|Completed||Phase 2|200|Actual|Novartis||8|||f||||t||||||||||2018-05-31 23:12:25.835796|2018-05-31 23:12:25.835796
NCT01229163|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2018-04-04|2010-10-26|2010-10-27|Estimate|||||||2018-04-04|2018-04-05|Actual|October 3, 2010||2010-10-03|May 31, 2013|2013-05-31|April 19, 2012|Actual|2012-04-19|April 9, 2012|Actual|2012-04-09||Interventional|||Automated Prize-based Contingency Management to Increase Counseling Attendance in Opiate-Replacement-Therapy Patients|Automated Prize-Based Contigency Management to Increase Counseling Attendance in Opiate-Replacement-Therapy Patients|Completed||Early Phase 1|25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:12:27.084088|2018-05-31 23:12:27.084088
NCT01229150|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|2014-10-23||2017-04-17|2010-10-26|2010-10-27|Estimate|2014-10-23|2014-10-29|Estimate||||2017-04-17|2017-05-23|Actual|October 26, 2010|Actual|2010-10-26|April 2017|2017-04-30|November 21, 2015|Actual|2015-11-21|September 30, 2013|Actual|2013-09-30||Interventional|||Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...|Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|89|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||f|t|f||||||No||2018-05-31 23:12:27.22107|2018-05-31 23:12:27.22107
NCT01229137|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-09-10|2010-10-25|2010-10-27|Estimate|||||||2012-09-10|2012-09-12|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|PRE-SENSE||Physiological Response to Exercise: Sensor Evaluation at Specified Exertions|Physiological Response to Exercise: Sensor Evaluation at Specified Exertions|Completed|||71|Actual|Boston Scientific Corporation|||3||f||||f||||||||||2018-05-31 23:12:29.552975|2018-05-31 23:12:29.552975
NCT01229124|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2016-05-13|2010-10-26|2010-10-27|Estimate|||||||2016-05-13|2016-05-17|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia|SCOR in Targeted Therapies for Infant Leukemias Project 4: MicroRNA Sequencing of Infant AML|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:12:29.843608|2018-05-31 23:12:29.843608
NCT01229111|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|2017-02-10||2017-02-10|2010-10-26|2010-10-27|Estimate|2017-02-10|2017-03-29|Actual||||2017-02-10|2017-03-29|Actual|October 2010||2010-10-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||All patients who signed consent.|Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers|A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers|Terminated||Phase 2|14|Actual|National Cancer Institute (NCI)||1||Lack of Drug Supply|f||||t||||||||||2018-05-31 23:12:29.944103|2018-05-31 23:12:29.944103
NCT01229098|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2015-03-25|2010-10-26|2010-10-27|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris|A Phase 2 Maximal Use Systemic Exposure Study Evaluating the Safety and Efficacy of Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Gel Applied Once Daily in Subjects With Extensive Psoriasis Vulgaris on the Scalp and Non-scalp Regions of the Body (Trunk and/or Limbs)|Completed||Phase 2|102|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 23:12:30.332467|2018-05-31 23:12:30.332467
NCT01229085|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|Psoriasis||Efficacy Study of the Combination Mometasone + Salicylic Acid in Patients With Psoriasis|CLINICAL ASSESSMENT OF THE EFFECTIVENESS OF ASSOCIATION MONETASONE FUROATE 0.1% SALICYLIC ACID AND 5% FOR SUBMISSION OF OINTMENT TOPICAL DERMATOLOGICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS.|Completed||Phase 3|71|Actual|Azidus Brasil||1|||f||||f||||||||||2018-05-31 23:12:30.411359|2018-05-31 23:12:30.411359
NCT01229072|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|July 2008||2008-07-31|October 2008|2008-10-31||||July 2008|Anticipated|2008-07-31||Interventional|Heparin||Safe Use of Heparin Sodium Laboratory Blausiegel Compared to Liquemine ® Laboratory Roche in Patients With Chronic Renal Failure.|Clinical Study to Assess the Safety of the Use of the Drug Heparin Sodium Produced by the Laboratory Blausiegel Compared in Parallel to the Product Liquemine ® Laboratory Roche in Patients With Chronic Renal Failure.|Suspended||Phase 2/Phase 3|60|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-05-31 23:12:30.477738|2018-05-31 23:12:30.477738
NCT01229059|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-20|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Observational|FFAIR||Free Fatty Acid Induced Insulin Resistance|Assessment of the Time Course of Lipid Induced Insulin Resistance|Unknown status|Recruiting||15|Anticipated|German Diabetes Center|||1||f||||f||||||Samples With DNA|"~     muscle biopsies~   "|||2018-05-31 23:12:30.554377|2018-05-31 23:12:30.554377
NCT01229046|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-11-12|2010-10-26|2010-10-27|Estimate|||||||2012-11-12|2012-11-14|Estimate|September 2010||2010-09-30|November 2012|2012-11-30||||||||Interventional|||Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants|Pharmacokinetics and Safety of Ticarcillin-clavulanate in Infants|Withdrawn||Phase 1|0|Actual|Duke University||1||No enrollment occured. Subjects will be enrolled under a new protocol.|f||||f||||||||||2018-05-31 23:12:30.668115|2018-05-31 23:12:30.668115
NCT01229033|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2017-04-10|2010-10-26|2010-10-27|Estimate|||||||2017-04-10|2017-04-11|Actual|January 2010||2010-01-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|ATTAC CFAE||Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF|Ablating Atrial Tachycardias Occuring During Ablation of Complex Fractionated Electrograms in Persistent AF - ATTAC CFAE Trial|Completed||N/A|186|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:12:30.800014|2018-05-31 23:12:30.800014
NCT01229020|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|February 2004||2004-02-29|October 2010|2010-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Distribution of Regional Lung Function by Vibration Response Imaging|Distribution of Regional Lung Function, as Determined by the Vibration Response Image Generated by the VRI-2000 System as Compared With Standard Radio-nuclear Method|Completed|||25|Actual|Deep Breeze|||1||f||||f||||||||||2018-05-31 23:12:30.864802|2018-05-31 23:12:30.864802
NCT01229007|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2017-08-23|2010-10-26|2010-10-27|Estimate|||||||2017-08-23|2017-08-24|Actual|August 2010||2010-08-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study of Biostate® in Children With Hemophilia A|A Phase III, Open-Label, Multicentre Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Biostate® in Paediatric Subjects With Haemophilia A|Completed||Phase 3|35|Actual|CSL Behring||1|||f||||t||||||||||2018-05-31 23:12:30.931896|2018-05-31 23:12:30.931896
NCT01228994|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2013-09-11|2010-10-26|2010-10-27|Estimate|||||||2013-09-11|2013-09-12|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Baclofen||Baclofen for Smoking Cessation in a Non-Psychiatric Population|Testing the GABAergic Hypothesis of Nicotine Dependence: a Randomized Clinical Trial of Baclofen|Terminated||Phase 2|6|Actual|Centre for Addiction and Mental Health||3||The study was terminated because of difficulties recruiting subjects.|f||||f||||||||||2018-05-31 23:12:31.013441|2018-05-31 23:12:31.013441
NCT01228981|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2016-04-22|2010-10-26|2010-10-27|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|March 2013|Actual|2013-03-31|June 2011|Actual|2011-06-30||Observational|CEC120||Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy|Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy|Completed|||400|Actual|Association for Innovation and Biomedical Research on Light and Image|||1||f||||f||||||||||2018-05-31 23:12:31.081197|2018-05-31 23:12:31.081197
NCT01228968|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2011-04-11||2011-05-11|2010-10-26|2010-10-27|Estimate|2011-04-11|2011-05-06|Estimate||||2011-05-11|2011-05-13|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Toward an Automated Method of Abdominal Fat Segmentation of MR Images|Toward an Automated Method of Abdominal Fat Segmentation of MR Images|Completed|||9|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 23:12:31.153808|2018-05-31 23:12:31.153808
NCT01228942|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-06-05|2010-10-25|2010-10-27|Estimate|||||||2014-06-05|2014-06-06|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|October 2012|Anticipated|2012-10-31||Interventional|||A Prospective Trial of COXEN Chemotherapy Prediction|A Prospective Trial of COXEN Chemotherapy Prediction in Persistent and Recurrent Ovarian, Fallopian Tube, and Peritoneal Carcinomas|Withdrawn||N/A|0|Actual|University of Virginia||2||Lack of funding/resources|f||||t||||||||||2018-05-31 23:12:31.349581|2018-05-31 23:12:31.349581
NCT01228929|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2015-07-31||2015-09-17|2010-10-25|2010-10-27|Estimate|2015-09-17|2015-10-12|Estimate||||2015-09-17|2015-10-12|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Non-invasive Ocular Surface Measurements Before and After Interventions|Non-invasive Ocular Surface Measurements Before and After Interventions|Terminated||N/A|18|Actual|University of Rochester||3||The study was terminated.|f||||f||||||||||2018-05-31 23:12:31.416964|2018-05-31 23:12:31.416964
NCT01228916|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2016-04-19|2010-10-25|2010-10-27|Estimate|||||||2016-04-19|2016-04-21|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Community-Partnered Dominican Republic Tobacco Control|Community-Partnered Tobacco Control in Underserved Dominican Republic Communities|Completed||N/A|3273|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 23:12:31.842075|2018-05-31 23:12:31.842075
NCT01228903|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2016-10-24||2017-06-09|2010-10-25|2010-10-27|Estimate|2017-01-03|2017-02-23|Actual||||2017-06-09|2017-06-28|Actual|October 2010||2010-10-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Uric Acid and the Endothelium in CKD|Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?|Completed||N/A|80|Actual|University of Colorado, Denver||2|||f||||t||||||||Yes|De-identified data will be made available to investigators upon request from the PI|2018-05-31 23:12:31.923204|2018-05-31 23:12:31.923204
NCT01228890|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-12-13|2010-10-25|2010-10-27|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|CATCH-IT||Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)|Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT)|Withdrawn||Phase 3|0|Actual|University of Chicago||2||no one enrolled; PI left institution|f||||f||||||||||2018-05-31 23:12:32.17692|2018-05-31 23:12:32.17692
NCT01228877|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2017-10-25|2010-10-26|2010-10-27|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2010||2010-12-31|October 2017|2017-10-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|Ad/Ab||The Effect of 16 Weeks of Hip Adduction and Abduction Resistance Exercise|The Effect of 16 Weeks of Hip Adduction and Abduction Resistance Exercise Training on Strength and Density of the Proximal Femur|Completed||N/A|22|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:12:32.299715|2018-05-31 23:12:32.299715
NCT01228864|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2017-12-06|2010-10-25|2010-10-27|Estimate|||||||2017-12-06|2017-12-08|Actual|September 22, 2009|Actual|2009-09-22|December 2017|2017-12-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag|Brody Belt - Alternative Method of Securing a Patient's Urinary Drainage Bag|Terminated||N/A|12|Actual|Roswell Park Cancer Institute||2||low accrual|f||||t||||||||||2018-05-31 23:12:32.561617|2018-05-31 23:12:32.561617
NCT01228851|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2011-07-26|2010-10-25|2010-10-27|Estimate|||||||2011-07-26|2011-07-27|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Balance Training in Parkinson's Disease Using the Wii Balance Board|A Pilot Study of the Effects of Balance Training Using the Wii Balance Board on Balance and Ambulation in Adults With Parkinson's Disease|Completed||N/A|10|Actual|Shirley Ryan AbilityLab||1|||f||||f||||||||||2018-05-31 23:12:32.918543|2018-05-31 23:12:32.918543
NCT01228838|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-09-06|2010-10-25|2010-10-27|Estimate|||||||2012-09-06|2012-09-10|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of NGX-1998 for the Treatment of Postherpetic Neuralgia|A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects With Postherpetic Neuralgia (PHN)|Completed||Phase 2|183|Actual|NeurogesX||3|||f||||f||||||||||2018-05-31 23:12:33.209463|2018-05-31 23:12:33.209463
NCT01228825|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|May 2007||2007-05-31|October 2010|2010-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Pharmacokinetics of Cefuroxime in Cardiac Surgery With Cardiopulmonary Bypass|Evaluation of Plasma Concentrations and Pharmacokinetics of Cefuroxime Administered Prophylactically in Patients Undergoing Coronary Surgery With Cardiopulmonary Bypass|Completed|||19|Actual|University of Sao Paulo|||2||f||||f||||||Samples With DNA|"~     Blood samples were collected sequentially after the administration of initial bolus of~     cefuroxime every 15 minutes during the first hour, then within two, three and six hours.~      Samples were also collected every 15 minutes during CPB. Group Off-Pump had equivalent~     collections, considering the time after heparinization and anastomosis initiation. Four other~     blood samples were collected at times considered as high risk for bacterial contamination,~     i.e.~      chest incision, beginning of anastomosis, after protamine administration, and chest suture.~      After each bolus of 750 mg, samples were collected within 30 minutes, one, three, and six~     hours.~   "|||2018-05-31 23:12:33.544321|2018-05-31 23:12:33.544321
NCT01228812|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2018-05-11|2010-10-26|2010-10-27|Estimate|||||||2018-05-11|2018-05-17|Actual|April 2010||2010-04-30|May 2018|2018-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Physical Activity Behavior of Rheumatoid Arthritis Patients and Healthy Controls|An Observational Study of Physical Activity Behavior of Swiss Rheumatoid Arthritis Patients and Healthy Matched Controls|Completed|||505|Actual|University of Lausanne|||2||f||||f||||||||No||2018-05-31 23:12:33.610424|2018-05-31 23:12:33.610424
NCT01228799|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2013-08-16|2010-10-26|2010-10-27|Estimate|||||||2013-08-16|2013-08-19|Estimate|June 2010||2010-06-30|October 2010|2010-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TVC||Trabeculectomy Versus Canaloplasty|Longterm Comparison Between Trabeculectomy and Canaloplasty in Open-angle Glaucoma|Completed||N/A|64|Actual|University Eye Hospital, Würzburg||2|||f||||f||||||||||2018-05-31 23:12:33.676942|2018-05-31 23:12:33.676942
NCT01228786|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-26|||2012-07-19|2010-10-26|2010-10-27|Estimate|||||||2012-07-19|2012-07-20|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|||Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism|Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism|Unknown status|Recruiting||50|Anticipated|Postgraduate Institute of Medical Education and Research|||2||f||||t||||||Samples With DNA|"~     Parathyroid Adenoma and normal parathyroid gland~   "|||2018-05-31 23:12:33.744737|2018-05-31 23:12:33.744737
NCT01228773|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-10-26|2010-10-26|2010-10-27|Estimate|||||||2010-10-26|2010-10-27|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||The Efficacy of Health Navigation® for Cancer-Related Fatigue in Cancer Survivors|The Efficacy of Web-based, Tailored Program(Health Navigation®) for the Management of Cancer-Related Fatigue in Cancer Survivors|Unknown status|Enrolling by invitation|Phase 2|266|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 23:12:33.815588|2018-05-31 23:12:33.815588
NCT01228760|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2013-06-06|2010-10-25|2010-10-26|Estimate|||||||2013-06-06|2013-06-07|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer|A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)|Completed||Phase 1|46|Actual|Astellas Pharma Inc||12|||f||||f||||||||||2018-05-31 23:12:33.908413|2018-05-31 23:12:33.908413
NCT01228747|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2015-04-27||2017-02-21|2010-10-25|2010-10-26|Estimate|2015-04-27|2015-05-13|Estimate||||2017-02-21|2017-03-24|Actual|October 2010||2010-10-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional||Baseline Characteristics refer to the Safety Set (SS), which is a subset of the Randomized Set and consisted of all subjects who received at least 1 dose of study medication after randomization, either Placebo or Levetiracetam.|A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)|A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged ≥16 Years, With Generalized Tonic-clonic (GTC) Seizures|Completed||Phase 3|361|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 23:12:34.003936|2018-05-31 23:12:34.003936
NCT01228734|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2017-01-13||2017-12-07|2010-10-25|2010-10-26|Estimate|2017-01-13|2017-03-06|Actual||||2017-12-07|2017-12-08|Actual|September 30, 2010|Actual|2010-09-30|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|January 25, 2016|Actual|2016-01-25||Interventional|TAILOR|Modified intent-to-treat (MITT) population included all subjects with RAS wild-type tumor status who were randomized to study treatment and who received at least 1 dose of study treatment. Subjects were analyzed as randomized.|A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients|An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status|Active, not recruiting||Phase 3|553|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 23:12:34.405435|2018-05-31 23:12:34.405435
NCT01228721|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|December 2010||2010-12-31|||||Interventional|||Reproducibility of Retinal Nerve Fiber Layer Thickness Measurements Using the Eye Tracker and Retest Function of Spectralis® SD-OCT in Glaucomatous Eyes and Healthy Controls||Terminated||Phase 4|||University of Zurich|||||f||||||||||||||2018-05-31 23:12:36.180815|2018-05-31 23:12:36.180815
NCT01228708|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-03-27|2010-10-25|2010-10-26|Estimate|||||||2012-03-27|2012-03-28|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|October 2010|Actual|2010-10-31||Interventional|||Effects of an Active Implementation of a Guideline for Chronic Obstructive Pulmonary Disease|Effects of an Active Implementation of a Chronic Disease Management Programme for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|3021|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:12:36.442176|2018-05-31 23:12:36.442176
NCT01228695|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Prospective Study of the Impact of Systemic Corticosteroid Use on Measures of Sleep Disordered Breathing||Completed|||20||Rambam Health Care Campus|||1||f||||||||||||||2018-05-31 23:12:36.87307|2018-05-31 23:12:36.87307
NCT01228682|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2013-04-30|2010-10-25|2010-10-26|Estimate|||||||2013-04-30|2013-05-01|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Observational|||Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice|A Multi-Centre, Multi-National, Observational Post-Authorisation Safety Study to Document the Drug Utilisation of Samsca and to Collect Information on the Safety of Samsca When Used in Routine Medical Practice|Unknown status|Active, not recruiting||200|Anticipated|Otsuka Frankfurt Research Institute GmbH|||1||f||||f||||||||||2018-05-31 23:12:37.181236|2018-05-31 23:12:37.181236
NCT01228669|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2017-02-09|2010-10-25|2010-10-26|Estimate|||||||2017-02-09|2017-02-10|Actual|October 2010||2010-10-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Explorer 1||Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-0000-2021 Administered Intravenously and Subcutaneously to Healthy Male Subjects and Haemophilia Subjects|Completed||Phase 1|52|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 23:12:37.585274|2018-05-31 23:12:37.585274
NCT01228656|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Interventional|Psoriasis||Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate|CLINICAL EVALUATION OF EFFECTIVENESS OF ASSOCIATION MOMETASONE FUROATE 0.1% AND SALICYLIC ACID 5% COMPARED WITH 0.1% MOMETASONE FUROATE INSULATED TOPICAL USE OF LABORATORY Glenmark Pharmaceuticals Ltd, IN PATIENTS WITH PSORIASIS IN PLATE|Suspended||Phase 2|40|Actual|Azidus Brasil||2|||f||||f||||||||||2018-05-31 23:12:37.935217|2018-05-31 23:12:37.935217
NCT01228643|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|June 2007||2007-06-30|February 2008|2008-02-29|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs|STUDY OF EFFECTIVENESS OF THE USE OF PANCREATIC ENZYME: NORZYME® -(MADE IN THE LABORATORY PANCREALIPASE BERGAMO) INPATIENTS WITH PANCREATIC INSUFFICIENCY IN USE SUBSTITUTEENZYMATIC WHEN COMPARED TO PRODUCT CREON®|Withdrawn||Phase 3|5|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-05-31 23:12:38.230952|2018-05-31 23:12:38.230952
NCT01227291|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-09-26|2010-10-22|2010-10-25|Estimate|||||||2012-09-26|2012-09-27|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm Hg|Study With SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With IOP >= 21 mm Hg.|Completed||Phase 1/Phase 2|30|Actual|Sylentis, S.A.||1|||f||||t||||||||||2018-05-31 23:13:17.124802|2018-05-31 23:13:17.124802
NCT01228630|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2016-04-07|2010-10-25|2010-10-26|Estimate|||||||2016-04-07|2016-04-11|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.|Randomized Clinical Study for Efficacy Assessment Between Cloratadd-D, Loratadine + Pseudoephedrine (Coated Pill), Produced by EMS S/A Laboratories and Allegra-D , Produced by Sanofi-Aventis for Patients With Perennial Allergic Rhinitis.|Completed||Phase 3|156|Actual|Azidus Brasil||2|||f||||f||||||||Undecided|It believed that after the data analysis and presentation to the IRC, all data will become public.|2018-05-31 23:12:38.54454|2018-05-31 23:12:38.54454
NCT01228617|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2011-10-04|2010-10-25|2010-10-26|Estimate|||||||2011-10-04|2011-10-06|Estimate|September 2007||2007-09-30|October 2011|2011-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Single-dose Pharmacokinetics of Oral Nicotine Replacement Products|Single-dose Pharmacokinetics of Oral Nicotine Replacement Products - An Exploratory Study in Healthy Volunteers|Completed||N/A|40|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||7|||f||||f||||||||||2018-05-31 23:12:38.836068|2018-05-31 23:12:38.836068
NCT01228604|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2014-07-17|2010-10-25|2010-10-26|Estimate|||||||2014-07-17|2014-07-21|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Cost-Effectiveness Study Of The Treatment Of Attention Deficit/Hyperactivity Disorder In Brazil|COST-EFFECTIVENESS STUDY OF THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN BRAZIL|Completed||Phase 4|23|Actual|Hospital de Clinicas de Porto Alegre||1|||f||||||||||||||2018-05-31 23:12:38.914286|2018-05-31 23:12:38.914286
NCT01228591|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2013-09-17||2015-05-06|2010-10-25|2010-10-26|Estimate|2013-12-16|2014-02-03|Estimate||||2015-05-06|2015-05-22|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Baseline summary was conducted on subjects who successfully completed the study. There were 38 subjects that started, 3 discontinued, and 2 were ineligible.|Pilot Dispensing Evaluation of a Plus Power Lens||Completed||N/A|38|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 23:12:39.016155|2018-05-31 23:12:39.016155
NCT01228578|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2014-05-20|2010-10-25|2010-10-26|Estimate|||||||2014-05-20|2014-05-22|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Multi-vitamins, HAART and HIV/AIDS in Uganda|Multi-vitamins, HAART and HIV/AIDS in Uganda|Completed||Phase 3|400|Anticipated|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 23:12:39.640581|2018-05-31 23:12:39.640581
NCT01228565|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2015-03-23|2010-10-25|2010-10-26|Estimate|||||||2015-03-23|2015-03-24|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|GORTEC 2009-01||Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®|Placebo Controlled Randomized Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®|Completed||Phase 3|76|Actual|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||f||||||||||2018-05-31 23:12:39.761112|2018-05-31 23:12:39.761112
NCT01228552|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2011-06-04|2010-10-25|2010-10-26|Estimate|||||||2011-06-04|2011-06-08|Estimate|December 2011||2011-12-31|October 2010|2010-10-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine|A Randomized Double Blind, Placebo Controlled Phase III Trial to Determine the Efficacy and Safety of Topical Intra-oral Ketoprofen for the Treatment of Acute Migraine|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Behar, Caren, M.D.||2|||f||||t||||||||||2018-05-31 23:12:39.826384|2018-05-31 23:12:39.826384
NCT01228539|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2013-05-09|2010-10-25|2010-10-26|Estimate|||||||2013-05-09|2013-05-13|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MPTSD||Breaking the Cycle IV: Military PTSD (MPTSD) Treatment Study|Breaking the Cycle IV: Military PTSD (MPTSD) Treatment Study|Completed||N/A|31|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 23:12:39.921177|2018-05-31 23:12:39.921177
NCT01228526|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2016-08-25|2010-10-25|2010-10-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||A Multicenter, Prospective, Observational Study With PriMatrix for the Treatment of Neuropathic Diabetic Foot Ulcers||Completed|||22|Actual|Integra LifeSciences Corporation|||||f||||||||||||||2018-05-31 23:12:39.985387|2018-05-31 23:12:39.985387
NCT01228513|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14||2015-06-04|2015-12-17|2010-10-25|2010-10-26|Estimate||||2015-06-04|2015-07-01|Estimate|2015-12-17|2016-01-21|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|April 2012|Actual|2012-04-30|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)|Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)|Completed||Phase 2|263|Actual|Bayer||4|||f||||f||||||||||2018-05-31 23:12:40.039185|2018-05-31 23:12:40.039185
NCT01228500|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2016-05-15|2010-10-25|2010-10-26|Estimate|||||||2016-05-15|2016-05-17|Estimate|January 2008||2008-01-31|May 2016|2016-05-31||||January 2013|Actual|2013-01-31||Interventional|||The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial|The Use of Bioscaffolds in Conjunction With Negative Pressure Therapy: A Prospective Randomized Double-Blinded Trial|Withdrawn||N/A|0|Actual|Integra LifeSciences Corporation||1|||f||||t||||||||||2018-05-31 23:12:40.133514|2018-05-31 23:12:40.133514
NCT01228487|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2011-07-25|2010-10-25|2010-10-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Observational|||Influence of Oxidative Dysbalance on Secondary Osteoarthritis|Biomechanical Factors of Secondary Osteoarthritis: Oxidative and Nitrosative Stress as Predictive Factors of Joint Destruction|Unknown status|Recruiting||60|Anticipated|Heinrich-Heine University, Duesseldorf|||3||f||||f||||||Samples Without DNA|"~     Arthroscopical obtained wash- out preparations of synovial space Synovial biopsies Blood~     serum samples~   "|||2018-05-31 23:12:40.187602|2018-05-31 23:12:40.187602
NCT01228474|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2015-06-30|2010-10-25|2010-10-26|Estimate|||||||2015-06-30|2015-07-01|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Single Embryo Transfer vs. Double Embryo Transfer in an Oocyte Donation Programme|A Prospective, Randomized, Controlled Trial Comparing SET vs DET in an Oocyte Donation Programme|Terminated||N/A|65|Actual|Institut Universitari Dexeus||2||"Due to the high number of multiples pregnancies in the double embryo transfer group, we have~   decided to stop the enrollment of patients at 07/31/2012"|f||||||||||||||2018-05-31 23:12:40.242288|2018-05-31 23:12:40.242288
NCT01228461|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2017-03-30|2010-10-25|2010-10-26|Estimate|||||||2017-03-30|2017-04-04|Actual|February 2010||2010-02-28|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients||Completed|||10|Actual|Vanderbilt University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Serum samples for IL-1ra and CRP~   "|||2018-05-31 23:12:40.448992|2018-05-31 23:12:40.448992
NCT01228435|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|2013-05-28||2017-10-28|2010-10-25|2010-10-26|Estimate|2013-08-18|2013-10-23|Estimate||||2017-10-28|2017-12-04|Actual|October 2010||2010-10-31|October 2017|2017-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||IPI-504 in NSCLC Patients With ALK Translocations|A Phase II Study of IPI-204, A Novel Hsp90 Inhibitor in NSCLC Patients With ALK Translocations|Terminated||Phase 2|3|Actual|Massachusetts General Hospital|The study was unable to accrue sufficient participants due to competing studies. Therefore, the study results are not sufficiently powered to draw any conclusions.|2||slow accrual|f||||t||||||||||2018-05-31 23:12:40.58471|2018-05-31 23:12:40.58471
NCT01228422|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|interferon||Pharmacokinetics and Pharmacodynamics of Interferon Alpha 2A|Study of Pharmacokinetics and Pharmacodynamics of Alpha Interferon-2A of Blausiegel Trade and Industry the Compared the Product Roferon A, of Laboratory of Roche|Completed|||24|Anticipated|Azidus Brasil|||2||f||||f||||||||||2018-05-31 23:12:40.822377|2018-05-31 23:12:40.822377
NCT01228409|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-06-21|2010-10-25|2010-10-26|Estimate|||||||2011-06-21|2011-06-22|Estimate|October 2010||2010-10-31|June 2011|2011-06-30||||December 2011|Anticipated|2011-12-31||Interventional|||Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?|An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability|Unknown status|Recruiting|Phase 4|20|Anticipated|Frankel, Amylynne, M.D.||1|||f||||t||||||||||2018-05-31 23:12:40.891601|2018-05-31 23:12:40.891601
NCT01228396|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-26|||2011-08-16|2010-10-25|2010-10-26|Estimate|||||||2011-08-16|2011-08-18|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|March 2012|Anticipated|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis|A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis|Unknown status|Active, not recruiting|Phase 2|20|Actual|Daval International Limited|||||f||||t||||||||||2018-05-31 23:12:40.964659|2018-05-31 23:12:40.964659
NCT01228383|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13||2013-03-20|2013-04-03|2010-10-25|2010-10-26|Estimate||||2013-03-20|2013-03-28|Estimate|2013-04-03|2013-04-10|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults|A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects|Completed||Phase 2|240|Actual|Crucell Holland BV||5|||f||||t||||||||||2018-05-31 23:12:41.095955|2018-05-31 23:12:41.095955
NCT01228370|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2012-10-03|2010-10-25|2010-10-26|Estimate|||||||2012-10-03|2012-10-05|Estimate|April 2011||2011-04-30|October 2010|2010-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder|A 12-week, Open-label, Multi-center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder|Completed||Phase 4|95|Actual|JW Pharmaceutical||1|||f||||f||||||||||2018-05-31 23:12:41.22544|2018-05-31 23:12:41.22544
NCT01228357|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-24|||2015-12-30|2010-10-24|2010-10-26|Estimate|||||||2015-12-30|2015-12-31|Estimate|February 2003||2003-02-28|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Predict Antidepressant Responsiveness Using Pharmacogenomics|Predict Antidepressant Responsiveness Using Pharmacogenomics|Recruiting||N/A|1000|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 23:12:41.323944|2018-05-31 23:12:41.323944
NCT01228344|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2017-04-06|2010-10-25|2010-10-26|Estimate|||||||2017-04-06|2017-04-07|Actual|May 1, 2010|Actual|2010-05-01|April 2017|2017-04-30|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Observational|||Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria|Surveillance for the Effectiveness and Safety of Artemether-lumefantrine in Pediatric and Adult Patients With Malaria|Completed|||324|Actual|Novartis|||1||f||||||||||||||2018-05-31 23:12:41.439883|2018-05-31 23:12:41.439883
NCT01228331|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-23|||2017-05-26|2010-10-23|2010-10-26|Estimate|||||||2017-05-26|2017-05-30|Actual|October 2010||2010-10-31|May 2017|2017-05-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL|A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology|Recruiting||Phase 2/Phase 3|660|Anticipated|Universitätsklinikum Hamburg-Eppendorf||4|||f||||t||||||||No||2018-05-31 23:12:41.5252|2018-05-31 23:12:41.5252
NCT01228318|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-23|||2017-04-25|2010-10-25|2010-10-26|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2011||2011-01-31|April 2017|2017-04-30|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|BLIR-HIV||Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)|Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)|Completed||Phase 2|63|Actual|Emory University||2|||f||||t||||||||Undecided||2018-05-31 23:12:41.668186|2018-05-31 23:12:41.668186
NCT01228305|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2017-04-19|2010-10-25|2010-10-26|Estimate|||||||2017-04-19|2017-04-21|Actual|July 2011||2011-07-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass|Does Preoperative Acetaminophen Reduce Biochemical Markers of Oxidative Stress From Cardiopulmonary Bypass?|Completed||N/A|30|Actual|Vanderbilt University Medical Center||2|||f||||t|f|f||||||||2018-05-31 23:12:41.764253|2018-05-31 23:12:41.764253
NCT01228292|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.|Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.|Unknown status|Not yet recruiting|Phase 4|250|Anticipated|University Hospital, Antwerp||2|||f||||t||||||||||2018-05-31 23:12:41.850607|2018-05-31 23:12:41.850607
NCT01228279|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2018-04-03|2010-10-22|2010-10-26|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2007||2007-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SAPD||Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis|"Effects of Non-Glucose-Based Peritoneal Dialysis Solution EXTRANEAL on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate DIANEAL in Patients on Peritoneal Dialysis"|Recruiting||Phase 4|50|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 23:12:41.935914|2018-05-31 23:12:41.935914
NCT01228266|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2014-02-12|2010-10-25|2010-10-26|Estimate|||||||2014-02-12|2014-02-13|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|CMM-EM||Mesenchymal Stem Cell Transplantation in MS|Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study|Terminated||Phase 2|9|Actual|Hospital Clinic of Barcelona||1||Ended the recruitment in June 2012 for low enrollement accrual|f||||f||||||||||2018-05-31 23:12:42.015562|2018-05-31 23:12:42.015562
NCT01228253|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2015-09-29|2010-10-25|2010-10-26|Estimate|||||||2015-09-29|2015-09-30|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Treatment of PTSD on Reduced Recall for Fear Extinction|Effects of Treatment of Post-traumatic Stress Disorder on Reduced Recall for Fear Extinction|Completed||N/A|25|Actual|Centre Hospitalier Universitaire de Nice||6|||f||||f||||||||||2018-05-31 23:12:42.070674|2018-05-31 23:12:42.070674
NCT01228240|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co. in Glycemic Control of Diabetic Patients||Completed||N/A|||Zanjan University of Medical Sciences||1|||f||||||||||||||2018-05-31 23:12:42.134164|2018-05-31 23:12:42.134164
NCT01228227|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-01-03|2010-10-25|2010-10-26|Estimate|||||||2013-01-03|2013-01-04|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|ROMAIIReload||ROsuvastatin Pretreatment to Reduce MyocArdial Periprocedural Necrosis:Comparison With Atorvastatin Reloading|High Loading ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis : Comparison With Atorvastatin High Dose Reloading.|Completed||Phase 3|310|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 23:12:42.176944|2018-05-31 23:12:42.176944
NCT01228214|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2013-03-18|2010-10-25|2010-10-26|Estimate|||||||2013-03-18|2013-03-19|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|September 2013|Anticipated|2013-09-30|April 2013|Anticipated|2013-04-30||Interventional|||Novel Treatment for Coronary Artery Disease|Randomized Double-Blind Placebo-Controlled Study of Pyrazinoylguanidine Hydrochloride (Amiloride) in Subjects With Coronary Artery Disease|Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Actual|University of Carabobo||2|||f||||f||||||||||2018-05-31 23:12:42.233622|2018-05-31 23:12:42.233622
NCT01228201|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2013-04-10|2010-10-25|2010-10-26|Estimate|||||||2013-04-10|2013-04-11|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Physical Exercise and Coronary Artery Plaque Composition|Physical Exercise and Coronary Artery Plaque Composition|Completed||N/A|40|Anticipated|Trondheim University Hospital||2|||f||||f||||||||||2018-05-31 23:12:42.302855|2018-05-31 23:12:42.302855
NCT01228188|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|August 2013|Anticipated|2013-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Inverted ILM Repositioning as Treatment for Full Thickness Macular Holes|Surgical Inverted ILM Repositioning as Autologous Dressing for Idiopathic Full Thickness Macular Holes Treatment|Unknown status|Recruiting|N/A|25|Anticipated|Military Institute of Medicine, Poland||1|||f||||t||||||||||2018-05-31 23:12:42.359635|2018-05-31 23:12:42.359635
NCT01228175|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2016-09-16||2018-04-09|2010-10-25|2010-10-26|Estimate|2016-09-16|2016-11-04|Estimate||||2018-04-09|2018-05-09|Actual|March 2010||2010-03-31|April 2018|2018-04-30|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|Varenicline||Effectiveness of Varenicline: Testing Individual Differences|Effectiveness of Varenicline: Testing Individual Differences|Completed||Phase 4|218|Actual|The Mind Research Network||2|||f||||t||||||||Undecided||2018-05-31 23:12:42.559734|2018-05-31 23:12:42.559734
NCT01228162|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2013-06-22|2010-10-25|2010-10-26|Estimate|||||||2013-06-22|2013-06-25|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Influence of Muscle Relaxation With Rocuronium Bromide During General Anaesthesia on Muscle Trauma and Postoperative Analgetic Consumption in Patients With Total Hip Prosthesis Implantation||Completed||Phase 4|120|Anticipated|Klinikum Hildesheim GmbH||2|||f||||t||||||||||2018-05-31 23:12:42.746054|2018-05-31 23:12:42.746054
NCT01228149|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2015-04-27||2017-06-27|2010-10-25|2010-10-26|Estimate|2017-03-03|2017-04-14|Actual||||2017-06-27|2017-08-01|Actual|August 2010||2010-08-31|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy|Investigation of the Efficacy and Safety of Preoperative Intraocular Pressure (IOP) Reduction With Preservative-free COSOPT-S® (Dorzolamide/Timolol, MSD) Eye Drops Versus Oral Acetazolamide and Dexamethasone Eye Drops|Completed||Phase 4|62|Actual|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 23:12:42.83481|2018-05-31 23:12:42.83481
NCT01228136|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-12-21|2010-10-25|2010-10-26|Estimate|||||||2010-12-21|2010-12-22|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Tranexamic Acid and Pediatric Adenotonsillectomy|Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children|Completed||Phase 4|95|Actual|Irmandade Santa Casa de Misericórdia de Porto Alegre||2|||f||||f||||||||||2018-05-31 23:12:43.274805|2018-05-31 23:12:43.274805
NCT01228123|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2011-05-23|2010-10-25|2010-10-26|Estimate|||||||2011-05-23|2011-05-25|Estimate|January 2002||2002-01-31|July 2010|2010-07-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|CONVINT||Clinical Trial Comparing Continuous Versus Intermittent Hemodialysis in ICU Patients|Prospective Randomised Clinical Trial of the Effect of Continuous Versus Intermittent Renal Replacement Therapy on the Mortality and Outcome of Acute Renal Failure in ICU Patients|Completed||Phase 2/Phase 3|252|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:12:43.339711|2018-05-31 23:12:43.339711
NCT01228110|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-25|||2010-10-25|2010-10-25|2010-10-26|Estimate|||||||2010-10-25|2010-10-26|Estimate||||July 2009|2009-07-31||||||||Interventional|||Corticosteroids in Community Acquired Pneumonea|Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings|Completed||N/A|80|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 23:12:43.405927|2018-05-31 23:12:43.405927
NCT01228097|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-03-09|2010-10-22|2010-10-25|Estimate|||||||2015-03-09|2015-03-10|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|NEWS||Neural Response to Eating and Weight Status|Changes in Neural Response to Eating After Bariatric Surgery: MRI Results|Completed|||75|Actual|University of Pennsylvania|||3||f||||t||||||Samples With DNA|"~     Whole blood will be drawn for safety labs. Blood plasma will be archived for analysis.~   "|||2018-05-31 23:12:43.454536|2018-05-31 23:12:43.454536
NCT01228084|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2013-11-05||2017-04-26|2010-10-22|2010-10-25|Estimate|2014-01-14|2014-03-03|Estimate||||2017-04-26|2017-04-28|Actual|November 2010||2010-11-30|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||Sulforaphane in Treating Patients With Recurrent Prostate Cancer|The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer|Completed||Phase 2|20|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 23:12:43.504953|2018-05-31 23:12:43.504953
NCT01228071|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2013-03-27||2017-09-07|2010-10-22|2010-10-25|Estimate|2013-06-18|2013-07-22|Estimate||||2017-09-07|2017-10-05|Actual|November 2010|Actual|2010-11-30|September 2017|2017-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||The pharmacokinetic (PK) population consisted of all subjects who had a drug drying time, required trough concentrations values, and no protocol violations significantly affecting the PK data. All subjects who received at least 1 dose of study drug were included in the safety population.|Time to Eugonadal Range, Time to Steady State and Drying Time|Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application|Completed||Phase 3|34|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:12:43.677549|2018-05-31 23:12:43.677549
NCT01228058|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2012-12-17|2010-10-22|2010-10-25|Estimate|||||||2012-12-17|2012-12-18|Estimate|November 2010||2010-11-30|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|RapidTEG||A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients|A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients|Completed|||1450|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 23:12:44.789835|2018-05-31 23:12:44.789835
NCT01228045|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2016-06-21|2010-10-22|2010-10-25|Estimate|||||||2016-06-21|2016-06-22|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer|A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer.|Active, not recruiting||Phase 2|30|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 23:12:44.875664|2018-05-31 23:12:44.875664
NCT01228032|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2016-02-25|2010-10-22|2010-10-25|Estimate|||||||2016-02-25|2016-02-26|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|HOME||The Health Outcomes Management and Evaluation (HOME) Study|Improving Primary Care of Patients With Mental Disorders|Completed||Phase 3|447|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:12:44.951225|2018-05-31 23:12:44.951225
NCT01228019|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2014-03-25||2015-04-01|2010-10-22|2010-10-25|Estimate|2014-03-25|2014-04-25|Estimate||||2015-04-01|2015-04-21|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational||Baseline characteristics presented for participants in the Safety Population|Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of TREDAPTIVE Tablet in Usual Practice|Terminated|||1166|Actual|Merck Sharp & Dohme Corp.|Study enrollment stopped early due to termination of all TREDAPTIVE studies. Data obtained for participants enrolled prior to termination was analyzed and reported.||1|"In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a~   significant increase in incidence of some types of non-fatal SAEs"|f||||f||||||||||2018-05-31 23:12:45.033735|2018-05-31 23:12:45.033735
NCT01228006|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|September 2011||2011-09-30|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Study for Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals (Natugerin®) in Improvement of Stress and Fatigue||Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-05-31 23:12:45.354667|2018-05-31 23:12:45.354667
NCT01227993|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2013-07-02||2013-10-28|2010-10-22|2010-10-25|Estimate|2013-07-16|2013-09-23|Estimate||||2013-10-28|2013-11-20|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|CSC-Ext||Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Completed||Phase 1/Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 23:12:45.502981|2018-05-31 23:12:45.502981
NCT01227980|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2015-11-04||2015-12-30|2010-10-22|2010-10-25|Estimate|2015-11-04|2015-12-10|Estimate||||2015-12-30|2016-02-02|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^|Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics|Completed||Phase 2|70|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-05-31 23:12:45.774182|2018-05-31 23:12:45.774182
NCT01227967|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2017-05-31||2017-07-10|2010-10-22|2010-10-25|Estimate|2017-07-10|2017-07-11|Actual||||2017-07-10|2017-07-11|Actual|September 2010||2010-09-30|July 2017|2017-07-31|March 30, 2017|Actual|2017-03-30|May 2, 2016|Actual|2016-05-02||Interventional|IRC003|Intent To Treat (ITT) Population: all participants who were randomized properly and who had received at least one dose of study drug.|Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications|A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications|Completed||Phase 2|881|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 23:12:46.371444|2018-05-31 23:12:46.371444
NCT01227954|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2017-08-23||2017-09-25|2010-10-22|2010-10-25|Estimate|2017-09-25|2017-09-27|Actual||||2017-09-25|2017-09-27|Actual|March 2011||2011-03-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|May 2013|Actual|2013-05-31||Interventional||Eligible patients|Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases|Completed||Phase 2|113|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-05-31 23:12:48.845071|2018-05-31 23:12:48.845071
NCT01227941|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2016-10-18|2010-10-22|2010-10-25|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)|A Phase Ib Dose Escalation Study of MK-4827 in Combination With Pegylated Liposomal Doxorubicin (Doxil™ or Caelyx™) in Patients With Advanced Solid Tumors With a Cohort Expansion in Patients With Platinum Resistant/Refractory High Grade Serous Ovarian Cancer|Terminated||Phase 1|6|Actual|Tesaro, Inc.||2|||f||||f||||||||||2018-05-31 23:12:49.195997|2018-05-31 23:12:49.195997
NCT01227109|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|February 2011||2011-02-28|October 2010|2010-10-31|October 2012|Anticipated|2012-10-31|February 2012|Anticipated|2012-02-29||Observational|||Procalcitonin as a Marker of Infection in Cancer Patients|Procalcitonin as a Marker of Infection in Cancer Patients|Unknown status|Not yet recruiting||80|Anticipated|Herlev Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood will be drawn for CRP and procalcitonin analysis~   "|||2018-05-31 23:13:19.508248|2018-05-31 23:13:19.508248
NCT01227928|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2013-04-18||2015-02-12|2010-10-21|2010-10-25|Estimate|2013-04-18|2013-06-04|Estimate||||2015-02-12|2015-03-03|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|January 2014|Actual|2014-01-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women|A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655|Completed||Phase 2|145|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 23:12:49.470438|2018-05-31 23:12:49.470438
NCT01227915|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|February 2011||2011-02-28|October 2010|2010-10-31||||February 2011|Anticipated|2011-02-28||Interventional|||Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis|RANDOMIZED CLINICAL EVALUATION OF EFFECTIVENESS COMPARISON BETWEEN DRUGS OPHTHALMOLOGICAL TOBRACORT® (TOBRAMYCIN + DEXAMETHASONE - LAB. UNIÃO QUÍMICA)AND TOBRADEX® (TOBRAMYCIN + DEXAMETHASONE - LAB. ALCON) IN REDUCING THE SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS|Unknown status|Not yet recruiting|Phase 3|70|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 23:12:50.341376|2018-05-31 23:12:50.341376
NCT01227902|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2013-07-25||2014-10-09|2010-10-21|2010-10-25|Estimate|2013-10-17|2013-11-11|Estimate||||2014-10-09|2014-10-17|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|IR||Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures|An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial -Onset Seizures|Completed||Phase 3|203|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:12:50.475769|2018-05-31 23:12:50.475769
NCT01227889|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2013-06-06|2013-01-04|2017-09-06|2010-10-21|2010-10-25|Estimate|2014-04-17|2014-05-16|Estimate|2013-01-04|2013-01-10|Estimate|2017-09-06|2017-10-04|Actual|December 23, 2010|Actual|2010-12-23|August 2017|2017-08-31|September 16, 2016|Actual|2016-09-16|December 19, 2011|Actual|2011-12-19||Interventional|||A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma|A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma|Completed||Phase 3|251|Actual|GlaxoSmithKline||3|||f||||t|t|f||||||||2018-05-31 23:12:52.496757|2018-05-31 23:12:52.496757
NCT01227876|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|January 2011||2011-01-31|October 2010|2010-10-31||||February 2011|Anticipated|2011-02-28||Interventional|||Clinical Efficacy of the Drug Ster® Compared With Predfort® in Control of Postoperative Inflammation in Cataract Surgery|Assessment of Clinical Efficacy of 1% Prednisolone Acetate (Ster ®), Produced by união química, Compared to 1% Prednisolone Acetate (Pred ® Fort), Produced by Allergan, in the Control of Postoperative Inflammation in Cataract Surgery.|Unknown status|Not yet recruiting|Phase 3|106|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 23:12:54.039673|2018-05-31 23:12:54.039673
NCT01227863|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|February 2011||2011-02-28|October 2010|2010-10-31||||February 2011|Anticipated|2011-02-28||Interventional|||Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis|Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis|Unknown status|Not yet recruiting|Phase 3|70|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 23:12:54.139579|2018-05-31 23:12:54.139579
NCT01227850|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate||||October 2010|2010-10-31||||||||Observational|||Leptin, IGF1 and the Refeeding Index|Leptin and IGF1; Diagnostic Markers of Refeeding Syndrome and Mortality|Completed|||35|Actual|King's College Hospital NHS Trust|||1||f||||f||||||||||2018-05-31 23:12:54.235601|2018-05-31 23:12:54.235601
NCT01227837|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|March 2010||2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Effect of omega3 on Congestive Heart Failure|Effect of Omega 3 Supplementation on Brain Natriuretic Peptide (BNP) Serum Levels Functional Capacity and Systolic and Diastolic Function of Heart Failure Patients|Completed||N/A|70|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:12:54.315087|2018-05-31 23:12:54.315087
NCT01227824|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2013-08-15|2013-03-21|2018-03-08|2010-10-21|2010-10-25|Estimate|2014-06-19|2014-06-23|Estimate|2013-03-21|2013-04-01|Estimate|2018-03-08|2018-03-12|Actual|October 19, 2010||2010-10-19|March 2018|2018-03-31|December 27, 2016|Actual|2016-12-27|February 6, 2012|Actual|2012-02-06||Interventional|SPRING-2||A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily|A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|Completed||Phase 3|828|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 23:12:54.639831|2018-05-31 23:12:54.639831
NCT01227811|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.|Single Dose, Two-period, Crossover, Fed Bioequivalence Study of Darifenacin Extended Release Oral Formulation (Darisec(R) 15 mg) vs. Enablex(R) 15 mg in Healthy Volunteers.|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Center for Clinical Pharmacology Research Bdbeq S.A.||2|||f||||f||||||||||2018-05-31 23:12:58.174184|2018-05-31 23:12:58.174184
NCT01227798|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|November 2010||2010-11-30|August 2010|2010-08-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza|A Pilot Study to Evaluate the Safety and Efficacy of IFN-alfacon1 (INFERGEN) in the Treatment of Hospitalized Patients Presenting With Influenza-like Illnesses Due to the Pandemic 2009 Swine Origin Influenza A Virus (S-OIV) H1N1 and Other Circulating Influenza Viruses|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:12:58.318841|2018-05-31 23:12:58.318841
NCT01227096|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2011-06-22|2010-10-22|2010-10-25|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|May 2011|Actual|2011-05-31||Observational|||Randomized Controlled Trial of the Effects of Electroacupuncture Preconditioning in Children Undergoing Cardiac Surgery|National Natural Science Foundation of China|Unknown status|Active, not recruiting||60|Anticipated|Fourth Military Medical University|||2||f||||t||||||Samples Without DNA|"~     blood serum~   "|||2018-05-31 23:13:19.58047|2018-05-31 23:13:19.58047
NCT01227785|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2013-12-11||2014-04-09|2010-10-22|2010-10-25|Estimate|2014-03-03|2014-04-08|Estimate||||2014-04-09|2014-04-25|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|NOTICE-HF||Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study|Next Generation INCEPTA ICD and CRT-D Field Following Study: Respiratory Rate Trend Evaluation in Heart Failure (HF) Patients|Completed|||120|Actual|Guidant Corporation|||1||f||||f||||||||||2018-05-31 23:12:58.435051|2018-05-31 23:12:58.435051
NCT01227772|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2016-06-21|2010-10-21|2010-10-25|Estimate|||||||2016-06-21|2016-06-22|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|||Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer|A Phase I/IIa Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer|Active, not recruiting||Phase 1/Phase 2|23|Anticipated|National University Hospital, Singapore||3|||f||||f||||||||||2018-05-31 23:12:59.00075|2018-05-31 23:12:59.00075
NCT01227759|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-10-25|2010-10-22|2010-10-25|Estimate|||||||2010-10-25|2010-10-26|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Tyrosur® Gel-Investigation on Wound Healing Efficacy|A Phase IIa, Single-center, Randomized, Observer-blind Trial With Intraindividual Comparison of Treated Versus Untreated to Assess the Wound Healing Efficacy of Topical Tyrosur® Gel|Completed||Phase 2|33|Actual|Engelhard Arzneimittel GmbH & Co.KG||3|||f||||t||||||||||2018-05-31 23:12:59.079469|2018-05-31 23:12:59.079469
NCT01227746|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2014-01-21|2010-10-22|2010-10-25|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.||Unknown status|Recruiting||||National University Hospital, Singapore|||1||f||||f||||||||||2018-05-31 23:12:59.142381|2018-05-31 23:12:59.142381
NCT01227733|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2014-01-21|2010-10-21|2010-10-25|Estimate|||||||2014-01-21|2014-01-22|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Comparative Genomic and Genetic Analysis of Paired Primary Breast - Metastatic Tumor Specimens Using High-throughput Platforms||Unknown status|Active, not recruiting||||National University Hospital, Singapore|||1||f||||f||||||||||2018-05-31 23:12:59.219032|2018-05-31 23:12:59.219032
NCT01227720|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2012-07-06|2010-10-22|2010-10-25|Estimate|||||||2012-07-06|2012-07-10|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products.|Comparative Pharmacokinetic Study of New Oral Nicotine Replacement Therapy Products - A Study in Healthy Smokers.|Completed||N/A|104|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||6|||f||||f||||||||||2018-05-31 23:12:59.275949|2018-05-31 23:12:59.275949
NCT01227707|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2014-05-28||2015-07-21|2010-10-22|2010-10-25|Estimate|2014-07-24|2014-08-15|Estimate||||2015-07-21|2015-08-17|Estimate|November 2005||2005-11-30|July 2015|2015-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||Intent to treat (ITT) population: all participants who were included in the trial by signing the informed consent and were assigned to a study patient number.|A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.|An Open-label Study to Assess the Effect of Combination Treatment With Avastin and Xeloda, Plus Pre-operative Standard Radiotherapy, on Response Rate in Patients With Locally Advanced Rectal Cancer.|Completed||Phase 2|43|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:12:59.496723|2018-05-31 23:12:59.496723
NCT01227694|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-12-10|2010-10-22|2010-10-25|Estimate|||||||2015-12-10|2015-12-11|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis|Articular Cartilage Regeneration in Gonarthrosis Grade II and III by Articular Infiltration of Xcel-m-condro-alpha.|Completed||Phase 1/Phase 2|15|Actual|Banc de Sang i Teixits||1|||f||||f||||||||||2018-05-31 23:12:59.874227|2018-05-31 23:12:59.874227
NCT01227681|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2014-07-17||2016-03-03|2010-10-22|2010-10-25|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease|A Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease|Terminated||Phase 2|4|Actual|Buddhist Tzu Chi General Hospital||3||Difficulty in Recruitment|f||||t||||||||||2018-05-31 23:12:59.9434|2018-05-31 23:12:59.9434
NCT01227668|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2013-11-07||2014-03-31|2010-10-22|2010-10-25|Estimate|2014-03-31|2014-05-02|Estimate||||2014-03-31|2014-05-02|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||All participants who were randomized to receive treatment in Phase 2|Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder|Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder|Completed||Phase 4|215|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 23:13:00.229823|2018-05-31 23:13:00.229823
NCT01227655|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2014-11-26||2015-09-21|2010-10-22|2010-10-25|Estimate|2015-01-12|2015-01-13|Estimate||||2015-09-21|2015-10-19|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|BIPARKII|Four subjects from safety set who had no post-baseline OFF-time efficacy assessment were excluded from the full analysis set: three (1.9%) subjects in the OPC 50 mg group and one (0.7%) subject in the placebo group.|Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.|"Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With Wearing-off Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Study."|Completed||Phase 3|427|Actual|Bial - Portela C S.A.||3|||f||||t||||||||||2018-05-31 23:13:00.770929|2018-05-31 23:13:00.770929
NCT01227642|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2016-03-11|2010-10-22|2010-10-25|Estimate|||||||2016-03-11|2016-03-14|Estimate|February 2007||2007-02-28|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|USA||Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy|Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy|Completed||Phase 1/Phase 2|14|Actual|Beth Israel Medical Center||1|||f||||t||||||||||2018-05-31 23:13:01.198566|2018-05-31 23:13:01.198566
NCT01227629|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2010-11-18||2014-04-22|2010-10-22|2010-10-25|Estimate|2011-01-14|2011-02-10|Estimate||||2014-04-22|2014-05-05|Estimate|September 2003||2003-09-30|April 2014|2014-04-30||||November 2004|Actual|2004-11-30||Interventional|||PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin|Dose Exploration in Patients With Atrial Fibrillation|Completed||Phase 2|502|Actual|Boehringer Ingelheim||10|||f||||||||||||||2018-05-31 23:13:01.40778|2018-05-31 23:13:01.40778
NCT01227616|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2017-11-14|2010-10-22|2010-10-25|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2013|Actual|2013-08-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|February 2016|Actual|2016-02-29||Interventional|FACT||A Phase IV Trial of Repeated Doses of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients With Chronic Kidney Disease on Hemodialysis|Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis|Completed||Phase 4|296|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:13:05.535695|2018-05-31 23:13:05.535695
NCT01227603|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-12-08|2010-10-22|2010-10-25|Estimate|||||||2015-12-08|2015-12-10|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions|Single Dose Study to Compare the Pharmacokinetics as Well as Safety and Tolerability of a Novel Fixed Dose Combination of Nifedipine GITS and Candesartan, the Loose Combination of Both and the Single Components Alone and to Investigate the Bioequivalence Between the Fixed Dose and the Loose Combination in Healthy Male Volunteers Under Fasting Conditions in an Open Label, Randomized, 4-way-crossover Design|Completed||Phase 1|49|Actual|Bayer||4|||f||||f||||||||||2018-05-31 23:13:05.627097|2018-05-31 23:13:05.627097
NCT01227590|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-05-06|2010-10-22|2010-10-25|Estimate|||||||2015-05-06|2015-05-07|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Interventional|AP6142||Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)|Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)|Completed||Phase 1|18|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:13:05.726825|2018-05-31 23:13:05.726825
NCT01227577|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2015-11-19||2016-01-11|2010-10-21|2010-10-25|Estimate|2016-01-11|2016-02-08|Estimate||||2016-01-11|2016-02-08|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|MACS1428||CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib|A Single-arm, Open-label, Multi-center Study of Complete Molecular Response (CMR) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Completed||Phase 4|128|Actual|Novartis||1|||f||||f||||||||||2018-05-31 23:13:05.833644|2018-05-31 23:13:05.833644
NCT01227564|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2015-02-09||2016-01-28|2010-10-22|2010-10-25|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease|A Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease.|Completed||Phase 2|63|Actual|Pfizer|In 2013 Pfizer and Janssen Alzheimer Immunotherapy Alliance made the decision that ACC-001 would not be further developed in mild to moderate AD.|3|||f||||t||||||||||2018-05-31 23:13:06.589334|2018-05-31 23:13:06.589334
NCT01227551|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2017-02-07||2018-01-10|2010-10-22|2010-10-25|Estimate|2017-05-11|2017-05-15|Actual||||2018-01-10|2018-02-07|Actual|October 2011||2011-10-31|July 2017|2017-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|CALM||A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )|A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )|Completed||Phase 2|57|Actual|Viralytics||1|||f||||t||||||||No||2018-05-31 23:13:11.331186|2018-05-31 23:13:11.331186
NCT01227538|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2016-01-06|2010-10-22|2010-10-25|Estimate|||||||2016-01-06|2016-01-07|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Towards Simple and Non-invasive Assessment of Residual Beta-cell Function in Type 1 Diabetes|Towards Simple and Non-invasive Assessment of Residual Beta-cell Function in Type 1 Diabetes|Completed|||17|Actual|University Hospitals Bristol NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 23:13:11.675566|2018-05-31 23:13:11.675566
NCT01227525|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-08-17|2010-10-21|2010-10-25|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2008||2008-08-31|August 2017|2017-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Vibraject||Assessing the Benefits of the Vibraject Attachment|Assessing Pain Behaviors of Children Receiving Local Anesthesia Using VibraJect Attachment|Completed||N/A|90|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 23:13:11.762501|2018-05-31 23:13:11.762501
NCT01227512|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2014-05-29||2014-10-21|2010-10-22|2010-10-25|Estimate|2014-10-10|2014-10-17|Estimate||||2014-10-21|2014-10-30|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SALACIA||Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia|Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia|Terminated||Phase 3|124|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2||"Recruitment challenges and results of interim futility analysis, which showed less than likely~   to achieve primary endpoint goal-length of hospital stay."|f||||f||||||||||2018-05-31 23:13:11.912175|2018-05-31 23:13:11.912175
NCT01227499|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2014-05-02|2010-10-22|2010-10-25|Estimate|||||||2014-05-02|2014-05-05|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Differential Diagnosis of STA-PSV in Thyrotoxicosis|Differential Diagnosis Value of Peak Systolic Velocity of Thyroid Superior Artery Using Color Flow Doppler Sonography in Transient Thyrotoxicosis Caused by Thyroiditis and Graves Disease|Completed|||169|Actual|Huashan Hospital|||||f||||t||||||||||2018-05-31 23:13:13.171178|2018-05-31 23:13:13.171178
NCT01227486|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2010-11-23|2010-10-22|2010-10-25|Estimate|||||||2010-11-23|2010-11-24|Estimate|October 2010||2010-10-31|November 2010|2010-11-30||||||||Observational|||Verification of Endotracheal Tube Placement by Ultrasound in the Obese Patient||Completed|||24|Anticipated|Bispebjerg Hospital|||1||f||||f||||||||||2018-05-31 23:13:13.316267|2018-05-31 23:13:13.316267
NCT01227473|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2012-06-13|2010-10-21|2010-10-25|Estimate|||||||2012-06-13|2012-06-15|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||We Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans|A Mindfulness-based Intervention to Reduce Diabetes Risk in Pre-diabetic African Americans|Completed||Phase 1/Phase 2|74|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 23:13:13.459423|2018-05-31 23:13:13.459423
NCT01227460|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2014-05-19|2010-10-22|2010-10-25|Estimate|||||||2014-05-19|2014-05-21|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Sitagliptin (Januvia®) on Blood Glucose Control in Patients With Type 1 Diabetes|Effects of Sitagliptin (Januvia®) on Blood Glucose Control in Patients With Type 1 Diabetes and CGM Substudy of the Investigator Initiated Study Protocol Effects of Sitagliptin (Januvia) on Glucagon Suppression and GLP-1 Levels in Patients With Type 1 Diabetes; CGM Substudy|Completed||N/A|140|Actual|University of Colorado Denver School of Medicine Barbara Davis Center||2|||f||||t||||||||||2018-05-31 23:13:13.589988|2018-05-31 23:13:13.589988
NCT01227447|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2012-03-02|2010-10-22|2010-10-25|Estimate|||||||2012-03-02|2012-03-05|Estimate|January 2010||2010-01-31|March 2012|2012-03-31||||||||Observational|||Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Human Urinary Outflow Tract|Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Continent and Incontinent Human Urinary Outflow Tract|Unknown status|Recruiting||200|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||f|||||||"~     Human tissue from the urinary outflow tract (bladder base and urethra) of patients undergoing~     cystectomy or radical prostatectomy (for cancer treatment) with pre-operatively documented~     voiding disorders/incontinence - in particular SUI~   "|||2018-05-31 23:13:13.720917|2018-05-31 23:13:13.720917
NCT01227434|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2015-05-18||2015-06-15|2010-10-22|2010-10-25|Estimate|2015-06-09|2015-06-12|Estimate||||2015-06-15|2015-07-17|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PD0332991||A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma|A Phase II Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma|Terminated||Phase 2|23|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:13:14.038272|2018-05-31 23:13:14.038272
NCT01227421|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2012-05-30||2014-01-08|2010-10-22|2010-10-25|Estimate|2013-11-18|2014-01-08|Estimate||||2014-01-08|2014-02-07|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza|A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza|Completed||Phase 2/Phase 3|624|Actual|Romark Laboratories L.C.||3|||f||||f||||||||||2018-05-31 23:13:14.851169|2018-05-31 23:13:14.851169
NCT01227408|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2017-04-29|2010-10-22|2010-10-25|Estimate|||||||2017-04-29|2017-05-02|Actual|February 2009|Anticipated|2009-02-28|April 2017|2017-04-30|February 2011|Anticipated|2011-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer|Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer|Withdrawn||Phase 2|0|Actual|University of Southern California||1||Sponsor withdrew due to funding issues|f||||t|t|f||||||||2018-05-31 23:13:15.617101|2018-05-31 23:13:15.617101
NCT01227395|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2013-03-04||2013-04-18|2010-10-21|2010-10-25|Estimate|2013-03-04|2013-04-16|Estimate||||2013-04-18|2013-04-26|Estimate|July 2002||2002-07-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients|Drug Use Investigation On Zithromac Tablets 600mg In HIV Patients (Post Marketing Commitment Plan)|Completed|||476|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:13:15.756878|2018-05-31 23:13:15.756878
NCT01227382|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2015-06-29||2015-07-29|2010-10-21|2010-10-25|Estimate|2015-07-29|2015-08-03|Estimate||||2015-07-29|2015-08-03|Estimate|November 2006||2006-11-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods|"Prospective Evaluation of the Accuracy of Spybite Biopsy Forceps for the Tissue Diagnosis of Lesion of the Pancreatobiliary System. ( Part of the The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Treatment of Pancreaticobiliary Disorders Study)"|Completed||N/A|26|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 23:13:16.258525|2018-05-31 23:13:16.258525
NCT01227369|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-06-06|2010-10-21|2010-10-25|Estimate|||||||2017-06-06|2017-06-07|Actual|June 2008||2008-06-30|June 2017|2017-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|BRAVO||Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment|Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment|Completed|||4376|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:13:16.440194|2018-05-31 23:13:16.440194
NCT01227356|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|September 2004||2004-09-30|October 2010|2010-10-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia|A Randomized Study Comparing Imatinib And Imatinib/Pegylated Interferon Alpha-2B in Newly Diagnosed Non-high Risk Chronic Myeloid Leukemia Patients in Complete Hematological Remission After Imatinib Induction Therapy|Completed||Phase 2|112|Actual|Uppsala University||1|||f||||f||||||||||2018-05-31 23:13:16.525865|2018-05-31 23:13:16.525865
NCT01227343|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2018-01-31|2010-10-22|2010-10-25|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2010|Actual|2010-03-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Observational|||Nicotine and Brain Imaging Research Study|Sex, GABA and Nicotine: A 1H-MRS Study|Completed|||54|Anticipated|University of Pennsylvania|||4||f||||f||||||Samples Without DNA|"~     Whole blood, plasma, urine~   "|||2018-05-31 23:13:16.64839|2018-05-31 23:13:16.64839
NCT01227330|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2016-10-21|2010-10-22|2010-10-25|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults|Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults|Completed||Phase 1/Phase 2|43|Actual|University of Missouri-Columbia||3|||f||||f||||||||No||2018-05-31 23:13:16.76949|2018-05-31 23:13:16.76949
NCT01227317|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-12-06|2010-10-22|2010-10-25|Estimate|||||||2011-12-06|2011-12-07|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|BIODINER||BIOmarkers of Dyspnea IN Emergency Room|Prognostic Value of Novel Biomarkers in Patients With Shortness of Breath Attending an Emergency Department|Completed|||444|Actual|ThermoFisher Scientific Brahms Biomarkers France|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 23:13:16.910165|2018-05-31 23:13:16.910165
NCT01227304|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|July 2010||2010-07-31|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|SMOOCH||SMOOCH - Small Volume Challenges to Predict Volume Responsiveness: Prospective Interventional Study||Unknown status|Recruiting|N/A|100|Anticipated|Technische Universität München||1|||f||||||||||||||2018-05-31 23:13:17.00425|2018-05-31 23:13:17.00425
NCT01227278|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2016-08-11||2016-08-11|2010-10-22|2010-10-25|Estimate|2016-08-11|2016-10-05|Estimate||||2016-08-11|2016-10-05|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional||Intent-to-treat (ITT) population included all participants randomized into the study.|A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia|Completed||Phase 2|421|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 23:13:17.239281|2018-05-31 23:13:17.239281
NCT01227265|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|2016-03-14||2016-03-14|2010-10-22|2010-10-25|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||All Participants as Treated - all participants who received at least one dose of study drug|Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)|A Phase 3, 12 Week, Double-blind, Placebo-controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease.|Completed||Phase 3|476|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 23:13:17.913737|2018-05-31 23:13:17.913737
NCT01227252|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-05-09|2010-10-21|2010-10-25|Estimate|||||||2011-05-09|2011-05-10|Estimate|December 2010||2010-12-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Safety Study of LY2886721 Multiple Doses in Healthy Subjects|Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects|Completed||Phase 1|42|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:13:18.490768|2018-05-31 23:13:18.490768
NCT01227239|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-11-26|2010-10-21|2010-10-25|Estimate|||||||2012-11-26|2012-11-27|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|August 2016|Anticipated|2016-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting|A Phase I/II Study of S-1 and Oxaliplatin Combined With Radiation for Preoperative Locally Advanced Rectal Carcinoma. (SHOGUN Trial)|Unknown status|Active, not recruiting|Phase 1/Phase 2|45|Anticipated|Japan Clinical Cancer Research Organization||1|||f||||t||||||||||2018-05-31 23:13:18.564737|2018-05-31 23:13:18.564737
NCT01227226|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-02-04|2010-10-22|2010-10-25|Estimate|||||||2011-02-04|2011-02-07|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Tear Osmolarity Over Time With Artificial Tears||Unknown status|Enrolling by invitation|Phase 4|48|Anticipated|Hom, Milton M., OD, FAAO||4|||f||||t||||||||||2018-05-31 23:13:18.670811|2018-05-31 23:13:18.670811
NCT01227213|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2015-10-29|2010-10-22|2010-10-25|Estimate|||||||2015-10-29|2015-10-30|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma|The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma|Completed|||20|Actual|Radboud University|||||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 23:13:18.801635|2018-05-31 23:13:18.801635
NCT01227200|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|November 2011||2011-11-30|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|pta||The Effect of Adding Pain Relievers to Local Anesthesia Before Preforming Drainage in Peritonsillar Abscess|The Efficiency of DYPIRON and TRAMADOL in Addition to Local Anesthesia Prior to Incision and Drainage Procedure in Peritonsillar Abscess|Unknown status|Not yet recruiting|N/A|32|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-05-31 23:13:18.851409|2018-05-31 23:13:18.851409
NCT01227187|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2012-07-20|2010-10-21|2010-10-25|Estimate|||||||2012-07-20|2012-07-24|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|Xigris1003||Safety and Dose Finding Study of Xigris in Hemodialysis Patients|Safety and Dose Finding Study of Xigris (Drotrecogin Alfa Activated) as an Anti-coagulant in End Stage Renal Disease (ESRD) Patients Treated With Hemodialysis (HD)|Completed||Phase 2|12|Actual|George Washington University||1|||f||||f||||||||||2018-05-31 23:13:18.906881|2018-05-31 23:13:18.906881
NCT01227174|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-16|||2010-10-21|2010-10-21|2010-10-25|Estimate|||||||2010-10-21|2010-10-25|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery|Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery|Unknown status|Not yet recruiting|Phase 4|169|Anticipated|Atlantic Center for Oral and Maxillofacial Surgery||1|||f||||t||||||||||2018-05-31 23:13:18.994514|2018-05-31 23:13:18.994514
NCT01227161|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2011-05-12|2010-10-22|2010-10-25|Estimate|||||||2011-05-12|2011-05-13|Estimate|February 2010||2010-02-28|May 2011|2011-05-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||New Formula for Selection of Proper Size of Endotracheal Tube (ETT) in Children: Ultrasonographic Examination|New Formula for Selection of Proper Size of ETT in Children: Ultrasonographic Examination|Completed|||215|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 23:13:19.086549|2018-05-31 23:13:19.086549
NCT01227148|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-22|2010-10-22|2010-10-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein Catabolism in Critically Ill Patients|Influence of Tightly Glucose Control on Hyperglycemic Toxicity and Protein|Completed||Phase 3|112|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 23:13:19.184859|2018-05-31 23:13:19.184859
NCT01227135|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-11-29|2010-10-22|2010-10-25|Estimate|||||||2011-11-29|2011-11-30|Estimate|March 2010||2010-03-31|November 2011|2011-11-30||||March 2012|Anticipated|2012-03-31||Interventional|||Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia|CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR).|Unknown status|Recruiting|Phase 2|66|Anticipated|University of Glasgow|||||f||||t||||||||||2018-05-31 23:13:19.284185|2018-05-31 23:13:19.284185
NCT01227122|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2013-03-01|2010-10-22|2010-10-25|Estimate|||||||2013-03-01|2013-03-04|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Observational|NGAL-CKF||NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients With Preoperative Chronic Kidney Failure|Plasmatic Level of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Predictive Marker of Acute Kidney Failure in Patients With Preoperative Chronic Kidney Failure Undergoing Cardiac Surgery.|Unknown status|Recruiting||100|Anticipated|Hopital Jean Minjoz|||||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 23:13:19.437869|2018-05-31 23:13:19.437869
NCT01227083|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-22|||2013-11-10|2010-10-22|2010-10-25|Estimate|||||||2013-11-10|2013-11-13|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|2nd_cAQOL||2nd_Computerized Asthma Specific Quality of Life(cAQOL)|Comparison of the Responsiveness of Two Different Asthma-specific QOL Measures (AQLQ and cAQOL) in Korean Patients With Persistent Asthma|Completed|||150|Actual|Ajou University School of Medicine|||2||f||||f||||||Samples With DNA|"~     Sub-group of ADRB2 and NK2R genotypes~   "|||2018-05-31 23:13:19.664491|2018-05-31 23:13:19.664491
NCT01227070|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2010-10-20|2010-10-20|2010-10-22|Estimate|||||||2010-10-20|2010-10-22|Estimate|January 2006||2006-01-31|October 2010|2010-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma|Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma|Completed|||80|Actual|Seattle Children's Hospital|||2||f||||f||||||Samples Without DNA|"~     Exhaled breath condensate~   "|||2018-05-31 23:13:19.727961|2018-05-31 23:13:19.727961
NCT01227057|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2016-03-11||2016-07-20|2010-10-20|2010-10-22|Estimate|2016-04-27|2016-06-03|Estimate||||2016-07-20|2016-09-01|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Hoarding Older Adults|Treatment of Late Life Compulsive Hoarding|Completed||Phase 1|58|Actual|VA Office of Research and Development|The study was under-powered to fully detect the differences between CREST and Case Management.|2|||f||||t||||||||||2018-05-31 23:13:19.805161|2018-05-31 23:13:19.805161
NCT01227044|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2018-01-12|2010-10-20|2010-10-22|Estimate|||||||2018-01-12|2018-01-17|Actual|April 2011||2011-04-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|DAWN||Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention|Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention|Completed||Phase 2/Phase 3|51|Actual|Yale University||2|||f||||t||||||||||2018-05-31 23:13:20.118491|2018-05-31 23:13:20.118491
NCT01227031|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2010-11-10|2010-10-21|2010-10-22|Estimate|||||||2010-11-10|2010-11-12|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|October 2010|Actual|2010-10-31||Observational|||Pharmacogenomic Study of Androgenetic Alopecia|Pharmacogenomic Study of Androgenetic Alopecia|Unknown status|Not yet recruiting||400|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||Samples With DNA|"~     DNA extraction from blood sample~   "|||2018-05-31 23:13:20.19294|2018-05-31 23:13:20.19294
NCT01227018|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2014-06-23||2014-06-23|2010-10-20|2010-10-22|Estimate|2014-06-23|2014-07-23|Estimate||||2014-06-23|2014-07-23|Estimate|December 2010||2010-12-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer|Phase II Study of STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer|Terminated||Phase 2|15|Actual|Vanderbilt-Ingram Cancer Center||1||interim analysis found the study drug to be ineffective|f||||t||||||||||2018-05-31 23:13:20.262841|2018-05-31 23:13:20.262841
NCT01227005|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2014-05-19||2015-05-27|2010-10-21|2010-10-22|Estimate|2015-05-26|2015-05-28|Estimate||||2015-05-27|2015-06-24|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Early Whole Blood in Patients Requiring Transfusion After Major Trauma|Early Whole Blood in Patients Requiring Transfusion After Major Trauma|Completed||Phase 4|107|Actual|The University of Texas Health Science Center, Houston|First, we failed to specifically exclude patients with severe TBI from our initial protocol. Finally, we did not use an objective scoring system to randomize patients and, therefore, did not always include patients who would have received an MT.|2|||f||||t||||||||||2018-05-31 23:13:20.595455|2018-05-31 23:13:20.595455
NCT01226992|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-12-04|2010-10-21|2010-10-22|Estimate|||||||2014-12-04|2014-12-08|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin|Phase II/III Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin for Recurrent Clostridium Difficile Infection (CDI)|Terminated||Phase 2/Phase 3|81|Actual|University Health Network, Toronto||2||Unavailable study resources|f||||t||||||||||2018-05-31 23:13:20.803644|2018-05-31 23:13:20.803644
NCT01226979|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-03-29|2010-10-20|2010-10-22|Estimate|||||||2017-03-29|2017-03-31|Actual|September 2010||2010-09-30|March 2017|2017-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|HDRBT||Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer|Phase II Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer|Active, not recruiting||Phase 2|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||Undecided||2018-05-31 23:13:20.870142|2018-05-31 23:13:20.870142
NCT01226966|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-02-10|2010-10-21|2010-10-22|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2010||2010-09-30|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|EVIDENCE||Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes|Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes|Completed|||3152|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 23:13:20.940177|2018-05-31 23:13:20.940177
NCT01226953|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-12-27|2010-10-21|2010-10-22|Estimate|||||||2011-12-27|2011-12-30|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants|A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants|Completed||Phase 3|660|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:13:21.009478|2018-05-31 23:13:21.009478
NCT01226927|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2010-10-21|2010-10-21|2010-10-22|Estimate|||||||2010-10-21|2010-10-22|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||The Efficacy of Automated Intermittent Boluses for Continuous Femoral Nerve Block: a Prospective, Randomized Comparison to Continuous Infusions|The Efficacy of Automated Intermittent Boluses for Continuous Femoral Nerve Block: a Prospective, Randomized Comparison to Continuous Infusions|Completed||N/A|45|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 23:13:21.070066|2018-05-31 23:13:21.070066
NCT01226914|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2014-08-19|2010-10-21|2010-10-22|Estimate|||||||2014-08-19|2014-08-20|Estimate|June 2010||2010-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy|A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy|Completed||N/A|120|Anticipated|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 23:13:21.139012|2018-05-31 23:13:21.139012
NCT01226888|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2012-11-02|2010-10-21|2010-10-22|Estimate|||||||2012-11-02|2012-11-05|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Changes in Brown Adipose Tissue Activity In Men Receiving Androgen Deprivation Therapy for Prostate Cancer|Prospective Study of Changes in Brown Adipose Tissue (BAT) Activity in Men Receiving Androgen Deprivation Therapy (ADT) With a GnRH Agonist or Antagonist for Prostate Cancer|Terminated|||2|Actual|Massachusetts General Hospital||||Slow accrual|f||||t||||||Samples With DNA|"~     fine needle aspirate biopsies of subcutaneous fat~   "|||2018-05-31 23:13:21.247811|2018-05-31 23:13:21.247811
NCT01226875|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-10-04|2010-10-20|2010-10-22|Estimate|||||||2017-10-04|2017-10-06|Actual|January 2011|Actual|2011-01-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi|Multicentred, Randomized Control Trial Comparing Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi|Completed||N/A|275|Actual|St. Michael's Hospital, Toronto||4|||f||||f||||||||||2018-05-31 23:13:21.301064|2018-05-31 23:13:21.301064
NCT01226862|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2013-12-04|2010-10-21|2010-10-22|Estimate|||||||2013-12-04|2013-12-05|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|ATC||Advancing Telestroke Care: A Prospective Observational Study|Advancing Telestroke Care: A Prospective Observational Study|Completed|||508|Actual|National Stroke Association, United States|||3||f||||t||||||||||2018-05-31 23:13:21.366475|2018-05-31 23:13:21.366475
NCT01226849|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2017-04-25|2010-10-21|2010-10-22|Estimate|||||||2017-04-25|2017-04-27|Actual|November 2010||2010-11-30|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SGH652||Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma|An Open-Label, Pilot Study To Investigate Feasibility and Safety Of Using Bortezomib, Rituximab, Ifosfamide, Carboplatin, Etoposide As Salvage Regime In Previously Treated Patients With Diffuse Large B-Cell Lymphoma|Completed||Phase 1|6|Actual|Singapore General Hospital||1|||f||||t||||||||||2018-05-31 23:13:21.434562|2018-05-31 23:13:21.434562
NCT01226836|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-11-08|2010-10-21|2010-10-22|Estimate|||||||2012-11-08|2012-11-09|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD): the Development and Feasibility of an Education Package|Pulmonary Rehabilitation in COPD: the Development and Feasibility of an Education Package|Completed||N/A|53|Actual|University of Ulster||1|||f||||f||||||||||2018-05-31 23:13:21.561133|2018-05-31 23:13:21.561133
NCT01226823|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2016-05-10|2010-10-21|2010-10-22|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|CERTO||Ursodeoxycholic Acid And Cholestasis Of Pregnancy|Intrahepatic Cholestasis Of Pregnancy: Clinical Impact Of Ursodeoxycholic Acid Treatment|Withdrawn||Phase 3|0|Actual|University of Bologna||2||Modified insurance requests by a new law released after its approval.|f||||f||||||||||2018-05-31 23:13:21.635702|2018-05-31 23:13:21.635702
NCT01226810|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2010-10-21|2010-10-21|2010-10-22|Estimate|||||||2010-10-21|2010-10-22|Estimate|January 2011||2011-01-31|October 2010|2010-10-31||||||||Observational|||The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration|A Novel Approach to Ultrafast Parathyroid SPECT Imaging Using a Solid State CZT SPECT Camera|Unknown status|Not yet recruiting||50|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 23:13:21.743329|2018-05-31 23:13:21.743329
NCT01226797|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-03-19|2010-10-21|2010-10-22|Estimate|||||||2012-03-19|2012-03-20|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate The Efficacy And Safety Of Oral PF-04136309 500 Mg BID In Subjects With Chronic HCV Infection And Raised Aminotransferases|Terminated||Phase 2|24|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:13:21.803188|2018-05-31 23:13:21.803188
NCT01226784|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2015-09-30|2010-10-21|2010-10-22|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2010||2010-10-31|September 2015|2015-09-30||||May 2015|Actual|2015-05-31||Interventional|||The Effects of Training and Relaxation on Fibromyalgia.||Unknown status|Enrolling by invitation|N/A|240|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 23:13:21.982837|2018-05-31 23:13:21.982837
NCT01226771|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2015-03-23|2010-10-21|2010-10-22|Estimate|||||||2015-03-23|2015-03-24|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|RibaC||Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1||Completed||Phase 3|105|Actual|Göteborg University||3|||f||||t||||||||||2018-05-31 23:13:22.06769|2018-05-31 23:13:22.06769
NCT01226758|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-11-01|2010-10-21|2010-10-22|Estimate|||||||2012-11-01|2012-11-02|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Influenza Vaccine Challenge Study in Healthy Subjects|A Randomised Double-blind, Placebo-controlled, Phase 1b Trial to Evaluate the Safety, Tolerability and Protective Efficacy of the Influenza Vaccine Candidate, FLU-v, in an Influenza Challenge Model|Completed||Phase 1|32|Actual|PepTcell Limited||2|||f||||f||||||||||2018-05-31 23:13:22.157818|2018-05-31 23:13:22.157818
NCT01226745|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2016-01-31||2016-06-02|2010-10-21|2010-10-22|Estimate|2016-06-02|2016-07-12|Estimate||||2016-06-02|2016-07-12|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|DreaMS|Safety analysis set consisted of all the enrolled subjects.|Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)|A Safety and Efficacy Extension Study of ONO-4641 (MSC2430913A) in Patients With Relapsing-Remitting Multiple Sclerosis|Terminated||Phase 2|340|Actual|EMD Serono|Company has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The decision was not related to any safety and efficacy findings.|6||"Merck has decided to not pursue phase 3 development of ceralifimod (ONO-4641). The decision was~   not related to any safety and efficacy findings"|f||||t||||||||||2018-05-31 23:13:22.320371|2018-05-31 23:13:22.320371
NCT01226732|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2015-01-06||2015-01-06|2010-10-20|2010-10-22|Estimate|2015-01-06|2015-01-14|Estimate||||2015-01-06|2015-01-14|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|July 2013|Actual|2013-07-31||Interventional|||A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors|A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors|Completed||Phase 1|23|Actual|SCRI Development Innovations, LLC||6|||f||||f||||||||||2018-05-31 23:13:24.52535|2018-05-31 23:13:24.52535
NCT01139346|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2012-07-18|2010-06-04|2010-06-08|Estimate|||||||2012-07-18|2012-07-19|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study of Oral Darinaparsin in Patients With Advanced Solid Tumors|Phase I Study of Oral Darinaparsin in Advanced Solid Tumors|Completed||Phase 1|12|Actual|Ziopharm||1|||f||||f||||||||||2018-05-31 23:42:32.113357|2018-05-31 23:42:32.113357
NCT01226719|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2015-02-26||2015-05-07|2010-10-20|2010-10-22|Estimate|2015-05-07|2015-05-27|Estimate||||2015-05-07|2015-05-27|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||All patients on study|FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only|A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only|Completed||Phase 2|15|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 23:13:26.167635|2018-05-31 23:13:26.167635
NCT01226706|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2015-08-04||2017-04-11|2010-10-20|2010-10-22|Estimate|2017-04-11|2017-07-03|Actual||||2017-04-11|2017-07-03|Actual|June 2008||2008-06-30|April 2017|2017-04-30|October 2012|Actual|2012-10-31|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence|Efficacy of Botulinum Toxin A Intradetrusor Injections for the Treatment of Non-neurogenic Urinary Urge Incontinence- A Randomized Double-Blind Control Trial|Completed||N/A|21|Actual|Saskatchewan Health Authority - Regina Area|Poor recruitment. Recruitment slowed significantly when newer anticholinergic medications became available. Those who were previously eligible for the study had darifenacin and solifenacin to try before considering botulinum toxin treatment.|2|||f||||f||||||||No||2018-05-31 23:13:29.404767|2018-05-31 23:13:29.404767
NCT01226693|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-03-09|2010-10-20|2010-10-22|Estimate|||||||2011-03-09|2011-03-10|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study In Healthy Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of Three Formulations Of PH-797804|A Phase 1, Randomized, Open Label, Single Dose, 3 Treatment, Two Period, Balanced Incomplete Block Study In Healthy Fasted Volunteers To Assess The Safety, Tolerability, And Relative Oral Bioavailability Of A 6 Mg Dose Of The PH-797804 Material Sparing Tablet (MST) And Two Modified Versions Of The MST Formulation With And Without The Solubilizing Agent Sodium Lauryl Sulphate (SLS)|Completed||Phase 1|18|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 23:13:32.124727|2018-05-31 23:13:32.124727
NCT01226680|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2010-12-21|2010-10-20|2010-10-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|November 2011|Anticipated|2011-11-30|October 2011|Anticipated|2011-10-31||Interventional|||A Study Of Tasocitinib In Dry Eye Subjects|A Phase II, Randomized, Double Masked, Parallel Group, Vehicle Controlled, Multiple-Dose Study Of Tasocitinib (CP-690,550) In Subjects With Dry Eye Disease|Withdrawn||Phase 2|240|Anticipated|Pfizer||3|||f||||f||||||||||2018-05-31 23:13:32.247933|2018-05-31 23:13:32.247933
NCT01226667|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-07-30|2010-10-20|2010-10-22|Estimate|||||||2012-07-30|2012-07-31|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Flexdose||Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia|Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia|Completed||Phase 4|174|Actual|Osteoporosis Medical Center, Beverly Hills, CA||2|||f||||f||||||||||2018-05-31 23:13:32.342778|2018-05-31 23:13:32.342778
NCT01226654|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-07-28|2010-10-21|2010-10-22|Estimate|||||||2017-07-28|2017-08-01|Actual|August 1991||1991-08-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis|Quantitative MR Imaging and Proton Spectroscopy in MS|Terminated||N/A|69|Actual|New York University School of Medicine||2|||f||||t|f|f|||f|||||2018-05-31 23:13:32.677699|2018-05-31 23:13:32.677699
NCT01226641|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2013-01-16|2010-10-21|2010-10-22|Estimate|||||||2013-01-16|2013-01-17|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|TELESAS||Usefulness of a Telemedicine System for OSA Patients Follow-up With High Cardiovascular Risk|Usefulness of a Telemedicine System for OSA Patients Follow-up With High Cardiovascular Risk|Terminated||N/A|107|Actual|Initiative Pour la Sante||2|||f||||t||||||||||2018-05-31 23:13:32.95381|2018-05-31 23:13:32.95381
NCT01226628|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21||2016-03-02|2017-08-01|2010-10-21|2010-10-22|Estimate||||2016-03-02|2016-03-30|Estimate|2017-08-01|2017-08-08|Actual|October 21, 2010|Actual|2010-10-21|August 2017|2017-08-31|May 31, 2017|Actual|2017-05-31|March 31, 2015|Actual|2015-03-31||Interventional|||A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration|Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled, Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age-related Macular Degeneration|Completed||Phase 1/Phase 2|39|Actual|Janssen Research & Development, LLC||8|||f||||t|t|f||||||||2018-05-31 23:13:33.107252|2018-05-31 23:13:33.107252
NCT01226615|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-10-01|2010-10-21|2010-10-22|Estimate|||||||2012-10-01|2012-10-02|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI)|Randomized, Double-blind, Placebo-controlled Study to Asses the Effect of Chondroitin Sulphate in Patients With Knee Osteoarthritis by Functional Magnetic Resonance Imaging|Unknown status|Active, not recruiting|Phase 4|64|Actual|Bioiberica||2|||f||||||||||||||2018-05-31 23:13:33.861991|2018-05-31 23:13:33.861991
NCT01226602|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-02-10|2010-10-21|2010-10-22|Estimate|||||||2012-02-10|2012-02-13|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.|A Randomized, Double-blind, Placebo Controlled, Crossover, Single Centre Phase I Study to Assess the Effect of Ticagrelor on Adenosine-induced Coronary Blood Flow Velocity in Healthy Male Subjects|Completed||Phase 1|39|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:13:34.645034|2018-05-31 23:13:34.645034
NCT01226589|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-04-18|2010-10-21|2010-10-22|Estimate|||||||2011-04-18|2011-04-19|Estimate|October 2007||2007-10-31|April 2011|2011-04-30|October 2008|Actual|2008-10-31|||||Interventional|||Pharmacist Discharge Medication Reconciliation Study|The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute|Completed||N/A|50|Anticipated|AHS Cancer Control Alberta|||||f||||t||||||||||2018-05-31 23:13:34.779408|2018-05-31 23:13:34.779408
NCT01226576|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2018-02-27|2010-10-21|2010-10-22|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2010||2010-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study|Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study|Active, not recruiting||N/A|8|Actual|InSightec||1|||f||||f||||||||||2018-05-31 23:13:34.971672|2018-05-31 23:13:34.971672
NCT01224301|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-04-03|2010-10-19|2010-10-20|Estimate|||||||2012-04-03|2012-04-04|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|MCSkipp||School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities|Monroe COunty School Kids Influenza Prevention Project|Completed||N/A|25366|Actual|Monroe County Department of Public Health||3|||f||||f||||||||||2018-05-31 23:14:54.120571|2018-05-31 23:14:54.120571
NCT01226563|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20||2016-11-14|2016-12-16|2010-10-21|2010-10-22|Estimate||||2016-11-14|2016-11-15|Estimate|2016-12-16|2016-12-19|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|PRESERVATION 1||IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction|A Placebo Controlled , Multicenter, Randomized, Double Blind Trial to Evaluate the Safety and Effectiveness of IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction - Preservation I Trial|Completed||Phase 2|306|Actual|Bellerophon||2|||f||||t||||||||||2018-05-31 23:13:35.189712|2018-05-31 23:13:35.189712
NCT01226550|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-12-28|2010-10-21|2010-10-22|Estimate|||||||2011-12-28|2011-12-30|Estimate|June 2007||2007-06-30|December 2011|2011-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan|Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan|Completed||Phase 1/Phase 2|18|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 23:13:35.850815|2018-05-31 23:13:35.850815
NCT01226537|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-11-07|2010-10-21|2010-10-22|Estimate|||||||2012-11-07|2012-11-09|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients|Effect of Taurine on Glycemic Control in Type I and Type II Diabetic Patients|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Hamad Medical Corporation||4|||f||||t||||||||||2018-05-31 23:13:35.971503|2018-05-31 23:13:35.971503
NCT01226524|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2015-08-17|2010-10-21|2010-10-22|Estimate|||||||2015-08-17|2015-08-18|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP)||Terminated||Phase 2/Phase 3|7|Actual|Hadassah Medical Organization||1||Slow recruitment|f||||f||||||||||2018-05-31 23:13:36.733772|2018-05-31 23:13:36.733772
NCT01226511|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2014-01-17||2014-01-17|2010-10-21|2010-10-22|Estimate|2014-01-17|2014-03-05|Estimate||||2014-01-17|2014-03-05|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional||All randomized participants, excluding 9 participants from 1 site with major quality issues.|A Study in Pediatric Participants With Generalized Anxiety Disorder|A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder|Completed||Phase 3|281|Actual|Eli Lilly and Company|Nine (9) randomized participants (5 duloxetine, 4 placebo) from 1 site were excluded from efficacy and safety analyses due to major quality issues at that site.|2|||f||||f||||||||||2018-05-31 23:13:37.739853|2018-05-31 23:13:37.739853
NCT01226498|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2014-01-29|2010-10-20|2010-10-22|Estimate|||||||2014-01-29|2014-01-30|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Effects of Blood Transfusion in Healthy Volunteers|Effects of Duration of Stored Red Blood Cell Transfusion on Physiological Parameters and Inflammatory Mediators in Healthy Adult Volunteers|Completed||N/A|10|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:13:42.698194|2018-05-31 23:13:42.698194
NCT01226485|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-10-11|2010-10-20|2010-10-22|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2010||2010-09-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|January 2015|Actual|2015-01-31||Interventional|||A Study in Advanced Cancer|A Phase 1 Dose-Escalation Study of LY2940680 in Patients With Advanced Cancer|Completed||Phase 1|86|Actual|Ignyta, Inc.||1|||f||||f||||||||||2018-05-31 23:13:43.541584|2018-05-31 23:13:43.541584
NCT01226472|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19||2013-08-26|2016-06-14|2010-10-20|2010-10-22|Estimate||||2013-08-26|2013-09-02|Estimate|2016-06-14|2016-06-16|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001|Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001|Completed||Phase 2|1|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-05-31 23:13:44.127901|2018-05-31 23:13:44.127901
NCT01226459|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2014-03-26|2012-08-30|2014-06-03|2010-10-21|2010-10-22|Estimate|2014-05-08|2014-06-03|Estimate|2012-08-30|2012-09-05|Estimate|2014-06-03|2014-06-10|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Intent to Treat (ITT) population defined as all participants randomly assigned to a treatment group who received dispensed investigational product.|Clinical Trial in Females for Female Pattern Hair Loss|A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia)|Completed||Phase 3|404|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 23:13:44.912199|2018-05-31 23:13:44.912199
NCT01226446|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-08-08|2010-10-21|2010-10-22|Estimate|||||||2014-08-08|2014-08-11|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|ANRS VITAVIC||Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C Null-Responders|Multicenter Open and Prospective Trial Assessing the Efficacy of Vitamin D Supplementation in Addition to Pegylated Interferon Plus Ribavirin in Null-Responders Patients With Chronic Viral Hepatitis C Genotype 1 or 4|Completed||Phase 2|32|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 23:13:46.871536|2018-05-31 23:13:46.871536
NCT01226433|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-03-28|2010-10-21|2010-10-22|Estimate|||||||2013-03-28|2013-03-29|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Family Planning Through Dairy Cooperatives|Providing Family Planning Services Sustainably Through Dairy Cooperatives in Kenya|Completed|||319|Actual|FHI 360|||||f||||f||||||||||2018-05-31 23:13:47.220518|2018-05-31 23:13:47.220518
NCT01226420|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|2013-01-28||2013-08-11|2010-10-21|2010-10-22|Estimate|2013-08-11|2013-08-13|Estimate||||2013-08-11|2013-08-13|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease|A Phase II, Open-Label, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease|Terminated||Phase 2|6|Actual|Dana-Farber Cancer Institute||1||Discontinuation of drug supply from Astellas.|f||||t||||||||||2018-05-31 23:13:47.343726|2018-05-31 23:13:47.343726
NCT01225874|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2016-02-19|2010-10-20|2010-10-21|Estimate|||||||2016-02-19|2016-02-23|Estimate|December 1999||1999-12-31|February 2016|2016-02-29||||March 2006|Actual|2006-03-31||Interventional|||Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL|ALinC 17, Classification ©), B-precursor Induction Treatment (I)|Completed||N/A|3762|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 23:14:16.035853|2018-05-31 23:14:16.035853
NCT01226407|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-12-27|2010-10-21|2010-10-22|Estimate|||||||2012-12-27|2012-12-31|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile|Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer|Unknown status|Recruiting|Phase 1|36|Anticipated|CrystalGenomics, Inc.||1|||f||||f||||||||||2018-05-31 23:13:47.987423|2018-05-31 23:13:47.987423
NCT01226394|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-01-25|2010-10-21|2010-10-22|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2010||2010-04-30|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ProphyloCHIP||"Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus in Principle (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients"|"Multicentric Phase III Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus in Principle HIPEC (Hyperthermic Intraperitoneal Chemotherapy) in Colorectal Patients Initially Treated With Surgery and Adjuvant Chemotherapy Who Have a High Risk of Developing Colorectal Peritoneal Carcinomatosis"|Recruiting||Phase 3|130|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 23:13:48.451769|2018-05-31 23:13:48.451769
NCT01226381|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-02-02|2010-10-21|2010-10-22|Estimate|||||||2012-02-02|2012-02-03|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Interaction Between tropisétron / granisétron - paracétamol|Comparative Study of the Influence of Two Antagonist Receptors 5-HT3, tropisétron and granisétron, on the Analgesic Effect of Paracétamol|Completed||Phase 1|30|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:13:49.241329|2018-05-31 23:13:49.241329
NCT01226368|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2014-10-29|2010-10-21|2010-10-22|Estimate|||||||2014-10-29|2014-10-30|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|January 2011|Actual|2011-01-31||Observational|HP2V-AG||Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.|Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.|Completed|||455|Actual|University Hospital Center of Martinique|||||f||||f||||||Samples With DNA|"~     cervix cells~   "|||2018-05-31 23:13:50.236744|2018-05-31 23:13:50.236744
NCT01226355|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-05-20|2010-10-21|2010-10-22|Estimate|||||||2012-05-20|2012-05-22|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|November 2014|Anticipated|2014-11-30|December 2010|Actual|2010-12-31||Interventional|||NOYA CoCr Biodegradable Coating Sirolimus-Eluting Coronary Stent System|Clinical Trial Program of a Medical Instrument Product|Unknown status|Active, not recruiting|N/A|300|Actual|Medfavour (Beijing) Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 23:13:50.466617|2018-05-31 23:13:50.466617
NCT01226342|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-04-10|2010-10-21|2010-10-22|Estimate|||||||2013-04-10|2013-04-11|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Transcutaneous Electrical Muscle Stimulation In Chronic Obstructive Pulmonary Disease (COPD)|Transcutaneous Electrical Muscle Stimulation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|19|Actual|The University Clinic of Pulmonary and Allergic Diseases Golnik||1|||f||||f||||||||||2018-05-31 23:13:50.614752|2018-05-31 23:13:50.614752
NCT01226329|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2016-06-02|2010-10-21|2010-10-22|Estimate|||||||2016-06-02|2016-06-03|Estimate|July 2008||2008-07-31|June 2016|2016-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|RQP-MH||The Right Question Project-Mental Health: An Intervention to Increase Engagement and Retention in Mental Health Care|The Right Question Project-Mental Health: An Intervention to Increase Engagement and Retention in Mental Health Care|Completed||N/A|724|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:13:50.701317|2018-05-31 23:13:50.701317
NCT01226316|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2018-05-15|2010-10-21|2010-10-22|Estimate|||||||2018-05-15|2018-05-16|Actual|December 1, 2010|Actual|2010-12-01|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|April 18, 2019|Anticipated|2019-04-18||Interventional|||Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.|Recruiting||Phase 1|304|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:13:50.978241|2018-05-31 23:13:50.978241
NCT01226303|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-01-25|2010-10-21|2010-10-22|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia|Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia|Recruiting||Phase 3|300|Anticipated|Associazione Italiana Ematologia Oncologia Pediatrica||2|||f||||t||||||||||2018-05-31 23:13:51.396831|2018-05-31 23:13:51.396831
NCT01226290|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20||2015-03-13|2015-03-13|2010-10-20|2010-10-22|Estimate||||2015-03-13|2015-04-02|Estimate|2015-03-13|2015-04-02|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|FAST-EU||Fibroid Ablation Study|Symptom Effectiveness Study of VizAblate™ Intrauterine Ultrasound-Guided RF Ablation (IUUSgRFA) in the Ablation of Uterine Fibroids|Terminated||N/A|51|Actual|Gynesonics||1||Investigational device changes; adequate enrollment achieved|f||||f||||||||||2018-05-31 23:13:51.722461|2018-05-31 23:13:51.722461
NCT01226277|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2016-11-01|2010-10-20|2010-10-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma|An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered Daily in Patients With Refractory Solid Tumors or Lymphoma|Completed||Phase 1|42|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 23:13:51.916623|2018-05-31 23:13:51.916623
NCT01226264|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2015-12-01|2010-10-21|2010-10-22|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|s52647||Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence|Diffusion MRI; Predictive Value for Cervical Uterine Cancer Recurrence.|Unknown status|Active, not recruiting|N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 23:13:52.254442|2018-05-31 23:13:52.254442
NCT01226251|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2012-10-01|2010-10-21|2010-10-22|Estimate|||||||2012-10-01|2012-10-02|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Observational|Striptest||"New in Vitro Diagnostic Test for Oral Malodour"|"New in Vitro Diagnostic Test for Oral Malodour: First Prototype Evaluation"|Unknown status|Recruiting||150|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 23:13:52.330409|2018-05-31 23:13:52.330409
NCT01226225|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2010-11-09|2010-10-21|2010-10-22|Estimate|||||||2010-11-09|2010-11-10|Estimate|November 2010||2010-11-30|August 2010|2010-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|SAINTEX-CAD||A Multicentre Trial on the Effectiveness of Physical Rehabilitation of Patients With Coronary Artery Disease: Aerobic Interval Training Versus Moderate Continuous Training.||Unknown status|Recruiting|Phase 3|200|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||||2018-05-31 23:13:52.923164|2018-05-31 23:13:52.923164
NCT01226212|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-05-02|2010-10-21|2010-10-22|Estimate|||||||2013-05-02|2013-05-03|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Can Synbiotic Use Effect Gut Bacteria and the Immune Response in Older People|Can Synbiotic Use Improve Dysbiosis in the Gut Microbiome and Modify Inflammatory Processes in Older People|Completed||N/A|49|Actual|University of Dundee||2|||f||||t||||||||||2018-05-31 23:13:53.04679|2018-05-31 23:13:53.04679
NCT01226199|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-06-07|2010-10-21|2010-10-22|Estimate|||||||2011-06-07|2011-06-08|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Observational|||The Expression of TLR2 and TLR4 in the Lung of Chronic Obstructive Pulmonary Disease (COPD) Patients|The Expression of TLR2 and TLR4 in the Lung of COPD Patients|Unknown status|Recruiting||60|Anticipated|Seoul National University Bundang Hospital|||||f||||f||||||Samples Without DNA|"~     Lung tissues are retained till the study ends.~   "|||2018-05-31 23:13:53.174185|2018-05-31 23:13:53.174185
NCT01226186|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2012-12-03|2010-10-21|2010-10-22|Estimate|||||||2012-12-03|2012-12-04|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Self Medication With Oral Morphine After Total Knee Arthroplasty.|Self Medication With Oral Morphine After Total Knee Arthroplasty. A Randomised Controlled Trial Comparing Self Medication With Standard Nurse Dispensing. Is There a Difference in Morphine Consumption, Pain, Patient Satisfaction or Safety?|Completed||N/A|144|Actual|The Royal Bournemouth Hospital||2|||f||||f||||||||||2018-05-31 23:13:53.304836|2018-05-31 23:13:53.304836
NCT01226173|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2012-09-20|2010-10-20|2010-10-22|Estimate|||||||2012-09-20|2012-09-24|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol|Study of Bio-Rad Laboratories Platelia Dengue NS1 Ag Assay in Blood Donors.|Completed|||182353|Actual|Bio-Rad Laboratories|||||f||||f||||||Samples With DNA|"~     EDTA plasma samples contained in plasma preparation tubes (PPTs) that have been frozen within~     24 hours of collection and following centrifugation (under the same centrifugation conditions~     as used for PPTs used for nucleic acid testing, NAT) will be the primary samples for~     prospective testing.~   "|||2018-05-31 23:13:53.906127|2018-05-31 23:13:53.906127
NCT01226160|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2010-10-21|2010-10-21|2010-10-22|Estimate|||||||2010-10-21|2010-10-22|Estimate|January 2005||2005-01-31|August 2006|2006-08-31|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Interventional|||Pilot Randomised Controlled Trial of Posturing Following Surgery for Full-thickness Macular Hole|Pilot Randomised Controlled Trial of Posturing Following Surgery for Full-thickness Macular Hole|Completed||Early Phase 1|30|Actual|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 23:13:54.640834|2018-05-31 23:13:54.640834
NCT01226147|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2011-07-21|2010-10-21|2010-10-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis||Unknown status|Recruiting|Phase 2|20|Anticipated|Kinki University|||||f||||||||||||||2018-05-31 23:13:55.17831|2018-05-31 23:13:55.17831
NCT01226134|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-21|||2010-10-21|2010-10-21|2010-10-22|Estimate|||||||2010-10-21|2010-10-22|Estimate|February 2009||2009-02-28|July 2010|2010-07-31|May 2011|Anticipated|2011-05-31|March 2011|Anticipated|2011-03-31||Interventional|EIGEAPFD||Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia|Effect Of Itopride On Gastric Emptying And Accommodation In Patients With Functional Dyspepsia|Unknown status|Recruiting|N/A|30|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-05-31 23:13:56.192551|2018-05-31 23:13:56.192551
NCT01226121|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2014-04-21||2014-05-16|2010-10-20|2010-10-21|Estimate|2014-05-16|2014-06-16|Estimate||||2014-05-16|2014-06-16|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture|A Post Market, Open-Label Study of the Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture|Terminated||Phase 4|37|Actual|Indiana Hand to Shoulder Center|Study was terminated early due to slow enrollment|3||difficulty enrolling additional patients|f||||f||||||||||2018-05-31 23:13:56.478381|2018-05-31 23:13:56.478381
NCT01226108|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-09-23|2010-10-20|2010-10-21|Estimate|||||||2011-09-23|2011-09-26|Estimate|October 2010||2010-10-31|September 2011|2011-09-30||||August 2011|Actual|2011-08-31||Interventional|Aktin||The Akloma Tinnitus Patch in Patients With Manifested Tinnitus|The Akloma Tinnitus Patch in Patients With Manifested Tinnitus (the Aktin Study)|Completed||N/A|16|Anticipated|Akloma Bioscience AB||1|||f||||f||||||||||2018-05-31 23:13:57.592255|2018-05-31 23:13:57.592255
NCT01226095|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2011-11-04||2013-09-16|2010-10-20|2010-10-21|Estimate|2011-12-16|2012-01-23|Estimate||||2013-09-16|2013-09-20|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Evaluation of the Effectiveness, Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients|A Prospective, Multi-center, Post-marketing Observational Study to Evaluate the Effectiveness and Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients|Completed|||519|Actual|Abbott|||1||f||||||||||||||2018-05-31 23:13:58.729543|2018-05-31 23:13:58.729543
NCT01226082|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|tDCS||The Effect of Transcranial Direct Current Stimulation for Chronic Pain on Ophthalmologic Parameters|The Effect of Transcranial Direct Current Stimulation for Chronic Pain on Ophthalmologic Parameters|Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 23:14:02.04082|2018-05-31 23:14:02.04082
NCT01226069|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effectiveness of Topical Glycerine Sulphate Paste, Hirudoid Cream and Nil Application on Superficial Phlebitis|To Investigate the Effectiveness of Topical Glycerine Sulphate, Hirudoid Cream and Nil Application in Treating Peripheral Cannula Related Phlebitis|Completed||N/A|147|Actual|Tan Tock Seng Hospital||3|||f||||t||||||||||2018-05-31 23:14:02.124251|2018-05-31 23:14:02.124251
NCT01225861|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-05-14|2010-10-20|2010-10-21|Estimate|||||||2014-05-14|2014-05-15|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Observational|||Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK||Completed|||750|Anticipated|Mundipharma Research Limited|||||f||||f||||||||||2018-05-31 23:14:16.138068|2018-05-31 23:14:16.138068
NCT01226056|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|March 2009||2009-03-31|October 2010|2010-10-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets|Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets|Suspended||Phase 1/Phase 2|45|Anticipated|Southern Europe New Drug Organization||1||toxicity (protocol amendment under approval)|f||||f||||||||||2018-05-31 23:14:02.991426|2018-05-31 23:14:02.991426
NCT01226043|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2013-05-03||2013-07-30|2010-10-20|2010-10-21|Estimate|2013-07-29|2013-07-30|Estimate||||2013-07-30|2013-08-12|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|Pen Preference|Baseline characteristics provided for the population randomized for the first phase of the study: crossover phase.|Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus|An Open Label Randomized Multicenter Study to Assess Patient Preference for and Evaluate Clinical Benefit of Insulin Glargine (Lantus®) SoloSTAR® Pen Versus Conventional Vial/Syringe Method of Insulin Glargine (Lantus®) Injection Therapy in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|405|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:14:03.432914|2018-05-31 23:14:03.432914
NCT01226030|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-09|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors|Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|24|Anticipated|Protgen Ltd||4|||f||||t||||||||||2018-05-31 23:14:07.547916|2018-05-31 23:14:07.547916
NCT01226017|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-11-22|2010-10-20|2010-10-21|Estimate|||||||2011-11-22|2011-11-23|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|Oxytocin2010||A Possible Effect of Oxytocin During Interaction Between Humans and Animals|A Possible Effect of Oxytocin During Interaction Between Humans and Animals|Completed||N/A|18|Actual|Norwegian University of Life Sciences|||||f||||f||||||||||2018-05-31 23:14:08.060651|2018-05-31 23:14:08.060651
NCT01226004|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2015-03-09|2010-10-20|2010-10-21|Estimate|||||||2015-03-09|2015-03-10|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|July 2020|Anticipated|2020-07-31|July 2015|Anticipated|2015-07-31||Observational|RPCR||Multi-Institutional Registry for Prostate Cancer Radiosurgery|Multi-Institutional Registry for Prostate Cancer Radiosurgery. An IRB Approved Observational Trial|Recruiting|||3000|Anticipated|Florida Robotic Radiosurgery Association|||||f||||t||||||||||2018-05-31 23:14:08.652217|2018-05-31 23:14:08.652217
NCT01225991|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2014-08-12||2018-02-27|2010-10-20|2010-10-21|Estimate|2014-09-15|2014-09-17|Estimate||||2018-02-27|2018-03-29|Actual|November 2010||2010-11-30|February 2018|2018-02-28|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis|An Open-label Trial of Milnacipran for the Treatment of Pain in Rheumatoid Arthritis (RA) in Older Adults|Completed||Phase 4|18|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 23:14:09.194572|2018-05-31 23:14:09.194572
NCT01225978|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-01-23|2010-10-20|2010-10-21|Estimate|||||||2014-01-23|2014-01-24|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2012|Actual|2012-12-31||Observational|RISGIM||Refining Information Technology Support for Genetics in Medicine|Refining Information Technology Support for Genetics in Medicine|Unknown status|Active, not recruiting||40|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||None Retained|"~     None Retained~   "|||2018-05-31 23:14:09.964351|2018-05-31 23:14:09.964351
NCT01225965|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2012-08-06|2010-10-20|2010-10-21|Estimate|||||||2012-08-06|2012-08-07|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Interventional|EFECT||Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung|An Efficacy and Feasibility Study to Investigate the Effect of Ectoin® Inhalation Solution (EIL) in Subjects With Inflammation and Airway Obstruction Followed by a Long Term Study Extension on the Prevention of Lung Function Decline|Completed||N/A|36|Actual|Bitop AG||2|||f||||t||||||||||2018-05-31 23:14:10.522222|2018-05-31 23:14:10.522222
NCT01225952|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2012-08-31||2012-12-11|2010-10-20|2010-10-21|Estimate|2012-12-11|2013-01-18|Estimate||||2012-12-11|2013-01-18|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction|A Three Arm Prospective Clinical Evaluation of Three FDA-approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction|Completed||Phase 4|93|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-05-31 23:14:11.035291|2018-05-31 23:14:11.035291
NCT01225939|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-03-01|2010-10-20|2010-10-21|Estimate|||||||2011-03-01|2011-03-02|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study Conducted Over 3 Periods to Look at the Drug in the Body|A Randomised, Open-label, Three-way Cross-over, Phase I Study in Healthy Subjects to Assess the Pharmacokinetics of AZD8329 After Single Doses of the Oral Solid Formulation and the Oral Solution|Completed||Phase 1|18|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:14:13.863337|2018-05-31 23:14:13.863337
NCT01225926|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2013-07-22||2013-09-24|2010-10-20|2010-10-21|Estimate|2013-07-22|2013-09-24|Estimate||||2013-09-24|2013-10-29|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Comparison of Aspheric Toric Intraocular Lens (IOL) Implantation Versus Aspheric Non-Toric Lens Implantation|A Randomized, Prospective, Multi-Center, Patient-Masked, Bilateral Comparison of Aspheric Toric Intraocular Lens (IOL) Implantation Versus Aspheric Non-Toric Lens Implantation|Completed||N/A|24|Actual|Alcon Research|This study was considered a pilot study and did not have an expectation to meet any of the study endpoints.|2|||f||||f||||||||||2018-05-31 23:14:14.139099|2018-05-31 23:14:14.139099
NCT01225913|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2017-07-07|2010-10-20|2010-10-21|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2007||2007-10-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Mechanism(s) of Airflow Limitation During Exacerbation of Asthma|Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers|Recruiting||N/A|50|Anticipated|Gelb, Arthur F., M.D.||1|||f||||t||||||||No||2018-05-31 23:14:15.148385|2018-05-31 23:14:15.148385
NCT01225887|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2017-08-07||2017-09-08|2010-10-20|2010-10-21|Estimate|2017-09-08|2017-10-09|Actual||||2017-09-08|2017-10-09|Actual|October 2011||2011-10-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|37|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 23:14:15.458625|2018-05-31 23:14:15.458625
NCT01225848|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-01-25|2010-10-20|2010-10-21|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|October 2013|Actual|2013-10-31|December 2010|Actual|2010-12-31||Interventional|||Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy Patients With Advanced Urothelial Carcinoma|Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy Patients With Advanced Urothelial Carcinoma|Completed||Phase 2|1|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:14:16.251291|2018-05-31 23:14:16.251291
NCT01225835|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2013-12-19||2014-02-17|2010-10-20|2010-10-21|Estimate|2013-12-19|2014-02-11|Estimate||||2014-02-17|2014-03-14|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|PREDICT|Safety|Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)|Effect of Highly Purified Menotrophin and Recombinant Follicle Stimulating (rFSH, Follitrophin Alpha) in Subfertile Female Patients Undergoing IVF on Progesterone Serum Levels During the Follicular Phase and Their Possible Use as Predictors for the Success Rate of Ongoing Pregnancies|Completed||Phase 4|124|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:14:16.367728|2018-05-31 23:14:16.367728
NCT01225822|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|2010-11-18||2014-05-08|2010-10-20|2010-10-21|Estimate|2010-11-18|2010-12-16|Estimate||||2014-05-08|2014-05-19|Estimate|November 2002||2002-11-30|February 2014|2014-02-28||||August 2003|Actual|2003-08-31||Interventional|||BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery|BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery|Completed||Phase 2|1973|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 23:14:18.515052|2018-05-31 23:14:18.515052
NCT01225809|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-01-25|2010-10-20|2010-10-21|Estimate|||||||2011-01-25|2011-01-26|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||AD01 Follow up Extension Visit|Observational Follow-up Extension Study-visit to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD01 Applied During AFFiRiS001 in Patients With Alzheimer's Disease|Completed|||17|Actual|Affiris AG|||1||f||||t||||||||||2018-05-31 23:14:20.544128|2018-05-31 23:14:20.544128
NCT01225796|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2016-04-05|2010-10-19|2010-10-21|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of Sodium Bicarbonate in Kidney Transplant Recipients|Randomized Trial of Sodium Bicarbonate in Renal Transplant Recipients With Low-normal Serum Bicarbonate Levels|Completed||Early Phase 1|29|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 23:14:20.601031|2018-05-31 23:14:20.601031
NCT01225783|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2012-03-16|2010-10-20|2010-10-21|Estimate|||||||2012-03-16|2012-03-19|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||The Validity and Reliability of Self Measurement of Upper Limb Volume|The Validity and Reliability of Self Measurement of Upper Limb Volume in Treating Lymphedema in Breast Cancer Patients|Unknown status|Recruiting|N/A|50|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:14:20.682732|2018-05-31 23:14:20.682732
NCT01225770|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2013-02-12|2010-10-20|2010-10-21|Estimate|||||||2013-02-12|2013-02-15|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|August 2014|Anticipated|2014-08-31|April 2014|Anticipated|2014-04-30||Interventional|||Gargling With Green Tea for Prophylaxis of Influenza Infection in Teenagers|Effects of Gargling With Green Tea on Preventing Influenza Infection Among High School Students: A Randomized Clinical Study|Unknown status|Recruiting|Phase 3|640|Anticipated|University of Shizuoka||2|||f||||f||||||||||2018-05-31 23:14:20.772557|2018-05-31 23:14:20.772557
NCT01225757|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2014-05-21|2010-10-19|2010-10-21|Estimate|||||||2014-05-21|2014-05-22|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Comparison of Traditional and Echocardiography Guided Fluid Management During Cytoreductive Surgery With HIPEC|Comparison of Traditional (Central Venous Pressure (CVP) and Urine Output Guided) Versus Echocardiography Guided Fluid Management in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Withdrawn||N/A|0|Actual|University of Nebraska||2||Logistical problems prior to the recruitment phase.|f||||t||||||||||2018-05-31 23:14:20.87484|2018-05-31 23:14:20.87484
NCT01225744|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-06-10|2010-10-20|2010-10-21|Estimate|||||||2014-06-10|2014-06-11|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|eSCOUT||Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy|A Phase II Study Evaluating the Use of Concurrent Cetuximab, Irinotecan, Oxaliplatin and UFT in the First Line Treatment of Patients With Metastatic Colorectal Cancer|Completed||Phase 2|47|Actual|The Christie NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 23:14:20.952433|2018-05-31 23:14:20.952433
NCT01225731|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2015-03-18||2017-07-25|2010-10-20|2010-10-21|Estimate|2015-03-18|2015-03-30|Estimate||||2017-07-25|2017-08-25|Actual|October 2010||2010-10-31|July 2017|2017-07-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Interventional|||A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)|Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)|Completed||Phase 2|355|Actual|Merck Sharp & Dohme Corp.||14|||f||||t||||||||||2018-05-31 23:14:21.088249|2018-05-31 23:14:21.088249
NCT01225718|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-04-13|2010-10-20|2010-10-21|Estimate|||||||2017-04-13|2017-04-17|Actual|August 2010||2010-08-31|April 2017|2017-04-30|June 25, 2016|Actual|2016-06-25|June 25, 2016|Actual|2016-06-25||Observational|||Ceftriaxone in Non-neutropenic Fever|Ceftriaxone in Non-neutropenic Fever|Completed|||463|Actual|Vanderbilt University Medical Center|||||f||||f||||||||||2018-05-31 23:14:22.793942|2018-05-31 23:14:22.793942
NCT01225705|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2015-06-02|2010-10-20|2010-10-21|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety Study of Raltegravir in HIV/HCV Co-infected Patients|An Open, Prospective Study to Compare the Safety and Efficacy of Raltegravir vs. Atazanavir / Ritonavir, Both in Combination With Tenofovir DF and Emtricitabine, in the Treatment of HIV-infection in ART Naive Subjects With HCV Co-infection.|Withdrawn||Phase 4|0|Actual|University Hospital, Bonn||2||no pts recruited|f||||f||||||||||2018-05-31 23:14:22.847705|2018-05-31 23:14:22.847705
NCT01225692|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|February 2004||2004-02-29|October 2010|2010-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|BTOS||Brain Trauma Outcomes in Nova Scotia Study|Brain Trauma Outcomes in Nova Scotia|Completed||N/A|52|Actual|Queen Elizabeth II Health Sciences Centre|||||f||||f||||||||||2018-05-31 23:14:22.945562|2018-05-31 23:14:22.945562
NCT01223742|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|June 2002||2002-06-30|December 2000|2000-12-31|December 2006||2006-12-31|||||Interventional|||Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy|ORAL ACETYL-L-CARNITINE THERAPY REDUCES FATIGUE IN HEPATIC ENCEPHALOPATHY|Completed||N/A|||University of Catania||2|||f||||t||||||||||2018-05-31 23:14:59.116095|2018-05-31 23:14:59.116095
NCT01225679|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2014-02-05|2010-10-20|2010-10-21|Estimate|||||||2014-02-05|2014-02-06|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Observational|CCHS||Late-onset Congenital Central Hypoventilation Syndrome and the Mutation of Phox2B Gene|Late-onset, Insidious Course and Invasive Treatment of Congenital Central Hypoventilation Syndrome in a Case With the Phox2B Mutation|Completed|||1|Actual|Associação Fundo de Incentivo à Pesquisa|||1||f||||f||||||Samples With DNA|"~     Human~   "|||2018-05-31 23:14:23.096672|2018-05-31 23:14:23.096672
NCT01225666|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19||2013-11-14|2015-04-05|2010-10-19|2010-10-21|Estimate||||2013-12-23|2014-01-29|Estimate|2015-04-05|2015-04-23|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|April 2012|Actual|2012-04-30|July 2011|Actual|2011-07-31||Interventional|||MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)|A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA)|Completed||Phase 2|52|Actual|Opko Biologics||4|||f||||t||||||||||2018-05-31 23:14:23.186512|2018-05-31 23:14:23.186512
NCT01225653|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2014-12-17|2010-10-20|2010-10-21|Estimate|||||||2014-12-17|2014-12-18|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Latano-2||Topical Application of Latanoprost in Diabetic Retinopathy|Topical Application of Latanoprost in Diabetic Retinopathy|Completed||Phase 4|27|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:14:23.293806|2018-05-31 23:14:23.293806
NCT01225640|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19||2013-03-19|2015-12-14|2010-10-19|2010-10-21|Estimate||||2013-03-19|2013-03-25|Estimate|2015-12-14|2016-01-14|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay|A Phase 2a, Open-Label, Randomized Study In Treatment-Naive, Sputum Smear Positive Subjects With Drug-Sensitive Pulmonary Tuberculosis To Assess Early Bactericidal Activity (EBA) And Whole Blood Activity (WBA) Of PNU-100480 (PF-02341272)|Completed||Phase 2|59|Actual|Sequella, Inc.||3|||f||||f||||||||||2018-05-31 23:14:23.385523|2018-05-31 23:14:23.385523
NCT01225627|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-04-08|2010-10-20|2010-10-21|Estimate|||||||2013-04-08|2013-04-09|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Discharge Coordinator Intervention in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effects of Discharge Coordinator Intervention on Hospitalizations and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease: a Randomized Controlled Clinical Trial|Completed||N/A|253|Actual|The University Clinic of Pulmonary and Allergic Diseases Golnik||2|||f||||t||||||||||2018-05-31 23:14:23.480283|2018-05-31 23:14:23.480283
NCT01225614|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2017-11-17|2010-10-20|2010-10-21|Estimate|||||||2017-11-17|2017-11-20|Actual|October 2010|Actual|2010-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|DYVINE||Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive|Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1)|Active, not recruiting||Phase 3|77|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:14:23.566493|2018-05-31 23:14:23.566493
NCT01225601|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-04-15|2010-10-20|2010-10-21|Estimate|||||||2016-04-15|2016-04-18|Estimate|May 2006||2006-05-31|March 2015|2015-03-31|September 2010|Actual|2010-09-30|May 2009|Actual|2009-05-31||Observational|LCHA1||Prospective Evaluation of Adult Pulmonary Langerhans Cell Histiocytosis|Epidemiology of Adult Adult Pulmonary Langerhans Cell Histiocytosis - A Multicenter Cohort Study|Completed|||62|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 23:14:23.706991|2018-05-31 23:14:23.706991
NCT01225575|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2018-03-15|2010-10-20|2010-10-21|Estimate|||||||2018-03-15|2018-03-19|Actual|October 2010|Actual|2010-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|September 2013|Actual|2013-09-30||Interventional|||Assessment of Efficacy and Safety of 3 Different Doses of co.Don Chondrosphere to Treat Large Cartilage Defects|Prospective, Randomised, Open Label, Multicentre Phase II Clinical Trial to Investigate the Efficacy and Safety of the Treatment of Large Cartilage Knee Defects(4-10 cm²) With 3 Diff. Doses of the ACT Product co.Don Chondrosphere®|Completed||Phase 2|75|Actual|co.don AG||3|||f||||t||||||||||2018-05-31 23:14:24.016273|2018-05-31 23:14:24.016273
NCT01225562|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2015-11-04||2015-12-18|2010-10-20|2010-10-21|Estimate|2015-11-04|2015-12-09|Estimate||||2015-12-18|2016-01-25|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PEGASUS||Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin|A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction|Completed||Phase 3|21379|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 23:14:24.775616|2018-05-31 23:14:24.775616
NCT01225549|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2015-01-15||2015-03-31|2010-10-20|2010-10-21|Estimate|2015-03-31|2015-04-02|Estimate||||2015-03-31|2015-04-02|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Allergen||The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen|A Double-blind, Double-dummy, Randomised, Placebo-controlled, 4-way, Crossover, Multi-centre Phase II Study With Budesonide as an Active Control to Evaluate the Efficacy and Safety of 2 Doses of Inhaled AZD5423 Over 7 Days in Patients With Mild Allergic Asthma Challenged With an Inhaled Allergen|Completed||Phase 2|27|Actual|AstraZeneca|Of the 27 patients enrolled, 20 (74.1%) patient were randomised to receive a treatment sequence consisting of 4 different treatment in random order. 19 patients completed each individual treatment period and 17 patients completed all 4 treatment|4|||f||||||||||||||2018-05-31 23:14:33.149272|2018-05-31 23:14:33.149272
NCT01225536|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2013-05-02|2010-10-20|2010-10-21|Estimate|||||||2013-05-02|2013-05-03|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations|A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations|Completed||Phase 1|24|Actual|ArQule||1|||f||||f||||||||||2018-05-31 23:14:33.723617|2018-05-31 23:14:33.723617
NCT01225523|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|January 1997||1997-01-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|December 2008|Actual|2008-12-31||Interventional|||Perioperative Vs. Preoperative Chemotherapy With Surgery in the Squamous Carcinoma of Esophagus|Perioperative Versus Preoperative Chemotherapy With Surgery in Patients With Locoregional Squamous Carcinoma of Esophagus|Completed||Phase 1|350|Actual|Health Science Center of Xi’an Jiaotong University||2|||f||||||||||||||2018-05-31 23:14:33.78946|2018-05-31 23:14:33.78946
NCT01225510|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2015-03-10|2010-10-19|2010-10-21|Estimate|||||||2015-03-10|2015-03-11|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma|A Phase 2 Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (Ang-2) Binding CovX-body, In Patients With Recurrent Glioblastoma|Withdrawn||Phase 2|0|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:14:33.862978|2018-05-31 23:14:33.862978
NCT01225497|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Eccentric Exercise for Chronic Mid-portion Achilles Tendinopathy|Effects of Two Eccentric Exercise Protocols on Reported Pain Intensity, Function, and Treatment Satisfaction in Adults With Chronic Mid-portion Achilles Tendinopathies|Unknown status|Not yet recruiting|N/A|52|Anticipated|Queen Margaret University||2|||f||||f||||||||||2018-05-31 23:14:33.934249|2018-05-31 23:14:33.934249
NCT01225484|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2015-04-08|2010-10-20|2010-10-21|Estimate|||||||2015-04-08|2015-04-09|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Perioperative Analgesia After Knee Arthroplasty|Perioperative Analgetic Therapy After Knee Arthroplasty|Unknown status|Recruiting|Phase 4|123|Anticipated|Landeskrankenhaus Feldbach||2|||f||||f||||||||||2018-05-31 23:14:34.012044|2018-05-31 23:14:34.012044
NCT01225471|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2011-06-22|2010-10-20|2010-10-21|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|May 2012|Anticipated|2012-05-31|May 2011|Actual|2011-05-31||Interventional|||Novel Peptide Vaccination for Patients With Advanced Prostate Cancer|Phase1/2 Study of Vaccination With CDCA1 Derived Epitope Peptide for HLA-A24-positive Patients With Advanced Prostate Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Iwate Medical University|||||f||||t||||||||||2018-05-31 23:14:34.082027|2018-05-31 23:14:34.082027
NCT01225458|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2016-09-14|2010-10-20|2010-10-21|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|BCDE||Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)|Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)|Terminated||N/A|48|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 23:14:34.15099|2018-05-31 23:14:34.15099
NCT01225445|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-20|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|April 2002||2002-04-30|April 2002|2002-04-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial|Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial|Completed||Phase 3|60|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:14:34.219663|2018-05-31 23:14:34.219663
NCT01225432|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-10-20|2010-10-20|2010-10-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|August 2007||2007-08-31|October 2010|2010-10-31||||September 2011|Anticipated|2011-09-30||Interventional|VRVO2||The Effect of Gait Training Using Virtual Reality and Real-Time Feedback on Physiological and Functional Gait Performance in Persons With a Traumatic Lower Extremity Amputation|The Effect of Gait Training Using Virtual Reality and Real-Time Feedback on Physiological and Functional Gait Performance in Persons With a Traumatic Lower Extremity Amputation|Unknown status|Enrolling by invitation|N/A|66|Anticipated|Brooke Army Medical Center||1|||f||||f||||||||||2018-05-31 23:14:34.28016|2018-05-31 23:14:34.28016
NCT01225419|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2014-07-04|2010-10-20|2010-10-21|Estimate|||||||2014-07-04|2014-07-08|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|MEP1||Mobilization by Plerixafor of Haematopoietic Stem Cells in Children|Mobilization by Plerixafor of Haematopoietic Stem Cells in Children|Completed||Phase 2|5|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:14:34.395682|2018-05-31 23:14:34.395682
NCT01225406|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2017-01-25|2010-10-19|2010-10-21|Estimate|||||||2017-01-25|2017-01-26|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Observational|||Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children|Treatment Cohort of HIV-infected Children With Resistance or Intolerance to Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) First Line and PI Second Line Antiretroviral Therapy|Completed|||56|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||2||f||||f||||||Samples Without DNA|"~     Plasma and PBMC~   "|||2018-05-31 23:14:34.456638|2018-05-31 23:14:34.456638
NCT01225393|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18||2013-08-20|2016-11-01|2010-10-19|2010-10-21|Estimate||||2013-08-20|2013-08-28|Estimate|2016-11-01|2016-11-02|Estimate|November 2010||2010-11-30|November 2016|2016-11-30||||July 2012|Actual|2012-07-31||Interventional|||A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis|A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patient With Active Rheumatoid Arthritis|Completed||Phase 2|211|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:14:34.553235|2018-05-31 23:14:34.553235
NCT01225380|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18||2013-10-31|2013-12-20|2010-10-19|2010-10-21|Estimate||||2013-10-31|2013-11-26|Estimate|2013-12-20|2014-01-28|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0123)|Completed||Phase 2|324|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 23:14:34.796422|2018-05-31 23:14:34.796422
NCT01225367|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2015-08-12|2010-10-19|2010-10-21|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2010||2010-08-31|May 2011|2011-05-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Observational|||The Use of a Ultra-sound of the Lung to Diagnose Lung Diseases|Detection and Characterization of Cardio-pulmonary Patho-physiological States and Diseases by Ultrasound Transthoracic Doppler|Completed|||120|Actual|Echosense Ltd.|||1||f||||f||||||||||2018-05-31 23:14:35.027023|2018-05-31 23:14:35.027023
NCT01225354|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2012-08-29||2012-09-27|2010-10-19|2010-10-21|Estimate|2012-08-29|2012-09-28|Estimate||||2012-09-27|2012-10-04|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Injectable Filler for Cheek Flattening|An Open-label, Prospective, Postmarket Study to Assess Altering First Impressions and Self-esteem Following Radiesse® Injections.|Completed||Phase 4|20|Actual|DeNova Research||1|||f||||f||||||||||2018-05-31 23:14:35.097554|2018-05-31 23:14:35.097554
NCT01225341|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2015-02-10|2010-10-19|2010-10-21|Estimate|||||||2015-02-10|2015-02-12|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Botulinum Toxin A for Herpes Labialis|A Double-Blind, Randomized, Placebo Controlled, Crossover Study to Assess the Safety and Efficacy of Botulinum Toxin A Injections as a Preventative Measure for Herpes Labialis.|Completed||N/A|20|Actual|DeNova Research||2|||f||||f||||||||||2018-05-31 23:14:35.437926|2018-05-31 23:14:35.437926
NCT01225328|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2014-12-18|2010-10-20|2010-10-21|Estimate|||||||2014-12-18|2014-12-19|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Participation Restrictions in Breast Cancer Survivors|Participation Restrictions in Young-Middle Adult Rural Breast Cancer Survivors|Completed||N/A|24|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 23:14:35.5093|2018-05-31 23:14:35.5093
NCT01225315|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19||2013-03-27|2016-10-12|2010-10-20|2010-10-21|Estimate||||2013-03-27|2013-04-04|Estimate|2016-10-12|2016-10-13|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|CONTROL||Study of ACT-129968 in Adult Patients With Partly Controlled Asthma.|A Multi-center, Double-blind, Placebo-controlled, Parallel-group Study to Establish Proof-of-concept and Explore the Efficacy of Different Doses of ACT-129968 in Adult Patients With Partly Controlled Asthma|Completed||Phase 2|438|Actual|Actelion||4|||f||||t||||||||||2018-05-31 23:14:35.60517|2018-05-31 23:14:35.60517
NCT01225302|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-11-17|2010-10-19|2010-10-21|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2010||2010-09-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase 1 Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment|Completed||Phase 1|12|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 23:14:35.884604|2018-05-31 23:14:35.884604
NCT01225289|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|2013-10-29||2014-02-12|2010-10-20|2010-10-21|Estimate|2014-02-12|2014-03-14|Estimate||||2014-02-12|2014-03-14|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients|The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis|Completed||Phase 4|36|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:14:35.991389|2018-05-31 23:14:35.991389
NCT01225276|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06||2015-06-05|2017-02-20|2010-10-19|2010-10-20|Estimate||||2015-10-16|2015-11-06|Estimate|2017-02-20|2017-02-23|Actual|October 2011||2011-10-31|February 2017|2017-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|POINT||Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP|Double-blind, Placebo-controlled, Randomised, Multicentre, Adaptive, Two-stage Phase 2/3 Study Evaluating Safety and Efficacy of Three Dosages of NewGam in CIDP Patients|Terminated||Phase 2/Phase 3|2|Actual|Octapharma||4||Study Terminated.priority changes in product development.|f||||t||||||||No|no (IPD) data exist for this study|2018-05-31 23:14:36.269028|2018-05-31 23:14:36.269028
NCT01225263|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2015-12-17||2015-12-17|2010-10-19|2010-10-20|Estimate|2015-12-17|2016-01-26|Estimate||||2015-12-17|2016-01-26|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Statin/Vitamin D & Migraine Study|Combined Statin and Vitamin D Therapy for Prophylactic Treatment of Episodic Migraine|Completed||Phase 2|89|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 23:14:36.346599|2018-05-31 23:14:36.346599
NCT01225250|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2015-02-10|2010-10-19|2010-10-20|Estimate|||||||2015-02-10|2015-02-12|Estimate|November 2010||2010-11-30|February 2015|2015-02-28|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Safety and Efficacy Study of Polydioxanone (PDS) Plates in Rhinoplasty|An Open-Label, Randomized, 2-Arm Parallel Study Comparing the Efficacy, Ease of Use, and Safety of PDS Plated Cartilagenous Grafting Versus Non-Plated Cartilagenous Grafting as Performed Through Endonasal Rhinoplasty|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|DeNova Research||2|||f||||f||||||||||2018-05-31 23:14:36.583114|2018-05-31 23:14:36.583114
NCT01225237|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2014-10-14|2010-10-19|2010-10-20|Estimate|||||||2014-10-14|2014-10-15|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients|Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome|Completed||Phase 4|296|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:14:36.649921|2018-05-31 23:14:36.649921
NCT01225224|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers|Phase I Study of ASP015K: Single-Dose and Multiple-Dose Oral Administration in Healthy Nonelderly Men|Completed||Phase 1|72|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 23:14:36.727137|2018-05-31 23:14:36.727137
NCT01225211|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2015-08-01|2015-05-08|2015-09-02|2010-10-19|2010-10-20|Estimate|2015-09-02|2015-10-05|Estimate|2015-05-08|2015-06-02|Estimate|2015-09-02|2015-10-05|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Full Analysis Set (FAS) for Cohort 1, 2, and 3 included all randomized participants who received at least 1 dose of study drug and FAS for Cohort 4 included all randomized participants who received any amount of study drug.|Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation|A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation|Completed||Phase 2|312|Actual|Vertex Pharmaceuticals Incorporated||10|||f||||t||||||||||2018-05-31 23:14:36.961728|2018-05-31 23:14:36.961728
NCT01225198|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|May 2008||2008-05-31|October 2010|2010-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Vitamin/Mineral Supplement for Children and Adults With Autism|New Vitamin/Mineral Supplement for Children and Adults With Autism - National Study|Completed||Phase 2|143|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 23:14:41.406716|2018-05-31 23:14:41.406716
NCT01225185|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2017-08-17|2010-10-19|2010-10-20|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2010||2010-07-31|August 2017|2017-08-31|April 2015|Actual|2015-04-30|March 2014|Actual|2014-03-31||Observational|||Assessing Cerebral Blood Flow Autoregulation During Surgery in the Head-up Position|Assessing Cerebral Blood Flow Autoregulation in the Head-up Versus Supine Position During General Anesthesia and Its Relationship With Postoperative Neurocognitive Changes and Serum Biomarkers of Brain Injury|Completed|||240|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 23:14:41.580836|2018-05-31 23:14:41.580836
NCT01225172|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19||2017-03-22|2017-03-22|2010-10-19|2010-10-20|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|December 2010||2010-12-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors|A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors|Completed||Phase 2|59|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 23:14:41.651976|2018-05-31 23:14:41.651976
NCT01225159|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2014-04-14||2015-11-15|2010-10-19|2010-10-20|Estimate|2015-11-15|2015-12-18|Estimate||||2015-11-15|2015-12-18|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|TGC|Baseline and clinical characteristics of the study patients did not significantly differ between the two groups. There were 18 diabetic patients in the intensive group and 17 diabetic patients in the control group, and there was no difference in terms of the diabetic treatment given (P = 0.77).|Tight Glycaemic Control During Cardiac Surgery|Safety and Efficacy of Tight Glycaemic Control During Cardiac Surgery|Terminated||N/A|200|Actual|Prince of Songkla University||2||Hypoglycaemia is significantly higher in TGC|f||||t||||||||||2018-05-31 23:14:41.750081|2018-05-31 23:14:41.750081
NCT01225146|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2016-02-08||2017-05-02|2010-10-19|2010-10-20|Estimate|2017-05-02|2017-08-14|Actual||||2017-05-02|2017-08-14|Actual|October 2010||2010-10-31|May 2017|2017-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|RAVE2||Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)|A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)|Terminated||Phase 1|8|Actual|Greater Houston Retina Research||2||The collaborator, Genentech, stopped supplying the study drug to the site.|f||||f|t|f||||||No||2018-05-31 23:14:42.147511|2018-05-31 23:14:42.147511
NCT01225133|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-03-30|2010-10-19|2010-10-20|Estimate|||||||2015-03-30|2015-03-31|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|CARAKA||Complex Āyurvedic Treatment in Osteoarthritis of the Knee Compared to Standard Care.|The CARAKA-Trial: Complex Āyurvedic Treatment in Osteoarthritis of the Knee Against Standard Care.A Multicentre, Randomized, Controlled Clinical Trial Based on Traditional Āyurveda-Diagnosis.|Completed||Phase 3|150|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:14:42.51505|2018-05-31 23:14:42.51505
NCT01225120|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|August 2007||2007-08-31|October 2010|2010-10-31||||September 2011|Anticipated|2011-09-30||Interventional|VRGAIT||Amputee Gait Training Using Virtual Reality and Real-Time Feedback|Amputee Gait Training Using Virtual Reality and Real-Time Feedback|Unknown status|Enrolling by invitation|N/A|66|Anticipated|Brooke Army Medical Center||1|||f||||f||||||||||2018-05-31 23:14:42.587204|2018-05-31 23:14:42.587204
NCT01225107|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2016-10-12|2010-10-19|2010-10-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Cranberry Extract on Infections in Burn Patients|A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Cranberry Extract on the Incidence of Infections in Burn Patients|Withdrawn||N/A|0|Actual|Saint Elizabeth Regional Medical Center||2|||f||||f||||||||||2018-05-31 23:14:42.849479|2018-05-31 23:14:42.849479
NCT01225094|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2017-03-06|2010-10-19|2010-10-20|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2011||2011-11-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|November 2014|Actual|2014-11-30||Interventional|||Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair|Curcumin to Prevent Perioperative Complications After Elective Abdominal Aortic Aneurysm Repair: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|606|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 23:14:42.93653|2018-05-31 23:14:42.93653
NCT01225081|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2016-01-18|2010-10-19|2010-10-20|Estimate|||||||2016-01-18|2016-01-20|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients|A Phase 3, Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone|Completed||Phase 3|152|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 23:14:43.052322|2018-05-31 23:14:43.052322
NCT01225068|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2013-04-17||2013-12-05|2010-10-19|2010-10-20|Estimate|2013-07-17|2013-09-25|Estimate||||2013-12-05|2014-01-17|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Effect of Milnacipran in Chronic Neuropathic Low Back Pain|An Exploratory Randomized Placebo Controlled Trial of Milnacipran in Patients With Chronic Neuropathic Low Back Pain|Completed||Phase 2|40|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 23:14:43.150875|2018-05-31 23:14:43.150875
NCT01225055|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2017-05-30||2018-04-10|2010-10-19|2010-10-20|Estimate|2017-05-30|2017-06-22|Actual||||2018-04-10|2018-05-11|Actual|October 2010||2010-10-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury|Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury|Completed||Phase 2|60|Actual|Northwestern University||3|||f||||f||||||||No||2018-05-31 23:14:43.410072|2018-05-31 23:14:43.410072
NCT01225042|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2015-08-26|2010-10-19|2010-10-20|Estimate|||||||2015-08-26|2015-08-27|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|PRETEC||The Effect of Probiotics on E. Coli Gastroenteritis|The Effect of Probiotics on E. Coli Gastroenteritis|Completed||N/A|40|Actual|NIZO Food Research||2|||f||||f||||||||||2018-05-31 23:14:44.095808|2018-05-31 23:14:44.095808
NCT01225029|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2013-09-24||2013-09-24|2010-10-19|2010-10-20|Estimate|2013-09-24|2013-11-28|Estimate||||2013-09-24|2013-11-28|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Fluid Management in Transient Tachypnea of the Newborn|A Randomized Controlled Trial of Fluid Management in Transient Tachypnea of the Newborn|Completed||N/A|64|Actual|Icahn School of Medicine at Mount Sinai|As a small, single center study, our results may not be fully generalizable to the TTN patient population in all hospital types on a national level.|2|||f||||t||||||||||2018-05-31 23:14:44.182217|2018-05-31 23:14:44.182217
NCT01225016|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-01-27|2010-10-19|2010-10-20|Estimate|||||||2012-01-27|2012-01-31|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound|Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound|Withdrawn||N/A|0|Actual|University of Alabama at Birmingham||||"Due to lack of funding and issues with ability to complete all procedures, it was decided that~   this study could not be carried out and therefore withdrawn."|f||||t||||||||||2018-05-31 23:14:44.426803|2018-05-31 23:14:44.426803
NCT01225003|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2011-09-28|2010-10-19|2010-10-20|Estimate|||||||2011-09-28|2011-09-29|Estimate|July 2010||2010-07-31|October 2010|2010-10-31||||||||Observational|||Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas|Diffusion Kurtosis Imaging en MR Spectroscopy in Grading and the Characterization of Tumour Infiltration in Gliomas|Completed|||30|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||||||||Samples Without DNA|"~     standard neurosurgical procedure to obtain specimens; standard histopathological examination~   "|||2018-05-31 23:14:44.479014|2018-05-31 23:14:44.479014
NCT01224990|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2015-04-09|2010-10-19|2010-10-20|Estimate|||||||2015-04-09|2015-04-10|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|November 2014|Actual|2014-11-30||Interventional|s51240||Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Gastro-intestinal Tumors|Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Gastro-intestinal Tumors.|Unknown status|Active, not recruiting|N/A|150|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 23:14:44.541812|2018-05-31 23:14:44.541812
NCT01224977|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2018-02-05|2010-10-19|2010-10-20|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2011||2011-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|BioSput-Air||Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 4.|Recruiting||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 23:14:44.603106|2018-05-31 23:14:44.603106
NCT01224964|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2014-10-22|2010-10-19|2010-10-20|Estimate|||||||2014-10-22|2014-10-23|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BioSput-Air||Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3|Terminated||N/A|1|Actual|Universitaire Ziekenhuizen Leuven||2||"A lot of patients recruited in our center were already on montelukast treatment. It was not~   possible to recruit sufficient patients for the study."|f||||t||||||||||2018-05-31 23:14:44.674342|2018-05-31 23:14:44.674342
NCT01224951|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2018-02-05|2010-10-19|2010-10-20|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2011||2011-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|February 2015|Actual|2015-02-28||Interventional|BioSput-Air||Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 2|Active, not recruiting||N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 23:14:44.732092|2018-05-31 23:14:44.732092
NCT01224938|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-09-25|2010-10-19|2010-10-20|Estimate|||||||2013-09-25|2013-09-27|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|March 2012|Actual|2012-03-31||Observational|BioSput-Air||Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 1.|Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 1.|Completed|||395|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||t||||||Samples Without DNA|"~     lysed sputum cells~   "|||2018-05-31 23:14:44.815235|2018-05-31 23:14:44.815235
NCT01224925|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2015-12-10|2010-10-19|2010-10-20|Estimate|||||||2015-12-10|2015-12-11|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||RCT of Pulp Capping Over Carious Exposures Comparing Mineral Trioxide Aggregate (MTA) With Dycal|Randomized Controlled Trial of Pulp Capping Over Carious Exposures Comparing MTA With Dycal|Completed||N/A|80|Actual|University of Tromso||2|||f||||f||||||||||2018-05-31 23:14:44.873745|2018-05-31 23:14:44.873745
NCT01224912|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-01-07|2010-10-19|2010-10-20|Estimate|||||||2013-01-07|2013-01-08|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|||Internet Delivered Self-Help CBT for Insomnia|Phase 3 Study of Internet-based Self-help for Insomnia: Factors That Are Associated With Success of the Intervention|Completed||Phase 3|479|Actual|Utrecht University||1|||f||||t||||||||||2018-05-31 23:14:44.957679|2018-05-31 23:14:44.957679
NCT01224899|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|December 2006||2006-12-31|October 2010|2010-10-31|July 2010|Actual|2010-07-31|November 2009|Actual|2009-11-30||Interventional|SymBlock||Surgical Sympathetic Blockade in Heart Failure|Left Cervico-Thoracic Sympathetic Blockade by Clipping in Systolic Heart Failure: A Randomised Controlled Trial|Completed||Phase 1|15|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:14:45.127706|2018-05-31 23:14:45.127706
NCT01224886|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2018-05-02|2010-10-19|2010-10-20|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2010||2010-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|AGIR||Age and Insulin Resistance|In French AGIR Means to Get Into Action. This is the Generic Title of Our Study.|Recruiting||N/A|150|Anticipated|University of Lausanne||3|||f||||f||||||||Undecided||2018-05-31 23:14:45.190983|2018-05-31 23:14:45.190983
NCT01224873|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2011-01-10|2010-10-19|2010-10-20|Estimate|||||||2011-01-10|2011-01-11|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|September 2013|Anticipated|2013-09-30|October 2012|Anticipated|2012-10-31||Observational|||Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET|Diagnosis of Sceletal Metastases in c. Mammae: 18F-NaF-PET/Lowdose-CT Versus 99mTc HDP Bone Scintigraphy|Unknown status|Recruiting||110|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 23:14:45.26901|2018-05-31 23:14:45.26901
NCT01224860|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2014-02-24|2010-10-19|2010-10-20|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|COSTANT||Telmisartan Versus Losartan in Kidney Transplantation|A Prospective, Randomized, Open Label Blinded End Point (Probe), Crossover Study to Compare the Effects of Telmisartan and Losartan on Metabolic Profile of Renal Transplant Patients|Completed||Phase 2|20|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 23:14:45.326607|2018-05-31 23:14:45.326607
NCT01224847|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-04-17|2010-10-19|2010-10-20|Estimate|||||||2012-04-17|2012-04-19|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Intravitreal Injection Anesthesia - Comparison of Different Topical Agents|Intravitreal Injection Anesthesia - Comparison of Different Topical Agents.|Completed||N/A|92|Actual|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 23:14:45.395608|2018-05-31 23:14:45.395608
NCT01224834|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-11-05|2010-10-19|2010-10-20|Estimate|||||||2010-11-05|2010-11-08|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Tolerability Study of Ragweed SLIT Tablets|Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets Given in Single Rising Doses and in Multi Dose Regimens to Subjects With an Allergy to Ragweed Pollen.|Completed||Phase 1|60|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-05-31 23:14:45.463177|2018-05-31 23:14:45.463177
NCT01224821|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2012-03-22||2016-10-28|2010-10-19|2010-10-20|Estimate|2012-03-22|2012-04-17|Estimate||||2016-10-28|2016-12-12|Estimate|December 1995||1995-12-31|October 2016|2016-10-31|May 2008|Actual|2008-05-31|November 1997|Actual|1997-11-30||Interventional|RIT-II-001||Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies|Multicenter, Phase II Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies|Completed||Phase 2|47|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:14:45.565666|2018-05-31 23:14:45.565666
NCT01224808|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-10-02|2010-10-19|2010-10-20|Estimate|||||||2017-10-02|2017-10-03|Actual|October 2010||2010-10-31|October 2017|2017-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Extension Study of Biostate in Subjects With Von Willebrand Disease|An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects With Von Willebrand Disease Who Completed Clinical Studies CSLCT-BIO-08-52 or CSLCTBIO-08-54|Completed||Phase 3|20|Actual|CSL Behring||1|||f||||t||||||||||2018-05-31 23:14:46.119391|2018-05-31 23:14:46.119391
NCT01224795|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19||2011-12-14|2014-12-15|2010-10-19|2010-10-20|Estimate||||2011-12-14|2011-12-22|Estimate|2014-12-15|2015-01-06|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.|A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.|Terminated||Phase 3|1|Actual|BioCryst Pharmaceuticals||2||This study was terminated for administrative reasons|f||||t||||||||||2018-05-31 23:14:46.21569|2018-05-31 23:14:46.21569
NCT01224782|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2014-08-13||2014-09-12|2010-10-19|2010-10-20|Estimate|2014-09-12|2014-09-15|Estimate||||2014-09-12|2014-09-15|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)|Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) Stage 3 or 4 in the Conditions of Routine Clinical Practice. A Multi-country, Multi-center Post Marketing Observational Study in Routine Clinical Use in Eastern European Countries.|Completed|||994|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:14:46.441911|2018-05-31 23:14:46.441911
NCT01224769|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2010-10-20|2010-10-19|2010-10-20|Estimate|||||||2010-10-20|2010-10-21|Estimate|September 2005||2005-09-30|October 2010|2010-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders|A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders|Completed|||109|Actual|Gruppo Italiano Studio Linfomi|||1||f||||f||||||||||2018-05-31 23:14:46.839408|2018-05-31 23:14:46.839408
NCT01224756|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2012-01-11|2010-10-19|2010-10-20|Estimate|||||||2012-01-11|2012-01-12|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Tinoridine in Treating Pain and Inflammation in Adults|Safety and Efficacy of Tinoridine in the Treatment of Pain and Inflammation in Patients With Acute Tonsillitis and/or Acute Pharyngitis: a Randomized, Double-blind Study Versus Placebo|Completed||Phase 4|342|Actual|Takeda||2|||f||||t||||||||||2018-05-31 23:14:46.89267|2018-05-31 23:14:46.89267
NCT01224743|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|December 2004||2004-12-31|October 2010|2010-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome|Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome: A Randomized, Controlled, Crossover Trial|Completed||Phase 1/Phase 2|64|Actual|Griffin Hospital||3|||f||||f||||||||||2018-05-31 23:14:46.962087|2018-05-31 23:14:46.962087
NCT01224730|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2018-03-12|2010-10-19|2010-10-20|Estimate|||||||2018-03-12|2018-03-14|Actual|January 24, 2012|Actual|2012-01-24|May 2012|2012-05-31|November 4, 2013|Actual|2013-11-04|November 4, 2013|Actual|2013-11-04||Interventional|||A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies|A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies|Completed||Phase 1|24|Actual|AEterna Zentaris||1|||f||||t||||||||||2018-05-31 23:14:47.026558|2018-05-31 23:14:47.026558
NCT01224717|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-05-12|2010-10-19|2010-10-20|Estimate|||||||2011-05-12|2011-05-13|Estimate|September 2010||2010-09-30|May 2011|2011-05-31||||April 2011|Actual|2011-04-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women|A Phase I, Partially Blinded, Randomized, Placebo Controlled, Active Comparator Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Post-menopausal Women After Daily Oral Doses of PTH134|Completed||Phase 1|104|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:14:47.205687|2018-05-31 23:14:47.205687
NCT01224704|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2018-03-20|2010-10-19|2010-10-20|Estimate|||||||2018-03-20|2018-03-21|Actual|October 19, 2010||2010-10-19|March 14, 2018|2018-03-14||||||||Observational|||Water Deprivation Protocol|Assessment of Thirst and Role of Water/Electrolytes Homeostasis During Water Deprivation in Obesity|Recruiting|||88|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:14:47.277385|2018-05-31 23:14:47.277385
NCT01224691|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2018-01-09|2010-10-19|2010-10-20|Estimate|||||||2018-01-09|2018-01-10|Actual|October 19, 2010||2010-10-19|December 27, 2017|2017-12-27||||||||Observational|||TGF-(Beta) and Susceptibility to RSV|The Role of TGF-Beta in Asthmatic Epithelial Cell Susceptibility to RSV Infection|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:14:47.342694|2018-05-31 23:14:47.342694
NCT01224678|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2016-06-17|2010-10-19|2010-10-20|Estimate|||||||2016-06-17|2016-06-21|Estimate|October 2010||2010-10-31|June 2016|2016-06-30||||December 2014|Actual|2014-12-31||Interventional|||Vitamin D and Breast Cancer Biomarkers in Female Patients|Vitamin D and Breast Cancer Biomarkers|Active, not recruiting||Phase 3|250|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 23:14:47.434245|2018-05-31 23:14:47.434245
NCT01224665|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2017-04-20|2010-10-19|2010-10-20|Estimate|||||||2017-04-20|2017-04-24|Actual|August 2011||2011-08-31|April 2017|2017-04-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer|A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer|Recruiting||N/A|620|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 23:14:47.762833|2018-05-31 23:14:47.762833
NCT01224652|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate||||October 2010|2010-10-31||||||||Interventional|||Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy|A Randomized, Multicenter Phase III Study to Assess the Efficacy of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy|Unknown status|Recruiting|Phase 3|518|Anticipated|Korean Cancer Study Group||2|||f||||t||||||||||2018-05-31 23:14:47.983306|2018-05-31 23:14:47.983306
NCT01224639|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-09|2017-01-09||2018-01-05|2010-10-19|2010-10-20|Estimate|2017-01-09|2017-02-27|Actual||||2018-01-05|2018-01-30|Actual|October 11, 2010|Actual|2010-10-11|January 2018|2018-01-31|November 9, 2011|Actual|2011-11-09|June 9, 2011|Actual|2011-06-09||Interventional||The safety population included all randomized participants who received at least one dose of study vaccine and for whom post-dosing safety data was obtained.|Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever|Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults|Completed||Phase 1|96|Actual|Takeda||6|||f||||f|t|f||||||||2018-05-31 23:14:48.169244|2018-05-31 23:14:48.169244
NCT01224626|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2012-03-28||2012-05-29|2010-10-19|2010-10-20|Estimate|2012-05-29|2012-07-02|Estimate||||2012-05-29|2012-07-02|Estimate|May 2006||2006-05-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)|Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)(Regulatory Post Marketing Commitment Plan)|Completed|||41|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:14:50.210295|2018-05-31 23:14:50.210295
NCT01224613|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2011-06-14|2010-10-19|2010-10-20|Estimate|||||||2011-06-14|2011-06-15|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine|A Randomized Controlled Trial To Compare The Immunogenicity Of Self-Administered And Nurse-Administered Intradermal Influenza Vaccine|Completed||Phase 4|276|Anticipated|Dalhousie University||2|||f||||f||||||||||2018-05-31 23:14:50.454242|2018-05-31 23:14:50.454242
NCT01224600|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-03-05|2010-10-19|2010-10-20|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2011|Actual|2011-03-31||Observational|EVART||EValuation of Systemic Atherothrombosis in Patients With ARTerial Disease of the Lower Limbs|EValuation of Systemic Atherothrombosis in Patients With ARTerial Disease of the Lower Limbs|Completed|||1056|Actual|Institut de l'Atherothrombose|||1||f||||t||||||||||2018-05-31 23:14:50.587833|2018-05-31 23:14:50.587833
NCT01224587|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-11-03|2010-10-19|2010-10-20|Estimate|||||||2010-11-03|2010-11-04|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|MMM||Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions|Characterisation of Gastrointestinal Transit of Four New Developed Gel Matrix Tablets With Different Erosion Rates by Means of MMM Measurement Under Fasting and Fed Conditions|Completed||Phase 1|5|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 23:14:51.73355|2018-05-31 23:14:51.73355
NCT01224574|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|January 2001||2001-01-31|September 2010|2010-09-30|July 2007|Actual|2007-07-31|July 2006|Actual|2006-07-31||Observational|COAGFAII||To Assess the Predictive Value of D-dimer Level on the Occurrence of Cardiovascular Events|Place Des D-dimères Dans la Prise en Charge Des Patients en Fibrillation Auriculaire : Evaluation de la Valeur prédictive Des D-dimères Sur la Survenue d'événements Thromboemboliques|Completed|||425|Actual|Hopital Lariboisière|||||f||||f||||||Samples Without DNA|"~     No biospecimens are to be retained~   "|||2018-05-31 23:14:51.795447|2018-05-31 23:14:51.795447
NCT01224561|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-05-04|2010-10-19|2010-10-20|Estimate|||||||2011-05-04|2011-05-05|Estimate|March 2008||2008-03-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|Surnutrition||Adaptation of Lipid and Energy Metabolism During a Lipid Overnutrition in Constitutional Thinness|Adaptation of Lipid and Energy Metabolism During a Lipid Overnutrition in Constitutional Thinness|Completed|||26|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples With DNA|"~     muscle tissue fat tissue~   "|||2018-05-31 23:14:51.84929|2018-05-31 23:14:51.84929
NCT01224548|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-01-23|2010-10-18|2010-10-20|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|WNS2||Multicenter Worksite Nutrition Study|Multicenter Worksite Nutrition Study|Completed||N/A|292|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 23:14:52.007446|2018-05-31 23:14:52.007446
NCT01224535|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-09-28|2010-10-19|2010-10-20|Estimate|||||||2011-09-28|2011-09-29|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Improving Iron Status of Children: Potential of Amaranth|Improving Iron Status of Children in a Semi-arid Area of Kenya: the Potential of Amaranth Grain Flour|Completed||N/A|270|Anticipated|Wageningen University||3|||f||||f||||||||||2018-05-31 23:14:52.118768|2018-05-31 23:14:52.118768
NCT01224522|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2015-04-13|2010-10-19|2010-10-20|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Visionaire||Axial Alignment in Patients Operated Using the Visionaire Patient Matched Cutting Blocks|PATIENT-MATCHED INSTRUMENTATION Versus (vs) STANDARD INSTRUMENTATION: A RANDOMIZED CLINICAL TRIAL COMPARING POSTOPERATIVE AXIAL ALIGNMENT and COMPONENT POSITION|Terminated||Phase 3|70|Actual|Smith & Nephew, Inc.||2||protocol deviations|f||||f||||||||||2018-05-31 23:14:52.192879|2018-05-31 23:14:52.192879
NCT01224509|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|September 2004||2004-09-30|October 2010|2010-10-31|March 2005|Actual|2005-03-31|||||Interventional|EP3||The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors|Cervical Prostaglandin EP3 Receptor mRNA Expression 48 Hours After Administration of Mifepristone|Terminated||N/A|18|Actual|University of Southern California||2||Longer than expected recruitment period.|f||||f||||||||||2018-05-31 23:14:52.277003|2018-05-31 23:14:52.277003
NCT01224496|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2017-02-09|2010-10-18|2010-10-20|Estimate|||||||2017-02-09|2017-02-10|Actual|July 2009||2009-07-31|February 2017|2017-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders|Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders|Completed||Phase 1/Phase 2|38|Actual|Singapore General Hospital||1|||f||||t||||||||||2018-05-31 23:14:52.35217|2018-05-31 23:14:52.35217
NCT01224314|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|September 2007||2007-09-30|August 2007|2007-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Potassium in Haemodialysis Fluids and Haemodynamics|Haemodynamic Consequences of Changing Potassium Concentrations in Haemodialysis Fluids|Completed||N/A|24|Actual|Ospedale Regionale di Locarno||2|||f||||f||||||||||2018-05-31 23:14:53.993903|2018-05-31 23:14:53.993903
NCT01224483|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Observational|||Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients|Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Patients With PNH|Unknown status|Recruiting||350|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-05-31 23:14:52.420477|2018-05-31 23:14:52.420477
NCT01224470|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2011-04-27|2010-10-19|2010-10-20|Estimate|||||||2011-04-27|2011-04-28|Estimate|November 2010||2010-11-30|April 2011|2011-04-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate|The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate|Completed||N/A|51|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:14:52.476428|2018-05-31 23:14:52.476428
NCT01224457|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2012-01-26|2010-10-19|2010-10-20|Estimate|||||||2012-01-26|2012-01-31|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.|Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.|Completed||N/A|52|Actual|Yonsei University|||||f||||f||||||||||2018-05-31 23:14:52.531385|2018-05-31 23:14:52.531385
NCT01224444|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|2013-12-16||2014-12-30|2010-10-19|2010-10-20|Estimate|2014-12-30|2015-01-12|Estimate||||2014-12-30|2015-01-12|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Observational|CARE||Complete Histologic Resection of Adenomatous Polyps?|Complete Histologic Resection of Adenomatous Polyps? (Complete Adenoma REsection Trial - CARE Trial)|Completed|||269|Actual|White River Junction Veterans Affairs Medical Center|||1||f||||t||||||Samples Without DNA|"~     Biopsies will be taken from resection margins: 2 biopsies will be obtained from opposite~     margins for polyps 5-9mm, and 4 biopsies will be taken for polyps 10-20mm from all four~     quadrants of the resection margins.~   "|||2018-05-31 23:14:52.581857|2018-05-31 23:14:52.581857
NCT01224431|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2011-04-05||2017-09-18|2010-10-19|2010-10-20|Estimate|2011-05-13|2011-06-14|Estimate||||2017-09-18|2017-09-20|Actual|June 2009||2009-06-30|September 2017|2017-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Needle-Free Jet Injection of Lidocaine During Lumbar Puncture|Needle-Free Jet Injection of Lidocaine for Local Anesthesia During Lumbar Puncture: A Randomized Controlled Trial|Completed||N/A|60|Actual|Phoenix Children's Hospital||2|||f||||f||||||||||2018-05-31 23:14:52.718776|2018-05-31 23:14:52.718776
NCT01224418|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|May 2008||2008-05-31|October 2010|2010-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate|Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study|Completed||Phase 4|50|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 23:14:52.892461|2018-05-31 23:14:52.892461
NCT01224405|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|April 2016|Anticipated|2016-04-30|August 2010|Actual|2010-08-31||Interventional|PON-PC-02||Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy|Androgen Deprivation Withdrawal Versus Maintenance and Intermittent Chemotherapy Versus Continuous in Prostate Cancer Patients With Castrate Resistant Disease|Unknown status|Active, not recruiting|Phase 3|600|Anticipated|University of Turin, Italy||4|||f||||t||||||||||2018-05-31 23:14:52.994627|2018-05-31 23:14:52.994627
NCT01224392|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2013-04-29|2010-10-19|2010-10-20|Estimate|||||||2013-04-29|2013-04-30|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|RectumSIB||Simultaneous Integrated Boost Preoperative Radiotherapy for Rectum Cancer|Randomized Trial of Preoperative Radiotherapy With an Integrated Simultaneous Boost Compared to Chemoradiotherapy for T3-4 Rectal Cancer|Unknown status|Recruiting|Phase 3|156|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 23:14:53.19309|2018-05-31 23:14:53.19309
NCT01224379|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|Topping-off||"Comparison of Standard Fusion With Topping Off-System in Lumbar Spine"|Clinical Trial of the Efficacy of Hybrid Systems(Topping Off)in Comparison to the Conventional Spondylodesis in Fusion-surgery in the Lumbal Spine: a Prospective, Randomised Study|Unknown status|Not yet recruiting|N/A|30|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 23:14:53.297546|2018-05-31 23:14:53.297546
NCT01224366|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2017-02-21|2010-10-19|2010-10-20|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2010||2010-09-30|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus|A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.|Completed||Phase 3|448|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:14:53.432968|2018-05-31 23:14:53.432968
NCT01224353|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-17|||2010-10-19|2010-10-18|2010-10-20|Estimate|||||||2010-10-19|2010-10-21|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|May 2011|Anticipated|2011-05-31||Interventional|||Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy|Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Thioctacid Oral Tablet 600mg Once Daily in Chinese Diabetic Patients With Distal Symmetric Polyneuropathy|Unknown status|Not yet recruiting|Phase 2/Phase 3|200|Anticipated|NovaMed Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 23:14:53.633941|2018-05-31 23:14:53.633941
NCT01224340|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|May 2008||2008-05-31|May 2007|2007-05-31||||June 2010|Actual|2010-06-30||Interventional|||Active and Passive Distraction in Children Undergoing Wound Dressings||Completed||N/A|60|Actual|Sahlgrenska University Hospital, Sweden||3|||f||||||||||||||2018-05-31 23:14:53.727947|2018-05-31 23:14:53.727947
NCT01224327|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-19|2010-10-19|2010-10-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients|The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion Via Hepatic Artery in Cirrhosis Patients.|Unknown status|Not yet recruiting|Phase 1/Phase 2|50|Anticipated|Qingdao University||2|||f||||t||||||||||2018-05-31 23:14:53.791065|2018-05-31 23:14:53.791065
NCT01224288|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2017-10-23|2010-10-18|2010-10-20|Estimate|||||||2017-10-23|2017-10-25|Actual|January 2011|Actual|2011-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble|Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Companion to Protocol 2010-0085|Active, not recruiting||Phase 3|120|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:14:54.195212|2018-05-31 23:14:54.195212
NCT01224275|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2011-06-24|2010-10-19|2010-10-20|Estimate|||||||2011-06-24|2011-06-27|Estimate|August 2008||2008-08-31|September 2008|2008-09-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Group Based Care Versus Individual Care|Group Based Care Versus Individual Care- Effects on Parents Satisfaction and Health|Unknown status|Recruiting|N/A|1150|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 23:14:54.286801|2018-05-31 23:14:54.286801
NCT01224262|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14||2013-01-22|2013-02-25|2010-10-19|2010-10-20|Estimate||||2013-02-21|2013-02-25|Estimate|2013-02-25|2013-03-01|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|LIfT||A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001|A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older.|Completed||Phase 1/Phase 2|152|Actual|Liquidia Technologies, Inc.||3|||f||||||||||||||2018-05-31 23:14:54.345755|2018-05-31 23:14:54.345755
NCT01224249|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-09-28|2010-10-19|2010-10-20|Estimate|||||||2011-09-28|2011-09-29|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Selenium Status Measured in Blood After a Higher Intake of Fish and Shellfish - a Randomized Dietary Intervention Study|Selenium Status Measured in Blood After a Higher Intake of Fish and Shellfish - a Randomized Dietary Intervention Study|Completed||Phase 1|102|Actual|Danish Cancer Society||2|||f||||t||||||||||2018-05-31 23:14:54.414515|2018-05-31 23:14:54.414515
NCT01224236|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2013-07-03||2015-06-17|2010-10-18|2010-10-19|Estimate|2015-06-17|2015-06-19|Estimate||||2015-06-17|2015-06-19|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Randomized Trial of Iron Supplementation to Prevent Anemia in Very-low-birth-weight Infants|Randomized Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight (VLBW) Infants|Completed||Phase 2/Phase 3|150|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:14:54.481181|2018-05-31 23:14:54.481181
NCT01224223|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-06-27|2010-10-18|2010-10-19|Estimate|||||||2012-06-27|2012-06-28|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Myeloid Suppressors in Inflammation|Myeloid Suppressors in Inflammation|Completed|||20|Actual|University of South Florida|||2||f||||f||||||||||2018-05-31 23:14:54.726062|2018-05-31 23:14:54.726062
NCT01224210|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2018-04-23|2010-10-18|2010-10-19|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2010||2010-03-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2016|Actual|2016-10-31||Interventional|Portopulm||Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial|Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial|Active, not recruiting||N/A|30|Actual|Tufts Medical Center||1|||f||||t||||||||No||2018-05-31 23:14:54.785713|2018-05-31 23:14:54.785713
NCT01224197|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2014-05-07|2010-10-18|2010-10-19|Estimate|||||||2014-05-07|2014-05-08|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese Volunteers|Phase I, Open Label, Randomized Study to Examine the Pharmacokinetics, Safety and Tolerability of Different Oral Doses of TMC435 After Single and Repeated Dosing in Healthy Chinese Subjects|Completed||Phase 1|32|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||f||||||||||2018-05-31 23:14:54.866289|2018-05-31 23:14:54.866289
NCT01224184|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2013-10-16|2010-10-18|2010-10-19|Estimate|||||||2013-10-16|2013-10-17|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|YWC||Young Women's CoOp Study|Adapting the Women's CoOp for At-Risk Teens|Completed||N/A|237|Actual|RTI International||2|||f||||f||||||||||2018-05-31 23:14:54.938561|2018-05-31 23:14:54.938561
NCT01224171|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2014-06-19|2013-03-07|2014-06-19|2010-10-18|2010-10-19|Estimate|2014-06-19|2014-07-21|Estimate|2013-03-07|2013-03-15|Estimate|2014-06-19|2014-07-21|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|GEMINI III|The Overall Intent-to-treat (ITT) Population consisted of all randomized participants who received any amount of blinded study drug.|Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease|A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn's Disease|Completed||Phase 3|416|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:14:55.050537|2018-05-31 23:14:55.050537
NCT01224158|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2011-10-04|2010-10-18|2010-10-19|Estimate|||||||2011-10-04|2011-10-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:14:55.967239|2018-05-31 23:14:55.967239
NCT01224145|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-04-29|2010-10-18|2010-10-19|Estimate|||||||2013-04-29|2013-04-30|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Assess the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant in Men After Laparoscopic Inguinal or Umbilical Herniorrhaphy|A Phase II, Single-dose, Open-label Study to Investigate the Feasibility and Efficacy of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Laparoscopic Inguinal or Umbilical Herniorrhaphy|Completed||Phase 2|10|Actual|Innocoll||1|||f||||f||||||||||2018-05-31 23:14:56.001557|2018-05-31 23:14:56.001557
NCT01224132|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Probiotics in the Atopic Dermatitis|Effect of Probiotics in the Treatment of Children With Atopic Dermatitis|Completed||Phase 3|40|Actual|Yuzuncu Yıl University||2|||f||||f||||||||||2018-05-31 23:14:56.071336|2018-05-31 23:14:56.071336
NCT01224119|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-03-07|2010-10-18|2010-10-19|Estimate|||||||2012-03-07|2012-03-09|Estimate|January 2011||2011-01-31|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||A Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery|A Multi-Center, Randomized, Pilot Study Evaluating Amplex Compared To Autograft Bone In Foot and Ankle Fusion Surgery|Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Anticipated|BioSurface Engineering Technologies, Inc||2|||f||||t||||||||||2018-05-31 23:14:56.125025|2018-05-31 23:14:56.125025
NCT01224106|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2018-05-10|2010-10-18|2010-10-19|Estimate|||||||2018-05-10|2018-05-11|Actual|November 30, 2010|Actual|2010-11-30|May 2018|2018-05-31|July 22, 2020|Anticipated|2020-07-22|June 22, 2015|Actual|2015-06-22||Interventional|||A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease and Up to Three Years of an Open-Label Extension With Active Study Treatment|Active, not recruiting||Phase 3|799|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:14:56.224299|2018-05-31 23:14:56.224299
NCT01224093|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2016-11-01|2010-10-18|2010-10-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)|A Multicentre, Observational, Prospective Study to Assess the Safety Profile of Rituximab in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (B-CLL)|Completed|||219|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 23:14:56.559424|2018-05-31 23:14:56.559424
NCT01224080|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||October 2011|Anticipated|2011-10-31||Interventional|||Use of Adiana Tubal Occlusive Devices in Women With Hydrosalpinx Prior to In Vitro Fertilization||Unknown status|Recruiting|Phase 2|10|Anticipated|Reproductive Science Center||1|||f||||||||||||||2018-05-31 23:14:56.708456|2018-05-31 23:14:56.708456
NCT01224067|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2017-04-17|2010-10-18|2010-10-19|Estimate|||||||2017-04-17|2017-04-18|Actual|March 2006||2006-03-31|April 2017|2017-04-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults|A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults|Completed||Phase 4|40|Anticipated|Cambridge Health Alliance||2|||f||||f||||||||||2018-05-31 23:14:56.77368|2018-05-31 23:14:56.77368
NCT01224054|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2008||2008-07-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Observational|||Food and Gastrointestinal Habits After Bariatric Surgery|Food Tolerance in Patients Submitted to Bariatric Surgery|Completed|||34|Actual|University of Campinas, Brazil|||3||f||||f||||||||||2018-05-31 23:14:56.83509|2018-05-31 23:14:56.83509
NCT01224041|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2015-12-28|2010-10-18|2010-10-19|Estimate|||||||2015-12-28|2015-12-29|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate|Clinical Study to Evaluate the Efficacy of Tacrolimus in Active Rheumatoid Arthritis Patients Shown Unsuccessful Response Against Methotrexate: Non-comparative, Single Arm, Multi-center, Phase 4 Study|Completed||Phase 4|78|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 23:14:56.886796|2018-05-31 23:14:56.886796
NCT01224028|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2014-08-20|2010-10-18|2010-10-19|Estimate|||||||2014-08-20|2014-08-21|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients|Double-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA Nephropathy|Completed||Phase 2|40|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:14:56.981671|2018-05-31 23:14:56.981671
NCT01224015|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2013-09-27|2012-10-22|2014-02-24|2010-10-18|2010-10-19|Estimate|2014-02-24|2014-02-25|Estimate|2012-10-22|2012-10-26|Estimate|2014-02-24|2014-02-25|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines||Completed||Phase 3|684|Actual|Allergan||3|||f||||f||||||||||2018-05-31 23:14:57.05759|2018-05-31 23:14:57.05759
NCT01224002|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-16|||2012-11-20|2010-10-18|2010-10-19|Estimate|||||||2012-11-20|2012-11-21|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|November 2012||2012-11-30|||||Observational|||A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine|A Comparative Feasibility Study to Assess the Prevalence and Severity of Dental Caries in Incarcerated People Who Abuse Methamphetamine|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:14:57.345302|2018-05-31 23:14:57.345302
NCT01223989|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|March 2009||2009-03-31|October 2010|2010-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Bread in Overweight/Obesity Treatment|Evaluation of the Utility of an Hypocaloric Diet With or Without Bread in Overweight/Obesity Treatment|Completed||Phase 4|122|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||2|||f||||f||||||||||2018-05-31 23:14:57.397908|2018-05-31 23:14:57.397908
NCT01223976|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|August 2011|Anticipated|2011-08-31|June 2011|Anticipated|2011-06-30||Interventional|||Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis|Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:14:57.456369|2018-05-31 23:14:57.456369
NCT01223963|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2014-03-14||2017-05-12|2010-10-18|2010-10-19|Estimate|2017-05-12|2017-12-15|Actual||||2017-05-12|2017-12-15|Actual|March 2010||2010-03-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Macrolane Retrospective Study|A Multi-center Retrospective Chart Review of Medical Records on the Use of Macrolane Volume Restoration Factor for Breast Enhancement|Completed|||93|Actual|Q-Med AB|||1||f||||f||||||||||2018-05-31 23:14:57.541413|2018-05-31 23:14:57.541413
NCT01223950|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|August 2010||2010-08-31|October 2010|2010-10-31||||September 2010|Actual|2010-09-30||Observational|||Monitoring the Prevalence of E.R Admissions and Hospitalizations as a Result of Drug Related Problems (DRPs)||Completed|||12350|Actual|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-05-31 23:14:57.694416|2018-05-31 23:14:57.694416
NCT01223729|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|April 2002||2002-04-30|December 2000|2000-12-31|November 2005||2005-11-30|||||Interventional|||Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy|Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy|Completed||N/A|67||University of Catania||2|||f||||t||||||||||2018-05-31 23:14:59.166591|2018-05-31 23:14:59.166591
NCT01223937|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2015-06-19|2012-04-26|2015-09-16|2010-10-18|2010-10-19|Estimate|2015-09-16|2015-10-15|Estimate|2012-04-26|2012-04-27|Estimate|2015-09-16|2015-10-15|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|COMFORT|Demographic data offered from the Full Analysis Set population.|Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Demonstrate the Efficacy and Safety of Desmopressin Orally Disintegrating Tablet for the Treatment of Nocturia in Adult Females|Completed||Phase 3|268|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:14:57.771124|2018-05-31 23:14:57.771124
NCT01223924|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-09|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|May 2009||2009-05-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Single-dose Escalation Trial of M2ES in Healthy Volunteer|Randomized ，Placebo-controlled,Single-dose Escalation Trial of M2ES in Healthy Volunteer|Completed||Phase 1|33|Actual|Protgen Ltd||2|||f||||t||||||||||2018-05-31 23:14:58.215334|2018-05-31 23:14:58.215334
NCT01223911|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14||2013-04-10|2017-02-08|2010-10-18|2010-10-19|Estimate||||2013-04-10|2013-04-16|Estimate|2017-02-08|2017-02-09|Estimate|January 2011||2011-01-31|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis|Completed||Phase 2|34|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:14:58.350595|2018-05-31 23:14:58.350595
NCT01223898|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2016-04-20|2010-10-18|2010-10-19|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib|An Open-label, Two-period, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics of Midazolam in CML Patients Who Are Resistant and/or Intolerant Against at Least One Prior Therapy With a BCR-ABL Tyrosine Kinase Inhibitor|Completed||Phase 1|19|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:14:58.443975|2018-05-31 23:14:58.443975
NCT01223885|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2015-10-07|2010-10-18|2010-10-19|Estimate|||||||2015-10-07|2015-10-08|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Camel's Milk as a Safe Alternative in Cow's Milk Allergy||Completed||N/A|30|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 23:14:58.5116|2018-05-31 23:14:58.5116
NCT01223872|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-03-30|2010-10-18|2010-10-19|Estimate|||||||2017-03-30|2017-04-04|Actual|August 2010||2010-08-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|||Childhood Cancer Survivors' Knowledge of Diagnosis,Treatment and Risk of Late Effects: Specialized Survivorship Clinic|Childhood Cancer Survivors' Knowledge of Their Diagnosis, Treatment, and Risk of Late Effects: The Impact of Care in a Specialized Survivorship Clinic|Completed|||188|Actual|Vanderbilt University Medical Center|||3||f||||f||||||||||2018-05-31 23:14:58.571974|2018-05-31 23:14:58.571974
NCT01223859|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|January 2008||2008-01-31|October 2007|2007-10-31|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|||Pretreatment Assessment of Oropharynx Ans Soft Palate Radiofrequency Surgery - a Multi-center Study|The Impact of Pretreatment Assessment of Oropharynx on Interstitial Soft Palate Radiofrequency Surgery Outcome - a Multi-center Study in Patients With Habitual Snoring|Completed||N/A|74|Actual|Helsinki University||1|||f||||f||||||||||2018-05-31 23:14:58.631313|2018-05-31 23:14:58.631313
NCT01223833|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2013-07-24|2010-10-18|2010-10-19|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|LOGRIBMET||A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen|A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen|Completed|||296|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:14:58.703764|2018-05-31 23:14:58.703764
NCT01223820|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-09-30|2010-10-18|2010-10-19|Estimate|||||||2011-09-30|2011-10-03|Estimate|January 2011||2011-01-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin.|Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin.|Completed||Phase 4|36|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||||2018-05-31 23:14:58.767749|2018-05-31 23:14:58.767749
NCT01223807|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|June 2008||2008-06-30|June 2008|2008-06-30||||December 2009|Actual|2009-12-31||Interventional|||Effects of a Diaphragmatic Breathing Training Program in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of a Short-term Diaphragmatic Breathing Training Program in COPD Patients: a Randomized Controlled Trial|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:14:58.834361|2018-05-31 23:14:58.834361
NCT01223794|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-17|||2011-04-21|2010-10-18|2010-10-19|Estimate|||||||2011-04-21|2011-04-26|Estimate|February 2010||2010-02-28|April 2011|2011-04-30|December 2010|Actual|2010-12-31|||||Observational|||Fall Risk Assessment for Inpatient|Fall Risk Assessment for Inpatient|Completed|||1000|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 23:14:58.88548|2018-05-31 23:14:58.88548
NCT01223781|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-17|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|May 2012|Anticipated|2012-05-31|January 2012|Anticipated|2012-01-31||Interventional|||Biofeedback-based Motor Learning to Ameliorate Freezing of Gait|Biofeedback-based Motor Learning to Ameliorate Freezing of Gait|Unknown status|Not yet recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 23:14:58.933149|2018-05-31 23:14:58.933149
NCT01223768|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2002||2002-07-31|December 2000|2000-12-31|December 2005||2005-12-31|||||Interventional|||Acetyl-L-Carnitine In Severe Hepatic Encephalopathy||Completed||N/A|||University of Catania||2|||f||||||||||||||2018-05-31 23:14:59.000354|2018-05-31 23:14:59.000354
NCT01223755|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-02-22|2010-10-18|2010-10-19|Estimate|||||||2013-02-22|2013-02-25|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SIRENA-II||Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency|EFFECTS OF SIROLIMUS ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND SEVERE RENAL INSUFFICIENCY|Terminated||Phase 2/Phase 3|41|Actual|Mario Negri Institute for Pharmacological Research||2||safety and efficacy reason|f||||f||||||||||2018-05-31 23:14:59.049876|2018-05-31 23:14:59.049876
NCT01223716|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2016-05-14|2010-10-18|2010-10-19|Estimate|||||||2016-05-14|2016-05-17|Estimate|December 2004||2004-12-31|May 2016|2016-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||An Active Approach to Treat Amblyopia: Video Game Play|Does Video Game Play Induce Plasticity in the Visual System of Adults With Amblyopia?|Completed||N/A|20|Actual|University of California, Berkeley||3|||f||||f||||||||Undecided||2018-05-31 23:14:59.233033|2018-05-31 23:14:59.233033
NCT01223703|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2011-04-11||2012-01-27|2010-10-18|2010-10-19|Estimate|2011-06-24|2011-07-25|Estimate||||2012-01-27|2012-01-31|Estimate|November 2007||2007-11-30|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|CS-PUFA-02||PUFAs and Left Ventricular Function in Heart Failure|Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy|Completed||Phase 3|133|Actual|Università degli Studi di Brescia|Our investigation was a single-center trial with a small sample size and a limited number of clinical events. Therefore, our results cannot be generalized to HF patients.|2|||f||||t||||||||||2018-05-31 23:14:59.314384|2018-05-31 23:14:59.314384
NCT01223690|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2011-08-03|2010-10-18|2010-10-19|Estimate|||||||2011-08-03|2011-08-04|Estimate|July 2007||2007-07-31|October 2010|2010-10-31|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|||Clarithromycin as Immunomodulator for the Management of Sepsis|A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis|Completed||Phase 3|600|Actual|University of Athens||2|||f||||t||||||||||2018-05-31 23:14:59.568154|2018-05-31 23:14:59.568154
NCT01223677|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2014-12-01|2010-10-18|2010-10-19|Estimate|||||||2014-12-01|2014-12-03|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Rumination-focused CBT Training for the Prevention of Depression and Anxiety|Randomized Controlled Trial Evaluating Two Versions of a Rumination-focused CBT Training for the Presence of Depression and Anxiety in Adolescents and Young Adults|Completed||Phase 1|251|Actual|VU University of Amsterdam||3|||f||||t||||||||||2018-05-31 23:14:59.684706|2018-05-31 23:14:59.684706
NCT01223664|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis|The Efficacy of Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis Resulting From Chronic Hepatitis B|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:14:59.762153|2018-05-31 23:14:59.762153
NCT01223651|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2015-10-26|2010-10-18|2010-10-19|Estimate|||||||2015-10-26|2015-10-28|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Performance of Continuous Glucose Monitoring Systems at Altitude|Performance of Continuous Glucose Monitoring Systems at Altitude.|Terminated||N/A|10|Actual|The Royal Bournemouth Hospital||2||Suspended awaiting Ministry of Defence ethics approval.|f||||f||||||||||2018-05-31 23:14:59.835329|2018-05-31 23:14:59.835329
NCT01223638|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2015-07-06|2010-10-18|2010-10-19|Estimate|||||||2015-07-06|2015-07-08|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2012|Actual|2012-12-31||Observational|||The Prevalence of Hearing Loss Among Children With Congenital Hypothyroidism||Withdrawn|||0|Actual|HaEmek Medical Center, Israel|||2|written here by mistake|f||||||||||||||2018-05-31 23:14:59.951501|2018-05-31 23:14:59.951501
NCT01223625|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|November 2007||2007-11-30|July 2007|2007-07-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Endothelial Function|Completed||Phase 4|87|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 23:15:00.03549|2018-05-31 23:15:00.03549
NCT01223612|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2013-02-19|2010-10-18|2010-10-19|Estimate|||||||2013-02-19|2013-02-20|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|LUCIDATE||Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation|Diabetic Macula Oedema. A Prospective Randomised Study Comparing the Detailed Functional and Anatomical Changes of Repeated Pan Anti-VEGF Therapy With Ranibizumab Versus Conventional Macular Laser Therapy.|Completed||Phase 4|37|Actual|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 23:15:00.121516|2018-05-31 23:15:00.121516
NCT01223599|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|April 2008||2008-04-30|October 2010|2010-10-31|March 2010||2010-03-31|||||Observational|non||Rhomboid Flap Versus Primary Closure After Excision of Sacrococcygeal Pilonidal Sinus. (A Prospective Randomized Study)|Rhomboid Flap Versus Primary Closure|Withdrawn|||140|Actual|Mansoura University|||||f||||t||||||||||2018-05-31 23:15:00.231381|2018-05-31 23:15:00.231381
NCT01223586|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-04-21|2010-10-18|2010-10-19|Estimate|||||||2012-04-21|2012-04-24|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|Ex JAPAN-ACS||Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome|Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome|Completed|||238|Actual|Kyoto University|||2||f||||f||||||||||2018-05-31 23:15:00.27365|2018-05-31 23:15:00.27365
NCT01223573|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|August 2010||2010-08-31|August 2010|2010-08-31||||December 2010|Anticipated|2010-12-31||Observational|newborn O2 sat||Neonatal Pulse Oximetry Compared With Apgar Scores|Newborn Pulse Oximety as a Predictor for Newborn Status and Future Outcome As Compared With the Apgar Score|Unknown status|Active, not recruiting||100|Anticipated|Kern Medical Center|||||f||||||||||||||2018-05-31 23:15:00.34738|2018-05-31 23:15:00.34738
NCT01223560|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-10-18|2010-10-18|2010-10-19|Estimate|||||||2010-10-18|2010-10-19|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Collection of Information-Rich Type 1 Diabetes Data||Completed||N/A|12|Actual|Hvidovre University Hospital|||||f||||t||||||||||2018-05-31 23:15:00.404768|2018-05-31 23:15:00.404768
NCT01223547|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2014-01-26|2010-10-18|2010-10-19|Estimate|||||||2014-01-26|2014-01-28|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study of the Effects of Carbohydrate Counting|The Effect of Carbohydrate Counting and Bolus Calculation Using an Electronic Calculator in Carbohydrate Counting-naïve Persons With Non-optimally Treated Type 1 Diabetes|Completed||N/A|64|Anticipated|Hvidovre University Hospital||3|||f||||f||||||||||2018-05-31 23:15:00.453914|2018-05-31 23:15:00.453914
NCT01223170|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2014-12-11|2010-10-15|2010-10-18|Estimate|||||||2014-12-11|2014-12-12|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|October 2013|Actual|2013-10-31||Interventional|eRehab||eRehab: Can Information and Communication Technology (ICT) Enhance Self-management of Cardiovascular Disease?|eRehab: Can Information and Communication Technology (ICT) Enhance Self-management of Cardiovascular Disease?|Completed||N/A|69|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 23:15:08.331805|2018-05-31 23:15:08.331805
NCT01223534|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2016-05-26|2010-10-18|2010-10-19|Estimate|||||||2016-05-26|2016-05-27|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OPTIMIST||QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.|Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT)|Completed||Phase 4|871|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||No||2018-05-31 23:15:00.543225|2018-05-31 23:15:00.543225
NCT01223521|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2018-01-15|2010-10-18|2010-10-19|Estimate|||||||2018-01-15|2018-01-17|Actual|September 2010||2010-09-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion.|Systematic Provision of Intrauterine Contraception After First Trimester Abortion - Effects on Quality of Life and Risk of Repeat Abortion. A Randomized, Prospective Trial.|Active, not recruiting||N/A|700|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 23:15:00.604517|2018-05-31 23:15:00.604517
NCT01223482|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2010-12-16|2010-10-18|2010-10-19|Estimate|||||||2010-12-16|2010-12-17|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|February 2011|Anticipated|2011-02-28||Observational|||A Study Looking at Women's Experiences After a Miscarriage|An Investigation of Women's Experiences Following Karyotyping Products of Conception After a Miscarriage|Unknown status|Recruiting||400|Anticipated|California State University, Stanislaus|||2||f||||t||||||||||2018-05-31 23:15:00.657858|2018-05-31 23:15:00.657858
NCT01223469|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|2014-03-24||2014-05-07|2010-10-18|2010-10-19|Estimate|2014-05-07|2014-06-03|Estimate||||2014-05-07|2014-06-03|Estimate|September 2008||2008-09-30|May 2014|2014-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|TOCCATA||TOCCATA - Touch+™ for Catheter Ablation|A Prospective Safety, Performance and Preliminary Effectiveness, Multi-centre, Clinical Investigation Using the Irrigated TactiCath™ Percutaneous Ablation Catheter for the Treatment of Supra-Ventricular Tachyarrhythmia Using RF Ablation|Completed||N/A|77|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 23:15:00.704624|2018-05-31 23:15:00.704624
NCT01223456|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2013-10-07|2010-10-18|2010-10-19|Estimate|||||||2013-10-07|2013-10-08|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|ONGLYZA PMS||Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use|A Descriptive Study of the Efficacy and Safety of ONGLYZA (Saxagliptin) Under Conditions of Actual Use in the Philippines|Terminated|||542|Actual|AstraZeneca||||Inability to recruit adequate number of patients within the specified time period.|f||||f||||||||||2018-05-31 23:15:00.979122|2018-05-31 23:15:00.979122
NCT01223443|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2016-10-26|2010-10-18|2010-10-19|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2015|Actual|2015-08-31||Interventional|VELETI II||Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents|Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents as a New Approach to MainTaining VeIn Graft Patency and Reducing Cardiac Events|Terminated||Phase 4|125|Actual|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2||The trial was prematurely stopped due to slow patient enrolment.|f||||t||||||||||2018-05-31 23:15:01.06952|2018-05-31 23:15:01.06952
NCT01223430|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-18|||2012-05-21|2010-10-18|2010-10-19|Estimate|||||||2012-05-21|2012-05-23|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Simultaneously Using Traditional Chinese Medicine (Si-Ni-Tang) to Treat Septic Shock Patients|Simultaneously Using Traditional Chinese Medicine (Si-Ni-Tang) to Treat Septic Shock Patients - a Double Blind, Prospective, Randomized Controlled Study|Terminated||Phase 2|8|Actual|Changhua Christian Hospital||2||"The IRB considered our trial risky. Although there were debates between investigators and IRB,~   we terminated our trial in accordance with the suggestion of IRB."|f||||t||||||||||2018-05-31 23:15:01.176235|2018-05-31 23:15:01.176235
NCT01223404|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2017-05-02||2018-01-24|2010-10-15|2010-10-19|Estimate|2018-01-24|2018-01-25|Actual||||2018-01-24|2018-01-25|Actual|October 2010|Actual|2010-10-31|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||21 healthy non-smokers were randomized.|Nicotinic Modulation of the Default Network|Nicotinic Modulation of the Default Network of Resting Brain Function|Completed||N/A|21|Actual|University of Maryland||6|||f||||t||||||||||2018-05-31 23:15:01.303713|2018-05-31 23:15:01.303713
NCT01223391|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-05-09|2010-10-15|2010-10-19|Estimate|||||||2014-05-09|2014-05-12|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Abdominal Compression in Orthostatic Hypotension|The Efficacy of Adjustable Lower Abdominal Compression in Neurogenic Orthostatic Hypotension|Completed||N/A|13|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:15:02.323707|2018-05-31 23:15:02.323707
NCT01223378|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11||2012-08-10|2013-11-22|2010-10-15|2010-10-19|Estimate||||2012-08-10|2012-08-20|Estimate|2013-11-22|2013-12-17|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|355|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:15:02.61661|2018-05-31 23:15:02.61661
NCT01223365|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2017-02-19|2013-05-02|2017-05-02|2010-10-18|2010-10-19|Estimate|2017-02-19|2017-04-05|Actual|2013-05-02|2013-05-10|Estimate|2017-05-02|2017-06-05|Actual|October 2010||2010-10-31|May 2017|2017-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Enrolled patients|Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time|A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time|Completed||Phase 3|330|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 23:15:02.960673|2018-05-31 23:15:02.960673
NCT01223352|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2017-03-02|2014-08-22|2017-11-07|2010-10-15|2010-10-19|Estimate|2017-05-29|2017-06-29|Actual|2014-08-22|2014-08-26|Estimate|2017-11-07|2017-12-11|Actual|March 8, 2011|Actual|2011-03-08|November 2017|2017-11-30|August 19, 2013|Actual|2013-08-19|April 3, 2013|Actual|2013-04-03||Interventional|FUTURE 3||Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension|An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension|Completed||Phase 3|64|Actual|Actelion||2|||f||||t|t|f||||||||2018-05-31 23:15:04.483051|2018-05-31 23:15:04.483051
NCT01223339|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2016-05-19|2010-10-17|2010-10-19|Estimate|||||||2016-05-19|2016-05-20|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)|A Phase 1, Randomized, Double Blind, Placebo-Controlled, Parallel Cohort, Single Dose Escalation And Multiple Dose Study In Japanese Healthy Subjects, And Open Label, Single Dose Escalation Study In Western Healthy Subjects To Investigate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 23:15:05.427192|2018-05-31 23:15:05.427192
NCT01223326|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2012-06-07|2010-10-18|2010-10-19|Estimate|||||||2012-06-07|2012-06-08|Estimate|January 2003||2003-01-31|June 2012|2012-06-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection|A Randomized Controlled Trial of N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection Performed Under Ischemic Preconditioning and Intermittent Portal Triad Clamping|Completed||Phase 4|46|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-05-31 23:15:06.597333|2018-05-31 23:15:06.597333
NCT01223313|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2016-02-19|2010-10-14|2010-10-18|Estimate|||||||2016-02-19|2016-02-23|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|September 2015|Actual|2015-09-30|November 2012|Actual|2012-11-30||Interventional|||A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom|A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom|Completed||Phase 3|500|Actual|Health Decisions||1|||f||||t||||||||||2018-05-31 23:15:06.679009|2018-05-31 23:15:06.679009
NCT01223300|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2016-12-16|2010-10-14|2010-10-18|Estimate|||||||2016-12-16|2016-12-19|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Osteoporosis Research Registry|Osteoporosis Research Registry|Completed|||12|Actual|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Two (10 ml) blood samples~   "|||2018-05-31 23:15:06.776631|2018-05-31 23:15:06.776631
NCT01223287|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2017-09-22|2010-10-14|2010-10-18|Estimate|||||||2017-09-22|2017-09-26|Actual|May 2005||2005-05-31|September 2017|2017-09-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Observational|PhysiologicDef||Physiologic Definition of Bronchopulmonary Dysplasia|Physiologic Definition of Bronchopulmonary Dysplasia|Completed|||410|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-05-31 23:15:06.849973|2018-05-31 23:15:06.849973
NCT01223274|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2017-09-22|2010-10-14|2010-10-18|Estimate|||||||2017-09-22|2017-09-26|Actual|July 2002||2002-07-31|September 2017|2017-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|DR-CPAP||Delivery Room CPAP in Extremely Low Birth Weight Infants|Delivery Room Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) in Extremely Low Birth Weight (ELBW) Infants|Completed||Phase 1/Phase 2|104|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 23:15:06.964048|2018-05-31 23:15:06.964048
NCT01223261|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2017-09-22|2010-10-14|2010-10-18|Estimate|||||||2017-09-22|2017-09-26|Actual|March 2001||2001-03-31|September 2017|2017-09-30|March 2004|Actual|2004-03-31|September 2002|Actual|2002-09-30||Observational|NEC Surgery||Observational Study of Surgical Treatment of Necrotizing Enterocolotis|Observational Study of Surgical Treatment of Necrotizing Enterocolotis or Isolated Intestinal Perforation|Completed|||156|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-05-31 23:15:07.15232|2018-05-31 23:15:07.15232
NCT01223248|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2017-06-13|2010-10-14|2010-10-18|Estimate|||||||2017-06-13|2017-06-14|Actual|October 2010|Actual|2010-10-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy|A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients With Metastatic Cancer|Active, not recruiting||Phase 3|220|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 23:15:07.273579|2018-05-31 23:15:07.273579
NCT01223235|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2018-03-16||2018-04-13|2010-10-15|2010-10-18|Estimate|2018-04-13|2018-05-14|Actual||||2018-04-13|2018-05-14|Actual|October 2010||2010-10-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab|A PILOT STUDY OF A POLYVALENT VACCINE-KLH CONJUGATE + OPT-821 GIVEN IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN SECOND OR GREATER COMPLETE OR PARTIAL CLINICAL REMISSION|Completed||N/A|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:15:07.399089|2018-05-31 23:15:07.399089
NCT01223222|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2011-02-15|2010-10-15|2010-10-18|Estimate|||||||2011-02-15|2011-02-16|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection|A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection|Completed||Phase 2|24|Anticipated|Lytix Biopharma AS||3|||f||||f||||||||||2018-05-31 23:15:07.640704|2018-05-31 23:15:07.640704
NCT01223209|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-01-10|2010-10-15|2010-10-18|Estimate|||||||2012-01-10|2012-01-11|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma|A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma|Completed||Phase 1|12|Actual|Lytix Biopharma AS||1|||f||||f||||||||||2018-05-31 23:15:07.720435|2018-05-31 23:15:07.720435
NCT01223196|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2013-02-19||2015-12-09|2010-10-15|2010-10-18|Estimate|2014-11-11|2014-11-13|Estimate||||2015-12-09|2016-01-11|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PIO-TACE||Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes|Effect of Pioglitazone on Tissue Inhibitor of Metalloproteinases 3 (TIMP-3) and TNF (Tumor Necrosis Factor)-α Converting Enzyme (TACE) in Skeletal Muscle and Their Circulating Substrates.|Completed||Phase 4|60|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 23:15:07.800969|2018-05-31 23:15:07.800969
NCT01223183|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2017-04-05||2017-07-24|2010-10-15|2010-10-18|Estimate|2017-07-24|2018-02-05|Actual||||2017-07-24|2018-02-05|Actual|September 2010||2010-09-30|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis|Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis|Completed||Phase 1|20|Actual|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 23:15:08.097634|2018-05-31 23:15:08.097634
NCT01223157|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2011-04-27|2010-10-15|2010-10-18|Estimate|||||||2011-04-27|2011-04-28|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|SALIVENDO||Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index|Saliva and Plasma Endocannabinoids Concentrations According to Feeding Status and Body Mass Index|Completed||N/A|24|Actual|University Hospital, Bordeaux||2|||f||||||||||||||2018-05-31 23:15:08.49926|2018-05-31 23:15:08.49926
NCT01223144|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2012-06-07|2010-10-15|2010-10-18|Estimate|||||||2012-06-07|2012-06-08|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|EMOTREM||Decision-making and Emotion Recognition in Essential Tremor|Decision-making and Emotion Recognition in Essential Tremor|Completed||N/A|39|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 23:15:08.573053|2018-05-31 23:15:08.573053
NCT01223131|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2014-03-31|2010-10-15|2010-10-18|Estimate|||||||2014-03-31|2014-04-01|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Lantus-P-CN||Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.|A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus® (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Mellitus Aged at Least 6 Years to Less Than 18 Years|Completed||Phase 3|162|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:15:08.661112|2018-05-31 23:15:08.661112
NCT01223118|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-22|2010-10-15|2010-10-18|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Evaluation of the Impact of Vitrification on Oocytes|Evaluation of the Impact of Vitrification on the Reproductive Performance and Potential of Human Oocytes|Completed||N/A|120|Actual|Reproductive Medicine Associates of New Jersey||1|||f||||f||||||||||2018-05-31 23:15:08.7471|2018-05-31 23:15:08.7471
NCT01223105|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-11-18|2010-10-15|2010-10-18|Estimate|||||||2013-11-18|2013-11-19|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Oocyte Cryopreservation by Slow Freezing and Vitrification|Longitudinal Evaluation of Vitrification of Human Oocytes|Terminated||Phase 2/Phase 3|2|Actual|Reproductive Medicine Associates of New Jersey||2||Poor recruitment|f||||f||||||||||2018-05-31 23:15:08.817527|2018-05-31 23:15:08.817527
NCT01223092|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-03-23|2010-10-15|2010-10-18|Estimate|||||||2018-03-23|2018-03-26|Estimate|February 2006||2006-02-28|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Study of Gene Associations and Infertility|Genes and Gene Polymorphisms Associated With Infertility: Utilization of DNA Characteristics to Better Understand Reproductive Competence|Enrolling by invitation|||5000|Anticipated|Reproductive Medicine Associates of New Jersey|||1||f||||f||||||Samples With DNA|"~     whole blood serum, follicular fluid and sperm~   "|||2018-05-31 23:15:08.893816|2018-05-31 23:15:08.893816
NCT01223079|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-03-04|2010-10-15|2010-10-18|Estimate|||||||2013-03-04|2013-03-05|Estimate|December 2005||2005-12-31|March 2013|2013-03-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Use of r-hLH (Luveris) in Donors Previously Treated With r-hFSH (Gonal F)|Use of r-hLH (Luveris) Late Follicular Phase for Controlled Ovarian Stimulation (COS) in Donor Patients Previously Treated With r-hFSH (Gonal F)in a Long Luteal Downregulated Cycle With GnRH Agonist. A Cross-over Study|Completed||N/A|20|Actual|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 23:15:08.959825|2018-05-31 23:15:08.959825
NCT01223066|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-05-12|2010-10-15|2010-10-18|Estimate|||||||2017-05-12|2017-05-15|Actual|September 2010|Actual|2010-09-30|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Macrolane Prospective Survey|A Multi-center, Non-interventional, Prospective Study to Monitor Long Term Safety in Female Subjects After Treatment With Macrolane Volume Restoration Factor 20 and/or Macrolane Volume Restoration Factor 30 in the Breasts.|Withdrawn|||0|Actual|Q-Med AB|||1|no patients recruited|f||||f||||||||||2018-05-31 23:15:09.056516|2018-05-31 23:15:09.056516
NCT01223053|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-09-04|2010-10-15|2010-10-18|Estimate|||||||2012-09-04|2012-09-05|Estimate||||September 2012|2012-09-30||||||||Interventional|||Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Confirmatory Phase 3 Study to Assess the Efficacy and Safety of TDLP-110 (Ketotransdel®, Ketoprofen 10% Cream) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury|Withdrawn||Phase 3|0|Actual|Imprimis Pharmaceuticals, Inc.||2||Revised Development Program|f||||||||||||||2018-05-31 23:15:09.112972|2018-05-31 23:15:09.112972
NCT01223040|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2012-04-07|2010-10-15|2010-10-18|Estimate|||||||2012-04-07|2012-04-10|Estimate|August 2010||2010-08-31|January 2012|2012-01-31||||September 2010|Actual|2010-09-30||Interventional|||An Open-Label, Single-Center Study Evaluating the Effect of Systane Balance on Video Ocular Protection Index (OPI) and Blink Patterns in Patients Diagnosed With Dry Eye||Completed||N/A|30|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:15:09.175712|2018-05-31 23:15:09.175712
NCT01223027|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2015-06-29||2015-11-05|2010-10-15|2010-10-18|Estimate|2015-10-06|2015-11-06|Estimate||||2015-11-05|2015-12-07|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Full Analysis Set (FAS) consisted of all randomized patients.|Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma|An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies|Completed||Phase 3|564|Actual|Novartis||2|||f||||t||||||||||2018-05-31 23:15:09.332102|2018-05-31 23:15:09.332102
NCT01223014|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2011-02-06|2010-10-15|2010-10-18|Estimate|||||||2011-02-06|2011-02-08|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ADME||Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers|An Open Label, Single Dose, Phase I Study to Evaluate the Excretion of Radioactivity, the Metabolic Profile, Pharmacokinetics, Safety and Tolerability Following Single Oral Administration of [14C]AZD2423 to Healthy Male Volunteers|Completed|||6|Anticipated|AstraZeneca|||1||f||||f||||||Samples With DNA|"~     Pharmacogenetic samples~   "|||2018-05-31 23:15:10.897184|2018-05-31 23:15:10.897184
NCT01223001|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2014-11-06||2014-12-15|2010-10-15|2010-10-18|Estimate|2014-12-15|2014-12-17|Estimate||||2014-12-15|2014-12-17|Estimate|September 1996||1996-09-30|November 2014|2014-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Duloxetine||Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury|Prevention of Depression and Enhancement of Cognitive Recovery Following Traumatic Brain Injury With Duloxetine|Terminated||Phase 2|8|Actual|Rehabilitation Hospital of Indiana|All subjects excluded (n=6) had already been prescribed Duloxetine. Completion of the study by the remaining 4 per group was not achieved due to noncompliance.|2||Most potential subjects had already been prescribed Cymbalta.|f||||t||||||||||2018-05-31 23:15:10.974645|2018-05-31 23:15:10.974645
NCT01222975|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|October 2004||2004-10-31|October 2010|2010-10-31|December 2004|Actual|2004-12-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions|Single Dose Two-way Crossover Fasted Bioequivalence Study of Risperidone 1 mg ODT Tablets in Healthy Volunteers|Completed||N/A|44|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 23:15:11.225416|2018-05-31 23:15:11.225416
NCT01222962|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2010-10-14|2010-10-14|2010-10-18|Estimate|||||||2010-10-14|2010-10-18|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers|Study of the Effect of Food on the Pharmacokinetics of DHA and PQP After Single Oral Administration of Eurartesim™ in Healthy Male Adult Volunteers|Completed||Phase 1|37|Actual|sigma-tau i.f.r. S.p.A.||2|||f||||f||||||||||2018-05-31 23:15:11.282029|2018-05-31 23:15:11.282029
NCT01222949|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2010-10-14|2010-10-14|2010-10-18|Estimate|||||||2010-10-14|2010-10-18|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™|A Phase I, Pharmacokinetic Trial, in Healthy Asian and Caucasian Volunteers for Investigating the Pharmacokinetic Profiles of Eurartesim™ (40 mg Dihydroartemisinin (DHA)/320 mg Piperaquine (PQ) Phosphate.|Completed||Phase 1|80|Actual|sigma-tau i.f.r. S.p.A.||2|||f||||f||||||||||2018-05-31 23:15:11.335983|2018-05-31 23:15:11.335983
NCT01222936|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2010-10-14|2010-10-14|2010-10-18|Estimate|||||||2010-10-14|2010-10-18|Estimate|May 2008||2008-05-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|June 2009|Actual|2009-06-30||Interventional|||LBH Phase II in Small Cell Lung Cancer (SCLC)|A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Patients With Advanced Small Cell Lung Cancer (SCLC)|Completed||Phase 2|21|Actual|Southern Europe New Drug Organization|||||f||||f||||||||||2018-05-31 23:15:11.490682|2018-05-31 23:15:11.490682
NCT01222923|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|October 2004||2004-10-31|October 2010|2010-10-31|January 2005|Actual|2005-01-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions|Single Dose Two-way Crossover Fed Bioequivalence Study of Risperidone 1 mg ODT Tablets in Healthy Volunteers|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 23:15:11.569513|2018-05-31 23:15:11.569513
NCT01222910|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|May 2009||2009-05-31|October 2010|2010-10-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||A Relative Bioavailability Study of Valacyclovir Hydrochloride Tablets 1gm Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period,Two-sequence,Single-dose, Crossover, Bioequivalence Study Comparing Valacyclovir Hydrochloride Tablets 1 Gram of Ohm Laboratories Inc. (a Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With VALTREX® Caplets 1 Gram (Containing Valacyclovir Hydrochloride 1 Gram) of GlaxoSmithKline in Healthy, Adult, Male, Human Subjects Under Fasting Condition|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 23:15:11.634847|2018-05-31 23:15:11.634847
NCT01222897|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|May 2009||2009-05-31|October 2010|2010-10-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||A Relative Bioavailability Study of Valacyclovir Hydrochloride Tablets 1gm Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Valacyclovir Hydrochloride Tablets 1 Gram of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With VALTREX® Caplets 1 Gram (Containing Valacyclovir Hydrochloride 1 Gram) of GlaxoSmithKline in Healthy, Adult, Male, Human Subjects Under Fed Condition.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 23:15:11.722139|2018-05-31 23:15:11.722139
NCT01222884|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2015-06-26||2015-11-02|2010-10-15|2010-10-18|Estimate|2015-06-26|2015-07-24|Estimate||||2015-11-02|2015-12-02|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D|A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With Intravenous Iron Sucrose in Subjects With Stage 5 Chronic Kidney Disease on Dialysis Therapy (CKD-5D)|Completed||Phase 3|351|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 23:15:11.81295|2018-05-31 23:15:11.81295
NCT01222871|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2014-01-02|2010-10-15|2010-10-18|Estimate|||||||2014-01-02|2014-01-03|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Treatment of Early Nasal Polyposis With Topical Triamcinolone|Treatment of Early Nasal Polyposis With Topical Triamcinolone|Terminated||Phase 2|2|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.||1||not enough particpants|f||||f||||||||||2018-05-31 23:15:12.190411|2018-05-31 23:15:12.190411
NCT01222858|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2014-07-07|2010-10-15|2010-10-18|Estimate|||||||2014-07-07|2014-07-08|Estimate|August 2010||2010-08-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Innovative Technology To Improve Patient Adherence To Weight Loss Recommendations|Innovative Technology to Improve Patient Adherence to Weight Loss Recommendations|Completed||N/A|250|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 23:15:12.276818|2018-05-31 23:15:12.276818
NCT01222845|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2012-05-01|2010-10-15|2010-10-18|Estimate|||||||2012-05-01|2012-05-02|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge|Glycaemic, Insulinaemic and Appetite Responses to Two Different Types of Porridge|Completed||N/A|13|Actual|Northumbria University||2|||f||||||||||||||2018-05-31 23:15:12.342203|2018-05-31 23:15:12.342203
NCT01222832|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2015-05-19||2017-05-02|2010-10-15|2010-10-18|Estimate|2017-05-02|2017-05-31|Actual||||2017-05-02|2017-05-31|Actual|July 2010||2010-07-31|May 2017|2017-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge|Effectiveness of Antibiotic Delivery Via Bio-absorbable Sponge After Functional Endoscopic Sinus Surgery|Completed||Phase 2|226|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.||2|||f||||f||||||||No||2018-05-31 23:15:12.409311|2018-05-31 23:15:12.409311
NCT01222819|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2016-04-04|2010-10-15|2010-10-18|Estimate|||||||2016-04-04|2016-04-06|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|G-CSF||SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients|Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial|Terminated||Phase 4|120|Actual|Rabin Medical Center||2||Physycians' refusal to continue the study|f||||t||||||||||2018-05-31 23:15:12.601161|2018-05-31 23:15:12.601161
NCT01222806|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-10-05|2010-10-15|2010-10-18|Estimate|||||||2017-10-05|2017-10-06|Actual|October 11, 2010||2010-10-11|May 2, 2013|2013-05-02|May 2, 2013|Actual|2013-05-02|||||Interventional|||Pilot Study of Repetitive Transcranial Magnetic Stimulation in Cocaine Craving|Pilot Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in Cocaine Craving|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:15:12.670357|2018-05-31 23:15:12.670357
NCT01222793|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-06-30|2010-10-15|2010-10-18|Estimate|||||||2017-06-30|2017-07-02|Actual|September 26, 2010||2010-09-26|May 3, 2012|2012-05-03|May 3, 2012||2012-05-03|||||Observational|||Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia|Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia|Completed|||60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:15:12.723135|2018-05-31 23:15:12.723135
NCT01222780|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-10-16|2010-10-15|2010-10-18|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2010||2010-09-30|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer|Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer|Completed||Phase 1/Phase 2|22|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||t||||||||||2018-05-31 23:15:12.782276|2018-05-31 23:15:12.782276
NCT01222767|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-06-04|2010-10-15|2010-10-18|Estimate|||||||2012-06-04|2012-06-05|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy|Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy|Completed||Phase 2|17|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 23:15:12.933565|2018-05-31 23:15:12.933565
NCT01222754|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2018-05-23|2010-10-15|2010-10-18|Estimate|||||||2018-05-23|2018-05-24|Actual|October 15, 2010||2010-10-15|November 17, 2017|2017-11-17|April 30, 2021|Anticipated|2021-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas|A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas|Active, not recruiting||Phase 1|29|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 23:15:13.010001|2018-05-31 23:15:13.010001
NCT01222741|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2018-03-27|2010-10-15|2010-10-18|Estimate|||||||2018-03-27|2018-03-29|Actual|September 24, 2010||2010-09-24|January 22, 2018|2018-01-22||||||||Observational|||Studies of Disorders With Increased Susceptibility to Fungal Infections|Studies of Disorders With Increased Susceptibility to Fungal Infections|Recruiting|||850|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:15:13.104056|2018-05-31 23:15:13.104056
NCT01222728|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2018-05-11|2010-10-15|2010-10-18|Estimate|||||||2018-05-11|2018-05-14|Actual|September 22, 2010||2010-09-22|June 3, 2015|2015-06-03|June 3, 2015||2015-06-03|||||Observational|||Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients|Using Positron Emission Tomography (PET) to Predict Intracranial Tumor Growth in Neurofibromatosis Type II (NF2) Patients|Completed|||5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:15:13.174292|2018-05-31 23:15:13.174292
NCT01222715|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2017-01-09||2017-03-24|2010-10-15|2010-10-18|Estimate|2017-03-24|2017-05-05|Actual||||2017-03-24|2017-05-05|Actual|October 2010||2010-10-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma|A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma|Completed||Phase 2|87|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:15:13.313832|2018-05-31 23:15:13.313832
NCT01222702|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08||2013-10-28|2017-06-09|2010-10-15|2010-10-18|Estimate||||2013-12-16|2014-01-17|Estimate|2017-06-09|2017-06-14|Actual|January 25, 2011|Actual|2011-01-25|June 2017|2017-06-30|November 12, 2012|Actual|2012-11-12|October 16, 2012|Actual|2012-10-16||Interventional|||Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)|A Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of a 10-day Twice Daily Oral Administration of Three Doses of Cadazolid (ACT-179811) in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)|Completed||Phase 2|84|Actual|Actelion||4|||f||||t|t|f||||||||2018-05-31 23:15:14.272726|2018-05-31 23:15:14.272726
NCT01222689|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2016-07-13||2016-09-20|2010-10-15|2010-10-18|Estimate|2016-09-20|2016-11-07|Estimate||||2016-09-20|2016-11-07|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|September 2014|Actual|2014-09-30|April 2013|Actual|2013-04-30||Interventional|||Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase 2 Study of AZD6244 Plus Erlotinib for the Second-Line Treatment of Advanced Pancreatic Adenocarcinoma|Completed||Phase 2|46|Actual|National Cancer Institute (NCI)|In this single arm, nonrandomized study, an inherent selection bias was likely due to enrollment of patients with favorable disease biology, who had undergone prior resection and fare better compared with those with stage IV disease at diagnosis.|1|||f||||t||||||||||2018-05-31 23:15:14.439039|2018-05-31 23:15:14.439039
NCT01222676|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2013-08-09|2010-10-15|2010-10-18|Estimate|||||||2013-08-09|2013-08-12|Estimate|October 2010||2010-10-31|October 2010|2010-10-31||||October 2013|Anticipated|2013-10-31||Interventional|||Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder|A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder|Unknown status|Recruiting|Phase 2|45|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:15:14.908192|2018-05-31 23:15:14.908192
NCT01222663|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-12-17|2010-10-15|2010-10-18|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|ABDO-MIX||Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock|Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock|Completed||Phase 3|243|Actual|Meditor SAS||2|||f||||t||||||||||2018-05-31 23:15:14.97637|2018-05-31 23:15:14.97637
NCT01222650|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2011-06-30|2010-10-15|2010-10-18|Estimate|||||||2011-06-30|2011-07-04|Estimate||||June 2011|2011-06-30||||||||Interventional|||A Comparative Study of KSO-0400 in BPH Patients With LUTS|A Randomized, Double-blind, Placebo-controlled, Multicentre Study of KSO-0400 in BPH Patients With LUTS|Completed||Phase 2|400||Kissei Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 23:15:15.062349|2018-05-31 23:15:15.062349
NCT01222637|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2013-12-16|2010-10-15|2010-10-18|Estimate|||||||2013-12-16|2013-12-17|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||CetuGEX™: Dose Escalation Study|Dose-escalation, PK- and Safety Study With Single Agent CetuGEX™ in Patients With EGFR Positive Locally Advanced and/or Metastatic Cancer|Completed||Phase 1|41|Actual|Glycotope GmbH||2|||f||||t||||||||||2018-05-31 23:15:15.220801|2018-05-31 23:15:15.220801
NCT01222624|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2013-05-15|2010-10-15|2010-10-18|Estimate|||||||2013-05-15|2013-05-16|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||PankoMab-GEX™: Dose Escalation Study|Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX™ in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy|Completed||Phase 1|72|Actual|Glycotope GmbH||3|||f||||t||||||||||2018-05-31 23:15:15.285119|2018-05-31 23:15:15.285119
NCT01222611|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2014-05-29|2010-10-15|2010-10-18|Estimate|||||||2014-05-29|2014-05-30|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|FOSTER-C||HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir|Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir|Completed||Phase 4|42|Actual|Fundacion SEIMC-GESIDA||2|||f||||t||||||||||2018-05-31 23:15:15.356749|2018-05-31 23:15:15.356749
NCT01222598|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-10-05|2010-10-15|2010-10-18|Estimate|||||||2012-10-05|2012-10-08|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|||A Study of Minirin Melt in Patients With Nocturia|Minirin Melt Tolerance With Nocturia in the Common Practice Conditions in Czech Republic|Completed|||588|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:15:15.439669|2018-05-31 23:15:15.439669
NCT01222585|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2013-07-23||2014-01-07|2010-10-15|2010-10-18|Estimate|2013-10-29|2013-12-18|Estimate||||2014-01-07|2014-02-06|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|PTN_METRO||Metronidazole Pharmacokinetics (PK) in Premature Infants|Safety and Pharmacokinetics of Multiple Dose Metronidazole in Premature Infants|Completed||Phase 1|24|Actual|Duke University||1|||f||||t||||||||||2018-05-31 23:15:15.536802|2018-05-31 23:15:15.536802
NCT01222572|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2014-08-25||2015-05-11|2010-10-15|2010-10-18|Estimate|2014-08-25|2014-09-05|Estimate||||2015-05-11|2015-06-04|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer|Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|1|Actual|Dana-Farber Cancer Institute|Study was closed due to poor accrual after enrollment of 1 patient and results of trial are not interpretable.|3||Slow accrual due to restrictive eligibility criteria|f||||t||||||||||2018-05-31 23:15:15.884036|2018-05-31 23:15:15.884036
NCT01222559|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2018-03-15|2010-10-15|2010-10-18|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2010||2010-10-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|September 2017|Actual|2017-09-30||Interventional|||Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects|Prospective, Randomised, Open Label, Multicentre Phase-III Clinical Trial to Compare the Efficacy and Safety of the Treatment With the Autologous Chondrocyte Transplantation Product co.Don Chondrosphere (ACT3D-CS) With Microfracture in Subjects With Cartilage Defects of the Knee With a Defect Size Between 1 an 4 cm2|Active, not recruiting||Phase 3|102|Actual|co.don AG||2|||f||||t||||||||||2018-05-31 23:15:16.082127|2018-05-31 23:15:16.082127
NCT01222546|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2014-06-20|2010-10-15|2010-10-18|Estimate|||||||2014-06-20|2014-06-23|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors|Phase I, Open-label, Multi-center, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Activity of CH5132799 Administered Orally as a Monotherapy in Patients With Advanced Solid Tumors|Completed||Phase 1|38|Actual|Chugai Pharma Europe Ltd.||1|||f||||f||||||||||2018-05-31 23:15:16.17944|2018-05-31 23:15:16.17944
NCT01222533|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2012-11-13||2014-05-07|2010-10-15|2010-10-18|Estimate|2012-11-13|2012-12-10|Estimate||||2014-05-07|2014-05-16|Estimate|October 2010||2010-10-31|August 2013|2013-08-31||||November 2011|Actual|2011-11-30||Interventional|||Tiotropium Respimat Pharmacokinetic Study in COPD|A Multicenter, Randomised, Placebo- and Active-controlled, 5 Way, Crossover Trial to Characterise the Pharmacokinetics and Evaluate the Bronchodilator Efficacy and Safety of Once-daily Tiotropium Delivered (Double-blind) From the Respimat Inhaler as Solution for Inhalation (1.25, 2.5, 5 mcg or Placebo) and as Inhalation Powder (18mcg) From the HandiHaler (Open Label) After 4 Week-treatment Periods in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|154|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 23:15:16.325055|2018-05-31 23:15:16.325055
NCT01222520|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2012-05-31||2014-06-17|2010-10-15|2010-10-18|Estimate|2012-05-31|2012-07-04|Estimate||||2014-06-17|2014-06-27|Estimate|October 2010||2010-10-31|January 2014|2014-01-31||||June 2011|Actual|2011-06-30||Interventional|||Telmisartan 80mg Non-responder Trial|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg+ Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 80 mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg Monotherapy|Completed||Phase 3|174|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:15:17.523164|2018-05-31 23:15:17.523164
NCT01222507|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|2012-09-18||2012-09-18|2010-10-15|2010-10-18|Estimate|2012-09-18|2012-10-25|Estimate||||2012-09-18|2012-10-25|Estimate|July 2010||2010-07-31|September 2012|2012-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|BST||Processing Speed as an Objective Measure of Tinnitus|Processing Speed as an Objective Measure of Tinnitus|Completed|||60|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 23:15:17.83535|2018-05-31 23:15:17.83535
NCT01222494|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2017-05-11|2010-10-15|2010-10-18|Estimate|||||||2017-05-11|2017-05-12|Actual|July 2011|Actual|2011-07-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Healthy Bodies, Healthy Kids|Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children|Completed||N/A|50|Actual|Washington University School of Medicine||3|||f||||t||||||||Undecided||2018-05-31 23:15:17.951934|2018-05-31 23:15:17.951934
NCT01222481|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2012-02-29|2010-10-15|2010-10-18|Estimate|||||||2012-02-29|2012-03-02|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|CAHNCA||Comprehensive Assessment of Head and Neck Cancer Survivors|A Comprehensive Assessment of Adult Head and Neck Cancer Survivors (A Pilot Study)|Completed|||15|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 23:15:18.02391|2018-05-31 23:15:18.02391
NCT01137201|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-12-02|2010-06-03|2010-06-04|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2010||2010-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|December 2013|Actual|2013-12-31||Interventional|||Internal Hernia After Laparoscopic Gastric Bypass|Internal Hernia After Laparoscopic Gastric Bypass|Completed||N/A|2507|Actual|Region Örebro County||2|||f||||t||||||||||2018-05-31 23:43:08.955686|2018-05-31 23:43:08.955686
NCT01222468|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2015-02-24|2010-10-15|2010-10-18|Estimate|||||||2015-02-24|2015-02-25|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons|A Randomized Double-Blinded Crossover Trial Assessing the Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons|Completed||Phase 2|12|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 23:15:18.079108|2018-05-31 23:15:18.079108
NCT01222455|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2011-07-05|2010-10-15|2010-10-18|Estimate|||||||2011-07-05|2011-07-06|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function|An Open-label, Single-center Study to Assess the Pharmacokinetics of R406 in Subjects With Hepatic Impairment and in Healthy Subjects Following Administration of a Single Dose of Fostamatinib Disodium 150 mg|Completed||Phase 1|32|Anticipated|AstraZeneca||4|||f||||||||||||||2018-05-31 23:15:18.139475|2018-05-31 23:15:18.139475
NCT01222442|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-02-15|2010-10-15|2010-10-18|Estimate|||||||2011-02-15|2011-02-16|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart|A Single-centre, Randomised, Double-blind, Double-dummy, Placebo Controlled, 4-way Crossover Phase I Study to Investigate the Effect of 2 Single Doses (400 μg and 1200 µg) of Inhaled AZD3199 on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers|Completed||Phase 1|40|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:15:18.196785|2018-05-31 23:15:18.196785
NCT01222429|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2012-08-06|2010-10-14|2010-10-18|Estimate|||||||2012-08-06|2012-08-07|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|||Practice Based Nutrition Intervention|Practice-Based Nutrition Intervention|Completed||N/A|50|Actual|Physicians Committee for Responsible Medicine||2|||f||||f||||||||||2018-05-31 23:15:18.262031|2018-05-31 23:15:18.262031
NCT01222416|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2017-03-21||2017-06-26|2010-10-14|2010-10-18|Estimate|2017-06-26|2017-07-02|Actual||||2017-06-26|2017-07-02|Actual|October 2010||2010-10-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Subjects must have histologically proven breast cancer|PET/CT Evaluation of Treatment Response in Breast Cancer|Positron Emission Tomography (PET)-Computed Tomography (CT) PET/CT Evaluation of Treatment Response in Breast Cancer|Terminated||N/A|50|Actual|Vanderbilt-Ingram Cancer Center||2||Slow accrual|f||||t||||||||||2018-05-31 23:15:18.323839|2018-05-31 23:15:18.323839
NCT01222403|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2015-09-09||2015-09-09|2010-10-14|2010-10-18|Estimate|2015-09-09|2015-10-12|Estimate||||2015-09-09|2015-10-12|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).|A Post-marketing Study to Monitor the Safety of a MF59-adjuvanted Influenza Vaccine Administered in Korean Subjects Aged 65 Years or Older|A Multicenter, Post-marketing Surveillance Study to Monitor the Safety of Novartis Vaccine MF59-adjuvanted Influenza Subunit Vaccine FLUAD® and Sandoz Korea Vaccine MF59-adjuvanted Influenza Subunit Vaccine VANTAFLU® Administered According to the Prescribing Information in Korean Subjects Aged 65 Years or Older at the Time of Vaccination.|Completed||Phase 4|767|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:15:18.566603|2018-05-31 23:15:18.566603
NCT01222390|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2014-10-29||2014-11-14|2010-10-14|2010-10-18|Estimate|2014-11-14|2014-11-17|Estimate||||2014-11-14|2014-11-17|Estimate|November 2010||2010-11-30|November 2014|2014-11-30|April 2014|Actual|2014-04-30|July 2013|Actual|2013-07-31||Interventional|CPX3||Tissue Expander Breast Reconstruction Study on Breast Volume and Shape Change|The Contour Profile® Tissue Expander in Immediate Breast Reconstruction: A Three-Dimensional Look Into Shape and Volume Changes|Completed||N/A|12|Actual|Northwestern University|The number of subjects studied is small; projection measurements may have been subject to human error.|1|||f||||t||||||||||2018-05-31 23:15:19.831014|2018-05-31 23:15:19.831014
NCT01222377|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2014-02-05|2010-10-15|2010-10-18|Estimate|||||||2014-02-05|2014-02-06|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Endoscopic Breast Surgery in Treating Patients With Breast Cancer|Endoscopic Breast Surgery Feasibility Study|Terminated||N/A|2|Actual|University of Southern California||1||P.I. left|f||||t||||||||||2018-05-31 23:15:19.957387|2018-05-31 23:15:19.957387
NCT01222364|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2017-09-22|2010-10-14|2010-10-18|Estimate|||||||2017-09-22|2017-09-26|Actual|June 2000||2000-06-30|September 2017|2017-09-30|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Delayed Cord Clamping in VLBW Infants|Delayed Cord Clamping in VLBW Infants Pilot Study|Completed||Phase 1/Phase 2|54|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 23:15:20.027539|2018-05-31 23:15:20.027539
NCT01222351|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2018-05-17|2010-10-15|2010-10-18|Estimate|||||||2018-05-17|2018-05-21|Actual|December 2010||2010-12-31|May 2018|2018-05-31|January 2029|Anticipated|2029-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172|BAY 94-9172 PET/CT in Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease|Active, not recruiting||N/A|161|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 23:15:20.201653|2018-05-31 23:15:20.201653
NCT01222338|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2012-08-02|2010-10-14|2010-10-18|Estimate|||||||2012-08-02|2012-08-03|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients|Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients|Completed||Phase 2|123|Actual|Lisichansk Regional Tuberculosis Dispensary||2|||f||||t||||||||||2018-05-31 23:15:20.289248|2018-05-31 23:15:20.289248
NCT01222325|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-10-14|2010-10-14|2010-10-18|Estimate|||||||2010-10-14|2010-10-18|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|November 2008|Actual|2008-11-30||Interventional|||Comparison Between Two Shock Wave Regimens for Treating Urinary Stones|Comparison Between Two Shock Wave Regimens Using Frequencies of 60 and 90 Impulses Per Minute for Urinary Stones|Completed||N/A|302|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 23:15:20.38054|2018-05-31 23:15:20.38054
NCT01222312|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-11-28|2010-10-14|2010-10-18|Estimate|||||||2011-11-28|2011-11-29|Estimate|August 2008||2008-08-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|Taxelox||Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel|Multicenter Randomized Phase II Study for the Therapy of Locally Advanced or Metastatic NSCLC (Stage IIIB/IV) With Cisplatin/Docetaxel or Oxaliplatin/Docetaxel|Completed||Phase 2|88|Actual|Krankenhaus Nordwest||2|||f||||t||||||||||2018-05-31 23:15:20.456437|2018-05-31 23:15:20.456437
NCT01222299|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14||2011-09-02|2013-12-04|2010-10-15|2010-10-18|Estimate||||2011-09-02|2011-09-12|Estimate|2013-12-04|2013-12-30|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety and Efficacy of Bepotastine Besilate Nasal Product in Seasonal Allergic Rhinitis Patients||Completed||Phase 1/Phase 2|89|Actual|Bausch & Lomb Incorporated||4|||f||||t||||||||||2018-05-31 23:15:20.549842|2018-05-31 23:15:20.549842
NCT01222286|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2013-11-07||2014-04-11|2010-10-15|2010-10-18|Estimate|2014-04-11|2014-05-09|Estimate||||2014-04-11|2014-05-09|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|KIRMONO||Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma|Multicenter Phase II Study on the Anti-tumor Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Fully Human Monoclonal Anti KIR Antibody, in Patients With Smoldering Multiple Myeloma (KIRMONO)|Completed||Phase 2|30|Actual|Innate Pharma||2|||f||||f||||||||||2018-05-31 23:15:20.672029|2018-05-31 23:15:20.672029
NCT01222273|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2017-11-09||2018-03-02|2010-10-14|2010-10-18|Estimate|2018-03-02|2018-03-29|Actual||||2018-03-02|2018-03-29|Actual|September 2010||2010-09-30|March 2018|2018-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Subjects with CF with a prior history of clinically diagnosed ABPA|Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis|Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis|Completed||N/A|7|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 23:15:21.016513|2018-05-31 23:15:21.016513
NCT01222260|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2018-02-02|2010-10-14|2010-10-18|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2012|Actual|2012-06-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis|Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis|Active, not recruiting||Phase 2|40|Actual|Columbia University||1|||f||||t|t|f|||t|||Undecided||2018-05-31 23:15:21.192089|2018-05-31 23:15:21.192089
NCT01222247|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2018-01-08|2010-10-14|2010-10-18|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2010||2010-10-31|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|March 2015|Actual|2015-03-31||Interventional|ALPS||Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial|Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial|Active, not recruiting||Phase 3|2831|Actual|The George Washington University Biostatistics Center||2|||f||||t||||||||Yes|Data will be shared after completion and publication of the main analyses per NIH policy. Requests can be sent to mfmudatasets@bsc.gwu.edu.|2018-05-31 23:15:21.27667|2018-05-31 23:15:21.27667
NCT01222234|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2015-11-24||2016-04-11|2010-10-15|2010-10-18|Estimate|2016-04-11|2016-05-16|Estimate||||2016-04-11|2016-05-16|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Impact of Vitamin D Therapies on Chronic Kidney Disease|Impact of Vitamin D Therapies on Monocyte Function in Chronic Kidney Disease|Completed||N/A|56|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-05-31 23:15:21.403629|2018-05-31 23:15:21.403629
NCT01222221|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2015-10-13|2010-10-14|2010-10-18|Estimate|||||||2015-10-13|2015-10-14|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma|Completed||Phase 1|45|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 23:15:21.767087|2018-05-31 23:15:21.767087
NCT01222208|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-02-03|2010-10-15|2010-10-18|Estimate|||||||2012-02-03|2012-02-07|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Oral Versus Parenteral Nutrition Support to Improve Protein Balance in Colorectal Surgical Patients|Oral Versus Parenteral Perioperative Nutrition Support to Improve Protein Balance: Stable Isotope Study in Colorectal Surgical Patients|Completed||N/A|20|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:15:21.848494|2018-05-31 23:15:21.848494
NCT01222195|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2011-03-30||2012-08-01|2010-10-14|2010-10-18|Estimate|2011-03-30|2011-04-26|Estimate||||2012-08-01|2012-08-07|Estimate|February 2008||2008-02-29|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)|Phase II Study of Lenalidomide and Darbepoetin Alfa in Myelodysplastic Syndrome (Low to Intermediate-1 Risk Category Excluding 5q Deletion)|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||1||Low accrual.|f||||t||||||||||2018-05-31 23:15:21.927195|2018-05-31 23:15:21.927195
NCT01222182|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2012-05-25|2010-10-14|2010-10-18|Estimate|||||||2012-05-25|2012-05-28|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Observational|||Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)|Statin Therapeutic Interchange by Pharmacist Collaborative Practice Process|Completed|||260|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 23:15:22.071734|2018-05-31 23:15:22.071734
NCT01222169|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-10-29|2010-10-14|2010-10-18|Estimate|||||||2015-10-29|2015-10-30|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|LR6||Laryngeal Reflex Study Under Propofol Anesthesia: Effect of Intravenous Lidocaine|Impact of Intravenous Lidocaine on Laryngeal Reflex Responses in Pediatric Patients Anesthetized With Propofol|Completed||Phase 3|80|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 23:15:22.149301|2018-05-31 23:15:22.149301
NCT01222156|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|RICTAM||Accuracy and Safety Study of the Magnetecs CGCI System for Intracardiac Mapping|Remote Intracardiac Catheter Target Acquisition Using the Magnetecs Catheter Guidance Control and Imaging (CGCI) System|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Magnetecs Corporation||1|||f||||t||||||||||2018-05-31 23:15:22.22604|2018-05-31 23:15:22.22604
NCT01222143|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2015-06-19|2010-10-14|2010-10-18|Estimate|||||||2015-06-19|2015-06-22|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia|A Phase I/II Study Evaluating the Safety and Efficacy of Nilotinib Combined With Mitoxantrone, Etoposide, and High-Dose Cytarabine (NOVE-HiDAC) Induction Chemotherapy Followed by Consolidation Therapy for Poor-Risk Patients With C-kit Positive Acute Myeloid Leukemia (AML) up to Age 65|Terminated||Phase 1/Phase 2|12|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 23:15:22.355703|2018-05-31 23:15:22.355703
NCT01131520|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2016-12-20||2017-11-15|2010-05-25|2010-05-27|Estimate|2017-07-19|2017-08-21|Actual||||2017-11-15|2017-12-12|Actual|June 2010||2010-06-30|November 2017|2017-11-30|July 2015|Actual|2015-07-31|December 2012|Actual|2012-12-31||Interventional|||Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico|SBIRT in New Mexico|Completed||N/A|360|Actual|Friends Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 23:45:03.900058|2018-05-31 23:45:03.900058
NCT01222130|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2014-09-16|2010-10-14|2010-10-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|July 2009||2009-07-31|September 2014|2014-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|IDX||Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants|CIDRZ 1234 - Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants|Completed|||1126|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 23:15:22.428312|2018-05-31 23:15:22.428312
NCT01222117|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2016-03-09||2016-11-28|2010-10-14|2010-10-18|Estimate|2016-04-27|2016-05-30|Estimate||||2016-11-28|2017-01-16|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion|A Phase 2, Randomized, Open-label (With Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Compared to Plasminogen Activator and Placebo In Patients With Acute Lower Extremity Native Artery or Bypass Graft Occlusion|Completed||Phase 2|174|Actual|Grifols Therapeutics LLC||11|||f||||t||||||||||2018-05-31 23:15:22.550849|2018-05-31 23:15:22.550849
NCT01222104|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2014-04-28||2014-12-15|2010-10-14|2010-10-18|Estimate|2014-11-07|2014-11-19|Estimate||||2014-12-15|2015-01-06|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Angio-Seal Interventional Radiology (IR) Registry|Clinical Registry of St. Jude Medical Angio-Seal™ Vascular Closure Devices Following Interventional Radiology Procedures|Completed|||634|Actual|St. Jude Medical|Major and minor vascular complications were collected as Serious Adverse Event and Other Adverse Events as defined in the protocol.||2||f||||f||||||||||2018-05-31 23:15:25.080167|2018-05-31 23:15:25.080167
NCT01222091|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|February 2009||2009-02-28|October 2010|2010-10-31|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Interventional|||Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids|Effect of Beta Blockade on Opioid-Induced Hyperalgesia in Humans|Unknown status|Recruiting|Phase 2|30|Anticipated|Stanford University|||||f||||||||||||||2018-05-31 23:15:25.366403|2018-05-31 23:15:25.366403
NCT01222078|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2017-04-03||2017-07-27|2010-10-14|2010-10-18|Estimate|2017-04-03|2017-06-16|Actual||||2017-07-27|2017-08-25|Actual|November 22, 2010|Actual|2010-11-22|July 2017|2017-07-31|May 19, 2011|Actual|2011-05-19|May 19, 2011|Actual|2011-05-19||Interventional|||Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus|Evaluation of the Safety and Tolerability of Re-dosing With Intravenous (iv) Otelixizumab in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus|Terminated||Phase 2|1|Actual|GlaxoSmithKline||1||"A Phase 3 study recently reported and demonstrated that the dose of otelixizumab in OTX113390~   is not effective."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:15:25.503014|2018-05-31 23:15:25.503014
NCT01222065|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-03-26|2010-10-15|2010-10-18|Estimate|||||||2012-03-26|2012-03-27|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|PSOCT||Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis|Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis|Completed|||85|Actual|University of Texas at Austin|||1||f||||t||||||||||2018-05-31 23:15:25.952094|2018-05-31 23:15:25.952094
NCT01222052|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2017-06-23|2010-10-15|2010-10-18|Estimate|||||||2017-06-23|2017-06-26|Actual|January 2002||2002-01-31|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2009|Actual|2009-02-28||Interventional|NNBC3-Europe||6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients|Randomized Multicenter Study Comparing 6xFEC With 3xFEC-3xDoc in High-risk Node-negative Patients With Operable Breast Cancer: Comparison of Efficacy and Evaluation of Clinico-pathological and Biochemical Markers as Risk Selection Criteria|Active, not recruiting||Phase 3|4150|Actual|Martin-Luther-Universität Halle-Wittenberg||3|||f||||t||||||||||2018-05-31 23:15:26.025334|2018-05-31 23:15:26.025334
NCT01222039|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2016-11-17|2010-10-15|2010-10-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CMM/EICH/2008||Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.|Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.|Completed||Phase 1/Phase 2|19|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t||||||||||2018-05-31 23:15:26.11177|2018-05-31 23:15:26.11177
NCT01222026|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2015-01-16|2010-10-15|2010-10-18|Estimate|||||||2015-01-16|2015-01-21|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate|Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium- and Bone Metabolism After Successful Surgery? - Part I|Completed||Phase 4|63|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 23:15:26.246573|2018-05-31 23:15:26.246573
NCT01222013|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2013-03-25|2010-10-15|2010-10-18|Estimate|||||||2013-03-25|2013-03-26|Estimate||||March 2013|2013-03-31||||||||Interventional|||Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)|Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)|Suspended||Phase 2|20|Anticipated|Hospital Santa Marcelina||1||Study was suspended before recruitment, due to logistic issues.|f||||f||||||||||2018-05-31 23:15:26.329736|2018-05-31 23:15:26.329736
NCT01222000|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous|TREATMENT OF THE RECESSIVE NONBULLOUS CONGENITAL ICHTHYOSIS BY THE EPIGALLOCATECHINE CUTANEOUS|Unknown status|Not yet recruiting|Phase 3|8|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||||||||||||2018-05-31 23:15:26.384243|2018-05-31 23:15:26.384243
NCT01221987|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-04-26|2010-10-15|2010-10-18|Estimate|||||||2012-04-26|2012-04-30|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer|A Cross-sectional, Hospital-based, Epidemiological Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) and/or Cervical Intraepithelial Neoplasia (CIN) II and/or CIN III in Sri Lanka|Completed|||40|Actual|GlaxoSmithKline|||2||f||||||||||Samples With DNA|"~     Tissue samples of invasive cervical cancer~   "|||2018-05-31 23:15:26.447024|2018-05-31 23:15:26.447024
NCT01221974|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2010-10-15|2010-10-15|2010-10-18|Estimate|||||||2010-10-15|2010-10-18|Estimate|July 2008||2008-07-31|October 2010|2010-10-31||||July 2009|Actual|2009-07-31||Interventional|||Use of Essure® Micro-inserts in Women With Hydrosalpinx Prior to In Vitro Fertilization: A Prospective, Multicenter, International Feasibility Study||Completed||Phase 1/Phase 2|||Reproductive Science Center||1|||||||f||||||||||2018-05-31 23:15:26.510608|2018-05-31 23:15:26.510608
NCT01221961|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2013-11-13|2010-10-15|2010-10-18|Estimate|||||||2013-11-13|2013-11-15|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Masimo Radical-7 Monitor a Useful Adjuvant During Major Spine Surgery|A Study to Determine the Agreement Between Masimo Monitor and Standard of Care|Terminated|||62|Actual|Cedars-Sinai Medical Center||||We completed the 62% of the cases, enough data to get a conclusion of the study.|f||||f||||||||||2018-05-31 23:15:26.563071|2018-05-31 23:15:26.563071
NCT01221948|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2015-07-27||2018-01-16|2010-10-14|2010-10-18|Estimate|2015-10-14|2015-11-13|Estimate||||2018-01-16|2018-02-13|Actual|October 2010||2010-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2013|Actual|2013-05-31||Interventional|VANTAGE|40 enrolled subjects who met study eligibility were implanted with the Vercise DBS system.|Vercise Implantable Stimulator for Treating Parkinson's Disease|VANTAGE STUDY Vercise™ Implantable Stimulator for Treating Parkinson's Disease|Active, not recruiting||Phase 2|53|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 23:15:26.635974|2018-05-31 23:15:26.635974
NCT01221935|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2011-01-25|2010-10-14|2010-10-18|Estimate|||||||2011-01-25|2011-01-26|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder|A Retrospective Study To Evaluate The Current Utilization Of Desvenlafaxine Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder|Completed|||2701|Actual|Pfizer|||4||f||||f||||||||||2018-05-31 23:15:27.20524|2018-05-31 23:15:27.20524
NCT01221922|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-11-27|2010-10-15|2010-10-18|Estimate|||||||2012-11-27|2012-11-28|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI|A Study of the RevLite Q-Switched Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG) Laser for the Treatment of Acne Scars in Fitzpatrick Skin Types III-VI|Completed||N/A|20|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 23:15:27.279012|2018-05-31 23:15:27.279012
NCT01221909|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-18|||2010-10-14|2010-10-14|2010-10-15|Estimate|||||||2010-10-14|2010-10-15|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|TA-DCR||Tranexamic Acid in Dacryocystorhinostomy|Single Dose Tranexamic Acid for Dacryocystorhinostomy|Unknown status|Not yet recruiting|N/A|80|Anticipated|HaEmek Medical Center, Israel||2|||f||||||||||||||2018-05-31 23:15:27.350028|2018-05-31 23:15:27.350028
NCT01221896|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-14|2010-10-14|2010-10-15|Estimate|||||||2010-10-14|2010-10-15|Estimate|January 2011||2011-01-31|October 2010|2010-10-31||||January 2014|Anticipated|2014-01-31||Observational|||Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma||Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 23:15:27.485996|2018-05-31 23:15:27.485996
NCT01221883|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2013-03-19|2010-10-14|2010-10-15|Estimate|||||||2013-03-19|2013-03-20|Estimate|May 2013||2013-05-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|May 2014|Anticipated|2014-05-31||Interventional|||Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam|Early Pharmacological Intervention With Diazepam in the Emergency Room Setting to Prevent Posttraumatic Stress Disorder (PTSD).|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 23:15:27.549898|2018-05-31 23:15:27.549898
NCT01221870|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2012-07-20|2010-10-14|2010-10-15|Estimate|||||||2012-07-20|2012-07-24|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|January 2013|Anticipated|2013-01-31|October 2012|Anticipated|2012-10-31||Interventional|||Tesetaxel as First-line Therapy for Metastatic Breast Cancer|A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|81|Anticipated|Genta Incorporated||2|||f||||f||||||||||2018-05-31 23:15:27.684875|2018-05-31 23:15:27.684875
NCT01221857|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2014-02-24|2010-10-14|2010-10-15|Estimate|||||||2014-02-24|2014-02-25|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|||Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies|Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hematological Malignancies|Completed||Phase 1/Phase 2|11|Actual|Gamida Cell ltd||1|||f||||t||||||||||2018-05-31 23:15:27.774528|2018-05-31 23:15:27.774528
NCT01221844|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-06-24|2010-10-14|2010-10-15|Estimate|||||||2011-06-24|2011-06-27|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies|Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women|Completed||Phase 4|300|Anticipated|Clinica Fabia Mater||2|||f||||f||||||||||2018-05-31 23:15:27.867161|2018-05-31 23:15:27.867161
NCT01221831|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2012-09-13|2010-10-14|2010-10-15|Estimate|||||||2012-09-13|2012-09-14|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|FIESTA||Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2|A Randomised Open-label Multi-centre Comparative Study to Evaluate Cycle Control of 2 Dosages of Estetrol Combined With Either P1 or P2, Compared to a Combined Oral Contraceptive Containing E2V and DNG|Completed||Phase 2|396|Actual|Estetra||5|||f||||f||||||||||2018-05-31 23:15:27.957521|2018-05-31 23:15:27.957521
NCT01221818|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2014-07-10|2010-10-14|2010-10-15|Estimate|||||||2014-07-10|2014-07-11|Estimate|September 2010||2010-09-30|July 2014|2014-07-31||||October 2011|Actual|2011-10-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects|Completed||Phase 1|48|Actual|Eisai Inc.||6|||f||||||||||||||2018-05-31 23:15:28.051761|2018-05-31 23:15:28.051761
NCT01221805|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-08-04|2010-10-14|2010-10-15|Estimate|||||||2016-08-04|2016-08-05|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|DiET||STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism|STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism|Completed|||2040|Actual|Diagnostica Stago|||||f||||f||||||Samples Without DNA|"~     plasma samples (at least 1 aliquot 0.5 ml) will be collected at the initial visit of patients~     with low or moderate PTP~   "|||2018-05-31 23:15:28.142392|2018-05-31 23:15:28.142392
NCT01221792|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2011-06-06|2010-10-14|2010-10-15|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|June 2011|Anticipated|2011-06-30||Interventional|||Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)|A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Carvedilol Versus Placebo in the Treatment of Post Traumatic Stress Disorder|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Columbia Northwest Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:15:28.236525|2018-05-31 23:15:28.236525
NCT01221779|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2013-08-26|2010-10-14|2010-10-15|Estimate|||||||2013-08-26|2013-08-27|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|CATS||Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation|Chronic Aphasia - Improved by Intensive Training and Electrical Brain|Unknown status|Recruiting|Phase 2|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:15:28.327641|2018-05-31 23:15:28.327641
NCT01221766|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2015-03-27|2010-10-14|2010-10-15|Estimate|||||||2015-03-27|2015-03-31|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|April 2013|Actual|2013-04-30||Observational|||Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease|The Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease|Completed|||12|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-05-31 23:15:28.397221|2018-05-31 23:15:28.397221
NCT01221753|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2016-08-15||2017-11-01|2010-10-14|2010-10-15|Estimate|2016-10-13|2016-12-06|Estimate||||2017-11-01|2017-12-06|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2012|Actual|2012-07-31||Interventional|||Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study|A Phase II Study of Docetaxel/Cisplatin/5-Fluorouracil (TPF) Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Using a Modified Radiation Dose in Patients With Newly Diagnosed HPV Positive, Locally Advanced Squamous Cell Carcinoma of the Oropharynx|Terminated||Phase 2|7|Actual|Dana-Farber Cancer Institute|The study was terminated early due to weak accrual. Because of the designation of study completed at the institution conducting the study, data collected systematically on the case report forms were not accessible for results reporting.|1||Due to slow accrual|f||||t||||||||No|There is no data available.|2018-05-31 23:15:28.455666|2018-05-31 23:15:28.455666
NCT01221740|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2017-01-11|2010-10-14|2010-10-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran|Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran|Withdrawn||Phase 3|0|Actual|Brigham and Women's Hospital||1||Company decided to discontinue|f||||f||||||||||2018-05-31 23:15:28.622191|2018-05-31 23:15:28.622191
NCT01221727|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2013-02-13||2014-07-18|2010-10-14|2010-10-15|Estimate|2013-09-05|2013-11-07|Estimate||||2014-07-18|2014-07-25|Estimate|November 2010||2010-11-30|July 2014|2014-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam|The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam, a Cytochrome P450 3A4/P-gp (CYP3A4) Substrate, in Postmenopausal Osteoporotic Women|Completed||Phase 1|30|Actual|Amgen||2|||f||||f||||||||||2018-05-31 23:15:28.708179|2018-05-31 23:15:28.708179
NCT01221714|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2018-01-22|2010-10-14|2010-10-15|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2010||2010-10-31|January 2018|2018-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Toxicity and Safety Evaluation of an Omega-3 Fatty Acid and a Multivitamin and Antioxidant Nutritional Preparation|Toxicity and Safety Evaluation of an Omega-3 Fatty Acid and a Multivitamin and Antioxidant Nutritional Preparation|Terminated|||200|Anticipated|AmeriSciences LP|||4|Ameriscience went bankrupt.|f||||t||||||Samples Without DNA|"~     Blood samples will be drawn at baseline and three months to monitor hematology, blood~     chemistry, and urinalysis values for major changes. CBC, Chem-17, uric acid, lipid panel,~     PT/PTT, and urinalysis will be evaluated under fasting conditions.~   "|||2018-05-31 23:15:29.314785|2018-05-31 23:15:29.314785
NCT01221701|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2013-03-15|2010-10-14|2010-10-15|Estimate|||||||2013-03-15|2013-03-18|Estimate|October 2006||2006-10-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|October 2010|Actual|2010-10-31||Interventional|MIDIS||Treatment of Depression in Mothers in Home Visitation|Treatment of Depression in Mothers in Home Visitation|Completed||N/A|93|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 23:15:29.383586|2018-05-31 23:15:29.383586
NCT01221688|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-08-30|2010-10-14|2010-10-15|Estimate|||||||2016-08-30|2016-08-31|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2015|Actual|2015-07-31||Interventional|GANEA 2||Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer|Evaluation of Sentinel Lymph Node Detection After Neoadjuvant Chemotherapy for Large Operable Breast Cancer|Active, not recruiting||N/A|858|Anticipated|Institut Cancerologie de l'Ouest||2|||f||||f||||||||||2018-05-31 23:15:29.466924|2018-05-31 23:15:29.466924
NCT01221675|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-08-30|2010-10-14|2010-10-15|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||TF2- Small Cell Lung Cancer Radio Immunotherapy|Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)|Completed||Phase 1/Phase 2|18|Actual|Centre René Gauducheau|||||f||||f||||||||||2018-05-31 23:15:29.622288|2018-05-31 23:15:29.622288
NCT01221662|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2010-10-14|2010-10-14|2010-10-15|Estimate|||||||2010-10-14|2010-10-15|Estimate|July 2010||2010-07-31|October 2010|2010-10-31|November 2012|Anticipated|2012-11-30|July 2012|Anticipated|2012-07-31||Interventional|||Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome|Complementary Therapy of Siwu Tang on Patients With Brain Hypoperfusion Syndrome|Unknown status|Recruiting|N/A|80|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-05-31 23:15:29.696622|2018-05-31 23:15:29.696622
NCT01221649|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2015-10-08|2010-10-14|2010-10-15|Estimate|||||||2015-10-08|2015-10-12|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan (J-HomeCARE II)|Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement in Japan|Completed||Phase 4|198|Actual|Biotronik Japan, Inc.|||||f||||f||||||||||2018-05-31 23:15:29.771744|2018-05-31 23:15:29.771744
NCT01221129|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2011-09-16|2010-10-13|2010-10-14|Estimate|||||||2011-09-16|2011-09-20|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)|Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)|Completed|||10|Actual|University of Florida|||1||f||||f||||||Samples With DNA|"~     Blood cells in clotted blood~   "|||2018-05-31 23:15:35.796764|2018-05-31 23:15:35.796764
NCT01221636|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2015-08-31|2010-10-14|2010-10-15|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept|A Study to Compare the Pharmacokinetics of Abatacept (BMS-188667) Drug Product Using Active Pharmaceutical Ingredient Manufactured With a High Concentration of Metals Relative to the Active Pharmaceutical Ingredient Manufactured With a Low Concentration of Metals|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 23:15:29.835265|2018-05-31 23:15:29.835265
NCT01221623|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2015-02-04||2017-09-07|2010-10-14|2010-10-15|Estimate|2015-03-24|2015-04-07|Estimate||||2017-09-07|2017-10-05|Actual|October 2010||2010-10-31|September 2017|2017-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of AA4500 in the Treatment of Peyronie's Disease|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease|Completed||Phase 3|418|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:15:29.938484|2018-05-31 23:15:29.938484
NCT01221610|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2015-02-06|2010-10-14|2010-10-15|Estimate|||||||2015-02-06|2015-02-09|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|||BIOLUX P-I First in Man Study|A Prospective, Multi-centre, Randomized Controlled, First in Man Study to Assess the Safety and Performance of the Passeo-18 Lux Paclitaxel Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Patients With Stenosis and Occlusion of the Femoropopliteal Arteries (BIOLUX P-I).|Completed||N/A|60|Actual|Biotronik AG||2|||f||||t||||||||||2018-05-31 23:15:30.387338|2018-05-31 23:15:30.387338
NCT01221597|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2015-02-04||2017-09-07|2010-10-14|2010-10-15|Estimate|2015-03-24|2015-04-07|Estimate||||2017-09-07|2017-10-05|Actual|September 2010||2010-09-30|September 2017|2017-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study of AA4500 in the Treatment of Peyronie's Disease|A Phase 3, Double-blind, Randomized, Placebo-controlled Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease|Completed||Phase 3|418|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:15:30.486699|2018-05-31 23:15:30.486699
NCT01221584|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-02-29|2010-10-14|2010-10-15|Estimate|||||||2012-02-29|2012-03-01|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|CEPHEUS||Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia|Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia|Completed|||1000|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:15:31.020563|2018-05-31 23:15:31.020563
NCT01221571|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2013-06-25|2010-10-14|2010-10-15|Estimate|||||||2013-06-25|2013-06-26|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||A Study to Assess AFM13 in Patients With Hodgkin Lymphoma|A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma|Completed||Phase 1|28|Actual|Affimed GmbH||1|||f||||t||||||||||2018-05-31 23:15:31.254183|2018-05-31 23:15:31.254183
NCT01221558|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-14|2010-10-14|2010-10-15|Estimate|||||||2010-10-14|2010-10-15|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men|Effects of Lycopene Supplementation on Oxidative Stress and Markers of Endothelial Function in Healthy Men|Completed||Phase 3|126|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 23:15:31.323655|2018-05-31 23:15:31.323655
NCT01221545|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2011-02-16|2010-10-14|2010-10-15|Estimate|||||||2011-02-16|2011-02-17|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After High Single Ascending Oral Supratherapeutic Doses of AZD1656 in Male Type 2 Diabetes Mellitus (T2DM) Patients|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:15:31.397147|2018-05-31 23:15:31.397147
NCT01221532|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-07-05|2010-10-13|2010-10-15|Estimate|||||||2013-07-05|2013-07-09|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|February 2012|Actual|2012-02-29||Interventional|SHHE||Support From Hospital to Home for Elders: A Randomized Controlled Study|Support From Hospital to Home for Elders: A Randomized Controlled Study|Completed||N/A|699|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:15:31.456163|2018-05-31 23:15:31.456163
NCT01221519|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2012-01-18|2010-10-14|2010-10-15|Estimate|||||||2012-01-18|2012-01-19|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients|Randomized, Open, 4-way Crossover, Single Center, Phase I Relative Bioavailability Study in Type 2 Diabetes Mellitus Patients to Measure the Extent and Rate of Absorption of AZD1656 From Different Tablet Formulations|Completed||Phase 1|20|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:15:31.515662|2018-05-31 23:15:31.515662
NCT01221506|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2016-09-23|2010-10-14|2010-10-15|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 2010||2010-10-31|September 2016|2016-09-30||||June 2015|Actual|2015-06-30||Interventional|||Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)|Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma|Completed||Early Phase 1|20|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:15:31.612029|2018-05-31 23:15:31.612029
NCT01221493|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-14|2010-10-14|2010-10-15|Estimate|||||||2010-10-14|2010-10-15|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||EBUS Guided Cryo Biopsy of Solitary Pulmonary Nodules||Unknown status|Recruiting|N/A|30|Anticipated|Heidelberg University||1|||f||||t||||||||||2018-05-31 23:15:31.672053|2018-05-31 23:15:31.672053
NCT01221480|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2016-11-30|2010-10-14|2010-10-15|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||What Influences Patient Outcome in Obstructive Airway Disease?|Beta-Blockers Reduce Mortality and Exacerbations When Added to Stepwise Inhaled Therapy for COPD Without Adverse Effects on Lung Function.|Completed|||5977|Actual|University of Dundee|||2||f||||f||||||||||2018-05-31 23:15:31.816024|2018-05-31 23:15:31.816024
NCT01221116|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-11-01|2010-10-13|2010-10-14|Estimate|||||||2010-11-01|2010-11-02|Estimate|January 2003||2003-01-31|January 2003|2003-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery|Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery|Terminated||N/A|23|Actual|Ullevaal University Hospital||1||The study was stopped due to difficulties in including patients|f||||f||||||||||2018-05-31 23:15:35.866111|2018-05-31 23:15:35.866111
NCT01221467|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2013-09-22|2010-10-14|2010-10-15|Estimate|||||||2013-09-22|2013-09-24|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Closing the Loop in Youth With Type 1 Diabetes in the Home Setting|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy, Safety and Utility of Real-time Continuous Subcutaneous Glucose Monitoring Combined With Overnight Closed-loop Glucose Control in the Home Setting in Comparison With Real-time Continuous Subcutaneous Glucose Monitoring Alone in Adolescents With Type 1 Diabetes on Subcutaneous Insulin Infusion Pump Therapy.|Completed||Phase 2|17|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 23:15:31.869429|2018-05-31 23:15:31.869429
NCT01221454|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-15|2010-10-14|2010-10-15|Estimate|||||||2010-10-15|2010-10-18|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure|Efficacy of Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Failure Resulting From Chronic Hepatitis B|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:15:31.937682|2018-05-31 23:15:31.937682
NCT01221441|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2015-11-05||2016-01-19|2010-10-13|2010-10-15|Estimate|2016-01-19|2016-02-15|Estimate||||2016-01-19|2016-02-15|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee|A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-β1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee|Completed||Phase 2|102|Actual|TissueGene, Inc.||2|||f||||t||||||||||2018-05-31 23:15:32.032471|2018-05-31 23:15:32.032471
NCT01221428|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2010-10-14|2010-10-14|2010-10-15|Estimate|||||||2010-10-14|2010-10-15|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion for Ulcerative Colitis|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Qingdao University||1|||f||||t||||||||||2018-05-31 23:15:32.585131|2018-05-31 23:15:32.585131
NCT01221415|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2011-10-26|2010-10-14|2010-10-15|Estimate|||||||2011-10-26|2011-10-27|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||A Comparison of Ultrasound and Nerve Stimulator Techniques for Nerve Localization in Regional Anesthesia|A Comparison of Ultrasound and Nerve Stimulator Techniques for Nerve Localization in Regional Anesthesia|Completed|||220|Anticipated|Ochsner Health System|||6||f||||t||||||||||2018-05-31 23:15:32.654983|2018-05-31 23:15:32.654983
NCT01221402|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2017-08-14|2010-10-14|2010-10-15|Estimate|||||||2017-08-14|2017-08-17|Actual|October 2010||2010-10-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|ALPINE-SVG||Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis|Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial|Completed||Phase 2|38|Actual|North Texas Veterans Healthcare System||2|||f||||t||||||||||2018-05-31 23:15:32.71948|2018-05-31 23:15:32.71948
NCT01221389|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2011-07-19|2010-10-13|2010-10-15|Estimate|||||||2011-07-19|2011-07-21|Estimate|March 2011||2011-03-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|SUPPRES||Study Using Plasma for Patients Requiring Emergency Surgery|Study Using Plasma for Patients Requiring Emergency Surgery: A Randomized Pilot Trial of Early Plasma for Patients Undergoing Emergency Surgery for Hemorrhagic Shock|Unknown status|Recruiting|Phase 4|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 23:15:32.799293|2018-05-31 23:15:32.799293
NCT01221376|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2013-03-25|2010-10-14|2010-10-15|Estimate|||||||2013-03-25|2013-03-26|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)|Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Hospital Santa Marcelina||1|||f||||f||||||||||2018-05-31 23:15:32.873735|2018-05-31 23:15:32.873735
NCT01221363|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2015-01-12||2015-01-19|2010-10-14|2010-10-15|Estimate|2015-01-19|2015-01-21|Estimate||||2015-01-19|2015-01-21|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|SIT||Reduction of Sitting Time: Sedentarism Intervention Trial|Reduction of Sitting Time - a Randomized Controlled Intervention Study|Completed||N/A|171|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 23:15:32.943083|2018-05-31 23:15:32.943083
NCT01221350|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|2013-04-23||2013-10-16|2010-10-14|2010-10-15|Estimate|2013-06-24|2013-07-30|Estimate||||2013-10-16|2013-11-08|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Patients with asthma from the occidental region of Mexico|Effects of Lipoic Acid on Oxidative, Inflammatory and Functional Markers in Asthmatic Patients|Exploratory Study of Lipoic Acid Supplementation on Oxidative Stress, Inflammatory and Functional Markers in Asthmatic Patients: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial.|Completed||N/A|55|Actual|Centro Universitario de Ciencias de la Salud, Mexico||2|||f||||f||||||||||2018-05-31 23:15:33.163396|2018-05-31 23:15:33.163396
NCT01221337|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2016-06-10|2010-10-14|2010-10-15|Estimate|||||||2016-06-10|2016-06-13|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||"Heparin Free Haemodialysis With Haemodialyzers VIE Versus EVODIAL"|"Comparative Study of Two Haemodialyzers VIE 2.1 Versus EVODIAL2.2 in a Strategy of Heparin-free Haemodialysis (HFH)"|Completed||N/A|32|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 23:15:33.567049|2018-05-31 23:15:33.567049
NCT01221324|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-14|||2012-02-10|2010-10-14|2010-10-15|Estimate|||||||2012-02-10|2012-02-13|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Diagnostic Value of C-reactive Protein and White Blood Cell Counts for Early Detection of Inflammatory Complications After Open Resection of Colorectal Cancer||Completed|||1200|Actual|Cantonal Hospital of St. Gallen|||1||f||||f||||||||||2018-05-31 23:15:33.630035|2018-05-31 23:15:33.630035
NCT01221311|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2017-03-21||2017-05-02|2010-10-13|2010-10-15|Estimate|2017-03-21|2017-05-01|Actual||||2017-05-02|2017-06-02|Actual|January 2011||2011-01-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|||Covered Metallic Stents for First-Line Treatment of Benign Bile Duct Strictures|Use of Fully-covered, Self-expandable Metallic Stents for First-line Treatment of Benign Bile Duct Strictures|Completed||N/A|112|Actual|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 23:15:33.680041|2018-05-31 23:15:33.680041
NCT01221298|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2014-12-29|2012-10-18|2014-12-29|2010-10-14|2010-10-15|Estimate|2014-12-29|2015-01-08|Estimate|2012-10-18|2012-10-23|Estimate|2014-12-29|2015-01-08|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|April 2012|Actual|2012-04-30|May 2011|Actual|2011-05-31||Interventional||Baseline analyses included all participants.|A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)|An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|11|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:15:33.837009|2018-05-31 23:15:33.837009
NCT01221285|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2014-04-24||2014-06-05|2010-10-13|2010-10-14|Estimate|2014-04-24|2014-05-23|Estimate||||2014-06-05|2014-06-11|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium|A Biomarker-Based Pilot Study of Cockroach Subcutaneous Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-18)|Completed||Phase 1|11|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 23:15:34.17309|2018-05-31 23:15:34.17309
NCT01221272|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2014-07-01|2013-08-08|2014-08-21|2010-10-13|2010-10-14|Estimate|2014-08-21|2014-09-03|Estimate|2013-08-08|2013-08-20|Estimate|2014-08-21|2014-09-03|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Safety Analysis Set|Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging|A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging|Completed||Phase 4|81|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 23:15:34.437413|2018-05-31 23:15:34.437413
NCT01221259|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2013-05-20|2010-10-13|2010-10-14|Estimate|||||||2013-05-20|2013-05-22|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional|||A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects|Completed||Phase 1|60|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 23:15:34.909477|2018-05-31 23:15:34.909477
NCT01221246|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2018-02-21|2010-10-13|2010-10-14|Estimate|||||||2018-02-21|2018-02-23|Actual|March 8, 2011|Actual|2011-03-08|February 2018|2018-02-28|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Interventional|GMAIS||Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours|A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window|Completed||Phase 2|34|Actual|Genervon Biopharmaceuticals, LLC||2|||f||||f||||||||No||2018-05-31 23:15:34.979496|2018-05-31 23:15:34.979496
NCT01221233|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2013-06-17|2010-10-13|2010-10-14|Estimate|||||||2013-06-17|2013-06-19|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Investigation of Trunk Muscle Size and Function in Older Adults With Chronic Low Back Pain|Lumbar Stabilization Exercises and Neuromuscular Electrical Stimulation: An Investigation of Muscle Size and Function in Older Adults With Chronic Low Back Pain|Completed||N/A|36|Anticipated|University of Delaware||2|||f||||f||||||||||2018-05-31 23:15:35.115223|2018-05-31 23:15:35.115223
NCT01221220|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2014-01-23|2010-10-13|2010-10-14|Estimate|||||||2014-01-23|2014-01-27|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Environmental Strategies & Behavior Change to Reduce Overeating in Obese Children|Environmental Strategies & Behavior Change to Reduce Overeating in Obese Children|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 23:15:35.21133|2018-05-31 23:15:35.21133
NCT01221207|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-15|2010-10-13|2010-10-14|Estimate|||||||2010-10-15|2010-10-18|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|ITCC||Instant Total Contact Cast to Heal Diabetic Foot Ulcers|Instant Total Contact Cast to Heal Diabetic Foot Ulcers|Unknown status|Recruiting|N/A|225|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-05-31 23:15:35.28975|2018-05-31 23:15:35.28975
NCT01221194|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Therapeutic Stockings to Prevent Foot Ulcers|Therapeutic Stockings to Prevent Foot Ulcers|Unknown status|Recruiting|N/A|400|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 23:15:35.384184|2018-05-31 23:15:35.384184
NCT01221181|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2014-02-05|2010-10-13|2010-10-14|Estimate|||||||2014-02-05|2014-02-07|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy|Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy|Unknown status|Active, not recruiting|Phase 1|6|Anticipated|Columbia University||1|||f||||t||||||||||2018-05-31 23:15:35.46708|2018-05-31 23:15:35.46708
NCT01221168|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2015-02-11|2010-10-13|2010-10-14|Estimate|||||||2015-02-11|2015-02-12|Estimate|October 1996||1996-10-31|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Epidemiologic and Genetic Study on Familial Prostate Cancer|ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial|Unknown status|Recruiting||6000|Anticipated|Centre de Recherche sur les Pathologies Prostatiques|||1||f||||f||||||Samples With DNA|"~     DNA extracted from blood/saliva or urine Serum~   "|||2018-05-31 23:15:35.55326|2018-05-31 23:15:35.55326
NCT01221155|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2012-09-21|2010-10-13|2010-10-14|Estimate|||||||2012-09-21|2012-09-25|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|||||Observational|||Extending Ultrasound Elastography to Manual Treatment Methods|Extending Ultrasound Elastography to Manual Treatment Methods|Completed|||101|Actual|Canadian Memorial Chiropractic College|||||f||||f||||||||||2018-05-31 23:15:35.654529|2018-05-31 23:15:35.654529
NCT01221142|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-12-27|2010-10-13|2010-10-14|Estimate|||||||2010-12-27|2010-12-28|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|June 2012||2012-06-30|September 2011||2011-09-30||Interventional|||Pilot Study of Hypothermia for Intracerebral Hemorrhage in Croatia||Unknown status|Not yet recruiting|Phase 3|20||University of Rijeka||1|||f||||t||||||||||2018-05-31 23:15:35.713117|2018-05-31 23:15:35.713117
NCT01115478|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2015-04-22|2010-04-30|2010-05-04|Estimate|||||||2015-04-22|2015-04-24|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MAL2||Malaria in Pregnancy: Nutrition and Immunologic Effects|Malaria in Pregnancy: Nutrition and Immunologic Effects|Completed||N/A|2500|Actual|Harvard School of Public Health||4|||f||||t||||||||||2018-05-31 23:50:38.075217|2018-05-31 23:50:38.075217
NCT01221103|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2011-09-12|2010-10-13|2010-10-14|Estimate|||||||2011-09-12|2011-09-13|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Interventional|||Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)|Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Southern Europe New Drug Organization||1|||f||||||||||||||2018-05-31 23:15:35.929651|2018-05-31 23:15:35.929651
NCT01221090|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2013-06-03||2013-08-07|2010-10-13|2010-10-14|Estimate|2013-08-07|2013-10-14|Estimate||||2013-08-07|2013-10-14|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|P20-P2||Diabetes Self-Management Models to Reduce Health Disparities|Employing Diabetes Self-Management Models to Reduce Health Disparities in Texas|Completed||Phase 4|376|Actual|Scott and White Hospital & Clinic|Differential dropout across interventions. Failure to obtain 50% minority and 50% non-minority participants, preventing further analyses regarding race/ethnicity differences in outcome. Could only provide information in an exploratory manner.|4|||f||||t||||||||||2018-05-31 23:15:36.045448|2018-05-31 23:15:36.045448
NCT01221077|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05||2014-02-20|2014-10-03|2010-10-13|2010-10-14|Estimate||||2014-02-20|2014-03-21|Estimate|2014-10-03|2014-10-13|Estimate|December 2011||2011-12-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|March 2013|Actual|2013-03-31||Interventional|||Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene|A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene|Completed||Phase 2|88|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-05-31 23:15:37.452949|2018-05-31 23:15:37.452949
NCT01221064|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-01-30|2010-10-13|2010-10-14|Estimate|||||||2012-01-30|2012-01-31|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|May 2014|Anticipated|2014-05-31|May 2013|Anticipated|2013-05-31||Interventional|CHLONKA||Effect of Early vs Late Drainage Removal in Women After Radical Mastectomy With Axillary Clearance|Prospective Randomised Clinical Trial Comparing the Effect of Early and Late Drainage Removal in Female Patients After Radical Mastectomy With Axillary Clearance|Unknown status|Recruiting|N/A|100|Anticipated|Medical University of Gdansk||2|||f||||t||||||||||2018-05-31 23:15:37.599321|2018-05-31 23:15:37.599321
NCT01221051|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2012-03-30|2010-10-13|2010-10-14|Estimate|||||||2012-03-30|2012-04-02|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Third Stage of Labor a Swedish Randomized Controlled Trial|A Comparison of Active and Expectant Management of the Third Stage of Labor|Completed||N/A|1800|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 23:15:37.683763|2018-05-31 23:15:37.683763
NCT01221038|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2011-07-12|2010-10-13|2010-10-14|Estimate|||||||2011-07-12|2011-07-13|Estimate|February 2011||2011-02-28|June 2011|2011-06-30||||November 2011|Anticipated|2011-11-30||Observational|||Standardization of a Heat Tolerance Test for Young Women as a Basis for Heat Tolerance Tests in Female Soldiers|Preliminary Study for Standardization of Heat Tolerance Test for Young Women|Unknown status|Recruiting||30|Anticipated|Medical Corps, Israel Defense Force|||3||f||||f||||||||||2018-05-31 23:15:37.752923|2018-05-31 23:15:37.752923
NCT01221025|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-03-24|2010-10-13|2010-10-14|Estimate|||||||2011-03-24|2011-03-25|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Effect Study of Parecoxib to Treat Emergence Delirium and Postoperative Pain|Effects of Parecoxib on Emergence Delirium and Postoperative Pain in Elderly Patients Undergoing Abdominal Surgery After General Anesthesia|Unknown status|Recruiting|Phase 4|900|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 23:15:37.812056|2018-05-31 23:15:37.812056
NCT01221012|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2012-03-28|2010-10-13|2010-10-14|Estimate|||||||2012-03-28|2012-03-29|Estimate|December 2010||2010-12-31|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Heat Stress and Physiological Strain of Permeable vs. Impermeable CB Protective Garment||Unknown status|Recruiting||12|Anticipated|Medical Corps, Israel Defense Force|||5||f||||||||||||||2018-05-31 23:15:37.880787|2018-05-31 23:15:37.880787
NCT01220999|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-02-27|2010-10-13|2010-10-14|Estimate|||||||2013-02-27|2013-02-28|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||An Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer|A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.|Completed||Phase 1|19|Actual|Ludwig Institute for Cancer Research||1|||f||||f||||||||||2018-05-31 23:15:37.935446|2018-05-31 23:15:37.935446
NCT01220986|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|August 2012|Anticipated|2012-08-31|December 2011|Anticipated|2011-12-31||Observational|||Liver Regeneration After Liver Resection|An Observational Study of Liver Regeneration After Right Hepatectomy: Understanding the Molecular Primers of Liver Regeneration|Unknown status|Recruiting||20|Anticipated|Nottingham University Hospitals NHS Trust|||1||f||||t||||||Samples With DNA|"~     Liver tissue & serum~   "|||2018-05-31 23:15:37.99659|2018-05-31 23:15:37.99659
NCT01220973|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2017-04-17||2018-03-21|2010-10-13|2010-10-14|Estimate|2018-03-21|2018-04-20|Actual||||2018-03-21|2018-04-20|Actual|February 2009||2009-02-28|March 2018|2018-03-31|November 18, 2014|Actual|2014-11-18|November 18, 2014|Actual|2014-11-18||Interventional|||Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer|Phase II Trial of Atorvastatin and Celecoxib in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer.|Completed||Phase 2|27|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 23:15:38.066412|2018-05-31 23:15:38.066412
NCT01220960|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-09|||2013-10-24|2010-10-13|2010-10-14|Estimate|||||||2013-10-24|2013-10-25|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Art Therapy Intervention for Breast Cancer Patients|A Mixed Methods Approach to Evaluating How Art Therapy Can Benefit Women Recently Diagnosed With Breast Cancer|Completed||N/A|64|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 23:15:38.222911|2018-05-31 23:15:38.222911
NCT01220947|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07||2016-07-08|2016-11-01|2010-10-13|2010-10-14|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection||Completed||Phase 2|421|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 23:15:38.295722|2018-05-31 23:15:38.295722
NCT01114919|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-12-01|2010-04-30|2010-05-03|Estimate|||||||2010-12-01|2010-12-02|Estimate|May 2010||2010-05-31|December 2010|2010-12-31||||November 2010|Actual|2010-11-30||Interventional|||Helping Problem Drinkers on the Internet|Helping Problem Drinkers on the Internet|Completed||N/A|246|Anticipated|Centre for Addiction and Mental Health|||||f||||f||||||||||2018-05-31 23:50:43.490044|2018-05-31 23:50:43.490044
NCT01220934|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-03-21|2010-10-13|2010-10-14|Estimate|||||||2017-03-21|2017-03-23|Actual|April 16, 2010|Actual|2010-04-16|March 2017|2017-03-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Observational|||An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer|Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES)|Completed|||443|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:15:39.557283|2018-05-31 23:15:39.557283
NCT01220921|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2015-12-03|2010-10-13|2010-10-14|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|Neuropoint SD||Neurosurgery Patient Outcomes in Treating Spinal Disorders|Neurosurgery Patient Outcomes in Treating Spinal Disorders|Completed||Phase 3|198|Actual|Greenwich Hospital||2|||f||||f||||||||||2018-05-31 23:15:39.630308|2018-05-31 23:15:39.630308
NCT01220908|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2014-03-11|2010-10-13|2010-10-14|Estimate|||||||2014-03-11|2014-03-12|Estimate|January 2008||2008-01-31|December 2010|2010-12-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Evaluation of the PneumRx Lung Volume Reduction Coil to Treat Emphysema|Evaluation of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema|Completed||Phase 1/Phase 2|36|Actual|PneumRx, Inc.||1|||f||||f||||||||||2018-05-31 23:15:39.755211|2018-05-31 23:15:39.755211
NCT01220895|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2018-01-23|2010-10-13|2010-10-14|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2010||2010-10-31|January 2018|2018-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|CMV-ACE/ASPECT||Alternate Donor Study of Pre-Emptive Cellular Therapy|A Prospective Phase II Study to Investigate the Efficacy and Safety of Pre-emptive Cytomegalovirus Adoptive Cellular Therapy in Patients Receiving Allogeneic Haematopoietic Stem Cell Transplant From an Unrelated Donor|Completed||Phase 2|52|Actual|Cell Medica Ltd||2|||f||||t||||||||||2018-05-31 23:15:40.652469|2018-05-31 23:15:40.652469
NCT01220882|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-12-24|2010-10-12|2010-10-14|Estimate|||||||2013-12-24|2013-12-25|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Evaluation of Skeletal Maturity for Slipped Capital Femoral Epiphysis|Skeletal Age Assessment From the Olecranon For Slipped Capital Femoral Epiphysis|Unknown status|Recruiting|N/A|60|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-05-31 23:15:40.729098|2018-05-31 23:15:40.729098
NCT01220869|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2013-10-14||2013-12-06|2010-10-13|2010-10-14|Estimate|2013-10-14|2013-12-06|Estimate||||2013-12-06|2014-01-08|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||The number of baseline participants is identical to the number of patients exposed to degarelix.|A Study of Degarelix in Taiwanese Patients With Prostate Cancer|An Open-label, Multi-centre Registration Trial, Investigating Efficacy and Safety of Degarelix One-month Dosing Regimen in Taiwanese Patients With Prostate Cancer Requiring Androgen Ablation Therapy|Completed||Phase 3|110|Actual|Ferring Pharmaceuticals||1|||f||||t||||||||||2018-05-31 23:15:40.833215|2018-05-31 23:15:40.833215
NCT01220856|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2014-06-27|2010-10-13|2010-10-14|Estimate|||||||2014-06-27|2014-06-30|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|September 2012|Actual|2012-09-30||Interventional|||Reparixin in Pancreatic Islet Transplantation|A Phase 2 Multicenter, Randomized, Open Label, Parallel Assignment, Pilot Study to Assess the Efficacy and Safety of Reparixin Following Islet Transplantation in Patients With Type 1 Diabetes Mellitus|Completed||Phase 2|9|Actual|Dompé Farmaceutici S.p.A||2|||f||||f||||||||||2018-05-31 23:15:41.057509|2018-05-31 23:15:41.057509
NCT01220843|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-04-27|2010-10-13|2010-10-14|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|FRENCH||FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease|Randomized Placebo Controlled Double-blind Trial in CKD Patients Not on Dialysis to Evaluate the Effect of Sevelamer Carbonate in the Control of FGF-23 Serum Levels and Its Consequences in the Evolution of PTH, Calcitriol and Mineral Metabolism Parameters Levels|Completed||Phase 3|98|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 23:15:41.232441|2018-05-31 23:15:41.232441
NCT01220830|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-09|||2011-09-16|2010-10-13|2010-10-14|Estimate|||||||2011-09-16|2011-09-19|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|RFQMR||Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis|Efficacy of Rotational Field Quantum Nuclear Magnetic Resonance (RFQMR) Based Tissue Engineering in the Treatment of Multiple Sclerosis|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|The Centre for Advanced Research & Development, India||1|||f||||t||||||||||2018-05-31 23:15:41.356522|2018-05-31 23:15:41.356522
NCT01220817|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-04-05|2010-10-12|2010-10-14|Estimate|||||||2012-04-05|2012-04-06|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study|Safety and Efficacy of POMx in Men With Prostate Cancer: An 18-Month, Randomized, Double-Blind, Dose-Finding Study of the Effects of Two (2) Doses of Pomegranate Juice Extract Capsules (1 or 3 Capsules/Day) on Rising Prostate Specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer|Completed||Phase 2|104|Actual|POM Wonderful LLC||2|||f||||f||||||||||2018-05-31 23:15:41.433421|2018-05-31 23:15:41.433421
NCT01220804|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-04-22|2010-10-13|2010-10-14|Estimate|||||||2016-04-22|2016-04-25|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|March 2013|Actual|2013-03-31|December 2011|Actual|2011-12-31||Observational|CNTM025A OCT||Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography|Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography|Completed|||30|Actual|Association for Innovation and Biomedical Research on Light and Image|||2||f||||f||||||||||2018-05-31 23:15:41.522736|2018-05-31 23:15:41.522736
NCT01220791|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Methylprednisolone Addition in IVF Treatment of Infertile Couples|Methylprednisolone vs. Placebo to Control Late Follicular Progesterone Elevation in GnRH-Antagonist IVF Cycles|Unknown status|Recruiting|Phase 4|130|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 23:15:41.590514|2018-05-31 23:15:41.590514
NCT01220778|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate||||September 2010|2010-09-30||||||||Interventional|||Effects of Physical Activity During Pregnancy on the Newborn's Cognitive Function|Effects of Physical Activity During Pregnancy on the Newborn's Cognitive Function, the Healthy Mom, Bright Child Randomized Trial|Unknown status|Recruiting|N/A|||Université de Montréal||2|||f||||f||||||||||2018-05-31 23:15:41.705267|2018-05-31 23:15:41.705267
NCT01113853|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-04-30|2010-04-28|2010-04-30|Estimate|||||||2010-04-30|2010-05-03|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2010|Actual|2010-01-31|||||Observational|||Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients|Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients Stopping Anti-inflammatory Treatment|Completed|||40|Actual|Universita di Verona|||||f||||f||||||||||2018-05-31 23:51:02.215647|2018-05-31 23:51:02.215647
NCT01220765|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-06-09|2010-10-13|2010-10-14|Estimate|||||||2011-06-09|2011-06-10|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Capnography During Nurse Administered Propofol Sedation|Assessment of Capnography in Monitoring Patients During Nurse Administered Deep Sedation With Propofol|Completed||N/A|440|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 23:15:41.786047|2018-05-31 23:15:41.786047
NCT01220752|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-04-23|2010-10-13|2010-10-14|Estimate|||||||2013-04-23|2013-04-24|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|November 2016|Anticipated|2016-11-30|November 2014|Anticipated|2014-11-30||Interventional|IMRT-HIT-SNT||Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12)|Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12)|Unknown status|Recruiting|Phase 2|30|Anticipated|Heidelberg University||1|||f||||f||||||||||2018-05-31 23:15:41.884677|2018-05-31 23:15:41.884677
NCT01220739|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|2014-12-03||2016-10-07|2010-10-13|2010-10-14|Estimate|2016-10-07|2016-12-05|Estimate||||2016-10-07|2016-12-05|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|StELLAR||Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery|Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery|Terminated||Phase 2|12|Actual|University of California, San Diego|Study was terminated early due to device sponsor filing bankruptcy.|2||Device sponsor no longer in business.|f||||t||||||||Yes|Data will be uploaded to the NINDS data sharing website.|2018-05-31 23:15:41.990736|2018-05-31 23:15:41.990736
NCT01220726|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2010-10-12|2010-10-12|2010-10-14|Estimate|||||||2010-10-12|2010-10-14|Estimate|June 2009||2009-06-30|October 2010|2010-10-31||||June 2011|Anticipated|2011-06-30||Interventional|||Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction|Randomized Double-blind Placebo Controlled Trial of Intradetrusor Injections of Botox for the Treatment of Refractory Overactive Bladder Secondary to Benign Prostatic Obstruction-BTX0621|Unknown status|Recruiting|Phase 3|20|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 23:15:42.274132|2018-05-31 23:15:42.274132
NCT01220713|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2013-08-26|2010-10-12|2010-10-14|Estimate|||||||2013-08-26|2013-08-27|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|HBOT||Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI)|Hyperbaric Oxygen Therapy (HBO2T) for Post-Concussive Symptoms (PSC) After Mild Traumatic Brain Injury (mTBI): A Randomized, Double-Blinded, Sham Controlled, Variable Dose, Prospective Trial|Completed||Phase 2|60|Actual|Virginia Commonwealth University||3|||f||||t||||||||||2018-05-31 23:15:42.372471|2018-05-31 23:15:42.372471
NCT01220700|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2015-02-05|2010-10-12|2010-10-14|Estimate|||||||2015-02-05|2015-02-06|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Antimicrobial Coated Sutures in Paediatric Surgery|Antimicrobial Coated Sutures in Paediatric Surgery|Completed||N/A|1635|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 23:15:42.583902|2018-05-31 23:15:42.583902
NCT01220687|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2018-01-03|2010-10-12|2010-10-14|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2011||2011-04-30|January 2018|2018-01-31|May 1, 2017|Actual|2017-05-01|January 2017|Actual|2017-01-31||Interventional|iNO||Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation|Administration of Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation Protocol: A Pilot Trial|Completed||N/A|33|Actual|University of Oklahoma||2|||f||||t||||||||No|Abstract presented to The Pediatric Academic Society Meeting, May 9, 2017|2018-05-31 23:15:42.661158|2018-05-31 23:15:42.661158
NCT01220674|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2018-01-29|2010-10-13|2010-10-14|Estimate|||||||2018-01-29|2018-01-31|Actual|November 1, 2010|Actual|2010-11-01|January 2018|2018-01-31|October 31, 2012|Actual|2012-10-31|October 31, 2012|Actual|2012-10-31||Observational|||Pilot Testing a New Computer-based Screening Tool to Detect Cognitive Impairment|Pilot Testing a New Computer-based Screening Tool to Detect Cognitive Impairment|Completed|||152|Actual|University of Nebraska|||2||f||||f||||||||||2018-05-31 23:15:42.738728|2018-05-31 23:15:42.738728
NCT01220661|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-12-11|2010-10-13|2010-10-14|Estimate|||||||2011-12-11|2011-12-13|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery|Phase 2 Study of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery|Completed||Phase 2|312|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 23:15:42.800537|2018-05-31 23:15:42.800537
NCT01220648|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-05-01|2010-10-12|2010-10-14|Estimate|||||||2015-05-01|2015-05-05|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|NICOLI||Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)|An Open Label, Nonrandomized, Single-center, Phase I Trial of Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) With Nilotinib in Combination With Low Dose Interferon-alpha (IFN) - NICOLI Study -|Completed||Phase 1|4|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:15:42.8809|2018-05-31 23:15:42.8809
NCT01220635|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2014-02-13|2010-10-12|2010-10-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|MSM||Middle School Matters Study|Prevention of Depression Within Salient Adolescent Contexts|Completed||N/A|120|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 23:15:43.014832|2018-05-31 23:15:43.014832
NCT01220622|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Interventional|NICE||Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes|Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE)|Unknown status|Recruiting|Phase 4|656|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-05-31 23:15:43.179294|2018-05-31 23:15:43.179294
NCT01220609|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2015-09-30||2017-10-20|2010-10-12|2010-10-14|Estimate|2015-09-30|2015-11-03|Estimate||||2017-10-20|2017-11-22|Actual|November 2010||2010-11-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|July 2014|Actual|2014-07-31||Interventional||Eligible and treated patients|Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy|A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Completed||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:15:43.361022|2018-05-31 23:15:43.361022
NCT01220414|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2015-12-07||2018-01-22|2010-10-11|2010-10-13|Estimate|2018-01-22|2018-02-16|Estimate||||2018-01-22|2018-02-16|Estimate|September 2010||2010-09-30|January 2018|2018-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Attenuation of Pain in Men and Women|Attenuation of Pain in Men and Women: Mechanisms of Exercise-Induced Analgesia|Completed||N/A|60|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 23:15:47.330701|2018-05-31 23:15:47.330701
NCT01220596|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2011-07-01|2010-10-13|2010-10-14|Estimate|||||||2011-07-01|2011-07-04|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|POTENT||Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.|A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.|Unknown status|Recruiting|Phase 3|228|Anticipated|Hanyang University||2|||f||||t||||||||||2018-05-31 23:15:43.920315|2018-05-31 23:15:43.920315
NCT01220583|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2018-04-30|2010-10-12|2010-10-14|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2011||2011-01-31|April 2018|2018-04-30|October 2028|Anticipated|2028-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery|A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors|Recruiting||Phase 2|120|Anticipated|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 23:15:44.096945|2018-05-31 23:15:44.096945
NCT01220570|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2015-01-19|2010-10-13|2010-10-14|Estimate|||||||2015-01-19|2015-01-21|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)|A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer|Completed||Phase 1|63|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 23:15:44.489068|2018-05-31 23:15:44.489068
NCT01220557|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2014-08-08||2014-08-08|2010-10-13|2010-10-14|Estimate|2014-08-08|2014-08-26|Estimate||||2014-08-08|2014-08-26|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PRIMAS||Evaluation of a Treatment and Education Programme for Type 1 Diabetic Patients (PRIMAS)|Prospective Randomized Trial for the Evaluation of a Treatment and Education Programme for Type 1 Diabetic Patients (PRIMAS)|Completed||N/A|162|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||||2018-05-31 23:15:44.58541|2018-05-31 23:15:44.58541
NCT01220544|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-13|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate|July 2001||2001-07-31|October 2010|2010-10-31|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells|Transplantation of Hematopoetic Stem Cells and Infusion of CD56+CD3- NK Cells From Haploidentical Donors for Patients With Hematological Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 23:15:45.03775|2018-05-31 23:15:45.03775
NCT01220531|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2018-05-17|2010-10-12|2010-10-14|Estimate|||||||2018-05-17|2018-05-21|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Thymus Transplantation Safety-Efficacy|Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836|Available|||||Duke University|||||||t|t|||||||||||2018-05-31 23:15:45.315065|2018-05-31 23:15:45.315065
NCT01220518|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-03-11|2010-10-12|2010-10-14|Estimate|||||||2013-03-11|2013-03-12|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)|Randomized, Double-blind, Parallel-group, Phase 1 Study|Completed||Phase 1|257|Actual|Celltrion||2|||f||||t||||||||||2018-05-31 23:15:45.425914|2018-05-31 23:15:45.425914
NCT01220505|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2017-08-01|2010-10-13|2010-10-14|Estimate|||||||2017-08-01|2017-08-02|Actual|September 2010||2010-09-30|August 2017|2017-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Post Market Surveillance to Evaluate the Effectiveness the Polaris Deformity Spinal System|A Post Market Surveillance Validation to Evaluate the Effectiveness of the Following System: Polaris Deformity Spinal System|Completed|||66|Actual|Zimmer Biomet|||||f||||f||||||||Undecided||2018-05-31 23:15:45.517241|2018-05-31 23:15:45.517241
NCT01220492|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-05-30|2010-10-12|2010-10-14|Estimate|||||||2013-05-30|2013-05-31|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells for Patients With Liver Cirrhosis|Phase 1/2 Study of UC-MSC Treatment for the Evaluation the Efficacy and Safety in Patients With Liver Cirrhosis|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 23:15:45.61707|2018-05-31 23:15:45.61707
NCT01220479|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate|September 2001||2001-09-30|October 2010|2010-10-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|Diabex||Exercise Training Intervention in Children With Type 1 Diabetes|Impact of an Exercise Training Program on Bone Development and Cardiovascular Disease Risk Factors in Children With Type 1 Diabetes Mellitus|Completed||N/A|59|Actual|University Hospital, Geneva||4|||f||||f||||||||||2018-05-31 23:15:45.802839|2018-05-31 23:15:45.802839
NCT01220466|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2013-02-15||2013-05-16|2010-10-12|2010-10-14|Estimate|2013-05-16|2013-05-20|Estimate||||2013-05-16|2013-05-20|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Performance and Acceptability of iDesign|A Prospective Study to Evaluate the Performance and Acceptability of the iDesign Advanced WaveScan Study(tm) System|Completed||N/A|77|Actual|Abbott Medical Optics||1|||f||||f||||||||||2018-05-31 23:15:46.12778|2018-05-31 23:15:46.12778
NCT01220453|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-10-05|2010-10-13|2010-10-14|Estimate|||||||2012-10-05|2012-10-08|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Observational|CLEAR||Compliance and Efficacy in the Use of PICOPREP®|Compliance and Efficacy in the Use of PICOPREP® for Bowel Cleansing|Completed|||2165|Actual|Ferring Pharmaceuticals|||||f||||||||||||||2018-05-31 23:15:46.70526|2018-05-31 23:15:46.70526
NCT01220440|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-10-13|2010-10-13|2010-10-14|Estimate|||||||2010-10-13|2010-10-14|Estimate|January 2006||2006-01-31|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD|Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD|Completed||Phase 4|36|Actual|Ostfold Hospital Trust||1|||f||||||||||||||2018-05-31 23:15:46.978118|2018-05-31 23:15:46.978118
NCT01220427|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-03-02|2010-10-12|2010-10-13|Estimate|||||||2016-03-02|2016-03-03|Estimate|June 2007||2007-06-30|August 2010|2010-08-31||||||||Observational|||Micro-RNA Expression Profiles in High Risk Prostate Cancer|Micro-RNA Expression Profiles in High Risk Prostate Cancer|Terminated|||300|Anticipated|Wuerzburg University Hospital|||1||f||||f||||||||||2018-05-31 23:15:47.1703|2018-05-31 23:15:47.1703
NCT01220401|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|2014-03-29||2014-09-12|2010-10-11|2010-10-13|Estimate|2014-07-15|2014-08-08|Estimate||||2014-09-12|2014-09-25|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy of a Brief Nightmare Treatment for Veterans|Efficacy of a Brief Nightmare Treatment for Veterans|Completed||N/A|21|Actual|University of Tulsa||1|||f||||f||||||||||2018-05-31 23:15:47.754065|2018-05-31 23:15:47.754065
NCT01220388|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2013-06-17|2010-10-12|2010-10-13|Estimate|||||||2013-06-17|2013-06-18|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|L-Lysine||Effects of L-lysine on Adrenal Secretion|Pilot Study of the Action L-lysine on Aldosterone and Cortisol Secretion in Healthy Volunteers.|Completed||N/A|20|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 23:15:48.116504|2018-05-31 23:15:48.116504
NCT01220375|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2014-04-16|2010-10-12|2010-10-13|Estimate|||||||2014-04-16|2014-04-17|Estimate|April 2010||2010-04-30|April 2014|2014-04-30|October 2013|Actual|2013-10-31|January 2012|Actual|2012-01-31||Interventional|PAV||PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma|PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma. A Pilot Phase II Study.|Completed||Phase 2|44|Actual|University Hospital Inselspital, Berne||1|||f||||t||||||||||2018-05-31 23:15:48.246834|2018-05-31 23:15:48.246834
NCT01220362|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2011-12-14|2010-10-11|2010-10-13|Estimate|||||||2011-12-14|2011-12-15|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study|Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study|Completed||N/A|40|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 23:15:48.406346|2018-05-31 23:15:48.406346
NCT01220349|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2013-04-18|2010-10-11|2010-10-13|Estimate|||||||2013-04-18|2013-04-19|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ECHO-DIAB||Alteration of Myocardial Deformations in Diabetes: Relationship to Micro-angiopathy|Early Detection of Diabetic Cardiomyopathy by Analysis of Myocardial Deformations by Two-dimensional Speckle Tracking Strain Echocardiography and Relationship to Micro-angiopathy|Completed||N/A|61|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 23:15:48.490709|2018-05-31 23:15:48.490709
NCT01220336|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2014-10-17|2010-10-11|2010-10-13|Estimate|||||||2014-10-17|2014-10-21|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|HCPC||Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions||Completed||N/A|441|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:15:48.589583|2018-05-31 23:15:48.589583
NCT01220323|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-11|2010-10-11|2010-10-13|Estimate|||||||2010-10-11|2010-10-13|Estimate|November 2010||2010-11-30|October 2010|2010-10-31||||November 2011|Anticipated|2011-11-30||Interventional|||Transcranial Direct Current Stimulation for Chronic Pain Relief|Transcranial Direct Current Stimulation for Chronic Pain Relief|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 23:15:48.695051|2018-05-31 23:15:48.695051
NCT01220310|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2016-04-18|2010-10-11|2010-10-13|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Doctors and Web-based Self-management Support Pilot Study|Doctors and Web-based Self-management Support Pilot Study.|Completed||Phase 3|57|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 23:15:48.778571|2018-05-31 23:15:48.778571
NCT01220297|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2017-03-13||2017-05-31|2010-10-11|2010-10-13|Estimate|2017-05-31|2017-06-05|Actual||||2017-05-31|2017-06-05|Actual|August 2006||2006-08-31|May 2017|2017-05-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT|Sirolimus and Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation|Terminated||Phase 2|3|Actual|Stanford University||2||Low accrual|f||||f|t|f|||f|||No||2018-05-31 23:15:48.893277|2018-05-31 23:15:48.893277
NCT01220284|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2010-10-11|2010-10-11|2010-10-13|Estimate|||||||2010-10-11|2010-10-13|Estimate|February 2008||2008-02-29|September 2010|2010-09-30|February 2011|Anticipated|2011-02-28|November 2010|Anticipated|2010-11-30||Interventional|||Satraplatin and Vinorelbine in Advanced Solid Tumors|Dose-finding Study of Satraplatin in Combination With Oral Vinorelbine in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|27|Actual|Southern Europe New Drug Organization||1|||f||||f||||||||||2018-05-31 23:15:49.720024|2018-05-31 23:15:49.720024
NCT01220271|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12||2015-12-23|2017-02-15|2010-10-12|2010-10-13|Estimate||||2015-12-23|2016-01-29|Estimate|2017-02-15|2017-02-16|Actual|April 2011||2011-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|August 2015|Actual|2015-08-31||Interventional|||A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma|Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma|Completed||Phase 1/Phase 2|75|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 23:15:49.828965|2018-05-31 23:15:49.828965
NCT01220258|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-12-13|2010-10-12|2010-10-13|Estimate|||||||2013-12-13|2013-12-16|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)|A Single-Center, Open-Label Study to Characterize Eyelid Margin Erythema, Markers of Clinical Inflammation and Levels of Inflammatory Mediators in the Lid Margins and Conjunctivae of Untreated Healthy Volunteers and Subjects Diagnosed With Posterior Blepharoconjunctivitis Following Dosing With Azithromycin Ophthalmic Solution, 1% for Four Weeks|Terminated||Phase 2|29|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 23:15:49.957562|2018-05-31 23:15:49.957562
NCT01220245|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2018-04-25|2010-10-11|2010-10-13|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2010||2010-10-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|SuperB||SuperB Trial: SUrgical Versus PERcutaneous Bypass|Heparin-bonded Endoluminal Versus Surgical Femoropopliteal Bypass; a Multicentre Randomized Controlled Trial|Active, not recruiting||N/A|126|Anticipated|Rijnstate Hospital||2|||f||||f||||||||||2018-05-31 23:15:50.071957|2018-05-31 23:15:50.071957
NCT01220232|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-02-03|2010-10-12|2010-10-13|Estimate|||||||2011-02-03|2011-02-04|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects|Open-Label, Fixed-Sequence, Crossover Study To Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:15:50.240159|2018-05-31 23:15:50.240159
NCT01220219|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-01-10|2010-10-12|2010-10-13|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2010||2010-11-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers|An Open-Label, Multiple-Dose, Randomized, 3-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 82.5 Mg And 165 Mg Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal And 75 Mg Of The Immediate Release Formulation Administered Twice Daily|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:15:50.371466|2018-05-31 23:15:50.371466
NCT01220206|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2012-10-04|2010-10-11|2010-10-13|Estimate|||||||2012-10-04|2012-10-05|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||POMx In the Treatment of Erectile Dysfunction|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of POM Wonderful Pomegranate Extract Capsules In Male Subjects With Moderate to Severe Erectile Dysfunction|Completed||Phase 2|120|Actual|POM Wonderful LLC||3|||f||||f||||||||||2018-05-31 23:15:50.563906|2018-05-31 23:15:50.563906
NCT01220193|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2011-02-16|2010-10-12|2010-10-13|Estimate|||||||2011-02-16|2011-02-18|Estimate|April 2009||2009-04-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Evaluation of RTVue in Corneal Measurement|Evaluation of RTVue in Corneal Measurement|Completed|||196|Anticipated|Optovue|||4||f||||||||||||||2018-05-31 23:15:50.630507|2018-05-31 23:15:50.630507
NCT01220180|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2011-11-03||2011-11-03|2010-10-12|2010-10-13|Estimate|2011-11-03|2011-12-08|Estimate||||2011-11-03|2011-12-08|Estimate|July 2006||2006-07-31|November 2011|2011-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Lyrica (Pregabalin) Korean Post Marketing Surveillance Study|Post Marketing Surveillance Study For Observing Safety And Efficacy Of Lyrica|Completed|||4175|Actual|Pfizer|It is highly likely that Adverse Events were under reported for this study as it was a Non Interventional study.||3||f||||f||||||||||2018-05-31 23:15:50.726618|2018-05-31 23:15:50.726618
NCT01220167|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-07-25|2010-10-12|2010-10-13|Estimate|||||||2011-07-25|2011-07-26|Estimate|August 2008||2008-08-31|October 2010|2010-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Three-way Crossover Comparative Water-effect Bioavailability to Compare Ondansetron ODFS 8mg With and Without Water With Zofran ODT 8mg Without Water in 18 Healthy Participants Under Fasting Conditions|An Open-label Randomized, Single Oral Dose, Three-way Crossover Comparative Water-effect Bioavailability Study to Compare Ondansetron Orally Dissolving Filmstrop (ODFS)8mg (MonoSol Rx USA) With and Without Water With Zofran Orally Dissolving Tablets (ODT) (Containing Ondansetron 8mg) (Glaxo SmithKline, USA) Without Water in 18 Adult, Healthy Human Study Participants Under Fasting Conditions.|Completed||Phase 3|18|Actual|Par Pharmaceutical, Inc.||2|||f||||||||||||||2018-05-31 23:15:51.887329|2018-05-31 23:15:51.887329
NCT01220154|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-10-12|2010-10-12|2010-10-13|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2010||2010-10-31|October 2016|2016-10-31||||March 2021|Anticipated|2021-03-31||Interventional|||Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer|Phase I Study of Intraperitoneal Carboplatin With Intravenous Paclitaxel and Bevacizumab in Patients With Previously Untreated Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma|Active, not recruiting||Phase 1|9|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:15:52.223231|2018-05-31 23:15:52.223231
NCT01220141|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2015-04-15|2010-10-12|2010-10-13|Estimate|||||||2015-04-15|2015-04-16|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B|Prospective Observational Study on NovoSeven® Room Temperature Stable (VII25) in Patients With Haemophilia A or B|Completed|||51|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 23:15:52.756378|2018-05-31 23:15:52.756378
NCT01220128|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2016-11-28|2015-03-12|2017-04-24|2010-10-12|2010-10-13|Estimate|2017-04-24|2017-05-25|Actual|2015-03-12|2015-04-01|Estimate|2017-04-24|2017-05-25|Actual|April 1, 2011|Actual|2011-04-01|April 2017|2017-04-30|November 14, 2014|Actual|2014-11-14|November 1, 2014|Actual|2014-11-01||Interventional|INDUCT||Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer|Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer|Terminated||Phase 2|66|Actual|GlaxoSmithKline||9||"Study termination due to negative Ph III of another study product from same technology~   platform."|f||||||||||||||2018-05-31 23:15:53.148142|2018-05-31 23:15:53.148142
NCT01220115|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2015-05-18|2010-10-12|2010-10-13|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|FISCO||A 5-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients|A 5-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease Patients|Completed|||498|Actual|Novartis|||3||f||||f||||||||||2018-05-31 23:15:56.42176|2018-05-31 23:15:56.42176
NCT01220102|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-02-15|2010-10-12|2010-10-13|Estimate|||||||2016-02-15|2016-02-17|Estimate|May 2010||2010-05-31|February 2016|2016-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|TEENA||Efficacy of Epiduo and Treatment Adherence of Adolescent Patients With Inflammatory Acne|Efficacy of Epiduo and Adherence of Patients Between 12 to 20 Years Using This Drug First Time in the Monotherapy of Moderate Inflammatory Acne|Completed|||3113|Actual|Galderma Laboratorium GmbH|||||f||||f||||||||No||2018-05-31 23:15:57.701408|2018-05-31 23:15:57.701408
NCT01220089|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-08-12|2010-10-12|2010-10-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|October 2013|Actual|2013-10-31||Interventional|||Adaptation of the Diabetes Prevention Program for Primary Care|Adaptation of the Diabetes Prevention Program for Primary Care|Completed||N/A|106|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 23:15:57.759872|2018-05-31 23:15:57.759872
NCT01220076|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-08-30|2010-10-12|2010-10-13|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|TAM||Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+|Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+|Recruiting||Phase 2|265|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f||||||||||2018-05-31 23:15:57.831835|2018-05-31 23:15:57.831835
NCT01220063|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-08-30|2010-10-12|2010-10-13|Estimate|||||||2016-08-30|2016-08-31|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|June 2018||2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|RS CAMPTO||RSHF in Colorectal Cancer|CLINICAL MULTICENTER STUDY OF PHASE II AND RADIOBIOLOGY ASSESSING Hypofractionated Stereotactic Radiotherapy With Irinotecan (Campto) IN THE TREATMENT OF LIVER METASTASIS AND / OR PULMONARY, Unoperated or Recurrent After Surgery of a Colorectal Cancer|Active, not recruiting||Phase 2|48|Actual|Institut Cancerologie de l'Ouest|||||f||||f||||||||No||2018-05-31 23:15:57.909383|2018-05-31 23:15:57.909383
NCT01219894|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-11-18|2010-10-11|2010-10-13|Estimate|||||||2013-11-18|2013-11-20|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|FDI-DAPT-ZES||Intravascular Optical Coherence Tomography Imaging - Length of Anti-Platelet Therapy After Drug Eluting Stent Placement|Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement|Withdrawn|||0|Actual|Emory University|||2|Number of patients to meet individual IDE requirements was not obtained.|f||||t||||||||||2018-05-31 23:16:00.329653|2018-05-31 23:16:00.329653
NCT01220050|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2013-02-21|2010-10-12|2010-10-13|Estimate|||||||2013-02-21|2013-02-22|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Interventional|APPLE||Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism|A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH SECONDARY HYPERPARATHYROIDISM|Completed||Phase 2|43|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 23:15:58.008587|2018-05-31 23:15:58.008587
NCT01220037|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2013-10-25|2010-10-12|2010-10-13|Estimate|||||||2013-10-25|2013-10-28|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Resistance Exercise in Healthy Men|The Effect of Age and Dietary Protein Intake on Myocellular Characteristics Following a Single Bout of Resistance Exercise in Healthy Men|Completed||N/A|34|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 23:15:58.277799|2018-05-31 23:15:58.277799
NCT01220024|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2014-09-02|2010-10-11|2010-10-13|Estimate|||||||2014-09-02|2014-09-04|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy|A Phase II, Randomized, Single Dose, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety Profile of the CollaRx® Bupivacaine Implant (200 mg Bupivacaine Hydrochloride) in Men After Open Laparotomy Herniorrhaphy|Completed||Phase 2|50|Actual|Innocoll||2|||f||||f||||||||||2018-05-31 23:15:58.363818|2018-05-31 23:15:58.363818
NCT01220011|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-12-20|2010-10-11|2010-10-13|Estimate|||||||2016-12-20|2016-12-21|Estimate|April 2011||2011-04-30|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|TTTS1||Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery|A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery|Recruiting||Phase 4|142|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:15:58.465898|2018-05-31 23:15:58.465898
NCT01219998|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2013-05-22|2010-10-12|2010-10-13|Estimate|||||||2013-05-22|2013-05-23|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Observational|NGAL||NGAL, an Early Predictive Marker of Acute Kidney Injury After Cardiac Surgery in Neonates and Infants|Evaluation of the Predictive Ability of Urinary NGAL as an Early Marker of Acute Kidney Injury Following Cardiac Surgery in Neonates and Infants|Completed|||205|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Blood and urine samples are collected during the early postoperative period, stored, than~     NGAL concentrations are measures on the ARCHITECT platform.~   "|||2018-05-31 23:15:58.608071|2018-05-31 23:15:58.608071
NCT01219985|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2012-06-29||2016-04-27|2010-10-12|2010-10-13|Estimate|2013-07-25|2013-10-10|Estimate||||2016-04-27|2016-05-27|Estimate|April 2008||2008-04-30|April 2016|2016-04-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|RespiTEP|Patients presenting liver lesions planned for hepatic surgery|Benefits Study of Respiratory-gated Positron Emission Tomography Acquisitions of the Liver|Benefits Study of a Respiratory Gating Protocol for 18F-FDG PET: Application on the Liver|Completed||N/A|50|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 23:15:58.695479|2018-05-31 23:15:58.695479
NCT01219972|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2017-01-03|2010-10-12|2010-10-13|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2006||2006-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|February 2009|Actual|2009-02-28||Observational|ALLOPULM||Pulmonary Complications of Allografts|Prospective Cohort Study of Late Pulmonary Complications in Patients Who Received Allogeneic Hematopoietic Stem Cells Transplantation: Estimation of Incidence and Identification of Distinct Nosologic Entities|Completed|||245|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||Undecided||2018-05-31 23:15:58.890685|2018-05-31 23:15:58.890685
NCT01219959|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2017-04-19|2010-10-12|2010-10-13|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2010||2010-10-31|April 2017|2017-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|EDEN||Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients|Multi-center, Prospective, Randomized Trial to Demonstrate Improved Metabolic Control of Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in the Treatment of Diabetic CAPD Patients|Completed||Phase 3|71|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-05-31 23:15:58.951899|2018-05-31 23:15:58.951899
NCT01219946|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-03-20|2010-10-12|2010-10-13|Estimate|||||||2012-03-20|2012-03-21|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|COPD Language||A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)|A Cross Sectional Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease and the Limitations of Patients' Activities in Primary Care.|Completed|||700|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:15:59.055913|2018-05-31 23:15:59.055913
NCT01219933|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|2014-08-26||2015-01-15|2010-10-11|2010-10-13|Estimate|2015-01-15|2015-01-19|Estimate||||2015-01-15|2015-01-19|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Safety observational (obs): all participants included in the study who were eligible for the study at Visit (V) 1.|A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)|An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE)|Completed||Phase 4|68|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:15:59.216816|2018-05-31 23:15:59.216816
NCT01219920|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-03-10|2010-10-11|2010-10-13|Estimate|||||||2015-03-10|2015-03-11|Estimate|November 2001||2001-11-30|March 2015|2015-03-31|November 2009|Actual|2009-11-30|November 2005|Actual|2005-11-30||Interventional|||FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer|Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer|Completed||Phase 3|244|Actual|Gruppo Oncologico del Nord-Ovest||2|||f||||t||||||||||2018-05-31 23:16:00.126097|2018-05-31 23:16:00.126097
NCT01219907|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2013-05-15|2010-10-11|2010-10-13|Estimate|||||||2013-05-15|2013-05-17|Estimate|June 2012||2012-06-30|May 2013|2013-05-31||||June 2014|Anticipated|2014-06-30||Interventional|||Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer|Phase I Study of Adoptive T-Cell Therapy With HER-2/Neu (HER-2)-Specific Memory CD8+ T Lymphocytes Obtained Following In Vivo Priming With a Peptide Vaccine in Patients With Advanced Stage HER-2-Positive Breast Cancer|Withdrawn||Phase 1|0|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:16:00.253539|2018-05-31 23:16:00.253539
NCT01219881|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2012-10-30||2013-01-02|2010-10-12|2010-10-13|Estimate|2012-10-30|2012-11-29|Estimate||||2013-01-02|2013-01-07|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery|A Randomized, Double-Blind, Double-Arm Trial Comparing Desflurane to Sevoflurane for the Effect on Recovery Time in Patients Undergoing Urological Cystoscope Surgery Under General Anesthesia With a Laryngeal Mask Airway (LMA)|Completed||Phase 3|75|Actual|Ohio State University|Nine patients which were screen failures and not included in final analysis. Patients assessed for SOMCT score every 15 minutes in the PACU, which did not allow for an exact time for the return to cognition endpoint.|2|||f||||t||||||||||2018-05-31 23:16:00.409502|2018-05-31 23:16:00.409502
NCT01219868|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2013-03-19|2010-10-12|2010-10-13|Estimate|||||||2013-03-19|2013-03-20|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Physician-nurse Team to Reduce Emergency Department (ED) Overcrowding|Impact of Physician-nurse Team on ED Length of Stay|Completed||N/A|8000|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 23:16:00.721587|2018-05-31 23:16:00.721587
NCT01219855|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|2016-07-08|2014-09-16|2016-08-24|2010-10-12|2010-10-13|Estimate|2016-08-24|2016-08-25|Estimate|2014-09-16|2014-09-29|Estimate|2016-08-24|2016-08-25|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Intent to treat population (excludes a single subject randomized to the 90 µg treatment arm who was lost to follow-up prior to receiving study drug)|Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)|A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism|Completed||Phase 2/Phase 3|78|Actual|OPKO Health, Inc.||5|||f||||t||||||||No||2018-05-31 23:16:00.814321|2018-05-31 23:16:00.814321
NCT01219842|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-10-12|2010-10-12|2010-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Interventional|IRONIC||Invasive Revascularization or Not in Intermittent Claudication|Invasive Revascularization or Not in Intermittent Claudication|Active, not recruiting||N/A|159|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 23:16:01.550682|2018-05-31 23:16:01.550682
NCT01219829|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2018-02-06|2010-10-12|2010-10-13|Estimate|||||||2018-02-06|2018-02-08|Actual|March 18, 2009|Actual|2009-03-18|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma|Refining the Molecular Progression From Intraductal to Invasive Pancreatic Cancer: Correlating Genetic Profiles and Clinicopathological Phenotypes in Sporadic and Familial Pancreatic Adenocarcinoma|Active, not recruiting|||5|Actual|Columbia University|||2||f||||t|f|f||||Samples With DNA|"~     -  Blood samples~        -  Specimens of tumors, pre-cancerous lesions, and normal tissue from patients who need to~          have endoscopy or surgery for diagnosis or treatment of tumors that develop~        -  Samples of urine and stool, and duodenal aspirates if an individual will be having an~          endoscopy~   "|No||2018-05-31 23:16:01.619799|2018-05-31 23:16:01.619799
NCT01219816|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2018-02-26|2010-10-12|2010-10-13|Estimate|||||||2018-02-26|2018-02-27|Actual|November 2010||2010-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|CHEPRALL||Multi-centric Study|Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study.|Completed||Phase 2|57|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 23:16:01.684628|2018-05-31 23:16:01.684628
NCT01219803|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2012-05-05|2010-10-12|2010-10-13|Estimate|||||||2012-05-05|2012-05-08|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Trial of Different Dosages' Ge Gen Qin Lian Decoction in the Treatment of Type 2 Diabetes|Dosage-efficacy Relationship Clinical Trial of Ge Gen Qin Lian Decoction|Unknown status|Recruiting|N/A|240|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||4|||f||||t||||||||||2018-05-31 23:16:01.767227|2018-05-31 23:16:01.767227
NCT01219790|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2016-04-18|2010-10-12|2010-10-13|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|GEMO||ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma|STUDY OF PHASE ID'ACIDE ZOLEDRONIC ASSOCIATED WITH A STRONG DOSE Hypofractionated Radiotherapy in Bone Metastases Vertebral Prostate Adenocarcinoma|Completed||Phase 1|30|Actual|Institut Cancerologie de l'Ouest||1|||f||||f||||||||||2018-05-31 23:16:01.850656|2018-05-31 23:16:01.850656
NCT01219777|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|2015-05-06||2018-02-07|2010-10-12|2010-10-13|Estimate|2015-06-03|2015-06-29|Estimate||||2018-02-07|2018-02-08|Actual|September 2010||2010-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2012|Actual|2012-05-31||Interventional|||Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian|Phase I Evaluation of Intravenous Carboplatin With Weekly Paclitaxel and Bevacizumab in Patients Undergoing Neoadjuvant Chemotherapy for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Completed||Phase 1|9|Actual|Ohio State University Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 23:16:01.9118|2018-05-31 23:16:01.9118
NCT01219764|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2014-01-24|2010-10-12|2010-10-13|Estimate|||||||2014-01-24|2014-01-27|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection|A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection|Completed||Phase 4|200|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 23:16:02.079451|2018-05-31 23:16:02.079451
NCT01219751|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-06-16|2010-10-12|2010-10-13|Estimate|||||||2011-06-16|2011-06-17|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma|Phase II Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 23:16:02.141976|2018-05-31 23:16:02.141976
NCT01219738|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|2014-11-12||2015-01-07|2010-10-12|2010-10-13|Estimate|2015-01-07|2015-01-16|Estimate||||2015-01-07|2015-01-16|Estimate|July 2008||2008-07-31|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide|Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide|Completed||N/A|20|Actual|University of Miami||5|||f||||f||||||||||2018-05-31 23:16:02.208121|2018-05-31 23:16:02.208121
NCT01219725|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-27|2010-10-12|2010-10-13|Estimate|||||||2010-10-27|2010-10-28|Estimate|July 2005||2005-07-31|May 2009|2009-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Cardiovascular Prophylaxis for Postmenopausal Women|Can a Moderate Intensity Exercise Training Programme Improve Cardiac Function and Known Cardiovascular Risk Factors in Middle-aged Women?|Unknown status|Recruiting|Phase 2|100|Anticipated|University of Leeds|||||f||||f||||||||||2018-05-31 23:16:02.495966|2018-05-31 23:16:02.495966
NCT01219712|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-10-12|2010-10-12|2010-10-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Interventional|||Optimization Study of Cardiac Risk Patients With Hip Fracture|Preoperative Optimization of the High-Risk Patient Undergoing Hip Fracture Surgery|Unknown status|Not yet recruiting|N/A|200|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 23:16:02.623057|2018-05-31 23:16:02.623057
NCT01219699|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2018-05-29|2010-10-11|2010-10-13|Estimate|||||||2018-05-29|2018-05-30|Actual|October 5, 2010|Actual|2010-10-05|May 2018|2018-05-31|December 25, 2018|Anticipated|2018-12-25|May 2, 2013|Actual|2013-05-02||Interventional|||A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene|A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene|Active, not recruiting||Phase 1|221|Actual|Novartis||2|||f|||||t|f||||||No||2018-05-31 23:16:02.794501|2018-05-31 23:16:02.794501
NCT01219686|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2015-05-26|2010-10-12|2010-10-13|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|ESPION||EScitalopram PIndolol ONset of Action|Antidepressant Effect of Escitalopram: Delay of Onset. Clinical Randomized Double-blinded Study With Three Parallel Treatment Groups (Escitalopram 20mg vs Escitalopram 30mg vs Escitalopram 20 mg + Pindolol 15 mg/Day|Terminated||Phase 2/Phase 3|18|Actual|University Hospital, Geneva||3||Recruitment difficulties|f||||t||||||||||2018-05-31 23:16:02.906666|2018-05-31 23:16:02.906666
NCT01219673|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|2015-01-15||2015-01-15|2010-10-11|2010-10-13|Estimate|2015-01-15|2015-02-10|Estimate||||2015-01-15|2015-02-10|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Study halted due to low enrollment (one participant). No analysis completed.|Symptom Burden in Head and Neck Cancer|A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Head and Neck Cancer|Terminated||Phase 1/Phase 2|1|Actual|M.D. Anderson Cancer Center|Analysis was not possible due to early termination with only one participant accrued.|8||Low accrual.|f||||t||||||||||2018-05-31 23:16:03.076562|2018-05-31 23:16:03.076562
NCT01219660|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-12|2010-10-12|2010-10-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|OSA||Obstructive Sleep Apnea (OSA) Anesthesia and Positive Airway Pressure|Obstructive Sleep Apnea (OSA) Anesthesia and Positive Airway Pressure|Unknown status|Enrolling by invitation||75|Anticipated|University of California, San Diego|||||f||||f||||||||||2018-05-31 23:16:03.476438|2018-05-31 23:16:03.476438
NCT01219647|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2014-12-05|2010-10-12|2010-10-13|Estimate|||||||2014-12-05|2014-12-09|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CogEx||Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis|Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis|Completed||Phase 1/Phase 2|35|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 23:16:03.524605|2018-05-31 23:16:03.524605
NCT01219621|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-12|2010-10-12|2010-10-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|April 2006||2006-04-30|September 2006|2006-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|CAN-SAVE R||Comparison of AAIsafeR and DDD Modes in Non-selected Patients|A Prospective Canadian Multi-Center Randomized Study; Spontaneous AtrioVEntricular Conduction PReservation|Completed||Phase 3|450|Actual|Sorin Group Canada||2|||f||||f||||||||||2018-05-31 23:16:03.596386|2018-05-31 23:16:03.596386
NCT01219608|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2011-06-13|2010-10-12|2010-10-13|Estimate|||||||2011-06-13|2011-06-14|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Iranian Intensive Care Unit (ICU) Glutamine Study|Iranian Intensive Care Unit (ICU) Glutamine Study|Completed||N/A|60|Anticipated|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-05-31 23:16:03.674736|2018-05-31 23:16:03.674736
NCT01219595|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2016-01-28|2010-10-08|2010-10-13|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women|Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women|Completed||N/A|65|Actual|University of Wisconsin, Madison||6|||f||||f||||||||||2018-05-31 23:16:03.730268|2018-05-31 23:16:03.730268
NCT01219582|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2013-11-11|2010-10-11|2010-10-13|Estimate|||||||2013-11-11|2013-11-13|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Observational|GLOBE||GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients|Open, Prospective, Multicentric, Single-arm, Non-interventional Study to Evaluate the Effectiveness & Safety of Oral Glucobay®-M Tablets in Type 2 Diabetes Patient|Completed|||9364|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:16:03.940616|2018-05-31 23:16:03.940616
NCT01219569|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2015-04-23|2010-10-08|2010-10-13|Estimate|||||||2015-04-23|2015-04-24|Estimate|August 2007||2007-08-31|August 2013|2013-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry|The Effects of Sevoflurane and Propofol on Light Flashed Evoked Pupillometry|Completed|||35|Actual|Rutgers, The State University of New Jersey|||2||f||||f||||||||||2018-05-31 23:16:04.01857|2018-05-31 23:16:04.01857
NCT01219556|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2014-01-25|2010-10-11|2010-10-13|Estimate|||||||2014-01-25|2014-01-28|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Observational|XCITE||Xirtam H Combination In the Treatment of Hypertension Evaluation Study.|Prospective, Multicentric, Large Scale Observational Study to Evaluate the Effectiveness & Safety of Xirtam H in Indian Patients Suffering From Hypertension.|Completed|||8704|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:16:04.100588|2018-05-31 23:16:04.100588
NCT01219374|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-22|2010-10-08|2010-10-13|Estimate|||||||2013-01-22|2013-01-24|Estimate|December 2006||2006-12-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Study of Ovum Donors After Donation|A Longitudinal Prospective Study of Ovum Donors After Donation|Completed|||500|Actual|Reproductive Medicine Associates of New Jersey|||1||f||||f||||||||||2018-05-31 23:16:05.044902|2018-05-31 23:16:05.044902
NCT01219543|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2013-01-07|2010-10-12|2010-10-13|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.|A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 in Asian Patients With Advanced Solid Malignancies and Asian Patients With Child-Pugh A to B7 Advanced Hepatocellular Carcinoma (HCC) in the Escalation Phase, Estimated Glomerular Filtration Rate(EGFR) or ROS Mutant NSCLC and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour With Biopsy Available in the Expansion Phase.|Terminated||Phase 1|47|Actual|AstraZeneca||4||Compound development discontinued|f||||||||||||||2018-05-31 23:16:04.176103|2018-05-31 23:16:04.176103
NCT01219530|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-22|2010-10-08|2010-10-13|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Follow Up of Gestational Carriers and Intended Parents|Follow Up of Gestational Carriers and Intended Parents|Withdrawn|||0|Actual|Reproductive Medicine Associates of New Jersey|||2||f||||f||||||||||2018-05-31 23:16:04.240365|2018-05-31 23:16:04.240365
NCT01219517|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-22|2010-10-08|2010-10-13|Estimate|||||||2013-01-22|2013-01-23|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Validation of the Accuracy of DNA Fingerprinting Using Polar Bodies and Embryonic Cells|Validation of the Accuracy of DNA Fingerprinting Using Polar Bodies and Embryonic Cells|Completed||N/A|100|Actual|Reproductive Medicine Associates of New Jersey||1|||f||||f||||||||||2018-05-31 23:16:04.291097|2018-05-31 23:16:04.291097
NCT01219504|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-22|2010-10-12|2010-10-13|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing In Vitro Fertilization (IVF)|Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing IVF|Completed|||200|Actual|Reproductive Medicine Associates of New Jersey|||||f||||f||||||Samples With DNA|"~     Blood samples on female and male patients. Buccal swabs on infant(s).~   "|||2018-05-31 23:16:04.352816|2018-05-31 23:16:04.352816
NCT01219491|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-03-04|2010-10-08|2010-10-13|Estimate|||||||2013-03-04|2013-03-05|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Egg Donor Recipient Characteristics Preferences|Do Egg Donor Recipient Characteristics Change Over Time?|Completed|||131|Actual|Reproductive Medicine Associates of New Jersey|||1||f||||f||||||||||2018-05-31 23:16:04.401338|2018-05-31 23:16:04.401338
NCT01219478|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2010-12-19|2010-10-12|2010-10-13|Estimate|||||||2010-12-19|2010-12-21|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|December 2009|Actual|2009-12-31|||||Observational|||Research of the Correlation Between Metabolic Syndrome, Retinal Thickness and Visual Acuity|Research of the Correlation Between Metabolic Syndrome, Retinal Thickness and Visual Acuity|Completed|||100|Actual|Taipei Medical University WanFang Hospital|||4||f||||f||||||||||2018-05-31 23:16:04.527571|2018-05-31 23:16:04.527571
NCT01219465|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-12|2010-10-12|2010-10-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes Mellitus|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Infusion for Initial Type 1 Diabetes|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Qingdao University||1|||f||||t||||||||||2018-05-31 23:16:04.58738|2018-05-31 23:16:04.58738
NCT01219452|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-27|2010-10-12|2010-10-13|Estimate|||||||2010-10-27|2010-10-28|Estimate|October 2010||2010-10-31|May 2010|2010-05-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy|Effects of Intramuscular Injection of Umbilical Cord Mesenchymal Stem Cell on the Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Qingdao University||1|||f||||t||||||||||2018-05-31 23:16:04.659466|2018-05-31 23:16:04.659466
NCT01219439|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-03-23|2010-10-12|2010-10-13|Estimate|||||||2018-03-23|2018-03-26|Estimate|July 2007||2007-07-31|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Evaluation of Discarded Laboratory Pathological Specimens and Media|Laboratory Evaluation of IVF Discarded Pathological Specimens and Media for Optimization of Techniques for Assisted Reproduction|Active, not recruiting|||10000|Anticipated|Reproductive Medicine Associates of New Jersey|||||f||||f||||||Samples With DNA|"~     Samples with DNA: Non-viable oocytes, spermatozoa, granulosa cells and follicular fluid~     Samples without DNA: seminal fluid, serum and conditioned IVF media~   "|||2018-05-31 23:16:04.737407|2018-05-31 23:16:04.737407
NCT01219426|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-05-19|2010-10-12|2010-10-13|Estimate|||||||2011-05-19|2011-05-20|Estimate|March 2008||2008-03-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||A Transversal Study for the French Validation of Two Assessment Tools of Gambling Related Cognitions.|A Transversal Study for the French Validation of Two Assessment Tools of Gambling Related Cognitions.|Completed|||||Nantes University Hospital|||2||f||||f||||||||||2018-05-31 23:16:04.792603|2018-05-31 23:16:04.792603
NCT01219413|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2015-09-23|2010-10-12|2010-10-13|Estimate|||||||2015-09-23|2015-09-24|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|ALIPRES||Influence of Aliskiren on Proteinuria|The Effect of Aliskiren on Proteinuria in Chronic Nondiabetic Kidney Disease: a Double Blind Cross-over Randomized Controlled Trial|Completed||Phase 4|16|Actual|Medical University of Gdansk||2|||f||||t||||||||||2018-05-31 23:16:04.850379|2018-05-31 23:16:04.850379
NCT01219400|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2014-09-29|2010-10-12|2010-10-13|Estimate|||||||2014-09-29|2014-09-30|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes|Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes|Completed||Phase 4|28|Actual|Lund University||1|||f||||t||||||||||2018-05-31 23:16:04.916766|2018-05-31 23:16:04.916766
NCT01219387|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-22|2010-10-08|2010-10-13|Estimate|||||||2013-01-22|2013-01-23|Estimate|February 2006||2006-02-28|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old|Evaluation of Serum Anti-Mullerian Hormone (AMH) and Inhibin B Levels as Early Predictors of a Successful IVF Cycle in Women Over 38 Years Old.|Completed|||300|Actual|Reproductive Medicine Associates of New Jersey|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:16:04.98884|2018-05-31 23:16:04.98884
NCT01219361|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-03-23|2010-10-08|2010-10-13|Estimate|||||||2018-03-23|2018-03-26|Estimate|July 2005||2005-07-31|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Evaluation of Donated Human Embryos Following in Vitro Fertilization|Evaluation of Donated Human Embryos for Study of Normal and Abnormal Differentiation and Development Following in Vitro Fertilization.|Enrolling by invitation|||5000|Anticipated|Reproductive Medicine Associates of New Jersey|||||f||||f||||||Samples With DNA|"~     Donated embryos~   "|||2018-05-31 23:16:05.101047|2018-05-31 23:16:05.101047
NCT01219348|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-08-17|2010-10-12|2010-10-13|Estimate|||||||2015-08-17|2015-08-18|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|IDOvaccine||IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.|IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.|Completed||Phase 1|14|Actual|Herlev Hospital||1|||f||||t||||||||||2018-05-31 23:16:05.153104|2018-05-31 23:16:05.153104
NCT01219335|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-03-23|2010-10-08|2010-10-13|Estimate|||||||2018-03-23|2018-03-27|Actual|April 2003||2003-04-30|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Discarded Materials Study|Laboratory Evaluation of De-identified, Developmentally Arrested Embryos of Embryos Diagnosed as Having an Abnormal Number of Chromosomes for Optimization of Techniques for Assisted Reproduction|Recruiting|||10000|Anticipated|Reproductive Medicine Associates of New Jersey|||||f||||f||||||Samples With DNA|"~     Discarded non-viable oocytes, granulosa cells, spermatozoa, developmentally arrested embryos,~     serum, follicular fluid, and conditioned IVF media.~   "|||2018-05-31 23:16:05.219524|2018-05-31 23:16:05.219524
NCT01219322|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2010-10-27|2010-10-12|2010-10-13|Estimate|||||||2010-10-27|2010-10-28|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Intravenous Sodium Bicarbonate Verifies Intravenous Position of Catheters in Anesthetized Children|Intravenous Bicarbonate Identifies the Correct Position of Intravenous Catheter|Unknown status|Recruiting|Phase 1|30|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:16:05.289102|2018-05-31 23:16:05.289102
NCT01219309|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-10-12|2010-10-12|2010-10-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|August 2004||2004-08-31|April 2010|2010-04-30|April 2007|Actual|2007-04-30|June 2006|Actual|2006-06-30||Interventional|||Omega-3/Omega-6 Fatty Acids for Attention-Deficit/Hyperactivity Disorder (ADHD): A Trial in Children and Adolescents|Omega-3/Omega-6 Fatty Acids for ADHD. A Randomized Placebo-controlled Trial in Children and Adolescents|Completed||Phase 3|82|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 23:16:05.376981|2018-05-31 23:16:05.376981
NCT01219296|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-11-16|2010-10-08|2010-10-13|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2002||2002-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|||Retrospective Database Studies|Retrospective Database Studies From Reproductive Endocrinology Practice Looking at Relationships Between Demographics, Stimulation Protocols and Outcomes, Retrieval and Transfer Outcomes, Number and Quality of Oocytes and Embryos Retrieved and Transferred, Pregnancy Rates and Pregnancy Outcomes.|Completed|||1|Actual|Reproductive Medicine Associates of New Jersey|||||f||||f||||||||||2018-05-31 23:16:05.435851|2018-05-31 23:16:05.435851
NCT01219283|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-03-25|2010-10-12|2010-10-13|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Study of the Efficacy of 24 Chromosome Preimplantation Genetic Diagnosis (PGD)|A Prospective Randomized Clinical Trial to Determine the Efficacy of 24 Chromosome Preimplantation Genetic Diagnosis|Completed|||334|Actual|Reproductive Medicine Associates of New Jersey|||2||f||||f||||||Samples With DNA|"~     Blood samples from the male and female partners. Buccal swabs from infants.~   "|||2018-05-31 23:16:05.487121|2018-05-31 23:16:05.487121
NCT01219270|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-10-13|2010-10-12|2010-10-13|Estimate|||||||2010-10-13|2010-10-14|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|June 2011|Anticipated|2011-06-30|February 2011|Anticipated|2011-02-28||Observational|||Radiocontrast Media Induced Hyponatremia|Radiocontrast Media Induced Hyponatremia After Percutaneous Coronary Intervention: Observational Study|Unknown status|Recruiting||100|Anticipated|Gachon University Gil Medical Center|||2||f||||f||||||||||2018-05-31 23:16:05.547684|2018-05-31 23:16:05.547684
NCT01219257|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-01-19|2010-10-12|2010-10-13|Estimate|||||||2016-01-19|2016-01-20|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|ULSPABIT||Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy|Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting First Time or Switching to a New Biological Therapy; the ULSpABiT Study.|Completed|||50|Actual|Diakonhjemmet Hospital|||1||f||||f||||||Samples With DNA|"~     At the first visit, one glass with blood will be frozen for later genetical analyzes, all~     related to questions regarding SpA.~   "|||2018-05-31 23:16:05.601616|2018-05-31 23:16:05.601616
NCT01219244|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2017-07-26|2010-10-12|2010-10-13|Estimate|||||||2017-07-26|2017-07-28|Actual|August 2010||2010-08-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)|Enhancing Memory Functions in Patients With Mild Cognitive Impairment by Dietary Interventions and in Combination With Exercise and Cognitive Training - Proof of Concept and Mechanisms|Completed||Phase 2/Phase 3|330|Anticipated|Charite University, Berlin, Germany||6|||f||||t||||||||||2018-05-31 23:16:05.661771|2018-05-31 23:16:05.661771
NCT01219231|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2016-03-15|2010-10-12|2010-10-13|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Physical Activity on the Brain in Impaired Glucose Tolerance (IGT)|Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons?|Completed||Phase 4|46|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:16:05.728539|2018-05-31 23:16:05.728539
NCT01219218|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2013-02-17|2010-10-12|2010-10-13|Estimate|||||||2013-02-17|2013-02-20|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris|Shockwave Treatment for Advanced Angina in Maastricht (SWAAM). A Pilot Study|Completed||Phase 1|33|Actual|Medispec||1|||f||||f||||||||||2018-05-31 23:16:05.785723|2018-05-31 23:16:05.785723
NCT01219205|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2010-10-12|2010-10-12|2010-10-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|February 2009|Actual|2009-02-28||Interventional|||Major and Macular Branched Retinal Venous Occlusion|Intravitreal Bevacizumab for Macular Edema Secondary to Major and Macular Branch Retinal Vein Occlusion|Completed||N/A|46|Actual|Hallym University Medical Center||2|||f||||t||||||||||2018-05-31 23:16:05.931947|2018-05-31 23:16:05.931947
NCT01219192|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-27|2010-10-08|2010-10-13|Estimate|||||||2010-10-27|2010-10-28|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure|Phase I Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure|Unknown status|Recruiting|Phase 1|24|Anticipated|Protgen Ltd||4|||f||||t||||||||||2018-05-31 23:16:05.994953|2018-05-31 23:16:05.994953
NCT01219179|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2013-02-26|2010-10-12|2010-10-13|Estimate|||||||2013-02-26|2013-02-27|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Use of Sterile Water Feeds for Treatment of Hypernatremia in Extremely Low Birth Weight Infants|The Use of Enteral Sterile Water Feeds for the Treatment of Hypernatremia in Extremely Low Birth Weight Infants|Completed||N/A|19|Actual|Case Western Reserve University||1|||f||||t||||||||||2018-05-31 23:16:06.067126|2018-05-31 23:16:06.067126
NCT01219166|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2010-12-09|2010-10-12|2010-10-13|Estimate|||||||2010-12-09|2010-12-10|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Is Routine Cholecystectomy Reasonable in All Patients Receiving a Bypass Procedure: a Comparative Cohort Study||Completed|||437|Anticipated|Cantonal Hospital of St. Gallen|||2||f||||f||||||||||2018-05-31 23:16:06.119334|2018-05-31 23:16:06.119334
NCT01219153|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2011-07-11|2010-10-12|2010-10-13|Estimate|||||||2011-07-11|2011-07-12|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET|Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Patients With Poor Ovarian Response Undergoing IVF-ET, a Randomized Controlled Trial|Completed||Phase 2|136|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 23:16:06.17255|2018-05-31 23:16:06.17255
NCT01219140|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-08|2010-10-08|2010-10-13|Estimate|||||||2010-10-08|2010-10-13|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pomegranate Extract Biomarker Study in Osteopenic Women|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of Pomegranate Extract Capsules in Post-Menopausal Subjects With Decreased Bone Mineral Density|Completed||Phase 1|64|Actual|POM Wonderful LLC||2|||f||||f||||||||||2018-05-31 23:16:06.238697|2018-05-31 23:16:06.238697
NCT01219127|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2010-10-12|2010-10-12|2010-10-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||The Regeneration Effects of Derma-PACE Shockwave in Chronic Diabetic Ulcers|The Regeneration Effects of Derma-PACE Shockwave in Chronic Diabetic Ulcers|Unknown status|Active, not recruiting|N/A|100|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 23:16:06.290671|2018-05-31 23:16:06.290671
NCT01219114|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-10|||2011-09-27|2010-10-10|2010-10-13|Estimate|||||||2011-09-27|2011-09-28|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Observational|||Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use|A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines|Withdrawn|||200|Anticipated|AstraZeneca|||1|"Inability to recruit patients within the specified time period. No patients have been enrolled~   in the study."|f||||f||||||||||2018-05-31 23:16:06.338781|2018-05-31 23:16:06.338781
NCT01219101|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-09|||2014-11-05|2010-10-09|2010-10-13|Estimate|||||||2014-11-05|2014-11-06|Estimate|March 2011||2011-03-31|March 2009|2009-03-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination|Evaluate the Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination|Completed||Phase 4|95|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 23:16:06.453209|2018-05-31 23:16:06.453209
NCT01219088|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2011-08-03|2010-10-09|2010-10-13|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Intrathecal Morphine,Femoral Nerve Block,Periarticular Bupivacaine Infiltration for Pain After Intramedullary Hip Screw|Post Operative Pain Control Among Intrathecal 0.1 mg Morphine, Femoral Nerve Block, or Periarticular Infiltration of 20 mL of 0.25% Bupivacaine in Patients Post Intramedullary Hip Screw|Unknown status|Recruiting|Phase 4|80|Anticipated|Mahidol University||4|||f||||f||||||||||2018-05-31 23:16:06.530451|2018-05-31 23:16:06.530451
NCT01219075|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2018-03-30|2010-10-08|2010-10-13|Estimate|||||||2018-03-30|2018-04-03|Actual|July 1, 2010|Actual|2010-07-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer|Soy Treatment for High-risk Women|Active, not recruiting||N/A|110|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 23:16:06.606786|2018-05-31 23:16:06.606786
NCT01219062|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-10-03|2010-10-12|2010-10-13|Estimate|||||||2016-10-03|2016-10-04|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Postoperative Pain Control After Hip Hemiarthroplasty: Intrathecal Morphine vs Periarticular Infiltration of Bupivacaine|Comparative of Postoperative Pain Control at 24 and 48 Hours Between Intrathecal 0.1 mg. of Morphine or Local Infiltration of 20 ml. of 0.25% Bupivacaine in Patients Post Hip Hemiarthroplasty Under Spinal Anesthesis|Terminated||Phase 4|10|Actual|Mahidol University||3||"Surgeon team were not happy with the study protocol, the periarticular injection of local~   anesthetics"|f||||f||||||||||2018-05-31 23:16:06.691003|2018-05-31 23:16:06.691003
NCT01219049|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2017-04-07|2010-10-08|2010-10-13|Estimate|||||||2017-04-07|2017-04-11|Actual|January 2010||2010-01-31|April 2017|2017-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||L-Tyrosine Supplementation in Patients With Fibromyalgia|L-Tyrosine Supplementation in Patients With Fibromyalgia|Terminated||N/A|15|Actual|Icahn School of Medicine at Mount Sinai||3||"Due to FDA comments, changes required unavailable resources. There are no results for this~   study."|f||||f|f|f||||||||2018-05-31 23:16:06.75852|2018-05-31 23:16:06.75852
NCT01219036|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-12|||2012-02-01|2010-10-12|2010-10-13|Estimate|||||||2012-02-01|2012-02-03|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Use of Fractional Exhaled Nitric Oxide in the Identification of Non-adherence in Difficult Asthma|The Use of Fractional Exhaled Nitric Oxide (FeNO) and Induced Sputum in the Identification of Non-adherence in Difficult to Control Asthma|Completed||N/A|40|Actual|Belfast Health and Social Care Trust||2|||f||||t||||||||||2018-05-31 23:16:06.832449|2018-05-31 23:16:06.832449
NCT01217736|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2016-02-26|2010-10-06|2010-10-08|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Direct Renin Inhibition and the Kidney|Direct Renin Inhibition and the Kidney|Completed||Phase 1|22|Actual|Vitae Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 23:16:44.12341|2018-05-31 23:16:44.12341
NCT01219023|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-10-29|2010-10-12|2010-10-13|Estimate|||||||2012-10-29|2012-10-30|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|JADE||Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil|Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil|Completed||Phase 1|10|Actual|Duke University|||||f||||f||||||||||2018-05-31 23:16:06.90243|2018-05-31 23:16:06.90243
NCT01219010|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-01-16|2010-10-12|2010-10-13|Estimate|||||||2015-01-16|2015-01-19|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|June 2012|Actual|2012-06-30||Interventional|||A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma|A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma|Completed||Phase 1|30|Actual|Janssen Research & Development, LLC||1|||f||||||||||||||2018-05-31 23:16:06.963164|2018-05-31 23:16:06.963164
NCT01218997|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2010-11-08||2010-12-27|2010-10-12|2010-10-13|Estimate|2010-11-08|2010-12-13|Estimate||||2010-12-27|2011-01-04|Estimate|August 2003||2003-08-31|December 2010|2010-12-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)|A Randomized, Open Label, Long-Term, Multi-Center Study of the Safety of Medisorb® Naltrexone|Completed||Phase 3|436|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 23:16:07.045758|2018-05-31 23:16:07.045758
NCT01218984|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2010-11-08||2016-11-21|2010-10-12|2010-10-13|Estimate|2010-11-08|2010-12-13|Estimate||||2016-11-21|2017-01-11|Estimate|March 2002||2002-03-31|November 2016|2016-11-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids|A Randomized, Single-Dose Opiate Challenge Study of Medisorb® Naltrexone in Opioid-Using Adults|Completed||Phase 2|27|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 23:16:07.396775|2018-05-31 23:16:07.396775
NCT01218971|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2010-11-08||2010-12-08|2010-10-08|2010-10-13|Estimate|2010-11-08|2010-12-08|Estimate||||2010-12-08|2010-12-24|Estimate|August 2002||2002-08-31|December 2010|2010-12-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)|A Multicenter Double-Blind Extension of Alkermes Study ALK21-003 to Evaluate the Long-Term Safety of Medisorb® Naltrexone|Completed||Phase 3|332|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 23:16:07.704932|2018-05-31 23:16:07.704932
NCT01218958|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2010-11-05||2017-06-08|2010-10-12|2010-10-13|Estimate|2010-11-05|2010-12-07|Estimate||||2017-06-08|2017-07-11|Actual|February 2002||2002-02-28|June 2017|2017-06-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol-Dependent Adults|Completed||Phase 3|624|Actual|Alkermes, Inc.||4|||f||||f||||||||||2018-05-31 23:16:08.09231|2018-05-31 23:16:08.09231
NCT01218945|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2013-06-18|2010-10-08|2010-10-11|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Development of Bone Grafts Using Adipose Derived Stem Cells and Different Scaffolds|Development of Bone Grafts Using Adipose Derived Stem Cells and Different Scaffolds: Impact of Pre-engineered Capillaries in Critical Size Grafts|Completed|||33|Actual|University of Zurich|||1||f||||f||||||Samples With DNA|"~     Human adipose-derived stem cells from human fat~   "|||2018-05-31 23:16:08.518291|2018-05-31 23:16:08.518291
NCT01218932|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-06-13|2010-10-08|2010-10-11|Estimate|||||||2012-06-13|2012-06-14|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|PQCQ||Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects|Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects|Completed||Phase 1|16|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 23:16:08.579677|2018-05-31 23:16:08.579677
NCT01218919|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-02-27|2010-10-08|2010-10-11|Estimate|||||||2015-02-27|2015-03-02|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Post Market (Brio™ System) Deep Brain Stimulation (DBS) PD Study|A CLINICAL EVALUATION OF A RECHARGEABLE DEEP BRAIN STIMULATION SYSTEM AS AN ADJUNCTIVE TREATMENT FOR REDUCING SOME OF THE SYMPTOMS OF ADVANCED, LEVODOPA-RESPONSIVE PARKINSON'S DISEASE THAT ARE NOT ADEQUATELY CONTROLLED WITH MEDICATION|Withdrawn|||0|Actual|St. Jude Medical|||1|Business reasons|f||||t||||||||||2018-05-31 23:16:08.645591|2018-05-31 23:16:08.645591
NCT01218906|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-01-11|2010-10-08|2010-10-11|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2010||2010-08-31|January 2018|2018-01-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Observational|||Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia|Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia|Completed|||1500|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 23:16:08.695817|2018-05-31 23:16:08.695817
NCT01218893|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-03-30|2010-10-08|2010-10-11|Estimate|||||||2012-03-30|2012-04-02|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|ZonMw1||Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Completed||N/A|30|Actual|Radboud University||4|||f||||t||||||||||2018-05-31 23:16:08.76588|2018-05-31 23:16:08.76588
NCT01218880|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-18|2010-10-08|2010-10-11|Estimate|||||||2010-10-18|2010-10-19|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer|Phase I Study of M2ES Combined Gemcitabine in Patients With Advanced Pancreatic Cancer|Unknown status|Recruiting|Phase 1|21|Anticipated|Protgen Ltd||4|||f||||t||||||||||2018-05-31 23:16:08.840079|2018-05-31 23:16:08.840079
NCT01218867|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2016-04-15||2016-11-08|2010-10-08|2010-10-11|Estimate|2016-06-09|2016-07-22|Estimate||||2016-11-08|2016-12-29|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer|Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes|Completed||Phase 1/Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||11|||f||||t||||||||No||2018-05-31 23:16:08.948986|2018-05-31 23:16:08.948986
NCT01218854|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-05-09|2010-10-08|2010-10-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 20, 2010||2010-09-20|November 9, 2017|2017-11-09|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|||A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy|A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy|Completed||Phase 1|17|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 23:16:10.53159|2018-05-31 23:16:10.53159
NCT01218841|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-08|2010-10-08|2010-10-11|Estimate|||||||2010-10-08|2010-10-11|Estimate|November 2005||2005-11-30|October 2010|2010-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Pure Fish Oil Parenteral Lipid Emulsion in Patients With Gastrointestinal Cancer|Clinical and Immunological Benefits of the Infusion of Pure Fish Oil Lipid Emulsion in Surgical Patients With Gastrointestinal Cancer.|Completed||Phase 2|85|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:16:10.602685|2018-05-31 23:16:10.602685
NCT01218828|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-03-10|2010-10-08|2010-10-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|POSEIDON||Prevention of Contrast Renal Injury With Different Hydration Strategies|Hydration With Different Sodium Chloride Protocols for the Prevention of Contrast Medium-induced Nephropathy in Patients Undergoing Coronary Angiography: a Randomized Trial|Completed||Phase 3|396|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 23:16:10.662027|2018-05-31 23:16:10.662027
NCT01218815|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2015-03-05|2010-10-08|2010-10-11|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CORAMI||Complete Infarct Related Artery Revascularization|Complete Infarct Related Artery Revascularization in Acute Myocardial Infarction Patients - CORAMI Trial|Terminated||N/A|1|Actual|Fundacja Ośrodek Badań Medycznych||2||Due to very low enrollment rate the study was terminated.|f||||f||||||||||2018-05-31 23:16:10.723873|2018-05-31 23:16:10.723873
NCT01218802|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2015-12-11||2016-03-03|2010-10-08|2010-10-11|Estimate|2016-03-03|2016-03-08|Estimate||||2016-03-03|2016-03-08|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks|Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation|Completed||Phase 2|147|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 23:16:11.048524|2018-05-31 23:16:11.048524
NCT01218789|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-11-14|2010-10-08|2010-10-11|Estimate|||||||2017-11-14|2017-11-17|Actual|September 2010||2010-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception|Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Perception|Recruiting||Phase 3|140|Anticipated|Vanda Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:16:11.361034|2018-05-31 23:16:11.361034
NCT01218776|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2018-01-16|2010-10-08|2010-10-11|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2010||2010-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|ISACS-TC||International Survey of Acute Coronary Syndromes in Transitional Countries|International Survey of Acute Coronary Syndromes in Transitional Countries|Recruiting|||24000|Anticipated|University of Bologna|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells,~   "|||2018-05-31 23:16:11.431642|2018-05-31 23:16:11.431642
NCT01218763|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2011-06-10|2010-10-08|2010-10-11|Estimate|||||||2011-06-10|2011-06-13|Estimate|April 2010||2010-04-30|April 2010|2010-04-30||||||||Observational|CAN-DETECT||CANadian Clinical Evaluation of SpiderFlash Arrhythmia DETECTion in SpiderFlash™ Device|CANadian Clinical Evaluation of the Automatic Arrhythmia DETECTion in SpiderFlash™ Device|Unknown status|Recruiting||101|Anticipated|Sorin Group Canada|||1||f||||f||||||||||2018-05-31 23:16:11.502744|2018-05-31 23:16:11.502744
NCT01218750|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-18|2010-10-08|2010-10-11|Estimate|||||||2010-10-18|2010-10-19|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|TTDDME||Triple Therapy for Diffuse Diabetic Macular Edema|Combined Phako-Vitrectomy With ILM Peeling, Retinal Endophotocoagulation, and Intraoperative Use of Bevacizumab for Diffuse Diabetic Macular Edema|Unknown status|Recruiting|N/A|30|Anticipated|Military Institute of Medicine, Poland||1|||f||||t||||||||||2018-05-31 23:16:11.582945|2018-05-31 23:16:11.582945
NCT01218737|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-03-19|2010-10-08|2010-10-11|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2009||2009-01-31|October 2010|2010-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation|Double-Masked, Randomized, Parallel Group Study for Evaluation of Non-Inferiority of 0.3%Gatifloxacin/1.0% Prednisolone Association Compared With Their Isolated Administration in the Prevention of Ocular Infection/Inflammation After LASIK Surgery|Completed||Phase 3|101|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 23:16:12.571502|2018-05-31 23:16:12.571502
NCT01218724|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-10-23|2010-10-08|2010-10-11|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Fixed Dose Combination (FDC) of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 23:16:12.645484|2018-05-31 23:16:12.645484
NCT01218711|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-10-23|2010-10-08|2010-10-11|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Fixed Dose Combination (FDC) of Losartan Potassium and Hydrochlorothiazide (100 mg / 25 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Hyzaar® (100 mg / 25 mg Tablet) [Reference Formulation, Merck & Co., Inc., USA] in Healthy Human Volunteers Under Fasting Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 23:16:12.689618|2018-05-31 23:16:12.689618
NCT01218698|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-10-23|2010-10-08|2010-10-11|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition|An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 23:16:12.7285|2018-05-31 23:16:12.7285
NCT01218685|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-02-05|2010-10-08|2010-10-11|Estimate|||||||2013-02-05|2013-02-06|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Observational|||Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants|Evaluation Aof Safety and Immunogenicity of Non-adjuvanted Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants, Produced by Butantan Institute|Completed|||1152|Actual|Butantan Institute|||9||f||||t||||||||||2018-05-31 23:16:12.77445|2018-05-31 23:16:12.77445
NCT01218672|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2014-10-29|2010-10-08|2010-10-11|Estimate|||||||2014-10-29|2014-10-30|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|January 2015|Anticipated|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia|A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia (The Goliath Study)|Unknown status|Active, not recruiting|Phase 4|290|Anticipated|American Medical Systems||2|||f||||f||||||||||2018-05-31 23:16:12.848298|2018-05-31 23:16:12.848298
NCT01218659|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06||2015-06-25|2015-06-25|2010-10-08|2010-10-11|Estimate||||2015-06-25|2015-07-20|Estimate|2015-06-25|2015-07-20|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease|A Randomized, Open-Label Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT|Completed||Phase 3|60|Actual|Amicus Therapeutics||2|||f||||t||||||||||2018-05-31 23:16:13.065906|2018-05-31 23:16:13.065906
NCT01218646|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2013-07-03|2011-12-12|2013-09-13|2010-10-08|2010-10-11|Estimate|2013-07-03|2013-09-12|Estimate|2011-12-12|2011-12-22|Estimate|2013-09-13|2013-10-23|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Study of Quadrivalent Influenza Vaccine Among Adults|Safety and Immunogenicity Trial Among Adults Administered Quadrivalent Influenza Vaccine|Completed||Phase 3|739|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:16:13.241753|2018-05-31 23:16:13.241753
NCT01218633|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-18|2010-10-08|2010-10-11|Estimate|||||||2013-01-18|2013-01-23|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Dose-response Study of Exendin-9,39 on Glucose Metabolism|A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.|Completed||Phase 1|11|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 23:16:13.87415|2018-05-31 23:16:13.87415
NCT01218620|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2014-12-19|2010-10-08|2010-10-11|Estimate|||||||2014-12-19|2014-12-23|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|July 2012|Actual|2012-07-31||Interventional|||Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors|Randomized Drug Interaction Study of RO4929097 for Advanced Solid Tumors|Completed||Phase 1|17|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-05-31 23:16:13.936154|2018-05-31 23:16:13.936154
NCT01218607|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2014-03-04|2010-10-08|2010-10-11|Estimate|||||||2014-03-04|2014-03-05|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BOMPA||Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.|BOsentan for Mild Pulmonary Vascular Disease in Asd Patients (the BOMPA Trial): a Double-blind, Randomized Controlled, Pilot Trial|Completed||Phase 3|10|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 23:16:14.02808|2018-05-31 23:16:14.02808
NCT01218594|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2012-08-19||2012-09-17|2010-10-08|2010-10-11|Estimate|2012-09-17|2012-10-17|Estimate||||2012-09-17|2012-10-17|Estimate|May 2009||2009-05-31|August 2012|2012-08-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|DP-EN-RT||Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer|Phase I/II Clinical Trial of Recombinant Human Endostatin in Combination With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|50|Actual|Sun Yat-sen University|This was a single-arm study, no comparison between Endostar to CCRT and CCRT alone was performed. It is not clear whether the observed improvement in survival is a result of the addition of Endostar or patient selection.The patient samples are small.|1|||f||||t||||||||||2018-05-31 23:16:14.100759|2018-05-31 23:16:14.100759
NCT01218581|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-08|2010-10-08|2010-10-11|Estimate|||||||2010-10-08|2010-10-11|Estimate|December 2005||2005-12-31|December 2005|2005-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis|Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|32|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 23:16:14.337269|2018-05-31 23:16:14.337269
NCT01218568|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2013-04-02|2010-10-08|2010-10-11|Estimate|||||||2013-04-02|2013-04-04|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial|Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial|Completed||N/A|120|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||t||||||||||2018-05-31 23:16:14.408191|2018-05-31 23:16:14.408191
NCT01218555|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2018-03-15|2010-10-08|2010-10-11|Estimate|||||||2018-03-15|2018-03-19|Actual|September 2010|Actual|2010-09-30|March 2018|2018-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Study of Everolimus (RAD001) in Combination With Lenalidomide|Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma|Completed||Phase 1|44|Actual|Emory University||1|||f||||t||||||||||2018-05-31 23:16:14.487472|2018-05-31 23:16:14.487472
NCT01218542|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2017-06-12|2010-10-08|2010-10-11|Estimate|||||||2017-06-12|2017-06-14|Actual|April 2013||2013-04-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc|Whole Brain Radiation Therapy With Simultaneous Boost to Gross Metastatic Tumor Volume Using Volumetric Modulated Arc Therapy (RapidArc)|Active, not recruiting||N/A|22|Actual|Emory University||1|||f||||t||||||||Undecided||2018-05-31 23:16:14.561421|2018-05-31 23:16:14.561421
NCT01218529|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2014-12-30|2010-10-08|2010-10-11|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors|Lapatinib and Whole Brain Radiotherapy for Patients With Brain Metastases From Lung and Breast Tumors. A Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG).|Completed||Phase 2|82|Actual|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 23:16:14.635082|2018-05-31 23:16:14.635082
NCT01218516|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07||2015-06-25|2016-06-16|2010-10-07|2010-10-11|Estimate||||2015-06-25|2015-07-20|Estimate|2016-06-16|2016-06-20|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|||A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung|A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum Containing Doublet in Chemotherapy-Naive Subjects With Stage IV Adenocarcinoma of the Lung|Completed||Phase 2|130|Actual|Morphotek||2|||f||||t||||||||||2018-05-31 23:16:14.742579|2018-05-31 23:16:14.742579
NCT01218503|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2013-07-25|2010-10-08|2010-10-11|Estimate|||||||2013-07-25|2013-07-29|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|CHOICES||The Neural Correlates of Food Choice Decision-making in Obesity and Weight Loss|The Neural Correlates of Food Choice Decision-making in Obesity and Weight Loss (CHOICES)|Unknown status|Recruiting|N/A|90|Anticipated|The Miriam Hospital||1|||f||||f||||||||||2018-05-31 23:16:14.943298|2018-05-31 23:16:14.943298
NCT01218490|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2016-08-30|2010-10-08|2010-10-11|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|CARACO||Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer|Pelvic and Aortic-cava Lymphadenectomy Randomized Phase III for Advanced Ovarian Cancer|Recruiting||Phase 3|450|Anticipated|Institut Cancerologie de l'Ouest||2|||f||||f||||||||||2018-05-31 23:16:15.008323|2018-05-31 23:16:15.008323
NCT01218477|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2014-04-22||2016-05-16|2010-10-08|2010-10-11|Estimate|2014-04-22|2014-05-20|Estimate||||2016-05-16|2016-06-17|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||All participants who received at least 1 dose of study medication|Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)|Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI|Completed||Phase 1/Phase 2|33|Actual|Bristol-Myers Squibb|Bristol-Myers Squibb discontinued research in the area of smoothened inhibitors. This study was completed early and limited efficacy data was published in a synoptic clinical study report .|4|||f||||f||||||||||2018-05-31 23:16:15.249464|2018-05-31 23:16:15.249464
NCT01218464|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-05-30|2010-10-08|2010-10-11|Estimate|||||||2013-05-30|2013-05-31|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure|Phase Ⅰ/Ⅱ Study of Human Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs) for Treatment of Liver Failure|Unknown status|Recruiting|Phase 1/Phase 2|70|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 23:16:16.379876|2018-05-31 23:16:16.379876
NCT01218451|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-05-20|2010-10-08|2010-10-11|Estimate|||||||2015-05-20|2015-05-21|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||NeisVac-C Single Prime Study in Infants|A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants|Completed||Phase 3|956|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 23:16:16.461875|2018-05-31 23:16:16.461875
NCT01218438|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2016-12-22|2016-05-06|2017-10-19|2010-10-08|2010-10-11|Estimate|2016-12-22|2017-02-15|Actual|2016-05-06|2016-06-03|Estimate|2017-10-19|2017-10-23|Actual|January 2013||2013-01-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety Analysis Dataset: All participants who received at least one dose of immunoglobulin.|Phase 2/3 Study of IGSC, 20% in PIDD|A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)|Completed||Phase 2/Phase 3|86|Actual|Shire||1|||f||||f||||||||||2018-05-31 23:16:16.659328|2018-05-31 23:16:16.659328
NCT01218425|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2012-10-24|2010-10-07|2010-10-11|Estimate|||||||2012-10-24|2012-10-25|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Dopaminergic Modulation of Cognition and Psychomotor Function|Dopaminergic Modulation of Cognition and Psychomotor Function|Completed||N/A|20|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 23:16:18.230836|2018-05-31 23:16:18.230836
NCT01218412|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2015-04-03|2010-10-07|2010-10-11|Estimate|||||||2015-04-03|2015-04-06|Estimate|October 2014||2014-10-31|April 2014|2014-04-30||||May 2016|Anticipated|2016-05-31||Interventional|||Web-based Physical Activity Program|Investigation of Web-based Motivational Interviewing to Increase Physical Activity Participation Among Adults|Unknown status|Recruiting|Phase 1|132|Anticipated|Karnes, Sasha||1|||f||||t||||||||||2018-05-31 23:16:18.308765|2018-05-31 23:16:18.308765
NCT01218399|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2015-01-23||2017-07-18|2010-10-08|2010-10-11|Estimate|2017-07-18|2017-08-18|Actual||||2017-07-18|2017-08-18|Actual|September 2009||2009-09-30|June 2017|2017-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations|A Randomized, Blinded, Single-center Study in Mild to Moderate Asthmatics Over the Age of 12 Years Who Have a Viral-mediated Exacerbation and Are Treated With Symbicort or Pulmicort Flexhaler|Completed||N/A|10|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 23:16:18.390016|2018-05-31 23:16:18.390016
NCT01218386|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2012-03-27|2010-10-08|2010-10-11|Estimate|||||||2012-03-27|2012-03-28|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pretreatment With Estradiol Valerate|Programmation of GnRH Antagonist Cycles With Estradiol Valerate: Impact on the Stimulation in IVF/ICSI.|Completed||Phase 4|80|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 23:16:18.587954|2018-05-31 23:16:18.587954
NCT01218373|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2017-01-24|2010-10-08|2010-10-11|Estimate|||||||2017-01-24|2017-01-25|Estimate|December 1, 2010|Actual|2010-12-01|January 2017|2017-01-31|July 1, 2013|Actual|2013-07-01|May 1, 2013|Actual|2013-05-01||Interventional|HOMESWEETHOME||The Clinical Evaluation of Continuous Assistance Offered to Older People Living Independently.|Health Monitoring and sOcial Integration environMEnt for Supporting WidE ExTension of Independent Life at HOME (HOMESWEETHOME)|Completed||N/A|2010|Actual|Him SA||2|||f||||t||||||||||2018-05-31 23:16:18.655476|2018-05-31 23:16:18.655476
NCT01218360|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2015-03-18|2010-10-08|2010-10-11|Estimate|||||||2015-03-18|2015-03-19|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)|Observational Study on Disease Severity, Evaluation Tools and the Long Term Impact of Each Treatment Strategy in the Daily Clinical Practice in Patients With Moderate to Severe Active Crohn's Disease (Protocol P06484)|Completed|||71|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:16:18.729538|2018-05-31 23:16:18.729538
NCT01092247|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|September 2011|Anticipated|2011-09-30|May 2011|Anticipated|2011-05-31||Interventional|||The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress||Unknown status|Not yet recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 23:57:40.388469|2018-05-31 23:57:40.388469
NCT01218347|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-01-04|2010-10-08|2010-10-11|Estimate|||||||2011-01-04|2011-01-06|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|OATP||Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles|Influence of OATP1B1 Genotype on the Pharmacokinetics,Lipid Lowering Effect, and Lipid Profiles After Rosuvastatin Administration|Completed||Phase 4|34|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 23:16:18.792994|2018-05-31 23:16:18.792994
NCT01218334|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-11-07|2010-10-08|2010-10-11|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2008||2008-06-30|November 2017|2017-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|HandEKG||A Comparative Trial of Standard 12 Lead ECG to the 12 Lead ECG Glove to Assess Cardiac Electrical Function|A Randomized, Single Blind, Comparative Trial of Standardized 12 Lead ECG to the 12 Lead ECG Glove for the Assessmant of Cardiac Electrical Function|Completed|||300|Actual|New York University School of Medicine|||3||f||||f|f|f||||||||2018-05-31 23:16:18.934162|2018-05-31 23:16:18.934162
NCT01218321|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2018-03-04|2010-10-07|2010-10-11|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2011|Actual|2011-01-31|October 2010|2010-10-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Observational|||The Effect of Anti-epileptic Drugs on Mitochondrial Activity|Phase 1 Study for Measuring the Effect of Antiepileptic Drugs on Mitochondrial Activity|Completed|||60|Actual|Hadassah Medical Organization|||1||f||||t||||||Samples Without DNA|"~     White blood cells from peripheral blood samples~   "|||2018-05-31 23:16:18.995345|2018-05-31 23:16:18.995345
NCT01218308|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2013-02-21|2012-07-26|2016-08-29|2010-10-07|2010-10-11|Estimate|2013-02-21|2013-04-02|Estimate|2012-07-26|2012-08-03|Estimate|2016-08-29|2016-10-07|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children|Efficacy Study of GSK Biologicals' Quadrivalent Influenza Vaccine, GSK2282512A, (FLU Q-QIV) When Administered in Children|Completed||Phase 3|5220|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:16:19.110212|2018-05-31 23:16:19.110212
NCT01218295|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2010-10-08|2010-10-08|2010-10-11|Estimate|||||||2010-10-08|2010-10-11|Estimate|May 2009||2009-05-31|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Inspiratory Muscle Training With Normocapnic Hyperpnea in Chronic Obstructive Pulmonary Disease (COPD)|Efficacy of Inspiratory Muscle Training by Means of Spirotiger® in COPD Patients.|Unknown status|Recruiting|N/A|20|Anticipated|Università degli Studi di Ferrara||1|||f||||f||||||||||2018-05-31 23:16:19.892815|2018-05-31 23:16:19.892815
NCT01218282|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2010-10-26|2010-10-08|2010-10-11|Estimate|||||||2010-10-26|2010-10-27|Estimate|January 2008||2008-01-31|October 2010|2010-10-31|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Interventional|||Exercise Training in Chronic Obstructive Pulmonary Disease (COPD)|Different Methods of Home Exercise Training in COPD Patients|Completed||N/A|80|Actual|Università degli Studi di Ferrara||3|||f||||f||||||||||2018-05-31 23:16:19.951429|2018-05-31 23:16:19.951429
NCT01218269|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2011-02-28|2010-10-08|2010-10-11|Estimate|||||||2011-02-28|2011-03-01|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||U-clip Pilot Study in Plastic Surgery|A Prospective Evaluation of U-clips for Arterial Microvascular Anastomoses|Completed||Phase 4|25|Actual|Scott and White Hospital & Clinic||1|||f||||f||||||||||2018-05-31 23:16:20.009068|2018-05-31 23:16:20.009068
NCT01218256|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-08|2010-10-08|2010-10-11|Estimate|||||||2010-10-08|2010-10-11|Estimate|July 2007||2007-07-31|June 2007|2007-06-30|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Secondary Prevention in Type 2 Diabetes: Comparison of Two Different Resistance Exercise Training Protocols|Combined Resistance and Endurance Training in Patients With Type 2 Diabetes: A Pilot-study to Assess the Effects of 2 Different Resistance Protocols on Muscle Mass, Strength and Glycemic Control.|Completed||Phase 1|32|Actual|Paracelsus Medical University||2|||f||||f||||||||||2018-05-31 23:16:20.073856|2018-05-31 23:16:20.073856
NCT01218243|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|2012-05-31||2013-05-18|2010-10-08|2010-10-11|Estimate|2012-07-16|2012-08-23|Estimate||||2013-05-18|2013-05-27|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia|An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia|Completed||Phase 2|100|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 23:16:20.159637|2018-05-31 23:16:20.159637
NCT01218230|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2015-09-01|2010-10-08|2010-10-11|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2010||2010-12-31|September 2015|2015-09-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|INGECT||Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia|A Clinical Trial to Study the Efficacy and Safety of Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia|Withdrawn||N/A|0|Actual|L.V. Prasad Eye Institute||1||Funding did not come through as the product was sold to another company.|f||||f||||||||||2018-05-31 23:16:20.485978|2018-05-31 23:16:20.485978
NCT01218217|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2013-01-11|2010-10-08|2010-10-11|Estimate|||||||2013-01-11|2013-01-14|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|September 2011|Actual|2011-09-30||Interventional|SQ109EBA||Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB|A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|Completed||Phase 2|90|Actual|Ludwig-Maximilians - University of Munich||6|||f||||||||||||||2018-05-31 23:16:20.554801|2018-05-31 23:16:20.554801
NCT01218204|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2017-08-31|2015-04-27|2017-10-09|2010-10-07|2010-10-11|Estimate|2017-10-09|2017-11-08|Actual|2015-04-27|2015-05-13|Estimate|2017-10-09|2017-11-08|Actual|September 14, 2010|Actual|2010-09-14|August 2017|2017-08-31|June 29, 2011|Actual|2011-06-29|June 29, 2011|Actual|2011-06-29||Interventional||One participant was withdrawn prior to washout period. 34 participants did not complete washout phase. 111 participants did not qualify to continue in the study after completing the Washout Phase. 6 participants were withdrawn during run-in phase and 3 participants were withdrawn during treatment phase.|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin|Completed||Phase 2|287|Actual|GlaxoSmithKline||16|||f||||f||||||||||2018-05-31 23:16:20.751463|2018-05-31 23:16:20.751463
NCT01215461|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2013-05-13|2010-10-05|2010-10-06|Estimate|||||||2013-05-13|2013-05-14|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Factors Associated With Mortality in Neonates|Evaluation of Factors Associated With Mortality in Neonates|Completed|||645|Actual|Mednax Center for Research, Education, Quality and Safety|||||f||||f||||||||||2018-05-31 23:17:24.2582|2018-05-31 23:17:24.2582
NCT01218191|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-02-17|2010-10-08|2010-10-11|Estimate|||||||2012-02-17|2012-02-20|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|HSA-2||Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage.|Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage Assessed With Cardiac 18F-FDG PET and 123I-MIBG Scintigraphy: a Prospective Observational Study.|Completed|||30|Actual|Direction Centrale du Service de Santé des Armées|||1||f||||t||||||||||2018-05-31 23:16:24.226271|2018-05-31 23:16:24.226271
NCT01218178|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2015-03-12|2010-10-08|2010-10-11|Estimate|||||||2015-03-12|2015-03-13|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|BINARIO||Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction|BIcarbonato di Sodio e N-Acetilcisteina Nella Prevenzione Della Nefropatia da Mezzo di Contrasto Nell'infaRto mIocardico acutO(Registro BINARIO)|Completed|||520|Actual|Catholic University of the Sacred Heart|||2||f||||f||||||||||2018-05-31 23:16:24.45827|2018-05-31 23:16:24.45827
NCT01218165|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2011-10-27|2010-10-08|2010-10-11|Estimate|||||||2011-10-27|2011-10-28|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Low Grade Inflammation, Gut Microbiota and Barrier Function in Elderly Humans|The Inflammaging Network: Bridging Low Grade Inflammation With Gut Microbiota and Intestinal Barrier Function in Elderly Humans|Completed||Early Phase 1|48|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:16:24.764047|2018-05-31 23:16:24.764047
NCT01218152|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-08|2010-10-08|2010-10-11|Estimate|||||||2010-10-08|2010-10-11|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs|Analysis of Circulating Tumor DNA in Plasma of Neurofibromatosis Type 1 Patients With MPNSTs Using Microarray CGH|Unknown status|Active, not recruiting||20|Anticipated|Katholieke Universiteit Leuven|||2||f||||f||||||||||2018-05-31 23:16:24.846708|2018-05-31 23:16:24.846708
NCT01218139|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-08|||2010-10-08|2010-10-08|2010-10-11|Estimate|||||||2010-10-08|2010-10-11|Estimate|September 2007||2007-09-30|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients|Analysis of Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients|Unknown status|Active, not recruiting||50|Anticipated|Katholieke Universiteit Leuven|||||f||||f||||||||||2018-05-31 23:16:24.964065|2018-05-31 23:16:24.964065
NCT01218126|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2017-08-03|2012-11-15|2018-01-10|2010-10-07|2010-10-11|Estimate|2017-12-04|2018-01-04|Actual|2012-11-15|2012-11-20|Estimate|2018-01-10|2018-02-06|Actual|November 4, 2010|Actual|2010-11-04|January 2018|2018-01-31|December 21, 2011|Actual|2011-12-21|December 21, 2011|Actual|2011-12-21||Interventional|||Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|604|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:16:25.066334|2018-05-31 23:16:25.066334
NCT01218113|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2017-09-27|2013-04-11|2018-04-19|2010-10-07|2010-10-11|Estimate|2018-04-19|2018-05-21|Actual|2013-04-11|2013-04-18|Estimate|2018-04-19|2018-05-21|Actual|November 8, 2010|Actual|2010-11-08|March 2018|2018-03-31|November 5, 2012|Actual|2012-11-05|November 5, 2012|Actual|2012-11-05||Interventional|||Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons|Efficacy and Safety of HIV Vaccine 732462 in ART-naïve HIV-1 Infected Persons|Completed||Phase 2|191|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 23:16:27.192047|2018-05-31 23:16:27.192047
NCT01218100|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2012-05-18||2012-05-18|2010-10-08|2010-10-11|Estimate|2012-05-18|2012-06-21|Estimate||||2012-05-18|2012-06-21|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension|A Randomized, Double-blind, Parallel-Group Study to Evaluate the Effects of First-Line Treatment With a Free Combination of Nebivolol and Lisinopril Compared With Placebo and the Monotherapy Components on Blood Pressure in Patients With Stage 2 Diastolic Hypertension|Completed||Phase 4|664|Actual|Forest Laboratories||4|||f||||f||||||||||2018-05-31 23:16:36.945856|2018-05-31 23:16:36.945856
NCT01218087|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2015-03-17||2016-12-08|2010-10-07|2010-10-11|Estimate|2015-07-29|2015-08-26|Estimate||||2016-12-08|2017-02-03|Estimate|April 2010||2010-04-30|December 2016|2016-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Approximately 800 infants from the 4 participating NICUs were screened; most were excluded for an anticipated length of stay of < 14 days, for medical reasons, and a few parents declined. The total number enrolled out of the approximately 800 screened was 88.|Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU|Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU|Terminated||N/A|88|Actual|Boston Children’s Hospital|During the second interim analysis, safety monitors recommended early closure due to loss of study equipoise. Clinical staff had been reporting observable differences in infant head shapes for the two study groups.|2||Study discontinued by DSMB due to loss of equipoise.|f||||f||||||||||2018-05-31 23:16:37.492403|2018-05-31 23:16:37.492403
NCT01218074|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2018-01-24|2010-10-07|2010-10-11|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2010||2010-12-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Interventional|PACE||Platelets Antiaggregation Control Enhancement (PACE) Study|Platelets Antiaggregation Control Enhancement Study: an Independent Randomized Blind Prospective Study|Terminated||N/A|200|Actual|Cardiochirurgia E.H.||2|||f||||t||||||||||2018-05-31 23:16:37.731512|2018-05-31 23:16:37.731512
NCT01218061|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-06-14|2010-10-08|2010-10-11|Estimate|||||||2017-06-14|2017-06-16|Actual|June 2010|Actual|2010-06-30|June 2017|2017-06-30|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|IT-DIAB||Therapeutic Innovation in Type 2 DIABetes (IT-DIAB)|IT-DIAB (Therapeutic Innovation in Type 2 Diabetes) : Prospective Follow-up of a Cohort of Patients With Pre-diabetes Over 10 Years|Active, not recruiting||N/A|366|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 23:16:37.866989|2018-05-31 23:16:37.866989
NCT01217723|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2010-10-07|2010-10-07|2010-10-08|Estimate|||||||2010-10-07|2010-10-08|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation|A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors|Unknown status|Recruiting|Phase 3|198|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 23:16:44.181487|2018-05-31 23:16:44.181487
NCT01218048|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-09-04|2010-10-07|2010-10-08|Estimate|||||||2017-09-04|2017-09-07|Actual|February 2011||2011-02-28|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|September 2017|Anticipated|2017-09-30||Interventional|||ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma|Phase II Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Followed by Adjuvant Therapy With Concurrent Chemoradiotherapy or Radiotherapy With or Without Cetuximab for Locally Advanced Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 2|40|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 23:16:37.925984|2018-05-31 23:16:37.925984
NCT01218035|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-02-10|2010-10-07|2010-10-08|Estimate|||||||2017-02-10|2017-02-13|Actual|May 2007||2007-05-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis|Completed||Phase 4|49|Actual|Turku University Hospital|||||f||||t||||||||||2018-05-31 23:16:38.012543|2018-05-31 23:16:38.012543
NCT01218022|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-10-23|2010-10-07|2010-10-08|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fasting Condition|An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Losartan Potassium (100 mg Tablet) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Cozaar® (100 mg Tablet) [Reference Formulation, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fasting Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 23:16:38.16691|2018-05-31 23:16:38.16691
NCT01218009|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2015-05-01|2013-08-27|2015-05-01|2010-10-07|2010-10-08|Estimate|2015-05-01|2015-05-20|Estimate|2013-08-27|2013-09-04|Estimate|2015-05-01|2015-05-20|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Randomized participants|A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing|A Multi-Center 52-Week Study to Assess the Safety of an Albuterol Dry-powder Inhaler in Subjects With Asthma|Terminated||Phase 3|331|Actual|Teva Pharmaceutical Industries||2||Change to study required.|f||||f||||||||||2018-05-31 23:16:38.237693|2018-05-31 23:16:38.237693
NCT01217996|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2014-04-28|2010-10-07|2010-10-08|Estimate|||||||2014-04-28|2014-04-29|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional|||Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors|Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors|Completed||N/A|128|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-05-31 23:16:38.756153|2018-05-31 23:16:38.756153
NCT01217983|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2012-10-29|2010-10-07|2010-10-08|Estimate|||||||2012-10-29|2012-10-30|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Utility of Renal Biomarkers in Cirrhosis|Utility of Renal Biomarkers in Cirrhotic Patients|Completed|||105|Actual|University Hospital, Geneva|||||f||||t||||||Samples Without DNA|"~     Plasma, serum, urine and ascitis~   "|||2018-05-31 23:16:38.83283|2018-05-31 23:16:38.83283
NCT01217970|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2013-12-02|2010-10-07|2010-10-08|Estimate|||||||2013-12-02|2013-12-04|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety Interaction Trial Ibudilast and Methamphetamine|Phase I Safety Interaction Trial of Ibudilast With Methamphetamine|Completed||Phase 1|11|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 23:16:38.889306|2018-05-31 23:16:38.889306
NCT01217957|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2015-12-04||2018-03-12|2010-10-07|2010-10-08|Estimate|2015-12-19|2016-01-27|Estimate||||2018-03-12|2018-03-14|Actual|November 22, 2010|Actual|2010-11-22|March 2018|2018-03-31|February 2, 2018|Actual|2018-02-02|March 8, 2013|Actual|2013-03-08||Interventional||Safety Analysis Population: all participants who received at least one dose of any of the 3 study drugs.|A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment|Completed||Phase 1/Phase 2|65|Actual|Takeda||5|||f||||f||||||||||2018-05-31 23:16:39.012213|2018-05-31 23:16:39.012213
NCT01217944|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2013-08-14||2014-01-14|2010-10-07|2010-10-08|Estimate|2013-08-14|2013-10-18|Estimate||||2014-01-14|2014-02-10|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|Completed||Phase 3|277|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:16:40.064395|2018-05-31 23:16:40.064395
NCT01217931|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2018-03-30|2010-10-07|2010-10-08|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2011|Actual|2011-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial|Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial|Active, not recruiting||Phase 2|240|Anticipated|M.D. Anderson Cancer Center||6|||f||||t|t|f||||||||2018-05-31 23:16:40.739185|2018-05-31 23:16:40.739185
NCT01217918|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2011-02-14|2010-10-07|2010-10-08|Estimate|||||||2011-02-14|2011-02-15|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects|APhase 1, Placebo-Controlled, Randomized, Parallel Group, Subject- And Investigator-Blind, Sponsor-Open Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PH-797804 Following Multiple Escalating Oral Doses In Healthy Japanese Adult Subjects|Completed||Phase 1|30|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:16:40.877305|2018-05-31 23:16:40.877305
NCT01217905|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2012-02-10|2010-10-07|2010-10-08|Estimate|||||||2012-02-10|2012-02-13|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|JSMAD||Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687|A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Single and Multiple Ascending Doses in Healthy Male Japanese Subjects|Completed||Phase 1|36|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:16:40.948614|2018-05-31 23:16:40.948614
NCT01217892|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2013-01-21||2014-10-16|2010-10-07|2010-10-08|Estimate|2013-10-31|2013-11-01|Estimate||||2014-10-16|2014-10-27|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Evaluation of Dapagliflozin Taken Twice-daily|A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy|Completed||Phase 3|400|Actual|AstraZeneca|For participants who did not complete 16 weeks LOCF (last observation carried forward) was used.|4|||f||||f||||||||||2018-05-31 23:16:41.032525|2018-05-31 23:16:41.032525
NCT01217879|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-11-14|2010-10-07|2010-10-08|Estimate|||||||2012-11-14|2012-11-16|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|COUGH||COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia|Cough Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop Previous ACE-i Treatment Due to Cough|Completed|||980|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:16:41.682462|2018-05-31 23:16:41.682462
NCT01217866|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-12-19|2010-10-07|2010-10-08|Estimate|||||||2012-12-19|2012-12-20|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||A Retrospective Review of Enseal Laparoscopic Vaginal Assisted Hysterectomy (LAVH) Versus Traditional LAVH|A Retrospective Analysis of a Complete Enseal Laparoscopic Vaginal Assisted Hysterectomy Versus a Traditional Suture Laparoscopic Vaginal Hysterectomy|Completed|||79|Actual|Womens Care|||1||f||||f||||||||||2018-05-31 23:16:41.756605|2018-05-31 23:16:41.756605
NCT01217853|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2011-08-02|2010-10-07|2010-10-08|Estimate|||||||2011-08-02|2011-08-03|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Observational|||24h Continuous Intraocular Pressure (IOP) Monitoring vs Goldmann Applanation Tonometry|Comparison of 24-hour Continuous IOP Monitoring With a Contact Lens-based Sensor to Goldmann Applanation Tonometry|Completed|||30|Anticipated|Sensimed AG|||1||f||||f||||||||||2018-05-31 23:16:41.83406|2018-05-31 23:16:41.83406
NCT01217840|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2015-02-13||2017-10-24|2010-10-07|2010-10-08|Estimate|2015-02-13|2015-03-02|Estimate||||2017-10-24|2017-11-29|Actual|September 2010||2010-09-30|October 2017|2017-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents|The Effect of Vitamin D on Cytokines and Cardiometabolic Risk in Obese Adolescents|Completed||N/A|40|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 23:16:41.94726|2018-05-31 23:16:41.94726
NCT01217827|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2016-10-13||2016-10-13|2010-10-07|2010-10-08|Estimate|2016-10-13|2016-12-07|Estimate||||2016-10-13|2016-12-07|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|December 2013|Actual|2013-12-31|January 2011|Actual|2011-01-31||Interventional|||Implantable Cardioverter-Defibrillator Use in the VA System|Implantable Cardioverter-Defibrillator (ICD) Utilization in a Potentially Eligible VA Population|Completed||Phase 3|89|Actual|Stanford University||2|||f||||||||||||||2018-05-31 23:16:42.317642|2018-05-31 23:16:42.317642
NCT01217814|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2017-05-23|2012-10-31|2017-07-31|2010-10-07|2010-10-08|Estimate|2017-07-31|2017-09-01|Actual|2012-10-31|2012-11-02|Estimate|2017-07-31|2017-09-01|Actual|November 2010||2010-11-30|July 2017|2017-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers|A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of MTX in Patients With Active RA Who Have Failed Previous TNF-α Antagonists|Terminated||Phase 2|16|Actual|Sanofi|The study was prematurely terminated due to small number of participants entering randomization.|3||"Due to delay in the study and the impact on the development timelines, not due to any~   identified safety concerns"|f||||t||||||||||2018-05-31 23:16:42.496377|2018-05-31 23:16:42.496377
NCT01217801|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2011-07-25||2017-03-21|2010-10-07|2010-10-08|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|October 2008||2008-10-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||This is a crossover study so the total number of participants is 48|Two Way Bioequivalence Study Under Fed Conditions|Open-label Randomized, Two Way Crossover Bioequivalence Study to Compare Ondansetron Orally Dissolving FilmStrip 8mg With Zofran Orally Disintegrating Tablets 8 mg in 48 Healthy, Adult, Participants Under Fed Conditions.|Completed||Phase 1|48|Actual|Aquestive Therapeutics||2|||f||||f||||||||No||2018-05-31 23:16:42.767715|2018-05-31 23:16:42.767715
NCT01217788|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2011-05-09|2010-10-07|2010-10-08|Estimate|||||||2011-05-09|2011-05-10|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|PH94B-SAD||Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia|Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia|Completed||Phase 2|90|Anticipated|Pherin Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:16:43.047987|2018-05-31 23:16:43.047987
NCT01217775|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2015-12-01|2010-10-07|2010-10-08|Estimate|||||||2015-12-01|2015-12-03|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|PH80-PMD||Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder|A Phase 3 Study of the Use of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder|Unknown status|Not yet recruiting|Phase 3|1400|Anticipated|Pherin Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:16:43.112467|2018-05-31 23:16:43.112467
NCT01217762|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-01-18|2010-10-07|2010-10-08|Estimate|||||||2012-01-18|2012-01-19|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|October 2014|Anticipated|2014-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|A Pilot Study to Evaluate the Safety and Tolerability of the IRay Stereotactic Radiosurgery System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|Unknown status|Active, not recruiting|Phase 1|62|Actual|Oraya Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 23:16:43.212382|2018-05-31 23:16:43.212382
NCT01217749|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2015-04-02||2015-05-28|2010-10-07|2010-10-08|Estimate|2015-04-02|2015-04-16|Estimate||||2015-05-28|2015-06-25|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|PCYC-1109-CA||Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL|An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia|Completed||Phase 1/Phase 2|71|Actual|Pharmacyclics LLC.||3|||f||||t||||||||||2018-05-31 23:16:43.332092|2018-05-31 23:16:43.332092
NCT01217710|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-05-11|2010-10-07|2010-10-08|Estimate|||||||2015-05-11|2015-05-13|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Promoting Physical Activity in Chronic Obstructive Pulmonary Disease (COPD) Through New Technology and Health Coaching|Next Generation Technology for Chronic Care Self Management|Completed||Phase 2|38|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 23:16:45.25574|2018-05-31 23:16:45.25574
NCT01217697|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-03-23|2010-10-07|2010-10-08|Estimate|||||||2017-03-23|2017-03-24|Actual||||March 2017|2017-03-31||||||||Expanded Access|||Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer|An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy|Approved for marketing|||||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-05-31 23:16:45.407932|2018-05-31 23:16:45.407932
NCT01217684|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-06-14|2010-10-07|2010-10-08|Estimate|||||||2012-06-14|2012-06-15|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Test-retest Reliability of a Standard Protocol on the Biodex Dynamometer||Completed|||60|Actual|Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-05-31 23:16:46.666495|2018-05-31 23:16:46.666495
NCT01217671|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-06-08|2010-10-07|2010-10-08|Estimate|||||||2016-06-08|2016-06-09|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional|||International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema|A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema|Completed||Phase 2/Phase 3|168|Actual|Kamada, Ltd.||2|||f||||t||||||||||2018-05-31 23:16:46.715519|2018-05-31 23:16:46.715519
NCT01217658|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-12-04|2010-10-07|2010-10-08|Estimate|||||||2015-12-04|2015-12-08|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|UTHealth THB||Measuring and Reducing Excessive Infant Crying|Measuring and Reducing Excessive Infant Crying: A Randomized Trial|Completed||N/A|28|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:16:46.804247|2018-05-31 23:16:46.804247
NCT01217645|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2014-10-10|2010-10-07|2010-10-08|Estimate|||||||2014-10-10|2014-10-13|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|AZD6765||Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration|A Phase I, Open-label, Single-Centre Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration to Healthy Male Subjects|Completed||Phase 1|6|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:16:46.87409|2018-05-31 23:16:46.87409
NCT01217632|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2016-08-12|2010-10-07|2010-10-08|Estimate|||||||2016-08-12|2016-08-16|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection|Terminated||Phase 2|114|Actual|FibroGen||2||"Study terminated due to an unexpected prominent effect of entecavir alone in this patient~   population."|f||||f||||||||||2018-05-31 23:16:46.944141|2018-05-31 23:16:46.944141
NCT01217619|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2017-09-11|2010-10-07|2010-10-08|Estimate|||||||2017-09-11|2017-09-12|Actual|March 2, 2011|Actual|2011-03-02|September 2017|2017-09-30|October 30, 2016|Actual|2016-10-30|June 30, 2016|Actual|2016-06-30||Interventional|ML25444||Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.|A Single Arm, One Center, Phase Ⅱ Study of Erlotinib as Neoadjuvent Treatment in Patients With Endobronchial Ultrasound Confirmed Stage ⅢA N2 NSCLC With EGFR Mutation in Exon 19 or 21|Completed||Phase 2|25|Actual|Shanghai Chest Hospital||1|||f||||f||||||||||2018-05-31 23:16:47.127427|2018-05-31 23:16:47.127427
NCT01217606|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2015-10-12||2016-11-01|2010-10-07|2010-10-08|Estimate|2015-10-12|2015-11-09|Estimate||||2016-11-01|2016-12-20|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|185|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:16:47.495431|2018-05-31 23:16:47.495431
NCT01217593|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2014-03-20|2010-10-07|2010-10-08|Estimate|||||||2014-03-20|2014-03-21|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Ultrasound vs. Predetermined Distance Techniques for Paravertebral Nerve Block in Patients Having Breast Surgery|A Comparison Of Ultrasound and Predetermined Distance Techniques For Paravertebral Space Localization In Breast Surgery: A Randomized Prospective Trial|Unknown status|Recruiting|N/A|60|Anticipated|Ochsner Health System||2|||f||||f||||||||||2018-05-31 23:16:47.971025|2018-05-31 23:16:47.971025
NCT01217580|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2011-10-25|2010-10-07|2010-10-08|Estimate|||||||2011-10-25|2011-10-26|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|TAP||Pain Relief Study of Ultrasound Guided Transverse Abdominis Plane(TAP)Block|Analgesic Efficacy of Ultrasound Guided Transversus Abdominis Plane Block After Cesarean Delivery in Patients With a BMI > 30|Withdrawn||N/A|50|Anticipated|Ochsner Health System||2||"The study was not feasible to perform at one institution with the amount of subjects that were~   needed to complete it."|f||||t||||||||||2018-05-31 23:16:48.088673|2018-05-31 23:16:48.088673
NCT01217567|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2012-02-07|2010-10-07|2010-10-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|||Subcuticular Suture Versus Staples for Closure of the Skin After Caesarean Section.|Subcuticular Suture Versus Staples for Closure of the Skin After Caesarean Section: A Prospective Randomized Single-blinded Case-Control Study With the Case as it's Own Control.|Completed||N/A|60|Anticipated|Holbaek Sygehus||4|||f||||f||||||||||2018-05-31 23:16:48.232077|2018-05-31 23:16:48.232077
NCT01217554|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-02-08|2010-10-07|2010-10-08|Estimate|||||||2012-02-08|2012-02-09|Estimate|February 2011||2011-02-28|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Kinematical Evaluation of Lumbar Rotation in Chronic Low Back Pain|Kinematical Evaluation of Lumbar Rotation in Neutral Position and Full Flexion in Sitting and Standing in Patients With Non-specific Chronic Low Back Pain|Completed|||50|Actual|Clalit Health Services|||2||f||||f||||||||||2018-05-31 23:16:48.690371|2018-05-31 23:16:48.690371
NCT01217541|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2014-12-11|2010-10-07|2010-10-08|Estimate|||||||2014-12-11|2014-12-12|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|SAM-AKS||Collaboration Between Department of Old Age Psychiatry and Nursing Homes|Collaboration Between Department of Old Age Psychiatry and Nursing Homes|Completed||N/A|700|Actual|Sykehuset Innlandet HF||2|||f||||t||||||||||2018-05-31 23:16:48.763607|2018-05-31 23:16:48.763607
NCT01217528|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2013-07-26|2010-10-07|2010-10-08|Estimate|||||||2013-07-26|2013-07-29|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|DECREASE||Reduction of Inappropriate Implantable Cardioverter Defibrillator (ICD) Therapies in Primary Prevention Patients|Reduction of Inappropriate ICD Therapies in Patients With Approved Indication for Primary Prevention of Sudden Cardiac Death|Completed||N/A|543|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 23:16:49.16115|2018-05-31 23:16:49.16115
NCT01217515|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2013-11-07||2014-07-07|2010-10-07|2010-10-08|Estimate|2014-06-30|2014-07-01|Estimate||||2014-07-07|2014-07-17|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Diltiazem Hydrochloride Cream for Anal Fissure|A Randomised,Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Diltiazem Hydrochloride Cream in Subjects With Anal Fissure|Completed||Phase 3|465|Actual|S.L.A. Pharma AG||3|||f||||f||||||||||2018-05-31 23:16:49.324023|2018-05-31 23:16:49.324023
NCT01217502|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2014-11-21|2010-10-07|2010-10-08|Estimate|||||||2014-11-21|2014-11-24|Estimate|November 2010||2010-11-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Self-management for Dual Sensory Impaired|Self-management for Dual Sensory Impaired Older People and Their Caregivers: an Effective Approach?|Completed||N/A|89|Actual|Radboud University||1|||f||||t||||||||||2018-05-31 23:16:49.910523|2018-05-31 23:16:49.910523
NCT01217489|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2017-10-11|2010-10-07|2010-10-08|Estimate|||||||2017-10-11|2017-10-12|Actual|August 2009||2009-08-31|October 2017|2017-10-31|September 21, 2012|Actual|2012-09-21|March 1, 2011|Actual|2011-03-01||Observational|Signascan||Study Into the Use of Electrical Impedance Mammography in the Diagnosis and Characterisation of Breast Disease|Use of Non-invasive Electrical Impedance Mammography in the Detection, Diagnosis and Characterisation of Breast Lesions|Terminated|||300|Anticipated|Oxford University Hospitals NHS Trust|||1||f||||t||||||||||2018-05-31 23:16:50.150345|2018-05-31 23:16:50.150345
NCT01217476|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2014-07-02||2014-08-04|2010-10-07|2010-10-08|Estimate|2014-08-04|2014-08-05|Estimate||||2014-08-04|2014-08-05|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional|TRANS-North|The intent-to-treat (ITT) population was defined as all randomized patients who have at least one medical evaluation during the study. Demographic and baseline characteristics were presented in terms of descriptive statistics in ITT population.|The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study|A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment With Trafermin 0.01% Spray in Patients With Diabetic Foot Ulcer of Neuropathic Origin|Completed||Phase 3|207|Actual|Olympus Biotech Corporation||2|||f||||t||||||||||2018-05-31 23:16:50.229816|2018-05-31 23:16:50.229816
NCT01217463|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2014-07-02||2014-08-04|2010-10-07|2010-10-08|Estimate|2014-08-04|2014-08-05|Estimate||||2014-08-04|2014-08-05|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|February 2013|Actual|2013-02-28|March 2012|Actual|2012-03-31||Interventional|TRANS-South|The intent-to-treat (ITT) population was defined as all randomized patients who have at least one medical evaluation during the study. Demographic and baseline characteristics were presented in terms of descriptive statistics in ITT population.|The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study|A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment With Trafermin 0.01% Spray in Patients With Diabetic Foot Ulcer of Neuropathic Origin|Completed||Phase 3|201|Actual|Olympus Biotech Corporation||2|||f||||t||||||||||2018-05-31 23:16:50.768586|2018-05-31 23:16:50.768586
NCT01217450|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2014-05-28|2010-10-07|2010-10-08|Estimate|||||||2014-05-28|2014-05-29|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|May 2014|Actual|2014-05-31|December 2012|Actual|2012-12-31||Interventional|||Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors|A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors|Completed||Phase 1|33|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:16:51.292563|2018-05-31 23:16:51.292563
NCT01217437|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2018-05-24|2010-10-07|2010-10-08|Estimate|||||||2018-05-24|2018-05-25|Actual|November 22, 2010|Actual|2010-11-22|May 2018|2018-05-31||||December 31, 2017|Actual|2017-12-31||Interventional|||Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors|Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial|Active, not recruiting||Phase 2|108|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:16:51.453353|2018-05-31 23:16:51.453353
NCT01217424|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2016-10-31|2010-10-07|2010-10-08|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Reflexology or Aromatherapy Massage in Relieving Symptoms in Patients With Cancer|Is Reflexology as Effective as Aromatherapy Massage for Symptom Relief in an Outpatient Oncology Population?|Completed||N/A|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:16:51.852562|2018-05-31 23:16:51.852562
NCT01217411|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2015-01-22||2015-01-22|2010-10-07|2010-10-08|Estimate|2015-01-22|2015-02-06|Estimate||||2015-01-22|2015-02-06|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer|Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative|Terminated||Phase 1/Phase 2|5|Actual|National Cancer Institute (NCI)|Due to small number of patients enrolled on study, researchers were unable to make meaningful conclusions from the data.|2||Slow accrual coupled with discontinuation of study drug.|f||||||||||||||2018-05-31 23:16:51.938217|2018-05-31 23:16:51.938217
NCT01217398|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2013-08-23|2010-10-07|2010-10-08|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2009||2009-10-31|August 2012|2012-08-31||||October 2012|Anticipated|2012-10-31||Interventional|||Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye|Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma|Unknown status|Recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:16:52.216227|2018-05-31 23:16:52.216227
NCT01217385|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2013-10-14|2010-10-07|2010-10-08|Estimate|||||||2013-10-14|2013-10-16|Estimate|March 2011||2011-03-31|October 2013|2013-10-31||||June 2013|Actual|2013-06-30||Interventional|ACRIN 6691||Diffuse Optical Spectroscopy Imaging in Monitoring and Predicting Response in Patients With Locally Advanced Breast Cancer Undergoing Chemotherapy Before Surgery|Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|American College of Radiology Imaging Network||1|||f||||t||||||||||2018-05-31 23:16:52.284604|2018-05-31 23:16:52.284604
NCT01217372|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2018-01-15|2010-10-07|2010-10-08|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2009|Actual|2009-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|LIMONE||Nephrolithiasis Prevention by Lemon Juice|A Prospective, Randomized, Open Blind Endpoint (Probe) Trial to Assess the Possibility to Prevent Stone Recurrence by Lemon Juice Supplementation in Patients With Recurrent Calcium Oxalate Nephrolithiasis (LIMONE Study)|Active, not recruiting||Phase 2|202|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 23:16:52.379961|2018-05-31 23:16:52.379961
NCT01217359|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2016-11-11|2010-10-06|2010-10-08|Estimate|||||||2016-11-11|2016-11-15|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling|Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling|Completed||Phase 1|22|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 23:16:52.451767|2018-05-31 23:16:52.451767
NCT01217346|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-08-01|2010-10-07|2010-10-08|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Prevalence Study of Obstructive Sleep Apnea in Subjects With Chest Pain, Positive Exercise Treadmill Test and Normal Coronary Angiogram||Terminated|||20|Actual|The University of Hong Kong|||1||f||||t||||||||||2018-05-31 23:16:52.510137|2018-05-31 23:16:52.510137
NCT01217333|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2012-10-16|2010-10-06|2010-10-08|Estimate|||||||2012-10-16|2012-10-18|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Telephone-Based Decision Support for Rural Patients|Telephone-Based Decision Support for Rural Patients|Completed||N/A|74|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:16:52.566761|2018-05-31 23:16:52.566761
NCT01217320|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-01-12|2010-10-07|2010-10-08|Estimate|||||||2012-01-12|2012-01-16|Estimate|January 2011||2011-01-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Creatine Supplementation in Pediatric Rheumatology|Efficacy and Safety of Creatine Supplementation in Patients With Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:16:52.655723|2018-05-31 23:16:52.655723
NCT01217307|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2017-07-31||2017-07-31|2010-10-07|2010-10-08|Estimate|2017-07-31|2018-01-30|Actual||||2017-07-31|2018-01-30|Actual|January 2011||2011-01-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2013|Actual|2013-10-31||Interventional|GIPS-III||Metformin to Reduce Heart Failure After Myocardial Infarction|Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.|Completed||Phase 2/Phase 3|380|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 23:16:52.752252|2018-05-31 23:16:52.752252
NCT01217294|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2014-04-08|2010-10-07|2010-10-08|Estimate|||||||2014-04-08|2014-04-10|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study Comparing a Nerve Block With Spinal Opiate to Provide Pain Relief for Hip Replacement Surgery|Intrathecal Opioid Versus Ultrasound Guided Fascia Iliaca Plane Block for Analgesia After Primary Hip Arthroplasty|Completed||N/A|108|Actual|University of Glasgow||2|||f||||f||||||||||2018-05-31 23:16:52.990535|2018-05-31 23:16:52.990535
NCT01217281|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2017-10-25|2010-10-07|2010-10-08|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2010||2010-06-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of Non-surgical Periodontal Treatment in the Renal Function of Patients With Chronic Kidney Disease: RCT|The Effect of Non-surgical Periodontal Treatment in the Renal Function of Patients With Chronic Kidney Disease: A Randomized Clinical Trial|Active, not recruiting||N/A|48|Actual|University of Athens||2|||f||||f||||||||||2018-05-31 23:16:53.099279|2018-05-31 23:16:53.099279
NCT01217268|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2011-05-05|2010-10-07|2010-10-08|Estimate|||||||2011-05-05|2011-05-06|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|TESAM||Use of Telemedicine in Collaboration Between a Psychogeriatric Unit and Nursing Homes|Use of Telemedicine in Collaboration Between a Psychogeriatric Unit and Nursing|Unknown status|Recruiting|N/A|15|Anticipated|Sykehuset Innlandet HF||1|||f||||f||||||||||2018-05-31 23:16:53.178627|2018-05-31 23:16:53.178627
NCT01217255|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2013-12-17|2010-10-07|2010-10-08|Estimate|||||||2013-12-17|2013-12-19|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World|Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World: The Sao Paulo - Toronto Hemophilia Study|Completed|||100|Actual|The Hospital for Sick Children|||2||f||||f||||||||||2018-05-31 23:16:53.265809|2018-05-31 23:16:53.265809
NCT01217242|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2012-01-04|2010-10-06|2010-10-08|Estimate|||||||2012-01-04|2012-01-05|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Observational|APCP||Activity and Participation in Ambulatory Cerebral Palsy|Cross-sectional Descriptive Study to Quantify to What Extent Activity Capacity, Performance and Body Composition Predict Day to Day Life Participation in Ambulatory Children With CP.|Completed|||128|Actual|Seattle Children's Hospital|||1||f||||f||||||||||2018-05-31 23:16:53.35567|2018-05-31 23:16:53.35567
NCT01217229|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2013-02-12||2013-04-03|2010-10-06|2010-10-08|Estimate|2013-02-12|2013-03-15|Estimate||||2013-04-03|2013-04-10|Estimate|December 2010||2010-12-31|April 2013|2013-04-30||||May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma|A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma|Completed||Phase 2|20|Actual|Plexxikon||1|||f||||f||||||||||2018-05-31 23:16:53.436067|2018-05-31 23:16:53.436067
NCT01217216|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-11-02|2010-10-06|2010-10-08|Estimate|||||||2012-11-02|2012-11-06|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CASTLE||Cancer Survival Through Weight Loss and Exercise|Cancer Survival Through Weight Loss and Exercise (CASTLE)|Completed||N/A|52|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-05-31 23:16:53.576545|2018-05-31 23:16:53.576545
NCT01217203|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2014-02-27|2010-10-07|2010-10-08|Estimate|||||||2014-02-27|2014-02-28|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|KIRIMID||Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse|Multicenter Phase I Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101, a Human Monoclonal Anti-KIR, Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse|Completed||Phase 1|15|Actual|Innate Pharma||1|||f||||f||||||||||2018-05-31 23:16:53.674191|2018-05-31 23:16:53.674191
NCT01217190|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2011-07-25|2010-10-06|2010-10-08|Estimate|||||||2011-07-25|2011-07-26|Estimate|September 2008||2008-09-30|June 2011|2011-06-30||||September 2008|Actual|2008-09-30||Interventional|||Cross-over Bioequivalence Fasting Study to Compare Ondansetron Oral Soluble Film (OSF)With Zofran Orally Disintegrating Tablets(ODT)|An Open-Label Randomized, Single Oral Dose, Two Way Crossover Bioequivalence Study to Compare Ondansetron OSF 8mg (Manufactured by MonoSol RX, USA) With Zofran ODT (Containing Ondansetron 8mg) (Manufactured by Cardinal Health Blagrove, Swindon, Wiltshire, UK, SN58RU for Glaxo Smithkline, Research Triangle Park NC 27709, Made in England) in 48 Healthy, Adult, Human Study Participants Under Fasting Conditions|Completed||Phase 3|48|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-05-31 23:16:53.743252|2018-05-31 23:16:53.743252
NCT01217177|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-04-01|2010-10-07|2010-10-08|Estimate|||||||2015-04-01|2015-04-03|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PHOENIX I||A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer|A Phase I Study of Oral Administration of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for the Treatment of Locally Advanced Cervix Cancer|Completed||Phase 1|14|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:16:53.808645|2018-05-31 23:16:53.808645
NCT01217164|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-10-07|2010-10-07|2010-10-08|Estimate|||||||2010-10-07|2010-10-08|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|SPN||Strategy to Minimize In-hospital Malnutrition in Premature Babies|Strategy to Minimize In-hospital Malnutrition in Premature Babies|Completed||Early Phase 1|64|Actual|Hospital Universitario Pedro Ernesto||1|||f||||t||||||||||2018-05-31 23:16:53.928945|2018-05-31 23:16:53.928945
NCT01217151|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2012-11-19|2010-10-07|2010-10-08|Estimate|||||||2012-11-19|2012-11-20|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Perioperative Hemodynamic Optimization Using the NICOM Device|Perioperative Hemodynamic Goal-directed Optimization Using the Noninvasive NICOM™ Monitoring Device in Major Abdominal Surgery|Completed||N/A|142|Actual|Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 23:16:54.095359|2018-05-31 23:16:54.095359
NCT01217138|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2010-10-07|2010-10-07|2010-10-08|Estimate|||||||2010-10-07|2010-10-08|Estimate|June 2009||2009-06-30|October 2010|2010-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Make up for the Epinephrine Autoinjector|Make up for the Epinephrine Autoinjector: Effect on Its Use by Untrained Users|Completed||Phase 4|164|Actual|Gazi University||2|||f||||f||||||||||2018-05-31 23:16:54.319497|2018-05-31 23:16:54.319497
NCT01217125|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-03-07|2010-10-07|2010-10-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|October 2008||2008-10-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis|CLINICAL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF RAPAMYCIN IN ANGIOMYOLIPOMAS IN PATIENTS WITH TUBEROUS SCLEROSIS|Completed||Phase 4|18|Actual|Fundacio Puigvert|||||f||||f||||||||||2018-05-31 23:16:54.40297|2018-05-31 23:16:54.40297
NCT01217112|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|2013-10-22||2014-09-09|2010-10-07|2010-10-08|Estimate|2013-12-16|2014-01-20|Estimate||||2014-09-09|2014-09-18|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes|A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes|Completed||Phase 2|62|Actual|GW Research Ltd||5|||f||||f||||||||||2018-05-31 23:16:54.566518|2018-05-31 23:16:54.566518
NCT01217099|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-07|2010-10-07|2010-10-08|Estimate|||||||2010-10-07|2010-10-08|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|MPP||Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children|A Prospective, Open-label Trial of Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children|Terminated||N/A|47|Actual|Chongqing Medical University||2||terminated|f||||t||||||||||2018-05-31 23:16:56.764685|2018-05-31 23:16:56.764685
NCT01217086|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-03-11|2010-10-07|2010-10-08|Estimate|||||||2013-03-11|2013-03-12|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|||Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)|Randomized, Double-blind, Parallel-group, Phase 3 Study|Completed||Phase 3|617|Actual|Celltrion||2|||f||||t||||||||||2018-05-31 23:16:56.82554|2018-05-31 23:16:56.82554
NCT01217073|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2015-09-29||2017-06-01|2010-10-06|2010-10-08|Estimate|2015-09-29|2015-10-29|Estimate||||2017-06-01|2017-06-29|Actual|October 8, 2010|Actual|2010-10-08|June 2017|2017-06-30|April 1, 2013|Actual|2013-04-01|January 3, 2012|Actual|2012-01-03||Interventional||Population includes all participants randomized during the base period. The extension period only included participants who completed the base period and consented to enter the extension period.|A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)|A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control|Completed||Phase 2|685|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 23:16:56.98367|2018-05-31 23:16:56.98367
NCT01217060|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2018-04-27|2010-10-06|2010-10-08|Estimate|||||||2018-04-27|2018-04-30|Actual|October 2010|Actual|2010-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trimodality Management of T1b Esophageal Cancers|Phase IIB Study of Trimodality Management of Clinical T1bN0M0 Cancers of the Esophagus|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:16:58.314561|2018-05-31 23:16:58.314561
NCT01217047|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2016-08-29|2010-10-07|2010-10-08|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|CURE-SCI||Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury|CURE-SCI. Clinical Utilization of CNS Growth Factor Release in Response to Electrical Stimulation Following Spinal Cord Injury.|Completed||Phase 2/Phase 3|30|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||4|||f||||f||||||||||2018-05-31 23:16:58.435811|2018-05-31 23:16:58.435811
NCT01217034|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-02|||2017-10-30|2010-10-06|2010-10-08|Estimate|||||||2017-10-30|2017-10-31|Actual|October 2010||2010-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|TACTICS||Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib|Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS)|Active, not recruiting||Phase 2|228|Anticipated|Japan Liver Oncology Group||2|||f||||t||||||||||2018-05-31 23:16:58.510165|2018-05-31 23:16:58.510165
NCT01088295|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|2013-01-16||2014-06-19|2010-03-16|2010-03-17|Estimate|2013-01-16|2013-02-18|Estimate||||2014-06-19|2014-06-30|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|MATH||HIV and Fat Accumulation|Metabolic Abnormalities, Telmisartan and HIV Infection|Completed||Phase 2|35|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 23:58:49.757478|2018-05-31 23:58:49.757478
NCT01217021|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-07-22|2010-10-06|2010-10-08|Estimate|||||||2011-07-22|2011-07-25|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|MNI-558||Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558|An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate Efficacy & Safety of MNI-558 Positron Emission Tomography for Detection/Exclusion of Cerebral Amyloid Beta in Patients w/ Alzheimer Disease Compared to Healthy Volunteers|Completed||Early Phase 1|10|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-05-31 23:16:58.589718|2018-05-31 23:16:58.589718
NCT01217008|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2014-01-06|2010-10-07|2010-10-08|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety Study of GRNOPC1 in Spinal Cord Injury|A Phase 1 Safety Study of GRNOPC1 in Patients With Neurologically Complete, Subacute, Spinal Cord Injury|Completed||Phase 1|5|Actual|Asterias Biotherapeutics, Inc.||1|||f||||t||||||||||2018-05-31 23:16:58.717198|2018-05-31 23:16:58.717198
NCT01216995|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2014-11-19|2010-10-07|2010-10-08|Estimate|||||||2014-11-19|2014-11-21|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ADVANCE||Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI)|A Phase II Trial of Safety and Efficacy of ADRCs Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction - The ADVANCE Study|Completed||Phase 2|23|Actual|Cytori Therapeutics||2|||f||||t||||||||||2018-05-31 23:16:58.949801|2018-05-31 23:16:58.949801
NCT01216982|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2011-03-08|2010-10-06|2010-10-07|Estimate|||||||2011-03-08|2011-03-09|Estimate|November 2010||2010-11-30|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders|Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders: A Mood Resilience Trial|Unknown status|Active, not recruiting|Phase 2|256|Anticipated|United States Department of Defense||2|||f||||||||||||||2018-05-31 23:16:59.184842|2018-05-31 23:16:59.184842
NCT01216956|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|September 2006||2006-09-30|October 2010|2010-10-31|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia|Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia|Completed||N/A|24|Actual|Centre de Recherche en Nutrition Humaine Rhone-Alpe||2|||f||||f||||||||||2018-05-31 23:16:59.364566|2018-05-31 23:16:59.364566
NCT01216943|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2013-07-16||2013-07-16|2010-10-06|2010-10-07|Estimate|2013-07-16|2013-09-19|Estimate||||2013-07-16|2013-09-19|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension|A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Twice-daily 0.01% Bimatoprost/0.15% Brimonidine/0.5% Timolol Ophthalmic Solution (Triple Combination) in Patients in India, Who Have Glaucoma or Ocular Hypertension With Elevated IOP, and Are on Twice-daily 0.2% Brimonidine/0.5% Timolol Ophthalmic Solution (Dual Combination) Therapy|Completed||Phase 3|126|Actual|Allergan||1|||f||||f||||||||||2018-05-31 23:16:59.468166|2018-05-31 23:16:59.468166
NCT01216930|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-09-11|2010-10-06|2010-10-07|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|October 2012|Actual|2012-10-31||Observational|||Molecular Screening for Lynch Syndrome in Southern Denmark|Molecular Screening for Lynch Syndrome in Southern Denmark|Completed|||2000|Actual|Vejle Hospital|||1||f||||f||||||||||2018-05-31 23:16:59.598873|2018-05-31 23:16:59.598873
NCT01216917|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-10-03|2010-10-06|2010-10-07|Estimate|||||||2012-10-03|2012-10-04|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Influence of Ageing on Muscle Quality||Completed|||45|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||t||||||||||2018-05-31 23:16:59.658196|2018-05-31 23:16:59.658196
NCT01216904|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2013-05-10|2010-10-06|2010-10-07|Estimate|||||||2013-05-10|2013-05-14|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Nicotine Treatment of Impulsivity in Parkinson's Disease|Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study|Unknown status|Recruiting|Phase 4|20|Anticipated|University of Vermont||2|||f||||||||||||||2018-05-31 23:16:59.7064|2018-05-31 23:16:59.7064
NCT01216891|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2016-11-02|2010-10-06|2010-10-07|Estimate|||||||2016-11-02|2016-11-03|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|January 2015|Actual|2015-01-31||Interventional|||Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis|Recovery After an Initial Schizophrenia Episode (RAISE): The RAISE Connection Program Duration of Untreated Psychosis (DUP)|Completed||N/A|65|Actual|Research Foundation for Mental Hygiene, Inc.||1|||f||||t||||||||||2018-05-31 23:16:59.787511|2018-05-31 23:16:59.787511
NCT01216878|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2018-01-19|2010-10-06|2010-10-07|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2004||2004-09-30|January 2018|2018-01-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment Bioequivalency Study of Losartan Potassium Tablets 100 mg Under Fed Conditions|Completed||N/A|40|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:16:59.867084|2018-05-31 23:16:59.867084
NCT01216865|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-12|2010-10-06|2010-10-07|Estimate|||||||2010-10-12|2010-10-13|Estimate|January 2011||2011-01-31|January 2009|2009-01-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Injection for Diabetic Foot|Unknown status|Not yet recruiting|Phase 1/Phase 2|50|Anticipated|Qingdao University||2|||f||||t||||||||||2018-05-31 23:17:00.796237|2018-05-31 23:17:00.796237
NCT01216852|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2018-01-19|2010-10-06|2010-10-07|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2004||2004-08-31|January 2018|2018-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment Bioequivalency Study of Losartan Potassium Tablets 100 mg Under Fasted Conditions|Completed||N/A|40|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:17:00.911801|2018-05-31 23:17:00.911801
NCT01216839|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-03-25|2010-10-06|2010-10-07|Estimate|||||||2013-03-25|2013-03-26|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas|Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas|Unknown status|Recruiting|Phase 2|20|Anticipated|Hospital Santa Marcelina||1|||f||||f||||||||||2018-05-31 23:17:00.970752|2018-05-31 23:17:00.970752
NCT01216826|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-08-05|2010-10-06|2010-10-07|Estimate|||||||2013-08-05|2013-08-07|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma|Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma|Unknown status|Recruiting|Phase 2|20|Anticipated|Hospital Santa Marcelina||1|||f||||f||||||||||2018-05-31 23:17:01.04372|2018-05-31 23:17:01.04372
NCT01216813|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2016-10-31|2010-10-06|2010-10-07|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer|The Rehabilitation Needs of People Who Have Had an Upper Gastrointestinal or a Gynecological Cancer|Completed|||33|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:17:01.112965|2018-05-31 23:17:01.112965
NCT01216800|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|August 2008||2008-08-31|October 2010|2010-10-31||||August 2016|Anticipated|2016-08-31||Interventional|||Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors|A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors|Unknown status|Recruiting|Phase 3|84|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:17:01.176139|2018-05-31 23:17:01.176139
NCT01216787|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2013-01-30|2010-10-06|2010-10-07|Estimate|||||||2013-01-30|2013-01-31|Estimate|September 2010||2010-09-30|January 2013|2013-01-31||||November 2011|Actual|2011-11-30||Interventional|||RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery|A Pilot Trial to Evaluate the Molecular Effects of RO4929097 as Neoadjuvant Therapy for Resectable Stage IIIB, IIIC or IV Melanoma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1||Study drug not available.|f||||t||||||||||2018-05-31 23:17:01.252111|2018-05-31 23:17:01.252111
NCT01216774|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-06-15|2010-10-06|2010-10-07|Estimate|||||||2012-06-15|2012-06-18|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||December 2010|Actual|2010-12-31||Interventional|||The Role of Mechanical Stress and Muscle Fatigue in Strength Gains||Completed||N/A|36|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||||||||||||2018-05-31 23:17:01.331939|2018-05-31 23:17:01.331939
NCT01216761|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2011-10-07||2017-01-09|2010-10-06|2010-10-07|Estimate|2012-10-03|2012-11-01|Estimate||||2017-01-09|2017-01-11|Estimate|May 2008||2008-05-31|January 2017|2017-01-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions|Blood Culture Contamination: A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions|Completed||N/A|3879|Actual|University of Michigan|It is possible for subjects to have multiple blood culture sets obtained during the study.Thus, the # of blood culture sets will not equal the # of subjects. Also, cross-over assignment occurred at the hospital floor level - not the subject level.|3|||f||||f||||||||||2018-05-31 23:17:01.489748|2018-05-31 23:17:01.489748
NCT01216748|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2014-09-02||2016-04-27|2010-10-06|2010-10-07|Estimate|2014-12-15|2014-12-17|Estimate||||2016-04-27|2016-05-27|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway|Clinical Evidence of pH Dependent ß2 Adrenergic Transport Mechanisms in the Airway|Completed||N/A|10|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 23:17:01.708847|2018-05-31 23:17:01.708847
NCT01216735|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2014-09-05||2016-05-27|2010-10-06|2010-10-07|Estimate|2014-11-26|2014-12-05|Estimate||||2016-05-27|2016-06-29|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional||32 participants were enrolled divided in two groups smokers and controls|Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers|Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers|Completed||N/A|32|Actual|University of Miami||3|||f||||f||||||||||2018-05-31 23:17:01.973751|2018-05-31 23:17:01.973751
NCT01216722|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Interventional|||Study of Resistance Strengthening Versus Ambulation Post-Liver Transplant|Comparison of Targeted Lower Extremity Strengthening and Usual Care Progressive Ambulation in Subjects Post Liver Transplant: A Randomized Controlled Trial|Completed||N/A|52|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 23:17:02.301472|2018-05-31 23:17:02.301472
NCT01216709|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-06-13|2010-10-06|2010-10-07|Estimate|||||||2012-06-13|2012-06-14|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|MJAU||Iron Absorption From Infant Formula and Iron Drops in Infants (MJAU-studien)|Iron Absorption From Iron-fortified Infant Formula and Iron Drops in Infants (MJAU-studien)|Unknown status|Recruiting|N/A|72|Anticipated|Umeå University||3|||f||||f||||||||||2018-05-31 23:17:02.38919|2018-05-31 23:17:02.38919
NCT01216696|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2016-08-11|2010-10-06|2010-10-07|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CTLA4 NY-ESO-1||Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1|Phase II Trial of Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1|Completed||Phase 2|25|Actual|National Center for Tumor Diseases, Heidelberg||1|||f||||t||||||||||2018-05-31 23:17:02.461898|2018-05-31 23:17:02.461898
NCT01216683|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2017-12-12|2010-10-06|2010-10-07|Estimate|||||||2017-12-12|2017-12-14|Actual|December 2010||2010-12-31|December 2017|2017-12-31|April 2023|Anticipated|2023-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma|A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma|Active, not recruiting||Phase 2|250|Anticipated|Eastern Cooperative Oncology Group||3|||f||||f||||||||||2018-05-31 23:17:02.592096|2018-05-31 23:17:02.592096
NCT01216670|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2015-10-12|2010-10-06|2010-10-07|Estimate|||||||2015-10-12|2015-10-14|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Observational|CARRYINGON||Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure|Cardiac Rhythm Monitoring After Acute Decompensation for Heart Failure|Completed|||18|Actual|Medtronic Italia|||||f||||f||||||||||2018-05-31 23:17:03.169963|2018-05-31 23:17:03.169963
NCT01216657|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-06-03|2010-10-06|2010-10-07|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2009||2009-03-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma|An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma|Terminated||Phase 2|7|Actual|Krankenhaus Nordwest||1||slow recruitment|f||||||||||||||2018-05-31 23:17:03.309756|2018-05-31 23:17:03.309756
NCT01216644|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-03-06|2010-10-06|2010-10-07|Estimate|||||||2017-03-06|2017-03-07|Actual|July 2010||2010-07-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer|A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach|Active, not recruiting||Phase 2/Phase 3|716|Actual|Krankenhaus Nordwest||2|||f||||t||||||||||2018-05-31 23:17:03.402914|2018-05-31 23:17:03.402914
NCT01216631|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2015-05-26||2016-05-10|2010-10-06|2010-10-07|Estimate|2016-05-10|2016-05-13|Estimate||||2016-05-10|2016-05-13|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SOKS|Only 1 recruited|Seronegative Oligoarthritis of the Knee Study (SOKS)|Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee|Terminated||Phase 2|1|Actual|University of Leeds||3||Unable to recruit|f||||t||||||||||2018-05-31 23:17:03.560958|2018-05-31 23:17:03.560958
NCT01216618|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2014-09-03|2010-10-06|2010-10-07|Estimate|||||||2014-09-03|2014-09-04|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies|Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies|Completed||Phase 3|55|Actual|Insuline Medical Ltd.||2|||f||||f||||||||||2018-05-31 23:17:03.859406|2018-05-31 23:17:03.859406
NCT01216605|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Oxytocin and Emotion Recognition||Completed||Phase 4|56|Actual|University Hospital Freiburg||2|||f||||f||||||||||2018-05-31 23:17:03.925877|2018-05-31 23:17:03.925877
NCT01216592|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2011-12-04|2010-10-06|2010-10-07|Estimate|||||||2011-12-04|2011-12-06|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Observational|||Airway Inflammation, Symptoms and Lung Function in COPD|Correlations Between Airway Inflammation, Symptoms and Lung Functions in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)|Completed|||40|Actual|Università degli Studi di Ferrara|||1||f||||f||||||Samples With DNA|"~     Sputum cells.~   "|||2018-05-31 23:17:03.980077|2018-05-31 23:17:03.980077
NCT01216579|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|March 2004||2004-03-31|March 2008|2008-03-31||||February 2010|Actual|2010-02-28||Interventional|||Steroid Titration Against Mannitol IN Asthma|Titrating Inhaled Steroid Dose Against Mannitol Hyper-responsiveness or BTS Outcomes: Comparative Effects on Asthma Exacerbations Over 1 Year|Completed||N/A|164|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 23:17:04.054142|2018-05-31 23:17:04.054142
NCT01216566|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|||Computerized Mobilization of the Cervical Spine Utilizing the Occiflex Device for the Treatment of Chronic Neck Pain||Unknown status|Not yet recruiting|Phase 1/Phase 2|10|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 23:17:04.115058|2018-05-31 23:17:04.115058
NCT01216553|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2011-07-10|2010-10-06|2010-10-07|Estimate|||||||2011-07-10|2011-07-12|Estimate|October 2011||2011-10-31|July 2011|2011-07-31|August 2014|Anticipated|2014-08-31|May 2013|Anticipated|2013-05-31||Interventional|O2-Rx||Home Oxygen Therapy in Bronchiolitis|Home Oxygen Therapy in the Ambulatory Treatment of Bronchiolitis|Unknown status|Not yet recruiting|Phase 4|135|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 23:17:04.196047|2018-05-31 23:17:04.196047
NCT01216540|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-08|2010-10-06|2010-10-07|Estimate|||||||2010-10-08|2010-10-11|Estimate|November 2010||2010-11-30|October 2010|2010-10-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Observational|||Vancomycin-Associated Nephrotoxicity|Occurrence and Economic Impact of Nephrotoxicity Associated With Vancomycin Exposure|Unknown status|Not yet recruiting||400|Anticipated|University at Buffalo|||1||f||||f||||||||||2018-05-31 23:17:04.386796|2018-05-31 23:17:04.386796
NCT01216527|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2017-02-24|2010-10-06|2010-10-07|Estimate|||||||2017-02-24|2017-02-27|Actual|June 2007||2007-06-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer|A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery Versus Surgery for Locally Advanced Squamous Cell Esophageal Carcinoma|Active, not recruiting||Phase 3|430|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:17:04.471915|2018-05-31 23:17:04.471915
NCT01216514|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-11-02|2010-10-06|2010-10-07|Estimate|||||||2011-11-02|2011-11-03|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Serologic Markers for Inflammatory Bowel Disease During Clinical Forms With Weak or Strong Evolution Capacities|Differential Characteristics of All Serologic Markers for Chronic Inflammatory Bowel Diseases During Clinical Forms With Weak or Strong Evolution Capacities|Completed|||194|Actual|Centre Hospitalier Universitaire de Saint Etienne|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 23:17:04.569034|2018-05-31 23:17:04.569034
NCT01216501|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2014-11-19|2010-10-06|2010-10-07|Estimate|||||||2014-11-19|2014-11-20|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Sevoflurane and Isoflurane for RF or Cryo Ablation in Children.|Comparison of Electrophysiological Effects of Sevoflurane and Isoflurane-based Anesthesia in Children Undergoing RF Ablation or Cryoablation for SVT Treatment. A Randomized Double Blind Study.|Terminated|||32|Actual|Schneider Children's Medical Center, Israel||||Recruiting was not as anticipated.|f||||f||||||||||2018-05-31 23:17:04.633314|2018-05-31 23:17:04.633314
NCT01216488|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2011-12-20|2010-10-06|2010-10-07|Estimate|||||||2011-12-20|2011-12-21|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|COMBAX||Comparison Between Two Different Volumes of Anesthesia Drug in Forearm Surgery|Comparison of Axillary Block Under Ultrasound With 40 or 25 ml of Xylocaine 1.5% Adrenalin in Forearm or Arm Surgery.|Completed||Phase 3|72|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 23:17:04.69001|2018-05-31 23:17:04.69001
NCT01216475|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2016-07-19|2010-10-06|2010-10-07|Estimate|||||||2016-07-19|2016-07-20|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|November 2016|Anticipated|2016-11-30||Interventional|||Randomized, Non-inferiority Trial Comparing SMILE and LASIK|Comparison of Small Incision Lenticule Extraction (SMILE) and VisuMax Femtosecond Laser In Situ Keratomileusis (FemtoLASIK): A Randomized, Non-inferiority Trial|Recruiting||N/A|70|Anticipated|Singapore National Eye Centre||2|||f||||t||||||||No||2018-05-31 23:17:04.764365|2018-05-31 23:17:04.764365
NCT01216462|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2015-05-20|2010-10-06|2010-10-07|Estimate|||||||2015-05-20|2015-05-21|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Observational|NET-SCA||Registry of Acute Coronary Syndromes in the Lazio Region of Italy|First Prospective Observational Registry of the Lazio Regional Network for Acute Coronary Syndromes|Recruiting|||3000|Anticipated|San Filippo Neri General Hospital|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 23:17:04.85511|2018-05-31 23:17:04.85511
NCT01216449|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2018-04-09|2010-10-06|2010-10-07|Estimate|||||||2018-04-09|2018-04-10|Actual|April 2009||2009-04-30|April 2018|2018-04-30|March 2016|Actual|2016-03-31|October 2011|Actual|2011-10-31||Interventional|||Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults|Pharmacodynamics of Intravenous Citalopram in the Elderly: a Functional Magnetic Resonance Imaging Analysis|Completed||N/A|29|Actual|Rotman Research Institute at Baycrest||2|||f||||t||||||||||2018-05-31 23:17:05.009227|2018-05-31 23:17:05.009227
NCT01216436|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2015-05-22|2010-10-06|2010-10-07|Estimate|||||||2015-05-22|2015-05-25|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma|Phase 1 Study of Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects With Metastatic Melanoma|Terminated||Phase 1|2|Actual|Duke University||4||The PI retired|f||||f||||||||||2018-05-31 23:17:05.098956|2018-05-31 23:17:05.098956
NCT01216423|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-01-11|2010-10-06|2010-10-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2009||2009-11-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Observational|EPIC-FOP||Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale|Is There a Link Between Venous Thromboembolism and Stroke in Patient With Patent Foramen Ovale ? Research for Stroke in Hospitalized Patients With Pulmonary Embolism.|Completed|||374|Actual|University Hospital, Brest|||2||f||||t||||||||No||2018-05-31 23:17:05.18442|2018-05-31 23:17:05.18442
NCT01216410|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2012-11-19||2014-08-04|2010-10-06|2010-10-07|Estimate|2013-02-19|2013-03-25|Estimate||||2014-08-04|2014-08-06|Estimate|December 2008||2008-12-31|July 2014|2014-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Prevention of Intraoperative Nausea and Vomiting During Cesarean Section|The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section|Completed||N/A|306|Actual|Duke University||3|||f||||f||||||||||2018-05-31 23:17:05.283567|2018-05-31 23:17:05.283567
NCT01216397|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2012-02-03||2014-06-18|2010-10-06|2010-10-07|Estimate|2012-03-28|2012-04-25|Estimate||||2014-06-18|2014-06-27|Estimate|September 2010||2010-09-30|February 2014|2014-02-28||||December 2010|Actual|2010-12-31||Interventional|||Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers|Relative Bioavailability of Two Different Batches of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet (FDC) in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial)|Completed||Phase 1|40|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:17:05.706425|2018-05-31 23:17:05.706425
NCT01216384|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2013-11-18|2010-10-06|2010-10-07|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2010||2010-10-31|November 2013|2013-11-30||||December 2010|Actual|2010-12-31||Interventional|||Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers|A Randomised, Double-blind (Within Dose Groups), Parallel Group, Placebocontrolled Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Rising Doses (50 mg, 200 mg, 400 mg) of BI 671800 HEA in Chinese Healthy Male Volunteers and Multiple Rising Doses (50 mg b.i.d., 200 mg b.i.d., 400 mg b.i.d.) of BI 671800 HEA in Japanese Healthy Male Volunteers|Completed||Phase 1|73|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:17:06.192422|2018-05-31 23:17:06.192422
NCT01216371|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-02-10|2010-10-06|2010-10-07|Estimate|||||||2012-02-10|2012-02-13|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|SMAT||Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)|Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO|Unknown status|Recruiting|Phase 2|60|Anticipated|Association of Urologic Oncology (AUO)||2|||f||||t||||||||||2018-05-31 23:17:06.268422|2018-05-31 23:17:06.268422
NCT01216358|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2012-05-08|2010-10-06|2010-10-07|Estimate|||||||2012-05-08|2012-05-10|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|BMAC||Boston Migraine and Contraception Study|The Boston Migraine and Contraception Study|Completed|||171|Actual|Planned Parenthood League of Massachusetts|||3||f||||f||||||||||2018-05-31 23:17:06.383831|2018-05-31 23:17:06.383831
NCT01216345|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|October 2006||2006-10-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Cetuximab + Gemox in Biliary Tract Cancer|Cetuximab Plus Gemcitabine-Oxaliplatin (GEMOX) in Patients With Unresectable Advanced or Metastatic Biliary Tract Cancer: a Phase II Study|Completed||Phase 2|30|Actual|Association of Research on the Biology of Liver Tumors|||||f||||f||||||||||2018-05-31 23:17:06.523767|2018-05-31 23:17:06.523767
NCT01216332|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2011-10-31|2010-10-05|2010-10-07|Estimate|||||||2011-10-31|2011-11-02|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients|Randomized, Double Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High Dose Trivalent Inactivated Influenza Vaccine in Pediatric Patients With Acute Lymphoblastic Leukemia|Unknown status|Enrolling by invitation|Phase 1|60|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-05-31 23:17:06.587429|2018-05-31 23:17:06.587429
NCT01216319|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2015-04-30||2016-05-19|2010-10-06|2010-10-07|Estimate|2015-04-30|2015-05-15|Estimate||||2016-05-19|2016-06-23|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|NRC||Evaluation of the Cook Biodesign® Nipple Reconstruction Cylinder (NRC)|A Single Arm Multicenter Study Evaluating the Cook Biodesign® Nipple Reconstruction Cylinder (NRC)|Completed||N/A|50|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 23:17:06.698051|2018-05-31 23:17:06.698051
NCT01216306|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-12-04|2010-10-06|2010-10-07|Estimate|||||||2013-12-04|2013-12-06|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Reducing Television Viewing To Prevent Obesity in Hispanic Preschool Children|Reducing Television Viewing To Prevent Obesity in Hispanic Preschool Children|Completed||N/A|252|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 23:17:06.872122|2018-05-31 23:17:06.872122
NCT01216293|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2015-03-02|2010-10-05|2010-10-07|Estimate|||||||2015-03-02|2015-03-03|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||Effect of Dexlansoprazole on Bone Homeostasis|Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dexlansoprazole 60 mg Delayed Release Capsules and Esomeprazole 40 mg Delayed Release Capsules on Bone Homeostasis in Healthy Postmenopausal Female Subjects|Completed||Phase 1|247|Actual|Takeda||3|||f||||f||||||||||2018-05-31 23:17:06.965148|2018-05-31 23:17:06.965148
NCT01216280|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2011-06-24|2010-10-06|2010-10-07|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|September 2011|Anticipated|2011-09-30|July 2011|Anticipated|2011-07-31||Interventional|||Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis|Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis|Unknown status|Active, not recruiting|Phase 2|75|Anticipated|Natrogen Therapeutics International, Inc||3|||f||||f||||||||||2018-05-31 23:17:07.067561|2018-05-31 23:17:07.067561
NCT01216267|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2013-01-14|2010-10-05|2010-10-07|Estimate|||||||2013-01-14|2013-01-16|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples|Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples|Completed||N/A|200|Actual|University of Western Ontario, Canada||1|||f||||f||||||||||2018-05-31 23:17:07.175383|2018-05-31 23:17:07.175383
NCT01216254|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2012-01-30|2010-10-06|2010-10-07|Estimate|||||||2012-01-30|2012-01-31|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Clinical Trial Comparing Outcomes of Breast Conserving Operations With Classic v High-frequency Electrocoagulation|Prospective, Randomized Clinical Trial Comparing Pain Sensation, Seroma Formation and Quality od Life Following BCT With SLND in Breast Cancer Patients Operated With Classic Versus High-frequency Electrocoagulation.|Unknown status|Recruiting|Phase 4|150|Anticipated|Medical University of Gdansk||2|||f||||t||||||||||2018-05-31 23:17:07.275124|2018-05-31 23:17:07.275124
NCT01216241|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2013-11-06||2014-03-04|2010-10-06|2010-10-07|Estimate|2014-03-04|2014-04-10|Estimate||||2014-03-04|2014-04-10|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Daptomycin Versus Placebo in Patients With Neutropenia and Fever|A Single Center, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Daptomycin Versus Placebo in Patients With Neutropenia and Fever.|Terminated||Phase 3|36|Actual|University of Rochester|It was felt that this study had shown futility and objectives could not be reached without enrolling a very large number of subjects in a reasonable time frame.|2||"The study has shown futility and the objectives could not be reached without enrolling a very~   large number of subjects."|f||||t||||||||||2018-05-31 23:17:07.382588|2018-05-31 23:17:07.382588
NCT01216228|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|March 1991||1991-03-31|October 2006|2006-10-31||||||||Observational|||Food Patterns, Inflammation Markers of Cardiovascular Disease Risk and Incidence of CVD||Completed|||||Skane University Hospital|||||f||||f||||||||||2018-05-31 23:17:07.653779|2018-05-31 23:17:07.653779
NCT01216215|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2014-04-13|2010-10-06|2010-10-07|Estimate|||||||2014-04-13|2014-04-15|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Novel Gentic Variations Contributing to Asthma Susceptability in Saudi Arabia|Novel Gentic Variations Contributing to Asthma Susceptability in Saudi Arabia|Completed|||2000|Actual|King Saud University|||2||f||||t||||||||||2018-05-31 23:17:07.700622|2018-05-31 23:17:07.700622
NCT01216202|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2018-03-06|2010-10-06|2010-10-07|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2010||2010-04-30|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 2014|Actual|2014-05-31||Observational|||Sexual Function and Wellbeing in Males Diagnosed With Rectal Cancer||Completed|||100|Anticipated|Karolinska Institutet|||||f||||t||||||||||2018-05-31 23:17:07.758972|2018-05-31 23:17:07.758972
NCT01216189|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2018-03-06|2010-10-06|2010-10-07|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2010||2010-04-30|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Observational|||Sexual Function and Wellbeing in Females Diagnosed With Rectal Cancer||Completed|||145|Actual|Karolinska Institutet|||||f||||t||||||||||2018-05-31 23:17:07.808479|2018-05-31 23:17:07.808479
NCT01216176|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2018-02-13|2010-10-06|2010-10-07|Estimate|||||||2018-02-13|2018-02-14|Actual|October 21, 2008|Actual|2008-10-21|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer|A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer|Completed||Phase 1/Phase 2|59|Actual|University of Miami||3|||f||||t||||||||||2018-05-31 23:17:07.86001|2018-05-31 23:17:07.86001
NCT01216163|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2012-07-12|2012-03-27|2012-07-13|2010-10-05|2010-10-07|Estimate|2012-07-13|2012-08-20|Estimate|2012-03-27|2012-03-30|Estimate|2012-07-13|2012-08-20|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain|Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain|Completed||Phase 3|218|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:17:08.042077|2018-05-31 23:17:08.042077
NCT01216150|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2011-06-22|2010-10-06|2010-10-07|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|ICARE||Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding in Coronary Surgical Patients|Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding and Platelets Functions in Coronary Surgical Patients Treated Prophylactically With Tranexamic Acid: the ICARE Study.|Completed|||150|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||2||f||||f||||||||||2018-05-31 23:17:09.986937|2018-05-31 23:17:09.986937
NCT01216137|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2013-01-25|2010-10-06|2010-10-07|Estimate|||||||2013-01-25|2013-01-29|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Vestibular Rehabilitation on MS-related Fatigue: a Randomized Control Trial|The Effects of Vestibular Rehabilitation on MS-related Fatigue and Upright Postural Control: a Randomized Controlled Trial|Completed||N/A|38|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 23:17:10.074537|2018-05-31 23:17:10.074537
NCT01216124|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate||||September 2009|2009-09-30||||||||Expanded Access|||Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients|A Prospective, Open and Unicentric Phase II Clinical Trial of Docetaxel Combined With Oxaliplatin for Triple Negative Local Advanced Breast Cancer Patients (TNLABC)|Available|||||Fudan University|||||f||||||||||||||2018-05-31 23:17:10.196204|2018-05-31 23:17:10.196204
NCT01216111|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate||||June 2010|2010-06-30||||||||Expanded Access|||Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer|A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients|Available|||||Fudan University|||||f||||||||||||||2018-05-31 23:17:10.277935|2018-05-31 23:17:10.277935
NCT01216098|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2015-05-05|2010-10-06|2010-10-07|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|March 2014|Actual|2014-03-31||Interventional|||Impact of Doula Support on Childbirth Outcomes for Women Undergoing a Vaginal Birth After Cesarean (VBAC)|Impact of Doula Support on Intrapartum Outcomes for Women Undergoing a Vaginal Birth After Cesarean (VBAC)|Completed||N/A|82|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 23:17:10.360209|2018-05-31 23:17:10.360209
NCT01216085|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2017-04-05|2010-10-05|2010-10-07|Estimate|||||||2017-04-05|2017-04-07|Actual|August 2010||2010-08-31|April 2016|2016-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CML||An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints|An Exploratory Single Center Study of High-dose Treatment of Glivec® in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study|Completed||Phase 2|10|Actual|Novartis||1|||f||||f||||||||||2018-05-31 23:17:10.432202|2018-05-31 23:17:10.432202
NCT01216072|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2013-07-29||2014-01-14|2010-10-05|2010-10-07|Estimate|2013-11-10|2013-12-05|Estimate||||2014-01-14|2014-02-10|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|EPOC||A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis|A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)|Completed||Phase 4|1053|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:17:10.585132|2018-05-31 23:17:10.585132
NCT01216059|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2012-11-29|2010-10-05|2010-10-07|Estimate|||||||2012-11-29|2012-12-03|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Text Messaging and Atopic Dermatitis|The Use of Text Messages to Improve Adherence to Health Maintenance Behaviors in Adolescents With Atopic Dermatitis|Completed||N/A|26|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 23:17:12.813209|2018-05-31 23:17:12.813209
NCT01216046|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2012-01-16|2010-10-06|2010-10-07|Estimate|||||||2012-01-16|2012-01-18|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multiple-Dose, Dose-Escalation, Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects|Completed||Phase 1|48|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 23:17:13.067647|2018-05-31 23:17:13.067647
NCT01216033|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2013-04-12|2010-10-06|2010-10-07|Estimate|||||||2013-04-12|2013-04-15|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ABY0125||Exploratory Study of Breast Cancer With ABY025|An Exploratory Study to Evaluate the Distribution of [111In]ABY-025 Uptake for SPECT Imaging in Subjects With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|7|Actual|Biomedical Radiation Sciences|||||f||||t||||||||||2018-05-31 23:17:13.28049|2018-05-31 23:17:13.28049
NCT01216020|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|||2018-01-16|2010-10-06|2010-10-07|Estimate|||||||2018-01-16|2018-01-17|Actual|October 2010||2010-10-31|January 2018|2018-01-31|May 20, 2015|Actual|2015-05-20|May 20, 2015|Actual|2015-05-20||Interventional|CTXMAB+RT||Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer|Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC)|Terminated||Phase 2|70|Actual|Azienda USL 4 Prato||2||insufficient recruitment|f||||t||||||||||2018-05-31 23:17:13.353534|2018-05-31 23:17:13.353534
NCT01216007|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-06-22|2010-10-06|2010-10-07|Estimate|||||||2017-06-22|2017-06-26|Actual|October 2010||2010-10-31|June 2017|2017-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia|A Pilot Study to Investigate Plasma Bupivacaine Concentrations in Children Receiving Total Intravenous Anaesthesia and Caudal Analgesia|Completed||Phase 1/Phase 2|30|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 23:17:13.480383|2018-05-31 23:17:13.480383
NCT01215994|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2015-04-19|2010-10-06|2010-10-07|Estimate|||||||2015-04-19|2015-04-21|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Estimation of Glomerular Filtration Rate (GFR) in Patients With Type 2 Diabetes Mellitus.|Comparative Study of New Formulae of GFR Estimation Based on Creatinine, Cystatin C and Cr51-EDTA.|Unknown status|Recruiting||600|Anticipated|AHEPA University Hospital|||||f||||f||||||Samples Without DNA|"~     serum, urine~   "|||2018-05-31 23:17:13.613493|2018-05-31 23:17:13.613493
NCT01215981|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2013-06-11||2017-12-03|2010-10-05|2010-10-07|Estimate|2016-07-07|2016-08-16|Estimate||||2017-12-03|2017-12-28|Actual|September 2010||2010-09-30|December 2017|2017-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Influenza Vaccine Post Allogeneic Transplant|MT2010-08R Influenza Vaccine Specific Immune Responses After Allogeneic Hematopoietic Cell Transplantation: Are One or Two Vaccine Doses Needed?|Terminated||N/A|68|Actual|Masonic Cancer Center, University of Minnesota||2||Lack of patients and no longer influenza vaccine season.|f||||t||||||||||2018-05-31 23:17:13.691651|2018-05-31 23:17:13.691651
NCT01215968|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2014-10-03||2014-10-03|2010-10-05|2010-10-07|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus|A Study to Evaluate the Effect of LY2189265 on Gastric Emptying Using Scintigraphy in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|38|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:17:13.979343|2018-05-31 23:17:13.979343
NCT01215955|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2014-01-09||2014-04-03|2010-10-05|2010-10-07|Estimate|2014-01-09|2014-02-27|Estimate||||2014-04-03|2014-04-23|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|AUTONOMY|Full Analysis Set-all participants who entered this study, completed the lead-in period (if applicable), were randomized and received ≥1 dose of study insulin, except the participants from the site excluded due to quality issues and data validity.|Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes|Two Approaches to Escalate Lispro Therapy in Patients With Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone (AUTONOMY)|Completed||Phase 4|1117|Actual|Eli Lilly and Company|Five (5) randomized participants (3 Study B Q1D, 2 Study B Q3D) from 1 site were excluded from efficacy and safety analyses due to quality issues and validity of the data at that site.|2|||f||||f||||||||||2018-05-31 23:17:14.63527|2018-05-31 23:17:14.63527
NCT01215942|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05||2014-04-14|2014-04-14|2010-10-05|2010-10-07|Estimate||||2014-04-14|2014-05-06|Estimate|2014-04-14|2014-05-06|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||An Open Label Study for Patients With Rheumatoid Arthritis|A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA)|Completed||Phase 3|1505|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 23:17:16.735196|2018-05-31 23:17:16.735196
NCT01215929|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|2014-06-12||2014-07-14|2010-10-05|2010-10-07|Estimate|2014-07-14|2014-08-04|Estimate||||2014-07-14|2014-08-04|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|April 2013|Actual|2013-04-30||Interventional|||Studying Amphetamine Withdrawal in Humans|Amphetamine Withdrawal Paradigm in Humans|Completed||Phase 2|35|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 23:17:17.293825|2018-05-31 23:17:17.293825
NCT01215916|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-02-10|2010-10-05|2010-10-07|Estimate|||||||2012-02-10|2012-02-13|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Phase 1 Study in Patients With Solid Tumors|A Phase 1b Study of LY573636-sodium in Combination With Alimta (Pemetrexed) in Patients With Solid Tumors|Completed||Phase 1|30|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:17:17.516897|2018-05-31 23:17:17.516897
NCT01215903|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-10-22|2010-10-06|2010-10-07|Estimate|||||||2010-10-22|2010-10-25|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Fish Gelatin Supplement and Omega-3 Supplement in Obese or Overweight Subjects With Insulin Resistance|The Beneficial Effects of Fish Nutrients on the Obesity-linked Metabolic Syndrome and Cardiovascular Risk Profile|Completed||Phase 2|21|Actual|Laval University||2|||f||||t||||||||||2018-05-31 23:17:17.586128|2018-05-31 23:17:17.586128
NCT01215890|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-10-05|2010-10-05|2010-10-07|Estimate|||||||2010-10-05|2010-10-07|Estimate||||October 2010|2010-10-31||||||||Interventional|||Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease|A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients|Completed||Phase 4|||University of Alberta||2|||f||||||||||||||2018-05-31 23:17:17.656066|2018-05-31 23:17:17.656066
NCT01215877|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-07-09|2010-10-05|2010-10-07|Estimate|||||||2012-07-09|2012-07-11|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Tesetaxel for Previously Treated Patients With Bladder Cancer|A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium|Unknown status|Recruiting|Phase 2|33|Anticipated|Genta Incorporated|||||f||||f||||||||||2018-05-31 23:17:17.722309|2018-05-31 23:17:17.722309
NCT01215864|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2014-08-07|2010-10-06|2010-10-07|Estimate|||||||2014-08-07|2014-08-08|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study of Intravenous TCD-717 in Patients With Advanced Solid Tumors|A Multicenter Phase I Study of TCD-717 Given by 4-Hour Intravenous Infusion in Patients With Advanced Solid Tumors|Completed||Phase 1|28|Actual|Traslational Cancer Drugs Pharma, SL||1|||f||||||||||||||2018-05-31 23:17:17.79595|2018-05-31 23:17:17.79595
NCT01215851|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2013-01-07||2017-01-16|2010-10-06|2010-10-07|Estimate|2016-03-02|2016-04-01|Estimate||||2017-01-16|2017-02-28|Actual|October 2010||2010-10-31|January 2017|2017-01-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)|A Phase II Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Alone, TMC207 Plus Pyrazinamide,TMC207 Plus PA-824,PA-824 Plus Pyrazinamide and PA-824 Plus Pyrazinamide and Moxifloxacin, in Adult Patients With Newly Diagnosed, Smear-Positive Pulmonary Tuberculosis.|Completed||Phase 2|85|Actual|Global Alliance for TB Drug Development|With the small sample, individual results can influence overall results. Comparison between groups and studies is difficult. The ability to assign AEs to a particular compound is limited. The value of EBA studies for predicting relapse is uncertain.|6|||f||||f||||||||||2018-05-31 23:17:18.004486|2018-05-31 23:17:18.004486
NCT01215838|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2013-10-11|2010-10-05|2010-10-07|Estimate|||||||2013-10-11|2013-10-14|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Observational|||MRI of the Liver With Eovist|Dynamic Contrast Evaluation of the Liver Using Gadoxetate Disodium (Eovist®) for Hepatocellular Carcinoma (HCC)|Terminated|||4|Actual|University of Washington||||Unable to meet enrollment expectations.|f||||f||||||||||2018-05-31 23:17:18.659087|2018-05-31 23:17:18.659087
NCT01215825|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-10-06|2010-10-06|2010-10-07|Estimate|||||||2010-10-06|2010-10-07|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||The Doses of Systemic Steroid in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)|The Therapeutic Impact of Various Doses of Systemic Steroid in Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Completed|||164|Actual|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 23:17:18.71603|2018-05-31 23:17:18.71603
NCT01215812|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2015-12-01|2010-10-05|2010-10-07|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|||Analysis of Cases of Sexual Assault in Taiwan||Completed|||500|Actual|Far Eastern Memorial Hospital|||||f||||||||||||||2018-05-31 23:17:18.764859|2018-05-31 23:17:18.764859
NCT01215799|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2011-12-14|2010-10-05|2010-10-07|Estimate|||||||2011-12-14|2011-12-15|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|PROACT||Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer|A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer|Completed||Phase 2|23|Actual|CytRx||1|||f||||t||||||||||2018-05-31 23:17:18.877901|2018-05-31 23:17:18.877901
NCT01215786|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2011-12-08||2015-07-22|2010-10-06|2010-10-07|Estimate|2011-12-08|2012-01-16|Estimate||||2015-07-22|2015-08-17|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma||Completed||Phase 1|50|Actual|Allergan||3|||f||||f||||||||||2018-05-31 23:17:18.98999|2018-05-31 23:17:18.98999
NCT01215773|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2013-10-31|2010-10-06|2010-10-07|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2010||2010-10-31|October 2013|2013-10-31||||December 2010|Actual|2010-12-31||Interventional|||Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.|Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given 200 mg b.i.d. or 400 mg b.i.d. Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:17:19.376451|2018-05-31 23:17:19.376451
NCT01215760|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2015-05-26|2010-10-05|2010-10-06|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|October 2010|Actual|2010-10-31||Interventional|HandtherRCT||Sensory Reeducation in Peripheral Nerve Injuries of Hand|Proposal of Sensory Reeducation in Peripheral Nerve Injuries of Median and Ulnar Nerves of the Hand: RANDOMIZED CONTROLLED CLINICAL STUDY|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:17:19.484414|2018-05-31 23:17:19.484414
NCT01215747|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2016-03-09|2010-10-05|2010-10-06|Estimate|||||||2016-03-09|2016-03-10|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis|International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis|Completed||Phase 3|261|Actual|C.T. Development America, Inc.||2|||f||||t||||||||||2018-05-31 23:17:19.584725|2018-05-31 23:17:19.584725
NCT01215734|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2013-02-04||2013-02-04|2010-10-05|2010-10-06|Estimate|2013-02-04|2013-03-08|Estimate||||2013-02-04|2013-03-08|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|||Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients|Randomized Double-Blind, Comparison of Standard Dose Trivalent Inactivated Influenza Vaccine Versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Stem Cell Hematopoetic Transplant Recipients|Completed||Phase 1|44|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-05-31 23:17:19.715385|2018-05-31 23:17:19.715385
NCT01215721|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2013-12-04||2013-12-04|2010-10-05|2010-10-06|Estimate|2013-12-04|2014-01-23|Estimate||||2013-12-04|2014-01-23|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Baseline Population: Men presenting with urinary incontinence requiring 3 pads or more at post-catheter day 6 or 7 after RARP (robotic assisted radical prostatectomy).|Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)|Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy|Completed||N/A|40|Actual|University of California, Irvine|One limitation of this study was finding a reasonable Control group. This is problematic as symptoms that definitively identify detrusor overactivity preoperatively don’t exist; hence we used pad usage 7 dys post catheter removal as a surrogate.|1|||f||||t||||||||||2018-05-31 23:17:20.080347|2018-05-31 23:17:20.080347
NCT01215708|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-10-05|2010-10-05|2010-10-06|Estimate|||||||2010-10-05|2010-10-06|Estimate|August 2006||2006-08-31|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus|Effect of Tamsulosin and Nifedipine on the Elimination of Fragments After Extracorporeal Shock Waves Lithotripsy in Patients With Kidney Stones - a Prospective, Double-blind and Randomized Study|Unknown status|Active, not recruiting|Phase 3|136|Actual|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 23:17:20.24495|2018-05-31 23:17:20.24495
NCT01215695|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2017-04-09||2017-08-08|2010-10-05|2010-10-06|Estimate|2017-06-27|2017-07-27|Actual||||2017-08-08|2017-09-08|Actual|August 2010||2010-08-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Video-laryngoscope With a Novel Video-stylet for Difficult Intubation|Feasibility of a Combined Use of a Video-laryngoscope With a Novel Video-stylet for Predicted Difficult Intubation|Completed||N/A|140|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 23:17:20.335313|2018-05-31 23:17:20.335313
NCT01215682|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-03-22|2010-10-05|2010-10-06|Estimate|||||||2012-03-22|2012-03-26|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vitamin D Supplementation and Upper Respiratory Tract Infections in Adolescent Swimmers|Vitamin D Supplementation, Upper Respiratory Tract Infections, Immune and Physical Functions in Adolescent Swimmers|Completed||N/A|82|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:17:20.668391|2018-05-31 23:17:20.668391
NCT01215669|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2014-01-10|2010-10-05|2010-10-06|Estimate|||||||2014-01-10|2014-01-14|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea|Immunogenicity and Safety of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea|Completed||Phase 4|240|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:17:20.746842|2018-05-31 23:17:20.746842
NCT01215656|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-10-06|2010-10-05|2010-10-06|Estimate|||||||2010-10-06|2010-10-07|Estimate|May 2008||2008-05-31|October 2010|2010-10-31||||January 2010|Actual|2010-01-31||Interventional|||Effect of a Follow on Formula With Lactobacillus Fermentum on the Incidence of Infections||Completed||Phase 2/Phase 3|188|Actual|Puleva Biotech||2|||f||||t||||||||||2018-05-31 23:17:20.825338|2018-05-31 23:17:20.825338
NCT01215643|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2016-07-20||2016-07-20|2010-10-05|2010-10-06|Estimate|2016-07-20|2016-08-30|Estimate||||2016-07-20|2016-08-30|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||All randomized participants|Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants|A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNα2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype 2 and 3 Patients|Completed||Phase 2|340|Actual|Debiopharm International SA||5|||f||||||||||||||2018-05-31 23:17:20.952084|2018-05-31 23:17:20.952084
NCT01215630|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2017-02-07|2010-10-05|2010-10-06|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2010|Actual|2010-10-31|February 2017|2017-02-28|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|||Cardiovascular Fitness and Venous Function in Trained and Untrained Subjects|Cardiovascular Fitness and Venous Function in Trained and Untrained Subjects|Completed|||30|Actual|Norwegian University of Science and Technology|||1||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 23:17:22.870625|2018-05-31 23:17:22.870625
NCT01215617|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2017-03-28|2010-10-05|2010-10-06|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2010|Actual|2010-10-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|||The Effect of Aerobic Interval Training on Obstructive Sleep Apnea|The Effect of Aerobic Interval Training on Obstructive Sleep Apnea, Cardiovascular and Pulmonary Function in Obese Patients|Completed||N/A|30|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-05-31 23:17:22.924341|2018-05-31 23:17:22.924341
NCT01215604|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2012-03-16|2010-10-05|2010-10-06|Estimate|||||||2012-03-16|2012-03-19|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2011|Actual|2011-10-31||Observational|||Involvement of Translation Initiation Factors in the Immune Response in the Elderly|Characterization of the Involvement of Translation Initiation Factors in the Immune Response to Acute Infection in the Elderly and Very Elderly|Unknown status|Recruiting||40|Anticipated|Meir Medical Center|||||f||||t||||||Samples With DNA|"~     Blood samples of elderly patients diagnosed with acute infection will be collected at~     admittance to Meir hospital and on recovery (24-48 hours without fever and leukocytosis)~   "|||2018-05-31 23:17:22.989618|2018-05-31 23:17:22.989618
NCT01215591|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2012-10-22|2010-10-05|2010-10-06|Estimate|||||||2012-10-22|2012-10-24|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Trial of Weaning of Nasal Continuous Positive Airway Pressure (CPAP)|Randomized Controlled Trial of Gradual Versus Sudden Weaning From Nasal CPAP in Preterm Neonates|Completed||N/A|56|Actual|Maimonides Medical Center||2|||f||||f||||||||||2018-05-31 23:17:23.067533|2018-05-31 23:17:23.067533
NCT01215578|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-04-29|2010-10-05|2010-10-06|Estimate|||||||2015-04-29|2015-04-30|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|NET||Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors|A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.|Terminated||Phase 2|33|Actual|Assistance Publique - Hôpitaux de Paris||1||lack of recruitement|f||||t||||||||||2018-05-31 23:17:23.132663|2018-05-31 23:17:23.132663
NCT01215565|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2014-03-12|2010-10-05|2010-10-06|Estimate|||||||2014-03-12|2014-03-13|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|Fibrolam||Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma|A Multicenter National Phase II Open Study Coupled With Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Hepatocellular Carcinoma.|Terminated||Phase 2|4|Actual|Assistance Publique - Hôpitaux de Paris||1||lack of inclusion|f||||t||||||||||2018-05-31 23:17:23.194016|2018-05-31 23:17:23.194016
NCT01215552|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2011-05-27|2010-10-05|2010-10-06|Estimate|||||||2011-05-27|2011-06-01|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712|A PET Study: Single-dose, Open-label Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712|Terminated||Phase 1|3|Actual|Dart NeuroScience, LLC||1||"The experimental design was not sufficient to answer the proposed questions. A new study design~   is now being considered."|f||||f||||||||||2018-05-31 23:17:23.354444|2018-05-31 23:17:23.354444
NCT01215539|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2015-03-17|2010-10-05|2010-10-06|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients|A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS.|Completed||Phase 2|78|Actual|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 23:17:23.425831|2018-05-31 23:17:23.425831
NCT01215526|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2015-08-18|2010-10-05|2010-10-06|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|FAST-NL||A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer|Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands|Completed|||274|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:17:23.51817|2018-05-31 23:17:23.51817
NCT01215513|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|2013-04-04||2013-04-04|2010-10-05|2010-10-06|Estimate|2013-04-04|2013-05-22|Estimate||||2013-04-04|2013-05-22|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||The 156 participants included in the CS42 and CS42A saftey analysis set are included in this baseline analysis population.|Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients|An Open-Label, Multi-Centre, Extension Trial, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients Requiring Androgen Ablation Therapy|Completed||Phase 3|127|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:17:23.630762|2018-05-31 23:17:23.630762
NCT01215500|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2017-07-05|2010-10-04|2010-10-06|Estimate|||||||2017-07-05|2017-07-06|Actual|January 2005||2005-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer|A Study of Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer|Active, not recruiting||Phase 1|63|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 23:17:24.018302|2018-05-31 23:17:24.018302
NCT01215487|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2018-01-31|2010-10-04|2010-10-06|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2010||2010-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib|A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid in Chronic Phase Receiving Treatment With Imatinib|Recruiting|||250|Anticipated|University of British Columbia|||1||f||||f||||||Samples With DNA|"~     Specimens of whole blood will be collected, and used for measurement of sensitivity of the~     patient's individual pretreatment colony-forming cells (CFCs) to IM exposure in vitro, the~     level of expression of BCR-ABL, OCT1, ABCB1/MDR and ABCG2 transcripts in their CD34+ cells~     and the frequency of mutant BCR-ABL transcripts in the same cells. The cells are cultured for~     3 weeks~   "|||2018-05-31 23:17:24.11513|2018-05-31 23:17:24.11513
NCT01215474|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2011-06-15|2010-10-05|2010-10-06|Estimate|||||||2011-06-15|2011-06-16|Estimate||||October 2010|2010-10-31||||||||Observational|||Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC||Completed|||500|Actual|Provitro GmbH|||1||f||||||||||||||2018-05-31 23:17:24.214616|2018-05-31 23:17:24.214616
NCT01215448|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-06-16|2010-10-05|2010-10-06|Estimate|||||||2014-06-16|2014-06-17|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|4001||Wheatgrass Juice / Lifestyle Recommendations / Cancer Patients' Quality of Life / Chemotherapy Treatment|Impact of Wheatgrass Juice and Lifestyle Recommendations on Cancer Patients' Quality of Life During Chemotherapy Treatment|Completed||N/A|17|Actual|Carmel Medical Center||2|||f||||t||||||||||2018-05-31 23:17:24.304538|2018-05-31 23:17:24.304538
NCT01215435|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|2013-09-23|2012-12-19|2014-10-22|2010-10-05|2010-10-06|Estimate|2013-09-23|2013-11-25|Estimate|2012-12-19|2012-12-24|Estimate|2014-10-22|2014-10-30|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone|An Open Labelled, Randomised, Parallel Trial; Efficacy and Safety Comparison of Two Different Biphasic Insulin Aspart 30 Treatment Initiation Regimens Followed by Intensification in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs Alone in Iran|Completed||Phase 4|245|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:17:24.375868|2018-05-31 23:17:24.375868
NCT01215422|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2012-02-03||2012-10-05|2010-10-04|2010-10-06|Estimate|2012-10-05|2012-10-08|Estimate||||2012-10-05|2012-10-08|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Success of Pediatric Anesthesiologists in Learning to Use Videolaryngoscopes|Anesthesiologists Learning to Use Videolaryngoscopes in Children|Completed|||646|Actual|University of Alberta|Level of success could only be determined for the 8 anesthesiologists who completed minimum 18 intubations with the GS or KS video laryngoscope. Only 6 of 14 completed the whole study so had data could be used in comparing the two scopes.||2||f||||f||||||||||2018-05-31 23:17:24.683842|2018-05-31 23:17:24.683842
NCT01215409|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-05-16|2010-10-05|2010-10-06|Estimate|||||||2014-05-16|2014-05-19|Estimate|February 2008||2008-02-29|May 2014|2014-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Real Life Safety and Efficacy of Vardenafil|Vardenafil in Routine Treatment of Erectile Dysfunction|Terminated|||372|Actual|Bayer|||1|Slow recruitment|f||||f||||||||||2018-05-31 23:17:26.23252|2018-05-31 23:17:26.23252
NCT01215396|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2010-11-01|2010-10-05|2010-10-06|Estimate|||||||2010-11-01|2010-11-02|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Impact of Varying Doses of Amino Acids on Exercise, Muscular and Mental Performance|Impact of Varying Doses of Amino Acids on Exercise, Muscular and Mental Performance|Completed||Phase 1|12|Actual|McMaster University||3|||f||||t||||||||||2018-05-31 23:17:26.309033|2018-05-31 23:17:26.309033
NCT01215383|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-02-19|2010-10-05|2010-10-06|Estimate|||||||2013-02-19|2013-02-20|Estimate|November 2010||2010-11-30|February 2013|2013-02-28||||December 2014|Anticipated|2014-12-31||Observational|||The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy|The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy|Unknown status|Recruiting||20|Anticipated|Ziv Hospital|||2||f||||f||||||||||2018-05-31 23:17:26.404861|2018-05-31 23:17:26.404861
NCT01215370|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2011-09-06|2010-10-04|2010-10-06|Estimate|||||||2011-09-06|2011-09-07|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|PEA||Pea Protein and Postprandial Response (PEA)|Effect of Arginine-rich Dietary Protein on Postprandial Metabolism, Inflammation and Endothelial Function|Completed||N/A|18|Actual|Wageningen University|||||f||||f||||||||||2018-05-31 23:17:26.461259|2018-05-31 23:17:26.461259
NCT01215357|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2012-12-18||2013-02-28|2010-10-05|2010-10-06|Estimate|2013-02-11|2013-02-12|Estimate||||2013-02-28|2013-03-08|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble|Ecopipam Treatment of Pathological Gambling|Completed||Phase 2|34|Actual|Psyadon Pharma|This was an open label trial of ecopipam for the treatment of pathological gambling. A significant effect of drug treatment was demonstrated. These data need to be verified with a double-blind, placebo controlled trial.|1|||f||||f||||||||||2018-05-31 23:17:26.527132|2018-05-31 23:17:26.527132
NCT01215344|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2017-02-24||2018-04-15|2010-10-05|2010-10-06|Estimate|2017-05-24|2017-06-28|Actual||||2018-04-15|2018-05-15|Actual|November 2010||2010-11-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|November 2015|Actual|2015-11-30||Interventional|||First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade|Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Based Therapy|Completed||Phase 2|36|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-05-31 23:17:26.709497|2018-05-31 23:17:26.709497
NCT01215331|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2018-05-02|2010-10-05|2010-10-06|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2010||2010-08-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|April 2014|Actual|2014-04-30||Interventional|DG5||Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?|Gestational Diabetes Mellitus: Insulin or Oral Hypoglycemic Agents?|Completed||Phase 3|73|Actual|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 23:17:27.176575|2018-05-31 23:17:27.176575
NCT01215318|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2010-10-04|2010-10-04|2010-10-06|Estimate|||||||2010-10-04|2010-10-06|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|July 2010||2010-07-31|||||Observational|||Etiology and Prevention of Urinary Contamination of Vaginal Tampons During (18F)-FDG PET/CT Examinations||Completed|||60|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 23:17:27.259396|2018-05-31 23:17:27.259396
NCT01215305|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-05|||2011-04-05|2010-10-05|2010-10-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|GERDQ-XS||A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece|A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of GERD in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece. The 'GERDQ-XS' Study|Completed|||600|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 23:17:27.357378|2018-05-31 23:17:27.357378
NCT01215292|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2013-08-20||2014-03-03|2010-10-04|2010-10-06|Estimate|2013-12-10|2014-01-29|Estimate||||2014-03-03|2014-03-31|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ITT4|Fifty two men were screened for the study and 46 met all inclusion criteria. Six subject withdrew from the study prior to any procedures and 40 were randomized to treatment 8/group.|ITT4 Intratesticular Hormonal Milieu in Man (ITT4)|Mechanisms of Control of the Intratesticular Hormonal Milieu in Man|Completed||Phase 1/Phase 2|46|Actual|University of Washington||5|||f||||f||||||||||2018-05-31 23:17:27.478993|2018-05-31 23:17:27.478993
NCT01214928|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-07-19|2010-10-04|2010-10-05|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2011||2011-01-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Hemodialysis Vitamin D Pilot|Oral Cholecalciferol (Vitamin D3) Therapy in Prevalent Hemodialysis Patients: A Randomized Placebo Controlled Pilot Study|Completed||N/A|20|Actual|St. Joseph's Healthcare Hamilton||2|||f||||t||||||||||2018-05-31 23:17:41.98092|2018-05-31 23:17:41.98092
NCT01215279|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2013-07-15||2014-10-17|2010-10-05|2010-10-06|Estimate|2014-10-17|2014-10-23|Estimate||||2014-10-17|2014-10-23|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)|A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD|Completed||Phase 2|63|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:17:28.505108|2018-05-31 23:17:28.505108
NCT01215266|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-09-07|2010-10-05|2010-10-06|Estimate|||||||2011-09-07|2011-09-08|Estimate|October 2006||2006-10-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Sorafenib in Urothelium Cancer of Bladder|Prospektiv, Randomisierte, Doppelblinde, Multizentrische Phase-II- Studie Zum Vergleich Der Wirksamkeit Einer Chemotherapie Mit Gemcitabin Plus Cisplatin Und Sorafenib (BAY 43-9006) Versus Gemcitabin Plus Cisplatin Und Plazebo in Der Therapie Des Lokal Fortgeschrittenen Bzw. Metastasierten Urothelkarzinoms AB 31/05 - RUTT 204 - SUSE|Terminated||Phase 2|98|Actual|Association of Urologic Oncology (AUO)||2||Slow recruitment|f||||t||||||||||2018-05-31 23:17:30.297805|2018-05-31 23:17:30.297805
NCT01215253|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2017-03-24|2010-10-04|2010-10-06|Estimate|||||||2017-03-24|2017-03-27|Actual|September 2011||2011-09-30|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|RAID||Ranolazine Implantable Cardioverter-Defibrillator Trial|Late Sodium Current Blockade in High-Risk ICD Patients|Completed||Phase 3|1012|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 23:17:30.881528|2018-05-31 23:17:30.881528
NCT01215240|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2015-06-22|2010-10-05|2010-10-06|Estimate|||||||2015-06-22|2015-06-23|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure|Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure|Completed||Phase 3|22|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 23:17:31.518675|2018-05-31 23:17:31.518675
NCT01215227|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2016-10-18||2016-10-18|2010-10-04|2010-10-06|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||All Participants as Treated: All participants who received at least one dose of study drug in Extension Study P06153. Data were not reported for 3 participants who were randomized but not treated.|An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)|A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)|Terminated||Phase 3|839|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to the lack of efficacy of preladenant in the parent studies NCT1155466 and NCT01227265.|6|||f||||t||||||||||2018-05-31 23:17:32.171054|2018-05-31 23:17:32.171054
NCT01215214|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-02-19|2010-10-05|2010-10-06|Estimate|||||||2011-02-19|2011-02-23|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics|Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics|Completed||Phase 1|24|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 23:17:35.407668|2018-05-31 23:17:35.407668
NCT01215201|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2010-10-04|2010-10-04|2010-10-06|Estimate|||||||2010-10-04|2010-10-06|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Diode Laser Study for Periodontal Maintenance Patients|Adjunctive Non-Surgical Therapy of Inflamed Periodontal Pockets Using Diode Lasers During Maintenance Therapy|Unknown status|Active, not recruiting|Phase 2|110|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 23:17:35.546801|2018-05-31 23:17:35.546801
NCT01215188|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2014-12-29|2010-10-05|2010-10-06|Estimate|||||||2014-12-29|2014-12-30|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003 AM2)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13™ in Healthy Infants|Completed||Phase 2|1152|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 23:17:36.368762|2018-05-31 23:17:36.368762
NCT01215175|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2015-04-20|2010-10-05|2010-10-06|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|January 2011|Actual|2011-01-31|April 2010|Actual|2010-04-30||Interventional|||Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001 EXT1)(COMPLETED)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar™ in Healthy Adults and Toddlers|Completed||Phase 1|150|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-05-31 23:17:36.494278|2018-05-31 23:17:36.494278
NCT01215162|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2014-04-02|2010-10-04|2010-10-06|Estimate|||||||2014-04-02|2014-04-03|Estimate|January 2003||2003-01-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2005|Actual|2005-01-31||Interventional|||Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer|Phase II Study of Intra-Operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With T1N0M0 and T2N0M0 Breast Cancer|Completed||Phase 2|65|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 23:17:36.710861|2018-05-31 23:17:36.710861
NCT01215149|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2012-12-13|2010-10-05|2010-10-06|Estimate|||||||2012-12-13|2012-12-17|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults|A Phase 1 Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Safety and Immunogenicity of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adult Volunteers|Completed||Phase 1|218|Actual|International AIDS Vaccine Initiative||12|||f||||t||||||||||2018-05-31 23:17:37.131872|2018-05-31 23:17:37.131872
NCT01215136|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2018-04-23|2010-10-04|2010-10-06|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2010||2010-12-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma|Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147|Active, not recruiting||Phase 2|36|Actual|Hoosier Cancer Research Network||2|||f||||t||||||||||2018-05-31 23:17:37.225721|2018-05-31 23:17:37.225721
NCT01057446|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-02-04|2010-01-26|2010-01-27|Estimate|||||||2010-02-04|2010-02-05|Estimate||||November 2009|2009-11-30||||||||Observational|||Comparison of Oral Sodium Phosphate and Sennoside A+B Calcium Lavage for Colonoscopy Preparation|Prospective Randomized Comparison of Oral Sodium Phosphate and Sennoside A+B Calcium Lavage for Colonoscopy Preparation|Completed|||||Maltepe University|||||f||||f||||||||||2018-06-01 00:09:02.834608|2018-06-01 00:09:02.834608
NCT01215123|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2016-01-25||2016-01-25|2010-10-04|2010-10-06|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational||All enrolled participants|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer|Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study|Completed|||28|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:17:37.325698|2018-05-31 23:17:37.325698
NCT01215110|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2016-10-19||2017-03-15|2010-10-04|2010-10-06|Estimate|2017-03-15|2017-04-26|Actual||||2017-03-15|2017-04-26|Actual|April 2010||2010-04-30|January 2017|2017-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)|A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of TMC207 in Adult Patients With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis.|Completed||Phase 2|68|Actual|Global Alliance for TB Drug Development||5|||f||||f||||||||||2018-05-31 23:17:37.631646|2018-05-31 23:17:37.631646
NCT01215097|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2013-04-16||2016-07-25|2010-10-05|2010-10-06|Estimate|2013-04-16|2013-06-03|Estimate||||2016-07-25|2016-08-25|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy|A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 Over 24 Weeks in T2D Patients With Insufficient Glycaemic Control Despite Metformin Therapy|Completed||Phase 3|306|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:17:39.377438|2018-05-31 23:17:39.377438
NCT01215084|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2014-07-07|2010-10-04|2010-10-06|Estimate|||||||2014-07-07|2014-07-09|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers|A Single-Dose, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers|Completed||Phase 1|36|Actual|Biogen||3|||f||||f||||||||||2018-05-31 23:17:40.060715|2018-05-31 23:17:40.060715
NCT01215071|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-01-23|2010-10-05|2010-10-06|Estimate|||||||2018-01-23|2018-01-24|Actual|February 2006||2006-02-28|January 2018|2018-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA|Prospektiv Randomisierte Studie Zum Vergleich Einer Ausgedehnten Mit Einer eingeschränkten Pelvinen Lymphadenektomie Bei Der Operativen Therapie Des Harnblasenkarzinoms|Completed||N/A|401|Actual|Association of Urologic Oncology (AUO)||2|||f||||f|f|f||||||||2018-05-31 23:17:40.229876|2018-05-31 23:17:40.229876
NCT01215058|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-10-21|2010-10-04|2010-10-05|Estimate|||||||2010-10-21|2010-10-22|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Observational|||Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer|Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal Bleeding Ulcer or a Symptomatic Ulcer With Non-steroidal Anti-inflammatory Drug (NSAID) in France|Withdrawn|||0|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:17:40.355359|2018-05-31 23:17:40.355359
NCT01215045|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-10-04|2010-10-04|2010-10-05|Estimate|||||||2010-10-04|2010-10-05|Estimate|June 2007||2007-06-30|October 2010|2010-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Visual Performance of Bilateral AcrySof ReSTOR Aspheric +4||Completed|||17|Actual|Alcon Research|||1||f||||f||||||||||2018-05-31 23:17:40.428156|2018-05-31 23:17:40.428156
NCT01215032|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2017-01-09||2017-04-03|2010-10-04|2010-10-05|Estimate|2017-01-09|2017-02-27|Actual||||2017-04-03|2017-05-15|Actual|September 2010||2010-09-30|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Metformin in Castration-Resistant Prostate Cancer|Prospective Study of Metformin in Castration-Resistant Prostate Cancer|Terminated||Phase 2|21|Actual|Massachusetts General Hospital|Early termination due to slow accrual led to small numbers of subjects. Therefore, meaningful assessment of the study endpoints is severely limited by the small sample size.|1||slow accrual, competing clinical trials|f||||t||||||||No||2018-05-31 23:17:40.492635|2018-05-31 23:17:40.492635
NCT01215019|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2013-04-01|2010-10-04|2010-10-05|Estimate|||||||2013-04-01|2013-04-04|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Osmotic Therapy for Treatment of Intracranial Hypertension for Traumatic Brain Injury|20% Mannitol vs 3% Hypertonic Saline in the Treatment of Intracranial Hypertension in Patients With Traumatic Brain Injury: A Double-blinded, Randomized Trial|Withdrawn||N/A|0|Actual|Indiana University||2||Lack of funding; not subjects enrolled|f||||t||||||||||2018-05-31 23:17:40.793108|2018-05-31 23:17:40.793108
NCT01214993|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-06-07|2010-10-04|2010-10-05|Estimate|||||||2012-06-07|2012-06-11|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects|A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects|Completed||Phase 1|38|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 23:17:40.886116|2018-05-31 23:17:40.886116
NCT01214980|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2014-12-11||2014-12-18|2010-10-04|2010-10-05|Estimate|2014-12-18|2014-12-19|Estimate||||2014-12-18|2014-12-19|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional||All enrolled subjects|Split Thickness Donor Site Healing With MIST Study|A Prospective, Randomized, Controlled Pilot Study of the MIST Therapy System for the Treatment of Split Thickness Donor Sites|Completed||N/A|32|Actual|Celleration, Inc.|Participants were not blinded to study treatment.|2|||f||||f||||||||||2018-05-31 23:17:40.994365|2018-05-31 23:17:40.994365
NCT01214967|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2016-10-07|2010-10-04|2010-10-05|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|Project Solve||Problem Solving Education and Neonatal Intensive Care Unit (NICU) Mothers|Empowering Low Income Mothers With Preterm Infants: a Randomized Controlled Trial|Completed||N/A|50|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 23:17:41.708894|2018-05-31 23:17:41.708894
NCT01214954|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2013-11-21|2010-10-04|2010-10-05|Estimate|||||||2013-11-21|2013-11-25|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|January 2013|Actual|2013-01-31||Interventional|||Early Rehabilitation After Total Hip Replacement|Early Rehabilitation After Toal Hip Replacement. -Effect of Supervised Progressive Resistance Training|Completed||N/A|73|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:17:41.80047|2018-05-31 23:17:41.80047
NCT01214941|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-04-12|2010-10-04|2010-10-05|Estimate|||||||2011-04-12|2011-04-13|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol||Completed||Phase 4|12|Actual|Turku University Hospital||3|||f||||f||||||||||2018-05-31 23:17:41.875412|2018-05-31 23:17:41.875412
NCT01214915|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2013-07-24||2013-09-27|2010-10-04|2010-10-05|Estimate|2013-07-24|2013-09-25|Estimate||||2013-09-27|2013-10-30|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia|A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment|Completed||Phase 3|53|Actual|Shire||1|||f||||||||||||||2018-05-31 23:17:42.115474|2018-05-31 23:17:42.115474
NCT01214902|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-06-20|2010-10-04|2010-10-05|Estimate|||||||2011-06-20|2011-06-21|Estimate|May 2011||2011-05-31|June 2010|2010-06-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Constraint Induced Movement Therapy (CIMT) in Babies Home Program||Unknown status|Recruiting|N/A|30|Anticipated|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-05-31 23:17:42.57254|2018-05-31 23:17:42.57254
NCT01214889|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-04-13|2010-10-04|2010-10-05|Estimate|||||||2012-04-13|2012-04-17|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.|Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Versus Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given Simultaneously at Separate Sites With PRP~T Conjugate Vaccine (ACTHIB™) as a Three-dose Primary Vaccination at 2, 4 and 6 Months of Age in South Korean Infants|Completed||Phase 3|370|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:17:42.656796|2018-05-31 23:17:42.656796
NCT01214876|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-03-03|2010-10-04|2010-10-05|Estimate|||||||2011-03-03|2011-03-04|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires||Completed|||500|Anticipated|Radboud University|||3||f||||f||||||Samples With DNA|"~     Plasma samples Human DNA samples Parasite DNA samples~   "|||2018-05-31 23:17:42.76255|2018-05-31 23:17:42.76255
NCT01214863|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2012-09-27|2010-10-04|2010-10-05|Estimate|||||||2012-09-27|2012-10-01|Estimate|August 2007||2007-08-31|October 2010|2010-10-31||||April 2008|Actual|2008-04-30||Observational|||AcrySof Toric Clinical Results|Clinical Results With the AcrySof Toric Intraocular Lens (IOL)|Completed|||144|Actual|Alcon Research|||3||f||||f||||||||||2018-05-31 23:17:42.836953|2018-05-31 23:17:42.836953
NCT01214850|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2013-09-04|2012-12-11|2016-03-22|2010-10-04|2010-10-05|Estimate|2013-12-17|2014-01-23|Estimate|2012-12-11|2012-12-13|Estimate|2016-03-22|2016-04-21|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Novartis Vaccine and Diagnostics Carriage Trial|A Phase 3 Observer Blind Randomized, Multi-center, Controlled Study to Evaluate the Effect of Novartis Vaccine's Meningococcal B Recombinant and MenACWY Conjugate Vaccines on Pharyngeal Carriage of N. Meningitidis in Young Adults|Completed||Phase 3|2968|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:17:42.968727|2018-05-31 23:17:42.968727
NCT01214837|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2014-08-20|2011-12-13|2014-09-30|2010-10-04|2010-10-05|Estimate|2014-09-30|2014-10-02|Estimate|2011-12-13|2011-12-22|Estimate|2014-09-30|2014-10-02|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional||All enrolled population- All subjects who had signed an informed consent, undergone screening procedure(s) and were randomized.|Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life|A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life.|Completed||Phase 3|751|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:17:44.755599|2018-05-31 23:17:44.755599
NCT01214824|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2013-03-01||2013-06-21|2010-10-04|2010-10-05|Estimate|2013-04-30|2013-06-06|Estimate||||2013-06-21|2013-07-02|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Use of the FreeStyle Navigator Continuous Glucose Monitoring System to Enhance Education and Glycaemic Control|Use of the FreeStyle Navigator Continuous Glucose Monitoring System to Enhance Education and Glycaemic Control|Completed||N/A|32|Actual|Abbott Diabetes Care|After an enrolment review recruitment was ceased on 02 Sep 11 with only 32/50 enrolled subjects. The screening/recruitment phase had been 12 weeks but was significantly extended. Only 7/32 subjects had completed 6 month HbA1c when recruitment ceased.||||f||||f||||||||||2018-05-31 23:17:45.837635|2018-05-31 23:17:45.837635
NCT01214811|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2013-01-22||2013-02-28|2010-10-04|2010-10-05|Estimate|2013-01-22|2013-02-26|Estimate||||2013-02-28|2013-03-08|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing|Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing|Completed||Phase 3|27|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 23:17:46.003948|2018-05-31 23:17:46.003948
NCT01214798|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-02|||2010-10-04|2010-10-04|2010-10-05|Estimate|||||||2010-10-04|2010-10-05|Estimate|January 2008||2008-01-31|October 2010|2010-10-31|April 2010|Actual|2010-04-30|January 2008|Actual|2008-01-31||Observational|SDL||A Case of Sesamoid Displacement Causing the First Metacarpophalangeal Joint Locking|Study of the Second Hospital of Qinhuangdao|Completed|||1|Actual|The Second Hospital of Qinhuangdao|||||f||||t||||||||||2018-05-31 23:17:46.117759|2018-05-31 23:17:46.117759
NCT01214785|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2017-08-22|2010-10-04|2010-10-05|Estimate|||||||2017-08-22|2017-08-24|Actual|September 2010||2010-09-30|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|December 2013|Actual|2013-12-31||Interventional|||Cluster Randomised Trial of Improved Sanitation in Rural Orissa, India|Assessing the Effect of Improved Rural Sanitation on Diarrhoea and Intestinal Nematode Infections: a Cluster Randomised Controlled Trial in Orissa, India|Completed||N/A|100|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 23:17:46.157428|2018-05-31 23:17:46.157428
NCT01214772|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-10-01|2010-10-01|2010-10-05|Estimate|||||||2010-10-01|2010-10-05|Estimate|May 2009||2009-05-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|September 2009|Actual|2009-09-30||Interventional|||The Effect of Heparin in Treatment IVF-ET Failure|the Effect of Unfractionated Heparin in Treatment of IVF-ET Failure|Completed||Phase 4|86|Actual|Yazd Medical University||1|||f||||t||||||||||2018-05-31 23:17:46.343434|2018-05-31 23:17:46.343434
NCT01214577|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2011-01-23|2010-10-03|2010-10-05|Estimate|||||||2011-01-23|2011-01-25|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin|A Phase 2a, Multi-Centre, Single Arm Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin on the Face|Completed||Phase 2|24|Actual|Peplin||1|||f||||f||||||||||2018-05-31 23:17:49.102023|2018-05-31 23:17:49.102023
NCT01214759|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2016-01-07||2016-01-07|2010-10-01|2010-10-05|Estimate|2016-01-07|2016-02-08|Estimate||||2016-01-07|2016-02-08|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|December 2013|Actual|2013-12-31||Interventional||All who were enrolled|Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)|A Pilot Project to Assess the Safety and Tolerability of Truvada Plus Raltegravir as Post-exposure Prophylaxis (nPEP) Following Sexual Exposure to Human Immunodeficiency Virus (HIV)|Completed||Phase 4|103|Actual|The University of Texas Health Science Center, Houston|This is a pilot study with a small sample size.|1|||f||||t||||||||||2018-05-31 23:17:46.428198|2018-05-31 23:17:46.428198
NCT01214746|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2011-08-15|2010-10-04|2010-10-05|Estimate|||||||2011-08-15|2011-08-16|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|STAR||The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man|The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man|Completed||Phase 2|26|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 23:17:46.575019|2018-05-31 23:17:46.575019
NCT01214733|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2015-12-01|2010-10-04|2010-10-05|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis|An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|30|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:17:46.647917|2018-05-31 23:17:46.647917
NCT01214720|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2014-07-23||2014-07-23|2010-10-04|2010-10-05|Estimate|2014-07-23|2014-08-13|Estimate||||2014-07-23|2014-08-13|Estimate|July 2005||2005-07-31|July 2014|2014-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Intent-to-Treat (ITT) Population: All 607 participants randomized to treatment.|A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer|A Randomized, Double-blind Study of the Effect of Avastin Plus Gemcitabine and Erlotinib Compared With Placebo Plus Gemcitabine and Erlotinib on Overall Survival in Patients With Metastatic Pancreatic Cancer|Completed||Phase 3|607|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:17:46.771738|2018-05-31 23:17:46.771738
NCT01214707|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-03-13|2010-10-04|2010-10-05|Estimate|||||||2012-03-13|2012-03-15|Estimate|September 2010||2010-09-30|March 2012|2012-03-31||||October 2011|Actual|2011-10-31||Observational|||Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy|Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy|Completed|||30|Actual|Cyberonics, Inc.|||1||f||||f||||||||||2018-05-31 23:17:47.765368|2018-05-31 23:17:47.765368
NCT01214694|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2016-03-07|2010-10-04|2010-10-05|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|I-InTERACT||Internet-based Interacting Together Everyday, Recovery After Childhood TBI (I-InTERACT)--RRTC|Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions--Internet-based Interacting Together Everyday, Recovery After Childhood TBI|Completed||N/A|117|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-05-31 23:17:47.827302|2018-05-31 23:17:47.827302
NCT01214681|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-10-25|2010-10-04|2010-10-05|Estimate|||||||2011-10-25|2011-10-26|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates|Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates|Unknown status|Active, not recruiting|N/A|75|Anticipated|Newcastle University||4|||f||||f||||||||||2018-05-31 23:17:47.897915|2018-05-31 23:17:47.897915
NCT01214668|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-02-10|2010-10-04|2010-10-05|Estimate|||||||2012-02-10|2012-02-14|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors|A Phase 1b, Multicenter, Dose-Escalation Study of LY573636-sodium in Combination With Liposomal Doxorubicin in Patients With Advanced Solid Tumors|Completed||Phase 1|40|Anticipated|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 23:17:47.971437|2018-05-31 23:17:47.971437
NCT01214655|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-08-01|2010-10-04|2010-10-05|Estimate|||||||2012-08-01|2012-08-02|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study for Patients With Acute Leukemia|Phase 1 Study of LY2523355 in Patients With Acute Leukemia|Terminated||Phase 1|33|Actual|Eli Lilly and Company||2||Primary objective has been met and in the absence of clinically meaningful remissions|f||||f||||||||||2018-05-31 23:17:48.045842|2018-05-31 23:17:48.045842
NCT01214642|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-07-13|2010-10-04|2010-10-05|Estimate|||||||2012-07-13|2012-07-17|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||A Dose-Escalation Study for Patients With Advanced Cancer|A Phase 1 Dose-Escalation Study of LY2523355 in Patients With Advanced Cancer|Completed||Phase 1|50|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 23:17:48.10679|2018-05-31 23:17:48.10679
NCT01214629|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-07-13|2010-10-04|2010-10-05|Estimate|||||||2012-07-13|2012-07-17|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study for Patients With Advanced Cancer|A Phase I Study of LY2523355 in Patients With Advanced Cancer|Completed||Phase 1|70|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:17:48.275836|2018-05-31 23:17:48.275836
NCT01214616|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2014-05-09||2014-06-24|2010-10-04|2010-10-05|Estimate|2014-06-24|2014-07-22|Estimate||||2014-06-24|2014-07-22|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours|An Open-label Phase I Study of Once Daily Oral Treatment With BIBW 2992 in Combination With Weekly Vinorelbine Intravenous Injection in Japanese Patients With Advanced Solid Tumours|Completed||Phase 1|17|Actual|Boehringer Ingelheim|MTD was not determined and below Cohort 2 due to DLTs likely related to vinorelbine. After the revised dose criteria for afatinib and vinorelbine were implemented, Cohort 3 was established as a recommended dose.|1|||f||||||||||||||2018-05-31 23:17:48.388542|2018-05-31 23:17:48.388542
NCT01214603|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29||2013-04-30|2013-04-30|2010-10-04|2010-10-05|Estimate||||2013-04-30|2013-05-08|Estimate|2013-04-30|2013-05-08|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study in Participants With Acute Leukemia|A Phase 2 Study of LY2090314 in Participants With Acute Leukemia|Completed||Phase 2|38|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:17:48.984471|2018-05-31 23:17:48.984471
NCT01214590|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2011-04-12|2010-10-03|2010-10-05|Estimate|||||||2011-04-12|2011-04-13|Estimate|March 2011||2011-03-31|April 2011|2011-04-30||||February 2012|Anticipated|2012-02-29||Interventional|||Preliminary Assessment of the Efficacy of the VascuActive™ Device on Diabetic Peripheral Neuropathy|Preliminary Assessment of the Efficacy of the VascuActive™ Device on Diabetic Peripheral Neuropathy|Unknown status|Recruiting|N/A|15|Anticipated|VascuActive LTD||1|||f||||f||||||||||2018-05-31 23:17:49.043524|2018-05-31 23:17:49.043524
NCT01214564|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2011-01-23|2010-10-03|2010-10-05|Estimate|||||||2011-01-23|2011-01-25|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis|A Phase 2a, Multi-Centre, Open-Label Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis on Non-head Locations|Completed||Phase 2|24|Actual|Peplin||1|||f||||f||||||||||2018-05-31 23:17:49.151995|2018-05-31 23:17:49.151995
NCT01214551|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-02-07|2010-10-03|2010-10-05|Estimate|||||||2017-02-07|2017-02-09|Estimate|August 2010|Actual|2010-08-31|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Exercise-induced Bronchoconstriction Diagnostics: Impact of a Repeated Exercise Challenge Test|Exercise-induced Bronchoconstriction Diagnostics: Impact of a Repeated Exercise Challenge Test|Completed|||20|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-05-31 23:17:49.204875|2018-05-31 23:17:49.204875
NCT01214538|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2011-09-26|2010-10-04|2010-10-05|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|July 2014|Anticipated|2014-07-31|March 2014|Anticipated|2014-03-31||Observational|||Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children|Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children|Unknown status|Recruiting||100|Anticipated|NasVax Ltd|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:17:49.254019|2018-05-31 23:17:49.254019
NCT01214525|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2012-03-16|2010-10-03|2010-10-05|Estimate|||||||2012-03-16|2012-03-19|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|December 2011|Actual|2011-12-31||Observational|||The Improvement in Uroflow and Postvoid Residual Urine After Urethral Meatotomy in Children With Meatal Stenosis|The Improvement in Uroflow and Postvoid Residual Urine After Urethral Meatotomy in Children With Meatal Stenosis|Unknown status|Recruiting||30|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 23:17:49.305735|2018-05-31 23:17:49.305735
NCT01214512|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-03-10|2010-10-03|2010-10-05|Estimate|||||||2013-03-10|2013-03-12|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Performance Evaluation of the Micromedic CD24 in Vitro Diagnostic Assay|Performance Evaluation of the Micromedic CD24 Western Blot and ELISA in Vitro Diagnostic Assay|Completed|||229|Actual|Meir Medical Center|||||f||||f||||||Samples Without DNA|"~     Fresh blood samples are collected and separated. Plasma is collected and stored and rest is~     discarded of. Leukocytes are separated, lysed and the supernatant is stored. As DNA is~     retained in the pellet, which is discarded, no DNA is retained in the samples stored.~   "|||2018-05-31 23:17:50.371749|2018-05-31 23:17:50.371749
NCT01214499|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2010-11-27|2010-10-04|2010-10-05|Estimate|||||||2010-11-27|2010-11-30|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina|Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina|Unknown status|Recruiting|Phase 2|20|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||2|||f||||f||||||||||2018-05-31 23:17:50.437983|2018-05-31 23:17:50.437983
NCT01214486|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-08-16|2010-10-01|2010-10-05|Estimate|||||||2017-08-16|2017-08-21|Actual|October 1, 2010|Actual|2010-10-01|August 2017|2017-08-31|June 30, 2011|Actual|2011-06-30|April 30, 2011|Actual|2011-04-30||Interventional|||Measurement of Plasma and Intracellular Concentrations of Raltegravir|Measurement of Plasma and Intracellular Concentrations of Raltegravir in Patients Infected With Human Immunodeficiency Virus|Completed||N/A|12|Actual|University of Nebraska||1|||f||||f||||||||||2018-05-31 23:17:50.537091|2018-05-31 23:17:50.537091
NCT01214473|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2014-08-23|2010-10-01|2010-10-05|Estimate|||||||2014-08-23|2014-08-26|Estimate|June 2007||2007-06-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|||Probiotics for Prevention Neonatal Infection|Prevention of Neonatal Infection in the Indian Community Setting Using Probiotics|Terminated||Phase 2/Phase 3|4556|Actual|University of Nebraska||2||DSMB stopped the study due to early effectiveness|f||||t||||||||||2018-05-31 23:17:50.617713|2018-05-31 23:17:50.617713
NCT01214460|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2017-04-28|2010-10-01|2010-10-05|Estimate|||||||2017-04-28|2017-05-02|Actual|January 2010||2010-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|July 2016|Actual|2016-07-31||Observational|||Impact of Medical Emergency Team and EMS in Tampere University Hospital|Impact of Medical Emergency Team and EMS on ICU Readmissions and Sudden Cardiac Arrests in Tampere University Hospital|Active, not recruiting|||10000|Actual|Tampere University Hospital|||3||f||||t||||||||||2018-05-31 23:17:50.694309|2018-05-31 23:17:50.694309
NCT01214447|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2010-10-04|2010-10-04|2010-10-05|Estimate|||||||2010-10-04|2010-10-05|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||Validity and Reproducibility of OSND (Objective Score of Nutrition on Dialysis) as a Nutritional Marker in End-stage Renal Disease||Unknown status|Recruiting||300|Anticipated|Assaf-Harofeh Medical Center|||3||f||||||||||||||2018-05-31 23:17:50.755647|2018-05-31 23:17:50.755647
NCT01214434|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2013-07-08||2017-01-23|2010-10-01|2010-10-05|Estimate|2013-09-17|2013-11-20|Estimate||||2017-01-23|2017-03-07|Actual|March 2010||2010-03-31|January 2017|2017-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Promiseb Topical Cream for Cradle Cap|A Double Blind, Placebo-Controlled, Pilot Study to Estimate the Efficacy and Tolerability of Twice Daily Promiseb Topical Cream in Pediatric Subjects With Cradle Cap (Seborrheic Dermatitis)|Completed||Phase 4|42|Actual|Promius Pharma, LLC|Small number of subjects enrolled and analyzed.|2|||f||||f||||||||||2018-05-31 23:17:50.844394|2018-05-31 23:17:50.844394
NCT01214421|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-26||2017-03-02|2018-05-23|2010-10-01|2010-10-05|Estimate||||2017-03-23|2017-03-27|Actual|2018-05-23|2018-05-25|Actual|May 2010||2010-05-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|TEMPO 4/4||Open-Label Tolvaptan Study in Subjects With ADPKD|Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Completed||Phase 3|1083|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-05-31 23:17:51.286788|2018-05-31 23:17:51.286788
NCT01214408|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-03|||2012-12-26|2010-10-04|2010-10-05|Estimate|||||||2012-12-26|2012-12-28|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Digene Total (Buffered Pantoprazole) on 24 Hour Gastric Potential Hydrogen (pH) in Patients From Acid Peptic Disorder After Single and Repeated Dosing.|Effect of Digene Total on 24 Hrs Ambulatory Gastric ph in Pts Suffering From Acid Peptic Disorder After Single and Repeated Dosing.|Completed||Phase 4|47|Actual|Abbott||2|||f||||f||||||||||2018-05-31 23:17:51.532382|2018-05-31 23:17:51.532382
NCT01214395|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|2012-05-14||2012-06-22|2010-10-04|2010-10-05|Estimate|2012-06-22|2012-08-03|Estimate||||2012-06-22|2012-08-03|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Nasal Tea Tree Oil for the Prevention of Infections in PD Patients|An Investigator Blinded Controlled Study of the Nasal Application of 5% Tea Tree Oil (TTO) for the Prevention of Catheter-associated Infections in Renal Dialysis Patients|Completed||Phase 2|5|Actual|PathWest Laboratory Medicine WA|||||f||||f||||||||||2018-05-31 23:17:51.616439|2018-05-31 23:17:51.616439
NCT01214382|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2016-04-04|2010-10-01|2010-10-05|Estimate|||||||2016-04-04|2016-04-06|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetic Properties of Sertraline Before and After Gastric Bypass Surgery|A Prospective, Longitudinal Comparison of the Pharmacokinetic Properties of Sertraline Before and After Roux-en-Y Gastric Bypass|Completed||Phase 3|31|Actual|North Dakota State University||1|||f||||t||||||||||2018-05-31 23:17:51.760415|2018-05-31 23:17:51.760415
NCT01214369|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2010-10-26|2010-10-04|2010-10-05|Estimate|||||||2010-10-26|2010-10-27|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|January 2011|Anticipated|2011-01-31|November 2010|Anticipated|2010-11-30||Interventional|||Anesthetic Efficacy of X-tip Intraosseous Injection|Anesthetic Efficacy of X-tip Intraosseous Injection Following Mandibular Nerve Block in Molars With Acute Irreversible Pulpitis|Unknown status|Recruiting|N/A|40|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:17:51.821697|2018-05-31 23:17:51.821697
NCT01214356|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-06-13|2010-10-04|2010-10-05|Estimate|||||||2011-06-13|2011-06-14|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Impact of Vitamin D on Diabetic Kidney Disease in African Americans|Impact of Vitamin D on Diabetic Kidney Disease in African Americans|Unknown status|Recruiting|N/A|102|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 23:17:51.885363|2018-05-31 23:17:51.885363
NCT01214343|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-06-14|2010-10-04|2010-10-05|Estimate|||||||2011-06-14|2011-06-15|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC|Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 3|190|Anticipated|Ministry of Health, Labour and Welfare, Japan||2|||f||||t||||||||||2018-05-31 23:17:52.007634|2018-05-31 23:17:52.007634
NCT01214330|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2014-10-10||2014-11-20|2010-10-01|2010-10-05|Estimate|2014-11-04|2014-11-20|Estimate||||2014-11-20|2014-11-21|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SoloPaP|102 females, age >18|Clinician-Collected Versus Patient-Collected Cervical Pap Smears|A Pilot Study for a Non-Inferiority Trial of Clinician-Collected Versus Patient-Collected Cervical Papanicolaou Smears|Completed||N/A|150|Actual|Mike O'Callaghan Military Hospital|"Limitations:~Higher socioeconomic status of participants"|1|||f||||f||||||||||2018-05-31 23:17:52.262292|2018-05-31 23:17:52.262292
NCT01214317|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-08-16|2010-10-04|2010-10-05|Estimate|||||||2011-08-16|2011-08-17|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|February 2012|Anticipated|2012-02-29|January 2012|Anticipated|2012-01-31||Interventional|IMPAMS||Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis|Study of Combinative Effect of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Patients With Aggressive Multiple Sclerosis|Unknown status|Active, not recruiting|N/A|40|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:17:52.422673|2018-05-31 23:17:52.422673
NCT01214304|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-11-21|2010-10-01|2010-10-05|Estimate|||||||2013-11-21|2013-11-25|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|Lavender Colpo||Aromatherapy to Reduce Pain and Anxiety During Cervical Colposcopy|Aromatherapy With Lavender Oil to Reduce Pain and Anxiety During Cervical Colposcopy: A Randomized, Controlled Trial|Completed||N/A|262|Actual|Mike O'Callaghan Military Hospital||2|||f||||f||||||||||2018-05-31 23:17:52.505354|2018-05-31 23:17:52.505354
NCT01214291|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2013-11-13|2010-10-01|2010-10-05|Estimate|||||||2013-11-13|2013-11-15|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|TREAT2||Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer|Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy|Withdrawn||Phase 3|0|Actual|GTx||||"cost of conducting the study and increased burden on the clinical trial professionals make it~   impossible for us to proceed with the development of the drug."|f||||t||||||||||2018-05-31 23:17:52.57373|2018-05-31 23:17:52.57373
NCT01214278|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-04|||2011-12-06|2010-10-04|2010-10-05|Estimate|||||||2011-12-06|2011-12-07|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Bioavailability of Different n-3 Fatty Acid Formulations|Relative Bioavailability of Different n-3 Fatty Acid Formulations in Humans|Completed||Phase 4|12|Actual|Gottfried Wilhelm Leibniz Universität Hannover||4|||f||||f||||||||||2018-05-31 23:17:52.642017|2018-05-31 23:17:52.642017
NCT01214265|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2010-10-22|2010-10-04|2010-10-05|Estimate|||||||2010-10-22|2010-10-26|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive Bladder|A Pilot Clinical Study to Evaluate the Initial Feasibility of Neuromodulation Therapy in Treating Patients With Overactive Bladder Via Magnetic Stimulation of the Posterior Tibial Nerve|Completed||N/A|8|Actual|EMKinetics, Inc|||||f||||f||||||||||2018-05-31 23:17:52.737453|2018-05-31 23:17:52.737453
NCT01214252|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2012-06-21||2014-04-08|2010-10-01|2010-10-05|Estimate|2012-12-19|2012-12-20|Estimate||||2014-04-08|2014-05-09|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Observational|||A Retrospective Study Evaluating the Use of Permacol Surgical Implant in the Repair of Abdominal Wall Defects||Completed|||343|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-05-31 23:17:52.811535|2018-05-31 23:17:52.811535
NCT01214239|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2013-05-24||2016-07-25|2010-10-04|2010-10-05|Estimate|2013-05-24|2013-07-19|Estimate||||2016-07-25|2016-08-25|Estimate|October 2010||2010-10-31|July 2016|2016-07-31||||May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control|A Randomized, db, Placebo Controlled Parallel Group Efficacy and Safety Study Over 24 Weeks in T2D Patients in China|Completed||Phase 3|300|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:17:53.000372|2018-05-31 23:17:53.000372
NCT01214226|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-05-31|2010-10-01|2010-10-04|Estimate|||||||2011-05-31|2011-06-01|Estimate|December 2007||2007-12-31|September 2010|2010-09-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|CorpentoxHAA||Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis|Evaluation of the Survival Benefit of the Adjunction of Pentoxifylline to Corticosteroids in Patients Suffering From Severe Alcoholic Hepatitis|Completed||Phase 3|278|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 23:17:53.410838|2018-05-31 23:17:53.410838
NCT01214213|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2016-09-26|2010-10-01|2010-10-04|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Observational|||Non-Specific Chronic Back Pain; Insight From Spatial Aspects of Lumbar Spinal Muscle Activation|NON-SPECIFIC CHRONIC BACK PAIN; INSIGHT FROM SPATIAL ASPECTS OF LUMBAR SPINAL MUSCLE ACTIVATION|Completed|||57|Actual|Oslo University Hospital|||||f||||||||||||||2018-05-31 23:17:53.60547|2018-05-31 23:17:53.60547
NCT01214200|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-10-23|2010-10-01|2010-10-04|Estimate|||||||2012-10-23|2012-10-24|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|HINPPV||High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)|High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV) for Stable Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients|Unknown status|Active, not recruiting|N/A|20|Anticipated|Philips Respironics||1|||f||||f||||||||||2018-05-31 23:17:53.661814|2018-05-31 23:17:53.661814
NCT01214187|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2017-03-01||2017-05-18|2010-10-01|2010-10-04|Estimate|2017-05-18|2017-06-14|Actual||||2017-05-18|2017-06-14|Actual|July 2011||2011-07-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis|Phase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary Fibrosis|Completed||Phase 2|58|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 23:17:53.754335|2018-05-31 23:17:53.754335
NCT01214174|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2013-06-24||2013-09-16|2010-10-01|2010-10-04|Estimate|2013-09-16|2013-09-18|Estimate||||2013-09-16|2013-09-18|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients|A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Treating Inflammation in Cataract Surgery Patients|Terminated||Phase 2|42|Actual|ICON Bioscience Inc|Early termination leading to small numbers of subjects analyzed|3||Study C11-01 started|f||||f||||||||||2018-05-31 23:17:54.342528|2018-05-31 23:17:54.342528
NCT01214161|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2015-09-29||2016-03-08|2010-10-01|2010-10-04|Estimate|2016-03-08|2016-04-07|Estimate||||2016-03-08|2016-04-07|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|March 2011|Actual|2011-03-31||Interventional|||Intracervical Lidocaine Gel for IUD Insertional Pain|Intracervical Two Percent Lidocaine Gel as an Analgesic During Intrauterine Device Insertion: A Randomized Controlled Trial|Completed||N/A|200|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 23:17:54.844795|2018-05-31 23:17:54.844795
NCT01214148|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-08-08|2010-10-01|2010-10-04|Estimate|||||||2013-08-08|2013-08-12|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|April 2010|Actual|2010-04-30||Interventional|BIOFLOW-I||First in Man Experience With a Drug Eluting Stent in De Novo Coronary Artery Lesions|A Prospective, Multi-centre, Single Treatment Clinical Trial With Follow-up Investigations at 1, 4, 9, 12, 24 and 36 Months|Completed||Phase 1/Phase 2|30|Actual|Biotronik AG||1|||f||||t||||||||||2018-05-31 23:17:55.348899|2018-05-31 23:17:55.348899
NCT01214135|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2011-01-10|2010-10-01|2010-10-04|Estimate|||||||2011-01-10|2011-01-11|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|SPIN||A Retrospective Non-interventional Study to Evaluate the Use of Seroquel Extended Release (XR) and Immediate Release (IR) in the Clinical Practice of Inpatients With Schizophrenia|A Retrospective, Non-interventional Study to Evaluate the Use of Seroquel XR and Seroquel IR in the Clinical Practice of Inpatients With Schizophrenia|Completed|||300|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:17:55.448614|2018-05-31 23:17:55.448614
NCT01214122|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-01-28|2010-10-01|2010-10-04|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin|A Phase I, Open Label, Fixed Sequence, Single Centre Study in Healthy Volunteers to Investigate the Effects of Repeated Oral Doses AZD9668 on the Pharmacokinetics and Pharmacodynamics of a Single Dose of Warfarin|Withdrawn||Phase 1|0|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:17:55.589478|2018-05-31 23:17:55.589478
NCT01214109|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|2012-01-25||2014-06-17|2010-10-01|2010-10-04|Estimate|2012-01-25|2012-02-27|Estimate||||2014-06-17|2014-06-27|Estimate|December 2010||2010-12-31|March 2014|2014-03-31||||January 2011|Actual|2011-01-31||Interventional|||Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers|A Multiple Dose Bioequivalence Study of Pramipexole With Increasing Doses (0.375mg to 1.5mg q.d.) of Oral Extended Release (ER) Tablet in Two-way Cross-over Comparison of 0.375mg Extended Release Tablet q.d. Versus 0.125mg Immediate Release (IR) Tablet t.i.d and 1.5 mg Extended Release Tablet q.d. Versus 0.5mg Immediate Release Tablet t.i.d. in Chinese Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:17:55.805428|2018-05-31 23:17:55.805428
NCT01214096|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-12-19|2010-10-01|2010-10-04|Estimate|||||||2017-12-19|2017-12-21|Actual|July 2010||2010-07-31|November 2017|2017-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure|A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure|Terminated||Phase 3|15|Actual|Zensun Sci. & Tech. Co., Ltd.||2||The same protocol has been launched in United States.|f||||t||||||||||2018-05-31 23:17:56.771465|2018-05-31 23:17:56.771465
NCT01214083|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2016-12-12||2018-02-21|2010-09-30|2010-10-04|Estimate|2017-02-07|2017-03-28|Actual||||2018-02-21|2018-03-20|Actual|October 15, 2010|Actual|2010-10-15|February 2018|2018-02-28|October 30, 2016|Actual|2016-10-30|September 30, 2015|Actual|2015-09-30||Interventional|||N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence|N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence|Completed||Phase 2|111|Actual|VA Office of Research and Development||3|||f||||f|t|f||||||Undecided||2018-05-31 23:17:57.047408|2018-05-31 23:17:57.047408
NCT01214070|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-06-14|2010-09-30|2010-10-04|Estimate|||||||2017-06-14|2017-06-16|Actual|June 1, 2012|Actual|2012-06-01|June 2017|2017-06-30|November 21, 2013|Actual|2013-11-21|November 21, 2013|Actual|2013-11-21||Interventional|||Functional Vision in TBI|Functional Vision Consequences of Rehabilitation for TBI Vision Loss|Terminated||Phase 4|110|Anticipated|VA Office of Research and Development||7||Administrative Closure|f||||f||||||||||2018-05-31 23:17:57.733333|2018-05-31 23:17:57.733333
NCT01214057|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2013-05-17|2010-10-01|2010-10-04|Estimate|||||||2013-05-17|2013-05-20|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Total Intravenous Anesthesia (TIVA) vs. Inhaled Anesthesia for Endoscopic Sinus Surgery.|Preliminary Study to Assess the Effects of Total Intravenous Anesthesia With Propofol/Remifentanyl Compared to Sevoflurane/Remifentanyl for Endoscopic Sinus Surgery: Novel Approach.|Terminated||N/A|23|Actual|The University of Texas Health Science Center, Houston||2||the study was terminated for patient recruitment difficulty and interim power analysis|f||||t||||||||||2018-05-31 23:17:57.838756|2018-05-31 23:17:57.838756
NCT01214044|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2010-10-01|2010-10-01|2010-10-04|Estimate|||||||2010-10-01|2010-10-04|Estimate|May 2008||2008-05-31|October 2010|2010-10-31||||May 2011|Anticipated|2011-05-31||Interventional|||Circadian Effects of Escitalopram|Circadian Effects of Escitalopram|Unknown status|Recruiting|N/A|15|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-05-31 23:17:57.918217|2018-05-31 23:17:57.918217
NCT01214031|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-04-06|2010-10-01|2010-10-04|Estimate|||||||2012-04-06|2012-04-09|Estimate|September 2012||2012-09-30|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Prospective Study for Evaluating Colon Polyp Histology With in Vivo Probe Based Confocal Laser Endomicroscopy|Prospective Study for Evaluating Colon Polyp Histology With in Vivo Probe Based Confocal Laser Endomicroscopy|Unknown status|Not yet recruiting|N/A|70|Anticipated|Midwest Biomedical Research Foundation||1|||f||||f||||||||||2018-05-31 23:17:57.995058|2018-05-31 23:17:57.995058
NCT01214018|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2018-01-02|2010-10-01|2010-10-04|Estimate|||||||2018-01-02|2018-01-03|Actual|May 15, 2011|Actual|2011-05-15|January 2018|2018-01-31|May 15, 2016|Actual|2016-05-15|May 15, 2016|Actual|2016-05-15||Observational|||Evaluation of Post-traumatic Stress Among the Nearest Relatives of Brain-dead Organ Donors|Evaluation of Post-traumatic Stress Among the Nearest Relatives of Brain-dead Organ Donors: Comparison With the Nearest-relatives of Brain-dead Patients Who Were Not Organ Donors for Medical or Legal Reasons, or Because of Donation Opposition|Terminated|||91|Actual|Centre Hospitalier Universitaire de Nīmes|||3|No recruitment|f||||f||||||||||2018-05-31 23:17:58.111803|2018-05-31 23:17:58.111803
NCT01214005|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-04-26|2010-10-01|2010-10-04|Estimate|||||||2012-04-26|2012-04-27|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|WREN||Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls|Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls|Completed||Phase 2|60|Actual|Brown University||2|||f||||f||||||||||2018-05-31 23:17:58.185184|2018-05-31 23:17:58.185184
NCT01213992|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2013-11-13|2010-10-01|2010-10-04|Estimate|||||||2013-11-13|2013-11-14|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|PK-CKD-03||Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-Dialysis Dependent Chronic Kidney Disease (PK-CKD-03)|Completed||Phase 1|16|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 23:17:58.248976|2018-05-31 23:17:58.248976
NCT01213979|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2013-06-26|2010-10-01|2010-10-04|Estimate|||||||2013-06-26|2013-06-27|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|PK-CIA-04||Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)|Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)(PK-CIA-04)|Completed||Phase 1|16|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 23:17:58.318868|2018-05-31 23:17:58.318868
NCT01213966|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|2013-07-22||2014-11-17|2010-10-01|2010-10-04|Estimate|2014-11-06|2014-11-18|Estimate||||2014-11-17|2014-12-03|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection|Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection|Completed||Phase 2|82|Actual|Medicines for Malaria Venture||4|||f||||t||||||||||2018-05-31 23:17:58.388522|2018-05-31 23:17:58.388522
NCT01213953|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2010-10-18|2010-10-01|2010-10-04|Estimate|||||||2010-10-18|2010-10-19|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Isolation and Authentication of Mesenchymal Stem Cell-like Progenitor Cells From the Degenerated Intervertebral Disc of Lumbar Spine|Isolation and Authentication of Mesenchymal Stem Cell-like Progenitor Cells From the Degenerated Intervertebral Disc of Lumbar Spine|Unknown status|Active, not recruiting||20|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||Samples Without DNA|"~     The biospecimen is the tissue waste after the surgery of discectomy.~   "|||2018-05-31 23:17:58.744025|2018-05-31 23:17:58.744025
NCT01213940|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-08-12|2010-09-30|2010-10-04|Estimate|||||||2013-08-12|2013-08-14|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|EPC||Vascular Endothelium Changes After Bariatric Surgery (Endothelial Progenitor Cells)|Vascular Endothelium Changes After Bariatric Surgery|Unknown status|Recruiting|N/A|70|Anticipated|University of South Alabama||2|||f||||f||||||||||2018-05-31 23:17:58.795638|2018-05-31 23:17:58.795638
NCT01213927|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2017-12-07|2010-10-01|2010-10-04|Estimate|||||||2017-12-07|2017-12-08|Actual|October 2010||2010-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|November 2016|Actual|2016-11-30||Observational|CIRRAL||National Cohort of Uncomplicated Alcoholic Cirrhosis|CIRRAL: Hepatocellular Carcinoma in Patients With Uncomplicated Alcoholic Cirrhosis: Incidence and Predictive Factors. A Multicentric Prospective Cohort|Active, not recruiting|||709|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     At enrollement, 20 ml of blood will be collected for freezing and storage of serum and~     plasma, and constitution of a DNA library~   "|||2018-05-31 23:17:58.866363|2018-05-31 23:17:58.866363
NCT01213914|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2018-04-05|2010-10-01|2010-10-04|Estimate|||||||2018-04-05|2018-04-06|Actual|August 2011||2011-08-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|RESCUE||Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)|The American Burn Association's Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure|Active, not recruiting||N/A|37|Actual|United States Army Institute of Surgical Research||2|||f||||t||||||||||2018-05-31 23:17:58.925474|2018-05-31 23:17:58.925474
NCT01213901|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-01-16|2010-09-30|2010-10-04|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2010||2010-09-30|January 2018|2018-01-31|March 2014|Actual|2014-03-31|July 2012|Actual|2012-07-31||Interventional|||Optimizing Insulin Absorption and Insulin Injection Technique in Older Adults|Optimizing Insulin Absorption and Insulin Injection Technique in Older Adults|Completed||N/A|20|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 23:17:59.011988|2018-05-31 23:17:59.011988
NCT01213888|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-05-01|2010-10-01|2010-10-04|Estimate|||||||2013-05-01|2013-05-03|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy|Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy|Terminated||N/A|3|Actual|University of British Columbia||2||"Low enrollment & superior treatments available for diabetic macular edema including anti-VEFG~   therapies such as bevacizumab and ranibizumab."|f||||f||||||||||2018-05-31 23:17:59.073534|2018-05-31 23:17:59.073534
NCT01213875|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2014-01-01|2010-10-01|2010-10-04|Estimate|||||||2014-01-01|2014-01-03|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|HELEN II||A Multifaceted Nurse-based Strategy Reduces HEart FaiLure Morbidity in PatiENts Admitted for Acute Decompensated Heart Failure in Brazil|A Multifaceted Nurse-based Strategy Reduces HEart FaiLure Morbidity in PatiENts Admitted for Acute Decompensated Heart Failure in Brazil|Completed||N/A|252|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 23:17:59.144869|2018-05-31 23:17:59.144869
NCT01213862|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-12-31|2010-10-01|2010-10-04|Estimate|||||||2013-12-31|2014-01-03|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|HFHELENI||Home Based Intervention Led by Nurse in Brazil|Home Visit Impact on Knowledge of Disease, Self-Care Skills and Quality of Life of Heart Failure Patients: Randomized Clinical Trial|Completed||N/A|200|Actual|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-05-31 23:17:59.207723|2018-05-31 23:17:59.207723
NCT01213849|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2017-06-13|2010-10-01|2010-10-04|Estimate|||||||2017-06-13|2017-06-14|Actual|October 4, 2010|Actual|2010-10-04|June 2017|2017-06-30|November 25, 2010|Actual|2010-11-25|November 25, 2010|Actual|2010-11-25||Interventional|||Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler|An Open-label, Randomised, 3-way Crossover Single Dose Study to Demonstrate Dose Proportionality of Fluticasone Furoate (FF) and Equivalence of Vilanterol (VI) When Administered as FF/VI Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subjects.|Completed||Phase 1|24|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:17:59.267686|2018-05-31 23:17:59.267686
NCT01213836|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|2012-05-15||2012-06-21|2010-10-01|2010-10-04|Estimate|2012-06-21|2012-07-27|Estimate||||2012-06-21|2012-07-27|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|eXtRa||Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia|A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR®) Dosed Twice Daily and Quetiapine Fumarate Extended Release (Seroquel XR®) Dosed Once Daily in the Evening in Patients With Stable Schizophrenia|Completed||Phase 4|75|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:17:59.362344|2018-05-31 23:17:59.362344
NCT01213823|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2012-04-09||2016-03-02|2010-09-30|2010-10-04|Estimate|2016-01-04|2016-02-04|Estimate||||2016-03-02|2016-03-30|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins|Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins|Terminated|||536|Actual|Pfizer|Study results were invalidated due to lack of temporality, a critical methodological element of the study that was never established for the majority of the cases of severe hepatic injury.||2|"The study was terminated on May 5, 2011, due to methodological issues. The decision to~   terminate the study was not based on any safety or efficacy concerns."|f||||f||||||||||2018-05-31 23:17:59.846078|2018-05-31 23:17:59.846078
NCT01213810|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2013-02-28|2010-10-01|2010-10-04|Estimate|||||||2013-02-28|2013-03-01|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study||Withdrawn||Phase 1/Phase 2|0|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 23:18:00.05239|2018-05-31 23:18:00.05239
NCT01213797|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-10-24|2010-10-01|2010-10-04|Estimate|||||||2011-10-24|2011-10-25|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|IMTAP||IMTAP : Impact of the Suicide Attempt on the Nearly Entourage in Term of Traumatic Stress and Medico-economic Impact|Impact of the Suicide Attempt on the Close Entourage: Traumatic Stress and Medico-economic Concerns, in Medium and Long Term|Completed|||372|Actual|University Hospital, Lille|||1||f||||f||||||||||2018-05-31 23:18:00.107091|2018-05-31 23:18:00.107091
NCT01213784|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2015-03-05|2010-10-01|2010-10-04|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|HFDM||"Optimized Glycemic Control in Heart Failure Patients With DM2:Effect on Left Ventricular Function and Skeletal Muscle"|"Optimized Glycemic Control in Type 2 Diabetics With Heart Failure:Effect on Left Ventricular Function and Skeletal Muscle"|Completed||Phase 2|40|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:18:00.180399|2018-05-31 23:18:00.180399
NCT01213771|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-06-15|2010-10-01|2010-10-04|Estimate|||||||2011-06-15|2011-06-16|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Health and Coping Prior to Ovarian Cancer Surgery|Health and Coping Prior to Ovarian Cancer Surgery|Completed||N/A|279|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 23:18:00.248908|2018-05-31 23:18:00.248908
NCT01213758|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2017-10-27|2010-10-01|2010-10-04|Estimate|||||||2017-10-27|2017-10-30|Actual|June 2010||2010-06-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT|Radiation Induced Change of Liver Function Measured by Uptake of the Galactose Analogue FDGal and PET/CT|Completed|||14|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 23:18:00.324655|2018-05-31 23:18:00.324655
NCT01213745|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2010-10-20|2010-10-01|2010-10-04|Estimate|||||||2010-10-20|2010-10-21|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||The Use of a Quality of Life Questionnaire in Patients With Lung Cancer|A Prospective Randomised Controlled Study to Investigate the Effectiveness of Using a Quality of Life Questionnaire to Target Interventions to Improve Quality of Life in Patients With Lung Cancer|Unknown status|Recruiting|N/A|138|Anticipated|Royal Marsden NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 23:18:00.393122|2018-05-31 23:18:00.393122
NCT01213732|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-09-22|2010-10-01|2010-10-04|Estimate|||||||2011-09-22|2011-09-23|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma|Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma.|Completed||Phase 1|19|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:18:00.471798|2018-05-31 23:18:00.471798
NCT01213719|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-01-12|2010-10-01|2010-10-04|Estimate|||||||2012-01-12|2012-01-16|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Betaine Supplementation on Strength and Muscle Creatine Content|Effects of Betaine Supplementation Combined or Not With Creatine Supplementation on Muscle Creatine Content and Strength|Completed||N/A|40|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 23:18:00.54323|2018-05-31 23:18:00.54323
NCT01213706|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|2014-03-25||2016-07-07|2010-10-01|2010-10-04|Estimate|2014-09-05|2014-09-12|Estimate||||2016-07-07|2016-08-10|Estimate|October 2009||2009-10-31|July 2016|2016-07-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Whole Body Periodic Acceleration on Airway Endothelial Function|Effect of Whole Body Periodic Acceleration on Airway Endothelial Function in Healthy Smokers, Non-smokers and Asthmatics|Completed||N/A|45|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 23:18:00.623791|2018-05-31 23:18:00.623791
NCT01213693|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2016-04-06|2010-10-01|2010-10-04|Estimate|||||||2016-04-06|2016-04-08|Estimate|May 2009||2009-05-31|April 2016|2016-04-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD|Long-term Effects of Inhaled Corticosteroids (ICS) Treatment on Sputum Bacterial and Viral Loads in Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||N/A|60|Actual|Università degli Studi di Ferrara||2|||f||||f||||||||||2018-05-31 23:18:00.79512|2018-05-31 23:18:00.79512
NCT01213680|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2013-11-13|2010-10-01|2010-10-04|Estimate|||||||2013-11-13|2013-11-14|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease|Open-label Pharmakokinetic Study of Iron Isomaltoside 1000 (Monofer)Administered by 500 mg IV Injection or 1000 mg Intravenous Infusion to Patients With Inflammatory Bowel Disease (PK-IBD-02)|Completed||Phase 1|16|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 23:18:00.861764|2018-05-31 23:18:00.861764
NCT01213667|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2016-10-24|2010-10-01|2010-10-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RESPONSE||Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD|Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations|Active, not recruiting||Phase 4|110|Anticipated|University of Cologne||1|||f||||f||||||||||2018-05-31 23:18:00.914883|2018-05-31 23:18:00.914883
NCT01213654|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2010-10-01|2010-10-01|2010-10-04|Estimate|||||||2010-10-01|2010-10-04|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Inter Costal Catheters for Video-Assisted Thoroscopic (VATS) Lobectomy|Pain Relief After VATS Lobectomy Using Interoperatively Placed Inter Costal Catheters.|Completed|||50|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 23:18:00.970713|2018-05-31 23:18:00.970713
NCT01213641|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2016-03-25|2010-10-01|2010-10-04|Estimate|||||||2016-03-25|2016-03-28|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|B-Confident||Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients|An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients|Completed|||288|Actual|Novartis|||||f||||||||||||||2018-05-31 23:18:01.019037|2018-05-31 23:18:01.019037
NCT01213628|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2010-10-01|2010-10-01|2010-10-04|Estimate|||||||2010-10-01|2010-10-04|Estimate|March 2007||2007-03-31|October 2010|2010-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Local CO2 Increases Core and Wound Temperature|Intraoperative Local Insufflation of Humidified Warmed CO2 Increases Core and Open Wound Temperatures? - A Randomized Clinical Trial|Completed||N/A|80|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 23:18:01.089613|2018-05-31 23:18:01.089613
NCT01213615|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2015-10-29|2010-10-01|2010-10-04|Estimate|||||||2015-10-29|2015-10-30|Estimate|August 2008||2008-08-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Observational|||Hancock II Ultra Porcine Bioprosthesis Hemodynamic Study||Completed|||179|Actual|Medtronic Cardiovascular|||1||f||||f||||||||||2018-05-31 23:18:01.163155|2018-05-31 23:18:01.163155
NCT01213602|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2011-07-22|2010-10-01|2010-10-04|Estimate|||||||2011-07-22|2011-07-25|Estimate|February 2010||2010-02-28|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Bilateral Bispectral Index (BIS)-Monitoring in Trauma Surgery|Bilateral Bispectral Index Changes During Knee Replacement Surgery With and Without Femoral Block|Completed|||85|Actual|Hospital Universitari de Bellvitge|||2||f||||t||||||||||2018-05-31 23:18:01.227017|2018-05-31 23:18:01.227017
NCT01213589|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|2013-10-21||2013-10-21|2010-10-01|2010-10-04|Estimate|2013-10-21|2013-12-11|Estimate||||2013-10-21|2013-12-11|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|VIRTUE||The VIRTUE Post Marketing Surveillance Registry|The VIRTUE Post Marketing Surveillance Registry - VALIANT Thoracic Stent Graft Evaluation For the Treatment of Descending Thoracic Aortic Dissections|Completed|||100|Actual|Medtronic Endovascular|||1||f||||t||||||||||2018-05-31 23:18:01.299123|2018-05-31 23:18:01.299123
NCT01213576|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2015-02-10||2015-02-26|2010-10-01|2010-10-04|Estimate|2015-02-26|2015-02-27|Estimate||||2015-02-26|2015-02-27|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|FED||Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi|Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study|Terminated||N/A|70|Actual|London School of Hygiene and Tropical Medicine||4||"Introduction of National Mass Drug Administration Campaign and failure to identify appropriate~   participants."|f||||f||||||||||2018-05-31 23:18:01.634473|2018-05-31 23:18:01.634473
NCT01213563|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2017-08-09|2010-10-01|2010-10-04|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2009||2009-01-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Management of Type 2 Diabetes After Gastric Bypass Surgery|Protocol Driven Management of Type 2 Diabetes After Gastric Bypass Surgery|Completed||N/A|50|Actual|Imperial College London||2|||f||||f||||||||No||2018-05-31 23:18:01.915277|2018-05-31 23:18:01.915277
NCT01213550|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2010-10-01|2010-10-01|2010-10-04|Estimate|||||||2010-10-01|2010-10-04|Estimate|March 2006||2006-03-31|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects Of Chlorhexidine Mouthrinse On Peridontopathogens: A Randomized, Placebo-Controlled Study||Completed||Phase 4|50|Actual|Ege University||2|||f||||f||||||||||2018-05-31 23:18:01.981774|2018-05-31 23:18:01.981774
NCT01213537|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2015-10-21|2010-10-01|2010-10-04|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Cardiac Resynchronisation Study|A Study of the Effect of Cardiac Resynchronisation Therapy (CRT) on Chemosensitivity in Patients With Chronic Heart Failure With and Without Sleep Disordered Breathing.|Completed|||182|Actual|Imperial College London|||1||f||||f||||||||||2018-05-31 23:18:02.046794|2018-05-31 23:18:02.046794
NCT01213524|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-07-26|2010-10-01|2010-10-04|Estimate|||||||2012-07-26|2012-07-27|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia|Biological and Behavioral Mechanisms of Smoking in Schizophrenia|Completed||Phase 2|76|Actual|Brown University||5|||f||||f||||||||||2018-05-31 23:18:02.103081|2018-05-31 23:18:02.103081
NCT01213511|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2013-11-27|2010-10-01|2010-10-04|Estimate|||||||2013-11-27|2013-11-28|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|January 2011|Actual|2011-01-31||Interventional|||Neurocognitive Outcome After Coronary Artery Bypass Surgery Using Minimal Versus Conventional Extracorporeal Circulation|Neurocognitive Outcome After Coronary Artery Bypass Surgery Using Minimal Versus Conventional Extracorporeal Circulation|Completed||N/A|64|Actual|AHEPA University Hospital||2|||f||||f||||||||||2018-05-31 23:18:02.18616|2018-05-31 23:18:02.18616
NCT01213498|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|||2015-08-19|2010-10-01|2010-10-04|Estimate|||||||2015-08-19|2015-08-21|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|STAN||The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy|The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy|Completed||Phase 2|25|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 23:18:02.248343|2018-05-31 23:18:02.248343
NCT01213485|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-11-01|2010-10-01|2010-10-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease on Dialysis (HORTENSIA)|Observational Cohort Study in Chronic Kidney Disease Patients on Dialysis Initiating Treatment With Mircera During the Correction and Maintenance Phase|Completed|||419|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:18:02.320859|2018-05-31 23:18:02.320859
NCT01213472|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2018-04-23|2010-10-01|2010-10-04|Estimate|||||||2018-04-23|2018-04-24|Actual|January 31, 2011|Actual|2011-01-31|April 2018|2018-04-30|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|||Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma|Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma|Completed||Phase 1|33|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 23:18:02.467997|2018-05-31 23:18:02.467997
NCT01213459|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2012-11-21|2010-10-01|2010-10-04|Estimate|||||||2012-11-21|2012-11-22|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia|An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women >= 15 Years of Age, in the Kingdom of Saudi Arabia|Completed|||420|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Cervical samples~   "|||2018-05-31 23:18:02.718627|2018-05-31 23:18:02.718627
NCT01213446|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-01|||2017-10-02|2010-10-01|2010-10-04|Estimate|||||||2017-10-02|2017-10-03|Actual|August 2010||2010-08-31|October 2017|2017-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of Biostate® in Children With Von Willebrand Disease|A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects With Von Willebrand Disease|Completed||Phase 3|17|Actual|CSL Behring||1|||f||||t||||||||||2018-05-31 23:18:02.865175|2018-05-31 23:18:02.865175
NCT01213433|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2015-07-29|2010-10-01|2010-10-04|Estimate|||||||2015-07-29|2015-07-31|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|ASAQ-MAL||Amodiaquine+Artesunate for Uncomplicated Malaria Treatment|Amodiaquine+Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso|Completed||Phase 4|150|Actual|Centre Muraz||1|||f||||f||||||||||2018-05-31 23:18:03.058771|2018-05-31 23:18:03.058771
NCT01213420|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2012-06-13|2010-09-30|2010-10-04|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Site After Wound Closure|A Prospective, Randomized Controlled, Double Blinded, Clinical Multicentre Trial of the Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure|Completed||Phase 4|60|Actual|University Hospital, Ghent||4|||f||||f||||||||||2018-05-31 23:18:03.186678|2018-05-31 23:18:03.186678
NCT01213407|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2016-05-18|2010-10-01|2010-10-04|Estimate|||||||2016-05-18|2016-05-19|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|GBM-Vax||Dendritic Cell Cancer Vaccine for High-grade Glioma|First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells|Completed||Phase 2|87|Actual|Activartis Biotech||2|||f||||f||||||||||2018-05-31 23:18:03.319827|2018-05-31 23:18:03.319827
NCT01213394|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2012-04-18|2010-09-30|2010-10-04|Estimate|||||||2012-04-18|2012-04-19|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|MMCR||Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients|A 6-month, Prospective, Open-label, Randomized, Controlled, Pilot Study Evaluating the Efficacy, Safety and Toxicity of an Optimized Immunosuppressive Regimen of CellCept (Mycophenolate Mofetil, MMF) and Reduced Doses of Both Calcineurin-inhibitors and Prednisone in Renal Transplant Recipients With an Increased 10-year Coronary Heart Disease Risk|Terminated||Phase 3|2|Actual|St. Michael's Hospital, Toronto||2||Poor recruitment.|f||||f||||||||||2018-05-31 23:18:03.448655|2018-05-31 23:18:03.448655
NCT01213381|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-05-23|2010-10-01|2010-10-04|Estimate|||||||2013-05-23|2013-05-24|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors|A Phase I Study Evaluating the Safety and Pharmacokinetics of SAR240550 Administered Twice Weekly in Patients With Advanced Solid Tumors.|Completed||Phase 1|18|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:18:03.561045|2018-05-31 23:18:03.561045
NCT01213368|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-10-12|2010-09-30|2010-10-04|Estimate|||||||2013-10-12|2013-10-16|Estimate|September 2010||2010-09-30|October 2013|2013-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation|Double Blind, Randomized, Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Dronedarone (SR33589B) at 300, 400, or 600 mg BID for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation|Completed||Phase 2|181|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 23:18:03.648666|2018-05-31 23:18:03.648666
NCT01213355|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2011-10-25|2010-09-30|2010-10-04|Estimate|||||||2011-10-25|2011-10-27|Estimate|April 2011||2011-04-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Scopolamine Challenge Study|A Randomized, Double-Blind, Sponsor Unblinded, Placebo Controlled, 5-Way, Crossover Study To Evaluate The Effects Of Single Oral Administrations of PF-05212377 (SAM-760), A 5-HT6 Antagonist, On Scopolamine Induced Deficits In Psychomotor And Cognitive Function In Healthy Young Adults|Completed||Phase 1|38|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 23:18:03.782005|2018-05-31 23:18:03.782005
NCT01213342|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2012-03-19|2010-09-30|2010-10-04|Estimate|||||||2012-03-19|2012-03-20|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Omega-3 Fatty Acid Supplements and Dry Eye|Omega-3 Fatty Acid Supplementation and Dry Eye|Terminated||N/A|35|Actual|Ohio State University||2||Researchers left institution|f||||f||||||||||2018-05-31 23:18:03.933797|2018-05-31 23:18:03.933797
NCT01213329|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2011-05-03||2017-09-12|2010-09-30|2010-10-04|Estimate|2011-06-07|2011-07-04|Estimate||||2017-09-12|2017-10-13|Actual|February 2006||2006-02-28|September 2017|2017-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab|Immunophenotyping and Functional Profiles of Peripheral Lymphocytes in Renal Transplant Recipients After T-cell Depletion With Alemtuzumab (Anti-CD52 Monoclonal Antibody)-Potential Implications for Safe Immunosuppressive Minimization|Terminated||Phase 4|52|Actual|Northwestern University|Processing of blood samples was inconsistent and lab results were questionable. Research blood specimens were in addition to Standard of Care (SOC) required blood. Most research visits were planned at the same time as SOC visits.|1|||f||||f||||||||||2018-05-31 23:18:04.030154|2018-05-31 23:18:04.030154
NCT01213316|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2016-03-08||2016-04-15|2010-09-30|2010-10-04|Estimate|2016-04-15|2016-05-23|Estimate||||2016-04-15|2016-05-23|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|WIP||A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)|A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany|Completed|||451|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-05-31 23:18:04.280901|2018-05-31 23:18:04.280901
NCT01213303|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2015-12-10|2010-09-30|2010-10-01|Estimate|||||||2015-12-10|2015-12-11|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|December 2021|Anticipated|2021-12-31|December 2015|Anticipated|2015-12-31||Observational|||Cardiovascular Risk Factors, Lipid Metabolism and Oxidative Stress|Relation Between Fatty Acids and Oxidative Stress Markers With Cardiovascular Risk Factors in a Healthy Population|Active, not recruiting|||500|Anticipated|University of Roma La Sapienza|||1||f||||t||||||Samples Without DNA|"~     Collection of plasma and serum samples~   "|||2018-05-31 23:18:04.69019|2018-05-31 23:18:04.69019
NCT01213290|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2010-09-30|2010-09-30|2010-10-01|Estimate|||||||2010-09-30|2010-10-01|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|March 2010|Anticipated|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Randomized Controlled Trial Of Endoscopic Ultrasound-Guided Fine-Needle Aspiration With And Without A Stylet|A Randomized Controlled Trial Of Endoscopic Ultrasound-Guided Fine-Needle Aspiration With And Without A Stylet : A Pilot Study|Unknown status|Active, not recruiting|N/A|100|Anticipated|Kansas City Veteran Affairs Medical Center||2|||f||||f||||||||||2018-05-31 23:18:04.745425|2018-05-31 23:18:04.745425
NCT01213277|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2011-07-25|2010-09-30|2010-10-01|Estimate|||||||2011-07-25|2011-07-26|Estimate|October 2010||2010-10-31|September 2010|2010-09-30||||May 2011||2011-05-31||Interventional|||A1c Discordance in Diabetes Patients|Differences in Hemoglobin Glycation Rate in Diabete Mellitus Patients|Suspended||N/A|25|Anticipated|Endocrine Research Society||2||"a pilot study of 7 patients did not reveal a temperature dependent difference in glycation~   rates"|f||||f||||||||||2018-05-31 23:18:04.807547|2018-05-31 23:18:04.807547
NCT01213264|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2013-04-04||2015-02-26|2010-09-30|2010-10-01|Estimate|2013-04-04|2013-05-27|Estimate||||2015-02-26|2015-03-17|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)|Observational Project on the Current Neuromuscular Monitoring Practice (Including Extubation Practice) Via TOF-ratio (Train-of-four) Measurements in Different Types of Surgery After Administration of Neuromuscular Blocking Agents With or Without Reversal (Protocol No. P06556)|Completed|||659|Actual|Merck Sharp & Dohme Corp.|||3||f||||f||||||||||2018-05-31 23:18:04.89035|2018-05-31 23:18:04.89035
NCT01213251|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2016-08-08||2016-10-21|2010-09-30|2010-10-01|Estimate|2016-10-21|2016-12-15|Estimate||||2016-10-21|2016-12-15|Estimate|December 2010||2010-12-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|PRomPT||Post-Myocardial Infarction Remodeling Prevention Therapy|Post-Myocardial Infarction Remodeling Prevention Therapy|Completed||Phase 2|129|Actual|Medtronic Cardiac Rhythm and Heart Failure||3|||f||||t||||||||||2018-05-31 23:18:05.267265|2018-05-31 23:18:05.267265
NCT01213238|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2018-03-14|2010-09-30|2010-10-01|Estimate|||||||2018-03-14|2018-03-15|Actual|September 2010|Actual|2010-09-30|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab|A Phase I Clinical Trial of Hepatic Arterial Infusion of Oxaliplatin, Oral Capecitabine, With or Without Systemic Bevacizumab for Patients With Advanced Cancer Metastatic to the Liver|Active, not recruiting||Phase 1|116|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 23:18:07.412837|2018-05-31 23:18:07.412837
NCT01213225|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-08-17|2010-09-30|2010-10-01|Estimate|||||||2011-08-17|2011-08-18|Estimate|December 2010||2010-12-31|August 2011|2011-08-31||||||||Observational|||Geriatric Education and Its Effect on Certain Aspects of Hospital Care of the Nursing Home Patients - 12 Month Retrospective Study|Geriatric Education and Its Effect on Certain Aspects of Hospital Care of the Nursing Home Patients - 12 Month Retrospective Study|Completed|||20|Anticipated|Maimonides Medical Center|||||f||||f||||||||||2018-05-31 23:18:07.495553|2018-05-31 23:18:07.495553
NCT01213212|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-02-20|2010-09-30|2010-10-01|Estimate|||||||2013-02-20|2013-02-21|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|CRESO||Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk|Preventing Renal Functional Abnormalities Predisposing to Chronic Kidney Disease in Abdominal Obesity: A Randomized, Parallel-Group, Pilot Study of Calorie REstriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk|Completed||Phase 2|73|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 23:18:07.55593|2018-05-31 23:18:07.55593
NCT01213199|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2013-11-22||2015-03-09|2010-09-30|2010-10-01|Estimate|2015-03-09|2015-03-23|Estimate||||2015-03-09|2015-03-23|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional||Analysis population includes all 20 subjects enrolled into the study (Intent-to-Treat population).|Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars|Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.|Completed||Phase 2|20|Actual|Galderma||1|||f||||f||||||||||2018-05-31 23:18:07.730396|2018-05-31 23:18:07.730396
NCT01213186|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2013-05-26|2010-09-30|2010-10-01|Estimate|||||||2013-05-26|2013-05-29|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients|Phase 2 Study of UC-MSC in Restoring CD4 T Cell Counts and Reducing Immune Activation in HIV-infected Patients Underlying Long-term Antiviral Therapy: a Multicenter, Does-escalating, Randomized, Double-blind, Controlled Trial.|Unknown status|Recruiting|Phase 2|72|Anticipated|Beijing 302 Hospital||3|||f||||t||||||||||2018-05-31 23:18:07.858823|2018-05-31 23:18:07.858823
NCT01213173|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|2012-11-08||2014-08-26|2010-09-30|2010-10-01|Estimate|2013-07-02|2013-08-26|Estimate||||2014-08-26|2014-09-05|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients|A Randomised, Open Label, Parallel Group, Multicentre, Phase IV Study on the Effect of 8 Weeks Succinate Metoprolol (Betaloc ZOK®) (95 - 190 mg) on Heart Rate in the Stable Angina Patients|Completed||Phase 4|251|Actual|AstraZeneca|The sample size was insufficient for the secondary endpoints. Besides, the treatment prior to study did not correlate well with 47.5 mg metoprolol succinate, but with some higher dose. last the quality control of the study needs further improvement.|2|||f||||f||||||||||2018-05-31 23:18:07.996284|2018-05-31 23:18:07.996284
NCT01213160|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2016-06-28|2010-09-30|2010-10-01|Estimate|||||||2016-06-28|2016-06-29|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients With Advanced Solid Malignancies|Completed||Phase 1|40|Actual|AstraZeneca||1|||f||||t||||||||||2018-05-31 23:18:08.411236|2018-05-31 23:18:08.411236
NCT01213147|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2010-09-30|2010-09-30|2010-10-01|Estimate|||||||2010-09-30|2010-10-01|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional|||Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders|The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial|Completed||Phase 4|159|Actual|Yazd Medical University||2|||f||||t||||||||||2018-05-31 23:18:08.489627|2018-05-31 23:18:08.489627
NCT01213134|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2010-09-30|2010-09-30|2010-10-01|Estimate|||||||2010-09-30|2010-10-01|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|August 2012|Anticipated|2012-08-31|May 2010|Anticipated|2010-05-31||Observational|||Evaluating the Implementation of Portfolio Assessment in Resident Training Program|Evaluating the Implementation of Portfolio Assessment in Resident Training Program|Unknown status|Enrolling by invitation||70|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:18:08.557408|2018-05-31 23:18:08.557408
NCT01213121|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-11-19|2010-09-30|2010-10-01|Estimate|||||||2013-11-19|2013-11-21|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Neurophysiologic Changes in Patients With Bipolar Depression|Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression|Unknown status|Recruiting|Phase 4|60|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 23:18:08.609236|2018-05-31 23:18:08.609236
NCT01213108|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2010-09-30|2010-09-30|2010-10-01|Estimate|||||||2010-09-30|2010-10-01|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effects of the Örebro Prevention Program on Youth Drinking||Completed||N/A|1752|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 23:18:08.803988|2018-05-31 23:18:08.803988
NCT01213095|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2016-04-07|2010-09-30|2010-10-01|Estimate|||||||2016-04-07|2016-04-11|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|September 2015|Actual|2015-09-30|September 2013|Actual|2013-09-30||Interventional|||Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)|R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma|Completed||Phase 2|48|Actual|Dong-A University Hospital||1|||f||||t||||||||||2018-05-31 23:18:08.88405|2018-05-31 23:18:08.88405
NCT01213082|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-02-14|2010-09-30|2010-10-01|Estimate|||||||2017-02-14|2017-02-15|Actual|September 2010||2010-09-30|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|PBAMD2||ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)|Phase I/II Prospective, Randomized, Double-blinded Study of Intravitreal Anti-VEGF Therapy Combined With Proton Beam Radiation Versus Sham Irradiation in Treating Exudative Age-related Macular Degeneration|Completed||Phase 1/Phase 2|30|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 23:18:08.995534|2018-05-31 23:18:08.995534
NCT01213069|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2015-03-24|2010-09-30|2010-10-01|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Staff Opinions and Knowledge Concerning Organ and Tissue Harvesting: an Investigation Among the Patient Care Personnel in the South-Mediterranean Region of France|Staff Opinions and Knowledge Concerning Organ and Tissue Harvesting: an Investigation Among the Patient Care Personnel in the South-Mediterranean Region of France|Completed|||1859|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 23:18:09.149428|2018-05-31 23:18:09.149428
NCT01213056|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2015-11-30|2010-09-30|2010-10-01|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Mindfulness-Based Cognitive Therapy for the Treatment of Chronic Headache Pain|Mindfulness-Based Cognitive Therapy for the Treatment of Chronic Headache Pain|Completed||Phase 1/Phase 2|32|Actual|University of Alabama, Tuscaloosa||2|||f||||f||||||||||2018-05-31 23:18:09.216202|2018-05-31 23:18:09.216202
NCT01213043|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2013-02-26||2013-04-08|2010-09-29|2010-10-01|Estimate|2013-04-08|2013-05-20|Estimate||||2013-04-08|2013-05-20|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SPARK|Demographic and other baseline characteristics were analyzed on the intent-to-treat population, which included all subjects who were randomized.|Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency|A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin®-C in Subjects With Alpha1-Antitrypsin Deficiency|Completed||Phase 2|30|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-05-31 23:18:09.317787|2018-05-31 23:18:09.317787
NCT01213030|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-09-20|2010-09-29|2010-10-01|Estimate|||||||2012-09-20|2012-09-25|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Clinical Evaluation of the New Hypoxia Imaging Agent HX4|Clinical Evaluation of the New Hypoxia Imaging Agent HX4|Completed||Phase 1/Phase 2|12|Actual|Siemens Molecular Imaging||2|||f||||t||||||||||2018-05-31 23:18:09.784311|2018-05-31 23:18:09.784311
NCT01213017|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-12-06|2010-09-29|2010-10-01|Estimate|||||||2017-12-06|2017-12-07|Actual|September 2010||2010-09-30|December 2017|2017-12-31|April 2012|Actual|2012-04-30|January 2011|Actual|2011-01-31||Interventional|PICS||The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients|The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients|Completed||Phase 3|20|Actual|Oklahoma Medical Research Foundation||1|||f||||f|t|f|||f|||No|There is no plan to make individual participant data available|2018-05-31 23:18:09.871957|2018-05-31 23:18:09.871957
NCT01213004|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-02-02|2010-09-30|2010-10-01|Estimate|||||||2018-02-02|2018-02-06|Actual|September 2010||2010-09-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers|Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers|Completed||N/A|52|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 23:18:09.989951|2018-05-31 23:18:09.989951
NCT01212991|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2014-10-08||2018-03-13|2010-09-30|2010-10-01|Estimate|2014-10-08|2014-10-16|Estimate||||2018-03-13|2018-03-15|Actual|June 22, 2010|Actual|2010-06-22|March 2018|2018-03-31|December 28, 2018|Anticipated|2018-12-28|September 30, 2013|Actual|2013-09-30||Interventional|PREVAIL||A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer|Prevail: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Chemotherapy-naïve Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy|Active, not recruiting||Phase 3|1735|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:18:10.186939|2018-05-31 23:18:10.186939
NCT01212978|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2013-10-28|2010-09-29|2010-10-01|Estimate|||||||2013-10-28|2013-10-30|Estimate|September 2010||2010-09-30|October 2013|2013-10-31||||July 2013|Actual|2013-07-31||Interventional|||Overcoming Inactivity in Older Adults: Impact on Vascular Homeostasis|Overcoming Inactivity in Older Adults: Impact on Vascular Homeostasis|Completed||N/A|114|Actual|Medical College of Wisconsin||3|||f||||f||||||||||2018-05-31 23:18:12.176671|2018-05-31 23:18:12.176671
NCT01212965|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2013-04-22|2010-09-29|2010-10-01|Estimate|||||||2013-04-22|2013-04-23|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Interventional|||Selenium in the Treatment of Complicated Lymphatic Malformations|Pilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults|Terminated||Phase 1|5|Actual|Medical College of Wisconsin||||"The investigators chose to terminate the study due to participant attrition. Of the limited~   data evaluable, none of the patients experienced adverse events."|f||||t||||||||||2018-05-31 23:18:12.234664|2018-05-31 23:18:12.234664
NCT01212952|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-03-22|2010-09-29|2010-10-01|Estimate|||||||2018-03-22|2018-03-26|Estimate|September 2011|Actual|2011-09-30|March 2018|2018-03-31|March 22, 2018|Actual|2018-03-22|March 22, 2018|Actual|2018-03-22||Interventional|||Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|MC1082: A Phase I/II Trial of Pomalidomide (CC-4047), Bortezomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|54|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 23:18:12.295748|2018-05-31 23:18:12.295748
NCT01212939|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2014-04-03|2010-09-30|2010-10-01|Estimate|||||||2014-04-03|2014-04-04|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Revitalization of Teeth With Necrotic Pulps and Open Apexes Using Platelet-Rich Plasma|Revitalization of Teeth With Necrotic Pulps and Open Apexes Using Platelet-Rich Plasma|Terminated|||10|Anticipated|Loma Linda University||||No advantage seen during continued animal studies. Difficult recruitment.|f||||f||||||||||2018-05-31 23:18:12.367249|2018-05-31 23:18:12.367249
NCT01212926|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2014-05-09|2010-09-30|2010-10-01|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|April 2015|Anticipated|2015-04-30|April 2014|Actual|2014-04-30||Interventional|CA2D||Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain|Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain|Unknown status|Active, not recruiting|N/A|100|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 23:18:12.471615|2018-05-31 23:18:12.471615
NCT01212913|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-07-05|2010-09-30|2010-10-01|Estimate|||||||2013-07-05|2013-07-08|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|B to B||Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)|Comparison of a Basal Plus (Insulin Glargine/Insulin Glulisine) Regimen to Biphasic Insulin (InsulinAspart/Insulin Aspart Protamine 30/70) in T2DM Patients Who Require Insulin Intensification After Basal Insulin Optimization.|Completed||Phase 4|161|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:18:12.533909|2018-05-31 23:18:12.533909
NCT01212900|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2018-02-13|2010-09-30|2010-10-01|Estimate|||||||2018-02-13|2018-02-14|Actual|September 30, 2010||2010-09-30|February 12, 2018|2018-02-12|February 22, 2017|Actual|2017-02-22|November 30, 2016|Actual|2016-11-30||Interventional|||Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression|The RIGHT Study: Risk Stratification With Image Guidance of HMG Coa Reductase Inhibitor Therapy|Completed||Phase 4|242|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 23:18:12.602485|2018-05-31 23:18:12.602485
NCT01212887|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2012-02-27|2010-09-30|2010-10-01|Estimate|||||||2012-02-27|2012-02-28|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer|A Cancer Research UK Phase I Trial of Adoptive Transfer of Autologous Tumor Antigen-Specific T Cells With Preconditioning Chemotherapy and Intravenous IL2 in Patients With Advanced CEA Positive Tumors|Terminated||Phase 1|14|Actual|Cancer Research UK||||due to safety concerns and lack of efficacy|f||||||||||||||2018-05-31 23:18:12.743572|2018-05-31 23:18:12.743572
NCT01212874|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2016-04-05||2017-10-25|2010-09-30|2010-10-01|Estimate|2016-07-06|2016-08-17|Estimate||||2017-10-25|2017-11-30|Actual|December 2010||2010-12-31|October 2017|2017-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery|Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass(CPB) in Cardiac Surgery: a Randomized, Controlled Trial|Completed||N/A|70|Actual|Loma Linda University|Only 25 of 70 patients received the assigned intervention. Individualized BP ranges based on day of surgery measurement likely decreased treatment.|2|||f||||t||||||||No||2018-05-31 23:18:12.833115|2018-05-31 23:18:12.833115
NCT01212861|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2012-09-11|2010-09-30|2010-10-01|Estimate|||||||2012-09-11|2012-09-12|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Surgical Treatment of Refractory Open Angle Glaucoma|Surgical Treatment of Refractory Open Angle Glaucoma - A Prospective, Open-Label, Pilot Study|Completed||N/A|4|Actual|iScience Interventional Corporation||1|||f||||f||||||||||2018-05-31 23:18:13.060302|2018-05-31 23:18:13.060302
NCT01212848|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2013-04-24|2010-09-30|2010-10-01|Estimate|||||||2013-04-24|2013-04-26|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|October 2013|Anticipated|2013-10-31|March 2013|Actual|2013-03-31||Interventional|||Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation|A Pilot Safety and Feasibility Study of High Dose Left Prefrontal Transcranial Magnetic Stimulation (TMS) to Rapidly Stabilize Suicidal Patients With PTSD|Unknown status|Active, not recruiting|Phase 3|42|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium||2|||f||||t||||||||||2018-05-31 23:18:13.126746|2018-05-31 23:18:13.126746
NCT01212835|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2015-12-21|2010-09-30|2010-10-01|Estimate|||||||2015-12-21|2015-12-23|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|March 2012|Actual|2012-03-31||Interventional|RING||Effect of RING on Gastroesophageal Reflux (GERD) After RYGBP|The Use of a Silastic Ring in Open Gastric Bypass for Morbid Obesity and Its Association With Gastroesophageal Reflux Disease|Terminated||N/A|114|Anticipated|Clinica Gastrobese||2||lack of follow up|f||||f||||||||||2018-05-31 23:18:13.229798|2018-05-31 23:18:13.229798
NCT01212822|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-02-23|2010-09-30|2010-10-01|Estimate|||||||2018-02-23|2018-02-26|Actual|April 27, 2011|Actual|2011-04-27|January 2017|2017-01-31|January 3, 2018|Actual|2018-01-03|October 24, 2014|Actual|2014-10-24||Interventional|||Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer|Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer|Completed||Phase 2|20|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 23:18:13.306751|2018-05-31 23:18:13.306751
NCT01212809|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-09-09|2010-09-30|2010-10-01|Estimate|||||||2011-09-09|2011-09-12|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|JUVE_COSMO_1||Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles|A Prospective, Open Label, Randomized, Comparative, Split-Face Study Evaluating Reconstituted JUVÉDERM® Ultra Injectable Gel Versus COSMODERM® 1 Human Based Collagen Implant for the Treatment of Vertical Lip Rhytids and Radial Cheek Lines|Completed||Phase 4|30|Actual|Fagien, Steven, M.D., PA||2|||f||||f||||||||||2018-05-31 23:18:13.405612|2018-05-31 23:18:13.405612
NCT01212796|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2010-09-30|2010-09-30|2010-10-01|Estimate|||||||2010-09-30|2010-10-01|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Observational|||Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH|Second and Further Allogeneic Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH|Unknown status|Not yet recruiting||350|Anticipated|Grupo Espanol de trasplantes hematopoyeticos y terapia celular|||||f||||t||||||||||2018-05-31 23:18:13.474767|2018-05-31 23:18:13.474767
NCT01212783|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-07-28|2010-09-29|2010-10-01|Estimate|||||||2017-07-28|2017-07-31|Actual|October 2010||2010-10-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Interventional|MIDISII||Treatment of Maternal Depression in Home Visitation: Mother and Child Impacts|Treatment of Maternal Depression in Home Visitation: Mother and Child Impacts|Active, not recruiting||N/A|170|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 23:18:13.52801|2018-05-31 23:18:13.52801
NCT01212770|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2014-04-22|2013-07-23|2018-02-09|2010-09-30|2010-10-01|Estimate|2014-04-22|2014-05-20|Estimate|2013-07-23|2013-07-30|Estimate|2018-02-09|2018-03-12|Actual|September 30, 2010|Actual|2010-09-30|February 2018|2018-02-28|February 9, 2017|Actual|2017-02-09|August 21, 2012|Actual|2012-08-21||Interventional|PALACE 3|The full analysis dataset (FAS) consisted of all participants who were randomized as specified in the protocol.|PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis and a Qualifying Psoriasis Lesion|Completed||Phase 3|505|Actual|Celgene||4|||f||||t||||||||||2018-05-31 23:18:13.692967|2018-05-31 23:18:13.692967
NCT01212757|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2014-04-21|2013-05-29|2018-01-26|2010-09-30|2010-10-01|Estimate|2014-04-21|2014-05-19|Estimate|2013-05-29|2013-06-06|Estimate|2018-01-26|2018-02-28|Actual|September 27, 2010|Actual|2010-09-27|January 2018|2018-01-31|January 25, 2017|Actual|2017-01-25|July 26, 2012|Actual|2012-07-26||Interventional|PALACE2|Full analysis set consisting of all participants who were randomized as specified in the protocol. Four participants who were randomized in error and did not receive any dose of investigational product are excluded.|PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis|Completed||Phase 3|488|Actual|Celgene||4|||f||||t||||||||||2018-05-31 23:18:16.711162|2018-05-31 23:18:16.711162
NCT01212744|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29||2017-08-17|2017-08-17|2010-09-30|2010-10-01|Estimate||||2017-08-17|2017-08-21|Actual|2017-08-17|2017-08-21|Actual|March 2011||2011-03-31|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)|A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Dose Levels of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria|Completed||Phase 2|16|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||No||2018-05-31 23:18:19.570915|2018-05-31 23:18:19.570915
NCT01212731|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-09-23|2010-09-30|2010-10-01|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2010||2010-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Observational|||Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study|Detection of Vascular and Neuronal Changes Following Proton and/or Photon Radiotherapy in Patients Receiving Skull Base and/or Brain Radiation|Recruiting|||70|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 23:18:19.638525|2018-05-31 23:18:19.638525
NCT01212718|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-30|2010-09-30|2010-10-01|Estimate|||||||2010-09-30|2010-10-01|Estimate|July 2001||2001-07-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|FOGT5||Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase|Stratified and Randomized Multi-center Phase II - to Determine Potential Benefit of Treating Patients With Advanced Colorectal Cancer According to the Intratumoral TS RNA Levels|Completed||Phase 2|168|Actual|University of Ulm||2|||f||||t||||||||||2018-05-31 23:18:19.789557|2018-05-31 23:18:19.789557
NCT01212705|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2010-09-30|2010-09-30|2010-10-01|Estimate|||||||2010-09-30|2010-10-01|Estimate||||September 2010|2010-09-30||||||||Interventional|||Effect of Adaptive Servoventilation on Cardiac Function in Chronic Heart Failure and Cheyne-Stokes Respiration|Effect of Adaptive Servoventilation on Cardiac Function, Exercise Tolerance and Quality of Life in Patients With Chronic Heart Failure and Cheyne-Stokes Respiration|Unknown status|Recruiting|N/A|||Military Institute of Medicine, Poland||1|||f||||||||||||||2018-05-31 23:18:19.845784|2018-05-31 23:18:19.845784
NCT01212692|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2015-12-08|2010-09-30|2010-10-01|Estimate|||||||2015-12-08|2015-12-09|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Mental Stimulation in Patients With Mild Cognitive Impairment|A Theoretically Based Memory Training Intervention in Mild Cognitive Impairment|Completed||Phase 2|63|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:18:19.898054|2018-05-31 23:18:19.898054
NCT01212679|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2017-10-30|2010-09-30|2010-10-01|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2010||2010-12-31|November 2016|2016-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Effects of Intranasal Nerve Growth Factor for Traumatic Brain Injury|Pilot Study of Intranasal Nerve Growth Factor for Traumatic Brain Injury(TBI)|Completed||Phase 2|106|Actual|Jinling Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 23:18:19.971229|2018-05-31 23:18:19.971229
NCT01212666|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-09-09|2010-09-30|2010-10-01|Estimate|||||||2012-09-09|2012-09-11|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Efficacy of Adductor-Canal-Block (ACB) in Patients After Anterior Cruciate Ligament (ACL) Reconstruction|The Effect of Adductor-Canal-Block (ACB) in Patients After Anterior Cruciate Ligament (ACL) Reconstruction in Day Case Surgery|Completed||Phase 4|50|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 23:18:20.037107|2018-05-31 23:18:20.037107
NCT01212653|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2014-09-10|2010-09-30|2010-10-01|Estimate|||||||2014-09-10|2014-09-11|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|AS||Effect of Anti-TNF (Alpha) Treatment on Vascular Stiffness in Ankylosing Spondylitis (AS)|Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS|Completed||Phase 4|50|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:18:20.113702|2018-05-31 23:18:20.113702
NCT01212640|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2010-09-29|2010-09-29|2010-09-30|Estimate|||||||2010-09-29|2010-09-30|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||GROUP FOR TRALI STUDY. SEMICYUC.|GROUP FOR TRALI STUDY. SEMICYUC.|Unknown status|Not yet recruiting||18|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|||||f||||f||||||||||2018-05-31 23:18:20.18462|2018-05-31 23:18:20.18462
NCT01212627|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2015-05-20||2015-06-24|2010-09-29|2010-09-30|Estimate|2015-06-24|2015-06-25|Estimate||||2015-06-24|2015-06-25|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer|BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer|Terminated||Phase 1|12|Actual|Brown University||1||Determination to stop enrollment made due to funding|f||||t||||||||||2018-05-31 23:18:20.254054|2018-05-31 23:18:20.254054
NCT01212614|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2012-09-11|2010-09-29|2010-09-30|Estimate|||||||2012-09-11|2012-09-12|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Measurement of Gastric Secretion by MRI Under Inhibition by ProtonPump Inhibitors in Healthy Subjects & in GERD Patients|A Study for Measurement of Gastric Secretion by Magnetic Resonance Imaging (MRI) Under Inhibition of Gastric Secretion by Proton Pump Inhibitors in Healthy Subjects and Patients With Reflux Disease|Completed||N/A|24|Actual|University of Zurich|||||f||||||||||||||2018-05-31 23:18:20.446651|2018-05-31 23:18:20.446651
NCT01212601|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-11-23|2010-09-29|2010-09-30|Estimate|||||||2012-11-23|2012-11-27|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice|A Multicenter, Observational, Non-interventional Registry Designed to Collect Clinical Data in Chinese Patients Who Have Received CUBICIN® Treatment Under Condition of Actual Usage in Clinical Practice|Completed|||203|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:18:20.723216|2018-05-31 23:18:20.723216
NCT01212588|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-10-09|2010-09-29|2010-09-30|Estimate|||||||2017-10-09|2017-10-11|Actual|September 2010||2010-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)|Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse|Recruiting||Phase 2|24|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 23:18:20.808309|2018-05-31 23:18:20.808309
NCT01212575|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-03-04|2010-09-29|2010-09-30|Estimate|||||||2011-03-04|2011-03-08|Estimate|October 2010||2010-10-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia|A Retrospective, Non-interventional Study to Evaluate the Use of Seroquel XR and Seroquel IR in the Clinical Practice of Outpatients With Schizophrenia|Completed|||186|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:18:20.912368|2018-05-31 23:18:20.912368
NCT01212211|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2012-05-22|2010-09-29|2010-09-30|Estimate|||||||2012-05-22|2012-05-23|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|January 2011|Actual|2011-01-31||Interventional|NATRIPHAR||Hyponatremia in the Elderly: Benefit From a Change in Drug Therapy?|Hyponatremia in the Elderly: Benefit From a Change in Drug Therapy?|Completed||N/A|18|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 23:18:24.718378|2018-05-31 23:18:24.718378
NCT01212562|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-08-31|2010-09-29|2010-09-30|Estimate|||||||2011-08-31|2011-09-02|Estimate|April 2007||2007-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|April 2010|Actual|2010-04-30||Observational|IMCX||Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery|Open Label, Phase 3 Study of the Efficacy of Combination of Imiquimod and Cryosurgery in the Treatment of Primary Basal Cell Carcinomas of the Skin|Completed|||70|Anticipated|University of Ioannina|||1||f||||t||||||Samples With DNA|"~     Blood samples with anticoagulant at -20C~   "|||2018-05-31 23:18:20.990992|2018-05-31 23:18:20.990992
NCT01212549|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-08-31|2010-09-29|2010-09-30|Estimate|||||||2011-08-31|2011-09-02|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|IMCXvsCIMT||Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma|Open Label, Randomized Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma of the Skin|Completed||Phase 3|14|Actual|University of Ioannina||2|||f||||t||||||||||2018-05-31 23:18:21.054786|2018-05-31 23:18:21.054786
NCT01212536|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-12-14|2010-09-29|2010-09-30|Estimate|||||||2011-12-14|2011-12-15|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Airtraq Versus Conventional Laryngoscopy in Children|Randomised Controlled Trial of the Airtraq Optical Laryngoscope and Conventional Laryngoscopy in Children|Completed||N/A|60|Actual|University Hospitals Bristol NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 23:18:21.117615|2018-05-31 23:18:21.117615
NCT01212523|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2011-12-14|2010-09-29|2010-09-30|Estimate|||||||2011-12-14|2011-12-15|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance|Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension.|Completed||Phase 4|10|Actual|University Hospitals Bristol NHS Foundation Trust|||||f||||f||||||||||2018-05-31 23:18:21.238488|2018-05-31 23:18:21.238488
NCT01212510|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2016-08-16|2010-09-29|2010-09-30|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Coca-Colon||Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer|Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer|Completed||N/A|200|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 23:18:21.292559|2018-05-31 23:18:21.292559
NCT01212497|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2010-09-29|2010-09-29|2010-09-30|Estimate|||||||2010-09-29|2010-09-30|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Virtual Coach for Mindfulness Meditation Training|Virtual Coach for Mindfulness Meditation Training|Completed||N/A|22|Actual|Psychometrix Associates||1|||f||||f||||||||||2018-05-31 23:18:21.355205|2018-05-31 23:18:21.355205
NCT01212484|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2014-12-29||2016-03-07|2010-09-29|2010-09-30|Estimate|2016-03-07|2016-03-28|Estimate||||2016-03-07|2016-03-28|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|October 2012|Actual|2012-10-31|February 2012|Actual|2012-02-29||Interventional|||Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia|Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia|Completed||Phase 3|12|Actual|New York University School of Medicine||2|||f||||f||||||||No||2018-05-31 23:18:21.415362|2018-05-31 23:18:21.415362
NCT01212471|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28||2013-03-14|2013-12-04|2010-09-29|2010-09-30|Estimate||||2013-03-14|2013-03-20|Estimate|2013-12-04|2013-12-30|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease||Completed||Phase 3|840|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-05-31 23:18:21.579218|2018-05-31 23:18:21.579218
NCT01212458|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2014-03-14|2010-09-29|2010-09-30|Estimate|||||||2014-03-14|2014-03-17|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study||Completed|||24|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 23:18:21.642906|2018-05-31 23:18:21.642906
NCT01212445|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2012-11-20||2016-02-17|2010-09-29|2010-09-30|Estimate|2013-02-05|2013-03-11|Estimate||||2016-02-17|2016-03-15|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)|A Randomized, Open-Label, Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation|Completed||Phase 2|154|Actual|Bayer||3|||f||||f||||||||||2018-05-31 23:18:21.717431|2018-05-31 23:18:21.717431
NCT01212432|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2010-10-15|2010-09-29|2010-09-30|Estimate|||||||2010-10-15|2010-10-18|Estimate|December 2009||2009-12-31|July 2010|2010-07-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study||Unknown status|Recruiting|Phase 2|15|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 23:18:22.183842|2018-05-31 23:18:22.183842
NCT01212419|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2010-09-30|2010-09-29|2010-09-30|Estimate|||||||2010-09-30|2010-10-01|Estimate|March 2009||2009-03-31|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||SWC on aEEG in Post-surgical Neonates on Morphine and Midazolam|Effects of Morphine and Midazolam on Sleep-wake Cycling in Amplitude-integrated Electroencephalography in Post-surgical Neonates > 32 Weeks' Gestational Age|Completed|||47|Actual|Royal Children's Hospital|||||f||||t||||||||||2018-05-31 23:18:22.286686|2018-05-31 23:18:22.286686
NCT01212406|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2015-11-10|2010-09-29|2010-09-30|Estimate|||||||2015-11-10|2015-11-11|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|August 2015|Actual|2015-08-31|September 2013|Actual|2013-09-30||Interventional|VIT001||Vitamin D in Bronchiolitis Obliterans Syndrome|A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation|Completed||Phase 4|100|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 23:18:22.382427|2018-05-31 23:18:22.382427
NCT01212393|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-04-05|2010-09-29|2010-09-30|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2009||2009-09-30|December 2016|2016-12-31|June 2013|Actual|2013-06-30|March 2011|Actual|2011-03-31||Observational|PREVENU||Prevention of Venous Thromboembolism Disease in Emergency Departments|Prevention of Venous Thromboembolism Disease for Acutelly Ill Medical Patients Admitted to Hospital : Systematic Analysis of Thrombosis Risk Factors and Remember of Prevention Treatment Indications in Emergency Departments.|Completed|||20000|Actual|University Hospital, Angers|||2||f||||t||||||None Retained|"~     observational study at the patient level - cluster randomized study~   "|||2018-05-31 23:18:22.557312|2018-05-31 23:18:22.557312
NCT01212380|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2016-05-06|2010-09-29|2010-09-30|Estimate|||||||2016-05-06|2016-05-09|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|||Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)|A Phase I Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL)|Completed||Phase 1|21|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:18:22.662347|2018-05-31 23:18:22.662347
NCT01212367|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2015-09-21|2010-09-29|2010-09-30|Estimate|||||||2015-09-21|2015-09-22|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|IFN-alpha||Intrapleural Gene Transfer for Pleural Mesothelioma|A Pilot Study of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-Alpha (SCH 721015, Ad.hIFN-a2b) Gene Transfer for Malignant Pleural Mesothelioma|Completed||Phase 1|13|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:18:22.85367|2018-05-31 23:18:22.85367
NCT01212354|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2016-02-08|2010-09-29|2010-09-30|Estimate|||||||2016-02-08|2016-02-09|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|September 2025|Anticipated|2025-09-30|January 2025|Anticipated|2025-01-31||Interventional|Escalox||Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT|Phase III A Prospective, Randomized, Rater-blinded, Multicentre Interventional Clinical Trial. Do Selective Radiation Dose Escalation and Tumour Hypoxia Status Impact the Locoregional Tumour Control After Radiochemotherapy of Head & Neck Tumours?|Recruiting||Phase 3|270|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 23:18:23.034966|2018-05-31 23:18:23.034966
NCT01212341|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-18|||2013-08-15|2010-09-29|2010-09-30|Estimate|||||||2013-08-15|2013-08-19|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|MG4101||Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor|A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor|Completed||Phase 1|18|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:18:23.218603|2018-05-31 23:18:23.218603
NCT01212328|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2011-09-02|2010-09-29|2010-09-30|Estimate|||||||2011-09-02|2011-09-05|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|CARRS||A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia|Developing and Testing Integrated, Multi-factorial Cardiovascular Disease Risk Reduction Strategies in South Asia (CARRS Translation Trial)|Unknown status|Recruiting|N/A|1120|Anticipated|Public Health Foundation of India||2|||f||||t||||||||||2018-05-31 23:18:23.381707|2018-05-31 23:18:23.381707
NCT01212315|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2012-12-19|2010-09-29|2010-09-30|Estimate|||||||2012-12-19|2012-12-20|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effects of Triclosan-coated Sutures in Cardiac Surgery|Triclosan-coated Sutures in Cardiac Surgery:Effects on Leg Wound Infections and Costs|Completed||Phase 4|392|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 23:18:23.618602|2018-05-31 23:18:23.618602
NCT01212302|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2011-02-28||2011-08-11|2010-09-29|2010-09-30|Estimate|2011-08-11|2011-09-16|Estimate||||2011-08-11|2011-09-16|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|BOCLAplan||Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)|Optimizing Therapy With Aspirin and Clopidogrel. The BOchum CLopidogrel and Aspirin Plan to Improve Dual Antiplatelet Therapy.|Completed||N/A|500|Actual|Ruhr University of Bochum||1|||f||||f||||||||||2018-05-31 23:18:23.698491|2018-05-31 23:18:23.698491
NCT01212289|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2016-02-16|2010-09-28|2010-09-30|Estimate|||||||2016-02-16|2016-02-18|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|PedsROTEM||Use of ROTEM® in Pediatric Cardiac Surgical Patients|The Use of Rotational Thromboelastometry ROTEM® to Characterize Coagulation Abnormalities in Pediatric Cardiac Surgical Patients: A Prospective Pilot Study|Completed|||23|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples Without DNA|"~     For each group, a small amount of blood will be obtained for ROTEM® analysis after induction~     of anesthesia but before skin incision and again following cardiopulmonary bypass, 5 minutes~     following protamine administration.~   "|No|There is no plan to share IPD|2018-05-31 23:18:24.057099|2018-05-31 23:18:24.057099
NCT01212276|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2014-07-15|2010-09-29|2010-09-30|Estimate|||||||2014-07-15|2014-07-16|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma|A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma|Terminated||Phase 1|18|Actual|Morphotek||4||Sponsor terminated protocol|f||||f||||||||||2018-05-31 23:18:24.122942|2018-05-31 23:18:24.122942
NCT01212263|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2013-05-29|2010-09-29|2010-09-30|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS|Clomiphene Citrate Co-treatment With Low Dose HP Urinary FSH vs. HP Urinary FSH Step-up Protocol for Clomiphene-citrate Resistant PCOS Anovulatory Infertility: Randomized Controlled Trial|Completed||N/A|174|Actual|Mansoura Integrated Fertility Center||2|||f||||f||||||||||2018-05-31 23:18:24.280771|2018-05-31 23:18:24.280771
NCT01212250|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2018-02-05|2010-09-29|2010-09-30|Estimate|||||||2018-02-05|2018-02-06|Actual|September 1, 2010|Actual|2010-09-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis|A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis|Recruiting||N/A|132|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 23:18:24.369561|2018-05-31 23:18:24.369561
NCT01212237|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2012-12-20|2010-09-28|2010-09-30|Estimate|||||||2012-12-20|2012-12-21|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|October 2016|Anticipated|2016-10-31|October 2014|Anticipated|2014-10-31||Observational|||Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy|Phase I Study of Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy|Unknown status|Recruiting||25|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-05-31 23:18:24.441434|2018-05-31 23:18:24.441434
NCT01212224|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2014-01-03|2010-09-29|2010-09-30|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Observational|||A Study of Minirin Melt in Patients With Nocturia|Retrospective Safety Study in 12 Months Treatment Nocturia With Minirin Melt in Clinical Practice in Czech Republic|Completed|||2187|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:18:24.561091|2018-05-31 23:18:24.561091
NCT01212198|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2010-10-22|2010-09-29|2010-09-30|Estimate|||||||2010-10-22|2010-10-25|Estimate|May 2005||2005-05-31|September 2010|2010-09-30|March 2014|Anticipated|2014-03-31|||||Observational|KNDP||Korea National Diabetes Program|Clinical Research Center For Type 2 Diabetes Mellitus - Observational Cohort Study of Type 2 Diabetes Mellitus|Unknown status|Recruiting||6000|Anticipated|Kyunghee University Medical Center|||3||f||||t||||||Samples With DNA|"~     whole blood, serum, and urine~   "|||2018-05-31 23:18:24.792971|2018-05-31 23:18:24.792971
NCT01212185|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2013-12-14||2014-04-12|2010-09-28|2010-09-30|Estimate|2014-04-12|2014-05-13|Estimate||||2014-04-12|2014-05-13|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||This was an intent to treat study in which data were collected and analyzed on all subjects in both treatment arms who were enrolled in the study and met eligibility criteria.|Oxytocin Treatment of Alcohol Withdrawal|Oxytocin Treatment of Alcohol Withdrawal|Completed||Phase 1|14|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 23:18:24.925358|2018-05-31 23:18:24.925358
NCT01212172|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2014-12-04||2016-01-07|2010-09-28|2010-09-30|Estimate|2016-01-07|2016-02-05|Estimate||||2016-01-07|2016-02-05|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction|Side-by-Side Comparison of 810 nm Diode Laser Technology With Low Fluence-High Repetition Rate vs Low Fluence-Vacuum Assist - A Split - Extremity Efficacy , Safety and Tolerability Study|Completed||Phase 3|20|Actual|University of California, Irvine||2|||f||||t||||||||||2018-05-31 23:18:25.230319|2018-05-31 23:18:25.230319
NCT01212159|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2015-08-11||2015-09-24|2010-09-29|2010-09-30|Estimate|2015-09-24|2015-09-25|Estimate||||2015-09-24|2015-09-25|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Telephone Based Management of Hyperlipidemia|Telephone Based Management of Hyperlipidemia Utilizing a Self Monitoring Testing Device|Completed||Phase 4|70|Actual|Temple University|Recruiting did not reach goal due to change in FDA approval for simvastatin use requiring protocol modification.|2|||f||||f||||||||||2018-05-31 23:18:25.386657|2018-05-31 23:18:25.386657
NCT01212146|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-12-23|2010-09-29|2010-09-30|Estimate|||||||2011-12-23|2011-12-26|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|PAFC||Probiotic-enriched Artichoke in Functional Constipation|A Randomized Double-blind, Crossover Clinical Trial to Assess the Efficacy of Lactobacillus Paracasei Enriched Artichokes in the Treatment of Functional Constipation|Completed||N/A|30|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||2|||f||||f||||||||||2018-05-31 23:18:25.655818|2018-05-31 23:18:25.655818
NCT01212133|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2016-12-15|2010-09-29|2010-09-30|Estimate|||||||2016-12-15|2016-12-16|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|Lead-In||A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India|A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India|Completed|||1386|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 23:18:25.724861|2018-05-31 23:18:25.724861
NCT01212120|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2015-03-26|2010-09-29|2010-09-30|Estimate|||||||2015-03-26|2015-03-27|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections|The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections|Completed|||278|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples With DNA|"~     The DNA samples correspond to the bacteria present in the nose and feet of diabetic patients.~   "|||2018-05-31 23:18:25.78339|2018-05-31 23:18:25.78339
NCT01212107|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-02-24|2010-09-29|2010-09-30|Estimate|||||||2015-02-24|2015-02-26|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||A Study of LY2874455 in Patients With Advanced Cancer|A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.|Completed||Phase 1|94|Actual|Eli Lilly and Company||11|||f||||t||||||||||2018-05-31 23:18:25.866467|2018-05-31 23:18:25.866467
NCT01212094|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|2016-03-09||2016-03-09|2010-09-29|2010-09-30|Estimate|2016-03-09|2016-03-28|Estimate||||2016-03-09|2016-03-28|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)|Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)|Terminated||Phase 1/Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)|The trial was closed prematurely for futility, because pre-determined interim analysis demonstrated that selected dosing led to <50% depletion of B cells from the brain/spinal cord. Therefore, only 5 patients per group finished trial.|3||The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial|t||||t||||||||No||2018-05-31 23:18:26.186287|2018-05-31 23:18:26.186287
NCT01212081|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-04-04|2010-09-29|2010-09-30|Estimate|||||||2018-04-04|2018-04-05|Actual|September 26, 2010||2010-09-26|November 26, 2012|2012-11-26|November 26, 2012||2012-11-26|||||Observational|||Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality|Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality|Completed|||17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:26.975187|2018-05-31 23:18:26.975187
NCT01212068|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-10-05|2010-09-29|2010-09-30|Estimate|||||||2017-10-05|2017-10-06|Actual|September 10, 2010||2010-09-10|April 4, 2017|2017-04-04|April 4, 2017||2017-04-04|||||Observational|||Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy|Connectivity Analysis for Investigation of Auditory Impairment in Epilepsy|Terminated|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:27.068911|2018-05-31 23:18:27.068911
NCT01212055|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-04-20|2010-09-29|2010-09-30|Estimate|||||||2018-04-20|2018-04-23|Actual|September 1, 2010||2010-09-01|November 3, 2017|2017-11-03||||||||Observational|||Apheresis of Patients With Immunodeficiency|Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells From Patients With DOCK8 Deficiency, LAD-1, and GATA2 Deficiency|Recruiting|||6|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:27.133425|2018-05-31 23:18:27.133425
NCT01212042|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-04-04|2010-09-29|2010-09-30|Estimate|||||||2018-04-04|2018-04-05|Actual|September 1, 2010||2010-09-01|April 5, 2016|2016-04-05|April 5, 2016||2016-04-05|||||Observational|||Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections|Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections|Terminated|||129|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:27.275454|2018-05-31 23:18:27.275454
NCT01212029|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-05-22|2010-09-29|2010-09-30|Estimate|||||||2018-05-22|2018-05-23|Actual|August 31, 2010||2010-08-31|May 11, 2018|2018-05-11||||||||Observational|||Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging|Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:27.344543|2018-05-31 23:18:27.344543
NCT01212016|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-10-05|2010-09-29|2010-09-30|Estimate|||||||2017-10-05|2017-10-06|Actual|August 30, 2010||2010-08-30|May 13, 2015|2015-05-13|May 13, 2015||2015-05-13|||||Observational|||Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders|Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders|Terminated|||162|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:27.492319|2018-05-31 23:18:27.492319
NCT01212003|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2018-03-27|2010-09-29|2010-09-30|Estimate|||||||2018-03-27|2018-03-29|Actual|September 1, 2010||2010-09-01|January 24, 2018|2018-01-24||||||||Observational|||Training Protocol on the Natural History of Tuberculosis|Training Protocol on the Natural History of Tuberculosis|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:27.726454|2018-05-31 23:18:27.726454
NCT01211990|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-10-05|2010-09-29|2010-09-30|Estimate|||||||2017-10-05|2017-10-06|Actual|August 31, 2010||2010-08-31|May 13, 2013|2013-05-13|May 13, 2013||2013-05-13|||||Observational|||An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States|An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States|Completed|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:27.974055|2018-05-31 23:18:27.974055
NCT01211977|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-06-30|2010-09-29|2010-09-30|Estimate|||||||2017-06-30|2017-07-02|Actual|August 27, 2010||2010-08-27|April 29, 2011|2011-04-29|April 29, 2011|Actual|2011-04-29|April 29, 2011|Actual|2011-04-29||Interventional|||A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease|A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD)|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:18:28.061482|2018-05-31 23:18:28.061482
NCT01211964|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2013-11-01|2010-09-29|2010-09-30|Estimate|||||||2013-11-01|2013-11-04|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects|LEO 22811 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects|Completed||Phase 1|15|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 23:18:28.157104|2018-05-31 23:18:28.157104
NCT01211951|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-26|||2011-06-30|2010-09-29|2010-09-30|Estimate|||||||2011-06-30|2011-07-04|Estimate||||June 2011|2011-06-30||||||||Interventional|||A Study of KCT-0809 in Patients With Dry Eye Syndromes|A Randomized, Double Blind, Placebo Controlled, Exploratory Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes|Completed||Phase 2|160||Kissei Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 23:18:28.368004|2018-05-31 23:18:28.368004
NCT01211938|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2017-05-15|2010-09-29|2010-09-30|Estimate|||||||2017-05-15|2017-05-16|Actual|June 15, 2010|Actual|2010-06-15|May 2017|2017-05-31|February 25, 2017|Actual|2017-02-25|February 25, 2017|Actual|2017-02-25||Interventional|JANORL2||Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract|Randomized Phase 2 Trial Evaluating the Acute Toxicity of Two Protocols of Reirradiation After Surgery in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract - Single-fraction Radiotherapy With Concomitant 5FU and Hydrea Administered Every Other Week - Continuous Hyperfractionated Radiotherapy With Concomitant Cetuximab|Completed||Phase 2/Phase 3|60|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 23:18:28.483316|2018-05-31 23:18:28.483316
NCT01211925|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2010-09-29|2010-09-29|2010-09-30|Estimate|||||||2010-09-29|2010-09-30|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|July 2011|Anticipated|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||Distal Venous Arterialisation of Ischemic Limb|Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb|Unknown status|Active, not recruiting|Phase 2/Phase 3|30|Actual|Clinical Centre of Serbia||2|||f||||f||||||||||2018-05-31 23:18:28.577065|2018-05-31 23:18:28.577065
NCT01211912|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-08-29|2010-09-29|2010-09-30|Estimate|||||||2014-08-29|2014-09-01|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-being|Acetaminophen Transfer Across the Placenta and the Assessment of Fetal Well-being|Completed||Phase 1|56|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:18:28.690441|2018-05-31 23:18:28.690441
NCT01211899|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-10-04|2010-09-29|2010-09-30|Estimate|||||||2011-10-04|2011-10-05|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||September 2012|Anticipated|2012-09-30||Observational|||4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock|Incidence and Prognosis of Disseminated Intravscular Coagulation in Patients Severe Sepsis and Septic Shock; Association With 4G/5G Polymorphism of PAI-1 Gene|Unknown status|Not yet recruiting||160|Anticipated|Hallym University Medical Center|||||f||||t||||||Samples With DNA|"~     Blood sample for 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1)~   "|||2018-05-31 23:18:28.968637|2018-05-31 23:18:28.968637
NCT01211886|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2011-10-04|2010-09-29|2010-09-30|Estimate|||||||2011-10-04|2011-10-05|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||August 2012|Anticipated|2012-08-31||Observational|||Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)|Utility of BNP in Patients With Type IV Cardio-renal Syndrome Admitted to the ICU: a Prospective Observational Study|Unknown status|Not yet recruiting||83|Anticipated|Hallym University Medical Center|||||f||||t||||||Samples Without DNA|"~     Serum sample for BNP level~   "|||2018-05-31 23:18:29.076448|2018-05-31 23:18:29.076448
NCT01211873|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2013-07-25||2016-04-19|2010-09-29|2010-09-30|Estimate|2014-04-29|2014-05-29|Estimate||||2016-04-19|2016-05-19|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|SENTIO||Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions|Safety and Efficacy Evaluation of DOTAREM® in Magnetic Resonance Imaging (MRI) in Patients With Central Nervous System (CNS) Lesions.|Completed||Phase 3|416|Actual|Guerbet||3|||f||||f||||||||||2018-05-31 23:18:29.174162|2018-05-31 23:18:29.174162
NCT01211860|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-01-09|2010-09-29|2010-09-30|Estimate|||||||2014-01-09|2014-01-10|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects|A Multiple-Dose Pharmacokinetic Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects With Elevated Fasting Triglyceride Levels|Completed||Phase 1|9|Actual|Essentialis, Inc.||1|||f||||f||||||||||2018-05-31 23:18:29.783881|2018-05-31 23:18:29.783881
NCT01211847|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2014-01-09|2010-09-29|2010-09-30|Estimate|||||||2014-01-09|2014-01-10|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind DCCR-Fenofibrate Combination Extension|Completed||Phase 2|44|Actual|Essentialis, Inc.||2|||f||||f||||||||||2018-05-31 23:18:29.844298|2018-05-31 23:18:29.844298
NCT01211834|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-29|||2010-11-01|2010-09-29|2010-09-30|Estimate|||||||2010-11-01|2010-11-03|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and the Safety During Treatment With Tocilizumab vs Placebo in Combination With Traditional DMARD Therapy in Patients With Moderate to Severe Active RA and an Inadequate Response to Current DMARD Therapy|Completed||Phase 3|90|Anticipated|JW Pharmaceutical||2|||f||||t||||||||||2018-05-31 23:18:29.952609|2018-05-31 23:18:29.952609
NCT01211821|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2011-02-01|2010-09-28|2010-09-30|Estimate|||||||2011-02-01|2011-02-02|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effect of BMS-914392 on Pharmacokinetics of Metoprolol|Effect of BMS-914392 on the Pharmacokinetics of Metoprolol and on Heart Rate After Co-administration of BMS-914392 and Metoprolol in Healthy Subjects|Completed||Phase 1|18|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 23:18:30.168154|2018-05-31 23:18:30.168154
NCT01211808|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2011-02-01|2010-09-28|2010-09-30|Estimate|||||||2011-02-01|2011-02-02|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Diltiazem on Pharmacokinetics of BMS-914392|Effect of Diltiazem on the Pharmacokinetics of BMS-914392 and on Heart Rate After Single-dose Administration of BMS-914392 in Healthy Subjects|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 23:18:30.249441|2018-05-31 23:18:30.249441
NCT01211795|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-06-04|2010-09-28|2010-09-30|Estimate|||||||2011-06-04|2011-06-08|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Topical Intra-Oral Ketoprofen for Migraine Prevention|Phase III Double Blind Randomized Placebo Controlled Trial Using 20% Intra-Oral Ketoprofen Gel for Migraine Prevention.|Completed||Phase 3|67|Actual|Behar, Caren, M.D.||2|||f||||t||||||||||2018-05-31 23:18:30.350988|2018-05-31 23:18:30.350988
NCT01211782|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2012-12-03|2010-09-28|2010-09-30|Estimate|||||||2012-12-03|2012-12-04|Estimate||||December 2012|2012-12-31||||||||Interventional|ALERT||AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)|A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)|Withdrawn||Phase 2/Phase 3|0|Actual|Accera, Inc.||2||Study never started. Study was redesgined.|f||||f||||||||||2018-05-31 23:18:30.420421|2018-05-31 23:18:30.420421
NCT01211769|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2008-12-05||2010-09-02|2010-09-02|2010-09-29|Estimate|2010-09-02|2010-09-29|Estimate||||2010-09-02|2010-09-29|Estimate|February 2006||2006-02-28|September 2010|2010-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effects of Omegas 3 and 6 on Alcohol Dependence|Alcohol Dependence: Study of the Possible Reduction of Compulsion by Association of Naltrexone With Poly-unsaturated Fatty Acids (PUFAs)|Completed||Phase 3|80|Actual|Federal University of São Paulo||4|||f||||f||||||||||2018-05-31 23:18:30.52336|2018-05-31 23:18:30.52336
NCT01211756|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-12-20|2010-09-28|2010-09-29|Estimate|||||||2016-12-20|2016-12-22|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Oxytocin Add-on for Stable Depressed Patients|Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antidepressant Medication in Depressed Patients.|Terminated||N/A|1|Actual|University of California, San Diego||2||Break in funding|f||||f||||||||||2018-05-31 23:18:30.930682|2018-05-31 23:18:30.930682
NCT01211743|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Oxidative Stress in Standard Laparoscopic vs Single Port Cholecystectomy|Study of Oxidative Stress in Standard Laparoscopic vs Single Port Cholecystectomy for Uncomplicated Cholelithiasis (Lap vs SILS)|Completed||Phase 4|20|Actual|G. Hatzikosta General Hospital||2|||f||||t||||||||||2018-05-31 23:18:31.061108|2018-05-31 23:18:31.061108
NCT01211730|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2016-09-12||2016-10-31|2010-09-28|2010-09-29|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|April 2009||2009-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional||Patients undergoing liver transplantation|Study of Glycemic Control on Liver Transplantation Outcomes|Prospective, Randomized, Open-Label, Controlled Study to Evaluate the Safety and Efficacy of Intensive Glycemic Control on Outcomes Following Liver Transplantation|Completed||Phase 4|164|Actual|Northwestern University|Single-center study with experienced nurses, glucose management service and endocrinologists. May not be applicable to other care settings|2|||f||||f||||||||No||2018-05-31 23:18:31.147767|2018-05-31 23:18:31.147767
NCT01211717|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2011-04-21|2010-09-28|2010-09-29|Estimate|||||||2011-04-21|2011-04-22|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients|The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients|Completed||N/A|50|Anticipated|Loma Linda University||2|||f||||f||||||||||2018-05-31 23:18:31.557019|2018-05-31 23:18:31.557019
NCT01211704|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-11-19|2010-09-28|2010-09-29|Estimate|||||||2014-11-19|2014-11-21|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism|Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism: A Double-blind, Placebo-controlled, Randomized, Parallel Groups, Multi-center Study.|Withdrawn||Phase 4|0|Actual|University of Miami||2||lack of funding|f||||f||||||||||2018-05-31 23:18:31.616151|2018-05-31 23:18:31.616151
NCT01211691|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2015-11-13|2010-09-28|2010-09-29|Estimate|||||||2015-11-13|2015-11-17|Estimate|September 2010||2010-09-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)|Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies|Suspended||Phase 1/Phase 2|120|Anticipated|Humanigen, Inc.||2||KaloBios to Wind Down Operations|f||||f||||||||||2018-05-31 23:18:32.675119|2018-05-31 23:18:32.675119
NCT01211678|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-06-06|2010-09-28|2010-09-29|Estimate|||||||2014-06-06|2014-06-09|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|BATTER-UP||Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients|Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients (BATTER-UP)|Completed|||301|Actual|Biogen|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma.~   "|||2018-05-31 23:18:32.799087|2018-05-31 23:18:32.799087
NCT01211665|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2014-07-23||2014-08-26|2010-09-28|2010-09-29|Estimate|2014-07-23|2014-08-13|Estimate||||2014-08-26|2014-09-05|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|IRIS||Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)|High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab|Terminated||Phase 4|3|Actual|Biogen||2||This study was stopped prematurely due to lack of enrollment within a 1-5-year period.|f||||||||||||||2018-05-31 23:18:32.919873|2018-05-31 23:18:32.919873
NCT01211652|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2013-01-28|2010-09-28|2010-09-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France|Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France|Completed|||8186|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:18:36.248003|2018-05-31 23:18:36.248003
NCT01211639|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-01-15|2010-09-28|2010-09-29|Estimate|||||||2015-01-15|2015-01-19|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy|Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy|Terminated|||24|Actual|Biogen||||Due to lack of enrollment.|f||||f||||||Samples With DNA|"~     Whole Blood collection for genetic analysis Urine collection for archiving and future~     research use Plasma, Serum, and Peripheral Blood Mononuclear Cells (PBMC) collection for~     archiving and future research use~   "|||2018-05-31 23:18:42.826261|2018-05-31 23:18:42.826261
NCT01211626|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2012-11-12|2010-09-28|2010-09-29|Estimate|||||||2012-11-12|2012-11-14|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study in Healthy Volunteers and Patients With Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANA773 Tosylate|Completed||Phase 1|75|Actual|Hoffmann-La Roche||9|||f||||t||||||||||2018-05-31 23:18:42.892953|2018-05-31 23:18:42.892953
NCT01211613|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2014-11-05||2016-12-01|2010-09-28|2010-09-29|Estimate|2014-11-18|2014-11-24|Estimate||||2016-12-01|2017-01-30|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Interventional|||Chiropractic Manipulation and Medical Care for Low Back Pain|A Comparison of Chiropractic Manipulation Methods and Standard Medical Care for Low Back Pain|Completed||N/A|107|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 23:18:43.086896|2018-05-31 23:18:43.086896
NCT01211600|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-02-04|2010-09-28|2010-09-29|Estimate|||||||2014-02-04|2014-02-06|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|CROSS||Cesarean Trial of Staples vs. Sutures|Cesarean Randomized Control Trial Of Sutures vs. Staples (CROSS)|Unknown status|Active, not recruiting|N/A|936|Anticipated|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 23:18:43.408817|2018-05-31 23:18:43.408817
NCT01211587|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2013-03-28|2010-09-28|2010-09-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|September 2010||2010-09-30|June 2012|2012-06-30||||April 2012|Actual|2012-04-30||Interventional|||A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease|A Double-blind, Randomized, Placebo-controlled, Parallel-group Phase II Study to Explore the Potential Beneficial Effects of Safinamide on Cognition in Non-demented Patients With Idiopathic Parkinson's Disease (PD) and Cognitive Impairment|Completed||Phase 2|103|Actual|Newron Pharmaceuticals SPA||2|||f||||t||||||||||2018-05-31 23:18:43.495251|2018-05-31 23:18:43.495251
NCT01211574|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2012-07-12|2010-09-28|2010-09-29|Estimate|||||||2012-07-12|2012-07-13|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pilot Study Testing Professional, Peer, and Mentor Health Coaches for Weight Loss||Completed||Phase 2/Phase 3|44|Actual|The Miriam Hospital||3|||f||||||||||||||2018-05-31 23:18:43.637873|2018-05-31 23:18:43.637873
NCT01211561|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|December 2010||2010-12-31|September 2010|2010-09-30|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Colon Cancer Prevention Using Selenium||Unknown status|Not yet recruiting|Early Phase 1|50|Anticipated|University of Illinois at Chicago||2|||f||||||||||||||2018-05-31 23:18:43.720849|2018-05-31 23:18:43.720849
NCT01211548|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-03-06|2010-09-28|2010-09-29|Estimate|||||||2017-03-06|2017-03-07|Actual|February 2011||2011-02-28|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|CARE||Coronary CT Angiography in Aneurysms Repaired With Open or Endovascular Approach|Coronary CT Angiography in Aneurysms Repaired With Open or Endovascular Approach|Completed|||40|Actual|The Cleveland Clinic|||1||f||||t||||||||No||2018-05-31 23:18:43.803421|2018-05-31 23:18:43.803421
NCT01211535|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2012-10-15||2012-10-15|2010-09-28|2010-09-29|Estimate|2012-10-15|2012-11-12|Estimate||||2012-10-15|2012-11-12|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers|Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers|Completed||N/A|104|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:18:43.870854|2018-05-31 23:18:43.870854
NCT01211522|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2018-04-23|2010-09-28|2010-09-29|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2011||2011-12-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|MIND-USA||The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study|MIND-USA Study: Modifying the Impact of ICU-Associated Neurological Dysfunction|Recruiting||Phase 3|561|Anticipated|Vanderbilt University Medical Center||3|||f||||t||||||||||2018-05-31 23:18:44.058156|2018-05-31 23:18:44.058156
NCT01211509|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2015-03-04|2010-09-28|2010-09-29|Estimate|||||||2015-03-04|2015-03-05|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MLK002||Montelukast in Bronchiolitis Obliterans Syndrome|A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation|Completed||Phase 4|30|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 23:18:44.291082|2018-05-31 23:18:44.291082
NCT01211483|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28||2015-10-22|2017-11-16|2010-09-28|2010-09-29|Estimate||||2015-10-22|2015-11-16|Estimate|2017-11-16|2017-11-20|Actual|September 2010|Actual|2010-09-30|November 2017|2017-11-30|November 23, 2013|Actual|2013-11-23|October 2013|Actual|2013-10-31||Interventional|||Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer|Randomized, Placebo-controlled, Double-blind Phase 1b/2 Study of U3 1287 (AMG 888) in Combination With Erlotinib in EGFR Treatment Naïve Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Chemotherapy|Completed||Phase 1/Phase 2|222|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 23:18:44.436545|2018-05-31 23:18:44.436545
NCT01211470|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2012-05-16|2010-09-28|2010-09-29|Estimate|||||||2012-05-16|2012-05-17|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus|Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus|Completed||Phase 2|215|Actual|PolyMedix, Inc.||2|||f||||t||||||||||2018-05-31 23:18:44.63009|2018-05-31 23:18:44.63009
NCT01211457|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2014-03-25|2010-09-28|2010-09-29|Estimate|||||||2014-03-25|2014-03-27|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Study of Sapacitabine in Acute Myeloid Leukemia (AML)|A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|Cyclacel Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:18:44.720703|2018-05-31 23:18:44.720703
NCT01211444|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2015-04-14|2010-09-28|2010-09-29|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||US Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea|US Prospective Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea|Completed||Phase 2/Phase 3|20|Anticipated|Apnex Medical, Inc.||1|||f||||t||||||||||2018-05-31 23:18:44.801106|2018-05-31 23:18:44.801106
NCT01211431|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2015-03-24|2010-09-28|2010-09-29|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine|Post-cesarean Pain Control Via Continuous Infusion of Ropivacain et Diclogenac Into the Wound Versus Intathecal Morphine: Comparison of the Quality of Analgesia, Side Effects, and the Incidence of Residual Scar Pain|Withdrawn||Phase 4|0|Actual|Centre Hospitalier Universitaire de Nīmes||2||No inclusions.|f||||f||||||||||2018-05-31 23:18:44.890387|2018-05-31 23:18:44.890387
NCT01211418|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|March 2009||2009-03-31|September 2010|2010-09-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Integrative Meditation (IM) for Cocaine Addiction|Treatment of Cocaine Addiction With Integrative Meditation|Unknown status|Recruiting|N/A|70|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 23:18:44.965201|2018-05-31 23:18:44.965201
NCT01211405|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06||2017-03-24|2017-03-24|2010-09-28|2010-09-29|Estimate||||2017-03-24|2017-03-28|Actual|2017-03-24|2017-03-28|Actual|October 2010||2010-10-31|October 2016|2016-10-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Study Comparing Three Doses of MDMA Along With Psychotherapy in Veterans With Posttraumatic Stress Disorder|Randomized, Triple-Blind, Phase 2 Pilot Study Comparing 3 Different Doses of MDMA in Conjunction With Manualized Psychotherapy in 24 Veterans, Firefighters and Police Officers With Chronic Posttraumatic Stress Disorder (PTSD)|Completed||Phase 2|26|Actual|Multidisciplinary Association for Psychedelic Studies||3|||f||||f||||||||||2018-05-31 23:18:45.075603|2018-05-31 23:18:45.075603
NCT01211392|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-03-29|2010-09-28|2010-09-29|Estimate|||||||2016-03-29|2016-03-30|Estimate|October 2010||2010-10-31|March 2016|2016-03-31||||January 2016|Actual|2016-01-31||Observational|||Detection of Bone Marrow Changes: Comparison of MRI and DECT||Completed|||40|Actual|University of Zurich|||||f||||||||||||||2018-05-31 23:18:45.249584|2018-05-31 23:18:45.249584
NCT01211379|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-25|||2010-10-14|2010-09-28|2010-09-29|Estimate|||||||2010-10-14|2010-10-18|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||The FLU-FOBT Program in Primary Care Settings Where Disparities Persist|The FLU-FOBT Program: Translation of an Evidence-Based Colorectal Cancer Screening Program to Primary Care Settings Where Disparities Persist|Completed||N/A|1372|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:18:45.313133|2018-05-31 23:18:45.313133
NCT01211366|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2012-02-10|2010-09-28|2010-09-29|Estimate|||||||2012-02-10|2012-02-13|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|cell salvage||Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions|Post-operative Infusion of Intra-operative Cell Salvage Reduces Allogeneic Blood Product Transfusions and Volume Resuscitation in Pediatric Cardiac Surgery and Improves Clinical Outcomes|Completed||N/A|106|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 23:18:45.386459|2018-05-31 23:18:45.386459
NCT01211353|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-06-15|2010-09-28|2010-09-29|Estimate|||||||2017-06-15|2017-06-16|Actual|January 2011||2011-01-31|June 2017|2017-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Personalized Drinking Feedback Interventions|Personalized Drinking Feedback Interventions for OEF/OIF Veterans|Completed||N/A|325|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 23:18:45.473733|2018-05-31 23:18:45.473733
NCT01211340|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2015-09-02||2017-04-04|2010-09-28|2010-09-29|Estimate|2017-04-04|2017-06-20|Actual||||2017-04-04|2017-06-20|Actual|September 2010||2010-09-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|April 2014|Actual|2014-04-30||Interventional|||The ACTIVE Intervention to Improve Hospice Care|The ACTIVE Intervention to Improve Hospice Care|Completed||N/A|446|Actual|University of Missouri-Columbia||2|||f||||t||||||||No||2018-05-31 23:18:45.56664|2018-05-31 23:18:45.56664
NCT01211327|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|July 2008||2008-07-31|September 2010|2010-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda|Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial|Completed||Phase 4|366|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:18:45.831957|2018-05-31 23:18:45.831957
NCT01211314|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-06-26|2010-09-28|2010-09-29|Estimate|||||||2016-06-26|2016-06-28|Estimate|January 2011||2011-01-31|August 2011|2011-08-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Antihypertensive Efficacy of Fixed Combination Drug|Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements|Terminated||Phase 4|10|Actual|Meir Medical Center||1||sponsor decision|f||||t||||||||Yes||2018-05-31 23:18:45.982578|2018-05-31 23:18:45.982578
NCT01211288|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-07-19|2010-09-28|2010-09-29|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2010|Actual|2010-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients|Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients|Active, not recruiting|||40|Anticipated|University of Alabama at Birmingham|||2||f||||f||||||||||2018-05-31 23:18:46.131435|2018-05-31 23:18:46.131435
NCT01211275|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2017-02-27|2010-09-28|2010-09-29|Estimate|||||||2017-02-27|2017-02-28|Actual|May 22, 2009|Actual|2009-05-22|February 2017|2017-02-28|May 6, 2013|Actual|2013-05-06|November 13, 2012|Actual|2012-11-13||Interventional|N08CPA||Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma|A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy|Completed||Phase 1/Phase 2|32|Actual|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 23:18:46.18862|2018-05-31 23:18:46.18862
NCT01211262|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2017-03-23|2010-09-28|2010-09-29|Estimate|||||||2017-03-23|2017-03-24|Actual|September 28, 2010|Actual|2010-09-28|March 2017|2017-03-31|February 16, 2017|Actual|2017-02-16|February 16, 2016|Actual|2016-02-16||Interventional|||Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma|A Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma|Completed||Phase 1|84|Actual|Immunocore Ltd||2|||f||||t||||||||||2018-05-31 23:18:46.258504|2018-05-31 23:18:46.258504
NCT01211249|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2011-04-22|2010-09-28|2010-09-29|Estimate|||||||2011-04-22|2011-04-26|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis|Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate|Completed||Phase 2|30|Actual|Galapagos NV||4|||f||||t||||||||||2018-05-31 23:18:46.404541|2018-05-31 23:18:46.404541
NCT01211236|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|February 2006||2006-02-28|September 2010|2010-09-30||||||||Interventional|MAGGOT||Maggot Therapy for Wound Debridement|Maggot Therapy for Wound Debridement: a Randomized Multicentric Double-blind Trial|Completed||Phase 3|120|Actual|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 23:18:46.507756|2018-05-31 23:18:46.507756
NCT01211223|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-06-15|2010-09-28|2010-09-29|Estimate|||||||2016-06-15|2016-06-16|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|March 2014|Actual|2014-03-31|March 2011|Actual|2011-03-31||Interventional|Metro + Amoxi||Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.|Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.|Completed||Phase 4|42|Actual|University of Chile||1|||f||||f||||||||||2018-05-31 23:18:46.572551|2018-05-31 23:18:46.572551
NCT01211210|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2015-05-21|2010-09-28|2010-09-29|Estimate|||||||2015-05-21|2015-05-22|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|June 2020|Anticipated|2020-06-30|June 2017|Anticipated|2017-06-30||Interventional|FOWARC||Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer|A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer|Active, not recruiting||Phase 2/Phase 3|495|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 23:18:46.639356|2018-05-31 23:18:46.639356
NCT01211197|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2015-06-26||2015-07-27|2010-09-28|2010-09-29|Estimate|2015-07-27|2015-08-21|Estimate||||2015-07-27|2015-08-21|Estimate|October 2010||2010-10-31|July 2015|2015-07-31||||December 2010|Actual|2010-12-31||Interventional|||Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability|Relative Bioavailability of a 12.5 mg BI 10773 / 1000 mg Metformin Fixed Dose Combination Tablet Compared With Its Monocomponents and Administered With and Without Food (an Open-label, Randomised, Single-dose, Three-way Crossover, Phase I Trial in Healthy Volunteers)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:18:46.741412|2018-05-31 23:18:46.741412
NCT01211184|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2011-09-12||2016-10-13|2010-09-28|2010-09-29|Estimate|2011-11-08|2011-12-13|Estimate||||2016-10-13|2016-11-25|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Fluid and Nutrition in Elective Hip Surgery|Fluid and Nutrition in Elective Hip Surgery|Completed||N/A|60|Actual|Sodertalje Hospital|A few glucose tolerance tests had to be discarded because of hemolysis in the samples taken for analysis of insulin.|3|||f||||f||||||||Yes|"Results have been published in international journals. Main article is:~Ljunggren S, Hahn RG. Oral nutrition or water loading before hip replacement surgery; a randomized clinical trial. Trials 2012; 13: 97."|2018-05-31 23:18:47.26025|2018-05-31 23:18:47.26025
NCT01211171|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-02-11|2010-09-28|2010-09-29|Estimate|||||||2014-02-11|2014-02-13|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|COUGH||COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland|COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH|Completed|||2498|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:18:47.51358|2018-05-31 23:18:47.51358
NCT01211158|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2011-11-16|2010-09-28|2010-09-29|Estimate|||||||2011-11-16|2011-11-17|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Ketofol vs Propofol for Emergency Department Procedural Sedation and Analgesia|A Randomized Double-blind Trial to Evaluate Ketamine-propofol Combination vs. Propofol Alone for Procedural Sedation and Analgesia in the Emergency Department.|Completed||Phase 3|284|Actual|Lions Gate Hospital||2|||f||||f||||||||||2018-05-31 23:18:47.574531|2018-05-31 23:18:47.574531
NCT01211145|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|2014-10-21||2016-04-18|2010-09-28|2010-09-29|Estimate|2014-10-21|2014-10-24|Estimate||||2016-04-18|2016-05-18|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|TEENZ||Zomig - Treatment of Acute Migraine Headache in Adolescents|A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents|Completed||Phase 4|1653|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:18:47.669575|2018-05-31 23:18:47.669575
NCT01211132|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Interventional|||Cap Assisted Colonoscopy for the Detection of Colon Polyps|Prospective Randomized Controlled Study of Cap Assisted Colonoscopy for the Detection of Colon Polyps|Unknown status|Recruiting|N/A|462|Anticipated|Kansas City Veteran Affairs Medical Center||2|||f||||f||||||||||2018-05-31 23:18:48.357947|2018-05-31 23:18:48.357947
NCT01211119|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2011-04-21|2010-09-27|2010-09-29|Estimate|||||||2011-04-21|2011-04-26|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Novel One-step Repair of Knee Meniscal Tear Using Platelet-rich Fibrin|Novel One-step Repair of Knee Meniscal Tear Using Platelet-rich Fibrin|Unknown status|Enrolling by invitation|N/A|18|Anticipated|Taipei Medical University WanFang Hospital||1|||f||||f||||||||||2018-05-31 23:18:48.504943|2018-05-31 23:18:48.504943
NCT01211106|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2017-01-17||2017-01-17|2010-09-28|2010-09-29|Estimate|2017-01-17|2017-03-09|Actual||||2017-01-17|2017-03-09|Actual|February 2011||2011-02-28|January 2017|2017-01-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Integrated vs Sequential Treatment for PTSD and Addiction|Integrated vs Sequential Treatment for PTSD and Addiction Among OEF/OIF Veterans|Completed||N/A|183|Actual|VA Office of Research and Development|Both arms of the study were active treatments. There was no control conditions.|2|||f||||t||||||||No||2018-05-31 23:18:48.572936|2018-05-31 23:18:48.572936
NCT01211093|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2012-11-26|2010-09-28|2010-09-29|Estimate|||||||2012-11-26|2012-11-28|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|April 2013|Anticipated|2013-04-30||Interventional|||Acute Effects of Whole Body Vibration in Chronic Stroke|The Acute Effects of Whole Body Vibration Training With Different Frequencies on Neuromotor Performance in Individuals With Stroke|Unknown status|Recruiting|N/A|50|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 23:18:48.859806|2018-05-31 23:18:48.859806
NCT01211080|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-11-09|2010-09-28|2010-09-29|Estimate|||||||2014-11-09|2014-11-11|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|PIHS||Off Label Use of Propranolol for Infancy Hemangiomas|Open-label, Uncontrolled Study of the Off Label Use of Propranolol for Infancy Hemangiomas to Identify Side Effects|Completed|||72|Actual|Hannover Medical School|||1||f||||f||||||||||2018-05-31 23:18:48.94445|2018-05-31 23:18:48.94445
NCT01211067|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Study of Histological Findings of the Internal Inguinal Ring in Patients With Indirect Inguinal Hernia|Histological Findings of the Internal Inguinal Ring in Patients With Indirect Inguinal Hernia|Completed|||72|Actual|Cirujanos la Serena|||3||f||||f||||||Samples Without DNA|"~     A 1 cm tissue sample of the internal inguinal ring taken during elective hernioplasty~   "|||2018-05-31 23:18:49.018672|2018-05-31 23:18:49.018672
NCT01211054|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|July 2010||2010-07-31|September 2010|2010-09-30||||||||Observational|||Epidemiologic Analysis for the Prevalence of Chronic Airway Diseases in Old Population|Epidemiologic Analysis for the Prevalence of Chronic Airway Diseases in Old Population in Korea|Unknown status|Active, not recruiting||500|Anticipated|Chonbuk National University|||||f||||||||||||||2018-05-31 23:18:49.083083|2018-05-31 23:18:49.083083
NCT01211041|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2011-04-21|2010-09-28|2010-09-29|Estimate|||||||2011-04-21|2011-04-25|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|July 2011|Anticipated|2011-07-31|||||Observational|||The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia|The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia|Unknown status|Recruiting||100|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:18:49.118156|2018-05-31 23:18:49.118156
NCT01211028|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-05-10|2010-09-28|2010-09-29|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2009||2009-01-31|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|ACELLDREAM||Adipose CELL Derived Regenerative Endothelial Angiogenic Medicine|Safety of Autologous Adipose Derived Stroma/Stem Cells to Treat Critical Leg Ischemia.|Completed||Phase 1/Phase 2|13|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 23:18:49.1695|2018-05-31 23:18:49.1695
NCT01211015|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|July 2010||2010-07-31|September 2010|2010-09-30||||||||Observational|||Endoplasmic Reticulum Stress in Chronic Respiratory Diseases|Endoplasmic Reticulum (ER) Stress in Patients With Various Chronic Pulmonary Diseases|Unknown status|Recruiting||50|Anticipated|Chonbuk National University|||2||f||||||||||Samples With DNA|"~     blood~   "|||2018-05-31 23:18:49.231951|2018-05-31 23:18:49.231951
NCT01211002|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2010-09-28|2010-09-28|2010-09-29|Estimate|||||||2010-09-28|2010-09-29|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)|The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) )|Unknown status|Not yet recruiting|Phase 4|170|Anticipated|Simcere Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 23:18:49.293203|2018-05-31 23:18:49.293203
NCT01210989|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-02-20|2010-09-28|2010-09-29|Estimate|||||||2014-02-20|2014-02-24|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis|A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis|Completed||N/A|60|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:18:49.377645|2018-05-31 23:18:49.377645
NCT01210976|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2011-09-20|2010-09-28|2010-09-29|Estimate|||||||2011-09-20|2011-09-21|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting (CABG) Surgery|The Effects of Levosimendan on Haemodynamics in Patients Undergoing Elective Aortic Valve Replacement (AVR)Together With Coronary Artery Bypass Grafting|Completed||Phase 4|24|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 23:18:49.450068|2018-05-31 23:18:49.450068
NCT01210963|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-03-17|2010-09-28|2010-09-29|Estimate|||||||2011-03-17|2011-03-18|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|09/08||Central Corneal Thickness With SENSIMED Triggerfish|Central Corneal Thickness After Overnight IOP Monitoring With SENSIMED Triggerfish|Completed|||20|Anticipated|Sensimed AG|||1||f||||f||||||||||2018-05-31 23:18:49.514344|2018-05-31 23:18:49.514344
NCT01210950|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-25|||2014-04-24|2010-09-28|2010-09-29|Estimate|||||||2014-04-24|2014-04-28|Estimate|September 2009||2009-09-30|April 2008|2008-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Distraction Osteogenesis in Limb-length Discrepancy With Mesenchymal Cell Transplantation|Autologous Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Distraction Osteogenesis in Patients With Limb-length Discrepancy|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 23:18:49.578345|2018-05-31 23:18:49.578345
NCT01210937|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2012-12-20|2010-09-28|2010-09-29|Estimate|||||||2012-12-20|2012-12-24|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|December 2014|Anticipated|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Early Warning and Optimization Strategy in Carotid Endarterectomy|Early Warning and Optimization Strategy in Carotid Endarterectomy|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 23:18:49.645435|2018-05-31 23:18:49.645435
NCT01210924|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2018-03-28|2010-09-27|2010-09-29|Estimate|||||||2018-03-28|2018-03-30|Actual|April 2010||2010-04-30|November 2013|2013-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CN-PART||Chinese Network of Pediatric Antiretroviral Therapy|Chinese Study of Pediatric Antiretroviral Therapy|Completed|||400|Actual|National Center for AIDS/STD Control and Prevention, China CDC|||1||f||||t||||||Samples With DNA|"~     plamsa, PMBC, whole blood~   "|Undecided||2018-05-31 23:18:49.709156|2018-05-31 23:18:49.709156
NCT01210911|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2014-05-19|2010-09-28|2010-09-29|Estimate|||||||2014-05-19|2014-05-20|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|GEM||Metformin Combined With Chemotherapy for Pancreatic Cancer|A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gemcitabine, Erlotinib and Metformin in Patients With Locally Advanced and Metastatic Pancreatic Cancer|Completed||Phase 2|120|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 23:18:49.759165|2018-05-31 23:18:49.759165
NCT01210898|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2016-11-30|2010-09-28|2010-09-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Immunogenicity and Safety of V70P5 Revaccination Subjects|A Phase IIIB, Observer-Blind, Randomized, Parallel Groups, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of a Sub-unit Adjuvanted or a Non-adjuvanted Influenza Vaccines in Healthy Children Previously Vaccinated in the V70P5 Study|Completed||Phase 3|197|Actual|Novartis||13|||f||||||||||||||2018-05-31 23:18:49.830807|2018-05-31 23:18:49.830807
NCT01210885|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-10-21|2010-09-28|2010-09-29|Estimate|||||||2011-10-21|2011-10-24|Estimate|December 2010||2010-12-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents|Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB Plus MenACWY Formulations|Completed||Phase 2|495|Actual|Novartis||6|||f||||||||||||||2018-05-31 23:18:49.95718|2018-05-31 23:18:49.95718
NCT01210872|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2013-08-06|2010-09-28|2010-09-29|Estimate|||||||2013-08-06|2013-08-07|Estimate|September 2009||2009-09-30|September 2010|2010-09-30||||September 2013|Anticipated|2013-09-30||Observational|||Quality-Of-Life Assessment in Patients With Head and Neck Cancer Treated With Radiation Therapy|Impact of Quality of Life Assessment in Routine Oncology Practice for Head and Neck's Cancer Patients, Treated by Radiotherapy: Impact on the Satisfaction With Care, the Health Related Quality of Life and on the Toxicity|Unknown status|Recruiting||200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:18:50.030238|2018-05-31 23:18:50.030238
NCT01210859|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-28|||2013-09-25|2010-09-28|2010-09-29|Estimate|||||||2013-09-25|2013-09-26|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents|Effects of Antimuscarinic Drugs on OAB Symptoms After Insertion of Ureteral Stents|Withdrawn|||0|Actual|Meir Medical Center|||1||f||||||||||||||2018-05-31 23:18:50.094756|2018-05-31 23:18:50.094756
NCT01210846|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-09-23|2010-09-27|2010-09-29|Estimate|||||||2011-09-23|2011-09-26|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors|An Open-Label Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors|Completed||Phase 1|50|Anticipated|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:18:50.161674|2018-05-31 23:18:50.161674
NCT01210833|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-29|||2018-04-12|2010-09-28|2010-09-29|Estimate|||||||2018-04-12|2018-04-17|Actual|October 2010|Actual|2010-10-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|February 2012|Actual|2012-02-29||Interventional|||Using HandTutor With Traumatic Hand Injuries: Characterizing the System|Using HandTutor With Traumatic Hand Injuries: Characterizing the System|Completed||N/A|30|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 23:18:50.226498|2018-05-31 23:18:50.226498
NCT01210820|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2013-01-22||2013-04-25|2010-09-27|2010-09-29|Estimate|2013-03-14|2013-04-26|Estimate||||2013-04-25|2013-05-01|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Feasibility of iFS™ for Intrastromal Arcuate Keratotomy (ISAK) Procedures|A Prospective Single Center Study To Evaluate the Feasibility of Intrastromal Arcuate Keratotomy Performed With the IntraLase iFS™ Femtosecond Laser System|Completed||N/A|21|Actual|Abbott Medical Optics|This evaluation was performed on a small number of subjects and should be repeated in a larger number of subjects.|2|||f||||f||||||||||2018-05-31 23:18:50.303329|2018-05-31 23:18:50.303329
NCT01210807|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2013-05-15||2015-10-29|2010-09-28|2010-09-29|Estimate|2013-11-20|2013-12-13|Estimate||||2015-10-29|2015-11-02|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||A total of 34 ZMB00 multifocal and 33 ZCB00 monofocal subjects were implanted bilaterally. Data analysis for baseline characteristics was completed on these 67 subjects.|Clinical Evaluation of the One-Piece Tecnis Multifocal Intraocular Lens (IOL)|Clinical Evaluation of the One-Piece Tecnis Multifocal IOL, Model ZMB00|Completed||Phase 4|70|Actual|Abbott Medical Optics||2|||f||||f||||||||||2018-05-31 23:18:50.855586|2018-05-31 23:18:50.855586
NCT01210794|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2012-01-09|2010-09-27|2010-09-28|Estimate|||||||2012-01-09|2012-01-10|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|June 2010||2010-06-30|||||Observational|||The Influence of Different Food Componente on Zinc Absorption in Young Adults Consuming Zinc Fortified Porridges Prepared From Maize, Beans and Sorghum: a Series of Six Similar Randomized, Single-blind Studies||Completed|||90|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 23:18:51.168996|2018-05-31 23:18:51.168996
NCT01210781|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2016-05-27|2010-09-27|2010-09-28|Estimate|||||||2016-05-27|2016-05-30|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation|Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation|Enrolling by invitation|||100|Anticipated|University of Zurich|||||f||||t||||||||||2018-05-31 23:18:51.214951|2018-05-31 23:18:51.214951
NCT01210768|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-02-06|2010-09-27|2010-09-28|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2010||2010-06-30|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients|A Phase II Randomized Study of Pegylated Liposomal Doxorubicin, Cyclophosphamide Versus Epirubicin-Cyclophosphamide as Adjuvant Chemotherapy in Her2-negative Stage I and II Breast Cancer Patients|Recruiting||Phase 2|254|Anticipated|TTY Biopharm||2|||f||||f||||||||||2018-05-31 23:18:51.281423|2018-05-31 23:18:51.281423
NCT01210755|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-06-30|2010-09-27|2010-09-28|Estimate|||||||2011-06-30|2011-07-01|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|REVNEWANTICO||Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics|Reversion of the Anticoagulant Effect of the New Antithrombotic Agents Anti-Xa and Anti IIa by Specific and Non-specific Haemostatic Drugs,: an Ex-Vivo Study in Healthy Volunteers|Completed||Phase 4|10|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 23:18:51.447677|2018-05-31 23:18:51.447677
NCT01210742|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2012-06-15|2010-09-27|2010-09-28|Estimate|||||||2012-06-15|2012-06-18|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|October 2013|Anticipated|2013-10-31|June 2013|Anticipated|2013-06-30||Interventional|EVOKE||The Efficacy of Viscosupplementation for Early Knee Osteoarthritis|The Efficacy of Hylan G-F 20 (Synvisc One) Injections in the Routine Management of Patients With Early Osteoarthritis of the Knee -a Randomised Controlled Trial (Pilot)|Unknown status|Recruiting|N/A|60|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 23:18:51.597813|2018-05-31 23:18:51.597813
NCT01210729|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-12-01|2010-09-27|2010-09-28|Estimate|||||||2011-12-01|2011-12-02|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|ReFlow||Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke|Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke (ReFlow Study)|Completed||Phase 2|40|Anticipated|Saarland University|||||f||||f||||||||||2018-05-31 23:18:51.812576|2018-05-31 23:18:51.812576
NCT01210716|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-26|2012-03-13||2013-09-20|2010-09-27|2010-09-28|Estimate|2013-09-20|2013-09-23|Estimate||||2013-09-20|2013-09-23|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Demographics were reported for the evaluable patient population.|Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device|Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device|Completed||Phase 3|37|Actual|Fenwal, Inc.||2|||f||||f||||||||||2018-05-31 23:18:52.327546|2018-05-31 23:18:52.327546
NCT01210703|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2010-10-14|2010-09-27|2010-09-28|Estimate|||||||2010-10-14|2010-10-15|Estimate|May 2009||2009-05-31|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|APOSAS||Acoustic Pharyngometry in Obstructive Sleep Apnea Syndrome Patients, With Indication of Continuous Positive Air Pressure|Evaluation of Effect of Continuous Positive Air Pressure (CPAP) on Upper Airway Dimensions, by Acoustic Pharyngometry (AP), in Severe Obstructive Sleep Apnea Syndrome (OSAS) and Primary Snore Patients|Unknown status|Active, not recruiting||50|Anticipated|University of Sao Paulo General Hospital|||||f||||f||||||||||2018-05-31 23:18:52.752856|2018-05-31 23:18:52.752856
NCT01210690|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2014-11-11||2014-11-18|2010-09-27|2010-09-28|Estimate|2014-11-18|2014-11-19|Estimate||||2014-11-18|2014-11-19|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational||The Baseline Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication.|Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution|Observational Sentinel Sites Study in Infants Younger Than 12 Months Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution in Usual Clinical Practice|Completed|||101|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 23:18:52.860025|2018-05-31 23:18:52.860025
NCT01210677|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2013-10-29|2010-09-27|2010-09-28|Estimate|||||||2013-10-29|2013-10-30|Estimate|April 2014||2014-04-30|October 2013|2013-10-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|CASTOR||Cardiac Sarcoidosis Response To Steroids Trial|CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial|Withdrawn||Phase 4|0|Actual|Ottawa Heart Institute Research Corporation||2||No funding obtained.|f||||f||||||||||2018-05-31 23:18:53.262247|2018-05-31 23:18:53.262247
NCT01210664|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2016-05-18|2010-09-27|2010-09-28|Estimate|||||||2016-05-18|2016-05-20|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|Treg||T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs|A Phase I Safety Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy for the Treatment of Type 1 Diabetes|Unknown status|Active, not recruiting|Phase 1|14|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 23:18:53.322408|2018-05-31 23:18:53.322408
NCT01210651|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2016-06-07||2016-11-14|2010-09-27|2010-09-28|Estimate|2016-11-14|2017-01-11|Estimate||||2016-11-14|2017-01-11|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||Baseline population comprised of all participants randomized to the 2 intervention groups, regardless of whether participants subsequently began intervention by attending the first assigned session at 0 weeks.|Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial|Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial|Completed||N/A|38|Actual|University of California, San Francisco|Small sample size; not possible to blind participants to intervention; sub-optimal adherence/completion rates, especially in attention control group; however, adherence/completion rates comparable to many exercise-based interventions for depression.|2|||f||||f||||||||Yes|Individual participant data from this clinical trial have been de-identified of any protected health information, and made available for sharing with other researchers. The dataset includes demographic/clinical variables obtained from all randomized participants at screening, as well as primary and secondary outcome measures obtained from participants in both intervention groups over the course of the 8-week intervention period. The dataset is accessible as an Excel file via the following web link: http://prathikanti.com/studydata/|2018-05-31 23:18:53.433846|2018-05-31 23:18:53.433846
NCT01210638|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2018-01-19|2010-09-27|2010-09-28|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2008||2008-06-30|January 2018|2018-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxymorphone Hydrochloride IR 10 mg Tablets, With a Naltrexone Block, Under Fasted Conditions|Completed||Phase 1|42|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 23:18:54.128778|2018-05-31 23:18:54.128778
NCT01210625|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2018-04-11|2010-09-27|2010-09-28|Estimate|||||||2018-04-11|2018-04-12|Actual|July 2010||2010-07-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|NTX||Starch-entrapped Microspheres [Nutrabiotix Fiber] for Gut Health|A Randomized, Double Blind, Controlled, Dose Ranging Trial to Compare Nutrabiotix Fiber to Psyllium Fiber in Patients Experiencing Constipation.|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|Rush University Medical Center||3|||f||||f||||||||||2018-05-31 23:18:54.279925|2018-05-31 23:18:54.279925
NCT01210612|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-12-15|2010-09-27|2010-09-28|Estimate|||||||2010-12-15|2010-12-17|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Effect of Five-Toed Socks on Postural Control Among Active Individuals Who Have Chronic Ankle Instabilities|The Effect of Five-Toed Socks on Postural Control Among Active Individuals Who Have Chronic Ankle Instabilities|Unknown status|Recruiting|N/A|30|Anticipated|University of Toledo Health Science Campus||2|||f||||f||||||||||2018-05-31 23:18:54.364183|2018-05-31 23:18:54.364183
NCT01210599|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2010-10-12|2010-09-27|2010-09-28|Estimate|||||||2010-10-12|2010-10-13|Estimate|April 2004||2004-04-30|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Pilot Trial of IV Pamidronate for Low Back Pain|A Pilot Trial of Intravenous Pamidronate for Low Back Pain|Completed||Phase 1/Phase 2|44|Actual|Pappagallo, Marco, M.D.||1|||f||||t||||||||||2018-05-31 23:18:54.467112|2018-05-31 23:18:54.467112
NCT01210586|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2015-05-26|2010-09-27|2010-09-28|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 1999||1999-01-31|May 2015|2015-05-31|January 2008|Actual|2008-01-31|January 2004|Actual|2004-01-31||Interventional|||Tobacco Cessation in Postmenopausal Women|Tobacco Cessation in Postmenopausal Women - Part I & Part II|Completed||N/A|160|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 23:18:54.534398|2018-05-31 23:18:54.534398
NCT01210573|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2014-12-16|2010-09-27|2010-09-28|Estimate|||||||2014-12-16|2014-12-18|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Prospective Observation of Exercise Parameters in Advanced Heart Failure|Prospective Observation of Exercise Parameters in Advanced Heart Failure|Completed|||20|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||||2018-05-31 23:18:54.606687|2018-05-31 23:18:54.606687
NCT01210560|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21||2012-02-20|2012-02-20|2010-09-27|2010-09-28|Estimate||||2012-02-20|2012-02-23|Estimate|2012-02-20|2012-02-23|Estimate|October 2010||2010-10-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD|A Multi-center, Parallel-group, Randomized, Double-blind, Placebo-masked, Multiple Dose Trial of Modified-release (MR) and Immediate-release (IR) Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Completed||Phase 2|25|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||5|||f||||f||||||||||2018-05-31 23:18:54.673857|2018-05-31 23:18:54.673857
NCT01210547|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2017-11-02|2010-09-27|2010-09-28|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2010||2010-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 2013|Actual|2013-10-31||Observational|||Three-dimensional Assessment of Craniofacial Structures|Assessment of Dental, Skeletal Pattern, and Soft Tissue Using Three-dimensional Images|Terminated|||58|Actual|University of Minnesota - Clinical and Translational Science Institute||||Lack of funding, departure of key personnel|f||||t||||||||||2018-05-31 23:18:54.770431|2018-05-31 23:18:54.770431
NCT01210534|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2017-08-22|2010-09-27|2010-09-28|Estimate|||||||2017-08-22|2017-08-23|Actual|August 2010||2010-08-31|August 2017|2017-08-31|August 2025|Anticipated|2025-08-31|August 2020|Anticipated|2020-08-31||Observational|||Physiological Brain Atlas Development|Physiological Brain Atlas Development|Recruiting|||500|Anticipated|Ohio State University|||||f||||f||||||||||2018-05-31 23:18:54.817335|2018-05-31 23:18:54.817335
NCT01210521|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2016-08-09|2010-09-27|2010-09-28|Estimate|||||||2016-08-09|2016-08-10|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients|Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients|Withdrawn||Phase 2|0|Actual|Florida Atlantic University||2||Sponsor terminated study due to inability to enroll subjects.|f||||t||||||||No|Study withdrwan|2018-05-31 23:18:54.875446|2018-05-31 23:18:54.875446
NCT01210508|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2015-05-22|2010-09-27|2010-09-28|Estimate|||||||2015-05-22|2015-05-25|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Analysis of Tokuhashi Score|A Prospective Analysis of the Tokuhashi Score and Its Effectiveness in Guiding Treatment and Predicting Survival in Patients With Metastases Spread to the Spine|Terminated|||2|Actual|State University of New York - Upstate Medical University||||low enrollment|f||||f||||||||||2018-05-31 23:18:54.933953|2018-05-31 23:18:54.933953
NCT01210495|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2015-03-03|2014-03-04|2018-01-22|2010-09-27|2010-09-28|Estimate|2015-05-11|2015-05-27|Estimate|2014-03-04|2014-04-02|Estimate|2018-01-22|2018-01-23|Actual|December 2010|Actual|2010-12-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|March 2014|Actual|2014-03-31||Interventional||Full analysis set (FAS) included all randomized participants, and participants were classified according to the randomized treatment arm regardless of what treatment, if any, was received.|Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma|A Multicenter, Global, Randomized, Double-blind Study Of Axitinib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced Hepatocellular Carcinoma Following Failure Of One Prior Antiangiogenic Therapy|Terminated||Phase 2|224|Actual|Pfizer||2||Study Terminated by Sponsor|f||||t||||||||||2018-05-31 23:18:56.115752|2018-05-31 23:18:56.115752
NCT01210482|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2017-04-03|2010-09-27|2010-09-28|Estimate|||||||2017-04-03|2017-04-05|Actual|August 2010|Actual|2010-08-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Basis Plan For Postmarketing Survelillances, Etc. Of New Ethical Drugs For Torisel|Active, not recruiting|||600|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 23:19:00.057116|2018-05-31 23:19:00.057116
NCT01210469|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2010-10-05|2010-09-27|2010-09-28|Estimate|||||||2010-10-05|2010-10-06|Estimate|July 2007||2007-07-31|March 2008|2008-03-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Effectiveness of Two Treatments on Posture and Balance in Elderly Women With Osteoporosis|Effectiveness of Two Treatments on Posture and Balance in Elderly Women With Osteoporosis: a Randomized Clinical Trial|Completed||N/A|50|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 23:19:00.135555|2018-05-31 23:19:00.135555
NCT01210456|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-11|||2014-09-13|2010-09-27|2010-09-28|Estimate|||||||2014-09-13|2014-09-16|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|PREKIT||Efficacy Trial of N-Acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-Induced Acute Kidney Injury|The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|Unknown status|Enrolling by invitation|Phase 3|458|Anticipated|Tokushukai Medical Group||2|||f||||f||||||||||2018-05-31 23:19:00.215986|2018-05-31 23:19:00.215986
NCT01210443|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2011-11-10||2011-11-10|2010-09-27|2010-09-28|Estimate|2011-11-10|2011-12-14|Estimate||||2011-11-10|2011-12-14|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients|A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|2|Actual|Pfizer||1||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,~   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2018-05-31 23:19:00.307136|2018-05-31 23:19:00.307136
NCT01210430|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-01-12|2010-09-27|2010-09-28|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2010||2010-07-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Local Vasoconstriction in Postural Tachycardia Syndrome|Local Vasoconstriction in Postural Tachycardia Syndrome|Completed||Early Phase 1|90|Anticipated|New York Medical College||3|||f||||t||||||||||2018-05-31 23:19:00.47488|2018-05-31 23:19:00.47488
NCT01210417|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2012-02-20|2010-09-27|2010-09-28|Estimate|||||||2012-02-20|2012-02-22|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|May 2011|Actual|2011-05-31|||||Observational|THAT||Trauma Heart to Arm Time||Completed|||100|Actual|Niguarda Hospital|||1||f||||t||||||||||2018-05-31 23:19:00.55552|2018-05-31 23:19:00.55552
NCT01210404|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-06-06|2010-09-27|2010-09-28|Estimate|||||||2011-06-06|2011-06-07|Estimate|February 2011||2011-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance|Open Label Single Sequence Study To Estimate The Effect Of Filibuvir (PF-00868554) On S-And R-Methadone In Subjects Receiving Chronic Methadone Treatment And To Evaluate The Pharmacokinetics Of Filibuvir|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:19:00.633845|2018-05-31 23:19:00.633845
NCT01210391|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2014-06-25|2010-09-27|2010-09-28|Estimate|||||||2014-06-25|2014-06-26|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Growth of Infants Fed an Extensively Hydrolyzed Infant Formula|Assessment of Growth of Infants Fed a 100% Whey Extensively Hydrolyzed Formula.|Completed||N/A|282|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 23:19:00.71071|2018-05-31 23:19:00.71071
NCT01210378|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2017-03-27|2010-09-27|2010-09-28|Estimate|||||||2017-03-27|2017-03-28|Actual|December 2011|Actual|2011-12-31|September 2016|2016-09-30|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|Nitroglycerin||Nitroglycerin in Non-small Cell Lung Cancer|Nitroglycerin as a Sensitizer in the Treatment of Non Small Cell Lung Cancer: a Phase II Trial|Completed||Phase 2|47|Actual|Maastricht Radiation Oncology||1|||f||||f||||||||||2018-05-31 23:19:00.797531|2018-05-31 23:19:00.797531
NCT01210365|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-09-15|2010-09-27|2010-09-28|Estimate|||||||2017-09-15|2017-09-18|Actual|January 2011|Actual|2011-01-31|September 2017|2017-09-30|September 2017|Anticipated|2017-09-30|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema|Safety and Efficacy of the Combination of Furosemide 40 mg + Amiloride Hydrochloride 10 mg in the Reduction of Edema of Cardiac Origin in Patients With Congestive Heart Failure Functional Class II (NYHA)|Suspended||Phase 3|60|Anticipated|Eurofarma Laboratorios S.A.||2||The company decided to suspended the study because the investigational product will change.|f||||t||||||||||2018-05-31 23:19:00.920939|2018-05-31 23:19:00.920939
NCT01210352|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2018-01-15|2010-09-27|2010-09-28|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2010||2010-12-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects|An Open-Label, Non-randomized, Multicenter, Ascending Dose by Age, Single- and Multiple-Dose Evaluation of the Effectiveness, Safety, and Tolerability of Oral Liquid Oxymorphone HCl Immediate-Release Oral Liquid for Acute Postoperative Pain in Pediatric Subjects|Active, not recruiting||Phase 3|72|Anticipated|Endo Pharmaceuticals||1|||f||||t||||||||||2018-05-31 23:19:00.988709|2018-05-31 23:19:00.988709
NCT01210339|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-10-06|2010-09-27|2010-09-28|Estimate|||||||2011-10-06|2011-10-07|Estimate|November 2010||2010-11-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel|An Open-label, Randomized, Single-center, 2-way Cross-over Interaction Study, Evaluating the Effect of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg on the Pharmacodynamics and the Pharmacokinetics of Clopidogrel on Days 1 and 9 in Healthy Volunteers|Completed||Phase 1|58|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:19:01.118867|2018-05-31 23:19:01.118867
NCT01210326|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-07-14|2010-09-27|2010-09-28|Estimate|||||||2011-07-14|2011-07-15|Estimate|September 2009||2009-09-30|August 2008|2008-08-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||The Comparison of Diagnostic TESE and TESA in Non-obstructive Azoospermic|The Comparison of Diagnostic Testicular Sperm Extraction(TESE) and Testicular Sperm Aspiration(TESA) in Non-obstructive Azoospermic Patients a Randomized Clinical Trial Study|Completed||Phase 2/Phase 3|180|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 23:19:01.1934|2018-05-31 23:19:01.1934
NCT01210313|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2014-03-06|2010-09-27|2010-09-28|Estimate|||||||2014-03-06|2014-03-07|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma|Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma|Completed|||30|Actual|Austrian Breast & Colorectal Cancer Study Group|||1||f||||f||||||||||2018-05-31 23:19:01.273822|2018-05-31 23:19:01.273822
NCT01210300|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-26|||2011-04-22|2010-09-27|2010-09-28|Estimate|||||||2011-04-22|2011-04-26|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|September 2010|Actual|2010-09-30|||||Observational|||Exploring Taiwanese Womens' Decision-making Regarding Vaginal Birth After Caesarean Section|Exploring Taiwanese Womens' Decision-making Regarding Vaginal Birth After Caesarean Section|Completed|||40|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:19:01.367968|2018-05-31 23:19:01.367968
NCT01210287|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2014-01-07|2010-09-27|2010-09-28|Estimate|||||||2014-01-07|2014-01-08|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|IHBVRL||Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP|Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|110|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 23:19:01.422015|2018-05-31 23:19:01.422015
NCT01208350|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2014-09-04|2010-09-22|2010-09-23|Estimate|||||||2014-09-04|2014-09-08|Estimate|March 2011||2011-03-31|September 2012|2012-09-30|August 2014|Actual|2014-08-31|January 2012|Actual|2012-01-31||Interventional|||Testing Strategies to Encourage Weight Loss in an Employer Setting|Testing Strategies to Encourage Weight Loss in an Employer Setting|Completed||N/A|105|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 23:19:29.797029|2018-05-31 23:19:29.797029
NCT01210274|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2017-08-22|2010-09-27|2010-09-28|Estimate|||||||2017-08-22|2017-08-23|Actual|September 2010||2010-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2014|Actual|2014-09-30||Observational|||Characterization of the Mechanisms of Resistance to Azacitidine|Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia|Recruiting|||90|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||Samples With DNA|"~     bone marrow samples~   "|||2018-05-31 23:19:01.490049|2018-05-31 23:19:01.490049
NCT01210261|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2012-04-03|2010-09-26|2010-09-28|Estimate|||||||2012-04-03|2012-04-05|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|APAP||New Versus Existing Auto-titrating CPAP Device to Treat Obstructive Sleep Apnea in Adults|New Versus Existing Auto-titrating CPAP Device to Treat Obstructive Sleep Apnea in Adults: Randomised Non-inferiority Double Blinded Trial.|Completed||N/A|30|Actual|Compumedics Limited||2|||f||||t||||||||||2018-05-31 23:19:01.560594|2018-05-31 23:19:01.560594
NCT01210248|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-26|||2010-09-27|2010-09-27|2010-09-28|Estimate|||||||2010-09-27|2010-09-28|Estimate|September 2010||2010-09-30|May 2010|2010-05-31||||January 2012||2012-01-31||Observational|||Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status||Unknown status|Recruiting||500|Anticipated|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-05-31 23:19:01.630716|2018-05-31 23:19:01.630716
NCT01210235|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-25|||2015-03-05|2010-09-27|2010-09-28|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||FLU-FIT Program at Kaiser Permanente Northern California|FLU-FIT Program at Kaiser Permanente Northern California|Completed||N/A|7465|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:19:01.684493|2018-05-31 23:19:01.684493
NCT01210222|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-25|2017-10-30||2018-01-26|2010-09-25|2010-09-28|Estimate|2017-10-30|2017-11-29|Actual||||2018-01-26|2018-02-23|Actual|June 6, 2011|Actual|2011-06-06|August 2017|2017-08-31|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Interventional||Eligible and evaluable patients|Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer|A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium|Completed||Phase 2|35|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 23:19:01.782845|2018-05-31 23:19:01.782845
NCT01210209|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-25|||2013-08-23|2010-09-27|2010-09-28|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2009||2009-09-30|September 2010|2010-09-30||||September 2011|Anticipated|2011-09-30||Observational|||Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives|GENEWING - A Genome Wide Association Study in Ewing Sarcoma|Unknown status|Recruiting||600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:19:02.582574|2018-05-31 23:19:02.582574
NCT01210196|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-25|||2014-03-25|2010-09-27|2010-09-28|Estimate|||||||2014-03-25|2014-03-26|Estimate|October 2010||2010-10-31|March 2014|2014-03-31||||September 2013|Actual|2013-09-30||Observational|SOPHIA||Sophisticated Assessment of Disease Burden in Patients With Fabry Disease|Sophisticated Assessment of Disease Burden in Patients With Fabry Disease - The SOPHIA in Fabry Disease Study|Completed|||36|Actual|Shire|||1||f||||t||||||||||2018-05-31 23:19:02.667724|2018-05-31 23:19:02.667724
NCT01210183|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2014-05-19|2010-09-27|2010-09-28|Estimate|||||||2014-05-19|2014-05-20|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose|Biological Response of Stage IV Knee Osteoarthritis to Serial 12.5% Dextrose Injections Without Weight Bearing Restriction: A Double Arthroscopic Assessment|Completed||Phase 2/Phase 3|6|Actual|Universidad Nacional de Rosario|||||f||||t||||||||||2018-05-31 23:19:02.855171|2018-05-31 23:19:02.855171
NCT01210170|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2014-09-05||2017-10-20|2010-09-27|2010-09-28|Estimate|2014-11-17|2014-11-19|Estimate||||2017-10-20|2017-11-21|Actual|October 2010||2010-10-31|October 2017|2017-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma|Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma|Completed||N/A|22|Actual|University of Miami||9|||f||||f||||||||||2018-05-31 23:19:02.991745|2018-05-31 23:19:02.991745
NCT01210157|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-09-27|2010-09-27|2010-09-28|Estimate|||||||2010-09-27|2010-09-28|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|September 2008|Actual|2008-09-30||Observational|GALACTIC||Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart Failure|GALectin-3 Binding Protein for Risk Assessment in Coronary arTery dIsease and Chronic Heart Failure|Completed|||373|Actual|Heidelberg University|||2||f||||f||||||Samples Without DNA|"~     Serum, plasma~   "|||2018-05-31 23:19:03.370831|2018-05-31 23:19:03.370831
NCT01210144|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2012-08-30||2013-12-02|2010-09-27|2010-09-28|Estimate|2012-11-07|2012-11-14|Estimate||||2013-12-02|2013-12-27|Estimate|August 2008||2008-08-31|December 2013|2013-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|EXPRESS||EXpression PRofile Endometrium Samples Study|Open Label Pilot Study on Gene Expression Profiling of the Endometrial Tissue in Patients Undergoing Assisted Reproductive Technology [ART: In Vitro Fertilization (IVF)/ Intracytoplasmic Sperm Injection (ICSI)] With GONAL-f®|Terminated||Phase 4|27|Actual|Merck KGaA|Gene expression of the endometrium could not be analyzed due to poor quality of biopsy samples (poor mRNA quality) and poor recruitment in the study.|2||Study terminated due to recruitment failure|f||||f||||||||||2018-05-31 23:19:03.474869|2018-05-31 23:19:03.474869
NCT01210131|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-08-26|2010-09-27|2010-09-28|Estimate|||||||2013-08-26|2013-08-27|Estimate|July 2013||2013-07-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|January 2014|Anticipated|2014-01-31||Interventional|HX4 in SCLC||Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)|Individualized Hypoxia-guided Radiotherapy Combined With Standard Cisplatin-etoposide in Stage I-III SCLC|Withdrawn||N/A|0|Actual|Maastricht Radiation Oncology||1|||f||||f||||||||||2018-05-31 23:19:03.802852|2018-05-31 23:19:03.802852
NCT01210118|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2013-01-23||2013-04-07|2010-09-25|2010-09-28|Estimate|2013-04-07|2013-04-09|Estimate||||2013-04-07|2013-04-09|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Interventions of Smoking Cessation During Pregnancy|The Effectiveness of High and Low Intensity Intervention for Smoking Cessation During Pregnancy|Completed||Phase 1|92|Actual|Hellenic Anticancer Society||2|||f||||t||||||||||2018-05-31 23:19:03.897101|2018-05-31 23:19:03.897101
NCT01210105|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-09-21|2010-09-27|2010-09-28|Estimate|||||||2011-09-21|2011-09-22|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Observational|||Ice-pick Intubation With Video Laryngoscopes in a Manikin With Restricted Access to the Airway|Comparison of Different Video Laryngoscopes in Ice-pick Position in an Manikin With Restricted Access to the Airway|Completed|||25|Anticipated|University of Cologne|||6||f||||f||||||||||2018-05-31 23:19:04.139161|2018-05-31 23:19:04.139161
NCT01210092|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2011-09-21|2010-09-27|2010-09-28|Estimate|||||||2011-09-21|2011-09-22|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Observational|||Comparison of Different Video Laryngoscopes in a Manikin With Immobilized Cervical Spine|Comparison of Different Video Laryngoscopes in a Manikin With Immobilized Cervical Spine|Completed|||25|Anticipated|University of Cologne|||6||f||||f||||||||||2018-05-31 23:19:04.193343|2018-05-31 23:19:04.193343
NCT01210079|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2011-12-05||2012-03-11|2010-09-27|2010-09-28|Estimate|2012-03-11|2012-04-06|Estimate||||2012-03-11|2012-04-06|Estimate|September 2002||2002-09-30|February 2012|2012-02-29|May 2010|Actual|2010-05-31|March 2008|Actual|2008-03-31||Interventional|||Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?|Hyperalgesia in Methadone-Maintained Patients: Can it be Treated?|Completed||Phase 2|26|Actual|University of California, Los Angeles|Baseline hyperalgesia not established. Duration of trial only 5 weeks. Findings can only be generalized to methadone-maintained patients who are able to abstain from illicit drug use over an extended period of time.|2|||f||||f||||||||||2018-05-31 23:19:04.256609|2018-05-31 23:19:04.256609
NCT01210066|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2016-12-27|2010-09-27|2010-09-28|Estimate|||||||2016-12-27|2016-12-29|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pain, Opioids and Pro-Inflammatory Immune Responses|Pain, Opioids and Pro-Inflammatory Immune Responses|Terminated||Phase 1|21|Actual|University of California, Los Angeles||3||"Unable to recruit prescription opioid abusers; ultimately no potential POA recruit passed the~   pre-screening process"|f||||t||||||||||2018-05-31 23:19:04.447896|2018-05-31 23:19:04.447896
NCT01210053|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2010-09-27|2010-09-27|2010-09-28|Estimate|||||||2010-09-27|2010-09-28|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|March 2012|Anticipated|2012-03-31|November 2011|Anticipated|2011-11-30||Interventional|||Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|This Phase II Trial is Studying Sunitinib to See How Well it Works When Given as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer Which is Previously Treated With Combination Chemotherapy.|Unknown status|Recruiting|Phase 2|30|Anticipated|Third Military Medical University||1|||f||||t||||||||||2018-05-31 23:19:04.514139|2018-05-31 23:19:04.514139
NCT01210040|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2014-03-18|2010-09-27|2010-09-28|Estimate|||||||2014-03-18|2014-03-19|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|PALUFER||Long-term Iron Supplements and Malaria Risk in Early Pregnancy: a Randomized Controlled Trial|Malaria Risk Prior to and During Early Pregnancy in Nulliparous Women Receiving Long-term Weekly Iron and Folic Acid Supplementation (WIFS): a Non-inferiority Randomized Controlled Trial|Completed||N/A|1959|Actual|Liverpool School of Tropical Medicine||2|||f||||t||||||||||2018-05-31 23:19:04.731064|2018-05-31 23:19:04.731064
NCT01210027|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2017-11-03|2010-09-27|2010-09-28|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2006||2006-11-30|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|||A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion|A Pilot Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion|Recruiting|||140|Anticipated|University of Michigan Cancer Center|||||f||||t||||||||||2018-05-31 23:19:04.807522|2018-05-31 23:19:04.807522
NCT01210014|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-27|2010-09-27|2010-09-28|Estimate|||||||2010-09-27|2010-09-28|Estimate|April 2008||2008-04-30|September 2010|2010-09-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Systemic Zinc Sulphate in Treatment of Recurrent Aphthous Ulcerations:A Doubleblind, Placebo Controled Study|Zinc Sulphate in Treatment of Recurrent Aphthous Stomatitis|Completed||Phase 2|14|Actual|Qazvin University Of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:19:04.864003|2018-05-31 23:19:04.864003
NCT01210001|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|2014-05-16||2014-05-16|2010-09-27|2010-09-28|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|September 2010||2010-09-30|May 2014|2014-05-31||||April 2012|Actual|2012-04-30||Interventional||Treated set (TS): all patients treated with at least one dose of randomised study medication|Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin|A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Trial of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite a Background Therapy of Pioglitazone Alone or in Combination With Metformin|Completed||Phase 3|499|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:19:04.972124|2018-05-31 23:19:04.972124
NCT01209988|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-27|||2010-09-27|2010-09-27|2010-09-28|Estimate|||||||2010-09-27|2010-09-28|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy|A Prospective Randomized Study Examining the Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-Assisted Laparoscopic Radical Prostatectomy|Unknown status|Recruiting|N/A|220|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:19:05.618244|2018-05-31 23:19:05.618244
NCT01209975|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-09-27|2010-09-27|2010-09-28|Estimate|||||||2010-09-27|2010-09-28|Estimate|November 2008||2008-11-30|September 2010|2010-09-30||||November 2011|Anticipated|2011-11-30||Observational|||Retinal Vascular Reactivity in Subjects With Newly Diagnosed Glaucoma Before and After Selective Laser Trabeculoplasty|Retinal Vascular Reactivity in Response to Isoxic Hypercapnia in Subjects With Newly Diagnosed Glaucoma|Unknown status|Recruiting||12|Anticipated|University of Toronto|||1||f||||f||||||||||2018-05-31 23:19:05.705947|2018-05-31 23:19:05.705947
NCT01209962|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2017-07-03|2010-09-24|2010-09-27|Estimate|||||||2017-07-03|2017-07-05|Actual|May 2008||2008-05-31|July 2017|2017-07-31|May 26, 2015|Actual|2015-05-26|May 26, 2015|Actual|2015-05-26||Observational|||A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response|A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response|Completed|||20|Actual|University of Michigan Cancer Center|||1||f||||t||||||||||2018-05-31 23:19:05.782982|2018-05-31 23:19:05.782982
NCT01209949|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2011-12-13||2012-01-18|2010-09-24|2010-09-27|Estimate|2012-01-18|2012-01-19|Estimate||||2012-01-18|2012-01-19|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris|Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris|Completed||Phase 4|30|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 23:19:05.850684|2018-05-31 23:19:05.850684
NCT01209936|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2017-03-30|2010-09-24|2010-09-27|Estimate|||||||2017-03-30|2017-04-04|Actual|September 2009||2009-09-30|March 2017|2017-03-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Hydration Factor Study for the Stayhealthy BC3|Pilot Study for the Validation of the BC3 Bioelectrical Impedance Hydration Factor|Completed||N/A|15|Actual|University of Southern California||1|||f||||f|f|f||||||No||2018-05-31 23:19:05.995605|2018-05-31 23:19:05.995605
NCT01209910|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-08-06|2010-09-24|2010-09-27|Estimate|||||||2013-08-06|2013-08-09|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Free Water Protocol on Inpatients in a Neurological Rehabilitation Setting|Effects of Free Water Protocol on Inpatients in a Neurological Rehabilitation Setting|Completed||N/A|30|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 23:19:06.135602|2018-05-31 23:19:06.135602
NCT01209897|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2012-12-11|2010-09-24|2010-09-27|Estimate|||||||2012-12-11|2012-12-13|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Stage Models||Testing Different Theories of Smoking Cessation: An Intervention Study|Testing Alternative Stage Models of Smoking Cessation: An Intervention Study|Completed||Phase 2|1826|Anticipated|University of Hawaii||3|||f||||t||||||||||2018-05-31 23:19:06.201399|2018-05-31 23:19:06.201399
NCT01209884|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2014-01-07|2010-09-24|2010-09-27|Estimate|||||||2014-01-07|2014-01-09|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|Metabolomics||Metabolomics of Aging: Sub-study of the Healthy Elderly Active Longevity (HEAL) Study|Metabolomics of Aging: Sub-study of the Healthy Elderly Active Longevity (HEAL) Cohort|Completed|||14|Actual|Scripps Translational Science Institute|||1||f||||f||||||Samples Without DNA|"~     Blood sample will be collected from each subject after informed consent is obtained~      Blood collection~      Approximately 10mL of blood will be collected. The blood will be collected for the purpose of~     isolating plasma, as follows:~      1 X 10mls Sodium (Na) Heparin tube~      Blood will be drawn by hospital/clinic phlebotomy services, a nurse or a medical assistant.~     Blood will be collected from each subject one time.~      Once aliquoted, the plasma will be catalogued in a central registry (LIMS database) and then~     stored. Metabolite extraction and protein precipitation will be performed to remove proteins~     and extract the maximum number of metabolites. The samples will be maintained at 4 degrees~     Celcius in the autosampler and then analyzed.~   "|||2018-05-31 23:19:06.26324|2018-05-31 23:19:06.26324
NCT01209871|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2018-05-29|2010-09-24|2010-09-27|Estimate|||||||2018-05-29|2018-05-30|Actual|February 26, 2015|Actual|2015-02-26|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma|Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma With DNA Vaccines Encoding Antigen-Chemokine Fusion|Active, not recruiting||Phase 1|9|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 23:19:06.317378|2018-05-31 23:19:06.317378
NCT01209858|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2013-05-15|2010-09-24|2010-09-27|Estimate|||||||2013-05-15|2013-05-17|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects|A Open-label Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects|Completed||Phase 1|48|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:19:06.387132|2018-05-31 23:19:06.387132
NCT01209845|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-06-12|2010-09-24|2010-09-27|Estimate|||||||2012-06-12|2012-06-13|Estimate|April 2010||2010-04-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Ketamine for Low Mood States in the ER|Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients|Completed||N/A|14|Actual|Yale University|||||f||||f||||||||||2018-05-31 23:19:06.456178|2018-05-31 23:19:06.456178
NCT01209832|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2011-04-12|2010-09-23|2010-09-27|Estimate|||||||2011-04-12|2011-04-14|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients|The Effect of Tasisulam on CYP3A-mediated Metabolism of Midazolam: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Tumors or Lymphoma|Terminated||Phase 1|10|Actual|Eli Lilly and Company||1||Terminated based on safety results from another trial|f||||f||||||||||2018-05-31 23:19:06.514029|2018-05-31 23:19:06.514029
NCT01209819|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2015-06-11|2010-09-24|2010-09-27|Estimate|||||||2015-06-11|2015-06-12|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Bone Mineral Density in Adults With Hyperphenylalaninemia|Bone Mineral Density in Adults With Hyperphenylalaninemia|Completed|||28|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-05-31 23:19:06.580842|2018-05-31 23:19:06.580842
NCT01209806|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2014-12-05|2010-09-24|2010-09-27|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2009||2009-11-30|November 2014|2014-11-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||The Effects of Moviprep With Simethicone on Colonic Bubbles|The Effects of Moviprep With Simethicone on Colonic Bubbles|Completed||N/A|140|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 23:19:06.63365|2018-05-31 23:19:06.63365
NCT01209793|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2012-05-31|2010-09-24|2010-09-27|Estimate|||||||2012-05-31|2012-06-01|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety and Tolerability of Intravenously Administered REGN846 (SAR302352) in Healthy Volunteers|Completed||Phase 1|40|Actual|Regeneron Pharmaceuticals||5|||f||||t||||||||||2018-05-31 23:19:06.702617|2018-05-31 23:19:06.702617
NCT01209780|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2013-12-10|2011-12-13|2014-02-07|2010-09-24|2010-09-27|Estimate|2014-02-07|2014-03-11|Estimate|2011-12-13|2011-12-22|Estimate|2014-02-07|2014-03-11|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional||Demography reported for all enrolled set except for 312 subjects (3-8 year olds) who were enrolled in the Mexico site.|Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age|A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age|Completed||Phase 3|3116|Actual|Novartis|Due to GCP non-compliance at the Mexico site, data of 312 subjects (3-8 year olds) enrolled from this site were excluded from the final immunogenicity and safety analysis.|4|||f||||||||||||||2018-05-31 23:19:06.78337|2018-05-31 23:19:06.78337
NCT01209767|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2013-09-03||2013-12-17|2010-09-24|2010-09-27|Estimate|2013-12-17|2014-02-03|Estimate||||2013-12-17|2014-02-03|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Cryolipolysis and Subcision for Treatment of Cellulite|Comparison of the Efficacy Between Cryolipolysis and Subcision for Treatment of Cellulite: A Prospective Randomized Control Trial.|Completed||N/A|22|Actual|Northwestern University||3|||f||||f||||||||||2018-05-31 23:19:07.558985|2018-05-31 23:19:07.558985
NCT01209754|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-08-28|2010-09-24|2010-09-27|Estimate|||||||2017-08-28|2017-08-30|Actual|October 2009||2009-10-31|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|EMBRACE||EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)|HIV Prevention Agent Pregnancy Exposure Registry: EMBRACE Study|Recruiting|||950|Anticipated|Microbicide Trials Network|||2||f||||t||||||||||2018-05-31 23:19:07.794614|2018-05-31 23:19:07.794614
NCT01209741|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2015-08-17|2010-09-24|2010-09-27|Estimate|||||||2015-08-17|2015-08-18|Estimate|October 2007||2007-10-31|August 2015|2015-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)|An Open Label, Randomized, 3-Period Crossover Study to Evaluate the Comparative Bioavailability of Variably Aged MK-0974 Capsules Administered Orally as Single Doses in Healthy Male and Female Subjects|Completed||Phase 1|48|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-05-31 23:19:07.889734|2018-05-31 23:19:07.889734
NCT01209728|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2015-04-09|2010-09-24|2010-09-27|Estimate|||||||2015-04-09|2015-04-10|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Insomnia on Simulated Driving (MK-0000-183-00)|A Randomized Clinical Trial to Study the Effects of Simulated Driving on Primary Insomniacs|Completed||Phase 1|76|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 23:19:07.954083|2018-05-31 23:19:07.954083
NCT01209715|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2014-07-31|2010-09-24|2010-09-27|Estimate|||||||2014-07-31|2014-08-01|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD|Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD|Withdrawn||Phase 2|0|Actual|University of Miami||2||"Due to the ubiquitous use of ICS in the treatment of COPD in 2012, it was hard to find the~   study population."|f||||f||||||||||2018-05-31 23:19:08.076793|2018-05-31 23:19:08.076793
NCT01209702|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2012-11-26||2013-01-10|2010-09-24|2010-09-27|Estimate|2013-01-10|2013-02-11|Estimate||||2013-01-10|2013-02-11|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs|A Ph II/III Seamless, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Reduction in Signs and Symptoms and Inhibition of Structural Damage During Treatment With Tocilizumab Versus Placebo in Patients With Ankylosing Spondylitis Who Have Failed Non-steroidal Anti-inflammatory Drugs and Are naïve to TNF Antagonist Therapy NSAIDs|Terminated||Phase 3|306|Actual|Hoffmann-La Roche||5||Recruitment halted: Failed to achieve efficacy|f||||||||||||||2018-05-31 23:19:08.172794|2018-05-31 23:19:08.172794
NCT01209689|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2012-12-11||2012-12-11|2010-09-24|2010-09-27|Estimate|2012-12-11|2013-01-17|Estimate||||2012-12-11|2013-01-17|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy|A Randomized, Double-blind, Parallel Group Placebo-controlled Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab (TCZ) Versus Placebo in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous TNF Antagonist Therapy|Terminated||Phase 3|113|Actual|Hoffmann-La Roche||3||Clinical development program terminated due to failure to achieve efficacy|f||||||||||||||2018-05-31 23:19:08.895722|2018-05-31 23:19:08.895722
NCT01209676|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2016-11-11|2010-09-24|2010-09-27|Estimate|||||||2016-11-11|2016-11-15|Estimate|September 2010||2010-09-30|November 2016|2016-11-30||||March 2013|Actual|2013-03-31||Interventional|||IMCgp100 in Advanced Unresectable Melanoma|A Phase 0, Exploratory Study of the Pharmacodynamics of a Single Intratumoral Dose of IMCgp100, a Monoclonal Receptor Anti-CD3 scFv Fusion Protein, in Subjects With Advanced Unresectable Melanoma|Completed||Early Phase 1|1|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 23:19:09.265329|2018-05-31 23:19:09.265329
NCT01209663|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2015-06-23|2010-09-24|2010-09-27|Estimate|||||||2015-06-23|2015-06-24|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|InCare||Intermediate Care - Effect on Mortality Following Emergency Abdominal Surgery|Intermediate Care - Effect on Mortality Following Emergency Abdominal Surgery|Terminated||N/A|286|Actual|Copenhagen University Hospital at Herlev||2||30th November 2012. Please see breif summary.|f||||t||||||||||2018-05-31 23:19:09.328914|2018-05-31 23:19:09.328914
NCT01209650|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2016-11-09|2010-09-24|2010-09-27|Estimate|||||||2016-11-09|2016-11-10|Estimate||||November 2016|2016-11-30||||||||Expanded Access|||LUX Lung Special Access Scheme Australia Named Patient Use (NPU)|Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment|Approved for marketing|||||Boehringer Ingelheim|||||f||||||||||||||2018-05-31 23:19:09.404905|2018-05-31 23:19:09.404905
NCT01209637|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2016-10-25|2010-09-24|2010-09-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CAD|Impact of Intensive Exercise Training Compared to Inactive Controls on Coronary Collateral Circulation and Plaque Composition in Patients With Significant Stable Coronary Artery Disease|Completed||N/A|60|Actual|University of Leipzig||3|||f||||f||||||||||2018-05-31 23:19:09.599865|2018-05-31 23:19:09.599865
NCT01209624|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2010-09-29||2011-07-07|2010-09-24|2010-09-27|Estimate|2010-09-29|2010-10-26|Estimate||||2011-07-07|2011-07-12|Estimate|August 2006||2006-08-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|NTG-X-PERT||Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma|Prospective, Observational Study to Investigate the Long-term Effect of Xalatan® on Intraocular Pressure (IOP) and on Maintenance of Visual Field in Patients With Normal Tension Glaucoma (NTG)|Completed|||902|Actual|Pfizer|Outcome measures for this observational non-interventional study were not designated as primary or secondary measures.||||f||||f||||||||||2018-05-31 23:19:09.728971|2018-05-31 23:19:09.728971
NCT01209611|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-04-21|2010-09-24|2010-09-27|Estimate|||||||2014-04-21|2014-04-22|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|October 2013|Actual|2013-10-31||Interventional|||Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in Accelerating Tissue Expansion and Skin Regeneration|Phase 1/2 Study of Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in Accelerating Soft Tissue Expansion|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 23:19:10.317426|2018-05-31 23:19:10.317426
NCT01209598|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|2017-09-08||2017-10-05|2010-09-24|2010-09-27|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|September 23, 2010|Actual|2010-09-23|February 2017|2017-02-28|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|||PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma|A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma|Completed||Phase 2|90|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-05-31 23:19:10.444527|2018-05-31 23:19:10.444527
NCT01209585|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2013-07-23|2010-09-24|2010-09-27|Estimate|||||||2013-07-23|2013-07-25|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Observational|||A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis|Study to Evaluate Biomarkers in Blood and Synovial Fluid in Subjects With Rheumatoid Arthritis|Completed|||23|Actual|MedImmune LLC|||3||f||||f||||||||||2018-05-31 23:19:10.772512|2018-05-31 23:19:10.772512
NCT01209572|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2010-09-24|2010-09-24|2010-09-27|Estimate|||||||2010-09-24|2010-09-27|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|November 2009|Actual|2009-11-30||Interventional|Modelheart||Modelling of Energy Expenditure From Heart Rate, Accelerometry and Other Physiological Parameters|Modelling of 24h Energy Expenditure From Heart Rate, Actimetry and Other Parameters Recorded Under Free-living Conditions|Completed||N/A|120|Actual|Institut National de la Recherche Agronomique||2|||f||||t||||||||||2018-05-31 23:19:10.851068|2018-05-31 23:19:10.851068
NCT01209559|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-01-30|2010-09-24|2010-09-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2011||2011-01-31|January 2017|2017-01-31||||January 2011|Actual|2011-01-31||Observational|||A Comparative Study of the Air-Q ILA and the ILMA for Ventilation and Intubation||Suspended|||60|Anticipated|Nova Scotia Health Authority|||2|Study never initiated.|f||||||||||||||2018-05-31 23:19:10.927807|2018-05-31 23:19:10.927807
NCT01209546|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2012-06-26|2010-09-24|2010-09-27|Estimate|||||||2012-06-26|2012-06-28|Estimate|July 2007||2007-07-31|September 2010|2010-09-30|December 2010|Actual|2010-12-31|January 2008|Actual|2008-01-31||Interventional|FLUTTER®VRP1||Study of the Effect of FLUTTER® VRP1 (PEP and Oscillating High Frequency).|Study of the Effect of FLUTTER VRP1 in Patients With Bronchiectasis.|Terminated||Phase 1|30|Actual|University of Sao Paulo||4||The protocol finished.|f||||t||||||||||2018-05-31 23:19:10.984132|2018-05-31 23:19:10.984132
NCT01209533|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2011-08-01|2010-09-23|2010-09-27|Estimate|||||||2011-08-01|2011-08-03|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Inhaled Iloprost in Mild Asthma|Inhaled Iloprost in Mild Asthma|Completed||Early Phase 1|24|Anticipated|Vanderbilt University|||||f||||t||||||||||2018-05-31 23:19:11.083968|2018-05-31 23:19:11.083968
NCT01209520|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2015-01-09||2015-02-05|2010-09-23|2010-09-27|Estimate|2015-02-05|2015-02-24|Estimate||||2015-02-05|2015-02-24|Estimate|July 2009||2009-07-31|February 2015|2015-02-28||||December 2013|Actual|2013-12-31||Interventional|||Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy|Pilot Study Targeting Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer As Part of Adjuvant Therapy and Preventive Strategy|Completed||N/A|6|Actual|University of Miami|Study data were not analyzed due to insufficient number of evaluable patients.|1|||f||||t||||||||||2018-05-31 23:19:11.16873|2018-05-31 23:19:11.16873
NCT01209507|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-03-23|2010-09-24|2010-09-27|Estimate|||||||2017-03-23|2017-03-24|Actual|February 2010|Actual|2010-02-28|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy|A Prevalence Study of Adrenal Suppression After Adjuvant Corticosteroid Administration During Gynecologic Cancer Chemotherapy|Completed|||19|Actual|University of Colorado, Denver|||2||f||||f||||||||No||2018-05-31 23:19:11.363389|2018-05-31 23:19:11.363389
NCT01209494|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2015-12-01|2010-09-24|2010-09-27|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Observational|EUTrigTreat||An Arrhythmia Risk Stratification and Genetic Trial|The EU TrigTreat Clinical Study: An Advanced Diagnostics and Observational Trial for Arrhythmia Risk Stratification and Correlation With Genotype|Completed|||672|Actual|University Medical Center Goettingen|||2||f||||t||||||Samples With DNA|"~     Whole blood specimens for genetic analyses~   "|||2018-05-31 23:19:11.430633|2018-05-31 23:19:11.430633
NCT01209481|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-09-24|2010-09-24|2010-09-27|Estimate|||||||2010-09-24|2010-09-27|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|March 2012|Anticipated|2012-03-31|January 2011|Anticipated|2011-01-31||Interventional|fvphc||Impact of Educational Group Intervention on the Consumption of Fruit and Vegetables|Impact of Educational Group Intervention on the Consumption of Fruit and Vegetables by Adult People Attended to Primary Health Care.|Unknown status|Not yet recruiting|N/A|80|Anticipated|UPECLIN HC FM Botucatu Unesp||2|||f||||f||||||||||2018-05-31 23:19:11.500464|2018-05-31 23:19:11.500464
NCT01209468|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2010-09-24|2010-09-24|2010-09-27|Estimate|||||||2010-09-24|2010-09-27|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Treatment of Sleep Apnea With Oral Appliances|A Randomized Clinical Trial of the Treatment of Obstructive Sleep Apnoea Using Oral Appliances|Unknown status|Recruiting|N/A|45|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:19:11.562439|2018-05-31 23:19:11.562439
NCT01209455|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2011-07-18|2010-09-24|2010-09-27|Estimate|||||||2011-07-18|2011-07-19|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|September 2012|Anticipated|2012-09-30|October 2011|Anticipated|2011-10-31||Interventional|||Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects|Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects|Unknown status|Recruiting|N/A|24|Anticipated|University of Edinburgh||4|||f||||f||||||||||2018-05-31 23:19:11.630534|2018-05-31 23:19:11.630534
NCT01209442|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-06-08|2010-09-24|2010-09-27|Estimate|||||||2017-06-08|2017-06-12|Actual|September 16, 2010|Actual|2010-09-16|June 2017|2017-06-30|February 3, 2017|Actual|2017-02-03|September 7, 2014|Actual|2014-09-07||Interventional|||Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme|A Pilot Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) and Bevacizumab for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)|Completed||Phase 2|30|Actual|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 23:19:11.701058|2018-05-31 23:19:11.701058
NCT01209429|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2011-09-12|2010-09-24|2010-09-27|Estimate|||||||2011-09-12|2011-09-13|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Importance of the GH/IGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction|Importance of the GH/IGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction|Completed||N/A|10|Anticipated|University of Aarhus||4|||f||||f||||||||||2018-05-31 23:19:11.801362|2018-05-31 23:19:11.801362
NCT01209416|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2017-10-27|2010-09-24|2010-09-27|Estimate|||||||2017-10-27|2017-10-30|Actual|June 2012|Actual|2012-06-30|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin|The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin|Completed||N/A|8|Anticipated|University of Aarhus||4|||f||||f||||||||||2018-05-31 23:19:11.975204|2018-05-31 23:19:11.975204
NCT01209403|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-09-29|2010-09-24|2010-09-27|Estimate|||||||2011-09-29|2011-09-30|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients|Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients|Completed||Phase 4|12|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:19:12.058525|2018-05-31 23:19:12.058525
NCT01209390|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2011-09-19|2010-09-24|2010-09-27|Estimate|||||||2011-09-19|2011-09-20|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|April 2016|Anticipated|2016-04-30|September 2015|Anticipated|2015-09-30||Observational|OMCM||A Prospective, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects|A Prospective, Open Label, Multi-centre, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects|Terminated|||8|Actual|TiGenix n.v.|||1|Slow recruitment rate|f||||f||||||||||2018-05-31 23:19:12.133435|2018-05-31 23:19:12.133435
NCT01209377|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2010-09-24|2010-09-24|2010-09-27|Estimate|||||||2010-09-24|2010-09-27|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|April 2012|Anticipated|2012-04-30|January 2012|Anticipated|2012-01-31||Interventional|||Study of Eye Movement Desensitization and Reprocessing (EMDR) Working Mechanism|Randomized Controlled Study of Eye Movement Desensitization and Reprocessing (EMDR) Working Mechanism|Unknown status|Recruiting|N/A|192|Anticipated|Technische Universität München||3|||f||||f||||||||||2018-05-31 23:19:12.204901|2018-05-31 23:19:12.204901
NCT01209364|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2012-11-06|2010-09-24|2010-09-27|Estimate|||||||2012-11-06|2012-11-07|Estimate|March 2007||2007-03-31|August 2007|2007-08-31|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|||Durolane Versus Methylprednisolone in Knee Osteoarthritis|Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects With Osteoarthritis of the Knee|Completed||Phase 3|442|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 23:19:12.297064|2018-05-31 23:19:12.297064
NCT01209351|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2015-11-10|2010-09-24|2010-09-27|Estimate|||||||2015-11-10|2015-11-13|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Teduglutide on Gastric Emptying in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dosing, Parallel Group Study to Assess the Effects of Teduglutide (ALX-0600) on Gastric Emptying in Healthy Subjects|Completed||Phase 1|36|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:19:12.385465|2018-05-31 23:19:12.385465
NCT01209338|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2010-09-27|2010-09-24|2010-09-27|Estimate|||||||2010-09-27|2010-09-28|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Acceptability and Feasibility of Human Papilloma Virus Vaccine|Acceptability and Feasibility of Human Papilloma Virus Vaccine|Unknown status|Recruiting|N/A|1000|Anticipated|Tata Memorial Hospital||2|||f||||f||||||||||2018-05-31 23:19:12.444874|2018-05-31 23:19:12.444874
NCT01209325|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2018-05-03|2010-09-24|2010-09-27|Estimate|||||||2018-05-03|2018-05-08|Actual|June 28, 2011|Actual|2011-06-28|January 2018|2018-01-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males|AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males|Completed||Phase 2|149|Actual|AIDS Malignancy Consortium||1|||f||||f|t|f|||f|||No||2018-05-31 23:19:12.527133|2018-05-31 23:19:12.527133
NCT01209312|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2012-11-20|2010-09-24|2010-09-27|Estimate|||||||2012-11-20|2012-11-22|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes|Timing of Pre-meal Insulin Versus Accurate Carbohydrate Counting in Youth With Type 1 Diabetes|Completed||N/A|21|Actual|University of Colorado, Denver||4|||f||||f||||||||||2018-05-31 23:19:12.614974|2018-05-31 23:19:12.614974
NCT01209299|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2017-05-16|2010-09-24|2010-09-27|Estimate|||||||2017-05-16|2017-05-17|Actual|January 19, 2012|Actual|2012-01-19|May 2017|2017-05-31|February 19, 2012|Actual|2012-02-19|February 19, 2012|Actual|2012-02-19||Observational|||Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate|Integrated Molecular Signature for the Prediction of Response to Carboplatin/Paclitaxel-Based Chemotherapy in Metastatic Melanoma|Completed|||80|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:19:12.691119|2018-05-31 23:19:12.691119
NCT01209286|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2014-12-23||2017-01-23|2010-09-24|2010-09-27|Estimate|2014-12-23|2015-01-07|Estimate||||2017-01-23|2017-03-06|Actual|October 2010||2010-10-31|July 2016|2016-07-31|October 2016|Actual|2016-10-31|March 2012|Actual|2012-03-31||Interventional|||Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)|An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2|36|Actual|Amgen Research (Munich) GmbH||3|||f||||t||||||||||2018-05-31 23:19:12.784635|2018-05-31 23:19:12.784635
NCT01209273|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2015-09-11|2010-09-24|2010-09-27|Estimate|||||||2015-09-11|2015-09-15|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|February 2013|Actual|2013-02-28||Observational|EQlips||Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis|Prospective, Observational and Multi-center Study of a Comparison of Quality of Life on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis|Completed|||260|Actual|Kyungpook National University|||2||f||||t||||||Samples Without DNA|"~     blood 24hr urine PD dialysate~   "|||2018-05-31 23:19:15.518131|2018-05-31 23:19:15.518131
NCT01209260|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2013-12-05||2014-01-28|2010-09-23|2010-09-27|Estimate|2013-12-09|2014-01-28|Estimate||||2014-01-28|2014-02-28|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TRAVERSE-LA|per protocol|Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access|Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access (TRAVERSE-LA): A Randomized Controlled Trial|Completed||N/A|72|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:19:15.929787|2018-05-31 23:19:15.929787
NCT01209247|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2016-04-18|2010-09-24|2010-09-27|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|FQEMERG||Emergence of Fluoroquinolone Resistance in Commensal Flora|Emergence of Fluoroquinolone Resistance in the Commensal Flora of Patients Receiving Fluoroquinolone Treatment.|Completed||N/A|571|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:19:16.660166|2018-05-31 23:19:16.660166
NCT01209234|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2018-05-04|2010-09-23|2010-09-27|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2011||2011-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|CLEAR||Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance|Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance|Active, not recruiting||N/A|2200|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-05-31 23:19:16.931384|2018-05-31 23:19:16.931384
NCT01208558|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-06-19|2010-09-23|2010-09-24|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2010||2010-08-31|June 2017|2017-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|GET||Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss|Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss|Completed||Phase 2/Phase 3|105|Actual|Lund University||5|||f||||f||||||||Undecided||2018-05-31 23:19:26.220236|2018-05-31 23:19:26.220236
NCT01209221|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-24|||2016-11-01|2010-09-24|2010-09-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers|A Phase 1 Placebo-controlled, Randomized, Observer-blind Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5271983 in Healthy Subjects.|Completed||Phase 1|82|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:19:17.065048|2018-05-31 23:19:17.065048
NCT01209208|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-07-25|2010-09-24|2010-09-27|Estimate|||||||2017-07-25|2017-07-26|Actual|May 2010||2010-05-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis|Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Study on the Efficacy and Tolerability of a 8-week Treatment With Budesonide vs. Mesalazine vs. Placebo in Patients With Lymphocytic Colitis|Completed||Phase 3|57|Actual|Dr. Falk Pharma GmbH||3|||f||||t||||||||||2018-05-31 23:19:17.159268|2018-05-31 23:19:17.159268
NCT01209195|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2016-07-12||2016-09-06|2010-09-23|2010-09-27|Estimate|2016-09-06|2016-09-08|Estimate||||2016-09-06|2016-09-08|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers|A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers|Completed||Phase 1|41|Actual|Merrimack Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 23:19:17.397307|2018-05-31 23:19:17.397307
NCT01209182|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2010-09-23|2010-09-23|2010-09-27|Estimate|||||||2010-09-23|2010-09-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:19:18.240216|2018-05-31 23:19:18.240216
NCT01209169|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2013-02-21|2010-09-23|2010-09-27|Estimate|||||||2013-02-21|2013-02-22|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|April 2012|Actual|2012-04-30||Observational|||Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury|Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury|Completed|||890|Actual|Astute Medical, Inc.|||||f||||f||||||||||2018-05-31 23:19:18.297179|2018-05-31 23:19:18.297179
NCT01209156|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2013-11-08|2010-09-23|2010-09-27|Estimate|||||||2013-11-08|2013-11-11|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PBR111||Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions|A Phase 1 Evaluation of the Kinetics, Clearance and Cerebral Distribution of One Novel PBR PET Imaging Agent, 18F-PBR-111 Following Intravenous Administration in Healthy Subjects and Alzheimer Disease Patients|Completed||Phase 1|11|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-05-31 23:19:18.427024|2018-05-31 23:19:18.427024
NCT01209143|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2015-06-05||2015-06-05|2010-09-23|2010-09-27|Estimate|2015-06-05|2015-06-29|Estimate||||2015-06-05|2015-06-29|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Safety-evaluable population: All participants who received any amount of study drug (vismodegib or rosiglitazone or norethindrone/ethinyl estradiol).|A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists|A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists|Completed||Phase 1|52|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:19:18.527656|2018-05-31 23:19:18.527656
NCT01209130|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2016-11-01|2010-09-23|2010-09-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma|An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma|Completed||Phase 1|91|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:19:18.807167|2018-05-31 23:19:18.807167
NCT01209117|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-06-06|2010-09-23|2010-09-27|Estimate|||||||2017-06-06|2017-06-08|Actual|September 2010||2010-09-30|June 2017|2017-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435|A Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435|Completed||Phase 1|24|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 23:19:18.888477|2018-05-31 23:19:18.888477
NCT01209104|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-06-13|2010-09-23|2010-09-27|Estimate|||||||2017-06-13|2017-06-14|Actual|April 14, 2010|Actual|2010-04-14|June 2017|2017-06-30|May 24, 2010|Actual|2010-05-24|May 24, 2010|Actual|2010-05-24||Interventional|||Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors|A Single-dose, Open, Randomized, Crossover Investigation of Age, Gender, Food-effect and Proton-pump Interaction on the Pharmacokinetics of GSK1325756 in Healthy Adult Subjects and a Single-dose, Double Blind, Parallel-group, Placebo- Controlled Investigation of the Pharmacokinetics of GSK1325756|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:19:19.011292|2018-05-31 23:19:19.011292
NCT01209091|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2016-02-01|2010-09-23|2010-09-27|Estimate|||||||2016-02-01|2016-02-03|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden|Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden|Completed|||200|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:19:19.09195|2018-05-31 23:19:19.09195
NCT01208545|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2010-09-22|2010-09-22|2010-09-24|Estimate|||||||2010-09-22|2010-09-24|Estimate|July 2008||2008-07-31|September 2010|2010-09-30||||July 2010|Anticipated|2010-07-31||Observational|||Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs|Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs|Unknown status|Active, not recruiting||120|Anticipated|NeuroMetrix, Inc.|||||f||||f||||||||||2018-05-31 23:19:26.297386|2018-05-31 23:19:26.297386
NCT01209078|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2017-09-22|2012-03-29|2017-10-25|2010-09-23|2010-09-24|Estimate|2017-10-25|2017-12-04|Actual|2012-03-29|2012-04-02|Estimate|2017-10-25|2017-12-04|Actual|August 17, 2010|Actual|2010-08-17|September 2017|2017-09-30|January 18, 2011|Actual|2011-01-18|January 18, 2011|Actual|2011-01-18||Interventional|||GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection|A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection|Completed||Phase 2|84|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:19:19.396149|2018-05-31 23:19:19.396149
NCT01209065|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-01-17|2010-09-23|2010-09-24|Estimate|||||||2017-01-17|2017-01-19|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir|Phase I, Open Label, Two Period Study to Evaluate the Effects of Fosamprenavir/Ritonavir on GSK1349572 Pharmacokinetics and a Phase I, Randomized, Three-Way Crossover Study to Evaluate the Relative Bioavailability of Three Tablet Variants Made Using Micronized, Unmicronized and Intermediate Particle Sizes of GSK1349572 in Healthy Adult Subjects|Completed||Phase 1|27|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 23:19:21.832495|2018-05-31 23:19:21.832495
NCT01209052|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-06-13|2010-09-23|2010-09-24|Estimate|||||||2017-06-13|2017-06-14|Actual|October 15, 2009|Actual|2009-10-15|June 2017|2017-06-30|March 2, 2010|Actual|2010-03-02|March 2, 2010|Actual|2010-03-02||Interventional|||First Time in Human Study With GSK1325756|A Single-centre, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerabilty, Pharmacokinetics, and Pharmacodynamics of Single, Oral, Ascending Doses and Repeat Oral Doses of GSK1325756 in Healthy Male Subjects.|Completed||Phase 1|58|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:19:21.911471|2018-05-31 23:19:21.911471
NCT01209039|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-06-19|2010-09-23|2010-09-24|Estimate|||||||2017-06-19|2017-06-20|Actual|July 1, 2009|Actual|2009-07-01|June 2017|2017-06-30|October 25, 2009|Actual|2009-10-25|October 25, 2009|Actual|2009-10-25||Interventional|NK1 NK3 PET||A Repeat Dose Positron Emission Tomography Study With GSK1144814|A Healthy Volunteer Repeat Dose Study to Evaluate; the Safety, Tolerability, Pharmacokinetics, Effects on the Pharmacokinetics of Midazolam and the Neurokinin 1 Receptor Occupancy of GSK1144814|Completed||Phase 1|41|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 23:19:22.001039|2018-05-31 23:19:22.001039
NCT01209026|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-06-07|2010-09-23|2010-09-24|Estimate|||||||2017-06-07|2017-06-08|Actual|June 23, 2010|Actual|2010-06-23|June 2017|2017-06-30|January 4, 2011|Actual|2011-01-04|January 4, 2011|Actual|2011-01-04||Interventional|||Corrected QT (QTc) Study With Flucticasone Furoate and GW642444|A Randomised, Placebo-controlled, Four-way Crossover Repeat Dose Study to Evaluate the Effect of the Inhaled Fluticasone Furoate (FF)/GW642444M Combination on Electrocardiographic Parameters, With Moxifloxacin as a Positive Control, in Healthy Subjects|Completed||Phase 1|85|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:19:22.08953|2018-05-31 23:19:22.08953
NCT01209013|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2012-05-07|2010-09-23|2010-09-24|Estimate|||||||2012-05-07|2012-05-08|Estimate||||May 2012|2012-05-31||||||||Interventional|Oedisse||Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE)|Multicenter, Prospective, Open-label, Single-arm Phase IIIb/IV Clinical Study on the Safety of Photodynamic Therapy With Porfimer Sodium for Injection for the Ablation of High-grade Dysplasia in Barrett's Esophagus|Withdrawn||Phase 3|0|Actual|Pinnacle Biologics Inc.||1||Sponsor cancelled the study|f||||f||||||||||2018-05-31 23:19:22.198766|2018-05-31 23:19:22.198766
NCT01209000|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-10-24|2010-09-23|2010-09-24|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2010||2010-04-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|NEPTUNE||Nephrotic Syndrome Study Network|Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network|Recruiting|||1200|Anticipated|University of Michigan|||4||f||||t||||||Samples With DNA|"~     Renal tissue core (from clinically indicated kidney biopsy procedure) Blood products Urine~     products DNA/RNA specimens (declining consent does not forego participant eligibility)~   "|||2018-05-31 23:19:22.284325|2018-05-31 23:19:22.284325
NCT01208987|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|January 2011|Anticipated|2011-01-31|October 2009|Actual|2009-10-31||Interventional|||Improving Laboratory Follow-up by Delivering an Enhanced Medication List to Outpatient Physician Practices||Suspended||N/A|4449|Actual|Indiana University||1|||f||||f||||||||||2018-05-31 23:19:22.511328|2018-05-31 23:19:22.511328
NCT01208974|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2018-03-28|2010-09-23|2010-09-24|Estimate|||||||2018-03-28|2018-03-30|Actual|March 16, 2010|Actual|2010-03-16|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction|A Phase I Trial Assessing the Safety and Feasibility of Prophylactic Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Immediate Reconstruction in Patients With In-Situ or Invasive Breast Cancer|Recruiting||N/A|30|Anticipated|University of Miami||2|||f||||t||||||||||2018-05-31 23:19:22.574111|2018-05-31 23:19:22.574111
NCT01208961|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2013-07-16|2012-01-05|2015-06-19|2010-09-23|2010-09-24|Estimate|2013-11-14|2014-01-06|Estimate|2012-01-05|2012-01-09|Estimate|2015-06-19|2015-07-15|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ECLIPSE|To be included in the baseline analysis, subjects had to receive at least one dose of investigational product; all randomized subjects (n = 54) were included in the baseline analysis.|Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation|A Randomized, Open-label, Four-Way Crossover Study to Compare the Relative Bioavailability of a Single Dose of Epanova® With Lovaza® After a Low-Fat and High-Fat Meal|Completed||Phase 2|54|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:19:22.678297|2018-05-31 23:19:22.678297
NCT01208948|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|July 2000||2000-07-31|September 2010|2010-09-30|December 2005|Actual|2005-12-31|April 2005|Actual|2005-04-30||Interventional|RETIPON||Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema|Alpha Lipoic Acid in the Treatment of Diabetic Retinopathy|Completed||Phase 3|520|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 23:19:22.912671|2018-05-31 23:19:22.912671
NCT01208935|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-01-11|2010-09-23|2010-09-24|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1999||1999-08-31|September 2010|2010-09-30|August 2004|Actual|2004-08-31|June 2004|Actual|2004-06-30||Interventional|||Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence|Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence|Completed||Phase 2/Phase 3|157|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-05-31 23:19:22.983458|2018-05-31 23:19:22.983458
NCT01208922|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-05-26|2010-09-23|2010-09-24|Estimate|||||||2017-05-26|2017-05-30|Actual|October 2010||2010-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|January 2016|Actual|2016-01-31||Interventional|ERASE||Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea|A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers|Completed||Phase 3|835|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-05-31 23:19:23.071186|2018-05-31 23:19:23.071186
NCT01208909|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-10-21|2010-09-23|2010-09-24|Estimate|||||||2010-10-21|2010-10-22|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)|Combined Approach to GBM-resection by 5-ALA and Intraoperative MRI|Unknown status|Recruiting||40|Anticipated|University of Zurich|||||f||||f||||||Samples Without DNA|"~     tumor samples for pathophysiology~   "|||2018-05-31 23:19:23.138469|2018-05-31 23:19:23.138469
NCT01208896|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2016-08-19|2010-09-23|2010-09-24|Estimate|||||||2016-08-19|2016-08-22|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|RITALLO||Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma|Safety and Efficacy of a Strategy of Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Chemosensitive Relapsed Follicular Lymphoma|Active, not recruiting||Phase 2|32|Actual|University Hospital, Bordeaux||1|||f||||t||||||||No||2018-05-31 23:19:23.202074|2018-05-31 23:19:23.202074
NCT01208883|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2014-01-23|2010-09-23|2010-09-24|Estimate|||||||2014-01-23|2014-01-24|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer|A FEASIBILITY STUDY ON CONTINUOUS ADAPTIVE [18F]FDG-PET-GUIDED RADIOTHERAPY FOR HEAD AND NECK CANCER|Completed||Phase 1|10|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 23:19:23.28859|2018-05-31 23:19:23.28859
NCT01208870|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2016-01-08||2017-08-23|2010-09-23|2010-09-24|Estimate|2017-08-23|2017-10-02|Actual||||2017-08-23|2017-10-02|Actual|October 2009||2009-10-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|EAT|Families including an overweight child and parent.|Translating Habituation Research to Interventions for Pediatric Obesity|Translating Habituation Research to Interventions for Pediatric Obesity|Completed||N/A|94|Actual|State University of New York at Buffalo|Two different measures were used to assess variety and calorie intake.|2|||f||||f||||||||No|Individual participant data will not be shared under the specifics of this protocol. Outcome data will be published.|2018-05-31 23:19:23.360222|2018-05-31 23:19:23.360222
NCT01208844|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2015-04-27|2010-09-23|2010-09-24|Estimate|||||||2015-04-27|2015-04-29|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Study of Physical Health for Women With Posttraumatic Stress or Depression|Cardiovascular Risk in Relation to Posttraumatic Stress Disorder in Young Women|Completed|||59|Actual|Nova Southeastern University|||3||f||||f||||||||||2018-05-31 23:19:24.216163|2018-05-31 23:19:24.216163
NCT01208831|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2016-04-20|2010-09-23|2010-09-24|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||An East Asian Study of LDE225|An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors|Completed||Phase 1|45|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:19:24.26947|2018-05-31 23:19:24.26947
NCT01208818|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-12-07|2010-09-23|2010-09-24|Estimate|||||||2017-12-07|2017-12-08|Actual|June 2011||2011-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|September 2015|Actual|2015-09-30||Interventional|MYRE||Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy|Treatment of Renal Failure Due to Myeloma Cast Nephropathy: Comparison of Two Different Chemotherapy Regimens and Evaluation of Optimized Removal of Monoclonal Immunoglobulin Light Chains Using a High Permeability Hemodialysis Membrane.|Completed||Phase 3|284|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||t||||||||Undecided||2018-05-31 23:19:24.339356|2018-05-31 23:19:24.339356
NCT01208805|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Observational|SCEPTISM||Spinal Cord Evoked Potentials as a Tool to Investigate Sensorimotor Processing|Spinal Cord Evoked Potentials in Candidates for Dorsal Column Stimulation|Unknown status|Not yet recruiting||10|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 23:19:24.440196|2018-05-31 23:19:24.440196
NCT01208792|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-08-11|2010-09-23|2010-09-24|Estimate|||||||2017-08-11|2017-08-14|Actual|June 15, 2010|Actual|2010-06-15|August 2017|2017-08-31|May 15, 2017|Actual|2017-05-15|July 15, 2014|Actual|2014-07-15||Interventional|Auto-HTAP||Auto-immunity and Pulmonary Arterial Hypertension|Auto-immunity and Prognosis of Pulmonary Arterial Hypertension|Completed||N/A|629|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 23:19:24.564029|2018-05-31 23:19:24.564029
NCT01208779|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2013-07-16|2010-09-23|2010-09-24|Estimate|||||||2013-07-16|2013-07-17|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer|An Epidemiological, Non-interventional Study to Evaluate Patient Compliance in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer|Completed|||90|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:19:24.665562|2018-05-31 23:19:24.665562
NCT01208766|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-03-19|2010-09-23|2010-09-24|Estimate|||||||2015-03-19|2015-03-20|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|HO95||Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma|A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 3|1500|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||4|||f||||t||||||||||2018-05-31 23:19:24.740794|2018-05-31 23:19:24.740794
NCT01208753|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2011-03-22|2010-09-23|2010-09-24|Estimate|||||||2011-03-22|2011-03-23|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of GLPG0555 in Healthy Subjects.|Completed||Phase 1|24|Actual|Galapagos NV||3|||f||||f||||||||||2018-05-31 23:19:24.834096|2018-05-31 23:19:24.834096
NCT01208740|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-05-23|2010-09-23|2010-09-24|Estimate|||||||2011-05-23|2011-05-24|Estimate|January 2009||2009-01-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||Metformin in Patients With PCOS and Predictors of Poor Ovarian Response Ongoing In-vitro Fertilization|Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response|Terminated||Phase 4|88|Actual|University Magna Graecia||2||Concerns about safety at the first interim analysis|f||||t||||||||||2018-05-31 23:19:24.928112|2018-05-31 23:19:24.928112
NCT01208727|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2013-05-07|2010-09-23|2010-09-24|Estimate|||||||2013-05-07|2013-05-08|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|March 2011|Actual|2011-03-31|April 2009|Actual|2009-04-30||Interventional|||Post Cond No Reflow|The POSTCONDITIONING and THE NO REFLOW Phenomenon in Acute Myocardial Infarction|Completed||N/A|44|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 23:19:25.022898|2018-05-31 23:19:25.022898
NCT01208714|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2010-11-03|2010-09-23|2010-09-24|Estimate|||||||2010-11-03|2010-11-04|Estimate|December 2010||2010-12-31|September 2010|2010-09-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|METRAS||Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study)|Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|University Hospital Padova||2|||f||||t||||||||||2018-05-31 23:19:25.111258|2018-05-31 23:19:25.111258
NCT01208701|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|||2015-08-19|2010-09-23|2010-09-24|Estimate|||||||2015-08-19|2015-08-21|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|STAD||The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy|The Effect of Atorvastatin on the NO-system in Patients With Type 2 Diabetes and Nephropathy|Completed||Phase 2|25|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 23:19:25.223879|2018-05-31 23:19:25.223879
NCT01208688|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2012-09-24|2010-09-23|2010-09-24|Estimate|||||||2012-09-24|2012-09-25|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||FES Therapy:Restoring Voluntary Grasping Function in Chronic SCI|FES Therapy:Restoring Voluntary Grasping Function in Chronic SCI|Completed||Phase 2|15|Actual|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-05-31 23:19:25.334839|2018-05-31 23:19:25.334839
NCT01208675|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2018-04-16|2010-09-23|2010-09-24|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2010||2010-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||The Swedish BioFINDER Study|The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach|Active, not recruiting|||900|Actual|Skane University Hospital|||2||f||||f||||||Samples With DNA|"~     Cerebrospinal fluid, plasma, DNA, mRNA~   "|||2018-05-31 23:19:25.42124|2018-05-31 23:19:25.42124
NCT01208662|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-01-19|2010-09-23|2010-09-24|Estimate|||||||2017-01-19|2017-01-20|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|DFCI 10-106||Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65|A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age|Recruiting||Phase 3|660|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 23:19:25.536145|2018-05-31 23:19:25.536145
NCT01208649|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|July 2008||2008-07-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)|Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 4|13|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 23:19:25.785695|2018-05-31 23:19:25.785695
NCT01208636|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Environmental & Genetic Influences on Vitamin D Status|Environmental & Genetic Influences on Vitamin D Status|Completed|||40|Actual|Creighton University|||1||f||||f||||||Samples With DNA|"~     Blood was obtained for genetic testing of selected 13 candidate genes important for vitamin D~     metabolism~   "|||2018-05-31 23:19:25.850257|2018-05-31 23:19:25.850257
NCT01208623|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||A Large Series of Clinical and Imaging Investigation to Patients With Chronic Lower Limb Edema With Unclear Etiology|A Large Series of Clinical and Imaging Investigation to Patients With Chronic Lower Limb Edema With Unclear Etiology|Unknown status|Active, not recruiting||300|Anticipated|Taipei Medical University WanFang Hospital|||3||f||||f||||||||||2018-05-31 23:19:25.908971|2018-05-31 23:19:25.908971
NCT01208610|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|June 2010|Actual|2010-06-30|||||Observational|||The Effectiveness of Adopting Humanized Service Program on Transabdominal Ultrasound About Pregnant Women's Service Quality and Satisfaction|The Effectiveness of Adopting Humanized Service Program on Transabdominal Ultrasound About Pregnant Women's Service Quality and Satisfaction|Completed|||200|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:19:25.960737|2018-05-31 23:19:25.960737
NCT01208597|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2010-09-23|2010-09-23|2010-09-24|Estimate|||||||2010-09-23|2010-09-24|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|June 2010|Actual|2010-06-30|||||Observational|||The Effectiveness of Adopting Humanized Service Program on Transvaginal Ultrasound About Women's Service Quality and Satisfaction|The Effectiveness of Adopting Humanized Service Program on Transvaginal Ultrasound About Women's Service Quality and Satisfaction.|Completed|||100|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:19:26.004864|2018-05-31 23:19:26.004864
NCT01208584|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-03-10|2010-09-23|2010-09-24|Estimate|||||||2015-03-10|2015-03-11|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions|Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions|Completed|||22|Actual|University Hospital, Basel, Switzerland|||4||f||||f||||||||||2018-05-31 23:19:26.058839|2018-05-31 23:19:26.058839
NCT01208571|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2012-08-29|2010-09-23|2010-09-24|Estimate|||||||2012-08-29|2012-08-30|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Effect of a Interdisciplinary Alcohol Cessation Intervention|"The Effect of an Interdisciplinary Booster Session in Primary Care Following Brief Intervention in Hospitals - a Randomized Clinical Trial"|Unknown status|Recruiting|N/A|120|Anticipated|Helse Stavanger HF||2|||f||||f||||||||||2018-05-31 23:19:26.134284|2018-05-31 23:19:26.134284
NCT01208532|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-04-21|2010-09-23|2010-09-24|Estimate|||||||2015-04-21|2015-04-23|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Validation Study of the Korean Version of the EORTC QLQ-HDC29|Quality of Life in Patients With Stem Cell Transplant After High Dose Chemotherapy: Validation Study of the Korean Version of the EORTC QLQ-HDC29|Completed|||226|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 23:19:26.347795|2018-05-31 23:19:26.347795
NCT01208519|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2013-02-12|2010-09-23|2010-09-24|Estimate|||||||2013-02-12|2013-02-13|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|January 2015||2015-01-31|November 2012|Actual|2012-11-30||Observational|SATURN||SATURN 04 Nosocomial Acquisition Study|Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria in Hospitalised Patients (SATURN 04)|Unknown status|Active, not recruiting||16680|Anticipated|Catholic University of the Sacred Heart|||2||f||||t||||||Samples Without DNA|"~     Nasal and rectal swabs~   "|||2018-05-31 23:19:26.39436|2018-05-31 23:19:26.39436
NCT01208506|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-02-06|2010-09-23|2010-09-24|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2010||2010-09-30|February 2017|2017-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis|First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis|Completed||Phase 1|64|Actual|Novo Nordisk A/S||8|||f||||f||||||||||2018-05-31 23:19:26.457808|2018-05-31 23:19:26.457808
NCT01208493|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2015-03-25|2010-09-23|2010-09-24|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Dietary Protein in the Very-low-birth-weight Infant|Dietary Protein in the Very-low-birth-weight Infant: Effects of the Level of Dietary Protein on Growth and Feeding Tolerance|Terminated||N/A|70|Actual|Nestlé||2|||f||||t||||||||||2018-05-31 23:19:26.536237|2018-05-31 23:19:26.536237
NCT01208480|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2012-04-09|2010-09-23|2010-09-24|Estimate|||||||2012-04-09|2012-04-10|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer|A Phase II Trial of Neoadjuvant Bevacizumab, Docetaxel and Carboplatin for Triple Negative Breast Cancer (Neat Trial)|Completed||Phase 2|45|Actual|Severance Hospital|||||f||||f||||||||||2018-05-31 23:19:26.599702|2018-05-31 23:19:26.599702
NCT01208467|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2017-08-22|2010-09-23|2010-09-24|Estimate|||||||2017-08-22|2017-08-23|Actual|September 2010|Actual|2010-09-30|August 2017|2017-08-31||||May 2014|Actual|2014-05-31||Observational|||Prognostic Biomarkers in Patients With Endometrial Cancer|Validating The Prognostic Role of ATR Mutation in Patients With Endometrioid Endometrial Cancer|Completed|||2824|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 23:19:26.660556|2018-05-31 23:19:26.660556
NCT01208454|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2015-11-23|2010-09-23|2010-09-24|Estimate|||||||2015-11-23|2015-11-24|Estimate|December 2010||2010-12-31|November 2015|2015-11-30||||September 2014|Actual|2014-09-30||Interventional|||Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma|Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma|Completed||Phase 1|29|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:19:27.887284|2018-05-31 23:19:27.887284
NCT01208441|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2013-09-27|2010-09-23|2010-09-24|Estimate|||||||2013-09-27|2013-09-30|Estimate|November 2010||2010-11-30|September 2013|2013-09-30||||December 2011|Actual|2011-12-31||Interventional|||RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer|A Phase Ib Neoadjuvant Study of the Gamma Secretase Inhibitor (RO4929097) in Combination With the Aromatase Inhibitor Letrozole in Post-Menopausal Women With Stage II/III Hormone Receptor-Positive Breast Cancer|Terminated||Phase 1|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:19:28.247833|2018-05-31 23:19:28.247833
NCT01208428|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2015-03-13|2010-09-22|2010-09-24|Estimate|||||||2015-03-13|2015-03-17|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Cognitive Behavioral Treatments for Depression in Chronic Illness|Cognitive Behavioral Treatments for Depression in Patients With Chronic Illness|Completed||N/A|132|Actual|Duke University||2|||f||||t||||||||||2018-05-31 23:19:28.569408|2018-05-31 23:19:28.569408
NCT01208415|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|2017-07-18||2018-03-08|2010-09-23|2010-09-24|Estimate|2017-07-18|2017-08-16|Actual||||2018-03-08|2018-04-04|Actual|January 2011||2011-01-31|September 2017|2017-09-30|October 10, 2017|Actual|2017-10-10|October 2012|Actual|2012-10-31||Interventional|||PRESERVE-Zenith® Iliac Branch System Clinical Study|PRESERVE-Zenith® Iliac Branch System Clinical Study|Completed||N/A|40|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 23:19:28.858272|2018-05-31 23:19:28.858272
NCT01208402|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2014-11-13||2014-11-25|2010-09-22|2010-09-24|Estimate|2014-11-13|2014-11-19|Estimate||||2014-11-25|2014-12-12|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Esmolol for Treatment of Perioperative Tachycardia|Safety and Efficacy of Esmolol for the Treatment of Peri-operative Tachycardia in Patients at Risk for Post Operative Adverse Ischemic Outcomes|Terminated||Phase 3|76|Actual|Duke University||2||Baxter has terminated the study for inadequate enrollment rate accrual.|f||||f||||||||||2018-05-31 23:19:29.154497|2018-05-31 23:19:29.154497
NCT01208389|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2018-03-28|2010-09-22|2010-09-24|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2010|Actual|2010-11-30|March 2018|2018-03-31|November 2026|Anticipated|2026-11-30|November 2026|Anticipated|2026-11-30||Interventional|||Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2|A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study|Active, not recruiting||Phase 1/Phase 2|12|Anticipated|Spark Therapeutics||1|||f||||t|t|f||||||||2018-05-31 23:19:29.564042|2018-05-31 23:19:29.564042
NCT01208376|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2016-12-19|2010-09-22|2010-09-23|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Prevalence of Liver Fibrosis and Progression of Liver Fibrosis|Prevalence of Liver Fibrosis and Progression of Liver Fibrosis in HIV-infected, Hepatitis C (HCV) and Hepatitis B (HBV) Seronegative Patients With Chronic Alanine Aminotransferase (ALT) Elevation|Active, not recruiting|||195|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 23:19:29.658515|2018-05-31 23:19:29.658515
NCT01208363|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2011-09-28|2010-09-22|2010-09-23|Estimate|||||||2011-09-28|2011-09-29|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Improving Iron Status Through Consumption Of Iron Fortified Cowpea: An Intervention Study|Improving Iron Status Through Consumption Of Iron Fortified Cowpea: An Intervention Study|Completed||N/A|240|Anticipated|Wageningen University||2|||f||||f||||||||||2018-05-31 23:19:29.723856|2018-05-31 23:19:29.723856
NCT01208337|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2016-01-13||2017-03-31|2010-09-22|2010-09-23|Estimate|2016-05-11|2016-06-20|Estimate||||2017-03-31|2017-05-09|Actual|April 2007||2007-04-30|March 2017|2017-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation|Pharmacodynamics, Pharmacogenomics, and Preliminary Safety and Efficacy of Alemtuzumab Induction and Tacrolimus in Pediatric Intestinal Transplantation (IND # 100496)|Completed||Phase 2|23|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 23:19:29.872412|2018-05-31 23:19:29.872412
NCT01208324|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2017-09-15|2010-09-22|2010-09-23|Estimate|||||||2017-09-15|2017-09-18|Actual|March 4, 2010|Actual|2010-03-04|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Estrogen and Serotonin on Changing Brain Chemistry|Interaction of Estrogen and Serotonin in Modulating Brain Activation in Menopause|Active, not recruiting||N/A|150|Anticipated|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 23:19:30.050254|2018-05-31 23:19:30.050254
NCT01208311|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2016-12-28|2010-09-22|2010-09-23|Estimate|||||||2016-12-28|2016-12-29|Estimate|December 2004||2004-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound|Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound.|Completed|||7|Actual|Northwell Health|||1||f||||f||||||||No||2018-05-31 23:19:30.130847|2018-05-31 23:19:30.130847
NCT01208298|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2011-10-04|2010-09-22|2010-09-23|Estimate|||||||2011-10-04|2011-10-06|Estimate|April 2009||2009-04-30|October 2011|2011-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Evaluate Using a Cold Sore Patch to Treat Herpes Labialis|Study to Evaluate the Safety and Performance of Compeed® Cold Sore Patch Night in the Treatment of Herpes Labialis|Completed||N/A|45|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-05-31 23:19:30.275032|2018-05-31 23:19:30.275032
NCT01208285|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2011-01-11|2010-09-22|2010-09-23|Estimate|||||||2011-01-11|2011-01-12|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects|A Phase 1 Non-Randomized, Open-Label Study to Assess the Safety and Pharmacokinetics of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects|Completed||Phase 1|24|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 23:19:30.348306|2018-05-31 23:19:30.348306
NCT01208272|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-22|2010-09-22|2010-09-23|Estimate|||||||2010-09-22|2010-09-23|Estimate|April 1994||1994-04-30|September 2010|2010-09-30|March 1999|Actual|1999-03-31|March 1998|Actual|1998-03-31||Interventional|||Psychological Treatment of Overweight Binge Eaters|A Randomized Comparison of Group-Behavioral Therapy and Group Interpersonal Psychotherapy for the Treatment of Overweight Individuals With Binge-Eating Disorder|Completed||Phase 1/Phase 2|162|Actual|Washington University School of Medicine||1|||f||||||||||||||2018-05-31 23:19:30.415075|2018-05-31 23:19:30.415075
NCT01208259|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-24|2010-09-22|2010-09-23|Estimate|||||||2010-09-24|2010-09-28|Estimate|April 1997||1997-04-30|September 2010|2010-09-30|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||The Psychological Treatment of Overweight Binge Eaters Minority Supplement|A Randomized Comparison of Group-Behavioral Therapy and Group Interpersonal Psychotherapy for the Treatment of Overweight Individuals With Binge-Eating Disorder Minority Supplement|Completed||Phase 1/Phase 2|162|Actual|Washington University School of Medicine||1|||f||||||||||||||2018-05-31 23:19:30.490344|2018-05-31 23:19:30.490344
NCT01208246|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2014-02-19|2010-09-22|2010-09-23|Estimate|||||||2014-02-19|2014-02-21|Estimate|April 2010||2010-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|PregUS||Impact of Pelvic Floor Musculature on Peripartum Outcomes|Impact of Pelvic Floor Musculature on Peripartum Outcomes: A Prospective Study|Completed|||34|Actual|University of Rochester|||||f||||f||||||||||2018-05-31 23:19:30.588006|2018-05-31 23:19:30.588006
NCT01208233|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2015-02-19||2016-01-22|2010-09-22|2010-09-23|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||The Full Analysis Set (FAS) consisted of all randomized participants who took any study medication (active or placebo).|Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke|A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke|Terminated||Phase 2|181|Actual|Pfizer|The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.|4||See termination reason in detailed description.|f||||t||||||||||2018-05-31 23:19:30.851348|2018-05-31 23:19:30.851348
NCT01208220|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2013-09-24||2014-07-16|2010-09-22|2010-09-23|Estimate|2014-07-16|2014-07-17|Estimate||||2014-07-16|2014-07-17|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effectiveness Study of Santyl Ointment to Treat Pressure Ulcers|The Effects of Collagenase Santyl Ointment and Negative Pressure Wound Therapy(Npwt) for the Treatment of Chronic Pressure Ulcers.|Terminated||N/A|2|Actual|Louisiana State University Health Sciences Center Shreveport|No adverse events noted or reported|2||Low enrollment of qualified subjects|f||||t||||||||||2018-05-31 23:19:33.729592|2018-05-31 23:19:33.729592
NCT01208207|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2015-05-04||2017-03-07|2010-09-22|2010-09-23|Estimate|2015-06-30|2015-07-02|Estimate||||2017-03-07|2017-04-04|Actual|September 2010||2010-09-30|March 2017|2017-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)|A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Ankylosing Spondylitis|Completed||Phase 3|1015|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:19:34.49682|2018-05-31 23:19:34.49682
NCT01208194|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2014-06-19|2010-09-22|2010-09-23|Estimate|||||||2014-06-19|2014-06-20|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|IMPACT||Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma|Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy|Completed||Phase 2|59|Actual|Mologen AG||2|||f||||t||||||||||2018-05-31 23:19:35.701289|2018-05-31 23:19:35.701289
NCT01208181|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|2015-05-05||2017-03-10|2010-09-22|2010-09-23|Estimate|2015-05-05|2015-05-21|Estimate||||2017-03-10|2017-04-10|Actual|September 2010||2010-09-30|March 2017|2017-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)|A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK‑0663/Etoricoxib in Patients With Rheumatoid Arthritis|Completed||Phase 3|1404|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:19:35.921991|2018-05-31 23:19:35.921991
NCT01208168|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20||2013-07-08|2013-07-08|2010-09-22|2010-09-23|Estimate||||2013-07-08|2013-07-11|Estimate|2013-07-08|2013-07-11|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks|Terminated||Phase 3|468|Actual|Promius Pharma, LLC||2|||f||||f||||||||||2018-05-31 23:19:37.057924|2018-05-31 23:19:37.057924
NCT01208155|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2010-12-07|2010-09-22|2010-09-23|Estimate|||||||2010-12-07|2010-12-08|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets|An Open-label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of 4 Different Fostamatinib Tablets|Completed||Phase 1|24|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:19:37.38843|2018-05-31 23:19:37.38843
NCT01208142|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2013-08-08|2010-09-22|2010-09-23|Estimate|||||||2013-08-08|2013-08-12|Estimate|September 2010||2010-09-30|August 2013|2013-08-31||||September 2016|Anticipated|2016-09-30||Interventional|TW||Toe Walker Gait Trial|Dynamic Splinting for Toe Walking: a Randomized, Controlled Study With Gait Analysis|Terminated||N/A|10|Actual|Dynasplint Systems, Inc.||2||Unrelated to trial|f||||f||||||||||2018-05-31 23:19:38.433696|2018-05-31 23:19:38.433696
NCT01208129|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20||2013-07-08|2013-07-08|2010-09-22|2010-09-23|Estimate||||2013-07-08|2013-07-11|Estimate|2013-07-08|2013-07-11|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks|Terminated||Phase 3|458|Actual|Promius Pharma, LLC||2|||f||||f||||||||||2018-05-31 23:19:38.737275|2018-05-31 23:19:38.737275
NCT01208116|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2010-09-22|2010-09-22|2010-09-23|Estimate|||||||2010-09-22|2010-09-23|Estimate|April 2010||2010-04-30|September 2010|2010-09-30||||||||Observational|||A Prospective Study on Predictive Value of Non-Invasive Atherosclerotic Measurements in Elderly Chinese|A Prospective Study on Predictive Value of Non-Invasive Atherosclerotic Measurements in Elderly Chinese|Unknown status|Recruiting||1290|Anticipated|Tianjin Medical University General Hospital|||1||f||||||||||||||2018-05-31 23:19:39.498602|2018-05-31 23:19:39.498602
NCT01208103|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2018-03-13|2010-09-22|2010-09-23|Estimate|||||||2018-03-13|2018-03-15|Actual|May 6, 2011|Actual|2011-05-06|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|||Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater|Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:19:39.990445|2018-05-31 23:19:39.990445
NCT01208090|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2013-01-23|2010-09-22|2010-09-23|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis|Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety & Tolerability of Two Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|326|Actual|Actelion||3|||f||||||||||||||2018-05-31 23:19:40.257927|2018-05-31 23:19:40.257927
NCT01208077|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2015-08-03|2010-09-22|2010-09-23|Estimate|||||||2015-08-03|2015-08-04|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|PREMIUM||PREMIUM Registry: PRognostic HEModynamIc Profiling in the AcUtely Ill EMergency Department Patient|PROGNOSTIC HEMODYNAMIC PROFILING IN THE ACUTELY ILL EMERGENCY DEPARTMENT PATIENT|Completed|||514|Actual|Henry Ford Health System|||3||f||||f||||||||||2018-05-31 23:19:40.55566|2018-05-31 23:19:40.55566
NCT01208064|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2016-01-21|2010-09-22|2010-09-23|Estimate|||||||2016-01-21|2016-01-22|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy|Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study.|Terminated||Phase 2/Phase 3|102|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||based on IDMC decision|f||||||||||||||2018-05-31 23:19:40.756571|2018-05-31 23:19:40.756571
NCT01208051|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2018-05-23|2010-09-22|2010-09-23|Estimate|||||||2018-05-23|2018-05-24|Actual|September 9, 2010|Actual|2010-09-09|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer|Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer|Active, not recruiting||Phase 1/Phase 2|128|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 23:19:40.973693|2018-05-31 23:19:40.973693
NCT01208038|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2010-09-22|2010-09-22|2010-09-23|Estimate|||||||2010-09-22|2010-09-23|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Testosterone Patch's Effects on the Cardiovascular System and Libido|Pilot Study: Evaluating the Effect of 300 Micrograms Testosterone Patches in Addition to Hormone Replacement Therapy on Arterial Compliance, Insulin Resistance and Sexual Desire.|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Imperial College Healthcare NHS Trust|||||f||||f||||||||||2018-05-31 23:19:41.21167|2018-05-31 23:19:41.21167
NCT01208025|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-09-04|2010-09-22|2010-09-23|Estimate|||||||2017-09-04|2017-09-06|Actual|September 2010||2010-09-30|September 2016|2016-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ParisK||ParisK: Validation of Imaging Techniques|The Assessment of the Plaque at RISK by Non-invasive (Molecular) Imaging and Modelling (ParisK): Prospective Clinical Study for Diagnosis Efficacy for High Risk Plaque and Stroke.|Completed|||244|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 23:19:42.053291|2018-05-31 23:19:42.053291
NCT01208012|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-03-14|2010-09-22|2010-09-23|Estimate|||||||2011-03-14|2011-03-15|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus|Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus|Completed||Phase 4|44|Actual|ikfe-CRO GmbH||2|||f||||f||||||||||2018-05-31 23:19:42.744768|2018-05-31 23:19:42.744768
NCT01207999|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2012-11-21|2010-09-22|2010-09-23|Estimate|||||||2012-11-21|2012-11-22|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer|Human Papillomavirus (HPV) Type Distribution in Adult African Women Diagnosed With Invasive Cervical Cancer|Completed|||591|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Cervical specimen~   "|||2018-05-31 23:19:43.064625|2018-05-31 23:19:43.064625
NCT01207986|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-07-17|2010-09-22|2010-09-23|Estimate|||||||2015-07-17|2015-07-20|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|August 2014|Actual|2014-08-31|June 2012|Actual|2012-06-30||Interventional|EP48 HIV CHEST||Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study|Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study|Completed||N/A|450|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 23:19:44.180781|2018-05-31 23:19:44.180781
NCT01207973|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2013-11-04|2010-09-22|2010-09-23|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2010||2010-09-30|November 2013|2013-11-30||||January 2011|Actual|2011-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Multiple Rising Oral Doses (50, 100, 200 and 350 mg qd and 100 mg Bid for 12 Days) of BI 113823 as Tablet in Male and Female Patients With Osteoarthritis of the Knee (Randomised, Double-blind, Placebo-controlled Within the Dose Groups, Clinical Phase I)|Terminated||Phase 1|36|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:19:45.404015|2018-05-31 23:19:45.404015
NCT01207960|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-05-03|2010-09-22|2010-09-23|Estimate|||||||2012-05-03|2012-05-04|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|EMDR-DP||Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Dental Phobia|A Randomized Wait-list Control Study of the Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Patients With Dental Phobia|Completed||N/A|24|Actual|University Hospital Muenster||2|||f||||f||||||||||2018-05-31 23:19:45.461525|2018-05-31 23:19:45.461525
NCT01207947|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2015-01-19|2010-09-22|2010-09-23|Estimate|||||||2015-01-19|2015-01-21|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Observational|||LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers|LEVITRA® Specific Drug Use Investigation. To Investigate the Safety Profile in Combination Use With Alpha-blockers|Completed|||491|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:19:45.537546|2018-05-31 23:19:45.537546
NCT01207934|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2011-06-06||2015-06-11|2010-09-22|2010-09-23|Estimate|2011-07-13|2011-08-10|Estimate||||2015-06-11|2015-07-09|Estimate|August 1998||1998-08-31|June 2015|2015-06-30|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|Leptin||Recombinant Human Leptin Therapy Effects on Insulin Action|Recombinant Human Leptin Therapy Effects on Insulin Action|Completed||N/A|18|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 23:19:45.623734|2018-05-31 23:19:45.623734
NCT01207921|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-06-14|2010-09-22|2010-09-23|Estimate|||||||2017-06-14|2017-06-15|Actual|April 28, 2011|Actual|2011-04-28|June 2017|2017-06-30|October 31, 2018|Anticipated|2018-10-31|September 19, 2016|Actual|2016-09-19||Interventional|||Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma|A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma|Active, not recruiting||Phase 1|28|Actual|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 23:19:45.943244|2018-05-31 23:19:45.943244
NCT01207908|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2012-06-12|2010-09-22|2010-09-23|Estimate|||||||2012-06-12|2012-06-13|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|October 2012|Anticipated|2012-10-31||Interventional|||Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy|IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 23:19:46.014824|2018-05-31 23:19:46.014824
NCT01207895|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-02-18|2010-09-21|2010-09-23|Estimate|||||||2017-02-18|2017-02-23|Actual|March 2010||2010-03-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer|Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer|Completed||Phase 1|5|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 23:19:46.081598|2018-05-31 23:19:46.081598
NCT01207869|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-11|||2010-09-22|2010-09-22|2010-09-23|Estimate|||||||2010-09-22|2010-09-23|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|||Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia|Intratracheal Instillation of Umbilical Cord-derived Mesenchymal Stem Cells as a Rescue Treatment for Severe Bronchopulmonary Dysplasia|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 23:19:46.276572|2018-05-31 23:19:46.276572
NCT01207856|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2016-02-08|2010-09-22|2010-09-23|Estimate|||||||2016-02-08|2016-02-09|Estimate|May 2011||2011-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional|REACTIV||Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis|Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis and Assessment by Neuroimaging|Completed||N/A|65|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 23:19:46.37178|2018-05-31 23:19:46.37178
NCT01207843|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2014-08-18|2010-09-22|2010-09-23|Estimate|||||||2014-08-18|2014-08-19|Estimate|October 2009||2009-10-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|April 2011|Actual|2011-04-30||Observational|||Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias|Verbesserung Der Radiologischen Diagnose Von Hepatolienaler Candidiasis während Der Therapie Der Leukämie|Completed|||88|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 23:19:46.452481|2018-05-31 23:19:46.452481
NCT01207830|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2016-03-15|2010-09-21|2010-09-23|Estimate|||||||2016-03-15|2016-03-17|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||Feasibility Trial of ValenTx Endo Bypass System of the ValenTx Endo Bypass System in Obese Subjects|A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Subjects|Completed||N/A|10|Actual|ValenTx, Inc.||1|||f||||f||||||||||2018-05-31 23:19:46.513527|2018-05-31 23:19:46.513527
NCT01207817|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-09-22|2010-09-22|2010-09-23|Estimate|||||||2010-09-22|2010-09-23|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Effect of Ambient Light on the Parameters of the Pupillary Light Reflex|Effect of Ambient Light on the Parameters of the Pupillary Light Reflex|Completed|||30|Anticipated|Rutgers, The State University of New Jersey|||1||f||||f||||||||||2018-05-31 23:19:46.581697|2018-05-31 23:19:46.581697
NCT01207804|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2016-03-15|2010-09-21|2010-09-23|Estimate|||||||2016-03-15|2016-03-17|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Feasibility Trial of ValenTx Endo Bypass System|A Single Center Feasibility Trial of the Safety and Efficacy of the ValenTx Endo Bypass System in Obese Patients|Completed||N/A|12|Actual|ValenTx, Inc.||1|||f||||f||||||||||2018-05-31 23:19:46.648755|2018-05-31 23:19:46.648755
NCT01207791|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-05-22|2010-09-21|2010-09-23|Estimate|||||||2013-05-22|2013-05-24|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|SMART-ED||Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments|Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments|Completed||N/A|1285|Actual|University of New Mexico||3|||f||||t||||||||||2018-05-31 23:19:46.76911|2018-05-31 23:19:46.76911
NCT01207778|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-01-30|2010-09-21|2010-09-23|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2010||2010-03-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 31, 2016|Actual|2016-12-31||Observational|BRITE||Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin|Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin|Active, not recruiting|||105|Actual|University of New Mexico|||3||f||||f|f|f||||Samples With DNA|"~     saliva collected for DNA~   "|Undecided|Plan to submit data to data and specimen hub (DASH)|2018-05-31 23:19:46.872333|2018-05-31 23:19:46.872333
NCT01207765|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2016-09-07||2017-02-10|2010-09-22|2010-09-23|Estimate|2016-09-07|2016-10-28|Estimate||||2017-02-10|2017-03-20|Actual|April 2008||2008-04-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional||Simon two-stage, min-max design test the hypothesis H0: p</=0.05 (the expected response rate for no treatment) versus Ha: p>/=0.30 (a clinically significant response rate) with a=0.05 and b=0.20.|Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma|A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma|Terminated||Phase 2|8|Actual|Tufts Medical Center|Study ended at end of stage 1|1||changes in practice|f||||f||||||||No||2018-05-31 23:19:46.999167|2018-05-31 23:19:46.999167
NCT01207752|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-05-31|2010-09-22|2010-09-23|Estimate|||||||2013-05-31|2013-06-04|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction|Evaluation of the Efficacy of an Ocular Emulsion on the Signs and Symptoms of Meibomian Gland Dysfunction|Completed||N/A|54|Actual|Southern California College of Optometry||2|||f||||f||||||||||2018-05-31 23:19:47.204425|2018-05-31 23:19:47.204425
NCT01207739|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2016-09-06|2010-09-22|2010-09-23|Estimate|||||||2016-09-06|2016-09-08|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|PLEASE||Persistent Lyme Empiric Antibiotic Study Europe|Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease|Completed||Phase 4|280|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 23:19:47.28534|2018-05-31 23:19:47.28534
NCT01207726|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2015-04-30|2010-09-21|2010-09-23|Estimate|||||||2015-04-30|2015-05-01|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery|Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-Azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care|Terminated||Phase 2|13|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:19:47.369649|2018-05-31 23:19:47.369649
NCT01207713|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2010-09-22|2010-09-22|2010-09-23|Estimate|||||||2010-09-22|2010-09-23|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||A Modified Orbital Implantation Technique in Enucleation|Evaluation of the Functional and Cosmetic Outcome of Enucleation With Rectus End-to-end Suturing Surgical Technique in Coralline Hydroxyapatite Orbital Implants|Completed|||45|Actual|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||f||||||None Retained|"~     The investigators reviewed surgical records from July 2005 to March 2009, to identify~     patients who had received hydroxyapatite orbital implants after primary enucleation by a~     single surgeon~   "|||2018-05-31 23:19:47.499039|2018-05-31 23:19:47.499039
NCT01207700|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2014-11-27|2010-09-22|2010-09-23|Estimate|||||||2014-11-27|2014-12-02|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|SPREAD||Secondary Prevention of coRonary Events After Discharge From Hospital (SPREAD)|A Randomized, Open Trial Comparing Post Discharge Interventions to Standard Care|Completed||N/A|806|Actual|St. John's Research Institute||2|||f||||t||||||||||2018-05-31 23:19:47.564152|2018-05-31 23:19:47.564152
NCT01207687|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2017-05-18||2017-11-22|2010-09-21|2010-09-23|Estimate|2017-07-17|2017-08-17|Actual||||2017-11-22|2017-12-21|Actual|October 2010||2010-10-31|November 2017|2017-11-30|March 2014|Actual|2014-03-31|February 2013|Actual|2013-02-28||Interventional|||Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)|Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma|Completed||Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||||||||||No|No individual patient data will be shared|2018-05-31 23:19:47.690466|2018-05-31 23:19:47.690466
NCT01207674|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2018-02-14|2010-09-22|2010-09-23|Estimate|||||||2018-02-14|2018-02-15|Actual|April 2009||2009-04-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|November 2011|Actual|2011-11-30||Interventional|||Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers (JEU)|Transversal Multiaxial Evaluation and 5-year Follow-up of a Cohort of French Gamblers.|Completed||N/A|641|Actual|Nantes University Hospital|||||f||||||||||||||2018-05-31 23:19:48.163403|2018-05-31 23:19:48.163403
NCT01207661|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2012-01-02|2010-09-22|2010-09-23|Estimate|||||||2012-01-02|2012-01-05|Estimate|August 2009||2009-08-31|April 2009|2009-04-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Articular Cartilage Resurfacing With Mesenchymal Stem Cells In Osteoarthritis Of Knee Joint|Mesenchymal Stem Cells Transplantation for Articular Cartilage Resurfacing in Patient With Osteoarthritis of Knee Joint|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 23:19:48.224123|2018-05-31 23:19:48.224123
NCT01207648|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2013-04-08||2015-04-27|2010-09-21|2010-09-23|Estimate|2013-04-08|2013-05-30|Estimate||||2015-04-27|2015-05-15|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|REPLAY||Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)|Retrospective Cohort Study of Rebif® Use in Pediatric MS Patients|Completed|||307|Actual|EMD Serono|||1||f||||f||||||||||2018-05-31 23:19:48.323824|2018-05-31 23:19:48.323824
NCT01207635|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2012-07-27|2010-09-22|2010-09-23|Estimate|||||||2012-07-27|2012-07-30|Estimate|November 2002||2002-11-30|July 2012|2012-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer|Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer|Completed|||42|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||None Retained|"~     Blood drawn; and, fluids collected from ductal lavage.~   "|||2018-05-31 23:19:48.594835|2018-05-31 23:19:48.594835
NCT01207622|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2013-03-04|2010-09-22|2010-09-23|Estimate|||||||2013-03-04|2013-03-05|Estimate||||March 2013|2013-03-31||||||||Interventional|||Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD|Efficacy of Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents and Young Adults With Substance Use Disorders (SUD)|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||Poor enrollment|f||||t||||||||||2018-05-31 23:19:48.649794|2018-05-31 23:19:48.649794
NCT01207609|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2016-02-01|2010-09-22|2010-09-23|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Laparoscopic Gastric Plication Operation for Patients With Severe or Morbid Obesity|A Prospective Study to Evaluate the Safety and Efficacy of the Laparoscopic Gastric Plication Operation for Patients With Severe or Morbid Obesity|Completed||N/A|35|Actual|Ponce, Jaime, M.D.||1|||f||||f||||||||No||2018-05-31 23:19:48.722439|2018-05-31 23:19:48.722439
NCT01207596|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2011-10-04||2012-05-17|2010-09-22|2010-09-23|Estimate|2012-05-17|2012-06-20|Estimate||||2012-05-17|2012-06-20|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain|Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain: An Open Label Study|Completed||Phase 4|30|Actual|International Clinical Research Institute||1|||f||||f||||||||||2018-05-31 23:19:48.801618|2018-05-31 23:19:48.801618
NCT01207583|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2012-07-26||2012-07-26|2010-09-21|2010-09-23|Estimate|2012-07-26|2012-08-31|Estimate||||2012-07-26|2012-08-31|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Prevenar (PCV-7) Post-Licensure Safety Study In Russia|Prevenar Post-Licensure Safety Study in Russia: Frequency Of Fever Post Vaccination|Completed|||100|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:19:49.187177|2018-05-31 23:19:49.187177
NCT01207570|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2011-08-08||2011-10-07|2010-09-22|2010-09-23|Estimate|2011-08-08|2011-09-13|Estimate||||2011-10-07|2011-10-10|Estimate|February 2010||2010-02-28|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Endermotherapy for Children With Developmental Disabilities|Effect of Endermotherapy on Passive Ankle Range of Motion in Children With Developmental Disabilities|Completed||Phase 2|54|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 23:19:50.041287|2018-05-31 23:19:50.041287
NCT01207557|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-10-24|2010-09-21|2010-09-23|Estimate|||||||2011-10-24|2011-10-26|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|OIDA||A Randomized Controlled Trial of the Effectiveness of the Ottawa Influenza Decision Aid|"A Randomized Controlled Trial of the Effectiveness of the Ottawa Influenza Decision Aid - A Component of the Optimizing Healthcare Workers Interpandemic Vaccine Uptake in Acute and Long-term Care CIHR Project"|Completed||N/A|300|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 23:19:50.363084|2018-05-31 23:19:50.363084
NCT01207544|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2012-11-26|2010-09-22|2010-09-23|Estimate|||||||2012-11-26|2012-11-28|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Fitball Program Versus Task-oriented Motor Program on Improving Postural Control in Developmental Coordination Disorder|The Effectiveness of Fitball Program Versus Task-oriented Motor Program on Improving Postural Control and Motor Proficiency in Children With Developmental Coordination Disorder|Completed||N/A|22|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 23:19:50.446808|2018-05-31 23:19:50.446808
NCT01207531|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-22|2010-09-22|2010-09-23|Estimate|||||||2010-09-22|2010-09-23|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|April 2011|Anticipated|2011-04-30|November 2010|Anticipated|2010-11-30||Observational|METPS||MiRNAs Evaluate the Prognosis of Sepsis|miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study|Unknown status|Recruiting||100|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||Samples Without DNA|"~     human serum~   "|||2018-05-31 23:19:50.530852|2018-05-31 23:19:50.530852
NCT01207518|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-07-27|2010-09-22|2010-09-23|Estimate|||||||2011-07-27|2011-07-28|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|August 2012|Anticipated|2012-08-31|March 2012|Anticipated|2012-03-31||Interventional|||Cluster RCT - Evaluating Effectiveness of a Guide and Tools for Influenza Immunization Campaign Planners|"Cluster RCT Evaluating the Effectiveness of Successful Influenza Immunization Campaigns in Healthcare Organizations: A Guide for Campaign Planners, Part of Optimizing Healthcare Workers Interpandemic Vaccine Uptake Study"|Unknown status|Recruiting|N/A|46|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 23:19:50.632674|2018-05-31 23:19:50.632674
NCT01207505|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2015-04-09|2010-09-21|2010-09-23|Estimate|||||||2015-04-09|2015-04-10|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Emotion Regulation Group Therapy for Bipolar Disorder|Emotion Regulation Group Therapy for Bipolar Disorder|Completed||N/A|38|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 23:19:50.739538|2018-05-31 23:19:50.739538
NCT01207492|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2015-06-08||2018-02-12|2010-09-22|2010-09-23|Estimate|2015-06-08|2015-06-25|Estimate||||2018-02-12|2018-03-12|Actual|September 2010||2010-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|April 2014|Actual|2014-04-30||Interventional|||Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor|A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor|Active, not recruiting||Phase 2|17|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 23:19:50.832827|2018-05-31 23:19:50.832827
NCT01207479|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-07-29|2010-09-22|2010-09-23|Estimate|||||||2013-07-29|2013-07-30|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Multi-Center Feasibility Study to Assess the Safety and Performance of The VitalaTM Continence Control Device With Natura Moldable Skin Barriers|A Multi-Center, Open-Label, Feasibility Study to Assess the Safety and Performance of the VitalaTM Continence Control Device When Worn With SUR FIT Natura® Moldable TechnologyTM Skin Barrier Products Over a 12 Hour Period|Completed||N/A|28|Actual|ConvaTec Inc.||1|||f||||f||||||||||2018-05-31 23:19:51.050989|2018-05-31 23:19:51.050989
NCT01207466|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2011-07-28||2012-06-27|2010-09-21|2010-09-23|Estimate|2011-07-28|2011-08-26|Estimate||||2012-06-27|2012-07-10|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Evaluation of Two Daily Disposable Contact Lenses for Wearers With Astigmatism||Completed||N/A|95|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:19:51.099867|2018-05-31 23:19:51.099867
NCT01207453|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2014-10-16||2014-11-07|2010-09-21|2010-09-23|Estimate|2014-11-07|2014-11-17|Estimate||||2014-11-07|2014-11-17|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||49 individuals signed the informed consent document. Of these individuals, 8 did not meet inclusion/exclusion criteria. 41 subjects were randomized and received study drug.|Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis|Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis|Completed||Phase 4|49|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 23:19:51.241089|2018-05-31 23:19:51.241089
NCT01207440|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2018-05-15|2010-09-22|2010-09-23|Estimate|||||||2018-05-15|2018-05-16|Actual|September 30, 2010|Actual|2010-09-30|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|PACE||Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)|A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|449|Actual|Takeda||6|||f||||t||||||||||2018-05-31 23:19:51.706799|2018-05-31 23:19:51.706799
NCT01207427|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2015-04-21||2016-01-05|2010-09-21|2010-09-23|Estimate|2015-04-21|2015-05-07|Estimate||||2016-01-05|2016-02-03|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All participants who received at least 1 dose of study drug|Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain|Completed||Phase 2|131|Actual|Cubist Pharmaceuticals LLC||3|||f||||f||||||||||2018-05-31 23:19:51.85972|2018-05-31 23:19:51.85972
NCT01207414|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|2012-12-18||2013-02-04|2010-09-21|2010-09-22|Estimate|2013-02-04|2013-03-15|Estimate||||2013-02-04|2013-03-15|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|i-FANS||Switching to Iloperidone From Other Antipsychotics in Schizophrenia|A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24 mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole|Completed||Phase 4|501|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:19:52.195433|2018-05-31 23:19:52.195433
NCT01207401|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2012-07-25||2013-05-02|2010-09-21|2010-09-22|Estimate|2013-05-02|2013-06-10|Estimate||||2013-05-02|2013-06-10|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Paracervical Block Before Intrauterine Device (IUD) Insertion|Pain Control for Intrauterine Device Insertion: A Randomized Trial of 1% Lidocaine Paracervical Block|Completed||N/A|50|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 23:19:52.531472|2018-05-31 23:19:52.531472
NCT01207388|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2015-01-28||2017-03-30|2010-09-21|2010-09-22|Estimate|2015-01-28|2015-02-12|Estimate||||2017-03-30|2017-05-01|Actual|November 2010||2010-11-30|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|February 2014|Actual|2014-02-28||Interventional|BLAST|Full analysis set (all participants who received any infusion of blinatumomab)|Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)|A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST)|Active, not recruiting||Phase 2|116|Actual|Amgen Research (Munich) GmbH||1|||f||||t||||||||||2018-05-31 23:19:53.753902|2018-05-31 23:19:53.753902
NCT01207375|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2015-04-01|2010-09-21|2010-09-22|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Improving New Learning and Memory in Traumatic Brain Injury|Improving New Learning in Traumatic Brain Injury: A Randomized Clinical Trial|Completed||N/A|120|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-05-31 23:19:54.684302|2018-05-31 23:19:54.684302
NCT01207362|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2010-09-21|2010-09-21|2010-09-22|Estimate|||||||2010-09-21|2010-09-22|Estimate|August 2009||2009-08-31|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Observational|||Assessing and Improving Balance Using Platform Perturbations|Assessing and Improving Balance Using Platform Perturbations|Unknown status|Active, not recruiting||4|Anticipated|Kessler Foundation|||2||f||||f||||||||||2018-05-31 23:19:54.752405|2018-05-31 23:19:54.752405
NCT01207349|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-01-27|2010-09-21|2010-09-22|Estimate|||||||2012-01-27|2012-01-31|Estimate|August 2002||2002-08-31|January 2012|2012-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|RP2||Type 2 Diabetes Secondary Prevention|Type 2 Diabetes Secondary Prevention Trial at the Reunion Island|Completed|||398|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||t||||||||||2018-05-31 23:19:54.802728|2018-05-31 23:19:54.802728
NCT01207336|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2012-04-05|2010-09-21|2010-09-22|Estimate|||||||2012-04-05|2012-04-06|Estimate|September 2010||2010-09-30|April 2012|2012-04-30||||September 2012|Anticipated|2012-09-30||Interventional|||Combined tDCS+PNS After Acute Stroke|Effect of Combined Anodal tDCS and Peripheral Nerve Stimulation on Motor Recovery in Acute Stroke|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-05-31 23:19:54.890316|2018-05-31 23:19:54.890316
NCT01207323|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2018-04-30|2010-09-21|2010-09-22|Estimate|||||||2018-04-30|2018-05-01|Actual|November 9, 2010|Actual|2010-11-09|April 2018|2018-04-30|April 23, 2018|Actual|2018-04-23|December 3, 2013|Actual|2013-12-03||Interventional|||A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients With Locally Advanced or Metastatic Epithelial Tumors|Completed||Phase 1|66|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:19:54.971494|2018-05-31 23:19:54.971494
NCT01207310|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-10-29|2010-09-21|2010-09-22|Estimate|||||||2017-10-29|2017-10-31|Actual|May 2003||2003-05-31|October 2017|2017-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|Pager||Pager-Assisted Smoking Cessation Treatment|Pager-Assisted Smoking Cessation Treatment|Completed||N/A|224|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:19:55.048502|2018-05-31 23:19:55.048502
NCT01207297|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-08-22|2010-09-21|2010-09-22|Estimate|||||||2011-08-22|2011-08-23|Estimate|March 2003||2003-03-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis|Tacrolimus Versus Cyclophosphamide as Treatment for Diffuse Proliferative or Membranous Lupus Nephritis: Prospective Cohort Study|Completed||Phase 1|40|Actual|Zhejiang University||2|||f||||t||||||||||2018-05-31 23:19:55.1396|2018-05-31 23:19:55.1396
NCT01207284|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2013-09-26|2010-09-21|2010-09-22|Estimate|||||||2013-09-26|2013-09-27|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|||Influence of Physical Therapy for Foot and Ankle in the Gait of Individuals With Diabetic Neuropathy|Influence of Physical Therapy Intervention on the Foot and Ankle in Gait Biomechanics in Individuals With Diabetic Neuropathy: a Randomized Clinical Trial|Completed||Phase 1|55|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 23:19:55.227592|2018-05-31 23:19:55.227592
NCT01207271|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-04-28|2010-09-21|2010-09-22|Estimate|||||||2017-04-28|2017-05-02|Actual|November 2010||2010-11-30|April 2017|2017-04-30|December 9, 2014|Actual|2014-12-09|December 9, 2014|Actual|2014-12-09||Interventional|||A Comparison of Cognitive and Dynamic Therapy for Depression in Community Settings|A Comparison of Cognitive and Dynamic Therapy for MDD in Community Settings|Completed||N/A|237|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:19:55.418365|2018-05-31 23:19:55.418365
NCT01207258|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2016-08-18|2010-09-21|2010-09-22|Estimate|||||||2016-08-18|2016-08-22|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Brief Intervention for Problem Drinking and Partner Violence|A Randomized Control Trial of Brief Intervention for Problem Drinking and Partner Violence|Completed||Phase 2|600|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 23:19:55.533717|2018-05-31 23:19:55.533717
NCT01207245|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2015-06-22|2010-09-21|2010-09-22|Estimate|||||||2015-06-22|2015-06-23|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|CRITIC||Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis|Circadian Rhythm In Tobramycin Elimination In Cystic Fibrosis (CRITIC) A Randomized Pharmacokinetic Comparison of Tobramycin in Cystic Fibrosis|Completed||Phase 4|18|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 23:19:55.608794|2018-05-31 23:19:55.608794
NCT01207232|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-21|2010-09-21|2010-09-22|Estimate|||||||2010-09-21|2010-09-22|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates|The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates|Completed||N/A|3272|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 23:19:55.686305|2018-05-31 23:19:55.686305
NCT01207219|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2014-06-17||2014-12-08|2010-09-21|2010-09-22|Estimate|2014-12-08|2014-12-09|Estimate||||2014-12-08|2014-12-09|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|April 2013|Actual|2013-04-30||Interventional|YEP||Yoga and Aerobic Exercise in Psychosis|The Impacts of Yoga and Aerobic Exercise on Neuro-cognitive Function and Symptoms in Early Psychosis - A Single-blind Randomized Controlled Clinical Trial|Completed||N/A|140|Actual|The University of Hong Kong|Lack of a healthy control group; a measurement bias may exist in the HKLLT because the same word list was used for baseline and 12 weeks.|3|||f||||t||||||||||2018-05-31 23:19:55.796448|2018-05-31 23:19:55.796448
NCT01207206|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-10-31|2010-09-21|2010-09-22|Estimate|||||||2011-10-31|2011-11-01|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients|Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients|Unknown status|Recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:19:56.378417|2018-05-31 23:19:56.378417
NCT01207193|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-12-13|2010-09-21|2010-09-22|Estimate|||||||2011-12-13|2011-12-14|Estimate|October 2009||2009-10-31|March 2009|2009-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Treatment Of Bone Cyst With Bone Marrow Mesenchymal Cell Transplantation|Effect of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Reconstructing Bone Defects.|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 23:19:56.445495|2018-05-31 23:19:56.445495
NCT01207180|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-11-17|2010-09-21|2010-09-22|Estimate|||||||2011-11-17|2011-11-18|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Discharge Planning for Elderly Patients in the Emergency Department: Use of a Brief Phone Call After Discharge to Improve Medication Utilization and Physician Follow-up|Discharge Planning for Elderly Patients in the Emergency Department: Use of a Brief Phone Call After Discharge to Improve Medication Utilization and Physician Follow-up|Completed||N/A|157|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 23:19:56.517472|2018-05-31 23:19:56.517472
NCT01207167|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2018-04-30|2010-09-21|2010-09-22|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2010||2010-09-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2013|Actual|2013-03-31||Observational|MASALA||Mediators of Atherosclerosis in South Asians Living in America|Mediators of Atherosclerosis in South Asians Living in America|Enrolling by invitation|||1000|Anticipated|University of California, San Francisco|||||f||||f||||||||||2018-05-31 23:19:56.602493|2018-05-31 23:19:56.602493
NCT01207154|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-10-11|2010-09-21|2010-09-22|Estimate|||||||2017-10-11|2017-10-13|Actual|December 2010||2010-12-31|May 2013|2013-05-31|October 31, 2012|Actual|2012-10-31|October 31, 2012|Actual|2012-10-31||Observational|||Feasibility of Using Depth-of-sedation Measuring Equipment (BIS) to Guide Awake Fibreoptic Intubation|BIS-guided Conscious Sedation for Awake Intubation|Withdrawn|||0|Actual|Oxford University Hospitals NHS Trust|||2|Difficulty in Recruitment due to lack of investigators and suitable patients|f||||f||||||||||2018-05-31 23:19:56.665976|2018-05-31 23:19:56.665976
NCT01207141|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-03-31|2010-09-21|2010-09-22|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2006||2006-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation|Pharmacodynamics, Pharmacogenomics, and Preliminary Safety and Efficacy of rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation|Active, not recruiting|||110|Actual|University of Pittsburgh|||2||f||||t||||||None Retained|"~     Blood~   "|||2018-05-31 23:19:56.719562|2018-05-31 23:19:56.719562
NCT01207128|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2012-04-18|2010-09-21|2010-09-22|Estimate|||||||2012-04-18|2012-04-20|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis|A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer|Withdrawn||Phase 2|0|Actual|University of Arkansas||2||None enrolled|f||||t||||||||||2018-05-31 23:19:56.775193|2018-05-31 23:19:56.775193
NCT01207115|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21||2012-05-04|2013-01-02|2010-09-21|2010-09-22|Estimate||||2012-05-04|2012-05-08|Estimate|2013-01-02|2013-01-07|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee|A Global Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Osteoarthritis Pain of the Knee|Completed||Phase 2|322|Actual|AbbVie||4|||f||||t||||||||||2018-05-31 23:19:56.844265|2018-05-31 23:19:56.844265
NCT01207102|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2014-12-08||2014-12-08|2010-09-21|2010-09-22|Estimate|2014-12-08|2014-12-15|Estimate||||2014-12-08|2014-12-15|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer|"A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for Triple Negative (Demonstrating no Expression for Estrogen, Progesterone, or Human Epidermal Growth Factor Receptor 2 (HER2)Receptors) Metastatic Breast Cancer"|Terminated||Phase 2|10|Actual|Duke University||1||Low enrollment and there is insufficient data to publish.|f||||f||||||||||2018-05-31 23:19:57.064226|2018-05-31 23:19:57.064226
NCT01207089|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-05-09|2010-09-21|2010-09-22|Estimate|||||||2011-05-09|2011-05-10|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|AZ8329||To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329|A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD8329 After Administration of Multiple Ascending Doses in Abdominally Obese But Otherwise Healthy Male Subjects|Completed||Phase 1|45|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 23:19:57.3213|2018-05-31 23:19:57.3213
NCT01207076|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-12-03|2010-09-21|2010-09-22|Estimate|||||||2017-12-03|2017-12-05|Actual|December 2013||2013-12-31|December 2017|2017-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||AHN-12 Biodistribution in Advanced Leukemia|Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 In Patients With Advanced Leukemia HM2010-05|Terminated||Phase 1|8|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||t||||||||||2018-05-31 23:19:57.408577|2018-05-31 23:19:57.408577
NCT01207063|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2018-03-22|2010-09-21|2010-09-22|Estimate|||||||2018-03-22|2018-03-23|Actual|March 2011|Actual|2011-03-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)|Adaptive Radiotherapy for Stage II-III Non-small Cell Lung Cancer|Active, not recruiting||Phase 2|40|Anticipated|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-05-31 23:19:57.553237|2018-05-31 23:19:57.553237
NCT01207050|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2014-09-08|2010-09-21|2010-09-22|Estimate|||||||2014-09-08|2014-09-09|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Rozerem on Sleep Among People With Traumatic Brain Injury|Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 23:19:57.61647|2018-05-31 23:19:57.61647
NCT01207037|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-12-20|2010-09-21|2010-09-22|Estimate|||||||2017-12-20|2017-12-21|Actual|August 12, 2010|Actual|2010-08-12|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 22, 2014|Actual|2014-12-22||Interventional|SSADREPA||Prognostic Factors of Acute Splenic Sequestration|Study of Prognostic Factors of Acute Splenic Sequestration in a Cohort of Sickle Cell Disease (SCD) Children Diagnosed at Birth|Active, not recruiting||N/A|58|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:19:57.69247|2018-05-31 23:19:57.69247
NCT01207024|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2014-12-19|2010-09-21|2010-09-22|Estimate|||||||2014-12-19|2014-12-23|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|September 2014|Actual|2014-09-30|April 2013|Actual|2013-04-30||Observational|BASIK||Assessment of Knee Arthrosis After Bariatric Surgery|Assessment of Knee Arthrosis in Severely Obese Patients After Bariatric Surgery.|Completed|||80|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 23:19:57.748577|2018-05-31 23:19:57.748577
NCT01207011|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2015-08-27|2010-09-21|2010-09-22|Estimate|||||||2015-08-27|2015-08-28|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer|A Randomised, Open-Label Phase 3 Trial Comparing Amrubicin Versus Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy|Completed||Phase 3|202|Actual|Sumitomo Dainippon Pharma Co., Ltd.||2|||f||||||||||||||2018-05-31 23:19:57.812449|2018-05-31 23:19:57.812449
NCT01206998|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2012-09-28|2010-09-21|2010-09-22|Estimate|||||||2012-09-28|2012-10-01|Estimate|July 2010||2010-07-31|September 2012|2012-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|VagPro||Vaginal Progesterone as a Treatment for Women Active Preterm Labor|Vaginal Progesterone in Patients With Active Preterm Labor|Withdrawn||N/A|0|Actual|University of Rochester||2||Withdrawal of support of the drug company for drug and placebo|f||||t||||||||||2018-05-31 23:19:57.872396|2018-05-31 23:19:57.872396
NCT01206985|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2012-01-26|2010-09-21|2010-09-22|Estimate|||||||2012-01-26|2012-01-30|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Paracétamol PMB by Sublingual et Buccal Routes|Pharmacodynamic Study of 125 mg of Paracetamol Permucosal Administered by Sublingual and Buccal Route|Completed||Phase 1|20|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:19:57.940334|2018-05-31 23:19:57.940334
NCT01206972|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2017-01-17|2010-09-21|2010-09-22|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Dose-confirmatory Bridging Study in Total Knee Replacement|Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement|Completed||Phase 3|302|Actual|Bayer||4|||f||||f||||||||||2018-05-31 23:19:58.011516|2018-05-31 23:19:58.011516
NCT01206959|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2015-06-23|2010-09-21|2010-09-22|Estimate|||||||2015-06-23|2015-06-25|Estimate||||June 2015|2015-06-30||||||||Observational|||Clinical Test for Armed-used Blood Pressure Monitor With Preformed Cuff(Monitor When Being Inflated)||Completed|||88|Actual|Andon Health Co., Ltd|||1||f||||f||||||||||2018-05-31 23:19:58.143069|2018-05-31 23:19:58.143069
NCT01206946|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-06-22|2010-09-21|2010-09-22|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants|Effect of Antenatal Steroids for Women at Risk of Late Preterm Delivery on Neonatal Respiratory Morbidity|Unknown status|Recruiting|Phase 2|700|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 23:19:58.191305|2018-05-31 23:19:58.191305
NCT01206933|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2016-02-08|2010-09-21|2010-09-22|Estimate|||||||2016-02-08|2016-02-10|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System|The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System.|Completed|||20|Actual|George Washington University|||6||f||||f||||||||No||2018-05-31 23:19:58.296308|2018-05-31 23:19:58.296308
NCT01206920|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2018-03-01|2010-09-21|2010-09-22|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2011||2011-01-31|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|DC Cohort||Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort|Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort|Recruiting|||10000|Anticipated|George Washington University|||||f||||f||||||||||2018-05-31 23:19:58.361688|2018-05-31 23:19:58.361688
NCT01206907|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2012-08-15|2010-09-21|2010-09-22|Estimate|||||||2012-08-15|2012-08-17|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects|AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER EFFECTIVENESS, SAFETY AND TOLERABILITY STUDY OF OXYMORPHONE HCl IMMEDIATE-RELEASE ORAL LIQUID IN OPIOID-TOLERANT PEDIATRIC SUBJECTS WITH CHRONIC PAIN REQUIRING AN AROUND THE CLOCK OPIOID|Withdrawn||Phase 3|0|Actual|Endo Pharmaceuticals||||The study is no longer required for the PREA for this product.|f||||t||||||||||2018-05-31 23:19:58.444221|2018-05-31 23:19:58.444221
NCT01206894|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2014-09-25|2010-09-21|2010-09-22|Estimate|||||||2014-09-25|2014-09-29|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|CT0010||Pre-Operative Assessment of Chest Wall Invasion in NSCLC Using Pre-Operative, Surgeon Performed Ultrasound|Pre-Operative Assessment of Chest Wall Invasion in Non-Small Cell Lung Cancer (NSCLC)Using Pre-Operative, Surgeon Performed Ultrasound|Completed||N/A|25|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 23:19:58.488621|2018-05-31 23:19:58.488621
NCT01206881|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-30|2010-09-21|2010-09-22|Estimate|||||||2011-06-30|2011-07-04|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer|A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer|Completed||Phase 2|45|Anticipated|Herlev Hospital|||||f||||t||||||||||2018-05-31 23:19:58.539337|2018-05-31 23:19:58.539337
NCT01206868|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2010-09-21|2010-09-21|2010-09-22|Estimate|||||||2010-09-21|2010-09-22|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|May 2009|Actual|2009-05-31|||||Interventional|PROFFEN||Prophylactic Fenestration of the Peritoneum in Kidney Transplantation|Prospective Open Randomized Study to Evaluate the Efficiency of Prophylactic Fenestration of the Peritoneum in Kidney Transplantation in Preventing the Occurrence of Postoperative Lymphoceles|Completed||N/A|130|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:19:58.60506|2018-05-31 23:19:58.60506
NCT01206855|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2014-10-06|2010-09-21|2010-09-22|Estimate|||||||2014-10-06|2014-10-08|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Effectiveness Study of MIST Therapy After Cosmetic Surgery Procedures of the Face and Body|Use of MIST Ultrasound Therapy to Minimize Edema, Bruising and Scarring After Cosmetic Surgery Procedures of the Face and Body|Completed||Phase 4|3440|Actual|Celleration, Inc.||2|||f||||f||||||||||2018-05-31 23:19:58.77798|2018-05-31 23:19:58.77798
NCT01206842|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2018-05-19|2010-09-21|2010-09-22|Estimate|||||||2018-05-19|2018-05-22|Actual|August 2011|Actual|2011-08-31|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Social Cognition Training in Schizophrenia|Social Cognition Training in Schizophrenia|Completed||N/A|48|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:19:58.865204|2018-05-31 23:19:58.865204
NCT01206829|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-06-13|2010-09-21|2010-09-22|Estimate|||||||2013-06-13|2013-06-14|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Hearing Impairment, Cognitive Therapy and Coping|Hearing Impairment, Tinnitus, Mental Health and Vocational Coping. A Randomized, Controlled Study of a Cognitive Therapy Program to Reduce Social Safety Seeking.|Unknown status|Active, not recruiting|Phase 1|180|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 23:19:58.92903|2018-05-31 23:19:58.92903
NCT01206816|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2013-10-31|2010-09-21|2010-09-22|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours|An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBW 2992 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|57|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:19:59.005861|2018-05-31 23:19:59.005861
NCT01206803|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2016-01-04|2010-09-21|2010-09-22|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||Ovarian Response Prediction in In Vitro Fertilization (IVF) Patients|Polymorphisms of FSH Receptor, LH Receptor, LH and Ovarian Response to FSH in Controlled Ovarian Stimulation Using a GnRH Antagonist Protocol|Completed|||294|Actual|University of Schleswig-Holstein|||||f||||f||||||Samples With DNA|"~     Serum samples for analysis of gonadotropins and Anti-Muellerian Hormone EDTA samples for DNA~     extraction~   "|||2018-05-31 23:19:59.067349|2018-05-31 23:19:59.067349
NCT01206790|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2012-02-21|2010-09-21|2010-09-22|Estimate|||||||2012-02-21|2012-02-22|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||Immunological Changes Through Narrative Treatment of Post-Traumatic Stress Disorder (PTSD) in Torture Victims|Immunological Changes Through Narrative Treatment of PTSD in Torture Victims|Completed||N/A|47|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 23:19:59.180131|2018-05-31 23:19:59.180131
NCT01206777|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2014-10-28||2017-12-19|2010-09-21|2010-09-22|Estimate|2015-02-05|2015-02-23|Estimate||||2017-12-19|2017-12-20|Actual|October 2010||2010-10-31|December 2017|2017-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies|Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center|Completed||Phase 2|52|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:19:59.263676|2018-05-31 23:19:59.263676
NCT01206764|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2017-02-27|2010-09-21|2010-09-22|Estimate|||||||2017-02-27|2017-03-01|Actual|April 13, 2010|Actual|2010-04-13|February 2017|2017-02-28|March 30, 2017|Anticipated|2017-03-30|March 30, 2017|Anticipated|2017-03-30||Interventional|||A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.|An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE).|Recruiting||Phase 4|110|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 23:19:59.438084|2018-05-31 23:19:59.438084
NCT01206751|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-21|2010-09-21|2010-09-22|Estimate|||||||2010-09-21|2010-09-22|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Multi-detector Computer Tomography Protocol Project: Chest Imaging Technique and Case Presentation|Multi-detector Computer Tomography Protocol Project: Chest Imaging Technique and Case Presentation|Completed|||30|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:19:59.562612|2018-05-31 23:19:59.562612
NCT01206738|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|2014-01-30||2017-05-01|2010-09-21|2010-09-22|Estimate|2014-01-30|2014-03-18|Estimate||||2017-05-01|2017-06-02|Actual|November 2010||2010-11-30|May 2017|2017-05-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|WIME|GPs across Scotland|Developing and Evaluating Interventions to Reduce Inappropriate Prescribing of Antibiotics in Primary Care|Developing and Evaluating Interventions to Reduce Inappropriate Prescribing by General Practitioners of Antibiotics for Upper Respiratory Tract Infections: an RCT to Compare Paper-based and Web-based Modelling Experiments|Completed||N/A|270|Actual|University of Dundee||3|||f||||f||||||||No|There are no patient-level data in this trial because no patients were involved. More information about the study and what was collected can be obtained from the Shaun Treweek at streweek@mac.com.|2018-05-31 23:19:59.646894|2018-05-31 23:19:59.646894
NCT01206725|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2018-01-03|2010-09-21|2010-09-22|Estimate|||||||2018-01-03|2018-01-05|Actual|September 2010|Actual|2010-09-30|January 2018|2018-01-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction|The Effect of Aerobic Interval Training on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction|Completed||N/A|47|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 23:19:59.908948|2018-05-31 23:19:59.908948
NCT01206712|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2010-09-21|2010-09-21|2010-09-22|Estimate|||||||2010-09-21|2010-09-22|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients|Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients - Investigation on Postprandial Excursions of Proinsulin and PAI-1 Levels|Completed|||106|Actual|ikfe-CRO GmbH|||4||f||||f||||||||||2018-05-31 23:19:59.986588|2018-05-31 23:19:59.986588
NCT01206699|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2015-11-02|2010-09-21|2010-09-22|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Involvement of Transverso-sacral- Neo- Articulations or of Transverso-iliac Articulations in Chronic Lumbago|Involvement of Transverso-sacral- Neo- Articulations or of Transverso-iliac Articulations in Chronic Lumbago: Prospective Multicentric , Double-Blinded, Randomized of the Efficacy of corticoïd Infiltration Versus Physiological Solution Infiltration|Terminated||Phase 4|16|Actual|Nantes University Hospital||2||"after 4 years of recruitment only 16 patients have been included. Due to this low rate of~   recruitment it was decided to stop the study"|f||||f||||||||||2018-05-31 23:20:00.053044|2018-05-31 23:20:00.053044
NCT01206686|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2016-08-15|2010-09-20|2010-09-22|Estimate|||||||2016-08-15|2016-08-17|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Time-Slot Scheduling on Flu Vaccination Rates|Effect of Time-Slot Scheduling on Flu Vaccination Rates|Completed||N/A|50000|Anticipated|University of Pennsylvania||5|||f||||f||||||||||2018-05-31 23:20:00.122067|2018-05-31 23:20:00.122067
NCT01206673|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-12-01|2010-09-21|2010-09-22|Estimate|||||||2011-12-01|2011-12-02|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Gaucher||Macrophagic Activation and Immunophenotypic Profile of Patients With Gaucher's Disease|Evaluation of Macrophagic Activation and Immunophenotypic Profile of Patients With Gaucher's Disease.|Completed||N/A|10|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 23:20:00.214734|2018-05-31 23:20:00.214734
NCT01206660|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2014-01-22||2014-06-03|2010-09-21|2010-09-22|Estimate|2014-06-03|2014-07-03|Estimate||||2014-06-03|2014-07-03|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis|A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|120|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:20:00.307828|2018-05-31 23:20:00.307828
NCT01206647|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-21|2010-09-21|2010-09-22|Estimate|||||||2010-09-21|2010-09-22|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus|Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|ikfe-CRO GmbH||2|||f||||f||||||||||2018-05-31 23:20:00.686707|2018-05-31 23:20:00.686707
NCT01206634|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-20|2010-09-20|2010-09-22|Estimate|||||||2010-09-20|2010-09-22|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Regenerative Injection Therapy and Osteoarthritis|Effect of Regenerative Injection Therapy on Function and Pain in Patients With Knee Osteoarthritis|Completed||Phase 4|45|Actual|Réseau de Santé Vitalité Health Network||2|||f||||f||||||||||2018-05-31 23:20:00.782174|2018-05-31 23:20:00.782174
NCT01206621|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2011-05-12|2010-09-21|2010-09-22|Estimate|||||||2011-05-12|2011-05-13|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Vibration Response Imaging (VRI) in Dyspnea Patients Presenting to the ED|Assessment of the Utility of Vibration Response Imaging (VRI) in Evaluating Dyspnea Patients Presenting to the Emergency Department|Unknown status|Recruiting||530|Anticipated|Deep Breeze|||1||f||||f||||||None Retained|"~     Blood drawn for BNP testing~   "|||2018-05-31 23:20:00.847368|2018-05-31 23:20:00.847368
NCT01206608|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|2011-11-23|2010-09-22|2013-07-03|2010-09-20|2010-09-22|Estimate|2013-07-03|2013-08-06|Estimate|2010-09-22|2010-09-27|Estimate|2013-07-03|2013-08-06|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty|A Randomized, Double-Blind, Active-Control Study to Evaluate the Safety and Efficacy of a Single Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Augmentation Mammoplasty|Completed||Phase 2|40|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 23:20:00.952316|2018-05-31 23:20:00.952316
NCT01206439|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|2015-08-24||2018-02-13|2010-09-20|2010-09-21|Estimate|2015-10-22|2015-11-25|Estimate||||2018-02-13|2018-02-15|Actual|September 2010||2010-09-30|February 2018|2018-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||An Advanced Echocardiographic Evaluation of Nebivolol|An Advanced Echocardiographic Evaluation of Nebivolol|Terminated||Phase 4|2|Actual|University of Cincinnati||1||Slow enrollment|f||||f||||||||||2018-05-31 23:20:04.825502|2018-05-31 23:20:04.825502
NCT01206595|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|2011-11-30|2010-09-22|2012-04-15|2010-09-20|2010-09-22|Estimate|2012-04-15|2012-05-15|Estimate|2010-09-22|2010-09-27|Estimate|2012-04-15|2012-05-15|Estimate|March 2005||2005-03-31|November 2011|2011-11-30|December 2006|Actual|2006-12-31|March 2006|Actual|2006-03-31||Interventional|||Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy|A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De-Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sustained Release Encapsulated Bupivacaine (SKY0402) Administered as a Nerve Block in the Management of Postoperative Pain in Subjects Undergoing Bunionectomy|Completed||Phase 2|58|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 23:20:01.184523|2018-05-31 23:20:01.184523
NCT01206582|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2015-11-21||2016-01-05|2010-09-21|2010-09-22|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)|A Pilot Study of Hemin Therapy for Gastroparesis|Completed||Phase 2|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:20:01.820217|2018-05-31 23:20:01.820217
NCT01206569|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-21|||2012-12-03|2010-09-21|2010-09-22|Estimate|||||||2012-12-03|2012-12-04|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis|Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis|Completed||Phase 4|2|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 23:20:02.711137|2018-05-31 23:20:02.711137
NCT01206556|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2015-03-30|2010-09-20|2010-09-22|Estimate|||||||2015-03-30|2015-04-01|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Observational|HPV||IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody|Duration of Human Papilloma Virus (HPV) Type-Specific Antibody After Administration of Quadrivalent HPV Vaccine (QHPV) to HIV-1 Infected Children Previously Enrolled in IMPAACT P1047|Completed|||97|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||||f||||t||||||||||2018-05-31 23:20:02.843847|2018-05-31 23:20:02.843847
NCT01206543|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-21|2010-09-21|2010-09-22|Estimate|||||||2010-09-21|2010-09-22|Estimate|April 2002||2002-04-30|September 2010|2010-09-30|August 2006|Actual|2006-08-31|September 2005|Actual|2005-09-30||Interventional|||1.5T Intraoperative MR Imaging in Craniopharyngiomas|"Intraoperative Use of a MR Tomography System Combined With Neuronavigation - Analysis of the Craniopharyngioma Subgroup (Intraoperative Nutzung Eines Kernspintomographie-Systems in Direkter Kopplung Mit Einem Neuronavigations-System)"|Completed||N/A|25|Actual|Hofmann, Bernd, M.D.||1|||f||||||||||||||2018-05-31 23:20:03.013571|2018-05-31 23:20:03.013571
NCT01206530|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2017-04-04|2010-09-20|2010-09-22|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2010||2010-09-30|September 2016|2016-09-30||||November 2016|Actual|2016-11-30||Interventional|||FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer|A Phase I/II Pharmacodynamic Study of Hydroxychloroquine in Combination With FOLFOX Plus Bevacizumab to Inhibit Autophagy in Colorectal Cancer|Active, not recruiting||Phase 1/Phase 2|35|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:20:03.169052|2018-05-31 23:20:03.169052
NCT01206517|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2012-11-20||2017-05-29|2010-09-21|2010-09-22|Estimate|2012-11-20|2012-12-21|Estimate||||2017-05-29|2017-06-21|Actual|July 18, 2010|Actual|2010-07-18|May 2017|2017-05-31|August 4, 2011|Actual|2011-08-04|August 4, 2011|Actual|2011-08-04||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)|A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:20:03.316276|2018-05-31 23:20:03.316276
NCT01206504|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-07-05|2010-09-21|2010-09-22|Estimate|||||||2011-07-05|2011-07-06|Estimate||||July 2011|2011-07-31||||||||Expanded Access|||Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure|Expanded Access to MGAWN1 in Subjects With: Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection and a Compromised Immune System; or Substantial Accidental Exposure to West Nile Virus|No longer available|||||MacroGenics|||||||||||||||||||2018-05-31 23:20:03.944676|2018-05-31 23:20:03.944676
NCT01206491|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-10-05|2010-09-20|2010-09-21|Estimate|||||||2010-10-05|2010-10-06|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|||||Observational|||Development of Intervention Model for Osteoporosis and Fall Prevention in Taiwan|Development of Intervention Model for Osteoporosis and Fall Prevention in Taiwan|Unknown status|Active, not recruiting||35|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:20:04.018384|2018-05-31 23:20:04.018384
NCT01206478|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2016-04-12||2016-07-01|2010-09-20|2010-09-21|Estimate|2016-07-01|2016-08-15|Estimate||||2016-07-01|2016-08-15|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||A total of 21 patients were consented to the study.|Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age|A Phase II, Randomized-Controlled, Multicenter Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age|Completed||Phase 2|21|Actual|University of Kansas Medical Center|Major weakness was our small sample size, which was directly due to problems with recruitment, which occurred uniformly across sites. The primary reason for refusal was that parents did not want to be randomly assigned to the amitriptyline/placebo.|2|||f||||t||||||||No||2018-05-31 23:20:04.100369|2018-05-31 23:20:04.100369
NCT01206465|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-08-15|2010-09-20|2010-09-21|Estimate|||||||2011-08-15|2011-08-16|Estimate|September 2010||2010-09-30|August 2011|2011-08-31||||September 2013|Anticipated|2013-09-30||Interventional|||Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors|A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors|Unknown status|Recruiting|Phase 1|24|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 23:20:04.361809|2018-05-31 23:20:04.361809
NCT01206452|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2016-01-25||2017-04-11|2010-09-20|2010-09-21|Estimate|2017-04-11|2017-05-17|Actual||||2017-04-11|2017-05-17|Actual|September 2010||2010-09-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes|Use of Oral Steroids Before Circumferential Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation to Improve Outcomes|Completed||Phase 4|60|Actual|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 23:20:04.510754|2018-05-31 23:20:04.510754
NCT01205386|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-09-06|2010-09-17|2010-09-20|Estimate|||||||2013-09-06|2013-09-10|Estimate|February 2010||2010-02-28|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|CENTRAL||Crosser Enters The Right Arterial Lumen|Crosser Enters The Right Arterial Lumen|Completed|||100|Actual|C. R. Bard|||1||f||||f||||||||||2018-05-31 23:20:26.199472|2018-05-31 23:20:26.199472
NCT01206426|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2018-05-01|2010-09-20|2010-09-21|Estimate|||||||2018-05-01|2018-05-04|Actual|October 2009|Actual|2009-10-31|May 2018|2018-05-31|October 16, 2017|Actual|2017-10-16|July 2016|Actual|2016-07-31||Observational|||Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer|Identification of Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer|Completed|||79|Actual|University of Chicago|||||f||||f|f|f||||Samples With DNA|"~     Blood (germline) and tumor tissue samples will be used to perform genetic analysis. The~     purpose of this analysis is to determine whether a set of cisplatin susceptibility~     polymorphisms predict complete pathologic response to cisplatin-based chemotherapy and to~     identify novel determinants which may predict response to cisplatin-based chemotherapy.~      Samples will be biobanked for future analysis of genetic determinants.~   "|||2018-05-31 23:20:04.971456|2018-05-31 23:20:04.971456
NCT01206413|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|October 2003||2003-10-31|September 2010|2010-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Randomized Clinical Trial of Home-based Exercise Combined With a Slight Caloric Restriction on Obesity Prevention Among Women|A Randomized Clinical Trial of Home-based Exercise Combined With a Slight Caloric Restriction on Obesity Prevention Among Women|Completed||Phase 4|203|Actual|Rio de Janeiro State University||4|||f||||t||||||||||2018-05-31 23:20:05.048398|2018-05-31 23:20:05.048398
NCT01206400|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2011-06-28|2010-09-20|2010-09-21|Estimate|||||||2011-06-28|2011-06-30|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Observational|||Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study|Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study|Unknown status|Recruiting||45|Anticipated|Postgraduate Institute of Medical Education and Research|||1||f||||t||||||||||2018-05-31 23:20:05.12641|2018-05-31 23:20:05.12641
NCT01206387|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2014-01-22||2017-05-03|2010-09-20|2010-09-21|Estimate|2014-07-14|2014-08-07|Estimate||||2017-05-03|2017-06-05|Actual|August 2010||2010-08-31|May 2017|2017-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis|A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|120|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 23:20:05.224865|2018-05-31 23:20:05.224865
NCT01206374|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2015-05-22|2010-09-20|2010-09-21|Estimate|||||||2015-05-22|2015-05-25|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|October 2010|Actual|2010-10-31||Observational|||Questionnaire and Laboratory Data on Vitiligo Vulgaris|Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris|Completed|||57|Actual|St. Luke's-Roosevelt Hospital Center|||||f||||t||||||||||2018-05-31 23:20:06.674761|2018-05-31 23:20:06.674761
NCT01206361|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2011-06-28|2010-09-20|2010-09-21|Estimate|||||||2011-06-28|2011-06-29|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom|Persistence Of Use Of Topical Prostaglandin Fixed Dose Combination In The United Kingdom Primary Care: An Observational Study In Thin|Completed|||2015|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:20:06.754031|2018-05-31 23:20:06.754031
NCT01206348|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-11-28|2010-09-20|2010-09-21|Estimate|||||||2011-11-28|2011-11-30|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Combination Treatment for Moderate to Severe Acne|A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin|Completed||Phase 4|97|Actual|Medicis Global Service Corporation||1|||f||||f||||||||||2018-05-31 23:20:06.844199|2018-05-31 23:20:06.844199
NCT01206335|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2012-11-26|2010-09-20|2010-09-21|Estimate|||||||2012-11-26|2012-11-27|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia|A Phase II Open Label Study With OHR/AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Ohr Pharmaceutical Inc.||1|||f||||t||||||||||2018-05-31 23:20:06.939479|2018-05-31 23:20:06.939479
NCT01206322|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2014-07-24||2014-10-28|2010-09-20|2010-09-21|Estimate|2014-10-23|2014-10-28|Estimate||||2014-10-28|2014-10-29|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Twenty nine consented subjects, 15 type 2 diabetic and 14 controls completed the protocol.|Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes|Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes|Completed||Phase 2|30|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 23:20:07.045795|2018-05-31 23:20:07.045795
NCT01206309|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2016-10-06|2010-09-20|2010-09-21|Estimate|||||||2016-10-06|2016-10-07|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation|Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)|Completed|||911|Actual|Fred Hutchinson Cancer Research Center|||2||f||||t||||||Samples With DNA|"~     blood and urine specimens~   "|||2018-05-31 23:20:07.517153|2018-05-31 23:20:07.517153
NCT01206296|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2015-12-07|2010-09-20|2010-09-21|Estimate|||||||2015-12-07|2015-12-09|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma|A Phase 2 Study of Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma|Terminated||Phase 2|9|Actual|Washington Hospital Center||1||Study suspended|f||||t||||||||||2018-05-31 23:20:07.625814|2018-05-31 23:20:07.625814
NCT01206283|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|January 2006||2006-01-31|September 2010|2010-09-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||A Study Comparing Modified Lund Concept and Cerebral Perfusion Pressure-targeted Therapy in Secondary Brain Ischaemia.|Modified Lund Concept Versus Cerebral Perfusion Pressure-targeted Therapy: A Randomized Controlled Study in Patients With Secondary Brain Ischaemia.|Completed||N/A|60|Actual|University of Sarajevo||2|||f||||t||||||||||2018-05-31 23:20:07.746341|2018-05-31 23:20:07.746341
NCT01206270|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2014-10-25|2010-09-20|2010-09-21|Estimate|||||||2014-10-25|2014-10-28|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|August 2013|Actual|2013-08-31||Interventional|ALCeP||Androgen for Leydig Cell Proliferation|Androgen Treatment in Leydig Cell Proliferation|Completed||Phase 2/Phase 3|56|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 23:20:07.85229|2018-05-31 23:20:07.85229
NCT01206257|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2013-06-10|2010-09-20|2010-09-21|Estimate|||||||2013-06-10|2013-06-11|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|TRUST||The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)|This is an International, Prospective, Non-interventional Study, Company Sponsored, Multi-center Study. Patients Undergo Coronary Angiography or PCI Procedure With Ultravist. The Primary Objective is to Evaluate the Safety and Tolerability.|Completed|||17513|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:20:07.963078|2018-05-31 23:20:07.963078
NCT01206244|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2013-06-11|2010-09-20|2010-09-21|Estimate|||||||2013-06-11|2013-06-13|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Diurnal Variation of Tear Meniscus and Tear Osmolarity|Diurnal Variation of Tear Meniscus and Tear Osmolarity|Completed|||20|Actual|University of Miami|||2||f||||f||||||||||2018-05-31 23:20:08.083751|2018-05-31 23:20:08.083751
NCT01206231|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2011-11-07|2010-09-20|2010-09-21|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2010||2010-12-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia|An Epidemiological Study Aimed to Record Standard Daily Practice in Managing Patients With Hypercholesterolemia|Completed|||330|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:20:08.170979|2018-05-31 23:20:08.170979
NCT01206218|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|October 2010||2010-10-31|September 2010|2010-09-30||||October 2012|Anticipated|2012-10-31||Interventional|BREC-AGC||Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer|Evaluation of Customized Treatment According to BRCA1 Assessment in Patients With Advanced Gastric Cancer|Unknown status|Not yet recruiting|Phase 2/Phase 3|96|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||||||||||||2018-05-31 23:20:08.25425|2018-05-31 23:20:08.25425
NCT01206205|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-05-10|2010-09-20|2010-09-21|Estimate|||||||2017-05-10|2017-05-12|Actual|August 2009||2009-08-31|May 2017|2017-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|IFM2008||Frontline Therapy in de Novo Multiple Myeloma Patients Under 65|IFM2008: Frontline Therapy in de Novo Multiple Myeloma Patients Under 65, (a Phase 2 Multicenter Trial)|Completed||Phase 2|31|Actual|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 23:20:08.335185|2018-05-31 23:20:08.335185
NCT01206192|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|||2014-12-02|2010-09-20|2010-09-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Differential Effects of Intimate Partner Violence (IPV) on Mental Health|The Differential Effects of Intimate Terrorism and Situational Couple Violence on the Mental Health of Abused Chinese Women|Completed|||600|Anticipated|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 23:20:08.439381|2018-05-31 23:20:08.439381
NCT01206179|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2011-12-13|2010-09-20|2010-09-21|Estimate|||||||2011-12-13|2011-12-14|Estimate|March 2009||2009-03-31|June 2008|2008-06-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell|Effect of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Reconstructing Human Bone Defects|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 23:20:08.510631|2018-05-31 23:20:08.510631
NCT01206166|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-04-04|2010-09-20|2010-09-21|Estimate|||||||2017-04-04|2017-04-05|Actual|June 2011||2011-06-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TOP-UP||Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients (TOP-UP)|A Randomized Trial of Supplemental Parenteral Nutrition in Under and Over Weight Critically Ill Patients: The TOP UP Trial (Pilot)|Terminated||Phase 3|125|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||2||Low enrollment rates.|f||||f||||||||||2018-05-31 23:20:08.615801|2018-05-31 23:20:08.615801
NCT01206153|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|June 2008||2008-06-30|February 2008|2008-02-29|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients|Metformin for Treatment Antipsychotic Induced Amenorrhea in Female Schizophrenic Patients: a Double Blind, Placebo-controlled Study|Completed||Phase 4|84|Actual|Central South University||1|||f||||t||||||||||2018-05-31 23:20:08.837175|2018-05-31 23:20:08.837175
NCT01206140|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-18|2015-07-27||2015-09-04|2010-09-18|2010-09-21|Estimate|2015-09-04|2015-10-05|Estimate||||2015-09-04|2015-10-05|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery|Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas|Completed||Phase 2|70|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:20:09.090704|2018-05-31 23:20:09.090704
NCT01206127|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||DSAEK- Postoperative Positioning and Transplant Dislocation|DSAEK- Postoperative Positioning and Transplant Dislocation|Unknown status|Recruiting|N/A|40|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:20:10.213869|2018-05-31 23:20:10.213869
NCT01206114|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2014-09-24|2010-09-20|2010-09-21|Estimate|||||||2014-09-24|2014-09-25|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|April 2011|Actual|2011-04-30||Observational|||Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11|Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11|Completed|||2351|Actual|National Institute for Health and Welfare, Finland|||2||f||||f||||||Samples With DNA|"~     nasal/oral swabs, serum samples~   "|||2018-05-31 23:20:10.309481|2018-05-31 23:20:10.309481
NCT01206101|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2014-06-02||2017-02-28|2010-09-20|2010-09-21|Estimate|2014-06-02|2014-07-03|Estimate||||2017-02-28|2017-03-30|Actual|March 21, 2012|Actual|2012-03-21|February 2017|2017-02-28|June 3, 2013|Actual|2013-06-03|June 3, 2013|Actual|2013-06-03||Interventional|||Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation|A 52 Week Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center, Multinational Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Determine If The Early Use Of Liraglutide As An Adjunct To Standard Care Increases The Proportion Of Subjects Achieving Insulin Independence After First Transplantation|Terminated||Phase 2|3|Actual|Novo Nordisk A/S|Due to the premature termination of the trial prior to islet cell transplantation in any randomised subject, no results are available.|2||"The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well~   as challenges relating to trial execution and study completion."|f||||f||||||||||2018-05-31 23:20:10.447203|2018-05-31 23:20:10.447203
NCT01206088|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2017-02-24|2010-09-20|2010-09-21|Estimate|||||||2017-02-24|2017-02-28|Actual|February 2009||2009-02-28|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Tasigna in Glivec-resistant or Intolerant Patients in CML|A Phase IV Study for Nilotinib in Patients With Imatinib-resistant or Intolerant Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase.|Completed||Phase 4|93|Actual|Novartis||1|||f||||f||||||||||2018-05-31 23:20:10.890647|2018-05-31 23:20:10.890647
NCT01206075|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2014-12-27|2010-09-20|2010-09-21|Estimate|||||||2014-12-27|2014-12-30|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major|A Pilot Study to Assess the Safety and Efficacy of Mozobil ± G-CSF in Mobilizing Hematopoietic Stem Cells (CD34+ Cells) in Adults With Beta-thalassemia Major|Completed||N/A|20|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 23:20:11.10354|2018-05-31 23:20:11.10354
NCT01206062|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|2017-07-13||2017-11-29|2010-09-20|2010-09-21|Estimate|2017-11-29|2017-12-04|Actual||||2017-11-29|2017-12-04|Actual|October 2010|Actual|2010-10-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|July 2016|Actual|2016-07-31||Interventional|SPRINT||Systolic Blood Pressure Intervention Trial|Systolic Blood Pressure Intervention Trial|Active, not recruiting||N/A|9361|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||Yes||2018-05-31 23:20:11.259229|2018-05-31 23:20:11.259229
NCT01206049|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2017-03-09|2010-09-20|2010-09-21|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2010||2010-09-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|GOC-B-P||Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations|Randomized Phase II Trial of Combination Chemotherapy With Panitumumab or Bevacizumab for Patients With Inoperable Cholangiocarcinoma Without KRAS Mutations|Completed||Phase 2|88|Actual|Vejle Hospital||2|||f||||t||||||||||2018-05-31 23:20:12.283383|2018-05-31 23:20:12.283383
NCT01206036|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2016-01-26|2010-09-19|2010-09-21|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2014|Actual|2014-09-30||Interventional|CEPTAS||CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)|Phase I/II Study With Temsirolimus Versus no add-on in Patients With Castration Resistant Prostate Cancer (CRPC) Receiving First-line Docetaxel Chemotherapy|Completed||Phase 1/Phase 2|19|Actual|Central European Society for Anticancer Drug Research|||||f||||f||||||||Undecided||2018-05-31 23:20:12.415825|2018-05-31 23:20:12.415825
NCT01206023|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|||2017-02-19|2010-09-20|2010-09-21|Estimate|||||||2017-02-19|2017-02-23|Actual|November 2010||2010-11-30|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Observational|MS-NANOSE||Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples|Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Multiple Sclerosis by Respiratory Samples|Completed|||71|Actual|Carmel Medical Center|||2||f||||t||||||||||2018-05-31 23:20:12.561213|2018-05-31 23:20:12.561213
NCT01206010|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-04-24|2010-09-20|2010-09-21|Estimate|||||||2013-04-24|2013-04-25|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|TVIN||Tailoring Varenicline to Individual Needs (TVIN Study)|Effects of a Tailored Dose of Varenicline on Post-quitting Urges to Smoke|Completed||Phase 3|200|Actual|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 23:20:12.683716|2018-05-31 23:20:12.683716
NCT01205997|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2012-10-10|2010-09-20|2010-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Postoperative Analgesic Effect of Intrathecal Magnesium and Fentanyl Added to Bupivacaine in Patients Undergoing Lower Limb Orthopedic Surgery|The Effects of Intrathecal Magnesium and Fentanyl Added to Bupivacaine on Postoperative Analgesic Requirement in Patients Undergoing Lower Limb Orthopedic Surgery|Completed||Phase 1/Phase 2|90|Actual|Qazvin University Of Medical Sciences||3|||f||||t||||||||||2018-05-31 23:20:12.823554|2018-05-31 23:20:12.823554
NCT01205984|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|July 2007||2007-07-31|September 2010|2010-09-30|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||Systemic Methylprednisolone in Chronic Rhinosinusitis|Efficacy and Tolerability of Systemic Methylprednisolone in Children and Adolescents With Chronic Rhinosinusitis|Completed||Phase 4|48|Actual|Ondokuz Mayıs University||2|||f||||t||||||||||2018-05-31 23:20:12.936468|2018-05-31 23:20:12.936468
NCT01205971|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|||2018-02-11|2010-09-20|2010-09-21|Estimate|||||||2018-02-11|2018-02-13|Actual|January 2011|Actual|2011-01-31|February 2018|2018-02-28|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|||Tooth Smart Healthy Start: Oral Health Advocates in Public Housing|Oral Health Advocates in Public Housing|Completed||N/A|2842|Actual|Boston University||2|||f||||t|f|f||||||Yes|Researchers can make a data request through the EC4 website oralhealthdisparities.ucsf.edu|2018-05-31 23:20:13.089172|2018-05-31 23:20:13.089172
NCT01205958|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|February 2011|Anticipated|2011-02-28|January 2011|Anticipated|2011-01-31||Interventional|||The Effect of East-West Collaborative Medicine on Chronic Cervical Pain|Clinical Trial to Evaluate the Effect of East-West Collaborative Medicine on Chronic Cervical Pain: a Pilot Study|Unknown status|Recruiting|N/A|45|Anticipated|Kyunghee University Medical Center||3|||f||||t||||||||||2018-05-31 23:20:13.213853|2018-05-31 23:20:13.213853
NCT01205945|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|August 2017|Anticipated|2017-08-31|August 2012|Anticipated|2012-08-31||Observational|||The Effect of Abdominal Aortic Aneurysm Screening on Mortality in Asian Population|The Effect of Abdominal Aortic Aneurysm Screening on Mortality in Asian: A Randomized, Controlled Trial|Unknown status|Recruiting||12000|Anticipated|Kyunghee University Medical Center|||||f||||f||||||||||2018-05-31 23:20:13.367505|2018-05-31 23:20:13.367505
NCT01205932|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-19|||2017-01-20|2010-09-19|2010-09-21|Estimate|||||||2017-01-20|2017-01-23|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Dose-confirmatory Bridging Study in Total Hip Replacement|Randomized, Double-blind, Parallel-group, Active-controlled, Dose-confirmatory Bridging Study of Rivaroxaban (BAY59-7939) 5 to 10 mg Once-daily Regimen With a Reference Drug of Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement|Completed||Phase 3|402|Actual|Bayer||4|||f||||f||||||||||2018-05-31 23:20:13.588271|2018-05-31 23:20:13.588271
NCT01205919|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2014-04-02|2010-09-20|2010-09-21|Estimate|||||||2014-04-02|2014-04-03|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|TITUS||Internet-based Guided Self-help for Chronic Tinnitus|Efficacy of an Internet-based Guided Self-help Training for Chronic Tinnitus: A Randomized Controlled Trial|Completed||N/A|124|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 23:20:13.909987|2018-05-31 23:20:13.909987
NCT01205906|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2014-04-01|2010-09-20|2010-09-21|Estimate|||||||2014-04-01|2014-04-03|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|MINT||Comparison of an Internet-based Guided Self-help and a Group Therapy for Chronic Tinnitus|Comparison of the Efficacy of an Internet-based Self-help Training and a Well-established Outpatient Group Therapy for the Treatment of Chronic Tinnitus: A Randomized Controlled Trial|Completed||N/A|128|Actual|Johannes Gutenberg University Mainz||3|||f||||f||||||||||2018-05-31 23:20:14.060023|2018-05-31 23:20:14.060023
NCT01205893|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2013-11-22|2010-09-20|2010-09-21|Estimate|||||||2013-11-22|2013-11-25|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|COSIRA||Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA|Study to Confirm the Safety and Efficacy of the Reducer on Patients With Refractory Angina|Completed||Phase 2|104|Actual|Neovasc Inc.||2|||f||||t||||||||||2018-05-31 23:20:14.199947|2018-05-31 23:20:14.199947
NCT01205880|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis|Spray® and Vectical Ointment® in the Treatment of Plaque Psoriasis|Completed||Phase 4|12|Actual|Emer, Jason, M.D.||1|||f||||t||||||||||2018-05-31 23:20:14.298376|2018-05-31 23:20:14.298376
NCT01205867|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2015-08-13|2010-09-20|2010-09-21|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional|||Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects|An Open, Non-controlled, Non-randomised, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD 8848 Administered Intranasally to Male and Female Butyrylcholinesterase Deficient Subjects and to Sex and Age Matched Controls|Completed||Phase 1|22|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:20:14.385855|2018-05-31 23:20:14.385855
NCT01205854|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-04-15|2010-09-20|2010-09-21|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ARCTIC||Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial|Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen|Completed||Phase 4|238|Actual|Diakonhjemmet Hospital||2|||f||||t||||||||||2018-05-31 23:20:14.472106|2018-05-31 23:20:14.472106
NCT01205841|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|LEFO||A Prospective Study Comparing Different Clinical Decision Rules in Adult and Pediatric Ankle Trauma|A Prospective Study Comparing Different Clinical Decision Rules in Adult and Pediatric Ankle Trauma|Unknown status|Not yet recruiting|N/A|1500|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 23:20:14.564637|2018-05-31 23:20:14.564637
NCT01205828|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-18|2015-09-07||2017-03-11|2010-09-18|2010-09-21|Estimate|2016-03-02|2016-04-01|Estimate||||2017-03-11|2017-04-11|Actual|August 2010||2010-08-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||ABT-888 and Temozolomide for Liver Cancer|Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib|Terminated||Phase 2|16|Actual|Georgetown University||1||Lack of efficacy|f||||t||||||||||2018-05-31 23:20:14.662445|2018-05-31 23:20:14.662445
NCT01205815|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-11-08|2010-09-17|2010-09-21|Estimate|||||||2017-11-08|2017-11-13|Actual|June 3, 2010|Actual|2010-06-03|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment||Recruiting|||2500|Anticipated|Vanderbilt-Ingram Cancer Center|||||f||||||||||||||2018-05-31 23:20:14.859382|2018-05-31 23:20:14.859382
NCT01205802|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-20|||2010-09-20|2010-09-20|2010-09-21|Estimate|||||||2010-09-20|2010-09-21|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Interventional|MHVLDLT||Usability of Ringed Polytetrafluoroethylene Graft for Venous Vascular Reconstruction of Living Donor Liver Transplantation|Prospective Study on Usability of Ringed Polytetrafluoroethylene Graft for Venous Vascular Reconstruction of Living Donor Liver Transplantation|Unknown status|Enrolling by invitation|Phase 2/Phase 3|200|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:20:14.926188|2018-05-31 23:20:14.926188
NCT01205789|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-11-30|2010-09-17|2010-09-20|Estimate|||||||2012-11-30|2012-12-04|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|EXCEL||EXCEL Clinical Trial (Universal Registry)||Completed|||1000|Actual|Abbott Vascular|||1||f||||t||||||||||2018-05-31 23:20:14.987517|2018-05-31 23:20:14.987517
NCT01205776|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2018-03-01||2018-03-01|2010-09-17|2010-09-20|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-01|2018-03-29|Actual|September 2010||2010-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|April 2017|Actual|2017-04-30||Interventional|EXCEL||EXCEL Clinical Trial|Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.|Active, not recruiting||N/A|1905|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 23:20:15.150489|2018-05-31 23:20:15.150489
NCT01205763|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-17|2010-09-17|2010-09-20|Estimate|||||||2010-09-17|2010-09-20|Estimate|December 2007||2007-12-31|September 2010|2010-09-30|January 2009|Actual|2009-01-31|||||Observational|||Evaluation of Effects of Clavicular Hook Plate on Subacromial Space|Evaluation of Effects of Clavicular Hook Plate on Subacromial Space|Completed|||25|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:20:17.338734|2018-05-31 23:20:17.338734
NCT01205750|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2011-06-16|2010-09-17|2010-09-20|Estimate|||||||2011-06-16|2011-06-17|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Hepatic Insulin Sensitivity and Very Low Density Lipoprotein Triglyceride (VLDL-TG) Kinetics|Basal and Insulin Mediated VLDL-triglyceride Kinetics in Obesity; Relationship With Hepatic Insulin Sensitivity|Completed||N/A|24|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 23:20:17.741419|2018-05-31 23:20:17.741419
NCT01205737|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2013-10-21|2010-09-17|2010-09-20|Estimate|||||||2013-10-21|2013-10-22|Estimate|September 2010||2010-09-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects|A Phase Ib, Double Blind RCT to Evaluate and Compare the PK, PD and Safety of MabThera® With TL011, in Combination With CHOP, in Subjects With CD20+ DLBCL|Completed||Phase 1|186|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 23:20:17.916493|2018-05-31 23:20:17.916493
NCT01204879|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-06-22|2010-09-16|2010-09-17|Estimate|||||||2017-06-22|2017-06-26|Actual|April 2010||2010-04-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Reinforcing Exercise in Substance Abusing Patients|Reinforcing Exercise in Substance Abusing Patients|Completed||N/A|120|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 23:20:34.708441|2018-05-31 23:20:34.708441
NCT01205724|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-02-09|2010-09-17|2010-09-20|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2010||2010-09-30|February 2017|2017-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|pathfinder™1||Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A|A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A|Completed||Phase 1|27|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 23:20:18.063979|2018-05-31 23:20:18.063979
NCT01205711|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2014-07-07|2010-09-17|2010-09-20|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|FOLFERA||Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer|A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy|Completed||Phase 2|111|Actual|Cardiff University|||||f||||t||||||||||2018-05-31 23:20:18.217682|2018-05-31 23:20:18.217682
NCT01205698|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-17|2010-09-17|2010-09-20|Estimate|||||||2010-09-17|2010-09-20|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Glycemic Index of Foods|Glycemic Index of Foods|Completed||N/A|||Mead Johnson Nutrition||4|||f||||||||||||||2018-05-31 23:20:18.385015|2018-05-31 23:20:18.385015
NCT01205685|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2012-06-07||2012-08-10|2010-09-17|2010-09-20|Estimate|2012-08-10|2012-09-11|Estimate||||2012-08-10|2012-09-11|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer|A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva®, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer|Terminated||Phase 2|11|Actual|Vanderbilt-Ingram Cancer Center||1||PI closed study early, all patients experienced severe toxicities and progressed|f||||t||||||||||2018-05-31 23:20:18.46003|2018-05-31 23:20:18.46003
NCT01205672|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-05-31|2010-09-17|2010-09-20|Estimate|||||||2017-05-31|2017-06-02|Actual|September 16, 2010|Actual|2010-09-16|May 2017|2017-05-31|May 28, 2017|Actual|2017-05-28|May 28, 2017|Actual|2017-05-28||Interventional|||Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer|Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer|Completed||Early Phase 1|21|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:20:19.771499|2018-05-31 23:20:19.771499
NCT01205659|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-17|2010-09-17|2010-09-20|Estimate|||||||2010-09-17|2010-09-20|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Allergy and Ashthma in Children Who Were Fed Supplemented Infant Formula|Allergy and Asthma in Children Who Were Fed Supplemented Infant Formula (3-7 Years of Age)|Completed|||||Mead Johnson Nutrition|||||f||||f||||||||||2018-05-31 23:20:19.919191|2018-05-31 23:20:19.919191
NCT01205646|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2014-04-18||2017-11-10|2010-09-17|2010-09-20|Estimate|2014-06-05|2014-06-06|Estimate||||2017-11-10|2017-12-12|Actual|September 2010||2010-09-30|November 2017|2017-11-30|August 2015|Actual|2015-08-31|August 2013|Actual|2013-08-31||Interventional|||PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer|Pilot Trial to Evaluate Change in Positron Emission Tomography Scanning (PET) as a Surrogate for Zoledronate (Zometa) Efficacy in Patients With Metastatic Prostate Cancer|Completed||N/A|11|Actual|Barbara Ann Karmanos Cancer Institute|Small sample size.|1|||f||||t||||||||||2018-05-31 23:20:19.982123|2018-05-31 23:20:19.982123
NCT01205633|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2012-09-15|2010-09-17|2010-09-20|Estimate|||||||2012-09-15|2012-09-18|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|CCSVI||Multi-center Registry for CCSVI Testing and Treatment|Multi-center Registry for CCSVI Testing and Treatment|Suspended|||1000|Anticipated|Hubbard Foundation|||1|9/12/12 FDA stopped enrollment pending device exemption(IDE)application.|f||||f||||||||||2018-05-31 23:20:20.20722|2018-05-31 23:20:20.20722
NCT01205620|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-17|2010-09-17|2010-09-20|Estimate|||||||2010-09-17|2010-09-20|Estimate|August 2010||2010-08-31|September 2010|2010-09-30||||||||Interventional|||IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery|IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery|Unknown status|Enrolling by invitation|Phase 2|30|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 23:20:20.310294|2018-05-31 23:20:20.310294
NCT01205607|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-17|2010-09-17|2010-09-20|Estimate|||||||2010-09-17|2010-09-20|Estimate|May 2009||2009-05-31|September 2010|2010-09-30||||||||Interventional|||IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance|IRB-HSR# 14299: The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Cerebral Perfusion Pressure in Patients With Altered Intracranial Elastance|Unknown status|Enrolling by invitation|Phase 2|20|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 23:20:20.393822|2018-05-31 23:20:20.393822
NCT01205594|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-08-09|2010-09-17|2010-09-20|Estimate|||||||2011-08-09|2011-08-10|Estimate|May 2009||2009-05-31|August 2011|2011-08-31||||May 2010|Actual|2010-05-31||Interventional|||IRB-HSR# 14296 The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Systemic Blood Pressure in Patient Undergoing CABG Surgery|IRB-HSR# 14296 The Use of the Intrathoracic Pressure Regulator (ITPR) to Improve Systemic Blood Pressure in Patient Undergoing CABG Surgery|Completed||Phase 2|20|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 23:20:20.494597|2018-05-31 23:20:20.494597
NCT01205581|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2014-07-24||2016-09-20|2010-09-17|2010-09-20|Estimate|2014-09-05|2014-09-12|Estimate||||2016-09-20|2016-09-23|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||This was an open-label study where participants were randomized at a 1:1 ratio into Fluzone high-dose (HD) and Fluzone standard dose (SD) groups by disease group with the use of a computer-generated randomization schedule.|Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV|Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV|Completed||Phase 2|85|Actual|St. Jude Children's Research Hospital||6|||f||||f||||||||||2018-05-31 23:20:20.780604|2018-05-31 23:20:20.780604
NCT01205568|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2017-04-18||2018-04-25|2010-09-17|2010-09-20|Estimate|2018-04-25|2018-05-25|Actual||||2018-04-25|2018-05-25|Actual|August 1, 2003|Actual|2003-08-01|April 2018|2018-04-30|September 9, 2009|Actual|2009-09-09|March 17, 2009|Actual|2009-03-17||Interventional|CB|Baseline data prior to vessel randomization|Cutting Balloon Study|Safety and Efficacy of the Cutting Balloon to Treat Resistant Pulmonary Artery Stenosis|Completed||N/A|73|Actual|Boston Children’s Hospital||1|||||||t||||||||||2018-05-31 23:20:21.631706|2018-05-31 23:20:21.631706
NCT01205555|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-07-24|2010-09-17|2010-09-20|Estimate|||||||2017-07-24|2017-07-26|Actual|November 15, 2010|Actual|2010-11-15|July 2017|2017-07-31|August 18, 2016|Actual|2016-08-18|August 18, 2016|Actual|2016-08-18||Interventional|||Combining LHu With Ultrasound Monitoring in IUI|Combining Urinary Luteinizing Hormone Testing With Ultrasound Monitoring in Intrauterine Insemination Cycles|Terminated||N/A|367|Actual|OVO R & D||2||sufficient participants for analysis|f||||f||||||||||2018-05-31 23:20:21.918171|2018-05-31 23:20:21.918171
NCT01205542|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-01-03|2010-09-17|2010-09-20|Estimate|||||||2011-01-03|2011-01-04|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|VIMS03||Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Shoulder Function|Completed||N/A|50|Anticipated|National Research Centre for the Working Environment, Denmark||2|||f||||||||||||||2018-05-31 23:20:21.993486|2018-05-31 23:20:21.993486
NCT01205529|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2017-09-20||2018-03-29|2010-09-17|2010-09-20|Estimate|2018-03-29|2018-05-02|Actual||||2018-03-29|2018-05-02|Actual|November 2010||2010-11-30|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Proc||ST-segment Elevation as an AF Endophenotype|ST-segment Elevation With Procainamide as an ECG Endophenotype of AF|Completed||N/A|161|Actual|Vanderbilt University Medical Center||1|||f||||t||||||||Undecided||2018-05-31 23:20:22.119922|2018-05-31 23:20:22.119922
NCT01205516|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-07-25|2010-09-17|2010-09-20|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Methadone in Neuropathic Pain||Recruiting||Phase 4|180|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 23:20:22.365682|2018-05-31 23:20:22.365682
NCT01205503|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2015-09-18||2016-01-27|2010-09-17|2010-09-20|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|April 2015|Actual|2015-04-30|August 2012|Actual|2012-08-31||Interventional||All subjects that received treatment.|Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release|Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release|Completed||Phase 2|32|Actual|University of Kentucky|We did not measure any cognitive outcomes. We did not measure levels of anti-inflammatory cytokines, which could play a role in pathophysiology of Chemotherapy induced cognitive impairment (CICI). Small sample size, needs future trials to confirm.|2|||f||||t||||||||Yes|The de-identified data is already available as part of the published article supplement. PubMed Identification (ID) # 25909710|2018-05-31 23:20:22.509976|2018-05-31 23:20:22.509976
NCT01205490|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2011-06-27|2010-09-17|2010-09-20|Estimate|||||||2011-06-27|2011-06-28|Estimate|July 2011||2011-07-31|June 2011|2011-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Changes in Cerebral Blood Flow With Spinal Manipulative Therapy vs. Voluntary Motion|Changes in Cerebral Blood Flow With Spinal Manipulative Therapy vs. Voluntary Motion|Unknown status|Not yet recruiting|N/A|10|Anticipated|Canadian Memorial Chiropractic College|||||f||||||||||||||2018-05-31 23:20:23.162671|2018-05-31 23:20:23.162671
NCT01205477|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-09-17|2010-09-17|2010-09-20|Estimate|||||||2010-09-17|2010-09-20|Estimate|September 2009||2009-09-30|June 2009|2009-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment|Phase 2 Double-blinded, Placebo-controlled, Clinical Trial for Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment|Completed||Phase 2|58|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||||2018-05-31 23:20:23.23143|2018-05-31 23:20:23.23143
NCT01205464|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2010-09-17|2010-09-17|2010-09-20|Estimate|||||||2010-09-17|2010-09-20|Estimate|February 2005||2005-02-28|February 2005|2005-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis|Immunomodulatory and Clinical Effects of Doxycycline on Persistent Symptoms After Treatment of Neuroborreliosis: A Double-blind, Randomised, Crossover Study|Completed||N/A|15|Actual|Linkoeping University||2|||f||||t||||||||||2018-05-31 23:20:23.311489|2018-05-31 23:20:23.311489
NCT01205451|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-07-19||2017-01-16|2010-09-17|2010-09-20|Estimate|2012-08-23|2012-09-24|Estimate||||2017-01-16|2017-02-28|Actual|September 2010||2010-09-30|January 2017|2017-01-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity|A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity|Completed||Phase 3|109|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 23:20:23.4227|2018-05-31 23:20:23.4227
NCT01205438|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17||2014-09-29|2015-06-26|2010-09-17|2010-09-20|Estimate||||2014-09-29|2014-10-08|Estimate|2015-06-26|2015-07-21|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||A Study of LY2127399 in Patients With Systemic Lupus Erythematosus|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)|Completed||Phase 3|1124|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 23:20:24.631033|2018-05-31 23:20:24.631033
NCT01205425|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2011-07-04|2010-09-17|2010-09-20|Estimate|||||||2011-07-04|2011-07-06|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Computed Tomography Coronary Angiography Before Stent Implantation|Role of Computed Tomography Coronary Angiography in Optimalization of Percutaneous Coronary Interventions With Stent Implantation.|Completed||N/A|60|Actual|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-05-31 23:20:25.650787|2018-05-31 23:20:25.650787
NCT01205412|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-11-21|2010-09-17|2010-09-20|Estimate|||||||2012-11-21|2012-11-22|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain|An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women in the Kingdom of Bahrain|Completed|||552|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Endocervical samples~   "|||2018-05-31 23:20:25.820354|2018-05-31 23:20:25.820354
NCT01205399|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2012-07-05||2017-01-13|2010-09-17|2010-09-20|Estimate|2012-07-05|2012-08-23|Estimate||||2017-01-13|2017-01-18|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|AlloMax||A Retrospective Study With Prospective Follow-Up of Complex Ventral Hernia Repair Utilizing the AlloMax Surgical Graft|A Single Arm, Multi-Center, Retrospective Study With Prospective Follow-Up of Complex Ventral Hernia Repair Utilizing the AlloMax Surgical Graft|Completed|||78|Actual|C. R. Bard|Study was designed to use existing data. Limitations include: limited data generalizability given the retrospective, single arm, observational study design.||1||f||||f||||||||||2018-05-31 23:20:25.906375|2018-05-31 23:20:25.906375
NCT01205373|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2013-10-31|2010-09-17|2010-09-20|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2010||2010-09-30|October 2013|2013-10-31||||October 2010|Actual|2010-10-31||Interventional|||A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers|A Phase I Trial to Investigate the Metabolism and Pharmacokinetics of an Open-label Single Dose of 400 mg [14C]BI 671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers.|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:20:26.270658|2018-05-31 23:20:26.270658
NCT01205360|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-09-20|2010-09-17|2010-09-20|Estimate|||||||2017-09-20|2017-09-21|Actual|August 2010||2010-08-31|September 2010|2010-09-30|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|||Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia|A Randomized, Control Study to Evaluate Dosing Strategies for Automated Mandatory Intermittent Boluses Technique for Epidural Labour Analgesia|Withdrawn||N/A|0|Actual|Pravara Institute of Medical Sciences University||3|||f||||t||||||||||2018-05-31 23:20:26.340338|2018-05-31 23:20:26.340338
NCT01205347|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2013-09-08|2010-09-17|2010-09-20|Estimate|||||||2013-09-08|2013-09-10|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Statin Treatment on Insulin Sensitivity During Myocardial Infarction|Phase 4 Study of the Effect of Statin Treatment on Insulin Sensitivity During Myocardial Infarction|Completed||Phase 4|27|Actual|Brasilia Heart Study Group||2|||f||||f||||||||||2018-05-31 23:20:26.407252|2018-05-31 23:20:26.407252
NCT01205334|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17||2013-08-17|2013-08-17|2010-09-17|2010-09-20|Estimate||||2013-08-17|2013-08-26|Estimate|2013-08-17|2013-08-26|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|COGLI||Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme|Phase I/II Administration of CMV (Cytomegalovirus)-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (COGLI)|Terminated||Phase 1/Phase 2|2|Actual|Baylor College of Medicine||1||poor accrual|f||||t||||||||||2018-05-31 23:20:26.475678|2018-05-31 23:20:26.475678
NCT01205321|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2013-01-18|2010-09-17|2010-09-20|Estimate|||||||2013-01-18|2013-01-21|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers|Open-label, Multi Center PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 68Ga Labeled PET Tracer BAY86-7548 Following a Single Intravenous Administration of 140 MBq (Corresponding to ≤ 28 µg Mass Dose) in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers|Completed||Phase 1|19|Actual|Piramal Imaging SA||2|||f||||f||||||||||2018-05-31 23:20:26.67452|2018-05-31 23:20:26.67452
NCT01205308|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2012-04-16|2010-09-17|2010-09-20|Estimate|||||||2012-04-16|2012-04-17|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||Plant Stanols and Type 1 Diabetes|Effects of Plant Stanol Esters on Serum Lipids, Precursors of Cholesterol Synthesis and Plant Sterols in Type 1 Diabetics on Stabile Statin Drug Use|Completed||N/A|24|Actual|University of Eastern Finland||2|||f||||f||||||||||2018-05-31 23:20:26.753739|2018-05-31 23:20:26.753739
NCT01205295|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-22|2010-09-17|2010-09-20|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Observational|||Patient Anxiety and Concern as Predictors for the Perceived Quality and Efficacy of Treatment|Patient Anxiety and Concern as Predictors for the Perceived Quality and Efficacy of Treatment|Unknown status|Recruiting||800|Anticipated|Kolding Sygehus|||1||f||||t||||||||||2018-05-31 23:20:26.832773|2018-05-31 23:20:26.832773
NCT01205282|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2017-03-17|2010-09-17|2010-09-20|Estimate|||||||2017-03-17|2017-03-20|Actual|April 2013||2013-04-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Dose Finding Study of Pioglitazone in Children With Autism Spectrum Disorders (ASD) (PIO)|A Pilot Dose Finding Study of Pioglitazone in Children With ASD|Completed||Phase 2|28|Actual|Anagnostou, Evdokia, M.D.||2|||f||||f||||||||No||2018-05-31 23:20:26.919525|2018-05-31 23:20:26.919525
NCT01205269|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2013-09-10||2014-02-24|2010-09-17|2010-09-20|Estimate|2013-09-10|2013-11-13|Estimate||||2014-02-24|2014-03-19|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Double-blind, Placebo-controlled, Randomised, Multi-centre, 3-way Cross-over, Single-dose Phase II Study to Investigate the Local and Systemic Effects of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|28|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 23:20:27.018092|2018-05-31 23:20:27.018092
NCT01205256|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2016-03-01|2010-09-17|2010-09-20|Estimate|||||||2016-03-01|2016-03-03|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction|IRB-HSR# 14145 R,S Methadone: Analgesia and Pharmacokinetics in Adolescents Undergoing Scoliosis Correction|Completed||Phase 3|11|Actual|University of Virginia||1|||f||||f||||||||No||2018-05-31 23:20:27.382704|2018-05-31 23:20:27.382704
NCT01205243|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2018-05-17|2010-09-17|2010-09-20|Estimate|||||||2018-05-17|2018-05-22|Actual|November 1, 2010||2010-11-01|May 2018|2018-05-31|February 5, 2015|Actual|2015-02-05|February 1, 2015|Actual|2015-02-01||Observational|||ZIAGEN® Post-marketing Surveillance|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ZIAGEN® Administered in Korean Patients According to the Prescribing Information|Completed|||671|Actual|ViiV Healthcare|||1||f||||f||||||||||2018-05-31 23:20:27.450907|2018-05-31 23:20:27.450907
NCT01205230|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2012-03-29||2012-05-17|2010-09-17|2010-09-20|Estimate|2012-03-29|2012-04-24|Estimate||||2012-05-17|2012-05-22|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK|An Open-Label Study to Evaluate the Effects of Ketoconazole and the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Repeat Doses of Pazopanib in Subjects With Solid Tumor Malignancies|Completed||Phase 4|34|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:20:27.542135|2018-05-31 23:20:27.542135
NCT01204554|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2010-09-16|2010-09-16|2010-09-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Microcirculation in Perforator Flaps. Enhancing Tissue Survival|Microcirculation in Perforator Flaps. Enhancing Tissue Survival|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Oslo University Hospital|||||f||||t||||||||||2018-05-31 23:20:43.145799|2018-05-31 23:20:43.145799
NCT01205217|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2017-06-06|2010-09-17|2010-09-20|Estimate|||||||2017-06-06|2017-06-07|Actual|December 2010||2010-12-31|June 2017|2017-06-30|December 2010|Anticipated|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ELATE||Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer|Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer.|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||Data presented at SABCS 2010 showing that dual blockade is superior to monotherapy|f||||f||||||||||2018-05-31 23:20:29.302337|2018-05-31 23:20:29.302337
NCT01205204|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-09-20|2010-09-17|2010-09-20|Estimate|||||||2017-09-20|2017-09-21|Actual|August 2010||2010-08-31|September 2010|2010-09-30|November 2011|Anticipated|2011-11-30|July 2011|Anticipated|2011-07-31||Interventional|||Comparison of Different Doses of Clonidine to Fentanyl as an Adjuvant to Bupivacaine 0.5% for Spinal Anesthesia|A Randomized Clinical Study to Compare Different Doses of Clonidine to Fentanyl as an Adjuvant to Hyperbaric Bupivacaine 0.5% for Spinal Anesthesia in Patients Undergoing LSCS|Withdrawn||N/A|0|Actual|Pravara Institute of Medical Sciences University||4||This study was registered with Clinical Trials.gov by mistake.|f||||t||||||||||2018-05-31 23:20:29.629728|2018-05-31 23:20:29.629728
NCT01205191|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2011-06-14|2010-09-17|2010-09-20|Estimate|||||||2011-06-14|2011-06-15|Estimate|April 2011||2011-04-30|September 2010|2010-09-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|LINNEA||Cell Phone-supported Cognitive Behavioural Therapy|Effectiveness Study of Cell Phone-supported Cognitive Behavioural Therapy for Anxiety Disorders in Frontline Settings|Unknown status|Recruiting|Phase 2/Phase 3|400|Anticipated|Linkoeping University||3|||f||||t||||||||||2018-05-31 23:20:29.735297|2018-05-31 23:20:29.735297
NCT01205178|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2017-06-05|2010-09-17|2010-09-20|Estimate|||||||2017-06-05|2017-06-07|Actual|July 2, 2009|Actual|2009-07-02|June 2017|2017-06-30|April 1, 2013|Actual|2013-04-01|April 1, 2013|Actual|2013-04-01||Interventional|||G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)|A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects With Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium Vivax Malaria Patients With Glucose-6-phosphate Dehydrogenase Deficiency|Completed||Phase 1|192|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 23:20:29.810078|2018-05-31 23:20:29.810078
NCT01205165|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2017-08-29||2017-08-29|2010-09-17|2010-09-20|Estimate|2017-08-29|2018-03-26|Actual||||2017-08-29|2018-03-26|Actual|December 17, 2004|Actual|2004-12-17|August 2017|2017-08-31|April 28, 2006|Actual|2006-04-28|April 28, 2006|Actual|2006-04-28||Interventional|||An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)|An Open Label, Multicenter Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)|Completed||Phase 4|104|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:20:29.94242|2018-05-31 23:20:29.94242
NCT01205152|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|2017-08-14||2017-10-12|2010-09-17|2010-09-20|Estimate|2017-10-12|2017-11-17|Actual||||2017-10-12|2017-11-17|Actual|April 2009||2009-04-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||Of the 11 patients who were enrolled in Study ENB-002-08, 10 patients completed Study ENB-002-08 and were enrolled in extension study ENB-003-08.|Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)|Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children With Hypophosphatasia (HPP)|Completed||Phase 2|10|Actual|Alexion Pharma GmbH||1|||f||||t|t|f||||||||2018-05-31 23:20:31.41436|2018-05-31 23:20:31.41436
NCT01205139|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-11-23|2010-09-16|2010-09-20|Estimate|||||||2012-11-23|2012-11-27|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir|A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, TMC278 and Tenofovir Disoproxil Fumarate (TDF), at Steady State|Completed||Phase 1|48|Actual|Tibotec Pharmaceuticals, Ireland||6|||f||||f||||||||||2018-05-31 23:20:31.969554|2018-05-31 23:20:31.969554
NCT01205126|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2013-09-13||2013-12-31|2010-09-16|2010-09-20|Estimate|2013-09-13|2013-11-25|Estimate||||2013-12-31|2014-02-03|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||Full analysis set (FAS) population set included all the participants who were randomly assigned either of the 2 treatment groups and with at least 1 dose of medication administered during the titration phase and at least one assessment of efficacy.|An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain|A Randomized, Double-Blind, Active Controlled, Multi-center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Once-daily Compared With Oxycodone HCL Controlled-release Twice Daily in Subjects With Cancer Pain|Completed||Phase 3|260|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 23:20:32.068033|2018-05-31 23:20:32.068033
NCT01205100|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2016-07-26|2010-09-16|2010-09-20|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Treatment of Abdominal Distension by Biofeedback - a Randomized Controlled Trial|Feedback-assisted Treatment of Abdominal Distension - a Randomized Controlled Trial|Completed||N/A|48|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||Yes|Publication in scientific journal.|2018-05-31 23:20:32.531541|2018-05-31 23:20:32.531541
NCT01205087|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-23|||2011-06-22|2010-09-16|2010-09-20|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome|Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial|Completed||Phase 2|36|Anticipated|Hadassah Medical Organization||4|||f||||t||||||||||2018-05-31 23:20:32.604823|2018-05-31 23:20:32.604823
NCT01205074|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-08-27|2010-09-17|2010-09-20|Estimate|||||||2012-08-27|2012-08-28|Estimate|September 2010||2010-09-30|June 2011|2011-06-30||||||||Interventional|||¹³C-Methacetin Breath Test (MBT) Methodology Study|¹³C-Methacetin Breath Test (MBT) Methodology Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|||Hadassah Medical Organization||6|||f||||||||||||||2018-05-31 23:20:32.682047|2018-05-31 23:20:32.682047
NCT01204541|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-02-13|2010-09-16|2010-09-17|Estimate|||||||2012-02-13|2012-02-14|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||A Single-Center Pilot Study to Assess Macular Function||Completed|||24|Actual|ORA, Inc.|||3||f||||||||||||||2018-05-31 23:20:43.220973|2018-05-31 23:20:43.220973
NCT01205061|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16||2012-08-28|2012-08-28|2010-09-16|2010-09-20|Estimate||||2012-08-28|2012-09-03|Estimate|2012-08-28|2012-09-03|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds|A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel Classic Lidocaine Versus Juvederm® Ultra in the Treatment of Moderate to Severe Facial Wrinkles and Folds|Completed||Phase 3|162|Actual|Galderma||2|||f||||f||||||||||2018-05-31 23:20:32.775125|2018-05-31 23:20:32.775125
NCT01205048|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16||2012-08-28|2012-08-28|2010-09-17|2010-09-20|Estimate||||2012-08-28|2012-09-03|Estimate|2012-08-28|2012-09-03|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds|A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel Classic Lidocaine Versus Juvederm® Ultra in the Treatment of Moderate to Severe Facial Wrinkle Folds|Completed||Phase 3|171|Actual|Galderma||2|||f||||f||||||||||2018-05-31 23:20:32.871442|2018-05-31 23:20:32.871442
NCT01205035|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2015-03-18||2015-03-30|2010-09-17|2010-09-20|Estimate|2015-03-30|2015-04-10|Estimate||||2015-03-30|2015-04-10|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|HD-LIPT||High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia|High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia [HD-LIPT]|Completed||Phase 2|6|Actual|Eye Center of Northern Colorado, P.C.||2|||f||||t||||||||||2018-05-31 23:20:32.98021|2018-05-31 23:20:32.98021
NCT01205022|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-06-03|2010-09-17|2010-09-20|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Phase I Trial of Radioimmunotherapy (Y-90 M5A) in Combination With FOLFIRI and Bevacizumab Chemotherapy for Metastatic Colorectal Carcinoma|Completed||Phase 1|3|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:20:33.262062|2018-05-31 23:20:33.262062
NCT01205009|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-03-01|2010-09-16|2010-09-20|Estimate|||||||2011-03-01|2011-03-02|Estimate|April 2011||2011-04-30|September 2010|2010-09-30||||March 2012|Anticipated|2012-03-31||Interventional|||Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 23:20:33.366573|2018-05-31 23:20:33.366573
NCT01204996|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-05-29|2010-09-16|2010-09-20|Estimate|||||||2012-05-29|2012-05-30|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|||||Interventional|||A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors|An Open-label, Multicenter, Phase 1b Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors|Completed||Phase 1|53|Actual|Centocor, Inc.||4|||f||||||||||||||2018-05-31 23:20:33.441154|2018-05-31 23:20:33.441154
NCT01204983|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2018-05-14|2010-09-16|2010-09-20|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2010||2010-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|NICU||Quality Improvement Project - Evaluation of Current Standard of Care for Feeding Practices in the NICU|Quality Improvement Project - Evaluation of Current Standard of Care for Feeding Practices With Donor Human Milk Products in the NICU|Recruiting|||150|Anticipated|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 23:20:33.530446|2018-05-31 23:20:33.530446
NCT01204970|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2016-12-29|2010-09-17|2010-09-20|Estimate|||||||2016-12-29|2016-12-30|Estimate|September 2010||2010-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Observational|||Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients|Confocal Laser Micro-endoscopy: New Insights in COPD and Lung Transplant Recipients|Completed|||176|Actual|Katholieke Universiteit Leuven|||3||f||||||||||||||2018-05-31 23:20:33.604289|2018-05-31 23:20:33.604289
NCT01204957|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-04-02|2010-09-16|2010-09-17|Estimate|||||||2015-04-02|2015-04-06|Estimate|October 1998||1998-10-31|April 2015|2015-04-30|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||Brown Seaweed as a Breast Cancer Preventive|Brown Seaweed as a Breast Cancer Preventive|Completed||Phase 1/Phase 2|33|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 23:20:33.667766|2018-05-31 23:20:33.667766
NCT01204944|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2017-01-03|2010-09-16|2010-09-17|Estimate|||||||2017-01-03|2017-01-04|Estimate|May 2008||2008-05-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|STCS||Swiss Transplant Cohort Study|Swiss Transplant Cohort Study|Recruiting|||7500|Anticipated|University of Zurich|||||f||||t||||||||||2018-05-31 23:20:33.740916|2018-05-31 23:20:33.740916
NCT01204931|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2016-01-19|2010-09-16|2010-09-17|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|July 2013|Actual|2013-07-31||Observational|||Can We Predict Who Has Gastroesophageal Reflux Disease (GERD)?|Can We Predict Who Has GERD? Systematic Evaluation of Role of pH Monitoring and the Specific Physiologic pH Parameters in Defining GERD, Bravo, Impedence and SISAP|Completed|||254|Actual|Vanderbilt University|||2||f||||f||||||||||2018-05-31 23:20:33.787518|2018-05-31 23:20:33.787518
NCT01204918|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2017-10-10||2018-01-11|2010-09-16|2010-09-17|Estimate|2018-01-11|2018-02-08|Actual||||2018-01-11|2018-02-08|Actual|June 2011||2011-06-30|January 2018|2018-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy and Tolerability of Riluzole in Treatment Resistant Depression|Efficacy and Tolerability of Riluzole in Treatment Resistant Depression|Completed||Phase 2|104|Actual|Yale University||3|||f||||t||||||||||2018-05-31 23:20:33.872476|2018-05-31 23:20:33.872476
NCT01204905|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-11-08|2010-09-16|2010-09-17|Estimate|||||||2012-11-08|2012-11-09|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|September 2014|Anticipated|2014-09-30|December 2013|Anticipated|2013-12-31||Interventional|||R5 Integrase Study in HIV-1 Naive Patients|Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naïve HIV-1 Infected Patients|Unknown status|Recruiting|N/A|10|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 23:20:34.551741|2018-05-31 23:20:34.551741
NCT01204892|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-07-11|2010-09-16|2010-09-17|Estimate|||||||2012-07-11|2012-07-12|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pain After Laparoscopic Cholecystectomy With Bilateral Tranversus Abdominis Plane (TAP) Block Versus Local Anesthetic Infiltration|Postoperative Pain After Laparoscopic Cholecystectomy in Patients Receiving Bilateral Ultrasound-guided Transverse Abdominis Plane Block Compared With Local Anesthetic Infiltration of Trochar Insertion Sites With Ropivacaine 0.5%|Completed||N/A|80|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 23:20:34.634603|2018-05-31 23:20:34.634603
NCT01204866|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2010-09-23|2010-09-16|2010-09-17|Estimate|||||||2010-09-23|2010-09-24|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use|A Phase I, Open Label, Controlled Study of Valortim® (MDX-1303) and Its Selected Formulation Components When Introduced Percutaneously in Subjects Who Have and Have Not Been Exposed to Valortim Administered Intravenously|Completed||Phase 1|5|Actual|PharmAthene, Inc.||2|||f||||t||||||||||2018-05-31 23:20:34.796704|2018-05-31 23:20:34.796704
NCT01204853|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2011-10-26||2011-10-26|2010-09-16|2010-09-17|Estimate|2011-10-26|2011-12-01|Estimate||||2011-10-26|2011-12-01|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients|A Phase 3, Multi-Center, Open Label Study To Evaluate The Safety And Efficacy Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|2|Actual|Pfizer||1||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,~   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2018-05-31 23:20:34.910005|2018-05-31 23:20:34.910005
NCT01204840|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2015-06-29|2010-09-16|2010-09-17|Estimate|||||||2015-06-29|2015-07-01|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)|Co-treatment With Recombinant Growth Hormone (GH) in Poor Responders Treated by in Vitro Fertilization (IVF-ET)|Completed||Phase 2|38|Actual|Ottawa Fertility Centre||2|||f||||t||||||||||2018-05-31 23:20:35.092971|2018-05-31 23:20:35.092971
NCT01204827|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-08-27|2010-09-16|2010-09-17|Estimate|||||||2012-08-27|2012-08-28|Estimate||||June 2011|2011-06-30||||||||Interventional|||Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test|Follow Up of Patients With HBeAg Negative Chronic Hepatitis B Virus Infection Treated With Sebivo (Telbivudine) Using the 13C Methacetin Breath Test (BreathID®)|Withdrawn||Phase 2/Phase 3|0|Actual|Hadassah Medical Organization||1|||f||||||||||||||2018-05-31 23:20:35.171803|2018-05-31 23:20:35.171803
NCT01204814|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2017-08-28|2010-09-16|2010-09-17|Estimate|||||||2017-08-28|2017-08-30|Actual|August 2010||2010-08-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Observational|||HIV-1 Resistance at Screening for HIV Prevention Studies|Prevalence of HIV-1 Drug Resistance Within a Female Screening Population for HIV Prevention Trials|Completed|||1074|Actual|Microbicide Trials Network|||||f||||t||||||Samples With DNA|"~     Blood Plasma~   "|||2018-05-31 23:20:35.233106|2018-05-31 23:20:35.233106
NCT01204801|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2015-09-23|2010-09-16|2010-09-17|Estimate|||||||2015-09-23|2015-09-24|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|Medifocus301||Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors|Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast|Unknown status|Recruiting|Phase 3|238|Anticipated|Medifocus, Inc.||2|||f||||f||||||||||2018-05-31 23:20:35.303993|2018-05-31 23:20:35.303993
NCT01204788|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2015-05-28||2015-05-28|2010-09-16|2010-09-17|Estimate|2015-05-28|2015-06-10|Estimate||||2015-05-28|2015-06-10|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia|A Prospective Randomized Comparative Study of the Effect on Infections of Radiated Prophylactic White Cell Transfusions Versus Therapeutic Radiated White Cell Transfusions|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center||2||Low Recruitment|f||||t||||||||||2018-05-31 23:20:35.409427|2018-05-31 23:20:35.409427
NCT01204775|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2017-03-07||2017-03-07|2010-09-16|2010-09-17|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|June 2011||2011-06-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patients With Type 2 Diabetes|Completed||Phase 3|26|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 23:20:35.624115|2018-05-31 23:20:35.624115
NCT01204762|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16||2015-09-23|2015-09-23|2010-09-16|2010-09-17|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LIRA-B||Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen|Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients With Chronic Hepatitis B Virus Infection Who Are HBeAg-positive|Completed||Phase 2|197|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 23:20:35.861614|2018-05-31 23:20:35.861614
NCT01204749|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26||2014-06-02|2016-12-14|2010-09-16|2010-09-17|Estimate||||2014-06-02|2014-06-17|Estimate|2016-12-14|2016-12-15|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2013|Actual|2013-03-31||Interventional|||TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer|A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers|Completed||Phase 3|919|Actual|Amgen||2|||f||||t||||||||||2018-05-31 23:20:36.102499|2018-05-31 23:20:36.102499
NCT01204736|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2015-12-02||2016-02-08|2010-09-16|2010-09-17|Estimate|2015-12-02|2016-01-07|Estimate||||2016-02-08|2016-03-08|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Comparing Outcomes of Elbow Extension Tendon Transfers|A Comparison of Two Surgical Procedures That Restore Elbow Extension|Completed|||14|Actual|VA Office of Research and Development|||4||f||||f||||||||||2018-05-31 23:20:36.690691|2018-05-31 23:20:36.690691
NCT01204723|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-05-31|2010-09-15|2010-09-17|Estimate|||||||2012-05-31|2012-06-01|Estimate|August 2009||2009-08-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|MTC||Medications Development for the Treatment of Cannabis Related Disorders|Medications Development for the Treatment of Cannabis Related Disorders|Completed||Phase 1|63|Actual|University of Virginia||3|||f||||t||||||||||2018-05-31 23:20:36.915241|2018-05-31 23:20:36.915241
NCT01204177|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2013-09-05|2010-09-16|2010-09-17|Estimate|||||||2013-09-05|2013-09-06|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|BASIL||Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.|A Phase II Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)|Completed||Phase 2|70|Actual|Bayer||1|||f||||f||||||||||2018-05-31 23:20:47.231153|2018-05-31 23:20:47.231153
NCT01204710|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16||2014-01-22|2014-01-22|2010-09-16|2010-09-17|Estimate||||2014-01-22|2014-02-17|Estimate|2014-01-22|2014-02-17|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|September 2012|Actual|2012-09-30||Interventional|||A Study of IMC-3G3 in Prostate Cancer|A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy|Completed||Phase 2|123|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 23:20:37.009082|2018-05-31 23:20:37.009082
NCT01204697|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2015-10-15||2015-10-15|2010-09-16|2010-09-17|Estimate|2015-10-15|2015-11-16|Estimate||||2015-10-15|2015-11-16|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Full analysis set (FAS) included all randomized participants who received at least one dose of study medication. Participants were analyzed according to treatment received.|A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)|A Randomized Phase II Trial of Erlotinib or Intermittent Dosing of Erlotinib and Docetaxel in Male Former-smokers With Locally Advanced or Metastatic Squamous NSCLC in Second-line Setting After Failure on Chemotherapy|Completed||Phase 2|74|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:20:37.273348|2018-05-31 23:20:37.273348
NCT01204684|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2017-10-11|2010-09-16|2010-09-17|Estimate|||||||2017-10-11|2017-10-13|Actual|October 8, 2010|Actual|2010-10-08|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Dendritic Cell Vaccine for Patients With Brain Tumors|A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma|Active, not recruiting||Phase 2|60|Anticipated|Jonsson Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 23:20:37.688475|2018-05-31 23:20:37.688475
NCT01204671|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2012-12-13|2012-07-23|2017-02-23|2010-09-16|2010-09-17|Estimate|2013-05-09|2013-06-17|Estimate|2012-07-23|2012-07-31|Estimate|2017-02-23|2017-03-27|Actual|October 2010||2010-10-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)|Partially-blind Immunogenicity and Safety Study of GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults.|Completed||Phase 3|4659|Actual|GlaxoSmithKline|Concerns arose about data integrity for a Romanian site (102 subjects) after completion of analysis. These data were not excluded from this reporting as they did not reveal irregularities and GSK does not plan to use them towards regulatory filing.|5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:20:37.814658|2018-05-31 23:20:37.814658
NCT01204658|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2016-08-05|2012-11-16|2017-03-21|2010-09-16|2010-09-17|Estimate|2016-08-05|2016-09-28|Estimate|2012-11-16|2012-11-21|Estimate|2017-03-21|2017-03-23|Actual|September 2010||2010-09-30|March 2017|2017-03-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Interventional|||Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants|Safety, Reactogenicity & Immunogenicity of GSK Biologicals' Pneumococcal Vaccine 2189242A When Co-administered With DTPa-HBV-IPV/Hib Vaccine in Healthy Infants|Completed||Phase 2|576|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 23:20:39.630152|2018-05-31 23:20:39.630152
NCT01204645|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2017-06-14|2010-09-16|2010-09-17|Estimate|||||||2017-06-14|2017-06-15|Actual|May 2010||2010-05-31|June 2017|2017-06-30|January 2024|Anticipated|2024-01-31|May 2022|Anticipated|2022-05-31||Observational|KKT||Karolinska Cardiorenal Theme-centre and StockholmHeartbank|Stockholmheartbank and Karolinska Cardiorenal Theme-centre, From Genome to Clinical Practice in Patients With Acute Coronary Syndrome and Impaired Kidney Function|Recruiting|||10000|Anticipated|Danderyd Hospital|||3||f||||t||||||Samples With DNA|"~     Blood and plasma.~   "|||2018-05-31 23:20:42.244245|2018-05-31 23:20:42.244245
NCT01204632|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2016-02-17|2010-09-16|2010-09-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Cardiometabolic Risk, Obesity and Cardiovascular Disease in People With Spinal Cord Injury|Cardiometabolic Risk, Obesity and Cardiovascular Disease in People With Spinal Cord Injury|Completed|||74|Actual|University of Miami|||||f||||f||||||||||2018-05-31 23:20:42.333356|2018-05-31 23:20:42.333356
NCT01204619|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2016-04-12|2010-09-16|2010-09-17|Estimate|||||||2016-04-12|2016-04-14|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|TEACH||Trial on Education And Clinical Outcomes for Home PD Patients (TEACH)|Trial on Education And Clinical Outcomes for Home PD Patients (TEACH)|Completed||N/A|104|Actual|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 23:20:42.413168|2018-05-31 23:20:42.413168
NCT01204606|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2013-03-11|2010-09-16|2010-09-17|Estimate|||||||2013-03-11|2013-03-12|Estimate|September 2010||2010-09-30|March 2013|2013-03-31||||March 2011|Actual|2011-03-31||Interventional|||Arthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA)|Arthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA): A Randomized, Double-blind, Placebo-controlled Trial|Completed||N/A|54|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:20:42.580721|2018-05-31 23:20:42.580721
NCT01204593|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2014-03-14|2010-09-16|2010-09-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|SUBSTITUTE||baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus|Phase IV, Multicenter, International, Non-comparative, Open Label Study of Efficacy and Safety of Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in Patients With T1 Diabetes Previously Uncontrolled on Any Insulin Regimen.|Completed||Phase 4|206|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:20:42.659348|2018-05-31 23:20:42.659348
NCT01204580|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-04-02|2010-09-16|2010-09-17|Estimate|||||||2012-04-02|2012-04-03|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DIAGRAM||ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination|ADIponectin and ADMA Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination (Amaryl-M)|Completed||Phase 4|40|Actual|Sanofi||1|||f||||||||||||||2018-05-31 23:20:42.852596|2018-05-31 23:20:42.852596
NCT01204567|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2012-08-23|2010-09-16|2010-09-17|Estimate|||||||2012-08-23|2012-08-24|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Influence of Exercise on Mental Health After Discharge From Hospital|The Aim of the Study is to Evaluate the Effect of Aerobic Fitness Training on Mental Health (Health-related Quality of Life), Cognitive and Physical Capacity in Older People Discharged From Hospital.|Completed||N/A|116|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 23:20:42.995932|2018-05-31 23:20:42.995932
NCT01204528|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2013-09-04|2010-09-16|2010-09-17|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|SOLID||Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease|Diastolic Dysfunction, Microcirculation Disturbance, Sympathetic Activation and Inflammation in Moderate Kidney Failure and in Diabetic Nephropathy: Disease Modification With Vitamin-D Receptor Activation. A Double-blind, Placebo-controlled, Randomised Trial - the SOLID Trial|Completed||Phase 2/Phase 3|36|Actual|Danderyd Hospital||3|||f||||t||||||||||2018-05-31 23:20:43.278659|2018-05-31 23:20:43.278659
NCT01204515|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2013-02-04|2010-09-16|2010-09-17|Estimate|||||||2013-02-04|2013-02-06|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|ASPPNB||Abdominal Symptom Phenotype Study in Children|Abdominal Symptom Phenotype: Pathways to New Biomarkers|Completed|||45|Actual|Baylor College of Medicine|||2||f||||f||||||Samples With DNA|"~     We will be banking DNA for future analysis. The samples will be retained according to the~     legal and ethical laws.~   "|||2018-05-31 23:20:43.384133|2018-05-31 23:20:43.384133
NCT01204502|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2013-09-17|2010-09-16|2010-09-17|Estimate|||||||2013-09-17|2013-09-18|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Suicide Gene Therapy Trial|Phase I/II Clinical Trial of T-cell Suicide Gene Therapy Following Haploidentical Stem Cell Transplantation|Terminated||Phase 1/Phase 2|2|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||1||Changes in the clinical practice|f||||||||||||||2018-05-31 23:20:43.460315|2018-05-31 23:20:43.460315
NCT01204489|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-06-20|2010-09-16|2010-09-17|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|LIFT||Lifestyle Intervention for Toddlers Pilot Study|Lifestyle Intervention for Toddlers at Finnish Welfare Clinics|Completed||N/A|148|Actual|National Institute for Health and Welfare, Finland||2|||f||||f||||||||||2018-05-31 23:20:43.537259|2018-05-31 23:20:43.537259
NCT01204476|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2016-07-14|2010-09-16|2010-09-17|Estimate|||||||2016-07-14|2016-07-15|Estimate|October 2010||2010-10-31|July 2016|2016-07-31||||July 2014|Actual|2014-07-31||Interventional|||Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma|Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma|Completed||Phase 1|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:20:43.599161|2018-05-31 23:20:43.599161
NCT01204450|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2016-12-22|2010-09-16|2010-09-17|Estimate|||||||2016-12-22|2016-12-23|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma|A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors|Terminated||Phase 1|7|Actual|UNC Lineberger Comprehensive Cancer Center||1||Funding has become unavailable|f||||t||||||||||2018-05-31 23:20:43.717115|2018-05-31 23:20:43.717115
NCT01204437|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2016-02-09|2010-09-16|2010-09-17|Estimate|||||||2016-02-09|2016-02-10|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ICE-II||Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast|An Investigational Randomized Study on Epirubicin Plus Cyclophospamide (EC) or Cyclophosphamide Plus Methotrexat Plus 5-fluorouracil (CMF) Versus Nab-paclitaxel Plus Capecitabine as Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast|Completed||Phase 2/Phase 3|400|Actual|German Breast Group||3|||f||||t||||||||||2018-05-31 23:20:43.799999|2018-05-31 23:20:43.799999
NCT01204424|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2010-09-16|2010-09-16|2010-09-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Interventional|DKK SVP||Clinical Investigation to Assess the Safety and Feasibility of the Crestal, Minimal-invasive Sinus Floor Augmentation With the Pressure Chamber Drill (DKK) and the Sinus Vibration Pump (SVP)|Klinische Prüfung Zur Untersuchung Der Sicherheit Und Machbarkeit Des Crestalen, Minimal-invasiven Kieferknochenaufbaus (Sinuslift) Mit Der Druck-kammerknochenfräse (DDK) Und Der Sinusvibrationspumpe (SVP)|Unknown status|Recruiting|Phase 1|20|Anticipated|Jeder GmbH|||||f||||t||||||||||2018-05-31 23:20:43.918124|2018-05-31 23:20:43.918124
NCT01204411|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2012-11-29|2010-09-16|2010-09-17|Estimate|||||||2012-11-29|2012-11-30|Estimate||||November 2012|2012-11-30||||||||Interventional|||Efficacy of Artesunate-amodiaquine (AS-AQ) in Children With Malaria and Severe Acute Malnutrition, Madaoua, Niger 2010|Efficacy of the Artesunate-amodiaquine Combination for Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Between 6 and 59 Months of Age With Severe Acute Malnutrition in Madaoua, Tahoua Region, Niger|Withdrawn||Phase 4|0|Actual|Epicentre||||The ethics committee did not approve the pharmacokinetic part of the study.|f||||f||||||||||2018-05-31 23:20:44.02335|2018-05-31 23:20:44.02335
NCT01204398|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2012-07-20||2014-06-17|2010-09-16|2010-09-17|Estimate|2012-07-20|2012-08-24|Estimate||||2014-06-17|2014-06-27|Estimate|November 2010||2010-11-30|December 2013|2013-12-31||||July 2011|Actual|2011-07-31||Interventional|||Telmisartan+Amlodipine Fixed Dose Combination in Hypertension|An Open-label Study to Evaluate the Antihypertensive Effects of the Fixed-dose Combination of Telmisartan 80 mg and Amlodipine 5 mg (T80/A5) Given Once Daily by 24 h ABPM in Patients With Moderate to Severe Hypertension|Completed||Phase 3|27|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:20:44.10427|2018-05-31 23:20:44.10427
NCT01204385|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2014-01-09|2010-09-16|2010-09-17|Estimate|||||||2014-01-09|2014-01-13|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Saudi Arabia|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Saudi Arabia|Completed|||66|Actual|GlaxoSmithKline|||1||f||||||||||Samples Without DNA|"~     Middle ear fluid and urine~   "|||2018-05-31 23:20:44.745224|2018-05-31 23:20:44.745224
NCT01204372|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-08-16|2010-09-16|2010-09-17|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2010|Actual|2010-06-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|February 2012|Actual|2012-02-29||Interventional|GATE 1||Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma|Phase II Trial Evaluating the Combination of Gemcitabine, Trastuzumab and Erlotinib as First-line Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|63|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||t||||||||||2018-05-31 23:20:44.812985|2018-05-31 23:20:44.812985
NCT01204359|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-05-22|2010-09-16|2010-09-17|Estimate|||||||2015-05-22|2015-05-25|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions|"5010 Clinical Research Programmeof Sun Yat-sen University"|Unknown status|Recruiting|Phase 3|627|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 23:20:44.937899|2018-05-31 23:20:44.937899
NCT01204346|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2014-10-02|2010-09-16|2010-09-17|Estimate|||||||2014-10-02|2014-10-03|Estimate|December 2010||2010-12-31|July 2011|2011-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|MBT||Mentalization - Based Treatment: Adolescents With Co-morbid Depression and Personality Disorder|Mentalization - Based Treatment for Young People Presenting With Co-morbid Depression and Symptoms of Emerging Personality Disorder: Prospective Controlled Trial.|Unknown status|Recruiting|N/A|75|Anticipated|North East London Foundation Trust||2|||f||||f||||||||||2018-05-31 23:20:45.015985|2018-05-31 23:20:45.015985
NCT01204333|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-02-11|2010-09-16|2010-09-17|Estimate|||||||2017-02-11|2017-02-14|Actual|September 2011||2011-09-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|December 2016|Actual|2016-12-31||Interventional|TOACT||Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis|Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (TOACT)|Terminated||Phase 2/Phase 3|67|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 23:20:45.158762|2018-05-31 23:20:45.158762
NCT01204320|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2010-09-16|2010-09-16|2010-09-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|January 2008||2008-01-31|October 2009|2009-10-31||||January 2010|Anticipated|2010-01-31||Interventional|COMPACT-ISR||A COMparison Between PAClitaxel-coated Balloon and pacliTaxel-eluting Stent in the Treatment of In-Stent Restenosis (COMPACT-ISR)||Terminated||Phase 4|154|Anticipated|Ospedale San Donato||2|||f||||f||||||||||2018-05-31 23:20:45.2839|2018-05-31 23:20:45.2839
NCT01204307|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-07-27|2010-09-16|2010-09-17|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation|A Phase III Study to Investigate the Differential Influence of Prior Chemotherapy on the Efficacy of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (IIIB, IV) With or Without EGFR Gene Mutation|Completed||Phase 2|101|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 23:20:45.379452|2018-05-31 23:20:45.379452
NCT01204294|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|2012-12-18||2014-02-27|2010-09-16|2010-09-17|Estimate|2012-12-18|2013-01-23|Estimate||||2014-02-27|2014-03-28|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comprehensive Add on Study in Japan|An Open Label, Randomised, Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Background Mono-therapy With an Approved Antidiabetic Drug|Completed||Phase 3|574|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 23:20:45.498447|2018-05-31 23:20:45.498447
NCT01204281|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-11-23|2010-09-16|2010-09-17|Estimate|||||||2012-11-23|2012-11-27|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients|High-assistance Proportional Assist Ventilation (PAV) vs. Assist-Control Ventilation (ACV) in Early Stage of Critically Ill Patients|Completed||Phase 4|110|Actual|Althaia Xarxa Assistencial Universitària de Manresa||2|||f||||t||||||||||2018-05-31 23:20:46.29568|2018-05-31 23:20:46.29568
NCT01204268|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-16|2010-09-15|2010-09-17|Estimate|||||||2010-09-16|2010-09-20|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|October 2011|Anticipated|2011-10-31|August 2011|Anticipated|2011-08-31||Interventional|||The Neuroprotection of Sevoflurane Preconditioning on Intracranial Aneurysm Surgery|The Neuroprotection of Sevoflurane Preconditioning on Perioperative Ischemia-reperfusion Injury During Intracranial Aneurysm Surgery|Unknown status|Recruiting|N/A|80|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 23:20:46.360266|2018-05-31 23:20:46.360266
NCT01204255|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2011-07-11||2017-10-16|2010-09-15|2010-09-17|Estimate|2011-07-11|2011-08-05|Estimate||||2017-10-16|2017-11-17|Actual|November 15, 2010|Actual|2010-11-15|October 2017|2017-10-31|May 17, 2011|Actual|2011-05-17|April 18, 2011|Actual|2011-04-18||Interventional|||Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers|"Absorption of ABH Gel (Ativan®, Lorazepam; Benadryl®, Diphenhydramine; and Haldol®, Haloperidol Gel) From the Skin of Normal Volunteers"|Completed||N/A|11|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 23:20:46.494832|2018-05-31 23:20:46.494832
NCT01204242|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2011-08-09|2010-09-16|2010-09-17|Estimate|||||||2011-08-09|2011-08-10|Estimate|August 2009||2009-08-31|August 2011|2011-08-31||||||||Interventional|||IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence|IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery: Effects on Postoperative Recovery and Cancer Recurrence|Unknown status|Enrolling by invitation|Phase 2|80|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 23:20:46.649679|2018-05-31 23:20:46.649679
NCT01204229|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2011-04-21|2010-09-16|2010-09-17|Estimate|||||||2011-04-21|2011-04-22|Estimate|May 2010||2010-05-31|April 2011|2011-04-30||||May 2012|Anticipated|2012-05-31||Interventional|MCID||Motivational and Cognitive Intervention for College Drinkers|Motivational and Cognitive Intervention for College Drinkers|Unknown status|Recruiting|Phase 1|100|Anticipated|University of Cincinnati||2|||f||||f||||||||||2018-05-31 23:20:46.717764|2018-05-31 23:20:46.717764
NCT01204216|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-09-01|2010-09-15|2010-09-17|Estimate|||||||2017-09-01|2017-09-05|Actual|September 1, 2010|Actual|2010-09-01|September 2017|2017-09-30|September 1, 2016|Actual|2016-09-01|July 1, 2016|Actual|2016-07-01||Interventional|||Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c|Does Variation in Mean Red Cell Age Impact HbA1C Interpretation?|Completed||N/A|35|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:20:46.922739|2018-05-31 23:20:46.922739
NCT01204203|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2017-03-03||2017-04-24|2010-09-15|2010-09-17|Estimate|2017-04-24|2017-05-24|Actual||||2017-04-24|2017-05-24|Actual|June 2009||2009-06-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|UAB0901||Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)|A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma|Completed||Phase 2|8|Actual|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-05-31 23:20:47.007062|2018-05-31 23:20:47.007062
NCT01204190|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2014-11-03|2010-09-16|2010-09-17|Estimate|||||||2014-11-03|2014-11-04|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Investigation of Three Contraceptive Hormone Patches in Regard to Inhibition of Ovulation Following Application Over 3 Treatment Cycles in Healthy, Young Women.|Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation During Treatment With Three Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol (EE) and 2.10 mg Gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles|Completed||Phase 2|173|Actual|Bayer||3|||f||||f||||||||||2018-05-31 23:20:47.152396|2018-05-31 23:20:47.152396
NCT01204164|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2016-05-05|2010-09-15|2010-09-17|Estimate|||||||2016-05-05|2016-05-06|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|TG02-101||Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies|Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies|Completed||Phase 1|120|Anticipated|Tragara Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 23:20:47.320369|2018-05-31 23:20:47.320369
NCT01204151|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-16|2010-09-16|2010-09-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Teaching Math Skills to Individuals With Fragile X Syndrome|Evaluating a Brief Intensive Intervention for Individuals With Fragile X Syndrome|Unknown status|Recruiting|N/A|60|Anticipated|Stanford University|||||f||||||||||||||2018-05-31 23:20:47.471062|2018-05-31 23:20:47.471062
NCT01204138|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2016-02-03|2010-09-15|2010-09-17|Estimate|||||||2016-02-03|2016-02-05|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|CATARA||Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA|Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA|Withdrawn||Phase 2|0|Actual|Stanford University||2||decision of sponsor to withdraw before initiation; 0 patients enrolled|f||||||||||||||2018-05-31 23:20:47.537226|2018-05-31 23:20:47.537226
NCT01204125|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2017-03-21|2010-09-15|2010-09-17|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2010||2010-09-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|October 2012|Actual|2012-10-31||Interventional|SOLTI NEOPARP||Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients|Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC)|Completed||Phase 2|141|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 23:20:47.621011|2018-05-31 23:20:47.621011
NCT01204112|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-10-21|2010-09-15|2010-09-17|Estimate|||||||2010-10-21|2010-10-22|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers|A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:20:47.741861|2018-05-31 23:20:47.741861
NCT01204099|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15||2015-04-30|2018-05-14|2010-09-15|2010-09-17|Estimate||||2015-04-30|2015-05-19|Estimate|2018-05-14|2018-05-16|Actual|September 2010||2010-09-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Study of PX-866 and Docetaxel in Solid Tumors|Phase 1/2 Study of PX-866 and Docetaxel in Patients With Solid Tumors|Completed||Phase 1/Phase 2|223|Actual|Seattle Genetics, Inc.||4|||f||||t||||||||||2018-05-31 23:20:47.841257|2018-05-31 23:20:47.841257
NCT01204086|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-15|2010-09-15|2010-09-17|Estimate|||||||2010-09-15|2010-09-17|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|||Pharmacogenomics Studies of Antidepressants||Unknown status|Recruiting|Phase 4|200|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 23:20:47.965719|2018-05-31 23:20:47.965719
NCT01204073|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-07-01|2010-09-16|2010-09-17|Estimate|||||||2013-07-01|2013-07-02|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-Label, Dose-Escalation, Phase 1 Study of TAK-441, an Oral Hedgehog Signaling Pathway Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies|Completed||Phase 1|34|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:20:48.052995|2018-05-31 23:20:48.052995
NCT01204060|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-10-31|2010-09-16|2010-09-17|Estimate|||||||2012-10-31|2012-11-01|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Effect of Allergen Challenge on Inflammation Induced by Toll-like Receptor Stimulation in a Nasal Model|Effect of Allergen Challenge on Inflammation Induced by Toll-like Receptor Stimulation in a Nasal Model.|Unknown status|Recruiting|N/A|20|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 23:20:48.118819|2018-05-31 23:20:48.118819
NCT01204047|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2014-07-21|2010-09-16|2010-09-17|Estimate|||||||2014-07-21|2014-07-22|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Wheelchair Mobility Assessment of Individuals With Spinal Cord Injury|Wheelchair Propulsion Function and Physical Capacity in Persons With Spinal Cord Injury|Completed|||62|Actual|University of Miami|||||f||||f||||||||||2018-05-31 23:20:48.186423|2018-05-31 23:20:48.186423
NCT01204034|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-06-29|2010-09-16|2010-09-17|Estimate|||||||2012-06-29|2012-07-03|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Open-label, Prospective Exploratory Study to Assess the Effects of Formoterol and Beclometasone Dipropionate Combination Therapy on Central and Peripheral Airway Dimensions in COPD Patients|Completed||Phase 3|29|Actual|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 23:20:48.251166|2018-05-31 23:20:48.251166
NCT01204021|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2016-11-16|2010-09-16|2010-09-17|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2008||2008-05-31|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Managing Stress and Social Ties for Health Aging|Managing Stress and Social Ties for Health Aging|Completed||N/A|26|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 23:20:48.319014|2018-05-31 23:20:48.319014
NCT01204008|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-16|2010-09-16|2010-09-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|September 2009||2009-09-30|August 2007|2007-08-31|December 2015|Anticipated|2015-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy|A Prospective Randomized Trails for Primary Disc Herniation With Radiculopathy:Conservative Versus Aggressive Discectomy|Unknown status|Recruiting|Phase 4|100|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:20:48.378793|2018-05-31 23:20:48.378793
NCT01203995|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2013-03-29|2010-09-15|2010-09-17|Estimate|||||||2013-03-29|2013-04-02|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|RICE||Remote Information Counseling for Elders|Remote Information Counseling for Elders|Completed||N/A|64|Actual|Indiana University||4|||f||||f||||||||||2018-05-31 23:20:48.451553|2018-05-31 23:20:48.451553
NCT01203280|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-15|2010-09-15|2010-09-16|Estimate|||||||2010-09-15|2010-09-16|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Icing Effects on Neck Functions of the Boxers|Icing Effects on Neck Functions of the Boxers|Completed||N/A|50|Actual|Taipei Physical Education College||1|||f||||t||||||||||2018-05-31 23:20:59.962063|2018-05-31 23:20:59.962063
NCT01203982|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-16|2010-09-16|2010-09-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|November 2007||2007-11-30|September 2010|2010-09-30|June 2009|Actual|2009-06-30|||||Interventional|||Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT)|Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima Media Thickness and Its Relation to Plaque Components of the Coronary Arteries in Patients With ST-Segment Elevation Acute Myocardial Infarction|Completed||Phase 4|87|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 23:20:48.515947|2018-05-31 23:20:48.515947
NCT01203969|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-02-02|2010-09-16|2010-09-17|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy of Single Port Laparoscopic Surgery in Colon Cancer||Completed||Phase 1|62|Actual|Kyunghee University Medical Center||2|||f||||||||||||||2018-05-31 23:20:48.595314|2018-05-31 23:20:48.595314
NCT01203956|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2015-03-24||2015-04-08|2010-09-16|2010-09-17|Estimate|2015-04-08|2015-04-28|Estimate||||2015-04-08|2015-04-28|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Compliant participants completing study with evaluable results|DeVilbiss AutoAdjust With SmartFlex Comparative Study|"A Multi Center, Prospective, Randomized, Double Blind, Crossover Study to Compare the DeVilbiss AutoAdjust With and Without the Smartflex Device Modification; AutoAdjust With SmartFlex Study"|Completed||N/A|28|Actual|DeVilbiss Healthcare LLC||2|||f||||f||||||||||2018-05-31 23:20:48.661913|2018-05-31 23:20:48.661913
NCT01203943|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15||2013-09-05|2013-09-05|2010-09-16|2010-09-17|Estimate||||2013-09-05|2013-09-16|Estimate|2013-09-05|2013-09-16|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)|Terminated||Phase 2|28|Actual|Celgene||4||The benefit/ risk profile does not support continuation of this study.|f||||t||||||||||2018-05-31 23:20:49.009723|2018-05-31 23:20:49.009723
NCT01203930|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2016-08-03||2017-05-19|2010-09-16|2010-09-17|Estimate|2017-04-10|2017-05-22|Actual||||2017-05-19|2017-05-23|Actual|October 2010|Actual|2010-10-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional||Intent-to-treat (ITT) Analysis Set: participants who received at least 1 dose of idelalisib.|A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL|A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Terminated||Phase 2|105|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 23:20:49.16216|2018-05-31 23:20:49.16216
NCT01203917|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2013-08-05||2016-11-14|2010-09-15|2010-09-17|Estimate|2013-08-05|2013-10-14|Estimate||||2016-11-14|2017-01-02|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|August 2012|Actual|2012-08-31||Interventional|IFUM|This is a subset of all the screened patients who are found to be EGFR M+ and who have taken at least one dose of study medication (i.e. EGFR M+ patients are those who have activating sensitising EGFR mutation eligible for the study).|Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC|An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 4|1060|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:20:49.996604|2018-05-31 23:20:49.996604
NCT01203904|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2016-06-06|2010-09-15|2010-09-17|Estimate|||||||2016-06-06|2016-06-07|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PEACE-Peds||Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation|Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation for Long Term Use in Pediatrics|Completed|||301|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 23:20:50.351794|2018-05-31 23:20:50.351794
NCT01203891|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-17|2010-09-15|2010-09-17|Estimate|||||||2010-09-17|2010-09-20|Estimate|January 2003||2003-01-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Single Photon Emission Computed Tomography of the Normal Human Brain|Single Photon Emission Computed Tomography of the Normal Human Brain|Completed|||97|Actual|Amen Clinics, Inc.|||1||f||||t||||||||||2018-05-31 23:20:50.457069|2018-05-31 23:20:50.457069
NCT01203878|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2014-11-13||2014-11-20|2010-09-15|2010-09-17|Estimate|2014-11-19|2014-11-20|Estimate||||2014-11-20|2014-12-08|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Patients completing week 18 visit|Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy|An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy|Terminated||Phase 4|21|Actual|Tennessee Clinical Research Center|Early termination (slow enrollment) leading to small numbers of subjects analyzed; missing measurement(s) on a patient|2||Unable to reach target enrollment of 60 subjects|f||||f||||||||||2018-05-31 23:20:50.527801|2018-05-31 23:20:50.527801
NCT01203865|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2011-10-10|2010-09-15|2010-09-16|Estimate|||||||2011-10-10|2011-10-12|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|March 2012|Anticipated|2012-03-31|November 2011|Anticipated|2011-11-30||Observational|||Prevalence of Fibromyalgia in Israel|Prevalence of Fibromyalgia in Israel|Unknown status|Recruiting||1200|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:20:50.809148|2018-05-31 23:20:50.809148
NCT01203852|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2015-04-29||2018-04-04|2010-09-15|2010-09-16|Estimate|2015-04-29|2015-05-19|Estimate||||2018-04-04|2018-04-06|Actual|August 2010||2010-08-31|April 2018|2018-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PEAR2|Approximately 1000 males or females with mild to moderate primary HTN, of any race or ethnicity, between the ages of 18 and 65 will be enrolled into the PEAR2 protocol. Prospective study participants will be those with newly diagnosed HTN, untreated HTN or known HTN currently treated with antihypertensive drugs.|Pharmacogenomic Evaluation of Antihypertensive Responses 2|Pharmacogenomic Evaluation of Antihypertensive Responses 2|Completed||Phase 4|839|Actual|University of Florida||1|||f||||t|f|f||||||||2018-05-31 23:20:50.866491|2018-05-31 23:20:50.866491
NCT01203839|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2018-04-04|2010-09-15|2010-09-16|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2010|Actual|2010-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer|A Phase II Study of Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer|Active, not recruiting||Phase 2|110|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:20:51.02845|2018-05-31 23:20:51.02845
NCT01203826|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2017-06-27||2017-10-10|2010-09-15|2010-09-16|Estimate|2017-06-27|2017-07-26|Actual||||2017-10-10|2017-11-09|Actual|April 2010||2010-04-30|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)|Extension Study of Protocol ENB-006-09 Evaluating the Long-term Safety and Efficacy of Asfotase Alfa (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)|Completed||Phase 2|12|Actual|Alexion Pharma GmbH||1|||f||||t|t|f||||||||2018-05-31 23:20:51.101942|2018-05-31 23:20:51.101942
NCT01203813|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-02-14|2010-09-15|2010-09-16|Estimate|||||||2013-02-14|2013-02-15|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Risk Based Approach to Improving Chronic Kidney Disease Management|A Risk Based Approach to Improving Chronic Kidney Disease Management|Completed||Phase 3|10000|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 23:20:51.817402|2018-05-31 23:20:51.817402
NCT01203800|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-02-08|2010-09-15|2010-09-16|Estimate|||||||2016-02-08|2016-02-09|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Evaluation of Blood Brain Barrier Permeability in Chronic Stroke|Evaluation of Blood Brain Barrier Permeability in Chronic Stroke|Completed|||30|Actual|Wolfson Medical Center|||||f||||f||||||||||2018-05-31 23:20:51.88333|2018-05-31 23:20:51.88333
NCT01203787|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2015-01-27||2015-02-13|2010-09-15|2010-09-16|Estimate|2015-01-27|2015-02-11|Estimate||||2015-02-13|2015-03-05|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)|Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery|Completed||Phase 4|120|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 23:20:51.960734|2018-05-31 23:20:51.960734
NCT01203774|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-07-20|2010-09-15|2010-09-16|Estimate|||||||2017-07-20|2017-07-24|Actual|September 2010||2010-09-30|July 2017|2017-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital|"Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients Discharged From the Hospital"|Completed||Phase 4|61|Actual|University of Colorado, Denver||2|||f||||f|t|f|||f|||||2018-05-31 23:20:52.786011|2018-05-31 23:20:52.786011
NCT01203761|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2010-09-15|2010-09-15|2010-09-16|Estimate|||||||2010-09-15|2010-09-16|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|November 2011|Anticipated|2011-11-30|September 2011|Anticipated|2011-09-30||Observational|||The Experience of Loneliness Among Patients During the Perioperative Period|The Experience of Loneliness Among Ear, Nose and Throat (ENT) Surgical Patients During the Perioperative Period|Unknown status|Not yet recruiting||600|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||f||||||||||2018-05-31 23:20:52.853654|2018-05-31 23:20:52.853654
NCT01203748|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2014-01-30|2010-09-15|2010-09-16|Estimate|||||||2014-01-30|2014-02-03|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Star AF II||Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study|Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study|Completed||N/A|589|Actual|St. Jude Medical||3|||f||||t||||||||||2018-05-31 23:20:52.924696|2018-05-31 23:20:52.924696
NCT01203735|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2011-03-27|2010-09-15|2010-09-16|Estimate|||||||2011-03-27|2011-03-29|Estimate|February 2011||2011-02-28|September 2010|2010-09-30|February 2015|Anticipated|2015-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Valproic Acid With Chemoradiotherapy for Non-Small-Cell Lung Cancer|Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Vinorelbine and Cisplatin for Inoperable Locally Advanced Non-Small-Cell Lung Cancer|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Soroka University Medical Center||1|||f||||f||||||||||2018-05-31 23:20:52.994244|2018-05-31 23:20:52.994244
NCT01203722|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-05-17|2010-09-15|2010-09-16|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies|Reduced Intensity, Partially HLA Mismatched Allogeneic BMT for Hematologic Malignancies Using Donors Other Than First-degree Relatives|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 23:20:53.087089|2018-05-31 23:20:53.087089
NCT01203709|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2014-03-03|2010-09-15|2010-09-16|Estimate|||||||2014-03-03|2014-03-04|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis|Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study|Completed||Phase 4|20|Actual|Tuen Mun Hospital||1|||f||||t||||||||||2018-05-31 23:20:53.163785|2018-05-31 23:20:53.163785
NCT01203696|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-06-05|2010-09-15|2010-09-16|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease|Effect of Amlodipine on Platelet Inhibition by Clopidogrel in Patients With Ischemic Heart Disease- a Prospective Randomized Controlled Trial|Completed||Phase 4|97|Actual|Ruttonjee Hospital||2|||f||||f||||||||||2018-05-31 23:20:53.230266|2018-05-31 23:20:53.230266
NCT01203683|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-10-09|2010-09-15|2010-09-16|Estimate|||||||2013-10-09|2013-10-10|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Testing the Effectiveness of a Computer-based Program for Depression|Attention Training for Major Depressive Disorder|Completed||Phase 3|53|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 23:20:53.320493|2018-05-31 23:20:53.320493
NCT01203670|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-21|2010-09-15|2010-09-16|Estimate|||||||2010-09-21|2010-09-22|Estimate||||September 2010|2010-09-30|December 2009|Actual|2009-12-31|||||Interventional|||Renal and Digestive Tolerance of a Food Supplement, Phytalgic, in Elderly Volunteers - A Multicentric Open Trial|Renal and Digestive Tolerance of a Food Supplement, Phytalgic, in Elderly Volunteers - A Multicentric Open Trial|Completed||N/A|50|Actual|Phythea||1|||f||||f||||||||||2018-05-31 23:20:53.520098|2018-05-31 23:20:53.520098
NCT01203657|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-08-17|2010-09-15|2010-09-16|Estimate|||||||2016-08-17|2016-08-19|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||UCLA Tai Chi in a Community Setting Study|Tai Chi, Vitality and Activity in a Community Setting|Completed||N/A|47|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:20:53.606908|2018-05-31 23:20:53.606908
NCT01203267|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2010-09-15|2010-09-15|2010-09-16|Estimate|||||||2010-09-15|2010-09-16|Estimate|December 2007||2007-12-31|November 2007|2007-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer|Phase 2 Study of Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer Patients|Completed||Phase 2|108|Actual|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||||2018-05-31 23:21:00.184597|2018-05-31 23:21:00.184597
NCT01203644|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2011-11-23|2010-09-22|2012-04-15|2010-09-15|2010-09-16|Estimate|2012-04-15|2012-05-14|Estimate|2010-09-22|2010-09-27|Estimate|2012-04-15|2012-05-14|Estimate|December 2004||2004-12-31|November 2011|2011-11-30|December 2006|Actual|2006-12-31|January 2006|Actual|2006-01-31||Interventional|||Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair|A Phase 2, Multicenter, Randomized, Double Blind, Dose Escalating/ De Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of a Single Dose of Sustained Release Encapsulated Bupivacaine (SKY0402) in the Management of Postoperative Pain in Subjects Undergoing Inguinal Hernia Repair|Completed||Phase 2|76|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 23:20:53.67951|2018-05-31 23:20:53.67951
NCT01203631|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15||2016-07-20|2016-07-29|2010-09-15|2010-09-16|Estimate||||2016-07-20|2016-07-22|Estimate|2016-07-29|2016-08-01|Estimate|February 2011||2011-02-28|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease|A Randomised, Double-blind, Parallel-group, Placebo Controlled Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease|Completed||Phase 2|78|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 23:20:54.052502|2018-05-31 23:20:54.052502
NCT01203618|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2013-11-01|2010-09-15|2010-09-16|Estimate|||||||2013-11-01|2013-11-04|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas|Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma|Withdrawn||Phase 2|0|Actual|Morphotek||||Trial terminated due to focus of primary therapeutic areas.|f||||t||||||||||2018-05-31 23:20:54.249623|2018-05-31 23:20:54.249623
NCT01203605|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-09-04|2010-09-15|2010-09-16|Estimate|||||||2012-09-04|2012-09-05|Estimate|April 2011||2011-04-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|EuSOS||European Surgical Outcomes Study|European Surgical Outcomes Study: A Multi-centre, International Seven Day Evaluation of Patient Care and Clinical Outcomes for Patients Undergoing Non-cardiac Surgery|Completed|||46985|Actual|Queen Mary University of London|||1||f||||f||||||||||2018-05-31 23:20:54.350322|2018-05-31 23:20:54.350322
NCT01203592|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-12-31|2010-09-15|2010-09-16|Estimate|||||||2015-12-31|2016-01-01|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes|Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes|Completed||Phase 1|21|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 23:20:54.436361|2018-05-31 23:20:54.436361
NCT01203579|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-06-20|2010-09-15|2010-09-16|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Chest Computed Tomography (CT) Screening Study With Antibody Testing|Different Strategies Using Autoantibodies and/or CT in the Detection of Lung Cancer|Withdrawn|||0|Actual|Mayo Clinic||||Due to lack of funding|f||||f||||||||||2018-05-31 23:20:54.495234|2018-05-31 23:20:54.495234
NCT01203566|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2011-07-19|2010-09-15|2010-09-16|Estimate|||||||2011-07-19|2011-07-21|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||A Randomised Controlled Trial on LESS Versus Conventional Laparoscopic Appendicectomy.|A Double-blinded Randomised Controlled Trial of Laparoendoscopic Single-site Access (LESS) Versus Conventional Three-port Appendicectomy.|Completed||Phase 3|200|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:20:54.542405|2018-05-31 23:20:54.542405
NCT01203553|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-04-10|2010-09-14|2010-09-16|Estimate|||||||2017-04-10|2017-04-11|Actual|January 2011||2011-01-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|ProphMesh||Prophylactic Mesh Implantation for the Prevention of Incisional Hernia|Mesh Implantation for Prophylaxis of Incisional Hernia|Completed|||150|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 23:20:54.605729|2018-05-31 23:20:54.605729
NCT01203540|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-01-27|2010-09-15|2010-09-16|Estimate|||||||2012-01-27|2012-01-31|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|||||Interventional|||Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients|Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients|Completed||Phase 4|21|Anticipated|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 23:20:54.662091|2018-05-31 23:20:54.662091
NCT01203527|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-10-08|2010-09-15|2010-09-16|Estimate|||||||2013-10-08|2013-10-09|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||A Study of the Pharmacology of Tamiflu in Pregnancy|A Study of the Pharmacology of Oseltamivir (Tamiflu-Roche) in Pregnancy|Completed|||63|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||4||f||||f||||||Samples With DNA|"~     Blood and urine~   "|||2018-05-31 23:20:55.798581|2018-05-31 23:20:55.798581
NCT01203514|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-09-22|2010-09-15|2010-09-16|Estimate|||||||2017-09-22|2017-09-26|Actual|August 1997||1997-08-31|September 2017|2017-09-30|August 2000|Actual|2000-08-31|August 1998|Actual|1998-08-31||Interventional|EPO||The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants|The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Preterm Infants 401-1250 Grams: Two Multi-Center, Randomized, Double-Masked, Placebo Controlled Studies|Completed||Phase 2/Phase 3|318|Actual|NICHD Neonatal Research Network||4|||f||||t||||||||||2018-05-31 23:20:55.952914|2018-05-31 23:20:55.952914
NCT01203501|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-09-22|2010-09-15|2010-09-16|Estimate|||||||2017-09-22|2017-09-26|Actual|July 1996||1996-07-31|September 2017|2017-09-30|June 2000|Actual|2000-06-30|June 1998|Actual|1998-06-30||Observational|MgSO4||In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants|In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants|Completed|||1339|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-05-31 23:20:56.145336|2018-05-31 23:20:56.145336
NCT01203488|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-09-22|2010-09-15|2010-09-16|Estimate|||||||2017-09-22|2017-09-26|Actual|January 1996||1996-01-31|September 2017|2017-09-30|July 1999|Actual|1999-07-31|July 1997|Actual|1997-07-31||Interventional|Vitamin A||Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants|Randomized Trial of Vitamin A Supplementation for Extremely-Low-Birth-Weight|Completed||Phase 1/Phase 2|807|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 23:20:56.346498|2018-05-31 23:20:56.346498
NCT01203475|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-06-03|2010-09-15|2010-09-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|August 1994||1994-08-31|June 2015|2015-06-30|August 1995|Actual|1995-08-31|August 1995|Actual|1995-08-31||Observational|Growth||Growth Observational Study|Growth Observational Study|Completed|||1660|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-05-31 23:20:56.456799|2018-05-31 23:20:56.456799
NCT01203462|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-02-08|2010-09-15|2010-09-16|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PRIDE||The PRIDE Study Probiotics on Regulation and Improving Digestive hEalth|A Probiotic Double-blind Randomized Placebo Crossover Trial of Colonic Transit Time in Adult Females, The PRIDE Study The Study to Determine the Effects of Probiotics on Regulation and Improving Digestive hEalth|Completed||Phase 3|68|Actual|Georgetown University||2|||f||||t||||||||||2018-05-31 23:20:56.647975|2018-05-31 23:20:56.647975
NCT01203449|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-06-03|2010-09-15|2010-09-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 1994||1994-06-30|June 2015|2015-06-30|March 1996|Actual|1996-03-31|March 1996|Actual|1996-03-31||Observational|Ballard||Development of Standards for the New Ballard Maturation Score|Development of Standards for the New Ballard Maturation Score|Completed|||1090|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-05-31 23:20:56.820213|2018-05-31 23:20:56.820213
NCT01203436|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-06-03|2010-09-15|2010-09-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|February 1994||1994-02-28|June 2015|2015-06-30|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|STOP-ROP||Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity|Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity|Completed||Phase 2/Phase 3|649|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 23:20:56.974263|2018-05-31 23:20:56.974263
NCT01203423|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-06-03|2010-09-15|2010-09-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|October 1993||1993-10-31|June 2015|2015-06-30|December 1994|Actual|1994-12-31|December 1994|Actual|1994-12-31||Observational|PPHN||Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study|Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study|Completed|||385|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-05-31 23:20:57.201183|2018-05-31 23:20:57.201183
NCT01203410|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2016-09-20|2010-09-15|2010-09-16|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 1991||1991-11-30|September 2016|2016-09-30|November 1992|Actual|1992-11-30|November 1992|Actual|1992-11-30||Observational|||Prediction of Jaundice in Term Infants|BilirubinProduction in Healthy Term Infants as Measured by Carbon Monoxide in Breath|Completed|||535|Actual|NICHD Neonatal Research Network|||1||f||||f||||||||||2018-05-31 23:20:57.483512|2018-05-31 23:20:57.483512
NCT01203397|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-03-01|2010-09-15|2010-09-16|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2014||2014-09-30|March 2013|2013-03-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate In The Superficial Varicose Veins Treatment|PHASE III OF SAFETY AND EFFICACY STUDY OF TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G IN THE SUPERFICIAL VARICOSE VEINS TREATMENT|Suspended||Phase 3|70|Anticipated|EMS||2||Study suspended by decision strategically.|f||||t||||||||||2018-05-31 23:20:58.354965|2018-05-31 23:20:58.354965
NCT01203384|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-02-09|2010-09-15|2010-09-16|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|CT02||Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects|Completed||Phase 1|48|Actual|CERESPIR||4|||f||||t||||||||||2018-05-31 23:20:58.42613|2018-05-31 23:20:58.42613
NCT01203371|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-15|2010-09-15|2010-09-16|Estimate|||||||2010-09-15|2010-09-16|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|January 2012|Anticipated|2012-01-31|September 2011|Anticipated|2011-09-30||Interventional|||Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS|PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF NAFTOPIDIL AND TAMSULOSIN TO TREATMENT THE SYMPTOMS OF LOWER URINARY TRACT IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA|Unknown status|Not yet recruiting|Phase 3|250|Anticipated|Apsen Farmaceutica S.A.||2|||f||||t||||||||||2018-05-31 23:20:58.490151|2018-05-31 23:20:58.490151
NCT01203358|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-06-03|2010-09-15|2010-09-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 1991||1991-01-31|June 2015|2015-06-30|January 1992|Actual|1992-01-31|January 1992|Actual|1992-01-31||Interventional|Surfactant 1||Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome|Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome|Completed||Phase 2/Phase 3|617|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 23:20:58.574049|2018-05-31 23:20:58.574049
NCT01203345|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-06-03|2010-09-15|2010-09-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 1988||1988-01-31|September 2010|2010-09-30|March 1991|Actual|1991-03-31|March 1991|Actual|1991-03-31||Interventional|IVIG||Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection|Randomized Clinical Trial of Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection in Very-Low-Birth-Weight Infants|Completed||Phase 2/Phase 3|2416|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 23:20:58.702824|2018-05-31 23:20:58.702824
NCT01203332|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2017-02-27|2010-09-15|2010-09-16|Estimate|||||||2017-02-27|2017-02-28|Actual|July 2010||2010-07-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults|Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults|Completed|||1917|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-05-31 23:20:58.981928|2018-05-31 23:20:58.981928
NCT01203319|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|2012-03-29||2012-04-21|2010-09-15|2010-09-16|Estimate|2012-03-29|2012-04-23|Estimate||||2012-04-21|2012-04-27|Estimate|November 2006||2006-11-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines|The Immunogenicity and Safety of 60mcg and 30mcg Recombinant Hepatitis B Vaccines in People Aged 16 and Older Who Failed to Respond to Routine Administration of 10mcg Recombinant Hepatitis B Vaccines|Completed||Phase 2/Phase 3|1091|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 23:20:59.150208|2018-05-31 23:20:59.150208
NCT01203306|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-15|2010-09-15|2010-09-16|Estimate|||||||2010-09-15|2010-09-16|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|May 2009|Anticipated|2009-05-31||Interventional|XELBEVOCT||Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors|Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors|Unknown status|Recruiting|Phase 2|42|Anticipated|University of Turin, Italy||1|||f||||t||||||||||2018-05-31 23:20:59.609109|2018-05-31 23:20:59.609109
NCT01203293|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2014-08-26|2010-09-15|2010-09-16|Estimate|||||||2014-08-26|2014-08-28|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector|CBT for Latinos With Generalized Anxiety Disorder in the General Medical Sector|Completed||Phase 1|90|Actual|University of Puerto Rico||2|||f||||f||||||||||2018-05-31 23:20:59.863706|2018-05-31 23:20:59.863706
NCT01203254|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-04-17|2010-09-15|2010-09-16|Estimate|||||||2013-04-17|2013-04-18|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|COBAM||Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease|Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease|Terminated||Phase 4|34|Actual|Klinikum der Universitaet Muenchen, Grosshadern||2||insufficient enrollment|f||||f||||||||||2018-05-31 23:21:00.364783|2018-05-31 23:21:00.364783
NCT01203241|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-12-11|2010-09-15|2010-09-16|Estimate|||||||2013-12-11|2013-12-12|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Benefit of Left Atrial Roof Ablation in Paroxysmal Atrial Fibrillation||Completed||Phase 3|120|Actual|Hospital Clinic of Barcelona||2|||f||||||||||||||2018-05-31 23:21:00.492127|2018-05-31 23:21:00.492127
NCT01203228|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-04-02|2010-09-15|2010-09-16|Estimate|||||||2015-04-02|2015-04-03|Estimate|May 2004||2004-05-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|RICMAC||Dose-reduced Versus Standard Conditioning in MDS/sAML|Dose-reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study (RICMAC)|Terminated||Phase 3|129|Actual|European Group for Blood and Marrow Transplantation||2|||f||||t||||||||||2018-05-31 23:21:00.573211|2018-05-31 23:21:00.573211
NCT01203215|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-11-04|2010-09-14|2010-09-16|Estimate|||||||2011-11-04|2011-11-07|Estimate|June 2002||2002-06-30|September 2010|2010-09-30|December 2005|Actual|2005-12-31|June 2005|Actual|2005-06-30||Interventional|WWP||Examining Two Print-based Exercise Interventions for Women|Evaluating Self-Help Programs for Exercise Adoption and Maintenance in Women|Completed||Phase 2|280|Actual|Temple University||3|||f||||f||||||||||2018-05-31 23:21:00.721148|2018-05-31 23:21:00.721148
NCT01203202|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-10-01|2010-09-14|2010-09-16|Estimate|||||||2012-10-01|2012-10-03|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation|A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped Clinical Study to Evaluate the Tolerability and to Determine the Adequate Dosage of PED-1 and PED-2 in Male Patients With Premature Ejaculation|Completed||Phase 2|104|Actual|Symyoo||3|||f||||f||||||||||2018-05-31 23:21:00.78625|2018-05-31 23:21:00.78625
NCT01203189|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2016-03-16||2017-10-03|2010-09-14|2010-09-16|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|September 2010||2010-09-30|October 2017|2017-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Subjects in the S group were able to cross over into the F group if the TDSS score does not improve by 60% at the end of the 4 week treatment period. These cross over subjects remained in the study for an additional 4 weeks to apply ketoconazole foam 2%. The 4 subject in the cross over group were originally in the shampoo group.|Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo|Seborrheic Dermatitis of the Scalp in Populations Practicing Less Frequent Hair Washing: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo|Completed||N/A|23|Actual|St. Louis University|"Small Sample Size.~Unable to control for wash frequency between the two groups, i.e. shampoo group vs foam group.~Study group was comprised of patients with moderate seborrheic dermatitis, results may vary in mild or severe cases."|3|||f||||t||||||||No||2018-05-31 23:21:00.877012|2018-05-31 23:21:00.877012
NCT01203176|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2013-12-02|2010-09-15|2010-09-16|Estimate|||||||2013-12-02|2013-12-03|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Incidence of Malignant and Premalignant Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women|Incidence of Malignant and Pre-malignant Findings in Endometrial Polyp in Asymptomatic and Symptomatic Postmenopausal Women|Unknown status|Recruiting|N/A|1400|Anticipated|Carmel Medical Center||2|||f||||f||||||||||2018-05-31 23:21:01.221159|2018-05-31 23:21:01.221159
NCT01203163|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2012-05-07|2010-09-15|2010-09-16|Estimate|||||||2012-05-07|2012-05-09|Estimate||||May 2012|2012-05-31||||||||Observational|CALIPSO||Case Analysis on Real Life Incidence of Photodynamic Therapy (PDT) Safety Outcomes|Case Analysis on Real Life Incidence of PDT Safety Outcomes: Multicentre, Observational Post-marketing Safety Surveillance Registry of Patients Exposed to Photodynamic Therapy With Porfimer Sodium: The CALIPSO Registry|Withdrawn|||0|Actual|Pinnacle Biologics Inc.|||1|Sponsor cancelled the study|f||||f||||||||||2018-05-31 23:21:01.301326|2018-05-31 23:21:01.301326
NCT01203150|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-03-23|2010-09-15|2010-09-16|Estimate|||||||2015-03-23|2015-03-24|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Exercise in People With Paraplegia|Exercise Treatment of Obesity-Related Secondary Conditions in Adults With Paraplegia|Completed||N/A|32|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 23:21:01.358214|2018-05-31 23:21:01.358214
NCT01203137|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-12-11|2010-09-14|2010-09-16|Estimate|||||||2012-12-11|2012-12-13|Estimate|January 2009||2009-01-31|December 2012|2012-12-31||||February 2011|Actual|2011-02-28||Observational|||Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation||Completed|||60|Anticipated|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 23:21:01.441259|2018-05-31 23:21:01.441259
NCT01203124|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2015-08-13|2010-09-15|2010-09-16|Estimate|||||||2015-08-13|2015-08-14|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|||A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers|A Single-blind, Randomized, Placebo Controlled, Parallel-group, Adaptive-design Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 Administered Intranasally for up to 7 Days, on the Biomarker|Completed||Phase 1|55|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 23:21:01.606936|2018-05-31 23:21:01.606936
NCT01203111|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-08-29|2010-09-14|2010-09-16|Estimate|||||||2012-08-29|2012-08-30|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CHANGING||Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs|Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs|Completed||Phase 4|207|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:21:01.726413|2018-05-31 23:21:01.726413
NCT01203098|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2015-01-15||2015-02-06|2010-09-14|2010-09-16|Estimate|2015-02-06|2015-02-09|Estimate||||2015-02-06|2015-02-09|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional||Number of baseline participants reflects the efficacy analysis population|A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty|A Phase 2b, Randomized, Multi-Dose Efficacy,Safety Study of the Oral Factor Xa Inhibitor DU-176b Versus Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-2)|Completed||Phase 2|264|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-05-31 23:21:01.889397|2018-05-31 23:21:01.889397
NCT01203085|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-09-12|2010-09-15|2010-09-16|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2010|Actual|2010-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|INC-6603||Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT|Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth|Recruiting|||500|Anticipated|University of Iowa|||1||f||||f||||||||||2018-05-31 23:21:02.465691|2018-05-31 23:21:02.465691
NCT01203072|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2015-01-15||2015-01-15|2010-09-14|2010-09-16|Estimate|2015-01-15|2015-01-26|Estimate||||2015-01-15|2015-01-26|Estimate|July 2006||2006-07-31|January 2015|2015-01-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty|A Phase 2b, Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Dose-finding Study of the Oral Factor Xa Inhibitor DU-176b Compared With Placebo for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS J-1)|Completed||Phase 2|523|Actual|Daiichi Sankyo, Inc.||5|||f||||t||||||||||2018-05-31 23:21:02.704905|2018-05-31 23:21:02.704905
NCT01203046|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2012-02-10||2012-08-08|2010-09-14|2010-09-16|Estimate|2012-06-21|2012-07-26|Estimate||||2012-08-08|2012-08-10|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days|SP1 - Early Short-term Antibiotic Therapy in Penetrating Abdominal Trauma, 3 vs 7 Days|Completed||Phase 2/Phase 3|56|Actual|Pinango, Silvia M. L., M.D.|Presented limitations because patients with penetrating abdominal trauma usually had associated bone fractures or haemodynamic instability.Identifying other predisposing factors is not reached since the sample size was restricted to only two groups.|2|||f||||f||||||||||2018-05-31 23:21:03.763703|2018-05-31 23:21:03.763703
NCT01203033|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-02-06|2010-09-15|2010-09-16|Estimate|||||||2017-02-06|2017-02-07|Estimate|September 2010||2010-09-30|February 2017|2017-02-28|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)|Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From Acute Myeloid Leukemia (AML) Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)|Completed|||68|Actual|West Virginia University|||1||f||||t||||||Samples Without DNA|"~     whole blood~   "|No||2018-05-31 23:21:04.025993|2018-05-31 23:21:04.025993
NCT01203020|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2018-05-25|2010-09-14|2010-09-16|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2010||2010-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation|Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study|Recruiting||Phase 2|32|Anticipated|West Virginia University||1|||f||||t||||||||||2018-05-31 23:21:04.09712|2018-05-31 23:21:04.09712
NCT01203007|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-16|2010-09-15|2010-09-16|Estimate|||||||2010-09-16|2010-09-17|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|DIIGA||Diet Intervention in Food Sensitive Patients With IgA Nephropathy|A Pilot Study of 6 Months Diet Intervention in Food Sensitive Patients With IgA Nephropathy|Unknown status|Not yet recruiting|N/A|40|Anticipated|Uppsala University Hospital||2|||f||||f||||||||||2018-05-31 23:21:04.18948|2018-05-31 23:21:04.18948
NCT01202994|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2017-05-01||2018-01-11|2010-09-14|2010-09-16|Estimate|2017-12-12|2018-01-11|Actual||||2018-01-11|2018-02-07|Actual|May 2011||2011-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2016|Actual|2016-05-31||Interventional|||Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET|Practice Effects and Amyloid Imaging Using 18F-PIB (18F-39-F-6-OH-BTA1) Known as [18FGE067]) or Flutemetamol PET and FDG-PET|Active, not recruiting||Phase 2|27|Actual|University of Utah||1|||f||||t||||||||No||2018-05-31 23:21:04.294863|2018-05-31 23:21:04.294863
NCT01202981|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2014-12-09|2010-09-14|2010-09-16|Estimate|||||||2014-12-09|2014-12-11|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||Impact of Glistenings in AcrySof Intraocular Lenses on Visual Quality|Impact of IOL Glistenings on Visual Quality and Function in Patients Implanted With a Single-Piece AcrySof IOL That Exhibits Glistening Formation|Completed|||200|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 23:21:04.472231|2018-05-31 23:21:04.472231
NCT01202968|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-12-22|2010-09-15|2010-09-16|Estimate|||||||2013-12-22|2013-12-24|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Effect of Pre-emptive Transcutaneous Neuro-muscular Electrical Stimulation for Dysphagia in Long Term Intubated Patients|Effect of Pre-emptive Transcutaneous Neuro-muscular Electrical Stimulation for Dysphagia in Long Term Intubated Patients|Withdrawn||N/A|0|Actual|Ulsan University Hospital|||||f||||t||||||||||2018-05-31 23:21:04.599307|2018-05-31 23:21:04.599307
NCT01202955|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2010-10-06||2011-05-04|2010-09-15|2010-09-16|Estimate|2011-03-24|2011-04-22|Estimate||||2011-05-04|2011-05-06|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Pilot Study of Tolcapone in Smokers|Pilot Study of Tolcapone Effects on Abstinence-Induced Cognitive Symptoms in Smokers|Completed||Phase 2|19|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:21:04.667616|2018-05-31 23:21:04.667616
NCT01202942|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-12-17|2010-09-15|2010-09-16|Estimate|||||||2013-12-17|2013-12-19|Estimate|July 2007||2007-07-31|November 2012|2012-11-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Use and Harm Exposure in New Low Nicotine Cigarettes|Smoking Topography and Harm Exposure in a New Potentially Reduced Exposure Product|Completed||N/A|246|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:21:04.904592|2018-05-31 23:21:04.904592
NCT01202929|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-04-06|2010-09-14|2010-09-16|Estimate|||||||2017-04-06|2017-04-10|Actual|February 2010||2010-02-28|April 2017|2017-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Correlation of High Resolution Esophageal Manometry With Symptoms|Correlation of High Resolution Esophageal Manometry With Symptoms|Withdrawn|||0|Actual|University of Louisville|||3|Principal investigator has left the Institution|f||||f||||||||||2018-05-31 23:21:04.955267|2018-05-31 23:21:04.955267
NCT01202916|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2018-02-06|2010-09-15|2010-09-16|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2009||2009-09-30|February 2018|2018-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Quality of Life Among Children With Congenital Heart Disease|Quality of Life Among Children With Congenital Heart Disease|Completed|||316|Actual|University Hospital, Montpellier|||2||f||||t||||||||||2018-05-31 23:21:05.022383|2018-05-31 23:21:05.022383
NCT01202123|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2014-02-20|2010-09-14|2010-09-15|Estimate|||||||2014-02-20|2014-02-21|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Observational|||Post Marketing Surveillance of MENOPUR|Post Marketing Surveillance of MENOPUR|Completed|||2501|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:21:24.778098|2018-05-31 23:21:24.778098
NCT01202903|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2014-10-24||2015-03-16|2010-09-14|2010-09-16|Estimate|2015-03-16|2015-03-23|Estimate||||2015-03-16|2015-03-23|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||The Safety Set consisted of all patients who received at least one dose of study medication whether or not being randomized. Patients were analyzed according to the treatment they actually received. If patients switched between placebo and omalizumab during the study, they were analyzed according to omalizumab.|Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy|A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of Xolair® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy|Completed||Phase 3|616|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:21:05.099399|2018-05-31 23:21:05.099399
NCT01202890|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2014-01-07|2010-09-15|2010-09-16|Estimate|||||||2014-01-07|2014-01-08|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer|Phase IB Study of Lenalidomide (Revlimid®) With Liposomal Doxorubicin (Doxil®) and Bevacizumab (Avastin®) for Patients With Platinum Resistant Ovarian Cancer.|Terminated||Phase 1|1|Actual|New Mexico Cancer Care Alliance||1||Terminated due to inadequate rate of accrual.|f||||f||||||||||2018-05-31 23:21:05.604081|2018-05-31 23:21:05.604081
NCT01202877|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2016-09-16||2016-09-16|2010-09-15|2010-09-16|Estimate|2016-09-16|2016-11-07|Estimate||||2016-09-16|2016-11-07|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||PKC412 and 5-Azacytidine|A Combination of PKC412 and 5-Azacytidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS)|Completed||Phase 1/Phase 2|54|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:21:05.740664|2018-05-31 23:21:05.740664
NCT01202864|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-08-31|2010-09-14|2010-09-16|Estimate|||||||2017-08-31|2017-09-01|Actual|August 1, 2010|Actual|2010-08-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|July 31, 2017|Actual|2017-07-31||Observational|ERICH||Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)|Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)|Completed|||6000|Actual|University of Cincinnati|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 23:21:06.183108|2018-05-31 23:21:06.183108
NCT01202851|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2018-05-04|2010-09-15|2010-09-16|Estimate|||||||2018-05-04|2018-05-10|Estimate|February 10, 2011|Actual|2011-02-10|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Relaxation for Women With Breast Cancer Undergoing Radiotherapy|Biobehavioral Effects of Relaxation for Women With Breast Cancer Undergoing Radiotherapy|Active, not recruiting||Phase 3|681|Actual|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 23:21:06.275928|2018-05-31 23:21:06.275928
NCT01202838|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-09-14|2010-09-14|2010-09-16|Estimate|||||||2010-09-14|2010-09-16|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Bioactive Glass Composite Implants in Cranial Bone Reconstruction|Bioactive Glass Composite Implants in Cranial Bone Reconstruction|Unknown status|Recruiting||10|Anticipated|Turku University Hospital|||1||f||||f||||||||||2018-05-31 23:21:06.351388|2018-05-31 23:21:06.351388
NCT01202825|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-03-01|2010-09-14|2010-09-16|Estimate|||||||2013-03-01|2013-03-04|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients|Phase I, First-in-human Trial in Healthy Volunteers to Examine Increasing Single and Repeated Oral Doses of TMC647055, Followed by a Repeated-dose Part in Chronic HCV-genotype 1 Infected Patients to Examine TMC647055 Given Alone or in Combination With TMC435|Completed||Phase 1|72|Actual|Tibotec Pharmaceuticals, Ireland||10|||f||||f||||||||||2018-05-31 23:21:06.420519|2018-05-31 23:21:06.420519
NCT01202812|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2010-10-22|2010-09-15|2010-09-16|Estimate|||||||2010-10-22|2010-10-25|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)|Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)|Unknown status|Not yet recruiting|Phase 2|48|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 23:21:06.512537|2018-05-31 23:21:06.512537
NCT01202799|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2014-09-22|2010-09-14|2010-09-16|Estimate|||||||2014-09-22|2014-09-23|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel|A Phase 1, Randomized, Single Center, Open-Label, Multiple-Dose, Three-Way Crossover Study to Evaluate the Pharmacokinetics, Bioavailability and Safety of PENNSAID Gel in Comparison With Sandoz 75 mg Diclofenac Sodium Delayed Release Tablet and PENNSAID (Diclofenac Sodium Topical Solution) in Healthy Volunteers|Completed||Phase 1|30|Actual|Mallinckrodt||3|||f||||f||||||||||2018-05-31 23:21:06.601553|2018-05-31 23:21:06.601553
NCT01202786|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-08-14|2010-09-14|2010-09-16|Estimate|||||||2012-08-14|2012-08-15|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Observational|||Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)|An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel|Completed|||60|Actual|Teva Pharmaceutical Industries|||2||f||||f||||||Samples Without DNA|"~     Formalin Fixed Paraffin Embedded tumor tissue~   "|||2018-05-31 23:21:06.660296|2018-05-31 23:21:06.660296
NCT01202773|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2018-03-24|2014-04-14|2018-05-11|2010-09-14|2010-09-16|Estimate|2018-05-11|2018-05-14|Actual|2014-04-14|2014-05-07|Estimate|2018-05-11|2018-05-14|Actual|January 2011||2011-01-31|May 2018|2018-05-31|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|FLEX V|All randomized participants, including participants who did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol.|A Study in Participants With Rheumatoid Arthritis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to One or More TNF-α Inhibitors (FLEX V)|Terminated||Phase 3|456|Actual|Eli Lilly and Company|This study has been terminated not based on safety concerns, but due to insufficient efficacy. Early termination led to lower than expected enrollment and was responsible for the large number of discontinuation reason as Sponsor Decision.|3||Terminated not based on safety concerns, but due to insufficient efficacy.|f||||t||||||||||2018-05-31 23:21:06.885659|2018-05-31 23:21:06.885659
NCT01202760|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2018-03-24|2013-04-30|2018-03-24|2010-09-14|2010-09-16|Estimate|2018-03-24|2018-04-25|Actual|2013-04-30|2013-05-08|Estimate|2018-03-24|2018-04-25|Actual|January 2011||2011-01-31|March 2018|2018-03-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|FLEX O|All randomized participants, including participants who did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol.|A Rheumatoid Arthritis Study in Participants|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)|Completed||Phase 3|1004|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 23:21:09.403451|2018-05-31 23:21:09.403451
NCT01202747|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2011-09-16||2011-11-01|2010-09-14|2010-09-16|Estimate|2011-11-01|2011-12-06|Estimate||||2011-11-01|2011-12-06|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction|Pilot Study for Evaluation of LipiFlow Screening Methods|Completed||Phase 2/Phase 3|50|Actual|TearScience, Inc.||1|||f||||f||||||||||2018-05-31 23:21:12.680389|2018-05-31 23:21:12.680389
NCT01202734|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2014-05-15|2010-09-14|2010-09-16|Estimate|||||||2014-05-15|2014-05-16|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers|An Open-label, Single-Ascending-Dose Study to Investigate the Pharmacokinetics and Safety of CONCERTA in Healthy Japanese Adult Male Subjects|Completed||Phase 1|10|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 23:21:12.868965|2018-05-31 23:21:12.868965
NCT01202721|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2016-12-09|2010-09-15|2010-09-16|Estimate|||||||2016-12-09|2016-12-12|Estimate|June 2011||2011-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|April 2016|Actual|2016-04-30||Interventional|BAV||Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)|Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)|Completed||Phase 3|85|Actual|Hamilton Health Sciences Corporation||2|||f||||t||||||||||2018-05-31 23:21:12.936561|2018-05-31 23:21:12.936561
NCT01202708|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-07-11|2010-09-14|2010-09-16|Estimate|||||||2017-07-11|2017-07-13|Actual|August 1997||1997-08-31|July 2017|2017-07-31||||April 2002|Actual|2002-04-30||Interventional|||Gambro AK200 ULTRA Hemodiafiltration Study|Safety and Efficacy of Hemodiafiltration With On-Line Preparation of Substitution Fluid Using the Gambro AK 200 ULTRA System|Completed||N/A|14|Actual|Baxter Healthcare Corporation|||||f||||f|f|t|t|||||||2018-05-31 23:21:13.033278|2018-05-31 23:21:13.033278
NCT01202695|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2012-11-20|2010-09-14|2010-09-16|Estimate|||||||2012-11-20|2012-11-22|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)|A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating Pharmacokinetics and Safety of a Human Monoclonal Antibody (AVP-21D9) in Normal Healthy Volunteers|Completed||Phase 1|50|Actual|Emergent BioSolutions||2|||f||||t||||||||||2018-05-31 23:21:13.094218|2018-05-31 23:21:13.094218
NCT01202682|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-01-20|2010-09-15|2010-09-16|Estimate|||||||2011-01-20|2011-01-24|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Heart Rate Changes During Normal Activity, Exercise, and Sleep in Normal Healthy Subjects With and Without Epilepsy|Heart Rate Changes During Normal Activity, Exercise, and Sleep in Normal Healthy Subjects With and Without Epilepsy|Completed|||50|Anticipated|Cyberonics, Inc.|||||f||||f||||||||||2018-05-31 23:21:13.166672|2018-05-31 23:21:13.166672
NCT01202669|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2014-08-06|2010-09-15|2010-09-16|Estimate|||||||2014-08-06|2014-08-07|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|October 2012|Actual|2012-10-31||Observational|||Heart Rate Changes in Subjects With Epilepsy|Heart Rate Changes in Subjects With Epilepsy During an Epilepsy Monitoring Unit Admission|Completed|||98|Actual|Cyberonics, Inc.|||1||f||||f||||||||||2018-05-31 23:21:13.222429|2018-05-31 23:21:13.222429
NCT01202656|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2014-05-18||2014-11-24|2010-09-14|2010-09-16|Estimate|2014-11-24|2014-12-02|Estimate||||2014-11-24|2014-12-02|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)|G-CSF(Granulocyte Colony Stimulating Factor) and Embryo Implantation and Pregnancy Following IVF (in Vitro Fertilization)|Completed||Phase 1/Phase 2|129|Actual|Center for Human Reproduction|The study results are applicable only to women undergoing routine IVF. Most of the women in this trial had normal endometrial thickness at randomization.|2|||f||||t||||||||||2018-05-31 23:21:13.295358|2018-05-31 23:21:13.295358
NCT01202643|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2014-05-18||2014-11-25|2010-09-15|2010-09-16|Estimate|2014-11-25|2014-12-04|Estimate||||2014-11-25|2014-12-04|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||The transfer rate among controls should be < 1%. If the true transfer rate for experimental subjects is 25%, we will need to study 38 experimental subjects and 38 control subjects to be able to reject the null hypothesis that the transfer rates for experimental and control subjects are equal with probability (power) 0.8.|Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF|G-CSF and Endometrial Growth, Embryo Implantation and Pregnancy Following FET or Donor ET|Terminated||Phase 1/Phase 2|12|Actual|Center for Human Reproduction||2||Insufficient recruitment|f||||t||||||||||2018-05-31 23:21:13.66198|2018-05-31 23:21:13.66198
NCT01202630|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2016-01-14|2010-09-14|2010-09-16|Estimate|||||||2016-01-14|2016-01-15|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection|A Triple-blind, Randomized, Placebo-controlled, Multi-center Study on the Effect of BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection|Suspended||Phase 3|140|Anticipated|Bio-K Plus International Inc.||2||The site is unable to recruit patients.|f||||f||||||||||2018-05-31 23:21:14.142744|2018-05-31 23:21:14.142744
NCT01202617|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-10-21|2010-09-14|2010-09-16|Estimate|||||||2011-10-21|2011-10-24|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|SereNIS||Seroquel XR in the Long Term Treatment of Schizophrenia|Seroquel XR in the Long Term Treatment of Schizophrenia Focus on Affective Symptoms|Completed|||1606|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:21:14.267693|2018-05-31 23:21:14.267693
NCT01202604|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-12-19|2010-09-14|2010-09-16|Estimate|||||||2011-12-19|2011-12-20|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||A Study Evaluating the Efficacy of Administered Maintenance Treatments in Bipolar Disorder I and II.|Prospective, Observational Study for the Maintenance Treatment of Patients With Bipolar Disorder I and II in Greece.|Completed|||294|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:21:14.493624|2018-05-31 23:21:14.493624
NCT01202591|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2015-09-07||2016-01-13|2010-09-14|2010-09-16|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|GLOW||Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients|A Randomised Double-blind Phase IIa Study (With Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients With FGFR1 Polysomy or Gene Amplification Who Have Progressed Following Treatment With Prior Endocrine Therapy (Adjuvant or First-line Metastatic) (GLOW)|Completed||Phase 1/Phase 2|127|Actual|AstraZeneca|Enrolment to the Part B was terminated on 27 March 2014. Slow recruitment led to concerns that enrolment would not be completed in a realistic timeframe. This led to a business decision to terminate the enrolment.|3|||f||||f||||||||||2018-05-31 23:21:14.685269|2018-05-31 23:21:14.685269
NCT01202578|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2014-05-07||2014-06-10|2010-09-14|2010-09-16|Estimate|2014-06-10|2014-07-11|Estimate||||2014-06-10|2014-07-11|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|inVENT-OR||Evaluation of the Tympanostomy Tube Delivery System|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media|Completed||Phase 2/Phase 3|53|Actual|Acclarent||1|||f||||f||||||||||2018-05-31 23:21:16.466871|2018-05-31 23:21:16.466871
NCT01202565|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2014-07-15||2014-07-15|2010-09-14|2010-09-16|Estimate|2014-07-15|2014-08-07|Estimate||||2014-07-15|2014-08-07|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational||Full analysis set, which included participants with a signed informed consent and with any available data regarding treatment with adalimumab.|Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice|Effectiveness of Adalimumab (Humira) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice|Completed|||506|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:21:16.644456|2018-05-31 23:21:16.644456
NCT01202552|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2018-04-05|2010-09-15|2010-09-16|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2010||2010-10-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Two-site Intradermal Influenza Vaccination in Elderly|Two-site Intradermal Influenza Vaccination in Elderly|Completed||N/A|180|Actual|Queen Saovabha Memorial Institute||3|||f||||t||||||||||2018-05-31 23:21:17.093371|2018-05-31 23:21:17.093371
NCT01202539|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2010-09-15|2010-09-15|2010-09-16|Estimate|||||||2010-09-15|2010-09-16|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||Real-time Assessment of Frameless Intrafraction Motion|Use of Real-time Infrared Reflective Marker Tracking and Surface Texture Mapping to Assess the Integrity of a Novel Thermoplastic Mask System for Frameless Immobilization|Unknown status|Active, not recruiting||20|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-05-31 23:21:18.198748|2018-05-31 23:21:18.198748
NCT01202526|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2013-10-24|2010-09-15|2010-09-16|Estimate|||||||2013-10-24|2013-10-25|Estimate|September 2010||2010-09-30|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity in Type 2 Diabetes||Completed|||20|Actual|Hvidovre University Hospital|||2||f||||f||||||Samples Without DNA|"~     serum, plasma, urine, muscle, subcutaneous fat, visceral fat~   "|||2018-05-31 23:21:18.248382|2018-05-31 23:21:18.248382
NCT01202513|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-08-02|2010-09-15|2010-09-16|Estimate|||||||2011-08-02|2011-08-03|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Topical Bimatoprost Solution 0.03%in Stable Vitiligo|Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study|Withdrawn||Phase 4|20|Actual|Gian Sagar Medical College and Hospital||1||regulatory reasons|f||||t||||||||||2018-05-31 23:21:18.312281|2018-05-31 23:21:18.312281
NCT01202500|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-15|||2014-06-02|2010-09-15|2010-09-16|Estimate|||||||2014-06-02|2014-06-03|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|September 2016|Anticipated|2016-09-30|July 2010|Actual|2010-07-31||Interventional|TOSCANE||Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis|Multicentre, Randomised Study to Determine the Relative Efficacy of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis|Unknown status|Recruiting|Phase 3|486|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-05-31 23:21:18.381971|2018-05-31 23:21:18.381971
NCT01202487|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-04-09|2010-09-15|2010-09-16|Estimate|||||||2013-04-09|2013-04-10|Estimate|April 2011||2011-04-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|GLUE||Gluing Lacerations Utilizing Epinephrine|Pretreatment of Lacerations With Topical LET (Lidocaine-Epinephrine-Tetracaine) Reduces Pain During Tissue Adhesive Repair in Children: Double-blind, Randomized, Controlled Trial of Efficacy|Completed||Phase 2|222|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||||2018-05-31 23:21:18.452179|2018-05-31 23:21:18.452179
NCT01202474|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-12-17|2010-09-14|2010-09-15|Estimate|||||||2012-12-17|2012-12-18|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Apidra Children & Adolescents Study|A Study of Effectiveness and Safety of Apidra in Combination With Lantus Therapy in Basal-bolus Insulin Regimen in Inadequately Controlled Children and Adolescents With Type 1 Diabetes in the Russian Federation.|Completed||Phase 4|100|Actual|Sanofi||1|||f||||||||||||||2018-05-31 23:21:18.523172|2018-05-31 23:21:18.523172
NCT01202461|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2010-09-14|2010-09-14|2010-09-15|Estimate|||||||2010-09-14|2010-09-15|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME)|Three-year Result of Triple Therapy of Vitrectomy, Intravitreal Triamcinolone and Macular Laser Photocoagulation for Intractable Diabetic Macular Edema|Completed||Phase 1|41|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-05-31 23:21:18.588467|2018-05-31 23:21:18.588467
NCT01202448|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-03-01|2010-09-14|2010-09-15|Estimate|||||||2015-03-01|2015-03-03|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PROCESS||Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma|Prospective Cohort Study With Risk-adapted Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma|Completed||N/A|600|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 23:21:18.646968|2018-05-31 23:21:18.646968
NCT01202110|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2016-03-08||2016-05-12|2010-09-14|2010-09-15|Estimate|2016-05-12|2016-05-13|Estimate||||2016-05-12|2016-05-13|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|EPAT: Phase II||Early Propranolol After Traumatic Brain Injury: Phase II|A Phase II, Dose Escalation, Single Center Study on the Effects of Early Propranolol on Heart Rate, Blood Pressure, and Cerebral Perfusion Pressure in Subjects Who Present With Moderate to Severe Traumatic Brain Injury.|Terminated||Phase 2|10|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 23:21:24.870766|2018-05-31 23:21:24.870766
NCT01202435|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2010-12-06|2010-09-14|2010-09-15|Estimate|||||||2010-12-06|2010-12-07|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule|An Open-Label, Multiple-Dose, Randomized, 2-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 82.5 Mg Pregabalin Controlled Release Formulation Administered Following An Evening Meal Relative To The 25 Mg Of The Immediate Release Formulation Administered Three Times Daily|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:21:18.836|2018-05-31 23:21:18.836
NCT01202422|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2010-12-09|2010-09-14|2010-09-15|Estimate|||||||2010-12-09|2010-12-10|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule|An Open-Label, Multiple-Dose, Randomized, 3-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 165 Mg And 330 Mg Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal And 150 Mg Of The Immediate Release Formulation Administered Twice Daily|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:21:18.919422|2018-05-31 23:21:18.919422
NCT01202409|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2018-03-16|2010-09-14|2010-09-15|Estimate|||||||2018-03-16|2018-03-20|Actual|November 2010|Actual|2010-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater|Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater|Active, not recruiting||Phase 2|27|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 23:21:19.020078|2018-05-31 23:21:19.020078
NCT01202396|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-14|2010-09-14|2010-09-15|Estimate|||||||2010-09-14|2010-09-15|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Observational|||The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis|The Interaction Between the Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis: a Multifactorial Approach|Unknown status|Not yet recruiting||30|Anticipated|Maastricht University Medical Center|||1||f||||||||||Samples With DNA|"~     In the prospective study the following biospecimens will be collected: faeces, serum, plasma,~     leucocytes, urine, intestinal biopsies and mucus~   "|||2018-05-31 23:21:19.110977|2018-05-31 23:21:19.110977
NCT01202383|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2013-06-18|2010-09-14|2010-09-15|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Double-blinded Trial of Household-based Chlorination in India|Household-based Chlorination of Drinking Water to Prevent Diarrhoeal Disease: a Randomized, Placebo-controlled Trial in India Using Sodium Dichloroisocyanurate (NaDCC) Tablets|Completed||Phase 3|2163|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 23:21:19.188696|2018-05-31 23:21:19.188696
NCT01202370|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2013-08-12|2010-09-13|2010-09-15|Estimate|||||||2013-08-12|2013-08-14|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies|A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies|Completed||Phase 1|3|Actual|University of Kentucky||1|||f||||t||||||||||2018-05-31 23:21:19.284408|2018-05-31 23:21:19.284408
NCT01202357|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-13|2010-09-13|2010-09-15|Estimate|||||||2010-09-13|2010-09-15|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Optimal Duration of Early Intervention for Psychosis|Community Case Management for Early Psychosis: is Two Year an Optimal Duration? A Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|160|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:21:19.367475|2018-05-31 23:21:19.367475
NCT01202344|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2018-02-27|2010-09-13|2010-09-15|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2010||2010-09-30|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Interventional|||Computer Prediction of Restenosis Following Peripheral Angioplasty|Computer Prediction of Restenosis Following Peripheral Angioplasty|Suspended||N/A|15|Anticipated|University Health Network, Toronto||2||lack of funding|f||||||||||||||2018-05-31 23:21:19.454865|2018-05-31 23:21:19.454865
NCT01202331|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2017-10-09|2010-09-13|2010-09-15|Estimate|||||||2017-10-09|2017-10-11|Actual|November 2010||2010-11-30|October 2017|2017-10-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|TIRET||Tripartite International Research for the Elimination of Trachoma|Tripartite International Research for the Elimination of Trachoma|Completed||Phase 4|29000|Actual|University of California, San Francisco||6|||f||||t||||||||||2018-05-31 23:21:19.525427|2018-05-31 23:21:19.525427
NCT01202318|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2012-06-13|2010-09-13|2010-09-15|Estimate|||||||2012-06-13|2012-06-15|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|MeDS||Comparative Evaluation of Stroke Triage Algorithms for Emergency Medical Dispatchers|Pilot Prospective Cohort to Determine the Comparative Diagnostic Accuracy of Card 28 to Card 28 and Cincinnati Stroke Scale.|Withdrawn|||0|Actual|University of California, San Francisco||||"The study design was changed to a prospective cohort study due to difficulties in using a~   randomized approach in an emergency setting"|f||||f||||||||||2018-05-31 23:21:19.59855|2018-05-31 23:21:19.59855
NCT01202305|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-06-26|2010-09-13|2010-09-15|Estimate|||||||2015-06-26|2015-06-30|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies|The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies|Unknown status|Recruiting||50|Anticipated|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     Inguinal LN~   "|||2018-05-31 23:21:19.649681|2018-05-31 23:21:19.649681
NCT01202292|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2010-09-30|2010-09-14|2010-09-15|Estimate|||||||2010-09-30|2010-10-01|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|October 2009|Anticipated|2009-10-31||Interventional|IMOAP||Group Motivational Intervention in Overweight/Obese Patients.|Group Motivational Intervention in Overweight/Obese Patients in Primary Prevention of Cardiovascular Disease in the Primary Healthcare Area.|Unknown status|Recruiting|N/A|1200|Anticipated|Jordi Gol i Gurina Foundation||1|||f||||t||||||||||2018-05-31 23:21:19.712765|2018-05-31 23:21:19.712765
NCT01202279|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2011-04-04||2017-07-21|2010-09-13|2010-09-15|Estimate|2012-10-04|2012-11-05|Estimate||||2017-07-21|2017-08-21|Actual|October 2009||2009-10-31|July 2017|2017-07-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|Wait and See||Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Mucinex D for Symptomatic Therapy in Patients With Acute Upper Respiratory Tract Who Seek Treatment|Completed||Phase 4|1179|Actual|Reckitt Benckiser LLC||2|||f||||f||||||||||2018-05-31 23:21:19.796579|2018-05-31 23:21:19.796579
NCT01202266|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-03-09|2010-09-13|2010-09-15|Estimate|||||||2011-03-09|2011-03-11|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Multiple Dose Study Of PF-05161704 In Healthy Volunteers|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Pf-05161704 After Administration Of Multiple Escalating Oral Doses In Healthy Volunteers|Terminated||Phase 1|32|Actual|Pfizer||8||The study was terminated on October 29, 2010 due to gastrointestinal adverse events.|f||||f||||||||||2018-05-31 23:21:20.144933|2018-05-31 23:21:20.144933
NCT01202253|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2012-04-06||2014-03-25|2010-09-13|2010-09-15|Estimate|2012-09-10|2012-10-11|Estimate||||2014-03-25|2014-04-16|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom|A Study To Describe The Early Clinical Experience With Anidulafungin In Patients With Liver Disease At King's College Hospital NHS Trust, London|Completed|||50|Actual|Pfizer|Protocol-specified endpoint, percentage of participants with presumed eradication of infecting species, was not presented as a separate outcome measure because the ‘presumed eradication’ was considered same as favorable clinical response.||1||f||||f||||||||||2018-05-31 23:21:20.304126|2018-05-31 23:21:20.304126
NCT01202240|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-02-15|2010-09-13|2010-09-15|Estimate|||||||2011-02-15|2011-02-17|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers|A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:21:21.181356|2018-05-31 23:21:21.181356
NCT01202227|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2013-01-10||2013-04-05|2010-09-13|2010-09-15|Estimate|2013-04-05|2013-05-17|Estimate||||2013-04-05|2013-05-17|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain|An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)|Completed||Phase 3|104|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:21:21.302306|2018-05-31 23:21:21.302306
NCT01202214|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-01-28|2010-09-13|2010-09-15|Estimate|||||||2011-01-28|2011-01-31|Estimate|September 2010||2010-09-30|January 2011|2011-01-31||||||||Interventional|||Repeat Dose Safety Study for Compound to Treat Asthma|A Randomized, Single-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK1440115 After a Single Dose and 7 Days of Repeat Dosing in Healthy Volunteers|Completed||Phase 1|||Accenture||2|||f||||t||||||||||2018-05-31 23:21:22.07408|2018-05-31 23:21:22.07408
NCT01202201|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2017-06-06|2010-09-14|2010-09-15|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2010||2010-09-30|June 2017|2017-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in Japan|A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in Children <6 Years of Age in Japan|Completed|||13767|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 23:21:22.191201|2018-05-31 23:21:22.191201
NCT01202188|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2013-02-07||2013-08-26|2010-09-13|2010-09-15|Estimate|2013-03-19|2013-05-03|Estimate||||2013-08-26|2013-09-09|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|SHINE|Baseline measures are based on the Safety Set that includes all participants who received study drug.|A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled (Open Label) Study to Assess the Efficacy, Safety and Tolerability of QVA149 (110/50 μg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|2144|Actual|Novartis||5|||f||||||||||||||2018-05-31 23:21:22.349872|2018-05-31 23:21:22.349872
NCT01202175|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2014-05-24|2010-09-14|2010-09-15|Estimate|||||||2014-05-24|2014-05-28|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension|Effects of the Novel Beta-adrenergic Antagonist Nebivolol (Bystolic) on Prehypertensive Subjects at Genetic Risk of Hypertension: Implications for Inflammation, Endothelial Dysfunction, and Oxidative Stress.|Completed||Phase 4|50|Actual|University of California, San Diego||2|||f||||||||||||||2018-05-31 23:21:24.064464|2018-05-31 23:21:24.064464
NCT01202162|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2013-04-08||2013-10-29|2010-09-14|2010-09-15|Estimate|2013-06-19|2013-07-25|Estimate||||2013-10-29|2013-11-25|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Comparison of Desflurane vs. Sevoflurane and the Time to Awakening and the Incidence and Severity of Cough|A Comparison of Desflurane vs. Sevoflurane on Time to Awakening and the Incidence and Severity of Cough After Ambulatory Surgery Using Laryngeal Mask Airway|Completed||N/A|85|Actual|Northwestern University|Our study is only valid if interpreted within the context of its limitations. We have only evaluated female subjects undergoing ambulatory hysteroscopic surgery which limits the generalizability of our results.|2|||f||||f||||||||||2018-05-31 23:21:24.163165|2018-05-31 23:21:24.163165
NCT01202149|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-04-14|2010-09-14|2010-09-15|Estimate|||||||2011-04-14|2011-04-15|Estimate|March 2010||2010-03-31|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis|Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis|Completed||Phase 4|30|Anticipated|Frankel, Amylynne, M.D.||2|||f||||t||||||||||2018-05-31 23:21:24.621624|2018-05-31 23:21:24.621624
NCT01202136|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-05-22|2010-09-14|2010-09-15|Estimate|||||||2018-05-22|2018-05-24|Actual|October 2012||2012-10-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|January 2018|Actual|2018-01-31||Observational|PCyst||The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study|The Clinical,Radiologic, Pathologic and Molecular Marker Characteristics of Premalignant and Malignant Pancreatic Cysts Study|Active, not recruiting|||450|Anticipated|Johns Hopkins University|||1||f||||f||||||Samples With DNA|"~     Blood, pancreatic cyst fluid~   "|||2018-05-31 23:21:24.696771|2018-05-31 23:21:24.696771
NCT01202097|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-05-04|2010-09-14|2010-09-15|Estimate|||||||2012-05-04|2012-05-08|Estimate|August 2011||2011-08-31|September 2010|2010-09-30|May 2012|Actual|2012-05-31|||||Interventional|CAINAS SF||A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients With Asthma|A PHASE III, RANDOMIZED, OPEN-LABEL, NON-INFERIORITY COMPARATIVE STUDY BETWEEN SERETIDE® 50/250 µG AND SALMETEROL/FLUTICASONE SINGLE INHALATION CAPSULE 50/250 µG EUROFARMA IN PATIENTS WITH ASTHMA|Completed||Phase 3|334|Anticipated|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-05-31 23:21:25.018645|2018-05-31 23:21:25.018645
NCT01202084|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2015-06-17|2010-09-14|2010-09-15|Estimate|||||||2015-06-17|2015-06-18|Estimate|January 2012||2012-01-31|May 2012|2012-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients|A Phase III, Randomized, Open-label, Non-inferiority Study Comparative of Formoterol/Fluticasone Eurofarma 12/250 µg, Foraseq® 12/400 µg and Fluticasone 500 µg in Asthma Patients|Completed||Phase 3|222|Actual|Eurofarma Laboratorios S.A.||3|||f||||t||||||||||2018-05-31 23:21:25.08975|2018-05-31 23:21:25.08975
NCT01202071|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|2012-10-26||2012-11-27|2010-09-14|2010-09-15|Estimate|2012-10-26|2012-11-27|Estimate||||2012-11-27|2012-11-30|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)|A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers|Completed||Phase 2|24|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 23:21:25.166997|2018-05-31 23:21:25.166997
NCT01202058|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-10-24|2010-09-14|2010-09-15|Estimate|||||||2012-10-24|2012-10-25|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Interventional|NEVO II||An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)|An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent.|Terminated||Phase 3|156|Actual|Cordis Corporation||2||"The NEVO™ stent will not be commercialized. Cordis decided to close the study after 1 years.~   This decision took the absence of safety signals into account."|f||||f||||||||||2018-05-31 23:21:25.416415|2018-05-31 23:21:25.416415
NCT01202045|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2013-07-03|2010-09-14|2010-09-15|Estimate|||||||2013-07-03|2013-07-08|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|October 2011|Anticipated|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients|Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients With Indirect Signs of Pulmonary Arterial Hypertension|Withdrawn|||0|Actual|Université de Sherbrooke|||1||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 23:21:25.4887|2018-05-31 23:21:25.4887
NCT01202032|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2016-05-17|2010-09-14|2010-09-15|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|PARASOL||Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors|Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors|Completed||Phase 1|36|Anticipated|Centre Leon Berard|||||f||||t||||||||||2018-05-31 23:21:25.628877|2018-05-31 23:21:25.628877
NCT01202019|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2014-07-21|2010-09-14|2010-09-15|Estimate|||||||2014-07-21|2014-07-22|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Exercise in People With Tetraplegia|Effects of Exercise on Post-Prandial Lipemia and Fat Oxidation After Tetraplegia|Completed||N/A|18|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 23:21:25.922471|2018-05-31 23:21:25.922471
NCT01202006|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2015-07-07|2010-09-14|2010-09-15|Estimate|||||||2015-07-07|2015-07-08|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|STRETCH||Strategy to Recognize and Initiate Treatment of Chronic Heart Failure|A Combined Diagnostic-therapeutic Strategy to Optimize Management of Patients With Previously Unrecognized Heart Failure in Primary Care|Completed||N/A|585|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 23:21:26.160223|2018-05-31 23:21:26.160223
NCT01201993|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-06-19|2010-09-14|2010-09-15|Estimate|||||||2011-06-19|2011-06-21|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|||||Observational|||Clinical and Laboratory Characteristics of Patients Admitted With Syncope; Diagnosis and Follow up After These Patients|Observational Study Following After Patients Admitted With Syncope|Suspended|||40|Anticipated|Carmel Medical Center|||||f||||f||||||||||2018-05-31 23:21:26.222519|2018-05-31 23:21:26.222519
NCT01201980|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2012-01-09|2010-09-14|2010-09-15|Estimate|||||||2012-01-09|2012-01-10|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension|An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension and to Evaluate Patients' Quality of Life|Completed|||300|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:21:26.270444|2018-05-31 23:21:26.270444
NCT01201967|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2014-05-12||2014-09-24|2010-09-14|2010-09-15|Estimate|2014-09-24|2014-09-25|Estimate||||2014-09-24|2014-09-25|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MOSAIC|Intent-to-treat analysis was employed. All randomized participants were included in analysis.|A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients|A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC)|Completed||Phase 4|183|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:21:26.357518|2018-05-31 23:21:26.357518
NCT01201954|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-14|||2011-04-25|2010-09-14|2010-09-15|Estimate|||||||2011-04-25|2011-04-26|Estimate|March 2010||2010-03-31|September 2010|2010-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PRPS||Pain Relief of Newborn Preterm Infants During Endotracheal Suctioning|Pain Relief of Newborn Preterm Infants During Endotracheal Suctioning: a Randomized Clinical Trial|Completed||Phase 2|43|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 23:21:27.169736|2018-05-31 23:21:27.169736
NCT01201941|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-10-24|2010-09-14|2010-09-15|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2004||2004-11-30|October 2017|2017-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru|Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru|Completed|||1849|Actual|Brigham and Women's Hospital|||2||f||||f||||||||||2018-05-31 23:21:27.268898|2018-05-31 23:21:27.268898
NCT01201928|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2012-12-05|2010-09-13|2010-09-15|Estimate|||||||2012-12-05|2012-12-06|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|||Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166|A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in a Subset of Subjects With Type 1 or Type 2 Diabetes|Terminated|||3|Actual|Mannkind Corporation|||2|Parent trials were either not initiated or terminated|f||||f||||||||||2018-05-31 23:21:27.329995|2018-05-31 23:21:27.329995
NCT01201915|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2014-05-22||2014-05-22|2010-09-13|2010-09-15|Estimate|2014-05-22|2014-06-24|Estimate||||2014-05-22|2014-06-24|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Treated participants population: All study participants who received at least 1 dose of study drug.|A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma|A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)|Completed||Phase 2|74|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:21:27.417926|2018-05-31 23:21:27.417926
NCT01201902|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-17|2010-09-13|2010-09-15|Estimate|||||||2010-09-17|2010-09-20|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine|Randomized, Open, Clinical Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine GC1116 With Adjuvant in Healthy Adults|Completed||Phase 3|592|Actual|Green Cross Corporation||5|||f||||f||||||||||2018-05-31 23:21:27.768985|2018-05-31 23:21:27.768985
NCT01201889|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2013-06-27|2010-09-13|2010-09-15|Estimate|||||||2013-06-27|2013-06-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:21:27.850239|2018-05-31 23:21:27.850239
NCT01201876|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-14|2010-09-13|2010-09-15|Estimate|||||||2011-06-14|2011-06-16|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||DPBRN Reasons for Replacement or Repair of Dental Restorations|Reasons for Replacement or Repair of Dental Restorations|Completed|||6368|Actual|Dental Practice-Based Research Network|||||f||||f||||||||||2018-05-31 23:21:27.892375|2018-05-31 23:21:27.892375
NCT01201863|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2014-08-11|2010-09-14|2010-09-15|Estimate|||||||2014-08-11|2014-08-13|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy|Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy|Completed||Phase 4|62|Actual|Craig Hospital||2|||f||||t||||||||||2018-05-31 23:21:27.976103|2018-05-31 23:21:27.976103
NCT01201850|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2017-09-19|2010-09-13|2010-09-15|Estimate|||||||2017-09-19|2017-09-21|Actual|July 2010|Actual|2010-07-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors|The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors|Completed||N/A|8|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 23:21:28.087919|2018-05-31 23:21:28.087919
NCT01201837|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13||2014-01-29|2014-01-29|2010-09-13|2010-09-15|Estimate||||2014-01-29|2014-03-03|Estimate|2014-01-29|2014-03-03|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|CHI SQUARE||Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial|CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome|Completed||Phase 2|507|Actual|Cerenis Therapeutics, SA||4|||f||||t||||||||||2018-05-31 23:21:28.17687|2018-05-31 23:21:28.17687
NCT01201824|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2015-11-24|2010-09-13|2010-09-15|Estimate|||||||2015-11-24|2015-11-26|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|CT0007||Thoracoscopic Localization of Pulmonary Nodules Using Direct Intracavitary Thoracoscopic Ultrasound|Thoracoscopic Localization of Pulmonary Nodules Using Direct Intracavitary Thoracoscopic Ultrasound|Completed||N/A|93|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 23:21:28.314329|2018-05-31 23:21:28.314329
NCT01201811|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2014-05-21||2016-03-24|2010-09-13|2010-09-15|Estimate|2014-05-21|2014-06-24|Estimate||||2016-03-24|2016-04-22|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||The intention-to-treat (ITT) population was defined as all enrolled participants.|Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)|A Phase 4, Open-Label, Single-Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes.|Completed||Phase 4|44|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 23:21:28.422531|2018-05-31 23:21:28.422531
NCT01201798|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2012-08-31||2012-10-15|2010-09-13|2010-09-15|Estimate|2012-10-15|2012-11-15|Estimate||||2012-10-15|2012-11-15|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis|A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis|Completed||Phase 3|111|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:21:28.979555|2018-05-31 23:21:28.979555
NCT01201785|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2011-10-31||2012-03-05|2010-09-14|2010-09-15|Estimate|2012-03-05|2012-03-06|Estimate||||2012-03-05|2012-03-06|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Aspirin Dosing in Diabetic Patients|Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease|Completed||Phase 4|20|Actual|University of Florida||1|||f||||t||||||||||2018-05-31 23:21:29.40343|2018-05-31 23:21:29.40343
NCT01201772|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2013-01-09||2013-01-17|2010-09-14|2010-09-15|Estimate|2013-01-17|2013-01-18|Estimate||||2013-01-17|2013-01-18|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||Prasugrel Re-load Strategies|Impact of Prasugrel Re-load on Platelet Aggregation in Patients on Chronic Prasugrel Therapy|Completed||Phase 4|65|Actual|University of Florida||3|||f||||t||||||||||2018-05-31 23:21:29.595419|2018-05-31 23:21:29.595419
NCT01201759|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2015-01-28||2015-06-08|2010-09-14|2010-09-15|Estimate|2015-06-08|2015-06-10|Estimate||||2015-06-08|2015-06-10|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Salsalate on Prandial-Induced Vascular Inflammation After Spinal Cord Injury (SCI)|Effects of Salsalate on Prandial-Induced Vascular Inflammation After SCI|Completed||N/A|18|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 23:21:29.88409|2018-05-31 23:21:29.88409
NCT01201746|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2016-10-13|2010-09-14|2010-09-15|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2008||2008-07-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|Perio-CHD||Influence of Periodontal Treatment on Systemic Inflammatory Mediators|Influence of Periodontal Treatment on Systemic Inflammatory Mediators:hsC-reactive Protein, Fibrinogen and White Blood Cells in CHD Patients|Completed||N/A|317|Actual|Sheikh Zayed Federal Postgraduate Medical Institute||2|||f||||t||||||||||2018-05-31 23:21:30.193561|2018-05-31 23:21:30.193561
NCT01201733|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2012-08-13|2010-09-14|2010-09-15|Estimate|||||||2012-08-13|2012-08-14|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Traditional Thai Massage and Brain Electrical Activity|The Immediate Effect of Traditional Thai Massage on Brain Electrical Activity in Patients With Scapulocostal Syndrome|Completed||N/A|40|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 23:21:30.287853|2018-05-31 23:21:30.287853
NCT01201720|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2015-06-16|2010-09-14|2010-09-15|Estimate|||||||2015-06-16|2015-06-17|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||"Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With Acute-on-chronic Liver Failure"|"Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Liver Failure"|Completed||Phase 4|12|Actual|Instituto Grifols, S.A.||1|||f||||f||||||||||2018-05-31 23:21:30.36426|2018-05-31 23:21:30.36426
NCT01201707|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2013-11-25|2010-09-14|2010-09-15|Estimate|||||||2013-11-25|2013-11-26|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Evaluation of Angioplasty in the Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis|The Effectiveness of Endovascular Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis|Terminated||N/A|18|Actual|Community Care Physicians, P.C.||2||Inability to enroll adequate number of patients|f||||t||||||||||2018-05-31 23:21:30.45783|2018-05-31 23:21:30.45783
NCT01201694|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-01-07|2010-09-13|2010-09-14|Estimate|||||||2015-01-07|2015-01-08|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)|Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) in Patients With Advanced Malignancies|Completed||Phase 1|28|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 23:21:30.556412|2018-05-31 23:21:30.556412
NCT01201681|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-09-16|2010-09-13|2010-09-14|Estimate|||||||2011-09-16|2011-09-20|Estimate|July 2010||2010-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||DPBRN Peri-operative Pain and Root Canal Therapy|Peri-operative Pain and Root Canal Therapy|Completed|||500|Anticipated|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:30.638255|2018-05-31 23:21:30.638255
NCT01201668|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-09-16|2010-09-13|2010-09-14|Estimate|||||||2011-09-16|2011-09-20|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||DPBRN Persistent Pain and Root Canal Therapy|Persistent Pain and Root Canal Therapy|Completed|||500|Anticipated|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:30.727127|2018-05-31 23:21:30.727127
NCT01201655|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis|Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis|Unknown status|Recruiting||5000|Anticipated|Xijing Hospital|||||f||||t||||||||||2018-05-31 23:21:30.810116|2018-05-31 23:21:30.810116
NCT01201642|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2014-08-18|2010-09-13|2010-09-14|Estimate|||||||2014-08-18|2014-08-20|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|||Prednisone and Acupuncture for the Treatment of Facial Neuritis: a Multiple Center, CER in China|Prednisone Acetate and Acupuncture for the Treatment of Facial Neuritis: a Multiple Center, Comparative Effectiveness Research in China|Unknown status|Recruiting|N/A|1800|Anticipated|Xijing Hospital||6|||f||||t||||||||||2018-05-31 23:21:30.889082|2018-05-31 23:21:30.889082
NCT01201629|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2017-03-29||2017-03-29|2010-09-13|2010-09-14|Estimate|2017-03-29|2017-05-10|Actual||||2017-03-29|2017-05-10|Actual|September 16, 2010|Actual|2010-09-16|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm|Does Transcranial Direct Current Stimulation Improve Functional Motor Recovery in the Affected Arm-Hand in Patients After an Acute Ischemic Stroke: A Randomized Control Trial|Terminated||N/A|16|Actual|University of Oklahoma||2||Slow accrual over 6 year period|f||||f||||||||||2018-05-31 23:21:30.985713|2018-05-31 23:21:30.985713
NCT01201616|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2018-03-23|2010-09-13|2010-09-14|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2010||2010-07-31|March 2018|2018-03-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of Diet on Mood, Cognition and Appetite|The Effects of a High Fat, Low Carbohydrate or a Low Fat, High Carbohydrate Diet on Mood Cognition and Appetite|Completed||N/A|20|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 23:21:31.347006|2018-05-31 23:21:31.347006
NCT01201603|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2018-03-04|2010-09-13|2010-09-14|Estimate|||||||2018-03-04|2018-03-06|Actual|July 2010||2010-07-31|March 2018|2018-03-31|November 2013|Actual|2013-11-30|December 2011|Actual|2011-12-31||Interventional|||The Effects of Orange Juice on Insulin Sensitivity and Plasma Lipids|The Effects of Orange Juice on Insulin Sensitivity and Plasma Lipids|Completed||N/A|36|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 23:21:31.426313|2018-05-31 23:21:31.426313
NCT01201590|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2018-03-23|2010-09-13|2010-09-14|Estimate|||||||2018-03-23|2018-03-27|Actual|March 2009||2009-03-31|March 2018|2018-03-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||The Effects of Cocoa Flavanols on Insulin Resistance in an 'At-risk' Population|The Effects of Cocoa Flavanols on Insulin Resistance in at 'At-risk' Population|Completed||N/A|32|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 23:21:31.488971|2018-05-31 23:21:31.488971
NCT01201577|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-05-31|2010-09-13|2010-09-14|Estimate|||||||2011-05-31|2011-06-01|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals|Biological Modulation of Bacterial QSSMs, Innate and Adaptive Immunity by Antibiotics, Probiotics and Prebiotics in Healthy Individuals|Completed||Phase 1|40|Anticipated|University of Nottingham||4|||f||||f||||||||||2018-05-31 23:21:31.559839|2018-05-31 23:21:31.559839
NCT01201564|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2018-01-08|2010-09-13|2010-09-14|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2010||2010-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparative Study Matching Intraperitoneal Onlay Mesh (IPOM) and Sublay Mesh to Treat Umbilical Hernia|Prospective Randomized Multicenter Trial Comparing Laparoscopic (IPOM) vs. Sublay Mesh Plasty for Umbilical Hernia in Adults|Recruiting||Phase 3|306|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 23:21:31.637628|2018-05-31 23:21:31.637628
NCT01201551|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2013-12-10|2010-09-13|2010-09-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature|Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature|Completed||N/A|40|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 23:21:31.767162|2018-05-31 23:21:31.767162
NCT01201538|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2017-01-10|2010-09-13|2010-09-14|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Nilotinib in Growing Vestibular Schwannomas|A Phase II Study of Nilotinib in Growing Vestibular Schwannomas|Terminated||Phase 2|2|Actual|University Health Network, Toronto||1||Study PI passed away We had trouble recruiting for the drug arm|f||||f||||||||||2018-05-31 23:21:31.839181|2018-05-31 23:21:31.839181
NCT01201525|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2011-08-09|2010-09-13|2010-09-14|Estimate|||||||2011-08-09|2011-08-10|Estimate|November 2009||2009-11-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pulsed Dye Laser Treatment of Recent Surgical Scars|Pulsed Dye Laser Treatment of Recent Surgical Scars: A Prospective Single Blinded Within Patient Controlled Randomized Trial|Completed||N/A|30|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:21:31.907721|2018-05-31 23:21:31.907721
NCT01201512|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-14|2010-09-13|2010-09-14|Estimate|||||||2011-06-14|2011-06-16|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||CONDOR Temporomandibular Muscle and Joint Disorders (TMJD) Survey|Primary Care Management for TMJD Pain|Completed|||503|Actual|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:31.967145|2018-05-31 23:21:31.967145
NCT01201499|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|January 2012|Anticipated|2012-01-31|November 2011|Anticipated|2011-11-30||Interventional|||Comparing the Outcome of Two Intraoperative Analgesia Techniques After Hepato-pancreato-biliary Surgery|The Impact of Two Different Intraoperative Analgesia Techniques on Post-operative Outcome After Hepato-pancreato-biliary Surgery|Unknown status|Not yet recruiting|N/A|140|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 23:21:32.021019|2018-05-31 23:21:32.021019
NCT01201486|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2015-08-21||2016-04-26|2010-09-13|2010-09-14|Estimate|2016-04-25|2016-04-26|Estimate||||2016-04-26|2016-04-27|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational||The number of heart defects detected by color Doppler in the second trimester was compared to the number of major heart defects detected at birth to determine the sensitivity of the color Doppler examination to detect major heart defects in the second trimester.|Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester|Use of Color Doppler in Routine Examination of Fetal Heart in Second Trimester.|Completed|||6781|Actual|Helse Stavanger HF|||1||f||||f||||||||No|Data wil not be shared outside the research group. Results are published (see references).|2018-05-31 23:21:32.096309|2018-05-31 23:21:32.096309
NCT01201473|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-14|2010-09-13|2010-09-14|Estimate|||||||2011-06-14|2011-06-16|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|CONDOR PIRG||CONDOR Impact of Dental Practice-Based Research Network|CONDOR Impact of Dental Practice-Based Research Network (PIRG)|Completed|||687|Actual|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:32.214413|2018-05-31 23:21:32.214413
NCT01201460|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-14|2010-09-13|2010-09-14|Estimate|||||||2011-06-14|2011-06-16|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||DPBRN Blood Sugar Testing in Dental Patients|Blood Sugar Testing in Dental Patients|Completed|||498|Actual|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:32.270029|2018-05-31 23:21:32.270029
NCT01201447|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-03-03|2010-09-13|2010-09-14|Estimate|||||||2011-03-03|2011-03-04|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||DPBRN Prevalence of Questionable Occlusal Caries Lesions|Prevalence of Questionable Occlusal Caries Lesions|Completed|||2624|Anticipated|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:32.326237|2018-05-31 23:21:32.326237
NCT01201434|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2014-07-21|2010-09-13|2010-09-14|Estimate|||||||2014-07-21|2014-07-22|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Probiotics on Sputum Inflammation and Pulmonary Infections in Patients With Cystic Fibrosis|The Effect of Probiotics on Sputum Bacteria, Sputum Inflammation, and Pulmonary Infections in Patients With Cystic Fibrosis: A Double-blind Placebo-controlled Trial|Terminated||N/A|12|Actual|Sheba Medical Center||1||Severe allergic reaction in one patient|f||||f||||||||||2018-05-31 23:21:33.389446|2018-05-31 23:21:33.389446
NCT01201421|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-14|2010-09-13|2010-09-14|Estimate|||||||2011-06-14|2011-06-16|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||DPBRN Patient Satisfaction With Dental Restorations|Patient Satisfaction With Dental Restorations|Completed|||5932|Actual|Dental Practice-Based Research Network|||||f||||f||||||||||2018-05-31 23:21:33.455595|2018-05-31 23:21:33.455595
NCT01201408|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-09-16|2010-09-13|2010-09-14|Estimate|||||||2011-09-16|2011-09-20|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||DPBRN Longitudinal Study of Dental Restorations Placed on Previously Un-restored Surfaces|Longitudinal Study of Dental Restorations Placed on Previously Un-restored Surfaces|Completed|||9291|Anticipated|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:33.529949|2018-05-31 23:21:33.529949
NCT01201395|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-09-16|2010-09-13|2010-09-14|Estimate|||||||2011-09-16|2011-09-20|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||DPBRN Longitudinal Study of Repaired or Replaced Dental Restorations|Longitudinal Study of Repaired or Replaced Dental Restorations|Completed|||9813|Anticipated|Dental Practice-Based Research Network|||1||f||||f||||||||||2018-05-31 23:21:33.604906|2018-05-31 23:21:33.604906
NCT01201382|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2017-08-25|2010-09-13|2010-09-14|Estimate|||||||2017-08-25|2017-08-28|Actual|October 2010||2010-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2015|Actual|2015-06-30||Interventional|||Depression Prevention Initiative - A Study of Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) in School Settings|Depression Prevention Initiative - A Study of IPT-AST in School Settings|Completed||N/A|185|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 23:21:33.793166|2018-05-31 23:21:33.793166
NCT01201369|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2011-07-11|2010-09-13|2010-09-14|Estimate|||||||2011-07-11|2011-07-12|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ORCA-2||A Study to Examine the Implantation Characteristics of Two Drug-Eluting Stents|Comparison of Rates of Strut Malapposition Between Everolimus and Sirolimus Eluting Stents - A Randomised Optical Coherence Tomography Study|Completed||N/A|40|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 23:21:33.937802|2018-05-31 23:21:33.937802
NCT01201356|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2018-03-27|2010-09-13|2010-09-14|Estimate|||||||2018-03-27|2018-03-29|Actual|September 13, 2010|Actual|2010-09-13|March 2018|2018-03-31|September 28, 2018|Anticipated|2018-09-28|June 29, 2018|Anticipated|2018-06-29||Interventional|||Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis|A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis|Active, not recruiting||Phase 3|4125|Actual|Novartis||1|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 23:21:34.211045|2018-05-31 23:21:34.211045
NCT01201343|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2012-03-15||2013-12-02|2010-09-13|2010-09-14|Estimate|2012-03-15|2012-04-11|Estimate||||2013-12-02|2013-12-27|Estimate|January 2005||2005-01-31|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SEPTIME||Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients|Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients|Completed||Phase 4|79|Actual|Merck KGaA|||||f||||t||||||||||2018-05-31 23:21:35.178548|2018-05-31 23:21:35.178548
NCT01201330|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-14|2010-09-13|2010-09-14|Estimate|||||||2011-06-14|2011-06-16|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||DPBRN Retrospective Cohort Study of Osteonecrosis of the Jaw|Retrospective Cohort Study of ONJ|Completed|||572606|Actual|Dental Practice-Based Research Network|||2||f||||f||||||||||2018-05-31 23:21:35.48418|2018-05-31 23:21:35.48418
NCT01201317|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|2013-07-25||2014-04-08|2010-09-13|2010-09-14|Estimate|2013-07-25|2013-09-25|Estimate||||2014-04-08|2014-04-25|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy|A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo|Completed||Phase 2|134|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:21:35.55531|2018-05-31 23:21:35.55531
NCT01201304|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2012-01-26|2010-09-13|2010-09-14|Estimate|||||||2012-01-26|2012-01-31|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Comparison of Methods for the Delivery of Interoceptive Exposure|Comparison of Methods for the Delivery of Interoceptive Exposure|Unknown status|Enrolling by invitation|Phase 2|120|Anticipated|University of Wyoming||2|||f||||f||||||||||2018-05-31 23:21:36.070424|2018-05-31 23:21:36.070424
NCT01201291|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2017-03-02|2010-09-13|2010-09-14|Estimate|||||||2017-03-02|2017-03-03|Actual|November 2010||2010-11-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|BRAINOXY||Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury|Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury|Terminated||N/A|67|Actual|Kuopio University Hospital||2||Due to slow recruitment the study was terminated|f||||t||||||||Undecided||2018-05-31 23:21:36.170826|2018-05-31 23:21:36.170826
NCT01201278|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-06-15|2010-09-13|2010-09-14|Estimate|||||||2011-06-15|2011-06-17|Estimate||||June 2011|2011-06-30||||||||Interventional|||PK/PD Study of Intranasal Insulin in Type I Diabetes|A Phase 1, Randomized, 3-Way Crossover, Investigator Initiated Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Two Doses of Intranasally Administered Regular Human Insulin Compared to a Single Dose of a Subcutaneously Injected Rapid Acting Insulin Analog (Humalog®) in Subjects With Type I Diabetes|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Hompesch, Marcus, M.D.||3|||f||||f||||||||||2018-05-31 23:21:36.249081|2018-05-31 23:21:36.249081
NCT01201265|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|2016-04-21||2016-04-21|2010-09-13|2010-09-14|Estimate|2016-04-21|2016-05-27|Estimate||||2016-04-21|2016-05-27|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer|A Multi Centre, Pilot Phase II Trial Assessing the Efficacy and Safety of Bevacizumab + Gemcitabine + Carboplatin as First Line Treatment for Patients Diagnosed With Triple Negative Metastatic Breast Cancer|Completed||Phase 2|40|Actual|Hoffmann-La Roche||1|||f||||f||||||||||2018-05-31 23:21:36.345396|2018-05-31 23:21:36.345396
NCT01201252|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2012-11-15|2010-09-13|2010-09-14|Estimate|||||||2012-11-15|2012-11-19|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Study to Estimate the Disease Burden of Acute Rotavirus Gastroenteritis in Children < 5 Years in United Arab Emirates|An Observational, Hospital-based Surveillance to Estimate the Disease Burden of Acute Rotavirus (RV) Gastroenteritis (GE) in Children < 5 Years of Age in United Arab Emirates (UAE).|Completed|||717|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Stool~   "|||2018-05-31 23:21:36.643718|2018-05-31 23:21:36.643718
NCT01201239|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|October 2012|Anticipated|2012-10-31|May 2012|Anticipated|2012-05-31||Interventional|||Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients|An Open Pilot Study to Evaluate the Efficacy and Safety, Tolerability of Raltegravir（RAL）in Treatment-experienced HIV-1 Infected Adult Chinese Patients|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Shanghai Public Health Clinical Center||1|||f||||t||||||||||2018-05-31 23:21:36.709414|2018-05-31 23:21:36.709414
NCT01201226|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive?|Can Dormant Ovarian Follicles From Perimenopausal Women Become Gonadotropin Responsive by Incubation With PTEN Inhibitor and PI3K Activating Peptide?|Unknown status|Not yet recruiting|N/A|10|Anticipated|The Baruch Padeh Medical Center, Poriya||1|||f||||f||||||||||2018-05-31 23:21:36.770639|2018-05-31 23:21:36.770639
NCT01201213|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2017-05-29|2010-09-13|2010-09-14|Estimate|||||||2017-05-29|2017-05-31|Actual|September 2009||2009-09-30|May 2017|2017-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bupivacaine, Levobupivacaine and Ropivacaine After Intrathecal and Extradural Injection in Labour|Median Effective Concentration of Bupivacaine, Levobupivacaine and Ropivacaine After Intrathecal and Extradural Injection for Pain Relief in the First Stage of Labour|Terminated||Phase 4|14|Actual|NHS Tayside||6||Audit pre regulatory inspection|f||||f||||||||No|study terminated|2018-05-31 23:21:36.841423|2018-05-31 23:21:36.841423
NCT01201200|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2012-05-07|2010-09-13|2010-09-14|Estimate|||||||2012-05-07|2012-05-08|Estimate|June 2007||2007-06-30|June 2010|2010-06-30|November 2007|Actual|2007-11-30|||||Observational|||Right Ventricular Function in Patients With Obstructive Sleep Apnea|Right Ventricular Function in Patients With Obstructive Sleep Apnea Assessed by Real-time Three-dimensional Echocardiography|Completed|||106|Actual|Associação Fundo de Incentivo à Pesquisa|||4||f||||t||||||||||2018-05-31 23:21:36.910163|2018-05-31 23:21:36.910163
NCT01201187|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2012-01-09|2010-09-12|2010-09-14|Estimate|||||||2012-01-09|2012-01-11|Estimate|March 2010||2010-03-31|September 2010|2010-09-30|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|yuyu||Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD|Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162) in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks|Completed||Phase 3|144|Anticipated|Yuyu Pharma, Inc.||2|||f||||t||||||||||2018-05-31 23:21:36.96347|2018-05-31 23:21:36.96347
NCT01201174|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Hemolysis in Patients With Hereditary Spherocytosis (HS)|Oxidative Stress Contributes to Hemolysis in Patients With Hereditary Spherocytosis (HS) and Can be Ameliorated by Fermented Papaya Preparation (FPP)|Unknown status|Not yet recruiting|N/A|15|Anticipated|Wolfson Medical Center||1|||f||||f||||||||||2018-05-31 23:21:37.039474|2018-05-31 23:21:37.039474
NCT01201161|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|RANITRA||Ranibizumab for Diabetic Traction Retinal Detachment|The Effect of Intravitreous Ranibizumab on Intra-Operative Bleeding During Pars Plana Vitrectomy for Diabetic Traction Retinal Detachment|Completed||Phase 2|19|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:21:37.211754|2018-05-31 23:21:37.211754
NCT01201148|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-11-30|2010-09-13|2010-09-14|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2010||2010-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Open Pilot Trial of TES for Depression|A Study of Transcranial Electrical Stimulation (TES) for the Treatment of Depression|Completed||Phase 2|7|Actual|The University of New South Wales||1|||f||||t||||||||||2018-05-31 23:21:37.307154|2018-05-31 23:21:37.307154
NCT01201135|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2010-09-12|2010-09-12|2010-09-14|Estimate|||||||2010-09-12|2010-09-14|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|GDF 15||GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis|The Impact of Growth Differentiating Factor (GDF) 15 in Sickle Cell Disease and Hereditary Spherocytosis|Unknown status|Not yet recruiting||80|Anticipated|Wolfson Medical Center|||2||f||||f||||||||||2018-05-31 23:21:37.367949|2018-05-31 23:21:37.367949
NCT01201122|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2015-12-06|2010-09-13|2010-09-14|Estimate|||||||2015-12-06|2015-12-08|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MUPPIT||Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis|Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC.|Completed||Phase 4|86|Actual|Wolfson Medical Center||2|||f||||t||||||||||2018-05-31 23:21:37.421608|2018-05-31 23:21:37.421608
NCT01201109|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-27|2010-09-13|2010-09-14|Estimate|||||||2010-09-27|2010-09-28|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Carpal Tunnel Release in Diabetic Patients|Five Years Follow-up After Carpal Tunnel Release in Diabetic and Non-diabetic Patients|Unknown status|Enrolling by invitation||66|Actual|Skane University Hospital|||2||f||||f||||||||||2018-05-31 23:21:37.535355|2018-05-31 23:21:37.535355
NCT01201096|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2010-09-22|2010-09-13|2010-09-14|Estimate|||||||2010-09-22|2010-09-23|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2018|Anticipated|2018-09-30|September 2015|Anticipated|2015-09-30||Observational|NEO-LEBE||Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)|Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors|Recruiting|||50|Anticipated|University of Jena|||1||f||||f||||||||||2018-05-31 23:21:37.598182|2018-05-31 23:21:37.598182
NCT01201083|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|February 2009||2009-02-28|July 2010|2010-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|MetroMates||Study of Recently HIV Infected Men and Transmission Behaviors|Transmission Behavior in Partnerships of Newly HIV Infected Southern Californians|Unknown status|Recruiting||600|Anticipated|University of California, Los Angeles|||||f||||f||||||Samples With DNA|"~     We collect a sample of blood/plasma and have a repository (blood) and for future analysis.~     After noting that subject has consented to main study as well as consenting to have his blood~     stored for later research purposes, appropriate research staff will direct the phlebotomist~     to draw and additional tube of blood (approximately 7mls of blood) into a purple cap (EDTA)~     tube. After processing, each sample will be securely stored at the participating site under~     appropriate conditions .~   "|||2018-05-31 23:21:37.688466|2018-05-31 23:21:37.688466
NCT01201070|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-09-14|2010-09-13|2010-09-14|Estimate|||||||2010-09-14|2010-09-15|Estimate|September 2009||2009-09-30|July 2010|2010-07-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|ATIII||Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery|Effects of the Administration Of Antithrombin on the Coagulation Status and on the Inflammatory Response in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery|Unknown status|Recruiting|Phase 4|90|Anticipated|University of Bari||3|||f||||t||||||||||2018-05-31 23:21:37.753034|2018-05-31 23:21:37.753034
NCT01201057|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30||2012-04-18|2012-04-18|2010-09-12|2010-09-14|Estimate||||2012-04-18|2012-04-19|Estimate|2012-04-18|2012-04-19|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)|A Double-blind, Multi-center, Randomized, Placebo Controlled, Dose-ranging Study to Determine the Efficacy and Safety of SPL7013 Gel (VivaGel®) Administered Vaginally in the Treatment of Bacterial Vaginosis|Completed||Phase 2|132|Actual|Starpharma Pty Ltd||4|||f||||||||||||||2018-05-31 23:21:37.839516|2018-05-31 23:21:37.839516
NCT01200706|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2011-07-19|2010-09-13|2010-09-14|Estimate|||||||2011-07-19|2011-07-20|Estimate|November 2006||2006-11-30|September 2010|2010-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PNEUMOPACEf||Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Pneumonia|Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Community-acquired Pneumonia|Completed||Phase 4|820|Actual|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 23:21:43.913248|2018-05-31 23:21:43.913248
NCT01201044|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|DO201001||Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized, Two Arm Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|N/A|80|Anticipated|Third Military Medical University||2|||f||||f||||||||||2018-05-31 23:21:37.930229|2018-05-31 23:21:37.930229
NCT01201031|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2011-03-14|2010-09-13|2010-09-14|Estimate|||||||2011-03-14|2011-03-16|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Observational|||Reduction of Nosocomial Vancomycin -Resistant Enterococci (VRE) Colonization and Infection by Active Surveillance and Intervention of Infection Control|Reduction of Nosocomial VRE Colonization and Infection by Active Surveillance and Intervention of Infection Control (no)|Completed|||80|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:21:38.00826|2018-05-31 23:21:38.00826
NCT01201018|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2012-06-20|2010-09-13|2010-09-14|Estimate|||||||2012-06-20|2012-06-21|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment|A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment - A Phase I Study|Completed||Phase 1|7|Actual|Oshadi Drug Administration||1|||f||||f||||||||||2018-05-31 23:21:38.081137|2018-05-31 23:21:38.081137
NCT01201005|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||B Vitamin Status in Premature and Small for Gestational Age(SGA) Infants|B VITAMIN STATUS IN PREMATURE AND SMALL FOR GESTATIONAL AGE INFANTS|Completed||N/A|80|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 23:21:38.152942|2018-05-31 23:21:38.152942
NCT01200992|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-12|2014-08-29||2017-08-23|2010-09-12|2010-09-14|Estimate|2014-09-10|2014-09-11|Estimate||||2017-08-23|2017-08-24|Actual|November 2010||2010-11-30|August 2017|2017-08-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|EMBARC-RF||Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer|A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer|Terminated||Phase 3|84|Actual|Bioniche Life Sciences Inc.||2||Lack of Recruitment|f||||t||||||||||2018-05-31 23:21:38.244454|2018-05-31 23:21:38.244454
NCT01200979|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-11|||2018-03-27|2010-09-11|2010-09-14|Estimate|||||||2018-03-27|2018-03-29|Actual|September 7, 2010||2010-09-07|December 15, 2017|2017-12-15||||||||Observational|||Assessment of Alterations in Immune Function During Pregnancy and Post Parturition|Assessment of Alterations in Immune Function During Pregnancy and Post Parturition|Completed|||41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:21:38.574234|2018-05-31 23:21:38.574234
NCT01200966|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-11|||2018-05-22|2010-09-11|2010-09-14|Estimate|||||||2018-05-22|2018-05-23|Actual|August 30, 2010||2010-08-30|January 4, 2017|2017-01-04|January 4, 2017||2017-01-04|||||Observational|||Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates|Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates|Completed|||96|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:21:38.632729|2018-05-31 23:21:38.632729
NCT01200953|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-11|||2018-03-27|2010-09-11|2010-09-14|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2, 2010||2010-09-02|February 9, 2018|2018-02-09||||||||Observational|||Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases|Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:21:38.690817|2018-05-31 23:21:38.690817
NCT01200940|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-11|||2018-05-08|2010-09-11|2010-09-14|Estimate|||||||2018-05-08|2018-05-09|Actual|July 1, 2010||2010-07-01|April 24, 2018|2018-04-24|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Metabolic Effects of Non-Nutritive Sweeteners|Metabolic Effects of Non-Nutritive Sweeteners|Recruiting||Phase 1/Phase 2|250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:21:38.754683|2018-05-31 23:21:38.754683
NCT01200927|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|December 2004||2004-12-31|September 2010|2010-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Sitting Postural Control in Infants With Cerebral Palsy|INVESTIGATION OF THE DYNAMICS OF SITTING POSTURAL CONTROL IN INFANTS WITH CEREBRAL PALSY|Completed||N/A|35|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 23:21:38.830233|2018-05-31 23:21:38.830233
NCT01200914|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2016-05-10|2010-09-13|2010-09-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins|Placement of Covered Stents to Treat Hemodialysis Access Stenosis in the Cephalic Arch and Central Veins|Terminated||N/A|14|Actual|University Health Network, Toronto||2||poor recruitment|f||||f||||||||||2018-05-31 23:21:38.885699|2018-05-31 23:21:38.885699
NCT01200901|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2013-01-16|2010-09-13|2010-09-14|Estimate|||||||2013-01-16|2013-01-18|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Quetiapine in Melancholic Depression|Quetiapine in Melancholic Depression: an fMRI Study of Treatment-induced Changes in the Neurocircuitry of the Stress Response|Completed||Phase 4|20|Actual|University of Cincinnati||1|||f||||f||||||||||2018-05-31 23:21:39.029489|2018-05-31 23:21:39.029489
NCT01200888|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2018-04-20|2010-09-13|2010-09-14|Estimate|||||||2018-04-20|2018-04-23|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 1, 2017|Actual|2017-06-01||Observational|||Controlled Ventilation CT in CF Infants|Differentiating Outcome Measures in Infants/Young Children With Cystic Fibrosis Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing|Terminated|||1|Actual|Stanford University|||||f||||f||||||||||2018-05-31 23:21:39.190194|2018-05-31 23:21:39.190194
NCT01200875|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2016-10-12||2016-12-07|2010-09-13|2010-09-14|Estimate|2016-10-12|2016-12-06|Estimate||||2016-12-07|2017-02-02|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|May 2013|Actual|2013-05-31|December 2011|Actual|2011-12-31||Observational|||Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections|Effect of Intramuscular and Intratendinous Platelet-Rich Plasma Injections on Systemic Concentrations of Performance-Enhancing Growth Factors|Completed|||25|Actual|Stanford University|||||f||||t||||||Samples Without DNA|"~     Blood serum, blood plasma, and platelet-rich-plasma (PRP)~   "|||2018-05-31 23:21:39.255301|2018-05-31 23:21:39.255301
NCT01200862|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2014-06-19|2010-09-13|2010-09-14|Estimate|||||||2014-06-19|2014-06-23|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|OHH||Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men|An Open-label Dose Finding Study Followed by a Parallel Group, Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Pharmacodynamics of 12 Week BGS649 Treatment in Obese, Hypogonadotropic Hypogonadal Men|Terminated||Phase 2|29|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:21:39.410166|2018-05-31 23:21:39.410166
NCT01200849|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-11-17|2010-09-13|2010-09-14|Estimate|||||||2014-11-17|2014-11-18|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Enhanced Spanish Drug Label Study to Promote Patient Understanding and Use|Enhanced Spanish Drug Label Design to Promote Patient Understanding and Use|Completed||N/A|420|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 23:21:39.489087|2018-05-31 23:21:39.489087
NCT01200836|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2018-03-27|2010-09-10|2010-09-14|Estimate|||||||2018-03-27|2018-03-29|Actual|July 1, 2010||2010-07-01|December 6, 2017|2017-12-06||||||||Observational|||Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol|Effects of Rosuvastatin on the Immune System in Healthy Volunteers With Normal Cholesterol|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:21:39.557617|2018-05-31 23:21:39.557617
NCT01200823|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2018-03-27|2010-09-10|2010-09-14|Estimate|||||||2018-03-27|2018-03-29|Actual|July 1, 2010||2010-07-01|February 12, 2018|2018-02-12||||||||Observational|||Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases Laboratory Research Studies|Collection of Blood, Bone Marrow, Leukapheresis, and Tissue Biopsy Samples From Patients and Their Family Members for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies|Completed|||96|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:21:39.643915|2018-05-31 23:21:39.643915
NCT01200810|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2014-10-20||2017-10-25|2010-09-10|2010-09-14|Estimate|2014-10-20|2014-10-23|Estimate||||2017-10-25|2017-12-02|Actual|August 2010||2010-08-31|October 2017|2017-10-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer|A Randomized Phase II Study of Peripheral Androgen Blockade With Bicalutamide Followed by Placebo or Treatment With the Gamma Secretase Inhibitor RO4929097 in Men With Rising PSA After Definitive Local Therapy for Adenocarcinoma of the Prostate|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)|Early termination leading to small numbers of subjects analyzed.|2||Drug was no longer available|f||||f||||||||||2018-05-31 23:21:39.725531|2018-05-31 23:21:39.725531
NCT01200797|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2013-10-07||2015-05-07|2010-09-10|2010-09-14|Estimate|2015-05-07|2015-05-25|Estimate||||2015-05-07|2015-05-25|Estimate|July 2010||2010-07-31|May 2015|2015-05-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional||All participants|SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin|A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma|Terminated||Phase 2|19|Actual|National Cancer Institute (NCI)|The death reported in the SAE section was not related to study drug.|1||Slow accrual was the reason for study termination.|f||||t||||||||||2018-05-31 23:21:40.546005|2018-05-31 23:21:40.546005
NCT01200784|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2012-01-16|2010-09-13|2010-09-14|Estimate|||||||2012-01-16|2012-01-18|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|DONATO||Nicotinamide in Hemodialysis Patients With Hyperphosphatemia|Dose Finding Study of Nicotinamide in Hemodialysis Patients With Hyperphosphatemia|Completed||Phase 2|252|Actual|Medice Arzneimittel Pütter GmbH & Co KG||5|||f||||||||||||||2018-05-31 23:21:41.042524|2018-05-31 23:21:41.042524
NCT01200771|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2014-02-17|2010-09-13|2010-09-14|Estimate|||||||2014-02-17|2014-02-19|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|February 2014|Actual|2014-02-28|May 2012|Actual|2012-05-31||Interventional|FUO-TEP||Impact of the PET in the Diagnosis Strategy of FUO or Inflammatory Syndrome in Immunocompetent Patients FUO-TEP|Impact of the PET-scan in the Diagnosis Strategy of Fever Unknown Origin or Inflammatory Syndrome in Immunocompetent Patients|Completed||N/A|116|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 23:21:41.265924|2018-05-31 23:21:41.265924
NCT01200758|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2015-07-07||2017-05-30|2010-09-13|2010-09-14|Estimate|2015-07-07|2015-08-05|Estimate||||2017-05-30|2017-06-26|Actual|February 15, 2011|Actual|2011-02-15|May 2017|2017-05-31|November 3, 2017|Anticipated|2017-11-03|June 12, 2012|Actual|2012-06-12||Interventional||Intent-to-Treat (ITT) Population included all participants who were randomized into study irrespective whether they received study drug or not.|A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma|A Two-Stage Phase III, International, Multi-Center, Randomized, Controlled, Open-Label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV|Active, not recruiting||Phase 3|410|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 23:21:41.576592|2018-05-31 23:21:41.576592
NCT01200745|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|February 2011|Anticipated|2011-02-28|January 2011|Anticipated|2011-01-31||Interventional|||Efficacy of Topical Capsaicin on Chronic Neck Pain|Efficacy of Topical Capsaicin on Chronic Neck Pain ; Double-blinded Randomized Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 23:21:43.552824|2018-05-31 23:21:43.552824
NCT01200732|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|February 2008||2008-02-29|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome|Clinical Efficacy of Phosphodiesterase-5 Inhibitor Tadalafil in Eisenmenger Syndrome - A Randomised, Placebo Controlled, Double Blind, Crossover Study|Completed||Phase 2|28|Actual|Govind Ballabh Pant Hospital||2|||f||||f||||||||||2018-05-31 23:21:43.65654|2018-05-31 23:21:43.65654
NCT01200719|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2010-09-13|2010-09-13|2010-09-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|November 2006||2006-11-30|October 2006|2006-10-31|September 2009|Actual|2009-09-30|June 2007|Actual|2007-06-30||Interventional|||Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) Enhances Neurological Function Recovery Among Post-stroke Patients|Completed||Phase 4|312|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 23:21:43.832239|2018-05-31 23:21:43.832239
NCT01054235|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-22|Estimate|||||||2010-01-20|2010-01-22|Estimate|August 2000||2000-08-31|January 2010|2010-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|EPCP||Prenatal Care Program in Dingyuan County|Evaluation of Prenatal Care Program in Rural China|Completed||N/A|5000|Actual|National Institute for Health and Welfare, Finland||1|||f||||t||||||||||2018-06-01 00:10:06.717444|2018-06-01 00:10:06.717444
NCT01200693|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2013-02-13|2010-09-13|2010-09-14|Estimate|||||||2013-02-13|2013-02-15|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|Z-SEA-SIDE||Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|Completed||Phase 4|80|Actual|Catholic University of the Sacred Heart||3|||f||||f||||||||||2018-05-31 23:21:44.006082|2018-05-31 23:21:44.006082
NCT01200680|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-05-16|2010-09-09|2010-09-13|Estimate|||||||2018-05-16|2018-05-17|Actual|October 1, 2010||2010-10-01|March 22, 2018|2018-03-22||||||||Observational|||Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes|Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:21:44.133127|2018-05-31 23:21:44.133127
NCT01200667|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2010-09-14|2010-09-10|2010-09-13|Estimate|||||||2010-09-14|2010-09-15|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|uPHI||uPHI: Wireless Body Area Network Core Technology|uPHI: Wireless Body Area Network Core Technology|Unknown status|Active, not recruiting||380|Anticipated|Taipei Medical University WanFang Hospital|||||f||||t||||||||||2018-05-31 23:21:44.190266|2018-05-31 23:21:44.190266
NCT01200654|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2012-10-22|2010-09-10|2010-09-13|Estimate|||||||2012-10-22|2012-10-23|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Population Pharmacokinetics of Linezolid|Population Pharmacokinetics of Linezolid in Intensive Care Units Patients Treated for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections|Completed||Phase 4|60|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 23:21:44.237022|2018-05-31 23:21:44.237022
NCT01200641|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2012-10-10|2010-09-10|2010-09-13|Estimate|||||||2012-10-10|2012-10-11|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Anxiolysis and Pain Associated With Retrobulbar Eye Block for Cataract Surgery : Melatonin Versus Gabapentin|Evaluation of Anxiolysis and Pain Associated With Retrobulbar Eye Block for Cataract Surgery : Melatonin Versus Gabapentin ( A Randomized, Double-blind, Placebo-controlled Study)|Completed||Phase 1/Phase 2|90|Actual|Qazvin University Of Medical Sciences||3|||f||||t||||||||||2018-05-31 23:21:44.308763|2018-05-31 23:21:44.308763
NCT01200628|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-06-16|2010-09-10|2010-09-13|Estimate|||||||2015-06-16|2015-06-17|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|DEPITAC||DEPITAC : Short Screening Scale for Psychotraumatic Disorders After Motor Vehicle Accident|Construction and Validation of a Short Screening Scale for Psychotraumatic Disorders for Inpatients Hospitalized in Surgical Unit Following a Road Traffic Accident|Completed|||274|Actual|University Hospital, Lille|||1||f||||f||||||||||2018-05-31 23:21:44.388559|2018-05-31 23:21:44.388559
NCT01200615|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-09-10|2010-09-10|2010-09-13|Estimate|||||||2010-09-10|2010-09-13|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Interventional|||The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects|The Nocebo Effect: a Prospective Study of Informed Consent as a Factor in the Prevalence of SSRI's Side Effects|Unknown status|Not yet recruiting|N/A|150|Anticipated|Shalvata Mental Health Center||3|||f||||t||||||||||2018-05-31 23:21:44.451692|2018-05-31 23:21:44.451692
NCT01200602|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2013-03-29||2015-10-29|2010-09-10|2010-09-13|Estimate|2013-03-29|2013-05-24|Estimate||||2015-10-29|2015-11-25|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional||Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.|Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy|A Randomized Megestrol Acetate/Placebo Controlled Trial in Pediatric Patients With Malignancies With Weight Loss/Anorexia|Terminated||Phase 2|1|Actual|Mayo Clinic||2||The study closed due to slow accrual.|f||||t||||||||||2018-05-31 23:21:44.561214|2018-05-31 23:21:44.561214
NCT01200589|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2017-12-06||2018-04-16|2010-09-10|2010-09-13|Estimate|2018-04-16|2018-05-16|Actual||||2018-04-16|2018-05-16|Actual|October 11, 2010|Actual|2010-10-11|April 2018|2018-04-30|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|HOMER||Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy|Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy|Terminated||Phase 3|438|Actual|Novartis||2||The study stopped due to futility.|f||||t||||||||||2018-05-31 23:21:44.837831|2018-05-31 23:21:44.837831
NCT01200576|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2013-03-28|2010-09-10|2010-09-13|Estimate|||||||2013-03-28|2013-03-29|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||A Prospective Observational Study of the Clinical Performance of Zarin in Madagascar|A Prospective Observational Study of the Clinical Performance of Zarin in Madagascar|Completed|||621|Actual|FHI 360|||1||f||||f||||||||||2018-05-31 23:21:45.695248|2018-05-31 23:21:45.695248
NCT01200563|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2014-12-11|2010-09-10|2010-09-13|Estimate|||||||2014-12-11|2014-12-15|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparative Effectiveness Study of MIST Therapy Versus Negative Pressure Wound Therapy|Comparative, Prospective, Randomized Study of MIST Therapy vs NPWT vs MIST Therapy in Conjunction With NPWT on the Rate of Healing and Its Economic Value in the Treatment of Full Thickness Wounds in a LTACH and SNF|Withdrawn||Phase 4|0|Actual|Celleration, Inc.||3||Study site compliance|f||||f||||||||||2018-05-31 23:21:45.782554|2018-05-31 23:21:45.782554
NCT01200550|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2012-04-16|2010-09-10|2010-09-13|Estimate|||||||2012-04-16|2012-04-17|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Observational|||The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients|An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease (GERD)|Completed|||1233|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:21:45.855707|2018-05-31 23:21:45.855707
NCT01200537|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2012-11-19|2010-09-10|2010-09-13|Estimate|||||||2012-11-19|2012-11-21|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Optimizing Ovulation Induction in the Poor Responder|Optimizing Ovulation Induction in the Poor Responder: a Randomized Clinical Trial of Luteal Phase Estradiol Versus Combined Oral Contraceptive Pill on Ovarian Morphology and Biomarkers Prior to Ovulation Induction|Withdrawn||N/A|0|Actual|Duke University||2||Change in staffing|f||||f||||||||||2018-05-31 23:21:45.941828|2018-05-31 23:21:45.941828
NCT01200524|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2013-07-25||2014-04-08|2010-09-10|2010-09-13|Estimate|2013-07-25|2013-09-25|Estimate||||2014-04-08|2014-04-25|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..|A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..|Completed||Phase 2|133|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:21:46.041002|2018-05-31 23:21:46.041002
NCT01200511|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2017-01-13||2017-03-09|2010-09-10|2010-09-13|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|August 2010||2010-08-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||This analysis population includes all patients receiving IOL implantation in both eyes that completed the study.|Pilot Study of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)|A Prospective Pilot Clinical Study of the AcrySof® IQ ReSTOR® Multifocal Toric IOL|Completed||N/A|49|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:21:46.464661|2018-05-31 23:21:46.464661
NCT01200498|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2013-12-13||2013-12-13|2010-09-10|2010-09-13|Estimate|2013-12-13|2014-01-30|Estimate||||2013-12-13|2014-01-30|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of SB939 in Subjects With Myelofibrosis|A Phase 2, Prospective, Open-Label Study to Determine the Safety and Efficacy of SB939, A Histone Deacetylase Inhibitor, in Subjects With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (PMF; Post-Polycythemia Vera (PV) Myelofibrosis (MF), Or Post- Essential Thrombosis (ET) MF|Completed||Phase 2|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:21:46.646698|2018-05-31 23:21:46.646698
NCT01200485|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2016-07-14|2010-09-10|2010-09-13|Estimate|||||||2016-07-14|2016-07-18|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2|A Randomized Phase 2 Study to Evaluate the Efficacy of Rasburicase in Patients at Risk for TLS During Two Cycles of Chemotherapy|Completed||Phase 2|55|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-05-31 23:21:46.805263|2018-05-31 23:21:46.805263
NCT01200472|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2013-10-18|2010-09-10|2010-09-13|Estimate|||||||2013-10-18|2013-10-21|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy Study of Apremilast (CC-10004) in Subjects With Erosive Hand Osteoarthritis|A Phase 2, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel-group,Efficacy Study of Apremilast (CC-10004)in Subjects With Erosive Hand Osteoarthritis|Completed||Phase 2|30|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 23:21:46.908231|2018-05-31 23:21:46.908231
NCT01200459|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2014-12-05|2010-09-10|2010-09-13|Estimate|||||||2014-12-05|2014-12-08|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SMART||SMART: A Social and Mobile Weight Control Program for Young Adults|SMART: A Social and Mobile Weight Control Program for Young Adults|Completed||N/A|404|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 23:21:47.003071|2018-05-31 23:21:47.003071
NCT01200446|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-05-25|2010-09-10|2010-09-13|Estimate|||||||2011-05-25|2011-05-26|Estimate|October 2010||2010-10-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Docosahexaenoic Acid (DHA) as a Nutritional Treatment for Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Completed||N/A|16|Anticipated|Indiana University||2|||f||||f||||||||||2018-05-31 23:21:47.054317|2018-05-31 23:21:47.054317
NCT01200433|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2016-05-05||2016-10-31|2010-09-10|2010-09-13|Estimate|2016-05-05|2016-06-13|Estimate||||2016-10-31|2016-12-14|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effects of Dexmedetomidine and Propofol on Cerebral Blood Flow and Brain Oxygenation During Deep Brain Stimulation||Completed||N/A|44|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 23:21:47.126827|2018-05-31 23:21:47.126827
NCT01200420|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2012-01-26|2010-09-10|2010-09-13|Estimate|||||||2012-01-26|2012-01-31|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (Miravirsen) Administered to Treatment-Naïve Subjects With Chronic Hepatitis C (CHC) Infection|Completed||Phase 2|38|Actual|Santaris Pharma A/S||2|||f||||t||||||||||2018-05-31 23:21:47.504634|2018-05-31 23:21:47.504634
NCT01200407|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2016-03-17|2010-09-10|2010-09-13|Estimate|||||||2016-03-17|2016-03-21|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients|An Open Label, Non-interventional Study Of The Safety, Tolerability, And Efficacy Of Amlodipine And Olmesartan Medoxomil (Normetec) In Filipino Patients With Hypertension: A Post Marketing Surveillance Study|Terminated|||615|Actual|Pfizer|||1|The requirement for Post Marketing Surveillance was lifted by the Philippine FDA|f||||f||||||||||2018-05-31 23:21:47.622322|2018-05-31 23:21:47.622322
NCT01200394|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10||2017-08-09|2017-08-09|2010-09-10|2010-09-13|Estimate||||2017-08-09|2017-08-11|Actual|2017-08-09|2017-08-11|Actual|December 2010|Actual|2010-12-31|August 2017|2017-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Once-daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) In Adults With Type 2 Diabetes And Overt Nephropathy|Completed||Phase 2|256|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:21:47.814059|2018-05-31 23:21:47.814059
NCT01200381|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2014-11-21|2010-09-10|2010-09-13|Estimate|||||||2014-11-21|2014-11-24|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|InContact||INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients With Remotely Monitored Implanted Cardioverter Defibrillators (ICD) SysTems|INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients With Remotely Monitored ICD SysTems|Completed||N/A|210|Actual|St. Jude Medical||3|||f||||f||||||||||2018-05-31 23:21:48.26161|2018-05-31 23:21:48.26161
NCT01200368|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2012-09-12||2014-07-25|2010-09-10|2010-09-13|Estimate|2012-09-12|2012-10-12|Estimate||||2014-07-25|2014-08-01|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants|A Phase 3, Randomized, Active-controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-label DTaP in Healthy Japanese Infants|Completed||Phase 3|551|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:21:48.581411|2018-05-31 23:21:48.581411
NCT01200355|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2017-05-05||2018-04-04|2010-09-10|2010-09-13|Estimate|2017-06-19|2017-07-24|Actual||||2018-04-04|2018-05-07|Actual|September 9, 2010|Actual|2010-09-09|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|April 20, 2017|Actual|2017-04-20||Interventional|||Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome|A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome|Completed||Phase 4|113|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 23:21:53.42115|2018-05-31 23:21:53.42115
NCT01200342|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2015-11-13||2016-01-13|2010-09-09|2010-09-13|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Due to inadequate enrollment of study participants, no statistical analysis were able to be performed.|Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma|Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma|Terminated||Phase 2|7|Actual|M.D. Anderson Cancer Center||1||Pharmaceutical company no longer manufacturing investigational product.|f||||f||||||||||2018-05-31 23:21:53.82714|2018-05-31 23:21:53.82714
NCT01200329|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-02-14|2010-09-10|2010-09-13|Estimate|||||||2018-02-14|2018-02-15|Actual|June 2011|Actual|2011-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease|High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic Cell Support for Patients With Relapsed/Refractory Hodgkin's Disease|Active, not recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:21:54.19922|2018-05-31 23:21:54.19922
NCT01200316|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-11-28|2010-09-10|2010-09-13|Estimate|||||||2017-11-28|2017-11-30|Actual|February 1, 2012|Actual|2012-02-01|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Rocking Motion: Physiologic Effect on the Surgical Stress Response|Rocking Motion: Physiologic Effect on the Surgical Stress Response|Completed||Phase 1|86|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 23:21:54.434361|2018-05-31 23:21:54.434361
NCT01200303|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-08-03|2010-09-10|2010-09-13|Estimate|||||||2015-08-03|2015-08-05|Estimate|June 2005||2005-06-30|August 2015|2015-08-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|ncCTC||Evaluation of Computer-assisted, Non-cathartic CT Colonography|Prospective Evaluation of Computer-Assisted, Non-Cathartic CT Colonography for Detection of Adenomatous Colonic Polyps in a Screening Cohort|Completed||Phase 2/Phase 3|605|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 23:21:54.520477|2018-05-31 23:21:54.520477
NCT01200290|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2018-03-24|2014-09-29|2018-05-11|2010-09-10|2010-09-13|Estimate|2018-05-11|2018-05-14|Actual|2014-09-29|2014-10-08|Estimate|2018-05-11|2018-05-14|Actual|April 2011||2011-04-30|May 2018|2018-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||All enrolled participants who received at least 1 dose of study drug.|A Study in Participants With End-Stage Renal Disease|An Exploratory/Proof of Concept Investigation of the Safety and Pharmacodynamics of LY2127399 in HLA-Presensitized Patients With End-Stage Renal Disease Awaiting Transplantation|Completed||Phase 2|18|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:21:54.656943|2018-05-31 23:21:54.656943
NCT01200277|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2014-11-17|2010-09-10|2010-09-13|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|VertosIV||A Trial of Vertebroplasty for Painful Acute Osteoporotic Vertebral Fractures|A Randomised Sham Controlled Trial of Vertebroplasty for Painful Acute Osteoporotic Vertebral Fractures|Completed||Phase 3|80|Actual|Elisabeth-TweeSteden Ziekenhuis||2|||f||||f||||||||||2018-05-31 23:21:55.251247|2018-05-31 23:21:55.251247
NCT01200264|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2014-07-14|2010-09-10|2010-09-13|Estimate|||||||2014-07-14|2014-07-15|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2012|Anticipated|2012-09-30|December 2011|Anticipated|2011-12-31||Interventional|||Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy|Open-Label Study to Assess the Safety and Efficacy of Apremilast in Patients With Chronic Plaque Psoriasis Who Have Failed One Course of Biologic Therapy.|Withdrawn||Phase 2|0|Actual|Duke University||1||Contract never executed; withdrawn by sponsor|f||||f||||||||||2018-05-31 23:21:55.322282|2018-05-31 23:21:55.322282
NCT01200251|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2014-07-14|2010-09-10|2010-09-13|Estimate|||||||2014-07-14|2014-07-16|Estimate|February 2007||2007-02-28|September 2010|2010-09-30|December 2008|Actual|2008-12-31|September 2007|Actual|2007-09-30||Interventional|||Study of Bimatoprost Gel on Eyelash Growth|The Role of Bimatoprost Eyelash Gel in Chemotherapy-induced Madarosis: an Analysis of Efficacy and Safety|Completed||Phase 3|20|Actual|Duke University||2|||f||||f||||||||||2018-05-31 23:21:55.454657|2018-05-31 23:21:55.454657
NCT01200238|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2018-01-30|2010-09-10|2010-09-13|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2010||2010-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|May 14, 2016|Actual|2016-05-14||Interventional|||STA-9090(Ganetespib) in Metastatic Ocular Melanoma|A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma|Active, not recruiting||Phase 2|30|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 23:21:55.617656|2018-05-31 23:21:55.617656
NCT01200225|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2016-11-01|2010-09-10|2010-09-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)|Prospective Observational Study to Asses the Insulin Resistance (IR) and Its Impact on Sustained Virological Response in a Cohort of HCV-infected Patients Treated With Pegasys and Copegus|Completed|||1155|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:21:55.695907|2018-05-31 23:21:55.695907
NCT01200212|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2013-05-21|2010-09-10|2010-09-13|Estimate|||||||2013-05-21|2013-05-22|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|TABEA||A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer|A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer|Terminated||Phase 3|432|Anticipated|German Breast Group||2||"A planed interim analysis shows no benefits, but higher adverse event rates for the~   experimental arm."|f||||t||||||||||2018-05-31 23:21:55.755821|2018-05-31 23:21:55.755821
NCT01200199|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2013-03-07|2010-09-10|2010-09-13|Estimate|||||||2013-03-07|2013-03-11|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Validity of Electronic Diary for Monitoring Varicose Veins Symptoms|Performance of Daily Electronic Diary to Capture Venous Symptoms Before and After Intervention for Great Saphenous Vein Incompetence|Completed|||45|Actual|BTG International Inc.|||1||f||||f||||||||||2018-05-31 23:21:55.854866|2018-05-31 23:21:55.854866
NCT01200186|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2015-10-15|2010-09-10|2010-09-13|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Observational|||Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction|Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction|Completed|||3258|Actual|Bayer|||2||f||||f||||||||||2018-05-31 23:21:55.909573|2018-05-31 23:21:55.909573
NCT01200173|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2016-11-23|2010-09-10|2010-09-13|Estimate|||||||2016-11-23|2016-11-25|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|July 2007|Actual|2007-07-31|April 2007|Actual|2007-04-30||Interventional|||Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers|Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers|Completed||N/A|600|Actual|Danone Research||2|||f||||||||||||||2018-05-31 23:21:55.994187|2018-05-31 23:21:55.994187
NCT01200160|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|2013-04-29||2014-05-15|2010-09-10|2010-09-13|Estimate|2014-05-15|2014-06-06|Estimate||||2014-05-15|2014-06-06|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational||Intent-To-Treat (ITT) population defined as all enrolled subjects who received at least one dose of study medication|Study of the Effectiveness and Safety of Niaspan ® in the Treatment of Lipid Abnormalities in Latin America|Post-Marketing Observational Study on the Effectiveness and Safety of Niaspan® in the Treatment of Lipid Abnormalities in Latin America|Completed|||128|Actual|Abbott|Expected sample size was not achieved due to supply issues with the new formulation in Mexico and the local decision in Colombia to cancel marketing the product in the country.||1||f||||||||||||||2018-05-31 23:21:56.06584|2018-05-31 23:21:56.06584
NCT01200147|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2010-09-10|2010-09-10|2010-09-13|Estimate|||||||2010-09-10|2010-09-13|Estimate||||September 2010|2010-09-30||||||||Interventional|||Effectiveness of Rupture of Schatzki's Ring Using Biopsy Forceps Versus SIngle Dilation|Effectiveness of Rupture of Schatzki's Ring Using Biopsy Forceps Versus SIngle Dilation|Unknown status|Not yet recruiting|N/A|||Nova Scotia Health Authority||2|||f||||t||||||||||2018-05-31 23:21:56.265574|2018-05-31 23:21:56.265574
NCT01200134|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2012-11-16|2010-09-10|2010-09-13|Estimate|||||||2012-11-16|2012-11-19|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|HYPONCO||HYPONCO - Hypoxia in Brain Tumors|Hypoxia Diagnosis and Evaluation Using F-MISO PET and Biomarkers in Brain Tumors|Completed||Phase 2|39|Actual|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 23:21:56.327718|2018-05-31 23:21:56.327718
NCT01200121|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-04-10|2010-09-10|2010-09-13|Estimate|||||||2015-04-10|2015-04-13|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers|Double-blind, Placebo-controlled, Randomized Phase II-study Investigating the Efficacy of Bevacizumab for Symptom Control in Patients With Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers|Completed||Phase 2|53|Actual|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 23:21:56.398938|2018-05-31 23:21:56.398938
NCT01200108|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2011-11-14|2010-09-10|2010-09-13|Estimate|||||||2011-11-14|2011-11-15|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma|A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Tolerability, Safety and Efficacy of AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects With Asthma Requiring Chronic Oral Corticosteroid Treatment|Completed||Phase 2|||Activaero GmbH||4|||f||||t||||||||||2018-05-31 23:21:56.510574|2018-05-31 23:21:56.510574
NCT01200095|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-10|2010-09-10|2010-09-13|Estimate|||||||2010-09-10|2010-09-13|Estimate|January 2003||2003-01-31|September 2010|2010-09-30|December 2008|Actual|2008-12-31|||||Observational|||Posterior Cruciate Ligament Reconstruction Using Knot/Press-fit Technique|Non-hardware Posterior Cruciate Ligament Reconstruction Using Knot/Press-fit Technique With Periosteum-Evenloping Hamstrings Tendon Autograft|Completed|||30|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:21:56.618762|2018-05-31 23:21:56.618762
NCT01200082|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-09-07|2010-09-09|2010-09-13|Estimate|||||||2017-09-07|2017-09-11|Actual|November 2011|Actual|2011-11-30|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases|Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases|Recruiting|||400|Anticipated|University of Nebraska|||2||f||||f|f|f||||Samples Without DNA|"~     lood samples will be collected from healthy volunteers at their 1st visit. Urine samples will~     be obtained from healthy controntrols and patients with hepatobiliary diseases over time.~   "|||2018-05-31 23:21:56.65714|2018-05-31 23:21:56.65714
NCT01200069|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2016-02-24||2017-02-27|2010-09-09|2010-09-13|Estimate|2016-09-27|2016-11-18|Estimate||||2017-02-27|2017-03-29|Actual|July 2010||2010-07-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia|Intravenous Ibuprofen/Caldolor for Post-Electroconvulsive Therapy Myalgia|Terminated||Phase 4|14|Actual|Rutgers, The State University of New Jersey||2||unable to increase to target enrollment|f||||f||||||||No||2018-05-31 23:21:56.734016|2018-05-31 23:21:56.734016
NCT01200056|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-02-27|2010-09-10|2010-09-13|Estimate|||||||2013-02-27|2013-02-28|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|VENUS||Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment|A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound|Completed||Phase 4|40|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:21:57.138587|2018-05-31 23:21:57.138587
NCT01200043|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-05-07|2010-09-10|2010-09-13|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2010||2010-07-31|May 2018|2018-05-31|December 1, 2014|Actual|2014-12-01|December 2014|Actual|2014-12-31||Interventional|SUCRE||Metabolic Impact of Fructose Restriction in Obese Children|Metabolic Impact of Fructose Restriction in Obese Children|Completed||N/A|54|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 23:21:57.257474|2018-05-31 23:21:57.257474
NCT01200030|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2010-09-10|2010-09-10|2010-09-13|Estimate|||||||2010-09-10|2010-09-13|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effects of Home-based Program in Improving Sitting Balance and Upper Limb Functions in Patients With Stroke||Unknown status|Recruiting|N/A|36|Anticipated|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 23:21:57.385783|2018-05-31 23:21:57.385783
NCT01199666|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2014-07-24|2010-09-10|2010-09-13|Estimate|||||||2014-07-24|2014-07-25|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Text Message Reminder-Recalls For Early Childhood Vaccination|Text 4 Health-Kids: Text Message Reminder-Recalls For Early Childhood Vaccination|Completed||N/A|2586|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 23:22:03.14839|2018-05-31 23:22:03.14839
NCT01200017|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-11-22|2010-09-10|2010-09-13|Estimate|||||||2017-11-22|2017-11-27|Actual||||November 2017|2017-11-30||||||||Expanded Access|||Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant|An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients|Available|||||University of California, San Francisco|||||||||||||||||||2018-05-31 23:21:57.462257|2018-05-31 23:21:57.462257
NCT01200004|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-07-31|2010-09-10|2010-09-13|Estimate|||||||2013-07-31|2013-08-02|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide|A Phase I Study of Epigenetic Immunomodulation Through the Use of Azacitidine, Lenalidomide, and Grifola Frondosa in Patients With Advanced Malignancy|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||4||Slow Accrual.|f||||f||||||||||2018-05-31 23:21:57.553376|2018-05-31 23:21:57.553376
NCT01199991|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-03-30|2010-09-09|2010-09-13|Estimate|||||||2016-03-30|2016-04-01|Estimate|August 2010||2010-08-31|March 2016|2016-03-31||||August 2026|Anticipated|2026-08-31||Observational|||Comparison of Xtreme CT and DXA Bone Densitometry|Comparison of Xtreme CT and DXA Bone Densitometry|Active, not recruiting|||400|Anticipated|Massachusetts General Hospital|||1||f||||||||||||||2018-05-31 23:21:57.632413|2018-05-31 23:21:57.632413
NCT01199978|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-12-19|2010-09-10|2010-09-13|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2010||2010-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma|Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:21:57.694385|2018-05-31 23:21:57.694385
NCT01199965|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2013-08-19||2013-12-09|2010-09-10|2010-09-13|Estimate|2013-08-19|2013-10-22|Estimate||||2013-12-09|2014-01-09|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers|An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004) in Smoking and Non-Smoking Adult Volunteers|Completed||Phase 1/Phase 2|47|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:21:57.777042|2018-05-31 23:21:57.777042
NCT01199952|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2014-10-28|2010-09-10|2010-09-13|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PPR||RCT: Can a Single Counseling Phone Call Improve Contraception After an Abortion?|A Randomized Controlled Trial: Contraceptive Counseling After an Abortion|Completed||N/A|234|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:21:58.095834|2018-05-31 23:21:58.095834
NCT01199939|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2013-10-04||2013-10-04|2010-09-09|2010-09-13|Estimate|2013-10-04|2013-12-04|Estimate||||2013-10-04|2013-12-04|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|INROADS||A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients|A Multicenter, Single Arm, Open-Label Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients|Completed||Phase 2|54|Actual|Tibotec, Inc||1|||f||||f||||||||||2018-05-31 23:21:58.196205|2018-05-31 23:21:58.196205
NCT01199926|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2015-04-29||2015-04-29|2010-09-10|2010-09-13|Estimate|2015-04-29|2015-05-15|Estimate||||2015-04-29|2015-05-15|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Effect of Vitamin D Supplementation on Muscle Mass and Function|Impact of Vitamin D Supplementation on Strength and Lean Mass Accumulation During an Exercise Intervention|Completed||Phase 4|34|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 23:21:58.51061|2018-05-31 23:21:58.51061
NCT01199913|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2014-09-08|2010-09-09|2010-09-13|Estimate|||||||2014-09-08|2014-09-09|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||POCD in Elderly Patients Following Desflurane or Sevoflurane General Anesthesia|Incidence of Postoperative Cognitive Dysfunction in Elderly Patients Following Desflurane or Sevoflurane General Anesthesia: A Randomized, Controlled Trial|Completed|||110|Actual|Loma Linda University|||1||f||||f||||||||||2018-05-31 23:21:58.77697|2018-05-31 23:21:58.77697
NCT01199900|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-12-16|2010-09-10|2010-09-13|Estimate|||||||2010-12-16|2010-12-17|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism|An Open Label Study Evaluating The Effect Of Single Doses Of PF-04171327 And Prednisone On Carbohydrate Metabolism Utilizing An Oral Glucose Tolerance Test In Healthy Adult Subjects|Completed||Phase 1|18|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 23:21:58.833712|2018-05-31 23:21:58.833712
NCT01199887|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-07-26|2010-09-10|2010-09-13|Estimate|||||||2013-07-26|2013-07-29|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis|A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 1|30|Actual|ImmuneWorks||1|||f||||f||||||||||2018-05-31 23:21:58.904687|2018-05-31 23:21:58.904687
NCT01199874|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-08-28|2010-09-09|2010-09-13|Estimate|||||||2013-08-28|2013-08-30|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|||Immunogenicity of Rotavirus Vaccine|The Immunogenicity of Rotavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding Around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine|Completed||Phase 4|1140|Actual|PATH||6|||f||||f||||||||||2018-05-31 23:21:58.988594|2018-05-31 23:21:58.988594
NCT01199861|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2012-05-15||2012-05-15|2010-09-10|2010-09-13|Estimate|2012-05-15|2012-06-19|Estimate||||2012-05-15|2012-06-19|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)|A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)|Completed||Phase 3|138|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:21:59.082059|2018-05-31 23:21:59.082059
NCT01199653|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2010-09-10|2010-09-10|2010-09-13|Estimate|||||||2010-09-10|2010-09-13|Estimate|August 2004||2004-08-31|September 2010|2010-09-30|November 2009|Actual|2009-11-30|October 2007|Actual|2007-10-31||Interventional|||Study Comparing Plate Stabilization to Conservative Treatment in Midshaft Clavicle Fractures|Nonoperative Versus Operative Treatment of Midshaft Clavicle Fractures - A Randomized Controlled Trial|Completed||Phase 2/Phase 3|60|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 23:22:03.259463|2018-05-31 23:22:03.259463
NCT01199848|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-03-15|2010-09-10|2010-09-13|Estimate|||||||2018-03-15|2018-03-16|Actual|September 15, 2010|Actual|2010-09-15|March 2018|2018-03-31|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|STRB||A Study of Strawberries and Disease Risk|Effect of Strawberry on Oxidative Stress- and Inflammatory-mediated Insulin Resistance (IR) in Humans: Combating a Major Risk Factor for Diabetes and Cardiovascular Disease Through Diet|Active, not recruiting||N/A|25|Actual|Institute for Food Safety and Health, United States||5|||f||||f||||||||No||2018-05-31 23:21:59.488563|2018-05-31 23:21:59.488563
NCT01199835|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-06-10|2010-09-10|2010-09-13|Estimate|||||||2014-06-10|2014-06-11|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|MEPEB||The Effects of Dairy Products on Energy Balance|The Effects of Dairy Products on Energy Balance|Completed||N/A|80|Actual|University of Copenhagen||2|||f||||||||||||||2018-05-31 23:21:59.637272|2018-05-31 23:21:59.637272
NCT01199822|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2016-11-18||2017-03-03|2010-09-09|2010-09-13|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|September 2010||2010-09-30|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||All enrolled participants who received at least 1 dose of study drug.|Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors|A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-3G3 Administered in a 2-week, or 3-week Schedule to Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|16|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:21:59.726353|2018-05-31 23:21:59.726353
NCT01199809|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2016-10-26|2010-09-09|2010-09-13|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of RO5310074 in Patients With Psoriatic Arthritis|A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis|Completed||Phase 1|19|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:22:00.310936|2018-05-31 23:22:00.310936
NCT01199783|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2015-05-04|2010-09-10|2010-09-13|Estimate|||||||2015-05-04|2015-05-05|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment|Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment|Terminated||Phase 3|1|Actual|Ruhr University of Bochum||2||"Patient number to be enrolled not reachable in prospected time frame, decision to stop the~   study prematurely was made."|f||||f||||||||||2018-05-31 23:22:00.396622|2018-05-31 23:22:00.396622
NCT01199770|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-03-15|2010-09-09|2010-09-13|Estimate|||||||2018-03-15|2018-03-16|Actual|September 15, 2010|Actual|2010-09-15|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|SET||Pasta Formulations, Portion Sizes and Their Effect on Appetite|Understanding Pasta Formulations and Portion Size on Satiety in Healthy Weight Women|Active, not recruiting||N/A|24|Actual|Institute for Food Safety and Health, United States||7|||f||||f||||||||||2018-05-31 23:22:00.477298|2018-05-31 23:22:00.477298
NCT01199757|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-08-11|2010-09-09|2010-09-13|Estimate|||||||2017-08-11|2017-08-14|Actual|July 10, 2009|Actual|2009-07-10|August 2017|2017-08-31|August 1, 2009|Actual|2009-08-01|August 1, 2009|Actual|2009-08-01||Observational|||A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures|A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures|Completed|||540|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 23:22:00.563863|2018-05-31 23:22:00.563863
NCT01199744|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2011-03-17||2017-06-06|2010-09-09|2010-09-13|Estimate|2011-03-17|2011-04-12|Estimate||||2017-06-06|2017-07-06|Actual|November 2009||2009-11-30|June 2017|2017-06-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Observational|SSMP||Relenza® Sentinel Site Monitoring Program in Japan|Collection of Patients' Background InformationRelenza® Sentinel Site Monitoring Program in Japan|Completed|||1575|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 23:22:00.693713|2018-05-31 23:22:00.693713
NCT01199731|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2017-08-17|2012-03-29|2017-10-12|2010-09-09|2010-09-13|Estimate|2017-10-09|2017-10-12|Actual|2012-03-29|2012-04-02|Estimate|2017-10-12|2017-11-17|Actual|October 5, 2010|Actual|2010-10-05|October 2017|2017-10-31|July 19, 2011|Actual|2011-07-19|July 19, 2011|Actual|2011-07-19||Interventional|SONNET||Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection|A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance|Terminated||Phase 2|30|Actual|ViiV Healthcare|Enrollment in this study was terminated prematurely on 01 April 2011 due to a safety finding (convulsion) in 5/20 participants receiving GSK2248761.|3||The study was stopped due to safety concerns|f||||f||||||||||2018-05-31 23:22:01.100595|2018-05-31 23:22:01.100595
NCT01199718|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2011-06-13|2010-09-09|2010-09-13|Estimate|||||||2011-06-13|2011-06-15|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|||Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|22|Anticipated|Cylene Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:22:02.068777|2018-05-31 23:22:02.068777
NCT01199705|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2013-01-01||2014-11-25|2010-09-09|2010-09-13|Estimate|2013-03-18|2013-03-20|Estimate||||2014-11-25|2014-12-12|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)|A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency|Completed||Phase 3|25|Actual|CSL Behring||1|||f||||f||||||||||2018-05-31 23:22:02.173514|2018-05-31 23:22:02.173514
NCT01199692|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-07-21|2010-09-09|2010-09-13|Estimate|||||||2017-07-21|2017-07-24|Actual|August 2010||2010-08-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|||Characterization of Metabolic Biomarkers in Varying Subjects|Characterization of Metabolic Biomarkers in Subjects of Varying Age, Gender, Ethnicity, Body Mass Distribution, Dietary Habits, Exercise Habits, Medication Requirements, and Disease State Burden|Recruiting|||250|Anticipated|CPL Associates|||8||f||||f||||||Samples With DNA|"~     Blood, stool, urine~   "|||2018-05-31 23:22:02.808869|2018-05-31 23:22:02.808869
NCT01199679|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-06-17|2010-09-10|2010-09-13|Estimate|||||||2015-06-17|2015-06-19|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|GERD||Rubber Band Ligation and Mucosectomy for Gastroesophageal Reflux Disease (GERD)|Evaluation of Distal Esophageal and Cardia Rubber Band Ligation and Mucosectomy in the Treatment of Subjects With Gastroesophageal Reflux Disease|Terminated||N/A|10|Actual|Cook Group Incorporated||2|||f||||||||||||||2018-05-31 23:22:02.993228|2018-05-31 23:22:02.993228
NCT01199640|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-09|2010-09-09|2010-09-13|Estimate|||||||2010-09-09|2010-09-13|Estimate|May 2005||2005-05-31|September 2010|2010-09-30|October 2007|Actual|2007-10-31|July 2007|Actual|2007-07-31||Interventional|||Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis|A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis|Completed||Phase 2|50|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:22:03.384141|2018-05-31 23:22:03.384141
NCT01199627|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2013-02-06|2010-09-10|2010-09-13|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|TXA-CRT||Tranexamic Acid Versus Placebo for the Reduction of Blood Loss in Total Hip Replacement Surgery|Tranexamic Acid Versus Placebo for the Reduction of Blood Loss in Total Hip Replacement Surgery - Randomized, Controlled and Double-masked Trial|Completed||Phase 3|114|Actual|Basque Health Service||3|||f||||f||||||||||2018-05-31 23:22:03.448469|2018-05-31 23:22:03.448469
NCT01199614|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-01-31|2010-09-09|2010-09-13|Estimate|||||||2017-01-31|2017-02-02|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism|HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism|Active, not recruiting||Phase 3|75|Anticipated|Columbia University||1|||f||||t||||||||Undecided||2018-05-31 23:22:03.53846|2018-05-31 23:22:03.53846
NCT01199601|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2013-09-04||2017-04-17|2010-09-09|2010-09-13|Estimate|2014-02-12|2014-03-28|Estimate||||2017-04-17|2017-05-17|Actual|June 2008||2008-06-30|April 2017|2017-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||The 1291 reflects the husbands interviewed at 12 months (n=447). The husbands were not analyzed as part of the RCT.|Blood-borne Infection Screening in an Afghan Antenatal Population|Pilot Educational Intervention to Determine Effect of Intrapartum Testing and Concentrated Postpartum Counseling on Birth Spacing, Breastfeeding, and Infant Vaccination Completion in a Kabul Urban Population.|Completed||N/A|1291|Actual|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 23:22:03.634084|2018-05-31 23:22:03.634084
NCT01199588|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2014-04-29|2010-09-09|2010-09-13|Estimate|||||||2014-04-29|2014-05-01|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|NOVEL2||A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers|A Randomized, Parallel Group, Dose-Ranging, Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nexagon® in the Treatment of Subjects With a Venous Leg Ulcer|Completed||Phase 2|300|Anticipated|CoDa Therapeutics Inc.||4|||f||||t||||||||||2018-05-31 23:22:03.901247|2018-05-31 23:22:03.901247
NCT01199575|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2016-05-23|2010-09-09|2010-09-13|Estimate|||||||2016-05-23|2016-05-24|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|January 2015|Actual|2015-01-31||Interventional|||Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 23:22:04.049907|2018-05-31 23:22:04.049907
NCT01199562|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-06-03|2010-09-10|2010-09-13|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant|Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function|Completed||N/A|153|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:22:04.194174|2018-05-31 23:22:04.194174
NCT01199549|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-09|2010-09-09|2010-09-13|Estimate|||||||2010-09-09|2010-09-13|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Bioavailability Study of Different Dietary Antioxidants in Volunteers|Phase 1 Bioavailability Study of Different Dietary Antioxidants in Volunteers|Completed|||90|Actual|Cambridge Theranostics Ltd|||3||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:22:04.345956|2018-05-31 23:22:04.345956
NCT01199536|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-11-22|2010-09-10|2010-09-13|Estimate|||||||2013-11-22|2013-11-25|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers|Observational Study to Evaluate Helicobacter Pylori Eradication at the End of Routine Triple Eradication Therapy With Duodenal Ulcer Relapses Control.|Completed|||59|Actual|AstraZeneca|||1||f||||f||||||Samples Without DNA|"~     Blood samples for Hematology (whole blood) and Chemistry (serum), gasric mucosa biopsies~     taken during esophagogastroduodenoscopy (EGDS) in routine practice of Moscow Medical Academy~     n/a I.M. Sechenov, Moscow State Medical and Stomatological University, Central Clinical~     Hospital of Presidential Administration~   "|||2018-05-31 23:22:04.411741|2018-05-31 23:22:04.411741
NCT01199523|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-07-01|2010-09-09|2010-09-13|Estimate|||||||2013-07-01|2013-07-03|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females|A Phase 1, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Crossover Study to Evaluate the Effect of Repeat Oral Doses of Mirabegron on Cardiac Repolarization in Healthy Male and Female Adult Subjects|Completed||Phase 1|352|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 23:22:04.471328|2018-05-31 23:22:04.471328
NCT01199510|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2016-11-17|2010-09-09|2010-09-13|Estimate|||||||2016-11-17|2016-11-18|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy Evaluation of SYSTANE® ULTRA in Patients Scheduled for Cataract Surgery||Completed||Phase 4|40|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:22:04.581633|2018-05-31 23:22:04.581633
NCT01199497|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-07-11|2010-09-10|2010-09-13|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2011||2011-08-31|July 2017|2017-07-31|January 2013|Anticipated|2013-01-31|August 2012|Anticipated|2012-08-31||Interventional|||Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute Rhinitis|Multicenter Clinical Trial Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms in Subjects Above 12 Years of Age, Suffering From Non-productive Cough and Acute Rhinitis.|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||||||||||||2018-05-31 23:22:04.63913|2018-05-31 23:22:04.63913
NCT01199471|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2011-11-30||2012-01-24|2010-09-09|2010-09-13|Estimate|2011-11-30|2012-01-06|Estimate||||2012-01-24|2012-01-26|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane|A Multi-center Registry to Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane|Completed|||4000|Actual|Abbott|Types of surgery not restricted/stratified in the study and no standard practice in China on inhalation and intravenous anesthesia methods may skew/bias results. Gaps in study design and multiple outcome parameters make drawing conclusions difficult.||1||f||||||||||||||2018-05-31 23:22:04.777092|2018-05-31 23:22:04.777092
NCT01199458|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2016-11-08|2010-09-10|2010-09-13|Estimate|||||||2016-11-08|2016-11-09|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of an Opioid on the Lower Esophageal Sphincter During Anesthesia Induction|The Effect of Alfentanil on the Lower Esophageal Sphincter During Anesthesia Induction - a Study in Volunteers|Completed||Phase 4|17|Actual|Region Örebro County||2|||f||||t||||||||Yes|Original data can be available by contacting the principal investigator|2018-05-31 23:22:04.990235|2018-05-31 23:22:04.990235
NCT01199445|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2016-01-05|2010-09-10|2010-09-13|Estimate|||||||2016-01-05|2016-01-06|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|||Efficacy of Vitamin A in Fortified Extruded Rice in School Children|Efficacy of Vitamin A in Fortified Extruded Rice in School Children in Satun, Thailand|Completed||Early Phase 1|50|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 23:22:05.059971|2018-05-31 23:22:05.059971
NCT01199432|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-06-09|2010-09-10|2010-09-13|Estimate|||||||2015-06-09|2015-06-10|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer|A Phase Ⅳ Randomized Clinical Trial of Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer|Completed||Phase 4|501|Anticipated|Peking University||3|||f||||t||||||||||2018-05-31 23:22:05.195827|2018-05-31 23:22:05.195827
NCT01199419|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2014-07-16|2010-09-10|2010-09-13|Estimate|||||||2014-07-16|2014-07-18|Estimate|January 2004||2004-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP|Cost-effectiveness of Percutaneous Coronary Intervention With TAXUS Stents in Patients With Multivessel Coronary Artery Disease Compared With Aortocoronary Bypass Surgery 5 Years After Intervention|Completed|||207|Actual|Medical University of Vienna|||2||f||||||||||||||2018-05-31 23:22:05.265485|2018-05-31 23:22:05.265485
NCT01199406|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-10|2010-09-10|2010-09-13|Estimate|||||||2010-09-10|2010-09-13|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|INTENSE||Pain Reduction After Cholecystectomy|Combined Preincisional Infiltration and Intraperitoneal Instillation of Levobupivacaine for Postoperative Pain Reduction After Laparoscopic Cholecystectomy; A Double-blind Placebo-controlled Randomised Clinical Trial|Completed||Phase 4|80|Actual|Meander Medical Center||2|||f||||t||||||||||2018-05-31 23:22:05.337753|2018-05-31 23:22:05.337753
NCT01199393|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2015-07-27|2010-09-10|2010-09-13|Estimate|||||||2015-07-27|2015-07-29|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Observational|||Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer|Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer|Completed|||153|Actual|Beijing Cancer Hospital|||||f||||t||||||Samples With DNA|"~     about 4ml peripheral vein blood~   "|||2018-05-31 23:22:05.404322|2018-05-31 23:22:05.404322
NCT01199380|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-12-07|2010-09-09|2010-09-10|Estimate|||||||2010-12-07|2010-12-09|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms|Stage II Trial of Novel Behavioral Activation Intervention for Smoking Cessation|Unknown status|Recruiting|Phase 2|200|Anticipated|University of Maryland||2|||f||||f||||||||||2018-05-31 23:22:05.481216|2018-05-31 23:22:05.481216
NCT01199367|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-04-04|2010-09-09|2010-09-10|Estimate|||||||2014-04-04|2014-04-07|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer|A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumors Overexpress HER2|Terminated||Phase 1|11|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1||"The results of the dose escalation phase did not identify a well-tolerated dose that would~   permit further study in Phase 2."|f||||f||||||||||2018-05-31 23:22:05.551782|2018-05-31 23:22:05.551782
NCT01199354|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-06-08|2010-09-09|2010-09-10|Estimate|||||||2011-06-08|2011-06-09|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|July 2017|Anticipated|2017-07-31|||||Interventional|M-RIC||Skin Sparing Mastectomy and Immediate Breast Reconstruction With Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy (M-RIC)|Phase II Study: Assessing the Feasibility and Morbidity of Skin Sparing Mastectomy and Immediate Breast Reconstruction With Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma.|Unknown status|Recruiting|Phase 2|80|Anticipated|Clinique Clementville|||||f||||||||||||||2018-05-31 23:22:05.616059|2018-05-31 23:22:05.616059
NCT01199341|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2011-02-08|2010-09-09|2010-09-10|Estimate|||||||2011-02-08|2011-02-09|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin|A Phase I, Open Label, Randomised, Parallel Group Study of Repeated Oral Doses of AZD1981 (100 mg Twice Daily and 400 mg Twice Daily) for Two Weeks and Single Doses of Warfarin (25 mg) to Evaluate the Pharmacokinetic Interaction of AZD1981 and Warfarin and the Effect of AZD1981 on Warfarin Pharmacodynamics in Healthy Male Volunteers|Completed||Phase 1|28|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:22:05.781684|2018-05-31 23:22:05.781684
NCT01199328|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-11-18|2010-09-09|2010-09-10|Estimate|||||||2010-11-18|2010-11-19|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Evaluate the Interaction Between Aspirin and Nexium|A Phase I, Open, Two-way Crossover, Drug-drug Interaction Study Evaluating the Effect of Esomeprazole on the Pharmacodynamics of Acetylsalicylic Acid After 5 Days of Treatment|Completed||Phase 1|34|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:22:05.86723|2018-05-31 23:22:05.86723
NCT01197937|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2013-12-10|2010-09-08|2010-09-09|Estimate|||||||2013-12-10|2013-12-11|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Relationship of Realize Mysuccess Usage to Outcomes of Bariatric Surgery|Relationship of Realize Mysuccess Usage to Outcomes of Bariatric Surgery|Completed|||25000|Actual|University of Pennsylvania|||||f||||f||||||||||2018-05-31 23:22:32.224796|2018-05-31 23:22:32.224796
NCT01199315|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2011-02-16|2010-09-09|2010-09-10|Estimate|||||||2011-02-16|2011-02-17|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 in Young and Elderly Healthy Japanese Volunteers After Oral Single and Repeated Doses|Completed||Phase 1|24|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:22:05.961566|2018-05-31 23:22:05.961566
NCT01199302|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09||2015-12-14|2015-12-14|2010-09-09|2010-09-10|Estimate||||2015-12-14|2016-01-14|Estimate|2015-12-14|2016-01-14|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety Study in Subjects With Crohn's Disease|A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease|Terminated||Phase 2|67|Actual|Amgen||1||Per recommendation from DRT|f||||||||||||||2018-05-31 23:22:06.048361|2018-05-31 23:22:06.048361
NCT01199289|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05||2015-04-28|2015-04-28|2010-09-09|2010-09-10|Estimate||||2015-04-28|2015-05-15|Estimate|2015-04-28|2015-05-15|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects With Inadequately Controlled Asthma|Completed||Phase 2|315|Actual|Amgen||4|||f||||f||||||||||2018-05-31 23:22:06.197938|2018-05-31 23:22:06.197938
NCT01199276|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-07-24|2010-09-09|2010-09-10|Estimate|||||||2015-07-24|2015-07-27|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|HIPELD||Hip Fracture Surgery in Elderly Patients|An International, Multi-center, Randomized, Controlled Trial Evaluating The Effect of Xenon on Post-operative Delirium in Elderly Patients Undergoing Hip Fracture Surgery|Completed||Phase 2|256|Actual|Air Liquide Santé International||2|||f||||f||||||||||2018-05-31 23:22:06.381458|2018-05-31 23:22:06.381458
NCT01199263|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-05-23|2010-09-09|2010-09-10|Estimate|||||||2018-05-23|2018-05-24|Actual|December 6, 2010|Actual|2010-12-06|May 2018|2018-05-31||||September 1, 2019|Anticipated|2019-09-01||Interventional|||Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin NSC # 729968) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|110|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:22:06.495107|2018-05-31 23:22:06.495107
NCT01199250|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-05-27|2010-09-09|2010-09-10|Estimate|||||||2015-05-27|2015-05-29|Estimate|January 2100||2100-01-31|May 2015|2015-05-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Samples From Patients With Endometrial Cancer|Specialized Program of Research Excellence (SPORE) in Endometrial Cancer|Not yet recruiting|||3600|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 23:22:06.638605|2018-05-31 23:22:06.638605
NCT01199237|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|2014-04-08||2014-05-07|2010-09-09|2010-09-10|Estimate|2014-04-08|2014-05-08|Estimate||||2014-05-07|2014-05-16|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|||Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block|Effect of Anesthetic Choice (Sevoflurane Versus Desflurane) on Speed and Sustained Nature of Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block|Completed||Phase 4|107|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:22:06.726862|2018-05-31 23:22:06.726862
NCT01199224|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2017-11-17|2010-09-09|2010-09-10|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2010||2010-06-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors|A Phase 1, Single-Dose, Randomized, Group Sequential Cross-Over Study Evaluating the Bioavailability and Food Effect of Three Formulations of Veliparib on Pharmacokinetics in Subjects With Solid Tumors|Completed||Phase 1|27|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 23:22:06.939129|2018-05-31 23:22:06.939129
NCT01199211|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-10-24|2010-09-09|2010-09-10|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2011||2011-02-28|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|||Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism|Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism in Healthy Female Volunteers Training for a Marathon|Active, not recruiting|||500|Anticipated|University of California, San Francisco|||1||f||||t||||||Samples With DNA|"~     Plasma~   "|||2018-05-31 23:22:07.003121|2018-05-31 23:22:07.003121
NCT01199198|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-01-07|2010-09-09|2010-09-10|Estimate|||||||2015-01-07|2015-01-09|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Tolvaptan in Hyponatremic Cancer Patients|Randomized Placebo-Controlled Trial of Tolvaptan in Hyponatremic Patients With Cancer|Completed||Phase 4|52|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 23:22:07.059779|2018-05-31 23:22:07.059779
NCT01199185|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-06-17|2010-09-09|2010-09-10|Estimate|||||||2013-06-17|2013-06-18|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|TARGIT||Treating Adults at Risk for Weight Gain With Interactive Technology|Targeted Approaches to Weight Control for Young Adults|Unknown status|Active, not recruiting|Phase 3|330|Anticipated|University of Tennessee||2|||f||||t||||||||||2018-05-31 23:22:07.123375|2018-05-31 23:22:07.123375
NCT01199172|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2016-01-21|2010-09-09|2010-09-10|Estimate|||||||2016-01-21|2016-01-25|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|Prevention||Prevention and Treatment of Voice Problems in Teachers|Prospective Study of Prevention and Treatment of Voice Problems in Teachers|Completed||N/A|140|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 23:22:07.182785|2018-05-31 23:22:07.182785
NCT01199159|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2010-09-09|2010-09-09|2010-09-10|Estimate|||||||2010-09-09|2010-09-10|Estimate|January 2007||2007-01-31|September 2010|2010-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Preoperative Misoprostol in Reducing Blood Loss in Total Abdominal Hysterectomy (TAH)|A Pilot Study of the Preoperative Misoprostol in Reducing Operative Blood Loss During Hysterectomy|Completed||N/A|77|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:22:07.237451|2018-05-31 23:22:07.237451
NCT01199146|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2017-12-06||2017-12-06|2010-09-09|2010-09-10|Estimate|2017-12-06|2018-01-08|Actual||||2017-12-06|2018-01-08|Actual|September 10, 2010|Actual|2010-09-10|December 2017|2017-12-31|March 14, 2016|Actual|2016-03-14|January 4, 2013|Actual|2013-01-04||Interventional|||Abiraterone Post Ketoconazole for Prostate Cancer|A Phase II Study of Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC) and Prior Therapy With Ketoconazole|Completed||Phase 2|42|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 23:22:07.385254|2018-05-31 23:22:07.385254
NCT01199133|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2011-12-20|2010-09-09|2010-09-10|Estimate|||||||2011-12-20|2011-12-21|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children|A Randomised,Double-blind,Placebo-controlled,Multi National,Phase III Trial to Assess the Efficacy and Safety of 300 IR Sublingual Immunotherapy Administered as Allergen-based Tablets Once Daily to Adolescents and Children Above the Age of 5 Years, Suffering From House Dust Mite Allergic Rhinitis|Terminated||Phase 3|471|Actual|Stallergenes Greer||2||"Following the DSMB recommendation. Study population being insufficiently symptomatic to enable~   differentiation between treatment and placebo. No safety concerns"|f||||t||||||||||2018-05-31 23:22:07.598546|2018-05-31 23:22:07.598546
NCT01199120|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2010-09-09|2010-09-09|2010-09-10|Estimate|||||||2010-09-09|2010-09-10|Estimate|March 2009||2009-03-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Cognitive Effects of Omega-3 Supplements in Children With Mild to Moderate Malnutrition|Cognitive Effects of Omega-3 Supplements in Children With Mild to Moderate Malnutrition|Completed||Phase 2|75|Actual|Universidad Autonoma de Ciudad Juarez||1|||f||||f||||||||||2018-05-31 23:22:07.659685|2018-05-31 23:22:07.659685
NCT01199107|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-12-08|2010-09-09|2010-09-10|Estimate|||||||2014-12-08|2014-12-10|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)||Completed||Phase 3|9|Actual|Southern Methodist University||2|||f||||||||||||||2018-05-31 23:22:07.712327|2018-05-31 23:22:07.712327
NCT01199094|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-09|2010-09-09|2010-09-10|Estimate|||||||2010-09-09|2010-09-10|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5|Clinical Assessment of Patients With High Bone Mass Due to Mutation in Low Density Lipoprotein l Receptor 5|Completed|||38|Actual|Odense University Hospital|||1||f||||f||||||Samples With DNA|"~     Serum, plasma, DNA as well as fat and skin biopsies~   "|||2018-05-31 23:22:07.768335|2018-05-31 23:22:07.768335
NCT01199081|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-06-06|2010-09-09|2010-09-10|Estimate|||||||2013-06-06|2013-06-07|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|ARTEMIS AF LT||Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation|A Randomized, International, Multi-center, Open-label Study to Document Pharmacokinetics and Optimal Timing of Initiation of Dronedarone Treatment Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Whatever the Reason for the Change of Treatment.|Completed||Phase 4|154|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 23:22:07.835798|2018-05-31 23:22:07.835798
NCT01199068|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-12-21|2010-09-09|2010-09-10|Estimate|||||||2011-12-21|2011-12-22|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)|Phase 1b Study of CS-7017 in Combination With Erlotinib in Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Who Failed First-line Therapy|Completed||Phase 1|16|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 23:22:07.935008|2018-05-31 23:22:07.935008
NCT01199055|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-07-11|2010-09-09|2010-09-10|Estimate|||||||2011-07-11|2011-07-12|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)|Phase 1b Study of CS-7017 in Combination With Carboplatin/Paclitaxel in Chemotherapy-naïve Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|21|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 23:22:08.031573|2018-05-31 23:22:08.031573
NCT01199042|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2015-08-05||2016-03-28|2010-09-09|2010-09-10|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Bipap Automatic Servo Ventilation (autoSV) Advanced in Central Apnea Patients|BiPAP (Automatic Servo Ventilation) autoSV Advanced in Central Apnea Patients|Completed||N/A|29|Actual|Philips Respironics||1|||f||||f||||||||||2018-05-31 23:22:08.097033|2018-05-31 23:22:08.097033
NCT01199029|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-12-15|2010-09-09|2010-09-10|Estimate|||||||2010-12-15|2010-12-16|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate|An Open Label Study Evaluating The Effect Of Single Doses Of Pf-04308515 And Prednisone On Carbohydrate Metabolism Utilizing An Oral Glucose Tolerance Test In Healthy Adult Subjects|Completed||Phase 1|18|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 23:22:09.365116|2018-05-31 23:22:09.365116
NCT01199016|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2017-01-10||2017-01-10|2010-09-09|2010-09-10|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|September 2010||2010-09-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational||Safety analysis set included all participants who had at least one dose of study drug and had undergone at least 1 of the study procedures.|Effect of Prevnar 13 on Ear Infections in Children|"a Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children"|Completed|||239|Actual|Pfizer|||1||f||||f||||||Samples Without DNA|"~     Middle Ear Fluid for microbiologic analysis Nose and throat swab for microbiologic analysis~   "|||2018-05-31 23:22:09.460446|2018-05-31 23:22:09.460446
NCT01198990|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2017-02-17|2010-09-08|2010-09-10|Estimate|||||||2017-02-17|2017-02-23|Actual|October 2009||2009-10-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|SCALE||SCALE: Small Changes and Lasting Effects|SCALE: Small Changes and Lasting Effects|Completed||N/A|405|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No|No plan to share IPD has been created|2018-05-31 23:22:09.690224|2018-05-31 23:22:09.690224
NCT01198977|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2016-08-09||2017-01-10|2010-09-08|2010-09-10|Estimate|2016-08-09|2016-08-12|Estimate||||2017-01-10|2017-02-24|Actual|October 2009||2009-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional|MS-FIT|Participants were individuals with MS recruited through (a) outpatient clinics at Veterans Affairs (VA) Puget Sound Health Care System, (b) targeted mailings to veterans in the VA MS National Data Repository who lived within the state of Washington, and (c) non-VA community-based MS support groups in the greater Puget Sound area.|Telehealth-Based Exercise Program to Treat Fatigue in MS|Telehealth-Based Exercise Program to Treat Fatigue in MS|Completed||N/A|64|Actual|VA Office of Research and Development|Only ambulatory individuals were enrolled, thus high exclusion rate due to ambulation status. Outcome and mediating variables measured by validated self-report methods. A broad range of physical activity levels were included (most were low).|2|||f||||f||||||||No||2018-05-31 23:22:09.932015|2018-05-31 23:22:09.932015
NCT01198938|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2013-02-21|2010-09-09|2010-09-10|Estimate|||||||2013-02-21|2013-02-22|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Postoperative Melatonin Administration and Delirium Prevention in Patients Undergoing Vascular and Cardiac Surgery|Postoperative Melatonin Administration and Delirium Prevention in Patients Undergoing Vascular and Cardiac Surgery|Completed||N/A|100|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 23:22:10.933386|2018-05-31 23:22:10.933386
NCT01198925|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2018-05-04|2010-09-08|2010-09-10|Estimate|||||||2018-05-04|2018-05-11|Actual|September 23, 2010|Actual|2010-09-23|May 2018|2018-05-31|May 3, 2018|Actual|2018-05-03|November 16, 2012|Actual|2012-11-16||Interventional|||Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion|Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion|Completed||Phase 4|14|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:22:11.006626|2018-05-31 23:22:11.006626
NCT01198912|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2017-04-18|2010-09-09|2010-09-10|Estimate|||||||2017-04-18|2017-04-19|Actual|November 2010||2010-11-30|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|DOXYPOSTOP||Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial|Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.|Completed||Phase 2|33|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:22:11.08724|2018-05-31 23:22:11.08724
NCT01198899|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2012-01-11|2010-09-08|2010-09-10|Estimate|||||||2012-01-11|2012-01-12|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy|Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy|Completed|||540|Actual|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 23:22:11.175184|2018-05-31 23:22:11.175184
NCT01198886|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-05-11|2010-09-09|2010-09-10|Estimate|||||||2015-05-11|2015-05-13|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|January 2013|Actual|2013-01-31||Interventional|VIVE-1||The Vitality, Independence, and Vigor in Elders Study I Clinical Trial|Vitality, Independence, and Vigor in Elders Study (VIVE Study): Effects of an Exercise and Nutrition Program on Functionality in the Elderly|Completed||N/A|121|Actual|Tufts University||2|||f||||t||||||||||2018-05-31 23:22:11.254666|2018-05-31 23:22:11.254666
NCT01198873|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2013-01-10||2013-01-10|2010-09-09|2010-09-10|Estimate|2013-01-10|2013-02-12|Estimate||||2013-01-10|2013-02-12|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ODYSSEUS||Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement|A Placebo-Controlled, Double-Blind, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement|Terminated||Phase 4|76|Actual|Sanofi|Due to the early termination of the study, results should be cautiously interpreted. Indeed the number of participants was lower than planned (76 instead of 334) and the treatment period was shorter than planned (6 months instead of 12 months).|2|||f||||f||||||||||2018-05-31 23:22:11.386013|2018-05-31 23:22:11.386013
NCT01198860|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|||2017-10-10|2010-09-09|2010-09-10|Estimate|||||||2017-10-10|2017-10-11|Actual||||October 2017|2017-10-31||||||||Expanded Access|HBV||Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B|Tenofovir Disoproxil Fumarat 300 mg - Phyllanthus Urinaria 300mg - Adenosma Glutinosum 150mg - Eclipta Prostrata 150mg, Ascorbic Acid 500 mg Daily is Effective in the Long-term Treatment of Chronic and Acute Hepatitis B.|Available|||||Triệu, Nguyễn Thị, M.D.|||||f||||||||||||||2018-05-31 23:22:11.867761|2018-05-31 23:22:11.867761
NCT01198847|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2011-06-22|2010-09-09|2010-09-10|Estimate|||||||2011-06-22|2011-06-27|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|March 2016|Anticipated|2016-03-31|January 2012|Anticipated|2012-01-31||Interventional|EarlySTOPP||Early Stockholm Obesity Prevention Program|A Randomised Controlled Trial for Overweight and Obese Parents to Prevent Childhood Obesity|Unknown status|Recruiting|N/A|250|Anticipated|Karolinska Institutet|||||f||||t||||||||||2018-05-31 23:22:11.964966|2018-05-31 23:22:11.964966
NCT01198834|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09||2012-06-28|2018-01-14|2010-09-09|2010-09-10|Estimate||||2012-06-28|2012-07-02|Estimate|2018-01-14|2018-01-17|Actual|September 2010||2010-09-30|January 2018|2018-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains|A Randomized, Multi-Center, Double-Blind, Factorial, Comparator and Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains|Completed||Phase 3|600|Actual|MEDRx USA, Inc.||4|||f||||f||||||||||2018-05-31 23:22:12.054372|2018-05-31 23:22:12.054372
NCT01198821|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2017-02-21|2010-09-09|2010-09-10|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2010||2010-08-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Gem-TABS in Unresectable Pancreatic Carcinoma|A Phase I Study of Oral Sodium Bicarbonate in Patients With Unresectable Pancreatic Carcinoma Treated With Gemcitabine|Completed||Phase 1|8|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 23:22:12.195217|2018-05-31 23:22:12.195217
NCT01198808|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2012-01-16|2010-09-09|2010-09-10|Estimate|||||||2012-01-16|2012-01-18|Estimate|August 2010||2010-08-31|January 2012|2012-01-31||||December 2011|Actual|2011-12-31||Observational|||Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker|Prospective Characterization of Tumor-specific T-cell Immunity in Muscle-invasive Bladder Cancer and Its Correlation With Clinical Parameters|Unknown status|Active, not recruiting||50|Anticipated|Technische Universität München|||||f||||f||||||Samples Without DNA|"~     Peripheral blood~   "|||2018-05-31 23:22:12.287869|2018-05-31 23:22:12.287869
NCT01198795|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2014-01-31||2014-01-31|2010-09-09|2010-09-10|Estimate|2014-01-31|2014-03-14|Estimate||||2014-01-31|2014-03-14|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional||A total of 162 unique patients were enrolled in the study. Of these, 118 patients received at least 1 dose of investigational product to comprise the Safety Population. All 118 patients in the Safety Population also had at least 1 postbaseline efficacy assessment, and comprise the Intent To Treat (ITT) Population.|Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder|An Open-label Long-term Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder|Completed||Phase 4|162|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 23:22:12.366484|2018-05-31 23:22:12.366484
NCT01198782|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2016-11-17|2010-09-09|2010-09-10|Estimate|||||||2016-11-17|2016-11-18|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%||Completed||Phase 4|48|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:22:12.603473|2018-05-31 23:22:12.603473
NCT01198769|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2012-03-22||2016-09-09|2010-09-09|2010-09-10|Estimate|2012-03-22|2012-04-17|Estimate||||2016-09-09|2016-10-20|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.|Immunogenicity, Reactogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.|Completed||Phase 4|15|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:22:12.706397|2018-05-31 23:22:12.706397
NCT01198756|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2012-12-06|2012-07-23|2018-04-16|2010-09-09|2010-09-10|Estimate|2013-02-07|2013-03-12|Estimate|2012-07-23|2012-07-31|Estimate|2018-04-16|2018-05-15|Actual|October 1, 2010||2010-10-01|April 2018|2018-04-30|July 1, 2011|Actual|2011-07-01|July 1, 2011|Actual|2011-07-01||Interventional|||A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children|Completed||Phase 3|3109|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:22:13.065272|2018-05-31 23:22:13.065272
NCT01198743|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-08-28|2010-09-09|2010-09-10|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2005||2005-11-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|ALGECOLS||Presence of Circulating Tumor DNA in Colorectal Cancer|Search for the Presence of Genetic Alteration in the Plasma of Patients With Stage II-III Colorectal Cancers: Prognosis Impact|Completed|||261|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     serum and tissue~   "|||2018-05-31 23:22:14.667027|2018-05-31 23:22:14.667027
NCT01198730|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2017-09-11|2010-09-08|2010-09-10|Estimate|||||||2017-09-11|2017-09-13|Actual|April 2009||2009-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Screen of DM by OGTT in Subjects Receiving CAG or MDCT for CAD|Screen of Diabetes Mellitus by Oral Glucose Tolerance Test in Subjects Receiving Catheterization or Multi-detector Computed Tomography (MDCT) for Coronary Artery Disease|Recruiting||N/A|2000|Anticipated|Taichung Veterans General Hospital||1|||f||||f||||||||||2018-05-31 23:22:14.728524|2018-05-31 23:22:14.728524
NCT01198717|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2016-03-14|2010-09-08|2010-09-10|Estimate|||||||2016-03-14|2016-03-15|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Pediatric Disease Registry in Essential Thrombocythaemia (ET)|Multicentre Paediatric Disease Registry in Essential Thrombocythaemia|Completed|||60|Actual|Shire|||||f||||f||||||||||2018-05-31 23:22:14.84199|2018-05-31 23:22:14.84199
NCT01198704|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-11-03|2010-09-09|2010-09-10|Estimate|||||||2017-11-03|2017-11-06|Actual|January 2009||2009-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2017|Actual|2017-01-31||Observational|EFAPRE||Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)|Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma|Active, not recruiting|||372|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Blood and serum sample (28 ml at M0, M3, M6) Tissues (one pretransplant, hepatic explant,~     potential resection)~   "|||2018-05-31 23:22:14.969035|2018-05-31 23:22:14.969035
NCT01198691|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2014-03-13||2014-05-13|2010-09-09|2010-09-10|Estimate|2014-05-13|2014-06-12|Estimate||||2014-05-13|2014-06-12|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Comparison of Metallic Staples Versus Absorbable Staples After a Cesarean Section (C-Section)|Closure of Pfannenstiel Skin Incisions After Cesarean Delivery: A Comparison of Metallic Staples Versus Absorbable Staples|Completed||Phase 2|100|Actual|TriHealth Inc.|Low response rate to patient surveys at discharge and at 6 weeks postpartum.|2|||f||||f||||||||||2018-05-31 23:22:15.059567|2018-05-31 23:22:15.059567
NCT01198678|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-03-29|2010-09-09|2010-09-10|Estimate|||||||2011-03-29|2011-03-31|Estimate|November 2010||2010-11-30|December 2010|2010-12-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Feasibility Study to Assess the Safety and Functionality of the GluSense Continuous Glucose Monitor in Diabetic Patients|Feasibility Study to Assess the Safety and Functionality of the GluSense-LTone 2e3 Continuous Glucose Monitor in Diabetic Patients|Completed||Phase 1|12|Actual|GluSense Ltd|||||f||||t||||||||||2018-05-31 23:22:15.294762|2018-05-31 23:22:15.294762
NCT01198665|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-03-01|2010-09-08|2010-09-10|Estimate|||||||2015-03-01|2015-03-03|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|RADCHOP||RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas|A Phase I/II Study of RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas|Completed||Phase 1/Phase 2|46|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 23:22:15.353898|2018-05-31 23:22:15.353898
NCT01198652|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2013-03-04|2010-09-09|2010-09-10|Estimate|||||||2013-03-04|2013-03-05|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program|Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program|Terminated|||300|Anticipated|Glenveigh Medical|||1|Study discontinued following 57 subjects enrolled over 2 years|f||||f||||||||||2018-05-31 23:22:15.512557|2018-05-31 23:22:15.512557
NCT01198639|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2018-02-14|2010-09-09|2010-09-10|Estimate|||||||2018-02-14|2018-02-15|Actual|September 13, 2010|Actual|2010-09-13|February 2018|2018-02-28|February 20, 2015|Actual|2015-02-20|February 20, 2014|Actual|2014-02-20||Interventional|ELA||One-year Mortality After Surgery and Low Bispectral Index|One-year Mortality According to the Method of Total Intravenous Anesthesia. A Prospective, Randomized and Multicenter Study|Completed||N/A|2044|Actual|Hopital Foch||2|||f||||t||||||||||2018-05-31 23:22:15.591689|2018-05-31 23:22:15.591689
NCT01198626|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07||2011-12-05|2011-12-05|2010-09-09|2010-09-10|Estimate||||2011-12-05|2011-12-08|Estimate|2011-12-05|2011-12-08|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia|A Randomized, Controlled, Double Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia (CABP) With a PORT Score of II or Greater|Terminated||Phase 2|32|Actual|Furiex Pharmaceuticals, Inc||3||"Enrollment would not have been met prior to the end of the pneumonia season. Termination is~   based on slow enrollment and not related to safety or efficacy."|f||||f||||||||||2018-05-31 23:22:15.715142|2018-05-31 23:22:15.715142
NCT01198613|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2011-10-06|2010-09-09|2010-09-10|Estimate|||||||2011-10-06|2011-10-07|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||ToleroMune Ragweed Exposure Chamber Study|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Two Doses of ToleroMune Ragweed in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber|Completed||Phase 2|275|Anticipated|Circassia Limited||5|||f||||f||||||||||2018-05-31 23:22:15.838367|2018-05-31 23:22:15.838367
NCT01198600|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2012-07-26||2012-07-26|2010-09-09|2010-09-10|Estimate|2012-07-26|2012-08-29|Estimate||||2012-07-26|2012-08-29|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||"Ocular Comfort and the Aging Lens (ERBIUM)"|"Ocular Comfort and the Aging Lens (ERBIUM)"|Completed||N/A|78|Actual|Alcon Research|The current study design and sample size was not able to uncover clinically meaningful differences between survivors and strugglers. There is considerable individual variation in lens performance with age, which requires further investigation.|4|||f||||f||||||||||2018-05-31 23:22:15.939705|2018-05-31 23:22:15.939705
NCT01198587|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-06-21|2010-09-09|2010-09-10|Estimate|||||||2014-06-21|2014-06-24|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Oral Zinc for the Treatment of Acute Diarrhea in US Children|A Double Blind Randomized Placebo Controlled Trial of Oral Zinc for Children With Acute Diarrhea in a Developed Nation.|Unknown status|Active, not recruiting|N/A|210|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 23:22:16.417372|2018-05-31 23:22:16.417372
NCT01198574|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2011-12-31||2012-05-15|2010-09-09|2010-09-10|Estimate|2012-04-17|2012-05-16|Estimate||||2012-05-15|2012-05-22|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|SCI&Anaemia||Sub-clinical Inflammation and Iron Supplementation|The Role of Sub-clinical Inflammation on the Iron Status of Myanmar Anaemic Adolescent Schoolgirls During Iron and Vitamin A Supplementation|Completed||Phase 3|402|Actual|Indonesia University||4|||f||||f||||||||||2018-05-31 23:22:16.511804|2018-05-31 23:22:16.511804
NCT01198561|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-12-30|2010-09-08|2010-09-10|Estimate|||||||2015-12-30|2015-12-31|Estimate|February 2006||2006-02-28|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression|Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression : Effect of TMS on Depression, Cognitive Function, and Regional Cerebral Glucose Metabolism|Unknown status|Recruiting||40|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     serum, plasma and DNAs~   "|||2018-05-31 23:22:16.89726|2018-05-31 23:22:16.89726
NCT01198548|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2014-01-28||2014-06-23|2010-09-08|2010-09-10|Estimate|2014-06-23|2014-07-21|Estimate||||2014-06-23|2014-07-21|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer|A Phase II Clinical Trial of High Dose Vitamin D3 Supplementation in Combination With FOLFOX + Bevacizumab in the 1st Line Treatment of Metastatic Colorectal Cancer|Terminated||Phase 2|10|Actual|Roswell Park Cancer Institute|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.|1||Lack of funding|f||||t||||||||||2018-05-31 23:22:16.991424|2018-05-31 23:22:16.991424
NCT01198535|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-05-15|2010-09-09|2010-09-10|Estimate|||||||2015-05-15|2015-05-18|Estimate|September 2010||2010-09-30|December 2012|2012-12-31||||July 2012|Actual|2012-07-31||Interventional|||Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer|Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer|Terminated||Phase 1|60|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:22:17.28164|2018-05-31 23:22:17.28164
NCT01198522|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-11-19|2010-09-08|2010-09-10|Estimate|||||||2014-11-19|2014-11-20|Estimate|June 2007||2007-06-30|October 2014|2014-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients|Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer|Terminated||Phase 1|28|Actual|Philogen S.p.A.||1||lack of recruitment|f||||f||||||||||2018-05-31 23:22:17.368796|2018-05-31 23:22:17.368796
NCT01198509|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2014-09-03||2014-12-31|2010-09-08|2010-09-10|Estimate|2014-12-31|2015-01-13|Estimate||||2014-12-31|2015-01-13|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)|Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)|Completed||N/A|178|Actual|New York University School of Medicine|Interpretation of results is limited by very small sample size. It should be noted that this was intended as a proof-of-concept study, and not a fully-powered clinical trial.|3|||f||||t||||||||||2018-05-31 23:22:17.454221|2018-05-31 23:22:17.454221
NCT01198496|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-28|||2012-07-29|2010-09-09|2010-09-10|Estimate|||||||2012-07-29|2012-07-31|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|RESPECTS||Recurrent Stroke Prevention Clinical Outcome Study|Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke|Recruiting||Phase 4|5000|Anticipated|Biomedis International Ltd.||1|||f||||t||||||||||2018-05-31 23:22:18.114573|2018-05-31 23:22:18.114573
NCT01198483|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-09-03|2010-09-08|2010-09-10|Estimate|||||||2016-09-03|2016-09-07|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Microincision Versus Smallincision Combined Surgery|Microincision Cataract Surgery Combined With 23-gauge Vitrectomy Versus Smallincision Cataract Surgery Combined With 23-gauge Vitrectomy|Recruiting||N/A|80|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||Undecided||2018-05-31 23:22:18.196444|2018-05-31 23:22:18.196444
NCT01198470|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2017-03-16|2010-09-08|2010-09-10|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2010||2010-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study|A Prospective Clinical Investigation of the TRIUMPH Lumbar Disc: A Pilot Study|Completed||N/A|20|Actual|Globus Medical Inc||1|||f||||f||||||||||2018-05-31 23:22:18.27377|2018-05-31 23:22:18.27377
NCT01198457|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2012-09-06|2010-09-09|2010-09-10|Estimate|||||||2012-09-06|2012-09-07|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|BONA||Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment|BONA (Adherence of Patients to Bonefos Therapy). Prospective Observational Non-interventional Study of Adherence of Patients to Bonefos Medication in Relation to Analgesic Effect and Incidence of Skeletal Events|Completed|||147|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:22:18.336144|2018-05-31 23:22:18.336144
NCT01198444|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2011-10-31|2010-09-09|2010-09-10|Estimate|||||||2011-10-31|2011-11-02|Estimate|December 2007||2007-12-31|November 2011|2011-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|DOC||To Evaluate Compliance to Treatment Regimen (Rate of Deviations From the Prescribed Regimen) in Polish Females Treated With Different Low Dose Oral Contraceptives|Prospective, Open-label Observational Survey Evaluating Patients Compliance to Administration Regimen During Low Dose Combined Oral Contraceptive Use in Everyday Praxis Data on Oral Contraceptives Compliance - DOC Study|Completed|||11884|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:22:18.392642|2018-05-31 23:22:18.392642
NCT01198431|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-08-09|2010-09-09|2010-09-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SLOPUS||Effects of Impaired Sleep on Energy Balance|Effects of Impaired Sleep on Energy Balance: A Randomized, 2-Condition, Crossover Study in Adolescents|Completed||N/A|21|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 23:22:18.448653|2018-05-31 23:22:18.448653
NCT01198418|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-03-31|2010-09-09|2010-09-10|Estimate|||||||2014-03-31|2014-04-02|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)|A Randomized Controlled Clinical Trial of an Internet-based Prevention Intervention to Reduce STI in High-risk HIV Infected MSM|Completed||Phase 1/Phase 2|181|Actual|California Collaborative Treatment Group||2|||f||||f||||||||||2018-05-31 23:22:18.514467|2018-05-31 23:22:18.514467
NCT01198405|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2010-09-09|2010-09-09|2010-09-10|Estimate|||||||2010-09-09|2010-09-10|Estimate|September 2008||2008-09-30|January 2008|2008-01-31|September 2013|Anticipated|2013-09-30|September 2010|Anticipated|2010-09-30||Interventional|PROBE-EECP||Study of Enahnced External Counterpulsation to Treat Coronary Heart Disease|A Prospective,Randomized,Open-labeled,and Blind Endpoint Study of Enhanced External Counterpulsation for Patients With Coronary Heart Disease|Unknown status|Recruiting|N/A|1050|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:22:18.727425|2018-05-31 23:22:18.727425
NCT01198392|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-07-22|2010-09-09|2010-09-10|Estimate|||||||2011-07-22|2011-07-25|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Trial of S-1 Plus Cisplatin in Gastric Cancer|A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer|Unknown status|Recruiting|Phase 3|270|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:22:18.824981|2018-05-31 23:22:18.824981
NCT01198379|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2010-09-23|2010-09-08|2010-09-10|Estimate|||||||2010-09-23|2010-09-27|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2013|Anticipated|2013-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients|Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis|Unknown status|Recruiting|Phase 4|250|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||t||||||||||2018-05-31 23:22:18.906107|2018-05-31 23:22:18.906107
NCT01198366|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2015-06-10||2017-03-31|2010-09-08|2010-09-10|Estimate|2015-07-06|2015-08-04|Estimate||||2017-03-31|2017-05-08|Actual|September 2010||2010-09-30|March 2017|2017-03-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Study of AERAS-402 in Healthy Infants|A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis|Completed||Phase 1/Phase 2|487|Actual|Aeras||6|||f||||t||||||||||2018-05-31 23:22:19.040851|2018-05-31 23:22:19.040851
NCT01198353|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-11-18|2010-09-09|2010-09-10|Estimate|||||||2014-11-18|2014-11-19|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Effectiveness of Ziprasidone for Patients With Schizophrenia|Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|67|Actual|Soonchunhyang University Hospital||1|||f||||t||||||||||2018-05-31 23:22:20.175838|2018-05-31 23:22:20.175838
NCT01198340|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-07-20|2010-09-09|2010-09-10|Estimate|||||||2011-07-20|2011-07-22|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|||Evaluation of Optimal Dose of Local Anesthetics for Patient Controlled Continuous Femoral Nerve Block|Evaluation of Optimal Dose of Local Anesthetics for Patient Controlled Continuous Femoral Nerve Block With Sciatic Nerve Block After Total Knee Arthroplasty|Unknown status|Recruiting|N/A|60|Anticipated|Okayama University||2|||f||||t||||||||||2018-05-31 23:22:20.263843|2018-05-31 23:22:20.263843
NCT01198327|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2013-09-23||2013-11-27|2010-09-09|2010-09-10|Estimate|2013-11-27|2014-01-13|Estimate||||2013-11-27|2014-01-13|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RETAIN||Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion|Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab|Completed||Phase 3|66|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 23:22:20.347754|2018-05-31 23:22:20.347754
NCT01198314|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-09|2010-09-09|2010-09-10|Estimate|||||||2010-09-09|2010-09-10|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|March 2013|Anticipated|2013-03-31|July 2012|Anticipated|2012-07-31||Interventional|tolerance||Withdrawal of Immunosuppression in Long Term Stable Liver Transplant Recipients|Gradual Withdrawal of Immunosuppression in Long Term Stable Liver Transplant Recipients Using Immunologic Profile Predicting Operational Tolerance|Unknown status|Recruiting|Phase 2|20|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 23:22:20.545771|2018-05-31 23:22:20.545771
NCT01198301|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2015-07-22|2010-09-09|2010-09-10|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy|Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy|Completed|||42|Actual|Beijing Cancer Hospital|||||f||||t||||||Samples Without DNA|"~     the tissue will be obtained by core niddle biopsy.~   "|||2018-05-31 23:22:20.627048|2018-05-31 23:22:20.627048
NCT01198288|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2012-01-30|2010-09-09|2010-09-10|Estimate|||||||2012-01-30|2012-01-31|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Effects of Home-based Pulmonary Rehabilitation in Patients With Severe or Very Severe Chronic Obstructive Pulmonary Disease (COPD)|Randomised Controlled Trial on the Effects of Home-based Pulmonary Rehabilitation in Patients With Severe or Very Severe COPD|Unknown status|Recruiting|Phase 3|182|Anticipated|Associazione Riabilitatori Insufficienza Respiratoria||2|||f||||f||||||||||2018-05-31 23:22:20.688259|2018-05-31 23:22:20.688259
NCT01198275|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|2011-04-13||2012-01-19|2010-09-09|2010-09-10|Estimate|2011-06-23|2011-07-21|Estimate||||2012-01-19|2012-01-20|Estimate|January 2006||2006-01-31|January 2012|2012-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation|N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.|Completed||Phase 3|199|Actual|Azienda Ospedaliera Spedali Civili di Brescia|The effect of n-3 PUFAs on the recurrence of Atrial Fibrillation (AF) in patients with persistent AF not on amiodarone and a renin-angiotensin-aldosterone system (RASS) inhibitor cannot be inferred from our findings|2|||f||||t||||||||||2018-05-31 23:22:20.756955|2018-05-31 23:22:20.756955
NCT01198262|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2010-09-09|2010-09-09|2010-09-10|Estimate|||||||2010-09-09|2010-09-10|Estimate|April 2008||2008-04-30|October 2008|2008-10-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Observational|||Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections|GeneXpert in Studying Staphylococcus Aureus Infections at the Michael E. DeBakey Medical Center, Houston, Texas|Completed|||260|Actual|VA Medical Center, Houston|||||f||||f||||||||||2018-05-31 23:22:20.929987|2018-05-31 23:22:20.929987
NCT01198249|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-03-25|2010-09-09|2010-09-10|Estimate|||||||2011-03-25|2011-03-28|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension|A Randomized, Open Label, Multiple Dose, Crossover Study to Investigate Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide(HCTZ) in Subjects With (Pre)Hypertension|Completed||Phase 1|23|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 23:22:20.988313|2018-05-31 23:22:20.988313
NCT01198236|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-09|||2011-10-13|2010-09-09|2010-09-10|Estimate|||||||2011-10-13|2011-10-14|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection|Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection|Completed||Phase 4|150|Actual|Zhejiang University|||||f||||t||||||||||2018-05-31 23:22:21.173144|2018-05-31 23:22:21.173144
NCT01198223|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-10-15|2010-09-09|2010-09-10|Estimate|||||||2010-10-15|2010-10-18|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Effect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis|Comparison of Therapeutic Effect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis|Completed||Phase 2|40|Anticipated|Qazvin University Of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:22:21.243905|2018-05-31 23:22:21.243905
NCT01198210|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2013-05-06|2010-09-09|2010-09-10|Estimate|||||||2013-05-06|2013-05-07|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||The Effect of Peritonsillar Infiltration of Ketamine and Dexamethasone for Postoperative Pain Relief in Children Following Adenotonsillectomy|Comparison of Peritonsillar Infiltration of Ketamine and Dexamethasone for Postoperative Pain Relief in Children Following Adenotonsillectomy|Unknown status|Recruiting|Phase 1/Phase 2|160|Anticipated|Qazvin University Of Medical Sciences||4|||f||||t||||||||||2018-05-31 23:22:21.321161|2018-05-31 23:22:21.321161
NCT01198197|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2018-04-28|2010-09-08|2010-09-09|Estimate|||||||2018-04-28|2018-05-01|Actual|September 3, 2010||2010-09-03|September 5, 2014|2014-09-05|February 28, 2014|Actual|2014-02-28|||||Interventional|||PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A|PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [(11)C]NOP-1A|Completed||Early Phase 1|41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:22:21.413344|2018-05-31 23:22:21.413344
NCT01198184|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-05-29|2010-09-08|2010-09-09|Estimate|||||||2014-05-29|2014-05-30|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors|Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers|Completed||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:22:21.477604|2018-05-31 23:22:21.477604
NCT01198171|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2015-05-27|2010-09-08|2010-09-09|Estimate|||||||2015-05-27|2015-05-29|Estimate|January 2100||2100-01-31|May 2015|2015-05-31||||January 2100|Anticipated|2100-01-31||Observational|||Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer|The Relationship of Racial Genetic Admixture With Endometrial Cancer Outcomes|Not yet recruiting|||243|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 23:22:21.563306|2018-05-31 23:22:21.563306
NCT01198158|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2018-05-24|2010-09-08|2010-09-09|Estimate|||||||2018-05-24|2018-05-25|Actual|September 15, 2010|Actual|2010-09-15|May 2018|2018-05-31||||July 31, 2018|Anticipated|2018-07-31||Interventional|||Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy|Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors|Active, not recruiting||Phase 3|700|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:22:21.816067|2018-05-31 23:22:21.816067
NCT01198145|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2016-11-28||2017-02-16|2010-09-08|2010-09-09|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|April 2011||2011-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|January 2014|Actual|2014-01-31||Interventional||Two patients in Arm I and one patient from Arm II were not included in the baseline analysis nor the endpoint analyses due to cancellations and protocol violations.|Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy|Phase III, Randomized, Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy|Completed||Phase 3|87|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 23:22:22.976367|2018-05-31 23:22:22.976367
NCT01198132|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2016-12-06||2017-05-09|2010-09-08|2010-09-09|Estimate|2017-05-09|2017-12-14|Actual||||2017-05-09|2017-12-14|Actual|November 2009|Actual|2009-11-30|May 2017|2017-05-31|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|CHOLINE|Intent-to-Treat (ITT) set included all randomized subjects.|A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly|A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing- Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly|Completed||Phase 2|129|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 23:22:24.221007|2018-05-31 23:22:24.221007
NCT01198119|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2012-07-31|2010-09-08|2010-09-09|Estimate|||||||2012-07-31|2012-08-01|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Excision Limits of Oral Cavity Tumor by Narrow Band Imaging|Excision Limits of Oral Cavity Tumor by NARROW BAND IMAGING (NBI): Feasibility Trial|Terminated||Phase 2|23|Actual|Centre Oscar Lambret||1||lack of recruitment|f||||f||||||||||2018-05-31 23:22:24.745225|2018-05-31 23:22:24.745225
NCT01198106|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-09-08|2010-09-08|2010-09-09|Estimate|||||||2010-09-08|2010-09-09|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness|A Double-blind Randomized Placebo Controlled Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness|Unknown status|Recruiting|N/A|100|Anticipated|Medical Corps, Israel Defense Force|||||f||||f||||||||||2018-05-31 23:22:24.843221|2018-05-31 23:22:24.843221
NCT01198093|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2012-09-26|2010-09-08|2010-09-09|Estimate|||||||2012-09-26|2012-09-28|Estimate|November 2005||2005-11-30|September 2012|2012-09-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|CREDOS||Clinical Research Center for Dementia of South Korea (CREDOS)(or CRCD)|Clinical Research Center for Dementia of South Korea (CREDOS)|Unknown status|Recruiting||800|Anticipated|Samsung Medical Center|||||f||||t||||||Samples With DNA|"~     Serum, plasma and DNAs were prepared~   "|||2018-05-31 23:22:24.897194|2018-05-31 23:22:24.897194
NCT01198080|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2013-08-27|2010-09-08|2010-09-09|Estimate|||||||2013-08-27|2013-08-28|Estimate|August 2009||2009-08-31|April 2009|2009-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head|Bone Marrow Derived CD133+ Stem Cells Transplantation in Femoral Head Osteonecrosis|Completed||Phase 1|10|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 23:22:24.955968|2018-05-31 23:22:24.955968
NCT01198067|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2018-04-05|2010-09-08|2010-09-09|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2010|Actual|2010-10-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Pomalidomide for Relapse/Refractory Waldenstrom's|Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom Macroglobulinemia|Active, not recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 23:22:25.157646|2018-05-31 23:22:25.157646
NCT01198054|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2014-04-04|2010-09-08|2010-09-09|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)|PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5|Terminated||Phase 4|4|Actual|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 23:22:25.23623|2018-05-31 23:22:25.23623
NCT01198028|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2017-09-25|2010-09-08|2010-09-09|Estimate|||||||2017-09-25|2017-09-27|Actual|March 2011|Actual|2011-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin|Phase II Study of Erlotinib, an Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin|Active, not recruiting||Phase 2|33|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 23:22:25.312795|2018-05-31 23:22:25.312795
NCT01198015|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2011-02-16|2010-09-08|2010-09-09|Estimate|||||||2011-02-16|2011-02-17|Estimate|August 2010||2010-08-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Creatine Metabolism in Rett Syndrome|Metabolic Evaluation of Nutrition in Rett Syndrome: Creatine Metabolism|Completed|||13|Anticipated|Maastricht University Medical Center|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, leucocytes, erythrocytes, fibroblasts.~   "|||2018-05-31 23:22:25.38214|2018-05-31 23:22:25.38214
NCT01198002|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2018-03-24|2013-04-30|2018-05-04|2010-09-08|2010-09-09|Estimate|2018-05-04|2018-05-08|Actual|2013-04-30|2013-05-08|Estimate|2018-05-04|2018-05-08|Actual|December 2010||2010-12-31|May 2018|2018-05-31|January 2014|Actual|2014-01-31|December 2012|Actual|2012-12-31||Interventional|FLEX M|All randomized participants.|A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate Therapy (FLEX M)|Terminated||Phase 3|1041|Actual|Eli Lilly and Company|This study has been terminated not based on safety concerns, but due to insufficient efficacy. Early termination led to lower than expected enrollment and was responsible for the large number of discontinuation reason as Sponsor Decision.|3||Terminated not based on safety concerns, but due to insufficient efficacy.|f||||t||||||||||2018-05-31 23:22:25.684316|2018-05-31 23:22:25.684316
NCT01197989|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2012-09-24|2010-09-08|2010-09-09|Estimate|||||||2012-09-24|2012-09-25|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy Study of TEPSO® Socks in Improving Palmoplantar Pustulosis|Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Pustulosis|Terminated||Phase 2|17|Actual|Lenzi Egisto S.P.A.||2||Unable to recruit suitable subjects within a reasonable time period.|f||||f||||||||||2018-05-31 23:22:31.826733|2018-05-31 23:22:31.826733
NCT01197976|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-09-26|2010-09-08|2010-09-09|Estimate|||||||2011-09-26|2011-09-27|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy Study of TEPSO® Socks in Improving Palmoplantar Psoriasis|Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Psoriasis|Completed||Phase 2|20|Actual|Lenzi Egisto S.P.A.||2|||f||||f||||||||||2018-05-31 23:22:31.927239|2018-05-31 23:22:31.927239
NCT01197963|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2015-06-11|2010-09-07|2010-09-09|Estimate|||||||2015-06-11|2015-06-12|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2|A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2|Terminated||N/A|3|Actual|The University of Texas Health Science Center, Houston||2||IRB temporarily halted enrollment|f||||t||||||||||2018-05-31 23:22:32.015257|2018-05-31 23:22:32.015257
NCT01197950|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2017-11-11|2010-09-07|2010-09-09|Estimate|||||||2017-11-11|2017-11-14|Actual|October 2008||2008-10-31|November 2017|2017-11-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Acupuncture With Manual and Electrical Stimulation to Reduce Labour Pain|A Randomized Controlled Trial of Acupuncture to Reduce Labour Pain|Completed||N/A|303|Actual|University of Skövde||3|||f||||f||||||||||2018-05-31 23:22:32.10047|2018-05-31 23:22:32.10047
NCT01197924|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-08|2010-09-08|2010-09-09|Estimate|||||||2010-09-08|2010-09-09|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|MEDIR||MEDIR Medulloblastome|Médulloblastome of the Child and After-effects Cognitive: Study Anatomo-functional by IRM of the Working Memory|Unknown status|Recruiting||80|Anticipated|University Hospital, Grenoble|||2||f||||f||||||||||2018-05-31 23:22:32.280515|2018-05-31 23:22:32.280515
NCT01197911|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2015-11-20||2015-11-20|2010-09-08|2010-09-09|Estimate|2015-11-20|2015-12-24|Estimate||||2015-11-20|2015-12-24|Estimate|September 2010||2010-09-30|November 2015|2015-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar|The Effect of Hepatic Impairment on the Pharmacokinetics of Aleglitazar: A Multiple-centre, Open-label Study Following a Single Oral Dose of Aleglitazar to Subjects With Mild or Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function.|Completed||Phase 1|38|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:22:33.631648|2018-05-31 23:22:33.631648
NCT01197898|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2013-03-13||2013-04-23|2010-09-08|2010-09-09|Estimate|2013-04-23|2013-05-30|Estimate||||2013-04-23|2013-05-30|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Wound Edge Changes Following Treatment With Santyl|Evaluation of the Edge of Non-Healing Cutaneous Ulcers Following Debridement With Collagenase Santyl Ointment|Completed||Phase 4|10|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 23:22:34.737028|2018-05-31 23:22:34.737028
NCT01197885|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2017-06-30|2010-09-08|2010-09-09|Estimate|||||||2017-06-30|2017-07-02|Actual|September 2010||2010-09-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer|International, Multicenter, Open-label, Phase II Study to Investigate the Efficacy and Safety of Multiple Doses of IMAB362 in Patients With Advanced Adenocarcinoma of the Stomach or the Lower Esophagus|Completed||Phase 2|54|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-05-31 23:22:34.972287|2018-05-31 23:22:34.972287
NCT01197872|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2013-07-12|2010-09-08|2010-09-09|Estimate|||||||2013-07-12|2013-07-16|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Clinical Use of Parental Support To Detect Single Gene Mutations|Phase II: Clinical Use of Parental Support To Detect Single Gene Mutations|Completed|||240|Anticipated|Natera, Inc.|||||f||||f||||||Samples With DNA|"~     Whole blood, cheek swab/saliva samples, sperm samples, embryo biopsy samples~   "|||2018-05-31 23:22:35.065023|2018-05-31 23:22:35.065023
NCT01197859|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-09|2010-09-08|2010-09-09|Estimate|||||||2010-09-09|2010-09-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:22:35.122758|2018-05-31 23:22:35.122758
NCT01197846|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2012-09-18|2010-09-08|2010-09-09|Estimate|||||||2012-09-18|2012-09-19|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|||Efficacy of Quetiapine XR Versus Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder|Efficacy of Quetiapine XR vs. Placebo as Concomitant Treatment to Mood Stabilizers in the Control of Subsyndromal Symptoms of Bipolar Disorder|Completed||Phase 3|28|Actual|Centro de Investigación Biomédica en Red de Salud Mental||2|||f||||f||||||||||2018-05-31 23:22:35.172513|2018-05-31 23:22:35.172513
NCT01197833|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2014-02-07|2013-07-23|2015-02-19|2010-09-08|2010-09-09|Estimate|2014-09-10|2014-09-15|Estimate|2013-12-09|2014-01-09|Estimate|2015-02-19|2015-03-06|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|017|all treated patients|Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities|A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolve™ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities|Completed||Phase 3|117|Actual|BTG International Inc.||3|||f||||t||||||||||2018-05-31 23:22:35.273021|2018-05-31 23:22:35.273021
NCT01197820|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2012-06-13|2010-09-07|2010-09-09|Estimate|||||||2012-06-13|2012-06-14|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|THeR-IRM||Hepatic and Renal Thermography Using Magnetic Resonance Imaging|Hepatic and Renal Thermography Using Magnetic Resonance Imaging|Terminated||N/A|15|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 23:22:35.62131|2018-05-31 23:22:35.62131
NCT01197807|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2012-08-12|2010-09-07|2010-09-09|Estimate|||||||2012-08-12|2012-08-14|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|TermWIPE||Oronasopharyngeal Suction Versus Simple Nose and Mouth Wiping in Term Newborns|Newborn Resuscitation: A Randomized Controlled Trial of Oronasopharyngeal Suction Versus Simple Nose and Mouth Wiping in Term Newborns|Completed||N/A|506|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 23:22:35.959708|2018-05-31 23:22:35.959708
NCT01197794|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2013-07-01||2013-10-11|2010-09-08|2010-09-09|Estimate|2013-07-01|2013-09-10|Estimate||||2013-10-11|2013-11-06|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Sweapea|Three patients (1 in the AZD1981 40 mg bid group and 2 in the placebo group) randomized at a Japanese centre were excluded from the analyses due to Good Clinical Practice violations identified after study completion.|Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients|A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients|Completed||Phase 2|1144|Actual|AstraZeneca||7|||f||||f||||||||||2018-05-31 23:22:36.157919|2018-05-31 23:22:36.157919
NCT01197781|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-11-19|2010-09-08|2010-09-09|Estimate|||||||2010-11-19|2010-11-23|Estimate|September 2010||2010-09-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers|An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers When Fostamatinib Disodium 150 mg is Administered Alone and in Combination With Verapamil|Completed||Phase 1|15|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 23:22:37.660608|2018-05-31 23:22:37.660608
NCT01197768|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2011-10-12|2010-09-07|2010-09-09|Estimate|||||||2011-10-12|2011-10-14|Estimate|September 2008||2008-09-30|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|MCBNIHE||A Multi-Component Behavioral Nutrition Intervention for Homebound Elderly|A Multi-Component Behavioral Nutrition Intervention for Homebound Older Adults|Completed||N/A|104|Anticipated|University of Alabama at Birmingham||2|||f||||||||||||||2018-05-31 23:22:37.758019|2018-05-31 23:22:37.758019
NCT01197755|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2013-11-21||2014-02-27|2010-09-08|2010-09-09|Estimate|2014-02-27|2014-04-07|Estimate||||2014-02-27|2014-04-07|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|OSKIRA - 3||Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist|(OSKIRA-3): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With Inadequate Response to a TNF-alpha Antagonist|Completed||Phase 3|323|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 23:22:37.931622|2018-05-31 23:22:37.931622
NCT01197742|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-07|2010-09-07|2010-09-09|Estimate|||||||2010-09-07|2010-09-09|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|||||Observational|Sweetheart||Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction|Sweetheart: Risiko-Management Von Diabetikern Mit Akutem Myokardinfarkt|Completed|||2772|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||||2018-05-31 23:22:39.003986|2018-05-31 23:22:39.003986
NCT01197729|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-07|2010-09-07|2010-09-09|Estimate|||||||2010-09-07|2010-09-09|Estimate|October 2005||2005-10-31|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Observational|OPTAMI||OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry|OPTAMI (Optimierte Therapie Des Akuten Myokard-Infarktes) - Register|Completed|||3248|Actual|Stiftung Institut fuer Herzinfarktforschung|||2||f||||f||||||||||2018-05-31 23:22:39.093904|2018-05-31 23:22:39.093904
NCT01197716|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-06-23|2010-09-08|2010-09-09|Estimate|||||||2016-06-23|2016-06-24|Estimate|December 2008||2008-12-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||German Chest Pain Unit (CPU)-Register|Deutsches CPU-Register. Unterstützt Durch Die Deutsche Gesellschaft für Kardiologie.|Completed|||34470|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No||2018-05-31 23:22:39.162976|2018-05-31 23:22:39.162976
NCT01197703|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2017-03-13|2010-09-07|2010-09-09|Estimate|||||||2017-03-13|2017-03-14|Actual|June 2010|Actual|2010-06-30|March 2017|2017-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||European Cardio Computer Tomography Registry|European Cardio CT Registry|Completed|||7115|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||||2018-05-31 23:22:39.221956|2018-05-31 23:22:39.221956
NCT01197690|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2015-09-17|2010-09-07|2010-09-09|Estimate|||||||2015-09-17|2015-09-18|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|FeNO_AS||Association Between Fractional Exhaled Nitric Oxide and Asthma Control|Association Between Fractional Exhaled Nitric Oxide and Asthma Control|Completed|||62|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 23:22:39.281929|2018-05-31 23:22:39.281929
NCT01197677|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-09-05|2010-09-07|2010-09-09|Estimate|||||||2016-09-05|2016-09-07|Estimate|April 2009||2009-04-30|September 2016|2016-09-30|October 2013|Actual|2013-10-31|September 2009|Actual|2009-09-30||Observational|||European CMR Registry|European Cardiovascular Magnetic Resonance Registry|Completed|||30000|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||||2018-05-31 23:22:39.339381|2018-05-31 23:22:39.339381
NCT01197664|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2017-05-25|2010-09-08|2010-09-09|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2010||2010-08-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|July 2012|Actual|2012-07-31||Interventional|||Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery|A Pilot Study of Paricalcitol Synergism in Conjunction With Standard-of-Care Chemo-Radiation for Resectable Rectal Cancers|Terminated||Phase 1|2|Actual|Wake Forest University Health Sciences||2||Study terminated due to funding issues|f||||f|t|f||||||||2018-05-31 23:22:39.408648|2018-05-31 23:22:39.408648
NCT01197651|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-06-20|2010-09-07|2010-09-09|Estimate|||||||2016-06-20|2016-06-21|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Aortic-Stent-Register|Aortenstent-Register Thorakale Aorta|Completed|||199|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No||2018-05-31 23:22:39.482996|2018-05-31 23:22:39.482996
NCT01197638|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2016-06-16|2010-09-07|2010-09-09|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2008||2008-06-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|August 2011|Actual|2011-08-31||Observational|||German Ablation Quality-Register|Deutsches Ablations-Qualitätsregister|Completed|||20663|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No|Not included in informed consent.|2018-05-31 23:22:39.541663|2018-05-31 23:22:39.541663
NCT01197625|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2018-03-13|2010-09-08|2010-09-09|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2010||2010-09-30|March 2018|2018-03-31|September 2025|Anticipated|2025-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Vaccine Therapy in Curative Resected Prostate Cancer Patients|Trial of Vaccine Therapy in Curative Resected Prostate Cancer Patients Using Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 23:22:39.61535|2018-05-31 23:22:39.61535
NCT01197612|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2018-04-24||2018-04-24|2010-09-08|2010-09-09|Estimate|2018-04-24|2018-05-28|Estimate||||2018-04-24|2018-05-28|Estimate|September 2010|Actual|2010-09-30|April 2018|2018-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis|Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis|Completed||Phase 3|23|Actual|University of Michigan|This was a pilot study with less enrollment than desired and poor rate of completion with only 5 participants completing the full 24 week trial. This study could be done on a larger/similar scale with some additional useful data obtained.|1|||f||||t||||||||||2018-05-31 23:22:39.691345|2018-05-31 23:22:39.691345
NCT01197599|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-07-21|2010-09-08|2010-09-09|Estimate|||||||2014-07-21|2014-07-22|Estimate|December 2008||2008-12-31|July 2014|2014-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Acute Tendon and Nerve Responses to Exercise|Acute Tendon and Nerve Responses to Exercise|Completed|||50|Actual|University of Miami|||2||f||||f||||||||||2018-05-31 23:22:39.878907|2018-05-31 23:22:39.878907
NCT01197586|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2013-06-21|2010-09-08|2010-09-09|Estimate|||||||2013-06-21|2013-06-24|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Evaluation of Surfactant Protein B in the Differential Diagnostics of Dyspnea||Completed|||55|Actual|Universitätsmedizin Mannheim|||||f||||t||||||||||2018-05-31 23:22:39.939758|2018-05-31 23:22:39.939758
NCT01197573|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2017-03-25|2010-09-08|2010-09-09|Estimate|||||||2017-03-25|2017-03-28|Actual|April 2010||2010-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy|Enhancing DCD Utilization With Thrombolytic Therapy|Active, not recruiting||N/A|50|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 23:22:39.989249|2018-05-31 23:22:39.989249
NCT01197560|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2014-07-31||2017-12-19|2010-09-08|2010-09-09|Estimate|2014-07-31|2014-08-20|Estimate||||2017-12-19|2018-01-19|Actual|September 1, 2010|Actual|2010-09-01|December 2017|2017-12-31|March 4, 2018|Anticipated|2018-03-04|July 4, 2013|Actual|2013-07-04||Interventional||Modified Intent to Treat (mITT) = all study participants randomized with a Diffuse Large B-Cell Lymphoma (DLBCL) diagnosis and Germinal center B-cell (GCB)/non-Germinal center B (non-GCB) subtype confirmed by Central Pathology, and who received at least one dose of study drug (lenalidomide or Investigator’s choice). Nine participants were excluded.|Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|Active, not recruiting||Phase 2/Phase 3|111|Actual|Celgene||2|||f||||t||||||||||2018-05-31 23:22:40.177423|2018-05-31 23:22:40.177423
NCT01197547|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2016-06-07||2017-04-07|2010-09-08|2010-09-09|Estimate|2017-04-07|2017-05-17|Actual||||2017-04-07|2017-05-17|Actual|November 2010||2010-11-30|April 2017|2017-04-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|Genesys HTA||Registry Study of Genesys HTA for Treatment of Menorrhagia|Genesys HTA Post Approval Registry A Multi-center, Single-arm, Prospective Registry of the Genesys HTA System for the Treatment of Menorrhagia|Completed||N/A|1014|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 23:22:41.097536|2018-05-31 23:22:41.097536
NCT01197534|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2013-11-22||2014-03-13|2010-09-08|2010-09-09|Estimate|2014-03-13|2014-04-17|Estimate||||2014-03-13|2014-04-17|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|OSKIRA - 2||Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.|(OSKIRA-2): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to DMARDs|Completed||Phase 3|913|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 23:22:41.374668|2018-05-31 23:22:41.374668
NCT01197521|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2013-11-22||2014-02-27|2010-09-08|2010-09-09|Estimate|2014-02-27|2014-04-07|Estimate||||2014-02-27|2014-04-07|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|OSKIRA - 1||Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.|(OSKIRA-1): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|Completed||Phase 3|923|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 23:22:42.643369|2018-05-31 23:22:42.643369
NCT01197508|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2012-06-26||2014-03-14|2010-09-08|2010-09-09|Estimate|2012-09-27|2012-10-29|Estimate||||2014-03-14|2014-04-11|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.|A Multicenter, Randomized, Double-Blind Parallel Group Placebo-Controlled Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressants in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy|Completed||Phase 3|696|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 23:22:43.916685|2018-05-31 23:22:43.916685
NCT01197495|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|2015-12-01||2016-04-29|2010-09-08|2010-09-09|Estimate|2016-04-29|2016-06-07|Estimate||||2016-04-29|2016-06-07|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation||Completed||N/A|213|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:22:45.264483|2018-05-31 23:22:45.264483
NCT01197482|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2015-12-14|2010-09-08|2010-09-09|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|INHALE||Inhaled Steroids and Control of Severe Asthma|Inhaled Steroids and Control of Severe Asthma: Comparison of the AKITA Technology Versus Conventional MDI (INHALE)|Recruiting|||20|Anticipated|University of Giessen|||||f||||f||||||||||2018-05-31 23:22:45.493338|2018-05-31 23:22:45.493338
NCT01197469|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2012-11-05|2010-09-08|2010-09-09|Estimate|||||||2012-11-05|2012-11-06|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?|Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension?|Completed||Phase 2|120|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 23:22:45.571583|2018-05-31 23:22:45.571583
NCT01197456|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2016-10-27|2010-09-08|2010-09-09|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2016|Actual|2016-06-30||Observational|POISE||Predictors of Ovarian Insufficiency in Young Breast Cancer Patients|Predictors of Ovarian Insufficiency Through Serial Exams in Young Breast Cancer Patients (POISE Study)|Active, not recruiting|||200|Anticipated|University of California, San Diego|||2||f||||f||||||Samples With DNA|"~     Serum DNA~   "|||2018-05-31 23:22:45.638138|2018-05-31 23:22:45.638138
NCT01197443|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2015-11-30|2010-09-08|2010-09-09|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PAAC||Parents as the Agent of Change for Childhood Obesity|Parents as the Agent of Change for Childhood Obesity|Completed||N/A|152|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 23:22:45.710711|2018-05-31 23:22:45.710711
NCT01197430|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-09-08|2010-09-08|2010-09-09|Estimate|||||||2010-09-08|2010-09-09|Estimate||||November 2009|2009-11-30||||||||Interventional|||Vertical Stability Training Effects on the Eye-Hand Coordination of Female Volleyball Players||Completed||Phase 1/Phase 2|23|Actual|Taipei Physical Education College|||||f||||t||||||||||2018-05-31 23:22:45.811812|2018-05-31 23:22:45.811812
NCT01197417|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2015-08-05||2015-12-21|2010-09-08|2010-09-09|Estimate|2015-08-07|2015-09-07|Estimate||||2015-12-21|2016-01-27|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|MAGiC||Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis|Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis|Completed||Phase 2/Phase 3|208|Actual|Medical College of Wisconsin||2|||f||||t||||||||||2018-05-31 23:22:45.87138|2018-05-31 23:22:45.87138
NCT01197404|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-03-02|2010-09-07|2010-09-09|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Affect Management for Early Adolescents|Affect Management Intervention for Early Adolescents With Mental Health Problems|Completed||Phase 2|420|Actual|Rhode Island Hospital||2|||f||||f||||||||||2018-05-31 23:22:46.355554|2018-05-31 23:22:46.355554
NCT01197391|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2012-11-09|2010-09-07|2010-09-09|Estimate|||||||2012-11-09|2012-11-12|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneous REGN 728 in Healthy Volunteers|Completed||Phase 1|48|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:22:46.412404|2018-05-31 23:22:46.412404
NCT01197378|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-07-17|2010-09-08|2010-09-09|Estimate|||||||2017-07-17|2017-07-18|Actual|August 24, 2010|Actual|2010-08-24|July 2017|2017-07-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)|A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis|Completed||Phase 3|60|Actual|Horizon Pharma USA, Inc.||1|||f||||f||||||||||2018-05-31 23:22:46.529735|2018-05-31 23:22:46.529735
NCT01197365|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2015-02-02|2010-09-08|2010-09-09|Estimate|||||||2015-02-02|2015-02-04|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Efficacy of an Infant Formula Supplemented With Galacto-oligosaccharides, Beta-palmitate and Acidified Milk|Double-blind Randomized Controlled Study for the Evaluation of Nutritional Outcomes of a Cow's Milk Based Infant Formula Containing Galacto-oligosaccharides, Beta-palmitate and Acidified Milk|Completed||N/A|148|Actual|Heinz Italia SpA||2|||f||||f||||||||||2018-05-31 23:22:46.611866|2018-05-31 23:22:46.611866
NCT01197352|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2012-05-18|2010-09-07|2010-09-09|Estimate|||||||2012-05-18|2012-05-21|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|PART||Pilot Study of a Text Message Platform to Reduce Risky Drinking in Young Adults|Pilot Study of a Computer-driven Platform That Uses Text Messages to Collect Drinking Information and Deliver Personalized Motivational Messages to At-risk Young Adults|Completed||N/A|45|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 23:22:46.679573|2018-05-31 23:22:46.679573
NCT01197339|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-01-21|2010-09-07|2010-09-09|Estimate|||||||2016-01-21|2016-01-25|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Hybrid Model of Vocal Inflammation and Tissue Mobilization|Hybrid Model of Vocal Inflammation and Tissue Mobilization|Completed||Phase 1|45|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 23:22:46.733371|2018-05-31 23:22:46.733371
NCT01197326|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-12-17||2016-04-01|2010-09-07|2010-09-09|Estimate|2014-11-19|2014-11-20|Estimate||||2016-04-01|2016-05-05|Estimate|August 2009||2009-08-31|April 2016|2016-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|VitalCare||The Prevention of Failure to Rescue Using Early Warning Scoring|"The Use of IntelliVue Patient Monitor MP5 Rel. G.1 for the Prevention of Failure to Rescue Using Early Warning Score"|Completed|||414|Actual|Philips Healthcare|||2||f||||f||||||||No||2018-05-31 23:22:46.796525|2018-05-31 23:22:46.796525
NCT01197313|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-07|2010-09-07|2010-09-09|Estimate|||||||2010-09-07|2010-09-09|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers|Depression and Quality of Life in Chronic Heart Failure Patients and the Caregivers|Completed||N/A|51|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 23:22:47.022213|2018-05-31 23:22:47.022213
NCT01197300|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2017-10-13|2010-09-08|2010-09-09|Estimate|||||||2017-10-13|2017-10-16|Actual|October 25, 2010|Actual|2010-10-25|October 2017|2017-10-31|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids|A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids|Recruiting||Phase 3|100|Anticipated|Novartis||1|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 23:22:47.165247|2018-05-31 23:22:47.165247
NCT01197287|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-16|2010-09-07|2010-09-09|Estimate|||||||2010-09-16|2010-09-17|Estimate|May 2004||2004-05-31|September 2010|2010-09-30||||February 2005|Actual|2005-02-28||Interventional|||Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-blind, Placebo-controlled Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of QAK423 in Healthy Subjects and COPD Patients and Multiple, Titrated Dosing in COPD Patients|Completed||Phase 1|76|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:22:47.259168|2018-05-31 23:22:47.259168
NCT01197274|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-09-08|2010-09-08|2010-09-09|Estimate|||||||2010-09-08|2010-09-09|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Comparison of Simple Blood Lancet(Vitrex®)With DuoTip as Skin Prick Test Devices Among Mite-sensitized Subjects|Comparison of Simple Blood Lancet(Vitrex®)With DuoTip as Devices for Skin Prick Test Among Mite-sensitized Subjects|Completed|||42|Actual|Siriraj Hospital|||1||f||||t||||||||||2018-05-31 23:22:47.328908|2018-05-31 23:22:47.328908
NCT01197261|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2013-07-23|2010-09-08|2010-09-09|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)|An Exploratory, Randomised, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Assess the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets (OXN PR) Compared to Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome.|Completed||Phase 2|120|Actual|Mundipharma Research GmbH & Co KG||2|||f||||||||||||||2018-05-31 23:22:47.395486|2018-05-31 23:22:47.395486
NCT01197248|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2016-12-17|2010-09-07|2010-09-09|Estimate|||||||2016-12-17|2016-12-20|Estimate|February 2009||2009-02-28|December 2016|2016-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|CPR||"Randomized Controlled Trial of Cystocele Plication Risks (CPR Trial): A Pilot Study"|"Randomized Controlled Trial of Cystocele Plication Risks (CPR Trial): A Pilot Study"|Completed||Phase 2|40|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 23:22:47.470432|2018-05-31 23:22:47.470432
NCT01195740|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2012-12-13|2010-09-03|2010-09-06|Estimate|||||||2012-12-13|2012-12-17|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters|Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters|Completed||Phase 2|20|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 23:23:18.345946|2018-05-31 23:23:18.345946
NCT01197235|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2014-11-20|2010-09-08|2010-09-09|Estimate|||||||2014-11-20|2014-11-21|Estimate|May 2009||2009-05-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Darbepoetin in Contrast-induced Nephropathy|Prevention of Contrast-Induced Nephropathy by Darbepoetin in Patients With Chronic Kidney Disease|Terminated||Phase 2/Phase 3|80|Actual|Seoul National University Bundang Hospital||2||difficult to enroll targeted participants|f||||f||||||||||2018-05-31 23:22:47.545132|2018-05-31 23:22:47.545132
NCT01197222|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-09-08|2010-09-08|2010-09-09|Estimate|||||||2010-09-08|2010-09-09|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of Safety and Efficacy of Using EndoClear-Endoscopic Lens Cleaning Device|Evaluation of Safety and Efficacy of Using EndoClear-Endoscopic Lens Cleaning Device|Completed||Early Phase 1|20|Actual|The Oregon Clinic||2|||f||||t||||||||||2018-05-31 23:22:47.627755|2018-05-31 23:22:47.627755
NCT01197209|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2013-08-21|2010-09-07|2010-09-09|Estimate|||||||2013-08-21|2013-08-23|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer|A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer|Withdrawn||Phase 1|0|Actual|Momotaro-Gene Inc.||1||Suspended due to change in development plans and investigator|f||||t||||||||||2018-05-31 23:22:47.690649|2018-05-31 23:22:47.690649
NCT01197196|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2016-12-20|2010-09-07|2010-09-09|Estimate|||||||2016-12-20|2016-12-21|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Behavioral Weight Loss as a Treatment for Migraine in Obese Women|Behavioral Weight Loss as a Treatment for Migraine in Obese Women|Active, not recruiting||N/A|112|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 23:22:47.773823|2018-05-31 23:22:47.773823
NCT01197183|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-02-03|2010-09-07|2010-09-09|Estimate|||||||2014-02-03|2014-02-04|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Observational|ORCHIDEE||Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in France|Survey for the Initial Treatment of Hypothyroidism in France|Completed|||1285|Actual|Merck KGaA|||||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 23:22:47.874453|2018-05-31 23:22:47.874453
NCT01197170|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2018-05-03|2010-09-08|2010-09-09|Estimate|||||||2018-05-03|2018-05-07|Actual|September 2010|Actual|2010-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance|Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance|Active, not recruiting||Phase 1|281|Anticipated|M.D. Anderson Cancer Center||5|||f||||f|t|f||||||||2018-05-31 23:22:47.952417|2018-05-31 23:22:47.952417
NCT01197157|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2014-09-27|2010-09-08|2010-09-09|Estimate|||||||2014-09-27|2014-09-30|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients|Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients With Genotype 4: A Placebo-controlled Randomized Trial|Completed||Phase 2/Phase 3|200|Actual|National Liver Institute, Egypt||2|||f||||t||||||||||2018-05-31 23:22:48.098445|2018-05-31 23:22:48.098445
NCT01197144|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2016-02-04|2010-09-08|2010-09-09|Estimate|||||||2016-02-04|2016-02-05|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PARADE||Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab|Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)|Unknown status|Recruiting|N/A|90|Anticipated|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 23:22:48.207341|2018-05-31 23:22:48.207341
NCT01197131|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2018-05-10|2010-09-08|2010-09-09|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2010||2010-09-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2011|Actual|2011-07-31||Observational|||Urinary Steroid Metabolites in Autism|Investigation of Urinary Steroid Metabolites in Children With Autism Spectrum Disorder|Active, not recruiting|||160|Actual|Intersci Research Association, Austria|||4||f||||f||||||Samples Without DNA|"~     noninvasive overnight urine (morning urine)~   "|||2018-05-31 23:22:48.337325|2018-05-31 23:22:48.337325
NCT01197118|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2010-09-08|2010-09-08|2010-09-09|Estimate|||||||2010-09-08|2010-09-09|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|May 2011|Anticipated|2011-05-31|December 2010|Anticipated|2010-12-31||Interventional|||Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer|Phase 2 Study of Chemoradiotherapy for Advanced Gastric Cancer|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Huazhong University of Science and Technology||2|||f||||f||||||||||2018-05-31 23:22:48.413773|2018-05-31 23:22:48.413773
NCT01197105|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-08|2010-09-08|2010-09-09|Estimate|||||||2010-09-08|2010-09-09|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||September 2010|Actual|2010-09-30||Interventional|||Evaluation Study of a Mouthwash Based on Schinus Terebinthifolius to Treat Gingivitis in Children|Clinical Evaluation of a Mouthwash Based on Schinus Terebinthifolius (Aroeira) Used by Children With Gingivitis|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Federal University of Paraíba||1|||f||||t||||||||||2018-05-31 23:22:48.504461|2018-05-31 23:22:48.504461
NCT01197092|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2010-11-15|2010-09-08|2010-09-09|Estimate|||||||2010-11-15|2010-11-16|Estimate|November 2010||2010-11-30|September 2010|2010-09-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||The Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II|A Study Evaluating the Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II|Unknown status|Recruiting|Phase 2|40|Anticipated|Center for Integrative Medicine, Germany||2|||f||||f||||||||||2018-05-31 23:22:48.595394|2018-05-31 23:22:48.595394
NCT01197079|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-08|||2011-07-14|2010-09-08|2010-09-09|Estimate|||||||2011-07-14|2011-07-15|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||Utilization of Human Papillomavirus (HPV) Vaccine Among Young Men Who Have Sex With Men (MSM) and Parents of Boys (Aged 9 to 18 Years)|Survey Study of the Awareness, Acceptance, and Barriers to Utilization of Human Papillomavirus (HPV) Vaccine Among Young Men Who Have Sex With Men (MSM) and Parents of Boys (Aged 9 to 18 Years)|Unknown status|Recruiting||800|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-05-31 23:22:48.700181|2018-05-31 23:22:48.700181
NCT01194752|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2017-05-03|2010-09-02|2010-09-03|Estimate|||||||2017-05-03|2017-05-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:23:36.223769|2018-05-31 23:23:36.223769
NCT01197066|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2016-01-27|2010-09-08|2010-09-09|Estimate|||||||2016-01-27|2016-01-29|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis|A Phase Ⅲ Multicenter, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Certolizumab Pegol as Additional Medication to Methotrexate, in Patients With Active Rheumatoid Arthritis Who Participated in Study 101-KOA-0801i|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 23:22:48.828683|2018-05-31 23:22:48.828683
NCT01197053|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2015-10-18|2010-09-07|2010-09-09|Estimate|||||||2015-10-18|2015-10-20|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|ARACHILD||Epicutaneous Immunotherapy in Peanut Allergy in Children|ARACHILD: A Multicentric, Double Blind Placebo-controlled Pilot Protocol to Study the Efficacy and Safety of an Epicutaneous Immunotherapy in Children Allergic to Peanut|Completed||Phase 2|60|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:22:49.125335|2018-05-31 23:22:49.125335
NCT01197040|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2017-06-27|2010-09-08|2010-09-09|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2009||2009-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|MSN||Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome|Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome|Completed||Phase 3|117|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:22:49.308994|2018-05-31 23:22:49.308994
NCT01197027|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2012-06-04|2010-09-08|2010-09-09|Estimate|||||||2012-06-04|2012-06-06|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|HPTN062||Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection|Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals With Acute and Early HIV-Infection|Completed||Phase 3|28|Actual|HIV Prevention Trials Network||2|||f||||f||||||||||2018-05-31 23:22:49.402213|2018-05-31 23:22:49.402213
NCT01197014|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2011-04-26|2010-09-07|2010-09-09|Estimate|||||||2011-04-26|2011-04-27|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan|A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects|Completed||Phase 1|72|Anticipated|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 23:22:49.630845|2018-05-31 23:22:49.630845
NCT01197001|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2011-04-26|2010-09-07|2010-09-09|Estimate|||||||2011-04-26|2011-04-27|Estimate|August 2010||2010-08-31|April 2011|2011-04-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan|A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects|Completed||Phase 1|72|Anticipated|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 23:22:49.72727|2018-05-31 23:22:49.72727
NCT01196988|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2012-12-17|2012-07-23|2017-03-21|2010-09-08|2010-09-09|Estimate|2013-02-14|2013-03-19|Estimate|2012-07-23|2012-07-31|Estimate|2017-03-21|2017-03-23|Actual|October 2010||2010-10-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children|Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children|Completed||Phase 3|3027|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:22:49.876244|2018-05-31 23:22:49.876244
NCT01196975|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2012-11-21|2012-03-07|2016-09-09|2010-09-08|2010-09-09|Estimate|2012-11-21|2012-12-24|Estimate|2012-03-07|2012-03-08|Estimate|2016-09-09|2016-10-20|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults|Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older|Completed||Phase 3|1707|Actual|GlaxoSmithKline|Analyses of duration for solicited local and general and unsolicited adverse events were not performed. Relationship to vaccination was not computed for medically-attended adverse events. Joint pain data were collected in Canada and Mexico only.|5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:22:56.164503|2018-05-31 23:22:56.164503
NCT01196962|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2012-11-22|2010-09-07|2010-09-09|Estimate|||||||2012-11-22|2012-11-27|Estimate|November 2010||2010-11-30|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Safety Study of Subclavian and Internal Jugular Venous Catheterization|A Randomize Controlled Trial to Compare the Complications of Subclavian and Internal Jugular Venous Catheterization in Critically Ill Patients|Unknown status|Recruiting|N/A|300|Anticipated|E-DA Hospital||1|||f||||t||||||||||2018-05-31 23:22:58.19774|2018-05-31 23:22:58.19774
NCT01196949|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-24|2010-09-07|2010-09-09|Estimate|||||||2010-09-24|2010-09-27|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Interventional|||Comparing Manipulation and Rehabilitation to Rehabilitation Only, in the Management of Chronic Ankle Instability|The Effectiveness of Combined Manipulation and Rehabilitation Versus Rehabilitation Only, in the Management of Chronic Ankle Instability|Unknown status|Recruiting|N/A|30|Anticipated|Cleveland Chiropractic College||2|||f||||f||||||||||2018-05-31 23:22:58.269345|2018-05-31 23:22:58.269345
NCT01196936|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-12-06|2010-09-07|2010-09-09|Estimate|||||||2017-12-06|2017-12-08|Actual|September 2010||2010-09-30|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|LDTam||Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors|Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial|Active, not recruiting||Phase 2|85|Actual|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 23:22:58.431908|2018-05-31 23:22:58.431908
NCT01196923|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|2016-04-18||2016-06-16|2010-09-08|2010-09-09|Estimate|2016-06-16|2016-07-27|Estimate||||2016-06-16|2016-07-27|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation|Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation|Completed||Phase 4|20|Actual|CardioFocus||1|||f||||||||||||||2018-05-31 23:22:58.553201|2018-05-31 23:22:58.553201
NCT01196910|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2018-01-24|2010-09-08|2010-09-09|Estimate|||||||2018-01-24|2018-01-25|Actual|July 2011||2011-07-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Deep Transcranial Magnetic Stimulation (DTMS) as a Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Adults|Test Efficiency of Deep Transcranial Magnetic Stimulation (DTMS) Using an H-coil for Dorso-Lateral Prefrontal Cortex (HLPFC) to Treat Attention Deficit Hyperactivity Disorder (ADHD) in Adults|Recruiting||Phase 1|45|Anticipated|Brainsway||3|||f||||f||||||||||2018-05-31 23:22:58.670227|2018-05-31 23:22:58.670227
NCT01196897|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2015-12-07|2010-09-08|2010-09-09|Estimate|||||||2015-12-07|2015-12-08|Estimate|May 2009||2009-05-31|August 2012|2012-08-31|November 2013|Actual|2013-11-30|September 2012|Actual|2012-09-30||Interventional|EVOLVE||Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)|Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients|Completed||N/A|69|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 23:22:58.730917|2018-05-31 23:22:58.730917
NCT01196884|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2018-03-19|2010-09-08|2010-09-09|Estimate|||||||2018-03-19|2018-03-20|Actual|September 2010||2010-09-30|September 2010|2010-09-30||||||||Observational|UNIT||Immune Thrombocytopenia (ITP) Immune-Genetic Assessment|IMMUNE-GENETIC ASSESSMENT OF PRIMARY ITP IN ADULT|Unknown status|Recruiting||190|Anticipated|Azienda Sanitaria-Universitaria Integrata di Udine|||3||f||||||||||||||2018-05-31 23:22:58.799125|2018-05-31 23:22:58.799125
NCT01196871|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07||2013-07-18|2013-12-19|2010-09-08|2010-09-09|Estimate||||2013-07-18|2013-07-22|Estimate|2013-12-19|2014-01-27|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease|An Open-label Phase 2A Study to Investigate Drug-Drug Interactions Between AT1001 and Agalsidase in Subjects With Fabry Disease.|Completed||Phase 2|21|Actual|Amicus Therapeutics||4|||f||||f||||||||||2018-05-31 23:22:58.883975|2018-05-31 23:22:58.883975
NCT01196858|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2014-01-06|2010-09-07|2010-09-09|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland|Duration of Untreated Psychosis (DUP) and Pathways to Care in Patients With First- and Multiple Episodes of Psychosis in Nordland - a Study of the Components of DUP in a Rural Mental Health System|Completed|||62|Actual|University Hospital of North Norway|||||f||||f||||||||||2018-05-31 23:22:58.960524|2018-05-31 23:22:58.960524
NCT01196845|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2016-06-15|2010-09-07|2010-09-09|Estimate|||||||2016-06-15|2016-06-16|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ADISAS||Inflammation and Oxidative Stress of Adipose Tissue in Sleep Apnea Syndrome|Inflammation and Oxidative Stress of Adipose Tissue in Obese and Non-obese Patients Having Sleep Apnea Syndrome|Recruiting||N/A|80|Anticipated|University Hospital, Grenoble||4|||f||||f||||||||||2018-05-31 23:22:59.016609|2018-05-31 23:22:59.016609
NCT01196832|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2014-10-29|2010-09-06|2010-09-09|Estimate|||||||2014-10-29|2014-10-30|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Observational|FIREBROB||Role of Fibrocytes in Chronic Obstructive Pulmonary Disease|Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting||160|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 23:22:59.113304|2018-05-31 23:22:59.113304
NCT01196819|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|2016-02-18||2017-07-31|2010-09-06|2010-09-08|Estimate|2017-07-31|2018-02-21|Estimate||||2017-07-31|2018-02-21|Estimate|September 2010|Actual|2010-09-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|May 2012|Actual|2012-05-31||Interventional|||Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial|A Prospective Multi-center Randomized Trial Assessing the Safety and Effectiveness of Biodegradable Polymer Target Release Rapamycin-Eluting STent vs. XIENCE V Everolimus-Eluting Stent for the Treatment of Coronary Artery Disease|Completed||N/A|460|Actual|Shanghai MicroPort Medical (Group) Co., Ltd.||2|||f||||t||||||||No||2018-05-31 23:22:59.333981|2018-05-31 23:22:59.333981
NCT01196806|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate||||September 2010|2010-09-30||||||||Observational|||Comparison of Measurement of Arterial Blood Pressure by L&T NIBP Module With Invasive Arterial Blood Pressure in Neonates|Comparison of Measurement of Arterial Blood Pressure by L&T NIBP Module With Invasive Arterial Blood Pressure in Neonates|Completed|||||Larsen & Toubro Limited|||||f||||f||||||||||2018-05-31 23:22:59.643594|2018-05-31 23:22:59.643594
NCT01196793|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2016-05-12|2010-09-07|2010-09-08|Estimate|||||||2016-05-12|2016-05-13|Estimate|November 2010||2010-11-30|September 2010|2010-09-30||||November 2011|Anticipated|2011-11-30||Observational|||Hospital Admissions in Children Aged 3 Months to 5 Years Presenting With Fever to the Emergency Department|Evaluation of Medical and Non-medical Factors Associated With Admission of Children Aged 3 Months to 5 Years Presenting to the Urban Paediatric Emergency Department With Febrile Illness in the United Kingdom and in Switzerland|Withdrawn|||0|Actual|Imperial College Healthcare NHS Trust|||1|study halted prematurely, prior to enrolment of first participant|f||||f||||||||||2018-05-31 23:22:59.689803|2018-05-31 23:22:59.689803
NCT01196780|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2016-11-01|2010-09-06|2010-09-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)|MabThera Post Marketing Observational Study in TNF-IR Patients to Assess Efficacy and Safety of REPeated Courses in routinE ClinicAl pracTice|Terminated|||1240|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:22:59.744647|2018-05-31 23:22:59.744647
NCT01196767|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-04-02|2010-09-07|2010-09-08|Estimate|||||||2013-04-02|2013-04-04|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Ropivacaine Though Laterosternal Catheters After Cardiac Surgery|Postoperative Analgesia After Cardiac Surgery: Effects of a Continuous Infusion of Ropivacaine Through Laterosternal Catheters|Completed||Phase 4|40|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 23:22:59.79868|2018-05-31 23:22:59.79868
NCT01196754|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate|March 2008||2008-03-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|Anaconda||Pharmacokinetic of Sevoflurane During a 48h Sedation in Intensive Care Unit With AnaConDa®|Pharmacokinetic of Sevoflurane During a 48h Sedation in ICU With AnaConDa®|Completed||N/A|12|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 23:22:59.868662|2018-05-31 23:22:59.868662
NCT01196741|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2014-09-18||2015-04-17|2010-09-07|2010-09-08|Estimate|2015-04-17|2015-05-05|Estimate||||2015-04-17|2015-05-05|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|November 2012|Actual|2012-11-30||Interventional|SaPPrOC||Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer|A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 2/Phase 3|107|Actual|University College, London||2|||f||||t||||||||||2018-05-31 23:23:00.016757|2018-05-31 23:23:00.016757
NCT01196728|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-12-03|2010-09-07|2010-09-08|Estimate|||||||2010-12-03|2010-12-06|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes|Single-centre, Randomised, Double-blind, Placebo-controlled, Four-way Crossover Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Doses of CM3.1-AC100 in Patients With Type 2 Diabetes|Completed||Phase 1|16|Anticipated|CellMed AG, a subsidiary of BTG plc.||4|||f||||f||||||||||2018-05-31 23:23:00.645378|2018-05-31 23:23:00.645378
NCT01196715|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-03-14|2010-09-06|2010-09-08|Estimate|||||||2012-03-14|2012-03-15|Estimate|November 2010||2010-11-30|July 2010|2010-07-31|November 2015|Anticipated|2015-11-30|November 2013|Anticipated|2013-11-30||Interventional|REGIME||Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes|REGIME: A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha, With or Without Recombinant Human Granulocyte Colony Stimulating Factor, Versus Best Supportive Care in Patients With Low-risk Myelodysplastic Syndromes (MDS).|Unknown status|Not yet recruiting|Phase 3|360|Anticipated|Barts & The London NHS Trust||3|||f||||t||||||||||2018-05-31 23:23:00.720545|2018-05-31 23:23:00.720545
NCT01196702|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-06|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate|March 2010||2010-03-31|September 2010|2010-09-30|July 2011|Anticipated|2011-07-31|June 2010|Actual|2010-06-30||Observational|||Lymphocyte Immunophenotyping in Common Variable Immunodeficiency|Investigation of the Lymphocyte Surface Expression of Patients With Primary Immunodeficiency (Common Variable Immunodeficiency (CVID)), Compared to Controls|Unknown status|Recruiting||210|Anticipated|Barts & The London NHS Trust|||7||f||||f||||||Samples With DNA|"~     Blood serum samples kept for one year in secure laboratory.~   "|||2018-05-31 23:23:00.827732|2018-05-31 23:23:00.827732
NCT01196689|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2011-03-04|2010-09-06|2010-09-08|Estimate|||||||2011-03-04|2011-03-07|Estimate|October 2010||2010-10-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|PEAK||Pharmacokinetics in Adolescents|An Open, Single Centre, Phase I Study in Male Adolescents With Asthma, Aged 12 to 17 Years, to Assess Pharmacokinetics of Orally Administered AZD1981 Tablets 100 mg Twice Daily for 61/2 Days|Completed||Phase 1|21|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:23:00.89649|2018-05-31 23:23:00.89649
NCT01196676|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2011-07-29|2010-09-06|2010-09-08|Estimate|||||||2011-07-29|2011-08-01|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|AZD4451 SAD||Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451|A Phase I, Randomized, Double- Blind, Placebo- Controlled, Single-center Study, to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 Following Single Ascending Oral Dose Administration in Healthy Subjects|Completed||Phase 1|63|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:23:00.954412|2018-05-31 23:23:00.954412
NCT01196663|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-09-21|2010-09-05|2010-09-08|Estimate|||||||2010-09-21|2010-09-22|Estimate|April 2008||2008-04-30|July 2010|2010-07-31||||December 2008|Anticipated|2008-12-31||Interventional|||Comparison of the Performance of TMS-thermometer With Standard Esophageal or Urine Bladder Thermometer|Clinical Evaluation of TMS (Temperature Monitoring System) Performance|Unknown status|Recruiting|N/A|500|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 23:23:01.013932|2018-05-31 23:23:01.013932
NCT01196650|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-05|||2011-05-02|2010-09-05|2010-09-08|Estimate|||||||2011-05-02|2011-05-03|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||||||Interventional|||Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep|A Double Blind, Polysomnographic, Three-Way Crossover Study to Compare the Efficacy of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep|Completed||Phase 2|24|Anticipated|Intec Pharma Ltd.||3|||f||||||||||||||2018-05-31 23:23:01.076039|2018-05-31 23:23:01.076039
NCT01196637|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-05|||2010-09-08|2010-09-05|2010-09-08|Estimate|||||||2010-09-08|2010-09-09|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Thoracic Outlet Syndrome: Case Reports and Analysis With Ultrasound Imaging|Thoracic Outlet Syndrome: Case Reports and Analysis - Ultrasound Imaging and Pathomechanics of Brachial Plexus Compression|Completed|||6|Actual|EMG Labs of Arizona Arthritis & Rheumatology Associates|||2||f||||f||||||||||2018-05-31 23:23:01.133025|2018-05-31 23:23:01.133025
NCT01196624|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2013-02-05|2010-09-07|2010-09-08|Estimate|||||||2013-02-05|2013-02-07|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|BSPTSDTMS2010||Repetitive Transcranial Magnetic Stimulation With Or Without Traumatic Stimuli in Post Traumatic Stress Disorder (PTSD)|Efficacy of Repetitive Transcranial Magnetic Stimulation Right Versus Left, With or Without Traumatic Stimuli in the Treatment of Posttraumatic Stress Disorder (PTSD) and Its Flashbacks|Completed||Phase 2|11|Actual|Beersheva Mental Health Center||4|||f||||f||||||||||2018-05-31 23:23:01.312956|2018-05-31 23:23:01.312956
NCT01196611|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-03-28|2010-09-07|2010-09-08|Estimate|||||||2017-03-28|2017-03-30|Actual|September 2010||2010-09-30|September 2010|2010-09-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Effectiveness of Two Therapeutic Approaches in Female Teachers With Voice Disorders|Effectiveness of Two Therapeutic Approaches in Female Teachers With Voice Disorders|Completed||N/A|162|Actual|Federal University of São Paulo||2|||f||||t||||||||No|The data of the participants are confidential|2018-05-31 23:23:01.420588|2018-05-31 23:23:01.420588
NCT01196598|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|January 2011|Anticipated|2011-01-31|October 2010|Anticipated|2010-10-31||Interventional|||Pelvic Floor Muscle Training and Hypopressive Exercises for Pelvic Organ Prolapse|Impact of Pelvic Floor Muscle Training and Hypopressive Exercises in Women With Pelvic Organ Prolapse: Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|84|Anticipated|Federal University of São Paulo||4|||f||||f||||||||||2018-05-31 23:23:01.489579|2018-05-31 23:23:01.489579
NCT01196585|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2011-05-16|2010-09-07|2010-09-08|Estimate|||||||2011-05-16|2011-05-17|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Ultrasonography Guided Pleural Biopsy Versus Computed Tomography Guided Pleural Biopsy|ULTRASONOGRAPHY GUIDED PLEURAL NEEDLE BIOPSY VERSUS COMPUTED TOMOGRAPHY GUIDED ABRAMS PLEURAL NEEDLE BIOPSY FOR DIAGNOSIS OF PATIENTS WITH PLEURAL EFFUSIONS: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|120|Anticipated|Eskisehir Osmangazi University||2|||f||||t||||||||||2018-05-31 23:23:01.561259|2018-05-31 23:23:01.561259
NCT01196572|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|||2011-08-07|2010-09-04|2010-09-08|Estimate|||||||2011-08-07|2011-08-09|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|IU||Efficiency of Cold vs. Laser Internal Urethrotomy Treatment of Urethral Strictures|Cold vs. Laser Internal Urethrotomy Treatment of Urethral Strictures|Unknown status|Recruiting|Phase 4|40|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:23:01.629936|2018-05-31 23:23:01.629936
NCT01196559|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2015-02-14|2010-09-07|2010-09-08|Estimate|||||||2015-02-14|2015-02-18|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer|A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma.|Completed||Phase 2|44|Actual|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 23:23:01.698936|2018-05-31 23:23:01.698936
NCT01196546|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-28|||2017-07-30|2010-09-04|2010-09-08|Estimate|||||||2017-07-30|2017-08-01|Actual|March 2010||2010-03-31|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)|Multi-center, Open-label, 24-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin 50/500 or 50/1000 mg Twice Daily in Patients With T2DM Inadequately Controlled With Metformin|Completed||Phase 4|161|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:23:01.769786|2018-05-31 23:23:01.769786
NCT01196533|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-29|||2015-02-08|2010-09-04|2010-09-08|Estimate|||||||2015-02-08|2015-02-10|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||A Comparative Clinical Trial to Assess the Accuracy of the TensorTip, a Novel Non Invasive Device for the Measurement of Physiological Parameters and Blood Parameters|A Comparative Clinical Trial to Assess the Accuracy of the TensorTip, a Novel Non Invasive Device for the Measurement of Physiological and Blood Chemistry Parameters|Completed||N/A|94|Actual|Cnoga Medical Ltd.||1|||f||||f||||||||||2018-05-31 23:23:01.898553|2018-05-31 23:23:01.898553
NCT01196520|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|||2018-05-08|2010-09-04|2010-09-08|Estimate|||||||2018-05-08|2018-05-09|Actual|May 24, 2010||2010-05-24|May 4, 2018|2018-05-04||||||||Observational|||Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)|Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)|Completed|||4893|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:23:02.056951|2018-05-31 23:23:02.056951
NCT01196507|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|||2016-06-14|2010-09-04|2010-09-08|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Early Primary Prophylaxis of Esophageal Varices|A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis.|Completed||N/A|140|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 23:23:02.127061|2018-05-31 23:23:02.127061
NCT01196494|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate||||January 2005|2005-01-31||||||||Interventional|||Study of Intraoperative Colonic Irrigation Versus Stent Placement in Obstructive Left-Sided Colonic Cancer|Prospective, Controlled, Randomized Study of Intraoperative Colonic Irrigation vs. Stent Placement in Obstructive Left-Sided Colonic Cancer|Terminated||N/A|||Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 23:23:02.193559|2018-05-31 23:23:02.193559
NCT01196481|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|||2017-08-14|2010-09-07|2010-09-08|Estimate|||||||2017-08-14|2017-08-16|Actual|December 2012||2012-12-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.|A Prospective,Open Labeled, Randomized Controlled Trial Comparing Carvedilol + VSL# 3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.|Completed||N/A|40|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 23:23:02.24926|2018-05-31 23:23:02.24926
NCT01196468|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2012-04-11|2010-09-07|2010-09-08|Estimate|||||||2012-04-11|2012-04-12|Estimate|July 2010||2010-07-31|October 2009|2009-10-31|February 2014|Anticipated|2014-02-28|July 2011|Actual|2011-07-31||Observational|||HIV Indicator Diseases Survey Across Europe - UK Arm|HIV Indicator Diseases Survey Across Europe|Unknown status|Recruiting||2000|Anticipated|Chelsea and Westminster NHS Foundation Trust|||5||f||||t||||||None Retained|"~     Salivary or serological HIV test~   "|||2018-05-31 23:23:02.317936|2018-05-31 23:23:02.317936
NCT01196455|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate|March 2006||2006-03-31|August 2010|2010-08-31||||April 2011|Anticipated|2011-04-30||Interventional|||Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer|Phase II Clinical Study of Capecitabine in Combination With Mitomycin C as First-Line Treatment in Patients With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|39|Anticipated|Croatian Cooperative Group for Clinical Research in Oncology|||||f||||f||||||||||2018-05-31 23:23:02.408645|2018-05-31 23:23:02.408645
NCT01196442|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-10-11||2013-08-21|2010-09-07|2010-09-08|Estimate|2013-01-09|2013-02-12|Estimate||||2013-08-21|2013-08-23|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer|An Expanded Trial of MC5-A Calmare Therapy in the Treatment of Cancer Pain Syndromes and Chronic Chemotherapy-Induced Peripheral Neuropathy Including Pain and Numbness|Completed||N/A|39|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 23:23:02.482955|2018-05-31 23:23:02.482955
NCT01196429|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|2016-12-21||2017-05-10|2010-09-04|2010-09-08|Estimate|2017-03-22|2017-05-03|Actual||||2017-05-10|2017-06-12|Actual|August 2010||2010-08-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Eligible and treated patients|Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer|A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary|Completed||Phase 2|90|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:23:02.797594|2018-05-31 23:23:02.797594
NCT01196416|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|2017-05-22||2017-09-18|2010-09-04|2010-09-08|Estimate|2017-09-18|2017-10-18|Actual||||2017-09-18|2017-10-18|Actual|August 2010||2010-08-31|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma|Phase Ib/II Study of the Gamma-Secretase Inhibitor (GSI) RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:23:04.042269|2018-05-31 23:23:04.042269
NCT01196403|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|||2011-03-31|2010-09-04|2010-09-08|Estimate|||||||2011-03-31|2011-04-01|Estimate|January 2009||2009-01-31|September 2010|2010-09-30||||December 2010|Anticipated|2010-12-31||Interventional|||Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer|Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer.|Unknown status|Recruiting|Phase 2|92|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:23:04.338329|2018-05-31 23:23:04.338329
NCT01196390|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-04|||2018-05-24|2010-09-04|2010-09-08|Estimate|||||||2018-05-24|2018-05-25|Actual|December 30, 2010|Actual|2010-12-30|May 2018|2018-05-31||||August 31, 2018|Anticipated|2018-08-31||Interventional|||Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer|A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma|Active, not recruiting||Phase 3|591|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:23:04.477523|2018-05-31 23:23:04.477523
NCT01196377|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-12-10||2017-09-04|2010-09-07|2010-09-08|Estimate|2017-09-04|2017-09-29|Actual||||2017-09-04|2017-09-29|Actual|September 2010||2010-09-30|September 2017|2017-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|OARS||Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study|Personalized Medicine, Biomarker-based Study of Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study|Completed||N/A|16|Actual|Vanderbilt University Medical Center|Limitations: small sample size and not powered to detect differences in outcomes (pilot feasibility study).|4|||f||||f||||||||||2018-05-31 23:23:05.708073|2018-05-31 23:23:05.708073
NCT01196364|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-09-03|2010-09-03|2010-09-08|Estimate|||||||2010-09-03|2010-09-08|Estimate|March 2009||2009-03-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|HIE||Activity at 25% Above the Ventilation Threshold on Appetite and Food Intake in Boys|Effect of Activity at 25% Above the Ventilation Threshold on Appetite and Food Intake After a Glucose Drink in Normal Weight Boys|Completed||N/A|19|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 23:23:05.977967|2018-05-31 23:23:05.977967
NCT01196351|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-09-03|2010-09-03|2010-09-08|Estimate|||||||2010-09-03|2010-09-08|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|VeT||Activity at Ventilation Threshold on Appetite and Food Intake in Boys|Effect of Activity at the Ventilation Threshold on Appetite and Food Intake After a Glucose Drink in Normal Weight, Overweight and Obese Boys|Completed||N/A|35|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 23:23:06.053749|2018-05-31 23:23:06.053749
NCT01196338|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-06-09|2010-09-03|2010-09-08|Estimate|||||||2011-06-09|2011-06-13|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|||Early Weightbearing and Mobilization Versus Non-Weightbearing and Mobilization in Unstable Ankle Fractures|Early Weightbearing and Mobilization Versus Non-Weightbearing and Immobilization After ORIF of Unstable Ankle Fractures: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|110|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 23:23:06.122574|2018-05-31 23:23:06.122574
NCT01196325|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2013-01-23|2010-09-07|2010-09-08|Estimate|||||||2013-01-23|2013-01-24|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|VEGF||Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy|Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy.|Unknown status|Recruiting||64|Anticipated|University of Toronto|||4||f||||f||||||||||2018-05-31 23:23:06.213119|2018-05-31 23:23:06.213119
NCT01196312|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-09-03|2010-09-03|2010-09-08|Estimate|||||||2010-09-03|2010-09-08|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|ASTH-HR||Anxiety Sensitivity Treatment for Heroin Users|Novel Intervention for Drug Use and HIV Risk Among Anxiety Sensitive Heroin Users|Unknown status|Recruiting|N/A|60|Anticipated|University of Maryland|||||f||||||||||||||2018-05-31 23:23:06.283224|2018-05-31 23:23:06.283224
NCT01196299|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2018-01-23|2010-09-03|2010-09-08|Estimate|||||||2018-01-23|2018-01-25|Actual|March 21, 2010|Actual|2010-03-21|January 2018|2018-01-31|September 5, 2015|Actual|2015-09-05|April 17, 2015|Actual|2015-04-17||Observational|Imaging of TBI||Imaging of Traumatic Brain Injury|Prognostic Value of MR Imaging Markers in the Assessment of Traumatic Brain Injury Patients|Completed|||150|Actual|University of Maryland|||4||f||||f||||||||||2018-05-31 23:23:06.343127|2018-05-31 23:23:06.343127
NCT01196286|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-04-24|2010-09-07|2010-09-08|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2010||2010-06-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis|Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis|Completed||N/A|40|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 23:23:06.506121|2018-05-31 23:23:06.506121
NCT01196273|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2012-06-27|2010-09-07|2010-09-08|Estimate|||||||2012-06-27|2012-06-28|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up|HIV-HEART STUDY: A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk in HIV-infected Patients|Completed|||1424|Actual|University Hospital, Essen|||1||f||||t||||||Samples Without DNA|"~     Stored blood samples~   "|||2018-05-31 23:23:06.587959|2018-05-31 23:23:06.587959
NCT01196260|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2018-02-18|2010-09-07|2010-09-08|Estimate|||||||2018-02-18|2018-02-20|Estimate|January 2004||2004-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III|Clinical Trial on Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III Among Chinese Population|Recruiting||Phase 2/Phase 3|8000|Anticipated|State Key Laboratory of Cancer Biology||1|||f||||t||||||||||2018-05-31 23:23:06.72168|2018-05-31 23:23:06.72168
NCT01196247|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2012-07-16|2010-09-07|2010-09-08|Estimate|||||||2012-07-16|2012-07-17|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer|Stand Up to Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated With Metastatic Pancreatic Cancer|Completed||Phase 2|35|Actual|Translational Drug Development|||||f||||f||||||||||2018-05-31 23:23:06.827742|2018-05-31 23:23:06.827742
NCT01196234|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-01-28|2010-09-07|2010-09-08|Estimate|||||||2013-01-28|2013-01-29|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|PRIDE||Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer|Paclitaxel/Carboplatin (PC) Followed by Gefitinib or Paclitaxel/Carboplatin (PC) in Advanced Non-small Cell Lung Cancer (NSCLC): Randomized Phase II Study|Completed||Phase 2|84|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:23:06.89941|2018-05-31 23:23:06.89941
NCT01196221|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||Technical Innovation Protocol for MR & US Plaque Imaging: Reproducibility.|Technical Innovation Protocol for Carotid Plaque Imaging by 3.0 Tesla MRI, MRS and Ultrasound: Reproducibility.|Completed|||30|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 23:23:06.96292|2018-05-31 23:23:06.96292
NCT01196208|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-09-07|2010-09-07|2010-09-08|Estimate|||||||2017-09-07|2017-09-11|Actual||||September 2017|2017-09-30||||||||Expanded Access|||A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001|An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma|Available|||||Seattle Genetics, Inc.|||||||||||||||||||2018-05-31 23:23:07.020231|2018-05-31 23:23:07.020231
NCT01196195|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2013-10-25|2010-09-07|2010-09-08|Estimate|||||||2013-10-25|2013-10-28|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|July 2012|Actual|2012-07-31||Interventional|KONCERT||KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)|KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)|Completed||Phase 2/Phase 3|173|Actual|PENTA Foundation||2|||f||||t||||||||||2018-05-31 23:23:07.241572|2018-05-31 23:23:07.241572
NCT01196182|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-04-04|2010-09-03|2010-09-08|Estimate|||||||2017-04-04|2017-04-05|Actual|November 2010||2010-11-30|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|CHD GENES||Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)|Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)|Recruiting|||10000|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||Samples With DNA|"~     Blood; possibly saliva and tissue.~   "|||2018-05-31 23:23:07.386488|2018-05-31 23:23:07.386488
NCT01196169|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-01-31|2010-09-03|2010-09-08|Estimate|||||||2014-01-31|2014-02-03|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty|Daptomycin Use For Prophylaxis In Prosthetic Joint Surgery, A Randomized Prospective Study Comparing The Efficacy Of Daptomycin Versus Vancomycin For Peri-Operative Antibiotic Prophylaxis In MRSA Colonized Adult Patients Undergoing Primary Elective Hip, Knee or Shoulder Arthroplasty|Terminated||Phase 4|28|Actual|Mountain Home Research & Education Corporation||2||"The study is closed to accrual. Enrollment of new patients stopped at the request of CUBIST~   Pharmaceuticals due to slow rate of enrollment."|f||||t||||||||||2018-05-31 23:23:07.505667|2018-05-31 23:23:07.505667
NCT01196156|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2018-05-02|2010-09-03|2010-09-08|Estimate|||||||2018-05-02|2018-05-03|Actual|September 30, 2005|Actual|2005-09-30|April 2018|2018-04-30|February 29, 2020|Anticipated|2020-02-29|December 31, 2019|Anticipated|2019-12-31||Observational|SGA||Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone|An Observational Phase IV Study for Prospective Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone|Active, not recruiting|||443|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:23:07.614216|2018-05-31 23:23:07.614216
NCT01196143|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2014-02-03|2010-09-03|2010-09-08|Estimate|||||||2014-02-03|2014-02-04|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation|Non-interventional Observational Study to Evaluate the Baseline FSH, Ovarian Volume and AFC (Antral Follicle Count) as Prognostic Factors of the Outcome of the In-vitro Fertilization/Intracytosolic Sperm Injection (IVF/ICSI) in Infertile Patients Who Receive r-FSH (GONAL-f®) for Controlled Ovarian Hyperstimulation|Completed|||356|Actual|Merck KGaA|||||f||||||||||Samples Without DNA|"~     Plasma, serum, urine~   "|||2018-05-31 23:23:07.709463|2018-05-31 23:23:07.709463
NCT01196130|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2018-01-29|2010-09-07|2010-09-08|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2010|Actual|2010-08-31|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|||Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol|Assessment of Targeted Therapy Against Colorectal Cancer (ATTACC) Screening Protocol|Recruiting|||1280|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood (16 mL) collected and archived tumor samples (primary tumor or metastatic site) from~     prior surgeries or biopsies.~   "|||2018-05-31 23:23:07.764515|2018-05-31 23:23:07.764515
NCT01196117|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2014-04-08|2010-09-07|2010-09-08|Estimate|||||||2014-04-08|2014-04-10|Estimate|November 2004||2004-11-30|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea|Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea|Completed||N/A|18|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 23:23:07.842276|2018-05-31 23:23:07.842276
NCT01196104|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2014-07-22|2012-05-09|2014-10-21|2010-09-03|2010-09-08|Estimate|2014-10-20|2014-10-21|Estimate|2012-05-09|2012-05-14|Estimate|2014-10-21|2014-10-30|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler|A Phase 3b, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder, Using the Gen2 Inhaler, in Combination With Insulin Glargine Versus Insulin Aspart in Combination With Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Over a 16-week Treatment Period|Terminated||Phase 3|39|Actual|Mannkind Corporation|- Early termination of trial leading to small numbers of subjects analyzed.|2||For Business Reasons|f||||f||||||||||2018-05-31 23:23:08.003347|2018-05-31 23:23:08.003347
NCT01196091|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03||2014-09-29|2015-12-31|2010-09-03|2010-09-08|Estimate||||2014-09-29|2014-10-08|Estimate|2015-12-31|2016-02-02|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|||A Study of LY2127399 in Patients With Systemic Lupus Erythematosus|A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE)|Completed||Phase 3|1164|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 23:23:08.962491|2018-05-31 23:23:08.962491
NCT01195922|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2016-10-27||2017-10-31|2010-09-03|2010-09-06|Estimate|2017-01-18|2017-01-19|Estimate||||2017-10-31|2017-12-06|Actual|August 2010||2010-08-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma|A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer|Completed||Phase 1/Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||No||2018-05-31 23:23:15.488589|2018-05-31 23:23:15.488589
NCT01196078|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-07-23||2015-06-29|2010-09-03|2010-09-08|Estimate|2015-06-29|2015-07-27|Estimate||||2015-06-29|2015-07-27|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Intent-to-treat (ITT) population: all randomized participants who received at least one dose of study medication.|A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan|Completed||Phase 4|114|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:23:09.457912|2018-05-31 23:23:09.457912
NCT01196065|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2016-11-01|2010-09-03|2010-09-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|November 2010||2010-11-30|||||Interventional|||A Study of the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of Single Dose RO5313534 in Healthy Volunteers, and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine|A Single Center, Open-label, Fixed Sequence, Two-period Study to Investigate the Effect of Memantine on Pharmacokinetics, Safety and Tolerability of RO5313534 After Single Dose Administration in Healthy Volunteers and the Effect of RO5313534 on Safety and Tolerability of Steady State Memantine|Completed||Phase 1|16|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:23:10.196987|2018-05-31 23:23:10.196987
NCT01196052|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-05-27||2014-09-26|2010-09-03|2010-09-08|Estimate|2014-05-27|2014-06-26|Estimate||||2014-09-26|2014-10-06|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Enrolled participant population: All participants enrolled in the study.|A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer|A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Cancer|Completed||Phase 2|153|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:23:10.268102|2018-05-31 23:23:10.268102
NCT01196039|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2016-11-01|2010-09-03|2010-09-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|||A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma|Completed||Phase 2|29|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:23:10.784989|2018-05-31 23:23:10.784989
NCT01196026|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-03-12||2016-09-09|2010-09-03|2010-09-08|Estimate|2012-05-24|2012-06-28|Estimate||||2016-09-09|2016-10-20|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™|Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine Fluarix™ in Children Previously Vaccinated With GSK Biologicals' H1N1 Vaccine Pandemrix™|Completed||Phase 4|162|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:23:11.015075|2018-05-31 23:23:11.015075
NCT01196013|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2014-03-17|2010-09-07|2010-09-08|Estimate|||||||2014-03-17|2014-03-19|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia|A Phase I, Open-label, Multi-center Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia|Completed||Phase 1|7|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 23:23:14.259983|2018-05-31 23:23:14.259983
NCT01196000|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2012-04-16|2010-09-07|2010-09-08|Estimate|||||||2012-04-16|2012-04-17|Estimate|December 2011||2011-12-31|April 2012|2012-04-30||||July 2013|Anticipated|2013-07-31||Interventional|||Laparoscopic Surgery or Robotic-Assisted Laparoscopic Surgery in Treating Patients With Rectal Cancer That Can Be Removed By Surgery|Laparoscopic Versus Robotic-Assisted Surgery for Rectal Cancer|Withdrawn||N/A|0|Actual|City of Hope Medical Center||2||"The study has never been opened to accrual at COH. Study to be closed at COH due to the lack of~   qualified robotic colorectal surgeons."|f||||t||||||||||2018-05-31 23:23:14.44691|2018-05-31 23:23:14.44691
NCT01195987|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-09-07|2010-09-07|2010-09-08|Estimate|||||||2010-09-07|2010-09-08|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||Immune Dysregulation in Hepatitis C Patients With or Without Arthritis|Immune Dysregulation in Hepatitis C Patients With or Without Arthritis|Unknown status|Recruiting||30|Anticipated|The Center for Rheumatic Disease, Allergy, & Immunology|||2||f||||f||||||||||2018-05-31 23:23:14.53076|2018-05-31 23:23:14.53076
NCT01195974|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2014-12-22|2010-09-03|2010-09-06|Estimate|||||||2014-12-22|2014-12-24|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.|A Double-Blind Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Drospirenone and Ethinyl Estradiol When Co-administered With GSK2248761 in Healthy Adult Female Subjects|Terminated||Phase 1|13|Actual|ViiV Healthcare||3||"In a Phase II study in HIV-infected patients there were a number of seizures, although exact~   causality could not be assessed phase 1 activity was terminated."|f||||f||||||||||2018-05-31 23:23:14.5962|2018-05-31 23:23:14.5962
NCT01195961|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-06-30|2010-09-03|2010-09-06|Estimate|||||||2017-06-30|2017-07-02|Actual|August 17, 2010||2010-08-17|July 1, 2011|2011-07-01|July 1, 2011||2011-07-01|||||Observational|||Facilitating Numerical Processing With Transcranial Stimulation in Developmental Dyscalculia|Facilitating Numerical Processing With Transcranial DC Stimulation in Developmental Dyscalculia|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:23:14.673826|2018-05-31 23:23:14.673826
NCT01195948|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-10-29||2014-12-01|2010-09-03|2010-09-06|Estimate|2014-12-01|2014-12-05|Estimate||||2014-12-01|2014-12-05|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis|Peptide B27PD (Optiquel®) as Corticosteroid-sparing Therapy for Chronic Non-infectious Uveitis (BOOTS)|Completed||Phase 1/Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)|The protocol was completed early due to lack of efficacy. The Data Safety Monitoring Committee (DSMC), along with the PI, reviewed an interim data report and agreed that Optiquel® was not efficacious and did not cause a proliferative response.|3|||f||||t||||||||||2018-05-31 23:23:14.762194|2018-05-31 23:23:14.762194
NCT01195896|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2012-01-13|2010-09-03|2010-09-06|Estimate|||||||2012-01-13|2012-01-16|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a New Negative Pressure Wound Therapy (NPWT) System to be Used in the Treatment of Acute Non-infected Wounds and Post Surgical Infected Wounds|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a New Negative Pressure Wound Therapy (NPWT) System to be Used in the Treatment of Acute Non-infected Wounds and Post Surgical Infected Wounds.|Completed||N/A|9|Actual|Molnlycke Health Care AB|||||f||||f||||||||||2018-05-31 23:23:15.724164|2018-05-31 23:23:15.724164
NCT01195883|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2018-01-05|2010-09-03|2010-09-06|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2010||2010-11-30|January 2018|2018-01-31|October 20, 2017|Actual|2017-10-20|November 2016|Actual|2016-11-30||Interventional|C-C||Effect of Goal-directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity|Effect of Goal-directed Crystalloid Versus Colloid Administration on Major Postoperative Morbidity|Completed||N/A|1112|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 23:23:15.784403|2018-05-31 23:23:15.784403
NCT01195870|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2014-02-14|2010-09-03|2010-09-06|Estimate|||||||2014-02-14|2014-02-17|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|||Assessment of Patient Use of a New Device: RebiSmart|Assessment of Patient Use of a New Device: RebiSmart|Completed|||63|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:23:15.867203|2018-05-31 23:23:15.867203
NCT01195857|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2014-02-03|2010-09-03|2010-09-06|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration|Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration|Completed|||100|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:23:15.923963|2018-05-31 23:23:15.923963
NCT01195844|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-11-08||2015-02-23|2010-09-03|2010-09-06|Estimate|2012-11-08|2012-12-05|Estimate||||2015-02-23|2015-03-12|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).|Rotavirus Gastroenteritis in Children Up to 5 Years of Age. Surveillance Performed in Hospitals From Four Brazilian Regions.|Terminated|||230|Actual|Merck Sharp & Dohme Corp.|||1|Inadequate recruitment|f||||f||||||||||2018-05-31 23:23:15.991166|2018-05-31 23:23:15.991166
NCT01195831|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-03-26||2015-03-25|2010-09-03|2010-09-06|Estimate|2012-03-26|2012-04-19|Estimate||||2015-03-25|2015-04-14|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis|Multicentre, Randomized, Investigator-Blinded, Parallel-group Study to Assess the Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis.|Completed||Phase 3|244|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 23:23:16.261484|2018-05-31 23:23:16.261484
NCT01195818|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2015-06-17|2010-09-03|2010-09-06|Estimate|||||||2015-06-17|2015-06-18|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|RAND||Albuminuria Reduction With Renin Angiotensin System Inhibitors in SCA Patients|Effect of RAS Inhibitors on Albuminuria, Hyperfiltration and Endothelial Dysfunction in a Sickle Cell Disease Population.|Completed||N/A|53|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:23:16.733461|2018-05-31 23:23:16.733461
NCT01195805|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2015-08-19|2010-09-03|2010-09-06|Estimate|||||||2015-08-19|2015-08-20|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|hass||The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables|The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study.|Completed||N/A|25|Anticipated|Regional Hospital Holstebro||3|||f||||t||||||||||2018-05-31 23:23:16.812806|2018-05-31 23:23:16.812806
NCT01195792|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2016-11-30|2010-09-03|2010-09-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.|A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour and Related Brain Function, in Obese Subjects With Over-Eating Behaviours.|Completed||Phase 2|60|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:23:16.887898|2018-05-31 23:23:16.887898
NCT01195779|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-03-22||2016-09-09|2010-09-03|2010-09-06|Estimate|2012-03-29|2012-04-24|Estimate||||2016-09-09|2016-10-20|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children|Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months|Terminated||Phase 2|4|Actual|GlaxoSmithKline||14||The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:23:17.02898|2018-05-31 23:23:17.02898
NCT01195766|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2016-02-23|2010-09-03|2010-09-06|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|September 2013|Actual|2013-09-30||Interventional|||Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma|Phase II-study Using Ofatumumab and ESHAP Followed by Autologous Trasplant of Hemopoietic Precursors for the Treatment of Classic Hodgkin's Lymphoma on Relapse, Partial Response or Refractory to First Line Treatment|Completed||Phase 2|64|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||||2018-05-31 23:23:18.137825|2018-05-31 23:23:18.137825
NCT01195753|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2016-02-05|2010-09-03|2010-09-06|Estimate|||||||2016-02-05|2016-02-08|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders|Open, Prospective, Historic-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Infusion of Liver Cell Suspension (HHLivC) in Children With Urea Cycle Disorders.|Terminated||Phase 2|10|Actual|Cytonet GmbH & Co. KG||1|||f||||t||||||||||2018-05-31 23:23:18.231821|2018-05-31 23:23:18.231821
NCT01195727|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-04-06|2010-09-03|2010-09-06|Estimate|||||||2017-04-06|2017-04-07|Actual|July 26, 2011|Actual|2011-07-26|April 2017|2017-04-30|July 16, 2012|Actual|2012-07-16|June 14, 2012|Actual|2012-06-14||Interventional|||Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter|Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter|Terminated||Phase 1|13|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 23:23:18.426261|2018-05-31 23:23:18.426261
NCT01195714|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2018-03-06|2010-09-03|2010-09-06|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2010||2010-05-31|March 2018|2018-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years|PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOUSLY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA|Completed||Phase 2|120|Actual|The Lymphoma Academic Research Organisation||1|||f||||f||||||||||2018-05-31 23:23:18.52208|2018-05-31 23:23:18.52208
NCT01195701|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-04-29||2014-11-24|2010-09-03|2010-09-06|Estimate|2014-11-24|2014-12-03|Estimate||||2014-11-24|2014-12-03|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational||A sample size calculation determined that with an alpha level of 0.05 a sample size of 13 participants in each arm (N=26) would yield 90% power to detect a mean difference of 5.6 between groups on the FSFI Orgasm subscale. We planned to enroll 40 patients (20 in each arm) to accommodate a predicted dropout rate of approximately 40%.|Clitoral Location in Relation to Sexual Function Using Pelvic Imaging|Clitoral Location in Relation to Sexual Function Using Pelvic MRI: A Case-Control Study|Completed|||35|Actual|TriHealth Inc.|||2||f||||f||||||Samples Without DNA|"~     Blood hormone levels~   "|||2018-05-31 23:23:18.692811|2018-05-31 23:23:18.692811
NCT01195688|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2011-06-01|2010-09-03|2010-09-06|Estimate|||||||2011-06-01|2011-06-02|Estimate|September 2010||2010-09-30|June 2011|2011-06-30||||December 2010|Actual|2010-12-31||Interventional|||Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1-700 mg) of BI 638683 Powder in Bottle (PiB) in Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)|Completed||Phase 1|63|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:23:19.01156|2018-05-31 23:23:19.01156
NCT01195675|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-05-16||2014-07-25|2010-09-03|2010-09-06|Estimate|2014-07-25|2014-07-28|Estimate||||2014-07-25|2014-07-28|Estimate|August 2010||2010-08-31|July 2014|2014-07-31||||November 2010|Actual|2010-11-30||Interventional|||Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects|Assessment of the Effect of 25 mg and 200 mg of BI 10773 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Five-period Crossover Phase-I-study With Moxifloxacin as Positive Control|Completed||Phase 1|30|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:23:19.075041|2018-05-31 23:23:19.075041
NCT01195662|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-02-07||2016-11-10|2010-09-03|2010-09-06|Estimate|2014-04-28|2014-05-23|Estimate||||2016-11-10|2016-12-29|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Participants in Double-Blind Period who were randomized and treated with at least one dose of double-blind study medication.|A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication|Completed||Phase 3|2245|Actual|AstraZeneca|Totality of data from dapagliflozin development program as of 1 NOV 2011 showed 10 mg dapagliflozin dose provided optimal efficacy, was safe and well tolerated for the general Type 2 diabetes population, allowing the 5 mg arm to be discontinued.|2|||f||||f||||||||||2018-05-31 23:23:19.383154|2018-05-31 23:23:19.383154
NCT01195649|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2014-10-11|2010-09-03|2010-09-06|Estimate|||||||2014-10-11|2014-10-15|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Observational|||Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy|Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy|Completed|||11|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:23:20.891329|2018-05-31 23:23:20.891329
NCT01195636|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2013-07-17||2013-09-20|2010-09-02|2010-09-06|Estimate|2013-09-20|2013-11-25|Estimate||||2013-09-20|2013-11-25|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|XEN402||A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, and Systemic Exposure of Topical XPF-002 in Subjects With Postherpetic Neuralgia|Completed||Phase 2|70|Actual|Xenon Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 23:23:20.981829|2018-05-31 23:23:20.981829
NCT01195623|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-06-14||2013-02-13|2010-09-03|2010-09-06|Estimate|2013-02-13|2013-02-15|Estimate||||2013-02-13|2013-02-15|Estimate|November 1997||1997-11-30|February 2013|2013-02-28|August 2010|Actual|2010-08-31|September 2003|Actual|2003-09-30||Interventional|||The Long-term Value of Preoperative Duplex Before Surgery for Varicose Veins|Randomized Clinical Trial of Routine Preoperative Duplex Imaging Before Varicose Vein Surgery; Long-term Follow-up|Completed||N/A|293|Actual|Uppsala University Hospital|The rate of hand-held Doppler device use was not known and may have influenced the results, however even now many Swedish surgeons plan varicose vein surgery clinical tests only|2|||f||||f||||||||||2018-05-31 23:23:21.304473|2018-05-31 23:23:21.304473
NCT01195610|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2017-10-30|2010-09-03|2010-09-06|Estimate|||||||2017-10-30|2017-10-31|Actual|August 2010||2010-08-31|October 2017|2017-10-31|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Interventional|SHOPUS||Dietary Intervention With Shop Model - SHOPUS|A Six Month Randomized Controlled Dietary Intervention Study of the New Nordic Diet vs Average Danish Diet in Adults (18-65y) Using the Shop Model for Optimal Dietary Adherence|Completed||N/A|181|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 23:23:21.614648|2018-05-31 23:23:21.614648
NCT01195597|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2012-05-22||2013-01-03|2010-09-03|2010-09-06|Estimate|2012-08-10|2012-09-11|Estimate||||2013-01-03|2013-01-09|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Smoking Cessation and Reduction With an Electronic Nicotine Delivery Device (ENDD)|Effect of an Electronic Nicotine Delivery Device (ENDD) on Smoking Cessation and Reduction: a Pilot Study|Completed||N/A|40|Actual|Universita degli Studi di Catania||1|||f||||t||||||||||2018-05-31 23:23:21.71695|2018-05-31 23:23:21.71695
NCT01194739|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2017-02-23|2010-09-02|2010-09-03|Estimate|||||||2017-02-23|2017-02-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:23:36.264667|2018-05-31 23:23:36.264667
NCT01195584|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2011-08-16||2015-03-16|2010-09-03|2010-09-06|Estimate|2011-08-16|2011-09-21|Estimate||||2015-03-16|2015-04-03|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease|Minimal Access Surgical Technique (MAST) in Obese Patients in Degenerative Lumbar Disease|Completed|||72|Actual|General Hospital Amstetten|The study is retrospective and all patients during the timeframe (who signed the patient informed consent) have been included into the study.||3||f||||f||||||||||2018-05-31 23:23:21.882464|2018-05-31 23:23:21.882464
NCT01195571|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2015-05-18|2010-09-03|2010-09-06|Estimate|||||||2015-05-18|2015-05-19|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age|A Dose Escalation Study to Assess the Safety and Immunogenicity of Four Live Attenuated Human Cytomegalovirus(HCMV) Vaccines in Healthy Adults Without Prior Immunity.|Completed||Phase 1|36|Actual|CMV Research Foundation||1|||f||||t||||||||||2018-05-31 23:23:22.232749|2018-05-31 23:23:22.232749
NCT01195558|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2017-12-12|2010-09-03|2010-09-06|Estimate|||||||2017-12-12|2017-12-14|Actual|April 2010||2010-04-30|December 2017|2017-12-31|April 2030|Anticipated|2030-04-30|April 2030|Anticipated|2030-04-30||Observational|||Patient Registry of Blind Subjects With Sleep-related Problems|Development of a Patient Registry of Blind Subjects With Sleep-related Problems|Recruiting|||10000|Anticipated|Vanda Pharmaceuticals|||1||f||||f||||||||||2018-05-31 23:23:22.319992|2018-05-31 23:23:22.319992
NCT01195545|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2016-11-08|2010-09-03|2010-09-06|Estimate|||||||2016-11-08|2016-11-10|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Veritas Laparoscopic Paraesophageal Hiatal Hernia (PEH) Repair Pilot Trial|Veritas Laparoscopic PEH Repair Pilot Trial|Completed||N/A|20|Actual|University of Washington|||||f||||f||||||||||2018-05-31 23:23:22.379792|2018-05-31 23:23:22.379792
NCT01195532|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-09-03|2010-09-03|2010-09-06|Estimate|||||||2010-09-03|2010-09-06|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Observational|||An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects|An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects|Unknown status|Recruiting||40|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:23:22.439769|2018-05-31 23:23:22.439769
NCT01195519|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2011-04-22|2010-09-03|2010-09-06|Estimate|||||||2011-04-22|2011-04-26|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|||||Observational|||The Assessment of Quality of Life in Patients With Peritoneal Dialysis and Hemodialysis|The Study Will Investigate the Quality of Life in PD or HD Patients|Unknown status|Recruiting||95|Anticipated|Taipei Medical University WanFang Hospital|||1||f||||t||||||||||2018-05-31 23:23:22.498285|2018-05-31 23:23:22.498285
NCT01195506|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2010-10-05|2010-09-03|2010-09-06|Estimate|||||||2010-10-05|2010-10-06|Estimate|September 2010||2010-09-30|October 2010|2010-10-31||||||||Observational|||Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)|Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)|Unknown status|Active, not recruiting||40|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:23:22.55293|2018-05-31 23:23:22.55293
NCT01195493|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2014-12-04|2010-09-03|2010-09-06|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|Listerine||Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care|Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:23:22.607557|2018-05-31 23:23:22.607557
NCT01195480|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2018-05-16|2010-09-03|2010-09-06|Estimate|||||||2018-05-16|2018-05-17|Actual|May 2012||2012-05-31|May 2018|2018-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CD19TPALL||CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)|Immunotherapy With CD19ζ Gene-modified EBV-specific CTLs After Stem Cell Transplant in Children With High-risk Acute Lymphoblastic Leukaemia|Terminated||Phase 1/Phase 2|29|Actual|University College, London||2||Due to lack of biological efficacy and CD19 CAR CTL persistence|f||||t||||||||||2018-05-31 23:23:22.683983|2018-05-31 23:23:22.683983
NCT01195467|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|2014-10-29||2014-11-13|2010-09-03|2010-09-06|Estimate|2014-10-29|2014-11-04|Estimate||||2014-11-13|2014-11-26|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SSAT036||Atripla to Raltegravir Switch Study for CNS Toxicity|A Phase III, Open-label, Single Centre, Single-arm, Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Raltegravir|Completed||Phase 3|40|Actual|St Stephens Aids Trust||1|||f||||f||||||||||2018-05-31 23:23:23.885655|2018-05-31 23:23:23.885655
NCT01195454|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2011-10-28|2010-09-03|2010-09-06|Estimate|||||||2011-10-28|2011-10-31|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®||Completed||Phase 1|24|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:23:24.08095|2018-05-31 23:23:24.08095
NCT01195441|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-02-10|2010-09-03|2010-09-06|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2010|Actual|2010-09-30|February 2017|2017-02-28|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Observational|Screen-tox||Prediction and Prevention of Preeclampsia by First Trimester Ultrasound|Prediction and Prevention of Preeclampsia by First Trimester Ultrasound|Completed|||602|Actual|Norwegian University of Science and Technology|||||f||||t||||||Samples With DNA|"~     Blood samples Urine~   "|||2018-05-31 23:23:24.157386|2018-05-31 23:23:24.157386
NCT01195428|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-01-06|2010-09-03|2010-09-06|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)|Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome|Withdrawn||N/A|0|Actual|University of Oklahoma||2||Minimal enrollment|f||||t||||||||||2018-05-31 23:23:24.22779|2018-05-31 23:23:24.22779
NCT01194726|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-06-28|2010-09-02|2010-09-03|Estimate|||||||2017-06-28|2017-06-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:23:36.304232|2018-05-31 23:23:36.304232
NCT01195415|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2015-09-09||2017-08-02|2010-09-03|2010-09-06|Estimate|2015-09-09|2015-10-07|Estimate||||2017-08-02|2017-08-07|Actual|June 2010||2010-06-30|August 2017|2017-08-31|October 10, 2014|Actual|2014-10-10|July 2013|Actual|2013-07-31||Interventional||Patients treated on protocol.|Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer|Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:23:24.324175|2018-05-31 23:23:24.324175
NCT01195402|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-03|2010-09-03|2010-09-06|Estimate|||||||2010-09-03|2010-09-06|Estimate|April 2004||2004-04-30|September 2010|2010-09-30|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|AIR||Ambulatory Interdisciplinary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)|Low Intensity Pulmonary Outpatient Rehabilitation in Moderate to Severe COPD|Completed||N/A|100|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 23:23:24.748938|2018-05-31 23:23:24.748938
NCT01195389|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-07-07|2010-09-02|2010-09-06|Estimate|||||||2011-07-07|2011-07-08|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease|A Randomized, Single-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety and Efficacy of the Application of Magnetic Fields Using the Resonator for the Treatment of Alzheimer's Disease in Addition to Standard of Care|Unknown status|Recruiting|N/A|30|Anticipated|pico-tesla Magnetic Therapies, LLC||2|||f||||t||||||||||2018-05-31 23:23:24.840982|2018-05-31 23:23:24.840982
NCT01195376|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2016-04-20|2010-09-03|2010-09-06|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors|A Phase I Study of BEZ235, Administered Orally in Adult Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|35|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:23:24.93758|2018-05-31 23:23:24.93758
NCT01195363|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2013-04-03||2017-03-21|2010-09-03|2010-09-06|Estimate|2015-02-10|2015-02-12|Estimate||||2017-03-21|2017-03-23|Actual|April 2007||2007-04-30|March 2017|2017-03-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder|A Randomized, Double-Blind, Placebo Controlled Study Of Quetiapine SR (QTP) As Adjunctive Treatment In Mixed States (MS) Of Bipolar Disorder|Completed||Phase 4|28|Actual|The University of Texas Health Science Center at San Antonio|Overall limitations were screen failures and lost to follow-ups which led to not reaching recruitment goals.|2|||f||||t||||||||||2018-05-31 23:23:25.072509|2018-05-31 23:23:25.072509
NCT01195350|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2011-07-04|2010-09-02|2010-09-06|Estimate|||||||2011-07-04|2011-07-06|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Blood Pressure Level and Prognosis in Acute Stroke|Relationship Between Blood Pressure Level and Lethality in Acute Phase of Stroke : Observational Prospective Study.|Unknown status|Recruiting||266|Anticipated|UPECLIN HC FM Botucatu Unesp|||1||f||||f||||||||||2018-05-31 23:23:25.965657|2018-05-31 23:23:25.965657
NCT01195337|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2018-02-19|2010-09-02|2010-09-06|Estimate|||||||2018-02-19|2018-02-21|Estimate|August 2010|Actual|2010-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Social Contextual Influences on Physical Activity|Social, Contextual, and Environmental Determinants of Physical Activity in Sedentary Minority Adults|Active, not recruiting|||380|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 23:23:26.232126|2018-05-31 23:23:26.232126
NCT01195324|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-05-07|2010-09-02|2010-09-06|Estimate|||||||2014-05-07|2014-05-08|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers|An Open-Label Drug Interaction Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Administered Alone and in Combination With Multiple-Dose JNJ-28431754 (Canagliflozin) in Healthy Male and Female Subjects|Completed||Phase 1|14|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 23:23:26.552587|2018-05-31 23:23:26.552587
NCT01195311|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2018-01-15|2010-09-02|2010-09-06|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2010||2010-07-31|January 2018|2018-01-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||A Dose-escalation Study in Subjects With Advanced Malignancies|A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies|Completed||Phase 1|52|Actual|Incyte Corporation||1|||f||||f||||||||||2018-05-31 23:23:26.723067|2018-05-31 23:23:26.723067
NCT01195298|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-09-03|2010-09-03|2010-09-06|Estimate|||||||2010-09-03|2010-09-06|Estimate|May 2010||2010-05-31|August 2010|2010-08-31||||August 2011|Anticipated|2011-08-31||Interventional|||Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer|Phase II Clinical Study of Bevacizumab in Combination With Capecitabine as First-line Treatment in Elderly Patients With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|88|Anticipated|South Eastern European Research Oncology Group|||||f||||f||||||||||2018-05-31 23:23:26.917043|2018-05-31 23:23:26.917043
NCT01195285|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2012-04-27|2010-09-03|2010-09-06|Estimate|||||||2012-04-27|2012-04-30|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic Cholecystectomy|Single-Incision Laparoscopic Cholecystectomy Versus Traditional Laparoscopic Cholecystectomy: A Randomized Prospective Trial|Terminated||N/A|87|Actual|Saint Luke's Health System||2||Investigator decisions based on slow enrollment.|f||||f||||||||||2018-05-31 23:23:27.057487|2018-05-31 23:23:27.057487
NCT01195272|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2014-10-17||2014-11-11|2010-09-03|2010-09-06|Estimate|2014-11-11|2014-11-13|Estimate||||2014-11-11|2014-11-13|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Safety Population: all participants who received at least 1 dose of tocilizumab treatment and had at least 1 post-baseline safety assessment.|A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.|A 52 Week, Single Center, Open-label Study to Evaluate Neutrophil Function and Survival Effects of Tocilizumab (TCZ) in Patients With Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy|Completed||Phase 4|21|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:23:27.282295|2018-05-31 23:23:27.282295
NCT01195259|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2013-10-24|2010-09-02|2010-09-06|Estimate|||||||2013-10-24|2013-10-28|Estimate|October 2009||2009-10-31|October 2013|2013-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Malignancy Meta Analysis for BRL49653|A Meta Analysis of Malignancy Serious Adverse Events in the ADOPT, 49653/048, and RECORD, 49653/231, Studies, Comparing Metformin With Rosiglitazone.|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 23:23:27.946039|2018-05-31 23:23:27.946039
NCT01195246|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2018-02-27|2010-09-02|2010-09-06|Estimate|||||||2018-02-27|2018-03-01|Actual|December 2010||2010-12-31|February 2018|2018-02-28|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis|An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccination and Are Not Seroprotected|Completed||Phase 3|155|Actual|Dynavax Technologies Corporation||3|||f||||f||||||||Undecided|a/o August 2016, decision is still pending.|2018-05-31 23:23:28.082804|2018-05-31 23:23:28.082804
NCT01195233|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2011-04-18|2010-09-03|2010-09-06|Estimate|||||||2011-04-18|2011-04-19|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|BioXtra||Comparative Analysis of BioXtra on Xerostomia|Comparison Study of BioXtra Spray and Mouth Rinse in Patient With Radiation-induced Xerostomia|Completed||Phase 2|20|Anticipated|Qazvin University Of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:23:28.288378|2018-05-31 23:23:28.288378
NCT01195220|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-03|||2015-05-07|2010-09-03|2010-09-06|Estimate|||||||2015-05-07|2015-05-08|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|AWARE||Project AWARE: Using the Emergency Department (ED) to Prevent Sexually Transmitted Infections (STIs) in Youth|Project AWARE: Using the ED to Prevent STIs in Youth|Withdrawn||N/A|0|Actual|North Bronx Healthcare Network||3||We could not obtain proper funding to complete this study.|f||||f||||||||||2018-05-31 23:23:28.383701|2018-05-31 23:23:28.383701
NCT01195207|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2012-11-22|2010-09-02|2010-09-06|Estimate|||||||2012-11-22|2012-11-27|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|January 2012|Actual|2012-01-31|||||Interventional|||A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Intravenous Study in Healthy Subjects and a Multiple-Dose Intravenous Study in Asthmatic Subjects to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of CNTO 3157|Completed||Phase 1|79|Actual|Centocor, Inc.||8|||f||||||||||||||2018-05-31 23:23:28.485232|2018-05-31 23:23:28.485232
NCT01195194|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2014-02-24|2010-09-03|2010-09-06|Estimate|||||||2014-02-24|2014-02-25|Estimate|March 2008||2008-03-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|SIRES||Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.|Pilot Study of Selection of Either Calcineurin Inhibitor(CNI)-Based or CNI-free Immunosuppressive Regimen Depending on the Result of Pre-transplantation Donor-specific T-cell Reactivity Measured by Enzyme-linked Immunosorbent Spot(ELISPOT) in Standard-risk Kidney Recipients.|Completed||Phase 4|61|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 23:23:28.565106|2018-05-31 23:23:28.565106
NCT01195181|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-03|2010-09-03|2010-09-06|Estimate|||||||2010-09-03|2010-09-06|Estimate|September 2005||2005-09-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional|||Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.|Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response.|Completed||Phase 4|506|Actual|Azienda Ospedaliera di Padova||2|||f||||t||||||||||2018-05-31 23:23:28.643937|2018-05-31 23:23:28.643937
NCT01195168|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-03|2010-09-03|2010-09-06|Estimate|||||||2010-09-03|2010-09-06|Estimate|November 2006||2006-11-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|CS||Cardiovascular Risk Markers in Polycystic Ovary Syndrome (PCOS)|Assessment of Cardiovascular Risk in PCOS-a Cross Sectional Study of Women With PCOS Compared With Controls Matched for Age, Body Mass Index and, or Insulin Resistance|Completed|||201|Actual|The Adelaide and Meath Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:23:28.712052|2018-05-31 23:23:28.712052
NCT01195155|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-03|2010-09-03|2010-09-06|Estimate|||||||2010-09-03|2010-09-06|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Transcriptomic Profile of Adipose Tissue Following n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation|Transcriptomic Profile of Subcutaneous Adipose Tissue of Young Women With PCOS Followin 6 Weeks Supplementation With n-3 PUFA Versus Olive Oil Placebo|Completed||N/A|10|Actual|The Adelaide and Meath Hospital||3|||f||||f||||||||||2018-05-31 23:23:28.772981|2018-05-31 23:23:28.772981
NCT01195142|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-03|2010-09-03|2010-09-06|Estimate|||||||2010-09-03|2010-09-06|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Adipose Tissue Gene Expression Profiles in Women With Polycystic Ovary Syndrome (PCOS) Versus Controls|Adipose Tissue Gene Expression Profiles in Women With PCOS Versus Controls Matched for BMI|Completed|||10|Actual|The Adelaide and Meath Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:23:28.921427|2018-05-31 23:23:28.921427
NCT01195129|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-12-11|2010-09-02|2010-09-03|Estimate|||||||2014-12-11|2014-12-12|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|April 2013|Actual|2013-04-30||Interventional|HCAT||HydroCoil Cerebral Aneurysm Treatment Trial|HydroCoil Cerebral Aneurysm Treatment Trial|Terminated||Phase 4|215|Actual|University of Virginia||2||Due to results shown by the Cerecyte Clinical Trial, HCAT stopped enrolling.|f||||t||||||||||2018-05-31 23:23:28.998926|2018-05-31 23:23:28.998926
NCT01195116|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2015-03-12||2015-03-25|2010-09-02|2010-09-03|Estimate|2015-03-12|2015-03-24|Estimate||||2015-03-25|2015-04-15|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||subjects were recruited if they were scheduled for bladder lavage under general anesthesia for the treatment of interstitial cystitis|Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis|Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis|Completed||Phase 4|41|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 23:23:29.136036|2018-05-31 23:23:29.136036
NCT01195103|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2012-02-27||2012-06-25|2010-09-02|2010-09-03|Estimate|2012-03-01|2012-03-29|Estimate||||2012-06-25|2012-06-29|Estimate|February 2011||2011-02-28|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery|A Prospective Randomized Study to Assess the Efficacy and Safety of Bolus-dose Lusedra (Fospropofol Disodium) 6.5 mg/kg or 10 mg/kg Versus a Placebo (With Midazolam Rescue) for Minimal-to-moderate Sedation in Patients Undergoing Procedural Sedation for Regional Anesthesia Blocks Prior to Orthopedic Surgery|Terminated||Phase 4|13|Actual|Mayo Clinic|The study was terminated early because funding was terminated by the funding source.|3||Funding terminated by funding source.|f||||f||||||||||2018-05-31 23:23:29.361347|2018-05-31 23:23:29.361347
NCT01195090|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2012-04-18||2012-09-09|2010-09-02|2010-09-03|Estimate|2012-09-09|2012-10-10|Estimate||||2012-09-09|2012-10-10|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|JAS||Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea|Efficacy of Adding Sitagliptin or Pioglitazone to Patients With Type 2 Diabetes Insufficiently Controlled With Metformin and Sulfonylurea|Completed||Phase 4|120|Actual|Mackay Memorial Hospital|"The reasons for withdrawal:~lost to follow-up:2 in pioglitazone and 2 in sitagliptin protocol violation:4 in pioglitazone and 3 in sitagliptin edema:1 in pioglitazone, ALT >3 times ULN:1 in pioglitazone gastrointestinal events:1 in sitagliptin"|2|||f||||t||||||||||2018-05-31 23:23:29.669417|2018-05-31 23:23:29.669417
NCT01195077|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2015-04-02|2010-09-02|2010-09-03|Estimate|||||||2015-04-02|2015-04-06|Estimate|February 2003||2003-02-28|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|HIV||Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?|Could Dietary Algae Affect Immunity and Viral Counts in People With HIV?|Completed||Phase 1/Phase 2|12|Actual|University of South Carolina||1|||f||||f||||||||||2018-05-31 23:23:30.620004|2018-05-31 23:23:30.620004
NCT01195064|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2016-03-23|2010-09-02|2010-09-03|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Observational|COPD-OSAS||Endothelial Function Study Before Cardiovascular Surgery|Endothelial Function Study Before Cardiovascular Surgery in COPD and/or SAS Patients|Unknown status|Recruiting||200|Anticipated|University Hospital, Grenoble|||4||f||||t||||||Samples With DNA|"~     Urinary, blood and adipose tissue samples will be collected for measurement of different~     parameters of inflammation and oxidative stress.~   "|||2018-05-31 23:23:30.947419|2018-05-31 23:23:30.947419
NCT01195051|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2014-03-04|2010-09-02|2010-09-03|Estimate|||||||2014-03-04|2014-03-05|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|MedMatch||Medication Reconciliation Technology to Improve Quality of Transitional Care|Medication Reconciliation Technology to Improve Quality of Transitional Care|Completed||Phase 3|4818|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 23:23:31.312458|2018-05-31 23:23:31.312458
NCT01195038|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2011-02-07|2010-09-02|2010-09-03|Estimate|||||||2011-02-07|2011-02-08|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults|A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine|Completed||Phase 2|87|Anticipated|UMN Pharma Inc.|||||f||||f||||||||||2018-05-31 23:23:31.631266|2018-05-31 23:23:31.631266
NCT01195025|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2014-03-12||2014-10-16|2010-09-02|2010-09-03|Estimate|2014-10-16|2014-10-22|Estimate||||2014-10-16|2014-10-22|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Volume Kinetics for Starch Solution and Acetated Ringers|Volume Kinetics for Starch Solution and Acetated Ringers|Completed||N/A|10|Actual|University Hospital, Linkoeping||5|||f||||f||||||||||2018-05-31 23:23:31.909186|2018-05-31 23:23:31.909186
NCT01195012|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-02|2010-09-02|2010-09-03|Estimate|||||||2010-09-02|2010-09-03|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|Helping HAND||Pilot RCT of an Obesity Intervention for Primary Care Pediatrics: Helping HAND|"Pilot Randomized Controlled Trial for Feasibility of an Obesity Prevention Plus Intervention for Primary Care Pediatrics: Helping HAND"|Completed||N/A|40|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 23:23:32.124515|2018-05-31 23:23:32.124515
NCT01194999|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2012-08-21||2012-08-21|2010-09-02|2010-09-03|Estimate|2012-08-21|2012-09-20|Estimate||||2012-08-21|2012-09-20|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence|Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence|Completed||Phase 4|132|Actual|Barrie Urology Associates|The V8 questionnaire used for patient surveying has been validated, but forms of such a nature present potential over and under reporting of symptoms. Loss to follow-up presents an issue, although we anticipate those lost experienced improvements.|1|||f||||t||||||||||2018-05-31 23:23:32.190274|2018-05-31 23:23:32.190274
NCT01194986|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2015-01-27|2010-09-02|2010-09-03|Estimate|||||||2015-01-27|2015-01-28|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration|An Open-label Positron Emission Tomography Study to Evaluate Use of Histamine H3 Receptor Radioligand [11C]AZ12807110 and to Determine Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration to Healthy Volunteers|Completed||Phase 1|13|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:23:32.326063|2018-05-31 23:23:32.326063
NCT01194973|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2015-04-07||2017-04-20|2010-09-02|2010-09-03|Estimate|2015-04-07|2015-04-24|Estimate||||2017-04-20|2017-05-30|Actual|July 2010||2010-07-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional||The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 41 patients who were treated with study drug were included in the ITT population.|An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome|An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome|Completed||Phase 2|44|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 23:23:32.415604|2018-05-31 23:23:32.415604
NCT01194960|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2012-11-26|2010-09-02|2010-09-03|Estimate|||||||2012-11-26|2012-11-27|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)|A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer|Terminated||Phase 2|25|Actual|Oxford BioMedica||2|||f||||f||||||||||2018-05-31 23:23:33.062624|2018-05-31 23:23:33.062624
NCT01194947|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2010-09-02|2010-09-02|2010-09-03|Estimate|||||||2010-09-02|2010-09-03|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Classification and Longitudinal Follow-up of Common Melanocytic Nevi With in Vivo Reflectance Confocal Microscopy||Unknown status|Not yet recruiting||90|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 23:23:33.1545|2018-05-31 23:23:33.1545
NCT01194934|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-06-25|2010-09-02|2010-09-03|Estimate|||||||2014-06-25|2014-06-26|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SNOXA12C101||NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers|A Single Center, Open-label, Repeated Dose, Phase I Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics and the Effect on Mobilization of Hematopoietic Stem Cells of NOX-A12 Alone and in Combination With Filgrastim|Completed||Phase 1|12|Actual|NOXXON Pharma AG||4|||f||||t||||||||||2018-05-31 23:23:33.239593|2018-05-31 23:23:33.239593
NCT01194908|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2015-01-18||2015-01-18|2010-09-02|2010-09-03|Estimate|2015-01-18|2015-01-26|Estimate||||2015-01-18|2015-01-26|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Re-expression of ER in Triple Negative Breast Cancers|Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabine and LBH 589 in Patients With Triple Negative Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|5|Actual|Emory University||1||Slow accrual|f||||t||||||||||2018-05-31 23:23:33.332953|2018-05-31 23:23:33.332953
NCT01194895|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2013-03-13|2010-09-02|2010-09-03|Estimate|||||||2013-03-13|2013-03-14|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||A Trial to Evaluate the Impact of Lung-protective Intervention in Patients Undergoing Esophageal Cancer Surgery|Impact of Intraoperative Protective One-lung Ventilation in Patients Undergoing Esophagectomy : a Prospective Randomized Controlled Trial|Completed||N/A|101|Actual|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 23:23:33.489064|2018-05-31 23:23:33.489064
NCT01194882|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2018-02-14|2010-09-02|2010-09-03|Estimate|||||||2018-02-14|2018-02-15|Actual|November 16, 2010||2010-11-16|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes|Evaluation of Insuman Implantable 400 IU/ml in Patients With Type 1 Diabetes Treated With the Medtronic MiniMed Implantable Pump System Using Insuplant 400IU/ml|Completed||Phase 3|479|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:23:33.574049|2018-05-31 23:23:33.574049
NCT01194869|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2016-06-17||2016-08-31|2010-09-02|2010-09-03|Estimate|2016-06-17|2016-07-28|Estimate||||2016-08-31|2016-10-18|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer|Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer|Terminated||Phase 2|25|Actual|Emory University||1||Slow accrual, availability of other clinical options|f||||t||||||||||2018-05-31 23:23:33.700083|2018-05-31 23:23:33.700083
NCT01194856|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2017-01-11||2017-08-10|2010-09-02|2010-09-03|Estimate|2017-08-10|2017-08-11|Actual||||2017-08-10|2017-08-11|Actual|October 2010||2010-10-31|August 2017|2017-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression|A Randomized Study to Evaluate the Effect of Switching From Efavirenz to Atazanavir/ Ritonavir on Lipoatrophy and Mitochondrial Dysfunction in HIV-infected Subjects With Good Virologic Suppression|Terminated||Phase 4|1|Actual|The Cleveland Clinic|Data not collected for analysis due to low enrollment and participant discontinuation.|2||Closed due to low enrollment|f||||t||||||||No||2018-05-31 23:23:33.926021|2018-05-31 23:23:33.926021
NCT01194843|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2015-04-20|2010-09-02|2010-09-03|Estimate|||||||2015-04-20|2015-04-21|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|April 2015|Actual|2015-04-30|February 2014|Actual|2014-02-28||Interventional|DPO||Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations|A Double-blind Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Per and Post Hepatectomy Infiltrations for Adult Pain Management|Completed||N/A|85|Actual|Centre Leon Berard||2|||f||||f||||||||||2018-05-31 23:23:34.181707|2018-05-31 23:23:34.181707
NCT01194830|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2012-09-26||2013-12-12|2010-09-02|2010-09-03|Estimate|2012-09-26|2012-10-26|Estimate||||2013-12-12|2014-01-29|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study|A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study|Completed||Phase 3|234|Actual|Boehringer Ingelheim|Eight randomized subjects were excluded from all analysis due to overall data integrity issues at the site|2|||f||||||||||||||2018-05-31 23:23:34.285779|2018-05-31 23:23:34.285779
NCT01194817|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2016-05-17|2010-09-02|2010-09-03|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|||A Prospective, Randomized Study Comparing Cemented and Cementless Total Knee Replacement|A Prospective, Randomized Study Comparing Cemented and Cementless Total Knee Replacement: Results of a New Modular Trabecular Metal Tibial Component Using the NexGen System|Active, not recruiting||N/A|100|Actual|Anderson Orthopaedic Research Institute||2|||f||||f||||||||||2018-05-31 23:23:34.861521|2018-05-31 23:23:34.861521
NCT01194804|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-02-15|2010-09-02|2010-09-03|Estimate|||||||2017-02-15|2017-02-17|Actual|April 2008||2008-04-30|February 2017|2017-02-28|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients|Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol|Completed||Phase 2|27|Actual|Alexion Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:23:35.199745|2018-05-31 23:23:35.199745
NCT01194791|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2017-04-23|2010-09-02|2010-09-03|Estimate|||||||2017-04-23|2017-04-25|Actual|October 2010||2010-10-31|November 2015|2015-11-30|December 2016|Actual|2016-12-31|September 2012|Actual|2012-09-30||Interventional|LENDEXAL||Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed|A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation|Completed||Phase 2|30|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 23:23:35.470503|2018-05-31 23:23:35.470503
NCT01194778|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-09-02|2010-09-02|2010-09-03|Estimate|||||||2010-09-02|2010-09-03|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional|||Comparison of Efficacy of Different Dosages Vitamin K2|Comparison of Efficacy of Different Dosages Vitamin K2|Completed||N/A|82|Actual|Maastricht University Medical Center||5|||f||||f||||||||||2018-05-31 23:23:35.847408|2018-05-31 23:23:35.847408
NCT01194765|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2014-01-20|2010-09-02|2010-09-03|Estimate|||||||2014-01-20|2014-01-22|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Distance-Based Cognitive-Behavioural Therapy for High Anxiety Sensitivity: A Randomized Controlled Trial|Distance-Based Cognitive-Behavioural Therapy for High Anxiety Sensitivity: A Randomized Controlled Trial|Completed||N/A|180|Actual|Dalhousie University||2|||f||||f||||||||||2018-05-31 23:23:36.102613|2018-05-31 23:23:36.102613
NCT01194713|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2014-05-09|2010-09-02|2010-09-03|Estimate|||||||2014-05-09|2014-05-13|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|AWAKE||Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics|Losing Sleep Over Alzheimer's Disease? Effects of Sleep Deprivation on Cerebrospinal Fluid Amyloid-beta Dynamics|Completed||N/A|26|Actual|University Medical Center Nijmegen||2|||f||||||||||||||2018-05-31 23:23:36.347683|2018-05-31 23:23:36.347683
NCT01194700|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2016-10-24|2010-09-02|2010-09-03|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers|Comparative Study of Lung Bioavailability of HFA-Seretide Via Current Spacer Devices in Healthy Volunteers|Completed||Phase 4|19|Actual|University of Dundee||4|||f||||f||||||||||2018-05-31 23:23:36.432562|2018-05-31 23:23:36.432562
NCT01194687|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2018-04-19|2010-09-02|2010-09-03|Estimate|||||||2018-04-19|2018-04-20|Actual|April 27, 2010||2010-04-27|October 18, 2017|2017-10-18||||||||Observational|||Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses|Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses|Completed|||98|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:23:36.545855|2018-05-31 23:23:36.545855
NCT01194674|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|2012-07-10||2012-08-14|2010-09-02|2010-09-03|Estimate|2012-07-10|2012-08-14|Estimate||||2012-08-14|2012-08-20|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|MIME||Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema|Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema|Terminated||Phase 1/Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated early due to lack of enrollment.|1||Lack of enrollment.|f||||f||||||||||2018-05-31 23:23:36.651316|2018-05-31 23:23:36.651316
NCT01194661|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2018-05-24|2010-09-02|2010-09-03|Estimate|||||||2018-05-24|2018-05-25|Actual|August 10, 2010||2010-08-10|November 16, 2017|2017-11-16|November 16, 2017||2017-11-16|||||Observational|||Neural Dynamics and Connectivity in Response Inhibition and Traumatic Brain Injury|Neural Dynamics and Connectivity in Response Inhibition and Traumatic Brain Injury|Completed|||129|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:23:36.858217|2018-05-31 23:23:36.858217
NCT01194648|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2018-04-18|2010-09-02|2010-09-03|Estimate|||||||2018-04-18|2018-04-20|Actual|June 29, 2011|Actual|2011-06-29|April 2018|2018-04-30|June 2029|Anticipated|2029-06-30|December 2028|Anticipated|2028-12-31||Interventional|INDEX||Focal Therapy for Prostate Cancer Using HIFU|A Multi-Center Prospective Single Arm Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound (Sonablate 500) for Localized Prostate Cancer|Recruiting||N/A|354|Anticipated|University College, London||1|||f||||f|f|f||||||||2018-05-31 23:23:36.932691|2018-05-31 23:23:36.932691
NCT01194635|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2017-05-16|2010-09-02|2010-09-03|Estimate|||||||2017-05-16|2017-05-17|Actual|August 5, 2010|Actual|2010-08-05|May 2017|2017-05-31|September 5, 2010|Actual|2010-09-05|September 5, 2010|Actual|2010-09-05||Observational|||Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy|Molecular Correlates of Response to C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck (E3303): A Phase II Trial of Eastern Cooperative Oncology Group|Completed|||69|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:23:37.044585|2018-05-31 23:23:37.044585
NCT01194622|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2016-04-26|2010-09-02|2010-09-03|Estimate|||||||2016-04-26|2016-04-27|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays|Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays Single-centre, Randomised, Open-label, Three-period, Six-sequence Cross-over Trial (William's Design)|Completed||Phase 1|30|Actual|MEDA Pharma GmbH & Co. KG||3|||f||||f||||||||||2018-05-31 23:23:37.12391|2018-05-31 23:23:37.12391
NCT01194609|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2014-05-07|2010-09-02|2010-09-03|Estimate|||||||2014-05-07|2014-05-09|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer|A Pilot Study of Radiation-Immune Cell Combination Therapy in Recurrent or Persistent Cervical Cancer|Terminated||Phase 1/Phase 2|2|Actual|Korea Cancer Center Hospital||1||No further enrollment after two patients|f||||t||||||||||2018-05-31 23:23:37.20151|2018-05-31 23:23:37.20151
NCT01194596|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2011-04-06|2010-09-02|2010-09-03|Estimate|||||||2011-04-06|2011-04-07|Estimate|June 2008||2008-06-30|April 2011|2011-04-30|July 2011|Anticipated|2011-07-31|June 2010|Actual|2010-06-30||Interventional|ESPITAP||Effectiveness of Smoking Cessation Advice Combined With Spirometric Results in Adult Smokers (ESPITAP)|Effectiveness of Smoking Cessation Advice Combined With a Detailed Discussion of the Spirometric Results With the Primary Care Practitioner on the Smoking Habit in Adult Smokers (ESPITAP)|Unknown status|Active, not recruiting|N/A|596|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 23:23:37.269301|2018-05-31 23:23:37.269301
NCT01194583|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2013-01-07|2010-09-02|2010-09-03|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) Without Nicotine Cartridges|Randomised Controlled Trial Investigating the Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) Without Nicotine Cartridges in Smokers|Completed|||100|Actual|Universita degli Studi di Catania|||1||f||||t||||||||||2018-05-31 23:23:37.340571|2018-05-31 23:23:37.340571
NCT01194570|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-28|2017-03-30|2016-10-14|2018-05-23|2010-09-02|2010-09-03|Estimate|2017-12-20|2017-12-26|Actual|2016-10-14|2016-10-17|Estimate|2018-05-23|2018-05-25|Actual|March 2, 2011|Actual|2011-03-02|May 2018|2018-05-31|April 29, 2021|Anticipated|2021-04-29|July 23, 2015|Actual|2015-07-23||Interventional||Analysis was performed on intent to treat (ITT) population which included all randomized participants in the study.|A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis|A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis|Active, not recruiting||Phase 3|732|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 23:23:37.493635|2018-05-31 23:23:37.493635
NCT01194557|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-02|||2012-10-11|2010-09-02|2010-09-03|Estimate|||||||2012-10-11|2012-10-12|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Introducing Rapid Diagnostic Tests Into the Private Health Sector|Introducing Rapid Diagnostic Tests Into the Private Health Sector in Uganda: a Randomised Trial Among Registered Drug Shops to Evaluate Impact on Antimalarial Drug Use|Completed||N/A|2600|Actual|DBL -Institute for Health Research and Development||2|||f||||t||||||||||2018-05-31 23:23:39.443431|2018-05-31 23:23:39.443431
NCT01194544|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2011-03-06|2010-09-01|2010-09-03|Estimate|||||||2011-03-06|2011-03-08|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Observational|||The Relationship Between Dietary Habit and Gastroesophageal Flap Valve Abnormality|The Relationship Between Dietary Habit and Gastroesophageal Flap Valve Abnormality|Unknown status|Recruiting||600|Anticipated|Taipei Medical University WanFang Hospital|||1||f||||f||||||||||2018-05-31 23:23:39.507324|2018-05-31 23:23:39.507324
NCT01194531|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2014-11-05||2014-11-12|2010-09-01|2010-09-03|Estimate|2014-11-05|2014-11-13|Estimate||||2014-11-12|2014-11-25|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|IPSO||Impact of Parental Support on Pregnancy Outcomes (IPSO) Trial- Day 3 Preimplantation Genetic Screening (PGS) With Day 5 Fresh Transfer|IPSO Trial - Impact of Parental Support on Pregnancy Outcomes: A Multi-Center, Randomized, Open-Label Study to Evaluate the Implantation and Pregnancy Rates Following 24 Chromosome Aneuploidy Screening With Parental Support in Patients Undergoing In Vitro Fertilization (IVF)|Terminated||Phase 4|59|Actual|Natera, Inc.||2||Slow enrollment and Natera is transitioning to a new PGS testing platform.|f||||f||||||||||2018-05-31 23:23:39.710067|2018-05-31 23:23:39.710067
NCT01194518|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-16|2010-09-02|2010-09-03|Estimate|||||||2010-09-16|2010-09-17|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Exploring Life Experience and Lifestyle Intervention Program Among Patients With Chronic Kidney Disease: A Longitudinal Study|Exploring Life Experience and Lifestyle Intervention Program Among Patients|Unknown status|Active, not recruiting|N/A|||National Cheng Kung University||1|||f||||t||||||||||2018-05-31 23:23:39.93225|2018-05-31 23:23:39.93225
NCT01194505|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-03-06|2010-09-02|2010-09-03|Estimate|||||||2017-03-06|2017-03-08|Actual|June 2010|Actual|2010-06-30|March 2017|2017-03-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Ultrasound Guided Obturator Nerve Block for Anterior Cruciate Ligament Reconstruction (ACL)|Comparison of Posterior Lumbar Plexus Block Plus Sciatic Nerve Block With Sciatic Plus Femoral Plus Obturator Nerve Block for Anterior Cruciate Ligament Reconstruction|Completed||N/A|106|Actual|Larissa University Hospital||2|||f||||f||||||||||2018-05-31 23:23:40.020111|2018-05-31 23:23:40.020111
NCT01194492|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2018-02-15|2010-09-02|2010-09-03|Estimate|||||||2018-02-15|2018-02-19|Actual|September 2010||2010-09-30|February 2018|2018-02-28|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Albumin Kinetics in Generalized Inflammation|Albumin Kinetics in Generalized Inflammation - an Exploratory Study on Patients Before and After Major Abdominal Surgery|Completed||Phase 4|10|Actual|Karolinska Institutet||1|||f||||t||||||||||2018-05-31 23:23:40.114271|2018-05-31 23:23:40.114271
NCT01194479|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2016-01-28||2016-02-26|2010-09-01|2010-09-03|Estimate|2016-02-26|2016-03-29|Estimate||||2016-02-26|2016-03-29|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.|The Effect of the Beta 2 Agonist, Formoterol, on Recovery From Hypoglycemia|Completed||N/A|14|Actual|Yale University||2|||f||||f||||||||||2018-05-31 23:23:40.219683|2018-05-31 23:23:40.219683
NCT01194466|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-03-20|2010-09-01|2010-09-03|Estimate|||||||2017-03-20|2017-03-21|Actual|June 15, 2011|Actual|2011-06-15|March 2017|2017-03-31|August 14, 2012|Actual|2012-08-14|August 14, 2012|Actual|2012-08-14||Interventional|||Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)|The Influence of TENS on Mucositis Pain and Function in Head and Neck Cancer Patients: A Randomized and Placebo-Controlled Double Blind Clinical Trial|Completed||N/A|42|Actual|University of Iowa||3|||f||||t|f|f||||||Yes||2018-05-31 23:23:40.579726|2018-05-31 23:23:40.579726
NCT01194453|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2016-05-10||2016-05-10|2010-09-01|2010-09-03|Estimate|2016-05-10|2016-06-16|Estimate||||2016-05-10|2016-06-16|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|August 2012|Actual|2012-08-31|September 2010|Actual|2010-09-30||Interventional|AP/GP||Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer|A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study|Completed||Phase 2|288|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:23:40.676268|2018-05-31 23:23:40.676268
NCT01194440|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2016-11-10||2017-10-05|2010-09-01|2010-09-03|Estimate|2016-11-10|2017-01-09|Estimate||||2017-10-05|2017-11-06|Actual|February 2011||2011-02-28|October 2017|2017-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms|A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial|Completed||Phase 2|63|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||No||2018-05-31 23:23:40.928568|2018-05-31 23:23:40.928568
NCT01194427|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2013-03-18||2013-05-15|2010-09-01|2010-09-03|Estimate|2013-05-15|2013-05-17|Estimate||||2013-05-15|2013-05-17|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer|A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer|Terminated||Phase 2|2|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Unable to recruit participants to complete the study.|1||Difficulty meeting patient accrual goals|f||||f||||||||||2018-05-31 23:23:41.11547|2018-05-31 23:23:41.11547
NCT01194414|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2013-01-07||2016-05-11|2010-09-01|2010-09-03|Estimate|2013-01-07|2013-02-12|Estimate||||2016-05-11|2016-06-20|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis|Completed||Phase 3|1262|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:23:41.448529|2018-05-31 23:23:41.448529
NCT01194401|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2016-11-01|2010-09-01|2010-09-03|Estimate|||||||2016-11-01|2016-11-02|Estimate||||November 2016|2016-11-30||||||||Observational|||An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)|A Prospective, Non-interventional Multi-center Observational Study to Evaluate the Long-term Effectiveness and Safety of Tocilizumab in Patients With Active Rheumatoid Arthritis in Daily Practice|Active, not recruiting|||3404|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:23:43.634554|2018-05-31 23:23:43.634554
NCT01192854|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-05-13|2010-08-31|2010-09-01|Estimate|||||||2013-05-13|2013-05-14|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||An Study of Efficacy and Safety of Clevudine|A Multi-center, Randomized, Double-blind, Positive-control, Phase III Trial of the Efficacy and Safety of Clevudine|Completed||Phase 3|288|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:24:28.039109|2018-05-31 23:24:28.039109
NCT01194388|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2010-09-01|2010-09-01|2010-09-03|Estimate|||||||2010-09-01|2010-09-03|Estimate|September 2010||2010-09-30|September 2010|2010-09-30||||December 2011|Anticipated|2011-12-31||Observational|ACCESS||Axium Coil in Completing Endovascular Aneurysm Surgery Study|Axium Coil in Completing Endovascular Aneurysm Surgery Study: A Single-center, Prospective Observational Registry|Unknown status|Active, not recruiting||25|Anticipated|ev3|||1||f||||f||||||||||2018-05-31 23:23:43.69973|2018-05-31 23:23:43.69973
NCT01194375|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01||2012-06-20|2012-06-20|2010-09-01|2010-09-03|Estimate||||2012-06-20|2012-07-02|Estimate|2012-06-20|2012-07-02|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris||Completed||Phase 2|180|Actual|Dow Pharmaceutical Sciences||3|||f||||||||||||||2018-05-31 23:23:43.790913|2018-05-31 23:23:43.790913
NCT01194362|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-07-12|2010-09-01|2010-09-03|Estimate|||||||2017-07-12|2017-07-13|Actual|September 2010||2010-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease|A Study to Establish Genomic Bio Signatures of Ascending Aortic Aneurysms in Patients With Bicuspid and Tricuspid Aortic Valve Disease With Aortic Stenosis|Active, not recruiting|||105|Anticipated|Baylor Research Institute|||3||f||||f||||||Samples With DNA|"~     Blood and Tissue~   "|||2018-05-31 23:23:43.918853|2018-05-31 23:23:43.918853
NCT01194349|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-01|2010-09-01|2010-09-03|Estimate|||||||2010-09-01|2010-09-03|Estimate||||May 2010|2010-05-31||||||||Observational|||The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection|The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection|Completed|||||Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:23:43.989984|2018-05-31 23:23:43.989984
NCT01194336|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-05-02|2010-09-02|2010-09-03|Estimate|||||||2017-05-02|2017-05-03|Actual|February 2012||2012-02-29|May 2017|2017-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance|Evaluation of Three Potential CNS Pretreatments for Soman Exposure - Huperzine A, Donepezil, and Galantamine - on Human Performance|Completed|||84|Actual|U.S. Army Medical Research and Materiel Command|||7||f||||f||||||||||2018-05-31 23:23:44.049723|2018-05-31 23:23:44.049723
NCT01194323|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-03-31|2010-08-31|2010-09-02|Estimate|||||||2017-03-31|2017-04-04|Actual|November 2010||2010-11-30|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|BENCH||Biology in Patients With Reflux Esophagitis|Biology in Patients With Reflux Esophagitis and Mucosal Impedance|Completed|||75|Actual|Vanderbilt University Medical Center|||2||f||||f||||||Samples With DNA|"~     Total RNA and proteins will be extracted from de-identified samples. Genes' and proteins'~     expression will be processed and analyzed at Vanderbilt Core Facilities.~   "|No||2018-05-31 23:23:44.136079|2018-05-31 23:23:44.136079
NCT01194310|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-07-10|2010-09-01|2010-09-02|Estimate|||||||2017-07-10|2017-07-13|Actual|January 1, 2009|Actual|2009-01-01|July 2017|2017-07-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Phaco vs. Phaco-ELT vs. Phaco-Trabectome 12m|Longtime Efficiency of Combined Cataract-Surgery and Excimer-Laser-Trabeculotomy or Trabectome in Glaucoma Surgery|Completed|||245|Actual|University of Zurich|||3||f||||f|f|f||||||No||2018-05-31 23:23:44.218117|2018-05-31 23:23:44.218117
NCT01194297|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2013-07-01||2014-08-04|2010-09-01|2010-09-02|Estimate|2014-08-04|2014-08-22|Estimate||||2014-08-04|2014-08-22|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants|Immune Responses in Preterm and Full-Term Infants Following Live, Attenuated Influenza Vaccination|Terminated||Phase 4|3|Actual|University of Rochester||2||Insufficient enrollment|f||||f||||||||||2018-05-31 23:23:44.305404|2018-05-31 23:23:44.305404
NCT01194284|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-01-17|2010-09-01|2010-09-02|Estimate|||||||2017-01-17|2017-01-19|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Surveillance Study of Patients With Newly Diagnosed Osteosarcoma|Observational, Noninterventional Surveillance Study of Patients With Newly Diagnosed Osteosarcoma|Terminated|||25|Actual|Takeda|||1|Regulatory agency commitment fulfilled.|f||||t||||||||||2018-05-31 23:23:44.537436|2018-05-31 23:23:44.537436
NCT01194271|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2016-08-18|2010-09-01|2010-09-02|Estimate|||||||2016-08-18|2016-08-22|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Neoadjuvant Ipilimumab in Prostate Cancer|A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.|Completed||Phase 2|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:23:44.622401|2018-05-31 23:23:44.622401
NCT01194258|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2014-08-01||2014-08-01|2010-09-01|2010-09-02|Estimate|2014-08-01|2014-08-20|Estimate||||2014-08-01|2014-08-20|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All participants in the study, including those who were enrolled but were not randomized.|Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus|A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 2 Diabetes|Completed||Phase 2|132|Actual|Halozyme Therapeutics||2|||f||||f||||||||||2018-05-31 23:23:44.822339|2018-05-31 23:23:44.822339
NCT01194245|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2014-08-01||2014-08-01|2010-09-01|2010-09-02|Estimate|2014-08-01|2014-08-19|Estimate||||2014-08-01|2014-08-19|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All enrolled participants.|Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus|A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 1 Diabetes|Completed||Phase 2|135|Actual|Halozyme Therapeutics||2|||f||||f||||||||||2018-05-31 23:23:46.035978|2018-05-31 23:23:46.035978
NCT01194232|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2012-12-10|2010-09-01|2010-09-02|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Sildenafil Trial in Children and Young Adults With CF|Randomized Controlled Study of Sildenafil in Children and Young Adults With Mild to Moderate Cystic Fibrosis Lung Disease|Withdrawn||Phase 1/Phase 2|0|Actual|Children's Hospital Medical Center, Cincinnati||1||Funding, MedWatch change to study drug|f||||t||||||||||2018-05-31 23:23:47.283649|2018-05-31 23:23:47.283649
NCT01193712|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2015-02-02|2010-09-01|2010-09-02|Estimate|||||||2015-02-02|2015-02-03|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Endocardial Pacing in On-table Non-responders in Cardiac Resynchronization Therapy|Non-Responders in Cardiac Resynchronization Therapy|Withdrawn||N/A|0|Actual|Catharina Ziekenhuis Eindhoven||2||too limited number of eligible patients|f||||f||||||||||2018-05-31 23:23:57.254646|2018-05-31 23:23:57.254646
NCT01194219|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2014-10-22|2013-05-24|2017-11-22|2010-09-01|2010-09-02|Estimate|2014-11-03|2014-11-05|Estimate|2013-05-24|2013-06-05|Estimate|2017-11-22|2017-12-26|Actual|September 9, 2010|Actual|2010-09-09|November 2017|2017-11-30|November 22, 2016|Actual|2016-11-22|February 23, 2012|Actual|2012-02-23||Interventional|ESTEEM 1|The full analysis set (FAS) consisted of all participants who were randomized as specified in the protocol. Those who were randomized in error and did not receive any dose of Investigational product were excluded from FAS. Participants were included in the treatment group to which they were randomized APR 30 BID or placebo for the FAS.|Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|844|Actual|Celgene||3|||f||||f||||||||||2018-05-31 23:23:47.380491|2018-05-31 23:23:47.380491
NCT01194206|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2012-04-17|2010-09-01|2010-09-02|Estimate|||||||2012-04-17|2012-04-18|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant|Downstaging of Hepatocellular Carcinoma by Stereotactic Body Radiotherapy for Non-Resectable and Non-Transplantable Tumors: Phase 2 Study|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center||1||Study being rewritten|f||||t||||||||||2018-05-31 23:23:48.865308|2018-05-31 23:23:48.865308
NCT01194193|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2011-05-13|2010-09-01|2010-09-02|Estimate|||||||2011-05-13|2011-05-16|Estimate||||May 2011|2011-05-31||||||||Interventional|||Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of the m-Tor Kinase Inhibitor AZD8055 Using Intermittent Dosing Schedules in Patients With Advanced Solid Malignancies and Lymphomas|Withdrawn||Phase 1|63|Anticipated|AstraZeneca||1||Amendment to study compound development programme|f||||f||||||||||2018-05-31 23:23:48.95331|2018-05-31 23:23:48.95331
NCT01194180|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2012-08-29|2010-09-01|2010-09-02|Estimate|||||||2012-08-29|2012-08-30|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A|A Phase 1 Study to Evaluate a BCG Challenge Model as a Method of Assessing Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A, Alone and in Combination|Completed||Phase 1|48|Actual|University of Oxford||4|||f||||t||||||||||2018-05-31 23:23:49.060293|2018-05-31 23:23:49.060293
NCT01194167|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-01-08|2010-09-01|2010-09-02|Estimate|||||||2012-01-08|2012-01-10|Estimate|August 2010||2010-08-31|January 2012|2012-01-31||||August 2012|Anticipated|2012-08-31||Interventional|||Study of Eltrombopag in Platelet Refractory Thrombocytopenia|A Phase II Study of Eltrombopag in Platelet Refractory Thrombocytopenia|Withdrawn||Phase 2|0|Actual|University of Cincinnati||1||Inability to identify eligible patients|f||||||||||||||2018-05-31 23:23:49.182302|2018-05-31 23:23:49.182302
NCT01194154|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2016-03-16||2017-04-03|2010-09-01|2010-09-02|Estimate|2016-05-05|2016-06-14|Estimate||||2017-04-03|2017-05-10|Actual|September 30, 2010|Actual|2010-09-30|April 2017|2017-04-30|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional||The Full Analysis Set (FAS) included all randomized participants who received at least one dose of the study medication and provided any successive estimated glomerular filtration rate (eGFR) measurement.|A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)|A Randomized Controlled, Single-blind, Proof-of-concept-study to Investigate the Protective Effects of Early Treatment With C.E.R.A. in Patients With Chronic Kidney Disease on Renal Disease Progression (PRIMAVERA-Study)|Completed||Phase 2|241|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:23:49.307551|2018-05-31 23:23:49.307551
NCT01194141|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-01-06|2010-09-01|2010-09-02|Estimate|||||||2017-01-06|2017-01-10|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Exercise Training in Barth Syndrome|Safety and Efficacy of Aerobic Exercise Training in Barth Syndrome|Completed||N/A|4|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 23:23:50.109179|2018-05-31 23:23:50.109179
NCT01194128|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2015-11-30|2010-09-01|2010-09-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2008||2008-01-31|November 2015|2015-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|FACTS||Facilitating Caregiver Adaptation to Patient Institutionalization|Intervention to Facilitate Family Caregiver Adaptation to Nursing Home Transition|Completed||Phase 3|217|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 23:23:50.184288|2018-05-31 23:23:50.184288
NCT01194115|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-11-10|2010-09-01|2010-09-02|Estimate|||||||2011-11-10|2011-11-11|Estimate|September 2010||2010-09-30|November 2011|2011-11-30||||September 2012|Anticipated|2012-09-30||Interventional|SSI||Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery|Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery|Unknown status|Enrolling by invitation|N/A|475|Anticipated|University of Cincinnati||2|||f||||f||||||||||2018-05-31 23:23:50.369273|2018-05-31 23:23:50.369273
NCT01194102|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2018-04-05|2010-09-01|2010-09-02|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2010||2010-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|FFF||Fit for Function: A Community Wellness Program for Persons With Stroke|Fit for Function: A Community Wellness Program for Persons With Stroke|Completed||N/A|61|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 23:23:50.513804|2018-05-31 23:23:50.513804
NCT01194089|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2015-05-13||2015-06-10|2010-09-01|2010-09-02|Estimate|2015-06-01|2015-06-03|Estimate||||2015-06-10|2015-07-09|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Nicotine Administration and Post-operative Opioid Use With Bariatric Surgery|A Randomized, Double Blind, Study to Evaluate the Efficacy of Nasal Nicotine Spray to Reduce Post-Operative Opioid Requirements in Nonsmokers in Elective Laparoscopic Bariatric Surgical Patients|Completed||Phase 4|95|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:23:50.600112|2018-05-31 23:23:50.600112
NCT01194076|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2012-05-29|2010-09-01|2010-09-02|Estimate|||||||2012-05-29|2012-05-30|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|5dayOCD||Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)|Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD|Completed||N/A|28|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 23:23:50.888793|2018-05-31 23:23:50.888793
NCT01194063|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-09-21|2010-09-01|2010-09-02|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2010||2010-09-30|September 2017|2017-09-30|August 2025|Anticipated|2025-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children|Use of Omegaven for Parenteral Nutrition Associated Liver Disease|Recruiting||Phase 3|10|Anticipated|Kapiolani Medical Center For Women & Children||1|||f||||t||||||||Undecided||2018-05-31 23:23:51.021298|2018-05-31 23:23:51.021298
NCT01194050|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2016-11-01|2010-09-01|2010-09-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer|Erlotinib (Tarceva) in Routine Clinical Practice for First Line Maintenance Therapy (1LM) in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)|Completed|||289|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:23:51.093565|2018-05-31 23:23:51.093565
NCT01194037|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2014-02-24|2010-09-01|2010-09-02|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C|A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C|Completed||Phase 1/Phase 2|30|Actual|HanAll BioPharma Co., Ltd.||3|||f||||f||||||||||2018-05-31 23:23:51.170513|2018-05-31 23:23:51.170513
NCT01194024|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2016-12-08|2010-09-01|2010-09-02|Estimate|||||||2016-12-08|2016-12-12|Estimate|November 2011||2011-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Scoring System for Inhalation Injury|Burn Multicenter Proposal: Development of an Inhalation Injury Scoring System to Predict Severity of Inhalation Injury|Active, not recruiting|||108|Actual|American Burn Association|||1||f||||f||||||Samples With DNA|"~     bronchioalveolar lavage specimens, blood samples~   "|||2018-05-31 23:23:51.304044|2018-05-31 23:23:51.304044
NCT01194011|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-08-31|2010-08-31|2010-09-02|Estimate|||||||2010-08-31|2010-09-02|Estimate||||June 2010|2010-06-30||||||||Expanded Access|||Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment|Study on Nation-wide Health Care Quality Information Openness and Transparency Mechanism Establishment|No longer available|||||Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:23:51.374338|2018-05-31 23:23:51.374338
NCT01193998|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2014-06-12|2010-09-01|2010-09-02|Estimate|||||||2014-06-12|2014-06-16|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department|Analysis of the Impact of Using a Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department|Completed||N/A|186|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 23:23:51.424907|2018-05-31 23:23:51.424907
NCT01193985|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-04-19|2010-09-01|2010-09-02|Estimate|||||||2011-04-19|2011-04-20|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||Safety and Performance Study of TIGR Matrix Surgical Mesh in Inguinal Hernia Repair|Safety and Performance Study of TIGR Matrix Surgical Mesh in Inguinal Hernia Repair|Completed||N/A|40|Actual|Novus Scientific||1|||f||||f||||||||||2018-05-31 23:23:51.500416|2018-05-31 23:23:51.500416
NCT01193972|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2013-02-25|2010-09-01|2010-09-02|Estimate|||||||2013-02-25|2013-02-27|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Decision Aid Development for Smokers|Decision Aid Development for Cigarette Smokers Undergoing Surgery: Specific Aim 1|Completed||Phase 1|46|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 23:23:51.567446|2018-05-31 23:23:51.567446
NCT01193959|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-10-11|2010-09-01|2010-09-02|Estimate|||||||2010-10-11|2010-10-13|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Observational|||Pemetrexed in Advanced Non-small Cell Lung Cancer|Retrospective Study of Molecular Predictors of Sensitivity and Resistance to Pemetrexed in Advanced Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting||33|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||||||2018-05-31 23:23:51.623208|2018-05-31 23:23:51.623208
NCT01193946|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2013-01-16|2010-09-01|2010-09-02|Estimate|||||||2013-01-16|2013-01-17|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Assessment of Dietary Protein Needs of Older Women|Assessment of Dietary Protein Needs of Older Women|Completed|||8|Actual|Purdue University|||1||f||||f||||||Samples With DNA|"~     plasma samples~   "|||2018-05-31 23:23:51.68805|2018-05-31 23:23:51.68805
NCT01193933|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2018-03-06|2010-09-01|2010-09-02|Estimate|||||||2018-03-06|2018-03-07|Actual|November 2008||2008-11-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Interventional|||Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment|Multicenter Clinical Trial for Adult Ph-negative ALL. Evaluation of the Impact of the Prolonged L-asparaginase Therapy During Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity.|Active, not recruiting||N/A|321|Anticipated|National Research Center for Hematology, Russia|||||f||||f||||||||||2018-05-31 23:23:51.755473|2018-05-31 23:23:51.755473
NCT01193920|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2013-12-17||2014-08-18|2010-09-01|2010-09-02|Estimate|2014-04-03|2014-05-05|Estimate||||2014-08-18|2014-08-22|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional||Analysis was done on the all enrolled population.|Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age|A Phase Ib/II Randomized, Observer-Blind, Controlled, Single Centre Study of a Trivalent Group B Streptococcus Vaccine in Healthy Non-Pregnant Women Leading Into a Dose-Ranging Study in Pregnant Women in South Africa|Completed||Phase 1/Phase 2|380|Actual|Novartis||6|||f||||||||||||||2018-05-31 23:23:52.145293|2018-05-31 23:23:52.145293
NCT01193907|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2012-03-06||2013-12-16|2010-09-01|2010-09-02|Estimate|2012-03-06|2012-04-03|Estimate||||2013-12-16|2014-01-17|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)|A Phase 2, Randomized, Observer-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the Novartis Vaccines Institute for Global Health (NVGH) Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age|Completed||Phase 2|88|Actual|Novartis||4|||f||||f||||||||||2018-05-31 23:23:54.708935|2018-05-31 23:23:54.708935
NCT01193894|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-12-16|2010-09-01|2010-09-02|Estimate|||||||2013-12-16|2013-12-17|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|CUPE2||Trial on Profermin and Fresubin in Ulcerative Colitis|A Randomized Trial on Profermin and Fresubin for Dietetic Treatment of Active Ulcerative Colitis|Completed||Phase 2/Phase 3|73|Actual|Nordisk Rebalance A/S||2|||f||||t||||||||||2018-05-31 23:23:55.345914|2018-05-31 23:23:55.345914
NCT01054066|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2012-04-11|2010-01-21|2010-01-22|Estimate|||||||2012-04-11|2012-04-12|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Managing Chronic Kidney Disease in Eastern North Carolina|Management of Chronic Kidney Disease in Eastern North Carolina (MARKER)|Completed||N/A|1257|Actual|East Carolina University|||||f||||f||||||||||2018-06-01 00:10:09.692358|2018-06-01 00:10:09.692358
NCT01193881|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2015-09-28|2010-09-01|2010-09-02|Estimate|||||||2015-09-28|2015-09-29|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer|Addition of the Gamma-Secretase Inhibitor RO4929097 to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:23:55.413298|2018-05-31 23:23:55.413298
NCT01193868|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|2015-10-15||2015-10-15|2010-09-01|2010-09-02|Estimate|2015-10-15|2015-11-18|Estimate||||2015-10-15|2015-11-18|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy|Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer|Terminated||Phase 2|6|Actual|National Cancer Institute (NCI)|The study closed June 2012 with the NCI discontinuation production of the study drug RO4929097.|1||Study drug production halted.|f||||||||||||||2018-05-31 23:23:55.522602|2018-05-31 23:23:55.522602
NCT01193855|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2013-08-23|2010-09-01|2010-09-02|Estimate|||||||2013-08-23|2013-08-26|Estimate|June 2010||2010-06-30|August 2011|2011-08-31||||January 2012|Anticipated|2012-01-31||Interventional|||Dutasteride in Treating Patients With Prostate Cancer|Single Site, Phase II, Double Blind, Randomized, Placebo Controlled Study of the Effect of Dutasteride (Avodart) 0.5mg on the Volume and Characteristics of Prostate Cancer, as Assessed by Multifunctional Magnetic Resonance Imaging (MRI) With Lower Risk Prostate Cancer Suitable for Active Surveillance. (MAPPED TRIAL)|Unknown status|Recruiting|Phase 2|42|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:23:55.823051|2018-05-31 23:23:55.823051
NCT01193842|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2017-08-07|2010-09-01|2010-09-02|Estimate|||||||2017-08-07|2017-08-08|Actual|October 6, 2010|Actual|2010-10-06|May 2017|2017-05-31||||October 14, 2016|Actual|2016-10-14||Interventional|||Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas|A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|112|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 23:23:55.99068|2018-05-31 23:23:55.99068
NCT01193829|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2014-04-24|2010-09-01|2010-09-02|Estimate|||||||2014-04-24|2014-04-28|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Development of Circulating Tumour Cell Molecular Diagnostics Using a Novel Microfluidic Device||Unknown status|Recruiting||30|Anticipated|National University Hospital, Singapore|||1||f||||f|||||||"~     Blood will be collected for circulating tumor cells (CTC) using previously optimized methods~     described by Tan et al. DNA will be extracted from CTC and matching tumor samples (for aim 1)~     and tested for somatic lung mutations by direct sequencing (2). Germline DNA will be analysed~     for genes related to putative genetic risks for NSCLC and, for treatment toxicities, for~     genes related to gefitinib and other chemotherapy metabolic pathways.~   "|||2018-05-31 23:23:56.210066|2018-05-31 23:23:56.210066
NCT01193816|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2014-07-17|2010-09-01|2010-09-02|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|Sevralox||Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning|Assessment of Loxapine in the Management of Restlessness During Mechanical Ventilation Weaning|Completed||Phase 4|100|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:23:56.271986|2018-05-31 23:23:56.271986
NCT01193803|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-05-30|2010-09-01|2010-09-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Observational|MOLOS||Molecular Microbiology in Osteo-arthritis Infection|Interest of Molecular Biology for Diagnostic of Osteo-arthritis Infections. EE Observational Prospective Study|Completed|||229|Actual|Assistance Publique - Hôpitaux de Paris|||6||f||||f||||||Samples Without DNA|"~     Detection of bacteria will be performed on sample provided from the osteoarticular infections~     like articular fluids, synovial biopsies, bone biopsies, intervertebral disc, paravertebral~     or epidural abscess, articular capsul...~   "|||2018-05-31 23:23:56.340813|2018-05-31 23:23:56.340813
NCT01193790|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2010-09-17|2010-09-01|2010-09-02|Estimate|||||||2010-09-17|2010-09-20|Estimate|January 2011||2011-01-31|September 2010|2010-09-30||||December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of Coblation Channeling in Treating Chronic Tonsillitis||Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Hillel Yaffe Medical Center||1|||f||||||||||||||2018-05-31 23:23:56.418248|2018-05-31 23:23:56.418248
NCT01193777|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-03-08|2010-09-01|2010-09-02|Estimate|||||||2012-03-08|2012-03-09|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||L-Carnitine Administration in Early Sepsis||Terminated||Phase 1|31|Actual|Carolinas Healthcare System||2||Study stopped to open expanded phase II study|f||||t||||||||||2018-05-31 23:23:56.489109|2018-05-31 23:23:56.489109
NCT01193764|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2010-09-01|2010-09-01|2010-09-02|Estimate|||||||2010-09-01|2010-09-02|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris|Double Blind Placebo Controlled Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris|Unknown status|Recruiting|N/A|24|Anticipated|University of Miami||2|||f||||t||||||||||2018-05-31 23:23:56.558688|2018-05-31 23:23:56.558688
NCT01193751|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2011-02-17|2010-09-01|2010-09-02|Estimate|||||||2011-02-17|2011-02-18|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Apgar-Score in Asphyxiated Infants Under Resuscitation|Prospective Multicenter Study to Evaluate the Validity of the Specified Apgar-score in Asphyxiated Infants Under Resuscitation|Unknown status|Recruiting||200|Anticipated|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 23:23:56.893672|2018-05-31 23:23:56.893672
NCT01193738|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2015-08-10|2010-09-01|2010-09-02|Estimate|||||||2015-08-10|2015-08-11|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Osteopathy and Obstructive Sleep Apnea Syndrome|a Single Blind Cross Over Trial to Compare Osteopathic Compression of Pterygopalatine Node to Placebo Compression in Obstructive Sleep Apnea Syndrome.|Completed||N/A|10|Actual|Groupe Hospitalier Pitie-Salpetriere||2|||f||||f||||||||||2018-05-31 23:23:56.955158|2018-05-31 23:23:56.955158
NCT01193725|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2015-04-13|2010-09-01|2010-09-02|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|VRPE||Exposure Therapy for Active Duty Soldiers With Post Traumatic Stress Disorder|Comparing Virtual Reality Exposure Therapy to Prolonged Exposure in the Treatment of Soldiers With PTSD|Completed||N/A|162|Actual|National Center for Telehealth and Technology||3|||f||||t||||||||||2018-05-31 23:23:57.048825|2018-05-31 23:23:57.048825
NCT01193699|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2018-01-29|2010-09-01|2010-09-02|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2010|Actual|2010-08-31|January 2018|2018-01-31|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|PEGINVERA||Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera|An Open-label, Prospective, Multicentre, Phase I/II Dose Escalation Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Efficacy of P1101, PEG-Proline-Interferon Alpha-2b in Patients With Polycythaemia Vera|Completed||Phase 1/Phase 2|24|Anticipated|AOP Orphan Pharmaceuticals AG||1|||f||||f||||||||||2018-05-31 23:23:57.358984|2018-05-31 23:23:57.358984
NCT01193686|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2014-12-11||2015-04-06|2010-08-31|2010-09-02|Estimate|2014-12-19|2015-01-05|Estimate||||2015-04-06|2015-04-28|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional||Descriptive demographics statistics were computed to characterize both baseline populations.|Peer Visitation for OEF/OIF Veterans|Evaluating a Peer Visitor Program for OIF/OEF Veterans With Polytrauma|Completed||N/A|30|Actual|VA Office of Research and Development|We had great difficulty recruiting Recipients of Peer Visitors, i.e., Veterans who wished to receive mentorship from our trained peer visitors. This rendered our sample size too small for planned analyses.|2|||f||||t||||||||||2018-05-31 23:23:57.443558|2018-05-31 23:23:57.443558
NCT01193673|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2018-03-12|2010-08-31|2010-09-02|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2010||2010-01-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Discovering the Gene(s) Causing Developmental Dysplasia of the Hip (DDH)|Discovering the Gene(s) Causing Developmental Dysplasia of the Hip|Active, not recruiting|||1000|Anticipated|University of Utah|||||f||||f||||||Samples With DNA|"~     DNA samples are kept~   "|||2018-05-31 23:23:57.835088|2018-05-31 23:23:57.835088
NCT01193660|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-29|2011-10-11||2012-03-01|2010-08-31|2010-09-02|Estimate|2012-01-30|2012-03-01|Estimate||||2012-03-01|2012-03-05|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy|Double-blind Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Allogenic Umbilical Cord Blood and Erythropoietin for Children With Cerebral Palsy|Completed||N/A|105|Actual|Sung Kwang Medical Foundation||3|||f||||f||||||||||2018-05-31 23:23:57.942301|2018-05-31 23:23:57.942301
NCT01193647|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2018-02-27|2010-08-31|2010-09-02|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2009||2009-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Genetic Factors Affecting Risks for Rotator Cuff Disease|Genetic Factors Affecting Risks for Rotator Cuff Disease|Enrolling by invitation|||400|Anticipated|University of Utah|||||f||||t||||||Samples With DNA|"~     DNA will be retained~   "|||2018-05-31 23:23:58.760559|2018-05-31 23:23:58.760559
NCT01193634|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2014-06-17|2010-08-31|2010-09-02|Estimate|||||||2014-06-17|2014-06-18|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Clinical Evaluation Of The PARADYM RF Device|Clinical Evaluation Of The PARADYM RF Device SORIN GROUP'S New IDC Platform|Completed||Phase 3|75|Actual|LivaNova||1|||f||||f||||||||||2018-05-31 23:23:58.808826|2018-05-31 23:23:58.808826
NCT01193621|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2013-07-10|2010-09-01|2010-09-02|Estimate|||||||2013-07-10|2013-07-11|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|July 2010|Actual|2010-07-31||Interventional|||Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers|Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers|Completed||Phase 1|12|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 23:23:58.867127|2018-05-31 23:23:58.867127
NCT01193608|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2016-06-15||2017-01-03|2010-08-30|2010-09-02|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|September 2010||2010-09-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All participants who were randomized.|Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease|A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of Aab-003 (Pf-05236812) In Subjects With Mild To Moderate Alzheimer's Disease|Completed||Phase 1|88|Actual|Pfizer||6|||f||||t||||||||||2018-05-31 23:23:59.125267|2018-05-31 23:23:59.125267
NCT01193595|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2014-12-02|2010-09-01|2010-09-02|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors|An Open-label, Non-randomized, Dose Escalation, Safety and Pharmacokinetic Phase I Study of Ombrabulin (AVE8062) in Combination With Bevacizumab Administered by Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.|Completed||Phase 1|39|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:24:01.442541|2018-05-31 23:24:01.442541
NCT01193582|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2013-09-17||2013-09-17|2010-08-31|2010-09-02|Estimate|2013-09-17|2013-11-20|Estimate||||2013-09-17|2013-11-20|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|6114A1-4000-CN||A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria|A Phase 4, Open-label Trial to Assess the Safety, Tolerability and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination.|Completed||Phase 4|505|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:24:01.533556|2018-05-31 23:24:01.533556
NCT01193569|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2018-04-10|2010-09-01|2010-09-02|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2010||2010-09-30|April 2018|2018-04-30|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Observational|SOS||A Study of Survival and Outcome After Stroke|The SOS Study: A Study of Survival and Outcome After Stroke|Completed|||142|Actual|Penumbra Inc.|||1||f||||f||||||||||2018-05-31 23:24:02.186259|2018-05-31 23:24:02.186259
NCT01193556|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2012-11-29||2012-11-29|2010-09-01|2010-09-02|Estimate|2012-11-29|2013-01-03|Estimate||||2012-11-29|2013-01-03|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|PRECISE||PEAK PlasmaBlade TnA Versus Traditional Electrosurgery in Subcapsular Tonsillectomy|A Prospective, Randomized, Double-blinded, Controlled Study to Evaluate Use of the PEAK PlasmaBlade TnA in Subcapsular Tonsillectomy|Terminated||N/A|51|Actual|Medtronic Surgical Technologies|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.|2||Termination due to acquisition of PEAK Surgical by Medtronic|f||||f||||||||||2018-05-31 23:24:02.25708|2018-05-31 23:24:02.25708
NCT01193543|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-01|||2012-09-03|2010-09-01|2010-09-02|Estimate|||||||2012-09-03|2012-09-05|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Effect of Calanus Oli on Intra-abdominal Fat, Glucose Tolerance and Lipids in Man|Effect of Calanus Oli on Intra-abdominal Fat, Glucose Tolerance and Lipids in Man|Completed||Phase 2/Phase 3|117|Actual|University of Tromso||2|||f||||f||||||||||2018-05-31 23:24:02.443335|2018-05-31 23:24:02.443335
NCT01193530|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2016-05-26|2010-09-01|2010-09-02|Estimate|||||||2016-05-26|2016-05-27|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer|The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer|Terminated||Phase 2/Phase 3|12|Actual|M.D. Anderson Cancer Center||2||Low Accrual|f||||f||||||||||2018-05-31 23:24:02.577041|2018-05-31 23:24:02.577041
NCT01193517|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2016-12-08|2010-09-01|2010-09-02|Estimate|||||||2016-12-08|2016-12-09|Estimate|August 2010||2010-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Azacitidine and CAPOX in Metastatic Colorectal Cancer|Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands|Completed||Phase 1/Phase 2|26|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 23:24:02.725835|2018-05-31 23:24:02.725835
NCT01193504|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2012-06-13|2010-09-01|2010-09-02|Estimate|||||||2012-06-13|2012-06-14|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification|Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification|Unknown status|Recruiting|Phase 4|100|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-05-31 23:24:02.837011|2018-05-31 23:24:02.837011
NCT01193491|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2015-04-14|2010-08-31|2010-09-02|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dose Escalation of IPI-493 in Hematologic Malignancies|A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of IPI-493 in Patients Experiencing Advanced Hematologic Malignancies With Client Proteins of Hsp90|Terminated||Phase 1|4|Actual|Infinity Pharmaceuticals, Inc.||1||"Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus on Retaspimycin~   HCL"|f||||f||||||||||2018-05-31 23:24:02.967114|2018-05-31 23:24:02.967114
NCT01193478|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2013-01-18|2010-08-31|2010-09-02|Estimate|||||||2013-01-18|2013-01-21|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Escalating, Multiple, Oral Doses of GS 5885 in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection|Completed||Phase 1|71|Actual|Gilead Sciences||6|||f||||t||||||||||2018-05-31 23:24:03.096257|2018-05-31 23:24:03.096257
NCT01193465|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-09-01|2010-09-01|2010-09-02|Estimate|||||||2010-09-01|2010-09-02|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|September 2010|Anticipated|2010-09-30||Interventional|humidity||Temperature and Humidity Among Different Anesthesia Work-station|Comparison of Heat and Humidity Conservation Among Different Anesthesia Workstation and Different Flow Rate.|Unknown status|Recruiting|Phase 4|60|Anticipated|Korea University Anam Hospital||1|||f||||f||||||||||2018-05-31 23:24:03.229642|2018-05-31 23:24:03.229642
NCT01193452|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-01|2010-09-01|2010-09-02|Estimate|||||||2010-09-01|2010-09-02|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|February 2012|Anticipated|2012-02-29|February 2011|Anticipated|2011-02-28||Interventional|||S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer|A Randomized Phase II Study of Comparing S-1/Leucovorin With sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 23:24:03.354646|2018-05-31 23:24:03.354646
NCT01193439|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-09-24|2010-09-01|2010-09-02|Estimate|||||||2012-09-24|2012-09-25|Estimate|January 2002||2002-01-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|January 2009|Actual|2009-01-31||Observational|||Safety of Thoracoscopy in Patients With High Risk|Safety of Thoracoscopy in Patients With High Risk|Completed|||355|Actual|Eskisehir Osmangazi University|||2||f||||t||||||||||2018-05-31 23:24:03.45248|2018-05-31 23:24:03.45248
NCT01193426|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2018-02-01|2010-09-01|2010-09-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2010|Actual|2010-09-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2015|Actual|2015-07-31||Observational|||Diagnostic of Spontaneous Bacterial Peritonitis|Evaluation of IL-6 and IL-8 Interleukin Rates to Diagnose Spontaneous Bacterial Peritonitis|Completed|||316|Actual|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||Samples Without DNA|"~     Ascitic fluid obtained by paracentesis~   "|||2018-05-31 23:24:03.531896|2018-05-31 23:24:03.531896
NCT01193413|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-09-01|2010-09-01|2010-09-02|Estimate|||||||2010-09-01|2010-09-02|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Observational|STREM-1||Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis|Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis: a Marker of Infected Necrosis and Indicator of Treatment|Completed|||30|Actual|Changhai Hospital|||3||f||||t||||||Samples Without DNA|"~     The FNA fluid specimens were performed under ultrasound or CT guidance, using a 18G needle~     attached to a 15 ml eppendorf tube. One percent xylocaine was used for local anaesthesia.~     Under real-time visualization, the needle was directed into the tissue part of the necrosis~     or pseudocyst.~   "|||2018-05-31 23:24:03.60288|2018-05-31 23:24:03.60288
NCT01193400|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2014-04-04|2010-08-31|2010-09-01|Estimate|||||||2014-04-04|2014-04-07|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years|Multicentric Phase II Trial, Prospective, Open, Single Group, to Discuss Induction Therapy With a Combination of Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy With Clofarabine and Low-dose Cytarabine for the Treatment of AML Patients Age Greater Than or Equal to 60 Years|Terminated||Phase 2|75|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 23:24:03.676546|2018-05-31 23:24:03.676546
NCT01193387|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2013-11-26|2010-08-31|2010-09-01|Estimate|||||||2013-11-26|2013-11-27|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparison of Two Identical NN1250 Formulations in Healthy Volunteers|A Trial to Test for Bioequivalence Between Identical NN1250 Formulations, IM1 and IM2, in Healthy Subjects|Completed||Phase 1|26|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:24:04.026671|2018-05-31 23:24:04.026671
NCT01193374|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2011-05-23|2010-08-31|2010-09-01|Estimate|||||||2011-05-23|2011-05-24|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|August 2009|Actual|2009-08-31|March 2008|Actual|2008-03-31||Interventional|HF||The Healthy Families Project|Promoting Healthy Families Through Enhanced Primary Care|Completed||N/A|149|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-05-31 23:24:04.101746|2018-05-31 23:24:04.101746
NCT01193361|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25||2015-09-23|2015-09-23|2010-08-31|2010-09-01|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|November 2012|Actual|2012-11-30|June 2011|Actual|2011-06-30||Interventional|HEPCAT||Ph IIA Study (SOC +/- NS5B)|A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|Completed||Phase 2|39|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 23:24:04.184769|2018-05-31 23:24:04.184769
NCT01193348|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2015-04-13||2015-04-13|2010-08-31|2010-09-01|Estimate|2015-04-13|2015-04-29|Estimate||||2015-04-13|2015-04-29|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|aHUS|The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 22 patients who were treated with study drug were included in the ITT population.|An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome|An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome|Completed||Phase 2|22|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 23:24:04.331123|2018-05-31 23:24:04.331123
NCT01193335|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2015-01-21||2017-04-05|2010-08-31|2010-09-01|Estimate|2015-01-21|2015-02-04|Estimate||||2017-04-05|2017-05-11|Actual|October 2010||2010-10-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety Analysis set included all participants who received at least 1 dose of 13vPnC.|Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.|A Phase 4, Open-label Trial Describing The Safety, Tolerability, And Immunogenicity Of The 13 Valent Pneumococcal Conjugate Vaccine In Preterm Compared To Term Infants|Completed||Phase 4|200|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:24:05.140013|2018-05-31 23:24:05.140013
NCT01193296|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2012-05-03|2010-08-31|2010-09-01|Estimate|||||||2012-05-03|2012-05-04|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|OPTIMA||Glycemic Holter Study (Continuous Glucose Monitoring) -|Prospective, Randomized, Open-label Study With Blinded Endpoint (PROBE Design) to Compare the 72 hr Glycemic Profiles Obtained by Continuous Subcutaneous Glucose Monitoring (CSGM) in Type 2 Diabetic Patients at Baseline With Metformin Monotherapy and After an 8-week Period With the Addition of Either Vildagliptin or Sitagliptin in Patients Insufficiently Controlled by Metformin After at Least 3 Months of Monotherapy|Completed||Phase 4|36|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:24:09.725624|2018-05-31 23:24:09.725624
NCT01193283|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2015-10-13||2017-04-11|2010-08-31|2010-09-01|Estimate|2015-10-13|2015-11-11|Estimate||||2017-04-11|2017-05-22|Actual|August 2010||2010-08-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia|Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia|Completed||Phase 1/Phase 2|22|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-05-31 23:24:09.812124|2018-05-31 23:24:09.812124
NCT01193270|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2015-11-10|2010-08-31|2010-09-01|Estimate|||||||2015-11-10|2015-11-11|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Vitamin E for Extremely Preterm Infants|Single-Dose Vitamin E for Prevention of Mortality and Morbidity in Extremely Preterm Infants: Pilot Study|Completed||Phase 1|93|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 23:24:10.004613|2018-05-31 23:24:10.004613
NCT01193257|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31||2016-03-04|2017-01-16|2010-08-31|2010-09-01|Estimate||||2016-03-04|2016-04-04|Estimate|2017-01-16|2017-01-18|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|September 2014|Actual|2014-09-30||Interventional|||Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy|Completed||Phase 3|1099|Actual|Takeda||2|||f||||t||||||||||2018-05-31 23:24:10.145081|2018-05-31 23:24:10.145081
NCT01193244|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2017-04-07|2016-03-04|2017-04-07|2010-08-31|2010-09-01|Estimate|2017-04-07|2017-05-17|Actual|2016-03-04|2016-04-04|Estimate|2017-04-07|2017-05-17|Actual|October 1, 2010|Actual|2010-10-01|April 2017|2017-04-30|April 7, 2016|Actual|2016-04-07|January 1, 2014|Actual|2014-01-01||Interventional||Intent-to-treat (ITT) population included all participants who were randomized.|Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 3|1560|Actual|Takeda||2|||f||||t|t|||||||||2018-05-31 23:24:10.462878|2018-05-31 23:24:10.462878
NCT01193231|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2012-02-13|2010-08-31|2010-09-01|Estimate|||||||2012-02-13|2012-02-14|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Observational|||A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing|A Single Center, Randomized, Contralateral, 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing|Completed|||10|Actual|Durrie Vision|||2||f||||f||||||||||2018-05-31 23:24:14.338313|2018-05-31 23:24:14.338313
NCT01193218|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2014-05-16||2014-05-16|2010-08-31|2010-09-01|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus|A Double-blind, Randomised, Parallel Group Efficacy and Safety Study of BI 10773 (5 mg, 10 mg, 25 mg, and 50 mg) Compared to Placebo When Administered Orally Once Daily Over 12 Weeks, as Monotherapy, in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Diet and Exercise, Followed by a 40 Week Randomised Extension Study to Assess Long Term Safety of BI 10773 (10 mg and 25 mg)|Completed||Phase 2|547|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 23:24:14.45394|2018-05-31 23:24:14.45394
NCT01193205|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2016-05-25|2010-08-31|2010-09-01|Estimate|||||||2016-05-25|2016-05-27|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||20 Weeks DBT Group Skills Training Study|Evaluating the Effectiveness of Dialectical Behaviour Skills Training for Suicidality in Borderline Personality Disorder|Completed||Phase 1|84|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 23:24:15.445305|2018-05-31 23:24:15.445305
NCT01193023|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-08-31|2010-08-31|2010-09-01|Estimate|||||||2010-08-31|2010-09-01|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|NavPed-Inv||Patient-ventilator Asynchrony During Mechanical Invasive Assisted-ventilation in Pediatric Patients|Patient-ventilator Asynchrony During Mechanical Invasive Assisted-ventilation in Pediatric Patients|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 23:24:25.093527|2018-05-31 23:24:25.093527
NCT01193192|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-11-22|2010-08-30|2010-09-01|Estimate|||||||2011-11-22|2011-11-23|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy|A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy|Terminated|||30|Actual|Pamlab, Inc.|||2|Inadequate number of charts available for Test Group|f||||f||||||||||2018-05-31 23:24:15.527358|2018-05-31 23:24:15.527358
NCT01193179|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2014-01-06|2010-08-31|2010-09-01|Estimate|||||||2014-01-06|2014-01-08|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes|Long-term Co-administration Study of OPC-262 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|450|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 23:24:15.610554|2018-05-31 23:24:15.610554
NCT01193166|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-07-04|2010-08-30|2010-09-01|Estimate|||||||2013-07-04|2013-07-08|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital|A Twelve-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital|Withdrawn||Phase 4|0|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC||8||"This study was stopped due to an internal reconsideration of priorities of the product~   portfolio."|f||||f||||||||||2018-05-31 23:24:15.6822|2018-05-31 23:24:15.6822
NCT01193153|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2014-12-22|2014-06-25|2014-12-22|2010-08-30|2010-09-01|Estimate|2014-12-22|2015-01-05|Estimate|2014-06-25|2014-06-27|Estimate|2014-12-22|2015-01-05|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Open-label (OL) intent-to-treat (ITT) analysis set included all participants who received at least 1 injection of open-label study drug.|A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder|Completed||Phase 3|667|Actual|Janssen Scientific Affairs, LLC||2|||f||||f||||||||||2018-05-31 23:24:15.804341|2018-05-31 23:24:15.804341
NCT01193140|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28||2012-11-16|2012-11-16|2010-08-31|2010-09-01|Estimate||||2012-11-16|2012-11-21|Estimate|2012-11-16|2012-11-21|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors|An Extension Study to Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors.|Completed||Phase 2|24|Actual|Abbott||1|||f||||f||||||||||2018-05-31 23:24:16.61604|2018-05-31 23:24:16.61604
NCT01193127|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|2014-07-02|2012-10-10|2014-08-27|2010-08-30|2010-09-01|Estimate|2014-08-27|2014-08-28|Estimate|2012-10-10|2012-10-12|Estimate|2014-08-27|2014-08-28|Estimate|July 2010||2010-07-31|August 2014|2014-08-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)||Completed||Phase 2|223|Actual|Omeros Corporation||4|||f||||f||||||||||2018-05-31 23:24:16.810933|2018-05-31 23:24:16.810933
NCT01193114|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2012-12-13||2013-01-26|2010-08-30|2010-09-01|Estimate|2013-01-26|2013-03-01|Estimate||||2013-01-26|2013-03-01|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Stage 1 Treatment Development With Homeless Mothers|Stage 1 Treatment Development With Homeless Mothers and Their 2-6 Year Old Children|Completed||N/A|60|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 23:24:22.081414|2018-05-31 23:24:22.081414
NCT01193101|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2015-07-23||2016-01-13|2010-08-30|2010-09-01|Estimate|2015-07-23|2015-08-19|Estimate||||2016-01-13|2016-02-15|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension|Completed||Phase 2|389|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:24:22.586129|2018-05-31 23:24:22.586129
NCT01193088|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-09-12|2010-08-31|2010-09-01|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2010|Actual|2010-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|INC-6602||Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2|Genetics of Charcot Marie Tooth Disease (CMT) - Modifiers of CMT1A, New Causes of CMT|Recruiting|||1050|Anticipated|University of Iowa|||2||f||||t||||||Samples With DNA|"~     DNA extracted from whole blood. Filter cards with blood spots.~   "|||2018-05-31 23:24:23.570155|2018-05-31 23:24:23.570155
NCT01193075|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-09-12|2010-08-31|2010-09-01|Estimate|||||||2017-09-12|2017-09-13|Actual|April 1, 2010|Actual|2010-04-01|September 2017|2017-09-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|INC-6601||Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others|Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Type (CMT1B), 2A (CMT2A), 4A (CMT4A), 4C (CMT4C), and Others|Recruiting|||5000|Anticipated|University of Iowa|||5||f||||t||||||||||2018-05-31 23:24:24.01328|2018-05-31 23:24:24.01328
NCT01193062|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2011-01-11|2010-08-30|2010-09-01|Estimate|||||||2011-01-11|2011-01-12|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274|A Phase 1 Investigator And Subject-Blind Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Doses Of PF-04995274 On Sapp-Alpha Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:24:24.241533|2018-05-31 23:24:24.241533
NCT01193049|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2012-06-27||2015-09-03|2010-08-30|2010-09-01|Estimate|2012-06-27|2012-08-02|Estimate||||2015-09-03|2015-09-04|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)|A Two-Part, Randomized Clinical Trial to Study the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics|Completed||Phase 1|11|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 23:24:24.410039|2018-05-31 23:24:24.410039
NCT01193036|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2015-01-07|2010-08-31|2010-09-01|Estimate|||||||2015-01-07|2015-01-08|Estimate|August 2010||2010-08-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems|Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems|Terminated|||11|Actual|M.D. Anderson Cancer Center|||2|Low accrual.|f||||f||||||||||2018-05-31 23:24:24.85413|2018-05-31 23:24:24.85413
NCT01193010|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2016-10-03|2010-08-30|2010-09-01|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2010||2010-08-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Computer Assisted Planing of Corrective Osteotomy for Distal Radius Malunion|Computer-Assisted Versus Non-Computer Assisted Preoperative Planning of Corrective Osteotomy for Extra-Articular Distal Radius Malunions: A Multi-Center Randomized Controlled Trial|Active, not recruiting||N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:24:25.179016|2018-05-31 23:24:25.179016
NCT01192997|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2015-08-11|2010-08-31|2010-09-01|Estimate|||||||2015-08-11|2015-08-13|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|PRIME||Comparison of Two Meningococcal ACWY Conjugate Vaccines|A Phase 2/3, Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY (Menveo) or GSK Meningococcal ACWY Conjugate Vaccine in Adolescents Primed With Meningitec, Menjugate or Neisvac-C in Preschool Vaccination|Completed||Phase 2/Phase 3|91|Actual|Public Health England||6|||f||||f||||||||||2018-05-31 23:24:25.245977|2018-05-31 23:24:25.245977
NCT01192984|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-02-28|2010-08-31|2010-09-01|Estimate|||||||2017-02-28|2017-03-03|Actual|September 2010||2010-09-30|February 2017|2017-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma|Phase II Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma|Completed||Phase 2|38|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-05-31 23:24:25.335713|2018-05-31 23:24:25.335713
NCT01192971|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2015-04-02|2010-08-30|2010-09-01|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|HCC||A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma|Single Arm, Open-label, Multi-center, Phase II Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 2|121|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 23:24:25.407238|2018-05-31 23:24:25.407238
NCT01192958|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-08-31|2010-08-31|2010-09-01|Estimate|||||||2010-08-31|2010-09-01|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|Snuffles||A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza|A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza|Completed|||||Public Health England|||||f||||f||||||||||2018-05-31 23:24:25.467522|2018-05-31 23:24:25.467522
NCT01192945|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2015-11-12|2010-08-30|2010-09-01|Estimate|||||||2015-11-12|2015-11-13|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Observational|Piaza||Non-interventional Study With Azacitidin (Vidaza®)|Piaza - Non-interventional Study on the Efficacy and Safety of Azacitidin (Vidaza®) in Patients With Myelodysplastic Syndromes (MDS, INT-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder)|Completed|||150|Actual|iOMEDICO AG|||||f||||f||||||||||2018-05-31 23:24:25.505849|2018-05-31 23:24:25.505849
NCT01192932|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2012-07-03|2010-08-31|2010-09-01|Estimate|||||||2012-07-03|2012-07-04|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Effects of Nycthemeral Variations on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent in Chronic Obstructive Pulmonary Disease (COPD)|Effects of Nycthemeral Variations on CT Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent in COPD: Comparisons Between CT Scans Obtained in the Morning and in the Afternoon and Relationships With Pulmonary Function Tests|Completed|||20|Actual|Erasme University Hospital|||1||f||||f||||||||||2018-05-31 23:24:25.638025|2018-05-31 23:24:25.638025
NCT01192919|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2016-11-07|2010-08-31|2010-09-01|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Tumour Registry Lung Cancer (TLK)|Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.|Completed|||2500|Actual|iOMEDICO AG|||1||f||||f||||||||No||2018-05-31 23:24:25.706132|2018-05-31 23:24:25.706132
NCT01192906|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30||2013-08-20|2016-11-01|2010-08-30|2010-09-01|Estimate||||2013-08-20|2013-08-28|Estimate|2016-11-01|2016-11-02|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)|A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.|Completed||Phase 3|624|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:24:25.780246|2018-05-31 23:24:25.780246
NCT01192893|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2015-08-13|2010-08-31|2010-09-01|Estimate|||||||2015-08-13|2015-08-14|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2011|Actual|2011-10-31||Observational|||Role of Oxytocin in Post-menopausal Osteoporosis: Evaluation on the Population of the OPUS Cohort||Completed|||1000|Actual|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||Samples Without DNA|"~     OPUS is a prospective study of postmenopausal women recruited in the general population~     between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin~     (Germany), Kiel (Germany), Paris (Hôpital Cochin, France), and Sheffield (UK)).~     Investigations were approved at each institution according to the Declaration of Helsinki.~     Written consent was obtained from all subjects. Each center recruited approximately 500~     postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79.~     Ninety-nine percent of subjects were of white ethnicity.~   "|||2018-05-31 23:24:26.184633|2018-05-31 23:24:26.184633
NCT01192880|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30||2016-06-30|2017-02-14|2010-08-30|2010-09-01|Estimate||||2016-07-01|2016-07-04|Estimate|2017-02-14|2017-02-15|Actual|November 2010||2010-11-30|February 2017|2017-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia|A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period|Completed||Phase 3|625|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:24:26.409793|2018-05-31 23:24:26.409793
NCT01192867|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30||2013-08-20|2017-06-23|2010-08-30|2010-09-01|Estimate||||2013-08-20|2013-08-28|Estimate|2017-06-23|2017-06-26|Actual|December 11, 2010|Actual|2010-12-11|June 2017|2017-06-30|May 26, 2014|Actual|2014-05-26|May 26, 2014|Actual|2014-05-26||Interventional|||A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)|A Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period|Completed||Phase 3|629|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:24:27.575728|2018-05-31 23:24:27.575728
NCT01192841|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-08-30|2010-08-30|2010-09-01|Estimate|||||||2010-08-30|2010-09-01|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Bacterial Contamination of Workwear|Physician Dress Code And Microbial Colonization Of The White Coat: Does Physician Dress Code Alter Bacterial Colonization Rate On The Clothing Of Physicians?|Completed||N/A|110|Actual|Denver Health and Hospital Authority||2|||f||||t||||||||||2018-05-31 23:24:28.109826|2018-05-31 23:24:28.109826
NCT01192828|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-07-18|2010-08-30|2010-09-01|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2010||2010-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|||Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine|Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine|Active, not recruiting||Phase 1/Phase 2|15|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 23:24:28.191094|2018-05-31 23:24:28.191094
NCT01192815|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-10-30|2010-08-30|2010-09-01|Estimate|||||||2012-10-30|2012-10-31|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck|A Phase II Study of Erlotinib and Radiation Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck|Terminated||Phase 2|2|Actual|Case Comprehensive Cancer Center||1||Funding unavailable|f||||t||||||||||2018-05-31 23:24:28.280572|2018-05-31 23:24:28.280572
NCT01192802|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2013-01-23|2010-08-31|2010-09-01|Estimate|||||||2013-01-23|2013-01-24|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora|Effect of Intestinal Helminths on Gut Microflora|Completed||Phase 4|200|Actual|Albert Schweitzer Hospital||3|||f||||f||||||||||2018-05-31 23:24:28.377712|2018-05-31 23:24:28.377712
NCT01192789|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-05-19|2010-08-31|2010-09-01|Estimate|||||||2017-05-19|2017-05-22|Actual|February 2008||2008-02-29|May 2017|2017-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of Age|Cluster Randomized Trial of Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of Age in Hala and Matiari District, Pakistan|Completed||N/A|4070|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 23:24:28.444664|2018-05-31 23:24:28.444664
NCT01192776|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2017-03-31||2017-09-05|2010-08-31|2010-09-01|Estimate|2017-07-17|2017-08-15|Actual||||2017-09-05|2017-10-03|Actual|September 2010||2010-09-30|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)|Optimizing Cooling Strategies at < 6 Hours of Age for Neonatal Hypoxic-Ischemic Encephalopathy|Terminated||Phase 3|364|Actual|NICHD Neonatal Research Network|This RCT was stopped for safety and futility reasons by the Data Safety and Monitoring Committee so did not enroll the target number of participants needed to achieve target power and statistically reliable results.|4||The trial closed for emerging safety profile and futility analysis and will not resume.|f||||t||||||||||2018-05-31 23:24:28.555813|2018-05-31 23:24:28.555813
NCT01192763|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2013-09-27|2010-08-31|2010-09-01|Estimate|||||||2013-09-27|2013-09-30|Estimate|August 2010||2010-08-31|September 2013|2013-09-30||||January 2012|Actual|2012-01-31||Interventional|||RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer|A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:24:29.319504|2018-05-31 23:24:29.319504
NCT01192750|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2017-05-16|2010-08-31|2010-09-01|Estimate|||||||2017-05-16|2017-05-17|Actual|August 5, 2010|Actual|2010-08-05|May 2017|2017-05-31|October 5, 2010|Actual|2010-10-05|October 5, 2010|Actual|2010-10-05||Observational|||Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab|Retrospective Analysis of ERCC1 Expression in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Received Cisplatin or Cisplatin and Cetuximab|Completed|||79|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:24:29.401955|2018-05-31 23:24:29.401955
NCT01192737|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2012-04-16|2010-08-31|2010-09-01|Estimate|||||||2012-04-16|2012-04-17|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|COFLUPREG||"COhort Study on A/H1N1 FLU During PREGnancy"|Cohort Study to Evaluate Clinical Expression and Maternofetal Consequences of A/H1N1 Influenza in Pregnant Women|Completed|||919|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||Samples Without DNA|"~     Serum, cord blood~   "|||2018-05-31 23:24:29.46224|2018-05-31 23:24:29.46224
NCT01192724|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2016-11-14|2010-08-31|2010-09-01|Estimate|||||||2016-11-14|2016-11-15|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ABCD||Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation|A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation|Completed||Phase 4|630|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:24:29.518673|2018-05-31 23:24:29.518673
NCT01192711|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-09-01|2010-08-31|2010-09-01|Estimate|||||||2010-09-01|2010-09-02|Estimate|May 2009||2009-05-31|September 2010|2010-09-30||||October 2011|Anticipated|2011-10-31||Interventional|DID3||Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice|An Open Label, Multicentre, Randomized Study of Insulin Glargine + Prandial Insulin Glulisine Associated With a Telemedicine System for Carbohydrates Counting vs. Insulin Glargine + Prandial Insulin Glulisine Associated With Common Practice|Unknown status|Recruiting|Phase 3|130|Anticipated|Consorzio Mario Negri Sud||2|||f||||f||||||||||2018-05-31 23:24:29.598365|2018-05-31 23:24:29.598365
NCT01192698|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2014-08-01||2017-07-31|2010-08-31|2010-09-01|Estimate|2017-07-31|2017-08-07|Actual||||2017-07-31|2017-08-07|Actual|October 2009||2009-10-31|July 2017|2017-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Intravenous Interferon During Liver Transplant|Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus|Completed||N/A|15|Actual|Carolinas Healthcare System|small sample size short duration of treatment|2|||f||||t||||||||No||2018-05-31 23:24:29.775744|2018-05-31 23:24:29.775744
NCT01192685|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-04-19|2010-08-31|2010-09-01|Estimate|||||||2017-04-19|2017-04-20|Actual|December 2012||2012-12-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Transcranial Magnetic Stimulation in Major Depression With EEG and Near Infrared Spectroscopy (NIRS) Monitoring|Transcranial Magnetic Stimulation in Major Depression With EEG and NIRS Monitoring|Terminated||Early Phase 1|2|Actual|Boston University||1||Neuronavigation system equipment failure caused unreliable data|f||||t|f|t|f|f|t|||No||2018-05-31 23:24:29.979409|2018-05-31 23:24:29.979409
NCT01192672|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-03-14|2010-08-31|2010-09-01|Estimate|||||||2017-03-14|2017-03-15|Actual|September 2008|Actual|2008-09-30|March 2017|2017-03-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Use of Expressive Writing in Irritable Bowel Syndrome (IBS)|Use of Expressive Writing in Irritable Bowel Syndrome (IBS)|Completed||N/A|197|Actual|Boston University||3|||f||||f||||||||No||2018-05-31 23:24:30.05984|2018-05-31 23:24:30.05984
NCT01192659|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2016-11-30|2010-08-30|2010-09-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes|Identification of Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes: An Analysis of Data From the SAVOR Study|Completed|||16492|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:24:30.122904|2018-05-31 23:24:30.122904
NCT01192646|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2010-08-31|2010-08-31|2010-09-01|Estimate|||||||2010-08-31|2010-09-01|Estimate|August 2011||2011-08-31|August 2010|2010-08-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|HBLSS||Home Based Life Saving Skills Training in a Rural Area in Tanzania|IMPACT OF HOME BASED LIFE SAVING SKILLS TRAINING IN A RURAL AREA IN TANZANIA IN FACILITY DELIVERY, PREPARATION OF BIRTH PLANS AND COST-EFFECTIVENESS. AN INTERVENTION CLUSTER RANDOMIZED TRIAL.|Unknown status|Not yet recruiting|N/A|28|Anticipated|Muhimbili University of Health and Allied Sciences||2|||f||||||||||||||2018-05-31 23:24:30.19543|2018-05-31 23:24:30.19543
NCT01192633|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-08-31|2010-08-31|2010-09-01|Estimate|||||||2010-08-31|2010-09-01|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|GVPS||Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma|Phase Ⅱ Study of Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma|Unknown status|Recruiting|Phase 2|40|Anticipated|Fudan University|||||f||||f||||||||||2018-05-31 23:24:30.280787|2018-05-31 23:24:30.280787
NCT01192620|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-05-01|2010-08-31|2010-09-01|Estimate|||||||2012-05-01|2012-05-02|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Pediatric Appendicitis Pathway Study|Pediatric Appendicitis Pathway Study|Unknown status|Recruiting||2000|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-05-31 23:24:30.386922|2018-05-31 23:24:30.386922
NCT01192607|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|||2011-03-01|2010-08-31|2010-09-01|Estimate|||||||2011-03-01|2011-03-02|Estimate|April 2007||2007-04-30|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|November 2007|Actual|2007-11-30||Interventional|||Endoscopic Treatment During Endodontic Procedures|Endoscopic Treatment During Endodontic Procedures|Unknown status|Recruiting|Phase 1|15|Anticipated|Barzilai Medical Center|||||f||||f||||||||||2018-05-31 23:24:30.453412|2018-05-31 23:24:30.453412
NCT01192594|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2016-09-06|2010-08-30|2010-09-01|Estimate|||||||2016-09-06|2016-09-08|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MAPP||Milestones of Adjustment Post-Psychosis|Outcomes of Psychiatric Case Manager Training on Medication Adherence, Progression Through the Four Phases of the MAPP Recovery Model, and Quality of Life in Patients With Schizophrenia|Terminated||Phase 3|110|Actual|Yale University||2|||f||||t||||||||||2018-05-31 23:24:30.691447|2018-05-31 23:24:30.691447
NCT01192581|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-10-28|2010-08-30|2010-09-01|Estimate|||||||2010-10-28|2010-11-01|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|October 2011|Anticipated|2011-10-31|April 2011|Anticipated|2011-04-30||Interventional|||Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection as Adjunctive Therapy in Subjects With Internal Carotid Artery Hypoperfusion|Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection as Adjunctive Therapy in Subjects With Internal Carotid Artery Hypoperfusion|Unknown status|Recruiting|Phase 2|120|Anticipated|Xijing Hospital||4|||f||||t||||||||||2018-05-31 23:24:30.76595|2018-05-31 23:24:30.76595
NCT01192568|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2018-04-19|2010-08-31|2010-09-01|Estimate|||||||2018-04-19|2018-04-23|Actual|May 2, 2011|Actual|2011-05-02|April 2018|2018-04-30|June 12, 2020|Anticipated|2020-06-12|March 9, 2020|Anticipated|2020-03-09||Interventional|||Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder|A Two-part, Multicenter, Dose-titration Study Evaluating Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for Treatment of Detrusor Overactivity Associated Neurological Condition in Pediatric Patients|Recruiting||Phase 4|58|Anticipated|Allergan||1|||f||||f||||||||||2018-05-31 23:24:31.022228|2018-05-31 23:24:31.022228
NCT01192555|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16||2015-01-29|2018-05-01|2010-08-30|2010-09-01|Estimate||||2015-01-29|2015-02-09|Estimate|2018-05-01|2018-05-03|Actual|September 2010||2010-09-30|May 2018|2018-05-31|September 2026|Anticipated|2026-09-30|July 2012|Actual|2012-07-31||Interventional|ATOMIC||Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma|A Phase I/II Study Using Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)|Active, not recruiting||Phase 1/Phase 2|11|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 23:24:31.121938|2018-05-31 23:24:31.121938
NCT01192542|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2013-09-17||2016-05-09|2010-08-31|2010-09-01|Estimate|2013-12-16|2014-01-17|Estimate||||2016-05-09|2016-06-10|Estimate|August 2010||2010-08-31|May 2016|2016-05-31||||September 2010|Actual|2010-09-30||Interventional||Baseline summary was conducted on all enrolled subjects.|Pilot Evaluation of a New Galyfilcon A Lens Prototype and Enfilcon A Lens|Dispensing Evaluation of a New Galyfilcon A Prototype and Avaira Lenses|Completed||N/A|39|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 23:24:31.219745|2018-05-31 23:24:31.219745
NCT01192529|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-06-21|2010-08-30|2010-09-01|Estimate|||||||2012-06-21|2012-06-22|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|SUPRESSI||Evaluation of a Diet in Patients With Senile Dementia|Clinical Evaluation of an Specific Diet for People With Dementia Disease|Unknown status|Recruiting|N/A|184|Anticipated|Vegenat, S.A.||2|||f||||f||||||||||2018-05-31 23:24:31.421956|2018-05-31 23:24:31.421956
NCT01192516|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2015-02-13||2015-03-18|2010-08-30|2010-09-01|Estimate|2015-03-04|2015-03-19|Estimate||||2015-03-18|2015-04-07|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|AIM||Effectiveness of Tailored Activity Pacing for Symptomatic Osteoarthritis|Effectiveness of Tailored Activity Pacing for Symptomatic Osteoarthritis|Completed||N/A|195|Actual|VA Office of Research and Development|Although overall effects were not found by group over time, additional data analyses will be conducted to determine if there were positive effects for specific subgroups of people.|3|||f||||f||||||||||2018-05-31 23:24:31.526233|2018-05-31 23:24:31.526233
NCT01192503|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-02-08|2010-08-31|2010-09-01|Estimate|||||||2013-02-08|2013-02-11|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|RAS-RLS||Safety and Efficacy of Rasagiline in Restless Legs Syndrome|Safety and Efficacy of Rasagiline in Restless Legs Syndrome|Terminated||Phase 2/Phase 3|52|Actual|University of Virginia||2||Slow enrollment|f||||f||||||||||2018-05-31 23:24:32.038197|2018-05-31 23:24:32.038197
NCT01192490|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2011-06-15|2010-08-30|2010-09-01|Estimate|||||||2011-06-15|2011-06-16|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|10-053||Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices|Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices|Unknown status|Recruiting|N/A|210|Anticipated|University of Tennessee||2|||f||||t||||||||||2018-05-31 23:24:32.125681|2018-05-31 23:24:32.125681
NCT01192477|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-12-02|2010-08-31|2010-09-01|Estimate|||||||2013-12-02|2013-12-04|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|OZCARD||Ozone Cardiovascular Effects in Genetically Susceptible People|Ozone Cardiovascular Effects in Genetically Susceptible People|Completed||N/A|80|Anticipated|University of Rochester||3|||f||||f||||||||||2018-05-31 23:24:32.212776|2018-05-31 23:24:32.212776
NCT01192464|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2018-03-22|2010-08-31|2010-09-01|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 10, 2011|Actual|2011-05-10|March 2018|2018-03-31|October 2033|Anticipated|2033-10-31|October 2018|Anticipated|2018-10-31||Interventional|CARCD30||EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma|Phase I Study of the Administration of EBV CTLs Expressing CD30 Chimeric Receptors for Relapsed CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma (CAR CD 30)|Active, not recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-05-31 23:24:32.282346|2018-05-31 23:24:32.282346
NCT01192451|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-09-10|2010-08-31|2010-09-01|Estimate|||||||2010-09-10|2010-09-13|Estimate|December 2008||2008-12-31|September 2010|2010-09-30||||||||Observational|RIO||Prospective Cohort of Respiratory Insufficiency Outcome|Prospective Cohort of Patients With Chronic Obstructive Pulmonary Disease (COPD) Undergoing Domiciliary Noninvasive Positive Pressure Ventilation|Unknown status|Recruiting||300|Anticipated|University Hospital, Grenoble|||||f||||t||||||||||2018-05-31 23:24:32.353823|2018-05-31 23:24:32.353823
NCT01192438|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2014-03-26|2010-08-31|2010-09-01|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Laser Based Focal Ablation of Low Grade Prostate Cancer|A Pilot Study to Evaluate Magnetic Resonance Thermal Image-guided Laser-Induced Interstitial Thermal Therapy for Focal Ablation of Prostate Cancer|Completed||N/A|9|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 23:24:32.412131|2018-05-31 23:24:32.412131
NCT01192425|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-08-31|2010-08-31|2010-09-01|Estimate|||||||2010-08-31|2010-09-01|Estimate||||August 2010|2010-08-31||||||||Observational|EXPLORE||Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes|P06-001: (EX)Amination of (P)NH, by (L)Evel (O)f CD59 on (RE)d and White Blood Cells, in Bone Marrow Failure Syndromes|Completed|||5580|Actual|Alexion Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:24:32.472299|2018-05-31 23:24:32.472299
NCT01192412|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2016-08-30||2016-11-15|2010-08-31|2010-09-01|Estimate|2016-11-15|2017-01-11|Estimate||||2016-11-15|2017-01-11|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The CHIPS Trial (Control of Hypertension In Pregnancy Study)|The CHIPS Trial (Control of Hypertension In Pregnancy Study)|Completed||N/A|987|Actual|University of British Columbia|Women with preexisting or gestational hypertension included, and may have differing management. Primary/secondary outcomes included causes of pregnancy loss and interventions for neonatal care not expected to be associated with maternal BP control|2|||f||||t||||||||||2018-05-31 23:24:32.541102|2018-05-31 23:24:32.541102
NCT01192399|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2017-11-06||2018-02-11|2010-08-30|2010-09-01|Estimate|2018-02-11|2018-03-13|Actual||||2018-02-11|2018-03-13|Actual|November 2007||2007-11-30|February 2018|2018-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients|Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients|Completed||Phase 2|29|Actual|Alexion Pharmaceuticals||1|||f||||f|t|f|||t|||No||2018-05-31 23:24:33.159427|2018-05-31 23:24:33.159427
NCT01192386|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-08-31|2010-08-31|2010-09-01|Estimate|||||||2010-08-31|2010-09-01|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Eosinophil Markers and Development of Disease in Allergic Rhinitis|Eosinophil Markers and Development of Disease in Allergic Rhinitis. A 15-year Follow-up of Patients With Grass Pollen Induced Hayfever.|Completed|||29|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 23:24:33.37769|2018-05-31 23:24:33.37769
NCT01192373|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2013-01-18|2010-08-30|2010-09-01|Estimate|||||||2013-01-18|2013-01-21|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|Metamod3||"Modulation of Free Fatty Acids in Heart Failure Patients With Diabetes: Effect on Left Ventricular Function"|"Short Term Modulation of Circulating Free Fatty Acids in Heart Failure Patients With Type 2 Diabetes: Effect on Myocardial Lipid Content, Left Ventricular Function and Exercise Capacity"|Completed||Phase 2|18|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:24:33.430427|2018-05-31 23:24:33.430427
NCT01192360|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-09-14|2010-08-30|2010-09-01|Estimate|||||||2010-09-14|2010-09-16|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease|Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease|Unknown status|Recruiting|Phase 3|50|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:24:33.50424|2018-05-31 23:24:33.50424
NCT01192347|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2013-07-24||2014-02-14|2010-08-30|2010-09-01|Estimate|2013-07-24|2013-09-25|Estimate||||2014-02-14|2014-03-14|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|FOX|Safety Set was used for Baseline measures. Safety Set comprised all patients who had taken at least 1 dose of Anagrelide Hydrochloride and had at least 1 post-baseline safety assessment. Two patients did not receive Anagrelide Hydrochloride, therefore n = 175 for the Safety Set.|French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia|A Phase 4, Observational Study to Explore How Different Treatment Regimens Affect Continuation With Treatment in the First 6 Months Following Initiation of XAGRID Into Adult Patients' Essential Thrombocythemia Therapy|Completed|||177|Actual|Shire|||||f||||f||||||||||2018-05-31 23:24:33.687331|2018-05-31 23:24:33.687331
NCT01192334|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-12-22|2010-08-31|2010-09-01|Estimate|||||||2013-12-22|2013-12-24|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Changes of the Single Limb Standing Balance After Total Knee Arthroplasty in Degenerative Osteoarthritis|Observational Study for Changes of the Single Limb Standing Balance After Total Knee Arthroplasty in Degenerative Osteoarthritis|Completed|||50|Actual|Ulsan University Hospital|||||f||||t||||||||||2018-05-31 23:24:34.112516|2018-05-31 23:24:34.112516
NCT01192321|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-10-19|2010-08-30|2010-09-01|Estimate|||||||2012-10-19|2012-10-22|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric IOL Implantation Compared to Monofocal IOL Implantation|Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric Intraocular Lens (IOL) Implantation Compared to Monofocal IOL Implantation|Terminated||Phase 4|9|Actual|Alcon Research||2||Business decision to close study based on low enrollment|f||||f||||||||||2018-05-31 23:24:34.173069|2018-05-31 23:24:34.173069
NCT01192308|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-05-21|2010-08-31|2010-09-01|Estimate|||||||2012-05-21|2012-05-22|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|KINETAM||PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)|PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)|Completed||Phase 1|42|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 23:24:34.235814|2018-05-31 23:24:34.235814
NCT01192295|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2015-01-22||2017-09-18|2010-08-31|2010-09-01|Estimate|2015-01-22|2015-02-06|Estimate||||2017-09-18|2017-10-18|Actual|November 2010||2010-11-30|September 2017|2017-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The safety population was the group of patients who received at least 1 dose of study drug during the study.|Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids|An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics|Completed||Phase 3|155|Actual|Purdue Pharma LP||1|||f||||t||||||||||2018-05-31 23:24:34.33598|2018-05-31 23:24:34.33598
NCT01192282|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-31|2012-12-15||2013-01-18|2010-08-31|2010-09-01|Estimate|2013-01-13|2013-01-15|Estimate||||2013-01-18|2013-01-24|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Observational|||Typing of Human Papilloma Virus (HPV) From Female Genital Warts|Clinico-Pathological HPV DNA Typing Study of Women With Genital Warts Presenting to Groote Schuur Hospital Over a One Year Period, Evaluated by HIV Status, Psychological Impact and Costs to the Health Care System|Completed|||156|Actual|University of Cape Town|Thirty (19.2%) specimens had to be rejected due to contamination that occurred during the analysis process. During the HPV DNA analysis, there were protocols for different aspect of controls during the analysis which needed to be negative.||1||f||||f||||||||||2018-05-31 23:24:34.896422|2018-05-31 23:24:34.896422
NCT01192269|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-07-02|2010-08-31|2010-09-01|Estimate|||||||2012-07-02|2012-07-03|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|February 2011|Actual|2011-02-28||Interventional|||Cheek Cells - Non-invasive Fatty Acid Status Marker|Buccal Cheek Cells - a New Non-invasive Fatty Acid Status Marker|Completed||N/A|13|Actual|Ludwig-Maximilians - University of Munich||1|||f||||f||||||||||2018-05-31 23:24:35.548989|2018-05-31 23:24:35.548989
NCT01192256|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2016-02-18|2010-08-31|2010-09-01|Estimate|||||||2016-02-18|2016-02-19|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|March 2019|Anticipated|2019-03-31|March 2017|Anticipated|2017-03-31||Observational|LungCast||Studies Examining the Importance of Smoking After Being Diagnosed With Lung Cancer|Does Smoking Status After Being Diagnosed With Lung Cancer Influence Outcome? An Observational Cohort Study.|Recruiting|||2400|Anticipated|Hywel Dda Health Board|||||f||||t||||||||||2018-05-31 23:24:35.635144|2018-05-31 23:24:35.635144
NCT01192243|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-09-02|2010-08-31|2010-09-01|Estimate|||||||2010-09-02|2010-09-03|Estimate|December 2009||2009-12-31|September 2010|2010-09-30||||December 2011|Anticipated|2011-12-31||Interventional|||Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients|Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small|Unknown status|Recruiting|Phase 2|68|Anticipated|Fudan University|||||f||||t||||||||||2018-05-31 23:24:35.816506|2018-05-31 23:24:35.816506
NCT01192230|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-09-15|2010-08-31|2010-09-01|Estimate|||||||2010-09-15|2010-09-16|Estimate|June 2009||2009-06-30|August 2010|2010-08-31||||December 2011|Anticipated|2011-12-31||Interventional|||Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients|A Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients|Unknown status|Recruiting|Phase 2|30|Anticipated|Fudan University|||||f||||||||||||||2018-05-31 23:24:35.980231|2018-05-31 23:24:35.980231
NCT01192217|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-08-31|2010-08-31|2010-09-01|Estimate|||||||2010-08-31|2010-09-01|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Video-assisted Thoracic Surgery (VATS) Versus Axillary Mini-thoracotomy for the Treatment of Recurrent Spontaneous Pneumothorax|A Prospective Randomized Study of a Modified Two-port Thoracoscopic Technique Versus Axillary Minithoracotomy for the Treatment of Recurrent Spontaneous Pneumothorax.|Completed||N/A|66|Actual|AHEPA University Hospital||2|||f||||f||||||||||2018-05-31 23:24:36.058398|2018-05-31 23:24:36.058398
NCT01192204|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2015-04-29||2015-08-12|2010-08-30|2010-08-31|Estimate|2015-08-12|2015-08-14|Estimate||||2015-08-12|2015-08-14|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention|Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention|Completed||Phase 1/Phase 2|41|Actual|Ohio State University|While we initially planned to include microvascular densities and COX-2 analyses, there were insufficient tissue samples to collect these data. Therefore as we do not have these data we can not report them.|2|||f||||f||||||||||2018-05-31 23:24:36.190215|2018-05-31 23:24:36.190215
NCT01192191|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2013-06-06|2013-03-28|2016-11-23|2010-08-30|2010-08-31|Estimate|2013-06-06|2013-08-12|Estimate|2013-03-28|2013-04-04|Estimate|2016-11-23|2017-01-11|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD|A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|187|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:24:36.665346|2018-05-31 23:24:36.665346
NCT01192178|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2011-09-29||2016-11-30|2010-08-30|2010-08-31|Estimate|2011-09-29|2011-11-03|Estimate||||2016-11-30|2017-01-18|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Fall Epidemic Viral Pediatric Study|A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season.|Completed||Phase 4|339|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:24:40.015227|2018-05-31 23:24:40.015227
NCT01192165|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2017-11-08|2010-08-30|2010-08-31|Estimate|||||||2017-11-08|2017-11-13|Actual|September 14, 2010|Actual|2010-09-14|November 2017|2017-11-30|October 7, 2013|Actual|2013-10-07|October 7, 2013|Actual|2013-10-07||Interventional|||Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel|An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid Tumors|Completed||Phase 1|169|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 23:24:40.768338|2018-05-31 23:24:40.768338
NCT01192152|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2011-03-09||2015-04-22|2010-08-30|2010-08-31|Estimate|2011-04-19|2011-05-17|Estimate||||2015-04-22|2015-05-12|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR Coadministered to Healthy Subjects in the Fed State and Steady State Pharmacokinetic Assessment of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR|Completed||Phase 1|30|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:24:40.954563|2018-05-31 23:24:40.954563
NCT01192139|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2011-03-11||2015-05-04|2010-08-30|2010-08-31|Estimate|2011-04-19|2011-05-17|Estimate||||2015-05-04|2015-05-21|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)|Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN) Coadministered to Healthy Subjects in a Fed Condition|Completed||Phase 1|30|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:24:42.008265|2018-05-31 23:24:42.008265
NCT01192126|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2013-05-28||2013-11-14|2010-08-30|2010-08-31|Estimate|2013-11-14|2014-01-03|Estimate||||2013-11-14|2014-01-03|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||All enrolled participants|A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens|A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens|Completed||N/A|102|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:24:42.825435|2018-05-31 23:24:42.825435
NCT01192113|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-11-05|2010-08-30|2010-08-31|Estimate|||||||2012-11-05|2012-11-07|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)|An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection|Completed||Phase 4|1072|Actual|Eisai Inc.||5|||f||||||||||||||2018-05-31 23:24:42.99573|2018-05-31 23:24:42.99573
NCT01192100|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2016-10-21|2010-08-30|2010-08-31|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||The Beneficial Effects of a Protein-rich Breakfast on Appetite Control & Cognition in Overweight and Obese Adolescents|The Beneficial Effects of a Protein-rich Breakfast on Appetite Control & Cognition in Overweight and Obese Adolescents|Completed||N/A|25|Actual|University of Missouri-Columbia||3|||f||||t||||||||No||2018-05-31 23:24:43.11394|2018-05-31 23:24:43.11394
NCT01192087|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-04-23|2010-08-30|2010-08-31|Estimate|||||||2013-04-23|2013-04-24|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|July 2017|Anticipated|2017-07-31|July 2015|Anticipated|2015-07-31||Interventional|ACCEPT||Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy|Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study|Unknown status|Recruiting|Phase 1/Phase 2|49|Anticipated|Heidelberg University||1|||f||||t||||||||||2018-05-31 23:24:43.216545|2018-05-31 23:24:43.216545
NCT01192074|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2016-09-02|2010-08-30|2010-08-31|Estimate|||||||2016-09-02|2016-09-05|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Use of Ultrasound in Obstetric Neuraxial Analgesia and Anesthesia Data Base|Use of Ultrasound in Obstetric Neuraxial Analgesia and Anesthesia Data Base|Terminated|||250|Actual|University of Missouri-Columbia|||1|Lack of personnel/research time to recruit participants.|f||||t||||||||||2018-05-31 23:24:43.297592|2018-05-31 23:24:43.297592
NCT01192061|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2011-01-24|2010-08-30|2010-08-31|Estimate|||||||2011-01-24|2011-01-25|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|ANS||Autonomic Nervous System Activity and Normal Tension Glaucoma|Autonomic Nervous System Activity, Peripheral Microcirculation and Retrobulbar Hemodynamics in Normal Tension Glaucoma Patients.|Completed|||97|Actual|Military Institute of Medicine, Poland|||2||f||||f||||||||||2018-05-31 23:24:43.361131|2018-05-31 23:24:43.361131
NCT01192048|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2018-02-26|2010-08-30|2010-08-31|Estimate|||||||2018-02-26|2018-02-27|Actual|December 2009||2009-12-31|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Genetics of Congenital Heart Disease|Genetics Testing of Individuals and Families With Congenital Heart Disease|Recruiting|||1000|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected in vacuum tubes containing acid citrate dextrose (ACD).~     Lymphocytes from blood drawn in appropriate anticoagulant (ACD) may be stored for subsequent~     immortalization. DNA will be extracted from these samples for analysis.~   "|||2018-05-31 23:24:43.420089|2018-05-31 23:24:43.420089
NCT01192035|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09||2015-05-28|2015-05-28|2010-08-30|2010-08-31|Estimate||||2015-05-28|2015-06-25|Estimate|2015-05-28|2015-06-25|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PIONA||PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial|PI or NNRTI as First-line Treatment of HIV in a West African Population With Low Adherence - the PIONA Trial|Completed||Phase 4|400|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:24:43.49976|2018-05-31 23:24:43.49976
NCT01191879|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2012-10-30|2010-08-30|2010-08-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction|A Comparison of p53-induced Genes Activation as Possible Markers Differentiating Between Patients Presenting With Acute Myocardial Infarction and Controls|Completed|||79|Actual|Meir Medical Center|||2||f||||f||||||||||2018-05-31 23:24:46.956725|2018-05-31 23:24:46.956725
NCT01192022|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2015-08-13||2015-10-22|2010-08-30|2010-08-31|Estimate|2015-10-22|2015-11-25|Estimate||||2015-10-22|2015-11-25|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||The TachoSil pediatric arm includes pediatric participants who were randomized to receive TachoSil, in addition to pediatric participants who were allocated to receive TachoSil via the extension phase.|TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery|A Randomized, Open Label, Parallel-group, Multi-center Trial to Compare the Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery|Completed||Phase 3|253|Actual|Takeda||2|||f||||t||||||||||2018-05-31 23:24:43.725006|2018-05-31 23:24:43.725006
NCT01192009|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-02-22|2010-08-30|2010-08-31|Estimate|||||||2013-02-22|2013-02-25|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Leucine Supplementation and Skeletal Muscle Disuse|Leucine and Skeletal Muscle Disuse: Clinical Anti-Atrophic Effectiveness and Related Mechanisms|Completed||N/A|22|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:24:45.285553|2018-05-31 23:24:45.285553
NCT01191996|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-12-05|2010-08-30|2010-08-31|Estimate|||||||2012-12-05|2012-12-07|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis|A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis|Completed||Phase 1/Phase 2|34|Actual|Innate Immunotherapeutics||1|||f||||f||||||||||2018-05-31 23:24:45.352229|2018-05-31 23:24:45.352229
NCT01191983|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2018-03-19|2010-08-30|2010-08-31|Estimate|||||||2018-03-19|2018-03-20|Actual|August 13, 2010|Actual|2010-08-13|March 2018|2018-03-31|July 19, 2018|Anticipated|2018-07-19|July 19, 2018|Anticipated|2018-07-19||Interventional|||A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy|A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA.|Active, not recruiting||Phase 4|102|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 23:24:45.414572|2018-05-31 23:24:45.414572
NCT01191970|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-12-17|2010-08-30|2010-08-31|Estimate|||||||2010-12-17|2010-12-20|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|March 2012|Anticipated|2012-03-31|May 2011|Anticipated|2011-05-31||Observational|||Epidural Analgesia, Beta-Endorphin Concentrations in Colostrum, and Infant Neurobehavior as Breast-Feeding Predictors|Investigating Potential Determinants of Breast-Feeding Probability: Epidural Analgesia, Beta-Endorphin Concentrations in Colostrum, and Infant Feeding Behavior|Unknown status|Not yet recruiting||500|Anticipated|MetroHealth Medical Center|||2||f||||f|||||||"~     Colostrum samples collected 2x/d for duration of postpartum hospital stay, which is, on~     average, 2d.~   "|||2018-05-31 23:24:45.489475|2018-05-31 23:24:45.489475
NCT01191957|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2015-09-02|2010-08-30|2010-08-31|Estimate|||||||2015-09-02|2015-09-03|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|December 2012|Actual|2012-12-31||Interventional|GITMO-AMLR2||Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML|Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission.|Completed||Phase 3|252|Actual|Gruppo Italiano Trapianto di Midollo Osseo||2|||f||||t||||||||||2018-05-31 23:24:45.667536|2018-05-31 23:24:45.667536
NCT01191944|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|2012-12-19||2014-10-22|2010-08-30|2010-08-31|Estimate|2012-12-19|2013-01-24|Estimate||||2014-10-22|2014-10-31|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Treated Set, all randomized patients that received treatment|Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients|A Double-blind, Double-dummy, Randomised, Parallel-group Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release Versus Pramipexole Immediate Release Administered Orally for 18 Weeks in Chinese Parkinson's Disease (PD) Patients Who Can be Concomitantly Treated With Levodopa|Completed||Phase 3|475|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:24:45.8393|2018-05-31 23:24:45.8393
NCT01191931|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-10-26|2010-08-30|2010-08-31|Estimate|||||||2012-10-26|2012-10-29|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|June 2012|Actual|2012-06-30|||||Observational|PHS-02||Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)|Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)|Completed|||52|Actual|Advanced Medical Diagnostics s.a.|||1||f||||t||||||Samples Without DNA|"~     paraffin blocks of prostate specimens~   "|||2018-05-31 23:24:46.372861|2018-05-31 23:24:46.372861
NCT01191918|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-29|||2010-08-30|2010-08-30|2010-08-31|Estimate|||||||2010-08-30|2010-08-31|Estimate|May 2005||2005-05-31|August 2010|2010-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania|A Double-Blind, Placebo-Controlled Evaluation of The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania|Completed||Phase 4|40|Actual|Shanghai Mental Health Center||2|||f||||t||||||||||2018-05-31 23:24:46.437807|2018-05-31 23:24:46.437807
NCT01191905|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-29|||2015-08-18|2010-08-30|2010-08-31|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HICORES||Effects of HIgh Volume COntinuous REnal Replacement Therapy in Patients With Septic Acute Kidney Injury|Effects of HIgh Volume COntinuous REnal Replacement Therapy in Patients With Septic Acute Kidney Injury|Completed||N/A|212|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:24:46.51051|2018-05-31 23:24:46.51051
NCT01191892|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-29|||2012-07-30|2010-08-29|2010-08-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer|A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin|Unknown status|Recruiting|Phase 2|122|Anticipated|Wales Cancer Trials Unit||2|||f||||t||||||||||2018-05-31 23:24:46.799165|2018-05-31 23:24:46.799165
NCT01191866|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-29|||2010-08-30|2010-08-30|2010-08-31|Estimate|||||||2010-08-30|2010-08-31|Estimate|September 2009||2009-09-30|August 2010|2010-08-31||||September 2011|Anticipated|2011-09-30||Observational|||Psychosocial Interventions in the Treatment of Youth With Type 1 Diabetes Mellitus|Intensive Individual and Familial Psychosocial Interventions in the Treatment of Children and Adolescents With Type 1 Diabetes Mellitus|Unknown status|Recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-05-31 23:24:47.018274|2018-05-31 23:24:47.018274
NCT01191853|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-28|||2018-05-26|2010-08-28|2010-08-31|Estimate|||||||2018-05-26|2018-05-30|Actual|September 18, 2009||2009-09-18|May 23, 2018|2018-05-23||||||||Observational|||Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines|Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees at Baseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines|Completed|||203|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:24:47.079499|2018-05-31 23:24:47.079499
NCT01191840|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-28|2017-11-12||2017-12-12|2010-08-30|2010-08-31|Estimate|2017-11-12|2017-12-12|Actual||||2017-12-12|2018-01-05|Actual|February 2011||2011-02-28|December 2017|2017-12-31|March 4, 2017|Actual|2017-03-04|March 4, 2017|Actual|2017-03-04||Interventional|Bacteremia||Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection|A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci|Completed||Phase 2|509|Actual|Duke University||2|||f||||t||||||||||2018-05-31 23:24:47.178042|2018-05-31 23:24:47.178042
NCT01191827|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2014-12-23||2015-05-12|2010-08-27|2010-08-31|Estimate|2015-05-12|2015-05-15|Estimate||||2015-05-12|2015-05-15|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational||Individuals with schizophrenia.|fMRI Cholinergic Mechanisms in Schizophrenia|fMRI Cholinergic Mechanisms in Schizophrenia|Completed|||40|Actual|VA Office of Research and Development|||2||f||||t||||||||||2018-05-31 23:24:47.993141|2018-05-31 23:24:47.993141
NCT01191814|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-10-05|2010-08-30|2010-08-31|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2010||2010-07-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression|A Randomized Trial Comparing Covered Metal and Plastic Stents for Preoperative Biliary Decompression in Pancreatic Cancer|Recruiting||N/A|84|Anticipated|Florida Hospital||2|||f||||t||||||||No|A manuscript will be developed following the closure of the study.|2018-05-31 23:24:48.163074|2018-05-31 23:24:48.163074
NCT01191801|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2016-04-12||2017-03-29|2010-08-30|2010-08-31|Estimate|2017-03-29|2017-05-09|Actual||||2017-03-29|2017-05-09|Actual|December 17, 2010||2010-12-17|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|September 26, 2014|Actual|2014-09-26||Interventional|VALOR|Intent to Treat Population: Patients who were randomized.|Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML|A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)|Completed||Phase 3|711|Actual|Sunesis Pharmaceuticals||2|||f||||t||||||||Yes|De-identified data of individual participants experiencing Serious Adverse Events|2018-05-31 23:24:48.296147|2018-05-31 23:24:48.296147
NCT01191788|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2011-10-24||2012-05-22|2010-08-30|2010-08-31|Estimate|2012-05-22|2012-06-25|Estimate||||2012-05-22|2012-06-25|Estimate|August 2006||2006-08-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|BRIGHT||Building Recovery By Improving Goals, Habits, and Thoughts|Group Cognitive Behavioral Therapy (CBT) For Depression in Clients With Alcohol and Other Drug (AOD) Disorders|Completed||Phase 2/Phase 3|299|Actual|RAND||2|||f||||t||||||||||2018-05-31 23:24:49.572614|2018-05-31 23:24:49.572614
NCT01191775|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2017-01-20|2010-08-27|2010-08-31|Estimate|||||||2017-01-20|2017-01-24|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of PNT2258 in Patients With Advanced Solid Tumors|A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors|Completed||Phase 1|22|Actual|Sierra Oncology, Inc.||1|||f||||f||||||||No||2018-05-31 23:24:49.797391|2018-05-31 23:24:49.797391
NCT01191762|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2013-11-13||2016-09-26|2010-08-30|2010-08-31|Estimate|2014-07-30|2014-07-31|Estimate||||2016-09-26|2016-11-01|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional||Post-treatment data were not obtained from patient who withdrew on third treatment day.|Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease|The Effect of Sevelamer Carbonate on Critical Variables in the Pathogenesis of Secondary Hyperparathyroidism|Completed||Phase 3|30|Actual|Phelps, Kenneth R., M.D.|All intended measurements were made. The desired number of participants was recruited.|2|||f||||f||||||||No||2018-05-31 23:24:49.871791|2018-05-31 23:24:49.871791
NCT01191749|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2017-03-28||2017-03-28|2010-08-30|2010-08-31|Estimate|2017-03-28|2017-05-09|Actual||||2017-03-28|2017-05-09|Actual|August 2010||2010-08-31|March 2017|2017-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)|Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL)|Terminated||Phase 2|7|Actual|M.D. Anderson Cancer Center||1||Low Accrual|f||||f||||||||||2018-05-31 23:24:50.092618|2018-05-31 23:24:50.092618
NCT01191736|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2010-09-17||2011-03-02|2010-08-30|2010-08-31|Estimate|2010-09-17|2010-10-07|Estimate||||2011-03-02|2011-03-07|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice|Comparison of the Effectiveness of Ultra-Brief and Brief Hands-Only CPR Video Training With and Without Psychomotor Skill Practice for Lay Responders: a Controlled Randomized Study|Completed||N/A|336|Actual|Maricopa Integrated Health System||7|||f||||f||||||||||2018-05-31 23:24:50.27647|2018-05-31 23:24:50.27647
NCT01191723|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2013-08-19||2013-12-09|2010-08-30|2010-08-31|Estimate|2013-08-19|2013-10-22|Estimate||||2013-12-09|2014-01-09|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo|A Randomized, Double Blind, Placebo Controlled, Three- Period Crossover Study Comparing the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo on QT Intervals in Healthy Adults|Completed||Phase 1|54|Actual|Allergan||6|||f||||f||||||||||2018-05-31 23:24:50.772133|2018-05-31 23:24:50.772133
NCT01191528|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-12-10|2010-08-30|2010-08-31|Estimate|||||||2010-12-10|2010-12-13|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Comparison of Pulse Oximetry, End-tidal Capnometry, and Integrated Pulmonary Index (IPI)|The Comparison of Pulse Oximetry, End-tidal Capnometry, and Integrated Pulmonary Index in Adult Post-operative Patients|Completed|||60|Actual|Allenmore Hospital|||||f||||f||||||||||2018-05-31 23:24:52.223227|2018-05-31 23:24:52.223227
NCT01191710|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-09-14|2010-08-30|2010-08-31|Estimate|||||||2010-09-14|2010-09-15|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles|Is the Clinical Outcome Affected by the Incidence of Progesterone Elevation on the Day of hCG Triggering When Agonist Protocol is Compared to Antagonist Protocol for IVF|Unknown status|Active, not recruiting|Phase 4|200|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 23:24:50.989914|2018-05-31 23:24:50.989914
NCT01191697|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2018-05-03|2010-08-30|2010-08-31|Estimate|||||||2018-05-03|2018-05-04|Actual|February 2011||2011-02-28|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer|Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer|Active, not recruiting||Phase 2|36|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-05-31 23:24:51.053942|2018-05-31 23:24:51.053942
NCT01191684|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2017-07-28|2010-08-30|2010-08-31|Estimate|||||||2017-07-28|2017-08-01|Actual|October 2011||2011-10-31|July 2017|2017-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer|A Phase I Study of an MVA Vaccine Targeting P53 in Cancer|Completed||Phase 1|12|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:24:51.115321|2018-05-31 23:24:51.115321
NCT01191671|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2010-08-30|2010-08-30|2010-08-31|Estimate|||||||2010-08-30|2010-08-31|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|LDC||Language and Deglutition in Children|Feeding and Sociolinguist Profile in Children|Completed|||89|Actual|Fortaleza University|||||f||||t||||||||||2018-05-31 23:24:51.186689|2018-05-31 23:24:51.186689
NCT01191658|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2011-07-14|2010-08-30|2010-08-31|Estimate|||||||2011-07-14|2011-07-15|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Can Neck Circumference Measurements Less Than 43cm or Greater Than 43cm Predict Difficulty of Tracheal Intubation?|Can Neck Circumference Measurements Less Than 43cm or Greater Than 43cm Predict Difficulty of Tracheal Intubation?|Completed|||100|Anticipated|CAMC Health System|||||f||||f||||||||||2018-05-31 23:24:51.233256|2018-05-31 23:24:51.233256
NCT01191645|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-01-31|2010-08-30|2010-08-31|Estimate|||||||2012-01-31|2012-02-02|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Opioid Effects on Swallowing and Esophageal Sphincter Pressure|Can Opioid Induced Effects on Esophageal Motility and Lower Esophageal Sphincter be Counteracted by a Dopamine Receptor Antagonist?|Completed||Phase 4|14|Actual|Region Örebro County||4|||f||||t||||||||||2018-05-31 23:24:51.399186|2018-05-31 23:24:51.399186
NCT01191632|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-10-21|2010-08-30|2010-08-31|Estimate|||||||2010-10-21|2010-10-22|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases|Randomised Controlled Phase I/II Trail to Evaluate the Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation Therapy in Resectable Colorectal Liver Metastases Patients|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Heidelberg University||4|||f||||f||||||||||2018-05-31 23:24:51.489736|2018-05-31 23:24:51.489736
NCT01191619|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-30|2010-08-30|2010-08-31|Estimate|||||||2010-08-30|2010-08-31|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Comparison of Two Insertion Techniques of Proseal Laryngeal Mask Airway by Unskilled Personnel in Children|Comparison of Two Insertion Techniques of Proseal Laryngeal Mask Airway by Unskilled Personnel in Children|Unknown status|Recruiting|N/A|134|Anticipated|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-05-31 23:24:51.588621|2018-05-31 23:24:51.588621
NCT01191606|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-30|2010-08-30|2010-08-31|Estimate|||||||2010-08-30|2010-08-31|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Pressure-controlled Versus Volume-controlled Ventilation During Protective One Lung Ventilation|Pressure-controlled Versus Volume-controlled Ventilation During Protective One Lung Ventilation for Thoracic Surgery|Unknown status|Recruiting|Phase 2|34|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 23:24:51.68172|2018-05-31 23:24:51.68172
NCT01191593|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2013-08-21|2010-08-30|2010-08-31|Estimate|||||||2013-08-21|2013-08-22|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty|The Efficacy of Adductor-Canal-Blockade on Pain and Morphine Consumption After Revision Knee Arthroplasty|Completed||Phase 4|36|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 23:24:51.773254|2018-05-31 23:24:51.773254
NCT01191580|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-07-13|2010-08-30|2010-08-31|Estimate|||||||2017-07-13|2017-07-18|Actual|October 2009||2009-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|April 2016|Actual|2016-04-30||Interventional|||Interpersonal Therapy for Depression in Breast Cancer|Interpersonal Therapy for Depression in Breast Cancer|Completed||Phase 4|134|Actual|New York State Psychiatric Institute||3|||f||||f||||||||Undecided||2018-05-31 23:24:51.860755|2018-05-31 23:24:51.860755
NCT01191567|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2017-11-15|2010-08-30|2010-08-31|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2010||2010-09-30|November 2017|2017-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life|Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life|Terminated||N/A|30|Actual|Karolinska Institutet||2||insufficient recruitement speed|f||||t||||||||||2018-05-31 23:24:51.990413|2018-05-31 23:24:51.990413
NCT01191554|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-30|||2012-11-02|2010-08-30|2010-08-31|Estimate|||||||2012-11-02|2012-11-06|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Dose-ranging Study of Tranexamic Acid in Valve Surgery|Comparison of Two Tranexamic Acid Dose Regimens on Postoperative Bleeding and Transfusion Needs in Primary Valve Surgery|Completed||N/A|175|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 23:24:52.063573|2018-05-31 23:24:52.063573
NCT01191541|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2010-08-30|2010-08-30|2010-08-31|Estimate|||||||2010-08-30|2010-08-31|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Ara-C||Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)|Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia in Children: Remission Induction With All-transretinoic Acid (ATRA) and Arsenic Trioxide (As2O3). Consolidation With Daunorubicin(DNR)+Ara-c or DNR Alone.|Recruiting||N/A|100|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:24:52.131586|2018-05-31 23:24:52.131586
NCT01191515|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2012-06-13|2010-08-27|2010-08-30|Estimate|||||||2012-06-13|2012-06-14|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|||Prospective Evaluation of Near and Intermediate Visual Outcomes With Monofocal Intraocular Lenses: The Mast Study|Prospective Evaluation of Near and Intermediate Visual Outcomes With Monofocal Intraocular Lenses: The Mast Study|Unknown status|Recruiting||200|Anticipated|Innovative Medical|||2||f||||f||||||||||2018-05-31 23:24:52.281675|2018-05-31 23:24:52.281675
NCT01191502|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2011-10-05|2010-08-27|2010-08-30|Estimate|||||||2011-10-05|2011-10-06|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Comparative Study of Photopic and Mesopic Distance, Intermediate and Near Visual Acuity, and Spectacle Independence|Comparative Study of Photopic and Mesopic Distance Intermediate and Near Visual Acuity, and Spectacle Independence With Binocular Implantation of the Tecnis Multifocal (TMF) Intraocular Lens or Crystalens HD (CHD) Intraocular Lens|Completed|||50|Anticipated|Innovative Medical|||2||f||||f||||||||||2018-05-31 23:24:52.337279|2018-05-31 23:24:52.337279
NCT01191489|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2014-09-10|2010-08-27|2010-08-30|Estimate|||||||2014-09-10|2014-09-12|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||High-flow Conditioned Oxygen Therapy Versus Non-invasive Ventilation: Prevention of Post-extubation Failure|Comparison Between High-flow Conditioned Oxygen Therapy and Non-invasive Ventilation in Prevention of Post-extubation Respiratory Failure. A Randomized Controlled Trial|Completed||Phase 3|1042|Actual|Hospital Infanta Sofia||4|||f||||t||||||||||2018-05-31 23:24:52.396685|2018-05-31 23:24:52.396685
NCT01191476|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2012-05-31||2012-05-31|2010-08-27|2010-08-30|Estimate|2012-05-31|2012-07-03|Estimate||||2012-05-31|2012-07-03|Estimate|November 2010||2010-11-30|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Compare Pharmaceutical Economics and Efficacy of Sevoflurane With Low Fresh Gas Flow Balanced Anesthesia, Propofol Target Controlled Infusion Anesthesia and Propofol Induction Sevoflurane Maintenance Anesthesia|A Prospective, Randomized, Open-label Multicenter Study Comparing the Pharmaceutical Economics and Effectiveness of Sevoflurane With Low Fresh Gas Flow Balanced Anesthesia, Propofol Target Controlled Infusion Anesthesia and Propofol Induction Sevoflurane Maintenance Anesthesia in Laparoscopic Surgeries in China|Completed||Phase 4|336|Actual|Abbott||3|||f||||f||||||||||2018-05-31 23:24:52.490274|2018-05-31 23:24:52.490274
NCT01191463|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2011-09-28|2010-08-27|2010-08-30|Estimate|||||||2011-09-28|2011-09-29|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|MUGUST_2||The Efficacy of a Local Vitamin-C Rich Fruit (Guava) in Improving Iron Absorption From Mungbean Based Meals and Its Effect on Iron Status of Rural Indian Children (6-10 Years)|The Efficacy of a Local Vitamin-C Rich Fruit (Guava) in Improving Iron Absorption From Mungbean Based Meals in Indian Children (6-10 Years)|Completed||N/A|300|Anticipated|Wageningen University||3|||f||||f||||||||||2018-05-31 23:24:52.870431|2018-05-31 23:24:52.870431
NCT01191450|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-01-31|2010-08-27|2010-08-30|Estimate|||||||2012-01-31|2012-02-01|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|CARD||Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension|A Study to Evaluate the Safety and Efficacy of Chlorthalidone in Combination With Amiloride as a Treatment for Elderly Patients With Arterial Hypertension|Unknown status|Recruiting|Phase 3|280|Anticipated|Eurofarma Laboratorios S.A.||2|||f||||f||||||||||2018-05-31 23:24:53.051141|2018-05-31 23:24:53.051141
NCT01191424|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2017-03-28|2010-08-27|2010-08-30|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2010||2010-10-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ADONE||A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.|A Multicenter, Multinational, Single-Dose, Open Label, Randomized, 2-Way Crossover, Clinical Pharmacology Study of CHF 1535 100/6 Next™ DPI (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg) Versus the Free Combination of Licensed Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescents and Adult Patients|Completed||Phase 2|57|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 23:24:53.201937|2018-05-31 23:24:53.201937
NCT01191411|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2014-10-13||2017-04-12|2010-08-27|2010-08-30|Estimate|2014-10-13|2014-10-20|Estimate||||2017-04-12|2017-05-23|Actual|October 2010||2010-10-31|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Men and women, aged 54 to 64 years, who were uninsured but enrolled in the JPS medical assistance program for the uninsured. Not up-to-date with colorectal cancer screening; no history of colorectal cancer, inflammatory bowel disease, or colorectal polyps.|Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs|Increasing Colorectal Cancer Screening in a Safety-net Health System With a Focus on the Uninsured: Benefits and Costs.|Completed||N/A|5970|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||No||2018-05-31 23:24:53.293334|2018-05-31 23:24:53.293334
NCT01191398|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2013-12-11||2014-03-20|2010-08-27|2010-08-30|Estimate|2014-01-30|2014-03-20|Estimate||||2014-03-20|2014-04-16|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation|Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation|Completed||N/A|52|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||||2018-05-31 23:24:53.735151|2018-05-31 23:24:53.735151
NCT01191385|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2017-08-14|2010-08-27|2010-08-30|Estimate|||||||2017-08-14|2017-08-16|Actual|November 2010||2010-11-30|March 2015|2015-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start|Non Interventional Study in Patients With Diagnosis of HCC in Whom a Decision to Treat With Sorafenib Has Not Been Made at Time of Study Enrollment|Withdrawn|||0|Actual|Bayer|||1|Study is officially cancelled bevore FPFV.|f||||f||||||||||2018-05-31 23:24:54.262431|2018-05-31 23:24:54.262431
NCT01191372|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2017-10-19|2010-08-27|2010-08-30|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2010||2010-09-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients|First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients|Terminated||Phase 1|17|Actual|Shire||4|||f||||f||||||||||2018-05-31 23:24:54.468897|2018-05-31 23:24:54.468897
NCT01190488|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-10-12|2010-08-26|2010-08-27|Estimate|||||||2012-10-12|2012-10-15|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Feasibility Of An Advanced Care Decision Aid Among Patients And Physicians_Matlock|Feasibility Of An Advanced Care Decision Aid Among Patients And Physicians|Completed||N/A|120|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 23:25:25.09251|2018-05-31 23:25:25.09251
NCT01191359|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2013-02-07|2010-08-27|2010-08-30|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch|A Multicentre Randomised Phase II Clinical Pilot Study to Compare the Pharmacodynamic Efficacy and Tolerability of the Sublingual and the Vestibular Administration Route for SLITonePLUS® Birch|Completed||Phase 2|66|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-05-31 23:24:54.540375|2018-05-31 23:24:54.540375
NCT01191346|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-08-21|2010-08-27|2010-08-30|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2010||2010-06-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Radiation Planning Study for High Grade Brain Tumors|3T Versus 1.5T MR Approaches in Target Definition for Malignant Gliomas: Is There a Significant Difference in Tumor Extent and Radiation Treatment Volume?|Completed|||24|Actual|University of Cincinnati|||1||f||||f||||||||No||2018-05-31 23:24:54.65903|2018-05-31 23:24:54.65903
NCT01191333|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2018-01-10||2018-02-08|2010-08-27|2010-08-30|Estimate|2018-01-10|2018-02-07|Actual||||2018-02-08|2018-03-09|Actual|July 2, 2012|Actual|2012-07-02|February 2018|2018-02-28|March 31, 2017|Actual|2017-03-31|February 15, 2017|Actual|2017-02-15||Interventional|||The Effectiveness of rTMS in Depressed VA Patients|CSP #556 - The Effectiveness of rTMS in Depressed VA Patients|Completed||N/A|164|Actual|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||No||2018-05-31 23:24:54.97954|2018-05-31 23:24:54.97954
NCT01191320|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2014-06-18||2014-06-27|2010-08-27|2010-08-30|Estimate|2014-06-27|2014-07-24|Estimate||||2014-06-27|2014-07-24|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Safety population|Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus|A Study to Evaluate the Efficacy of Androxal® in Improving Glycemic Control in Men With Secondary Hypogonadism or Adult-onset Idiopathic Hypogonadotropic Hypogonadism (AIHH) and Type 2 Diabetes Mellitus With Sub-Optimum Treatment|Completed||Phase 2|102|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 23:24:59.86842|2018-05-31 23:24:59.86842
NCT01191307|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2016-10-24|2010-08-26|2010-08-30|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Assess Specific Kinds of Children Challenges for Neurologic Devices Study|Assess Specific Kinds of Children Challenges for Neurologic Devices Study|Terminated|||16|Actual|Food and Drug Administration (FDA)|||5|Slow enrollment|f||||t||||||||No|Data sharing will occur via publication.|2018-05-31 23:25:03.206108|2018-05-31 23:25:03.206108
NCT01191294|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2014-09-24|2010-08-27|2010-08-30|Estimate|||||||2014-09-24|2014-09-25|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma|Development and Evaluation of a Simulation Training Module to Identify Lesions Requiring Further Visual Screen or Skin Biopsy for Melanoma|Completed||N/A|270|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 23:25:03.576344|2018-05-31 23:25:03.576344
NCT01191281|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-10-17|2010-08-27|2010-08-30|Estimate|||||||2012-10-17|2012-10-18|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Improving Food Security and Nutrition to Promote ART Adherence in Latin America|Improving Food Security and Nutrition to Promote ART Adherence in Latin America|Completed||N/A|400|Actual|RAND||2|||f||||f||||||||||2018-05-31 23:25:03.764517|2018-05-31 23:25:03.764517
NCT01191268|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|2014-10-03|2012-05-24|2014-10-03|2010-08-27|2010-08-30|Estimate|2014-10-03|2014-10-08|Estimate|2012-05-24|2012-06-01|Estimate|2014-10-03|2014-10-08|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Interventional||Participants who were randomized and received at least 1 dose of LY2189265 or Insulin Glargine.|A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)|The Impact of LY2189265 Versus Insulin Glargine in Combination With Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus (AWARD-4: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 4)|Completed||Phase 3|884|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:25:04.207671|2018-05-31 23:25:04.207671
NCT01191255|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2014-10-04||2014-12-08|2010-08-27|2010-08-30|Estimate|2014-12-08|2014-12-10|Estimate||||2014-12-08|2014-12-10|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional||Total number of subjects in the full analysis population in the SAP was 427. 182 subjects that were treated with KRX-0502 in the SAP were randomized 1:1 to receive either KRX-0502 or Placebo in the EAP.|A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis|A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) on Dialysis|Completed||Phase 3|441|Actual|Keryx Biopharmaceuticals||3|||f||||t||||||||||2018-05-31 23:25:10.460352|2018-05-31 23:25:10.460352
NCT01191242|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2016-12-21||2017-02-28|2010-08-27|2010-08-30|Estimate|2016-12-21|2017-02-17|Actual||||2017-02-28|2017-03-29|Actual|August 2010||2010-08-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Observational|MEMORIES||Methadone Monitoring for Insights Into Adverse Events|Methadone Monitoring for Insights Into Adverse Events|Completed|||31|Actual|Intermountain Health Care, Inc.|The principal limitations are small sample size and the limited number of genetic variants tested. Also, study endpoints were not examined beyond 21 days of treatment; thus the durability of study findings over longer time periods is not known.||||f||||f||||||Samples With DNA|"~     Plasma and DNA~   "|||2018-05-31 23:25:12.950899|2018-05-31 23:25:12.950899
NCT01191229|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2012-06-13|2010-08-27|2010-08-30|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens Aspheric Optic (AO)|Prospective Evaluation of Visual Outcomes With Tecnis One-Piece Multifocal Intraocular Lenses Compared With Patients Previously Implanted With Crystalens AO|Completed||Phase 4|12|Actual|Innovative Medical||2|||f||||||||||||||2018-05-31 23:25:13.316856|2018-05-31 23:25:13.316856
NCT01191216|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2014-07-23|2010-08-27|2010-08-30|Estimate|||||||2014-07-23|2014-07-24|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors|A Phase 1 Study of 1-Methyl-D-tryptophan (NSC-721782) in Combination With Docetaxel in Metastatic Solid Tumors|Completed||Phase 1|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:25:13.388569|2018-05-31 23:25:13.388569
NCT01191203|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2013-10-23|2010-08-27|2010-08-30|Estimate|||||||2013-10-23|2013-10-25|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi|Prospective Assessment of Acceptability and Adherence Associated With Use of the Copper Intrauterine Device (CuT380A-IUCD) Compared to Depo-medroxyprogesterone Acetate (DMPA) Among HIV Positive Women in Lilongwe, Malawi|Completed||N/A|200|Actual|Emory University||2|||f||||f||||||||||2018-05-31 23:25:13.469657|2018-05-31 23:25:13.469657
NCT01191190|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2015-08-24||2018-04-09|2010-08-27|2010-08-30|Estimate|2015-10-19|2015-11-20|Estimate||||2018-04-09|2018-05-08|Actual|August 2010||2010-08-31|April 2018|2018-04-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|CRC027||Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|21|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 23:25:13.562826|2018-05-31 23:25:13.562826
NCT01191177|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2017-06-20|2010-08-27|2010-08-30|Estimate|||||||2017-06-20|2017-06-22|Actual|January 2011||2011-01-31|June 2017|2017-06-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease|An Initial Trial of Enteral Fish Oil Supplementation in the Treatment of Parenteral Nutrition-associated Liver Disease in Patients With Short Bowel Syndrome|Withdrawn||Phase 1/Phase 2|0|Actual|Boston Children’s Hospital||2||no subjects recruited|f||||t||||||||No||2018-05-31 23:25:13.849478|2018-05-31 23:25:13.849478
NCT01191164|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2011-08-23|2010-08-27|2010-08-30|Estimate|||||||2011-08-23|2011-08-25|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Pilot Study of Partial Breast Irradiation Utilizing Permanent Breast Seed Implant to Treat Breast Cancer|A Prospective Study to Evaluate the Feasibility of Partial Breast Irradiation Utilizing Permanent Breast Seed Implant in British Columbia|Unknown status|Not yet recruiting|N/A|5|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 23:25:13.916507|2018-05-31 23:25:13.916507
NCT01191151|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2018-04-06|2010-08-27|2010-08-30|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2010||2010-09-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Observational|||OrthoIllustrated Web Based Orthopaedic Sports Medicine Registry|Orthopaedic Sports Medicine, Arthroscopy, and Related Surgery Registry Using the Web-based OrthoIllustrated Surgical Outcome System|Recruiting|||12500|Anticipated|Arthrex, Inc.|||1||f||||f||||||||||2018-05-31 23:25:14.062817|2018-05-31 23:25:14.062817
NCT01191138|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-06-19|2010-08-27|2010-08-30|Estimate|||||||2012-06-19|2012-06-20|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Gastric Emptying After Infracolic or Supracolic Gastrojejunostomy Following Pancreaticoduodenectomy|Randomized Control Trial Comparing Gastric Emptying Following Infracolic vs Supracolic Gastrojejunostomy After Whipples Pancreaticoduodenectomy|Completed||N/A|60|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t||||||||||2018-05-31 23:25:15.256091|2018-05-31 23:25:15.256091
NCT01191125|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2013-03-05|2010-08-27|2010-08-30|Estimate|||||||2013-03-05|2013-03-07|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of an Oral Nutritional Supplement Containing AN777|Evaluation of an Oral Nutritional Supplement Containing AN777 in Malnourished and Frail Subjects|Completed||Phase 3|331|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 23:25:15.329747|2018-05-31 23:25:15.329747
NCT01191112|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2015-03-02|2010-08-27|2010-08-30|Estimate|||||||2015-03-02|2015-03-03|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population|Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population|Completed||Phase 3|27|Actual|Abbott Nutrition||1|||f||||f||||||||||2018-05-31 23:25:15.53026|2018-05-31 23:25:15.53026
NCT01191099|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2011-11-07|2010-08-27|2010-08-30|Estimate|||||||2011-11-07|2011-11-08|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|August 2020|Anticipated|2020-08-31|August 2012|Anticipated|2012-08-31||Observational|||Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance|Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance|Recruiting|||150|Anticipated|University of Zurich|||||f||||t||||||Samples With DNA|"~     prostate~   "|||2018-05-31 23:25:15.599601|2018-05-31 23:25:15.599601
NCT01191086|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2015-02-09||2015-02-09|2010-08-27|2010-08-30|Estimate|2015-02-09|2015-02-23|Estimate||||2015-02-09|2015-02-23|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures|Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study|Completed||Phase 3|210|Actual|Upsher-Smith Laboratories||1|||f||||||||||||||2018-05-31 23:25:15.690783|2018-05-31 23:25:15.690783
NCT01191073|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2014-12-04|2010-08-27|2010-08-30|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Manually Versus Digitally Fabricated Removable Partial Dentures|A Study on the Fit and Behaviour of Computer-aided Design and Rapid Prototyping Fabrication of Removable Partial Dentures|Unknown status|Recruiting|Phase 4|50|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 23:25:15.995532|2018-05-31 23:25:15.995532
NCT01191060|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2018-01-03|2010-08-27|2010-08-30|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2010||2010-10-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|IFM/DFCI2009||Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years|Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age|Active, not recruiting||Phase 3|700|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 23:25:16.094874|2018-05-31 23:25:16.094874
NCT01191034|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-08-27|2010-08-27|2010-08-30|Estimate|||||||2010-08-27|2010-08-30|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma|Phase I/II Study of Peptide Vaccination Associated With Tumoral Immunomodulation With Proinflammatory Cytokines and Imiquimod in Patients With Advanced Metastatic Melanoma|Unknown status|Recruiting|Phase 1/Phase 2|21|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-05-31 23:25:16.273579|2018-05-31 23:25:16.273579
NCT01191021|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2013-06-04|2010-08-26|2010-08-30|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|EPIGA||Monitoring Exhaled Propofol to Individualize General Anesthesia|Pilot Study to Estimate Central Propofol Effect by Measuring Exhaled Propofol Concentrations|Completed||Phase 1|20|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:25:16.347306|2018-05-31 23:25:16.347306
NCT01191008|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2016-12-22||2017-04-17|2010-08-27|2010-08-30|Estimate|2017-04-17|2017-07-17|Actual||||2017-04-17|2017-07-17|Actual|October 2010||2010-10-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational||A total of 661 participants were registered in the study. 28 participants were excluded from the study because their case report forms were not collected.Of the 633 participants, 15 participants were excluded from the baseline analysis due to following reasons: protocol violation (7 participants) and lost to follow-up (8 participants).|Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension|Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan)|Completed|||661|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:25:16.465598|2018-05-31 23:25:16.465598
NCT01190995|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2011-11-23|2010-08-27|2010-08-30|Estimate|||||||2011-11-23|2011-11-24|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Role of Repeated Painful Procedures in Preterm Neonates on Short Term Neurobehavioural Outcome|A Randomised Controlled Trial to Evaluate the Role of Repeated Painful Procedures in Preterm Neonates on Short Term Neurobehavioural Outcome|Completed||Phase 3|106|Actual|Lady Hardinge Medical College||2|||f||||f||||||||||2018-05-31 23:25:16.69469|2018-05-31 23:25:16.69469
NCT01190982|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-08-23|2010-08-27|2010-08-30|Estimate|||||||2012-08-23|2012-08-24|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer|A Multicenter, Open-Label, Phase II Study of LEP-ETU for Efficacy and Safety in Patients With Metastatic Breast Cancer|Completed||Phase 2|70|Actual|INSYS Therapeutics Inc||1|||f||||t||||||||||2018-05-31 23:25:16.759233|2018-05-31 23:25:16.759233
NCT01190969|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2017-02-12|2010-08-27|2010-08-30|Estimate|||||||2017-02-12|2017-02-14|Actual|September 2010||2010-09-30|February 2017|2017-02-28|November 2012|Anticipated|2012-11-30|June 2012|Anticipated|2012-06-30||Interventional|||A Trial of Oral Nutritional Supplements on Nutritional Status and Clinical Outcomes|A Randomized Controlled Trial of Oral Nutritional Supplements on Nutritional Status and Clinical Outcomes in Malnourished Elderly|Withdrawn||N/A|0|Actual|Singapore General Hospital||||difficulty in recruiting elderly subjects|f||||t||||||||||2018-05-31 23:25:16.818276|2018-05-31 23:25:16.818276
NCT01190943|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2017-10-05|2010-08-27|2010-08-30|Estimate|||||||2017-10-05|2017-10-09|Actual|August 2010||2010-08-31|October 2017|2017-10-31||||January 2100|Anticipated|2100-01-31||Observational|||DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma|Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Osteosarcoma|Active, not recruiting|||200|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:25:16.873192|2018-05-31 23:25:16.873192
NCT01190930|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2018-03-19|2010-08-27|2010-08-30|Estimate|||||||2018-03-19|2018-03-21|Actual|August 2010||2010-08-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma|Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)|Active, not recruiting||Phase 3|9022|Anticipated|Children's Oncology Group||6|||f||||||||||||||2018-05-31 23:25:16.965478|2018-05-31 23:25:16.965478
NCT01190917|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2012-10-01|2010-08-26|2010-08-30|Estimate|||||||2012-10-01|2012-10-02|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Neural and Behavioral Outcomes of Social Skills Groups in Children With Autism Spectrum Disorder (ASD)|Acute and Sustained Effects of Social Skills Intervention on Neural and Behavioral Outcomes in Children With ASD|Completed||N/A|50|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 23:25:17.598076|2018-05-31 23:25:17.598076
NCT01190904|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2016-08-10|2010-08-27|2010-08-30|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|HEART-MEND||Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes|Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes|Completed|||568|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples Without DNA|"~     Inflammatory markers; Hormones: testosterone, estradiol, SHBG~   "|||2018-05-31 23:25:17.689329|2018-05-31 23:25:17.689329
NCT01190891|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2015-10-14||2016-03-28|2010-08-26|2010-08-30|Estimate|2016-03-28|2016-04-29|Estimate||||2016-03-28|2016-04-29|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|||Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome|A Manual Physical Therapy Approach Versus Subacromial Corticosteroid Injection for Treatment of Shoulder Impingement Syndrome: a Randomized Clinical Trial|Completed||N/A|104|Actual|Madigan Army Medical Center||2|||f||||f||||||||Yes|Data sharing can only occur after a Data Sharing Agreement has been approved by the US Defense Health Agency|2018-05-31 23:25:17.78347|2018-05-31 23:25:17.78347
NCT01190878|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2016-04-26|2012-01-26|2016-06-02|2010-08-27|2010-08-30|Estimate|2016-06-02|2016-07-13|Estimate|2012-01-27|2012-01-31|Estimate|2016-06-02|2016-07-13|Estimate|August 2010||2010-08-31|June 2016|2016-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||All randomized subjects|Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers|A Randomized Double-masked 14-day Study to Compare the Ocular Safety, Tolerability, and Efficacy of Differing Dosing Regimens of ISV-303 to Vehicle and Xibrom™ in Post Cataract Surgery Volunteers|Completed||Phase 1/Phase 2|169|Actual|InSite Vision||4|||f||||f||||||||||2018-05-31 23:25:18.006566|2018-05-31 23:25:18.006566
NCT01190865|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2016-09-13||2017-06-02|2010-08-27|2010-08-30|Estimate|2016-09-13|2016-11-01|Estimate||||2017-06-02|2017-07-02|Actual|September 2010||2010-09-30|June 2017|2017-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds|A Phase I Study Investigating the Survival of HP802-247 Allogeneic Cells in Excisional Acute Cutaneous Wounds|Completed||Phase 1|28|Actual|Healthpoint||1|||f||||f||||||||||2018-05-31 23:25:18.320584|2018-05-31 23:25:18.320584
NCT01190852|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2016-04-26|2010-08-27|2010-08-30|Estimate|||||||2016-04-26|2016-04-27|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays|Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays Single-centre, Randomised, Open-label, Three-period, Six-sequence Cross-over Trial (William's Design)|Completed||Phase 1|30|Actual|MEDA Pharma GmbH & Co. KG||3|||f||||f||||||||||2018-05-31 23:25:18.512669|2018-05-31 23:25:18.512669
NCT01190670|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-10-12|2010-08-27|2010-08-30|Estimate|||||||2010-10-12|2010-10-14|Estimate|July 2010||2010-07-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus|A Phase 1, Open Label, Drug Interaction Study of the Pharmacokinetics of ASP015K and Tacrolimus After Separate and Concomitant Administration to Healthy Adult Subjects|Completed||Phase 1|40|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 23:25:21.91376|2018-05-31 23:25:21.91376
NCT01190839|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2014-10-16||2016-01-05|2010-08-26|2010-08-30|Estimate|2014-10-16|2014-10-22|Estimate||||2016-01-05|2016-02-04|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Analysis population included all the participants who were randomly assigned to receive 1 of the study treatments.|A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence|Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence|Terminated||Phase 3|297|Actual|Janssen Biotech, Inc.||2||Study is terminated as per Sponsor's Decision.|f||||t||||||||||2018-05-31 23:25:18.655618|2018-05-31 23:25:18.655618
NCT01190826|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-03-14|2010-08-27|2010-08-30|Estimate|||||||2012-03-14|2012-03-15|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma|Single-Center, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of a Single Dose of ASM-024 Administered by Inhalation to Subjects With Stable Moderate Asthma|Completed||Phase 2|20|Actual|Asmacure Ltée||3|||f||||f||||||||||2018-05-31 23:25:19.717905|2018-05-31 23:25:19.717905
NCT01190813|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2015-01-28||2016-05-03|2010-08-27|2010-08-30|Estimate|2015-01-28|2015-02-13|Estimate||||2016-05-03|2016-06-02|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|ATS17||Levodopa for the Treatment of Residual Amblyopia|A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17)|Completed||Phase 3|139|Actual|Jaeb Center for Health Research||2|||f||||t||||||||Yes|A de-identified dataset is available on the PEDIG public website at http://pedig.jaeb.org/Studies.aspx?RecID=196|2018-05-31 23:25:19.863624|2018-05-31 23:25:19.863624
NCT01190800|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2014-10-13|2010-08-27|2010-08-30|Estimate|||||||2014-10-13|2014-10-15|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|MACAP||Capacity Assessment in Persons With Alzheimer's Disease|Decision Capacity Assessment in Persons With Alzheimer's Disease: Approach by Capacity to Appoint a Proxy, to Consent to Treatment and to Vote|Completed|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||None Retained|"~     None Retained~   "|||2018-05-31 23:25:21.184645|2018-05-31 23:25:21.184645
NCT01190787|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2016-05-09|2010-08-27|2010-08-30|Estimate|||||||2016-05-09|2016-05-10|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|May 2012|Actual|2012-05-31||Interventional|||Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone|A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients|Active, not recruiting||Phase 2|150|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||3|||f||||t||||||||||2018-05-31 23:25:21.238075|2018-05-31 23:25:21.238075
NCT01190774|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-08-27|2010-08-27|2010-08-30|Estimate|||||||2010-08-27|2010-08-30|Estimate|September 2003||2003-09-30|July 2003|2003-07-31|September 2004|Actual|2004-09-30|April 2004|Actual|2004-04-30||Interventional|ANXDEN||Anxiety Assessment Intervention in Dental Patients|An Investigation Into Patients' State Anxiety Reduction Following the Administration of a Dental Anxiety Questionnaire in the Dental Treatment Setting|Completed||Phase 2/Phase 3|182|Actual|University of St Andrews||2|||f||||t||||||||||2018-05-31 23:25:21.320529|2018-05-31 23:25:21.320529
NCT01190761|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-08-27|2010-08-27|2010-08-30|Estimate|||||||2010-08-27|2010-08-30|Estimate|December 2004||2004-12-31|August 2010|2010-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Actavis Inc.||2|||f||||f||||||||||2018-05-31 23:25:21.400151|2018-05-31 23:25:21.400151
NCT01190748|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-08-27|2010-08-27|2010-08-30|Estimate|||||||2010-08-27|2010-08-30|Estimate|November 2004||2004-11-30|August 2010|2010-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Actavis Inc.||2|||f||||f||||||||||2018-05-31 23:25:21.476352|2018-05-31 23:25:21.476352
NCT01190735|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2015-04-15|2010-08-27|2010-08-30|Estimate|||||||2015-04-15|2015-04-16|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Caffeine for Motor Manifestations of Parkinson's Disease|Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study.|Completed||Phase 2|28|Actual|McGill University Health Center||1|||f||||f||||||||||2018-05-31 23:25:21.554722|2018-05-31 23:25:21.554722
NCT01190722|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2017-11-29|2010-08-27|2010-08-30|Estimate|||||||2017-11-29|2017-12-02|Actual|November 10, 2010|Actual|2010-11-10|November 2017|2017-11-30|December 12, 2010|Actual|2010-12-12|December 11, 2010|Actual|2010-12-11||Interventional|||A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain|A Randomized Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain|Withdrawn||Phase 4|0|Actual|Karolinska Institutet||2||The study site was closed down|f||||t||||||||||2018-05-31 23:25:21.64584|2018-05-31 23:25:21.64584
NCT01190709|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-08-27|2010-08-27|2010-08-30|Estimate|||||||2010-08-27|2010-08-30|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of Tibial Shaft Fracture Fixation: Intramedullary Nailing Comparing With Dynamic Compression Plate|Study of Surgical Methods for Treatment of Tibial Fractures|Completed||Phase 2|100|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:25:21.716909|2018-05-31 23:25:21.716909
NCT01190696|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2010-08-27|2010-08-27|2010-08-30|Estimate|||||||2010-08-27|2010-08-30|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Titanium Elastic Nailing Versus Hip Spica Cast in Treatment of Femoral Fractures in Children|Study of Surgical Method Versus Casting for Treatment of Femoral Fracture in Children|Completed||Phase 2|46|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:25:21.783444|2018-05-31 23:25:21.783444
NCT01190683|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-27|||2011-06-14|2010-08-27|2010-08-30|Estimate|||||||2011-06-14|2011-06-15|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Vitamin D and Muscle Strength and Surface (Electromyography) EMG|Skeletal Muscle Strength,Bone Mineral Homeostasis and Th1 and Th2 Cytokines Expression in Asian Indians With Chronic Hypovitaminosis D Before and After Oral Cholecalciferol Supplementation|Completed||Phase 3|170|Actual|Indian Council of Medical Research||4|||f||||f||||||||||2018-05-31 23:25:21.846725|2018-05-31 23:25:21.846725
NCT01190657|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2013-03-29|2010-08-26|2010-08-27|Estimate|||||||2013-03-29|2013-04-01|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer|A Multiple-center, Self-controlled Open Study to Evaluate Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer|Completed||Phase 4|1184|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 23:25:21.97723|2018-05-31 23:25:21.97723
NCT01190644|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21||2014-01-30|2016-05-25|2010-08-26|2010-08-27|Estimate||||2014-01-30|2014-03-04|Estimate|2016-05-25|2016-06-06|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors|A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors|Terminated||Phase 2|4|Actual|Celgene Corporation||1||"Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from~   manufacturer. No alternatives available for use."|f||||f||||||||||2018-05-31 23:25:22.183704|2018-05-31 23:25:22.183704
NCT01190631|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-11-27|2010-08-26|2010-08-27|Estimate|||||||2012-11-27|2012-11-29|Estimate|July 2010||2010-07-31|November 2012|2012-11-30||||November 2011|Actual|2011-11-30||Interventional|||An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation Following Intraocular Lens (IOL) Implantation|An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation After SN60WF IOL Implantation|Completed||N/A|100|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:25:22.265856|2018-05-31 23:25:22.265856
NCT01190618|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2017-02-14|2010-08-26|2010-08-27|Estimate|||||||2017-02-14|2017-02-16|Actual|August 2010||2010-08-31|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Surgical Outcomes of Vaginal Prolapse Repair With Elevate|Surgical Outcomes of Vaginal Prolapse Repair With the Elevate Prolapse Repair Kit|Completed|||417|Actual|William Beaumont Hospitals|||||f||||f||||||||No||2018-05-31 23:25:22.348266|2018-05-31 23:25:22.348266
NCT01190605|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2014-12-05|2010-08-26|2010-08-27|Estimate|||||||2014-12-05|2014-12-09|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Observational|||Evaluating Factors That Impact Loss to Follow-up Among Postpartum HIV-infected Women in Mississippi|Evaluating Factors That Impact Loss to Follow-up Among Postpartum HIV-infected Women in Mississippi|Completed|||53|Actual|University of Mississippi Medical Center|||||f||||f||||||||||2018-05-31 23:25:22.400672|2018-05-31 23:25:22.400672
NCT01190592|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2011-06-20|2010-08-26|2010-08-27|Estimate|||||||2011-06-20|2011-06-21|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Resistance Training With Milk Supplementation in Adolescents|Effects of Resistance Training With Milk Supplementation on Body Composition in Middle School Children|Completed||N/A|150|Anticipated|University of Kansas Medical Center||3|||f||||t||||||||||2018-05-31 23:25:22.455989|2018-05-31 23:25:22.455989
NCT01190579|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|MEDIC||Dual Source CT Angiography for Detection of Coronary Artery Stenoses|Multicenter Evaluation of Coronary Dual Source CT Angiography in Patients With Intermediate Risk of Coronary Artery Stenoses|Unknown status|Recruiting||398|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||t||||||||||2018-05-31 23:25:22.527667|2018-05-31 23:25:22.527667
NCT01190566|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-12-30||2015-06-11|2010-08-26|2010-08-27|Estimate|2015-06-11|2015-07-07|Estimate||||2015-06-11|2015-07-07|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer|PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients|Completed|||57|Actual|Seoul National University Hospital|||||f||||f||||||None Retained|"~     Core biopsy specimens of breast cancer~   "|||2018-05-31 23:25:22.617346|2018-05-31 23:25:22.617346
NCT01190553|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-10-10|2010-08-26|2010-08-27|Estimate|||||||2010-10-10|2010-10-13|Estimate|November 2010||2010-11-30|August 2010|2010-08-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Pilot Study of Maintenance Therapy With Intravenous AMANTADINE|Maintenance Therapy of Intravenous Amantadine in Patients With Idiopathic Parkinson Disease Who Are Not Optimally Treated With Anti Parkinson Medications|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 23:25:23.000259|2018-05-31 23:25:23.000259
NCT01190540|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2014-12-01|2010-08-25|2010-08-27|Estimate|||||||2014-12-01|2014-12-03|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|IDCAP||Integrated Infectious Disease Capacity-Building Evaluation|Cost Effectiveness of Building Capacity of Mid-level Practitioners in Sub-Saharan Africa for the Care and Prevention of HIV, Tuberculosis, Malaria and Related Infectious Diseases|Completed||N/A|72|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:25:23.066987|2018-05-31 23:25:23.066987
NCT01190527|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2015-01-06||2017-05-03|2010-08-25|2010-08-27|Estimate|2015-01-06|2015-01-14|Estimate||||2017-05-03|2017-06-02|Actual|August 2008||2008-08-31|May 2017|2017-05-31|January 6, 2015|Actual|2015-01-06|July 2014|Actual|2014-07-31||Interventional|HUM15709||Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer|Using FDG-PET Acquired During the Course of Radiation Therapy to Individualize Adaptive Radiation Dose Escalation in Patients With Non-Small Cell Lung Cancer|Completed||N/A|42|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 23:25:23.148145|2018-05-31 23:25:23.148145
NCT01190514|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2011-12-21||2011-12-21|2010-08-26|2010-08-27|Estimate|2011-12-21|2012-01-27|Estimate||||2011-12-21|2012-01-27|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)|Phase 1, Open-Label, Randomized, Single-Dose, 4-Treatment, 4-Period Crossover Bioequivalence Study Comparing 25 Mg and 50 Mg Formulations of DVS-233 SR and Investigate Food Effect on 50 Mg Formulations of DVS-233 SR Tablet Under Fed and Fasted Conditions|Completed||Phase 1|41|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:25:24.544343|2018-05-31 23:25:24.544343
NCT01190501|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-02-21|2010-08-25|2010-08-27|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2009||2009-06-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|February 2014|Actual|2014-02-28||Interventional|||Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism|Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism|Completed||N/A|96|Actual|University Hospital, Toulouse||1|||f||||t||||||||No||2018-05-31 23:25:24.939285|2018-05-31 23:25:24.939285
NCT01190475|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2017-11-16|2012-07-31|2017-11-16|2010-08-26|2010-08-27|Estimate|2017-11-16|2017-12-14|Actual|2012-07-31|2012-08-07|Estimate|2017-11-16|2017-12-14|Actual|July 2010||2010-07-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||BGS649 Monotherapy in Moderate to Severe Endometriosis Patients|A Randomized, Double-blind, Double-dummy, Placebo-controlled Study of Oral BGS649 Monotherapy Assessing Safety and Tolerability in Patients With Moderate to Severe Endometriosis|Completed||Phase 2|6|Actual|Mereo BioPharma|The study was prematurely terminated because the safety endpoint was reached after a total of 6 patients were randomized into one of the 3 treatment arms.|3|||f||||||||||||No||2018-05-31 23:25:25.234543|2018-05-31 23:25:25.234543
NCT01190462|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2013-08-09|2010-08-26|2010-08-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|August 2010||2010-08-31|April 2011|2011-04-30||||August 2012|Anticipated|2012-08-31||Interventional|||Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer|Safety and Efficacy of the Addition of Simvastatin to Cetuximab in K-ras Mutant Advanced or Metastatic Colorectal Cancer Patients. A Single-Arm, Multicenter, Phase II Study Using a Simon Two Stage Design.|Unknown status|Recruiting|Phase 2|51|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:25:25.532677|2018-05-31 23:25:25.532677
NCT01190449|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2017-08-07|2010-08-26|2010-08-27|Estimate|||||||2017-08-07|2017-08-08|Actual|August 2011|Actual|2011-08-31|August 2017|2017-08-31||||March 2015|Actual|2015-03-31||Interventional|||Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma|A Phase II Trial of Ofatumumab (CALGB IND #) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)|Active, not recruiting||Phase 2|51|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 23:25:25.625697|2018-05-31 23:25:25.625697
NCT01190436|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2014-04-24||2017-01-12|2010-08-26|2010-08-27|Estimate|2014-04-24|2014-05-23|Estimate||||2017-01-12|2017-01-30|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Intent-to-treat (ITT) population included all participants who received at least 1 dose of study drug.|A 12-week, Multicentric Study to Evaluate the Safety and Efficacy of Bisoprolol in Filipino Hypertensive Subjects With Diabetes|A Study on the Efficacy of Bisoprolol and Its Influence on Selected Biochemical Parameters in Filipino Hypertensive Patients With Diabetes|Completed||Phase 4|125|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 23:25:25.823432|2018-05-31 23:25:25.823432
NCT01190423|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2018-04-13|2010-08-25|2010-08-27|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2010||2010-07-31|April 2018|2018-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Treatment for Young Adults With Anorexia Nervosa|Family-Based Treatment for Weight Restoration in Young Adults With Anorexia Nervosa|Completed||N/A|22|Actual|Temple University||1|||f||||t||||||||||2018-05-31 23:25:26.102021|2018-05-31 23:25:26.102021
NCT01190410|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-12-20|2010-08-26|2010-08-27|Estimate|||||||2017-12-20|2017-12-21|Actual|August 2010|Actual|2010-08-31|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol|An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035|Completed||Phase 2|16|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 23:25:26.174609|2018-05-31 23:25:26.174609
NCT01190397|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-12-03|2010-08-26|2010-08-27|Estimate|||||||2010-12-03|2010-12-06|Estimate|September 2010||2010-09-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy|Phase I, Prospective, Comparative Study, Investigator Masked , Monocentric Measuring Warming Efficiency and Safety of Blephasteam® Versus Warm Compresses in Eyelid Therapy|Completed||Phase 1|20|Anticipated|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 23:25:26.253631|2018-05-31 23:25:26.253631
NCT01190384|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-07-06|2010-08-25|2010-08-27|Estimate|||||||2017-07-06|2017-07-11|Actual|August 2010||2010-08-31|July 2017|2017-07-31|April 2014|Actual|2014-04-30|April 2012|Actual|2012-04-30||Interventional|BEAN||The Effect of Whole Beans on Inflammation and Satiety|Bean Consumption: A Pilot Study in Overweight Men and Women on Immuno-metabolic and Food Intake Endpoints|Completed||N/A|12|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 23:25:26.420203|2018-05-31 23:25:26.420203
NCT01190371|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2018-02-22|2010-08-26|2010-08-27|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2011||2011-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|November 2011|Actual|2011-11-30||Interventional|CATMAP||Have Malaria Infections in Kenya Become Less Responsive to Artemisinin Treatment?|Confirmation of Artemisinin Tolerance in Malaria Parasites Trial in Kilifi|Active, not recruiting||Phase 4|175|Actual|KEMRI-Wellcome Trust Collaborative Research Program||1|||f||||f||||||||||2018-05-31 23:25:26.507923|2018-05-31 23:25:26.507923
NCT01190358|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-07-17|2010-08-25|2010-08-27|Estimate|||||||2017-07-17|2017-07-19|Actual|August 2010|Actual|2010-08-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|March 2011|Actual|2011-03-31||Interventional|GSEMetS||Grape Seed Extract and Postprandial Oxidation and Inflammation|Grape Seed Extract and Postprandial Oxidation and Inflammation: A Pilot Study in People With the Metabolic Syndrome.|Completed||N/A|12|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 23:25:26.588573|2018-05-31 23:25:26.588573
NCT01190345|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2013-03-19|2010-08-26|2010-08-27|Estimate|||||||2013-03-19|2013-03-20|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|AVASTEM||Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer|"Phase II Proof of Concept  Trial Evaluating Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab in Combination With Chemotherapy in Breast Cancer"|Unknown status|Active, not recruiting|Phase 2|75|Anticipated|Institut Paoli-Calmettes||2|||f||||f||||||||||2018-05-31 23:25:26.664497|2018-05-31 23:25:26.664497
NCT01190332|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Conventional Versus Rendezvous Technique of Intraoperative Endoscopic Retrograde Cholangiopancreatography||Completed||N/A|98|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 23:25:26.741697|2018-05-31 23:25:26.741697
NCT01190319|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2017-07-11|2010-08-25|2010-08-27|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2007|Actual|2007-09-30|July 2017|2017-07-31|December 2015|Actual|2015-12-31|October 2011|Actual|2011-10-31||Interventional|CSCBP||Study: Effects of Strawberries on Blood Pressure|Effect of Strawberry Powder on Blood Pressure in Individuals With Pre-Hypertension|Completed||N/A|50|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 23:25:26.814954|2018-05-31 23:25:26.814954
NCT01189981|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2014-09-30|2010-08-26|2010-08-27|Estimate|||||||2014-09-30|2014-10-01|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|PReVaiL||Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease|Effect of Internet, Mobil Applications and SMS-based Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease|Completed||Phase 2|158|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 23:25:33.441408|2018-05-31 23:25:33.441408
NCT01190306|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2012-12-13||2016-12-05|2010-08-25|2010-08-27|Estimate|2013-01-28|2013-03-04|Estimate||||2016-12-05|2017-02-01|Estimate|August 2010||2010-08-31|December 2016|2016-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety Study of the VEGA UV-A System to Treat Keratoconus|Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus|Terminated||Phase 3|118|Actual|Topcon Medical Systems, Inc.||2||The sponsor terminated the study prior to data analysis for financial reasons.|f||||f||||||||||2018-05-31 23:25:26.913825|2018-05-31 23:25:26.913825
NCT01190293|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-04-11|2010-08-25|2010-08-27|Estimate|||||||2012-04-11|2012-04-12|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|SSAT033||PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen|A Pilot Evaluation of the Pharmacokinetics, Efficacy and Safety of Switching From Efavirenz to Maraviroc Administered at 600mg Then 300mg Twice-daily in Patients Suppressed on an Efavirenz-containing Regimen as Initial Therapy|Completed||Phase 4|12|Actual|St Stephens Aids Trust||1|||f||||f||||||||||2018-05-31 23:25:27.145783|2018-05-31 23:25:27.145783
NCT01190280|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 1991||1991-10-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Indications for Gallbladder Surgery in Gallstone Disease|Indications for Gallbladder Surgery in Gallstone Disease|Completed|||500|Actual|Haraldsplass Deaconess Hospital|||8||f||||f||||||Samples Without DNA|"~     Resected gallbladders for histological and bacteriological investigation~   "|||2018-05-31 23:25:27.220288|2018-05-31 23:25:27.220288
NCT01190267|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2014-07-14||2015-08-04|2010-08-25|2010-08-27|Estimate|2014-07-14|2014-08-06|Estimate||||2015-08-04|2015-08-21|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All participants who received at least one dose of extension study medication|Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)|A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia|Completed||Phase 3|204|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-05-31 23:25:27.309103|2018-05-31 23:25:27.309103
NCT01190254|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2014-03-10||2015-08-04|2010-08-25|2010-08-27|Estimate|2014-05-15|2014-06-06|Estimate||||2015-08-04|2015-08-21|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)|An 8-week, Placebo-controlled, Double-blind, Randomized, Fixed-dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia|Completed||Phase 3|306|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 23:25:27.619429|2018-05-31 23:25:27.619429
NCT01190241|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2015-06-02|2010-08-26|2010-08-27|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2010||2010-08-31|June 2015|2015-06-30||||May 2016|Anticipated|2016-05-31||Interventional|TSAP||Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study|Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study|Unknown status|Active, not recruiting|N/A|45|Anticipated|VU University Medical Center||1|||f||||f||||||||||2018-05-31 23:25:28.674481|2018-05-31 23:25:28.674481
NCT01190228|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2017-08-31||2017-10-09|2010-08-25|2010-08-27|Estimate|2017-10-09|2017-11-08|Actual||||2017-10-09|2017-11-08|Actual|August 25, 2010|Actual|2010-08-25|October 2017|2017-10-31|October 12, 2015|Actual|2015-10-12|October 29, 2010|Actual|2010-10-29||Interventional|||Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV|Assessment of the Memory Immune Response, Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV and Long-Term Follow-Up|Completed||Phase 3|454|Actual|Sanofi||3|||f||||t|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com.|2018-05-31 23:25:28.786007|2018-05-31 23:25:28.786007
NCT01190215|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2012-01-12||2017-08-31|2010-08-26|2010-08-27|Estimate|2012-06-07|2012-07-13|Estimate||||2017-08-31|2017-09-29|Actual|October 4, 2010||2010-10-04|August 2017|2017-08-31|July 7, 2011|Actual|2011-07-07|July 7, 2011|Actual|2011-07-07||Interventional|||Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM|Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine FluarixTM in Adolescents Previously Vaccinated With GSK Biologicals' H1N1 Vaccine PandemrixTM|Completed||Phase 4|77|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:25:29.326979|2018-05-31 23:25:29.326979
NCT01190202|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2015-09-28|2010-08-26|2010-08-27|Estimate|||||||2015-09-28|2015-09-30|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Epidemiology Study of Malaria Transmission Intensity in Africa|Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa|Completed|||13380|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 23:25:30.097943|2018-05-31 23:25:30.097943
NCT01190189|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2018-05-29|2010-08-26|2010-08-27|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 1, 2011||2011-04-01|May 2018|2018-05-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Interventional|||Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study|Completed||Phase 3|137|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 23:25:30.181452|2018-05-31 23:25:30.181452
NCT01190176|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2017-10-25|2010-08-26|2010-08-27|Estimate|||||||2017-10-25|2017-10-26|Actual|September 12, 2011|Actual|2011-09-12|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects|Gynaecological Follow-up of a Subset of HPV-015 Study Subjects|Completed||Phase 3|34|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 23:25:30.290401|2018-05-31 23:25:30.290401
NCT01190163|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-08-22|2010-08-26|2010-08-27|Estimate|||||||2012-08-22|2012-08-23|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SOFTNES||Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction|Phase IV, Multicenter, Open Label, Randomized Trial to Compare the Effectiveness and Safety of the Dinoprostone Vaginal Pessary vs. Oxytocin for Women Requiring Cervical Ripening Prior to Induction of Labor|Terminated||Phase 4|170|Actual|Ferring Pharmaceuticals||2||Study was early terminated due to problems enrolling adequate number of patients|f||||f||||||||||2018-05-31 23:25:30.467731|2018-05-31 23:25:30.467731
NCT01190150|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2012-05-30||2012-07-10|2010-08-26|2010-08-27|Estimate|2012-05-30|2012-07-03|Estimate||||2012-07-10|2012-07-16|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PREA||Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding|Randomized, 2-way Crossover, Pharmacokinetic Study of Lysteda (Xanodyne Modified-Immediate Release Tranexamic Acid) Tablets at 2 Doses in Fasting Adolescent Females With Evidence of Heavy Menstrual Bleeding|Completed||Phase 4|20|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:25:30.548179|2018-05-31 23:25:30.548179
NCT01190137|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2012-03-01|2010-08-26|2010-08-27|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study Comparing Two Isoforms of Vitamin D Supplements for Infants|Bio-equivalency Study of the Effects of Vitamin D2 and Vitamin D3 Supplements on 25-hydroxyvitamin D Levels in Exclusively Breast Fed Canadian Infants|Completed||Phase 3|52|Actual|McGill University||2|||f||||f||||||||||2018-05-31 23:25:30.918972|2018-05-31 23:25:30.918972
NCT01190124|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2011-01-03||2011-04-20|2010-08-26|2010-08-27|Estimate|2011-04-20|2011-05-19|Estimate||||2011-04-20|2011-05-19|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients|Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients: a Retrospective Analysis of a Portuguese Cohort Treated Within the Expanded Access Program|Completed|||151|Actual|Doroana, Maria Manuela, M.D.|||1||f||||f||||||||||2018-05-31 23:25:31.025939|2018-05-31 23:25:31.025939
NCT01190111|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-07-31|2010-08-26|2010-08-27|Estimate|||||||2013-07-31|2013-08-01|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Inspire 2||Study on Interleukin-7 (CYT107) in HIV Patients|An Open-label, Multicenter Study of Subcutaneous Intermittent Recombinant Interleukin-7 (CYT107) in Chronically HIV-infected Patients With CD4 T-lymphocyte Counts Between 101-400 Cells/mm3 and Plasma HIV RNA< 50 Copies/mL After at Least 12 Months of HAART|Terminated||Phase 2|23|Actual|Cytheris SA||1||"CYTHERISSA filed for banckcuptcy in June 2013.Subjects treated by CYT 107 were followed up for~   at the least 3 months."|f||||t||||||||||2018-05-31 23:25:31.543206|2018-05-31 23:25:31.543206
NCT01190098|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2016-12-01||2016-12-01|2010-08-26|2010-08-27|Estimate|2016-12-01|2016-12-05|Estimate||||2016-12-01|2016-12-05|Estimate|August 2010||2010-08-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy|"Searching for Sleep Friendly Therapies for a Sleepy Population: A Double-Blind, Placebo-Controlled, Randomized Trial to Assess the Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy"|Completed||Phase 4|59|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 23:25:31.664391|2018-05-31 23:25:31.664391
NCT01190085|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|2013-12-01||2014-04-30|2010-08-26|2010-08-27|Estimate|2014-03-30|2014-04-29|Estimate||||2014-04-30|2014-05-15|Estimate|April 2011||2011-04-30|April 2014|2014-04-30||||November 2012|Actual|2012-11-30||Interventional|||Effects of Ghrelin on Alcohol Cue Reactivity and Craving|Effects of Ghrelin on Alcohol Cue Reactivity and Craving|Completed||N/A|45|Actual|Brown University|Small proof-of-concept study|3|||f||||t||||||||||2018-05-31 23:25:32.125204|2018-05-31 23:25:32.125204
NCT01190072|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2013-01-28|2010-08-26|2010-08-27|Estimate|||||||2013-01-28|2013-01-29|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)|LIPID-LOWERING THERAPY FOR SECONDARY PREVENTION IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) A 10-week, Open-label, Non-interventional Study of Total Cholesterol/LDL-cholesterol Management in Real Life in Coronary Patients Hospitalised for Elective PCI|Terminated|||120|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:25:32.460156|2018-05-31 23:25:32.460156
NCT01190059|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-11-12|2010-08-25|2010-08-27|Estimate|||||||2010-11-12|2010-11-16|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|HELP||Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation|Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation|Completed||Phase 1|22|Actual|XVIVO Perfusion||1|||f||||t||||||||||2018-05-31 23:25:32.516484|2018-05-31 23:25:32.516484
NCT01190046|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2016-11-15|2010-08-26|2010-08-27|Estimate|||||||2016-11-15|2016-11-16|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Chronic Muscle Disuse in the Elderly|Muscle Disuse and Contractile Dysfunction in the Elderly|Completed||N/A|35|Actual|University of Vermont||1|||f||||f||||||||||2018-05-31 23:25:32.583223|2018-05-31 23:25:32.583223
NCT01190033|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-03-22|2010-08-26|2010-08-27|Estimate|||||||2013-03-22|2013-03-26|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|July 2013|Anticipated|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Study Of The Efficacy Of Neurolysis In Functional Recovery From Chronic Nonspecific Low Back Pain|STUDY OF THE EFFICACY OF NEUROLYSIS IN FUNCTIONAL RECOVERY FROM CHRONIC NONSPECIFIC LOW BACK PAIN|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:25:32.655737|2018-05-31 23:25:32.655737
NCT01190020|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2011-02-09|2010-08-26|2010-08-27|Estimate|||||||2011-02-09|2011-02-10|Estimate|February 2009||2009-02-28|February 2011|2011-02-28||||August 2011|Anticipated|2011-08-31||Interventional|||Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation.|Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation|Unknown status|Recruiting|Phase 1|45|Anticipated|University of Iowa||2|||f||||f||||||||||2018-05-31 23:25:32.748057|2018-05-31 23:25:32.748057
NCT01190007|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2012-11-01||2012-12-19|2010-08-25|2010-08-27|Estimate|2012-11-01|2012-12-03|Estimate||||2012-12-19|2012-12-24|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients|A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia|Completed||Phase 4|159|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:25:32.846879|2018-05-31 23:25:32.846879
NCT01189994|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-09-03|2010-08-26|2010-08-27|Estimate|||||||2010-09-03|2010-09-06|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Trial of Acupuncture in the Treatment of Fibromyalgia|Pragmatic Randomized Controlled Trial of Acupuncture Effectiveness in the Treatment of Fibromyalgia|Unknown status|Recruiting|N/A|60|Anticipated|Santa Casa da Misericordia do Rio de Janeiro Hospital||2|||f||||f||||||||||2018-05-31 23:25:33.342134|2018-05-31 23:25:33.342134
NCT01189799|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate||||August 2010|2010-08-31||||||||Interventional|Aftercare||Motivational Therapy for Substance Users With Depression|Motivational Therapy for Substance Users With Depression|Unknown status|Recruiting|N/A|80|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:25:35.072619|2018-05-31 23:25:35.072619
NCT01189968|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2016-09-16|2010-08-25|2010-08-27|Estimate|||||||2016-09-16|2016-09-20|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer|A Phase 1b Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) as 1st-line Treatment in Subjects With Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 1|50|Anticipated|OncoMed Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:25:33.525585|2018-05-31 23:25:33.525585
NCT01189955|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|HS||the Use of Harmonic Scalpel Versus Knot Tying for Total Thyroidectomy|The Use of Harmonic Scalpel Versus Knot Tying for Total Thyroidectomy: A Prospective Randomized Study|Completed||N/A|130|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 23:25:33.640827|2018-05-31 23:25:33.640827
NCT01189942|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2016-09-16|2010-08-25|2010-08-27|Estimate|||||||2016-09-16|2016-09-20|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer|A Phase 1b Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer|Completed||Phase 1|18|Actual|OncoMed Pharmaceuticals, Inc.|||||f||||t||||||||||2018-05-31 23:25:33.737162|2018-05-31 23:25:33.737162
NCT01189929|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-01-23|2010-08-25|2010-08-27|Estimate|||||||2017-01-23|2017-01-25|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer|A Phase 1b Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 1|57|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 23:25:33.822701|2018-05-31 23:25:33.822701
NCT01189916|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2015-02-12|2010-08-25|2010-08-27|Estimate|||||||2015-02-12|2015-02-13|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Transrectal NOTES Appendectomy - Feasibility Study|Transrectal - Natural Orifice Translumenal Endoscopic Surgery (NOTES)|Completed||N/A|4|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 23:25:33.931435|2018-05-31 23:25:33.931435
NCT01189903|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2014-01-26|2010-08-25|2010-08-27|Estimate|||||||2014-01-26|2014-01-28|Estimate|January 2011||2011-01-31|January 2014|2014-01-31||||August 2013|Actual|2013-08-31||Interventional|||Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients|Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients|Unknown status|Active, not recruiting|Phase 2/Phase 3|||National University Hospital, Singapore|||||f||||||||||||||2018-05-31 23:25:34.00108|2018-05-31 23:25:34.00108
NCT01189890|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-05-08||2017-05-04|2010-08-25|2010-08-27|Estimate|2013-05-08|2013-06-27|Estimate||||2017-05-04|2017-06-05|Actual|August 16, 2010|Actual|2010-08-16|May 2017|2017-05-31|October 31, 2012|Actual|2012-10-31|October 31, 2012|Actual|2012-10-31||Interventional|||Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)|A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control|Completed||Phase 3|480|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:25:34.079805|2018-05-31 23:25:34.079805
NCT01189877|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-10-10|2010-08-25|2010-08-27|Estimate|||||||2012-10-10|2012-10-11|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins|Characterization of Rectal Cancer Hypoxia Using pO2 Histography and Immunohistochemistry for Hypoxia-Related Proteins|Completed||N/A|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:25:34.471646|2018-05-31 23:25:34.471646
NCT01189864|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2015-08-26|2010-08-25|2010-08-27|Estimate|||||||2015-08-26|2015-08-28|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Recruiting|||500|Anticipated|Cxlusa|||3||f||||||||||||||2018-05-31 23:25:34.548281|2018-05-31 23:25:34.548281
NCT01189851|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2018-01-18|2010-08-25|2010-08-27|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2010||2010-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2013|Actual|2013-09-30||Interventional|IORT||Intraoperative Radiotherapy for Early Stage Breast Cancer|Intraoperative Radiotherapy (IORT) for the Management of Carcinoma of the Breast: Use of Mammography, Ultrasonography,and Contrast-Enhanced Magnetic Resonance Imaging (CE-MRI) to Identify Candidates for IORT|Active, not recruiting||N/A|200|Anticipated|Hoag Memorial Hospital Presbyterian||1|||f||||f||||||||||2018-05-31 23:25:34.661028|2018-05-31 23:25:34.661028
NCT01189838|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-10-05|2010-08-26|2010-08-27|Estimate|||||||2010-10-05|2010-10-07|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma|The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma|Unknown status|Recruiting||100|Anticipated|Far Eastern Memorial Hospital|||2||f||||f||||||Samples With DNA|"~     Surgical resection of tumor~   "|||2018-05-31 23:25:34.728947|2018-05-31 23:25:34.728947
NCT01189825|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2013-02-25|2010-08-26|2010-08-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy of Exercise for Sexual Side Effects of Antidepressants|Effects of Acute Exercise on Sexual Arousal in Women Taking a Selective Serotonin Reuptake Inhibitor (SSRI) or Selective Serotonin/Norepinephrine Reuptake Inhibitor|Completed||N/A|48|Actual|University of Texas at Austin||1|||f||||f||||||||||2018-05-31 23:25:34.788717|2018-05-31 23:25:34.788717
NCT01189812|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2011-03-28||2011-08-22|2010-08-26|2010-08-27|Estimate|2011-05-06|2011-06-08|Estimate||||2011-08-22|2011-08-24|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders|Completed||Phase 2|80|Actual|Columbia Northwest Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:25:34.859551|2018-05-31 23:25:34.859551
NCT01189786|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2018-04-26|2010-08-25|2010-08-27|Estimate|||||||2018-04-26|2018-04-30|Actual|October 2010||2010-10-31|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|October 2020|Anticipated|2020-10-31||Interventional|EXCESS||Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection|Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection (EXCESS)|Recruiting||N/A|144|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 23:25:35.131419|2018-05-31 23:25:35.131419
NCT01189773|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|February 2008||2008-02-29|May 2010|2010-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Combined Analgesia to Control Pain in Children Seen in Emergency Department (ED) for a Trauma of a Limb|Efficacy and Security of Combined Analgesia (Opioid and Anti-inflammatory Agent) to Control Pain in Children Seen in the Emergency Department for a Trauma of a Limb|Completed||Phase 4|200|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 23:25:35.196685|2018-05-31 23:25:35.196685
NCT01189760|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-09-27|2012-04-02|2013-09-27|2010-08-25|2010-08-27|Estimate|2013-09-27|2013-12-03|Estimate|2012-04-02|2012-04-05|Estimate|2013-09-27|2013-12-03|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines||Completed||Phase 3|917|Actual|Allergan||3|||f||||f||||||||||2018-05-31 23:25:35.296942|2018-05-31 23:25:35.296942
NCT01189747|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-09-27|2012-04-02|2013-09-27|2010-08-25|2010-08-27|Estimate|2013-09-27|2013-12-03|Estimate|2012-04-02|2012-04-05|Estimate|2013-09-27|2013-12-03|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines||Completed||Phase 3|446|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:25:35.684144|2018-05-31 23:25:35.684144
NCT01189734|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate||||February 2010|2010-02-28||||||||Interventional|||Comparison Between Laparoscopic Common Bile Duct Exploration and Intraoperative ERCP for Management of Common Bile Duct Stones||Completed||N/A|248|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 23:25:37.009643|2018-05-31 23:25:37.009643
NCT01189721|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Effect of Propofol on Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Thyroid Surgery|Effect of Propofol on Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Thyroid Surgery|Unknown status|Recruiting|Phase 4|84|Anticipated|Gangnam Severance Hospital||2|||f||||||||||||||2018-05-31 23:25:37.074572|2018-05-31 23:25:37.074572
NCT01189708|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2015-07-09|2010-08-26|2010-08-27|Estimate|||||||2015-07-09|2015-07-10|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|April 2011|Actual|2011-04-30|April 2009|Actual|2009-04-30||Interventional|||Prevention of Incisional Hernia After Elective Open Abdominal Aortic Aneurysm (AAA) Repair|Prevention of Incisional Hernia After Elective Open Abdominal Aortic Aneurysm Repair|Terminated||N/A|9|Actual|Cantonal Hospital of St. Gallen||2||Treatment without success, low enrollment, one serious adverse event|f||||f||||||||||2018-05-31 23:25:37.160506|2018-05-31 23:25:37.160506
NCT01189695|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-26|||2013-05-10|2010-08-26|2010-08-27|Estimate|||||||2013-05-10|2013-05-13|Estimate|December 2010||2010-12-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|BIDI-MONO||Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure|A Randomized Controlled Study Compares the 48 Weeks Results of HIV-1 RNA Between Ritonavir-boosted Lopinavir Monotherapy and Ritonavir-boosted Lopinavir + Optimized Background Regimens in HIV-1 Infected Patients Who Have HIV-1 RNA <50 Copies/ml More Than 6 Months While Receiving Salvage PI-based Regimen and Previously Failed NNRTI-based Regimen|Completed||Phase 4|63|Actual|Bamrasnaradura Infectious Diseases Institute||2|||f||||f||||||||||2018-05-31 23:25:37.227569|2018-05-31 23:25:37.227569
NCT01189682|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2013-10-18|2010-08-26|2010-08-27|Estimate|||||||2013-10-18|2013-10-21|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DRESSING2||Impact of Tegaderm HP and CHG in Major Catheter Related Infections and Dressing Detachment|Impact of Tegaderm HP and Tegaderm CHG in Major Catheter Related Infections and Dressing Detachment in ICU Patients a Prospective Randomized Study|Completed||Phase 4|1960|Actual|University Hospital, Grenoble||3|||f||||f||||||||||2018-05-31 23:25:37.293123|2018-05-31 23:25:37.293123
NCT01189669|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2010-09-10|2010-08-26|2010-08-27|Estimate|||||||2010-09-10|2010-09-13|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS)|Long Chain (LC) n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS): A Cross-over, Placebo Controlled Dietary Intervention Study|Completed||N/A|25|Actual|The Adelaide and Meath Hospital||3|||f||||f||||||||||2018-05-31 23:25:37.373663|2018-05-31 23:25:37.373663
NCT01189656|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-08-26|2010-08-26|2010-08-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||A Clinical Study on Therapeutic Double-plasmid Hepatitis B Virus (HBV) DNA Vaccine in Patients With HBeAg-positive Chronic Hepatitis B|A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on Specific-Population to Evaluate the Safety and Efficacy of Therapeutic Double-plasmid HBV DNA Vaccine in HBeAg-positive Patients With Chronic Hepatitis B|Unknown status|Active, not recruiting|Phase 2|33|Actual|The 458 Hospital of Chinese PLA||2|||f||||t||||||||||2018-05-31 23:25:37.449304|2018-05-31 23:25:37.449304
NCT01189643|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-10-25|2010-08-25|2010-08-26|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2010|Actual|2010-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor|A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor|Active, not recruiting||Early Phase 1|15|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:25:37.610798|2018-05-31 23:25:37.610798
NCT01189630|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2011-03-29|2010-08-25|2010-08-26|Estimate|||||||2011-03-29|2011-03-30|Estimate|December 2010||2010-12-31|March 2011|2011-03-31|December 2015|Anticipated|2015-12-31|||||Observational|OBSERVE||"Medtronic Observational Study in the Real World of Implantable Electronic Cardiac Devices"|"Medtronic Observational Study in the Real World of Implantable Electronic Cardiac Devices"|Unknown status|Enrolling by invitation||3500|Anticipated|Medtronic Comercial Ltda.|||||f||||t||||||||||2018-05-31 23:25:37.685942|2018-05-31 23:25:37.685942
NCT01189617|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-04-26||2017-01-11|2010-08-25|2010-08-26|Estimate|2013-12-09|2014-01-10|Estimate||||2017-01-11|2017-02-27|Actual|June 2010||2010-06-30|January 2017|2017-01-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional||Full Analysis Set|Safety Study for an All-in-One Body and Personal Lubricant|A Single-center, Medically Supervised, Safety Evaluation Study of an All-in-One Body and Lubricant Product|Completed||N/A|70|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-05-31 23:25:37.748794|2018-05-31 23:25:37.748794
NCT01189604|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2011-11-09||2011-12-15|2010-08-25|2010-08-26|Estimate|2011-11-09|2011-12-13|Estimate||||2011-12-15|2011-12-19|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Dose Rate Range Finding Study of Propofol for minimal-to Moderate Sedation on Upper & Lower Endoscopic Tests|A Multi-centre, Single-blind, Randomised, Parallel Group, Phase IIb Dose Rate Range Finding Study to Find Maintenance Dose Rate Range of ICI35,868 for the Minimal-to-moderate Sedation on Gastrointestinal Endoscopic Tests (Including Endoscopic Polypectomy)|Completed||Phase 2|123|Actual|AstraZeneca||7|||f||||f||||||||||2018-05-31 23:25:38.023404|2018-05-31 23:25:38.023404
NCT01189591|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2017-11-06|2010-08-25|2010-08-26|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2009||2009-06-30|November 2017|2017-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Slow-wave Sleep Deprivation in Depression|Slow-wave Sleep Deprivation as a Possible Treatment for Major Depressive Disorder|Completed||N/A|25|Actual|University of Wisconsin, Madison||1|||f||||f|f|f||||||||2018-05-31 23:25:38.645334|2018-05-31 23:25:38.645334
NCT01189578|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-10-25|2010-08-25|2010-08-26|Estimate|||||||2012-10-25|2012-10-29|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Brain Imaging of Cocaine Craving in Recreational Cocaine Users|Neural Correlates of Craving and Impulsivity in Recreational Cocaine Users|Completed|||9|Actual|Medical University of South Carolina|||1||f||||t||||||||||2018-05-31 23:25:38.711466|2018-05-31 23:25:38.711466
NCT01189565|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2013-05-21|2010-08-25|2010-08-26|Estimate|||||||2013-05-21|2013-05-22|Estimate|March 2010||2010-03-31|August 2010|2010-08-31||||March 2011|Actual|2011-03-31||Observational|||Continuous Postoperative Pulse Oximetry in Patients Presenting for Total Hip and Total Knee Replacement|Continuous Postoperative Pulse Oximetry in Patients Presenting for Total Hip and Total Knee Replacement|Completed|||150|Anticipated|Medical University of South Carolina|||1||f||||||||||||||2018-05-31 23:25:38.761572|2018-05-31 23:25:38.761572
NCT01189552|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2017-02-17|2010-08-25|2010-08-26|Estimate|||||||2017-02-17|2017-02-23|Actual|October 2010|Actual|2010-10-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LET'S ACT||Depression Treatment for Low Income Substance Users|Depression Treatment for Urban Low Income Minority Substance Users|Completed||N/A|263|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 23:25:38.810595|2018-05-31 23:25:38.810595
NCT01189526|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2010-08-25|2010-08-25|2010-08-26|Estimate|||||||2010-08-25|2010-08-26|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|August 2011|Anticipated|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)|A Randomized Trial Comparing Intravitreal Ranibizumab and Macular Laser Photocoagulation for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion|Unknown status|Recruiting|Phase 3|60|Anticipated|Seoul Retina Investigator Group||2|||f||||t||||||||||2018-05-31 23:25:38.874705|2018-05-31 23:25:38.874705
NCT01189513|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-02-17|2010-08-25|2010-08-26|Estimate|||||||2012-02-17|2012-02-20|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||SCH-900105 in Recurrent Glioblastoma|A Phase I Evaluation of SCH 900105 With Correlative Tissue Studies in the Treatment of Adult Patients With Recurrent Glioblastoma|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Sponsor decision.|f||||f||||||||||2018-05-31 23:25:39.059883|2018-05-31 23:25:39.059883
NCT01189500|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2011-09-09||2011-11-01|2010-08-25|2010-08-26|Estimate|2011-09-09|2011-10-17|Estimate||||2011-11-01|2011-11-07|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects|An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Tamoxifen When Co-Administered In Healthy Post-Menopausal Female Subjects|Completed||Phase 4|30|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:25:39.19255|2018-05-31 23:25:39.19255
NCT01189487|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2012-04-19||2012-07-09|2010-08-25|2010-08-26|Estimate|2012-04-19|2012-05-18|Estimate||||2012-07-09|2012-07-13|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)|A Multicenter, Unblinded, Non-Comparative Study Of Unasyn-S 12 G/Day Evaluating The Safety And Efficacy In Japanese Adult Subjects With Community Acquired Pneumonia|Completed||Phase 3|47|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:25:40.020426|2018-05-31 23:25:40.020426
NCT01189474|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2012-10-02|2010-08-25|2010-08-26|Estimate|||||||2012-10-02|2012-10-03|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ESPOIR Ext||Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases|Phase IV Multicentric Study, 140 Patients Suffering of Meibomian Glands Dysfunction.|Completed||Phase 4|104|Actual|Laboratoires Thea|||||f||||f||||||||||2018-05-31 23:25:40.272282|2018-05-31 23:25:40.272282
NCT01189461|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2013-06-27||2013-06-27|2010-08-25|2010-08-26|Estimate|2013-06-27|2013-09-06|Estimate||||2013-06-27|2013-09-06|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema|An Open Label, One Year, Non-Comparative Study To Evaluate The Safety And Tolerability Of Intravitreous Pegaptanib Sodium In Patients With Diabetic Macular Edema|Completed||Phase 3|46|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:25:40.371379|2018-05-31 23:25:40.371379
NCT01189448|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2016-09-28|2010-08-25|2010-08-26|Estimate|||||||2016-09-28|2016-09-29|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|July 2014|Actual|2014-07-31||Interventional|TOXOGEST||Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy|Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy|Completed||Phase 3|149|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 23:25:40.625722|2018-05-31 23:25:40.625722
NCT01188642|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate|March 2009||2009-03-31|August 2010|2010-08-31||||June 2009|Actual|2009-06-30||Observational|OBAPA||Effects of Physical Training and Nutrition Education on Adipocytokines in Severely Obese Teenagers||Completed|||32||Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 23:25:53.689466|2018-05-31 23:25:53.689466
NCT01189435|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2015-04-07||2015-10-17|2010-08-25|2010-08-26|Estimate|2015-04-07|2015-04-21|Estimate||||2015-10-17|2015-11-18|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib|A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib|Terminated||Phase 2|2|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||t||||||||||2018-05-31 23:25:40.71896|2018-05-31 23:25:40.71896
NCT01189422|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2015-09-22|2010-08-25|2010-08-26|Estimate|||||||2015-09-22|2015-09-24|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SUBCUE||Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Teplizumab (MGA031) in Adults With Type 1 Diabetes Mellitus|Terminated||Phase 1|1|Actual|MacroGenics||2|||f||||f||||||||||2018-05-31 23:25:40.857296|2018-05-31 23:25:40.857296
NCT01189409|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-12-21|2010-08-25|2010-08-26|Estimate|||||||2017-12-21|2017-12-26|Actual|June 2010||2010-06-30|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients|A Randomized, Double Blind, Double-dummy, 2-treatment, 2-period Crossover Comparison of Sennosides and Polyethylene Glycol in Treatment of Opioid-induced Constipation in Outpatients With Cancer|Suspended||Phase 4|64|Actual|British Columbia Cancer Agency||2||This study has been suspended because of staffing issues and pending review.|f||||t||||||||No||2018-05-31 23:25:40.914036|2018-05-31 23:25:40.914036
NCT01189396|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24||2017-04-17|2017-06-27|2010-08-25|2010-08-26|Estimate||||2017-05-18|2017-05-19|Actual|2017-06-27|2017-07-02|Actual|July 2010||2010-07-31|June 2017|2017-06-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006|A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients|Completed||Phase 2|27|Actual|Amphastar Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 23:25:40.994301|2018-05-31 23:25:40.994301
NCT01189383|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2016-12-20|2010-08-25|2010-08-26|Estimate|||||||2016-12-20|2016-12-22|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma|IL15-DC Vaccine in Patients With High Risk Melanoma - Exploratory Phase I/II Trial|Completed||Phase 1/Phase 2|20|Actual|Baylor Research Institute||1|||f||||t||||||||||2018-05-31 23:25:41.072625|2018-05-31 23:25:41.072625
NCT01189370|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2017-01-19||2017-04-26|2010-08-25|2010-08-26|Estimate|2017-04-26|2017-06-01|Actual||||2017-04-26|2017-06-01|Actual|June 2008||2008-06-30|April 2017|2017-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer|A Phase II Study of the Efficacy and Tolerability of the Dose Escalation of Sorafenib in Advanced Renal Cell Cancer|Completed||Phase 2|25|Actual|University of Kansas Medical Center||1|||f||||t||||||||No||2018-05-31 23:25:41.163333|2018-05-31 23:25:41.163333
NCT01189357|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2011-07-13|2010-08-25|2010-08-26|Estimate|||||||2011-07-13|2011-07-14|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Revision Meniscal Transplants; Lateral and Medial|Revision Meniscal Transplants; Lateral and Medial|Completed|||19|Actual|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 23:25:41.450494|2018-05-31 23:25:41.450494
NCT01189344|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-25|2010-08-25|2010-08-26|Estimate|||||||2010-08-25|2010-08-26|Estimate|September 2007||2007-09-30|June 2007|2007-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|RYS||Levothyroxine (L-T4) Absorption After Bariatric Surgery|Levothyroxine Absorption in Morbidly Obese Patients Before and After Roux-en-Y Bariatric Surgery|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:25:41.505243|2018-05-31 23:25:41.505243
NCT01189331|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-15|||2013-12-01|2010-08-25|2010-08-26|Estimate|||||||2013-12-01|2013-12-03|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|||CT Coronary Angiography and Computational Fluid Dynamics|Non-invasive Functional Assessment of Coronary Stenoses Using CT Coronary Angiography and Computational Fluid Dynamics|Unknown status|Recruiting|N/A|300|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 23:25:41.571645|2018-05-31 23:25:41.571645
NCT01189318|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2015-08-05|2010-08-25|2010-08-26|Estimate|||||||2015-08-05|2015-08-07|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder|Effects of Seroquel XR (Quetiapine Fumarate Extended-Release) on Sleep Architecture in Patients With Major Depressive Disorder|Withdrawn||Phase 2|0|Actual|Ewha Womans University||2|||f||||t||||||||||2018-05-31 23:25:41.637981|2018-05-31 23:25:41.637981
NCT01189305|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2015-03-19|2010-08-25|2010-08-26|Estimate|||||||2015-03-19|2015-03-23|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|CPW-D||Behavioral Couples Therapy for Female Drug-Abusing Patients|Behavioral Couples Therapy for Female Drug-Abusing Patients|Completed||Phase 2|185|Actual|Harvard University||2|||f||||f||||||||||2018-05-31 23:25:41.696963|2018-05-31 23:25:41.696963
NCT01189292|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2015-02-26||2015-06-29|2010-08-25|2010-08-26|Estimate|2015-06-29|2015-07-07|Estimate||||2015-06-29|2015-07-07|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|tPONV||Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery|Preoperative Single-dose Steroid Application for the Treatment of Nausea and Vomiting After Thyroid Surgery|Completed||Phase 3|152|Actual|Cantonal Hospital of St. Gallen|all patients received a bilateral superficial cervical plexus block during surgery which could explain the very low postoperative pain scores compared to other similar studies|2|||f||||f||||||||||2018-05-31 23:25:41.790381|2018-05-31 23:25:41.790381
NCT01189279|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-06-24||2013-06-24|2010-08-25|2010-08-26|Estimate|2013-06-24|2013-08-30|Estimate||||2013-06-24|2013-08-30|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia||Completed||Phase 1|42|Actual|Allergan||3|||f||||f||||||||||2018-05-31 23:25:42.241298|2018-05-31 23:25:42.241298
NCT01189266|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2018-05-24|2010-08-25|2010-08-26|Estimate|||||||2018-05-24|2018-05-25|Actual|August 9, 2010|Actual|2010-08-09|May 2018|2018-05-31||||November 30, 2020|Anticipated|2020-11-30||Interventional|||Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma|A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)|Active, not recruiting||Phase 1/Phase 2|80|Anticipated|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-05-31 23:25:42.556274|2018-05-31 23:25:42.556274
NCT01189253|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2014-08-07|2010-08-25|2010-08-26|Estimate|||||||2014-08-07|2014-08-08|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|June 2013|Actual|2013-06-30||Interventional|||Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma|TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma|Terminated||Phase 2/Phase 3|133|Actual|European Organisation for Research and Treatment of Cancer - EORTC||3||"Results of step1: none of the experimental arms fulfills expectations and the study will not~   continue as a phase III."|||||||||||||||2018-05-31 23:25:42.948529|2018-05-31 23:25:42.948529
NCT01189240|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2015-05-05||2015-11-13|2010-08-25|2010-08-26|Estimate|2015-06-22|2015-07-14|Estimate||||2015-11-13|2015-12-14|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|January 2013|Actual|2013-01-31||Interventional||1 pt not eligible for study and hence was not included in the analytical analysis|RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma|Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma|Terminated||Phase 1/Phase 2|13|Actual|National Cancer Institute (NCI)|This is Phase 1/Phase 2 Study. It closed prematurely by Roche, study still in Phase 1. Roche halted pt enrollment in ALL clinical trials w/ RO4929097 & cease production of drug & development. Phase 2 of this study was never activated.|7||Company decided to stop development of drug - 7/31/12|f||||t||||||||||2018-05-31 23:25:43.130115|2018-05-31 23:25:43.130115
NCT01189227|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-02-05||2013-05-08|2010-08-25|2010-08-26|Estimate|2013-02-05|2013-03-15|Estimate||||2013-05-08|2013-05-10|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery|A Phase III Study Evaluating the Role of Perioperative Chemotherapy in Patients With Potentially Resectable Hepatic Colorectal Metastases|Terminated||Phase 3|9|Actual|NSABP Foundation Inc||2||The study was terminated due to low accrual.|f||||t||||||||||2018-05-31 23:25:43.503055|2018-05-31 23:25:43.503055
NCT01189214|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-02-27|2010-08-25|2010-08-26|Estimate|||||||2013-02-27|2013-02-28|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|MM opioid||Psychopharmacotherapy in Multiple Substances Abuse|Psychopharmacotherapy in Multiple Substances Abuse / Dependence - the Pharmacological and Immunological Approach to the New Indication of Memantine|Completed||Phase 3|200|Actual|National Cheng-Kung University Hospital||1|||f||||t||||||||||2018-05-31 23:25:44.091717|2018-05-31 23:25:44.091717
NCT01189201|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2015-03-10||2015-03-10|2010-08-25|2010-08-26|Estimate|2015-03-10|2015-03-19|Estimate||||2015-03-10|2015-03-19|Estimate|August 2010||2010-08-31|March 2015|2015-03-31||||November 2010|Actual|2010-11-30||Interventional|||Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food|Relative Bioavailability Investigations of a 25 mg BI 10773 / 5 mg Linagliptin Fixed Dose Combination (FDC) Tablet (Formulation A1) Including the Comparison With Its Mono-components, the Comparison With a Second FDC Tablet (Formulation A3), and the Investigation of Food (an Open-label, Randomised, Single Dose, Crossover, Phase I Trial in Healthy Male and Female Volunteers)|Completed||Phase 1|42|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:25:44.174504|2018-05-31 23:25:44.174504
NCT01189188|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2015-03-25|2010-08-25|2010-08-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Ultrasound Guidance for Radial Arterial Blood Sampling|Ultrasound Guidance for Radial Arterial Blood Sampling|Completed||N/A|74|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 23:25:44.815537|2018-05-31 23:25:44.815537
NCT01189175|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2013-10-31|2010-08-25|2010-08-26|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2010||2010-08-31|October 2013|2013-10-31||||September 2010|Actual|2010-09-30||Interventional|||Study in Healthy Male Subjects to Investigate Whether Ketoconazole Affects Plasma Exposure of BI 113823|Relative Bioavailability of a Single Oral Dose of BI 113823 (50 mg qd) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Bid) in Healthy Male Volunteers (an Open Label, Two Periods, Fixed-sequence, Clinical Phase I Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:25:44.888104|2018-05-31 23:25:44.888104
NCT01189162|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2015-08-11|2010-08-25|2010-08-26|Estimate|||||||2015-08-11|2015-08-13|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||High Flow Nasal Cannula (HFNC) Versus Nasal Intermittent Mandatory Ventilation (NIMV)for Respiratory Distress Syndrome (RDS): a Randomized, Controlled, Prospective Study|High Flow Nasal Cannula Versus Nasal Intermittent Mandatory Ventilation for Respiratory Distress Syndrome: a Randomized, Controlled, Prospective Study|Unknown status|Recruiting|N/A|80|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||||2018-05-31 23:25:44.974372|2018-05-31 23:25:44.974372
NCT01189149|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-02-05|2010-08-25|2010-08-26|Estimate|||||||2013-02-05|2013-02-06|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Intravenous Fluids Versus Naso/Orogastric-tube Feeding in Hospitalized Infants With Bronchiolitis|Intravenous Fluids vs. Naso/Orogastric-tube Feeding in Hospitalized Infants With Acute Viral Bronchiolitis: a Randomized, Controlled, Prospective Clinical Trial|Completed||N/A|35|Actual|Bnai Zion Medical Center||2|||f||||f||||||||||2018-05-31 23:25:45.053706|2018-05-31 23:25:45.053706
NCT01189136|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2016-01-08||2017-01-09|2010-08-25|2010-08-26|Estimate|2016-10-03|2016-11-23|Estimate||||2017-01-09|2017-02-23|Actual|July 2006||2006-07-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PTNS||Treatment for Acute Postoperative Voiding Dysfunction|Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of Acute Postoperative Voiding Dysfunction|Completed||N/A|84|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||No|No plans to make IPD available|2018-05-31 23:25:45.123419|2018-05-31 23:25:45.123419
NCT01189123|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|2014-01-17||2014-04-03|2010-08-24|2010-08-26|Estimate|2014-01-17|2014-03-03|Estimate||||2014-04-03|2014-04-24|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|CMI||Cell Mediated Immunity in Older Adults|Evaluation of Cell-mediated Immunity and Antibody Response to Influenza Vaccination and Correlates of Protection in Seniors|Completed||N/A|105|Actual|Vanderbilt University|Due to cost and time limitations, a random sample from each treatment group were pulled for CMI testing. Hence not all samples were tested.|2|||f||||f||||||||||2018-05-31 23:25:45.337028|2018-05-31 23:25:45.337028
NCT01188629|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2015-11-16|2010-08-24|2010-08-25|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2007||2007-07-31|November 2015|2015-11-30|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|PHP||Conversational IT for Better, Safer Pediatric Primary Care|The Personal Health Care Partner Project, Conversational IT for Better, Safer Pediatric Primary Care|Completed||Phase 2|475|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 23:25:53.742982|2018-05-31 23:25:53.742982
NCT01189110|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2013-09-30||2015-04-06|2010-08-24|2010-08-26|Estimate|2014-03-18|2014-04-15|Estimate||||2015-04-06|2015-04-28|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional||Demographic data, smoking history, fagerstrom nicotine dependence, stage of change, PHQ-9, Percieved stress scale, Minnesota withdrawal scale|Auriculotherapy for Smoking Cessation: Pilot|Auriculotherapy for Smoking Cessation|Completed||N/A|125|Actual|VA Office of Research and Development|"It is possible that the pressure alone applied to these points provided a therapeutic effect and therefore was not a true placebo.~Other stimulation frequencies or intensities may have produced a different outcome condition."|2|||f||||t||||||||||2018-05-31 23:25:45.542278|2018-05-31 23:25:45.542278
NCT01189097|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-25|2010-08-25|2010-08-26|Estimate|||||||2010-08-25|2010-08-26|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|DM||Combined Therapy of Methadone and Dextromethrophan|Combined Therapy of Methadone and Dextromethrophan: A Novel Strategy for the Treatment of Opioid Dependence|Unknown status|Recruiting|Phase 3|1500|Anticipated|National Cheng-Kung University Hospital||1|||f||||t||||||||||2018-05-31 23:25:45.732719|2018-05-31 23:25:45.732719
NCT01189084|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2011-07-12|2010-08-24|2010-08-26|Estimate|||||||2011-07-12|2011-07-13|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|||||Observational|||Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease|An Observational Study to the Patients With Alzheimer's Disease Who Previously Received UB311-Treatment in the V118-AD Trial|Completed|||14|Actual|United Biomedical|||1||f||||f||||||Samples Without DNA|"~     Periodic blood samples collected for serum and measurement of anti-Amyloid-beta antibody~     levels.~   "|||2018-05-31 23:25:45.879589|2018-05-31 23:25:45.879589
NCT01189071|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2016-09-23||2016-11-18|2010-08-24|2010-08-26|Estimate|2016-11-18|2016-11-21|Estimate||||2016-11-18|2016-11-21|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Three participants were recruited to the study, but no data were collected or analyzed as the author of the study left the institution and the study was terminated.|Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain|Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain|Terminated||N/A|3|Actual|University of Missouri-Columbia|Three participants were recruited to the study, but no data were collected or analyzed as the author of the study left the institution and the study was terminated.|2||Co-Investigator left institution. No data analysis occurred.|f||||f||||||||Undecided||2018-05-31 23:25:45.954027|2018-05-31 23:25:45.954027
NCT01189058|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2013-10-21|2010-08-24|2010-08-26|Estimate|||||||2013-10-21|2013-10-23|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|PLASTIC CHAMPS||Modulation of Brain Plasticity After Perinatal Stroke|Modulation of Brain Plasticity After Perinatal Stroke: The PLASTIC CHAMPS Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|64|Anticipated|University of Calgary||4|||f||||t||||||||||2018-05-31 23:25:46.115207|2018-05-31 23:25:46.115207
NCT01189045|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2017-05-08|2010-08-24|2010-08-26|Estimate|||||||2017-05-08|2017-05-10|Actual|September 2010||2010-09-30|May 2017|2017-05-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Understanding Changes in Heart Function After Exercise in People With Stroke|Beyond VO2peak: Understanding Exercise-induced Changes in Cardiovascular Function After Stroke|Completed||N/A|60|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:25:46.21163|2018-05-31 23:25:46.21163
NCT01189032|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2014-05-23||2014-08-08|2010-08-24|2010-08-26|Estimate|2014-07-16|2014-08-08|Estimate||||2014-08-08|2014-08-13|Estimate||||August 2014|2014-08-31||||July 2006|Actual|2006-07-31||Interventional|||Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye|Dose-Response Study of DE-089 Ophthalmic Solution in Patients With Dry Eye -Late Phase II Confirmatory Study-|Completed||Phase 2|320|Actual|Santen Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 23:25:46.280073|2018-05-31 23:25:46.280073
NCT01189019|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2016-03-28|2010-08-25|2010-08-26|Estimate|||||||2016-03-28|2016-03-29|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|HiPED||HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration|High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study|Terminated||Phase 2|40|Actual|Pacific Eye Associates||2||Drug dose became unavailable|f||||t||||||||Yes|Presented at medical conferences, manuscript in preparation|2018-05-31 23:25:46.466168|2018-05-31 23:25:46.466168
NCT01189006|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-02-27|2010-08-24|2010-08-26|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2005||2005-01-31|August 2010|2010-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|DM||Add-On Therapy to Risperidonein Schizophrenia|A Double-blind, Placebo-Controlled, Randomized Study of the Efficacy of Dextromethorphan as Add-On Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia|Completed||Phase 2/Phase 3|161|Actual|National Cheng-Kung University Hospital||1|||f||||t||||||||||2018-05-31 23:25:46.535233|2018-05-31 23:25:46.535233
NCT01188993|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2013-10-31|2010-08-25|2010-08-26|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2011||2011-01-31|August 2010|2010-08-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|HEMOSEPSIS||Transpulmonary Thermodilution and Transesophageal Echocardiography in Early Septic Shock|Hemodynamic Assessment With Transpulmonary Thermodilution and Transesophageal Echocardiography in Patients With Early Septic Shock|Unknown status|Recruiting|Phase 3|153|Anticipated|University Hospital, Limoges||1|||f||||t||||||||||2018-05-31 23:25:46.592467|2018-05-31 23:25:46.592467
NCT01188980|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2016-04-21|2010-08-25|2010-08-26|Estimate|||||||2016-04-21|2016-04-22|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|EIBS in BE||Early Increase in Blood Supply in Patients With Barrett's Esophagus|Detectable Esophageal Early Increase in Blood Supply (EIBS) in Patients With Barrett's Esophagus|Completed|||90|Actual|Mayo Clinic|||3||f||||||||||||||2018-05-31 23:25:46.652008|2018-05-31 23:25:46.652008
NCT01188967|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2015-04-07||2017-01-09|2010-08-24|2010-08-26|Estimate|2016-11-10|2017-01-09|Estimate||||2017-01-09|2017-02-23|Actual|August 2010||2010-08-31|January 2017|2017-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention|A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of the Selective D3 Antagonist, GSK598809, Added to CBT and NRT for Smoking Cessation and Prevention of Very Early Relapse to Smoking|Completed||Phase 2|84|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:25:46.703238|2018-05-31 23:25:46.703238
NCT01188616|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate|July 2005||2005-07-31|August 2010|2010-08-31||||May 2010|Actual|2010-05-31||Interventional|HEAT||IT-Supported Early Treatment Of Childhood Overweight|Automated Self-management System to Promote Healthy Eating and Activity in Overweight Children|Completed||Phase 2|||Boston Medical Center|||||f||||t||||||||||2018-05-31 23:25:53.798448|2018-05-31 23:25:53.798448
NCT01188954|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-04-10|2010-08-25|2010-08-26|Estimate|||||||2015-04-10|2015-04-14|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Doxycycline Versus Standard Care to Prevent Seroma Formation|Randomized Clinical Trial of Doxycycline Versus Standard Care to Prevent Seroma Formation at Femoral Artery/Vein Cannulation Site After Cardiopulmonary By-Pass|Withdrawn||N/A|0|Actual|Northwell Health||2||The recruitment process was slower than expected.|f||||t||||||||||2018-05-31 23:25:47.850634|2018-05-31 23:25:47.850634
NCT01188941|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2017-04-17|2010-08-24|2010-08-26|Estimate|||||||2017-04-17|2017-04-19|Actual|August 2010||2010-08-31|April 2017|2017-04-30|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|Sizanani||Linkage and Retention: A Randomized Trial to Optimize HIV/TB Care in South Africa|Linkage and Retention: A Randomized Trial to Optimize HIV/TB Care in South Africa|Completed||N/A|1899|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:25:47.920674|2018-05-31 23:25:47.920674
NCT01188928|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2013-01-21|2013-01-11|2016-12-08|2010-08-25|2010-08-26|Estimate|2013-02-28|2013-04-09|Estimate|2013-01-11|2013-01-14|Estimate|2016-12-08|2017-02-02|Estimate|September 2010||2010-09-30|December 2016|2016-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)|A Phase 3 Study Comparing Once Daily Treatment With Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension With Betamethasone 0.5 mg/g (as Dipropionate) in the Topical Suspension Vehicle, Calcipotriol 50 mcg/g in the Topical Suspension Vehicle and the Topical Suspension Vehicle Alone in Subjects With Psoriasis Vulgaris on Non-scalp Regions of the Body (Trunk and/or Limbs)|Completed||Phase 3|1152|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 23:25:48.051375|2018-05-31 23:25:48.051375
NCT01188915|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2016-10-13|2010-08-25|2010-08-26|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|July 2026|Anticipated|2026-07-31|September 2016|Actual|2016-09-30||Interventional|PROPER||Personalised Program for Women Treated for Hodgkin Disease|Personalised Program for Women Treated for Hodgkin Disease : Risk Evaluation of Breast Cancer and Intensive Screening Program for Women at High Risk of Breast Cancer. PROPER/IPC 2010-001|Terminated||N/A|51|Actual|Institut Paoli-Calmettes||1||Sponsor decision|f||||f||||||||||2018-05-31 23:25:48.631111|2018-05-31 23:25:48.631111
NCT01188902|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2013-01-07|2010-08-25|2010-08-26|Estimate|||||||2013-01-07|2013-01-08|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women|The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women|Completed||N/A|60|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 23:25:48.714114|2018-05-31 23:25:48.714114
NCT01188889|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|||2015-05-14|2010-08-25|2010-08-26|Estimate|||||||2015-05-14|2015-05-15|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.|An Open Label, Time-To-Event Continuous Reassessment Method, Phase I/II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib (Gleevec) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) With Persistent Molecular Disease.|Withdrawn||Phase 1/Phase 2|0|Actual|University of Michigan Cancer Center||||Unable to obtain sufficient funding.|f||||t||||||||||2018-05-31 23:25:48.783971|2018-05-31 23:25:48.783971
NCT01188876|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2017-11-22||2017-12-20|2010-08-24|2010-08-26|Estimate|2017-12-20|2018-01-19|Actual||||2017-12-20|2018-01-19|Actual|August 2010||2010-08-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer|Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer|Completed||Phase 1/Phase 2|50|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:25:48.902396|2018-05-31 23:25:48.902396
NCT01188863|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2011-03-29|2010-08-24|2010-08-26|Estimate|||||||2011-03-29|2011-03-30|Estimate|September 2010||2010-09-30|March 2011|2011-03-31||||October 2010|Actual|2010-10-31||Interventional|||Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Open-Label, Three-Way Crossover Study of Two Oral Formulations of LX4211 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|15|Anticipated|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 23:25:49.220435|2018-05-31 23:25:49.220435
NCT01188850|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2011-12-08|2010-08-25|2010-08-26|Estimate|||||||2011-12-08|2011-12-12|Estimate|July 2010||2010-07-31|December 2011|2011-12-31||||October 2011|Actual|2011-10-31||Interventional|||Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100|Phase I, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Previously Immunized With VGX-3100|Completed||Phase 1|14|Actual|Inovio Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:25:49.296193|2018-05-31 23:25:49.296193
NCT01188837|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2012-08-08|2010-08-24|2010-08-26|Estimate|||||||2012-08-08|2012-08-09|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparing Manipulation, Rehabilitation and Combination of the Two in the Treatment of Knee Osteoarthritis|The Relative Effectiveness of Three Full Kinetic Chain Treatment Protocols for Osteoarthritis of the Knee: Manual Therapy, Rehabilitation and a Combination Thereof|Completed||N/A|144|Actual|Cleveland Chiropractic College||3|||f||||f||||||||||2018-05-31 23:25:49.353959|2018-05-31 23:25:49.353959
NCT01188824|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-09-30|2010-08-24|2010-08-26|Estimate|||||||2013-09-30|2013-10-07|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)|The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)|Completed||Phase 4|801|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 23:25:49.423087|2018-05-31 23:25:49.423087
NCT01188811|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-25|2016-06-24||2016-12-07|2010-08-25|2010-08-26|Estimate|2016-12-07|2017-02-02|Estimate||||2016-12-07|2017-02-02|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)|Lipoic Acid for Neuroprotection in Secondary Progressive MS|Completed||Phase 2/Phase 3|54|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 23:25:49.603272|2018-05-31 23:25:49.603272
NCT01188603|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2011-05-04||2014-05-15|2010-08-24|2010-08-25|Estimate|2012-03-14|2012-04-10|Estimate||||2014-05-15|2014-05-21|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)|Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder|Completed||Phase 1|24|Actual|Sprout Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 23:25:53.965905|2018-05-31 23:25:53.965905
NCT01188798|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2013-02-12||2013-03-14|2010-08-24|2010-08-25|Estimate|2013-02-12|2013-03-14|Estimate||||2013-03-14|2013-03-21|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies|Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies|Completed||Phase 3|6|Actual|St. Jude Children's Research Hospital|This study was terminated prematurely. The Data Safety and Monitoring Board (DSMB) requested major scientific study changes. This was deemed infeasible by institutional leadership and study was terminated. Therefore, no final results exist to report.|2|||f||||t||||||||||2018-05-31 23:25:50.072203|2018-05-31 23:25:50.072203
NCT01188785|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2014-11-18|2010-08-24|2010-08-25|Estimate|||||||2014-11-18|2014-11-19|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas|Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas|Completed||Phase 1|15|Actual|Silenseed Ltd|||||f||||t||||||||||2018-05-31 23:25:50.351152|2018-05-31 23:25:50.351152
NCT01188772|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|2014-01-06|2012-05-16|2014-04-02|2010-08-24|2010-08-25|Estimate|2014-01-06|2014-02-19|Estimate|2012-05-16|2012-05-21|Estimate|2014-04-02|2014-04-21|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|April 2011|Actual|2011-04-30||Interventional||Safety Analysis Set: participants who were randomized and at least one dose of study drug|Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients|A Multi-center, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1, and an Open Label Assessment of PSI-7977 in Patients With HCV Genotypes 2 or 3|Completed||Phase 2|147|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 23:25:50.483819|2018-05-31 23:25:50.483819
NCT01188759|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2012-05-10|2010-08-24|2010-08-25|Estimate|||||||2012-05-10|2012-05-11|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects|A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years|Withdrawn||Phase 3|0|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:25:51.411025|2018-05-31 23:25:51.411025
NCT01188746|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2017-09-05|2010-08-24|2010-08-25|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2010||2010-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites|Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites|Active, not recruiting||N/A|50|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:25:51.557637|2018-05-31 23:25:51.557637
NCT01188733|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate|June 1998||1998-06-30|August 2010|2010-08-31|December 2000|Actual|2000-12-31|July 2000|Actual|2000-07-31||Interventional|||Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis|Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis Hepatic Hemodynamic Responses to Long-acting Octreotide in Patients With Cirrhosis|Completed||Phase 1/Phase 2|39|Actual|Mayo Clinic||3|||f||||t||||||||||2018-05-31 23:25:51.641881|2018-05-31 23:25:51.641881
NCT01188720|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2015-05-26|2010-08-24|2010-08-25|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|January 2012|Actual|2012-01-31||Interventional|SHAPE||Sexual Health on Antidepressants Through Physical Exercise|Sexual Health on Antidepressants Through Physical Exercise|Completed||N/A|52|Actual|University of Texas at Austin||3|||f||||f||||||||||2018-05-31 23:25:51.709263|2018-05-31 23:25:51.709263
NCT01188707|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2011-08-03|2010-08-24|2010-08-25|Estimate|||||||2011-08-03|2011-08-04|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|August 2012|Anticipated|2012-08-31|March 2012|Anticipated|2012-03-31||Interventional|||A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer|A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer|Terminated||Phase 1/Phase 2|5|Actual|Herlev Hospital||1||Dose over MTD reached|f||||t||||||||||2018-05-31 23:25:51.787706|2018-05-31 23:25:51.787706
NCT01188694|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2017-01-06||2017-05-16|2010-08-24|2010-08-25|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|September 2009||2009-09-30|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|HELP||Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)|Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)|Completed||Phase 2|42|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 23:25:51.881078|2018-05-31 23:25:51.881078
NCT01188681|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2016-05-17||2017-06-26|2010-08-24|2010-08-25|Estimate|2016-11-08|2017-01-06|Estimate||||2017-06-26|2017-06-28|Actual|September 2010||2010-09-30|June 2017|2017-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||patients with relapsed chronic lymphocytic leukemia|Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia|A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|79|Actual|Aptevo Therapeutics||4|||f||||t||||||||No||2018-05-31 23:25:52.179073|2018-05-31 23:25:52.179073
NCT01188668|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2011-09-09||2011-11-01|2010-08-24|2010-08-25|Estimate|2011-09-09|2011-10-17|Estimate||||2011-11-01|2011-11-07|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects|An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects|Completed||Phase 4|38|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:25:52.974561|2018-05-31 23:25:52.974561
NCT01188655|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2011-03-29||2011-09-08|2010-08-24|2010-08-25|Estimate|2011-03-29|2011-04-26|Estimate||||2011-09-08|2011-09-12|Estimate|May 2008||2008-05-31|September 2011|2011-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis|Observational Non-Interventional Study With Enbrel in Patients With Ankylosing Spondylitis|Completed|||89|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:25:53.435563|2018-05-31 23:25:53.435563
NCT01188590|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2016-01-11|2010-08-24|2010-08-25|Estimate|||||||2016-01-11|2016-01-13|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Transcutaneous Carbon Dioxide Monitoring Post Cardiac Surgery: Incidence and Severity Resp Insufficiency|Pilot Study: Transcutaneous Carbon Dioxide Monitoring Post Cardiac Surgery: Incidence and Severity of Respiratory Insufficiency|Completed|||50|Actual|Baylor Research Institute|||1||f||||f||||||||||2018-05-31 23:25:54.23503|2018-05-31 23:25:54.23503
NCT01188577|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2014-10-21||2017-06-27|2010-08-24|2010-08-25|Estimate|2014-10-21|2014-10-24|Estimate||||2017-06-27|2017-07-25|Actual|August 2010||2010-08-31|June 2017|2017-06-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics|Epinephrine Inhalation Aerosol USP, an HFA-MDI CLINICAL STUDY-B2 FOR ASSESSMENT OF PHARMACOKINETICS (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)|Completed||Phase 1/Phase 2|23|Actual|Amphastar Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:25:54.397366|2018-05-31 23:25:54.397366
NCT01188564|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2015-06-10|2013-07-02|2015-08-03|2010-08-24|2010-08-25|Estimate|2015-08-03|2015-08-07|Estimate|2013-07-02|2013-07-09|Estimate|2015-08-03|2015-08-07|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks|A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE|Completed||Phase 3|75|Actual|Pharming Technologies B.V.||2|||f||||f||||||||||2018-05-31 23:25:54.750693|2018-05-31 23:25:54.750693
NCT01188551|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2013-06-26||2014-02-17|2010-08-24|2010-08-25|Estimate|2014-02-17|2014-04-01|Estimate||||2014-02-17|2014-04-01|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement|Pain Management Following Myringotomy and Tube Placement: Intranasal Dexmedetomidine Versus Fentanyl|Completed||Phase 2/Phase 3|100|Actual|Nationwide Children's Hospital||4|||f||||f||||||||||2018-05-31 23:25:55.031199|2018-05-31 23:25:55.031199
NCT01188538|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2011-06-09||2016-03-15|2010-08-24|2010-08-25|Estimate|2011-06-09|2011-07-07|Estimate||||2016-03-15|2016-04-14|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel|Anti P. Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel in the Treatment of Subjects With Acne Vulgaris|Completed||Phase 4|40|Actual|Galderma||2|||f||||f||||||||||2018-05-31 23:25:55.339187|2018-05-31 23:25:55.339187
NCT01188525|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2012-05-14|2010-08-24|2010-08-25|Estimate|||||||2012-05-14|2012-05-15|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CIME1||Pharmacokinetic Study to Characterize Individual Metabolic Profile|Pharmacokinetic of Ten Parent Drugs and Their Metabolits in Order to Characterise Individual Metabolic Profile|Completed||Phase 1|10|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-05-31 23:25:55.543839|2018-05-31 23:25:55.543839
NCT01188512|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2012-01-27|2010-08-24|2010-08-25|Estimate|||||||2012-01-27|2012-01-31|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine|A Phase 1, Single Centre, Dose-escalating, Placebo-controlled Study of a Genetically Modified B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Male Volunteers|Completed||Phase 1|48|Actual|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||t||||||||||2018-05-31 23:25:55.621339|2018-05-31 23:25:55.621339
NCT01188499|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|2016-04-21||2016-04-21|2010-08-23|2010-08-25|Estimate|2016-04-21|2016-05-30|Estimate||||2016-04-21|2016-05-30|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1/Phase 2|176|Actual|TetraLogic Pharmaceuticals||5|||f||||f||||||||||2018-05-31 23:25:55.77611|2018-05-31 23:25:55.77611
NCT01188486|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2018-04-13|2010-08-23|2010-08-25|Estimate|||||||2018-04-13|2018-04-17|Actual|August 2010||2010-08-31|April 2018|2018-04-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Pulmonary Interstitial Lymphography in Early Stage Lung Cancer|Pulmonary Interstitial Lymphography in Early Stage Lung Cancer|Terminated||N/A|12|Actual|Stanford University||1||Business decision|f||||t|f|t|f|f|f|||No||2018-05-31 23:25:57.609108|2018-05-31 23:25:57.609108
NCT01188473|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2014-12-18|2010-08-23|2010-08-25|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus|Safety and Efficacy of Early Initiation of Noninvasive Positive Pressure Ventilation in Pediatric Patients Admitted With Status Asthmaticus|Withdrawn||Phase 1|0|Actual|Southern Illinois University||2||Pilot early noninvasive ventilation on all children who met the criteria was effective.|f||||f||||||||||2018-05-31 23:25:57.704955|2018-05-31 23:25:57.704955
NCT01188460|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2017-01-20||2017-08-10|2010-08-23|2010-08-25|Estimate|2017-08-10|2018-02-19|Actual||||2017-08-10|2018-02-19|Actual|April 2010||2010-04-30|August 2017|2017-08-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||A Cognitive-Behaviour Therapy (CBT) Self-Management Approach for Insomnia in Chronic Pain: A Randomized Control Trial|A Cognitive-Behaviour Therapy (CBT) Self-Management Approach for Insomnia in Chronic Pain: A Randomized Control Trial|Completed||N/A|48|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-05-31 23:25:57.802294|2018-05-31 23:25:57.802294
NCT01188447|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2017-01-20||2017-04-26|2010-08-23|2010-08-25|Estimate|2017-04-26|2017-08-04|Actual||||2017-04-26|2017-08-04|Actual|January 2011||2011-01-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Evaluation of the Safety of C-Spine Clearance by Paramedics|Evaluation of the Safety of C-Spine Clearance by Paramedics|Completed||N/A|4034|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||No||2018-05-31 23:25:58.144643|2018-05-31 23:25:58.144643
NCT01188434|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2015-04-27|2010-08-23|2010-08-25|Estimate|||||||2015-04-27|2015-04-29|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|ITSAN||Integrating Interventions for Maternal Substance Abuse|Integrating Interventions for Maternal Substance Abuse and Child Neglect|Completed||Phase 1|31|Actual|Oregon Social Learning Center||2|||f||||f||||||||||2018-05-31 23:25:58.311008|2018-05-31 23:25:58.311008
NCT01188421|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2017-04-17||2017-06-06|2010-08-24|2010-08-25|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|October 2010||2010-10-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Medications Development for Drug Abuse Disorders|Medications Development for Drug Abuse Disorders|Completed||Phase 1/Phase 2|106|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 23:25:58.415542|2018-05-31 23:25:58.415542
NCT01188408|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-03-08|2010-08-23|2010-08-25|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2010||2010-06-30|March 2018|2018-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer|A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|INSYS Therapeutics Inc||1||Study shut-down in 12/2010 when NeoPharm merged with Insys.|f||||t||||||||||2018-05-31 23:25:58.816095|2018-05-31 23:25:58.816095
NCT01188395|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-25|Estimate|||||||2010-08-23|2010-08-25|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Bipolar Disorder With Alcoholism in Han Chinese||Unknown status|Recruiting||105|Anticipated|National Cheng-Kung University Hospital|||1||f||||t||||||||||2018-05-31 23:25:58.88382|2018-05-31 23:25:58.88382
NCT01188382|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Reference Values of Cerebrospinal Fluid Outflow Resistance and Intracranial Pressure in Healthy Elderly|Reference Values of Cerebrospinal Fluid Outflow Resistance and Intracranial Pressure in Healthy Elderly|Completed|||40|Actual|Umeå University|||1||f||||f||||||||||2018-05-31 23:25:58.948935|2018-05-31 23:25:58.948935
NCT01188369|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2012-08-03|2010-08-24|2010-08-25|Estimate|||||||2012-08-03|2012-08-06|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy|Effects of Levosimendan on Systolic Deformation and Diastolic Function in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy|Terminated||Phase 4|20|Actual|University of Aarhus||2||"Terminated prematurely due to high incidence of postoperative atrial fibrillation. The study~   has not been unblinded."|f||||t||||||||||2018-05-31 23:25:59.027138|2018-05-31 23:25:59.027138
NCT01188356|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2018-03-20|2010-08-24|2010-08-25|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2010||2010-03-31|March 2018|2018-03-31|August 31, 2017|Actual|2017-08-31|April 2015|Actual|2015-04-30||Observational|EMERALD||EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients|AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients|Completed|||4350|Actual|LivaNova|||||f||||f||||||||||2018-05-31 23:25:59.181464|2018-05-31 23:25:59.181464
NCT01188343|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2014-06-25||2014-07-25|2010-08-24|2010-08-25|Estimate|2014-07-25|2014-08-15|Estimate||||2014-07-25|2014-08-15|Estimate|August 2010||2010-08-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers|Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan.|Completed||Phase 3|542|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 23:25:59.496841|2018-05-31 23:25:59.496841
NCT01188330|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2013-10-30|2010-08-24|2010-08-25|Estimate|||||||2013-10-30|2013-10-31|Estimate|March 2010||2010-03-31|October 2013|2013-10-31||||September 2016|Anticipated|2016-09-30||Interventional|MLSP||Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival|Randomized Study Comparing the Interest of a Program of Evaluation and Geriatric Intervention on the Functional Status, Quality of the Life, and Survival of Elderly Patients With Acute Myeloid Leukaemia. MLSP/IPC 2009-003|Unknown status|Recruiting|N/A|100|Anticipated|Institut Paoli-Calmettes||2|||f||||f||||||||||2018-05-31 23:26:00.1516|2018-05-31 23:26:00.1516
NCT01188317|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2012-05-21|2010-08-24|2010-08-25|Estimate|||||||2012-05-21|2012-05-22|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|||||Interventional|||A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of Ibuprofen on Top of Multiple Doses of 150 µg Aleglitazar Once Daily on Renal Function, Renin-angiotensin System, and Pharmacokinetics of Both Compounds in Healthy Subjects|Completed||Phase 1|44|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:26:01.170476|2018-05-31 23:26:01.170476
NCT01188304|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2016-11-01|2010-08-24|2010-08-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of 150 µg Aleglitazar Once Daily in Healthy Subjects Treated With 325 mg Aspirin Once Daily on Renal Function, Renin-angiotensin System and Platelet Aggregation|Completed||Phase 1|44|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:26:01.235572|2018-05-31 23:26:01.235572
NCT01188291|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2012-03-09|2010-08-24|2010-08-25|Estimate|||||||2012-03-09|2012-03-12|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Retinal Nerve Fiber Layer Thickness Measurements in Patients With Sleep Apnea Syndrome|Retinal Nerve Fiber Layer Thickness Measurements Using Optical Coherence Tomography in Patients With Sleep Apnea Syndrome|Completed|||166|Actual|Carmel Medical Center|||1||f||||f||||||||||2018-05-31 23:26:01.299827|2018-05-31 23:26:01.299827
NCT01188278|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2016-09-28|2010-08-24|2010-08-25|Estimate|||||||2016-09-28|2016-09-30|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey|Treatment With Second Generation TYROSINE KINASE INHIBITORS (2G TKI) Post Imatinib Failure: Factors Predicting Response and Predictive Value of Response|Completed|||173|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 23:26:01.357321|2018-05-31 23:26:01.357321
NCT01188265|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-09-16|2010-08-23|2010-08-25|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|DM||Add-on Dextromethorphan in Bipolar Disorders|Dextromethorphan Enhances the Therapeutic Efficacy of Valoproate in Bipolar Disorder Patients|Completed||Phase 3|300|Actual|National Cheng-Kung University Hospital||3|||f||||t||||||||||2018-05-31 23:26:01.419751|2018-05-31 23:26:01.419751
NCT01188252|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-01-06|2010-08-24|2010-08-25|Estimate|||||||2017-01-06|2017-01-09|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies|Completed||Phase 1|112|Actual|Bayer||1|||f||||f||||||||||2018-05-31 23:26:01.501618|2018-05-31 23:26:01.501618
NCT01188239|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-01-07|2010-08-24|2010-08-25|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||A Structured Protocol to Evaluate Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette) Efficacy and Safety of a Popular Electronic Nicotine Delivery Device (E-Cigarette)|Twelve Weeks Study Investigating the Efficacy and Safety of a Widely Marketed Electronic Nicotine Delivery Device (E-Cigarette): 6 Weeks on High Dose Nicotine and 6 Weeks on Low Dose Nicotine Cartridges in Smokers|Completed|||100|Actual|Universita degli Studi di Catania|||1||f||||t||||||||||2018-05-31 23:26:01.588661|2018-05-31 23:26:01.588661
NCT01188226|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|2016-03-15||2016-05-04|2010-08-24|2010-08-25|Estimate|2016-05-04|2016-06-10|Estimate||||2016-05-04|2016-06-10|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|December 2011|Actual|2011-12-31||Interventional||Subjects that signed consent|Wear Characteristics of Denture Teeth|Evaluation of Wear Characteristics of Nano-Hybrid Denture Teeth|Terminated||N/A|10|Actual|University of California, Los Angeles||1||Enrollment difficulties and drop outs|f||||f||||||||||2018-05-31 23:26:01.778019|2018-05-31 23:26:01.778019
NCT01188213|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-21|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate||||May 2005|2005-05-31||||||||Interventional|||Efficacy of Methylsulfonylmethane Supplementation on Osteoarthritis of The Knee: A Randomized Controlled Study||Completed||N/A|||Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 23:26:02.310158|2018-05-31 23:26:02.310158
NCT01188200|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate|December 2009||2009-12-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes|Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes|Completed||Phase 3|168|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 23:26:02.36045|2018-05-31 23:26:02.36045
NCT01188187|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23||2016-10-07|2016-10-13|2010-08-24|2010-08-25|Estimate||||2016-10-11|2016-10-12|Estimate|2016-10-13|2016-10-14|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|SYNERGY||Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer|A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer|Completed||Phase 3|1022|Actual|Achieve Life Sciences||2|||f||||||||||||||2018-05-31 23:26:02.466017|2018-05-31 23:26:02.466017
NCT01188174|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2014-12-04|2010-08-24|2010-08-25|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|setric||Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure|Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure|Completed||Phase 2|26|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 23:26:02.8231|2018-05-31 23:26:02.8231
NCT01188161|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-08-23|2010-08-23|2010-08-25|Estimate|||||||2010-08-23|2010-08-25|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|Gyro||Postural Effects of Being Rotated in a Whole Body Gyroscope|The Effects of Whole Body Rotations in the Pitch and Yaw Planes on Postural Stability|Completed|||25|Actual|Carrick Institute for Graduate Studies|||1||f||||t||||||||||2018-05-31 23:26:02.923667|2018-05-31 23:26:02.923667
NCT01188148|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2013-09-16|2010-08-23|2010-08-25|Estimate|||||||2013-09-16|2013-09-17|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|MM||Series Studies of Bipolar Disorder-Valproate add-on Memantine|Series Studies of Bipolar Disorder-Valproate add-on Memantine Treatment|Completed||Phase 2/Phase 3|219|Actual|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-05-31 23:26:03.057414|2018-05-31 23:26:03.057414
NCT01188135|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2015-03-12|2010-08-24|2010-08-25|Estimate|||||||2015-03-12|2015-03-17|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|November 2014|Actual|2014-11-30|February 2013|Actual|2013-02-28||Interventional|AD_IVR||Antidepressant Adherence Via AD_IVR|Antidepressant Adherence Via Telephonic Interactive Voice Recognition (IVR)|Completed||Phase 3|6058|Actual|Kaiser Permanente||3|||f||||t||||||||||2018-05-31 23:26:03.156999|2018-05-31 23:26:03.156999
NCT01188122|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-25|Estimate|||||||2010-08-23|2010-08-25|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Optimal Endotracheal Cuff Pressure During Hospitalization in Intensive Care Units Using AnapnoGuard 100 System|Optimal Endotracheal Cuff Pressure During Hospitalization in Intensive Care Units Using AnapnoGuard 100 System|Completed||N/A|12|Actual|Hospitech Respiration||1|||f||||f||||||||||2018-05-31 23:26:03.280042|2018-05-31 23:26:03.280042
NCT01188109|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2016-06-30||2016-08-19|2010-08-23|2010-08-25|Estimate|2016-06-30|2016-08-09|Estimate||||2016-08-19|2016-09-28|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision|Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision|Terminated||Phase 2|25|Actual|Emory University|This study was limited by the small sample size and failure to accrue the 45 patients estimated to appreciate potential differences in outcomes of patients with differential ERCC1 expression.|1||Slow accrual|f||||t||||||||||2018-05-31 23:26:03.381111|2018-05-31 23:26:03.381111
NCT01188096|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2017-06-16|2010-08-23|2010-08-25|Estimate|||||||2017-06-16|2017-06-20|Actual|August 2010||2010-08-31|June 2016|2016-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|Poly-ICLC||A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas|A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas|Recruiting||Phase 2|23|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 23:26:03.598434|2018-05-31 23:26:03.598434
NCT01188083|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-11-20|2010-08-23|2010-08-25|Estimate|||||||2013-11-20|2013-11-21|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Sweet Bev||Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis|Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis|Completed||N/A|53|Actual|Emory University||2|||f||||f||||||||||2018-05-31 23:26:03.703438|2018-05-31 23:26:03.703438
NCT01188070|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2017-02-20|2010-08-24|2010-08-25|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2010||2010-01-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Caregiver Stress: Interventions to Promote Health and Wellbeing|Caregiver Stress: Interventions to Promote Health and Wellbeing|Completed||N/A|354|Actual|Emory University||3|||f||||t|f|f||||||||2018-05-31 23:26:03.775743|2018-05-31 23:26:03.775743
NCT01188057|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-25|Estimate|||||||2010-08-23|2010-08-25|Estimate|July 2006||2006-07-31|August 2010|2010-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Non-fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-05-31 23:26:03.844318|2018-05-31 23:26:03.844318
NCT01188044|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-01-05|2010-08-24|2010-08-25|Estimate|||||||2011-01-05|2011-01-06|Estimate|September 2010||2010-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Validating Accelerometers to Study Physical Activity of Toddlers|Validating the Use of Accelerometers for the Study of Physical Activity Among Young Malawian Toddlers|Completed|||56|Actual|University of Tampere|||1||f||||f||||||||||2018-05-31 23:26:03.915882|2018-05-31 23:26:03.915882
NCT01188031|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-25|Estimate|||||||2010-08-23|2010-08-25|Estimate|June 2006||2006-06-30|August 2010|2010-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions|A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-05-31 23:26:03.980363|2018-05-31 23:26:03.980363
NCT01188018|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2012-07-03|2010-08-24|2010-08-25|Estimate|||||||2012-07-03|2012-07-04|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Testing Counseling Styles to Motivate Smokers to Quit|Can Motivational Interviewing be Effective for Smoking Cessation?|Completed||Phase 3|255|Actual|University of Missouri, Kansas City||3|||f||||f||||||||||2018-05-31 23:26:04.047105|2018-05-31 23:26:04.047105
NCT01188005|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Inflammatory Mediators in Obstructive Sleep Apnoea Syndrome; Mechanisms of Production and the Effect of Long Term Antioxidants Administration|Inflammatory Mediators in Obstructive Sleep Apnoea Syndrome; Mechanisms of Production and the Effect of Long Term Antioxidants Administration|Unknown status|Recruiting|N/A|30|Anticipated|University of Athens||2|||f||||t||||||||||2018-05-31 23:26:04.111406|2018-05-31 23:26:04.111406
NCT01187992|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-24|||2010-08-24|2010-08-24|2010-08-25|Estimate|||||||2010-08-24|2010-08-25|Estimate|September 2003||2003-09-30|May 2010|2010-05-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|APRIRE||Full-dose Atorvastatin After Acute Coronary Syndrome (ACS) in Non-revascularisable Coronary Artery Disease|Full-dose Atorvastatin Versus Conventional Medical Therapy After Non-ST-elevation Acute Myocardial Infarction in Patients With Advanced Non-revascularisable Coronary Artery Disease|Terminated||Phase 3|290|Actual|San Filippo Neri General Hospital||2||Interim analysis showed significant effect in favour of full-dose atorvastatin.|f||||t||||||||||2018-05-31 23:26:04.265403|2018-05-31 23:26:04.265403
NCT01187979|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-01-18|2010-08-24|2010-08-25|Estimate|||||||2017-01-18|2017-01-19|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|RHIVA||Reducing HIV in Adolescents|A Proof of Concept Cluster Randomised Controlled Trial to Evaluate the Impact of a Cash Incentivised Prevention Intervention to Reduce HIV Infection in High School Learners in Rural KwaZulu-Natal, South Africa|Completed||Phase 2|3217|Actual|Centre for the AIDS Programme of Research in South Africa||2|||f||||f||||||||No||2018-05-31 23:26:04.347283|2018-05-31 23:26:04.347283
NCT01187966|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2010-08-23|2010-08-23|2010-08-24|Estimate|||||||2010-08-23|2010-08-24|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease|A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic|Completed||Phase 3|669|Actual|Newron Pharmaceuticals SPA||3|||f||||t||||||||||2018-05-31 23:26:04.443676|2018-05-31 23:26:04.443676
NCT01187953|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|2015-04-23||2016-04-18|2010-08-23|2010-08-24|Estimate|2015-05-12|2015-05-29|Estimate||||2016-04-18|2016-05-18|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|LCPTacro3002|The patient sample was predominantly White (76.8%) and male (65.4%).|Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx|Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant|Completed||Phase 3|543|Actual|Veloxis Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 23:26:04.627485|2018-05-31 23:26:04.627485
NCT01187940|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-24|Estimate|||||||2010-08-23|2010-08-24|Estimate|September 2010||2010-09-30|August 2010|2010-08-31||||September 2012|Anticipated|2012-09-30||Interventional|||Evaluating PEGASUS - a Group Intervention for Young People With an Autism Spectrum Disorder|Evaluating Psychoeducation for People With Autism Spectrum Disorder|Unknown status|Not yet recruiting|N/A|40|Anticipated|Institute of Child Health||2|||f||||f||||||||||2018-05-31 23:26:06.782882|2018-05-31 23:26:06.782882
NCT01187927|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2015-01-22|2010-08-23|2010-08-24|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Drug Use Investigation for Cervarix®|Drug Use Investigation for Cervarix®|Completed|||1230|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:26:07.085748|2018-05-31 23:26:07.085748
NCT01187914|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2011-09-23||2012-02-09|2010-08-23|2010-08-24|Estimate|2012-01-09|2012-01-10|Estimate||||2012-02-09|2012-02-13|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|RADAR||Effect of Structural Remodeling on Scar Formation as Assessed by DE-MRI of the Left Atrium|RADAR: Effect of Structural Remodeling on Scar Formation as Assessed by DE-MRI of the Left Atrium Following Open-Irrigation Cooled-Tip Radiofrequency Catheter Ablation of Paroxysmal Atrial Fibrillation|Completed|||40|Actual|University of Utah|The sample size was too small to see any significant relationship.||1||f||||f||||||||||2018-05-31 23:26:07.250283|2018-05-31 23:26:07.250283
NCT01187901|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2016-05-10||2016-05-10|2010-08-23|2010-08-24|Estimate|2016-05-10|2016-06-17|Estimate||||2016-05-10|2016-06-17|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|FAPEST||A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients|Genetic Events Leading to APC-Dependent Colon Cancer in High-Risk Families; a Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients|Completed||Phase 2|92|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 23:26:07.498895|2018-05-31 23:26:07.498895
NCT01187888|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2013-04-23|2010-08-23|2010-08-24|Estimate|||||||2013-04-23|2013-04-24|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PROSPERA||Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)|Terminated||Phase 3|44|Actual|Ludwig-Maximilians - University of Munich||2||"IMP used off label by phys. in pat. with PSP. Thus no more eligible patients were available for~   the study(pre-treatm.with Rasagiline=exclusion criterion"|f||||t||||||||||2018-05-31 23:26:07.954774|2018-05-31 23:26:07.954774
NCT01187875|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-03-28|2010-08-23|2010-08-24|Estimate|||||||2012-03-28|2012-03-29|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Resistant Starch and Satiety|Satiety Response of Resistant Starches|Completed||Early Phase 1|20|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 23:26:08.093448|2018-05-31 23:26:08.093448
NCT01187862|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2015-04-16|2010-08-23|2010-08-24|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2010||2010-07-31|April 2015|2015-04-30||||February 2011|Actual|2011-02-28||Interventional|||Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes|"Single-center, Randomized, Five-way Crossover Study to Investigate Low-dose Combinations of Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol, Chlorzoxazone and Midazolam (Basel Cocktail) for Simultaneous Phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in Healthy Male Subjects"|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||||||||||||2018-05-31 23:26:08.201448|2018-05-31 23:26:08.201448
NCT01187849|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2016-04-27|2010-08-23|2010-08-24|Estimate|||||||2016-04-27|2016-04-28|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Metformin to Prevent Metabolic Complications in Glucocorticoid Excess|Metformin to Prevent Metabolic Complications in Glucocorticoid Excess|Completed||Phase 4|29|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||No||2018-05-31 23:26:08.273172|2018-05-31 23:26:08.273172
NCT01187836|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20||2017-07-07|2017-07-07|2010-08-23|2010-08-24|Estimate||||2017-07-07|2017-07-11|Actual|2017-07-07|2017-07-11|Actual|December 2010||2010-12-31|July 2017|2017-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure|A Randomized, Double-Blind, Placebo-Controlled, Adaptive, Ascending Dose-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Invasive Hemodynamics of TRV120027 in Patients With Stable Heart Failure|Completed||Phase 1/Phase 2|33|Actual|Trevena Inc.||2|||f||||||||||||||2018-05-31 23:26:08.343384|2018-05-31 23:26:08.343384
NCT01187823|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2015-04-13|2010-08-23|2010-08-24|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Adaptive Servo Ventilation and Oxygen Therapy in Central Sleep Apnea Patients|Comparison of Adaptive Servo Ventilation(Bipap® Auto SV Advanced) and Oxgen Therapy in Chronic Heart Failure Patients Complicated With Central Sleep Apnea|Completed||N/A|43|Actual|Kyoto University, Graduate School of Medicine||2|||f||||f||||||||||2018-05-31 23:26:08.42499|2018-05-31 23:26:08.42499
NCT01187810|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2017-05-22|2010-08-23|2010-08-24|Estimate|||||||2017-05-22|2017-05-24|Actual|August 2010||2010-08-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL|"A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058"|Active, not recruiting||Phase 1|18|Anticipated|South Plains Oncology Consortium||1|||f||||t||||||||Undecided||2018-05-31 23:26:08.502242|2018-05-31 23:26:08.502242
NCT01187797|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-10-22|2010-08-23|2010-08-24|Estimate|||||||2010-10-22|2010-10-25|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Emotional Stimulation on the Stress Levels of Healthy Persons|Evaluation of the Effects of a Body-centered Emotional Stimulation in Healthy Persons|Completed||Phase 1/Phase 2|21|Actual|Charite University, Berlin, Germany||1|||f||||||||||||||2018-05-31 23:26:08.580011|2018-05-31 23:26:08.580011
NCT01187784|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-24|Estimate|||||||2010-08-23|2010-08-24|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and Anxiety|Effectiveness of Cognitive-Behavioral Therapy for Children With High-Functioning Autism Spectrum Disorder and Anxiety|Completed||Phase 1|22|Actual|Alliant International University||2|||f||||f||||||||||2018-05-31 23:26:08.648116|2018-05-31 23:26:08.648116
NCT01187771|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|2017-03-22||2017-05-26|2010-08-23|2010-08-24|Estimate|2017-05-26|2017-07-31|Actual||||2017-05-26|2017-07-31|Actual|November 2010||2010-11-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ABC||Apnea, Bariatric Surgery Versus Continuous Positive Airway Pressure (CPAP) Trial|A Randomized Trial of Bariatric Surgery for the Treatment of Sleep Apnea|Completed||Phase 2|53|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 23:26:08.747492|2018-05-31 23:26:08.747492
NCT01187758|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-24|Estimate|||||||2010-08-23|2010-08-24|Estimate|February 2002||2002-02-28|August 2010|2010-08-31|December 2007|Actual|2007-12-31|October 2005|Actual|2005-10-31||Interventional|IJAP||Israeli Judicious Antibiotic Prescription Study|Can Change in Physicians' Prescribing Habits Decrease Carriage of Resistant Bacteria in the Community?|Completed||N/A|5700|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:26:09.154775|2018-05-31 23:26:09.154775
NCT01187745|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-06-27|2010-08-23|2010-08-24|Estimate|||||||2011-06-27|2011-06-28|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Study to Look for Artifact on Computed Tomography (CT) Representing Kidney Stones|Evaluation of Twinkling Artifact Compared to Computed Tomography for Evaluation of Kidney Stones|Completed|||52|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-05-31 23:26:09.243941|2018-05-31 23:26:09.243941
NCT01187732|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2017-04-24|2010-08-23|2010-08-24|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2011||2011-04-30|April 2017|2017-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|WWW||Washing Without Water: Cost-effectiveness of a Rapidly Spreading Nursing Intervention in Bedridden Patients'|WASHING WITHOUT WATER Cost-effectiveness of a Rapidly Spreading Nursing Intervention om Bedridden Patients'|Completed||N/A|500|Actual|Radboud University||2|||f||||t||||||||No||2018-05-31 23:26:09.322835|2018-05-31 23:26:09.322835
NCT01187550|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-22|2012-05-09||2014-01-20|2010-08-23|2010-08-24|Estimate|2012-06-28|2012-08-07|Estimate||||2014-01-20|2014-02-13|Estimate|March 2007||2007-03-31|January 2014|2014-01-31|April 2009||2009-04-30|September 2008|Actual|2008-09-30||Interventional|||Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®|A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen®|Completed||Phase 4|214|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:26:10.674266|2018-05-31 23:26:10.674266
NCT01187719|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2012-09-17|2010-08-23|2010-08-24|Estimate|||||||2012-09-17|2012-09-18|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|VITA 2||The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance|The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)|Completed||Phase 2|66|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 23:26:09.43657|2018-05-31 23:26:09.43657
NCT01187706|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-24|Estimate|||||||2010-08-23|2010-08-24|Estimate|August 2010||2010-08-31|August 2010|2010-08-31||||||||Observational|||A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors|A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors|Unknown status|Recruiting||140|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 23:26:09.548357|2018-05-31 23:26:09.548357
NCT01187693|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-01-20|2010-08-23|2010-08-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Outcome Effect of Shoe Lift for Individuals With Low Back Pain and Pronated Foot Due to Anatomical Leg Length Discrepancy|The Outcome Effect of Shoe Lift for Individuals With Low Back Pain and Pronated Foot Due to Anatomical Leg Length Discrepancy|Completed||N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 23:26:09.657471|2018-05-31 23:26:09.657471
NCT01187680|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-12-28|2010-08-23|2010-08-24|Estimate|||||||2010-12-28|2010-12-29|Estimate|October 2002||2002-10-31|August 2010|2010-08-31|July 2009|Actual|2009-07-31|April 2004|Actual|2004-04-30||Interventional|||Efficacy of Sprayable PEG Barrier in Gynecologic Laparoscopy|Polyethylene Glycol Adhesion Barrier Reduces Adhesions After Gynecologic Laparoscopy; a Prospective Randomized Controlled Pilot Study|Terminated||Phase 4|16|Actual|Radboud University||2||Financial and organisational reasons|f||||f||||||||||2018-05-31 23:26:09.724438|2018-05-31 23:26:09.724438
NCT01187667|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2012-08-09|2010-08-23|2010-08-24|Estimate|||||||2012-08-09|2012-08-10|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Observational|||Evaluation of Delirium Prevention in Critically Ill Patients|Evaluation Study of a Delirium Prevention Policy Using Prophylactic Haloperidol in Critically Ill Patients With a High Risk for Delirium|Completed|||650|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 23:26:09.783408|2018-05-31 23:26:09.783408
NCT01187654|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-12-25|2010-08-23|2010-08-24|Estimate|||||||2012-12-25|2012-12-27|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient|Comparison the Therapeutic Outcomes of Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Patient With Acute Myocardial Infarction Underwent PCI Procedure|Completed||Phase 2/Phase 3|80|Actual|Royan Institute||3|||f||||t||||||||||2018-05-31 23:26:09.909012|2018-05-31 23:26:09.909012
NCT01187641|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2017-06-19|2010-08-23|2010-08-24|Estimate|||||||2017-06-19|2017-06-20|Actual|August 18, 2010|Actual|2010-08-18|June 2017|2017-06-30|May 17, 2016|Actual|2016-05-17|March 31, 2015|Actual|2015-03-31||Observational|||Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer|Comparison of the Diagnostic Accuracy of 3D Volume Acquisition MRI With CT in Staging Colonic Cancer|Completed|||60|Actual|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 23:26:10.028876|2018-05-31 23:26:10.028876
NCT01187628|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2015-04-02|2010-08-23|2010-08-24|Estimate|||||||2015-04-02|2015-04-03|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Long-term Study in Chronic Kidney Disease (Extension From Study 14817)|An Open-label, Long-term Extension Study of Lanthanum Carbonate 750 to 2,250 mg in Hyperphosphatemia in Patients With Chronic Kidney Disease Not on Dialysis (52 Weeks Extension From Study 14817)|Completed||Phase 3|123|Actual|Bayer||1|||f||||f||||||||||2018-05-31 23:26:10.113522|2018-05-31 23:26:10.113522
NCT01187615|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2014-07-07|2010-08-23|2010-08-24|Estimate|||||||2014-07-07|2014-07-08|Estimate|August 2010||2010-08-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||"Determination of Safety, Efficacy, and Pharmacokinetics of Regorafenib Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer"|"An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 Regorafenib, Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer"|Terminated||Phase 1|9|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:26:10.242048|2018-05-31 23:26:10.242048
NCT01187602|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-22|||2014-12-04|2010-08-22|2010-08-24|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|sncRNA||Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer|A Pilot Study of Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer|Unknown status|Recruiting||103|Anticipated|University of Virginia|||3||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 23:26:10.315361|2018-05-31 23:26:10.315361
NCT01187589|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-09-22|2010-08-23|2010-08-24|Estimate|||||||2011-09-22|2011-09-23|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||PulseHaler Drug Deposition Study in Chronic Obstructive Pulmonary Disease Patients|Preliminary Assessment of the Effect of PulseHaler™ With Albuterol on Lung Deposition of Aerosol and on Pulmonary Functions in COPD Patients|Completed||N/A|15|Anticipated|Respinova LTD||2|||f||||f||||||||||2018-05-31 23:26:10.404354|2018-05-31 23:26:10.404354
NCT01187576|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2012-10-15|2010-08-23|2010-08-24|Estimate|||||||2012-10-15|2012-10-16|Estimate|November 2010||2010-11-30|October 2012|2012-10-31||||June 2013|Anticipated|2013-06-30||Interventional|DALICO||A Multi-professional Team Intervention on Physical Activity Referrals in Primary Care Patients With Cardiovascular Risk Factors—the Dalby Lifestyle Intervention Cohort (DALICO) Study|A Multi-professional Team Intervention on Physical Activity Referrals in Primary Care Patients With Cardiovascular Risk factors-the Dalby Lifestyle Intervention Cohort Study (DALICO) Study|Unknown status|Recruiting|N/A|200|Anticipated|Region Skane||3|||f||||f||||||||||2018-05-31 23:26:10.503573|2018-05-31 23:26:10.503573
NCT01187563|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2011-10-12|2010-08-23|2010-08-24|Estimate|||||||2011-10-12|2011-10-13|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||A Study of Tocilizumab in Patients With Rheumatoid Arthritis|A Phase 4, Open-label, Repeat-Dose Study of the Safety and Pharmacodynamic Profile of Tocilizumab and Concomitant Methotrexate in Patients With Rheumatoid Arthritis|Completed|||16|Actual|Regeneron Pharmaceuticals|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:26:10.57594|2018-05-31 23:26:10.57594
NCT01187537|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-22|||2016-05-12|2010-08-23|2010-08-24|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2009||2009-07-31|August 2010|2010-08-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|PCA||Effects of Continuous Nerve Block vs Single Injection Block With PCA vs PCA on Pain and Function After Knee Replacement|Effects of Continuous Femoral Nerve Block Versus Single-Injection Femoral Nerve Block With Intravenous Patient Controlled Analgesia Versus Intravenous Patient Controlled Analgesia on Knee Pain and Function After Total Knee Replacement|Completed||N/A|200|Actual|Tan Tock Seng Hospital||3|||f||||t||||||||||2018-05-31 23:26:11.070158|2018-05-31 23:26:11.070158
NCT01187524|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-21|||2017-10-05|2010-08-21|2010-08-24|Estimate|||||||2017-10-05|2017-10-06|Actual|August 5, 2010||2010-08-05|May 31, 2013|2013-05-31|May 31, 2013||2013-05-31|||||Observational|||The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene; Creation of a Patient Registry|The Natural History of Reproductive and Overall Health in Women With a Pre-Mutation in the FMR1 Gene: Creation of a Patient Registry|Terminated|||7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:26:11.20521|2018-05-31 23:26:11.20521
NCT01187511|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-21|2016-09-19||2016-09-19|2010-08-21|2010-08-24|Estimate|2016-09-19|2016-11-07|Estimate||||2016-09-19|2016-11-07|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||CRF1 Antagonist GSK561679 in Alcoholism|Effects of Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism on Stress-Induced Craving in Alcoholic Women With High Anxiety: an Experimental Medicine Study|Completed||Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||No||2018-05-31 23:26:11.326693|2018-05-31 23:26:11.326693
NCT01187498|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2013-10-28||2014-04-22|2010-08-20|2010-08-24|Estimate|2014-04-22|2014-05-20|Estimate||||2014-04-22|2014-05-20|Estimate|January 2005||2005-01-31|December 2013|2013-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|MOTIVE||Behavioral Treatment of Overactive Bladder in Men|Behavioral Treatment of Overactive Bladder in Men|Completed||Phase 3|143|Actual|VA Office of Research and Development|Results can only be generalized to men without evidence of obstruction as determined by uroflowmetry, post-void residual urine (PVR) volume, and a trial of an alpha-blocker.|2|||f||||f||||||||||2018-05-31 23:26:12.301986|2018-05-31 23:26:12.301986
NCT01187485|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2014-01-16|2010-08-23|2010-08-24|Estimate|||||||2014-01-16|2014-01-17|Estimate|June 2004||2004-06-30|January 2014|2014-01-31|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer|A Randomized Phase I Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer|Completed||Phase 1|15|Actual|University of Chicago||3|||f||||f||||||||||2018-05-31 23:26:12.621056|2018-05-31 23:26:12.621056
NCT01187472|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2013-01-15|2010-08-23|2010-08-24|Estimate|||||||2013-01-15|2013-01-16|Estimate|March 2003||2003-03-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer|Organ Preservation in the Multispeciality Therapy of Stage II-IV Locally Advanced Head and Neck Cancer|Completed|||35|Actual|University of Chicago|||1||f||||f||||||||||2018-05-31 23:26:12.735138|2018-05-31 23:26:12.735138
NCT01187459|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2012-02-10|2010-08-23|2010-08-24|Estimate|||||||2012-02-10|2012-02-14|Estimate|September 2010||2010-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Vitamin D in Pediatric Crohn's Disease|Vitamin D in Pediatric Crohn's Disease|Completed||Phase 4|87|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 23:26:12.786949|2018-05-31 23:26:12.786949
NCT01187446|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2016-12-28||2017-10-19|2010-08-23|2010-08-24|Estimate|2017-10-19|2017-11-20|Actual||||2017-10-19|2017-11-20|Actual|December 2010||2010-12-31|October 2017|2017-10-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides|A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)|Terminated||Phase 1/Phase 2|28|Actual|Stanford University||2||Business decision by funding source|f||||t|t|f|||f|||No||2018-05-31 23:26:12.92578|2018-05-31 23:26:12.92578
NCT01187433|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2016-09-25|2013-11-04|2016-09-25|2010-08-20|2010-08-24|Estimate|2016-09-25|2016-11-11|Estimate|2013-11-04|2013-11-27|Estimate|2016-09-25|2016-11-11|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America|Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America|Completed||Phase 2|150|Actual|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 23:26:13.629492|2018-05-31 23:26:13.629492
NCT01187420|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-02-10|2010-08-23|2010-08-24|Estimate|||||||2017-02-10|2017-02-13|Actual|June 2009||2009-06-30|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|BIS||Bilateral Bispectral Index (BIS) Study|Real Time Monitoring for Cerebral Vasospasm Using Bilateral Processed Electroencephalogram (EEG)|Completed|||30|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||||||2018-05-31 23:26:15.015521|2018-05-31 23:26:15.015521
NCT01187407|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2018-02-17|2013-09-20|2018-03-25|2010-08-23|2010-08-24|Estimate|2018-03-25|2018-04-24|Actual|2013-09-20|2013-09-27|Estimate|2018-03-25|2018-04-24|Actual|March 2011||2011-03-31|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Participants who completed the Confirmation (CF) Phase and were randomized to adjunctive LY2216684 or adjunctive placebo or who did not meet randomization criteria and continued on placebo to maintain the blind.|A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment|A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment|Completed||Phase 3|1480|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 23:26:15.129373|2018-05-31 23:26:15.129373
NCT01187394|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2012-05-22|2010-08-23|2010-08-24|Estimate|||||||2012-05-22|2012-05-23|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Observational|PUCS||Plasma Utilization Following Cardiac Surgery|Plasma Utilization Following Cardiac Surgery|Completed|||970|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 23:26:17.300234|2018-05-31 23:26:17.300234
NCT01187381|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2017-05-30||2017-05-30|2010-08-20|2010-08-24|Estimate|2017-05-30|2017-10-20|Actual||||2017-05-30|2017-10-20|Actual|April 14, 2010|Actual|2010-04-14|May 2017|2017-05-31|October 15, 2015|Actual|2015-10-15|October 15, 2015|Actual|2015-10-15||Observational|HERODOT|All enrolled participants|An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|Multicenter, Single-Arm, Observational Study of Mean Duration of Trastuzumab (Herceptin) Treatment in Patients With HER2-Positive Early or Metastatic Breast Cancer in Romanian Population|Terminated|||250|Actual|Hoffmann-La Roche|Study was prematurely terminated because of missing data collection.||1|Study was prematurely terminated because of missing data collection.|f|||||t|f||||||||2018-05-31 23:26:17.425318|2018-05-31 23:26:17.425318
NCT01187368|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-04-23|2010-08-20|2010-08-24|Estimate|||||||2018-04-23|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 1, 2021|Anticipated|2021-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||EVAHEART LVAS Bridge-to-Transplant Pivotal Study|A Prospective Study to Evaluate the Safety and Efficacy of the EVAHEART LVAS for Use as a Bridge-to-Transplant|Recruiting||N/A|20|Anticipated|Evaheart, Inc.||1|||f||||t|f|t|f|||||||2018-05-31 23:26:17.899347|2018-05-31 23:26:17.899347
NCT01187355|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2012-06-26||2012-06-26|2010-08-23|2010-08-24|Estimate|2012-06-26|2012-07-30|Estimate||||2012-06-26|2012-07-30|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Alcon Multi-Purpose Disinfecting Solution Versus Renu Fresh Multi-Purpose Solution in Symptomatic Contact Lens Wearers|SiH MPDS FID 114675A Compared to Renu Fresh MPS in Symptomatic Contact Lens Wearers|Completed||N/A|591|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:26:18.112794|2018-05-31 23:26:18.112794
NCT01187342|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2016-08-19|2010-08-23|2010-08-24|Estimate|||||||2016-08-19|2016-08-22|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|POSTPSYDIS||Post Stroke Psychological Distress|Depression and Posttraumatic Stress Disorder in Stroke Patients: an Observational Study of Neuro-psychiatric, Cognitive, and MR-Changes Over Time After Stroke|Recruiting|||120|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 23:26:18.878597|2018-05-31 23:26:18.878597
NCT01187329|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2014-06-12|2010-08-23|2010-08-24|Estimate|||||||2014-06-12|2014-06-13|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose|The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose|Completed||N/A|100|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 23:26:19.043252|2018-05-31 23:26:19.043252
NCT01187316|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-24|2010-08-23|2010-08-24|Estimate|||||||2010-08-24|2010-08-25|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Treatment of Temporomandibular Disorders|Massage and Transcutaneous Electrical Nerve Stimulation Therapies for Temporomandibular Disorders in Adolescents|Completed||N/A|8|Actual|University of Pernambuco||2|||f||||f||||||||||2018-05-31 23:26:19.175945|2018-05-31 23:26:19.175945
NCT01187303|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-10-30|2010-08-23|2010-08-24|Estimate|||||||2015-10-30|2015-11-02|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|November 2013|Actual|2013-11-30||Interventional|||Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)|Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)|Completed||Phase 2|28|Actual|University of Cologne|||||f||||f||||||||||2018-05-31 23:26:19.298617|2018-05-31 23:26:19.298617
NCT01187290|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2010-08-23|2010-08-23|2010-08-24|Estimate|||||||2010-08-23|2010-08-24|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases|Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase II Trial|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 23:26:19.418576|2018-05-31 23:26:19.418576
NCT01187277|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2012-07-15|2010-08-23|2010-08-24|Estimate|||||||2012-07-15|2012-07-17|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|BB200810||Robotic Versus Conventional Training on Hemiplegic Gait.|A Randomized Controlled Trial on Hemiplegic Gait Rehabilitation: Robotic Locomotor Training Versus Conventional Training in Subacute Stroke.|Completed||Phase 3|60|Actual|Prasat Neurological Institute||2|||f||||t||||||||||2018-05-31 23:26:19.544427|2018-05-31 23:26:19.544427
NCT01187264|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-24|2010-08-23|2010-08-24|Estimate|||||||2010-08-24|2010-08-25|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Dose Ranging Study to Compare the Efficacy and Safety of Methotrexate in Plaque Type Psoriasis|Efficacy and Safety of Methotrexate in 2 Fixed Doses of 10mg or 25mg Orally Once Weekly in Patients With Severe Plaque Type Psoriasis: a Prospective, Randomized, Double Blind, Dose Ranging Study|Completed||Phase 4|100|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 23:26:19.670751|2018-05-31 23:26:19.670751
NCT01187251|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-23|||2010-08-23|2010-08-23|2010-08-24|Estimate|||||||2010-08-23|2010-08-24|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Incidence of Tinnitus Amongst Teenagers and Young Adults mp3 Users||Completed|||100|Actual|Faculdade de Medicina de Valenca|||2||f||||f||||||||||2018-05-31 23:26:19.758193|2018-05-31 23:26:19.758193
NCT01187238|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-09-09|2010-08-23|2010-08-24|Estimate|||||||2014-09-09|2014-09-10|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2013|Actual|2013-05-31||Interventional|||The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma|A Randomized Multicenter Phase II Study of Intensity-modulated Radiotherapy Combined With Chemotherapy Versus Intensity-modulated Radiotherapy Alone for Stage II Nasopharyngeal Carcinoma|Completed||Phase 2|86|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:26:19.83469|2018-05-31 23:26:19.83469
NCT01187225|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2013-01-02|2010-08-23|2010-08-24|Estimate|||||||2013-01-02|2013-01-04|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|January 2011|Actual|2011-01-31||Interventional|FiCCS||Fibrinogen Concentrate In Children After Cardiac Surgery|Fibrinogen Concentrate to Treat Bleeding in Children Undergoing Cardiac Surgery With Pump: a Randomised Controlled Clinical Trial|Completed||Phase 2|63|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:26:19.953474|2018-05-31 23:26:19.953474
NCT01187212|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2014-10-10|2010-08-23|2010-08-24|Estimate|||||||2014-10-10|2014-10-13|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|STARGATE||Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation|A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer|Completed||Phase 2|195|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:26:20.114563|2018-05-31 23:26:20.114563
NCT01187199|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2017-10-23|2010-08-20|2010-08-23|Estimate|||||||2017-10-23|2017-10-25|Actual|August 2010|Actual|2010-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer|Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer|Active, not recruiting||Phase 1|278|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 23:26:20.253556|2018-05-31 23:26:20.253556
NCT01187186|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-10-05|2010-08-20|2010-08-23|Estimate|||||||2010-10-05|2010-10-07|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941|A Phase 1, Open-Label, Single-Dose Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941|Completed||Phase 1|16|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:26:20.426325|2018-05-31 23:26:20.426325
NCT01187173|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2017-04-07|2010-08-20|2010-08-23|Estimate|||||||2017-04-07|2017-04-10|Actual|July 2010||2010-07-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||The Fibrosis-Lymphedema Continuum in Head and Neck Cancer|The Fibrosis-Lymphedema Continuum in Head and Neck Cancer|Completed|||100|Actual|Vanderbilt University|||||f||||f||||||Samples With DNA|"~     Blood from blood draws~   "|||2018-05-31 23:26:20.590657|2018-05-31 23:26:20.590657
NCT01187160|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-08-18|2010-08-20|2010-08-23|Estimate|||||||2016-08-18|2016-08-22|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Transoral Robotic Surgery (TORS) for Sleep Apnea|A Pilot Study Assessing Surgical Exposure During Transoral Robotic Surgery (TORS) for Sleep Apnea Using the da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA)|Completed||N/A|154|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 23:26:20.810947|2018-05-31 23:26:20.810947
NCT01187147|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-08-20|2010-08-20|2010-08-23|Estimate|||||||2010-08-20|2010-08-23|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Green Tea Extract (GTE) on Systemic Oxidative and Antioxidative Status in Chinese Patients With Stable Asthma|Effects of Green Tea Extract (GTE) on Systemic Oxidative and Antioxidative Status in Chinese Patients With Stable Asthma|Completed||N/A|30|Actual|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 23:26:20.980811|2018-05-31 23:26:20.980811
NCT01187134|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2017-08-08|2010-08-20|2010-08-23|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2011||2011-07-31|August 2017|2017-08-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|MEDUSA||Medical Education for Sepsis Source Control and Antibiotics|Medical Education for Sepsis Source Control and Antibiotics|Completed||N/A|4138|Actual|Center for Sepsis Control and Care, Germany||2|||f||||t||||||||||2018-05-31 23:26:21.135378|2018-05-31 23:26:21.135378
NCT01187121|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-08-20|2010-08-20|2010-08-23|Estimate|||||||2010-08-20|2010-08-23|Estimate|June 2010||2010-06-30|August 2010|2010-08-31||||||||Observational|DYT||Evaluating A Drug Testing and Graduated Sanctions Program in Delaware|Evaluating A Drug Testing and Graduated Sanctions Program in Delaware|Unknown status|Active, not recruiting||800|Anticipated|University of Delaware|||2||f||||f||||||||||2018-05-31 23:26:21.393944|2018-05-31 23:26:21.393944
NCT01187108|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2015-05-13|2010-08-20|2010-08-23|Estimate|||||||2015-05-13|2015-05-15|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CoCMS||Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru|Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness|Completed||Phase 1/Phase 2|85|Actual|University of Colorado, Denver||4|||f||||t||||||||||2018-05-31 23:26:21.489923|2018-05-31 23:26:21.489923
NCT01187095|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-02-05|2010-08-20|2010-08-23|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2010||2010-11-30|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Involuntary Childlessness and Stress Management|A Randomized Controlled Intervention Study: The Effect of Expressive Writing on Psychosocial Stress and Pregnancy Results With Couples Undergoing In Vitro Fertility(IVF) Treatment Due to Involuntary Childlessness.|Completed||N/A|298|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:26:21.717314|2018-05-31 23:26:21.717314
NCT01187082|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2015-03-09|2010-08-20|2010-08-23|Estimate|||||||2015-03-09|2015-03-10|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Grouptraining for Overactive Bladder in Adults|A Clinical, Randomized, Comparative, Non-blinded Study on the Effect of Bladdertraining in Groups Compared to Individual Bladdertraining for Female Patients With Overactive Bladder.|Completed||N/A|91|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:26:21.920601|2018-05-31 23:26:21.920601
NCT01187069|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2012-08-17|2010-08-20|2010-08-23|Estimate|||||||2012-08-17|2012-08-20|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Practice-nurse Addressed Intervention to Improve Type 2 Diabetes Care|A Practice-nurse Addressed Intervention to Improve Type 2 Diabetes Care. A Pragmatic Cluster Randomised Controlled Trial in Primary Health Care|Completed||N/A|40|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:26:22.031958|2018-05-31 23:26:22.031958
NCT01187056|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2017-05-08|2010-08-20|2010-08-23|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2007||2007-11-30|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|RISAP||The RISAP-study: a Complex Intervention in Risk Communication and Shared Decision-making in General Practice|The RISAP-study: a Complex Intervention in Risk Communication and Shared Decision-making in General Practice|Completed||N/A|179|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:26:22.295505|2018-05-31 23:26:22.295505
NCT01187043|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2014-06-23||2014-06-27|2010-08-20|2010-08-23|Estimate|2014-06-27|2014-07-28|Estimate||||2014-06-27|2014-07-28|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||ITT|Determination of the Lowest, Safe and Effective Dose of Proellex|A Single-Blind, Placebo Run-in, Phase I/II Study Comparing Five Oral Doses of Proellex®|Completed||Phase 1/Phase 2|52|Actual|Repros Therapeutics Inc.||5|||f||||t||||||||||2018-05-31 23:26:22.429838|2018-05-31 23:26:22.429838
NCT01187030|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2012-05-22|2010-08-20|2010-08-23|Estimate|||||||2012-05-22|2012-05-23|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Appropriateness of Frozen Plasma Use in Canada|Appropriateness of Frozen Plasma Use in Canada|Completed|||2580|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 23:26:23.120186|2018-05-31 23:26:23.120186
NCT01187017|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2014-06-05||2016-02-03|2010-08-20|2010-08-23|Estimate|2016-02-03|2016-03-02|Estimate||||2016-02-03|2016-03-02|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia|A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia|Completed||Phase 1/Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-05-31 23:26:23.270939|2018-05-31 23:26:23.270939
NCT01187004|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2011-08-08||2013-02-05|2010-08-20|2010-08-23|Estimate|2011-11-30|2012-01-06|Estimate||||2013-02-05|2013-02-12|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|||Extracardiac Complications After Cardiac Surgery|Extracardiac Complications After Cardiopulmonary by Pass in Cardiac Surgery|Completed|||164|Actual|University of Turin, Italy|The main limitation of the trial was the observational nature and the relatively small number of patients||1||f||||t||||||||||2018-05-31 23:26:23.643485|2018-05-31 23:26:23.643485
NCT01186991|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09||2016-07-15|2017-01-19|2010-08-20|2010-08-23|Estimate||||2016-07-15|2016-07-19|Estimate|2017-01-19|2017-01-20|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple-Negative Breast Cancer|Completed||Phase 2|185|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:26:24.233221|2018-05-31 23:26:24.233221
NCT01186978|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-01-19|2010-08-20|2010-08-23|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2010||2010-10-31|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|DLBCL||Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma|Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma|Active, not recruiting||N/A|62|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 23:26:24.548056|2018-05-31 23:26:24.548056
NCT01186965|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-03-04|2010-08-20|2010-08-23|Estimate|||||||2015-03-04|2015-03-06|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|SLIDES||Ehealth: Second Life Impacts Diabetes Education & Self-Management|Ehealth: Second Life Impacts Diabetes Education & Self-Management|Completed||N/A|20|Actual|Duke University|||||f||||t||||||||||2018-05-31 23:26:24.673678|2018-05-31 23:26:24.673678
NCT01186952|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2016-04-18|2010-08-20|2010-08-23|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PEP-2||Exercise Program Combined or Not With Nutritional intErvention in Adults With tyPe 2 Diabetes|Effects of an Exercise Program Combined or Not With Nutritional intErvention on Total Fat, Epicardial Fat and Metabolic Profile of Obese and Overweight Adults With tyPe 2 Diabetes (The PEP-2 Study)|Completed||N/A|90|Anticipated|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||||2018-05-31 23:26:24.780983|2018-05-31 23:26:24.780983
NCT01186939|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2010-08-26||2017-01-17|2010-08-20|2010-08-23|Estimate|2010-08-26|2010-09-21|Estimate||||2017-01-17|2017-03-01|Actual|April 2007||2007-04-30|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)|AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)|Completed||Phase 3|40|Actual|Celgene||1|||f||||f||||||||||2018-05-31 23:26:24.987406|2018-05-31 23:26:24.987406
NCT01186926|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2015-04-14|2010-08-20|2010-08-23|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|May 2013|Actual|2013-05-31|December 2010|Actual|2010-12-31||Interventional|||Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea|Australian Prospective Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea|Completed||Phase 2/Phase 3|40|Anticipated|Apnex Medical, Inc.||1|||f||||t||||||||||2018-05-31 23:26:25.498321|2018-05-31 23:26:25.498321
NCT01186913|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2017-10-10|2010-08-20|2010-08-23|Estimate|||||||2017-10-10|2017-10-12|Actual|August 2010||2010-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Natural History Study of SCID Disorders|A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)|Recruiting|||209|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||f||||||Samples With DNA|"~     Peripheral blood samples, tissue, and bone marrow samples collected during participation in~     this study.~   "|||2018-05-31 23:26:25.69436|2018-05-31 23:26:25.69436
NCT01186900|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2011-08-04|2010-08-20|2010-08-23|Estimate|||||||2011-08-04|2011-08-08|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Comparison of Ultrasound-Guided Needle Aspiration and Open Incision and Drainage for Cutaneous Abscesses|Comparison of Ultrasound-Guided Needle Aspiration and Open Incision and Drainage in the Management of Cutaneous Abscesses|Terminated||N/A|20|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 23:26:25.993141|2018-05-31 23:26:25.993141
NCT01186887|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2014-06-16|2010-08-20|2010-08-23|Estimate|||||||2014-06-16|2014-06-17|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction|A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament Reconstruction|Completed||N/A|40|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 23:26:26.096649|2018-05-31 23:26:26.096649
NCT01186874|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-10-25|2010-08-20|2010-08-23|Estimate|||||||2011-10-25|2011-10-26|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|November 2011|Anticipated|2011-11-30|March 2011|Actual|2011-03-31||Observational|||Epidemiology Research on Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) in Adult ICU in Shanghai||Unknown status|Recruiting||100|Anticipated|Tongji University|||||f||||t||||||||||2018-05-31 23:26:26.213529|2018-05-31 23:26:26.213529
NCT01186861|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19||2014-06-19|2015-04-07|2010-08-19|2010-08-23|Estimate||||2014-06-19|2014-06-23|Estimate|2015-04-07|2015-04-29|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|July 2013|Actual|2013-07-31||Interventional|||Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy|A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC|Completed||Phase 2|205|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-05-31 23:26:26.348583|2018-05-31 23:26:26.348583
NCT01186848|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2013-09-03||2013-12-17|2010-08-19|2010-08-23|Estimate|2013-12-17|2014-02-03|Estimate||||2013-12-17|2014-02-03|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Fractional Laser and Ultrasound for Striae Distensae|Comparison of Fractional Photothermolysis Alone Versus Fractional Photothermolysis Plus Intense Focused Ultrasound for Treatment of Striae Distensae: A Prospective Randomized Control Trial.|Completed||N/A|30|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 23:26:26.663063|2018-05-31 23:26:26.663063
NCT01186835|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2014-05-22|2010-08-19|2010-08-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone|Treatment of Forehead/Glabellar Rhytide Complex With Combination Botulinum Toxin A and Hyaluronic Acid Versus Botulinum Toxin A Injection Alone: A Split-face, Rater-blinded Randomized Control Trial|Completed||N/A|20|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 23:26:26.910358|2018-05-31 23:26:26.910358
NCT01186822|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-01-29|2010-08-20|2010-08-23|Estimate|||||||2015-01-29|2015-01-30|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease|A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease.|Completed||N/A|69|Actual|Medical Acoustics LLC||2|||f||||f||||||||||2018-05-31 23:26:27.047663|2018-05-31 23:26:27.047663
NCT01186809|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2016-10-04|2010-08-20|2010-08-23|Estimate|||||||2016-10-04|2016-10-05|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2016|Actual|2016-09-30||Interventional|CIK2||Cytokine Induced Killer (CIK) Cells In Leukemia Patients|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)Cells After Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 2|72|Actual|A.O. Ospedale Papa Giovanni XXIII||1|||f||||t||||||||Yes|final report|2018-05-31 23:26:27.224079|2018-05-31 23:26:27.224079
NCT01186796|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2015-02-24||2015-03-24|2010-08-19|2010-08-23|Estimate|2015-03-24|2015-03-27|Estimate||||2015-03-24|2015-03-27|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All subjects are healthy post-menopausal women from the community.|Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women|Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women|Completed||Phase 1|30|Actual|Mayo Clinic|Strengths and limitations of the study include the potentially confounding effects of body composition (not studied here except at the level of BMI), underlying physical fitness of subjects, size of the cohort, and the brevity of the study (2 months)|1|||f||||t||||||||||2018-05-31 23:26:27.364944|2018-05-31 23:26:27.364944
NCT01186783|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-09-07|2010-08-20|2010-08-23|Estimate|||||||2010-09-07|2010-09-08|Estimate|May 2010||2010-05-31|September 2010|2010-09-30|May 2012|Anticipated|2012-05-31|November 2011|Anticipated|2011-11-30||Interventional|MODIfY||Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine|"Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by the Funny Channel Current (If) Inhibitor Ivabradine"|Unknown status|Recruiting|Phase 2|70|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 23:26:27.969434|2018-05-31 23:26:27.969434
NCT01186770|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-11-07|2010-08-20|2010-08-23|Estimate|||||||2013-11-07|2013-11-08|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Oral Methylnaltrexone (OM) for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic, Non-Malignant Pain|Completed||Phase 3|700|Anticipated|Valeant Pharmaceuticals International, Inc.||4|||f||||t||||||||||2018-05-31 23:26:28.294791|2018-05-31 23:26:28.294791
NCT01186757|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-01-11|2010-08-20|2010-08-23|Estimate|||||||2011-01-11|2011-01-12|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|MD-MULTI DOSE||Multiple Dose Healthy Volunteer Study of PF-03715455.|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Inhaled Doses Of PF-03715455 In Healthy Subjects|Completed||Phase 1|36|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:26:28.512763|2018-05-31 23:26:28.512763
NCT01186744|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2014-01-27||2014-05-14|2010-08-20|2010-08-23|Estimate|2014-05-14|2014-06-04|Estimate||||2014-05-14|2014-06-04|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Full Analysis Set (FAS) included all participants who were randomized at baseline and received at least one dose of the randomized investigational drug (CP-690,550 5 mg BID or 10 mg BID) during Period A.|A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi-Site, Randomized, Mixed-Blind, Parallel-Group Treatment Withdrawal And Re-Treatment Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis|Completed||Phase 3|666|Actual|Pfizer|Clinical interpretation regarding sub-phenotypes of psoriasis (e.g., scalp psoriasis) should not be made based on the reported assessments by body regions. For example, the body region of head does not reflect solely scalp psoriasis.|4|||f||||t||||||||||2018-05-31 23:26:29.132549|2018-05-31 23:26:29.132549
NCT01186731|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-09-11|2010-08-20|2010-08-23|Estimate|||||||2012-09-11|2012-09-12|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer|A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|40|Actual|INSYS Therapeutics Inc||1|||f||||t||||||||||2018-05-31 23:26:38.950143|2018-05-31 23:26:38.950143
NCT01186718|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2011-11-28|2010-08-20|2010-08-23|Estimate|||||||2011-11-28|2011-11-29|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Interexaminer Reliability, Outcomes for Manipulation of Cervical Dysfunction, 3-D Kinematics|Three-dimensional Study of Cervical Kinematics|Completed|||30|Actual|Michigan State University|||2||f||||t||||||||||2018-05-31 23:26:39.022166|2018-05-31 23:26:39.022166
NCT01186705|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2015-04-07||2015-10-17|2010-08-20|2010-08-23|Estimate|2015-04-07|2015-04-21|Estimate||||2015-10-17|2015-11-18|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer|A Phase II Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer|Terminated||Phase 2|1|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||t||||||||||2018-05-31 23:26:39.110504|2018-05-31 23:26:39.110504
NCT01186692|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|2016-09-30||2018-04-24|2010-08-20|2010-08-23|Estimate|2016-10-31|2016-12-26|Estimate||||2018-04-24|2018-04-26|Actual|July 2010|Actual|2010-07-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|January 2013|Actual|2013-01-31||Interventional|||Melody® Transcatheter Pulmonary Valve Post-Approval Study|Implantation of the Medtronic Melody Transcatheter Pulmonary Valve (TPV) in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Post-Market Approval Study|Completed||N/A|131|Actual|Medtronic Cardiovascular||1|||f||||f||||||||Undecided||2018-05-31 23:26:39.293935|2018-05-31 23:26:39.293935
NCT01186679|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-08-20|2010-08-20|2010-08-23|Estimate|||||||2010-08-20|2010-08-23|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional|ABMST-SCI||Safety and Efficacy of Autologous Bone Marrow Stem Cells in Treating Spinal Cord Injury|Surgical Transplantation of Autologous Bone Marrow Stem Cells With Glial Scar Resection for Patients of Chronic Spinal Cord Injury and Intra-thecal Injection for Acute and Subacute Injury - A Preliminary Study|Completed||Phase 1/Phase 2|12|Actual|International Stemcell Services Limited||2|||f||||t||||||||||2018-05-31 23:26:39.586824|2018-05-31 23:26:39.586824
NCT01186666|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-02-24|2010-08-20|2010-08-23|Estimate|||||||2015-02-24|2015-02-25|Estimate|February 2010||2010-02-28|February 2015|2015-02-28|August 2013|Actual|2013-08-31|July 2012|Actual|2012-07-31||Interventional|BIOCORE-2||Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease|BIOmarkers of CORonary Events-2 : Imaging and Biomarkers of Atherosclerosis in Patients With Stable or Unstable Coronary Artery Disease|Completed||N/A|85|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:26:39.654095|2018-05-31 23:26:39.654095
NCT01186653|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-09-03|2010-08-20|2010-08-23|Estimate|||||||2010-09-03|2010-09-06|Estimate|October 2007||2007-10-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)|Effect of High Dose Inhaled Budesonide and Fluticasone on Adrenal Function in Patients With Moderate to Severe COPD|Completed||Phase 4|22|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 23:26:39.73566|2018-05-31 23:26:39.73566
NCT01186640|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2018-05-09|2010-08-20|2010-08-23|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2010||2010-06-30|May 2018|2018-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)|Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia|Completed||Phase 2|16|Actual|German CLL Study Group||1|||f||||f||||||||No||2018-05-31 23:26:39.843329|2018-05-31 23:26:39.843329
NCT01186627|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-10-13|2010-08-20|2010-08-23|Estimate|||||||2010-10-13|2010-10-14|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|December 2012||2012-12-31|April 2012||2012-04-30||Observational|||Trial to Evaluate a Specified Type of Apgar (TEST-APGAR) Follow Up Study|Trial to Evaluate a Specified Type of Apgar (TEST-APGAR) Follow-Up Study|Unknown status|Recruiting||1500|Anticipated|Technische Universität Dresden|||||f||||f||||||||||2018-05-31 23:26:39.932877|2018-05-31 23:26:39.932877
NCT01186614|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2014-03-06|2010-08-20|2010-08-23|Estimate|||||||2014-03-06|2014-03-10|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|CHEER||Refractory Out-Of-Hospital Cardiac Arrest Treated With Mechanical CPR, Hypothermia, ECMO and Early Reperfusion|Refractory Out-Of-Hospital Cardiac Arrest Treated With Mechanical CPR, Hypothermia, ECMO and Early Reperfusion|Unknown status|Recruiting|Phase 1|24|Anticipated|Bayside Health||1|||f||||t||||||||||2018-05-31 23:26:40.01001|2018-05-31 23:26:40.01001
NCT01186601|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2014-11-11|2010-08-20|2010-08-23|Estimate|||||||2014-11-11|2014-11-13|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer|Open-label Study for an Exploration of Tumor Accumulation of the 18F Labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to </= 0.1 mg Total Quantity) in Patients With Prostate Cancer or Other Malignant Tumors|Completed||Phase 1|30|Actual|Piramal Imaging SA||1|||f||||f||||||||||2018-05-31 23:26:40.184704|2018-05-31 23:26:40.184704
NCT01186588|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-05-27|2010-08-19|2010-08-23|Estimate|||||||2013-05-27|2013-05-29|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Canagliflozin in Study Participants With Various Degrees of Impaired Hepatic (Liver) Function|An Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of 300 mg JNJ-28431754 (Canagliflozin) in Subjects With Various Degrees of Impaired Hepatic Function Compared With Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 23:26:40.260145|2018-05-31 23:26:40.260145
NCT01186575|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-01-15|2010-08-20|2010-08-23|Estimate|||||||2015-01-15|2015-01-16|Estimate|August 2010||2010-08-31|January 2015|2015-01-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Text Messaging to Improve Adherence to Clinic Visits and Reduce Early Resumption of Sexual Intercourse After Male Circumcision|Text Messaging to Improve Adherence to Post-Operative Clinic Appointments and Reduce Early Resumption of Sexual Intercourse After Adult Male Circumcision: A Randomized Controlled Trial|Completed||N/A|1200|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:26:40.332208|2018-05-31 23:26:40.332208
NCT01186562|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2016-10-28||2017-05-02|2010-08-20|2010-08-23|Estimate|2016-10-28|2016-12-28|Estimate||||2017-05-02|2017-05-31|Actual|August 2010||2010-08-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|||Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant|A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation|Completed||Phase 4|83|Actual|University of Minnesota - Clinical and Translational Science Institute|It is also possible that the study is not powered enough to detect small differences in insulin independence. The feasibility of conducting any larger trial in the small population of adult islet autograft recipients is limited, however.|2|||f||||t||||||||No||2018-05-31 23:26:40.436091|2018-05-31 23:26:40.436091
NCT01186549|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2012-10-10|2010-08-20|2010-08-23|Estimate|||||||2012-10-10|2012-10-11|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||The Effect of Combined Ephedrine and Lidocaine Pretreatment on Pain and Hemodynamic Changes Due to Propofol Injection|Title: The Effect of Combined Ephedrine and Lidocaine Pretreatment on Pain Due to Propofol Injection in Patients Undergoing Elective Surgery Under General Anaesthesia|Completed||Phase 1/Phase 2|165|Actual|Qazvin University Of Medical Sciences||5|||f||||f||||||||||2018-05-31 23:26:40.996275|2018-05-31 23:26:40.996275
NCT01186536|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2012-11-07|2010-08-20|2010-08-23|Estimate|||||||2012-11-07|2012-11-09|Estimate|June 2007||2007-06-30|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Whey Protein, Resistance Training, and Changes in Body Composition|Whey Protein Supp. w/ Resistance Training; Effects on Body Comp. of Young Adults.|Completed||N/A|85|Actual|University of Kansas||3|||f||||t||||||||||2018-05-31 23:26:41.081217|2018-05-31 23:26:41.081217
NCT01186523|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2012-08-08|2010-08-20|2010-08-23|Estimate|||||||2012-08-08|2012-08-09|Estimate|July 2005||2005-07-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Long-term Exercise, Weight Loss and Energy Balance|Long-term Exercise, Weight Loss and Energy Balance|Completed||N/A|136|Actual|University of Kansas||3|||f||||t||||||||||2018-05-31 23:26:41.353313|2018-05-31 23:26:41.353313
NCT01186510|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-06-03|2010-08-20|2010-08-23|Estimate|||||||2013-06-03|2013-06-04|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PulPer-001-Sch||Lung Perfusion With Oxygenated Blood During Aortic Clamping|Lung Perfusion With Oxygenated Blood During Aortic Clamping|Completed||N/A|50|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 23:26:41.42846|2018-05-31 23:26:41.42846
NCT01186497|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-01-21|2010-08-19|2010-08-23|Estimate|||||||2013-01-21|2013-01-23|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers|Relative Bioavailability of Rabeprazole Sodium Sprinkle Capsule Formulation Using Different Dosing Vehicles Following Single-dose Administration in Healthy Adult Subjects|Completed||Phase 1|35|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||5|||f||||||||||||||2018-05-31 23:26:41.576415|2018-05-31 23:26:41.576415
NCT01186484|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2017-10-19|2010-08-19|2010-08-23|Estimate|||||||2017-10-19|2017-10-23|Actual|June 1, 2010|Actual|2010-06-01|October 2017|2017-10-31|October 2, 2014|Actual|2014-10-02|October 2, 2014|Actual|2014-10-02||Interventional|||Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer|Phase 1 Study of JNJ-212082 (Abiraterone Acetate) in Patients With Castration-Resistant Prostate Cancer|Completed||Phase 1|27|Actual|Janssen Pharmaceutical K.K.||1|||f||||f|f|||||||||2018-05-31 23:26:41.871493|2018-05-31 23:26:41.871493
NCT01186471|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2012-03-19|2010-08-19|2010-08-23|Estimate|||||||2012-03-19|2012-03-20|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|||||Interventional|||The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients|A Double-Blind, Placebo-Controlled, Randomized Three-Way Crossover Study to Investigate The Effect of Nicotine on Arousal, Standard Cognitive Tasks And Social Cognition in Patients With Schizophrenia (Smoking and Non-Smoking)|Completed||Early Phase 1|32|Actual|Janssen Pharmaceutica N.V., Belgium||3|||f||||||||||||||2018-05-31 23:26:42.201595|2018-05-31 23:26:42.201595
NCT01186458|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2016-08-30||2016-08-30|2010-08-20|2010-08-23|Estimate|2016-08-30|2016-10-24|Estimate||||2016-08-30|2016-10-24|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma|A Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma: Hoosier Oncology Group LYM08-134|Terminated||Phase 2|4|Actual|Hoosier Cancer Research Network|This trial was terminated after accruing four subjects to do slow accrual. Sufficient data was not collected to complete the primary objective.|1||Slow accrual|f||||t||||||||||2018-05-31 23:26:42.518526|2018-05-31 23:26:42.518526
NCT01186445|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2017-02-03|2010-08-20|2010-08-23|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 2011||2011-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MIAMI||Morphine In Acute Myocardial Infarction|Evaluation of the Cardioprotective Effect of Intracoronary Injection of Morphine During Reperfusion in Acute Myocardial Infarction|Completed||Phase 3|94|Actual|French Cardiology Society||2|||f||||t||||||||||2018-05-31 23:26:44.041248|2018-05-31 23:26:44.041248
NCT01186432|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-03-04|2010-08-20|2010-08-23|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|May 2012|Actual|2012-05-31||Interventional|||Preliminary Safety and Efficacy of the PDS-1.0 in Patients With Neovascular Age Related Macular Degeneration (AMD)||Completed||Phase 1|20|Actual|Forsight Vision4||1|||f||||f||||||||||2018-05-31 23:26:44.397333|2018-05-31 23:26:44.397333
NCT01186419|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2015-04-23|2014-07-01|2015-06-03|2010-08-19|2010-08-23|Estimate|2015-05-18|2015-06-03|Estimate|2014-07-01|2014-07-03|Estimate|2015-06-03|2015-07-01|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional||All subjects who received any amount of investigational product.|Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload|A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy, With a 72 Week Dosing Extension|Completed||Phase 2|51|Actual|Shire|Only data from all subjects (ie, total) are presented because dose adjustments that occurred after Week 24 obviated the meaningful interpretation of data presented by the original 16 and 32 mg/kg/day dose groups.|2|||f||||f||||||||||2018-05-31 23:26:44.694683|2018-05-31 23:26:44.694683
NCT01186406|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2014-10-17||2018-02-01|2010-08-20|2010-08-23|Estimate|2014-10-17|2014-10-22|Estimate||||2018-02-01|2018-03-01|Actual|April 2011||2011-04-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|May 2014|Actual|2014-05-31||Interventional|||Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)|Phase II Trial for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Concurrent Radiation Therapy, Temodar and Avastin, Then Followed by Avastin and Temodar Post-Radiation|Active, not recruiting||Phase 2|41|Actual|Duke University||1|||f||||t||||||||||2018-05-31 23:26:45.913057|2018-05-31 23:26:45.913057
NCT01186393|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-05-14|2010-08-19|2010-08-23|Estimate|||||||2015-05-14|2015-05-18|Estimate|May 2007||2007-05-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|November 2010|Actual|2010-11-30||Interventional|BBFUSPB||STUDY: Effects of Potatoes in a Weight Loss Program|CCRC: Assessing the Role of Glycemic Index in Body Weight Management and Glucose Control|Completed||N/A|90|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 23:26:46.650154|2018-05-31 23:26:46.650154
NCT01186380|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2010-11-19|2010-08-20|2010-08-23|Estimate|||||||2010-11-19|2010-11-23|Estimate|August 2010||2010-08-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|TEE||Safety of the PET-512MC Transesophageal Transducer|Safety of the PET-512MC Transesophageal Transducer (TEE)|Completed|||50|Actual|Toshiba America Medical Systems, Inc.|||1||f||||t||||||||||2018-05-31 23:26:46.969471|2018-05-31 23:26:46.969471
NCT01186367|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-02-26|2010-08-19|2010-08-23|Estimate|||||||2018-02-26|2018-02-27|Actual|August 2010||2010-08-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|Excite||Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer|Exercise Intensity Trial (EXCITE): A Randomized Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer|Recruiting||N/A|174|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||f||||||||||2018-05-31 23:26:47.272825|2018-05-31 23:26:47.272825
NCT01186354|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2012-12-12|2010-08-20|2010-08-23|Estimate|||||||2012-12-12|2012-12-17|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Understanding of Genetic Risk Information for Type 2 Diabetes|Implications of Health and Genetic Literacy for Genomic Medicine|Completed||N/A|300|Actual|Duke University||1|||f||||f||||||||||2018-05-31 23:26:47.622253|2018-05-31 23:26:47.622253
NCT01186341|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-03-24|2010-08-19|2010-08-23|Estimate|||||||2015-03-24|2015-03-26|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|SIMTAP||BraveNet Multi-Center Study on Integrative Medicine Treatment Approaches for Pain|BraveNet Multi-Center Study on Integrative Medicine Treatment Approaches for Pain|Completed|||418|Actual|Duke University|||1||f||||f||||||||||2018-05-31 23:26:47.924548|2018-05-31 23:26:47.924548
NCT01186328|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-05-14|2010-08-20|2010-08-23|Estimate|||||||2015-05-14|2015-05-18|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)|T2009-007: A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) [IND 108753]|Terminated||Phase 1|6|Actual|Therapeutic Advances in Childhood Leukemia Consortium||||"The company (Enzon Pharmaceuticals)providing the drug EZN-3042 decided to end its development~   of EZN-3042."|f||||t||||||||||2018-05-31 23:26:48.197602|2018-05-31 23:26:48.197602
NCT01186315|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2014-08-19|2010-08-20|2010-08-23|Estimate|||||||2014-08-19|2014-08-21|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Post-traumatic Stress Disorder (PTSD), Addiction, and Virtual Reality|Developing a Computer-Based Intervention to Enhance Behavioral Treatments for PTSD and Addiction|Completed||N/A|38|Actual|Duke University||2|||f||||t||||||||||2018-05-31 23:26:48.926575|2018-05-31 23:26:48.926575
NCT01186302|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2010-08-20|2010-08-20|2010-08-23|Estimate|||||||2010-08-20|2010-08-23|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of the Safety and Efficacy of Medical Abortion Provided by Physicians and Midlevel Providers in Nepal|Comparison of the Safety, Efficacy, and Feasibility of Medical Abortion Provided by Physicians and Non-physicians in Nepal: a Randomized Controlled, Equivalence Trial.|Completed||N/A|1104|Actual|World Health Organization||2|||f||||f||||||||||2018-05-31 23:26:49.339952|2018-05-31 23:26:49.339952
NCT01186289|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-10-11|2010-08-20|2010-08-23|Estimate|||||||2015-10-11|2015-10-14|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery|Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery|Withdrawn||N/A|0|Actual|Duke University||2||Principal Investigator decided not to pursue enrollment due to changes in standard of care.|f||||t||||||||||2018-05-31 23:26:49.667329|2018-05-31 23:26:49.667329
NCT01186276|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2014-11-19|2010-08-20|2010-08-23|Estimate|||||||2014-11-19|2014-11-20|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dietary Maneuvers to Reduce Production of Colon-Derived Uremic Solutes|Dietary Maneuvers to Reduce Production of Colon-Derived Uremic Solutes|Enrolling by invitation||N/A|50|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 23:26:50.204949|2018-05-31 23:26:50.204949
NCT01186263|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2014-09-03|2010-08-20|2010-08-23|Estimate|||||||2014-09-03|2014-09-04|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|July 2011|Actual|2011-07-31||Interventional|EXPLOSIVE||Predictive Value of 99mTc- Albumin Spheres Before 90Y- SIR Therapy|Exploratory Study to Assess the Predictive Value of 99mTc-labeled Albumin Spheres for the Intrahepatic Distribution of 90Y SIR Spheres in Patients With Liver Metastases of Colorectal Tumors|Completed||Phase 2|24|Actual|University of Magdeburg||2|||f||||f||||||||||2018-05-31 23:26:50.469627|2018-05-31 23:26:50.469627
NCT01186250|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2015-06-19||2016-07-08|2010-08-20|2010-08-23|Estimate|2016-07-08|2016-08-18|Estimate||||2016-07-08|2016-08-18|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional||Double-blind randomized clinical trial of pioglitazone versus placebo from 2010 to 2013 in heart transplant recipients who were 1-4 years post-transplant.Eighteen heart transplant patients aged 22 to 72 years were randomized (9 to pioglitazone, 9 to placebo)|Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation|Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation|Completed||Phase 2|18|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 23:26:50.615552|2018-05-31 23:26:50.615552
NCT01186237|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2014-02-12|2010-08-20|2010-08-23|Estimate|||||||2014-02-12|2014-02-14|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study|Early Removal of Urinary Catheters in Patients After Rectal Surgery: a Prospective Study|Unknown status|Recruiting|N/A|100|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 23:26:50.958462|2018-05-31 23:26:50.958462
NCT01186224|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2010-08-20|2010-08-20|2010-08-23|Estimate|||||||2010-08-20|2010-08-23|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|May 2012|Anticipated|2012-05-31|October 2011|Anticipated|2011-10-31||Interventional|PHANTASTIC||Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)|A Comparison of Plerixafor/G-CSF With Chemotherapy/G-CSF for Stem Cell Mobilisation|Unknown status|Recruiting|N/A|60|Anticipated|University of Liverpool|||||f||||t||||||||||2018-05-31 23:26:51.046506|2018-05-31 23:26:51.046506
NCT01186211|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-03-22|2010-08-20|2010-08-23|Estimate|||||||2018-03-22|2018-03-26|Estimate|November 2010||2010-11-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Observational|||Feasibility of Outpatient Total Knee Arthroplasty|Feasibility of Outpatient Total Knee Arthroplasty|Active, not recruiting|||177|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-05-31 23:26:51.122475|2018-05-31 23:26:51.122475
NCT01186198|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-02-28|2010-08-19|2010-08-23|Estimate|||||||2012-02-28|2012-03-01|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|CROSS||A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions|A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions|Completed|||71|Actual|Abbott Vascular|||1||f||||f||||||||||2018-05-31 23:26:51.178112|2018-05-31 23:26:51.178112
NCT01186185|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-04-21|2010-08-20|2010-08-23|Estimate|||||||2015-04-21|2015-04-22|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Fludrocortisone for Sudden Hearing Loss|Mineralocorticoid Treatment for Sudden Sensorineural Hearing Loss|Unknown status|Recruiting|N/A|20|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 23:26:51.263367|2018-05-31 23:26:51.263367
NCT01186172|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2012-01-04|2010-08-20|2010-08-23|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Ethanol Lock for the Salvage of Infected Long-term Vascular Access|Lock Con Etanolo Per il Salvataggio di Dispositivi Vascolari a Lungo Termine. Un Trial Clinico Multicentrico Controllato Randomizzato|Unknown status|Recruiting|Phase 3|200|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-05-31 23:26:51.356847|2018-05-31 23:26:51.356847
NCT01186159|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-04-16|2010-08-20|2010-08-23|Estimate|||||||2015-04-16|2015-04-17|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||The Correlation of COX-2 Expression in Human Polymorphonuclear Leukocytes/Macrophages (PMNL/MP) and Postoperative Pain|The Correlation of COX-2 Expression in Human Polymorphonuclear Leukocytes/Macrophages and Postoperative Pain|Completed||Phase 4|90|Actual|Huazhong University of Science and Technology||1|||f||||t||||||||||2018-05-31 23:26:51.43894|2018-05-31 23:26:51.43894
NCT01186146|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-03-19|2010-08-20|2010-08-23|Estimate|||||||2014-03-19|2014-03-20|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|DES-LATE||Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)|Optimal Duration of Clopidogrel Therapy After Drug-Eluting Stent Implantation to Reduce Late Coronary Arterial Thrombotic Events|Completed||Phase 4|5000|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-05-31 23:26:51.505363|2018-05-31 23:26:51.505363
NCT01186133|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2017-12-17|2010-08-20|2010-08-23|Estimate|||||||2017-12-17|2017-12-19|Actual|January 2009||2009-01-31|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|IRIS-DES||Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice|Evaluation of Effectiveness and Safety of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice|Recruiting|||40000|Anticipated|CardioVascular Research Foundation, Korea|||21||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 23:26:51.606562|2018-05-31 23:26:51.606562
NCT01186120|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2013-11-05|2010-08-20|2010-08-23|Estimate|||||||2013-11-05|2013-11-06|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|LONG-DES-V||Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-V:Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents|Completed||Phase 4|500|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-05-31 23:26:51.697443|2018-05-31 23:26:51.697443
NCT01186107|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2014-07-28|2010-08-20|2010-08-23|Estimate|||||||2014-07-28|2014-07-29|Estimate|August 2010||2010-08-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|ESSENCE-DM2||Comparison of Zotarolimus-Eluting Stent vs Sirolimus-Eluting Stent for Diabetic Patients|Randomized Comparison of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus|Completed||Phase 4|256|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-05-31 23:26:51.789696|2018-05-31 23:26:51.789696
NCT01186094|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2012-08-06|2010-08-20|2010-08-23|Estimate|||||||2012-08-06|2012-08-08|Estimate|May 2009||2009-05-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|LONG-DES-IV||Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: (LONG-DES-IV)|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-IV: Sirolimus vs. Zotarolimus-eluting Stent|Completed||Phase 4|502|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-05-31 23:26:51.87034|2018-05-31 23:26:51.87034
NCT01186081|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2010-08-20|2010-08-20|2010-08-23|Estimate|||||||2010-08-20|2010-08-23|Estimate|March 2004||2004-03-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Comparison of Preoperative and Postoperative Radiotherapy and Capecitabine in Locally Advanced Rectal Cancer|Comparison of Preoperative and Postoperative Radiotherapy and Capecitabine in Locally Advanced Rectal Cancer|Completed||Phase 3|240|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:26:51.964666|2018-05-31 23:26:51.964666
NCT01186068|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-11-22|2010-08-19|2010-08-20|Estimate|||||||2010-11-22|2010-11-24|Estimate|August 2010||2010-08-31|August 2010|2010-08-31||||||||Interventional|||Dose Response Study of Patients With Erythematous Rosacea|A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study of the Dose-Response Profile of V-101 Cream in Subjects With Erythematous Rosacea|Completed||Phase 2|175|Anticipated|Vicept Therapeutics, Inc.||5|||f||||f||||||||||2018-05-31 23:26:52.037951|2018-05-31 23:26:52.037951
NCT01186055|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-07-11|2010-08-19|2010-08-20|Estimate|||||||2013-07-11|2013-07-15|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Brain Activity and Smoking Cessation|Neural Mechanisms Underlying Smoking Relapse (Center for Interdisciplinary Research on Nicotine Addiction - CIRNA)|Completed|||80|Actual|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     1. A 2ml saliva sample for DNA collection & genotyping (Oragene™).~        2. A 5ml saliva sample to assess nicotine metabolites (e.g. cotinine and~          3-hydroxycotinine).~   "|||2018-05-31 23:26:52.117029|2018-05-31 23:26:52.117029
NCT01186042|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-09-07|2010-08-19|2010-08-20|Estimate|||||||2017-09-07|2017-09-11|Actual|August 2010||2010-08-31|September 2017|2017-09-30|December 17, 2014|Actual|2014-12-17|December 17, 2014|Actual|2014-12-17||Observational|CHAIN||Chronic HIV Infection and Aging in NeuroAIDS (CHAIN)|Chronic HIV Infection and Aging in NeuroAIDS (CHAIN)|Completed|||21|Actual|University of Nebraska|||1||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 23:26:52.18039|2018-05-31 23:26:52.18039
NCT01186029|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-01-29|2010-08-19|2010-08-20|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2010||2010-10-31|January 2018|2018-01-31|October 2011|Anticipated|2011-10-31|January 2011|Anticipated|2011-01-31||Interventional|||Comparison of Adding EMEND to PONV/PDNV Treatment Regimen|A Comparison Study to Determine the Increased Efficacy of Adding EMEND to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting|Withdrawn||N/A|0|Actual|University of Nebraska||||It didn't get IRB approval.|f||||t||||||||||2018-05-31 23:26:52.266787|2018-05-31 23:26:52.266787
NCT01186016|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-01-17|2010-08-19|2010-08-20|Estimate|||||||2013-01-17|2013-01-21|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Developing Genetic Education for Smoking Cessation|Developing Genetic Education for Smoking Cessation|Completed||N/A|103|Actual|University of Nebraska||2|||f||||t||||||||||2018-05-31 23:26:52.330332|2018-05-31 23:26:52.330332
NCT01186003|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2018-02-05|2010-08-19|2010-08-20|Estimate|||||||2018-02-05|2018-02-06|Actual|August 2010|Actual|2010-08-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|March 2017|Actual|2017-03-31||Interventional|||Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy|Effectiveness of a Subcutaneously Administered Long-Acting Insulin Detemir Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment|Completed||N/A|33|Actual|University of Colorado, Denver||2|||f||||f||f||||||||2018-05-31 23:26:52.408471|2018-05-31 23:26:52.408471
NCT01185990|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-03-22|2010-08-19|2010-08-20|Estimate|||||||2011-03-22|2011-03-23|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||Tinnitus Measured by MEG and Synchronous Neural Interaction™ Test: Template Development|Moderate to Severe Tinnitus as Measured by MEG and the Synchronous Neural Interaction™ Test: Template Development Study|Unknown status|Recruiting||45|Anticipated|Orasi Medical, Inc.|||2||f||||f||||||||||2018-05-31 23:26:52.621674|2018-05-31 23:26:52.621674
NCT01185977|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-07-02|2010-08-19|2010-08-20|Estimate|||||||2014-07-02|2014-07-03|Estimate|April 2010||2010-04-30|July 2014|2014-07-31||||October 2011|Actual|2011-10-31||Interventional|||Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)|Biomarkers of Antidepressant Treatment in Adolescents With Major Depression|Completed||Phase 4|26|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 23:26:52.700713|2018-05-31 23:26:52.700713
NCT01185964|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2016-11-18|2015-01-16|2017-03-03|2010-08-19|2010-08-20|Estimate|2017-03-03|2017-04-14|Actual|2015-01-16|2015-01-29|Estimate|2017-03-03|2017-04-14|Actual|October 2010||2010-10-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|August 2014|Actual|2014-08-31||Interventional|||A Study of Olaratumab in Soft Tissue Sarcoma|A Phase 1b/2, With Phase 2 Randomized, Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma|Completed||Phase 1/Phase 2|148|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:26:52.855776|2018-05-31 23:26:52.855776
NCT01185951|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-08-19|2010-08-19|2010-08-20|Estimate|||||||2010-08-19|2010-08-20|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Interventional|TENDOSHOCK||TENDOSHOCK-2010 Combination Therapy for Athletic Tendinopathies|TENDOSHOCK-2010 - Combined Sclerosing Therapy, Extracorporeal Shockwave Therapy, Eccentric Training and Topical Glyceryl Trinitrate for Athletic Tendinopathies|Unknown status|Active, not recruiting|Phase 2|114|Actual|Hannover Medical School||3|||f||||f||||||||||2018-05-31 23:26:54.337299|2018-05-31 23:26:54.337299
NCT01185938|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-10-18|2010-08-19|2010-08-20|Estimate|||||||2012-10-18|2012-10-19|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|PRATO-ACS||Statin Contrast Induced Nephropathy Prevention|Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial|Completed||Phase 4|500|Actual|Centro Cardiopatici Toscani||2|||f||||t||||||||||2018-05-31 23:26:54.502628|2018-05-31 23:26:54.502628
NCT01185925|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2011-08-04|2010-08-19|2010-08-20|Estimate|||||||2011-08-04|2011-08-05|Estimate|April 2008||2008-04-30|May 2008|2008-05-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Exercise Oscillatory Breathing and Sildenafil in Heart Failure|PDE5-Inhibition With Sildenafil Reverses Exercise Oscillatory Breathing in Chronic Heart Failure: a Long-Term Cardiopulmonary Exercise Testing Placebo-Controlled Study|Completed||Phase 2|32|Actual|University of Milan||2|||f||||||||||||||2018-05-31 23:26:54.600086|2018-05-31 23:26:54.600086
NCT01185912|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2015-05-19|2010-08-19|2010-08-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Cardiomyocyte Apoptosis Following Antegrade and Retrograde Cardioplegia||Completed|||20|Actual|Turku University Hospital|||1||f||||f||||||Samples Without DNA|"~     Transmyocardial needle biopsies~   "|||2018-05-31 23:26:54.668861|2018-05-31 23:26:54.668861
NCT01185899|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2015-11-18|2010-08-19|2010-08-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Usefulness of High-frequency QRS Analysis in the Evaluation of Patients With Chest Pain|The Usefulness of High-frequency QRS Analysis in the Evaluation of Patients Presenting to the Emergency Department With Chest Pain|Completed|||324|Actual|Soroka University Medical Center|||1||f||||f||||||||||2018-05-31 23:26:54.767031|2018-05-31 23:26:54.767031
NCT01185886|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2017-07-26|2010-08-19|2010-08-20|Estimate|||||||2017-07-26|2017-07-28|Actual|June 2011|Actual|2011-06-30|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia|Translational Research - Observational Study for Identification of New Possible Prognostic Factors and Future Therapeutic Targets in Children With Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting|||1200|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||t||||||||||2018-05-31 23:26:54.877215|2018-05-31 23:26:54.877215
NCT01185873|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2016-11-01|2010-08-19|2010-08-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment|The Effect of Hepatic Impairment on the Pharmacokinetics of RO5190591/Ritonavir: A Multiple-Center, Open-Label Study Following Multiple Oral Doses of RO5190591/Ritonavir to Subjects With Mild, Moderate, or Severe Hepatic Impairment and Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|81|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:26:55.192457|2018-05-31 23:26:55.192457
NCT01185860|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2016-11-01|2010-08-19|2010-08-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1|A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1|Completed||Phase 1|59|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:26:55.321429|2018-05-31 23:26:55.321429
NCT01185847|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2015-12-31|2010-08-19|2010-08-20|Estimate|||||||2015-12-31|2016-01-01|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-label Phase Ib/II Study of RO5083945 in Combination With Cisplatin and Gemcitabine/Pemetrexed Versus Cisplatin and Gemcitabine/Pemetrexed in Patients With Advanced or Recurrent Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy|Completed||Phase 2|90|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:26:55.449304|2018-05-31 23:26:55.449304
NCT01185834|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2011-12-20||2012-06-26|2010-08-19|2010-08-20|Estimate|2011-12-20|2012-01-24|Estimate||||2012-06-26|2012-07-10|Estimate|July 2010||2010-07-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Assessment of Lotrafilcon A Contact Lenses|Assessment of Lotrafilcon A Contact Lenses|Completed||N/A|118|Actual|Alcon Research|||||f||||||||||||||2018-05-31 23:26:55.599233|2018-05-31 23:26:55.599233
NCT01185821|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|2017-10-10||2018-02-27|2010-08-19|2010-08-20|Estimate|2017-11-12|2017-12-12|Actual||||2018-02-27|2018-03-27|Actual|August 30, 2010|Actual|2010-08-30|February 2018|2018-02-28|October 10, 2016|Actual|2016-10-10|October 10, 2016|Actual|2016-10-10||Interventional||The Extension set consisted of all patients who received at least one dose of Extension study drug who do not have a major protocol deviation.|Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis|A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|185|Actual|Novartis||5|||f||||t|t|f||||||||2018-05-31 23:26:55.820112|2018-05-31 23:26:55.820112
NCT01185808|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2018-04-27|2010-08-19|2010-08-20|Estimate|||||||2018-04-27|2018-05-01|Actual|October 2013||2013-10-31|April 2018|2018-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|VDinCRS||Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps|Vitamin D Supplementation in Chronic Rhinosinusitis With Nasal Polyps|Withdrawn||N/A|0|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 23:26:58.473752|2018-05-31 23:26:58.473752
NCT01185795|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-06-29|2010-08-19|2010-08-20|Estimate|||||||2012-06-29|2012-07-02|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Efficacy of Cardioviva™ Probiotic Yogurt Formulation|Efficacy of a Microencapsulated Probiotic Yogurt Formulation as a Health Promoting Agent|Completed||Phase 2|150|Actual|Micropharma Limited||2|||f||||f||||||||||2018-05-31 23:26:58.632304|2018-05-31 23:26:58.632304
NCT01185782|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2011-09-26||2013-12-02|2010-08-19|2010-08-20|Estimate|2012-01-19|2012-02-24|Estimate||||2013-12-02|2013-12-27|Estimate|February 2007||2007-02-28|December 2013|2013-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women|Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study|Completed||Phase 3|300|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 23:26:58.878448|2018-05-31 23:26:58.878448
NCT01185769|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2010-08-19|2010-08-19|2010-08-20|Estimate|||||||2010-08-19|2010-08-20|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Tocotrienol Absorption and Distribution Under Different Fat Status|Mechanism of Absorption and Distribution of Tocotrienols Under Different Food Status|Completed||N/A|10|Actual|Malaysia Palm Oil Board||2|||f||||t||||||||||2018-05-31 23:26:59.565392|2018-05-31 23:26:59.565392
NCT01185756|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-01-10|2010-08-19|2010-08-20|Estimate|||||||2018-01-10|2018-01-11|Actual|September 2010|Actual|2010-09-30|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|March 2017|Actual|2017-03-31||Interventional|MISTIC||MIBG Scintigraphy as a Tool for Selecting Patients Requiring Implantable Cardioverter Defibrillator (ICD)|Can we Better Select Patients With Heart Failure for a Primary Prevention Indication of Implantable Cardioverter Defibrillator (ICD)? Evaluation of the Diagnostic Value of 123I Meta-iodobenzylguanidine (MIBG)|Active, not recruiting||N/A|330|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||Undecided||2018-05-31 23:26:59.725698|2018-05-31 23:26:59.725698
NCT01185743|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2017-03-22|2010-08-19|2010-08-20|Estimate|||||||2017-03-22|2017-03-23|Actual|July 2010||2010-07-31|March 2017|2017-03-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Antipsychotics and Gene Expression in Soft Tissues|Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study|Completed||Phase 4|16|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 23:26:59.830952|2018-05-31 23:26:59.830952
NCT01185730|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2016-04-08|2010-08-19|2010-08-20|Estimate|||||||2016-04-08|2016-04-11|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|EFORT||Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics|Evaluation of Prognostic Factors and Therapeutic Targets in Pulmonary Arterial Hypertension|Completed||N/A|165|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:26:59.917361|2018-05-31 23:26:59.917361
NCT01185717|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2014-05-29|2010-08-19|2010-08-20|Estimate|||||||2014-05-29|2014-06-02|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|JEMS||JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)|Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients|Completed|||7726|Actual|Biogen|||||f||||f||||||||||2018-05-31 23:27:00.008755|2018-05-31 23:27:00.008755
NCT01185704|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2013-03-25||2014-01-20|2010-08-19|2010-08-20|Estimate|2013-07-02|2013-07-03|Estimate||||2014-01-20|2014-02-13|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|ATTAC-PCO||Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)|A Phase IIIb Randomized Open-label Study to Compare the Estradiol Level on the Releasing Day in Two Regimen of Cetrotide® 0.25 mg Used From Day 1 or From Day 7 of the Menstrual Cycle (Day 0 or Day 6 of Stimulation) in Polycystic Ovarian (PCO) Women in ART (IVF/ICSI).|Completed||Phase 3|136|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:27:00.180165|2018-05-31 23:27:00.180165
NCT01185691|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-05-01|2010-08-19|2010-08-20|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RELIEF I||Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients|RELIEF I: Investigating the Role of IMPELLA 2.5 System In Acutely Decompensated Chronic Heart Failure Patients. A Prospective, Single Center Feasibility Study|Terminated||N/A|1|Actual|Abiomed Inc.||||Low enrollment|f||||f||||||||||2018-05-31 23:27:01.134052|2018-05-31 23:27:01.134052
NCT01185678|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2013-06-25|2010-08-19|2010-08-20|Estimate|||||||2013-06-25|2013-06-27|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|DOC Non Stop||Data on Oral Contraceptives Compliance in Non Stop Regimen|Observation of Compliance With Dosage in Women Using Oral Contraceptives Designed for the Non Stop Use, (it Means 28 Pills for 28-days Cycle).|Completed|||8416|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:27:01.313522|2018-05-31 23:27:01.313522
NCT01185665|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-19|||2010-08-19|2010-08-19|2010-08-20|Estimate|||||||2010-08-19|2010-08-20|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Predicting Outcome of Transcutaneous Electrical Nerve Stimulator (TENS) in Failed Back Surgery Syndrome||Unknown status|Not yet recruiting|N/A|40|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 23:27:01.426772|2018-05-31 23:27:01.426772
NCT01185652|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2011-05-12|2010-08-18|2010-08-20|Estimate|||||||2011-05-12|2011-05-13|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|September 2012|Anticipated|2012-09-30|April 2012|Anticipated|2012-04-30||Observational|||A Study on Smoking-related Lung Function Abnormalities and Correlation With Serum Biomarkers in Chinese|A Study on Smoking-related Lung Function Abnormalities and Correlation With Serum Biomarkers in Chinese|Unknown status|Recruiting||1000|Anticipated|The University of Hong Kong|||||f||||t||||||Samples With DNA|"~     10 ml Peripheral blood will be collected upon recruitment for storage and later extraction of~     DNA and serum biomarkers~   "|||2018-05-31 23:27:01.519433|2018-05-31 23:27:01.519433
NCT01185639|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2017-08-14|2010-08-19|2010-08-20|Estimate|||||||2017-08-14|2017-08-17|Actual|August 2010|Actual|2010-08-31|August 2017|2017-08-31|June 27, 2016|Actual|2016-06-27|June 27, 2016|Actual|2016-06-27||Interventional|||Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer|Phase II Study of Stereotactic Body Radiation Therapy (SBRT) After First-Line Chemotherapy for Metastatic NSCLC|Completed||N/A|29|Actual|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 23:27:01.60528|2018-05-31 23:27:01.60528
NCT01185626|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2017-05-08|2010-08-19|2010-08-20|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2011||2011-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ROGYcare||ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers|ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers. A Pragmatic Cluster Randomized Controlled Trial|Completed||N/A|396|Actual|University of Tilburg||2|||f||||t||||||||||2018-05-31 23:27:01.721077|2018-05-31 23:27:01.721077
NCT01185613|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-04-03|2010-08-18|2010-08-20|Estimate|||||||2012-04-03|2012-04-04|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|FACT-AF||Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|Completed||Phase 2|50|Anticipated|St. Jude Medical||1|||f||||f||||||||||2018-05-31 23:27:01.950406|2018-05-31 23:27:01.950406
NCT01185600|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2016-07-18||2017-06-02|2010-08-19|2010-08-20|Estimate|2016-10-03|2016-11-23|Estimate||||2017-06-02|2017-07-02|Actual|July 2010||2010-07-31|June 2017|2017-06-30|May 2015|Actual|2015-05-31|April 2014|Actual|2014-04-30||Interventional|||Microparticles in Stored RBC as Potential Mediators of Transfusion Complications|Microparticles in Stored Red Blood Cells (RBC) as Potential Mediators of Transfusion Complications (II): Clinical Study|Completed||N/A|177|Actual|University of Miami|A major limitation of the present study is its small sample size and its restriction to CABG surgery. Larger-scale controlled studies comparing transfusion with washed vs. unwashed PCs are warranted.|2|||f||||t||||||||||2018-05-31 23:27:02.201059|2018-05-31 23:27:02.201059
NCT01185587|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-04-21|2010-08-19|2010-08-20|Estimate|||||||2014-04-21|2014-04-23|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|SOCS-HEFT||Sodium Channel Splicing in Heart Failure Trial|Sodium Channel Splicing in Heart Failure Trial|Completed|||147|Actual|University of Illinois at Chicago|||4||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 23:27:03.598964|2018-05-31 23:27:03.598964
NCT01185574|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2013-07-10|2010-08-18|2010-08-20|Estimate|||||||2013-07-10|2013-07-11|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Vitamin D for Improving Metabolic Control and Depressive Symptoms|Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study|Completed||N/A|50|Actual|Loyola University||1|||f||||t||||||||||2018-05-31 23:27:03.676366|2018-05-31 23:27:03.676366
NCT01185561|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2016-10-19||2016-10-19|2010-08-18|2010-08-20|Estimate|2016-10-19|2016-12-14|Estimate||||2016-10-19|2016-12-14|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|SWEEP|All randomized participants are included in the baseline analysis population.|A Pychoeducational Intervention for Women With Diabetes|A Pychoeducational Intervention for Women With Diabetes|Completed||N/A|74|Actual|Loyola University|There are no limitations or caveats to report.|2|||f||||t||||||||No||2018-05-31 23:27:03.807072|2018-05-31 23:27:03.807072
NCT01185548|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2011-04-12|2010-08-18|2010-08-20|Estimate|||||||2011-04-12|2011-04-14|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma|The Effect of Tasisulam on the CYP2C9-Mediated Metabolism of Tolbutamide: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma|Terminated||Phase 1|4|Actual|Eli Lilly and Company||1||Terminated based on safety results from another trial|f||||f||||||||||2018-05-31 23:27:04.179918|2018-05-31 23:27:04.179918
NCT01185535|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-08-19|2010-08-19|2010-08-20|Estimate|||||||2010-08-19|2010-08-20|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Interventional|||Effects of Topical Anesthesia With Pressure Nebulized 2% Lidocaine During Awake Intubation|Effects of Topical Anesthesia With Pressure Nebulized 2% Lidocaine During Awake Intubation|Unknown status|Active, not recruiting|Phase 2/Phase 3|90|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 23:27:04.24823|2018-05-31 23:27:04.24823
NCT01185522|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2016-03-30||2016-05-16|2010-08-18|2010-08-20|Estimate|2016-05-16|2016-06-23|Estimate||||2016-05-16|2016-06-23|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational||Safety population consisted of all participants included in the study who respected the inclusion and non-inclusion criteria and received at least one tocilizumab infusion.|An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)|Pharmacoepidemiological Study of the Impact of Roactemra® Treatment on Fatigue in Rheumatoid Arthritis Patients in a Real Life Setting|Completed|||719|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:27:04.44032|2018-05-31 23:27:04.44032
NCT01185509|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2017-04-17||2017-07-29|2010-08-19|2010-08-20|Estimate|2017-04-17|2017-05-24|Actual||||2017-07-29|2017-08-28|Actual|November 2010|Actual|2010-11-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|January 2017|Actual|2017-01-31||Interventional||The analysis dataset is comprised of all treated patients.|Trastuzumab and Vinorelbine in Advanced Breast Cancer|A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells|Terminated||Phase 2|31|Actual|Dana-Farber Cancer Institute|The study terminated early due to insufficient response per statistical design.|2||Not enough confirmed responses to continue treatment.|f||||t|t|f||||||No||2018-05-31 23:27:05.122631|2018-05-31 23:27:05.122631
NCT01185496|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2011-06-10|2010-08-19|2010-08-20|Estimate|||||||2011-06-10|2011-06-13|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Observational|||Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus|Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes Mellitus|Completed|||64|Anticipated|DexCom, Inc.|||1||f||||f||||||||||2018-05-31 23:27:05.721598|2018-05-31 23:27:05.721598
NCT01185483|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-09-03|2010-08-19|2010-08-20|Estimate|||||||2010-09-03|2010-09-06|Estimate|November 2009||2009-11-30|August 2010|2010-08-31|February 2011|Anticipated|2011-02-28|November 2010|Anticipated|2010-11-30||Observational|||Endoscopic Submucosal Dissection in Upper Gastrointestinal Canal With HybridKnife|Endoscopic Submucosal Dissection in Upper Gastrointestinal Canal With HybridKnife|Unknown status|Recruiting||20|Anticipated|Odense University Hospital|||||f||||f||||||||||2018-05-31 23:27:05.776956|2018-05-31 23:27:05.776956
NCT01185470|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2017-04-20|2010-08-19|2010-08-20|Estimate|||||||2017-04-20|2017-04-24|Actual|February 2011||2011-02-28|April 2017|2017-04-30|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Interventional|||The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain|THE CLINICAL EVALUATION OF IMPLANTABLE PUMP SYSTEM FOR SAFETY AND DELIVERY ACCURACY IN PATIENTS REQUIRING INTRATHECAL ADMINISTRATION OF MORPHINE SULFATE FOR CHRONIC PAIN|Completed||Phase 2/Phase 3|75|Actual|Medallion Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 23:27:05.838337|2018-05-31 23:27:05.838337
NCT01185457|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-10-26|2010-08-19|2010-08-20|Estimate|||||||2012-10-26|2012-10-29|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|||Effect of Interscalene Block on Heart Rate Variability (HRV)|Effect of Interscalene Block on Heart's Autonomic Nervous System With Heart Rate Variability Measurement|Completed|||50|Anticipated|Larissa University Hospital|||2||f||||f||||||||||2018-05-31 23:27:05.911858|2018-05-31 23:27:05.911858
NCT01185444|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-08-19|2010-08-19|2010-08-20|Estimate|||||||2010-08-19|2010-08-20|Estimate|February 2009||2009-02-28|December 2008|2008-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of Three Weekly Injections of a Bacterial-- Sourced Hyaluronate on Pain and Function in Patients With Knee Osteoarthritis (OA)|Efficacy of 3 Weekly Injections of a Bacterial-- Sourced Hyaluronate on Pain and Physical Function in Patients With Knee Osteoarthritis—a Randomized Controlled Clinical Trial|Completed||Phase 2|89|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 23:27:05.98133|2018-05-31 23:27:05.98133
NCT01185431|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-02-06|2010-08-19|2010-08-20|Estimate|||||||2012-02-06|2012-02-07|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||The Effects of a Ficus Carica on Improvement in Bowl Movements in Female Volunteer With Functional Constipation|Randomized, Double-Blind, Placebo-Controlled, Parallel Trial in Female Volunteers With Functional Constipation, to Evaluate the Improvement in Bowl Movement of Ficus Carica|Completed||N/A|40|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 23:27:06.071147|2018-05-31 23:27:06.071147
NCT01185418|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2010-08-19|2010-08-19|2010-08-20|Estimate|||||||2010-08-19|2010-08-20|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer|Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer: a Double-blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, Amisulpride, Risperidone and Aripiprazole|Completed|||80|Actual|Chonbuk National University Hospital|||5||f||||f||||||||||2018-05-31 23:27:06.1323|2018-05-31 23:27:06.1323
NCT01185405|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2013-09-29|2010-08-19|2010-08-20|Estimate|||||||2013-09-29|2013-10-01|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients|Prediction and Adjustment of Voriconazole Plasma Level in Critically Ill Patients|Withdrawn||N/A|0|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 23:27:06.203796|2018-05-31 23:27:06.203796
NCT01185392|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-07|||2015-07-27|2010-08-18|2010-08-19|Estimate|||||||2015-07-27|2015-07-28|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|June 2009|Actual|2009-06-30||Observational|||European Cardiac Resynchronisation Therapy Survey|European Cardiac Resynchronisation Therapy Survey|Completed|||2438|Actual|Helse Stavanger HF|||||f||||f||||||||||2018-05-31 23:27:06.267552|2018-05-31 23:27:06.267552
NCT01185379|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-09-25|2010-08-18|2010-08-19|Estimate|||||||2012-09-25|2012-09-26|Estimate|July 2010||2010-07-31|November 2010|2010-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Effects of Efalex Active 50+ on Cognitive Performance, Well-being and Cerebral Hemodynamics in Healthy Older Adults|Investigation of the Effects of Efalex Active 50+ on Cognitive Performance, Well-being and Cerebral Hemodynamics in Healthy Adults Aged 50-70 Years Reporting Subjective Memory Deficits|Completed||N/A|261|Actual|Northumbria University||3|||f||||f||||||||||2018-05-31 23:27:06.331745|2018-05-31 23:27:06.331745
NCT01185366|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2018-01-03|2010-08-18|2010-08-19|Estimate|||||||2018-01-03|2018-01-05|Actual|August 2010|Actual|2010-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma|Everolimus Versus Sunitinib Therapy in Patients With Advanced Non-clear Cell Renal Cell Carcinoma|Active, not recruiting||Phase 2|108|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 23:27:06.562117|2018-05-31 23:27:06.562117
NCT01185353|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2017-03-10|2012-02-10|2017-05-22|2010-08-18|2010-08-19|Estimate|2017-03-10|2017-04-21|Actual|2012-02-10|2012-02-14|Estimate|2017-05-22|2017-06-16|Actual|October 2010||2010-10-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|December 2011|Actual|2011-12-31||Interventional||All randomized participants who received at least 1 dose of study drug.|A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy|Completed||Phase 2|301|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 23:27:07.499091|2018-05-31 23:27:07.499091
NCT01185340|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2018-02-17|2013-09-20|2018-03-26|2010-08-18|2010-08-19|Estimate|2018-03-26|2018-04-27|Actual|2013-09-20|2013-09-27|Estimate|2018-03-26|2018-04-27|Actual|March 2011||2011-03-31|March 2018|2018-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Participants who completed the Confirmation (CF) Phase and were randomized to adjunctive LY2216684 or adjunctive placebo or who did not met randomization criteria and continued on placebo to maintain the blind.|A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor|A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment|Completed||Phase 3|1056|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:27:12.368344|2018-05-31 23:27:12.368344
NCT01185327|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-06-05|2010-08-18|2010-08-19|Estimate|||||||2011-06-05|2011-06-08|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Do Isreali Infants of Ethiopian Origin Mother Regurgitate More Than Other Infants?|Do Isreali Infants of Ethiopian Origin Mother Regurgitate More Than Other Infants?|Completed|||220|Actual|Hillel Yaffe Medical Center|||2||f||||f||||||||||2018-05-31 23:27:13.68736|2018-05-31 23:27:13.68736
NCT01185314|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-08-05|2010-08-18|2010-08-19|Estimate|||||||2011-08-05|2011-08-08|Estimate|September 2010||2010-09-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PIONEER||To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|A Molecular Epidemiology Study in Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) of Adeno Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status|Completed||N/A|1270|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:27:13.761362|2018-05-31 23:27:13.761362
NCT01185301|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2013-09-11||2013-09-11|2010-08-18|2010-08-19|Estimate|2013-09-11|2013-11-15|Estimate||||2013-09-11|2013-11-15|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|CONCERTO||Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)|A Double-Blind, Randomized, Parallel-Arm, Multicenter Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy With Adalimumab in Subjects With Early Rheumatoid Arthritis (CONCERTO)|Completed||Phase 3|395|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 23:27:13.998925|2018-05-31 23:27:13.998925
NCT01185288|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2014-01-31||2014-01-31|2010-08-18|2010-08-19|Estimate|2014-01-31|2014-03-18|Estimate||||2014-01-31|2014-03-18|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MUSICA||A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)|A Multicenter, Double-Blind, Randomized, Parallel-Arm Study to Determine the Effect of Methotrexate Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis Treated With Adalimumab (MUSICA)|Completed||Phase 4|309|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 23:27:15.239558|2018-05-31 23:27:15.239558
NCT01185275|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2017-06-23|2010-08-18|2010-08-19|Estimate|||||||2017-06-23|2017-06-26|Actual|August 2010||2010-08-31|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|BTR||A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)|A Prospective Observational Study of Biopredictors of Bronchial Thermoplasty Response in Patients With Severe Refractory Asthma (BTR Study)|Recruiting|||190|Anticipated|Washington University School of Medicine|||1||f||||f||||||Samples With DNA|"~     DNA and RNA extraction, serum, plasma and sputum~   "|||2018-05-31 23:27:16.069654|2018-05-31 23:27:16.069654
NCT01185262|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-09-27|2010-08-18|2010-08-19|Estimate|||||||2013-09-27|2013-09-30|Estimate|April 2009||2009-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|LLC-LENAR-08||Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia|Phase I Study of the Activity and Safety of Lenalidomide and Rituximab as Non-chemotherapy Therapy for Patients With Recurrent and Refractory Chronic Lymphocytic Leukemia|Completed||Phase 1|25|Actual|MD Anderson International Spain SA||1|||f||||f||||||||||2018-05-31 23:27:16.234465|2018-05-31 23:27:16.234465
NCT01185249|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2012-12-03||2013-06-19|2010-08-18|2010-08-19|Estimate|2013-06-19|2013-07-25|Estimate||||2013-06-19|2013-07-25|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Congestive Heart Failure Weight Study|Time of Day and Accurate Weights for Patients With Congestive Heart Failure (CHF)|Completed||N/A|66|Actual|Central DuPage Hospital|Pilot study with small sample size in one patient population.|1|||f||||t||||||||||2018-05-31 23:27:16.348709|2018-05-31 23:27:16.348709
NCT01185236|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2010-08-18|2010-08-18|2010-08-19|Estimate|||||||2010-08-18|2010-08-19|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes|A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes|Unknown status|Not yet recruiting|Phase 4|132|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:27:16.611423|2018-05-31 23:27:16.611423
NCT01185223|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-12-07|2010-08-18|2010-08-19|Estimate|||||||2012-12-07|2012-12-10|Estimate|September 2010||2010-09-30|December 2012|2012-12-31||||December 2012|Anticipated|2012-12-31||Interventional|CONVINCE||Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation|Multicenter, Randomized Study Comparing Oral Valganciclovir Versus Intravenous Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation|Terminated||Phase 3|212|Anticipated|Pierrel Research Europe GmbH||2|||f||||f||||||||||2018-05-31 23:27:16.706134|2018-05-31 23:27:16.706134
NCT01185210|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-07-11|2010-08-18|2010-08-19|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2007||2007-09-30|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Investigation of Alanine in Fructose Intolerance: A Dose Ranging Study|Investigation of Alanine in Fructose Intolerance: A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study|Active, not recruiting||N/A|40|Anticipated|Augusta University||3|||f||||f||||||||||2018-05-31 23:27:16.865972|2018-05-31 23:27:16.865972
NCT01185197|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2016-10-25|2010-08-18|2010-08-19|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study|Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome|Recruiting||Phase 4|20|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:27:16.938402|2018-05-31 23:27:16.938402
NCT01185184|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2010-09-13|2010-08-18|2010-08-19|Estimate|||||||2010-09-13|2010-09-14|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers|A Phase 1, Randomized, 3-Period, Open Label, Single Dose, Cross Over Study To Evaluate The Pharmacokinetics And Safety Of Two Controlled Release Formulations Of CP-690,550|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:27:17.02414|2018-05-31 23:27:17.02414
NCT01185171|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2017-09-08|2010-08-18|2010-08-19|Estimate|||||||2017-09-08|2017-09-12|Actual|January 27, 2003|Actual|2003-01-27|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer|Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer|Active, not recruiting||Phase 2|65|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 23:27:17.108493|2018-05-31 23:27:17.108493
NCT01185158|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-01-16|2010-08-18|2010-08-19|Estimate|||||||2014-01-16|2014-01-17|Estimate|May 2002||2002-05-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|August 2004|Actual|2004-08-31||Interventional|||A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma|A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma|Completed||Phase 2|46|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 23:27:17.216225|2018-05-31 23:27:17.216225
NCT01185145|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2013-07-10|2010-08-18|2010-08-19|Estimate|||||||2013-07-10|2013-07-11|Estimate|February 2004||2004-02-29|July 2013|2013-07-31|August 2024|Anticipated|2024-08-31|August 2014|Anticipated|2014-08-31||Interventional|APBI||Accelerated Partial Breast Radiotherapy With Either Mammosite or Intensity Modulated Radiotherapy|A Phase II Study of Accelerated Partial Breast Radiotherapy With Either a Novel Breast Brachytherapy Technique - Mammosite or Intensity Modulated Radiotherapy|Active, not recruiting||Phase 2|291|Actual|Rocky Mountain Cancer Centers||2|||f||||f||||||||||2018-05-31 23:27:17.400878|2018-05-31 23:27:17.400878
NCT01185132|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-06-24|2010-08-18|2010-08-19|Estimate|||||||2014-06-24|2014-06-26|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|July 2028|Anticipated|2028-07-31|July 2018|Anticipated|2018-07-31||Interventional|2009-APBI||Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy|A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy|Recruiting||Phase 3|660|Anticipated|Rocky Mountain Cancer Centers||2|||f||||f||||||||||2018-05-31 23:27:17.500174|2018-05-31 23:27:17.500174
NCT01185119|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2011-03-21|2010-08-18|2010-08-19|Estimate|||||||2011-03-21|2011-03-22|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET|The Effect of Native GLP-1 on Glucose Metabolism in the CNS During Hyperglycemia in Healthy Young Men Assessed by PET|Completed||Phase 2/Phase 3|10|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:27:17.645838|2018-05-31 23:27:17.645838
NCT01185093|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-02-13|2010-08-18|2010-08-19|Estimate|||||||2012-02-13|2012-02-14|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||St. Jude Cancer Education for Children Program: Evaluation at 4th-Grade Level|St. Jude Cancer Education for Children Program: Evaluation at 4th-Grade Level|Completed|||481|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 23:27:17.737123|2018-05-31 23:27:17.737123
NCT01185080|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2015-08-31||2015-12-02|2010-08-18|2010-08-19|Estimate|2015-12-02|2016-01-07|Estimate||||2015-12-02|2016-01-07|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848|A Double-blind, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Investigate the Efficacy, Tolerability, and Safety of Different Dosing Regimens of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients Out of Pollen Season in a Nasal Allergen Challenge Model|Completed||Phase 2|93|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:27:17.836015|2018-05-31 23:27:17.836015
NCT01185067|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2017-06-02|2010-08-18|2010-08-19|Estimate|||||||2017-06-02|2017-06-06|Actual|October 2010|Actual|2010-10-31|June 2017|2017-06-30|February 24, 2014|Actual|2014-02-24|November 4, 2013|Actual|2013-11-04||Interventional|GRAPEVINE-HF||Physiological Effects of Grape Seed Extract in Diastolic Heart Failure|GRAPe Seed Extract and Ventriculovascular Investigation in Normal Ejection-Fraction Heart Failure|Completed||Phase 1|15|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 23:27:18.591925|2018-05-31 23:27:18.591925
NCT01185054|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2018-04-16|2010-08-18|2010-08-19|Estimate|||||||2018-04-16|2018-04-17|Actual|November 2010||2010-11-30|April 2018|2018-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Is Electrolyte Maintenance Solution Required in Low-Risk Children With Gastroenteritis?|Is Electrolyte Maintenance Solution Required in Low-Risk Children With Gastroenteritis?|Completed||Phase 2|624|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 23:27:18.727899|2018-05-31 23:27:18.727899
NCT01185041|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2012-03-17|2010-08-18|2010-08-19|Estimate|||||||2012-03-17|2012-03-20|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Watermelon Supplementation and Arterial Stiffness|Effects of Oral L-citrulline/L-arginine in Watermelon on Central Blood Pressure and Arterial Stiffness in Individuals With Obesity-related High Blood Pressure|Completed||Phase 1/Phase 2|20|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 23:27:18.803237|2018-05-31 23:27:18.803237
NCT01185028|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2013-03-21||2018-03-14|2010-08-18|2010-08-19|Estimate|2013-03-21|2013-05-15|Estimate||||2018-03-14|2018-03-21|Actual|August 2010||2010-08-31|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures|An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders|Completed||Phase 1/Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 23:27:18.886435|2018-05-31 23:27:18.886435
NCT01185015|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-07-01|2010-08-18|2010-08-19|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2011||2011-01-31|July 2012|2012-07-31||||January 2011|Actual|2011-01-31||Interventional|SIGMART||A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization|A Clinical Trial to Assess the Efficacy of Sigmart in Patients With Recurrent Angina After Coronary Revascularization|Withdrawn||Phase 4|0|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:27:19.104529|2018-05-31 23:27:19.104529
NCT01185002|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2011-06-09|2010-08-18|2010-08-19|Estimate|||||||2011-06-09|2011-06-10|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen|Evaluation of PillCam® Colon 2 Capsule Endoscopy Regimen|Completed||Phase 2/Phase 3|80|Anticipated|Given Imaging Ltd.||3|||f||||f||||||||||2018-05-31 23:27:19.193654|2018-05-31 23:27:19.193654
NCT01184989|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2014-03-03||2014-06-03|2010-08-18|2010-08-19|Estimate|2014-04-25|2014-05-23|Estimate||||2014-06-03|2014-06-09|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Treated Set (TS): Patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate|An Open Label, Non-comparative, Pharmacokinetic and Pharmacodynamic Study to Evaluate the Effect of Dabigatran Etexilate on Coagulation Parameters Including a Calibrated Thrombin Time Test in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Primary Unilateral Elective Total Knee or Hip Replacement Surgery|Completed||Phase 4|142|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:27:19.370245|2018-05-31 23:27:19.370245
NCT01184976|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2015-03-16|2010-08-18|2010-08-19|Estimate|||||||2015-03-16|2015-03-17|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males|Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adult Males of a DNA Plasmid Vaccine for HS Avian Influenza (VGX-3400) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)|Completed||Phase 1|30|Actual|GeneOne Life Science, Inc.||3|||f||||t||||||||||2018-05-31 23:27:19.61882|2018-05-31 23:27:19.61882
NCT01184963|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-08-18|2010-08-18|2010-08-19|Estimate|||||||2010-08-18|2010-08-19|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||High Versus Normal Protein Diet in Polycystic Ovary Syndrome (PCOS)|Effect of High-protein or Normal-protein Diet on Weight Loss, Body Composition, Hormone and Metabolic Profile in Women With Polycystic Ovary Syndrome From South Brazil: A Randomized Study|Completed||N/A|40|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 23:27:19.704608|2018-05-31 23:27:19.704608
NCT01184937|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-12-02|2010-08-18|2010-08-19|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Patient Education on Kidney Recipients Knowledge, Coping and Quality of Life|Effect of Patient Education on Kidney Recipients Knowledge, Coping and Quality of Life. A Randomized Controlled Trial.|Completed||N/A|159|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||t||||||||||2018-05-31 23:27:19.852912|2018-05-31 23:27:19.852912
NCT01184924|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2013-11-04|2010-08-17|2010-08-19|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|August 2011|Actual|2011-08-31|June 2010|Actual|2010-06-30||Interventional|||Evaluation of the Arthritis Foundation Tai Chi Program|Evaluation of the Arthritis Foundation Tai Chi Program|Completed||N/A|358|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:27:19.923818|2018-05-31 23:27:19.923818
NCT01184911|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2015-03-03|2010-08-17|2010-08-19|Estimate|||||||2015-03-03|2015-03-05|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|SP IPTp||Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda|Assessment of the Efficacy of Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||1||Research plan changed; no longer conducting clinical trial.|f||||f||||||||||2018-05-31 23:27:19.990912|2018-05-31 23:27:19.990912
NCT01184898|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2014-08-12||2016-10-19|2010-08-18|2010-08-19|Estimate|2014-08-12|2014-08-27|Estimate||||2016-10-19|2016-11-29|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|January 2012|Actual|2012-01-31||Interventional|||Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)|A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia|Completed||N/A|36|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 23:27:20.098912|2018-05-31 23:27:20.098912
NCT01184885|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2013-11-13||2017-11-10|2010-08-17|2010-08-19|Estimate|2013-11-13|2014-01-03|Estimate||||2017-11-10|2017-12-18|Actual|July 2010||2010-07-31|November 2017|2017-11-30|April 2013|Actual|2013-04-30|March 2011|Actual|2011-03-31||Interventional|||A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy|A Pilot Study of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD) With Sirolimus for the Treatment of Adult Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies|Completed||Early Phase 1|7|Actual|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-05-31 23:27:20.580362|2018-05-31 23:27:20.580362
NCT01184872|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2012-03-22||2012-07-09|2010-08-18|2010-08-19|Estimate|2012-03-22|2012-04-18|Estimate||||2012-07-09|2012-07-13|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections|An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With Complicated Skin and Soft Tissue Infections (cSSTI)|Completed||Phase 3|120|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:27:20.876128|2018-05-31 23:27:20.876128
NCT01184859|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2012-04-24||2012-04-24|2010-08-18|2010-08-19|Estimate|2012-04-24|2012-05-25|Estimate||||2012-04-24|2012-05-25|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|NOC||Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo|A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-group, Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo in Water-loaded Male and Female Japanese Nocturia Patients (Single Dose), and to Study the Efficacy of 4 Different Dose Levels of Minirin Melt and Placebo After 28 Days of Dosing (Multiple Doses)|Completed||Phase 2|116|Actual|Ferring Pharmaceuticals||5|||f||||f||||||||||2018-05-31 23:27:21.303636|2018-05-31 23:27:21.303636
NCT01184846|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|2013-01-30||2013-08-27|2010-08-18|2010-08-19|Estimate|2013-03-26|2013-04-04|Estimate||||2013-08-27|2013-09-06|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy|A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Completed||Phase 3|31|Actual|CSL Behring||1|||f||||t||||||||||2018-05-31 23:27:22.332781|2018-05-31 23:27:22.332781
NCT01184833|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2013-06-24|2010-08-18|2010-08-19|Estimate|||||||2013-06-24|2013-06-25|Estimate|September 2008||2008-09-30|June 2013|2013-06-30|August 2011|Actual|2011-08-31|||||Observational|BREAK||Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis|Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis|Completed|||852|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:27:22.789098|2018-05-31 23:27:22.789098
NCT01184820|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2014-10-31|2010-08-18|2010-08-19|Estimate|||||||2014-10-31|2014-11-03|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration|An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A|Completed||Phase 1|14|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:27:22.859288|2018-05-31 23:27:22.859288
NCT01184807|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-03-24|2010-08-18|2010-08-19|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2009||2009-12-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors|A Phase 1, Open-label, Non-randomized, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors|Completed||Phase 1|51|Actual|Otsuka Beijing Research Institute||1|||f||||f||||||||||2018-05-31 23:27:22.942608|2018-05-31 23:27:22.942608
NCT01184794|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2013-11-12|2010-08-18|2010-08-19|Estimate|||||||2013-11-12|2013-11-13|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Postoperative Pain Control Using ON-Q Painbuster Pump|Postoperative Pain Control Using Continuous Infusion of Levobupivacaine in Women Undergoing Pelvic Operative Laparoscopy: A Randomised Controlled Trial|Completed||Phase 3|60|Actual|Ashford and St. Peter's Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 23:27:23.015659|2018-05-31 23:27:23.015659
NCT01183338|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2011-06-21|2010-08-16|2010-08-17|Estimate|||||||2011-06-21|2011-06-22|Estimate||||June 2011|2011-06-30||||||||Observational|SPO2||Accuracy of Continuous SpO2 Measurement in Adults|SpO2 Accuracy Validation of Sotera Wireless Pulse Oximetry Systems During Non-Motion and Motion Conditions of Induced Hypoxia as Compared to Arterial Blood CO-Oximetry|Withdrawn|||15|Anticipated|Sotera Wireless, Inc.|||||f||||f||||||||||2018-05-31 23:27:43.509911|2018-05-31 23:27:43.509911
NCT01184781|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-04-23|2010-08-18|2010-08-19|Estimate|||||||2013-04-23|2013-04-24|Estimate|August 2010||2010-08-31|May 2010|2010-05-31|November 2013|Anticipated|2013-11-30|September 2010|Actual|2010-09-30||Interventional|||Project PREVAM : Prospective Comparison of Capsule Endoscopy Pillcam II™ Versus Colonoscopy|Prospective Comparison of Capsule Endoscopy Pillcam II™ Versus Colonoscopy for the Detection of Adenomatous Polyps and Cancer in a High Risk Population|Unknown status|Recruiting|N/A|210|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 23:27:23.125052|2018-05-31 23:27:23.125052
NCT01184768|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-07-19|2010-08-18|2010-08-19|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Observational|||HBA1c and Diagnosis of Type 2 Diabetes|HBA1c and Diagnosis of Type 2 Diabetes|Completed|||3509|Actual|University of Tromso|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:27:23.203194|2018-05-31 23:27:23.203194
NCT01184755|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2017-01-11||2017-04-11|2010-08-17|2010-08-19|Estimate|2017-04-11|2017-05-16|Actual||||2017-04-11|2017-05-16|Actual|May 2008||2008-05-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|RESPeRate||RCT of Effects of Device-guided Breathing on Ambulatory BP|RCT of Device-guided Breathing Effects on Ambulatory BP|Completed||N/A|253|Actual|Rutgers, The State University of New Jersey||3|||f||||t||||||||Undecided||2018-05-31 23:27:23.274491|2018-05-31 23:27:23.274491
NCT01184742|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-07-21|2010-08-18|2010-08-19|Estimate|||||||2014-07-21|2014-07-22|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||6 Minute Push & 30 Second Sprint Tests Reliability & Relationship to Fitness, Participation, & Environmental Assessments|6 Minute Push and 30 Second Sprint Tests Reliability and Relationship to Fitness, Participation, and Environmental Assessments|Completed|||56|Actual|University of Miami|||||f||||f||||||||||2018-05-31 23:27:23.529288|2018-05-31 23:27:23.529288
NCT01184729|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2014-07-21|2010-08-18|2010-08-19|Estimate|||||||2014-07-21|2014-07-22|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||6 Minute Propulsion Test Sensitivity to Increased Aerobic Capacity|6 Minute Propulsion Test Sensitivity to Increased Aerobic Capacity|Completed|||27|Actual|University of Miami|||1||f||||f||||||||||2018-05-31 23:27:23.581399|2018-05-31 23:27:23.581399
NCT01184716|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-05-06|2010-08-18|2010-08-19|Estimate|||||||2011-05-06|2011-05-09|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|VitMaD||The Effect of Vitamin D Fortification of Bread and Milk in Danish Families|The Effect of Vitamin D Fortification of Bread and Milk in Danish Families|Completed||N/A|782|Actual|Technical University of Denmark||2|||f||||f||||||||||2018-05-31 23:27:23.634947|2018-05-31 23:27:23.634947
NCT01184703|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-09-02|2010-08-18|2010-08-19|Estimate|||||||2010-09-02|2010-09-06|Estimate|June 2007||2007-06-30|August 2010|2010-08-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|LGID1||Low Glycemic Index Diet in Patients With Type 1 Diabetes|Effects of a Low Glycemic Index Diet on HbA1c and Lipids in Patients With Type I Diabetes|Completed||Phase 3|65|Actual|Steno Diabetes Center|||||f||||f||||||||||2018-05-31 23:27:23.698999|2018-05-31 23:27:23.698999
NCT01184690|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2010-08-18|2010-08-18|2010-08-19|Estimate|||||||2010-08-18|2010-08-19|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|DBE||Single-Operator Versus Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders|Prospective Trial Comparing Single-Operator and Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders|Unknown status|Enrolling by invitation|Phase 4|80|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-05-31 23:27:23.75328|2018-05-31 23:27:23.75328
NCT01184677|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2012-08-24|2010-08-18|2010-08-19|Estimate|||||||2012-08-24|2012-08-27|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||ProSeal Laryngeal Mask Airway (LMA) Size 3 vs 4 in Non-paralyzed Female Patients|Comparison of the Size 3 ProsealTM Laryngeal Mask Airway Versus Size 4 in Anaesthetized, Non-paralyzed Women: A Randomised Controlled Trial|Completed||N/A|154|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 23:27:23.818057|2018-05-31 23:27:23.818057
NCT01184664|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2012-10-10|2010-08-18|2010-08-19|Estimate|||||||2012-10-10|2012-10-11|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CONVICT||Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study)|Effects of a Combination of Varenicline and Transdermal Nicotine Patch on Post-quitting Urges to Smoke|Completed||Phase 3|117|Actual|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 23:27:23.874724|2018-05-31 23:27:23.874724
NCT01184651|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2018-01-04|2010-08-18|2010-08-19|Estimate|||||||2018-01-04|2018-01-08|Actual|August 2009||2009-08-31|January 2018|2018-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|T2T@PSU||Tweens to Teens Project at Penn State|"Gender Development in Early Adolescence: Prenatal Hormones and Family Socialization"|Completed|||188|Actual|Penn State University|||2||f||||f||||||Samples With DNA|"~     Samples of saliva will be collected from participants with CAH for genetic testing (specific~     mutations of CYP21 gene) and to obtain hormone levels.~   "|||2018-05-31 23:27:24.147987|2018-05-31 23:27:24.147987
NCT01184638|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2014-01-11|2010-08-18|2010-08-19|Estimate|||||||2014-01-11|2014-01-14|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|LOGAND||Long-term Outcome of General Anesthesia on Dysgnosia|Long-term Outcome Followed-up of the Cognitive Disorders After General Anesthesia|Recruiting||Phase 4|10000|Anticipated|Nanjing Medical University||3|||f||||t||||||||||2018-05-31 23:27:24.269575|2018-05-31 23:27:24.269575
NCT01184625|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-06-24|2010-08-18|2010-08-19|Estimate|||||||2011-06-24|2011-06-27|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|August 2012|Anticipated|2012-08-31|January 2012|Anticipated|2012-01-31||Interventional|||Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation|Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation|Unknown status|Recruiting|N/A|30|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 23:27:24.367874|2018-05-31 23:27:24.367874
NCT01184612|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-18|||2010-08-18|2010-08-18|2010-08-19|Estimate|||||||2010-08-18|2010-08-19|Estimate|April 2004||2004-04-30|October 2003|2003-10-31|July 2008|Actual|2008-07-31|March 2007|Actual|2007-03-31||Interventional|||Effects of Motivational Interviewing in Prison|Motivational Interviewing Delivered by Existing Prison Staff: A Randomized Controlled Study of Effectiveness on Substance Use After Release|Completed||Phase 3|296|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 23:27:24.437556|2018-05-31 23:27:24.437556
NCT01184599|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-06-23|2010-08-18|2010-08-19|Estimate|||||||2011-06-23|2011-06-27|Estimate|June 2010||2010-06-30|May 2010|2010-05-31||||March 2013|Anticipated|2013-03-31||Interventional|||A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy||Unknown status|Recruiting|Phase 4|30|Anticipated|Kagawa University|||||f||||t||||||||||2018-05-31 23:27:24.508491|2018-05-31 23:27:24.508491
NCT01184586|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-12-01|2010-08-18|2010-08-19|Estimate|||||||2011-12-01|2011-12-02|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|DupuyShock||Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010)|Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) - a Randomized Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Hannover Medical School||2|||f||||f||||||||||2018-05-31 23:27:24.582268|2018-05-31 23:27:24.582268
NCT01184573|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-02-06|2010-08-18|2010-08-19|Estimate|||||||2014-02-06|2014-02-10|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Observational|||Novel Breath Test to Detect Early Stage Chronic Pancreatitis|Phase 1 Study of the Pancreatic Breath Test to Detect Early Stage Chronic Pancreatitis Utilizing the Secretin Stimulation Test|Completed|||50|Anticipated|Metabolic Solutions Inc.|||2||f||||t||||||Samples Without DNA|"~     Breath samples~   "|||2018-05-31 23:27:24.68675|2018-05-31 23:27:24.68675
NCT01184560|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2010-08-18|2010-08-18|2010-08-19|Estimate|||||||2010-08-18|2010-08-19|Estimate|February 2010||2010-02-28|October 2009|2009-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine|A Randomized, Double-blind, Placebo-controlled, Investigator-initiated Study to Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine|Completed||N/A|174|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 23:27:24.751552|2018-05-31 23:27:24.751552
NCT01184547|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2017-07-09|2010-08-18|2010-08-19|Estimate|||||||2017-07-09|2017-07-11|Actual|April 2010||2010-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|COMBEX||Effects of a Community Based Exercise Program in Adults With Severe Burns|"Effects of a Community Based Exercise Program in Adults With Severe Burns"|Recruiting||N/A|60|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 23:27:24.822776|2018-05-31 23:27:24.822776
NCT01184534|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2013-02-11|2010-08-18|2010-08-19|Estimate|||||||2013-02-11|2013-02-12|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Multimedia Patient Education|Increasing Patient Preparedness for the Procedural Experience and Improving Qualitative Outcomes Through Patient Education|Completed|||50|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 23:27:24.89571|2018-05-31 23:27:24.89571
NCT01184521|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2012-01-27|2010-08-18|2010-08-19|Estimate|||||||2012-01-27|2012-01-31|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Masimo CO-Oximeter Study|Use of the Masimo Rainbow SET Pulse CO-Oximeter in Patients Undergoing Isovolemic Hemodilution|Completed|||50|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 23:27:24.961863|2018-05-31 23:27:24.961863
NCT01184508|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17||2012-10-25|2012-10-25|2010-08-17|2010-08-19|Estimate||||2012-10-25|2012-10-30|Estimate|2012-10-25|2012-10-30|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study in Migraine Prevention|A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study of LY2300559 in Patients With Migraine|Terminated||Phase 2|87|Actual|Eli Lilly and Company||2||Elevation of ALT and AST in some patients.|f||||f||||||||||2018-05-31 23:27:25.025852|2018-05-31 23:27:25.025852
NCT01184495|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2017-02-24|2010-08-17|2010-08-19|Estimate|||||||2017-02-24|2017-02-27|Actual|April 2008||2008-04-30|February 2017|2017-02-28|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy Study of Two Formulations of Erythropoietin|Comparison of the Efficacy of Erythropoietin Produced in the Institute of Technology in Immunobiology of the Oswald Cruz Foundation (BioMaguinhos/FioCruz/MS) and Erythropoietin Industrialized in Patients With Chronic Renal Failure|Completed||Phase 3|74|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 23:27:25.121794|2018-05-31 23:27:25.121794
NCT01184482|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2013-10-29|2010-08-17|2010-08-19|Estimate|||||||2013-10-29|2013-10-31|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|TYKERB-ITUX 1||Lapatinib and Cetuximab in Patients With Solid Tumors|A Phase I Study of Lapatinib and Cetuximab in Patients With Solid Tumors|Completed||Phase 1|22|Actual|Georgetown University||1|||f||||t||||||||||2018-05-31 23:27:26.143024|2018-05-31 23:27:26.143024
NCT01184469|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2012-10-12|2010-08-17|2010-08-19|Estimate|||||||2012-10-12|2012-10-15|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|||Prospective Observational Study of Peri-implantation Serum hCG Levels|Prospective Observational Study of Peri-implantation Serum hCG Levels|Completed|||451|Actual|Fertility Center of Las Vegas|||2||f||||f||||||||||2018-05-31 23:27:26.266136|2018-05-31 23:27:26.266136
NCT01184456|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-08-17|2010-08-17|2010-08-19|Estimate|||||||2010-08-17|2010-08-19|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System|A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System|Unknown status|Recruiting|Phase 2|24|Anticipated|AIDS Healthcare Foundation||2|||f||||t||||||||||2018-05-31 23:27:26.326796|2018-05-31 23:27:26.326796
NCT01184443|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2014-09-03|2010-08-18|2010-08-19|Estimate|||||||2014-09-03|2014-09-04|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents|Evaluation of the Efficacy and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Children and Adolescents: An Open-label Trial|Terminated||Phase 3|38|Actual|Children's Hospital of Eastern Ontario||2||Poor recruitment|f||||t||||||||||2018-05-31 23:27:26.399975|2018-05-31 23:27:26.399975
NCT01184430|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2013-08-08|2010-08-18|2010-08-19|Estimate|||||||2013-08-08|2013-08-12|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Interventional|Algebra||Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery|Monocentric Pilot Study of Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery|Unknown status|Not yet recruiting|N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:27:26.47988|2018-05-31 23:27:26.47988
NCT01184417|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2012-02-18||2012-03-07|2010-08-18|2010-08-19|Estimate|2012-03-07|2012-03-09|Estimate||||2012-03-07|2012-03-09|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phenobarbital for Acute Alcohol Withdrawal|Phenobarbital Versus Placebo for Acute Alcohol Withdrawal|Completed||N/A|102|Actual|Alameda County Medical Center||2|||f||||t||||||||||2018-05-31 23:27:26.584665|2018-05-31 23:27:26.584665
NCT01184209|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-01-03|2010-08-17|2010-08-18|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 2007||2007-02-28|January 2014|2014-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Prospective Study on the Incidence of Adrenal Crisis in Patients With Chronic Adrenal Insufficiency|Prospective Cohort-study on the Incidence of Adrenal Crisis in Patients With Chronic Adrenal Insufficiency|Completed|||444|Actual|University of Wuerzburg|||||f||||t||||||||||2018-05-31 23:27:29.215396|2018-05-31 23:27:29.215396
NCT01184404|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2015-12-21|2010-08-18|2010-08-19|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2011||2011-09-30|December 2015|2015-12-31||||July 2016|Anticipated|2016-07-31||Interventional|BOCA||Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery|Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery|Unknown status|Recruiting|N/A|100|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 23:27:27.752041|2018-05-31 23:27:27.752041
NCT01184391|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-08-17|2010-08-17|2010-08-18|Estimate|||||||2010-08-17|2010-08-18|Estimate|July 2007||2007-07-31|August 2010|2010-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg|Single-Dose Fasting Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets (500 mg; Mylan) and Depakote Tablets (500 mg; Abbott) in Healthy Adult Male And Female (Not of Childbearing Potential) Volunteers|Completed||Phase 1|17|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-05-31 23:27:27.858163|2018-05-31 23:27:27.858163
NCT01184378|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-01-25|2010-08-17|2010-08-18|Estimate|||||||2011-01-25|2011-01-26|Estimate|November 2008||2008-11-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Tolerance and Digestibility of a New Formula in Healthy Infants|Study of Tolerance and Lipid Digestibility of a Formula in Healthy 3 Months Infants|Completed||Phase 2|100|Anticipated|Lactalis||2|||f||||t||||||||||2018-05-31 23:27:27.916045|2018-05-31 23:27:27.916045
NCT01184365|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2014-03-14|2010-08-17|2010-08-18|Estimate|||||||2014-03-14|2014-03-17|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Spinal Cord Injury Energy Management Program|Spinal Cord Injury Energy Management Program|Completed||Phase 2/Phase 3|28|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:27:27.97886|2018-05-31 23:27:27.97886
NCT01184352|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-12-05|2010-08-17|2010-08-18|Estimate|||||||2012-12-05|2012-12-06|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Glider PTCA Balloon Catheter Registry|Registry for PCI With the TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Completed|||125|Actual|TriReme Medical, LLC|||1||f||||f||||||||||2018-05-31 23:27:28.083466|2018-05-31 23:27:28.083466
NCT01184339|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-08-17|2010-08-17|2010-08-18|Estimate|||||||2010-08-17|2010-08-18|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Observational|||Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives|Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives|Completed|||1165|Actual|MicroPhage, Inc.|||2||f||||t||||||Samples With DNA|"~     Approximately 100 uL of deidentified blood culture sample per test sample run.~   "|||2018-05-31 23:27:28.163201|2018-05-31 23:27:28.163201
NCT01184326|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2017-10-03|2010-08-17|2010-08-18|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2010||2010-09-30|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer|An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer|Completed||Phase 1|23|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 23:27:28.225794|2018-05-31 23:27:28.225794
NCT01184313|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-09-02|2010-08-17|2010-08-18|Estimate|||||||2010-09-02|2010-09-03|Estimate|September 2010||2010-09-30|August 2010|2010-08-31||||||||Observational|||Acute Lung Injury After Aortic Valve Surgery|Acute Lung Injury After Aortic Valve Surgery|Unknown status|Not yet recruiting||100|Anticipated|University of Oulu|||1||f||||||||||||||2018-05-31 23:27:28.409939|2018-05-31 23:27:28.409939
NCT01184300|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-11-10|2010-08-17|2010-08-18|Estimate|||||||2011-11-10|2011-11-11|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|RAPID GENE||ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation|ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)|Completed||Phase 2/Phase 3|200|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 23:27:28.501874|2018-05-31 23:27:28.501874
NCT01184287|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2015-08-31|2010-08-17|2010-08-18|Estimate|||||||2015-08-31|2015-09-02|Estimate||||August 2015|2015-08-31||||||||Interventional|||A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer|A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Tamir Biotechnology, Inc.||1||Program discontinued|f||||t||||||||||2018-05-31 23:27:28.637575|2018-05-31 23:27:28.637575
NCT01184274|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-01-16|2010-08-17|2010-08-18|Estimate|||||||2014-01-16|2014-01-17|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2012|Actual|2012-01-31||Interventional|||A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia|A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia|Completed||Phase 1|12|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-05-31 23:27:28.76985|2018-05-31 23:27:28.76985
NCT01184261|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2014-03-24|2010-08-17|2010-08-18|Estimate|||||||2014-03-24|2014-03-26|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Integrated Behavioral Intervention for Cigarette Smoking and Binge Drinking in Young Adults|Integrated Intervention for Cigarette Smoking and Binge Drinking for Young Adults|Completed||N/A|170|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 23:27:28.881916|2018-05-31 23:27:28.881916
NCT01184248|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-09-07|2010-08-17|2010-08-18|Estimate|||||||2011-09-07|2011-09-08|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of Sound Stimulation on Pure-tone Hearing Threshold|The Effect of Sound Stimulation on Pure-tone Hearing Threshold|Completed||N/A|30|Anticipated|Earlogic Korea, Inc.|||||f||||||||||||||2018-05-31 23:27:28.967833|2018-05-31 23:27:28.967833
NCT01184235|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2014-01-02|2010-08-17|2010-08-18|Estimate|||||||2014-01-02|2014-01-06|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Multidimensional Measurement of Psychopharmacological Treatment Response|Actigraphic, Observational, Psychometric and Biological Measurement of Psychopharmacological Treatment Response|Completed|||44|Actual|Child Psychopharmacology Institute|||4||f||||f||||||||||2018-05-31 23:27:29.067677|2018-05-31 23:27:29.067677
NCT01184222|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-02-20|2010-08-17|2010-08-18|Estimate|||||||2012-02-20|2012-02-22|Estimate|November 2010||2010-11-30|May 2010|2010-05-31|December 2012|Anticipated|2012-12-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy Evaluation Of Great Occipital Nerve Electrical Stimulation On Rebound Headache|EFFICACY EVALUATION OF GREAT OCCIPITAL NERVE ELECTRICAL STIMULATION ON REBOUND HEADACHE AFTER WITHDRAWAL IN MEDICATION OVERUSE HEADACHE OCCURING IN MIGRAINE PATIENTS (SENGO-CAM Study)|Unknown status|Recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 23:27:29.142101|2018-05-31 23:27:29.142101
NCT01184196|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2013-04-15|2010-08-17|2010-08-18|Estimate|||||||2013-04-15|2013-04-16|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||ChloraPrep Versus Betadine for Elective Knee Replacement Surgery|A Comparison of Chlorhexadine Gluconate Versus Povidone Iodine Surgical Preparation in Skin Bacterial Colony Counts for Elective Knee Replacement Surgery|Terminated||Phase 4|55|Actual|Central DuPage Hospital||2||ChloroPrep Wipes no longer available|f||||f||||||||||2018-05-31 23:27:29.287494|2018-05-31 23:27:29.287494
NCT01184183|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2013-02-18|2010-08-17|2010-08-18|Estimate|||||||2013-02-18|2013-02-20|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy|Prospective Randomized Trial Comparison of Accuseal and Bovine Pericardial Patch During Endarterectomy|Unknown status|Recruiting||400|Anticipated|CAMC Health System|||2||f||||f||||||||||2018-05-31 23:27:29.380467|2018-05-31 23:27:29.380467
NCT01184170|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-06-29|2010-08-17|2010-08-18|Estimate|||||||2017-06-29|2017-07-02|Actual|August 2010||2010-08-31|June 2017|2017-06-30|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||Metabolically Normal and Metabolically Abnormal Obesity|Metabolically Normal and Metabolically Abnormal Obesity|Completed||N/A|71|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 23:27:29.452215|2018-05-31 23:27:29.452215
NCT01184157|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-08-17|2010-08-17|2010-08-18|Estimate|||||||2010-08-17|2010-08-18|Estimate||||August 2010|2010-08-31||||||||Interventional|||Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections|Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections in Long-Acting Reversible Contraceptive Users|Completed||N/A|||Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 23:27:29.520152|2018-05-31 23:27:29.520152
NCT01184144|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2015-10-01|2010-08-17|2010-08-18|Estimate|||||||2015-10-01|2015-10-02|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Endometriosis: Immunomodulation|Effect of Pioglitazone on Peritoneal Cytokines in Women With Endometriosis|Withdrawn||Phase 2/Phase 3|0|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 23:27:29.681321|2018-05-31 23:27:29.681321
NCT01184131|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2016-10-24|2010-08-17|2010-08-18|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||NCRR ARRA Development-Workforce Development|Implementation and Evaluation of Formal Training for Mentors of K-Series Mentored Career Awards|Completed||N/A|300|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 23:27:29.76458|2018-05-31 23:27:29.76458
NCT01184118|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2014-12-01||2016-07-28|2010-08-17|2010-08-18|Estimate|2016-05-04|2016-06-13|Estimate||||2016-07-28|2016-09-07|Estimate|March 2009||2009-03-31|July 2016|2016-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|DREAM||DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?|Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea? DREAM-A Pilot Study|Completed||N/A|36|Actual|University of Wisconsin, Madison|We were unsuccessful at securing placebo MDI, and the lack of a control group raises the possibility that our findings may reflect natural history of pharyngeal upper airway patency in asthma.|2|||f||||t||||||||Yes||2018-05-31 23:27:29.858002|2018-05-31 23:27:29.858002
NCT01184105|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2016-08-09|2010-08-17|2010-08-18|Estimate|||||||2016-08-09|2016-08-10|Estimate|September 2010||2010-09-30|September 2015|2015-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation|A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Safety and Pharmacokinetic Study to Evaluate Systemic and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites, 2,6-Dimethylaniline (2,6-DMA) and O-Toluidine, in Female Healthy Volunteer Subjects Following Daily Application of 60 mg PSD502 or Placebo to the Vagina and Cervix for 7 Days|Completed||Phase 1|30|Actual|Plethora Solutions Ltd||2|||f||||f||||||||||2018-05-31 23:27:30.086738|2018-05-31 23:27:30.086738
NCT01184092|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2010-10-12|2010-08-16|2010-08-18|Estimate|||||||2010-10-12|2010-10-14|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)|Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, Cross-Over, Bioequivalence Study Comparing Phase 2b, Phase 3 And Commercial Image Tablet Formulations Of Tasocitinib (CP-690,550) Under Fasted Conditions|Completed||Phase 1|24|Anticipated|Pfizer||6|||f||||f||||||||||2018-05-31 23:27:30.179519|2018-05-31 23:27:30.179519
NCT01184079|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2013-11-04||2014-02-26|2010-08-17|2010-08-18|Estimate|2014-01-03|2014-02-26|Estimate||||2014-02-26|2014-03-27|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting|Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting|Completed||N/A|220|Actual|University of Pittsburgh|Drop-out rates higher in the Alternate group; however, sample size was met for all HPV types. The effect of the Alternate dosing schedule on long-term clinical outcomes is unknown. One syncopal episode related to phlebotomy prior to vaccination.|2|||f||||f||||||||||2018-05-31 23:27:30.310773|2018-05-31 23:27:30.310773
NCT01184066|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-03-08|2010-08-17|2010-08-18|Estimate|||||||2011-03-08|2011-03-09|Estimate|January 2010||2010-01-31|March 2011|2011-03-31||||July 2014|Anticipated|2014-07-31||Interventional|||The ACTS Intervention to Reduce Breast Cancer Treatment Disparity|The ACTS Intervention to Reduce Breast Cancer Treatment Disparity|Unknown status|Recruiting|N/A|260|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 23:27:30.65|2018-05-31 23:27:30.65
NCT01184053|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2017-03-28||2017-05-16|2010-08-17|2010-08-18|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|March 2010||2010-03-31|May 2017|2017-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|NRR||Trisenox® in Women With Metastatic Endometrial Cancer|A Phase II Trial of Trisenox in Women With Recurrent or Metastatic Endometrial Adenocarcinoma|Terminated||Phase 2|3|Actual|UNC Lineberger Comprehensive Cancer Center|The study accrued few patients secondary to the strict entry criteria regarding labs, EKG, etc in a sick endometrial cancer population.|1||Accrual was very low. No subject had been enrolled in a year.|f||||t||||||||No||2018-05-31 23:27:30.764176|2018-05-31 23:27:30.764176
NCT01184040|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2012-06-14|2010-08-17|2010-08-18|Estimate|||||||2012-06-14|2012-06-18|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Extending Contingency Management's Benefits With Progressively Increasing Variable Interval Prize Reinforcement|Extending Contingency Management's Benefits With Progressively Increasing Variable Interval Prize Reinforcement|Completed||Phase 2|61|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 23:27:31.281399|2018-05-31 23:27:31.281399
NCT01184027|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2016-05-19|2010-08-17|2010-08-18|Estimate|||||||2016-05-19|2016-05-23|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment|Impact of Nutrition and Swallowing Function in a Randomized Controlled Trial of Head and Neck Cancer Patients During the Course of Treatment|Withdrawn|||0|Actual|University of Alberta|||4|The study did not receive funding.|f||||f||||||||||2018-05-31 23:27:31.409513|2018-05-31 23:27:31.409513
NCT01184014|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2013-09-13||2018-04-11|2010-08-17|2010-08-18|Estimate|2013-09-13|2013-11-18|Estimate||||2018-04-11|2018-05-11|Actual|August 2010||2010-08-31|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia|Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia|Completed||Phase 4|72|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-05-31 23:27:31.502263|2018-05-31 23:27:31.502263
NCT01184001|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-10-12|2010-08-17|2010-08-18|Estimate|||||||2010-10-12|2010-10-13|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects|A Phase 1, Randomized, 2-Period, 2-Sequence, Open Label, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On Pharmacokinetics Of Tasocitinib (CP-690,550) Tablets In Healthy Subjects|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:27:31.769772|2018-05-31 23:27:31.769772
NCT01183975|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|2014-04-09||2014-08-06|2010-08-17|2010-08-18|Estimate|2014-07-14|2014-08-07|Estimate||||2014-08-06|2014-08-08|Estimate|September 2007||2007-09-30|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30|36 Months|Observational [Patient Registry]||a longitudinal prospective cohort study of consecutive patients treated with SAGB in a representative sample of centers for this activity in France.|Swedish Adjustable Gastric Banding Observational Cohort Study|Prospective National Cohort Study on Swedish Adjustable Gastric Band (SAGB) for Gastroplasty (Étude de Cohorte Nationale Prospective de l'Implant Annulaire Ajustable Pour Gastroplastie SAGB)|Completed|||517|Actual|Ethicon Endo-Surgery (Europe) GmbH|||1||f||||t||||||||||2018-05-31 23:27:31.898867|2018-05-31 23:27:31.898867
NCT01183962|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-08-03|2010-08-17|2010-08-18|Estimate|||||||2011-08-03|2011-08-04|Estimate|February 2010||2010-02-28|August 2011|2011-08-31||||August 2011|Actual|2011-08-31||Interventional|||Vitamin D and T-Regulatory Cells in Coronary Artery Disease|Vitamin D and T-Regulatory Cells in Coronary Artery Disease|Terminated||N/A|50|Anticipated|Creighton University||2||slow enrollment, funding ended|f||||f||||||||||2018-05-31 23:27:32.321664|2018-05-31 23:27:32.321664
NCT01183949|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17||2016-09-06|2016-09-09|2010-08-17|2010-08-18|Estimate||||2016-09-06|2016-09-08|Estimate|2016-09-09|2016-09-23|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma|A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma|Completed||Phase 1/Phase 2|18|Actual|Astex Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:27:32.417384|2018-05-31 23:27:32.417384
NCT01183936|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2010-08-17|2010-08-17|2010-08-18|Estimate|||||||2010-08-17|2010-08-18|Estimate|January 1992||1992-01-31|June 1991|1991-06-30|December 2006|Actual|2006-12-31|May 2004|Actual|2004-05-31||Interventional|||Trial of Surgical Excision Margins in Thick Primary Melanoma|A Randomised Trial of Surgical Excision Margins for Thick Primary Cutaneous Melanoma (>2 mm). A Multicenter Trial Comparing 2-cm vs 4-cm|Completed||N/A|936|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 23:27:32.561443|2018-05-31 23:27:32.561443
NCT01183923|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2015-09-05|2010-08-17|2010-08-18|Estimate|||||||2015-09-05|2015-09-09|Estimate|November 2010||2010-11-30|September 2015|2015-09-30||||November 2012|Actual|2012-11-30||Interventional|||Dietary Interventions in Asthma Treatment: Sprouts Study|Dietary Interventions in Asthma Treatment: Sprouts Study|Suspended||Phase 1/Phase 2|38|Actual|Johns Hopkins University||2||reworking protocol|f||||t||||||||||2018-05-31 23:27:32.698682|2018-05-31 23:27:32.698682
NCT01183910|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-06-06|2010-08-17|2010-08-18|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|||A Novel Oral Natural Extract for the Treatment of Senile Purpura|A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Safety and Efficacy of a Novel Oral Natural Extract for the Treatment of Senile Purpura|Unknown status|Active, not recruiting|N/A|75|Anticipated|Nexgen Dermatologics, Inc.||2|||f||||t||||||||||2018-05-31 23:27:32.815594|2018-05-31 23:27:32.815594
NCT01183897|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2017-09-05|2010-08-17|2010-08-18|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2010||2010-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow: A Phase II Study|Active, not recruiting||Phase 2|31|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:27:32.921426|2018-05-31 23:27:32.921426
NCT01183884|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2017-09-05|2010-08-17|2010-08-18|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2010||2010-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma: A Phase II Study|Active, not recruiting||Phase 2|63|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:27:33.005339|2018-05-31 23:27:33.005339
NCT01183871|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2012-03-22|2010-08-17|2010-08-18|Estimate|||||||2012-03-22|2012-03-26|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Cerebral Oxygenation After Lung Resection|Changes in Cerebral Oxygenation in Patients With Pulmonary Dysfunction After Lung Resection|Completed||Phase 1|120|Anticipated|King Faisal University||4|||f||||t||||||||||2018-05-31 23:27:33.126981|2018-05-31 23:27:33.126981
NCT01183858|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2015-02-05||2015-07-23|2010-08-16|2010-08-18|Estimate|2015-02-05|2015-02-23|Estimate||||2015-07-23|2015-08-19|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional||Intent-to-treat Population included all randomized participants. 2 participants were excluded from analysis: 1 participant randomized in error and 1 participant with missing source data.|A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)|A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)|Completed||Phase 3|315|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:27:33.352466|2018-05-31 23:27:33.352466
NCT01183845|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2015-04-26|2010-08-16|2010-08-18|Estimate|||||||2015-04-26|2015-04-28|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CAPSCOL||Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease|A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease|Completed||Phase 4|24|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f||||||||||2018-05-31 23:27:34.297528|2018-05-31 23:27:34.297528
NCT01183832|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2014-08-21|2010-08-17|2010-08-18|Estimate|||||||2014-08-21|2014-08-22|Estimate|August 2005||2005-08-31|August 2014|2014-08-31|October 2015|Anticipated|2015-10-31|December 2014|Anticipated|2014-12-31||Observational|ORACLES||Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects|Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects|Unknown status|Active, not recruiting||490|Actual|Centre Oscar Lambret|||2||f||||f||||||||||2018-05-31 23:27:34.413043|2018-05-31 23:27:34.413043
NCT01183819|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2015-08-03|2010-08-16|2010-08-18|Estimate|||||||2015-08-03|2015-08-05|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Cognitive Control and Physical Exercise|Cognitive Control and Physical Exercise: A Multi-Modal Intervention|Terminated||N/A|12|Actual|Columbia University||3||insufficient recruitment|f||||t||||||||||2018-05-31 23:27:34.506719|2018-05-31 23:27:34.506719
NCT01183806|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-03-19|2010-08-17|2010-08-18|Estimate|||||||2012-03-19|2012-03-20|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients|Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients|Completed||Phase 3|40|Actual|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 23:27:34.571609|2018-05-31 23:27:34.571609
NCT01183793|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-17|2010-08-17|2010-08-18|Estimate|||||||2010-08-17|2010-08-18|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|July 2012|Anticipated|2012-07-31|October 2010|Anticipated|2010-10-31||Interventional|||Magnetic Resonance (MR) Enterography Assessment of Post Operative Small Bowel Length in Short Bowel Syndrome Patients|MR Enterography Assessment of Post Operative Small Bowel Length in Short Bowel Syndrome Patients|Unknown status|Recruiting|N/A|50|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 23:27:34.649459|2018-05-31 23:27:34.649459
NCT01183780|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2015-06-19||2017-06-09|2010-08-17|2010-08-18|Estimate|2015-06-19|2015-07-15|Estimate||||2017-06-09|2017-07-11|Actual|December 2, 2010|Actual|2010-12-02|June 2017|2017-06-30|June 20, 2016|Actual|2016-06-20|July 17, 2014|Actual|2014-07-17||Interventional||All randomized participants.|A Study in Second Line Metastatic Colorectal Cancer|A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine|Completed||Phase 3|1072|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:27:34.792132|2018-05-31 23:27:34.792132
NCT01183767|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2017-12-21|2010-08-17|2010-08-18|Estimate|||||||2017-12-21|2017-12-22|Actual|December 2010||2010-12-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SUNIMUD||Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy|Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy|Active, not recruiting||Phase 2/Phase 3|40|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:27:36.769091|2018-05-31 23:27:36.769091
NCT01183754|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-17|||2011-01-31|2010-08-17|2010-08-18|Estimate|||||||2011-01-31|2011-02-01|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ASAN-VERIFY||Use of a Point-of-Care Platelet Function Assay for the Prediction of Atherothrombotic Events|Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events After Implantation of Drug-Eluting Stents: ASAN-VerifyNow Registry|Completed|||3000|Actual|CardioVascular Research Foundation, Korea|||1||f||||t||||||Samples With DNA|"~     Blood sampling for genotyping (genetic subgroup analysis)~   "|||2018-05-31 23:27:36.853276|2018-05-31 23:27:36.853276
NCT01183741|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2011-06-21|2010-08-16|2010-08-18|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|NIBP||Accuracy of Non-Invasive Blood Pressure Measurement in Adults|Clinical Evaluation of the Sotera VisiTM System for Measurement of Systolic and Diastolic Blood Pressures in Adults|Withdrawn|||150|Anticipated|Sotera Wireless, Inc.|||||f||||f||||||||||2018-05-31 23:27:36.915198|2018-05-31 23:27:36.915198
NCT01183728|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2014-12-17||2015-01-07|2010-08-13|2010-08-18|Estimate|2015-01-07|2015-01-15|Estimate||||2015-01-07|2015-01-15|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|KDD&MSV|All included patients met the inclusion criteria and no exclusion criteria.|Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells|Regeneration of Articular Cartilage in Grade II, III and IV Knee Osteoarthritis by Intraarticular Injection of Autologous Bone Marrow Stem Cells Expanded ex Vivo With a GMP Procedure Developed by IBGM-Valladolid (MSV)|Completed||Phase 1/Phase 2|12|Actual|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 23:27:36.987261|2018-05-31 23:27:36.987261
NCT01183715|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-09-23|2010-08-13|2010-08-18|Estimate|||||||2010-09-23|2010-09-24|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Single Dose Study Of PF-05161704 In Healthy Volunteers|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-05161704 After Administration Of Single Escalating Oral Doses Under Fed And Fasted Conditions In Healthy Volunteers|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:27:37.333975|2018-05-31 23:27:37.333975
NCT01183702|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2017-01-11|2010-08-13|2010-08-18|Estimate|||||||2017-01-11|2017-01-13|Estimate|February 2004||2004-02-29|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Corneal Biomechanics With Hydration in Normal and LASIK Eyes|Analysis of Corneal Biomechanics Based Upon Central and Peripheral Corneal Thickness in Normal and Post Refractive Surgery Eyes|Completed||N/A|44|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 23:27:37.4488|2018-05-31 23:27:37.4488
NCT01183520|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2013-09-24|2010-08-16|2010-08-17|Estimate|||||||2013-09-24|2013-09-26|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of High Omega-3 Fish Intake on Lipid Peroxidation|Effect of High Omega-3 Fish Intake on Lipid Peroxidation|Completed||N/A|30|Actual|USDA Grand Forks Human Nutrition Research Center||3|||f||||f||||||||||2018-05-31 23:27:40.740898|2018-05-31 23:27:40.740898
NCT01183689|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2017-11-01||2018-04-04|2010-08-17|2010-08-18|Estimate|2018-04-04|2018-05-07|Actual||||2018-04-04|2018-05-07|Actual|August 2010|Actual|2010-08-31|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|December 31, 2014|Actual|2014-12-31||Interventional|SNAP||Study of Novel Approaches for Prevention|Study of Novel Approaches for Prevention|Active, not recruiting||N/A|599|Actual|Wake Forest University Health Sciences||3|||f||||t|f|f||||||No|De-identified data can be obtained by request, conditional on a data use agreement.|2018-05-31 23:27:37.582415|2018-05-31 23:27:37.582415
NCT01183676|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-08-13|2010-08-13|2010-08-18|Estimate|||||||2010-08-13|2010-08-18|Estimate|July 2007||2007-07-31|August 2010|2010-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg|Single-Dose Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets (500 mg; Mylan) and Depakote Tablets (500 mg; Abbott) in Healthy Adult Male And Female (Not of Childbearing Potential) Volunteers|Completed||Phase 1|20|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-05-31 23:27:38.790358|2018-05-31 23:27:38.790358
NCT01183663|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2016-06-01|2010-08-16|2010-08-17|Estimate|||||||2016-06-01|2016-06-03|Estimate|August 2010||2010-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)|A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers|Completed||Phase 1|180|Actual|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-05-31 23:27:38.86318|2018-05-31 23:27:38.86318
NCT01183650|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2012-04-19||2012-04-19|2010-08-13|2010-08-17|Estimate|2012-04-19|2012-05-16|Estimate||||2012-04-19|2012-05-16|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Tadalafil in Benign Prostatic Hyperplasia|A Study to Evaluate the Pharmacokinetics of Tadalafil Administered Once Daily in Japanese and Non-Japanese Subjects With Benign Prostatic Hyperplasia|Completed||Phase 1|24|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:27:39.005396|2018-05-31 23:27:39.005396
NCT01183637|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28||2015-05-07|2015-05-07|2010-08-13|2010-08-17|Estimate||||2015-05-07|2015-05-25|Estimate|2015-05-07|2015-05-25|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|EAGLE Pilot||Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions Pilot Trial|Initial Safety and Effectiveness Study of the Kensey Nash Corp. Cartilage Repair Device for Knee Cartilage Lesion Repair|Terminated||Phase 2|2|Actual|Kensey Nash Corporation||2||Study enrollment rate was far slower than anticipated. Study was stopped for business purposes.|f||||t||||||||||2018-05-31 23:27:39.42343|2018-05-31 23:27:39.42343
NCT01183624|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2016-01-06|2010-08-13|2010-08-17|Estimate|||||||2016-01-06|2016-01-08|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Controlled Study of an Herbal Topical Patch in Treating Osteoarthritis (OA) of the Knee|A Multi-Center, Randomized, Double-Blind, Parallel, Placebo Control Study of a Traditional Chinese Medicine Topical Analgesic Patch in the Treatment of Osteoarthritis of the Knee|Completed||Phase 4|626|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 23:27:39.505735|2018-05-31 23:27:39.505735
NCT01183611|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-09-16|2010-08-16|2010-08-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|April 2007||2007-04-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates|The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates Born to Mother With Positive for Both HBsAg and HBeAg, Positive for HBsAg But Negative for HBeAg, Negative for HBsAg, HBeAg, HBeAb and HBcAb|Completed||Phase 3|1740|Anticipated|Jiangsu Province Centers for Disease Control and Prevention||7|||f||||t||||||||||2018-05-31 23:27:39.599422|2018-05-31 23:27:39.599422
NCT01183598|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2016-11-01|2010-08-16|2010-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2006||2006-08-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment|Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment|Completed||Phase 1|3|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:27:39.688098|2018-05-31 23:27:39.688098
NCT01183585|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2016-11-01|2010-08-13|2010-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of RO4917838 With Rosuvastatin in Healthy Volunteers|A Single Center, Open-label, Fixed Sequence, Two-period Study to Investigate the Effect of RO4917838 on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers|Completed||Phase 1|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:27:39.772654|2018-05-31 23:27:39.772654
NCT01183572|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2012-09-08|2010-08-13|2010-08-17|Estimate|||||||2012-09-08|2012-09-11|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|TOPPS||Trial of Pre-Pregnancy Supplements|Trial of Pre-Pregnancy Supplements|Completed||N/A|802|Actual|Harvard School of Public Health||3|||f||||t||||||||||2018-05-31 23:27:39.842717|2018-05-31 23:27:39.842717
NCT01183559|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2011-02-08|2010-08-16|2010-08-17|Estimate|||||||2011-02-08|2011-02-10|Estimate|August 2008||2008-08-31|February 2011|2011-02-28||||||||Interventional|||A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery|Induction Therapy for Locally Advanced, Resectable Cancer of the Esophagus, GE Junction and Gastric Cancer: A Phase I Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery (IRUSZACT0064)|Unknown status|Recruiting|Phase 1|12|Anticipated|Fox Chase Cancer Center|||||f||||t||||||||||2018-05-31 23:27:39.949722|2018-05-31 23:27:39.949722
NCT01183546|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2016-01-08||2016-02-11|2010-08-16|2010-08-17|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Biomechanical Validation of the Transfer Assessment Instrument (TAI)|Biomechanical Validation of the Transfer Assessment Instrument (TAI)|Completed|||53|Actual|VA Office of Research and Development|||1||f||||f||||||||No||2018-05-31 23:27:40.166967|2018-05-31 23:27:40.166967
NCT01183533|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2014-10-28||2014-11-24|2010-08-16|2010-08-17|Estimate|2014-11-24|2014-11-25|Estimate||||2014-11-24|2014-11-25|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|Wake-Up Stroke||Safety of Intravenous Thrombolysis for Wake-up Stroke|Safety of Intravenous Thrombolysis for Wake-up Stroke|Completed||Phase 2|40|Actual|The University of Texas Health Science Center, Houston|The single-arm / open-label design suffers from limitations such as possible bias in patient selection and outcome assessment. However, adverse events were adjudicated by the DSMB. Small trial size warrants caution; further studies are necessary.|1|||f||||t||||||||||2018-05-31 23:27:40.354128|2018-05-31 23:27:40.354128
NCT01183494|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-05-22|2010-08-16|2010-08-17|Estimate|||||||2017-05-22|2017-05-23|Actual|December 2009||2009-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients|A Genotype-guided Phase I Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients|Active, not recruiting||Phase 1|45|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 23:27:40.976508|2018-05-31 23:27:40.976508
NCT01183481|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2013-06-24||2014-11-17|2010-08-16|2010-08-17|Estimate|2013-12-03|2014-01-20|Estimate||||2014-11-17|2014-12-05|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study|Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study|Terminated||Phase 2|19|Actual|Sunnybrook Health Sciences Centre|Small number of subjects results in early termination of study|1||Study was stopped due to inadequate accrual.|f||||f||||||||||2018-05-31 23:27:41.131065|2018-05-31 23:27:41.131065
NCT01183468|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2015-01-06||2015-01-14|2010-08-16|2010-08-17|Estimate|2015-01-14|2015-01-16|Estimate||||2015-01-14|2015-01-16|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|RETAIN|Enrolled Sample|A Research Trial of Aralast in New Onset Diabetes (RETAIN)|Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus (ITN041AI)|Terminated||Phase 1|17|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|This (Part 1) was the drug dosing portion of the study; however, due to lack of a mechanistic signal and competing industry studies, the study was terminated and the trial portion (Part II, NCT01183455) was withdrawn.|4||Due to lack of mechanistic signal and competing industry studies|f||||t||||||||||2018-05-31 23:27:41.50588|2018-05-31 23:27:41.50588
NCT01183455|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2014-12-30|2010-08-16|2010-08-17|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|RETAIN||A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II|Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus (ITN041AI)- Part II|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||Sponsor decision-lack of mechanistic signal and competing industry studies|f||||t||||||||||2018-05-31 23:27:42.240762|2018-05-31 23:27:42.240762
NCT01183442|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2015-04-16|2010-08-16|2010-08-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Vitamin D Supplementation in CAD and Postchallenge Hyperglycemia|Effects of Vitamin D Supplementation in Coronary Artery Disease Patients With Postchallenge Hyperglycemia and Vitamin D Deficiency on Endothelial Function and Insulin Sensitivity|Terminated||Phase 3|22|Actual|Medical University of Graz||2||unable to recruit|f||||f||||||||||2018-05-31 23:27:42.37537|2018-05-31 23:27:42.37537
NCT01183429|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2018-04-03|2010-08-16|2010-08-17|Estimate|||||||2018-04-03|2018-04-04|Actual|August 2010||2010-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma: A Phase II Study|Active, not recruiting||Phase 2|58|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:27:42.484403|2018-05-31 23:27:42.484403
NCT01183416|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2017-09-05|2010-08-16|2010-08-17|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2010||2010-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation|High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation in Patients With High-Risk Neuroblastoma: A Phase II Study|Active, not recruiting||Phase 2|43|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:27:42.568307|2018-05-31 23:27:42.568307
NCT01183403|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2015-06-21|2010-08-16|2010-08-17|Estimate|||||||2015-06-21|2015-06-23|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|CREOLE||CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease|Value of Contrast-enhanced Ultrasonography and Magnetic Resonance Enterography to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease Complicated by Symptomatic Small Bowel Stricture|Completed|||80|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|||||f||||f||||||||||2018-05-31 23:27:42.67848|2018-05-31 23:27:42.67848
NCT01183390|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2010-10-15||2010-10-15|2010-08-13|2010-08-17|Estimate|2010-10-15|2010-11-16|Estimate||||2010-10-15|2010-11-16|Estimate|September 2005||2005-09-30|October 2010|2010-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Anastrozole 1 mg Tablets Under Fed Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Anastrozole 1 mg Tablets Under Fed Conditions|Completed||Phase 1|22|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:27:42.821374|2018-05-31 23:27:42.821374
NCT01183377|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|March 2009|Anticipated|2009-03-31|February 2009|Actual|2009-02-28||Observational|||Frequency of Female Athlete Triad Among Elite Female Athlete of Iran in Different Sport in 2007|Screening of Menstrual Disorder in Elite Feamle Athlete in Iran|Terminated|||250|Anticipated|Tehran University of Medical Sciences|||1|the study terminated last week|f||||t||||||||||2018-05-31 23:27:43.27003|2018-05-31 23:27:43.27003
NCT01183364|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2014-09-18|2010-08-16|2010-08-17|Estimate|||||||2014-09-18|2014-09-19|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors|A Phase 1, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies|Completed||Phase 1|27|Actual|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-05-31 23:27:43.362445|2018-05-31 23:27:43.362445
NCT01183351|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2014-12-11|2010-08-16|2010-08-17|Estimate|||||||2014-12-11|2014-12-12|Estimate|May 2011||2011-05-31|May 2011|2011-05-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|TID||Multidisciplinary Intervention for Challenging Behaviour (Agitation) in Patients With Dementia|Pilot Study of a Multidisciplinary Intervention for Challenging Behaviour (Agitation) in Patients With Dementia|Completed||N/A|30|Actual|Sykehuset Innlandet HF||1|||f||||t||||||||||2018-05-31 23:27:43.434687|2018-05-31 23:27:43.434687
NCT01183325|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2014-12-04|2010-08-16|2010-08-17|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|April 2011|Actual|2011-04-30||Interventional|||Prospective Evaluation of the Proceed Ventral Patch With and Without Laparoscopic Evaluation|Multicentric Evaluation of the Proceed Ventral Patch for Umbilical and Small Primary Ventral Hernias Less Than 3cm Diameter With One Year Follow-up|Completed||N/A|160|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 23:27:43.60388|2018-05-31 23:27:43.60388
NCT01183312|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2013-01-11||2017-11-06|2010-08-16|2010-08-17|Estimate|2013-02-20|2013-03-27|Estimate||||2017-11-06|2017-12-12|Actual|September 2010||2010-09-30|November 2017|2017-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Flumazenil for the Treatment of Primary Hypersomnia|A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors|Completed||Phase 1/Phase 2|10|Actual|Emory University|EEG power was specified as a secondary outcome measure. Second-by-second manual artifact removal has been necessary to ensure interpretable data. This artifact removal is in progress and results will be reported separately.|2|||f||||f||||||||||2018-05-31 23:27:43.718243|2018-05-31 23:27:43.718243
NCT01183299|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2011-07-07|2010-08-13|2010-08-17|Estimate|||||||2011-07-07|2011-07-08|Estimate|April 2005||2005-04-30|July 2011|2011-07-31|April 2006||2006-04-30|||||Interventional|SL7||Salty Life 7 Study: Effect of High Salt Intake on Several Physiological Systems in Immobilisation|Influence of a High Salt Intake on Sodium Retention, Bone Metabolism and Acid-base Balance in Immobilised Test Subjects|Completed||N/A|8|Actual|DLR German Aerospace Center||2|||f||||f||||||||||2018-05-31 23:27:44.118588|2018-05-31 23:27:44.118588
NCT01183286|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|September 2010||2010-09-30|August 2010|2010-08-31||||April 2012|Anticipated|2012-04-30||Interventional|||CFfone: A Cell Phone Support Program for Adolescents With Cystic Fibrosis|CFfone: A Cell Phone Support Program for Adolescents With Cystic Fibrosis|Unknown status|Not yet recruiting|Phase 2|146|Anticipated|Dawkins Productions, Inc.||2|||f||||t||||||||||2018-05-31 23:27:44.200788|2018-05-31 23:27:44.200788
NCT01183273|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2014-08-21|2010-08-13|2010-08-17|Estimate|||||||2014-08-21|2014-08-22|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Randomized Trial Comparing Laparoscopic Roux-en-y Gastric Bypass to Micro-laparoscopic Roux-en-y Gastric Bypass|Prospective Randomized Trial Comparing Laparoscopic Roux-en-y Gastric Bypass to Micro-laparoscopic Roux-en-y Gastric Bypass|Completed||N/A|50|Actual|Danbury Hospital||2|||f||||f||||||||||2018-05-31 23:27:44.265791|2018-05-31 23:27:44.265791
NCT01183260|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2017-09-11||2017-10-09|2010-08-13|2010-08-17|Estimate|2017-10-09|2017-11-07|Actual||||2017-10-09|2017-11-07|Actual|August 2010||2010-08-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of the Trabecular Metal™ Revision Hip Cup Using Bone Mineral Density (DEXA)|Evaluation of the Trabecular Metal™ Acetabular Revision Cup Using Dual-Energy X-ray Absorptiometry (DEXA)|Completed||N/A|25|Actual|The Cleveland Clinic|A large amount of variability was present in the data leading to reduced statistical power during hypothesis testing|2|||f||||t||||||||||2018-05-31 23:27:44.361519|2018-05-31 23:27:44.361519
NCT01183247|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|July 2008||2008-07-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|SterFreePlus||An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens|An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens for de Novo Renal Transplant Recipients: A Comparison of a Sirolimus / EC-MPS (Myfortic) / Tacrolimus Regimen, an Everolimus / EC-MPS / Tacrolimus Regimen and a EC-MPS / Tacrolimus Prednisone Regimen|Completed||Phase 4|63|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 23:27:45.827849|2018-05-31 23:27:45.827849
NCT01183234|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2011-07-27||2011-08-31|2010-08-16|2010-08-17|Estimate|2011-07-27|2011-08-25|Estimate||||2011-08-31|2011-09-02|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||SPD544 High Strength Bioequivalence Study|Phase 1,Randomized,Open-Label,Two Period Single Dose Crossover Bioequivalence Study of Two Capsule Strengths of SPD544 In Healthy Volunteers.|Completed||Phase 1|28|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:27:45.986626|2018-05-31 23:27:45.986626
NCT01183221|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-08-13|2010-08-13|2010-08-17|Estimate|||||||2010-08-13|2010-08-17|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders|The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders|Unknown status|Recruiting|N/A|35|Anticipated|Bartz, Jennifer, Ph.D.||1|||f||||t||||||||||2018-05-31 23:27:46.470684|2018-05-31 23:27:46.470684
NCT01183208|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-08-09|2010-08-16|2010-08-17|Estimate|||||||2016-08-09|2016-08-10|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Safety and Tolerability Study of Administration of PSD502|A Phase I, Single-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Pharmacokinetic and Safety Study to Evaluate Systemic Exposure and Local Vaginal Exposure to Lidocaine and Prilocaine and the Metabolites 2,6 DiMethylAlanine (2, 6, DMA) and O-Toluidine; and the Safety and Tolerability of PSD502 in Female Healthy Volunteer Subjects Following Daily Application to the Vagina and Cervix for Seven Days With Three Different Doses of PSD502 or Placebo|Completed||Phase 1|21|Actual|Plethora Solutions Ltd||3|||f||||f||||||||||2018-05-31 23:27:46.691338|2018-05-31 23:27:46.691338
NCT01183195|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2011-11-15|2010-08-13|2010-08-17|Estimate|||||||2011-11-15|2011-11-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:27:46.784629|2018-05-31 23:27:46.784629
NCT01183182|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2012-12-20|2010-08-16|2010-08-17|Estimate|||||||2012-12-20|2012-12-21|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Safety and Effectiveness Study for a Needle Guidance System in Lung Biopsies|Confirmation of Clinical Effectiveness and Safety of CT-guided Percutaneous Lung Aspiration and Biopsy Performed With the Aid of the ActiSightTM Needle Guidance System|Completed||Phase 4|48|Actual|ActiViews Ltd.||1|||f||||f||||||||||2018-05-31 23:27:46.844978|2018-05-31 23:27:46.844978
NCT01182831|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-14|||2010-08-27|2010-08-16|2010-08-17|Estimate|||||||2010-08-27|2010-08-30|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Trial Comparing Two Techniques of Celiac Plexus Neurolysis for Treatment of Pain in Carcinoma Pancreas|A Randomized Trial Comparing Fluoroscopy Guided Percutaneous Technique Versus Endoscopic Ultrasound Guided Technique of Celiac Plexus Neurolysis for Treatment of Pain in Carcinoma Pancreas|Unknown status|Recruiting|Phase 1|100|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t||||||||||2018-05-31 23:28:10.501187|2018-05-31 23:28:10.501187
NCT01183169|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2016-07-14||2016-07-14|2010-08-16|2010-08-17|Estimate|2016-07-14|2016-08-25|Estimate||||2016-07-14|2016-08-25|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All randomized participants|Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study on Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders to Previous Peg-IFN Alfa-2 Plus Ribavirin Treatment|Completed||Phase 2|459|Actual|Debiopharm International SA|In April 2012, ALV and placebo were discontinued in all participants. Participants remained on PEG and RBV treatment.|5|||f||||t||||||||||2018-05-31 23:27:47.13285|2018-05-31 23:27:47.13285
NCT01183156|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-02-14|2010-08-16|2010-08-17|Estimate|||||||2011-02-14|2011-02-16|Estimate|August 2010||2010-08-31|February 2011|2011-02-28|March 2011|Anticipated|2011-03-31|December 2010|Actual|2010-12-31||Interventional|REINVITE||Re-invitation to Screening Colonoscopy: a Randomized Study|Re-invitation to Screening Colonoscopy: a Randomized Controlled Trial of Reminding Letter and Educational Intervention on Attendance in Nonresponders to Initial Invitation to Screening Colonoscopy|Unknown status|Recruiting|N/A|1000|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 23:27:49.802254|2018-05-31 23:27:49.802254
NCT01183143|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2017-08-30||2018-04-05|2010-08-16|2010-08-17|Estimate|2018-04-05|2018-04-06|Actual||||2018-04-05|2018-04-06|Actual|May 11, 2004|Actual|2004-05-11|April 2018|2018-04-30|March 2, 2006|Actual|2006-03-02|March 2, 2006|Actual|2006-03-02||Interventional|Prestyje|The ITT population included all the subjects who received at least 1 dose of the IMP.|Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization|A Multicentre, Open-label, Non-comparative Phase IIIb Study to Evaluate the Acceptability of GONAL-f® Prefilled Liquid Formulation Administered by Pen in an Outpatient Setting for Ovarian Stimulation|Completed||Phase 3|215|Actual|Merck KGaA||1|||f||||||||||||||2018-05-31 23:27:49.941774|2018-05-31 23:27:49.941774
NCT01183130|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2015-03-31|2010-08-16|2010-08-17|Estimate|||||||2015-03-31|2015-04-01|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Compliance Monitoring in Real Time During Opioid Substitution Treatment|Compliance Monitoring in Real Time During Opioid Substitution Treatment|Withdrawn||N/A|0|Actual|Kuopio University Hospital||2||"The technology planned to be used in the study got outdated and therefore the study will not be~   conducted according to the initial protocol."|f||||f||||||||||2018-05-31 23:27:50.303191|2018-05-31 23:27:50.303191
NCT01183117|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-01|||2015-03-31|2010-08-16|2010-08-17|Estimate|||||||2015-03-31|2015-04-02|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|September 2012|Actual|2012-09-30||Interventional|||A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease|A Clinical Investigation of SM-01 Stenting Versus PTA for the Treatment of Superficial Femoral Artery Disease|Completed||Phase 3|105|Actual|Johnson & Johnson K.K. Medical Company||2|||f||||f||||||||||2018-05-31 23:27:50.402168|2018-05-31 23:27:50.402168
NCT01183104|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2016-12-05||2017-03-03|2010-08-16|2010-08-17|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|August 2010||2010-08-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|START-J|Analysis set of evaluation for efficacy ; Per Protocol Set|START-J: SiTAgliptin in eldeRly Trial in Japan|Efficacy and Safety Comparison of Sitagliptin and Glimepiride in Elderly Japanese Patients With Type 2 Diabetes|Completed||N/A|305|Actual|Japan Association for Diabetes Education and Care||2|||f||||t||||||||||2018-05-31 23:27:50.505638|2018-05-31 23:27:50.505638
NCT01183091|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-09-19|2010-08-16|2010-08-17|Estimate|||||||2012-09-19|2012-09-20|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|October 2010|Actual|2010-10-31|July 2008|Actual|2008-07-31||Observational|EVABLAF||Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of AF|Medical Economical Evaluation of the Ablation by Catheter of the Atrial Tissue in the Treatment of the Atrial Fibrillation|Completed|||503|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 23:27:51.203385|2018-05-31 23:27:51.203385
NCT01183078|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2017-04-11|2010-08-16|2010-08-17|Estimate|||||||2017-04-11|2017-04-13|Actual|August 2010||2010-08-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|Sure Shot||Distal Locking Using an Electromagnetic Field Guided Computer Based Real Time System for Orthopaedic Trauma Patients|Distal Locking Using an Electromagnetic Field Guided Computer Based Real Time System for Orthopaedic Trauma Patients|Completed||N/A|55|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 23:27:51.485129|2018-05-31 23:27:51.485129
NCT01183065|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2015-10-19||2015-10-19|2010-08-11|2010-08-17|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)|A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)|Completed||Phase 2|13|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:27:52.017517|2018-05-31 23:27:52.017517
NCT01183052|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-09-03|2010-08-16|2010-08-17|Estimate|||||||2012-09-03|2012-09-05|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Mitochondrial Dysfunction and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD) Patients|Mitochondrial Respiratory Chain and Peripheral Muscle Dysfunction in COPD Patients|Completed||N/A|30|Actual|5 Santé||1|||f||||t||||||||||2018-05-31 23:27:53.203764|2018-05-31 23:27:53.203764
NCT01183039|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-09-03|2010-08-16|2010-08-17|Estimate|||||||2012-09-03|2012-09-05|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Training in Healthy Sedentary Subjects|Cellular Effects of Training in Healthy Sedentary Subjects|Completed||N/A|30|Actual|5 Santé||2|||f||||t||||||||||2018-05-31 23:27:54.753599|2018-05-31 23:27:54.753599
NCT01183026|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|January 2004||2004-01-31|August 2010|2010-08-31|December 2006|Actual|2006-12-31|||||Observational|||V/Q SPECT for Diagnosis of Pulmonary Embolism|Performance of V/Q SPECT for the Diagnosis of Pulmonary Embolism|Completed|||300|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 23:27:55.65061|2018-05-31 23:27:55.65061
NCT01182129|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-11|2010-08-11|2010-08-16|Estimate|||||||2010-08-11|2010-08-16|Estimate|March 2006||2006-03-31|August 2010|2010-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|SMWS06||4 mg Nicotine Polacrilex Gum and Swedish Portion Snus|Nicotine Delivery and Subjective Effects of 4 mg Nicotine Polacrilex Chewing Gum Compared With Swedish Portion Snus|Completed||Phase 1/Phase 2|15|Actual|Contract Research Organization el AB||3|||f||||t||||||||||2018-05-31 23:28:28.570213|2018-05-31 23:28:28.570213
NCT01183013|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|2014-03-12||2014-10-09|2010-08-16|2010-08-17|Estimate|2014-03-14|2014-04-21|Estimate||||2014-10-09|2014-10-20|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All patients from the Full Analysis Set (FAS) which includes those patients in the treated set who had a baseline HbA1c value and at least one on-treatment HbA1c value.|30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks|A Randomised, Double-blind Parallel Group Study to Compare the Efficacy and Safety of Initial Combination Therapy With Linagliptin 5 mg + Pioglitazone 15 mg, 30 mg, or 45 mg, vs. Monotherapy With Pioglitazone (15 mg, 30 mg, or 45 mg) or Linagliptin 5 mg Once Daily for 30 Weeks, Followed by a Blinded Trial Period on Linagliptin 5 mg + Pioglitazone 30 or 45 mg Versus Pioglitazone Monotherapy 30 or 45 mg or Linagliptin 5 mg for up to 54 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control on Diet and Exercise|Completed||Phase 3|936|Actual|Boehringer Ingelheim|The study (Part B treatment only) was stopped early by protocol amendment #5, although Part A (time frame for all efficacy outcomes) proceeded to completion|7|||f||||||||||||||2018-05-31 23:27:56.517059|2018-05-31 23:27:56.517059
NCT01183000|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate||||August 2010|2010-08-31||||||||Interventional|cs adhesions||Closure of Peritoneum at Cesarean Section and Postoperative Adhesion|Effects of Closure Versus Non-closure of the Visceral and Parietal Peritoneum at Cesarean Section on Adhesions: A Prospective Randomized Study|Completed||N/A|||Barzilai Medical Center||2|||f||||||||||||||2018-05-31 23:28:05.291146|2018-05-31 23:28:05.291146
NCT01182987|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|SMPES||SCAN Memory Program Evaluation Study|SCAN Memory Program Evaluation Study|Unknown status|Recruiting|N/A|500|Anticipated|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||||2018-05-31 23:28:05.494397|2018-05-31 23:28:05.494397
NCT01182974|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-03-01|2010-08-16|2010-08-17|Estimate|||||||2011-03-01|2011-03-02|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Paracetamol Toxicity in Septic Patients|Paracetamol-induced Liver Toxicity in Septic Patients|Suspended||Phase 3|80|Anticipated|Barzilai Medical Center||2||Difficulty in patient enrollment|f||||f||||||||||2018-05-31 23:28:05.781499|2018-05-31 23:28:05.781499
NCT01182961|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-08-27|2010-08-16|2010-08-17|Estimate|||||||2010-08-27|2010-08-30|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|April 2013|Anticipated|2013-04-30|September 2012|Anticipated|2012-09-30||Interventional|VR-Fallers||The Use of Virtual Reality for the Gait Training of Elderly Fallers|Gait Training Intervention to Evaluate the Efficacy of Using Virtual Reality to Decrease Fall Risk in the Elderly Population|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||t||||||||||2018-05-31 23:28:05.927969|2018-05-31 23:28:05.927969
NCT01182948|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2011-08-24|2010-08-16|2010-08-17|Estimate|||||||2011-08-24|2011-08-25|Estimate|January 2009||2009-01-31|August 2011|2011-08-31||||December 2010|Actual|2010-12-31||Interventional|RAED2||Effects of Different Types of Exercise in Type 2 Diabetes|Comparison of Aerobic and Resistance Training Effects on Glycemic Control in Type 2 Diabetes|Completed||N/A|40|Actual|Universita di Verona||2|||f||||f||||||||||2018-05-31 23:28:06.142505|2018-05-31 23:28:06.142505
NCT01182935|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-07-19|2010-08-16|2010-08-17|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|||Elevated Triglyceride Levels and Later Type 2 Diabetes|Elevated Triglyceride Levels and Later Type 2 Diabetes|Completed|||3509|Actual|University of Tromso|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:28:06.361036|2018-05-31 23:28:06.361036
NCT01182922|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-15|||2011-11-17|2010-08-15|2010-08-17|Estimate|||||||2011-11-17|2011-11-18|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Information About a Doctor or a Possibility of Choosing Doctor's Gender and Attendance to Screening Colonoscopy|Is the Information About a Doctor or Possibility of Choosing Doctor's Gender Associated With Attendance to Screening Colonoscopy: Randomized Study With Three Types of Invitations.|Completed||Early Phase 1|5100|Actual|Maria Sklodowska-Curie Institute - Oncology Center||3|||f||||f||||||||||2018-05-31 23:28:06.45621|2018-05-31 23:28:06.45621
NCT01182909|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-15|||2011-09-16|2010-08-16|2010-08-17|Estimate|||||||2011-09-16|2011-09-19|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC)|Far Eastern Memorial Hospital|Unknown status|Recruiting||4000|Anticipated|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-05-31 23:28:06.625617|2018-05-31 23:28:06.625617
NCT01182883|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-14|||2017-06-30|2010-08-14|2010-08-17|Estimate|||||||2017-06-30|2017-07-02|Actual|July 28, 2010||2010-07-28|April 4, 2012|2012-04-04|April 4, 2012|Anticipated|2012-04-04|April 4, 2012|Actual|2012-04-04||Interventional|||A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of IMC-A12 (Anti-Insulin-like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:28:06.749126|2018-05-31 23:28:06.749126
NCT01182870|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-07-19|2010-08-16|2010-08-17|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Vitamin D and the Influenza Epidemic|Vitamin D and the Influenza Epidemic|Completed||Phase 3|569|Actual|University of Tromso||2|||f||||f||||||||||2018-05-31 23:28:07.49583|2018-05-31 23:28:07.49583
NCT01182857|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-14|||2018-05-19|2010-08-14|2010-08-17|Estimate|||||||2018-05-19|2018-05-22|Actual|August 5, 2010||2010-08-05|September 25, 2014|2014-09-25|September 25, 2014||2014-09-25|||||Observational|||Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents|Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:28:09.08611|2018-05-31 23:28:09.08611
NCT01182844|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2015-06-03|2010-08-16|2010-08-17|Estimate|||||||2015-06-03|2015-06-04|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota|Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota|Completed||N/A|30|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 23:28:09.958305|2018-05-31 23:28:09.958305
NCT01034670|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2016-12-05|2009-12-16|2009-12-17|Estimate|||||||2016-12-05|2016-12-06|Estimate|June 2009||2009-06-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Advanced Gastrointestinal Endoscopic Imaging|Advanced Gastrointestinal Endoscopic Imaging|Suspended||N/A|500|Anticipated|Stanford University||1||Device not ready|f||||t||||||||||2018-06-01 00:15:09.292859|2018-06-01 00:15:09.292859
NCT01182818|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-06-13|2010-08-16|2010-08-17|Estimate|||||||2012-06-13|2012-06-14|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|FASEP||Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease|FASEP Fabry and Stroke Epidemiological Protocol RISK FACTORS IN ISCHEMIC STROKE PATIENTS WITH FABRY DISEASE AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Completed|||1000|Actual|University of Rostock|||1||f||||t||||||Samples With DNA|"~     Fabry diagnostic will be done centrally: blood samples will be stored for analysis of~     a-galactosidase in blood, Gb3 as well as lyso-Gb3. In all cases direct analysis of the gene~     will be done, especially in females where due to the Lyonisation effect a-galactosidase~     activity might be normal in blood although the patient might suffer from Fabry disease.~   "|||2018-05-31 23:28:10.646122|2018-05-31 23:28:10.646122
NCT01182805|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2012-06-25||2012-08-02|2010-08-16|2010-08-17|Estimate|2012-08-02|2012-08-03|Estimate||||2012-08-02|2012-08-03|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|RF-SPEED||Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function|Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function|Completed||Phase 1/Phase 2|50|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 23:28:10.901531|2018-05-31 23:28:10.901531
NCT01182792|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2013-09-05|2010-08-16|2010-08-17|Estimate|||||||2013-09-05|2013-09-06|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|CMS||Chronic Mountain Sickness, Systemic Vascular Function|Chronic Hypoxemia and Systemic Vascular Function|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of Lausanne Hospitals||2|||f||||||||||||||2018-05-31 23:28:11.726908|2018-05-31 23:28:11.726908
NCT01182779|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|August 2023|Anticipated|2023-08-31|August 2015|Anticipated|2015-08-31||Interventional|HIT-1||Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base|Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III Study-|Recruiting||Phase 3|319|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-05-31 23:28:12.38253|2018-05-31 23:28:12.38253
NCT01182766|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-03-31|2010-08-16|2010-08-17|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||New Treatment for Alcohol and Nicotine Dependence|High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers|Recruiting||Phase 2/Phase 3|294|Anticipated|University of Virginia||2|||f||||t|t|f||||||No||2018-05-31 23:28:12.824972|2018-05-31 23:28:12.824972
NCT01182753|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|CSP12C||Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base|Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base, Clinical Phase III Study|Recruiting||Phase 3|154|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 23:28:13.129818|2018-05-31 23:28:13.129818
NCT01182740|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-11-10|2010-08-16|2010-08-17|Estimate|||||||2010-11-10|2010-11-11|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|November 2010|Actual|2010-11-30|||||Observational|||Comparison of Endotracheal Intubation Success Rates Using Video Laryngoscopes in Entrapped Patients - a Manikin Study|Comparison of Endotracheal Intubation Success Rates Using Video Laryngoscopes in Entrapped Patients - a Manikin Study|Completed|||30|Anticipated|University of Cologne|||6||f||||f||||||||||2018-05-31 23:28:13.335974|2018-05-31 23:28:13.335974
NCT01182727|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2013-01-28||2013-05-07|2010-08-16|2010-08-17|Estimate|2013-05-07|2013-06-14|Estimate||||2013-05-07|2013-06-14|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Salsalate for Insulin Resistance in Schizophrenia|Salsalate for the Treatment of Insulin Resistance in People With Schizophrenia|Completed||N/A|13|Actual|University of Maryland||1|||f||||t||||||||||2018-05-31 23:28:13.520691|2018-05-31 23:28:13.520691
NCT01182714|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-18|2010-08-13|2010-08-17|Estimate|||||||2010-08-18|2010-08-20|Estimate|November 2007||2007-11-30|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Prospective Randomized Control Trial Comparing Immediate and 24-hours Delayed Catheter Removal Following Hysterectomy|A Prospective Randomized Trial to Compare Immediate and 24-hours Delayed Catheter Removal Following Total Abdominal Hysterectomy|Completed||N/A|70|Actual|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 23:28:13.686556|2018-05-31 23:28:13.686556
NCT01182701|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2010-08-13|2010-08-13|2010-08-17|Estimate|||||||2010-08-13|2010-08-17|Estimate|August 2004||2004-08-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Cognitive Behavioral Intervention in Diabetes Self-Management|Cognitive Behavioral Intervention in Diabetes Self-Management|Completed||N/A|207|Actual|University of Hawaii||2|||f||||t||||||||||2018-05-31 23:28:13.953004|2018-05-31 23:28:13.953004
NCT01182688|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|May 2009||2009-05-31|October 2009|2009-10-31||||September 2009|Actual|2009-09-30||Observational|||Prospective Review of Procalcitonin After Cardiac Surgery|Prospective Review of Procalcitonin After Cardiac Surgery|Completed|||105|Actual|Tampa Bay Heart Foundation|||||f||||f||||||||||2018-05-31 23:28:14.115695|2018-05-31 23:28:14.115695
NCT01182675|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2014-10-28||2017-10-26|2010-08-13|2010-08-17|Estimate|2014-11-06|2014-11-10|Estimate||||2017-10-26|2017-12-02|Actual|August 2010||2010-08-31|October 2017|2017-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim|Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease Utilizing Alemtuzumab and Mobilization With Plerixafor & Filgrastim|Terminated||Phase 2|7|Actual|University of California, San Francisco||2||Insufficient evidence of efficacy|f||||f||||||||||2018-05-31 23:28:14.206313|2018-05-31 23:28:14.206313
NCT01182662|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-30|2010-08-16|2010-08-17|Estimate|||||||2010-08-30|2010-08-31|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia|Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat SAA|Unknown status|Recruiting|Phase 2|30|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 23:28:14.443416|2018-05-31 23:28:14.443416
NCT01182649|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-16|2010-08-16|2010-08-17|Estimate|||||||2010-08-16|2010-08-17|Estimate|March 2007||2007-03-31|May 2010|2010-05-31|June 2010|Actual|2010-06-30|December 2008|Actual|2008-12-31||Interventional|RACES||Everolimus Stent in Patients With Coronary Artery Disease (CAD)|Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With Coronary Artery Disease|Completed||Phase 3|600|Actual|San Giuseppe Moscati Hospital||2|||f||||f||||||||||2018-05-31 23:28:14.550247|2018-05-31 23:28:14.550247
NCT01182636|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-11-22|2010-08-13|2010-08-17|Estimate|||||||2010-11-22|2010-11-24|Estimate|July 2007||2007-07-31|November 2010|2010-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris|A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of Adapalene Gel 0.1% (PLIVA Research & Development Ltd.) Compared to Differin® (Adapalene 0.1%) Topical Gel (Galderma Laboratories) in Patients With Acne Vulgaris|Completed||Phase 1|601|Actual|Teva Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 23:28:14.63273|2018-05-31 23:28:14.63273
NCT01182623|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-08-17|2010-08-16|2010-08-17|Estimate|||||||2010-08-17|2010-08-18|Estimate|December 2009||2009-12-31|August 2010|2010-08-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|||The Value of Polyp Surface Pattern Recognition in the Identification of Neoplasia: a Prospective Study|Polyp Surface Pattern Recognition in the Identification of Neoplastic Polyps|Unknown status|Recruiting||260|Anticipated|Portsmouth Hospitals NHS Trust|||1||f||||f||||||Samples With DNA|"~     All polyps are sent for histological analysis as per standard protocol. This is not~     additional for the study and part of routine NHS practice. They will be kept and stored as~     per standard NHS protocols.~   "|||2018-05-31 23:28:14.826556|2018-05-31 23:28:14.826556
NCT01182610|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2012-10-30||2012-11-29|2010-08-13|2010-08-17|Estimate|2012-10-30|2012-11-28|Estimate||||2012-11-29|2012-12-03|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma|A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma|Terminated||Phase 2|1|Actual|Accelerated Community Oncology Research Network|This study was closed due to notification and preliminary results from a trial including panitumumab as part of combination chemotherapy for gastroesophageal cancer. The study was closed by mutual consent from the PI, Sponsor, and Funder.|1||Safety concern in a similar trial enrolling the same patient population|f||||f||||||||||2018-05-31 23:28:14.99584|2018-05-31 23:28:14.99584
NCT01182597|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2012-06-20|2010-08-16|2010-08-17|Estimate|||||||2012-06-20|2012-06-21|Estimate|August 2010||2010-08-31|June 2012|2012-06-30||||August 2013|Anticipated|2013-08-31||Interventional|||Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis|Oral Versus Intravenous Proton Pump Inhibitor Treatment in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis: a Prospective Randomized Comparative Study|Unknown status|Recruiting|Phase 3|190|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 23:28:15.272858|2018-05-31 23:28:15.272858
NCT01182584|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-12-21|2010-08-16|2010-08-17|Estimate|||||||2010-12-21|2010-12-22|Estimate|December 2009||2009-12-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Application of Digital Infrared Thermal Imaging (DITI) in Graves' Disease|Application of Digital Infrared Thermal Imaging in Thyroid Disease and Associated Ophthalmopathy and Dermopathy|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 23:28:15.546855|2018-05-31 23:28:15.546855
NCT01182571|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-08-27|2010-08-16|2010-08-17|Estimate|||||||2010-08-27|2010-08-30|Estimate|October 2008||2008-10-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients|Exploration of Fatigue ,Uncertainty ,Depression and Quality of Life in Heart Transplantation Recipients|Completed|||127|Actual|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 23:28:15.865176|2018-05-31 23:28:15.865176
NCT01182558|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-07-26|2010-08-16|2010-08-17|Estimate|||||||2017-07-26|2017-07-27|Actual|October 2010||2010-10-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|May 2011|Actual|2011-05-31||Interventional|||The Effect of Prior Muscle Activation on the Compound Muscle Action Potential (CMAP)|The Effect of Prior Muscle Activation on the Compound Muscle Action Potential (CMAP)- Implications for Routine Nerve Conduction Studies (NCS) and Serial NCS|Active, not recruiting||N/A|20|Anticipated|Loma Linda University||4|||f||||f||||||||||2018-05-31 23:28:16.042978|2018-05-31 23:28:16.042978
NCT01182545|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-11-18|2010-08-16|2010-08-17|Estimate|||||||2010-11-18|2010-11-19|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||The Effects of Hyperventilation Prior to CO2 Insufflation During Laparoscopic Cholecystectomy|A Prospective Randomized Study of the Effects of Hyperventilation Prior to Carbon Dioxide Insufflation on Hemodynamic Changes During Laparoscopic Cholecystectomy|Completed||Phase 1|100|Actual|King Faisal University||2|||f||||t||||||||||2018-05-31 23:28:16.153612|2018-05-31 23:28:16.153612
NCT01182532|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-16|||2012-07-20|2010-08-16|2010-08-17|Estimate|||||||2012-07-20|2012-07-23|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease||Completed||N/A|3000|Actual|The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 23:28:16.217953|2018-05-31 23:28:16.217953
NCT01182519|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2016-07-11|2010-08-13|2010-08-16|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Lung Inflammation and Lung Metastases From Breast Cancer|Association of Smoking, Lung Inflammation and Lung Metastases From Breast Cancer|Completed|||400|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Urine and Blood~   "|||2018-05-31 23:28:16.314383|2018-05-31 23:28:16.314383
NCT01182506|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-09-05|2010-08-13|2010-08-16|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2010||2010-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Rehabilitation of Cognitive Changes in Breast Cancer Survivors|Rehabilitation of Cognitive Changes in Breast Cancer Survivors|Active, not recruiting||N/A|60|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 23:28:16.37899|2018-05-31 23:28:16.37899
NCT01182493|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2016-02-17||2018-02-06|2010-08-13|2010-08-16|Estimate|2016-02-17|2016-03-15|Estimate||||2018-02-06|2018-03-12|Actual|December 2010||2010-12-31|February 2018|2018-02-28|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|OpT2mise||OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy|OpT2mise Glucose Control in Type 2 DM With Insulin Pump Therapy|Completed||N/A|331|Actual|Medtronic Diabetes||2|||f||||t||||||||No||2018-05-31 23:28:16.559655|2018-05-31 23:28:16.559655
NCT01182116|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-05-08|2010-08-13|2010-08-16|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2009||2009-03-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Quality of Life in Patients That Undergo J Pouch or Side to End Coloanal Anastomosis for Rectal Cancer|A Randomized, Controlled Trial to Compare the Functional Outcome and Quality of Life in Patients With Low Rectal Cancer Who Undergo a J Pouch or a Side to End Coloanal Anastomosis|Completed||N/A|46|Actual|The Cleveland Clinic||1|||f||||t||||||||No||2018-05-31 23:28:28.649954|2018-05-31 23:28:28.649954
NCT01182480|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2012-07-11||2014-10-29|2010-08-12|2010-08-16|Estimate|2014-10-29|2014-11-05|Estimate||||2014-10-29|2014-11-05|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Chronic Care Management/Patient Relationship Management Proof of Concept|Chronic Care Management/Patient Relationship Management Proof of Concept|Completed||N/A|47|Actual|Denver Health and Hospital Authority|Insufficient power (# appointments) to detect changes in attendance rates; technical issues with self-efficacy data resulting in inability to compare pre- and post- intervention; intervention period insufficient to assess impact on glycemic control.||||f||||f||||||||||2018-05-31 23:28:17.56953|2018-05-31 23:28:17.56953
NCT01182467|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2015-04-09|2010-08-12|2010-08-16|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Use of PET-CT in the Management of Crohn's Disease|Pilot Study in the Use of Positron Emission Tomography-Computed Tomography (PET-CT)in the Management of Crohn's Disease|Terminated|||5|Actual|Columbia University|||1|PI left the institution|f||||f||||||||||2018-05-31 23:28:19.186076|2018-05-31 23:28:19.186076
NCT01182454|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-08-13|2010-08-13|2010-08-16|Estimate|||||||2010-08-13|2010-08-16|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Clinical Test Report for Blood Pressure Meter of CH-658||Completed|||96|Actual|Citizen Systems Japan Co., Ltd.|||||f||||f||||||||||2018-05-31 23:28:20.066647|2018-05-31 23:28:20.066647
NCT01182441|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2015-01-26|2010-08-12|2010-08-16|Estimate|||||||2015-01-26|2015-01-27|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|August 2017|Anticipated|2017-08-31|January 2013|Actual|2013-01-31||Interventional|PREVAIL||Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy|Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy|Unknown status|Active, not recruiting|Phase 3|475|Anticipated|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 23:28:20.310652|2018-05-31 23:28:20.310652
NCT01182428|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|2012-05-03||2012-07-23|2010-08-12|2010-08-16|Estimate|2012-06-07|2012-07-13|Estimate||||2012-07-23|2012-08-07|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||XIENCE V: SPIRIT WOMEN Sub-study|A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions|Completed||Phase 4|455|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 23:28:20.981659|2018-05-31 23:28:20.981659
NCT01182415|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2017-11-27||2017-11-27|2010-08-13|2010-08-16|Estimate|2017-11-27|2017-12-29|Actual||||2017-11-27|2017-12-29|Actual|June 2010||2010-06-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma|Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma|Completed||Phase 2|30|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:28:22.428402|2018-05-31 23:28:22.428402
NCT01182402|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-03-21|2010-08-13|2010-08-16|Estimate|||||||2011-03-21|2011-03-22|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|EHSO||Electronic Compliance Monitoring in Opioid Substitution Treatment|Electronic Compliance Monitoring in Opioid Substitution Treatment|Completed||N/A|37|Actual|Kuopio University Hospital||1|||f||||f||||||||||2018-05-31 23:28:22.769043|2018-05-31 23:28:22.769043
NCT01182389|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2017-09-01|2010-08-13|2010-08-16|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2011||2011-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|ERASE-VT||A Study of Early Robotic Ablation by Substrate Elimination of Ventricular Tachycardia|A Prospective Randomised Study of Early Robotic Ablation by Substrate Elimination of Ventricular Tachycardia|Completed||N/A|51|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 23:28:22.991199|2018-05-31 23:28:22.991199
NCT01182376|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2015-09-10||2016-01-22|2010-08-11|2010-08-16|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SOAR||SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI|SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI|Completed||Phase 3|33|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 23:28:23.215935|2018-05-31 23:28:23.215935
NCT01182363|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-08-26|2010-08-13|2010-08-16|Estimate|||||||2014-08-26|2014-08-28|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Reducing Risk After an Adverse Pregnancy Outcome|Reducing Risk After an Adverse Pregnancy Outcome: Addressing Maternal Depression During Internatal Periods|Completed||N/A|188|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 23:28:23.653439|2018-05-31 23:28:23.653439
NCT01182350|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2018-04-02|2010-08-13|2010-08-16|Estimate|||||||2018-04-02|2018-04-04|Actual|September 2011||2011-09-30|April 2018|2018-04-30||||March 2018|Actual|2018-03-31||Interventional|||Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)|Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas|Active, not recruiting||Phase 2|53|Actual|Dana-Farber Cancer Institute||4|||f||||t||||||||||2018-05-31 23:28:24.224017|2018-05-31 23:28:24.224017
NCT01182337|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2015-12-18||2016-01-26|2010-08-13|2010-08-16|Estimate|2015-12-18|2016-01-27|Estimate||||2016-01-26|2016-02-26|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration|A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration|Completed||Phase 1/Phase 2|31|Actual|DePuy Spine||2|||f||||f||||||||||2018-05-31 23:28:24.416874|2018-05-31 23:28:24.416874
NCT01182324|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2018-04-04|2010-08-13|2010-08-16|Estimate|||||||2018-04-04|2018-04-05|Actual|July 30, 2010||2010-07-30|June 24, 2013|2013-06-24|June 24, 2013||2013-06-24|||||Observational|||The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor|The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Clinician Researchers, and the Industry Sponsor|Completed|||21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:28:24.796036|2018-05-31 23:28:24.796036
NCT01182311|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2018-05-23|2010-08-13|2010-08-16|Estimate|||||||2018-05-23|2018-05-24|Actual|August 10, 2010||2010-08-10|March 19, 2018|2018-03-19||||||||Observational|||Duration of Long-term Immunity After Hepatitis B Virus Immunization|Duration of Long-Term Immunity After Hepatitis B Virus Immunization|Completed|||205|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:28:24.857573|2018-05-31 23:28:24.857573
NCT01182298|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2014-04-23||2014-09-26|2010-08-13|2010-08-16|Estimate|2014-09-26|2014-10-02|Estimate||||2014-09-26|2014-10-02|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|LATHCV|LATINO PARTICIPANTS WITH hepatitis C|Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection|Study to Evaluate the Genetic, Epigenetic, and Proteomic Expression in Latino Participants With and Without HIV Coinfection Receiving Treatment for Hepatitis C|Terminated|||10|Actual|National Institutes of Health Clinical Center (CC)|Early termination due to small numbers of subjects enrolled as the options for HCV treatment changed significantly since the start of the study planning.||1|small number of patients enrolled|f||||||||||Samples With DNA|"~     Plasma and serum storage.~   "|||2018-05-31 23:28:24.914183|2018-05-31 23:28:24.914183
NCT01182285|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2016-08-22||2018-04-16|2010-08-13|2010-08-16|Estimate|2016-10-20|2016-12-14|Estimate||||2018-04-16|2018-05-16|Actual|September 24, 2010|Actual|2010-09-24|April 2018|2018-04-30|April 28, 2016|Actual|2016-04-28|September 28, 2015|Actual|2015-09-28||Interventional||Five and eight participants were enrolled from University of California San Francisco (UCSF), and the National Institutes of Health, respectively.|A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin|A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Origin|Completed||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f|t|f||||||No||2018-05-31 23:28:26.175584|2018-05-31 23:28:26.175584
NCT01182272|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-08-13|2010-08-13|2010-08-16|Estimate|||||||2010-08-13|2010-08-16|Estimate|May 2010||2010-05-31|August 2010|2010-08-31||||June 2012|Anticipated|2012-06-30||Interventional|||Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery|Proof-of-Concept Phase II Study to Evaluate the Anti-Tumor Activity of Sorafenib Along With Pathological and Molecular Changes in Tumor Samples From Patients With Resectable Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:28:26.588171|2018-05-31 23:28:26.588171
NCT01182259|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-08-13|2010-08-13|2010-08-16|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2009||2009-10-31|August 2010|2010-08-31||||||||Observational|||The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study||Unknown status|Recruiting||200|Anticipated|E-DA Hospital|||||f||||||||||||||2018-05-31 23:28:26.691612|2018-05-31 23:28:26.691612
NCT01182246|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2014-04-22|2010-08-13|2010-08-16|Estimate|||||||2014-04-22|2014-04-23|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer|Safety, Pharmacokinetics and Efficacy of AXP107-11 in Combination With Standard Gemcitabine (Gemzar®) Treatment in Patients With Locally Advanced or Metastatic, Unresectable, Adenocarcinoma of the Pancreas, Stage III-IV: A Prospective, Open Label, Multi-centre, Sequential Phase Ib/IIa Study|Unknown status|Recruiting|Phase 1/Phase 2|44|Anticipated|Axcentua Pharmaceuticals AB||1|||f||||t||||||||||2018-05-31 23:28:26.788194|2018-05-31 23:28:26.788194
NCT01182233|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2016-05-14|2010-08-13|2010-08-16|Estimate|||||||2016-05-14|2016-05-17|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation|Evaluation of a Method Designed to Improve Outcome of HD Chemotherapy and AHSCT for Patients With Myeloma: Total Marrow Irradiation Administered Via Helical Tomotherapy Plus High-Dose Melphalan and Amifostine Before AHSCT2|Terminated||Phase 1|4|Actual|University of Rochester||1||low enrollment|f||||f||||||||||2018-05-31 23:28:26.910231|2018-05-31 23:28:26.910231
NCT01182220|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2016-10-31|2010-08-13|2010-08-16|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Comparison of Ultrasound Guided Low Epidural Catheter Placement With Standard Epidural Catheter Placement|Comparison of Ultrasound Guided L5/S1 Epidural Catheter Placement With Standard Epidural Catheter Placement: A Randomized Trial|Completed|||90|Actual|University of Chicago|||2||f||||f||||||||||2018-05-31 23:28:27.071691|2018-05-31 23:28:27.071691
NCT01182207|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2010-09-15||2010-11-22|2010-08-13|2010-08-16|Estimate|2010-09-15|2010-10-07|Estimate||||2010-11-22|2010-12-08|Estimate|July 2006||2006-07-31|November 2010|2010-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Non-Fasting Conditions.|Completed||Phase 1|33|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:28:27.169044|2018-05-31 23:28:27.169044
NCT01182194|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2010-09-15||2010-11-22|2010-08-13|2010-08-16|Estimate|2010-09-15|2010-10-07|Estimate||||2010-11-22|2010-12-08|Estimate|June 2006||2006-06-30|November 2010|2010-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.|A Relative Bioavailability Study of 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets Under Fasting Conditions.|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:28:27.579303|2018-05-31 23:28:27.579303
NCT01182181|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2010-10-15||2010-10-15|2010-08-13|2010-08-16|Estimate|2010-10-15|2010-11-15|Estimate||||2010-10-15|2010-11-15|Estimate|August 2005||2005-08-31|October 2010|2010-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Anastrozole 1 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Anastrozole 1 mg Tablets Under Fasting Conditions|Completed||Phase 1|22|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:28:27.986948|2018-05-31 23:28:27.986948
NCT01182168|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2016-03-29|2010-08-11|2010-08-16|Estimate|||||||2016-03-29|2016-03-31|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies|Phase I Trial of Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies|Completed||Phase 1|12|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:28:28.269772|2018-05-31 23:28:28.269772
NCT01182155|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2016-06-30|2010-08-13|2010-08-16|Estimate|||||||2016-06-30|2016-07-01|Estimate|August 2010||2010-08-31|June 2016|2016-06-30|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Observational|||Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation|Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation: A Feasibility Study|Completed|||20|Actual|Stanford University|||||f||||t||||||||||2018-05-31 23:28:28.335724|2018-05-31 23:28:28.335724
NCT01182142|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-22|2010-08-13|2010-08-16|Estimate|||||||2010-08-22|2010-08-24|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|||Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients|Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients|Completed||Phase 2|51|Anticipated|Kidney Cancer Research Bureau||1|||f||||f||||||||||2018-05-31 23:28:28.420417|2018-05-31 23:28:28.420417
NCT01182103|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2013-06-07||2014-07-24|2010-08-13|2010-08-16|Estimate|2014-07-24|2014-08-15|Estimate||||2014-07-24|2014-08-15|Estimate|August 2010||2010-08-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Observational|||Epigenetic Regulation of BDNF in Major Depression|Epigenetic Regulation of Brain-Derived Neurotropic Factor (BDNF) in Patients With Major Depression|Completed|||110|Actual|Chang Gung Memorial Hospital|Limited funding prevented all samples from receiving all analyses.||2||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 23:28:28.734993|2018-05-31 23:28:28.734993
NCT01182090|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2014-05-19|2010-08-13|2010-08-16|Estimate|||||||2014-05-19|2014-05-20|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Surgical Correction of Pelvic Organ Prolapse|OPEN SURGERY VS LAPAROSCOPY IN SURGERY OF PELVIC ORGAN PROLAPSE|Completed||Phase 3|40|Actual|University Of Perugia||2|||f||||f||||||||||2018-05-31 23:28:29.061835|2018-05-31 23:28:29.061835
NCT01182077|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-11|2010-08-11|2010-08-16|Estimate|||||||2010-08-11|2010-08-16|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Assess Drug Interaction of ASP015K and Midazolam|A Phase 1, Open Label, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP015K and Midazolam After Separate and Concomitant Administration to Healthy Adult Subjects|Completed||Phase 1|30|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:28:29.158667|2018-05-31 23:28:29.158667
NCT01182064|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-08-13|2010-08-13|2010-08-16|Estimate|||||||2010-08-13|2010-08-16|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|April 2008|Actual|2008-04-30|||||Observational|||Acute Myocardial Infarction by Penetrating Cardiac Trauma|Relationship of Echocardiographic and Coronary Angiographic Findings in Patients With Acute Myocardial Infarction Secondary to Penetrating Cardiac Trauma|Completed|||51|Actual|Universidad de Antioquia|||3||f||||f||||||||||2018-05-31 23:28:29.239227|2018-05-31 23:28:29.239227
NCT01182051|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-05-22|2010-08-13|2010-08-16|Estimate|||||||2013-05-22|2013-05-24|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of Family-based Cognitive-behavioral Therapy for Chronic Pediatric Headache and Anxiety|A Pilot Study of Family-based Cognitive-behavioral Therapy for Treating Chronic Pediatric Headache/Migraine and Comorbid Anxiety|Completed||N/A|15|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:28:29.302457|2018-05-31 23:28:29.302457
NCT01182038|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-13|2010-08-13|2010-08-16|Estimate|||||||2010-08-13|2010-08-16|Estimate|November 2007||2007-11-30|August 2010|2010-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Swedish Birth Seat Trial|The Swedish Birth Seat Trial|Completed||N/A|1002|Actual|Helsingborgs Hospital||2|||f||||t||||||||||2018-05-31 23:28:29.384115|2018-05-31 23:28:29.384115
NCT01182025|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|||2010-08-16|2010-08-13|2010-08-16|Estimate|||||||2010-08-16|2010-08-17|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|May 2011|Anticipated|2011-05-31||Interventional|||A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease||Unknown status|Recruiting|N/A|360|Anticipated|The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 23:28:29.458151|2018-05-31 23:28:29.458151
NCT01182012|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-13|2010-08-13|2010-08-16|Estimate|||||||2010-08-13|2010-08-16|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|December 2012|Anticipated|2012-12-31|August 2011|Anticipated|2011-08-31||Interventional|RISCA-TMS||Reduction of Cardiovascular Risk in Severe Mental Illness|Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs|Unknown status|Recruiting|Phase 4|391|Anticipated|Consorci Hospitalari de Vic||1|||f||||t||||||||||2018-05-31 23:28:29.564771|2018-05-31 23:28:29.564771
NCT01181999|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-09-21|2010-08-13|2010-08-16|Estimate|||||||2011-09-21|2011-09-22|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|September 2014|Anticipated|2014-09-30|March 2012|Anticipated|2012-03-31||Interventional|||Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma|Phase II Trial of Rituximab (R) Augmentation Following R-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma (DLBCL)|Unknown status|Recruiting|Phase 2|50|Anticipated|Chonnam National University Hospital||1|||f||||t||||||||||2018-05-31 23:28:29.672925|2018-05-31 23:28:29.672925
NCT01181986|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-13|2013-12-26||2014-05-12|2010-08-13|2010-08-16|Estimate|2014-04-25|2014-04-28|Estimate||||2014-05-12|2014-05-20|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes|Exenatide and Postprandial Endothelial Dysfunction: Effects and Mechanisms|Completed||Phase 4|76|Actual|Carl T. Hayden VA Medical Center||2|||f||||f||||||||||2018-05-31 23:28:29.769358|2018-05-31 23:28:29.769358
NCT01181973|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2012-01-04|2010-08-12|2010-08-13|Estimate|||||||2012-01-04|2012-01-05|Estimate|October 2010||2010-10-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects|An Open-label, Randomized, Phase 1, Single-Dose Crossover Study to Evaluate Safety, Tolerability and Relative Bioavailability of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered in Healthy Subjects|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:28:30.1815|2018-05-31 23:28:30.1815
NCT01181960|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2014-02-11|2010-08-12|2010-08-13|Estimate|||||||2014-02-11|2014-02-12|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations|Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations|Completed|||1066|Actual|Janssen Scientific Affairs, LLC|||4||f||||f||||||||||2018-05-31 23:28:30.267279|2018-05-31 23:28:30.267279
NCT01181947|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2014-12-17||2015-01-22|2010-08-12|2010-08-13|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-22|2015-01-26|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Observational|VCOUS||VALIANT CAPTIVIA Post-market Registry|VALIANT CAPTIVIA Post-market Registry A Multi-center, Post-market, Non Interventional, Prospective Study|Terminated|||100|Actual|Medtronic Endovascular|||1|"CIP was amended to include long-term FU but, not all sites accepted it so the nr. of pts~   participating in the extended FU will be small."|f||||f||||||||||2018-05-31 23:28:30.465115|2018-05-31 23:28:30.465115
NCT01181934|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2012-03-19|2010-08-12|2010-08-13|Estimate|||||||2012-03-19|2012-03-20|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|||||Interventional|||The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects.|A Double-Blind, Placebo-Controlled, Randomized Three-Way Crossover Study to Investigate The Effect of Nicotine on Arousal, Standard Cognitive Tasks And Social Cognition in Young and Elderly Healthy Subjects|Completed||Early Phase 1|32|Actual|Janssen Pharmaceutica N.V., Belgium||3|||f||||||||||||||2018-05-31 23:28:30.755042|2018-05-31 23:28:30.755042
NCT01181921|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2012-04-04||2014-04-15|2010-08-12|2010-08-13|Estimate|2012-07-06|2012-08-14|Estimate||||2014-04-15|2014-05-01|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease|Phase IV Study for the Assessment of Modulating Effect of Galantamine (Reminyl PRC) on Circadian Rhythm in Patients With Moderate Alzheimer's Disease|Terminated||Phase 4|1|Actual|Janssen-Cilag, S.A.||1||The recruitment rate was very low (one screening failure and one early withdrawal patient)|f||||f||||||||||2018-05-31 23:28:30.833898|2018-05-31 23:28:30.833898
NCT01181908|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-06-26|2010-08-12|2010-08-13|Estimate|||||||2017-06-26|2017-06-27|Actual|November 11, 2009|Actual|2009-11-11|June 2017|2017-06-30|December 30, 2009|Actual|2009-12-30|December 30, 2009|Actual|2009-12-30||Interventional|||Alcohol Interaction Study|A Study to Investigate the Psychomotor and Cognitive Effects of Alcohol When Co-administered With GSK1144814 or Matching Placebo in Healthy Subjects.|Completed||Phase 1|21|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:28:30.96202|2018-05-31 23:28:30.96202
NCT01181895|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2013-06-06|2012-07-26|2017-10-09|2010-08-12|2010-08-13|Estimate|2013-08-22|2013-08-26|Estimate|2012-07-26|2012-08-03|Estimate|2017-10-09|2017-11-08|Actual|September 1, 2010||2010-09-01|October 2017|2017-10-31|August 26, 2011|Actual|2011-08-26|August 1, 2011|Actual|2011-08-01||Interventional|||Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids|Completed||Phase 3|348|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:28:31.069644|2018-05-31 23:28:31.069644
NCT01181882|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2013-10-07|2010-08-11|2010-08-13|Estimate|||||||2013-10-07|2013-10-08|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|November 2012|Actual|2012-11-30|March 2012|Actual|2012-03-31||Interventional|R-21||Fish Oil and Aspirin With Type 2 Diabetes|The Effects of Fish Oil and Aspirin on Cardiovascular Risk in Type 2 Diabetes|Completed||Phase 2|30|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 23:28:31.750187|2018-05-31 23:28:31.750187
NCT01181869|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2012-04-12|2010-08-12|2010-08-13|Estimate|||||||2012-04-12|2012-04-13|Estimate|January 1983||1983-01-31|April 2012|2012-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|observatory||Database of Patients Treated With Respiratory Support|Observatoire de l'ANTADIR - Database of Patients Registered as Treated With Respiratory Support in a Multicenter Homecare Federation for Patients Wirh Respiratory Problems|Unknown status|Recruiting||120000|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|||3||f||||t||||||||||2018-05-31 23:28:31.823191|2018-05-31 23:28:31.823191
NCT01181856|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-03-25|2010-08-11|2010-08-13|Estimate|||||||2011-03-25|2011-03-28|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route|Safety and Immunogenicity of Candidate Tuberculosis (TB) Vaccine MVA85A Administered by the Intramuscular Route and the Intradermal Route: a Phase I Randomised Active Controlled Trial|Completed||Phase 1|24|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 23:28:31.904227|2018-05-31 23:28:31.904227
NCT01181843|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-11-06|2010-08-12|2010-08-13|Estimate|||||||2017-11-06|2017-11-08|Actual|July 2010||2010-07-31|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Incidence of Respiratory Depression in Cesarean Section|A Prospective, Observational, Double-blind (Black-Box) Study Evaluating Incidence, Severity and Predictive Factors of Respiratory Depression During Postoperative Neuraxial Opioid Analgesia in Obstetric Patients After Cesarean Delivery Using Current Standard Intermittent Postoperative Monitoring Compared to Continuous Pulse Oximetry / Capnography|Terminated|||100|Actual|Wake Forest University Health Sciences|||1|departmental financial support withdrawn|f||||t||||||||||2018-05-31 23:28:31.972053|2018-05-31 23:28:31.972053
NCT01181830|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2013-10-15|2010-08-12|2010-08-13|Estimate|||||||2013-10-15|2013-10-16|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome|Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome|Completed||Phase 4|14|Actual|Universita di Verona||2|||f||||f||||||||||2018-05-31 23:28:32.033803|2018-05-31 23:28:32.033803
NCT01181817|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-17|2010-08-12|2010-08-13|Estimate|||||||2010-08-17|2010-08-18|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Evaluation of the Brain Activity During Spinal Cord Stimulation in Failed Back Surgery Syndrome Using Functional MRI and MRS|Evaluation of the Brain Activity During Spinal Cord Stimulation (SCS) in Failed Back Surgery Syndrome Using Functional Magnetic Resonance Imaging (fMRI) and Magnetic ResonanceSpectroscopy (MRS)|Unknown status|Recruiting|N/A|40|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||t||||||||||2018-05-31 23:28:32.100533|2018-05-31 23:28:32.100533
NCT01181804|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2012-03-23||2017-03-09|2010-08-12|2010-08-13|Estimate|2012-03-23|2012-04-18|Estimate||||2017-03-09|2017-04-07|Actual|June 2010||2010-06-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)|A Definitive Bioequivalence Study of a New Boceprevir (SCH 503034) Tablet Formulation Compared to the Current Capsule Form in Healthy Male and Female Subjects.|Completed||Phase 1|177|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:28:32.176413|2018-05-31 23:28:32.176413
NCT01181791|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2017-08-24|2010-08-12|2010-08-13|Estimate|||||||2017-08-24|2017-08-28|Actual|July 2010||2010-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|Reuteri||Effects of Lactobacillus Reuteri in Premature Infants|Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns|Terminated||N/A|65|Actual|University of Miami||2||Poor recruitment|f||||f||||||||No||2018-05-31 23:28:32.493324|2018-05-31 23:28:32.493324
NCT01181778|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2013-07-21||2015-10-01|2010-08-12|2010-08-13|Estimate|2013-07-21|2013-09-24|Estimate||||2015-10-01|2015-10-21|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|ECOS||Evaluation of Participant Responses to Educational Counseling About Different Combined Hormonal Contraceptive Choices (P06557)|Observational, Prospective, Multicenter Study to Evaluate the Educational Counseling Effects in the Choice of Different Combined Hormonal Contraceptives|Completed|||1919|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:28:32.562267|2018-05-31 23:28:32.562267
NCT01181765|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2013-12-13|2010-08-12|2010-08-13|Estimate|||||||2013-12-13|2013-12-16|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ICE||The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy|The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)|Completed||Phase 4|1|Actual|Janssen Inc.||1|||f||||f||||||||||2018-05-31 23:28:32.813581|2018-05-31 23:28:32.813581
NCT01181752|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2012-02-28|2010-08-12|2010-08-13|Estimate|||||||2012-02-28|2012-03-01|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|||Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana|Educational Intervention, Observing Participants' Proficiency of Eye Drop Instillation|Unknown status|Not yet recruiting||300|Anticipated|University of British Columbia|||3||f||||f||||||||||2018-05-31 23:28:32.884661|2018-05-31 23:28:32.884661
NCT01181739|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2013-04-09|2010-08-12|2010-08-13|Estimate|||||||2013-04-09|2013-04-11|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Computed Tomography (CT) Colonography Versus Optical Colonoscopy|The Effect of Experience and Training on the Accuracy of CT (Computed Tomography) Colonography in Comparison With Optical Colonoscopy in the Detection of Colonic Neoplasia|Unknown status|Recruiting||100|Anticipated|University of British Columbia|||||f||||f||||||Samples Without DNA|"~     Colonic Mucosal Biopsy specimens obtained at the time of colonoscopy~   "|||2018-05-31 23:28:32.961286|2018-05-31 23:28:32.961286
NCT01181726|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2010-09-15||2010-11-22|2010-08-11|2010-08-13|Estimate|2010-09-15|2010-10-07|Estimate||||2010-11-22|2010-12-08|Estimate|January 2007||2007-01-31|November 2010|2010-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects.|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:28:33.080474|2018-05-31 23:28:33.080474
NCT01181713|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-12-02|2010-08-11|2010-08-13|Estimate|||||||2011-12-02|2011-12-05|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use|Antibiotic Resistance of Ocular Surface Flora After Continued Use of Topical Antibiotics Post Intravitreal Injections|Unknown status|Active, not recruiting||168|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||f||||||||||2018-05-31 23:28:33.727931|2018-05-31 23:28:33.727931
NCT01181700|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-01-21|2010-08-11|2010-08-13|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2010||2010-10-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers|Completed||Phase 1|42|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 23:28:33.796002|2018-05-31 23:28:33.796002
NCT01181687|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2013-02-12|2010-08-12|2010-08-13|Estimate|||||||2013-02-12|2013-02-13|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||Psychometric Testing of the Norwegian Version of the Comfort Behavioral Scale|Psychometric Testing of the Norwegian Version of the Comfort Behavioral Scale|Completed|||50|Actual|Sykehuset Telemark|||||f||||f||||||||||2018-05-31 23:28:33.874882|2018-05-31 23:28:33.874882
NCT01181674|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2015-10-20|2010-08-12|2010-08-13|Estimate|||||||2015-10-20|2015-10-22|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)|Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial|Completed||Phase 4|83|Actual|Population Health Research Institute||3|||f||||f||||||||||2018-05-31 23:28:33.932576|2018-05-31 23:28:33.932576
NCT01181661|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2014-09-23|2010-08-12|2010-08-13|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Internet-based Group Contingency Management to Promote Smoking Abstinence|Internet-based Group Contingency Management to Promote Smoking Abstinence|Completed||N/A|40|Actual|National Development and Research Institutes, Inc.||2|||f||||f||||||||||2018-05-31 23:28:34.016692|2018-05-31 23:28:34.016692
NCT01181648|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2018-01-12|2010-08-12|2010-08-13|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2010||2010-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life|Surviving Oropharynx Cancer: Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life|Recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 23:28:34.098236|2018-05-31 23:28:34.098236
NCT01181635|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2016-04-21|2010-08-12|2010-08-13|Estimate|||||||2016-04-21|2016-04-22|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Can Psychotherapy Reduce Sickness Absence?|Can Psychotherapy Reduce Sickness Absence?|Unknown status|Active, not recruiting|N/A|400|Anticipated|Lovisenberg Diakonale Hospital||1|||f||||f||||||||No||2018-05-31 23:28:34.182013|2018-05-31 23:28:34.182013
NCT01181622|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12||2011-03-24|2014-12-29|2010-08-12|2010-08-13|Estimate||||2011-03-30|2011-04-07|Estimate|2014-12-29|2015-01-13|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|REACH-1||A Safety and Tolerability Study of Denufosol in 2-4 Year Olds|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC® Star in Patients 2 to 4 Years of Age With Cystic Fibrosis|Completed||Phase 2|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 23:28:34.249117|2018-05-31 23:28:34.249117
NCT01181609|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2014-06-04||2014-07-24|2010-08-12|2010-08-13|Estimate|2014-07-24|2014-07-28|Estimate||||2014-07-24|2014-07-28|Estimate|June 2005||2005-06-30|July 2014|2014-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Intent-to-treat (ITT) population: included participants who received at least 1 dose of treatment.|A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum|An Open-label Study of Avastin in Combination With Chemotherapy Regimens as Second-line Treatment in Patients With Metastatic Colon or Rectal Cancer|Completed||Phase 2|54|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:28:34.368065|2018-05-31 23:28:34.368065
NCT01181596|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2012-02-09|2010-08-12|2010-08-13|Estimate|||||||2012-02-09|2012-02-10|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||NICU-TECH RM9L-RS Probe ME Feasibility Study|NICU-TECH RM9L-RS Probe ME Feasibility Study|Completed||Phase 1/Phase 2|32|Actual|GE Healthcare|||||f||||||||||||||2018-05-31 23:28:34.618076|2018-05-31 23:28:34.618076
NCT01181583|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-12-27|2010-08-12|2010-08-13|Estimate|||||||2010-12-27|2010-12-28|Estimate||||December 2010|2010-12-31||||||||Interventional|TAYLOR1||Tailored Internet-delivered Cognitive Behaviour Therapy for Symptoms of Depression and Comorbid Problems|Efficacy Testing of a Tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Symptoms of Depression and Comorbid Problems|Completed||N/A|121|Actual|Linkoeping University||3|||f||||t||||||||||2018-05-31 23:28:34.701624|2018-05-31 23:28:34.701624
NCT01181570|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-10-27|2010-08-12|2010-08-13|Estimate|||||||2011-10-27|2011-10-28|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea|Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea|Completed||Phase 4|20|Actual|Innovaderm Research Inc.||2|||f||||f||||||||||2018-05-31 23:28:34.803209|2018-05-31 23:28:34.803209
NCT01181557|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-08-12|2010-08-12|2010-08-13|Estimate|||||||2010-08-12|2010-08-13|Estimate|September 2008||2008-09-30|July 2008|2008-07-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Observational|||A Questionnaire to Assess the Quality of Life of Rectal Cancer Patients With or Without Stoma|Prospective Evaluation of Quality of Life in Patient With Rectal Cancer|Completed|||236|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||3||f||||t||||||||||2018-05-31 23:28:34.915858|2018-05-31 23:28:34.915858
NCT01181544|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2017-05-05|2010-08-11|2010-08-13|Estimate|||||||2017-05-05|2017-05-08|Actual|March 2011||2011-03-31|May 2017|2017-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis|Heparin Dose Reduction During Hemodialysis With the Gambro Revaclear and Revaclear MAX Hemodialyzers: Pilot Study I and II|Completed||N/A|5|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-05-31 23:28:35.011655|2018-05-31 23:28:35.011655
NCT01181531|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2013-12-03||2017-02-07|2010-08-12|2010-08-13|Estimate|2014-03-28|2014-04-25|Estimate||||2017-02-07|2017-03-15|Actual|October 2010||2010-10-31|February 2017|2017-02-28|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis|A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis|Completed||Phase 4|312|Actual|Amgen||2|||f||||f||||||||||2018-05-31 23:28:35.124053|2018-05-31 23:28:35.124053
NCT01181518|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2013-05-31|2010-08-12|2010-08-13|Estimate|||||||2013-05-31|2013-06-03|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|Tamoxifen||Tamoxifen Pharmacogenetics in Asian Breast Cancer Women|Observational Study: Biomarker Research for Tamoxifen Pharmacogenetics Among Asian Breast Cancer Patients|Unknown status|Recruiting||1000|Anticipated|Inje University|||||f||||f||||||Samples With DNA|"~     Blood samples for genotyping and pharmacokinetic analysis~   "|||2018-05-31 23:28:36.059979|2018-05-31 23:28:36.059979
NCT01181505|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-08-12|2010-08-12|2010-08-13|Estimate|||||||2010-08-12|2010-08-13|Estimate|January 2007||2007-01-31|November 2008|2008-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|HNF4a||STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study|STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study|Completed||Phase 1|31|Actual|Inje University||1|||f||||f||||||||||2018-05-31 23:28:36.146113|2018-05-31 23:28:36.146113
NCT01181492|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2012-12-04||2013-08-28|2010-08-12|2010-08-13|Estimate|2013-08-28|2013-11-01|Estimate||||2013-08-28|2013-11-01|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery|Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery|Completed|||176|Actual|Huazhong University of Science and Technology|The preoperative and postoperative data were not all integrallty recorded in a relative short period and entered into Excel.||3||f||||t||||||Samples With DNA|"~     176 blood samples were extracted~   "|||2018-05-31 23:28:36.22183|2018-05-31 23:28:36.22183
NCT01181479|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12||2013-01-22|2013-01-30|2010-08-12|2010-08-13|Estimate||||2013-01-30|2013-02-01|Estimate|2013-01-30|2013-02-01|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System|Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.|Completed||Phase 3|1504|Actual|Agile Therapeutics||2|||f||||f||||||||||2018-05-31 23:28:36.52698|2018-05-31 23:28:36.52698
NCT01181466|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2011-10-20|2010-08-12|2010-08-13|Estimate|||||||2011-10-20|2011-10-21|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema|A Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema|Completed||Phase 2/Phase 3|20|Actual|Aeris Therapeutics|||||f||||t||||||||||2018-05-31 23:28:36.720682|2018-05-31 23:28:36.720682
NCT01181453|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2018-05-16|2010-08-12|2010-08-13|Estimate|||||||2018-05-16|2018-05-21|Actual|December 1998||1998-12-31|May 2018|2018-05-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers|A Prospective, Multicenter, Randomized, Single-Blind, Phase III, Clinical Investigation of Dermagraft(R) in Patients With Plantar Diabetic Foot Ulcers|Completed||Phase 3|314|Actual|Organogenesis||2|||||||||||||||||2018-05-31 23:28:36.792361|2018-05-31 23:28:36.792361
NCT01181440|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2018-05-16|2010-08-12|2010-08-13|Estimate|||||||2018-05-16|2018-05-21|Actual|September 1994||1994-09-30|May 2018|2018-05-31|January 1997|Actual|1997-01-31|January 1997|Actual|1997-01-31||Interventional|||Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers|A Prospective, Multicenter, Randomized, Single-Blind Clinical Investigation of Dermagraft(R) in Patients With Plantar Diabetic Foot Ulcers|Completed||Phase 3|281|Actual|Organogenesis||2|||||||||||||||||2018-05-31 23:28:36.858355|2018-05-31 23:28:36.858355
NCT01181427|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2012-01-20|2010-08-12|2010-08-13|Estimate|||||||2012-01-20|2012-01-24|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|||Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects|A Blinded, Randomized, Placebo-Controlled Study in Healthy and HCV Genotype 1-infected Adults, to Evaluate the Safety, Tolerability, Antiviral Activity, Pharmacokinetics (Including the Effect of Food) and Resistance Profile of Single and Multiple Doses of ABT-267|Completed||Phase 1|137|Actual|Abbott||5|||f||||f||||||||||2018-05-31 23:28:36.929236|2018-05-31 23:28:36.929236
NCT01181414|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2015-03-09|2010-08-12|2010-08-13|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|SPAREIII||Spanish Atrial Fibrillation And Resynchronization Study|Phase 4. Study of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation.|Completed||Phase 4|60|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 23:28:36.991398|2018-05-31 23:28:36.991398
NCT01181401|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-08-26|2010-08-12|2010-08-13|Estimate|||||||2010-08-26|2010-08-30|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|ICRAT||InductionChemo-Radio-Antibody-Treatment|Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck|Unknown status|Recruiting|Phase 2|90|Anticipated|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-05-31 23:28:37.093881|2018-05-31 23:28:37.093881
NCT01181388|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-12|2010-08-12|2010-08-13|Estimate|||||||2010-08-12|2010-08-13|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|October 2012|Anticipated|2012-10-31|April 2012|Anticipated|2012-04-30||Interventional|SUIT-AMI||Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients|Impacts of Superselective Infarct-related Artery Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in ST Segment Elevation Myocardial Infarction (STEMI) Patients|Unknown status|Recruiting|N/A|200|Anticipated|Beijing Anzhen Hospital||2|||f||||||||||||||2018-05-31 23:28:37.201717|2018-05-31 23:28:37.201717
NCT01181375|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-09-20|2010-08-12|2010-08-13|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2006||2006-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Predictive Assays In Cervix Cancer|Predictive Assays in Cervix Cancer: Assessment of Hypoxia, Interstitial Fluid Pressure, and Tissue and Plasma Biomarkers of Hypoxia (CXTF10)|Active, not recruiting||N/A|500|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 23:28:37.268431|2018-05-31 23:28:37.268431
NCT01181362|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2013-05-28|2010-08-12|2010-08-13|Estimate|||||||2013-05-28|2013-05-29|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparing Head and Neck Endoscopy Procedures|A Feasibility Study Comparing Head And Neck Endoscopy Procedures In The Upright And Supine Positions|Completed||N/A|10|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 23:28:37.337641|2018-05-31 23:28:37.337641
NCT01181349|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2012-02-29||2015-10-12|2010-08-12|2010-08-13|Estimate|2012-02-29|2012-04-02|Estimate||||2015-10-12|2015-10-14|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|INSPIRE||Incidence of Incomplete Postoperative Neuromuscular Recovery From Anesthesia (P07535)(Completed)|Incidence of Postoperative Residual Neuromuscular Blockade - A Multicenter, Observational Study in Portugal|Completed|||350|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-05-31 23:28:37.403228|2018-05-31 23:28:37.403228
NCT01181336|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-10-14|2010-08-12|2010-08-13|Estimate|||||||2010-10-14|2010-10-15|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Phase 1b Influenza Vaccine Study in Healthy Subjects|A Single Centre, Randomised, Double Blind, Phase 1 Study of the Safety, Tolerability, and Immunogenicity of an Influenza Vaccine Candidate (FLU-v)|Completed||Phase 1|48|Anticipated|PepTcell Limited||5|||f||||f||||||||||2018-05-31 23:28:38.498156|2018-05-31 23:28:38.498156
NCT01181323|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2014-04-17||2015-01-15|2010-08-12|2010-08-13|Estimate|2014-04-17|2014-05-16|Estimate||||2015-01-15|2015-01-28|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All enrolled subjects are included in the baseline analysis population.|Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women|A Randomized, Double-Blind Trial, Comparing the Safety in Mothers and Their Infants and Immunogenicity in Mothers of Live Attenuated Influenza Vaccine (LAIV) to Inactivated Trivalent Influenza Vaccine (TIV) When Administered to Breast Feeding Women|Completed||Phase 2|240|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 23:28:38.661013|2018-05-31 23:28:38.661013
NCT01181310|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2015-11-05|2010-08-12|2010-08-13|Estimate|||||||2015-11-05|2015-11-06|Estimate|June 2007||2007-06-30|November 2015|2015-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED)|A Five-Period, Placebo-Controlled, Crossover Study to Evaluate the Effect of Donepezil and MK-3134 on Reversal of Cognitive Impairment Associated With a Single-Dose of Scopolamine.|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 23:28:40.152775|2018-05-31 23:28:40.152775
NCT01181297|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2010-08-12|2010-08-12|2010-08-13|Estimate|||||||2010-08-12|2010-08-13|Estimate|January 2003||2003-01-31|August 2010|2010-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Double Blind Controlled Trial of an Extensively Hydrolyzed Formula With a Probiotic vs. an Extensively Hydrolyzed Formula Without a Probiotic||Completed||N/A|||Mead Johnson Nutrition||2|||f||||||||||||||2018-05-31 23:28:40.268186|2018-05-31 23:28:40.268186
NCT01181284|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2012-02-03|2010-08-12|2010-08-13|Estimate|||||||2012-02-03|2012-02-07|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|MELISSA||Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)|Modulating Effects of Lisinopril on Sildenafil Activity in PAH (MELISSA)|Completed|||24|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 23:28:40.339347|2018-05-31 23:28:40.339347
NCT01181271|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2017-01-19||2017-01-19|2010-08-12|2010-08-13|Estimate|2017-01-19|2017-03-09|Actual||||2017-01-19|2017-03-09|Actual|August 2010||2010-08-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2014|Actual|2014-02-28||Interventional|||Tandem Auto-Allo Transplant for Lymphoma|Sequential Myeloablative Autologous Stem Cell Transplantation Followed by Allogeneic Non-Myeloablative Stem Cell Transplantation for Patients With Poor Risk Lymphomas|Completed||Phase 2|42|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 23:28:40.438701|2018-05-31 23:28:40.438701
NCT01181258|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2017-04-10||2018-01-10|2010-08-12|2010-08-13|Estimate|2017-04-10|2017-05-18|Actual||||2018-01-10|2018-02-06|Actual|August 2010||2010-08-31|January 2016|2016-01-31|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|||Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies|Lymphodepleting Chemotherapy With Rituximab and Allogeneic Natural Killer Cells for Patients With Refractory Lymphoid Malignancies (MT2009-15)|Completed||Phase 2|16|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 23:28:40.902869|2018-05-31 23:28:40.902869
NCT01181245|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2014-08-04|2010-08-12|2010-08-13|Estimate|||||||2014-08-04|2014-08-06|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer|A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 1|50|Anticipated|FibroGen||1|||f||||t||||||||||2018-05-31 23:28:41.206334|2018-05-31 23:28:41.206334
NCT01181232|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2014-09-09|2010-08-12|2010-08-13|Estimate|||||||2014-09-09|2014-09-10|Estimate|October 2009||2009-10-31|August 2014|2014-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients|A Randomized, Active Control, Parallel Study to Evaluate the Efficacy and Safety of Zolpidem MR (Stilnox CR) Versus Zolpidem (Stilnox) in Patients With Primary Insomnia|Completed||Phase 4|132|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 23:28:41.30155|2018-05-31 23:28:41.30155
NCT01181219|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2014-12-11|2010-08-12|2010-08-13|Estimate|||||||2014-12-11|2014-12-12|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transepithelial Corneal Collagen Cross-linking (CXL) in Treatment of Keratoconus|"Behandling av Keratoconus Med Cornea Collagen Cross-linking Uten Hornhinneepitelfjerning"|Completed||Phase 2|20|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 23:28:41.387688|2018-05-31 23:28:41.387688
NCT01181206|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2017-09-19|2010-08-12|2010-08-13|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2010||2010-08-31|December 2012|2012-12-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|BaFo||Covering of the Abdominal Wall in Laparotomies: Differences in Surgical Site Infections Between an Approved Abdominal 3M™ Steri-Drape™ Wound Edge Protector and Standard Woven Swabs at Technische Universität München|Standard-Bauchwandabdeckung Mit Bauchtüchern vs. Abdeckung Mittels ringförmiger Folie: Eine Doppelblinde Randomisiert-kontrollierte Studie|Completed||N/A|516|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 23:28:41.597298|2018-05-31 23:28:41.597298
NCT01181193|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2011-03-27|2010-08-12|2010-08-13|Estimate|||||||2011-03-27|2011-03-29|Estimate|March 2011||2011-03-31|August 2010|2010-08-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Vitamin D for Treatment of Glioblastoma Multiforme|High-Dose Vitamin D in Combination With Chemoradiotherapy in the Treatment of Glioblastoma Multiforme|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Soroka University Medical Center|||||f||||f||||||||||2018-05-31 23:28:41.819533|2018-05-31 23:28:41.819533
NCT01181180|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2012-06-18|2010-08-12|2010-08-13|Estimate|||||||2012-06-18|2012-06-19|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effect of Fluids Consumption on Balance and Gait Function in Old Adults|The Effect of Fluids Consumption in the Elderly on Balance and Gait Function - A Single Blind Randomized Control Trial|Completed||N/A|44|Actual|Soroka University Medical Center||1|||f||||t||||||||||2018-05-31 23:28:41.962855|2018-05-31 23:28:41.962855
NCT01181167|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2015-01-15||2015-02-03|2010-08-12|2010-08-13|Estimate|2015-01-15|2015-01-26|Estimate||||2015-02-03|2015-02-23|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional||Number of baseline participants reflects the efficacy analysis population.|A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty|A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)|Completed||Phase 3|610|Actual|Daiichi Sankyo, Inc.||2|||f||||||||||||||2018-05-31 23:28:42.119446|2018-05-31 23:28:42.119446
NCT01181154|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2017-10-18|2010-08-12|2010-08-13|Estimate|||||||2017-10-18|2017-10-19|Actual|March 3, 2011|Actual|2011-03-03|October 2017|2017-10-31|January 8, 2016|Actual|2016-01-08|January 8, 2015|Actual|2015-01-08||Interventional|RAHIA||Rituximab in Auto-Immune Hemolytic Anemia|Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial|Completed||Phase 3|32|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:28:42.672935|2018-05-31 23:28:42.672935
NCT01181141|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2015-01-15||2015-02-03|2010-08-12|2010-08-13|Estimate|2015-01-15|2015-01-26|Estimate||||2015-02-03|2015-02-23|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional||Number of baseline participants reflects the safety analysis population|Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery|A Phase 3, Randomized, Open Label, Safety and Efficacy Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery (STARS J-4 Trial)|Completed||Phase 3|92|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 23:28:42.773984|2018-05-31 23:28:42.773984
NCT01181128|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2014-06-09||2017-07-17|2010-08-12|2010-08-13|Estimate|2014-08-18|2014-08-29|Estimate||||2017-07-17|2017-08-18|Actual|November 2010||2010-11-30|July 2017|2017-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A|A-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A|Completed||Phase 3|165|Actual|Bioverativ Therapeutics Inc.||3|||f||||t||||||||||2018-05-31 23:28:43.295749|2018-05-31 23:28:43.295749
NCT01181115|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-09-12|2010-08-12|2010-08-13|Estimate|||||||2013-09-12|2013-09-16|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Avonex China||Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)|An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis|Completed||Phase 3|60|Actual|Biogen||1|||f||||f||||||||||2018-05-31 23:28:44.46637|2018-05-31 23:28:44.46637
NCT01181102|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2015-01-15||2015-02-03|2010-08-12|2010-08-13|Estimate|2015-02-03|2015-02-19|Estimate||||2015-02-03|2015-02-19|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional||Number of baseline participants reflects the efficacy analysis population|A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty|A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS E-3 Trial)|Completed||Phase 3|716|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||||2018-05-31 23:28:44.538567|2018-05-31 23:28:44.538567
NCT01181089|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-09-12|2010-08-12|2010-08-13|Estimate|||||||2013-09-12|2013-09-16|Estimate|September 2010||2010-09-30|January 2012|2012-01-31||||||||Interventional|||Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)|A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis|Withdrawn||Phase 1/Phase 2|0|Actual|Biogen|||||f||||t||||||||||2018-05-31 23:28:45.024577|2018-05-31 23:28:45.024577
NCT01181076|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2017-10-14|2010-08-12|2010-08-13|Estimate|||||||2017-10-14|2017-10-17|Actual|August 10, 2010|Actual|2010-08-10|October 2017|2017-10-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|NASQ||Individualized Nutrition for Adult Recipients of Allogeneic Stem Cell Transplants - Effect on Quality of Life|Individualized Nutrition for Adult Recipients of Allogeneic Stem Cell Transplants - Effect on Quality of Life|Completed||N/A|88|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 23:28:45.07852|2018-05-31 23:28:45.07852
NCT01181063|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2011-06-09|2010-08-12|2010-08-13|Estimate|||||||2011-06-09|2011-06-10|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|Reco-Pilot||Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers|Pharmacokinetic Pilot Study on Budesonide/Formoterol Easyhalers and Symbicort Turbuhaler; an Open, Randomised, Single Centre, Single Dose Study With Crossover Design in Healthy Subjects|Completed||Phase 1|20|Actual|Orion Corporation, Orion Pharma||5|||f||||f||||||||||2018-05-31 23:28:45.142748|2018-05-31 23:28:45.142748
NCT01181050|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|2013-04-25|2012-05-10|2016-08-24|2010-08-12|2010-08-13|Estimate|2014-03-26|2014-04-28|Estimate|2012-05-10|2012-05-15|Estimate|2016-08-24|2016-10-03|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)|A Randomised, Single-dose, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0142-0002 in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|63|Actual|Janssen Research & Development, LLC|As per protocol, this clinical proof-of-principle trial investigated a limited number of participants and doses (single-dose regimen).|2|||f||||f||||||||||2018-05-31 23:28:45.251058|2018-05-31 23:28:45.251058
NCT01181037|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|||2012-03-16|2010-08-12|2010-08-13|Estimate|||||||2012-03-16|2012-03-19|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Bipolar H.A Versus Trochanteric Antegrade Nail for Treatment of Displaced Subcapital Femoral Fractures||Unknown status|Recruiting||200|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 23:28:45.555533|2018-05-31 23:28:45.555533
NCT01181024|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-12|||2016-11-01|2010-08-12|2010-08-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1|A Single Ascending Dose Tolerability and Pharmacokinetic Study of RO5303253 With a Pilot Food-effect Investigation in Healthy Subjects and Exploratory Pharmacokinetic, Pharmacodynamic, and Safety Assessments in Chronic Hepatitis C Genotype 1 Patients Following 5 Days of Oral Administration|Completed||Phase 1|82|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:28:45.617173|2018-05-31 23:28:45.617173
NCT01181011|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2011-11-21||2014-07-15|2010-08-12|2010-08-13|Estimate|2012-04-12|2012-05-10|Estimate||||2014-07-15|2014-07-24|Estimate|August 2010||2010-08-31|July 2014|2014-07-31||||November 2010|Actual|2010-11-30||Interventional|||Telmisartan, Amlodipine and Combination in Healthy Subjects|A Single-centre, Randomized, Open-label, Three-period Crossover Pharmacokinetic Study of 80 mg Telmisartan / 5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Chinese Subjects|Completed||Phase 1|28|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:28:45.726354|2018-05-31 23:28:45.726354
NCT01180998|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2011-11-29||2017-06-13|2010-08-12|2010-08-13|Estimate|2013-10-30|2013-12-20|Estimate||||2017-06-13|2017-07-06|Actual|June 1, 2010|Actual|2010-06-01|June 2017|2017-06-30|October 1, 2010|Actual|2010-10-01|October 1, 2010|Actual|2010-10-01||Interventional||Baseline characteristics are of those subjects that met the inclusion/ exclusion criteria and are enrolled and randomized to a study arm.|Clinical Evaluation of Two Toric Contact Lenses in Current Non-toric Lens Users||Completed||N/A|200|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f|f|t|f|f|t|||||2018-05-31 23:28:46.178113|2018-05-31 23:28:46.178113
NCT01180985|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2011-11-07||2017-08-31|2010-08-12|2010-08-13|Estimate|2014-01-03|2014-02-05|Estimate||||2017-08-31|2017-09-29|Actual|June 1, 2010|Actual|2010-06-01|August 2017|2017-08-31|July 1, 2010|Actual|2010-07-01|July 1, 2010|Actual|2010-07-01||Interventional|||Dispensing Evaluation of a Galyfilcon A Prototype Lens and a Marketed Contact Lens||Completed||N/A|53|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 23:28:46.514968|2018-05-31 23:28:46.514968
NCT01180972|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2013-12-09|2010-08-11|2010-08-13|Estimate|||||||2013-12-09|2013-12-10|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Effects of Environmental Opportunities and Barriers on Physical Activity, Fitness, and Health in Hispanic Children in Wisconsin|Effects of Environmental Opportunities and Barriers on Physical Activity, Fitness, and Health in Hispanic Children in Wisconsin|Completed|||214|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-05-31 23:28:46.757908|2018-05-31 23:28:46.757908
NCT01180959|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2017-10-04|2010-08-11|2010-08-12|Estimate|||||||2017-10-04|2017-10-06|Actual|April 2011|Actual|2011-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy|A Phase II Trial of Erlotinib Plus Bevacizumab in Advanced Hepatocellular Carcinoma as a Second-line Therapy in Patients Who Have Received First-line Sorafenib Therapy (AVF4572)|Active, not recruiting||Phase 2|44|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 23:28:46.807277|2018-05-31 23:28:46.807277
NCT01180946|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2013-11-01|2010-08-11|2010-08-12|Estimate|||||||2013-11-01|2013-11-05|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Vitamin D Deficiency in Adolescent Girls|Vitamin D Deficiency in Adolescent Girls|Completed||N/A|90|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:28:46.880483|2018-05-31 23:28:46.880483
NCT01180933|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2014-07-29|2010-08-11|2010-08-12|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 2001||2001-11-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|August 2003|Actual|2003-08-31||Interventional|NUHEAL||Fish Oil and Folate Supplementation During Pregnancy|Dietary Supply of Docosahexaenoic Acid (DHA) and 5-methyl-tetrahydro-folate (MTHF) During the Second Half of Pregnancy and Early Infancy|Completed||N/A|315|Actual|Ludwig-Maximilians - University of Munich||4|||f||||f||||||||||2018-05-31 23:28:46.948702|2018-05-31 23:28:46.948702
NCT01180920|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2014-12-01|2010-08-11|2010-08-12|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||The Importance of Periostin in Periodontal Health and Disease|The Importance of Periostin in Periodontal Health and Disease|Completed|||22|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Each patient will be have 5ml of blood collected at 3 different visits. Saliva, and gingival~     crevicular fluid will also be collected at 7-8 visits during the study. Gingival tissue will~     be collected on the day of surgery.~   "|||2018-05-31 23:28:47.015634|2018-05-31 23:28:47.015634
NCT01180907|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2012-07-27|2010-08-11|2010-08-12|Estimate|||||||2012-07-27|2012-07-31|Estimate|November 2007||2007-11-30|July 2012|2012-07-31||||November 2011|Actual|2011-11-30||Observational|||The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases|The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study|Completed|||10|Actual|Jonsson Comprehensive Cancer Center|||3||f||||f||||||||||2018-05-31 23:28:47.080066|2018-05-31 23:28:47.080066
NCT01180894|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2015-09-16||2018-01-10|2010-08-11|2010-08-12|Estimate|2016-11-23|2017-01-20|Estimate||||2018-01-10|2018-02-05|Actual|June 2011||2011-06-30|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|IATCI||IV Iron for the Anemia of Traumatic Critical Illness|A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness|Completed||N/A|150|Actual|Denver Health and Hospital Authority||2|||f||||t||||||||No||2018-05-31 23:28:47.136809|2018-05-31 23:28:47.136809
NCT01180881|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2017-08-28|2010-08-11|2010-08-12|Estimate|||||||2017-08-28|2017-08-30|Actual|October 2009||2009-10-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment|Neurobehavioral Functioning and Utilization of Special Education Services in Pediatric Brain and CNS Tumor Patients After Proton Radiation Treatment: A Longitudinal Study|Active, not recruiting|||150|Anticipated|Massachusetts General Hospital|||1||f||||t||||||||||2018-05-31 23:28:47.583591|2018-05-31 23:28:47.583591
NCT01180868|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2012-07-27|2010-08-11|2010-08-12|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 2008||2008-05-31|July 2012|2012-07-31||||November 2011|Actual|2011-11-30||Observational|||The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases|The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases|Completed|||1|Actual|Jonsson Comprehensive Cancer Center|||3||f||||f||||||||||2018-05-31 23:28:47.660629|2018-05-31 23:28:47.660629
NCT01180855|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate|August 2007||2007-08-31|August 2010|2010-08-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|CBT||Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia|Effects of Ramelteon (8mg) Alone and in Combination With Multi-Component Behavioral Therapy on Sleep and Circadian Phase in Patients With Chronic Insomnia: A Randomized, Double-Blind, Placebo Controlled Study (Investigator Initiated Study)|Unknown status|Active, not recruiting|Phase 4|30|Actual|University of Arizona||3|||f||||t||||||||||2018-05-31 23:28:47.735802|2018-05-31 23:28:47.735802
NCT01180842|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-02-13|2010-08-11|2010-08-12|Estimate|||||||2014-02-13|2014-02-14|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF)|Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With CF|Completed||Phase 2|20|Actual|Children's Hospitals and Clinics of Minnesota||1|||f||||f||||||||||2018-05-31 23:28:47.801424|2018-05-31 23:28:47.801424
NCT01180829|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-08-29|2010-08-11|2010-08-12|Estimate|||||||2012-08-29|2012-08-30|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pilot Study of Text Message Brief Interventions for Problem Drinkers|Pilot Study of Text Message Brief Interventions for Problem Drinkers|Completed||N/A|91|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-05-31 23:28:47.87418|2018-05-31 23:28:47.87418
NCT01180816|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2018-01-05|2010-08-11|2010-08-12|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2010||2010-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA|Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma|Active, not recruiting||Phase 1|30|Anticipated|Northwell Health||1|||f||||f||||||||||2018-05-31 23:28:47.950973|2018-05-31 23:28:47.950973
NCT01180803|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2017-11-20|2010-08-11|2010-08-12|Estimate|||||||2017-11-20|2017-11-22|Actual|July 2010||2010-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy of Oxygen Therapy Delivered by Systems Using Oxygen-Saving Valves in COPD Patients||Recruiting||N/A|200|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||2|||f||||f||||||||||2018-05-31 23:28:48.068106|2018-05-31 23:28:48.068106
NCT01180790|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|2014-07-29||2014-09-08|2010-08-11|2010-08-12|Estimate|2014-09-08|2014-09-10|Estimate||||2014-09-08|2014-09-10|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|March 2012|Actual|2012-03-31||Interventional||The intent-to-treat (ITT) population, which was defined as all subjects randomized and treated with at least one dose of ACH 0141625 or Placebo. Subjects were analyzed according to the randomized treatment.|Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects|A Phase IIa, Randomized, Double-blind (Subject and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Subjects With Chronic Hepatitis C Virus Genotype 1|Completed||Phase 2|122|Actual|Achillion Pharmaceuticals||7|||f||||||||||||||2018-05-31 23:28:48.271238|2018-05-31 23:28:48.271238
NCT01180777|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2013-11-13||2017-08-31|2010-08-10|2010-08-12|Estimate|2014-01-16|2014-03-05|Estimate||||2017-08-31|2017-10-02|Actual|July 1, 2010|Actual|2010-07-01|August 2017|2017-08-31|August 1, 2010|Actual|2010-08-01|August 1, 2010|Actual|2010-08-01||Interventional|||Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP)|Dispensing Evaluation of Printed Etafilcon A With Polyvinylpyrrolidone (PVP) Contact Lenses|Completed||N/A|95|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||f||||||||||2018-05-31 23:28:49.999192|2018-05-31 23:28:49.999192
NCT01180764|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2016-02-04|2010-08-10|2010-08-12|Estimate|||||||2016-02-04|2016-02-08|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia|Effects of Lovaza Monotherapy vs. Placebo on Composition and Function of HDL and Other Lipoproteins, and on Other Lipid-Related Parameters|Withdrawn||Phase 4|0|Actual|University of Utah||2||Withdrawn for administrative reasons.|f||||f||||||||||2018-05-31 23:28:50.309047|2018-05-31 23:28:50.309047
NCT01180751|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2013-08-14|2010-08-11|2010-08-12|Estimate|||||||2013-08-14|2013-08-15|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology|18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology|Unknown status|Enrolling by invitation|Phase 3|1000|Anticipated|University of Manitoba||1|||f||||t||||||||||2018-05-31 23:28:50.385244|2018-05-31 23:28:50.385244
NCT01180738|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-01-28|2010-08-10|2010-08-12|Estimate|||||||2013-01-28|2013-01-30|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Body Weight Supported Treadmill Training vs. Overground Walking Training in Persons With Chronic Stroke|Comparison of Short Bursts of Body Weight Supported Treadmill Training vs. Overground Walking Training in Persons With Chronic Stroke|Completed||Phase 1/Phase 2|20|Actual|University of Indianapolis||2|||f||||f||||||||||2018-05-31 23:28:50.458487|2018-05-31 23:28:50.458487
NCT01180725|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate||||August 2010|2010-08-31||||||||Interventional|||Investigation of Dried Plums in the Treatment of Adults With Constipation||Completed||Phase 4|||University of Iowa|||||f||||||||||||||2018-05-31 23:28:50.528678|2018-05-31 23:28:50.528678
NCT01180712|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2018-05-11|2010-08-11|2010-08-12|Estimate|||||||2018-05-11|2018-05-14|Actual|June 2010||2010-06-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of Oral Anthocyanins on Insulin Resistance|Study of Oral Anthocyanins on Insulin Resistance|Recruiting||N/A|60|Anticipated|University of Aberdeen||2|||f||||t||||||||||2018-05-31 23:28:50.59233|2018-05-31 23:28:50.59233
NCT01180699|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2015-05-26|2010-08-10|2010-08-12|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients|A Randomized Controlled Trial Comparing Intradermal vs. Intramuscular Trivalent Inactivated Influenza Vaccine in Adult Solid Organ Transplant Recipients|Completed||N/A|229|Actual|University of Alberta||2|||f||||||||||||||2018-05-31 23:28:50.673162|2018-05-31 23:28:50.673162
NCT01180686|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate|September 2010||2010-09-30|June 2010|2010-06-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|AECC||Comparison of a Multiple Thrust Instrument to a Single Thrust Instrument in Treating the Low Back|Comparative Effectiveness of the Multiple Thrust Impulse Instrument and the Activator IV Single Thrust Instrument in Correcting a Lumbar Spinal Manipulable Lesion and Improving Lumbar Erector Spinae Flexion-relaxation|Unknown status|Not yet recruiting|Phase 1/Phase 2|40|Anticipated|Anglo-European College of Chiropractic||2|||f||||f||||||||||2018-05-31 23:28:50.732527|2018-05-31 23:28:50.732527
NCT01180673|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2013-11-12|2010-08-10|2010-08-12|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2008||2008-02-29|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|COACH||Counseling Older Adults to Control Hypertension|Counseling Older Adults to Control Hypertension|Completed||Phase 3|251|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 23:28:50.824106|2018-05-31 23:28:50.824106
NCT01180660|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2014-04-08||2014-07-15|2010-08-11|2010-08-12|Estimate|2014-07-15|2014-08-07|Estimate||||2014-07-15|2014-08-07|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||IV Lidocaine on Postoperative Pain and QOR on Morbid Obese Patients Undergoing Bypass Surgery|The Effect of Systemic Intraoperative Lidocaine on Postoperative Pain and Quality of Recovery on Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery|Completed||N/A|51|Actual|Northwestern University|We did not evaluate if the opioid sparing properties of systemic lidocaine resulted in a lower incidence of adverse respiratory events (hypoxemia/hypoventilation). We were underpowered to detect significant differences in certain parts of the qor-40.|2|||f||||f||||||||||2018-05-31 23:28:50.883153|2018-05-31 23:28:50.883153
NCT01180647|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2015-04-13||2016-03-08|2010-08-10|2010-08-12|Estimate|2016-03-08|2016-04-07|Estimate||||2016-03-08|2016-04-07|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Baseline analysis determined based on: (1) successful randomization into one of two treatment arms (ETAU;XR-NTX) and (2) actual release from jail back to the community. One participant who successfully randomized to XR-NTX was never released from jail custody and was instead sent to prison and therefore excluded from final analysis.|Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail|Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail|Completed||Phase 3|48|Actual|New York University School of Medicine|Limitations of this pilot study are: small sample size, no females enrolled in study, and no placebo control group.|2|||f||||t||||||||No||2018-05-31 23:28:51.084819|2018-05-31 23:28:51.084819
NCT01180634|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10||2018-01-17|2018-01-17|2010-08-10|2010-08-12|Estimate||||2018-01-17|2018-01-19|Actual|2018-01-17|2018-01-19|Actual|November 2010||2010-11-30|January 2018|2018-01-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis|A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin™) In Stable Cystic Fibrosis Patients|Completed||Phase 3|330|Actual|Horizon Pharma USA, Inc.||2|||f||||t||||||||||2018-05-31 23:28:51.348605|2018-05-31 23:28:51.348605
NCT01180621|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-06-21|2010-08-11|2010-08-12|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children|PCIRN Evaluation of Seasonal Trivalent Influenza Vaccine for 2010-2011 in Young Children in the First Year After the H1N1 Pandemic|Completed||Phase 2|200|Actual|Dalhousie University||1|||f||||t||||||||||2018-05-31 23:28:52.50712|2018-05-31 23:28:52.50712
NCT01180608|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|September 2012|Anticipated|2012-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain|Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain in Patients With Diabetic Polyneuropathy Using Proton MR Spectroscopy|Unknown status|Not yet recruiting|N/A|30|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 23:28:52.598074|2018-05-31 23:28:52.598074
NCT01180595|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2018-01-30|2010-08-11|2010-08-12|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2011||2011-02-28|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Roentgen Stereophotogrammetric Analysis (RSA) Trial Comparing Trabecular Metal Monoblock and Modular Tibial Components|Randomized Control Study Using Roentgen Stereophotogrammetric Analysis (RSA) to Compare the Fixation of the Trabecular Metal Monoblock and the Trabecular Metal Modular Total Knee Arthroplasties|Active, not recruiting||Phase 4|50|Anticipated|Dalhousie University||2|||f||||f||||||||||2018-05-31 23:28:52.763933|2018-05-31 23:28:52.763933
NCT01180582|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2014-03-28|2010-08-11|2010-08-12|Estimate|||||||2014-03-28|2014-03-31|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Roentgen Stereophotogrammetric Analysis (RSA) and Dual Energy X-ray Absorptiometry (DEXA) to Evaluate Fixation of Periapatite Coated Triathlon Total Knee Arthroplasty (TKA) Components|Prospective Clinical Study Using Roentgen Stereophotogrammetric Analysis (RSA) and DEXA to Evaluate Fixation of Periapatite Coated Triathlon Total Knee Arthroplasty Components|Completed||N/A|30|Actual|Dalhousie University|||||f||||f||||||||||2018-05-31 23:28:52.857225|2018-05-31 23:28:52.857225
NCT01180569|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2015-09-24|2010-08-10|2010-08-12|Estimate|||||||2015-09-24|2015-09-25|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma|Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:28:52.92349|2018-05-31 23:28:52.92349
NCT01180556|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2016-03-27|2010-08-11|2010-08-12|Estimate|||||||2016-03-27|2016-03-29|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Probiotics in Childhood Abdominal Pain|The Effect of Probiotics in Childhood Abdominal Pain|Completed||N/A|101|Actual|Soroka University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 23:28:52.993479|2018-05-31 23:28:52.993479
NCT01180543|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2011-06-09|2010-08-11|2010-08-12|Estimate|||||||2011-06-09|2011-06-10|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Acne Treatment With Active Oplon's Patches|Phase II- Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid|Completed||Phase 2|40|Anticipated|Oplon-Pure Science Ltd.||2|||f||||t||||||||||2018-05-31 23:28:53.100675|2018-05-31 23:28:53.100675
NCT01180530|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2017-02-06|2010-08-11|2010-08-12|Estimate|||||||2017-02-06|2017-02-08|Estimate|October 2010||2010-10-31|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|REMIND™||Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes|A Multicentre, Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction of Insulin Therapy in Children and Adolescents With Diabetes Mellitus|Completed|||358|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 23:28:53.180909|2018-05-31 23:28:53.180909
NCT01180517|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2016-02-18|2010-08-11|2010-08-12|Estimate|||||||2016-02-18|2016-02-19|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2014|Actual|2014-11-30||Interventional|PEPCAD-BIF||The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations|The Paclitaxel-Eluting PTCA-Balloon Catheter for the Treatment of Coronary Bifurcations|Completed||Phase 4|64|Actual|Heart Centre Rotenburg||2|||f||||t||||||||||2018-05-31 23:28:53.274049|2018-05-31 23:28:53.274049
NCT01180504|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2016|Anticipated|2016-08-31|August 2013|Anticipated|2013-08-31||Interventional|OVAR-IMRT-02||Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer|Consolidation Intensity-Modulated Whole Abdominal Radiotherapy for High-Risk Patients With Ovarian Cancer Stage FIGO III|Unknown status|Recruiting|Phase 2|36|Anticipated|University Hospital Heidelberg|||||f||||t||||||||||2018-05-31 23:28:53.349085|2018-05-31 23:28:53.349085
NCT01180491|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2013-06-25|2010-08-11|2010-08-12|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis||Completed||N/A|75|Actual|Moberg Pharma AB|||||f||||f||||||||||2018-05-31 23:28:53.437186|2018-05-31 23:28:53.437186
NCT01180478|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2017-08-10||2018-03-27|2010-08-11|2010-08-12|Estimate|2018-03-27|2018-04-25|Actual||||2018-03-27|2018-04-25|Actual|August 2010||2010-08-31|March 2018|2018-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer|A Multi-center, International Study to Compare Use of Narrow Band Imaging (NBI) Versus White Light(WL) During Transurethral Resection of Bladder Tumors (TURB) to Asses Recurrence of Bladder Cancer in Terms of Safety and Efficacy|Completed||N/A|965|Actual|Clinical Research Office of the Endourological Society|There is a possibility of observer bias favouring NBI as a limitation of this single-blind study|2|||f||||f||||||||||2018-05-31 23:28:53.520931|2018-05-31 23:28:53.520931
NCT01180465|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10||2015-03-05|2015-03-05|2010-08-11|2010-08-12|Estimate||||2015-03-05|2015-03-26|Estimate|2015-03-05|2015-03-26|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity|A Multi-center, Randomized, Double-masked, Placebo-controlled, Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity|Completed||Phase 2|160|Actual|Neothetics, Inc||3|||f||||f||||||||||2018-05-31 23:28:54.395354|2018-05-31 23:28:54.395354
NCT01180452|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2015-06-21|2010-08-11|2010-08-12|Estimate|||||||2015-06-21|2015-06-23|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DYDJI||Endoscopic Detection of Dysplasia in Crohn 's Disease Patient|Endoscopic Detection of Small Bowel Dysplasia and Cancer in Patients With Jejuna or Ileal Crohn Disease : Prospective Study in a Cohort of High Risk Patients|Completed||Phase 4|107|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f||||||||||2018-05-31 23:28:54.526875|2018-05-31 23:28:54.526875
NCT01180439|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Patient-Ventilator Interactions in Chronic Obstructive Pulmonary Diseases (COPD) Under Non-Invasive Ventilation|Patient-Ventilator Interactions During Sleep Under Non-Invasive Ventilation in Severe Stable COPD|Completed||N/A|8|Actual|Ligue Pulmonaire Genevoise|||||f||||f||||||||||2018-05-31 23:28:54.655375|2018-05-31 23:28:54.655375
NCT01180426|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-02-14|2010-08-11|2010-08-12|Estimate|||||||2012-02-14|2012-02-15|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia|The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Chroma Therapeutics||1|||f||||t||||||||||2018-05-31 23:28:54.780104|2018-05-31 23:28:54.780104
NCT01180413|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-11|||2012-04-18|2010-08-11|2010-08-12|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Vasomore||Intensive Vasodilator Therapy in Patients With Essential Hypertension|Effects of Intensive Vasodilating add-on Therapy on Peripheral Vascular Resistance and Coronary Flow Reserve in Patients With Essential Hypertension|Completed||Phase 4|48|Actual|Aarhus University Hospital||1|||f||||t||||||||||2018-05-31 23:28:54.95301|2018-05-31 23:28:54.95301
NCT01180400|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2012-06-26||2014-03-14|2010-08-11|2010-08-12|Estimate|2012-11-19|2012-11-20|Estimate||||2014-03-14|2014-04-11|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy|Completed||Phase 3|295|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:28:55.124733|2018-05-31 23:28:55.124733
NCT01180387|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2015-03-02|2010-08-10|2010-08-12|Estimate|||||||2015-03-02|2015-03-04|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30|1 Week|Observational [Patient Registry]|||Reproductive Medicine Network Biologic Specimen Repository|Reproductive Medicine Network Biologic Specimen Repository|Completed|||1640|Anticipated|Yale University|||||f||||f||||||Samples With DNA|"~     The RMN plans to collect baseline serum samples (5 cc) and DNA for storage and eventual DNA~     extraction. The whole blood will also be collected by the clinical sites.~      As part of the RMN effort, pregnancies conceived as part of the study protocols are entered~     into a pregnancy registry if the subjects consent to be part of the registry. Saliva samples~     from the child conceived as part of the protocols, as well as the parent from whom the DNA~     was not collected as part of the original protocols will be collected at that time. The~     newborn's saliva will be collected with up to 5 saliva sponges, the tips of which are cut off~     and stored using an Oragene® kit. The adults will be asked to provide 2 cc of saliva, which~     will be stored with the same kits. These saliva samples will be stored at -20°C.~      Two of the RMN studies involve assessing semen parameters. As part of this protocol, we~     anticipate collecting semen samples from male subjects.~   "|||2018-05-31 23:28:56.031279|2018-05-31 23:28:56.031279
NCT01180374|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-02-22|2010-08-10|2010-08-12|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2010||2010-06-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Effects of Cannabidiol and ∆-9-THC in Humans|Cannabidiol Modulation of ∆-9-THC's Psychotomimetic Effects in Healthy Humans|Active, not recruiting||Phase 1|75|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 23:28:56.123084|2018-05-31 23:28:56.123084
NCT01180361|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2018-01-25|2010-08-11|2010-08-12|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2008||2008-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance|Atherosclerosis in RA and Lupus: Restoring Cholesterol Balance|Recruiting|||160|Anticipated|Winthrop University Hospital|||4||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 23:28:56.192699|2018-05-31 23:28:56.192699
NCT01180348|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2016-03-03|2010-08-11|2010-08-12|Estimate|||||||2016-03-03|2016-03-04|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines|Randomized Study of Clinical Non-inferiority of Medicine Botulift (Laboratório Químico Farmacêutico Bergamo Ltd.) Compared to Botox ® (Allergan Inc.) in the Improvement of Wrinkles in the Facial Region.|Completed||Phase 3|192|Actual|Azidus Brasil||2|||f||||f||||||||Yes|The study data will be maked available after journal's approbation. The manuscript contained all of data it has been submitted.|2018-05-31 23:28:56.280143|2018-05-31 23:28:56.280143
NCT01180335|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-03-15|2010-08-10|2010-08-12|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|REMAGUS04||Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer|Randomized Trial Comparing Standard Neoadjuvant Chemotherapy to Genomic Driven Chemotherapy Regimen in Patients With Breast Cancer|Completed||Phase 3|303|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 23:28:56.403773|2018-05-31 23:28:56.403773
NCT01180322|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2013-08-30|2010-08-11|2010-08-12|Estimate|||||||2013-08-30|2013-09-02|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|October 2016|Anticipated|2016-10-31|June 2012|Actual|2012-06-30||Interventional|azacitidine||Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine|Randomized Phase-II Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine|Unknown status|Active, not recruiting|Phase 2|336|Anticipated|University of Ulm||4|||f||||t||||||||||2018-05-31 23:28:56.520476|2018-05-31 23:28:56.520476
NCT01180309|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate|June 2009||2009-06-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Lingual Frenum and Articulation of Phonemes|Lingual Frenum and Possible Alterations in the Articulation of Phonemes|Completed|||16|Actual|Fortaleza University|||1||f||||f||||||||||2018-05-31 23:28:56.718878|2018-05-31 23:28:56.718878
NCT01180296|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2011-06-22||2018-02-08|2010-08-11|2010-08-12|Estimate|2011-06-22|2011-07-21|Estimate||||2018-02-08|2018-02-09|Actual|November 2006||2006-11-30|February 2018|2018-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Oral Progesterone for Prevention of Preterm Birth|Prevention of Recurrent Preterm Birth With Micronized Progesterone|Completed||Phase 3|36|Actual|Fetal Medicine Foundation||2|||f||||f||||||||||2018-05-31 23:28:56.787084|2018-05-31 23:28:56.787084
NCT01180283|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2010-08-10|2010-08-10|2010-08-12|Estimate|||||||2010-08-10|2010-08-12|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|April 2010||2010-04-30|||||Interventional|||Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes.|Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patient With Type II Diabetes. Multicentric Study.|Completed||Phase 4|||Cristália Produtos Químicos Farmacêuticos Ltda.||1|||f||||||||||||||2018-05-31 23:28:57.054981|2018-05-31 23:28:57.054981
NCT01180270|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2012-01-28|2010-08-11|2010-08-12|Estimate|||||||2012-01-28|2012-01-31|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Static Graviceptive Functions in Patients With Cervical Dystonia (CD)|Experimental Pilot Trial Assessing Static Graviceptive Function in Patients With Cervical Dystonia|Completed|||45|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 23:28:57.12849|2018-05-31 23:28:57.12849
NCT01180257|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2012-01-26|2010-08-10|2010-08-12|Estimate|||||||2012-01-26|2012-01-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:28:57.200212|2018-05-31 23:28:57.200212
NCT01180244|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2014-03-19|2010-10-06|2014-05-30|2010-08-11|2010-08-12|Estimate|2014-04-28|2014-05-30|Estimate|2010-10-07|2010-10-08|Estimate|2014-05-30|2014-06-09|Estimate|January 2002||2002-01-31|May 2014|2014-05-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients|The Clinical Effect of Low-Intensity Electromagnetic Field Neurostimulation in Fibromyalgia Syndrome Patients|Completed||N/A|91|Actual|McLaren Regional Medical Center||2|||f||||f||||||||||2018-05-31 23:28:57.265298|2018-05-31 23:28:57.265298
NCT01180231|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2013-11-03|2010-08-10|2010-08-12|Estimate|||||||2013-11-03|2013-11-05|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity|Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity|Unknown status|Recruiting|Phase 4|77|Anticipated|Baker IDI Heart and Diabetes Institute||4|||f||||||||||||||2018-05-31 23:28:57.606661|2018-05-31 23:28:57.606661
NCT01180218|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-04-24|2010-08-11|2010-08-12|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2011||2011-07-31|April 2017|2017-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Expanded Access|COCUA||Complete Lesion Versus Culprit Lesion Revascularization|Comparison of Complete Lesion Versus Culprit Lesion Revascularization in Acute ST Elevation Myocardial Infarction Patients With Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention|Available|||||Korea University Guro Hospital|||||f||||||||||||||2018-05-31 23:28:57.711407|2018-05-31 23:28:57.711407
NCT01180205|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2011-07-11|2010-08-11|2010-08-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|August 2010||2010-08-31|April 2010|2010-04-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|TEAMSTAprotect||Telmisartan, Amlodipine and Flow Mediated Dilation|A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure|Unknown status|Active, not recruiting|Phase 4|576|Anticipated|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 23:28:57.784406|2018-05-31 23:28:57.784406
NCT01180192|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-02-11|2010-08-11|2010-08-12|Estimate|||||||2011-02-11|2011-02-14|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage|Phase 3 Study of Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage|Unknown status|Recruiting|Phase 4|450|Anticipated|Erzincan Military Hospital||1|||f||||||||||||||2018-05-31 23:28:57.858399|2018-05-31 23:28:57.858399
NCT01180179|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2017-08-15|2010-08-11|2010-08-12|Estimate|||||||2017-08-15|2017-08-17|Actual|June 2010|Actual|2010-06-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers|Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial|Active, not recruiting||Phase 4|228|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-05-31 23:28:57.932004|2018-05-31 23:28:57.932004
NCT01180166|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2013-09-17|2010-08-11|2010-08-12|Estimate|||||||2013-09-17|2013-09-19|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer|Phase II Study of Nimotuzumab and Concurrent Radiotherapy and Capecitabine for Inoperable Locally Advanced or Recurrent Gastric Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:28:57.99867|2018-05-31 23:28:57.99867
NCT01180153|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-11|2010-08-11|2010-08-12|Estimate|||||||2010-08-11|2010-08-12|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)|An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Beijing Cancer Hospital||1|||f||||t||||||||||2018-05-31 23:28:58.093739|2018-05-31 23:28:58.093739
NCT01180140|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2006||2006-03-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||Use of Seamguard to Prevent Leak and Bleeding in Gastrointestinal Surgery|Use of Seamguard to Prevent Digestive Leak and Bleeding on Lineal Stapled Anastomoses: a Prospective Randomized Clinical Trial|Completed||Phase 4|113|Actual|Hospital Universitario de Canarias||2|||f||||t||||||||||2018-05-31 23:28:58.1919|2018-05-31 23:28:58.1919
NCT01180127|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2014-12-23||2015-01-14|2010-08-10|2010-08-11|Estimate|2015-01-14|2015-01-27|Estimate||||2015-01-14|2015-01-27|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Mars Flavanol Exercise and Cognitive Function Study|Study of the Impact of a Flavanol Containing Food Product and Exercise on Cognitive Function and Brain Structure|Completed||Phase 2|41|Actual|New York State Psychiatric Institute||4|||f||||f||||||||||2018-05-31 23:28:58.364222|2018-05-31 23:28:58.364222
NCT01180114|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2012-11-22|2010-08-10|2010-08-11|Estimate|||||||2012-11-22|2012-11-27|Estimate|August 2008||2008-08-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Suubi-Maka||Economic Empowerment Program Suubi-Maka|"SUUBI MAKA (Hope for Families): A Family-Based Economic Empowerment Model for Orphaned Children in Uganda"|Completed||N/A|300|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 23:28:58.942948|2018-05-31 23:28:58.942948
NCT01180101|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2016-10-26|2010-08-10|2010-08-11|Estimate|||||||2016-10-26|2016-10-27|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease|Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease|Completed||Phase 2/Phase 3|37|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 23:28:59.054786|2018-05-31 23:28:59.054786
NCT01178463|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|October 2010|Anticipated|2010-10-31|May 2010|Actual|2010-05-31||Observational|||Spermatogonial Stem Cells in Azoospermic Patients: a Comparison Between Obstructive and Non-obstructive Azoospermia||Unknown status|Active, not recruiting||25|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 23:29:37.373565|2018-05-31 23:29:37.373565
NCT01180088|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|August 2011|Anticipated|2011-08-31|September 2010|Anticipated|2010-09-30||Interventional|AA||Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy|Effectiveness of Routine Application Of Anterior Approach During Right Hepatectomy: A Randomized Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Azienda Ospedaliera Ordine Mauriziano di Torino||1|||f||||f||||||||||2018-05-31 23:28:59.125392|2018-05-31 23:28:59.125392
NCT01180075|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2014-12-01|2010-08-10|2010-08-11|Estimate|||||||2014-12-01|2014-12-02|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population|Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population|Completed|||85|Actual|University of North Carolina, Chapel Hill|||4||f||||f||||||Samples With DNA|"~     Blood samples for determining drug concentrations and for future genetic testing of drug~     metabolizing enzymes and transporters will be stored for up to 5 years.~   "|||2018-05-31 23:28:59.204024|2018-05-31 23:28:59.204024
NCT01180062|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2014-12-04|2010-08-10|2010-08-11|Estimate|||||||2014-12-04|2014-12-08|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Latanoprost SR||Safety Study of Latanoprost Slow Release Insert|A Phase 1, Open-label, Dose Escalation Study to Evaluate the Safety and Tolerability of Latanoprost Sustained Release (SR) Insert in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|Terminated||Phase 1|12|Actual|University of Kentucky||3||"Study terminated early due to manufacturer not replenishing study site supply of inserts,~   despite repeated requests for more inserts."|f||||t||||||||||2018-05-31 23:28:59.286796|2018-05-31 23:28:59.286796
NCT01180049|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2016-11-04||2018-05-16|2010-08-10|2010-08-11|Estimate|2017-04-11|2017-05-19|Actual||||2018-05-16|2018-05-18|Actual|March 10, 2011|Actual|2011-03-10|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|November 12, 2015|Actual|2015-11-12||Interventional||The analysis was done on Intent-to-Treat (ITT) Population which included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug dose from that to which they were randomized.|Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma|A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (Temsr) Regimens In Subjects With Relapsed, Refractory Mantle Cell Lymphoma|Active, not recruiting||Phase 4|101|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:28:59.412509|2018-05-31 23:28:59.412509
NCT01180036|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2018-02-21|2010-08-10|2010-08-11|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2011||2011-11-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 1, 2017|Actual|2017-10-01||Interventional|MENTOR||MEmbranous Nephropathy Trial Of Rituximab|"A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"|Active, not recruiting||Phase 2/Phase 3|126|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 23:29:00.06027|2018-05-31 23:29:00.06027
NCT01180023|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2013-02-13|2010-08-10|2010-08-11|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Membrane Sweeping in Group B Streptococcus (GBS) Positive Patients|Membrane Sweeping in GBS Positive Patients at 37 Weeks Gestation: A Randomized Controlled Trial|Completed||N/A|120|Anticipated|George Washington University||2|||f||||t||||||||||2018-05-31 23:29:00.148683|2018-05-31 23:29:00.148683
NCT01180010|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2016-12-28|2010-08-10|2010-08-11|Estimate|||||||2016-12-28|2016-12-29|Estimate|August 2010||2010-08-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Low Dose Chest Computed Tomography (CT) Screening|Low-Dose Chest CT for Lung Cancer Screening in Survivors of Hodgkin's Disease|Completed|||31|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 23:29:00.20537|2018-05-31 23:29:00.20537
NCT01179997|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2014-02-26|2010-08-10|2010-08-11|Estimate|||||||2014-02-26|2014-02-27|Estimate||||May 2010|2010-05-31||||||||Interventional|||Tissue Doppler Imaging (TDI) Versus Electrocardiography (ECG) Interventricular Pacing Delay Optimization in Cardiac Resynchronization Therapy (CRT)||Completed||Phase 3|156|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 23:29:00.255845|2018-05-31 23:29:00.255845
NCT01179984|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2016-11-09||2017-01-18|2010-08-10|2010-08-11|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|June 2010||2010-06-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional||The baseline analysis population is comprised of subjects who present with lifestyle-limiting claudication or ischemic rest pain that are candidates for PTA and stenting.|Bard® LifeStent® Vascular Stent Delivery System Study|Bard® LifeStent® Vascular Stent Delivery System Study|Completed||N/A|76|Actual|C. R. Bard||1|||f||||f||||||||||2018-05-31 23:29:00.322919|2018-05-31 23:29:00.322919
NCT01179971|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-25|2010-08-10|2010-08-11|Estimate|||||||2010-08-25|2010-08-26|Estimate|December 2008||2008-12-31|August 2010|2010-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||n-3 and n-6 Fatty Acids in Rheumatoid Arthritis|Incorporation of n-3 Long Chain Polyunsaturated Fatty Acids and Gamma Linolenic Acid in Plasma Lipids, Cholesteryl Esters, and Erythrocyte Membranes and Their Influence on Disease Activity in Patients With Rheumatoid Arthritis|Completed||Phase 2|60|Actual|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 23:29:00.664711|2018-05-31 23:29:00.664711
NCT01179958|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2018-02-13|2010-08-10|2010-08-11|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2010||2010-08-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|May 2016|Actual|2016-05-31||Interventional|||Cognitive Benefits of Aerobic Exercise Across the Age Span|Cognitive Benefits of Aerobic Exercise Across the Age Span|Active, not recruiting||N/A|260|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 23:29:00.737906|2018-05-31 23:29:00.737906
NCT01179945|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2012-09-28|2010-08-10|2010-08-11|Estimate|||||||2012-09-28|2012-10-01|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Effects of a Food Preservative on Glucose Homeostasis|Effects of a Food Preservative on Glucose Homeostasis|Completed||N/A|13|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 23:29:00.812488|2018-05-31 23:29:00.812488
NCT01179932|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|August 2010|Anticipated|2010-08-31||Observational|||Anesthesia Charting Fidelity Study|Acute Anesthesia Charting Fidelity Quality Assessment Pilot Study|Unknown status|Not yet recruiting||30|Anticipated|University Hospitals Cleveland Medical Center|||1||f||||f||||||||||2018-05-31 23:29:00.883801|2018-05-31 23:29:00.883801
NCT01179204|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-09-25|2010-08-10|2010-08-11|Estimate|||||||2012-09-25|2012-09-26|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Prediction of Pain in Total Knee Arthroplasty|Is Preoperative Pain Response Upon Tonic Heat Stimulation Predictive for Pain After Total Knee Arthroplasty?|Completed|||100|Actual|Hvidovre University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood-samples~   "|||2018-05-31 23:29:17.519532|2018-05-31 23:29:17.519532
NCT01179919|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2016-10-11||2016-12-16|2010-08-10|2010-08-11|Estimate|2016-10-11|2016-12-06|Estimate||||2016-12-16|2017-02-09|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional||Subjects administered at least 1 dose of oseltamivir|Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects|Oseltamivir and Oseltamivir Carboxylate Pharmacokinetics in Obese Adults|Completed||Phase 1/Phase 2|21|Actual|University of Michigan|This study only evaluated obese subjects. The concentrations measured in plasma may not reflect concentrations in tissues such as the lungs.|1|||f||||f||||||||No|The summative data have been published and are available as open-access to the public: doi10.1128/AAC.00422-11|2018-05-31 23:29:01.031423|2018-05-31 23:29:01.031423
NCT01179906|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Lifestyle Modifications and the Progression of Chronic Kidney Disease|Effect of Lifestyle Interventions on the Progression of Kidney Disease in Patients With Chronic Kidney Disease|Completed||N/A|21|Actual|Springfield College||1|||f||||f||||||||||2018-05-31 23:29:01.202755|2018-05-31 23:29:01.202755
NCT01179893|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-09|2010-08-09|2010-08-11|Estimate|||||||2010-08-09|2010-08-11|Estimate|March 2007||2007-03-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis|A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis|Completed||Phase 4|87|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:29:01.278299|2018-05-31 23:29:01.278299
NCT01179880|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2018-02-28|2010-08-09|2010-08-11|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2010||2010-09-30|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of E6005 in Japanese Patients With Atopic Dermatitis|A Phase 1/2 Study of E6005 in Japanese Patients With Atopic Dermatitis|Completed||Phase 1/Phase 2|40|Actual|Dermavant Sciences GmbH||2|||f||||||||||||||2018-05-31 23:29:01.38062|2018-05-31 23:29:01.38062
NCT01179867|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-08-24|2010-08-10|2010-08-11|Estimate|||||||2017-08-24|2017-08-25|Actual|October 2014||2014-10-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|March 2017|Actual|2017-03-31||Interventional|||Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge|Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge|Active, not recruiting||N/A|4014|Actual|McGill University||2|||f||||t||||||||||2018-05-31 23:29:01.462806|2018-05-31 23:29:01.462806
NCT01179854|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-05-10|2010-08-10|2010-08-11|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2009||2009-09-30|May 2017|2017-05-31|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Interventional|||Remegal Different Doses in Patients With Refractory Partial Seizures|Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures|Completed||Phase 2|60|Actual|Valexfarm||4|||f||||t||||||||||2018-05-31 23:29:01.553901|2018-05-31 23:29:01.553901
NCT01179841|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2018-05-21|2010-08-10|2010-08-11|Estimate|||||||2018-05-21|2018-05-22|Actual|January 2008||2008-01-31|May 2018|2018-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Intervention for Toddlers at Risk for Autism Spectrum Disorders (ASD)|A Comprehensive Approach to Intervention for Toddlers at Risk for ASD|Completed||N/A|49|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||||2018-05-31 23:29:01.653755|2018-05-31 23:29:01.653755
NCT01179828|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2016-04-05|2010-08-10|2010-08-11|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|Predictio||Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)|Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain|Completed||Phase 3|150|Actual|University Hospital Inselspital, Berne||4|||f||||t||||||||||2018-05-31 23:29:01.761419|2018-05-31 23:29:01.761419
NCT01179815|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-05-01|2010-08-10|2010-08-11|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2010||2010-01-31|May 2017|2017-05-31|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Observational|SwissDiab||Swiss Diabetes Registry - SwissDiab Study|Swiss Diabetes Registry - SwissDiab Study, a Prospective Cohort Study of Patients With Diabetes in Switzerland|Recruiting|||1500|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||Samples Without DNA|"~     Serum and full blood samples~   "|||2018-05-31 23:29:01.895134|2018-05-31 23:29:01.895134
NCT01179802|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2011-02-14|2010-08-10|2010-08-11|Estimate|||||||2011-02-14|2011-02-15|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Exercise-induced Changes in Cardiac Function & Morphology|Magnetic Resonance Technique in the Assessment of Exercise-induced Long- and Short-Term Changes in Cardiac Function and Morphology|Completed||N/A|11|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 23:29:01.98831|2018-05-31 23:29:01.98831
NCT01179789|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2011-10-27|2010-08-10|2010-08-11|Estimate|||||||2011-10-27|2011-10-31|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Interventional|RISTOMED||New E-Service for a Dietary Approach to the Elderly|Open Label, Randomized Study of the Impact of Diet on Gut Microbiota, Inflammageing and Oxidative Stress in Elderly People. Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene. German Part of a Multicentric European Study|Completed||Early Phase 1|48|Anticipated|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 23:29:02.068423|2018-05-31 23:29:02.068423
NCT01179776|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2011-06-01|2010-08-10|2010-08-11|Estimate|||||||2011-06-01|2011-06-02|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)|A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin® in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)|Completed||Phase 1/Phase 2|16|Actual|Thrombologic ApS||2|||f||||f||||||||||2018-05-31 23:29:02.150978|2018-05-31 23:29:02.150978
NCT01179763|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|April 2010||2010-04-30|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Thickness of Retinal Layers in Amblyopia|Analysis of Spectral Domain Optical Coherence Tomography Measurements in Amblyopia|Completed|||22|Actual|Samsung Medical Center|||1||f||||t||||||||||2018-05-31 23:29:02.248402|2018-05-31 23:29:02.248402
NCT01179750|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-12-14|2010-08-10|2010-08-11|Estimate|||||||2010-12-14|2010-12-16|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||The Use of Ultrasonic Coagulating Shears Compared to Monopolar Electrocautery in Open Gastric Cancer Surgery|The Use of Ultrasonic Coagulating Shears Compared to Monopolar Electrocautery in Open Gastric Cancer Surgery|Unknown status|Recruiting|Phase 3|256|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 23:29:02.394586|2018-05-31 23:29:02.394586
NCT01179737|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2014-01-14||2014-04-14|2010-08-10|2010-08-11|Estimate|2014-01-14|2014-02-27|Estimate||||2014-04-14|2014-05-01|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||an end of study evaluation was only available for 14 of these patients|Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)|A 24 Week, Randomized, Double Blind, Multicenter, Placebocontrolled Efficacy, Safety, Tolerability and PK Trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)|Terminated||Phase 2|23|Actual|Novartis||2||Study was terminated due to serious adverse event (SAE)|f||||t||||||||||2018-05-31 23:29:02.512873|2018-05-31 23:29:02.512873
NCT01179724|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial|Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial|Unknown status|Recruiting|N/A|206|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 23:29:03.842107|2018-05-31 23:29:03.842107
NCT01179711|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|June 2009||2009-06-30|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Under-correction in Refractive Accommodative Esotropia|The Maximal Tolerable Reduction in Hyperopic Correction in Patients With Refractive Accommodative Esotropia: A 6-month Follow-up Study|Completed||N/A|41|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 23:29:03.939047|2018-05-31 23:29:03.939047
NCT01179698|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Navigation Surgery for Bone and Soft Tissue Tumor|Navigation Surgery for Bone and Soft Tissue Tumor|Unknown status|Recruiting|N/A|45|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 23:29:04.042821|2018-05-31 23:29:04.042821
NCT01179685|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2011-07-20|2010-08-10|2010-08-11|Estimate|||||||2011-07-20|2011-07-21|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Diagnostic Utility of Pleural Fluid MAGE Assay in Patients With Pleural Effusion From Primary Lung Cancer|Diagnostic Utility of Pleural Fluid MAGE Assay in Patients With Pleural Effusion From Primary Lung Cancer|Completed||N/A|100|Anticipated|Samsung Medical Center|||||f||||||||||||||2018-05-31 23:29:04.276787|2018-05-31 23:29:04.276787
NCT01179672|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2014-06-12||2014-10-03|2010-08-10|2010-08-11|Estimate|2014-06-12|2014-07-14|Estimate||||2014-10-03|2014-10-13|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All randomized participants.|A Study in Participants With Diabetic Peripheral Neuropathic Pain in China|Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo|Completed||Phase 3|405|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:29:04.40391|2018-05-31 23:29:04.40391
NCT01179659|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|September 2005||2005-09-30|August 2010|2010-08-31|March 2006|Actual|2006-03-31|November 2005|Actual|2005-11-30||Interventional|||Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets Under Fed Conditions|A Pharmacokinetic Study to Assess the Bioequivalence of a Single-Dose of KUDCO and Wyeth Pharmaceuticals (Protonix) 40 mg Pantoprazole Sodium Delayed-Release Tablet When Administered to Healthy Adult Volunteers Under Fed Conditions|Completed||Phase 1|150|Actual|Kremers Urban Development Company||2|||f||||f||||||||||2018-05-31 23:29:05.933293|2018-05-31 23:29:05.933293
NCT01179646|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|June 2004||2004-06-30|August 2010|2010-08-31|August 2004|Actual|2004-08-31|June 2004|Actual|2004-06-30||Interventional|||Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets|A Pharmacokinetic Study to Determine the Bioequivalence of a Test 40 mg Pantoprazole Delayed-Release Tablet, Compared to a Marketed 40 mg Pantoprazole Delayed-Release Tablet (Protonix, Wyeth Pharmaceuticals) When Administered to Healthy Adult Subjects in the Fasted State|Completed||Phase 1|48|Actual|Kremers Urban Development Company||2|||f||||f||||||||||2018-05-31 23:29:06.012961|2018-05-31 23:29:06.012961
NCT01179633|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2010||2010-03-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid||Completed||Phase 1/Phase 2|35|Actual|Oplon-Pure Science Ltd.||2|||f||||t||||||||||2018-05-31 23:29:06.117524|2018-05-31 23:29:06.117524
NCT01179620|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2012-07-09|2010-08-10|2010-08-11|Estimate|||||||2012-07-09|2012-07-10|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|MEMBRANE||Certoparin in Renal Patients Undergoing Hemodialysis|A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis|Completed||Phase 3|109|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:29:06.197382|2018-05-31 23:29:06.197382
NCT01179607|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia|A Randomized, Double Blind, Placebo Controlled, Phase II, Dose-titration Trial to Explore the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of M0002 in Cirrhotic Subjects With Ascites and Hypo- or Normonatraemia.|Completed||Phase 2|15|Actual|Movetis||2|||f||||f||||||||||2018-05-31 23:29:06.28743|2018-05-31 23:29:06.28743
NCT01179594|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-02-16|2010-08-10|2010-08-11|Estimate|||||||2017-02-16|2017-02-17|Actual|September 18, 2010|Anticipated|2010-09-18|February 2017|2017-02-28|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.|A Phase IV, 2x2 Factorial, Double Blind Study of 48 Versus 96 Weeks of PEGASYS 180µg, With or Without 24 Weeks of Entecavir in Adult Patients With HBeAg Negative Chronic Hepatitis B.|Withdrawn||Phase 4|0|Actual|Hoffmann-La Roche||4||This study was canceled for operational reasons.|f||||||||||||||2018-05-31 23:29:06.431306|2018-05-31 23:29:06.431306
NCT01179581|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2011-03-23|2010-08-10|2010-08-11|Estimate|||||||2011-03-23|2011-03-24|Estimate|August 2010||2010-08-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||First-in-Human Single Ascending and Multiple Dose of GLPG0634|Double-blind Placebo-controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG0634 in Healthy Subjects|Completed||Phase 1|48|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 23:29:06.519425|2018-05-31 23:29:06.519425
NCT01179568|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2016-09-06||2016-11-28|2010-08-10|2010-08-11|Estimate|2016-11-28|2017-01-24|Estimate||||2016-11-28|2017-01-24|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|HEAL||A Study of Medication With or Without Psychotherapy for Complicated Grief|Optimizing Treatment for Complicated Grief (Healing Emotions After Loss:HEAL)|Completed||Phase 2|395|Actual|New York State Psychiatric Institute|Two limitations of note: 1) FDA lowered the maximum safe dose of study medication (citalopram) after the study started; 2) our recruitment rate was 90% of target, while the assessment drop-out rate was over double what we expected.|4|||f||||t||||||||||2018-05-31 23:29:06.618252|2018-05-31 23:29:06.618252
NCT01179555|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-04-06|2010-08-10|2010-08-11|Estimate|||||||2017-04-06|2017-04-10|Actual|October 2010||2010-10-31|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Confronting Unequal Eye Care in Pennsylvania|Confronting Unequal Eye Care in Pennsylvania|Completed||N/A|206|Actual|Wills Eye||2|||f||||t||||||||Yes|Several manuscripts have been published.|2018-05-31 23:29:07.128326|2018-05-31 23:29:07.128326
NCT01179542|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-09-12|2010-08-10|2010-08-11|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2010||2010-09-30|August 2010|2010-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR|The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR.|Withdrawn|||0|Actual|Meir Medical Center|||4|recruiting problems|f||||f||||||||||2018-05-31 23:29:07.274022|2018-05-31 23:29:07.274022
NCT01179529|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2012-01-09|2010-08-09|2010-08-11|Estimate|||||||2012-01-09|2012-01-10|Estimate||||January 2012|2012-01-31||||||||Interventional|AMB-WEI-1052-I||Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage|Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair®) Treatment in Atopic Dermatitis|Completed||Phase 2|||Technische Universität München||1|||f||||f||||||||||2018-05-31 23:29:07.319458|2018-05-31 23:29:07.319458
NCT01179516|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2013-10-25||2013-10-25|2010-08-09|2010-08-11|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder|Completed||Phase 3|469|Actual|Takeda||3|||f||||f||||||||||2018-05-31 23:29:07.39746|2018-05-31 23:29:07.39746
NCT01179503|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2011-08-03|2010-08-10|2010-08-11|Estimate|||||||2011-08-03|2011-08-04|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Vitamin D Supplementation and Physical Function in Older Adults|Vitamin D Supplementation, Skeletal Muscle Gene Expression, and Physical Performance in Older Adults|Completed||N/A|16|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 23:29:09.491904|2018-05-31 23:29:09.491904
NCT01179490|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2012-12-02||2013-03-15|2010-08-09|2010-08-11|Estimate|2013-03-15|2013-03-18|Estimate||||2013-03-15|2013-03-18|Estimate|September 2010||2010-09-30|March 2013|2013-03-31||||September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma|A Multicenter, Open-Label, Phase 2 Study of SyB L-0501 (Bendamustine Hydrochloride) for Patients With Multiple Myeloma|Terminated||Phase 2|5|Actual|SymBio Pharmaceuticals||1|||f||||t||||||||||2018-05-31 23:29:09.620658|2018-05-31 23:29:09.620658
NCT01179477|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2016-07-18|2010-08-09|2010-08-11|Estimate|||||||2016-07-18|2016-07-20|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||QuickFlex Micro Left Ventricular Lead Post Approval Study|QuickFlex® μ Model 1258T Left Heart Pacing Lead Post Approval Study|Active, not recruiting|||1930|Actual|St. Jude Medical|||||f||||f||||||||No||2018-05-31 23:29:10.108863|2018-05-31 23:29:10.108863
NCT01179464|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2013-06-13|2010-08-10|2010-08-11|Estimate|||||||2013-06-13|2013-06-14|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells|Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells|Completed||N/A|19|Actual|VU University Medical Center||2|||f||||f||||||||||2018-05-31 23:29:10.38438|2018-05-31 23:29:10.38438
NCT01179451|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2013-02-19|2010-08-10|2010-08-11|Estimate|||||||2013-02-19|2013-02-20|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Observational|||Late Cardial Assessment in Children Who Were Diagnosed With Post Streptococcal Reactive Arthritis - a Long Term Study|Late Cardial Assessment in Children Who Were Diagnosed With Post Streptococcal Reactive Arthritis - a Long Term Study|Completed|||146|Actual|Meir Medical Center|||1||f||||||||||||||2018-05-31 23:29:10.450578|2018-05-31 23:29:10.450578
NCT01179438|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-12-06|2010-08-10|2010-08-11|Estimate|||||||2012-12-06|2012-12-10|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Effect of Dexmedetomidine on Microcirculation in Patients Undergoing Extracorporeal Shock Wave Lithotripsy|Effect of Dexmedetomidine on Microcirculation in Patients Undergoing Extracorporeal Shock Wave Lithotripsy|Withdrawn||Phase 4|0|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-05-31 23:29:10.535342|2018-05-31 23:29:10.535342
NCT01179425|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-04-13|2010-08-10|2010-08-11|Estimate|||||||2011-04-13|2011-04-14|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Sex Differences in Attentional Bias in Marijuana-dependent Individuals|Sex Differences in Attentional Bias and Cognitive Functioning in Response to Stress in Marijuana-dependent Individuals|Completed||N/A|40|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 23:29:10.601938|2018-05-31 23:29:10.601938
NCT01179412|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|July 2004||2004-07-31|August 2010|2010-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine|Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine|Completed||Phase 4|172|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 23:29:10.676415|2018-05-31 23:29:10.676415
NCT01179399|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2013-10-28||2014-01-13|2010-08-09|2010-08-11|Estimate|2014-01-13|2014-03-03|Estimate||||2014-01-13|2014-03-03|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies|A Phase 1, Open-Label, Dose-Escalation Study of Orally Administered TAK-960, a Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Nonhematologic Malignancies|Terminated||Phase 1|32|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:29:10.765341|2018-05-31 23:29:10.765341
NCT01179386|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-08-27|2010-08-10|2010-08-11|Estimate|||||||2011-08-27|2011-08-30|Estimate|November 2011||2011-11-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Expectation of Driving Performance in Young Adults With ADHD Assessed by Driving Simulator and Seat Pressure Mapping|Expectation of Driving Performance in Young Adults With ADHD Assessed by Driving Simulator and Seat Pressure Mapping|Unknown status|Not yet recruiting||60|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 23:29:10.965601|2018-05-31 23:29:10.965601
NCT01179373|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2018-01-24|2010-08-10|2010-08-11|Estimate|||||||2018-01-24|2018-01-25|Actual|August 2010|Actual|2010-08-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease|Phase 2 Study of Trans Cranial Magnetic Stimulation as Additional Therapy Patients With Alzheimer's Disease|Completed||Phase 2|45|Anticipated|Brainsway||3|||f||||f||||||||||2018-05-31 23:29:11.038712|2018-05-31 23:29:11.038712
NCT01179360|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-11-16|2010-08-10|2010-08-11|Estimate|||||||2017-11-16|2017-11-17|Actual|February 2011||2011-02-28|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ECLYPS||Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Clinical Value of Combined [18F]Fluoro-2-deoxy-D-glucose (FDG) PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Potentially Operable Locally Advanced Head and Neck Squamous Cell Carcinoma.|Completed|||152|Actual|University Hospital, Antwerp|||1||f||||f||||||||||2018-05-31 23:29:11.101302|2018-05-31 23:29:11.101302
NCT01179347|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2013-02-13||2013-11-27|2010-08-10|2010-08-11|Estimate|2013-02-13|2013-03-26|Estimate||||2013-11-27|2013-12-24|Estimate|September 2010||2010-09-30|October 2013|2013-10-31||||March 2012|Actual|2012-03-31||Interventional|||Tiotropium Bromide in Cystic Fibrosis|A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.|Completed||Phase 3|464|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:29:11.236925|2018-05-31 23:29:11.236925
NCT01179334|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2013-11-06||2016-07-27|2010-08-10|2010-08-11|Estimate|2013-11-06|2013-12-25|Estimate||||2016-07-27|2016-08-29|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|June 2012|Actual|2012-06-30||Interventional|PATENT PLUS||Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.|An Interaction Study to Evaluate Changes in Blood Pressure Following 1, 1.5, 2, and 2.5 mg Riociguat Tid (Dose Titration) Compared to Placebo Treatment on the Background of Stable Sildenafil Pretreatment in Subjects With Symptomatic Pulmonary Arterial Hypertension|Completed||Phase 2|18|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:29:12.256|2018-05-31 23:29:12.256
NCT01179321|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|April 2006||2006-04-30|March 2006|2006-03-31||||||||Interventional|||Malnutrition Screening in Acute Aged Care|Malnutrition Screening and Intervention in Hospitalised Older Patients: A Randomised Controlled Trial|Completed||N/A|||Prince of Wales Hospital, Sydney||2|||f||||||||||||||2018-05-31 23:29:13.961864|2018-05-31 23:29:13.961864
NCT01179308|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2016-09-13|2010-08-10|2010-08-11|Estimate|||||||2016-09-13|2016-09-15|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Regional Anesthesia and Lung Cancer Recurrence|The Effect of Adding Intraoperative Regional Anesthesia on Cancer Recurrence in Patients Undergoing Lung Cancer Resection|Terminated||N/A|67|Actual|The Cleveland Clinic||2||The principal investigator decided to close this study site.|f||||f||||||||No||2018-05-31 23:29:14.544451|2018-05-31 23:29:14.544451
NCT01179295|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-06-19|2010-08-10|2010-08-11|Estimate|||||||2017-06-19|2017-06-20|Actual|November 19, 2010|Actual|2010-11-19|June 2017|2017-06-30|April 27, 2012|Actual|2012-04-27|April 27, 2012|Actual|2012-04-27||Interventional|||Japanese BAY86-9766 Monotherapy Phase I Study|Phase 1 Study of Single Agent BAY86-9766 in Japanese Patients With Advanced or Refractory Solid Tumors|Completed||Phase 1|12|Actual|Bayer||4|||f||||t||||||||||2018-05-31 23:29:14.925389|2018-05-31 23:29:14.925389
NCT01179282|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-01-31|2010-08-10|2010-08-11|Estimate|||||||2013-01-31|2013-02-01|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DUSTMITE||Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients|Repeated Nasal Challenge in Skin Prick-puncture Negative and Intradermal Positive Dust Mite Allergic Rhinitis Patients.|Completed||N/A|42|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 23:29:15.495937|2018-05-31 23:29:15.495937
NCT01179269|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2016-10-10|2010-08-10|2010-08-11|Estimate|||||||2016-10-10|2016-10-12|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer|Pazopanib and Weekly Paclitaxel in Stage IIIB/IV Non-small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Loyola University||1||The study was stopped because the research team was unable to enroll any participants|f||||t||||||||No||2018-05-31 23:29:15.769704|2018-05-31 23:29:15.769704
NCT01179256|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|CURCUMIN||Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma|Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma|Completed||N/A|16|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 23:29:15.915097|2018-05-31 23:29:15.915097
NCT01179243|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-10-31|2010-08-10|2010-08-11|Estimate|||||||2012-10-31|2012-11-01|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Observational|||Prevalence of Microcirculatory Alterations in Intensive Care Patients|Observation of the Prevalence of Sublingual Microcirculatory Alterations With SDF Imaging in Intensive Care Patients|Completed|||500|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||||2018-05-31 23:29:16.148643|2018-05-31 23:29:16.148643
NCT01179230|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2015-03-19|2010-08-09|2010-08-11|Estimate|||||||2015-03-19|2015-03-23|Estimate|January 2005||2005-01-31|July 2012|2012-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|PETvsSPECT||Rubidium-82 Position Emission Computed Tomography (PET) Versus Gated, Rest / Stress Technetium 99-m SPECT|A Prospective Comparison of Gated, Rest/Stress Rubidium-82 Position Emission Computed Tomography (PET) vs. Gated, Rest / Stress Technetium 99-m SPECT|Completed|||136|Actual|Hartford Hospital|||1||f||||f||||||||||2018-05-31 23:29:16.282877|2018-05-31 23:29:16.282877
NCT01179217|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2016-12-14|2014-06-24|2017-08-08|2010-08-09|2010-08-11|Estimate|2017-08-08|2017-08-10|Actual|2014-06-24|2014-06-26|Estimate|2017-08-08|2017-08-10|Actual|May 2010||2010-05-31|July 2017|2017-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia|A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA|Completed||Phase 3|230|Actual|Emmaus Medical, Inc.||2|||f||||f||||||||Undecided||2018-05-31 23:29:16.478782|2018-05-31 23:29:16.478782
NCT01179191|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2012-07-30|2012-04-05|2012-10-09|2010-08-10|2010-08-11|Estimate|2012-07-30|2012-09-05|Estimate|2012-04-05|2012-04-09|Estimate|2012-10-09|2012-10-11|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ConvERT||Conversion to Embeda With Rescue Trial|A Multi-Center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, With Chronic, Moderate to Severe Pain, to EMBEDA Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion|Terminated||Phase 4|684|Actual|Pfizer|The study was prematurely terminated due to drug supply issues.|1||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:29:17.775256|2018-05-31 23:29:17.775256
NCT01179178|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2006||2006-03-31|January 2006|2006-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A Dangerous Triad in Ageing and in Chronic Obstructive Pulmonary Disease (COPD) - Reduced Muscle Mass, Impaired Muscle Function and Malnutrition|A Dangerous Triad in Ageing and in COPD - Reduced Muscle Mass, Impaired Muscle Function and Malnutrition|Completed|||||Göteborg University|||2||f||||f||||||||||2018-05-31 23:29:19.725445|2018-05-31 23:29:19.725445
NCT01179165|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-03-07|2010-08-10|2010-08-11|Estimate|||||||2017-03-07|2017-03-08|Actual|January 2011|Actual|2011-01-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Noninvasive Methods in Diagnosing Coronary Heart Disease in Diabetic Patients|Application in High Risk Groups of Recently Developed Noninvasive Methods in Diagnosing Coronary Heart Disease.A Community Based Study.|Completed|||104|Actual|Norwegian University of Science and Technology|||1||f||||f|f|f||||Samples Without DNA|"~     Routine laboratory tests, parameters to caracterize diabetes controle, inflammatory markers.~   "|||2018-05-31 23:29:19.790337|2018-05-31 23:29:19.790337
NCT01179152|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-03-16|2010-08-10|2010-08-11|Estimate|||||||2012-03-16|2012-03-19|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Preventive Treatment With Symbicort or Budicort Turbohaler in Childhood Asthma Return to School Epidemic|Childhood Asthma and Return to School: the September Epidemic Exacerbation in Israel.A Controlled Trial of the Effectiveness of Preventive Treatment With Symbicort or Budicort Turbuhaler|Unknown status|Recruiting|N/A|225|Anticipated|Meir Medical Center||3|||f||||f||||||||||2018-05-31 23:29:19.865287|2018-05-31 23:29:19.865287
NCT01179139|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2018-05-15|2010-08-10|2010-08-11|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2003||2003-12-31|May 2018|2018-05-31|April 2011|Actual|2011-04-30|July 2010|Actual|2010-07-31||Interventional|FAMRI||Pathogenesis of Chronic Sinusitis in Relationship to Tobacco Smoke Exposure|Pathogenesis of Chronic Sinusitis in Relationship to Tobacco Smoke Exposure|Completed||N/A|97|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:29:19.987957|2018-05-31 23:29:19.987957
NCT01179126|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2013-09-02|2010-08-10|2010-08-11|Estimate|||||||2013-09-02|2013-09-04|Estimate|September 2010||2010-09-30|September 2013|2013-09-30||||September 2014|Anticipated|2014-09-30||Interventional|CROSS-AMI||Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multivessel Disease|Complete Revascularization Or streSS Echo in Patients With Multivessel Disease and ST-segment Elevation Acute Myocardial Infarction|Unknown status|Recruiting|Phase 3|400|Anticipated|Complexo Hospitalario Universitario de A Coruña||2|||f||||f||||||||||2018-05-31 23:29:20.08271|2018-05-31 23:29:20.08271
NCT01179113|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|2016-06-09||2016-09-27|2010-08-10|2010-08-11|Estimate|2016-07-19|2016-08-30|Estimate||||2016-09-27|2016-11-02|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Esmolol Infusion During Laminectomy: Effect on Quality of Recovery|Esmolol Infusion for Maintaining Hemodynamic Stability During Single or Double Level Lumbar Laminectomy: Effect on Quality of Recovery.|Terminated||Phase 4|33|Actual|Cedars-Sinai Medical Center||2||The preliminary result didn't show any benefit.|f||||f||||||||||2018-05-31 23:29:20.193852|2018-05-31 23:29:20.193852
NCT01179100|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-09-03|2010-08-10|2010-08-11|Estimate|||||||2015-09-03|2015-09-07|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||How Lidocaine Affects Outcomes In Orthopedic Surgery Patients|The Effects Of Lidocaine Infusion On The Recovery Of Cognitive Function Following General Anesthesia In Elderly Patients Undergoing Orthopedic Surgeries Requiring A Minimum Two Day Hospitalization|Withdrawn||Phase 4|0|Actual|Cedars-Sinai Medical Center||2||Patient population require high amount of opioids.|f||||f||||||||||2018-05-31 23:29:20.515253|2018-05-31 23:29:20.515253
NCT01179087|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-08-05|2010-08-10|2010-08-11|Estimate|||||||2013-08-05|2013-08-07|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Sleep Disordered Breathing and Lung Transplantation|Sleep Disordered Breathing and Lung Transplantation|Unknown status|Recruiting||40|Anticipated|Katholieke Universiteit Leuven|||||f||||f||||||||||2018-05-31 23:29:20.623707|2018-05-31 23:29:20.623707
NCT01179074|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-08-10|2010-08-10|2010-08-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|April 2007||2007-04-30|February 2010|2010-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Role of Radiotherapy Following Oesophageal Stenting in Cancer|Palliative Stenting With or Without Radiotherapy for Inoperable Oesophageal Carcinoma: a Randomised Trial|Completed||N/A|84|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-05-31 23:29:20.69334|2018-05-31 23:29:20.69334
NCT01179061|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-01-13|2010-08-09|2010-08-10|Estimate|||||||2011-01-13|2011-01-14|Estimate|August 2010||2010-08-31|August 2010|2010-08-31||||August 2011|Anticipated|2011-08-31||Interventional|INO-apelin||Investigating the Inotropic Potential of Apelin|Investigating the Inotropic Potential of Apelin in Healthy Volunteers and Patients With Chronic Stable Heart Failure|Unknown status|Recruiting|N/A|24|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-05-31 23:29:20.769401|2018-05-31 23:29:20.769401
NCT01179048|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2016-12-16||2018-04-20|2010-08-09|2010-08-10|Estimate|2017-01-10|2017-03-01|Actual||||2018-04-20|2018-05-21|Actual|August 31, 2010|Actual|2010-08-31|April 2018|2018-04-30|December 17, 2015|Actual|2015-12-17|December 17, 2015|Actual|2015-12-17||Interventional|LEADER®|All the randomised subjects.|Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results|A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events|Completed||Phase 3|9340|Actual|Novo Nordisk A/S||2|||f||||t||||||||||2018-05-31 23:29:21.085798|2018-05-31 23:29:21.085798
NCT01179035|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate||||August 2010|2010-08-31||||||||Interventional|||Evaluation of Transitions Clinic: A Post-Release Clinic for Recently Released Parolees With Chronic Medical Conditions|The Impact of Parolee-Targeted Care Versus Expedited Usual Care on Health Care Utilization and Recidivism|Completed||N/A|150|Actual|Transitions Clinic||2|||f||||f||||||||||2018-05-31 23:29:28.766567|2018-05-31 23:29:28.766567
NCT01179022|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2013-03-12|2010-08-08|2010-08-10|Estimate|||||||2013-03-12|2013-03-13|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions|Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions|Completed|||46|Actual|Meir Medical Center|||||f||||t||||||||||2018-05-31 23:29:28.88083|2018-05-31 23:29:28.88083
NCT01179009|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2017-05-24|2010-08-09|2010-08-10|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2012||2012-04-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Treatment Resistant Depression (Pilot)|A Safe Ketamine-Based Therapy for Treatment Resistant Depression|Recruiting||N/A|40|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 23:29:28.971212|2018-05-31 23:29:28.971212
NCT01178996|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|December 2004||2004-12-31|August 2010|2010-08-31|July 2009|Actual|2009-07-31|May 2008|Actual|2008-05-31||Interventional|||Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.|A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + Peginterferon Alpha-2a Plus Ribavirin With Peginterferon Alpha-2a + Ribavirin + Placebo|Completed||Phase 3|552|Actual|sigma-tau i.f.r. S.p.A.||2|||f||||f||||||||||2018-05-31 23:29:29.102592|2018-05-31 23:29:29.102592
NCT01178983|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-06-20|2010-08-09|2010-08-10|Estimate|||||||2011-06-20|2011-06-21|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Efficacy of Telerehabilitation Intervention Program Using Telebiofeedback Among Computer Operators||Unknown status|Recruiting|N/A|50|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:29:29.194922|2018-05-31 23:29:29.194922
NCT01178970|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Effects of Lower Body Resistance Training on Balance and Fall Prevention in the Elderly|The Effects of Lower Body Resistance Training on Balance and Fall Prevention in the Elderly|Completed||N/A|25|Actual|University of Oklahoma|||||f||||f||||||||||2018-05-31 23:29:29.416148|2018-05-31 23:29:29.416148
NCT01178957|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-08-05|2010-08-09|2010-08-10|Estimate|||||||2013-08-05|2013-08-07|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia|Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia|Completed|||8|Actual|University of Aarhus|||1||f||||t||||||Samples With DNA|"~     Blood Samples~   "|||2018-05-31 23:29:29.502513|2018-05-31 23:29:29.502513
NCT01178944|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2017-07-19||2017-11-14|2010-08-09|2010-08-10|Estimate|2017-11-14|2017-12-13|Actual||||2017-11-14|2017-12-13|Actual|September 2010||2010-09-30|November 2017|2017-11-30|November 2015|Actual|2015-11-30|January 2015|Actual|2015-01-31||Interventional||All treated and eligible patients|Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer|Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates|Completed||Phase 2|35|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 23:29:29.606272|2018-05-31 23:29:29.606272
NCT01178931|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2014-01-27|2010-08-09|2010-08-10|Estimate|||||||2014-01-27|2014-01-29|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Dydrogesterone Versus Intravaginal Progesterone in the Luteal Phase Support|Oral Dydrogesterone Versus Vaginal Progesterone Gel in the Luteal Phase Support: Randomized Controlled Trial|Completed||N/A|853|Actual|University of Zagreb||2|||f||||t||||||||||2018-05-31 23:29:30.089808|2018-05-31 23:29:30.089808
NCT01178918|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|November 2009||2009-11-30|August 2010|2010-08-31||||||||Observational|||Non-specific Response to H1N1 Vaccine|Enhanced Non-Specific T Lymphocytes Response to Influenza A (H1N1) AS03-Adjuvanted Vaccine|Unknown status|Active, not recruiting||15|Anticipated|The University Clinic of Pulmonary and Allergic Diseases Golnik|||1||f||||f||||||||||2018-05-31 23:29:30.36428|2018-05-31 23:29:30.36428
NCT01178905|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-04-23|2010-08-09|2010-08-10|Estimate|||||||2013-04-23|2013-04-24|Estimate|August 2010||2010-08-31|February 2013|2013-02-28||||October 2012|Actual|2012-10-31||Interventional|||Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants|Clinical Evaluation of a Gentle But Safe Ultrashort-term Heat Inactivation Procedure of Raw Breast Milk (BM) Containing Virulent Cytomegalovirus for Preventing CMV-infection of Preterm Infants|Completed||N/A|||University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 23:29:30.573799|2018-05-31 23:29:30.573799
NCT01178892|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2014-08-20|2010-08-09|2010-08-10|Estimate|||||||2014-08-20|2014-08-22|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation|MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation|Completed||N/A|355|Actual|Fred Hutchinson Cancer Research Center||6|||f||||t||||||||||2018-05-31 23:29:30.641618|2018-05-31 23:29:30.641618
NCT01178879|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-06-27|2010-08-09|2010-08-10|Estimate|||||||2013-06-27|2013-06-28|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Randomised Trial of Telehealth Consultations for Nursing Care of Chronic Obstructive Pulmonary Disease (COPD) Patients|Effectiveness of Nurse Lead Telehealth Consultations in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|266|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 23:29:30.83656|2018-05-31 23:29:30.83656
NCT01178866|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Observational|||Laboratory Outcome Predictors in Coronary Surgery|Markers of Tissue Perfusion as Predictors of Complicated Evolution in Patients With Left Ventricular Dysfunction Submitted to Coronary Artery Bypass Surgery|Completed|||87|Actual|University of Sao Paulo|||1||f||||t||||||||||2018-05-31 23:29:31.293225|2018-05-31 23:29:31.293225
NCT01178853|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2012-03-29||2012-09-06|2010-08-09|2010-08-10|Estimate|2012-09-06|2012-10-08|Estimate||||2012-09-06|2012-10-08|Estimate|July 2010||2010-07-31|September 2012|2012-09-30|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers|Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers|Completed||Phase 4|48|Actual|Kowa Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 23:29:31.85012|2018-05-31 23:29:31.85012
NCT01178840|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2013-12-11|2010-08-09|2010-08-10|Estimate|||||||2013-12-11|2013-12-12|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CONRAD-108||Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom|A Randomized Cross-Over Study of Vaginal Semen Exposure and Clinical Failure Comparing the PATH Woman's Condom and the FC2 Female Condom|Completed||N/A|505|Anticipated|CONRAD||2|||f||||f||||||||||2018-05-31 23:29:33.008186|2018-05-31 23:29:33.008186
NCT01178827|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|2012-03-23||2016-01-28|2010-08-09|2010-08-10|Estimate|2012-07-10|2012-08-16|Estimate||||2016-01-28|2016-02-26|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial||Completed||Phase 4|20|Actual|Allergan||3|||f||||f||||||||||2018-05-31 23:29:33.25523|2018-05-31 23:29:33.25523
NCT01178814|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2016-01-15|2010-08-09|2010-08-10|Estimate|||||||2016-01-15|2016-01-18|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Revlimid in Transfusion Dependent Patients|A Prospective Trial of Revlimid® in Transfusion Dependent Patients With Non-del (5q) Low/Intermediate-1 Risk Myelodysplastic Syndrome|Unknown status|Active, not recruiting|Phase 2|56|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 23:29:33.864671|2018-05-31 23:29:33.864671
NCT01178801|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-30|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Sharable Knowledge Mining Platform|Sharable Knowledge Mining Platform for Clinical Data Extraction, and Medical Knowledge and Mining Services Sharing|Unknown status|Recruiting||10000|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 23:29:33.939246|2018-05-31 23:29:33.939246
NCT01178788|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2016-09-21|2010-08-09|2010-08-10|Estimate|||||||2016-09-21|2016-09-23|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PROTECT||Progestagens for the Tertiary Prophylaxis of Preterm Delivery|Progestagens for the Tertiary Prophylaxis of Preterm Delivery in Women With Short Cervix. A Randomized Multicentre Trial|Completed||Phase 3|254|Actual|University of Modena and Reggio Emilia||3|||f||||t||||||||||2018-05-31 23:29:34.007573|2018-05-31 23:29:34.007573
NCT01178775|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-11|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|March 2010|Anticipated|2010-03-31||Interventional|PFMS||Development and Validation of Perceived Fatigue Meaning Scale on Walking Program|Development and Validation of Perceived Fatigue Meaning Scale and Its Effect on Individualized Patient Education and Walking Program for Managing Fatigue in Patients With Cancer|Unknown status|Recruiting|N/A|105|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 23:29:34.150154|2018-05-31 23:29:34.150154
NCT01178762|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|2010-08-12||2010-10-05|2010-08-09|2010-08-10|Estimate|2010-10-05|2010-10-27|Estimate||||2010-10-05|2010-10-27|Estimate|September 2007||2007-09-30|September 2010|2010-09-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis|The Effect of Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis|Completed||N/A|42|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 23:29:34.238108|2018-05-31 23:29:34.238108
NCT01178749|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-11|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|July 2011|Anticipated|2011-07-31|July 2010|Anticipated|2010-07-31||Observational|||Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments|Exploration of Symptom Experience and Related Factors for Patients With Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments: Development of a Prediction Model|Unknown status|Recruiting||390|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 23:29:34.383551|2018-05-31 23:29:34.383551
NCT01178736|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2010-08-08|2010-08-08|2010-08-10|Estimate|||||||2010-08-08|2010-08-10|Estimate|March 2011||2011-03-31|August 2010|2010-08-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Early Detection of Cancers in Low Resource Countries|Efficacy of a Combined Program for Early Detection of Breast and Gynecological Cancers in Low Resource Countries|Unknown status|Not yet recruiting||36000|Anticipated|Woman's Cancer Foundation|||1||f||||f||||||||||2018-05-31 23:29:34.484563|2018-05-31 23:29:34.484563
NCT01178723|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2010-08-08|2010-08-08|2010-08-10|Estimate|||||||2010-08-08|2010-08-10|Estimate||||August 2010|2010-08-31||||||||Interventional|||The Effects of Breakfast Size on Hormonal Profile in Adults With Type 2 Diabetes Mellitus||Unknown status|Not yet recruiting|N/A|48|Anticipated|Wolfson Medical Center|||||f||||t||||||||||2018-05-31 23:29:34.639615|2018-05-31 23:29:34.639615
NCT01178710|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-07-25|2010-08-09|2010-08-10|Estimate|||||||2012-07-25|2012-07-26|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional|||Effect of Simvastatin on Cardiac Function|The Cardiac Protective Effect of Simvastatin on Cardiac Surgery: a Double Blind, Randomised Clinical Trial|Completed||N/A|151|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:29:34.711346|2018-05-31 23:29:34.711346
NCT01178697|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)|Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion|Unknown status|Recruiting|Phase 2|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 23:29:34.960729|2018-05-31 23:29:34.960729
NCT01178684|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2014-09-25|2010-08-09|2010-08-10|Estimate|||||||2014-09-25|2014-09-26|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Epidermal Nerve Fiber Density, Fat and Mitochondrial Parameters in Thai HIV+ Patients on d4T and HIV- Patients|Study of Epidermal Nerve Fiber Density, Subcutaneous Fat, and Mitochondrial Parameters in Thai HIV-positive Patients on Long-term Stavudine Treatment and in Thai HIV-negative Patients|Completed|||113|Actual|South East Asia Research Collaboration with Hawaii|||4||f||||f||||||Samples Without DNA|"~     Plasma PBMC Urine CBC~   "|||2018-05-31 23:29:35.059658|2018-05-31 23:29:35.059658
NCT01178671|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2015-12-08||2016-04-02|2010-08-09|2010-08-10|Estimate|2016-01-29|2016-02-29|Estimate||||2016-04-02|2016-04-08|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial|Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD)|Completed||Phase 4|38|Actual|Research Foundation for Mental Hygiene, Inc.|small sample due to low recruitment|2|||f||||f||||||||No||2018-05-31 23:29:35.201076|2018-05-31 23:29:35.201076
NCT01178658|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-08-22|2010-08-08|2010-08-10|Estimate|||||||2014-08-22|2014-08-25|Estimate|July 2010||2010-07-31|August 2014|2014-08-31||||December 2014|Anticipated|2014-12-31||Interventional|||Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma|Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With T Cell or NK Cell Lymphoma|Unknown status|Recruiting|Phase 2|42|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 23:29:35.853014|2018-05-31 23:29:35.853014
NCT01178645|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-08-22|2010-08-08|2010-08-10|Estimate|||||||2014-08-22|2014-08-25|Estimate|July 2010||2010-07-31|August 2014|2014-08-31||||December 2014|Anticipated|2014-12-31||Interventional|||Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma|Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma|Unknown status|Recruiting|Phase 2|42|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 23:29:35.964777|2018-05-31 23:29:35.964777
NCT01178632|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|October 2010||2010-10-31|August 2010|2010-08-31|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Therapeutic Effect of an Herbal Medicine on Anxiety|A Double-blind, Randomized, Controlled, Phase III Study of an Herbal Medicine Association for Generalized Anxiety Disorder|Unknown status|Not yet recruiting|Phase 3|136|Anticipated|Millet Roux||2|||f||||t||||||||||2018-05-31 23:29:36.098192|2018-05-31 23:29:36.098192
NCT01178619|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2013-08-27|2010-08-09|2010-08-10|Estimate|||||||2013-08-27|2013-08-28|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Sonographic Differences in Brain Measurements Between Normal and Intrauterine Growth Restriction (IUGR) Fetuses||Withdrawn|||0|Actual|Meir Medical Center|||3||f||||||||||||||2018-05-31 23:29:36.201041|2018-05-31 23:29:36.201041
NCT01178606|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2013-08-27|2010-08-09|2010-08-10|Estimate|||||||2013-08-27|2013-08-28|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|February 2011|Actual|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Measurement of Echogenic Area in the Border of the Fetal Ventricles||Withdrawn|||0|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:29:36.253634|2018-05-31 23:29:36.253634
NCT01178593|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-12-11|2010-08-09|2010-08-10|Estimate|||||||2011-12-11|2011-12-13|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|July 2011|Actual|2011-07-31|September 2010|Actual|2010-09-30||Interventional|IBS||Group Hypnosis for Irritable Bowel Syndrome|GUT-FOCUSED GROUP HYPNOSIS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME - A RANDOMISED CONTROLLED TRIAL|Completed||N/A|100|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 23:29:36.311718|2018-05-31 23:29:36.311718
NCT01178580|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2011-09-05|2010-08-09|2010-08-10|Estimate|||||||2011-09-05|2011-09-07|Estimate|November 2010||2010-11-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Procoagulant Activity in Patients With Community Acquired Pneumonia, Pleural Effusion and Empyema|Procoagulant Activity in Patients With Community Acquired Pneumonia, Pleural Effusion and Empyema|Completed|||75|Actual|Meir Medical Center|||||f||||t||||||||||2018-05-31 23:29:36.377739|2018-05-31 23:29:36.377739
NCT01178567|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2013-05-06|2010-08-09|2010-08-10|Estimate|||||||2013-05-06|2013-05-07|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Comparison of Pulmonary Complications Related to Sleeve Gastrectomy and Gastric Banding|Comparison of Pulmonary Complications Related to Laparoscopic Sleeve Gastrectomy and Laparoscopic Adjustable Gastric Banding|Completed|||307|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:29:36.472297|2018-05-31 23:29:36.472297
NCT01178554|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2011-03-15|2010-08-09|2010-08-10|Estimate|||||||2011-03-15|2011-03-16|Estimate|June 2005||2005-06-30|March 2011|2011-03-31|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|CTP||The Clinic Treatment Project|Child System and Treatment Enhancement Projects (Child STEPs); The Clinic Treatment Project - Phase II|Completed||N/A|203|Actual|Judge Baker Children's Center||3|||f||||t||||||||||2018-05-31 23:29:36.525813|2018-05-31 23:29:36.525813
NCT01178541|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-08|||2013-02-18|2010-08-09|2010-08-10|Estimate|||||||2013-02-18|2013-02-20|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Simultaneous Measurement of Both Fetal's Lateral Ventricles of the Brain|Simultaneous Measurement of Both Fetal's Lateral Ventricles of the Brain|Completed|||400|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:29:36.640179|2018-05-31 23:29:36.640179
NCT01178528|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2013-09-19||2014-09-29|2010-08-09|2010-08-10|Estimate|2014-09-29|2014-09-30|Estimate||||2014-09-29|2014-09-30|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|CARVIVA-HF||Heart Rate Reduction in Heart Failure|Effect of Ivabradine, Carvedilol or Their Combination in Patients With Heart Failure|Completed||Phase 3|121|Actual|IRCCS San Raffaele||3|||f||||t||||||||||2018-05-31 23:29:36.751091|2018-05-31 23:29:36.751091
NCT01178515|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-06-24|2010-08-09|2010-08-10|Estimate|||||||2011-06-24|2011-06-27|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Low Fat Milk Intake and Cardio Vascular Risk (CVR) Indicators in Children|Impact of Low Fat Milk Intake on Cardiovascular Risk Indicators in Children 6-13 Years of Age|Completed||Phase 4|650|Actual|Instituto Nacional de Salud Publica, Mexico||3|||f||||t||||||||||2018-05-31 23:29:37.131995|2018-05-31 23:29:37.131995
NCT01178502|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-05-30|2010-08-09|2010-08-10|Estimate|||||||2013-05-30|2013-06-03|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||PGx Study to Develop and Validate the Predictive Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy|Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy in Korean Patients|Completed|||405|Actual|Inje University|||||f||||f||||||Samples With DNA|"~     Blood samples were taken from patients for genotyping about 8ml~   "|||2018-05-31 23:29:37.213272|2018-05-31 23:29:37.213272
NCT01178489|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2011-09-21|2010-08-09|2010-08-10|Estimate|||||||2011-09-21|2011-09-22|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Recovery at the Post Anaesthetic Care Unit After Hip and Knee Arthroplasty|Recovery at the Post Anaesthetic Care Unit After Fast-track Hip and Knee Arthroplasty|Completed|||170|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 23:29:37.262632|2018-05-31 23:29:37.262632
NCT01178476|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2014-03-07|2010-08-09|2010-08-10|Estimate|||||||2014-03-07|2014-03-10|Estimate|November 2009||2009-11-30|August 2010|2010-08-31|March 2011|Anticipated|2011-03-31|January 2010|Anticipated|2010-01-31||Interventional|||Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device|Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device|Withdrawn||N/A|0|Actual|UNEEG Medical A/S||2|||f||||t||||||||||2018-05-31 23:29:37.317168|2018-05-31 23:29:37.317168
NCT01178450|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2015-04-27|2010-08-09|2010-08-10|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation|A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation|Completed||Phase 4|30|Actual|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-05-31 23:29:37.425609|2018-05-31 23:29:37.425609
NCT01178437|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2011-03-07|2010-08-09|2010-08-10|Estimate|||||||2011-03-07|2011-03-08|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy|Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy - a Prospective Pilot Study Regarding Safety, Effectiveness and Clinical Performance|Completed||N/A|7|Actual|cerbomed GmbH|||||f||||f||||||||||2018-05-31 23:29:37.488816|2018-05-31 23:29:37.488816
NCT01178424|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2018-03-10|2010-08-09|2010-08-10|Estimate|||||||2018-03-10|2018-03-13|Actual|August 2010|Actual|2010-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|||My Depression Wellness Toolkit Study|My Depression Wellness Toolkit Study|Completed||N/A|166|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 23:29:37.543234|2018-05-31 23:29:37.543234
NCT01178411|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2018-01-31|2010-08-09|2010-08-10|Estimate|||||||2018-01-31|2018-02-02|Estimate|August 2010||2010-08-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols|An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols|Active, not recruiting||Phase 1/Phase 2|60|Actual|ArQule||1|||f||||f||||||||||2018-05-31 23:29:37.755742|2018-05-31 23:29:37.755742
NCT01178398|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Understanding Fish Consumption Habits During Pregnancy|A Qualitative Study of Fish Consumption During Pregnancy|Completed|||22|Actual|Harvard Pilgrim Health Care|||||f||||f||||||||||2018-05-31 23:29:37.83445|2018-05-31 23:29:37.83445
NCT01178385|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2012-12-12||2013-02-25|2010-08-07|2010-08-10|Estimate|2013-02-25|2013-04-02|Estimate||||2013-02-25|2013-04-02|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders|Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders|Completed||Phase 2/Phase 3|45|Actual|University of South Florida|"Modest sample size was modest.~Only ~75% of families in the treatment as usual arm had some form of active intervention.~Short follow-up interval that only included treatment responders in the CBT arm."|2|||f||||f||||||||||2018-05-31 23:29:37.920187|2018-05-31 23:29:37.920187
NCT01178372|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|September 2010|Anticipated|2010-09-30|||||Interventional|HE||Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis|Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy|Unknown status|Recruiting|Phase 4|||Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-05-31 23:29:38.295012|2018-05-31 23:29:38.295012
NCT01178359|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2017-05-16|2010-08-06|2010-08-10|Estimate|||||||2017-05-16|2017-05-18|Actual|January 2010||2010-01-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pilot Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients|Phase 1 Hospital Based Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients|Completed||Phase 1|11|Actual|University of Washington|||||f||||t||||||||||2018-05-31 23:29:38.36279|2018-05-31 23:29:38.36279
NCT01178346|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-05-08|2010-08-06|2010-08-10|Estimate|||||||2012-05-08|2012-05-09|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies|Health-Related Quality-of-Life and Health-Care Resource Utilization Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies|Completed||Phase 3|500|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 23:29:38.484781|2018-05-31 23:29:38.484781
NCT01178333|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2015-03-17||2015-05-06|2010-08-06|2010-08-10|Estimate|2015-04-16|2015-05-04|Estimate||||2015-05-06|2015-05-22|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|HIT-RADIO|Of 668 consecutive patients with a positive heparin-PF4 ELISA test, 225 were excluded, primarily due to lack of recent heparin exposure. Of 442 eligible patients, 71 had HIT-T, 284 had Isolated HIT and 87 had no HIT.|Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study|Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study (HIT-RADIO Study)|Completed|||668|Actual|New England Research Institutes|||||f||||t||||||||||2018-05-31 23:29:38.631584|2018-05-31 23:29:38.631584
NCT01178320|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2018-02-07|2010-08-06|2010-08-10|Estimate|||||||2018-02-07|2018-02-09|Actual|March 2008||2008-03-31|February 2018|2018-02-28|February 2015|Actual|2015-02-28|April 2013|Actual|2013-04-30||Observational|||Carotid Plaque Characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)|Carotid Plaque Characteristics by MRI in AIM-HIGH|Completed|||230|Actual|University of Washington|||2||f||||t||||||||||2018-05-31 23:29:40.630708|2018-05-31 23:29:40.630708
NCT01178307|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2018-02-20|2010-08-09|2010-08-10|Estimate|||||||2018-02-20|2018-02-22|Actual|July 2010|Actual|2010-07-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Symptom Inventory for Gastrointestinal Stromal Tumors|Symptom Burden in Patients With Gastrointestinal Stromal Tumors (GISTs)|Active, not recruiting|||188|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||||||2018-05-31 23:29:41.099648|2018-05-31 23:29:41.099648
NCT01178294|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2015-04-28|2014-09-09|2017-10-19|2010-08-09|2010-08-10|Estimate|2015-11-17|2015-12-21|Estimate|2014-09-17|2014-09-29|Estimate|2017-10-19|2017-10-23|Actual|November 2010||2010-11-30|November 2015|2015-11-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional||The baseline analysis population comprises all 29 treated subjects (=safety analysis set).|Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A|Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies|Completed||Phase 2/Phase 3|29|Actual|Shire|Due to the low number of subjects available for evaluation, statistical tests could only be performed for the primary outcome measure. The results of all other outcome measures are descriptive.|1|||f||||t||||||||||2018-05-31 23:29:41.258814|2018-05-31 23:29:41.258814
NCT01177592|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2014-03-18|2010-08-06|2010-08-09|Estimate|||||||2014-03-18|2014-03-19|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|TARGET-PCI||Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)|Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)|Terminated||N/A|7|Actual|LifeBridge Health||2||Lack of financial support|f||||f||||||||||2018-05-31 23:30:04.221378|2018-05-31 23:30:04.221378
NCT01178281|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2014-01-31||2018-03-01|2010-08-09|2010-08-10|Estimate|2014-01-31|2014-03-14|Estimate||||2018-03-01|2018-03-29|Actual|September 8, 2010|Actual|2010-09-08|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|January 1, 2013|Actual|2013-01-01||Interventional|RESUME|Intent to Treat (ITT) population included all randomized participants|Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence|A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell Transfusion Dependence|Active, not recruiting||Phase 3|252|Actual|Celgene||2|||f||||t||||||||||2018-05-31 23:29:42.106965|2018-05-31 23:29:42.106965
NCT01178268|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2016-05-17||2016-07-14|2010-08-06|2010-08-10|Estimate|2016-07-14|2016-08-24|Estimate||||2016-07-14|2016-08-24|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|October 2012|Actual|2012-10-31||Interventional||All of the 546 patients, 57 were excluded from the Per-protocol (PP) population, leaving a baseline population of 489 patients and a total of 488 patients (Based on angiographic follow-up) in the PP population for final analysis. In which 367 were randomized to receive XIENCE V EECSS and 121 to CYPHER SELECT Plus SECSS group.|XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)|XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)|Completed||Phase 4|546|Actual|Abbott Vascular||2|||f||||f||||||||||2018-05-31 23:29:42.985112|2018-05-31 23:29:42.985112
NCT01178255|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2012-07-09|2010-08-09|2010-08-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DEP-HOM||Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)|Homeopathy for Depression: a Randomized, Partially Double-blind, Placebo Controlled, Four Armed Study DEP-HOM|Terminated||Phase 3|44|Actual|Charite University, Berlin, Germany||4||recruitment difficulties|f||||t||||||||||2018-05-31 23:29:46.469643|2018-05-31 23:29:46.469643
NCT01178242|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2016-08-09|2010-08-09|2010-08-10|Estimate|||||||2016-08-09|2016-08-11|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome.|Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome.|Completed||N/A|19|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 23:29:46.547847|2018-05-31 23:29:46.547847
NCT01178229|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|January 2006||2006-01-31|July 2006|2006-07-31|November 2007||2007-11-30|June 2007|Actual|2007-06-30||Interventional|||Physiotherapy on the Airway of Bruxist Children|AWARNESS THROUGH MOVEMENT PHYSIOTERAPEUTIC TECHNIQUE INCREASED THE AIRWAY DIMENSIONS OF BRUXIST CHILDREN: A SINGLE BLIND RANDOMIZED CLINICAL TRIAL.|Completed||Phase 1/Phase 2|26|Actual|CES University||2|||f||||f||||||||||2018-05-31 23:29:46.61622|2018-05-31 23:29:46.61622
NCT01178216|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2017-12-22|2010-08-09|2010-08-10|Estimate|||||||2017-12-22|2017-12-27|Actual|September 2013||2013-09-30|December 2017|2017-12-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation|Use of Immune Globulin Intravenous (Human), 10% (IVIG), Plus Rituximab as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation|Completed||Phase 1/Phase 2|41|Actual|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 23:29:46.862204|2018-05-31 23:29:46.862204
NCT01178203|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||The Effects of Three Oral Medications on Post-operative Pain Following Endodontic Treatment||Completed||Phase 1/Phase 2|||Azad University of Medical Sciences|||||f||||t||||||||||2018-05-31 23:29:47.680906|2018-05-31 23:29:47.680906
NCT01178190|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-08-09|2010-08-09|2010-08-10|Estimate|||||||2010-08-09|2010-08-10|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|NBI||The Role of Narrow Band Imaging Videobronchoscopy in Lung Cancer|The Diagnostic Yield of Narrow Band Imaging Videobronchoscopy in Lung Cancer|Completed|||101|Actual|Asan Medical Center|||1||f||||t||||||||||2018-05-31 23:29:47.921052|2018-05-31 23:29:47.921052
NCT01178177|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-05-14|2010-08-09|2010-08-10|Estimate|||||||2013-05-14|2013-05-16|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Radiologic Features of Invasive Pulmonary Aspergillosis|Retrospective Analysis of Radiologic Features of Invasive Pulmonary Aspergillosis in Transplant Recipients and Neutropenic Patients.Transplant Recipients and Neutropenic Patients|Completed|||130|Actual|Asan Medical Center|||2||f||||t||||||||||2018-05-31 23:29:48.198524|2018-05-31 23:29:48.198524
NCT01178164|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2013-04-03|2010-08-09|2010-08-10|Estimate|||||||2013-04-03|2013-04-04|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|DOUFAB||Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains|Prevalence of Fabry's Disease in a Population of Patients With Chronic Pains|Completed||N/A|137|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 23:29:48.374132|2018-05-31 23:29:48.374132
NCT01178151|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2015-04-21|2010-08-09|2010-08-10|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|EVAMP||Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome|Pilot Study of Everolimus in the Treatment of Neoplasms in Patients With Peutz-Jeghers Syndrome|Withdrawn||Phase 2|0|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1||No patients|f||||t||||||||||2018-05-31 23:29:48.480618|2018-05-31 23:29:48.480618
NCT01178138|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2014-07-31||2016-11-09|2010-08-06|2010-08-09|Estimate|2014-09-05|2014-09-08|Estimate||||2016-11-09|2016-12-30|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MATMA|These participants are the only ones who entered the study proper, meaning these were the only ones who received any study medications.|Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin|Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin|Completed||Phase 2|24|Actual|University of Arkansas|24 enrolled, 3 started study (1 withdrew after 5 sessions, 1 after 3 sessions; both for personal reasons), 1 completed. Data were collected on sessions completed.|1|||f||||t||||||||||2018-05-31 23:29:48.630847|2018-05-31 23:29:48.630847
NCT01177787|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-08-05|2010-08-05|2010-08-09|Estimate|||||||2010-08-05|2010-08-09|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|||Clinical Efficacy of Cryolipolysis on the Fat of Thigh in Korean Women|Clinical Efficacy of Local Fat Reduction on the Thigh of Korean Women Through Cryolipolysis|Unknown status|Active, not recruiting|Phase 1/Phase 2|15|Anticipated|Wonik Trade Company, Korea||2|||f||||f||||||||||2018-05-31 23:29:59.98968|2018-05-31 23:29:59.98968
NCT01178125|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2013-10-18||2013-12-13|2010-08-06|2010-08-09|Estimate|2013-10-18|2013-12-11|Estimate||||2013-12-13|2014-01-16|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Safety Population|A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy|A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-102) for the Prevention of Pregnancy in Women|Completed||Phase 3|2858|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 23:29:49.397336|2018-05-31 23:29:49.397336
NCT01178112|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2015-11-16|2010-08-06|2010-08-09|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2010||2010-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Trientine and Carboplatin in Advanced Malignancies|Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies|Completed||Phase 1|56|Actual|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-05-31 23:29:50.363682|2018-05-31 23:29:50.363682
NCT01178099|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2012-01-12||2012-01-12|2010-08-06|2010-08-09|Estimate|2012-01-12|2012-02-15|Estimate||||2012-01-12|2012-02-15|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults|A Pharmacokinetic and Pharmacodynamic Assessment of Prasugrel in Healthy Adults and Adults With Sickle Cell Disease|Completed||Phase 1|26|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:29:50.572414|2018-05-31 23:29:50.572414
NCT01178086|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2016-11-01|2010-08-06|2010-08-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||An Observational Study on MabThera/Rituxan (Rituximab) in Patients With Chronic Lymphocytic Leukemia|Non-interventional Study on Rituximab in the Therapy of Chronic Lymphocytic Leukemia (CLL NIS)|Completed|||703|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:29:51.719153|2018-05-31 23:29:51.719153
NCT01178073|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2015-03-23||2017-08-14|2010-08-06|2010-08-09|Estimate|2015-04-09|2015-04-28|Estimate||||2017-08-14|2017-09-13|Actual|October 1, 2010||2010-10-01|August 2017|2017-08-31|July 31, 2014|Actual|2014-07-31|July 31, 2014|Actual|2014-07-31||Interventional|AMBITION||A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)|AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 3|610|Actual|GlaxoSmithKline||3|||f||||t||||||||||2018-05-31 23:29:51.932321|2018-05-31 23:29:51.932321
NCT01178060|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2010-08-20|2010-08-06|2010-08-09|Estimate|||||||2010-08-20|2010-08-23|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|RiskCom||The Effectiveness of Personalized Stroke Risk Communication|The Effectiveness of Personalized Stroke Risk Communication - A Pilot Randomized Controlled Trial|Completed||N/A|90|Actual|Durham VA Medical Center||2|||f||||f||||||||||2018-05-31 23:29:54.480425|2018-05-31 23:29:54.480425
NCT01178047|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2012-10-03|2010-08-06|2010-08-09|Estimate|||||||2012-10-03|2012-10-04|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Ras-PDS-1||Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease|A Multicenter, Randomized, Double-blind Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease (PD)|Terminated||Phase 4|1|Actual|University of Zurich||2||payments stopped by grant provider|f||||f||||||||||2018-05-31 23:29:54.663371|2018-05-31 23:29:54.663371
NCT01178034|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2012-10-21|2010-08-06|2010-08-09|Estimate|||||||2012-10-21|2012-10-23|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Early Identification of Warfarin Maintenance Dosage|Early Identification of Warfarin Maintenance Dose in Patients With Atrial Fibrillation: a Randomized Trial Evaluating a New Genotype-based Versus Usual Care Initiation of Treatment|Completed||Phase 3|180|Actual|University of Padova||1|||f||||t||||||||||2018-05-31 23:29:54.846586|2018-05-31 23:29:54.846586
NCT01178021|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2013-08-27|2010-08-06|2010-08-09|Estimate|||||||2013-08-27|2013-08-28|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|VRA||Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan|Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan|Unknown status|Recruiting|Phase 4|600|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 23:29:55.343989|2018-05-31 23:29:55.343989
NCT01178008|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-01|||2013-01-14|2010-08-06|2010-08-09|Estimate|||||||2013-01-14|2013-01-16|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Pilot Study on the Use of Acupuncture for Postpartum Depression|Pilot Study on the Use of Acupuncture for Postpartum Depression|Completed||N/A|20|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:29:55.713223|2018-05-31 23:29:55.713223
NCT01177995|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2013-08-21|2010-08-06|2010-08-09|Estimate|||||||2013-08-21|2013-08-23|Estimate|October 2008||2008-10-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|September 2011|Actual|2011-09-30||Interventional|||Russian Labor Migrant HIV Prevention Trial|Fostering an AIDS Research and Training Center Infrastructure in Russia (Labor Migrant HIV Prevention Trial)|Completed||Phase 2|207|Actual|Medical College of Wisconsin||1|||f||||f||||||||||2018-05-31 23:29:55.945449|2018-05-31 23:29:55.945449
NCT01177982|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2017-01-10|2010-08-06|2010-08-09|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|January 2014|Actual|2014-01-31||Interventional|HOME II||Reinforcement-Based Treatment for Pregnant Drug Abusers|Reinforcement-Based Treatment for Pregnant Drug Abusers|Completed||Phase 2/Phase 3|220|Actual|National Institute on Drug Abuse (NIDA)||8|||f||||f||||||||||2018-05-31 23:29:56.108681|2018-05-31 23:29:56.108681
NCT01177969|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2014-04-25||2014-06-27|2010-08-06|2010-08-09|Estimate|2014-06-27|2014-07-01|Estimate||||2014-06-27|2014-07-01|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents|CBT for Anxiety Disorders in Autism: Adapting Treatment for Adolescents|Completed||Phase 1/Phase 2|33|Actual|University of South Florida|Modest sample size Lack of objective measures of anxiety that go beyond diagnostic interview or checklist measures|2|||f||||t||||||||||2018-05-31 23:29:56.373497|2018-05-31 23:29:56.373497
NCT01177774|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-06-08|2010-08-06|2010-08-09|Estimate|||||||2017-06-08|2017-06-09|Actual|August 2010||2010-08-31|June 2017|2017-06-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Observational|NewTics||Assessment of Children With Tic Onset in the Past 6 Months|Predictive Biomarkers of Conversion to Tourette Syndrome in Children With New-Onset Tics|Recruiting|||100|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples With DNA|"~     saliva~   "|Yes|Beginning in June, 2017, all data other than PHI will follow the NIMH RDoC data sharing policy.|2018-05-31 23:30:00.106253|2018-05-31 23:30:00.106253
NCT01177956|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2012-07-03||2014-08-25|2010-08-06|2010-08-09|Estimate|2012-07-03|2012-08-10|Estimate||||2014-08-25|2014-09-03|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|November 2012|Actual|2012-11-30|January 2011|Actual|2011-01-31||Interventional|CHANGE|Intention to treat (ITT) population included all participants who received at least one dose of the investigational medicinal product (IMP) cetuximab or chemotherapy.|A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck|Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Asian Subjects|Completed||Phase 3|73|Actual|Merck KGaA||1|||f||||t||||||||||2018-05-31 23:29:56.856658|2018-05-31 23:29:56.856658
NCT01177943|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2011-09-20||2011-09-20|2010-08-06|2010-08-09|Estimate|2011-09-20|2011-10-27|Estimate||||2011-09-20|2011-10-27|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Bioequivalence (BE) Study in Healthy Subjects|LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects|Completed||Phase 1|42|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:29:57.354999|2018-05-31 23:29:57.354999
NCT01177930|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2011-06-21|2010-08-06|2010-08-09|Estimate|||||||2011-06-21|2011-06-22|Estimate|October 2009||2009-10-31|June 2011|2011-06-30||||May 2011|Actual|2011-05-31||Observational|||Evaluation of the Health Related Quality of Life and Disease Prevalence of Children From Spain at 6-8 Years of Age Who Participated in a Qualifying Infant Formula Study at Birth||Completed|||||Mead Johnson Nutrition|||2||f||||||||||||||2018-05-31 23:29:57.615801|2018-05-31 23:29:57.615801
NCT01177917|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2010-08-06|2010-08-06|2010-08-09|Estimate|||||||2010-08-06|2010-08-09|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Evaluation of Mineral Absorption in Infants Fed Infant Formula||Completed||N/A|||Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 23:29:57.676699|2018-05-31 23:29:57.676699
NCT01177904|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2011-03-16|2010-08-06|2010-08-09|Estimate|||||||2011-03-16|2011-03-17|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Early Progesterone Cessation After in Vitro Fertilization|Early Progesterone Cessation After in Vitro Fertilization|Completed||Phase 4|220|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 23:29:57.744747|2018-05-31 23:29:57.744747
NCT01177891|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2015-03-25|2010-08-06|2010-08-09|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|FAMIOP||Genetic Analysis of Familial Cases of Premature Ovarian Failure|Genetic Analysis of Familial Cases of Premature Ovarian Failure|Completed|||110|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples With DNA|"~     Blood Sample~   "|||2018-05-31 23:29:57.813373|2018-05-31 23:29:57.813373
NCT01177865|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2013-08-23|2010-08-06|2010-08-09|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2010||2010-09-30|November 2010|2010-11-30||||September 2012|Anticipated|2012-09-30||Interventional|||Study of Treatment Choice in Patients With Localized Prostate Cancer|Evaluating Patient Preferences for the Treatment of Localized Prostate Cancer - A Discrete Choice Experiment|Unknown status|Recruiting|N/A|432|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:29:57.883957|2018-05-31 23:29:57.883957
NCT01177852|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2016-10-18|2010-08-06|2010-08-09|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2011||2011-10-31|October 2016|2016-10-31||||April 2012|Anticipated|2012-04-30||Interventional|||Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis|Multicenter Clinical Trial, Phase III, Controlled, Open, Parallel Group, Randomized, Comparing the Fixed Dose Combination of Diphenhydramine + Dropropizine + Pseudoephedrine and the Combined Use of Dropropizine and Fixed Dose Combination of Pseudoephedrine Hydrochloride + Brompheniramine Maleate Used Orally for Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2 to 12 Years Old, Suffering From Non-productive Cough and Acute Rhinitis.|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f||||||||||2018-05-31 23:29:57.95282|2018-05-31 23:29:57.95282
NCT01177839|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2012-11-21|2010-08-06|2010-08-09|Estimate|||||||2012-11-21|2012-11-22|Estimate|May 2002||2002-05-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore|Prospective, Hospital-based, Multicentre Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore|Completed|||178|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 23:29:58.050007|2018-05-31 23:29:58.050007
NCT01177826|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2016-09-27|2010-08-06|2010-08-09|Estimate|||||||2016-09-27|2016-09-28|Estimate|February 2008||2008-02-29|September 2016|2016-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children|Case-control Study to Evaluate the Vaccine Effectiveness of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix™) Against Community-acquired Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 October 2006, in Belgium|Completed|||643|Actual|GlaxoSmithKline|||2||f||||||||||Samples Without DNA|"~     Stool samples~   "|Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:29:58.154687|2018-05-31 23:29:58.154687
NCT01177813|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2014-05-16||2014-05-16|2010-08-06|2010-08-09|Estimate|2014-05-16|2014-06-16|Estimate||||2014-05-16|2014-06-16|Estimate|July 2010||2010-07-31|May 2014|2014-05-31||||March 2012|Actual|2012-03-31||Interventional||Full analysis set (FAS) including all randomised and treated patients who had a baseline HbA1c value (non-open label groups) and Open-label set including all patients entered in the empagliflozin 25 mg open-label treatment arm.|Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 and Sitagliptin Administered Orally Over 24 Weeks, in Drug naïve Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Diet and Exercise|Completed||Phase 3|986|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 23:29:58.519495|2018-05-31 23:29:58.519495
NCT01177800|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2013-06-06||2014-09-04|2010-08-05|2010-08-09|Estimate|2014-02-17|2014-03-17|Estimate||||2014-09-04|2014-09-12|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Interventional|||A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Infliximab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis|Completed||Phase 3|129|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-05-31 23:29:59.525664|2018-05-31 23:29:59.525664
NCT01177761|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2017-10-24|2010-08-06|2010-08-09|Estimate|||||||2017-10-24|2017-10-26|Actual|October 1998||1998-10-31|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|EFOPS||16 Year Follow-up of the Erlangen Fitness and Prevention Study.|Effects of Exercise on Fracture Risk, Bone Mineral Density and Falls in Postmenopausal Women. A 16 Year Follow-up of the Erlangen Fitness and Prevention Study.|Active, not recruiting||N/A|50|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 23:30:00.212978|2018-05-31 23:30:00.212978
NCT01177748|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-03-30|2010-08-06|2010-08-09|Estimate|||||||2012-03-30|2012-04-02|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|SAMBA||Stroke Arrhythmia Monitoring Database||Completed|||501|Actual|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 23:30:00.295534|2018-05-31 23:30:00.295534
NCT01177735|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2014-11-25||2017-10-17|2010-08-06|2010-08-09|Estimate|2015-02-18|2015-03-04|Estimate||||2017-10-17|2017-11-20|Actual|October 2011||2011-10-31|October 2017|2017-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma|Phase II Trial of Pomalidomide in GEP-defined High-risk Multiple Myeloma That is Relapsing or Refractory to Prior Therapy|Completed||Phase 2|71|Actual|University of Arkansas||1|||f||||t||||||||||2018-05-31 23:30:00.36485|2018-05-31 23:30:00.36485
NCT01177722|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|2014-02-22||2014-04-03|2010-08-06|2010-08-09|Estimate|2014-04-03|2014-05-05|Estimate||||2014-04-03|2014-05-05|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants|Lot-to-Lot Consistency Study of DTaP-IPV-Hep B-PRP-T Vaccine Administered at 2-4-6 Months of Age in Healthy Latin American Infants Concomitantly With Prevenar™ and Rotarix™|Completed||Phase 3|1375|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 23:30:00.841547|2018-05-31 23:30:00.841547
NCT01177709|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2016-12-15||2017-08-02|2010-08-05|2010-08-09|Estimate|2016-12-15|2017-02-07|Estimate||||2017-08-02|2017-09-01|Actual|May 2008||2008-05-31|August 2017|2017-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Metformin for Weight Loss in Schizophrenia|Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication|Terminated||N/A|12|Actual|Nathan Kline Institute for Psychiatric Research|This is an open non-blinded study in a small number of subjects. However, it is unlikely that outcomes measures of weight, glucose, and insulin, would have been likely to be affected by non-blinding of subjects and investigators. .|1||PI moved to different institution. Decided to concentrate on different studies.|f||||f||||||||||2018-05-31 23:30:02.097607|2018-05-31 23:30:02.097607
NCT01177696|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2010-08-05|2010-08-05|2010-08-09|Estimate|||||||2010-08-05|2010-08-09|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|September 2010|Anticipated|2010-09-30|June 2009|Anticipated|2009-06-30||Interventional|IGFC||Intervention in Groups of Family Caregivers in Primary Health Care|VALIDATION OF AN INTERVENTION EFFECTIVE IN GROUPS OF FAMILY CAREGIVERS OF DEPENDENT PATIENTS FOR THEIR APPLICATION IN CENTRES OF PRIMARY HEALTH CARE.|Unknown status|Active, not recruiting|N/A|150|Anticipated|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||f||||||||||2018-05-31 23:30:02.817465|2018-05-31 23:30:02.817465
NCT01177683|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2018-02-20|2010-08-06|2010-08-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 2010||2010-07-31|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|January 2018|Actual|2018-01-31||Interventional|||Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma|A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141|Active, not recruiting||Phase 1/Phase 2|69|Anticipated|Hoosier Cancer Research Network||1|||f||||t||||||||||2018-05-31 23:30:03.082681|2018-05-31 23:30:03.082681
NCT01177670|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2012-09-18||2012-10-19|2010-08-06|2010-08-09|Estimate|2012-10-19|2012-11-20|Estimate||||2012-10-19|2012-11-20|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|||||Observational|APACS||Adiana Post-Approval Clinical Study (APACS)|Adiana Post-Approval Clinical Study|Terminated|||169|Actual|Hologic, Inc.|After determining Adiana was not financially viable and would not become so, Hologic decided to discontinue manufacturing & sales. Hologic decided to terminate the study. All subjects were notified of termination and withdrawn by April 30, 2012.|||Hologic made business decision to no longer sell or manufacture Adiana device.|f||||f||||||||||2018-05-31 23:30:03.37762|2018-05-31 23:30:03.37762
NCT01177657|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-11-15|2010-08-05|2010-08-09|Estimate|||||||2012-11-15|2012-11-19|Estimate|May 2008||2008-05-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in Brazil|Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalized Children Born After 6 March 2006 and at Least 12 Weeks of Age, in Belem, Brazil|Completed|||1944|Actual|GlaxoSmithKline|||3||f||||||||||Samples Without DNA|"~     Stool sample~   "|||2018-05-31 23:30:03.690088|2018-05-31 23:30:03.690088
NCT01177644|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-08-21|2010-08-05|2010-08-09|Estimate|||||||2012-08-21|2012-08-22|Estimate|January 2011||2011-01-31|August 2012|2012-08-31||||July 2011|Anticipated|2011-07-31||Interventional|||Safety and Preliminary Efficacy Study of PDS-1.0 in Patients With Neovascular AMD||Withdrawn||Phase 1|0|Actual|Forsight Vision4||1|||f||||||||||||||2018-05-31 23:30:03.823718|2018-05-31 23:30:03.823718
NCT01177631|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-02-04|2010-08-05|2010-08-09|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Proteomic Analysis of Human Hepatocellular Carcinoma|Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis|Completed||N/A|5|Actual|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-05-31 23:30:03.923456|2018-05-31 23:30:03.923456
NCT01177618|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2018-01-16|2010-08-06|2010-08-09|Estimate|||||||2018-01-16|2018-01-18|Actual|July 1994||1994-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study|Genetic Epidemiology of Severe, Early-Onset Chronic Obstructive Pulmonary Disease|Recruiting|||2000|Anticipated|Brigham and Women's Hospital|||2||f||||f||||||Samples With DNA|"~     DNA, Serum, Plasma, Buccal Brushings, and Urine~   "|Yes|For subjects approved for data sharing by our IRB, we will release genome sequencing data through dbGaP.|2018-05-31 23:30:04.037475|2018-05-31 23:30:04.037475
NCT01177605|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2011-08-31|2010-08-06|2010-08-09|Estimate|||||||2011-08-31|2011-09-02|Estimate|September 2006||2006-09-30|August 2011|2011-08-31||||March 2007|Actual|2007-03-31||Interventional|||Assessment of Efficacy and Tolerance of a Follow-On Milk Containing a Mixture of Prebiotics Fed to Young Children in Salvador, Bahia, Brazil||Completed||N/A|||Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 23:30:04.130213|2018-05-31 23:30:04.130213
NCT01177579|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-04-18|2010-08-05|2010-08-09|Estimate|||||||2017-04-18|2017-04-19|Actual|November 2010||2010-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Human Biomarkers for Assessing Copper Deficiency|Human Biomarkers for Assessing Copper Deficiency and Repletion: A Pilot Study|Recruiting||Phase 1|70|Anticipated|Purdue University||3|||f||||f||||||||||2018-05-31 23:30:04.44077|2018-05-31 23:30:04.44077
NCT01177566|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-05|2010-08-05|2010-08-09|Estimate|||||||2010-08-05|2010-08-09|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.|Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.|Completed||Phase 4|20|Actual|Emer, Jason, M.D.||2|||f||||t||||||||||2018-05-31 23:30:04.605035|2018-05-31 23:30:04.605035
NCT01177553|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2012-09-21||2013-02-20|2010-08-06|2010-08-09|Estimate|2012-11-14|2012-12-12|Estimate||||2013-02-20|2013-02-21|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery|Randomized Clinical Trial: Expectant Management vs. Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation And Absent or Reverse Diastolic Flow in the Umbilical Artery|Completed||N/A|5|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 23:30:04.770434|2018-05-31 23:30:04.770434
NCT01177540|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-10-21|2010-08-05|2010-08-09|Estimate|||||||2013-10-21|2013-10-22|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects|A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects|Completed||Phase 2|25|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:30:05.049603|2018-05-31 23:30:05.049603
NCT01177527|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-10-12|2010-08-06|2010-08-09|Estimate|||||||2017-10-12|2017-10-16|Actual|December 2009||2009-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders|Medical Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders|Recruiting|||1000|Anticipated|Dana-Farber Cancer Institute|||||f||||f||||||Samples With DNA|"~     Peripheral blood Bone marrow samples~   "|||2018-05-31 23:30:05.695817|2018-05-31 23:30:05.695817
NCT01177514|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-07-27|2010-08-05|2010-08-09|Estimate|||||||2015-07-27|2015-07-29|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy|The Role of Gabapentin in Postoperative Pain and Epithelialization After Photorefractive Keratectomy A Prospective, Randomized, Double Blinded, Placebo Controlled Study|Completed||Phase 4|40|Actual|Codet Vision Institute||2|||f||||t||||||||||2018-05-31 23:30:06.207731|2018-05-31 23:30:06.207731
NCT01177501|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-06|||2012-11-16|2010-08-06|2010-08-09|Estimate|||||||2012-11-16|2012-11-19|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ITOV04||Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma|Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months|Terminated||Phase 1|3|Actual|Assistance Publique - Hôpitaux de Paris||1||choice of the principal investigator|f||||t||||||||||2018-05-31 23:30:06.457805|2018-05-31 23:30:06.457805
NCT01177488|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-09-11|2010-08-05|2010-08-09|Estimate|||||||2015-09-11|2015-09-14|Estimate|March 2008||2008-03-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||Innovative Service Delivery for Secondary Prevention of PTSD|Innovative Service Delivery for Secondary Prevention of PTSD in At-Risk OIF-OEF Service Men and Women|Completed||N/A|280|Actual|Charleston Research Institute||2|||f||||f||||||||||2018-05-31 23:30:06.647614|2018-05-31 23:30:06.647614
NCT01177475|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-09-29|2010-08-06|2010-08-09|Estimate|||||||2015-09-29|2015-10-01|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Intake in Bioactive Molecules From Natural or Pasteurised Milk on Gut Maturation in Very Premature Newborns|Effect of Intake in Bioactive Molecules From Natural or Pasteurised Milk on Gut Maturation in Very Premature Newborns|Completed||N/A|55|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 23:30:07.092783|2018-05-31 23:30:07.092783
NCT01177462|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2013-09-23|2010-08-05|2010-08-09|Estimate|||||||2013-09-23|2013-09-25|Estimate|March 2011||2011-03-31|September 2013|2013-09-30||||December 2014|Anticipated|2014-12-31||Observational|||Transformation of Somatosensory and Visual Coordinate Systems|The Transformation of Coordinates Between Somatosensory and Visual Systems: a Neurophysiological Study|Unknown status|Recruiting||90|Anticipated|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-05-31 23:30:07.54173|2018-05-31 23:30:07.54173
NCT01177449|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-05|2010-08-05|2010-08-09|Estimate|||||||2010-08-05|2010-08-09|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|November 2008|Actual|2008-11-30||Interventional|||The Effect of Prolotherapy on Balance and Lumbar Flexibility in the Patients With a Sacralized L5 Vertebra|The Effect of Prolotherapy on Balance and Lumbar Flexibility in the Patients With a Sacralized L5 Vertebra|Completed||N/A|17|Actual|Chang Gung Memorial Hospital|||||f||||f||||||||||2018-05-31 23:30:07.637684|2018-05-31 23:30:07.637684
NCT01177436|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2014-08-28|2010-08-06|2010-08-09|Estimate|||||||2014-08-28|2014-08-29|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Prostate Cancer Antigen 3 (PCA-3) Gene Project|PCA-3 Gene Project|Completed||N/A|31|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 23:30:07.865476|2018-05-31 23:30:07.865476
NCT01177423|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2014-08-28|2010-08-06|2010-08-09|Estimate|||||||2014-08-28|2014-08-29|Estimate|October 2009||2009-10-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block|Efficiency Evaluation of Intradiploic Intra-osseus Anesthesia Versus Inferior Alveolar Nerve Block|Completed||N/A|37|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 23:30:08.218993|2018-05-31 23:30:08.218993
NCT01177085|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2018-03-30|2010-08-05|2010-08-06|Estimate|||||||2018-03-30|2018-04-03|Actual|May 2009||2009-05-31|March 2018|2018-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Substituting Mushrooms for Meat to Control Body Weight|Substituting Mushrooms for Meat: A Controlled Clinical Trial to Control Body Weight|Completed||N/A|100|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 23:30:21.238744|2018-05-31 23:30:21.238744
NCT01177410|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2012-08-21||2012-08-28|2010-08-06|2010-08-09|Estimate|2012-08-28|2012-09-27|Estimate||||2012-08-28|2012-09-27|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea|A Phase II, Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week Study to Assess the Efficacy and Safety of Mesalamine Granules 750 mg and 1,500 mg Capsules Administered Once Daily in the Treatment of Irritable Bowel Syndrome With Diarrhea|Completed||Phase 2|148|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||f||||||||||2018-05-31 23:30:08.395093|2018-05-31 23:30:08.395093
NCT01177397|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05||2017-11-13|2017-11-13|2010-08-06|2010-08-09|Estimate||||2017-11-13|2017-11-14|Actual|2017-11-13|2017-11-14|Actual|July 20, 2010|Actual|2010-07-20|November 2017|2017-11-30|December 9, 2016|Actual|2016-12-09|November 15, 2016|Actual|2016-11-15||Interventional|||Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma|A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Multiple Myeloma|Completed||Phase 1/Phase 2|173|Actual|Celgene||1|||f||||f||||||||||2018-05-31 23:30:08.932944|2018-05-31 23:30:08.932944
NCT01177384|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2014-03-10||2017-03-22|2010-08-06|2010-08-09|Estimate|2014-03-10|2014-04-28|Estimate||||2017-03-22|2017-04-18|Actual|January 25, 2011|Actual|2011-01-25|March 2017|2017-03-31|March 25, 2013|Actual|2013-03-25|March 25, 2013|Actual|2013-03-25||Interventional||All participants randomized population. The baseline characteristics module does not include the second sequential randomization of a participant in the placebo group. Data for the second sequential randomization were excluded from the efficacy and safety analyses.|Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)|A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Acarbose Monotherapy|Completed||Phase 3|380|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:30:09.064392|2018-05-31 23:30:09.064392
NCT01177371|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-05|2010-08-05|2010-08-09|Estimate|||||||2010-08-05|2010-08-09|Estimate|March 1988||1988-03-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2000|Actual|2000-02-29||Interventional|||High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma|High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma|Completed||Phase 2|13|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:30:09.598222|2018-05-31 23:30:09.598222
NCT01177358|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-09-15|2010-08-06|2010-08-09|Estimate|||||||2014-09-15|2014-09-16|Estimate|September 2011||2011-09-30|August 2010|2010-08-31|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|||Botox in the Healing of Surgical Wounds of the Neck|Botulinum Toxin A in the Healing of Surgical Wounds of the Neck: a Randomized, Prospective, Placebo-controlled Trial|Unknown status|Recruiting|Phase 2|100|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 23:30:09.919947|2018-05-31 23:30:09.919947
NCT01177345|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-09-03|2010-08-06|2010-08-09|Estimate|||||||2010-09-03|2010-09-06|Estimate|October 2010||2010-10-31|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Observational|||Burden of Cervical Cancer in Tanzania|Survey Assessment and Projection of the Social and Economic Burdens of Cervical Cancer in Tanzania|Unknown status|Not yet recruiting||105|Anticipated|Kilimanjaro Christian Medical Centre, Tanzania|||3||f||||t||||||||||2018-05-31 23:30:10.046723|2018-05-31 23:30:10.046723
NCT01177332|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2015-11-10|2010-08-06|2010-08-09|Estimate|||||||2015-11-10|2015-11-11|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Elevated Circulating FFA and Intrahepatic Lipid Content|Effects of Acute Elevation of Circulating Fatty Acids on Hepatic Lipid Accumulation and Metabolism in Healthy Overweight and Obese Men|Completed||N/A|34|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 23:30:10.135111|2018-05-31 23:30:10.135111
NCT01177319|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-06|2010-08-06|2010-08-09|Estimate|||||||2010-08-06|2010-08-09|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Glutathione (GSH) In The Treatment of Parkinson's Disease|Glutathione (GSH) In The Treatment of Parkinson's Disease|Completed||Phase 2|20|Actual|University of South Florida|||||f||||f||||||||||2018-05-31 23:30:10.218684|2018-05-31 23:30:10.218684
NCT01177306|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2014-07-25|2010-08-05|2010-08-09|Estimate|||||||2014-07-25|2014-07-28|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Inuniv and Working Memory|Phase 4 Study of the Effect of Extended Release Guanfacine on Working Memory in Children With ADHD|Completed||Phase 4|18|Actual|Schweickert, Lori A., M.D.||1|||f||||t||||||||||2018-05-31 23:30:10.301944|2018-05-31 23:30:10.301944
NCT01177293|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2011-06-28||2011-08-01|2010-08-05|2010-08-06|Estimate|2011-08-01|2011-08-30|Estimate||||2011-08-01|2011-08-30|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules|Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablets, Manufactured By Aurobindo Pharma Ltd., India To 10 Mg Amlodipine Besylate Capsules, Manufactured By Pfizer France Under Fasted Conditions|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:30:10.43568|2018-05-31 23:30:10.43568
NCT01177280|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-04-28|2010-08-05|2010-08-06|Estimate|||||||2012-04-28|2012-05-01|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes||Completed|||10000||NEMA Research, Inc.|||||f||||||||||||||2018-05-31 23:30:10.717662|2018-05-31 23:30:10.717662
NCT01177267|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-04-28|2010-08-05|2010-08-06|Estimate|||||||2012-04-28|2012-05-01|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions(DDI) Among Osteoarthritis Patients|Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Osteoarthritis Patients Taking Opioid Analgesics and Associated Economic Outcomes|Completed|||10000||NEMA Research, Inc.|||||f||||t||||||||||2018-05-31 23:30:10.805958|2018-05-31 23:30:10.805958
NCT01177254|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-04-28|2010-08-05|2010-08-06|Estimate|||||||2012-04-28|2012-05-01|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions|Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions|Completed|||10000|Actual|NEMA Research, Inc.|||||f||||||||||||||2018-05-31 23:30:10.953184|2018-05-31 23:30:10.953184
NCT01177241|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-04-28|2010-08-05|2010-08-06|Estimate|||||||2012-04-28|2012-05-01|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids|Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids|Completed|||10000|Actual|NEMA Research, Inc.|||2||f||||t||||||||||2018-05-31 23:30:11.003583|2018-05-31 23:30:11.003583
NCT01177228|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2014-06-19|2012-06-19|2014-06-19|2010-08-05|2010-08-06|Estimate|2014-06-19|2014-07-18|Estimate|2012-06-19|2012-06-29|Estimate|2014-06-19|2014-07-18|Estimate|May 2007||2007-05-31|June 2014|2014-06-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional||Baseline measures are reported for the Safety Analysis Set - all enrolled participants who received at least 1 dose of study treatment. One participant was randomized but not dosed and is not included in this population.|Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis|A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN0002 Following Multiple Intravenous Doses in Patients With Ulcerative Colitis|Completed||Phase 2|47|Actual|Millennium Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 23:30:11.067643|2018-05-31 23:30:11.067643
NCT01177215|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2013-05-05|2010-08-05|2010-08-06|Estimate|||||||2013-05-05|2013-05-07|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|AATD||Investigation of an Adaptive Treatment Algorithm for Post-op Thoracic Patients to Reduce the Length of Drainage|Implementation of an Adaptive Algorithm to Improve Chest Tube Therapy in Patients With Pulmonary Leaks Following Thoracic Surgery|Terminated|||39|Actual|Medela AG|||1|Interim analysis showed that the tested protocol did not improve treatment|f||||t||||||||||2018-05-31 23:30:15.117172|2018-05-31 23:30:15.117172
NCT01177202|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2016-07-22|2010-08-05|2010-08-06|Estimate|||||||2016-07-22|2016-07-26|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|October 2012|Actual|2012-10-31|May 2011|Actual|2011-05-31||Interventional|||Study of the Safety and Immunogenicity of H1N1 Vaccine|A Phase I Dose-Escalation Study to Investigate the Safety and Immunogenicity of the Fusion Protein Recombinant Influenza A (HAC1) Vaccine Derived From Influenza A/California/04/09 (H1N1) in Healthy Adults|Completed||Phase 1|80|Actual|Fraunhofer, Center for Molecular Biotechnology||8|||f||||f||||||||Undecided||2018-05-31 23:30:17.477241|2018-05-31 23:30:17.477241
NCT01177189|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-09-19|2010-08-05|2010-08-06|Estimate|||||||2017-09-19|2017-09-21|Actual|July 1, 2011|Actual|2011-07-01|September 2017|2017-09-30|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|||Oxidative Stress Links Aging, Activity, and Mobility Limitation|Oxidative Stress Links Aging, Activity and Mobility Limitation|Terminated||N/A|111|Actual|VA Office of Research and Development||2||Inadequate effect size.|f||||t|f|f|||f|||No||2018-05-31 23:30:18.235508|2018-05-31 23:30:18.235508
NCT01177176|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-09-16|2010-08-05|2010-08-06|Estimate|||||||2014-09-16|2014-09-18|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|Helping HAND||Smoking Interventions for Hospital Patients|Smoking Interventions for Hospital Patients: A Comparative Effectiveness Trial|Completed||N/A|397|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:30:18.753706|2018-05-31 23:30:18.753706
NCT01177163|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-05-27|2010-08-05|2010-08-06|Estimate|||||||2013-05-27|2013-05-29|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|March 2009|Actual|2009-03-31|||||Interventional|||A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Type-2 Diabetes Mellitus Subjects Not Optimally Controlled (A1C >=7.0%) on Fixed Doses of Insulin Therapy|Completed||Phase 1|29|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-05-31 23:30:19.207112|2018-05-31 23:30:19.207112
NCT01177150|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-10|2010-08-05|2010-08-06|Estimate|||||||2010-08-10|2010-08-11|Estimate|November 2006||2006-11-30|August 2010|2010-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers|A First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of JNJ 28431754 in Healthy Male Subjects|Completed||Phase 1|71|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 23:30:19.869939|2018-05-31 23:30:19.869939
NCT01177137|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-03-02|2010-08-05|2010-08-06|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2011|Actual|2011-07-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|TRTT||Tinnitus Retraining Therapy Trial|Tinnitus Retraining Therapy Trial|Completed||Phase 3|151|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||Yes|Requests for limited datasets may be made to the TRTT Data Coordinating Center|2018-05-31 23:30:19.985247|2018-05-31 23:30:19.985247
NCT01177124|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2014-02-25|2010-08-05|2010-08-06|Estimate|||||||2014-02-25|2014-02-27|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors|Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors|Completed||N/A|300|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 23:30:20.209293|2018-05-31 23:30:20.209293
NCT01177111|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2018-04-19|2010-08-05|2010-08-06|Estimate|||||||2018-04-19|2018-04-23|Actual|November 1, 2010|Actual|2010-11-01|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|January 31, 2017|Actual|2017-01-31||Interventional|NOMS||Impact of Sunflower Seed Oil Massage on Neonatal Mortality and Morbidity in Nepal|Impact of Sunflower Seed Oil Massage on Neonatal Mortality and Morbidity in Nepal|Completed||Phase 3|29260|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 23:30:20.402311|2018-05-31 23:30:20.402311
NCT01177098|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2013-02-07||2013-03-22|2010-08-05|2010-08-06|Estimate|2013-02-07|2013-03-12|Estimate||||2013-03-22|2013-03-29|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|561|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:30:20.553258|2018-05-31 23:30:20.553258
NCT01177072|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2013-05-01|2010-08-05|2010-08-06|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of Effectiveness of Mental Health Interventions Among Torture Survivors in Southern Iraq|Study of Effectiveness of Mental Health Interventions Among Torture Survivors in Southern Iraq|Completed||N/A|342|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||||2018-05-31 23:30:21.353801|2018-05-31 23:30:21.353801
NCT01177059|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2018-05-28|2010-08-05|2010-08-06|Estimate|||||||2018-05-28|2018-05-30|Actual|December 6, 2004|Actual|2004-12-06|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial|A Long Term Follow-up Protocol to Evaluate the Safety and Survival of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection|Completed||Phase 2|68|Actual|Janssen-Cilag Pty Ltd||1|||f||||f||f||||||||2018-05-31 23:30:21.450206|2018-05-31 23:30:21.450206
NCT01177046|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2016-04-13|2010-08-05|2010-08-06|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30||Observational|||Development of a Multi-attribute Health Index: to Measure the Quality of Labour Analgesia: The QLA Index|Development of a Multi-attribute Health Index to Measure the Quality of Labour Analgesia: Psychometric Development of a Quality of Neuraxial Labour Analgesia Scale|Recruiting|||60|Anticipated|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-05-31 23:30:21.57974|2018-05-31 23:30:21.57974
NCT01177033|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-05|2010-08-05|2010-08-06|Estimate|||||||2010-08-05|2010-08-06|Estimate|August 2010||2010-08-31|May 2010|2010-05-31|December 2014|Anticipated|2014-12-31|August 2012|Anticipated|2012-08-31||Observational|ABC||Angioplasty or Bypass Surgery in Intermittent Claudication|ABC-Trial - Angioplasty or Bypass Surgery in Intermittent Claudication:|Unknown status|Recruiting||470|Anticipated|Institut für Klinisch-Kardiovaskuläre Forschung GmbH|||2||f||||t||||||||||2018-05-31 23:30:21.662875|2018-05-31 23:30:21.662875
NCT01177020|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-08-05|2010-08-05|2010-08-06|Estimate|||||||2010-08-05|2010-08-06|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Observational|||The Role of Pro-angiogenic Immune Cells in Human Pregnancies||Unknown status|Recruiting||300|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-05-31 23:30:21.796111|2018-05-31 23:30:21.796111
NCT01177007|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2017-04-19||2017-07-24|2010-08-05|2010-08-06|Estimate|2017-07-24|2017-08-28|Actual||||2017-07-24|2017-08-28|Actual|September 2010||2010-09-30|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors|Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors|Completed||Phase 2|50|Actual|Yale University||1|||f||||t||||||||||2018-05-31 23:30:21.929472|2018-05-31 23:30:21.929472
NCT01176994|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-05|2010-08-05|2010-08-06|Estimate|||||||2010-08-05|2010-08-06|Estimate|December 2010||2010-12-31|July 2010|2010-07-31|May 2012|Anticipated|2012-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.|Safety of Formalin-free Fixatives for In-Vivo Fixation of Skin Lesions.|Unknown status|Not yet recruiting|Early Phase 1|200|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 23:30:22.469726|2018-05-31 23:30:22.469726
NCT01176981|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2017-04-26|2010-08-04|2010-08-06|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2010||2010-10-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma|Assessing the Safety, Feasibility, Cost Effectiveness and Patient Satisfaction of Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma|Completed||Phase 3|6|Actual|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 23:30:22.597806|2018-05-31 23:30:22.597806
NCT01176968|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2013-10-18||2016-07-01|2010-08-04|2010-08-06|Estimate|2016-07-01|2016-08-15|Estimate||||2016-07-01|2016-08-15|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|REMINDER||Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction|A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction|Completed||Phase 4|1012|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:30:22.767912|2018-05-31 23:30:22.767912
NCT01176955|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2011-07-01||2017-12-20|2010-08-05|2010-08-06|Estimate|2011-09-13|2011-10-21|Estimate||||2017-12-20|2018-01-19|Actual|May 2009||2009-05-31|January 2017|2017-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Novel Method to Improve Acne Outcomes|A Novel Method for Improving Acne Outcomes|Completed||N/A|20|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 23:30:25.101785|2018-05-31 23:30:25.101785
NCT01176942|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-12-08|2010-08-05|2010-08-06|Estimate|||||||2014-12-08|2014-12-09|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|PROMS-01||Probiotics and Endotoxemia|Probiotics and Endotoxemia in Humans|Completed||N/A|90|Actual|Danisco||2|||f||||||||||||||2018-05-31 23:30:26.256789|2018-05-31 23:30:26.256789
NCT01176929|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-04-10|2010-08-05|2010-08-06|Estimate|||||||2013-04-10|2013-04-11|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|OSTA||Randomized Controlled and Prospective Trial of a Cohort of People Who Made a Suicide Attempt|Effectiveness of Telephone Contact and Professional Coordination for Preventing Recurrent Suicidal Acts|Completed||N/A|320|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:30:26.371491|2018-05-31 23:30:26.371491
NCT01176916|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2018-05-16|2010-08-04|2010-08-06|Estimate|||||||2018-05-16|2018-05-17|Actual|February 9, 2011|Actual|2011-02-09|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China|A Prospective Pragmatic Clinical Trial Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin|Recruiting||Phase 4|550|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 23:30:26.549631|2018-05-31 23:30:26.549631
NCT01176903|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-03-28|2010-08-05|2010-08-06|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2010||2010-08-31|March 2017|2017-03-31|August 2011|Actual|2011-08-31|November 2010|Actual|2010-11-30||Interventional|GLY2||Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration|Randomized, Double-blind, Placebo-controlled, Cross-over Study to Investigate the Bronchodilator Efficacy and Safety After Single and Repeated Administrations of Different Doses of Glycopyrrolate Via pMDI in Moderate to Severe COPD Patients.|Completed||Phase 1/Phase 2|65|Actual|Chiesi Farmaceutici S.p.A.||11|||f||||f||||||||||2018-05-31 23:30:27.540322|2018-05-31 23:30:27.540322
NCT01176084|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-19|2010-08-04|2010-08-05|Estimate|||||||2010-08-19|2010-08-20|Estimate|January 2004||2004-01-31|July 2010|2010-07-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Low Carb Diets & Exercise for Cardiovascular Disease (CVD) Reduction|The Efficacy of a Low Carbohydrate Diet, With and Without Exercise, on Cardiovascular Disease Risk in Obese Men|Completed||N/A|56|Actual|University of Surrey||2|||f||||f||||||||||2018-05-31 23:30:43.941819|2018-05-31 23:30:43.941819
NCT01176890|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-12-06|2010-08-05|2010-08-06|Estimate|||||||2012-12-06|2012-12-07|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|August 2011|Actual|2011-08-31||Interventional|||Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects|The Significance of Intact Vagal Innervation for the GLP-1 Induced Inhibition of Gastric Emptying, Appetite and Food Intake|Unknown status|Active, not recruiting|N/A|30|Anticipated|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-05-31 23:30:27.667393|2018-05-31 23:30:27.667393
NCT01176877|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2012-08-29||2012-11-30|2010-08-04|2010-08-06|Estimate|2012-11-30|2013-01-03|Estimate||||2012-11-30|2013-01-03|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Assessing and Improving Patient Knowledge About Keloid Scars (Keloids)|Assessing and Improving Patient Knowledge About Keloids|Completed||N/A|40|Actual|Northwestern University|limitation of the study is the accrual of a majority of participants from keloid patients at a single academic center.|1|||f||||f||||||||||2018-05-31 23:30:27.796014|2018-05-31 23:30:27.796014
NCT01176864|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-08-05|2010-08-05|2010-08-06|Estimate|||||||2010-08-05|2010-08-06|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|DBE;SBE||Double- Versus Single-balloon Enteroscopy for Obscure Small-bowel Bleeding|Prospective Trial Comparing Push-and-Pull Enteroscopy With the Single- and Double-Balloon Techniques in Patients With Obscure Small-Bowel Bleeding|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-05-31 23:30:28.017473|2018-05-31 23:30:28.017473
NCT01176851|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-10-26|2010-08-05|2010-08-06|Estimate|||||||2010-10-26|2010-10-27|Estimate|July 2010||2010-07-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|Gly1||Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers|Pharmacokinetic, Randomized, Open-label, Single-dose, 3-way Cross-over Study of Intravenous and Inhaled Glycopyrrolate With or Without Charcoal Block Ingestion in Healthy Volunteers.|Completed||Phase 1|20|Anticipated|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 23:30:28.201715|2018-05-31 23:30:28.201715
NCT01176838|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-11-03|2010-08-05|2010-08-06|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2008||2008-11-30|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients|A Prospective Study on Newly Diagnosed Breast Cancer Patients: A 5 Year Follow Up on Quality of Life|Terminated|||20|Actual|Wake Forest University Health Sciences|||||f||||f|f|f||||||||2018-05-31 23:30:28.310564|2018-05-31 23:30:28.310564
NCT01176825|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-04-25|2010-08-05|2010-08-06|Estimate|||||||2012-04-25|2012-04-26|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Cognitive-Behavior Therapy for Young Adults With Bipolar Disorder|Reducing High-Risk Behaviors Among Bipolar Patients Transitioning to Adulthood|Completed||Phase 1|55|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:30:28.390928|2018-05-31 23:30:28.390928
NCT01176812|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-11-03|2010-08-05|2010-08-06|Estimate|||||||2017-11-03|2017-11-07|Actual|May 2009||2009-05-31|February 2011|2011-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Dermal Fillers Patient Satisfaction|Dermal Filling Agents: Patient Satisfaction|Withdrawn|||0|Actual|Wake Forest University Health Sciences|||1|Difficult to recruit subjects in the area.|f||||f||||||||||2018-05-31 23:30:28.498813|2018-05-31 23:30:28.498813
NCT01176799|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2016-06-21|2010-08-05|2010-08-06|Estimate|||||||2016-06-21|2016-06-22|Estimate|August 2010||2010-08-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor|Phase II Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor|Recruiting||Phase 2|73|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 23:30:28.571915|2018-05-31 23:30:28.571915
NCT01176786|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-11-03|2010-08-05|2010-08-06|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2009||2009-09-30|June 2017|2017-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Reusable Versus Disposable Draping System in Breast Reconstruction Surgery|The Effect of Reusable Versus Disposable Draping on Implant Based Breast Reconstruction Infection Rates: a Prospective Randomized Study|Completed||N/A|107|Actual|Wake Forest University Health Sciences|||||f||||f|f|f||||||||2018-05-31 23:30:28.717317|2018-05-31 23:30:28.717317
NCT01176773|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2012-06-07||2014-10-06|2010-08-05|2010-08-06|Estimate|2012-06-07|2012-07-12|Estimate||||2014-10-06|2014-10-13|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancement||Completed||N/A|62|Actual|Allergan||1|||f||||||||||||||2018-05-31 23:30:28.817688|2018-05-31 23:30:28.817688
NCT01176760|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-12-06|2010-08-05|2010-08-06|Estimate|||||||2012-12-06|2012-12-07|Estimate|August 2009||2009-08-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects|The Significances of Intact Vagal Innervation for the Glucose and GLP1 Induced Insulin Secretion|Unknown status|Active, not recruiting|N/A|30|Anticipated|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-05-31 23:30:29.226465|2018-05-31 23:30:29.226465
NCT01176747|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-03-28|2010-08-05|2010-08-06|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2010||2010-08-31|March 2017|2017-03-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients|In-vivo Deposition Measurement of Beclometasone and Formoterol After Inhalation of a Single Dose of the Combination BDP Plus Formoterol NEXT DPI in Healthy Volunteers, Asthmatic and COPD Patients.|Completed||Phase 1/Phase 2|28|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 23:30:29.468922|2018-05-31 23:30:29.468922
NCT01176734|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-04-29|2010-08-05|2010-08-06|Estimate|||||||2013-04-29|2013-04-30|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|||The Treatment of Tinnitus With Transcutaneous Non-invasive Vagus Nerve Stimulation|The Treatment of Tinnitus With Transcutaneous Non-invasive Vagus Nerve stimulation-a Controlled Randomized Pilot Study Assessing Safety, Compatibility and Clinical Performance|Completed||N/A|50|Actual|cerbomed GmbH||1|||f||||f||||||||||2018-05-31 23:30:29.614864|2018-05-31 23:30:29.614864
NCT01176721|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-09-11|2010-08-05|2010-08-06|Estimate|||||||2012-09-11|2012-09-12|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|02VNS2009||Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia|Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia: a Randomized, Controlled, Double Blind, Two-armed Clinical Trial|Completed||Phase 2|20|Actual|cerbomed GmbH||2|||f||||t||||||||||2018-05-31 23:30:29.734791|2018-05-31 23:30:29.734791
NCT01176708|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-01-05|2010-08-05|2010-08-06|Estimate|||||||2012-01-05|2012-01-06|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion|The Significance of Intact Liver Innervation for the Glucose and GLP-1 Induced Insulin Secretion|Unknown status|Recruiting|N/A|30|Anticipated|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-05-31 23:30:29.964473|2018-05-31 23:30:29.964473
NCT01176695|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2012-01-09|2010-08-05|2010-08-06|Estimate|||||||2012-01-09|2012-01-10|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of a Fish Oil Containing Lipid Emulsion|A Randomized, Double Blind, Controlled, Parallel Group, Multicenter Study on the Efficacy and Safety of a Fish Oil Containing Lipid Emulsion vs. a Medium and Long Chain Lipid Emulsion in Patients Undergoing Elective Abdominal Surgery of Moderate Severity|Completed||Phase 3|240|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-05-31 23:30:30.158068|2018-05-31 23:30:30.158068
NCT01176682|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2012-06-05|2010-08-05|2010-08-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|EVIDENCE||Observational Study on Non-steroid Anti-inflammatory Drugs (NSAIDs) Treated Patients With Arthritic Disorder|European Real Life Study on NSAIDs Treated Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS): Assessment of Pain Relieve, Gastrointestinal (GI) Symptoms, Adherence and Health Resource Consumption|Completed|||1149|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:30:30.418399|2018-05-31 23:30:30.418399
NCT01176669|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2015-09-08|2010-08-05|2010-08-06|Estimate|||||||2015-09-08|2015-09-09|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients|A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Metastatic Triple-Negative Breast Cancer|Completed||Phase 2|60|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 23:30:30.90777|2018-05-31 23:30:30.90777
NCT01176656|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2011-09-12|2010-08-05|2010-08-06|Estimate|||||||2011-09-12|2011-09-13|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Hypoglycemia: Physician and Patient Perspectives|Hypoglycemia: Physician and Patient Perspectives|Completed|||800|Actual|AstraZeneca|||3||f||||f||||||||||2018-05-31 23:30:31.100649|2018-05-31 23:30:31.100649
NCT01176643|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2013-09-23|2010-08-04|2010-08-06|Estimate|||||||2013-09-23|2013-09-24|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|May 2012|Actual|2012-05-31||Interventional|||Development and Evaluation of Modified Yoga in Systemic Lupus Erythematosus (SLE)|Development and Evaluation of an Adapted Yoga Program as Adjunct Therapy for Persons With Systemic Lupus Erythematosus (SLE): a Pilot Study|Completed||N/A|57|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:30:31.194438|2018-05-31 23:30:31.194438
NCT01176630|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2012-02-24|2010-08-04|2010-08-06|Estimate|||||||2012-02-24|2012-02-27|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population|Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population|Completed|||108|Actual|Winthrop University Hospital|||||f||||f||||||||||2018-05-31 23:30:31.283148|2018-05-31 23:30:31.283148
NCT01176617|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2017-04-19||2018-04-03|2010-08-04|2010-08-06|Estimate|2018-04-03|2018-04-05|Actual||||2018-04-03|2018-04-05|Actual|June 2012||2012-06-30|April 2018|2018-04-30|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|ABACUS||Assessing Arrhythmias After Ablation Using Implantable Recorders|Assessment of Arrhythmia Burden in Patients Undergoing Atrial Fibrillation Using an Implantable Loop Recorder (ILR) Versus Conventional Monitoring Strategy|Completed||N/A|44|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:30:31.385251|2018-05-31 23:30:31.385251
NCT01176604|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2018-03-06|2010-08-05|2010-08-06|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2010|Actual|2010-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Humanitarian Device Exemption (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular Carcinoma|Protocol For Use of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma|Recruiting||N/A|200|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|t|f|||||||2018-05-31 23:30:31.978515|2018-05-31 23:30:31.978515
NCT01176591|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2014-04-02|2010-08-05|2010-08-06|Estimate|||||||2014-04-02|2014-04-03|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||HBPL Study of the Impact of the NK1 Antagonist Aprepitant|Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (Emend®) on Stress-Induced Cocaine and Alcohol Craving|Terminated||Phase 2|12|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 23:30:32.085483|2018-05-31 23:30:32.085483
NCT01176578|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-05-01|2010-08-05|2010-08-06|Estimate|||||||2017-05-01|2017-05-02|Actual|July 2011||2011-07-31|May 2017|2017-05-31||||September 2018|Anticipated|2018-09-30||Interventional|EPC-DM||Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes|Exercise Training, CACs, and Vascular Function in Older Veterans With IGT (Impaired Glucose Tolerance)|Recruiting||N/A|70|Anticipated|Baltimore VA Medical Center||3|||f||||t||||||||||2018-05-31 23:30:32.219908|2018-05-31 23:30:32.219908
NCT01176565|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2017-01-01||2017-03-13|2010-08-04|2010-08-06|Estimate|2017-03-13|2017-04-25|Actual||||2017-03-13|2017-04-25|Actual|May 15, 2011|Actual|2011-05-15|March 2017|2017-03-31|March 8, 2016|Actual|2016-03-08|December 21, 2015|Actual|2015-12-21||Interventional|ATACH-II|Subjects were randomized to standard vs. intensive SBP control. Below-range SBP was not artifically elevated in the standard SBP reduction arm; euvolemic fluid balance was maintained but spontaneous recovery was not prevented. For below-range SBP in the intensive SBP control arm, nicardipine was discontinued and if needed IV fluid bolus was given.|Antihypertensive Treatment of Acute Cerebral Hemorrhage-II|Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage|Terminated||Phase 3|1000|Actual|University of Minnesota - Clinical and Translational Science Institute|Treatment failures, randomization window, demographics, pre-randomization treatment, low death/disability, favorable baselines, and early termination could limit generalizability of primary (all with intent-to-treat) results and some sub-analyses.|2||Planned interim analysis: no significant outcome differences between groups|f||||t||||||||Yes|A public use data set from the study database will be made available. A process for sharing subject head imaging studies that may be associated with the data set is under evaluation.|2018-05-31 23:30:32.43724|2018-05-31 23:30:32.43724
NCT01173354|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-09-07|2010-07-30|2010-08-02|Estimate|||||||2017-09-07|2017-09-08|Actual|January 2009||2009-01-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2014|Actual|2014-06-30||Interventional|||EAA Intake to Optimize Protein Anabolism in COPD|Essential Amino Acid Intake to Optimize Protein Anabolism in Elderly COPD Patients|Active, not recruiting||N/A|34|Actual|Texas A&M University||1|||f||||f||||||||||2018-05-31 23:31:56.942604|2018-05-31 23:31:56.942604
NCT01176552|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-08-22|2010-08-05|2010-08-06|Estimate|||||||2010-08-22|2010-08-24|Estimate|May 2004||2004-05-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|September 2008|Actual|2008-09-30||Interventional|||Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer|Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma|Completed||Phase 2|35|Anticipated|Kidney Cancer Research Bureau||1|||f||||t||||||||||2018-05-31 23:30:34.978596|2018-05-31 23:30:34.978596
NCT01176539|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2011-06-06|2010-08-04|2010-08-06|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|||||Observational|||Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitor|How Does the New Kai R Spot 100 Respiratory Monitor Compare to the Currently Used Respiratory Monitor for Measuring Respiratory Rate During Overnight Sleep Studies?|Completed|||50|Actual|Kai Medical, Inc.|||1||f||||f||||||||||2018-05-31 23:30:35.219268|2018-05-31 23:30:35.219268
NCT01176526|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2018-05-24|2010-08-05|2010-08-06|Estimate|||||||2018-05-24|2018-05-25|Actual|July 19, 2010||2010-07-19|January 27, 2016|2016-01-27|January 27, 2016||2016-01-27|||||Observational|||The Role of Social Comparisons in Coping and Quality of Life Following a Prostate Cancer Diagnosis|The Role of Social Comparisons in Coping and Quality of Life Following a Prostate Cancer Diagnosis|Completed|||196|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:30:35.403151|2018-05-31 23:30:35.403151
NCT01176513|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|2013-09-20||2014-01-21|2010-08-05|2010-08-06|Estimate|2013-09-20|2013-11-21|Estimate||||2014-01-21|2014-02-14|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||25 subjects were enrolled in the study and 3 subjects withdrew prior to dosing with the product. As a result, 22 subjects were used in the analysis.|GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer|GE148-002: A Phase 2, Open-label, Single-Center, Study to Assess GE-148 (18F) Injection Positron Emission Tomography(PET) Imaging to Detect Localized Prostate Cancer|Terminated||Phase 2|25|Actual|GE Healthcare||1||Lack of Subject enrollment|f||||f||||||||||2018-05-31 23:30:35.608773|2018-05-31 23:30:35.608773
NCT01176500|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2017-06-30|2010-08-05|2010-08-06|Estimate|||||||2017-06-30|2017-07-02|Actual|July 28, 2010||2010-07-28|November 18, 2011|2011-11-18|November 18, 2011|Actual|2011-11-18|November 18, 2011|Actual|2011-11-18||Interventional|||A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors|A Pilot, Open-Label, Proof-of-Concept Study of the Use of [18F]Fluciclatide PET/CT Imaging in the Evaluation of Anti-Angiogenic Therapy in Solid Tumors|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:30:35.940182|2018-05-31 23:30:35.940182
NCT01176487|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2016-03-30|2010-08-05|2010-08-06|Estimate|||||||2016-03-30|2016-03-31|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2013|Actual|2013-12-31||Interventional|||Palliative 3-Dimensional Conformal Radiation Therapy in Reducing Radiation Side Effects in Patients With Lung Cancer. ICORG 06-34|A Clinical Trial Using 3-Dimensional Conformal Radiation Therapy to Reduce the Toxicity of Palliative Radiation for Lung Cancer|Completed||N/A|40|Anticipated|Cancer Trials Ireland||1|||f||||||||||||||2018-05-31 23:30:36.068878|2018-05-31 23:30:36.068878
NCT01176474|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2018-02-14|2010-08-05|2010-08-06|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 28, 2010|Actual|2010-07-28|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma|A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma|Active, not recruiting||Phase 1|73|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 23:30:36.324779|2018-05-31 23:30:36.324779
NCT01176461|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2018-02-26|2010-08-05|2010-08-06|Estimate|||||||2018-02-26|2018-02-27|Actual|August 4, 2010||2010-08-04|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 12, 2016|Actual|2016-12-12||Interventional|||Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558|A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma|Active, not recruiting||Phase 1|127|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 23:30:36.522794|2018-05-31 23:30:36.522794
NCT01176448|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2011-11-09||2013-06-25|2010-08-04|2010-08-06|Estimate|2013-06-25|2013-06-27|Estimate||||2013-06-25|2013-06-27|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional||12 long scars were recruited for individual study. Only 6 patients were needed as each patient had two separate scars to be studied. Each scar was divided in half, and the halves randomized to fractionated laser resurfacing or dermabrasion.|Laser Resurfacing Versus Dermabrasion for Scar Revision|A Comparison Evaluation of Fractional Laser Therapy and Dermabrasion for Scar Revision|Completed||N/A|6|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 23:30:36.741232|2018-05-31 23:30:36.741232
NCT01176435|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|2016-06-22||2018-04-30|2010-08-04|2010-08-06|Estimate|2018-04-30|2018-05-02|Actual||||2018-04-30|2018-05-02|Actual|September 2010||2010-09-30|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Trial of L-DOPA as a Treatment to Improve Vision in Albinism|Clinical Trial to Evaluate Levodopa as Treatment to Improve Vision in Individuals With Albinism|Completed||Phase 2|45|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 23:30:37.091162|2018-05-31 23:30:37.091162
NCT01176422|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2017-01-06|2010-08-04|2010-08-06|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Telomere and Telomerase|Telomere and Telomerase|Withdrawn|||0|Actual|University of Kansas Medical Center|||1|lack of resources; no patient enrollment|f||||f||||||Samples With DNA|"~     Two teaspoons of blood will be collected - one teaspoon before subject begins treatment for~     disease and one teaspoon will be collected when subject completes treatment.~   "|||2018-05-31 23:30:37.555447|2018-05-31 23:30:37.555447
NCT01176409|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2016-05-10|2010-08-04|2010-08-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|VALIANT Pilot||Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2?|VALacyclovir for Inflammation AttenuatioN Trial Pilot (VALIANT Pilot)|Completed||Phase 3|60|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-05-31 23:30:37.754567|2018-05-31 23:30:37.754567
NCT01176396|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2017-05-08|2010-08-05|2010-08-06|Estimate|||||||2017-05-08|2017-05-10|Actual|April 2012|Actual|2012-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|January 2017|Actual|2017-01-31||Interventional|CAMBRA-PBRN||CAMBRA - PBRN Caries Management By Risk Assessment In A Practice-Based Research Network|CAMBRA - PBRN Caries Management By Risk Assessment In A Practice-Based Research Network|Completed||N/A|460|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:30:37.960567|2018-05-31 23:30:37.960567
NCT01176383|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-05-13|2010-08-05|2010-08-06|Estimate|||||||2014-05-13|2014-05-14|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers|"A Protocol for an Randomised Controlled Trial of Smoking Cessation Success Rate With or Without a Genetic Test, Respiragene, to Assess Lung Cancer Risk - an Exploratory Study"|Completed||N/A|67|Actual|Sussex NHS Research Consortium||2|||f||||t||||||||||2018-05-31 23:30:38.255274|2018-05-31 23:30:38.255274
NCT01176370|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2015-03-31|2010-08-05|2010-08-06|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|March 2015|Anticipated|2015-03-31||Interventional|||The Purpose of the Study is to Evaluate Whether the Use of C-Pulse™ as Treatment for Patients in Moderate to Severe Heart Failure (HF) is Associated With Reasonable Assurance of Safety and Performance|A Prospective Study to Assess the Safety and Indications of Performance of the C-Pulse™ System in Relieving Heart Failure Symptoms in Patients With ACC/AHA Stage C, NYHA Class III-ambulatory Class IV Heart Failure.|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Sunshine Heart Inc.||1|||f||||t||||||||||2018-05-31 23:30:38.710026|2018-05-31 23:30:38.710026
NCT01176357|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-08-04|2010-08-04|2010-08-06|Estimate|||||||2010-08-04|2010-08-06|Estimate|January 2008||2008-01-31|August 2010|2010-08-31||||December 2008|Anticipated|2008-12-31||Observational|||Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues|Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues Between Patients With Coronary Artery Diseases and With Valvular Diseases|Unknown status|Recruiting||60|Anticipated|Far Eastern Memorial Hospital|||2||f||||t||||||Samples Without DNA|"~     Adipose tissue biopsy samples from mediastinal fat, epicardial fat, subcutaneous fat in~     thoracic region or abdominal region and subcutaneous fat in leg were obtained soon after~     sternotomy or thoracotomy before the initiation of cardiopulmonary bypass.~   "|||2018-05-31 23:30:38.897586|2018-05-31 23:30:38.897586
NCT01176344|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2015-09-07|2010-08-05|2010-08-06|Estimate|||||||2015-09-07|2015-09-09|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|VIDEO||VItamin D Effect on Osteoarthritis Study|Does Vitamin D Supplementation Prevent Progression of Knee Osteoarthritis? A Randomised Controlled Trial|Completed||Phase 3|413|Actual|Menzies Institute for Medical Research||2|||f||||f||||||||||2018-05-31 23:30:39.012978|2018-05-31 23:30:39.012978
NCT01176331|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2010-08-05|2010-08-05|2010-08-06|Estimate|||||||2010-08-05|2010-08-06|Estimate||||July 2010|2010-07-31||||||||Observational|||Outcomes of 20 and 23-gauge Combined Transconjunctival Pars Plana Vitrectomy|Outcomes of 20 and 23-gauge Combined Transconjunctival Pars Plana Vitrectomy|Completed|||||Kocaeli University|||1||f||||||||||||||2018-05-31 23:30:39.103839|2018-05-31 23:30:39.103839
NCT01176318|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2012-01-09|2010-08-05|2010-08-06|Estimate|||||||2012-01-09|2012-01-10|Estimate||||July 2010|2010-07-31||||||||Interventional|||Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|A Double Blind, Placebo Controlled Multicentre Study of the Effects of Standard Care Plus Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|Withdrawn||Phase 4|0|Actual|Hull and East Yorkshire Hospitals NHS Trust||2||pharmaceutical grant was withdrawn, thus no financial support to conduct the study.|f||||f||||||||||2018-05-31 23:30:39.163162|2018-05-31 23:30:39.163162
NCT01176305|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2010-08-05|2010-08-05|2010-08-06|Estimate|||||||2010-08-05|2010-08-06|Estimate||||October 2009|2009-10-31||||||||Observational|||Venous Thromboembolism in Pregnant and Puerperal Women in Denmark 1995-2005|Venous Thromboembolism in Pregnant and Puerperal Women in Denmark 1995-2005|Completed|||||Hillerod Hospital, Denmark|||1||f||||t||||||||||2018-05-31 23:30:39.251899|2018-05-31 23:30:39.251899
NCT01176292|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2013-07-23||2015-07-31|2010-08-05|2010-08-06|Estimate|2015-07-31|2015-08-31|Estimate||||2015-07-31|2015-08-31|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Comparison of High Flex and Standard Rotating Platform Total Knee Arthroplasty (TKA)|A Prospective Comparison of Rotating Platform Cruciate Substituting Total Knee Arthroplasty With Rotating Platform High-Flex Cruciate Substituting Total Knee Arthroplasty|Completed||N/A|142|Actual|Anderson Orthopaedic Research Institute||2|||f||||f||||||||||2018-05-31 23:30:39.314635|2018-05-31 23:30:39.314635
NCT01176279|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-05|2010-08-05|2010-08-06|Estimate|||||||2010-08-05|2010-08-06|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|CAT-GLIC||Arterial Catheter to Monitor Glycemia|Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels|Unknown status|Recruiting|Phase 4|100|Anticipated|Consorci Hospitalari de Vic||2|||f||||t||||||||||2018-05-31 23:30:39.845751|2018-05-31 23:30:39.845751
NCT01176266|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2017-10-03||2018-01-26|2010-08-04|2010-08-05|Estimate|2018-01-26|2018-02-26|Actual||||2018-01-26|2018-02-26|Actual|July 2010||2010-07-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Full Analysis Set (defined as all patients who received any asfotase alfa treatment)|Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)|An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)|Completed||Phase 2/Phase 3|69|Actual|Alexion Pharma GmbH||1|||f||||t|t|f||||||||2018-05-31 23:30:39.998641|2018-05-31 23:30:39.998641
NCT01176253|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2015-04-29|2010-08-04|2010-08-05|Estimate|||||||2015-04-29|2015-05-01|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)|Detection of Human Beta Cell Death in T1DM by Methylation Specific PCR|Completed|||6|Actual|City of Hope Medical Center|||2||f||||t||||||||||2018-05-31 23:30:40.949651|2018-05-31 23:30:40.949651
NCT01176071|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-04|2010-08-04|2010-08-05|Estimate|||||||2010-08-04|2010-08-05|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Observational|||Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis|An Observational Assessment of the Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome in the Setting of Invasive Aspergillosis in Patients With an Underlying Hematological Disorder|Unknown status|Active, not recruiting||50|Anticipated|University Hospital, Gasthuisberg|||||f||||f||||||||||2018-05-31 23:30:44.058963|2018-05-31 23:30:44.058963
NCT01176240|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2014-03-18|2013-03-27|2014-04-22|2010-08-04|2010-08-05|Estimate|2014-04-22|2014-05-20|Estimate|2013-03-27|2013-04-04|Estimate|2014-04-22|2014-05-20|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|306A/306B|"The population only includes those patients who were randomized and took at least one dose of study drug (n=222).~The first 51 patients enrolled in the study were analyzed as a separate group in an interim analysis (Study 306A).~The final 171 patients remained blinded until the end of the study and analyzed as a separate study (Study 306B)."|A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease|A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease|Completed||Phase 3|225|Actual|Chelsea Therapeutics||2|||f||||t||||||||||2018-05-31 23:30:41.194356|2018-05-31 23:30:41.194356
NCT01176227|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2011-03-31|2010-08-04|2010-08-05|Estimate|||||||2011-03-31|2011-04-01|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)|The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Irritable Bowel Syndrome (IBS)|Completed||Phase 1/Phase 2|128|Anticipated|The Canadian College of Naturopathic Medicine||2|||f||||t||||||||||2018-05-31 23:30:42.342618|2018-05-31 23:30:42.342618
NCT01176214|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2014-04-25|2010-08-04|2010-08-05|Estimate|||||||2014-04-25|2014-04-28|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|WEANING||"WEANING-Study: Weaning by Early Versus lAte Tracheostomy iN supratentorIal iNtracerebral Bleedings"|Weaning by Early Versus lAte Tracheostomy iN supratentorIal iNtracerebral Bleedings|Terminated||Phase 2|7|Actual|University of Erlangen-Nürnberg Medical School||2||slow recruitment of patients|f||||f||||||||||2018-05-31 23:30:42.463648|2018-05-31 23:30:42.463648
NCT01176201|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2011-08-25|2010-08-04|2010-08-05|Estimate|||||||2011-08-25|2011-08-26|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man|An Open-Label Study to Determine ADME of 14C Labeled SLV337 After a Single Dose of an Oral Suspension|Completed||Phase 1|12|Actual|Abbott||2|||f||||f||||||||||2018-05-31 23:30:42.583976|2018-05-31 23:30:42.583976
NCT01176188|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2015-09-23|2010-08-04|2010-08-05|Estimate|||||||2015-09-23|2015-09-25|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||A Nursing Intervention to Enhance Child Comfort and Psychological Well-Being During and Following PICU Hospitalization|A Nursing Intervention to Enhance Comfort and Promote Psychological Well-Being in Children During and Following PICU Hospitalization: A Pilot Study|Completed||Phase 1|20|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:30:42.756918|2018-05-31 23:30:42.756918
NCT01176175|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2011-10-12|2010-08-04|2010-08-05|Estimate|||||||2011-10-12|2011-10-13|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Progesterone Microspheres Pharmacokinetic - Pharmacodynamic (PK-PD) Study|Randomized, Controlled, Open-label, Parallel, Clinical Trial to Assess Pharmacokinetics and Endometrial Effect of an Injectable Formulation of Progesterone Microspheres in Doses of 50 mg, 100 mg, 200 mg and 300 mg, in Postmenopausal Women.|Completed||Phase 1|48|Actual|Productos Científicos S. A. de C. V.||4|||f||||f||||||||||2018-05-31 23:30:42.898581|2018-05-31 23:30:42.898581
NCT01176162|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2014-04-28|2010-08-04|2010-08-05|Estimate|||||||2014-04-28|2014-04-30|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|PREMALDO||Aldosterone Resistance in Preterm Infants|PREMALDO : Aldosterone Resistance in Preterm Infants : Assessment by a Non Invasive Measurement of Urinary Aldosterone|Completed|||170|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||Samples Without DNA|"~     -  Urinary samples will be collected onto a gauze compress, during the first 24 hours of~          life, at day three, and at 1, 3, 6 and 12 months.~        -  A blood sample will be obtained from systematic umbilical cord blood collection at birth~          and during the Guthrie test at day three~   "|||2018-05-31 23:30:43.127849|2018-05-31 23:30:43.127849
NCT01176149|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-05|2010-08-04|2010-08-05|Estimate|||||||2010-08-05|2010-08-06|Estimate|March 2007||2007-03-31|August 2010|2010-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|ROSES||Role Of Self-monitoring of Blood Glucose and Intensive Education in Patients With Type 2 Diabetes Not Receiving Insulin|Role Of Self-monitoring of Blood Glucose and Intensive Education in Patients With Type 2 Diabetes Not Receiving Insulin: a Pilot Study|Completed||Phase 3|62|Actual|Consorzio Mario Negri Sud||2|||f||||f||||||||||2018-05-31 23:30:43.274454|2018-05-31 23:30:43.274454
NCT01176136|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2013-07-29|2010-08-04|2010-08-05|Estimate|||||||2013-07-29|2013-07-30|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Organizational Skills Interventions for Children With Attention Deficit Hyperactivity Disorder (ADHD)|Organizational Skills Interventions for Children With ADHD|Completed||N/A|60|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 23:30:43.367682|2018-05-31 23:30:43.367682
NCT01176123|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-04|2010-08-04|2010-08-05|Estimate|||||||2010-08-04|2010-08-05|Estimate||||August 2010|2010-08-31||||||||Interventional|CBT-I Telemed||Cognitive Behavioral Therapy for Trauma-Related Insomnia in Veterans|Comparing Telemedicine to In Person Delivery of Cognitive Behavioral Therapy for Trauma-Related Insomnia in Rural Veterans|Unknown status|Not yet recruiting|N/A|||Southeast Louisiana Veterans Health Care System||2|||f||||f||||||||||2018-05-31 23:30:43.515559|2018-05-31 23:30:43.515559
NCT01176110|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2011-05-18|2010-08-04|2010-08-05|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|TIMI||Thermal Management in Patients With Interventional Minimally Invasive Valve Replacement|A Randomized Pilot Study for Thermal Management in Patients With Interventional Minimally Invasive Valve Replacement|Completed||N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:30:43.680558|2018-05-31 23:30:43.680558
NCT01176097|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-02-01|2010-08-04|2010-08-05|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes|A Randomized, Single-Blind, Placebo-Controlled, Single-Center, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Fasting After Single Ascending Oral Doses of AZD5658 in Type 2 Diabetes Mellitus Patients|Completed||Phase 1|24|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 23:30:43.823706|2018-05-31 23:30:43.823706
NCT01176058|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2012-10-29||2015-10-06|2010-08-03|2010-08-05|Estimate|2015-08-18|2015-09-21|Estimate||||2015-10-06|2015-10-28|Estimate|December 2010||2010-12-31|August 2015|2015-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis|A Phase Iiib, Open-label, Randomized, Multi-center Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole, In The Treatment Of Subjects With Candidemia And/or Other Forms Of Invasive Candidiasis|Terminated||Phase 3|17|Actual|Pfizer|Due to small enrollment, the per-protocol population was not determined, and analysis was performed on the mITT population.|1||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:30:44.165129|2018-05-31 23:30:44.165129
NCT01176045|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2016-02-02|2010-08-03|2010-08-05|Estimate|||||||2016-02-02|2016-02-04|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||TearLab Refractive Surgery Dry Eye Study|Measurement of Refractive Surgery Induced Dry Eye Using Tear Osmolarity Testing|Completed|||128|Actual|TearLab Corporation|||2||f||||f||||||||Yes|Study data has been shared in Vienna 2011. Patients with pre-operative hyperosmolarity (≥ 308 mOsms/L) demonstrated worse long-term uncorrected visual acuity. An abnormal tear film may cause inaccurate wavefront aberrometry. For patients with preoperative osmolarity ≥ 308 mOsms/L, it may be important to continue therapy for at least 3 months. Similarly, surgeons should measure tear osmolarity preoperatively as staining was too insensitive to identify at-risk patients. Patients treated pre-operatively with AMO Blink® Tears achieved normal osmolarity faster than those untreated before surgery.|2018-05-31 23:30:45.080041|2018-05-31 23:30:45.080041
NCT01176032|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2014-04-22||2014-07-22|2010-08-03|2010-08-05|Estimate|2014-07-22|2014-07-24|Estimate||||2014-07-22|2014-07-24|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ALLMARK|Intention-to-treat (ITT) population|ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling|"The ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK) Study"|Completed||Phase 4|74|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:30:45.233286|2018-05-31 23:30:45.233286
NCT01176019|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-11-05|2010-08-03|2010-08-05|Estimate|||||||2014-11-05|2014-11-07|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An Interactive Informed Consent and Education Program for Pregnant Women|An Interactive Informed Consent and Education Program for Pregnant Women|Completed||Phase 1|150|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 23:30:46.143307|2018-05-31 23:30:46.143307
NCT01176006|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2018-05-26|2010-08-04|2010-08-05|Estimate|||||||2018-05-26|2018-05-30|Actual|July 29, 2010||2010-07-29|May 23, 2018|2018-05-23|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency|Related and Unrelated Donor Hematopoietic Stem Cell Transplant of DOCK8 Deficiency|Recruiting||Phase 2|90|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 23:30:46.282394|2018-05-31 23:30:46.282394
NCT01175993|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2018-05-22|2010-08-04|2010-08-05|Estimate|||||||2018-05-22|2018-05-23|Actual|June 22, 2010||2010-06-22|December 27, 2017|2017-12-27|February 4, 2014|Actual|2014-02-04|February 4, 2014|Actual|2014-02-04||Interventional|||Effects of Rapid-Resisted Exercise and Bright Light Therapy on Ambulatory Adults With Traumatic Brain Injury|Effects of Rapid-Resisted Exercise on Ambulatory Adults With Traumatic Brain Injury|Completed||Phase 1/Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 23:30:46.440293|2018-05-31 23:30:46.440293
NCT01175980|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2018-05-23|2010-08-04|2010-08-05|Estimate|||||||2018-05-23|2018-05-24|Actual|August 6, 2010|Actual|2010-08-06|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma|A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)|Active, not recruiting||Phase 2|29|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:30:46.633303|2018-05-31 23:30:46.633303
NCT01175967|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2015-10-09|2010-08-04|2010-08-05|Estimate|||||||2015-10-09|2015-10-12|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer|Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer|Terminated|||11|Actual|UNC Lineberger Comprehensive Cancer Center||||Unable to meet accrual due to changing practice patters|f||||t||||||||||2018-05-31 23:30:46.797618|2018-05-31 23:30:46.797618
NCT01175954|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2017-09-12|2010-08-04|2010-08-05|Estimate|||||||2017-09-12|2017-09-14|Actual|May 2010||2010-05-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cognitive and Behavioral Effects of Lacosamide|Phase IV Study of Cognitive and Behavioral Effects of Lacosamide as Adjunctive Therapy in Patients With Partial Epilepsy|Completed||Phase 4|32|Actual|Northeast Regional Epilepsy Group||1|||f||||f||||||||||2018-05-31 23:30:46.971695|2018-05-31 23:30:46.971695
NCT01175941|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2012-11-02|2010-08-04|2010-08-05|Estimate|||||||2012-11-02|2012-11-05|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence|A Double-blind, Randomized, Placebo-controlled, Cross Over Study in Patient Volunteers With Faecal Incontinence to Evaluate the Effect on Rectal Compliance, Rectal Sensitivity, Recto-anal Inhibitory Reflex, Sphincter Pressures, Safety and Tolerability of a Daily Rectal Application of a 10 mg NRL001 Suppository for Seven Consecutive Days|Completed||Phase 1|14|Actual|Norgine||2|||f||||f||||||||||2018-05-31 23:30:47.154577|2018-05-31 23:30:47.154577
NCT01175928|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-04-18|2010-08-03|2010-08-05|Estimate|||||||2012-04-18|2012-04-20|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy|Phase 2 Study of the NormaTec PCD in the Treatment of Diabetic Peripheral Neuropathy|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|NormaTec Industries LP||2|||f||||f||||||||||2018-05-31 23:30:47.297191|2018-05-31 23:30:47.297191
NCT01175915|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-04|2010-08-04|2010-08-05|Estimate|||||||2010-08-04|2010-08-05|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease||Unknown status|Recruiting|N/A|360|Anticipated|Jiangsu Kanion Pharmaceutical Co., Ltd||3|||f||||t||||||||||2018-05-31 23:30:47.553979|2018-05-31 23:30:47.553979
NCT01173341|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2016-09-23|2010-07-29|2010-08-02|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 2010||2010-07-31|September 2016|2016-09-30||||July 2018|Anticipated|2018-07-31||Observational|||Cardiotoxicity of Cancer Therapy (CCT)|Cardiotoxicity of Cancer Therapy: Mechanisms and Predictors|Recruiting|||250|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||3||f||||t||||||||||2018-05-31 23:31:57.164664|2018-05-31 23:31:57.164664
NCT01175902|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2014-11-26||2014-12-12|2010-08-04|2010-08-05|Estimate|2014-12-09|2014-12-12|Estimate||||2014-12-12|2015-01-08|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma|To Prove the Non-inferiority of Cosopt Compared to Xalatan in the Aspects of Intraocular Pressure and Ocular Perfusion Pressure in Subjects With Normal Tension Glaucoma|Completed||N/A|44|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 23:30:47.733109|2018-05-31 23:30:47.733109
NCT01175889|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-10-24|2010-08-03|2010-08-05|Estimate|||||||2012-10-24|2012-10-25|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|ACE||Megadyne Ace Incision/Dissection Study|Megadyne ACE Incision/Dissection Study|Unknown status|Active, not recruiting|Phase 4|52|Anticipated|Megadyne Medical Products Inc.||2|||f||||f||||||||||2018-05-31 23:30:48.647271|2018-05-31 23:30:48.647271
NCT01175876|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2010-08-05|2010-08-04|2010-08-05|Estimate|||||||2010-08-05|2010-08-06|Estimate|July 2010||2010-07-31|August 2010|2010-08-31||||December 2010|Anticipated|2010-12-31||Interventional|||The Effect Of Remote Limb Ischemic Preconditioning For Carotid Artery Stenting|The Effect Of Remote Limb Ischemic Preconditioning For Carotid Artery Stenting|Unknown status|Recruiting|Phase 1|60|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-05-31 23:30:48.76584|2018-05-31 23:30:48.76584
NCT01175863|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-02-11|2010-08-04|2010-08-05|Estimate|||||||2014-02-11|2014-02-12|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|FAVOR||Fractional Flow Reserve (FFR) Versus Intravascular Ultrasound (IVUS) in Intermediate Coronary Artery Disease|Fractional Flow Reserve- And Intra-vascular Ultrasound-Guided Percutaneous Coronary Intervention With Drug-Eluting Stents in Intermediate Coronary Artery Lesion (FAVOR Study)|Terminated||Phase 4|1400|Anticipated|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 23:30:48.896724|2018-05-31 23:30:48.896724
NCT01175850|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2015-02-24||2017-04-12|2010-08-03|2010-08-05|Estimate|2015-09-03|2015-10-06|Estimate||||2017-04-12|2017-05-16|Actual|September 2010||2010-09-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|February 2014|Actual|2014-02-28||Interventional|INPACT SFA I||Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease|Randomized Trial of IN.PACT Admiral(TM) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease|Completed||N/A|331|Actual|Medtronic Endovascular||2|||f||||t||||||||||2018-05-31 23:30:49.101461|2018-05-31 23:30:49.101461
NCT01175837|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-11-14|2010-08-03|2010-08-05|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2010|Actual|2010-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Short-Term Fasting Before Chemotherapy in Treating Patients With Cancer|Short-Term Fasting Prior to Systemic Chemotherapy: A Pilot Feasibility Study|Active, not recruiting||N/A|12|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 23:30:50.369013|2018-05-31 23:30:50.369013
NCT01175824|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2013-11-12||2014-01-24|2010-08-03|2010-08-05|Estimate|2014-01-24|2014-02-24|Estimate||||2014-01-24|2014-02-24|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Intent-to-treat population: randomized participants who received at least 1 dose of study drug. Participants were analyzed per the assigned treatment arm regardless of the treatment they actually received.|Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies|Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone|Completed||Phase 4|478|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:30:51.625473|2018-05-31 23:30:51.625473
NCT01175811|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2013-10-29||2013-10-29|2010-08-03|2010-08-05|Estimate|2013-10-29|2013-12-18|Estimate||||2013-10-29|2013-12-18|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus|A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin|Completed||Phase 4|402|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:30:56.987116|2018-05-31 23:30:56.987116
NCT01175798|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2014-09-15||2014-09-15|2010-08-03|2010-08-05|Estimate|2014-09-15|2014-09-22|Estimate||||2014-09-15|2014-09-22|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Impact of Vitamin D Repletion in Hemodialysis Patients|Immunologic Impact of Vitamin D Repletion in Hemodialysis Patients: A Randomized Controlled Trial|Completed||N/A|116|Actual|Mehrotra, Anita, M.D.||2|||f||||t||||||||||2018-05-31 23:30:58.324702|2018-05-31 23:30:58.324702
NCT01175785|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03||2017-04-05|2017-04-05|2010-08-04|2010-08-05|Estimate||||2017-04-05|2017-04-06|Actual|2017-04-05|2017-04-06|Actual|August 2010||2010-08-31|April 2017|2017-04-30||||August 2014|Actual|2014-08-31||Interventional|||Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies|Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies|Completed||Phase 2|15|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 23:30:58.750498|2018-05-31 23:30:58.750498
NCT01175772|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-01|||2015-06-21|2010-08-04|2010-08-05|Estimate|||||||2015-06-21|2015-06-23|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy|Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy With Metronomic/Oral Chemotherapy (Cytophosphan Combined With Low-dose Methotrexate)and COX-2 Inhibition (Celecoxib)|Terminated||Phase 2|6|Actual|HaEmek Medical Center, Israel||1||Due to change in the national policy of medications|f||||t||||||||||2018-05-31 23:30:58.921921|2018-05-31 23:30:58.921921
NCT01175759|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-08-04|2010-08-04|2010-08-05|Estimate|||||||2010-08-04|2010-08-05|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss|Evaluation of the Efficacy and Safety of the EVE- Skin-Test Panel in Detecting Sensitivity to Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss|Unknown status|Recruiting|Phase 2|40|Anticipated|EVE Medical Systems Ltd.||2|||f||||||||||||||2018-05-31 23:30:59.035491|2018-05-31 23:30:59.035491
NCT01175746|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2013-06-11|2010-08-04|2010-08-05|Estimate|||||||2013-06-11|2013-06-13|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||The Effect of Nicardipine on Kidney Function During Orthognathic Surgery Under Hypotensive Anesthesia||Completed||N/A|46|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:30:59.17748|2018-05-31 23:30:59.17748
NCT01175733|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2017-03-17|2010-08-04|2010-08-05|Estimate|||||||2017-03-17|2017-03-20|Actual|July 8, 2010|Actual|2010-07-08|March 2017|2017-03-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|Vectibix||Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer|Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|18|Actual|VU University Medical Center||1|||f||||f||||||||||2018-05-31 23:30:59.29263|2018-05-31 23:30:59.29263
NCT01175720|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2011-11-11|2010-08-04|2010-08-05|Estimate|||||||2011-11-11|2011-11-16|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Clinical Comparison Between Two Surgical Techniques for the Treatment of Gingival Recessions|Clinical Comparison Between Two Surgical Techniques With Acellular Dermal Matrix Graft in the Treatment of Gingival Recessions|Completed||N/A|15|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:30:59.411768|2018-05-31 23:30:59.411768
NCT01175707|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2013-04-05||2016-01-05|2010-08-03|2010-08-05|Estimate|2015-04-28|2015-05-13|Estimate||||2016-01-05|2016-01-07|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||All study participants|Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting|A Phase 4, Prospective, Randomized, Open-label Study to Compare Use of Cubicin With Vancomycin Administered Intravenously in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Confirmed Gram-positive Bacteria in a Home Infusion Setting|Terminated||Phase 4|80|Actual|Cubist Pharmaceuticals LLC|The study was terminated prematurely.|2||Business decision|f||||f||||||||||2018-05-31 23:30:59.544433|2018-05-31 23:30:59.544433
NCT01175694|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-04|||2010-08-19|2010-08-04|2010-08-05|Estimate|||||||2010-08-19|2010-08-20|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|January 2015|Anticipated|2015-01-31|June 2012|Anticipated|2012-06-30||Interventional|||Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer|Phase II Study - Dose Optimization PDR/HDR Brachytherapy Alone for Early Breast Cancer|Unknown status|Recruiting|Phase 2|200|Anticipated|University Hospital Erlangen||1|||f||||f||||||||||2018-05-31 23:31:00.309694|2018-05-31 23:31:00.309694
NCT01175681|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2011-07-20|2010-08-04|2010-08-05|Estimate|||||||2011-07-20|2011-07-21|Estimate|December 2007||2007-12-31|July 2010|2010-07-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Effect of Remote Ischemia Preconditioning on Myocardial Injury in Patients Undergoing Heart Valve Surgery|Effect of Remote Ischemia Preconditioning on Myocardial Injury in Patients Undergoing Heart Valve Surgery|Completed||N/A|73|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:31:00.427354|2018-05-31 23:31:00.427354
NCT01175668|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2013-09-03||2013-11-18|2010-08-04|2010-08-05|Estimate|2013-11-18|2014-01-06|Estimate||||2013-11-18|2014-01-06|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Clonidine for Neonatal Abstinence Syndrome Study|Comparison of Clonidine Versus Phenobarbital as an Adjunct Therapy for Neonatal Abstinence Syndrome|Terminated||N/A|68|Actual|Baystate Medical Center|One of the major limitations to our study was the inability to blind the two groups for the study medications.|2||"Based on the planned interim analysis results at 50% recruitment, after IRB reviewed the~   results, further enrollment was stopped."|f||||t||||||||||2018-05-31 23:31:00.50198|2018-05-31 23:31:00.50198
NCT01175655|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2016-10-10|2010-08-04|2010-08-05|Estimate|||||||2016-10-10|2016-10-11|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|MSC in OB||A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation|A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation|Completed||Phase 1|10|Actual|The Prince Charles Hospital||1|||f||||t||||||||||2018-05-31 23:31:00.751357|2018-05-31 23:31:00.751357
NCT01175642|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2016-11-16|2010-08-04|2010-08-05|Estimate|||||||2016-11-16|2016-11-17|Estimate|July 2007||2007-07-31|August 2010|2010-08-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Cognitive Remediation and Functional Skills Training in Schizophrenia|Specificity and Generalizability of Cognitive Remediation and Functional Skills Training in Schizophrenia|Completed||Early Phase 1|75|Actual|National Alliance for Research on Schizophrenia and Depression||3|||f||||f||||||||No||2018-05-31 23:31:00.87287|2018-05-31 23:31:00.87287
NCT01175629|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-06-30|2010-08-03|2010-08-05|Estimate|||||||2014-06-30|2014-07-02|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Observational|||Veteran Health Study|CSP #569 - A Twin Study of the Course and Consequences of PTSD in Vietnam Era Veterans|Completed|||7568|Actual|VA Office of Research and Development|||1||f||||t||||||||||2018-05-31 23:31:00.957411|2018-05-31 23:31:00.957411
NCT01175616|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2016-08-11|2010-08-04|2010-08-05|Estimate|||||||2016-08-11|2016-08-15|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Creatine Augmentation in Veterans With SSRI-Resistant Major Depression|Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder|Withdrawn||Phase 4|0|Actual|University of Utah||1||Study withdrawn from ClinicalTrials.gov.|f||||t||||||||No|The study was closed prior to human subjects receiving investigational treatment.|2018-05-31 23:31:01.040682|2018-05-31 23:31:01.040682
NCT01175603|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2016-04-05|2010-08-04|2010-08-05|Estimate|||||||2016-04-05|2016-04-07|Estimate|October 2009||2009-10-31|April 2016|2016-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Preventing Postpartum Depression in African American Home Visiting Clients||Completed||Phase 2|82|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:31:01.11926|2018-05-31 23:31:01.11926
NCT01175590|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2013-02-13||2013-03-19|2010-08-04|2010-08-05|Estimate|2013-03-19|2013-05-01|Estimate||||2013-03-19|2013-05-01|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional||Intent to treat population (ITT)|Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle|A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days|Completed||Phase 3|518|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:31:01.221609|2018-05-31 23:31:01.221609
NCT01175577|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-02-02|2010-08-03|2010-08-05|Estimate|||||||2012-02-02|2012-02-03|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|FRIED||Feeding the Rainbow to Investigate Endothelial Dysfunction|Evaluating the Effects of Mixed-Carotenoids on Biomarkers of Endothelial Dysfunction|Completed||Early Phase 1|60|Actual|Bastyr University||4|||f||||f||||||||||2018-05-31 23:31:01.802226|2018-05-31 23:31:01.802226
NCT01171261|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-06-08|2010-07-27|2010-07-28|Estimate|||||||2012-06-08|2012-06-11|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Testing Health Games for Adolescent Physical Activity|Health Games Research: Advancing Effectiveness of Interactive Games for Health|Completed||N/A|63|Actual|University of California, San Diego||4|||f||||f||||||||||2018-05-31 23:32:50.379182|2018-05-31 23:32:50.379182
NCT01175564|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2013-02-05|2010-08-03|2010-08-05|Estimate|||||||2013-02-05|2013-02-06|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects|A Phase I, Single Centre, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose and Multiple Doses of TC-5214 (S-Mecamylamine) in Healthy Male Japanese Subjects|Completed||Phase 1|48|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:31:01.873681|2018-05-31 23:31:01.873681
NCT01175551|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2014-01-06|2010-08-04|2010-08-05|Estimate|||||||2014-01-06|2014-01-07|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Observational|||Direct Measurements of Cervical Remodeling for Predicting Preterm Birth|Direct Measurements of Cervical Remodeling for Predicting Preterm Birth|Completed|||1207|Actual|University of Pennsylvania|||2||f||||f||||||Samples With DNA|"~     maternal serum, maternal cervical vaginal fluid~   "|||2018-05-31 23:31:01.927723|2018-05-31 23:31:01.927723
NCT01175538|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-04|2010-08-04|2010-08-05|Estimate|||||||2010-08-04|2010-08-05|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis|Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose|Unknown status|Recruiting|Phase 4|||Govind Ballabh Pant Hospital||1|||f||||t||||||||||2018-05-31 23:31:02.086527|2018-05-31 23:31:02.086527
NCT01175525|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-02|2010-08-02|2010-08-05|Estimate|||||||2010-08-02|2010-08-05|Estimate||||August 2010|2010-08-31||||||||Interventional|||Treatment of Acute Stroke With Cromolyn(Single Dose)||Unknown status|Not yet recruiting|Phase 3|||Wolfson Medical Center||2|||||||||||||||||2018-05-31 23:31:02.195842|2018-05-31 23:31:02.195842
NCT01175512|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2013-10-07|2010-08-03|2010-08-04|Estimate|||||||2013-10-07|2013-10-09|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SHE||Stress, Hormones, and Eating|Novel Interventions to Reduce Stress Induced Non-homeostatic Eating|Completed||N/A|44|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:31:02.266324|2018-05-31 23:31:02.266324
NCT01175499|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2014-08-15|2010-08-02|2010-08-04|Estimate|||||||2014-08-15|2014-08-19|Estimate|July 2010||2010-07-31|August 2014|2014-08-31||||||||Interventional|TNFE-NBI||Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract|Accuracy of Endoscopic Diagnosis of Carcinoma of the UpperAerodigestive Tract: A Tandem Trial of Direct Rigid Endoscopy and Transnasal Flexible Endoscopy With Narrowband Imaging|Withdrawn||N/A|0|Actual|University of California, San Francisco||||Unable to obtain funding to continue recruitment; no accrual|f||||f||||||||||2018-05-31 23:31:02.332732|2018-05-31 23:31:02.332732
NCT01175486|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2011-01-04|2010-08-03|2010-08-04|Estimate|||||||2011-01-04|2011-01-05|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|December 2015|Anticipated|2015-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy|The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy|Unknown status|Recruiting|Phase 4|200|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 23:31:02.398143|2018-05-31 23:31:02.398143
NCT01175473|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2016-08-18|2012-02-23|2016-10-14|2010-08-02|2010-08-04|Estimate|2016-08-18|2016-10-11|Estimate|2012-02-23|2012-02-28|Estimate|2016-10-14|2016-11-28|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes|An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin|Completed||Phase 2|148|Actual|Sanofi|"Data for Percentages of patients by ranges of oxyntomodulin levels was reported instead of Change from Baseline in oxyntomodulin concentration at Day 28 due to change in planned analysis as there were high numbers of values below the LOD."|2|||f||||f||||||||||2018-05-31 23:31:02.495121|2018-05-31 23:31:02.495121
NCT01175460|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-31|||2012-03-04|2010-08-03|2010-08-04|Estimate|||||||2012-03-04|2012-03-06|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer|Phase I Study of S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer|Completed||Phase 1|15|Actual|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 23:31:03.360929|2018-05-31 23:31:03.360929
NCT01175447|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-31|||2012-03-04|2010-08-03|2010-08-04|Estimate|||||||2012-03-04|2012-03-06|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||S-1 and Radiotherapy in Elderly Patients With Esophageal Cancer|A Phase I Study of S-1 With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer|Completed||Phase 1|12|Actual|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 23:31:03.521942|2018-05-31 23:31:03.521942
NCT01175434|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2013-01-14||2013-12-31|2010-08-03|2010-08-04|Estimate|2013-12-31|2014-02-17|Estimate||||2013-12-31|2014-02-17|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|SB-PACT||School-Based Preventive Asthma Care Technology: A Trial Using a Novel Technology to Improve Adherence|School-Based Preventive Asthma Care Technology: A Randomized Control Trial Using a Novel Technology to Improve Adherence|Completed||N/A|99|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 23:31:03.646711|2018-05-31 23:31:03.646711
NCT01175421|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2015-03-19|2010-08-03|2010-08-04|Estimate|||||||2015-03-19|2015-03-23|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|OSA-SCORE||Multidimensional System as Predictor of Outcomes in Obstructive Sleep Apnea: The OSA-SCORE|Development and Validation of a Multidimensional System as Predictor of Outcomes in Obstructive Sleep Apnea: The OSA-SCORE|Completed|||1100|Actual|Hospital Miguel Servet|||1||f||||f||||||||||2018-05-31 23:31:04.013481|2018-05-31 23:31:04.013481
NCT01175408|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2014-09-09|2010-08-03|2010-08-04|Estimate|||||||2014-09-09|2014-09-11|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin|Blood Monitoring and Data Acquisition and Utilization in Patients With Type 2 Diabetes Treated With Insulin|Completed||N/A|100|Actual|Endocrine Research Society||4|||f||||f||||||||||2018-05-31 23:31:04.108923|2018-05-31 23:31:04.108923
NCT01175070|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2014-12-23|2010-08-03|2010-08-04|Estimate|||||||2014-12-23|2014-12-24|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|MIDME||Intravitreal Macugen for Ischaemic Diabetic Macular Oedema|A Phase IV OpenLabelled Prospective Pilot Study of Intravitreal Macugen (Pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME Study)|Completed||Phase 4|30|Actual|University of Oxford||1|||f||||t||||||||||2018-05-31 23:31:18.545699|2018-05-31 23:31:18.545699
NCT01175395|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2013-05-23||2014-10-13|2010-08-03|2010-08-04|Estimate|2014-10-13|2014-10-20|Estimate||||2014-10-13|2014-10-20|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|20089/Combo||20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)|An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD|Completed||Phase 1/Phase 2|10|Actual|University of Illinois at Chicago||1|||f||||f||||||||||2018-05-31 23:31:04.261874|2018-05-31 23:31:04.261874
NCT01175382|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2016-12-31||2017-04-17|2010-08-03|2010-08-04|Estimate|2017-04-17|2017-05-25|Actual||||2017-04-17|2017-05-25|Actual|July 2010||2010-07-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|COBALT||Combined Behavioral and Drug Treatment of Overactive Bladder in Men|Combined Behavioral and Drug Treatment of Overactive Bladder in Men|Completed||Phase 2/Phase 3|204|Actual|University of Alabama at Birmingham|No limitations or caveats for this trial|3|||f||||t||||||||No||2018-05-31 23:31:04.468233|2018-05-31 23:31:04.468233
NCT01175369|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2013-01-14||2014-07-25|2010-08-03|2010-08-04|Estimate|2013-01-14|2013-02-15|Estimate||||2014-07-25|2014-08-01|Estimate|August 2006||2006-08-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|June 2009|Actual|2009-06-30||Interventional|SBAT||School-based Asthma Therapy: Stage 2 Effectiveness Study|School-Based Asthma Therapy: Stage 2 Effectiveness Study|Completed||N/A|530|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 23:31:05.590494|2018-05-31 23:31:05.590494
NCT01175356|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2017-07-26||2017-10-03|2010-08-03|2010-08-04|Estimate|2017-08-29|2017-09-28|Actual||||2017-10-03|2017-11-06|Actual|October 2010||2010-10-31|October 2017|2017-10-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin|A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma|Completed||N/A|99|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 23:31:06.004817|2018-05-31 23:31:06.004817
NCT01175343|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2017-02-23||2017-04-17|2010-08-03|2010-08-04|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|July 2010||2010-07-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|October 2012|Actual|2012-10-31||Interventional|||RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:31:06.57705|2018-05-31 23:31:06.57705
NCT01175330|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2015-03-23|2010-08-03|2010-08-04|Estimate|||||||2015-03-23|2015-03-24|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting|Randomized Trial of Fish Oil Infusion to Prevent Atrial Fibrillation After Cardiac Surgery|Terminated||Phase 3|39|Actual|Meshalkin Research Institute of Pathology of Circulation||2||Interim analysis did not reveal of anticipated benefits of intervention|f||||t||||||||||2018-05-31 23:31:06.990805|2018-05-31 23:31:06.990805
NCT01175317|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2013-11-05||2014-05-19|2010-08-03|2010-08-04|Estimate|2014-05-19|2014-06-19|Estimate||||2014-05-19|2014-06-19|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|HOC||Improvement of Fluid Balance in Patients Undergoing Surgery of the Colon and Rectum|Does Hemodynamic Optimization During and After Colorectal Surgery Result in Improved Intestinal Perfusion, Sustained Intestinal Barrier and Improved Postoperative Recovery?|Completed||Phase 4|58|Actual|Maastricht University Medical Center|Tolerance of esophageal Doppler probe postoperatively was low. Therefore, optimization based on cardiac output could only be achieved within 3 hours in most patients.|2|||f||||t||||||||||2018-05-31 23:31:07.151056|2018-05-31 23:31:07.151056
NCT01175304|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-07-04|2010-08-03|2010-08-04|Estimate|||||||2011-07-04|2011-07-06|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Study of Sleep Habits and Prevalence of Sleepiness in a Health Care Environment in Barcelona|Study of Sleep Habits and Prevalence of Sleepiness in a Health Care Environment in Barcelona|Completed|||500|Actual|Hospital Universitari Vall d'Hebron Research Institute|||1||f||||f||||||||||2018-05-31 23:31:07.465972|2018-05-31 23:31:07.465972
NCT01175291|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2011-12-02|2010-08-03|2010-08-04|Estimate|||||||2011-12-02|2011-12-05|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer|Randomized, Double Blind Phase II Study of FOLFOX/Bevacizumab Combined With MK-0646 Versus FOLFOX/Bevacizumab Combined With Placebo in First-Line Treatment of Metastatic Colorectal Cancer|Withdrawn||Phase 2|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||2||treatment deemed ineffective so accrual was closed|f||||t||||||||||2018-05-31 23:31:07.589934|2018-05-31 23:31:07.589934
NCT01175278|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-01-11|2010-08-03|2010-08-04|Estimate|||||||2012-01-11|2012-01-12|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures|A Pilot Study of Vertebral Augmentation With Kyphoplasty Versus Nonsurgical Management in Multiple Myeloma Patients With Mildly Symptomatic Vertebral Body Compression Fractures|Withdrawn||N/A|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||3||No enrollment|f||||t||||||||||2018-05-31 23:31:07.776451|2018-05-31 23:31:07.776451
NCT01175265|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-08-03|2010-08-03|2010-08-04|Estimate|||||||2010-08-03|2010-08-04|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Interventional|||Effects of Breathing Retraining in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effects of Breathing Retraining on Pulmonary Function, Exercise Capacity, Quality of Life and Cardiac Autonomic Function in Patients With COPD|Completed||Phase 1|40|Actual|University Hospital, Essen||2|||f||||t||||||||||2018-05-31 23:31:07.859753|2018-05-31 23:31:07.859753
NCT01175252|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-11-08|2010-08-03|2010-08-04|Estimate|||||||2012-11-08|2012-11-12|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Trends Over Time (1990-2010) of Diarrhoea-related Hospitalizations and Deaths in Children < 5 Years of Age in Brazil|Time Trend Analysis of Diarrhea-related Hospitalizations and Deaths in Children < 5 Years of Age in Brazil, 1990-2010|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 23:31:07.978267|2018-05-31 23:31:07.978267
NCT01175239|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-07-31|2010-08-03|2010-08-04|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2011||2011-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)|Gene Therapy for SCID-X1 Using a Self-inactivating (SIN) Gammaretroviral Vector|Active, not recruiting||N/A|1|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||f|f|f||||||||2018-05-31 23:31:08.093099|2018-05-31 23:31:08.093099
NCT01175226|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2017-03-17|2013-09-12|2018-05-29|2010-08-03|2010-08-04|Estimate|2017-04-27|2017-06-01|Actual|2013-09-12|2013-09-18|Estimate|2018-05-29|2018-05-31|Estimate|August 2010||2010-08-31|May 2018|2018-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|RHINO|Safety population - all randomized subjects who received at least 1 dose of investiational product.|A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection|Completed||Phase 2|300|Actual|Vaxart||2|||f||||t||||||||||2018-05-31 23:31:08.211315|2018-05-31 23:31:08.211315
NCT01175213|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2016-02-26|2014-09-08|2017-10-19|2010-08-03|2010-08-04|Estimate|2016-05-24|2016-05-26|Estimate|2014-09-15|2014-09-29|Estimate|2017-10-19|2017-10-23|Actual|July 2010||2010-07-31|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Safety Analysis Set|Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID|Long-Term Tolerability and Safety of Immune Globulin Subcutaneous (IGSC) Solution Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases|Completed||Phase 3|66|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:31:08.770698|2018-05-31 23:31:08.770698
NCT01175200|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-07-03|2010-08-03|2010-08-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|DOSAPI||Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.|Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study.|Completed||N/A|82|Actual|Ascopharm Groupe Novasco||4|||f||||t||||||||||2018-05-31 23:31:14.901014|2018-05-31 23:31:14.901014
NCT01175187|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-08|2010-08-02|2010-08-04|Estimate|||||||2010-08-08|2010-08-10|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|October 2010|Anticipated|2010-10-31|March 2010|Anticipated|2010-03-31||Observational|||Intrapartum Fever and Histopathological Placental Findings|Intrapartum Fever and Histopathological Placental Findings|Unknown status|Enrolling by invitation||200|Actual|Wolfson Medical Center|||3||f||||t|||||||"~     degree and location of inflamation~   "|||2018-05-31 23:31:15.097518|2018-05-31 23:31:15.097518
NCT01175174|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2011-09-04|2010-08-02|2010-08-04|Estimate|||||||2011-09-04|2011-09-07|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Observational|||Clinical, Airway Inflammatory, and HRA Phenotypes, in Preschool Children With Acute Asthmatic Attack Presenting to the ED.|Clinical, Airway Inflammatory, and HRA Phenotypes, in Preschool Children With Acute Asthmatic Attack Presenting to the ED.|Completed|||30|Actual|Wolfson Medical Center|||||f||||f||||||||||2018-05-31 23:31:15.161614|2018-05-31 23:31:15.161614
NCT01175161|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2011-12-06|2010-08-03|2010-08-04|Estimate|||||||2011-12-06|2011-12-07|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PPIUD||Postpartum Intrauterine Device Study|A Pilot Study Of A Randomized Trial Comparing Two Different Time Frames For Copper T380A Intrauterine Contraception Insertion; Immediately Postpartum Compared To 4-6 Weeks Postpartum In Lilongwe, Malawi|Completed||N/A|115|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 23:31:15.240854|2018-05-31 23:31:15.240854
NCT01175148|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2016-11-04||2017-05-08|2010-08-03|2010-08-04|Estimate|2017-05-08|2017-06-07|Actual||||2017-05-08|2017-06-07|Actual|July 2010||2010-07-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation|Phase II Study Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft-versus-host Disease in Patients Undergoing Matched Sibling Hematopoietic Stem Cell Transplantation|Completed||Phase 2|60|Actual|West Virginia University||2|||f||||t||||||||||2018-05-31 23:31:15.375104|2018-05-31 23:31:15.375104
NCT01175135|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|2018-01-05|2013-04-09|2018-04-27|2010-08-03|2010-08-04|Estimate|2018-02-21|2018-03-20|Actual|2013-04-09|2013-04-16|Estimate|2018-04-27|2018-05-22|Actual|October 2010|Actual|2010-10-31|April 2018|2018-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Included all randomized participants who received at least 1 dose of study medication.|An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia|A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control|Completed||Phase 2|259|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 23:31:15.756087|2018-05-31 23:31:15.756087
NCT01175122|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2013-02-08|2010-08-03|2010-08-04|Estimate|||||||2013-02-08|2013-02-11|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza|Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H2N3 (6-2) AA ca Recombinant (A/Swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N3 Infection in the Event of a Pandemic|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-05-31 23:31:18.107555|2018-05-31 23:31:18.107555
NCT01175109|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-12-26|2010-08-03|2010-08-04|Estimate|||||||2012-12-26|2012-12-27|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma|Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 23:31:18.242346|2018-05-31 23:31:18.242346
NCT01175096|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-03|2010-08-03|2010-08-04|Estimate|||||||2010-08-03|2010-08-04|Estimate|July 2010||2010-07-31|May 2010|2010-05-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor|A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Guangdong General Hospital||1|||f||||t||||||||||2018-05-31 23:31:18.334067|2018-05-31 23:31:18.334067
NCT01175083|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03||2013-04-11|2014-12-04|2010-08-03|2010-08-04|Estimate||||2013-04-11|2013-04-18|Estimate|2014-12-04|2014-12-22|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Pneumococcal Vaccine 1024850A When Administered to Children Between 8 Weeks and 2 Years of Age|Completed||Phase 3|300|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 23:31:18.444351|2018-05-31 23:31:18.444351
NCT01175057|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2013-03-21|2010-08-03|2010-08-04|Estimate|||||||2013-03-21|2013-03-22|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Observational|||MeDiNa Pilot Study for Evaluation of the MeDiNa Concept of Homely Rehabilitation After Myocardial Infarction|Pilot Study for Evaluation of the MeDiNa Concept of Homely Rehabilitation of Patients With Acute Myocardial Infarction|Completed|||18|Actual|RWTH Aachen University|||2||f||||f||||||||||2018-05-31 23:31:18.611914|2018-05-31 23:31:18.611914
NCT01175044|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2016-10-04|2010-08-03|2010-08-04|Estimate|||||||2016-10-04|2016-10-06|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dilute Betadine Lavage in the Prevention of Postoperative Infection|Efficacy of a Dilute Betadine Lavage in the Prevention of Postoperative Infection in Revision Total Knee Arthroplasty|Recruiting||Phase 4|600|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 23:31:18.693004|2018-05-31 23:31:18.693004
NCT01175031|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2015-10-29||2016-03-29|2010-08-02|2010-08-04|Estimate|2016-03-29|2016-05-02|Estimate||||2016-03-29|2016-05-02|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Breathing Event Detection by a Continuous Positive Airway Pressure Device to Clinical Polysomnography|Validation of Breathing Event Detection of the Philips Respironics Sleep Therapy System REMstar Auto A-Flex Compared to Clinical Polysomnography|Completed||N/A|45|Actual|Philips Respironics||2|||f||||f||||||||||2018-05-31 23:31:18.779901|2018-05-31 23:31:18.779901
NCT01175018|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2013-10-22||2016-05-09|2010-08-03|2010-08-04|Estimate|2016-05-09|2016-05-23|Estimate||||2016-05-09|2016-05-23|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|VCU-ART2||Anakinra to Prevent Adverse Post-infarction Remodeling (2)|Anakinra to Prevent Adverse Post-infarction Remodeling (2)|Completed||Phase 2|30|Actual|Virginia Commonwealth University||2|||f||||f||||||||No||2018-05-31 23:31:19.14107|2018-05-31 23:31:19.14107
NCT01175005|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2011-03-29||2011-05-05|2010-08-03|2010-08-04|Estimate|2011-03-29|2011-04-27|Estimate||||2011-05-05|2011-05-30|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Procalcitonin Levels in Patients With Fever and a Central Line|Procalcitonin as a Marker of Serious Infection in Patients With Fever and a Central Venous Catheter|Completed|||62|Actual|Phoenix Children's Hospital|||1||f||||t||||||||||2018-05-31 23:31:19.659694|2018-05-31 23:31:19.659694
NCT01174992|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2012-06-19|2010-08-03|2010-08-04|Estimate|||||||2012-06-19|2012-06-20|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair|A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL as an Adjunct to Sutured Dural Repair|Completed||Phase 2/Phase 3|139|Actual|Ethicon, Inc.||2|||f||||f||||||||||2018-05-31 23:31:19.812332|2018-05-31 23:31:19.812332
NCT01174979|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2015-08-04|2010-08-02|2010-08-04|Estimate|||||||2015-08-04|2015-08-07|Estimate|January 2011||2011-01-31|August 2015|2015-08-31||||August 2015|Anticipated|2015-08-31||Interventional|||Caroverin and Inner Ear Diseases|Double Blind, Placebo-controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Transtympanic Treatment of Tinnitus With Caroverine|Suspended||Phase 3|170|Anticipated|Phafag AG||2||due to less patient the study was suspended|f||||t||||||||||2018-05-31 23:31:19.895688|2018-05-31 23:31:19.895688
NCT01174966|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-03|2010-08-03|2010-08-04|Estimate|||||||2010-08-03|2010-08-04|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|ICUPtO2OCT||Assessment of Transcutaneous Oxygen Tension/Oxygen Challenge Test in Intensive Care Unit (ICU) Patients|Assessment of Transcutaneous Oxygen Tension and Oxygen Challenge Test in Adult Intensive Care Patients|Unknown status|Recruiting||60|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||||||2018-05-31 23:31:19.957293|2018-05-31 23:31:19.957293
NCT01174953|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-12-30|2010-08-02|2010-08-04|Estimate|||||||2013-12-30|2014-01-01|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||High Risk Prostate Cancer Prevention Study|High Risk Prostate Cancer Prevention Study|Completed||N/A|18|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 23:31:20.024574|2018-05-31 23:31:20.024574
NCT01174940|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2017-01-05|2010-08-03|2010-08-04|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|||Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease|A Study of Extracorporeal Photopheresis With UVADEX® in the Setting of a Standard Myeloablative Conditioning Regimen in Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for the Prevention of Graft Versus Host Disease|Completed||Early Phase 1|22|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 23:31:20.097418|2018-05-31 23:31:20.097418
NCT01174927|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2015-10-13|2010-08-03|2010-08-04|Estimate|||||||2015-10-13|2015-10-15|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|February 2012|Actual|2012-02-29|December 2010|Actual|2010-12-31||Interventional|||Effects of Diacetylmorphine (DAM) on Brain Function and Stress Response|The Effects of Diacetylmorphine (Heroin) on Human Brain Functions and Stress Response|Completed||Phase 1|60|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 23:31:20.163028|2018-05-31 23:31:20.163028
NCT01174914|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-02|2010-08-02|2010-08-04|Estimate|||||||2010-08-02|2010-08-04|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+|Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression|Completed||Phase 2|171|Actual|The Ojai Foundation||3|||f||||t||||||||||2018-05-31 23:31:20.229237|2018-05-31 23:31:20.229237
NCT01174901|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2014-05-23|2010-08-02|2010-08-04|Estimate|||||||2014-05-23|2014-05-26|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|CoHead||Copeptin for Risk Stratification in Non-traumatic Headache in the Emergency Setting - The CoHead Study|Copeptin for Risk Stratification in Non-traumatic Headache in the Emergency Setting - The CoHead Study|Completed|||400|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     7.5 ml of EDTA blood, 7.5 ml of serum, 4.3 ml of citrate blood~   "|||2018-05-31 23:31:20.299214|2018-05-31 23:31:20.299214
NCT01174888|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2016-07-04|2010-08-02|2010-08-04|Estimate|||||||2016-07-04|2016-07-06|Estimate|August 2010||2010-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|April 2014|Actual|2014-04-30||Interventional|||Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia|Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia|Completed||Phase 1|34|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 23:31:20.611475|2018-05-31 23:31:20.611475
NCT01174875|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-02-06|2010-08-03|2010-08-04|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2009||2009-06-30|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|GUSTO||Developmental Pathways to Health and Disease: Metabolic, Neurodevelopmental and Related Outcomes.|Growing Up in Singapore Towards Healthy Outcomes|Active, not recruiting|||1247|Actual|National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     During pregnancy; Mother: blood, buccal and hair samples. At delivery; cord, cord blood and~     placenta. During infancy and childhood; Stool, nasal, buccal samples, saliva, urine, blood~     and exfoliated teeth from the children, breast milk from breastfeeding mothers~   "|No||2018-05-31 23:31:20.719366|2018-05-31 23:31:20.719366
NCT01174862|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2015-03-09|2010-08-03|2010-08-04|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|||Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery|Comparative Cohort Study on the Outcome of Patients With Normal and Reduced Acetylsalicylic Acid Responsiveness Undergoing Coronary Artery Bypass Surgery|Completed|||304|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-05-31 23:31:20.78726|2018-05-31 23:31:20.78726
NCT01174849|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2017-11-09|2010-08-03|2010-08-04|Estimate|||||||2017-11-09|2017-11-13|Actual|August 2011||2011-08-31|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|September 21, 2017|Actual|2017-09-21||Interventional|PREVIX_COMBO||Pneumococcal Vaccines Early and in Combination|A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes|Active, not recruiting||Phase 4|425|Actual|Menzies School of Health Research||3|||f||||t||||||||||2018-05-31 23:31:20.853995|2018-05-31 23:31:20.853995
NCT01174836|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2012-04-25|2010-08-03|2010-08-04|Estimate|||||||2012-04-25|2012-04-26|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|CT Consent||Patient and Physician Attitudes About Informed Consent for Emergency Department (ED) Computerized Axial Tomography (CT) Scans|Patient and Physician Attitudes About Informed Consent for Emergency Department (ED) Computerized Axial Tomography (CT) Scans|Completed||N/A|77|Actual|Lehigh Valley Hospital|||||f||||t||||||||||2018-05-31 23:31:20.977651|2018-05-31 23:31:20.977651
NCT01174823|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02||2013-02-04|2013-12-04|2010-08-03|2010-08-04|Estimate||||2013-02-04|2013-02-06|Estimate|2013-12-04|2013-12-30|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis Patients||Completed||Phase 2|240|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:31:21.04126|2018-05-31 23:31:21.04126
NCT01174810|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2012-03-22|2010-08-03|2010-08-04|Estimate|||||||2012-03-22|2012-03-23|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study|An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 23:31:21.117132|2018-05-31 23:31:21.117132
NCT01174797|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2013-05-23|2010-08-03|2010-08-04|Estimate|||||||2013-05-23|2013-05-27|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|MTWA-CAD||Evaluation of Microvolt T-Wave Alternans(MTWA) Testing for the Detection of Active Ischemia|Evaluation of Microvolt T-Wave Alternans Testing for the Detection of Active Ischemia in Patients With Known or Suspected Coronary Artery Disease: A Feasibility Study|Completed|||186|Actual|Cambridge Heart Inc.|||1||f||||||||||||||2018-05-31 23:31:21.263272|2018-05-31 23:31:21.263272
NCT01174784|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2013-07-29||2013-07-29|2010-08-03|2010-08-04|Estimate|2013-07-29|2013-09-27|Estimate||||2013-07-29|2013-09-27|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|CONNECT||Chronic Total Occlusion Crossing With the Wildcat Catheter|A Non-randomized Study of the Avinger Wildcat Used to Cross Femoropopliteal CTOs|Completed||Phase 3|88|Actual|Avinger, Inc.|||||f||||||||||||||2018-05-31 23:31:21.470842|2018-05-31 23:31:21.470842
NCT01174771|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-05-07|2010-08-03|2010-08-04|Estimate|||||||2014-05-07|2014-05-08|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Observational|||Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration|Noninvasive Cortical Stimulation (rTMS) for Motor and Non-Motor Features of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD)|Completed|||30|Actual|University of California, Los Angeles|||3||f||||f||||||||||2018-05-31 23:31:21.712057|2018-05-31 23:31:21.712057
NCT01174758|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2014-10-31|2010-08-03|2010-08-04|Estimate|||||||2014-10-31|2014-11-03|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Development of an Instrumented System to Measure Mobility in Parkinson's Disease|Development of an Instrumented System to Measure Mobility in Parkinson's Disease|Completed|||160|Actual|Oregon Health and Science University|||1||f||||||||||||||2018-05-31 23:31:21.820072|2018-05-31 23:31:21.820072
NCT01174732|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29||2017-04-17|2017-04-17|2010-08-02|2010-08-04|Estimate||||2017-04-17|2017-04-19|Actual|2017-04-17|2017-04-19|Actual|July 2010||2010-07-31|April 2017|2017-04-30|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Dose-Ranging Study of A006 DPI, in Adult Asthma Patients|Phase II Study Randomized, Double- or Evaluator-blind, Active- and Placebo-controlled, Single Dose, Seven-arm, Cross-over and Dose-ranging Study of A006 DPI, Albuterol Inhalation Powder, in Adult Asthma Patients|Completed||Phase 2|26|Actual|Amphastar Pharmaceuticals, Inc.||7|||f||||f||||||||||2018-05-31 23:31:21.909987|2018-05-31 23:31:21.909987
NCT01174719|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2015-04-06|2010-08-03|2010-08-04|Estimate|||||||2015-04-06|2015-04-08|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery|Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery|Completed||Phase 4|240|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 23:31:22.03275|2018-05-31 23:31:22.03275
NCT01174706|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2011-06-24|2010-08-03|2010-08-04|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients|Impact of Information Prescriptions on Medication Adherence in ED Patients|Unknown status|Recruiting|N/A|3800|Anticipated|Johns Hopkins University||4|||f||||f||||||||||2018-05-31 23:31:22.1866|2018-05-31 23:31:22.1866
NCT01172327|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-01-14|2010-07-28|2010-07-29|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Self-Directed Exercise Program for Adults With Arthritis|Evaluation of a Self-directed, Packaged Physical Activity Program for Adults With Arthritis|Completed||Phase 2|401|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 23:32:35.773859|2018-05-31 23:32:35.773859
NCT01174693|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-03|||2015-03-16|2010-08-03|2010-08-04|Estimate|||||||2015-03-16|2015-03-17|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|MAESTRO||Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping|Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping|Completed||Phase 4|795|Actual|Gangnam Severance Hospital||2|||f||||t||||||||||2018-05-31 23:31:22.305502|2018-05-31 23:31:22.305502
NCT01174680|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2017-03-13|2010-08-03|2010-08-04|Estimate|||||||2017-03-13|2017-03-14|Actual|December 2010|Actual|2010-12-31|August 2010|2010-08-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Cardiogoniometry for Early Diagnosis of Coronary Artery Disease Symptomatik|Cardiogoniometry Zur Früherkennung CAD Symptomatik|Completed||N/A|43|Actual|Stiftung Institut fuer Herzinfarktforschung||1|||f||||f||||||||||2018-05-31 23:31:22.559883|2018-05-31 23:31:22.559883
NCT01174667|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-03|2010-08-03|2010-08-04|Estimate|||||||2010-08-03|2010-08-04|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Massage of the Low Back Muscles Assessed With Ultrasound Scanning|Effect of Fascial Release on Connective Tissue Structure in Human Subjects With Chronic Low Back Pain as Determined by Ultrasound Imaging: a Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|70|Anticipated|Anglo-European College of Chiropractic||2|||f||||f||||||||||2018-05-31 23:31:22.61196|2018-05-31 23:31:22.61196
NCT01174654|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2012-12-12|2010-08-02|2010-08-03|Estimate|||||||2012-12-12|2012-12-13|Estimate|December 2006||2006-12-31|December 2012|2012-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Development of a Methamphetamine Early Intervention|Development of a Methamphetamine Early Intervention|Completed||Phase 1/Phase 2|127|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:31:22.68382|2018-05-31 23:31:22.68382
NCT01174641|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2010-08-02|2010-08-02|2010-08-03|Estimate|||||||2010-08-02|2010-08-03|Estimate|October 2010||2010-10-31|August 2010|2010-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Test of Trans-cranial Magnetic Stimulation (TMS) Intervention on Unilateral Neglect|A Randomised Double-blind Test of TMS Intervention on Unilateral Neglect|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Birmingham||2|||f||||t||||||||||2018-05-31 23:31:22.780552|2018-05-31 23:31:22.780552
NCT01174628|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-11-24|2010-08-02|2010-08-03|Estimate|||||||2014-11-24|2014-11-26|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Observational|ELOPE||Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism|The ELOPE Study: Prospective Evaluation of Long-term Outcomes After Pulmonary Embolism|Unknown status|Active, not recruiting||150|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital|||||f||||t||||||Samples With DNA|"~     platelet-poor plasma~   "|||2018-05-31 23:31:23.005137|2018-05-31 23:31:23.005137
NCT01174615|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2018-03-27|2010-08-02|2010-08-03|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2009||2009-09-30|March 2018|2018-03-31|December 2100|Anticipated|2100-12-31|December 2099|Anticipated|2099-12-31||Observational|||Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth|Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth in Patients With Malignancy or Hematologic Disorders|Recruiting|||1000|Anticipated|University of Massachusetts, Worcester|||||f||||f||||||Samples Without DNA|"~     Tissue/cells from patients' samples.~   "|||2018-05-31 23:31:23.430216|2018-05-31 23:31:23.430216
NCT01174602|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2015-01-28|2010-08-02|2010-08-03|Estimate|||||||2015-01-28|2015-01-29|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2011|Actual|2011-10-31||Interventional|||Inpatient Exposure Therapy and Response Prevention & Cognitive Remediation Therapy for Anorexia Nervosa|Randomized Controlled Trial of Inpatient Exposure Therapy and Response Prevention for Anorexia Nervosa|Completed||N/A|40|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 23:31:23.753959|2018-05-31 23:31:23.753959
NCT01174589|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2014-08-06|2010-08-02|2010-08-03|Estimate|||||||2014-08-06|2014-08-07|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Training of Patients With Hip Fracture|Strength Training of Patients With Hip Fracture - a Randomized Clinical Trial|Completed||Phase 2|100|Actual|Lolland Community, Denmark||2|||f||||f||||||||||2018-05-31 23:31:23.87252|2018-05-31 23:31:23.87252
NCT01174576|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2012-09-04||2013-07-26|2010-08-02|2010-08-03|Estimate|2013-07-26|2013-09-30|Estimate||||2013-07-26|2013-09-30|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Acute Effects of Coffee on Appetite and Inflammation Markers, Glucose Metabolism and Energy Intake|Acute Effects of Caffeinated and Decaffeinated Coffee Consumption on Energy Intake, Appetite, Inflammation and Glucose Metabolism|Completed||N/A|16|Actual|Harokopio University|the results cannot be generalized to other population groups, as participants were selected according to specific criteria.|3|||f||||f||||||||||2018-05-31 23:31:23.970477|2018-05-31 23:31:23.970477
NCT01174563|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2017-05-30|2010-08-02|2010-08-03|Estimate|||||||2017-05-30|2017-06-01|Actual|May 31, 2011|Actual|2011-05-31|May 2017|2017-05-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Patients With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy|A Multi-Center Study Investigating the Correlation Between TARCEVA ®-Induced Rash and Efficacy Among EGFR-mutated NSCLC Patients Receiving First-line Therapy|Completed||Phase 2|60|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:31:24.333193|2018-05-31 23:31:24.333193
NCT01174550|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2015-10-19||2016-02-02|2010-08-02|2010-08-03|Estimate|2016-02-02|2016-02-29|Estimate||||2016-02-02|2016-02-29|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PROMISE||PROspective Multicenter Imaging Study for Evaluation of Chest Pain|PROspective Multicenter Imaging Study for Evaluation of Chest Pain - The PROMISE Trial|Completed||N/A|10003|Actual|Duke University||2|||f||||t||||||||Yes|"Data will be submitted to the NHLBI according to their guidelines which stateThe data sets must be submitted to the study NHLBI study Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the PO for review prior to release."|2018-05-31 23:31:24.564539|2018-05-31 23:31:24.564539
NCT01174537|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2015-06-10|2010-08-02|2010-08-03|Estimate|||||||2015-06-10|2015-06-11|Estimate|July 2011||2011-07-31|August 2010|2010-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma|Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities|Withdrawn||Phase 1/Phase 2|0|Actual|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 23:31:25.116617|2018-05-31 23:31:25.116617
NCT01174524|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2010-08-02|2010-08-02|2010-08-03|Estimate|||||||2010-08-02|2010-08-03|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme|Improvement of Quality of Life in Patients Using Low-dose Pills in the Different Phases of Menacme|Completed||Phase 4|100|Actual|Hospital Geral de Fortaleza||1|||f||||f||||||||||2018-05-31 23:31:25.225278|2018-05-31 23:31:25.225278
NCT01174511|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2011-07-03|2010-08-02|2010-08-03|Estimate|||||||2011-07-03|2011-07-06|Estimate|July 2011||2011-07-31|July 2010|2010-07-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Evaluation of A-1 Cool Cream Efficacy for Treatment Atopic Dermatitis|Clinical Trial Study for Evaluation of A-1 Cool Cream Efficacy for Treatment Patients With Atopic Dermatitis|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 23:31:25.303724|2018-05-31 23:31:25.303724
NCT01174498|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2011-03-07|2010-08-02|2010-08-03|Estimate|||||||2011-03-07|2011-03-08|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Pilot Study of the Effect of Transcutaneous Stimulation of the Vagus Nerve on Pain Perception and Parameters of the Autonomic Nervous System|Controlled, Randomized Study of Pain Perception and Psychophysiological Reactions of the Autonomic Nervous System Under Transcutaneous, Electrical Stimulation of the Vagus Nerve in Healthy Volunteers|Completed||N/A|48|Anticipated|cerbomed GmbH||2|||f||||f||||||||||2018-05-31 23:31:25.365987|2018-05-31 23:31:25.365987
NCT01174485|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2011-05-11|2010-08-02|2010-08-03|Estimate|||||||2011-05-11|2011-05-13|Estimate|August 2010||2010-08-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effects of Liposuction and Exercise Training on Metabolism, Lipid Profile and Adiposity in Women|Effects of Liposuction and Exercise Training on Metabolism, Lipid Profile and Adiposity in Women|Completed||Early Phase 1|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:31:25.428262|2018-05-31 23:31:25.428262
NCT01174472|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2012-01-20|2010-08-02|2010-08-03|Estimate|||||||2012-01-20|2012-01-23|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||Drug Eluting Balloon Angioplasty for Dialysis Access Treatment|Drug Eluting Versus Conventional Balloon Angioplasty for the Treatment of Failing Dialysis Access. A Prospective Randomized Single-Center Trial.|Completed||Phase 2/Phase 3|40|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 23:31:25.492249|2018-05-31 23:31:25.492249
NCT01174459|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2014-07-09||2014-08-28|2010-08-02|2010-08-03|Estimate|2014-08-28|2014-08-29|Estimate||||2014-08-28|2014-08-29|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational||"Safety set: all patients who were documented to have taken at least one dose of pramipexole except for patients who had no observation documented after entry, made invalid registration or were not under the appropriate site contact.~56 patients who didn't visit hospital after the treatment of pramipexole for RLS were excluded from safety set."|Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome|Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome|Completed|||571|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:31:25.595213|2018-05-31 23:31:25.595213
NCT01174446|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|2013-09-20||2017-10-19|2010-08-02|2010-08-03|Estimate|2013-09-20|2013-11-25|Estimate||||2017-10-19|2017-11-24|Actual|July 2010||2010-07-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients|Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B|Completed||Phase 3|86|Actual|Shire||2|||f||||t||||||||||2018-05-31 23:31:26.14396|2018-05-31 23:31:26.14396
NCT01174433|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-07-03|2010-08-02|2010-08-03|Estimate|||||||2012-07-03|2012-07-04|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SAFE-TRY||Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)|Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)|Completed||Phase 1/Phase 2|241|Actual|University of Padua||1|||f||||t||||||||||2018-05-31 23:31:27.933692|2018-05-31 23:31:27.933692
NCT01174420|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2011-05-05|2010-08-02|2010-08-03|Estimate|||||||2011-05-05|2011-05-09|Estimate|November 2009||2009-11-30|May 2011|2011-05-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany|A Prospective Randomized Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy|Unknown status|Recruiting|N/A|40|Anticipated|Aeon Astron Europe B.V.||2|||f||||f||||||||||2018-05-31 23:31:28.005365|2018-05-31 23:31:28.005365
NCT01174407|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2010-08-02|2010-08-02|2010-08-03|Estimate|||||||2010-08-02|2010-08-03|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|August 2010|Anticipated|2010-08-31|December 2009|Anticipated|2009-12-31||Observational|||Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration|Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration|Unknown status|Active, not recruiting||120|Anticipated|Rudolf Foundation Clinic|||1||f||||f||||||||||2018-05-31 23:31:28.100248|2018-05-31 23:31:28.100248
NCT01174394|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2013-04-30|2010-08-01|2010-08-03|Estimate|||||||2013-04-30|2013-05-01|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Electroacupuncture Combined With Antidepressants for Post-stroke Depression|A Randomized, Assessor-blind, Controlled Trial of Electroacupuncture Combined With Antidepressants in Treating Patients With Post-stroke Depression|Completed||N/A|43|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:31:28.177703|2018-05-31 23:31:28.177703
NCT01174381|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2015-05-26|2010-08-02|2010-08-03|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||The Use of a Community-based Organization to Change Lifestyle Characteristics Related to Non Communicable Diseases|The Use of a Community-based Organization to Change Lifestyle Characteristics Related to Non Communicable Diseases: A Community Based Intervention Study Among 25-60 Year Olds|Completed||N/A|440|Actual|University of Kelaniya||1|||f||||f||||||||||2018-05-31 23:31:28.256922|2018-05-31 23:31:28.256922
NCT01174199|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2016-09-09|2010-08-02|2010-08-03|Estimate|||||||2016-09-09|2016-09-13|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer|A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination With the HDAC Inhibitor Vorinostat in Patients With Metastatic Prostate Cancer|Terminated||Phase 1|13|Actual|Roswell Park Cancer Institute||1||no value in finding efficacy|f||||t||||||||||2018-05-31 23:31:30.089947|2018-05-31 23:31:30.089947
NCT01174368|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-01|||2018-04-09|2010-08-02|2010-08-03|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2010|Actual|2010-06-30|April 2018|2018-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T|An Open-Label, Phase II Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T|Completed||Phase 2|1|Actual|The Rogosin Institute||1|||f||||t||||||||||2018-05-31 23:31:28.316068|2018-05-31 23:31:28.316068
NCT01174355|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-01|||2017-12-26|2010-08-02|2010-08-03|Estimate|||||||2017-12-26|2017-12-27|Actual|October 2010||2010-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)|A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)|Recruiting||Phase 1/Phase 2|45|Anticipated|NeuroDerm Ltd.||1|||f||||f||||||||||2018-05-31 23:31:28.372507|2018-05-31 23:31:28.372507
NCT01174342|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-01|2012-11-26||2013-01-09|2010-08-02|2010-08-03|Estimate|2012-11-26|2012-12-27|Estimate||||2013-01-09|2013-01-14|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Effect of Child Delivery on Intraocular Pressure|The Effect of Child Delivery on the Intraocular Pressure|Completed|||30|Actual|Meir Medical Center|The number of participants was small due to difficulties in recruitment.||1||f||||f||||||||||2018-05-31 23:31:28.431128|2018-05-31 23:31:28.431128
NCT01174329|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-08-17|2010-08-02|2010-08-03|Estimate|||||||2010-08-17|2010-08-18|Estimate|August 2010||2010-08-31|July 2010|2010-07-31||||December 2010|Anticipated|2010-12-31||Interventional|SALELECTROSTIM||Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation|Difference in Salivary Flow in Patients With Salivary Gland Hypofunction of the Following Application of Neuro-electrostimulation|Unknown status|Recruiting|Phase 2/Phase 3|14|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||f||||||||||2018-05-31 23:31:28.661315|2018-05-31 23:31:28.661315
NCT01174316|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2014-04-30|2010-08-02|2010-08-03|Estimate|||||||2014-04-30|2014-05-02|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Acute Exacerbation of Respiratory Failure|Autotitrating Non-invasive Ventilation (NIV) Versus Standard NIV; a Randomised Crossover Trial in Patients With Acute Exacerbation of Chronic Respiratory Failure|Unknown status|Enrolling by invitation|N/A|20|Anticipated|ResMed||2|||f||||f||||||||||2018-05-31 23:31:28.730775|2018-05-31 23:31:28.730775
NCT01174303|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2017-02-09|2010-08-02|2010-08-03|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2010||2010-08-31|February 2017|2017-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN5401 in Young Adults and Geriatric Subjects With Type 1 Diabetes|Completed||Phase 1|28|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:31:28.813846|2018-05-31 23:31:28.813846
NCT01174290|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-04-12|2010-08-02|2010-08-03|Estimate|||||||2017-04-12|2017-04-14|Actual|September 2010||2010-09-30|April 2017|2017-04-30|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol|Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study|Completed||Phase 4|68|Actual|Northeastern University||2|||f||||t||||||||||2018-05-31 23:31:28.891151|2018-05-31 23:31:28.891151
NCT01174277|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2017-01-06|2010-07-30|2010-08-03|Estimate|||||||2017-01-06|2017-01-10|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.|Immunological Changes in Chronic Graft Versus Host Disease Treated With Extracorporeal Photopheresis|Completed|||23|Actual|University of Kansas Medical Center|||1||f||||t||||||Samples With DNA|"~     Blood samples will be collected at study entry and at 2, 4, 6 and 12 months following~     treatment~   "|||2018-05-31 23:31:28.972284|2018-05-31 23:31:28.972284
NCT01174264|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2016-02-16||2017-04-11|2010-07-30|2010-08-03|Estimate|2016-02-16|2016-03-15|Estimate||||2017-04-11|2017-05-19|Actual|October 2009||2009-10-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of Food Effect on Pharmacokinetics of Vismodegib|Evaluation of Food Effect on Pharmacokinetics of GDC-0449, an Inhibitor of Hedgehog Signaling|Completed||Phase 1/Phase 2|63|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-05-31 23:31:29.05404|2018-05-31 23:31:29.05404
NCT01174251|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2013-10-07|2010-08-02|2010-08-03|Estimate|||||||2013-10-07|2013-10-08|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|10-02725||The Effect of General Anesthesia on the Risk for Arrhythmia|The Effect of General Anesthesia on the Risk for Arrhythmia -A Pilot Study|Completed|||125|Actual|University of California, San Francisco|||||f||||f||||||||||2018-05-31 23:31:29.804776|2018-05-31 23:31:29.804776
NCT01174238|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2013-12-11|2010-08-02|2010-08-03|Estimate|||||||2013-12-11|2013-12-12|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852)|A Two Arm Phase II Trial of Sequential Axitinib and Carboplatin/Paclitaxel in Melanoma With Correlative FLT PET Scans (3'Deoxy-3'-18F-Fluorothymidine Positron Emission Tomography Scans)(CC# 10852)|Completed||Phase 2|40|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:31:29.8607|2018-05-31 23:31:29.8607
NCT01174225|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2018-05-01|2010-08-02|2010-08-03|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2010||2010-09-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|September 2013|Actual|2013-09-30||Interventional|||IUD Insertion Post First Trimester Abortion|Contraception Satisfaction and Effectiveness: A Randomized Controlled Trial|Active, not recruiting||Phase 4|534|Actual|University of British Columbia||3|||f||||t||||||||No||2018-05-31 23:31:29.944546|2018-05-31 23:31:29.944546
NCT01174212|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2012-08-29|2010-08-02|2010-08-03|Estimate|||||||2012-08-29|2012-08-31|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Prophylactic Antibiotics on Intra-Operative Culture Results|Effect of Prophylactic Antibiotics on Intra-Operative Culture Results|Completed||Phase 4|65|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 23:31:30.015106|2018-05-31 23:31:30.015106
NCT01174186|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2014-04-12||2014-11-18|2010-08-02|2010-08-03|Estimate|2014-11-06|2014-11-17|Estimate||||2014-11-18|2014-12-02|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Interventional|INTASAH|n=15 in each group was determined by power calculations from previous pilot trials on differences in calprotectin|Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing|Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing|Completed||Phase 4|30|Actual|Regionshospitalet Silkeborg|"15 participants in each group is not many, but the number was selected based on an a priori analysis.~NSAID wash-out period of 4 weeks was chosen as best estimate. Loading dose of adalimumab was given to calprotectin elevated group"|2|||f||||t||||||||||2018-05-31 23:31:30.170239|2018-05-31 23:31:30.170239
NCT01174173|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2015-03-09||2018-04-10|2010-08-02|2010-08-03|Estimate|2015-04-22|2015-04-23|Estimate||||2018-04-10|2018-05-10|Estimate|June 2010||2010-06-30|April 2018|2018-04-30|October 2014|Actual|2014-10-31|January 2014|Actual|2014-01-31||Interventional||We prospectively enrolled 11 patients with WHO Group 1 PAH with mean age was 48±13 years and 73% of patients were women. Nearly half of the study participants were non-white.|Ranolazine and Pulmonary Hypertension|Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension|Completed||Phase 3|11|Actual|Northwestern University|This study was a small pilot Interventional study to test safety and tolerability of ranolazine in 11 patients with sx WHO Group 1 PAH patients.|1|||f||||f||||||||||2018-05-31 23:31:30.424219|2018-05-31 23:31:30.424219
NCT01174160|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2015-10-09||2015-11-09|2010-07-30|2010-08-03|Estimate|2015-11-09|2015-12-15|Estimate||||2015-11-09|2015-12-15|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)|A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation|Completed||Phase 3|123|Actual|Cardiome Pharma||2|||f||||f||||||||||2018-05-31 23:31:30.685809|2018-05-31 23:31:30.685809
NCT01174147|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2016-10-12|2010-08-02|2010-08-03|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)|Brazilian Network of Candidemia: a Laboratory-based Surveillance Study on Candida Bloodstream Infections in 10 Medical Centers|Completed|||436|Actual|Merck Sharp & Dohme Corp.|||1||f||||||||||||||2018-05-31 23:31:31.132445|2018-05-31 23:31:31.132445
NCT01174134|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2011-08-31|2010-08-02|2010-08-03|Estimate|||||||2011-08-31|2011-09-02|Estimate|July 2006||2006-07-31|August 2011|2011-08-31||||May 2007|Actual|2007-05-31||Interventional|||The Effects of Study Products Containing Varying Quantities of Docosahexaenoic Acid (DHA)||Completed||N/A|||Mead Johnson Nutrition||3|||f||||f||||||||||2018-05-31 23:31:31.176283|2018-05-31 23:31:31.176283
NCT01174121|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-31|||2018-05-23|2010-07-31|2010-08-03|Estimate|||||||2018-05-23|2018-05-24|Actual|July 15, 2010||2010-07-15|May 16, 2018|2018-05-16|December 27, 2024|Anticipated|2024-12-27|December 29, 2023|Anticipated|2023-12-29||Interventional|||Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer|A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumabat Time of Progression|Recruiting||Phase 2|332|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 23:31:31.233959|2018-05-31 23:31:31.233959
NCT01174108|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-31|||2018-05-08|2010-07-31|2010-08-03|Estimate|||||||2018-05-08|2018-05-09|Actual|July 30, 2010||2010-07-30|April 20, 2018|2018-04-20|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells|Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells|Recruiting||Phase 2|117|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:31:31.32152|2018-05-31 23:31:31.32152
NCT01174095|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-05-23|2010-08-02|2010-08-03|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2009||2009-05-31|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy|A Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy for the Treatment of Coronary Artery Disease Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA|Completed|||31|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||Undecided||2018-05-31 23:31:31.508209|2018-05-31 23:31:31.508209
NCT01174082|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-12-01|2010-07-30|2010-08-03|Estimate|||||||2017-12-01|2017-12-05|Actual|July 20, 2010|Actual|2010-07-20|December 2017|2017-12-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant|Phase II Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||4||Slow Accrual|f||||f|t|f||||||||2018-05-31 23:31:31.574217|2018-05-31 23:31:31.574217
NCT01174069|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2012-10-03|2010-08-02|2010-08-03|Estimate|||||||2012-10-03|2012-10-04|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|NOTESchole||Natural Orifice Transgastric Endoscopic Surgical Removal of the Gallbladder|Clinical Outcomes Trial of Laparoscopic Assisted Transgastric Endoscopic Cholecystectomy|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|The Oregon Clinic||1|||f||||f||||||||||2018-05-31 23:31:31.67115|2018-05-31 23:31:31.67115
NCT01174056|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2014-04-22|2010-07-30|2010-08-03|Estimate|||||||2014-04-22|2014-04-23|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging|Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone|Completed||Early Phase 1|39|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 23:31:31.742639|2018-05-31 23:31:31.742639
NCT01174043|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2015-03-18||2015-03-18|2010-07-30|2010-08-03|Estimate|2015-03-18|2015-03-27|Estimate||||2015-03-18|2015-03-27|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia|Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia|Completed||Phase 2|11|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 23:31:31.836136|2018-05-31 23:31:31.836136
NCT01174030|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2013-09-19|2011-06-06|2014-01-24|2010-08-02|2010-08-03|Estimate|2014-01-24|2014-03-11|Estimate|2011-06-06|2011-06-16|Estimate|2014-01-24|2014-03-11|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea|A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea|Completed||Phase 2|269|Actual|Galderma||5|||f||||f||||||||||2018-05-31 23:31:32.171344|2018-05-31 23:31:32.171344
NCT01174017|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2013-02-08|2010-08-02|2010-08-03|Estimate|||||||2013-02-08|2013-02-12|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|FAST||Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate|A Study Assessing the Ability of AnchorSeed Iodine-125 Sources to Hold Fast in Tissue When Implanted for Treatment of Localized Prostate Cancer|Completed||Phase 3|41|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 23:31:32.83356|2018-05-31 23:31:32.83356
NCT01174004|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2014-02-06||2014-02-06|2010-07-30|2010-08-03|Estimate|2014-02-06|2014-03-26|Estimate||||2014-02-06|2014-03-26|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis|A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease|Completed||Phase 3|199|Actual|ACADIA Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 23:31:32.943783|2018-05-31 23:31:32.943783
NCT01173991|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-08-02|2010-08-02|2010-08-03|Estimate|||||||2010-08-02|2010-08-03|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|GIOCAR||Carbohydrate Counting in Adults With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion|Clinical Assessment of Carbohydrate Counting in Adult Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion: a Randomized Controlled Study (GIOCAR)|Completed||Phase 3|61|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-05-31 23:31:33.339709|2018-05-31 23:31:33.339709
NCT01173978|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-06-20|2010-08-02|2010-08-03|Estimate|||||||2011-06-20|2011-06-21|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance|Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Induced by Steroid Treatment, Relative Physical Inactivity and High Calorie Diet|Completed||N/A|10|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 23:31:33.412485|2018-05-31 23:31:33.412485
NCT01173965|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-02|||2012-07-11|2010-08-02|2010-08-03|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|||Endometrial Ablation With Non-hysteroscopic Methods|Treatment of Dysfunctional Uterine Bleeding With Second Generation Ablation Devices: Microwaves (MEA®) vs Bipolar Impedance Control System (Novasure®)|Completed||Phase 4|66|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 23:31:33.482388|2018-05-31 23:31:33.482388
NCT01173952|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2010-07-30|2010-07-30|2010-08-02|Estimate|||||||2010-07-30|2010-08-02|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Observational|||Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Versus Radical Retropubic Prostatectomy|Prospective Evaluation of Quality of Life in Men Undergoing Robotic Assisted Laparoscopic Radical Prostatectomy Vs. Radical Retropubic Prostatectomy|Unknown status|Not yet recruiting||350|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-05-31 23:31:33.538934|2018-05-31 23:31:33.538934
NCT01173939|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-05-30|2010-07-30|2010-08-02|Estimate|||||||2011-05-30|2011-06-01|Estimate|July 2010||2010-07-31|November 2010|2010-11-30||||June 2014|Anticipated|2014-06-30||Interventional|POSITIVE||Primary Prevention of Major Adverse Cardiac Events (MACE) With Standard and Intensive Statin Treatment in Patients With Diabetes: Survival and Cardiovascular Event Assessments|Primary Prevention of MACE With Standard and Intensive Statin Treatment in Hypercholesterolemia Patients With Concomitant Diabetes and Hypertension|Terminated||N/A|10000|Anticipated|Positive Trial Group||2||"With recommendation from IDMC, Steering Committee terminated this trial due to ethical concerns~   raised by J-ART study."|f||||||||||||||2018-05-31 23:31:33.625048|2018-05-31 23:31:33.625048
NCT01173926|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2013-11-26|2010-07-30|2010-08-02|Estimate|||||||2013-11-26|2013-11-27|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes|A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties Between NN5401 and NN1250 and Between NN5401 and Insulin Aspart in Subjects With Type 1 Diabetes|Completed||Phase 1|27|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 23:31:34.18345|2018-05-31 23:31:34.18345
NCT01173913|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2016-12-14|2010-07-30|2010-08-02|Estimate|||||||2016-12-14|2016-12-15|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|||Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir|Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir|Unknown status|Active, not recruiting|Phase 1|58|Anticipated|The Netherlands Cancer Institute||3|||f||||f||||||||||2018-05-31 23:31:34.245494|2018-05-31 23:31:34.245494
NCT01173900|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2011-11-05|2010-07-30|2010-08-02|Estimate|||||||2011-11-05|2011-11-08|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls|Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls|Completed||Phase 4|5532|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 23:31:35.764845|2018-05-31 23:31:35.764845
NCT01173887|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2017-03-29|2010-07-30|2010-08-02|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2010||2010-07-31|March 2017|2017-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15|Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma (Untreated Primary Disease)|Completed||Phase 2|44|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f|||||f|f||||||||2018-05-31 23:31:35.954871|2018-05-31 23:31:35.954871
NCT01173692|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-11-21|2010-07-29|2010-08-02|Estimate|||||||2017-11-21|2017-11-24|Actual|July 2010|Actual|2010-07-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.|Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.|Active, not recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 23:31:38.090124|2018-05-31 23:31:38.090124
NCT01173874|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2016-11-01||2017-02-28|2010-07-30|2010-08-02|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|July 2010||2010-07-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional||Randomized participants|Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone|Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone|Completed||Phase 3|120|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 23:31:36.061019|2018-05-31 23:31:36.061019
NCT01173861|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2012-07-12|2010-07-30|2010-08-02|Estimate|||||||2012-07-12|2012-07-13|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effectiveness of a Cancer Center Based Physical Activity Intervention|Effectiveness of a Cancer Center Based Physical Activity Intervention|Completed||N/A|20|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 23:31:36.316748|2018-05-31 23:31:36.316748
NCT01173848|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|2017-02-15||2017-03-30|2010-07-30|2010-08-02|Estimate|2017-03-30|2017-04-04|Actual||||2017-03-30|2017-04-04|Actual|July 2010||2010-07-31|July 2013|2013-07-31|October 18, 2011|Actual|2011-10-18|September 2011|Actual|2011-09-30||Interventional|UPGRADE||Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients|A Randomized Study to Evaluate the Effectiveness of Cholecalciferol Versus Ergocalciferol Following Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines for Vitamin D Therapy in Stages 3 & 4 Chronic Kidney Disease (CKD) Patients|Terminated||Phase 3|19|Actual|The Cleveland Clinic|"Adverse Events were not logged by study arms.~Early termination of the study lead to small numbers of subjects analyzed."|2|||f||||f||||||||||2018-05-31 23:31:36.497299|2018-05-31 23:31:36.497299
NCT01173835|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2012-07-02|2010-07-30|2010-08-02|Estimate|||||||2012-07-02|2012-07-04|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|Rise Above||Incentive-based Intervention for Smoking Cessation and Prevention in High Schools|Incentive-based Intervention for Smoking Cessation and Prevention in High Schools|Completed||Phase 1|1651|Actual|Yale University|||||f||||t||||||||||2018-05-31 23:31:36.745982|2018-05-31 23:31:36.745982
NCT01173822|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-30|2010-07-30|2010-08-02|Estimate|||||||2010-07-30|2010-08-02|Estimate|December 2004||2004-12-31|July 2010|2010-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|PRBC||Processed Residual Pump Blood in Cardiac Surgery: The PRBC Trial|Processed Residual Pump Blood in Cardiac Surgery: The PRBC Trial|Completed||N/A|200|Actual|McMaster University||2|||f||||t||||||||||2018-05-31 23:31:36.822596|2018-05-31 23:31:36.822596
NCT01173809|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2014-08-20|2010-07-29|2010-08-02|Estimate|||||||2014-08-20|2014-08-21|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|SPECULATE||Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation|Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation|Completed||Phase 3|176|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-05-31 23:31:36.914368|2018-05-31 23:31:36.914368
NCT01173796|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-07-10|2010-07-29|2010-08-02|Estimate|||||||2012-07-10|2012-07-11|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PROPOSE||Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes|Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillation: Impact on Outcomes|Completed||Phase 3|44|Actual|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-05-31 23:31:36.995961|2018-05-31 23:31:36.995961
NCT01173783|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2016-06-23|2010-07-30|2010-08-02|Estimate|||||||2016-06-23|2016-06-24|Estimate|March 2007||2007-03-31|June 2016|2016-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Deutsches Device Qualitätsregister|Deutsches Device Qualitätsregister|Completed|||4008|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No||2018-05-31 23:31:37.076797|2018-05-31 23:31:37.076797
NCT01173770|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2011-02-01|2010-07-29|2010-08-02|Estimate|||||||2011-02-01|2011-02-02|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ADC3680B in Healthy Volunteers|A Double-Blind Randomized, Placebo-Controlled, Dose Escalating Study to Assess The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ADC3680B Administered Orally to Healthy Volunteers and to Investigate Food Effects on Pharmacokinetics After Single Oral Doses of ADC3680B|Completed||Phase 1|52|Actual|Pulmagen Therapeutics||6|||f||||f||||||||||2018-05-31 23:31:37.148519|2018-05-31 23:31:37.148519
NCT01173757|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2011-05-31|2010-07-29|2010-08-02|Estimate|||||||2011-05-31|2011-06-01|Estimate|August 2010||2010-08-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers|A Phase I, Healthy Volunteer Determination Of 5HT4 Receptor Occupancy Of PF-04995274, Using PET With Ligand [11C]PF-05127401.|Completed||Phase 1|8|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:31:37.213381|2018-05-31 23:31:37.213381
NCT01173744|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-06-16|2010-07-29|2010-08-02|Estimate|||||||2011-06-16|2011-06-17|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Comparison of Gamma Nail Versus Dynamic Hip Screw for the Treatment of Unstable Intertrochanteric Fractures||Unknown status|Recruiting|N/A|60|Anticipated|Wolfson Medical Center||2|||f||||||||||||||2018-05-31 23:31:37.277074|2018-05-31 23:31:37.277074
NCT01173731|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2017-03-17|2010-07-29|2010-08-02|Estimate|||||||2017-03-17|2017-03-21|Actual|October 2010||2010-10-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias|Completed||Phase 2|66|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:31:37.350341|2018-05-31 23:31:37.350341
NCT01173718|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2013-05-08||2013-07-19|2010-07-30|2010-08-02|Estimate|2013-05-08|2013-07-02|Estimate||||2013-07-19|2013-07-26|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|ACUSEAL||Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access|Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access (ACUSEAL, AVG 08-06)|Completed||Phase 2/Phase 3|138|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-05-31 23:31:37.484721|2018-05-31 23:31:37.484721
NCT01173705|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-01-19|2010-07-29|2010-08-02|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Factors Involved in Obesity-related Inflammation and Insulin Resistance|Genetic and Nutritional Factors Involved in Obesity-related Inflammation and Insulin Resistance|Terminated|||62|Actual|Vanderbilt University Medical Center|||2||f||||f||||||Samples With DNA|"~     Whole blood, omentum biopsy, subcutaneous fat biopsy, muscle biopsy (abdominal wall)~   "|||2018-05-31 23:31:37.991218|2018-05-31 23:31:37.991218
NCT01173679|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2017-01-25||2017-03-17|2010-07-30|2010-08-02|Estimate|2017-01-30|2017-03-20|Actual||||2017-03-17|2017-04-14|Actual|July 2010||2010-07-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL|Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Terminated||Phase 2|10|Actual|Massachusetts General Hospital||1||Slow accrual|f||||t||||||||No|I do not plan to share IPD.|2018-05-31 23:31:38.209346|2018-05-31 23:31:38.209346
NCT01173666|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2010-07-30|2010-07-30|2010-08-02|Estimate|||||||2010-07-30|2010-08-02|Estimate|April 2006||2006-04-30|July 2010|2010-07-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|RASCAD||Stenting of Renal Artery Stenosis in Coronary Artery Disease Study|Renal Artery Stenosis in Coronary Artery Disease: Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing Cardiac and Renal Outcomes. The Rationale and Study Design of a Prospective,Randomized Trial: the RASCAD Study|Unknown status|Recruiting|Phase 3|168|Anticipated|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele||2|||f||||t||||||||||2018-05-31 23:31:38.553642|2018-05-31 23:31:38.553642
NCT01173653|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2012-01-09||2012-12-19|2010-07-30|2010-08-02|Estimate|2012-10-18|2012-11-19|Estimate||||2012-12-19|2012-12-27|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Smoking Cessation Invention in the Emergency Department (ED)|A Randomized Controlled Trial of Directed Smoking Cessation Intervention in the Emergency Care Population|Completed||N/A|199|Actual|Vanderbilt University|This is a preliminary study with a convenience sample of patients at a single academic medical center. A larger multicenter trial targeting consecutive ED patients who smoke will be essential to validate the applicability of our findings.|2|||f||||f||||||||||2018-05-31 23:31:38.871223|2018-05-31 23:31:38.871223
NCT01173640|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-10-27|2010-07-30|2010-08-02|Estimate|||||||2017-10-27|2017-10-31|Actual|July 2010||2010-07-31|October 2017|2017-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Resveratrol and Midazolam Metabolism|Resveratrol and Midazolam Metabolism|Completed||N/A|6|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 23:31:39.939337|2018-05-31 23:31:39.939337
NCT01173627|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2016-10-18|2010-07-30|2010-08-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Oral Transmucosal Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Actiq 400 mcg, Cephalon, Inc.) in Normal Human Subjects Under Fasting Conditions|Completed||Phase 1|50|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 23:31:40.118608|2018-05-31 23:31:40.118608
NCT01173614|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2016-06-14|2010-07-30|2010-08-02|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Observational|Gullstrand||Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes|Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes|Completed|||1646|Actual|European Vision Institute Clinical Research Network|||1||f||||f||||||||||2018-05-31 23:31:40.23963|2018-05-31 23:31:40.23963
NCT01173601|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2018-02-17|2014-01-07|2018-03-17|2010-07-29|2010-08-02|Estimate|2018-03-17|2018-04-17|Actual|2014-01-07|2014-02-06|Estimate|2018-03-17|2018-04-17|Actual|November 2010||2010-11-30|March 2018|2018-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Participants who completed the Confirmation Phase and were randomized to adjunctive LY2216684 or adjunctive placebo or who did not meet randomization criteria and continued on placebo to maintain the blind.|A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder|A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 Milligrams (mg) and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment|Completed||Phase 3|1416|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 23:31:40.47412|2018-05-31 23:31:40.47412
NCT01173588|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2010-07-29|2010-07-29|2010-08-02|Estimate|||||||2010-07-29|2010-08-02|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function.|Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function: A Randomized, Double-blind, Longitudinal Controlled Study in Mexican Adult.|Completed||Phase 3|174|Actual|Instituto Lala||2|||f||||t||||||||||2018-05-31 23:31:43.672505|2018-05-31 23:31:43.672505
NCT01173575|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-01-31|2010-07-29|2010-08-02|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection|Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection|Completed|||214|Actual|Infectopharm Arzneimittel GmbH|||1||f||||f||||||||||2018-05-31 23:31:43.95596|2018-05-31 23:31:43.95596
NCT01173562|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2014-03-11|2010-07-29|2010-08-02|Estimate|||||||2014-03-11|2014-03-12|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Safety Study of Mebendazole in Children 2 to 10 Years of Age|An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive|Completed||Phase 3|397|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 23:31:44.210327|2018-05-31 23:31:44.210327
NCT01173549|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2011-12-30|2010-07-29|2010-08-02|Estimate|||||||2011-12-30|2012-01-02|Estimate|November 2010||2010-11-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|||||Interventional|||A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers|A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Subjects|Completed||Phase 1|26|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 23:31:44.386701|2018-05-31 23:31:44.386701
NCT01173536|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-02-16|2010-07-29|2010-08-02|Estimate|||||||2017-02-16|2017-02-17|Actual|August 25, 2010|Actual|2010-08-25|February 2017|2017-02-28|March 18, 2011|Actual|2011-03-18|March 18, 2011|Actual|2011-03-18||Interventional|||A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects|A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Parallel-Group Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects|Completed||Phase 1|61|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:31:45.147206|2018-05-31 23:31:45.147206
NCT01173523|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2017-02-28||2018-01-29|2010-07-30|2010-08-02|Estimate|2017-02-28|2017-04-11|Actual||||2018-01-29|2018-02-23|Actual|July 28, 2010|Actual|2010-07-28|January 2018|2018-01-31|November 4, 2016|Actual|2016-11-04|June 7, 2013|Actual|2013-06-07||Interventional||The analysis dataset is comprised of all treated patients.|Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer|A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer|Completed||Phase 2|25|Actual|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 23:31:45.703309|2018-05-31 23:31:45.703309
NCT01173510|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-06-13|2010-07-29|2010-08-02|Estimate|||||||2017-06-13|2017-06-14|Actual|August 23, 2010|Anticipated|2010-08-23|June 2017|2017-06-30|October 19, 2012|Actual|2012-10-19|October 19, 2012|Actual|2012-10-19||Interventional|||A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells|A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells|Withdrawn||Phase 4|0|Actual|Community Research Initiative of New England||2||This study was not feasible due to facility budget and contractual issues.|f||||t||||||||||2018-05-31 23:31:46.313029|2018-05-31 23:31:46.313029
NCT01173497|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28||2016-02-17|2016-02-17|2010-07-29|2010-08-02|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|July 2013|Actual|2013-07-31|October 2012|Actual|2012-10-31||Interventional|||A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis|A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis|Completed||Phase 2|44|Actual|Sanofi||1|||t||||||||||||||2018-05-31 23:31:46.447137|2018-05-31 23:31:46.447137
NCT01173484|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-04-06|2010-07-29|2010-08-02|Estimate|||||||2017-04-06|2017-04-10|Actual|June 2010||2010-06-30|April 2017|2017-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification|Idiopathic Gastroparesis Registry to Define Severity, Treatment Response, and Prognosis Using a Predominant-Symptom Classification|Terminated|||15|Actual|University of Louisville|||3|Principal investigator has left the Institution|f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:31:46.866609|2018-05-31 23:31:46.866609
NCT01173471|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2013-08-02||2014-01-20|2010-07-29|2010-08-02|Estimate|2013-08-02|2013-10-14|Estimate||||2014-01-20|2014-02-14|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure|A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure|Completed||Phase 2|50|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:31:47.279116|2018-05-31 23:31:47.279116
NCT01173458|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2017-01-06|2010-07-30|2010-08-02|Estimate|||||||2017-01-06|2017-01-10|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|November 2012|Actual|2012-11-30||Observational|||Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)|A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)|Completed|||25|Actual|University of Kansas Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected before treatment begins, at completion of treatment, and~     every 6 to 8 weeks during follow-up visits.~   "|||2018-05-31 23:31:50.987873|2018-05-31 23:31:50.987873
NCT01173445|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-10-19|2010-07-30|2010-08-02|Estimate|||||||2011-10-19|2011-10-20|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma|A Pilot Study on the Assessment of Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma|Completed|||19|Actual|University of Kansas Medical Center|||||f||||f||||||None Retained|"~     Blood samples will be collected at the following times:~        -  one draw prior to treatment initiation~        -  one draw after completion of two treatment cycles~        -  one draw at the time of disease progression~   "|||2018-05-31 23:31:52.671993|2018-05-31 23:31:52.671993
NCT01173432|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2018-02-25|2010-07-30|2010-08-02|Estimate|||||||2018-02-25|2018-02-27|Actual|June 2008||2008-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Exploring the Role of Adipocyte Fatty Acid Binding Protein in the Association of Obstructive Sleep Apnea and Metabolic Dysfunction|Randomized Controlled Trial of the Effect of Continuous Positive Airway Pressure on Adipocyte Fatty Acid Binding Protein and Other Metabolic Markers in Obstructive Sleep Apnea|Active, not recruiting||N/A|90|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:31:53.41517|2018-05-31 23:31:53.41517
NCT01173419|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-07-12|2010-07-30|2010-08-02|Estimate|||||||2012-07-12|2012-07-13|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|February 2012|Anticipated|2012-02-29|February 2011|Anticipated|2011-02-28||Interventional|RECoN||Comparison Study for Safety and Efficacy of Two Devices for the Treatment of the Great Saphenous Vein|A Multi-Center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Subjects Comparing the NeverTouch Versus the RF ClosureFAST Methods of Treatment of the Great Saphenous Vein|Withdrawn||N/A|0|Actual|Angiodynamics, Inc.||2||Business decision to reevaluate clinical needs.|f||||f||||||||||2018-05-31 23:31:54.518292|2018-05-31 23:31:54.518292
NCT01173406|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2013-10-18|2010-07-30|2010-08-02|Estimate|||||||2013-10-18|2013-10-21|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Education Programme on Continuous Positive Airway Pressure Treatment|The Efficacy of a Brief Motivational Enhancement Education Programme on Continuous Positive Airway Pressure Adherence in Obstructive Sleep Apnea: A Randomised Controlled Trial|Completed||N/A|100|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:31:55.850029|2018-05-31 23:31:55.850029
NCT01173393|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2015-01-20|2010-07-29|2010-08-02|Estimate|||||||2015-01-20|2015-01-22|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|RINSE||Rapid Infusion of Cold Normal Saline During CPR for Patients With Out-of-hospital Cardiac Arrest|The RINSE Trial: Rapid Infusion of Cold Saline During CPR for Patients With Cardiac Arrest|Completed||Phase 3|1220|Actual|Ambulance Victoria||1|||f||||t||||||||||2018-05-31 23:31:56.386719|2018-05-31 23:31:56.386719
NCT01173380|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-05-25|2010-07-29|2010-08-02|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2010||2010-08-31|May 2017|2017-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Soy Nut Study on Markers of Health|Effects of Soy on Metabolite Markers of Health|Completed||N/A|18|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 23:31:56.661198|2018-05-31 23:31:56.661198
NCT01173367|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-02-21|2010-07-29|2010-08-02|Estimate|||||||2012-02-21|2012-02-23|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Anti-pyretic Therapy in Critically Ill Adults|Assessment of the Safety of Anti-pyretic Therapy in Critically Ill Adults|Completed||Phase 2|26|Actual|University of Calgary||2|||f||||||||||||||2018-05-31 23:31:56.797241|2018-05-31 23:31:56.797241
NCT01173328|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-30|2010-07-30|2010-08-02|Estimate|||||||2010-07-30|2010-08-02|Estimate|March 2007||2007-03-31|August 2008|2008-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effects of Pursed-lip Breathing on Exercise Tolerance and Dynamic Hyperinflation in COPD|Effects of Pursed-lip Breathing on Exercise Tolerance and Dynamic Hyperinflation in Chronic Obstructive Pulmonary Disease|Completed||N/A|40|Actual|Universidade Federal do Rio de Janeiro||1|||f||||t||||||||||2018-05-31 23:31:57.377332|2018-05-31 23:31:57.377332
NCT01173315|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2010-07-30|2010-07-30|2010-08-02|Estimate|||||||2010-07-30|2010-08-02|Estimate|June 2007||2007-06-30|April 2006|2006-04-30|September 2009|Actual|2009-09-30|August 2008|Actual|2008-08-31||Interventional|||The Impact of Vitamins and Minerals Supplementation on Neuropathy and Nephropathy Complications|The Impact of Vitamins and Minerals Supplementation on Neuropathy and Nephropathy Complications in Type 2 Diabetic Patients: a Randomised Clinical Trial|Completed||Phase 2|75|Actual|Shahid Beheshti University of Medical Sciences||3|||f||||||||||||||2018-05-31 23:31:57.791031|2018-05-31 23:31:57.791031
NCT01173302|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-30|2010-07-30|2010-08-02|Estimate|||||||2010-07-30|2010-08-02|Estimate|May 2010||2010-05-31|July 2010|2010-07-31|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Interventional|||Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose|Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose|Unknown status|Enrolling by invitation|Phase 4|160|Anticipated|Peking University People's Hospital||1|||f||||t||||||||||2018-05-31 23:31:58.487417|2018-05-31 23:31:58.487417
NCT01173289|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-10-05|2010-07-30|2010-08-02|Estimate|||||||2015-10-05|2015-10-07|Estimate|December 2009||2009-12-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of External Beam Radiotherapy to Thyroid Carcinoma|A Phase II Study of External Beam Radiotherapy for Locoregionally Advanced or Recurrent Differentiated Thyroid Carcinoma|Completed||Phase 2|62|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 23:31:59.999521|2018-05-31 23:31:59.999521
NCT01173276|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2016-02-19|2010-07-30|2010-08-02|Estimate|||||||2016-02-19|2016-02-22|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|October 2013|Actual|2013-10-31|September 2012|Actual|2012-09-30||Interventional|ARTEMIS||Intrauterine Insemination In HIV-Discordant Couples|Intrauterine Insemination In HIV-Discordant Couples|Terminated||N/A|10|Actual|Boston Medical Center||||The field has changed, and we have decided to develop a PrEP program.|f||||f||||||||||2018-05-31 23:32:00.324906|2018-05-31 23:32:00.324906
NCT01173263|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2014-03-04|2010-07-30|2010-08-02|Estimate|||||||2014-03-04|2014-03-05|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Bispectral Index (BIS) Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients|Effect of BIS Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients|Terminated||N/A|1|Actual|The Cleveland Clinic||3||recruitment difficulties|f||||t||||||||||2018-05-31 23:32:00.834427|2018-05-31 23:32:00.834427
NCT01173250|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2010-08-13|2010-07-30|2010-08-02|Estimate|||||||2010-08-13|2010-08-16|Estimate||||October 2010|2010-10-31||||||||Interventional|||Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?||Completed||N/A|||Mansoura University||2|||f||||||||||||||2018-05-31 23:32:01.156544|2018-05-31 23:32:01.156544
NCT01173237|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2011-06-27|2010-07-30|2010-08-02|Estimate|||||||2011-06-27|2011-06-28|Estimate|July 2011||2011-07-31|July 2010|2010-07-31|July 2013|Anticipated|2013-07-31|March 2012|Anticipated|2012-03-31||Interventional|||Efficacy Evaluation of Surfactant Administration Via Laryngeal Mask Airway|Efficacy Evaluation of Surfactant Administration for Respiratory Distress Syndrome Treatment Via Laryngeal Mask Airway. A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 23:32:01.516761|2018-05-31 23:32:01.516761
NCT01173224|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2013-07-18|2010-07-29|2010-07-30|Estimate|||||||2013-07-18|2013-07-19|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Influenza Antiviral DAS181-F03|A Phase I C Clinical Study With Influenza Antiviral DAS181-F03: Double-Blind, Randomized, Placebo-Controlled, Single Dose and Multiple Dose Escalation Study in Healthy Adults|Completed||Phase 1|18|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-05-31 23:32:03.220498|2018-05-31 23:32:03.220498
NCT01173211|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2012-11-15||2014-12-04|2010-07-29|2010-07-30|Estimate|2012-12-20|2013-01-31|Estimate||||2014-12-04|2014-12-24|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women|A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Seasonal 2010-2011 Inactivated Trivalent Influenza Vaccine in Pregnant Women|Completed||Phase 2|183|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-05-31 23:32:03.540924|2018-05-31 23:32:03.540924
NCT01173198|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-06-13|2010-07-29|2010-07-30|Estimate|||||||2012-06-13|2012-06-14|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||An Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients|A Prospective Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients|Completed||Phase 4|37|Actual|Innovative Medical||2|||f||||f||||||||||2018-05-31 23:32:10.06342|2018-05-31 23:32:10.06342
NCT01173172|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-07-30|2010-07-28|2010-07-30|Estimate|||||||2010-07-30|2010-08-03|Estimate|July 2010||2010-07-31|April 2010|2010-04-30|October 2012|Anticipated|2012-10-31|June 2012|Anticipated|2012-06-30||Interventional|BNCT||Boron Neutron Capture Therapy (BNCT) for Locally Recurrent Head and Neck Cancer|A Phase I/II Trial of Boron Neutron Capture Therapy (BNCT) for Recurrent Head and Neck Cancer at Tsing-Hua Open Pool Reactor|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f||||t||||||||||2018-05-31 23:32:10.357778|2018-05-31 23:32:10.357778
NCT01173159|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2018-01-25|2010-07-29|2010-07-30|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2010||2010-07-31|January 2018|2018-01-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Interventional|||Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis|Compassionate Use of a Fish Oil-derived Intravenous Fat Emulsion (Omegaven) to Reverse Parenteral Nutrition (PN) Induced Cholestasis|Recruiting||N/A|25|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 23:32:10.672542|2018-05-31 23:32:10.672542
NCT01173146|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2016-05-23|2010-07-29|2010-07-30|Estimate|||||||2016-05-23|2016-05-25|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Imaging of Residual Tumor During Prostatectomy|Imaging of Residual Prostate Cancer During Prostatectomy Using ProstaFluor®, a Prostate-Specific Membrane Antigen (PSMA)-Targeted Fluorescent Agent FDA Trial|Withdrawn|||0|Actual|Spectros Corporation||||Costs for antibody production rose; supplemental funding request not approved.|f||||t||||||||No|Study withdrawn, no data collected.|2018-05-31 23:32:11.047095|2018-05-31 23:32:11.047095
NCT01173133|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2011-01-30|2010-07-29|2010-07-30|Estimate|||||||2011-01-30|2011-02-01|Estimate|April 2009||2009-04-30|January 2011|2011-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery|Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery|Unknown status|Recruiting||50|Anticipated|Spectros Corporation|||||f||||t||||||||||2018-05-31 23:32:11.286364|2018-05-31 23:32:11.286364
NCT01173120|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2011-05-03||2012-01-09|2010-07-29|2010-07-30|Estimate|2011-06-08|2011-07-06|Estimate||||2012-01-09|2012-01-12|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Interventional|MTX-IR||Methotrexate - Inadequate Response Device Sub-Study|Sub-study-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate|Completed||Phase 3|62|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 23:32:12.498208|2018-05-31 23:32:12.498208
NCT01173107|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-12-27|2010-07-28|2010-07-30|Estimate|||||||2010-12-27|2010-12-29|Estimate|December 2010||2010-12-31|December 2010|2010-12-31||||December 2010|Actual|2010-12-31||Interventional|||A Pilot Study for PK/PD Parameter of Colchicine in Chronic Kidney Disease Patient.||Completed||Phase 4|80|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 23:32:14.3781|2018-05-31 23:32:14.3781
NCT01173094|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-12-20|2010-07-28|2010-07-30|Estimate|||||||2012-12-20|2012-12-24|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|July 2016|Anticipated|2016-07-31|July 2013|Anticipated|2013-07-31||Interventional|DCLI-II||Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part II) (DCLI-II)|DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II)|Unknown status|Enrolling by invitation|Phase 4|130|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 23:32:14.512078|2018-05-31 23:32:14.512078
NCT01173081|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-06-04|2010-07-28|2010-07-30|Estimate|||||||2012-06-04|2012-06-05|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures|The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures|Unknown status|Recruiting|Phase 4|38|Anticipated|Ohio Orthopedic Center of Excellence||2|||f||||f||||||||||2018-05-31 23:32:14.634773|2018-05-31 23:32:14.634773
NCT01173068|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-04-01|2010-07-29|2010-07-30|Estimate|||||||2014-04-01|2014-04-03|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.|A Prospective Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.|Unknown status|Recruiting||60|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 23:32:14.779315|2018-05-31 23:32:14.779315
NCT01173055|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2014-08-05||2017-10-04|2010-07-29|2010-07-30|Estimate|2015-02-03|2015-02-20|Estimate||||2017-10-04|2017-11-08|Actual|June 2010||2010-06-30|October 2017|2017-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||The milnacipran then placebo arm was reduced from eight to six participants for the analysis due to tolerating a dose of Milnacipran less than 200mg/day. This was done to be consistent with the dosing of all other participants.|A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia|A Randomized, Double-blind,Placebo-controlled, Two-way Crossover Study to Evaluate the Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging Activation Patterns in Patients With Fibromyalgia|Completed||Phase 4|22|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 23:32:14.923164|2018-05-31 23:32:14.923164
NCT01173042|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-05-26|2010-07-29|2010-07-30|Estimate|||||||2017-05-26|2017-05-31|Actual|August 2009||2009-08-31|May 2017|2017-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|PKEPEANUT||Effects of Peanut Consumption on Postprandial Inflammation, Glucose and Triglycerides|Pilot Study of the Effect of Peanut Consumption on Postprandial Inflammatory Status, Glucose and Triglycerides|Completed||Phase 1|6|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 23:32:15.58588|2018-05-31 23:32:15.58588
NCT01173029|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2011-04-21||2013-04-13|2010-07-29|2010-07-30|Estimate|2013-01-25|2013-03-06|Estimate||||2013-04-13|2013-04-22|Estimate|June 2001||2001-06-30|April 2013|2013-04-30|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Observational|GENHART|"Subjects referred from primary care with diagnosis of resistant arterial hypertension. Each one had a clinical visit scheduled in the center within one week of referral. All were taking two AH drugs plus diuretic.~ABP was measured in seated position, after 5 min of rest. If the highest average of two measures was >140/90mmHg, subject was admitted."|Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events|Observational Study of the Polymorphisms of the Renin-angiotensin-aldosterone System and Their Relation to Resistant Systemic Arterial Hypertension and Adverse Cardiovascular Events|Completed|||92|Actual|Universidade Gama Filho|Drugs prescribed were at the discretion of attending physician. The impact of anti-hypertensive drugs on the outcomes was not assessed.||2||f||||f||||||||||2018-05-31 23:32:15.756409|2018-05-31 23:32:15.756409
NCT01173016|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2016-02-23|2010-07-28|2010-07-30|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Administration of IV Laronidase Post Bone Marrow Transplant in Hurler|Pilot Study of Administration of Intravenous Laronidase Following Allogeneic Transplantation for Hurler Syndrome|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 23:32:16.45955|2018-05-31 23:32:16.45955
NCT01173003|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-02-18|2010-07-29|2010-07-30|Estimate|||||||2014-02-18|2014-02-19|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Expansion Study of a Simplified Regimen of Medical Abortion Thru 63 Last Menstrual Period (LMP) in Tunisia|An Open Label Study of 400 mcg Sublingual Misoprostol Following Mifepristone 200 mg for Abortion up to 63 Days LMP|Completed||N/A|688|Actual|Gynuity Health Projects|||||f||||||||||||||2018-05-31 23:32:16.552852|2018-05-31 23:32:16.552852
NCT01172990|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2014-09-15|2010-07-29|2010-07-30|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|DANCE||Direct Angioplasty for Non ST Elevation Acute Coronary Events: DANCE Pilot Study|Direct Angioplasty for Non ST Elevation Acute Coronary Events: DANCE Pilot Study|Terminated||N/A|108|Actual|Royal Brompton & Harefield NHS Foundation Trust||2||Slow recruitment|f||||t||||||||||2018-05-31 23:32:16.726584|2018-05-31 23:32:16.726584
NCT01172977|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2011-06-21|2010-07-28|2010-07-30|Estimate|||||||2011-06-21|2011-06-23|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|SDM||Neurological Complications at Stroke Patients With Diabetes Mellitus|Neurological Complications at Stroke Patients With Diabetes Mellitus During the First Six Months After a Cerebral Ischemia|Completed|||100|Actual|Evangelisches Krankenhaus Bielefeld gGmbH|||2||f||||t||||||||||2018-05-31 23:32:16.794969|2018-05-31 23:32:16.794969
NCT01172964|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2017-11-07|2010-07-28|2010-07-30|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2010||2010-08-31|November 2017|2017-11-30|February 11, 2015|Actual|2015-02-11|February 11, 2015|Actual|2015-02-11||Interventional|||A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas|A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas|Completed||Phase 1|15|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:32:16.866675|2018-05-31 23:32:16.866675
NCT01172951|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2011-01-10|2010-07-29|2010-07-30|Estimate|||||||2011-01-10|2011-01-11|Estimate|December 2008||2008-12-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MECHE||Nutrigenomics Investigation of the Body's Metabolic Response to 2 Different Meal Challenges|A Nutrigenomics Study of Post-prandial Metabolic Responses in Individuals of Varying Body Weight: An Assessment of the Body's Response to Meals Containing Different Levels of Fat and Carbohydrate|Completed||N/A|200|Anticipated|University College Dublin||3|||f||||f||||||||||2018-05-31 23:32:16.995372|2018-05-31 23:32:16.995372
NCT01172938|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2014-04-22|2013-05-29|2018-02-12|2010-07-28|2010-07-30|Estimate|2014-04-22|2014-05-20|Estimate|2013-05-29|2013-06-06|Estimate|2018-02-12|2018-03-12|Actual|June 2, 2010|Actual|2010-06-02|February 2018|2018-02-28|October 27, 2016|Actual|2016-10-27|April 27, 2012|Actual|2012-04-27||Interventional|PALACE-1|Full analysis set consisting of all participants who were randomized as specified in the protocol.|Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis|Completed||Phase 3|504|Actual|Celgene||4|||f||||t||||||||||2018-05-31 23:32:17.173044|2018-05-31 23:32:17.173044
NCT01172925|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-05-22|2010-07-29|2010-07-30|Estimate|||||||2015-05-22|2015-05-27|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|TIDAL||Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer|Randomized Phase II Crossover Study of Tiotropium For Dyspnea in Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|34|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 23:32:20.236323|2018-05-31 23:32:20.236323
NCT01172912|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2013-08-09|2010-07-29|2010-07-30|Estimate|||||||2013-08-09|2013-08-12|Estimate|October 2010||2010-10-31|August 2011|2011-08-31||||October 2012|Anticipated|2012-10-31||Interventional|||High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy|Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment|Unknown status|Recruiting|Phase 2|47|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:32:20.310049|2018-05-31 23:32:20.310049
NCT01172899|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2016-09-20|2010-07-29|2010-07-30|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|BASIC||Bariatric Surgery in Children.|The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery|Recruiting||Phase 2|60|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 23:32:20.389942|2018-05-31 23:32:20.389942
NCT01172886|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2010-07-29|2010-07-29|2010-07-30|Estimate|||||||2010-07-29|2010-07-30|Estimate|January 2008||2008-01-31|February 2010|2010-02-28||||December 2009|Actual|2009-12-31||Observational|||Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer|Metabolic Syndrome as Modifiable Risk Factor for Breast Cancer|Unknown status|Recruiting||777|Anticipated|Sbarro Health Research Organization|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 23:32:20.610061|2018-05-31 23:32:20.610061
NCT01172873|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2012-12-18||2014-08-15|2010-07-29|2010-07-30|Estimate|2013-11-04|2013-12-23|Estimate||||2014-08-15|2014-08-19|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional||Sixteen participants ages 12-17 were enrolled in the study. All met criteria for a principal disorder of OCD. One participant consented but was then deemed ineligible to participate prior to baseline.|D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD|Open-Label Exploratory Investigation of D-Cycloserine Augmentation to Cognitive Behavioral Therapy With Exposure and Response Prevention for Adults and Adolescents Diagnosed With Obsessive Compulsive Disorder - A Feasibility Study|Completed||N/A|16|Actual|New York State Psychiatric Institute|"Due to small sample size of treatment groups, analyses comparing groups were not conducted. Therefore, we cannot conclude that findings were due to D-cycloserine (DCS) augmentation.~All participants received treatment from the same therapist."|2|||f||||f||||||||||2018-05-31 23:32:20.778055|2018-05-31 23:32:20.778055
NCT01172860|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2017-11-08|2010-07-29|2010-07-30|Estimate|||||||2017-11-08|2017-11-09|Actual|March 2010||2010-03-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CCEE EndoVe||Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System|Treatment of Inoperable Colorectal Cancer With Electrochemotherapy Through an Endoscopic System|Completed||Phase 1|10|Anticipated|Mercy University Hospital, Cork, Ireland||1|||f||||t||||||||Yes||2018-05-31 23:32:21.15979|2018-05-31 23:32:21.15979
NCT01172847|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2016-01-05||2016-08-17|2010-07-29|2010-07-30|Estimate|2016-02-19|2016-03-21|Estimate||||2016-08-17|2016-08-19|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers|An Open-label, Multiple Dose, Randomized, Three-period Crossover Study in Healthy Subjects to Evaluate the Effect of Co-administration of Oseltamivir (Ro 64-0796) 75 mg Twice Daily and Rimantadine 100 mg Twice Daily on the Pharmacokinetic Properties of Oseltamivir and Rimantadine.|Completed||Phase 1|24|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:32:21.294392|2018-05-31 23:32:21.294392
NCT01172834|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2010-07-29|2010-07-29|2010-07-30|Estimate|||||||2010-07-29|2010-07-30|Estimate|January 2011||2011-01-31|July 2010|2010-07-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|||The Possible Influence of Health Promotion Coaching on Health Related and Organizational Outcomes Among Nurses|The Possible Influence of Health Promotion Coaching on Health Related and Organizational Outcomes Among Nurses|Unknown status|Not yet recruiting|N/A|120|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 23:32:21.789808|2018-05-31 23:32:21.789808
NCT01172821|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2013-10-25||2014-06-03|2010-07-29|2010-07-30|Estimate|2014-01-07|2014-02-07|Estimate||||2014-06-03|2014-06-09|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Treated Set (TS) - all randomised patients who received at least 1 dose of randomised trial medication.|Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma|Completed||Phase 3|1032|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:32:22.005558|2018-05-31 23:32:22.005558
NCT01172808|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2013-10-25||2014-06-03|2010-07-29|2010-07-30|Estimate|2014-01-07|2014-02-07|Estimate||||2014-06-03|2014-06-09|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Treated Set (TS) - all randomised patients who received at least 1 dose of randomised trial medication.|Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma|Completed||Phase 3|1071|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:32:23.34928|2018-05-31 23:32:23.34928
NCT01172795|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2010-07-29|2010-07-29|2010-07-30|Estimate|||||||2010-07-29|2010-07-30|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Observational|||Diffuse Noxious Inhibitory Controls (DNIC): Nociceptive Modulation and Interaction With Neurocognitive Performance in Chronic Pain||Unknown status|Recruiting||100|Anticipated|Vrije Universiteit Brussel|||3||f||||||||||||||2018-05-31 23:32:25.397416|2018-05-31 23:32:25.397416
NCT01172782|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2011-06-23|2010-07-29|2010-07-30|Estimate|||||||2011-06-23|2011-06-27|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Interventional|||The Analgesic Effect of Intrathecal Hydromorphone Injection on Spinal Anesthesia||Completed||N/A|60|Actual|Korea University Anam Hospital||4|||f||||t||||||||||2018-05-31 23:32:25.476|2018-05-31 23:32:25.476
NCT01172769|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2013-11-07|2010-07-29|2010-07-30|Estimate|||||||2013-11-07|2013-11-08|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|TEMHEAD||Efficacy Study of Temsirolimus to Treat Head and Neck Cancer|A Single Arm, Open-label Multicenter Phase II Trial of Temsirolimus in Patients With Relapsed/Recurrent Squamous Cell Cancer of the Head and Neck (HNSCC)|Completed||Phase 2|42|Actual|Hannover Medical School||1|||f||||f||||||||||2018-05-31 23:32:25.539836|2018-05-31 23:32:25.539836
NCT01172756|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2014-11-03|2010-07-29|2010-07-30|Estimate|||||||2014-11-03|2014-11-04|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|DILATE||A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction|Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts|Terminated||Phase 2|39|Actual|Bayer||4||"Recruitment was only stopped after the statistical power of the study was reached and the study~   objectives could be met despite the premature discontinuation."|f||||t||||||||||2018-05-31 23:32:26.483271|2018-05-31 23:32:26.483271
NCT01172743|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2018-04-30|2010-07-28|2010-07-30|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2009||2009-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)|Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)|Suspended|||500|Anticipated|Weill Medical College of Cornell University|||2|Closed Administratively|f||||f||||||Samples With DNA|"~     Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes~     will be obtained. The goal is to find single nucleotide polymorphims (SNP), small changes in~     single genes that affect disease risk, to see if they correlate with diabetes. Serum will be~     stored for future studies, for a period of 6 years, to look at levels of proteins. Subjects~     who consent to participate in this study will have their serum stored for up to 6 years,~     inorder to be used for future studies on genomics.~   "|Undecided||2018-05-31 23:32:26.593013|2018-05-31 23:32:26.593013
NCT01172730|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-04-09|2010-07-29|2010-07-30|Estimate|||||||2013-04-09|2013-04-11|Estimate|May 2010||2010-05-31|April 2013|2013-04-30||||April 2013|Actual|2013-04-30||Observational|||The Use of Ultrasound to Measure Depth of Thoracic Epidural Space|Use of Ultrasound to Measure Depth of Thoracic Epidural Space Compared With Blind Technique|Completed|||29|Actual|University of Massachusetts, Worcester|||1||f||||f||||||||||2018-05-31 23:32:26.699157|2018-05-31 23:32:26.699157
NCT01172717|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2013-07-25|2010-07-29|2010-07-30|Estimate|||||||2013-07-25|2013-07-26|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study of Panitumumab in the Treatment of Carcinoid Syndrome|Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome|Withdrawn||Phase 2|0|Actual|Boston Medical Center||1||Study never began|f||||t||||||||||2018-05-31 23:32:26.811178|2018-05-31 23:32:26.811178
NCT01172704|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2016-03-30|2010-07-29|2010-07-30|Estimate|||||||2016-03-30|2016-04-01|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Interventional|||HIV/AIDS, Severe Mental Illness and Homelessness|HIV/AIDS, Severe Mental Illness and Homelessness|Completed||Phase 2|240|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 23:32:26.907741|2018-05-31 23:32:26.907741
NCT01172691|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2015-03-13|2010-07-29|2010-07-30|Estimate|||||||2015-03-13|2015-03-17|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts|Randomized, Blinded, Controlled Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts.|Unknown status|Active, not recruiting|Phase 2|2|Anticipated|Baylor Research Institute||1|||f||||f||||||||||2018-05-31 23:32:26.993141|2018-05-31 23:32:26.993141
NCT01172665|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2016-08-29|2010-07-29|2010-07-30|Estimate|||||||2016-08-29|2016-08-31|Estimate|September 2008||2008-09-30|August 2016|2016-08-31||||September 2017|Anticipated|2017-09-30||Observational|||Celiac Disease Database|University of Chicago Celiac Disease Database|Recruiting|||3500|Anticipated|University of Chicago|||||f||||f||||||||||2018-05-31 23:32:27.089988|2018-05-31 23:32:27.089988
NCT01172652|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2012-03-16|2010-07-29|2010-07-30|Estimate|||||||2012-03-16|2012-03-19|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Pfizer Anxiety||Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)|A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder|Completed||Phase 4|49|Actual|VA Palo Alto Health Care System||2|||f||||t||||||||||2018-05-31 23:32:27.347308|2018-05-31 23:32:27.347308
NCT01172639|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2015-06-09|2010-07-29|2010-07-30|Estimate|||||||2015-06-09|2015-06-10|Estimate|February 2009||2009-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.|A 2 Year Prospective Multicentre Randomised Controlled Trial Comparing Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.|Completed||Phase 4|400|Actual|Universitaire Ziekenhuizen Leuven||5|||f||||t||||||||||2018-05-31 23:32:27.46916|2018-05-31 23:32:27.46916
NCT01172626|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2010-07-29|2010-07-29|2010-07-30|Estimate|||||||2010-07-29|2010-07-30|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Observational|EGBPPVPA||Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment|Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment|Unknown status|Not yet recruiting||150|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     Whole blood for DNA extraction as well as for pharmacokinetic studies~   "|||2018-05-31 23:32:27.6027|2018-05-31 23:32:27.6027
NCT01172613|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|||2010-07-29|2010-07-29|2010-07-30|Estimate|||||||2010-07-29|2010-07-30|Estimate|June 2010||2010-06-30|July 2010|2010-07-31||||December 2010|Anticipated|2010-12-31||Observational|DSPT||Optimal Concentration of Dermatophagoides Pteronyssinus (Dp) Allergen Extract for Skin Prick Test (SPT) of Thai Population|Optimal Concentration of Allergen Extract of Dermatophagoides Pteronyssinus to be Used in Diagnostic Allergy Skin Prick Test Among Thai Population|Unknown status|Recruiting||110|Anticipated|Siriraj Hospital|||2||f||||f||||||||||2018-05-31 23:32:27.707432|2018-05-31 23:32:27.707432
NCT01172600|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2016-01-05||2016-08-24|2010-07-29|2010-07-30|Estimate|2016-08-24|2016-10-17|Estimate||||2016-08-24|2016-10-17|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Nitrous Oxide in Treating Neuropathic Pain: A Study in Chronic Low Back Pain Patients|Effect of Nitrous Oxide in Treating Neuropathic Pain: A Pilot Study in Chronic Low Back Pain Patients|Completed||N/A|78|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 23:32:27.830268|2018-05-31 23:32:27.830268
NCT01172587|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2016-03-29|2010-07-29|2010-07-30|Estimate|||||||2016-03-29|2016-03-31|Estimate|July 2009||2009-07-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Secondary Effects of Parent Treatment for Drug Abuse on Children|Secondary Effects of Parent Treatment for Drug Abuse on Children|Unknown status|Active, not recruiting|N/A|366|Actual|Old Dominion University||1|||f||||t||||||||No||2018-05-31 23:32:28.384385|2018-05-31 23:32:28.384385
NCT01172574|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-07-29|2010-07-29|2010-07-30|Estimate|||||||2010-07-29|2010-07-30|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|January 2008|Actual|2008-01-31|||||Interventional|||Motor Control Exercise in Osteoporotic Women|Motor Control Exercise Can Reduce Pain and Improve Postural Alignment in Osteoporotic Women With Vertebral Fractures: a Randomized Controlled Trial|Completed||N/A|20|Actual|National and Kapodistrian University of Athens||2|||f||||f||||||||||2018-05-31 23:32:28.451235|2018-05-31 23:32:28.451235
NCT01172561|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2018-01-29|2010-07-28|2010-07-29|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2005||2005-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2008|Actual|2008-05-31||Interventional|CARE||Community Awareness Resources and Education - Project 1|Reducing Cervical Cancer in Appalachia|Active, not recruiting||N/A|280|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 23:32:28.518419|2018-05-31 23:32:28.518419
NCT01172548|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-05-28|2010-07-28|2010-07-29|Estimate|||||||2017-05-28|2017-05-31|Actual|August 2008||2008-08-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|INV555||Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)|A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec®) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)|Completed||Phase 2|132|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:32:28.635818|2018-05-31 23:32:28.635818
NCT01172535|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2015-11-16||2015-11-16|2010-07-28|2010-07-29|Estimate|2015-11-16|2015-12-21|Estimate||||2015-11-16|2015-12-21|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All participants enrolled in the study|A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines|A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines|Completed||Phase 2/Phase 3|97|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 23:32:28.904047|2018-05-31 23:32:28.904047
NCT01172522|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2014-02-03||2015-02-16|2010-07-28|2010-07-29|Estimate|2015-02-16|2015-02-19|Estimate||||2015-02-16|2015-02-19|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional||Adult with evidence of dark peri-orbital areas|Topical Treatment of Under Eye Dark Circles and Swelling|A Pilot Randomized Double Blind Study to Assess the Safety and Efficacy of 1% Ibuprofen/ 1%Fexofenadine Topical Cream for the Treatment of Dark Circles Under the Eyes|Completed||Phase 2|30|Actual|The Connecticut Sinus Center, PC||2|||f||||t||||||||||2018-05-31 23:32:29.279286|2018-05-31 23:32:29.279286
NCT01172509|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2015-08-20|2010-07-28|2010-07-29|Estimate|||||||2015-08-20|2015-08-21|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal Volunteers|Transcranial Magnetic Stimulation (TMS) Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers for R-baclofen Effects in Normal Volunteers|Terminated||Phase 1|6|Actual|Gonzalez-Heydrich, Joseph, M.D.||5||too much variability in the TMS measures|f||||t||||||||||2018-05-31 23:32:29.58152|2018-05-31 23:32:29.58152
NCT01172496|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-10-08|2010-07-28|2010-07-29|Estimate|||||||2010-10-08|2010-10-13|Estimate|August 2010||2010-08-31|July 2010|2010-07-31||||August 2010|Actual|2010-08-31||Interventional|||A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers|A Comparative Bioavailability Study of UT-15C SR (Treprostinil Diethanolamine, Sustained Release) Oral Tablets and UT-15C (Treprostinil Diethanolamine) Administered as an Oral Solution in Healthy Volunteers|Completed||Phase 1|24|Anticipated|United Therapeutics||2|||f||||||||||||||2018-05-31 23:32:29.897488|2018-05-31 23:32:29.897488
NCT01172483|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-12-03|2010-07-28|2010-07-29|Estimate|||||||2014-12-03|2014-12-04|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|March 2017|Anticipated|2017-03-31|January 2013|Actual|2013-01-31||Interventional|ECACOM||Effectiveness of Community-Based Physiotherapy Versus General Practice|Effectiveness of Community-Based Physiotherapy in Chronic Disorders Versus General Practice in Primary Care. Multicenter Randomized Control Trial|Unknown status|Recruiting|Phase 1|100|Anticipated|University of Malaga||2|||f||||t||||||||||2018-05-31 23:32:30.19584|2018-05-31 23:32:30.19584
NCT01172470|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-01-16|2010-07-28|2010-07-29|Estimate|||||||2014-01-16|2014-01-17|Estimate|June 2005||2005-06-30|January 2014|2014-01-31|July 2010|Actual|2010-07-31|June 2007|Actual|2007-06-30||Interventional|||Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients|Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients|Completed||Phase 2|34|Actual|University of Chicago|||||f||||f||||||||||2018-05-31 23:32:30.536319|2018-05-31 23:32:30.536319
NCT01172457|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2013-08-28|2010-07-28|2010-07-29|Estimate|||||||2013-08-28|2013-08-30|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Epiduroscopy||The Effect of Epiduroscopy and Ozone Therapy in Patients With Failed Back Surgery Syndrome|A Randomized, Double-Blind Study to Evaluate the Effect of Epiduroscopy and Ozone Therapy in Patients With Failed Back Surgery Syndrome|Completed||Phase 2|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:32:30.826974|2018-05-31 23:32:30.826974
NCT01172444|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2017-03-22|2010-07-28|2010-07-29|Estimate|||||||2017-03-22|2017-03-27|Actual|June 2010||2010-06-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical Trial With Mesalamine 1g Suppositories|AN INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ESTABLISH THERAPEUTIC EQUIVALENCE OF 1000 mg MESALAMINE RECTAL SUPPOSITORIES AND CANASA® RECTAL SUPPOSITORIES (1000 mg MESALAMINE, USP) IN THE TREATMENT OF MILD TO MODERATE ULCERATIVE PROCTITIS|Terminated||Phase 3|158|Actual|Sandoz||3||Enrollment difficulties|f||||f||||||||||2018-05-31 23:32:31.184723|2018-05-31 23:32:31.184723
NCT01172431|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2014-06-23|2010-07-28|2010-07-29|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|March 2012|Actual|2012-03-31||Interventional|||Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency|A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Old Patients With Mild to Moderate Renal Insufficiency and Hypertension|Completed||Phase 4|240|Actual|West China Hospital||2|||f||||t||||||||||2018-05-31 23:32:31.510164|2018-05-31 23:32:31.510164
NCT01172418|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2014-08-01||2017-11-05|2010-07-28|2010-07-29|Estimate|2014-08-01|2014-08-20|Estimate||||2017-11-05|2017-12-08|Actual|February 2006||2006-02-28|November 2017|2017-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Intent to treat analysis performed on all 200 patients in the trial.|Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols|Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Accompanied by Maintenance Therapy With Prograf® and Myfortic®|Completed||Phase 4|200|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 23:32:31.807784|2018-05-31 23:32:31.807784
NCT01172405|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|October 2010||2010-10-31|July 2010|2010-07-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Efficacy and Safety Study to Compare Ibuprofen + Caffeine With Ibuprofen Alone in the Treatment of Headache|A Clinical Multicenter, Phase III, Randomized, Double-blind, Prospective and Comparative Trial to Evaluate the Efficacy and Safety of the Combination of Ibuprofen + Caffeine in the Treatment of Headache Attacks, Compared to Ibuprofen Alone.|Unknown status|Not yet recruiting|Phase 3|144|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||t||||||||||2018-05-31 23:32:33.08305|2018-05-31 23:32:33.08305
NCT01172392|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2013-03-28|2010-07-28|2010-07-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|PEGAN||A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B|A Randomized, Multicenter, Unblinded, Phase III Study Assessing the Loss of HbsAg at W96 After a 48-week Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (HbeAg Negative) Under Treatment and Responders (Undetectable Viral Load) to a Nucleoside(s) or Nucleotide(s) Analog(s) Treatment for at Least 12 Months. ANRS HB 06 Pegan|Unknown status|Active, not recruiting|Phase 3|185|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 23:32:33.391943|2018-05-31 23:32:33.391943
NCT01172379|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2014-08-21|2010-07-28|2010-07-29|Estimate|||||||2014-08-21|2014-08-22|Estimate|May 2004||2004-05-31|August 2014|2014-08-31||||February 2005|Actual|2005-02-28||Interventional|||"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period Dyskinesias"|"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With Wearing Off Motor Fluctuations and On Period Dyskinesias"|Completed||Phase 2|2||Eisai Inc.||4|||f||||f||||||||||2018-05-31 23:32:33.733284|2018-05-31 23:32:33.733284
NCT01172366|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-09-02|2010-07-28|2010-07-29|Estimate|||||||2010-09-02|2010-09-06|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application|A Phase I Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application of 2% Testosterone Metered Dose (MD) Lotion®|Completed|||20|Anticipated|Acrux DDS Pty Ltd|||||f||||f||||||||||2018-05-31 23:32:34.137153|2018-05-31 23:32:34.137153
NCT01172353|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2014-01-07||2014-01-07|2010-07-28|2010-07-29|Estimate|2014-01-07|2014-02-19|Estimate||||2014-01-07|2014-02-19|Estimate|July 2004||2004-07-31|January 2014|2014-01-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy|Hydration With Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy: A Multicenter Clinical Trial|Completed||Phase 3|301|Actual|Hospital Sao Lucas da PUCRS||2|||f||||||||||||||2018-05-31 23:32:34.419048|2018-05-31 23:32:34.419048
NCT01172340|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-02-02|2010-07-28|2010-07-29|Estimate|||||||2012-02-02|2012-02-06|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Diet and Exercise for Underserved Women|Behavioral/Support Intervention for Diet and Exercise Among Underserved Women|Completed||N/A|180|Actual|University of South Carolina||2|||f||||t||||||||||2018-05-31 23:32:35.48654|2018-05-31 23:32:35.48654
NCT01172314|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2018-04-24|2010-07-28|2010-07-29|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2010||2010-07-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|July 2012|Actual|2012-07-31||Interventional|||Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients|Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients|Active, not recruiting||N/A|47|Anticipated|Texas A&M University||2|||f||||f||||||||||2018-05-31 23:32:35.978386|2018-05-31 23:32:35.978386
NCT01172301|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2015-08-07|2010-07-28|2010-07-29|Estimate|||||||2015-08-07|2015-08-11|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis|Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis|Completed||N/A|14|Actual|Texas A&M University||1|||f||||f||||||||||2018-05-31 23:32:36.059324|2018-05-31 23:32:36.059324
NCT01172288|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2016-06-30||2016-12-19|2010-07-28|2010-07-29|Estimate|2016-10-25|2016-12-19|Estimate||||2016-12-19|2017-02-10|Actual|July 2010||2010-07-31|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||N-acetylcysteine (NAC) for Children With Tourette Syndrome|Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome|Completed||Phase 2|31|Actual|Yale University||2|||f||||f||||||||No||2018-05-31 23:32:36.156592|2018-05-31 23:32:36.156592
NCT01172275|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2017-01-12|2010-07-28|2010-07-29|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder|Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Pediatric Obsessive-Compulsive Disorder|Active, not recruiting||Phase 2|11|Actual|Yale University||2|||f||||f||||||||||2018-05-31 23:32:36.449754|2018-05-31 23:32:36.449754
NCT01172262|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2018-04-30|2010-07-28|2010-07-29|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2011||2011-02-28|April 2018|2018-04-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Task-Based Functional MRI (fMRI) in Patients With Severely Bothersome Tinnitus|Task-Based Functional MRI (fMRI) Exploration of the Cortical Attention Network in Patients With Severely Bothersome Tinnitus|Withdrawn|||0|Actual|Washington University School of Medicine|||1|Study did not recieve funding, currenlty undergoing protocol revision.|f||||f||||||||||2018-05-31 23:32:36.532777|2018-05-31 23:32:36.532777
NCT01172249|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate||||July 2010|2010-07-31||||||||Interventional|||Non-inferiority Study of the Glucosamine Sulfate + Chondroitin Sulfate Association Capsule in Comparison to the CONDROFLEX® Product in Osteoarthrosis of the Knee|Non-inferiority Study of the Glucosamine Sulfate + Chondroitin Sulfate Association Capsule in Comparison to the CONDROFLEX® Product in Osteoarthrosis of the Knee|Unknown status|Not yet recruiting|Phase 3|250|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||f||||||||||2018-05-31 23:32:36.614717|2018-05-31 23:32:36.614717
NCT01172236|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|January 2011||2011-01-31|April 2010|2010-04-30|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|lactoprenew||Supplementation With Lactoferrin in Preterm Newborns|Supplementation With Lactoferrin in Preterm Newborns|Unknown status|Not yet recruiting|Phase 4|1300|Anticipated|University of Siena||1|||f||||||||||||||2018-05-31 23:32:36.692383|2018-05-31 23:32:36.692383
NCT01172223|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2016-11-01|2010-07-28|2010-07-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|LAPADO||Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer|Phase I/II Trial of Primary Chemotherapy With Non-pegylated Liposomal Doxorubicin, Paclitaxel and Lapatinib in Patients With HER2-positive Early|Completed||Phase 1/Phase 2|81|Actual|Sana-Klinikum Lichtenberg||1|||f||||f||||||||||2018-05-31 23:32:36.761862|2018-05-31 23:32:36.761862
NCT01172210|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-08-20|2010-07-28|2010-07-29|Estimate|||||||2014-08-20|2014-08-21|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Examining Common Substrates of Eating and Alcohol Use Disorders|Examining Common Substrates of Eating and Alcohol Use Disorders|Completed|||61|Actual|New York State Psychiatric Institute|||3||f||||f||||||||||2018-05-31 23:32:36.830642|2018-05-31 23:32:36.830642
NCT01172197|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2018-04-09||2018-04-09|2010-07-28|2010-07-29|Estimate|2018-04-09|2018-05-09|Actual||||2018-04-09|2018-05-09|Actual|January 2009||2009-01-31|April 2018|2018-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Levobupivacaine and Ropivacaine for Femoral Neural Block|A Randomised Single Blind Study Comparing the Molar Median Effective Dose of Levobupivacaine and Molar Median Effective Dose of Ropivacaine When Administered as a Femoral Perineural Infusion for Pain Relief After Total Knee Replacement|Terminated||Phase 4|14|Actual|NHS Tayside||2||Terminated prior to its planned completion as anticipated by the protocol).|f||||f||||||||||2018-05-31 23:32:36.907263|2018-05-31 23:32:36.907263
NCT01172184|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2011-03-03||2011-05-09|2010-07-28|2010-07-29|Estimate|2011-05-09|2011-06-07|Estimate||||2011-05-09|2011-06-07|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation|Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation|Completed|||111|Actual|Kaohsiung Veterans General Hospital.|LV filling pressure was obtained using fluid-filled pigtail catheters.Although micromanometer-tipped catheters would have been ideal, the method we used to measure LV filling pressure is standard in the clinical setting and is well validated.||1||f||||t||||||||||2018-05-31 23:32:37.076487|2018-05-31 23:32:37.076487
NCT01172171|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2017-01-03|2010-07-28|2010-07-29|Estimate|||||||2017-01-03|2017-01-04|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction|Intracoronary Injection of Melatonin for Patients With ST-elevation Myocardial Infarction: a Placebo Controlled Randomized Study|Completed||Phase 2|41|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 23:32:37.221053|2018-05-31 23:32:37.221053
NCT01172158|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|May 2010||2010-05-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|October 2010|Anticipated|2010-10-31||Observational|sms&FUS||SMS Reminder for Forgotten Ureteral Stents|A Solution for Medical and Legal Problems Arising From Forgotten Ureteral Stents: Reminder Short Message Service (SMS)|Unknown status|Enrolling by invitation||250|Anticipated|Dicle University|||1||f||||t||||||||||2018-05-31 23:32:37.29161|2018-05-31 23:32:37.29161
NCT01172145|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2010-08-04||2011-02-09|2010-07-28|2010-07-29|Estimate|2011-02-09|2011-03-04|Estimate||||2011-02-09|2011-03-04|Estimate|July 2005||2005-07-31|September 2010|2010-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Treatment of Apathy in Alzheimer's Disease With Modafinil|Treatment of Apathy in Alzheimer's Disease With Modafinil|Completed||Phase 3|22|Actual|Brown University||2|||f||||f||||||||||2018-05-31 23:32:37.350855|2018-05-31 23:32:37.350855
NCT01172132|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2016-04-15|2010-07-28|2010-07-29|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Observational|||"The Use of Intensive Care in Critically Ill Cancer Haematological Patients: TRIAL-OH"|Long Term Outcomes in Critically Ill Haematological Patients. The Use of Intensive Care in Critically Ill Cancer Haematological Patients|Completed|||1011|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 23:32:38.2276|2018-05-31 23:32:38.2276
NCT01172119|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2014-09-06|2010-07-28|2010-07-29|Estimate|||||||2014-09-06|2014-09-09|Estimate|August 2008||2008-08-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|June 2010|Actual|2010-06-30||Interventional|||BioFreedom FIM Clinical Trial.|A Prospective, Single Blinded, Randomized Study to Evaluate the Safety and Effictiveness of a Low and Standard Dose Biolimus A9TM Drug-Eluteing Coronary Stent Delivery System Compared With a TaxusTM LiberteTM Control Arm for Treatment of Stenotic Lesions in Native Coronary Arteries.|Completed||Phase 2/Phase 3|182|Actual|Biosensors Europe SA||3|||f||||t||||||||||2018-05-31 23:32:38.514872|2018-05-31 23:32:38.514872
NCT01172106|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|September 2010|Anticipated|2010-09-30||Interventional|||Impact of Family Psychoeducation on Psychosis|The Role of Psychoeducation on Perceived Social Support of Postpartum Others With a Psychotic Illness|Unknown status|Recruiting|N/A|200|Anticipated|Makerere University||2|||f||||t||||||||||2018-05-31 23:32:38.811249|2018-05-31 23:32:38.811249
NCT01172093|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|January 2007||2007-01-31|July 2010|2010-07-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Observational|||A Study on the Prevalence of Obstructive Sleep Apnea in Patients With Type II Diabetes Mellitus|Prevalence and Recognition of Obstructive Sleep Apnea in Chinese With Type 2 Diabetes Mellitus|Completed|||177|Actual|The University of Hong Kong|||||f||||t||||||Samples Without DNA|"~     Plasma and serum samples were collected from subjects for batch assays for further research~     purposes~   "|||2018-05-31 23:32:38.961428|2018-05-31 23:32:38.961428
NCT01172080|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2018-03-16|2010-07-28|2010-07-29|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2009||2009-01-31|March 2018|2018-03-31|October 2011|Actual|2011-10-31|April 2010|Actual|2010-04-30||Interventional|||Utility Analysis of an Endoscopy Follow-up System|Utility Analysis of an Endoscopy Follow-up System|Completed||N/A|830|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 23:32:39.024059|2018-05-31 23:32:39.024059
NCT01172067|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2016-07-28|2010-07-28|2010-07-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||QuickOpt Chronic Study|Clinical Impact of Cardiac Resynchronization Therapy on Heart Failure Patients With QuickOpt and Echo Optimization|Completed||N/A|400|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 23:32:39.08986|2018-05-31 23:32:39.08986
NCT01172054|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-07-30|2010-07-27|2010-07-29|Estimate|||||||2012-07-30|2012-07-31|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Interventional|VAX128-01||Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults|A Phase I Escalating Dose Ranging Study to Evaluate the Safety and Immunogenicity of the VAX128 A, B, and C Novel H1N1 Influenza Vaccine Constructs in Healthy Adults 18-49 Years of Age and in Community Living Adults ≥65 Years of Age|Completed||Phase 1|292|Actual|VaxInnate Corporation||2|||f||||t||||||||||2018-05-31 23:32:39.162165|2018-05-31 23:32:39.162165
NCT01172041|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2016-06-29|2010-07-27|2010-07-29|Estimate|||||||2016-06-29|2016-07-01|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging|Investigating the Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging|Completed|||10|Actual|Stanford University|||||f||||t||||||||||2018-05-31 23:32:39.245309|2018-05-31 23:32:39.245309
NCT01172028|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2015-12-02|2010-07-28|2010-07-29|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2005||2005-09-30|February 2014|2014-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients|Completed||Phase 1|33|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 23:32:39.346785|2018-05-31 23:32:39.346785
NCT01172015|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2015-04-20|2010-07-28|2010-07-29|Estimate|||||||2015-04-20|2015-04-22|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|||NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults|NK-ITP STUDY : NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURPURA OF ADULTS.|Completed||N/A|80|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 23:32:39.437454|2018-05-31 23:32:39.437454
NCT01172002|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-08-10|2010-07-28|2010-07-29|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2010||2010-03-31|August 2010|2010-08-31||||June 2018|Anticipated|2018-06-30||Interventional|||Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis|A Randomized Multicenter Trial Comparing Leflunomide and Azathioprine as Remission-Maintaining Treatment for Proliferative Lupus Glomerulonephritis.|Recruiting||N/A|200|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 23:32:39.498967|2018-05-31 23:32:39.498967
NCT01171989|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2017-02-28|2010-12-23|2017-04-12|2010-07-28|2010-07-29|Estimate|2017-02-28|2017-04-11|Actual|2010-12-23|2010-12-30|Estimate|2017-04-12|2017-05-17|Actual|August 1, 2010||2010-08-01|February 2017|2017-02-28|December 3, 2010|Actual|2010-12-03|December 3, 2010|Actual|2010-12-03||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children|Completed||Phase 2|391|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:32:39.628136|2018-05-31 23:32:39.628136
NCT01171976|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2014-03-31||2014-09-10|2010-07-27|2010-07-29|Estimate|2014-09-10|2014-09-15|Estimate||||2014-09-10|2014-09-15|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|RETAIN|The Randomized Set comprised all randomized patients, ie those given a randomization number.|"Efficacy and Safety of Ranibizumab in Two Treat and Extend Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus"|"A 2 Year Randomized, Single-masked, Multicenter, Controlled Phase IIIb Trial Assessing the Efficacy and Safety of 0.5 mg Ranibizumab in Two Treat and Extend Treatment Algorithms vs. 0.5 mg Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus"|Completed||Phase 3|373|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:32:40.503763|2018-05-31 23:32:40.503763
NCT01171963|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|2013-05-02||2017-04-17|2010-07-28|2010-07-29|Estimate|2013-05-02|2013-06-24|Estimate||||2017-04-17|2017-06-01|Actual|August 29, 2010||2010-08-29|April 2017|2017-04-30|May 12, 2012|Actual|2012-05-12|May 12, 2012|Actual|2012-05-12||Interventional|||Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants|Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants|Completed||Phase 3|3340|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:32:42.047102|2018-05-31 23:32:42.047102
NCT01171950|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2016-04-08|2010-07-27|2010-07-29|Estimate|||||||2016-04-08|2016-04-11|Estimate|June 2009||2009-06-30|April 2016|2016-04-30||||December 2012|Anticipated|2012-12-31||Interventional|||CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients|CentriMag Ventricular Assist System (VAS): Treatment of Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients|Withdrawn||N/A|0|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 23:32:42.946679|2018-05-31 23:32:42.946679
NCT01171937|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2017-05-02|2010-07-28|2010-07-29|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2008||2008-09-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|ProjectV||Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior|Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels of Repetitive Behavior|Completed||Phase 2|41|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:32:43.001557|2018-05-31 23:32:43.001557
NCT01171924|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2015-04-23||2016-02-01|2010-07-28|2010-07-29|Estimate|2015-09-17|2015-10-16|Estimate||||2016-02-01|2016-03-01|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors|A Phase Ib Open Label, Expansion Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors|Completed||Phase 1|47|Actual|Curis, Inc.||2|||f||||f||||||||||2018-05-31 23:32:43.109672|2018-05-31 23:32:43.109672
NCT01171911|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|October 2010||2010-10-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery|Nanjing First Hospital, Nanjing Medical University|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Nanjing Medical University|||||f||||t||||||||||2018-05-31 23:32:43.5302|2018-05-31 23:32:43.5302
NCT01171898|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27||2014-01-24|2018-03-06|2010-07-27|2010-07-29|Estimate||||2014-04-17|2014-05-07|Estimate|2018-03-06|2018-03-08|Actual|July 26, 2010|Actual|2010-07-26|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|August 20, 2012|Actual|2012-08-20||Interventional|||Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)|An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|127|Actual|Aragon Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 23:32:43.599166|2018-05-31 23:32:43.599166
NCT01171885|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2010-07-28|2010-07-28|2010-07-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|July 2009||2009-07-31|May 2009|2009-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Bilateral Superficial Cervical Block for Thyroidectomy|Evaluation of the Postoperative Analgesic Efficacy of Bilateral Superficial Cervical Block for Thyroidectomy and Mini Incision Under General Balanced Anesthesia: a Randomized, Triple Masked, Placebo Controlled Trial.|Unknown status|Recruiting|Phase 4|120|Anticipated|Lifecenter Hospital||3|||f||||t||||||||||2018-05-31 23:32:43.679042|2018-05-31 23:32:43.679042
NCT01171872|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2018-02-02|2010-07-28|2010-07-29|Estimate|||||||2018-02-02|2018-02-06|Actual|November 1999|Actual|1999-11-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Gene Expression in Inflammatory Bowel Disease|Gene Expression in Inflammatory Bowel Disease|Recruiting|||1100|Anticipated|Johns Hopkins University|||2||f||||t||||||Samples With DNA|"~     whole blood, serum, tissue~   "|||2018-05-31 23:32:43.77847|2018-05-31 23:32:43.77847
NCT01171859|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2016-02-24|2010-07-28|2010-07-29|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis|A Single Center, Twelve-month, Open-label, Prospective Study Followed by a Six-month Withdrawal Period to Evaluate the Efficacy, Tolerability, Safety and Pharmacokinetics of Doxycycline in Combination With Tauroursodeoxycholic Acid in Transthyretin Amyloidosis|Completed||Phase 2|40|Actual|IRCCS Policlinico S. Matteo||1|||f||||t||||||||||2018-05-31 23:32:43.845618|2018-05-31 23:32:43.845618
NCT01171846|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2015-03-16|2010-07-28|2010-07-29|Estimate|||||||2015-03-16|2015-03-17|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PREVPROL||A Study of the Effects of Physiotherapy to Prevent Pelvic Organ Prolapse|A Multicentre Randomised Controlled Trial of Pelvic Floor Muscle Training to Prevent Pelvic Organ Prolapse in Women|Completed||N/A|337|Actual|Glasgow Caledonian University||2|||f||||f||||||||||2018-05-31 23:32:43.91882|2018-05-31 23:32:43.91882
NCT01171833|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2012-08-09|2010-07-28|2010-07-29|Estimate|||||||2012-08-09|2012-08-13|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Ventilatory Effect on Speed of Anesthesia Under Various Inhaled Anesthetics|Effect of Ventilation on Speed of Induction of Anesthesia in Desflurane, Sevoflurane, and Isoflurane|Completed||N/A|36|Actual|DongGuk University||3|||f||||t||||||||||2018-05-31 23:32:44.004165|2018-05-31 23:32:44.004165
NCT01171820|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2010-08-31||2016-06-06|2010-07-27|2010-07-29|Estimate|2010-10-01|2010-10-21|Estimate||||2016-06-06|2016-06-27|Estimate|November 2006||2006-11-30|June 2016|2016-06-30|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)|SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions|Completed||Phase 4|324|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 23:32:44.098159|2018-05-31 23:32:44.098159
NCT01171807|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-28|||2011-06-27|2010-07-28|2010-07-29|Estimate|||||||2011-06-27|2011-06-28|Estimate|April 2003||2003-04-30|January 2003|2003-01-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|Crocodex||Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis|PHASE 2 STUDY OF DEXAMETHASONE 21-PHOSPHATE LOADED INTO AUTOLOGOUS ERYTHROCYTES IN STEROID-DEPENDENT ULCERATIVE COLITIS PATIENTS|Unknown status|Recruiting|Phase 2|40|Anticipated|Casa Sollievo della Sofferenza IRCCS||2|||f||||t||||||||||2018-05-31 23:32:45.153401|2018-05-31 23:32:45.153401
NCT01171794|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2014-10-08||2017-03-09|2010-07-27|2010-07-28|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|July 2010||2010-07-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||Participants meeting all inclusion criteria were analyzed|Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)|Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)|Completed||Phase 3|89|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 23:32:45.241385|2018-05-31 23:32:45.241385
NCT01171781|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|June 2014|Anticipated|2014-06-30|June 2012|Anticipated|2012-06-30||Interventional|||A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma|A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|110|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 23:32:45.494155|2018-05-31 23:32:45.494155
NCT01171768|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2011-07-20|2010-07-27|2010-07-28|Estimate|||||||2011-07-20|2011-07-21|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|||||Observational|||The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis|The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis|Completed|||52|Anticipated|Samsung Medical Center|||2||f||||||||||||||2018-05-31 23:32:45.573841|2018-05-31 23:32:45.573841
NCT01171755|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2014-05-20|2010-07-27|2010-07-28|Estimate|||||||2014-05-20|2014-05-21|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|GetBil||Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer|A Phase II Study of Gemcitabine and TS-1 in Patients With Previously Untreated Metastatic or Recurrent Biliary Tract Cancer|Terminated||Phase 2|19|Actual|Samsung Medical Center||1||The objective response rate by more than two people are confirmed.|f||||t||||||||||2018-05-31 23:32:45.630189|2018-05-31 23:32:45.630189
NCT01171742|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|July 2008||2008-07-31|July 2010|2010-07-31|August 2010|Anticipated|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Living Donor Liver Transplantation|Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Adult Living Donor Liver Transplantation Using Right Hemiliver Grafts|Unknown status|Active, not recruiting|Phase 3|50|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 23:32:45.696705|2018-05-31 23:32:45.696705
NCT01171729|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-08-10|2010-07-27|2010-07-28|Estimate|||||||2010-08-10|2010-08-11|Estimate|July 2006||2006-07-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer|A Phase I/IIa Study of Autologous Cell-based Vaccine Therapy With CreaVax-PC in Hormone-Refractory Metastatic Prostate Cancer Patients With PSA Relapse to Evaluate the Safety and Efficacy|Completed||Phase 1/Phase 2|12|Actual|Samsung Medical Center|||||f||||t||||||||||2018-05-31 23:32:45.766913|2018-05-31 23:32:45.766913
NCT01171716|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2013-01-16|2010-07-27|2010-07-28|Estimate|||||||2013-01-16|2013-01-17|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Body's Response to Changes in Dietary Protein and Meal-Frequency In Men||Completed||N/A|13|Actual|Purdue University||1|||f||||t||||||||||2018-05-31 23:32:45.850291|2018-05-31 23:32:45.850291
NCT01171703|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-12-20|2010-07-27|2010-07-28|Estimate|||||||2012-12-20|2012-12-24|Estimate|November 2010||2010-11-30|July 2010|2010-07-31|July 2016|Anticipated|2016-07-31|July 2013|Anticipated|2013-07-31||Interventional|DCLI-I||Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I)|Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I)|Unknown status|Enrolling by invitation|Phase 4|70|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 23:32:45.914985|2018-05-31 23:32:45.914985
NCT01171690|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2014-12-02||2014-12-19|2010-07-27|2010-07-28|Estimate|2014-12-19|2014-12-22|Estimate||||2014-12-19|2014-12-22|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Patients with severe and symptomatic hypocalcemia within the first 24 hours postoperatively.|Teriparatide for Postsurgical Hypoparathyroidism|Pilot Study of Teriparatide for Postsurgical Hypoparathyroidism|Terminated||Phase 2|5|Actual|Mayo Clinic||1||Funding problems|f||||t||||||||||2018-05-31 23:32:46.000169|2018-05-31 23:32:46.000169
NCT01171677|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2012-10-22||2013-01-30|2010-07-27|2010-07-28|Estimate|2013-01-30|2013-03-06|Estimate||||2013-01-30|2013-03-06|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits|Impact of Exercise and Affirmations (IntenSati) on Addiction-related Cognitive and Psychosocial Deficits|Completed||N/A|40|Actual|New York University School of Medicine|Overall small sample size, limited exercise intensity and capacity, missed exercise classes, dropout because of placement, work schedules and non-study-related medical conditions.|2|||f||||t||||||||||2018-05-31 23:32:46.230473|2018-05-31 23:32:46.230473
NCT01171664|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2014-03-24|2010-07-27|2010-07-28|Estimate|||||||2014-03-24|2014-03-26|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|STA-2||Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects|A Bi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of STAHIST in Adult Subjects With a History of Seasonal Allergic Rhinitis|Completed||Phase 2|100|Actual|Magna Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:32:46.608338|2018-05-31 23:32:46.608338
NCT01171651|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2016-01-19|2010-07-27|2010-07-28|Estimate|||||||2016-01-19|2016-01-20|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|December 2015|Actual|2015-12-31|February 2013|Actual|2013-02-28||Interventional|||A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma|A Phase 2 Open-Label Pilot Safety Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by IV Infusion Followed by Intratumoral Injection Prior to Standard Sorafenib Treatment in Patients With Unresectable Primary Hepatocellular Carcinoma|Completed||Phase 2|25|Actual|SillaJen, Inc.||1|||f||||f||||||||||2018-05-31 23:32:46.674296|2018-05-31 23:32:46.674296
NCT01171638|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-06-14|2010-07-27|2010-07-28|Estimate|||||||2011-06-14|2011-06-15|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome|The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome|Unknown status|Not yet recruiting||120|Anticipated|J&M Shuler|||2||f||||t||||||||||2018-05-31 23:32:46.740654|2018-05-31 23:32:46.740654
NCT01171625|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2017-09-22|2010-07-27|2010-07-28|Estimate|||||||2017-09-22|2017-09-26|Actual|October 2007||2007-10-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX|Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis in the Aortic Position, Model 3300TFX|Active, not recruiting||N/A|225|Anticipated|Edwards Lifesciences||1|||f||||f||||||||||2018-05-31 23:32:46.811062|2018-05-31 23:32:46.811062
NCT01171612|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2013-08-13||2016-03-08|2010-07-27|2010-07-28|Estimate|2013-09-16|2013-11-25|Estimate||||2016-03-08|2016-04-07|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|July 2012|Actual|2012-07-31|February 2010|Actual|2010-02-28||Observational|RegistStents|20 patienet were not taking previous antiplatelet agents|Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery|Evaluation and Monitoring of Perioperative Management of Patients With Coronary Stents Undergoing Noncardiac Surgery|Completed|||483|Actual|Corporacion Parc Tauli|This is a prospective and observational study||1||f||||t||||||||||2018-05-31 23:32:46.890493|2018-05-31 23:32:46.890493
NCT01171599|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-06-08|2010-07-27|2010-07-28|Estimate|||||||2012-06-08|2012-06-11|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|PACE-CALL||PACE-CALL: A Weight Control Intervention for Survivors of Childhood Leukemia|PACE-CALL: A Weight Control Intervention for Survivors of Childhood Leukemia|Completed||N/A|12|Actual|University of California, San Diego|||||f||||f||||||||||2018-05-31 23:32:47.197148|2018-05-31 23:32:47.197148
NCT01171586|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2014-12-03|2010-07-27|2010-07-28|Estimate|||||||2014-12-03|2014-12-05|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||mDiet: A Text Message Intervention for Weight Loss|mDiet: A Text Message Intervention for Weight Loss|Completed||N/A|318|Actual|University of California, San Diego||3|||f||||f||||||||||2018-05-31 23:32:47.260844|2018-05-31 23:32:47.260844
NCT01171573|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2016-10-14|2010-07-27|2010-07-28|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2001||2001-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|AOMIC||Investigating Genes in Patients With Polymyositis and Dermatomyositis|Identification of Disease Susceptibility Genes Associated With Development and Clinical Characteristics of Primary Inflammatory Muscle Diseases, PM, DM and IBM.|Recruiting|||1000|Anticipated|Salford Royal NHS Foundation Trust|||2||f||||t||||||Samples With DNA|"~     DNA and serum~   "|||2018-05-31 23:32:47.323506|2018-05-31 23:32:47.323506
NCT01171560|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-08-11|2010-07-27|2010-07-28|Estimate|||||||2010-08-11|2010-08-12|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|August 2010|Anticipated|2010-08-31|July 2010|Anticipated|2010-07-31||Interventional|||Evaluation of the EZ Blocker|Prospective Randomized Clinical Trial for Single-Lung-Ventilation Comparing Double-Lume Tube and the EZ-Blocker®|Unknown status|Recruiting|Phase 4|40|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 23:32:47.392007|2018-05-31 23:32:47.392007
NCT01171547|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|February 2010||2010-02-28|July 2010|2010-07-31||||February 2010|Anticipated|2010-02-28||Interventional|||Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration|Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Find Study|Unknown status|Recruiting|Phase 2|15|Anticipated|University of Zurich|||||f||||t||||||||||2018-05-31 23:32:47.48419|2018-05-31 23:32:47.48419
NCT01171534|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2014-09-08||2018-01-03|2010-07-27|2010-07-28|Estimate|2014-12-03|2014-12-10|Estimate||||2018-01-03|2018-01-29|Actual|July 2010||2010-07-31|January 2018|2018-01-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Closure of Fasciotomy Wounds: A Prospective, Observational Study of a Continuous External Tissue Expander|Closure of Fasciotomy Wounds: A Prospective, Observational Study of a Continuous External Tissue Expander|Terminated||N/A|7|Actual|University of Missouri-Columbia||2||Study determined not to be feasible to continue.|f||||f||||||||||2018-05-31 23:32:47.550092|2018-05-31 23:32:47.550092
NCT01171521|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2014-09-12||2016-01-27|2010-07-27|2010-07-28|Estimate|2015-01-07|2015-01-09|Estimate||||2016-01-27|2016-02-26|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|October 2013|Actual|2013-10-31||Interventional||5 males, 1 female|Management of Complex Wounds Using a Constant Tension External Tissue Expander|Management of Complex Wounds Using a Constant Tension External Tissue Expander|Terminated||N/A|6|Actual|University of Missouri-Columbia|enrollment was less than predicted and no subject completed the intended 12-month followup. Only SF-12 and pain data were collected for enrolled patients. There was also one screen failure.|1||enrollment did not meet projections and numerous lost to follow-up|f||||f||||||||||2018-05-31 23:32:47.813528|2018-05-31 23:32:47.813528
NCT01171508|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-03-07|2010-07-27|2010-07-28|Estimate|||||||2013-03-07|2013-03-08|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|CIRCA||Circadian Disturbances After Breast Cancer Surgery|Circadian Disturbances After Breast Cancer Surgery|Completed|||12|Actual|Herlev Hospital|||1||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 23:32:47.954626|2018-05-31 23:32:47.954626
NCT01171495|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|INI||Impact of Nutrition Intervention on HIV/AIDS Infected Patients|Phase 3 Study That Assesses the Impact of a Nutrition Intervention on HIV/AIDS Infected Patients: Kingston, Jamaica|Completed||Phase 3|121|Actual|Caribbean Health Research Council||2|||f||||t||||||||||2018-05-31 23:32:48.061132|2018-05-31 23:32:48.061132
NCT01171482|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-04-24|2010-07-27|2010-07-28|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2015||2015-11-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma|An Open Label, Phase 2 Trial Comparing Sorafenib and 5-fluorouracil/Mitomycin in Hepatocellular Carcinoma With Pulmonary Metastasis|Terminated||Phase 2|5|Actual|Seoul National University Hospital||2||There were problems with national reimbursement policies.|f||||f||||||||No||2018-05-31 23:32:48.130916|2018-05-31 23:32:48.130916
NCT01171469|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2017-11-29|2010-07-27|2010-07-28|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2010||2010-09-30|November 2017|2017-11-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor|Phase I Study of Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Recurrent or Progressive Malignant Gliomas|Completed||Phase 1|8|Actual|Masonic Cancer Center, University of Minnesota||3|||f||||t||||||||||2018-05-31 23:32:48.206201|2018-05-31 23:32:48.206201
NCT01171456|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-01-15|2010-07-27|2010-07-28|Estimate|||||||2013-01-15|2013-01-16|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Early Intervention for Gestational Diabetes|Early Medical Intervention in Women at Risk for Gestational Diabetes|Withdrawn||N/A|0|Actual|Intermountain Health Care, Inc.||2||"Insufficient funding for enrollment of patients. The invesitgators realized the study could not~   be performed."|f||||f||||||||||2018-05-31 23:32:48.282329|2018-05-31 23:32:48.282329
NCT01171443|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|BIPN||The Pathophysiology of Bortezomib Induced Peripheral Neuropathy|Is There a Role of Oxidative Stress in the Pathophysiology of Bortezomib Induced Peripheral Neuropathy (BIPN) in Multiple Myeloma Patients?|Unknown status|Not yet recruiting||30|Anticipated|Wolfson Medical Center|||||f||||f||||||||||2018-05-31 23:32:48.351674|2018-05-31 23:32:48.351674
NCT01171430|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2017-11-03|2010-07-27|2010-07-28|Estimate|||||||2017-11-03|2017-11-06|Actual|July 2010|Actual|2010-07-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2016|Actual|2016-02-29||Interventional|EVALICEMM||"WB-DCE-MRI in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival"|Assessment of Dynamic Contrast Enhanced Whole Body MRI (DCE-WB-MRI) as Independent Prognostic Factor for Disease-free Survival in Multiple Myeloma (After Intensification Therapy and Autologous Stem Cell Transplantation Suppressed by Amendment n°3)|Active, not recruiting||N/A|104|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 23:32:48.408589|2018-05-31 23:32:48.408589
NCT01171417|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-02-26|2010-07-27|2010-07-28|Estimate|||||||2014-02-26|2014-02-27|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|ACT-FASTER:||A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer|An Epidemiological Prospective Cohort Study to Describe Treatment Patterns of Fulvestrant And ExemeSTane in Postmenopausal Patients With Advanced HR+ Breast Cancer Under Real-life Conditions in GERmany|Completed|||570|Actual|AstraZeneca|||4||f||||f||||||||||2018-05-31 23:32:48.504107|2018-05-31 23:32:48.504107
NCT01171404|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2013-04-16|2010-07-27|2010-07-28|Estimate|||||||2013-04-16|2013-04-17|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|EPICOR||Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge|Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients|Completed|||10568|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:32:48.721482|2018-05-31 23:32:48.721482
NCT01171391|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-11-30|2010-07-27|2010-07-28|Estimate|||||||2010-11-30|2010-12-01|Estimate|July 2010||2010-07-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||VA106483 Dose Response in Females|An Open Label, Dose Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Female Subjects|Completed||Phase 1|21|Actual|Vantia Ltd||4|||f||||f||||||||||2018-05-31 23:32:49.517776|2018-05-31 23:32:49.517776
NCT01171378|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2018-04-23|2010-07-27|2010-07-28|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2011||2011-04-30|April 2018|2018-04-30|April 19, 2016|Actual|2016-04-19|February 2015|Actual|2015-02-28||Interventional|CHOP-OR||Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome|Single Arm NCRI Feasibility Study of CHOP in Combination With Ofatumumab in Induction and Maintenance for Patients With Newly Diagnosed Richter's Syndrome|Completed||Phase 2|43|Actual|University of Oxford||1|||f||||f||||||||||2018-05-31 23:32:49.614011|2018-05-31 23:32:49.614011
NCT01171365|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2014-01-30|2010-07-27|2010-07-28|Estimate|||||||2014-01-30|2014-01-31|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|SPIRA||Small Particle Steroids in Refractory Asthma|Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma|Completed||Phase 4|30|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 23:32:49.714371|2018-05-31 23:32:49.714371
NCT01171352|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-03-03|2010-07-27|2010-07-28|Estimate|||||||2011-03-03|2011-03-04|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Predicting Hypotension During Dialysis in the ICU|Predicting Hypotension During Dialysis in the ICU|Unknown status|Recruiting||120|Anticipated|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 23:32:49.791246|2018-05-31 23:32:49.791246
NCT01171339|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2017-10-29|2010-07-27|2010-07-28|Estimate|||||||2017-10-29|2017-10-31|Actual|August 1, 2010|Actual|2010-08-01|October 2017|2017-10-31|February 29, 2012|Actual|2012-02-29|February 29, 2012|Actual|2012-02-29||Interventional|PRIMUM||Prioritising and Optimising Multi-medication in Multimorbidity|Prioritising and Optimising Multiple Medications in Elderly Multimorbid Patients in General Practice. - A Pragmatic Cluster-randomised Controlled Trial.|Completed||N/A|505|Actual|Goethe University||2|||f||||t||||||||No||2018-05-31 23:32:49.875078|2018-05-31 23:32:49.875078
NCT01171326|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2013-12-09|2010-07-27|2010-07-28|Estimate|||||||2013-12-09|2013-12-10|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients|A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo|Completed||Phase 2|32|Actual|Foamix Ltd.||2|||f||||f||||||||||2018-05-31 23:32:49.950047|2018-05-31 23:32:49.950047
NCT01171313|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26||2013-01-31|2013-02-04|2010-07-27|2010-07-28|Estimate||||2013-01-31|2013-02-04|Estimate|2013-02-04|2013-02-06|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects|A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations|Completed||Phase 2|35|Actual|XenoPort, Inc.||4|||f||||f||||||||||2018-05-31 23:32:50.019525|2018-05-31 23:32:50.019525
NCT01171300|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2015-12-03|2010-07-27|2010-07-28|Estimate|||||||2015-12-03|2015-12-04|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients|Assessment of Response Before, During and After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients|Unknown status|Active, not recruiting|N/A|94|Actual|Universitaire Ziekenhuizen Leuven|||||f||||t||||||||||2018-05-31 23:32:50.0998|2018-05-31 23:32:50.0998
NCT01171287|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2015-06-04|2010-07-27|2010-07-28|Estimate|||||||2015-06-04|2015-06-08|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|April 2014|Actual|2014-04-30|October 2008|Actual|2008-10-31||Interventional|||Effects of Right Lower Limb Orthopedic Immobilization on Braking Function|Effects of Right Lower Limb Orthopedic Immobilization on Braking Function : An On-the-Road Experimental Study by Healthy Volunteers|Completed||N/A|14|Actual|Université de Sherbrooke||3|||f||||f||||||||||2018-05-31 23:32:50.249312|2018-05-31 23:32:50.249312
NCT01171274|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2011-02-18|2010-07-27|2010-07-28|Estimate|||||||2011-02-18|2011-02-21|Estimate|August 2010||2010-08-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Hatha Yoga on Chronic Neck Pain|Randomisierte Kontrollierte Studie Zum Einfluss Von Hatha Yoga Auf Sensorische Schwellen, Kinästhetik Und Körperbild Bei Patienten Mit Chronischen Nackenschmerzen|Completed||N/A|58|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 23:32:50.316104|2018-05-31 23:32:50.316104
NCT01171248|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2011-09-21|2010-07-27|2010-07-28|Estimate|||||||2011-09-21|2011-09-22|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|PROFIL||Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 Diabetes|Central and Peripheral 24h BP and the Association to Autonomic Neuropathy and Diabetic Nephropathy in Type 1 Diabetic Patients|Completed|||650|Anticipated|Steno Diabetes Center|||2||f||||f||||||||||2018-05-31 23:32:50.444513|2018-05-31 23:32:50.444513
NCT01171235|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|July 2010||2010-07-31|March 2009|2009-03-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma|Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma|Unknown status|Enrolling by invitation||200|Anticipated|Southern Medical University, China|||||f||||t||||||Samples With DNA|"~     blood and tissue samples~   "|||2018-05-31 23:32:50.500499|2018-05-31 23:32:50.500499
NCT01171222|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-08-26|2010-07-27|2010-07-28|Estimate|||||||2011-08-26|2011-08-29|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Health Status and Cardiovascular Stress of Veteran Soccer Players|Health Status and Cardiovascular Stress of Veteran Soccer Players|Completed|||100|Anticipated|Saarland University|||1||f||||f||||||||||2018-05-31 23:32:50.544711|2018-05-31 23:32:50.544711
NCT01171209|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2012-11-29|2010-07-27|2010-07-28|Estimate|||||||2012-11-29|2012-11-30|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|REPAIR||REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients|REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients|Completed||Phase 2|10|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 23:32:50.594239|2018-05-31 23:32:50.594239
NCT01171196|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2015-11-05|2010-07-27|2010-07-28|Estimate|||||||2015-11-05|2015-11-09|Estimate|July 2010||2010-07-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Observational|||Questionnaires to Identify Chinese Patients at Risk for Obstructive Sleep Apnea|Validation of Questionnaires to Identify Chinese Patients at Risk for Obstructive Sleep Apnea|Completed|||378|Actual|The University of Hong Kong|||||f||||t||||||||||2018-05-31 23:32:50.691807|2018-05-31 23:32:50.691807
NCT01171183|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2015-06-10||2015-07-29|2010-07-27|2010-07-28|Estimate|2015-07-29|2015-07-31|Estimate||||2015-07-29|2015-07-31|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Those who were admitted to the residential unit and received at least one dose of medication. The data for one person in the carvedilol arm was excluded from analyses as the person did not meet inclusion criteria for the study and was discharged by the third day.|Carvedilol for Psychostimulant Dependence|Clinical Efficacy of Carvedilol for Psychostimulant Dependence|Completed||Phase 2|32|Actual|University of Arkansas|Small numbers of participants analyzed. Primary outcome measure based on successfully transition to outpatient phase of the study.|2|||f||||t||||||||||2018-05-31 23:32:50.761005|2018-05-31 23:32:50.761005
NCT01171170|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2011-07-26|2010-07-27|2010-07-28|Estimate|||||||2011-07-26|2011-07-27|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|NVALT12||Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer|A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12|Unknown status|Recruiting|Phase 2|222|Anticipated|Dutch Society of Physicians for Pulmonology and Tuberculosis||2|||f||||f||||||||||2018-05-31 23:32:51.069188|2018-05-31 23:32:51.069188
NCT01171157|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2015-05-07|2010-07-27|2010-07-28|Estimate|||||||2015-05-07|2015-05-12|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling Elderly With Influenza Like Illness in Brazil|An Observational Case Control Study of Effectiveness of Influenza Vaccination and Burden of Illness in Community-dwelling Elderly With Influenza-like Illness in Southern Brazil|Terminated|||4|Actual|GlaxoSmithKline|||1|"In the context of the World Health Organization's (WHO) Phase 6 pandemic influenza declaration~   the conduct of the study was deemed no longer feasible"|f||||||||||Samples With DNA|"~     One nose/throat swab~   "|||2018-05-31 23:32:51.178086|2018-05-31 23:32:51.178086
NCT01171144|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2017-06-06|2010-07-27|2010-07-28|Estimate|||||||2017-06-06|2017-06-07|Actual|January 2009||2009-01-31|June 2017|2017-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Trends Over Time (1990-2010) of Diarrhoea-related Incidence, Hospitalizations and Deaths in Children of Panama|Time Trend Analysis of Diarrhoea-related Incidence, Hospitalizations, and Deaths in Children < 5 Years of Age in Panama by Monitoring Secondary Data Sources From 1990-2010|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||None Retained|"~     No samples are retained.~   "|||2018-05-31 23:32:51.24357|2018-05-31 23:32:51.24357
NCT01171131|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2018-02-06|2010-07-26|2010-07-28|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2010||2010-04-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|Chronic TBI||A Pilot Study to Identify Biomarkers Associated With Chronic Traumatic Brain Injury|A Pilot Study to Identify Biomarkers Associated With Chronic TBI|Enrolling by invitation|||180|Anticipated|The University of Texas Health Science Center, Houston|||3||f||||f||||||Samples Without DNA|"~     Saliva sample Blood sample (plasma)~   "|No|There is no plan to share individual participant data|2018-05-31 23:32:52.263118|2018-05-31 23:32:52.263118
NCT01171118|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2013-03-08||2015-04-24|2010-07-27|2010-07-28|Estimate|2015-04-24|2015-04-27|Estimate||||2015-04-24|2015-04-27|Estimate|August 2009||2009-08-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|PHYSO|10 subjects were studied in a crossover format but each subject completed all arms of the study.|Phamacological Reversal of Airway Instability During Sedation|Phamacological Reversal of Airway Instability During Sedation|Completed||N/A|10|Actual|University of Rochester|Study done on healthy non OSA male patients. Has to be confirmed with patients suffering from moderate to severe OSA.|4|||f||||t||||||||||2018-05-31 23:32:52.338689|2018-05-31 23:32:52.338689
NCT01171105|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-01-27|2010-07-27|2010-07-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects|A Phase I, Double-blind, Randomized, Placebo-controlled', Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD5213 After Administration of Multiple Ascending Doses for 10 Days in Healthy Male and Non-fertile Female Volunteers|Completed||Phase 1|73|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 23:32:52.514585|2018-05-31 23:32:52.514585
NCT01171092|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2017-01-09|2010-07-27|2010-07-28|Estimate|||||||2017-01-09|2017-01-11|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Interventional|||A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma|A Pilot Trial to Assess Mobilization of Hematopoietic Progenitor Cells With a Combination of Bortezomib and G-CSF in Patients Undergoing Autologous Transplant for Myeloma and Lymphoma|Completed||Early Phase 1|21|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 23:32:52.595233|2018-05-31 23:32:52.595233
NCT01171079|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate||||July 2010|2010-07-31||||||||Interventional|ORC||Use of an Oxidized Regenerated Cellulose After Thyroid Surgery: A Prospective, Randomized Study|Use of an Oxidized Regenerated Cellulose After Thyroid Surgery: A Prospective, Randomized Study|Completed||N/A|||Seoul National University Hospital||1|||f||||||||||||||2018-05-31 23:32:52.662122|2018-05-31 23:32:52.662122
NCT01171066|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-04-11|2010-07-27|2010-07-28|Estimate|||||||2013-04-11|2013-04-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:32:52.71359|2018-05-31 23:32:52.71359
NCT01171053|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Internet-delivered CBT for Irritable Bowel Syndrome|Internet-delivered Exposure and Mindfulness Based Therapy for Irritable Bowel Syndrome - A Randomized Controlled Trial|Completed||N/A|86|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 23:32:52.750166|2018-05-31 23:32:52.750166
NCT01171040|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2011-03-07|2010-07-27|2010-07-28|Estimate|||||||2011-03-07|2011-03-08|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Observational|||Left Atrial Distensibility to Predict Prognosis in Consecutive Patients|Studies on Assessment of Left Atrial Distensibility to Predict Late Prognosis in Consecutive Patients Received Echocardiographic Examination|Unknown status|Recruiting||2000|Anticipated|Kaohsiung Veterans General Hospital.|||1||f||||t||||||||||2018-05-31 23:32:52.937127|2018-05-31 23:32:52.937127
NCT01171027|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2011-11-30|2010-07-27|2010-07-28|Estimate|||||||2011-11-30|2011-12-02|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy|Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy|Unknown status|Recruiting|N/A|200|Anticipated|Natural Orifice Surgery Consortium for Assessment and Research||2|||f||||t||||||||||2018-05-31 23:32:53.078063|2018-05-31 23:32:53.078063
NCT01171014|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Bifidobacterium Lactis HN019 on Colonic Transit Time and Digestive Symptoms|A Three‐Arm, Placebo Controlled, Double‐Blind, Single Center Study to Evaluate the Impact of Probiotic Strain Bifidobacterium Lactis HN019 on Intestinal Well‐Being, Colonic Transit Time and Digestive Discomfort|Completed||Phase 2/Phase 3|100|Actual|Fonterra Research Centre||3|||f||||f||||||||||2018-05-31 23:32:53.188287|2018-05-31 23:32:53.188287
NCT01170988|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2014-08-05|2010-07-27|2010-07-28|Estimate|||||||2014-08-05|2014-08-06|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Coronary Flow Rate Measurement in T-Grafts|Comparison of Coronary Flow Reserve in Two Different Bypass Techniques (T-graft Technique Versus Isolated Graft Technique) Using Magnetic Resonance Technology (MRT)|Completed||N/A|20|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||||2018-05-31 23:32:53.263778|2018-05-31 23:32:53.263778
NCT01170975|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-07-20|2010-07-27|2010-07-28|Estimate|||||||2012-07-20|2012-07-24|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules|An Open-label, Single-dose, Randomized, Crossover Study to Determine the Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsule in Solid Tumor Cancer Subjects|Completed||Phase 1|12|Actual|Genta Incorporated||2|||f||||f||||||||||2018-05-31 23:32:53.327531|2018-05-31 23:32:53.327531
NCT01170962|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2015-08-10||2015-09-11|2010-07-26|2010-07-28|Estimate|2015-09-11|2015-10-12|Estimate||||2015-09-11|2015-10-12|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|HEPCAT||Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment|A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy|Completed||Phase 2|512|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 23:32:53.480739|2018-05-31 23:32:53.480739
NCT01170949|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2015-07-29||2016-11-01|2010-07-27|2010-07-28|Estimate|2016-11-01|2016-12-26|Estimate||||2016-11-01|2016-12-26|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|April 2010|Actual|2010-04-30|September 2008|Actual|2008-09-30||Interventional|MIARCU||Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria|Randomised, Double-blind, Placebo-controlled Study|Terminated||Phase 2|76|Actual|Charite University, Berlin, Germany||2||Study medication expired|f||||t||||||||||2018-05-31 23:32:54.912422|2018-05-31 23:32:54.912422
NCT01170936|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-05-30|2010-07-27|2010-07-28|Estimate|||||||2012-05-30|2012-05-31|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|ILUVIT||Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses|An Open-label Pilot Study to Assess the Efficacy and Safety of a Single Dose Regime of Canakinumab (ACZ885) in Patients With Active, Refractory Urticarial Vasculitis|Completed||Phase 2|10|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 23:32:55.331191|2018-05-31 23:32:55.331191
NCT01170923|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2010-07-27|2010-07-27|2010-07-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|September 2008||2008-09-30|July 2010|2010-07-31||||August 2010|Anticipated|2010-08-31||Interventional|||FDG-PET Scan Response Guided Chemotherapy Strategy for Advanced Non-small Cell Lung Cancer|Standard Chemotherapy Strategy Versus Changing Chemotherapy Strategy as to FDG-PET Response After 1st Cycle of Standard Chemotherapy for Advanced Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:32:55.404217|2018-05-31 23:32:55.404217
NCT01170910|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2017-05-29|2010-07-26|2010-07-27|Estimate|||||||2017-05-29|2017-05-31|Actual|April 2010|Actual|2010-04-30|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|IMPULSION||Pulsatile Perfusion Preservation in Kidney Transplantation From Expanded Criteria Donors|Interest of Pulsatile Perfusion Preservation on Outcomes in Kidney Transplantation From Expanded Criteria Donors|Completed||N/A|162|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 23:32:55.467627|2018-05-31 23:32:55.467627
NCT01170897|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2014-01-27|2010-07-26|2010-07-27|Estimate|||||||2014-01-27|2014-01-29|Estimate|July 2010||2010-07-31|September 2012|2012-09-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors|Completed||Phase 1|27|Actual|Halozyme Therapeutics||1|||f||||f||||||||||2018-05-31 23:32:55.545517|2018-05-31 23:32:55.545517
NCT01170884|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2011-12-07||2011-12-07|2010-07-26|2010-07-27|Estimate|2011-12-07|2012-01-12|Estimate||||2011-12-07|2012-01-12|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®||Completed||Phase 4|121|Actual|Allergan||2|||f||||||||||||||2018-05-31 23:32:55.61674|2018-05-31 23:32:55.61674
NCT01170871|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2014-05-19|2010-07-23|2010-07-27|Estimate|||||||2014-05-19|2014-05-21|Estimate||||May 2014|2014-05-31||||||||Interventional|||Ixabepilone and Pemetrexed/Solid Tumors|Phase I Clinical Trial of Ixabepilone and Pemetrexed in Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|University of Southern California||1||Sponsor withdrew support|f||||f||||||||||2018-05-31 23:32:55.778826|2018-05-31 23:32:55.778826
NCT01170858|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2016-01-18|2010-07-26|2010-07-27|Estimate|||||||2016-01-18|2016-01-20|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal Dialysis||Completed||N/A|100|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:32:55.837845|2018-05-31 23:32:55.837845
NCT01170845|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|NEIE||Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy|A Pilot Study of Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy|Completed||N/A|31|Actual|Yokohama City University Medical Center||2|||f||||f||||||||||2018-05-31 23:32:55.994302|2018-05-31 23:32:55.994302
NCT01170832|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2017-07-28|2010-07-26|2010-07-27|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2010||2010-05-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2016|Actual|2016-08-31||Observational|||To Evaluate if Wide Blood Sugar Fluctuations Lead to Injury of Heart Function and Heart Nerves|Cardiac Autonomic Neuropathy and Myocardial Dysfunction in Type 1 Diabetes|Active, not recruiting|||55|Anticipated|University of Michigan|||||f||||t||||||Samples With DNA|"~     We will collect approximately 15 ml of whole blood for DNA sampling and storage.~   "|||2018-05-31 23:32:56.083188|2018-05-31 23:32:56.083188
NCT01170819|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2011-12-09|2010-07-26|2010-07-27|Estimate|||||||2011-12-09|2011-12-13|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening.|Double Balloon Catheter Versus Vaginal PGE2 for Pre-induction Cervical Ripening: a Randomized Study.|Completed||Phase 4|210|Actual|Università degli Studi dell'Insubria||2|||f||||f||||||||||2018-05-31 23:32:56.135628|2018-05-31 23:32:56.135628
NCT01170806|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2011-01-28|2010-07-26|2010-07-27|Estimate|||||||2011-01-28|2011-01-31|Estimate|October 2009||2009-10-31|January 2011|2011-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Study of Fat Malabsorption by Lipiblock Versus Xenical|Study of Pharmacodynamic Equivalence of Two Commercial Formulations of Orlistat (Lipiblock vs Xenical) on Intestinal Lipases Inhibition|Completed||N/A|20|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 23:32:56.21797|2018-05-31 23:32:56.21797
NCT01170793|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-12-26|2010-07-26|2010-07-27|Estimate|||||||2012-12-26|2012-12-27|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CAM-ET||Medicine Abuse Headache|Medication Overuse Headaches: the Impact of Educative Telephone Coaching Administered by Nurses Prior to the Medical Appointment in a Tertiary Consultation Center: a Comparative Randomized Trial|Completed||N/A|88|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 23:32:56.293646|2018-05-31 23:32:56.293646
NCT01170780|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-01-26|2010-07-26|2010-07-27|Estimate|||||||2012-01-26|2012-01-31|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair|Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair|Completed||Phase 3|80|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 23:32:56.358993|2018-05-31 23:32:56.358993
NCT01170767|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-07-26|2010-07-26|2010-07-27|Estimate|||||||2013-07-26|2013-07-29|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GEFAL||French Evaluation Group Avastin Versus Lucentis|French Evaluation Group Avastin Versus Lucentis|Completed||Phase 3|501|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 23:32:56.434385|2018-05-31 23:32:56.434385
NCT01170754|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2015-04-16||2017-08-14|2010-07-26|2010-07-27|Estimate|2016-05-06|2016-06-14|Estimate||||2017-08-14|2017-09-13|Actual|April 2010||2010-04-30|August 2017|2017-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy|A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy|Completed||Phase 4|136|Actual|Temple University||2|||f||||f||||||||No||2018-05-31 23:32:56.536569|2018-05-31 23:32:56.536569
NCT01170741|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-10-24|2010-07-26|2010-07-27|Estimate|||||||2012-10-24|2012-10-25|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|CATCH||Computer-Assisted Tailored Cue-card Health [CATCH] Study|A Tailored Cue Card HIV/STI Intervention for High Risk Groups Pilot Study|Completed||Phase 1|122|Actual|RTI International||1|||f||||f||||||||||2018-05-31 23:32:56.930046|2018-05-31 23:32:56.930046
NCT01170728|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2015-08-20|2010-07-26|2010-07-27|Estimate|||||||2015-08-20|2015-08-24|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Virtue® Male Sling Fixation Study|Virtue® Male Sling Fixation Study|Terminated|||44|Actual|Coloplast A/S|||1|The study has been terminated due to lack of subject enrollment.|f||||f||||||||||2018-05-31 23:32:57.138579|2018-05-31 23:32:57.138579
NCT01170715|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2018-02-07|2010-07-26|2010-07-27|Estimate|||||||2018-02-07|2018-02-09|Actual|July 13, 2010|Actual|2010-07-13|February 2018|2018-02-28|September 9, 2013|Actual|2013-09-09|September 9, 2013|Actual|2013-09-09||Interventional|||Psoriasis Inflammation and Systemic Co Morbidities|Psoriasis Inflammation and Systemic Co-Morbidities: Is it Preventable or Reversible?|Completed||N/A|30|Anticipated|Rockefeller University||1|||f||||f|f|f||||||||2018-05-31 23:32:57.228921|2018-05-31 23:32:57.228921
NCT01170702|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-01-17|2010-07-26|2010-07-27|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Transverse Abdominis Plane (TAP) Block After Cesarean Delivery|The Postoperative Analgesic Efficacy of Varied Concentrations of Ropivacaine Used for the Transverse Abdominis Plane (TAP) Block After Cesarean Delivery|Completed||Phase 4|120|Actual|Northwestern University||4|||f||||f||||||||No||2018-05-31 23:32:57.311042|2018-05-31 23:32:57.311042
NCT01170689|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-07-27|2010-07-26|2010-07-27|Estimate|||||||2010-07-27|2010-07-28|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan|The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan|Completed|||710|Actual|TsaoTun Psychiatric Center, Department of Health, Taiwan|||1||f||||t||||||||||2018-05-31 23:32:57.391369|2018-05-31 23:32:57.391369
NCT01170676|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-01-29|2010-07-26|2010-07-27|Estimate|||||||2015-01-29|2015-02-02|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2012|Actual|2012-05-31||Interventional|||Promoting Asthma Wellness in Rural Communities|Promoting Asthma Wellness in Rural Communities|Completed||N/A|700|Actual|Augusta University||2|||f||||t||||||||||2018-05-31 23:32:57.454059|2018-05-31 23:32:57.454059
NCT01170663|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2014-07-01|2010-09-01|2018-02-17|2010-07-26|2010-07-27|Estimate|2014-07-01|2014-07-31|Estimate|2010-09-01|2010-09-06|Estimate|2018-02-17|2018-03-19|Actual|December 2010||2010-12-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|July 2013|Actual|2013-07-31||Interventional|RAINBOW|All randomized participants.|A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine|Completed||Phase 3|665|Actual|Eli Lilly and Company|One (1) participant was randomized to the placebo/paclitaxel group but received ramucirumab in error. For ITT population this participant was included in placebo/paclitaxel group and for the Safety population included in the ramucirumab group.|2|||f||||t||||||||Yes|Lilly provides access to the individual participant data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 23:32:57.661629|2018-05-31 23:32:57.661629
NCT01170650|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2015-08-03|2010-07-26|2010-07-27|Estimate|||||||2015-08-03|2015-08-04|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|May 2015|Actual|2015-05-31||Interventional|PROCEED||Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)|A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer|Suspended||Phase 3|640|Anticipated|Endocyte||2||DSMB decision|f||||t||||||||||2018-05-31 23:32:59.356535|2018-05-31 23:32:59.356535
NCT01170637|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-05-18|2010-07-26|2010-07-27|Estimate|||||||2012-05-18|2012-05-21|Estimate|July 2010||2010-07-31|May 2012|2012-05-31||||September 2010|Actual|2010-09-30||Interventional|||Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.|Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil® (200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Male and Female Volunteers (Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial).|Completed||Phase 1|47|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:32:59.435828|2018-05-31 23:32:59.435828
NCT01170624|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2015-01-09|2010-07-26|2010-07-27|Estimate|||||||2015-01-09|2015-01-12|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|TUTOR||Clinical Status Monitoring in Implantable Cardiac Defibrillator (ICD) Patients by Physiological Diagnosis (PhD) Function|Clinical Status Monitoring in ICD Patients by Physiological Diagnosis (PhD) Function|Terminated||Phase 4|388|Actual|LivaNova||||"Field Safety Notice related to potential ventricular oversensing associated to the PhD feature~   on Paradym ICDs"|f||||t||||||||||2018-05-31 23:32:59.536743|2018-05-31 23:32:59.536743
NCT01170611|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|July 2004||2004-07-31|July 2010|2010-07-31|January 2007|Actual|2007-01-31|||||Interventional|||Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease|Prevention of Atrial Arrhythmia in Patients Without AV Conduction Disease|Completed||Phase 4|400|Actual|LivaNova||1|||||||||||||||||2018-05-31 23:32:59.650003|2018-05-31 23:32:59.650003
NCT01170598|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2012-02-08||2012-04-18|2010-07-26|2010-07-27|Estimate|2012-03-18|2012-04-13|Estimate||||2012-04-18|2012-04-20|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy|A Pilot Exercise RCT for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy: Pre-randomization Phase|Completed||Phase 2|35|Actual|Toronto Rehabilitation Institute|Although as per study design, limitations include the lack of a control group due to non-randomization, a small sample size and lack of generalizability.|1|||f||||f||||||||||2018-05-31 23:32:59.853774|2018-05-31 23:32:59.853774
NCT01170585|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2015-06-22|2010-07-26|2010-07-27|Estimate|||||||2015-06-22|2015-06-23|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||A Trial of Rosuvastatin in Systemic Lupus Erythematosus|A Randomised Placebo Controlled Trial of Rosuvastatin in Systemic Lupus Erythematosus|Completed||Phase 2|33|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 23:33:00.10259|2018-05-31 23:33:00.10259
NCT01170572|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2012-11-06|2010-07-26|2010-07-27|Estimate|||||||2012-11-06|2012-11-07|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Longitudinal Study of Patients Following Long Bone Fracture|Longitudinal Study of Vitamin D Metabolism and Bone Healing in Adult Patients With Recent Long Bone Fracture|Completed|||33|Actual|Barts & The London NHS Trust|||1||f||||f||||||Samples With DNA|"~     Whole blood samples will be retained~   "|||2018-05-31 23:33:00.186845|2018-05-31 23:33:00.186845
NCT01170559|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2014-08-12|2010-07-26|2010-07-27|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2010||2010-04-30|August 2014|2014-08-31||||August 2015|Anticipated|2015-08-31||Interventional|LIAISE||Use of Loop Recorders for Diagnosis of Palpitations in A&E|Use of Implantable Loop Recorders as a Primary Investigation of Infrequent Undiagnosed ArrhythmIa Symptoms in the Emergency Department|Unknown status|Active, not recruiting|N/A|56|Anticipated|Barts & The London NHS Trust||2|||f||||f||||||||||2018-05-31 23:33:00.254331|2018-05-31 23:33:00.254331
NCT01170546|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2010-08-02||2010-11-15|2010-07-26|2010-07-27|Estimate|2010-08-09|2010-09-06|Estimate||||2010-11-15|2010-11-23|Estimate|January 2006||2006-01-31|September 2010|2010-09-30|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|||Effects of Hamstring Training in Different Modes on Stabilizing Knee Joints With Anterior Drawer Laxity|Effects of Hamstring Training in Different Modes on Stabilizing Knee Joints With Anterior Drawer Laxity|Completed||N/A|28|Actual|Taipei Physical Education College|small size, participant: not real ACL-injured patient but knee with anterior laxity instead|3|||f||||t||||||||||2018-05-31 23:33:00.331476|2018-05-31 23:33:00.331476
NCT01170533|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2011-10-31||2012-03-05|2010-07-26|2010-07-27|Estimate|2012-03-05|2012-03-06|Estimate||||2012-03-05|2012-03-06|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||PPI and Clopidogrel Response|Effects of PPI Therapy on Clopidogrel-Induced Antiplatelet Effects: A Randomized Study|Completed||Phase 1|20|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 23:33:00.598389|2018-05-31 23:33:00.598389
NCT01170520|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-01-04|2010-07-26|2010-07-27|Estimate|||||||2012-01-04|2012-01-05|Estimate|August 2010||2010-08-31|January 2012|2012-01-31||||September 2013|Anticipated|2013-09-30||Interventional|||Repetitive Transcranial Stimulation (rTMS) for Resistant Depression in Adolescents|The Addition of rTMS to the Therapy of Adolescents That Suffer From Treatment Resistant Depression: An Open Label Study|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|Shalvata Mental Health Center||1|||f||||||||||||||2018-05-31 23:33:00.782664|2018-05-31 23:33:00.782664
NCT01170507|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-25|||2018-03-06|2010-07-26|2010-07-27|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2011||2011-12-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation|Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation: A Randomized Controlled Study|Withdrawn||Phase 1/Phase 2|0|Actual|King Faisal Specialist Hospital & Research Center||4||No funding|f||||f||||||||||2018-05-31 23:33:00.854816|2018-05-31 23:33:00.854816
NCT01170494|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-25|||2016-08-29|2010-07-26|2010-07-27|Estimate|||||||2016-08-29|2016-08-31|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels|Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels: A Randomized Controlled Trial|Completed||N/A|279|Actual|King Faisal Specialist Hospital & Research Center||8|||f||||f||||||||||2018-05-31 23:33:00.930767|2018-05-31 23:33:00.930767
NCT01170481|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-11-17|2010-07-26|2010-07-27|Estimate|||||||2015-11-17|2015-11-18|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Observational|||Assessment of Retinal Nerve Fibre Layer by Optical Coherence Tomography in Uveitis Patients With Papilloedema|Retinal Nerve Fibre Layer in Uveitic Secondary Glaucoma|Completed|||50|Actual|St. Franziskus Hospital|||3||f||||f||||||||||2018-05-31 23:33:01.010149|2018-05-31 23:33:01.010149
NCT01170468|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-25|||2018-03-06|2010-07-26|2010-07-27|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2011||2011-12-31|March 2018|2018-03-31|January 15, 2014|Actual|2014-01-15|January 15, 2014|Actual|2014-01-15||Interventional|||Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals|Does Vitamin D Reduce Risk of Developing Type II DM in Prediabetics? A Double Blind Randomized Controlled Trial|Terminated||Phase 3|25|Actual|King Faisal Specialist Hospital & Research Center||2||inadequate enrollement|f||||f||||||||||2018-05-31 23:33:01.069125|2018-05-31 23:33:01.069125
NCT01170455|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-10-28|2010-07-26|2010-07-27|Estimate|||||||2010-10-28|2010-10-29|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|BID||Nasal Intubation Using the Blind Intubation Device|Nasal Intubation Using the Blind Intubation Device:a Prospective,Randomized,Controlled Comparison With the Direct Laryngoscope|Completed||N/A|50|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 23:33:01.134867|2018-05-31 23:33:01.134867
NCT01170442|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-25|||2015-03-31|2010-07-26|2010-07-27|Estimate|||||||2015-03-31|2015-04-01|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Does Vitamin D Improve Glycemic Control in Type II DM?|Does Vitamin D Improve Glycemic Control in Type II DM? A Double Blind Randomized Controlled Trial|Terminated||Phase 3|25|Actual|King Faisal Specialist Hospital & Research Center||3||In adequate enrollment|f||||f||||||||||2018-05-31 23:33:01.203944|2018-05-31 23:33:01.203944
NCT01170429|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Efficacy and Safety Study of Procaterol Hydrochloride to Treat Patients With Cough Variant Asthma (CVA)|A Multicentered, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Procaterol Hydrochloride With Inhaled Glucocorticoid in Treatment Patients With Cough Variant Asthma (CVA)|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 23:33:01.270082|2018-05-31 23:33:01.270082
NCT01170416|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-25|||2016-05-13|2010-07-26|2010-07-27|Estimate|||||||2016-05-13|2016-05-17|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Testing Objective Methods for Template Matching Ventricular Tachycardia and Pacemapping|Quantitative Measurements Comparing Body Surface Potentials During Pacemapping and Spontaneous Ventricular Tachycardia|Completed|||20|Actual|Nova Scotia Health Authority|||4||f||||f||||||||No||2018-05-31 23:33:01.350767|2018-05-31 23:33:01.350767
NCT01170403|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2014-07-07|2010-07-26|2010-07-27|Estimate|||||||2014-07-07|2014-07-09|Estimate|January 2006||2006-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Comprehensive Analyses of Multidetector-row Cardiac Computed Tomography Data in Koreans|Comprehensive Analyses of Multidetector-row Cardiac Computed Tomography Data of Over 15,000 Individuals in Korea|Completed|||15000|Anticipated|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 23:33:01.412368|2018-05-31 23:33:01.412368
NCT01170390|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2014-05-07||2015-11-25|2010-07-26|2010-07-27|Estimate|2015-11-20|2015-11-26|Estimate||||2015-11-25|2015-12-31|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Oral Contraceptives and Body Mass Index|Improving Contraceptive Effectiveness in Obese Women|Completed||Phase 4|32|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-05-31 23:33:01.57379|2018-05-31 23:33:01.57379
NCT01170377|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-10-20|2010-07-26|2010-07-27|Estimate|||||||2015-10-20|2015-10-21|Estimate|April 2007||2007-04-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Effect of Valproate on Propofol|The Effect of Valproate on the Required Dose of Propofol for Sedation in Patients With Mental Retardation|Completed|||50|Anticipated|Okayama University|||1||f||||f||||||||||2018-05-31 23:33:01.823204|2018-05-31 23:33:01.823204
NCT01170026|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-07-02|2010-07-26|2010-07-27|Estimate|||||||2013-07-02|2013-07-04|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Individual and Family Motivational Interviews for Substance Using Truant Teens|Individual and Family Motivational Interviews for Substance Using Truant Teens|Completed||Phase 1|68|Actual|Brown University||2|||f||||t||||||||||2018-05-31 23:33:07.862161|2018-05-31 23:33:07.862161
NCT01170364|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2012-12-13||2017-08-01|2010-07-26|2010-07-27|Estimate|2017-07-03|2017-07-31|Actual||||2017-08-01|2017-08-30|Actual|February 2009||2009-02-28|June 2017|2017-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Studying the Effects of Sibutramine on Eating Behavior|Studying the Effects of Sibutramine on Eating Behavior|Terminated||Phase 4|14|Actual|New York State Psychiatric Institute|Early termination of the study given the withdrawal of sibutramine from the US market.|2||Terminated due to sibutramine being withdrawn from the market.|f||||f||||||||||2018-05-31 23:33:01.913849|2018-05-31 23:33:01.913849
NCT01170351|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-24|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|December 2005||2005-12-31|July 2010|2010-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis|Comparing Efficacy and Tolerability of Cyclosporine-A vs. Prednisolone for Induction of Remission in Auto-immune Hepatitis|Unknown status|Recruiting|Phase 3|70|Anticipated|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 23:33:02.167326|2018-05-31 23:33:02.167326
NCT01170338|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|January 2008||2008-01-31|July 2010|2010-07-31||||July 2011|Anticipated|2011-07-31||Interventional|||Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome|Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome|Unknown status|Recruiting|Phase 4|100|Anticipated|Newark Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 23:33:02.261848|2018-05-31 23:33:02.261848
NCT01170325|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-24|||2017-06-30|2010-07-24|2010-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|June 30, 2010||2010-06-30|January 28, 2011|2011-01-28|January 28, 2011|Actual|2011-01-28|January 28, 2011|Actual|2011-01-28||Interventional|||A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG|A Study of Divalproex Sodium in Children With Autism Spectrum Disorder and Epileptiform EEG|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 23:33:02.411734|2018-05-31 23:33:02.411734
NCT01170312|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2012-10-31|2010-07-26|2010-07-27|Estimate|||||||2012-10-31|2012-11-01|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ASPIRE||Arthroscopic Surgery and Platelet Rich Plasma In Rotator Cuff Tear Evaluation|Arthroscopic Surgery and Platelet Rich Plasma In Rotator Cuff Tear Evaluation (A.S.P.I.R.E.): The Use of Platelet Rich Plasma Following Arthroscopic Repair of Rotator Cuff Tears, A Pilot Study|Completed||N/A|25|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 23:33:02.496125|2018-05-31 23:33:02.496125
NCT01170299|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-24|||2016-10-31|2010-07-24|2010-07-27|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|January 2014|Actual|2014-01-31|December 2012|Actual|2012-12-31||Interventional|||Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer|A Randomized Controlled Trial to Investigate the Role of Low or High 'Fibre' Diets in Patients Undergoing Pelvic Radiotherapy - The Fibre Study|Completed||N/A|177|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:33:02.606869|2018-05-31 23:33:02.606869
NCT01170286|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-24|||2012-03-22|2010-07-26|2010-07-27|Estimate|||||||2012-03-22|2012-03-23|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy|Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Safety Study in Adult and Pediatric Subjects|Completed||Phase 1|100|Actual|DBV Technologies||2|||f||||t||||||||||2018-05-31 23:33:02.726466|2018-05-31 23:33:02.726466
NCT01170273|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2016-05-17||2016-10-28|2010-07-23|2010-07-27|Estimate|2016-10-28|2016-12-21|Estimate||||2016-10-28|2016-12-21|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|VIVA-VA||Vitamin D in Vulnerable Adults (VIVA-VA)|Vitamin D in Vulnerable Adults|Completed||Phase 3|130|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:33:02.894604|2018-05-31 23:33:02.894604
NCT01170260|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2011-08-16|2010-07-26|2010-07-27|Estimate|||||||2011-08-16|2011-08-17|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|MARS||Alcohol, Marijuana, and Risky Sex: Group Interventions With Detained Adolescents|Alcohol, Marijuana, and Risky Sex: Group Interventions With Detained Adolescents|Unknown status|Recruiting|N/A|520|Anticipated|University of New Mexico||3|||f||||||||||||||2018-05-31 23:33:03.2302|2018-05-31 23:33:03.2302
NCT01170247|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2017-03-16||2017-06-03|2010-07-23|2010-07-27|Estimate|2017-06-03|2017-07-02|Actual||||2017-06-03|2017-07-02|Actual|January 2011||2011-01-31|June 2017|2017-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients|Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation: A Prospective Randomized, Double-blinded, Placebo Controlled Study|Terminated||N/A|3|Actual|University of Iowa||2||lack of enrollment|f||||t||||||||||2018-05-31 23:33:03.377751|2018-05-31 23:33:03.377751
NCT01170234|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-02-28|2010-07-26|2010-07-27|Estimate|||||||2012-02-28|2012-02-29|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis|Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis|Completed|||14|Actual|Tufts Medical Center|||1||f||||f||||||||||2018-05-31 23:33:03.676021|2018-05-31 23:33:03.676021
NCT01170221|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2014-07-15|2014-04-02|2018-02-23|2010-07-26|2010-07-27|Estimate|2014-08-31|2014-09-03|Estimate|2014-04-02|2014-04-30|Estimate|2018-02-23|2018-03-22|Actual|August 15, 2010|Actual|2010-08-15|February 2018|2018-02-28|September 30, 2011|Actual|2011-09-30|September 30, 2011|Actual|2011-09-30||Interventional|ABSSSI|All randomized participants|TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.|A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 3|667|Actual|Trius Therapeutics LLC||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:33:03.771971|2018-05-31 23:33:03.771971
NCT01170208|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2013-09-05||2015-11-30|2010-07-26|2010-07-27|Estimate|2013-11-14|2014-01-06|Estimate||||2015-11-30|2015-12-29|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes|Open-Label, Uncontrolled, Single-Arm, Single-Center, 16-Week Study Assessing Efficacy and Safety of Frequently Modified Insulin Therapy Using Dosage Recommending Device Software in 3-Groups of Subjects With Diabetes|Completed||N/A|46|Actual|HealthPartners Institute|Study was limited by lack of a control group.|3|||f||||f||||||||||2018-05-31 23:33:04.319027|2018-05-31 23:33:04.319027
NCT01170195|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms|Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms|Unknown status|Not yet recruiting|Phase 1/Phase 2|120|Anticipated|F&C Licorice Ltd|||||f||||f||||||||||2018-05-31 23:33:04.66364|2018-05-31 23:33:04.66364
NCT01170182|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|February 2006||2006-02-28|May 2010|2010-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study to Compare Omeprazole 40 mg DR Capsules Dr. Reddy's Laboratories Ltd.,With Prilosec® 40 mg Merck & Co., Inc.,USA Under Fed Condition|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:33:04.738044|2018-05-31 23:33:04.738044
NCT01170169|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fasting Conditions|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study to Compare Omeprazole 40 mg DR Capsules Dr. Reddy's Laboratories Ltd.,With Prilosec® 40 mg Merck & Co.Inc., USA Under Fasting Conditions|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:33:04.808877|2018-05-31 23:33:04.808877
NCT01170156|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-03-04|2010-07-26|2010-07-27|Estimate|||||||2011-03-04|2011-03-07|Estimate|September 2010||2010-09-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Fluid Leakage Past Tracheal Tube Cuff : Effect of Suctioning Manoeuvre|Fluid Leakage Past Tracheal Tube Cuff : Effect of Suctioning Manoeuvre|Completed||N/A|25|Actual|Centre Hospitalier de Roanne|||||f||||f||||||||||2018-05-31 23:33:04.882932|2018-05-31 23:33:04.882932
NCT01170143|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-26|2010-07-26|2010-07-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|August 2009||2009-08-31|June 2009|2009-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PCH||Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer|A Randomized Study to Investigate the Efficacy and Safety of qw or q3w Trastuzumab, Paclitaxel and Carboplatin in Patients With IIB-IIIB HER2 Positive Breast Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 23:33:04.962587|2018-05-31 23:33:04.962587
NCT01170130|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2015-02-23|2010-07-26|2010-07-27|Estimate|||||||2015-02-23|2015-02-24|Estimate|December 2009||2009-12-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Lidocaine Usage for Pupil Dilatation (Mydriasis)|Efficiency and Safety of Lidocaine Usage for Pupil Dilatation (Mydriasis) During Cataract Surgery|Completed||N/A|100|Actual|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 23:33:05.315074|2018-05-31 23:33:05.315074
NCT01170117|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2017-02-14||2017-08-24|2010-07-26|2010-07-27|Estimate|2017-08-24|2017-08-25|Actual||||2017-08-24|2017-08-25|Actual|August 2010|Actual|2010-08-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa|Olanzapine vs Placebo for Outpatients With Anorexia Nervosa|Completed||N/A|152|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 23:33:05.417193|2018-05-31 23:33:05.417193
NCT01170104|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2011-06-22|2010-07-26|2010-07-27|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|June 2013|Anticipated|2013-06-30|May 2012|Anticipated|2012-05-31||Interventional|||Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)|Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|63|Anticipated|Chung-Ang University|||||f||||f||||||||||2018-05-31 23:33:05.732793|2018-05-31 23:33:05.732793
NCT01170091|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|2012-06-27||2014-03-14|2010-07-26|2010-07-27|Estimate|2012-08-09|2012-09-11|Estimate||||2014-03-14|2014-04-11|Estimate|December 2007||2007-12-31|March 2014|2014-03-31||||February 2011|Actual|2011-02-28||Observational||Safety Analysis Set|Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS|Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS|Completed|||651|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:33:05.803282|2018-05-31 23:33:05.803282
NCT01170078|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-03-16|2010-07-26|2010-07-27|Estimate|||||||2017-03-16|2017-03-20|Actual|July 2010||2010-07-31|June 2015|2015-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|A Phase 1 Study Comparing the Pharmacokinetics of Epoetin Hospira and Epoetin Alfa (Amgen) When Administered Intravenously in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|Completed||Phase 1|107|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-05-31 23:33:07.003557|2018-05-31 23:33:07.003557
NCT01170065|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-03-01|2010-07-26|2010-07-27|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2010||2010-06-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)|A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|198|Anticipated|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:33:07.124706|2018-05-31 23:33:07.124706
NCT01170052|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2011-03-15|2010-07-26|2010-07-27|Estimate|||||||2011-03-15|2011-03-16|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|April 2014|Anticipated|2014-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)|Phase I/II Study With Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-hodgkin's Lymphoma (NHL) Not Eligible for High Dose Chemotherapy and Autologous/Allogeneic Stem Cell Transplantation|Withdrawn||Phase 1/Phase 2|20|Anticipated|Charite University, Berlin, Germany||||insufficient enrollment|f||||f||||||||||2018-05-31 23:33:07.376101|2018-05-31 23:33:07.376101
NCT01170039|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2015-12-11||2016-02-17|2010-07-26|2010-07-27|Estimate|2016-02-17|2016-03-15|Estimate||||2016-02-17|2016-03-15|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effectiveness of Lubiprostone in Constipated Diabetics|A Randomized, Double Blind, Placebo-controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients|Completed||Phase 4|121|Actual|Emory University||2|||f||||f||||||||||2018-05-31 23:33:07.481694|2018-05-31 23:33:07.481694
NCT01031264|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2015-07-28|2009-12-11|2009-12-14|Estimate|||||||2015-07-28|2015-07-30|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Chronic Alcohol and Brain Stress Circuit Response|Chronic Alcohol and Brain Stress Circuit Response|Completed|||120|Anticipated|Yale University|||1||f||||f||||||||||2018-06-01 00:16:23.329298|2018-06-01 00:16:23.329298
NCT01170013|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-07-28|2010-07-26|2010-07-27|Estimate|||||||2012-07-28|2012-07-31|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|tCheckup||Substance Use Prevention in Teen Psychiatric Patients|Substance Abuse Prevention for Preadolescents With Psychiatric Disorders|Completed||Phase 1|68|Actual|Brown University||2|||f||||t||||||||||2018-05-31 23:33:07.937491|2018-05-31 23:33:07.937491
NCT01170000|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2011-06-27|2010-07-26|2010-07-27|Estimate|||||||2011-06-27|2011-06-28|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Timely End-of-Life Communication to Parents of Children With Brain Tumors|Timely End-of-Life Communication to Parents of Children With Brain Tumors|Unknown status|Recruiting||6|Anticipated|Barnes-Jewish Hospital|||||f||||f||||||||||2018-05-31 23:33:08.016586|2018-05-31 23:33:08.016586
NCT01169987|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|2016-03-23||2016-06-13|2010-07-23|2010-07-27|Estimate|2016-05-06|2016-06-14|Estimate||||2016-06-13|2016-07-13|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life|Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life|Completed|||191|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:33:08.1602|2018-05-31 23:33:08.1602
NCT01169974|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-10-30|2010-07-23|2010-07-26|Estimate|||||||2017-10-30|2017-11-01|Actual|February 1, 2011|Actual|2011-02-01|October 2017|2017-10-31|December 4, 2012|Actual|2012-12-04|September 2012|Actual|2012-09-30||Observational|SpeckleShake||Use of Laser Speckle to Study Post Occlusive Reactive Hyperhemia in Healthy Subjects|Evaluation Chez Des Sujets Volontaires Sains de l'ischémie-reperfusion cutanée|Completed|||41|Actual|University Hospital, Angers|||1||f||||f||||||||||2018-05-31 23:33:09.305389|2018-05-31 23:33:09.305389
NCT01169961|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-07-23|2010-07-23|2010-07-26|Estimate|||||||2010-07-23|2010-07-26|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Observational|||Assessment of Iron Deposition in Major Organs of Hemodialysis Patients|Assessment of Iron Deposition in Major Organs of Hemodialysis Patients, Using T2*MRI and Novel Biomarkers of Free Iron Species|Unknown status|Recruiting||20|Anticipated|Wolfson Medical Center|||||f||||f||||||||||2018-05-31 23:33:09.474348|2018-05-31 23:33:09.474348
NCT01169948|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2013-03-13|2010-07-23|2010-07-26|Estimate|||||||2013-03-13|2013-03-14|Estimate|June 2010||2010-06-30|March 2013|2013-03-31||||||||Observational|||320 Multidetector Computed Tomography Prior to Coronary Artery Bypass Surgery|320 Multidetector Computed Tomography in the Preoperative Assessment for Coronary Artery Bypass Graft Surgery|Withdrawn|||0|Actual|University of Edinburgh|||1|Not funded.|f||||f||||||||||2018-05-31 23:33:09.5357|2018-05-31 23:33:09.5357
NCT01169935|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2013-02-04|2010-07-23|2010-07-26|Estimate|||||||2013-02-04|2013-02-05|Estimate|July 2010||2010-07-31|February 2013|2013-02-28||||April 2011|Actual|2011-04-30||Interventional|||Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)|In Vivo Tracking of Magnetically-labelled Human Mononuclear Cells Using MRI Scanning|Completed||N/A|12|Actual|University of Edinburgh||5|||f||||f||||||||||2018-05-31 23:33:09.60388|2018-05-31 23:33:09.60388
NCT01169922|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-09-11|2010-07-23|2010-07-26|Estimate|||||||2017-09-11|2017-09-13|Actual|October 2007|Actual|2007-10-31|September 2017|2017-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SHARP||HIV Prevention With Adolescents: Neurocognitive Deficits and Treatment Response||Completed||N/A|284|Actual|University of New Mexico||2|||f||||||||||||||2018-05-31 23:33:09.675725|2018-05-31 23:33:09.675725
NCT01169909|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2016-05-13|2010-07-23|2010-07-26|Estimate|||||||2016-05-13|2016-05-17|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia|The Use of Ranibizumab to Control Pterygium Growth in Recurrences and in Non-surgical Primary Lesions.|Completed||Phase 1|10|Actual|University of New Mexico||1|||f||||f||||||||||2018-05-31 23:33:09.753703|2018-05-31 23:33:09.753703
NCT01169896|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-12-02|2010-07-23|2010-07-26|Estimate|||||||2015-12-02|2015-12-03|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|FIRST||Impact of Ventricular Pacing in Unselected ICD/CRT-D Patients|Impact of Ventricular Pacing in Unselected ICD/CRT-D Patients|Completed|||616|Actual|LivaNova|||||f||||f||||||||||2018-05-31 23:33:09.817997|2018-05-31 23:33:09.817997
NCT01169883|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-10-23|2010-07-23|2010-07-26|Estimate|||||||2012-10-23|2012-10-25|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Coping Peer Intervention for Adherence|Coping Peer Intervention for Adherence|Completed||N/A|107|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 23:33:09.959488|2018-05-31 23:33:09.959488
NCT01169870|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2012-01-01|2010-07-23|2010-07-26|Estimate|||||||2012-01-01|2012-01-04|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients|A Randomized Phase II Trial of Genexol-PM vs Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients|Withdrawn||Phase 2|0|Actual|National Cancer Center, Korea||2||withdrawn studies|f||||f||||||||||2018-05-31 23:33:10.043176|2018-05-31 23:33:10.043176
NCT01169857|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-04-23|2010-07-23|2010-07-26|Estimate|||||||2012-04-23|2012-04-24|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Velcade for Proliferative Lupus Nephritis|Velcade for Proliferative Lupus Nephritis|Withdrawn||Phase 4|0|Actual|The Rogosin Institute||1||No participants were enrolled.|f||||f||||||||||2018-05-31 23:33:10.116901|2018-05-31 23:33:10.116901
NCT01169844|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2016-11-16|2010-07-23|2010-07-26|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis|An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Psoriatic Arthritis|Completed||Phase 2|28|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:33:10.1934|2018-05-31 23:33:10.1934
NCT01169831|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-02-27|2010-07-23|2010-07-26|Estimate|||||||2017-02-27|2017-02-28|Actual|July 2011||2011-07-31|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2014|Actual|2014-11-30||Interventional|EPC-Ex||Regulation of Endothelial Progenitor Cells by Short-Term Exercise|Regulation of Endothelial Progenitor Cells by Short-Term Exercise|Active, not recruiting||N/A|60|Anticipated|Baltimore VA Medical Center||2|||f||||t||||||||||2018-05-31 23:33:10.318295|2018-05-31 23:33:10.318295
NCT01169649|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2015-04-08||2016-01-21|2010-07-22|2010-07-26|Estimate|2016-01-21|2016-02-18|Estimate||||2016-01-21|2016-02-18|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)|A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)|Completed||Phase 2|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 23:33:13.923084|2018-05-31 23:33:13.923084
NCT01169818|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-07-05|2010-07-23|2010-07-26|Estimate|||||||2013-07-05|2013-07-08|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ATLAS||Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus|Asian Treat to Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label, Parallel-Group, 24-Week Phase IV Study Evaluating the Effectiveness and Safety of Physician Versus Patient-led Initiation and Titration of Insulin Glargine in Type 2 Diabetes Mellitus|Completed||Phase 4|555|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:33:10.39073|2018-05-31 23:33:10.39073
NCT01169805|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-11-16|2010-07-23|2010-07-26|Estimate|||||||2011-11-16|2011-11-18|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery|Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery|Completed||N/A|105|Actual|Yonsei University||4|||f||||t||||||||||2018-05-31 23:33:10.473151|2018-05-31 23:33:10.473151
NCT01169792|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-07-23|2010-07-23|2010-07-26|Estimate|||||||2010-07-23|2010-07-26|Estimate||||October 2009|2009-10-31||||||||Observational|||Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients|Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment|Completed|||||Yonsei University|||1||f||||||||||Samples With DNA|"~     Blood samples with DNA~   "|||2018-05-31 23:33:10.537746|2018-05-31 23:33:10.537746
NCT01169779|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2016-08-18|2012-11-29|2016-08-18|2010-07-23|2010-07-26|Estimate|2016-08-18|2016-10-13|Estimate|2012-11-29|2012-12-03|Estimate|2016-08-18|2016-10-13|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|GetGoal-M-Asia|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin|Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period|Completed||Phase 3|391|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 23:33:10.627808|2018-05-31 23:33:10.627808
NCT01169753|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2015-11-04||2015-11-04|2010-07-23|2010-07-26|Estimate|2015-11-04|2015-12-08|Estimate||||2015-11-04|2015-12-08|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients|Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia (CML) on Imatinib, Dasatinib, Nilotinib (or Any Other FDA Approved TKI for CML)|Terminated||N/A|1|Actual|M.D. Anderson Cancer Center||2||Slow Enrollment|f||||t||||||||||2018-05-31 23:33:11.365756|2018-05-31 23:33:11.365756
NCT01169740|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-03-27|2010-07-23|2010-07-26|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2010|Actual|2010-07-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Observational|TcBili||Transcutaneous Measurement of Jaundice in the Newborn|Comparison of Transcutaneous or Laboratory Measurement of Bilirubin in the Newborn|Completed|||1000|Actual|Norwegian University of Science and Technology|||1||f||||f|f|f||||||No||2018-05-31 23:33:11.568259|2018-05-31 23:33:11.568259
NCT01169727|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-05-30|2010-07-23|2010-07-26|Estimate|||||||2012-05-30|2012-05-31|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand|Observational Study to Evaluate Health Status of Chronic Obstructive Pulmonary Disease (COPD) Patients in Response to Real-life Treatments in Thailand|Completed|||684|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:33:11.643707|2018-05-31 23:33:11.643707
NCT01169714|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-01-19|2010-07-22|2010-07-26|Estimate|||||||2011-01-19|2011-01-20|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.|An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Subjects|Completed||Phase 1|60|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:33:11.79268|2018-05-31 23:33:11.79268
NCT01169701|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2015-04-10||2015-11-06|2010-07-23|2010-07-26|Estimate|2015-04-10|2015-04-30|Estimate||||2015-11-06|2015-12-07|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|EVITA||24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients|Multicenter, Open-label, Randomized, 24 Months Follow-up, Two Arm Study to Compare the Efficacy of Everolimus in Improving the Cardiovascular Profile in a Regimen With Mycophenolic Acid vs. a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients.|Completed||Phase 4|71|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:33:11.910979|2018-05-31 23:33:11.910979
NCT01169688|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-07-22|2010-07-22|2010-07-26|Estimate|||||||2010-07-22|2010-07-26|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Preoperative Cataract Pupillary Dilation: Inpatient At The Ambulatory Surgery Center vs Outpatient Dilation Prior To Arrival At The Ambulatory Surgery Center|Preoperative Cataract Pupillary Dilation: Inpatient vs Outpatient|Completed||N/A|50|Actual|Northwest Kansas Surgery Center|||||f||||f||||||||||2018-05-31 23:33:12.456341|2018-05-31 23:33:12.456341
NCT01169675|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2013-10-30||2014-06-03|2010-07-23|2010-07-26|Estimate|2013-10-30|2013-12-20|Estimate||||2014-06-03|2014-06-09|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Treated Set includes all randomized patients that received Afatinib or Pemetrexed|BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours|BIBW 2992 Phase I Combination With Pemetrexed in Advanced Solid Tumours|Completed||Phase 1|53|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 23:33:12.551189|2018-05-31 23:33:12.551189
NCT01169662|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-10-11|2010-07-22|2010-07-26|Estimate|||||||2010-10-11|2010-10-13|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Dietary Nitrate From Vegetable/Fruit Juice on Cerebral Blood Flow Parameters|Effects of Dietary Nitrate From Vegetable/Fruit Juice on Cerebral Blood Flow Parameters|Completed||Phase 4|40|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 23:33:13.851204|2018-05-31 23:33:13.851204
NCT01169636|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-05-18|2010-07-23|2010-07-26|Estimate|||||||2017-05-18|2017-05-19|Actual|January 31, 2011|Actual|2011-01-31|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma|Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma|Completed||Phase 1/Phase 2|62|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 23:33:14.083297|2018-05-31 23:33:14.083297
NCT01169623|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2015-01-04|2010-07-23|2010-07-26|Estimate|||||||2015-01-04|2015-01-06|Estimate|July 2010||2010-07-31|January 2010|2010-01-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|EEIBSL||Effect Of Educational Intervention Based On Supportive Leadership|Assessing The Effect Of Educational Intervention Based On Supportive Behaviour Leadership Model On Head Nurses' Performance In TUMS Hospitals: RCT In 2010|Completed||N/A|110|Actual|University of Tehran||2|||f||||t||||||||||2018-05-31 23:33:14.229364|2018-05-31 23:33:14.229364
NCT01169610|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2013-07-19||2013-07-19|2010-07-23|2010-07-26|Estimate|2013-07-19|2013-09-26|Estimate||||2013-07-19|2013-09-26|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Varenicline and Alcohol in Inpatient Addictions Program (IAP)|A 24-week Open-Label Feasibility Trial of Varenicline for Alcoholic Cigarette Smokers|Terminated||Phase 3|1|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 23:33:14.311721|2018-05-31 23:33:14.311721
NCT01169597|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-23|2010-07-23|2010-07-26|Estimate|||||||2010-07-23|2010-07-26|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients|Short Term Study on the Effect of a Fixed Dose of 12.5 mg of Prednisone as Starting Dose in Polymyalgia Rheumatica|Completed||Phase 4|60|Actual|University of Genova|||||f||||f||||||||||2018-05-31 23:33:14.517021|2018-05-31 23:33:14.517021
NCT01169584|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2016-01-19|2010-07-23|2010-07-26|Estimate|||||||2016-01-19|2016-01-21|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|March 2012|Actual|2012-03-31||Interventional|||Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients|A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors.|Completed||Phase 1|6|Actual|SillaJen, Inc.||1|||f||||t||||||||||2018-05-31 23:33:14.584848|2018-05-31 23:33:14.584848
NCT01169571|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-07-23|2010-07-22|2010-07-26|Estimate|||||||2015-07-23|2015-07-24|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients|Phase 4, Open-Label Study Evaluating the Hemodynamic Effect of Differing Loading Regimens of Precedex in a Post-Surgical Intensive Care Patient Population|Completed|||373|Actual|Hospira, now a wholly owned subsidiary of Pfizer|||3||f||||f||||||||||2018-05-31 23:33:14.677818|2018-05-31 23:33:14.677818
NCT01169558|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2016-08-25||2016-10-26|2010-07-23|2010-07-26|Estimate|2016-08-25|2016-10-18|Estimate||||2016-10-26|2016-12-08|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||The intent to treat (ITT) population included all participants receiving at least one dose of the study drug.|A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.|First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum First BEAT (Bevacizumab Expanded Access Trial)- Brazilian Extension|Completed||Phase 3|168|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:33:14.845288|2018-05-31 23:33:14.845288
NCT01169545|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-05-14|2010-07-23|2010-07-26|Estimate|||||||2015-05-14|2015-05-18|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Cancer, Vulnerability, and Financial Quality of Life: A Mixed Methods Study|Cancer, Vulnerability, and Financial Quality of Life: A Mixed Methods Study|Completed|||90|Actual|Georgetown University|||1||f||||f||||||||||2018-05-31 23:33:15.18495|2018-05-31 23:33:15.18495
NCT01169532|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-11-03|2010-07-22|2010-07-26|Estimate|||||||2015-11-03|2015-11-04|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)|Completed||Phase 1|16|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 23:33:15.258171|2018-05-31 23:33:15.258171
NCT01169519|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2013-07-29||2013-10-10|2010-07-23|2010-07-26|Estimate|2013-10-10|2013-12-05|Estimate||||2013-10-10|2013-12-05|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Overall 21 subjects were enrolled and all subjects received a baseline assessment followed by sildenafil administration.|Sildenafil in Single Ventricle Patients|Safety, Pharmacokinetics and Hemodynamic Efficacy of Sildenafil in Single Ventricle Patients|Completed||Phase 1|21|Actual|Duke University||1|||f||||t||||||||||2018-05-31 23:33:15.376903|2018-05-31 23:33:15.376903
NCT01169506|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-08-06|2010-07-23|2010-07-26|Estimate|||||||2010-08-06|2010-08-09|Estimate|August 2009||2009-08-31|March 2009|2009-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|subton||Sublingual Tonometry to Assess Tissue Perfusion in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A New Method of Sublingual Tonometry to Assess Tissue Perfusion in Patients With COPD and Healthy Individuals|Completed||N/A|66|Actual|Szeged University||1|||f||||f||||||||||2018-05-31 23:33:15.565353|2018-05-31 23:33:15.565353
NCT01169493|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2015-08-28||2016-08-01|2010-07-22|2010-07-26|Estimate|2015-08-28|2015-09-30|Estimate||||2016-08-01|2016-09-23|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PACE-RBBB||Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)|Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)|Terminated||N/A|16|Actual|Duke University|We were unable to enroll adequately, and the study was underpowered to assess either the safety or efficacy of RV only, or BIV pacing in patients with right bundle branch block.|6||Lack of funding|f||||t||||||||||2018-05-31 23:33:15.644462|2018-05-31 23:33:15.644462
NCT01169480|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2017-06-16|2010-07-23|2010-07-26|Estimate|||||||2017-06-16|2017-06-20|Actual|June 2010||2010-06-30|June 2017|2017-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Impact of Giving a Massage|The Impact of Giving a Massage on Perceived Depression, Anxiety and Stress of Massage Therapists: A Randomized Clinical Trial|Completed||Early Phase 1|20|Actual|Parker Research Institute||2|||f||||t||||||||||2018-05-31 23:33:16.032407|2018-05-31 23:33:16.032407
NCT01168960|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2014-12-02|2010-07-22|2010-07-23|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Identifying Multiple Mechanisms of Change in Alcoholism Treatment||Completed||Phase 4|61|Actual|State University of New York at Buffalo||1|||f||||t||||||||||2018-05-31 23:33:26.249011|2018-05-31 23:33:26.249011
NCT01169467|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2014-11-05||2015-10-06|2010-07-22|2010-07-26|Estimate|2015-10-06|2015-11-02|Estimate||||2015-10-06|2015-11-02|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|C3PO||Cerebral Perfusion Pressure Using Precedex and Other Sedatives|Cerebral Perfusion Pressure Using Precedex and Other Sedatives|Completed||Phase 3|89|Actual|Duke University||2|||f||||f||||||||||2018-05-31 23:33:16.198531|2018-05-31 23:33:16.198531
NCT01169454|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-04-03|2010-07-23|2010-07-26|Estimate|||||||2015-04-03|2015-04-06|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|VISION 2||Ventriculostomy in Subarachnoid Hemorrhage (SAH): Intracranial Pressure (ICP) Open or Not?|Ventriculostomy in SAH: ICP Open or Not?|Terminated|||60|Actual|Duke University|||2||f||||f||||||||||2018-05-31 23:33:16.689866|2018-05-31 23:33:16.689866
NCT01169441|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2010-07-23|2010-07-23|2010-07-26|Estimate|||||||2010-07-23|2010-07-26|Estimate|November 2006||2006-11-30|May 2009|2009-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|EXTRACT||Lead Extract Study|EXTRACT Study (Data Collection on the Extraction of 2nd and 3rd Generation Defibrillation Leads)|Completed|||100|Actual|St. Paul Heart Clinic|||||f||||f||||||||||2018-05-31 23:33:16.749766|2018-05-31 23:33:16.749766
NCT01169428|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-03-12|2010-07-22|2010-07-26|Estimate|||||||2013-03-12|2013-03-14|Estimate|July 2007||2007-07-31|March 2013|2013-03-31|June 2010|Actual|2010-06-30|July 2009|Actual|2009-07-31||Interventional|EMPOWER||Engaging Motivation for the Prevention of Weight Regain|Mindfulness Based Weight Loss Maintenance|Completed||Phase 2|95|Actual|Duke University||2|||f||||t||||||||||2018-05-31 23:33:16.80844|2018-05-31 23:33:16.80844
NCT01169415|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-05-15|2010-07-22|2010-07-26|Estimate|||||||2014-05-15|2014-05-19|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Steroid Tapering on Functional Capacity and Neurocognition|Effects of Dexamethasone Tapering Schedules on Functional Capacity and Neurocognition in Patients With Newly Diagnosed Glioblastoma Multiforme|Withdrawn||N/A|0|Actual|Duke University||2||Funding not obtained|f||||t||||||||||2018-05-31 23:33:16.891586|2018-05-31 23:33:16.891586
NCT01169402|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-11-20|2010-07-23|2010-07-26|Estimate|||||||2017-11-20|2017-11-22|Actual|July 2010||2010-07-31|November 2017|2017-11-30|February 20, 2013|Actual|2013-02-20|February 20, 2013|Actual|2013-02-20||Interventional|||Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)|Safety and Pharmacokinetics of Fluconazole Prophylaxis in Children Supported With Extracorporeal Membrane Oxygenation|Completed||Phase 1|21|Actual|Duke University||1|||f||||f||||||||||2018-05-31 23:33:16.95782|2018-05-31 23:33:16.95782
NCT01169389|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-07-29|2010-07-23|2010-07-26|Estimate|||||||2010-07-29|2010-07-30|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Analgesic Control Following Knee Arthroscopy|Analgesic Control Following Knee Arthroscopy: Results of a Randomised , Double-blinded Trial Comparing a Hyaluronic Acid Supplement to Bupivacaine|Completed||N/A|98|Actual|Orthopaedic Research and Innovation Foundation||2|||f||||t||||||||||2018-05-31 23:33:17.020129|2018-05-31 23:33:17.020129
NCT01169376|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2016-05-17|2010-07-23|2010-07-26|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarkers in Young Patients With Neuroblastoma|Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Neuroblastoma|Completed|||380|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:33:17.153125|2018-05-31 23:33:17.153125
NCT01169363|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2017-05-16|2010-07-23|2010-07-26|Estimate|||||||2017-05-16|2017-05-17|Actual|July 8, 2010|Actual|2010-07-08|May 2017|2017-05-31|August 8, 2010|Actual|2010-08-08|August 8, 2010|Actual|2010-08-08||Observational|||Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy|Validation of AML Proteomic Signature Associated With Clinical Response to Ara-C Based Induction Therapy in Patients 60 Years of Age or Older Using Samples From ECOG Studies 3999, 3993 and 1490|Completed|||200|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:33:17.226861|2018-05-31 23:33:17.226861
NCT01169350|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|2017-06-08||2017-10-17|2010-07-23|2010-07-26|Estimate|2017-10-17|2017-11-17|Actual||||2017-10-17|2017-11-17|Actual|February 2010||2010-02-28|October 2017|2017-10-31|August 2013|Actual|2013-08-31|October 2011|Actual|2011-10-31||Interventional||Received Baseline FDG PET and FMISO PET|18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma|A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Soft Tissue Sarcoma|Terminated||Phase 2|8|Actual|National Cancer Institute (NCI)||1||funding source ended earlier than anticipated|f||||t||||||||No||2018-05-31 23:33:17.309207|2018-05-31 23:33:17.309207
NCT01169337|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2018-05-24|2010-07-23|2010-07-26|Estimate|||||||2018-05-24|2018-05-25|Actual|October 5, 2010|Actual|2010-10-05|May 2018|2018-05-31||||July 1, 2026|Anticipated|2026-07-01||Interventional|||Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma|Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma|Active, not recruiting||Phase 3|180|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:33:17.643667|2018-05-31 23:33:17.643667
NCT01169324|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2018-03-22|2010-07-23|2010-07-26|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2010||2010-07-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Deep Brain Stimulation (DBS) on Sleep Architecture in Patients With Movement Disorders|Effect of DBS on Sleep Architecture in Patients With Movement Disorders.|Active, not recruiting||N/A|17|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 23:33:18.586473|2018-05-31 23:33:18.586473
NCT01169311|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2014-01-17||2014-09-30|2010-07-23|2010-07-26|Estimate|2014-09-30|2014-10-06|Estimate||||2014-09-30|2014-10-06|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Performance of the Covidien EEA Hemorrhoid and Prolapse Stapling Set in a Hemorrhoidopexy Procedure|A Prospective, Multi-Center Investigation Of The Safety And Performance Of The Covidien EEA™ Hemorrhoid And Prolapse Stapling Set With DST Series™ Technology Im A Hemorrhoidopexy Procedure|Completed||N/A|27|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 23:33:18.65269|2018-05-31 23:33:18.65269
NCT01169298|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2016-10-27|2010-07-23|2010-07-26|Estimate|||||||2016-10-27|2016-10-31|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma|A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma|Completed||Phase 1|13|Actual|Celgene Corporation||1|||f||||t||||||||||2018-05-31 23:33:19.743041|2018-05-31 23:33:19.743041
NCT01169285|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-07-23|2010-07-23|2010-07-26|Estimate|||||||2010-07-23|2010-07-26|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Efficiency and Efficacy of the Distress Thermometer in the Burn and Wound Population (Research Mentoring High Student Project)|Prospective Observational|Completed|||||Saint Elizabeth Regional Medical Center|||||f||||||||||||||2018-05-31 23:33:19.873772|2018-05-31 23:33:19.873772
NCT01169272|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2014-06-17|2010-07-23|2010-07-26|Estimate|||||||2014-06-17|2014-06-18|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Clinical Evaluation Of The SonR Atrial Lead In Paradym RF Device|Clinical Evaluation Of SonR Atrial Lead In Paradym RF Device SORIN GROUP'S New ICD Plateform|Completed||Phase 3|100|Actual|LivaNova||1|||f||||f||||||||||2018-05-31 23:33:19.925296|2018-05-31 23:33:19.925296
NCT01169259|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-04-06|2010-07-22|2010-07-26|Estimate|||||||2018-04-06|2018-04-10|Actual|July 2010||2010-07-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VITAL||Vitamin D and Omega-3 Trial (VITAL)|Vitamin D and Omega-3 Trial (VITAL)|Active, not recruiting||Phase 3|25871|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 23:33:19.996716|2018-05-31 23:33:19.996716
NCT01169246|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-02-23|2010-07-23|2010-07-26|Estimate|||||||2015-02-23|2015-02-25|Estimate|November 2009||2009-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|ASAP||Efficacy of the ATP Switch Automatic Programming in Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) Implanted Patients|Efficacy of the ATP Switch Automatic Programming in ICD and CRT-D Implanted Patients|Terminated|||1254|Actual|LivaNova|||1|Low recruitement rate|f||||f||||||||||2018-05-31 23:33:20.0968|2018-05-31 23:33:20.0968
NCT01169233|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-04-28|2010-07-22|2010-07-26|Estimate|||||||2015-04-28|2015-04-30|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|Mars 105||Operational Evaluation of a Photic Countermeasure to Improve Alertness, Performance, and Mood During Nightshift Work on a 105-day Simulated Human Exploration Mission to Mars|Operational Evaluation of a Photic Countermeasure to Improve Alertness, Performance, and Mood During Nightshift Work on a 105-day Simulated Human Exploration Mission to Mars|Completed||N/A|25|Actual|Brigham and Women's Hospital||3|||f||||f||||||||||2018-05-31 23:33:20.1579|2018-05-31 23:33:20.1579
NCT01169220|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2017-10-03|2010-07-23|2010-07-26|Estimate|||||||2017-10-03|2017-10-05|Actual|July 2010||2010-07-31|October 2017|2017-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Bowel Preparation for Inpatient Colonoscopy|Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy|Completed||Phase 4|55|Actual|Santa Clara Valley Health & Hospital System||2|||f||||t||||||||||2018-05-31 23:33:20.290224|2018-05-31 23:33:20.290224
NCT01169207|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2018-02-02|2010-07-23|2010-07-26|Estimate|||||||2018-02-02|2018-02-06|Actual|July 1996||1996-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Johns Hopkins Crohn's Disease and Ulcerative Colitis Study|Johns Hopkins Crohn's Disease and Ulcerative Colitis Study|Recruiting|||2500|Anticipated|Johns Hopkins University|||2||f||||f||||||Samples With DNA|"~     whole blood and derivative from blood, saliva~   "|||2018-05-31 23:33:21.152711|2018-05-31 23:33:21.152711
NCT01169194|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2018-01-31|2010-07-23|2010-07-26|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 2003|Actual|2003-06-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|MAAIS||Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)|Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)|Recruiting|||2400|Anticipated|Johns Hopkins University|||2||f||||t||||||Samples With DNA|"~     whole blood and derivatives from blood, saliva~   "|No||2018-05-31 23:33:21.236544|2018-05-31 23:33:21.236544
NCT01169181|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2016-12-07|2010-07-22|2010-07-26|Estimate|||||||2016-12-07|2016-12-08|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|AMES||AMES + Brain Stimulation|AMES + Brain Stimulation: Treatment for Profound Plegia in Stroke|Active, not recruiting||Phase 1|6|Anticipated|AMES Technology||2|||f||||t||||||||No||2018-05-31 23:33:21.345219|2018-05-31 23:33:21.345219
NCT01169168|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2010-07-23|2010-07-23|2010-07-26|Estimate|||||||2010-07-23|2010-07-26|Estimate|April 2010||2010-04-30|July 2010|2010-07-31||||||||Observational|||Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome (SIRS), Sepsis or Chronicle Liver Disease on Intensive Care Units (ICU)|Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome, Sepsis, Chronicle Liver Disease or After Lysis on Intensive Care Units|Unknown status|Recruiting||250|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples Without DNA|"~     citrated plasma~   "|||2018-05-31 23:33:21.412357|2018-05-31 23:33:21.412357
NCT01169155|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2017-07-18|2010-07-23|2010-07-26|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2010||2010-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Critical Smoke Alarm Characteristics to Awaken Children From Stage 4 Sleep|Critical Smoke Alarm Characteristics to Awaken Children From Stage 4 Sleep|Recruiting||N/A|708|Anticipated|Nationwide Children's Hospital||5|||f||||f||||||||||2018-05-31 23:33:21.481318|2018-05-31 23:33:21.481318
NCT01169142|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-07-20|2010-07-23|2010-07-26|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Study of Vitamin D in the Severely Mentally Ill|A Pilot Study of Vitamin D Supplementation in Bronx Psychiatric Patients|Unknown status|Active, not recruiting|N/A|40|Anticipated|Bronx Psychiatric Center||2|||f||||f||||||||||2018-05-31 23:33:21.587208|2018-05-31 23:33:21.587208
NCT01169129|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2014-02-02|2010-07-23|2010-07-26|Estimate|||||||2014-02-02|2014-02-04|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resectable Brain Metastases|Surgery and Whole Brain Radiotherapy Versus Whole Brain Radiotherapy and Radiosurgery for 1-3 Resectable Brain Metastases: Phase III Prospective Pilot Study|Withdrawn||Phase 3|0|Actual|Barretos Cancer Hospital||2||No participants enrolled.|f||||t||||||||||2018-05-31 23:33:21.770554|2018-05-31 23:33:21.770554
NCT01169116|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2014-02-02|2010-07-23|2010-07-26|Estimate|||||||2014-02-02|2014-02-04|Estimate|July 2010||2010-07-31|February 2014|2014-02-28||||July 2010|Anticipated|2010-07-31||Interventional|||Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis|Exclusive Hypofractionated Stereotactic Radiotherapy in Non-resectable Single Brain Metastasis: Prospective Study|Withdrawn||Phase 2|0|Actual|Barretos Cancer Hospital||||No participants enrolled.|f||||t||||||||||2018-05-31 23:33:21.85061|2018-05-31 23:33:21.85061
NCT01168427|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2012-06-19||2018-01-30|2010-07-21|2010-07-23|Estimate|2012-06-19|2012-07-26|Estimate||||2018-01-30|2018-02-28|Actual|August 2010||2010-08-31|January 2018|2018-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Reveal In-Office Implants|Reveal® In-Office Implants Study|Completed|||66|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||No||2018-05-31 23:33:32.870916|2018-05-31 23:33:32.870916
NCT01169103|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2013-12-10||2015-04-06|2010-07-22|2010-07-23|Estimate|2014-07-18|2014-07-21|Estimate||||2015-04-06|2015-04-28|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|April 2013|Actual|2013-04-30||Interventional|||Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls|Effect of rhGH Administration on Visceral Adiposity and Markers of Cardiovascular Risk in Obese Adolescent Girls: Phase 2|Completed||Phase 2|22|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:33:21.949202|2018-05-31 23:33:21.949202
NCT01169090|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-08-15|2010-07-22|2010-07-23|Estimate|||||||2011-08-15|2011-08-17|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Phase 2 Dose Finding Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy|Completed||Phase 2|620|Anticipated|Kowa Research Institute, Inc.||6|||f||||f||||||||||2018-05-31 23:33:22.316022|2018-05-31 23:33:22.316022
NCT01169077|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2012-11-15|2010-07-22|2010-07-23|Estimate|||||||2012-11-15|2012-11-16|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria|A Phase I, Randomized, Controlled Dosage-Escalation Study of the Safety and Reactogenicity of the EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria Administered Via Electroporation to Healthy Adults|Completed||Phase 1|39|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-05-31 23:33:22.42704|2018-05-31 23:33:22.42704
NCT01169064|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2016-03-14||2017-04-19|2010-07-22|2010-07-23|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|July 2010||2010-07-31|April 2017|2017-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Age ranged from 16-45 but was not analyzed by treatment arm.|Topical Silver for Prevention of Wound Infection After Cesarean Delivery|Topical Silver for Prevention of Wound Infection Post Cesarean Delivery: A Randomized Controlled Trial|Terminated||N/A|475|Actual|Vanderbilt University Medical Center||2||Interim analysis showed no statistical significance achieved.|f||||f||||||||||2018-05-31 23:33:22.504611|2018-05-31 23:33:22.504611
NCT01169051|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-03-30|2010-07-22|2010-07-23|Estimate|||||||2017-03-30|2017-04-04|Actual|July 2010||2010-07-31|March 2017|2017-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||A Retrospective Analysis of Statin Use and Outcome After Thoracic Cancer Surgery|A Retrospective Analysis of Statin Use and Outcome After Thoracic Cancer Surgery|Completed|||569|Actual|Vanderbilt University Medical Center|||2||f||||t||||||||||2018-05-31 23:33:22.775906|2018-05-31 23:33:22.775906
NCT01169038|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2012-09-17||2012-10-26|2010-07-22|2010-07-23|Estimate|2012-09-17|2012-10-19|Estimate||||2012-10-26|2012-10-31|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|CLEAR Lung||Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis|Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis|Completed||Phase 1|15|Actual|Vanderbilt University||1|||f||||t||||||||||2018-05-31 23:33:22.929153|2018-05-31 23:33:22.929153
NCT01169025|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2012-06-01|2010-07-22|2010-07-23|Estimate|||||||2012-06-01|2012-06-04|Estimate|September 2012||2012-09-30|June 2012|2012-06-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients|Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients|Withdrawn||N/A|0|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 23:33:23.111593|2018-05-31 23:33:23.111593
NCT01169012|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-08-18|2010-07-22|2010-07-23|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2010|Actual|2010-09-30|August 2017|2017-08-31|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias|A Pharmacokinetic Study of Oral and Intravenous Clofarabine in Patients With High Risk Myelodysplasia and Acute Leukemias - Determination of Oral Bioavailability and the Effect of Cimetidine on Clofarabine Clearance|Completed||Phase 1|13|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:33:23.240384|2018-05-31 23:33:23.240384
NCT01168999|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2013-05-10||2015-10-05|2010-07-22|2010-07-23|Estimate|2013-11-04|2013-12-23|Estimate||||2015-10-05|2015-10-28|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Mechanisms of Manual Therapy in the Treatment of Low Back Pain|The Mechanisms of Manual Therapy in the Treatment of Low Back Pain|Completed||Phase 1/Phase 2|110|Actual|University of Florida||4|||f||||f||||||||||2018-05-31 23:33:23.34042|2018-05-31 23:33:23.34042
NCT01168986|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2016-01-28||2016-05-11|2010-07-22|2010-07-23|Estimate|2016-05-11|2016-06-20|Estimate||||2016-05-11|2016-06-20|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain|The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain|Completed||Phase 1/Phase 2|62|Actual|University of Florida|Participants were individuals with neck pain responding to a study and not necessarily seeking care. As a result, the findings may not directly translate to individuals with neck pain seeking care from a healthcare provider.|3|||f||||f||||||||||2018-05-31 23:33:23.910753|2018-05-31 23:33:23.910753
NCT01168973|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2014-12-17|2014-05-01|2017-07-12|2010-07-22|2010-07-23|Estimate|2014-12-17|2014-12-29|Estimate|2014-05-01|2014-05-19|Estimate|2017-07-12|2017-08-11|Actual|December 2010||2010-12-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|December 2013|Actual|2013-12-31||Interventional||Intent-to-Treat (ITT) population: All randomized participants grouped according to their assigned treatment at randomization.|A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy|A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy|Completed||Phase 3|1253|Actual|Eli Lilly and Company|Three participants randomized to placebo and docetaxel received 1 dose of ramucirumab in error. They are included in the placebo and docetaxel arm in the ITT population and are included in the ramucirumab and docetaxel arm in the Safety population.|2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:33:24.410591|2018-05-31 23:33:24.410591
NCT01168947|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-04-10|2010-07-22|2010-07-23|Estimate|||||||2017-04-10|2017-04-12|Actual|July 2010||2010-07-31|April 2017|2017-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Sodium Concentration of Priming and Rinsing Fluids on Weight Gain|Effect of Sodium Concentration of Priming and Rinsing Fluids on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients: a Prospective Pilot Study|Completed||N/A|17|Actual|Renal Research Institute||1|||f||||||||||||||2018-05-31 23:33:26.319301|2018-05-31 23:33:26.319301
NCT01168934|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2011-09-12||2011-10-20|2010-07-22|2010-07-23|Estimate|2011-09-12|2011-10-19|Estimate||||2011-10-20|2011-10-24|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers|A Phase 1, Single Dose, Randomized, Cross-Over Absolute Bioavailability Study In Healthy Volunteers Comparing Oral To Intravenous Administration Of Crizotinib (PF-02341066)|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:33:26.402219|2018-05-31 23:33:26.402219
NCT01168921|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-12-11|2010-07-22|2010-07-23|Estimate|||||||2017-12-11|2017-12-13|Actual|November 2010|Actual|2010-11-30|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)|A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia|Active, not recruiting||Phase 2|36|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:33:26.863014|2018-05-31 23:33:26.863014
NCT01168908|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2017-08-24||2018-03-20|2010-07-22|2010-07-23|Estimate|2018-03-20|2018-03-21|Actual||||2018-03-20|2018-03-21|Actual|September 2010||2010-09-30|March 2018|2018-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|REVERSE-DBMD||Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy|Phase 2 Clinical Trial of Sildenafil for Cardiac Dysfunction in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy|Terminated||Phase 2|20|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2||As recommended by the DSMB.|f||||t||||||||||2018-05-31 23:33:26.979633|2018-05-31 23:33:26.979633
NCT01168895|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2014-04-10|2010-07-22|2010-07-23|Estimate|||||||2014-04-10|2014-04-14|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder|Randomized, Double-blind, Cross-over Study in COPD Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder|Completed||Phase 1|12|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:33:27.401209|2018-05-31 23:33:27.401209
NCT01168882|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2012-08-01|2010-07-22|2010-07-23|Estimate|||||||2012-08-01|2012-08-02|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|July 2015|Anticipated|2015-07-31|June 2014|Anticipated|2014-06-30||Interventional|||Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies|Phase 1 Open-label, Dose-escalation Clinical Study of the Safety and Tolerability of RGB-286638, a Novel, Multi-targeted Kinase Inhibitor, Administered to Patients With Selected, Relapsed or Refractory Hematological Malignancies|Withdrawn||Phase 1|0|Actual|Agennix||||Sponsor decision to not initiate clinical trial at this time|f||||t||||||||||2018-05-31 23:33:27.500508|2018-05-31 23:33:27.500508
NCT01168869|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2015-10-01|2010-07-22|2010-07-23|Estimate|||||||2015-10-01|2015-10-02|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Myocardial Infarction as the First Manifestation of Coronary Heart Disease: Rates of Heralded and Unheralded Myocardial Infarction|Myocardial Infarction as the First Manifestation of Coronary Heart Disease: Rates of Heralded and Unheralded Myocardial Infarction. A CALIBER Study|Completed|||9000|Actual|London School of Hygiene and Tropical Medicine|||1||f||||t||||||||||2018-05-31 23:33:27.568902|2018-05-31 23:33:27.568902
NCT01168856|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2015-12-30||2016-02-12|2010-07-22|2010-07-23|Estimate|2016-02-12|2016-03-11|Estimate||||2016-02-12|2016-03-11|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational||Eligible population included all enrolled participants excluding participants with protocol violations.|An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens|A Long-term Monitoring Study to Evaluate the Persistence of Direct Antiviral (DAA) Treatment Resistant Mutations or the Durability of Sustained Virological Response (SVR) in Patients Treated With DAA Containing Regimens for Chronic Hepatitis C Infections (CHC)|Terminated|||734|Actual|Hoffmann-La Roche|Investigators were notified of the early termination of study in Jan2015 due to the completion of assessment for resistance monitoring arm and were encouraged to complete scheduled visits until Apr2015 for participants enrolled in SVR durability arm.||1|This study was terminated due to the decrease in percentage of participants.|f||||||||||None Retained|"~     Serum specimens collected from patients with partial viral response or viral load rebound of~     viral response to monitor for resistance mutations in viral RNA~   "|||2018-05-31 23:33:27.694426|2018-05-31 23:33:27.694426
NCT01168843|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-08-23|2010-07-22|2010-07-23|Estimate|||||||2010-08-23|2010-08-24|Estimate|October 2010||2010-10-31|July 2010|2010-07-31||||||||Observational|||Computer Program for Evaluation of the Symmetry Between the Primary Sulci of the Two Fetal Brain Hemispheres and Midsagittal Fetal Head Biometry Using 3-dimensional Ultrasound Planes.||Unknown status|Not yet recruiting||200|Anticipated|Bnai Zion Medical Center|||1||f||||||||||||||2018-05-31 23:33:28.730325|2018-05-31 23:33:28.730325
NCT01168830|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2015-02-04|2010-07-22|2010-07-23|Estimate|||||||2015-02-04|2015-02-05|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31||Interventional|BIOSOLVE-I||First in Man Trial - BIOSOLVE-I|BIOTRONIKS-Safety and Clinical Performance Of the First Drug-Eluting Generation Absorbable Metal Stent In Patients With de Novo Lesions in NatiVE Coronary Arteries (BIOSOLVE - I)|Completed||N/A|46|Actual|Biotronik AG||1|||f||||t||||||||||2018-05-31 23:33:28.786966|2018-05-31 23:33:28.786966
NCT01168817|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2014-11-03|2010-07-22|2010-07-23|Estimate|||||||2014-11-03|2014-11-04|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors|A Prospective, Randomized, Double-blind, Double-dummy, Placebo- and Active Controlled, Multicenter Study Assessing the Efficacy and Safety of the Combination BAY60-4552 / Vardenafil Compared to Vardenafil (20 mg) for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 (Phosphodiesterase 5) Inhibitors|Completed||Phase 2|140|Actual|Bayer||3|||f||||f||||||||||2018-05-31 23:33:28.884896|2018-05-31 23:33:28.884896
NCT01168804|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-11-21|2010-07-22|2010-07-23|Estimate|||||||2013-11-21|2013-11-25|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|BBD||Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma|Bendamustine Plus Bortezomib Plus Dexamethasone in the Treatment of Stage II/III Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|79|Actual|Austrian Forum Against Cancer||1|||f||||t||||||||||2018-05-31 23:33:29.021468|2018-05-31 23:33:29.021468
NCT01168791|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2013-07-17|2010-07-21|2010-07-23|Estimate|||||||2013-07-17|2013-07-18|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PICASSO III||Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma|A Phase III Multicenter, International, Randomized, Double-blind, Placebo-controlled Study of Doxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients With Front-line Metastatic Soft Tissue Sarcoma.|Completed||Phase 3|447|Actual|Ziopharm||2|||f||||t||||||||||2018-05-31 23:33:29.132346|2018-05-31 23:33:29.132346
NCT01168778|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-23|Estimate|||||||2010-07-21|2010-07-23|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Improving Communication During Pediatric Visits for Acute Respiratory Illness|Improving Communication During Pediatric Visits for Acute Respiratory Illness|Completed||N/A|1313|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:33:29.451708|2018-05-31 23:33:29.451708
NCT01168765|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2013-05-07|2010-07-21|2010-07-23|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|UTCO||Tu Salud Si Cuenta: UT Community Outreach Program for Community-based Diabetes Prevention and Control.|Tu Salud Si Cuenta: UT Community Outreach Program for Community-based Diabetes Prevention and Control|Completed||N/A|500|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:33:29.520714|2018-05-31 23:33:29.520714
NCT01168752|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2014-01-31|2010-07-22|2010-07-23|Estimate|||||||2014-01-31|2014-02-03|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma|Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma|Completed||Phase 1|81|Actual|Debiopharm International SA||2|||f||||f||||||||||2018-05-31 23:33:29.600924|2018-05-31 23:33:29.600924
NCT01168739|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-07-21|2010-07-21|2010-07-23|Estimate|||||||2010-07-21|2010-07-23|Estimate|September 2009||2009-09-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response|Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response|Completed||N/A|9|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 23:33:29.688912|2018-05-31 23:33:29.688912
NCT01168726|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2015-05-26||2017-06-15|2010-07-21|2010-07-23|Estimate|2015-06-09|2015-06-29|Estimate||||2017-06-15|2017-07-13|Actual|January 2010||2010-01-31|June 2017|2017-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Protective Behavioral Strategies and Brief Alcohol Interventions|Protective Behavioral Strategies and Brief Alcohol Interventions|Completed||N/A|365|Actual|University of Missouri-Columbia||3|||f||||f||||||||No||2018-05-31 23:33:29.778493|2018-05-31 23:33:29.778493
NCT01168713|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22||2012-06-20|2017-03-01|2010-07-22|2010-07-23|Estimate||||2012-06-29|2012-07-03|Estimate|2017-03-01|2017-03-03|Actual|August 2010||2010-08-31|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia|A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia|Completed||Phase 2|132|Actual|Cempra Inc||2|||f||||t||||||||||2018-05-31 23:33:30.033453|2018-05-31 23:33:30.033453
NCT01168700|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-23|Estimate|||||||2010-07-21|2010-07-23|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|Kymes||Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome|"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. KYMES"|Unknown status|Recruiting|Phase 4|46|Anticipated|Universidad de Santander||2|||f||||f||||||||||2018-05-31 23:33:30.247427|2018-05-31 23:33:30.247427
NCT01168687|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2013-01-16||2013-02-22|2010-07-22|2010-07-23|Estimate|2013-02-22|2013-02-25|Estimate||||2013-02-22|2013-02-25|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|||Effects of Levetiracetam (Keppra) on Alcohol Consumption|Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake|Completed||N/A|46|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:33:30.388395|2018-05-31 23:33:30.388395
NCT01168674|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2015-05-13||2017-02-21|2010-07-22|2010-07-23|Estimate|2016-12-20|2017-02-13|Actual||||2017-02-21|2017-02-24|Actual|February 2010||2010-02-28|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder|Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder : A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial|Completed||Phase 4|49|Actual|Tufts Medical Center|All crossover studies have the limitation of order effects: the order in which treatments were given could impact the results. The definition of bipolarity predictors also may not have effectively identified groups correctly.|2|||f||||t||||||||No||2018-05-31 23:33:30.622816|2018-05-31 23:33:30.622816
NCT01168661|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-07-22|2010-07-22|2010-07-23|Estimate|||||||2010-07-22|2010-07-23|Estimate|August 2007||2007-08-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Yoga, Mindfulness and Cognitive Psychotherapy as Treatment for Stress and Burnout|Yoga, Mindfulness and Cognitive Psychotherapy as Treatment for Stress and Burnout|Completed||N/A|90|Actual|Karolinska Institutet||4|||f||||f||||||||||2018-05-31 23:33:30.849189|2018-05-31 23:33:30.849189
NCT01168648|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-07-22|2010-07-22|2010-07-23|Estimate|||||||2010-07-22|2010-07-23|Estimate|August 2003||2003-08-31|July 2010|2010-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Yoga for Stress Management in Health Care Personnel|Yoga for Stress Management in Health Care Personnel and Its Relation to the Hypothalamus-pituitary-adrenal(HPA)Axis|Completed||N/A|71|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 23:33:30.946714|2018-05-31 23:33:30.946714
NCT01168635|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2015-05-18|2010-07-21|2010-07-23|Estimate|||||||2015-05-18|2015-05-20|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Improving Asthma Outcomes Through Spirometry Distance Learning|Improving Asthma Outcomes Through Spirometry Distance Learning|Completed||N/A|660|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 23:33:31.04948|2018-05-31 23:33:31.04948
NCT01168622|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2013-03-12|2010-07-22|2010-07-23|Estimate|||||||2013-03-12|2013-03-14|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Impact of Race/Ethnicity on Platelet Function|Impact of Race/Ethnicity on Platelet Function|Completed|||625|Anticipated|University of Nebraska|||||f||||f||||||Samples With DNA|"~     Blood or saliva samples will be collected for DNA extraction and genotyping of CYP2C19 and~     other relevant genes.~   "|||2018-05-31 23:33:31.145736|2018-05-31 23:33:31.145736
NCT01168609|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-07-22|2010-07-22|2010-07-23|Estimate|||||||2010-07-22|2010-07-23|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|July 2010|Actual|2010-07-31|March 2009|Actual|2009-03-31||Observational|||Left Atrial Distensibility and Left Ventricular Filling Pressure in Acute Myocardial Infarction|Usefulness of Left Atrial Distensibility to Assess Left Ventricular Filling Pressure and to Predict Prognosis in Acute Myocardial Infarction|Completed|||521|Actual|Kaohsiung Veterans General Hospital.|||1||f||||t||||||||||2018-05-31 23:33:31.218551|2018-05-31 23:33:31.218551
NCT01168596|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2013-06-14||2013-12-10|2010-07-22|2010-07-23|Estimate|2013-12-10|2014-01-10|Estimate||||2013-12-10|2014-01-10|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|REST||Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease|Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial)|Completed||Phase 4|30|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 23:33:31.360913|2018-05-31 23:33:31.360913
NCT01168583|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-09-19|2010-07-22|2010-07-23|Estimate|||||||2011-09-19|2011-09-21|Estimate|July 2010||2010-07-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Fluid Balance and Clinical Outcomes|Investigation of the Effect of Post-operative Fluid Balance on Inflammatory Mediators in Patients Undergoing Cardiovascular Surgery|Completed|||300|Anticipated|University of Florida|||2||f||||f||||||||||2018-05-31 23:33:31.942951|2018-05-31 23:33:31.942951
NCT01168570|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2010-08-16|2010-07-22|2010-07-23|Estimate|||||||2010-08-16|2010-08-17|Estimate|September 2010||2010-09-30|August 2010|2010-08-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|||Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level|Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level|Unknown status|Not yet recruiting||20|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 23:33:31.99092|2018-05-31 23:33:31.99092
NCT01168557|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-11-26|2010-07-22|2010-07-23|Estimate|||||||2013-11-26|2013-11-27|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Stress Echo and Electric Impedance Tomography (EIT) Pilot Study|Stress Echo and Electric Impedance Tomography (EIT) Pilot Study to Investigate the Influence of Cardiac Output on Parameters of the EIT|Completed||N/A|8|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 23:33:32.044723|2018-05-31 23:33:32.044723
NCT01168544|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-01-03|2010-07-22|2010-07-23|Estimate|||||||2013-01-03|2013-01-04|Estimate|May 2011||2011-05-31|January 2013|2013-01-31||||||||Interventional|VIDIV||Daily Vitamin D Supplementation Compared to a Loading Dose and Monthly Supplementation in Elderly Nursing Home Residents|Vitamin D Supplementation in Elderly Nursing Home Residents: Daily Supplementation Compared to a Loading Dose an Monthly Supplementation, a Randomised Trial|Completed||Phase 3|160|Anticipated|Rijnstate Hospital||3|||f||||f||||||||||2018-05-31 23:33:32.09891|2018-05-31 23:33:32.09891
NCT01168531|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2011-08-18|2010-07-22|2010-07-23|Estimate|||||||2011-08-18|2011-08-19|Estimate|December 2009||2009-12-31|January 2011|2011-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Effect of Pregabalin and Dexamethasone on Acute and Chronic Pain After Lumbar Spinal Surgery|The Effect of Pregabalin and Dexamethasone on Acute and Chronic Pain After Lumbar Spinal Surgery|Completed||N/A|108|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 23:33:32.157174|2018-05-31 23:33:32.157174
NCT01168518|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2014-09-26|2010-07-22|2010-07-23|Estimate|||||||2014-09-26|2014-09-29|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|XFine & Beflex||An Observational Study on the Sorin Group New Brady Leads XFine and Beflex|Performance of the New Generation of Sorin Group Brady Leads In a Normal Hospital Practice|Completed|||2254|Actual|LivaNova|||||f||||f||||||||||2018-05-31 23:33:32.217995|2018-05-31 23:33:32.217995
NCT01168505|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2014-05-20|2010-07-22|2010-07-23|Estimate|||||||2014-05-20|2014-05-21|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients|The Role of Intravenous Iron to Prevent Anemia in Women With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy|Unknown status|Recruiting|Phase 2|100|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||f||||||||||2018-05-31 23:33:32.347244|2018-05-31 23:33:32.347244
NCT01168492|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2014-12-03|2010-07-22|2010-07-23|Estimate|||||||2014-12-03|2014-12-04|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Analgesia During Pediatric Digestive Endoscopy: a Comparison of Two Protocols for Procedural Sedation|Analgesia During Pediatric Digestive Endoscopy: a Comparison of Two Protocols for Procedural Sedation|Completed||Phase 4|90|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 23:33:32.477348|2018-05-31 23:33:32.477348
NCT01168479|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2016-07-04|2010-07-22|2010-07-23|Estimate|||||||2016-07-04|2016-07-06|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|FLAME||FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer|FLAME: Single Blind Randomized Phase III Trial to Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer|Completed||Phase 3|567|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 23:33:32.57113|2018-05-31 23:33:32.57113
NCT01168466|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2018-03-30|2010-07-22|2010-07-23|Estimate|||||||2018-03-30|2018-04-02|Actual|June 2007||2007-06-30|March 2018|2018-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|QMFFTD||EEG Biofeedback to Improve Memory in Adults With Dementia|Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness.|Completed||N/A|37|Actual|Quietmind Foundation||2|||f||||t||||||||||2018-05-31 23:33:32.654434|2018-05-31 23:33:32.654434
NCT01168453|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-08-06|2010-07-22|2010-07-23|Estimate|||||||2010-08-06|2010-08-09|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Observational|||Changes in Anatomical Landmark Locations|Changes in the Relationship Between the Right Internal Jugular Vein and Anatomical Landmark After Head Rotation|Completed|||100|Actual|Soonchunhyang University Hospital|||2||f||||f||||||||||2018-05-31 23:33:32.724065|2018-05-31 23:33:32.724065
NCT01168440|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2012-09-12|2010-07-22|2010-07-23|Estimate|||||||2012-09-12|2012-09-13|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|VHLSUT||Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease|A Single-arm, Phase II Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease|Completed||Phase 2|5|Actual|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|||||f||||f||||||||||2018-05-31 23:33:32.793769|2018-05-31 23:33:32.793769
NCT01168414|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2011-07-07|2010-07-22|2010-07-23|Estimate|||||||2011-07-07|2011-07-08|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|A Randomized, Comparison of the Effects of Ganfort and Duotrav on Intraocular Pressure in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Open Label/Evaluator-blind/Cross-over Study|Completed||Phase 3|42|Actual|Ministry of Health, Malaysia||2|||f||||||||||||||2018-05-31 23:33:33.04928|2018-05-31 23:33:33.04928
NCT01168401|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-05-05|2010-07-22|2010-07-23|Estimate|||||||2015-05-05|2015-05-06|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Bivalent Norovirus Vaccine Study|Phase 1, Randomized Controlled Dose Escalation, Safety and Immunogenicity Study of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine Adjuvanted With Monophosphoryl Lipid A (MPL) and Aluminum Hydroxide (AlOH) in Adults|Completed||Phase 1|102|Actual|Takeda||2|||f||||t||||||||||2018-05-31 23:33:33.107587|2018-05-31 23:33:33.107587
NCT01168388|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2011-07-20|2010-07-22|2010-07-23|Estimate|||||||2011-07-20|2011-07-21|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|MDS||Movement Disorder Survey in East China|Movement Disorder Survey in East China|Completed|||1600|Anticipated|Sir Run Run Shaw Hospital|||1||f||||t||||||||||2018-05-31 23:33:33.168595|2018-05-31 23:33:33.168595
NCT01168375|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-22|2010-07-22|2010-07-23|Estimate|||||||2010-07-22|2010-07-23|Estimate||||March 2010|2010-03-31||||||||Interventional|||The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy|The Role of Umbilical Cord Serum Therapy on Improvement of Corneal Epithelial Defect Following Diabetic Vitrectomy|Unknown status|Active, not recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 23:33:33.222929|2018-05-31 23:33:33.222929
NCT01168362|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-10-24|2010-07-22|2010-07-23|Estimate|||||||2013-10-24|2013-10-25|Estimate|February 2006||2006-02-28|October 2013|2013-10-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|KAS3||Korea Atherosclerosis Study-3|Evaluation of Coronary Artery Disease With Multidetector-Row Cardiac Computed Tomography in Positive Cardiovascular Risk or Not|Completed|||4000|Actual|Seoul National University Bundang Hospital|||2||f||||f||||||Samples Without DNA|"~     Biochemical paramteres including lipid, glucose, insulin, and other novel cardiometabolic~     factors~   "|||2018-05-31 23:33:33.284209|2018-05-31 23:33:33.284209
NCT01168349|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2015-07-23||2015-09-01|2010-07-22|2010-07-23|Estimate|2015-09-01|2015-10-02|Estimate||||2015-09-01|2015-10-02|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational||Efficacy population included participants who had received at least 1 dose of NeoRecormon® injection and without inclusion or exclusion criteria violation.|An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)|Pharmaco-epidemiological Observational Study of the Clinical Benefit of NeoRecormon® in Cancer Patients With Anemia, According to Early Response to Treatment|Completed|||1060|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:33:33.367343|2018-05-31 23:33:33.367343
NCT01168336|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-12-29|2010-07-22|2010-07-23|Estimate|||||||2010-12-29|2010-12-30|Estimate|July 2010||2010-07-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects|Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Escalating Doses of Extended Release and Standard Formulations of Betahistine as Monotherapy and as Adjunctive to Olanzapine in Healthy Subjects|Completed||Phase 1|90|Anticipated|OBEcure Ltd.||3|||f||||f||||||||||2018-05-31 23:33:35.485698|2018-05-31 23:33:35.485698
NCT01168323|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-08-06|2010-07-21|2010-07-23|Estimate|||||||2010-08-06|2010-08-09|Estimate|January 2007||2007-01-31|July 2010|2010-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Spaced Education to Optimize Prostate Cancer Screening|Spaced Education to Optimize Prostate Cancer Screening|Completed||N/A|95|Actual|Harvard University Faculty of Medicine||2|||f||||f||||||||||2018-05-31 23:33:35.566343|2018-05-31 23:33:35.566343
NCT01168310|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21||2013-05-10|2013-05-17|2010-07-21|2010-07-23|Estimate||||2013-05-17|2013-05-27|Estimate|2013-05-17|2013-05-27|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|October 2011|Actual|2011-10-31|August 2010|Actual|2010-08-31||Interventional|||A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Pharmacodynamic Response of Fluticasone Propionate in Fixed-Dose Combination With Formoterol Fumarate in Subjects With COPD|Completed||Phase 2|468|Actual|Dey||7|||f||||f||||||||||2018-05-31 23:33:35.683217|2018-05-31 23:33:35.683217
NCT01168297|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2018-04-04|2010-07-22|2010-07-23|Estimate|||||||2018-04-04|2018-04-05|Actual|July 6, 2010||2010-07-06|August 7, 2017|2017-08-07||||||||Observational|||Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction|Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction|Completed|||657|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:33:35.800576|2018-05-31 23:33:35.800576
NCT01168284|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2018-05-05|2010-07-22|2010-07-23|Estimate|||||||2018-05-05|2018-05-08|Actual|July 5, 2010||2010-07-05|November 21, 2016|2016-11-21|May 6, 2011|Actual|2011-05-06|April 4, 2011|Actual|2011-04-04||Interventional|||A Coping Effectiveness Training Intervention for Caregivers of Children With Autism Spectrum: A Feasibility Study|A Coping Effectiveness Training Intervention for Caregivers of Children With Autism Spectrum Disorders: A Feasibility Study|Completed||N/A|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:33:35.868774|2018-05-31 23:33:35.868774
NCT01168271|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2018-05-17|2010-07-22|2010-07-23|Estimate|||||||2018-05-17|2018-05-18|Actual|June 30, 2010||2010-06-30|November 30, 2017|2017-11-30||||||||Observational|||Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali|Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali|Completed|||3713|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:33:35.955827|2018-05-31 23:33:35.955827
NCT01168258|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2017-10-05|2010-07-22|2010-07-23|Estimate|||||||2017-10-05|2017-10-06|Actual|July 7, 2010||2010-07-07|August 7, 2013|2013-08-07|August 7, 2013||2013-08-07|||||Observational|||Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema|Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema|Terminated|||68|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:33:36.027404|2018-05-31 23:33:36.027404
NCT01168245|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-03-26|2010-07-22|2010-07-23|Estimate|||||||2013-03-26|2013-03-28|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||TMS Stimulation and Cognitive Training in Alzheimer Patients|Effects of a Combined TMS Stimulation and Cognitive Training in Alzheimer Patients: a Single-center, Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 1|15|Actual|Neuronix Ltd||2|||f||||f||||||||||2018-05-31 23:33:36.094863|2018-05-31 23:33:36.094863
NCT01168232|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2016-09-19||2018-03-20|2010-07-22|2010-07-23|Estimate|2016-11-28|2017-01-23|Estimate||||2018-03-20|2018-04-19|Actual|September 7, 2010|Actual|2010-09-07|March 2018|2018-03-31|November 26, 2013|Actual|2013-11-26|November 26, 2013|Actual|2013-11-26||Interventional||Eligible and treated patients|Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus|Completed||Phase 2|42|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:33:36.237089|2018-05-31 23:33:36.237089
NCT01168219|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|2018-03-05||2018-03-05|2010-07-22|2010-07-23|Estimate|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|July 15, 2010||2010-07-15|March 2018|2018-03-31|November 15, 2015|Actual|2015-11-15|November 15, 2015|Actual|2015-11-15||Interventional|||Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia|Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML|Completed||Phase 2|68|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:33:36.864947|2018-05-31 23:33:36.864947
NCT01168206|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2011-09-08|2010-07-22|2010-07-23|Estimate|||||||2011-09-08|2011-09-09|Estimate|December 2010||2010-12-31|September 2011|2011-09-30|August 2012|Anticipated|2012-08-31|December 2011|Anticipated|2011-12-31||Interventional|||Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy|Assessment of Quality of Life and the Toxicity of Chemotherapy in Patients With Malignancies in Clinical Stages III and IV Under Palliative Treatment With Chemotherapy or Hormone Therapy With or Without Nutritional Supplement TK3|Unknown status|Recruiting|Phase 3|80|Anticipated|Lavilabor Natural Products Ltd||2|||f||||f||||||||||2018-05-31 23:33:37.609537|2018-05-31 23:33:37.609537
NCT01168193|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2013-09-24|2010-07-22|2010-07-23|Estimate|||||||2013-09-24|2013-09-25|Estimate|January 2009||2009-01-31|September 2013|2013-09-30||||December 2009|Actual|2009-12-31||Interventional|||Evaluation of Surgical Complications|Evaluation of Surgical Complications Using a Novel Grading System - A Prospective Single Arm Study|Completed||N/A|2200|Actual|Hadassah Medical Organization||1|||f||||||||||||||2018-05-31 23:33:37.676852|2018-05-31 23:33:37.676852
NCT01168180|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-08-13|2010-07-22|2010-07-23|Estimate|||||||2012-08-13|2012-08-14|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Traditional Thai Massage and Scapulocostal Syndrome|Efficacy of Traditional Thai Massage on Patients With Scapulocostal Syndrome|Completed||N/A|60|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 23:33:37.726471|2018-05-31 23:33:37.726471
NCT01168167|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2016-03-22|2010-07-22|2010-07-23|Estimate|||||||2016-03-22|2016-03-23|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|May 2012|Actual|2012-05-31|March 2011|Actual|2011-03-31||Observational|||Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation|Comparing the Dynamics of Different HIV-1 cDNA Species in CD4-positive T-cells and HIV-1 RNA in Plasma of Infected Individuals After Initiation of Antiretroviral Therapy With or Without Raltegravir|Completed|||20|Actual|Goethe University|||2||f||||f||||||||||2018-05-31 23:33:37.881075|2018-05-31 23:33:37.881075
NCT01168154|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-22|||2011-06-27|2010-07-22|2010-07-23|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2009||2009-02-28|October 2008|2008-10-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|ReDiCo||Role Of Lactobacillus Reuteri DSM 17938 In The Non-Complicated Diverticular Disease|Phase 3 Study of Lactobacillus Reuterii in Patients With Symptomatic Non-complicated Diverticular Disease|Unknown status|Recruiting|Phase 3|160|Anticipated|Casa Sollievo della Sofferenza IRCCS||2|||f||||t||||||||||2018-05-31 23:33:37.977778|2018-05-31 23:33:37.977778
NCT01168141|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-07-22|2010-07-22|2010-07-23|Estimate|||||||2010-07-22|2010-07-23|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Window Study of ZD4054 in Metastatic Prostate Cancer|Assessment of the Effects of the Specific Endothelin-A Antagonist ZD4054 on Prostate Cancer Biomarkers in Patients With Castrate-resistant Metastatic Disease|Unknown status|Enrolling by invitation|N/A|30|Anticipated|The Christie NHS Foundation Trust|||||f||||f||||||||||2018-05-31 23:33:38.071208|2018-05-31 23:33:38.071208
NCT01168128|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-22|2010-07-22|2010-07-23|Estimate|||||||2010-07-22|2010-07-23|Estimate|September 2009||2009-09-30|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|PERFECTIS||PERFormance Enhancement of the Canadian Nutrition Guidelines by a Tailored Implementation Strategy: The PERFECTIS Study|PERFormance Enhancement of the Canadian Nutrition Guidelines by a Tailored Implementation Strategy: The PERFECTIS Study|Unknown status|Active, not recruiting|N/A|280|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital||1|||f||||f||||||||||2018-05-31 23:33:38.150141|2018-05-31 23:33:38.150141
NCT01168115|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Near-Infrared Spectroscopy for Blood Glucose Measurements|Near-Infrared Spectroscopy for Blood Glucose Measurements|Completed|||50|Actual|InLight Solutions|||||f||||||||||||||2018-05-31 23:33:38.263386|2018-05-31 23:33:38.263386
NCT01168102|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2007||2007-03-31|February 2008|2008-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Noninvasive Blood Ethanol Measurement With Infrared Spectroscopy|Noninvasive Blood Ethanol Measurement With Infrared Spectroscopy|Completed|||500|Anticipated|InLight Solutions|||||f||||||||||||||2018-05-31 23:33:38.310113|2018-05-31 23:33:38.310113
NCT01168089|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|April 2008||2008-04-30|February 2008|2008-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Near Infrared Spectroscopy for Blood Glucose Measurement in Critical Care Settings|Near Infrared Spectroscopy for Blood Glucose Measurement in Critical Care Settings|Completed|||50|Anticipated|InLight Solutions|||||f||||f||||||||||2018-05-31 23:33:38.363146|2018-05-31 23:33:38.363146
NCT01168076|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|December 2001||2001-12-31|February 2008|2008-02-29|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Observational|||Noninvasive Transcutaneous Glucometer Development|Noninvasive Transcutaneous Glucometer Development|Completed|||500|Anticipated|InLight Solutions|||||f||||||||||||||2018-05-31 23:33:38.408351|2018-05-31 23:33:38.408351
NCT01168063|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2013-11-07|2010-07-21|2010-07-22|Estimate|||||||2013-11-07|2013-11-08|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|HELICOSTIC||Molecular Detection of Antibiotic Resistance and H Pylori Eradication|Medico-economic Evaluation of a Therapeutic Strategy Based on Molecular Detection of Antibiotic Resistance in the Management of H Pylori Infection|Completed||N/A|1386|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:33:38.4728|2018-05-31 23:33:38.4728
NCT01168050|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2011-02-07|2010-07-21|2010-07-22|Estimate|||||||2011-02-07|2011-02-08|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|NILOMEL||Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.|Phase II Multicentric Uncontrolled National Trial Assessing the Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification.|Unknown status|Recruiting|Phase 2|25|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 23:33:38.557054|2018-05-31 23:33:38.557054
NCT01168037|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2017-10-18|2010-07-21|2010-07-22|Estimate|||||||2017-10-18|2017-10-19|Actual|June 17, 2009|Actual|2009-06-17|October 2017|2017-10-31|February 9, 2015|Actual|2015-02-09|February 9, 2015|Actual|2015-02-09||Observational|Windows1||Medical & Economical Evaluation of Fenestrated & Branched Stent-grafts to Treat Complex Aortic Aneurysms|Medical and Economical Evaluation of Endovascular Therapy of Complex Aortic Aneurysms (Para- & Supra- Renal Abdominal Aortic Aneurysms, Type 4 THORACO-Abdominal Aneurysms) by Fenestrated & Branched Stent-grafts|Completed|||270|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||||||2018-05-31 23:33:38.638153|2018-05-31 23:33:38.638153
NCT01168024|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2016-06-27||2016-10-18|2010-07-21|2010-07-22|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional||Enrollment allowed for both non-randomized roll-in and randomized subjects. Up to three roll-in subjects (maximum of 150 in the trial) were allowed per center to address learning curve issues associated with the coronary sinus cannulation technique and device use.|Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)|PRESERV (Prospective Randomized Evaluation to Study the Effects of Reduced Contrast Media on the Vitality of the Kidney) Pivotal Trial|Terminated||N/A|16|Actual|Osprey Medical, Inc||2||Study closed by sponsor prior to completing enrollment goal.|f||||t||||||||No||2018-05-31 23:33:38.74362|2018-05-31 23:33:38.74362
NCT01168011|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2017-06-22|2010-07-21|2010-07-22|Estimate|||||||2017-06-22|2017-06-23|Actual|July 2010||2010-07-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors|A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer|Completed||Phase 1|68|Actual|Onconova Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 23:33:39.000902|2018-05-31 23:33:39.000902
NCT01167998|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2017-02-22|2010-07-21|2010-07-22|Estimate|||||||2017-02-22|2017-02-23|Actual|July 2010||2010-07-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions|Early Diagnosis of Malignant Melanoma Transformation in Pigmentary Skin Lesions|Active, not recruiting|||20|Actual|Hadassah Medical Organization|||||f||||t||||||||||2018-05-31 23:33:39.076422|2018-05-31 23:33:39.076422
NCT01167985|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-07-20|2010-07-21|2010-07-22|Estimate|||||||2013-07-20|2013-07-23|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|IABN||A Clinical Study: the Antibacterial Effect of Insoluble Antibacterial Nanoparticles (IABN) Incorporated in Dental Materials for Root Canal Treatment|Clinical Study: Evaluation of the Antibacterial Effect of Insoluble Antibacterial Nanonparticles Incorporated in Dental Materials for Endodontic Treatment|Unknown status|Recruiting|Phase 2|200|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 23:33:39.123706|2018-05-31 23:33:39.123706
NCT01167972|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2012-09-07|2010-07-21|2010-07-22|Estimate|||||||2012-09-07|2012-09-10|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|MUTACT||Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma|Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)|Completed|||2000|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:33:39.238566|2018-05-31 23:33:39.238566
NCT01167959|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2012-12-20|2010-07-21|2010-07-22|Estimate|||||||2012-12-20|2012-12-24|Estimate|June 2009||2009-06-30|December 2012|2012-12-31|May 2012|Actual|2012-05-31|February 2011|Actual|2011-02-28||Observational|||Hypothalamic Function Before and After Bariatric Surgery|Hypothalamic Morphology, Neuronal Activity and Systems Biology in Response to Food Intake in Obese Patients With Type 2 Diabetes Mellitus Compared to Obese and Lean Controls|Completed|||48|Actual|Leiden University Medical Center|||1||f||||t||||||Samples Without DNA|"~     Blood/Sera Adipose tissue biopsies~   "|||2018-05-31 23:33:39.437146|2018-05-31 23:33:39.437146
NCT01167946|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|January 2003||2003-01-31|January 2003|2003-01-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata|Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata|Completed||Phase 4|42|Actual|King Saud University||3|||f||||t||||||||||2018-05-31 23:33:39.494675|2018-05-31 23:33:39.494675
NCT01167933|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-08-05|2010-07-21|2010-07-22|Estimate|||||||2010-08-05|2010-08-09|Estimate|January 2005||2005-01-31|July 2010|2010-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Bioequivalence Study of Simvastatin Tablets, 80 mg of Dr. Reddy's Under Fed Conditions|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Simvastatin 80 mg Tablets of Dr. Reddy's to be Compared With Zocor® 80 mg Tablets of Merck & Co. Inc., USA in Healthy Adult Subjects Under Fed Conditions|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:33:39.563734|2018-05-31 23:33:39.563734
NCT01167920|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2016-10-26|2010-07-21|2010-07-22|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|VHC||Virtual Hypertension Clinic|Virtual Hypertension Clinic (VHC) Study|Completed||N/A|74|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 23:33:39.689636|2018-05-31 23:33:39.689636
NCT01167907|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2017-09-07||2017-11-09|2010-07-21|2010-07-22|Estimate|2017-11-09|2017-12-08|Actual||||2017-11-09|2017-12-08|Actual|July 2010||2010-07-31|November 2017|2017-11-30|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|||Evaluation of Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block After Ankle Surgery|Evaluation of a Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block for Postoperative Analgesia Following Ankle Surgery|Completed||N/A|32|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 23:33:39.787799|2018-05-31 23:33:39.787799
NCT01167894|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|January 2005||2005-01-31|July 2010|2010-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Bioequivalence Study of Simvastatin Tablets 80 mg of Dr. Reddy's Under Fasting Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Simvastatin 80 mg Tablets of Dr. Reddy's to be Compared With Zocor® 80 mg Tablets of Merck & Co. Inc., USA in Healthy Adult Subjects Under Fasting Conditions|Completed||Phase 1|72|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:33:40.115335|2018-05-31 23:33:40.115335
NCT01167881|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2014-07-17||2016-07-28|2010-07-21|2010-07-22|Estimate|2014-07-17|2014-08-08|Estimate||||2016-07-28|2016-09-02|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2013|Actual|2013-08-31||Interventional||Full Analysis Set (FAS), All patients randomised, treated with at least one dose of study drug, and with a baseline HbA1c value.|Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 10773 Compared to Glimepiride Administered Orally During 104 Weeks With a 104 Week Extension Period in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control Despite Metformin Treatment|Completed||Phase 3|1549|Actual|Boehringer Ingelheim|It should be noted that not all patients were followed up for 4 years with regard to the frequencies of adverse events presented up to 4 years.|2|||f||||||||||||||2018-05-31 23:33:40.313465|2018-05-31 23:33:40.313465
NCT01167868|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2013-02-06|2010-07-21|2010-07-22|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Fostamatinib Disodium in Healthy Japanese and White Subjects After Single and Multiple Ascending Doses|Completed||Phase 1|56|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 23:33:41.960894|2018-05-31 23:33:41.960894
NCT01167855|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2017-05-15|2010-07-21|2010-07-22|Estimate|||||||2017-05-15|2017-05-16|Actual|May 25, 2011|Actual|2011-05-25|May 2017|2017-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Reducing Asthma Disparities Through School-Based Telemedicine for Rural Children|Reducing Asthma Disparities Through School-Based Telemedicine for Rural Children|Completed||N/A|823|Actual|Arkansas Children's Hospital Research Institute||1|||f||||t||||||||No|There is no plan to share individual participant data.|2018-05-31 23:33:42.062484|2018-05-31 23:33:42.062484
NCT01167842|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2016-10-31|2010-07-20|2010-07-22|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer)|Analysis of Inherited Cancers|Recruiting|||150|Anticipated|University of Washington|||||f||||f||||||Samples With DNA|"~     We will collect blood as a source for DNA from lymphocytes as well as tumor blocks as a~     source for tumor DNA~   "|||2018-05-31 23:33:42.140503|2018-05-31 23:33:42.140503
NCT01167829|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2012-09-25||2013-08-23|2010-07-21|2010-07-22|Estimate|2013-08-21|2013-08-23|Estimate||||2013-08-23|2013-09-06|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|October 2010|Actual|2010-10-31||Interventional|Oral T8||ORAL T-8 Oral Testosterone for Male Hormonal Contraception|Pharmacokinetics of Modified Slow-Release Oral Testosterone Over 10 Days in Normal Men With Experimental Hypogonadism|Completed||Phase 1|14|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:33:42.214271|2018-05-31 23:33:42.214271
NCT01167816|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2014-05-19|2010-07-21|2010-07-22|Estimate|||||||2014-05-19|2014-05-20|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer|Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer|Terminated||Phase 1|9|Actual|University of Oklahoma||1||"The study was terminated as the Prinicipal Investigator left the site- all previous subjects~   enrolled are deceased"|f||||t||||||||||2018-05-31 23:33:42.580171|2018-05-31 23:33:42.580171
NCT01167803|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-03-26|2010-07-21|2010-07-22|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|XENON||Anesthesia for Obese Patients: Desflurane Versus Xenon|Coming Out of Anesthesia After Bariatric Surgery : Desflurane Versus Xenon|Completed||Phase 4|192|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 23:33:42.679257|2018-05-31 23:33:42.679257
NCT01167790|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2012-06-13|2010-07-21|2010-07-22|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|FLUOK||Autofluorescence for the Screening of Precancerous and Malignant Lesions|Interest of Oral Tissue Autofluorescence for the Screening of Precancerous Lesions and Cancer in Population With Tobacco and Alcohol Abuse.|Completed||N/A|180|Actual|University Hospital, Bordeaux|||||f||||f||||||||||2018-05-31 23:33:42.777683|2018-05-31 23:33:42.777683
NCT01167777|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-11-24|2010-07-21|2010-07-22|Estimate|||||||2015-11-24|2015-11-26|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae|Multi-center Evaluation of the VERSANT® CT/GC DNA 1.0 Assay (kPCR)in Detecting C. Trachomatis and N. Gonorrhoeae|Terminated|||2296|Actual|Siemens Healthcare Diagnostics Inc|||1|Siemens Management decided not to release the product in the USA.|f||||f||||||||||2018-05-31 23:33:42.868107|2018-05-31 23:33:42.868107
NCT01167764|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2014-01-06|2010-07-21|2010-07-22|Estimate|||||||2014-01-06|2014-01-07|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis|Effect of Tranexamic Acid on Prevention of Recurrence of Hemoptysis: Multicenter, Prospective, Randomized, Double-blind Phase 3 Trial|Withdrawn||Phase 3|0|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:33:42.955117|2018-05-31 23:33:42.955117
NCT01167751|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2016-06-19|2010-07-21|2010-07-22|Estimate|||||||2016-06-19|2016-06-21|Estimate|January 2008||2008-01-31|July 2010|2010-07-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction|Autologous Bone Marrow Derived Ac 133+ and Mono Nuclear Cells In-patient With Acute Myocardial Infarction During Coronary Artery Bypass Grafting (CABG): A Randomized Phase III Clinical Trial|Completed||Phase 3|90|Actual|Royan Institute||3|||f||||t||||||||||2018-05-31 23:33:43.066357|2018-05-31 23:33:43.066357
NCT01166503|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2018-05-07|2010-07-19|2010-07-21|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2004||2004-05-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||Early Versus Delayed Surgery for Infantile Esotropia|Early Versus Delayed Surgery for Infantile Esotropia: A Clinical Evaluation of Sensory and Motor Outcomes|Completed|||71|Actual|The Hospital for Sick Children|||2||f||||f||||||||No||2018-05-31 23:33:59.167374|2018-05-31 23:33:59.167374
NCT01167738|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-04-23|2010-07-21|2010-07-22|Estimate|||||||2015-04-23|2015-04-24|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|PACT-17||Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer|A Randomized Phase II Study of Chemotherapy ± Metformin in Metastatic Pancreatic Cancer|Terminated||Phase 2|60|Actual|IRCCS San Raffaele||2||concern of detrimental effect|f||||f||||||||||2018-05-31 23:33:43.159316|2018-05-31 23:33:43.159316
NCT01167725|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2012-01-21|2010-07-21|2010-07-22|Estimate|||||||2012-01-21|2012-01-24|Estimate|August 2010||2010-08-31|January 2012|2012-01-31||||May 2014|Anticipated|2014-05-31||Interventional|||Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer|Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma|Unknown status|Active, not recruiting|Phase 3|340|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:33:43.271722|2018-05-31 23:33:43.271722
NCT01167712|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|2017-10-02||2017-12-28|2010-07-21|2010-07-22|Estimate|2017-12-28|2018-01-23|Actual||||2017-12-28|2018-01-23|Actual|September 2010||2010-09-30|December 2017|2017-12-31|June 6, 2027|Anticipated|2027-06-06|December 2015|Actual|2015-12-31||Interventional||Newly diagnosed women with high-risk early stage or advanced stage epithelial ovarian cancer.|Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Randomized Phase III Trial of Dose Dense Weekly Paclitaxel Combined With Carboplatin Versus Dose Dense Weekly Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921), Combined With Carboplatin Versus Every-3-Weeks Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921) Combined With Carboplatin in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer|Active, not recruiting||Phase 3|692|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:33:43.657015|2018-05-31 23:33:43.657015
NCT01167699|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2013-02-11|2010-07-21|2010-07-22|Estimate|||||||2013-02-11|2013-02-12|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain|An Open Study With OXN to Evaluate the Patient Preference for Pain Treatment With Respect to Quality of Life After WHO Stap I or Step II Analgesics for Patients With Moderate to Severe Non-malignant Pain|Completed||Phase 3|174|Actual|Mundipharma Pharmaceuticals B.V.|||||f||||||||||||||2018-05-31 23:33:46.622575|2018-05-31 23:33:46.622575
NCT01167686|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2012-03-16|2010-07-21|2010-07-22|Estimate|||||||2012-03-16|2012-03-19|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|November 2010|Actual|2010-11-30||Interventional|||Effects of Gardemont S.A Food Supplement on Upper Respiratory Illness|Phase 2 Study of Gardemont S.A Food Supplement on Symptoms of Upper Respiratory Illness|Unknown status|Recruiting|Phase 2|182|Anticipated|Meir Medical Center||1|||f||||t||||||||||2018-05-31 23:33:46.684466|2018-05-31 23:33:46.684466
NCT01167673|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2016-06-13|2010-07-21|2010-07-22|Estimate|||||||2016-06-13|2016-06-14|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel Syndrome|A Double Blind Placebo Controlled Cross Over Study for the Use of Coltect (Green Tea, Selenium and Curcumin) in Irritable Bowel Syndrome|Recruiting||Phase 2|40|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 23:33:46.78108|2018-05-31 23:33:46.78108
NCT01167660|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2013-02-11|2010-07-21|2010-07-22|Estimate|||||||2013-02-11|2013-02-12|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|||Non Invasive Measurement of Coagulation in Term and Preterm Neonates|Non Invasive Measurement of Coagulation in Term and Preterm Neonates|Unknown status|Recruiting||120|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 23:33:46.919354|2018-05-31 23:33:46.919354
NCT01167647|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2013-03-05|2010-07-21|2010-07-22|Estimate|||||||2013-03-05|2013-03-06|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||The Role of Routine Bacterial Culture Including Tuberculosis During Bronchoscopy: A Prospective Study|The Role of Routine Bacterial Culture Including Tuberculosis During|Completed|||300|Actual|Meir Medical Center|||1||f||||t||||||||||2018-05-31 23:33:46.985612|2018-05-31 23:33:46.985612
NCT01167634|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2017-05-01||2017-08-22|2010-07-20|2010-07-22|Estimate|2017-08-22|2017-08-23|Actual||||2017-08-22|2017-08-23|Actual|May 24, 2011|Actual|2011-05-24|August 2017|2017-08-31|July 2016|Actual|2016-07-31|March 15, 2012|Actual|2012-03-15||Interventional|||University Of Pennsylvania Weight Loss Study|University Of Pennsylvania Weight Loss Study|Completed||N/A|132|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 23:33:47.05298|2018-05-31 23:33:47.05298
NCT01167621|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2015-07-28|2010-07-21|2010-07-22|Estimate|||||||2015-07-28|2015-07-29|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation|Assessment of Extravascular Lung Water and Hemodynamics Changes in Patients Treated by High Frequency Oscillation-ventilation for Refractory ARDS|Completed|||23|Actual|Centre Hospitalier Universitaire de la Réunion|||||f||||f||||||||||2018-05-31 23:33:47.293535|2018-05-31 23:33:47.293535
NCT01167608|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2014-03-10||2014-06-03|2010-07-21|2010-07-22|Estimate|2014-06-03|2014-07-04|Estimate||||2014-06-03|2014-07-04|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Barriers to Mental Healthcare Utilization in Parkinson's Disease|Barriers to Mental Healthcare Utilization in Parkinson's Disease|Completed|||883|Actual|Rutgers, The State University of New Jersey|Self-report biases (social desirability or recall); idiopathic PD could not be confirmed given the anonymous nature of study participation; results may not generalize to all people with PD; participants were self-selected (non-random sample)||1||f||||f||||||||||2018-05-31 23:33:47.362834|2018-05-31 23:33:47.362834
NCT01167595|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2013-04-23|2010-07-21|2010-07-22|Estimate|||||||2013-04-23|2013-04-24|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|PEP uP||Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients|A Multicenter, Cluster Randomized Trial of Enhanced Protein-Energy Provision Via the Enteral Route Feeding Protocol in Critically Ill Patients: The PEP uP Protocol|Completed||N/A|1059|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||f||||||||||2018-05-31 23:33:47.54853|2018-05-31 23:33:47.54853
NCT01167582|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2014-08-14||2016-11-28|2010-07-21|2010-07-22|Estimate|2014-08-14|2014-08-28|Estimate||||2016-11-28|2017-01-13|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MINT Pilot|Randomized patients|Myocardial Ischemia and Transfusion Pilot|Myocardial Ischemia and Transfusion Pilot|Completed||Phase 3|110|Actual|Rutgers, The State University of New Jersey|This pilot trial was not designed to enroll enough patients to answer the transfusion dilemma currently facing clinicians in practice.|2|||f||||t||||||||||2018-05-31 23:33:47.659606|2018-05-31 23:33:47.659606
NCT01167569|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2014-05-20|2010-07-21|2010-07-22|Estimate|||||||2014-05-20|2014-05-22|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Vit C||Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients|Double-Blind, Randomized Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients|Completed||Phase 4|63|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 23:33:47.958531|2018-05-31 23:33:47.958531
NCT01167556|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2006||2006-03-31|February 2008|2008-02-29|February 2011|Anticipated|2011-02-28|August 2010|Anticipated|2010-08-31||Interventional|FMI||Family Motivational Intervention in Schizophrenia|Motivational Interviewing and Interaction Skills Training for Carers to Change Cannabis Use in Young Adults With Recent-onset Schizophrenia: Randomised Controlled Trial|Unknown status|Enrolling by invitation|N/A|147|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||||||||||||2018-05-31 23:33:48.048714|2018-05-31 23:33:48.048714
NCT01167543|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|September 2005||2005-09-30|May 2010|2010-05-31|November 2008|Actual|2008-11-30|||||Observational|||Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease||Completed|||79|Actual|University of California, San Francisco|||2||f||||f||||||||||2018-05-31 23:33:48.113649|2018-05-31 23:33:48.113649
NCT01167530|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2012-04-03|2010-07-21|2010-07-22|Estimate|||||||2012-04-03|2012-04-04|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|RAD001||Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer||Unknown status|Recruiting|Phase 1|36|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||f||||||||||2018-05-31 23:33:48.227292|2018-05-31 23:33:48.227292
NCT01167517|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2017-11-02|2010-07-21|2010-07-22|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2010||2010-07-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Lactation Education Study in Mothers of Very Low Birth Weight Infants|Lactation Education Study in Mothers of Very Low Birth Weight Infants|Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 23:33:48.297072|2018-05-31 23:33:48.297072
NCT01167504|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2013-08-21||2013-11-14|2010-07-21|2010-07-22|Estimate|2013-11-14|2014-01-06|Estimate||||2013-11-14|2014-01-06|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Observational|SalFilm|Volunteers were required to donate saliva for ex-vivo study, as described in protocol. A pool of 12 volunteers was maintained. 3 further volunteers had to be recruited following 3 losses due to personal reasons, i.e. not connected with study.|Factors Controlling the Formation of Salivary Films|Investigating the Formation of Salivary Films and How They Change in the Presence of Ingredients From Food and Oral Hygiene Products|Completed|||15|Actual|Quadram Institute|No adverse events were reported. The number of volunteers required gave acceptable statistics as anticipated. The study was completed on time||1||f||||f||||||||||2018-05-31 23:33:48.400643|2018-05-31 23:33:48.400643
NCT01167491|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-04-20|2010-07-21|2010-07-22|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|November 2013|Actual|2013-11-30||Interventional|DAP12WEGENER||Study of One Protein Implicated in Wegener Disease|Activating Receptors and DAP12 Protein in Wegener's Granulomatosis|Completed||N/A|138|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:33:48.621643|2018-05-31 23:33:48.621643
NCT01167478|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2014-12-04|2010-07-21|2010-07-22|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Neurophysiological Reserve With Caffeine Manipulation|Neurophysiological Reserve: Peripheral and Central Effects of Caffeine Manipulation|Completed||N/A|20|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:33:48.688605|2018-05-31 23:33:48.688605
NCT01167465|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2014-12-16|2010-07-21|2010-07-22|Estimate|||||||2014-12-16|2014-12-17|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper Rash Prophylaxis|A Clinical Observation to Assess the Safety and Consumers' Satisfaction of Moussik vs Desitin Creamy Ointment in Prophylaxis of Diaper Rash. A Single Blind, Multicenter, Randomized, Cross-over Study|Withdrawn||Phase 4|0|Actual|Trima, Israel Pharmaceutical Products|||||f||||t||||||||||2018-05-31 23:33:48.759967|2018-05-31 23:33:48.759967
NCT01167452|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2016-08-16|2014-02-04|2017-05-17|2010-07-21|2010-07-22|Estimate|2016-10-25|2016-11-02|Estimate|2014-05-06|2014-05-22|Estimate|2017-05-17|2017-06-14|Actual|July 2010||2010-07-31|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations|Population Pharmacokinetic Analysis of Sulfamethoxazole and Trimethoprim in Normal Weight, Overweight, and Obese Volunteers|Completed||Phase 4|36|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||No||2018-05-31 23:33:48.817206|2018-05-31 23:33:48.817206
NCT01167439|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|July 2009||2009-07-31|December 2009|2009-12-31||||July 2011|Anticipated|2011-07-31||Interventional|OPMD||Dysphagia in Oculopharyngeal Muscular Dystrophy (OPMD)- Evaluation, Endoscopic Examination of Swallowing, Treatment and Long Term Follow up|Dysphagia in Oculopharyngeal Muscular Dystrophy. Evaluation, Endoscopic Examination of Swallowing, Treatment and Long Term Follow up.|Unknown status|Recruiting|Phase 1|40|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||||2018-05-31 23:33:48.987214|2018-05-31 23:33:48.987214
NCT01167426|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2012-08-17||2013-08-08|2010-07-21|2010-07-22|Estimate|2013-08-08|2013-10-17|Estimate||||2013-08-08|2013-10-17|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|ENCORE||Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients|An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method.|Completed||Phase 3|148|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 23:33:49.077754|2018-05-31 23:33:49.077754
NCT01167413|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2010-08-05|2010-07-21|2010-07-22|Estimate|||||||2010-08-05|2010-08-06|Estimate|August 2010||2010-08-31|January 2010|2010-01-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Observational|||Frequency of Axial Spondyloarthropathy Among Patients Suffering From Fibromyalgia|Frequency of Axial Spondyloarthropathy Among Patients Suffering From Fibromyalgia - Application of the ASAS Classification Criteria|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 23:33:49.284206|2018-05-31 23:33:49.284206
NCT01167400|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2014-09-04|2010-07-21|2010-07-22|Estimate|||||||2014-09-04|2014-09-05|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Cybercycling for Cognitive Health|Cybercycling for Older Adults: Neuropsychological, Physiological and Behavioral Effects|Completed||N/A|63|Actual|Union College, New York||2|||f||||f||||||||||2018-05-31 23:33:49.361555|2018-05-31 23:33:49.361555
NCT01167387|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2016-08-05|2010-07-21|2010-07-22|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|PROCY||Preoperative Carbohydrate Loading in Elective Surgery|PREOPERATIVE ORAL CARBOHYDRATE LOADING: EFFECTS ON THE GLUCOSE METABOLISM AND POSTOPERATIVE INFECTIONS|Completed||Phase 3|880|Actual|University of Milano Bicocca||2|||f||||t||||||||Yes||2018-05-31 23:33:49.45081|2018-05-31 23:33:49.45081
NCT01167374|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2018-05-11|2010-07-21|2010-07-22|Estimate|||||||2018-05-11|2018-05-17|Actual|August 2011|Actual|2011-08-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|PROMETHEUS-01||Carbon Ion Radiotherapy for Hepatocellular Carcinoma|Phase I Study Evaluating the Treatment of Patients With Hepatocellular Carcinoma (HCC) With Carbon Ion Radiotherapy|Recruiting||N/A|22|Anticipated|University Hospital Heidelberg||1|||f||||t||||||||||2018-05-31 23:33:49.531623|2018-05-31 23:33:49.531623
NCT01167361|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2012-10-30|2010-07-21|2010-07-22|Estimate|||||||2012-10-30|2012-10-31|Estimate|September 2010||2010-09-30|July 2011|2011-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Epidemiology Of Respiratory Virus Infections In Children|Epidemiology Of Respiratory Virus Infections In Children|Completed|||350|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples Without DNA|"~     Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal~     aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic studies~     on this specimen will be performed as ordered and the results will be available to the~     treating physicians after reporting. An aliquot from the leftover sample remaining after~     clinical diagnostic testing will be used for FilmArrayTM analysis~   "|||2018-05-31 23:33:49.605384|2018-05-31 23:33:49.605384
NCT01167348|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-22|2010-07-21|2010-07-22|Estimate|||||||2010-07-22|2010-07-23|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||The Effectiveness Of Auricular Acupressure On Body Weight Parameters On Patients With Schizophrenia|The Effectiveness Of Auricular Acupressure On Body Weight Parameters On Patients With Schizophrenia|Unknown status|Recruiting|N/A|86|Anticipated|TsaoTun Psychiatric Center, Department of Health, Taiwan|||||f||||t||||||||||2018-05-31 23:33:49.673832|2018-05-31 23:33:49.673832
NCT01167335|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-04-30|2010-07-20|2010-07-22|Estimate|||||||2012-04-30|2012-05-01|Estimate|August 2010||2010-08-31|April 2012|2012-04-30||||November 2010|Actual|2010-11-30||Interventional|||Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures|A 12-week, Randomized, Double-blind, Placebo-controlled Exploratory Study to Assess the Antiepileptic Activity of BGG492 Given Orally as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures|Withdrawn||Phase 2|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:33:49.749936|2018-05-31 23:33:49.749936
NCT01167322|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2012-04-26|2010-07-20|2010-07-22|Estimate|||||||2012-04-26|2012-04-27|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas|Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV)|Completed||Phase 3|45|Actual|Nobelpharma||1|||f||||t||||||||||2018-05-31 23:33:49.842743|2018-05-31 23:33:49.842743
NCT01167309|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2012-01-20|2010-07-20|2010-07-22|Estimate|||||||2012-01-20|2012-01-23|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients|LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease|Completed||Phase 1|72|Actual|LEO Pharma|||||f||||f||||||||||2018-05-31 23:33:49.927043|2018-05-31 23:33:49.927043
NCT01167296|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2013-06-07|2010-07-21|2010-07-22|Estimate|||||||2013-06-07|2013-06-10|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Safety of Leaving Cook Balloon Uterine Stent in Uterus for One Month||Completed||Phase 4|60|Actual|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-05-31 23:33:50.013243|2018-05-31 23:33:50.013243
NCT01167283|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-08-05|2010-07-20|2010-07-22|Estimate|||||||2010-08-05|2010-08-06|Estimate|July 2006||2006-07-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|ExaEMS2005||Effect of Electrostimulation in Chronic Obstructive Pulmonary Disease (COPD)|Effect of Electromyostimulation in Severe Chronic Obstructive Pulmonary Disease|Completed||N/A|15|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 23:33:50.079389|2018-05-31 23:33:50.079389
NCT01167270|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2017-07-28|2010-07-21|2010-07-22|Estimate|||||||2017-07-28|2017-08-01|Actual|January 2012||2012-01-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|April 2017|Actual|2017-04-30||Interventional|INSIGHT||The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study|The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study|Active, not recruiting||N/A|316|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 23:33:50.137566|2018-05-31 23:33:50.137566
NCT01167257|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2014-09-10||2014-09-19|2010-07-20|2010-07-22|Estimate|2014-09-19|2014-09-22|Estimate||||2014-09-19|2014-09-22|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome|Comparative Study of the Efficacy and Safety of Liposome Encapsulated Botulinum Toxin-A (Lipotoxin) Versus Normal Saline Instillation in Treatment of Patients With Refractory Overactive Bladder Syndrome|Completed||Phase 2|62|Actual|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 23:33:50.278329|2018-05-31 23:33:50.278329
NCT01167244|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16||2015-09-23|2015-09-23|2010-07-20|2010-07-22|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response|Phase 2 Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response|Completed||Phase 2|11|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 23:33:50.759569|2018-05-31 23:33:50.759569
NCT01167231|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-08-24|2010-07-20|2010-07-22|Estimate|||||||2010-08-24|2010-08-25|Estimate|May 2007||2007-05-31|August 2010|2010-08-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Observational|ABDOMEN||Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease|Acarbose in Cardiovascular Risk Management. Assessment of Clinical Efficacy and Safety of Acarbose and Its Effect on Selected Cardiovascular Risk Factors in Type 2 Diabetes Patients.|Completed|||3310|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:33:50.834717|2018-05-31 23:33:50.834717
NCT01167218|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-08-08|2010-07-21|2010-07-22|Estimate|||||||2012-08-08|2012-08-10|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Study to Assess Platelet Dysfunction With Verify Now Assay|"In-vitro Characterization of Platelet Dysfunction in Common Hematological Disorders Using the Verify Now Assay"|Completed|||79|Actual|Winthrop University Hospital|||1||f||||f||||||||||2018-05-31 23:33:50.908327|2018-05-31 23:33:50.908327
NCT01167205|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-20|2010-07-20|2010-07-22|Estimate|||||||2010-07-20|2010-07-22|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|March 2011||2011-03-31|December 2010||2010-12-31||Interventional|||Positive Effects of Haematococcus Astaxanthin on Oxidative Stress and Lipid Profile in Overweight and Obese Adults||Unknown status|Not yet recruiting|N/A|30||Seoul National University Hospital|||||f||||t||||||||||2018-05-31 23:33:50.97114|2018-05-31 23:33:50.97114
NCT01167192|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2016-09-08||2016-11-09|2010-07-19|2010-07-22|Estimate|2016-09-08|2016-10-28|Estimate||||2016-11-09|2016-12-30|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2012|Actual|2012-08-31||Interventional|||Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer|Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters|Terminated||Phase 2|10|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 23:33:51.071634|2018-05-31 23:33:51.071634
NCT01167179|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2012-12-06||2017-05-16|2010-07-20|2010-07-22|Estimate|2017-05-16|2017-12-15|Actual||||2017-05-16|2017-12-15|Actual|December 2008||2008-12-31|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Nurse-led Follow-up Care for Head and Neck Cancer Patients|Nurse-led Follow-up Care for Head and Neck Cancer Patients: a Quasi-experimental Study|Completed||N/A|160|Actual|Radboud University|"A historical control group being the comparison group was the 'usual care' group that included participants who were enrolled during the study and received usual care, as described.~Lack of randomization may have been a confounding factor."|2|||f||||f||||||||No||2018-05-31 23:33:51.451446|2018-05-31 23:33:51.451446
NCT01167166|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19||2015-01-20|2017-06-22|2010-07-21|2010-07-22|Estimate||||2015-01-20|2015-01-29|Estimate|2017-06-22|2017-06-26|Actual|July 2010||2010-07-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)|A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms|Completed||Phase 1/Phase 2|30|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 23:33:51.749906|2018-05-31 23:33:51.749906
NCT01167153|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2012-04-19||2012-05-31|2010-07-21|2010-07-22|Estimate|2012-05-31|2012-06-01|Estimate||||2012-05-31|2012-06-01|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|EXAM||Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients|A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment|Completed||Phase 4|564|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:33:51.859167|2018-05-31 23:33:51.859167
NCT01167140|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2012-05-23||2012-08-29|2010-07-21|2010-07-22|Estimate|2012-08-29|2012-10-01|Estimate||||2012-08-29|2012-10-01|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Cryo-Touch II for the Treatment of Wrinkles||Completed||Phase 2/Phase 3|42|Actual|MyoScience, Inc||1|||f||||||||||||||2018-05-31 23:33:52.136979|2018-05-31 23:33:52.136979
NCT01167127|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2013-02-11|2010-07-21|2010-07-22|Estimate|||||||2013-02-11|2013-02-12|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain|An Open Study to Observe OXN Treatment for Patients With Moderate to Severe Non-malignant Pain|Completed||Phase 3|113|Actual|Mundipharma Pharmaceuticals B.V.||1|||f||||||||||||||2018-05-31 23:33:52.278318|2018-05-31 23:33:52.278318
NCT01167114|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13||2017-01-06|2018-03-20|2010-07-21|2010-07-22|Estimate||||2017-01-06|2017-01-09|Estimate|2018-03-20|2018-03-22|Actual|August 2010||2010-08-31|March 2018|2018-03-31|April 2017|Actual|2017-04-30|May 2016|Actual|2016-05-31||Interventional|||STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer|A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers|Completed||Phase 2|20|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:33:52.333413|2018-05-31 23:33:52.333413
NCT01167101|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2015-09-03|2010-07-21|2010-07-22|Estimate|||||||2015-09-03|2015-09-04|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?|Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection? : Multicenter, Randomized, and Prospective Study|Completed||N/A|290|Actual|Kangdong Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 23:33:52.394843|2018-05-31 23:33:52.394843
NCT01167088|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2011-05-28|2010-07-20|2010-07-22|Estimate|||||||2011-05-28|2011-06-01|Estimate|November 2010||2010-11-30|May 2011|2011-05-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|MARVEL||A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)|A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants With Raised Liver Enzymes Due to Non-Alcoholic Fatty Liver Disease (NAFLD)|Terminated||Phase 2|110|Anticipated|Antipodean Pharmaceuticals, Inc.||2||This study has been terminated due to poor participant recruitment|f||||f||||||||||2018-05-31 23:33:52.449231|2018-05-31 23:33:52.449231
NCT01167075|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|February 2006||2006-02-28|December 2005|2005-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|Intestamin||A Study in Critically Ill Patients Investigating Tolerability and Efficacy of Low-volume Pharmaconutrition (Intestamin)|A Randomized, Prospective, Controlled, Double-blind, Single-center Pilot Study in Critically Ill Patients Investigating Tolerability and Efficacy of Low-volume Pharmaconutrition (Intestamin)|Completed||N/A|58|Actual|Hannover Medical School||2|||f||||f||||||||||2018-05-31 23:33:52.516712|2018-05-31 23:33:52.516712
NCT01167062|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|June 2010||2010-06-30|June 2010|2010-06-30||||April 2011|Anticipated|2011-04-30||Interventional|||Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones|Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study|Unknown status|Recruiting|Phase 4|120|Anticipated|ChaingMai University||2|||f||||t||||||||||2018-05-31 23:33:52.608354|2018-05-31 23:33:52.608354
NCT01167049|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-21|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis|Neoadjuvant Chemotherapy With Xeloda in Combination With Paclitaxel in Gastric Cancer With Liver Metastasis|Unknown status|Recruiting|Phase 2|60|Anticipated|Beijing Cancer Hospital||1|||f||||t||||||||||2018-05-31 23:33:52.696465|2018-05-31 23:33:52.696465
NCT01167036|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2010-07-21|2010-07-21|2010-07-22|Estimate|||||||2010-07-21|2010-07-22|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effectiveness of a Massage Instrument Compared to Placebo for Upper Trapezius Muscle Pain|Immediate Effectiveness of Instrument Assisted Soft Tissue Mobilization Compared to Placebo on the Sensitivity of Latent Upper Trapezius Trigger Points: A Randomized Double Blind, Placebo-controlled, Parallel-group Study|Completed||N/A|50|Actual|Anglo-European College of Chiropractic||2|||f||||f||||||||||2018-05-31 23:33:52.883931|2018-05-31 23:33:52.883931
NCT01167023|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2012-04-09||2012-04-09|2010-07-20|2010-07-21|Estimate|2012-04-09|2012-05-03|Estimate||||2012-04-09|2012-05-03|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Prasugrel Versus Placebo in Adult Sickle Cell Disease|A Double-Blind, Randomized, Multicenter Study of Prasugrel Compared to Placebo in Adult Patients With Sickle Cell Disease|Completed||Phase 2|62|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 23:33:53.050817|2018-05-31 23:33:53.050817
NCT01167010|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2012-05-04|2010-07-20|2010-07-21|Estimate|||||||2012-05-04|2012-05-08|Estimate|April 2011||2011-04-30|May 2011|2011-05-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|UNIK||A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma|A Phase III, Randomized, Non-inferiority, Open-label, Comparative Study Between Foraseq® Inhalation Capsules, Eurofarma's Single Formoterol / Budesonide Inhalation Capsule and Single Alenia® Inhalation Capsule in Asthmatic Patients|Completed||Phase 3|552|Anticipated|Eurofarma Laboratorios S.A.||3|||f||||t||||||||||2018-05-31 23:33:53.953323|2018-05-31 23:33:53.953323
NCT01166997|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2016-08-23||2016-08-24|2010-07-20|2010-07-21|Estimate|2016-08-24|2016-10-18|Estimate||||2016-08-24|2016-10-18|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|ULTIMA||ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism|Randomized, Controlled Study Comparing EKOS EkoSonic Ultrasound Accelerated Thrombolysis to Anticoagulation in the Treatment of Sub-massive Pulmonary Embolism|Completed||Phase 3|59|Actual|EKOS Corporation||2|||f||||t||||||||||2018-05-31 23:33:54.063169|2018-05-31 23:33:54.063169
NCT01166984|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2011-06-06|2010-07-20|2010-07-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||AB103 Peptide Antagonist in Healthy Volunteers|Phase 1, Double Blind, Placebo-Controlled, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Clinical Trial of AB103, A Peptide Antagonist in Healthy Volunteers|Completed||Phase 1|25|Actual|Atox Bio Ltd||2|||f||||t||||||||||2018-05-31 23:33:54.446676|2018-05-31 23:33:54.446676
NCT01166971|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2011-10-04||2011-11-21|2010-07-20|2010-07-21|Estimate|2011-10-04|2011-11-08|Estimate||||2011-11-21|2011-11-24|Estimate|July 2010||2010-07-31|November 2011|2011-11-30||||March 2011|Actual|2011-03-31||Interventional|||A Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting Intraocular Lenses (IOLs)|A Randomized, Subject-masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting IOLs|Completed||Phase 4|65|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:33:54.574329|2018-05-31 23:33:54.574329
NCT01166958|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2014-06-18||2014-09-18|2010-07-20|2010-07-21|Estimate|2014-09-18|2014-09-22|Estimate||||2014-09-18|2014-09-22|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?|Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?|Completed||Phase 4|26|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 23:33:54.795525|2018-05-31 23:33:54.795525
NCT01166945|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2016-09-09|2010-07-20|2010-07-21|Estimate|||||||2016-09-09|2016-09-12|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|April 2016|Actual|2016-04-30||Interventional|||Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children|Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children|Active, not recruiting||N/A|98|Actual|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 23:33:55.109231|2018-05-31 23:33:55.109231
NCT01166932|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-10-29|2010-07-20|2010-07-21|Estimate|||||||2010-10-29|2010-11-01|Estimate|April 2005||2005-04-30|October 2010|2010-10-31|April 2009|Actual|2009-04-30|April 2007|Actual|2007-04-30||Interventional|||Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia|COMPARISON OF CLINICAL EFFICACY OF COMBINATION Amoxycillin Plus Clavulanic Acid and Oxacillin Plus Ceftriaxone for HOSPITAL TREATMENT OF COMMUNITY Acquired PNEUMONIA IN CHILDREN : A Randomized Clinical Study|Completed||Phase 4|104|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||f||||||||||2018-05-31 23:33:55.192476|2018-05-31 23:33:55.192476
NCT01166919|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2017-02-08|2010-07-20|2010-07-21|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2009||2009-12-31|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pilot Study on the Use of the Matrix Radiofrequencyfor Treatment of Port Wine Stain Birthmarks|Pilot Study on the Use of the Matrix Radiofrequency for Treatment of Port Wine Stain Birthmarks|Withdrawn||Phase 1|0|Actual|University of California, Irvine||1||Laser company cannot provide laser unit for the study.|f||||t||||||||||2018-05-31 23:33:55.287004|2018-05-31 23:33:55.287004
NCT01166906|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2017-02-08|2010-07-20|2010-07-21|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2010||2010-03-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Pain Blocking During Drug Administration or Blood Collection With Needles|Pain Blocking During Drug Administration or Blood Collection With Needles|Completed|||53|Actual|University of California, Irvine|||||f||||f||||||||||2018-05-31 23:33:55.349166|2018-05-31 23:33:55.349166
NCT01166893|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2018-02-27|2010-07-20|2010-07-21|Estimate|||||||2018-02-27|2018-03-01|Actual|March 2010||2010-03-31|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential|Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential|Withdrawn|||0|Actual|University of California, Irvine|||1|Not NIH defined clinical trial study.|f||||f||||||||||2018-05-31 23:33:55.42875|2018-05-31 23:33:55.42875
NCT01166880|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2017-02-08|2010-07-20|2010-07-21|Estimate|||||||2017-02-08|2017-02-10|Actual|August 2009||2009-08-31|February 2017|2017-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Pilot Study Using Laser Speckle Imaging of Neonate Cerebral Vasculature|Imaging of Neonate Cerebral Vasculature|Withdrawn|||0|Actual|University of California, Irvine|||1|Unable to find grant fundingsupport to continue builds the study device.|f||||f||||||||||2018-05-31 23:33:55.4913|2018-05-31 23:33:55.4913
NCT01166867|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2017-02-08|2010-07-20|2010-07-21|Estimate|||||||2017-02-08|2017-02-10|Actual|September 2009||2009-09-30|February 2017|2017-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||A Pilot Study Using Photo-plethysmographic (PPG) Camera|Photo-plethysmographic (PPG) Camera to Monitor Heart Rate, Respiration Rate and Oxygen Saturation in Infants.|Completed|||10|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 23:33:55.554946|2018-05-31 23:33:55.554946
NCT01166854|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2018-02-12|2010-07-20|2010-07-21|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2010||2010-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Characterization of Familial Myopathy and Paget Disease of Bone|Phase 1 Study Non-invasive Use Diffuse Optical Spectroscopy Will Measure the Concentrations of Blood, Water, and Lipids (Fats, for Example) in Tissues|Recruiting|||25|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-05-31 23:33:55.644607|2018-05-31 23:33:55.644607
NCT01166841|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2013-05-14|2010-07-20|2010-07-21|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|NIRSinMICS||The Effect of Percutaneous Superior Venae Cava Cannulation Clamping on Cerebral Near Infrared Spectroscopy in MICS|The Effect of Percutaneous Superior Venae Cava Cannulation Clamping on Cerebral Near Infrared Spectroscopy During Minimally Invasive Mitral Valve Surgery|Completed||N/A|35|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:33:55.734175|2018-05-31 23:33:55.734175
NCT01166828|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2015-06-25|2010-07-19|2010-07-21|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|May 2014|Anticipated|2014-05-31|January 2014|Anticipated|2014-01-31||Interventional|TELEPUPPS||Pressure Ulcer Prevention for SCI Using a Tele Home Program|Pressure Ulcer Prevention for SCI Using a Tele Home Program|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Project not funded - withdrawn by VA|f||||t||||||||||2018-05-31 23:33:55.816157|2018-05-31 23:33:55.816157
NCT01166815|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-21|2010-07-19|2010-07-21|Estimate|||||||2010-07-21|2010-07-22|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Zinc Supplementation to Reduce Diarrhea Rates in Adults in Western Kenya.|A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya.|Completed||Phase 2/Phase 3|500|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||t||||||||||2018-05-31 23:33:55.893121|2018-05-31 23:33:55.893121
NCT01166802|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-19|2010-07-19|2010-07-21|Estimate|||||||2010-07-19|2010-07-21|Estimate|February 2008||2008-02-29|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Development of a Questionnaire to Measure Hypervigilance for Visceral Pain|Development of a Questionnaire to Measure Hypervigilance for Visceral Pain|Completed|||157|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 23:33:55.980505|2018-05-31 23:33:55.980505
NCT01166789|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2011-09-14|2010-07-19|2010-07-21|Estimate|||||||2011-09-14|2011-09-16|Estimate|February 2008||2008-02-29|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Lubiprostone Effects on Visceral Pain Sensitivity|Lubiprostone Effects on Visceral Pain Sensitivity|Completed||Phase 1|62|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:33:56.039343|2018-05-31 23:33:56.039343
NCT01166776|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2016-08-19|2010-07-20|2010-07-21|Estimate|||||||2016-08-19|2016-08-22|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Observational|||A Research Study Looking at Specific Tissue of the Umbilical Cord|Decellularization of Umbilical Cord Wharton's Jelly for Tissue Regenerative Applications Including Avascular Necrosis|Completed|||64|Actual|University of Kansas Medical Center|||1||f||||f||||||Samples With DNA|"~     umbilical cord tissue~   "|||2018-05-31 23:33:56.120588|2018-05-31 23:33:56.120588
NCT01166763|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2014-01-27||2016-06-16|2010-07-19|2010-07-21|Estimate|2014-01-27|2014-03-10|Estimate||||2016-06-16|2016-07-18|Estimate|May 2009||2009-05-31|June 2016|2016-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D|Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D|Completed||N/A|30|Actual|University of Kansas Medical Center|Single arm pilot trial so all comparisons are within subject for change over the course of the study.|1|||f||||f||||||||No|Global results only will be published.|2018-05-31 23:33:56.199733|2018-05-31 23:33:56.199733
NCT01166750|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2012-09-24||2013-05-30|2010-07-19|2010-07-21|Estimate|2013-05-30|2013-05-31|Estimate||||2013-05-30|2013-05-31|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Jointstrong Intervention for Juvenile Arthritis|Jointstrong Intervention for Juvenile Arthritis|Completed||N/A|35|Actual|University of Kansas Medical Center|It was difficult to find subjects with pain resulting in significantly fewer subjects entered in the study.|2|||f||||f||||||||||2018-05-31 23:33:56.387726|2018-05-31 23:33:56.387726
NCT01166737|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2017-02-13|2010-07-20|2010-07-21|Estimate|||||||2017-02-13|2017-02-14|Actual|July 2010||2010-07-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|DESKTOP III||Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer|A Randomized Multicenter Study to Compare the Efficacy of Additional Tumor Debulking Surgery vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer|Active, not recruiting||N/A|408|Anticipated|AGO Study Group||2|||f||||t||||||||||2018-05-31 23:33:56.631261|2018-05-31 23:33:56.631261
NCT01166724|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|2017-02-14||2017-05-09|2010-07-20|2010-07-21|Estimate|2017-05-09|2017-06-07|Actual||||2017-05-09|2017-06-07|Actual|July 2010||2010-07-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-|Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- Clinical and Mechanistic Impact|Terminated||Phase 3|12|Actual|The Cleveland Clinic|Early termination; Sponsor discontinued the study for corporate reasons. No data analyzed.|2||Collaborator stopped study|f||||t||||||||||2018-05-31 23:33:56.948813|2018-05-31 23:33:56.948813
NCT01166711|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2018-01-09|2010-07-20|2010-07-21|Estimate|||||||2018-01-09|2018-01-10|Actual|August 2010||2010-08-31|January 2018|2018-01-31|July 2015|Actual|2015-07-31|February 2013|Actual|2013-02-28||Interventional|||Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent|SeQuent 1000 - Treatment of Coronary Artery Disease With Bare Metal Stent Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent: Randomized Trial|Completed||N/A|202|Actual|Aesculap AG||2|||f||||f|f|f||||||No||2018-05-31 23:33:57.202088|2018-05-31 23:33:57.202088
NCT01166516|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2018-04-16|2010-07-19|2010-07-21|Estimate|||||||2018-04-16|2018-04-17|Actual|April 2010||2010-04-30|April 2018|2018-04-30|July 2017|Actual|2017-07-31|March 2016|Actual|2016-03-31||Interventional|HUD-PAS||IBV Valve System for the Treatment of Prolonged Air Leak Under HDE H060002 - Post Approval Study|A Prospective Study With the IBV Valve System for the Treatment of Prolonged Air Leak|Completed||N/A|32|Actual|Spiration, Inc.||1|||f||||f||||||||||2018-05-31 23:33:59.086193|2018-05-31 23:33:59.086193
NCT01166698|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2011-11-08|2010-07-20|2010-07-21|Estimate|||||||2011-11-08|2011-11-09|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group, 2-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects|Completed||Phase 1|100|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:33:57.320733|2018-05-31 23:33:57.320733
NCT01166685|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2014-06-04|2010-07-20|2010-07-21|Estimate|||||||2014-06-04|2014-06-05|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Study Comparing 3 New Types of Coronary Stents|Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II)|Completed||Phase 4|2291|Actual|University Hospital, Basel, Switzerland||3|||f||||t||||||||||2018-05-31 23:33:57.413498|2018-05-31 23:33:57.413498
NCT01166672|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2012-10-11|2010-07-20|2010-07-21|Estimate|||||||2012-10-11|2012-10-12|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||BCRL Prevention Pilot|Weight Loss to Prevent BCRL: A Pilot Study|Completed|||20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:33:57.53025|2018-05-31 23:33:57.53025
NCT01166659|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2016-08-25||2017-05-12|2010-07-19|2010-07-21|Estimate|2016-09-08|2016-10-28|Estimate||||2017-05-12|2017-05-15|Actual|February 2010||2010-02-28|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|DUETTE||Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy||Completed||N/A|48|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:33:57.695279|2018-05-31 23:33:57.695279
NCT01166646|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2016-03-10|2012-12-05|2016-04-11|2010-07-19|2010-07-21|Estimate|2016-04-11|2016-05-16|Estimate|2012-12-05|2012-12-07|Estimate|2016-04-11|2016-05-16|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||The Intent-To-Treat (ITT) population included all participants enrolled in the study who were dispensed and applied test article at least once and had at least one follow-up visit after the Baseline visit (Visit 2). All 43 enrolled subjects were included in the ITT population.|Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis||Completed||Phase 2|43|Actual|Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 23:33:57.95188|2018-05-31 23:33:57.95188
NCT01166633|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2013-04-02|2010-07-20|2010-07-21|Estimate|||||||2013-04-02|2013-04-04|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|PITCH||Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia|A Randomized , Open Label, Dose Titration Study to Evaluate the Effect of Pitavastatin Versus Atorvastatin in Patients With Hypercholesterolemia and Mild to Moderate Hepatic Damage|Completed||Phase 4|200|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-05-31 23:33:58.352645|2018-05-31 23:33:58.352645
NCT01166620|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-04-12|2010-07-20|2010-07-21|Estimate|||||||2012-04-12|2012-04-13|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Observational|||Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on Biologics|Observational Real-world Evaluation of Cost of Infections of RA Patients on Biologics|Completed|||4000|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 23:33:58.419516|2018-05-31 23:33:58.419516
NCT01166607|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2014-11-30|2010-07-19|2010-07-21|Estimate|||||||2014-11-30|2014-12-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:33:58.46838|2018-05-31 23:33:58.46838
NCT01166594|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2015-02-17|2010-07-20|2010-07-21|Estimate|||||||2015-02-17|2015-02-19|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Use of Bevacizumab in Trabeculectomy Surgery|Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial|Completed||Phase 4|47|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 23:33:58.499718|2018-05-31 23:33:58.499718
NCT01166581|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2015-02-03|2010-07-20|2010-07-21|Estimate|||||||2015-02-03|2015-02-04|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates|Evaluation of Breast Magnetic Resonance Imaging (MRI) Impact on Mastectomy Rate at Summa Akron City Hospital|Terminated|||300|Actual|Summa Health System||||Not enough data collected to work with|f||||f||||||||||2018-05-31 23:33:58.577217|2018-05-31 23:33:58.577217
NCT01166568|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2015-05-04|2010-07-19|2010-07-21|Estimate|||||||2015-05-04|2015-05-05|Estimate|December 2003||2003-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Trial of the PresView Implant for the Improvement of Near Vision in Patients With Presbyopia|A Prospective, Multicenter Clinical Trial Of the PresVIEW Scleral Implant (PSI) For the Improvement Of Near Visual Acuity In Presbyopic Patients|Completed||N/A|360|Actual|Refocus Group, Inc.||1|||f||||f||||||||||2018-05-31 23:33:58.639573|2018-05-31 23:33:58.639573
NCT01166555|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-11-19|2010-07-19|2010-07-21|Estimate|||||||2010-11-19|2010-11-23|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers|Phase I Pharmacokinetics And Tolerability Of PF-04236921 Following Subcutaneous Administration To Healthy Volunteers|Completed||Phase 1|10|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:33:58.719789|2018-05-31 23:33:58.719789
NCT01166542|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2014-11-03|2010-07-19|2010-07-21|Estimate|||||||2014-11-03|2014-11-05|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|April 2012|Actual|2012-04-30||Interventional|||Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers|Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy|Completed||Phase 3|167|Actual|Oncolytics Biotech||2|||f||||t||||||||||2018-05-31 23:33:58.820169|2018-05-31 23:33:58.820169
NCT01166529|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2014-09-23|2010-07-20|2010-07-21|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Management of Pain in Abdominal Non-pancreatic Malignancies|Endoscopic Ultrasound (EUS)-Guided Celiac Plexus Neurolysis (CPN) in the Management of Pain in Abdominal Non-pancreatic Malignancies|Withdrawn||N/A|0|Actual|Northwestern University||1||Unable to identify appropriate patients.|f||||t||||||||||2018-05-31 23:33:59.026737|2018-05-31 23:33:59.026737
NCT01166490|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2013-08-23|2010-07-19|2010-07-21|Estimate|||||||2013-08-23|2013-08-27|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma|A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Patients With Pancreatic or Gastric Adenocarcinoma|Completed||Phase 1|51|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-05-31 23:33:59.235668|2018-05-31 23:33:59.235668
NCT01166477|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2013-03-19|2010-07-19|2010-07-21|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|QoLKAMON||Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor|Ensayo clínico, Abierto, Aleatorizado Para Comparar la Calidad de Vida de Los Pacientes VIH+ Que Inician Monoterapia Con Comprimidos de LPV/r vs Triple Terapia Que Contenga un IP Potenciado|Completed||Phase 4|228|Actual|Sociedad Andaluza de Enfermedades Infecciosas||2|||f||||f||||||||||2018-05-31 23:33:59.311708|2018-05-31 23:33:59.311708
NCT01166464|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2014-01-31|2010-07-20|2010-07-21|Estimate|||||||2014-01-31|2014-02-03|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Examining a Text Message Intervention for Smoking Cessation|Examining a Text Message Intervention for Smoking Cessation|Completed||N/A|84|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 23:34:00.413489|2018-05-31 23:34:00.413489
NCT01166451|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2011-10-17|2010-07-19|2010-07-21|Estimate|||||||2011-10-17|2011-10-18|Estimate|September 1991||1991-09-30|October 2011|2011-10-31|March 2004|Actual|2004-03-31|August 1994|Actual|1994-08-31||Interventional|||The Anemia Control Program: High or Low Iron Supplementation|Iron Deficiency Anemia and Infant Behavior: Preventive Trial|Completed||N/A|835|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||||||||||||2018-05-31 23:34:00.478512|2018-05-31 23:34:00.478512
NCT01166438|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2017-04-18||2018-04-30|2010-07-19|2010-07-21|Estimate|2017-11-02|2017-12-06|Actual||||2018-04-30|2018-05-02|Actual|March 2010||2010-03-31|April 2018|2018-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|ABC||Anticholinergic vs. Botox Comparison Study|Efficacy and Impact of Botulinum Toxin A Versus Anticholinergic Therapy for the Treatment of Bothersome Urge Urinary Incontinence|Completed||Phase 3|249|Actual|NICHD Pelvic Floor Disorders Network||2|||f||||t||||||||No||2018-05-31 23:34:00.579871|2018-05-31 23:34:00.579871
NCT01166425|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2013-10-08|2010-07-19|2010-07-21|Estimate|||||||2013-10-08|2013-10-09|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Lithium2||Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.|A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.|Completed||Phase 2/Phase 3|81|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-05-31 23:34:01.536177|2018-05-31 23:34:01.536177
NCT01166412|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19||2014-01-21|2016-02-19|2010-07-19|2010-07-21|Estimate||||2016-02-19|2016-03-21|Estimate|2016-02-19|2016-03-21|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CCN009||A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)|CCN009: A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate the Effects on the Mechanisms of Contraceptive Efficacy and, Secondarily, to Assess the Pharmacokinetic Profile and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)|Completed||Phase 1/Phase 2|121|Actual|Health Decisions||2|||f||||t||||||||||2018-05-31 23:34:01.661317|2018-05-31 23:34:01.661317
NCT01166399|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2018-04-30|2010-07-19|2010-07-21|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2010||2010-07-31|April 2018|2018-04-30|October 2012|Actual|2012-10-31|June 2011|Actual|2011-06-30||Observational|BOOST||Behavioral Therapy Of Obstetric Sphincter Tears|BOOST: Behavioral Therapy of Obstetric Sphincter Tears: A Cohort Study|Completed|||362|Actual|NICHD Pelvic Floor Disorders Network|||1||f||||t||||||||||2018-05-31 23:34:01.757414|2018-05-31 23:34:01.757414
NCT01166386|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-03-12|2010-07-19|2010-07-21|Estimate|||||||2012-03-12|2012-03-13|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|September 2013|Anticipated|2013-09-30|December 2012|Anticipated|2012-12-31||Interventional|||Acute Neurobehavioral Program for Improving Functional Status After TBI|An Acute Neurobehavioral Program for Improving Functional Status After TBI|Unknown status|Recruiting|Phase 3|150|Anticipated|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 23:34:01.839686|2018-05-31 23:34:01.839686
NCT01166373|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2018-04-30|2010-07-19|2010-07-21|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2010||2010-04-30|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|E-OPTIMAL||The Extended Operations And Pelvic Muscle Training In The Management Of Apical Support Loss Study|Long-Term Effectiveness Of Sacrospinous Ligament Fixation vs Uterosacral Ligament Suspension With and Without Perioperative Behavioral Therapy/Pelvic Muscle Training: Extended Operations & Pelvic Muscle Training Of Apical Support Loss Study|Completed||N/A|218|Actual|NICHD Pelvic Floor Disorders Network||6|||f||||t||||||||No||2018-05-31 23:34:02.025939|2018-05-31 23:34:02.025939
NCT01166360|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2011-03-14|2010-07-20|2010-07-21|Estimate|||||||2011-03-14|2011-03-15|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Usefulness of Growth Differentiation Factor 15 (GDF-15) for Risk Stratification in Cardiac Surgery|The Prognostic Relevance of Cerebral Oxygen Saturation, NTproBNP and Preoperative Creatinine Clearance in Cardiac Surgical Patients; Amendment 4: the Prognostic Relevance of Growth Differentiation Factor 15 (GDF-15) and High Sensitive Troponin-t (hsTnT)|Completed|||2000|Actual|University of Luebeck|||2||f||||f||||||Samples Without DNA|"~     Plasma and urine samples~   "|||2018-05-31 23:34:02.125192|2018-05-31 23:34:02.125192
NCT01166347|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2017-12-19||2018-05-24|2010-07-19|2010-07-21|Estimate|2018-01-29|2018-02-28|Actual||||2018-05-24|2018-05-30|Actual|August 2010||2010-08-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2014|Actual|2014-05-31||Interventional|ENDURANCE|Only randomized subjects who successfully received an implant are included.|The HeartWare™ Ventricular Assist System as Destination Therapy of Advanced Heart Failure: the ENDURANCE Trial|A Prospective, Randomized, Controlled, Un-blinded, Multi-Center Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (VAS) for Destination Therapy of Advanced Heart Failure|Completed||N/A|451|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-05-31 23:34:02.240283|2018-05-31 23:34:02.240283
NCT01166334|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2013-10-10|2010-07-20|2010-07-21|Estimate|||||||2013-10-10|2013-10-11|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|WebQuit||WebQuit Online Smoking Cessation Study|WebQuit Online Smoking Cessation Study|Completed||Phase 1|721|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 23:34:03.046181|2018-05-31 23:34:03.046181
NCT01166321|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2018-05-11|2010-07-20|2010-07-21|Estimate|||||||2018-05-11|2018-05-17|Actual|June 2012|Actual|2012-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|MARCIE||Carbon Ion Radiotherapy for Atypical Meningiomas|Treatment of Patients With Atypical Meningiomas Simpson Grade 4 and 5 With a Carbon Ion Boost in Combination With Postoperative Photon Radiotherapy: A Phase II Trial|Recruiting||N/A|40|Anticipated|University Hospital Heidelberg||1|||f||||t||||||||||2018-05-31 23:34:03.198141|2018-05-31 23:34:03.198141
NCT01166308|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2018-05-11|2010-07-20|2010-07-21|Estimate|||||||2018-05-11|2018-05-17|Actual|December 2010|Actual|2010-12-31|May 2018|2018-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CINDERELLA||Carbon Ion Radiotherapy for Recurrent Gliomas|Randomised Phase I/II Study to Evaluate Carbon Ion Radiotherapy Versus Fractionated Stereotactic Radiotherapy in Patients With Recurrent or Progressive Gliomas: The CINDERELLA Trial|Completed||N/A|56|Actual|University Hospital Heidelberg||2|||f||||t||||||||||2018-05-31 23:34:03.285212|2018-05-31 23:34:03.285212
NCT01166295|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-08-03|2010-07-20|2010-07-21|Estimate|||||||2010-08-03|2010-08-05|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Observational|BSTK||Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia|Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia|Unknown status|Recruiting||12|Anticipated|Analgesic Solutions|||||f||||f||||||||||2018-05-31 23:34:03.386721|2018-05-31 23:34:03.386721
NCT01166282|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2016-05-12||2016-06-24|2010-07-20|2010-07-21|Estimate|2016-05-12|2016-06-21|Estimate||||2016-06-24|2016-06-27|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|November 2012|Actual|2012-11-30||Interventional||Intent-to-treat (ITT) population: All randomized participants who received at least 1 dose of study drug.|A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis|A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis|Completed||Phase 3|46|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 23:34:03.534686|2018-05-31 23:34:03.534686
NCT01166269|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-20|||2012-11-07|2010-07-20|2010-07-21|Estimate|||||||2012-11-07|2012-11-08|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ILIT||Study to Asses Efficacy of Intralymphatic Immunotherapy|Intralymphatic Specific Immunotherapy - as a New Treatment Form for Grass-pollen Allergic Subjects|Completed||Phase 2/Phase 3|44|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 23:34:04.61753|2018-05-31 23:34:04.61753
NCT01166256|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-20|2010-07-20|2010-07-21|Estimate|||||||2010-07-20|2010-07-21|Estimate|July 2010||2010-07-31|July 2010|2010-07-31||||July 2011|Anticipated|2011-07-31||Interventional|||Comparison Between High-flow Nasal Cannula System and Non-invasive Ventilation in Acute Hypoxemic Respiratory Failure|Prospective, Open-labeled, Randomized Controlled Trial of Comparison Between High-flow Nasal Cannula System and Non-invasive Ventilation in Acute Hypoxemic Respiratory Failure|Unknown status|Recruiting|Phase 2/Phase 3|74|Anticipated|Asan Medical Center||2|||f||||||||||||||2018-05-31 23:34:04.702934|2018-05-31 23:34:04.702934
NCT01166243|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2014-01-17|2010-07-20|2010-07-21|Estimate|||||||2014-01-17|2014-01-20|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||The Fibrin Pad Liver Study|A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery|Completed||Phase 3|84|Actual|Ethicon, Inc.||2|||f||||t||||||||||2018-05-31 23:34:04.780672|2018-05-31 23:34:04.780672
NCT01166230|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2013-08-05||2013-11-14|2010-07-19|2010-07-20|Estimate|2013-10-22|2013-11-14|Estimate||||2013-11-14|2013-12-09|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB|An Open, Non-interventional, Retrospective, Comparative, Multicenter Follow-up Study in Patients Included in the Previously Completed Clinical Study PCB305/04, to Assess Longer-term Recurrence Rates in Patients After Hexvix® (Cysview®)Fluorescence Cystoscopy/Transurethral Resection of the Bladder (TURB) or White Light Cystoscopy/TURB|Completed|||551|Actual|Photocure|||2||f||||f||||||||||2018-05-31 23:34:04.880166|2018-05-31 23:34:04.880166
NCT01166217|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2010-08-18|2010-07-19|2010-07-20|Estimate|||||||2010-08-18|2010-08-20|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Single Dose Study Of PF-04620110 In Healthy Subjects|A Phase 1, Cross-over, Single-dose, Open-label Study to Estimate the Relative Bioavailability of Three Different Formulations of Pf-04620110 Under Fed/Fasted Conditions in Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:34:05.145345|2018-05-31 23:34:05.145345
NCT01166204|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2017-05-22|2010-07-19|2010-07-20|Estimate|||||||2017-05-22|2017-05-23|Actual|May 2009|Actual|2009-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)|Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With IMRT for Stage I-III Non-small Cell Lung Cancer to an Individualised MLD|Completed||Phase 2|300|Actual|Maastricht Radiation Oncology||1|||f||||f||||||||||2018-05-31 23:34:05.211821|2018-05-31 23:34:05.211821
NCT01166191|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2017-05-22|2010-07-19|2010-07-20|Estimate|||||||2017-05-22|2017-05-23|Actual|May 2009|Actual|2009-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)|Concurrent Chemo-radiotherapy With IMRT for Stage I-III Small Cell Lung Cancer|Completed||Phase 2|60|Actual|Maastricht Radiation Oncology||1|||f||||f||||||||||2018-05-31 23:34:05.358336|2018-05-31 23:34:05.358336
NCT01166178|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|2013-06-03||2013-10-24|2010-07-19|2010-07-20|Estimate|2013-10-24|2013-11-26|Estimate||||2013-10-24|2013-11-26|Estimate|October 2010||2010-10-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EXALT||Zoledronic Acid in MS-patients With Osteoporosis|A 1-year, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Zoledronic Acid 5 mg (Aclasta®) on Bone Mineral Density in Patients With Multiple Sclerosis Followed by a 1-year Open-label Treatment Phase|Terminated||Phase 3|29|Actual|Novartis|Study termination due to small number of participants recruited lead to lack of power for analysis of all outcome measures.|2|||f||||||||||||||2018-05-31 23:34:05.473003|2018-05-31 23:34:05.473003
NCT01166165|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2012-06-18|2010-07-19|2010-07-20|Estimate|||||||2012-06-18|2012-06-19|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Vitamin D Replacement During Winter Months in Patients With Hypertension|Effect of Cholecalciferol on 24-hr ABPM and Vasoactive Hormones in Patients With Hypertension.|Completed||Phase 2|136|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 23:34:05.896138|2018-05-31 23:34:05.896138
NCT01166152|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2011-07-20|2010-07-19|2010-07-20|Estimate|||||||2011-07-20|2011-07-21|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|March 2013|Anticipated|2013-03-31|November 2011|Anticipated|2011-11-30||Interventional|DIDD||Development of a New Diagnosis and Intervention Method for Developmental Disorders|Development of a New Diagnosis and Intervention Method for Developmental Disorders|Unknown status|Recruiting|N/A|20|Anticipated|Tokyo University of Agriculture and Technology|||||f||||||||||||||2018-05-31 23:34:05.982094|2018-05-31 23:34:05.982094
NCT01166139|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2017-05-25||2017-10-02|2010-07-19|2010-07-20|Estimate|2017-10-02|2017-10-04|Actual||||2017-10-02|2017-10-04|Actual|July 2010||2010-07-31|October 2017|2017-10-31|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||Nilotinib in the Treatment of Systemic Sclerosis|Phase IIA Study of the Safety and Tolerability of the Use of Nilotinib in the Treatment of Systemic Sclerosis|Completed||Phase 2|10|Actual|Hospital for Special Surgery, New York||1|||f||||t||||||||||2018-05-31 23:34:06.075465|2018-05-31 23:34:06.075465
NCT01166126|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2013-03-29||2014-04-29|2010-07-19|2010-07-20|Estimate|2013-03-29|2013-05-23|Estimate||||2014-04-29|2014-05-15|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||All baseline participants|Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV|Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma|Terminated||Phase 2|4|Actual|National Cancer Institute (NCI)|The study was terminated due to overall low accrual and a high rate of screening failures. Accrual goal was 38 participants and only 4 participants were actually treated.|1|||f||||||||||||||2018-05-31 23:34:06.328482|2018-05-31 23:34:06.328482
NCT01166113|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2017-09-05|2010-07-19|2010-07-20|Estimate|||||||2017-09-05|2017-09-06|Actual|July 2010||2010-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|June 2011|Actual|2011-06-30||Interventional|PCP||Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide|A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide|Active, not recruiting||Phase 1/Phase 2|67|Actual|Fondazione Neoplasie Sangue Onlus||1|||f||||f||||||||||2018-05-31 23:34:06.545728|2018-05-31 23:34:06.545728
NCT01166100|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-20|2010-07-19|2010-07-20|Estimate|||||||2010-07-20|2010-07-21|Estimate|February 2006||2006-02-28|July 2010|2010-07-31|August 2006|Actual|2006-08-31|March 2006|Actual|2006-03-31||Interventional|||Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg DR Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:06.621953|2018-05-31 23:34:06.621953
NCT01166087|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-20|2010-07-19|2010-07-20|Estimate|||||||2010-07-20|2010-07-21|Estimate|February 2006||2006-02-28|July 2010|2010-07-31|September 2006|Actual|2006-09-30|March 2006|Actual|2006-03-31||Interventional|||Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg Delayed Release Capsules of Eli Lilly and Company, USA in Healthy Adult Human Subjects Under Fed Conditions.|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:06.698558|2018-05-31 23:34:06.698558
NCT01166074|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2011-02-10|2010-07-19|2010-07-20|Estimate|||||||2011-02-10|2011-02-11|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Retrospective Chart Review of Subcutaneous IgG Use in Infants|Retrospective Chart Review Study: Subcutaneous IgG in Children Under 2 Years of Age|Completed|||27|Actual|CSL Behring|||1||f||||f||||||||||2018-05-31 23:34:06.80594|2018-05-31 23:34:06.80594
NCT01166061|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-05-19|2010-07-19|2010-07-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|July 2010||2010-07-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis|An Escalating, Multiple-dose Study in Grass Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Grass|Completed||Phase 2|50|Anticipated|Circassia Limited||5|||f||||f||||||||||2018-05-31 23:34:06.881394|2018-05-31 23:34:06.881394
NCT01166048|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2014-07-29|2010-07-19|2010-07-20|Estimate|||||||2014-07-29|2014-07-31|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component|Randomized Double-blind Study Comparing the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component|Completed||Phase 4|41|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 23:34:07.042965|2018-05-31 23:34:07.042965
NCT01166035|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|TEXO||Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors|Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Medical University Innsbruck|||||f||||||||||||||2018-05-31 23:34:07.142851|2018-05-31 23:34:07.142851
NCT01166022|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2016-08-11|2010-07-19|2010-07-20|Estimate|||||||2016-08-11|2016-08-12|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)|Randomized, Controlled Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)|Completed||N/A|14|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 23:34:07.224168|2018-05-31 23:34:07.224168
NCT01166009|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2018-04-20|2010-07-19|2010-07-20|Estimate|||||||2018-04-20|2018-04-24|Actual|July 2002||2002-07-31|October 2016|2016-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries|Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries|Recruiting|||99999999|Anticipated|Center for International Blood and Marrow Transplant Research|||||f||||f||||||||||2018-05-31 23:34:07.287704|2018-05-31 23:34:07.287704
NCT01165996|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2013-01-02||2013-02-25|2010-07-19|2010-07-20|Estimate|2013-01-22|2013-02-26|Estimate||||2013-02-25|2013-03-01|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome|A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome|Completed||Phase 1/Phase 2|25|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:34:07.419699|2018-05-31 23:34:07.419699
NCT01165983|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2014-11-10||2017-02-27|2010-07-19|2010-07-20|Estimate|2015-01-26|2015-02-09|Estimate||||2017-02-27|2017-03-28|Actual|November 2009||2009-11-30|February 2017|2017-02-28||||January 2012|Actual|2012-01-31||Interventional|||The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes|The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes|Completed||N/A|124|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 23:34:07.748032|2018-05-31 23:34:07.748032
NCT01165970|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-11-12|2010-07-19|2010-07-20|Estimate|||||||2011-11-12|2011-11-15|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|March 2012|Anticipated|2012-03-31||Interventional|T-01||Effect of Saliva Substitutes on Dental Hard Tissues in Situ|Vergleichende, Randomisierte, Kontrollierte Und Doppelblinde In-situ-Studie Zur Wirkung Von Speichelersatzmitteln Auf Schmelz Und Dentin|Terminated||Phase 2/Phase 3|19|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:34:08.397351|2018-05-31 23:34:08.397351
NCT01165957|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2012-07-30|2010-07-19|2010-07-20|Estimate|||||||2012-07-30|2012-08-01|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||A Comparison of Wear Among Mobile and Fixed Bearing Knee Replacements|A Comparison of Volumetric Wear Among DePuy Mobile and Fixed Bearing Knee Tibial Inserts|Completed|||24|Actual|Anderson Orthopaedic Research Institute|||2||f||||f||||||||||2018-05-31 23:34:08.486055|2018-05-31 23:34:08.486055
NCT01165944|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-10-02|2010-07-19|2010-07-20|Estimate|||||||2012-10-02|2012-10-03|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus|Effectiveness of Pramlintide on Control of Post-Transplant Diabetes Mellitus|Withdrawn||Phase 1/Phase 2|0|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 23:34:08.566583|2018-05-31 23:34:08.566583
NCT01165931|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2013-10-21|2010-07-19|2010-07-20|Estimate|||||||2013-10-21|2013-10-23|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|CORONARIES||Coronary Vasomotor Response After Riociguat Exposure|A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease|Withdrawn||Phase 2|0|Actual|Bayer||1|||f||||f||||||||||2018-05-31 23:34:08.654076|2018-05-31 23:34:08.654076
NCT01165918|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-18|2010-07-18|2010-07-20|Estimate|||||||2010-07-18|2010-07-20|Estimate|October 2010||2010-10-31|June 2010|2010-06-30||||||||Observational|||Derivation of New Human Embryonic Stem Cell Lines: Identification of Instructive Factors for Germ Cells Development|Basic Research. Unveiling Factors That Contribute to Germ Cell Differentiation|Unknown status|Not yet recruiting||50|Anticipated|Soroka University Medical Center|||1||f||||f||||||||||2018-05-31 23:34:08.716692|2018-05-31 23:34:08.716692
NCT01165905|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2017-06-22|2010-07-19|2010-07-20|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2010||2010-01-31|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors|Phase I Dose Escalation Study of Gemcitabine and 24 Hour Infusion of ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|10|Actual|Onconova Therapeutics, Inc.|||||f||||f||||||||||2018-05-31 23:34:08.789773|2018-05-31 23:34:08.789773
NCT01165892|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2014-12-08|2010-07-19|2010-07-20|Estimate|||||||2014-12-08|2014-12-10|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)|Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using a Single Dose of Gadofosveset (Ablavar)|Completed|||15|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 23:34:08.860841|2018-05-31 23:34:08.860841
NCT01165879|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2011-06-09|2010-07-18|2010-07-20|Estimate|||||||2011-06-09|2011-06-10|Estimate|May 2010||2010-05-31|July 2010|2010-07-31||||May 2012|Anticipated|2012-05-31||Observational|||Measuring Uterine Electrical Activity Throughout Pregnancy and Labor Measuring Uterine Electrical Activity Throughout Pregnancy and Labor||Unknown status|Recruiting||100|Anticipated|OB-Tools Ltd.|||||f||||f||||||||||2018-05-31 23:34:08.911051|2018-05-31 23:34:08.911051
NCT01165866|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2010-10-25|2010-07-19|2010-07-20|Estimate|||||||2010-10-25|2010-10-26|Estimate|June 2008||2008-06-30|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis|Ondansetron Vs Metoclopramide in the Treatment of Vomiting in Gastroenteritis Patients: A Randomized Controlled Trial|Completed||Phase 4|170|Actual|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 23:34:08.969942|2018-05-31 23:34:08.969942
NCT01165853|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2017-05-25|2010-07-16|2010-07-20|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2005||2005-07-31|May 2017|2017-05-31|July 2012|Actual|2012-07-31|November 2007|Actual|2007-11-30||Interventional|IPOP||Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks|Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks on Hormones and Lipids|Completed||N/A|32|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 23:34:09.034591|2018-05-31 23:34:09.034591
NCT01165840|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2015-10-28|2014-02-04|2016-06-09|2010-07-19|2010-07-20|Estimate|2016-06-09|2016-07-21|Estimate|2014-05-06|2014-05-22|Estimate|2016-06-09|2016-07-21|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Weight and/or Obesity on Dapsone Drug Concentrations|Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers|Completed||Phase 4|37|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||||2018-05-31 23:34:09.101654|2018-05-31 23:34:09.101654
NCT01165827|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2018-03-13|2010-07-19|2010-07-20|Estimate|||||||2018-03-13|2018-03-14|Actual|July 2010||2010-07-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|GARY||German Aortic Valve Registry|National Prospective German Registry for Aortic Valve Therapy|Recruiting|||100000|Anticipated|German Aortic Valve Registry|||1||f||||t||||||||||2018-05-31 23:34:09.30582|2018-05-31 23:34:09.30582
NCT01165814|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|August 2006||2006-08-31|July 2010|2010-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Naproxen Versus Tramadol for Post Cesarean Pain Control|Oral Naproxen Versus Oral Tramadol for Analgesia After Cesarean Delivery - A Randomized Controlled Trial|Completed||N/A|120|Actual|Bnai Zion Medical Center||4|||f||||f||||||||||2018-05-31 23:34:09.412393|2018-05-31 23:34:09.412393
NCT01165801|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-17|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|January 2002||2002-01-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|September 2007|Actual|2007-09-30||Interventional|||Size Progression of Macular Degeneration After Cataract Surgery|Size Progression of Non-Exudative Age-Related Macular Degeneration After Cataract Surgery|Completed||Phase 4|54|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||1|||f||||f||||||||||2018-05-31 23:34:09.475726|2018-05-31 23:34:09.475726
NCT01165788|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2017-11-29|2010-07-19|2010-07-20|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2009||2009-11-30|November 2017|2017-11-30|June 28, 2017|Actual|2017-06-28|November 2010|Actual|2010-11-30||Observational|||Social Adaptation in Long Term Survivors of Blood and Marrow Transplantation|Social Adaptation in Long Term Survivors of Blood and Marrow Transplantation|Completed|||50|Actual|Stanford University|||1||f||||t||||||||||2018-05-31 23:34:09.530004|2018-05-31 23:34:09.530004
NCT01165775|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2016-05-11||2016-07-28|2010-07-16|2010-07-20|Estimate|2016-07-28|2016-09-16|Estimate||||2016-07-28|2016-09-16|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational||Women receiving clinically indicated betamethasone between 24 and 34 weeks of pregnancy. Data are available for 15 of 17 participants.|Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy|Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy|Completed|||17|Actual|Stanford University|||1||f||||f||||||||No||2018-05-31 23:34:09.595741|2018-05-31 23:34:09.595741
NCT01165762|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2016-12-05|2010-07-19|2010-07-20|Estimate|||||||2016-12-05|2016-12-07|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.|Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion in HLA Haplotype Match Living Donor Kidney Transplantation|Recruiting||N/A|25|Anticipated|Stanford University||1|||f||||t||||||||No||2018-05-31 23:34:09.808268|2018-05-31 23:34:09.808268
NCT01165749|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|May 2010||2010-05-31|July 2010|2010-07-31|April 2012|Anticipated|2012-04-30|December 2011|Anticipated|2011-12-31||Observational|||Exercise Study Including Patients With Hypertrophic Cardiomyopathy|A Randomized Trial of Moderate Intensity Exercise Training in Patients With Hypertrophic Cardiomyopathy|Unknown status|Recruiting||120|Anticipated|Stanford University|||||f||||||||||||||2018-05-31 23:34:09.877241|2018-05-31 23:34:09.877241
NCT01165736|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-08-23|2010-07-16|2010-07-20|Estimate|||||||2010-08-23|2010-08-24|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity|An Exploratory, Open Label, Randomized, Parallel Group Study To Investigate The Pharmacokinetics Of Single Intravenous And Oral Micro Doses Of PF-05186462, PF-05089771, PF-05241328 And PF-05150122 In Healthy Male Subjects|Completed||Phase 1|40|Actual|Pfizer||8|||f||||f||||||||||2018-05-31 23:34:09.935809|2018-05-31 23:34:09.935809
NCT01165723|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2012-02-21|2010-07-16|2010-07-20|Estimate|||||||2012-02-21|2012-02-22|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Clinical Study Evaluating The Safety And Tolerability Of PF-04427429 In Healthy Adult Volunteers. The Pharmacokinetics And Pharmacodynamics Of PF-04427429 Will Also Be Investigated|A Randomised, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group Study To Evaluate the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses PF-04427429 Administered Intravenously To Healthy Adult Volunteers|Completed||Phase 1|21|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:34:10.968939|2018-05-31 23:34:10.968939
NCT01165710|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2017-01-23|2010-07-19|2010-07-20|Estimate|||||||2017-01-23|2017-01-24|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)|Completed|||10179|Actual|Janssen Scientific Affairs, LLC|||1||f||||f||||||||||2018-05-31 23:34:11.065358|2018-05-31 23:34:11.065358
NCT01165697|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2017-01-11|2010-07-19|2010-07-20|Estimate|||||||2017-01-11|2017-01-13|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|||Establishment of Biomarkers for Fabry Disease|Establishment of Biomarkers for Fabry Disease|Completed|||4|Actual|Ohio State University|||1||f||||f||||||||||2018-05-31 23:34:11.469557|2018-05-31 23:34:11.469557
NCT01165684|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2013-04-25||2017-01-02|2010-07-16|2010-07-20|Estimate|2013-04-25|2013-06-11|Estimate||||2017-01-02|2017-02-17|Actual|October 2010||2010-10-31|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Full STEP™||Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen|A Randomised, Controlled, Open Label, Multicentre, Multinational, Treat-to-target Trial Investigating the Efficacy and Safety of Intensification With Addition of Bolus Insulin Aspart in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin With or Without Oral Anti-diabetic Drugs: Step-wise Addition Versus Complete Basal-bolus Therapy|Completed||Phase 4|401|Actual|Novo Nordisk A/S|A higher proportion of subjects did not complete the trial in the basal-bolus arm (52 subjects, 26.0%) than in the step-wise arm (28 subjects, 13.9%).|2|||f||||f||||||||||2018-05-31 23:34:11.644974|2018-05-31 23:34:11.644974
NCT01165671|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-02-19|2010-07-19|2010-07-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|July 2010||2010-07-31|February 2013|2013-02-28||||June 2014|Anticipated|2014-06-30||Interventional|CLEOPATRA||Carbon Ion Radiotherapy for Primary Glioblastoma|Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma|Unknown status|Recruiting|Phase 2|150|Anticipated|University Hospital Heidelberg||2|||f||||t||||||||||2018-05-31 23:34:12.349725|2018-05-31 23:34:12.349725
NCT01165658|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2018-01-09|2010-07-16|2010-07-20|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2010|Actual|2010-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies|Phase I Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies|Active, not recruiting||Phase 1|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:34:12.433643|2018-05-31 23:34:12.433643
NCT01165645|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2016-06-03|2010-07-19|2010-07-20|Estimate|||||||2016-06-03|2016-06-06|Estimate|November 2010||2010-11-30|October 2015|2015-10-31||||May 2011|Actual|2011-05-31||Interventional|||Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma|Lopinavir/Ritonavir as an Immunomodulator to Enhance Vaccine Responsiveness|Withdrawn||N/A|0|Actual|Mayo Clinic||2||no patients enrolled|f||||t||||||||||2018-05-31 23:34:12.525244|2018-05-31 23:34:12.525244
NCT01165632|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2018-04-30|2010-07-16|2010-07-20|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2010|Actual|2010-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|August 26, 2016|Actual|2016-08-26||Interventional|||Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma|A Pilot Study of Utility of 18F-FDOPA-PET for Neurosurgical Planning and Radiotherapy Target Delineation in Glioma Patients: Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Brain Tumors|Active, not recruiting||N/A|30|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 23:34:12.613024|2018-05-31 23:34:12.613024
NCT01165619|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2011-05-23|2010-07-19|2010-07-20|Estimate|||||||2011-05-23|2011-05-24|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders|Detailed Clinical, Biochemical and Genetic Characterization in GnRH Deficiency Disorders|Terminated|||50|Actual|Massachusetts General Hospital|||4|the Principal Investigator left the institution|f||||f||||||Samples With DNA|"~     serum, plasma, DNA~   "|||2018-05-31 23:34:12.72737|2018-05-31 23:34:12.72737
NCT01165606|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate||||July 2010|2010-07-31||||||||Interventional|||Effects of Respiratory Physiotherapy in Critically Ill Patients Ventilated for More Than 48 Hours||Completed||N/A|||Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude||1|||f||||f||||||||||2018-05-31 23:34:12.791105|2018-05-31 23:34:12.791105
NCT01165593|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2015-04-15|2010-07-19|2010-07-20|Estimate|||||||2015-04-15|2015-04-16|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases|Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases|Completed|||96|Actual|Kardium Inc.|||1||f||||f||||||||||2018-05-31 23:34:12.859398|2018-05-31 23:34:12.859398
NCT01165580|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2016-11-01|2010-07-16|2010-07-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age|Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients < 4 Months of Age|Completed||Phase 1|17|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:34:12.988789|2018-05-31 23:34:12.988789
NCT01165567|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|December 2009||2009-12-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease|Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy|Unknown status|Active, not recruiting|Phase 4|212|Anticipated|Seoul National University Boramae Hospital||2|||f||||f||||||||||2018-05-31 23:34:13.160587|2018-05-31 23:34:13.160587
NCT01165554|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2013-05-07||2013-11-08|2010-07-19|2010-07-20|Estimate|2013-11-08|2013-12-04|Estimate||||2013-11-08|2013-12-04|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels|A Principal Open-Label Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Amyloid Levels Determined Post-Mortem|Completed||Phase 3|203|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 23:34:13.404279|2018-05-31 23:34:13.404279
NCT01165541|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2013-12-19||2018-03-12|2010-07-16|2010-07-20|Estimate|2014-02-13|2014-03-31|Estimate||||2018-03-12|2018-04-09|Actual|September 2010||2010-09-30|March 2018|2018-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Entire study population|A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency|An Open-Label, Sequential Study of Quetiapine Fumarate Extended Release (XR) and Mirtazapine for the Treatment of Alcohol Dependency in Very Heavy Drinkers|Completed||Phase 2|20|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 23:34:13.794554|2018-05-31 23:34:13.794554
NCT01165528|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|January 2010||2010-01-31|December 2009|2009-12-31||||June 2011|Anticipated|2011-06-30||Interventional|||Adaptive Support Ventilation in Acute Respiratory Distress Syndrome (ARDS)|Adaptive Support Ventilation vs. Conventional Ventilation Strategy in the Management of Acute Respiratory Distress Syndrome:A Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 23:34:14.320916|2018-05-31 23:34:14.320916
NCT01165515|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2014-05-18|2010-07-19|2010-07-20|Estimate|||||||2014-05-18|2014-05-20|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Observational|||Endostatin Serum Levels During Bicycle Stress Test|Endostatin Serum Levels During Bicycle Stress Test in Different Samples|Completed|||240|Actual|Medical University of Vienna|||13||f||||t||||||||||2018-05-31 23:34:14.463305|2018-05-31 23:34:14.463305
NCT01165502|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2011-01-18|2010-07-19|2010-07-20|Estimate|||||||2011-01-18|2011-01-19|Estimate|July 2010||2010-07-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers|Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers|Completed||Phase 1|40|Anticipated|CellMed AG, a subsidiary of BTG plc.||2|||f||||f||||||||||2018-05-31 23:34:14.644099|2018-05-31 23:34:14.644099
NCT01165489|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-19|||2010-07-19|2010-07-19|2010-07-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|January 2007||2007-01-31|December 2009|2009-12-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Observational|||Discovering Laryngomalacia|Discovering Laryngomalacia|Completed|||1500|Actual|Boushahri Clinic Medical Center|||2||f||||t||||||||||2018-05-31 23:34:14.734865|2018-05-31 23:34:14.734865
NCT01165476|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-04-18|2010-07-15|2010-07-19|Estimate|||||||2011-04-18|2011-04-19|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities|An Evaluation of the Comparative Bioavailability of a Single Oral Dose of 1mg UT-15C (Treprostinil Diethanolamine) SR Tablets Manufactured by Two Independent Facilities Administered to Healthy Volunteers in the Fed State|Completed||Phase 1|64|Actual|United Therapeutics||2|||f||||f||||||||||2018-05-31 23:34:14.798162|2018-05-31 23:34:14.798162
NCT01165463|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2018-05-01|2010-07-16|2010-07-19|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2009||2009-09-30|May 2018|2018-05-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|IHAMS||Iowa Healthy and Active Minds Study|RCT of Two Speed of Processing Modes to Prevent Cognitive Decline in Older Adults|Completed||N/A|681|Actual|University of Iowa||4|||f||||t||||||||No||2018-05-31 23:34:14.889602|2018-05-31 23:34:14.889602
NCT01165294|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2010-08-05|2010-07-15|2010-07-19|Estimate|||||||2010-08-05|2010-08-06|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|||||Interventional|||The Effect of Ketamine on Attentiveness|Investigate the Effect of S-Ketamine, as Pharmacological Model of Schizophrenia, on the Attentiveness and Working Memory Simultaneously Measured With Functional Magnetic Resonance Imaging(fMRI)/Electroencephalogram(EEG)|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 23:34:17.264858|2018-05-31 23:34:17.264858
NCT01165450|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2015-04-07||2015-04-20|2010-07-16|2010-07-19|Estimate|2015-04-07|2015-04-20|Estimate||||2015-04-20|2015-05-07|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|NTX-PED-001|2 participants were randomized and participated in the study before its premature closure for lack of study drug.|Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects|Phase 2, Randomized, Double-masked, Vehicle-controlled, Dose-escalation Study Evaluating Efficacy/Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) Resulting From Corneal Epithelial Debridement During Diabetic Vitrectomy Surgery, Herpes Simples Virus (HSV) Keratitis, Herpes Zoster Virus (HZV) Keratitis, Corneal Burns, Post-photorefractive Keratectomy (Post-PRK), or Post-corneal Transplant Surgery.|Terminated||Phase 2|2|Actual|University of California, San Francisco|The study was terminated prematurely due to discontinued supply of study drug, and data were never analyzed; PI has left the institution and data are no longer available.|2||Drug manufacturer could not supply study drug.|f||||t||||||||||2018-05-31 23:34:15.092212|2018-05-31 23:34:15.092212
NCT01165437|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-02-22|2010-07-16|2010-07-19|Estimate|||||||2011-02-22|2011-02-24|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Validation of a Novel Oscillometric-Based Algorithm for Determination of the Ankle-Brachial Index|Validation of a Novel Oscillometric-Based Algorithm for Determination of the Ankle-Brachial Index|Completed|||161|Anticipated|Summit Doppler Systems, Inc.|||1||f||||f||||||||||2018-05-31 23:34:15.326331|2018-05-31 23:34:15.326331
NCT01165424|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2011-12-16||2017-03-17|2010-07-16|2010-07-19|Estimate|2011-12-16|2012-01-23|Estimate||||2017-03-17|2017-04-14|Actual|April 2010||2010-04-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)|A Study of Long-term (12-24 Weeks) Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No. P06333)|Completed||Phase 3|80|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:34:15.455737|2018-05-31 23:34:15.455737
NCT01165411|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2016-10-13|2010-07-16|2010-07-19|Estimate|||||||2016-10-13|2016-10-14|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Observational|||Developing and Maintaining a Central Venous Catheter Registry|Developing and Maintaining a Central Venous Catheter Registry|Completed|||4530|Actual|Lehigh Valley Hospital|||1||f||||f||||||||No||2018-05-31 23:34:15.693665|2018-05-31 23:34:15.693665
NCT01165398|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2016-10-13|2010-07-16|2010-07-19|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Comprehensive Evaluation of a Central Line Simulation Course|Comprehensive Evaluation of a Central Line Simulation Course|Completed|||383|Actual|Lehigh Valley Hospital|||1||f||||f||||||||No||2018-05-31 23:34:15.774488|2018-05-31 23:34:15.774488
NCT01165385|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-11-14|2010-07-16|2010-07-19|Estimate|||||||2014-11-14|2014-11-17|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|PACIFIK||Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors|An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|35|Actual|UNICANCER||1|||f||||t||||||||||2018-05-31 23:34:15.879197|2018-05-31 23:34:15.879197
NCT01165372|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-09-14|2010-07-15|2010-07-19|Estimate|||||||2011-09-14|2011-09-15|Estimate|August 2010||2010-08-31|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Malaria Treatment at Phuoc Long Hospital, Binh Phuoc Province, Vietnam|Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam|Completed||Phase 2|166|Actual|Oxford University Clinical Research Unit, Vietnam||3|||f||||t||||||||||2018-05-31 23:34:15.961811|2018-05-31 23:34:15.961811
NCT01165359|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2014-03-05|2010-07-15|2010-07-19|Estimate|||||||2014-03-05|2014-03-06|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults|A Randomized, Double-Blind, Phase 1b Study to Assess the Safety and Activity of the HCV Entry Inhibitor ITX 5061 in Treatment-Naive HCV Mono-Infected Adults|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-05-31 23:34:16.040761|2018-05-31 23:34:16.040761
NCT01165346|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2016-05-31|2010-07-16|2010-07-19|Estimate|||||||2016-05-31|2016-06-01|Estimate|August 2009||2009-08-31|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|April 2016|Actual|2016-04-30||Interventional|CKNO-HEP||Stereotaxic Irradiation of Hepatocellular Carcinoma|Stereotaxic Irradiation of Hepatocellular Carcinoma : Phase II Study|Unknown status|Active, not recruiting|Phase 2|44|Actual|Centre Oscar Lambret||1|||f||||t||||||||No||2018-05-31 23:34:16.12562|2018-05-31 23:34:16.12562
NCT01165333|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2016-02-15|2010-07-16|2010-07-19|Estimate|||||||2016-02-15|2016-02-17|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|January 2014|Actual|2014-01-31||Interventional|CILENT-0902||Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma|Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study|Completed||Phase 1|32|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 23:34:16.226098|2018-05-31 23:34:16.226098
NCT01165320|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2014-03-20||2017-02-21|2010-07-16|2010-07-19|Estimate|2014-03-20|2014-04-23|Estimate||||2017-02-21|2017-03-24|Actual|July 2010||2010-07-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)|A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections|Completed||Phase 2|20|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:34:16.311835|2018-05-31 23:34:16.311835
NCT01165307|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2016-09-26||2017-01-19|2010-07-15|2010-07-19|Estimate|2016-09-26|2016-11-15|Estimate||||2017-01-19|2017-01-20|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|iTOM||Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia|A Prospective Randomized Trial of Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia: Treatment Outcomes and Cost Utility Analysis|Completed||Phase 4|77|Actual|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 23:34:16.731457|2018-05-31 23:34:16.731457
NCT01165281|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2013-08-09||2017-06-22|2010-07-15|2010-07-19|Estimate|2013-12-13|2014-01-15|Estimate||||2017-06-22|2017-07-21|Actual|August 2010||2010-08-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain|A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain|Completed||Phase 3|343|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 23:34:17.407303|2018-05-31 23:34:17.407303
NCT01165268|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2016-11-16|2010-07-16|2010-07-19|Estimate|||||||2016-11-16|2016-11-17|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)|Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|24|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:34:18.054372|2018-05-31 23:34:18.054372
NCT01165255|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-06-06|2010-07-15|2010-07-19|Estimate|||||||2017-06-06|2017-06-07|Actual|June 2010||2010-06-30|June 2017|2017-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Bupropion and Specific Cardiovascular Malformations|Bupropion and Specific Cardiovascular Malformations|Completed|||7005|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:34:18.146904|2018-05-31 23:34:18.146904
NCT01165242|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2017-05-11|2011-04-13|2017-05-11|2010-07-15|2010-07-19|Estimate|2017-05-11|2017-06-08|Actual|2011-04-13|2011-04-26|Estimate|2017-05-11|2017-06-08|Actual|August 19, 2010||2010-08-19|October 2016|2016-10-31|July 29, 2011|Actual|2011-07-29|February 25, 2011|Actual|2011-02-25||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults|Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years|Completed||Phase 2|1005|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:34:18.309927|2018-05-31 23:34:18.309927
NCT01165229|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2017-05-09|2013-08-22|2018-01-08|2010-07-15|2010-07-19|Estimate|2017-11-10|2017-11-20|Actual|2013-08-22|2013-08-30|Estimate|2018-01-08|2018-02-01|Actual|August 2, 2010||2010-08-02|November 2017|2017-11-30|July 24, 2015|Actual|2015-07-24|July 24, 2015|Actual|2015-07-24||Interventional|||Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older|Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older|Completed||Phase 3|14819|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 23:34:19.260025|2018-05-31 23:34:19.260025
NCT01165216|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2014-06-23||2014-06-23|2010-07-16|2010-07-19|Estimate|2014-06-23|2014-07-22|Estimate||||2014-06-23|2014-07-22|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All participants who received at least 1 dose of study drug.|Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer|Phase 1 Study of Ipilimumab (BMS-734016) in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer|Completed||Phase 1|15|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 23:34:23.749246|2018-05-31 23:34:23.749246
NCT01165203|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2017-05-11|2013-04-11|2018-03-30|2010-07-15|2010-07-19|Estimate|2017-05-11|2017-06-07|Actual|2013-04-11|2013-04-18|Estimate|2018-03-30|2018-04-30|Actual|September 30, 2010|Actual|2010-09-30|October 2017|2017-10-31|May 14, 2013|Actual|2013-05-14|July 6, 2012|Actual|2012-07-06||Interventional|||Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects|Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A in Adult HIV-infected Subjects|Completed||Phase 2|123|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:34:24.479629|2018-05-31 23:34:24.479629
NCT01165190|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|May 2008||2008-05-31|July 2010|2010-07-31||||||||Observational|PIO||Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans|Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans|Unknown status|Recruiting||20|Anticipated|Arizona State University|||1||f||||f||||||Samples Without DNA|"~     Blood, urine, and adipose tissue will be collected.~   "|||2018-05-31 23:34:28.10934|2018-05-31 23:34:28.10934
NCT01165177|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2016-07-28|2013-08-22|2018-03-12|2010-07-15|2010-07-19|Estimate|2017-03-21|2017-05-01|Actual|2013-08-22|2013-08-30|Estimate|2018-03-12|2018-03-14|Actual|August 1, 2010||2010-08-01|March 2018|2018-03-31|July 27, 2015|Actual|2015-07-27|May 9, 2014|Actual|2014-05-09||Interventional|||Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older|Efficacy, Safety, and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older|Completed||Phase 3|16165|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 23:34:28.425416|2018-05-31 23:34:28.425416
NCT01165164|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2012-01-31|2010-07-16|2010-07-19|Estimate|||||||2012-01-31|2012-02-02|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||An Evaluation of the Nighttime Retention of Effect of an Investigational Lubricant Eye Drop (FID 115958D)||Completed||N/A|89|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:34:32.55266|2018-05-31 23:34:32.55266
NCT01165151|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2015-03-04|2010-07-16|2010-07-19|Estimate|||||||2015-03-04|2015-03-06|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Impact of Group Size in Weight Loss Interventions|Improving Weight Loss Maintenance Through Alternatives Schedules of Treatment|Completed||Phase 4|70|Anticipated|Florida State University||2|||f||||t||||||||||2018-05-31 23:34:32.741561|2018-05-31 23:34:32.741561
NCT01165138|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2013-05-30|2012-05-24|2018-01-18|2010-07-15|2010-07-19|Estimate|2013-05-30|2013-07-30|Estimate|2012-05-24|2012-05-31|Estimate|2018-01-18|2018-02-14|Actual|August 20, 2010||2010-08-20|January 2018|2018-01-31|October 19, 2011|Actual|2011-10-19|October 1, 2011|Actual|2011-10-01||Interventional|||Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics|HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents|Completed||Phase 3|612|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:34:32.880613|2018-05-31 23:34:32.880613
NCT01165125|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2017-06-07|2010-07-16|2010-07-19|Estimate|||||||2017-06-07|2017-06-08|Actual|July 1, 2010|Actual|2010-07-01|June 2017|2017-06-30|August 28, 2010|Actual|2010-08-28|August 28, 2010|Actual|2010-08-28||Interventional|||A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole|A Double-blind, Randomized, Placebo-controlled, Repeat Dose, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Administration of Fluticasone Furoate/GW642444M Inhalation Powder With Ketoconazole|Completed||Phase 1|18|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:34:34.058798|2018-05-31 23:34:34.058798
NCT01165112|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2017-04-17||2017-04-17|2010-07-16|2010-07-19|Estimate|2017-04-17|2017-05-25|Actual||||2017-04-17|2017-05-25|Actual|September 2010||2010-09-30|April 2017|2017-04-30||||June 2015|Actual|2015-06-30||Interventional|TREC||Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma|A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)|Active, not recruiting||Phase 1/Phase 2|48|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:34:34.262167|2018-05-31 23:34:34.262167
NCT01165099|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|August 2005||2005-08-31|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Acupuncture for Pain Relief During Induced Labour in Nulliparae|Acupuncture for Pain Relief During Induced Labour in Nulliparae: a Randomised Controlled Study|Completed||N/A|105|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 23:34:34.575405|2018-05-31 23:34:34.575405
NCT01165086|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2011-11-09|2010-07-16|2010-07-19|Estimate|||||||2011-11-09|2011-11-10|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Reducing Dietary Energy Density by Incorporating Vegetables in Order to Decrease Energy Intake||Completed||N/A|48|Actual|Penn State University|||||f||||||||||||||2018-05-31 23:34:34.65721|2018-05-31 23:34:34.65721
NCT01165073|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2011-02-27|2010-07-16|2010-07-19|Estimate|||||||2011-02-27|2011-03-01|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Short Term Feeding for Asian Patients With Liver Cirrhosis|Short Term Feeding for Hospitalised Asian Patients With Liver Cirrhosis - a Randomised Trial of Naso-gastric vs Oral Feeding|Completed||N/A|52|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 23:34:34.769913|2018-05-31 23:34:34.769913
NCT01165060|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2011-08-09|2010-07-16|2010-07-19|Estimate|||||||2011-08-09|2011-08-10|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|BEZA||The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)|Effect of Bezafibrate on Very Long Chain Fatty Acid Metabolism in Men With X-linked Adrenoleukodystrophy (X-ALD)|Completed||N/A|10|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 23:34:34.894535|2018-05-31 23:34:34.894535
NCT01165047|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2014-08-07||2014-08-21|2010-07-16|2010-07-19|Estimate|2014-08-21|2014-09-01|Estimate||||2014-08-21|2014-09-01|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Nitric Oxide, GeNO Nitrosyl Delivery System|An Open Label, Non-Randomized Pilot Study to Evaluate the Safety and Performance of the GeNO Nitrosyl Delivery System in Subjects Being Evaluated for Orthotopic Heart Transplantation (OHT), or Left Ventricular Assist Device (LVAD) Implantation|Completed||Phase 2|10|Actual|Aurora Health Care||1|||f||||t||||||||||2018-05-31 23:34:34.967227|2018-05-31 23:34:34.967227
NCT01165034|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2013-04-08|2010-07-16|2010-07-19|Estimate|||||||2013-04-08|2013-04-10|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Development of King's College Hospital Breathlessness Service|Development,Effectiveness and Cost-effectiveness of a New Respiratory and Palliative Care Out-patient Breathlessness Support Service|Unknown status|Active, not recruiting|Phase 3|110|Anticipated|King's College London||2|||f||||t||||||||||2018-05-31 23:34:35.164975|2018-05-31 23:34:35.164975
NCT01165021|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2014-04-23||2016-12-21|2010-07-16|2010-07-19|Estimate|2014-04-23|2014-05-21|Estimate||||2016-12-21|2017-02-14|Actual|November 2010||2010-11-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|July 2013|Actual|2013-07-31||Interventional||All participants who received at least 1 dose of chemotherapy.|A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer|An Exploratory Phase 2 Study of Pemetrexed/Cisplatin as Pre-operative Chemotherapy in the Treatment of Stage IIIAN2 Nonsquamous Non-Small Cell Lung Cancer|Completed||Phase 2|19|Actual|Eli Lilly and Company|Due to difficulties identifying suitable participants and enrollment delays, entries were closed after 26 of planned 33 participants signed consent. Results based on 19 participants who received ≥1 dose of chemotherapy. View results with caution.|1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:34:35.28167|2018-05-31 23:34:35.28167
NCT01165008|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|September 2003||2003-09-30|February 2005|2005-02-28|September 2008|Actual|2008-09-30|||||Interventional|||Anakinra in Myositis|Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies|Completed||Phase 2/Phase 3|||Karolinska Institutet|||||f||||f||||||||||2018-05-31 23:34:35.960266|2018-05-31 23:34:35.960266
NCT01164995|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2012-09-11|2010-07-16|2010-07-19|Estimate|||||||2012-09-11|2012-09-12|Estimate|July 2010||2010-07-31|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|M10MKO||Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer|Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line Treatment|Unknown status|Recruiting|Phase 2|21|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 23:34:36.022326|2018-05-31 23:34:36.022326
NCT01164982|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2015-04-27|2010-07-16|2010-07-19|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|November 2010|Anticipated|2010-11-30|August 2010|Anticipated|2010-08-31||Interventional|||Investigation Evaluating Handling of Mepitel® One Used in Acute Wounds in Home Care|An Open Non-controlled Proof of Concept Investigation Evaluating the Handling of a Soft Silicone Wound Contact Layer, Mepitel® One Used in Acute Wounds in Home Care|Withdrawn||N/A|0|Actual|Molnlycke Health Care AB||||No resources available at the clinic|f||||f||||||||||2018-05-31 23:34:36.130407|2018-05-31 23:34:36.130407
NCT01164969|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|November 2008||2008-11-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Observational|||Mixed Strain H. Pylori Infection in Patients Who Have Problems With Eradication of H. Pylori|Multi Locus Sequence Typing (MLST) Used as Tool to Confirm Ability of Susceptible Helicobacter Pylori Strains to Gain Resistance to Clarithromycin During Eradication Therapy Independently of Mixed Strain Helicobacter Pylori Infection|Completed|||10|Actual|University Medical Centre Ljubljana|||1||f||||t||||||Samples With DNA|"~     Isolated PBMC cell from patients, isolated H. pylori~   "|||2018-05-31 23:34:36.196263|2018-05-31 23:34:36.196263
NCT01164956|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2016-04-25|2010-07-15|2010-07-19|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Methylphenidate for Cancer-Related Fatigue|Methylphenidate for Cancer-Related Fatigue: A Pilot N-of-1 Study|Terminated||N/A|3|Actual|Dana-Farber Cancer Institute||2||Insufficient Resources|f||||t||||||||||2018-05-31 23:34:36.286138|2018-05-31 23:34:36.286138
NCT01164943|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2016-02-24|2010-07-16|2010-07-19|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Aneuploidy Rate and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH|Aneuploidy Rate Impact in Oocyte From Egg Donation Cycle With Different Stimulation Protocol: Recombinant FSH vs Human FSH|Terminated||N/A|80|Actual|IVI Madrid||2|||f||||f||||||||||2018-05-31 23:34:36.484|2018-05-31 23:34:36.484
NCT01164930|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-07-20|2010-07-16|2010-07-19|Estimate|||||||2011-07-20|2011-07-21|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|ACT||Impact of Acceptance and Commitment Therapy on Early Stage Breast Cancer|Impact of Acceptance and Commitment Therapy on Salivary Cortisol in Breast Cancer|Unknown status|Active, not recruiting|Phase 2/Phase 3|40|Anticipated|San Jose State University||2|||f||||f||||||||||2018-05-31 23:34:36.591937|2018-05-31 23:34:36.591937
NCT01164917|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2014-09-12|2010-07-15|2010-07-19|Estimate|||||||2014-09-12|2014-09-16|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled, Single Dose, Two-period, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of AMG 811 in Subjects With Discoid Lupus Erythematosus|Terminated||Phase 1|16|Actual|Amgen||2||"The 16 subjects enrolled in the study should enable Amgen to adequately assess safety and~   tolerabili"|f||||||||||||||2018-05-31 23:34:36.683893|2018-05-31 23:34:36.683893
NCT01164904|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2013-07-23|2010-07-15|2010-07-19|Estimate|||||||2013-07-23|2013-07-25|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis|A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis|Terminated||Phase 1|72|Actual|Amgen||1|||f||||||||||||||2018-05-31 23:34:36.811726|2018-05-31 23:34:36.811726
NCT01164891|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2015-07-29||2016-01-11|2010-07-16|2010-07-19|Estimate|2015-10-29|2015-12-08|Estimate||||2016-01-11|2016-02-05|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All enrolled participants were analyzed.|A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma|A Phase I, Open-label, Excretion Balance, Pharmacokinetic and Metabolism Study After Single Oral Dose of 14C-labeled RO5185426 in Previously Treated and Untreated Patients With Metastatic Melanoma|Completed||Phase 1|7|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:34:36.97819|2018-05-31 23:34:36.97819
NCT01164878|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2016-09-30|2010-07-16|2010-07-19|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Observational|||Cholestasis in Extreme Low Birth Weight Infants (ELBW)|Cholestasis in Extreme Low Birth Weight Infants (ELBW) - Possible Influences of a Change in Nutrition Policy|Completed|||122|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 23:34:37.475072|2018-05-31 23:34:37.475072
NCT01164865|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2012-09-13||2012-09-13|2010-07-16|2010-07-19|Estimate|2012-09-13|2012-10-12|Estimate||||2012-09-13|2012-10-12|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers|The Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers|Completed||N/A|78|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:34:37.552604|2018-05-31 23:34:37.552604
NCT01164852|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2012-08-13|2010-07-16|2010-07-19|Estimate|||||||2012-08-13|2012-08-14|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|MEXPRE-Latin||Aggressive Versus Expectant Management of Severe Preeclampsia Remote From Term|Expectant Management of Severe Preeclampsia at 28 to 33 Week`s Gestation:a Randomized Controlled Trial|Completed||N/A|264|Actual|Complejo Hospitalario Dr. Arnulfo Arias Madrid||2|||f||||f||||||||||2018-05-31 23:34:37.767129|2018-05-31 23:34:37.767129
NCT01164839|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Evaluation of the Factors Affecting the Diagnostic Performance of Coronary Computed Tomography Angiogram (CTA) With Multi-slice Computed Tomography (MSCT)|Evaluation of the Factors Affecting the Diagnostic Performance of Coronary CTA With MSCT: a National Multicenter Trial|Unknown status|Recruiting||1000|Anticipated|Capital Medical University|||||f||||f||||||||||2018-05-31 23:34:37.857034|2018-05-31 23:34:37.857034
NCT01164826|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's and Relafen® 750 mg Tablets of Glaxosmithkline, in Healthy Subjects Under Fed Conditions|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:37.991266|2018-05-31 23:34:37.991266
NCT01164813|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fasting Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's and Relafen® 750 mg Tablets of Glaxosmithkline, in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:38.100089|2018-05-31 23:34:38.100089
NCT01164800|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|May 2006|Actual|2006-05-31|April 2006|Actual|2006-04-30||Interventional|||Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healthy, Adult, Human Subjects Under Fed Conditions|Completed||Phase 1|52|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:38.347626|2018-05-31 23:34:38.347626
NCT01164787|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|May 2006|Actual|2006-05-31|April 2006|Actual|2006-04-30||Interventional|||Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|52|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:38.474631|2018-05-31 23:34:38.474631
NCT01164774|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|October 2005||2005-10-31|July 2010|2010-07-31|November 2005|Actual|2005-11-30|October 2005|Actual|2005-10-31||Interventional|||Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions|A Two-way Open Label Crossover Experimental Evaluation of Relative Bioavailabilities of Ramipril 10 mg Capsules of Dr.Reddy's Laboratories and ALTACE@ 10 mg Capsules of King Pharmaceuticals in Healthy Adult Human Male Subjects Under Non-fasting Conditions|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:38.575864|2018-05-31 23:34:38.575864
NCT01164761|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|September 2005||2005-09-30|July 2010|2010-07-31|October 2005|Actual|2005-10-31|September 2005|Actual|2005-09-30||Interventional|||Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions|A Two-way Open Label Crossover Experimental Evaluation of Relative Bioavailabilities of Ramipril 10 mg Capsules of Dr.Reddy's Laboratories and ALTACE@ 10 mg Capsules of King Pharmaceuticals in Healthy Adult Human Male Subjects Under Fasting Conditions|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:34:38.653025|2018-05-31 23:34:38.653025
NCT01164748|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate||||July 2010|2010-07-31||||||||Observational|LABS||Lymphatic Mapping After Previous Breast Surgery|Lymphatic Mapping After Previous Breast Surgery|Completed|||||Catharina Ziekenhuis Eindhoven|||2||f||||||||||||||2018-05-31 23:34:38.790149|2018-05-31 23:34:38.790149
NCT01164735|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2015-06-03|2010-07-16|2010-07-19|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2100||2100-01-31|June 2015|2015-06-30||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression as Well as Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated With Anthracycline-Based Therapy|Not yet recruiting|||169|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 23:34:38.84984|2018-05-31 23:34:38.84984
NCT01164722|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|2016-09-09||2016-12-21|2010-07-16|2010-07-19|Estimate|2016-09-09|2016-10-31|Estimate||||2016-12-21|2017-02-13|Actual|April 2011||2011-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional||Enrolled participants|Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia|A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults|Completed||Phase 3|120|Actual|AIDS Malignancy Consortium||2|||f||||t||||||||No||2018-05-31 23:34:38.937865|2018-05-31 23:34:38.937865
NCT01164709|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2014-01-31|2010-07-16|2010-07-19|Estimate|||||||2014-01-31|2014-02-03|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Interventional|||Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer|Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies|Completed||Phase 1|18|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-05-31 23:34:39.426705|2018-05-31 23:34:39.426705
NCT01164696|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2010-08-23|2010-07-16|2010-07-19|Estimate|||||||2010-08-23|2010-08-24|Estimate|August 2007||2007-08-31|August 2010|2010-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin|A Prospective Observational Study to Evaluate Quality of Life and Costs in a Real Life Setting in Patients Treated With 90Y-Zevalin|Completed|||30|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:34:39.526241|2018-05-31 23:34:39.526241
NCT01164683|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2015-04-06|2010-07-15|2010-07-19|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CPAPPs||A Pilot Study of CPAP Adherence Promotion by Peer Buddies With Sleep Apnea|A Pilot Study of CPAP Adherence Promotion by Peer Buddies With Sleep Apnea|Completed||N/A|60|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:34:39.597588|2018-05-31 23:34:39.597588
NCT01164670|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2015-10-01|2010-07-15|2010-07-19|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|Jump||Evaluation of the Reproducibility of Jumping Mechanography|Evaluation of the Reproducibility of Jumping Mechanography in Older Adults and Comparison With Current Functional Assessment Tools|Completed|||96|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||Samples Without DNA|"~     Serum will be collected for measurement of laboratory studies (serum chemistries, TSH and~     25[OH]D),~   "|||2018-05-31 23:34:39.699518|2018-05-31 23:34:39.699518
NCT01164657|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2010-07-16|2010-07-16|2010-07-19|Estimate|||||||2010-07-16|2010-07-19|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Swedish Trial of Birth on a Birthing Seat|A Swedish Randomized Controlled Trial of Birth on a Birthing Seat|Completed||N/A|68|Actual|Helsingborgs Hospital||2|||f||||f||||||||||2018-05-31 23:34:39.760515|2018-05-31 23:34:39.760515
NCT01164644|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2012-12-26||2017-04-11|2010-07-15|2010-07-16|Estimate|2013-03-20|2013-05-03|Estimate||||2017-04-11|2017-05-17|Actual|June 2010||2010-06-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery|The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery|Completed||N/A|28|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 23:34:39.834295|2018-05-31 23:34:39.834295
NCT01164631|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2012-06-21|2010-07-15|2010-07-16|Estimate|||||||2012-06-21|2012-06-22|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Interventional|||Pharyngeal Size in Patients With Obstructive Tonsils Under Orthodontic Treatment|Improvement of Pharyngeal Size in Patients With Obstructive Tonsils Treated With Bioajusta X Orthodontic Appliance - Randomized Clinical Trial|Completed||Phase 4|40|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 23:34:40.071173|2018-05-31 23:34:40.071173
NCT01164618|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2013-08-14|2010-07-15|2010-07-16|Estimate|||||||2013-08-14|2013-08-15|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|February 2013|Actual|2013-02-28||Interventional|||The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response|The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response|Unknown status|Active, not recruiting|Phase 2|12|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:34:40.16401|2018-05-31 23:34:40.16401
NCT01164605|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2012-05-16|2010-07-15|2010-07-16|Estimate|||||||2012-05-16|2012-05-18|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Pilot Study of Raltegravir Lipodystrophy IISP|Pilot Study on the Efficacy of a Two Drug, Raltegravir-based Regimen,(NRTI) Sparing Antiretroviral Treatment|Unknown status|Recruiting|N/A|30|Anticipated|Southern California Institute for Research and Education|||||f||||f||||||||||2018-05-31 23:34:40.247317|2018-05-31 23:34:40.247317
NCT01164592|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2015-08-04|2010-07-15|2010-07-16|Estimate|||||||2015-08-04|2015-08-07|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|MS||Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation|SERVE-HF: Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation|Completed||Phase 4|312|Actual|ResMed||2|||f||||t||||||||||2018-05-31 23:34:40.328736|2018-05-31 23:34:40.328736
NCT01164579|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2014-11-05||2015-04-21|2010-07-15|2010-07-16|Estimate|2015-04-21|2015-04-22|Estimate||||2015-04-21|2015-04-22|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Full Analysis Set (FAS): all participants who were randomized to study medication and received at least 1 dose of randomized study medication.|Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)|An Exploratory Phase 2, Randomized, Double-blind, Multicenter Study To Assess The Effects Of Tofacitinib (Cp-690,550) On Magnetic Resonance Imaging Endpoints, In Methotrexate Naive Subjects With Early Active Rheumatoid Arthritis|Completed||Phase 2|109|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 23:34:40.595507|2018-05-31 23:34:40.595507
NCT01164566|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2017-05-25|2010-07-15|2010-07-16|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2010||2010-12-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy|Prospective Evaluation of Esophageal Pathology Treatment of Head and Neck Carcinoma|Terminated||N/A|6|Actual|Wake Forest University Health Sciences||1||Inadequate Recruitment|f||||f|f|f||||||||2018-05-31 23:34:42.744308|2018-05-31 23:34:42.744308
NCT01164553|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2013-04-25|2010-07-15|2010-07-16|Estimate|||||||2013-04-25|2013-04-29|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Comparison of Flu Vaccine Doses in Children|A Randomized, Double-Blind, Phase I Study Comparing an Increased Dose(s) (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) With Standard Dose(s) (0.25 ml) TIV in Children 6-35 Months of Age|Completed||Phase 1|243|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 23:34:42.948694|2018-05-31 23:34:42.948694
NCT01164540|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-12-09|2010-07-15|2010-07-16|Estimate|||||||2010-12-09|2010-12-10|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|Du Lac||Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis|A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism|Withdrawn||Phase 3|3000|Anticipated|AstraZeneca||2||Due to discussion regarding the design of the study.|f||||f||||||||||2018-05-31 23:34:43.029813|2018-05-31 23:34:43.029813
NCT01164527|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2016-05-05|2010-07-15|2010-07-16|Estimate|||||||2016-05-05|2016-05-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:34:43.096351|2018-05-31 23:34:43.096351
NCT01164514|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2014-01-30|2010-07-15|2010-07-16|Estimate|||||||2014-01-30|2014-01-31|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant|A Randomized, Partial-Blinded, Placebo-Controlled, Phase I Safety and Immunogenicity Study in Healthy Subjects of Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram Negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant|Terminated||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 23:34:43.133219|2018-05-31 23:34:43.133219
NCT01164501|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2014-05-16||2014-05-16|2010-07-15|2010-07-16|Estimate|2014-05-16|2014-06-16|Estimate||||2014-05-16|2014-06-16|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Baseline characteristics are presented for treated patients only.|Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg and 25 mg Administered Once Daily) as Add on to Pre-existing Antidiabetic Therapy Over 52 Weeks in Patients With Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycaemic Control|Completed||Phase 3|741|Actual|Boehringer Ingelheim|In this trial, only patients with mild or moderate renal impairment were analysed. Patients with severe or no renal impairment were not analysed.|3|||f||||||||||||||2018-05-31 23:34:43.227277|2018-05-31 23:34:43.227277
NCT01164488|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2016-08-26|2010-07-15|2010-07-16|Estimate|||||||2016-08-26|2016-08-29|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of RO5190591 (Danoprevir) in Healthy Volunteers|A Two-Way Interaction Study Between RO5190591/RTV and Ketoconazole in Healthy Subjects|Completed||Phase 1|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:34:45.05109|2018-05-31 23:34:45.05109
NCT01162798|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2014-11-03|2010-07-14|2010-07-15|Estimate|||||||2014-11-03|2014-11-04|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|October 2013|Actual|2013-10-31||Interventional|||Preterm Infant Growth|Growth of Preterm Infants Consuming Formula|Completed||N/A|150|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 23:35:20.64113|2018-05-31 23:35:20.64113
NCT01164475|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2013-12-12||2014-02-07|2010-07-15|2010-07-16|Estimate|2013-12-12|2014-01-31|Estimate||||2014-02-07|2014-02-25|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Full analysis set (FAS) included all randomized patients who signed informed consent form and received at least one dose of plerixafor.|Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms|A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg|Completed||Phase 4|61|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:34:45.145198|2018-05-31 23:34:45.145198
NCT01164462|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2012-12-26|2010-07-15|2010-07-16|Estimate|||||||2012-12-26|2012-12-27|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|DRAG||Feasibility and Limitations of Offering Community Based Rapid HIV Testing to Men Who Have Sex With Men (MSM)||Completed||N/A|357|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3|||f||||f||||||||||2018-05-31 23:34:46.675717|2018-05-31 23:34:46.675717
NCT01164449|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-08-17|2010-07-15|2010-07-16|Estimate|||||||2011-08-17|2011-08-18|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|DELIOS 4||Usability of Blood Glucose Control With the Space TGC System in Medical ICU Patients|Monocentric, Open Study to Investigate the Usability of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) Over a Glucose Control Range of 4.4 to 8.3 mmol/L in Medical ICU Patients|Completed||N/A|20|Anticipated|B. Braun Melsungen AG||1|||f||||f||||||||||2018-05-31 23:34:46.767426|2018-05-31 23:34:46.767426
NCT01164436|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2017-10-31|2010-07-15|2010-07-16|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2008||2008-06-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2015|Actual|2015-06-30||Observational|ANRS CO16||Cohort of HIV Associated Lymphomas|French Cohort of HIV Associated Lymphomas|Completed|||205|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||||2018-05-31 23:34:46.846644|2018-05-31 23:34:46.846644
NCT01164423|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2011-02-08|2010-07-15|2010-07-16|Estimate|||||||2011-02-08|2011-02-09|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|DELIOS 01||Feasibility of Blood Glucose Control With the Space TGC System in Medical ICU Patients|Monocentric, Open Study to Investigate the Feasibility of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) in Medical ICU Patients|Completed||N/A|20|Anticipated|B. Braun Melsungen AG||1|||f||||f||||||||||2018-05-31 23:34:46.930778|2018-05-31 23:34:46.930778
NCT01164410|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2017-10-20|2010-07-15|2010-07-16|Estimate|||||||2017-10-20|2017-10-24|Actual|August 2009||2009-08-31|October 2017|2017-10-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children|The Efficacy Side Effects and the Tolerance of Polyethylene Glycol 3350 as a Bowel Prep in Children|Completed|||45|Actual|The Cleveland Clinic|||1||f||||f||||||||||2018-05-31 23:34:47.010875|2018-05-31 23:34:47.010875
NCT01164397|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2012-01-17|2010-07-15|2010-07-16|Estimate|||||||2012-01-17|2012-01-18|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|December 2010|Actual|2010-12-31|||||Observational|||Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients|Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin to Reduce the Cholesterol Levels in Outpatients in a Realistic Environment. A Retrospective Study|Completed|||268|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:34:47.105877|2018-05-31 23:34:47.105877
NCT01164384|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-15|2010-07-15|2010-07-16|Estimate|||||||2010-07-15|2010-07-16|Estimate|October 2010||2010-10-31|July 2010|2010-07-31|February 2013||2013-02-28|||||Interventional|||A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.||Unknown status|Not yet recruiting|Phase 1|||University of Zurich|||||f||||||||||||||2018-05-31 23:34:47.291468|2018-05-31 23:34:47.291468
NCT01164371|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2016-05-11|2010-07-15|2010-07-16|Estimate|||||||2016-05-11|2016-05-12|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|November 2013|Actual|2013-11-30|September 2012|Actual|2012-09-30||Observational|||Gender Differences in the Development, Treatment and Prognosis of Coronary Disease: A CALIBER Study|Gender Differences in the Development and Prognosis of Coronary Disease Where Initial Disease Manifestation is Stable Angina, Myocardial Infarction or Unheralded Coronary Death: A CALIBER Study Using Linked GPRD-MINAP Data|Completed|||1758584|Actual|University College, London|||4||f||||t||||||||No|Permissions to used anonymised linked data from data owners prohibit further sharing of the data|2018-05-31 23:34:47.374323|2018-05-31 23:34:47.374323
NCT01164358|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2013-10-18|2010-07-15|2010-07-16|Estimate|||||||2013-10-18|2013-10-21|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Observational|||Long Term Observation of Patient Satisfaction Post INTRACOR Treatment Based on Patient Perception and Diagnostic Data|Long Term Observation of Patient Satisfaction Post INTRACOR Treatment Based on Patient Perception and Diagnostic Data|Completed|||105|Actual|Technolas Perfect Vision GmbH|||2||f||||t||||||||||2018-05-31 23:34:47.448358|2018-05-31 23:34:47.448358
NCT01164345|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-12-01|2010-07-15|2010-07-16|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Mozobil for Autologous Stem Cell Mobilization|Plerixafor (Plerixafor AMD 3100) + Recombinant Human G-CSF (rhG-CSF) for Autologous Peripheral Blood Stem Cell Transplantation (AutoSCT) in Hard to Mobilise Patients: a Phase IIB Study|Completed||Phase 2|20|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 23:34:47.537708|2018-05-31 23:34:47.537708
NCT01164332|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2015-06-09|2010-07-15|2010-07-16|Estimate|||||||2015-06-09|2015-06-10|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Sensitivity of Alternative NRL972 Detection Methods in Healthy Subjects|Investigation of the Sensitivity of Different Methods to Detect NRL972 in Healthy Volunteers During and After a 2-hour Intravenous Infusion of 10 and 30mg NRL972|Completed||Phase 1|32|Actual|Norgine||2|||f||||f||||||||||2018-05-31 23:34:47.630255|2018-05-31 23:34:47.630255
NCT01164319|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2012-04-23|2010-07-15|2010-07-16|Estimate|||||||2012-04-23|2012-04-24|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|November 2010|Actual|2010-11-30|February 2010|Actual|2010-02-28||Interventional|||"UNMASKING Study For Atrial Fibrillation Recurrences Typing in Early Postoperative Period"|Typing of the Atrial Fibrillation Recurrences in Early Postoperative Period After Pulmonary Veins Isolation Through Continous Subcutaneous Monitoring.|Completed||Phase 3|150|Actual|Meshalkin Research Institute of Pathology of Circulation||4|||f||||t||||||||||2018-05-31 23:34:47.713145|2018-05-31 23:34:47.713145
NCT01164306|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-01-29|2010-07-15|2010-07-16|Estimate|||||||2015-01-29|2015-02-02|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2012|Actual|2012-05-31||Interventional|||The Impact of a Tobacco Control Intervention in African-American Families|The Impact of a Tobacco Control Intervention in African-American Families|Completed||N/A|688|Actual|Augusta University||2|||f||||t||||||||||2018-05-31 23:34:47.805607|2018-05-31 23:34:47.805607
NCT01164293|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2015-09-17|2010-07-15|2010-07-16|Estimate|||||||2015-09-17|2015-09-18|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|APT||Atopy Patch Test in Children With Food Allergy-related Gastrointestinal Symptoms|Prevalence of Positive Reactions in Atopy Patch Test in Children With Food Allergy-related Gastrointestinal Symptoms|Completed||Phase 1|40|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 23:34:47.911457|2018-05-31 23:34:47.911457
NCT01164280|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-15|2010-07-15|2010-07-16|Estimate|||||||2010-07-15|2010-07-16|Estimate|July 2008||2008-07-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Pulse Rate Changes on Clinical Outcome|The Effect of Pulse Rate Changes on Clinical Outcome in Sacral Neuromodulation|Completed||N/A|50|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 23:34:47.993986|2018-05-31 23:34:47.993986
NCT01164267|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2013-11-21|2010-07-15|2010-07-16|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2010||2010-03-31|May 2012|2012-05-31||||December 2012|Actual|2012-12-31||Interventional|||Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)|A Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus (RAD001) in Marginal Zone B-cell Lymphomas (MZL) EudraCT Number 2009-011725-14|Completed||Phase 2|30|Actual|International Extranodal Lymphoma Study Group (IELSG)|||||f||||t||||||||||2018-05-31 23:34:48.074006|2018-05-31 23:34:48.074006
NCT01164254|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2018-05-18|2010-07-15|2010-07-16|Estimate|||||||2018-05-18|2018-05-21|Actual|May 28, 2008||2008-05-28|November 30, 2016|2016-11-30|November 30, 2016||2016-11-30|||||Observational|||Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-hour Recall|Feasibility Study of a Web-Based Automated Self-Administered 24-hour Dietary Recall (ASA 24) and a Physical Activity 24-Hour Recall (ACT24)|Completed|||627|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:34:48.149863|2018-05-31 23:34:48.149863
NCT01164241|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2018-03-27|2010-07-15|2010-07-16|Estimate|||||||2018-03-27|2018-03-29|Actual|June 22, 2010||2010-06-22|December 19, 2017|2017-12-19||||||||Observational|||Natural History of Diseases Associated With Allergic Inflammation: Atopic Dermatitis and Genetic and Congenital Diseases Associated With Atopic Pathways|Natural History of Atopic Dermatitis and Other Genetic/Congenital Diseases Associated With Allergic Inflammation|Recruiting|||1650|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:34:48.209792|2018-05-31 23:34:48.209792
NCT01164228|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2017-12-12|2010-07-15|2010-07-16|Estimate|||||||2017-12-12|2017-12-14|Actual|June 17, 2010|Actual|2010-06-17|December 2017|2017-12-31|May 31, 2023|Anticipated|2023-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery|A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features|Active, not recruiting||Phase 2|100|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-05-31 23:34:48.325853|2018-05-31 23:34:48.325853
NCT01164215|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2015-10-07|2010-07-15|2010-07-16|Estimate|||||||2015-10-07|2015-10-09|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|September 2013|Actual|2013-09-30|November 2012|Actual|2012-11-30||Interventional|||Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy|Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab|Completed||Phase 1|76|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:34:48.658293|2018-05-31 23:34:48.658293
NCT01164202|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2016-12-27|2010-07-15|2010-07-16|Estimate|||||||2016-12-27|2016-12-28|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SATURNE||Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer|A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)|Active, not recruiting||Phase 2/Phase 3|190|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||f||||||||||2018-05-31 23:34:48.7642|2018-05-31 23:34:48.7642
NCT01164189|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2016-10-11|2010-07-15|2010-07-16|Estimate|||||||2016-10-11|2016-10-12|Estimate|February 2011||2011-02-28|October 2016|2016-10-31||||June 2017|Anticipated|2017-06-30||Interventional|TAVAREC||Bevacizumab in Recurrent Grade II and III Glioma|Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial|Active, not recruiting||Phase 2|144|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 23:34:48.921291|2018-05-31 23:34:48.921291
NCT01164176|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2014-11-26|2010-07-15|2010-07-16|Estimate|||||||2014-11-26|2014-12-02|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer|An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer|Completed||Phase 2|40|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 23:34:49.113414|2018-05-31 23:34:49.113414
NCT01164163|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2014-10-22|2010-07-15|2010-07-16|Estimate|||||||2014-10-22|2014-10-23|Estimate|September 2010||2010-09-30|October 2014|2014-10-31||||October 2014|Actual|2014-10-31||Interventional|||INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease|A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms|Completed||Phase 1|49|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 23:34:49.217006|2018-05-31 23:34:49.217006
NCT01164150|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2017-05-02|2010-07-15|2010-07-16|Estimate|||||||2017-05-02|2017-05-04|Actual|March 2010||2010-03-31|May 2017|2017-05-31|December 2033|Anticipated|2033-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06|Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer|Recruiting||Phase 2|154|Anticipated|Cancer Trials Ireland||2|||f||||||||||||||2018-05-31 23:34:49.355289|2018-05-31 23:34:49.355289
NCT01162278|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2018-01-22|2010-07-13|2010-07-14|Estimate|||||||2018-01-22|2018-01-23|Actual|July 2010|Actual|2010-07-31|January 2018|2018-01-31|November 25, 2017|Actual|2017-11-25|November 25, 2015|Actual|2015-11-25||Interventional|||Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases|Dose Escalating Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases|Completed||Phase 1|60|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 23:35:27.430251|2018-05-31 23:35:27.430251
NCT01164137|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2012-07-19||2013-02-12|2010-07-15|2010-07-16|Estimate|2012-12-18|2013-01-30|Estimate||||2013-02-12|2013-02-15|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CMR||Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care|Eliminating Risk of Preventable Adverse Drug Events at the Hospital-community Interface of Care: to Develop and Test a Community-based Medication Reconciliation Program and a Risk Prediction Model That Identifies High-risk Patient Groups|Completed||N/A|156|Actual|Westview Physician Collaborative||2|||f||||t||||||||||2018-05-31 23:34:49.471228|2018-05-31 23:34:49.471228
NCT01164124|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-15|2010-07-15|2010-07-16|Estimate|||||||2010-07-15|2010-07-16|Estimate|February 2008||2008-02-29|July 2010|2010-07-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|PAS||Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants|Probiotics-Supplemented Feeding in Extremely Low Birth Weight Infants|Completed||Phase 2/Phase 3|101|Actual|Vermont Oxford Network||2|||f||||t||||||||||2018-05-31 23:34:49.735474|2018-05-31 23:34:49.735474
NCT01164111|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-10-08|2010-07-15|2010-07-16|Estimate|||||||2015-10-08|2015-10-12|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Preoperative Resistance Training in Patients Scheduled for Total Hip Arthroplasty|Preoperative Resistance Training in Patients Scheduled for Total Hip Arthroplasty - a Prospective Randomized Study in Patients With Osteoarthritis|Completed||N/A|80|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 23:34:49.802482|2018-05-31 23:34:49.802482
NCT01164098|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15||2017-08-16|2017-08-25|2010-07-15|2010-07-16|Estimate||||2017-08-18|2017-08-22|Actual|2017-08-25|2017-08-29|Actual|February 2012||2012-02-29|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Rituximab to Prevent Recurrence of Proteinuria|The Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGS|Terminated||Phase 3|43|Actual|University of Miami||2||Voluntarily terminated by PI due to lack of feasibility.|f||||f||||||||||2018-05-31 23:34:49.895306|2018-05-31 23:34:49.895306
NCT01164085|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-12-30|2010-07-15|2010-07-16|Estimate|||||||2013-12-30|2013-12-31|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|INCITE||Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study|Intravitreal Ketorolac for Chronic Uveitis:A Phase I Investigational Safety Study|Completed||Phase 1|10|Actual|Vanderbilt University||1|||f||||f||||||||||2018-05-31 23:34:50.027929|2018-05-31 23:34:50.027929
NCT01164072|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2013-01-07|2010-07-15|2010-07-16|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette)|Randomised Controlled Trial Investigating the Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) in Smokers|Completed|||100|Actual|Universita degli Studi di Catania|||1||f||||t||||||||||2018-05-31 23:34:50.210171|2018-05-31 23:34:50.210171
NCT01164059|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2015-06-19|2010-07-15|2010-07-16|Estimate|||||||2015-06-19|2015-06-22|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|NeSSy||Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia|Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia|Completed||Phase 4|149|Actual|University of Bremen||2|||f||||t||||||||||2018-05-31 23:34:50.295328|2018-05-31 23:34:50.295328
NCT01164046|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2014-12-02|2010-07-15|2010-07-16|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Longheva||Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism|Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism|Terminated||Phase 3|56|Actual|University Medical Center Groningen||2||Due to slow inclusion of patients|f||||t||||||||||2018-05-31 23:34:50.41314|2018-05-31 23:34:50.41314
NCT01164033|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2016-11-01|2010-07-15|2010-07-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of RO5045337 in Patients With Solid Tumors|An Open-Label, Randomized 3-Way Crossover, Study to Examine the Food-Effect on Pharmacokinetics of the Current Formulation and Relative Bioavailability of Two New Formulations for RO5045337 in Patients With Solid Tumors Including Lymphoma|Completed||Phase 1|76|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:34:50.546075|2018-05-31 23:34:50.546075
NCT01164020|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2013-01-17|2010-07-15|2010-07-16|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Creatine Supplementation and Cognition||Completed||N/A|56|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 23:34:50.627792|2018-05-31 23:34:50.627792
NCT01164007|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2017-03-10||2017-03-10|2010-07-15|2010-07-16|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|June 30, 2006|Actual|2006-06-30|March 2017|2017-03-31|May 31, 2012|Actual|2012-05-31|May 31, 2012|Actual|2012-05-31||Interventional||Safety Population: All participants who signed the Informed Consent Form (ICF) and received at least one dose of study medications.|A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma|Phase II Study of Dacarbazine With the Anti-Vascular Endothelial Growth Factor Antibody (Bevacizumab) in Patients With Unresectable/Metastatic Melanoma|Completed||Phase 2|40|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:34:50.728151|2018-05-31 23:34:50.728151
NCT01163994|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2017-05-04|2010-07-15|2010-07-16|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2010||2010-06-30|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Antibiotic Treatment of Multiple Erythema Migrans|Comparison of Ceftriaxone and Doxycycline for Treatment of Multiple Erythema Migrans|Recruiting||N/A|500|Anticipated|University Medical Centre Ljubljana||4|||f||||f||||||||||2018-05-31 23:34:51.015282|2018-05-31 23:34:51.015282
NCT01163981|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2011-07-14|2010-07-15|2010-07-16|Estimate|||||||2011-07-14|2011-07-15|Estimate|November 2011||2011-11-30|July 2010|2010-07-31|August 2012|Anticipated|2012-08-31|May 2012|Anticipated|2012-05-31||Interventional|||Ultrasound Guided Cannulation of Dialysis Fistulas|A Randomised Controlled Trial of the Effectiveness of Ultrasound Guidance in Cannulation of Dialysis Arteriovenous Fistulas and Grafts in a University Hospital Dialysis Unit|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|University of Hull||2|||f||||f||||||||||2018-05-31 23:34:51.104155|2018-05-31 23:34:51.104155
NCT01163968|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2014-12-05|2010-07-15|2010-07-16|Estimate|||||||2014-12-05|2014-12-08|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|MOMENTUM||Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM)|Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM)|Completed||N/A|50|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 23:34:51.185357|2018-05-31 23:34:51.185357
NCT01163955|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|2011-06-02||2011-10-25|2010-07-15|2010-07-16|Estimate|2011-08-24|2011-09-30|Estimate||||2011-10-25|2011-11-02|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||A Postural Study Comparing Sitting on the Floor Versus Sitting in a Chair While Playing Video Games.|A Postural Analysis of Children Playing Video Games Sitting on the Floor vs. Sitting in a Chair: A Randomised Controlled Trial|Completed||N/A|56|Actual|Glinn and Giordano Physical Therapy||2|||f||||f||||||||||2018-05-31 23:34:51.259518|2018-05-31 23:34:51.259518
NCT01163942|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2015-04-02|2010-07-15|2010-07-16|Estimate|||||||2015-04-02|2015-04-03|Estimate|March 2001||2001-03-31|July 2010|2010-07-31|November 2010|Actual|2010-11-30|June 2008|Actual|2008-06-30||Interventional|SAA-G-CSF||Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)|A RANDOMIZED CONTROLLED STUDY IN NEWLY DIAGNOSED SEVERE APLASTIC ANEMIA PATIENTS RECEIVING ANTITHYMOCYTE GLOBULIN (ATG), CYCLOSPORIN A, WITH OR WITHOUT G-CSF|Terminated||Phase 3|205|Actual|European Group for Blood and Marrow Transplantation||4||"Ceased production of the study drug, Lymphoglobulin. Recruitment of patients onto the trial was~   too slow."|f||||t||||||||||2018-05-31 23:34:51.47055|2018-05-31 23:34:51.47055
NCT01163929|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2012-10-22|2010-07-15|2010-07-16|Estimate|||||||2012-10-22|2012-10-24|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer|A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer|Withdrawn||Phase 2|0|Actual|University of Kansas Medical Center||1||Study closed by Protocol Review Monitoring Committee because of lack of accrual|f||||t||||||||||2018-05-31 23:34:51.616438|2018-05-31 23:34:51.616438
NCT01163916|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2012-11-08||2012-12-05|2010-07-15|2010-07-16|Estimate|2012-11-08|2012-12-05|Estimate||||2012-12-05|2012-12-07|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care|A Multi-Center Post Marketing Observational Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed HUMIRA® (Adalimumab) as Part of Routine Clinical Care in Russia|Completed|||252|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:34:51.705452|2018-05-31 23:34:51.705452
NCT01163903|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2015-07-14|2010-07-14|2010-07-16|Estimate|||||||2015-07-14|2015-07-15|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Interventional|||Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours|A Phase I Study Evaluating the Proton Pump Inhibitor Pantoprazole in Combination With Doxorubicin for Advanced Cancer Patients With an Extension Cohort of Patients With Solid Tumours|Completed||Phase 1|24|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 23:34:52.334289|2018-05-31 23:34:52.334289
NCT01163890|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2014-04-07|2010-07-14|2010-07-16|Estimate|||||||2014-04-07|2014-04-08|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Preventing Mid- and Later-Life Work Limitations|Preventing Mid- and Later-Life Work Limitations: Community-Based Depression Care|Completed||N/A|431|Actual|Tufts Medical Center||2|||f||||f||||||||||2018-05-31 23:34:52.415117|2018-05-31 23:34:52.415117
NCT01163877|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2013-10-11|2010-07-15|2010-07-16|Estimate|||||||2013-10-11|2013-10-14|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma|Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma.|Completed||N/A|43|Actual|Swiss Federal Institute of Technology||4|||f||||f||||||||||2018-05-31 23:34:52.56943|2018-05-31 23:34:52.56943
NCT01163864|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2011-03-07|2010-07-15|2010-07-16|Estimate|||||||2011-03-07|2011-03-09|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Affect Regulation Training for Pregnant Smokers|Affect Regulation Training for Pregnant Smokers|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|State University of New York at Buffalo||2|||f||||t||||||||||2018-05-31 23:34:52.750536|2018-05-31 23:34:52.750536
NCT01163851|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2015-04-20||2018-01-31|2010-07-14|2010-07-16|Estimate|2015-04-20|2015-05-07|Estimate||||2018-01-31|2018-03-01|Actual|July 2010|Actual|2010-07-31|January 2018|2018-01-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional||Full analysis set included all participants who met the study enrollment criteria and received any amount of study medication.|Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin|A Phase 1 Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Rn316 In Combination With Atorvastatin In Hypercholesterolemic Subjects|Completed||Phase 1|25|Actual|Pfizer|All determinations of primary or secondary outcomes were arbitrary as study did not specify primary or secondary outcome measures.|1|||f||||f||||||||||2018-05-31 23:34:52.934824|2018-05-31 23:34:52.934824
NCT01163838|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2015-04-21|2010-07-15|2010-07-16|Estimate|||||||2015-04-21|2015-04-23|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of RN316 In Healthy Adult Subjects With Hypercholesterolemia|Withdrawn||Phase 1|0|Actual|Pfizer||7||Study was redesigned based on FDA feedback.|f||||f||||||||||2018-05-31 23:34:55.108186|2018-05-31 23:34:55.108186
NCT01163825|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-15|2010-07-15|2010-07-16|Estimate|||||||2010-07-15|2010-07-16|Estimate|January 2008||2008-01-31|July 2010|2010-07-31||||December 2011|Anticipated|2011-12-31||Interventional|NsG0202||Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients|An Open Label, Dose-Escalation Study of Encapsulated Cell Biodelivery of Nerve Growth Factor to the Cholinergic Basal Forebrain of Alzheimer´s Disease Patients|Unknown status|Active, not recruiting|Phase 1|6|Actual|NsGene A/S||2|||f||||t||||||||||2018-05-31 23:34:55.232234|2018-05-31 23:34:55.232234
NCT01163812|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-15|||2010-07-16|2010-07-15|2010-07-16|Estimate|||||||2010-07-16|2010-07-19|Estimate|April 2006||2006-04-30|July 2010|2010-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|NCC181||Clinical Trial for Laparoscopic D2 Gastrectomy|A Phase-II Clinical Trial of Laparoscopy-Assisted Distal Gastrectomy With D2 Lymph Node Dissection for Gastric Cancer|Completed||Phase 2|64|Actual|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 23:34:55.350399|2018-05-31 23:34:55.350399
NCT01153477|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-03-28|2010-06-29|2010-06-30|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2009||2009-10-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|EETDD||Effectiveness of Enhanced Treatments for Drug Dependence|Effectiveness of an Enhanced Adaptive Continuing Care Model for Cocaine Dependence|Completed||Phase 2|150|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 23:38:07.615407|2018-05-31 23:38:07.615407
NCT01163799|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2013-05-01|2010-07-15|2010-07-16|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|September 2011|Actual|2011-09-30||Interventional|||A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients|A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients|Terminated||Phase 1|9|Actual|Northwestern University||1||Noted increased risks, greater than expected for standard of care therapy.|f||||t||||||||||2018-05-31 23:34:55.43415|2018-05-31 23:34:55.43415
NCT01163786|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2018-01-09|2010-07-15|2010-07-16|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2010||2010-07-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD|A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD|Active, not recruiting||Phase 2|20|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 23:34:55.534109|2018-05-31 23:34:55.534109
NCT01163773|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-15|2010-07-15|2010-07-16|Estimate|||||||2010-07-15|2010-07-16|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|June 2006|Actual|2006-06-30|December 2005|Actual|2005-12-31||Interventional|MILK||Milk Consumption and the Metabolic Syndrome in Menopausal Women|Milk Consumption and the Metabolic Syndrome in Menopausal Women|Completed||N/A|29|Actual|Laval University|||||f||||f||||||||||2018-05-31 23:34:55.712381|2018-05-31 23:34:55.712381
NCT01163760|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2008-10-01||2015-05-05|2010-06-18|2010-07-16|Estimate|2010-06-18|2010-07-16|Estimate||||2015-05-05|2015-05-21|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Clinical Evaluation of Two Daily Disposable Contact Lenses||Completed||N/A|50|Actual|Johnson & Johnson Vision Care, Inc.|The integrity of the subject reported data is suspect and not reflective of lens’ performance due to a significant protocol deviation. Upon completion of the study it was found that subjects were unmasked and their data should be considered biased.|4|||f||||f||||||||||2018-05-31 23:34:55.786251|2018-05-31 23:34:55.786251
NCT01163747|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2012-11-12||2012-11-12|2010-07-14|2010-07-16|Estimate|2012-11-12|2012-12-07|Estimate||||2012-11-12|2012-12-07|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)|A Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Tocilizumab on Vaccination in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate|Completed||Phase 4|91|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:34:56.000505|2018-05-31 23:34:56.000505
NCT01163734|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2012-07-11|2010-07-14|2010-07-16|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|RALI-DHF||Ranolazine in Diastolic Heart Failure|A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction|Completed||Phase 2|20|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 23:34:56.529342|2018-05-31 23:34:56.529342
NCT01163721|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2013-07-19|2011-07-21|2013-07-19|2010-07-15|2010-07-16|Estimate|2013-07-19|2013-09-23|Estimate|2011-07-21|2011-07-25|Estimate|2013-07-19|2013-09-23|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Safety Analysis Set|Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Exploratory Study to Access the Metabolic Effects of Ranolazine When Added to Ongoing Non-Insulin Antidiabetic Therapy in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|80|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 23:34:56.644232|2018-05-31 23:34:56.644232
NCT01163708|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-27|2010-07-14|2010-07-16|Estimate|||||||2010-07-27|2010-07-29|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Prophecy Guide Outcomes in Total Knee Replacement Surgery|Phase IV Study - Prophecy Guide Outcomes in Total Knee Replacement Surgery|Unknown status|Not yet recruiting|Phase 4|188|Anticipated|Global Orthopaedic Technology||2|||f||||f||||||||||2018-05-31 23:34:57.009293|2018-05-31 23:34:57.009293
NCT01163695|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2014-03-13|2010-07-15|2010-07-16|Estimate|||||||2014-03-13|2014-03-14|Estimate|June 2005||2005-06-30|March 2014|2014-03-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|SUUBI||The SUUBI Program: Asset-Ownership for Orphaned Children in Uganda|The SUUBI Program: Creating Asset-Ownership Opportunities and Health Promotion Among Orphaned Children in Uganda|Completed||Phase 1|286|Actual|Columbia University|||||f||||f||||||||||2018-05-31 23:34:57.107973|2018-05-31 23:34:57.107973
NCT01163682|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2015-05-20|2010-07-14|2010-07-16|Estimate|||||||2015-05-20|2015-05-21|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Acupuncture Study for the Prevention of Taxane Induced Myalgias and Neuropathy|Randomized Sham Controlled Trial of Weekly Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 23:34:57.179712|2018-05-31 23:34:57.179712
NCT01163669|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2013-08-12|2010-07-15|2010-07-16|Estimate|||||||2013-08-12|2013-08-13|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients|A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients|Completed|||15|Actual|The Cleveland Clinic|||1||f||||f||||||||||2018-05-31 23:34:57.294765|2018-05-31 23:34:57.294765
NCT01163656|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|2012-12-13||2013-01-24|2010-07-14|2010-07-16|Estimate|2012-12-13|2013-01-18|Estimate||||2013-01-24|2013-01-31|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional|||Comparing Use of the Glidescope Cobalt to Direct Laryngoscopy in Infants|A Prospective Comparison of the Glidescope Cobalt to Standard Direct Laryngoscopy in Infants|Completed||N/A|66|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 23:34:57.361272|2018-05-31 23:34:57.361272
NCT01163643|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09||2012-03-27|2013-11-22|2010-07-15|2010-07-16|Estimate||||2012-05-03|2012-05-07|Estimate|2013-11-22|2013-12-17|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome|A Randomized, Double-Masked, Parallel-Group, Vehicle Controlled, Multicenter, Exploratory Study Assessing the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome|Completed||Phase 2|350|Actual|Bausch & Lomb Incorporated||6|||f||||f||||||||||2018-05-31 23:34:57.571352|2018-05-31 23:34:57.571352
NCT01162070|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2016-08-26|2010-07-13|2010-07-14|Estimate|||||||2016-08-26|2016-08-29|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ULISSE||Evaluation of a Standardized Strategy for Uveitis Etiological Diagnosis|Uveitis: Medico-economical and Clinical Evaluation of a Standardized Strategy for an Etiological Diagnosis|Completed||N/A|905|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 23:35:32.387285|2018-05-31 23:35:32.387285
NCT01163630|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-12-06|2010-07-15|2010-07-16|Estimate|||||||2010-12-06|2010-12-07|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg|A Phase I, Open-label, Randomized, Single-center, 2-way Crossover Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination Capsule of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg|Completed||Phase 1|24|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:34:57.686688|2018-05-31 23:34:57.686688
NCT01163617|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2013-11-01|2011-11-01|2014-01-24|2010-07-14|2010-07-16|Estimate|2014-01-24|2014-03-10|Estimate|2011-11-01|2011-11-07|Estimate|2014-01-24|2014-03-10|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients|A Multicenter, Randomized, Open-Label Study of the Injection Time and Usability of the Physiolis Syringe and Autoinjector in Injection-Experienced Rheumatoid Arthritis Patients|Completed||Phase 2|85|Actual|AbbVie||8|||f||||f||||||||||2018-05-31 23:34:57.763918|2018-05-31 23:34:57.763918
NCT01163604|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2014-10-25||2015-10-21|2010-07-15|2010-07-16|Estimate|2014-10-31|2014-11-07|Estimate||||2015-10-21|2015-11-23|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|APORIAS||Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting|Phase 4 Study of Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting|Completed||Phase 4|114|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 23:34:58.16911|2018-05-31 23:34:58.16911
NCT01163591|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2015-10-09|2010-07-15|2010-07-16|Estimate|||||||2015-10-09|2015-10-12|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy|A Phase II, Open-Label, Cross-Sectional, Study to Compare eZscan, With Standard Methods of Screening for Diabetic Nephropathy, As a Tool for Detection of Type 2 Diabetic Nephropathy|Completed|||100|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 23:34:58.395574|2018-05-31 23:34:58.395574
NCT01163578|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-03-31|2010-07-14|2010-07-15|Estimate|||||||2017-03-31|2017-04-04|Actual|March 2005||2005-03-31|March 2017|2017-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Biomarkers in Transplant Recipients|Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection|Recruiting|||1200|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     blood, saliva, intestinal and liver biospy samples, urine, stool~   "|||2018-05-31 23:34:58.446485|2018-05-31 23:34:58.446485
NCT01163565|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2014-12-02|2010-07-14|2010-07-15|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery|A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery|Completed||N/A|96|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 23:34:58.499719|2018-05-31 23:34:58.499719
NCT01163552|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2014-06-12|2010-07-14|2010-07-15|Estimate|||||||2014-06-12|2014-06-13|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity|Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies|Completed||Phase 2|5|Actual|St. Luke's-Roosevelt Hospital Center||1|||f||||f||||||||||2018-05-31 23:34:58.570048|2018-05-31 23:34:58.570048
NCT01163539|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2016-06-29|2010-07-14|2010-07-15|Estimate|||||||2016-06-29|2016-07-01|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Cyberknife Radiosurgery and Quality of Life|Cyberknife Radiosurgery and Quality of Life|Terminated|||15|Actual|Stanford University|||||f||||t||||||||||2018-05-31 23:34:58.634824|2018-05-31 23:34:58.634824
NCT01163526|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-01-26|2010-07-14|2010-07-15|Estimate|||||||2017-01-26|2017-01-30|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies|Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies|Terminated|||13|Actual|Stanford University|||4|accrual|f||||||||||||||2018-05-31 23:34:58.737433|2018-05-31 23:34:58.737433
NCT01163513|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2011-02-18|2010-07-14|2010-07-15|Estimate|||||||2011-02-18|2011-02-21|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Observational|CALIBER||Coronary Mortality in South Asians: Aetiologic and Prognostic Effects|Cardiovascular Disease Research Using Linked Bespoke Studies and Electronic Records|Unknown status|Active, not recruiting||100000|Anticipated|University College, London|||5||f||||t||||||||||2018-05-31 23:34:58.880089|2018-05-31 23:34:58.880089
NCT01163500|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-10-10|2010-07-14|2010-07-15|Estimate|||||||2013-10-10|2013-10-14|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Coenzyme Q10 in Relation of the Lipid Peroxidation, Antioxidant Enzyme Activities in Coronary Artery Disease Patients||Completed||Phase 2/Phase 3|59|Actual|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-05-31 23:34:58.947994|2018-05-31 23:34:58.947994
NCT01163487|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2016-06-22|2010-07-14|2010-07-15|Estimate|||||||2016-06-22|2016-06-24|Estimate|August 2010||2010-08-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|||Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers|Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers|Completed||Phase 1|17|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 23:34:59.039618|2018-05-31 23:34:59.039618
NCT01163474|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2014-12-09||2015-04-06|2010-07-14|2010-07-15|Estimate|2014-12-18|2015-01-05|Estimate||||2015-04-06|2015-04-28|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Telemedicine in Cardiac Surgery: A Pilot Study|Telemedicine in Cardiac Surgery: A Pilot Study|Completed||Early Phase 1|40|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-05-31 23:34:59.132831|2018-05-31 23:34:59.132831
NCT01163461|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2014-09-29||2017-08-30|2010-07-14|2010-07-15|Estimate|2015-07-09|2015-07-16|Estimate||||2017-08-30|2017-08-31|Actual|September 1, 2010|Actual|2010-09-01|August 2017|2017-08-31|September 30, 2014|Actual|2014-09-30|June 30, 2013|Actual|2013-06-30||Interventional|||Phonomotor Treatment of Word Retrieval Deficits in Individuals With Aphasia|Real Word Effects in Phonological Treatment for Word Retrieval|Completed||N/A|28|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 23:34:59.343965|2018-05-31 23:34:59.343965
NCT01162057|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|August 2010||2010-08-31|July 2010|2010-07-31||||||||Observational|||The Effect of Hemodialysis on Hearing|The Effect of Hemodialysis on Hearing in Hemodialysis Patients|Unknown status|Not yet recruiting||40|Anticipated|Hillel Yaffe Medical Center|||||f||||||||||||||2018-05-31 23:35:32.454944|2018-05-31 23:35:32.454944
NCT01163448|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2015-03-04|2010-07-14|2010-07-15|Estimate|||||||2015-03-04|2015-03-06|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer|Phase I Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer|Withdrawn||Phase 1|0|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 23:34:59.581268|2018-05-31 23:34:59.581268
NCT01163435|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2013-12-01|2010-07-14|2010-07-15|Estimate|||||||2013-12-01|2013-12-03|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication|Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication - A Prospective, Comparative Study|Completed||Phase 4|618|Actual|National Taiwan University Hospital||4|||f||||f||||||||||2018-05-31 23:34:59.679521|2018-05-31 23:34:59.679521
NCT01163422|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-14|2010-07-14|2010-07-15|Estimate|||||||2010-07-14|2010-07-15|Estimate|July 2010||2010-07-31|December 2009|2009-12-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|RVRT||Right Ventricular Resynchronization Therapy|Long-term Right Ventricular Resynchronization Therapy for Chronic Thromboembolic Pulmonary Hypertension|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 23:34:59.772759|2018-05-31 23:34:59.772759
NCT01163409|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-01-18|2010-07-14|2010-07-15|Estimate|||||||2012-01-18|2012-01-19|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|June 2014|Anticipated|2014-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Exercise, Acupuncture and Fibromyalgia|Acupuncture and Physical Activity in Patients With Fibromyalgia|Unknown status|Enrolling by invitation|N/A|60|Anticipated|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 23:34:59.871341|2018-05-31 23:34:59.871341
NCT01163396|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-03-10|2010-07-14|2010-07-15|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|FOIB||First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer|Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer|Completed||Phase 2|57|Actual|Gruppo Oncologico del Nord-Ovest||1|||f||||t||||||||||2018-05-31 23:35:00.005654|2018-05-31 23:35:00.005654
NCT01163383|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2017-07-25|2010-07-14|2010-07-15|Estimate|||||||2017-07-25|2017-07-27|Actual||||July 2017|2017-07-31||||||||Expanded Access|||131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma|I-Metaiodobenzylguanidine (131 I-MIBG) Therapy for Refractory Neuroblastoma and Paraganglioma/Pheochromocytoma Expanded Access Protocol|Available|||||Children's Hospital of Philadelphia|||||||||||||||||||2018-05-31 23:35:00.125166|2018-05-31 23:35:00.125166
NCT01163370|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2011-11-09|2010-07-14|2010-07-15|Estimate|||||||2011-11-09|2011-11-10|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Creatine Supplementation and Bone Mass||Completed||N/A|60|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 23:35:00.212207|2018-05-31 23:35:00.212207
NCT01163357|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2018-02-07|2010-07-14|2010-07-15|Estimate|||||||2018-02-07|2018-02-08|Actual|January 28, 2011||2011-01-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma|Phase I Study of Bortezomib With or Without Total Marrow Irradiation (TMI) Using Intensity Modulated Radiation Therapy (IMRT) in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With High Risk Multiple Myeloma|Recruiting||Phase 1|27|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 23:35:00.304855|2018-05-31 23:35:00.304855
NCT01163344|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-03-15|2010-07-14|2010-07-15|Estimate|||||||2017-03-15|2017-03-16|Actual|July 2010||2010-07-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|DANCE-PD||Dance Exercise as Novel Complementary Therapy for Parkinson's Disease|Dance Exercise as Novel Complementary Therapy for Parkinson's Disease|Completed|||31|Actual|Beth Israel Deaconess Medical Center|||2||f||||f|f|f||||||No||2018-05-31 23:35:00.416326|2018-05-31 23:35:00.416326
NCT01163331|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-03-15|2010-07-14|2010-07-15|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2010||2010-03-31|March 2017|2017-03-31||||August 2010|Actual|2010-08-31||Interventional|SING-PD||Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing Therapy for PD-related Voice/Speech Impairment|Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing|Completed||N/A|40|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-05-31 23:35:00.490707|2018-05-31 23:35:00.490707
NCT01163318|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2015-05-28||2015-05-28|2010-07-14|2010-07-15|Estimate|2015-05-28|2015-06-10|Estimate||||2015-05-28|2015-06-10|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||Safety analysis set, defined as participants who did not violate protocol criteria.|Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis|Special Investigation (Long-term Treatment in Patients With Rheumatoid Arthritis)|Completed|||552|Actual|AbbVie|||1||f||||||||||||||2018-05-31 23:35:00.607534|2018-05-31 23:35:00.607534
NCT01163305|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-05-03|2010-07-14|2010-07-15|Estimate|||||||2017-05-03|2017-05-08|Actual|June 30, 2010|Actual|2010-06-30|April 2017|2017-04-30|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Observational|||PET-CT and Circulating Tumor Cells in Colorectal Cancer|Identifying an Early Indicator of Drug Efficacy in Patients With Advanced Colorectal Cancer - a Prospective Evaluation of Circulating Tumor Cells, Positron-emission Tomography Scan and RECIST Criteria|Completed|||84|Actual|Chinese University of Hong Kong|||1||f||||f||||||Samples With DNA|"~     circulating tumor cells~   "|||2018-05-31 23:35:01.042878|2018-05-31 23:35:01.042878
NCT01163292|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2013-10-18||2013-12-11|2010-07-14|2010-07-15|Estimate|2013-10-18|2013-12-11|Estimate||||2013-12-11|2013-12-12|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|HOPE 3|All participants registered|Special Investigation (Follow up Survey of the Study of Adalimumab (D2E7)for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859(NCT00870467)|Humira 40 mg/0.8 mL Syringe for Subcutaneous Injection - Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859)]|Completed|||220|Actual|AbbVie|||2||f||||f||||||||||2018-05-31 23:35:01.131209|2018-05-31 23:35:01.131209
NCT01163279|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2016-01-12||2017-11-08|2010-07-14|2010-07-15|Estimate|2016-11-17|2017-01-12|Estimate||||2017-11-08|2017-12-18|Actual|August 2010||2010-08-31|November 2017|2017-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Maintaining Autonomy as we Age. Strategy Training for Age-related Executive Dysfunction.|Maintaining Autonomy as we Age: Investigating the Application of a Strategy Training Approach for Ameliorating the Effects of Age-related Executive Dysfunction - Part II|Completed||N/A|19|Actual|Baycrest||2|||f||||f||||||||||2018-05-31 23:35:01.828553|2018-05-31 23:35:01.828553
NCT01163266|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2013-10-25||2013-10-25|2010-07-14|2010-07-15|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder|Completed||Phase 3|462|Actual|Takeda||3|||f||||f||||||||||2018-05-31 23:35:03.730011|2018-05-31 23:35:03.730011
NCT01163253|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2017-05-30||2017-05-30|2010-07-14|2010-07-15|Estimate|2017-05-30|2017-06-26|Actual||||2017-05-30|2017-06-26|Actual|September 2010||2010-09-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Safety analysis set included all participants who received at least 1 dose of study drug.|A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis|A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis|Terminated||Phase 3|2867|Actual|Pfizer||1|||f||||t||||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 23:35:05.396396|2018-05-31 23:35:05.396396
NCT01163240|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2011-09-26|2010-07-14|2010-07-15|Estimate|||||||2011-09-26|2011-09-27|Estimate|June 2009||2009-06-30|September 2011|2011-09-30||||September 2011|Actual|2011-09-30||Observational|EPIC B||Epidemiological Study in Children and Adolescents With Chronic Hepatitis B|A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B|Completed|||1640|Actual|Novartis|||1||f||||||||||||||2018-05-31 23:35:09.5887|2018-05-31 23:35:09.5887
NCT01163227|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12||2013-02-18|2013-03-06|2010-07-14|2010-07-15|Estimate||||2013-02-18|2013-02-22|Estimate|2013-03-06|2013-03-14|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.|Completed||Phase 2|57|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:35:09.790365|2018-05-31 23:35:09.790365
NCT01163214|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2014-10-30||2014-11-03|2010-07-14|2010-07-15|Estimate|2014-11-03|2014-11-05|Estimate||||2014-11-03|2014-11-05|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Management of Postoperative Pain After Total Knee Replacement.|Prospective Randomized Study Comparing Regional Anesthetic Blocks and Periarticular Infiltration for the Management of Postoperative Pain After Total Knee Replacement.|Completed||Phase 4|160|Actual|Mayo Clinic|Participants and staff could not be blinded to the treatment arm received; participants' pain was evaluated at rest and not with activity; the study was not powered to identify certain rare events such as falls.|2|||f||||f||||||||||2018-05-31 23:35:09.903894|2018-05-31 23:35:09.903894
NCT01163201|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2017-11-29|2010-07-14|2010-07-15|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2014||2014-01-31|November 2017|2017-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies|Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies|Withdrawn||Phase 1/Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||1||Replaced by a new study|f||||t||||||||||2018-05-31 23:35:10.498866|2018-05-31 23:35:10.498866
NCT01163188|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2014-08-08|2010-07-14|2010-07-15|Estimate|||||||2014-08-08|2014-08-11|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Social Adjustment and Quality of Life After Very Preterm Birth|Social Adjustment and Quality of Life After Very Preterm Birth: Risk and Resiliency From Infancy to Adulthood|Completed|||520|Actual|University Hospital, Bonn|||2||f||||t||||||Samples Without DNA|"~     hair~   "|||2018-05-31 23:35:10.640882|2018-05-31 23:35:10.640882
NCT01163175|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2011-02-10|2010-07-14|2010-07-15|Estimate|||||||2011-02-10|2011-02-11|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|TRANS||Study of the Impact of Trans Fatty Acids From Dairy Products on Cardiovascular Risk Factors|Study of the Impact of Trans Fatty Acids From Dairy Products n Cardiovascular Risk Factors|Completed||N/A|48|Actual|Laval University|||||f||||f||||||||||2018-05-31 23:35:10.777093|2018-05-31 23:35:10.777093
NCT01163162|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2013-04-02||2013-04-02|2010-07-14|2010-07-15|Estimate|2013-04-02|2013-05-21|Estimate||||2013-04-02|2013-05-21|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|Paricalcitol||The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate|The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate|Completed||Phase 4|16|Actual|Indiana University||1|||f||||f||||||||||2018-05-31 23:35:11.021707|2018-05-31 23:35:11.021707
NCT01163149|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2017-06-27||2017-08-18|2010-07-14|2010-07-15|Estimate|2017-08-18|2017-09-18|Actual||||2017-08-18|2017-09-18|Actual|June 2010||2010-06-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||All efficacy analyses were performed on the full analysis set (intent-to-treat population), which consisted of all randomized patients (n=19).|Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)|A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, Pharmacokinetic of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults With Hypophosphatasia (HPP)|Completed||Phase 2|19|Actual|Alexion Pharma GmbH||3|||f||||t|t|f||||||||2018-05-31 23:35:11.39227|2018-05-31 23:35:11.39227
NCT01163136|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2017-09-29|2010-07-14|2010-07-15|Estimate|||||||2017-09-29|2017-10-03|Actual|July 2010||2010-07-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|November 2014|Actual|2014-11-30||Observational|DSPI||Decision Making in Serious Pediatric Illness|Decision Making in Serious Pediatric Illness|Completed|||358|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-05-31 23:35:15.518257|2018-05-31 23:35:15.518257
NCT01163123|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-15|2010-07-14|2010-07-15|Estimate|||||||2010-07-15|2010-07-16|Estimate|May 2010||2010-05-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan|Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan|Unknown status|Enrolling by invitation||312|Anticipated|Mennonite Christian Hospital|||||f||||f||||||Samples Without DNA|"~     The sera from volunteer was collected to detect IgG, IgM and anti-NS1 antibody against~     Japanese encephalitis virus~   "|||2018-05-31 23:35:15.601738|2018-05-31 23:35:15.601738
NCT01163110|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-11-14|2010-07-14|2010-07-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|March 2004||2004-03-31|November 2013|2013-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy|Phase II Dose of Escalation Design to Investigate the Therapeutic Role of RNA Fragments in the Protection of Platelet Production During Chemotherapy|Completed||Phase 1|32|Actual|Midwestern Regional Medical Center|||||f||||f||||||||||2018-05-31 23:35:15.729411|2018-05-31 23:35:15.729411
NCT01163097|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|2012-01-17||2014-10-31|2010-07-14|2010-07-15|Estimate|2012-07-03|2012-08-23|Estimate||||2014-10-31|2014-11-06|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study to Characterize the Effect of Heparin on Palifermin Activity|An Open-label, Randomized, Parallel-Design Study to Characterize the Effect of Heparin on Palifermin Activity in Healthy Adult Subjects|Completed||Phase 1|44|Actual|Swedish Orphan Biovitrum||3|||f||||f||||||||||2018-05-31 23:35:15.814708|2018-05-31 23:35:15.814708
NCT01163084|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2018-04-20|2010-07-14|2010-07-15|Estimate|||||||2018-04-20|2018-04-23|Actual|July 9, 2010|Actual|2010-07-09|April 2018|2018-04-30|June 1, 2012|Actual|2012-06-01|June 1, 2012|Actual|2012-06-01||Interventional|||Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer|A Randomized Phase Ib/II Study of Preoperative GDC-0449 and Androgen Ablation Compared to Androgen Ablation Alone Followed by Radical Prostatectomy for Select Patients With Locally Advanced Adenocarcinoma of the Prostate|Terminated||Phase 1/Phase 2|10|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:35:16.867341|2018-05-31 23:35:16.867341
NCT01163071|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2011-11-03|2010-07-14|2010-07-15|Estimate|||||||2011-11-03|2011-11-04|Estimate|March 2011||2011-03-31|October 2011|2011-10-31|September 2014|Anticipated|2014-09-30|July 2013|Anticipated|2013-07-31||Interventional|||A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas|Terminated||Phase 1|60|Anticipated|Celgene Corporation||1|||f||||f||||||||||2018-05-31 23:35:17.067857|2018-05-31 23:35:17.067857
NCT01163058|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-07-27|2010-07-14|2010-07-15|Estimate|||||||2010-07-27|2010-07-29|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|July 2010|Actual|2010-07-31||Observational|||Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer|Retrospective Analysis Evaluating Molecular Factors of Primary Resistance to Tyrosine Kinase Inhibitors in Metastatic Non Small Cell Lung Cancer Patients|Unknown status|Active, not recruiting||300|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||||||2018-05-31 23:35:17.139299|2018-05-31 23:35:17.139299
NCT01163045|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-14|2010-07-14|2010-07-15|Estimate|||||||2010-07-14|2010-07-15|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|January 2010|Actual|2010-01-31|February 2009|Actual|2009-02-28||Interventional|||Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerve Versus Neurostimulation|Intraoperative Neuromonitoring and Neurostimulation of the Recurrent Laryngeal Nerve Versus Neurostimulation Alone in Thyroid Surgery: a Randomized Clinical Trial|Completed||Phase 2|250|Actual|University of Bologna||2|||f||||t||||||||||2018-05-31 23:35:17.209097|2018-05-31 23:35:17.209097
NCT01163032|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2014-08-08|2013-05-21|2014-10-15|2010-07-13|2010-07-15|Estimate|2014-10-15|2014-10-16|Estimate|2013-05-21|2013-05-29|Estimate|2014-10-15|2014-10-16|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||52 patients entered the OLE Phase from screening and 3 patients rolled over after completing the Randomization Phase (2:tasimelteon; 1:placebo). For this analysis, 3 patients are included in the randomized arms and not the OLE. A separate analysis has been done for both age and gender for the 3 subjects (Rand to OLE).|Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder|A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon Versus Placebo in Totally Blind Subjects With N24HSWD Followed by an OLE Phase|Completed||Phase 3|136|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:35:17.314979|2018-05-31 23:35:17.314979
NCT01163019|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2014-10-27|2010-07-14|2010-07-15|Estimate|||||||2014-10-27|2014-10-28|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Observational|2DSPER||2D Strain Echocardiography for Diagnosing Chest Pain in the Emergency Room|Utility of 2D Strain Echocardiography in Triage of Patients With Chest Pain in the Emergency Department|Completed|||700|Actual|Technion, Israel Institute of Technology|||1||f||||f||||||||||2018-05-31 23:35:17.907868|2018-05-31 23:35:17.907868
NCT01163006|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2018-01-05|2010-07-14|2010-07-15|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2010||2010-03-31|July 2010|2010-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Soluble Dietary Fibres in the Prevention of Type 2 Diabetes Mellitus|Soluble Dietary Fibres as Dietetic Aid to Reduce the Risks of Type 2 Diabetes Mellitus|Completed||N/A|60|Anticipated|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 23:35:18.026452|2018-05-31 23:35:18.026452
NCT01162993|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2017-07-03|2010-07-14|2010-07-15|Estimate|||||||2017-07-03|2017-07-05|Actual|April 2010||2010-04-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2013|Actual|2013-01-31||Interventional|PDP||Effect of Spinal Cord Stimulation (SCS) in Painful Diabetic Polyneuropathy|Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy: a Multicenter Randomised Controlled Trial (PDP Study)|Active, not recruiting||N/A|40|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 23:35:18.104204|2018-05-31 23:35:18.104204
NCT01162980|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-14|2010-07-14|2010-07-15|Estimate|||||||2010-07-14|2010-07-15|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Observational|||The Angiotensin Converting Enzyme (ACE) Inhibitor SwitchBack Study|The ACEi SwitchBack Study|Unknown status|Recruiting||100|Anticipated|McGill University Health Center|||||f||||f||||||||||2018-05-31 23:35:18.345485|2018-05-31 23:35:18.345485
NCT01162967|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2013-09-09|2010-07-14|2010-07-15|Estimate|||||||2013-09-09|2013-09-10|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|CHAGASAZOL||Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole|PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE|Completed||Phase 2|78|Actual|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||f||||||||||2018-05-31 23:35:18.463736|2018-05-31 23:35:18.463736
NCT01162954|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2014-09-29|2010-07-14|2010-07-15|Estimate|||||||2014-09-29|2014-10-01|Estimate|September 2008||2008-09-30|September 2014|2014-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Local Tolerability After Administration of Eye Drop DA-6034 in Healthy Volunteers(Phase I)|Completed||Phase 1|||Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-05-31 23:35:18.835943|2018-05-31 23:35:18.835943
NCT01162941|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2010-07-14|2010-07-14|2010-07-15|Estimate|||||||2010-07-14|2010-07-15|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|January 2012|Anticipated|2012-01-31|July 2011|Anticipated|2011-07-31||Interventional|||Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)|Efficacy of Helicobacter Pylori Eradication, Anti-D and Danazol Combination in Steroid Dependant or Refractory Immune Thrombocytopenia (ITP)|Unknown status|Recruiting|Phase 2|38|Anticipated|Cooperative Study Group A for Hematology||1|||f||||f||||||||||2018-05-31 23:35:18.925439|2018-05-31 23:35:18.925439
NCT01162928|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2018-04-26|2010-07-14|2010-07-15|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2013||2013-05-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Parenteral Nutrition With Intravenous and Oral Fish Oil for Intensive Care Patients|Assessment of the Benefit From Combined Administration of Oral and Intravenous Nutrition - Enriched With Omega-3 Fatty Acids - for Intensive Care Patient|Completed||Phase 3|100|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-05-31 23:35:19.038898|2018-05-31 23:35:19.038898
NCT01162915|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2014-05-07|2010-07-13|2010-07-15|Estimate|||||||2014-05-07|2014-05-09|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury|Phase I, Single Center, Trial to Asses Safety and Tolerability of the Intrathecal Infusion of Ex-vivo Expanded Bone-marrow Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury|Suspended||Phase 1|10|Anticipated|TCA Cellular Therapy||1||Suspended due to lack of funding.|f||||t||||||||||2018-05-31 23:35:19.132386|2018-05-31 23:35:19.132386
NCT01162902|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2013-12-15|2010-07-13|2010-07-15|Estimate|||||||2013-12-15|2013-12-17|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|||Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation|Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 23:35:19.217051|2018-05-31 23:35:19.217051
NCT01162889|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-03-13|2010-07-13|2010-07-15|Estimate|||||||2012-03-13|2012-03-15|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People|Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ATR-107 Administered Subcutaneously And Intravenously To Healthy Subjects|Terminated||Phase 1|70|Actual|Pfizer||11||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:35:19.341613|2018-05-31 23:35:19.341613
NCT01162876|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-03-07|2010-07-14|2010-07-15|Estimate|||||||2017-03-07|2017-03-09|Actual|July 2010||2010-07-31|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus|A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|20|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 23:35:19.440719|2018-05-31 23:35:19.440719
NCT01162863|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2016-12-02||2016-12-02|2010-07-14|2010-07-15|Estimate|2016-12-02|2017-01-27|Estimate||||2016-12-02|2017-01-27|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||The baseline data is given for those persons who actually completed the study, so the two people who dropped out were not included in the baseline measures. We determined this to be the more useful way to identify the effects of the three randomized procedures. Therefore the baseline data is based on the 50 participants who completed the study.|Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation|A Pilot Study to Assess the Effects of Lubiprostone on Gastrointestinal and Colonic Motility and pH in Patients With the Irritable Bowel Syndrome and Constipation (IBS-C)|Completed||N/A|60|Actual|University of Michigan|This was a small study with wide variability among participants, so data should be interpreted with great caution.|3|||f||||||||||||||2018-05-31 23:35:19.667209|2018-05-31 23:35:19.667209
NCT01162850|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2011-08-04|2010-07-14|2010-07-15|Estimate|||||||2011-08-04|2011-08-05|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Oral Polypodium Leucotomos for Melasma|A Randomized Double-Blind Placebo Controlled Study Evaluating the Effectiveness and Tolerability of Oral Polypodium Leucotomos in Patients With Melasma|Completed||N/A|21|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 23:35:20.262156|2018-05-31 23:35:20.262156
NCT01162837|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2012-05-01|2010-07-13|2010-07-15|Estimate|||||||2012-05-01|2012-05-03|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne|An Evaluation of the Safety and Effectiveness of the BEAM Device in the Treatment of Mild-to-moderate Acne|Completed||N/A|33|Actual|Oregon Aesthetic Technologies||1|||f||||f||||||||||2018-05-31 23:35:20.344203|2018-05-31 23:35:20.344203
NCT01162824|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2011-02-22|2010-07-14|2010-07-15|Estimate|||||||2011-02-22|2011-02-23|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|April 2011|Anticipated|2011-04-30||Interventional|ACOVA||Blood Markers for Inflammation and Coronary Artery Vasoreactivity Testing in Patients With Chest Pain and Normal Coronary Arteries|Correlation Between Abnormal Coronary Vasoreactivity Testing, Expansion of CD4+CD28null T Cells and Biomarkers for Inflammation and Endothelial Dysfunction in Patients With Angina Despite Angiographically Normal Coronary Arteries.|Unknown status|Recruiting|N/A|50|Anticipated|St George's Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 23:35:20.458956|2018-05-31 23:35:20.458956
NCT01162811|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-07-20|2010-07-14|2010-07-15|Estimate|||||||2011-07-20|2011-07-21|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Visualization and Structured Attention Behaviour for Pain and Anxiety Reduction During Ablation of Atrial Fibrillation|Visualization and Structured Attention Behaviour -- Does it Reduce the Patient's Experience of Pain Intensity and Anxiety During Ablation of Atrial Fibrillation?|Completed||N/A|140|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 23:35:20.553865|2018-05-31 23:35:20.553865
NCT01162785|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2016-11-23|2010-07-13|2010-07-15|Estimate|||||||2016-11-23|2016-11-28|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer|Phase 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer|Completed||Phase 1|7|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 23:35:20.800786|2018-05-31 23:35:20.800786
NCT01162772|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-15|2010-07-14|2010-07-15|Estimate|||||||2010-07-15|2010-07-16|Estimate|January 2010||2010-01-31|July 2010|2010-07-31||||October 2011|Anticipated|2011-10-31||Observational|||Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects|Influence of a Modern Oral Anti-diabetic Medication on Endothelial Dysfunction and Cardiovascular Risk in Diabetic Women and Men: Gender Aspects|Unknown status|Recruiting||80|Anticipated|Medical University of Vienna|||2||f||||||||||||||2018-05-31 23:35:20.910873|2018-05-31 23:35:20.910873
NCT01162759|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2012-04-04|2010-07-13|2010-07-15|Estimate|||||||2012-04-04|2012-04-06|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|HBPM||Home Blood Pressure Monitoring Project|Home Blood Pressure Monitoring Program|Completed||N/A|348|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 23:35:20.998805|2018-05-31 23:35:20.998805
NCT01162746|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-05-23|2010-07-14|2010-07-15|Estimate|||||||2017-05-23|2017-05-25|Actual|October 2011||2011-10-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Comparison of Intravitreal Dexamethasone With Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Monotherapy in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration A Prospective, Randomized, Clinical Study|Completed||Phase 2|40|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 23:35:21.087246|2018-05-31 23:35:21.087246
NCT01162733|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|2013-09-23||2014-03-12|2010-07-13|2010-07-15|Estimate|2014-03-12|2014-03-13|Estimate||||2014-03-12|2014-03-13|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Loaded||Loading Vancomycin Doses in the Emergency Department|A Randomized Prospective Study of Vancomycin Dosing in the Emergency Department: Will a Loading Dose of 30mg/kg Lead to a More Rapid Attainment of Therapeutic Levels?|Completed||N/A|99|Actual|Christiana Care Health Services||2|||f||||t||||||||||2018-05-31 23:35:21.171916|2018-05-31 23:35:21.171916
NCT01162720|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2011-03-29|2010-07-14|2010-07-15|Estimate|||||||2011-03-29|2011-03-30|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Short- Versus Long-duration Tourniquet Use During Total Knee Replacement (TKR)|Feasibility of Tourniquet Use During Cement Fixation Only for TKR Surgery|Terminated||N/A|65|Actual|Fairfield Hospital, Australia||2||The risk of donor blood transfusion was unacceptably high in the Short Duration Group|f||||t||||||||||2018-05-31 23:35:21.357372|2018-05-31 23:35:21.357372
NCT01162707|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2015-01-16|2010-07-14|2010-07-15|Estimate|||||||2015-01-16|2015-01-19|Estimate|December 2006||2006-12-31|January 2015|2015-01-31|September 2012|Actual|2012-09-30|November 2007|Actual|2007-11-30||Interventional|||Wireless, Intermittent Monitoring of Right Heart Pressures in HF|A Multi-Center, Non-Randomized, Prospective Trial to Evaluate the Safety and Feasibility of Wireless, Intermittent Monitoring of Right Heart Pressures in Adult Heart Failure Subjects|Completed||N/A|17|Actual|CardioMEMS||1|||f||||t||||||||||2018-05-31 23:35:21.424152|2018-05-31 23:35:21.424152
NCT01162694|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-09-09|2010-07-14|2010-07-15|Estimate|||||||2014-09-09|2014-09-11|Estimate|July 2010||2010-07-31|September 2014|2014-09-30||||February 2011|Actual|2011-02-28||Interventional|||Comparing Internet Blood Glucose Monitoring System and Continuous Glucose Monitoring System|Protocol: Comparing the Effect of Using an Internet-Based Glucose Monitoring System Versus the Continuous Glucose Monitoring System on HbA1c Levels in Type 2 DM|Suspended||N/A|50|Anticipated|Endocrine Research Society||2||Study was expanded and included in another study.|f||||f||||||||||2018-05-31 23:35:21.500558|2018-05-31 23:35:21.500558
NCT01162681|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13||2014-01-30|2014-01-30|2010-07-13|2010-07-15|Estimate||||2014-01-30|2014-03-04|Estimate|2014-01-30|2014-03-04|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|PEARL-SC||PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus|A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus|Completed||Phase 2|547|Actual|Anthera Pharmaceuticals||4|||f||||t||||||||||2018-05-31 23:35:21.590148|2018-05-31 23:35:21.590148
NCT01162668|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2018-05-09|2010-07-13|2010-07-14|Estimate|||||||2018-05-09|2018-05-15|Actual|April 2010||2010-04-30|May 2018|2018-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employees|Assessment of Outcomes Following Bariatric Surgery for Mississippi State Employees|Completed|||165|Actual|University of Mississippi Medical Center|||||f||||f||||||||No||2018-05-31 23:35:21.876195|2018-05-31 23:35:21.876195
NCT01162655|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2017-05-25|2010-07-13|2010-07-14|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2010||2010-04-30|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cognitive-Behavioural Therapy (CBT) for Insomnia Via Internet or Telehealth|Delivery of Cognitive-Behavioral Treatment for Insomnia Via Telehealth or Internet|Completed||N/A|110|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 23:35:21.942662|2018-05-31 23:35:21.942662
NCT01162642|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-04-20|2010-07-13|2010-07-14|Estimate|||||||2015-04-20|2015-04-21|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Green Tea Anticancer Mechanisms in Smokers|Green Tea Anticancer Mechanisms in Smokers|Completed||N/A|43|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 23:35:22.005792|2018-05-31 23:35:22.005792
NCT01162629|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2010-07-14|2010-07-13|2010-07-14|Estimate|||||||2010-07-14|2010-07-15|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||Vertical Augmentation With Osteon at Dental Implant Placement|An Evaluation of Vertical Augmentation of Alveolar Bone With Osteon at Dental Implant Placement|Unknown status|Not yet recruiting||100|Anticipated|Research and Education in Dentistry|||1||f||||f||||||||||2018-05-31 23:35:22.067877|2018-05-31 23:35:22.067877
NCT01162616|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2012-07-03|2010-07-13|2010-07-14|Estimate|||||||2012-07-03|2012-07-04|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Polyphenols in Sorghum and Iron Absorption|Is There a Dose-dependant Effect of Sorghum Polyphenols on Human Iron Absorption and Can it be Overcome by Sodium Iron EDTA or by Adding Vitamin C or Laccase?|Completed||Early Phase 1|50|Actual|Swiss Federal Institute of Technology||1|||f||||||||||||||2018-05-31 23:35:22.206044|2018-05-31 23:35:22.206044
NCT01162603|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-05-05|2010-07-13|2010-07-14|Estimate|||||||2013-05-05|2013-05-07|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SAF-24H-IOP||Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)|Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions|Completed||Phase 4|40|Actual|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||f||||||||||2018-05-31 23:35:22.308017|2018-05-31 23:35:22.308017
NCT01162590|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2017-05-18|2010-07-13|2010-07-14|Estimate|||||||2017-05-18|2017-05-19|Actual|March 1, 2010|Actual|2010-03-01|May 2017|2017-05-31|March 31, 2010|Actual|2010-03-31|March 31, 2010|Actual|2010-03-31||Interventional|||Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults|Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Adults|Completed||Phase 1|52|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:35:22.386199|2018-05-31 23:35:22.386199
NCT01162577|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|OKRCT||Oklahoma Weight Concerns Quitline: a Randomized Cessation Trial|Oklahoma Weight Concerns Quitline: a Randomized Cessation Trial|Completed||N/A|2000|Actual|Alere Wellbeing||2|||f||||t||||||||||2018-05-31 23:35:22.47562|2018-05-31 23:35:22.47562
NCT01162564|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2011-04-25|2010-07-13|2010-07-14|Estimate|||||||2011-04-25|2011-04-27|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Flexible Composite Next Generation Tissue Separating Mesh in Laparoscopic Incisional/Ventral Hernia Repair|Single-Arm, Prospective, Multi-Center Observational Study of a Flexible Composite Next Generation Tissue Separating Mesh(NG-TSM)to Assess Ease of Use and Early Outcomes in Laparoscopic Incisional/Ventral Hernia|Completed|||48|Actual|Ethicon, Inc.|||1||f||||f||||||||||2018-05-31 23:35:22.559109|2018-05-31 23:35:22.559109
NCT01162551|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2017-09-29|2010-07-13|2010-07-14|Estimate|||||||2017-09-29|2017-10-03|Actual|May 2010||2010-05-31|September 2017|2017-09-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma|Phase 2 Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma|Completed||Phase 2|2|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-05-31 23:35:22.629754|2018-05-31 23:35:22.629754
NCT01162538|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|September 2010||2010-09-30|May 2010|2010-05-31|March 2012|Anticipated|2012-03-31|March 2011|Anticipated|2011-03-31||Observational|Ral'inNONB||To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients|The Main Objective of This Study is to Evaluate the Virologic Effectiveness at M6 of Regimen Containing Raltegravir in Treatment Naive HIV Subtype Non B or B Infected Subjects|Unknown status|Not yet recruiting||60|Anticipated|Centre Hospitalier Intercommunal Robert Ballanger|||||f||||f||||||||||2018-05-31 23:35:22.72556|2018-05-31 23:35:22.72556
NCT01162525|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2017-07-20|2010-07-13|2010-07-14|Estimate|||||||2017-07-20|2017-07-21|Actual|January 2010||2010-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Percutaneous Tibial Nerve Stimulation for Patients With Fecal Incontinence|Percutaneous Tibial Nerve Stimulation (pTNS) for Patients With Fecal Urge Incontinence|Recruiting||N/A|100|Anticipated|Cantonal Hospital of St. Gallen||1|||f||||f||||||||||2018-05-31 23:35:22.784176|2018-05-31 23:35:22.784176
NCT01162512|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2016-05-23|2010-07-13|2010-07-14|Estimate|||||||2016-05-23|2016-05-25|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|April 2013|Actual|2013-04-30|October 2011|Actual|2011-10-31||Interventional|TPAI||Telephone Physical Activity Intervention in Obese Youth|Telephone-Based Physical Activity Intervention in Obese Youth|Completed||N/A|60|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 23:35:22.874742|2018-05-31 23:35:22.874742
NCT01162499|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2016-07-29||2017-09-21|2010-07-13|2010-07-14|Estimate|2016-09-22|2016-11-09|Estimate||||2017-09-21|2017-10-23|Actual|April 2010||2010-04-30|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Baseline analysis population includes all subjects who were randomized and began treatment.|Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia|Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia After Nissen Fundoplication: Studies With the GLP-1 Receptor Antagonist Exendin-(9-39)|Completed||N/A|7|Actual|Children's Hospital of Philadelphia|The primary limitation in addition to small sample size, relates to the fact that none of the subjects experienced significant hypoglycemia during the 3 hour post-meal period.|2|||f||||f||||||||||2018-05-31 23:35:22.956059|2018-05-31 23:35:22.956059
NCT01162486|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2013-04-01|2010-07-13|2010-07-14|Estimate|||||||2013-04-01|2013-04-04|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|TBTC S29B||Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers|Phase I Dose Escalation Study of the Pharmacokinetics, Safety and Tolerability of Rifapentine and the Effects of Increasing Doses of Rifapentine on Induction of Metabolizing Enzymes in Healthy Volunteers|Completed||Phase 1|37|Actual|Johns Hopkins University||6|||f||||t||||||||||2018-05-31 23:35:23.312969|2018-05-31 23:35:23.312969
NCT01162473|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|2015-04-22||2015-05-11|2010-07-13|2010-07-14|Estimate|2015-05-11|2015-05-13|Estimate||||2015-05-11|2015-05-13|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Milk Oral Immunotherapy in Children to Treat Food Allergy|A Study of the Efficacy of Milk Oral Immunotherapy in Children|Completed||Early Phase 1|25|Actual|Children's Hospital of Philadelphia|The small sample size constrains the statistical significance of this study. While useful in indicating potential trends, the results of this pilot study should be cautiously interpreted.|2|||f||||f||||||||||2018-05-31 23:35:23.417733|2018-05-31 23:35:23.417733
NCT01162460|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2016-09-28|2010-07-13|2010-07-14|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures:a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study|Completed||Phase 3|815|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 23:35:23.676351|2018-05-31 23:35:23.676351
NCT01162083|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2016-02-15|2010-07-13|2010-07-14|Estimate|||||||2016-02-15|2016-02-17|Estimate|October 2010||2010-10-31|August 2011|2011-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|PVA||Identifying an Ideal Cardiopulmonary Exercise Test Parameter|Identifying the Ideal Parameter of the Cardiopulmonary Exercise Test to Distinguish Between the Cardiovascular and Respiratory Components of Functional Limitation and to Detect Relevant Physiological Changes in Function|Completed|||100|Actual|Imperial College London|||5||f||||f||||||||||2018-05-31 23:35:32.300735|2018-05-31 23:35:32.300735
NCT01162447|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Comparison of Bone Morphogenetic Protein-4 (BMP-4) and 7 Levels Between Control and Polycystic Ovarian Syndrome (PCOS) Patients.|Comparison of Bone Morphogenetic Protein-4 and -7 Levels (BMP-4 and 7) in the Serum, Ovarian Follicle Aspirates and Ovarian Organ Culture Supernatants Between Healthy Controls and Patients With Polycystic Ovarian Syndrome (PCOS).|Unknown status|Enrolling by invitation||50|Anticipated|V.K.V. American Hospital, Istanbul|||1||f||||f||||||Samples With DNA|"~     Blood samples, ovarian tissue samples, ovarian follicular fluid samples~   "|||2018-05-31 23:35:23.756336|2018-05-31 23:35:23.756336
NCT01162434|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2012-07-11|2010-07-13|2010-07-14|Estimate|||||||2012-07-11|2012-07-12|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Brain MRI (Magnetic Resonance Imaging) Scans of Patients With Treatment Resistant Depression (TRD) and Healthy Controls|Volumetric Brain MRI (Magnetic Resonance Imaging) Comparison of Patients With Treatment Resistant Depression (TRD) Undergoing Deep Brain Stimulation (DBS) With Age, Sex and Education Matched Healthy Controls|Completed|||21|Actual|University of Bristol|||2||f||||f||||||||||2018-05-31 23:35:23.847379|2018-05-31 23:35:23.847379
NCT01162421|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2016-07-22||2016-09-13|2010-07-13|2010-07-14|Estimate|2016-09-13|2016-11-01|Estimate||||2016-09-13|2016-11-01|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|RADAR|Intent-to-treat population: all participants who were randomized and received at least one dose of study drug.|A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis|Radiographic, Clinical and Patient Outcomes in a Multicenter, Open Label Phase IV Randomized Trial of Earlier Adalimumab Introduction Therapy Versus Later Introduction as Per Standard of Care After Initial Methotrexate Failure in Early Rheumatoid Arthritis Patients|Completed||Phase 4|77|Actual|AbbVie||2|||f||||||||||||||2018-05-31 23:35:24.051044|2018-05-31 23:35:24.051044
NCT01162408|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|July 2010||2010-07-31|July 2010|2010-07-31||||||||Observational|||The Study of Clinical Value of Acute Physiologic and Chronic Health Evaluation (APACHE) Scoring System in Medical Intensive Care Unit||Unknown status|Not yet recruiting||450|Anticipated|Sun Yat-sen University|||||f||||f||||||||||2018-05-31 23:35:26.136127|2018-05-31 23:35:26.136127
NCT01162395|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2016-01-11|2010-07-13|2010-07-14|Estimate|||||||2016-01-11|2016-01-12|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|March 2013|Actual|2013-03-31||Interventional|||Open Label Prostate Cancer Study|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients With Metastatic Castration-Resistant Prostate Cancer.|Completed||Phase 1|64|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:35:26.193541|2018-05-31 23:35:26.193541
NCT01162382|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-03-12|2010-07-13|2010-07-14|Estimate|||||||2012-03-12|2012-03-14|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Treating Depression: A Functional Magnetic Resonance Imaging Study|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder: A Functional Connectivity Magnetic Resonance Imaging (fcMRI) Study|Suspended||N/A|35|Anticipated|Washington University School of Medicine||1||Protocol currently undergoing changes. Will be relisted at later date.|f||||t||||||||||2018-05-31 23:35:26.27115|2018-05-31 23:35:26.27115
NCT01162369|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2018-05-01|2010-07-13|2010-07-14|Estimate|||||||2018-05-01|2018-05-07|Actual|July 2013||2013-07-31|May 2018|2018-05-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Observational|||Brief Delirium Assessments in Non-Intensive Care Unit (ICU) Patients|Validation of Brief Delirium Assessments in Non Critically Ill Hospitalized Patients|Withdrawn|||0|Actual|Vanderbilt University Medical Center|||2|Lack of funding.|f||||f||||||||||2018-05-31 23:35:26.357641|2018-05-31 23:35:26.357641
NCT01162356|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-02-20|2010-07-12|2010-07-14|Estimate|||||||2017-02-20|2017-02-23|Actual|July 2010|Actual|2010-07-31|February 2017|2017-02-28|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Observational|PROVE||Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study|A Prospective Analysis of Nerve Fiber Layer and Macular Changes After Pars Plana Vitrectomy|Completed|||45|Actual|Vanderbilt University Medical Center|||||f||||||||||||||2018-05-31 23:35:26.536271|2018-05-31 23:35:26.536271
NCT01162343|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2017-02-25||2018-05-01|2010-07-13|2010-07-14|Estimate|2018-05-01|2018-05-03|Actual||||2018-05-01|2018-05-03|Actual|July 2009||2009-07-31|May 2018|2018-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Delirium in the Emergency Department: Novel Screening|Delirium in the Emergency Department: Novel Screening|Completed|||498|Actual|Vanderbilt University Medical Center|This was a single center study and should be externally validated. Our findings cannot be generalized to those who are younger than 65 years old.||1||f||||f||||||||Undecided||2018-05-31 23:35:26.626546|2018-05-31 23:35:26.626546
NCT01162330|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2015-10-07|2010-07-13|2010-07-14|Estimate|||||||2015-10-07|2015-10-12|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|BEST||The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment|The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment After Their Neonatal Screen (BEST)|Completed|||411|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 23:35:26.816357|2018-05-31 23:35:26.816357
NCT01162317|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2016-11-14||2017-12-19|2010-07-12|2010-07-14|Estimate|2017-02-17|2017-04-05|Actual||||2017-12-19|2018-01-19|Actual|July 5, 2011|Actual|2011-07-05|December 2017|2017-12-31|December 18, 2017|Actual|2017-12-18|September 30, 2015|Actual|2015-09-30||Interventional|AcuTBI||AcuSleep in Mild Traumatic Brain Injury (TBI)|Novel Approaches to Sleep Difficulties: Application in Mild TBI|Completed||N/A|60|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 23:35:26.894722|2018-05-31 23:35:26.894722
NCT01162304|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2015-03-26||2015-06-25|2010-07-12|2010-07-14|Estimate|2015-06-25|2015-07-17|Estimate||||2015-06-25|2015-07-17|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|OUTCOMES||Open-Label Trial Comparing Oxycodone Medications|Open-Label Trial Comparing Oxycodone Medications for Effectiveness and Satisfaction (OUTCOMES)|Terminated||Phase 4|18|Actual|University of Rochester||1||unable to enroll subjects meeting Eligibility criteria|f||||t||||||||||2018-05-31 23:35:27.154841|2018-05-31 23:35:27.154841
NCT01162291|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2012-01-28|2010-07-13|2010-07-14|Estimate|||||||2012-01-28|2012-01-31|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Comparison of Intramuscular Distribution of Different Injection Volumes Via Diffusion Tensor Imaging (DTI)|Comparison of Intramuscular Distribution of Different Injection Volumes Via Diffusion Tensor Imaging (DTI)-A Pilot Trial|Completed|||8|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 23:35:27.371763|2018-05-31 23:35:27.371763
NCT01162265|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-04-04|2010-07-13|2010-07-14|Estimate|||||||2017-04-04|2017-04-06|Actual|August 2010||2010-08-31|April 2017|2017-04-30|June 30, 2016|Actual|2016-06-30|June 30, 2015|Actual|2015-06-30||Observational|PREDICT||Prognostic Value of Interferon Gamma Release Assays in Predicting Active Tuberculosis Among Individuals With, or at Risk of, Latent Tuberculosis Infection|Prognostic Value of Interferon Gamma Release Assays in Predicting Active Tuberculosis Among Individuals With, or at Risk of, Latent Tuberculosis Infection|Completed|||10000|Actual|Public Health England|||2||f||||t||||||Samples With DNA|"~     A biobank will be established from samples collected in this study, subject to routine HTA~     requirements in the UK. This has full ethical approval and is included in the consent to take~     part in the study.~   "|No||2018-05-31 23:35:27.505957|2018-05-31 23:35:27.505957
NCT01162252|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2014-08-12|2010-07-12|2010-07-14|Estimate|||||||2014-08-12|2014-08-13|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Improving Psoriasis Through Health and Well-Being|Improving Psoriasis Through Health and Well-Being|Completed||N/A|130|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 23:35:27.573387|2018-05-31 23:35:27.573387
NCT01162239|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-10-14|2010-07-12|2010-07-14|Estimate|||||||2015-10-14|2015-10-16|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Maintaining Nonsmoking|Maintaining Nonsmoking|Unknown status|Active, not recruiting|Phase 3|271|Actual|University of California, San Francisco||4|||f||||t||||||||||2018-05-31 23:35:27.659057|2018-05-31 23:35:27.659057
NCT01162226|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2012-04-17|2010-07-12|2010-07-14|Estimate|||||||2012-04-17|2012-04-19|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Computer-Based Balance Training for People With Parkinson's Disease|"PD Wii: Computer-based Gait and Balance Training for Parkinson's Patients."|Completed||Phase 2|62|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:35:27.7353|2018-05-31 23:35:27.7353
NCT01162213|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-08-19|2010-07-13|2010-07-14|Estimate|||||||2010-08-19|2010-08-23|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pilot Study of Lychee Fruit Extract to Promote Cardiovascular Health|Effects of Lychee Fruit Extract on Vascular Function and Inflammation in Postmenopausal Women: a Double-Blind, Crossover Study|Completed||Phase 1|44|Actual|University of California, Davis||4|||f||||f||||||||||2018-05-31 23:35:28.837395|2018-05-31 23:35:28.837395
NCT01162200|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2017-12-05|2010-07-13|2010-07-14|Estimate|||||||2017-12-05|2017-12-07|Actual|October 4, 2010|Actual|2010-10-04|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer|A Phase I Study of Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer|Active, not recruiting||Phase 1|75|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 23:35:28.904921|2018-05-31 23:35:28.904921
NCT01162187|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|July 2003||2003-07-31|July 2010|2010-07-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|||Secondary Prevention in Acute Coronary Syndromes: A CALIBER Study|Secondary Prevention in Acute Coronary Syndromes: Long-term Survival in Relation to the Number and Combination of Evidence-based Therapies Prescribed Prior to Discharge (a CALIBER Study)|Unknown status|Active, not recruiting||400000|Anticipated|University College, London|||||f||||f||||||||||2018-05-31 23:35:28.98759|2018-05-31 23:35:28.98759
NCT01162174|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pilot Study of Oligonol Supplementation to Promote Cardiovascular Health|Effects of Oligonol on Vascular Function and Inflammation in Healthy Men: A Double-Blind, Dose-Finding Study|Completed||Phase 1|16|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 23:35:29.052633|2018-05-31 23:35:29.052633
NCT01162161|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2015-09-22|2010-07-13|2010-07-14|Estimate|||||||2015-09-22|2015-09-23|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|09-045||Role of Sphingolipids in Pulmonary Edema|Role of Sphingolipids in Pulmonary Edema|Completed|||45|Actual|RWTH Aachen University|||3||f||||f||||||||||2018-05-31 23:35:29.113498|2018-05-31 23:35:29.113498
NCT01162148|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|September 2010||2010-09-30|June 2010|2010-06-30|September 2011|Anticipated|2011-09-30|December 2010|Anticipated|2010-12-31||Interventional|||Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation|Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation|Unknown status|Not yet recruiting|N/A|50|Anticipated|Rabin Medical Center||4|||f||||f||||||||||2018-05-31 23:35:29.180776|2018-05-31 23:35:29.180776
NCT01162135|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2014-04-23||2016-10-19|2010-07-12|2010-07-14|Estimate|2014-05-22|2014-06-05|Estimate||||2016-10-19|2016-11-29|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Digoxin for Recurrent Prostate Cancer|A Pilot Phase II Study of Digoxin in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA|Completed||Phase 2|16|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 23:35:29.277261|2018-05-31 23:35:29.277261
NCT01162122|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|2014-01-28|2011-03-25|2014-06-16|2010-07-13|2010-07-14|Estimate|2014-06-06|2014-06-12|Estimate|2011-03-25|2011-04-04|Estimate|2014-06-16|2014-06-26|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional||"Baseline demography is described for safety set population.~A vaccine different from the vaccine assigned at randomization was administered to 7 subjects in each vaccine group. For the safety analysis, these subjects were reassigned to the vaccine group for the vaccine they actually received."|Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects|A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity and the Consistency of Three Consecutive Lots of a MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects Aged 65 Years and Older|Completed||Phase 3|7109|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:35:29.806894|2018-05-31 23:35:29.806894
NCT01162109|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2017-10-24|2010-07-13|2010-07-14|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2010||2010-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|September 2017|Actual|2017-09-30||Interventional|||Zinc Therapy in Critical Illness|Pharmaconutrients as Therapies for Critical Illness: Zinc in Severe Sepsis|Active, not recruiting||Phase 1|55|Anticipated|University of Vermont||3|||f||||t||||||||||2018-05-31 23:35:31.875412|2018-05-31 23:35:31.875412
NCT01162096|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2015-01-07||2018-01-03|2010-07-12|2010-07-14|Estimate|2015-01-07|2015-01-15|Estimate||||2018-01-03|2018-02-01|Actual|September 2006||2006-09-30|January 2018|2018-01-31|April 2012|Actual|2012-04-30|September 2010|Actual|2010-09-30||Interventional|||Reduced Intensity Haploidentical Transplant for Hematological Malignancies|A Two Step Approach To Non-Myeloablative Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies|Completed||Phase 1/Phase 2|34|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 23:35:32.058147|2018-05-31 23:35:32.058147
NCT01162044|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|November 2010||2010-11-30|July 2010|2010-07-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|||Examining an Emergency Room Intervention for the Prevention of Post Traumatic Stress Disorder (PTSD)|Interrupting Traumatic Memories: An Emergency Room Intervention for the Prevention of PTSD|Unknown status|Not yet recruiting|N/A|80|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 23:35:32.497266|2018-05-31 23:35:32.497266
NCT01162031|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2018-05-16|2010-07-13|2010-07-14|Estimate|||||||2018-05-16|2018-05-21|Actual|June 2010||2010-06-30|May 2018|2018-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia|Phase II Study of Bortezomib (VELCADE) for the Treatment of Relapsed or Refractory T-cell Prolymphocytic Leukemia|Withdrawn||Phase 2|0|Actual|Stanford University||||no accrual|f||||t|t|f|||f|||||2018-05-31 23:35:32.576468|2018-05-31 23:35:32.576468
NCT01162018|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2013-05-30|2010-07-12|2010-07-14|Estimate|||||||2013-05-30|2013-05-31|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Acupuncture for Sleep Disruption in Cancer Survivors|Acupuncture for Sleep Disruption in Cancer Survivors|Completed||N/A|56|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 23:35:32.638468|2018-05-31 23:35:32.638468
NCT01162005|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2016-10-24|2010-07-13|2010-07-14|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children|Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children|Completed||Phase 4|80|Actual|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 23:35:32.717085|2018-05-31 23:35:32.717085
NCT01161992|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-08-21|2010-07-12|2010-07-14|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2002||2002-03-31|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Genomics of Primary Sclerosing Cholangitis (PSC)|P.R.O.G.R.E.S.S.: PSC Resource Of Genetic Risk, Environment and Synergy Studies.|Recruiting|||1500|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Blood sample will be drawn at local facility and sent to Mayo Clinic by mail. Stool sample~     will be collected and sent back to Mayo Clinic by mail. All study related charges will be~     charged to the study.~   "|No||2018-05-31 23:35:32.788488|2018-05-31 23:35:32.788488
NCT01161979|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|March 2005|Actual|2005-03-31|February 2005|Actual|2005-02-28||Interventional|||Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions|A Randomized. Single-Dose, Two-Way Crossover Relative Bioavailability Study of Zonisamide Formulations in Normal, Healthy Men and Women Following a Standard Meal|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:35:32.854452|2018-05-31 23:35:32.854452
NCT01161966|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|March 2005|Actual|2005-03-31|February 2005|Actual|2005-02-28||Interventional|||Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|A Randomized. Single-Dose, Two-Way Crossover Relative Bioavailability Study of Zonisamide Formulations in Fasted Normal, Healthy Men and Women|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:35:33.079829|2018-05-31 23:35:33.079829
NCT01161953|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-08-21|2010-07-13|2010-07-14|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2002||2002-03-31|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)|Understanding the Genetic Predisposition to the Development of Primary Biliary Cirrhosis (PBC).|Recruiting|||1500|Anticipated|Mayo Clinic|||||f||||t||||||Samples With DNA|"~     Blood and stool samples are collected.~   "|No||2018-05-31 23:35:33.151364|2018-05-31 23:35:33.151364
NCT01161940|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|July 2004||2004-07-31|July 2010|2010-07-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Fasting Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:35:33.245513|2018-05-31 23:35:33.245513
NCT01161927|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|July 2004||2004-07-31|July 2010|2010-07-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions|A Two-way Crossover Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Nizatidine 300 mg Capsules in Healthy Human Subjects Under Non-fasting Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:35:33.310418|2018-05-31 23:35:33.310418
NCT01161914|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-11|||2016-08-22|2010-07-13|2010-07-14|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2011||2011-01-31|July 2010|2010-07-31||||August 2011|Anticipated|2011-08-31||Interventional|||The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease|A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease|Withdrawn||Phase 3|0|Actual|ISU Abxis Co., Ltd.||2|||f||||||||||||||2018-05-31 23:35:33.370464|2018-05-31 23:35:33.370464
NCT01161901|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2014-07-04|2010-07-13|2010-07-14|Estimate|||||||2014-07-04|2014-07-08|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Impact of Inflammation Biomarkers on the Acute Respiratory Distress Syndrome (ARDS) Definition|Impact of Inflammation Biomarkers on the Acute Respiratory Distress Syndrome Definition in Intensive Care Unit|Completed|||134|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 23:35:33.43959|2018-05-31 23:35:33.43959
NCT01161888|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2012-06-18|2010-07-13|2010-07-14|Estimate|||||||2012-06-18|2012-06-20|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|LIMIT-1||Effect of Topical Imiquimod on Lentigo Maligna|Effect of Topical Imiquimod on Lentigo Maligna|Completed||Phase 4|30|Actual|University Hospital Birmingham NHS Foundation Trust|||||f||||t||||||||||2018-05-31 23:35:33.502353|2018-05-31 23:35:33.502353
NCT01161875|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2011-08-04|2010-07-13|2010-07-14|Estimate|||||||2011-08-04|2011-08-05|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|NAVAHELMET||Impact of Neurally Adjusted Ventilator Assist (NAVA) Mode on Patient Ventilator Asynchrony Using Helmet|Study of the Benefit of the NAVA Mode Versus PSV Mode on Patient Ventilator Asynchrony During Non Invasive Ventilation With Helmet|Completed|||10|Anticipated|Pierre and Marie Curie University|||||f||||f||||||||||2018-05-31 23:35:33.561331|2018-05-31 23:35:33.561331
NCT01161862|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2016-10-31||2017-10-13|2010-07-13|2010-07-14|Estimate|2017-10-13|2017-11-14|Actual||||2017-10-13|2017-11-14|Actual|July 2010||2010-07-31|October 2017|2017-10-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|CL2||Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas|Integration of Continuous Glucose Monitoring Into a Bi-Hormonal Closed-Loop Artificial Pancreas for Automated Management of Type 1 Diabetes|Completed||N/A|24|Actual|Boston University Charles River Campus||2|||f||||t||||||||||2018-05-31 23:35:33.688447|2018-05-31 23:35:33.688447
NCT01161849|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2011-01-03|2010-07-13|2010-07-14|Estimate|||||||2011-01-03|2011-01-04|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|lactate||Peritoneal/ Serum Lactate Ratio in Relaparotomy|Peritoneal/Serum Lactate Ratio in Relaparotomy|Completed|||60|Anticipated|Ospedale S. Giovanni Bosco|||||f||||t||||||||||2018-05-31 23:35:34.034711|2018-05-31 23:35:34.034711
NCT01161836|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2013-09-23|2010-07-12|2010-07-14|Estimate|||||||2013-09-23|2013-09-24|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)|An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi) Administered at Cycle 1 as a 60-minute Intravenous Infusion to Patients With Advanced Solid Tumors Followed by Extended Treatment With BSI-201 With or Without Additional Chemotherapy|Completed||Phase 1|7|Actual|Sanofi||1|||t||||f||||||||||2018-05-31 23:35:34.129308|2018-05-31 23:35:34.129308
NCT01161823|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2016-01-11|2010-07-13|2010-07-14|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2010||2010-01-31|April 2010|2010-04-30||||||||Observational|||Influence of Nebivolol on Postmenopausal Women|Effect of Nebivolol on Climacteric Disorders in Postmenopausal Women. A Randomized, Open Label Trial|Unknown status|Recruiting||60|Anticipated|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 23:35:34.196088|2018-05-31 23:35:34.196088
NCT01161810|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-01-14|2010-07-12|2010-07-14|Estimate|||||||2015-01-14|2015-01-15|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Observational|ACT||The Relationship of Rehabilitation Therapy Time To The Prevention of Burn Scar Contracture|Burn Patient Acuity Demographics, Scar Contractures and Rehabilitation Treatment Time Related to Patient Outcomes (ACT)|Completed|||386|Actual|American Burn Association|||1||f||||f||||||||||2018-05-31 23:35:34.273584|2018-05-31 23:35:34.273584
NCT01161797|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-09-29|2010-07-13|2010-07-14|Estimate|||||||2010-09-29|2010-09-30|Estimate|February 2008||2008-02-29|September 2010|2010-09-30|July 2010|Actual|2010-07-31|||||Observational|||1,5-AG as a Marker of Postprandial Hyperglycemia and Glucose Variability in Well-controlled Type 2 Diabetes Mellitus|Correlation Between 1,5-anhydroglucitol and Postprandial Hyperglycemia by Continuous Glucose Monitoring System and Clinical Usefulness of 1,5-anhydroglucitol in Well-controlled Diabetic Patients|Completed|||53|Actual|Kyunghee University Medical Center|||||f||||f||||||Samples Without DNA|"~     serum (HbA1c, fructosamine, 1,5-anhydroglucitol)~   "|||2018-05-31 23:35:34.357307|2018-05-31 23:35:34.357307
NCT01161784|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Effects of a Probiotic Fermented Milk on Functional Constipation in Adults|The Effects of a Probiotic Fermented Milk on Functional Constipation in Adults|Completed||Phase 3|100|Actual|International Medical University||2|||f||||t||||||||||2018-05-31 23:35:34.418536|2018-05-31 23:35:34.418536
NCT01161771|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2011-12-13||2012-07-17|2010-07-12|2010-07-14|Estimate|2012-07-17|2012-07-26|Estimate||||2012-07-17|2012-07-26|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye||Completed|||32|Actual|Allergan|||1||f||||f||||||||||2018-05-31 23:35:34.492398|2018-05-31 23:35:34.492398
NCT01161758|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|April 2005||2005-04-30|November 2005|2005-11-30|December 2005|Actual|2005-12-31|October 2005|Actual|2005-10-31||Interventional|||Study on the Effect of Cervical Mobilization on Motor Function and Pressure Pain Threshold in Pain Free Individuals|A Crossover Study on the Effect of Cervical Mobilization on Motor Function and Pressure Pain Threshold in Pain Free Individuals|Completed||N/A|24|Actual|Curtin University||3|||f||||f||||||||||2018-05-31 23:35:34.659418|2018-05-31 23:35:34.659418
NCT01161745|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-13|||2010-07-13|2010-07-13|2010-07-14|Estimate|||||||2010-07-13|2010-07-14|Estimate|December 2008||2008-12-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Observational|||PD-1/PD-L1 Pathway Study on Septic Patients|PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients|Completed|||39|Actual|Changhai Hospital|||||f||||f||||||Samples Without DNA|"~     peripheral venous blood from septic patients and healthy controls, anticoagulate with EDTA-K2~   "|||2018-05-31 23:35:34.720377|2018-05-31 23:35:34.720377
NCT01161732|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2018-04-08|2010-07-13|2010-07-14|Estimate|||||||2018-04-08|2018-04-10|Actual|July 2010|Actual|2010-07-31|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|RECOVERY||Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis|Randomized Comparison of Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis|Active, not recruiting||N/A|145|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 23:35:34.76998|2018-05-31 23:35:34.76998
NCT01161719|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2016-01-25|2010-07-12|2010-07-13|Estimate|||||||2016-01-25|2016-01-26|Estimate|April 2008||2008-04-30|January 2016|2016-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effectiveness Study of Videoconferencing on Teaching Parent Training Skills to Parents of Children With Attention Deficit Hyperactivity Disorder (ADHD)|The Effectiveness of Videoconferencing on Teaching Parent Training Skills to Parents of Children With ADHD|Completed||N/A|22|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 23:35:34.860222|2018-05-31 23:35:34.860222
NCT01161706|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|February 2009|Actual|2009-02-28|December 2007|Actual|2007-12-31||Interventional|||Clinical Investigation on the Effects of a Vegetable Juice Treatment|The Use of a Commercial Vegetable Juice as a Practical Means to Increase Vegetable Intake: A Randomized Controlled Trial|Completed||Phase 1|90|Actual|University of California, Davis||3|||f||||t||||||||||2018-05-31 23:35:34.921404|2018-05-31 23:35:34.921404
NCT01161693|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2011-08-09|2010-07-12|2010-07-13|Estimate|||||||2011-08-09|2011-08-10|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Effects of a Head Elevated Ramped Position During Elective Cesarean Delivery After Combined Spinal Epidural (CSE) Anesthesia|The Effects of a Head Elevated Ramped Position During Elective Cesarean Delivery After Combined Spinal Epidural (CSE) Anesthesia|Completed||N/A|60|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 23:35:34.986461|2018-05-31 23:35:34.986461
NCT01161680|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-04-15|2010-07-12|2010-07-13|Estimate|||||||2015-04-15|2015-04-16|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|May 2012|Actual|2012-05-31|September 2011|Actual|2011-09-30||Observational|||Breathing and Bones Initiative|A Prospective Baseline Assessment of the Risk of Osteoporosis in Patients With Chronic Obstructive Lung Disease and Outcomes After 2 Years; a Pilot Study|Completed|||30|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 23:35:35.196397|2018-05-31 23:35:35.196397
NCT01161667|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2018-01-19|2010-07-12|2010-07-13|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2007||2007-09-30|January 2018|2018-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fasted Conditions|Completed||N/A|35|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:35:35.268927|2018-05-31 23:35:35.268927
NCT01161654|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2018-01-19|2010-07-12|2010-07-13|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2007||2007-08-31|January 2018|2018-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fed Conditions|Completed||N/A|33|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:35:35.324359|2018-05-31 23:35:35.324359
NCT01161641|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-08-05|2010-07-12|2010-07-13|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery|" An Open Label Pilot Study Evaluating Safety and Evidence of Therapeutic Effect of IV Admin of 2-0, 3-0 Desulfated Heparin, Treatment of Exacerbation of Protein Losing Enteropathy (PLE) Associated With Single Ventricle Palliative Surgery"|Terminated||Phase 1|5|Actual|Cantex Pharmaceuticals||3||Extremely slow accural due to rarity of medical condition studied.|f||||f||||||||||2018-05-31 23:35:35.383516|2018-05-31 23:35:35.383516
NCT01161628|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2015-12-16||2016-03-22|2010-07-12|2010-07-13|Estimate|2016-01-27|2016-02-24|Estimate||||2016-03-22|2016-04-20|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|January 2014|Actual|2014-01-31||Interventional|||Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)|Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease|Completed||Phase 2|25|Actual|Northside Hospital, Inc.||1|||f||||f||||||||No||2018-05-31 23:35:35.493548|2018-05-31 23:35:35.493548
NCT01161615|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12||2012-06-28|2018-01-14|2010-07-12|2010-07-13|Estimate||||2012-06-28|2012-07-02|Estimate|2018-01-14|2018-01-17|Actual|July 2010||2010-07-31|January 2018|2018-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder|Completed||Phase 3|350|Actual|MEDRx USA, Inc.||2|||f||||f||||||||||2018-05-31 23:35:35.907963|2018-05-31 23:35:35.907963
NCT01161602|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2011-09-20|2010-07-12|2010-07-13|Estimate|||||||2011-09-20|2011-09-21|Estimate||||September 2011|2011-09-30|May 2011||2011-05-31|||||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Dose Levels of Pumosetrag in Patients With Symptoms Associated With Gastroesophageal Reflux Disease (GERD) Receiving a Standard Refluxogenic Meal|Completed||Phase 2|||Edusa Pharmaceuticals, Inc.||4|||||||||||||||||2018-05-31 23:35:36.022364|2018-05-31 23:35:36.022364
NCT01161589|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-02-14|2010-07-12|2010-07-13|Estimate|||||||2017-02-14|2017-02-16|Actual|October 2005||2005-10-31|February 2017|2017-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|FACTS||First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data|First Arrhythmia Collection of Transvenous and Simultaneous Subcutaneous Implantable Defibrillator Data|Completed|||142|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-05-31 23:35:36.088337|2018-05-31 23:35:36.088337
NCT01161576|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2018-04-30|2010-07-12|2010-07-13|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2010||2010-08-31|April 2018|2018-04-30|August 2032|Anticipated|2032-08-31|December 2020|Anticipated|2020-12-31||Interventional|||Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)|Direct CNS Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human CLN2 cDNA to Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)|Active, not recruiting||Phase 1|25|Anticipated|Weill Medical College of Cornell University||2|||f||||t|t|f||||||Undecided||2018-05-31 23:35:36.158668|2018-05-31 23:35:36.158668
NCT01161563|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2013-06-10||2013-09-05|2010-07-12|2010-07-13|Estimate|2013-09-05|2013-09-06|Estimate||||2013-09-05|2013-09-06|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration|Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer|Completed||Phase 4|118|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:35:36.243182|2018-05-31 23:35:36.243182
NCT01161550|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2013-07-22|2010-07-09|2010-07-13|Estimate|||||||2013-07-22|2013-07-23|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|CLAG ATRA AML||Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML|Phase 1 Study of Cladribine Based Induction Therapy (CLAG) With ATRA (All-Trans Retinoic Acid) and Midostaurin in Relapsed/Refractory AML|Completed||Phase 1|11|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 23:35:36.493431|2018-05-31 23:35:36.493431
NCT01161537|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2014-02-27||2014-07-01|2010-07-09|2010-07-13|Estimate|2014-07-01|2014-07-31|Estimate||||2014-07-01|2014-07-31|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Full Analysis Set (FAS) = all enrolled subjects who received at least 1 dose of study drug (VX-770 or placebo in Part A and VX-770 in Part B).|Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation|A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 ≥40% Predicted|Completed||Phase 2|13|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||t||||||||||2018-05-31 23:35:36.598239|2018-05-31 23:35:36.598239
NCT01161524|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2014-02-26|2010-07-12|2010-07-13|Estimate|||||||2014-02-26|2014-02-27|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|July 2013|Actual|2013-07-31||Interventional|||A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics When Administered as an Adjunctive Therapy in Adolescents (12 to Less Than 18 Years of Age) With Inadequately Controlled Partial-onset Seizures|Unknown status|Active, not recruiting|Phase 2|133|Actual|Eisai Inc.||2|||f||||t||||||||||2018-05-31 23:35:36.947813|2018-05-31 23:35:36.947813
NCT01161511|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-04-18|2010-07-12|2010-07-13|Estimate|||||||2014-04-18|2014-04-21|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia|A Phase 1 Study of XmAb®5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 1|27|Actual|Xencor, Inc.||1|||f||||f||||||||||2018-05-31 23:35:37.05262|2018-05-31 23:35:37.05262
NCT01161498|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2015-11-12||2016-01-14|2010-07-12|2010-07-13|Estimate|2015-11-12|2015-12-17|Estimate||||2016-01-14|2016-02-08|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer|A Phase 3 Randomized Trial of Concurrent Cisplatin & Radiotherapy With Or Without ONCOVEX^GM-CSF In Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck|Terminated||Phase 3|5|Actual|BioVex Limited||2||The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN).|f||||t||||||||||2018-05-31 23:35:37.129897|2018-05-31 23:35:37.129897
NCT01161485|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2017-01-18|2010-07-12|2010-07-13|Estimate|||||||2017-01-18|2017-01-20|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|May 25, 2016|Actual|2016-05-25|June 13, 2015|Actual|2015-06-13||Interventional|||Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users|Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users|Completed||N/A|502|Actual|University of Colorado, Denver||3|||f||||t|f|f||||||||2018-05-31 23:35:37.68212|2018-05-31 23:35:37.68212
NCT01161472|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2012-05-25||2012-05-25|2010-07-12|2010-07-13|Estimate|2012-05-25|2012-06-28|Estimate||||2012-05-25|2012-06-28|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects|A 4 Way Placebo And Active Controlled Study To Evaluate The Effects Of Fesoterodine On Cognitive Function In Healthy Elderly Subjects|Completed||Phase 1|20|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:35:37.802882|2018-05-31 23:35:37.802882
NCT01161459|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2014-05-29|2010-07-12|2010-07-13|Estimate|||||||2014-05-29|2014-06-02|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|April 2012|Actual|2012-04-30||Interventional|||Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid|Research Institute of Nephrology, Jinling Hospital|Completed||N/A|100|Anticipated|Nanjing University School of Medicine||2|||f||||t||||||||||2018-05-31 23:35:38.562455|2018-05-31 23:35:38.562455
NCT01161446|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2017-05-10||2017-05-10|2010-07-12|2010-07-13|Estimate|2017-05-10|2017-06-07|Actual||||2017-05-10|2017-06-07|Actual|July 2010||2010-07-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)|Comparisons of Public Health Screening Methods for Acute and Early HIV Infection: Home Self-Testing for HIV Infection|Completed||N/A|230|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 23:35:38.673225|2018-05-31 23:35:38.673225
NCT01161433|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-07-09|2010-07-09|2010-07-13|Estimate|||||||2010-07-09|2010-07-13|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Practical Model to Transform Childhood Asthma Care - Spirometry Training in the Primary Care Setting|Implementing Evidence-based Quality Improvement Strategies to Improve Asthma Care for Children|Completed||N/A|36|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:35:39.446114|2018-05-31 23:35:39.446114
NCT01161420|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2014-05-27||2017-07-27|2010-07-12|2010-07-13|Estimate|2014-12-11|2014-12-15|Estimate||||2017-07-27|2017-08-25|Actual|July 2010|Actual|2010-07-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|March 2013|Actual|2013-03-31||Interventional|STAR|Sample size was estimated using SAS V9.2 software using the two-sided, two-sample t-test for normal population.|Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)|Effects of the Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea|Completed||Phase 3|929|Actual|Inspire Medical Systems, Inc.||1|||f||||t||||||||||2018-05-31 23:35:39.57188|2018-05-31 23:35:39.57188
NCT01161407|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2013-05-30||2014-07-22|2010-07-12|2010-07-13|Estimate|2013-05-30|2013-07-31|Estimate||||2014-07-22|2014-07-29|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease|Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease|Completed||N/A|12|Actual|Indiana University|Due to the characteristic short treatment periods of balance studies, the results may not reflect the effects of chronic treatment with calcium carbonate on mineral balance.|2|||f||||f||||||||||2018-05-31 23:35:40.038951|2018-05-31 23:35:40.038951
NCT01161394|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-12-14|2010-07-12|2010-07-13|Estimate|||||||2015-12-14|2015-12-15|Estimate||||July 2010|2010-07-31|October 2003|Actual|2003-10-31|||||Interventional|||Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study|Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study|Completed||Phase 4|24|Anticipated|University at Buffalo||3|||f||||t||||||||||2018-05-31 23:35:40.288547|2018-05-31 23:35:40.288547
NCT01161381|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|November 2005||2005-11-30|December 2005|2005-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Evaluation Of Patients With Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) Based on Nonlinear Analysis Of Respiratory Signals|Evaluation Of Patients With Suspected Obstructive Sleep Apnea - Hypopnea Syndrome Using Two Models Based on Nonlinear Analysis Of Respiratory Signals|Completed|||100|Actual|Aristotle University Of Thessaloniki|||2||f||||f||||||||||2018-05-31 23:35:40.350749|2018-05-31 23:35:40.350749
NCT01161199|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-08-14|2010-07-12|2010-07-13|Estimate|||||||2015-08-14|2015-08-18|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||The Use of Leukapheresis to Support HIV Pathogenesis Studies|The Use of Leukapheresis to Support HIV Pathogenesis Studies|Recruiting|||100|Anticipated|University of California, San Francisco|||3||f||||f||||||Samples With DNA|"~     CD4+ T cells Plasma~   "|||2018-05-31 23:35:42.828417|2018-05-31 23:35:42.828417
NCT01161368|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2015-08-11|2010-07-12|2010-07-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients|A Phase II Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients Pretreated With Chemotherapy or Hormonal Treatment in Combination With Lapatinib for Metastatic Disease|Terminated||Phase 2|9|Actual|Central European Cooperative Oncology Group||1||poor recruitment|f||||t||||||||||2018-05-31 23:35:40.537443|2018-05-31 23:35:40.537443
NCT01161355|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2011-02-08|2010-07-12|2010-07-13|Estimate|||||||2011-02-08|2011-02-09|Estimate|June 2010||2010-06-30|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject|An Exploratory Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9668 With Respect to an Intra-venous Microdose of [14C]AZD9668 in Healthy Male Subjects|Completed||Phase 1|6|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:35:40.612987|2018-05-31 23:35:40.612987
NCT01161342|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-08-25|2010-07-12|2010-07-13|Estimate|||||||2015-08-25|2015-08-26|Estimate|March 2008||2008-03-31|May 2011|2011-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Nutritional Status Among Older Adults. Risk Factors and Consequences of Malnutrition|Nutritional Status Among Older Adults. Risk Factors and Consequences of Malnutrition|Completed|||1771|Actual|Uppsala University|||||f||||f||||||||||2018-05-31 23:35:40.680723|2018-05-31 23:35:40.680723
NCT01161329|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2016-02-10||2016-05-31|2010-07-12|2010-07-13|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|July 2012|Actual|2012-07-31||Interventional|||Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach|Description of Physical and Psychosocial Problems One Year After Stroke and the Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach|Completed||Phase 1|67|Actual|Uppsala University|The early termination of the study produced limited Power and increased the risk of type 1-errors.|2|||f||||t||||||||Yes||2018-05-31 23:35:40.750511|2018-05-31 23:35:40.750511
NCT01161316|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2015-07-24|2010-07-12|2010-07-13|Estimate|||||||2015-07-24|2015-07-27|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MACRO-2||Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours|Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-line Treatment in Patients With Metastatic Colorectal Cancer (mCRC) and Wild-type KRAS Tumours|Completed||Phase 2|194|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-05-31 23:35:40.973379|2018-05-31 23:35:40.973379
NCT01161303|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|July 2000||2000-07-31|July 2010|2010-07-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Observational|||An Investigation of Tumor Necrosis Factor (TNF)-Alpha in Asthma Using Biopsy Explants and Primary Bronchial Epithelial Cell Cultures|Study to Investigate the Role of TNF-alpha in Asthma Using Biopsy Explants and Primary Bronchial Epithelial Cell Cultures|Completed|||12|Actual|University Hospital Southampton NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     -  bronchial brushings and biopsies~        -  Blood~   "|||2018-05-31 23:35:41.049088|2018-05-31 23:35:41.049088
NCT01161290|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|E-Breathe||Real-Time Telehealth to Promote Self-care Management for Chronic Obstructive Pulmonary Disease|A Randomized Controlled Trial Using Real-Time Interactive Audio/Visual Telehealth to Promote Self-care Management for United States Veterans With Chronic Obstructive Pulmonary Disease: a Pilot Study|Completed||N/A|22|Actual|VA Greater Los Angeles Healthcare System|||||f||||f||||||||||2018-05-31 23:35:41.112454|2018-05-31 23:35:41.112454
NCT01161277|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-09-11|2010-07-12|2010-07-13|Estimate|||||||2014-09-11|2014-09-12|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Arip_200901||Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning|Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning: A Pharmacological fMRI Study|Completed||Phase 4|54|Actual|Oslo University Hospital||3|||f||||t||||||||||2018-05-31 23:35:41.165815|2018-05-31 23:35:41.165815
NCT01161264|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2016-11-30|2010-07-12|2010-07-13|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2010||2010-07-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects|A Phase III, Multicenter, Uncontrolled, Open Label Study to Evaluate Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects|Completed||Phase 3|126|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:35:41.251682|2018-05-31 23:35:41.251682
NCT01161251|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2016-03-08|2010-07-12|2010-07-13|Estimate|||||||2016-03-08|2016-03-09|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|October 2012|Actual|2012-10-31||Observational|ARAPACIS||Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study.|Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study.|Completed|||2027|Actual|University of Roma La Sapienza|||1||f||||t||||||||Yes||2018-05-31 23:35:41.322093|2018-05-31 23:35:41.322093
NCT01161238|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2014-04-24|2010-07-09|2010-07-13|Estimate|||||||2014-04-24|2014-04-25|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Amputee Residual Limb Volume Fluctuation|Measuring and Controlling In-Socket Residual Limb Volume Fluctuation|Completed|||28|Actual|University of Washington|||1||f||||f||||||||||2018-05-31 23:35:41.389679|2018-05-31 23:35:41.389679
NCT01161225|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2014-12-02||2014-12-09|2010-07-12|2010-07-13|Estimate|2014-12-09|2014-12-15|Estimate||||2014-12-09|2014-12-15|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|TAP||Teen Asthma Project|Peer-Assisted Asthma Self-Management Program for Adolescents|Completed||N/A|126|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 23:35:41.458169|2018-05-31 23:35:41.458169
NCT01161212|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-23|2010-07-12|2010-07-13|Estimate|||||||2010-07-23|2010-07-26|Estimate|September 2005||2005-09-30|July 2010|2010-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|REGUL'APS||REGULarity of Physical ActivitieS (REGUL'APS)|Physical Activity, Health-related Quality of Life and Corpulence Among French Schoolchildren|Completed||N/A|1600|Actual|University of Nancy||2|||f||||t||||||||||2018-05-31 23:35:42.749244|2018-05-31 23:35:42.749244
NCT01161186|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2012-10-10|2010-07-12|2010-07-13|Estimate|||||||2012-10-10|2012-10-11|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma|A Phase I Study of Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) (AGX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|Completed||Phase 1|15|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 23:35:42.915025|2018-05-31 23:35:42.915025
NCT01161173|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|2015-08-05||2016-02-25|2010-07-12|2010-07-13|Estimate|2016-02-25|2016-03-28|Estimate||||2016-02-25|2016-03-28|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|TEAM|Per-protocol population: All enrolled participants who started erlotinib therapy and did not violate the study protocol.|An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer|"A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a Real Life Clinical Setting"|Completed|||347|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:35:43.058402|2018-05-31 23:35:43.058402
NCT01161160|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2017-03-03|2011-03-23|2017-04-25|2010-07-12|2010-07-13|Estimate|2017-04-25|2017-08-04|Actual|2011-03-23|2011-03-29|Estimate|2017-04-25|2017-08-04|Actual|July 1, 2010||2010-07-01|March 2017|2017-03-31|January 31, 2011|Actual|2011-01-31|August 23, 2010|Actual|2010-08-23||Interventional|||Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old|An Observer-blind Safety and Immunogenicity Study of GSK Biologicals' A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340272A in Children 3 to Less Than 10 Years Old|Completed||Phase 2|209|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:35:43.590503|2018-05-31 23:35:43.590503
NCT01161147|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|October 2004||2004-10-31|August 2004|2004-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition|Comparative Bioavailability Study of Meloxicam 15 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics) Vs. Mobic® 15 mg Tablets (Boehringer Ingelheim Pharmaceuticals Inc.,Usa) in Healthy Male And/Or Female Volunteers Under Fed Conditions- P1CX04002|Completed||Phase 1|28|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:35:44.392122|2018-05-31 23:35:44.392122
NCT01161134|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|September 2004||2004-09-30|August 2004|2004-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition|Comparative Bioavailability Study of Meloxicam 15 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics) Vs. Mobic® 15 mg Tablets (Boehringer Ingelheim Pharmaceuticals Inc.,Usa) in Healthy Male And/Or Female Volunteers Under Fasting Conditions-P1cx04001|Completed||Phase 1|28|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:35:44.450565|2018-05-31 23:35:44.450565
NCT01161121|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2013-07-30||2017-06-22|2010-07-09|2010-07-13|Estimate|2017-04-04|2017-06-19|Actual||||2017-06-22|2017-06-23|Actual|July 2010||2010-07-31|June 2017|2017-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Patients with intermediate to severe, single vessel or multi-vessel, angiographic coronary artery disease(visual 40%-70% angiographic stenosis) whose lesion assessment with FFR is planned, were eligible for enrollment. A total of up to 50 subjects(25 at University of Florida Health Science Center and 25 at St. Louis University) will be enrolled.|Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia|Utilization of Lexiscan (Regadenoson)in the Cardiac Catheterization Lab to Achieve Maximal Hyperemia for Coronary Physiologic Assessment With Fractional Flow Reserve|Completed||Phase 1|46|Actual|St. Louis University||1|||f||||t||||||||No||2018-05-31 23:35:44.526629|2018-05-31 23:35:44.526629
NCT01161108|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2014-12-01|2010-07-12|2010-07-13|Estimate|||||||2014-12-01|2014-12-02|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Trial of Melatonin to Improve Sleep in Children With Epilepsy and Neurodevelopmental Disabilities|A Randomized Controlled Trial Pilot Project to Evaluate the Efficacy of Melatonin in Children With Insomnia, Intractable Epilepsy and Neurodevelopmental Disabilities|Completed||Phase 3|13|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 23:35:44.849568|2018-05-31 23:35:44.849568
NCT01161095|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-09-29|2010-07-12|2010-07-13|Estimate|||||||2010-09-29|2010-09-30|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|||A Multicenter Analysis of Levonorgestrel-Intrauterine System (LNG-IUS) Use in the Postpartum Period||Unknown status|Recruiting|N/A|170|Anticipated|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-05-31 23:35:44.956474|2018-05-31 23:35:44.956474
NCT01161082|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-01-24|2010-07-09|2010-07-13|Estimate|||||||2015-01-24|2015-01-27|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single to Multi-Dose Study of Safety, Tolerability, and Bioeffect of Subcutaneously Administered REGN727 in Patients With and Without Concomitant Atorvastatin|Completed||Phase 1|72|Actual|Regeneron Pharmaceuticals||8|||f||||f||||||||||2018-05-31 23:35:45.03404|2018-05-31 23:35:45.03404
NCT01161069|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2011-08-08|2010-07-09|2010-07-13|Estimate|||||||2011-08-08|2011-08-09|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03049423 In Healthy Adult Volunteers And Healthy Older Volunteers|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Multiple Dose Escalation Study To Evaluate The Safety, Toleration, Pharmacokinetics Of PF-03049423 In Healthy Young Adult Volunteers And Healthy Elderly Volunteers|Completed||Phase 1|48|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:35:45.120573|2018-05-31 23:35:45.120573
NCT01161056|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-09-09|2010-07-12|2010-07-13|Estimate|||||||2015-09-09|2015-09-10|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|GAP||Genes and Phenotype (GAP) A National Resource for Genotype-Phenotype Studies of Immunological and Inflammatory Pathways|Genes and Phenotype (GAP) A National Resource for Genotype-Phenotype Studies of Immunological and Inflammatory Pathways|Completed|||5000|Actual|Northwell Health|||1||f||||f||||||Samples With DNA|"~     Blood sample will be processed to isolate DNA and peripheral blood mononuclear cells, which~     will be stored in our Biorepository.~   "|||2018-05-31 23:35:45.227157|2018-05-31 23:35:45.227157
NCT01161030|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Almonds and Diabetes Management|Almond Ingestion at Meal-time Reduces Postprandial Glycemia and Chronic Ingestion Reduces Hemoglobin A1c in Individuals With Well-controlled Type 2 Diabetes|Completed||N/A|32|Actual|Arizona State University||1|||f||||f||||||||||2018-05-31 23:35:45.358525|2018-05-31 23:35:45.358525
NCT01161017|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-10|||2017-10-10|2010-07-12|2010-07-13|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2008|Actual|2008-07-31|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Mechanism-based Choice of Therapy for Pain: Can Successful Prevention of Migraine be Coupled to a Psychophysical Pain Modulation Profile?|Mechanism-based Choice of Therapy for Pain: Can Successful Prevention of Migraine be Coupled to a Psychophysical Pain Modulation Profile?|Completed||N/A|67|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 23:35:45.410038|2018-05-31 23:35:45.410038
NCT01161004|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2017-05-23|2010-07-12|2010-07-13|Estimate|||||||2017-05-23|2017-05-24|Actual|September 2010||2010-09-30|May 2017|2017-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Sugarecovery||Recovery Effect of Sugammadex Measured by Bispectral and Neurosense Indices|Pilot Study of EEG Signs of Awakening Secondary to Injection of Sugammadex: Evaluation by Recording Bispectral Index and NeuroSENSE (Prospective, Double-blind Study)|Completed||Phase 4|50|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 23:35:45.486156|2018-05-31 23:35:45.486156
NCT01160991|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-08-02|2010-07-12|2010-07-13|Estimate|||||||2010-08-02|2010-08-03|Estimate|May 2004||2004-05-31|August 2010|2010-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism|Effects of the Serotonin 2A Receptor on Insulin Sensitivity and Secretion: a Double-blind Controlled Comparison of Olanzapine vs. Amisulpride:|Completed||N/A|10|Actual|Central Institute of Mental Health, Mannheim||3|||f||||f||||||||||2018-05-31 23:35:45.553801|2018-05-31 23:35:45.553801
NCT01160978|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2017-09-17|2010-07-12|2010-07-13|Estimate|||||||2017-09-17|2017-09-19|Actual|June 1, 2010|Actual|2010-06-01|September 2017|2017-09-30|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|SIMVA||Donor Simvastatin Treatment in Organ Transplantation|Donor Simvastatin Treatment in Organ Transplantation|Completed||Phase 2/Phase 3|84|Actual|Helsinki University Central Hospital||2|||f||||t||||||||||2018-05-31 23:35:45.640295|2018-05-31 23:35:45.640295
NCT01160965|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-12-28|2010-07-12|2010-07-13|Estimate|||||||2011-12-28|2011-12-29|Estimate|August 2012||2012-08-31|December 2011|2011-12-31|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|RoLe||Ropivacaine 0.75% Versus Levobupivacaine 0.5% for Conversion of Labour Epidural|Ropivacaine 0.75% Versus Levobupivacaine 0.5% for Conversion of Labour Epidural to Surgical Anaesthesia for Emergency Caesarean Section.|Withdrawn||Phase 4|0|Actual|Guy's and St Thomas' NHS Foundation Trust||2||Not able provide staff for recruting at present|f||||t||||||||||2018-05-31 23:35:45.754527|2018-05-31 23:35:45.754527
NCT01160952|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-23|2010-07-12|2010-07-13|Estimate|||||||2010-07-23|2010-07-26|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation|Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|120|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 23:35:45.843122|2018-05-31 23:35:45.843122
NCT01160939|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|November 2004||2004-11-30|November 2009|2009-11-30|November 2008|Actual|2008-11-30|November 2006|Actual|2006-11-30||Interventional|||Assessment and Monitoring of Patients in Medium-term Heart Transplant Candidates Undergoing Low-intensity Exercise|Assessment and Monitoring of Patients in Medium-term Heart Transplant Candidates Undergoing Low-intensity Exercise|Completed||N/A|21|Actual|Federal University of São Paulo|||||f||||t||||||||||2018-05-31 23:35:45.924858|2018-05-31 23:35:45.924858
NCT01160926|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2016-01-26|2010-07-12|2010-07-13|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|October 2013|Actual|2013-10-31||Interventional|DREAMtherapy||Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial|Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy|Terminated||Phase 1|31|Actual|The Christie NHS Foundation Trust||2||2 DLTs had been reported from first 4 patients on lowest possible dose cohort.|f||||f||||||||||2018-05-31 23:35:46.030164|2018-05-31 23:35:46.030164
NCT01160913|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-12|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|October 2007||2007-10-31|September 2007|2007-09-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Optimal Site of Administration for Continuous Wound Infusion After Cesarean Section|Evaluation of Optimal Anatomical Layer for Continuous Wound Infusion of Local Anesthetics Combined With NSAIDs Through a Multiorifice Catheter for Postoperative Pain Intensity After Elective Cesarean Delivery|Completed||Phase 3|56|Actual|Association pour la Recherche et la Formation en Anesthésie Analgésie Réanimation||2|||f||||f||||||||||2018-05-31 23:35:46.121018|2018-05-31 23:35:46.121018
NCT01160900|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-12|2010-07-12|2010-07-13|Estimate|||||||2010-07-12|2010-07-13|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|FIT||FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.|Phase III Study, Multivessel Percutaneous Treatment During Myocardial Infarction|Unknown status|Active, not recruiting|Phase 3|180|Anticipated|Azienda Ospedaliera San Camillo Forlanini||1|||f||||t||||||||||2018-05-31 23:35:46.180859|2018-05-31 23:35:46.180859
NCT01160887|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2013-07-08|2010-07-09|2010-07-12|Estimate|||||||2013-07-08|2013-07-09|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Diabetes Peripheral Neuropathy and Small-fibre Nerve Damage: A Comparative Study|Is Diabetic Peripheral Neuropathy Accompanied by Internal Nerve Damage? A Comparative, Clinical Experimental Study of Peripheral and Visceral Nerve Damage in Diabetic Patients and Healthy Controls|Completed|||40|Actual|Haukeland University Hospital|||2||f||||f||||||||||2018-05-31 23:35:46.316392|2018-05-31 23:35:46.316392
NCT01160874|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2013-10-24|2010-07-09|2010-07-12|Estimate|||||||2013-10-24|2013-10-25|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SOMTDA/H||Sleepiness and Driving Performances in Adults With Attention-Deficit/ Hyperactivity Disorder (ADHD)|Sleepiness and Performances Degradation in Adults Presenting an Attention-Deficit/ Hyperactivity Disorder (ADHD)|Completed||N/A|80|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 23:35:46.386205|2018-05-31 23:35:46.386205
NCT01160861|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2012-01-02|2010-07-09|2010-07-12|Estimate|||||||2012-01-02|2012-01-05|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis|A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis|Completed||Phase 1|36|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:35:46.466327|2018-05-31 23:35:46.466327
NCT01160848|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2013-10-22||2014-04-22|2010-07-09|2010-07-12|Estimate|2014-04-22|2014-05-20|Estimate||||2014-04-22|2014-05-20|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients|A Clinical Study of Photoactive Porphyrins (PAP) Levels in Acne-affected Skin After Topical Visonac Application in Patients With Moderate to Severe Facial Acne Vulgaris|Completed||Phase 2|20|Actual|Photocure||2|||f||||f||||||||||2018-05-31 23:35:46.553164|2018-05-31 23:35:46.553164
NCT01160835|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|May 2005||2005-05-31|June 2010|2010-06-30|November 2007|Actual|2007-11-30|February 2006|Actual|2006-02-28||Interventional|||Comparison of Quadriceps-sparing Minimally Invasive and Medial Parapatellar Total Knee Arthroplasty|Comparison of Quadriceps-sparing Minimally Invasive and Medial Parapatellar Total Knee Arthroplasty|Completed||Phase 4|80|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 23:35:46.971228|2018-05-31 23:35:46.971228
NCT01160822|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2012-07-26||2012-09-28|2010-07-09|2010-07-12|Estimate|2012-07-26|2012-08-30|Estimate||||2012-09-28|2012-10-30|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee|A Randomized, Double Blind, Placebo and Naproxen Controlled, Multi-center, Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee|Completed||Phase 2|169|Actual|Novartis||5|||f||||||||||||||2018-05-31 23:35:47.202938|2018-05-31 23:35:47.202938
NCT01160809|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia|Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Southern Ethiopia: a Cluster-randomized Controlled Trial|Completed||Phase 4|6082|Actual|Malaria Consortium, Ethiopia||1|||f||||f||||||||||2018-05-31 23:35:48.557614|2018-05-31 23:35:48.557614
NCT01160796|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2016-03-24|2010-07-09|2010-07-12|Estimate|||||||2016-03-24|2016-03-25|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|April 2012|Actual|2012-04-30|May 2011|Actual|2011-05-31||Interventional|||Lcr35® for Bacterial Vaginosis Prevention|Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial|Completed||Phase 3|352|Actual|Laboratoires Lyocentre||2|||f||||f||||||||||2018-05-31 23:35:48.66506|2018-05-31 23:35:48.66506
NCT01160783|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-02-26|2010-07-09|2010-07-12|Estimate|||||||2018-02-26|2018-02-27|Actual|April 2007||2007-04-30|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Observational|||Genetic Contributions to Autism Spectrum Disorders|Genetic Contributions to Autism Spectrum Disorders|Active, not recruiting|||240|Actual|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood, DNA and RNA and/or Saliva, DNA~   "|No||2018-05-31 23:35:48.719673|2018-05-31 23:35:48.719673
NCT01160770|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|2013-02-15||2018-02-22|2010-07-09|2010-07-12|Estimate|2013-03-22|2013-05-06|Estimate||||2018-02-22|2018-03-21|Actual|December 2005||2005-12-31|February 2018|2018-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|LGS||Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome|Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome|Completed||Phase 3|267|Actual|Lundbeck LLC||1|||f||||f||||||||||2018-05-31 23:35:48.816651|2018-05-31 23:35:48.816651
NCT01160757|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|October 2008||2008-10-31|July 2010|2010-07-31||||July 2009|Actual|2009-07-31||Interventional|||A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions|A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions|Completed||Phase 1|35|Anticipated|Arizona State University||1|||f||||t||||||||||2018-05-31 23:35:49.357938|2018-05-31 23:35:49.357938
NCT01160744|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2014-12-17|2014-05-01|2017-12-08|2010-07-09|2010-07-12|Estimate|2014-12-17|2014-12-29|Estimate|2010-08-30|2010-09-01|Estimate|2017-12-08|2018-01-03|Actual|September 2010||2010-09-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|January 2014|Actual|2014-01-31||Interventional||All randomized participants.|A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination With Platinum-based Chemotherapy Versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|280|Actual|Eli Lilly and Company||4|||f||||t||||||||||2018-05-31 23:35:49.531959|2018-05-31 23:35:49.531959
NCT01160731|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2014-12-30|2010-07-09|2010-07-12|Estimate|||||||2014-12-30|2014-12-31|Estimate|November 2009||2009-11-30|October 2012|2012-10-31||||October 2010|Actual|2010-10-31||Interventional|||Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I Dose Finding Study of the Pan-DAC Inhibitor Panobinostat (LBH589) in Combination With Etoposide and Cisplatin in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer - An ICORG In-House Study|Withdrawn||Phase 1|0|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-05-31 23:35:51.133561|2018-05-31 23:35:51.133561
NCT01160718|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2016-09-16|2010-07-09|2010-07-12|Estimate|||||||2016-09-16|2016-09-19|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|December 2012|Actual|2012-12-31||Interventional|||Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy|Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) ½ Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial|Completed||Phase 2|46|Actual|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-05-31 23:35:51.207155|2018-05-31 23:35:51.207155
NCT01160692|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-07-30|2010-07-09|2010-07-12|Estimate|||||||2010-07-30|2010-08-02|Estimate|February 2006||2006-02-28|July 2010|2010-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study to Evaluate The Effects Of a Multivitamin/Mineral With Ginko In Subjects With Age Associated Memory Impairment|A Randomized, Placebo-controlled, Parallel Group, Double Blind Study to Evaluate the Cognitive Effects and Tolerance of a Multi-Vitamin/Mineral Preparation Containing Gingko in Elderly Subjects With Age Associated Memory Impairment|Completed||Phase 3|132|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:35:51.382535|2018-05-31 23:35:51.382535
NCT01160679|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-08-17|2010-07-09|2010-07-12|Estimate|||||||2011-08-17|2011-08-18|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|PLEASURE||Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia|Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia|Completed|||231|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:35:51.505985|2018-05-31 23:35:51.505985
NCT01160666|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2012-07-01|2010-07-09|2010-07-12|Estimate|||||||2012-07-01|2012-07-03|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|BELISS||Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome|A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS (BAFF) Antibody, in Subjects With Primary Sjögren's Syndrome|Completed||Phase 2|20|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:35:51.582|2018-05-31 23:35:51.582
NCT01160653|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2014-02-21|2010-07-08|2010-07-12|Estimate|||||||2014-02-21|2014-02-25|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Cognitive & Motor Training After Stroke For Everyday Walking Restoration|Cognitive and Motor Training After Stroke for Everyday Walking Restoration|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Never funded|f||||f||||||||||2018-05-31 23:35:51.713206|2018-05-31 23:35:51.713206
NCT01160640|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2016-10-26||2017-08-08|2010-07-09|2010-07-12|Estimate|2016-10-26|2016-12-21|Estimate||||2017-08-08|2017-09-08|Actual|November 2010||2010-11-30|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)|The Importance of Anti-anaerobic Therapy for Acute PID|Completed||Phase 2|233|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 23:35:51.807677|2018-05-31 23:35:51.807677
NCT01160627|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2013-03-21|2010-07-09|2010-07-12|Estimate|||||||2013-03-21|2013-03-22|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction|Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction|Completed||N/A|720|Actual|Odense University Hospital||4|||f||||t||||||||||2018-05-31 23:35:52.308537|2018-05-31 23:35:52.308537
NCT01160614|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2012-07-17||2012-10-11|2010-07-08|2010-07-12|Estimate|2012-07-17|2012-08-21|Estimate||||2012-10-11|2012-10-15|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients|An Open-label Study to Characterize the Pharmacokinetics and Safety of Oxycodone Hydrochloride q12h Controlled-Release (ORF) Tablets in Pediatric Patients Aged 6 to 16 Years Inclusive, Who Require Opioid Analgesia|Completed||Phase 1|30|Actual|Purdue Pharma LP||1|||f||||f||||||||||2018-05-31 23:35:52.442596|2018-05-31 23:35:52.442596
NCT01160601|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08||2017-04-18|2017-04-18|2010-07-08|2010-07-12|Estimate||||2017-04-18|2017-04-19|Actual|2017-04-18|2017-04-19|Actual|June 2010||2010-06-30|April 2017|2017-04-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer|A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients With Previously Untreated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer|Completed||Phase 2|86|Actual|Peregrine Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:35:53.045034|2018-05-31 23:35:53.045034
NCT01160588|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-05-26|2010-07-09|2010-07-12|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2010||2010-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents|Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents|Completed|||156|Actual|University of Michigan|||3||f||||t||||||Samples With DNA|"~     saliva~   "|||2018-05-31 23:35:53.168492|2018-05-31 23:35:53.168492
NCT01160575|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-05-23|2010-07-09|2010-07-12|Estimate|||||||2018-05-23|2018-05-24|Actual|June 23, 2010||2010-06-23|September 9, 2014|2014-09-09|September 9, 2014||2014-09-09|||||Observational|||A Semi-Factorial Cluster-Randomized Trial to Estimate the Effect Size of Community Mobilization and VCT Vans on the Adoption of Voluntary Counseling and Testing (VCT) Services in Andhra Pradesh, India: THE MCVCT STUDY|A Semi-Factorial Cluster-Randomized Trial to Estimate the Effect Size of Community Mobilization and VCT Vans on the Adoption of Voluntary Counseling and Testing (VCT) Services in Andhra Pradesh, India: THE MCVCT STUDY|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:35:53.244475|2018-05-31 23:35:53.244475
NCT01160562|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-05-23|2010-07-09|2010-07-12|Estimate|||||||2018-05-23|2018-05-24|Actual|June 23, 2010||2010-06-23|January 23, 2013|2013-01-23|January 23, 2013||2013-01-23|||||Observational|||Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity|Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity|Completed|||1719|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:35:53.303239|2018-05-31 23:35:53.303239
NCT01160549|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-04-04|2010-07-09|2010-07-12|Estimate|||||||2018-04-04|2018-04-05|Actual|August 1, 2010||2010-08-01|January 31, 2018|2018-01-31||||||||Observational|||Study of Pregnancy Hormone Concentrations in Urban and Nomadic Mongolian Women|Study of Pregnancy Hormone Concentrations in Urban and Nomadic Mongolian Women|Completed|||412|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:35:53.350261|2018-05-31 23:35:53.350261
NCT01160536|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-05-23|2010-07-09|2010-07-12|Estimate|||||||2018-05-23|2018-05-24|Actual|June 24, 2010||2010-06-24|August 2, 2017|2017-08-02|August 2, 2017||2017-08-02|||||Observational|||The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study|The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: An Exploratory Study|Completed|||47|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:35:53.422006|2018-05-31 23:35:53.422006
NCT01160523|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-05-23|2010-07-09|2010-07-12|Estimate|||||||2018-05-23|2018-05-24|Actual|June 14, 2010||2010-06-14|April 14, 2016|2016-04-14|April 14, 2016||2016-04-14|||||Observational|||Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis|Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis|Completed|||2106|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:35:53.48971|2018-05-31 23:35:53.48971
NCT01160484|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2014-01-10||2015-04-13|2010-07-09|2010-07-12|Estimate|2014-03-24|2014-04-21|Estimate||||2015-04-13|2015-05-04|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional||The estimated number of participants will allow to determine whether the true rate of response to DVD-R is at least 50%, at the one-sided alpha-level of 0.05 and having at least 85% power|Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma|A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients With Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|40|Actual|Oncotherapeutics||1|||f||||f||||||||||2018-05-31 23:35:53.611951|2018-05-31 23:35:53.611951
NCT01160471|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-03-27|2010-07-09|2010-07-12|Estimate|||||||2018-03-27|2018-03-29|Actual|July 1, 2010||2010-07-01|December 8, 2017|2017-12-08||||||||Observational|||Noninvasive Imaging of Heart Failure: A Pilot Study|Noninvasive Imaging of Heart Failure|Completed|||62|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:35:54.222317|2018-05-31 23:35:54.222317
NCT01160458|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2013-03-20||2018-03-13|2010-07-09|2010-07-12|Estimate|2013-03-20|2013-05-14|Estimate||||2018-03-13|2018-04-10|Actual|June 2, 2010|Actual|2010-06-02|March 2018|2018-03-31|February 24, 2017|Actual|2017-02-24|August 13, 2016|Actual|2016-08-13||Interventional|||Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy|Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy|Completed||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||Undecided||2018-05-31 23:35:54.471551|2018-05-31 23:35:54.471551
NCT01160445|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|2012-11-07||2015-10-06|2010-07-09|2010-07-12|Estimate|2012-11-07|2012-12-11|Estimate||||2015-10-06|2015-10-28|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer|Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer|Terminated||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||2||The study was terminated because we were not able to obtain the study drug.|f||||f||||||||||2018-05-31 23:35:55.170598|2018-05-31 23:35:55.170598
NCT01160432|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2013-07-03|2010-07-09|2010-07-12|Estimate|||||||2013-07-03|2013-07-04|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|NAMEKO||Naloxone Methadone Combination (NAMEKO)|The Safety and Tolerability of Methadone/Naloxone Combination in Opioid Substitution Treatment|Withdrawn||N/A|0|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 23:35:56.118093|2018-05-31 23:35:56.118093
NCT01160419|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-10-27|2010-07-09|2010-07-12|Estimate|||||||2010-10-27|2010-10-28|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|May 2014|Anticipated|2014-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer||Unknown status|Active, not recruiting|Phase 2|49|Anticipated|Ludwig-Maximilians - University of Munich||1|||f||||||||||||||2018-05-31 23:35:56.207685|2018-05-31 23:35:56.207685
NCT01160406|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2011-06-22|2010-07-09|2010-07-12|Estimate|||||||2011-06-22|2011-06-27|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Screening for Atrial Fibrillation, After Ischemic Stroke|Improving Screening for Silent Atrial Fibrillation, After Ischemic Stroke|Completed|||250|Anticipated|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 23:35:56.312512|2018-05-31 23:35:56.312512
NCT01160393|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2017-10-17|2010-07-09|2010-07-12|Estimate|||||||2017-10-17|2017-10-18|Actual|July 2010||2010-07-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Atrial Fibrillation After Cardiac Surgery-comparing Conventional and Miniaturized Bypass Systems|Atrial Fibrillation After Cardiac Surgery - Prospective, Randomized Study Comparing Conventional and Miniaturized Bypass Systems|Completed||N/A|240|Actual|Kuopio University Hospital||1|||f||||f||||||||||2018-05-31 23:35:56.41672|2018-05-31 23:35:56.41672
NCT01160380|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2014-10-22||2014-11-05|2010-07-08|2010-07-12|Estimate|2014-11-05|2014-11-06|Estimate||||2014-11-05|2014-11-06|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma|A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients With Multiple Myeloma|Completed||Phase 3|50|Actual|Oncotherapeutics||2|||f||||f||||||||||2018-05-31 23:35:56.571225|2018-05-31 23:35:56.571225
NCT01160367|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life|Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life|Unknown status|Recruiting|N/A|264|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:35:57.289055|2018-05-31 23:35:57.289055
NCT01160354|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2016-03-23|2010-07-08|2010-07-12|Estimate|||||||2016-03-23|2016-03-24|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)|Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit|Terminated||Phase 1/Phase 2|22|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-05-31 23:35:57.355265|2018-05-31 23:35:57.355265
NCT01160341|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|August 2009||2009-08-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism|Phase 4 Study of About the Effect of Testosterone Treatment on the Components of Metabolic Syndrome|Completed||Phase 4|312|Actual|Gulhane School of Medicine||1|||f||||f||||||||||2018-05-31 23:35:57.532967|2018-05-31 23:35:57.532967
NCT01160328|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-05-13|2010-07-09|2010-07-12|Estimate|||||||2014-05-13|2014-05-14|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Influence of Male Hormones on Regional Fat Metabolism|Influence of Male Hormones on Regional Fat Metabolism|Completed||Phase 1|39|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 23:35:57.62117|2018-05-31 23:35:57.62117
NCT01160315|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2015-10-29|2010-07-09|2010-07-12|Estimate|||||||2015-10-29|2015-10-30|Estimate|July 2002||2002-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|June 2010|Actual|2010-06-30||Interventional|Erasme-POF||Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure|A Prospective Open Randomized Trial on the Efficacy of Gonadotropin-releasing Hormone Agonist Depot-Triptorelin- to Prevent Chemotherapy Induced Premature Ovarian Failure in Lymphoma Patients.|Completed||Phase 2/Phase 3|118|Actual|Erasme University Hospital||2|||f||||f||||||||||2018-05-31 23:35:57.723873|2018-05-31 23:35:57.723873
NCT01160302|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2016-03-01|2010-07-08|2010-07-12|Estimate|||||||2016-03-01|2016-03-02|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Curcumin Biomarker Trial in Head and Neck Cancer|An Exploratory Biomarker Trial of the Food Substances Curcumin C3 Complex® in Subjects With Newly Diagnosed Head and Neck Squamous Cell Carcinoma|Completed||Early Phase 1|33|Actual|Louisiana State University Health Sciences Center Shreveport||1|||f||||t||||||||||2018-05-31 23:35:57.81684|2018-05-31 23:35:57.81684
NCT01160289|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08||2012-02-10|2012-02-10|2010-07-08|2010-07-12|Estimate||||2012-02-10|2012-02-14|Estimate|2012-02-10|2012-02-14|Estimate|October 2010||2010-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of LY900010 in Erectile Dysfunction|A Study of LY900010 (LY2452473 + Tadalafil) in the Treatment of Men With Erectile Dysfunction|Completed||Phase 2|378|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 23:35:57.889409|2018-05-31 23:35:57.889409
NCT01160276|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2013-04-10|2010-07-09|2010-07-12|Estimate|||||||2013-04-10|2013-04-11|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|COLCHINCAL||Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients|An Open Non Randomized Comparative Study Exploring Drug Interaction Between Colchicine and Calcineurin Inhibitors in 2 Groups (Ciclosporin Group and Tacrolimus Group) of Renal Graft Recipients|Completed||Phase 1|17|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:35:58.031966|2018-05-31 23:35:58.031966
NCT01160263|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-05-12|2010-07-09|2010-07-12|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|DOSERAL||Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls|Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT|Completed||Phase 3|16|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 23:35:58.117274|2018-05-31 23:35:58.117274
NCT01160250|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2015-08-04|2010-07-08|2010-07-12|Estimate|||||||2015-08-04|2015-08-06|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Expanded Access|||A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|A Single-Arm, Open-Label, Expanded Access Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|Approved for marketing|||||Genentech, Inc.|||||||||||||||||||2018-05-31 23:35:58.198995|2018-05-31 23:35:58.198995
NCT01160237|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2012-02-21||2016-09-09|2010-07-08|2010-07-12|Estimate|2012-02-21|2012-03-23|Estimate||||2016-09-09|2016-10-20|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM|Immunogenicity and Safety of Fluarix™/ Influsplit SSW® 2010/2011 or Pandemrix™|Terminated||Phase 3|7|Actual|GlaxoSmithKline|Only 7 subjects were enrolled in either the Pandemrix Group or the Fluarix Group and none in the Control Group since the study was terminated prematurely. Therefore most outcome measures (except unsolicited AEs and SAEs) were not analysed.|3||The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:35:58.260624|2018-05-31 23:35:58.260624
NCT01160224|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2017-04-11|2010-07-08|2010-07-12|Estimate|||||||2017-04-11|2017-04-13|Actual|September 8, 2010|Actual|2010-09-08|April 2017|2017-04-30|August 29, 2011|Actual|2011-08-29|August 29, 2011|Actual|2011-08-29||Interventional|||Oral GW766944 (Oral CCR3 Antagonist)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare GW766944 (an Oral CCR3 Receptor Antagonist) Versus Placebo in Patients With Asthma and Sputum Eosinophilia.|Completed||Phase 2|60|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:35:59.518001|2018-05-31 23:35:59.518001
NCT01160211|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-10-16|2010-07-08|2010-07-12|Estimate|||||||2017-10-16|2017-10-18|Actual|May 5, 2011|Actual|2011-05-05|October 2017|2017-10-31|May 5, 2019|Anticipated|2019-05-05|May 5, 2019|Anticipated|2019-05-05||Interventional|||A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer|A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies|Active, not recruiting||Phase 3|364|Actual|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 23:35:59.751073|2018-05-31 23:35:59.751073
NCT01160198|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2017-04-28||2017-09-11|2010-07-08|2010-07-12|Estimate|2017-09-11|2018-04-13|Actual||||2017-09-11|2018-04-13|Actual|October 13, 2010|Actual|2010-10-13|September 2017|2017-09-30|February 18, 2011|Actual|2011-02-18|February 18, 2011|Actual|2011-02-18||Interventional|||A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.|A Multicentre, Randomized, Laboratory-blinded, Parallel-group Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.|Completed||Phase 3|271|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 23:36:00.388711|2018-05-31 23:36:00.388711
NCT01160185|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-08|2010-07-08|2010-07-12|Estimate|||||||2010-07-08|2010-07-12|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Meta-analysis of Efficacy of Topotecan|Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix|Completed|||1|Actual|GlaxoSmithKline|||3||f||||||||||||||2018-05-31 23:36:00.962112|2018-05-31 23:36:00.962112
NCT01160172|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-05-24|2010-07-08|2010-07-12|Estimate|||||||2017-05-24|2017-05-30|Actual|July 19, 2010|Actual|2010-07-19|May 2017|2017-05-31|August 23, 2012|Actual|2012-08-23|August 23, 2012|Actual|2012-08-23||Interventional|||A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults|A Partially Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal 4-component Investigational Vaccine (GSK2392102A) in Healthy Adults|Completed||Phase 1|88|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 23:36:01.030213|2018-05-31 23:36:01.030213
NCT01160159|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|MICMAC||Arterial Microcirculation, Macrocirculation and Thrombophilias|Arterial Microcirculation, Macrocirculation and Thrombophilias|Unknown status|Recruiting||240|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 23:36:01.190641|2018-05-31 23:36:01.190641
NCT01160146|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2015-08-14|2010-07-09|2010-07-12|Estimate|||||||2015-08-14|2015-08-17|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|GEISO||Geisinger Education Intervention Study in Obesity Protocol|Geisinger Education Intervention Study in Obesity Protocol|Completed|||289|Actual|Geisinger Clinic|||1||f||||f||||||||||2018-05-31 23:36:01.304339|2018-05-31 23:36:01.304339
NCT01160133|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2012-04-07|2010-07-09|2010-07-12|Estimate|||||||2012-04-07|2012-04-10|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops||Completed||N/A|78|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:36:01.404681|2018-05-31 23:36:01.404681
NCT01160120|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2016-02-18|2010-07-09|2010-07-12|Estimate|||||||2016-02-18|2016-02-22|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|May 2013|Actual|2013-05-31||Interventional|||Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz|Generic Fixed Dose Combination (FDC) of Tenofovir(TDF) /Lamivudine(3TC)/Efavirenz (EFV) Tablets 300/300/600 mg|Completed||Phase 2|100|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-05-31 23:36:01.49528|2018-05-31 23:36:01.49528
NCT01160107|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2017-07-31|2010-07-09|2010-07-12|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2008||2008-07-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2012|Actual|2012-08-31||Interventional|RP_MPR||Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients|A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients|Active, not recruiting||Phase 2|46|Actual|Fondazione Neoplasie Sangue Onlus||1|||f||||t||||||||||2018-05-31 23:36:01.588687|2018-05-31 23:36:01.588687
NCT01160094|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2016-03-25|2010-07-08|2010-07-12|Estimate|||||||2016-03-25|2016-03-28|Estimate|February 2010||2010-02-28|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|TYCO||Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)|Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)|Completed|||288|Actual|Novartis|||1||f||||f||||||||||2018-05-31 23:36:01.665108|2018-05-31 23:36:01.665108
NCT01160081|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-01-22|2010-07-08|2010-07-12|Estimate|||||||2011-01-22|2011-01-25|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis|Sero-prevalence of Hepatitis A Varicella-Zoster Virus, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis in Mexico|Completed|||3658|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Serum samples~   "|||2018-05-31 23:36:01.751241|2018-05-31 23:36:01.751241
NCT01160068|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-12|2010-07-09|2010-07-12|Estimate|||||||2010-07-12|2010-07-13|Estimate|February 2005||2005-02-28|January 2005|2005-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fed Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Metformin Hydrochloride 1000 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics, India) to be Compared With Glucophage® (Metformin Hydrochloride) 1000 mg Tablets (Bristol-Myers Squibb, USA) in 48 + (2 Standby) Healthy, Adult, Human Subjects Under Fed Conditions|Completed||Phase 1|50|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:36:01.851862|2018-05-31 23:36:01.851862
NCT01160055|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2015-04-09|2010-07-08|2010-07-12|Estimate|||||||2015-04-09|2015-04-13|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Study to Characterize and Identify Bacteria Causing Acute Otitis Media in Young Egyptian Children|Identification and Characterisation of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Egypt|Withdrawn|||0|Actual|GlaxoSmithKline|||2|"Key aspects linked to sample management and analysis were not met during feasibility assessment~   limiting the ability of the study to reach its objectives."|f||||||||||Samples Without DNA|"~     Middle ear fluid, Urine.~   "|||2018-05-31 23:36:01.932493|2018-05-31 23:36:01.932493
NCT01160042|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-22|2010-07-09|2010-07-12|Estimate|||||||2010-07-22|2010-07-26|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Bioequivalence Study of Metformin Hydrochloride Tablets 1000 mg Tablets of Dr. Reddy's Laboratories Limited Under Fasting Condition|A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study of Metformin Hydrochloride 1000 mg Tablets (Dr. Reddy's Laboratories Ltd., Generics, India) to be Compared With Glucophage® (Metformin Hydrochloride) 1000 mg Tablets (Bristol-Myers Squibb, USA) in 52 + (2 Standby) Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:36:02.015056|2018-05-31 23:36:02.015056
NCT01160029|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-12|2010-07-09|2010-07-12|Estimate|||||||2010-07-12|2010-07-13|Estimate|October 2004||2004-10-31|September 2004|2004-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition|RANDOMIZED, 2-WAY CROSSOVER, BIOEQUIVALENCE STUDY OF NATEGLINIDE 120 mg TABLET AND STARLIX@ ADMINISTERED AS 1 x 120 mg TABLET IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS|Completed||Phase 1|58|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:36:02.111732|2018-05-31 23:36:02.111732
NCT01160003|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2017-06-13|2010-07-08|2010-07-12|Estimate|||||||2017-06-13|2017-06-14|Actual|July 29, 2010|Actual|2010-07-29|June 2017|2017-06-30|November 5, 2010|Actual|2010-11-05|November 5, 2010|Actual|2010-11-05||Interventional|SIG||A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.|A Randomised, Double-blind, Placebo-controlled, Dose Ascending,3-way Crossover Study to Assess the Pharmacokinetics, Safety Andtolerability of Repeat Inhaled Doses of Nebulised GW870086X Inhealthy Adult Male Volunteers.|Completed||Phase 1|12|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:36:02.192107|2018-05-31 23:36:02.192107
NCT01029483|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-09|2009-12-09|2009-12-10|Estimate|||||||2009-12-09|2009-12-10|Estimate|September 2005||2005-09-30|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|EBS||The Energy Balance Study|Energy and Appetite Regulation by Low CHO Diets|Completed||Phase 1|39|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 00:16:59.991486|2018-06-01 00:16:59.991486
NCT01159990|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2017-09-25|2010-07-08|2010-07-12|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2011||2011-01-31|September 2017|2017-09-30|February 28, 2017|Actual|2017-02-28|August 2012|Actual|2012-08-31||Interventional|||Antigenic Competition in HIV Preventive Vaccines|A Randomized, Double Blind Phase 1b Trial to Examine the Influence of Antigenic Competition on the Immunogenicity of HIV-1 Gag/Pol: A Comparison of rAd5 Gag/Pol Env A/B/C to rAd5 Gag/Pol|Completed||Phase 1|100|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-05-31 23:36:02.297327|2018-05-31 23:36:02.297327
NCT01159977|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2012-11-14|2010-07-09|2010-07-12|Estimate|||||||2012-11-14|2012-11-15|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Trial Evaluating the Effect of Facilitated Small Group Sessions on Physician Well-Being, Job Satisfaction, and Professionalism||Completed||Phase 2|74|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 23:36:02.381966|2018-05-31 23:36:02.381966
NCT01159964|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2017-05-12|2010-07-08|2010-07-12|Estimate|||||||2017-05-12|2017-05-15|Actual|July 20, 2010|Actual|2010-07-20|May 2017|2017-05-31|September 10, 2014|Actual|2014-09-10|October 19, 2011|Actual|2011-10-19||Interventional|||Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery|Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer|Terminated||Phase 1|60|Actual|GlaxoSmithKline||3||"Study termination due to negative Phase III of another study product from same technology~   platform."|f||||||||||||||2018-05-31 23:36:02.465039|2018-05-31 23:36:02.465039
NCT01159951|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2017-06-06|2010-07-08|2010-07-12|Estimate|||||||2017-06-06|2017-06-07|Actual|January 2009||2009-01-31|June 2017|2017-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Analysis of Trends Over Time of Hepatitis Related Incidence in Panama|Time Trend Analysis of the Incidence of Hepatitis- Related Outcomes (Viral Hepatitis A and Unspecified Viral Hepatitis) Reported to the Surveillance System of Panama, 2000-2010|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||None Retained|"~     No samples retained~   "|||2018-05-31 23:36:02.650995|2018-05-31 23:36:02.650995
NCT01159938|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2014-02-21||2014-02-21|2010-07-08|2010-07-12|Estimate|2014-02-21|2014-04-03|Estimate||||2014-02-21|2014-04-03|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All enrolled participants, with the exception of 1 healthy participant who completed the study but was later excluded from analyses due to major protocol violation.|A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes|The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes|Completed||Phase 4|72|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:36:02.923982|2018-05-31 23:36:02.923982
NCT01159925|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2012-11-21|2010-07-08|2010-07-12|Estimate|||||||2012-11-21|2012-11-22|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamanian Children|Epidemiologic Surveillance to Assess Trends in Acute Hepatitis A Among Children in Panama|Completed|||42|Actual|GlaxoSmithKline|||3||f||||||||||Samples With DNA|"~     Serum~   "|||2018-05-31 23:36:04.230351|2018-05-31 23:36:04.230351
NCT01159912|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2013-06-06|2012-07-12|2017-10-09|2010-07-08|2010-07-12|Estimate|2013-06-06|2013-08-08|Estimate|2012-07-12|2012-07-23|Estimate|2017-10-09|2017-11-09|Actual|June 30, 2010||2010-06-30|October 2017|2017-10-31|January 16, 2012|Actual|2012-01-16|January 1, 2012|Actual|2012-01-01||Interventional|||Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents|A Randomised, Double-blind, Double-dummy, Placebo Controlled (With Rescue Medication), Multicenter Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.|Completed||Phase 3|350|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:36:04.3532|2018-05-31 23:36:04.3532
NCT01159899|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2013-01-07|2010-07-09|2010-07-12|Estimate|||||||2013-01-07|2013-01-08|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Transplantation of Bone Marrow Stem Cells Stimulated by Proteins Scaffold to Heal Defects Articular Cartilage of the Knee|Pilot Study of A One-Step Procedure for the Use of Autologous Bone Marrow Mesenchymal Stem Cells Stimulated by Proteins Scaffold to Heal Under Arthroscopy Full-Thickness Defects Articular Cartilage and Osteoarthrosis of the Knee.|Unknown status|Recruiting|Early Phase 1|50|Anticipated|University of Marseille|||||f||||t||||||||||2018-05-31 23:36:05.112297|2018-05-31 23:36:05.112297
NCT01159886|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Interventional|PIC||Patient-posture and Ileal-intubation During Colonoscopy|Patient-posture and Ileal-intubation During Colonoscopy (PIC): a Randomized Controlled Open-label Trial|Unknown status|Recruiting|N/A|216|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 23:36:05.231274|2018-05-31 23:36:05.231274
NCT01159873|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-05-09|2010-07-08|2010-07-12|Estimate|||||||2014-05-09|2014-05-12|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women|Terminated||Phase 1|2|Actual|Teva Pharmaceutical Industries||2||Study has been stopped by sponsor decision|f||||||||||||||2018-05-31 23:36:05.303681|2018-05-31 23:36:05.303681
NCT01159860|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2018-05-23|2010-07-09|2010-07-12|Estimate|||||||2018-05-23|2018-05-25|Actual|July 2010||2010-07-31|May 2018|2018-05-31|June 6, 2013|Actual|2013-06-06|May 11, 2012|Actual|2012-05-11||Interventional|||Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?|Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?|Completed||N/A|25|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 23:36:05.365954|2018-05-31 23:36:05.365954
NCT01159847|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2010-07-09|2010-07-09|2010-07-12|Estimate|||||||2010-07-09|2010-07-12|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|DPP-ⅣLADA||Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA)|Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes(LADA)|Unknown status|Enrolling by invitation|Phase 1/Phase 2|60|Anticipated|European Foundation for the Study of Diabetes||2|||f||||t||||||||||2018-05-31 23:36:05.436077|2018-05-31 23:36:05.436077
NCT01158612|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-11-04|2010-07-07|2010-07-08|Estimate|||||||2011-11-04|2011-11-07|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||The Effect of Local Injectet GH on the Collagen Synthesis in the Ligamentum Patella|The Effect of Local Injectet GH on the Collagen Synthesis in the Ligamentum Patella|Completed||N/A|12|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:36:21.532572|2018-05-31 23:36:21.532572
NCT01159834|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-09|||2012-01-23|2010-07-09|2010-07-12|Estimate|||||||2012-01-23|2012-01-25|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)|Proposal for HPV Vaccination of Women in the City of Barretos. A Pioneering Project Designed by the Pio XII Foundation - Barretos Cancer Hospital.|Completed|||1574|Actual|Barretos Cancer Hospital|||1||f||||f||||||||||2018-05-31 23:36:05.531661|2018-05-31 23:36:05.531661
NCT01159821|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-04-07|2010-07-08|2010-07-09|Estimate|||||||2014-04-07|2014-04-08|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|October 2010|Actual|2010-10-31|||||Interventional|||A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers|An Open-Label Study to Assess the Effect of CYP2D6 Inhibitor Paroxetine on the Single-Dose Pharmacokinetics of JNJ-31001074 in Healthy Subjects|Completed||Phase 1|14|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 23:36:05.593037|2018-05-31 23:36:05.593037
NCT01159808|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2012-06-21|2010-07-08|2010-07-09|Estimate|||||||2012-06-21|2012-06-22|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects|A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects|Completed||Phase 1|42|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 23:36:05.68105|2018-05-31 23:36:05.68105
NCT01159795|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2016-11-10|2010-07-08|2010-07-09|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2010||2010-10-31|April 2012|2012-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Studying Innate Immune Responses in Infants With Bronchiolitis|Investigating Type I and Type III Interferon Responses in Infants With Respiratory Syncytial Virus|Terminated|||250|Actual|Imperial College London||||Awaiting further funding|f||||t||||||Samples With DNA|"~     Blood plasma - cytokines Blood EDTA - DNA Blood PAXgene tube - RNA Nasal lining fluid -~     cytokines Nasal mucosal lining - RNA~   "|||2018-05-31 23:36:05.756252|2018-05-31 23:36:05.756252
NCT01159782|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-22|2010-07-08|2010-07-09|Estimate|||||||2010-07-22|2010-07-23|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Mechanisms of Rhinovirus Induced Asthma Exacerbations|Human Model of Rhinovirus Induced Acute Asthma Exacerbations|Unknown status|Recruiting|N/A|45|Anticipated|Imperial College London||1|||f||||t||||||||||2018-05-31 23:36:05.832835|2018-05-31 23:36:05.832835
NCT01159769|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2012-03-05||2012-03-05|2010-07-08|2010-07-09|Estimate|2012-03-05|2012-04-03|Estimate||||2012-03-05|2012-04-03|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis||Completed||Phase 4|215|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:36:05.906565|2018-05-31 23:36:05.906565
NCT01159756|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2012-04-07|2010-07-08|2010-07-09|Estimate|||||||2012-04-07|2012-04-10|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure||Completed||Phase 4|468|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:36:06.0777|2018-05-31 23:36:06.0777
NCT01159743|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2012-09-28||2013-01-16|2010-07-08|2010-07-09|Estimate|2012-09-28|2012-10-30|Estimate||||2013-01-16|2013-01-24|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|LYNX||A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine|A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine|Completed|||346|Actual|AbbVie|||2||f||||f||||||||||2018-05-31 23:36:06.162877|2018-05-31 23:36:06.162877
NCT01159730|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-11-15|2010-07-08|2010-07-09|Estimate|||||||2011-11-15|2011-11-16|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers|Completed||Phase 2|320|Anticipated|Vascular Biogenics Ltd. operating as VBL Therapeutics||2|||f||||t||||||||||2018-05-31 23:36:06.554971|2018-05-31 23:36:06.554971
NCT01159717|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-12|2010-07-08|2010-07-09|Estimate|||||||2010-07-12|2010-07-13|Estimate|January 2007||2007-01-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|December 2008|Actual|2008-12-31||Observational|||CT Versus CEUS Findings of Complex Cystic Renal Lesions|Complex Cystic Renal Lesions: Evaluation of Computed Tomography Findings With Contrast Enhanced Ultrasound in Terms of the Bosniak Classification System.|Completed|||35|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 23:36:06.625772|2018-05-31 23:36:06.625772
NCT01159704|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2018-05-07|2010-07-08|2010-07-09|Estimate|||||||2018-05-07|2018-05-08|Actual|July 2010||2010-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2015|Actual|2015-11-30||Interventional|||Peer Leaders as HIV Risk Reduction Change Agents Among Injection Drug Users (IDUs) in Ukraine|Peer Leaders as HIV Risk Reduction Change Agents Among Injection Drug Users (IDUs) in Ukraine|Active, not recruiting||N/A|5250|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 23:36:06.694598|2018-05-31 23:36:06.694598
NCT01159691|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2013-03-11||2013-05-13|2010-07-08|2010-07-09|Estimate|2013-03-11|2013-04-23|Estimate||||2013-05-13|2013-05-21|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|NON-GI|Baseline Characteristics show the Enrolled Set (ES). ES encompasses those patients who have been included in this study and for whom data are available on the first Visit (initial examination).|Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch|A Multicentric, Non-interventional Study on Switching From Oral Parkinson Therapy to Neupro® in Patients With Idiopathic Parkinson's Disease With Gastrointestinal Symptoms|Completed|||76|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 23:36:06.792352|2018-05-31 23:36:06.792352
NCT01159678|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-06-11|2010-07-08|2010-07-09|Estimate|||||||2015-06-11|2015-06-15|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|OPES||Online Psychoeducation for Sexual Dysfunction in Cancer Survivors|Online Psychoeducation for Sexual Dysfunction in Cancer Survivors|Completed||N/A|112|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 23:36:07.058552|2018-05-31 23:36:07.058552
NCT01158989|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-04-11|2010-07-07|2010-07-08|Estimate|||||||2017-04-11|2017-04-13|Actual|May 2006||2006-05-31|April 2017|2017-04-30|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Observational|||Clinical Evaluation Gastrointestinal Motility With PillCam|Clinical Evaluation of Endoscopic Video Capsule for Investigation of Small Intestine Transit Time and Intestinal Pathology in Critically Ill Patients|Completed|||16|Actual|University of Louisville|||2||f||||f||||||||||2018-05-31 23:36:15.770101|2018-05-31 23:36:15.770101
NCT01159665|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2012-12-20||2014-12-02|2010-07-08|2010-07-09|Estimate|2012-12-20|2013-01-30|Estimate||||2014-12-02|2014-12-17|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|MIVI-10||The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)|An Open-Label, Ascending-Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects Scheduled for Primary Pars Plana Vitrectomy|Completed||Phase 2|38|Actual|ThromboGenics||6|||f||||f||||||||||2018-05-31 23:36:07.209274|2018-05-31 23:36:07.209274
NCT01159652|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-08-25|2010-07-08|2010-07-09|Estimate|||||||2014-08-25|2014-08-26|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Hypnotic Medications and Memory: Effect of Drug Exposure During the Night|Hypnotic Medications and Sleep-dependent Memory Consolidation: the Effect of Variable Drug Exposure During the Night|Completed||Phase 4|26|Actual|St. Luke's Hospital, Chesterfield, Missouri||4|||f||||f||||||||||2018-05-31 23:36:07.825444|2018-05-31 23:36:07.825444
NCT01159639|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2013-08-27|2010-07-08|2010-07-09|Estimate|||||||2013-08-27|2013-08-28|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting|Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting|Completed||Phase 4|200|Actual|University of Zagreb||2|||f||||f||||||||||2018-05-31 23:36:07.933785|2018-05-31 23:36:07.933785
NCT01159626|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-04-19|2010-07-08|2010-07-09|Estimate|||||||2011-04-19|2011-04-20|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetics, Safety and Tolerability Study of PF-03463275 in Healthy Male Japanese and Western Subjects|A Phase 1, Randomized, Subject- and Investigator-blind, Sponsor-open, Placebo-controlled, Single- and Multiple-dose Escalation Study to Investigate the Pharmacokinetics, Safety and Tolerability of PF-03463275 in Healthy Male Japanese and Western Subjects|Completed||Phase 1|40|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:36:08.04199|2018-05-31 23:36:08.04199
NCT01159613|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Observational|||Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?|Do Low HDL Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?|Completed|||80|Actual|Ziv Hospital|||2||f||||t||||||||||2018-05-31 23:36:08.143075|2018-05-31 23:36:08.143075
NCT01159600|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|2014-05-16||2014-05-16|2010-07-08|2010-07-09|Estimate|2014-05-16|2014-06-17|Estimate||||2014-05-16|2014-06-17|Estimate|July 2010||2010-07-31|May 2014|2014-05-31||||February 2012|Actual|2012-02-29||Interventional||"Full analysis set (FAS), which included all randomised patients treated with at least one dose of study drug with a baseline HbA1c value. Treatment assignment as randomised.~Open label set which included all patients entered in the empa 25mg open-label arm."|Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea|Completed||Phase 3|1504|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:36:08.286741|2018-05-31 23:36:08.286741
NCT01159587|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-04-12|2010-07-08|2010-07-09|Estimate|||||||2011-04-12|2011-04-13|Estimate|July 2004||2004-07-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|POTTER||Prophylaxis Versus On-demand Therapy Through Economic Report|Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A. POTTER|Completed|||58|Actual|Bayer|||2||f||||f||||||||||2018-05-31 23:36:09.578676|2018-05-31 23:36:09.578676
NCT01159574|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2017-02-28||2017-06-19|2010-07-08|2010-07-09|Estimate|2017-02-28|2017-04-12|Actual||||2017-06-19|2017-07-18|Actual|August 2010|Actual|2010-08-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|October 2013|Actual|2013-10-31||Interventional||121 subject signed consent; 1 subject was not considered to be evaluable and was not included in any analysis.|Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma|A Phase II Study of Dexamethasone (DECADRON®), Clarithromycin (BIAXIN®), and Pomalidomide (CC-4047®) for Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 2|121|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-05-31 23:36:09.671211|2018-05-31 23:36:09.671211
NCT01159561|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2015-06-05|2010-07-08|2010-07-09|Estimate|||||||2015-06-05|2015-06-09|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|WEE||Western Equine Encephalitis Vaccine|Phase 1 Study to Evaluate the Safety and Immunogenicity of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, In Healthy Adults|Completed||Phase 1|20|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-05-31 23:36:10.130756|2018-05-31 23:36:10.130756
NCT01159548|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-07-26|2010-07-07|2010-07-09|Estimate|||||||2011-07-26|2011-07-27|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Efficacy of Low Dose Promethazine for Postoperative Nausea and Vomiting||Terminated||N/A|400|Anticipated|Women's College Hospital||3||Population of interest was no longer available|f||||f||||||||||2018-05-31 23:36:10.215293|2018-05-31 23:36:10.215293
NCT01159535|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2015-06-17||2016-07-01|2010-07-07|2010-07-09|Estimate|2016-07-01|2016-08-15|Estimate||||2016-07-01|2016-08-15|Estimate|October 2009||2009-10-31|July 2016|2016-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|MBRP||Mindfulness Based Relapse Prevention: Efficacy and Mechanisms|Mindfulness Based Relapse Prevention: Efficacy and Mechanisms|Completed||Phase 1/Phase 2|286|Actual|University of Washington||3|||f||||t||||||||Undecided||2018-05-31 23:36:10.28754|2018-05-31 23:36:10.28754
NCT01159522|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2017-10-18|2010-07-07|2010-07-09|Estimate|||||||2017-10-18|2017-10-19|Actual|April 2011||2011-04-30|September 2015|2015-09-30|July 11, 2017|Actual|2017-07-11|July 2017|Actual|2017-07-31||Interventional|||A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy|A Phase 1 Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy|Completed||Phase 1|33|Actual|SynCore Biotechnology Co., Ltd.||1|||f||||t||||||||||2018-05-31 23:36:10.544804|2018-05-31 23:36:10.544804
NCT01159509|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||The Effect of Hypertrophic Pyloric Stenosis (HPS) on Sodium Intake in Childhood||Unknown status|Not yet recruiting||40|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 23:36:10.620871|2018-05-31 23:36:10.620871
NCT01159496|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-03-09|2010-07-07|2010-07-09|Estimate|||||||2011-03-09|2011-03-10|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MAD||Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760)|A Randomized Investigator And Subject-Blind, Sponsor Open, Placebo Controlled Phase 1 Study To Characterize The Safety, Tolerability, And Pharmacokinetics Of Ascending Multiple Doses Of PF-05212377 (SAM-760) Administered Orally To Healthy Young And Elderly Subjects|Completed||Phase 1|60|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:36:10.694284|2018-05-31 23:36:10.694284
NCT01159483|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2010-10-25|2010-07-07|2010-07-09|Estimate|||||||2010-10-25|2010-10-26|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||First-In-Human Study Of PF-04958242 In Healthy Volunteers|A Phase I, First-In-Human, Randomized, Subject And Investigator-Blind, Sponsor Open, Single Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-04958242 In Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:36:10.78973|2018-05-31 23:36:10.78973
NCT01159470|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|CRPv||The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children|CRP Velocity as a Marker for Bacterial Infections in Children|Unknown status|Not yet recruiting||200|Anticipated|Shaare Zedek Medical Center|||2||f||||t||||||||||2018-05-31 23:36:10.87223|2018-05-31 23:36:10.87223
NCT01159457|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-04-14|2010-07-08|2010-07-09|Estimate|||||||2011-04-14|2011-04-15|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|January 2013|Anticipated|2013-01-31|June 2012|Anticipated|2012-06-30||Interventional|||Comparison of Engerix B Vaccine Versus Sci-B-Vac Vaccine in Celiac Patients|Engerix B Versus Sci-B-Vac Immunization in a Celiac Population of Non-responders to Primary Hepatitis B Immunization Series - a Randomized Controlled Trial|Unknown status|Recruiting|N/A|210|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-05-31 23:36:10.959979|2018-05-31 23:36:10.959979
NCT01159444|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|February 2007||2007-02-28|July 2010|2010-07-31|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Observational|||What do built-in Softwares in Home Ventilators Tell us?|What do built-in Softwares in Home Ventilators Tell us? An Observational Study of 150 Patients on Home Ventilation|Completed|||150|Actual|Ligue Pulmonaire Genevoise|||||f||||f||||||||||2018-05-31 23:36:11.048079|2018-05-31 23:36:11.048079
NCT01159431|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2013-02-01||2013-05-06|2010-07-08|2010-07-09|Estimate|2013-05-06|2013-06-03|Estimate||||2013-05-06|2013-06-03|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||External Trigeminal Nerve Stimulation for Epilepsy|Randomized Double Blind Study of External Trigeminal Nerve Stimulation for Intractable Epilepsy|Completed||Phase 2|50|Actual|Olive View-UCLA Education & Research Institute|Due to sample size and high variability in seizure frequency, median change did not achieve significance. To constrain variability, the RRATIO was used to assess seizure frequency. The RRATIO demonstrated within groups differences, p=0.04 ANOVA.|2|||f||||t||||||||||2018-05-31 23:36:11.11329|2018-05-31 23:36:11.11329
NCT01159418|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2011-09-12|2010-07-08|2010-07-09|Estimate|||||||2011-09-12|2011-09-13|Estimate|June 2008||2008-06-30|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors|A Phase IB Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) Given Orally in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|Southern Europe New Drug Organization||1|||f||||f||||||||||2018-05-31 23:36:11.483458|2018-05-31 23:36:11.483458
NCT01159405|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2014-07-29|2010-07-08|2010-07-09|Estimate|||||||2014-07-29|2014-07-30|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|||The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer|A Pilot Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide (99mTc-GP) in Patients With Breast Cancer|Unknown status|Recruiting|Phase 1|9|Anticipated|SeeCure LLC||1|||f||||f||||||||||2018-05-31 23:36:11.582965|2018-05-31 23:36:11.582965
NCT01159392|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|February 2001||2001-02-28|February 2001|2001-02-28|November 2003|Actual|2003-11-30|||||Observational|||Alveolar Recruitment in Brain Injury|Effects of Recruitment Maneuvers in Patients With Acute Brain Injury and Acute Lung Injury|Completed|||9|Actual|Hospital Clinic of Barcelona|||1||f||||f||||||||||2018-05-31 23:36:11.674257|2018-05-31 23:36:11.674257
NCT01159379|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2011-01-04|2010-07-08|2010-07-09|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2011||2011-01-31|January 2010|2010-01-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Safety of Ertapenem in Beta-lactam Allergic Patients.|Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 23:36:11.737004|2018-05-31 23:36:11.737004
NCT01159366|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-09|2010-07-08|2010-07-09|Estimate|||||||2010-07-09|2010-07-12|Estimate|July 2006||2006-07-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Incidence of Occluded Culprit Arteries and Impact of Coronary Collaterals on Outcome in Patients With NSTEMI|Substudy of the Leipzig Immediate Versus Early and Late Percutaneous Coronary Intervention Trial in NSTEMI - LIPSIA-NSTEMI TRIAL|Completed||Phase 4|602|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 23:36:11.820761|2018-05-31 23:36:11.820761
NCT01159353|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-15|2010-07-08|2010-07-09|Estimate|||||||2010-07-15|2010-07-16|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart|A Randomized, Double Blind Study to Assess the Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart|Completed||Phase 1|37|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:36:11.897745|2018-05-31 23:36:11.897745
NCT01159340|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|November 2009|Actual|2009-11-30|||||Observational|||Icare Versus Haag-Streit Applanation Tonometer|Design Compliance Testing of the Icare One Rebound Tonometer According to the American National Standard ANSI Z80.10-2001 and International Standard ISO 8612.2 for Tonometers|Completed|||260|Actual|Icare Finland Oy|||||f||||f||||||||||2018-05-31 23:36:11.9804|2018-05-31 23:36:11.9804
NCT01153295|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2011-10-24|2010-06-29|2010-06-30|Estimate|||||||2011-10-24|2011-10-25|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||"Functional Bowel Disorder. Investigation in General Practice"|"Functional Bowel Disorder. Investigation in General Practice"|Completed||N/A|153|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 23:38:13.377189|2018-05-31 23:38:13.377189
NCT01159327|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2015-11-09|2010-07-08|2010-07-09|Estimate|||||||2015-11-09|2015-11-11|Estimate|December 2010||2010-12-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy|A Randomized Phase II Study of Sorafenib Maintenance in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC) After Response to Induction Chemotherapy|Terminated||Phase 2|13|Actual|National Cancer Center, Korea||2||low enrolling participants|f||||f||||||||||2018-05-31 23:36:12.033464|2018-05-31 23:36:12.033464
NCT01159314|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2018-04-23|2010-07-08|2010-07-09|Estimate|||||||2018-04-23|2018-04-25|Actual|June 2010||2010-06-30|April 2018|2018-04-30|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|BPAC||Baerveldt Plate Area Comparison (BPAC)|Baerveldt Plate Area Comparison (BPAC)|Terminated||N/A|69|Actual|Johns Hopkins University||2||Inadequate recruitment|f||||t||||||||||2018-05-31 23:36:12.107498|2018-05-31 23:36:12.107498
NCT01159301|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2013-09-18|2010-07-08|2010-07-09|Estimate|||||||2013-09-18|2013-09-19|Estimate|June 2010||2010-06-30|September 2013|2013-09-30||||September 2013|Actual|2013-09-30||Interventional|||Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia|A Phase I Study of Sorafenib in Combination With the Histone Deacetylase Inhibitor, Entinostat in Patients With Advanced Cancers|Terminated||Phase 1|44|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:36:12.183703|2018-05-31 23:36:12.183703
NCT01159288|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2018-03-27|2010-07-08|2010-07-09|Estimate|||||||2018-03-27|2018-03-29|Actual|May 19, 2010|Actual|2010-05-19|March 2018|2018-03-31|December 19, 2015|Actual|2015-12-19|December 19, 2015|Actual|2015-12-19||Interventional|CSET 1437||Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes|Phase II Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes on Patients With Unresectable Non Small Cell Lung Cancer Responding to Induction Chemotherapy|Completed||Phase 2|41|Actual|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-05-31 23:36:12.34656|2018-05-31 23:36:12.34656
NCT01159275|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|July 2009||2009-07-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Lopinavir (LPV) Dose Reduction|Pharmacokinetics of Pediatric Aluvia® (Lopinavir /Ritonavir 100/25 mg) and Generic Lopinavir/Ritonavir Tablet Formulation (200/50 mg) in Clinically and Virologically Stable HIV-1 Infected Thai Adults|Completed||Phase 1/Phase 2|20|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-05-31 23:36:12.408759|2018-05-31 23:36:12.408759
NCT01159262|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2014-01-24|2012-09-12|2015-07-23|2010-07-08|2010-07-09|Estimate|2014-12-05|2014-12-12|Estimate|2012-09-12|2012-09-14|Estimate|2015-07-23|2015-08-13|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age|A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥28 Weeks to ≤44 Weeks Gestational Age|Completed||Phase 2/Phase 3|36|Actual|Hospira, now a wholly owned subsidiary of Pfizer||3|||f||||t||||||||||2018-05-31 23:36:12.50023|2018-05-31 23:36:12.50023
NCT01159249|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07||2015-05-20|2015-05-20|2010-07-07|2010-07-09|Estimate||||2015-05-20|2015-06-15|Estimate|2015-05-20|2015-06-15|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes|A Multicenter, Open Label, Long-Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes|Completed||Phase 3|245|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:36:13.307752|2018-05-31 23:36:13.307752
NCT01159236|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2012-07-27|2010-07-07|2010-07-09|Estimate|||||||2012-07-27|2012-07-31|Estimate|September 2010||2010-09-30|July 2012|2012-07-31||||||||Interventional|||Molecular Triaging of Newly Diagnosed Breast Cancer|Molecular Triaging of Newly Diagnosed Breast Cancer for Preoperative Therapies|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||3||Recent developments lead to re-evaluation of study.|f||||t||||||||||2018-05-31 23:36:13.468827|2018-05-31 23:36:13.468827
NCT01159223|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2016-08-17|2010-07-08|2010-07-09|Estimate|||||||2016-08-17|2016-08-18|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)|A Multicenter Randomized Study to Compare the Efficacy and Safety of Lower Dose Atazanavir /Ritonavir (ATV/r 200/100 OD) Versus Standard Dose (ATV/r 300/100 mg OD) in Combination With 2NRTIs in Well Virology Suppressed HIV-infected Adults|Completed||Phase 4|559|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||Yes|study protocol available at www.hivnat.org|2018-05-31 23:36:13.596745|2018-05-31 23:36:13.596745
NCT01159210|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2017-10-19|2010-07-08|2010-07-09|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2010||2010-07-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal|An International, Multi-centre, Prospective, Open-Label, Non-Randomised, Uncontrolled Study to Assess the Efficacy and Safety of Prothromplex Total in Oral Anticoagulant Reversal in Patients With Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X)|Completed||Phase 4|61|Actual|Shire|||||f||||f||||||||||2018-05-31 23:36:13.715688|2018-05-31 23:36:13.715688
NCT01159197|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-08-04|2010-07-08|2010-07-09|Estimate|||||||2010-08-04|2010-08-06|Estimate|August 2009||2009-08-31|November 2008|2008-11-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis|Cognitive-Behavioral Therapy for Sleep Disturbance in Patients Undergoing Hemodialysis and Its Impacts on Their Inflammatory Cytokines, Oxidative Stress and Autonomic Dysfunction|Unknown status|Recruiting|N/A|100|Anticipated|Far Eastern Memorial Hospital||1|||f||||t||||||||||2018-05-31 23:36:13.828271|2018-05-31 23:36:13.828271
NCT01159184|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2012-03-26|2010-07-08|2010-07-09|Estimate|||||||2012-03-26|2012-03-27|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Stressors, Coping Methods and Social Support in Diabetic Patients|Stressors, Coping Methods and Social Support in Diabetic Patients|Completed|||301|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 23:36:13.996485|2018-05-31 23:36:13.996485
NCT01159171|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2014-05-20||2014-07-24|2010-07-08|2010-07-09|Estimate|2014-07-24|2014-08-15|Estimate||||2014-07-24|2014-08-15|Estimate|January 2006||2006-01-31|July 2014|2014-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||Safety population: all participants who received at least one dose of one study medication.|A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.|Phase II Study of the Combination of Bevacizumab (rhuMab VEGF) and Oxaliplatin Plus Capecitabine (XELOX) in Patients With Advanced Colorectal Cancer|Completed||Phase 2|50|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:36:14.086104|2018-05-31 23:36:14.086104
NCT01159158|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-12|2010-07-08|2010-07-09|Estimate|||||||2010-07-12|2010-07-13|Estimate|February 2007||2007-02-28|January 2007|2007-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition|RANDOMIZED, 2-WAY CROSSOVER, BIOEQUIVALENCE STUDY OF NATEGLINIDE 120 mg TABLET AND STARLIX@ ADMINISTERED AS 1 x 120 mg TABLET IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS|Completed||Phase 1|68|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:36:14.482275|2018-05-31 23:36:14.482275
NCT01159145|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-09-19|2010-07-08|2010-07-09|Estimate|||||||2010-09-19|2010-09-21|Estimate|July 2010||2010-07-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Assess the Pharmacodynamics/Pharmacokinetics After Repeated Dosing of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects|A Randomised, Single Blind, Two-way Cross-over, Single-centre Study to Assess the Pharmacodynamics (Intragastric pH) and Pharmacokinetics After Repeated Oral Administration of D961H 10 mg and Omeprazole 10 mg in Japanese Healthy Male Subjects|Completed||Phase 1|42|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:36:14.555273|2018-05-31 23:36:14.555273
NCT01159132|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-10-29|2010-07-07|2010-07-09|Estimate|||||||2011-10-29|2011-11-01|Estimate|April 2010||2010-04-30|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pharmacokinetics of Low Dose Raltegravir|Pharmacokinetics of Low Dose Raltegravir|Completed||Phase 2|24|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-05-31 23:36:14.628513|2018-05-31 23:36:14.628513
NCT01159119|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2010-07-07|2010-07-07|2010-07-09|Estimate|||||||2010-07-07|2010-07-09|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|EUR-1066||A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain|Single Center Randomized Single Blind Crossover Group Active Control Study to Evaluate Safety and Efficacy of EUR-1066 a Pancreatic Enzyme Product in Patients With Chronic Pancreatitis Exocrine Pancratic Insufficiency,Chronic Abdominal Pain|Unknown status|Not yet recruiting|Phase 1|15|Anticipated|Forest Laboratories||3|||f||||f||||||||||2018-05-31 23:36:14.704566|2018-05-31 23:36:14.704566
NCT01159106|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2010-07-08|2010-07-08|2010-07-09|Estimate|||||||2010-07-08|2010-07-09|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|NAVAChildren||The Use of Neurally Adjusted Ventilatory Assist (NAVA) Versus Pressure Support During Asynchrony in Children|The Use of NAVA vs. Pressure Support During Asynchrony in Children|Unknown status|Recruiting|N/A|12|Anticipated|Hospital Universitario La Paz|||||f||||f||||||||||2018-05-31 23:36:14.793397|2018-05-31 23:36:14.793397
NCT01159093|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2015-03-11|2010-07-07|2010-07-09|Estimate|||||||2015-03-11|2015-03-12|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|GIVE||Giving Immunizations Through Vaccine Education|Using Health Information Technology to Improve Healthcare Quality in Primary Care Practices and in Transitions Between Care Settings|Completed||N/A|23675|Actual|Children's Hospital of Philadelphia||4|||f||||f||||||||||2018-05-31 23:36:14.869808|2018-05-31 23:36:14.869808
NCT01159080|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-03-12|2010-07-08|2010-07-09|Estimate|||||||2017-03-12|2017-03-14|Actual|April 1, 2010|Actual|2010-04-01|March 2017|2017-03-31|November 30, 2016|Actual|2016-11-30|October 30, 2016|Actual|2016-10-30||Interventional|OPTIMUM||Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients|Organ Function Preservation by the Combination Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients: OPTIMUM Study|Completed||Phase 4|350|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:36:14.940368|2018-05-31 23:36:14.940368
NCT01159067|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-11-07|2010-07-08|2010-07-09|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2010||2010-07-31|November 2017|2017-11-30|August 9, 2011|Actual|2011-08-09|August 9, 2011|Actual|2011-08-09||Interventional|||Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload|Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation|Terminated||Phase 2|1|Actual|City of Hope Medical Center||1||Low enrollment|f||||t||||||||||2018-05-31 23:36:15.044116|2018-05-31 23:36:15.044116
NCT01159054|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2017-03-03||2017-05-26|2010-07-07|2010-07-09|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|July 2010||2010-07-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid|Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid|Terminated||N/A|22|Actual|Brigham and Women's Hospital||1||"The funding source is not going to fund this anymore. Only two subjects completed the study~   therefore meaningful analysis not possible."|f||||f||||||||||2018-05-31 23:36:15.148346|2018-05-31 23:36:15.148346
NCT01159041|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2018-01-22|2010-07-07|2010-07-09|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2010||2010-01-31|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Interventional|SOS||Systems of Support Study for Childhood Depression|Evaluation of Family Focused Treatment for Childhood Depression|Completed||N/A|134|Actual|Boston University Charles River Campus||2|||f||||t||||||||||2018-05-31 23:36:15.449303|2018-05-31 23:36:15.449303
NCT01159028|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2018-01-16|2010-07-08|2010-07-09|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2010||2010-06-30|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS|A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome|Active, not recruiting||Phase 1|60|Anticipated|Bio-Path Holdings, Inc.||2|||f||||t||||||||||2018-05-31 23:36:15.530895|2018-05-31 23:36:15.530895
NCT01159015|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06||2011-09-27|2013-11-22|2010-07-07|2010-07-09|Estimate||||2011-10-06|2011-10-10|Estimate|2013-11-22|2013-12-17|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers|A Multi-center, Double-masked, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy, Normal Volunteers|Completed||Phase 3|501|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:36:15.626709|2018-05-31 23:36:15.626709
NCT01159002|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-03-28|2010-07-07|2010-07-08|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2007||2007-11-30|March 2017|2017-03-31|January 2009|Actual|2009-01-31|May 2008|Actual|2008-05-31||Observational|||Evaluation of Gastrointestinal Motility With SmartPill|Clinical Evaluation of SmartPill Capsule for Investigation of Total Intestinal Transit Time and Intestinal Pathology in Critically Ill Patients|Completed|||8|Actual|University of Louisville|||1||f||||f||||||||||2018-05-31 23:36:15.696088|2018-05-31 23:36:15.696088
NCT01158976|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2017-05-02||2018-04-30|2010-07-07|2010-07-08|Estimate|2018-04-30|2018-05-30|Actual||||2018-04-30|2018-05-30|Actual|December 2009||2009-12-31|April 2018|2018-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NAPS||Effect of Omega-3 Supplementation During Pregnancy on Regulation of Stress|Impact of Omega-3 Intake During Pregnancy on Maternal Stress and Infant Outcome|Completed||N/A|64|Actual|University of Chicago|Small sample size and attrition of participants over time likely affect the reliability of the findings. There may have been some differential selection bias across the two groups. We relied on maternal report of uptake.|2|||f||||t||||||||||2018-05-31 23:36:15.84168|2018-05-31 23:36:15.84168
NCT01158963|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-12-10|2010-07-07|2010-07-08|Estimate|||||||2014-12-10|2014-12-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:36:16.321401|2018-05-31 23:36:16.321401
NCT01158950|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2017-10-16|2010-07-07|2010-07-08|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2010||2010-03-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors|A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors|Active, not recruiting||N/A|154|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 23:36:16.372872|2018-05-31 23:36:16.372872
NCT01158937|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2015-05-20|2010-07-07|2010-07-08|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients|Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patient With Exacerbation of Pulmonary Infection|Terminated||N/A|2|Actual|St. Michael's Hospital, Toronto||2||Inadequate enrolment and lack of resources|f||||f||||||||||2018-05-31 23:36:17.586444|2018-05-31 23:36:17.586444
NCT01158924|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2015-12-18||2016-01-26|2010-07-07|2010-07-08|Estimate|2015-12-18|2016-01-27|Estimate||||2016-01-26|2016-02-26|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration|A Phase I/IIa, Multicenter, Open-label, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration|Completed||Phase 1/Phase 2|40|Actual|DePuy Spine||1|||f||||f||||||||||2018-05-31 23:36:17.768543|2018-05-31 23:36:17.768543
NCT01158911|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-07|2010-07-07|2010-07-08|Estimate|||||||2010-07-07|2010-07-08|Estimate|February 2007||2007-02-28|October 2006|2006-10-31||||||||Observational|||Uric Acid and Long-term Outcomes in Chronic Kidney Disease|Does Uric Acid Promote Progression of Kidney Disease and Development of Cardiovascular Disease in Patients With Chronic Kidney Disease?|Completed|||838|Actual|Tufts Medical Center|||1||f||||f||||||||||2018-05-31 23:36:18.204198|2018-05-31 23:36:18.204198
NCT01158898|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2013-11-14|2010-07-06|2010-07-08|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Efficacy of TPI ASM8 During a 14-Day Allergen Challenge|A Double-Blind,Randomized, Placebo-controlled, 3-Way Cross Over Study to Evaluate the Efficacy and Safety of 14 Days TPI ASM8 in Subjects With Asthma|Completed||Phase 2|16|Actual|Pharmaxis||3|||f||||f||||||||||2018-05-31 23:36:18.537392|2018-05-31 23:36:18.537392
NCT01158885|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2012-10-24|2010-07-07|2010-07-08|Estimate|||||||2012-10-24|2012-10-26|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia|Clofarabine With Cytarabine for MRD Positive Leukemia|Terminated||Phase 2|2|Actual|Therapeutic Advances in Childhood Leukemia Consortium||||Study terminated for lack of accrual.|f||||t||||||||||2018-05-31 23:36:18.647918|2018-05-31 23:36:18.647918
NCT01158859|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2012-11-06|2010-07-07|2010-07-08|Estimate|||||||2012-11-06|2012-11-07|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Preoperative Pregabalin on Propofol Induction Dose|Effect of Preoperative Pregabalin on Propofol Induction Dose|Completed||Phase 4|50|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 23:36:18.978155|2018-05-31 23:36:18.978155
NCT01158846|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-07-07|2010-07-07|2010-07-08|Estimate|||||||2010-07-07|2010-07-08|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI|Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Unknown status|Not yet recruiting|Phase 4|800|Anticipated|Istituto Clinico Sant'Ambrogio||2|||f||||f||||||||||2018-05-31 23:36:19.148563|2018-05-31 23:36:19.148563
NCT01158833|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2014-06-26|2010-07-07|2010-07-08|Estimate|||||||2014-06-26|2014-06-27|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|||Validity of the Kinematic Classification of Gait in Diplegic Children With Cerebral Palsy (CP)|Validity of the Kinematic Classification of Gait in Diplegic Children With Cerebral Palsy|Completed|||86|Actual|University of Modena and Reggio Emilia|||1||f||||f||||||||||2018-05-31 23:36:19.261002|2018-05-31 23:36:19.261002
NCT01158820|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2017-11-28|2010-07-07|2010-07-08|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2010||2010-06-30|November 2017|2017-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|DEX||Alternative Sedation During Bronchoscopy|A Randomized, Placebo-controlled, Concealed Allocation Comparison of Respiratory Depression and Coughing During Bronchoscopy With Dexmedetomidine-ketamine as an Adjunct to Fentanyl-midazolam Sedation|Completed||Phase 4|50|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:36:19.356308|2018-05-31 23:36:19.356308
NCT01158807|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2017-05-17|2010-07-07|2010-07-08|Estimate|||||||2017-05-17|2017-05-18|Actual|April 2010||2010-04-30|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|BVMN6203||Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia|Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia (RDCRN# 6203, Protocol Version Date 07Jan10)|Recruiting|||1800|Anticipated|St. Michael's Hospital, Toronto|||2||f||||f||||||Samples With DNA|"~     blood and/or saliva~   "|Undecided||2018-05-31 23:36:19.443877|2018-05-31 23:36:19.443877
NCT01158638|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2015-05-27|2010-07-07|2010-07-08|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|StepCount||Utilizing Tailored Step-Count Feedback to Enhance Physical Activity in the Elderly|Utilizing Tailored Step-Count Feedback to Enhance Physical Activity in the Elderly|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|University of Wisconsin, Milwaukee||3|||f||||t||||||||||2018-05-31 23:36:21.302965|2018-05-31 23:36:21.302965
NCT01158794|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2017-09-07|2010-07-07|2010-07-08|Estimate|||||||2017-09-07|2017-09-08|Actual|September 21, 2010|Actual|2010-09-21|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2016|Actual|2016-07-31||Observational|||Genes Influencing Iron Overload State|Genes Influencing Iron Overload State|Active, not recruiting|||50|Actual|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     The total volume of blood transfused (in ml/kg) will be collected and stored in the study~     database. Cumulative transfused blood volume (in ml/kg) will be captured. Serum samples will~     be stored frozen at -20°C until the time of analysis. In addition to the protocol-specific~     testing of specimens, study participants will be offered the option of allowing any leftover~     purified DNA, serum, or blood cells to be saved or shared for future analyses. Leftover~     purified genomic DNA, serum, and blood cells from subjects enrolled in the GENIOS protocol~     will be de-identified prior to storage or any future testing and/or sharing.~   "|||2018-05-31 23:36:19.615602|2018-05-31 23:36:19.615602
NCT01158781|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2016-09-12|2010-07-07|2010-07-08|Estimate|||||||2016-09-12|2016-09-14|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Restoration of Life Role Participation Through Cognitive and Motor Training for TBI|Restoration of Life Role Participation Through Integrated Cognitive and Motor Training for Individuals With TBI|Active, not recruiting||N/A|24|Anticipated|Malcom Randall VA Medical Center||2|||f||||t||||||||||2018-05-31 23:36:19.721533|2018-05-31 23:36:19.721533
NCT01158768|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-01-27|2010-07-07|2010-07-08|Estimate|||||||2011-01-27|2011-01-28|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|||Questionnaire to Study Violence Against Women in the Climateric's Phase.|Questionnaire to Study Impacts in the Health of the Woman in the Climateric's Phase, Victim of Domestic and/or Sexual Violence|Completed|||288|Actual|University of Sao Paulo General Hospital|||1||f||||t||||||||||2018-05-31 23:36:19.787923|2018-05-31 23:36:19.787923
NCT01158755|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2012-06-06|2010-07-07|2010-07-08|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study|Comparison of Intensive Treatment Regimens and Standard Treatment Regimen for Tuberculous Meningitis: Pharmacokinetics, Pharmacodynamics and Tolerability Study|Completed||Phase 2|60|Actual|Universitas Padjadjaran||2|||f||||t||||||||||2018-05-31 23:36:19.846148|2018-05-31 23:36:19.846148
NCT01158742|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2017-03-23|2010-07-07|2010-07-08|Estimate|||||||2017-03-23|2017-03-27|Actual|September 2009||2009-09-30|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Live Kidney Donor Study -Renal Function Study|Live Kidney Donor Study -Renal Function Study|Completed|||402|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 23:36:19.959615|2018-05-31 23:36:19.959615
NCT01158729|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2014-01-16|2010-07-07|2010-07-08|Estimate|||||||2014-01-16|2014-01-20|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates|Antithrombin III Supplementation Prior to Cardiopulmonary Bypass for Neonates|Terminated||Phase 1|8|Actual|Medical College of Wisconsin||2||Grant funding expired, poor patient enrollment|f||||t||||||||||2018-05-31 23:36:20.081573|2018-05-31 23:36:20.081573
NCT01158716|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2014-03-01||2014-03-01|2010-07-07|2010-07-08|Estimate|2014-03-01|2014-04-09|Estimate||||2014-03-01|2014-04-09|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Remote Ischemic Preconditioning in ad Hoc Percutaneous Coronary Interventions|Remote Ischemic Preconditioning in ad Hoc Percutaneous Coronary Interventions: a Randomized Clinical Study|Completed||N/A|94|Actual|Cardiovascular Research Society, Greece||2|||f||||t||||||||||2018-05-31 23:36:20.281252|2018-05-31 23:36:20.281252
NCT01158703|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2015-02-23||2015-05-03|2010-07-07|2010-07-08|Estimate|2015-05-03|2015-05-19|Estimate||||2015-05-03|2015-05-19|Estimate|July 2010||2010-07-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ASAP-CABG|Two active treatment groups|Aspirin and Plavix Following Coronary Artery Bypass Grafting|Aspirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG)|Terminated||Phase 4|20|Actual|Brooke Army Medical Center|The study did not recruit enough patients due to strict exclusion criteria and low volume of consenting patients resulting in a sample size that was insufficient for power analysis.|2||poor recruitment and reduction in CT surgery support|f||||t||||||||||2018-05-31 23:36:20.508239|2018-05-31 23:36:20.508239
NCT01158690|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2017-10-12|2010-07-07|2010-07-08|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2010|Actual|2010-06-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|October 2012|Actual|2012-10-31||Interventional|MOM||Intimate Partner Violence and Pregnancy, a Perinatal Care Intervention Study|Intimate Partner Violence and Pregnancy, a Randomised Controlled Trial on the Effect of a Resource Card on the Incidence of Intimate Partner Violence|Completed||N/A|199|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 23:36:20.88025|2018-05-31 23:36:20.88025
NCT01158677|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2014-12-04|2010-07-07|2010-07-08|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Short Term Outcome After Meniscectomy|Short Term Outcome After Meniscectomy|Unknown status|Recruiting||150|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-05-31 23:36:20.981455|2018-05-31 23:36:20.981455
NCT01158664|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2014-12-04|2010-07-07|2010-07-08|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||What is the Influence of a Different Thread Pitch Design on Bone Remodelling Around Conical Southern Oral Implants?|A Prospective Multicenter Randomized Controlled Clinical Study on Conical Southern Implants With Different Thread Pitch|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:36:21.069204|2018-05-31 23:36:21.069204
NCT01158651|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2017-12-31|2010-07-07|2010-07-08|Estimate|||||||2017-12-31|2018-01-03|Actual|January 2011||2011-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|NFC-RAD001||Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas|A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas|Active, not recruiting||Phase 2|23|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 23:36:21.176624|2018-05-31 23:36:21.176624
NCT01158625|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2013-04-03|2010-07-07|2010-07-08|Estimate|||||||2013-04-03|2013-04-04|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Nighttime Dosing of Antihypertensive Drugs in Type 2 Diabetes|Nighttime Dosing of Antihypertensive Drugs in Type 2 Diabetes|Completed||N/A|46|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:36:21.422059|2018-05-31 23:36:21.422059
NCT01158599|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2012-03-22|2010-07-07|2010-07-08|Estimate|||||||2012-03-22|2012-03-23|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population|An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population|Completed||Phase 4|200|Actual|Valneva Austria GmbH||1|||f||||f||||||||||2018-05-31 23:36:21.618586|2018-05-31 23:36:21.618586
NCT01158586|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2010-07-07|2010-07-07|2010-07-08|Estimate|||||||2010-07-07|2010-07-08|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Postoperative Patient Controlled Epidural Analgesia After Total Knee Arthroplasty With 2ug/ml Fentanyl Combine With 0.2% Ropivacaine or 0.2% Levobupivcaine||Unknown status|Recruiting|Phase 4|60|Anticipated|United Christian Hospital||2|||f||||t||||||||||2018-05-31 23:36:21.724311|2018-05-31 23:36:21.724311
NCT01158573|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|2015-12-14||2017-06-14|2010-07-07|2010-07-08|Estimate|2017-06-14|2018-01-24|Actual||||2017-06-14|2018-01-24|Actual|July 2010||2010-07-31|June 2017|2017-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity|Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity|Completed|||117|Actual|University of Michigan|||4||f||||t||||||Samples Without DNA|"~     Subjects will provide 30 cc of blood, a urine sample and we will collect 1-2 ml. of exhaled~     breath condensate for analysis.~   "|||2018-05-31 23:36:21.844321|2018-05-31 23:36:21.844321
NCT01158560|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2012-03-02|2010-07-07|2010-07-08|Estimate|||||||2012-03-02|2012-03-05|Estimate|September 2010||2010-09-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections|McFlu2 COLD3 Prevention: A Randomized, Placebo-controlled, Double Blind Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections in McMaster University Students|Completed||Phase 3|600|Actual|St. Joseph's Healthcare Hamilton||4|||f||||t||||||||||2018-05-31 23:36:22.178994|2018-05-31 23:36:22.178994
NCT01158547|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2015-02-02|2010-07-07|2010-07-08|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Efficacy Study of CLR3001 in Depression|A Pilot Placebo Controlled, Double-Blind, Randomized Parallel Group Study to Evaluate the Efficacy of Treatment With CLR3001 in Depression|Completed|||86|Actual|Clera Inc.|||||f||||f||||||||||2018-05-31 23:36:22.2549|2018-05-31 23:36:22.2549
NCT01158534|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2012-04-26||2012-08-02|2010-07-07|2010-07-08|Estimate|2012-06-11|2012-07-12|Estimate||||2012-08-02|2012-08-07|Estimate|March 2006||2006-03-31|August 2012|2012-08-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery|A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining|Completed||Phase 2|17|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:36:22.413917|2018-05-31 23:36:22.413917
NCT01158521|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2016-01-08|2010-07-07|2010-07-08|Estimate|||||||2016-01-08|2016-01-12|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer|A Phase II Study of Pazopanib to Enable Partial Nephrectomy|Completed||Phase 2|25|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:36:22.730265|2018-05-31 23:36:22.730265
NCT01158508|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2016-11-23|2010-07-07|2010-07-08|Estimate|||||||2016-11-23|2016-11-28|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|RIPC-SAH||Remote Ischemic Preconditioning in Subarachnoid Hemorrhage|Prophylactic Remote Ischemic Preconditioning for Cerebral Vasospasm Following Subarachnoid Hemorrhage|Completed||Phase 1|20|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 23:36:22.851842|2018-05-31 23:36:22.851842
NCT01158495|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2013-04-01|2010-07-07|2010-07-08|Estimate|||||||2013-04-01|2013-04-04|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing|Differentiating Outcome Measures in Infant and Early Childhood Lung Disease Utilizing Controlled Ventilation Infant/Young Child Chest CT Scanning and Lung Function Testing|Completed|||30|Actual|Stanford University|||||f||||||||||||||2018-05-31 23:36:22.978522|2018-05-31 23:36:22.978522
NCT01158482|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2018-04-16|2010-07-07|2010-07-08|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2010||2010-06-30|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|June 2022|Anticipated|2022-06-30||Observational|FILTER||Filter Initial & Long Term Evaluation After Placement and Retrieval Registry|FILTER - Filter Initial & Long Term Evaluation After Placement and Retrieval (Including Laser-Assisted Retrieval) Registry|Recruiting|||400|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 23:36:23.067554|2018-05-31 23:36:23.067554
NCT01158456|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-03-13|2010-07-07|2010-07-08|Estimate|||||||2017-03-13|2017-03-14|Actual|December 2010||2010-12-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2014|Actual|2014-09-30||Observational|Project 5||Metabolism of NNK Among African Americans|Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking: Project 5: Metabolism of NNK Among African Americans|Completed|||161|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||Samples With DNA|"~     Venous blood sample (approximately 40 ml) will be drawn from each study participant at the~     baseline visit. Approximately 33 ml will be used immediately for the study, and the remaining~     two 3-ml volumes will be reserved for future use. The various components of the blood~     including buffy coat (white blood cells), red blood cells, plasma, and serum will be~     separated immediately after their collection, labelled using a unique subject number, and~     stored in a -80C freezer. Urine samples and oral cells will be collected from study subjects~     at various time points. All these samples will be labelled using a unique subject number, and~     stored at a -80C freezer.~   "|||2018-05-31 23:36:23.168193|2018-05-31 23:36:23.168193
NCT01158443|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2016-12-19|2010-07-07|2010-07-08|Estimate|||||||2016-12-19|2016-12-21|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS|Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS|Completed||Phase 4|46|Actual|Research Foundation for Mental Hygiene, Inc.||2|||f||||t||||||||||2018-05-31 23:36:23.249765|2018-05-31 23:36:23.249765
NCT01158430|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-04-12|2010-07-07|2010-07-08|Estimate|||||||2013-04-12|2013-04-15|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ACT||Acceptance and Commitment Group Therapy (ACT) for Patients With Health Anxiety|Treatment of Patients With Health Anxiety. A Randomized Controlled Trial of Acceptance and Commitment Therapy (ACT) Group Treatment Compared to a Waiting List|Completed||N/A|126|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:36:23.349623|2018-05-31 23:36:23.349623
NCT01158417|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2012-12-17|2010-07-07|2010-07-08|Estimate|||||||2012-12-17|2012-12-18|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|April 2014|Anticipated|2014-04-30||Interventional|||Resveratrol in Type2 Diabetes and Obesity|Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects|Unknown status|Active, not recruiting|Phase 2/Phase 3|102|Anticipated|Kaleida Health||3|||f||||f||||||||||2018-05-31 23:36:23.490603|2018-05-31 23:36:23.490603
NCT01158404|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2012-08-22|2010-07-06|2010-07-08|Estimate|||||||2012-08-22|2012-08-24|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Notch Inhibitor in Advanced Cancer|Phase 1 Study of a Notch Inhibitor in Patients With Advanced Cancer|Completed||Phase 1|35|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:36:23.605642|2018-05-31 23:36:23.605642
NCT01158391|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2016-05-17|2010-07-06|2010-07-08|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding|Trial of Patterned Oral Somatosensory Entrainment|Unknown status|Active, not recruiting|N/A|210|Actual|KC BioMediX, Inc||2|||f||||t||||||||||2018-05-31 23:36:23.684782|2018-05-31 23:36:23.684782
NCT01158378|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2014-02-26||2014-02-26|2010-07-07|2010-07-08|Estimate|2014-02-26|2014-04-08|Estimate||||2014-02-26|2014-04-08|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Only subjects with unknown cranial endpoint status, who died of known causes unrelated to the study device or procedure were excluded from baseline analysis population.|Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures|A Pivotal Clinical Trial Examining the Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures|Completed||Phase 3|250|Actual|HyperBranch Medical Technology, Inc||2|||f||||t||||||||||2018-05-31 23:36:23.851139|2018-05-31 23:36:23.851139
NCT01158365|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-01-03|2010-07-07|2010-07-08|Estimate|||||||2011-01-03|2011-01-04|Estimate|July 2010||2010-07-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Dermacyd in Odor Reducing.|Single Center, Open, Cross-over, Phase III Study for Comparative Evaluation of Safety Use and Efficacy in the Odor Reduce and Vaginal Moisturize Increase for Intimates Use Products Dermacyd Femina Delicata, Dermacyd Femina Breeze, Dermacyd Teen Sweet Flower, Dermacyd Teen Fresh Mix and Dermacyd Femina Comparing to the Control Product Glycerine Vegetal Soap Granado Traditional.|Completed||Phase 3|230|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:36:24.396507|2018-05-31 23:36:24.396507
NCT01158352|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-27|||2014-11-06|2010-07-07|2010-07-08|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2010||2010-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Formula||Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children|Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children|Completed||N/A|200|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 23:36:24.481559|2018-05-31 23:36:24.481559
NCT01158339|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2018-02-06|2010-07-07|2010-07-08|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2010|Actual|2010-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Ryggbra||Dare to Move: Treatment of Movement Phobia in Patient With Low Back Pain|Dare to Move: Treatment of Movement Phobia in Patient With Low Back Pain A Randomized Controlled Study of Two Methods Comparing the Role of Exposure in Session|Active, not recruiting||N/A|120|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 23:36:24.564388|2018-05-31 23:36:24.564388
NCT01158326|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-11-24|2010-07-07|2010-07-08|Estimate|||||||2011-11-24|2011-11-28|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu|Evaluation of Efficacy and Safety of Oral Solution Paracetamol, Maleate Chlorpheniramine and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu: a Double-blind|Completed||Phase 3|216|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 23:36:24.633841|2018-05-31 23:36:24.633841
NCT01158313|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2013-10-29|2010-07-07|2010-07-08|Estimate|||||||2013-10-29|2013-10-30|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|CABS||Bedside Screening Method for Patients With Potential Swallowing Impairment|Development and Validation of Clinician-administered Bedside Screening Method for Patients With Potential Swallowing Impairment|Completed|||120|Actual|Nestlé|||1||f||||f||||||||||2018-05-31 23:36:24.711012|2018-05-31 23:36:24.711012
NCT01158300|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2015-05-01|2010-07-07|2010-07-08|Estimate|||||||2015-05-01|2015-05-04|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors|Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumors|Completed||Phase 1|28|Actual|Pediatric Brain Tumor Consortium|||||f||||t||||||||||2018-05-31 23:36:24.786008|2018-05-31 23:36:24.786008
NCT01158287|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2014-12-30|2010-07-07|2010-07-08|Estimate|||||||2014-12-30|2014-12-31|Estimate|February 2009||2009-02-28|January 2014|2014-01-31||||November 2012|Actual|2012-11-30||Interventional|||Sorafenib. ICORG 06-41, V4|Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients|Completed||Phase 2|54|Anticipated|Cancer Trials Ireland||1|||f||||||||||||||2018-05-31 23:36:24.932834|2018-05-31 23:36:24.932834
NCT01158274|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2014-11-06|2010-07-07|2010-07-08|Estimate|||||||2014-11-06|2014-11-07|Estimate|June 2010||2010-06-30|June 2014|2014-06-30||||August 2012|Actual|2012-08-31||Interventional|||RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors|A Phase 1 Study of RO4929097 (NSC749225) in Combination With Capecitabine in Refractory Solid Tumors|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:36:25.11077|2018-05-31 23:36:25.11077
NCT01158261|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2015-07-22||2015-07-22|2010-07-06|2010-07-08|Estimate|2015-07-22|2015-08-19|Estimate||||2015-07-22|2015-08-19|Estimate|June 2010||2010-06-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||The Evicel Post-Authorization Surveillance Study|A Prospective, Single-Arm, Observational, Non-interventional Study for EVICEL ™ Fibrin Sealant (Human) When Used as an Adjunct to Haemostasis in Vascular Surgery|Completed|||300|Actual|Ethicon, Inc.|Limitations of the study include the small number of centers involved and the observational nature of the design.||1||f||||f||||||||||2018-05-31 23:36:25.252613|2018-05-31 23:36:25.252613
NCT01152879|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2014-02-20|2010-06-28|2010-06-29|Estimate|||||||2014-02-20|2014-02-21|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|||Home Parenteral Nutrition in Cancer Patients|An Evaluation of Quality of Life Outcomes in Cancer Patients Receiving Home Parenteral|Completed|||100|Anticipated|Southwestern Regional Medical Center|||1||f||||f||||||||||2018-05-31 23:38:18.223379|2018-05-31 23:38:18.223379
NCT01158248|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2010-07-08|2010-07-07|2010-07-08|Estimate|||||||2010-07-08|2010-07-09|Estimate|February 2010||2010-02-28|July 2010|2010-07-31||||March 2013|Anticipated|2013-03-31||Interventional|||Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer|A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB|Unknown status|Recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:36:25.549228|2018-05-31 23:36:25.549228
NCT01158235|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2011-06-07|2010-07-07|2010-07-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)|A Randomised, Double-blind, Placebo-controlled, Ascending Dose Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)|Completed||Phase 1/Phase 2|24|Anticipated|Lytix Biopharma AS||1|||f||||t||||||||||2018-05-31 23:36:25.637561|2018-05-31 23:36:25.637561
NCT01158222|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-08-15|2010-07-06|2010-07-08|Estimate|||||||2017-08-15|2017-08-17|Actual|August 18, 2010|Actual|2010-08-18|August 2017|2017-08-31|February 1, 2017|Actual|2017-02-01|June 20, 2013|Actual|2013-06-20||Interventional|||Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer|A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|37|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 23:36:25.729081|2018-05-31 23:36:25.729081
NCT01158209|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2012-07-12|2010-07-07|2010-07-08|Estimate|||||||2012-07-12|2012-07-16|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt|An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women >= 18 Years of Age, in Egypt|Completed|||490|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Endocervical samples~   "|||2018-05-31 23:36:25.846922|2018-05-31 23:36:25.846922
NCT01158196|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-07|2010-07-07|2010-07-08|Estimate|||||||2010-07-07|2010-07-08|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|||Safety and Efficacy of Infrared Diode Laser on Improvement of Scar and Prevention of Recurrence of Excised Keloid|Effect of Infra-red Diode Laser on Improvement of Surgical Scar and on the Prevention of Excised Keloids Recurrence-Pilot Study|Unknown status|Recruiting|Phase 3|60|Anticipated|Ekkyo||1|||f||||f||||||||||2018-05-31 23:36:25.927848|2018-05-31 23:36:25.927848
NCT01158183|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2010-07-07|2010-07-07|2010-07-08|Estimate|||||||2010-07-07|2010-07-08|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|ROBUST||Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis|Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon β-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis|Completed|||226|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:36:26.025936|2018-05-31 23:36:26.025936
NCT01158170|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-07-06|2010-07-06|2010-07-08|Estimate|||||||2010-07-06|2010-07-08|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Interventional|||Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)|A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001)|Unknown status|Recruiting|Phase 3|200|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 23:36:26.159|2018-05-31 23:36:26.159
NCT01158157|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2012-02-28|2010-07-06|2010-07-08|Estimate|||||||2012-02-28|2012-03-01|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV)|Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous|Completed||Phase 4|25|Actual|Cangene Corporation|||||f||||t||||||||||2018-05-31 23:36:26.253278|2018-05-31 23:36:26.253278
NCT01158144|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-07-06|2010-07-06|2010-07-08|Estimate|||||||2010-07-06|2010-07-08|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)|A Phase II Study of Endostar, Paclitaxel/Carboplatin and Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|134|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 23:36:26.341416|2018-05-31 23:36:26.341416
NCT01158131|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2012-12-21|2010-07-07|2010-07-08|Estimate|||||||2012-12-21|2012-12-24|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)|Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)|Completed||Phase 2|75|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:36:26.438044|2018-05-31 23:36:26.438044
NCT01158118|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2017-03-22||2017-05-03|2010-07-07|2010-07-08|Estimate|2017-03-22|2017-05-03|Actual||||2017-05-03|2017-06-05|Actual|April 1, 2011|Actual|2011-04-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|January 15, 2014|Actual|2014-01-15||Interventional|||Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors|A Phase II Trial Evaluating the Safety and Efficacy of Plerixafor and Sargramostim (GM-CSF) for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal, HLA-Matched Allogeneic Sibling Donors|Completed||Phase 2|48|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 23:36:26.547343|2018-05-31 23:36:26.547343
NCT01158105|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2016-01-15|2010-07-07|2010-07-08|Estimate|||||||2016-01-15|2016-01-18|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|May 2013|Actual|2013-05-31||Interventional|||Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)|Phase 2 Study of Bortezomib (Velcade) for the Treatment of Steroid Refractory Chronic Graft-vs-Host Disease|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|Baylor Research Institute||1|||f||||t||||||||||2018-05-31 23:36:27.154392|2018-05-31 23:36:27.154392
NCT01158092|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2013-05-03|2010-07-07|2010-07-08|Estimate|||||||2013-05-03|2013-05-06|Estimate|July 2010||2010-07-31|May 2013|2013-05-31||||March 2012|Actual|2012-03-31||Interventional|SI-RCT-Ross||Trial Comparing Treatment With SInergy™ System to Conservative Treatment for Chronic Sacroiliac Joint Pain|A Randomized Controlled Trial Comparing Cooled Radiofrequency Denervation to Conservative Treatment as a Treatment for Sacroiliac Joint Pain Using the SInergy™ System|Terminated||N/A|5|Actual|Baylis Medical Company||2|||f||||||||||||||2018-05-31 23:36:27.227167|2018-05-31 23:36:27.227167
NCT01158079|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2012-10-11|2010-07-06|2010-07-08|Estimate|||||||2012-10-11|2012-10-12|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment|A Multi-center, Open-Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment|Completed||Phase 1|7|Actual|Alnylam Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:36:27.305136|2018-05-31 23:36:27.305136
NCT01158066|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2011-04-05|2010-07-07|2010-07-08|Estimate|||||||2011-04-05|2011-04-06|Estimate|August 2011||2011-08-31|June 2010|2010-06-30|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|||Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification|Association Between NAFLD and Coronary Artery Calcification|Unknown status|Not yet recruiting|N/A|120|Anticipated|Ziv Hospital||1|||f||||t||||||||||2018-05-31 23:36:27.363997|2018-05-31 23:36:27.363997
NCT01158053|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-12-08|2010-07-07|2010-07-08|Estimate|||||||2015-12-08|2015-12-10|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|April 2012|Actual|2012-04-30||Observational|VERDICT||Vascular Evaluation for Revascularization: Defining the Indications for Coronary Therapy: A Pilot Study|A Prospective, Global, Multicenter, Non-Randomized, Non-Blinded Study in Patients With Intermediate Coronary Lesions to Examine the Correlation Between Fractional Flow Reserve (FFR) and Intravascular Ultrasound With Virtual Histology (VH-IVUS)|Completed|||291|Actual|Volcano Corporation|||||f||||f||||||||||2018-05-31 23:36:27.433852|2018-05-31 23:36:27.433852
NCT01158040|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2010-07-28|2010-07-07|2010-07-08|Estimate|||||||2010-07-28|2010-07-29|Estimate|August 2010||2010-08-31|July 2010|2010-07-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Intrapartum Maternal Glycemic Control Using Insulin Pump Versus Insulin Drip - Cohort Observational Trial|Intrapartum Maternal Glycemic Control Using Insulin Pump Versus Insulin Drip Cohort Retrospective and Prospective Observational Trial|Unknown status|Not yet recruiting||88|Anticipated|Sheba Medical Center|||3||f||||f||||||||||2018-05-31 23:36:27.486606|2018-05-31 23:36:27.486606
NCT01158027|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2011-10-17|2010-07-07|2010-07-08|Estimate|||||||2011-10-17|2011-10-18|Estimate|October 2011||2011-10-31|October 2011|2011-10-31||||||||Observational|||Evaluating Walking Kinetic of Children Who Suffer Central Nervous System (CNS) Damage|Evaluating Walking Kinetic of Children Who Suffer Central Nervous System (CNS)|Unknown status|Not yet recruiting||30|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 23:36:27.568272|2018-05-31 23:36:27.568272
NCT01158014|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2017-08-07|2010-07-07|2010-07-08|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2014|Actual|2014-01-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Fibrin Glue vs. Suture in Pterygium Surgery|Fibrin Glue vs. Vicryl Suture in Pterygium Surgery With Conjunctival Auto-graft|Completed||N/A|90|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:36:27.632015|2018-05-31 23:36:27.632015
NCT01158001|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2015-06-22|2010-07-06|2010-07-08|Estimate|||||||2015-06-22|2015-06-24|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder|Telemedicine for Improved Delivery of Psychosocial Treatments for Post Traumatic Stress Disorder|Completed||N/A|211|Actual|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-05-31 23:36:27.715046|2018-05-31 23:36:27.715046
NCT01157988|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-07|2010-07-07|2010-07-08|Estimate|||||||2010-07-07|2010-07-08|Estimate|January 2007||2007-01-31|April 2006|2006-04-30||||January 2009|Actual|2009-01-31||Interventional|||90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma|Phase II Study of 90Y-ibritumomab Tiuxetan Treatment as a Consolidation After 6th R-CHOP Chemotherapy in Patients With Limited-stage, Bulky Diffuse Large B Cell Lymphoma|Completed||Phase 2|20|Actual|Chonnam National University Hospital||1|||f||||t||||||||||2018-05-31 23:36:27.893696|2018-05-31 23:36:27.893696
NCT01157975|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2013-02-11|2010-07-06|2010-07-08|Estimate|||||||2013-02-11|2013-02-12|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|September 2014|Anticipated|2014-09-30|February 2014|Anticipated|2014-02-28||Interventional|||Study the Relationship Between Obesity and Hepatitis C Replication|A Randomized, Partially Blinded, Pilot Study of the Effects of Pioglitazone on HCV RNA in Overweight Subjects With Chronic HCV Genotypes 1 or 4 Infection.|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 23:36:27.984484|2018-05-31 23:36:27.984484
NCT01157962|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2011-06-30|2010-07-07|2010-07-08|Estimate|||||||2011-06-30|2011-07-01|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|January 2018|Anticipated|2018-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Sentinel Concept in Early Stage Cervical Cancer|Prospective, Randomized and Multicentre Study for Investigation of Valence of Sentinel Lymph Nodes Concept in Patients With Cervical Cancer ≤ 2 cm|Unknown status|Recruiting|N/A|1600|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 23:36:28.098962|2018-05-31 23:36:28.098962
NCT01157949|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2018-02-01|2010-07-07|2010-07-08|Estimate|||||||2018-02-01|2018-02-05|Actual|November 2010||2010-11-30|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|November 2013|Anticipated|2013-11-30||Interventional|||A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)|A Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® for the Prevention of Cardiac Allograft Vasculopathy in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients.|Withdrawn||Phase 3|0|Actual|Cedars-Sinai Medical Center||2||PI not planning to pursue this study and it was never IRB approved.|f||||||||||||||2018-05-31 23:36:28.196241|2018-05-31 23:36:28.196241
NCT01157936|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-07|||2014-07-23|2010-07-07|2010-07-08|Estimate|||||||2014-07-23|2014-07-24|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||Hyperuricemia on Hypertension and Metabolic Syndrome|Effect of Hyperuricemia Treatment on Hypertension and Metabolic Syndrome|Completed||Phase 2|40|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||t||||||||||2018-05-31 23:36:28.285217|2018-05-31 23:36:28.285217
NCT01157923|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-27|||2017-01-10|2010-07-04|2010-07-07|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||MD Logic Pump Advisor- Adults Study|Evaluation of Automated Insulin Pump Settings Using the MD-Logic Pump Advisor-Adults Sub Study|Completed||N/A|18|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 23:36:28.393209|2018-05-31 23:36:28.393209
NCT01157208|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2017-02-17|2010-07-02|2010-07-05|Estimate|||||||2017-02-17|2017-02-23|Actual|July 2009||2009-07-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Nutrition for Chronic Daily Headache|Dietary Interventions for Chronic Daily Headache (CDH): A Feasibility Study,|Completed||N/A|67|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||Yes|Deidentified data has been shared with NIH.|2018-05-31 23:36:38.115968|2018-05-31 23:36:38.115968
NCT01157910|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|November 2012|Anticipated|2012-11-30|September 2012|Anticipated|2012-09-30||Observational|||Bacterial Assessment of Middle Ear Fluid in Children Undergoing Ventilation Tube Placement Surgery|An Epidemiological and Bacteriological Assessment of Middle Ear Fluid in Children Undergoing Ventilation Tube Placement Surgery|Unknown status|Not yet recruiting||50|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 23:36:28.497818|2018-05-31 23:36:28.497818
NCT01157897|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2013-01-14|2010-07-06|2010-07-07|Estimate|||||||2013-01-14|2013-01-16|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Study of VMP001 and AS01B in Healthy Malaria-Naïve Adults|Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GSK Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults|Completed||Phase 1/Phase 2|48|Actual|U.S. Army Medical Research and Materiel Command||4|||f||||t||||||||||2018-05-31 23:36:28.566059|2018-05-31 23:36:28.566059
NCT01157884|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-01-03|2010-07-06|2010-07-07|Estimate|||||||2012-01-03|2012-01-05|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||Change of Body Composition After Kidney Transplantation in Korea||Completed|||50|Actual|Seoul National University Hospital|||1||f||||f||||||None Retained|"~     serum: total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, C-reactive protein~     (CRP)~   "|||2018-05-31 23:36:28.651682|2018-05-31 23:36:28.651682
NCT01157871|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2004||2004-06-30|July 2010|2010-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|TALISMAN 211||Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication|Double-blind, Randomized, Placebo-controlled, Parallel Group and Dose-finding, Multicentric, Safety and Efficacy Study With Intramuscular Injections of NV1FGF in Subjects With Intermittent Claudication|Completed||Phase 2|36|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 23:36:28.723733|2018-05-31 23:36:28.723733
NCT01157858|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2015-06-26|2010-07-06|2010-07-07|Estimate|||||||2015-06-26|2015-06-29|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|ELATE||Everolimus and LongActing Octreotide Trial in Polycystic Livers|Everolimus Added to Long Acting Octreotide as a Volume Reducing Treatment of Polycystic Livers|Completed||Phase 2|44|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 23:36:28.80716|2018-05-31 23:36:28.80716
NCT01157845|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2014-01-17||2014-04-29|2010-07-06|2010-07-07|Estimate|2014-01-17|2014-03-04|Estimate||||2014-04-29|2014-05-16|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All chronic liver disease patients with clinically proven cirrhosis and candidates for liver transplant.|Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis|Use of the BreathID Methacetin Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients Awaiting Liver Transplantation|Completed||Phase 3|165|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-05-31 23:36:28.910777|2018-05-31 23:36:28.910777
NCT01157832|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2013-06-10|2010-07-06|2010-07-07|Estimate|||||||2013-06-10|2013-06-11|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Evaluation of the Acute Effect of Water-Pipe Smoking on the Respiratory System||Completed|||45|Actual|Rambam Health Care Campus|||||f||||t||||||||||2018-05-31 23:36:29.169794|2018-05-31 23:36:29.169794
NCT01157819|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-04|||2011-03-14|2010-07-06|2010-07-07|Estimate|||||||2011-03-14|2011-03-15|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|Once-a-day||Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis|Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro (0.3% Ciprofloxacin Otic Foam) Compared to Twice-Daily Dosing of Ciloxan (0.3% Ciprofloxacin Otic Solution) in Patients With Acute External Otitis|Completed||Phase 2|70|Anticipated|Otic Pharma||2|||f||||t||||||||||2018-05-31 23:36:29.259025|2018-05-31 23:36:29.259025
NCT01157806|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2011-02-14|2010-07-06|2010-07-07|Estimate|||||||2011-02-14|2011-02-16|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|June 2012|Anticipated|2012-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Palliative Radiochemotherapy Against Palliative Surgery in Stage IV Rectal Cancer With Unresectable Metastases|Palliative Radiotherapy Followed by Chemotherapy Against Palliative Surgery in Patients With Rectal Cancer With Unresectable Synchronous Distant Metastases|Unknown status|Recruiting|Phase 2|20|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||1|||f||||t||||||||||2018-05-31 23:36:29.367933|2018-05-31 23:36:29.367933
NCT01157793|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2014-07-09|2010-07-06|2010-07-07|Estimate|||||||2014-07-09|2014-07-11|Estimate|September 2003||2003-09-30|July 2010|2010-07-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood|A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in GHD Subjects During the Transition Phase From Childhood to Adulthood|Completed||Phase 4|34|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:36:29.446512|2018-05-31 23:36:29.446512
NCT01157780|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2011-06-16|2010-07-06|2010-07-07|Estimate|||||||2011-06-16|2011-06-17|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation|Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation|Unknown status|Recruiting|N/A|100|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 23:36:29.536518|2018-05-31 23:36:29.536518
NCT01157767|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2018-05-01|2010-07-06|2010-07-07|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2010|Actual|2010-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation|A Feasibility Study of the Effects of a Directed Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation|Active, not recruiting|||90|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 23:36:29.629616|2018-05-31 23:36:29.629616
NCT01157754|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2015-04-21|2010-07-06|2010-07-07|Estimate|||||||2015-04-21|2015-04-22|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|Larganta||Oral Contraceptive Pill and GnRH Antagonist Versus Long Protocol in IVF Patients|Cycle Planning With OCP in GnRH Antagonists Cycles Versus Long Protocol in Good Prognosis IVF Patients|Completed||N/A|115|Actual|IVI Madrid||2|||f||||f||||||||||2018-05-31 23:36:29.690712|2018-05-31 23:36:29.690712
NCT01157741|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-07|2010-07-06|2010-07-07|Estimate|||||||2010-07-07|2010-07-08|Estimate|October 2003||2003-10-31|December 2003|2003-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Community-based Follow-up of Severely Malnourished Children|Efficacy of Community-based Follow-up, Food Supplementation and Psychosocial Stimulation in the Home-management of Young Severely Malnourished Bangladeshi Children: a Randomized Intervention Trial|Completed||Phase 2/Phase 3|507|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||5|||f||||t||||||||||2018-05-31 23:36:29.758298|2018-05-31 23:36:29.758298
NCT01157728|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2012-07-30|2010-07-06|2010-07-07|Estimate|||||||2012-07-30|2012-07-31|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|CogniSEP||Early Cognitive Impairment in Multiple Sclerosis|Early Cognitive Impairment in Multiple Sclerosis: a Multimodal MRI Study Evaluating the Relative Contribution of Cortical and White Matter Tract Injury|Completed|||69|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||||||2018-05-31 23:36:29.833551|2018-05-31 23:36:29.833551
NCT01157715|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2014-11-05|2010-07-06|2010-07-07|Estimate|||||||2014-11-05|2014-11-06|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|AURORA||A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD|A Randomized, Double-masked, Multicenter, Controlled Dose- and Interval-ranging Clinical Study of Intravitreal Injection of KH902 in Patients With Neovascular Age-related Macular Degeneration (the AURORA Study)|Completed||Phase 2|122|Actual|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||||||||||||2018-05-31 23:36:29.890593|2018-05-31 23:36:29.890593
NCT01157702|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-08-23|2010-07-06|2010-07-07|Estimate|||||||2010-08-23|2010-08-24|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Yearly Strain Variation Study, 2010/2011|An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2010/2011, in an Adult and Elderly Population|Completed||Phase 3|110|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-05-31 23:36:30.00708|2018-05-31 23:36:30.00708
NCT01157689|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2013-03-16|2010-07-06|2010-07-07|Estimate|||||||2013-03-16|2013-03-19|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|December 2012|Actual|2012-12-31||Observational|||Artemether-Lumefantrine Effectiveness in Guinea-Bissau|The Routine Use of Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum at the Bandim Health Centre|Unknown status|Active, not recruiting||500|Anticipated|Bandim Health Project|||1||f||||f||||||Samples Without DNA|"~     Capillary blood samples for drug concentration analysis and for PCR for identifying the~     malaria parasites~   "|||2018-05-31 23:36:30.073563|2018-05-31 23:36:30.073563
NCT01157676|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2018-03-28|2010-07-05|2010-07-07|Estimate|||||||2018-03-28|2018-03-29|Actual|July 2011||2011-07-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial|Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial|Active, not recruiting||N/A|350|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 23:36:30.164732|2018-05-31 23:36:30.164732
NCT01157663|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2014-12-04|2010-07-06|2010-07-07|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|May 2011|Actual|2011-05-31||Interventional|||The Effect of Balance Training in People With Functional Ankle Instability (FAI)|The Effect of Balance Training in People With Functional Ankle Instability|Completed||N/A|60|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 23:36:30.463027|2018-05-31 23:36:30.463027
NCT01157650|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2016-11-07|2010-07-06|2010-07-07|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue|Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue|Completed||Phase 1/Phase 2|15|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||t||||||||No||2018-05-31 23:36:30.594602|2018-05-31 23:36:30.594602
NCT01157624|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2011-08-15|2010-07-06|2010-07-07|Estimate|||||||2011-08-15|2011-08-17|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Application of Nasal Cannula With Oxygen Versus Air During Eye Surgery Under Local Anaesthetic||Completed||Phase 1|100|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 23:36:30.680857|2018-05-31 23:36:30.680857
NCT01157611|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2015-11-16|2010-07-06|2010-07-07|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2010||2010-07-31|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Online Based Mentoring Program on the Blood Glucose and Satisfaction Score in Type 1 Diabetes Patients|The Effect of Online Based Mentoring Program on the Blood Glucose and Satisfaction Score in Type 1 Diabetes Patients|Completed||N/A|57|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 23:36:30.763115|2018-05-31 23:36:30.763115
NCT01157598|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|September 2009||2009-09-30|July 2010|2010-07-31||||September 2010|Anticipated|2010-09-30||Interventional|||Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection|Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection|Unknown status|Recruiting|Phase 3|56|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 23:36:31.883913|2018-05-31 23:36:31.883913
NCT01157585|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2015-07-30|2010-07-06|2010-07-07|Estimate|||||||2015-07-30|2015-07-31|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Paliperidone ER in First Episode Psychosis|Efficacy and Safety of Paliperidone ER in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study|Completed||Phase 4|75|Actual|Chonbuk National University Hospital||1|||f||||f||||||||||2018-05-31 23:36:32.002165|2018-05-31 23:36:32.002165
NCT01157572|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2014-09-24|2010-07-06|2010-07-07|Estimate|||||||2014-09-24|2014-09-25|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|BAR||Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation|Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation|Completed||Phase 4|75|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:36:32.088366|2018-05-31 23:36:32.088366
NCT01157559|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate||||January 2007|2007-01-31|May 2010|Actual|2010-05-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety With Ziprasidone in First-episode Psychosis|Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study|Completed||Phase 4|27|Actual|Chonbuk National University Hospital|||||f||||f||||||||||2018-05-31 23:36:32.168724|2018-05-31 23:36:32.168724
NCT01157546|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2015-03-16|2010-07-06|2010-07-07|Estimate|||||||2015-03-16|2015-03-17|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||TAP Block for Open Radical Prostatectomy.|Continuous Transversus Abdominis Plane (TAP) Block for Open Radical Prostatectomy. A Double Blind Randomized Study.|Terminated||Phase 1|25|Actual|McGill University Health Center||2||"Low recruitment rate. In our center, open radical prostatectomies have been almost completely~   replaced by robotic prostatectomies."|f||||t||||||||||2018-05-31 23:36:32.23295|2018-05-31 23:36:32.23295
NCT01157533|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|2013-02-13||2013-02-13|2010-07-05|2010-07-07|Estimate|2013-02-13|2013-03-18|Estimate||||2013-02-13|2013-03-18|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients|Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients|Terminated||N/A|1|Actual|M.D. Anderson Cancer Center||1||Low Accrual.|f||||f||||||||||2018-05-31 23:36:32.314814|2018-05-31 23:36:32.314814
NCT01157520|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-08|2010-07-06|2010-07-07|Estimate|||||||2010-07-08|2010-07-09|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Study to Detect Hypotensive Episodes During Spinal Anesthesia for Cesarean Section Using a Noninvasive Continuous Device|Hypotensive Episodes During Cesarean Section Detected by a Continuous Non-invasive Arterial Pressure Measurement Device Are Missed by the Oscillometric Blood Pressure Measurement|Completed|||||University of Schleswig-Holstein|||1||f||||f||||||||||2018-05-31 23:36:32.551126|2018-05-31 23:36:32.551126
NCT01157507|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2011-04-19|2010-07-06|2010-07-07|Estimate|||||||2011-04-19|2011-04-20|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome|Botulinum A Toxin Intravesical Injections Versus Bladder Overdistension in the Treatment of Patients With Painful Bladder Syndrome: A Prospective Randomized Study|Unknown status|Enrolling by invitation|Phase 4|30|Anticipated|University Of Perugia||3|||f||||t||||||||||2018-05-31 23:36:32.608589|2018-05-31 23:36:32.608589
NCT01157494|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Observational|||Validity of Manipulation Taxonomy of Spastic Hemiplegic Cerebral Palsy (CP) Forms|Validity of Manipulation Taxonomy of Spastic Hemiplegic Cerebral Palsy Forms Proposed by Ferrari A et.al.|Completed|||30|Actual|University of Modena and Reggio Emilia|||1||f||||f||||||||||2018-05-31 23:36:32.706392|2018-05-31 23:36:32.706392
NCT01157481|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2016-01-21|2010-07-06|2010-07-07|Estimate|||||||2016-01-21|2016-01-25|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|DEMAND||Diastolic Heart Failure Management by Nifedipine|Diastolic Heart Failure Management by Nifedipine|Unknown status|Active, not recruiting|N/A|226|Actual|Demand Investigators||2|||f||||t||||||||||2018-05-31 23:36:32.787135|2018-05-31 23:36:32.787135
NCT01157468|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2016-09-07|2010-07-06|2010-07-07|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|LUMAB2||Catalytic Antibodies and Lupus in Martinique|Study of Catalytic Antibodies in a Cohort Population of Martinique|Completed|||200|Actual|University Hospital Center of Martinique|||2||f||||t||||||Samples With DNA|"~     -  For the case means the research will be done on a blood sample of 7 ml, reclassified~          from treatement to research, collected from the blood sampling usually prescribed by~          doctors to treat the patient come to be diagnosed a lupus or for continuing care.~        -  For the control means research will be done on a blood sample of 7 ml collected from~          people coming to donate blood at thethe French Blood Establishment of Martinique.~      The volume does not exceed the maximum amount allowed by French regulations for blood~     donation.~   "|||2018-05-31 23:36:32.88161|2018-05-31 23:36:32.88161
NCT01157455|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-05|||2010-07-08|2010-07-06|2010-07-07|Estimate|||||||2010-07-08|2010-07-12|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|June 2013|Anticipated|2013-06-30|March 2012|Anticipated|2012-03-31||Interventional|SEEDS||A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization|Clinical Trial Program of a Medical Instrument Product|Unknown status|Recruiting|Phase 4|1900|Anticipated|CCRF Consulting Co., Ltd.|||||f||||t||||||||||2018-05-31 23:36:32.963286|2018-05-31 23:36:32.963286
NCT01157442|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2011-03-22|2010-07-06|2010-07-07|Estimate|||||||2011-03-22|2011-03-23|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Study of Cell Phone SMS Messages for Prevention of Maternal to Child Transmission of HIV|Harnessing Mobile Phone Usage for HIV and Horizontal Health Systems Improvement: PMTCT|Unknown status|Recruiting|N/A|856|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 23:36:33.075005|2018-05-31 23:36:33.075005
NCT01157429|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|2016-08-20||2017-04-25|2010-07-06|2010-07-07|Estimate|2017-04-25|2017-06-06|Actual||||2017-04-25|2017-06-06|Actual|June 2010||2010-06-30|April 2017|2017-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents|D-cycloserine Adjunctive Treatment for PTSD in Adolescents|Completed||Phase 2|24|Actual|Tulane University||2|||f||||t||||||||||2018-05-31 23:36:33.16859|2018-05-31 23:36:33.16859
NCT01157416|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2016-08-20||2017-03-10|2010-07-06|2010-07-07|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|June 2010||2010-06-30|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of D-cycloserine on Treatment of Posttraumatic Stress Disorder (PTSD) in Youth|Effect of D-cycloserine on Treatment of PTSD in Youth|Completed||Phase 2|33|Actual|Tulane University||2|||f||||t||||||||||2018-05-31 23:36:33.387687|2018-05-31 23:36:33.387687
NCT01157403|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2013-06-15|2010-07-06|2010-07-07|Estimate|||||||2013-06-15|2013-06-18|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes|Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Third Military Medical University||1|||f||||t||||||||||2018-05-31 23:36:33.591767|2018-05-31 23:36:33.591767
NCT01157390|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-06-07|2010-07-06|2010-07-07|Estimate|||||||2017-06-07|2017-06-08|Actual|February 2010||2010-02-28|June 2017|2017-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Tolerance and Efficacy of Wondersun Infant Formula in Formula-fed Chinese Term Infants|Tolerance and Efficacy of Wondersun Infant Formula in Formula-fed Chinese Term Infants: an Open Label, Controlled Trial|Completed||Phase 4|75|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 23:36:33.684176|2018-05-31 23:36:33.684176
NCT01152333|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2015-06-17|2010-06-25|2010-06-29|Estimate|||||||2015-06-17|2015-06-19|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||The Role of GLP-1 in Satiety Perception in Humans|The Role of GLP-1 in Satiety Perception in Humans|Withdrawn||N/A|0|Actual|University of Washington||2||This study is delayed. It was not funded.|f||||t||||||||||2018-05-31 23:38:28.254896|2018-05-31 23:38:28.254896
NCT01157377|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2014-02-04||2014-02-04|2010-07-02|2010-07-07|Estimate|2014-02-04|2014-03-19|Estimate||||2014-02-04|2014-03-19|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional||Baseline characteristics are based on the Safety Population that included all participants who received study medication.|Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence||Completed||Phase 2|160|Actual|Allergan||7|||f||||t||||||||||2018-05-31 23:36:33.818465|2018-05-31 23:36:33.818465
NCT01157364|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02||2018-01-11|2018-01-11|2010-07-06|2010-07-07|Estimate||||2018-01-11|2018-01-16|Actual|2018-01-11|2018-01-16|Actual|September 23, 2010|Actual|2010-09-23|January 2018|2018-01-31|August 4, 2017|Actual|2017-08-04|July 27, 2016|Actual|2016-07-27||Interventional|||Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension|An Open-label (Stage 1) and Randomized (Stage 2), 24 Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 1/Phase 2|109|Actual|Allergan||6|||f||||f|t|f||||||No||2018-05-31 23:36:35.40686|2018-05-31 23:36:35.40686
NCT01157351|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2014-11-28||2015-04-07|2010-07-01|2010-07-07|Estimate|2014-11-28|2014-12-04|Estimate||||2015-04-07|2015-04-24|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Intent to Treat (ITT) population included all participants who were randomly assigned to treatment and who received at least 1 dose of their randomly assigned study treatment.|15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated|A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated|Completed||Phase 4|450|Actual|Janssen Scientific Affairs, LLC||8|||f||||f||||||||||2018-05-31 23:36:35.690998|2018-05-31 23:36:35.690998
NCT01157338|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization|Clinical Significance of Retinal Emboli During Diagnostic and Therapeutic Cardiac Catheterization|Completed||N/A|300|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:36:36.518475|2018-05-31 23:36:36.518475
NCT01157325|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2011-07-26|2010-07-06|2010-07-07|Estimate|||||||2011-07-26|2011-07-27|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CRINA||Cesarean Rate in Parturients Without Neuraxial Analgesia|Comparison of the Cesarean Rate Between Parturients Who Received Neuraxial Analgesia and Those Who Did Not|Completed||N/A|500|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 23:36:36.604794|2018-05-31 23:36:36.604794
NCT01157312|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-16|2010-07-06|2010-07-07|Estimate|||||||2010-07-16|2010-07-19|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Minimal Stimulation or Clomiphene Citrate in Treatment of Polycystic Ovary Syndrome|Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome|Completed||N/A|113|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 23:36:36.687186|2018-05-31 23:36:36.687186
NCT01157299|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Observational|PreloaDren||Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO|Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO|Unknown status|Recruiting||100|Anticipated|Hospital Universitario La Paz|||3||f||||t||||||||||2018-05-31 23:36:36.766997|2018-05-31 23:36:36.766997
NCT01157286|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2018-03-09|2010-07-06|2010-07-07|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2010||2010-06-30|July 2010|2010-07-31|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Observational|||Obstructive Apnea in Patients Submitted to Partial Laryngectomy|Obstructive Apnea in Patients Submitted to Partial Laryngectomy|Unknown status|Recruiting||20|Anticipated|Hospital do Servidor Publico Estadual|||1||f||||f||||||||||2018-05-31 23:36:36.884306|2018-05-31 23:36:36.884306
NCT01157273|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|February 2009||2009-02-28|July 2010|2010-07-31|July 2009|Actual|2009-07-31|||||Observational|||Evaluation of Physiological and Vocal Parameters in Volunteers of Both Genders Submitted to an Anxiogenic Task|Psychophysiological and Vocal Affections in Subjects Submitted to a Public Speaking Mock Test|Completed|||24|Actual|Federal University of São Paulo|||2||f||||t||||||||||2018-05-31 23:36:37.082334|2018-05-31 23:36:37.082334
NCT01157260|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|September 2010||2010-09-30|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|||The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease|The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Ewha Womans University||2|||f||||t||||||||||2018-05-31 23:36:37.137854|2018-05-31 23:36:37.137854
NCT01157247|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2010-07-06|2010-07-06|2010-07-07|Estimate|||||||2010-07-06|2010-07-07|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Intravenous Fentanyl or Local Anesthetic Infiltration for Pain Reducing During Spinal Needle Insertion||Completed||N/A|88|Actual|Croatian Society of Regional Anesthesia and Analgesia||4|||f||||t||||||||||2018-05-31 23:36:37.225408|2018-05-31 23:36:37.225408
NCT01157234|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2016-01-25||2016-02-23|2010-07-02|2010-07-05|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Full analysis set included all participants who signed informed consent and received at least one dose of study drug|Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients|Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients|Completed||Phase 4|32|Actual|University of Florida|"Small numbers of subjects analyzed in a single center limits precision and generalizability of results.~Technical limitations prevented measurements of asymmetric dimethyl-arginine and arginine leading to absence of analysis for these outcomes."|2|||f||||f||||||||||2018-05-31 23:36:37.346402|2018-05-31 23:36:37.346402
NCT01157221|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-02|2010-07-02|2010-07-05|Estimate|||||||2010-07-02|2010-07-05|Estimate|August 2006||2006-08-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Prediction Frozen Shoulder Validation|Determining Shoulder Kinematics in the Prediction of Progress of Frozen Shoulder Syndrome: a Prediction Method, Validation of the Method, and Clinical Application|Completed||Phase 1/Phase 2|30|Actual|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 23:36:38.041346|2018-05-31 23:36:38.041346
NCT01157195|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-10-04|2010-07-02|2010-07-05|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2010||2010-06-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2013|Actual|2013-08-31||Interventional|||Home-Based Automated Therapy of Arm Function After Stroke Via Tele-Rehabilitation|Home-Based Automated Therapy of Arm Function After Stroke Via Tele-Rehabilitation|Active, not recruiting||N/A|25|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 23:36:38.209048|2018-05-31 23:36:38.209048
NCT01157182|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2010-09-15||2010-11-22|2010-07-02|2010-07-05|Estimate|2010-11-22|2010-12-17|Estimate||||2010-11-22|2010-12-17|Estimate|February 2007||2007-02-28|November 2010|2010-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:36:38.312235|2018-05-31 23:36:38.312235
NCT01157169|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2010-08-18||2010-11-22|2010-07-02|2010-07-05|Estimate|2010-08-18|2010-09-13|Estimate||||2010-11-22|2010-12-08|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Buprenorphine 8 mg Sublingual Tablets Under Fasting Conditions.|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:36:39.000398|2018-05-31 23:36:39.000398
NCT01157156|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2010-07-02|2010-07-02|2010-07-05|Estimate|||||||2010-07-02|2010-07-05|Estimate|June 1999||1999-06-30|July 2010|2010-07-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease|A Phase I, Multi-Center, Open Label, Safety and Tolerability Study of Single and Repeated Administrations of Escalating Dose(s) of NV1FGF Administered by Intra-Muscular Injection in Patients With Severe Peripheral Artery Occlusive Disease|Completed||Phase 1|51|Actual|Sanofi|||||f||||f||||||||||2018-05-31 23:36:39.391604|2018-05-31 23:36:39.391604
NCT01157143|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2010-07-02|2010-07-02|2010-07-05|Estimate|||||||2010-07-02|2010-07-05|Estimate|January 2002||2002-01-31|July 2010|2010-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation|Phase I, Double Blind, Parallel-Group, Multi-center, Gene Expression (Synthesis of FGF-1 mRNA) and Tolerability Study of Increasing Single Dose of NV1FGF Administered by Intra-Muscular Injection in Subjects With Severe Peripheral Artery Occlusive Disease (PAOD) Planned to Undergo Amputation Above the Ankle|Completed||Phase 1|6|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 23:36:39.44964|2018-05-31 23:36:39.44964
NCT01157130|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2011-07-19|2010-07-02|2010-07-05|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2010||2010-07-31|July 2011|2011-07-31||||||||Interventional|||Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory|Prescriptive Exercise Intervention During Active Treatment for Early Stage Breast Cancer Patients: A Breast Cancer Rehabilitation & Exercise Laboratory|Unknown status|Recruiting|N/A|100|Anticipated|Nevada Cancer Institute||2|||f||||t||||||||||2018-05-31 23:36:39.514259|2018-05-31 23:36:39.514259
NCT01157117|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2016-01-05||2016-12-15|2010-07-02|2010-07-05|Estimate|2016-03-08|2016-04-06|Estimate||||2016-12-15|2017-02-08|Estimate|August 2010||2010-08-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|January 2015|Actual|2015-01-31||Interventional|||OIT and Xolair® (Omalizumab) in Cow's Milk Allergy|Oral Immunotherapy Combined With Humanized Monoclonal Anti-IgE Antibody Xolair® (Omalizumab)in the Treatment of Cow's Milk Allergy|Completed||Phase 2|77|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||||2018-05-31 23:36:39.752674|2018-05-31 23:36:39.752674
NCT01157104|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2016-01-20|2010-07-02|2010-07-05|Estimate|||||||2016-01-20|2016-01-22|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)|A Phase I, Double-Blind, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX320 and IDX184 in Healthy Subjects|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 23:36:40.562779|2018-05-31 23:36:40.562779
NCT01157091|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2018-05-16|2010-07-02|2010-07-05|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2010||2010-11-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer|A Phase II Study of Pazopanib in VEGF-TKI Refractory Metastatic Renal Cell Carcinoma (MRCC)|Active, not recruiting||Phase 2|28|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:36:40.703671|2018-05-31 23:36:40.703671
NCT01157078|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2012-06-26||2014-03-14|2010-07-02|2010-07-05|Estimate|2012-11-19|2012-11-20|Estimate||||2014-03-14|2014-04-11|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Therapy|Completed||Phase 3|319|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:36:40.835626|2018-05-31 23:36:40.835626
NCT01157065|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2013-04-19||2013-04-19|2010-07-02|2010-07-05|Estimate|2013-04-19|2013-06-04|Estimate||||2013-04-19|2013-06-04|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|RACE|This reporting group includes all randomized subjects who received study medication.|Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration|Controlled, Double-Masked, Randomized, Multicenter Study to Evaluate AL-78898A as a Treatment of Exudative AMD|Completed||Phase 2|99|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:36:41.720252|2018-05-31 23:36:41.720252
NCT01157052|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2014-09-29|2010-07-02|2010-07-05|Estimate|||||||2014-09-29|2014-10-01|Estimate|January 2015||2015-01-31|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients|Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients|Unknown status|Not yet recruiting|Phase 1|15|Anticipated|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-05-31 23:36:41.977397|2018-05-31 23:36:41.977397
NCT01157039|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2016-02-23|2010-07-02|2010-07-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2011||2011-10-31|October 2011|2011-10-31||||September 2012|Anticipated|2012-09-30||Interventional|||A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin|A Phase II Trial of Glutamin to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin.|Withdrawn||Phase 2|0|Actual|AHS Cancer Control Alberta||2||abandoned|f||||f||||||||||2018-05-31 23:36:42.075241|2018-05-31 23:36:42.075241
NCT01157026|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-02|2010-07-02|2010-07-05|Estimate|||||||2010-07-02|2010-07-05|Estimate|November 2001||2001-11-30|July 2010|2010-07-31|January 2010|Actual|2010-01-31|November 2006|Actual|2006-11-30||Interventional|BC||A Pilot Clinical Trial With Tocotrienol on Breast Cancer|Effectiveness of Tocotrienol-rich Fraction Combined With Tamoxifen in the Management of Women With Early Breast Cancer: A Pilot Clinical Trial|Completed||N/A|240|Actual|Malaysia Palm Oil Board||2|||f||||f||||||||||2018-05-31 23:36:42.151628|2018-05-31 23:36:42.151628
NCT01157013|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2010-07-02|2010-07-02|2010-07-05|Estimate|||||||2010-07-02|2010-07-05|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma|The Role of Positron Emission Tomography (PET) Imaging in the Evaluation of Response to Sorafenib Treatment in Advanced Hepatocellular Carcinoma.|Completed||N/A|40|Actual|Hospital Miguel Servet||1|||f||||f||||||||||2018-05-31 23:36:42.231536|2018-05-31 23:36:42.231536
NCT01157000|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2014-04-07|2010-07-01|2010-07-05|Estimate|||||||2014-04-07|2014-04-08|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|June 2010|Actual|2010-06-30|||||Interventional|||A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers|An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-28431754 (Canagliflozin) Administered as a 300-mg Oral Tablet and an Intravenous Microdose of 10 mcg 14C-canagliflozin in Healthy Male Subjects|Completed||Phase 1|9|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 23:36:42.311607|2018-05-31 23:36:42.311607
NCT01156987|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2015-12-09||2017-01-26|2010-07-02|2010-07-05|Estimate|2016-10-25|2016-12-19|Estimate||||2017-01-26|2017-03-09|Actual|August 2009||2009-08-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Improved Breast MRI With SWIFT|Improved Breast Dynamic Contrast Enhanced-magnetic Resonance Imaging (DCE-MRI) With Sweep Imaging With Fourier Transform (SWIFT)|Completed||N/A|31|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 23:36:42.396762|2018-05-31 23:36:42.396762
NCT01156974|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2015-01-14|2010-07-02|2010-07-05|Estimate|||||||2015-01-14|2015-01-16|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Care Guides in the Primary Care Office (Phase II)|Care Guides: Can Trained Laypersons Help Manage Chronic Disease? A Randomized Trial.|Completed||Phase 2|2135|Actual|Allina Hospitals and Clinics||2|||f||||f||||||||||2018-05-31 23:36:42.623971|2018-05-31 23:36:42.623971
NCT01156961|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2016-11-01|2010-07-02|2010-07-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)|Post Registration Observational Program for Patients With Locally Recurrent or Metastatic Breast Cancer Who Receive Bevacizumab (Avastin) in Combination With Paclitaxel for the First-line Treatment|Withdrawn||Phase 4|0|Actual|Hoffmann-La Roche||1||Absence of patient's recruitment in the study due to administrative reasons|f||||||||||||||2018-05-31 23:36:42.716368|2018-05-31 23:36:42.716368
NCT01156948|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2010-07-07|2010-07-02|2010-07-05|Estimate|||||||2010-07-07|2010-07-08|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|December 2011|Anticipated|2011-12-31|August 2010|Anticipated|2010-08-31||Interventional|||Misoprostol For Nulliparous Women Before Hysteroscopy|Comparison of Vaginal Versus Oral Misoprostol for Nulliparous Women Prior to Operative Hysteroscopy|Unknown status|Recruiting|Phase 3|120|Anticipated|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 23:36:42.790142|2018-05-31 23:36:42.790142
NCT01156935|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-09|2010-07-02|2010-07-05|Estimate|||||||2010-07-09|2010-07-12|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Effects of Laugh-yoga Intervention on Mood and Quality of Life Among Oncologic Patients in a Oncologic Clinic Setting.|Effects of Laugh-yoga Intervention on Mood and Quality of Life Among Oncologic Patients|Unknown status|Not yet recruiting|N/A|60|Anticipated|Wolfson Medical Center||1|||f||||||||||||||2018-05-31 23:36:42.870915|2018-05-31 23:36:42.870915
NCT01156922|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2016-04-11|2010-07-02|2010-07-05|Estimate|||||||2016-04-11|2016-04-12|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome|B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Severely Affected Chronic Fatigue Syndrome Patients. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment for Patients in WHO Performance Status III-IV|Terminated||Phase 2|8|Actual|Haukeland University Hospital||1||Difficulties in logistics handling the very severe patients (travel, hospital stay, follow-up)|f||||f||||||||||2018-05-31 23:36:42.916002|2018-05-31 23:36:42.916002
NCT01156909|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2014-08-29|2010-07-02|2010-07-05|Estimate|||||||2014-08-29|2014-09-01|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome|B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. An Open Label Phase II Study With Rituximab Induction and Maintenance Treatment|Completed||Phase 2|29|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 23:36:42.992853|2018-05-31 23:36:42.992853
NCT01156896|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2015-02-11|2010-07-02|2010-07-05|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MIA||Malaria and the Safety of Iron Supplements and Iron Fortification|Malaria and Iron Intervention Safety: Absorption and NTBI|Completed||N/A|23|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 23:36:43.239551|2018-05-31 23:36:43.239551
NCT01156883|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2018-02-20|2010-07-02|2010-07-05|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2010||2010-04-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|November 2014|Actual|2014-11-30||Interventional|LAL1308||Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia|Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment|Completed||N/A|30|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 23:36:43.345209|2018-05-31 23:36:43.345209
NCT01156870|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2017-05-09|2010-07-02|2010-07-05|Estimate|||||||2017-05-09|2017-05-10|Actual|September 8, 2010|Actual|2010-09-08|May 2017|2017-05-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor|Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors|Completed||Phase 1|114|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:36:43.503474|2018-05-31 23:36:43.503474
NCT01156857|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2016-01-14|2010-07-02|2010-07-05|Estimate|||||||2016-01-14|2016-01-15|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|PEARLIII||PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata|A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding.|Completed||Phase 3|209|Actual|PregLem SA||2|||f||||t||||||||||2018-05-31 23:36:43.585843|2018-05-31 23:36:43.585843
NCT01156844|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2011-07-22||2011-07-22|2010-07-02|2010-07-05|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|March 2010||2010-03-31|July 2011|2011-07-31||||July 2010|Actual|2010-07-31||Interventional|||Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Repeated-dose Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Three Different Dosing Regimens of Inhaled Indacaterol Maleate in Patients With Persistent Asthma|Completed||Phase 2|191|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:36:43.785304|2018-05-31 23:36:43.785304
NCT01156831|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2014-12-05|2010-07-02|2010-07-05|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2011|Actual|2011-05-31||Observational|||PET-CT Based Radiotherapy in Esophageal Cancer Patients|Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients|Completed|||115|Actual|Maastricht Radiation Oncology|||||f||||t||||||||||2018-05-31 23:36:44.805617|2018-05-31 23:36:44.805617
NCT01156818|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2011-06-08|2010-07-02|2010-07-05|Estimate|||||||2011-06-08|2011-06-09|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Wheezometer™ Exploratory (WM) Field Study|Wheezometer™ Exploratory (WM) Field Study|Unknown status|Recruiting||40|Anticipated|KarmelSonix Ltd.|||2||f||||f||||||||||2018-05-31 23:36:45.123643|2018-05-31 23:36:45.123643
NCT01156805|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2010-07-07|2010-07-02|2010-07-05|Estimate|||||||2010-07-07|2010-07-08|Estimate|September 2006||2006-09-30|July 2010|2010-07-31|September 2012|Anticipated|2012-09-30|September 2008|Actual|2008-09-30||Interventional|AVALL||Assessment of an School-based Intervention in Eating Habits and Physical Activity in Schoolchildren: the AVall Study|Assessment of an School-based Intervention in Eating Habits and Physical Activity in Schoolchildren: the AVall Study.|Unknown status|Active, not recruiting|N/A|598|Actual|Hospital de Granollers||1|||f||||f||||||||||2018-05-31 23:36:45.462356|2018-05-31 23:36:45.462356
NCT01156792|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2016-12-08|2012-04-12|2017-03-08|2010-07-01|2010-07-05|Estimate|2016-12-08|2017-02-03|Estimate|2012-04-12|2012-04-16|Estimate|2017-03-08|2017-04-05|Actual|September 2010||2010-09-30|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100mg, GSK2190915 300mg, Montelukast 10mg or Placebo Tablets Once Daily or Salmeterol 50mcg Inhalation Powder Twice Daily to Fluticasone Propionate 100mcg Inhalation Powder Twice Daily in Uncontrolled Asthmatic Subjects ≥ 12 Years of Age|Completed||Phase 2|162|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:36:45.973379|2018-05-31 23:36:45.973379
NCT01156779|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2013-08-12|2010-07-02|2010-07-05|Estimate|||||||2013-08-12|2013-08-13|Estimate|July 2010||2010-07-31|August 2013|2013-08-31||||April 2012|Actual|2012-04-30||Interventional|SR-Exenatide||Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating, Phase I Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of DA-3091 After Subcutaneous Injection in Healthy Male Subjects|Completed||Phase 1|31|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 23:36:48.513117|2018-05-31 23:36:48.513117
NCT01156766|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2013-06-11|2010-07-02|2010-07-05|Estimate|||||||2013-06-11|2013-06-12|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Metaphyseal Distal Radius Fractures|Locking Plate Versus Pins for Surgical Treatment of Posteriorly Tilted Distal Radius Fracture|Completed||N/A|90|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:36:48.594057|2018-05-31 23:36:48.594057
NCT01156753|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30||2016-02-16|2017-06-26|2010-07-02|2010-07-05|Estimate||||2016-02-16|2016-03-15|Estimate|2017-06-26|2017-07-02|Actual|July 2010||2010-07-31|June 2017|2017-06-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|EMERGE||A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer|A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer|Completed||Phase 2|120|Actual|Celldex Therapeutics||2|||f||||t||||||||||2018-05-31 23:36:48.675134|2018-05-31 23:36:48.675134
NCT01156740|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2010-07-02|2010-07-02|2010-07-05|Estimate|||||||2010-07-02|2010-07-05|Estimate|August 2001||2001-08-31|December 2009|2009-12-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|TOPS||Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings|Treatment of Pharyngitis Study (TOPS): A Randomized Equivalence Trial of Intramuscular Penicillin G vs. Oral Amoxicillin Antibiotics for the Treatment of Streptococcal Pharyngitis in Children in Developing Countries|Completed||N/A|558|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 23:36:48.908482|2018-05-31 23:36:48.908482
NCT01156727|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-06-02|2010-07-01|2010-07-05|Estimate|||||||2017-06-02|2017-06-06|Actual|July 1, 2010|Actual|2010-07-01|June 2017|2017-06-30|May 30, 2014|Actual|2014-05-30|January 31, 2014|Actual|2014-01-31||Observational|||Linking National Guard Veterans With Need to Mental Health Care|Linking National Guard Veterans With Need to Mental Health Care|Completed|||3015|Actual|VA Office of Research and Development|||3||f||||f||||||||||2018-05-31 23:36:49.007369|2018-05-31 23:36:49.007369
NCT01156714|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2017-10-25|2010-07-02|2010-07-05|Estimate|||||||2017-10-25|2017-10-27|Actual|October 1, 2010|Actual|2010-10-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|February 28, 2017|Actual|2017-02-28||Interventional|||Exercise and Cognitive Training in Parkinson's Disease|Effects of Exercise and Cognitive Training on Executive Function in Parkinson's Disease|Active, not recruiting||N/A|121|Anticipated|VA Office of Research and Development||3|||f||||t|f|f|||f|||No||2018-05-31 23:36:49.138421|2018-05-31 23:36:49.138421
NCT01156701|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2011-01-28||2017-05-24|2010-07-01|2010-07-05|Estimate|2011-01-28|2011-03-04|Estimate||||2017-05-24|2017-05-30|Actual|July 2009||2009-07-31|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Prophylactic Efficacy of Relenza Against Influenza A and B|Prophylactic Efficacy of Relenza Against Influenza A and B|Completed|||171705|Actual|GlaxoSmithKline|||4||f||||f||||||||||2018-05-31 23:36:49.264673|2018-05-31 23:36:49.264673
NCT01156688|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-08-03|2010-07-01|2010-07-05|Estimate|||||||2011-08-03|2011-08-05|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Prospective Randomized Comparison Trial on the Use of Mifepristone With Sublingual or Buccal Misoprostol for Medical Abortions of Less Than 9 Weeks Gestation|A Prospective Randomized Comparison Trial on the Use of Mifepristone With Sublingual or Buccal Misoprostol for Medical Abortions of Less Than 9 Weeks Gestation|Completed||Phase 4|90|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:36:49.984062|2018-05-31 23:36:49.984062
NCT01156675|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2017-12-13||2018-03-26|2010-07-02|2010-07-05|Estimate|2018-03-26|2018-04-27|Actual||||2018-03-26|2018-04-27|Actual|June 2008||2008-06-30|March 2018|2018-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study Evaluating the Safety and Effectiveness of the FLEXUS(TM) Interspinous Spacer|A Prospective Randomized Clinical Investigation of the FLEXUS(TM) Interspinous Spacer: A Pivotal Study|Terminated||N/A|215|Actual|Globus Medical Inc||2|||f||||||||||||||2018-05-31 23:36:50.093731|2018-05-31 23:36:50.093731
NCT01156662|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2013-04-13|2010-07-02|2010-07-05|Estimate|||||||2013-04-13|2013-04-16|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|ETAMI||Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction|Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction|Unknown status|Active, not recruiting|Phase 4|1400|Anticipated|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 23:36:51.848669|2018-05-31 23:36:51.848669
NCT01156649|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2016-11-03|2010-07-02|2010-07-05|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|November 2016|Anticipated|2016-11-30|September 2016|Actual|2016-09-30||Interventional|OSA||Effects of Positive Airway Pressure (PAP) in Children With Obstructive Sleep Apnea (OSA)|Neurobehavioral Effects of Positive Airway Pressure (PAP) Therapy in Children With Obstructive Sleep Apnea|Unknown status|Active, not recruiting|Phase 1/Phase 2|79|Actual|University of Tennessee||2|||f||||t||||||||No||2018-05-31 23:36:51.997438|2018-05-31 23:36:51.997438
NCT01156636|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2012-06-14|2010-07-02|2010-07-05|Estimate|||||||2012-06-14|2012-06-15|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure|Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study|Completed||Phase 2/Phase 3|44|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 23:36:52.099765|2018-05-31 23:36:52.099765
NCT01156623|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2015-02-11|2010-07-02|2010-07-05|Estimate|||||||2015-02-11|2015-02-12|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|||Endobronchial Ultrasound Guided Transbronchial Aspiration (EBUS-TBNA) in Non Small Cell Lung Cancer (NSCLC) in a Tuberculosis-endemic Country|Value of EBUS-TBNA for Mediastinal Lymph Nodes in Non-small Cell Lung Cancer in a Tuberculosis-endemic Country|Completed||N/A|36|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 23:36:52.216697|2018-05-31 23:36:52.216697
NCT01156610|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2014-03-04|2010-07-01|2010-07-05|Estimate|||||||2014-03-04|2014-03-06|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations|Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations|Completed||N/A|706|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:36:52.434822|2018-05-31 23:36:52.434822
NCT01156597|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|2014-04-18||2014-11-11|2010-07-02|2010-07-05|Estimate|2014-11-10|2014-11-11|Estimate||||2014-11-11|2014-11-21|Estimate|April 2008||2008-04-30|November 2014|2014-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes|Effects of Pioglitazone on Reverse Cholesterol Transport and HDL Function in Persons With Diabetes|Completed||Phase 3|30|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 23:36:52.622057|2018-05-31 23:36:52.622057
NCT01156584|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2018-05-16|2010-07-02|2010-07-05|Estimate|||||||2018-05-16|2018-05-21|Actual|July 2010||2010-07-31|May 2018|2018-05-31|August 18, 2016|Actual|2016-08-18|August 18, 2016|Actual|2016-08-18||Interventional|||A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma|A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma|Completed||Phase 1|54|Actual|Tocagen Inc.||1|||f||||t||||||||||2018-05-31 23:36:53.067138|2018-05-31 23:36:53.067138
NCT01156571|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2013-04-22||2014-01-02|2010-07-01|2010-07-05|Estimate|2013-04-22|2013-06-18|Estimate||||2014-01-02|2014-02-04|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CHAMPION|ITT population|A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)|A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)|Completed||Phase 3|11145|Actual|The Medicines Company||2|||f||||||||||||||2018-05-31 23:36:53.269702|2018-05-31 23:36:53.269702
NCT01156558|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2011-03-30|2010-07-01|2010-07-05|Estimate|||||||2011-03-30|2011-03-31|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Early Outcome Assessment of Revision Total Knee Arthroplasty Using Metaphyseal Sleeves|Early Outcome Assessment of Revision Total Knee Arthroplasty Using Metaphyseal Sleeves|Completed|||||Rothman Institute Orthopaedics|||||f||||f||||||||||2018-05-31 23:36:54.03359|2018-05-31 23:36:54.03359
NCT01156545|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-02|||2017-08-24|2010-07-02|2010-07-05|Estimate|||||||2017-08-24|2017-08-25|Actual|October 2010|Actual|2010-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC|A Randomized Open Label Phase II Trial Comparing BIBW2992 Plus Simvastatin With BIBW2992 Plus Best Supportive Care in Previously Treated Patients With Advanced (Stage IIIB/IV) Non-adenocarcinomatous Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|84|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 23:36:54.25836|2018-05-31 23:36:54.25836
NCT01156532|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2014-08-08||2014-08-08|2010-07-01|2010-07-05|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-08|2014-08-25|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy|Observational Study; Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy|Terminated|||30|Actual|AbbVie|Although a sample of 75 participants was originally planned, only 30 participants were enrolled in this study. The limited sample size can result in a potential sampling bias that cannot be tested.||1|This study was prematurely terminated due to low enrollment and not for safety reasons.|f||||||||||||||2018-05-31 23:36:54.415296|2018-05-31 23:36:54.415296
NCT01156519|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2014-07-21|2010-07-02|2010-07-05|Estimate|||||||2014-07-21|2014-07-22|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|ACIC||Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC)|Detection of Infra-clinic Cortisol Adenoma (ACIC) in a Population of Android Obese With High Metabolic Risk: Contribution of Salivary Cortisol at 23 Hours|Terminated||N/A|514|Actual|Nantes University Hospital||1||Number of patients with a serum cortisol > 18 ng/ml reached|f||||f||||||||||2018-05-31 23:36:54.744013|2018-05-31 23:36:54.744013
NCT01156506|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2012-12-11|2010-07-02|2010-07-05|Estimate|||||||2012-12-11|2012-12-12|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Focus Group Interviews of Patients With Permanent or Temporary Enterostomas|Patient Perspectives on Living With an Enterostoma and Rehabilitation|Completed|||22|Actual|Herlev Hospital|||||f||||f||||||||||2018-05-31 23:36:54.829384|2018-05-31 23:36:54.829384
NCT01156493|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-05-09|2010-07-01|2010-07-02|Estimate|||||||2017-05-09|2017-05-10|Actual|July 2010||2010-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|October 2013|Actual|2013-10-31||Interventional|||Hydrolized Protein Formula for Premature Infants|Randomized Trial of Hydrolyzed Protein Premature Formula|Completed||N/A|137|Actual|University of Miami||2|||f||||f||||||||No||2018-05-31 23:36:54.883508|2018-05-31 23:36:54.883508
NCT01156480|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2014-01-08||2014-04-15|2010-07-01|2010-07-02|Estimate|2014-02-10|2014-03-24|Estimate||||2014-04-15|2014-04-30|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|steroids/NEC|premature neonates|Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants|Anti-inflammatory Treatment at the Onset of NEC in Preterm Infants- a Pilot Study|Terminated||N/A|2|Actual|NorthShore University HealthSystem Research Institute|This study was terminated due to low enrollment. We had a drop in our incidence of NEC, so there were very few eligible infants. One subject that was enrolled was soon thereafter thought NOT to have NEC, so that subject never received study drug.|2||low enrollment|f||||t||||||||||2018-05-31 23:36:54.960092|2018-05-31 23:36:54.960092
NCT01156467|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2013-06-10|2010-07-01|2010-07-02|Estimate|||||||2013-06-10|2013-06-11|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Neurally Adjusted Ventilatory Assist (NAVA) in Ventilatory Care of Premature Infants|Neurally Adjusted Ventilatory Assist (NAVA) in Ventilatory Care of Premature Infants|Completed||N/A|60|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 23:36:55.261517|2018-05-31 23:36:55.261517
NCT01156454|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2016-12-22|2010-07-01|2010-07-02|Estimate|||||||2016-12-22|2016-12-23|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|GPS||Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling|Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling (GPS)|Completed|||20|Actual|University of Arkansas|||1||f||||f||||||||||2018-05-31 23:36:55.366073|2018-05-31 23:36:55.366073
NCT01156441|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2014-06-12|2010-07-01|2010-07-02|Estimate|||||||2014-06-12|2014-06-16|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Medical Versus Surgical Management of Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention|Medical Versus Surgical Management of Patients With Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention for Myocardial Infarction: A Pilot Prospective Randomized Trial|Withdrawn||Phase 1/Phase 2|0|Actual|Southern Illinois University||2||no patients enrolled|f||||f||||||||||2018-05-31 23:36:55.448317|2018-05-31 23:36:55.448317
NCT01156428|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2018-04-09|2010-07-01|2010-07-02|Estimate|||||||2018-04-09|2018-04-10|Actual|July 2010||2010-07-31|April 2018|2018-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease|Transcriptional Profiling of Kidney Tissue Obtained From Patients With Newly Identified Proteinuria, Nephrotic Syndrome or Nephritic Syndrome|Completed|||119|Actual|The Rogosin Institute|||2||f||||f||||||Samples Without DNA|"~     Whole blood, serum, urine, kidney tissue~   "|||2018-05-31 23:36:55.527004|2018-05-31 23:36:55.527004
NCT01156415|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30||2013-02-14|2013-03-06|2010-07-01|2010-07-02|Estimate||||2013-02-14|2013-02-20|Estimate|2013-03-06|2013-03-14|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)|A 52-week, Multi-center, Open-label Study of the Safety and Tolerability of Agomelatine Sublingual Tablets in Patients With Major Depressive Disorder (MDD)|Terminated||Phase 3|837|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:36:55.630359|2018-05-31 23:36:55.630359
NCT01156402|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2016-05-05|2010-07-01|2010-07-02|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|November 2013|Actual|2013-11-30||Interventional|||Childhood Obesity Prevention Program for Hispanics|Culturally-Appropriate Childhood Obesity Prevention Program for Hispanic Families|Completed||N/A|319|Actual|Meharry Medical College||2|||f||||f||||||||||2018-05-31 23:36:55.864107|2018-05-31 23:36:55.864107
NCT01156389|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2011-03-18|2010-07-01|2010-07-02|Estimate|||||||2011-03-18|2011-03-21|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Pyronaridine/Artesunate -Ritonavir Drug Drug Interaction Study|Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers|Completed||Phase 1|34|Anticipated|Medicines for Malaria Venture||2|||f||||f||||||||||2018-05-31 23:36:55.941535|2018-05-31 23:36:55.941535
NCT01156376|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2015-05-28||2015-08-05|2010-07-01|2010-07-02|Estimate|2015-05-28|2015-06-15|Estimate||||2015-08-05|2015-08-24|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Oral Irritation Study of Two Experimental Mouthrinses|Determination of the Oral Irritation and Sensitization Potential of Two Experimental Potassium Oxalate Containing Mouthrinses|Completed||N/A|80|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 23:36:56.209895|2018-05-31 23:36:56.209895
NCT01156363|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2015-10-30||2015-10-30|2010-07-01|2010-07-02|Estimate|2015-10-30|2015-12-03|Estimate||||2015-10-30|2015-12-03|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Intent-to-treat (ITT) population included participants who had received at least 1 dose of Mircera (Week 0) and for whom data for at least one follow-up variable was available.|A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous and Intravenous MIRCERA® for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia|Completed||Phase 4|86|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:36:58.933354|2018-05-31 23:36:58.933354
NCT01156350|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2011-01-18|2010-07-01|2010-07-02|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2011||2011-09-30|January 2011|2011-01-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|Rice NK||Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma|Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:36:59.528777|2018-05-31 23:36:59.528777
NCT01156337|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2011-11-18|2010-07-01|2010-07-02|Estimate|||||||2011-11-18|2011-11-21|Estimate|September 2000||2000-09-30|August 2007|2007-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|SMAC-HF||Sodium Management in Acute and Chronic Heart Failure|Sodium Management in Acute and Chronic Phases in Patients With New York Heart Association Class III (Class C) Heart Failure. Short and Long Term Findings.|Completed|||||Ospedale G. F. Ingrassia|||2||f||||t||||||||||2018-05-31 23:36:59.611004|2018-05-31 23:36:59.611004
NCT01156324|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2016-02-03|2010-07-01|2010-07-02|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Impact of an Online Stress Management Program on In Vitro Fertilization (IVF) Outcome|The Impact of an Online Stress Management Program on IVF Outcome|Withdrawn||N/A|0|Actual|Boston IVF||2||Loss of funding.|f||||f||||||||No||2018-05-31 23:36:59.680636|2018-05-31 23:36:59.680636
NCT01156311|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2015-05-26||2017-02-14|2010-07-01|2010-07-02|Estimate|2015-05-26|2015-06-09|Estimate||||2017-02-14|2017-03-21|Actual|June 2010||2010-06-30|February 2017|2017-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|EXPLORE|Intent-to-Treat (ITT) Population: participants who took at least 1 capsule of BG00012 concurrently with the background therapy (combination therapy).|BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis|An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)|Completed||Phase 2|108|Actual|Biogen||2|||f||||f||||||||||2018-05-31 23:36:59.779909|2018-05-31 23:36:59.779909
NCT01156298|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2012-08-02|2010-07-01|2010-07-02|Estimate|||||||2012-08-02|2012-08-03|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|CHAMPIONS CONT||Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance|Phase IV, Multi-center, Non-treatment, Observational, Registry Study to Determine Long Term Effects of AVONEX® Therapy on EDSS, MRI, QoL, and Cognition.|Terminated|||383|Anticipated|Biogen|||2|low enrollment|f||||f||||||||||2018-05-31 23:37:00.926952|2018-05-31 23:37:00.926952
NCT01156285|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2011-11-27|2010-07-01|2010-07-02|Estimate|||||||2011-11-27|2011-11-29|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|||||Observational|||Acute Anterior Uveitis: Psychic Burden and Pain|Acute Anterior Uveitis: Psychic Burden and Pain|Unknown status|Recruiting||35|Anticipated|Hospital Hietzing|||1||f||||f||||||||||2018-05-31 23:37:01.052333|2018-05-31 23:37:01.052333
NCT01156272|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2015-08-04|2010-07-01|2010-07-02|Estimate|||||||2015-08-04|2015-08-06|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Post Market ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm|3f 19mm IDE Study Rev D|Withdrawn|||0|Actual|Medtronic Cardiovascular|||1|Study terminated prematurely.|f||||f||||||||||2018-05-31 23:37:01.22044|2018-05-31 23:37:01.22044
NCT01156259|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy|Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy|Unknown status|Recruiting|Phase 3|400|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:37:01.377484|2018-05-31 23:37:01.377484
NCT01156246|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2012-05-31|2010-07-01|2010-07-02|Estimate|||||||2012-05-31|2012-06-01|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers|An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/1000 mg) in Healthy Male and Female Volunteers|Completed||Phase 1|18|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:37:01.50271|2018-05-31 23:37:01.50271
NCT01156233|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2013-02-09|2010-07-01|2010-07-02|Estimate|||||||2013-02-09|2013-02-12|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Tube Tip Position in Orally Intubated 0-4year Old Children: Assessment of the Precision of Two Clinical Techniques|Endotracheal Tube Tip Position in Orally Intubated 0-4 Year Old Children: Comparative Assessment of the Precision of Two Clinical Techniques|Completed||N/A|69|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 23:37:01.573731|2018-05-31 23:37:01.573731
NCT01156220|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2011-04-11|2010-07-01|2010-07-02|Estimate|||||||2011-04-11|2011-04-12|Estimate|January 2012||2012-01-31|April 2011|2011-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers|Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 23:37:01.647286|2018-05-31 23:37:01.647286
NCT01156207|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-06|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|July 2010||2010-07-31|June 2010|2010-06-30||||July 2013|Anticipated|2013-07-31||Interventional|VACHF||Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure|Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 23:37:01.814546|2018-05-31 23:37:01.814546
NCT01156194|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2012-02-19|2010-07-01|2010-07-02|Estimate|||||||2012-02-19|2012-02-22|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Homeopathic Remedy for the Third Stage of Delivery|Effect of a Homeopathic Remedy on the Third Stage of Delivery: a Prospective, Randomized, Double-Blind Study.|Completed||Phase 3|210|Anticipated|Shaare Zedek Medical Center||3|||f||||f||||||||||2018-05-31 23:37:01.9054|2018-05-31 23:37:01.9054
NCT01156181|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2011-09-20|2010-07-01|2010-07-02|Estimate|||||||2011-09-20|2011-09-21|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Cervical Discharge Removal During ET on Pregnancy Rate|Effect of Cervical Discharge Removal Before Embryo Transfer on ICSI Cycle Outcomes|Completed||Phase 2/Phase 3|492|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 23:37:01.989267|2018-05-31 23:37:01.989267
NCT01156168|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-05-16|2010-07-01|2010-07-02|Estimate|||||||2017-05-16|2017-05-17|Actual|April 5, 2011|Actual|2011-04-05|May 2017|2017-05-31|September 8, 2011|Actual|2011-09-08|September 8, 2011|Actual|2011-09-08||Observational|||Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab|VEGF Gene Amplification/Deletion and Haplotype as Biomarkers for Bevacizumab in Breast Cancer|Completed|||363|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:37:02.073896|2018-05-31 23:37:02.073896
NCT01156155|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2014-06-30|2010-06-30|2010-07-02|Estimate|||||||2014-06-30|2014-07-02|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis|Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis|Completed|||617|Actual|University of Nebraska|||2||f||||f||||||Samples With DNA|"~     Blood specimens (serum, plasma and DNA)will be collected during a one time visit. Also~     bacterial samples will be collected from the gums of the subject's mouth.~   "|||2018-05-31 23:37:02.151001|2018-05-31 23:37:02.151001
NCT01156142|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2016-12-12||2017-07-11|2010-07-01|2010-07-02|Estimate|2017-03-28|2017-05-08|Actual||||2017-07-11|2017-08-09|Actual|December 2010||2010-12-31|July 2017|2017-07-31|March 2, 2015|Actual|2015-03-02|May 2012|Actual|2012-05-31||Interventional|||Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy|A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy|Completed||Phase 3|155|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 23:37:02.358707|2018-05-31 23:37:02.358707
NCT01156129|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-10-24|2010-07-01|2010-07-02|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2010|Actual|2010-09-30|October 2017|2017-10-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery|Interventions to Decrease the Impact of Post-Operative Ileus After Liver Transplant or Resection Surgery|Completed||Phase 1|100|Anticipated|University of Nebraska||3|||f||||f||||||||||2018-05-31 23:37:03.16908|2018-05-31 23:37:03.16908
NCT01156116|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2015-04-29||2015-05-22|2010-07-01|2010-07-02|Estimate|2015-05-22|2015-05-27|Estimate||||2015-05-22|2015-05-27|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk|Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk|Completed||N/A|39|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 23:37:03.335572|2018-05-31 23:37:03.335572
NCT01156103|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2015-05-07|2010-07-01|2010-07-02|Estimate|||||||2015-05-07|2015-05-08|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Reducing Pediatric Obesity Through After-school Programs|Reducing Pediatric Obesity Through After-school Programs|Completed||N/A|158|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:37:03.723834|2018-05-31 23:37:03.723834
NCT01156090|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2015-08-27|2010-07-01|2010-07-02|Estimate|||||||2015-08-27|2015-08-28|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||A Retrospective Cohort Study of Infusion Reactions Due to Vectibix|A Retrospective Cohort Study of Infusion Reactions Due to Vectibix|Completed|||141|Actual|SCRI Development Innovations, LLC|||1||f||||f||||||||||2018-05-31 23:37:03.829067|2018-05-31 23:37:03.829067
NCT01156077|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-03-23|2010-06-30|2010-07-02|Estimate|||||||2017-03-23|2017-03-27|Actual|June 1, 2010|Actual|2010-06-01|March 2017|2017-03-31|September 1, 2011|Actual|2011-09-01|September 1, 2011|Actual|2011-09-01||Interventional|||Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients|A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 Year Old Adolescent Patients|Completed||Phase 1|20|Actual|Trius Therapeutics LLC||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:37:03.921483|2018-05-31 23:37:03.921483
NCT01156064|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-11-22|2010-07-01|2010-07-02|Estimate|||||||2010-11-22|2010-11-23|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|December 2011|Anticipated|2011-12-31|December 2009|Anticipated|2009-12-31||Observational|||Confocal Laser Endomicroscopy in Digestive Diseases|Confocal Laser Endomicroscopy in Digestive Diseases|Unknown status|Recruiting||500|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||Samples With DNA|"~     biopsy tissue~   "|||2018-05-31 23:37:03.998172|2018-05-31 23:37:03.998172
NCT01156051|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|2014-05-31||2014-07-21|2010-07-01|2010-07-02|Estimate|2014-07-21|2014-08-11|Estimate||||2014-07-21|2014-08-11|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||29 enrollees, but two were excluded due to (1) lost to follow up, and (2) noncompliance with the protocol.|Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia|Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia|Terminated||Phase 4|29|Actual|Children's Specialized Hospital||2||extended beyond completion date; chose to close out rather than renew IRB review|f||||t||||||||||2018-05-31 23:37:04.12534|2018-05-31 23:37:04.12534
NCT01156038|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-16|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Atopy Patch Test in Normal Population : Pilot Study|Atopy Patch Test in Normal Population : Pilot Study|Completed||Phase 1|15|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 23:37:04.613484|2018-05-31 23:37:04.613484
NCT01156025|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|March 2009||2009-03-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis|Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis (Phase II Pilot Study, Multicentre, International, Randomised, Double-masked, Placebo-controlled, 2x40 Patients)|Completed||Phase 2|16|Actual|Laboratoires Thea||2|||f||||t||||||||||2018-05-31 23:37:04.711924|2018-05-31 23:37:04.711924
NCT01156012|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2014-11-12||2015-01-09|2010-07-01|2010-07-02|Estimate|2014-11-12|2014-11-19|Estimate||||2015-01-09|2015-01-22|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Safety set|Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients||Completed||Phase 3|404|Actual|Laboratoires Thea||2|||f||||||||||||||2018-05-31 23:37:04.78725|2018-05-31 23:37:04.78725
NCT01155999|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2014-10-24||2014-10-24|2010-07-01|2010-07-02|Estimate|2014-10-24|2014-10-29|Estimate||||2014-10-24|2014-10-29|Estimate|December 2008||2008-12-31|September 2011|2011-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.||Completed||Phase 3|286|Actual|Laboratoires Thea||2|||f||||||||||||||2018-05-31 23:37:05.258876|2018-05-31 23:37:05.258876
NCT01155986|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2015-03-13|2010-07-01|2010-07-02|Estimate|||||||2015-03-13|2015-03-17|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Lidocaine 5% Medicated Plaster in Chronic Neuropathic Postoperative Pain|Lidocaine 5% Medicated Plaster for the Topical Treatment of Localized Chronic Postoperative Neuropathic Pain.|Terminated||Phase 2|74|Actual|Grünenthal GmbH||2||Trial was stopped due to difficult enrolment|f||||f||||||||||2018-05-31 23:37:05.582769|2018-05-31 23:37:05.582769
NCT01155973|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2018-02-22|2010-07-01|2010-07-02|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2010||2010-06-30|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|EDUCORE||Educore Project: Effect of a Visual Learning Method for Improving Blood Pressure Control|Educore Project: A Clinical Trial, Randomised by Clusters, to Assess the Effect of a Visual Learning Method on Blood Pressure Control in the Primary Health Care Setting|Completed||N/A|452|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 23:37:05.765831|2018-05-31 23:37:05.765831
NCT01155960|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fed Conditions.|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:37:05.869784|2018-05-31 23:37:05.869784
NCT01155947|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fasting Conditions.|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:37:06.01412|2018-05-31 23:37:06.01412
NCT01155934|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|August 2004||2004-08-31|July 2010|2010-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Ltd. and Janssen Pharmaceutica Products, LP. (Risperdal M-TABTM)1 mg Risperidone Orally Disintegrating Tablets in Healthy Adult Male Volunteers Under Fed Conditions|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:37:06.114739|2018-05-31 23:37:06.114739
NCT01155921|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|August 2004||2004-08-31|July 2010|2010-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Ltd. and Janssen Pharmaceutica Products, LP. (Risperdal M-TABTM)1 mg Risperidone Orally Disintegrating Tablets in Healthy Adult Male Volunteers Under Fasting Conditions|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:37:06.268208|2018-05-31 23:37:06.268208
NCT01155908|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|April 2005||2005-04-30|July 2010|2010-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Non-fasting (Fed) Conditions|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:37:06.364297|2018-05-31 23:37:06.364297
NCT01155895|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|March 2004||2004-03-31|July 2010|2010-07-31|April 2004|Actual|2004-04-30|March 2004|Actual|2004-03-31||Interventional|||Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Fasting Conditions|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:37:06.482883|2018-05-31 23:37:06.482883
NCT01155882|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2018-03-29|2010-07-01|2010-07-02|Estimate|||||||2018-03-29|2018-03-30|Actual|September 20, 2010|Actual|2010-09-20|March 2018|2018-03-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2023|Anticipated|2023-09-30||Observational|WATSA||Registry Study - Whipple at the Splenic Artery|Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study|Recruiting|||25|Anticipated|Washington University School of Medicine|||1||f||||f|f|f||||||No||2018-05-31 23:37:06.625577|2018-05-31 23:37:06.625577
NCT01155869|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2013-09-17||2014-06-16|2010-06-30|2010-07-02|Estimate|2014-06-16|2014-07-17|Estimate||||2014-06-16|2014-07-17|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|July 2011|Actual|2011-07-31||Interventional|||Pilot Study of Depot NTX in Homeless Veterans|Pilot Study of Depot Naltrexone in Alcohol-Dependent, Homeless Veterans|Terminated||Phase 4|7|Actual|VA Office of Research and Development|Only 15 of 215 alcohol-dependent, homeless veterans would consider a study that included an intramuscular injection of XR-NTX. Of 3 given XR-NTX, only 1 returned for injection #2. Aversion to injection likely contributed to poor acceptability.|2||Poor enrollment|f||||f||||||||||2018-05-31 23:37:06.814533|2018-05-31 23:37:06.814533
NCT01155856|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-06-19|2010-07-01|2010-07-02|Estimate|||||||2012-06-19|2012-06-20|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|TVH||The Virtual Hospital - a Clinical Trial|Consecutive, Randomized Controlled Multicenter Trial, Investigating the Feasibility and Safety of a Telemedicine Based Treatment Regimen in Patients With Chronic Obstructive Pulmonary Disease (COPD), Compared to Conventional Hospital Treatment|Unknown status|Active, not recruiting|N/A|175|Anticipated|Frederiksberg University Hospital||2|||f||||t||||||||||2018-05-31 23:37:07.209349|2018-05-31 23:37:07.209349
NCT01155843|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2015-09-30|2010-07-01|2010-07-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Neural Mechanisms in Asthma|Neural Mechanisms by Which Chronic Stress Regulates Inflammation in Asthma|Completed|||31|Actual|University of Wisconsin, Madison|||2||f||||t||||||||||2018-05-31 23:37:07.430467|2018-05-31 23:37:07.430467
NCT01155830|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2014-12-10||2015-05-01|2010-06-30|2010-07-02|Estimate|2015-05-01|2015-05-04|Estimate||||2015-05-01|2015-05-04|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|||Inflammatory Cytokine Quantification in Infants|Inflammatory Cytokine Quantification in Infants With Documented Sepsis, Congenital Diaphragmatic Hernia and/or ECMO Therapy|Completed|||21|Actual|University of Utah|||3||f||||f||||||||||2018-05-31 23:37:07.608362|2018-05-31 23:37:07.608362
NCT01155817|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2013-05-05|2010-07-01|2010-07-02|Estimate|||||||2013-05-05|2013-05-07|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease|A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease|Unknown status|Active, not recruiting|Phase 1|41|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 23:37:08.189974|2018-05-31 23:37:08.189974
NCT01155804|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2011-06-30|2010-07-01|2010-07-02|Estimate|||||||2011-06-30|2011-07-01|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|||Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery|Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery|Unknown status|Recruiting|Phase 4|192|Anticipated|Center for Research on Reproductive Health of Campinas||2|||f||||f||||||||||2018-05-31 23:37:08.285684|2018-05-31 23:37:08.285684
NCT01155791|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-03-13|2010-07-01|2010-07-02|Estimate|||||||2017-03-13|2017-03-15|Actual|April 2010||2010-04-30|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer|A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer|Terminated||Phase 1|2|Actual|Stanford University||1|||f||||||||||||||2018-05-31 23:37:08.427744|2018-05-31 23:37:08.427744
NCT01155778|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2012-09-28|2010-06-30|2010-07-02|Estimate|||||||2012-09-28|2012-10-01|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients|A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan N-Sulfatase (rhHNS) Intrathecal Administration Via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)|Completed||Phase 1/Phase 2|12|Actual|Shire Human Genetic Therapies, Inc.||1|||f||||t||||||||||2018-05-31 23:37:08.587388|2018-05-31 23:37:08.587388
NCT01155765|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-11-15|2010-07-01|2010-07-02|Estimate|||||||2010-11-15|2010-11-16|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis|Prasugrel in Comparison to High Clopidogrel Dose for Inhibition of Platelet Reactivity as Assessed With a Point-of-Care Platelet Function Assay in Patients Undergoing Chronic Hemodialysis Presenting Resistance to the Usual Clopidogrel Dose|Completed||Phase 3|70|Anticipated|University of Patras||2|||f||||f||||||||||2018-05-31 23:37:08.74988|2018-05-31 23:37:08.74988
NCT01155752|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2017-07-17|2010-07-01|2010-07-02|Estimate|||||||2017-07-17|2017-07-21|Actual|July 2013||2013-07-31|November 2012|2012-11-30|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Pulmozyme in Cystic Fibrosis With Sinusitis|Z4770s, Use of Recombinant Human DNASE in Cystic Fibrosis Patients With Chronic Sinusitis to Prevent Acute Sinusitis Exacerbations and Improve Symptoms and Outcomes - A Pilot Study|Withdrawn||Phase 3|0|Actual|Milton S. Hershey Medical Center||2||Never funded|f||||f||||||||||2018-05-31 23:37:08.894967|2018-05-31 23:37:08.894967
NCT01155739|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2014-12-18|2010-07-01|2010-07-02|Estimate|||||||2014-12-18|2014-12-19|Estimate|June 2009||2009-06-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections|Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales|Completed|||162|Actual|University of Lausanne Hospitals|||2||f||||t||||||||||2018-05-31 23:37:09.065068|2018-05-31 23:37:09.065068
NCT01155726|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2012-02-15||2012-06-26|2010-07-01|2010-07-02|Estimate|2012-04-18|2012-05-15|Estimate||||2012-06-26|2012-07-10|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|ARGON||The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies|The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies|Completed||N/A|134|Actual|Alcon Research||4|||f||||f||||||||||2018-05-31 23:37:09.356491|2018-05-31 23:37:09.356491
NCT01155713|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2016-05-02|2010-07-01|2010-07-02|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors|A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors|Completed||Phase 1|63|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:37:09.981608|2018-05-31 23:37:09.981608
NCT01155700|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2016-11-16|2010-07-01|2010-07-02|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)|A 24 Week, Open Label, Multi-center Evaluation of Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite Current Recommended Treatment|Completed||Phase 3|51|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:37:10.10491|2018-05-31 23:37:10.10491
NCT01155687|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-08-08|2010-07-01|2010-07-02|Estimate|||||||2011-08-08|2011-08-09|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Psychosocial Counseling in Afghanistan||Completed|||61|Actual|University of Konstanz|||2||f||||t||||||||||2018-05-31 23:37:10.205686|2018-05-31 23:37:10.205686
NCT01155674|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|October 2011|Anticipated|2011-10-31|August 2011|Anticipated|2011-08-31||Observational|||Innate Immune Functions of Immature Neutrophils|Innate Immune Functions of Immature Neutrophils|Unknown status|Recruiting||60|Anticipated|University Hospital, Geneva|||3||f||||f||||||Samples Without DNA|"~     No samples retained~   "|||2018-05-31 23:37:10.289766|2018-05-31 23:37:10.289766
NCT01154829|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2016-05-25|2010-06-30|2010-07-01|Estimate|||||||2016-05-25|2016-05-26|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2014|Actual|2014-05-31||Interventional|PECANS||Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)|Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes|Completed||N/A|136|Actual|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 23:37:32.576142|2018-05-31 23:37:32.576142
NCT01155661|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2018-02-17|2013-04-30|2018-03-16|2010-06-30|2010-07-02|Estimate|2018-03-16|2018-04-17|Actual|2013-04-30|2013-05-08|Estimate|2018-03-16|2018-04-17|Actual|October 2010||2010-10-31|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All enrolled participants|A Safety Study in Participants With Major Depressive Disorder|Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment|Completed||Phase 3|608|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:37:10.397298|2018-05-31 23:37:10.397298
NCT01155648|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|June 2009|Actual|2009-06-30||Interventional|||Pressure Support During Chest Wall Compression|Increasing Pressure Support During Chest Wall Compression is Useful During Respiratory Therapy?|Completed||N/A|66|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 23:37:12.247947|2018-05-31 23:37:12.247947
NCT01155635|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2017-06-25|2010-07-01|2010-07-02|Estimate|||||||2017-06-25|2017-06-27|Actual|July 2010||2010-07-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|June 2015|Actual|2015-06-30||Interventional|CAPITAL-RCT||Carvedilol Post-intervention Long-term Administration in Large-scale Trial|Carvedilol Post-intervention Long-term Administration in Large-scale Randomized Controlled Trial|Completed||Phase 4|801|Actual|Kyoto University, Graduate School of Medicine||2|||f||||t||||||||||2018-05-31 23:37:12.367368|2018-05-31 23:37:12.367368
NCT01155622|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2012-12-04|2010-07-01|2010-07-02|Estimate|||||||2012-12-04|2012-12-05|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Trial of Different Hypothermia Temperatures in Patients Recovered From Out-of-hospital Cardiac Arrest|Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest|Completed||Phase 4|36|Actual|Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 23:37:12.45935|2018-05-31 23:37:12.45935
NCT01155609|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2013-05-15|2010-06-30|2010-07-02|Estimate|||||||2013-05-15|2013-05-17|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|||L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer|L-lysine in the Treatment of Oral Mucositis in Head and Neck Cancer Patients- A Pilot Study|Completed||N/A|10|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:37:12.555625|2018-05-31 23:37:12.555625
NCT01155596|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-30|||2010-07-01|2010-07-01|2010-07-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Negative Pressure Ventilation Imapcts Weaning Ventilator In Medical Intensive Care Units (ICUs)|Phase 2 Study of Negative Pressure Ventilation That Imapcts Weaning Ventilator in Medical Intensive Care Units|Unknown status|Recruiting|Phase 2|120|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 23:37:12.669715|2018-05-31 23:37:12.669715
NCT01155583|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-06-09|2010-07-01|2010-07-02|Estimate|||||||2017-06-09|2017-06-12|Actual|June 2010||2010-06-30|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|May 28, 2016|Actual|2016-05-28||Interventional|||Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial Of Very Low to Low-Doses of Continuous Azacitidine in Combination With Standard Doses of Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|45|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 23:37:12.843833|2018-05-31 23:37:12.843833
NCT01155570|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2013-07-23||2013-09-30|2010-07-01|2010-07-02|Estimate|2013-09-30|2013-10-08|Estimate||||2013-09-30|2013-10-08|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational||Safety Analysis Population|Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)|Special Investigation (All Cases Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis)|Completed|||752|Actual|AbbVie|||1||f||||||||||||||2018-05-31 23:37:13.557112|2018-05-31 23:37:13.557112
NCT01155557|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2015-03-18|2010-07-01|2010-07-02|Estimate|||||||2015-03-18|2015-03-19|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|September 2013|Actual|2013-09-30||Interventional|||The Effect of Specific Strength-Training on Tension-Type Headache in Children 9-17 Years|Strength Capacity of Neck and Shoulder Muscles in Children and Adolescents 9-17 Years With Tension Type Headache and the Effect of Specific Strength-Training on Tension-Type Headache|Completed||N/A|58|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 23:37:15.956397|2018-05-31 23:37:15.956397
NCT01155544|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2018-03-15|2010-07-01|2010-07-02|Estimate|||||||2018-03-15|2018-03-19|Actual|June 2011||2011-06-30|March 2018|2018-03-31|June 2014|Anticipated|2014-06-30|September 2013|Anticipated|2013-09-30||Interventional|SIP||Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole|Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole|Withdrawn||Phase 4|0|Actual|Northwell Health||2||Seems to have simply stopped.|f||||t||||||||||2018-05-31 23:37:16.117124|2018-05-31 23:37:16.117124
NCT01155531|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2011-08-02||2015-03-04|2010-06-30|2010-07-01|Estimate|2012-12-05|2013-01-09|Estimate||||2015-03-04|2015-03-25|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects|A Phase I, Single Center, Open Label, Intra Subject, Dose Escalation Study to Evaluate Safety and Tolerability of Sertraline Plus Telenzepine in Overweight Healthy Subjects|Completed||Phase 1|40|Actual|Theracos||4|||f||||f||||||||||2018-05-31 23:37:16.233356|2018-05-31 23:37:16.233356
NCT01155518|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2018-04-17|2010-06-30|2010-07-01|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2010||2010-06-30|April 2018|2018-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Hypogonadism in Young Men With Type 2 Diabetes|Effect of Hypogonadotropic Hypogonadism and Replacement With Clomiphene Citrate and Testosterone on Insulin Sensitivity, Body Composition, Inflammation, Sexual Function and Spermatogenesis in Young Type 2 Diabetic Men|Terminated||Phase 2|5|Actual|State University of New York at Buffalo||4||lack of funding|f||||f||||||||||2018-05-31 23:37:17.210545|2018-05-31 23:37:17.210545
NCT01155505|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-09-12|2010-06-30|2010-07-01|Estimate|||||||2011-09-12|2011-09-13|Estimate|November 2009||2009-11-30|September 2011|2011-09-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Lenalidomide and Paclitaxel in Advanced Solid Tumors|Phase Ib of CC-5013 and Paclitaxel in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|28|Anticipated|Southern Europe New Drug Organization||1|||f||||f||||||||||2018-05-31 23:37:17.329165|2018-05-31 23:37:17.329165
NCT01155492|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2013-05-29|2010-06-30|2010-07-01|Estimate|||||||2013-05-29|2013-05-30|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational|||Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease|Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease|Completed|||43|Actual|Rush University Medical Center|||3||f||||f||||||Samples With DNA|"~     Colonic mucosa biopsies~   "|||2018-05-31 23:37:17.467827|2018-05-31 23:37:17.467827
NCT01155479|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2016-06-15||2017-08-31|2010-06-30|2010-07-01|Estimate|2016-06-15|2016-07-28|Estimate||||2017-08-31|2017-09-29|Actual|July 6, 2010|Actual|2010-07-06|August 2017|2017-08-31|July 16, 2013|Actual|2013-07-16|July 16, 2013|Actual|2013-07-16||Interventional|PARADYSE|All Participants as Randomized|A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)|A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease|Terminated||Phase 3|1022|Actual|Merck Sharp & Dohme Corp.||5||Termininated for business reasons|f||||t||||||||||2018-05-31 23:37:17.635857|2018-05-31 23:37:17.635857
NCT01155466|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2016-01-13||2017-06-02|2010-06-30|2010-07-01|Estimate|2016-01-13|2016-02-11|Estimate||||2017-06-02|2017-07-02|Actual|July 14, 2010|Actual|2010-07-14|June 2017|2017-06-30|December 20, 2012|Actual|2012-12-20|December 20, 2012|Actual|2012-12-20||Interventional||All randomized participants|A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)|A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3;Protocol No. P04938)|Completed||Phase 3|778|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-05-31 23:37:19.36865|2018-05-31 23:37:19.36865
NCT01155453|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2016-06-20|2010-06-30|2010-07-01|Estimate|||||||2016-06-20|2016-06-21|Estimate|April 2010||2010-04-30|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients|A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.|Completed||Phase 1|113|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:37:20.401211|2018-05-31 23:37:20.401211
NCT01155440|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-11-24|2010-06-30|2010-07-01|Estimate|||||||2011-11-24|2011-11-28|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Bowel Function After Laparoscopic Colon Surgery: Effect of IV Lidocaine|Restoration of Bowel Function After Laparoscopic Colorectal Surgery: Effect of Intravenous Lidocaine|Completed||Phase 2|60|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:37:20.498719|2018-05-31 23:37:20.498719
NCT01155427|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-30|2010-06-30|2010-07-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)|A Systematic Review of Literature on Common Antiretroviral Treatments Against Hepatitis B Virus (HBV)|Completed|||100|Actual|Bristol-Myers Squibb|||5||f||||f||||||||||2018-05-31 23:37:20.604143|2018-05-31 23:37:20.604143
NCT01155414|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2011-10-31|2010-06-30|2010-07-01|Estimate|||||||2011-10-31|2011-11-01|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Tolerance of Healthy Term Infants Fed Infant Formulas #4|Tolerance of Healthy Term Infants Fed Infant Formulas|Completed||Phase 3|168|Actual|Abbott Nutrition||3|||f||||t||||||||||2018-05-31 23:37:20.678817|2018-05-31 23:37:20.678817
NCT01155401|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2011-11-07|2010-06-30|2010-07-01|Estimate|||||||2011-11-07|2011-11-08|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding|Study of Incidence of Drug-induced Upper Gastrointestinal Bleeding|Completed|||300|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:37:20.778176|2018-05-31 23:37:20.778176
NCT01155388|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2017-08-10||2017-10-03|2010-06-30|2010-07-01|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|October 17, 2011|Actual|2011-10-17|October 2017|2017-10-31|June 24, 2014|Actual|2014-06-24|June 24, 2014|Actual|2014-06-24||Interventional||The Safety Population is defined as participants who received any amount of study drug. Data are for the combined AMAG-FER-CKD-251 and AMAG-FER-CKD-252 studies. The safety analysis is based on actual treatment received.|A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney Disease|A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-dependent Chronic Kidney Disease|Terminated||Phase 3|14|Actual|AMAG Pharmaceuticals, Inc.|While sample data were collected, it was not run through any analysis to obtain the necessary outcome measure data. As such, summary of the data set is not possible.|2||"Several factors contributed to significant challenges in enrollment and led the Sponsor to~   discontinue the AMAG-FER-CKD-252 study as designed."|f||||t|t|f||||||||2018-05-31 23:37:20.858695|2018-05-31 23:37:20.858695
NCT01155375|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2017-08-10||2017-10-03|2010-06-30|2010-07-01|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|October 17, 2011|Actual|2011-10-17|October 2017|2017-10-31|June 24, 2014|Actual|2014-06-24|June 24, 2014|Actual|2014-06-24||Interventional||The safety population is defined as participants who received any amount of study drug. Data are for the combined AMAG-FER-CKD-251 and AMAG-FER-CKD-252 studies. The safety analysis is based on actual treatment received.|A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease|A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared With Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease|Terminated||Phase 3|14|Actual|AMAG Pharmaceuticals, Inc.|While sample data were collected, it was not run through any analysis to obtain the necessary outcome measure data. As such, summary of the data set is not possible.|2||"Several factors contributed to significant challenges in enrollment and led the Sponsor to~   discontinue the AMAG-FER-CKD-251 study as designed."|f||||t|t|f||||||||2018-05-31 23:37:21.2564|2018-05-31 23:37:21.2564
NCT01155362|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26||2013-08-07|2018-02-28|2010-06-30|2010-07-01|Estimate||||2013-08-07|2013-08-12|Estimate|2018-02-28|2018-03-02|Actual|August 2010||2010-08-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|February 2012|Actual|2012-02-29||Interventional|||A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease|A Phase 2a, Randomized, Double Blind, Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease|Completed||Phase 2|50|Actual|Celularity Incorporated||3|||f||||t||||||||||2018-05-31 23:37:21.556551|2018-05-31 23:37:21.556551
NCT01155349|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-12-07|2010-06-29|2010-07-01|Estimate|||||||2012-12-07|2012-12-10|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Brain Fitness in Parkinson's Disease|Cognitive Speed of Processing Training Among Persons With Parkinson's Disease|Completed||Phase 3|87|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 23:37:21.671087|2018-05-31 23:37:21.671087
NCT01155336|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|2013-02-05||2017-10-05|2010-06-30|2010-07-01|Estimate|2013-02-05|2013-03-11|Estimate||||2017-10-05|2017-11-06|Actual|June 2010||2010-06-30|October 2017|2017-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|OmegaMI||The Effects of Lovaza® in Acute Myocardial Infarction|The Effects of Lovaza® on Platelet Function and Cardiac Electrophysiology in Acute Myocardial Infarction|Terminated||Phase 1/Phase 2|4|Actual|University of Rochester|no adverse events|2||Only 5 individuals were able to be recruited.|f||||t||||||||||2018-05-31 23:37:21.743618|2018-05-31 23:37:21.743618
NCT01155323|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2011-08-29||2017-08-31|2010-06-30|2010-07-01|Estimate|2011-08-29|2011-10-04|Estimate||||2017-08-31|2017-09-28|Actual|March 1, 2010|Actual|2010-03-01|August 2017|2017-08-31|June 1, 2010|Actual|2010-06-01|June 1, 2010|Actual|2010-06-01||Interventional|||Two Week Cross-Over Study Comparing Two Daily Disposable Contact Lenses|Proclear 1 Day Lens vs 1-Day Acuvue Moist Daily Disposable Contact Lens Crossover Study|Completed||N/A|118|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-05-31 23:37:22.017587|2018-05-31 23:37:22.017587
NCT01155310|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-10-06|2010-06-30|2010-07-01|Estimate|||||||2014-10-06|2014-10-07|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional|ECHO/ICU||Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|An International Phase III Randomised Trial Comparing in Severe Exacerbations of Chronic Obstructive Pulmonary Disease the Efficacy of Helium/Oxygen Versus Air/Oxygen Administered During Spontaneous Breathing and Intermittent Non-Invasive Ventilation.|Terminated||Phase 3|446|Actual|Air Liquide Santé International||2||the observed event rate is lower than expected by the protocol hypothesis.|f||||f||||||||||2018-05-31 23:37:22.523665|2018-05-31 23:37:22.523665
NCT01155297|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-29|2010-06-29|2010-07-01|Estimate|||||||2010-06-29|2010-07-01|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|November 2011|Anticipated|2011-11-30|May 2011|Anticipated|2011-05-31||Interventional|||Effect of PT on QL, FC, PWV and Biochemical Markers in CRF on Conservative Treatment|Effect of Physical Training on Quality of Life, Functional Capacity, Pulse Wave Velocity and Biochemical Markers in Patients With Chronic Renal Failure on Conservative Treatment|Unknown status|Not yet recruiting|N/A|68|Anticipated|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||||2018-05-31 23:37:22.655271|2018-05-31 23:37:22.655271
NCT01155284|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2014-12-18||2017-08-18|2010-06-30|2010-07-01|Estimate|2017-08-18|2017-09-18|Actual||||2017-08-18|2017-09-18|Actual|August 2010||2010-08-31|August 2017|2017-08-31|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|REPAIR-T1D|70 participants were randomized. After randomization, 2 participants withdrew (one was from treatment group and one from placebo group) before taking any drugs, leaving 46 participants in the active treatment group and 22 in the placebo.|Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes|Combination Therapy With Sitagliptin (DPP 4 Inhibitor) and Lansoprazole (PPI) Inhibitor) to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes|Completed||Phase 2|70|Actual|Sanford Health||2|||f||||t||||||||||2018-05-31 23:37:22.803608|2018-05-31 23:37:22.803608
NCT01155271|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-01-27|2010-06-30|2010-07-01|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|OBEX1||OBese Patients With Obstructive Sleep Apnea Syndrome(OSAS) and EXercise Training|Comparison of 3 Exercise Training Modalities in Obese Patient With Sleep Apnea Syndrome Treated by Continue Positive Airway Pressure : a Randomized Controlled Study|Active, not recruiting||N/A|60|Actual|AGIR à Dom||2|||f||||t||||||||||2018-05-31 23:37:23.226683|2018-05-31 23:37:23.226683
NCT01155258|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2016-06-09|2010-06-30|2010-07-01|Estimate|||||||2016-06-09|2016-06-13|Estimate|June 2010||2010-06-30|June 2016|2016-06-30|May 2014|Actual|2014-05-31|January 2013|Actual|2013-01-31||Interventional|||Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors|Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.|Completed||Phase 1|19|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 23:37:23.29985|2018-05-31 23:37:23.29985
NCT01155245|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-05-02|2010-06-30|2010-07-01|Estimate|||||||2017-05-02|2017-05-04|Actual|June 2008||2008-06-30|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Teriparatide (PTH) and Bone Strength in Postmenopausal Women|Study on the Effect of 24 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Postmenopausal Women With Osteoporosis|Active, not recruiting|||60|Anticipated|University Health Network, Toronto|||2||f||||f||||||||||2018-05-31 23:37:23.505234|2018-05-31 23:37:23.505234
NCT01155232|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2018-05-11|2010-06-30|2010-07-01|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2004||2004-11-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis|Effect of 24 Months of Teriparatide Therapy on Bone Microarchitecture and Bone Volume in Men and Women With Osteoporosis|Recruiting|||100|Anticipated|University Health Network, Toronto|||2||f||||f||||||||||2018-05-31 23:37:23.590657|2018-05-31 23:37:23.590657
NCT01155219|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2014-10-24||2017-03-06|2010-06-30|2010-07-01|Estimate|2014-10-24|2014-10-29|Estimate||||2017-03-06|2017-04-04|Actual|July 2008||2008-07-31|July 2010|2010-07-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|T1030||Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.|Safety and Efficacy Assessment of Geltim LP® 1 mg/g (Unpreserved Timolol Gel - TG1030) in Ocular Hypertensive or Glaucomatous Patients Stabilized by Xalatan® With Ocular Intolerance Signs.|Completed||Phase 4|150|Actual|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 23:37:23.69613|2018-05-31 23:37:23.69613
NCT01155206|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2015-11-30|2010-06-29|2010-07-01|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2009||2009-06-30|September 2007|2007-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|Glucagon||Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon|Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon|Completed||Phase 4|9|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:37:23.978567|2018-05-31 23:37:23.978567
NCT01155193|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2016-08-15|2010-06-30|2010-07-01|Estimate|||||||2016-08-15|2016-08-16|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Prospective, Study for the Use of Palivizumab (Synagis) in High Risk Children in Germany|Documentation of Safety and Efficacy of Synagis in Preterm Infants|Completed|||15446|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:37:24.298664|2018-05-31 23:37:24.298664
NCT01155180|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2015-12-22||2017-02-22|2010-06-30|2010-07-01|Estimate|2017-02-22|2017-04-07|Actual||||2017-02-22|2017-04-07|Actual|July 2008||2008-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2012|Actual|2012-12-31||Interventional|||Leptin in the Maintenance of Reduced Body Weight|Leptin in the Maintenance of Reduced Body Weight|Completed||Phase 2|24|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 23:37:26.525301|2018-05-31 23:37:26.525301
NCT01155167|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2013-01-31||2013-05-16|2010-06-30|2010-07-01|Estimate|2013-05-13|2013-05-15|Estimate||||2013-05-16|2013-05-27|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Topical Radial Artery Vasodilation|The Effect of Topical Administration of Lidocaine/Nitroglycerin Combination Versus Placebo on Radial Artery Access in Patients Undergoing Cardiac Catheterization Via the Radial Artery|Completed||Phase 2/Phase 3|86|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 23:37:26.725338|2018-05-31 23:37:26.725338
NCT01155154|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2014-01-03||2014-11-03|2010-06-29|2010-07-01|Estimate|2014-10-28|2014-11-04|Estimate||||2014-11-03|2014-11-07|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||The median age of the subjects was 40 years (quartiles: 29, 53), and 71% were male (n=52).|Antibiotic Prophylaxis for Simple Hand Lacerations|Antibiotic Prophylaxis for Prevention of Infection in Emergency Department Patients With Simple Hand Lacerations|Terminated||N/A|73|Actual|State University of New York - Downstate Medical Center||3|||f||||f||||||||||2018-05-31 23:37:26.971558|2018-05-31 23:37:26.971558
NCT01155141|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2014-08-01||2014-08-20|2010-06-30|2010-07-01|Estimate|2014-08-20|2014-09-01|Estimate||||2014-08-20|2014-09-01|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH|Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH|Completed||Phase 4|15|Actual|Stanford University||1|||f||||||||||||||2018-05-31 23:37:27.368194|2018-05-31 23:37:27.368194
NCT01155128|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2012-03-01|2010-06-30|2010-07-01|Estimate|||||||2012-03-01|2012-03-05|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease|Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial|Unknown status|Enrolling by invitation|Phase 4|200|Anticipated|Federal University of Pelotas||2|||f||||f||||||||||2018-05-31 23:37:27.785535|2018-05-31 23:37:27.785535
NCT01155115|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2015-05-21|2010-06-29|2010-07-01|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia|Inflammatory and Microbiologic Markers in Sputum in Response to Pulmonary Exacerbation: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia|Completed||N/A|46|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 23:37:27.880276|2018-05-31 23:37:27.880276
NCT01155102|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2018-01-19|2010-06-30|2010-07-01|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2006||2006-04-30|January 2018|2018-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fasting Conditions|Completed||N/A|31|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:37:27.96559|2018-05-31 23:37:27.96559
NCT01155089|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2018-01-19|2010-06-30|2010-07-01|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2006||2006-05-31|January 2018|2018-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions|Completed||N/A|32|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:37:28.050759|2018-05-31 23:37:28.050759
NCT01155076|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2013-11-12|2010-06-30|2010-07-01|Estimate|||||||2013-11-12|2013-11-14|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of a Vitality Dietary Supplement on Physical and Mental Function in Middle-aged Adults|Effects of a Proprietary Ginseng, Cordyceps, and Pomegranate Supplement on Physical and Mental Function in Middle-aged Adults: a Double-blind, Randomized, Placebo-controlled Trial|Completed||N/A|116|Actual|Pharmanex||2|||f||||f||||||||||2018-05-31 23:37:28.098013|2018-05-31 23:37:28.098013
NCT01155063|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2012-08-17||2012-09-25|2010-06-29|2010-07-01|Estimate|2012-08-17|2012-09-20|Estimate||||2012-09-25|2012-10-01|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients|A Non-Interventional Observational Study Evaluating The Effects Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy On Safety In Postmenopausal And Hormone Receptors Positive Early Breast Cancer Patients|Terminated|||89|Actual|Pfizer|The study was prematurely discontinued, therefore not all data was analyzed and only one outcome measure timeframe was presented.||1|See Detailed Description|f||||f||||||||||2018-05-31 23:37:28.174432|2018-05-31 23:37:28.174432
NCT01155050|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2011-10-28|2010-06-30|2010-07-01|Estimate|||||||2011-10-28|2011-11-01|Estimate|January 2010||2010-01-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population|Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population|Completed||N/A|240|Anticipated|Pennington Biomedical Research Center||4|||f||||t||||||||||2018-05-31 23:37:28.558273|2018-05-31 23:37:28.558273
NCT01155037|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-03-22|2010-06-29|2010-07-01|Estimate|||||||2012-03-22|2012-03-26|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Interventional|VIP-H1N1||Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults|Phase 2 Study to Evaluate the Safety of and the Immunogenicity to an Adjuvanted A(H1N1)v Influenza Vaccine in HIV-Infected Adults|Unknown status|Active, not recruiting|Phase 2|450|Anticipated|Oswaldo Cruz Foundation||3|||f||||f||||||||||2018-05-31 23:37:29.700847|2018-05-31 23:37:29.700847
NCT01155024|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2011-10-26||2011-12-06|2010-06-29|2010-07-01|Estimate|2011-12-06|2012-01-11|Estimate||||2011-12-06|2012-01-11|Estimate|September 2010||2010-09-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Clinical Evaluation of Direct Manufactured Prosthetic Sockets|Clinical Evaluation of Direct Manufactured Prosthetic Sockets|Completed||Phase 2|10|Actual|Ohio Willow Wood|Early termination by four participants for reasons unrelated to the interventions lead to smaller numbers completing the 3 month trial period for the direct manufactured socket.|2|||f||||f||||||||||2018-05-31 23:37:29.796675|2018-05-31 23:37:29.796675
NCT01155011|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2017-04-10||2017-08-01|2010-06-30|2010-07-01|Estimate|2017-06-12|2017-07-31|Actual||||2017-08-01|2017-08-31|Actual|January 2011||2011-01-31|August 2017|2017-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MIPARC||Multilevel Intervention for Physical Activity in Retirement Communities|MIPARC - Multilevel Intervention for Physical Activity in Retirement Communities|Completed||N/A|307|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 23:37:30.045287|2018-05-31 23:37:30.045287
NCT01154998|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-06-30|2010-06-30|2010-07-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Observational|||Case-Control Study of Fibrotic Interstitial Lung Disease (ILD) and Cardiac Disease / Interventions.|Case-Control Study of Fibrotic Interstitial Lung Disease and it's Association With Cardiac Disease or Cardiac Intervention.|Unknown status|Not yet recruiting||360|Anticipated|St George's Healthcare NHS Trust|||2||f||||f||||||||||2018-05-31 23:37:30.485849|2018-05-31 23:37:30.485849
NCT01154985|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2014-10-15|2013-10-17|2014-11-13|2010-06-30|2010-07-01|Estimate|2014-11-13|2014-11-20|Estimate|2013-10-17|2013-11-11|Estimate|2014-11-13|2014-11-20|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Full Analysis Set|Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)|A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH|Completed||Phase 2|243|Actual|Mochida Pharmaceutical Company, Ltd.||3|||f||||t||||||||||2018-05-31 23:37:30.713005|2018-05-31 23:37:30.713005
NCT01154972|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2018-05-07|2010-06-30|2010-07-01|Estimate|||||||2018-05-07|2018-05-11|Actual|April 2010||2010-04-30|May 2018|2018-05-31|May 10, 2013|Actual|2013-05-10|November 1, 2012|Actual|2012-11-01||Interventional|||Preoperative Localisation of the Sentinel Lymph Node in Breast Cancer|Preoperative Identification of the Sentinel Lymph Node in Breast Cancer, Using Ultrasound and Radio-isotope/Percutaneous Gamma Probe|Completed||N/A|59|Actual|NHS Tayside||1|||f||||f||||||||||2018-05-31 23:37:31.505714|2018-05-31 23:37:31.505714
NCT01154959|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-06-15|2010-06-30|2010-07-01|Estimate|||||||2011-06-15|2011-06-16|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|February 2015|Anticipated|2015-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Latency in Pulmonary Tuberculosis|Characterization of Immune Responses in Treatment-induced Latency in Pulmonary Tuberculosis|Unknown status|Recruiting|Phase 3|200|Anticipated|Tuberculosis Research Centre, India||5|||f||||f||||||||||2018-05-31 23:37:31.597729|2018-05-31 23:37:31.597729
NCT01154946|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-30|2010-06-30|2010-07-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|DAC||Clinical Implication of DAC (Detrusor After-contraction)|A New Approach to Clinical Implication of Detrusor After-contraction (DAC)|Completed|||2309|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 23:37:31.72334|2018-05-31 23:37:31.72334
NCT01154933|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2012-12-14|2010-06-30|2010-07-01|Estimate|||||||2012-12-14|2012-12-17|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Exeantide in Type 2 Diabetes on Insulin|The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin|Completed||Phase 2|63|Actual|Kaleida Health||3|||f||||f||||||||||2018-05-31 23:37:31.789165|2018-05-31 23:37:31.789165
NCT01154920|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2018-02-14|2010-06-30|2010-07-01|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2010|Actual|2010-07-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma|Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 2|128|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 23:37:31.865438|2018-05-31 23:37:31.865438
NCT01154907|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-09-18|2010-06-30|2010-07-01|Estimate|||||||2017-09-18|2017-09-19|Actual|April 2010||2010-04-30|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Observational|VIBE-FGS||Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa|Prevention of HIV and Improved Diagnosis of Adolescent Genital Disease in Bilharzia Endemic KwaZulu-Natal, South Africa|Recruiting|||6500|Anticipated|Oslo University Hospital|||2||f||||t||||||Samples Without DNA|"~     Urine, stool, blood, in the adults also vaginal lavage and Pap smears~   "|Yes|Still collecting and publishing|2018-05-31 23:37:31.975255|2018-05-31 23:37:31.975255
NCT01154894|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-06-22|2010-06-30|2010-07-01|Estimate|||||||2011-06-22|2011-06-23|Estimate|February 2009||2009-02-28|December 2008|2008-12-31|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|Fatty acid||Dietary Fatty Acids Improve Social Impairment in Autism Spectrum Disorders|Double-blind Randomized Placebo-controlled Trail|Completed||N/A|13|Actual|Ashiya University||1|||f||||f||||||||||2018-05-31 23:37:32.189724|2018-05-31 23:37:32.189724
NCT01154881|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2017-01-19|2010-06-30|2010-07-01|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes|A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State in Subjects With Type 2 Diabetes|Completed||Phase 1|49|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 23:37:32.27371|2018-05-31 23:37:32.27371
NCT01154868|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2015-12-11|2010-06-30|2010-07-01|Estimate|||||||2015-12-11|2015-12-14|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Clinical and Histological Evaluation of Healos® for Alveolar Ridge Augmentation|Clinical and Histological Evaluation of Healos® for Alveolar Ridge Augmentation|Withdrawn||Phase 4|0|Actual|University of Michigan||1||Sponsor withdrew funding of study.|f||||f||||||||||2018-05-31 23:37:32.355508|2018-05-31 23:37:32.355508
NCT01154855|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2015-12-11|2010-06-30|2010-07-01|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|CirCo||Periodontal Disease and Circulatory Microbial Components|Circulatory Microbial Components and Immune Regulators of Patients With Periodontal Disease and Rheumatoid Arthritis|Completed|||40|Actual|University of Michigan|||2||f||||t||||||Samples With DNA|"~     Dental plaque samples evaluated for microbial DNA~   "|||2018-05-31 23:37:32.429774|2018-05-31 23:37:32.429774
NCT01154842|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-07-12|2010-06-30|2010-07-01|Estimate|||||||2010-07-12|2010-07-14|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Observational|||Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients|Serum Fibroblast Growth Factor-23 (FGF-23) Levels Are Independently Associated With Left Ventricular Mass and Myocardial Performance Index in Maintenance Haemodialysis Patients|Unknown status|Active, not recruiting||128|Actual|Diskapi Teaching and Research Hospital|||1||f||||t||||||Samples With DNA|"~     Human plasma to measure FGF-23 levels~   "|||2018-05-31 23:37:32.508404|2018-05-31 23:37:32.508404
NCT01153828|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2013-06-06|2010-06-29|2010-06-30|Estimate|||||||2013-06-06|2013-06-10|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||EU PV for Retapamulin-Prescribing|Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the European Union|Completed|||1|Actual|GlaxoSmithKline|||5||f||||f||||||||||2018-05-31 23:38:00.90466|2018-05-31 23:38:00.90466
NCT01154816|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|2016-07-28||2017-09-21|2010-06-30|2010-07-01|Estimate|2017-05-03|2017-06-05|Actual||||2017-09-21|2017-10-23|Actual|February 2011||2011-02-28|September 2017|2017-09-30||||December 31, 2015|Actual|2015-12-31||Interventional|||Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia|A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias|Completed||Phase 2|118|Actual|Children's Oncology Group||12|||f||||||||||||||2018-05-31 23:37:32.793049|2018-05-31 23:37:32.793049
NCT01154803|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2013-10-15|2010-06-30|2010-07-01|Estimate|||||||2013-10-15|2013-10-16|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection|Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Nigeria|Completed||N/A|2213|Actual|Medecins Sans Frontieres, Netherlands||3|||f||||t||||||||||2018-05-31 23:37:36.018054|2018-05-31 23:37:36.018054
NCT01154790|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2016-01-26|2010-06-30|2010-07-01|Estimate|||||||2016-01-26|2016-01-28|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase I Study on Multiple Oral Dosing of CG100649|A Randomized, Double-blind Study Evaluating the Upper Gastrointestinal Safety on Multiple Doses of CG100649 in Healthy Subjects|Completed||Phase 1|120|Actual|CrystalGenomics, Inc.||3|||f||||f||||||||Undecided||2018-05-31 23:37:36.130616|2018-05-31 23:37:36.130616
NCT01154777|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-10-03|2010-06-30|2010-07-01|Estimate|||||||2010-10-03|2010-10-05|Estimate|July 2011||2011-07-31|October 2010|2010-10-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Collaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism|COLLABORATIVE STUDY OF NEUROFEEDBACK TRAINING OF 6-18YEAR OLDS WITH AUTISM|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Institute for Personal Excellence, P.A.|||||f||||f||||||||||2018-05-31 23:37:36.218491|2018-05-31 23:37:36.218491
NCT01154764|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2013-02-13|2010-06-30|2010-07-01|Estimate|||||||2013-02-13|2013-02-15|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649|A Randomized, Open, Crossover Clinical Study to Investigate the Effects of Ketoconazole on the Pharmacokinetics of CG100649 in Healthy Male Volunteers|Completed||Phase 1|28|Actual|CrystalGenomics, Inc.||2|||f||||f||||||||||2018-05-31 23:37:36.29691|2018-05-31 23:37:36.29691
NCT01154751|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2016-10-25||2017-08-22|2010-06-30|2010-07-01|Estimate|2017-08-16|2017-08-17|Actual||||2017-08-22|2017-09-19|Actual|November 2008||2008-11-30|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2012|Actual|2012-08-31||Interventional|STRONG||Data Registry Following Patients Using Supera Stent in the Femoral Arteries|Supera Treatment Registry Observing Neointimal Growth|Terminated||N/A|200|Actual|Abbott Vascular||1||Slow enrollment,increased loss to follow-ups and general lack of interest.|f||||f||||||||||2018-05-31 23:37:36.501191|2018-05-31 23:37:36.501191
NCT01154738|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2016-11-02|2010-06-29|2010-07-01|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|LoopLido||Lidocaine and Closed-Loop Anesthesia System|Influence of Lidocaine on a Closed-Loop Anesthesia System|Completed||Phase 3|82|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 23:37:36.905703|2018-05-31 23:37:36.905703
NCT01154725|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2012-12-11|2010-06-30|2010-07-01|Estimate|||||||2012-12-11|2012-12-12|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||The Effect of Patient Education and Rehabilitation on Quality of Life in Patients With Permanent Stomas|Effect of Patient Education and Rehabilitational Interventions on Health Related Quality of Life of Patients With Permanent Stomas Regardless of Cause|Completed||N/A|50|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 23:37:36.990712|2018-05-31 23:37:36.990712
NCT01154712|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-07-12|2010-06-30|2010-07-01|Estimate|||||||2010-07-12|2010-07-14|Estimate|June 2010||2010-06-30|January 2010|2010-01-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling|Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling|Unknown status|Recruiting|Phase 1|40|Anticipated|BeerYaakov Mental Health Center||2|||f||||f||||||||||2018-05-31 23:37:37.097404|2018-05-31 23:37:37.097404
NCT01154699|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|2017-01-13||2017-05-11|2010-06-29|2010-07-01|Estimate|2017-05-11|2017-05-17|Actual||||2017-05-11|2017-05-17|Actual|July 2010||2010-07-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Positive Airway Pressure for the Treatment of Asthma|Positive Airway Pressure for the Treatment of Asthma|Completed||N/A|31|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:37:37.194161|2018-05-31 23:37:37.194161
NCT01154686|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2010-06-30|2010-06-30|2010-07-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Working Memory Training in College Students With Attention-Deficit Hyperactivity Disorder/Learning Disabilities|Working Memory Training in College Students With ADHD/LD|Unknown status|Recruiting|N/A|30|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 23:37:37.859739|2018-05-31 23:37:37.859739
NCT01154673|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2015-10-26||2016-03-04|2010-06-29|2010-07-01|Estimate|2016-03-04|2016-04-05|Estimate||||2016-03-04|2016-04-05|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Intensive cART During Acute/Early HIV Infection|Randomized, Double-blinded, Controlled Trial of Intensive HAART Including Raltegravir, and Maraviroc, on HIV-1 Pro-viral DNA and Reservoir Decay in HIV-1-infected Individuals During the Acute/Early Infection|Completed||Phase 2/Phase 3|32|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 23:37:37.961983|2018-05-31 23:37:37.961983
NCT01154660|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2011-04-18|2010-06-30|2010-07-01|Estimate|||||||2011-04-18|2011-04-19|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Effects of Increased Tidal Volume on Internal Jugular Vein Cross-sectional Area|Effects of Increased Tidal Volume on Internal Jugular Vein Cross-sectional Area|Completed||N/A|40|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:37:38.260066|2018-05-31 23:37:38.260066
NCT01154647|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-30|2010-06-30|2010-07-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|September 2010||2010-09-30|April 2010|2010-04-30||||September 2012|Anticipated|2012-09-30||Interventional|||Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes|Unraveling Impaired Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes: a Series of Experiments Targeting Brain Neurotransmission|Unknown status|Not yet recruiting|N/A|70|Anticipated|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 23:37:38.322417|2018-05-31 23:37:38.322417
NCT01025245|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2010-06-15|2009-12-02|2009-12-03|Estimate|||||||2010-06-15|2010-06-16|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Intraoperative Magnesium on Remifentanil-induced Postoperative Hyperalgesia After Thyroidectomy||Completed||Phase 4|84|Actual|Yonsei University||1|||f||||t||||||||||2018-06-01 00:18:24.791088|2018-06-01 00:18:24.791088
NCT01154634|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2012-01-27||2012-08-17|2010-06-29|2010-07-01|Estimate|2012-07-05|2012-08-13|Estimate||||2012-08-17|2012-08-30|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers|Completed||Phase 2|20|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:37:38.481928|2018-05-31 23:37:38.481928
NCT01154621|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-08-02|2010-06-30|2010-07-01|Estimate|||||||2010-08-02|2010-08-03|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects|A Phase I, Double-blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability, and Pharmacokinetics of a Single Dose of AZD9742 in Healthy Elderly Male and Female Volunteers|Completed||Phase 1|12|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:37:39.367191|2018-05-31 23:37:39.367191
NCT01154608|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-06-30|2010-06-30|2010-07-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|April 2005||2005-04-30|May 2010|2010-05-31||||||||Interventional|||Effect of Enzyme Therapy on Protein Metabolism in Chronic Pancreatitis||Completed||N/A|11|Actual|Institut National de la Recherche Agronomique||2|||f||||t||||||||||2018-05-31 23:37:39.462691|2018-05-31 23:37:39.462691
NCT01154595|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2011-10-10|2010-06-30|2010-07-01|Estimate|||||||2011-10-10|2011-10-12|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|PREAMA||Effectiveness of a Ready-to-Use-Food (RUF) Supplement to Prevent Acute Child Malnutrition|Effectiveness and Cost-effectiveness of a Ready-to-Use-Food (RUF) Supplement to Prevent Acute Malnutrition in Children Between 6-36 Months in Urban Chad|Completed||Phase 4|2000|Anticipated|Action Contre la Faim||2|||f||||t||||||||||2018-05-31 23:37:39.585576|2018-05-31 23:37:39.585576
NCT01154582|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-07-12|2010-06-30|2010-07-01|Estimate|||||||2010-07-12|2010-07-14|Estimate|February 2009||2009-02-28|June 2010|2010-06-30||||||||Interventional|||Nutritional Quality of Egg Proteins and Effect on Satiety||Completed||N/A|43|Actual|Institut National de la Recherche Agronomique||2|||f||||t||||||||||2018-05-31 23:37:39.669629|2018-05-31 23:37:39.669629
NCT01154569|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2011-07-28|2010-06-30|2010-07-01|Estimate|||||||2011-07-28|2011-07-29|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Absorb-Azithro||Absorption of Drugs Post-Bariatric Surgery (Absorb-Azithromycin)|Absorption of Drugs Post-Bariatric Surgery (Absorb-Azithromycin)|Completed||N/A|30|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 23:37:39.781555|2018-05-31 23:37:39.781555
NCT01154556|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2015-09-17|2010-06-30|2010-07-01|Estimate|||||||2015-09-17|2015-09-21|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|February 2013|Actual|2013-02-28|September 2011|Actual|2011-09-30||Observational|||RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice|Non-nucleoside Reverse Transcriptase Inhibitor Failure in a High HIV Caseload Australian Primary Care Practice|Completed|||2044|Actual|Holdsworth House Medical Practice|||1||f||||||||||||||2018-05-31 23:37:39.904624|2018-05-31 23:37:39.904624
NCT01154543|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2013-03-19|2010-06-30|2010-07-01|Estimate|||||||2013-03-19|2013-03-20|Estimate|March 2008||2008-03-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Observational|||Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes|A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes.|Completed|||42|Actual|Holdsworth House Medical Practice|||1||f||||||||||||||2018-05-31 23:37:39.972417|2018-05-31 23:37:39.972417
NCT01154530|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2011-08-16|2010-06-30|2010-07-01|Estimate|||||||2011-08-16|2011-08-17|Estimate|January 2011||2011-01-31|December 2010|2010-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Chlorhexidine Mouthwash and Bacterial Contamination During Endoscopy|Chlorhexidine Mouthwash and Bacterial Contamination During Endoscopy. Implementation of Chlorhexidine Mouthwash Before Transgastric NOTES|Completed||N/A|102|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 23:37:40.029189|2018-05-31 23:37:40.029189
NCT01154517|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-30|||2010-06-30|2010-06-30|2010-07-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Utility of the History and Physical Exam in the Emergency Department|Utility of the History and Physical Exam in the Emergency Department|Completed|||128|Actual|Henry Ford Health System|||||f||||f||||||||||2018-05-31 23:37:40.173948|2018-05-31 23:37:40.173948
NCT01154504|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2016-11-02|2010-06-30|2010-07-01|Estimate|||||||2016-11-02|2016-11-04|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study|The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study|Withdrawn||N/A|0|Actual|Federal University of São Paulo||3||"We randomized 18 patients, but was impossible to measure adrenomedullin in Brazil. However, we~   analysed some interesting clinical and laboratorial results."|f||||t||||||||||2018-05-31 23:37:40.234915|2018-05-31 23:37:40.234915
NCT01154491|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2015-07-27|2010-06-30|2010-07-01|Estimate|||||||2015-07-27|2015-07-28|Estimate|June 2010||2010-06-30|July 2015|2015-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PAHFRAC||Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period|Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period.|Completed||Phase 3|303|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||3|||f||||f||||||||||2018-05-31 23:37:40.34088|2018-05-31 23:37:40.34088
NCT01154478|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2013-06-18|2010-06-30|2010-07-01|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Etherpaths||Effects of Dietary Polyphenols and ω-3 Fatty Acids on Cardiovascular Risk Factors in High Risk Subjects|Effects of Polyphenols and Omega-3 Fatty Acids on Cardiovascular Rik Factors (Focusing on Postprandial Lipids Metabolism) in Subjects With High Risk for Type 2 Diabetes and Cardiovascular Diseases|Completed||N/A|86|Actual|Federico II University||4|||f||||f||||||||||2018-05-31 23:37:40.613926|2018-05-31 23:37:40.613926
NCT01154465|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2016-08-01|2010-06-30|2010-07-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|CATHETER||A Trial to Study the Influence of Ultrasound Guidance on the Complications of Central Catheter|Impact of Ultrasound Guided Central Venous Catheterization on Complications in Obese Patients in Intensive Care Unit|Recruiting||N/A|450|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||No||2018-05-31 23:37:40.729087|2018-05-31 23:37:40.729087
NCT01154452|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2016-03-18||2016-06-09|2010-06-29|2010-06-30|Estimate|2016-06-09|2016-07-22|Estimate||||2016-06-09|2016-07-22|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma|A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas|Completed||Phase 1/Phase 2|78|Actual|National Cancer Institute (NCI)|Roche has discontinued further development of the Notch inhibitor (RO4929097) and this Phase II trial was prematurely closed.|2|||f||||t||||||||||2018-05-31 23:37:40.85311|2018-05-31 23:37:40.85311
NCT01154439|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2018-02-20|2010-06-29|2010-06-30|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 2010||2010-10-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|May 2013|Actual|2013-05-31||Interventional|AML1208||Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Study Investigating the Combination of RAD001 With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 1|18|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 23:37:41.644377|2018-05-31 23:37:41.644377
NCT01154426|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2015-06-30|2010-06-29|2010-06-30|Estimate|||||||2015-06-30|2015-07-02|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors|Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies|Completed||Phase 1|31|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:37:41.81237|2018-05-31 23:37:41.81237
NCT01154413|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate|December 2007||2007-12-31|June 2010|2010-06-30|May 2009|Actual|2009-05-31|December 2007|Actual|2007-12-31||Interventional|||Implementation of a Diabetes Management Protocol as Compared to Conventional Management in a Heart Hospital's Non-Intensive Care Unit: Randomized Clinical|Implementation of a Diabetes Management Protocol as Compared to Conventional Management in a Heart Hospital's Non-Intensive Care Unit: Randomized Clinical Trial|Completed||N/A|182|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 23:37:41.926858|2018-05-31 23:37:41.926858
NCT01154400|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2012-10-11|2010-06-29|2010-06-30|Estimate|||||||2012-10-11|2012-10-15|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients|Grant Title: Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in COPD|Completed||N/A|12|Actual|Texas A&M University||4|||f||||f||||||||||2018-05-31 23:37:42.026644|2018-05-31 23:37:42.026644
NCT01154387|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-26|||2013-06-10|2010-06-28|2010-06-30|Estimate|||||||2013-06-10|2013-06-11|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection|A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation|Unknown status|Active, not recruiting|Phase 1/Phase 2|85|Anticipated|Tolera Therapeutics, Inc||3|||f||||t||||||||||2018-05-31 23:37:42.144334|2018-05-31 23:37:42.144334
NCT01154374|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28||2013-07-19|2018-04-16|2010-06-28|2010-06-30|Estimate||||2013-07-19|2013-07-23|Estimate|2018-04-16|2018-04-18|Actual|November 2010||2010-11-30|April 2018|2018-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)|A Phase II, Randomized, Controlled, Two-Center Pilot Study of the Safety and Efficacy of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Diabetic Foot Ulcers|Completed||Phase 2|7|Actual|Skingenix, Inc.||2|||f||||||||||||||2018-05-31 23:37:42.283434|2018-05-31 23:37:42.283434
NCT01154361|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2011-12-22|2010-06-29|2010-06-30|Estimate|||||||2011-12-22|2011-12-23|Estimate||||December 2011|2011-12-31||||||||Interventional|||AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study|A Multicenter Study, Randomized, Double-blind With 2 Groups as Prove of Concept for the Treatment of ACEI Induced Angioedema With Subcutaneous Icatibant|Completed||Phase 2|||Technische Universität München||2|||f||||||||||||||2018-05-31 23:37:42.401802|2018-05-31 23:37:42.401802
NCT01154348|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2018-04-25|2010-06-29|2010-06-30|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2010||2010-06-30|April 2018|2018-04-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus|A Phase 1b, Randomized, Placebo-Controlled Study to Assess the Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|34|Actual|Shionogi Inc.||4|||f||||t||||||||||2018-05-31 23:37:42.512216|2018-05-31 23:37:42.512216
NCT01154335|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2015-01-06||2015-01-06|2010-06-29|2010-06-30|Estimate|2015-01-06|2015-01-14|Estimate||||2015-01-06|2015-01-14|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer|A Phase I Study of Everolimus (mTOR Inhibitor) and OSI-906 (Dual IGFR and IR Tyrosine Kinase Inhibitor) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer|Completed||Phase 1|18|Actual|SCRI Development Innovations, LLC||3|||f||||f||||||||||2018-05-31 23:37:42.630544|2018-05-31 23:37:42.630544
NCT01154322|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2012-11-07||2013-01-18|2010-06-28|2010-06-30|Estimate|2012-12-10|2013-01-16|Estimate||||2013-01-18|2013-01-24|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Pediatric Nasal Mask Usability Study|Pediatric Nasal Mask Usability Study|Completed||N/A|16|Actual|ResMed||1|||f||||f||||||||||2018-05-31 23:37:42.988881|2018-05-31 23:37:42.988881
NCT01154309|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2011-11-10|2010-06-29|2010-06-30|Estimate|||||||2011-11-10|2011-11-16|Estimate|September 2006||2006-09-30|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|BRIGHT2||Group CBT for Depression and AOD Disorders|Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders|Completed||Phase 1|73|Actual|RAND||2|||f||||t||||||||||2018-05-31 23:37:43.20539|2018-05-31 23:37:43.20539
NCT01154296|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2014-07-29||2014-09-23|2010-06-29|2010-06-30|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|Aware|6,239 patients approached provided consent to be screened. Of these, 5,028 were eligible (80.6%) and 5012 (99.5% of those eligible) were randomized; 16 screened eligible, but were not randomized due to: decision to decline (3), not returning (11), not testing with HIV/STD battery (1) and not completing baseline activities (1).|HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.|Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032|Completed||N/A|5012|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 23:37:43.32954|2018-05-31 23:37:43.32954
NCT01154283|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2015-09-26||2016-11-03|2010-06-29|2010-06-30|Estimate|2016-11-03|2017-01-02|Estimate||||2016-11-03|2017-01-02|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients|A Randomized Crossover Study of Standard, Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in Amyotrophic Lateral Sclerosis (ALS) Patients|Completed||N/A|28|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 23:37:43.870012|2018-05-31 23:37:43.870012
NCT01154270|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2013-04-23|2010-06-29|2010-06-30|Estimate|||||||2013-04-23|2013-04-24|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|September 2013|Anticipated|2013-09-30|September 2011|Actual|2011-09-30||Interventional|COSMIC||CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC|Combined Therapy of Malignant Salivary Gland Tumours With IMRT and Carbon Ions: COSMIC|Unknown status|Active, not recruiting|Phase 2|54|Anticipated|Heidelberg University||1|||f||||f||||||||||2018-05-31 23:37:44.161121|2018-05-31 23:37:44.161121
NCT01154257|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-30|2010-06-29|2010-06-30|Estimate|||||||2010-06-30|2010-07-01|Estimate|June 2010||2010-06-30|March 2010|2010-03-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Comparison of Swabs and Toothbrushes in Cleaning the Teeth of Mechanically Ventilated Patients|Comparison of Foam Swabs Versus Toothbrushes in Removing Dental Plaque From Orally Intubated Mechanically Ventilated Patients|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Cardiff and Vale University Health Board||2|||f||||f||||||||||2018-05-31 23:37:44.497422|2018-05-31 23:37:44.497422
NCT01154244|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2011-01-22|2010-06-29|2010-06-30|Estimate|||||||2011-01-22|2011-01-25|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|SURPRISE||Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea|Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea|Completed|||1439|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:37:44.63499|2018-05-31 23:37:44.63499
NCT01154231|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2017-02-28||2017-02-28|2010-06-29|2010-06-30|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|February 2010||2010-02-28|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||A total of 314 participants completed the study. Of the 314 participants, 2 participants were excluded from the baseline analysis. One was excluded due to no information after first day of treatment and no drug administration, the other due to safety not assessable and no drug administration.|BeneFIX Drug Use Results Survey [All-Case Surveillance]|Benefix(Registered) Intravenous 500 1000 2000 Drug Use Results Survey (All-case Surveillance)|Completed|||314|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:37:44.763922|2018-05-31 23:37:44.763922
NCT01154218|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2011-09-12||2011-10-20|2010-06-29|2010-06-30|Estimate|2011-09-12|2011-10-19|Estimate||||2011-10-20|2011-10-24|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers|A Phase 1, Single Dose Bioequivalence And Food Effect Study In Healthy Volunteers Comparing The Commercial Image Capsules To The Immediate Release Tablets And Powder In Capsule Formulations Of Crizotinib (PF-02341066), And The Commercial Image Capsule In The Fasted To Fed State|Completed||Phase 1|36|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:37:45.216565|2018-05-31 23:37:45.216565
NCT01154205|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|January 2012|Anticipated|2012-01-31|||||Observational|||Sheba Medical Center Home Monitoring Clinic Registry|Sheba Medical Center Home Monitoring Clinic Registry|Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 23:37:46.236673|2018-05-31 23:37:46.236673
NCT01154192|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2016-02-09|2010-06-29|2010-06-30|Estimate|||||||2016-02-09|2016-02-10|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)|Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)|Completed||Phase 3|24|Actual|University of California, San Diego||3|||f||||t||||||||No||2018-05-31 23:37:46.307962|2018-05-31 23:37:46.307962
NCT01154179|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-09-04|2010-06-29|2010-06-30|Estimate|||||||2012-09-04|2012-09-05|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Appropriate Controlled Feeding: a Single Blinded Prospective Randomised Study|Appropriate Controlled Feeding: a Single Blinded Prospective Randomised Study|Completed||N/A|93|Actual|Scarborough General Hospital||1|||f||||t||||||||||2018-05-31 23:37:46.43854|2018-05-31 23:37:46.43854
NCT01154166|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2012-05-10||2012-08-16|2010-06-29|2010-06-30|Estimate|2012-06-28|2012-08-07|Estimate||||2012-08-16|2012-08-20|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa|Completed||Phase 3|347|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:37:46.628204|2018-05-31 23:37:46.628204
NCT01154153|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2011-09-21||2012-06-21|2010-06-29|2010-06-30|Estimate|2011-09-21|2011-10-28|Estimate||||2012-06-21|2012-06-26|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [>=2 to < 12 Years of Age] With Allergic Rhinitis (AR).|Completed||Phase 4|140|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:37:47.366317|2018-05-31 23:37:47.366317
NCT01154140|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2014-11-26||2017-09-29|2010-06-29|2010-06-30|Estimate|2014-12-19|2015-01-05|Estimate||||2017-09-29|2017-11-06|Actual|January 13, 2011|Actual|2011-01-13|September 2017|2017-09-30|November 30, 2016|Actual|2016-11-30|November 30, 2013|Actual|2013-11-30||Interventional|PROFILE 1014|The Full Analysis (FA) population included all participants who were randomized with study treatment assignment designated according to the initial randomization.|A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung|Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus.|Completed||Phase 3|343|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:37:48.224461|2018-05-31 23:37:48.224461
NCT01154127|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2012-02-08||2012-04-10|2010-06-29|2010-06-30|Estimate|2012-04-10|2012-05-07|Estimate||||2012-04-10|2012-05-07|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|GLOW3||Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multi-center, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study to Assess the Effect of 50µg Inhaled NVA237 on Exercise Endurance in Patients With Moderate to Severe COPD|Completed||Phase 3|108|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:37:51.308301|2018-05-31 23:37:51.308301
NCT01154114|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-07-24|2010-06-29|2010-06-30|Estimate|||||||2017-07-24|2017-07-26|Actual|July 1, 2010|Actual|2010-07-01|July 2017|2017-07-31|October 15, 2010|Actual|2010-10-15|October 15, 2010|Actual|2010-10-15||Interventional|||Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and Subjects With Moderate Hepatic Impairment|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:37:51.845467|2018-05-31 23:37:51.845467
NCT01154101|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2017-08-07|2012-11-15|2017-09-12|2010-06-29|2010-06-30|Estimate|2017-09-12|2017-10-13|Actual|2012-11-15|2012-11-20|Estimate|2017-09-12|2017-10-13|Actual|June 7, 2010|Actual|2010-06-07|September 2017|2017-09-30|November 9, 2011|Actual|2011-11-09|November 9, 2011|Actual|2011-11-09||Interventional||Sex and Race assessments were performed for the entire population (40 participants). However, for Age only 39 participants were available (1 participant withdrew from the study from the 'No Treatment group') and hence data was not collected for that participant.|Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis|Completed||Phase 2|40|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:37:51.997456|2018-05-31 23:37:51.997456
NCT01154088|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29||2011-05-27|2016-09-20|2010-06-29|2010-06-30|Estimate||||2011-05-27|2011-06-03|Estimate|2016-09-20|2016-09-23|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds|Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Mencevax™ ACWY in Healthy Subjects Aged 18-25 Years|Completed||Phase 3|1173|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:37:53.13205|2018-05-31 23:37:53.13205
NCT01154075|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-12-21|2010-06-29|2010-06-30|Estimate|||||||2017-12-21|2017-12-26|Actual|August 2010||2010-08-31|December 2017|2017-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|MALT||Medication Adherence in Children Who Had a Liver Transplant|Medication Adherence in Children Who Had a Liver Transplant|Completed|||401|Actual|Icahn School of Medicine at Mount Sinai|||||f||||t||||||Samples Without DNA|"~     liver tissue samples (from biopsies performed for clinical, not investigational, reasons)~   "|||2018-05-31 23:37:53.303691|2018-05-31 23:37:53.303691
NCT01154062|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-11-07|2010-06-29|2010-06-30|Estimate|||||||2017-11-07|2017-11-09|Actual|August 16, 2010|Actual|2010-08-16|November 2017|2017-11-30|April 29, 2011|Actual|2011-04-29|April 29, 2011|Actual|2011-04-29||Interventional|||A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration|An Open-label Pilot Study to Evaluate the Safety, Tolerability,Pharmacokinetics, Exploratory Efficacy and Pharmacodynamics of Oral Pazopanib Administered for 28 Days to Neovascular Age-relatedmacular Degeneration Patients|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:37:53.396066|2018-05-31 23:37:53.396066
NCT01154049|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2016-08-09|2010-06-29|2010-06-30|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis|Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis|Completed||Phase 1|20|Actual|Oswaldo Cruz Foundation||1|||f||||t||||||||||2018-05-31 23:37:53.478036|2018-05-31 23:37:53.478036
NCT01154036|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2013-09-05||2015-10-30|2010-06-29|2010-06-30|Estimate|2013-12-23|2014-02-12|Estimate||||2015-10-30|2015-11-02|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)|A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin|Completed||Phase 3|1547|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 23:37:53.620047|2018-05-31 23:37:53.620047
NCT01154023|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate|September 2000||2000-09-30|June 2010|2010-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Behavioral Intervention for Insomnia in Older Adults|Behavioral Intervention for Insomnia in Older Adults|Completed||N/A|179|Actual|Carl T. Hayden VA Medical Center||3|||f||||f||||||||||2018-05-31 23:37:55.886297|2018-05-31 23:37:55.886297
NCT01154010|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2017-03-24||2018-01-31|2010-06-29|2010-06-30|Estimate|2017-03-24|2017-05-04|Actual||||2018-01-31|2018-02-28|Actual|August 2009||2009-08-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PEMF||PEMF: an Adjunct Therapy for Anterior Uveitis|PEMF an Adjunct Therapy for Anterior Uveitis|Completed||N/A|18|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||f||||||||Yes|A forthcoming article will include a chart that will document individual participant data.|2018-05-31 23:37:55.995473|2018-05-31 23:37:55.995473
NCT01153997|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2014-06-17|2010-06-29|2010-06-30|Estimate|||||||2014-06-17|2014-06-18|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers|A Randomised, Placebo-controlled Single-dose, Parallel-group, Double-blind Trial Evaluating Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Japanese Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 23:37:56.239182|2018-05-31 23:37:56.239182
NCT01153490|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2018-04-12|2010-06-29|2010-06-30|Estimate|||||||2018-04-12|2018-04-17|Actual|October 22, 2010|Actual|2010-10-22|April 2018|2018-04-30|August 6, 2012|Actual|2012-08-06|August 6, 2012|Actual|2012-08-06||Interventional|CD||Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine|Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine|Completed||Phase 4|124|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 23:38:07.538749|2018-05-31 23:38:07.538749
NCT01153984|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2017-03-01||2017-03-01|2010-06-29|2010-06-30|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|June 2011||2011-06-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|BIOTEC|Analysis population included all enrolled participants.|A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations|Biomarkers Impact on the Response to Treatment With Erlotinib in First Line Non-small Cell Lung Cancer With EGFR Activating Mutations - BIOTEC|Completed||Phase 2|23|Actual|Hoffmann-La Roche||1|||f||||f||||||||||2018-05-31 23:37:56.345471|2018-05-31 23:37:56.345471
NCT01153971|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2014-08-04||2017-06-26|2010-06-29|2010-06-30|Estimate|2014-08-04|2014-08-21|Estimate||||2017-06-26|2017-08-01|Actual|July 20, 2005|Actual|2005-07-20|June 2017|2017-06-30|September 24, 2010|Actual|2010-09-24|September 24, 2010|Actual|2010-09-24||Interventional||Intent-to-Treat (ITT) population: all enrolled participants who completed at least 2 cycles of treatment.|A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas|An Open-label Study of Fludarabine and Cyclophosphamide Plus MabThera Followed by Maintenance With MabThera on Failure-free Survival in Treatment-naïve Patients With Advanced Indolent B-cell Nonfollicular Lymphoma|Completed||Phase 2|47|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:37:56.62692|2018-05-31 23:37:56.62692
NCT01153958|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2012-07-18||2014-01-20|2010-06-29|2010-06-30|Estimate|2012-07-18|2012-08-21|Estimate||||2014-01-20|2014-02-13|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Colposeptine for the Treatment of Bacterial Vaginosis|The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study|Terminated||Phase 4|133|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:37:57.253231|2018-05-31 23:37:57.253231
NCT01153945|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2015-04-06|2010-06-29|2010-06-30|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2011||2011-02-28|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum|Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum|Withdrawn|||0|Actual|Meir Medical Center|||3|The sponsor stopped the study.|f||||t||||||||||2018-05-31 23:37:57.754843|2018-05-31 23:37:57.754843
NCT01153932|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2014-08-21|2010-06-29|2010-06-30|Estimate|||||||2014-08-21|2014-08-25|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy|A Phase II, Double Blind, Exploratory, Parallel-group, Placebocontrolled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy|Completed||Phase 2|53|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 23:37:57.84429|2018-05-31 23:37:57.84429
NCT01153919|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-04-09|2010-06-28|2010-06-30|Estimate|||||||2017-04-09|2017-04-11|Actual|June 30, 2010|Actual|2010-06-30|April 2017|2017-04-30|July 14, 2018|Anticipated|2018-07-14|July 14, 2014|Actual|2014-07-14||Interventional|||Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia|A Double-Blind, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who Are Not Candidates for Antiviral Treatment With Pegylated Interferon and Ribavirin Due to Persistent Thrombocytopenia|Terminated||Phase 2|27|Actual|University of Southern California||2||"Approval of several new agents for the treatment of HCV infection would mitigate the future~   need for interferon HCV treatment"|f||||f||||||||||2018-05-31 23:37:58.071519|2018-05-31 23:37:58.071519
NCT01153906|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2014-11-26|2010-06-29|2010-06-30|Estimate|||||||2014-11-26|2014-12-02|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination|Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination in Females Aged 9-25 Years in the US|Completed|||1516|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 23:37:58.245079|2018-05-31 23:37:58.245079
NCT01153893|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2012-02-09||2016-09-20|2010-06-29|2010-06-30|Estimate|2012-02-09|2012-03-15|Estimate||||2016-09-20|2016-10-20|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria|Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Nigerian Children|Completed||Phase 3|105|Actual|GlaxoSmithKline|Data were reanalyzed because an issue was discovered with the informed consent obtained for one child after the original statistical analysis. The child’s parent requested GlaxoSmithKline not to use the data of their child.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:37:58.383248|2018-05-31 23:37:58.383248
NCT01153880|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2013-06-06|2010-06-29|2010-06-30|Estimate|||||||2013-06-06|2013-06-10|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||United States Pharmacovigilence Retapamulin-Prescribing|Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the United States|Completed|||1|Actual|GlaxoSmithKline|||6||f||||f||||||||||2018-05-31 23:37:59.185858|2018-05-31 23:37:59.185858
NCT01153867|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2016-03-15|2010-06-29|2010-06-30|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Schema Focused Therapy for Chronic Depression|Schema-Focused Therapy for Chronic Depression: Efficacy and Mechanisms of Change|Completed||N/A|25|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 23:37:59.279442|2018-05-31 23:37:59.279442
NCT01153854|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|July 2008|Actual|2008-07-31||Interventional|Raceca-Mex||Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico|Efficacy, Safety and Cost-effectiveness Analysis of Impact of Racecadotril as an Adjunct in the Treatment of Acute Diarrhea in Mexican Children|Completed||Phase 3|454|Actual|National Institute of Pediatrics, Mexico||4|||f||||t||||||||||2018-05-31 23:37:59.563479|2018-05-31 23:37:59.563479
NCT01153841|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2017-01-09|2012-07-23|2017-02-28|2010-06-29|2010-06-30|Estimate|2017-01-09|2017-02-27|Actual|2012-07-23|2012-07-31|Estimate|2017-02-28|2017-03-29|Actual|February 2011||2011-02-28|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam|Primary Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, in Healthy Infants in Vietnam When Co-administered With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine|Completed||Phase 3|300|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:37:59.772805|2018-05-31 23:37:59.772805
NCT01153815|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2012-04-19||2017-06-26|2010-06-29|2010-06-30|Estimate|2012-04-19|2012-05-17|Estimate||||2017-06-26|2017-06-28|Actual|April 2010||2010-04-30|January 2017|2017-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity|Completed||Phase 3|170|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:38:00.98516|2018-05-31 23:38:00.98516
NCT01153802|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-06-26|2010-06-29|2010-06-30|Estimate|||||||2017-06-26|2017-06-27|Actual|April 3, 2009|Actual|2009-04-03|June 2017|2017-06-30|October 12, 2009|Actual|2009-10-12|October 12, 2009|Actual|2009-10-12||Interventional|||An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy, Pharmacokinetics and Safety of Single Oral Doses ofGSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:38:01.780932|2018-05-31 23:38:01.780932
NCT01153789|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2014-12-03|2010-06-29|2010-06-30|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|VERVE||Study of Oculomotor Dysfunction Leading to Children Vertigo|Evaluation and Medical Care of Oculomotor Dysfunction Leading to Vertigo in Children|Completed||N/A|183|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:38:01.910289|2018-05-31 23:38:01.910289
NCT01153776|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-06-27|2010-06-29|2010-06-30|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2008|Actual|2008-09-30|June 2017|2017-06-30|October 2011|Actual|2011-10-31|March 2010|Actual|2010-03-31||Interventional|SCANTGV||CT Coronary Angiography After Arterial Switch Operation|CT Coronary Angiography for the Detection of Reimplanted Coronary Lesions in Patients Who Had Undergone Arterial Switch Operation for Transposition of the Great Arteries|Completed||N/A|42|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:38:02.028502|2018-05-31 23:38:02.028502
NCT01153763|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2013-06-12|2012-03-01|2017-08-29|2010-06-29|2010-06-30|Estimate|2014-05-08|2014-06-02|Estimate|2012-03-01|2012-03-05|Estimate|2017-08-29|2017-09-27|Actual|August 9, 2010||2010-08-09|July 2017|2017-07-31|June 1, 2016|Actual|2016-06-01|July 1, 2011|Actual|2011-07-01||Interventional|||A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma|A Phase II (BRF113710) Single-arm, Open-label Study of GSK2118436 in BRAF Mutant Metastatic Melanoma|Completed||Phase 2|92|Actual|GlaxoSmithKline|This study met the criteria for completed. Participants who were still receiving study treatment at the time the study was closed were given the option to transfer to a rollover protocol.|1|||f||||t||||||||||2018-05-31 23:38:02.16158|2018-05-31 23:38:02.16158
NCT01153750|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate|April 2007||2007-04-30|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct|Phase II Study to Evaluate the Efficacy of a Chemotherapy Combination With Imatinib (Glivec®) and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct|Completed||Phase 2|44|Actual|University Hospital Dresden||1|||f||||f||||||||||2018-05-31 23:38:02.748575|2018-05-31 23:38:02.748575
NCT01153737|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-11-05|2010-06-29|2010-06-30|Estimate|||||||2017-11-05|2017-11-07|Actual|May 2005||2005-05-31|November 2017|2017-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Manual Therapy Effectiveness in Comparison With Electric Nerve Stimulation (TENS) in Patients With Neck Pain|Primary Care Randomized Clinical Trial: Manual Therapy Effectiveness in Comparison With TENS in Patients With Neck Pain|Completed||N/A|90|Actual|Gerencia Atencion Primaria Area 3||2|||f||||t||||||||||2018-05-31 23:38:02.854924|2018-05-31 23:38:02.854924
NCT01153724|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2014-03-28||2014-05-29|2010-06-29|2010-06-30|Estimate|2014-05-29|2014-06-10|Estimate||||2014-05-29|2014-06-10|Estimate|May 2010||2010-05-31|May 2014|2014-05-31||||July 2010|Actual|2010-07-31||Interventional|||Relative Bioavailability of Olodaterol and Fluconazole|Relative Bioavailability of 10 mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Fluconazole (Hard Capsule) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)|Completed||Phase 1|35|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:38:02.995402|2018-05-31 23:38:02.995402
NCT01153711|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2014-03-28||2014-03-28|2010-06-29|2010-06-30|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|May 2010||2010-05-31|March 2014|2014-03-31||||August 2010|Actual|2010-08-31||Interventional|||Relative Bioavailability of of Olodaterol and Ketoconazole|Relative Bioavailability of 10 mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Ketoconazole (Tablet) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:38:03.469249|2018-05-31 23:38:03.469249
NCT01153698|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2012-11-30||2014-05-06|2010-06-29|2010-06-30|Estimate|2012-11-30|2013-01-04|Estimate||||2014-05-06|2014-05-16|Estimate|August 2010||2010-08-31|May 2014|2014-05-31||||||||Observational|||Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery|Observational Cohort Study to Evaluate the Safety and Efficacy of Switching From Lovenox (Enoxaparin) 40mg to Pradaxa (Dabigatran Etexilate) 220mg in Patients Undergoing Elective Total Hip or Knee Replacement Surgery|Terminated|||167|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:38:03.898764|2018-05-31 23:38:03.898764
NCT01153685|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2011-07-26||2016-09-26|2010-06-29|2010-06-30|Estimate|2011-10-13|2011-11-17|Estimate||||2016-09-26|2016-10-27|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years|Immunogenicity and Safety Study of GSK Biologicals' (GSK1536489A) Trivalent Split Virion Influenza Vaccine Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years.|Completed||Phase 3|120|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:38:04.372823|2018-05-31 23:38:04.372823
NCT01153672|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2014-10-31||2018-05-24|2010-06-28|2010-06-30|Estimate|2014-11-05|2014-11-07|Estimate||||2018-05-24|2018-05-30|Actual|November 2010||2010-11-30|May 2018|2018-05-31|August 11, 2016|Actual|2016-08-11|July 2012|Actual|2012-07-31||Interventional|||Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy|A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy|Completed||N/A|8|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:38:04.961489|2018-05-31 23:38:04.961489
NCT01153659|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2013-10-31|2010-06-29|2010-06-30|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets|A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Effect on 24-hour, Intragastric pH Following Daily Oral Dose Administration of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40-mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets to H. Pylori-Negative Healthy Subjects in a 5-day Treatment Regimen|Completed||Phase 1|90|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 23:38:05.257472|2018-05-31 23:38:05.257472
NCT01153646|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2011-01-18|2010-06-29|2010-06-30|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Gene Transfer||Gene Transfer for HIV Using Autologous T Cells|A Pilot Study of Safety and Feasibility of T-Cell Immunotherapy Using Lentivirus Vector-Expressed RNAi in Autologous T-Cells of HIV-1 Infected Patients Who Have Failed Anti-Retroviral Therapy|Terminated||Early Phase 1|5|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:38:05.372622|2018-05-31 23:38:05.372622
NCT01153633|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2012-05-29||2014-03-18|2010-06-29|2010-06-30|Estimate|2014-03-18|2014-04-01|Estimate||||2014-03-18|2014-04-01|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Trial on the Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Pilot, Randomised, Double-blind, Controlled Clinical Trial on the Combined Efficacy of Prontosan Wound Irrigation Solution and Prontosan Wound Gel in the Reduction in Size and Change in Bioburden of Hard-to-heal Venous Leg Ulcers|Completed||Phase 4|34|Actual|B. Braun Ltd. Centre of Excellence Infection Control|Most likely the non-statistical significant results are due to the small sample size. No sample size calculation and statistical analysis was planned a priori because it was a pilot study.|2|||f||||f||||||||||2018-05-31 23:38:05.505455|2018-05-31 23:38:05.505455
NCT01153620|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2011-10-21||2012-04-05|2010-06-29|2010-06-30|Estimate|2011-10-21|2011-11-29|Estimate||||2012-04-05|2012-04-06|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Lavasept 2||The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds|Randomized, Double-blind, Controlled Clinical Trial on the Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds|Completed||Phase 4|61|Actual|B. Braun Ltd. Centre of Excellence Infection Control||2|||f||||t||||||||||2018-05-31 23:38:06.05387|2018-05-31 23:38:06.05387
NCT01153607|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-01-18|2010-06-29|2010-06-30|Estimate|||||||2013-01-18|2013-01-21|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers|Open-label, Non-randomized, Multicenter Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of BAY1006578 for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimers Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of BAY1006578 in Healthy Volunteers|Completed||Phase 1|24|Actual|Piramal Imaging SA||3|||f||||f||||||||||2018-05-31 23:38:06.34788|2018-05-31 23:38:06.34788
NCT01153594|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate|February 2004||2004-02-29|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|ERI2||Early Re-Intervention Experiment 2|Early Re-Intervention (ERI) Experiment 2|Completed||Phase 3|446|Actual|Chestnut Health Systems||2|||f||||t||||||||||2018-05-31 23:38:06.456097|2018-05-31 23:38:06.456097
NCT01153581|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2014-07-08||2016-12-01|2010-06-29|2010-06-30|Estimate|2016-12-01|2017-01-30|Estimate||||2016-12-01|2017-01-30|Estimate|February 2006||2006-02-28|December 2016|2016-12-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Sex Hormones and Orthostatic Tolerance|Sex Hormones and Orthostatic Tolerance|Completed||Phase 2|109|Actual|Yale University||3|||f||||f||||||||Yes|Our data are stored in locked files, and our spreadsheets and raw data are available should they be requested|2018-05-31 23:38:06.583309|2018-05-31 23:38:06.583309
NCT01153568|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2017-11-02|2010-06-28|2010-06-30|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2010||2010-08-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|NIHD||Vitamin D and Osteoporosis Prevention in Elderly African American Women|Vitamin D and Osteoporosis Prevention in Elderly African American Women: A 4-year Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Vitamin D Status in Elderly African American Women|Completed||Phase 3|260|Actual|Winthrop University Hospital||2|||f||||t||||||||||2018-05-31 23:38:06.811085|2018-05-31 23:38:06.811085
NCT01153555|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2015-02-27|2010-06-29|2010-06-30|Estimate|||||||2015-02-27|2015-03-04|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|FIRST||Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy|Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy: The FIRST Study|Completed|||350|Actual|Volcano Corporation|||1||f||||f||||||||||2018-05-31 23:38:06.892463|2018-05-31 23:38:06.892463
NCT01153542|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-12-08|2010-06-28|2010-06-30|Estimate|||||||2010-12-08|2010-12-09|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of VX-770 on Desipramine|An Open-Label Phase 1 Study to Examine the Effect of VX 770 on Desipramine in Healthy Subjects|Completed||Phase 1|24|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 23:38:06.969512|2018-05-31 23:38:06.969512
NCT01153529|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2014-05-16|2010-06-28|2010-06-30|Estimate|||||||2014-05-16|2014-05-19|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|PATRIOT||Post-Deployment Afghanistan/Iraq Trauma Related Inventory of Traits (PATRIOT): Phase 1 (Feasibility Study)|CSP #575 - Post-Deployment Afghanistan/Iraq Trauma Related Inventory of Traits (PATRIOT): Phase 1 (Feasibility Study)|Completed|||250|Anticipated|VA Office of Research and Development|||1||f||||t||||||||||2018-05-31 23:38:07.037376|2018-05-31 23:38:07.037376
NCT01153516|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2013-01-22|2010-06-28|2010-06-30|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Diabetes and Gastric By- Pass|Unraveling the Mechanisms of Rapid Improvement in Diabetes Following Gastric By-Pass Surgery|Completed|||10|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||Samples Without DNA|"~     whole blood samples, plasma, serum, urine,~   "|||2018-05-31 23:38:07.117493|2018-05-31 23:38:07.117493
NCT01153503|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2014-03-18||2018-01-31|2010-06-29|2010-06-30|Estimate|2014-03-18|2014-04-22|Estimate||||2018-01-31|2018-03-01|Actual|April 2010||2010-04-30|January 2018|2018-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TAP||Ultrasound-guided Transversus Abdominis Plane Block After Hysterectomy|Ultrasound-guided Transversus Abdominis Plane Block After Abdominal Hysterectomy: a Prospective Randomized Controlled Trial|Completed||N/A|75|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||||2018-05-31 23:38:07.283493|2018-05-31 23:38:07.283493
NCT01153464|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-03-28|2010-06-29|2010-06-30|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2009||2009-10-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effectiveness of Extended Treatment for Drug Dependence (ETDD) in the City Study|Effectiveness of Extended Treatment for Drug Dependence - City Supplement|Completed||Phase 2|200|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 23:38:07.687332|2018-05-31 23:38:07.687332
NCT01153451|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2013-06-04|2010-06-29|2010-06-30|Estimate|||||||2013-06-04|2013-06-05|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|May 2011|Actual|2011-05-31||Interventional|||An Automatic Notification System for Test Results Finalized After Discharge|An Automatic Notification System for Test Results Finalized After Discharge|Completed||N/A|441|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:38:07.785061|2018-05-31 23:38:07.785061
NCT01153438|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2016-08-15|2010-06-29|2010-06-30|Estimate|||||||2016-08-15|2016-08-17|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes|Role of Endogenous Glucagon-like Peptide-1 (GLP-1) in Improved Glucose Tolerance After Two Different Types of Bariatric Surgery|Completed|||8|Actual|University of Pennsylvania|||1||f||||t||||||Samples Without DNA|"~     Extra blood will be stored for the potential analysis of additional hormones.~   "|||2018-05-31 23:38:07.890687|2018-05-31 23:38:07.890687
NCT01153425|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2017-05-22||2017-08-01|2010-06-28|2010-06-30|Estimate|2017-08-01|2017-08-04|Actual||||2017-08-01|2017-08-04|Actual|July 2008||2008-07-31|August 2017|2017-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TERIZOL||µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis|NMR Imaging and Stereological Analysis of Trabecular Bone in Female Subjects 60 and Older at Risk of Fracture Receiving Either Zoledronic Acid or Teriparatide|Completed||Phase 4|33|Actual|University of Pennsylvania|Insufficient Power|2|||f||||f|t|f|||f|||No||2018-05-31 23:38:07.98096|2018-05-31 23:38:07.98096
NCT01153412|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2016-10-31|2010-06-29|2010-06-30|Estimate|||||||2016-10-31|2016-11-02|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of Osteopathic Manipulation on Postural Stability in the Elderly|Effect of Osteopathic Manipulation on Postural Stability in the Elderly|Completed||N/A|60|Actual|University of North Texas Health Science Center||2|||f||||f||||||||Yes|Can provide de-identified center of pressure data from the project.|2018-05-31 23:38:08.323523|2018-05-31 23:38:08.323523
NCT01153399|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-11-19|2010-06-29|2010-06-30|Estimate|||||||2015-11-19|2015-11-20|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|REASON||A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).|An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)-REASON STUDY.|Completed|||589|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:38:08.379136|2018-05-31 23:38:08.379136
NCT01153386|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-08-20|2010-06-28|2010-06-30|Estimate|||||||2010-08-20|2010-08-23|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine|An Evaluation of the Pharmacokinetic Linearity and Comparative Bioavailability of a Single Oral Dose of 0.5 mg, 1 mg and 2.5 mg UT-15C (Treprostinil Diethanolamine) SR Tablets in Healthy Volunteers in the Fed State|Completed||Phase 1|36|Anticipated|United Therapeutics||3|||f||||f||||||||||2018-05-31 23:38:08.442723|2018-05-31 23:38:08.442723
NCT01153373|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2015-04-08|2010-06-29|2010-06-30|Estimate|||||||2015-04-08|2015-04-09|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|DARSSA||Dynamic Assessment and Referral System - Evaluation|The Dynamic Assessment and Referral System for Substance Abuse: Evaluation|Completed||Phase 2|758|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 23:38:08.522403|2018-05-31 23:38:08.522403
NCT01153360|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-07-23|2010-06-29|2010-06-30|Estimate|||||||2012-07-23|2012-07-24|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery|Peri-operative Oral Triiodothyronine Replacement Therapy to Decrease the Risk of Transient Atrial Fibrillation After Off-pump Coronary Artery Bypass Surgery|Completed||N/A|100|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:38:09.920371|2018-05-31 23:38:09.920371
NCT01153347|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2012-06-26||2014-03-14|2010-06-29|2010-06-30|Estimate|2012-11-19|2012-11-20|Estimate||||2014-03-14|2014-04-11|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind Parallel Group Placebo-Controlled Phase III,Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy|Completed||Phase 3|2409|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:38:10.114623|2018-05-31 23:38:10.114623
NCT01153334|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2017-11-26|2010-06-29|2010-06-30|Estimate|||||||2017-11-26|2017-11-28|Actual|August 2, 2010|Actual|2010-08-02|November 2017|2017-11-30|June 27, 2013|Actual|2013-06-27|June 27, 2013|Actual|2013-06-27||Interventional|||Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial)||Completed||Phase 4|125|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:38:12.016205|2018-05-31 23:38:12.016205
NCT01153321|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2013-07-15||2015-03-23|2010-06-29|2010-06-30|Estimate|2014-10-17|2014-10-23|Estimate||||2015-03-23|2015-04-10|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)|A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation|Completed||Phase 2|71|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:38:12.152238|2018-05-31 23:38:12.152238
NCT01153308|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-21|||2015-08-17|2010-06-28|2010-06-30|Estimate|||||||2015-08-17|2015-08-19|Estimate|April 2005||2005-04-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Outcomes of Bariatric Surgery/UMMMC Bariatric Surgery Registry|Outcomes of Bariatric Surgery (UMMMC Bariatric Surgery Registry)|Completed|||4785|Actual|University of Massachusetts, Worcester|||1||f||||f||||||||||2018-05-31 23:38:13.281535|2018-05-31 23:38:13.281535
NCT01153282|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2016-01-25|2010-06-29|2010-06-30|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer|Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer|Completed|||30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:38:13.476046|2018-05-31 23:38:13.476046
NCT01153269|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2011-11-16||2011-11-16|2010-06-28|2010-06-30|Estimate|2011-11-16|2011-12-19|Estimate||||2011-11-16|2011-12-19|Estimate|May 2001||2001-05-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Long-term Effectiveness and Safety in Hepatitis-co-infected Patients|Long-term Effectiveness and Safety in Hepatitis-co-infected Patients|Completed|||33|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:38:13.589456|2018-05-31 23:38:13.589456
NCT01153256|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2012-01-06|2010-06-29|2010-06-30|Estimate|||||||2012-01-06|2012-01-09|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Intubating Condition After Magnesium Pre-treatment|The Influence of Magnesium Sulphate Pretreatment on Intubating Conditions During Rapid Sequence Induction|Completed||N/A|168|Actual|Seoul National University Bundang Hospital||3|||f||||||||||||||2018-05-31 23:38:14.35329|2018-05-31 23:38:14.35329
NCT01153243|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2011-04-06|2010-06-29|2010-06-30|Estimate|||||||2011-04-06|2011-04-07|Estimate|April 2007||2007-04-30|March 2009|2009-03-31|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Vitamin D and Inflammatory Markers of Cardiovascular Disease in African Americans With Type 2 Diabetes|Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease?|Unknown status|Active, not recruiting|Phase 4|117|Actual|John H. Stroger Hospital||2|||f||||f||||||||||2018-05-31 23:38:14.430578|2018-05-31 23:38:14.430578
NCT01153230|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate|December 2002||2002-12-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Frequencies of Histo-pathological Findings in Patients With Paraquat Toxicity|Study of Frequencies of Histo-pathological Findings in Paraquat Poisoned Patients|Completed|||42|Actual|Isfahan University of Medical Sciences|||1||f||||t||||||||||2018-05-31 23:38:14.612455|2018-05-31 23:38:14.612455
NCT01153217|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-10-16|2010-06-29|2010-06-30|Estimate|||||||2012-10-16|2012-10-17|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density|MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY|Completed||Phase 3|54|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-05-31 23:38:14.696551|2018-05-31 23:38:14.696551
NCT01153204|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2010-06-29|2010-06-29|2010-06-30|Estimate|||||||2010-06-29|2010-06-30|Estimate||||June 2010|2010-06-30||||||||Interventional|||Satisfaction, Confidence and Naturalness in Men With Psychogenic Erectile Dysfunction (ED)|Satisfaction With the Treatment, Confidence and Naturalness in Engaging in Sexual Activity in Men With Psychogenic Erectile Dysfunction: Randomized Controlled Trial of Three Therapeutic Approaches.|Completed||Phase 4|30|Actual|Federal University of São Paulo||3|||f||||f||||||||||2018-05-31 23:38:14.796176|2018-05-31 23:38:14.796176
NCT01153191|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2011-11-03|2010-06-29|2010-06-30|Estimate|||||||2011-11-03|2011-11-04|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Effectiveness for Interventions to Minimize Surgical Site Infections|Developing Evidence of Effectiveness for Adjuvant Interventions Designed to Minimize Surgical Site Infections|Unknown status|Enrolling by invitation|N/A|120|Anticipated|Dallas VA Medical Center||2|||f||||f||||||||||2018-05-31 23:38:14.879834|2018-05-31 23:38:14.879834
NCT01153165|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|||2012-02-01|2010-06-29|2010-06-30|Estimate|||||||2012-02-01|2012-02-03|Estimate|November 2010||2010-11-30|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Study of Treatment of Depression in Refractory Asthma|Pilot Study of Treatment of Depression in Refractory Asthma|Unknown status|Recruiting|N/A|40|Anticipated|Belfast Health and Social Care Trust||2|||f||||f||||||||||2018-05-31 23:38:14.983172|2018-05-31 23:38:14.983172
NCT01153152|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate||||February 2009|2009-02-28|September 2009|Actual|2009-09-30|||||Observational|||Study of Pain Following Removal of Wisdom Teeth With Acute Pulpitis||Completed|||||Wuhan University|||||f||||t||||||||||2018-05-31 23:38:15.078952|2018-05-31 23:38:15.078952
NCT01153139|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-07-13|2010-06-28|2010-06-29|Estimate|||||||2013-07-13|2013-07-16|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|TheBuS_D||Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression||Completed||Phase 2/Phase 3|32|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 23:38:15.136234|2018-05-31 23:38:15.136234
NCT01153126|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2014-02-27|2010-06-28|2010-06-29|Estimate|||||||2014-02-27|2014-03-03|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Moderating the Negative Impact of Abnormal Screening Mammograms|Moderating the Negative Impact of Abnormal Screening Mammograms|Completed||N/A|130|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 23:38:15.207402|2018-05-31 23:38:15.207402
NCT01153113|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2011-11-30|2010-06-28|2010-06-29|Estimate|||||||2011-11-30|2011-12-02|Estimate|January 2008||2008-01-31|February 2011|2011-02-28|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines|Phase II Study of Active Immunotherapy With Mature, Human Telomerase Reverse Transcriptase Messenger RNA -Transfected, Autologous Dendritic Cells (DC) Administered In A Prime-Boost Format to Subjects With Metastatic Prostate Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of Florida||2||IND has been withdrawn and the study is closed.|f||||f||||||||||2018-05-31 23:38:15.2844|2018-05-31 23:38:15.2844
NCT01153100|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2012-10-02|2010-06-28|2010-06-29|Estimate|||||||2012-10-02|2012-10-03|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy|Effectiveness of a Subcutaneously Administered Long-acting Insulin Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment|Completed||N/A|60|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 23:38:15.364005|2018-05-31 23:38:15.364005
NCT01153074|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2017-05-23|2010-06-28|2010-06-29|Estimate|||||||2017-05-23|2017-05-25|Actual|June 2010||2010-06-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||Bronchoscopic Closure of Bronchopleural Fistulas With Occlutech Figulla ASD N Occluder Device|Bronchoscopic Closure of Bronchopleural Fistulas With Occlutech Figulla ASD N Occluder Device|Completed||N/A|8|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 23:38:15.431232|2018-05-31 23:38:15.431232
NCT01153061|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2013-03-18|2010-06-28|2010-06-29|Estimate|||||||2013-03-18|2013-03-19|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|TEFGoreHelex||Endoscopic Closure of Tracheoesophageal Fistulas With Occluder Device|Endoscopic Closure of Tracheoesophageal Fistulas With a Cardiac Septal Defect Occluder|Terminated||Phase 4|4|Actual|University of Sao Paulo||1||The study was terminated because the rate of prothesis dislocation was too high.|f||||t||||||||||2018-05-31 23:38:15.509667|2018-05-31 23:38:15.509667
NCT01153048|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-27|||2011-07-20|2010-06-28|2010-06-29|Estimate|||||||2011-07-20|2011-07-21|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Trial on an Educative Structured Intervention by Peer Educators to Improve HbA1c of Patients With Type 2 Diabetes in the Sikasso Region in Mali|Randomized Controlled Trial on an Educative Structured Intervention by Peer Educators to Improve HbA1c of Patients With Type 2 Diabetes in the Sikasso Region in Mali|Unknown status|Active, not recruiting|Phase 1|150||Sante Diabete Mali||2|||f||||t||||||||||2018-05-31 23:38:15.580269|2018-05-31 23:38:15.580269
NCT01153035|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2018-01-29|2010-06-28|2010-06-29|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2010||2010-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|ABLATE||Excision Followed by Radiofrequency Ablation for Breast Cancer|ABLATE Registry: Radiofrequency Ablation After Breast Lumpectomy (eRFA) Added To Extend Intraoperative Margins in the Treatment of Breast Cancer|Recruiting||N/A|300|Anticipated|University of Arkansas||1|||f||||||||||||||2018-05-31 23:38:15.660397|2018-05-31 23:38:15.660397
NCT01153022|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|February 2008||2008-02-29|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|JM-HRreflex||Effect of Joint Mobilization on Alpha Motoneuron Reflex Excitability|Effect of Joint Mobilization on Alpha Motoneuron Reflex Excitability in People With Spasticity: Controlled Clinical Trial|Completed||N/A|24|Actual|Universidad Autónoma de Manizales, Colombia|||||f||||f||||||||||2018-05-31 23:38:15.780023|2018-05-31 23:38:15.780023
NCT01153009|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2013-10-25||2013-10-25|2010-06-28|2010-06-29|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder|Completed||Phase 3|614|Actual|Takeda||4|||f||||f||||||||||2018-05-31 23:38:15.903878|2018-05-31 23:38:15.903878
NCT01152996|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2014-04-29|2013-10-08|2014-04-29|2010-06-28|2010-06-29|Estimate|2014-04-29|2014-05-28|Estimate|2013-11-21|2013-12-16|Estimate|2014-04-29|2014-05-28|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study|A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder|Completed||Phase 3|1075|Actual|Takeda||1|||f||||f||||||||||2018-05-31 23:38:17.082621|2018-05-31 23:38:17.082621
NCT01152983|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-27|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Safety and Performance Evaluation of the Rapid Ring Device|Single Center, Open Label, Prospective, Non-comparative, Non-randomized Study to Assess the Safety and Performance of the Rapid Ring Device (Comparative Study to Assess the Pain Reduction)|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|RapiDx Ltd.|||||f||||t||||||||||2018-05-31 23:38:17.494207|2018-05-31 23:38:17.494207
NCT01152970|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2016-08-08|2010-06-28|2010-06-29|Estimate|||||||2016-08-08|2016-08-10|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|FYI||F.Y.I.: Flint Youth Injury Study|Substance Use Among Violently Injured Youth in Urban ER: Services & Outcomes|Completed|||638|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 23:38:17.570795|2018-05-31 23:38:17.570795
NCT01152957|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2013-12-11|2010-06-28|2010-06-29|Estimate|||||||2013-12-11|2013-12-12|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|MHHI||Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors|Miami Healthy Heart Initiative (MHHI) a Randomized Study of Behavioral Risk Factors for Cardiovascular Disease in Latino and Hispanic Patients With Poorly Controlled Diabetes|Completed||N/A|300|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 23:38:17.646187|2018-05-31 23:38:17.646187
NCT01152944|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2012-02-06|2010-06-28|2010-06-29|Estimate|||||||2012-02-06|2012-02-07|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Observational|MoSIS||Mechanisms of Stroke in Intracranial Stenosis|Mechanisms of Stroke in Intracranial Stenosis and Stenting|Terminated|||100|Actual|University of Miami||||"The affiliated study SAMMPRIS (Stenting and Aggressive Medical Management for Preventing~   Recurrent stroke in Intracranial Stenosis) has stopped enrollment."|f||||f||||||||||2018-05-31 23:38:17.733797|2018-05-31 23:38:17.733797
NCT01152931|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2012-05-30|2010-06-28|2010-06-29|Estimate|||||||2012-05-30|2012-05-31|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|AMM||Antioxidant Micronutrients in Malaria|Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial|Completed||Phase 3|10|Actual|University of Lagos, Nigeria||15|||f||||f||||||||||2018-05-31 23:38:17.813801|2018-05-31 23:38:17.813801
NCT01152918|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2017-04-24|2010-06-28|2010-06-29|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2010||2010-09-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluating Methods to Increase HIV Testing, Access to HIV Care, and HIV Prevention Strategies|TLC-Plus: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States|Completed||N/A|299038|Actual|HIV Prevention Trials Network||6|||f||||f||||||||||2018-05-31 23:38:17.934942|2018-05-31 23:38:17.934942
NCT01152905|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|April 2007||2007-04-30|November 2006|2006-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Effect of Nitrous Oxide on Cisatracurium Infusion Demands|Effect of Nitrous Oxide on Cisatracurium Infusion Demands. A Randomized Controlled Trial.|Completed|||70|Actual|Turku University Hospital|||2||f||||f||||||||||2018-05-31 23:38:18.094855|2018-05-31 23:38:18.094855
NCT01152892|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2016-01-25|2010-06-28|2010-06-29|Estimate|||||||2016-01-25|2016-01-26|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|ISAR||Risk Stratification in End Stage Renal Disease (ESRD) - ISAR Study|Risk Stratification in End Stage Renal Disease (ISAR)|Active, not recruiting|||500|Anticipated|Technische Universität München|||||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-05-31 23:38:18.147848|2018-05-31 23:38:18.147848
NCT01152866|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2013-08-04|2010-06-28|2010-06-29|Estimate|||||||2013-08-04|2013-08-06|Estimate|December 2003||2003-12-31|August 2013|2013-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)|An Observational Study Using Subcutaneous Ovidrel (Choriogonadotrophin Alfa) for Induction of Final Follicular Maturation and Early Luteinisation in Women Undergoing Ovarian Stimulation With Recombinant-human Follicle Stimulating Hormone (r-hFSH [Gonal-F®]).|Completed|||3|Actual|EMD Serono|||||f||||||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 23:38:18.287286|2018-05-31 23:38:18.287286
NCT01152853|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-20|||2015-11-17|2010-06-28|2010-06-29|Estimate|||||||2015-11-17|2015-11-20|Estimate|July 2010||2010-07-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|PF299804-AGC||PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer|A Phase II Open Label Trial of PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer After Failure of At Least One Prior Chemotherapy Regimen|Completed||Phase 2|28|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 23:38:18.35442|2018-05-31 23:38:18.35442
NCT01152840|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2015-05-19|2010-06-28|2010-06-29|Estimate|||||||2015-05-19|2015-05-20|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Interventional|ACCRAD001||Study of RAD001 in Adenoid Cystic Carcinoma|Phase II Study of RAD001monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma|Completed||Phase 2|33|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 23:38:18.442421|2018-05-31 23:38:18.442421
NCT01152827|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2015-05-19|2010-06-28|2010-06-29|Estimate|||||||2015-05-19|2015-05-20|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|PheoCarcRAD001||RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid|Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid|Completed||Phase 2|33|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 23:38:18.53895|2018-05-31 23:38:18.53895
NCT01152814|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2015-12-21||2015-12-21|2010-06-28|2010-06-29|Estimate|2015-12-21|2016-01-27|Estimate||||2015-12-21|2016-01-27|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional||Baseline analysis population included all participants who were enrolled and randomized into the study.|Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2010-2011, When Administered to Elderly Subjects|Completed||Phase 2|64|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:38:18.626903|2018-05-31 23:38:18.626903
NCT01152801|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-06-22|2010-06-28|2010-06-29|Estimate|||||||2014-06-22|2014-06-24|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer|A Phase Ib, Multi-center, Open-label Study to Evaluate the Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer Who Are Intolerant of or Who Have Progressed Despite Treatment With VEGF-targeted Therapies|Completed||Phase 1|64|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:38:18.825056|2018-05-31 23:38:18.825056
NCT01152788|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2014-04-22||2015-02-13|2010-06-28|2010-06-29|Estimate|2014-06-24|2014-07-21|Estimate||||2015-02-13|2015-03-02|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|March 2013|Actual|2013-03-31||Interventional|||Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma|A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma|Completed||Phase 2|64|Actual|Canadian Cancer Trials Group||2|||f||||f||||||||||2018-05-31 23:38:19.031671|2018-05-31 23:38:19.031671
NCT01152775|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-04-18|2010-06-28|2010-06-29|Estimate|||||||2012-04-18|2012-04-20|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of the Use of Multimedia to Enhance Patient and Family Understanding|Evaluation of the Use of Multimedia to Enhance Patient and Family Understanding|Unknown status|Enrolling by invitation|N/A|60|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 23:38:19.34402|2018-05-31 23:38:19.34402
NCT01152762|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|September 2007||2007-09-30|June 2010|2010-06-30|July 2010|Anticipated|2010-07-31|July 2008|Actual|2008-07-31||Interventional|||Effectiveness of Standardized Respiratory Physiotherapy in Primary Care|Effectiveness of Standardized Respiratory Physiotherapy in Primary Care in Patients With Mild COPD and Its Economic Assessment|Unknown status|Active, not recruiting|N/A|205|Actual|Jordi Gol i Gurina Foundation||1|||f||||f||||||||||2018-05-31 23:38:19.412968|2018-05-31 23:38:19.412968
NCT01152749|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2012-07-06|2010-06-28|2010-06-29|Estimate|||||||2012-07-06|2012-07-10|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum|Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Gum. A Study in Healthy Smokers.|Completed||N/A|76|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||||2018-05-31 23:38:19.50013|2018-05-31 23:38:19.50013
NCT01152736|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2012-07-06|2010-06-28|2010-06-29|Estimate|||||||2012-07-06|2012-07-10|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetics With a New Oral Nicotine Replacement Product and Nicorette® Gum|Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product and Nicorette® Gum. A Study in Healthy Smokers.|Completed||N/A|19|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 23:38:19.586803|2018-05-31 23:38:19.586803
NCT01152723|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2012-07-06|2010-06-28|2010-06-29|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum|Single-dose Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum. A Study in Healthy Smokers.|Completed||N/A|28|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 23:38:19.689001|2018-05-31 23:38:19.689001
NCT01152710|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|June 2004||2004-06-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|March 2006|Actual|2006-03-31||Interventional|||Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer|Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer|Completed||Phase 2|57|Actual|Institute of Oncology Ljubljana|||||f||||f||||||||||2018-05-31 23:38:19.792331|2018-05-31 23:38:19.792331
NCT01152697|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2013-12-28||2014-12-08|2010-06-28|2010-06-29|Estimate|2014-05-19|2014-06-04|Estimate||||2014-12-08|2014-12-30|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|CAE-L||Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic|A Prospective Trial of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAE-L) in Individuals With Schizophrenia or Schizoaffective Disorder at Risk for Treatment Non-adherence and for Homelessness|Completed||N/A|30|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-05-31 23:38:19.902094|2018-05-31 23:38:19.902094
NCT01152684|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-03-14|2010-06-28|2010-06-29|Estimate|||||||2012-03-14|2012-03-15|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border|Complementary & Alternative Care Behavior in HIV+ Latinos in the US-Mexico Border|Unknown status|Recruiting||260|Anticipated|University of California, San Diego|||1||f||||t||||||||||2018-05-31 23:38:20.270738|2018-05-31 23:38:20.270738
NCT01152671|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2016-11-01|2010-06-28|2010-06-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|August 2010||2010-08-31|||||Interventional|||A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers|A Multiple Center Randomized, Double-Blind, Single-Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics Following Oral Administration of RO5024048 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|97|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:38:20.369188|2018-05-31 23:38:20.369188
NCT01152658|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-01-28|2010-06-28|2010-06-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|PrgfRC001IL||Partial Tear of Supraspinatus (SSP) and Treatment With Plasma Rich in Growth Factors (PRGF)|Double Blind Prospective Randomize Trail of Partial Tear of SSP and Treatment With PRGF|Withdrawn||Phase 1|0|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 23:38:20.439997|2018-05-31 23:38:20.439997
NCT01152645|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2017-03-14|2010-06-27|2010-06-29|Estimate|||||||2017-03-14|2017-03-15|Actual|June 2010||2010-06-30|March 2017|2017-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ARQ 197-004||Study of ARQ 197 Monotherapy|Phase II Study of ARQ 197 Monotherapy for Previously Treated Advanced/Recurrent Gastric Cancer|Completed||Phase 2|31|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-05-31 23:38:20.518207|2018-05-31 23:38:20.518207
NCT01152632|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-27|||2014-11-25|2010-06-28|2010-06-29|Estimate|||||||2014-11-25|2014-12-02|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Acupuncture for Migraine: a Functional Magnetic Resonance Imaging (fMRI) Study|Acupuncture Treatment for Migraine: a Functional Magnetic Resonance Imaging Study|Completed||N/A|100|Actual|Chengdu University of Traditional Chinese Medicine||5|||f||||t||||||||||2018-05-31 23:38:20.648616|2018-05-31 23:38:20.648616
NCT01152619|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2016-11-01|2010-06-28|2010-06-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of RO4989991 in Patients With Allergic Rhinitis|A Multi-center, Randomized, Observer-blind, Placebo-controlled Safety and Tolerability Study of Repeated Administration of Two Dose Levels of RO4989991 Administered Subcutaneously to Patients With Allergic Rhinitis|Completed||Phase 1|24|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:38:20.741207|2018-05-31 23:38:20.741207
NCT01152606|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2018-01-23|2010-06-28|2010-06-29|Estimate|||||||2018-01-23|2018-01-25|Actual|August 30, 2007|Actual|2007-08-30|January 2018|2018-01-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Observational|||A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin|An Observational Study of Cardiac Events in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin|Completed|||3942|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:38:20.880982|2018-05-31 23:38:20.880982
NCT01152593|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Effect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections||Unknown status|Not yet recruiting|N/A|400|Anticipated|Hillel Yaffe Medical Center||1|||f||||||||||||||2018-05-31 23:38:21.231086|2018-05-31 23:38:21.231086
NCT01152580|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2012-01-04||2012-03-09|2010-06-28|2010-06-29|Estimate|2012-02-08|2012-03-12|Estimate||||2012-03-09|2012-03-13|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MOPS||Melatonin Osteoporosis Prevention Study|Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women|Completed||Phase 1|19|Actual|Duquesne University|Limitations to this study include small sample sizes, length of follow-up, and heterogeneity in terms of stage of perimenopause and prevalence of menopausal symptoms.|2|||f||||f||||||||||2018-05-31 23:38:21.296309|2018-05-31 23:38:21.296309
NCT01152567|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2011-09-26|2010-06-28|2010-06-29|Estimate|||||||2011-09-26|2011-09-27|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|ARBACE||Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension|Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension|Completed|||50000|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:38:21.862717|2018-05-31 23:38:21.862717
NCT01152554|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2012-06-26||2014-03-14|2010-06-28|2010-06-29|Estimate|2012-09-27|2012-10-29|Estimate||||2014-03-14|2014-04-11|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy|Completed||Phase 3|813|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:38:22.104136|2018-05-31 23:38:22.104136
NCT01152541|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2018-01-23|2010-06-28|2010-06-29|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2010||2010-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin|Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin|Active, not recruiting||Phase 3|160|Anticipated|Cornea and Laser Eye Institute||2|||f||||f||||||||||2018-05-31 23:38:22.864097|2018-05-31 23:38:22.864097
NCT01152346|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-01-27|2010-06-28|2010-06-29|Estimate|||||||2015-01-27|2015-01-28|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients|A Multi-Center Relative Bioavailability Study of Azacitidine 75 mg/m2 Subcutaneous Injection In Myelodysplastic Syndrome Patients Under Fasting Conditions|Completed||Phase 1|19|Actual|Bioniche Pharma USA LLC||2|||f||||f||||||||||2018-05-31 23:38:28.157671|2018-05-31 23:38:28.157671
NCT01152528|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery|VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY.|Unknown status|Not yet recruiting|Phase 3|248|Anticipated|Common Sense|||||f||||t||||||||||2018-05-31 23:38:22.945768|2018-05-31 23:38:22.945768
NCT01152515|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2011-03-10|2010-06-28|2010-06-29|Estimate|||||||2011-03-10|2011-03-11|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients|A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients|Completed||Phase 4|50|Anticipated|Severance Hospital||2|||f||||||||||||||2018-05-31 23:38:23.016166|2018-05-31 23:38:23.016166
NCT01152502|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|September 2008|Actual|2008-09-30||Observational|||Paracetamol Metabolism in Post Operative Conditions|Paracetamol Metabolism in Post Operative Conditions|Completed|||30|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:38:23.127088|2018-05-31 23:38:23.127088
NCT01152489|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-26|||2011-06-21|2010-06-26|2010-06-29|Estimate|||||||2011-06-21|2011-06-22|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Test of the Effectiveness of a Device and Distraction for Pediatric Immunization Pain|Phase II Study of the Effectiveness of a Device and Distraction for Pediatric Immunization Pain in Multiple Age Groups|Completed||Phase 2/Phase 3|345|Anticipated|MMJ Labs LLC||3|||f||||f||||||||||2018-05-31 23:38:23.198818|2018-05-31 23:38:23.198818
NCT01152476|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2011-01-05|2010-06-28|2010-06-29|Estimate|||||||2011-01-05|2011-01-06|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Emergency Agitation in T&A||Completed||N/A|42|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 23:38:23.268214|2018-05-31 23:38:23.268214
NCT01152463|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-06-20|2010-06-28|2010-06-29|Estimate|||||||2012-06-20|2012-06-22|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Sonography After Thoracic Surgery (SATS)|Sonography After Thoracic Surgery - SATS (CT0011)|Completed|||120|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 23:38:23.401896|2018-05-31 23:38:23.401896
NCT01152450|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2012-08-17||2014-05-07|2010-06-28|2010-06-29|Estimate|2012-09-27|2012-10-30|Estimate||||2014-05-07|2014-05-16|Estimate|July 2010||2010-07-31|February 2013|2013-02-28||||August 2011|Actual|2011-08-31||Interventional|||A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma|A Phase II, Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Administered Once Daily (in the Evening) and Tiotropium 2.5 µg Administered Twice Daily Delivered by the Respimat® Inhaler for Four Weeks Versus Placebo in Patients With Moderate Persistent Asthma|Completed||Phase 2|94|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:38:23.508623|2018-05-31 23:38:23.508623
NCT01152437|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|2013-08-08||2014-05-27|2010-06-28|2010-06-29|Estimate|2013-10-29|2013-11-21|Estimate||||2014-05-27|2014-06-26|Estimate|June 2010||2010-06-30|May 2014|2014-05-31||||March 2012|Actual|2012-03-31||Interventional||Treated set.|A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer|An Open Label, Partially Randomised Phase II Study to Investigate the Efficacy and Safety of BIBW 2992 in Patients With Metastatic Colorectal Cancer Who Never Received Prior Anti-EGFR (Epidermal Growth Factor Receptor) Treatment|Completed||Phase 2|94|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:38:25.829868|2018-05-31 23:38:25.829868
NCT01152424|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2011-06-07|2010-06-28|2010-06-29|Estimate|||||||2011-06-07|2011-06-08|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|April 2011|Actual|2011-04-30||Observational|||Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia|Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Community Acquired Pneumonia|Unknown status|Active, not recruiting||50|Anticipated|Seoul National University Bundang Hospital|||2||f||||f||||||||||2018-05-31 23:38:26.816107|2018-05-31 23:38:26.816107
NCT01152411|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-26|||2012-03-28|2010-06-28|2010-06-29|Estimate|||||||2012-03-28|2012-03-29|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Chronic Renal Failure|Use of Autologous Bone Marrow Stem Cell Transplantation in the Treatment of Chronic Renal Failure in 5 Indian Patients - ABMST-CRF Study (Autologous Bone Marrow Stem Cell Transplantation-CRF)|Unknown status|Active, not recruiting|Phase 1/Phase 2|5|Anticipated|International Stemcell Services Limited||1|||f||||t||||||||||2018-05-31 23:38:26.877824|2018-05-31 23:38:26.877824
NCT01152398|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2013-05-06|2010-06-28|2010-06-29|Estimate|||||||2013-05-06|2013-05-08|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy|A Phase I Safety and Immunogenicity Trial of MVA-BN®-HER2 Vaccine in HER-2-Positive Breast Cancer Patients Following Adjuvant Therapy|Completed||Phase 1|15|Actual|Bavarian Nordic, Inc.||1|||f||||f||||||||||2018-05-31 23:38:26.957678|2018-05-31 23:38:26.957678
NCT01152385|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2012-07-24||2012-07-24|2010-06-26|2010-06-29|Estimate|2012-07-24|2012-08-27|Estimate||||2012-07-24|2012-08-27|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients|A 4-month Treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients|Completed||Phase 2|224|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:38:27.074108|2018-05-31 23:38:27.074108
NCT01152372|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-02-22|2010-06-28|2010-06-29|Estimate|||||||2011-02-22|2011-02-23|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Experimental Study to Validate the Modified Glucose Disposal Test|Experimental Medicine Study to Validate the Modified Glucose Disposal Test in Healthy Subjects and Subjects With Type 2 Diabetes|Completed||Phase 1|36|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 23:38:27.687087|2018-05-31 23:38:27.687087
NCT01152359|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2014-10-17||2015-04-06|2010-06-25|2010-06-29|Estimate|2014-10-17|2014-10-22|Estimate||||2015-04-06|2015-04-28|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|DietChoice||Considering Patient Diet Preferences to Optimize Weight Loss|Considering Patient Diet Preference to Optimize Weight Loss|Completed||N/A|207|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:38:27.771266|2018-05-31 23:38:27.771266
NCT01152320|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Trial of Spirometry Fundamentals™ in the Primary Care Setting|Randomized Controlled Trial of Spirometry Fundamentals™ in the Primary Care Setting|Completed||N/A|52|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:38:28.365048|2018-05-31 23:38:28.365048
NCT01152307|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2012-06-12||2012-07-13|2010-06-25|2010-06-29|Estimate|2012-07-13|2012-08-20|Estimate||||2012-07-13|2012-08-20|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Measuring Quality of Decisions About Treatment of Depression|Measuring Quality of Decisions About Treatment of Depression|Completed||N/A|405|Actual|University of Massachusetts, Boston|Those who answered fewer than half of the knowledge questions do not have a total knowledge score (primary outcome).|2|||f||||f||||||||||2018-05-31 23:38:28.516988|2018-05-31 23:38:28.516988
NCT01152294|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2012-06-12||2012-07-13|2010-06-25|2010-06-29|Estimate|2012-07-13|2012-08-20|Estimate||||2012-07-13|2012-08-20|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Measuring Quality of Decisions About Treatment of Menopausal Symptoms|Measuring Quality of Decisions About Treatment of Menopausal Symptoms|Completed||N/A|401|Actual|University of Massachusetts, Boston|Participants who answered less than half the knowledge questions do not have a total knowledge score (primary outcome).|2|||f||||f||||||||||2018-05-31 23:38:28.794768|2018-05-31 23:38:28.794768
NCT01152281|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2018-01-12|2010-06-28|2010-06-29|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2010||2010-05-31|June 2010|2010-06-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Selective Exposure in HIV Prevention|Study to Test Meta-intervention to Increase Retention in HIV Prevention Counseling|Completed||Phase 2|722|Actual|University of Illinois at Urbana-Champaign||5|||f||||t||||||||||2018-05-31 23:38:29.129576|2018-05-31 23:38:29.129576
NCT01152268|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-03-06|2010-06-28|2010-06-29|Estimate|||||||2015-03-06|2015-03-10|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool|Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool|Completed|||282|Actual|St. Jude Children's Research Hospital|||1||f||||t||||||||||2018-05-31 23:38:29.2473|2018-05-31 23:38:29.2473
NCT01152255|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-10-16|2010-06-28|2010-06-29|Estimate|||||||2015-10-16|2015-10-19|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK6186 in HIV-1 Infected Patients|Terminated||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 23:38:29.339196|2018-05-31 23:38:29.339196
NCT01152242|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-07-22|2010-06-25|2010-06-29|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)|A Two-Part Clinical Trial to Assess Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 23:38:29.430621|2018-05-31 23:38:29.430621
NCT01152229|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2011-08-01|2010-06-25|2010-06-29|Estimate|||||||2011-08-01|2011-08-03|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|PLACID||Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine|Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine|Completed|||300|Anticipated|Medstar Health Research Institute|||3||f||||f||||||||||2018-05-31 23:38:29.503408|2018-05-31 23:38:29.503408
NCT01152216|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25||2016-09-26|2016-09-26|2010-06-28|2010-06-29|Estimate||||2016-09-26|2016-09-27|Estimate|2016-09-26|2016-09-27|Estimate|April 2010||2010-04-30|September 2016|2016-09-30||||May 2012|Actual|2012-05-31||Interventional|CONCERT PLUS||An Extension of the CONCERT Protocol (DIM18)|An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease|Terminated||Phase 3|672|Actual|Medivation, Inc.||1|||f||||||||||||||2018-05-31 23:38:29.581083|2018-05-31 23:38:29.581083
NCT01152203|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-11-16|2010-06-25|2010-06-29|Estimate|||||||2015-11-16|2015-11-18|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Bendamustine and Bevacizumab for Advanced Cancers|A Phase I Study of Bendamustine and Bevacizumab for Patients With Advanced Cancers|Completed||Phase 1|59|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:38:29.679314|2018-05-31 23:38:29.679314
NCT01152190|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|2013-03-27||2013-03-27|2010-06-25|2010-06-29|Estimate|2013-03-27|2013-05-20|Estimate||||2013-03-27|2013-05-20|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||The Primary Analysis Population was defined as all randomized participants who received at least 1 dose of study medication.|A Study in Benign Prostatic Hyperplasia|A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|97|Actual|Eli Lilly and Company|The primary and secondary efficacy analyses of resistive index (RI) and color pixel intensity (CPI) were based on centrally-read data.|2|||f||||f||||||||||2018-05-31 23:38:29.795304|2018-05-31 23:38:29.795304
NCT01152177|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-07-29|2010-06-28|2010-06-29|Estimate|||||||2014-07-29|2014-07-30|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|POCIP||Point Of Care Testing In Danish General Practice - Part II|Point-Of-Care Testing In Danish General Practice: A Randomised Controlled Trial - Part II|Completed||N/A|286|Actual|Research Unit Of General Practice, Copenhagen||2|||f||||f||||||||||2018-05-31 23:38:30.609431|2018-05-31 23:38:30.609431
NCT01152164|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-03-23|2010-06-28|2010-06-29|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Quality of Life in Patients After Combined Modality Treatment of Rectal Cancer|Quality of Life in Patients After Combined Modality Treatment of Rectal Cancer|Unknown status|Active, not recruiting||167|Actual|Institute of Oncology Ljubljana|||1||f||||f||||||||||2018-05-31 23:38:30.703286|2018-05-31 23:38:30.703286
NCT01152151|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2014-07-29|2010-06-28|2010-06-29|Estimate|||||||2014-07-29|2014-07-30|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|POCIP||Point Of Care Testing In Danish General Practice|Point-Of-Care Testing In Danish General Practice: A Randomised Controlled Trial|Completed||N/A|213|Actual|Research Unit Of General Practice, Copenhagen||2|||f||||f||||||||||2018-05-31 23:38:30.802356|2018-05-31 23:38:30.802356
NCT01152138|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-05-16|2010-06-28|2010-06-29|Estimate|||||||2012-05-16|2012-05-17|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|COCHISE||Closed Versus Open Cells Stent for Acute Myocardial Infarction|COCHISE Pilot Study: Closed vs Open Cells Stent for High Risk Percutaneous Coronary Interventions in ST Elevation Acute Myocardial Infarction|Completed||N/A|223|Actual|Policlinico Casilino ASL RMB||2|||f||||f||||||||||2018-05-31 23:38:30.866479|2018-05-31 23:38:30.866479
NCT01152125|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2011-06-08|2010-06-25|2010-06-29|Estimate|||||||2011-06-08|2011-06-09|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|January 2012|Anticipated|2012-01-31|August 2011|Anticipated|2011-08-31||Interventional|||Safety and Efficacy of Autologous Bone Marrow Stem Cells for Treating Osteoarthritis|Use of Autologous Bone Marrow Stem Cell Transplantation for Therapeutic Chondrogenesis in Moderate to Severe Osteoarthritis - ABM & LAM ST-OA Study|Unknown status|Enrolling by invitation|Phase 1/Phase 2|10|Anticipated|International Stemcell Services Limited||1|||f||||t||||||||||2018-05-31 23:38:30.954872|2018-05-31 23:38:30.954872
NCT01152112|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|2014-09-10||2017-08-09|2010-06-25|2010-06-29|Estimate|2017-08-09|2017-09-13|Actual||||2017-08-09|2017-09-13|Actual|June 2010||2010-06-30|August 2017|2017-08-31|June 2013|Actual|2013-06-30|January 2012|Actual|2012-01-31||Interventional|HOME||HOME Study: Hysteroscopic Office Myomectomy Evaluation|A Hysteroscopic Office Myomectomy Evaluation Using the MyoSure Tissue Removal System for the Removal of Uterine Fibroids and Polyps in the Treatment of Abnormal Uterine Bleeding (AUB)|Completed||N/A|74|Actual|Hologic, Inc.||2|||f||||f||||||||Yes|The Journal of Minimally Invasive Gynecology|2018-05-31 23:38:31.140823|2018-05-31 23:38:31.140823
NCT01152099|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2018-02-26|2010-06-28|2010-06-29|Estimate|||||||2018-02-26|2018-02-27|Actual|September 11, 2007|Actual|2007-09-11|February 2018|2018-02-28|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||A Clinical Trial About the Contribution of Manual Lymph Drainage in Complex Physical Therapy for Patients With Lymphoedema Secondary to Mastectomy|A Randomized, Controlled Clinical Trial About the Contribution of Manual Lymph Drainage in Complex Physical Therapy for Patients With Lymphoedema Secondary to Mastectomy|Completed||N/A|39|Actual|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||2|||f||||f||||||||||2018-05-31 23:38:31.464183|2018-05-31 23:38:31.464183
NCT01152086|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2011-09-22|2010-06-28|2010-06-29|Estimate|||||||2011-09-22|2011-09-23|Estimate|July 2010||2010-07-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MOHS2010||The Effects of Regular Mountain Hiking on Hopelessness in Chronically Suicidal Patients||Completed||Phase 4|24|Anticipated|Paracelsus Medical University||2|||f||||f||||||||||2018-05-31 23:38:31.585333|2018-05-31 23:38:31.585333
NCT01152073|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-03-15|2010-06-28|2010-06-29|Estimate|||||||2012-03-15|2012-03-16|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)|A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)|Completed||N/A|79|Actual|Healthy Drink Discoveries, Inc.||3|||f||||t||||||||||2018-05-31 23:38:31.701034|2018-05-31 23:38:31.701034
NCT01152060|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-28|2010-06-28|2010-06-29|Estimate|||||||2010-06-28|2010-06-29|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|||Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial|an Open Parallel Clinical Trial in HBV-GN Patients|Unknown status|Active, not recruiting||10|Anticipated|Nanchang University|||2||f||||f||||||Samples Without DNA|"~     not available~   "|||2018-05-31 23:38:31.854334|2018-05-31 23:38:31.854334
NCT01152047|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-04-06|2010-06-28|2010-06-29|Estimate|||||||2015-04-06|2015-04-07|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||The Effect of Oxytocin on Gastric Emptying|The Effect of Oxytocin on Satiety in Patients With Dyspepsia|Completed||N/A|14|Actual|Skane University Hospital||1|||f||||f||||||||||2018-05-31 23:38:31.988729|2018-05-31 23:38:31.988729
NCT01152034|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-04-07|2010-06-28|2010-06-29|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional|||MAPS Group Therapy Model for Bipolar Disorder|Effect of Psychoeducational Group Therapy Model for Bipolar Disorder Patients|Completed||N/A|68|Actual|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 23:38:32.144034|2018-05-31 23:38:32.144034
NCT01152021|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-07-17|2010-06-25|2010-06-29|Estimate|||||||2014-07-17|2014-07-18|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparing Safety and Efficacy of Dexmedetomidine and Propofol|Comparing Safety and Efficacy of Dexmedetomidine and Propofol in Patients Requiring Sedation for MRI Scanning|Terminated||Phase 3|15|Actual|Boston Children’s Hospital||2||Publication of a similar study. Not ethical to continue.|f||||t||||||||||2018-05-31 23:38:32.29149|2018-05-31 23:38:32.29149
NCT01152008|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-10-30|2010-06-28|2010-06-29|Estimate|||||||2017-10-30|2017-11-01|Actual|June 2010||2010-06-30|July 2010|2010-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|Speckle-move||Use of Laser Speckle to Study Cutaneous Blood Flow at Exercise in Healthy Subjects|Evaluation Chez Des Sujets Sains d'Une Nouvelle Technique d'étude de la Microcirculation cutanée|Completed|||30|Actual|University Hospital, Angers|||1||f||||f||||||||||2018-05-31 23:38:32.477328|2018-05-31 23:38:32.477328
NCT01151995|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2012-12-17|2010-06-28|2010-06-29|Estimate|||||||2012-12-17|2012-12-18|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Observational|||Effectiveness and Costs of Remote Monitoring for Clinical Trials|Effectiveness and Costs of Remote Monitoring for Clinical Trials|Completed|||20|Anticipated|University of Colorado, Denver|||2||f||||f|||||||"~     No biospecimens collected for this protocol~   "|||2018-05-31 23:38:32.606111|2018-05-31 23:38:32.606111
NCT01151982|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-11-17|2010-06-28|2010-06-29|Estimate|||||||2014-11-17|2014-11-19|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|predictD-CCRT||Primary Prevention of Major Depression Based on the Level and Profile of Risk of Primary Care Attenders: Cluster, Controlled, Randomised Trial|Primary Prevention of Major Depression Based on the Level and Profile of Risk of Primary Care Attenders: Cluster, Controlled, Randomised Trial|Completed||N/A|3326|Actual|The Mediterranean Institute for the Advance of Biotechnology and Health Research||2|||f||||f||||||||||2018-05-31 23:38:32.753412|2018-05-31 23:38:32.753412
NCT01151969|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2015-03-26|2010-06-28|2010-06-29|Estimate|||||||2015-03-26|2015-03-27|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|"7H"||"Effectiveness of the 7H Intervention to Reduce Frequent Attendance in Primary Care"|"Effectiveness of the 7H Intervention to Reduce Frequent Attendance in Primary Care: Cluster Randomised Controlled Trial. The 7H Study"|Completed||N/A|527|Actual|The Mediterranean Institute for the Advance of Biotechnology and Health Research||2|||f||||f||||||||||2018-05-31 23:38:32.872493|2018-05-31 23:38:32.872493
NCT01151956|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2010-06-30|2010-06-28|2010-06-29|Estimate|||||||2010-06-30|2010-07-01|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|May 2009|Actual|2009-05-31|||||Observational|||Imiquimod and Actinic Keratoses: an Observational Study|Actinic Keratoses and 5% Topical Imiquimod: Lessons to Learn From a Prospective Non-Interventional Study by 93 Office-based Dermatologists|Completed|||463|Actual|Federal University Teaching Hospital, Feldkirch, Austria|||1||f||||t||||||||||2018-05-31 23:38:32.971604|2018-05-31 23:38:32.971604
NCT01151943|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2016-11-02|2010-06-28|2010-06-29|Estimate|||||||2016-11-02|2016-11-03|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Cesar-Dol||Comparison of Two Types of Pain Relief After Cesarean Delivery|Comparison of Two Methods of Pain Relief After Cesarean Delivery: Transversus Abdominis Plane (TAP) Block Versus Incisional Infiltration With Local Anesthetic|Terminated||Phase 4|77|Actual|Hopital Foch||2||"The study has been halted prematurely beacuse of the occurence of convulsions in one case after~   TAP block."|f||||f||||||||||2018-05-31 23:38:33.085364|2018-05-31 23:38:33.085364
NCT01151930|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2017-10-18|2010-06-28|2010-06-29|Estimate|||||||2017-10-18|2017-10-19|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Long-Term Compassionate Use Study for Continued Administration of SCB01A-01|Long-Term Compassionate Use Study for Continued Administration of SCB01A In Subjects Who Completed Treatment With SCB01A in the Previous Protocol # SCB01A-01|Available|||||SynCore Biotechnology Co., Ltd.|||||||||||||||||||2018-05-31 23:38:33.204664|2018-05-31 23:38:33.204664
NCT01151917|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2014-01-29|2010-06-28|2010-06-29|Estimate|||||||2014-01-29|2014-01-30|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Observational|PROTOBESE||Proteomics in Morbid Obesity After Bariatric Surgery|Identification of a Novel Factor(s) of Importance to Insulin Resistance -Repeated Blood Sampling Before and After Biliopancreatic Diversion|Completed|||20|Actual|Catholic University of the Sacred Heart|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma samples at fasting and after a meal~   "|||2018-05-31 23:38:33.279822|2018-05-31 23:38:33.279822
NCT01151904|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-05|2013-01-03||2013-01-03|2010-06-28|2010-06-29|Estimate|2013-01-03|2013-02-06|Estimate||||2013-01-03|2013-02-06|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients||Terminated||Phase 4|17|Actual|Allergan|Due to lack of enrollment, this study was discontinued early and the outcome measures were not analyzed.|1||Difficulty with patient recruitment|f||||f||||||||||2018-05-31 23:38:33.374554|2018-05-31 23:38:33.374554
NCT01151891|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2011-01-11|2010-06-28|2010-06-29|Estimate|||||||2011-01-11|2011-01-12|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Natural History of Pedal Puncture Wounds in Diabetics|The Natural History of Pedal Puncture Wounds in Diabetics: a Cross-sectional Survey in the Parish of St. James, Jamaica.|Completed|||188|Anticipated|Cornwall Regional Hospital|||1||f||||f||||||||||2018-05-31 23:38:33.568598|2018-05-31 23:38:33.568598
NCT01151878|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-02-22|2010-06-28|2010-06-29|Estimate|||||||2017-02-22|2017-02-24|Actual|April 2009||2009-04-30|February 2017|2017-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Glucomannan for Childhood Functional Constipation.|Glucomannan in Treating Childhood Functional Constipation: a Randomized, Double-blind, Placebo-controlled Trial.|Completed||Phase 3|92|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 23:38:33.682874|2018-05-31 23:38:33.682874
NCT01151865|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2015-01-18|2010-06-28|2010-06-29|Estimate|||||||2015-01-18|2015-01-21|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DahLIA||Dexmedetomidine to Lessen Intensive Care Unit (ICU) Agitation|A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit|Completed||Phase 2/Phase 3|96|Actual|Austin Health||2|||f||||t||||||||||2018-05-31 23:38:33.79451|2018-05-31 23:38:33.79451
NCT01151852|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2013-11-19||2015-06-30|2010-06-28|2010-06-29|Estimate|2015-06-30|2015-07-28|Estimate||||2015-06-30|2015-07-28|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|RIGHT|Our analysis was based on intention-to treat population. So, all enrolled patients were analyzed.|Rechallenge of Imatinib in GIST Having no Effective Treatment|A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib|Completed||Phase 3|81|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:38:33.933239|2018-05-31 23:38:33.933239
NCT01151839|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-07-08|2010-06-28|2010-06-29|Estimate|||||||2010-07-08|2010-07-12|Estimate|June 2010||2010-06-30|June 2010|2010-06-30||||July 2012|Anticipated|2012-07-31||Interventional|||A Trial to Compare Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus|Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus - A Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||||||||||||2018-05-31 23:38:34.326775|2018-05-31 23:38:34.326775
NCT01151826|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2011-03-01|2010-06-25|2010-06-28|Estimate|||||||2011-03-01|2011-03-02|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Quantifying Physical and Biochemical Factors That Contribute to Primary Graft Dysfunction After Lung Transplantation|Measurement of Physical and Biochemical Markers of Reperfusion Edema During Primary Graft Dysfunction Following Lung Transplantation. Assessment of Their Diagnosis and Prognosis Values|Unknown status|Recruiting||45|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 23:38:34.452295|2018-05-31 23:38:34.452295
NCT01151813|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-04-02|2010-06-25|2010-06-28|Estimate|||||||2014-04-02|2014-04-03|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Human Behavioral Pharmacology Laboratory (HBPL) Study of Varenicline's Impact on Cocaine and Alcohol Craving||Completed||Phase 2|14|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:38:34.546046|2018-05-31 23:38:34.546046
NCT01151800|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-06-25|2010-06-25|2010-06-28|Estimate|||||||2010-06-25|2010-06-28|Estimate|January 2006||2006-01-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Using Automated Calls To Improve Compliance With Acute Coronary Syndrome Best Practice Guidelines|Using Interactive Voice Response To Improve Disease Management and Compliance With Acute Coronary Syndrome Best Practice Guidelines|Completed||N/A|1608|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 23:38:34.763162|2018-05-31 23:38:34.763162
NCT01151787|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-07-24|2010-06-25|2010-06-28|Estimate|||||||2014-07-24|2014-07-25|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine|Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial|Terminated||Phase 3|35|Actual|Kennedy Medical Group||2||"Study was never initiated under new location/provider group. Contract to continue was never~   signed between TEVA and Kennedy Headache Center"|f||||t||||||||||2018-05-31 23:38:34.841708|2018-05-31 23:38:34.841708
NCT01151774|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2016-02-01|2010-06-25|2010-06-28|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2010||2010-05-31|February 2016|2016-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Validation of Transesophageal Echocardiography (TEE) to Measure Renal Resistive Index and to Predict Renal Injury|Validation of Transesophageal Echocardiography With to Measure Renal Resistive Index and to Predict Acute Kidney Injury|Withdrawn|||0|Actual|Rutgers, The State University of New Jersey||||study entered twice, please see protocol 0120110047|f||||f||||||||No||2018-05-31 23:38:34.942932|2018-05-31 23:38:34.942932
NCT01151761|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2013-07-03||2016-06-30|2010-06-25|2010-06-28|Estimate|2016-04-20|2016-05-26|Estimate||||2016-06-30|2016-07-29|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation|Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation|Terminated||Phase 2|2|Actual|Stanford University|Early termination due to low accrual.|1||Poor accrual|f||||t||||||||||2018-05-31 23:38:35.064151|2018-05-31 23:38:35.064151
NCT01151748|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-05-10|2010-06-25|2010-06-28|Estimate|||||||2012-05-10|2012-05-14|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|March 2012|Anticipated|2012-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma|Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma|Withdrawn||Phase 2|0|Actual|Stanford University||||Study abandoned; Could not obtain final SRC approval due to IND disagreements|f||||||||||||||2018-05-31 23:38:35.429992|2018-05-31 23:38:35.429992
NCT01151735|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-11-29|2010-06-25|2010-06-28|Estimate|||||||2012-11-29|2012-11-30|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation|Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Determine the Efficacy of 1000u, and 1500u of C1-INH Compared to Placebo at the Time of Prodromal Symptoms in Preventing an Acute HAE Exacerbation.|Withdrawn||Phase 4|0|Actual|Penn State University||3||PennState would not allow the study to move forward|f||||f||||||||||2018-05-31 23:38:35.529693|2018-05-31 23:38:35.529693
NCT01151722|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-06-25|2010-06-25|2010-06-28|Estimate|||||||2010-06-25|2010-06-28|Estimate|December 2009||2009-12-31|February 2010|2010-02-28||||December 2010|Anticipated|2010-12-31||Interventional|ABeVi||Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage|Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage|Unknown status|Recruiting|Phase 2|2|Anticipated|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 23:38:35.634498|2018-05-31 23:38:35.634498
NCT01151709|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2012-03-05|2010-06-25|2010-06-28|Estimate|||||||2012-03-05|2012-03-07|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management|Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management|Completed|||838|Actual|University of Massachusetts, Worcester|||1||f||||f||||||||||2018-05-31 23:38:35.76067|2018-05-31 23:38:35.76067
NCT01151696|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2014-07-22|2010-06-25|2010-06-28|Estimate|||||||2014-07-22|2014-07-23|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Pain and Anxiety Management of Traumatic Emergency in a Pre-hospital Setting|Prise en Charge Pharmacologique de l'anxiété et de la Douleur Chez Les Patients Qui Souffrent en Situation d'Urgence Traumatique pré-hospitalière : étude randomisée contrôlée en Double Aveugle|Completed||Phase 4|140|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 23:38:35.855989|2018-05-31 23:38:35.855989
NCT01151683|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2013-01-04|2010-06-25|2010-06-28|Estimate|||||||2013-01-04|2013-01-07|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|MG600||Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients|Effects of Magnesium Supplementation on Vascular Structure and Function in Hypertensive Patients|Completed||Phase 4|52|Actual|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 23:38:35.953439|2018-05-31 23:38:35.953439
NCT01151670|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2017-05-25|2010-06-25|2010-06-28|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2010||2010-08-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors|Use of Pioglitazone for the Prevention of Radiation-Induced Cognitive Dysfunction|Completed||Phase 1|18|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||||2018-05-31 23:38:36.058733|2018-05-31 23:38:36.058733
NCT01151657|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2011-10-24|2010-06-25|2010-06-28|Estimate|||||||2011-10-24|2011-10-25|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Probiotics for Irritable Bowel Syndrome|Probiotics for Irritable Bowel Syndrome|Completed||N/A|150|Anticipated|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 23:38:36.152544|2018-05-31 23:38:36.152544
NCT01151644|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-06-25|2010-06-25|2010-06-28|Estimate|||||||2010-06-25|2010-06-28|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases|Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases|Unknown status|Active, not recruiting|Phase 4|5000|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:38:36.264445|2018-05-31 23:38:36.264445
NCT01151631|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2018-04-26|2010-06-25|2010-06-28|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2010||2010-10-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|ICON||Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache|Occipital Nerve Stimulation in Medically Intractable Chronic Cluster Headache|Active, not recruiting||Phase 3|144|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 23:38:36.349199|2018-05-31 23:38:36.349199
NCT01151618|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-12-28|2010-06-25|2010-06-28|Estimate|||||||2010-12-28|2010-12-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:38:36.463722|2018-05-31 23:38:36.463722
NCT01151605|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-12-17|2010-06-25|2010-06-28|Estimate|||||||2012-12-17|2012-12-18|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||The Suppression of Toll Like Receptors by Insulin|The Suppression of Toll Like Receptors by Insulin|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Kaleida Health||3|||f||||f||||||||||2018-05-31 23:38:36.506464|2018-05-31 23:38:36.506464
NCT01151241|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2015-02-20|2010-06-25|2010-06-28|Estimate|||||||2015-02-20|2015-02-24|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Early Discharge in Patients Undergoing Elbow Arthroscopy|Outpatient Versus Inpatient Continuous Brachial Plexus Block for Complex Arthroscopic Elbow Surgery: Safety and Functional Outcome|Completed||N/A|40|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:38:43.819745|2018-05-31 23:38:43.819745
NCT01151592|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2018-01-22|2010-06-25|2010-06-28|Estimate|||||||2018-01-22|2018-01-24|Actual||||January 2018|2018-01-31||||||||Interventional|ASSURED||Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)|Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)|Withdrawn||Phase 4|0|Actual|Luitpold Pharmaceuticals||||Sponsor Decision|f||||f||||||||||2018-05-31 23:38:36.614206|2018-05-31 23:38:36.614206
NCT01151579|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2015-03-12||2015-09-23|2010-06-25|2010-06-28|Estimate|2015-09-23|2015-10-23|Estimate||||2015-09-23|2015-10-23|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||The number analyzed was determined by the power calculation and based on the number of participants randomized to treatment.|Effect of Nebulized Bronchodilators on Heart Rate|Prospective Trial of Effect of Nebulized Bronchodilators on Heart Rate and Arrhythmias in Critically Ill Adult Patients|Completed||Phase 4|89|Actual|Genesys Regional Medical Center|Potential limitations are its single-center site and that the design may not have adequately eliminated all carryover effects from the levalbuterol. However, the number of side effects without carryover would be even lower than we observed.|2|||f||||f||||||||||2018-05-31 23:38:36.701154|2018-05-31 23:38:36.701154
NCT01151566|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2014-03-11|2010-06-25|2010-06-28|Estimate|||||||2014-03-11|2014-03-13|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CEUS_CT||Can Ultrasound Replace Computed Tomography (CT) Scan in Those Unable to Have Computed Tomography (CT) Contrast Agents|Can US With CEUS Replace the Nonenhanced CT Scan in Patients With Contraindication to CT Contrast Agent|Completed|||250|Actual|Foothills Medical Centre|||2||f||||f||||||||||2018-05-31 23:38:37.063195|2018-05-31 23:38:37.063195
NCT01151553|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|2013-07-24||2013-09-10|2010-06-25|2010-06-28|Estimate|2013-07-24|2013-08-14|Estimate||||2013-09-10|2013-09-19|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|July 2011|Actual|2011-07-31|March 2010|Actual|2010-03-31||Interventional|||Oxidative Stress Markers and Cardiac Resynchronization Therapy (CRT) Outcomes|Comparative of Markers of Oxidative Stress Present Pre and Post Cardiac Resynchronization Therapy Outcome Predictors|Terminated||N/A|5|Actual|Emory University|Early termination leading to small numbers of subjects; lost funding and staff, no data collected/processed.|1||No funding, lost support staff. No data collected/processed|f||||f||||||||||2018-05-31 23:38:37.157468|2018-05-31 23:38:37.157468
NCT01151540|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2014-02-20|2010-06-25|2010-06-28|Estimate|||||||2014-02-20|2014-02-21|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||A Long Term Extension Study of E2080 in Lennox-Gastaut Patients|A Long Term Extension Study of E2080 in Lennox-Gastaut Patients|Completed||Phase 3|54|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 23:38:37.348299|2018-05-31 23:38:37.348299
NCT01151527|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-09-08|2010-06-25|2010-06-28|Estimate|||||||2015-09-08|2015-09-09|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias|Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping|Terminated|||269|Actual|Duke University|||1||f||||f||||||Samples With DNA|"~     Tubes of blood will be drawn from the subject to extract RNA and DNA for laboratory purposes.~      Lung biopsy tissue (pathology slides) may be requested for specimen processing.~      Also Bronchoscopy fluid may be requested.~   "|||2018-05-31 23:38:37.481837|2018-05-31 23:38:37.481837
NCT01151514|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-06-25|2010-06-25|2010-06-28|Estimate|||||||2010-06-25|2010-06-28|Estimate||||August 2010|2010-08-31||||||||Observational|HA-AKI||Referral Patterns for Hospital Acquired Acute Kidney Injury and Relevance to Renal Outcomes|Referral Patterns for Hospital Acquired Acute Kidney Injury and Relevance to Renal Outcomes|Completed|||||Centre Hospitalier Universitaire Vaudois|||2||f||||t||||||||||2018-05-31 23:38:37.553331|2018-05-31 23:38:37.553331
NCT01151501|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2010-06-28|2010-06-25|2010-06-28|Estimate|||||||2010-06-28|2010-06-29|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|NPPV||Noninvasive Positive Pressure Ventilation for Early Extubation of Acute Hypoxemic Respiratory Failure|Noninvasive Positive Pressure Ventilation for Early Extubation of Acute Hypoxemic Respiratory Failure|Unknown status|Not yet recruiting|N/A|52|Anticipated|Beijing Chao Yang Hospital||1|||f||||t||||||||||2018-05-31 23:38:37.626488|2018-05-31 23:38:37.626488
NCT01151488|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2017-01-30|2010-06-25|2010-06-28|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|December 6, 2016|Actual|2016-12-06|August 2014|Actual|2014-08-31||Interventional|||Nutrition, Exercise, and Breast Cancer Survivorship|Impact of Nutrition and Exercise on Glucose Metabolism, Inflammation, and Body Composition in Older Breast Cancer Survivors|Completed||N/A|14|Actual|Baltimore VA Medical Center||1|||f||||t||||||||No||2018-05-31 23:38:37.707993|2018-05-31 23:38:37.707993
NCT01151475|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2012-06-18|2010-06-25|2010-06-28|Estimate|||||||2012-06-18|2012-06-19|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE)|Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of HE|Completed|||10|Actual|University of Aarhus|||||f||||t||||||||||2018-05-31 23:38:37.813973|2018-05-31 23:38:37.813973
NCT01151462|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|||2015-10-21|2010-06-25|2010-06-28|Estimate|||||||2015-10-21|2015-10-22|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Observational|||Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.|"Postnatal HCMV Infection in Very Preterm Infants. Implications on Acute and Chronic Morbidity, Growth and Neurodevelopmental Outcomes Part of the Study on Nutrition, Growth and Development Among Very Preterm Infants."|Withdrawn|||0|Actual|Oslo University Hospital||||The study was terminated prior to enrollment|f||||t||||||Samples With DNA|"~     Serum. Mothersmilk. Urine.~   "|||2018-05-31 23:38:38.0661|2018-05-31 23:38:38.0661
NCT01151449|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25|2016-12-07||2017-02-28|2010-06-25|2010-06-28|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|June 2010||2010-06-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|July 2012|Actual|2012-07-31||Interventional|||Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer|A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma|Terminated||Phase 2|6|Actual|National Cancer Institute (NCI)||1||Administratively Complete|f||||||||||||||2018-05-31 23:38:38.341726|2018-05-31 23:38:38.341726
NCT01151436|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2012-04-10||2012-05-29|2010-06-25|2010-06-28|Estimate|2012-04-10|2012-05-07|Estimate||||2012-05-29|2012-06-04|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|FRESH||Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers|Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers - Investigator and Subject Satisfaction|Completed||N/A|77|Actual|Galderma||1|||f||||f||||||||||2018-05-31 23:38:39.188173|2018-05-31 23:38:39.188173
NCT01151423|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-25||2015-06-29|2015-07-22|2010-06-25|2010-06-28|Estimate||||2015-06-29|2015-07-22|Estimate|2015-07-22|2015-08-11|Estimate|September 2010||2010-09-30|June 2015|2015-06-30||||April 2014|Actual|2014-04-30||Interventional|TITAN||Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)|A Phase II, Single-blind, Randomised, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura|Completed||Phase 2|75|Actual|Ablynx||2|||f||||t||||||||||2018-05-31 23:38:39.940995|2018-05-31 23:38:39.940995
NCT01151410|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2016-02-08||2016-02-08|2010-06-25|2010-06-28|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age|A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age|Completed||Phase 3|208|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:38:40.174273|2018-05-31 23:38:40.174273
NCT01151397|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-04-27|2010-06-25|2010-06-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|August 2011||2011-08-31|June 2010|2010-06-30|July 2012|Anticipated|2012-07-31|February 2012|Anticipated|2012-02-29||Interventional|||Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?|Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve SVR in Genotype 2,3 Chronic Hepatitis C Patients?|Unknown status|Not yet recruiting|N/A|60|Anticipated|Ziv Hospital||2|||f||||f||||||||||2018-05-31 23:38:41.021592|2018-05-31 23:38:41.021592
NCT01151384|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2011-06-30|2010-06-25|2010-06-28|Estimate|||||||2011-06-30|2011-07-04|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|LE-DT||Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors|A Phase 1 Study of Liposome Encapsulated Docetaxel (LE-DT) in Patients With Advanced Solid Tumors|Completed||Phase 1|30|Actual|INSYS Therapeutics Inc||1|||f||||t||||||||||2018-05-31 23:38:41.159173|2018-05-31 23:38:41.159173
NCT01151371|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2011-09-15||2017-08-31|2010-06-25|2010-06-28|Estimate|2011-11-14|2011-12-19|Estimate||||2017-08-31|2017-09-29|Actual|February 1, 2010|Actual|2010-02-01|August 2017|2017-08-31|April 1, 2010|Actual|2010-04-01|April 1, 2010|Actual|2010-04-01||Interventional|||Clinical Evaluation Of Two Daily Disposable Contact Lenses And A Monthly Replacement Lens||Completed||N/A|452|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f||||||||||2018-05-31 23:38:41.344468|2018-05-31 23:38:41.344468
NCT01151358|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2010-06-25|2010-06-25|2010-06-28|Estimate|||||||2010-06-25|2010-06-28|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|MERIT-NHL||Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy|Multicenter Prospective Evaluation of Patient- and Lesion Specific Prognostic Factors for Standard RadioImmunoTherapy With 90-Yttrium-labeled Anti-CD20 in Follicular Non-Hodgkin´s Lymphoma|Unknown status|Recruiting||150|Anticipated|University Hospital, Saarland|||||f||||t||||||||||2018-05-31 23:38:41.793143|2018-05-31 23:38:41.793143
NCT01151345|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2011-07-24||2011-09-06|2010-06-24|2010-06-28|Estimate|2011-07-24|2011-08-22|Estimate||||2011-09-06|2011-09-12|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. De C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. De C.V.|Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made By Pfizer, S.A. DE C.V., Versus Angiotrofin® 60 Mg Made By Amstrong Laboratorios De Mexico, S.A. DE C.V. Study In 26 Healthy Volunteers Of Both Genders Under Fasting Conditions|Completed||Phase 1|26|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:38:41.868669|2018-05-31 23:38:41.868669
NCT01151319|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2014-04-29|2010-06-25|2010-06-28|Estimate|||||||2014-04-29|2014-04-30|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|HIV-CORE 002||Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults|A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults|Completed||Phase 1|32|Actual|University of Oxford||7|||f||||t||||||||||2018-05-31 23:38:42.167906|2018-05-31 23:38:42.167906
NCT01151306|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2014-03-21|2010-06-25|2010-06-28|Estimate|||||||2014-03-21|2014-03-24|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||The Effect of Statins in Patients With Chronic Obstructive Pulmonary Disease (COPD)|The Cardiovascular and Inflammatory Effects of Statin Therapy in Patients With COPD|Completed||Phase 4|70|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-05-31 23:38:42.256304|2018-05-31 23:38:42.256304
NCT01151293|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2010-06-25|2010-06-25|2010-06-28|Estimate|||||||2010-06-25|2010-06-28|Estimate|July 2009||2009-07-31|July 2009|2009-07-31||||April 2010|Actual|2010-04-30||Observational|||Personality of Diabetic Patients Will Influence Their Medical compliance-a 5 Years Cohort Follow up With Type D Personality|Personality of Diabetic Patients Will Influence Their Medical compliance-a 5 Years Cohort Follow up With Type D Personality|Completed|||||Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 23:38:42.335919|2018-05-31 23:38:42.335919
NCT01151280|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2013-04-12||2013-11-27|2010-06-24|2010-06-28|Estimate|2013-06-11|2013-07-19|Estimate||||2013-11-27|2013-12-25|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional||All participants were included for analysis.|WallFlex Biliary Post Liver Transplant IDE Pilot|A Multi-Center, Prospective Study the WallFlex Biliary RX Fully Covered Stent for the Treatment of Anastomotic Biliary Strictures in Post Liver Transplant Patients.|Completed||N/A|10|Actual|Boston Scientific Corporation|This was a small, pilot, feasibility study. Further prospective studies are needed to optimize duration of fully covered self-expanding metal stent indwell and assess predictors of treatment success.|1|||f||||f||||||||||2018-05-31 23:38:42.397542|2018-05-31 23:38:42.397542
NCT01151267|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-02-21|2010-06-24|2010-06-28|Estimate|||||||2013-02-21|2013-02-22|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|January 2012|Actual|2012-01-31||Interventional|||Hypercapnic Spontaneous Hyperpnoea and Recovery From Sevoflurane Anesthesia|Hypercapnic Spontaneous Hyperpnoea and Recovery From Sevoflurane Anesthesia|Completed||N/A|44|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:38:42.633787|2018-05-31 23:38:42.633787
NCT01151254|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-02-11|2010-06-25|2010-06-28|Estimate|||||||2014-02-11|2014-02-12|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Propofol Based Versus Volatile Based Anesthesia and Postoperative Sedation|Comparison of Propofol Based Anesthesia and Postoperative Sedation (PA) Versus Volatile Anesthetics Based Anesthesia and Postoperative Sedation (VA) in Cardiac Surgical Patients|Completed||N/A|146|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:38:42.707921|2018-05-31 23:38:42.707921
NCT01151228|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2013-02-08|2010-06-25|2010-06-28|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2009||2009-12-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Bedside Ultrasound Assessment of Gastric Content and Volume|Bedside Ultrasound Assessment of Gastric Content and Volume. Validating a Mathematical Model Using Gastroscopic Examination|Completed||N/A|108|Actual|University Health Network, Toronto||6|||f||||f||||||||||2018-05-31 23:38:43.897564|2018-05-31 23:38:43.897564
NCT01151215|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2014-01-29||2014-07-15|2010-06-24|2010-06-28|Estimate|2014-04-07|2014-05-08|Estimate||||2014-07-15|2014-07-25|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MINT||Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer|A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination With Anastrozole, Compared to Anastrozole Alone, in Post Menopausal Women With Hormone Receptor Positive, Endocrine Therapy Naive, Locally Advanced or Metastatic Breast Cancer (MINT).|Terminated||Phase 2|482|Actual|AstraZeneca|The final analysis for this study is the analysis that was sent to the study's IDMC, based on a data cut-off of 31 August 2012. At the data cut-off point the data was cleaned, but 9 adverse events were not coded. These events are not included here.|3||Futility|f||||t||||||||||2018-05-31 23:38:44.040692|2018-05-31 23:38:44.040692
NCT01151202|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-10-03|2010-06-24|2010-06-28|Estimate|||||||2010-10-03|2010-10-05|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||"Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG NPP709 Syrup"|"Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG NPP709 Syrup in Acute Upper Respiratory Tract Infection and Chronic Inflammatory Bronchitis Patients: Double Blinded, Randomized, Active Drug Comparative, Parallel Designed, Multi-centered, Phase III Study"|Completed||Phase 3|236|Actual|Ahn-Gook Pharmaceuticals Co.,Ltd||2|||f||||t||||||||||2018-05-31 23:38:45.233364|2018-05-31 23:38:45.233364
NCT01151189|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2015-06-30||2016-04-25|2010-06-24|2010-06-28|Estimate|2015-07-29|2015-08-26|Estimate||||2016-04-25|2016-05-24|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional||"Safety:~All randomized subjects who received a dose of study vaccine, based on actual treatment received."|Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)|A Phase II, Proof of Concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Protective Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in Healthy, HIV-infected Adults|Completed||Phase 2|650|Actual|Aeras||2|||f||||t||||||||||2018-05-31 23:38:45.359748|2018-05-31 23:38:45.359748
NCT01151176|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-06-17|2010-06-25|2010-06-28|Estimate|||||||2012-06-17|2012-06-19|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome|Phase IV Study of a Feasible Insulin Algorithm for Glycemic Control in Patients With Acute Coronary Syndrome|Suspended||Phase 4|130|Anticipated|Universidade Positivo||2||Administrative problems makes changes in hospital staff New clinical research team will restart|f||||t||||||||||2018-05-31 23:38:45.922061|2018-05-31 23:38:45.922061
NCT01150916|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2012-12-19|2010-06-24|2010-06-28|Estimate|||||||2012-12-19|2012-12-20|Estimate|June 2010||2010-06-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites|B-type Natriuretic Peptide in the Diagnosis of Heart Failure Related Ascites|Completed||N/A|278|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 23:38:46.009119|2018-05-31 23:38:46.009119
NCT01150851|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-07-24|2010-06-25|2010-06-28|Estimate|||||||2014-07-24|2014-07-25|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Oxidative Stress in Chronic Kidney Disease: Diet and Exercise|Oxidative Stress in Chronic Kidney Disease: Diet and Exercise|Completed||N/A|122|Actual|Vanderbilt University||4|||f||||t||||||||||2018-05-31 23:38:46.089771|2018-05-31 23:38:46.089771
NCT01150838|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-08-09|2010-06-24|2010-06-28|Estimate|||||||2011-08-09|2011-08-10|Estimate|July 2008||2008-07-31|August 2011|2011-08-31||||June 2010|Actual|2010-06-30||Interventional|||Determination of the Amount of Propofol Needed to Supplement 5% Sevoflurane for Intubation of Children Without Neuromuscular Blockade|Determination of the Amount of Propofol Needed to Supplement 5% Sevoflurane for Intubation of Children Without Neuromuscular Blockade,IRB-HSR# 13666|Completed||Phase 4|150|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 23:38:46.168834|2018-05-31 23:38:46.168834
NCT01150747|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-12-01|2010-06-24|2010-06-28|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Chlamydia Trachomatis Immunology and Vaccinology Study|Chlamydia Trachomatis Immunology and Vaccinology Study: Determination of Protective T Cell Responses to Chlamydia Trachomatis Infection|Completed|||347|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 23:38:46.264762|2018-05-31 23:38:46.264762
NCT01149239|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2011-06-09|2010-06-22|2010-06-28|Estimate|||||||2011-06-09|2011-06-10|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||The Effect of Preoperative Anxiety Level on the Induction Dose of Propofol and Minimum Alveolar Concentration (MAC) Hour of Sevoflurane During Thyroidectomy|The Effect of Preoperative Anxiety Level on the Induction Dose of Propofol and MAC-hour of Sevoflurane During Thyroidectomy|Completed|||100|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 23:38:46.34839|2018-05-31 23:38:46.34839
NCT01149226|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-06-09|2010-06-22|2010-06-28|Estimate|||||||2011-06-09|2011-06-10|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Chloral Hydrate on Induction, Maintenance, and Recovery From Sevoflurane Anesthesia in Day-case Pediatric Surgery||Completed||N/A|100|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:38:46.395222|2018-05-31 23:38:46.395222
NCT01151163|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2011-02-07|2010-06-24|2010-06-25|Estimate|||||||2011-02-07|2011-02-08|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Observational|||Peripheral Arterial Tonometry (PAT) Evaluation of Sleep in Fibromyalgia|Evaluation of Sleep Disordered Breathing and Autonomic Dysfunction in Fibromyalgia Through Peripheral Arterial Tonometry|Unknown status|Recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:38:46.470735|2018-05-31 23:38:46.470735
NCT01151150|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2011-07-25|2010-06-24|2010-06-25|Estimate|||||||2011-07-25|2011-07-26|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Observational|||"The Phenomenon of Chronic Lyme; an Observational Study"||Completed|||30|Anticipated|Sorlandet Hospital HF|||||f||||f||||||Samples With DNA|"~     Blood, CSF~   "|||2018-05-31 23:38:46.553686|2018-05-31 23:38:46.553686
NCT01151137|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2012-09-14||2012-10-23|2010-06-24|2010-06-25|Estimate|2012-10-23|2012-10-26|Estimate||||2012-10-23|2012-10-26|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PALLAS||Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy|A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors|Terminated||Phase 3|3236|Actual|Sanofi|Given that the study was prematurely discontinued after 3236 patients were randomized (30% of the initial planned number), p-values were provided for information without any adjustment for multiplicity.|2||The study was stopped because of safety concerns|f||||t||||||||||2018-05-31 23:38:46.633564|2018-05-31 23:38:46.633564
NCT01151124|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2018-01-30|2010-06-24|2010-06-25|Estimate|||||||2018-01-30|2018-01-31|Actual|June 2010||2010-06-30|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|March 2015|Actual|2015-03-31||Interventional|PISCES||Pilot Investigation of Stem Cells in Stroke|A Phase I Safety Trial of CTX0E03 Drug Product Delivered Intracranially in the Treatment of Patients With Stable Ischemic Stroke|Active, not recruiting||Phase 1|12|Anticipated|ReNeuron Limited||1|||f||||t||||||||||2018-05-31 23:38:47.786631|2018-05-31 23:38:47.786631
NCT01151111|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2014-05-07|2010-06-24|2010-06-25|Estimate|||||||2014-05-07|2014-05-08|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2012|Actual|2012-05-31||Interventional|||Relaxation Guided Imagery for Treatment of Parkinson's Disease|Pilot Study of Relaxation Guided Imagery for the Treatment of Motor Fluctuations in Parkinson's Disease's|Completed||Early Phase 1|20|Actual|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 23:38:47.861871|2018-05-31 23:38:47.861871
NCT01151098|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2010-07-29||2012-09-05|2010-06-24|2010-06-25|Estimate|2010-08-30|2010-09-23|Estimate||||2012-09-05|2012-09-10|Estimate|April 2001||2001-04-30|September 2012|2012-09-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study|An Open-Label, Multi-Center, Titration Study to Establish the Long-term Safety and Tolerability of Buprenorphine Transdermal Delivery System (BTDS) 5 mg, 10 mg, and 20 mg in Patients With Chronic Non-Malignant Pain Syndromes Responsive to Opioid Combination Therapy - a 28-Week Extension Study.|Completed||Phase 3|189|Actual|Purdue Pharma LP||1|||f||||||||||||||2018-05-31 23:38:47.944753|2018-05-31 23:38:47.944753
NCT01151085|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2013-05-14||2013-05-14|2010-06-24|2010-06-25|Estimate|2013-05-14|2013-08-08|Estimate||||2013-05-14|2013-08-08|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Vfend Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Completed|||1002|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:38:48.21825|2018-05-31 23:38:48.21825
NCT01151072|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-01-19|2010-06-24|2010-06-25|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects|A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties of NN1250 After Different Routes of Administration in Healthy Subjects|Completed||Phase 1|20|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-05-31 23:38:48.543768|2018-05-31 23:38:48.543768
NCT01151059|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2012-03-27|2010-06-24|2010-06-25|Estimate|||||||2012-03-27|2012-03-28|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL® S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, When Administered to Non-elderly Adult and Elderly Subjects|Completed||Phase 2|138|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:38:48.622433|2018-05-31 23:38:48.622433
NCT01151046|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2016-02-14||2016-04-11|2010-06-24|2010-06-25|Estimate|2016-04-11|2016-05-12|Estimate||||2016-04-11|2016-05-12|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer|A Randomized Double-Blind Phase 2 Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+) Her2 Negative Breast Cancer|Completed||Phase 2|118|Actual|Merrimack Pharmaceuticals||2|||f||||t||||||||||2018-05-31 23:38:48.721523|2018-05-31 23:38:48.721523
NCT01151033|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2011-01-19|2010-06-24|2010-06-25|Estimate|||||||2011-01-19|2011-01-20|Estimate|November 2008||2008-11-30|January 2011|2011-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|EURONOVA||A Clinical Evaluation of the ProNOVA XR Polymer Free Drug Eluting Coronary Stent System|A Clinical Evaluation of the ProNOVA XR Polymer Free Drug Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions|Completed||Phase 2/Phase 3|50|Actual|KCRI||1|||f||||f||||||||||2018-05-31 23:38:49.474284|2018-05-31 23:38:49.474284
NCT01151020|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2015-10-16|2015-02-09|2018-05-03|2010-06-24|2010-06-25|Estimate|2016-02-01|2016-02-29|Estimate|2015-02-09|2015-02-26|Estimate|2018-05-03|2018-05-08|Actual|March 2010||2010-03-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|January 2014|Actual|2014-01-31||Interventional|TX2® LP||TX2® Low Profile TAA Endovascular Graft|Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study|Active, not recruiting||N/A|110|Actual|Cook Group Incorporated||1|||t||||||||||||||2018-05-31 23:38:49.661834|2018-05-31 23:38:49.661834
NCT01151007|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2016-09-21|2010-06-24|2010-06-25|Estimate|||||||2016-09-21|2016-09-23|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|KRAS||KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009|Study of KRAS Mutation in 250 Cases of Colorectal Carcinoma and Study of the Incidence of the Disease in Martinique, From 2007 to 2009|Completed|||250|Actual|University Hospital Center of Martinique|||1||f||||t||||||Samples With DNA|"~     Paraffin embedded block of colorectal carcinoma obtained after biopsy or surgery~   "|||2018-05-31 23:38:49.991575|2018-05-31 23:38:49.991575
NCT01150994|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2018-03-15|2010-06-24|2010-06-25|Estimate|||||||2018-03-15|2018-03-19|Actual|July 2010||2010-07-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ED-SAFE||Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)|Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)|Active, not recruiting||N/A|1440|Anticipated|University of Massachusetts, Worcester||3|||f||||t||||||||||2018-05-31 23:38:50.138296|2018-05-31 23:38:50.138296
NCT01150981|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2011-12-16||2012-02-25|2010-06-24|2010-06-25|Estimate|2012-02-25|2012-03-26|Estimate||||2012-02-25|2012-03-26|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|RAPA||Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue|Effect of Rosiglitazone on In-vivo Angiogenic Potential of Human Adipose Tissue|Completed||Phase 2|35|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 23:38:50.244138|2018-05-31 23:38:50.244138
NCT01150968|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2011-02-09|2010-06-24|2010-06-25|Estimate|||||||2011-02-09|2011-02-10|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Educational Intervention to Improve Resident Comfort With Communication at the End of Life|An Educational Intervention to Improve Resident Comfort With Communication at the End of Life|Completed||N/A|166|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:38:50.511714|2018-05-31 23:38:50.511714
NCT01150955|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2012-03-21|2010-06-24|2010-06-25|Estimate|||||||2012-03-21|2012-03-22|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Potential Beneficial Effects of Resveratrol|Potential Beneficial Effects of Resveratrol on Obesity, Metabolic Syndrome and Inflammation - Emphasis on Description of the Molecular Biology Underpinning the Interplay Between Calorie Restriction, SIRT1, STAT5 and the GH/IGF-I Axis|Completed||N/A|24|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:38:50.571844|2018-05-31 23:38:50.571844
NCT01150942|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2014-01-29|2010-06-24|2010-06-25|Estimate|||||||2014-01-29|2014-01-30|Estimate|August 2010||2010-08-31|February 2011|2011-02-28|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea|A Multi-center, Active-control, Randomized, Double-blind Phase 3 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine 'KD-287(JEIMMUGEN INJ.) in Korean Healthy Children Aged 12~23 Months|Completed||Phase 3|205|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 23:38:50.694164|2018-05-31 23:38:50.694164
NCT01150929|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-02-18|2010-06-24|2010-06-25|Estimate|||||||2011-02-18|2011-02-21|Estimate|March 2007||2007-03-31|February 2011|2011-02-28|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Rehabilitation After Total Knee Arthroplasty (TKA) - PFC Rotating Versus Fixed Bearing|Rehabilitation After Total Knee Arthroplasty - Rotating Platform Versus Fixed Bearing Polyethylene|Unknown status|Recruiting|N/A|50|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 23:38:50.780417|2018-05-31 23:38:50.780417
NCT01150903|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|2012-04-03||2012-04-03|2010-06-24|2010-06-25|Estimate|2012-04-03|2012-05-11|Estimate||||2012-04-03|2012-05-11|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor|Prevalence and Incidence of Underlying Disease Diagnosed in Men With Erectile Dysfunction When Prescribed a PDE5i for the First Time|Completed|||98832|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 23:38:50.881523|2018-05-31 23:38:50.881523
NCT01150890|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24||2015-12-14|2015-12-14|2010-06-24|2010-06-25|Estimate||||2015-12-14|2016-01-14|Estimate|2015-12-14|2016-01-14|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||AMG 827 in Subjects With Moderate to Severe Crohn's Disease|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease|Terminated||Phase 2|130|Actual|Amgen||4||Per recommendation from DRT|f||||||||||||||2018-05-31 23:38:51.273798|2018-05-31 23:38:51.273798
NCT01150877|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-03-01|2010-06-24|2010-06-25|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2011||2011-01-31|March 2017|2017-03-31|April 23, 2014|Actual|2014-04-23|April 23, 2014|Actual|2014-04-23||Interventional|||High Dose Vitamin D Study|Study of High-dose Vitamin D Supplementation in Stage-4 Colorectal Cancer Patients|Completed||Phase 1/Phase 2|40|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:38:51.400198|2018-05-31 23:38:51.400198
NCT01150864|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-05-23|2010-06-24|2010-06-25|Estimate|||||||2017-05-23|2017-05-25|Actual|April 2010||2010-04-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2015|Actual|2015-03-31||Interventional|AirconVAP||Effects of Airway Conditioning Devices on Ventilator Associated Pneumonia:a Randomized Clinical Trial|Effects of Airway Conditioning Devices on Ventilator Associated Pneumonia:a Randomized Clinical Trial|Completed||N/A|190|Actual|Università degli Studi dell'Insubria||3|||f||||f||||||||||2018-05-31 23:38:51.471682|2018-05-31 23:38:51.471682
NCT01150825|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2011-02-06|2010-06-24|2010-06-25|Estimate|||||||2011-02-06|2011-02-08|Estimate|June 2010||2010-06-30|February 2011|2011-02-28|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Feasibility of High Frequency QRS Analysis in Patients With Acute Myocardial Infarction|Feasibility of High Frequency QRS Analysis in Patients With Acute Myocardial Infarction|Unknown status|Recruiting||50|Anticipated|BSP Biological Signal Processing Ltd.|||2||f||||f||||||||||2018-05-31 23:38:51.532542|2018-05-31 23:38:51.532542
NCT01150812|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-09-16|2010-06-24|2010-06-25|Estimate|||||||2010-09-16|2010-09-17|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects|A Phase I, Single-center, Single-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects|Terminated||Phase 1|9|Actual|AstraZeneca||1||The study pharmacodynamic stopping criteria were met after the first dosing group|f||||f||||||||||2018-05-31 23:38:51.597517|2018-05-31 23:38:51.597517
NCT01150786|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2012-02-13|2010-06-24|2010-06-25|Estimate|||||||2012-02-13|2012-02-14|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Effect of Selenium on Serum Adiponectin, Homocystein and Malnutrition-inflammation Complex Syndrome in Hemodialysis Patients|Effect of Selenium Supplementation on Serum Adiponectin and Homocystein|Completed||Phase 3|80|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:38:51.659145|2018-05-31 23:38:51.659145
NCT01150760|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2010-08-17||2015-07-16|2010-06-24|2010-06-25|Estimate|2010-08-17|2010-09-08|Estimate||||2015-07-16|2015-08-07|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database|Comparison of Clinical Outcomes in Bowel Resection Patients Receiving Alvimopan vs. Patients Not Receiving Alvimopan in the Premier Perspective/Care Science Database|Completed|||7050|Actual|Cubist Pharmaceuticals LLC|||2||f||||f||||||||||2018-05-31 23:38:51.911678|2018-05-31 23:38:51.911678
NCT01150734|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2011-04-21|2010-06-24|2010-06-25|Estimate|||||||2011-04-21|2011-04-22|Estimate|October 2009||2009-10-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation)|Transcranial Direct Current Stimulation (tDCS)-Boosted Changes in Muscle Evoked Potentials (MEP) in Depressed and Schizophrenic Patients Reveal Deficits in Neuromodulation|Completed|||30|Actual|Ludwig-Maximilians - University of Munich|||||f||||f||||||||||2018-05-31 23:38:52.485448|2018-05-31 23:38:52.485448
NCT01148940|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2015-04-15|2010-06-22|2010-06-23|Estimate|||||||2015-04-15|2015-04-16|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|December 2011|Actual|2011-12-31||Observational|SCT&DVT||Sickle Cell Trait and the Risk of Venous Thromboembolism|Sickle Cell Trait and the Risk of Venous Thromboembolism|Terminated|||30|Actual|Albert Einstein College of Medicine, Inc.||||insufficent enrollment|f||||f||||||||||2018-05-31 23:39:36.101765|2018-05-31 23:39:36.101765
NCT01150721|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2018-05-17|2010-06-24|2010-06-25|Estimate|||||||2018-05-17|2018-05-18|Actual|July 31, 2010||2010-07-31|November 21, 2017|2017-11-21||||||||Observational|||Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection|Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection|Completed|||177|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:38:52.560547|2018-05-31 23:38:52.560547
NCT01150708|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2018-03-27|2010-06-24|2010-06-25|Estimate|||||||2018-03-27|2018-03-29|Actual|June 9, 2010||2010-06-09|November 14, 2017|2017-11-14||||||||Observational|||A Prospective Natural History Study of Patients With Syringomyelia|A Prospective Natural History Study of Patients With Syringomyelia|Recruiting|||180|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:38:52.632833|2018-05-31 23:38:52.632833
NCT01150695|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24||2013-07-08|2015-12-10|2010-06-24|2010-06-25|Estimate||||2013-07-08|2013-07-11|Estimate|2015-12-10|2016-01-13|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Phase II Tularemia Vaccine Comparison|A Phase II, Multi-Center, Double-Blind, Randomized Trial Comparing the Safety and Immunogenicity of a Francisella Tularensis Live Vaccine Strain (LVS) Vaccine Produced by DynPort Vaccine Company (DVC-LVS) to a LVS Vaccine in Use by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID-LVS)|Completed||Phase 2|228|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 23:38:52.717725|2018-05-31 23:38:52.717725
NCT01150682|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2011-04-28|2010-06-24|2010-06-25|Estimate|||||||2011-04-28|2011-04-29|Estimate|July 2010||2010-07-31|August 2010|2010-08-31||||July 2015|Anticipated|2015-07-31||Observational|||Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer|Role of Sex Hormone and Insulin/IGF Axes in Endometrial Cancer Recurrence|Unknown status|Active, not recruiting||865|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:38:52.839594|2018-05-31 23:38:52.839594
NCT01150669|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2016-05-17|2010-06-24|2010-06-25|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia|SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia|Completed|||18|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 23:38:52.916088|2018-05-31 23:38:52.916088
NCT01150656|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2016-05-17|2010-06-24|2010-06-25|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2010||2010-06-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia|SCOR in Targeted Therapies for Infant Leukemias Project 2: Targeting Apoptosis in Leukemia in Infants|Completed|||50|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:38:53.070382|2018-05-31 23:38:53.070382
NCT01150643|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-05-16|2010-06-24|2010-06-25|Estimate|||||||2017-05-16|2017-05-17|Actual|December 6, 2010|Actual|2010-12-06|May 2017|2017-05-31|January 6, 2011|Actual|2011-01-06|January 6, 2011|Actual|2011-01-06||Observational|||Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab|Identification of Biomarkers Predicting Responsiveness to Rituximab in Follicular Lymphoma|Completed|||559|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:38:53.155424|2018-05-31 23:38:53.155424
NCT01150630|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2017-08-31|2010-06-24|2010-06-25|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2010||2010-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|PACT-15||Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer|Randomized Phase II-III Trial of Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma|Completed||Phase 2|98|Actual|IRCCS San Raffaele||3|||f||||f||||||||No||2018-05-31 23:38:53.230025|2018-05-31 23:38:53.230025
NCT01150617|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2012-09-12|2010-06-24|2010-06-25|Estimate|||||||2012-09-12|2012-09-13|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|LIMBISCH||Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty|Effect of Normalization of Fasting Glucose by Intensified Insulin Therapy on the Incidence of Restenosis After Peripheral Angioplasty in Patients With Type 2 Diabetes.|Terminated||Phase 4|46|Actual|IRCCS San Raffaele||2||end-point reached|f||||f||||||||||2018-05-31 23:38:53.321305|2018-05-31 23:38:53.321305
NCT01150604|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-04-09|2010-06-24|2010-06-25|Estimate|||||||2014-04-09|2014-04-11|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|DMP||Depression Management Project||Completed||Phase 1|547|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:38:53.406633|2018-05-31 23:38:53.406633
NCT01150591|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-12-01|2010-06-24|2010-06-25|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2009||2009-12-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|ROMI||Microaspiration in Pulmonary Fibrosis|The Role of Microaspiration in Idiopathic Pulmonary Fibrosis|Completed|||20|Actual|University of California, San Francisco|||||f||||f|||||||"~     This is a prospective cohort study of patients with IPF. Subjects will undergo (1) an~     assessment of the presence or absence of microaspiration (via bronchoscopy and BAL pepsin~     level), (2) measurement of biomarkers of microaspiration (via esophageal function studies,~     laboratory tests, pulmonary function, chest imaging, and survey), and (3) longitudinal~     follow-up to document disease progression (via pulmonary function and survey).~   "|||2018-05-31 23:38:53.476657|2018-05-31 23:38:53.476657
NCT01150578|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2015-11-03|2010-06-24|2010-06-25|Estimate|||||||2015-11-03|2015-11-04|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Observational|Lexi-Echo||Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography|Lexi-Echo - a Rapid, Portable, Non-radiating Diagnostic Test for Myocardial Ischemia That is Accurate Relative to Simultaneously Obtained Nuclear SPECT MPI|Unknown status|Active, not recruiting||380|Anticipated|University of Arizona|||1||f||||f||||||||||2018-05-31 23:38:53.541218|2018-05-31 23:38:53.541218
NCT01150565|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-11-24|2010-06-24|2010-06-25|Estimate|||||||2014-11-24|2014-11-25|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety Study of LiRIS in Interstitial Cystitis (IC) Patients|Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis|Completed||Phase 1|18|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:38:53.616679|2018-05-31 23:38:53.616679
NCT01150383|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2013-10-30|2010-06-24|2010-06-25|Estimate|||||||2013-10-30|2013-10-31|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SCOPE||SCOPE-Study: Salzburg Chronic Obstructive Pulmonary Disease- Exercise and Oxygen Study|The Effect of Supplemental Oxygen During Physical Exercise Training on Exercise Capacity in COPD Patients.|Completed||Phase 4|50|Actual|Paracelsus Medical University||2|||f||||f||||||||||2018-05-31 23:38:56.715716|2018-05-31 23:38:56.715716
NCT01150552|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2014-07-11|2010-06-24|2010-06-25|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Studies of Avian Influenza Transmission to Humans in Egypt|Prospective Studies of Avian Influenza Transmission to Humans in Egypt|Completed|||1000|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||Samples With DNA|"~     Sera will be tested for human antibodies against AI viruses (types H4-H12) using a~     microneutralization assay. Study sera will be examined for antibodies against human influenza~     types H1 and H3 using a hemagglutination inhibition procedure.~   "|||2018-05-31 23:38:53.683147|2018-05-31 23:38:53.683147
NCT01150539|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2018-05-23|2010-06-24|2010-06-25|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2007||2007-01-31|May 2018|2018-05-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|POLY||Effects of Exercise for Overweight Women With Polycystic Ovary Syndrome|"Effects of Physical Activity on Insulin Resistance and Adiposity in Polycystic Ovary Syndrome Poly"|Completed||N/A|8|Actual|Pennington Biomedical Research Center||1|||f||||f||||||||||2018-05-31 23:38:53.751932|2018-05-31 23:38:53.751932
NCT01150526|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2012-07-16|2010-06-24|2010-06-25|Estimate|||||||2012-07-16|2012-07-18|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|November 2010|Actual|2010-11-30||Interventional|||Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate|Efficacy of a New Delivery System for Beta-hydroxy-beta-methylbutyrate|Completed||Phase 1|41|Actual|Metabolic Technologies Inc.||5|||f||||f||||||||||2018-05-31 23:38:53.913129|2018-05-31 23:38:53.913129
NCT01150513|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2017-02-11|2010-06-24|2010-06-25|Estimate|||||||2017-02-11|2017-02-14|Actual|June 2009||2009-06-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer|Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer|Completed||Phase 2/Phase 3|320|Actual|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 23:38:53.977147|2018-05-31 23:38:53.977147
NCT01150500|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2012-10-30||2017-02-03|2010-06-24|2010-06-25|Estimate|2012-11-01|2012-11-30|Estimate||||2017-02-03|2017-03-14|Actual|June 2010||2010-06-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|October 2011|Actual|2011-10-31||Interventional|RJ-SVS||RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries|RESOLUTE JAPAN SVS: The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries|Completed||N/A|65|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-05-31 23:38:54.17056|2018-05-31 23:38:54.17056
NCT01150487|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2016-04-28|2010-06-23|2010-06-25|Estimate|||||||2016-04-28|2016-04-29|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients|Paired Bone Marrow Aspirations to Assess the Variability of Allo-ELISPOT and Allo-Specificities Assays in Sensitized Renal Allograft Recipients|Recruiting||N/A|80|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 23:38:54.499031|2018-05-31 23:38:54.499031
NCT01150474|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2014-12-23||2014-12-23|2010-06-23|2010-06-25|Estimate|2014-12-23|2015-01-07|Estimate||||2014-12-23|2015-01-07|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Postoperative Belladonna and Morphine Suppositories in Vaginal Surgery|Randomized Clinical Trial of Postoperative Belladonna and Morphine Suppositories in Vaginal Surgery|Completed||Phase 4|103|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:38:54.598864|2018-05-31 23:38:54.598864
NCT01150461|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2013-05-02||2013-09-03|2010-06-24|2010-06-25|Estimate|2013-09-03|2013-09-05|Estimate||||2013-09-03|2013-09-05|Estimate|February 2007||2007-02-28|September 2013|2013-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy|Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy|Completed||Phase 2|20|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:38:55.004895|2018-05-31 23:38:55.004895
NCT01150448|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2014-05-26|2010-06-24|2010-06-25|Estimate|||||||2014-05-26|2014-05-28|Estimate|September 2007||2007-09-30|May 2014|2014-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia|An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of 150 mg eq. Paliperidone Palmitate in the Treatment of Subjects With Schizophrenia|Completed||Phase 1|212|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 23:38:55.278538|2018-05-31 23:38:55.278538
NCT01150435|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-06-24|2010-06-24|2010-06-25|Estimate|||||||2010-06-24|2010-06-25|Estimate|February 2008||2008-02-29|June 2010|2010-06-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||Driving Ability of Drug Dependant Patients in Maintenance Therapy|Driving Ability of Drug Dependant Patients in Maintenance Therapy|Completed|||121|Actual|Hummel, Christiane|||4||f||||f||||||Samples Without DNA|"~     Drug screen Urin~   "|||2018-05-31 23:38:55.379716|2018-05-31 23:38:55.379716
NCT01150422|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2011-04-29|2010-06-24|2010-06-25|Estimate|||||||2011-04-29|2011-05-02|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Acceptability and Feasibility of an Alternative to Routine Follow-up Visit After Medical Abortion in Vietnam|The Acceptability and Feasibility of an Alternative to a Routine Follow-up Visit After Medical Abortion in Vietnam|Completed||Phase 3|1500|Anticipated|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 23:38:55.427543|2018-05-31 23:38:55.427543
NCT01150409|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2015-08-25||2018-03-06|2010-06-24|2010-06-25|Estimate|2015-08-25|2015-09-02|Estimate||||2018-03-06|2018-04-02|Actual|May 2008||2008-05-31|March 2018|2018-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||Adult MICU pateints who meet criteria for corticosteroid therapy of septic shock|Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock|Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock|Terminated||Phase 4|11|Actual|The Cleveland Clinic||2||Difficulty in recruiting eligible subjects|f||||t||||||||||2018-05-31 23:38:55.492606|2018-05-31 23:38:55.492606
NCT01150396|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-06-01|2010-06-24|2010-06-25|Estimate|||||||2015-06-01|2015-06-02|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|BabyPEP||Prognosis of Extremely Premature Birth|Mortality and Morbidity of Infants Born With Gestational Age Less Than 28 Weeks|Recruiting|||160|Anticipated|University of Bergen|||||f||||f||||||Samples Without DNA|"~     Blood and amniotic fluid from mother Placenta Blood from umbilical cord and repeated blood~     samples from the infant Repeated urine samples from infant repeated tracheal spirates from~     the infant (while intubated)~   "|||2018-05-31 23:38:56.632475|2018-05-31 23:38:56.632475
NCT01150370|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2011-01-10|2010-06-24|2010-06-25|Estimate|||||||2011-01-10|2011-01-11|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings|A Pivotal Study to Assess the Safety and Efficacy of The PrePex System, a Male Circumcision Device and Methodology for Rapid Scale up of Painless and Bloodless National Circumcision Programs, in Urban and Remote Rural Settings|Completed||N/A|50|Anticipated|Ministry of Health, Rwanda||1|||f||||||||||||||2018-05-31 23:38:56.800128|2018-05-31 23:38:56.800128
NCT01150357|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|2015-08-10||2015-09-15|2010-06-23|2010-06-24|Estimate|2015-09-15|2015-10-15|Estimate||||2015-09-15|2015-10-15|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The analysis was performed in the full analysis set population consisted of all participants who were randomized into the study.|Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age|A Multicenter, Randomized, Double-blind, 8 Week Study to Evaluate the Dose Response, Efficacy and Safety of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age|Completed||Phase 3|267|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:38:56.939397|2018-05-31 23:38:56.939397
NCT01150344|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2015-12-08|2010-06-23|2010-06-24|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|November 2015|Actual|2015-11-30|April 2014|Actual|2014-04-30||Interventional|MalaRia||Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria|Effectiveness and Safety Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria : a Multicentric Study|Completed||Phase 4|317|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:38:57.872817|2018-05-31 23:38:57.872817
NCT01150331|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2014-06-20|2010-06-23|2010-06-24|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|SAMU-KEPPRA||Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus|Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus|Completed||Phase 3|203|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:38:57.948102|2018-05-31 23:38:57.948102
NCT01150318|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-08-06|2010-06-23|2010-06-24|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2006||2006-01-31|August 2013|2013-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|SAPIRA||Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients|Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma|Completed||N/A|48|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:38:58.056183|2018-05-31 23:38:58.056183
NCT01150305|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2013-08-06|2010-06-23|2010-06-24|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 2009||2009-04-30|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|SURDOM||Epidemiology of Non-syndromic Dominant Deafness|Genetic Epidemiology of Non-syndromic Dominant Deafness|Completed|||183|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Peripheral whole blood~   "|||2018-05-31 23:38:58.134553|2018-05-31 23:38:58.134553
NCT01150292|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-02-06|2010-06-23|2010-06-24|Estimate|||||||2014-02-06|2014-02-07|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effects of Docosahexaenoic Acid (DHA) on Cardiovascular Disease on Diabetic Patients|Intake of Low Dose of Docosahexaenoic Acid: Effects on Platelet Functions and Redox Status in Diabetic Patients|Completed||N/A|16|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 23:38:58.220991|2018-05-31 23:38:58.220991
NCT01150279|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2015-10-01|2010-06-23|2010-06-24|Estimate|||||||2015-10-01|2015-10-02|Estimate|August 2009||2009-08-31|October 2015|2015-10-31||||May 2014|Actual|2014-05-31||Observational|||Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up|Simplifying Medical Abortion Provision: Exploring the Role of At-home Semi-Quantitative Pregnancy Tests for Medical Abortion Follow-up|Completed|||1200|Actual|Gynuity Health Projects|||||f||||||||||||||2018-05-31 23:38:58.294475|2018-05-31 23:38:58.294475
NCT01150266|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2013-09-11|2010-06-23|2010-06-24|Estimate|||||||2013-09-11|2013-09-13|Estimate|August 2011||2011-08-31|September 2013|2013-09-30||||September 2013|Actual|2013-09-30||Interventional|AWOKE||Study for the Use of Alteplase in Patients Who Awaken With Stroke|Alteplase for Waking Onset STROKE|Withdrawn||Phase 1|0|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 23:38:58.472019|2018-05-31 23:38:58.472019
NCT01150253|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-01-13|2010-06-23|2010-06-24|Estimate|||||||2014-01-13|2014-01-14|Estimate|August 2006||2006-08-31|January 2014|2014-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effect of a Probiotic on Grass Pollen Allergic Rhinitis Subjects|Double Blind Randomised Comparison of Two Preparations, One Enriched in Probiotics and One Without Probiotics (Placebo) in Grass Pollen Allergic Rhinitis Patients, Using a Nasal Provocation Test|Completed||N/A|||Nestlé||2|||f||||f||||||||||2018-05-31 23:38:58.570924|2018-05-31 23:38:58.570924
NCT01150240|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2016-05-12|2010-06-23|2010-06-24|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2006||2006-10-31|May 2016|2016-05-31||||December 2018|Anticipated|2018-12-31||Observational|||Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland|Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland|Enrolling by invitation|||800|Anticipated|University of Zurich|||1||f||||||||||||||2018-05-31 23:38:58.659247|2018-05-31 23:38:58.659247
NCT01150227|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2014-12-10|2010-06-23|2010-06-24|Estimate|||||||2014-12-10|2014-12-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:38:58.72322|2018-05-31 23:38:58.72322
NCT01150214|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-06-01|2010-06-23|2010-06-24|Estimate|||||||2017-06-01|2017-06-02|Actual|July 2010||2010-07-31|June 2017|2017-06-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Observational|DECAAF||DECAAF: Delayed-Enhancement MRI (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation|DECAAF: DE-MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation|Completed|||339|Actual|University of Utah|||1||f||||t||||||||||2018-05-31 23:38:58.77268|2018-05-31 23:38:58.77268
NCT01150201|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-07-02|2010-06-23|2010-06-24|Estimate|||||||2015-07-02|2015-07-03|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease|Phase 4 Study of the Renoprotective Efficacy of Aliskiren in Addition to Angiotensin II Receptor Blocker in Chronic Kidney Disease|Completed||Phase 4|80|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:38:58.87483|2018-05-31 23:38:58.87483
NCT01150175|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-06-23|2010-06-23|2010-06-24|Estimate|||||||2010-06-23|2010-06-24|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|END-HF||Direct Endomyocardial Injection of Autologous Bone Marrow Cells to Treat Ischaemic Heart Failure|Double-blind Placebo Controlled Trial on Direct Endomyocardial Injection of Autologous Bone Marrow Cells for Enhancement of Neovascularization in Patients With Ischaemic Heart Failure (END-HF)|Unknown status|Recruiting|Phase 2|90|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:38:59.056103|2018-05-31 23:38:59.056103
NCT01150162|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2013-02-01|2010-06-23|2010-06-24|Estimate|||||||2013-02-01|2013-02-04|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|MGES||Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation|A Prospective Randomized, Multi-center Study to Assess the Safety and Efficacy of Mucosta (Rebamipide), in Combination With Omeprazole as Adjuvant Therapy in Gastric Ulcer Patients|Completed||Phase 3|129|Actual|Otsuka Pakistan Limited||2|||f||||f||||||||||2018-05-31 23:38:59.151023|2018-05-31 23:38:59.151023
NCT01150149|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-09-26|2010-06-23|2010-06-24|Estimate|||||||2012-09-26|2012-09-27|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Evaluating Modes of Influenza Transmission Between Humans|Evaluating Modes of Influenza Transmission Using a Human Challenge/Exposure Model|Withdrawn||N/A|0|Actual|University of Nottingham||4||funding application unsuccessful|f||||f||||||||||2018-05-31 23:38:59.240625|2018-05-31 23:38:59.240625
NCT01150136|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2015-04-21|2010-06-23|2010-06-24|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study|Choline Nutritional Status Of Children With Cystic Fibrosis X-Sectional Study|Completed|||57|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 23:38:59.328231|2018-05-31 23:38:59.328231
NCT01150123|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|2014-04-03||2017-05-08|2010-06-23|2010-06-24|Estimate|2017-05-08|2017-05-15|Actual||||2017-05-08|2017-05-15|Actual|May 2010||2010-05-31|May 2017|2017-05-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Interventional|||Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women|A Phase Ib Randomized, Observer-Blind, Controlled, Single Center, Dose-Ranging Study of a Group B Streptococcus Vaccine in Healthy Women 18-40 Years of Age|Completed||Phase 1|678|Actual|Novartis||9|||f||||||||||||||2018-05-31 23:38:59.516233|2018-05-31 23:38:59.516233
NCT01150110|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-06-23|2010-06-23|2010-06-24|Estimate|||||||2010-06-23|2010-06-24|Estimate|July 2007||2007-07-31|May 2007|2007-05-31|July 2008|Actual|2008-07-31|||||Interventional|||Resilient Occlusal and Patients With Temporomandibular Disorder (TMD)|Evaluation of Resilient Occlusal Splints in the Control of Patients With Temporomandibular Disorder (TMD)|Completed||Early Phase 1|||Federal University of Uberlandia|||||f||||t||||||||||2018-05-31 23:39:03.838681|2018-05-31 23:39:03.838681
NCT01150097|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2014-05-01||2015-03-12|2010-06-23|2010-06-24|Estimate|2014-05-01|2014-05-30|Estimate||||2015-03-12|2015-04-02|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients|Extension Study to the Multicenter, Open-label, Randomized, Controlled Study CRAD001H2304 to Evaluate the Long-term Efficacy and Safety of Concentration-controlled Everolimus in Liver Transplant Recipient|Completed||Phase 3|284|Actual|Novartis||3|||f||||t||||||||||2018-05-31 23:39:03.927534|2018-05-31 23:39:03.927534
NCT01150084|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-06-25|2010-06-23|2010-06-24|Estimate|||||||2010-06-25|2010-06-28|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||"Step by Step: A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees"|"Step by Step: A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees"|Unknown status|Active, not recruiting|Early Phase 1|75|Actual|University of Birmingham||2|||f||||t||||||||||2018-05-31 23:39:05.079377|2018-05-31 23:39:05.079377
NCT01150071|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-06-01|2010-06-23|2010-06-24|Estimate|||||||2015-06-01|2015-06-03|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|PEP11||Growth, Health and Development in Children Born Extremely Preterm|Growth, Health and Development in Children Born Extremely Preterm|Completed|||232|Actual|University of Bergen|||1||f||||f||||||Samples Without DNA|"~     On a subpopulation blood for inflammatory parameters will be collected~   "|||2018-05-31 23:39:05.141333|2018-05-31 23:39:05.141333
NCT01150058|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2015-05-11|2010-06-23|2010-06-24|Estimate|||||||2015-05-11|2015-05-12|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia|Preclinical Evaluation of Novel CD33-Targeting Therapeutics for Treatment of Acute Myeloid Leukemia (AML)|Completed|||40|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     cell samples~   "|||2018-05-31 23:39:05.214692|2018-05-31 23:39:05.214692
NCT01150045|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2017-06-26|2010-06-23|2010-06-24|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2010||2010-06-30|June 2017|2017-06-30||||December 2019|Anticipated|2019-12-31||Interventional|||Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery|A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer|Active, not recruiting||Phase 3|2500|Anticipated|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-05-31 23:39:05.540663|2018-05-31 23:39:05.540663
NCT01150032|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2017-07-06|2010-06-23|2010-06-24|Estimate|||||||2017-07-06|2017-07-07|Actual|September 20, 2010|Actual|2010-09-20|July 2017|2017-07-31|May 2025|Anticipated|2025-05-31|February 20, 2017|Actual|2017-02-20||Observational|QUALYOR||Bone Quality Lyon Orleans|Bone Quality and Improvement of Fracture Risk Prediction|Active, not recruiting|||1605|Actual|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     Frozen plasma: for later genetic studies Frozen serum: for later studies on new potential~     marker of bone remodelling~   "|||2018-05-31 23:39:07.122261|2018-05-31 23:39:07.122261
NCT01150019|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-07-07|2010-06-23|2010-06-24|Estimate|||||||2010-07-07|2010-07-08|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) (18FDG-PET)|Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18FDG-PET in Obese Person|Completed|||120|Actual|Korea University|||2||f||||t||||||Samples Without DNA|"~     Plasma, whole blood, serum~   "|||2018-05-31 23:39:07.182723|2018-05-31 23:39:07.182723
NCT01149668|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2013-06-17|2010-06-22|2010-06-23|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer|A Long-term Safety Study of the Pan-histone Deacetylase (HDAC) Inhibitor, PCI-24781, in Subjects With Cancer|Completed||Phase 1|7|Actual|Pharmacyclics LLC.||1|||f||||f||||||||||2018-05-31 23:39:12.999801|2018-05-31 23:39:12.999801
NCT01150006|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-06-28|2010-06-23|2010-06-24|Estimate|||||||2010-06-28|2010-06-29|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Correlation Between Various Adipokines and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG) (18FDG-PET)|Correlation Between Various Adipokines and Vascular Inflammation Measured by 18FDG-PET In Healthy Male Subjects|Completed|||90|Actual|Korea University|||1||f||||t||||||Samples Without DNA|"~     whole blood, plasma, serum~   "|||2018-05-31 23:39:07.264568|2018-05-31 23:39:07.264568
NCT01149993|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2014-06-06|2010-06-23|2010-06-24|Estimate|||||||2014-06-06|2014-06-09|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation|Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation|Withdrawn||Phase 4|0|Actual|Georgetown University||3||FDA clinical hold, IND withdrawn.|f||||f||||||||||2018-05-31 23:39:07.341153|2018-05-31 23:39:07.341153
NCT01149980|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-23|2010-06-23|2010-06-24|Estimate|||||||2010-06-23|2010-06-24|Estimate|October 2003||2003-10-31|June 2010|2010-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Citalopram Hydrobromide 40 mg Tablets and Celexa 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:39:07.413303|2018-05-31 23:39:07.413303
NCT01149967|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-23|2010-06-23|2010-06-24|Estimate|||||||2010-06-23|2010-06-24|Estimate|October 2003||2003-10-31|June 2010|2010-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Citalopram Hydrobromide 40 mg Tablets and Celexa 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:39:07.625357|2018-05-31 23:39:07.625357
NCT01149954|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-06-28|2010-06-23|2010-06-24|Estimate|||||||2010-06-28|2010-06-29|Estimate|January 2003||2003-01-31|June 2010|2010-06-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules of Dr. Reddy's Laboratories Limited Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Ibuprofen 200 mg Soft Gel Capsules and Advil Liquigels 200 mg Gel Capsules Administered as 1 x 200 mg Gel Capsules in Healthy Subjects Under Fed Conditions|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:39:07.700618|2018-05-31 23:39:07.700618
NCT01149941|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2010-06-25|2010-06-23|2010-06-24|Estimate|||||||2010-06-25|2010-06-28|Estimate|November 2002||2002-11-30|June 2010|2010-06-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Bioequivalence Study of Ibuprofen 200 mg Gel Capsules of Dr. Reddy's Laboratories Under Fasting Condition|Randomized, 2-way Crossover, Bioequivalence Study of Ibuprofen 200 mg Gel Capsules and Advil Liquigels 200 mg Gel Capsules Administered as 1 x 200 mg Gel Capsules in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:39:07.774773|2018-05-31 23:39:07.774773
NCT01149928|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-23|2010-06-23|2010-06-24|Estimate|||||||2010-06-23|2010-06-24|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Observational|||Role of Cord Blood Hormones and Epinephrine in the Development of Transient Tachypnea of the Newborn||Completed|||70|Actual|Ankara University|||2||f||||f||||||Samples Without DNA|"~     Cord blood serum samples were stored.~   "|||2018-05-31 23:39:07.86218|2018-05-31 23:39:07.86218
NCT01149915|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-05-05|2010-06-22|2010-06-24|Estimate|||||||2015-05-05|2015-05-07|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias|A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias|Completed||Phase 1|40|Anticipated|Threshold Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:39:07.935534|2018-05-31 23:39:07.935534
NCT01149902|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2011-08-23|2010-06-23|2010-06-24|Estimate|||||||2011-08-23|2011-08-24|Estimate|July 2010||2010-07-31|June 2010|2010-06-30||||March 2012|Anticipated|2012-03-31||Interventional|||Study of Chemo-Immunotherapy in Head and Neck Cancer Patients|Phase I Study of Chemo-Immunotherapy in Patients With Relapsed and Refractory Head and Neck Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 1|10|Anticipated|University of Yamanashi|||||f||||||||||||||2018-05-31 23:39:08.046923|2018-05-31 23:39:08.046923
NCT01149889|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2011-12-02|2010-06-23|2010-06-24|Estimate|||||||2011-12-02|2011-12-06|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Transcranial Direct Current Stimulation to Treat Major Depressive Disorder|An Open-label, Crossover Study on Major Depressive Disorder Using Transcranial Direct Current Stimulation|Completed||Phase 2/Phase 3|60|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:39:08.133609|2018-05-31 23:39:08.133609
NCT01149876|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2014-01-10||2014-10-30|2010-06-23|2010-06-24|Estimate|2014-10-30|2014-11-06|Estimate||||2014-10-30|2014-11-06|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots|A Single Blind, Placebo Controlled Trial to Evaluate Effects of a Study Medication, a Nu Skin Lightening Product With and Without Iontophoresis vs Tretinoin Cream vs Vehicle Control for Facial Hyperpigmentation|Completed||Phase 4|80|Actual|Massachusetts General Hospital|Scale of pigmentation didn't account for both change in color and number.|4|||f||||f||||||||||2018-05-31 23:39:08.296457|2018-05-31 23:39:08.296457
NCT01149863|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2013-01-10||2013-11-19|2010-06-23|2010-06-24|Estimate|2013-05-30|2013-07-08|Estimate||||2013-11-19|2013-12-13|Estimate|June 2010||2010-06-30|May 2013|2013-05-31||||December 2011|Actual|2011-12-31||Interventional|||Alteration in Timing of Plerixafor Administration|WCI1680-09: Evaluation of Alterations in Time of Administration of Plerixafor (Mozobil ®, AMD3100) in Combination With G-CSF on Safety and CD34+ Cell Mobilization|Completed||Phase 2|34|Actual|Emory University||1|||f||||t||||||||||2018-05-31 23:39:08.844344|2018-05-31 23:39:08.844344
NCT01149850|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2018-02-20|2010-06-23|2010-06-24|Estimate|||||||2018-02-20|2018-02-22|Actual|April 28, 2010|Actual|2010-04-28|March 2017|2017-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma|Active, not recruiting||Phase 2|50|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:39:09.093334|2018-05-31 23:39:09.093334
NCT01149837|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2018-01-24|2010-06-23|2010-06-24|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2013||2013-07-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Evaluation of InnoLIA HTLV I/II Score|In Vitro Diagnostic Study for Supplemental Testing of Anti-HTLV-I/II Reactive Human Blood Specimens|Enrolling by invitation|||4500|Anticipated|Creative Testing Solutions|||1||f||||t||||||Samples With DNA|"~     human serum and/or human plasma~   "|Undecided||2018-05-31 23:39:09.243474|2018-05-31 23:39:09.243474
NCT01149824|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2013-05-29|2010-06-23|2010-06-24|Estimate|||||||2013-05-29|2013-05-31|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|6A||Placebo Controlled Study of Sublingual Salvinorin A|A Double Blind Placebo Controlled Ascending Dose Pharmacodynamic and Tolerability Study of 100 to 4000 µg of Sublingual Salvinorin A|Completed||N/A|8|Actual|California Pacific Medical Center Research Institute||1|||f||||||||||||||2018-05-31 23:39:09.433025|2018-05-31 23:39:09.433025
NCT01149811|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2012-06-20|2010-06-22|2010-06-24|Estimate|||||||2012-06-20|2012-06-22|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|Fipamezole||A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease|A Randomized, Double-Blind, Crossover Study Comparing the Safety and Tolerability of Two Dose Regimens of Oromucosal Fipamezole ODT in Adult Patients With Parkinson's Disease Who Are Receiving Levodopa|Completed|||27|Actual|Valeant Pharmaceuticals International, Inc.|||2||f||||f||||||||||2018-05-31 23:39:09.639485|2018-05-31 23:39:09.639485
NCT01149798|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2012-08-05|2010-06-23|2010-06-24|Estimate|||||||2012-08-05|2012-08-07|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer|A Single Institutional Phase II Clinical Trial of Abraxane Combined With Cisplatin in Metastatic Breast Cancer|Completed||Phase 2|73|Actual|Fudan University||1|||f||||f||||||||||2018-05-31 23:39:09.766429|2018-05-31 23:39:09.766429
NCT01149785|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2011-09-12||2011-10-20|2010-06-22|2010-06-23|Estimate|2011-09-12|2011-10-19|Estimate||||2011-10-20|2011-10-24|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers|A Phase 1, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Doses Of Ketoconazole On The Single Dose Pharmacokinetics Of Crizotinib (PF-02341066) In Healthy Volunteers|Completed||Phase 1|15|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:39:09.877975|2018-05-31 23:39:09.877975
NCT01149772|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2015-10-13||2016-01-25|2010-06-22|2010-06-23|Estimate|2015-12-11|2016-01-18|Estimate||||2016-01-25|2016-02-24|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ACCESS|This is the total number of participants eligible after baseline and were randomized into each arm.|Adjusting to Chronic Conditions Using Education, Support, and Skills|Cognitive Behavioral Therapy in Primary Care: Treating the Medically Ill|Completed||N/A|302|Actual|VA Office of Research and Development|There were some deaths and hospitalizations during the study, however, none of the adverse events reported were determined to be related to the study.|2|||f||||t||||||||||2018-05-31 23:39:10.620223|2018-05-31 23:39:10.620223
NCT01149759|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2016-07-26||2017-02-06|2010-06-22|2010-06-23|Estimate|2017-02-06|2017-03-27|Actual||||2017-02-06|2017-03-27|Actual|June 2010||2010-06-30|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy|Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis With Suppression of Immune Activation During Cyclosporine Therapy|Completed||N/A|9|Actual|Rockefeller University||1|||f||||f||||||||Undecided||2018-05-31 23:39:11.033751|2018-05-31 23:39:11.033751
NCT01149746|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2010-06-22|2010-06-22|2010-06-23|Estimate|||||||2010-06-22|2010-06-23|Estimate|December 2004||2004-12-31|June 2010|2010-06-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:39:11.526992|2018-05-31 23:39:11.526992
NCT01149733|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2010-08-18||2010-08-18|2010-06-22|2010-06-23|Estimate|2010-08-18|2010-09-13|Estimate||||2010-08-18|2010-09-13|Estimate|November 2004||2004-11-30|August 2010|2010-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:39:11.761937|2018-05-31 23:39:11.761937
NCT01149720|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2018-02-22|2010-06-22|2010-06-23|Estimate|||||||2018-02-22|2018-02-23|Actual|July 2010||2010-07-31|February 2018|2018-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors|An Open-Label, Phase 1, Randomized, Two-Treatment, Two-Period, Two-Way Crossover, Relative Bioavailability Study Of A Capsule And A Tablet Formulation Of ARQ 197 In Subjects With Advanced Solid Tumors|Completed||Phase 1|24|Anticipated|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 23:39:12.37224|2018-05-31 23:39:12.37224
NCT01149707|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2018-04-27|2010-06-22|2010-06-23|Estimate|||||||2018-04-27|2018-05-01|Actual|June 1, 2010||2010-06-01|April 2018|2018-04-30|June 20, 2015|Actual|2015-06-20|October 1, 2014|Actual|2014-10-01||Interventional|||Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis|A 2-Week Exploratory Randomized, Double-Blind, Parallel-Group, Dose-Ranging, Placebo-Controlled Safety, Tolerability, Biomarker and Efficacy Clinical Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis|Completed||Phase 2|34|Actual|PurGenesis Technologies Inc.||4|||f||||f||||||||||2018-05-31 23:39:12.520326|2018-05-31 23:39:12.520326
NCT01149694|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2010-06-23|2010-06-22|2010-06-23|Estimate|||||||2010-06-23|2010-06-24|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers|A Randomized, Double-Blind, Parallel-Group, Single-Ascending Dose, Placebo-Controlled Safety and Tolerability Study of PUR 0110 Rectal Enema in Normal Healthy Volunteers|Completed||Phase 1|24|Actual|PurGenesis Technologies Inc.||4|||f||||f||||||||||2018-05-31 23:39:12.724787|2018-05-31 23:39:12.724787
NCT01149681|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2011-03-03|2010-06-22|2010-06-23|Estimate|||||||2011-03-03|2011-03-04|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis|Open-label, Phase II Clinical Trial of Aplidin® (Plitidepsin) in Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis|Completed||Phase 2|12|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 23:39:12.905192|2018-05-31 23:39:12.905192
NCT01149655|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2014-11-26||2015-04-01|2010-06-22|2010-06-23|Estimate|2015-04-01|2015-04-02|Estimate||||2015-04-01|2015-04-02|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|ATTAIN 266||Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia|A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia|Completed||Phase 3|252|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-05-31 23:39:13.354915|2018-05-31 23:39:13.354915
NCT01149642|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2016-03-14|2010-06-22|2010-06-23|Estimate|||||||2016-03-14|2016-03-15|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|IMPATOX||Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer|Phase III Multicenter, Randomised and Double-blind Study Comparing an Oral Immunomodulatory Solution Versus a Placebo in Preventing Severe Acute Mucositis in Head and Neck Cancer Patients Treated Surgically and Concomitantly With Radiochemotherapy|Completed||Phase 3|160|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||||||||||||2018-05-31 23:39:14.985799|2018-05-31 23:39:14.985799
NCT01149629|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2013-03-18|2010-06-22|2010-06-23|Estimate|||||||2013-03-18|2013-03-20|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa|A Randomized, Open-Label, Three-Period, Three-Sequence, Single-Dose Crossover and Separate Three-Daily-Dose Treatment Period Study Comparing the Pharmacokinetic Profiles Following Oral Dosing of 300 mg of Droxidopa in the Fed Versus Fasted State, the Bioequivalence of Three 100 mg Capsules of Droxidopa Versus a Single 300 mg Capsule of Droxidopa, and 300 mg of Droxidopa Given Three Times at Four Hour Intervals in Healthy, Elderly Subjects|Completed||Phase 1|24|Anticipated|Chelsea Therapeutics||4|||f||||f||||||||||2018-05-31 23:39:15.087895|2018-05-31 23:39:15.087895
NCT01149616|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2017-03-01||2017-06-29|2010-06-22|2010-06-23|Estimate|2017-06-29|2017-07-07|Actual||||2017-06-29|2017-07-07|Actual|December 2009||2009-12-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery|Effects of Perioperative Intravenous Dexamethasone on Pain in Out Patient Knee Surgery|Terminated||Phase 4|82|Actual|Beth Israel Deaconess Medical Center||2||investigators changed jobs, no longer affiliated with institution|f||||f||||||||No||2018-05-31 23:39:15.335817|2018-05-31 23:39:15.335817
NCT01149603|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-09-19|2010-06-22|2010-06-23|Estimate|||||||2017-09-19|2017-09-21|Actual|July 2010||2010-07-31|September 2017|2017-09-30|September 19, 2017|Actual|2017-09-19|September 19, 2017|Anticipated|2017-09-19||Interventional|DEFINe||The Destination Therapy Evaluation for Failing Fontan Study|The Destination Therapy Evaluation for Failing Fontan Study (DEFINe Study)|Withdrawn||N/A|0|Actual|Providence Health & Services||1||Lack of Enrollement|f||||t||||||||||2018-05-31 23:39:16.595141|2018-05-31 23:39:16.595141
NCT01149590|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2017-04-06|2010-06-22|2010-06-23|Estimate|||||||2017-04-06|2017-04-10|Actual|November 2010||2010-11-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SCOT-HEART||Scottish COmputed Tomography of the HEART Trial|Role of Multidetector Computed Tomography in the Diagnosis and Management of Patients Attending a Rapid Access Chest Pain Clinic|Completed||N/A|4138|Actual|University of Edinburgh||2|||f||||f||||||||Undecided||2018-05-31 23:39:16.877558|2018-05-31 23:39:16.877558
NCT01149577|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2010-06-22|2010-06-22|2010-06-23|Estimate|||||||2010-06-22|2010-06-23|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|April 2009|Actual|2009-04-30|December 2007|Actual|2007-12-31||Interventional|||Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients||Completed||Phase 4|25|Actual|Central Institute of Psychiatry, Ranchi, India||1|||f||||t||||||||||2018-05-31 23:39:17.671931|2018-05-31 23:39:17.671931
NCT01149564|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-20|||2010-06-22|2010-06-22|2010-06-23|Estimate|||||||2010-06-22|2010-06-23|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants|Comparison of Oral and Intravenous Ibuprofen for Treatment of Patent Ductus Arteriosus in Extremely Premature Infants: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|70|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 23:39:18.106408|2018-05-31 23:39:18.106408
NCT01149551|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2015-04-15|2010-06-21|2010-06-23|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Observational|||CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness|CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness|Completed|||9356|Actual|VA Office of Research and Development|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 23:39:18.261155|2018-05-31 23:39:18.261155
NCT01149538|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2016-02-29||2016-10-26|2010-06-21|2010-06-23|Estimate|2016-06-30|2016-08-11|Estimate||||2016-10-26|2016-12-19|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure|Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure|Completed||Phase 1/Phase 2|60|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 23:39:18.488151|2018-05-31 23:39:18.488151
NCT01149525|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2017-05-05|2010-06-21|2010-06-23|Estimate|||||||2017-05-05|2017-05-08|Actual|June 2010||2010-06-30|May 2017|2017-05-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|FACTSEP||Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis|A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis|Completed||Phase 3|59|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 23:39:19.537391|2018-05-31 23:39:19.537391
NCT01149512|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2017-01-05||2017-08-09|2010-06-22|2010-06-23|Estimate|2017-04-30|2017-08-07|Actual||||2017-08-09|2017-09-11|Actual|September 2011||2011-09-30|August 2017|2017-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Outcomes of the Adjustable Gastric Band in a Publicly Funded Obesity Program|Outcomes of the Adjustable Gastric Band in a Publicly Funded Obesity Program|Completed|||178|Actual|University of Alberta|||1||f||||f||||||||No||2018-05-31 23:39:19.827656|2018-05-31 23:39:19.827656
NCT01149499|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-21|2010-06-21|2010-06-23|Estimate|||||||2010-06-21|2010-06-23|Estimate|January 2005||2005-01-31|June 2010|2010-06-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Valacyclovir 1000 mg Tablet Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Valacyclovir 1000 mg Tablet and Valtrex Following a 1 x 1000 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:39:20.192875|2018-05-31 23:39:20.192875
NCT01149486|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2010-08-16||2010-11-22|2010-06-22|2010-06-23|Estimate|2010-08-16|2010-09-14|Estimate||||2010-11-22|2010-12-08|Estimate|January 2004||2004-01-31|November 2010|2010-11-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions|A Relative Bioavailability Study of 100/25 mg Losartan Potassium/Hydrochlorothiazide Tablets Under Fasting Conditions|Completed||Phase 1|20|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:39:20.365131|2018-05-31 23:39:20.365131
NCT01149473|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2010-08-16||2010-08-16|2010-06-22|2010-06-23|Estimate|2010-08-16|2010-09-14|Estimate||||2010-08-16|2010-09-14|Estimate|March 2004||2004-03-31|August 2010|2010-08-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions|A Relative Bioavailability Study of Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|80|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:39:21.539212|2018-05-31 23:39:21.539212
NCT01149460|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2010-08-18||2010-08-18|2010-06-22|2010-06-23|Estimate|2010-08-18|2010-09-14|Estimate||||2010-08-18|2010-09-14|Estimate|September 2004||2004-09-30|August 2010|2010-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Valacyclovir 1000 mg Tablet Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Valacyclovir 1000 mg Tablet and Valtrex Administered as 1 x 1000 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:39:22.968439|2018-05-31 23:39:22.968439
NCT01149447|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2012-08-15|2010-06-22|2010-06-23|Estimate|||||||2012-08-15|2012-08-16|Estimate|January 2001||2001-01-31|August 2011|2011-08-31||||||||Observational|PFO-HUG||Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale|Prospective Clinical Follow-up of Patients Presenting With Cryptogenic Stroke Treated With the Percutaneous Closure of a Patent Foramen Ovale|Unknown status|Recruiting||200|Anticipated|University Hospital, Geneva|||||f||||t||||||||||2018-05-31 23:39:23.903813|2018-05-31 23:39:23.903813
NCT01149434|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2014-09-08||2014-09-24|2010-06-22|2010-06-23|Estimate|2014-09-17|2014-09-25|Estimate||||2014-09-24|2014-10-06|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers|Drug- Drug Interaction Study of JI-101 & Everolimus in Advanced Solid Tumors, Expansion Pharmacodynamic Study of JI-101 in Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers|Terminated||Phase 1/Phase 2|19|Actual|University of Utah||2||Lack of drug efficacy|f||||t||||||||||2018-05-31 23:39:24.644541|2018-05-31 23:39:24.644541
NCT01149421|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2014-10-03|2011-11-04|2015-01-29|2010-06-22|2010-06-23|Estimate|2015-01-29|2015-02-02|Estimate|2011-11-04|2011-11-10|Estimate|2015-01-29|2015-02-02|Estimate|June 2010||2010-06-30|January 2015|2015-01-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional||Participants who received at least one dose of LY2189265 or Placebo.|A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes|The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|755|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:39:26.02148|2018-05-31 23:39:26.02148
NCT01149408|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-10-05|2010-06-22|2010-06-23|Estimate|||||||2015-10-05|2015-10-07|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients|A Pilot Study of Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Who Can Tolerate Aggressive Therapy|Completed||Phase 1|3|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 23:39:30.153527|2018-05-31 23:39:30.153527
NCT01149395|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2016-12-16|2010-06-22|2010-06-23|Estimate|||||||2016-12-16|2016-12-19|Estimate|June 2010||2010-06-30|December 2016|2016-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn|Can Detection of Fragments of Cleaved E-cadherin in Tissue and/or Blood be of Value for Identifying and Monitoring Patients With PPI-responsive Heartburn?|Completed||Phase 1|40|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 23:39:30.239328|2018-05-31 23:39:30.239328
NCT01149382|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2012-08-17|2010-06-22|2010-06-23|Estimate|||||||2012-08-17|2012-08-21|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Observational|||Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients|Humoral Immune Response To Influenza Vaccine In Islet Cell In Transplant Recipients|Completed|||61|Actual|University of Alberta|||1||f||||f||||||||||2018-05-31 23:39:30.350335|2018-05-31 23:39:30.350335
NCT01149369|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2016-03-18|2010-06-22|2010-06-23|Estimate|||||||2016-03-18|2016-03-21|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|APRON||Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial|Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial|Completed||Phase 3|126|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-05-31 23:39:30.450557|2018-05-31 23:39:30.450557
NCT01149356|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-05-22|2010-06-22|2010-06-23|Estimate|||||||2015-05-22|2015-05-25|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer|A Phase I Dose Escalation Trial of RO4929097 Administered in Combination With Exemestane in Pre- and Postmenopausal Patients With ER + Metastatic Breast Cancer|Terminated||Phase 1|15|Actual|National Cancer Institute (NCI)||2||Manufacturer discontinued drug development.|f||||||||||||||2018-05-31 23:39:30.561934|2018-05-31 23:39:30.561934
NCT01149343|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-05-18|2010-06-22|2010-06-23|Estimate|||||||2017-05-18|2017-05-22|Actual|July 1, 2010|Actual|2010-07-01|May 2017|2017-05-31|December 19, 2016|Actual|2016-12-19|February 11, 2014|Actual|2014-02-11||Interventional|||Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer|Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma|Completed||Phase 1|107|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 23:39:30.668439|2018-05-31 23:39:30.668439
NCT01149330|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2012-03-09|2010-06-22|2010-06-23|Estimate|||||||2012-03-09|2012-03-12|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|Estudo Epiduo||Evaluation of Efficacy and Safety of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|Evaluation of Efficacy and Safety of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|Completed||Phase 4|75|Actual|Galderma Brasil Ltda.||1|||f||||f||||||||||2018-05-31 23:39:30.857829|2018-05-31 23:39:30.857829
NCT01149304|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-11-16|2010-06-22|2010-06-23|Estimate|||||||2017-11-16|2017-11-20|Actual|June 2009||2009-06-30|November 2017|2017-11-30||||November 15, 2017|Actual|2017-11-15||Interventional|ELDORADO||Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity|Evaluation of the Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity After Brachytherapy of Liver Metastases From Colorectal Carcinoma, Assessed in a Prospective Randomised Trial|Completed||Phase 2|22|Actual|University of Magdeburg||2|||f||||||||||||||2018-05-31 23:39:31.093376|2018-05-31 23:39:31.093376
NCT01149291|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-01-09|2010-06-22|2010-06-23|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism|A 18 Months, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving sVDRA's for Prevention and Treatment of Secondary Hyperparathyroidism|Completed|||511|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:39:31.268662|2018-05-31 23:39:31.268662
NCT01149278|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-11-02|2010-06-22|2010-06-23|Estimate|||||||2012-11-02|2012-11-05|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SEPSISPAM||Assessment of Two Levels of Arterial Pressure on Survival in Patients With Septic Shock||Completed||N/A|800|Actual|University Hospital, Angers||2|||f||||||||||||||2018-05-31 23:39:31.479856|2018-05-31 23:39:31.479856
NCT01149265|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2010-07-20|2010-06-22|2010-06-23|Estimate|||||||2010-07-20|2010-07-21|Estimate|May 2010||2010-05-31|July 2010|2010-07-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Online Support Groups for Depression and Anxiety|Randomised Controlled Trial of an Existing Online Support Group for Depression and Anxiety|Unknown status|Active, not recruiting|Phase 1/Phase 2|1000|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 23:39:31.632502|2018-05-31 23:39:31.632502
NCT01149252|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-20|||2014-12-16|2010-06-22|2010-06-23|Estimate|||||||2014-12-16|2014-12-17|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis|Determination of the Efficacy and Safety of Psoralait Versus Placebo in the Treatment of Psoriasis.|Terminated||Phase 4|15|Actual|Trima, Israel Pharmaceutical Products||1||Difficulties arouse in recruiting new patients|f||||t||||||||||2018-05-31 23:39:31.723335|2018-05-31 23:39:31.723335
NCT01149213|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2012-03-24|2010-06-22|2010-06-23|Estimate|||||||2012-03-24|2012-03-27|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Follow-up Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder|An Open-label, Follow-up Study on Remitted Patients With Major Depressive Disorder Using Transcranial Direct Current Stimulation|Completed||Phase 2/Phase 3|42|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:39:31.810263|2018-05-31 23:39:31.810263
NCT01149200|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2013-11-27|2010-06-22|2010-06-23|Estimate|||||||2013-11-27|2013-12-02|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof-of-Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominant IBS|Completed||Phase 2|24|Actual|Targacept Inc.||2|||f||||f||||||||||2018-05-31 23:39:31.893606|2018-05-31 23:39:31.893606
NCT01149187|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-22|2010-06-22|2010-06-23|Estimate|||||||2010-06-22|2010-06-23|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules|Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules|Unknown status|Recruiting||400|Anticipated|Seoul National University Hospital|||1||f||||t||||||Samples With DNA|"~     the investigaters will use the whole blood sample for interferon-gamma release assay.~   "|||2018-05-31 23:39:31.987|2018-05-31 23:39:31.987
NCT01149174|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-10-03|2010-06-22|2010-06-23|Estimate|||||||2011-10-03|2011-10-04|Estimate|January 1994||1994-01-31|October 2011|2011-10-31|June 2009|Actual|2009-06-30|December 2003|Actual|2003-12-31||Interventional|EMDA/PRE-TUR||Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer|Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial.|Completed||Phase 3|352|Actual|University of Rome Tor Vergata||3|||f||||t||||||||||2018-05-31 23:39:32.060091|2018-05-31 23:39:32.060091
NCT01149161|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2016-04-20|2010-06-22|2010-06-23|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2009||2009-05-31|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma|Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study|Recruiting||Phase 2/Phase 3|2000|Anticipated|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 23:39:32.15467|2018-05-31 23:39:32.15467
NCT01149148|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2012-03-26||2015-04-27|2010-06-22|2010-06-23|Estimate|2012-07-10|2012-08-16|Estimate||||2015-04-27|2015-04-28|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|May 2010|Actual|2010-05-31||Interventional|||Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients|Effect of Regional Cerebral Oxygen Saturation Monitoring On Neurological Outcome In Patients Undergoing Aortic Arch Surgery|Completed||Phase 3|25|Actual|University of Michigan|The study was discontinued after 25 subjects completed.|2|||f||||f||||||||||2018-05-31 23:39:32.239122|2018-05-31 23:39:32.239122
NCT01149135|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2011-08-09|2010-06-22|2010-06-23|Estimate|||||||2011-08-09|2011-08-10|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Low Intensity 'Blue Light' Treatment of Seasonal Affective Disorder|Randomized and Controlled Study of the Effects of Low Intensity 'Blue Light'in the Treatment of Seasonal Affective Disorder|Completed||N/A|22|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 23:39:32.532545|2018-05-31 23:39:32.532545
NCT01149122|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2014-05-14|2010-06-22|2010-06-23|Estimate|||||||2014-05-14|2014-05-15|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma|Phase III Study of Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib in Unresectable, Metastatic Biliary Tract Carcinoma|Completed||Phase 3|266|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 23:39:32.624082|2018-05-31 23:39:32.624082
NCT01148927|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2013-01-10|2010-06-21|2010-06-22|Estimate|||||||2013-01-10|2013-01-11|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Observational|||Quality of Life Study for Adult Patients With Acute Lymphoblastic Leukemia|A Pilot Study to Evaluate the Quality of Life of Long Term Survivors of Adult Acute Lymphoblastic Leukemia|Completed|||29|Actual|University Health Network, Toronto|||1||f||||||||||||||2018-05-31 23:39:36.325501|2018-05-31 23:39:36.325501
NCT01149109|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2017-06-13|2010-06-22|2010-06-23|Estimate|||||||2017-06-13|2017-06-14|Actual|October 2010||2010-10-31|June 2017|2017-06-30|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|CeTeG||Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients|Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients|Completed||Phase 3|141|Actual|University Hospital, Bonn||2|||f||||t||||||||||2018-05-31 23:39:32.73437|2018-05-31 23:39:32.73437
NCT01149096|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2017-02-07|2010-06-22|2010-06-23|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2010||2010-06-30|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Collection of Bone Marrow From Donors Treated With or Without Filgrastim|A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631|Terminated|||13|Actual|Children's Oncology Group|||2|poor accrual|f||||t||||||Samples With DNA|"~     bone marrow~   "|||2018-05-31 23:39:32.863606|2018-05-31 23:39:32.863606
NCT01149083|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2018-03-22|2010-06-22|2010-06-23|Estimate|||||||2018-03-22|2018-03-23|Actual|June 30, 2010|Actual|2010-06-30|January 2018|2018-01-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Veliparib With or Without Carboplatin in Treating Patients With Stage III-IV Breast Cancer|Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer|Active, not recruiting||Phase 2|71|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:39:32.982848|2018-05-31 23:39:32.982848
NCT01149070|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-09-12|2010-06-22|2010-06-23|Estimate|||||||2014-09-12|2014-09-15|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|ESCORT||An Observational Study to Evaluate Efficacy, Safety and Clinical Outcomes of Currently Used Pharmaceutical Therapies for Controlled Ovarian Stimulation in Assisted Reproductive Techniques|An Observational Program to Evaluate Efficacy, Safety and Clinical Outcomes of Currently Used Pharmaceutical Therapies for Controlled Ovarian Stimulation (COS) in Assisted Reproductive Techniques (ART)|Completed|||10103|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:39:33.121779|2018-05-31 23:39:33.121779
NCT01149057|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|2015-10-01||2016-11-01|2010-06-22|2010-06-23|Estimate|2015-10-01|2015-10-29|Estimate||||2016-11-01|2016-11-02|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Intent-to-treat (ITT) Population: all participants who have received any part of an infusion of the study drug.|A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS|An Open-Label Study to Evaluate the Efficacy and Safety Of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARDs and/or Biologic DMARDs|Completed||Phase 4|145|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:39:33.30821|2018-05-31 23:39:33.30821
NCT01149044|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2015-10-19|2010-06-22|2010-06-23|Estimate|||||||2015-10-19|2015-10-20|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|TOTAL||A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI|TOTAL Trial: A Randomized Trial of Routine Aspiration ThrOmbecTomy With PCI Versus PCI ALone in Patients With STEMI Undergoing Primary PCI|Completed||N/A|10732|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-05-31 23:39:34.133034|2018-05-31 23:39:34.133034
NCT01149031|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2015-03-21|2010-06-22|2010-06-23|Estimate|||||||2015-03-21|2015-03-24|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|October 2012|Actual|2012-10-31||Interventional|LLLT||Low Level Laser Therapy for the Treatment of Provoked Vestibulodynia||Terminated||N/A|34|Actual|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 23:39:34.390185|2018-05-31 23:39:34.390185
NCT01149018|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-22|||2010-06-22|2010-06-22|2010-06-23|Estimate|||||||2010-06-22|2010-06-23|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|||Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia|A Randomized, Double-blind, Placebo-controlled Trial of Oral Tetrahydrocannabinol (∆-9-THC) in Patients With Fibromyalgia|Unknown status|Recruiting|N/A|80|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 23:39:34.478421|2018-05-31 23:39:34.478421
NCT01149005|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-06-22|2010-06-22|2010-06-23|Estimate|||||||2010-06-22|2010-06-23|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Cystic Fibrosis (CF) Exacerbation and Insulin Treatment|Evaluation of Glucose Tolerance and Insulin Treatment in Non Diabetic Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 23:39:34.590053|2018-05-31 23:39:34.590053
NCT01148992|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-01-10|2010-06-22|2010-06-23|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Interactions Between Intravenous (IV) Cocaine and Lofexidine|Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine|Terminated||Phase 1|16|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||No||2018-05-31 23:39:34.709352|2018-05-31 23:39:34.709352
NCT01148979|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2017-03-08||2017-04-19|2010-06-22|2010-06-23|Estimate|2017-04-19|2017-05-23|Actual||||2017-04-19|2017-05-23|Actual|September 2010||2010-09-30|April 2017|2017-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.|Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy|Completed||Phase 4|35|Actual|Mclean Hospital|The small sample size and crossover design both weaken group differences.|2|||f||||f|t|f|||f|||Undecided||2018-05-31 23:39:34.799331|2018-05-31 23:39:34.799331
NCT01148966|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2017-02-13|2010-06-21|2010-06-23|Estimate|||||||2017-02-13|2017-02-15|Actual|June 2010||2010-06-30|May 2013|2013-05-31||||April 2012|Actual|2012-04-30||Interventional|||Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors|A Phase 1 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|Terminated||Phase 1|6|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:39:35.475257|2018-05-31 23:39:35.475257
NCT01148953|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-05-23|2010-06-22|2010-06-23|Estimate|||||||2012-05-23|2012-05-24|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis|A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Tolerability of a Single Dose of Intravenous ALN-TTR01 in Patients With TTR Amyloidosis|Completed||Phase 1|32|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:39:35.822874|2018-05-31 23:39:35.822874
NCT01148914|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-05-31|2010-06-21|2010-06-22|Estimate|||||||2012-05-31|2012-06-01|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|IMPACT||The Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation|The Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation|Completed|||48|Actual|Texas Cardiac Arrhythmia Research Foundation|||1||f||||f||||||||||2018-05-31 23:39:36.453769|2018-05-31 23:39:36.453769
NCT01148901|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2015-04-29|2010-06-21|2010-06-22|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|HACER||Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)|Hip Arthritis Associated With AS Efficacy and Safety of Early Treatment With Infliximab (Remicade®)|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||1||"No patient enrolled after 6 months from the start. The decision to withdraw the study was based~   on a feasibility reevaluation conducted with investigators."|f||||f||||||||||2018-05-31 23:39:36.578339|2018-05-31 23:39:36.578339
NCT01148888|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2014-11-18|2010-06-21|2010-06-22|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||The Effect of Magnesium Sulfate on Motor and Somatosensory Evoked Potentials in Children Undergoing Scoliosis Surgery|The Effect of Magnesium Sulfate on Motor and Somatosensory Evoked Potentials in Children Undergoing Scoliosis Surgery|Completed||Phase 2|5|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 23:39:36.717159|2018-05-31 23:39:36.717159
NCT01148875|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2016-01-17|2010-06-21|2010-06-22|Estimate|||||||2016-01-17|2016-01-20|Estimate|September 2004||2004-09-30|January 2016|2016-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Mammography Reminders for Encouraging Women to Undergo Regular Mammography Screenings for Breast Cancer|Finding the M.I.N.C. for Mammography Maintenance|Completed|||3547|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-05-31 23:39:36.803109|2018-05-31 23:39:36.803109
NCT01148862|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2013-10-24||2017-03-02|2010-06-21|2010-06-22|Estimate|2017-03-02|2017-03-30|Actual||||2017-03-02|2017-03-30|Actual|June 2010||2010-06-30|March 2017|2017-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System|An In-clinic, Randomized, Cross-Over Study to Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System With Hypoglycemic Induction From Exercise|Completed||N/A|50|Actual|Medtronic Diabetes||2|||f||||t||||||||||2018-05-31 23:39:36.905362|2018-05-31 23:39:36.905362
NCT01148849|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-06-15|2010-06-21|2010-06-22|Estimate|||||||2017-06-15|2017-06-16|Actual|July 2010||2010-07-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety Study of MGAH22 in HER2-positive Carcinomas|A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available|Active, not recruiting||Phase 1|67|Anticipated|MacroGenics||1|||f||||f||||||||||2018-05-31 23:39:37.209209|2018-05-31 23:39:37.209209
NCT01148836|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2015-02-05||2015-03-19|2010-06-21|2010-06-22|Estimate|2015-03-19|2015-03-20|Estimate||||2015-03-19|2015-03-20|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Coenzyme Q-10 and Pulmonary Arterial Hypertension|Coenzyme Q-10 in the Treatment of Pulmonary Arterial Hypertension|Completed||N/A|18|Actual|The Cleveland Clinic|Length of the trial and number of subjects enrolled were both study limitations.|2|||f||||f||||||||||2018-05-31 23:39:37.316983|2018-05-31 23:39:37.316983
NCT01148823|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2015-02-22|2010-06-21|2010-06-22|Estimate|||||||2015-02-22|2015-02-24|Estimate|June 2007||2007-06-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Time of Permanence of Dressing Following Breast Reconstruction|Influence of Time of Permanence of Dressing Following Breast Reconstruction on Skin Colonization and on Surgical Site Infection Rates|Completed||N/A|200|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 23:39:37.740965|2018-05-31 23:39:37.740965
NCT01148810|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21||2013-07-25|2013-07-25|2010-06-21|2010-06-22|Estimate||||2013-07-25|2013-08-01|Estimate|2013-07-25|2013-08-01|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis|A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis|Terminated||Phase 2|29|Actual|Novartis||2|||f||||t||||||||||2018-05-31 23:39:37.848394|2018-05-31 23:39:37.848394
NCT01148797|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2016-11-16|2010-06-21|2010-06-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2010||2010-12-31|November 2016|2016-11-30||||February 2012|Actual|2012-02-29||Interventional|CONTROL FMF||Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)|A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever|Completed||Phase 2|15|Anticipated|Novartis||1|||f||||||||||||||2018-05-31 23:39:37.939975|2018-05-31 23:39:37.939975
NCT01148784|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2011-03-31|2010-06-21|2010-06-22|Estimate|||||||2011-03-31|2011-04-01|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Comparison of Doubled Quadrupled Versus Quadrupled Allograft Tissue Constructs for Anterior Cruciate Ligament (ACL) Reconstruction|A Prospective Randomized Comparison of Doubled Versus Quadrupled Allogenic Tissue Constructs for Anterior Cruciate Ligament Reconstruction|Unknown status|Recruiting|N/A|100|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 23:39:38.057536|2018-05-31 23:39:38.057536
NCT01148771|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|2012-03-15||2012-04-13|2010-06-21|2010-06-22|Estimate|2012-04-13|2012-05-11|Estimate||||2012-04-13|2012-05-11|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion|Comparative Pharmacokinetics, Safety, and Pharmacodynamics of Ertapenem 1 Gram Daily Administered as an IV Bolus Versus Standard 30 Minute Infusion to Healthy Adult Volunteers|Completed||Phase 4|12|Actual|Hartford Hospital||2|||f||||f||||||||||2018-05-31 23:39:38.154575|2018-05-31 23:39:38.154575
NCT01148758|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2016-11-01|2010-06-21|2010-06-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer|Open-label, Exploratory, Pharmacodynamic (PD) Dose-finding Study of Intravenous RO5323441 in Patients With Metastatic Treatment-refractory Colorectal and Ovarian Cancer|Completed||Phase 1|7|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:39:38.484011|2018-05-31 23:39:38.484011
NCT01148745|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2011-07-19||2012-03-28|2010-06-21|2010-06-22|Estimate|2012-03-28|2012-03-30|Estimate||||2012-03-28|2012-03-30|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Iron Indices and Intravenous Ferumoxytol: Time to Steady State|Iron Indices and Intravenous Ferumoxytol: Time to Steady State|Completed||Phase 4|15|Actual|Dialysis Clinic, Inc.||1|||f||||f||||||||||2018-05-31 23:39:38.581212|2018-05-31 23:39:38.581212
NCT01148732|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-21|2010-06-21|2010-06-22|Estimate|||||||2010-06-21|2010-06-22|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Tracheal Rapid Ultrasound Exam (T.R.U.E) for Confirming Endotracheal Tube Placement in Emergency Intubation|Tracheal Rapid Ultrasound Exam (T.R.U.E) for Confirming Endotracheal Tube Placement in Emergency Intubation|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 23:39:38.784529|2018-05-31 23:39:38.784529
NCT01148719|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2014-07-04|2010-06-21|2010-06-22|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|TREE||Triage of Reduced Exercise Tolerance in Frail Elderly|Triage of Reduced Exercise Tolerance in Frail Elderly|Completed||N/A|841|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 23:39:38.866429|2018-05-31 23:39:38.866429
NCT01148706|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-20|||2012-12-09|2010-06-21|2010-06-22|Estimate|||||||2012-12-09|2012-12-11|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ASNG||Effectiveness of ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Procedures|Phase IV Study of the ActiSight Needle Guidance System Which Assist in Guiding a Rigid Interventional Instrument Percutaneously, to a Designated Point Within the Body by Means of CT Visualization|Completed||Phase 4|20|Actual|ActiViews Ltd.||1|||f||||t||||||||||2018-05-31 23:39:38.966129|2018-05-31 23:39:38.966129
NCT01148693|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-19|2011-02-18||2011-09-18|2010-06-21|2010-06-22|Estimate|2011-07-25|2011-08-22|Estimate||||2011-09-18|2011-09-20|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting|Comparing Addition of Gentamicin vs. Placebo in Preventing Post ERCP Cholangitis in Non-calculus Stenting|Completed||N/A|114|Actual|Tehran University of Medical Sciences|No limitation other than small sample size|2|||f||||t||||||||||2018-05-31 23:39:39.048467|2018-05-31 23:39:39.048467
NCT01148680|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2017-07-20|2010-06-21|2010-06-22|Estimate|||||||2017-07-20|2017-07-21|Actual|June 2010||2010-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|TRIMECO||Trial Comparing Metabolic Efficiency of Islet Graft to Intensive Insulin Therapy for Type 1 Diabetes's Treatment|Randomized Controlled Trial Comparing the Metabolic Efficiency of Allogeneic Pancreatic Islet Transplantation to Intensive Insulin Therapy for the Treatment of Type 1 Diabetes|Active, not recruiting||Phase 3|50|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 23:39:39.2975|2018-05-31 23:39:39.2975
NCT01148667|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-21|2010-06-21|2010-06-22|Estimate|||||||2010-06-21|2010-06-22|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Lactobacillus Rhamnosus GG: Interaction With Human Microbiota and Immunity|Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis|Completed||Phase 4|40|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 23:39:39.371056|2018-05-31 23:39:39.371056
NCT01148654|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2014-01-06|2010-06-21|2010-06-22|Estimate|||||||2014-01-06|2014-01-07|Estimate|May 2008||2008-05-31|January 2014|2014-01-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||The Biomarker Study|Predicting Preterm Birth and Adverse Neonatal Outcomes With Novel Biomarkers: Identifying Those at Greatest Risk to Allow for Future Therapeutic Trials|Completed|||1076|Actual|University of Pennsylvania|||2||f||||||||||Samples With DNA|"~     maternal serum, plasma, saliva; Neonatal saliva~   "|||2018-05-31 23:39:39.456029|2018-05-31 23:39:39.456029
NCT01148641|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2018-01-25|2010-06-18|2010-06-22|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2010||2010-05-31|January 2018|2018-01-31|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Observational|||Acceptability of LNS for Infants and Young Children in Guatemala|Acceptability of Lipid-based Nutrient Supplements (LNS) for Infants and Young Children in Guatemala|Completed|||43|Actual|University of California, Davis|||2||f||||f||||||||||2018-05-31 23:39:39.513168|2018-05-31 23:39:39.513168
NCT01148628|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2011-09-12|2010-06-21|2010-06-22|Estimate|||||||2011-09-12|2011-09-13|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors|Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|54|Actual|Southern Europe New Drug Organization||1|||f||||f||||||||||2018-05-31 23:39:39.654357|2018-05-31 23:39:39.654357
NCT01148615|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-01-12|2010-06-21|2010-06-22|Estimate|||||||2012-01-12|2012-01-13|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors|A Phase I, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Docetaxel Administrated Every 3 Weeks in Chinese Patients With Advanced Solid Malignancies|Completed||Phase 1|20|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:39:39.737899|2018-05-31 23:39:39.737899
NCT01148602|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2015-12-07|2010-06-21|2010-06-22|Estimate|||||||2015-12-07|2015-12-09|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|CLOQS||The CLOQS Trial - Countdown Lights to Optimize Quality in Stroke|The CLOQS Trial - Countdown Lights to Optimize Quality in Stroke|Completed||N/A|3452|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 23:39:39.887979|2018-05-31 23:39:39.887979
NCT01148576|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2010-06-21|2010-06-21|2010-06-22|Estimate|||||||2010-06-21|2010-06-22|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients|Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial|Unknown status|Recruiting|Phase 4|1200|Anticipated|Zhejiang University||4|||f||||t||||||||||2018-05-31 23:39:40.011241|2018-05-31 23:39:40.011241
NCT01148563|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|2017-01-05||2018-04-11|2010-06-18|2010-06-22|Estimate|2017-11-21|2017-12-19|Actual||||2018-04-11|2018-05-14|Actual|March 2009||2009-03-31|April 2018|2018-04-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|TeleHealth:CHF||Louisiana State University Health Care Sciences Division (LSU HSCD) Tele-Health Projects: Adult CHF Patient Population|LSU HCSD Tele-Health Projects: Adult Systolic Heart Failure Patient Population|Completed||N/A|136|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-05-31 23:39:40.14561|2018-05-31 23:39:40.14561
NCT01148550|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2018-02-15|2010-06-18|2010-06-22|Estimate|||||||2018-02-15|2018-02-19|Actual|July 2010||2010-07-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|MITOHEP||Longitudinal Study of Mitochondrial Hepatopathies|Longitudinal Study of Mitochondrial Hepatopathies|Recruiting|||67|Anticipated|Arbor Research Collaborative for Health|||2||f||||t|f|f||||Samples With DNA|"~     Blood plasma and serum samples with DNA~   "|Yes|The data will be transferred to NIDDK at the end of the study.|2018-05-31 23:39:40.507321|2018-05-31 23:39:40.507321
NCT01148537|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2010-07-28||2012-08-27|2010-06-21|2010-06-22|Estimate|2010-09-07|2010-09-28|Estimate||||2012-08-27|2012-09-03|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers|A Randomized, Double-blind, Placebo- & Positive-Controlled, Parallel Group, Dose Escalating Study to Evaluate the Effect of Buprenorphine Delivered by Buprenorphine Transdermal System at 10- and 40-mg Dose Levels on QT Intervals in Healthy Adult Volunteers|Completed||Phase 1|132|Actual|Purdue Pharma LP|BUP1011 is a safety study. The comparison of buprenorphine vs placebo on QTc (interval corrected for heart rate) values is the primary outcome.|3|||f||||f||||||||||2018-05-31 23:39:40.763193|2018-05-31 23:39:40.763193
NCT01148524|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2013-12-11||2015-04-13|2010-06-21|2010-06-22|Estimate|2014-02-07|2014-03-11|Estimate||||2015-04-13|2015-04-29|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Analysis was performed on all enrolled subjects.|Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10|A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.|Completed||Phase 2/Phase 3|817|Actual|Novartis||9|||f||||||||||||||2018-05-31 23:39:41.367133|2018-05-31 23:39:41.367133
NCT01148511|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2013-04-02||2013-05-23|2010-06-21|2010-06-22|Estimate|2013-04-02|2013-05-20|Estimate||||2013-05-23|2013-05-30|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SALUTE|Safety population: All patients who received study drug (n=99). Not all patients who received study drug were randomized into the 2 treatment groups (n=93) due to discontinuation from the study in the first Period of the study. Baseline Characteristics are only reported for the randomized (n=93) patients.|"Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus Treat and Extend Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)"|"Comparison of Safety, Effectiveness, and Quality-of-life Outcomes Between Labeled Versus Treat and Extend Regimen in Turkish Patients With Choroidal Neovascularisation Due to AMD"|Completed||Phase 4|99|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:39:42.223465|2018-05-31 23:39:42.223465
NCT01148498|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18||2012-09-18|2012-09-18|2010-06-18|2010-06-22|Estimate||||2012-09-18|2012-09-25|Estimate|2012-09-18|2012-09-25|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's|Plasma Amyloid Beta Species After a Single Solanezumab Infusion in Nondemented Individuals and Those With Mild Dementia of the Alzheimer's Type|Completed||Phase 2|55|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 23:39:42.63351|2018-05-31 23:39:42.63351
NCT01148485|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-10-31|2010-06-21|2010-06-22|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2011||2011-01-31|June 2010|2010-06-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Observational|PSARM-S||Community-acquired Methicillin-Resistant Staphylococcus Aureus Carriage Among Athletes|Community-acquired Methicillin-Resistant Staphylococcus Aureus Carriage Among Athletes: a Study in Limousin. : CA-MRSA|Completed|||300|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 23:39:42.702683|2018-05-31 23:39:42.702683
NCT01148472|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2016-11-07|2010-06-21|2010-06-22|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2005||2005-09-30|November 2016|2016-11-30|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder|A Double-blind, Randomised, Multicenter, Comparative Study of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder|Completed||Phase 4|294|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 23:39:42.760582|2018-05-31 23:39:42.760582
NCT01148459|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-04-06|2010-06-21|2010-06-22|Estimate|||||||2017-04-06|2017-04-10|Actual|July 30, 2010||2010-07-30|April 2017|2017-04-30|May 24, 2013|Actual|2013-05-24|May 24, 2013|Actual|2013-05-24||Interventional|||Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children|Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children|Completed||Phase 3|200|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:39:42.82939|2018-05-31 23:39:42.82939
NCT01148446|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-21|2010-06-21|2010-06-22|Estimate|||||||2010-06-21|2010-06-22|Estimate|January 2003||2003-01-31|June 2010|2010-06-30||||January 2006|Actual|2006-01-31||Interventional|ANZINTER3||R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL|A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)|Completed||Phase 3|226|Actual|Fondazione Italiana Linfomi ONLUS||2|||f||||f||||||||||2018-05-31 23:39:42.935557|2018-05-31 23:39:42.935557
NCT01148433|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2011-12-21|2010-06-21|2010-06-22|Estimate|||||||2011-12-21|2011-12-22|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|LIFE||Quality of Life With TESTIM®|Quality of Life With TESTIM® in Testosterone Replacement Therapy for Male Patients With Hypogonadism|Completed|||157|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 23:39:43.055904|2018-05-31 23:39:43.055904
NCT01148420|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|2012-07-19||2014-02-12|2010-06-21|2010-06-22|Estimate|2013-12-17|2014-02-11|Estimate||||2014-02-12|2014-03-13|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|July 2012|Actual|2012-07-31|October 2010|Actual|2010-10-31||Interventional|||DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding|Pilot Trial of Use of DMPA Injection and High Dose MPA Tablets in Outpatient|Completed||Phase 4|48|Actual|Women's Health Care Clinic, Torrance, California|This was a single-arm, noncomparative pilot clinical trial. Impacts on bleeding beyond 5 days were not prospectively documented.|1|||f||||t||||||||||2018-05-31 23:39:44.223552|2018-05-31 23:39:44.223552
NCT01148407|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2011-04-21|2010-06-21|2010-06-22|Estimate|||||||2011-04-21|2011-04-22|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|August 2013|Anticipated|2013-08-31|August 2012|Anticipated|2012-08-31||Observational|||Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer|Platelet Modulation in the Control of Angiogenesis: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer|Unknown status|Recruiting||30|Anticipated|University of Vermont|||||f||||f||||||Samples Without DNA|"~     plasma, serum and platelet activated blood samples~   "|||2018-05-31 23:39:44.431168|2018-05-31 23:39:44.431168
NCT01148394|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-21|2010-06-21|2010-06-22|Estimate|||||||2010-06-21|2010-06-22|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Enhanced Recovery After Colorectal Surgery|Impact of the Introduction of a Multimodal Rehabilitation Programme for Colorectal Patients. A Prospective Randomized Trial.|Completed||N/A|119|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 23:39:44.494338|2018-05-31 23:39:44.494338
NCT01148381|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-19|||2018-04-03|2010-06-19|2010-06-22|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 4, 2010||2010-06-04|March 29, 2018|2018-03-29||||||||Observational|||Characterization of Phenotypic and Genotypic Regressors for Imaging|Characterization of Phenotypic and Genotypic Regressors for MRI|Recruiting|||2625|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:39:44.569258|2018-05-31 23:39:44.569258
NCT01148368|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2012-01-06|2010-06-21|2010-06-22|Estimate|||||||2012-01-06|2012-01-09|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers|A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers|Completed||Phase 1|16|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 23:39:44.751693|2018-05-31 23:39:44.751693
NCT01148355|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-19|||2017-06-30|2010-06-19|2010-06-22|Estimate|||||||2017-06-30|2017-07-02|Actual|June 10, 2008||2008-06-10|January 14, 2011|2011-01-14|January 14, 2011||2011-01-14|||||Observational|||Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Adolescent Smokers|Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Adolescent Smokers|Completed|||25|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:39:44.833898|2018-05-31 23:39:44.833898
NCT01148342|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-19|||2018-04-26|2010-06-19|2010-06-22|Estimate|||||||2018-04-26|2018-04-27|Actual|February 10, 2004||2004-02-10|July 18, 2012|2012-07-18|July 18, 2012|Actual|2012-07-18|||||Interventional|||Neurobiology and Pharmacokinets of Acute MDMA Administration|Neurobiology and Pharmacokinetics of Acute MDMA Administration|Completed||Phase 1|187|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:39:44.908973|2018-05-31 23:39:44.908973
NCT01148329|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2017-02-01|2010-06-21|2010-06-22|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2010||2010-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|June 2012|Actual|2012-06-30||Observational|PE-Prove||PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study|PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the PROMUS™ Element™ Coronary Stent System in Unselected Patients in Routine Clinical Practice|Completed|||1010|Actual|Boston Scientific Corporation|||1||f||||f||||||||No|Data are presented at the 2013 EuroPCR congress.|2018-05-31 23:39:44.997073|2018-05-31 23:39:44.997073
NCT01148316|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-10-23|2010-06-21|2010-06-22|Estimate|||||||2014-10-23|2014-10-24|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|SMART||Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.|"Adaptive Treatment Strategies for Children and Adolescents With Psychiatric Disorders in the Context of Public Health: Medicine in Practice"|Completed||N/A|144|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:39:45.176086|2018-05-31 23:39:45.176086
NCT01148303|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2011-03-07|2010-06-21|2010-06-22|Estimate|||||||2011-03-07|2011-03-08|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache|Randomized, Placebo Controlled Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache|Completed||Phase 4|220|Actual|Hartford Hospital||2|||f||||f||||||||||2018-05-31 23:39:45.29193|2018-05-31 23:39:45.29193
NCT01148290|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2013-04-05|2010-06-21|2010-06-22|Estimate|||||||2013-04-05|2013-04-08|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional|||Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence|A Comparison Between Tension-free Vaginal Tape and Bulking Agent for the Treatment of Post-vulvectomy Urinary Incontinence: a Randomized Controlled Trial|Completed||Phase 3|40|Actual|University Magna Graecia||2|||f||||||||||||||2018-05-31 23:39:45.388662|2018-05-31 23:39:45.388662
NCT01148277|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-13|||2011-04-05|2010-06-20|2010-06-22|Estimate|||||||2011-04-05|2011-04-06|Estimate|August 2011||2011-08-31|June 2010|2010-06-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Propofol and Remifentanyl Versus Midazolam and Fentanyl for Diagnostic Colonoscopy in Patients With Compensated Cirrhosis Child A-B|Propofol and Remifentanyl Versus Midazolam and Fentanyl for Diagnostic Colonoscopy in Patients With Compensated Cirrhosis Child A-B|Unknown status|Not yet recruiting|N/A|90|Anticipated|Ziv Hospital||3|||f||||t||||||||||2018-05-31 23:39:45.485553|2018-05-31 23:39:45.485553
NCT01148264|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2016-05-10|2010-06-21|2010-06-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|COMFORT||Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis|Efficacy of Olanzapine in Break-through Emesis After Prophylaxis With Dexamethasone, 5-HT3 Receptor Antagonists and Aprepitant Compared to Metoclopramide|Terminated||Phase 2|23|Actual|Martin-Luther-Universität Halle-Wittenberg||2||poor enrolment|f||||f||||||||||2018-05-31 23:39:45.584726|2018-05-31 23:39:45.584726
NCT01148251|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2014-11-28|2010-06-21|2010-06-22|Estimate|||||||2014-11-28|2014-12-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:39:45.66688|2018-05-31 23:39:45.66688
NCT01148238|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-12-07|2010-06-21|2010-06-22|Estimate|||||||2012-12-07|2012-12-10|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Autoimmune Diabetes: Markers of the Disease and Treatment of Latent Autoimmune Diabetes in Adults (LADA)|Autoimmune Diabetes: Disease Markers and Treatment of Latent Autoimmune Diabetes in Adults (LADA)|Withdrawn|||0|Actual|Norwegian University of Science and Technology|||3|changed research plan|f||||f||||||Samples With DNA|"~     Cytokines HLA T-reg~   "|||2018-05-31 23:39:45.700697|2018-05-31 23:39:45.700697
NCT01148225|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2018-04-04|2010-06-18|2010-06-22|Estimate|||||||2018-04-04|2018-04-06|Actual|November 23, 2010|Actual|2010-11-23|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|VISUAL III||A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis|A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate-, Posterior-, or Pan-uveitis|Completed||Phase 3|424|Actual|AbbVie||1|||f||||t|t|f|||f|||Undecided||2018-05-31 23:39:45.792946|2018-05-31 23:39:45.792946
NCT01148212|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2011-02-07|2010-06-21|2010-06-22|Estimate|||||||2011-02-07|2011-02-08|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Safety and Tolerability of Transcranial Direct Current Stimulation (tDCS)|Safety and Tolerability of Transcranial Direct Current Stimulation (tDCS)|Completed|||15|Actual|Ludwig-Maximilians - University of Munich|||||f||||f||||||||||2018-05-31 23:39:46.125777|2018-05-31 23:39:46.125777
NCT01148199|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2016-02-17|2010-06-21|2010-06-22|Estimate|||||||2016-02-17|2016-02-19|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|||Self-expandable Metallic Stent Versus Multiple Plastic Stents in Post Orthotopic Liver Transplantation Biliary Stenosis|Self-expandable Metalic Stent Versus Multiple Plastic Stents in Post OLT Biliary Stenosis: Prospective, Randomized, Controlled Trial.|Completed||Phase 2/Phase 3|64|Actual|Hospital Israelita Albert Einstein||2|||f||||f||||||||Undecided||2018-05-31 23:39:46.198936|2018-05-31 23:39:46.198936
NCT01148186|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2013-05-14|2010-06-21|2010-06-22|Estimate|||||||2013-05-14|2013-05-15|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults|The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults|Terminated||Phase 4|300|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2||"Study funding period reached conclusion. Sample size sufficient to complete the analysis on~   benzodiazepines."|f||||t||||||||||2018-05-31 23:39:46.314349|2018-05-31 23:39:46.314349
NCT01148173|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-21|||2010-06-21|2010-06-21|2010-06-22|Estimate|||||||2010-06-21|2010-06-22|Estimate|October 2007||2007-10-31|November 2007|2007-11-30|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas|Combined Systemic and Intrathecal Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation for CNS Relapse of Aggressive Lymphomas|Unknown status|Recruiting|Phase 2|30|Anticipated|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 23:39:46.40485|2018-05-31 23:39:46.40485
NCT01148160|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2014-04-09|2010-06-21|2010-06-22|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy|The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis|Terminated|||10|Actual|Asan Medical Center|||1||f||||f||||||Samples With DNA|"~     -  Venous blood sampling will be carried out at steady state for therapeutic drug~          monitoring(trough sampling:right before the dose)~        -  Genotyping will be performed using peripheral blood.~   "|||2018-05-31 23:39:46.545246|2018-05-31 23:39:46.545246
NCT01148147|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-11-07|2010-06-21|2010-06-22|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|PREVENT-ICARUS||Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty|Prevention of Cardiac and Vascular Periprocedural Complications in Patients Undergoing Coronary Angiography or Angioplasty: Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty. A Prospective Double-blind Randomized Trial.|Completed||Phase 3|260|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||t||||||||||2018-05-31 23:39:46.641499|2018-05-31 23:39:46.641499
NCT01148134|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2013-01-10|2010-06-18|2010-06-22|Estimate|||||||2013-01-10|2013-01-11|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL|Pharmacokinetic Profile of Vincristine Administered Along With Imatinib in the Induction Chemotherapy of Bcr-Abl (Philadelphia Chromosome) Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib in the Treatment of Bcr-Abl Negative ALL Patients|Terminated|||10|Actual|University Health Network, Toronto|||2|"Analysis of the first 10 patients did not show anyt trend toward differences in PK profiles~   between imatinib vs no imatinib groups."|f||||||||||||||2018-05-31 23:39:46.732778|2018-05-31 23:39:46.732778
NCT01148121|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2016-12-06|2010-06-21|2010-06-22|Estimate|||||||2016-12-06|2016-12-07|Estimate|June 2010||2010-06-30|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model|Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model|Completed||N/A|30|Actual|University of Arkansas|||||f||||f||||||||||2018-05-31 23:39:46.829144|2018-05-31 23:39:46.829144
NCT01148108|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2013-03-13|2010-06-18|2010-06-22|Estimate|||||||2013-03-13|2013-03-15|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma|Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)|Completed||Phase 2|14|Actual|Telik||3|||f||||t||||||||||2018-05-31 23:39:46.935984|2018-05-31 23:39:46.935984
NCT01148095|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2011-02-06|2010-06-18|2010-06-22|Estimate|||||||2011-02-06|2011-02-08|Estimate|June 2010||2010-06-30|February 2011|2011-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers|A Single Centre Two Part Randomized Phase I Study to Assess the Pharmacokinetics of an ER Formulation of AZD2516 and to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Ascending Doses in Healthy Volunteers|Completed||Phase 1|6|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:39:47.034372|2018-05-31 23:39:47.034372
NCT01148082|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2017-06-22|2010-06-18|2010-06-22|Estimate|||||||2017-06-22|2017-06-26|Actual|September 2010|Anticipated|2010-09-30|June 2017|2017-06-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||School Response to Families Who Have Children With Cancer|School Response to Families Who Have Children With Cancer|Withdrawn|||0|Actual|Stanford University||||Business decision|f||||||||||||||2018-05-31 23:39:47.135788|2018-05-31 23:39:47.135788
NCT01148069|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2017-08-21|2010-06-18|2010-06-22|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2010||2010-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TARGET||Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers|Surgery Combined With IMRT-IGRT in Locally-advanced Prostate Cancers|Active, not recruiting||Phase 2|65|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 23:39:47.203867|2018-05-31 23:39:47.203867
NCT01148056|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|2016-12-22||2016-12-22|2010-06-18|2010-06-22|Estimate|2016-12-22|2017-02-15|Actual||||2016-12-22|2017-02-15|Actual|March 2010||2010-03-31|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer|A Phase II Study of Neoadjuvant Short Course Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer: An Analysis of Quality of Life and Biomarkers of Response|Terminated||Phase 2|2|Actual|Massachusetts General Hospital|Study was closed early due to poor accrual. Analyses not completed.|1||The study was closed to enrollment due to slow accrual.|f||||t||||||||No||2018-05-31 23:39:47.318476|2018-05-31 23:39:47.318476
NCT01148043|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2015-04-10|2010-06-18|2010-06-22|Estimate|||||||2015-04-10|2015-04-13|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|FABIO||Pharmacological Treatment In Osteoarthritis|Pharmacological Treatment In Osteoarthritis|Completed||Phase 3|200|Actual|Maasstad Hospital||2|||f||||f||||||||||2018-05-31 23:39:47.592102|2018-05-31 23:39:47.592102
NCT01148030|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2014-02-28|2010-06-18|2010-06-22|Estimate|||||||2014-02-28|2014-03-03|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Impact of Pre-surgical Nasal Bacterial Reduction on Postoperative Surgical Site Infections / Standard Care Change||Terminated|||333|Actual|3M|||1|Outcome measures for pre-intervention were much lower than anticipated.|f||||f||||||||||2018-05-31 23:39:47.686453|2018-05-31 23:39:47.686453
NCT01148017|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2014-04-15||2017-07-12|2010-06-21|2010-06-22|Estimate|2014-04-15|2014-05-14|Estimate||||2017-07-12|2017-08-14|Actual|July 2010||2010-07-31|July 2017|2017-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Analysis was done on the all enrolled population, ie, all subjects who had signed an informed consent, undergone screening procedures, and were enrolled.|Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine|A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine|Completed||Phase 3|433|Actual|Novartis||4|||f||||f||||||||||2018-05-31 23:39:47.890418|2018-05-31 23:39:47.890418
NCT01148004|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2018-05-16|2010-06-18|2010-06-22|Estimate|||||||2018-05-16|2018-05-17|Actual|May 13, 2010||2010-05-13|July 29, 2013|2013-07-29|July 29, 2013|Actual|2013-07-29|July 29, 2013|Actual|2013-07-29||Interventional|||The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers|The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers|Completed||Phase 1|25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:39:48.773174|2018-05-31 23:39:48.773174
NCT01147991|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2012-02-27|2010-06-18|2010-06-22|Estimate|||||||2012-02-27|2012-02-28|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer|A Phase I, Dose Escalation Trial of Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine Encoding Epstein-Barr Virus Target Antigens|Completed||Phase 1|16|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 23:39:48.853348|2018-05-31 23:39:48.853348
NCT01147978|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2014-04-22|2010-06-18|2010-06-22|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|FAMIREAXV||Proactive Communication Strategy in Intensive Care Unit and Post Traumatic Stress Symptoms|Impact of a Proactive Strategy of Communication With Patients Hospitalized in ICU and Their Families With the Aim of Reducing Their Anxious and Depressive Symptoms and Their Post Traumatic Stress Symptoms|Completed||N/A|303|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:39:48.948948|2018-05-31 23:39:48.948948
NCT01147965|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2013-03-21|2010-06-18|2010-06-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA|A Phase I/II Study of Active Immunotherapy With Ad5[E1-,E2b-]-CEA Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA|Completed||Phase 1/Phase 2|35|Actual|Etubics Corporation||1|||f||||||||||||||2018-05-31 23:39:49.055152|2018-05-31 23:39:49.055152
NCT01147952|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2016-04-13|2010-06-18|2010-06-22|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 2010||2010-11-30|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of Exercise on Peripheral Blood Gene Expression in Angina|A Randomised Trial of the Effect of Exercise on Peripheral Blood Gene Expression in Patients With Stable Angina|Completed||N/A|60|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 23:39:49.156288|2018-05-31 23:39:49.156288
NCT01147939|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14||2013-09-12|2013-09-20|2010-06-21|2010-06-22|Estimate||||2013-09-12|2013-09-18|Estimate|2013-09-20|2013-09-27|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|CLAVELA||Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)|A Randomised Phase III Study of Elacytarabine vs. Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia|Completed||Phase 3|381|Actual|Clavis Pharma||2|||f||||t||||||||||2018-05-31 23:39:49.277146|2018-05-31 23:39:49.277146
NCT01147926|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2014-08-29||2015-03-04|2010-06-21|2010-06-22|Estimate|2014-08-29|2014-09-09|Estimate||||2015-03-04|2015-03-25|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||The Safety Population included all subjects randomized into the study and who took at least 1 dose of investigational product (n = 370).|Evaluation of Prucalopride in Male Subjects With Chronic Constipation.|A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Prucalopride in Male Subjects With Chronic Constipation|Completed||Phase 3|374|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:39:49.494383|2018-05-31 23:39:49.494383
NCT01147913|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2012-05-02|2010-06-18|2010-06-22|Estimate|||||||2012-05-02|2012-05-03|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Computerized Information-Processing Bias Retraining in Depressed Adolescents|Computerized Information-Processing Bias Retraining in Adolescents With Depression: A Controlled Trial|Completed||Phase 2|48|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:39:50.289275|2018-05-31 23:39:50.289275
NCT01147588|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2011-06-27|2010-06-17|2010-06-22|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel|An Open-label, Randomized, 4-treatment, 3-period, Crossover Interaction Study, Evaluating the Effect of Esomeprazole 40 mg, Omeprazole 80 mg or Lansoprazole 60 mg on the Pharmacodynamics and the Pharmacokinetics of Clopidogrel in Healthy Volunteers|Completed||Phase 1|149|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:40:04.656739|2018-05-31 23:40:04.656739
NCT01147900|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-04-25||2016-09-29|2010-06-18|2010-06-22|Estimate|2013-08-29|2013-10-08|Estimate||||2016-09-29|2016-11-03|Estimate|June 2010||2010-06-30|September 2016|2016-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||At Year 8.5, a total of 180 subjects (out of the 478 planned) were enrolled: 54, 60 and 66 subjects in the Boostrix-REF, Boostrix-US, and Boostrix-INV groups, respectively. At Year 10, a total of 177 subjects (out of the 180 planned) were enrolled: 55, 60 and 62 in the Boostrix-REF, Boostrix-US, and Boostrix-INV groups, respectively.|Evaluation of Boostrix™10 Years After Previous Booster Vaccination|Evaluation of GSK Biologicals' Boostrix™ in Healthy Adults, 10 Years After Previous Booster Vaccination|Completed||Phase 4|180|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:39:50.402165|2018-05-31 23:39:50.402165
NCT01147887|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2014-04-07|2010-06-17|2010-06-22|Estimate|||||||2014-04-07|2014-04-08|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|August 2010|Actual|2010-08-31|||||Interventional|||A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers|An Open-Label Study to Assess the Effect of Multiple-Dose JNJ26489112 on the Cytochrome P450 Enzymes Using a 3-Probe Substrate Drug Combination in Healthy Subjects|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 23:39:51.187675|2018-05-31 23:39:51.187675
NCT01147874|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2012-05-18||2012-05-18|2010-06-17|2010-06-22|Estimate|2012-05-18|2012-06-21|Estimate||||2012-05-18|2012-06-21|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PREPARE||Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice|Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice|Completed||Phase 4|1013|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:39:51.320597|2018-05-31 23:39:51.320597
NCT01147861|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-06-13|2010-06-17|2010-06-22|Estimate|||||||2017-06-13|2017-06-14|Actual|July 1, 2010|Actual|2010-07-01|June 2017|2017-06-30|September 7, 2010|Actual|2010-09-07|September 7, 2010|Actual|2010-09-07||Interventional|||A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics|A Randomized, Single Blind, Placebo-controlled, Three Period Crossover, Dose Selection Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA 24 Hour Profile in Type 2 Diabetic Patients.|Completed||Phase 1|39|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:39:51.54554|2018-05-31 23:39:51.54554
NCT01147848|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2013-06-06|2012-03-01|2016-11-30|2010-06-17|2010-06-22|Estimate|2013-06-27|2013-09-05|Estimate|2012-03-01|2012-03-05|Estimate|2016-11-30|2017-01-18|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents|A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents|Completed||Phase 3|810|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:39:51.696699|2018-05-31 23:39:51.696699
NCT01147835|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-15|2010-06-18|2010-06-22|Estimate|||||||2018-05-15|2018-05-18|Actual|September 2009|Actual|2009-09-30|April 2018|2018-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Lollipops||Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers|Effects of Herbal Lollipops on Streptococcus Mutans Levels and the Dental Caries Experience of Children With Asthma Taking beta2-adrenergic Agonist Drugs|Terminated||N/A|39|Actual|University of Nebraska||2||Study was stopped and not completed|f||||t||||||||||2018-05-31 23:39:52.538368|2018-05-31 23:39:52.538368
NCT01147822|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-01-18||2018-02-19|2010-06-17|2010-06-22|Estimate|2013-02-14|2013-03-15|Estimate||||2018-02-19|2018-02-21|Estimate|May 19, 2010|Actual|2010-05-19|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|May 21, 2012|Actual|2012-05-21||Interventional|||Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma|A Study to Evaluate Efficacy and Safety of Pazopanib Versus Sunitinib for the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma - A Substudy to VEG108844|Active, not recruiting||Phase 2|183|Actual|Novartis||2|||f||||t||||||||||2018-05-31 23:39:52.666412|2018-05-31 23:39:52.666412
NCT01147809|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2015-08-27||2016-03-17|2010-06-17|2010-06-22|Estimate|2016-03-17|2016-04-18|Estimate||||2016-03-17|2016-04-18|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag|A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin|Completed||Phase 2|130|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:39:53.696465|2018-05-31 23:39:53.696465
NCT01147796|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2015-03-06|2010-06-18|2010-06-22|Estimate|||||||2015-03-06|2015-03-10|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|THROMBI-SCAN||Accuracy of the 64 Slices Computed Tomography for the Diagnosis of Left Atrial Appendage Thrombus|Accuracy of the 64 Slices Computed Tomography for the Diagnosis of Left Atrial Appendage Thrombus|Terminated||N/A|52|Actual|Assistance Publique - Hôpitaux de Paris||2||defect of inclusion|f||||f||||||||||2018-05-31 23:39:57.399149|2018-05-31 23:39:57.399149
NCT01147783|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2010-07-02|2010-06-18|2010-06-22|Estimate|||||||2010-07-02|2010-07-05|Estimate|November 2008||2008-11-30|June 2010|2010-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Airway Anatomy of the SimBaby|A Comparison of Pediatric Airway Anatomy With the SimBaby High-Fidelity Simulator|Completed|||20|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 23:39:57.491599|2018-05-31 23:39:57.491599
NCT01147770|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2013-07-01|2010-06-18|2010-06-22|Estimate|||||||2013-07-01|2013-07-03|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Prolongation of Progesterone Supplementation in Antagonist Cycles and Pregnancy Outcomes|The Effect of Progesterone Supplementation During Early Gestations in Patients Treated With Rec FSH/GnRH Antagonist:a Randomized Controlled Trial|Completed||Phase 1/Phase 2|200|Actual|Universitair Ziekenhuis Brussel||1|||f||||t||||||||||2018-05-31 23:39:57.566477|2018-05-31 23:39:57.566477
NCT01147757|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2011-12-05|2010-06-18|2010-06-22|Estimate|||||||2011-12-05|2011-12-06|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Effect of Intraoperative Remifentanil Infusion Rate on Postoperative Tolerance and Analgesic Consumption in Pediatric Laparoscopic Ureteroneocystostomy||Unknown status|Recruiting|N/A|60|Anticipated|Yonsei University||4|||f||||f||||||||||2018-05-31 23:39:57.656326|2018-05-31 23:39:57.656326
NCT01147744|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2017-08-07|2012-04-12|2017-09-28|2010-06-17|2010-06-22|Estimate|2017-08-07|2017-09-06|Actual|2012-04-12|2012-04-16|Estimate|2017-09-28|2017-10-02|Actual|June 28, 2010|Actual|2010-06-28|September 2017|2017-09-30|October 6, 2011|Actual|2011-10-06|October 6, 2011|Actual|2011-10-06||Interventional|||Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily|A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma While Treated With Short Acting Beta2-agonist.|Completed||Phase 2|700|Actual|GlaxoSmithKline||7|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:39:57.778178|2018-05-31 23:39:57.778178
NCT01147731|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-06-21|2010-06-17|2010-06-22|Estimate|||||||2017-06-21|2017-06-22|Actual|June 4, 2010|Actual|2010-06-04|June 2017|2017-06-30|September 9, 2010|Actual|2010-09-09|September 9, 2010|Actual|2010-09-09||Interventional|||A Drug Interaction Study With Albiglutide and Warfarin|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Albiglutide in Healthy Adult Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:40:00.553003|2018-05-31 23:40:00.553003
NCT01147718|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-06-09|2010-06-17|2010-06-22|Estimate|||||||2017-06-09|2017-06-12|Actual|June 11, 2010|Actual|2010-06-11|June 2017|2017-06-30|November 29, 2010|Actual|2010-11-29|November 29, 2010|Actual|2010-11-29||Interventional|||A Drug Interaction Study of Albiglutide and Digoxin|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Albiglutide in Healthy Adult Subjects|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:40:00.675657|2018-05-31 23:40:00.675657
NCT01147705|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2017-05-01|2010-06-18|2010-06-22|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2011||2011-02-28|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|APOSA-PAD||Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease|Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease|Completed||Phase 4|50|Actual|University of Dundee||2|||f||||f||||||||No||2018-05-31 23:40:00.79484|2018-05-31 23:40:00.79484
NCT01147692|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-06-07|2010-06-17|2010-06-22|Estimate|||||||2017-06-07|2017-06-08|Actual|May 19, 2010|Actual|2010-05-19|June 2017|2017-06-30|August 27, 2010|Actual|2010-08-27|August 27, 2010|Actual|2010-08-27||Interventional|||A Drug Interaction Study of Simvastatin and Albiglutide|An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects|Completed||Phase 1|40|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:40:00.887772|2018-05-31 23:40:00.887772
NCT01147679|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2011-10-27|2010-06-18|2010-06-22|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|July 2014|Anticipated|2014-07-31|September 2013|Anticipated|2013-09-30||Observational|||Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls|Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls|Unknown status|Recruiting||99|Anticipated|University of California, Los Angeles|||3||f||||f||||||||||2018-05-31 23:40:00.986951|2018-05-31 23:40:00.986951
NCT01147666|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-03-18|2010-06-18|2010-06-22|Estimate|||||||2014-03-18|2014-03-19|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|October 2012|Actual|2012-10-31||Interventional|||Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis||Completed||Phase 2|161|Actual|FibroGen||5|||f||||t||||||||||2018-05-31 23:40:01.080226|2018-05-31 23:40:01.080226
NCT01147653|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2017-03-15||2017-10-25|2010-06-17|2010-06-22|Estimate|2017-05-11|2017-06-12|Actual||||2017-10-25|2017-11-30|Actual|June 2010||2010-06-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy|Is Autologous Umbilical Cord Blood Reinfusion Beneficial in Children With Cerebral Palsy: A Randomized, Blinded, Placebo-Controlled, Crossover Study|Completed||Phase 2|63|Actual|Duke University||2|||f||||f||||||||||2018-05-31 23:40:01.458518|2018-05-31 23:40:01.458518
NCT01147640|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2015-01-09||2016-01-06|2010-06-17|2010-06-22|Estimate|2015-01-14|2015-01-16|Estimate||||2016-01-06|2016-01-08|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional||Microbiological Intent-to-Treat|Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections|Completed||Phase 2|122|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 23:40:02.93512|2018-05-31 23:40:02.93512
NCT01147627|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|2013-06-06||2013-06-11|2010-06-18|2010-06-22|Estimate|2013-06-11|2013-08-21|Estimate||||2013-06-11|2013-08-21|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients|Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial|Completed||N/A|416|Actual|Sun Yat-sen University|The open-label design, which could have introduced bias by affecting patients’ expectations and adherence to therapy.|3|||f||||f||||||||||2018-05-31 23:40:03.41017|2018-05-31 23:40:03.41017
NCT01147614|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2016-04-12|2010-06-21|2010-06-22|Estimate|||||||2016-04-12|2016-04-14|Estimate|September 2010||2010-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BCBT-PC||Brief Cognitive Behavioral Therapy (CBT) for Pediatric Anxiety and Depression in Primary Care|Brief CBT for Pediatric Anxiety and Depression in Primary Care|Completed||N/A|185|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 23:40:04.08444|2018-05-31 23:40:04.08444
NCT01147601|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2017-04-19||2017-04-19|2010-06-18|2010-06-22|Estimate|2017-04-19|2017-07-05|Actual||||2017-04-19|2017-07-05|Actual|March 2010||2010-03-31|April 2017|2017-04-30|August 2014|Actual|2014-08-31|October 2012|Actual|2012-10-31||Interventional|||Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas|Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas: A Prospective Double Blinded Placebo Controlled Study|Terminated||Early Phase 1|6|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 23:40:04.247721|2018-05-31 23:40:04.247721
NCT01147575|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2010-06-18|2010-06-18|2010-06-22|Estimate|||||||2010-06-18|2010-06-22|Estimate|January 2005||2005-01-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects of Creatine Supplementation in Rett Syndrome|Effects of Creatine Supplementation in Rett Syndrome: A Randomized, Placebo-controlled Trial|Completed||N/A|21|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 23:40:04.766474|2018-05-31 23:40:04.766474
NCT01147562|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-01-18|2010-06-18|2010-06-22|Estimate|||||||2017-01-18|2017-01-19|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|October 2020|Anticipated|2020-10-31|July 2017|Anticipated|2017-07-31||Interventional|LCS||Biomarker Discovery and Validation in Lung Cancer|Biomarker Discovery and Validation in Lung Cancer|Recruiting||N/A|150|Anticipated|Public Research Centre Health, Luxembourg||1|||f||||f||||||||||2018-05-31 23:40:04.845662|2018-05-31 23:40:04.845662
NCT01147549|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2010-12-02|2010-06-17|2010-06-22|Estimate|||||||2010-12-02|2010-12-03|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ADME||Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers|An Open-Label, Single-Centre, Phase I Study to Assess the Excretion, Metabolism and Plasma Pharmacokinetics Following a Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers|Completed||Phase 1|4|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:40:04.948163|2018-05-31 23:40:04.948163
NCT01147536|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29||2014-01-14|2014-03-13|2010-06-17|2010-06-22|Estimate||||2014-02-12|2014-03-13|Estimate|2014-03-13|2014-04-10|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence|A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage)for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence|Terminated||Phase 2|12|Actual|Agenus Inc.||1||Sponsor's business decision|f||||f||||||||||2018-05-31 23:40:05.038033|2018-05-31 23:40:05.038033
NCT01147523|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-01-19|2010-06-18|2010-06-22|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|NAFLD||Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease|The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study|Completed||Phase 2|30|Actual|Aristotle University Of Thessaloniki||1|||f||||t||||||||||2018-05-31 23:40:05.187316|2018-05-31 23:40:05.187316
NCT01147510|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-18|||2013-11-10|2010-06-18|2010-06-22|Estimate|||||||2013-11-10|2013-11-13|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ACEM||Asthma Control in Elderly Patients With Montelukast|A Randomized Controlled Study of Montelukast Plus Low Dose Inhaled Budesonide Versus Medium Dose Inhaled Budesonide on Asthma Control in Elderly Patients|Completed||Phase 4|140|Actual|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 23:40:05.29069|2018-05-31 23:40:05.29069
NCT01147497|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2013-10-30||2018-01-10|2010-06-18|2010-06-22|Estimate|2014-02-24|2014-03-24|Estimate||||2018-01-10|2018-01-12|Actual|June 2010||2010-06-30|January 2018|2018-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|miso||Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in Intrauterine Device Insertion for Nulliparous Women|Completed||N/A|78|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:40:05.424324|2018-05-31 23:40:05.424324
NCT01147484|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2016-05-02|2010-06-18|2010-06-22|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|IND197||A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer|A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer|Completed||Phase 2|47|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-05-31 23:40:05.779127|2018-05-31 23:40:05.779127
NCT01147471|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2015-08-04||2015-08-04|2010-06-17|2010-06-22|Estimate|2015-08-04|2015-08-06|Estimate||||2015-08-04|2015-08-06|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Adult patients, 21 to 75 years old, admitted to the trauma unit with injuries that include either stove in chest (contiguous rib fractures with at least 2 ribs pushed in a distance greater than the rib diameter of the pushed in rib) or a unilateral flail chest (3 or more ribs fractures at two places). Patients must be on a ventilator.|Flail Chest - Rib Fixation Study|Flail Chest: Early Operative Fixation Versus Non-operative Management - a Prospective Randomized Study|Terminated||N/A|24|Actual|Virginia Commonwealth University|Subject enrollment too low leading to insufficient data to analyze.|2||Insufficient enrollment|f||||t||||||||||2018-05-31 23:40:05.905763|2018-05-31 23:40:05.905763
NCT01147458|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2012-12-21||2013-05-30|2010-06-17|2010-06-22|Estimate|2013-04-10|2013-05-21|Estimate||||2013-05-30|2013-06-06|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee|A Phase 2 Randomized, Double-Blinded, Double-Dummy, Placebo And Active Controlled Two Cohort Two-Way Cross-Over, Multi-Centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A 5-Lipoxygenase (5-Lox) Inhibitor PF-04191834 Alone And In Combination With Naproxen In Patients With Flare-Enriched Osteoarthritis Of The Knee|Terminated||Phase 2|190|Actual|Pfizer|The study was terminated early due to increases in hepatic enzymes for which a relationship to study drug could not be excluded and that could alter the potential benefit-risk for participants continuing in the study.|4||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:40:06.539034|2018-05-31 23:40:06.539034
NCT01147445|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2014-02-13|2010-06-17|2010-06-22|Estimate|||||||2014-02-13|2014-02-14|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Phase I Study of ETEC Vaccine|Phase I Study to Determine the Safety and Immunogenicity of an Oral ETEC Candidate Vaccine, Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) From Enterotoxigenic Escherichia Coli|Completed||Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-05-31 23:40:07.684875|2018-05-31 23:40:07.684875
NCT01147432|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-12-19|2010-06-17|2010-06-22|Estimate|||||||2011-12-19|2011-12-21|Estimate|August 2010||2010-08-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Acute Response Capsaicin Flare Study|A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Modified Cross-Over Study To Examine The Acute Effect Of PF-04427429 On Capsaicin Flare Response In Healthy Volunteers Using EMLA Cream As Positive Control|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:40:07.795553|2018-05-31 23:40:07.795553
NCT01147419|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2010-07-06|2010-06-17|2010-06-22|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|June 2015|Anticipated|2015-06-30|June 2012|Anticipated|2012-06-30||Interventional|SPACIAL||Comparison of Stent and Prothesis Bypass in Superficial Femoral Artery|The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions|Unknown status|Recruiting|Phase 4|200|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 23:40:07.907801|2018-05-31 23:40:07.907801
NCT01147406|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2013-11-26||2014-01-21|2010-06-17|2010-06-22|Estimate|2014-01-21|2014-03-07|Estimate||||2014-01-21|2014-03-07|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Any subject that received any active or placebo|Safety and Tolerability Study of N6022 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of N6022 in Healthy Subjects|Completed||Phase 1|41|Actual|Nivalis Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 23:40:08.067829|2018-05-31 23:40:08.067829
NCT01147393|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2017-02-23||2018-01-26|2010-06-17|2010-06-22|Estimate|2017-04-27|2017-06-02|Actual||||2018-01-26|2018-02-21|Estimate|October 2010|Actual|2010-10-31|January 2018|2018-01-31|July 31, 2015|Actual|2015-07-31|August 6, 2013|Actual|2013-08-06||Interventional|||Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma|Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma|Terminated||Phase 1/Phase 2|4|Actual|Weill Medical College of Cornell University||1||closed to enrollment due to slow patient accrual|f||||t||||||||||2018-05-31 23:40:08.832379|2018-05-31 23:40:08.832379
NCT01147380|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2015-05-26||2016-02-11|2010-06-17|2010-06-22|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MIAMINK||Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation|A Novel Immunotherapy for Liver Transplant Patients With Hepatocellular Carcinoma: Anti-tumor Effect of IL2-activated Donor Liver Natural Killer Cell|Completed||Phase 1|18|Actual|University of Miami||2|||f||||t||||||||No||2018-05-31 23:40:09.07352|2018-05-31 23:40:09.07352
NCT01147367|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2016-03-07|2010-06-17|2010-06-22|Estimate|||||||2016-03-07|2016-03-08|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ABLE||Physical Activity, Fatigue, Sleep, and Inflammation|Physical Activity Benefits After Breast Cancer: Exploring Cytokine Mechanisms|Completed||N/A|49|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 23:40:09.363998|2018-05-31 23:40:09.363998
NCT01147354|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-01-31|2010-06-17|2010-06-22|Estimate|||||||2012-01-31|2012-02-02|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Effect of Selenium Supplementation on Inflammatory,Oxidative and Nutritional Markers in Hemodialysis Patients|Effect of Selenium Supplementation on Inflammatory,Oxidative and Nutritional Markers in Hemodialysis Patients|Completed||Phase 3|80|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:40:09.433869|2018-05-31 23:40:09.433869
NCT01147341|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2014-02-03||2014-05-29|2010-06-17|2010-06-22|Estimate|2014-02-03|2014-03-26|Estimate||||2014-05-29|2014-06-09|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia|Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase|Completed||Phase 4|37|Actual|Schiff, Michael, M.D.||2|||f||||f||||||||||2018-05-31 23:40:09.627212|2018-05-31 23:40:09.627212
NCT01147328|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-01-11|2010-06-16|2010-06-22|Estimate|||||||2011-01-11|2011-01-12|Estimate|June 2011||2011-06-30|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|||||Observational|VHR||Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization|Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization|Unknown status|Not yet recruiting||157000|Anticipated|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-05-31 23:40:10.177069|2018-05-31 23:40:10.177069
NCT01147315|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2018-04-05|2010-06-17|2010-06-22|Estimate|||||||2018-04-05|2018-04-06|Actual|November 18, 2009||2009-11-18|May 2017|2017-05-31|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|ORN||ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution|10 Patients Bicentric Prospective Study of Hybrid Bone Substitution With Calcium-phosphate Ceramic Biomaterial and Autologous Bone Marrow for Mandibular Osteoradionecrosis (ORN) Treatment|Completed||N/A|13|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 23:40:10.257005|2018-05-31 23:40:10.257005
NCT01147302|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2015-06-16|2015-03-04|2015-07-22|2010-06-16|2010-06-22|Estimate|2015-06-16|2015-07-09|Estimate|2015-03-04|2015-03-24|Estimate|2015-07-22|2015-08-13|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional||The Intent-to-Treat (ITT) population, defined as all participants who received at least 1 dose (or any portion of a dose) of study drug (CINRYZE or placebo).|A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection|A Randomized Double-Blind Placebo-Controlled Pilot Study to Evaluate the Safety and Effect of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-Mediated Rejection in Recipients of Donor-Sensitized Kidney Transplants|Completed||Phase 2|18|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:40:10.361596|2018-05-31 23:40:10.361596
NCT01147289|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2012-05-14|2010-06-17|2010-06-22|Estimate|||||||2012-05-14|2012-05-15|Estimate|February 2011||2011-02-28|May 2012|2012-05-31|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|Dextra||Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain|A Phase III, Randomized, Multicenter, Open Label Clinical Trial: Efficacy and Safety of the Injectable Association of Dexamethasone, Dipyrone, and Hydrocobalamin in Lumbar Sciatic Pain|Completed||Phase 3|280|Actual|Eurofarma Laboratorios S.A.||2|||f||||f||||||||||2018-05-31 23:40:10.975242|2018-05-31 23:40:10.975242
NCT01147276|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-09-21|2010-06-17|2010-06-22|Estimate|||||||2012-09-21|2012-09-25|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes|Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Patients With Type 1 Diabetes|Completed||Phase 4|28|Actual|Lund University||1|||f||||t||||||||||2018-05-31 23:40:11.075222|2018-05-31 23:40:11.075222
NCT01147263|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2010-06-17|2010-06-17|2010-06-22|Estimate|||||||2010-06-17|2010-06-22|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Observational|||Palpitations and Tachycardia in Fibromyalgia Syndrome|Prevalence and Mechanism of Palpitations and Tachycardia in Fibromyalgia Syndrome|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 23:40:11.170732|2018-05-31 23:40:11.170732
NCT01147250|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2016-08-22|2016-02-16|2016-10-31|2010-06-17|2010-06-22|Estimate|2016-08-22|2016-10-14|Estimate|2016-02-16|2016-03-16|Estimate|2016-10-31|2016-12-20|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ELIXA||Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome|Completed||Phase 3|6068|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 23:40:11.392312|2018-05-31 23:40:11.392312
NCT01147237|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2010-06-17|2010-06-17|2010-06-22|Estimate|||||||2010-06-17|2010-06-22|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|December 2012|Anticipated|2012-12-31|September 2011|Anticipated|2011-09-30||Interventional|XILLION||Xience/Promus for Long Coronary Lesion Registry|A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease|Unknown status|Enrolling by invitation|Phase 4|450|Actual|Society for Advancement of Coronary Intervention Research||1|||f||||t||||||||||2018-05-31 23:40:15.59885|2018-05-31 23:40:15.59885
NCT01147224|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2016-12-02|2010-06-17|2010-06-22|Estimate|||||||2016-12-02|2016-12-05|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Observational|ATEM||ATEM (Alvesco Non-interventional Study)|Alvesco for the Therapy of Persistent Asthma With or Without Allergic Component|Completed|||400|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:40:16.584625|2018-05-31 23:40:16.584625
NCT01147211|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2013-05-01|2010-06-17|2010-06-22|Estimate|||||||2013-05-01|2013-05-03|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)|A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation|Unknown status|Active, not recruiting|Phase 1|21|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 23:40:16.795041|2018-05-31 23:40:16.795041
NCT01147198|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-01-23|2010-06-17|2010-06-22|Estimate|||||||2012-01-23|2012-01-24|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|April 2008|Actual|2008-04-30|August 2007|Actual|2007-08-31||Interventional|||Ready to Use Supplementary Food in Moderate Childhood Malnutrition|Effectiveness of a Ready-to-Use-Supplementary-Food for the Treatment of Moderate Childhood Malnutrition|Completed||N/A|570|Actual|Medecins Sans Frontieres, Netherlands||2|||f||||f||||||||||2018-05-31 23:40:16.975445|2018-05-31 23:40:16.975445
NCT01147185|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2016-06-28|2010-06-16|2010-06-22|Estimate|||||||2016-06-28|2016-06-29|Estimate|February 2010||2010-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effectiveness of Automated Locomotor Training in Patients With Acute Incomplete Spinal Cord Injury: A Multicenter Trial|Effectiveness of Automated Locomotor Training in Patients With Acute Incomplete Spinal Cord Injury: A Multicenter Trial|Completed||N/A|21|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 23:40:17.126989|2018-05-31 23:40:17.126989
NCT01147172|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2015-03-25||2017-09-15|2010-06-17|2010-06-22|Estimate|2015-04-03|2015-04-20|Estimate||||2017-09-15|2017-10-17|Actual|March 2009||2009-03-31|September 2017|2017-09-30|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional||Subjects of Fitzpatrick Skin Type IV, V or VI seeking treatment of nasolabial folds with injectable hyaluronic acid gel (Elevess).|Safety Study of Cosmetic Tissue Augmentation in People of Color|A Post Approval, Multicenter, Open-Label, Longitudinal, Uncontrolled Safety Study of Cosmetic Tissue Augmentation Product (ELEVESS™) in the Treatment of Nasolabial Folds in People of Color|Completed||N/A|100|Actual|Anika Therapeutics, Inc.||1|||f||||f||||||||No||2018-05-31 23:40:17.260731|2018-05-31 23:40:17.260731
NCT01147159|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2017-04-28|2010-06-17|2010-06-22|Estimate|||||||2017-04-28|2017-05-02|Actual|December 2010||2010-12-31|April 2017|2017-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus|Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus in Patients With Rhinoconjunctivitis With/ Without Asthma Sensitized to Betula Pendula, Dermatophagoides Pteronyssinus and Phleum Pratense An Open-label, Single-center Study|Completed||Phase 2|68|Actual|Roxall Medicina España S.A||1|||f||||||||||||||2018-05-31 23:40:17.627337|2018-05-31 23:40:17.627337
NCT01147146|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2011-05-12|2010-06-17|2010-06-22|Estimate|||||||2011-05-12|2011-05-13|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effects of Anesthetic Method on Cerebral Oxygen Saturation in Geriatric Patients Undergoing Transurethral Surgery|The Effects of Anesthetic Method on Cerebral Oxygen Saturation in Geriatric Patients Undergoing Transurethral Surgery|Completed||N/A|64|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 23:40:17.702927|2018-05-31 23:40:17.702927
NCT01147133|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-01-28|2010-06-17|2010-06-22|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|DOSER-GENERIC||Comparison of Generic and Original Formulation of Clopidogrel|Comparison of the Generic and Original Formulation of Clopidogrel Regarding the Potency of Platelet Inhibition in Patients After PCI|Completed||Phase 4|75|Actual|University of Pecs||2|||f||||f||||||||||2018-05-31 23:40:17.78004|2018-05-31 23:40:17.78004
NCT01147120|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2014-06-03|2010-06-16|2010-06-22|Estimate|||||||2014-06-03|2014-06-04|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Chronic Low Back Pain and Primary Health Care|CAM Referral and Outcomes: Chronic Low Back Pain in Urban and Rural Primary Care|Completed||N/A|138|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 23:40:17.858485|2018-05-31 23:40:17.858485
NCT01147107|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2017-03-06|2010-06-16|2010-06-22|Estimate|||||||2017-03-06|2017-03-08|Actual|February 2014||2014-02-28|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection|Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C|Active, not recruiting||Phase 4|80|Anticipated|University of Hawaii||2|||f||||t||||||||Yes|IPD will be shared with other researchers upon request following the publication of the data. Researchers will contact the PI.|2018-05-31 23:40:17.92443|2018-05-31 23:40:17.92443
NCT01147094|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-08-06|2010-06-16|2010-06-22|Estimate|||||||2015-08-06|2015-08-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:40:18.03878|2018-05-31 23:40:18.03878
NCT01146223|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2015-05-06|2010-06-16|2010-06-17|Estimate|||||||2015-05-06|2015-05-07|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia|Observational - WT-1's Role in Leukemogenesis|Completed|||10|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     bone marrow~   "|||2018-05-31 23:40:30.940608|2018-05-31 23:40:30.940608
NCT01147081|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-01-04|2010-06-17|2010-06-22|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Begrivac®, Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011 When Administered to Adult and Elderly Subjects|Completed||Phase 3|142|Actual|Novartis||1|||f||||f||||||||||2018-05-31 23:40:18.070244|2018-05-31 23:40:18.070244
NCT01147068|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2012-10-24||2012-10-24|2010-06-16|2010-06-22|Estimate|2012-10-24|2012-11-26|Estimate||||2012-10-24|2012-11-26|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults|A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49|Completed||Phase 1/Phase 2|392|Actual|Protein Sciences Corporation|The absence of a treatment group receiving a SE- or GLA-alone adjuvanted vaccine formulation is a limitation to the study conclusion.|7|||f||||t||||||||||2018-05-31 23:40:18.21233|2018-05-31 23:40:18.21233
NCT01147055|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2011-09-12||2011-10-20|2010-06-16|2010-06-22|Estimate|2011-09-12|2011-10-19|Estimate||||2011-10-20|2011-10-24|Estimate|July 2010||2010-07-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers|A Phase 1, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of Crizotinib (PF-02341066) In Healthy Volunteers|Completed||Phase 1|15|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:40:19.169029|2018-05-31 23:40:19.169029
NCT01147042|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|2017-07-20||2017-08-22|2010-06-17|2010-06-22|Estimate|2017-08-22|2017-09-20|Actual||||2017-08-22|2017-09-20|Actual|May 18, 2010||2010-05-18|August 2017|2017-08-31|November 14, 2014|Actual|2014-11-14|November 14, 2014|Actual|2014-11-14||Interventional|||Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease|Assessment of the Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease|Terminated||Phase 4|2|Actual|National Institutes of Health Clinical Center (CC)|Early termination due to only 2 subjects completing trial.|2||Early termination due to only 2 subjects completing trial.|f||||f|t|f|||f|||||2018-05-31 23:40:19.566548|2018-05-31 23:40:19.566548
NCT01147029|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-04-30|2010-06-17|2010-06-22|Estimate|||||||2012-04-30|2012-05-01|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy|A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors|Terminated||Phase 1|35|Actual|Cancer Research UK||||Sponsor Decision|f||||||||||||||2018-05-31 23:40:19.775444|2018-05-31 23:40:19.775444
NCT01147016|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2018-04-13|2010-06-17|2010-06-22|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2010||2010-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 1, 2017|Actual|2017-07-01||Interventional|||Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery|A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers|Active, not recruiting||Phase 2|8|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 23:40:19.898156|2018-05-31 23:40:19.898156
NCT01147003|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15||2013-02-18|2013-03-06|2010-06-16|2010-06-22|Estimate||||2013-02-18|2013-02-22|Estimate|2013-03-06|2013-03-14|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures|A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study Examining Seizure Frequency of BGG492 Capsules as Adjunctive Treatment in Patients With Partial Onset Seizures|Completed||Phase 2|93|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:40:20.077574|2018-05-31 23:40:20.077574
NCT01146990|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2018-04-09|2010-06-16|2010-06-22|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2010||2010-06-30|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Observational|||A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth|A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth|Recruiting|||584|Anticipated|AMAG Pharmaceuticals, Inc.|||1||f||||f||||||||||2018-05-31 23:40:20.215643|2018-05-31 23:40:20.215643
NCT01146977|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-06-17|2010-06-17|2010-06-22|Estimate|||||||2010-06-17|2010-06-22|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|December 2015|Anticipated|2015-12-31|January 2010|Anticipated|2010-01-31||Interventional|CBF(+)AML||Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)|Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission|Unknown status|Recruiting|Phase 2|43|Anticipated|Cooperative Study Group A for Hematology||2|||f||||f||||||||||2018-05-31 23:40:20.34999|2018-05-31 23:40:20.34999
NCT01146964|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-01-02|2010-06-17|2010-06-22|Estimate|||||||2014-01-02|2014-01-03|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparison of Manual Super Small Incision Cataract Surgery and Phacoemulsification|Comparison of Manual Super Small Incision Cataract Surgery and Phacoemulsification|Completed||N/A|100|Actual|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 23:40:20.451976|2018-05-31 23:40:20.451976
NCT01146951|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2013-05-13||2018-01-02|2010-06-17|2010-06-22|Estimate|2013-10-29|2013-11-21|Estimate||||2018-01-02|2018-01-24|Actual|June 2010||2010-06-30|January 2018|2018-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||One subject from the Rufinamide (E2080) group was excluded from the FAS because of the inappropriate diagnosis of the disease, dropping the total number from 29 to 28 participants.|A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)|A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients|Completed||Phase 3|66|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:40:20.544382|2018-05-31 23:40:20.544382
NCT01146782|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2014-01-13||2014-05-28|2010-06-16|2010-06-22|Estimate|2014-05-28|2014-06-30|Estimate||||2014-05-28|2014-06-30|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ATLAST|Baseline Demographics and Characteristics are presented for the Safety Cohort|Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea|The ATLAST Trial - A Multicenter, Prospective Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)|Completed||N/A|367|Actual|ApniCure, Inc.||1|||f||||f||||||||||2018-05-31 23:40:23.542119|2018-05-31 23:40:23.542119
NCT01146938|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2012-01-02|2010-06-17|2010-06-22|Estimate|||||||2012-01-02|2012-01-05|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers|A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers|Completed||Phase 1|18|Anticipated|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 23:40:21.157583|2018-05-31 23:40:21.157583
NCT01146925|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-06-23|2010-06-16|2010-06-22|Estimate|||||||2011-06-23|2011-06-27|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury|A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of CRMD-001 in Contrast-Induced Acute Oxidative Kidney Injury|Completed||Phase 2|60|Anticipated|CorMedix||2|||f||||f||||||||||2018-05-31 23:40:21.231041|2018-05-31 23:40:21.231041
NCT01146912|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2012-08-08||2015-09-06|2010-06-17|2010-06-22|Estimate|2013-04-08|2013-05-31|Estimate||||2015-09-06|2015-10-07|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Populations|TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Population|Completed||N/A|30537|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 23:40:21.367739|2018-05-31 23:40:21.367739
NCT01146899|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2014-06-22|2010-06-16|2010-06-22|Estimate|||||||2014-06-22|2014-06-24|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||FluAlert: Influenza Vaccine Alerts for Providers in the Electronic Health Record|FluAlert: Influenza Vaccine Alerts for Providers in the Electronic Health Record|Completed||N/A|6145|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 23:40:21.913408|2018-05-31 23:40:21.913408
NCT01146886|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2013-10-31|2010-06-21|2010-06-22|Estimate|||||||2013-10-31|2013-11-01|Estimate|June 2010||2010-06-30|October 2013|2013-10-31||||September 2010|Actual|2010-09-30||Interventional|||Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 10 mg to 1200 mg of BI 135585 XX Administered as a Solution to Healthy Male Volunteers (Trial Part 1), Followed by an Open, Randomised, Single-dose, Intra-individual Bioavailability Comparison of 200 mg BI 135585 XX as Tablet and as Solution (Trial Part 2)|Completed||Phase 1|60|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:40:22.004807|2018-05-31 23:40:22.004807
NCT01146873|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|2016-02-29||2017-01-31|2010-06-17|2010-06-22|Estimate|2016-03-31|2016-05-04|Estimate||||2017-01-31|2017-03-13|Actual|July 2010||2010-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NEVEREST-III||Treatment Options for Protease Inhibitor-exposed Children|Treatment Options for Protease Inhibitor-exposed Children|Completed||Phase 3|300|Actual|Columbia University||4|||f||||t||||||||||2018-05-31 23:40:22.106611|2018-05-31 23:40:22.106611
NCT01146860|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2012-10-09||2013-06-28|2010-06-17|2010-06-22|Estimate|2013-06-28|2013-08-02|Estimate||||2013-06-28|2013-08-02|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis|A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Study to Assess the Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis|Completed||Phase 3|386|Actual|Bionorica SE|Headache and facial pain are rated by investigator based on the description of the patient. This was done to ensure a uniform rating of symptom severity across the investigational sites but nevertheless subjective and open to error.|2|||f||||f||||||||||2018-05-31 23:40:22.49377|2018-05-31 23:40:22.49377
NCT01146847|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-11-01|2010-06-17|2010-06-22|Estimate|||||||2010-11-01|2010-11-02|Estimate|December 2009||2009-12-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|DELIOS 03||Feasibility of Tight Blood Glucose Control With the Space TGC System in Surgical ICU Patients|Single-centre, Open Study to Investigate the Feasibility of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) in Surgical ICU Patients|Completed||N/A|20|Actual|B. Braun Melsungen AG||1|||f||||f||||||||||2018-05-31 23:40:22.886006|2018-05-31 23:40:22.886006
NCT01146834|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2018-02-27|2010-06-17|2010-06-22|Estimate|||||||2018-02-27|2018-03-01|Actual|March 2011||2011-03-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|||Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma|A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma|Active, not recruiting||Phase 3|180|Anticipated|Weill Medical College of Cornell University||3|||f||||t||||||||||2018-05-31 23:40:22.948159|2018-05-31 23:40:22.948159
NCT01146821|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-04-17|2010-06-17|2010-06-22|Estimate|||||||2017-04-17|2017-04-19|Actual|October 2013||2013-10-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|FOILED||Fish OIL Optimal dosE Determination Study|Multi-centre, Open-label, Phase II Clinical Trial for Determination of the Optimal Dose of Fish Oil in Patients With Severe Sepsis|Terminated||Phase 2|7|Actual|University Hospital Carl Gustav Carus||3||Low enrollment/ expiration of the grant|f||||f||||||||||2018-05-31 23:40:23.048814|2018-05-31 23:40:23.048814
NCT01146808|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2017-01-25||2017-01-25|2010-06-17|2010-06-22|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|March 2006||2006-03-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver|Prevention of de Novo Hepatitis B Infection With Adefovir Dipivoxil (ADV) and Hepatitis B Vaccination in HBsAg Seronegative Recipients of Liver Grafts From Hepatitis B Core Antibody Positive (HBcAb+) Donors|Completed||Phase 1/Phase 2|16|Actual|Columbia University||1|||f||||f|t|f|||f|||No||2018-05-31 23:40:23.131383|2018-05-31 23:40:23.131383
NCT01146795|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2015-10-30|2010-06-17|2010-06-22|Estimate|||||||2015-10-30|2015-11-02|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Neoadjuvant Therapy for Ovarian Cancer|Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Terminated||Phase 2|32|Actual|Columbia University||1||Study encountered 7 cumulative protocol defined events in 30 patients during Stage II.|f||||t||||||||||2018-05-31 23:40:23.431759|2018-05-31 23:40:23.431759
NCT01146236|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-04-04|2010-06-16|2010-06-17|Estimate|||||||2011-04-04|2011-04-05|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Sutures Versus Staples for Wound Closure in Orthopaedic Surgery|Sutures vs Staples for Wound Closure in Orthopaedic Surgery: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|2560|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 23:40:30.808015|2018-05-31 23:40:30.808015
NCT01146769|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-06-17|2010-06-17|2010-06-22|Estimate|||||||2010-06-17|2010-06-22|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2012|Anticipated|2012-04-30|October 2011|Anticipated|2011-10-31||Interventional|||Early Pelvic Floor Muscle Training Improves Pelvic Floor Muscle Strength in Patient After Low Anterior Resection|Early Pelvic Floor Muscle Training Improves Pelvic Floor Muscle Strength in Patient After Low Anterior Resection|Unknown status|Recruiting|N/A|50|Anticipated|Kwong Wah Hospital||2|||f||||f||||||||||2018-05-31 23:40:23.803584|2018-05-31 23:40:23.803584
NCT01146756|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2018-02-22|2010-06-17|2010-06-22|Estimate|||||||2018-02-22|2018-02-23|Actual|June 4, 2010|Actual|2010-06-04|February 2018|2018-02-28|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|MEKRT||MEK Inhibitor and Thoracic Radiotherapy Trial|Phase I Trial of the MEK Inhibitor AZD6244 in Combination With Thoracic Radiotherapy in Non-small Cell Lung Cancer|Completed||Phase 1|21|Actual|The Christie NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 23:40:23.920301|2018-05-31 23:40:23.920301
NCT01146743|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-03-16|2010-06-17|2010-06-22|Estimate|||||||2011-03-16|2011-03-17|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Prospective Trial for Endoscopic Ultrasound Guided Gallbladder Drainage for Acute Cholecystitis in High Risk Patients|Prospective Randomized Controlled Trial for Endoscopic Ultrasound Guided and Percutaneous Transhepatic Gallbladder Drainage for Acute Cholecystitis in High Risk Patients|Completed||N/A|59|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:40:24.013418|2018-05-31 23:40:24.013418
NCT01146730|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-02-20|2010-06-16|2010-06-17|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2010||2010-06-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|March 2016|Actual|2016-03-31||Interventional|AWaC||At Work and Coping - Effect Study of Workcoping for Patients With Anxiety and Depression|At Work and Coping - Effect Evaluation of Center for Workcoping for Patients With Anxiety and Depression|Active, not recruiting||Phase 2|1202|Actual|Uni Research||2|||f||||t||||||||||2018-05-31 23:40:24.16109|2018-05-31 23:40:24.16109
NCT01146717|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2016-10-24|2010-06-16|2010-06-17|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|AETMCI||Aerobic Exercise Training in Mild Cognitive Impairment Study|Mild Cognitive Impairment:Cerebrovascular Dysfunction and Exercise|Completed||Phase 2|80|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 23:40:24.256309|2018-05-31 23:40:24.256309
NCT01146704|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2018-02-14|2010-06-16|2010-06-17|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 1, 2010|Actual|2010-09-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Gastrointestinal Hormonal Regulation of Obesity|Gastrointestinal Hormonal Regulation of Obesity|Recruiting||N/A|198|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 23:40:24.350571|2018-05-31 23:40:24.350571
NCT01146691|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|October 2008||2008-10-31|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Effect of Around the Clock Intensivist Coverage on Intensive Care Unit (ICU) Outcomes|The Effect of Alternative Attending Physician Staffing Models on Outcomes for Intensive Care Unit Patients, Families, and Health Care Workers|Completed|||627|Actual|University of Manitoba|||2||f||||f||||||||||2018-05-31 23:40:24.453037|2018-05-31 23:40:24.453037
NCT01146678|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-03-01|2010-06-16|2010-06-17|Estimate|||||||2011-03-01|2011-03-02|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1|A Randomized, Cross-over, Open, Euglycemic Clamp Study on the Relative Bioavailability and Activity of 0.6 U/kg Insulin Glargine and 20 μg Lixisenatide, Given as On-site Mix Compared to Separate Simultaneous Injections in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|22|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 23:40:24.553622|2018-05-31 23:40:24.553622
NCT01146665|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2013-05-09|2010-06-16|2010-06-17|Estimate|||||||2013-05-09|2013-05-13|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Pilot Study of a Computer-Based Intervention for Alcohol Misuse in the Emergency Department|Pilot Study of a Computer-Based Intervention for Alcohol Misuse in the Emergency Department|Completed||N/A|44|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 23:40:24.630595|2018-05-31 23:40:24.630595
NCT01146652|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2017-09-27|2010-06-16|2010-06-17|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2010|Actual|2010-06-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)|A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)|Active, not recruiting||Phase 3|2000|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 23:40:24.778915|2018-05-31 23:40:24.778915
NCT01146639|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2017-01-16|2010-06-16|2010-06-17|Estimate|||||||2017-01-16|2017-01-18|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|DynaCT||DynaCT in Preoperative Imaging Before Insertion of Stentgraft|Usefulness of DynaCT Compared to Multidetector CT as Preoperative Imaging Before Insertion of Aortic Stentgraft.|Completed||N/A|20|Actual|Norwegian University of Science and Technology||1|||f||||t||||||||||2018-05-31 23:40:25.418372|2018-05-31 23:40:25.418372
NCT01146626|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-04-27|2010-06-16|2010-06-17|Estimate|||||||2011-04-27|2011-04-28|Estimate|August 2011||2011-08-31|June 2010|2010-06-30|May 2012|Anticipated|2012-05-31|February 2012|Anticipated|2012-02-29||Interventional|||Does Vitamin D Improves Sustained Virologic Response (SVR) in Genotype 2,3 Chronic Hepatitis C Patients?|Does Vitamin D Supplement Improve SVR in Chronic Hepatitis C (Genotype 2,3) in naïve Patients Treated With Peginterferon Alpha and Ribavirin|Unknown status|Not yet recruiting|N/A|60|Anticipated|Ziv Hospital||2|||f||||f||||||||||2018-05-31 23:40:25.558305|2018-05-31 23:40:25.558305
NCT01146613|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2014-05-14||2014-08-20|2010-06-16|2010-06-17|Estimate|2014-07-17|2014-08-11|Estimate||||2014-08-20|2014-08-27|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|NCIG 003|One subject (two records) was excluded from analysis due to his dual study participation at two separate clinical sites. Both instances of participation were in the Varenicline arm and both instances were not considered in the mITT population.|Varenicline for Alcohol Dependence|A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy of Varenicline Tartrate for Alcohol Dependence in Very Heavy Drinkers|Completed||Phase 2|200|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||||||||||||2018-05-31 23:40:25.688199|2018-05-31 23:40:25.688199
NCT01146600|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2013-09-28||2017-10-05|2010-06-16|2010-06-17|Estimate|2014-05-14|2014-06-12|Estimate||||2017-10-05|2017-11-06|Actual|July 2010||2010-07-31|October 2017|2017-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Clarithromycin for the Treatment of Hypersomnia|Clarithromycin for the Treatment of Hypersomnia|Completed||Phase 2|26|Actual|Emory University||2|||f||||f||||||||||2018-05-31 23:40:26.080604|2018-05-31 23:40:26.080604
NCT01146587|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-06-04|2010-06-16|2010-06-17|Estimate|||||||2015-06-04|2015-06-08|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|galop||Comparative Study of GangTrainer GT1, Lokomat and Conventional Physiotherapy|Robot Assisted Therapy for Acute Stroke Patients: a Comparative Study of GangTrainer GT I, Lokomat System and Conventional Physiotherapy|Suspended||N/A|120|Anticipated|Research Department for Neurorehabilitation South Tyrol||3||GangTrainer GT1 is not state of the art anymore for the principal Invesigator|f||||f||||||||||2018-05-31 23:40:26.513334|2018-05-31 23:40:26.513334
NCT01146574|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16||2017-03-07|2017-03-07|2010-06-16|2010-06-17|Estimate||||2017-03-07|2017-03-08|Actual|2017-03-07|2017-03-08|Actual|June 30, 2010|Actual|2010-06-30|March 2017|2017-03-31|March 7, 2016|Actual|2016-03-07|March 7, 2016|Actual|2016-03-07||Interventional|||A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.|A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).|Completed||Phase 2|50|Actual|Celgene||5|||f||||t||||||||||2018-05-31 23:40:26.63527|2018-05-31 23:40:26.63527
NCT01146561|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24||2012-08-23|2012-08-23|2010-06-16|2010-06-17|Estimate||||2012-08-23|2012-08-30|Estimate|2012-08-23|2012-08-30|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Chronic Pancreatitis|Terminated||Phase 2|2|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:40:26.734972|2018-05-31 23:40:26.734972
NCT01146548|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2015-03-25|2010-06-16|2010-06-17|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|MSA-Fluox||Fluoxetine in Multiple System Atrophy Patients|Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial|Completed||Phase 2|87|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 23:40:26.808739|2018-05-31 23:40:26.808739
NCT01146535|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-08-19|2010-06-16|2010-06-17|Estimate|||||||2013-08-19|2013-08-21|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment|Pilot Study of Interferon Alpha Lozenges Plus Oseltamivir in the Treatment of Influenza A Infection|Completed||Phase 2|40|Actual|Amarillo Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 23:40:27.042202|2018-05-31 23:40:27.042202
NCT01146522|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09||2012-11-30|2012-12-28|2010-06-16|2010-06-17|Estimate||||2012-11-30|2012-12-04|Estimate|2012-12-28|2013-01-01|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia|A Multiple-dose, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCQ908 in Patients With Severe Hypertriglyceridemia and Chylomicronemia (Phenotypes I and V)|Completed||Phase 1/Phase 2|8|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:40:27.129799|2018-05-31 23:40:27.129799
NCT01146509|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2012-12-06|2010-06-16|2010-06-17|Estimate|||||||2012-12-06|2012-12-10|Estimate|January 2003||2003-01-31|December 2012|2012-12-31|March 2007|Actual|2007-03-31|April 2004|Actual|2004-04-30||Interventional|||An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis|An Open-Label, Multicenter, One-Year Extension Of The Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis|Completed||Phase 2|89|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 23:40:27.205189|2018-05-31 23:40:27.205189
NCT01146496|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2016-11-16|2010-06-16|2010-06-17|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2010||2010-12-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2013|Actual|2013-05-31||Interventional|||A Community Trial to Determine Whether 'Safe Storage' Reduces Pesticide Self-poisoning in Rural Asia|A Community Trial to Determine Whether 'Safe Storage' Reduces Pesticide Self-poisoning in Rural Asia|Completed||N/A|223000|Actual|University of Edinburgh||2|||f||||t||||||||No||2018-05-31 23:40:27.287457|2018-05-31 23:40:27.287457
NCT01146483|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-12-14|2010-06-16|2010-06-17|Estimate|||||||2011-12-14|2011-12-15|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin|Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin|Completed||Phase 1|16|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 23:40:27.375392|2018-05-31 23:40:27.375392
NCT01146470|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-02-17|2010-06-16|2010-06-17|Estimate|||||||2013-02-17|2013-02-20|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|RGC||The Influence of Red Grape Cells on Blood Pressure Vascular Function in People With Hypertension|A Single-Center, Double-blind, Random, Parallel Controlled Study|Completed||N/A|50|Actual|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-05-31 23:40:27.457197|2018-05-31 23:40:27.457197
NCT01146457|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2016-08-05||2017-03-14|2010-06-16|2010-06-17|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|July 2010||2010-07-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia|The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia|Terminated||N/A|83|Actual|Beth Israel Deaconess Medical Center||5||Principal Investigator|f||||f||||||||No||2018-05-31 23:40:27.551204|2018-05-31 23:40:27.551204
NCT01146444|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2016-03-08|2010-06-16|2010-06-17|Estimate|||||||2016-03-08|2016-03-09|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Interventional|||Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)|Investigation of the Efficacy of Different Sunscreens in Patients With Photosensitive Cutaneous Lupus Erythematosus|Completed||N/A|20|Actual|Spirig Pharma Ltd.||2|||f||||t||||||||||2018-05-31 23:40:27.951651|2018-05-31 23:40:27.951651
NCT01146431|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-02-08|2010-06-16|2010-06-17|Estimate|||||||2011-02-08|2011-02-09|Estimate|June 2010||2010-06-30|January 2010|2010-01-31||||||||Observational|||Memory During Inhalation Anesthesia Performed With or Without Bispectral Index (BIS) in Patients Undergoing Thyroidectomy||Unknown status|Recruiting||130|Anticipated|Catholic University of the Sacred Heart|||2||f||||||||||||||2018-05-31 23:40:28.071894|2018-05-31 23:40:28.071894
NCT01145144|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-06-15|2010-06-15|2010-06-16|Estimate|||||||2010-06-15|2010-06-16|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment||Completed||N/A|||Meir Medical Center||2|||f||||||||||||||2018-05-31 23:40:46.833687|2018-05-31 23:40:46.833687
NCT01146418|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2015-10-01||2017-06-02|2010-06-16|2010-06-17|Estimate|2016-01-04|2016-02-03|Estimate||||2017-06-02|2017-07-02|Actual|June 2, 2010|Actual|2010-06-02|June 2017|2017-06-30|April 29, 2014|Actual|2014-04-29|July 24, 2013|Actual|2013-07-24||Interventional||All Subjects Evaluable, restricted to subjects with ET|Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)|Follow-up Protocol to Collect the Outcome and Safety of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Study P06029 (Phase 3; Protocol No. P06031)|Completed||Phase 3|307|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 23:40:28.17218|2018-05-31 23:40:28.17218
NCT01146405|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-02-08|2010-06-16|2010-06-17|Estimate|||||||2011-02-08|2011-02-09|Estimate|June 2010||2010-06-30|October 2009|2009-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Observational|||Memory During Anesthesia: the Role of Stress Hormones||Unknown status|Recruiting||110|Anticipated|Catholic University of the Sacred Heart|||||f||||f||||||Samples Without DNA|"~     Whole blood and serum.~   "|||2018-05-31 23:40:29.08012|2018-05-31 23:40:29.08012
NCT01146392|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2014-06-17|2010-06-16|2010-06-17|Estimate|||||||2014-06-17|2014-06-18|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|PATHOS||An Investigation of the Past 10 Yrs Health Care for Primary Care Patients With Chronic Obstructive Pulmonary Disease|A Retrospective Epidemiological Study to Map Out Patients With Chronic Obstructive Pulmonary Disease (COPD) and Describe COPD Health Care in Real-Life Primary Care During the First Ten Years of the 21th Century|Completed|||27394|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:40:29.141965|2018-05-31 23:40:29.141965
NCT01146379|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2016-10-31||2017-01-03|2010-06-15|2010-06-17|Estimate|2017-01-03|2017-02-24|Actual||||2017-01-03|2017-02-24|Actual|May 2010||2010-05-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Does More Practice Improve Arm Movement After Stroke?|Dose Response of Movement Practice During Stroke Rehabilitation|Completed||Phase 2|85|Actual|Washington University School of Medicine||4|||f||||t||||||||No||2018-05-31 23:40:29.245167|2018-05-31 23:40:29.245167
NCT01146366|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2014-12-10|2010-06-15|2010-06-17|Estimate|||||||2014-12-10|2014-12-11|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|||Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)|Utility of Routine Cervical Mediastinoscopy in Clinically Staged T2N0M0 and Select T1N0M0 Non-Small Cell Lung Cancers by FDG-PET and CT Scans|Completed|||111|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 23:40:29.636617|2018-05-31 23:40:29.636617
NCT01146353|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2018-03-17|2010-06-16|2010-06-17|Estimate|||||||2018-03-17|2018-03-20|Actual|February 2010||2010-02-28|March 2018|2018-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy|Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy|Withdrawn|||0|Actual|Midwestern University|||1|Peramivir EUA terminated by FDA.|f||||f||||||||||2018-05-31 23:40:29.693542|2018-05-31 23:40:29.693542
NCT01146340|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2016-04-22|2010-06-16|2010-06-17|Estimate|||||||2016-04-22|2016-04-25|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer|Phase I/II Study of Dose-Escalated Hypofractionated Radiotherapy for Low- and Intermediate-Risk Prostate Cancer (PHART6)|Completed||Phase 1/Phase 2|30|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||Undecided||2018-05-31 23:40:29.874709|2018-05-31 23:40:29.874709
NCT01146327|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-04-18|2010-06-16|2010-06-17|Estimate|||||||2011-04-18|2011-04-19|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects|A Phase 1, Parallel, Randomized Trial To Assess The Effect Of Time Of Dosing On The Pharmacodynamics, Pharmacokinetics, Safety And Tolerability Of Multiple Oral Doses Of PF-04620110 In Otherwise Healthy Overweight Or Obese Adult Subjects|Completed||Phase 1|60|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 23:40:29.941122|2018-05-31 23:40:29.941122
NCT01146314|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-04-30|2010-06-16|2010-06-17|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|FBI||A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children|A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children|Completed||N/A|150|Actual|Nemours Children's Clinic||1|||f||||f||||||||||2018-05-31 23:40:30.025091|2018-05-31 23:40:30.025091
NCT01146301|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-21|2010-06-16|2010-06-17|Estimate|||||||2010-06-21|2010-06-22|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|IMPACT||Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery|Does the Magnitude of Platelet Inhibition Inversely Correlate With the Number of TCD-detected Microemboli in Asymptomatic Patients Undergoing Carotid Artery Stenting Prior to Cardiac Surgery Who Are Being Pre-treated With 300 mg or 600 mg Loading Dose of Clopidogrel?|Completed||Phase 4|||R&D Cardiologie||2|||f||||t||||||||||2018-05-31 23:40:30.091744|2018-05-31 23:40:30.091744
NCT01146288|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2014-11-20||2015-06-02|2010-06-16|2010-06-17|Estimate|2015-06-02|2015-06-04|Estimate||||2015-06-02|2015-06-04|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration|Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration|Completed||N/A|13|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 23:40:30.164524|2018-05-31 23:40:30.164524
NCT01146275|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|2013-11-29||2013-11-29|2010-06-16|2010-06-17|Estimate|2013-11-29|2014-01-16|Estimate||||2013-11-29|2014-01-16|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A 7-year Follow up of All Subjects Incuded in Protocol 31GB0106|A 7-year Follow up of All Subjects Incuded in Protocol 31GB0106|Completed||N/A|6|Actual|Q-Med AB||1|||f||||||||||||||2018-05-31 23:40:30.403784|2018-05-31 23:40:30.403784
NCT01146262|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2016-07-25|2010-06-16|2010-06-17|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|CD lam||Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)|Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for AML Patients in First or Second CR|Unknown status|Active, not recruiting|Phase 1/Phase 2|5|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 23:40:30.626471|2018-05-31 23:40:30.626471
NCT01146249|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|November 2007||2007-11-30|April 2010|2010-04-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|PREFSENSOR||Evaluation of the Sensorial Preference|Evaluation of the Sensorial Preference for Balance Control|Unknown status|Recruiting||125|Anticipated|Assistance Publique - Hôpitaux de Paris|||5||f||||f||||||||||2018-05-31 23:40:30.698628|2018-05-31 23:40:30.698628
NCT01146210|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2016-05-13|2010-06-16|2010-06-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia|Identification of de Novo Fanconi Anemia Patients Using FANCD2 Western Blots|Completed|||20|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tumor tissue~   "|||2018-05-31 23:40:31.010257|2018-05-31 23:40:31.010257
NCT01146197|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-12-09|2010-06-16|2010-06-17|Estimate|||||||2013-12-09|2013-12-10|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|GITAB||Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics|Evaluation of Safety and Efficacity of Indometacin and Two Potassium Sparing Diuretics in Adult Patients Affected by Gitelman Syndrome|Completed||Phase 1/Phase 2|33|Actual|Assistance Publique - Hôpitaux de Paris||6|||f||||f||||||||||2018-05-31 23:40:31.110164|2018-05-31 23:40:31.110164
NCT01146184|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2016-03-04|2010-06-15|2010-06-17|Estimate|||||||2016-03-04|2016-03-07|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|IRB#08-181||Single Incision Laparoscopic Cholecystectomy Using a Flexible Endoscope and Ethicon Manually Articulating Devices (MAD)|Single Incision Laparoscopic Cholecystectomy Using a Flexible Endoscope and Ethicon Manually Articulating Devices (MAD)|Withdrawn||N/A|0|Actual|St. Luke's-Roosevelt Hospital Center||1||the manufacturer never released the instruments|f||||t||||||||||2018-05-31 23:40:31.200009|2018-05-31 23:40:31.200009
NCT01146171|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2012-02-06|2010-06-16|2010-06-17|Estimate|||||||2012-02-06|2012-02-07|Estimate|November 2013||2013-11-30|February 2012|2012-02-29|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Japanese Phase 1 Study of BMS-844203 (CT322)|A Phase I Multiple Ascending Dose Study of BMS-844203 (CT-322) Monotherapy in Japanese Patients With Solid Tumors|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 23:40:31.280289|2018-05-31 23:40:31.280289
NCT01146158|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-04-07|2010-06-16|2010-06-17|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2009||2009-11-30|May 2009|2009-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SENTIBRAS||Axillary Reverse Mapping for Breast Carcinomas|Individualisation of the Lymphatic Arm Drainage During Axillary Dissection for Breast Carcinomas.|Completed||Phase 3|210|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 23:40:31.368469|2018-05-31 23:40:31.368469
NCT01146145|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|May 2003||2003-05-31|June 2010|2010-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|KEMO||Efficacity, Safety and Cost of Intravenous Morphine Titration Alone or Combined to Ketamine|Efficacity, Safety and Cost of Intravenous Morphine Titration Alone or Combined to Ketamine|Completed||N/A|160|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:40:31.459171|2018-05-31 23:40:31.459171
NCT01146132|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2012-10-04|2010-06-16|2010-06-17|Estimate|||||||2012-10-04|2012-10-05|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ALVINA||Nutrition and Physical Activity in Patients With Cerebrovascular Disease|Nutrition and Physical Activity in Patients With Cerebrovascular Disease|Completed||N/A|119|Actual|Public Research Centre Health, Luxembourg||4|||f||||f||||||||||2018-05-31 23:40:31.567237|2018-05-31 23:40:31.567237
NCT01146119|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-13|||2012-07-30|2010-06-16|2010-06-17|Estimate|||||||2012-07-30|2012-07-31|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)|A Phase II, Randomized, Two Stage, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers|Completed||Phase 2|200|Actual|BiondVax Pharmaceuticals ltd.||6|||f||||f||||||||||2018-05-31 23:40:31.669516|2018-05-31 23:40:31.669516
NCT01146106|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|December 2002||2002-12-31|June 2010|2010-06-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions|Single Dose Two-Way Crossover Fasting Bioequivalence Study of Pravastatin 80 mg Tablets in Healthy Volunteers|Completed||Phase 1|43|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:40:31.753463|2018-05-31 23:40:31.753463
NCT01146093|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2012-01-12|2010-06-16|2010-06-17|Estimate|||||||2012-01-12|2012-01-13|Estimate|November 2002||2002-11-30|June 2010|2010-06-30|March 2003|Actual|2003-03-31|November 2002|Actual|2002-11-30||Interventional|||Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Pravastatin 80 mg Tablets in Healthy Volunteers|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:40:31.841383|2018-05-31 23:40:31.841383
NCT01146080|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2015-10-14|2010-06-16|2010-06-17|Estimate|||||||2015-10-14|2015-10-16|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|OCTEVEREST||Optical Coherence Tomography for EVERolimus Eluting STent|Optical Coherence Tomography for EVERolimus Eluting STent (OCTEVEREST)|Completed||Phase 3|42|Actual|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-05-31 23:40:32.129736|2018-05-31 23:40:32.129736
NCT01146067|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2012-01-12|2010-06-16|2010-06-17|Estimate|||||||2012-01-12|2012-01-13|Estimate|January 2004||2004-01-31|June 2010|2010-06-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions|Bioequivalence Study of Rivastigmine 1.5 mg Capsules (Test)of Dr.Reddy's Laboratories Limited Versus Exelon (Reference),Administered as 1 x 1.5 mg Capsule Under Fasting Conditions|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:40:32.220322|2018-05-31 23:40:32.220322
NCT01146054|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2017-01-10||2017-11-20|2010-06-16|2010-06-17|Estimate|2017-04-06|2017-05-15|Actual||||2017-11-20|2017-12-19|Actual|October 2009||2009-10-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2013|Actual|2013-10-31||Interventional||The entire cohort is analyzed.|Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma|Phase II Multi-Institutional Study to Evaluate the Efficacy of Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma|Completed||Phase 2|59|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 23:40:32.310633|2018-05-31 23:40:32.310633
NCT01146041|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|February 2004||2004-02-29|June 2010|2010-06-30|April 2004|Actual|2004-04-30|February 2004|Actual|2004-02-29||Interventional|||Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Rivastigmine 1.5 mg Capsules and Exelon Administered as 1 x 1.5 mg Capsule in Healthy Subjects Under Fed Conditions|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:40:32.566246|2018-05-31 23:40:32.566246
NCT01146028|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2012-01-12|2010-06-16|2010-06-17|Estimate|||||||2012-01-12|2012-01-13|Estimate|September 2001||2001-09-30|June 2010|2010-06-30|November 2001|Actual|2001-11-30|September 2001|Actual|2001-09-30||Interventional|||Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Tizanidine Hydrochloride 4mg Tablets and Zanaflex® 4mg Tablets Administered As 1 x 4mg Tablet in Healthy Adult Subjects Under Fasting Conditions|Completed||Phase 1|42|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:40:32.630946|2018-05-31 23:40:32.630946
NCT01146015|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-08-24|2010-06-16|2010-06-17|Estimate|||||||2011-08-24|2011-08-26|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2010/2011 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2010/2011. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects|Completed||Phase 3|121|Actual|Abbott||1|||f||||f||||||||||2018-05-31 23:40:32.766055|2018-05-31 23:40:32.766055
NCT01146002|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2014-04-01|2010-06-16|2010-06-17|Estimate|||||||2014-04-01|2014-04-02|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine|Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine|Completed||Phase 4|30|Actual|Neurology Group of Bergen County, P.A.||1|||f||||f||||||||||2018-05-31 23:40:32.839854|2018-05-31 23:40:32.839854
NCT01145989|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2015-11-27|2010-06-16|2010-06-17|Estimate|||||||2015-11-27|2015-11-30|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|||A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|8|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-05-31 23:40:32.928405|2018-05-31 23:40:32.928405
NCT01145976|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2012-09-06|2010-06-16|2010-06-17|Estimate|||||||2012-09-06|2012-09-07|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|February 2016|Anticipated|2016-02-29|February 2015|Anticipated|2015-02-28||Interventional|CyATG-FluATG||Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia|Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia|Unknown status|Recruiting|Phase 3|98|Anticipated|Cooperative Study Group A for Hematology||2|||f||||t||||||||||2018-05-31 23:40:33.033334|2018-05-31 23:40:33.033334
NCT01145963|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2018-03-15|2010-06-16|2010-06-17|Estimate|||||||2018-03-15|2018-03-16|Actual|June 1, 2010|Actual|2010-06-01|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|SAT||Pasta Formulations and Their Effect on Appetite|Understanding Pasta Formulations on Satiation in Healthy Weight Women|Active, not recruiting||N/A|24|Actual|Institute for Food Safety and Health, United States||3|||f||||f||||||||||2018-05-31 23:40:33.117999|2018-05-31 23:40:33.117999
NCT01145950|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2011-02-17|2010-06-16|2010-06-17|Estimate|||||||2011-02-17|2011-02-18|Estimate|June 2010||2010-06-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®|A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers|Completed||Phase 1|36|Anticipated|LG Life Sciences||2|||f||||f||||||||||2018-05-31 23:40:33.196013|2018-05-31 23:40:33.196013
NCT01145937|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-12-02|2010-06-16|2010-06-17|Estimate|||||||2015-12-02|2015-12-03|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PENTACON||PENTACON Trial: Partial ENdothelial Trepanation in Addition to Anterior Lamellar Keratoplasty in keratoCONus|Pentacon Trial: Partial ENdothelial Trepanation in Addition to Anterior Lamellar Keratoplasty in keratoCONus. A Prospective Multicenter Randomized Controlled Trial|Terminated||N/A|14|Actual|UMC Utrecht||2||during anticipated study duration trial power was not attained.|f||||f||||||||||2018-05-31 23:40:33.26752|2018-05-31 23:40:33.26752
NCT01145924|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Transbronchial Needle Forceps for Endobronchial Ultrasound|Transbronchial Needle Forceps for EBUS|Unknown status|Recruiting|Phase 2|50|Anticipated|Heidelberg University||1|||f||||t||||||||||2018-05-31 23:40:33.345439|2018-05-31 23:40:33.345439
NCT01145911|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2017-03-06|2010-06-16|2010-06-17|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2008||2008-01-31|March 2017|2017-03-31|July 3, 2014|Actual|2014-07-03|July 3, 2014|Actual|2014-07-03||Observational|IGPS||The Study of Ocular Hemodynamics With Glaucoma Progression|The Study of Ocular Hemodynamics With Glaucoma Progression|Completed|||123|Actual|Indiana University|||1||f||||f||||||||||2018-05-31 23:40:33.438778|2018-05-31 23:40:33.438778
NCT01145898|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2013-09-20||2014-01-17|2010-06-16|2010-06-17|Estimate|2014-01-17|2014-01-22|Estimate||||2014-01-17|2014-01-22|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|October 2012|Actual|2012-10-31|January 2012|Actual|2012-01-31||Observational||glaucoma patients:There will be (as shown) differences in the number of subjects based upon the time of analysis due to patient loss, data of insufficient quality at visit, or change in the drug use during period of study (patient switched off treatment by their doctor) so the number of data points varies throughout the analysis by availability.|Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data|Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data|Completed|||56|Actual|Indiana University|Small numbers of participants at various time-points limited the power of analysis in our estimation, as did patients who changed medications and therefore further limited analysis options at various time-points.||1||f||||f||||||||||2018-05-31 23:40:33.525723|2018-05-31 23:40:33.525723
NCT01145885|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-10-31|2010-06-16|2010-06-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|June 2010||2010-06-30|October 2013|2013-10-31||||November 2010|Actual|2010-11-30||Interventional|||BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours|Investigation of the Metabolism, Excretion and Pharmacokinetics of an Openlabel Single Dose of 300 mg [14C]Volasertib Administered Intravenously in Patients With Various Solid Tumours With a Possible Extension Phase With Nonlabelled Drug|Completed||Phase 1|7|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:40:33.983163|2018-05-31 23:40:33.983163
NCT01145872|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2014-12-01|2010-06-16|2010-06-17|Estimate|||||||2014-12-01|2014-12-02|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|May 2012|Actual|2012-05-31||Interventional|MBCT||The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse|The Effects and Mechanisms of MBCT on Depressive Symptoms and Depression Relapse|Completed||Phase 3|92|Actual|University of Denver||2|||f||||t||||||||||2018-05-31 23:40:34.042113|2018-05-31 23:40:34.042113
NCT01145859|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2015-08-05|2010-06-16|2010-06-17|Estimate|||||||2015-08-05|2015-08-06|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects|Single-dose Pilot Study of Oral Rivaroxaban in Pediatric Subjects With Venous Thromboembolism|Completed||Phase 1|59|Actual|Bayer||1|||f||||t||||||||||2018-05-31 23:40:34.102925|2018-05-31 23:40:34.102925
NCT01145846|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|April 2014|Anticipated|2014-04-30|April 2012|Anticipated|2012-04-30||Interventional|AIvsAD||Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)|A Prospective Randomized Comparison of Idarubicin and High-dose Daunorubicin in Combination With Cytarabine in the Induction Chemotherapy for Acute Myeloid Leukemia|Unknown status|Recruiting|Phase 3|316|Anticipated|Cooperative Study Group A for Hematology||1|||f||||t||||||||||2018-05-31 23:40:34.197853|2018-05-31 23:40:34.197853
NCT01145833|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|GSH||Guided Self-help for Families With an Overweight Child|Guided Self-help Treatment for Families With an Overweight Child|Unknown status|Active, not recruiting|N/A|49|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 23:40:34.278163|2018-05-31 23:40:34.278163
NCT01145820|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2013-10-08|2010-06-16|2010-06-17|Estimate|||||||2013-10-08|2013-10-09|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|FAVOURITE||Fruit And Vegetables and OUtcomes After Removal of Impacted TEeth|Efficacy of Adjunctive Juice Plus in Reducing Post-operative Morbidity and Improving Quality of Life After Lower Third Molar Surgery: a Randomized Controlled Clinical Trial|Completed||N/A|246|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 23:40:34.489326|2018-05-31 23:40:34.489326
NCT01145807|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2012-07-31|2010-06-16|2010-06-17|Estimate|||||||2012-07-31|2012-08-01|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|August 2012|Anticipated|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||TDT 067 Onychomycosis Study|A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks|Unknown status|Active, not recruiting|Phase 3|738|Anticipated|Celtic Pharma Development Services||3|||f||||f||||||||||2018-05-31 23:40:34.596989|2018-05-31 23:40:34.596989
NCT01145794|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2011-06-23|2010-06-16|2010-06-17|Estimate|||||||2011-06-23|2011-06-27|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Secondhand Smoke Exposure Reduction Study|Reducing Secondhand Smoke Exposure Among Young Children in Shanghai, China|Completed||N/A|348|Anticipated|Boston University|||||f||||f||||||||||2018-05-31 23:40:34.716633|2018-05-31 23:40:34.716633
NCT01145781|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2018-04-27|2010-06-16|2010-06-17|Estimate|||||||2018-04-27|2018-05-01|Actual|January 2010||2010-01-31|April 2018|2018-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Trial to Evaluate Single- and Double- Freeze Cryotherapy in the Prevention of Cervical Neoplasia|Randomised Intervention Trial to Evaluate Single- and Double- Freeze Cryotherapy in the Prevention of Cervical Neoplasia|Completed||N/A|440|Actual|Tata Memorial Hospital||2|||f||||f||||||||Undecided||2018-05-31 23:40:34.773259|2018-05-31 23:40:34.773259
NCT01145768|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-12-06|2010-06-15|2010-06-17|Estimate|||||||2010-12-06|2010-12-08|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days|A Phase 1, Single Center, Double-blind, Randomized, Placebo- Controlled, Parallel-group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TC-5214 (S-Mecamylamine) After Administration of Single and Multiple Ascending Doses for up to 8 Days in Healthy Male and Female Subjects|Completed||Phase 1|72|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:40:34.845447|2018-05-31 23:40:34.845447
NCT01145755|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2012-08-28||2012-09-27|2010-06-16|2010-06-17|Estimate|2012-08-28|2012-09-27|Estimate||||2012-09-27|2012-10-03|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder|A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Effectiveness and Safety of AZD2066 After 6 Weeks of Treatment in Patients With Major Depressive Disorder - D0475C00020|Terminated||Phase 2|131|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 23:40:34.938192|2018-05-31 23:40:34.938192
NCT01145742|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-06-17|2010-06-16|2010-06-17|Estimate|||||||2010-06-17|2010-06-22|Estimate|November 2006||2006-11-30|June 2010|2010-06-30|September 2009||2009-09-30|September 2009|Actual|2009-09-30||Interventional|COACH-D||Controlling Hypertension in Diabetes- Feasibility Study|A Collaborative Approach to Control Hypertension in Diabetes|Completed||N/A|56|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 23:40:35.304414|2018-05-31 23:40:35.304414
NCT01145729|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|June 2010||2010-06-30|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure|Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure|Unknown status|Active, not recruiting|N/A|80|Anticipated|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 23:40:35.398332|2018-05-31 23:40:35.398332
NCT01145716|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-05-19|2010-06-16|2010-06-17|Estimate|||||||2011-05-19|2011-05-20|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Exploration of Wrist Soft Tissue Injuries Associated With Wrist Fractures|Exploration of Acute TFCC-injuries in Association With Distal Radius Fractures|Completed||N/A|20|Anticipated|Linkoeping University||1|||f||||f||||||||||2018-05-31 23:40:35.472667|2018-05-31 23:40:35.472667
NCT01145703|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2014-09-04|2010-06-16|2010-06-17|Estimate|||||||2014-09-04|2014-09-05|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|VitD||Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly|Effects of Vitamin D Supplementation With and With Out Exercise on Metabolic and Physical Consequences of Vitamin D Deficiency in the Elderly|Terminated||N/A|39|Actual|Baltimore VA Medical Center||4||Investigator terminated study due to low enrollment of eligible subjects|f||||t||||||||||2018-05-31 23:40:35.60355|2018-05-31 23:40:35.60355
NCT01145690|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-10-25|2010-06-16|2010-06-17|Estimate|||||||2010-10-25|2010-10-26|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|SOFIE-5YFU||Five Year Follow-up of Internet-based Cognitive Behaviour Therapy (CBT) for Social Anxiety Disorder (SAD)|Five Year Follow-up of Internet-based Cognitive Behaviour Therapy for Social Anxiety Disorder|Completed|||80|Anticipated|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 23:40:35.706769|2018-05-31 23:40:35.706769
NCT01145677|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2011-06-22|2010-06-16|2010-06-17|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|ETHoPA-R||Efficacy of Topiramate for Hospitalized Patients With Alcoholism|Efficacy of Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Randomized, Placebo-Controlled Trial|Completed||Phase 2/Phase 3|90|Actual|Chiang Mai University||1|||f||||f||||||||||2018-05-31 23:40:35.82647|2018-05-31 23:40:35.82647
NCT01145664|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-16|||2010-06-16|2010-06-16|2010-06-17|Estimate|||||||2010-06-16|2010-06-17|Estimate|May 2010||2010-05-31|May 2010|2010-05-31||||August 2010|Anticipated|2010-08-31||Interventional|||A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease||Unknown status|Recruiting|N/A|390|Anticipated|Beijing YouAn Hospital||3|||f||||t||||||||||2018-05-31 23:40:35.979109|2018-05-31 23:40:35.979109
NCT01145651|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-10-07|2010-06-15|2010-06-16|Estimate|||||||2010-10-07|2010-10-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:40:36.088625|2018-05-31 23:40:36.088625
NCT01145638|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2015-09-21||2015-11-02|2010-06-15|2010-06-16|Estimate|2015-11-02|2015-12-03|Estimate||||2015-11-02|2015-12-03|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)|A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)|Completed||Phase 3|350|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 23:40:36.142973|2018-05-31 23:40:36.142973
NCT01145625|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2014-03-26|2013-02-05|2014-05-19|2010-06-15|2010-06-16|Estimate|2014-03-26|2014-04-25|Estimate|2013-02-05|2013-02-07|Estimate|2014-05-19|2014-05-22|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Intent to Treat (ITT) population defined as all participants randomly assigned to a treatment group who received dispensed investigational product.|Clinical Trial in Females With Female Pattern Hair Loss|A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625)|Completed||Phase 3|322|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 23:40:36.589687|2018-05-31 23:40:36.589687
NCT01145612|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-08-11|2010-06-15|2010-06-16|Estimate|||||||2010-08-11|2010-08-12|Estimate|October 2008||2008-10-31|June 2010|2010-06-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|LO-AT-MARFAN01||Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome|A Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome.|Unknown status|Active, not recruiting|Phase 3|140|Actual|Forteza, Albert, M.D.||2|||f||||f||||||||||2018-05-31 23:40:36.96296|2018-05-31 23:40:36.96296
NCT01145599|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2015-02-10|2010-06-15|2010-06-16|Estimate|||||||2015-02-10|2015-02-11|Estimate|September 2010||2010-09-30|November 2013|2013-11-30||||October 2013|Actual|2013-10-31||Observational|||Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures|Identifying Progression of Retinal Disease in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures|Completed|||374|Actual|European Vision Institute Clinical Research Network|||1||f||||f||||||||||2018-05-31 23:40:37.024645|2018-05-31 23:40:37.024645
NCT01145586|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2012-06-26|2010-06-15|2010-06-16|Estimate|||||||2012-06-26|2012-06-28|Estimate|June 2011||2011-06-30|June 2010|2010-06-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|LAILAII||A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia|"A Phase III, Non-Inferiority, Randomized, Blind, Parallel-Group, Multicentre, Multiple-Dose, Comparative Clinical Study of Lactase Eurofarma and Lactaid®, Assessing the Efficacy and Safety in the Treatment of Patients With Lactose Intolerance"|Completed||Phase 3|140|Actual|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-05-31 23:40:37.085683|2018-05-31 23:40:37.085683
NCT01145573|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2013-08-05|2010-06-15|2010-06-16|Estimate|||||||2013-08-05|2013-08-07|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|B-Hip||Bone Health in Pregnancy|Testing the Calcium DRI During Pregnancy: A Study of Bone Health in Black and White Women|Unknown status|Active, not recruiting|N/A|60|Anticipated|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-05-31 23:40:37.145011|2018-05-31 23:40:37.145011
NCT01145560|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2013-07-19||2014-09-26|2010-06-15|2010-06-16|Estimate|2013-07-19|2013-09-23|Estimate||||2014-09-26|2014-10-06|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock|A MultiCentre, Randomized, Double-blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of AZD9773 (CytoFab™) in Adult Patients With Severe Sepsis and/or Septic Shock|Completed||Phase 2|300|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 23:40:37.239768|2018-05-31 23:40:37.239768
NCT01145547|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2015-09-01||2015-10-02|2010-06-15|2010-06-16|Estimate|2015-09-01|2015-10-05|Estimate||||2015-10-02|2015-10-23|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Continuous Glucose Monitoring to Measure Effect of Glycemic Index|The Effect of Glycemic Index on Post-prandial Glycemia (Breakfast vs. Lunch) in Patients With Type 1 Diabetes: Quantification With Continuous Glucose Monitoring|Completed||N/A|7|Actual|Legacy Health System||2|||f||||t||||||||||2018-05-31 23:40:37.995248|2018-05-31 23:40:37.995248
NCT01145534|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2011-11-08|2010-06-15|2010-06-16|Estimate|||||||2011-11-08|2011-11-09|Estimate|January 2009||2009-01-31|August 2008|2008-08-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes|Phase 1 Study for Testing Efficacy of Cissus Verticillata L Infusion in Controlling Glucose Concentration|Completed||Phase 1/Phase 2|15|Actual|Federal University of Paraíba||2|||f||||t||||||||||2018-05-31 23:40:38.142859|2018-05-31 23:40:38.142859
NCT01145508|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2014-04-25||2017-08-21|2010-06-15|2010-06-16|Estimate|2014-07-22|2014-07-23|Estimate||||2017-08-21|2017-09-19|Actual|August 2010||2010-08-31|August 2017|2017-08-31|October 2015|Actual|2015-10-31|October 2012|Actual|2012-10-31||Interventional||All randomized patients are included in this analysis.|Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Randomized Phase II Trial of Docetaxel With or Without PSA-TRICOM Vaccine in Patients With Castrate-Resistant Metastatic Prostate Cancer|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)||2||Poor accrual|f||||t||||||||||2018-05-31 23:40:38.299|2018-05-31 23:40:38.299
NCT01145495|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2014-01-06||2017-11-29|2010-06-15|2010-06-16|Estimate|2014-01-06|2014-02-20|Estimate||||2017-11-29|2017-12-22|Actual|June 15, 2010|Actual|2010-06-15|November 2017|2017-11-30||||December 31, 2012|Actual|2012-12-31||Interventional|||Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma|A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)|Completed||Phase 2|63|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:40:38.77841|2018-05-31 23:40:38.77841
NCT01145482|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2014-04-10||2014-10-30|2010-06-15|2010-06-16|Estimate|2014-10-30|2014-11-03|Estimate||||2014-10-30|2014-11-03|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Mean age 74.09, SD = 6.54 Gender, Female = 5, Male = 6|Mechanisms of Insulin Facilitation of Memory|Mechanisms of Insulin Facilitation of Memory|Completed||N/A|12|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 23:40:39.703145|2018-05-31 23:40:39.703145
NCT01145469|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2017-05-16|2010-06-15|2010-06-16|Estimate|||||||2017-05-16|2017-05-17|Actual|June 1, 2010|Actual|2010-06-01|May 2017|2017-05-31|August 1, 2010|Actual|2010-08-01|August 1, 2010|Actual|2010-08-01||Observational|||Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy|Genome Wide Association Study Evaluating Genetic Factors Related to the Efficacy and Tolerability of Fludarabine Treatment in Patients With CLL|Completed|||225|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:40:39.973219|2018-05-31 23:40:39.973219
NCT01145456|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2014-02-21|2010-06-15|2010-06-16|Estimate|||||||2014-02-21|2014-02-24|Estimate|June 2010||2010-06-30|December 2013|2013-12-31||||November 2013|Actual|2013-11-30||Interventional|||Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors|A Phase I Study of R04929097 in Combination With Gemcitabine in Patients With Advanced Solid Tumors|Completed||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:40:40.120058|2018-05-31 23:40:40.120058
NCT01145443|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-15|2010-06-15|2010-06-16|Estimate|||||||2010-06-15|2010-06-16|Estimate|June 2005||2005-06-30|June 2010|2010-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||Multicenter Intensivist Weekend Scheduling Study|A Multicenter Study of the Effect of Intensive Care Unit Attending Physician Work Schedules on Outcomes Relevant to Society|Completed|||1945|Actual|University of Manitoba|||2||f||||f||||||||||2018-05-31 23:40:40.61217|2018-05-31 23:40:40.61217
NCT01145430|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2017-12-21|2010-06-15|2010-06-16|Estimate|||||||2017-12-21|2017-12-22|Actual|June 1, 2010|Actual|2010-06-01|November 2017|2017-11-30||||May 23, 2017|Actual|2017-05-23||Interventional|||Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer|Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:40:41.051858|2018-05-31 23:40:41.051858
NCT01145417|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2013-05-07||2013-05-07|2010-06-15|2010-06-16|Estimate|2013-05-07|2013-06-27|Estimate||||2013-05-07|2013-06-27|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pregabalin Trial In HIV Neuropathic Pain|An Open-Label, Extension Safety Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081251)|Terminated||Phase 3|217|Actual|Pfizer|The parent double blind trial A0081244 (NCT01049217) was stopped at interim analysis due to lack of efficacy and therefore this open label extension study was also terminated.|1||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:40:41.514006|2018-05-31 23:40:41.514006
NCT01145404|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2014-07-01|2010-06-15|2010-06-16|Estimate|||||||2014-07-01|2014-07-02|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Interventional|GastroLap||Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer|Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial|Terminated||Phase 2|76|Anticipated|National Center for Tumor Diseases, Heidelberg||2||Changes of SoC for third line therapy resulting in poor recruitment|f||||t||||||||||2018-05-31 23:40:43.063501|2018-05-31 23:40:43.063501
NCT01145391|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2011-10-10||2012-10-24|2010-06-15|2010-06-16|Estimate|2012-10-24|2012-10-25|Estimate||||2012-10-24|2012-10-25|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial|Health Promotion Outreach To Overcome Clinical Inertia In The Treatment Of Patients With Poorly-Controlled Hypertension|Completed||N/A|591|Actual|University of Colorado, Denver|Adherence measures were not included. Patients with and without a formal diagnosis of hypertension were enrolled, but might require different intervention strategies.|2|||f||||f||||||||||2018-05-31 23:40:43.548048|2018-05-31 23:40:43.548048
NCT01145378|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-08-06|2010-06-15|2010-06-16|Estimate|||||||2015-08-06|2015-08-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:40:43.833728|2018-05-31 23:40:43.833728
NCT01145365|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2017-04-01|2010-06-15|2010-06-16|Estimate|||||||2017-04-01|2017-04-04|Actual|December 2010||2010-12-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas|A Prospective Multicenter Trial Evaluating the Benefit of INitial Surgically Established Drainage Prior to Medical Therapy for the Treatment for Crohn's Perianal Fistulas|Completed||N/A|21|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 23:40:43.882818|2018-05-31 23:40:43.882818
NCT01145352|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2014-08-20||2014-08-20|2010-06-15|2010-06-16|Estimate|2014-08-20|2014-09-04|Estimate||||2014-08-20|2014-09-04|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|Enbrel-JIA||Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]|Enbrel-JIA Use Results Survey [All-Case Surveillance]|Completed|||113|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:40:43.961916|2018-05-31 23:40:43.961916
NCT01145339|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2012-06-22|2010-06-15|2010-06-16|Estimate|||||||2012-06-22|2012-06-26|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|EF099||A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI)|A Phase III, Non-Inferiority, Randomized, Double-Blind, Parallel-Group, Multicentre, Single-Dose, Comparative Clinical Study of Lactase Eurofarma (Test Drug) and Lactaid® (Comparative Drug), Assessing the Efficacy and Safety in the Treatment of Patients With Lactose Intolerance (Hypolactasia)|Completed||Phase 3|140|Actual|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-05-31 23:40:45.357799|2018-05-31 23:40:45.357799
NCT01145326|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2017-03-14|2010-06-15|2010-06-16|Estimate|||||||2017-03-14|2017-03-16|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FAST||Functional Microarray Augmentation of Skin Treatment With Lidocaine|Functional Microarray Augmentation of Skin Treatment With Lidocaine (FAST Lidocaine)|Withdrawn||Phase 2/Phase 3|0|Actual|University of Oklahoma||2||The device is undergoing further study in China, per FDA requirements.|f||||f||||||||||2018-05-31 23:40:45.449765|2018-05-31 23:40:45.449765
NCT01145313|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2013-11-07|2010-06-15|2010-06-16|Estimate|||||||2013-11-07|2013-11-08|Estimate|October 2007||2007-10-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder|Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder|Completed|||501|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||1||f||||f||||||||||2018-05-31 23:40:45.576045|2018-05-31 23:40:45.576045
NCT01145300|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2012-01-25|2010-06-15|2010-06-16|Estimate|||||||2012-01-25|2012-01-26|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Biomarkers in Chronic Obstructive Pulmonary Disease (COPD)|Relationship Between Exhaled Markers and Airway Pathology in Smokers With and Without Airflow Obstruction|Completed|||32|Actual|Leiden University Medical Center|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 23:40:45.632794|2018-05-31 23:40:45.632794
NCT01145287|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2016-04-19|2010-06-15|2010-06-16|Estimate|||||||2016-04-19|2016-04-21|Estimate|February 2007||2007-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Impact of the Diagnosis of Celiac Disease|Impact of the Diagnosis of Celiac Disease|Completed|||760|Actual|Tampere University Hospital|||||f||||f||||||||||2018-05-31 23:40:45.699084|2018-05-31 23:40:45.699084
NCT01145274|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2011-08-12|2010-06-15|2010-06-16|Estimate|||||||2011-08-12|2011-08-16|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Observational|Allopurinol||A Pilot Study for Pharmacokinetic/Pharmacodynamic (PK/PD) Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient|A Pilot Study for PK/PD Parameter of Allopurinol and Its Metabolite-oxypurinol After Once-daily Allopurinol in Chronic Kidney Disease Patient|Unknown status|Recruiting||80|Anticipated|Seoul National University Hospital|||||f||||||||||||||2018-05-31 23:40:45.762985|2018-05-31 23:40:45.762985
NCT01145261|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2014-11-12|2010-06-15|2010-06-16|Estimate|||||||2014-11-12|2014-11-13|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||The Relationship Between Emotional Regulation Strategies And Cognitive Behavioral Treatment Effectiveness In Childhood Anxiety Disorders: A Longitudinal Prospective Study|The Relationship Between Emotional Regulation Strategies And Cognitive Behavioral Treatment Effectiveness In Childhood Anxiety Disorders: A Longitudinal Prospective Study|Completed|||54|Actual|Rabin Medical Center|||2||f||||||||||||||2018-05-31 23:40:45.96449|2018-05-31 23:40:45.96449
NCT01145248|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-15|2010-06-15|2010-06-16|Estimate|||||||2010-06-15|2010-06-16|Estimate|January 2006||2006-01-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Comparison of Biliary Forceps Biopsy and Brush Cytology|A Combination of Endoscopic Transpapillary Brush Cytology and a Novel Method of Forceps Biopsy to Diagnose Proximal Biliary Malignancies|Completed||N/A|43|Actual|University of Ulm||2|||f||||f||||||||||2018-05-31 23:40:46.039754|2018-05-31 23:40:46.039754
NCT01145235|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2017-05-09|2010-06-15|2010-06-16|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2010|Actual|2010-04-30|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Swedish Macrolane Registry||Active, not recruiting|||2500|Anticipated|Q-Med AB|||1||f||||||||||||||2018-05-31 23:40:46.108996|2018-05-31 23:40:46.108996
NCT01145222|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27||2011-08-04|2018-05-28|2010-06-15|2010-06-16|Estimate||||2011-08-04|2011-08-15|Estimate|2018-05-28|2018-05-30|Actual|May 2010||2010-05-31|May 2018|2018-05-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy|A Phase IIb Study Evaluating the Safety and Efficacy of Multiple Doses of CNS 7056 Compared to Midazolam in Patients Undergoing Colonoscopy|Completed||Phase 2|162|Actual|Paion UK Ltd.||4|||f||||f||||||||||2018-05-31 23:40:46.208474|2018-05-31 23:40:46.208474
NCT01145209|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2018-02-09|2010-06-15|2010-06-16|Estimate|||||||2018-02-09|2018-02-12|Actual|July 1, 2010||2010-07-01|January 11, 2018|2018-01-11|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Active, not recruiting||Phase 2|32|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:40:46.330942|2018-05-31 23:40:46.330942
NCT01145196|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2018-04-24|2010-06-15|2010-06-16|Estimate|||||||2018-04-24|2018-04-25|Actual|June 1, 2010||2010-06-01|April 4, 2018|2018-04-04||||||||Observational|||Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene|Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:40:46.432136|2018-05-31 23:40:46.432136
NCT01145183|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2017-02-04|2010-06-15|2010-06-16|Estimate|||||||2017-02-04|2017-02-07|Estimate|March 2010||2010-03-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacogenetics of Doxazosin for Cocaine Dependence|H-26605: Pharmacogenetics of Doxazosin for Cocaine Dependence|Completed||Phase 2|84|Actual|Baylor College of Medicine||2|||f||||t||||||||No||2018-05-31 23:40:46.532612|2018-05-31 23:40:46.532612
NCT01145170|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-07-24|2010-06-15|2010-06-16|Estimate|||||||2015-07-24|2015-07-27|Estimate|March 2011||2011-03-31|January 2012|2012-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|POLARIS||Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma|Use of Nimotuzumab and Radiotherapy in the Treatment of Pediatric Patients With Diffuse Intrinsic Brainstem Glioma|Completed||Phase 2|40|Actual|Eurofarma Laboratorios S.A.||1|||f||||t||||||||||2018-05-31 23:40:46.669648|2018-05-31 23:40:46.669648
NCT01145157|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2017-08-01|2010-06-15|2010-06-16|Estimate|||||||2017-08-01|2017-08-02|Actual|July 2010||2010-07-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||A Comparison Between Signature Total Knee Arthroplasty (TKA) to Conventional TKA and Computer Assisted TKA|A Comparison Between 'Signature™ Personalised Patient Care' to Conventional Total Knee Arthroplasty and Computer Assisted Navigation and a Cost Benefit Analysis for the Australian Market|Completed||N/A|150|Actual|Zimmer Biomet||3|||f||||f||||||||No|There is no plan to share Individual Patient Data|2018-05-31 23:40:46.757052|2018-05-31 23:40:46.757052
NCT01145118|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2012-01-21|2010-06-15|2010-06-16|Estimate|||||||2012-01-21|2012-01-24|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Reliability of Functional Outcome Measures in Plantar Fascitis Patients|Reliability of Functional Outcome Measures in Plantar Fascitis Patients|Completed|||80|Anticipated|Clalit Health Services|||||f||||f||||||||||2018-05-31 23:40:47.164392|2018-05-31 23:40:47.164392
NCT01145105|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-11-09|2010-06-15|2010-06-16|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Neural Dynamics Technique for the Treatment of Chronic Radicular Low Back Pain|Efficacy of Neural Dynamics Technique in the Treatment of Chronic Low Back Pain With Radiation to the Leg|Completed||N/A|34|Actual|Clalit Health Services|||||f||||f||||||||||2018-05-31 23:40:47.269952|2018-05-31 23:40:47.269952
NCT01145092|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-15|2010-06-15|2010-06-16|Estimate|||||||2010-06-15|2010-06-16|Estimate|February 2006||2006-02-28|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|RECO2||Effects of Six Months of Moderate Resistance- Versus Endurance-Training on Muscle ATP Synthesis in First-Degree Relatives of Patients With Type 2 Diabetes|Effects of Six Months of Moderate Resistance- Versus Endurance-Training on Muscle ATP Synthesis in First-Degree Relatives of Patients With Type 2 Diabetes|Completed||N/A|16|Actual|Landsteiner Institut|||||f||||f||||||||||2018-05-31 23:40:47.37338|2018-05-31 23:40:47.37338
NCT01145079|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2013-03-04|2010-06-15|2010-06-16|Estimate|||||||2013-03-04|2013-03-06|Estimate|May 2009||2009-05-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A New Strategy Regarding Discontinuation of Dual Antiplatelet|A New Strategy Regarding Discontinuation of Dual Antiplatelet; Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET Trial)|Completed||Phase 4|982|Actual|Yonsei University||4|||f||||t||||||||||2018-05-31 23:40:47.466064|2018-05-31 23:40:47.466064
NCT01145066|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2017-11-06|2010-06-15|2010-06-16|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2009||2009-05-31|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects|Modulation of Biomarkers and Gene Expression by Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects.|Completed||N/A|80|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||||2018-05-31 23:40:47.68719|2018-05-31 23:40:47.68719
NCT01145053|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|2012-12-18||2014-02-27|2010-06-15|2010-06-16|Estimate|2012-12-18|2013-01-30|Estimate||||2014-02-27|2014-03-27|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Drug Use Survey of RESPIMAT in Patients With COPD|Long Time Survey of RESPIMAT in Daily Clinical Use|Completed|||361|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:40:47.827674|2018-05-31 23:40:47.827674
NCT01145040|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2018-05-14|2010-06-15|2010-06-16|Estimate|||||||2018-05-14|2018-05-15|Actual|June 2010||2010-06-30|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|NOMOTHETICOS||NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation|NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation. A Correlation Study|Enrolling by invitation|||100|Anticipated|Ruhr University of Bochum|||3||f||||t||||||||Undecided||2018-05-31 23:40:48.200526|2018-05-31 23:40:48.200526
NCT01145027|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-10-20|2010-06-15|2010-06-16|Estimate|||||||2010-10-20|2010-10-21|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Cephalic Phase Insulin Secretion and Capillary Recruitment in Healthy Men|Relations Among Cephalic Phase of Insulin Secretion, Body Composition, Dietary Intake and Microvascular Reactivity in Healthy Young Men|Completed||N/A|39|Actual|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 23:40:48.312126|2018-05-31 23:40:48.312126
NCT01145014|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-10-31|2010-06-15|2010-06-16|Estimate|||||||2013-10-31|2013-11-01|Estimate|May 2010||2010-05-31|October 2013|2013-10-31||||December 2010|Actual|2010-12-31||Interventional|||To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Phase I - Study to a) Assess Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses 2 mg to 600 mg of BI 660848 Administered as Oral Drinking Solution (Powder in Bottle) in Healthy Male Volunteers, b) to Explore the Relative Oral Bioavailability of an Immediate Release Tablet Formulation and c) to Assess the Impact of a High Fat Meal on the Oral Bioavailability of the Oral Drinking Solution (Powder in Bottle).|Terminated||Phase 1|72|Actual|Boehringer Ingelheim||12|||f||||||||||||||2018-05-31 23:40:48.396983|2018-05-31 23:40:48.396983
NCT01145001|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2016-08-24||2016-11-04|2010-06-14|2010-06-16|Estimate|2016-08-24|2016-10-19|Estimate||||2016-11-04|2016-12-29|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||Enhancing a High School Based Smoking Cessation Program|Contingency Management for Smoking Cessation in Adolescent Smokers - Phase IV, Enhancing a High School Based Smoking Cessation Program|Completed||N/A|154|Actual|Yale University||4|||f||||t||||||||||2018-05-31 23:40:48.540401|2018-05-31 23:40:48.540401
NCT01144988|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2011-08-01|2010-06-15|2010-06-16|Estimate|||||||2011-08-01|2011-08-02|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|AVIRMA01-09||Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma|An Academic Prospective Single-arm Phase II Clinical Trial for Evaluation of Advanced Functional Neuroimaging Techniques and Molecular Markers in the Course of Anti-angiogenic Therapies in Malignant Gliomas|Unknown status|Recruiting|Phase 2|35|Anticipated|Medical University Innsbruck|||||f||||t||||||||||2018-05-31 23:40:49.01176|2018-05-31 23:40:49.01176
NCT01144975|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2012-05-15|2010-06-14|2010-06-16|Estimate|||||||2012-05-15|2012-05-16|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus|A Randomized Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy|Completed||Phase 2|76|Actual|XOMA (US) LLC||2|||f||||f||||||||||2018-05-31 23:40:49.127781|2018-05-31 23:40:49.127781
NCT01144962|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2014-12-29|2010-06-15|2010-06-16|Estimate|||||||2014-12-29|2014-12-30|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease|Completed||Phase 1/Phase 2|21|Actual|Leiden University Medical Center||4|||f||||t||||||||||2018-05-31 23:40:49.211207|2018-05-31 23:40:49.211207
NCT01144949|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2014-02-07||2014-07-21|2010-06-14|2010-06-16|Estimate|2014-07-21|2014-08-11|Estimate||||2014-07-21|2014-08-11|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of Silodosin to Facilitate Passage of Urinary Stones|A Double-Blind, Placebo-Controlled Study of Silodosin to Facilitate Urinary Stone Passage|Completed||Phase 2|239|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:40:49.341896|2018-05-31 23:40:49.341896
NCT01144936|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-03-08|2010-06-14|2010-06-16|Estimate|||||||2011-03-08|2011-03-09|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study of VX-985 in Subjects With Chronic Hepatitis C|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of VX-985 in Subjects With Genotype 1 Chronic Hepatitis C|Completed||Phase 1|21|Anticipated|Vertex Pharmaceuticals Incorporated||3|||f||||f||||||||||2018-05-31 23:40:49.766958|2018-05-31 23:40:49.766958
NCT01144923|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2014-04-23|2010-06-15|2010-06-16|Estimate|||||||2014-04-23|2014-04-24|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Conservative Therapy Versus Epidural Steroids for Cervical Radiculopathy|Randomized, Comparative-effectiveness Study Comparing Epidural Steroid Injections to Conservative Management With Medications and Physical Therapy in Patients With Cervical Radiculopathy|Completed||N/A|169|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 23:40:49.871395|2018-05-31 23:40:49.871395
NCT01144910|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-03-02|2010-06-15|2010-06-16|Estimate|||||||2017-03-02|2017-03-03|Actual|May 2011||2011-05-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|BHR||The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children|A Prospective, Open Label, Single-center Study of the Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children.|Withdrawn|||0|Actual|Johann Wolfgang Goethe University Hospital|||2|Due to few capacities 2011 to 2016 the study was withdrawn.|f||||f||||||Samples With DNA|"~     whole blood, serum, sputum~   "|||2018-05-31 23:40:50.03382|2018-05-31 23:40:50.03382
NCT01144897|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2018-05-09|2010-06-15|2010-06-16|Estimate|||||||2018-05-09|2018-05-15|Actual|June 2010||2010-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|November 2011|Actual|2011-11-30||Interventional|||PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy|PET Acetate for Docetaxel Response Assessment in Hormone-Refractory Prostate Cancer|Active, not recruiting||Phase 1|5|Actual|University of Iowa||1|||f||||t||||||||||2018-05-31 23:40:50.160361|2018-05-31 23:40:50.160361
NCT01144884|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2014-05-19|2010-06-15|2010-06-16|Estimate|||||||2014-05-19|2014-05-20|Estimate|August 2009||2009-08-31|May 2014|2014-05-31||||December 2012|Actual|2012-12-31||Interventional|||Identify Patients With Neck Pain Likely to Benefit From Education and Exercise|Development of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Education and Exercise|Completed||N/A|91|Actual|University of Central Florida||1|||f||||f||||||||||2018-05-31 23:40:50.295106|2018-05-31 23:40:50.295106
NCT01144871|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2014-10-25|2010-06-15|2010-06-16|Estimate|||||||2014-10-25|2014-10-28|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Parental Knowledge and Attitudes of Confidential Sexually Transmitted Infections (STI) Services for Teens|Parental Knowledge and Attitudes of Confidential STI Services for Teens|Completed|||1216|Actual|University of California, San Francisco|||2||f||||t||||||||||2018-05-31 23:40:51.539176|2018-05-31 23:40:51.539176
NCT01144858|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2010-06-15|2010-06-15|2010-06-16|Estimate|||||||2010-06-15|2010-06-16|Estimate|January 2009||2009-01-31|October 2008|2008-10-31|December 2009|Actual|2009-12-31|||||Observational|CLAAAF||Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation|Clinical Value of Left Atrial Appendage Flow for Prediction of Successful Catheter Ablation for Persistent Atrial Fibrillation|Terminated|||40|Actual|Clinique Pasteur|||1|40 patients|f||||f||||||||||2018-05-31 23:40:51.627024|2018-05-31 23:40:51.627024
NCT01144845|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-08-27|2010-06-14|2010-06-16|Estimate|||||||2011-08-27|2011-08-30|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Observational|PTPS-18||Chronic Pain Following Thoracic Surgery|Study of Persistent Postsurgical Pain Following Thoracic Surgery in Patients With Pulmonary Malignancies|Completed|||702|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 23:40:51.736402|2018-05-31 23:40:51.736402
NCT01144832|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2016-01-27|2010-06-15|2010-06-16|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists|IBS Treatment With H1-receptor Antagonists|Completed||Phase 4|55|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 23:40:51.830739|2018-05-31 23:40:51.830739
NCT01144819|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2013-09-06|2010-06-15|2010-06-16|Estimate|||||||2013-09-06|2013-09-09|Estimate|October 2009||2009-10-31|September 2013|2013-09-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Platelet Inhibition in the Acute Phase of STEMI|Platelet Inhibition in the Acute Phase of ST-segment Elevation Myocardial Infarction|Completed|||46|Actual|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood sample 1:~        -  Whole blood (Platelet aggregation tests and flowcytometry)~        -  Serum~        -  S-Thromboxane B2~        -  S-Trombopoeitin~        -  S-P-selectin~        -  Plasma~        -  DNA~        -  RNA~      Blood sample 2:~        -  Whole blood~        -  Plasma~      Blood sample 3:~        -  Whole blood~        -  Plasma~      Blood sample 4:~        -  Whole blood (Platelet aggregation tests and flowcytometry)~        -  Serum~        -  S-Thromboxane B2~        -  S-Trombopoeitin~        -  S-P-selectin~        -  Plasma~        -  DNA~        -  RNA~   "|||2018-05-31 23:40:51.927304|2018-05-31 23:40:51.927304
NCT01144806|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-15|||2012-02-23|2010-06-15|2010-06-16|Estimate|||||||2012-02-23|2012-02-27|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of Energy Expenditure, Body Composition and Recovery Rates in Children With Severe Acute Malnutrition|Evaluation of Energy Expenditure, Body Composition and Recovery Rates in Children With Severe Acute Malnutrition (SAM) Receiving Community-based Nutritional Rehabilitation Therapy|Completed||N/A|60|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 23:40:52.040687|2018-05-31 23:40:52.040687
NCT01144793|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2016-12-23|2010-06-15|2010-06-16|Estimate|||||||2016-12-23|2016-12-28|Estimate|April 2008||2008-04-30|December 2016|2016-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias|A Pilot/Observational Study Using a Biomarker Monitoring System to Evaluate Protein Profiles of Neutropenic Fever/Infection in Patients With Acute or Chronic Leukemias Undergoing Chemotherapy or Other Biologic Treatment|Completed|||17|Actual|Stanford University|||||f||||f||||||Samples Without DNA|"~     blood~   "|No||2018-05-31 23:40:52.133754|2018-05-31 23:40:52.133754
NCT01144780|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2016-06-29|2010-06-15|2010-06-16|Estimate|||||||2016-06-29|2016-07-01|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry|Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry|Terminated|||10|Actual|Stanford University|||||f||||||||||Samples Without DNA|"~     blood and bone marrow~   "|||2018-05-31 23:40:52.205676|2018-05-31 23:40:52.205676
NCT01144767|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-12-08|2010-06-15|2010-06-16|Estimate|||||||2015-12-08|2015-12-09|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Computer-Based Physical Activity Advice for Ethnic Minority Aging Adults|Computer-Based Physical Activity Advice for Ethnic Minority Aging Adults|Completed||N/A|40|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 23:40:52.271652|2018-05-31 23:40:52.271652
NCT01144754|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2016-06-29|2010-06-15|2010-06-16|Estimate|||||||2016-06-29|2016-07-01|Estimate|February 2009||2009-02-28|June 2016|2016-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT|A Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP With or Without Radiotherapy|Terminated|||1|Actual|Stanford University||||Low Accrual|f||||t||||||||||2018-05-31 23:40:52.357466|2018-05-31 23:40:52.357466
NCT01144741|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2018-03-30|2010-06-15|2010-06-16|Estimate|||||||2018-03-30|2018-04-02|Actual|February 2010|Actual|2010-02-28|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|STOP-FSS||Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome|Recruiting|||20|Anticipated|Freeman-Sheldon Research Group, Inc.|||6||f||||f|f|f||||Samples With DNA|"~     Any specimens received as part of records review, such as pathology microscope slides or~     frozen sections, will be retained as per institutional policy.~   "|No|Individual patient data will not be shared, due to concerns involved in masking identities of individuals with such a rare condition.|2018-05-31 23:40:52.417974|2018-05-31 23:40:52.417974
NCT01144728|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-01-28|2010-06-14|2010-06-16|Estimate|||||||2011-01-28|2011-01-31|Estimate|May 2010||2010-05-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|AMIT KZ||Initiation and Titration of Amaryl|AMIT Study - Amaryl M Initiation and Titration Study|Completed||Phase 4|172|Actual|Sanofi||1|||f||||||||||||||2018-05-31 23:40:52.588998|2018-05-31 23:40:52.588998
NCT01144715|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2014-10-21||2014-11-24|2010-06-14|2010-06-16|Estimate|2014-11-24|2014-11-27|Estimate||||2014-11-24|2014-11-27|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|HAAPI|Power analysis to achieve .80 power, alpha=0.05, two-tailed, in differential change across groups in Fugl-Meyer during the trial.|Rehabilitation of the Stroke Hand at Home|An Innovative Home Stroke Rehabilitation and Monitoring System|Completed||Phase 4|99|Actual|Kinetic Muscles||2|||f||||f||||||||||2018-05-31 23:40:52.674544|2018-05-31 23:40:52.674544
NCT01144702|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-05-15|2010-06-14|2010-06-15|Estimate|||||||2015-05-15|2015-05-19|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|July 2014|Actual|2014-07-31|April 2013|Actual|2013-04-30||Interventional|||Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum|Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Uncomplicated Malaria by Plasmodium Falciparum, Juruá Valley, State of Acre, Brazil, 2009.|Completed||Phase 2/Phase 3|163|Actual|Oswaldo Cruz Foundation||1|||f||||f||||||||||2018-05-31 23:40:53.092451|2018-05-31 23:40:53.092451
NCT01144689|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2016-07-05|2010-06-14|2010-06-15|Estimate|||||||2016-07-05|2016-07-07|Estimate|February 2009||2009-02-28|July 2016|2016-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Mindfulness Training for Smoking Cessation|Assessing Mindfulness Training as a Mechanistic Probe for Stress-Induced Brain Activation and Relapse Prevention for Tobacco Addiction|Completed||N/A|42|Actual|Yale University||2|||f||||t||||||||||2018-05-31 23:40:53.174689|2018-05-31 23:40:53.174689
NCT01144676|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-10-05|2010-06-14|2010-06-15|Estimate|||||||2010-10-05|2010-10-06|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring|A Double-Blind, Randomised, Placebo-Controlled Pharmacokinetic and Safety Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring and to Evaluate the Safety of a Matrix Vaginal Ring Containing 25 MG of Dapivirine|Completed||Phase 1|45|Actual|International Partnership for Microbicides, Inc.||4|||f||||t||||||||||2018-05-31 23:40:53.250269|2018-05-31 23:40:53.250269
NCT01144663|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03||2013-04-11|2014-05-01|2010-06-14|2010-06-15|Estimate||||2013-04-11|2013-04-18|Estimate|2014-05-01|2014-05-19|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|June 2012|Actual|2012-06-30||Interventional|||Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines|Immunogenicity and Safety of GSK Biologicals' Meningococcal Vaccine (GSK 134612) When Co-administered With a Pneumococcal Conjugate Vaccine and in Infanrix Hexa™ in Healthy Infants|Completed||Phase 3|2095|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 23:40:53.318952|2018-05-31 23:40:53.318952
NCT01144650|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-14|2010-06-14|2010-06-15|Estimate|||||||2010-06-14|2010-06-15|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|November 2010|Anticipated|2010-11-30|August 2010|Anticipated|2010-08-31||Interventional|DAISY||Dapsone for Acute Ischemia Stroke Study|Clinical Trial Randomized, Placebo-controlled, Using Dapsone as a Neuroprotector During Acute Ischemia Stroke|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Cidat, S.A. de C.V.||2|||f||||t||||||||||2018-05-31 23:40:53.600691|2018-05-31 23:40:53.600691
NCT01144637|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2015-11-30|2010-06-14|2010-06-15|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|||A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects|A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects|Completed||Phase 3|4005|Actual|Bavarian Nordic||4|||f||||t||||||||||2018-05-31 23:40:53.759036|2018-05-31 23:40:53.759036
NCT01144624|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2012-12-11||2014-09-26|2010-06-14|2010-06-15|Estimate|2013-07-19|2013-08-22|Estimate||||2014-09-26|2014-10-06|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock|A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous Infusions of AZD9773 (CytoFab™) in Japanese Patients With Severe Sepsis and/or Septic Shock|Completed||Phase 2|20|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 23:40:53.972923|2018-05-31 23:40:53.972923
NCT01144611|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2016-09-19|2010-06-14|2010-06-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|APPIRED-II||Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery|A Randomized, Double-blind, Placebo-controlled Phase IIIa Study on bIAP, an Anti-inflammatory Moiety, in Patients Undergoing Combined Aortic Valve Replacement and Coronary Artery Bypass Grafting|Completed||Phase 3|53|Actual|Alloksys Life Sciences B.V.||2|||f||||f||||||||||2018-05-31 23:40:54.917157|2018-05-31 23:40:54.917157
NCT01144598|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2012-08-17||2012-09-21|2010-06-14|2010-06-15|Estimate|2012-08-17|2012-09-19|Estimate||||2012-09-21|2012-10-02|Estimate|February 2010||2010-02-28|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Time to DMARD (Disease-Modifying Anti-Rheumatic Drug) Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey|Time to DMARD Treatment and Actual Work Limitation of Patients With Rheumatoid Arthritis in Turkey|Completed|||356|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:40:55.027814|2018-05-31 23:40:55.027814
NCT01144585|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2014-06-03|2010-06-14|2010-06-15|Estimate|||||||2014-06-03|2014-06-04|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effects of Remote Ischemic Preconditioning and Postconditioning on Lung Injury During Cardiopulmonary Bypass|Effects of Remote Ischemic Preconditioning and Postconditioning on Lung Ischemic-reperfusion Injury During Cardiopulmonary Bypass - Substudy of NCT00997217|Completed||N/A|76|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:40:55.418768|2018-05-31 23:40:55.418768
NCT01144572|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2014-02-13|2010-06-14|2010-06-15|Estimate|||||||2014-02-13|2014-02-14|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|BC Qol NIS||Quality of Life in Chinese Postmenopausal HR(+) Early Breast Cancer (EBC) Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment|A Prospective, Multicenter, Non-interventional Study to Evaluate Quality of Life in Chinese Postmenopausal HR(+) EBC Patients During Adjuvant Aromatase Inhibitors(AIs) Treatment|Completed|||494|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:40:55.512748|2018-05-31 23:40:55.512748
NCT01144559|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-10-29|2010-06-14|2010-06-15|Estimate|||||||2010-10-29|2010-11-01|Estimate|June 2010||2010-06-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Continuous Femoral Nerve Blocks: Relative Effects of Basal Infusion and Bolus Doses on Sensory and Motor Function|Continuous Femoral Nerve Blocks: Relative Effects of Basal Infusion and Bolus Doses on Sensory and Motor Function|Completed||Phase 4|15|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 23:40:55.603104|2018-05-31 23:40:55.603104
NCT01144546|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-14|2010-06-14|2010-06-15|Estimate|||||||2010-06-14|2010-06-15|Estimate|August 2009||2009-08-31|June 2010|2010-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Passive Leg Raising Test to Predict Hypotension During Induction of Anesthesia in Patients Undergoing Cardiac Surgery|Passive Leg Raising Test to Predict Hypotension During Induction of Anesthesia in Patients Undergoing Cardiac Surgery|Completed||Phase 2|42|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 23:40:55.67641|2018-05-31 23:40:55.67641
NCT01144533|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2013-12-17|2010-06-14|2010-06-15|Estimate|||||||2013-12-17|2013-12-19|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||Comparative Analysis of Intra-articular Injection of Steroid and/or Sodium Hyaluronate in Adhesive Capsulitis|Comparative Analysis of Intra-articular Injection of Steroid and/or Sodium Hyaluronate in Adhesive Capsulitis: A Randomized, Double-blind, Placebo-controlled Trial|Completed||N/A|60|Actual|Seoul National University Hospital||4|||f||||f||||||||||2018-05-31 23:40:55.740802|2018-05-31 23:40:55.740802
NCT01144520|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2018-03-16|2010-06-14|2010-06-15|Estimate|||||||2018-03-16|2018-03-20|Actual|March 2010||2010-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Leukocyte Dysfunction in Diabetic Patients.|Leukocyte Dysfunction in Diabetic Patients.|Active, not recruiting|||200|Anticipated|Ohio State University|||4||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 23:40:55.801972|2018-05-31 23:40:55.801972
NCT01144507|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2018-03-28|2010-06-14|2010-06-15|Estimate|||||||2018-03-28|2018-03-30|Actual|January 2009||2009-01-31|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|PUSH||Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis|Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH)|Active, not recruiting|||800|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||4||f||||t||||||Samples With DNA|"~     During this study, blood and urine specimens will be obtained, de-identified and shipped to~     and stored at the NIDDK repositories for use in future CFLD ancillary studies. This~     biobanking is a critical aspect of this longitudinal study to facilitate the creation of a~     resource of DNA and other specimens from a meaningful number of patients with CFLD. In~     addition, obtaining and storing DNA or EBV-transformed leukocytes (from which DNA can be~     extracted) will allow future studies to investigate genetic causes and influences (modifier~     genes) in CFLD.~   "|||2018-05-31 23:40:55.864969|2018-05-31 23:40:55.864969
NCT01144494|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-03-07|2010-06-14|2010-06-15|Estimate|||||||2018-03-07|2018-03-09|Actual|June 2010|Actual|2010-06-30|March 2018|2018-03-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|Brimonidine||Aqueous Humor Dynamics and Brimonidine|Circadian Rhythms of Aqueous Humor Dynamics in Subjects With Ocular Hypertension Using Brimonidine|Completed||N/A|35|Actual|University of Nebraska||2|||f||||f||||||||||2018-05-31 23:40:55.967401|2018-05-31 23:40:55.967401
NCT01144481|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2015-01-06|2010-06-14|2010-06-15|Estimate|||||||2015-01-06|2015-01-07|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|PROVISTII||Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases|Prospective Identification of Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases|Completed|||60|Actual|University Health Network, Toronto|||1||f||||f||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 23:40:56.160932|2018-05-31 23:40:56.160932
NCT01144468|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2016-05-12|2010-06-14|2010-06-15|Estimate|||||||2016-05-12|2016-05-16|Estimate|April 2007||2007-04-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|May 2017|Anticipated|2017-05-31||Observational|MAP3BSS||Effects of Exemestane on Bone Strength|Effects of Exemestane on Bone Strength in Postmenopausal Women at Increased Risk of Developing Breast Cancer|Active, not recruiting|||354|Actual|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 23:40:56.2388|2018-05-31 23:40:56.2388
NCT01144325|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2011-03-07|2010-06-14|2010-06-15|Estimate|||||||2011-03-07|2011-03-08|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|December 2016|Anticipated|2016-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Minimally Invasive Esophagectomy (MIE) in Prone Versus Left Decubitus Position|Minimally Invasive Esophagectomy in Prone or Left Decubitus Position: A Prospective Randomized Clinical Trial From A Single Institution|Unknown status|Recruiting|Phase 2|2|Anticipated|Fudan University|||||f||||t||||||||||2018-05-31 23:41:05.44022|2018-05-31 23:41:05.44022
NCT01144455|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2017-07-17||2017-11-20|2010-06-14|2010-06-15|Estimate|2017-09-25|2017-10-25|Actual||||2017-11-20|2017-12-19|Actual|June 2010||2010-06-30|November 2017|2017-11-30|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Interventional|||Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma|A Randomized Cross-over Phase 2 Study of the Safety and Efficacy of Two Dose Levels of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|214|Actual|Threshold Pharmaceuticals||3|||f||||t||||||||||2018-05-31 23:40:56.35896|2018-05-31 23:40:56.35896
NCT01144442|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2013-06-25||2016-02-23|2010-06-14|2010-06-15|Estimate|2013-06-25|2013-09-05|Estimate||||2016-02-23|2016-03-25|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer|WCC# 59: Pilot Study of Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence|Completed||N/A|10|Actual|Masonic Cancer Center, University of Minnesota|The primary weakness of this study is the small sample size.|1|||f||||t||||||||||2018-05-31 23:40:57.724843|2018-05-31 23:40:57.724843
NCT01144429|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2011-06-07|2010-06-14|2010-06-15|Estimate|||||||2011-06-07|2011-06-08|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma|Randomized, DB, Parallel Group, MC Study to Evaluate the Efficacy and Safety of Four Doses of Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depigoid Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma|Completed||Phase 2|344|Actual|Leti Pharma GmbH||4|||f||||t||||||||||2018-05-31 23:40:58.045834|2018-05-31 23:40:58.045834
NCT01144416|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2012-11-27|2012-07-13|2015-06-03|2010-06-14|2010-06-15|Estimate|2012-11-27|2012-12-27|Estimate|2012-07-13|2012-07-23|Estimate|2015-06-03|2015-06-30|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|April 2012|Actual|2012-04-30|July 2011|Actual|2011-07-31||Interventional|PURSUE||Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)|A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)|Completed||Phase 3|1424|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 23:40:58.216449|2018-05-31 23:40:58.216449
NCT01144403|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|2016-06-20||2016-08-31|2010-06-14|2010-06-15|Estimate|2016-07-18|2016-08-29|Estimate||||2016-08-31|2016-10-18|Estimate|June 2010||2010-06-30|July 2016|2016-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.|A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma|Terminated||Phase 2|8|Actual|Hoffmann-La Roche|The study was prematurely terminated with 8 participants enrolled, all of them are included into the statistical analyses.|1|||f||||||||||||||2018-05-31 23:40:59.715198|2018-05-31 23:40:59.715198
NCT01144390|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2011-03-10|2010-06-14|2010-06-15|Estimate|||||||2011-03-10|2011-03-11|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Effect Study of Optimized Intervention to Heroin Addicts|Barriers and Effect of Optimizing Intervention Protocols for Heroin Dependence in Community-based Methadone Maintenance Treatment (MMT): a Cohort Study|Unknown status|Active, not recruiting|N/A|240|Anticipated|Shanghai Mental Health Center||2|||f||||f||||||||||2018-05-31 23:41:00.220388|2018-05-31 23:41:00.220388
NCT01144377|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2017-09-27|2012-09-18|2017-10-28|2010-06-11|2010-06-15|Estimate|2017-10-28|2017-12-04|Actual|2012-09-18|2012-09-25|Estimate|2017-10-28|2017-12-04|Actual|August 2010||2010-08-31|October 2017|2017-10-31|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional||Participants who received at least one dose of study drug.|A Study of LY2541546 in Women With Low Bone Mineral Density|A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women With Low Bone Mineral Density: An Evaluation of the Dose Response Relationship Using Bone Mineral Density|Completed||Phase 2|154|Actual|Eli Lilly and Company||5|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:41:00.371943|2018-05-31 23:41:00.371943
NCT01144364|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2014-09-12||2017-07-06|2010-06-14|2010-06-15|Estimate|2014-12-03|2014-12-04|Estimate||||2017-07-06|2017-08-15|Actual|January 19, 2004|Actual|2004-01-19|June 2017|2017-06-30|July 21, 2011|Actual|2011-07-21|July 21, 2011|Actual|2011-07-21||Interventional||Intention-to-Treat (ITT) population: all participants who were randomized to the maintenance or observation arm. IP population: all enrolled participants who started the induction phase (Months 1-8 of the study)|A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)|A Randomized, Open-label Study of MabThera Maintenance Therapy Compared With no Further Therapy After a Brief Induction With Chemotherapy Plus MabThera on Failure-free Survival in Treatment-naïve Elderly Patients With Advanced Follicular Lymphoma|Completed||Phase 3|234|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:41:02.01799|2018-05-31 23:41:02.01799
NCT01144351|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2015-12-10|2010-06-11|2010-06-15|Estimate|||||||2015-12-10|2015-12-14|Estimate|March 2010||2010-03-31|December 2015|2015-12-31||||December 2012|Actual|2012-12-31||Interventional|||A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis|A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis|Terminated||Phase 1|32|Actual|Elan Pharmaceuticals||2|||f||||||||||||||2018-05-31 23:41:03.82759|2018-05-31 23:41:03.82759
NCT01144338|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2017-08-31|2010-06-14|2010-06-15|Estimate|||||||2017-08-31|2017-09-01|Actual|June 18, 2010|Actual|2010-06-18|August 2017|2017-08-31|April 24, 2017|Actual|2017-04-24|April 21, 2017|Actual|2017-04-21||Interventional|||Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus|Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.|Completed||Phase 3|14752|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 23:41:04.091348|2018-05-31 23:41:04.091348
NCT01144312|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-06-21|2010-06-14|2010-06-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Population Pharmacokinetics of Fentanyl in Patients Undergoing Living Donor Liver Transplantation|Population Pharmacokinetics of Fentanyl in Patients Undergoing Living Donor Liver Transplantation|Completed||N/A|20|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 23:41:05.567547|2018-05-31 23:41:05.567547
NCT01144299|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2010-10-01||2016-09-26|2010-06-14|2010-06-15|Estimate|2010-10-01|2010-10-27|Estimate||||2016-09-26|2016-10-27|Estimate|June 2010||2010-06-30|September 2016|2016-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™/Influsplit SSW® 2010/2011 in People Aged 18 Years or Above|Completed||Phase 3|114|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:41:06.784577|2018-05-31 23:41:06.784577
NCT01144286|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2013-05-08||2013-08-28|2010-06-14|2010-06-15|Estimate|2013-08-28|2013-10-09|Estimate||||2013-08-28|2013-10-09|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment|Multi-center, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study to Compare the Therapeutic Efficacy, Safety, and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate Pessaries in the Treatment of VVC|Completed||Phase 2|229|Actual|Ferrer Internacional S.A.||4|||f||||f||||||||||2018-05-31 23:41:07.257233|2018-05-31 23:41:07.257233
NCT01144273|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-29|2010-06-14|2010-06-15|Estimate|||||||2010-06-29|2010-06-30|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Transversus Abdominis Plane Block From Abdominal Approach|Transversus Abdominis Plane Block From Intraabdominal Approach in Patients Undergoing Total Abdominal Hysterectomy: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|United Christian Hospital||2|||f||||t||||||||||2018-05-31 23:41:07.850756|2018-05-31 23:41:07.850756
NCT01144260|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-05-14|2010-06-14|2010-06-15|Estimate|||||||2013-05-14|2013-05-15|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|December 2011|Actual|2011-12-31||Interventional|||Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|A Pilot Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Completed||Phase 2|20|Actual|CytRx||1|||f||||f||||||||||2018-05-31 23:41:08.045976|2018-05-31 23:41:08.045976
NCT01144247|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2016-05-26|2010-06-14|2010-06-15|Estimate|||||||2016-05-26|2016-05-27|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|alloCTL||Cellular Immunotherapy Study for Brain Cancer|A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas|Completed||Phase 1|10|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:41:08.1394|2018-05-31 23:41:08.1394
NCT01144234|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2013-01-12|2010-06-14|2010-06-15|Estimate|||||||2013-01-12|2013-01-15|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|InvolvMaleUg||Male Involvement in Antenatal Care and the Prevention Programme of Mother-to-child Transmission of HIV in Uganda|Facility-based Intervention to Increase Male Involvement in Antenatal Care and the Prevention Programme of Mother-to-child Transmission of HIV in Eastern Uganda|Completed||N/A|1060|Actual|Centre For International Health||2|||f||||f||||||||||2018-05-31 23:41:08.273256|2018-05-31 23:41:08.273256
NCT01144221|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2018-04-06|2010-06-14|2010-06-15|Estimate|||||||2018-04-06|2018-04-09|Actual|May 2010|Actual|2010-05-31|August 2012|2012-08-31|February 2015|Actual|2015-02-28|May 2013|Actual|2013-05-31||Interventional|Alster-Star||Bone Marrow Derived Mononuclear Cells for Ischemic Cardiomyopathy|Protocol on an Evaluative Study on Bone Marrow Derived Mononuclear Cells for Optimization of Biventricular Pacing in Patients With Chronic Ischemic Left Ventricular Dysfunction|Terminated||N/A|6|Actual|Asklepios proresearch||1||funding issues|f||||f||||||||||2018-05-31 23:41:08.374447|2018-05-31 23:41:08.374447
NCT01144208|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-15|2010-06-14|2010-06-15|Estimate|||||||2010-06-15|2010-06-16|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||The Influence of Local Bone Status on Complications After Surgical Treatment of Distal Radius Fractures|The Influence of Local Bone Status on Complications After Surgical Treatment of Distal Radius Fractures|Completed|||244|Actual|AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-05-31 23:41:08.509697|2018-05-31 23:41:08.509697
NCT01144195|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-11-09|2010-06-14|2010-06-15|Estimate|||||||2010-11-09|2010-11-10|Estimate|September 2009||2009-09-30|November 2010|2010-11-30||||December 2011|Anticipated|2011-12-31||Interventional|ACTIVE||A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy|An Open-label, Phase II Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials|||||f||||f||||||||||2018-05-31 23:41:08.665109|2018-05-31 23:41:08.665109
NCT01144182|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2015-02-09||2015-10-15|2010-06-10|2010-06-15|Estimate|2015-10-15|2015-10-16|Estimate||||2015-10-15|2015-10-16|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|VALOR in HF||Veterans Affairs Lowering Readmission in Heart Failure|VALOR (Veterans Affairs Lowering Readmissions) in Heart Failure Study|Completed||N/A|136|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:41:08.805238|2018-05-31 23:41:08.805238
NCT01144169|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2016-10-24|2010-06-14|2010-06-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma|A Phase IB Study of Hydroxychloroquine Prior to Nephrectomy in Patients With Primary Renal Cell Carcinoma|Terminated||Phase 1|7|Actual|University of Pittsburgh||1||barriers to accrual: delay until surgery and additional pre-operative visits|f||||t||||||||||2018-05-31 23:41:09.544794|2018-05-31 23:41:09.544794
NCT01144156|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-13|||2010-06-14|2010-06-14|2010-06-15|Estimate|||||||2010-06-14|2010-06-15|Estimate||||May 2010|2010-05-31||||||||Interventional|||Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy|Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy|Unknown status|Not yet recruiting|N/A|30|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-05-31 23:41:09.68678|2018-05-31 23:41:09.68678
NCT01144143|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2017-04-21||2018-01-12|2010-06-14|2010-06-15|Estimate|2018-01-12|2018-02-08|Actual||||2018-01-12|2018-02-08|Actual|July 2007||2007-07-31|January 2018|2018-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab|Single Center, Randomized, Double-Blind, Placebo-Controlled Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab|Completed||Phase 4|16|Actual|University of Kansas Medical Center||3|||f||||t||||||||||2018-05-31 23:41:09.876171|2018-05-31 23:41:09.876171
NCT01144130|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2011-09-19|2010-06-14|2010-06-15|Estimate|||||||2011-09-19|2011-09-20|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|||Postoperative Sleep Disturbances After Fast Track Hip and Knee Replacement|Postoperative Sleep Disturbances After Fast Track Hip and Knee Replacement|Completed|||10|Actual|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 23:41:10.436333|2018-05-31 23:41:10.436333
NCT01144117|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-08-04|2010-06-14|2010-06-15|Estimate|||||||2011-08-04|2011-08-08|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|EPO-ProgMS||The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis|Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis|Unknown status|Recruiting|Phase 2|56|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 23:41:10.520357|2018-05-31 23:41:10.520357
NCT01144104|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2017-05-25|2010-06-10|2010-06-15|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2010||2010-06-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|November 2011|Actual|2011-11-30||Interventional|AMEP2||Activating Messages for Enhancing Primary Care Practice (AMEP2): Effectiveness Study|Targeted and Tailored Messages to Enhance Depression Care|Completed||N/A|925|Actual|University of California, Davis||3|||f||||t||||||||||2018-05-31 23:41:10.616609|2018-05-31 23:41:10.616609
NCT01144091|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2015-04-07|2010-06-14|2010-06-15|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2012||2012-12-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|April 2013|Anticipated|2013-04-30||Interventional|||Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography|Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography|Withdrawn||N/A|0|Actual|Meir Medical Center||4|||f||||t||||||||||2018-05-31 23:41:10.69488|2018-05-31 23:41:10.69488
NCT01144078|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-01-02|2010-06-10|2010-06-15|Estimate|||||||2012-01-02|2012-01-05|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Exercise Intensity, Glycemic Control and Abdominal Fat in People With Type 2 Diabetes: A Pilot Study||Completed||N/A|15|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 23:41:10.772427|2018-05-31 23:41:10.772427
NCT01144065|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-05-15|2010-06-14|2010-06-15|Estimate|||||||2012-05-15|2012-05-16|Estimate|August 2010||2010-08-31|May 2012|2012-05-31||||||||Observational|||Hair Cortisol and Testosterone Levels in Patients With and Without Acute Myocardial Infarction(MI)|A Comparison of Hair Cortisol and Testosterone Levels in Patients With Acute MI and Controls With and Without Chronic Cardiovascular Disease or Diabetes|Completed|||180|Actual|Meir Medical Center|||3||f||||f||||||Samples Without DNA|"~     Heir samples for the measurement of cortisol and testosterone~   "|||2018-05-31 23:41:10.871089|2018-05-31 23:41:10.871089
NCT01144052|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2013-10-31||2014-03-13|2010-06-14|2010-06-15|Estimate|2014-03-13|2014-04-17|Estimate||||2014-03-13|2014-04-17|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Natalizumab De-escalation With Interferon Beta-1b|De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 4|19|Actual|Ospedale Civico, Lugano||2|||f||||t||||||||||2018-05-31 23:41:10.981868|2018-05-31 23:41:10.981868
NCT01144039|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-15|2010-06-14|2010-06-15|Estimate|||||||2010-06-15|2010-06-16|Estimate|February 2006||2006-02-28|September 2008|2008-09-30|September 2008|Actual|2008-09-30|November 2007|Actual|2007-11-30||Interventional|||Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair|Glutamate Infusion in Hypertrophied Ventricle After Aortic Valve Replacement - a Randomized Trial|Completed||Phase 4|27|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 23:41:11.394615|2018-05-31 23:41:11.394615
NCT01144026|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-12|2012-12-07||2013-01-14|2010-06-14|2010-06-15|Estimate|2012-12-07|2013-01-15|Estimate||||2013-01-14|2013-01-18|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|THYMON-10001||Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects|Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects|Completed||Phase 1/Phase 2|15|Actual|Thymon, LLC||2|||f||||f||||||||||2018-05-31 23:41:11.493505|2018-05-31 23:41:11.493505
NCT01144000|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2012-06-24|2010-06-14|2010-06-15|Estimate|||||||2012-06-24|2012-06-26|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|Dapto-Studie||Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection|Efficacy and Safety of Daptomycin (With or Without Rifampin) in the Treatment of Staphylococcal Hip, Knee and Shoulder Prosthetic Joint Infection|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||t||||||||||2018-05-31 23:41:11.98564|2018-05-31 23:41:11.98564
NCT01143987|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2013-11-11|2010-06-14|2010-06-15|Estimate|||||||2013-11-11|2013-11-13|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism|Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism|Completed||Phase 4|44|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 23:41:12.380836|2018-05-31 23:41:12.380836
NCT01143974|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2013-03-13|2010-06-14|2010-06-15|Estimate|||||||2013-03-13|2013-03-14|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer|Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer|Completed||Phase 4|28|Actual|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 23:41:12.499232|2018-05-31 23:41:12.499232
NCT01143961|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-14|2010-06-14|2010-06-15|Estimate|||||||2010-06-14|2010-06-15|Estimate|June 2010||2010-06-30|February 2010|2010-02-28|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Bedside Measurement of Ventilation With or Without a One-way Valve During Lung Lavage|Measurement of Changes in Ventilation and Catheter Placement During Non-directed Bronchoalveolar Lavage Using Electrical Impedance Tomography With and Without a One-way Valve|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Cardiff and Vale University Health Board||2|||f||||f||||||||||2018-05-31 23:41:12.606929|2018-05-31 23:41:12.606929
NCT01143948|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-14|2010-06-14|2010-06-15|Estimate|||||||2010-06-14|2010-06-15|Estimate|January 2011||2011-01-31|February 2010|2010-02-28|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|VIRDICT||Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial|Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes|Unknown status|Not yet recruiting|Phase 4|45|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 23:41:12.722227|2018-05-31 23:41:12.722227
NCT01143935|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-14|2010-06-14|2010-06-15|Estimate|||||||2010-06-14|2010-06-15|Estimate|January 2009||2009-01-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|||||Observational|||Estimation of Standard Liver Volume in the Indian Population|Estimation of Standard Liver Volume in the Indian Population|Unknown status|Recruiting||100|Anticipated|All India Institute of Medical Sciences, New Delhi|||2||f||||t||||||||||2018-05-31 23:41:12.84653|2018-05-31 23:41:12.84653
NCT01143922|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2010-06-14|2010-06-14|2010-06-15|Estimate|||||||2010-06-14|2010-06-15|Estimate|August 2009||2009-08-31|January 2010|2010-01-31||||||||Observational|||Role of Intraoperative Ultrasound in Gastrointestinal (GI) Malignancies||Unknown status|Recruiting||100|Anticipated|All India Institute of Medical Sciences, New Delhi|||1||f||||||||||||||2018-05-31 23:41:12.917899|2018-05-31 23:41:12.917899
NCT01143909|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-14|||2013-06-14|2010-06-14|2010-06-15|Estimate|||||||2013-06-14|2013-06-17|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TOPIC||Transfusion of Fresh Frozen Plasma in Non-bleeding Intensive Care Unit (ICU) Patients|Transfusion of Fresh Frozen Plasma in Non-bleeding ICU Patients|Completed||N/A|81|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 23:41:12.981988|2018-05-31 23:41:12.981988
NCT01143896|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2016-01-04||2016-04-12|2010-06-11|2010-06-14|Estimate|2016-03-11|2016-04-11|Estimate||||2016-04-12|2016-05-16|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|November 2015|Actual|2015-11-30|September 2014|Actual|2014-09-30||Interventional|HEPTIDES|A total of 292 participants completed baseline interviews.|Hepatitis C Translating Initiatives for Depression Into Effective Solutions|Hepatitis C Translating Initiatives for Depression Into Solutions|Completed||N/A|309|Actual|VA Office of Research and Development|Primary Outcome Initiation of HCV treatment was affected by the 2012 announcement that new interferon-sparing antiviral drugs might be released within 1 year. Most HCV clinicians advised patients to wait for the new drugs (released in 2014).|2|||f||||t||||||||||2018-05-31 23:41:13.067282|2018-05-31 23:41:13.067282
NCT01143883|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2012-12-10||2013-06-11|2010-06-11|2010-06-14|Estimate|2013-06-11|2013-06-13|Estimate||||2013-06-11|2013-06-13|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Study Looking at the Effect of Silverlon on Post Operative Wound Infections|A Randomized Controlled Clinical Trial Evaluating the Efficacy of Silverlon® in Preventing Surgical Site Infection Following Colorectal Surgery|Completed||N/A|110|Actual|University of South Florida|Members of the surgical team were not blinded to the treatment group.|2|||f||||t||||||||||2018-05-31 23:41:13.597445|2018-05-31 23:41:13.597445
NCT01143870|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2016-01-11||2018-02-26|2010-06-11|2010-06-14|Estimate|2018-02-26|2018-02-28|Actual||||2018-02-26|2018-02-28|Actual|April 2010||2010-04-30|February 2018|2018-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||New Ways to Help Patients Improve Their Diabetes Control|Examining Ways to Increase Patient Understanding of Diabetes Control and Disease Severity Through Reinterpretation of Hemoglobin A1C Values With the Goal of Improved Diabetes Control|Completed||N/A|177|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 23:41:13.826551|2018-05-31 23:41:13.826551
NCT01143857|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2013-10-14|2010-06-11|2010-06-14|Estimate|||||||2013-10-14|2013-10-16|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement|Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement|Withdrawn||Phase 2|0|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:41:14.122344|2018-05-31 23:41:14.122344
NCT01143844|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2016-08-24|2010-06-11|2010-06-14|Estimate|||||||2016-08-24|2016-08-25|Estimate|March 2006||2006-03-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Assessing Fertility Potential in Female Cancer Survivors|Assessing Fertility Potential in Female Cancer Survivors|Recruiting|||400|Anticipated|University of Pennsylvania|||3||f||||f||||||Samples With DNA|"~     Serum~   "|Yes|Data will be shared with Dr. Jill Ginsberg, a co-investigator of the study.|2018-05-31 23:41:14.232681|2018-05-31 23:41:14.232681
NCT01143831|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2012-06-11|2010-06-11|2010-06-14|Estimate|||||||2012-06-11|2012-06-12|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation|Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation|Completed||N/A|8|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 23:41:14.303326|2018-05-31 23:41:14.303326
NCT01143818|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2011-08-19||2011-10-12|2010-06-11|2010-06-14|Estimate|2011-08-19|2011-09-26|Estimate||||2011-10-12|2011-10-17|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||ESPRIT Study in Hypogonadal Men|Energy, Sexual Desire and Body PropoRtions wIth AndroGel®, Testosterone 1% Gel Therapy (ESPRIT) in Hypogonadal Men|Completed|||1053|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:41:14.450101|2018-05-31 23:41:14.450101
NCT01143805|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-08-06|2010-06-11|2010-06-14|Estimate|||||||2010-08-06|2010-08-10|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form|A Phase 1, Open Label, Single Dose, Randomized, Cross Over Study To Estimate The Absolute Oral Bioavailability Of CP-690,550 In Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:41:15.197143|2018-05-31 23:41:15.197143
NCT01143792|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2012-12-13||2013-04-12|2010-06-11|2010-06-14|Estimate|2013-04-12|2013-04-16|Estimate||||2013-04-12|2013-04-16|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional||The number of participants in each group varies because the urn randomization program didn't balance the groups equally.|Evaluation of Treatments for Homeless Youths|Evaluation of Treatments for Homeless Youth: CRA, MET and Case Management|Completed||Phase 2|270|Actual|Ohio State University||3|||f||||f||||||||||2018-05-31 23:41:15.306016|2018-05-31 23:41:15.306016
NCT01143779|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-10-27|2010-06-11|2010-06-14|Estimate|||||||2017-10-27|2017-10-31|Actual|June 2010|Actual|2010-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib|FLT-PET as an Imaging Biomarker in Patients Receiving the Combination of Cell Cycle Inhibitors Temsirolimus, Topotecan, and Bortezomib|Active, not recruiting||Phase 1|5|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:41:15.826938|2018-05-31 23:41:15.826938
NCT01143766|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2012-09-20||2017-12-26|2010-06-11|2010-06-14|Estimate|2012-11-06|2012-12-05|Estimate||||2017-12-26|2018-01-24|Actual|April 2010||2010-04-30|December 2017|2017-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)|Premedication With Single Dose Gabapentin to Improve Patient Tolerance in ERCP: A Double-Blind Randomized Controlled Trial|Completed||N/A|56|Actual|Indiana University|Limited sample size due to challenges with recruitment and transition to propofol-based anesthesia for sedation in ERCP. Study terminated at 50% enrollment for this reason.|2|||f||||f||||||||||2018-05-31 23:41:15.923347|2018-05-31 23:41:15.923347
NCT01143753|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-07-27|2010-06-11|2010-06-14|Estimate|||||||2017-07-27|2017-07-28|Actual|July 27, 2010|Actual|2010-07-27|July 2017|2017-07-31|May 2, 2017|Actual|2017-05-02|June 30, 2012|Actual|2012-06-30||Interventional|||A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors|An Open-Label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-Mutated Advanced Solid Tumours|Completed||Phase 1|45|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:41:16.193852|2018-05-31 23:41:16.193852
NCT01143740|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2016-11-01|2010-06-11|2010-06-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery|An Exploratory Biomarker Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery|Completed||Phase 1|20|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:41:16.291157|2018-05-31 23:41:16.291157
NCT01143727|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2013-03-14||2013-04-11|2010-06-11|2010-06-14|Estimate|2013-04-11|2013-05-31|Estimate||||2013-04-11|2013-05-31|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers|Comparison of SANTYL vs. Hydrogel in Debridement of Inflamed Diabetic Foot Ulcers|Completed||Phase 4|20|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 23:41:16.379289|2018-05-31 23:41:16.379289
NCT01143714|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2013-03-13||2013-05-02|2010-06-11|2010-06-14|Estimate|2013-03-20|2013-05-03|Estimate||||2013-05-02|2013-05-06|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers|A Vehicle-Controlled Study to Determine the Effect of Four Weeks of Debridement With Collagenase Santyl Ointment (Santyl) on the Healing of Diabetic Foot Ulcers|Completed||Phase 4|57|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 23:41:16.63841|2018-05-31 23:41:16.63841
NCT01143701|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2016-07-26||2016-09-21|2010-06-11|2010-06-14|Estimate|2016-09-21|2016-11-08|Estimate||||2016-09-21|2016-11-08|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31||Interventional|||Evaluation of an Intervention for Improving Community-based Pediatric Attention-Deficit Hyperactivity Disorder (ADHD) Care|Evaluation of an Intervention for Improving Community-based Pediatric ADHD Care|Completed||Phase 4|577|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 23:41:16.883375|2018-05-31 23:41:16.883375
NCT01143688|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2016-12-02||2017-03-29|2010-06-11|2010-06-14|Estimate|2017-03-29|2017-03-30|Actual||||2017-03-29|2017-03-30|Actual|January 2005||2005-01-31|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Characterization of Placebo Responses in Stable Asthma|Characterization of Placebo Responses in Stable Asthma|Completed||N/A|39|Actual|Brigham and Women's Hospital|The subjective scale did not encompass worsening of symptoms. Only studied acute asthmatic response, not chronic. Used single objective measure (FEV1) and single subjective measure. Did not assess subjective symptoms before each visit's intervention|3|||f||||f||||||||||2018-05-31 23:41:17.272973|2018-05-31 23:41:17.272973
NCT01143675|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-01-23|2010-06-11|2010-06-14|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2007||2007-03-31|January 2017|2017-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Influence of Local Bone Status on Complications After Surgical Treatment of Proximal Humerus Fractures|The Influence of Local Bone Status on Complications After Surgical Treatment of Proximal Humerus Fractures|Completed|||148|Actual|AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-05-31 23:41:17.477601|2018-05-31 23:41:17.477601
NCT01143662|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2013-01-31|2010-06-11|2010-06-14|Estimate|||||||2013-01-31|2013-02-04|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B|A Multi-center, Randomized, Open-label and Positive Controlled Phase II Clinical Trial to Assess Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Patients With Chronic Hepatitis B|Completed||Phase 2|205|Actual|Xiamen Amoytop Biotech Co., Ltd.||4|||f||||t||||||||||2018-05-31 23:41:17.68859|2018-05-31 23:41:17.68859
NCT01143649|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2014-08-27||2017-03-17|2010-06-11|2010-06-14|Estimate|2017-03-01|2017-03-06|Actual||||2017-03-17|2017-04-17|Actual|April 2010|Actual|2010-04-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|April 2011|Actual|2011-04-30||Interventional|tdcs||Use of Transcranial Direct Current Stimulation (tDCS) Coupled With Constraint Induced Movement Therapy in Stroke Patient|Effects of Transcranial DC Stimulation Coupled With Constraint Induced Movement Therapy on Motor Function in Stroke Patients|Completed||N/A|44|Actual|Spaulding Rehabilitation Hospital||6|||f||||f||||||||||2018-05-31 23:41:17.887262|2018-05-31 23:41:17.887262
NCT01143636|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2014-08-04||2017-03-14|2010-06-11|2010-06-14|Estimate|2017-03-14|2017-03-15|Actual||||2017-03-14|2017-03-15|Actual|April 2010||2010-04-30|March 2017|2017-03-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Transcranial Direct Stimulation in Chronic Pelvic Pain|Investigation and Treatment of Central Nervous System Dysfunction in Chronic Pelvic Pain.|Completed||Phase 2|35|Actual|Spaulding Rehabilitation Hospital||4|||f||||f||||||||||2018-05-31 23:41:18.432916|2018-05-31 23:41:18.432916
NCT01143623|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2011-09-19|2010-06-11|2010-06-14|Estimate|||||||2011-09-19|2011-09-20|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults|Dose Response Effect of a Proprietary Probiotic Formula for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults|Completed||Phase 2/Phase 3|510|Actual|Changhai Hospital||3|||f||||f||||||||||2018-05-31 23:41:18.952542|2018-05-31 23:41:18.952542
NCT01143610|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2011-10-29||2012-06-18|2010-06-11|2010-06-14|Estimate|2012-06-18|2012-07-24|Estimate||||2012-06-18|2012-07-24|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||A New Therapeutic Approach for Root Coverage|A New Regenerative Therapeutic Approach for Root Coverage: a Randomized Clinical Trial|Completed||N/A|15|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 23:41:19.053408|2018-05-31 23:41:19.053408
NCT01143597|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2013-10-09|2010-06-11|2010-06-14|Estimate|||||||2013-10-09|2013-10-10|Estimate|August 2007||2007-08-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Improving Hand and Arm Function After Spinal Cord Injury (SCI)|Improving Hand and Arm Function After SCI|Completed||N/A|48|Actual|University of Miami||3|||f||||f||||||||||2018-05-31 23:41:19.334569|2018-05-31 23:41:19.334569
NCT01143584|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-11|2010-06-11|2010-06-14|Estimate|||||||2010-06-11|2010-06-14|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.|Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.|Unknown status|Recruiting|N/A|20|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 23:41:19.430013|2018-05-31 23:41:19.430013
NCT01143571|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-23|2010-06-11|2010-06-14|Estimate|||||||2018-05-23|2018-05-24|Actual|November 20, 2009||2009-11-20|July 5, 2017|2017-07-05||||||||Observational|||Evaluation of Skin, Colonic, and Oral Microbiome and Effect of Time and Antibiotic Treatment on Organism Diversity at Each Site|Evaluation of Skin, Colonic and Oral Microbiota and Effect of Time and Antibiotic Treatment on Organism Diversity at Each Site|Completed|||150|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:19.58245|2018-05-31 23:41:19.58245
NCT01143558|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-04-04|2010-06-11|2010-06-14|Estimate|||||||2018-04-04|2018-04-05|Actual|August 1, 2010||2010-08-01|November 8, 2017|2017-11-08|December 30, 2014|Actual|2014-12-30|December 30, 2014|Actual|2014-12-30||Interventional|||Searching for Persistence of Infection in Lyme Disease|Searching for Persistence of Infection in Lyme Disease|Completed||Early Phase 1|45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:19.685534|2018-05-31 23:41:19.685534
NCT01143545|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-17|2010-06-11|2010-06-14|Estimate|||||||2018-05-17|2018-05-18|Actual|May 31, 2010||2010-05-31|January 3, 2018|2018-01-03|March 19, 2015|Actual|2015-03-19|February 9, 2015|Actual|2015-02-09||Interventional|||Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas|Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 23:41:19.79898|2018-05-31 23:41:19.79898
NCT01143532|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-16|2010-06-11|2010-06-14|Estimate|||||||2018-05-16|2018-05-17|Actual|May 28, 2010||2010-05-28|January 24, 2018|2018-01-24||||||||Observational|||Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes|Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes|Completed|||26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:19.933672|2018-05-31 23:41:19.933672
NCT01143519|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-22|2010-06-11|2010-06-14|Estimate|||||||2018-05-22|2018-05-23|Actual|May 24, 2010||2010-05-24|April 27, 2018|2018-04-27||||||||Observational|||Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage|Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage|Enrolling by invitation|||105|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:20.035618|2018-05-31 23:41:20.035618
NCT01143506|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-06-30|2010-06-11|2010-06-14|Estimate|||||||2017-06-30|2017-07-02|Actual|June 1, 2010||2010-06-01|January 4, 2012|2012-01-04|January 4, 2012||2012-01-04|||||Observational|||Physiology of Volition Studied With Nerve Block|Physiology of Volition Studied With Nerve Block|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:20.102319|2018-05-31 23:41:20.102319
NCT01143493|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-03-01|2010-06-11|2010-06-14|Estimate|||||||2018-03-01|2018-03-02|Actual|May 14, 2010||2010-05-14|February 13, 2018|2018-02-13||||||||Observational|||The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease|The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease|Enrolling by invitation|||278|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:20.20254|2018-05-31 23:41:20.20254
NCT01143480|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-26|2010-06-11|2010-06-14|Estimate|||||||2018-05-26|2018-05-30|Actual|May 14, 2010||2010-05-14|June 28, 2017|2017-06-28||||||||Observational|||Study of the Effect of Innate on the Inflammatory Response to Endotoxin|Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin|Enrolling by invitation|||138|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:20.280326|2018-05-31 23:41:20.280326
NCT01143467|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-10-05|2010-06-11|2010-06-14|Estimate|||||||2017-10-05|2017-10-06|Actual|May 24, 2010||2010-05-24|November 6, 2015|2015-11-06|November 6, 2015||2015-11-06|||||Observational|||Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy|Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy|Completed|||26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:20.348403|2018-05-31 23:41:20.348403
NCT01143454|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-08|2010-06-11|2010-06-14|Estimate|||||||2018-05-08|2018-05-09|Actual|May 14, 2010||2010-05-14|May 3, 2018|2018-05-03||||||||Observational|||Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System|Cardiovascular Disease Discovery Protocol|Recruiting|||100099|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:20.412315|2018-05-31 23:41:20.412315
NCT01143441|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-10-05|2010-06-11|2010-06-14|Estimate|||||||2017-10-05|2017-10-06|Actual|May 13, 2010||2010-05-13|August 11, 2017|2017-08-11|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)|Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)|Completed||Phase 1|48|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 23:41:20.486158|2018-05-31 23:41:20.486158
NCT01143428|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2018-05-23|2010-06-11|2010-06-14|Estimate|||||||2018-05-23|2018-05-24|Actual|May 13, 2010||2010-05-13|August 3, 2015|2015-08-03|August 3, 2015||2015-08-03|||||Observational|||Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study|Oxidative Stress in Motor Neuron Disease: COSMOS-PLS Add-On Study|Completed|||10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:41:20.595977|2018-05-31 23:41:20.595977
NCT01143402|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2017-04-07||2017-06-26|2010-06-11|2010-06-14|Estimate|2017-04-07|2017-05-18|Actual||||2017-06-26|2017-07-26|Actual|June 2010||2010-06-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye|Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma|Completed||Phase 2|120|Actual|National Cancer Institute (NCI)|Limitations of this study include the unblinded trial design and the lack of central review of imaging studies. Additionally, this trial was designed before activating mutations in exon 4 of GNAQ and GNA11 were reported.|2|||f||||t||||||||||2018-05-31 23:41:20.716693|2018-05-31 23:41:20.716693
NCT01142544|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2013-02-23|2010-06-10|2010-06-11|Estimate|||||||2013-02-23|2013-02-26|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Observational|PED-ALIEN||Incidence of Acute Lung Injury in Children|Acute Lung Injury in Children: Epidemiology and Natural History: The Pediatric ALIEN Study|Completed|||200|Actual|Dr. Negrin University Hospital|||1||f||||t||||||||||2018-05-31 23:41:42.925682|2018-05-31 23:41:42.925682
NCT01143389|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2018-04-03||2018-04-03|2010-06-11|2010-06-14|Estimate|2018-04-03|2018-05-04|Actual||||2018-04-03|2018-05-04|Actual|May 2010||2010-05-31|April 2018|2018-04-30|August 30, 2017|Actual|2017-08-30|May 30, 2017|Actual|2017-05-30||Interventional|||Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia|Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia|Completed||Phase 2|510|Actual|Price Vision Group|Limitations included the 6-month follow up duration and the reduced reproducibility of measurement techniques in eyes with ectasia as compared with normal eyes.|2|||f||||t||||||||||2018-05-31 23:41:22.171652|2018-05-31 23:41:22.171652
NCT01143376|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-04-19|2010-06-11|2010-06-14|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2010||2010-05-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|December 2012|Actual|2012-12-31||Interventional|||High-intensity Intermittent Training for Obese Individuals|High-intensity Intermittent Training to Maximize Metabolic and Cardiovascular Protection in Obese Individuals|Completed||N/A|46|Actual|Norwegian University of Science and Technology||3|||f||||f|f|f||||||||2018-05-31 23:41:22.593841|2018-05-31 23:41:22.593841
NCT01143363|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-02-05|2010-06-11|2010-06-14|Estimate|||||||2015-02-05|2015-02-06|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|December 2012|Actual|2012-12-31||Interventional|||Effect of High-intensity Intermittent Sprinting on Appetite Control on Obese Volunteers|Acute Effects of High-intensity Intermittent Sprinting vs. Moderate Intensity Continuous Cycling on Appetite Control on Obese Volunteers|Completed||N/A|12|Actual|Norwegian University of Science and Technology||4|||f||||f||||||||||2018-05-31 23:41:22.75214|2018-05-31 23:41:22.75214
NCT01143350|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-05-31|2010-06-11|2010-06-14|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Non Pharmacological Treatment in Alzheimer's Disease and Associated Disorders||Terminated||N/A|300|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||||||||||||2018-05-31 23:41:22.83441|2018-05-31 23:41:22.83441
NCT01143337|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2014-09-10||2014-10-07|2010-06-11|2010-06-14|Estimate|2014-10-07|2014-10-13|Estimate||||2014-10-07|2014-10-13|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis|A Multicenter Randomized, Double-blind, Placebo-controlled Study of MP-435 in Combination With MTX in Patients With Rheumatoid Arthritis - Exploratory Study|Completed||Phase 2|112|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 23:41:22.946037|2018-05-31 23:41:22.946037
NCT01143324|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2014-05-23||2016-01-26|2010-06-11|2010-06-14|Estimate|2014-07-30|2014-08-19|Estimate||||2016-01-26|2016-01-28|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|MASTERS-D|The original CIP planned the enrollment of approximately 200 patients (min 150 and max 250 pts). In total 255 patients were enrolled. Three patients were not submitted to a minimally invasive MAST fusion procedure and therefore excluded from further analysis. The total MAST population analysed at baseline consists of 252 patients.|A Prospective, Multicenter Observational Study on MAST™ (Minimal Access Spinal Technologies) Fusion Procedures for the Treatment of the Degenerative Lumbar Spine|A Prospective, Multicenter Observational Study on MAST™ (Minimal Access Spinal Technologies) Fusion Procedures for the Treatment of the Degenerative Lumbar Spine (MASTERS-D)|Completed|||255|Actual|Medtronic Spinal and Biologics|Limitations of this study include the lack of a direct comparison of outcomes of minimally invasive surgery and open surgery, since it was designed as an observational trial and not designed as a randomized controlled trial.||1||f||||f||||||||||2018-05-31 23:41:23.779996|2018-05-31 23:41:23.779996
NCT01143311|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-05-31|2010-06-11|2010-06-14|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional|||Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma||Terminated||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 23:41:24.43392|2018-05-31 23:41:24.43392
NCT01143298|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2013-12-10|2010-06-11|2010-06-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects|LEO 27847 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects|Completed||Phase 1|20|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 23:41:24.502786|2018-05-31 23:41:24.502786
NCT01143285|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2016-04-22|2010-06-11|2010-06-14|Estimate|||||||2016-04-22|2016-04-25|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|CHIMIODIET||Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer|Chimiodiet Study:Impact of Early and Active Nutritional and Dietary Management on grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer.|Completed||N/A|180|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 23:41:24.609379|2018-05-31 23:41:24.609379
NCT01143272|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|2016-03-17||2016-06-07|2010-06-11|2010-06-14|Estimate|2016-06-07|2016-07-18|Estimate||||2016-06-07|2016-07-18|Estimate|June 2010||2010-06-30|June 2016|2016-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|SacBo||Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea|Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea - Randomised, Double-blind, Placebo-controlled Trial|Terminated||Phase 3|477|Actual|Bernhard Nocht Institute for Tropical Medicine||2||Masked independent interim analysis: completion of the trial was unlikely.|f||||t||||||||Undecided||2018-05-31 23:41:24.821025|2018-05-31 23:41:24.821025
NCT01143259|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2014-01-07||2014-08-25|2010-06-11|2010-06-14|Estimate|2014-04-15|2014-05-19|Estimate||||2014-08-25|2014-09-04|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use|A Randomized, Double Blind, Placebo Controlled Study to Study Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use|Completed||N/A|274|Actual|Intermountain Health Care, Inc.||2|||f||||f||||||||||2018-05-31 23:41:25.422452|2018-05-31 23:41:25.422452
NCT01143246|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11||2014-03-12|2016-09-08|2010-06-11|2010-06-14|Estimate||||2014-03-12|2014-04-09|Estimate|2016-09-08|2016-09-23|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin|Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial)|Completed||Phase 3|196|Actual|Mallinckrodt||2|||f||||t||||||||||2018-05-31 23:41:25.728155|2018-05-31 23:41:25.728155
NCT01143233|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-11-29|2010-06-11|2010-06-14|Estimate|||||||2017-11-29|2017-11-30|Actual|April 2010||2010-04-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|July 2014|Actual|2014-07-31||Interventional|HippHA||Low-protein Infant Formula With Partial or Extensive Proteinhydrolysate 4 Year Follow-up|Suitability of an Infant Formula With Reduced Protein Content Based on a Partial Respectively an Extensive Proteinhydrolysate With and Without Pro- and Prebiotics for the Particular Nutritional Use by Infants.-Extension by 4 Year Follow-up|Completed||N/A|503|Actual|HiPP GmbH & Co. Vertrieb KG||5|||f||||t||||||||||2018-05-31 23:41:25.90069|2018-05-31 23:41:25.90069
NCT01143220|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2017-02-17|2010-06-11|2010-06-14|Estimate|||||||2017-02-17|2017-02-23|Actual|August 2010||2010-08-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|JASMINE||Japanese Assessment of Indication Based Programming|Japanese Assessment of Indication Based Programming|Completed|||235|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 23:41:25.989513|2018-05-31 23:41:25.989513
NCT01143207|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2013-08-05||2013-08-05|2010-06-11|2010-06-14|Estimate|2013-08-05|2013-08-19|Estimate||||2013-08-05|2013-08-19|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||PK of Depo SubQ Injected in the Upper Arm|Pharmacokinetics of Subcutaneous Depot Medroxyprogesterone Acetate Injected in the Upper Arm|Completed||N/A|26|Actual|FHI 360||1|||f||||f||||||||||2018-05-31 23:41:26.131447|2018-05-31 23:41:26.131447
NCT01143194|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2011-06-08|2010-06-11|2010-06-14|Estimate|||||||2011-06-08|2011-06-09|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women|A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women|Completed||Phase 1|44|Actual|DSM Nutritional Products, Inc.||4|||f||||f||||||||||2018-05-31 23:41:26.3691|2018-05-31 23:41:26.3691
NCT01143181|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2013-08-28|2010-06-11|2010-06-14|Estimate|||||||2013-08-28|2013-08-29|Estimate|December 2010||2010-12-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses|A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses|Completed||Phase 2/Phase 3|232|Actual|Chimerix|||||f||||||||||||||2018-05-31 23:41:26.518537|2018-05-31 23:41:26.518537
NCT01143168|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-11|2010-06-11|2010-06-14|Estimate|||||||2010-06-11|2010-06-14|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|||Stem Cell Therapy for Type 1 Diabetes Mellitus|A Pilot Study on Transplantation Therapy Using Autologous Bone Marrow Mononuclear Cells and Umbilical Cord Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Cellonis Biotechnology Co. Ltd.|||||f||||t||||||||||2018-05-31 23:41:26.622082|2018-05-31 23:41:26.622082
NCT01143155|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2013-12-31|2010-06-11|2010-06-14|Estimate|||||||2013-12-31|2014-01-03|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|FAILCAP||Failure and Cardiovascular Events in Community-acquired Pneumonia|Clinical Failure and Cardiovascular Events in Hospitalized Patients With Community-Acquired Pneumonia: The Failcap Study|Completed|||2000|Actual|University of Milan|||||f||||t||||||Samples Without DNA|"~     Urine Sputum Blood Exhaled Breath Condensate Tracheal Aspirate Pleural effusion~     Bronchoalveolar lavage Nasopharyngeal swabs~   "|||2018-05-31 23:41:26.684376|2018-05-31 23:41:26.684376
NCT01143142|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2014-12-08||2014-12-15|2010-06-11|2010-06-14|Estimate|2014-12-15|2014-12-22|Estimate||||2014-12-15|2014-12-22|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Vax Facts Human Papillomavirus (HPV): Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV|Vax Facts HPV: Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV|Completed||N/A|70|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 23:41:26.769605|2018-05-31 23:41:26.769605
NCT01143129|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2014-02-21|2010-06-11|2010-06-14|Estimate|||||||2014-02-21|2014-02-24|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|DECS-PNAF||Postoperative New-onset Atrial Fibrillation in Cardiac Surgery: DECS-PNAF Project|Postoperative New-onset Atrial Fibrillation in Cardiac Surgery: An Explanatory Study of the Prophylactic Effect of Corticosteroids (DECS-PNAF Project)|Completed||Phase 4|80|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 23:41:27.110913|2018-05-31 23:41:27.110913
NCT01143116|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-09-27|2010-06-11|2010-06-14|Estimate|||||||2012-09-27|2012-09-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:41:27.193346|2018-05-31 23:41:27.193346
NCT01143103|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-09-21|2010-06-11|2010-06-14|Estimate|||||||2012-09-21|2012-09-24|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Comparison Between Respiratory Therapy With Cough Assist Technique and Usual Respiratory Therapy in Intensive Care Patients Suffering of Neurologic Disorder|Comparison Between Respiratory Physiotherapy With Cough Assist Technique and Usual Respiratory Care in Intensive Care Patients Suffering of Neurologic Disorder|Withdrawn||N/A|0|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 23:41:27.22628|2018-05-31 23:41:27.22628
NCT01143090|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2012-11-15||2015-05-19|2010-06-11|2010-06-14|Estimate|2012-11-15|2012-12-17|Estimate||||2015-05-19|2015-06-12|Estimate|August 2010||2010-08-31|May 2015|2015-05-31||||November 2011|Actual|2011-11-30||Interventional|Switch Ext||A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder|A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Protocol No. D1050290)|Completed||Phase 3|149|Actual|Sunovion||1|||f||||t||||||||||2018-05-31 23:41:27.3208|2018-05-31 23:41:27.3208
NCT01143077|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2012-05-15||2013-04-09|2010-06-11|2010-06-14|Estimate|2012-07-10|2012-08-16|Estimate||||2013-04-09|2013-04-17|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|SWITCHCore||A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents|A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents|Completed||Phase 3|244|Actual|Sunovion||3|||f||||t||||||||||2018-05-31 23:41:27.587995|2018-05-31 23:41:27.587995
NCT01141660|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2010-11-10||2017-10-12|2010-06-08|2010-06-10|Estimate|2010-12-13|2011-01-13|Estimate||||2017-10-12|2017-11-13|Actual|December 2007||2007-12-31|October 2017|2017-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Use of Laryngeal Mask Airway in Pediatric Adenotonsillectomy|Use of Laryngeal Mask Airway in Pediatric Adenotonsillectomy|Completed||N/A|131|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 23:41:55.486171|2018-05-31 23:41:55.486171
NCT01143064|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10||2014-06-11|2014-06-11|2010-06-10|2010-06-14|Estimate||||2014-06-11|2014-06-19|Estimate|2014-06-11|2014-06-19|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|SyNAPSe||Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients With Severe Traumatic Brain Injury|Completed||Phase 3|1195|Actual|BHR Pharma, LLC||2|||f||||t||||||||||2018-05-31 23:41:28.06281|2018-05-31 23:41:28.06281
NCT01143051|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2014-02-05||2014-06-13|2010-06-11|2010-06-14|Estimate|2014-06-13|2014-07-15|Estimate||||2014-06-13|2014-07-15|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers|Phase I/II Study Epinephrine Inhalation Aerosol USP, an HFA-MDI Clinical Study-B for Assessment of Pharmacokinetics|Completed||Phase 1/Phase 2|24|Actual|Amphastar Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 23:41:28.34833|2018-05-31 23:41:28.34833
NCT01143038|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2016-01-27|2014-05-29|2017-02-07|2010-06-10|2010-06-14|Estimate|2016-01-27|2016-02-24|Estimate|2014-05-29|2014-06-02|Estimate|2017-02-07|2017-03-15|Actual|November 2010||2010-11-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim|A Phase 2 Interventional Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects With Immune Thrombocytopenia Purpura Receiving Romiplostim|Completed||Phase 2|75|Actual|Amgen||1|||f||||f||||||||||2018-05-31 23:41:29.013433|2018-05-31 23:41:29.013433
NCT01143025|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-05-18|2010-06-11|2010-06-14|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Intraperitoneal Ropivacaine Nebulization for Pain Control After Laparoscopic Surgery|Peritoneal Nebulization of Ropivacaine for Postoperative Pain Control After Laparoscopic Cholecystectomy|Completed||Phase 3|165|Anticipated|San Gerardo Hospital||3|||f||||f||||||||||2018-05-31 23:41:29.445939|2018-05-31 23:41:29.445939
NCT01143012|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-08-01|2010-06-11|2010-06-14|Estimate|||||||2011-08-01|2011-08-02|Estimate|May 2010||2010-05-31|May 2010|2010-05-31||||August 2011|Anticipated|2011-08-31||Interventional|||Group Eczema Education Visits:Impact on Patient and Family Quality of Life|Group Eczema Education Visits:Impact on Patient and Family Quality of Life|Unknown status|Recruiting|N/A|60|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 23:41:29.581333|2018-05-31 23:41:29.581333
NCT01142999|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2011-08-04|2010-06-11|2010-06-14|Estimate|||||||2011-08-04|2011-08-05|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|September 2012|Anticipated|2012-09-30|August 2011|Anticipated|2011-08-31||Interventional|BEEP||Feasibility Study of Barrier Enhancement for Eczema Prevention|Feasibility Study of Barrier Enhancement for Eczema Prevention (BEEP)|Unknown status|Active, not recruiting|N/A|46|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 23:41:29.683999|2018-05-31 23:41:29.683999
NCT01142986|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2018-01-11|2010-06-11|2010-06-14|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2010||2010-07-31|January 2018|2018-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance|Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance|Completed||N/A|223|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 23:41:29.778762|2018-05-31 23:41:29.778762
NCT01142973|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2010-09-10|2010-06-11|2010-06-14|Estimate|||||||2010-09-10|2010-09-13|Estimate|September 2005||2005-09-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|August 2010|Actual|2010-08-31||Observational|PREDICT||The Clinical Course of Coronary Artery Disease in Coronary Multidetector Computed Tomographic Angiogram|Prognostic Role of Coronary Artery plaquEs in Patients With Suspected Coronary Artery Disease Using Multislice of Computed Tomography (PREDICT)|Unknown status|Recruiting||5000|Anticipated|Inje University|||||f||||f||||||||||2018-05-31 23:41:29.856847|2018-05-31 23:41:29.856847
NCT01142960|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2016-05-10|2010-06-11|2010-06-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Effects of Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population|Effects of Lycium Barbarum Supplements on the Progression of Senile Cataract in Hong Kong Chinese Population|Completed||N/A|238|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||Undecided||2018-05-31 23:41:29.941014|2018-05-31 23:41:29.941014
NCT01142947|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2016-08-15|2010-06-11|2010-06-14|Estimate|||||||2016-08-15|2016-08-16|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2016|Actual|2016-02-29||Interventional|SAPPHIRE||Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)|Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)|Active, not recruiting||N/A|808|Anticipated|Henry Ford Health System||1|||f||||t||||||||||2018-05-31 23:41:30.009704|2018-05-31 23:41:30.009704
NCT01142934|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2012-01-31|2010-06-11|2010-06-14|Estimate|||||||2012-01-31|2012-02-01|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|October 2012|Anticipated|2012-10-31|April 2012|Anticipated|2012-04-30||Interventional|TegaCHG||Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections|A MULTICENTRE RANDOMIZED CONTROLLED CLINICAL TRIAL ON THE EFFICACY OF TEGADERM CHG IN REDUCING CATHETER RELATED BLOOD STREAM INFECTIONS|Unknown status|Recruiting|Phase 4|1200|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 23:41:30.10172|2018-05-31 23:41:30.10172
NCT01142921|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-04-20|2010-06-11|2010-06-14|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2008|Actual|2008-11-30|April 2017|2017-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Patency Period of the New Plastic Anti-reflux Biliary Stent|A Prospective Randomised Study on the Patency Period of the Plastic Anti-reflux Biliary Stent|Terminated||N/A|16|Actual|Chinese University of Hong Kong||2||Issue regarding the stent design|f||||f||||||||No||2018-05-31 23:41:30.220091|2018-05-31 23:41:30.220091
NCT01142908|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2016-03-01||2016-04-07|2010-06-10|2010-06-11|Estimate|2016-04-07|2016-05-09|Estimate||||2016-04-07|2016-05-09|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Cardiovascular Intervention Improvement Telemedicine Study|Cardiovascular Intervention Improvement Telemedicine Study|Completed||N/A|428|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 23:41:30.367308|2018-05-31 23:41:30.367308
NCT01142895|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|May 2010||2010-05-31|June 2010|2010-06-30||||May 2010|Actual|2010-05-31||Observational|G4||Validation Study of G4 User Interface|Simulated Usability Trial of the T-Slim Ambulatory Insulin Infusion Pump|Completed|||33|Actual|Tandem Diabetes Care, Inc.|||||f||||f||||||||||2018-05-31 23:41:31.20018|2018-05-31 23:41:31.20018
NCT01139333|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-05|||2016-05-17|2010-06-05|2010-06-08|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2009||2009-09-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia|Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples|Completed|||52|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     blood and tumor samples~   "|||2018-05-31 23:42:32.245969|2018-05-31 23:42:32.245969
NCT01142882|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-07-19|2010-06-10|2010-06-11|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention|Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention|Unknown status|Recruiting|N/A|120|Anticipated|National Development and Research Institutes, Inc.||2|||f||||f||||||||||2018-05-31 23:41:31.249481|2018-05-31 23:41:31.249481
NCT01142869|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2017-05-04|2010-06-10|2010-06-11|Estimate|||||||2017-05-04|2017-05-08|Actual|December 31, 2009|Actual|2009-12-31|May 2017|2017-05-31|August 5, 2014|Actual|2014-08-05|July 31, 2013|Actual|2013-07-31||Observational|||An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck|An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy, in the First-line Therapy of Recurrent/ Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)|Terminated|||133|Actual|Merck KGaA||||"The study was discontinued due to slow recruitment and subjects not completing follow up~   period."|f||||||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 23:41:31.339805|2018-05-31 23:41:31.339805
NCT01142856|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2012-05-02|2010-06-10|2010-06-11|Estimate|||||||2012-05-02|2012-05-03|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)|A Single Patient Treatment Protocol for Autologous Mesenchymal Stem Cell Intraspinal Therapy in Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 1|1|Actual|Mayo Clinic|||||f||||||||||||||2018-05-31 23:41:31.531177|2018-05-31 23:41:31.531177
NCT01142843|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-07-01|2010-06-10|2010-06-11|Estimate|||||||2010-07-01|2010-07-02|Estimate|August 2009||2009-08-31|May 2009|2009-05-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional|MGP||Preliminary Evidence of the Efficacy of a Mouthwash Containing 5% Propolis for the Control of Plaque and Gingivitis|Clinical Preliminary Evidence of the Efficacy of a Mouthwash Containing 5% Propolis for the Control of Plaque and Gingivitis: Phase II Study|Completed||Phase 2|25|Actual|Federal University of Minas Gerais|||||f||||t||||||||||2018-05-31 23:41:31.606976|2018-05-31 23:41:31.606976
NCT01142830|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-02-22|2010-06-10|2010-06-11|Estimate|||||||2013-02-22|2013-02-25|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Observational|Brainpain||Incidence of Pain After Craniotomy in Children|Prospective Multicenter Cohort Study Evaluating Incidence and Intensity of Postoperative Pain in Pediatric Patients After Craniotomy|Completed|||218|Actual|San Gerardo Hospital|||||f||||f||||||||||2018-05-31 23:41:31.703164|2018-05-31 23:41:31.703164
NCT01142817|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2013-08-06|2010-06-10|2010-06-11|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Metabolic and Psychological Changes Associated With Menopause Among Women With HIV|Metabolic and Psychological Changes Associated With Menopause Among Women With HIV|Completed|||66|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     Whole blood, serum~   "|||2018-05-31 23:41:31.797275|2018-05-31 23:41:31.797275
NCT01142804|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2015-08-12|2010-06-10|2010-06-11|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|WalkLink||WalkLink: Internet-based Walking Program|WalkLink:Internet-based Walking Program for Cardiovascular Disease Risk-Reduction|Completed||N/A|308|Actual|Milton S. Hershey Medical Center||3|||f||||t||||||||||2018-05-31 23:41:31.916753|2018-05-31 23:41:31.916753
NCT01142791|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2018-05-22|2010-06-10|2010-06-11|Estimate|||||||2018-05-22|2018-05-24|Actual|May 2010||2010-05-31|May 2018|2018-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety Study of ExAblate for the Treatment of Uterine Fibroids|A Phase IV Clinical Study To Evaluate the Safety of MR-Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques|Completed||N/A|115|Actual|InSightec||1|||f||||f||||||||||2018-05-31 23:41:32.01721|2018-05-31 23:41:32.01721
NCT01142778|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2018-03-15|2010-06-10|2010-06-11|Estimate|||||||2018-03-15|2018-03-16|Actual|May 19, 2010|Actual|2010-05-19|March 2018|2018-03-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|AVATAXHER||A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer|An Open-Label, Randomized, Multicenter, Phase II, Non Comparative, Exploratory Study on Neoadjuvant Treatment With Trastuzumab Plus Docetaxel Plus Bevacizumab According to Positon Emission Tomography (PET) Value Modification in Patients With Early Stage HER2 Positive Breast Cancer|Completed||Phase 2|152|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:41:32.128079|2018-05-31 23:41:32.128079
NCT01142765|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-03-25|2010-06-10|2010-06-11|Estimate|||||||2011-03-25|2011-03-28|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP|A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP|Completed||Phase 1/Phase 2|52|Anticipated|University of Oxford||5|||f||||t||||||||||2018-05-31 23:41:32.284944|2018-05-31 23:41:32.284944
NCT01142752|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2016-08-02|2010-06-10|2010-06-11|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|||Vaginal, Oral and Systemic Inflammation in Preterm Birth|Vaginal, Oral and Systemic Inflammation in Preterm Birth|Completed|||71|Actual|University Hospital Inselspital, Berne|||3||f||||t||||||Samples With DNA|"~     Blood, vaginal smears, oral specimens~   "|||2018-05-31 23:41:32.390311|2018-05-31 23:41:32.390311
NCT01142739|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2012-07-30|2010-06-10|2010-06-11|Estimate|||||||2012-07-30|2012-07-31|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|BIODYS (1)||Phosphorylation of ERK1/2 in Patients With Parkinson's Disease|A Descriptive Study of Lymphocytic Phosphorylation of ERK1/2 in Patients With Parkinson's Disease With Dyskinesias and in Controls|Completed|||30|Actual|University Hospital, Bordeaux|||2||f||||f||||||Samples With DNA|"~     whole blood urine~   "|||2018-05-31 23:41:32.447537|2018-05-31 23:41:32.447537
NCT01142726|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2014-09-25||2015-12-09|2010-06-10|2010-06-11|Estimate|2014-10-15|2014-10-17|Estimate||||2015-12-09|2016-01-14|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Interventional||All randomized patients who received at least 1 dose of double-blind study medication in the Treatment Period|Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis|A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA|Completed||Phase 3|511|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 23:41:32.654929|2018-05-31 23:41:32.654929
NCT01142713|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|August 2010||2010-08-31|February 2010|2010-02-28|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study|The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-05-31 23:41:34.605734|2018-05-31 23:41:34.605734
NCT01142700|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2011-03-14|2010-06-10|2010-06-11|Estimate|||||||2011-03-14|2011-03-15|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I|A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 23:41:34.889105|2018-05-31 23:41:34.889105
NCT01142687|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2016-11-23|2010-06-10|2010-06-11|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis With a High Protein Very Low Calorie Diet|Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis Following 4 Weeks of Very Low Calorie Diet|Completed||N/A|58|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 23:41:37.406477|2018-05-31 23:41:37.406477
NCT01142674|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2016-08-08|2010-06-10|2010-06-11|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2006||2006-09-30|August 2016|2016-08-31|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Observational|||T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma|Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project|Recruiting|||2000|Anticipated|Associazione Angela Serra per la ricerca sul cancro|||||f||||f||||||Samples Without DNA|"~     Formalin-fixed tissue for central diagnostic pathology review~   "|Yes|Preliminary analysis results will be made available during the study on the single population and separately for each subtype. Final results will be made available 6-12 months after the end of the study|2018-05-31 23:41:37.789106|2018-05-31 23:41:37.789106
NCT01142661|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2013-04-29||2013-09-19|2010-06-10|2010-06-11|Estimate|2013-09-19|2013-09-20|Estimate||||2013-09-19|2013-09-20|Estimate|August 2010||2010-08-31|September 2013|2013-09-30||||August 2011|Actual|2011-08-31||Interventional|||Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies|Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies|Completed||N/A|9|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 23:41:38.872838|2018-05-31 23:41:38.872838
NCT01142648|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Sugammadex and Brain Waves|The Effect of Sugammadex of EEG-derived Index Values|Completed||Phase 4|30|Anticipated|Tampere University Hospital|||||f||||f||||||||||2018-05-31 23:41:39.779631|2018-05-31 23:41:39.779631
NCT01142635|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Electromyographic (EMG) on the Anaesthesia Monitor|The Appearance of Electromyography on the Anaesthesia Monitor.|Completed||Phase 4|30|Anticipated|Tampere University Hospital|||||f||||f||||||||||2018-05-31 23:41:40.102694|2018-05-31 23:41:40.102694
NCT01142622|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-02-22|2010-06-10|2010-06-11|Estimate|||||||2013-02-22|2013-02-25|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intraperitoneal Ropivacaine Nebulization for Pain Control After Gynecologic Laparoscopic Surgery|Do Peritoneal Nebulization of Ropivacaine Reduce the Use of Morphine After Short Gynecologic Laparoscopic Surgery?|Completed||Phase 3|140|Anticipated|San Gerardo Hospital||2|||f||||f||||||||||2018-05-31 23:41:40.381665|2018-05-31 23:41:40.381665
NCT01142609|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2013-04-02|2010-06-10|2010-06-11|Estimate|||||||2013-04-02|2013-04-04|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Improving Substance Abuse Counseling Adherence Using Web-based Videoconferencing|Improving Substance Abuse Counseling Adherence Using Web-based Videoconferencing|Completed||N/A|85|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:41:40.473731|2018-05-31 23:41:40.473731
NCT01142596|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2016-04-12||2016-05-24|2010-06-10|2010-06-11|Estimate|2016-04-12|2016-05-18|Estimate||||2016-05-24|2016-06-24|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)|Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Phase 3 ; Protocol No. P06125)|Completed||Phase 3|201|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 23:41:40.723028|2018-05-31 23:41:40.723028
NCT01142583|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2014-03-17|2010-06-10|2010-06-11|Estimate|||||||2014-03-17|2014-03-18|Estimate|July 2006||2006-07-31|March 2014|2014-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|CanTOR||A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis|Canadian Assessment of the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis|Completed|||192|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:41:42.213137|2018-05-31 23:41:42.213137
NCT01142570|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-10-03|2010-06-10|2010-06-11|Estimate|||||||2010-10-03|2010-10-05|Estimate|September 2010||2010-09-30|January 2010|2010-01-31|November 2012|Anticipated|2012-11-30|September 2012|Anticipated|2012-09-30||Interventional|||Effect of Enteral Nutrition Enriched in Protein and Based on Indirect Calorimetry Measurement in Chronically Critically Ill Patients|Effect of Enteral Nutrition Enriched in Protein and Based on Indirect Calorimetry Measurement in Chronically Critically Ill Patients|Unknown status|Active, not recruiting|N/A|60|Anticipated|Rabin Medical Center||5|||f||||t||||||||||2018-05-31 23:41:42.457034|2018-05-31 23:41:42.457034
NCT01142557|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2014-07-09|2010-06-10|2010-06-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|June 2004||2004-06-30|June 2010|2010-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis|Therapy of the Chronic Multiple Sclerosis With Interferon-beta 1a (Rebif®)|Completed|||522|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:41:42.764399|2018-05-31 23:41:42.764399
NCT01142531|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2012-07-03|2010-06-10|2010-06-11|Estimate|||||||2012-07-03|2012-07-04|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Effects of Bronchodilation on Computed Tomography (CT) Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent.|Effects of Bronchodilation on CT Parameters Reflecting Airways Remodelling, and Pulmonary Emphysema Extent: Comparisons Between CT Scans Obtained Before and After Bronchodilation and Relationships With Pulmonary Function Tests.|Completed|||20|Actual|Erasme University Hospital|||1||f||||f||||||||||2018-05-31 23:41:43.059957|2018-05-31 23:41:43.059957
NCT01142518|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2014-03-17|2010-06-10|2010-06-11|Estimate|||||||2014-03-17|2014-03-18|Estimate|July 2005||2005-07-31|March 2014|2014-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|RETURN||An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone|A Prospective Analysis of MS Patients After Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment|Completed|||86|Actual|Merck KGaA|||||f||||||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 23:41:43.150305|2018-05-31 23:41:43.150305
NCT01142505|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2014-04-27|2010-06-10|2010-06-11|Estimate|||||||2014-04-27|2014-04-29|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|WAIT||Wheeze and Intermittent Treatment|Parent-determined Oral Montelukast Therapy for Preschool Wheeze With Stratification for Arachidonate-5-Lipoxygenase (ALOX5) Promoter Genotype|Completed||Phase 3|1358|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 23:41:43.270783|2018-05-31 23:41:43.270783
NCT01142492|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2014-03-17|2010-06-10|2010-06-11|Estimate|||||||2014-03-17|2014-03-18|Estimate|January 2005||2005-01-31|March 2014|2014-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|TOURIMS||A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)|Postmarketing Surveillance Study on the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis With Interferon Beta 1a (Rebif®)|Completed|||403|Actual|Merck KGaA|||||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 23:41:43.379587|2018-05-31 23:41:43.379587
NCT01142479|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2014-05-28|2010-06-10|2010-06-11|Estimate|||||||2014-05-28|2014-05-29|Estimate|May 2010||2010-05-31|May 2014|2014-05-31||||April 2011|Actual|2011-04-30||Interventional|||Compound Herbal Formula (TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy|The Effects of Compound Herbal Formula(TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy|Completed||Phase 2/Phase 3|60|Actual|Taipei City Hospital||2|||f||||||||||||||2018-05-31 23:41:43.435536|2018-05-31 23:41:43.435536
NCT01142466|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2011-04-07||2014-01-26|2010-06-10|2010-06-11|Estimate|2011-05-11|2011-06-10|Estimate||||2014-01-26|2014-02-27|Estimate|December 2005||2005-12-31|January 2014|2014-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|REMAIN||A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone|Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone|Completed||Phase 4|30|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:41:43.538132|2018-05-31 23:41:43.538132
NCT01142453|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2014-07-11|2010-06-10|2010-06-11|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 2005||2005-05-31|June 2010|2010-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients|Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its Monitoring|Completed|||231|Actual|Merck KGaA|||||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 23:41:43.983333|2018-05-31 23:41:43.983333
NCT01142440|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2011-06-28|2010-06-10|2010-06-11|Estimate|||||||2011-06-28|2011-06-29|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|February 2012|Anticipated|2012-02-29||Interventional|CAMBRA||Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel|Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among Israeli Defence Force (IDF) Personnel|Unknown status|Recruiting|Phase 4|400|Anticipated|Medical Corps, Israel Defense Force||2|||f||||f||||||||||2018-05-31 23:41:44.036013|2018-05-31 23:41:44.036013
NCT01142427|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2018-02-22|2010-06-10|2010-06-11|Estimate|||||||2018-02-22|2018-02-23|Actual|August 2010||2010-08-31|February 2018|2018-02-28||||January 2100|Anticipated|2100-01-31||Observational|||Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)|Recruiting|||14250|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Blood and bone marrow~   "|||2018-05-31 23:41:44.171266|2018-05-31 23:41:44.171266
NCT01142414|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2012-01-13|2010-06-10|2010-06-11|Estimate|||||||2012-01-13|2012-01-16|Estimate||||January 2012|2012-01-31||||||||Interventional|||Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence|Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence|Withdrawn||Phase 3|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-05-31 23:41:45.129162|2018-05-31 23:41:45.129162
NCT01142401|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2017-10-04|2010-06-10|2010-06-11|Estimate|||||||2017-10-04|2017-10-05|Actual|May 26, 2010|Actual|2010-05-26|May 2017|2017-05-31||||June 1, 2017|Actual|2017-06-01||Interventional|||Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer|A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer|Active, not recruiting||Phase 2|118|Actual|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-05-31 23:41:45.212818|2018-05-31 23:41:45.212818
NCT01142388|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2015-05-13||2018-04-26|2010-06-10|2010-06-11|Estimate|2015-06-02|2015-06-03|Estimate||||2018-04-26|2018-05-25|Actual|September 21, 2010|Actual|2010-09-21|March 2018|2018-03-31||||July 15, 2014|Actual|2014-07-15||Interventional||Per protocol, the primary population for all efficacy endpoints is all eligible patients|Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer|Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer|Active, not recruiting||Phase 2|94|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:41:45.390452|2018-05-31 23:41:45.390452
NCT01142375|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|April 2008||2008-04-30|June 2010|2010-06-30||||||||Observational|||Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells|Development and Exploration of the Feasibility of Using Locally Synthesized Small Molecule Inhibitors to Treat Human Acute Leukemia Cells|Unknown status|Active, not recruiting||100|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||Samples Without DNA|"~     Bone Marrow~   "|||2018-05-31 23:41:46.283909|2018-05-31 23:41:46.283909
NCT01142362|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-09-11|2010-06-10|2010-06-11|Estimate|||||||2017-09-11|2017-09-13|Actual|June 2010||2010-06-30|September 2017|2017-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults|Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity in Healthy Adults of a DNA Plasmid Vaccine for H5 Avian Influenza (VGX-3400X) Administered by Intramuscular (IM) Injection Followed by Electroporation (EP)|Completed||Phase 1|32|Actual|Inovio Pharmaceuticals||3|||f||||f||||||||||2018-05-31 23:41:46.391275|2018-05-31 23:41:46.391275
NCT01142349|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2013-12-17|2010-06-10|2010-06-11|Estimate|||||||2013-12-17|2013-12-19|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|Lifestyles||Cognitive Behavioral Therapy for Arthritis Pain and Insomnia in Older Adults|Cognitive Behavioral Therapy for Arthritis Pain and Insomnia in Older Adults|Completed||N/A|367|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 23:41:46.501055|2018-05-31 23:41:46.501055
NCT01142336|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2017-03-28||2017-06-30|2010-06-09|2010-06-11|Estimate|2017-06-30|2017-07-28|Actual||||2017-06-30|2017-07-28|Actual|June 2010||2010-06-30|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SimBio||Effects of Simvastatin on Biomarkers|Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects|Completed||Phase 4|49|Actual|University of Washington|Sample size is small and statistical power is limited.|2|||f||||t|t|||||||||2018-05-31 23:41:46.608694|2018-05-31 23:41:46.608694
NCT01142323|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|2013-03-12||2018-02-03|2010-06-10|2010-06-11|Estimate|2013-03-12|2013-04-23|Estimate||||2018-02-03|2018-02-06|Actual|October 2010||2010-10-31|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pilot Study of Fenofibrate for PSC|Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis|Terminated||Phase 1/Phase 2|8|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 23:41:47.035118|2018-05-31 23:41:47.035118
NCT01142310|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2016-03-10|2010-06-10|2010-06-11|Estimate|||||||2016-03-10|2016-03-11|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Reversing Corticosteroid Induced Memory Impairment|Reversing Corticosteroid Induced Memory Impairment|Completed||Phase 4|55|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 23:41:47.334331|2018-05-31 23:41:47.334331
NCT01142297|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2014-10-27||2017-12-04|2010-06-10|2010-06-11|Estimate|2014-12-15|2014-12-22|Estimate||||2017-12-04|2018-01-03|Actual|July 2008||2008-07-31|September 2016|2016-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Comparative Study of Implant Surfaces to Enhance Stabilization in Patients With Type 2 Diabetes|A Randomized, Controlled Trial Comparing the Stability of SLA Implants and SLActive Implants Using Resonance Frequency Analysis for Patients With Type 2 Diabetes Mellitus|Completed||N/A|24|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||||2018-05-31 23:41:47.479925|2018-05-31 23:41:47.479925
NCT01142284|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|April 2010||2010-04-30|June 2010|2010-06-30||||||||Interventional|||Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety|Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety in Peripheral Artery Disease Subjects Complicated With Coronary Artery Disease.|Unknown status|Recruiting|Phase 2|224|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||4|||f||||t||||||||||2018-05-31 23:41:47.920741|2018-05-31 23:41:47.920741
NCT01142271|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2011-11-04|2010-06-10|2010-06-11|Estimate|||||||2011-11-04|2011-11-07|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy|Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy for Gastric Cancer Patients : Prospective Randomized Study|Unknown status|Recruiting|Phase 3|120|Anticipated|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 23:41:48.059369|2018-05-31 23:41:48.059369
NCT01142258|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-10-12|2010-06-10|2010-06-11|Estimate|||||||2012-10-12|2012-10-15|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Trazodone for Sleep Disorders in Alzheimer's Disease|Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study|Completed||Phase 3|40|Actual|Brasilia University Hospital||2|||f||||f||||||||||2018-05-31 23:41:48.198064|2018-05-31 23:41:48.198064
NCT01142245|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2015-08-10|2010-06-10|2010-06-11|Estimate|||||||2015-08-10|2015-08-13|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|IOE||Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy|Phase 3 Study of Effect of Intravenous and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy (IOE Study)|Completed||Phase 3|263|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:41:48.411478|2018-05-31 23:41:48.411478
NCT01142232|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2017-01-26|2010-06-10|2010-06-11|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 27, 2010|Actual|2010-08-27|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma|Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|60|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 23:41:48.524295|2018-05-31 23:41:48.524295
NCT01142219|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|September 2006||2006-09-30|June 2010|2010-06-30|October 2009|Actual|2009-10-31|January 2008|Actual|2008-01-31||Interventional|||L-Arginine and Sickle Cell Disease|A Randomized, Controlled, Double-blind Clinical Trial of L-arginine as Adjuvant Therapy for Sickle Cell Disease|Completed||Phase 3|40|Actual|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-05-31 23:41:48.760616|2018-05-31 23:41:48.760616
NCT01142206|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2018-04-03|2010-06-09|2010-06-11|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2010||2010-06-30|April 2018|2018-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|LEAN||The Leisure-time Activity and Nutrition Program|The Effects of Two Different Leisure-time Activity Prescriptions on Eating and Activity Behaviors During Behavioral Weight Loss Treatment|Completed||N/A|28|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-05-31 23:41:49.276421|2018-05-31 23:41:49.276421
NCT01142193|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2014-04-03|2014-01-02|2014-05-19|2010-06-10|2010-06-11|Estimate|2014-04-03|2014-05-07|Estimate|2014-01-02|2014-02-04|Estimate|2014-05-19|2014-05-22|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures|Completed||Phase 3|249|Actual|Upsher-Smith Laboratories||2|||f||||||||||||||2018-05-31 23:41:49.459013|2018-05-31 23:41:49.459013
NCT01142180|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2017-04-20|2010-06-10|2010-06-11|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2010|Actual|2010-01-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Early Selective TAE to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis|Early Selective Angiographic Embolization to Severely Bleeding Peptic Ulcers After Their Initial Endoscopic Hemostasis - a Randomized Controlled Trial|Completed||N/A|258|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:41:50.010897|2018-05-31 23:41:50.010897
NCT01142167|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-07-29|2010-06-10|2010-06-11|Estimate|||||||2013-07-29|2013-07-31|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Comparison of an Ultra-thin and Standard Colonoscope in Achieving Caecal Intubation|A Study to Assess the Success Rate of Ultra-thin Colonoscopy Versus Conventional Colonoscopy for the First or Rescue Colonoscopy for Unsuccessful Procedures (UTC Study).|Completed||Phase 3|1121|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:41:50.183155|2018-05-31 23:41:50.183155
NCT01142154|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-06-22|2010-06-10|2010-06-11|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome|A Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne Syndrome|Completed||Phase 1/Phase 2|5|Actual|DNage B.V.||1|||f||||t||||||||||2018-05-31 23:41:50.283224|2018-05-31 23:41:50.283224
NCT01142141|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-06-09|2010-06-09|2010-06-11|Estimate|||||||2010-06-09|2010-06-11|Estimate|August 2006||2006-08-31|June 2010|2010-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Manual Therapy in Postoperative Breast Cancer|Manual Therapy in Postoperative Breast Cancer|Completed||N/A|136|Actual|University of Campinas, Brazil||1|||f||||f||||||||||2018-05-31 23:41:50.39001|2018-05-31 23:41:50.39001
NCT01142128|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2012-10-19||2013-02-20|2010-06-10|2010-06-11|Estimate|2013-02-20|2013-02-21|Estimate||||2013-02-20|2013-02-21|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|AZ||Viokase 16, Viokase16 Plus Nexium and Nexium Alone|A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis|Terminated||Phase 1|12|Actual|University of Florida||4||Viokase was taken off market during study and remained off over a year.|f||||f||||||||||2018-05-31 23:41:50.487729|2018-05-31 23:41:50.487729
NCT01142115|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2011-03-22||2011-10-04|2010-06-10|2010-06-11|Estimate|2011-07-12|2011-08-09|Estimate||||2011-10-04|2011-10-07|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Test of Discomfort and Malaise of Two Different Urine Catheters in Healthy Volunteers|Comparative Study of Two Different Urine Catheters.|Completed||N/A|41|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 23:41:50.865824|2018-05-31 23:41:50.865824
NCT01142102|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-01-22|2010-06-10|2010-06-11|Estimate|||||||2017-01-22|2017-01-24|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|February 2013|Actual|2013-02-28||Interventional|BOLART||Feasibility of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer|A Multicentre Feasibility Study of Online Adaptive Image Guided Radiotherapy for Muscle Invasive Bladder Cancer|Completed||N/A|50|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||t||||||||||2018-05-31 23:41:51.230465|2018-05-31 23:41:51.230465
NCT01142089|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2018-02-09|2013-04-05|2018-04-11|2010-06-10|2010-06-11|Estimate|2018-03-13|2018-04-10|Actual|2013-04-12|2013-04-19|Estimate|2018-04-11|2018-05-10|Estimate|May 27, 2010||2010-05-27|April 2018|2018-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Intent to Treat (ITT)|Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea|Completed||Phase 3|264|Actual|Cosmo Technologies Ltd||2|||f||||f||||||||||2018-05-31 23:41:51.427596|2018-05-31 23:41:51.427596
NCT01142076|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-12-10|2010-06-10|2010-06-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|XJXG||Xinju Xiaogao Prescription Study on Overweight|Xinju Xiaogao Prescription and 10% of it in the Treatment of Adiposity (Stagnation of QI Causing Phlegm Retention)Clinical Study|Completed||N/A|140|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 23:41:51.894277|2018-05-31 23:41:51.894277
NCT01142063|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-05-10|2010-06-09|2010-06-11|Estimate|||||||2012-05-10|2012-05-14|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects|A Single Dose Bioequivalence Study Comparing The Commercial Tablet Formulation To The Clinical Tablet Of Neratinib In Healthy Subjects|Completed|||28|Actual|Puma Biotechnology, Inc.|||4||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:41:51.955136|2018-05-31 23:41:51.955136
NCT01142050|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|||Stem Cell Therapy for Type 2 Diabetes Mellitus|A Open Labeled and Self Controlled, Safety/Efficacy Assessed Pilot Study on Transplantation Therapy Using Bone Marrow Mesenchymal Stem Cells for Insulin Resistance of Type 2 Diabetes Mellitus|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Cellonis Biotechnology Co. Ltd.|||||f||||||||||||||2018-05-31 23:41:52.045954|2018-05-31 23:41:52.045954
NCT01142037|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2014-08-21|2010-06-10|2010-06-11|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Development of a Biomarker for Dietary Furanocoumarins|Development of a Biomarker for Dietary Furanocoumarins|Completed||N/A|10|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 23:41:52.099873|2018-05-31 23:41:52.099873
NCT01139320|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-05|||2016-05-17|2010-06-05|2010-06-08|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2009||2009-09-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin|Pharmacogenetics of Mylotarg|Completed|||300|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:42:32.306739|2018-05-31 23:42:32.306739
NCT01142024|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2011-06-23|2010-06-10|2010-06-11|Estimate|||||||2011-06-23|2011-06-27|Estimate|March 2010||2010-03-31|December 2009|2009-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Polymorphism of Oxidative Stress Genes in the Pathogenesis and Antioxidant Prevention of Contrast Induced Nephropathy|Polymorphism of Oxidative Stress Relative Genes in Contrast Medium Induced Nephropathy:Implications in the Pathogenesis and the Effect of Antioxidant prevention-a Prospective,Randomized,Controlled Study|Completed||N/A|1000|Actual|Huashan Hospital||2|||f||||t||||||||||2018-05-31 23:41:52.167661|2018-05-31 23:41:52.167661
NCT01142011|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2012-02-08|2010-06-10|2010-06-11|Estimate|||||||2012-02-08|2012-02-10|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|January 2013|Anticipated|2013-01-31|June 2012|Anticipated|2012-06-30||Interventional|||A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia|A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia|Unknown status|Recruiting|Phase 2|15|Anticipated|Cancer Trials Australia||1|||f||||t||||||||||2018-05-31 23:41:52.234596|2018-05-31 23:41:52.234596
NCT01141998|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2011-12-22|2010-06-10|2010-06-11|Estimate|||||||2011-12-22|2011-12-23|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|||Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption|Vitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption|Completed||N/A|27|Actual|Hvidovre University Hospital||3|||f||||f||||||||||2018-05-31 23:41:52.325594|2018-05-31 23:41:52.325594
NCT01141985|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-10-20|2010-06-10|2010-06-11|Estimate|||||||2014-10-20|2014-10-22|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||New Disposable Contact Lens Patient Interface For The Lensx Laser|Evaluation Of A New Disposable Contact Lens Patient Interface For The Lensx Laser In Cataract And Corneal Surgery|Completed||Early Phase 1|110|Actual|LenSx Lasers Inc.||1|||f||||f||||||||||2018-05-31 23:41:52.407697|2018-05-31 23:41:52.407697
NCT01141972|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-05-28|2010-06-09|2010-06-11|Estimate|||||||2013-05-28|2013-05-30|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|FLASH||The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition|The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition|Completed||Phase 1|23|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 23:41:52.468447|2018-05-31 23:41:52.468447
NCT01141959|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2015-03-09|2010-06-10|2010-06-11|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients|Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients|Completed|||11|Actual|Fred Hutchinson Cancer Research Center|||||f||||f||||||Samples With DNA|"~     plasma, DNA~   "|||2018-05-31 23:41:52.582204|2018-05-31 23:41:52.582204
NCT01141946|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-07-16|2010-06-10|2010-06-11|Estimate|||||||2012-07-16|2012-07-17|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|CT0018||Pleural Ultrasonography in Lung Cancer|Pleural Ultrasonography in Lung Cancer - PULC|Completed|||46|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 23:41:52.746786|2018-05-31 23:41:52.746786
NCT01141933|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2018-03-02|2010-06-10|2010-06-11|Estimate|||||||2018-03-02|2018-03-06|Actual|February 2009||2009-02-28|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|December 2013|Actual|2013-12-31||Interventional|||Creating Meaning Following Cancer: An Intervention to Improve Existential and Global Quality of Life|Creating Meaning Following Cancer: An Cognitive-existential Intervention to Improve Existential and Global Quality of Life|Active, not recruiting||N/A|513|Anticipated|CHU de Quebec-Universite Laval||3|||f||||f||||||||||2018-05-31 23:41:52.848535|2018-05-31 23:41:52.848535
NCT01141920|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2015-09-16|2010-06-10|2010-06-11|Estimate|||||||2015-09-16|2015-09-17|Estimate|September 2008||2008-09-30|September 2015|2015-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparison of Two Counseling Induction Strategies|Comparison of Two Different Counseling Schedules on Treatment Response of New Admissions to Methadone Maintenance|Completed||N/A|120|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:41:52.968878|2018-05-31 23:41:52.968878
NCT01141907|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-05-25|2010-06-10|2010-06-11|Estimate|||||||2012-05-25|2012-05-28|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Nurse-Led Heart Failure Care Transition Intervention for African Americans: The Navigator Program|Nurse-Led Heart Failure Care Transition Intervention for African Americans|Completed||N/A|25|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 23:41:53.085453|2018-05-31 23:41:53.085453
NCT01141894|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2015-01-05|2010-06-10|2010-06-11|Estimate|||||||2015-01-05|2015-01-06|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|GDHT||Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral Fracture|Evaluation of Costs and Consequences of Alternative Strategies of Intraoperative Fluid and Pharmacological Optimization. A Randomized Clinical Trial|Terminated||N/A|150|Actual|Karolinska Institutet||2||slow recruitment|f||||t||||||||||2018-05-31 23:41:53.20794|2018-05-31 23:41:53.20794
NCT01141881|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-10-07|2010-06-10|2010-06-11|Estimate|||||||2010-10-07|2010-10-08|Estimate|May 2009||2009-05-31|September 2008|2008-09-30|March 2010|Actual|2010-03-31|January 2010|Anticipated|2010-01-31||Interventional|||Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema|Evaluation of the Role of Intravitreal Injection of TPA in Treatment of Refractory Diabetic Macular Edema|Terminated||N/A|||Mashhad University of Medical Sciences||1||occurrence of retinal hemorrhage , increase in macular edema of some patients in TPA group|f||||t||||||||||2018-05-31 23:41:53.313706|2018-05-31 23:41:53.313706
NCT01141868|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-05-16|2010-06-10|2010-06-11|Estimate|||||||2013-05-16|2013-05-17|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors|Evaluating an Internet-based Intervention for Insomnia in Breast Cancer Survivors|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||2||"The study never opened due to technical upgrades that were needed for the SHUTi computer~   system."|f||||f||||||||||2018-05-31 23:41:53.446611|2018-05-31 23:41:53.446611
NCT01141855|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2012-08-07|2010-06-10|2010-06-11|Estimate|||||||2012-08-07|2012-08-08|Estimate|May 2008||2008-05-31|April 2010|2010-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|STOP||Smoking Termination Opportunity for inPatients|Effectiveness of Inpatient Initiated Varenicline Tartrate for Smoking Cessation, for Smoking Related Illnesses.|Completed||Phase 2/Phase 3|392|Actual|The Queen Elizabeth Hospital||2|||f||||t||||||||||2018-05-31 23:41:53.567103|2018-05-31 23:41:53.567103
NCT01139307|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-05|||2016-02-19|2010-06-05|2010-06-08|Estimate|||||||2016-02-19|2016-02-23|Estimate|July 2009||2009-07-31|February 2016|2016-02-29||||August 2012|Actual|2012-08-31||Observational|||Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia|Development of Novel Therapeutics for AMKL|Completed|||10|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:42:32.404638|2018-05-31 23:42:32.404638
NCT01141842|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2013-05-06|2010-06-10|2010-06-11|Estimate|||||||2013-05-06|2013-05-07|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Early Detection of Lung Tumors by Sniffer Dogs - Evaluation of Sensitivity and Specificity|Prospective Clinical Study to Determine the Predictive Value of Sniffer Dogs to Identify Lung Cancer in the Exhalation of Patients With and Without Pulmonary Disease|Completed||Phase 1|230|Actual|Schillerhoehe Hospital||3|||f||||f||||||||||2018-05-31 23:41:53.697306|2018-05-31 23:41:53.697306
NCT01141829|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate||||January 2010|2010-01-31||||||||Observational|||NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)|NADPH Oxidase p22phox Polymorphisms and Oxidative Stress in Patients With Obstructive Sleep Apnea|Unknown status|Recruiting||||Sociedad Española de Neumología y Cirugía Torácica|||||f||||f||||||||||2018-05-31 23:41:53.845975|2018-05-31 23:41:53.845975
NCT01141816|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2018-04-02|2010-06-10|2010-06-11|Estimate|||||||2018-04-02|2018-04-03|Actual|January 2015||2015-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions|Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Renal Lesions: a Prospective, Blinded Study|Recruiting||N/A|30|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||||2018-05-31 23:41:54.015252|2018-05-31 23:41:54.015252
NCT01141803|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-07-19|2010-06-10|2010-06-11|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2008||2008-07-31|July 2016|2016-07-31|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Apple and Apple Pomace on Inflammation and Cholesterol Metabolism in Healthy Overweight|Isafruit: Nutrigenomics in Overweight|Completed||N/A|37|Actual|University of Copenhagen||3|||f||||f||||||||Yes||2018-05-31 23:41:54.144113|2018-05-31 23:41:54.144113
NCT01141790|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2010-06-10|2010-06-10|2010-06-11|Estimate|||||||2010-06-10|2010-06-11|Estimate||||June 2010|2010-06-30||||||||Interventional|||Analysis of Vital, Facial and Muscular Responses Front to Music or Message in Coma, Vegetative State or Sedated Patients|Analysis of Vital, Facial and Muscular Responses Front to Music or Message in Coma, Vegetative State or Sedated Patients|Completed||N/A|||University of Sao Paulo||1|||f||||t||||||||||2018-05-31 23:41:54.21692|2018-05-31 23:41:54.21692
NCT01141777|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-10|||2011-01-03|2010-06-10|2010-06-11|Estimate|||||||2011-01-03|2011-01-04|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Effects of Spirulina Platensis on Insulin Resistance in HIV-infected Patients|The Effects of Spirulina Platensis on Insulin Resistance in HIV-infected Patients|Completed||N/A|33|Actual|Yaounde Central Hospital||2|||f||||f||||||||||2018-05-31 23:41:54.317003|2018-05-31 23:41:54.317003
NCT01141764|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2014-11-20|2010-06-09|2010-06-10|Estimate|||||||2014-11-20|2014-11-21|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Cerebral Metabolic Changes Associated With Thalamic Stimulation|Cerebral Metabolic Changes Associated With Thalamic Stimulation|Terminated||Phase 3|4|Actual|The Hospital for Sick Children||1||Very slow and infrequent recruitment, availability of the imaging procedure at Adult Centre|f||||f||||||||||2018-05-31 23:41:54.408527|2018-05-31 23:41:54.408527
NCT01141751|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2014-07-11|2010-06-09|2010-06-10|Estimate|||||||2014-07-11|2014-07-14|Estimate|September 2005||2005-09-30|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|COMPARE||An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy|A Phase IV, Observational, Open-label, Multi-center Comparison Study of the Newly Developed and Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument With the Health-related QoL (MSQOL-54) Questionnaire in Subjects With Relapsing Forms of Multiple Sclerosis (RMS*) on Rebif® Therapy|Completed|||334|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:41:54.483745|2018-05-31 23:41:54.483745
NCT01141738|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-01-20|2010-06-09|2010-06-10|Estimate|||||||2015-01-20|2015-01-22|Estimate|April 2005||2005-04-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2009|Actual|2009-12-31||Interventional|CPSI||Problem-solving: A Stroke Caregiver Early Intervention|National Institute of Nursing Research #R01 NR09077-01: Problem-solving: A Stroke Caregiver Early Intervention|Unknown status|Active, not recruiting|N/A|362|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 23:41:54.537285|2018-05-31 23:41:54.537285
NCT01141725|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2017-03-07||2017-07-20|2010-06-09|2010-06-10|Estimate|2017-07-20|2017-08-18|Actual||||2017-07-20|2017-08-18|Actual|September 2010||2010-09-30|July 2017|2017-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS|Safety and Clinical Activity of Treanda® (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Age >= 50 With Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome|Completed||Phase 1/Phase 2|39|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 23:41:54.624701|2018-05-31 23:41:54.624701
NCT01141712|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2016-08-10||2017-09-27|2010-06-09|2010-06-10|Estimate|2017-02-07|2017-03-28|Actual||||2017-09-27|2017-10-27|Actual|April 2010||2010-04-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31||Interventional|||Autologous Transplant in HIV Patients (BMT CTN 0803)|High Dose Chemotherapy With Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN #0803)|Completed||Phase 2|43|Actual|Medical College of Wisconsin||1|||f||||t||||||||Yes|Findings will be published in a manuscript|2018-05-31 23:41:54.909046|2018-05-31 23:41:54.909046
NCT01141699|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-09-03|2010-06-09|2010-06-10|Estimate|||||||2010-09-03|2010-09-06|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||A Study of Compliant Behaviors and Associated Factors of Women Breast Screening|A Study of Compliant Behaviors and Associated Factors of Women Breast Screening in the Shuang Ho Region of Taipei City.|Completed|||191|Actual|Taipei Medical University WanFang Hospital|||1||f||||f||||||||||2018-05-31 23:41:55.319993|2018-05-31 23:41:55.319993
NCT01141686|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-08|2010-06-08|2010-06-10|Estimate|||||||2010-06-08|2010-06-10|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers|Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers|Completed|||90|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-05-31 23:41:55.362422|2018-05-31 23:41:55.362422
NCT01141673|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2011-04-22|2010-06-09|2010-06-10|Estimate|||||||2011-04-22|2011-04-26|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|||||Observational|||Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia|Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia|Unknown status|Recruiting||100|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-05-31 23:41:55.419044|2018-05-31 23:41:55.419044
NCT01141647|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|2016-06-28||2017-04-04|2010-06-08|2010-06-10|Estimate|2017-03-17|2017-03-31|Actual||||2017-04-04|2017-05-11|Actual|August 2011||2011-08-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PrOMOTE||SCI-VIP: Predictive Outcome Model Over Time for Employment (PrOMOTE)|Predictive Outcome Model Over Time for Employment (PROMOTE)|Completed||N/A|1047|Actual|VA Office of Research and Development|Majority of sample is male.|1|||f||||f||||||||No|Data will only be presented de-identified.|2018-05-31 23:41:55.705289|2018-05-31 23:41:55.705289
NCT01141634|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2014-03-06|2010-06-08|2010-06-10|Estimate|||||||2014-03-06|2014-03-07|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Pilot Trial of Homeopathic Treatment for Attention Deficit Hyperactivity Disorder|A Pilot Trial of Homeopathic Treatment for Attention Deficit Hyperactivity Disorder in Children and Adolescents|Completed||Phase 2|36|Actual|University of Toronto|||||f||||t||||||||||2018-05-31 23:41:57.140944|2018-05-31 23:41:57.140944
NCT01141621|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2013-05-13|2010-06-08|2010-06-10|Estimate|||||||2013-05-13|2013-05-14|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||The Dallas Hereditary Spherocytosis Cohort Study|The Dallas Hereditary Spherocytosis Cohort Study|Terminated|||55|Actual|University of Texas Southwestern Medical Center||||Insufficient staff to continue pursuing project|f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:41:57.199672|2018-05-31 23:41:57.199672
NCT01141608|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2015-12-09|2010-06-08|2010-06-10|Estimate|||||||2015-12-09|2015-12-11|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|STRIDE||Exercise as a Treatment for Substance Use Disorders Protocol|NIDA CTN Protocol 0037: Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)|Completed||N/A|302|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 23:41:57.287642|2018-05-31 23:41:57.287642
NCT01141595|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|2013-01-15||2014-02-28|2010-06-08|2010-06-10|Estimate|2014-01-25|2014-02-24|Estimate||||2014-02-28|2014-04-01|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Tetrahydrobiopterin Treatment in Children With Idiopathic Cognitive Developmental Disorders|Biomarkers of Central Nervous System Tetrahydrobiopterin Concentration and Response to Tetrahydrobiopterin Supplementation in Children With Idiopathic Cognitive Developmental Disorders|Completed||N/A|10|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 23:41:57.382243|2018-05-31 23:41:57.382243
NCT01141569|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2016-03-14||2017-01-19|2010-06-09|2010-06-10|Estimate|2017-01-19|2017-03-10|Actual||||2017-01-19|2017-03-10|Actual|June 2010||2010-06-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|May 2012|Actual|2012-05-31||Interventional|||A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy|A Phase 2 Study of RO4929097 (IND 109291) in Patients With Advanced Renal Cell Carcinoma (RCC, NOS 10038415) That Has Progressed After VEGF/VEGFR Directed Therapy|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:41:57.645119|2018-05-31 23:41:57.645119
NCT01141556|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2012-10-24|2010-06-09|2010-06-10|Estimate|||||||2012-10-24|2012-10-25|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery|Effects of High-dose Intravenous Selenium (Selenase®) on the Systemic Inflammatory Response Syndrome and Related Organ Dysfunction|Completed||Phase 3|410|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 23:41:57.959206|2018-05-31 23:41:57.959206
NCT01141543|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-07-16|2010-06-09|2010-06-10|Estimate|||||||2014-07-16|2014-07-18|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection|Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients With AML Undergoing Allografting: Assessment of Feasibility and Efficacy|Completed|||12|Actual|University Health Network, Toronto|||4||f||||t||||||||||2018-05-31 23:41:58.073517|2018-05-31 23:41:58.073517
NCT01141530|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-12-03|2010-06-09|2010-06-10|Estimate|||||||2013-12-03|2013-12-05|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Deep Sequencing of the Breast Cancer Transcriptome|Deep Sequencing of the Breast Cancer Transcriptome|Withdrawn|||0|Actual|University of Arkansas|||1|Study withdrawn due to inability to enroll subjects.|f||||t||||||Samples With DNA|"~     The informed consent process for biospecimen collection we expect to use in this research has~     already been obtained by the UAMS Tissue Bank personnel as a part of the UARK 2005-06~     protocol. Tissue is collected during biopsies or mastectomies after pathologist approval. We~     will sequence small non-coding molecules (microRNA), messenger RNA, chromatin~     immunoprecipated and bisulfite treated DNA.~   "|||2018-05-31 23:41:58.176193|2018-05-31 23:41:58.176193
NCT01141517|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2011-06-21|2010-06-09|2010-06-10|Estimate|||||||2011-06-21|2011-06-23|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|NOT||Predictors of Teen Smoking-cessation|Predictors of Smoking Cessation Among Teen Smokers|Unknown status|Recruiting||200|Anticipated|Nationwide Children's Hospital|||||f||||f||||||||||2018-05-31 23:41:58.239094|2018-05-31 23:41:58.239094
NCT01141504|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-01-09|2010-06-09|2010-06-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance|Effect of Oral ATP on Human Muscle Performance|Completed||Phase 1|16|Actual|Metabolic Technologies Inc.||4|||f||||f||||||||||2018-05-31 23:41:58.32026|2018-05-31 23:41:58.32026
NCT01141491|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2016-10-14||2017-03-14|2010-06-09|2010-06-10|Estimate|2016-10-14|2016-12-07|Estimate||||2017-03-14|2017-04-12|Actual|June 2010||2010-06-30|December 2016|2016-12-31|March 10, 2017|Actual|2017-03-10|September 2013|Actual|2013-09-30||Interventional||Adults (male or female), 16 years of age and older who have metastatic sarcoma at initial presentation or who had relapsed disease and are rendered disease-free following surgical metastectomy|Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free|A Randomized, Multicenter, Double-Blind, Phase II Trial of a KLH Conjugated Trivalent Ganglioside Vaccine Containing GM2, GD2 Lactone, and GD3 Lactone With the Immunological Adjuvant OPT-821 Versus OPT-821 Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free|Completed||Phase 2|136|Actual|MabVax Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 23:41:58.401768|2018-05-31 23:41:58.401768
NCT01141309|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2017-08-23|2010-06-09|2010-06-10|Estimate|||||||2017-08-23|2017-08-24|Actual|June 2010|Actual|2010-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer|Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer|Active, not recruiting||Phase 2|41|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:42:00.615342|2018-05-31 23:42:00.615342
NCT01141478|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2016-11-02|2010-06-09|2010-06-10|Estimate|||||||2016-11-02|2016-11-04|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria|Randomized Controlled Trial of Proton Beam Radiotherapy + Sorafenib vs. Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria|Recruiting||N/A|220|Anticipated|Loma Linda University||2|||f||||f||||||||||2018-05-31 23:41:58.74384|2018-05-31 23:41:58.74384
NCT01141465|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 2001||2001-01-31|June 2010|2010-06-30|February 2010|Actual|2010-02-28|June 2007|Actual|2007-06-30||Observational|||Real-world Effectiveness of Combination Therapy in Asthma|A Retrospective Evaluation of the Effectiveness of Fixed-dose Combination Inhaled Corticosteroid /. Long-acting Beta Agonist (ICS/LABA) Therapy in the Management of Asthma in a Representative UK Primary Care Population|Completed|||815377|Actual|Research in Real-Life Ltd|||6||f||||t||||||||||2018-05-31 23:41:58.822191|2018-05-31 23:41:58.822191
NCT01141452|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2011-03-07|2010-06-09|2010-06-10|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2001||2001-01-31|March 2011|2011-03-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Observational|QvarCOPD||Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD|Retrospective, Real-life Evaluation of the Effectiveness, Cost-effectiveness and Direct Healthcare Costs of Qvar Pressurised Metered-dose Inhaler (pMDI) Compared With Beclometasone Dipropionate pMDI and Fluticasone pMDI in the Management of Chronic Obstructive Pulmonary Disease (COPD) in a Representative UK Primary Care Patient Population|Completed|||815377|Actual|Research in Real-Life Ltd|||6||f||||t||||||||||2018-05-31 23:41:59.004933|2018-05-31 23:41:59.004933
NCT01141439|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-03-13|2010-06-09|2010-06-10|Estimate|||||||2013-03-13|2013-03-14|Estimate|January 2001||2001-01-31|March 2013|2013-03-31|July 2010|Actual|2010-07-31|June 2007|Actual|2007-06-30||Observational|QvarAsthma||Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management|A Retrospective Evaluation of the Effectiveness and Cost-effectiveness of HFA-BDP MDI (Qvar®) Compared With CFC-BDP MDI and FP MDI Used in the Management of Asthma in a Representative UK UK Primary Care Population|Completed|||815377|Actual|Research in Real-Life Ltd|||6||f||||t||||||||||2018-05-31 23:41:59.196559|2018-05-31 23:41:59.196559
NCT01141426|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2015-12-18|2010-06-09|2010-06-10|Estimate|||||||2015-12-18|2015-12-21|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Halifax Treatment Refractory Depression Trial|Halifax Treatment Refractory Depression Trial: A Randomized Controlled Trial of Intensive Short-Term Dynamic Psychotherapy (ISTDP) Compared to Secondary Care Treatment as Usual|Unknown status|Active, not recruiting|N/A|60|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 23:41:59.318028|2018-05-31 23:41:59.318028
NCT01141413|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-04-03|2010-06-09|2010-06-10|Estimate|||||||2012-04-03|2012-04-04|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Dose Escalation With Remicade® and Orencia®|Comparison of Dosing and Costs Between Rheumatoid Arthritis Patients Treated With Remicade® Versus Orencia®|Completed|||5451|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 23:41:59.429489|2018-05-31 23:41:59.429489
NCT01141400|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-11-07|2010-06-09|2010-06-10|Estimate|||||||2013-11-07|2013-11-08|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use|The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use|Completed|||48865|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||1||f||||f||||||||||2018-05-31 23:41:59.51383|2018-05-31 23:41:59.51383
NCT01141387|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-11-07|2010-06-09|2010-06-10|Estimate|||||||2013-11-07|2013-11-08|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|COMET||Outcomes in MEasurement-Based Treatment|Clinical Outcomes in MEasurement-Based Treatment (COMET)|Completed|||914|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||2||f||||f||||||||||2018-05-31 23:41:59.725024|2018-05-31 23:41:59.725024
NCT01141374|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2011-08-20||2013-01-17|2010-06-09|2010-06-10|Estimate|2012-01-19|2012-01-23|Estimate||||2013-01-17|2013-01-24|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Application of Auriculotherapy on Nursing Professional Stress Levels|Analysis of the Application of Different Forms in Auriculotherapy on Nursing Professional Stress Levels|Completed||Phase 2|75|Actual|University of Sao Paulo|"Study limitations: small sample size~Bias procedure with auricular seeds: the non-participation of the subject of research in self-massage of the points"|3|||f||||f||||||||||2018-05-31 23:41:59.875335|2018-05-31 23:41:59.875335
NCT01141361|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2013-03-15|2010-06-09|2010-06-10|Estimate|||||||2013-03-15|2013-03-18|Estimate|July 2009||2009-07-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|POST-GPS||Feasibility of Home-based Measurement of Walking Capacity Using Global Positioning System in Peripheral Artery Disease|Feasibility of Home-based Measurement of Walking Capacity Using Global Positioning System in Patients With Peripheral Arterial Disease|Completed|||251|Actual|University Hospital, Angers|||1||f||||t||||||||||2018-05-31 23:42:00.234842|2018-05-31 23:42:00.234842
NCT01141348|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|Weight-Wise||The Weight-Wise Weight Loss Translation Study|Intensive Behavioral Weight Management in Public Health Settings: Weight-Wise|Completed||N/A|189|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 23:42:00.32444|2018-05-31 23:42:00.32444
NCT01141335|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2016-11-20|2010-06-09|2010-06-10|Estimate|||||||2016-11-20|2016-11-22|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2010|Actual|2010-09-30||Interventional|||Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair|Lichtenstein's Repair of Inguinal Hernia With Polypropylene Mesh Versus Infinit® PTFE Mesh, a Prospective Randomized, Double-blind, Controlled Trial|Completed||Phase 4|70|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 23:42:00.413259|2018-05-31 23:42:00.413259
NCT01141322|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-06-08|2010-06-08|2010-06-10|Estimate|||||||2010-06-08|2010-06-10|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|July 2010|Anticipated|2010-07-31|April 2010|Anticipated|2010-04-30||Interventional|DILI||Cholestatic Drug-induced Liver Injury|Cholestatic Drug-induced Liver Injury: Correlation With Genotypes of UGT1A1 and 1A7, and Treatment Effect of Ursodeoxycholic Acid|Unknown status|Recruiting|Phase 4|180|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 23:42:00.531956|2018-05-31 23:42:00.531956
NCT01141296|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2014-03-31|2010-06-09|2010-06-10|Estimate|||||||2014-03-31|2014-04-02|Estimate|April 2011||2011-04-30|March 2014|2014-03-31||||||||Interventional|||Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis|Randomized Controlled Study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis|Withdrawn||Phase 2|0|Actual|University of Miami||2||Lack of funding|f||||f||||||||||2018-05-31 23:42:00.685157|2018-05-31 23:42:00.685157
NCT01141283|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2010-07-28||2012-08-27|2010-06-09|2010-06-10|Estimate|2010-08-24|2010-09-21|Estimate||||2012-08-27|2012-09-03|Estimate|April 2003||2003-04-30|August 2012|2012-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase|Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Mod to Sev OA Pain of Hip or Knee: A 6-Month Open-label Extension Phase|Completed||Phase 3|290|Actual|Purdue Pharma LP||1|||f||||f||||||||||2018-05-31 23:42:00.766356|2018-05-31 23:42:00.766356
NCT01141270|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-08-03|2010-06-09|2010-06-10|Estimate|||||||2010-08-03|2010-08-04|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|August 2009|Actual|2009-08-31||Interventional|||Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application|Comparative Pharmacokinetics of AFOLIA and Gonal-f® After Single Subcutaneous Application. A Randomised, Open Label, Cross Over Study|Completed||Phase 1|32|Actual|Polymun Scientific GmbH||2|||f||||f||||||||||2018-05-31 23:42:01.083476|2018-05-31 23:42:01.083476
NCT01141257|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2011-10-18|2010-06-09|2010-06-10|Estimate|||||||2011-10-18|2011-10-19|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug|A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Angiocal® (PRS-050-PEG40) in Patients With Solid Tumors|Completed||Phase 1|26|Actual|Pieris Pharmaceuticals GmbH||1|||f||||f||||||||||2018-05-31 23:42:01.149602|2018-05-31 23:42:01.149602
NCT01141244|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2014-04-09|2010-06-09|2010-06-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|June 2010||2010-06-30|December 2013|2013-12-31||||November 2013|Actual|2013-11-30||Interventional|||Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase 1 Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors|Completed||Phase 1|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:42:01.240364|2018-05-31 23:42:01.240364
NCT01141231|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2018-02-13|2010-06-09|2010-06-10|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2012|Actual|2012-11-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer|A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer|Active, not recruiting||Phase 3|240|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 23:42:01.361681|2018-05-31 23:42:01.361681
NCT01141218|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2017-04-21|2010-06-09|2010-06-10|Estimate|||||||2017-04-21|2017-04-25|Actual|July 2009||2009-07-31|April 2017|2017-04-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|||Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes|Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes|Terminated|||88|Actual|Vanderbilt-Ingram Cancer Center|||1|slow accrual|f||||t||||||||||2018-05-31 23:42:01.444296|2018-05-31 23:42:01.444296
NCT01141205|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2012-06-13||2013-08-02|2010-06-09|2010-06-10|Estimate|2012-09-13|2012-10-15|Estimate||||2013-08-02|2013-08-08|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|HIV-BIS||HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease|Phase I Study: HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease|Completed||Phase 1|18|Actual|Statens Serum Institut||2|||f||||f||||||||||2018-05-31 23:42:01.542321|2018-05-31 23:42:01.542321
NCT01141192|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|AVIS||The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults|The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults|Completed||N/A|48|Actual|Augusta University||2|||f||||f||||||||||2018-05-31 23:42:01.918282|2018-05-31 23:42:01.918282
NCT01141179|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-11-01|2010-06-09|2010-06-10|Estimate|||||||2013-11-01|2013-11-04|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847|The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847|Completed||Phase 1|25|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 23:42:01.992042|2018-05-31 23:42:01.992042
NCT01141166|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 2009||2009-01-31|June 2010|2010-06-30||||April 2011|Anticipated|2011-04-30||Interventional|||Octabaix Intervention Study|A Randomised Controlled Trial on Falls and Malnutrition Prevention in the Community in 85 Year Old Subjects|Unknown status|Active, not recruiting|Phase 2/Phase 3|328|Anticipated|Jordi Gol i Gurina Foundation||1|||f||||||||||||||2018-05-31 23:42:02.052668|2018-05-31 23:42:02.052668
NCT01141153|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2015-02-23|2010-06-09|2010-06-10|Estimate|||||||2015-02-23|2015-02-24|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|MUSICA-2||Anticoagulation in Stent Intervention|Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation|Unknown status|Active, not recruiting|Phase 4|304|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 23:42:02.120618|2018-05-31 23:42:02.120618
NCT01141140|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2012-02-13|2010-06-09|2010-06-10|Estimate|||||||2012-02-13|2012-02-14|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|COLLATION||(Mis)Perceptions About Healthy Eating: Effects on Food Intake and Appetite in Men and Women|(Mis)Perceptions About Healthy Eating: Effects on Food Intake and Appetite in Men and Women|Completed||N/A|355|Actual|Laval University||8|||f||||f||||||||||2018-05-31 23:42:02.214185|2018-05-31 23:42:02.214185
NCT01141127|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-07-21|2010-06-09|2010-06-10|Estimate|||||||2014-07-21|2014-07-23|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Exacyl||Tranexamic Acid (TXA) in Pediatric Cardiac Surgery|Tranexamic Acid (TXA) During Pediatric Cardiac Surgery: A Prospective Randomised Study Comparing Two Dosing Regimens|Completed||Phase 2|18|Actual|Centre Chirurgical Marie Lannelongue||2|||f||||f||||||||||2018-05-31 23:42:02.294214|2018-05-31 23:42:02.294214
NCT01141114|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2017-04-17|2010-06-09|2010-06-10|Estimate|||||||2017-04-17|2017-04-18|Actual|September 2008||2008-09-30|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Patient Navigation to Promote Colon Cancer Screening|Randomized Controlled Trial of Patient Navigation to Increase Colorectal Cancer Screening Rates Among Community Health Center Patients|Completed||N/A|465|Actual|Cambridge Health Alliance||2|||f||||f||||||||||2018-05-31 23:42:02.36916|2018-05-31 23:42:02.36916
NCT01141101|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2016-05-01|2010-06-09|2010-06-10|Estimate|||||||2016-05-01|2016-05-03|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus|Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus|Completed|||100|Actual|Boston Medical Center|||2||f||||f||||||Samples Without DNA|"~     MRSA isolates from the nose, axilla or perineum from mothers, infants and house hold contacts~     and caregivers enrolled in the study will be retained only for the duration of the study for~     use in molecular analysis for the purpose of this study.~   "|||2018-05-31 23:42:02.465257|2018-05-31 23:42:02.465257
NCT01141088|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-12-15|2010-06-09|2010-06-10|Estimate|||||||2017-12-15|2017-12-19|Actual|April 1, 2016|Actual|2016-04-01|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Two Bilateral Metal Stenting in Hilar Malignancy|Clinical Outcomes of Endoscopic Bilateral Stent-in-stent Placement Versus Side-by-side Method With Newly Designed Metallic Stent for Malignant Hilar Biliary|Recruiting||N/A|80|Anticipated|Soon Chun Hyang University||2|||f||||f||||||||No||2018-05-31 23:42:02.568118|2018-05-31 23:42:02.568118
NCT01141075|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2018-01-16|2010-06-08|2010-06-10|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2010||2010-06-30|January 2018|2018-01-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Ataluren for Nonsense Mutation Methylmalonic Acidemia|A Phase 2 Study of Ataluren (PTC124®) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia|Terminated||Phase 2|11|Actual|PTC Therapeutics||1|||f||||f||||||||||2018-05-31 23:42:02.720016|2018-05-31 23:42:02.720016
NCT01141062|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2012-12-03|2010-06-08|2010-06-10|Estimate|||||||2012-12-03|2012-12-04|Estimate|June 2010||2010-06-30|December 2012|2012-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|HIFU||Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Therapeutic MRI Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Completed||Phase 3|15|Actual|Philips Healthcare||1|||f||||f||||||||||2018-05-31 23:42:02.809561|2018-05-31 23:42:02.809561
NCT01141049|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2014-01-15|2010-06-09|2010-06-10|Estimate|||||||2014-01-15|2014-01-16|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GAINS||Gabapentin for Abstinence Initiation in Alcohol Dependence|Gabapentin for Abstinence Initiation in Alcohol Dependence|Completed||Phase 2/Phase 3|40|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 23:42:02.931183|2018-05-31 23:42:02.931183
NCT01141036|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients|Propofol Versus Midazolam for Upper Endoscopy in Cirrhotic Patients|Completed||N/A|60|Anticipated|Ziv Hospital||2|||f||||t||||||||||2018-05-31 23:42:03.08313|2018-05-31 23:42:03.08313
NCT01141023|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-08-07|2010-06-08|2010-06-10|Estimate|||||||2017-08-07|2017-08-08|Actual|June 2010||2010-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PPMI||Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression|The Parkinson's Progression Markers Initiative (PPMI)|Recruiting||Phase 2|680|Anticipated|Michael J. Fox Foundation for Parkinson's Research||1|||f||||t||||||||||2018-05-31 23:42:03.222691|2018-05-31 23:42:03.222691
NCT01141010|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-08-24|2010-06-09|2010-06-10|Estimate|||||||2010-08-24|2010-08-25|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|PIMAC||Effect of Psychological Interventions on Maternal Outcomes Undergoing Cesarean|Effect of Perioperative Psychological Interventions on Maternal Outcomes Undergoing Cesarean Delivery|Completed||N/A|365|Actual|Nanjing Medical University||5|||f||||t||||||||||2018-05-31 23:42:03.465231|2018-05-31 23:42:03.465231
NCT01140997|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2013-01-31|2010-06-09|2010-06-10|Estimate|||||||2013-01-31|2013-02-04|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|March 2012|Actual|2012-03-31|January 2011|Actual|2011-01-31||Interventional|PEGIFN||Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C|A Multi-center, Randomized, Open-label and Positive Controlled Phase II Clinical Trial to Assess Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C.|Completed||Phase 2|211|Actual|Xiamen Amoytop Biotech Co., Ltd.||4|||f||||t||||||||||2018-05-31 23:42:03.675118|2018-05-31 23:42:03.675118
NCT01140984|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2015-04-19|2010-06-09|2010-06-10|Estimate|||||||2015-04-19|2015-04-21|Estimate|September 2010||2010-09-30|February 2011|2011-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)|An Investigator Initiated Open Study to Evaluate the Efficacy and Safety of Intra Arterial Infusion for Treatment of Steroid Resistant Acute Hepatic Graft Versus Host Disease (AGVHD)|Terminated||N/A|2|Actual|Hadassah Medical Organization||1||technical issues|f||||f||||||||||2018-05-31 23:42:03.908221|2018-05-31 23:42:03.908221
NCT01140971|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|January 2009|Actual|2009-01-31|March 2008|Actual|2008-03-31||Interventional|||Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor|TRANSCERVICAL FOLEY CATHETER (FOLEY) Versus INTRAVAGINAL MISOPROSTOL FOR CERVICAL RIPENING AND INDUCTION OF LABOR: A RANDOMIZED CLINICAL TRIAL.|Completed||N/A|180|Actual|Municipal Hospital Vila Nova Cachoeirinha||2|||f||||f||||||||||2018-05-31 23:42:04.027896|2018-05-31 23:42:04.027896
NCT01140958|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|November 2010|Anticipated|2010-11-30|January 2010|Actual|2010-01-31||Observational|||A Retrospective Pharmacoeconomic Study of Lung Cancer|A Retrospective Pharmacoeconomic Study of Lung Cancer in Wan-Fang Hospital|Unknown status|Active, not recruiting||91|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:42:04.120493|2018-05-31 23:42:04.120493
NCT01140945|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2010-06-09|2010-06-09|2010-06-10|Estimate|||||||2010-06-09|2010-06-10|Estimate||||January 2010|2010-01-31||||||||Observational|||Association Study Between Periodontal Disease and Male Infertility|Periodontal Status of Males Attending in Vitro Fertilization Clinic|Completed|||||Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 23:42:04.171649|2018-05-31 23:42:04.171649
NCT01140932|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-12-07|2010-06-09|2010-06-10|Estimate|||||||2010-12-07|2010-12-08|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Electroretinogram in Healthy and Glucose Intolerant Young Men|Electroretinographic Changes in Healthy Young Men Before and After Induction of Glucose Intolerance by Glucocorticoids Treatment, Hyperphagia and Lack of Exercise|Completed||N/A|10|Actual|Glostrup University Hospital, Copenhagen||1|||f||||t||||||||||2018-05-31 23:42:04.271703|2018-05-31 23:42:04.271703
NCT01140919|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2015-07-22|2010-06-08|2010-06-10|Estimate|||||||2015-07-22|2015-07-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:42:04.39102|2018-05-31 23:42:04.39102
NCT01140906|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|2013-10-28||2013-12-23|2010-06-09|2010-06-10|Estimate|2013-12-23|2014-02-11|Estimate||||2013-12-23|2014-02-11|Estimate|May 2010||2010-05-31|December 2013|2013-12-31||||September 2011|Actual|2011-09-30||Interventional|||Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults|A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Lu AA21004 (15 and 20 mg/Day) in the Acute Treatment of Adult Patients With Major Depressive Disorder|Completed||Phase 3|607|Actual|H. Lundbeck A/S||4|||f||||f||||||||||2018-05-31 23:42:04.458828|2018-05-31 23:42:04.458828
NCT01140893|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2016-08-22|2010-06-09|2010-06-10|Estimate|||||||2016-08-22|2016-08-23|Estimate|November 2010||2010-11-30|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|EXEPUMP||Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes|Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.|Recruiting||Phase 2/Phase 3|110|Anticipated|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 23:42:05.203776|2018-05-31 23:42:05.203776
NCT01140880|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|2014-05-27||2015-03-18|2010-06-09|2010-06-10|Estimate|2014-06-27|2014-07-02|Estimate||||2015-03-18|2015-04-07|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||170 participants enrolled. 30 participants in the Yoked Contingency Management arm were involved in a protocol violation that rendered their data unusable. An additional 14 participants from each arm were either withdrawn, died (n = 1, not study related), or were lost to follow-up. Thus, baseline N = 140 (70/70), and follow-up N = 112 (56/56).|Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men|Optimizing Access to Non-occupational Post Exposure Prophylaxis for HIV Using Contingency Management in Stimulant-Using Men Who Have Sex With Men|Completed||Phase 2|170|Actual|Friends Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 23:42:05.354534|2018-05-31 23:42:05.354534
NCT01140867|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2011-08-05||2011-09-08|2010-06-08|2010-06-10|Estimate|2011-08-05|2011-09-08|Estimate||||2011-09-08|2011-09-12|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Interventional|||Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy|A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy|Completed||Phase 4|121|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 23:42:06.060994|2018-05-31 23:42:06.060994
NCT01140854|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-06-02|2010-06-09|2010-06-10|Estimate|||||||2015-06-02|2015-06-04|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Observational|HTN||Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery|Cognitive Dysfunction in Hypertensive Patients Having Spine Surgery|Completed|||179|Actual|Columbia University|||2||f||||f||||||||||2018-05-31 23:42:06.31735|2018-05-31 23:42:06.31735
NCT01140841|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2011-08-30|2010-06-09|2010-06-10|Estimate|||||||2011-08-30|2011-08-31|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|Fipamezole||A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa|A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose-Escalation Study of Safety and Tolerability of Oromucosal Fipamezole ODT in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa|Completed|||40|Actual|Valeant Pharmaceuticals International, Inc.|||2||f||||t||||||||||2018-05-31 23:42:06.393307|2018-05-31 23:42:06.393307
NCT01140828|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2015-08-21|2010-06-09|2010-06-10|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|October 2012|Actual|2012-10-31||Interventional|||A Study of Rabeprazole for Prevention of Non Steroidal Anti-inflammatory Drug -Associated Gastroduodenal Injury|A Double-blind Randomized Placebo Controlled Trial of Rabeprazole for Prevention of NSAID-associated Dyspepsia and Gastroduodenal Injury|Completed||Phase 3|112|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:42:06.467474|2018-05-31 23:42:06.467474
NCT01140815|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2013-11-25||2014-07-10|2010-06-08|2010-06-10|Estimate|2014-07-10|2014-08-04|Estimate||||2014-07-10|2014-08-04|Estimate|September 2007||2007-09-30|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Deuce|Preoperative osteoarthritis of the knee in medial and patellofemoral joints. BMI less than or equal to 35, Age less than or equal to 65. No previous knee surgery.|Functional Performance of the Journey Deuce Bicompartmental Versus the Genesis II Total Knee System|A Prospective, Single-Center, Randomized Study Comparing the Functional Performance of the Journey Deuce Bicompartmental With the Genesis II Total Knee System|Completed||Phase 4|50|Actual|Anderson Orthopaedic Research Institute||2|||f||||t||||||||||2018-05-31 23:42:06.591842|2018-05-31 23:42:06.591842
NCT01140802|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-04-23|2010-06-09|2010-06-10|Estimate|||||||2017-04-23|2017-04-25|Actual|March 2010|Actual|2010-03-31|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Gut Microbiota in the Healthy Population, Inflammatory Bowel Disease Patients, and Their Relatives|A Study of the Gut Microbiota in the Healthy Population, Patients With Inflammatory Bowel Disease and Their Relatives (IBD Microbe Study|Active, not recruiting|||72|Anticipated|Chinese University of Hong Kong|||3||f||||t||||||Samples With DNA|"~     Serum DNA will be collected and stored only if patients have provided consent separately. All~     serum DNA blood samples will be anonymised. Genetic results will not be made available to~     individual patients in a future date as there is no evidence to support genetic testing for~     risk prediction in routine practice, but these large scale genetic results will be useful to~     identify relevant future therapeutic targets for treatment of IBD. 10 ml of blood will be~     collected in EDTA tubes and stored at minus 80 degrees C, These samples will be transported~     to China for analysis at a later date.~   "|No||2018-05-31 23:42:06.943398|2018-05-31 23:42:06.943398
NCT01140620|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-11-07|2010-06-08|2010-06-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|Schiz_2||Effects of Ketamine and Risperidone on Cognition|Effects of NMDA Receptor Antagonism on Cognitive Processes in Healthy Volunteers and Its Reversal by a Dopamine Antagonist: Comparison to Patients With Schizophrenia|Completed||Phase 4|87|Actual|University of Manchester||5|||f||||f||||||||No||2018-05-31 23:42:08.719058|2018-05-31 23:42:08.719058
NCT01140607|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-07-20|2010-06-08|2010-06-09|Estimate|||||||2015-07-20|2015-07-21|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment|Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment|Completed||Phase 1|56|Actual|Sanofi||5|||f||||f||||||||||2018-05-31 23:42:08.829345|2018-05-31 23:42:08.829345
NCT01140789|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-04-23|2010-06-09|2010-06-10|Estimate|||||||2017-04-23|2017-04-25|Actual|April 2010|Actual|2010-04-30|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Chinese Patients With Inflammatory Bowel Disease|Genome Wide Association (GWA) Study in Chinese Patients With Inflammatory Bowel Disease|Recruiting|||3600|Anticipated|Chinese University of Hong Kong|||3||f||||t||||||Samples With DNA|"~     Blood~        1. Up to 50ml of blood sample will be collected and stored at -80°C.~        2. Some blood samples will be transported to Wuhan University for DNA extraction and~          genetic analysis. Some will be used for targeted gene capture, NGS and validation in~          Hong Kong. Some will be sent to Germany for transethnic response mapping. Some will be~          transported to the UK and DNA will be extracted and genetic analysis will be performed~          in the UK.~           Stool~        3. Stool samples will be collected and stored at -80°C. Some will be analysed with PCR for~          norovirus and faecal calprotectin in Hong Kong. Some will be sent to Germany for~          transethnic response mapping.Others will be stored for future analysis.~           Biopsy~        4. 5 biopsies from sigmoid will be collected, snap frozen and stored at -80°C, 1 routine~          biopsy will also be collected for histology. Some will be sent to Germany for analysis.~   "|No||2018-05-31 23:42:07.014281|2018-05-31 23:42:07.014281
NCT01140776|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2011-06-06|2010-06-08|2010-06-09|Estimate|||||||2011-06-06|2011-06-07|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy|OSNA Neoadjuvant Feasibility Study in Breast Cancer Patients|Terminated|||100|Anticipated|Sysmex America, Inc.|||1||f||||t||||||Samples With DNA|"~     Samples of the tissue homogenate will be retained and may be used for for further testing.~   "|||2018-05-31 23:42:07.191619|2018-05-31 23:42:07.191619
NCT01140763|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-08-27|2010-06-08|2010-06-09|Estimate|||||||2010-08-27|2010-08-30|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Observational|||Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer|Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer|Unknown status|Recruiting||75|Anticipated|Sysmex America, Inc.|||1||f||||t||||||||||2018-05-31 23:42:07.265524|2018-05-31 23:42:07.265524
NCT01140750|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|March 2008|Actual|2008-03-31|||||Observational|||Variability Analysis as a Predictor of Liberation From Mechanical Ventilation|Variability Analysis as a Predictor of Liberation From Mechanical Ventilation in Patients Admitted to the Respiratory Special Care Unit (ReSCU)|Completed|||30|Anticipated|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 23:42:07.361071|2018-05-31 23:42:07.361071
NCT01140737|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-10-04|2010-06-08|2010-06-09|Estimate|||||||2017-10-04|2017-10-05|Actual|August 2010||2010-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2016|Actual|2016-06-30||Interventional|Axi-STS||A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas|A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas|Active, not recruiting||Phase 2|145|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 23:42:07.44635|2018-05-31 23:42:07.44635
NCT01140724|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-12-18|2010-06-08|2010-06-09|Estimate|||||||2017-12-18|2017-12-20|Actual|April 2008||2008-04-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Personalizing Perioperative Analgesia in Children|Predicting Perioperative Opioid Adverse Effects and Personalizing Analgesia in Children|Active, not recruiting|||1200|Anticipated|Indiana University|||||f||||f||||||Samples With DNA|"~     DNA from blood is obtained and analyzed for genetic varaiations~   "|No||2018-05-31 23:42:07.584761|2018-05-31 23:42:07.584761
NCT01140711|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2018-02-04|2010-06-08|2010-06-09|Estimate|||||||2018-02-04|2018-02-06|Actual|January 2011||2011-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|May 2015|Actual|2015-05-31||Interventional|||Functional MRI Evaluation of Brain Response to Visual Food Stimulation in Morbidly Obese Patients Before and After Bariatric Surgery||Completed||N/A|30|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:42:07.689906|2018-05-31 23:42:07.689906
NCT01140698|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|July 2010||2010-07-31|June 2010|2010-06-30||||||||Observational|||Amino Acid Profile in the Fetus and the Neonate||Unknown status|Not yet recruiting||180|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 23:42:07.852939|2018-05-31 23:42:07.852939
NCT01140685|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|December 2009||2009-12-31|March 2010|2010-03-31||||September 2010|Anticipated|2010-09-30||Observational|||Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air||Unknown status|Active, not recruiting||70|Actual|Tel-Aviv Sourasky Medical Center|||||f||||f||||||Samples Without DNA|"~     induced sputum, exhaled CO levels~   "|||2018-05-31 23:42:08.014771|2018-05-31 23:42:08.014771
NCT01140672|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2011-06-07|2010-06-08|2010-06-09|Estimate|||||||2011-06-07|2011-06-08|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects|A Double Blind, 3rd Party Open, Placebo Controlled, Dose Escalating, Parallel Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04634817 In Healthy Volunteers|Completed||Phase 1|48|Actual|Pfizer||6|||f||||||||||||||2018-05-31 23:42:08.083501|2018-05-31 23:42:08.083501
NCT01140659|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-21|2010-06-08|2010-06-09|Estimate|||||||2010-06-21|2010-06-22|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|||Objective Evaluation of Patients With Palmar Hyperhidrosis Submitted to Two Levels of Sympathectomy: T3 and T4.|Objective Evaluation of Patients With Palmar Hyperhidrosis Submitted to Two Levels of Sympathectomy: T3 and T4.|Completed||N/A|40|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:42:08.219551|2018-05-31 23:42:08.219551
NCT01140646|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|2014-01-10||2014-04-10|2010-06-08|2010-06-09|Estimate|2014-03-06|2014-04-11|Estimate||||2014-04-10|2014-04-29|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SAMe||Evaluation of SAMe for Hot Flashes|Phase II Evaluation of S-Adenosyl-L-Methionine (SAMe) for the Treatment of Hot Flashes|Completed||Phase 2|45|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 23:42:08.325346|2018-05-31 23:42:08.325346
NCT01140633|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2013-08-30|2010-06-08|2010-06-09|Estimate|||||||2013-08-30|2013-09-02|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|January 2011|Actual|2011-01-31||Observational|||Novel Measures and Theory of Pediatric Antiretroviral Therapy Adherence in Uganda|Novel Measures and Theory of Pediatric Antiretroviral Therapy Adherence in Uganda|Completed|||46|Actual|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     Plasma samples with HIV viral DNA.~   "|||2018-05-31 23:42:08.613491|2018-05-31 23:42:08.613491
NCT01140594|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2018-04-22|2010-06-08|2010-06-09|Estimate|||||||2018-04-22|2018-04-24|Actual|August 2006||2006-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Wavefront-guided Photorefractive Keratectomy (PRK) Versus Wavefront-guided Lasik for Myopia|A Prospective Randomized Eye to Eye Comparison of Fellow Eyes Undergoing Lasik With the IntraLase(TM) FS Versus PRK|Active, not recruiting||Phase 4|34|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 23:42:08.982252|2018-05-31 23:42:08.982252
NCT01140581|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2012-01-20|2010-06-08|2010-06-09|Estimate|||||||2012-01-20|2012-01-23|Estimate|September 2010||2010-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ARTEMIS Load||Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation|A Randomized, International, Multi-center, Open-label Study to Document Optimal Timing of Initiation of Dronedarone Treatment After Conversion With Loading Dose of Amiodarone in Patients With Persistent Atrial Fibrillation Requiring Conversion of AF.|Completed||Phase 4|402|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 23:42:09.101097|2018-05-31 23:42:09.101097
NCT01140568|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-07-06|2010-06-08|2010-06-09|Estimate|||||||2016-07-06|2016-07-11|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas|A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas|Recruiting||Phase 2|50|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 23:42:09.32842|2018-05-31 23:42:09.32842
NCT01140555|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2011-02-16|2010-06-08|2010-06-09|Estimate|||||||2011-02-16|2011-02-17|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device|A Pilot Study to Determine the Optimal Procedure Steps to Obtain and Maintain Bilateral Uterine Artery Occlusion Using the GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device in Women With Uterine Fibroids|Terminated||N/A|2|Actual|Ethicon, Inc.||1||Further internal evaluation of the device was required.|f||||f||||||||||2018-05-31 23:42:09.398235|2018-05-31 23:42:09.398235
NCT01140542|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-10-24|2010-06-08|2010-06-09|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2006||2006-08-31|September 2016|2016-09-30|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|FORTUNA||Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study|Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Phase IIb, Proof of Concept Clinical Study|Completed||Phase 2|487|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 23:42:09.490216|2018-05-31 23:42:09.490216
NCT01140529|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2016-10-29|2010-06-08|2010-06-09|Estimate|||||||2016-10-29|2016-11-01|Estimate|May 2010||2010-05-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|DexinDelir||Dexmedetomidine for the Treatment of Delirium After Heart Surgery|A Prospective, Multi-centre, Randomised, Double-blind, Placebo-controlled Comparison of Intravenous Dexmedetomidine and Haloperidol in Treatment of Psychomotor Confusion After Heart Surgery|Terminated||Phase 3|3|Actual|Thorax-Kärlkliniken||3||Slow recruitment|f||||f||||||||||2018-05-31 23:42:09.567406|2018-05-31 23:42:09.567406
NCT01140516|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2018-03-08|2010-06-08|2010-06-09|Estimate|||||||2018-03-08|2018-03-12|Actual|July 2010||2010-07-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ALPHA||Effectiveness of Antibiotics Versus Placebo to Treat Antenatal Hydronephrosis|Antibiotic prophyLaxis Versus Placebo in Infants Diagnosed With Hydronephrosis Antenatally|Active, not recruiting||N/A|160|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 23:42:09.704676|2018-05-31 23:42:09.704676
NCT01140503|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2015-01-28||2015-03-03|2010-06-08|2010-06-09|Estimate|2015-03-03|2015-03-04|Estimate||||2015-03-03|2015-03-04|Estimate|February 2010||2010-02-28|March 2015|2015-03-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis|An Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Dermatomyositis|Terminated||N/A|5|Actual|Stanford University|Study was terminated early due to low enrollment. Therefore we only have data on 5 participants.|1||Slow recruitment of participants|f||||t||||||||||2018-05-31 23:42:09.778032|2018-05-31 23:42:09.778032
NCT01140490|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-03-10|2010-06-08|2010-06-09|Estimate|||||||2011-03-10|2011-03-11|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2011|Anticipated|2011-12-31|January 2011|Anticipated|2011-01-31||Interventional|||Sub-total Parathyroidectomy Reduces Vascular Calcification in Haemodialysis Patients|Sub-total Parathyroidectomy Reduces Vascular Calcification in Haemodialysis Patients|Unknown status|Recruiting|N/A|40|Anticipated|Guangdong General Hospital||1|||f||||t||||||||||2018-05-31 23:42:10.026936|2018-05-31 23:42:10.026936
NCT01140477|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|2014-08-07||2014-08-29|2010-06-08|2010-06-09|Estimate|2014-08-07|2014-08-22|Estimate||||2014-08-29|2014-09-08|Estimate|June 2010||2010-06-30|August 2014|2014-08-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|||Toric Intraocular Lens Following Cataract Surgery|A Prospective Multicenter Clinical Trial To Evaluate the Effectiveness of A Toric Accommodating Posterior Chamber Silicone Intraocular Lens Designed To Provide Near, Intermediate, And Distance Vision And Reduce The Effects Of Preoperative Corneal Astigmatism On Postoperative Refraction Following Cataract Surgery|Completed||N/A|229|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:42:10.177504|2018-05-31 23:42:10.177504
NCT01140464|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-04-27|2010-06-07|2010-06-09|Estimate|||||||2017-04-27|2017-05-01|Actual|April 2010||2010-04-30|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ROAD||Reaching Out to Adolescents With Depression|Adolescent Collaborative Care Treatment for Depression|Completed||N/A|101|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 23:42:11.75668|2018-05-31 23:42:11.75668
NCT01140451|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2017-12-13|2010-06-08|2010-06-09|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2010||2010-08-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Extension Study of Ataluren (PTC124) in Cystic Fibrosis|A Phase 3 Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Cystic Fibrosis|Completed||Phase 3|191|Actual|PTC Therapeutics||1|||f||||t||||||||No||2018-05-31 23:42:11.837386|2018-05-31 23:42:11.837386
NCT01140438|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-08-18|2010-06-08|2010-06-09|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2009|Actual|2009-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LADA||Treatment of Latent Autoimmune Diabetes of the Adult|"Is Beta Cell Rest by Insulin Treatment Beneficial Compared to State-of-the Art Enhancers of Insulin Secretion in Preserving Beta Cell Function in Subjects With Latent Autoimmune Diabetes of the Adult (LADA)?"|Active, not recruiting||N/A|78|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 23:42:11.990816|2018-05-31 23:42:11.990816
NCT01140425|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-12-22|2010-06-07|2010-06-09|Estimate|||||||2010-12-22|2010-12-23|Estimate|July 2010||2010-07-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects|A Phase 1, Randomized, Multiple Dose, Placebo And Active Controlled, 4-Way Crossover Study To Evaluate The Effect Of A Multiple Oral Dose of PF-00232798 On Qt Intervals In Healthy Subjects|Completed||Phase 1|44|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:42:12.160153|2018-05-31 23:42:12.160153
NCT01140412|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-02-03|2010-06-07|2010-06-09|Estimate|||||||2011-02-03|2011-02-04|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Open-Label, Fixed-Sequence, Crossover Study To Estimate The Pharmacokinetic Interaction Between Multiple Dose Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects|Terminated||Phase 1|14|Actual|ViiV Healthcare||2||"The trial prematurely terminated on November 1, 2010, due to healthy volunteer participants~   experiencing non-serious fosamprenavir-related skin rash."|f||||f||||||||||2018-05-31 23:42:12.341632|2018-05-31 23:42:12.341632
NCT01140399|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2017-04-07|2010-06-08|2010-06-09|Estimate|||||||2017-04-07|2017-04-10|Actual|February 2011|Actual|2011-02-28|April 2017|2017-04-30|April 2017|Actual|2017-04-30|June 2011|Actual|2011-06-30||Interventional|REWORD-HF||REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure|Impact of Different Therapeutic Approaches in Patients With Cardiorenal Syndrome in the Setting of Acute Decompensated Congestive Heart Failure (ADCHF)|Terminated||Phase 4|10|Actual|Niguarda Hospital||2||insufficient enrollment|f||||t||||||||||2018-05-31 23:42:12.503264|2018-05-31 23:42:12.503264
NCT01140386|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2017-11-21|2010-06-08|2010-06-09|Estimate|||||||2017-11-21|2017-11-24|Actual|May 2009||2009-05-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|pediatric DVT||Prevalence and Risk Factors of Venous Thromboembolism in Hospitalized Pediatric Patients||Completed|||25|Actual|Penn State University|||1||f||||f||||||||||2018-05-31 23:42:12.776871|2018-05-31 23:42:12.776871
NCT01140373|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2017-11-01|2010-06-08|2010-06-09|Estimate|||||||2017-11-01|2017-11-06|Actual|June 2010||2010-06-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)|Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)|Active, not recruiting||Phase 1|13|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:42:12.910758|2018-05-31 23:42:12.910758
NCT01140360|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|2016-12-21||2017-06-02|2010-06-08|2010-06-09|Estimate|2017-06-02|2017-07-02|Actual||||2017-06-02|2017-07-02|Actual|February 2012||2012-02-29|June 2017|2017-06-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|0908-09||Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas|Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas|Completed||Phase 1/Phase 2|21|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 23:42:13.284556|2018-05-31 23:42:13.284556
NCT01140347|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2015-03-13|2010-07-29|2015-11-24|2010-06-08|2010-06-09|Estimate|2015-03-13|2015-03-26|Estimate|2010-08-19|2010-08-23|Estimate|2015-11-24|2015-12-28|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|REACH|All randomized participants.|A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib|A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)|Completed||Phase 3|565|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 23:42:13.655598|2018-05-31 23:42:13.655598
NCT01140334|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2013-09-19|2010-06-08|2010-06-09|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Treatment for Psychological and Drug Abuse Problems|Maximizing Effectiveness of Integrated Treatment Approaches|Completed||N/A|158|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:42:15.721065|2018-05-31 23:42:15.721065
NCT01140321|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|January 2004||2004-01-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|Nerixia||Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI|A Randomized, Open-label Therapeutic Trial Evaluating the Efficacy and Safety of Neridronate (Nerixia®) in the Treatment of Osteoporosis in Patients With Thalassemia Major and Severe Thalassemia Intermedia.|Completed||Phase 2|120|Actual|Ente Ospedaliero Ospedali Galliera||2|||f||||f||||||||||2018-05-31 23:42:15.872677|2018-05-31 23:42:15.872677
NCT01140308|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2012-09-06|2010-06-08|2010-06-09|Estimate|||||||2012-09-06|2012-09-07|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||CoEnzyme Q10 in Statin Myopathy|CoEnzyme Q10 in Statin Myopathy|Unknown status|Active, not recruiting|N/A|135|Anticipated|Hartford Hospital||2|||f||||t||||||||||2018-05-31 23:42:15.957767|2018-05-31 23:42:15.957767
NCT01140295|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2012-12-12||2013-04-10|2010-06-08|2010-06-09|Estimate|2013-04-10|2013-04-12|Estimate||||2013-04-10|2013-04-12|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Bowel Preparation for Colonoscopy in Children|Polyethylene Glycol Powder Solution vs Senna for Bowel Preparation for Colonoscopy in Children: A Prospective, Randomized, Investigator-Blinded Trial.|Terminated||Phase 4|33|Actual|Children's Hospital of Philadelphia|Early termination due to poor efficacy in one of the study arms (senna preparation).|2|||f||||f||||||||||2018-05-31 23:42:16.058553|2018-05-31 23:42:16.058553
NCT01140282|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2018-05-23|2010-06-08|2010-06-09|Estimate|||||||2018-05-23|2018-05-25|Actual|May 21, 2012|Actual|2012-05-21|May 2018|2018-05-31|May 21, 2020|Anticipated|2020-05-21|May 21, 2019|Anticipated|2019-05-21||Interventional|||Exercise Program for Early Breast Cancer Survivors|Combined Exercise Program for Early Breast Cancer Survivors|Active, not recruiting||N/A|106|Actual|University of Southern California||2|||f||||t|f|f||||||||2018-05-31 23:42:16.28348|2018-05-31 23:42:16.28348
NCT01140269|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2016-12-08|2010-06-08|2010-06-09|Estimate|||||||2016-12-08|2016-12-12|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|PCR-Staph||Rapid Detection of Staphylococcus Aureus in Burn Patients|Rapid, Quantitative, PCR-Based Detection Of Staphylococcus Aureus in Burn Sepsis Patients|Active, not recruiting||N/A|218|Actual|American Burn Association||2|||f||||t||||||||||2018-05-31 23:42:16.363494|2018-05-31 23:42:16.363494
NCT01140256|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|||||Observational|EZP||Longitudinal Zinc Intakes and Exchangeable Zinc Pool Sizes in Breastfed Small for Gestational Age vs Appropriate for Gestational Age Infants in Pakistan|Longitudinal Zinc Intakes and Exchangeable Zinc Pool Sizes in Breastfed Small for Gestational Age vs Appropriate for Gestational Age Infants in Pakistan|Completed|||30|Actual|Aga Khan University|||3||f||||f||||||||||2018-05-31 23:42:16.523538|2018-05-31 23:42:16.523538
NCT01140243|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2013-05-27|2010-06-08|2010-06-09|Estimate|||||||2013-05-27|2013-05-29|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital|Efficacy and Suitability of Infant Formula With a Special Fat Formulation for Premature Infants Following Discharge From Hospital Following Discharge From Hospital|Completed||N/A|31|Actual|Materna Laboratories||2|||f||||t||||||||||2018-05-31 23:42:16.595546|2018-05-31 23:42:16.595546
NCT01140230|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|HBStud2||Outcomes After Repair of Acute Rotator Cuff Tears|Structural and Clinical Outcomes After Repair of Acute Rotator Cuff Tears|Completed|||42|Actual|University Hospital, Linkoeping|||||f||||t||||||||||2018-05-31 23:42:16.812898|2018-05-31 23:42:16.812898
NCT01140217|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18||2013-06-03|2013-09-13|2010-06-07|2010-06-09|Estimate||||2013-06-03|2013-06-11|Estimate|2013-09-13|2013-09-19|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Simplify||Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception|An Open Label Study to Evaluate the Contraceptive Efficacy and Safety of Norethindrone Acetate Transdermal Delivery System|Completed||Phase 3|1659|Actual|Watson Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:42:17.089597|2018-05-31 23:42:17.089597
NCT01140204|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|March 2003||2003-03-31|June 2010|2010-06-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media|Restenosis Inhibition by Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media|Completed||Phase 1/Phase 2|32|Actual|University Hospital, Saarland||5|||f||||t||||||||||2018-05-31 23:42:17.236375|2018-05-31 23:42:17.236375
NCT01140191|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2016-10-06|2015-04-22|2017-02-01|2010-06-07|2010-06-09|Estimate|2017-02-01|2017-03-22|Actual|2015-06-04|2015-07-02|Estimate|2017-02-01|2017-03-22|Actual|September 2013||2013-09-30|February 2017|2017-02-28|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|WRNMMC|Only 1 patient enrolled|Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis|An Open-Label Clinical Study to Examine the Safety, Efficacy, and Pharmacokinetics of WR 279,396 (Paromomycin + Gentamicin Topical Cream) for the Treatment of Cutaneous Leishmaniasis at Walter Reed National Military Medical Center (WRNMMC)|Terminated||Phase 2|1|Actual|U.S. Army Medical Research and Materiel Command|Only one subject was enrolled in the protocol and treated. Data for this single patient was the only data available for analysis.|1||This study was closed due to lack of enrollment (only one subject enrolled)|f||||f||||||||Undecided||2018-05-31 23:42:17.337919|2018-05-31 23:42:17.337919
NCT01140178|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2018-05-01|2010-06-08|2010-06-09|Estimate|||||||2018-05-01|2018-05-02|Actual|June 8, 2010|Actual|2010-06-08|May 2018|2018-05-31|July 29, 2018|Anticipated|2018-07-29|January 29, 2013|Actual|2013-01-29||Interventional|||A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx|A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.|Active, not recruiting||Phase 1|29|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 23:42:17.523433|2018-05-31 23:42:17.523433
NCT01140165|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|December 2011|Anticipated|2011-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Cheese and Human Health|Effects of Hard Cheese and Butter on Markers of Cardiovascular Disease -A Randomized Controlled Dietary Human Intervention|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 23:42:17.690795|2018-05-31 23:42:17.690795
NCT01140152|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction|Proteomic Analysis Reveals Innate Immune Activity In Intestinal Transplant Dysfunction|Completed|||17|Actual|University of California, Los Angeles|||2||f||||t||||||Samples With DNA|"~     Ostomy effluent~   "|||2018-05-31 23:42:17.769053|2018-05-31 23:42:17.769053
NCT01140139|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|September 2006||2006-09-30|February 2006|2006-02-28|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|Vac09||Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions|Active Immunotherapy Against HIV During Highly Active Anti-retroviral Therapy Followed by Repeated Treatment Interruptions|Completed||Phase 1|12|Actual|Swedish Institute for Infectious Disease Control||3|||f||||t||||||||||2018-05-31 23:42:17.883456|2018-05-31 23:42:17.883456
NCT01140126|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-07-07|2010-06-07|2010-06-09|Estimate|||||||2011-07-07|2011-07-11|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults|A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults|Completed||Phase 1|20|Actual|United Biomedical||1|||f||||t||||||||||2018-05-31 23:42:17.957926|2018-05-31 23:42:17.957926
NCT01140113|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2013-07-21|2010-06-08|2010-06-09|Estimate|||||||2013-07-21|2013-07-23|Estimate|July 2007||2007-07-31|July 2013|2013-07-31|March 2009|Actual|2009-03-31|July 2008|Actual|2008-07-31||Interventional|||Does Modified Ultrafiltration Improves Inflammatory Response and Cardiopulmonary Function After CABG Procedures?|Does Modified Ultrafiltration Improves Inflammatory Response and Cardiopulmonary Function After CABG Procedures?|Completed||N/A|60|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 23:42:18.063406|2018-05-31 23:42:18.063406
NCT01140100|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate||||January 2007|2007-01-31||||||||Interventional|||A Comparative Study of Depth of Anesthesia Monitored by Bispectral Index (BIS) Values|A Comparative Study of Depth of Anesthesia Monitored by BIS Values in Two Anesthesia Techniques|Completed||Phase 2|82|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-05-31 23:42:18.171988|2018-05-31 23:42:18.171988
NCT01140074|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-09|2010-06-07|2010-06-09|Estimate|||||||2010-06-09|2010-06-10|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|Zinc||Efficacy of Zinc Sulfate With Probiotics for the Treatment of Acute Diarrhea in Children|Effectiveness and Efficacy of Zinc With Probiotics for the Treatment of Acute Diarrhea in Young Children|Unknown status|Not yet recruiting|Phase 2|256|Anticipated|University Hospital No 1 Wroclaw||2|||f||||t||||||||||2018-05-31 23:42:18.32747|2018-05-31 23:42:18.32747
NCT01140061|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2014-10-29||2017-03-09|2010-06-07|2010-06-09|Estimate|2014-12-11|2014-12-12|Estimate||||2017-03-09|2017-04-07|Actual|May 2010||2010-05-31|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)|A 3-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of MK-0873 Following Cumulative Patch and Repeated Max Area Applications in Healthy Subjects and Psoriasis Patients|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 23:42:18.469173|2018-05-31 23:42:18.469173
NCT01140048|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2012-08-31||2016-07-18|2010-06-07|2010-06-09|Estimate|2012-08-31|2012-10-05|Estimate||||2016-07-18|2016-07-20|Estimate|October 2007||2007-10-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)|An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast|Completed|||343|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:42:19.152336|2018-05-31 23:42:19.152336
NCT01140035|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2011-09-19|2010-06-07|2010-06-09|Estimate|||||||2011-09-19|2011-09-20|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Intensive Insulin Therapy in Deceased Donors|Intensive Insulin Therapy in Deceased Donors - to Improve Renal Allograft Function and Transplanted Allograft Outcomes|Completed||N/A|200|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:42:19.33553|2018-05-31 23:42:19.33553
NCT01140022|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2014-10-01|2010-06-07|2010-06-09|Estimate|||||||2014-10-01|2014-10-03|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia|Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia|Completed|||346|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-05-31 23:42:19.420326|2018-05-31 23:42:19.420326
NCT01140009|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2015-04-14|2010-06-07|2010-06-09|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PCIRNRT06||Safety and Protectiveness of the Seasonal Influenza Vaccine for 2010-2011|A Randomized, Blinded, Placebo-controlled, Cross-over Study of the Safety and Immunogenicity of Trivalent, Inactivated Influenza Vaccine for 2010-2011|Completed||Phase 2|324|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 23:42:19.520474|2018-05-31 23:42:19.520474
NCT01139996|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2017-03-27||2017-05-15|2010-06-08|2010-06-09|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|May 2010||2010-05-31|May 2017|2017-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||baseline data were not collected|Use of Transdermal Clonidine in Trauma Patients|A Randomized Double Blinded Placebo Controlled Trial Of Transdermal Clonidine for Adjuvant Sedation in Ventilated Trauma Patients Experiencing Delirium|Terminated||Phase 4|22|Actual|Memorial Health University Medical Center||2||Difficulty in enrolling participants|f||||t||||||||||2018-05-31 23:42:19.63075|2018-05-31 23:42:19.63075
NCT01139983|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-05-17|2010-06-08|2010-06-09|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2010||2010-04-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||DNA Biomarkers in Samples From Patients With Osteosarcoma and Healthy Volunteers|Search for Novel Genes in Osteosarcoma Revealed by Analysis of Tumour Copy-Number Alterations and Constitutional Copy-Number Variations|Completed|||90|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:42:19.909381|2018-05-31 23:42:19.909381
NCT01139970|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2018-04-20|2010-06-08|2010-06-09|Estimate|||||||2018-04-20|2018-04-23|Actual|May 21, 2010|Actual|2010-05-21|April 2018|2018-04-30||||March 21, 2014|Actual|2014-03-21||Interventional|||Veliparib and Temozolomide in Treating Patients With Acute Leukemia|A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias|Active, not recruiting||Phase 1|66|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:42:19.987832|2018-05-31 23:42:19.987832
NCT01139957|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2015-06-03|2010-06-08|2010-06-09|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2010||2010-06-30|June 2015|2015-06-30||||December 2015|Anticipated|2015-12-31||Observational|||Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer|Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants|Unknown status|Active, not recruiting||1916|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-05-31 23:42:20.133867|2018-05-31 23:42:20.133867
NCT01139944|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-07-01|2010-06-08|2010-06-09|Estimate|||||||2016-07-01|2016-07-06|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer|Epigenetic Changes as Prognostic Markers in Patients With Early Stage Non-Small Cell Lung Cancer|Completed|||99|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     tissue and blood samples~   "|||2018-05-31 23:42:20.416876|2018-05-31 23:42:20.416876
NCT01139931|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2016-05-17|2010-06-08|2010-06-09|Estimate|||||||2016-05-17|2016-05-18|Estimate|October 2009||2009-10-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia|Epigenetic Alterations in AML|Completed|||15|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:42:20.499063|2018-05-31 23:42:20.499063
NCT01139918|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2014-07-23|2010-06-07|2010-06-09|Estimate|||||||2014-07-23|2014-07-24|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis|Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis|Completed|||105|Actual|Innovaderm Research Inc.|||3||f||||f||||||||||2018-05-31 23:42:20.574478|2018-05-31 23:42:20.574478
NCT01139905|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-03-24|2010-06-08|2010-06-09|Estimate|||||||2015-03-24|2015-03-26|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children|Pharmacokinetics of Low- Dose Lopinavir/Ritonavir Tablet Formulation HIV-1 Infected Children|Completed||Phase 2|24|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-05-31 23:42:20.657897|2018-05-31 23:42:20.657897
NCT01139892|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-12-13|2010-06-08|2010-06-09|Estimate|||||||2017-12-13|2017-12-15|Actual|September 26, 2010|Actual|2010-09-26|December 2017|2017-12-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Observational|CURES||The Canadian UnRuptured Endovascular Versus Surgery Trial (CURES)|Canadian Study on the Endovascular Treatment of Unruptured Intracranial Aneurysms Versus Surgical Treatment. A Randomized Comparison of Clinical and Angiographic Results of Intracranial Aneurysms|Recruiting|||260|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||2||f||||t||||||||||2018-05-31 23:42:20.757404|2018-05-31 23:42:20.757404
NCT01139879|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2015-04-23||2015-11-16|2010-06-08|2010-06-09|Estimate|2015-11-16|2015-12-17|Estimate||||2015-11-16|2015-12-17|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|P400|Patients with multiple Stage II or at least one Stage III or IV pressure ulcer having less than or equal to 25% necrotic tissue present in the pressure ulcer at the time of placement.|P400 for Stage II-IV Pressure Ulcers in Home and Extended Care|Assessment of the Incidence and Treatment of Stage II -IV Pressure Ulcers in the Home Care or Extended Care Environments Utilizing the P400 Mattress|Completed||N/A|10|Actual|Hill-Rom|Small study with no comparative arm.|1|||f||||f||||||||||2018-05-31 23:42:20.926435|2018-05-31 23:42:20.926435
NCT01139866|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-07-13|2010-06-08|2010-06-09|Estimate|||||||2011-07-13|2011-07-15|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery|A Multi-Center, Prospective, Observational, Extension Trial Following DURECT Protocol C803-017 to Investigate the Long-term Safety of SABER™-Bupivacaine Following Arthroscopic Shoulder Surgery|Completed|||47|Actual|Durect|||2||f||||f||||||||||2018-05-31 23:42:21.361842|2018-05-31 23:42:21.361842
NCT01139853|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2015-09-25|2010-06-08|2010-06-09|Estimate|||||||2015-09-25|2015-09-28|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|POINTS||Post-Operative Impact of Nasogastric Tubes on Rates of Emesis in Infants Diagnosed With Pyloric Stenosis|Post-Operative Impact of Nasogastric Tubes on Rates of Emesis in Infants Diagnosed With Pyloric Stenosis: A Prospective, Randomized Controlled Pilot Trial|Completed||Early Phase 1|50|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 23:42:21.506252|2018-05-31 23:42:21.506252
NCT01139840|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-10-27|2010-06-08|2010-06-09|Estimate|||||||2011-10-27|2011-10-31|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Relative Efficacy of Vitamins D2 and D3 in Adult Humans|Vitamin D Status: Relative Efficacy of Vitamins D2 and D3|Completed||N/A|32|Actual|Creighton University||2|||f||||f||||||||||2018-05-31 23:42:21.593232|2018-05-31 23:42:21.593232
NCT01139827|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-08|||2010-06-08|2010-06-08|2010-06-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography||Completed|||178|Actual|Korea University Guro Hospital|||2||f||||t||||||||||2018-05-31 23:42:21.682925|2018-05-31 23:42:21.682925
NCT01139814|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2013-03-01||2013-04-09|2010-06-08|2010-06-09|Estimate|2013-03-01|2013-04-10|Estimate||||2013-04-09|2013-04-11|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Study to Evaluate the Catheter Robotics Amigo for Performing Right-Sided Electrophysiology Mapping Studies|Clinical Study to Evaluate the Effectiveness and Safety of the Catheter Robotics Amigo Remote Catheter System for Performing Right-Sided Electrophysiology Mapping Studies|Completed||N/A|181|Actual|Catheter Robotics, Inc.||1|||f||||f||||||||||2018-05-31 23:42:21.750688|2018-05-31 23:42:21.750688
NCT01139801|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2014-01-06|2010-06-07|2010-06-09|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Cervical Ripening for Induction of Labor: Misoprostol Versus Oxytocin in Conjunction With Foley Balloon||Completed||N/A|50|Actual|Aultman Health Foundation||2|||f||||||||||||||2018-05-31 23:42:22.087502|2018-05-31 23:42:22.087502
NCT01139788|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2012-01-20|2010-06-08|2010-06-09|Estimate|||||||2012-01-20|2012-01-24|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of LY2624587 in Patients With Advanced Cancer|A Phase 1 Study of LY2624587 in Patients With Advanced Cancer|Completed||Phase 1|56|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:42:22.254324|2018-05-31 23:42:22.254324
NCT01139775|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2018-02-17|2014-04-25|2018-05-16|2010-06-08|2010-06-09|Estimate|2018-05-16|2018-05-18|Actual|2014-04-25|2014-05-13|Estimate|2018-05-16|2018-05-18|Actual|February 2011||2011-02-28|May 2018|2018-05-31|August 2014|Actual|2014-08-31|May 2013|Actual|2013-05-31||Interventional||All participants.|A Study in Non Small Cell Lung Cancer|A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed and Cisplatin in Patients With Stage IV Non-small Cell Lung Cancer|Completed||Phase 1/Phase 2|76|Actual|Eli Lilly and Company|Enrollment was halted on 25 October 2012 due to a numerical imbalance in events of thromboembolic nature between the experimental arm and the control arm.|3|||f||||f||||||||||2018-05-31 23:42:22.413238|2018-05-31 23:42:22.413238
NCT01139762|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2013-01-23||2013-01-23|2010-06-08|2010-06-09|Estimate|2013-01-23|2013-02-27|Estimate||||2013-01-23|2013-02-27|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms|A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia|Completed||Phase 3|696|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:42:23.747837|2018-05-31 23:42:23.747837
NCT01139749|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2011-10-09|2010-06-08|2010-06-09|Estimate|||||||2011-10-09|2011-10-12|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea|Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea.|Unknown status|Recruiting|Phase 4|50|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 23:42:26.418796|2018-05-31 23:42:26.418796
NCT01139736|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2013-01-18|2010-06-08|2010-06-09|Estimate|||||||2013-01-18|2013-01-21|Estimate|July 2010||2010-07-31|February 2011|2011-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome|Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome|Completed||Phase 4|12|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 23:42:26.504739|2018-05-31 23:42:26.504739
NCT01022814|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|January 2010||2010-01-31|November 2009|2009-11-30||||January 2012|Anticipated|2012-01-31||Observational|||Development of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine||Unknown status|Not yet recruiting||300|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-06-01 00:19:10.026594|2018-06-01 00:19:10.026594
NCT01139723|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2016-11-01|2010-06-07|2010-06-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors|A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors|Completed||Phase 1|54|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:42:26.59623|2018-05-31 23:42:26.59623
NCT01139710|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2013-03-12|2010-06-07|2010-06-08|Estimate|||||||2013-03-12|2013-03-13|Estimate|October 2010||2010-10-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Sarcoidosis-associated Pulmonary Hypertension||Completed|||75|Actual|Meir Medical Center|||||f||||t||||||||||2018-05-31 23:42:26.679789|2018-05-31 23:42:26.679789
NCT01139697|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2012-05-15|2010-06-07|2010-06-08|Estimate|||||||2012-05-15|2012-05-16|Estimate|August 2010||2010-08-31|May 2012|2012-05-31||||||||Observational|||Hair Cortisol and Testosterone in Heart Failure|Hair Cortisol and Testosterone Levels and Their Correlation With Heart Failure Status in Patients With Chronic Congestive Heart Failure|Completed|||46|Actual|Meir Medical Center|||1||f||||f||||||Samples Without DNA|"~     Hair samples for the measurment of cortisol and testosterone~   "|||2018-05-31 23:42:26.754377|2018-05-31 23:42:26.754377
NCT01139684|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|September 2010||2010-09-30|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Development of Field Test for Assessing the Human Anaerobic Capability||Unknown status|Not yet recruiting|N/A|20|Anticipated|Hillel Yaffe Medical Center||1|||f||||||||||||||2018-05-31 23:42:26.916072|2018-05-31 23:42:26.916072
NCT01139671|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-07-04|2010-06-07|2010-06-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SUF-REM-DDS||Comparison of Sufentanil and Remifentanil Infusion During General Anaesthesia for Removal of Wisdom Teeth in Ambulatory Surgery|Comparison of Sufentanil and Remifentanil Infusion During General Anaesthesia for Removal of Wisdom Teeth in Ambulatory Surgery|Completed||Phase 4|18|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:42:26.997142|2018-05-31 23:42:26.997142
NCT01139658|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2013-09-06||2013-11-27|2010-06-07|2010-06-08|Estimate|2013-11-27|2014-01-16|Estimate||||2013-11-27|2014-01-16|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational||Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.|Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA|Observational Cohort Study on the Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA|Completed|||1676|Actual|Boehringer Ingelheim|"Data for the following secondary endpoints were not collected:~Medical appointments with a general practitioner or specialist at visit 3, Frequency of medical appointments at visit 3, Prescription received at visit 3."||1||f||||||||||||||2018-05-31 23:42:27.112521|2018-05-31 23:42:27.112521
NCT01139645|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2013-01-25|2010-06-07|2010-06-08|Estimate|||||||2013-01-25|2013-01-28|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism|The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism: A Prospective Single-Blind Matched Controlled Study|Completed||N/A|58|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 23:42:28.108384|2018-05-31 23:42:28.108384
NCT01139632|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-06|||2011-04-05|2010-06-07|2010-06-08|Estimate|||||||2011-04-05|2011-04-06|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Observational|0030-10||The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease|The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease|Unknown status|Active, not recruiting||60|Anticipated|Ziv Hospital|||||f||||t||||||||||2018-05-31 23:42:28.202197|2018-05-31 23:42:28.202197
NCT01139619|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2013-02-22|2010-06-07|2010-06-08|Estimate|||||||2013-02-22|2013-02-25|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|MAPSY||A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients|A Retrospective, Medical Record Study to Investigate the Current Situation of Biopsy Testing in the Swedish Inoperable Non Small Cell Lung Cancer Patient Population|Completed|||136|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:42:28.308218|2018-05-31 23:42:28.308218
NCT01139606|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-06|||2015-12-08|2010-06-07|2010-06-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Vibration Training and Muscle Strength Development|The Effect of Resistance Training With Vibrating Weights on Muscle Strength Development and Everyday Functioning of Upper Limbs in Untrained Adults|Completed||N/A|20|Actual|Wingate Institute||1|||f||||||||||||||2018-05-31 23:42:28.465821|2018-05-31 23:42:28.465821
NCT01139593|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-06|||2015-12-08|2010-06-07|2010-06-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||A Trial Comparing Qam With Qpm Dosing in Assisted Reproductive Technologies (ART)|A Prospective Randomized Trial Comparing Qam With Qpm Daily Dosing in Assisted Reproductive Technologies|Completed|||128|Actual|Virginia Center for Reproductive Medicine|||2||f||||t||||||||||2018-05-31 23:42:28.56327|2018-05-31 23:42:28.56327
NCT01139580|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-06|2011-08-18||2016-11-30|2010-06-07|2010-06-08|Estimate|2011-08-18|2011-09-23|Estimate||||2016-11-30|2017-01-18|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis|A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis|Completed||Phase 3|363|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:42:28.726455|2018-05-31 23:42:28.726455
NCT01139567|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2013-06-28|2010-06-05|2010-06-08|Estimate|||||||2013-06-28|2013-07-02|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|WoundImager||Tissue Perfusion and Blood Flow Monitoring Technology|Tissue Perfusion and Blood Flow Monitoring Technology|Completed|||56|Anticipated|CW Optics, Inc.|||2||f||||||||||||||2018-05-31 23:42:29.312851|2018-05-31 23:42:29.312851
NCT01139528|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2015-04-23|2010-06-07|2010-06-08|Estimate|||||||2015-04-23|2015-04-24|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MC-studien||Conservative or Operative Treatment of Fractures in the Neck of the 5th Metacarpal Bone|Conservative Treatment Versus Operative Treatment of Extra-articular Fractures in the Neck of the 5th Metacarpal Bone- A Prospective Randomized Trial|Completed||N/A|85|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:42:29.543975|2018-05-31 23:42:29.543975
NCT01139515|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2011-06-13||2011-06-13|2010-06-07|2010-06-08|Estimate|2011-06-13|2011-07-12|Estimate||||2011-06-13|2011-07-12|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Eletriptan Pharmacokinetics In Korean Males|An Open Label, Single And Repeat Dose Randomized Crossover Study To Estimate The Pharmacokinetics And Safety Of Eletriptan Hydrobromide Tablets In Healthy Korean Male Subjects|Completed||Phase 1|16|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:42:29.674622|2018-05-31 23:42:29.674622
NCT01139502|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-10-15|2010-06-07|2010-06-08|Estimate|||||||2015-10-15|2015-10-16|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Cognitive Behaviour Therapy and Cognitive Training in Work Rehabilitation for Persons With Severe Mental Illness|Cognitive Therapy and Cognitive Training in Work Rehabilitation for Persons With Severe Mental Illness. A Randomised Controlled Trial|Completed||N/A|140|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 23:42:30.236387|2018-05-31 23:42:30.236387
NCT01139489|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2016-01-05|2010-06-07|2010-06-08|Estimate|||||||2016-01-05|2016-01-06|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|SAPS||Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's)|Stop Antibiotics on Procalcitonin Guidance Study|Completed||N/A|1575|Actual|VU University Medical Center||2|||f||||t||||||||||2018-05-31 23:42:30.333145|2018-05-31 23:42:30.333145
NCT01139476|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-05|||2018-05-23|2010-06-05|2010-06-08|Estimate|||||||2018-05-23|2018-05-24|Actual|June 15, 2010||2010-06-15|January 4, 2018|2018-01-04||||||||Observational|||Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study|Study of Biomarkers of Exposure and Effects in Agriculture|Recruiting|||2200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:42:30.443617|2018-05-31 23:42:30.443617
NCT01139463|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Study of Blood Lactate Levels in Patients Treated With Antipsychotics|Blood Lactate Levels in Patients Treated With Typical or Atypical Antipsychotics|Completed|||60|Actual|University Hospital of Split|||1||f||||t||||||||||2018-05-31 23:42:30.508187|2018-05-31 23:42:30.508187
NCT01139450|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2014-09-23|2014-06-16|2014-09-30|2010-06-07|2010-06-08|Estimate|2014-09-29|2014-09-30|Estimate|2014-06-16|2014-06-19|Estimate|2014-09-30|2014-10-09|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of 0417 Ointment in the Treatment of Atopic Dermatitis|Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0417 Ointment|Completed||Phase 3|899|Actual|Fougera Pharmaceuticals Inc.||3|||f||||f||||||||||2018-05-31 23:42:30.586964|2018-05-31 23:42:30.586964
NCT01139437|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2017-03-31|2010-06-07|2010-06-08|Estimate|||||||2017-03-31|2017-04-04|Actual|June 2010||2010-06-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/Δ1724 Lot PIV2#109C, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV2-Seropositive Children 15 to 59 Months of Age, and HPIV2-Seronegative Infants and Children 6 to 59 Months of Age|Completed||Phase 1|45|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||t||||||||||2018-05-31 23:42:30.830092|2018-05-31 23:42:30.830092
NCT01139424|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|GASTROSUTURE||Closure of Anastomotic Leaks in the Stomach and Esophagus by Endoscopic Suturing|Safety and Efficacy of Closure of Postoperative Anastomotic Leaks in the Stomach and Esophagus by Endoscopic Suturing: A Prospective Pilot Study|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Schleswig-Holstein||1|||f||||f||||||||||2018-05-31 23:42:30.960464|2018-05-31 23:42:30.960464
NCT01139411|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2016-06-20||2016-08-08|2010-06-07|2010-06-08|Estimate|2016-08-08|2016-09-30|Estimate||||2016-08-08|2016-09-30|Estimate|August 2009||2009-08-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||The Role of Parents in Adolescent Weight Loss|Parental Involvement as a Strategy to Enhance Adolescent Weight Control|Completed||N/A|49|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 23:42:31.186861|2018-05-31 23:42:31.186861
NCT01139398|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-02-21|2010-06-07|2010-06-08|Estimate|||||||2012-02-21|2012-02-22|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia|Effect of Dietary Supplement Limicol on LDL-cholesterol Levels in Moderate Hypercholesterolaemia|Completed||N/A|100|Actual|Lescuyer Laboratory|||||f||||t||||||||||2018-05-31 23:42:31.718597|2018-05-31 23:42:31.718597
NCT01139385|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-03-13|2010-06-07|2010-06-08|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|CLCHS||Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel Versus Conventional Method in Day Surgery|Comparative Study Between Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel Versus Conventional Method in Day Surgery: a Prospective Randomized Study|Completed|||218|Actual|University of Roma La Sapienza|||2||f||||f||||||||||2018-05-31 23:42:31.831011|2018-05-31 23:42:31.831011
NCT01139372|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-02-01|2010-06-07|2010-06-08|Estimate|||||||2012-02-01|2012-02-02|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop|An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop|Completed||N/A|96|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:42:31.924002|2018-05-31 23:42:31.924002
NCT01139359|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2012-07-18|2010-06-07|2010-06-08|Estimate|||||||2012-07-18|2012-07-19|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma|A Phase I Dose Escalation Study of Darinaparsin in Combination With CHOP in Previously Untreated Patients With Lymphomas Who Are Scheduled to Receive CHOP Alone|Withdrawn||Phase 1|0|Actual|Ziopharm||1||"Study enrollment was withdrawn as it is no longer the sponsor's intention to study this~   indication under this protocol."|f||||f||||||||||2018-05-31 23:42:32.03364|2018-05-31 23:42:32.03364
NCT01139294|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2017-06-02||2018-01-08|2010-06-07|2010-06-08|Estimate|2017-06-02|2017-06-26|Actual||||2018-01-08|2018-02-01|Actual|February 2010||2010-02-28|January 2018|2018-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|Hylenex|No baseline data available. Study data was lost. Data was left behind when PI left institution in 2013. Unable to find anyone with knowledge of data location.|Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics|Phase IV Randomized Study of Hylenex or Standard IV Hydration in the Pediatric Population With Moderate Dehydration|Completed||Phase 4|17|Actual|Vanderbilt University Medical Center|Study data was lost.Data was left behind when PI left institution in 2013. Unable to find anyone with knowledge of data location.|2|||f||||t||||||||||2018-05-31 23:42:32.490613|2018-05-31 23:42:32.490613
NCT01139281|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|June 2007||2007-06-30|May 2010|2010-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans|The Protective Effect of Ginkgo Biloba Extract on Cisplatin-Induced Ototoxicity in Humans Beings Evaluated by Distortion Product Otoacoustic Emissions|Completed||Phase 2|15|Actual|University of Brasilia||2|||f||||t||||||||||2018-05-31 23:42:32.700997|2018-05-31 23:42:32.700997
NCT01139268|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2013-07-17|2010-06-07|2010-06-08|Estimate|||||||2013-07-17|2013-07-18|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Identification of Viable Human Embryos Using Three Different Methods|Examination of Gene Expression, Time-lapse and Near-infrared Spectroscopy (NIR) to Identify Differences in Embryo Viability|Completed|||161|Actual|University of Aarhus|||||f||||t||||||Samples With DNA|"~     biopsies from human embryos~   "|||2018-05-31 23:42:32.811367|2018-05-31 23:42:32.811367
NCT01139255|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2011-06-02|2010-06-07|2010-06-08|Estimate|||||||2011-06-02|2011-06-06|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|POD||Pounds Off Digitally (POD): The Use of Podcasting and Mobile Media to Promote Weight Loss|The Use of Podcasting and Mobile Media to Promote Weight Loss and Increase Fruit and Vegetable Intake Among Overweight Adults|Completed||Phase 1|96|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:42:32.88228|2018-05-31 23:42:32.88228
NCT01139242|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|February 2008||2008-02-29|June 2010|2010-06-30|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional|ACTS||Increasing Colorectal Cancer Screening in Urban African American Communities Via Churches|Increasing CRC Screening in Urban African American Communities Via Churches|Completed||Early Phase 1|955|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:42:32.95073|2018-05-31 23:42:32.95073
NCT01139229|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|November 2007|Actual|2007-11-30||Interventional|||Hybrid-everted Versus Hand-sewn or Stapled Esophagogastrostomy in Prevention of Anastomotic Stricture|Phase III Study of Hybrid-everted Versus Hand-sewn of Stapled Esophagogastrostomy in Prevention of Anastomotic Stricture|Completed||N/A|144|Anticipated|Sichuan University||3|||f||||f||||||||||2018-05-31 23:42:33.048673|2018-05-31 23:42:33.048673
NCT01139216|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03||2012-12-27|2013-01-08|2010-06-04|2010-06-08|Estimate||||2012-12-27|2012-12-31|Estimate|2013-01-08|2013-01-14|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation|Effect of DAIKENCHUTO (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Female Patients With Functional Constipation|Completed||Phase 1/Phase 2|45|Actual|Tsumura USA||3|||f||||f||||||||||2018-05-31 23:42:33.126961|2018-05-31 23:42:33.126961
NCT01139203|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-25|2010-06-07|2010-06-08|Estimate|||||||2010-06-25|2010-06-28|Estimate|August 2009||2009-08-31|August 2009|2009-08-31||||December 2012|Anticipated|2012-12-31||Interventional|||Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation||Unknown status|Recruiting|N/A|300|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||||||||||||2018-05-31 23:42:33.203671|2018-05-31 23:42:33.203671
NCT01139190|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2015-06-22||2016-03-28|2010-06-07|2010-06-08|Estimate|2016-03-28|2016-04-11|Estimate||||2016-03-28|2016-04-11|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults|A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage|Completed||Phase 2|77|Actual|PLx Pharma||2|||f||||t||||||||||2018-05-31 23:42:33.287867|2018-05-31 23:42:33.287867
NCT01139177|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||SAMBA EU Femoropopliteal Trial|SAMBA EU Femoropopliteal Trial|Unknown status|Active, not recruiting|N/A|39|Actual|NovoStent Corporation||1|||f||||f||||||||||2018-05-31 23:42:33.478867|2018-05-31 23:42:33.478867
NCT01139164|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2016-02-11||2016-06-08|2010-06-07|2010-06-08|Estimate|2016-02-11|2016-03-10|Estimate||||2016-06-08|2016-07-11|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Interventional||Subjects who were enrolled to the study.|Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)|Allogeneic Hematopoietic Stem Cell Transplantation With Reduced-Intensity Pre-Transplant Conditioning for the Treatment of High-Risk Hematological Malignancies|Terminated||Phase 2|78|Actual|Medical University of South Carolina||1||Study halted prematurely due to low accrual.|f||||t||||||||||2018-05-31 23:42:33.57473|2018-05-31 23:42:33.57473
NCT01139151|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-06-16|2010-06-04|2010-06-08|Estimate|||||||2014-06-16|2014-06-17|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2011|Actual|2011-11-30||Interventional|||4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies|Phase I Study of 4'-Thio-araC in Patients With Advanced Hematologic Malignancies|Completed||Phase 1|31|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 23:42:33.897383|2018-05-31 23:42:33.897383
NCT01139138|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2017-11-02|2010-06-07|2010-06-08|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2010||2010-06-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|August 2015|Actual|2015-08-31||Interventional|PIE||Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer|A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT|Completed||Phase 1/Phase 2|49|Actual|The Queen Elizabeth Hospital||1|||f||||f||||||||||2018-05-31 23:42:34.081043|2018-05-31 23:42:34.081043
NCT01139125|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2014-03-27||2014-11-19|2010-06-04|2010-06-08|Estimate|2014-11-19|2014-11-20|Estimate||||2014-11-19|2014-11-20|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||An Open Trial of Cysteamine Treatment in Schizophrenia|An Open Trial of Cysteamine Treatment in Schizophrenia|Terminated||N/A|3|Actual|Augusta University|Recruitment challenges for this study are the number of pills that the subjects are required to take during treatment and the reported foul body odor that the subjects complianed of and was also noted by the Investigator and research staff.|1||The study was stopped after 4 years of recruitment difficulties.|f||||t||||||||||2018-05-31 23:42:34.187131|2018-05-31 23:42:34.187131
NCT01139112|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-11-14|2010-06-07|2010-06-08|Estimate|||||||2012-11-14|2012-11-15|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features|Klebsiella Pneumoniae Necrotizing Fasciitis: Clinical and Microbiological Features|Completed|||134|Actual|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     K. pneumoniae strains stored at -80oC~   "|||2018-05-31 23:42:34.343901|2018-05-31 23:42:34.343901
NCT01139099|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-12-26|2010-06-07|2010-06-08|Estimate|||||||2012-12-26|2012-12-27|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Evaluation of Therapeutic Efficacy on the Integrated Group Psychotherapy for Patients With Schizophrenia|Department of Psychiatry of NTUH Yun-Lin Branch|Completed||N/A|50|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 23:42:34.39827|2018-05-31 23:42:34.39827
NCT01139086|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF)|Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 23:42:34.46787|2018-05-31 23:42:34.46787
NCT01139073|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|||||Observational|||A New Portable Monitor for Measuring Odorous Compounds in Oral, Exhaled and Nasal Air||Completed|||20|Actual|Okayama University|||||f||||t||||||||||2018-05-31 23:42:34.538226|2018-05-31 23:42:34.538226
NCT01139060|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-10-11|2010-06-07|2010-06-08|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2009||2009-08-31|October 2017|2017-10-31||||April 2013|Actual|2013-04-30||Interventional|Stride||Organized Self-Management Support Services for Chronic Depression|Organized Self-Management Support Services for Chronic Depression|Completed||Phase 3|302|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 23:42:34.580821|2018-05-31 23:42:34.580821
NCT01139047|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2011-06-28||2012-09-21|2010-06-04|2010-06-08|Estimate|2011-06-28|2011-07-26|Estimate||||2012-09-21|2012-10-02|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between MetroGel® (Metronidazole Gel) 1% vs Finacea® (Azelaic Acid) 15% in Subjects With Healthy Skin|Completed||Phase 4|77|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-05-31 23:42:34.663963|2018-05-31 23:42:34.663963
NCT01139034|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-20|2010-06-07|2010-06-08|Estimate|||||||2010-06-20|2010-06-22|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||A Pilot Study of Shoulder Subluxation Treatment by Using the Self-Designed Surface Functional Electrical Stimulator|Rehabilitation Robot for Upper Limbs, Component Project 2: Hybrid of FES and Rehabilitation Robot for Treatment of Shoulder Subluxation|Unknown status|Recruiting|Phase 1|3|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 23:42:34.917195|2018-05-31 23:42:34.917195
NCT01139021|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2015-02-03||2015-04-09|2010-06-07|2010-06-08|Estimate|2015-04-09|2015-04-10|Estimate||||2015-04-09|2015-04-10|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Interventional|||One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age|A Phase 3, Open-Label, Multi-Center, Extension Study of V72P13E1 to Assess Antibody Persistence at One Year After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting at 12 Months of Age and to Evaluate the Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age|Completed||Phase 3|508|Actual|Novartis||6|||f||||t||||||||||2018-05-31 23:42:35.067629|2018-05-31 23:42:35.067629
NCT01139008|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2011-06-28||2012-09-21|2010-06-04|2010-06-08|Estimate|2011-06-28|2011-07-26|Estimate||||2012-09-21|2012-10-02|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between MetroGel® (Metronidazole Gel) 1% Versus Finacea® (Azelaic Acid) Gel 15% in Subjects With Healthy Skin|Completed||Phase 4|80|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-05-31 23:42:36.035969|2018-05-31 23:42:36.035969
NCT01138995|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2016-02-01||2016-03-28|2010-06-07|2010-06-08|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|L300||Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop|Functional Ambulation: Standard Treatment vs. Electronic Stimulation Therapy (FASTEST)Trial in Chronic Post-Stroke Subjects With Foot Drop|Completed||N/A|197|Actual|Bioness Inc||2|||f||||t||||||||||2018-05-31 23:42:36.272465|2018-05-31 23:42:36.272465
NCT01138982|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2016-03-05|2010-06-07|2010-06-08|Estimate|||||||2016-03-05|2016-03-08|Estimate|October 2007||2007-10-31|March 2016|2016-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effectiveness Study of a Swedish Youth Mentoring Program|A Randomized Effectiveness Trial of a One-to-one, Adult-to-youth Mentoring Program in Sweden|Completed||N/A|128|Actual|Karolinska Institutet||2|||f||||t||||||||No||2018-05-31 23:42:36.539501|2018-05-31 23:42:36.539501
NCT01138969|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|2012-12-31||2015-09-06|2010-06-07|2010-06-08|Estimate|2012-12-31|2013-02-04|Estimate||||2015-09-06|2015-09-09|Estimate|August 2008||2008-08-31|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer|Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer and Gastrointestinal Bleeding|Completed||Phase 2|165|Actual|Kaohsiung Veterans General Hospital.|The patients without symptoms who refused follow-up endoscopy were regarded as having no recurrent ulcers. Because peptic ulcer may be asymptomatic, the cumulative number of recurrent peptic ulcer might be underestimated in both groups.|2|||f||||t||||||||||2018-05-31 23:42:36.606874|2018-05-31 23:42:36.606874
NCT01138956|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-07|2010-06-07|2010-06-08|Estimate|||||||2010-06-07|2010-06-08|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|VLNAC||Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine|Study for Evaluation of the Immune Response of Visceral Leishmaniasis Patients Treated With Antimonial Pentavalent Associated to N-Acetylcysteine|Unknown status|Recruiting|N/A|40|Anticipated|Hospital Universitário Professor Edgard Santos||2|||f||||f||||||||||2018-05-31 23:42:36.916558|2018-05-31 23:42:36.916558
NCT01138943|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2011-05-13|2010-06-07|2010-06-08|Estimate|||||||2011-05-13|2011-05-16|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Chlorhexidine Mouthrinses and Plaque Control|Chlorhexidine Alcohol Base Mouthrinse Versus Chlorhexidine Formaldehyde Base Mouthrinse Efficacy on Plaque Control: Double Blind, Randomized Clinical Trials|Completed||N/A|30|Actual|Hôpital Militaire De Rabat||2|||f||||f||||||||||2018-05-31 23:42:37.034082|2018-05-31 23:42:37.034082
NCT01138930|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2013-05-08|2010-06-07|2010-06-08|Estimate|||||||2013-05-08|2013-05-10|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Effect of Berberine on Hormonal and Metabolic Features in Obese Women With Polycystic Ovary Syndrome (PCOS)|Effect of Berberine on Hormonal and Metabolic Features in Obese Women With PCOS|Unknown status|Recruiting|N/A|120|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||t||||||||||2018-05-31 23:42:37.126483|2018-05-31 23:42:37.126483
NCT01138917|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-01-24|2010-06-07|2010-06-08|Estimate|||||||2017-01-24|2017-01-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:42:37.275503|2018-05-31 23:42:37.275503
NCT01138904|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-11-02|2010-06-07|2010-06-08|Estimate|||||||2014-11-02|2014-11-04|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)|Randomized Phase II Study of FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Patients With Advanced or Relapsed Gastric Cancer|Completed||Phase 2|80|Actual|Dong-A University Hospital||2|||f||||f||||||||||2018-05-31 23:42:37.339514|2018-05-31 23:42:37.339514
NCT01138891|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2010-06-08|2010-06-07|2010-06-08|Estimate|||||||2010-06-08|2010-06-09|Estimate|February 2006||2006-02-28|June 2010|2010-06-30|June 2010|Actual|2010-06-30|March 2009|Actual|2009-03-31||Observational|||Sonication of Explanted Breast Implants for Detection of Subclinical Infection||Completed|||121|Actual|Centre Hospitalier Universitaire Vaudois|||1||f||||f||||||Samples Without DNA|"~     Breast implants~   "|||2018-05-31 23:42:37.451634|2018-05-31 23:42:37.451634
NCT01138878|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2012-04-11|2010-06-07|2010-06-08|Estimate|||||||2012-04-11|2012-04-12|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31||Observational|HINTS||HIV Testing in Non-traditional Settings Study|HIV Testing in Non-traditional Settings Study|Completed|||6350|Actual|Chelsea and Westminster NHS Foundation Trust|||4||f||||f||||||||||2018-05-31 23:42:37.551008|2018-05-31 23:42:37.551008
NCT01138865|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2013-06-21|2010-06-07|2010-06-08|Estimate|||||||2013-06-21|2013-06-24|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Interventional|CPAP||Effect of CPAP on Biomarkers in Patients With OSA|Effect of Continuous Positive Airway Pressure (CPAP) on Cardiovascular Biomarkers in Patients With Obstructive Sleep Apnea.|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 23:42:37.6546|2018-05-31 23:42:37.6546
NCT01138852|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate|July 2004||2004-07-31|July 2004|2004-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Ampicillin/Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section|Ampicillin / Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section: a Randomized Study|Completed||Phase 4|176|Actual|Attikon Hospital||2|||f||||t||||||||||2018-05-31 23:42:37.830521|2018-05-31 23:42:37.830521
NCT01138839|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Dexamethasone Efficacy in HELLP I Syndrome|Dexamethasone Efficacy in HELLP I Syndrome, a Multicentric, Double-blind, Placebo-controlled, Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|160|Anticipated|Universidad del Valle, Colombia||2|||f||||f||||||||||2018-05-31 23:42:37.967684|2018-05-31 23:42:37.967684
NCT01138826|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2011-06-21||2011-06-21|2010-06-04|2010-06-07|Estimate|2011-06-21|2011-07-20|Estimate||||2011-06-21|2011-07-20|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablet (ODT) And 10 Mg Amlodipine Besylate Tablets|Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 6-Sequence, 3-Period Crossover Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablets, Manufactured By Aurobindo Pharma Ltd., India To Amlodipine Besylate 10 Mg Tablets Manufactured by Pfizer Illertissen, Germany Under Fasted Conditions|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:42:38.109308|2018-05-31 23:42:38.109308
NCT01138813|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-10-09|2010-06-04|2010-06-07|Estimate|||||||2015-10-09|2015-10-12|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|MRS Tumor||Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145)|Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism|Completed|||8|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:42:38.488638|2018-05-31 23:42:38.488638
NCT01138800|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2012-11-15|2010-06-04|2010-06-07|Estimate|||||||2012-11-15|2012-11-16|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Assessing Chronic Pain Conditions in Patients (Pts) With and Without (w&wo) Interstitial Cystitis|Assessing Chronic Pain Conditions in Patients With and Without Interstitial Cystitis|Completed|||666|Actual|William Beaumont Hospitals|||||f||||f||||||||||2018-05-31 23:42:38.556197|2018-05-31 23:42:38.556197
NCT01138787|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-05-01|2010-06-04|2010-06-07|Estimate|||||||2017-05-01|2017-05-04|Actual|June 2010||2010-06-30|May 2017|2017-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|CASTELL||Cholesterol Absorption Inhibition Study|CASTELL = Cholesterol Absorption Study STErols (LL)|Completed||N/A|18|Anticipated|Unilever R&D||3|||f||||f||||||||||2018-05-31 23:42:38.630381|2018-05-31 23:42:38.630381
NCT01138774|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2015-05-27|2010-06-04|2010-06-07|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|OBEPALIP||Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) in Human Obesity|Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) on Adipose Tissue: Potential Application in Human Obesity|Completed||N/A|103|Actual|Clinica Universidad de Navarra, Universidad de Navarra||4|||f||||f||||||||||2018-05-31 23:42:38.710249|2018-05-31 23:42:38.710249
NCT01138761|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-06-17|2010-06-04|2010-06-07|Estimate|||||||2017-06-17|2017-06-20|Actual|June 2010||2010-06-30|June 2017|2017-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Health Literacy for Children With Atopic Dermatitis and Their Caregivers|Health Literacy for Children With Atopic Dermatitis and Their Caregivers|Terminated||N/A|33|Actual|University of Missouri-Columbia||2||Enrollment was significantly under target.|f||||f||||||||No||2018-05-31 23:42:38.818968|2018-05-31 23:42:38.818968
NCT01138748|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2013-02-01|2010-06-04|2010-06-07|Estimate|||||||2013-02-01|2013-02-04|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PEARL-2||Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers|Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers|Terminated||Phase 2|5|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 23:42:38.940337|2018-05-31 23:42:38.940337
NCT01138735|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2013-02-19|2012-05-07|2013-04-04|2010-06-04|2010-06-07|Estimate|2013-02-19|2013-03-26|Estimate|2012-05-07|2012-05-10|Estimate|2013-04-04|2013-04-11|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Epiduo Pediatric Acne Study|A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris|Completed||Phase 4|285|Actual|Galderma|LOCF data were used for primary efficacy and secondary efficacy data.|2|||f||||f||||||||||2018-05-31 23:42:39.018189|2018-05-31 23:42:39.018189
NCT01138722|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2011-08-24|2010-06-04|2010-06-07|Estimate|||||||2011-08-24|2011-08-25|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|May 2017|Anticipated|2017-05-31|August 2011|Actual|2011-08-31||Interventional|PEARL-1||Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial|Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer|Terminated||Phase 2|1|Actual|University Hospital, Ghent||||Poor recruitment rate.|f||||f||||||||||2018-05-31 23:42:39.357199|2018-05-31 23:42:39.357199
NCT01138709|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2013-07-29|2010-06-04|2010-06-07|Estimate|||||||2013-07-29|2013-07-30|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Vitala 12 Hour Wear Test With Convex Products|Phase II Vitala 12 Hour Wear Test With Convex Products|Completed||Phase 2|27|Actual|ConvaTec Inc.||1|||f||||f||||||||||2018-05-31 23:42:39.41714|2018-05-31 23:42:39.41714
NCT01138696|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-12-04|2010-06-04|2010-06-07|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||"Long Term Follow-up of the Stryker Dacron and Trevira Ligament for Anterior Cruciate Ligament (ACL) Repair"|"Long Term Follow-up of the Stryker Dacron and Trevira Ligament for ACL Repair"|Unknown status|Recruiting||80|Anticipated|University Hospital, Ghent|||2||f||||f||||||||||2018-05-31 23:42:39.531219|2018-05-31 23:42:39.531219
NCT01138683|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2012-01-09|2010-06-04|2010-06-07|Estimate|||||||2012-01-09|2012-01-10|Estimate|February 2010||2010-02-28|January 2012|2012-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|CRUF||Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration|Cardiorenal Interactions During Treatment of Acute Decompensated Heart Failure: Diuretics Versus Ultrafiltration|Completed||Phase 3|1|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:42:39.606717|2018-05-31 23:42:39.606717
NCT01138670|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2012-11-08|2010-06-04|2010-06-07|Estimate|||||||2012-11-08|2012-11-09|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Complications Following Pacemaker or Implantable Defibrillator Cardioverter (ICD) Implantation in Denmark|Complications Following Pacemaker or ICD Implantation in Denmark|Unknown status|Active, not recruiting||5500|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 23:42:39.677238|2018-05-31 23:42:39.677238
NCT01138657|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2016-07-11|2015-07-13|2016-07-11|2010-06-04|2010-06-07|Estimate|2016-07-11|2016-08-22|Estimate|2015-07-13|2015-08-03|Estimate|2016-07-11|2016-08-22|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|VISUAL l||Efficacy and Safety of Adalimumab in Patients With Active Uveitis|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients|Completed||Phase 3|239|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 23:42:39.756198|2018-05-31 23:42:39.756198
NCT01138644|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-04-28|2010-06-04|2010-06-07|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2013|Actual|2013-03-31||Observational|AFFORD||Atrial Fibrillation/Flutter Outcome Risk Determination|"The AFFORD Study: Atrial Fibrillation/Flutter Outcome Risk Determination"|Completed|||519|Actual|Vanderbilt University|||||f||||f||||||Samples With DNA|"~     whole blood for storing and conducting genetic testing.~   "|||2018-05-31 23:42:41.7032|2018-05-31 23:42:41.7032
NCT01138631|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-03-30|2010-06-04|2010-06-07|Estimate|||||||2017-03-30|2017-03-31|Actual|June 2010||2010-06-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Selection of Embryos by Time-lapse|Selection of Embryos for IVF Treatment by Time-lapse|Completed||N/A|59|Actual|University of Aarhus||2|||f||||t|f|f||||||||2018-05-31 23:42:41.783248|2018-05-31 23:42:41.783248
NCT01138618|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-11-04|2010-06-04|2010-06-07|Estimate|||||||2011-11-04|2011-11-07|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Observational|CHEMPAQ||Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)|Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)|Completed|||85|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 23:42:41.855537|2018-05-31 23:42:41.855537
NCT01138605|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2018-01-05|2010-06-03|2010-06-07|Estimate|||||||2018-01-05|2018-01-09|Actual|October 13, 2010|Actual|2010-10-13|January 2018|2018-01-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Interventional|||TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV|Continued Access to DRV/Rtv in HIV-1 Infected Children and Adolescents (Rollover Patients From C212, C228, C230)|Completed||Phase 2|46|Actual|Janssen Sciences Ireland UC||9|||f||||f||f||||||||2018-05-31 23:42:41.952453|2018-05-31 23:42:41.952453
NCT01138592|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2011-06-03|2010-06-04|2010-06-07|Estimate|||||||2011-06-03|2011-06-07|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Pilot Study to Evaluate the Clinical Utility of Auscultation Software at Remote Locations|Pilot Study to Evaluate the Clinical Utility of 3M Littmann Scope-to-Scope Software for Real-time Assessment of Patients at Remote Clinic Locations by Centrally-located Medical Providers|Completed|||150|Anticipated|3M|||1||f||||f||||||||||2018-05-31 23:42:42.171195|2018-05-31 23:42:42.171195
NCT01138579|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2016-04-25|2010-06-04|2010-06-07|Estimate|||||||2016-04-25|2016-04-26|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|STP-LYM-01||Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation|Phase I/II Dose-escalation Study of the Investigational Trifunctional Bispecific Anti-CD20 x Anti-CD3 Antibody FBTA05 in Combination With Donor Lymphocyte Infusion (DLI) in Patients With CD20 Positive Chronic Lymphocytic Leukemia (CLL), Low and High Grade Non-Hodgkin´s Lymphoma (NHL) After Allogeneic Stem Cell Transplantation|Terminated||Phase 1/Phase 2|9|Actual|Technische Universität München||1||Recruitment delayed, trial medication no loner available|f||||t||||||||||2018-05-31 23:42:42.23422|2018-05-31 23:42:42.23422
NCT01138566|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate||||April 2010|2010-04-30||||||||Observational|||Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae|Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae|Unknown status|Not yet recruiting||400|Anticipated|Taipei Veterans General Hospital, Taiwan|||1||f||||t||||||||||2018-05-31 23:42:42.346163|2018-05-31 23:42:42.346163
NCT01138553|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-11-30|2010-06-04|2010-06-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2010||2010-06-30|November 2015|2015-11-30||||June 2014|Actual|2014-06-30||Interventional|||Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer|A Biomarker Study of Mifepristone in Early Stage Breast Cancer|Terminated||Early Phase 1|4|Actual|University of California, San Diego||1||Inadequate subject accrual|f||||t||||||||||2018-05-31 23:42:42.40661|2018-05-31 23:42:42.40661
NCT01138540|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-06-14|2010-06-04|2010-06-07|Estimate|||||||2017-06-14|2017-06-16|Actual|November 2010|Actual|2010-11-30|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Gravity-VAP||The Gravity-VAP (Ventilator-Associated Pneumonia) Trial|Prospective, Randomized, Multi-Center Trial of Lateral Trendelenburg Versus Semi-Recumbent Body Position in Mechanically Ventilated Patients For The Prevention of Ventilator-Associated Pneumonia|Terminated||Phase 3|800|Anticipated|Policlinico Hospital||2||"Steering Committee accepted DSMB advise to terminate the study after review of data analysis at~   second interim analysis"|f||||t||||||||||2018-05-31 23:42:42.501242|2018-05-31 23:42:42.501242
NCT01138527|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-11-09|2010-06-04|2010-06-07|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|August 2015|Actual|2015-08-31||Observational|PCa-MAP||Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach|Prostate Cancer Localization With a Multiparametric MR Approach|Unknown status|Active, not recruiting||150|Anticipated|Radboud University|||1||f||||f||||||Samples Without DNA|"~     fixed histopathology slides of resected prostates at local institutions: Not different from~     clinical routine~   "|||2018-05-31 23:42:42.610253|2018-05-31 23:42:42.610253
NCT01138514|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2016-01-05|2012-03-15|2016-03-28|2010-06-04|2010-06-07|Estimate|2016-03-28|2016-03-29|Estimate|2012-03-15|2012-03-19|Estimate|2016-03-28|2016-03-29|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd., Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to a Comparator Clindamycin / Benzoyl Peroxide Topical Gel, and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris|Completed||Phase 3|1555|Actual|Perrigo Company||3|||f||||t||||||||||2018-05-31 23:42:42.721823|2018-05-31 23:42:42.721823
NCT01138501|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2013-11-14||2017-02-09|2010-06-04|2010-06-07|Estimate|2014-05-12|2014-06-11|Estimate||||2017-02-09|2017-03-17|Actual|June 2010||2010-06-30|February 2017|2017-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|guardian™ 3||Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A|A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A|Completed||Phase 3|65|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 23:42:43.141266|2018-05-31 23:42:43.141266
NCT01138488|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-02-09|2010-06-04|2010-06-07|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2010||2010-06-30|February 2017|2017-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of NN5401 in Children, Adolescents and Adults With Type 1 Diabetes|Completed||Phase 1|38|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 23:42:43.38271|2018-05-31 23:42:43.38271
NCT01138475|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|2016-11-10||2017-02-01|2010-06-04|2010-06-07|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|July 2010||2010-07-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ExtenD||Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery|A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery|Completed||Phase 3|49|Actual|William Beaumont Hospitals|The impact of malabsorption noted in Gastric Bypass patients may impact drug and nutritional absorption differently between patients and this effect can wane over time for some. Additionally, the study N and the short duration of treatment.|3|||f||||f||||||||No||2018-05-31 23:42:43.587052|2018-05-31 23:42:43.587052
NCT01138462|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-05-22|2010-06-04|2010-06-07|Estimate|||||||2014-05-22|2014-05-23|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions|Universal Screening and Decolonization vs Standard Precautions for Control of Methicillin-resistant Staphylococcus Aureus (MRSA) in Nursing Homes: a Cluster, Randomised Controlled Study.|Completed||N/A|157|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 23:42:44.255551|2018-05-31 23:42:44.255551
NCT01138449|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-05-29|2010-06-04|2010-06-07|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)|Efficacy of Neonatal Vitamin A Supplementation in Improving Child Survival in Haryana, India: Generation of Evidence Necessary for Informing Global Policy|Completed||N/A|44984|Actual|Society for Applied Studies||2|||f||||t||||||||||2018-05-31 23:42:44.348413|2018-05-31 23:42:44.348413
NCT01135849|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-11-16|2010-06-02|2010-06-03|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||B-Receptor Signaling in Cardiomyopathy|B-Receptor Signaling in Cardiomyopathy|Completed|||99|Actual|Stanford University|||||f||||t||||||Samples Without DNA|"~     cheek swab or blood drawn for DNA extraction~   "|||2018-05-31 23:43:27.900169|2018-05-31 23:43:27.900169
NCT01138436|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04||2013-07-19|2018-04-16|2010-06-04|2010-06-07|Estimate||||2013-07-19|2013-07-23|Estimate|2018-04-16|2018-04-18|Actual|November 2010||2010-11-30|April 2018|2018-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Venous Leg Ulcers|A Phase II, Randomized, Controlled, Two-Center Pilot Study of the Safety and Efficacy of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Venous Leg Ulcers|Completed||Phase 2|5|Actual|Skingenix, Inc.||2|||f||||f||||||||No||2018-05-31 23:42:44.425361|2018-05-31 23:42:44.425361
NCT01138423|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2012-02-23|2010-06-04|2010-06-07|Estimate|||||||2012-02-23|2012-02-24|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|TARGET||Treatment of Adiposity Related hypErTension (TARGET)|A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension|Completed||Phase 4|32|Actual|UMC Utrecht||4|||f||||f||||||||||2018-05-31 23:42:44.509362|2018-05-31 23:42:44.509362
NCT01138410|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-08-16|2010-06-04|2010-06-07|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2010|Actual|2010-05-31|August 2017|2017-08-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||Study of a DNA Immunotherapy to Treat Melanoma|A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma|Terminated||Phase 1/Phase 2|35|Actual|Scancell Ltd||1||Product availability|f||||f||||||||||2018-05-31 23:42:44.620397|2018-05-31 23:42:44.620397
NCT01138397|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-10-05|2010-06-04|2010-06-07|Estimate|||||||2015-10-05|2015-10-06|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)|Completed||Phase 3|129|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:42:44.70471|2018-05-31 23:42:44.70471
NCT01138384|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-05-09|2010-06-04|2010-06-07|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2010||2010-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|March 2014|Actual|2014-03-31||Interventional|||Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer|A Phase I/II Study of Foretinib in Combination With Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer|Completed||Phase 1/Phase 2|19|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-05-31 23:42:44.793195|2018-05-31 23:42:44.793195
NCT01138371|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2013-12-16|2010-06-04|2010-06-07|Estimate|||||||2013-12-16|2013-12-17|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|INFLAME||Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers|Inflammatory and Lipid Markers Pre- and Post-LDL Apheresis: A Multicenter Experience|Completed|||8|Actual|Emory University|||1||f||||t||||||Samples Without DNA|"~     Blood samples only~   "|||2018-05-31 23:42:44.880593|2018-05-31 23:42:44.880593
NCT01138358|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2013-08-23|2010-06-04|2010-06-07|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|October 2012|Actual|2012-10-31|August 2010|Actual|2010-08-31||Observational|||Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease|Experiences of Episodic Breathlessness (EB) in Patients With Advanced Disease|Completed|||50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:42:44.966091|2018-05-31 23:42:44.966091
NCT01138345|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2014-02-26|2010-06-04|2010-06-07|Estimate|||||||2014-02-26|2014-02-27|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Observational|||Biomarkers in Blood Samples From Older Breast Cancer Survivors|The Effect of Chemotherapy on Aging in Older Women With Breast Cancer as Measured by Expression of p16INK4a|Completed|||246|Actual|UNC Lineberger Comprehensive Cancer Center|||3||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 23:42:45.039229|2018-05-31 23:42:45.039229
NCT01138332|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-05-05|2010-06-04|2010-06-07|Estimate|||||||2015-05-05|2015-05-06|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Biomarkers in Young Patients With Acute Myeloid Leukemia|Stat3 Signaling Pathway Aberrancies in Pediatric AML|Completed|||20|Actual|Children's Oncology Group|||||f||||f||||||||||2018-05-31 23:42:45.148252|2018-05-31 23:42:45.148252
NCT01138319|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2015-05-05|2010-06-04|2010-06-07|Estimate|||||||2015-05-05|2015-05-06|Estimate|February 2009||2009-02-28|May 2015|2015-05-31||||March 2010|Actual|2010-03-31||Observational|||Biomarkers in Patients With Acute Myeloid Leukemia|Mitochondrial Mutations and AML|Completed|||18|Actual|Children's Oncology Group|||||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 23:42:45.19606|2018-05-31 23:42:45.19606
NCT01138306|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2016-05-17|2010-06-04|2010-06-07|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia|Implications of s-SHIP Expression and SHIP Alterations in AML|Completed|||149|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-05-31 23:42:45.256241|2018-05-31 23:42:45.256241
NCT01138293|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-25|2010-06-04|2010-06-07|Estimate|||||||2010-06-25|2010-06-28|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Electronic Health Technology for Assessment of Physical Activity and Eating Habits in Children and Adolescents Who Are Overweight and Those With Obesity||Completed||Phase 1|73|Actual|MEDIGREIF Inselklinik Heringsdorf||1|||f||||t||||||||||2018-05-31 23:42:45.325315|2018-05-31 23:42:45.325315
NCT01138280|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate|March 2005||2005-03-31|January 2005|2005-01-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Heat Disinfection of HD Water Treatment System in Hemodialysis Patients|Effect of Heat Disinfection of HD Water Treatment System on Cardiovascular Events and Outcome in Hemodialysis Patients|Completed||Phase 4|540|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 23:42:45.515186|2018-05-31 23:42:45.515186
NCT01138111|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2014-01-10||2014-05-22|2010-06-04|2010-06-07|Estimate|2014-05-22|2014-06-25|Estimate||||2014-05-22|2014-06-25|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||All enrolled subjects who received at least one florbetaben (BAY94-9172) injection|Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients|ß-amyloid Imaging With BAY94-9172 Positron Emission Tomography for Early Detection of Alzheimer's Disease in Patients With Mild Cognitive Impairment|Completed||Phase 1|45|Actual|Piramal Imaging SA||1|||f||||f||||||||||2018-05-31 23:42:48.864901|2018-05-31 23:42:48.864901
NCT01135654|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2018-02-09|2010-06-02|2010-06-03|Estimate|||||||2018-02-09|2018-02-13|Actual|January 2010||2010-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2012|Actual|2012-10-31||Interventional|ADVISE||Alcohol Drinking as a Vital Sign|Alcohol SBIRT Implementation in an HMO: Non-Physician Providers Vs Physicians|Active, not recruiting||N/A|466000|Anticipated|Kaiser Permanente||3|||f||||f||||||||||2018-05-31 23:43:29.873227|2018-05-31 23:43:29.873227
NCT01138267|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2011-02-03|2010-06-04|2010-06-07|Estimate|||||||2011-02-03|2011-02-07|Estimate|May 2009||2009-05-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)|Impact of Pharmacogenomics on Antiretroviral Drugs (Atazanavir and Efavirenz) Concentration and Treatment Response in HIV-infected Adults Study-team|Completed|||450|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration|||||f||||t||||||Samples With DNA|"~     Patients are divided into 4 groups based on whether they need to redraw their blood.~        1. have adequate samples stored and do not need additional blood draws.~        2. have EFV or ATV blood concentrations samples stored but do not have samples for~          genotyping. Need extra 5-ml sample.~        3. have samples stored but the samples cannot be used to test for EFV or ATV blood~          concentrations because the time of drug intake and blood drawn are unknown. Need to~          redraw 5-ml sample.~        4. have never had both drug concentration and genotyping done. Need to give 10 ml of blood~          sample to perform both tests.~   "|||2018-05-31 23:42:45.628463|2018-05-31 23:42:45.628463
NCT01138254|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-07-12|2010-06-04|2010-06-07|Estimate|||||||2011-07-12|2011-07-14|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients|The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease|Unknown status|Recruiting|Phase 4|200|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 23:42:45.709459|2018-05-31 23:42:45.709459
NCT01138241|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2017-08-09|2010-06-04|2010-06-07|Estimate|||||||2017-08-09|2017-08-10|Actual|March 2010||2010-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation|Incidence and Predictor of TDF Associated Nephrotoxicity and Pharmacokinetic of TDF in HIV-1 Infected Thai Patients: A Sub-study of HIV-NAT 006 Long Term Cohort|Completed|||700|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||3||f||||f||||||Samples With DNA|"~     PBMC collection~   "|||2018-05-31 23:42:45.809837|2018-05-31 23:42:45.809837
NCT01138228|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|VFvalidation||Does the VTS1000 Infra Red Vein Imager Allow Better Identification of Veins Than Normal Eyesight?|Validation of Vue Tek Digital Vein Viewing Device|Completed|||106|Actual|St. Luke's-Roosevelt Hospital Center|||2||f||||f||||||||||2018-05-31 23:42:45.91352|2018-05-31 23:42:45.91352
NCT01138215|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children|The Immunogenicity of Varicella-zoster Virus Vaccine in HIV-infected Children|Completed||Phase 4|60|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-05-31 23:42:46.040121|2018-05-31 23:42:46.040121
NCT01138202|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2016-02-19|2010-06-04|2010-06-07|Estimate|||||||2016-02-19|2016-02-22|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy|A Pilot Study of the Pharmacokinetics and Safety of Lopinavir/Ritonavir 400/100mg Bid Versus Lopinavir/Ritonavir 600/150 mg BID Combined With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy|Completed||Phase 2|40|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-05-31 23:42:46.145401|2018-05-31 23:42:46.145401
NCT01138189|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2018-04-22|2010-06-04|2010-06-07|Estimate|||||||2018-04-22|2018-04-24|Actual|April 2010||2010-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Wavefront-guided Versus Wavefront-optimized LASIK for Nearsightedness|A Prospective Eye to Eye Comparison of LASIK Using Wavefront-guided Treatment Versus Wavefront-optimized Treatment|Active, not recruiting|||50|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 23:42:46.296161|2018-05-31 23:42:46.296161
NCT01138176|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-03|2010-06-03|2010-06-07|Estimate|||||||2010-06-03|2010-06-07|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|August 2011|Anticipated|2011-08-31|January 2011|Anticipated|2011-01-31||Interventional|||Whole Body Cooling Using Phase Changing Material|Phase II Randomized Control Trial of Whole Body Cooling in Neonatal Encephalopathy Using Phase Changing Material|Unknown status|Active, not recruiting|Phase 1/Phase 2|35|Anticipated|Robertson, Nicola, M.D.||2|||f||||t||||||||||2018-05-31 23:42:46.403559|2018-05-31 23:42:46.403559
NCT01138163|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03||2017-04-18|2017-04-18|2010-06-04|2010-06-07|Estimate||||2017-04-18|2017-04-19|Actual|2017-04-18|2017-04-19|Actual|June 2010||2010-06-30|April 2017|2017-04-30|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer|Completed||Phase 2|121|Actual|Peregrine Pharmaceuticals||3|||f||||t||||||||||2018-05-31 23:42:46.576034|2018-05-31 23:42:46.576034
NCT01138150|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2016-02-09||2016-08-15|2010-06-03|2010-06-07|Estimate|2016-08-15|2016-10-06|Estimate||||2016-08-15|2016-10-06|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ictal and Interictal Inflammatory Markers in Migraine|Ictal and Interictal Inflammatory Markers in Migraine|Completed||Phase 4|36|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 23:42:46.812071|2018-05-31 23:42:46.812071
NCT01138137|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-04-19|2010-06-04|2010-06-07|Estimate|||||||2017-04-19|2017-04-21|Actual|June 2010||2010-06-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer|Phase I Dose Escalation Study of N-acetylcysteine (NAC) Administered Intravenously (IV) in Conjunction With Intraperitoneal (IP) Administered Cisplatin and IV/IP Paclitaxel in Patients With Stage III or IV Ovarian Cancer|Withdrawn||Phase 1|0|Actual|OHSU Knight Cancer Institute||1||No funding was available for the cost of the IV N-acetylcysteine (NAC).|f||||t||||||||||2018-05-31 23:42:47.378772|2018-05-31 23:42:47.378772
NCT01138124|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2010-12-16||2017-05-24|2010-06-03|2010-06-07|Estimate|2010-12-16|2011-01-07|Estimate||||2017-05-24|2017-05-30|Actual|March 2010||2010-03-31|May 2017|2017-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)|Risk of Pancreatic Cancer and Renal Cancer in Patients Exposed to Gabapentin in the United Kingdom General Practice Research Database|Completed|||54202|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:42:47.529104|2018-05-31 23:42:47.529104
NCT01138098|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2011-11-10||2016-09-22|2010-06-03|2010-06-07|Estimate|2011-11-17|2011-12-21|Estimate||||2016-09-22|2016-10-20|Estimate|June 2010||2010-06-30|September 2016|2016-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children|Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in 11-12 Year Old Children, Previously Vaccinated With DTPa-HBV-IPV/Hib Vaccine in Study 217744/031|Completed||Phase 4|185|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:42:49.313406|2018-05-31 23:42:49.313406
NCT01138085|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-11-08|2010-06-03|2010-06-07|Estimate|||||||2017-11-08|2017-11-13|Actual|May 4, 2010|Actual|2010-05-04|November 2017|2017-11-30|November 19, 2014|Actual|2014-11-19|November 19, 2014|Actual|2014-11-19||Interventional|||Safety, Pharmacokinetics (PK) of AKT and MEK Combination|A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795|Completed||Phase 1|240|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:42:49.69155|2018-05-31 23:42:49.69155
NCT01138072|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-11-04|2010-06-03|2010-06-07|Estimate|||||||2010-11-04|2010-11-05|Estimate|June 2010||2010-06-30|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.|A Phase I, Single-center, Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.|Completed||Phase 1|14|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 23:42:49.785589|2018-05-31 23:42:49.785589
NCT01138059|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|RESTORE||Reperfusion Therapy in Acute Ischemic Stroke With Unclear Onset|REperfusion Therapy in Acute Ischemic STroke With Unclear Onset by MRI Evaluation|Completed|||83|Actual|Asan Medical Center|||1||f||||t||||||||||2018-05-31 23:42:49.873712|2018-05-31 23:42:49.873712
NCT01138046|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2014-09-15||2014-09-29|2010-06-03|2010-06-07|Estimate|2014-09-15|2014-09-19|Estimate||||2014-09-29|2014-10-07|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC|An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients|Completed||Phase 2|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:42:49.973239|2018-05-31 23:42:49.973239
NCT01138033|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-05-10|2010-06-03|2010-06-07|Estimate|||||||2017-05-10|2017-05-11|Actual|July 27, 2010|Actual|2010-07-27|May 2017|2017-05-31|December 21, 2015|Actual|2015-12-21|December 21, 2015|Actual|2015-12-21||Interventional|||Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors|A Phase I Open-Label Dose Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects With Solid Tumors|Completed||Phase 1|74|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 23:42:50.496758|2018-05-31 23:42:50.496758
NCT01138020|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2018-01-31|2010-06-04|2010-06-07|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 1, 2011|Actual|2011-03-01|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|CRbTBI||Cognitive Rehabilitation of Blast Traumatic Brain Injury (TBI)|Cognitive Rehabilitation of Blast-induced Traumatic Brain Injury|Active, not recruiting||N/A|120|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 23:42:50.58108|2018-05-31 23:42:50.58108
NCT01138007|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2013-03-07||2016-11-20|2010-06-03|2010-06-07|Estimate|2013-05-02|2013-05-06|Estimate||||2016-11-20|2017-01-11|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)|Study AK1113351, a Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) - a Multi-center, Placebo-controlled, Randomized, Double-blind, Parallel-comparison Study|Completed||Phase 3|572|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:42:50.676219|2018-05-31 23:42:50.676219
NCT01137994|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2013-03-11|2010-06-03|2010-06-07|Estimate|||||||2013-03-11|2013-03-13|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|March 2018|Anticipated|2018-03-31|December 2016|Anticipated|2016-12-31||Interventional|||A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer|A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:42:51.515923|2018-05-31 23:42:51.515923
NCT01137981|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2017-10-20|2010-06-03|2010-06-07|Estimate|||||||2017-10-20|2017-10-24|Actual|February 15, 1993|Actual|1993-02-15|October 2017|2017-10-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31|31 Years|Observational [Patient Registry]|||Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects|Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects Associated With Exposure to GSK HIV Drugs During Pregnancy|Recruiting|||1|Anticipated|ViiV Healthcare|||1||f||||f|f|f||||||||2018-05-31 23:42:51.69823|2018-05-31 23:42:51.69823
NCT01137968|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03||2015-03-13|2015-12-22|2010-06-04|2010-06-07|Estimate||||2015-03-13|2015-04-02|Estimate|2015-12-22|2016-01-26|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)|Completed||Phase 2|116|Actual|Geron Corporation||2|||f||||f||||||||||2018-05-31 23:42:51.895076|2018-05-31 23:42:51.895076
NCT01137955|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2011-01-19|2010-06-03|2010-06-07|Estimate|||||||2011-01-19|2011-01-21|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease|Double-blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients With Celiac Disease|Completed||N/A|41|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 23:42:52.058805|2018-05-31 23:42:52.058805
NCT01137942|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-07-09|2010-06-04|2010-06-07|Estimate|||||||2010-07-09|2010-07-12|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|December 2009|Actual|2009-12-31||Observational|||The Role of Cathepsin X in Infection With the Helicobacter Pylori|Helicobacter Pylori and Gastric Cancer - the Role of Cytokine Polymorphism, Cytokine Expression and Expression of TLR on Persistence of Helicobacter Pylori Infection and Development of Gastric Cancer.|Unknown status|Recruiting||14|Anticipated|University Medical Centre Ljubljana|||1||f||||t||||||Samples With DNA|"~     Helicobacter pylori strains from patients are stored at -70oC.~   "|||2018-05-31 23:42:52.387263|2018-05-31 23:42:52.387263
NCT01137929|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2014-10-01|2010-06-04|2010-06-07|Estimate|||||||2014-10-01|2014-10-02|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Bacterial and Host Genetic Risk Factors in Acute Pyelonephritis|Bacterial and Host Genetic Risk Factors That Predispose Children to Acute Pyelonephritis and Renal Scarring|Withdrawn|||0|Actual|Children's Research Institute|||6|Difficulty identifying eligible candidates|f||||f||||||Samples With DNA|"~     Urine samples: Urine is routinely collected at the time of presentation with fever to~     diagnose UTI and an aliquot of this urine sample will be frozen for microbial genomic and~     metagenomic sequencing and analysis, that will allow us to identify~     unique/pathogenic/virulence factors in the genomes of these bacterial species when compared~     to non-pathogenic strains that have been subject to whole genome sequencing.~      Blood: DNA samples will be obtained at the time of renal scanning from the study subjects.~     The genomic DNA is used in PCR reactions and the resulting PCR products are screened for~     single nucelotide polymorphisms. Although we will be performing a genome wide association~     study, we will be particularly curious as to the behavior of SNP's among certain previously~     described candidates for the risk of renal scarring such as TLR2, TLR4, TGF-beta, and~     TNF-alpha. DNA samples will be stored for possible use in other future association studies.~   "|||2018-05-31 23:42:52.477581|2018-05-31 23:42:52.477581
NCT01137916|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-05-02|2010-06-04|2010-06-07|Estimate|||||||2017-05-02|2017-05-03|Actual|June 2010||2010-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study to Evaluate Imatinib in Desmoid Tumors|Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss|Completed||Phase 2|39|Actual|Heidelberg University||1|||f||||t||||||||||2018-05-31 23:42:52.54035|2018-05-31 23:42:52.54035
NCT01137903|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-04|||2010-06-04|2010-06-04|2010-06-07|Estimate|||||||2010-06-04|2010-06-07|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|November 2011|Anticipated|2011-11-30|April 2011|Anticipated|2011-04-30||Interventional|||Efficacy of Surgical Treatment of Osteomyelitis in Diabetic Foot Ulcers|Prospective Randomized Clinical Trial Comparing Efficacy Surgical Versus Medical Treatment of Osteomyelitis in Diabetic Foot Ulcers|Unknown status|Recruiting|N/A|88|Anticipated|Universidad Complutense de Madrid||2|||f||||t||||||||||2018-05-31 23:42:52.654073|2018-05-31 23:42:52.654073
NCT01137890|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2017-04-17||2017-09-01|2010-06-04|2010-06-07|Estimate|2017-09-01|2017-09-05|Actual||||2017-09-01|2017-09-05|Actual|June 2010||2010-06-30|September 2017|2017-09-30|August 2013|Actual|2013-08-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse|Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse|Completed||Phase 1/Phase 2|19|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:42:52.962182|2018-05-31 23:42:52.962182
NCT01137877|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-11-24|2010-06-03|2010-06-07|Estimate|||||||2010-11-24|2010-11-25|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Growth and Tolerance of Healthy Term Infants to a New Infant Formula|Growth and Tolerance of Healthy Term Infants to a New Infant Formula|Terminated||Phase 3|399|Actual|Abbott Nutrition||4||The control product was recalled.|f||||t||||||||||2018-05-31 23:42:53.88013|2018-05-31 23:42:53.88013
NCT01137864|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2014-07-28|2010-06-04|2010-06-07|Estimate|||||||2014-07-28|2014-07-29|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|ATBREFEMERG||Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards|Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Emergency Wards: a Multicenter Randomized Controlled Trial.|Completed||N/A|255|Actual|Henri Mondor University Hospital||2|||f||||f||||||||||2018-05-31 23:42:54.021418|2018-05-31 23:42:54.021418
NCT01137851|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-09-30|2010-06-04|2010-06-07|Estimate|||||||2010-09-30|2010-10-01|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients|Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients Treated With Biologic Disease Modifying Antirheumatic Drug (DMARD) Therapies|Completed|||3940|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 23:42:54.111176|2018-05-31 23:42:54.111176
NCT01137838|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-05-16|2010-06-04|2010-06-07|Estimate|||||||2011-05-16|2011-05-17|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents|Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents|Completed|||1810|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 23:42:54.195872|2018-05-31 23:42:54.195872
NCT01137825|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-07-26|2010-06-03|2010-06-04|Estimate|||||||2017-07-26|2017-07-31|Actual|September 2009||2009-09-30|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Registry of Older Patients With Cancer|Carolina Senior: UNC Registry for Older Cancer Patients|Recruiting|||150|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||f||||||||||2018-05-31 23:42:54.273586|2018-05-31 23:42:54.273586
NCT01137812|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2013-04-02|2012-06-01|2015-01-05|2010-06-03|2010-06-04|Estimate|2013-04-02|2013-05-17|Estimate|2012-06-12|2012-06-14|Estimate|2015-01-05|2015-01-15|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)|A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy|Completed||Phase 3|756|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 23:42:54.513801|2018-05-31 23:42:54.513801
NCT01137799|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2012-11-07|2010-06-03|2010-06-04|Estimate|||||||2012-11-07|2012-11-08|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|||||Interventional|||The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients|A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia|Terminated||Phase 1|47|Actual|Janssen Pharmaceutica N.V., Belgium||6||Efficacy signals were insufficiently strong to justify recruitment of additional patients.|f||||f||||||||||2018-05-31 23:42:55.765514|2018-05-31 23:42:55.765514
NCT01137617|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2018-04-03|2010-06-03|2010-06-04|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2010||2010-06-30|April 2018|2018-04-30|December 20, 2016|Actual|2016-12-20|August 2011|Actual|2011-08-31||Observational|SCS||Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients.|Effect of Spinal Cord Stimulation on Pain Thresholds and Sensory Perception in Chronic Pain Patients.|Completed|||19|Actual|Massachusetts General Hospital|||||f||||f|f|f||||||No||2018-05-31 23:43:00.270671|2018-05-31 23:43:00.270671
NCT01137786|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2013-05-22||2013-08-07|2010-06-03|2010-06-04|Estimate|2013-08-07|2013-09-30|Estimate||||2013-08-07|2013-09-30|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Evaluable patient population for NGAL analysis included all patients with both pre-dose baseline and post-dose blood and/or urine NGAL values for at least 2 out of the 4 planned measurements within 24 hours post-administration.|Kidney Damage in Patients With Normal eGFR|A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320|Completed||Phase 4|49|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-05-31 23:42:55.920753|2018-05-31 23:42:55.920753
NCT01137773|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2017-04-09||2017-08-08|2010-06-03|2010-06-04|Estimate|2017-08-08|2017-08-10|Actual||||2017-08-08|2017-08-10|Actual|January 2007||2007-01-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Normoglycemia and Neurological Outcome|Does Maintenance of Normoglycemia Change Neurological Outcome in Patients Recovering From Traumatic Brain Injury and Subarachnoid or Intraparenchymal Hemorrhage?|Terminated||Phase 4|56|Actual|University of Louisville||2||Slow enrollment|f||||f||||||||||2018-05-31 23:42:56.33523|2018-05-31 23:42:56.33523
NCT01137760|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2012-08-01|2010-06-03|2010-06-04|Estimate|||||||2012-08-01|2012-08-02|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Galactooligosaccharide, Immune Strength, and Digestive Health|Protocol 1: Galactooligosaccharide, Immune Strength, and Digestive Health in Academically Stressed University Students|Completed||N/A|427|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 23:42:56.64293|2018-05-31 23:42:56.64293
NCT01137747|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2016-06-13|2010-06-03|2010-06-04|Estimate|||||||2016-06-13|2016-06-14|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|AML ALL||Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia|A Phase I Trial of Carfilzomib in Adult Patients With Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia|Completed||Phase 1|18|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 23:42:56.737664|2018-05-31 23:42:56.737664
NCT01137734|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-12-22|2010-06-03|2010-06-04|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|February 2012|Actual|2012-02-29||Interventional|||CARDINAL Adjustable Annuloplasty Ring System For Treatment of Mitral Regurgitation|Valtech Cardinal Adjustable Semi-Rigid Annuloplasty Ring System For Treatment of Mitral Valve Regurgitation in Open Surgical Repair|Completed||Phase 2|30|Actual|Edwards Lifesciences|||||f||||t||||||||||2018-05-31 23:42:56.836868|2018-05-31 23:42:56.836868
NCT01137721|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2016-08-01|2010-06-03|2010-06-04|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||State Of The Art Functional Imaging In Sickle Cell Disease|State Of The Art Functional Imaging In Sickle Cell Disease|Completed|||38|Actual|St. Jude Children's Research Hospital|||4||f||||f||||||||||2018-05-31 23:42:56.913937|2018-05-31 23:42:56.913937
NCT01137708|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2010-08-05|2010-06-03|2010-06-04|Estimate|||||||2010-08-05|2010-08-06|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||CP-690,550 And Oral Contraception Drug-Drug Interaction Study|A Phase 1, Randomized, Open Label, 2-Way Crossover Study To Assess The Effect Of Multiple Dose CP-690,550 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids In Healthy Female Subjects|Completed||Phase 1|20|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:42:57.015692|2018-05-31 23:42:57.015692
NCT01137695|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2011-10-13|2010-06-03|2010-06-04|Estimate|||||||2011-10-13|2011-10-14|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|January 2012|Anticipated|2012-01-31||Interventional|||Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus|Symlin® Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|North Jersey Endocrine Consultants, LLC||4|||f||||f||||||||||2018-05-31 23:42:57.081817|2018-05-31 23:42:57.081817
NCT01137682|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2015-01-13|2014-11-04|2018-04-02|2010-06-03|2010-06-04|Estimate|2015-01-13|2015-01-21|Estimate|2014-11-04|2014-11-18|Estimate|2018-04-02|2018-04-05|Actual|July 19, 2010|Actual|2010-07-19|April 2018|2018-04-30|February 28, 2017|Actual|2017-02-28|January 22, 2013|Actual|2013-01-22||Interventional|PAOLA||Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly|A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly|Completed||Phase 3|198|Actual|Novartis||3|||f|||||t|f||||||Undecided||2018-05-31 23:42:57.315507|2018-05-31 23:42:57.315507
NCT01137669|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-01-05|2010-06-03|2010-06-04|Estimate|||||||2017-01-05|2017-01-09|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||ZOSTAVAX® in Renal Transplant Patients|Phase I Trial of ZOSTAVAX® Prior to Renal Transplantation|Completed||Phase 1|34|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 23:42:59.745393|2018-05-31 23:42:59.745393
NCT01137656|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2015-04-10|2010-06-03|2010-06-04|Estimate|||||||2015-04-10|2015-04-14|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis|Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis|Completed||Phase 1|53|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 23:42:59.950119|2018-05-31 23:42:59.950119
NCT01137643|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-09-20|2010-06-03|2010-06-04|Estimate|||||||2017-09-20|2017-09-21|Actual|July 2009||2009-07-31|September 2017|2017-09-30|July 2040|Anticipated|2040-07-31|July 2040|Anticipated|2040-07-31||Observational|||Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer|Tissue Procurement For Hematolymphoid Conditions|Recruiting|||15000|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||f||||||Samples With DNA|"~     Tumor tissue, blood, bone marrow, urine, ascites~   "|||2018-05-31 23:43:00.059347|2018-05-31 23:43:00.059347
NCT01137630|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-03|2010-06-03|2010-06-04|Estimate|||||||2010-06-03|2010-06-04|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp|A Multicenter, Randomised Double Blind, Placebo Controlled Study of Efficacy, Safety and Tolerability of Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp.|Completed||Phase 2/Phase 3|98|Actual|Moberg Pharma AB||3|||f||||f||||||||||2018-05-31 23:43:00.172845|2018-05-31 23:43:00.172845
NCT01137604|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2015-03-13||2016-05-20|2010-06-03|2010-06-04|Estimate|2016-05-20|2016-05-23|Estimate||||2016-05-20|2016-05-23|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|May 2014|Actual|2014-05-31|March 2013|Actual|2013-03-31||Interventional|||A Study in Subjects With Recurrent Malignant Glioma|An Open-Label, Three-Cohort, Phase 2 Study of E7080 (Lenvatinib) in Subjects With Recurrent Malignant Glioma|Completed||Phase 2|151|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 23:43:00.407731|2018-05-31 23:43:00.407731
NCT01137591|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2015-03-03|2010-06-03|2010-06-04|Estimate|||||||2015-03-03|2015-03-05|Estimate|April 2009||2009-04-30|March 2015|2015-03-31||||||||Interventional|||Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever|Acetaminophen in Combination With N-Acetylcysteine (NAC) vs. Placebo in the Treatment of Fever: A Double-Blind, Randomized Control Study|Withdrawn||N/A|0|Actual|Columbia University||2||Unable to recruit sufficient participants due to lack of funding; PI has left the institution.|f||||f||||||||||2018-05-31 23:43:01.534264|2018-05-31 23:43:01.534264
NCT01137578|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2014-11-19||2014-11-25|2010-06-03|2010-06-04|Estimate|2014-11-19|2014-11-25|Estimate||||2014-11-25|2014-12-15|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|AESOP|All participants who completed or partially completed at least one study-related radiographic procedure.|Pediatric Catheter-related Thrombosis Imaging Study|Pilot Study for Assessing Diagnostic Techniques for Central Venous Catheter-related Venous Thromboembolism|Completed||N/A|151|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-05-31 23:43:01.693205|2018-05-31 23:43:01.693205
NCT01137565|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-03-03|2010-06-03|2010-06-04|Estimate|||||||2014-03-03|2014-03-04|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 853 in Adolescent (≥ 12 to <18 Years) and Adult Subjects With Intermittent or Mild to Moderate Persistent Asthma|Completed||Phase 1|23|Anticipated|Amgen||2|||f||||||||||||||2018-05-31 23:43:02.590797|2018-05-31 23:43:02.590797
NCT01137552|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-03-02|2010-06-03|2010-06-04|Estimate|||||||2015-03-02|2015-03-04|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors|A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors|Terminated||Phase 1|44|Actual|Amgen||2||"Part A, the dose escalation and primary objective of the study, was completed. Part B, the dose~   expansion, was not conducted due to a business decision."|f||||f||||||||||2018-05-31 23:43:02.733621|2018-05-31 23:43:02.733621
NCT01137539|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2017-04-12||2017-05-25|2010-06-03|2010-06-04|Estimate|2017-05-25|2017-06-28|Actual||||2017-05-25|2017-06-28|Actual|October 2008||2008-10-31|May 2017|2017-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|TVTSOffice||TVT-SECUR as an Office-based Procedure|TVT-SECUR as an Office-based Procedure - A Pilot Study|Completed||N/A|50|Actual|Michigan Institution of Women's Health PC||1|||f||||f||||||||||2018-05-31 23:43:02.867016|2018-05-31 23:43:02.867016
NCT01137526|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07||2012-07-20|2013-01-24|2010-06-03|2010-06-04|Estimate||||2012-07-20|2012-07-27|Estimate|2013-01-24|2013-01-29|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease|Completed||Phase 2|267|Actual|AbbVie||4|||f||||t||||||||||2018-05-31 23:43:03.214699|2018-05-31 23:43:03.214699
NCT01137513|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2014-05-22|2010-06-03|2010-06-04|Estimate|||||||2014-05-22|2014-05-26|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|TWA||T-Wave Alternans in Patients With Suspected Acute Coronary Syndrome|T-Wave Alternans in Patients Acute Coronary Syndrome|Completed|||252|Actual|Loma Linda University|||1||f||||t||||||||||2018-05-31 23:43:03.413818|2018-05-31 23:43:03.413818
NCT01137500|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-03|2010-06-03|2010-06-04|Estimate|||||||2010-06-03|2010-06-04|Estimate|August 2010||2010-08-31|June 2010|2010-06-30||||||||Observational|||Changes in Aortic Diameter During Laparoscopic Surgery|Ultrasonic Assessment of Changes in Aortic Diameter During Laparoscopic Surgery|Unknown status|Not yet recruiting||100|Anticipated|Royal Surrey County Hospital|||||f||||f||||||||||2018-05-31 23:43:03.5565|2018-05-31 23:43:03.5565
NCT01137487|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2013-02-28|2010-06-03|2010-06-04|Estimate|||||||2013-02-28|2013-03-01|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|NUTRIREA1||Study of Impact of Not Measuring Residual Gastric Volume on Nosocomial Pneumonia Rates|Impact of Not Measuring Residual Gastric Volume on Nosocomial Pneumonia Rates in Mechanically Ventilated Patients Receiving Early Enteral Feeding: a Randomized-controlled Study|Completed||N/A|452|Actual|Centre Hospitalier Departemental Vendee||2|||f||||t||||||||||2018-05-31 23:43:03.656521|2018-05-31 23:43:03.656521
NCT01137474|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2014-02-07||2016-12-02|2010-06-03|2010-06-04|Estimate|2014-04-01|2014-05-01|Estimate||||2016-12-02|2017-01-26|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All randomized participants who received a least 1 dose of double-blind study medication|A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)|Completed||Phase 3|2996|Actual|AstraZeneca|Study originally had 2 additional arms, dapagliflozin 2.5 and 5 mg, but enrolment stopped after Protocol Amendment 8 (1-11-11) implemented. Because endpoints focused on comparison of dapagliflozin 10 mg with placebo, only these arms were summarized.|4|||f||||f||||||||||2018-05-31 23:43:03.93767|2018-05-31 23:43:03.93767
NCT01137461|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2011-04-13|2010-06-03|2010-06-04|Estimate|||||||2011-04-13|2011-04-14|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy of Embryo Transfer Procedure Guided by Transvaginal Ultrasound Versus Abdominal Ultrasound in Oocytes Recipients|Evaluation of Efficacy of Embryo Transfer Procedure Guided by Transvaginal Ultrasound Versus Abdominal Ultrasound in Recipients of Oocytes. A Single-centre, Randomized Clinical Trial.|Completed||Phase 4|330|Actual|Fundació Privada Eugin||2|||f||||t||||||||||2018-05-31 23:43:06.006104|2018-05-31 23:43:06.006104
NCT01137448|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2013-12-12|2010-06-03|2010-06-04|Estimate|||||||2013-12-12|2013-12-16|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients|The Effect of Weight Loss on Psoriasis Area Severity Index in Adult Psoriasis Patients|Withdrawn||N/A|0|Actual|The University of Texas Health Science Center, Houston||1||"The site did not have enough funds to complete study arrengments and start to enrolling. The~   site was not able to enroll subjects."|f||||f||||||||||2018-05-31 23:43:06.089738|2018-05-31 23:43:06.089738
NCT01137214|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-02-11|2010-06-02|2010-06-04|Estimate|||||||2015-02-11|2015-02-13|Estimate|June 2011||2011-06-30|October 2010|2010-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Outcome and Treatment of Complex Sleep Apnea|Outcome and Treatment of Complex Sleep Apnea|Withdrawn||Phase 2|0|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 23:43:08.831551|2018-05-31 23:43:08.831551
NCT01137435|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2016-11-06||2016-11-06|2010-06-03|2010-06-04|Estimate|2016-11-06|2017-01-04|Estimate||||2016-11-06|2017-01-04|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Post Marketing Surveillance for ADACEL™ in South Korea|Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult)|Completed||Phase 4|659|Actual|Sanofi||1|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 23:43:06.212502|2018-05-31 23:43:06.212502
NCT01137409|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2015-05-19|2010-06-03|2010-06-04|Estimate|||||||2015-05-19|2015-05-20|Estimate|August 2010||2010-08-31|May 2015|2015-05-31||||December 2014|Actual|2014-12-31||Observational|||Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion|Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion|Completed|||40|Actual|Yale University|||1||f||||f||||||||||2018-05-31 23:43:06.847531|2018-05-31 23:43:06.847531
NCT01137396|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2016-03-24||2016-03-24|2010-06-03|2010-06-04|Estimate|2016-03-24|2016-04-27|Estimate||||2016-03-24|2016-04-27|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Modafinil, Sleep Architecture and Cocaine Relapse|Modafinil, Sleep Architecture and Cocaine Relapse|Completed||Phase 2|114|Actual|Yale University||2|||f||||f||||||||||2018-05-31 23:43:06.919076|2018-05-31 23:43:06.919076
NCT01137383|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-28|2010-06-03|2010-06-04|Estimate|||||||2010-06-28|2010-06-30|Estimate|December 2007||2007-12-31|June 2010|2010-06-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Pegaferon and Ribavirin for Hepatitis C|Safety and Efficacy of Locally Manufactured Pegylated Interferon in Hepatitis C Patients|Completed||Phase 3|108|Actual|Tehran University of Medical Sciences||1|||f||||f||||||||||2018-05-31 23:43:07.103933|2018-05-31 23:43:07.103933
NCT01137370|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|2014-01-03||2014-01-03|2010-06-03|2010-06-04|Estimate|2014-01-03|2014-02-24|Estimate||||2014-01-03|2014-02-24|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Observational|||The Impact of Vitamin D on Tuberculosis Among Koreans|The Impact of Vitamin D Level and Single Nucleotide Polymorphisms of Vitamin D Receptor Gene on the Development and Treatment Response of Tuberculosis|Completed|||203|Actual|Seoul National University Hospital|We did not evaluate the participants' dietary intake of vitamin D or their outdoor activities,and DEXA and PTH were not measured which indicate vitamin D insufficiency.||2||f||||f||||||Samples With DNA|"~     Serums for vitamin D measurement DNA for genotyping of vitamin D receptor gene~   "|||2018-05-31 23:43:07.199403|2018-05-31 23:43:07.199403
NCT01137357|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-03|2010-06-03|2010-06-04|Estimate|||||||2010-06-03|2010-06-04|Estimate|November 2008||2008-11-30|June 2010|2010-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PROMISA||Probiotics for Reduction Of Markers In Subjects With Allergy|Probiotics for Reduction Of Markers In Subjects With Allergy|Completed||N/A|60|Actual|Rijnstate Hospital||6|||f||||f||||||||||2018-05-31 23:43:07.378231|2018-05-31 23:43:07.378231
NCT01137331|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-03|2010-06-03|2010-06-04|Estimate|||||||2010-06-03|2010-06-04|Estimate|February 2008||2008-02-29|June 2010|2010-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp|A Multicenter, Randomised, Double Blind, Placebo-controlled Study of Efficacy, Safety, and Tolerability of Kaprolac® K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp|Completed||Phase 3|201|Actual|Moberg Pharma AB||2|||f||||f||||||||||2018-05-31 23:43:07.444876|2018-05-31 23:43:07.444876
NCT01137318|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2012-11-10|2010-06-03|2010-06-04|Estimate|||||||2012-11-10|2012-11-14|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Interventional|||Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)|Combined Cognitive Remediation and Behavioral Intervention for Treatment of ADHD|Unknown status|Active, not recruiting|Phase 2|84|Actual|Queens College, The City University of New York||2|||f||||f||||||||||2018-05-31 23:43:07.525463|2018-05-31 23:43:07.525463
NCT01137305|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-16|2010-06-03|2010-06-04|Estimate|||||||2010-06-16|2010-06-17|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|SSPSP||Soft Skills and Surgical Performance|Do Soft Skills Predict Surgical Performance? Do Soft Skills Predict Surgical Performance? A Prospective Randomized Controlled Single Center Educational Trial Evaluating Predictors of Skill Acquisition in Virtual Reality Laparoscopy|Completed||N/A|50|Actual|Philipps University Marburg Medical Center|||||f||||f||||||||||2018-05-31 23:43:07.766813|2018-05-31 23:43:07.766813
NCT01137292|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2010-07-12||2011-08-31|2010-06-03|2010-06-04|Estimate|2010-07-15|2010-08-11|Estimate||||2011-08-31|2011-09-02|Estimate|April 2007||2007-04-30|August 2011|2011-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|Ve-RIFI||Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection|Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-Comparative Study|Completed|||177|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:43:07.972025|2018-05-31 23:43:07.972025
NCT01137266|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-10-07|2010-06-03|2010-06-04|Estimate|||||||2010-10-07|2010-10-08|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Disability in Patients With Osteoarthritis|Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Disability in Patients With Osteoarthritis|Completed||N/A|72|Actual|Maxima Medical Center||3|||f||||f||||||||||2018-05-31 23:43:08.426548|2018-05-31 23:43:08.426548
NCT01137253|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2018-02-27|2010-06-03|2010-06-04|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2010||2010-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Autonomic Nervous System and Nitric Oxide Interactions|The Autonomic Nervous System, Nitric Oxide and TPA Interactions|Completed||Phase 1|21|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 23:43:08.526005|2018-05-31 23:43:08.526005
NCT01137240|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-02-24|2010-06-03|2010-06-04|Estimate|||||||2012-02-24|2012-02-27|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders|Assessment and Prevalence of Gastrointestinal Dysfunction in Children With Mitochondrial Disorders (MD)|Completed|||26|Actual|The University of Texas Health Science Center, Houston|||1||f||||t||||||||||2018-05-31 23:43:08.683201|2018-05-31 23:43:08.683201
NCT01137227|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-10-14|2010-06-03|2010-06-04|Estimate|||||||2010-10-14|2010-10-15|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|October 2010|Anticipated|2010-10-31|August 2010|Actual|2010-08-31||Observational|FAPIA||Factors Associated With Physical Inactivity Among Adolescents|Factors Associated With Physical Inactivity Among Adolescents: a Systematic Review and Meta-analysis|Unknown status|Active, not recruiting||264|Anticipated|University of Sao Paulo General Hospital|||1||f||||t||||||||||2018-05-31 23:43:08.753787|2018-05-31 23:43:08.753787
NCT01137188|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2012-04-03|2010-06-03|2010-06-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Weight Loss on Psoriasis|Effect of Weight Loss on Skin Manifestations, Inflammatory Markers and Risk Factor for Comorbidity in Obese Patients With Psoriasis - a Randomized Cross-over Study|Completed||N/A|60|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 23:43:09.053261|2018-05-31 23:43:09.053261
NCT01137175|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2012-09-28|2010-06-03|2010-06-04|Estimate|||||||2012-09-28|2012-10-01|Estimate|January 2009||2009-01-31|June 2011|2011-06-30||||||||Observational|||Laboratory Diagnosis of of Rickettsial and Rickettsia-like Diseases|Laboratory Diagnosis of of Rickettsial and Rickettsia-like Diseases|Unknown status|Recruiting||4000|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-05-31 23:43:09.125472|2018-05-31 23:43:09.125472
NCT01137162|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2016-07-20|2010-06-03|2010-06-04|Estimate|||||||2016-07-20|2016-07-22|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors|Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors|Terminated|||10|Actual|Stanford University||||Low Accrual|f||||||||||Samples Without DNA|"~     skin biopsies and blood~   "|||2018-05-31 23:43:09.195756|2018-05-31 23:43:09.195756
NCT01137149|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-02|2010-06-02|2010-06-04|Estimate|||||||2010-06-02|2010-06-04|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Behavioral Activation With Depressed Adolescents|Behavioral Activation Therapy With Adolescents|Unknown status|Enrolling by invitation|Phase 1/Phase 2|60|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 23:43:09.280276|2018-05-31 23:43:09.280276
NCT01137136|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-04-18|2010-06-03|2010-06-04|Estimate|||||||2014-04-18|2014-04-21|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|CYP19||Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea|Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea|Suspended|||300|Anticipated|Samsung Medical Center|||1|Because of economic issue, we could just enrolled total 150 patients.|f||||t||||||||||2018-05-31 23:43:09.371269|2018-05-31 23:43:09.371269
NCT01137123|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2017-05-11|2010-06-03|2010-06-04|Estimate|||||||2017-05-11|2017-05-15|Actual|April 2010||2010-04-30|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Improve the Treatment of Thoracic Esophageal Cancer|A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer|Recruiting||Phase 3|122|Anticipated|Sun Yat-sen University||6|||f||||t||||||||||2018-05-31 23:43:09.440222|2018-05-31 23:43:09.440222
NCT01137110|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2018-01-29|2010-06-03|2010-06-04|Estimate|||||||2018-01-29|2018-01-31|Actual|May 1, 2010|Actual|2010-05-01|January 2018|2018-01-31|January 1, 2017|Actual|2017-01-01|January 1, 2013|Actual|2013-01-01||Interventional|DOPAST||Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH|Comparison of Short Duration Levetiracetam to Extended Course Levetiracetam for Seizure Prophylaxis Following Subarachnoid Hemorrhage|Completed||Phase 3|84|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 23:43:09.641596|2018-05-31 23:43:09.641596
NCT01137097|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2016-04-20|2010-06-03|2010-06-04|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2009||2009-06-30|April 2016|2016-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|LSLNB||Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC|Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study|Completed||Phase 2/Phase 3|278|Actual|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 23:43:09.781193|2018-05-31 23:43:09.781193
NCT01137084|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-03|2010-06-03|2010-06-04|Estimate|||||||2010-06-03|2010-06-04|Estimate|January 2005||2005-01-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|January 2008|Actual|2008-01-31||Interventional|||Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids||Completed||N/A|300|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 23:43:10.020522|2018-05-31 23:43:10.020522
NCT01137071|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|2016-09-01||2017-01-05|2010-06-02|2010-06-04|Estimate|2016-11-01|2016-12-29|Estimate||||2017-01-05|2017-02-23|Actual|April 2011||2011-04-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||A total of 37 patients were screened for this study of whom 29 were considered eligible and included in the study (baseline participants).|Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer|A Phase II Trial of Hu3S193 Consolidation Therapy for Patients With Relapsing Platinum-sensitive Ovarian, Primary Peritoneal and Fallopian Tubes Adenocarcinoma, Who Achieved a Second Complete Response|Terminated||Phase 2|29|Actual|Recepta Biopharma||1||Total number of pts expected to be enrolled would not be met.|f||||f||||||||No|Recepta Biopharma understands the importance of individual-patient data (IPD) sharing and will include it in its future clinical studies; however, as this clinical study initiated in Apr-2011, an IPD was not planned.|2018-05-31 23:43:10.141465|2018-05-31 23:43:10.141465
NCT01137058|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-05-25|2010-06-03|2010-06-04|Estimate|||||||2014-05-25|2014-05-28|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Ubiquitous Healthcare for Elderly Patients With Type 2 Diabetes Mellitus|Clinical Efficacy of Ubiquitous Healthcare System for Elderly Patients With Type 2 Diabetes Mellitus|Completed||N/A|150|Actual|Seoul National University Bundang Hospital||3|||f||||t||||||||||2018-05-31 23:43:11.052537|2018-05-31 23:43:11.052537
NCT01137045|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2018-04-05|2010-06-03|2010-06-04|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2010||2010-06-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG|An Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine(SPEEDA/TRCS SPEEDA) and Rabies Immunoglobulin|Completed||Phase 4|210|Actual|Queen Saovabha Memorial Institute||6|||f||||t||||||||||2018-05-31 23:43:11.152609|2018-05-31 23:43:11.152609
NCT01137032|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2016-02-26||2016-03-29|2010-06-03|2010-06-04|Estimate|2016-02-26|2016-03-29|Estimate||||2016-03-29|2016-05-04|Estimate|June 2004||2004-06-30|March 2016|2016-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population|An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population|Completed||Phase 4|19|Actual|Fougera Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 23:43:11.262245|2018-05-31 23:43:11.262245
NCT01135472|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2012-12-14|2010-06-01|2010-06-02|Estimate|||||||2012-12-14|2012-12-18|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers|Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers|Completed||Phase 1|10|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:43:36.350464|2018-05-31 23:43:36.350464
NCT01137019|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-08-02|2010-06-03|2010-06-04|Estimate|||||||2014-08-02|2014-08-05|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|OPTIMA||Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition|Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition: A Randomized Comparison of the Biolimus A9-eluting and Everolimus-eluting Coronary Stents|Unknown status|Active, not recruiting|Phase 3|80|Anticipated|Northern Hospital, Australia||2|||f||||t||||||||||2018-05-31 23:43:11.542224|2018-05-31 23:43:11.542224
NCT01137006|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-09-26|2010-06-03|2010-06-04|Estimate|||||||2012-09-26|2012-09-28|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma|An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated|Completed||Phase 1|27|Actual|ImClone LLC||2|||f||||f||||||||||2018-05-31 23:43:11.656511|2018-05-31 23:43:11.656511
NCT01136993|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2010-06-03|2010-06-03|2010-06-04|Estimate|||||||2010-06-03|2010-06-04|Estimate|May 2007||2007-05-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Finnish Telestroke Pilot 2007-2009|Finnish Telestroke Pilot 2007-2009|Unknown status|Recruiting||109|Anticipated|Helsinki University Central Hospital|||1||f||||f||||||||||2018-05-31 23:43:11.770653|2018-05-31 23:43:11.770653
NCT01136980|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-02-07|2010-06-03|2010-06-04|Estimate|||||||2017-02-07|2017-02-09|Estimate|April 2011||2011-04-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|April 2015|Actual|2015-04-30||Interventional|RESPECT||Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study|A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD Compared With Sham and Placebo Controls|Active, not recruiting||N/A|129|Actual|EndoGastric Solutions||2|||f||||f||||||||No||2018-05-31 23:43:11.848547|2018-05-31 23:43:11.848547
NCT01136967|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2015-03-13||2016-02-16|2010-06-03|2010-06-04|Estimate|2016-02-16|2016-03-16|Estimate||||2016-02-16|2016-03-16|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|April 2013|Actual|2013-04-30||Interventional|||An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma|An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma|Completed||Phase 2|182|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 23:43:11.982643|2018-05-31 23:43:11.982643
NCT01136954|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2012-11-12||2015-12-21|2010-06-03|2010-06-04|Estimate|2013-01-02|2013-02-06|Estimate||||2015-12-21|2016-01-25|Estimate|July 2008||2008-07-31|November 2015|2015-11-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)|An Open-label Extension Study Following a Double-blind, Randomized, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Pediatric Partial Onset Seizures|Completed||Phase 3|144|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 23:43:12.753606|2018-05-31 23:43:12.753606
NCT01136941|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2014-06-17|2010-06-03|2010-06-04|Estimate|||||||2014-06-17|2014-06-18|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Zileuton||Trial of Zileuton CR in Children and Adults With Sickle Cell Disease|Phase I Trial of Zileuton CR in Children and Adults With Sickle Cell Disease|Completed||Phase 1|9|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 23:43:13.034537|2018-05-31 23:43:13.034537
NCT01136928|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-05-09|2010-06-03|2010-06-04|Estimate|||||||2011-05-09|2011-05-10|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers|Phase I Pharmacokinetic Interaction Study of Efavirenz and American Ginseng in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 23:43:13.093046|2018-05-31 23:43:13.093046
NCT01136915|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2013-11-25||2014-02-20|2010-06-02|2010-06-04|Estimate|2013-11-25|2014-01-14|Estimate||||2014-02-20|2014-03-17|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Kidney Damage In Patients With Severe Fall In eGFR|A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Severe Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320|Terminated||Phase 4|15|Actual|Bracco Diagnostics, Inc||2||slow enrollment|f||||f||||||||||2018-05-31 23:43:13.188774|2018-05-31 23:43:13.188774
NCT01136902|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-12-07|2010-06-03|2010-06-04|Estimate|||||||2010-12-07|2010-12-08|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Observational|||Measuring Retinal Vessel Caliber in Relation to Dark Adaptation and Blood Glucose Level|Measuring Retinal Vessel Caliber in Relation to Dark Adaptation and Blood Glucose Level|Completed|||14|Actual|Glostrup University Hospital, Copenhagen|||1||f||||t||||||Samples Without DNA|"~     Venous blood sample. Na+, K+, Crea, HbA1c. Capillary glucose measurement. Samples will be~     analysed and destructed according to normal laboratory practice at the Glostrup Hospital.~   "|||2018-05-31 23:43:13.598423|2018-05-31 23:43:13.598423
NCT01136889|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-01-18|2010-06-03|2010-06-04|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|PEPPY||PEssary Plus Physiotherapy for Pelvic Organ Prolapse (PEPPY)|A Feasibility Study for a Randomised Controlled Trial of Pelvic Floor Muscle Training Combined With Vaginal Pessary for Women With Pelvic Organ Prolapse.|Completed||N/A|16|Actual|Glasgow Caledonian University||2|||f||||f||||||||||2018-05-31 23:43:13.674259|2018-05-31 23:43:13.674259
NCT01136876|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2013-09-17||2013-11-11|2010-06-03|2010-06-04|Estimate|2013-11-11|2013-12-30|Estimate||||2013-11-11|2013-12-30|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Kidney Damage in Patients With Moderate Fall in eGFR|A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320|Completed||Phase 4|57|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-05-31 23:43:13.771562|2018-05-31 23:43:13.771562
NCT01136863|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-23|2010-06-03|2010-06-04|Estimate|||||||2010-06-23|2010-06-25|Estimate|April 1998||1998-04-30|January 2005|2005-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|FEVER||Felodipine Event Reduction Study|Felodipine Event Reduction Study|Completed||N/A|9800|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:43:14.036071|2018-05-31 23:43:14.036071
NCT01136850|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2013-04-20|2010-06-03|2010-06-04|Estimate|||||||2013-04-20|2013-04-23|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|IPTp in PNG||Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea|Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea|Completed||Phase 3|2793|Actual|University of Melbourne||2|||f||||t||||||||||2018-05-31 23:43:14.129346|2018-05-31 23:43:14.129346
NCT01136837|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-03|2010-06-03|2010-06-04|Estimate|||||||2010-06-03|2010-06-04|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||The Prognostic Significance of a Fragmented QRS Complex After Primary Percutaneous Coronary Intervention||Completed|||85|Actual|Bursa Postgraduate Hospital|||1||f||||f||||||||||2018-05-31 23:43:14.286923|2018-05-31 23:43:14.286923
NCT01136824|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2016-07-26|2010-06-02|2010-06-03|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2010||2010-06-30|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden|Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden|Completed|||11|Actual|University of Pittsburgh|||1||f||||t||||||||||2018-05-31 23:43:14.36847|2018-05-31 23:43:14.36847
NCT01136811|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-11-17|2010-06-02|2010-06-03|Estimate|||||||2014-11-17|2014-11-18|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy of Computer Assisted Surgery for Use in Vascular Surgery Procedures|Safety and Efficacy of Computer Assisted Surgery for Use in Vascular Surgery Procedures|Terminated||N/A|8|Actual|University of Chicago||1||Study was terminated. P.I. left the institution before completing study|f||||t||||||||||2018-05-31 23:43:14.545827|2018-05-31 23:43:14.545827
NCT01136798|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2018-02-14|2010-06-02|2010-06-03|Estimate|||||||2018-02-14|2018-02-16|Estimate|June 1, 2010|Actual|2010-06-01|February 2018|2018-02-28|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Impact of Exenatide on Sleep in Type 2 Diabetes|Impact of Exenatide on Sleep and Circadian Function in Type 2 Diabetes: A Pilot Study|Completed||N/A|18|Actual|University of Chicago||2|||f||||||||||||No||2018-05-31 23:43:14.665113|2018-05-31 23:43:14.665113
NCT01136785|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2016-12-22||2017-02-24|2010-06-02|2010-06-03|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|November 2009||2009-11-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|CPAP|In a 2:1 ratio (2 active CPAP: 1 sham CPAP), 22 eligible subjects who had completed baseline assessments underwent 1 week of in-laboratory active CPAP or sham CPAP therapy and completed the post-treatment assessments. Two subjects assigned to the CPAP group and one subject assigned to the sham group were excluded for protocol violations.|Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes|Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes|Completed||N/A|22|Actual|University of Chicago|One limitation of the study is that two subjects assigned to sham CPAP received defective sham devices that delivered therapeutic pressure.|2|||f||||f||||||||||2018-05-31 23:43:14.785765|2018-05-31 23:43:14.785765
NCT01136772|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2015-03-25||2016-09-06|2010-06-02|2010-06-03|Estimate|2015-04-07|2015-04-24|Estimate||||2016-09-06|2016-10-21|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2013|Actual|2013-07-31||Interventional|ACLAIMS|Baseline characteristics of modified intent-to-treat population (those who received at least one injection and attended one follow-up appointment)|A Comparison of Long-acting Injectable Medications for Schizophrenia|A Comparison of Long-Acting Injectable Medications for Schizophrenia|Completed||Phase 4|311|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 23:43:15.166146|2018-05-31 23:43:15.166146
NCT01136759|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-09-22|2010-06-02|2010-06-03|Estimate|||||||2014-09-22|2014-09-23|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Tenofovir Gel in Pregnancy and Lactation|Expanded Safety Investigation of Tenofovir 1% Gel in Pregnancy and Lactation|Completed||Phase 1|232|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 23:43:15.454425|2018-05-31 23:43:15.454425
NCT01136746|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2012-09-12||2012-11-07|2010-06-02|2010-06-03|Estimate|2012-09-12|2012-10-12|Estimate||||2012-11-07|2012-11-13|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|HMH||Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin|Randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients Without Known History of Diabetes: The HMH Trial|Terminated||Phase 3|16|Actual|Eli Lilly and Company|Due to low enrollment, this trial was terminated early, leading to small numbers of participants analyzed or some outcome measures not being able to be analyzed at all.|2||Low enrollment|f||||t||||||||||2018-05-31 23:43:15.569634|2018-05-31 23:43:15.569634
NCT01136733|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26||2016-04-18|2016-09-15|2010-06-02|2010-06-03|Estimate||||2016-04-18|2016-05-17|Estimate|2016-09-15|2016-09-23|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|June 2014|Actual|2014-06-30||Interventional|||A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment|An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment|Active, not recruiting||Phase 1/Phase 2|153|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 23:43:16.126629|2018-05-31 23:43:16.126629
NCT01136720|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-06-23|2010-06-02|2010-06-03|Estimate|||||||2011-06-23|2011-06-27|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Clinical Trial to Evaluate the Safety and Clinical Utility of 18F-FDG Produced by the Molecular Imaging and Research Centre of Nova Scotia|Clinical Trial to Evaluate the Safety and Clinical Utility of18F-FDG Produced by the Molecular Imaging and Research Centre of Nova Scotia|Unknown status|Recruiting||3000|Anticipated|Nova Scotia Health Authority|||1||f||||f||||||||||2018-05-31 23:43:16.367528|2018-05-31 23:43:16.367528
NCT01136707|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2016-09-15|2010-06-02|2010-06-03|Estimate|||||||2016-09-15|2016-09-16|Estimate|December 2009||2009-12-31|September 2016|2016-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Predictors of Adherence to Orencia|Predictors of Adherence to Orencia|Completed|||422|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 23:43:16.448766|2018-05-31 23:43:16.448766
NCT01133964|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2011-06-23|2010-05-28|2010-05-31|Estimate|||||||2011-06-23|2011-06-27|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MAES||Dairy Proteins and Postprandial Appetite Regulation and Energy Expenditure|Dairy Proteins and Postprandial Appetite Regulation and Energy Expenditure|Completed||N/A|22|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 23:44:22.7356|2018-05-31 23:44:22.7356
NCT01136694|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-02-09|2010-06-02|2010-06-03|Estimate|||||||2012-02-09|2012-02-10|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Observational|||Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)|Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)|Completed|||695|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 23:43:16.49919|2018-05-31 23:43:16.49919
NCT01136681|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-12-09|2010-06-02|2010-06-03|Estimate|||||||2014-12-09|2014-12-10|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|WECC||Wales Electronic Cohort for Children|Wales Electronic Cohort for Children (WECC)|Completed|||900000|Actual|Swansea University|||||f||||t||||||||||2018-05-31 23:43:16.564697|2018-05-31 23:43:16.564697
NCT01136668|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2016-04-14|2010-06-02|2010-06-03|Estimate|||||||2016-04-14|2016-04-18|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery|Transversus Abdominis Plane Block in Children Undergoing Ostomy Surgery: A Prospective Randomized Controlled Trial|Terminated||Phase 2|9|Actual|The Hospital for Sick Children||2||Unable to recruit adequate number of subjects|f||||t||||||||||2018-05-31 23:43:16.637264|2018-05-31 23:43:16.637264
NCT01136655|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2012-11-12||2013-10-30|2010-06-02|2010-06-03|Estimate|2013-07-23|2013-08-30|Estimate||||2013-10-30|2013-10-31|Estimate|September 2010||2010-09-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CHASE 2||A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy|A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children|Completed||Phase 2|54|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 23:43:16.768593|2018-05-31 23:43:16.768593
NCT01136642|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2018-05-23|2010-06-02|2010-06-03|Estimate|||||||2018-05-23|2018-05-24|Actual|January 21, 2010||2010-01-21|November 13, 2012|2012-11-13|November 13, 2012|Actual|2012-11-13|||||Interventional|||Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray|Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray|Completed||Phase 1|43|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:43:17.231|2018-05-31 23:43:17.231
NCT01136629|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-01-26|2010-06-02|2010-06-03|Estimate|||||||2014-01-26|2014-01-28|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion|Clinical, Histological and Biochemical Characterization of Hyperpigmented Lesion.|Unknown status|Recruiting||160|Anticipated|National University Hospital, Singapore|||1||f||||t||||||||||2018-05-31 23:43:17.294291|2018-05-31 23:43:17.294291
NCT01136616|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-04-01|2010-06-02|2010-06-03|Estimate|||||||2014-04-01|2014-04-03|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||CT Analysis of Structural Buttresses in the Traumatised Nose|CT Analysis of Structural Buttresses in the Traumatised Nose - A Basis for Decision Making for Early Open Rhinoplasty and Biomechanical Study of Nasal Structural Support|Completed|||67|Actual|National University Hospital, Singapore|||1||f||||t||||||||||2018-05-31 23:43:18.367423|2018-05-31 23:43:18.367423
NCT01136603|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-01-27|2010-06-02|2010-06-03|Estimate|||||||2014-01-27|2014-01-28|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||TIGR vs Polypropylene (Permanent) Mesh: Randomised Trial|Abdominal Wall Closure After TRAM / DIEP Flap - Comparison of TIGR Mesh vs Polypropylene Mesh.|Unknown status|Recruiting|Phase 2|80|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 23:43:18.442508|2018-05-31 23:43:18.442508
NCT01136590|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-02-23|2010-06-02|2010-06-03|Estimate|||||||2015-02-23|2015-02-24|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery|Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery|Completed||Phase 4|96|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||||||||||||2018-05-31 23:43:18.548089|2018-05-31 23:43:18.548089
NCT01136577|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-12-10|2010-06-02|2010-06-03|Estimate|||||||2012-12-10|2012-12-11|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|DELF||Light-emitting Diodes (LED) Phototherapy for Hyperbilirubinemia of Term Newborn|Comparison of Light-emitting Diodes (LED) Phototherapy Versus Fluorescent Lamps Phototherapy for Treatment of Hyperbilirubinemia in Term Newborn|Terminated||N/A|44|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 23:43:18.632969|2018-05-31 23:43:18.632969
NCT01136564|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-01-24|2010-06-02|2010-06-03|Estimate|||||||2012-01-24|2012-01-25|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease|Reno- and Vascular Protective Effect of a Low-calcemic Vitamin-D-analogue (Paricalcitol) in Stage III-IV Chronic Kidney Disease|Completed||Phase 2|30|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 23:43:18.738218|2018-05-31 23:43:18.738218
NCT01136551|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|September 2010||2010-09-30|May 2010|2010-05-31|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Interventional|||Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A|An Open-label, Three-period, Crossover Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Different Release Rate Controlled Release Formulations of Huperzine A (0.4mg)Compared to the Equivalent Dose of an Immediate Release Formulation.|Unknown status|Not yet recruiting|N/A|8|Anticipated|Hadassah Medical Organization||3|||f||||t||||||||||2018-05-31 23:43:18.875764|2018-05-31 23:43:18.875764
NCT01136538|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-11|2010-06-02|2010-06-03|Estimate|||||||2010-06-11|2010-06-14|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|May 2007|Actual|2007-05-31|February 2007|Actual|2007-02-28||Interventional|||Bioavailability Study of Valacycovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fed Condition|An Open Label, Balanced, Randomized, Two Treatment, Two-sequence, Two-period, Single-dose Crossover Comparative Bioavailability Study of 1000 mg Valacyclovir HCl Tablets of Dr. Reddys's and Valtrex (R) 1 gm Caplets of GlaxoSmithkline in Healthy Volunteers Under Fed Conditions.|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:43:18.941881|2018-05-31 23:43:18.941881
NCT01136525|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-11|2010-06-02|2010-06-03|Estimate|||||||2010-06-11|2010-06-14|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|May 2007|Actual|2007-05-31|March 2007|Actual|2007-03-31||Interventional|||Bioavailability Study of Valacyclovir HCl Tablets, 1000 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two-sequence, Two-period, Single-dose Crossover Comparative Bioavailability Study of 1000 mg Valacyclovir HCl Tablets of Dr. Reddys's and Valtrex (R) 1 gm Caplets of GlaxoSmithkline in Healthy Volunteers Under Fasting Conditions.|Completed||Phase 1|41|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:43:19.11384|2018-05-31 23:43:19.11384
NCT01136512|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2013-07-29|2010-06-02|2010-06-03|Estimate|||||||2013-07-29|2013-07-31|Estimate|August 2007||2007-08-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Metformin Use and Vitamin B12 Deficiency|Metformin Use and Vitamin B12 Deficiency|Completed|||89|Actual|Northwell Health|||2||f||||f||||||||||2018-05-31 23:43:19.206517|2018-05-31 23:43:19.206517
NCT01136499|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2013-03-05|2010-06-02|2010-06-03|Estimate|||||||2013-03-05|2013-03-06|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|ESTIM-LBH||Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure|Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study|Completed||Phase 2|53|Actual|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 23:43:19.284686|2018-05-31 23:43:19.284686
NCT01136486|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2015-11-05||2016-05-23|2010-06-02|2010-06-03|Estimate|2016-05-23|2016-05-24|Estimate||||2016-05-23|2016-05-24|Estimate|April 2003||2003-04-30|May 2016|2016-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Pain in Traumatic Brain Injury - Basile, MD|The Role of Persistent Pain on Neuro Psychological Functioning and Community Integration in Traumatic Brain Injury|Terminated|||56|Actual|Northwell Health||||slow accrual|f||||f||||||||No||2018-05-31 23:43:19.411379|2018-05-31 23:43:19.411379
NCT01136473|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2015-02-22|2010-06-02|2010-06-03|Estimate|||||||2015-02-22|2015-02-24|Estimate|July 2011||2011-07-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Mechanism of Aphakic and Pseudophakic Glaucoma in Pediatric Patients|Mechanism of Aphakic and Pseudophakic Glaucoma in Pediatric Patients: Exploring the Pathophysiology Through Lens Epithelial Cell Culture and Isolation of Candidate Factors From Aqueous Humor|Completed|||40|Anticipated|Carmel Medical Center|||1||f||||t||||||||||2018-05-31 23:43:19.654628|2018-05-31 23:43:19.654628
NCT01136460|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2014-09-17|2010-06-02|2010-06-03|Estimate|||||||2014-09-17|2014-09-18|Estimate|May 2006||2006-05-31|September 2014|2014-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Genetic Testing in Primary Congenital Glaucoma Patients|Genetic Testing in Primary Congenital Glaucoma Patients|Recruiting|||400|Anticipated|Carmel Medical Center|||1||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 23:43:19.735405|2018-05-31 23:43:19.735405
NCT01136447|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2017-08-29|2010-06-02|2010-06-03|Estimate|||||||2017-08-29|2017-08-30|Actual|January 2010||2010-01-31|August 2017|2017-08-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Continuous Infraclavicular Blocks: Neurostimulation Versus Ultrasound|Success Rate of Infra-clavicular Blocks: Comparison of Ultrasound Versus Neurostimulation Guided Catheter Placement|Completed||N/A|210|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:43:19.814569|2018-05-31 23:43:19.814569
NCT01136421|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|January 2005||2005-01-31|May 2010|2010-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease||Completed||Phase 3|124|Actual|University of Monastir||2|||f||||f||||||||||2018-05-31 23:43:19.875984|2018-05-31 23:43:19.875984
NCT01136408|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2010-11-18||2014-02-18|2010-06-02|2010-06-03|Estimate|2010-11-18|2010-12-17|Estimate||||2014-02-18|2014-03-19|Estimate|November 2005||2005-11-30|February 2014|2014-02-28||||September 2006|Actual|2006-09-30||Interventional|||A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin|Open Label, Randomised Exploratory Dose Response Study in Pharmacodynamics and Safety of BIBR 1048 (110 mg Twice Daily (b.i.d.) and 150 mg b.i.d.) for 12 Weeks in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin|Completed||Phase 2|174|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:43:19.992449|2018-05-31 23:43:19.992449
NCT01136395|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-11-20|2010-06-02|2010-06-03|Estimate|||||||2017-11-20|2017-11-21|Actual|January 2010|Actual|2010-01-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation|Impact of Rituximab Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation - a Prospective Pilot Study|Active, not recruiting||Phase 2|85|Actual|University of Giessen||3|||f||||t||||||||Undecided||2018-05-31 23:43:20.774292|2018-05-31 23:43:20.774292
NCT01136382|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2014-03-25||2014-07-30|2010-06-01|2010-06-03|Estimate|2014-07-18|2014-07-21|Estimate||||2014-07-30|2014-08-01|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CHASE 1||A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo|Phase 2, Double-blind, Randomized, Parallel-group, Placebo-controlled, Multicenter Study, Comparing Budesonide pMDI 160 ug Bid With Placebo: a 6-week Efficacy and Safety Study in Children Aged 6 to <12 Years With Asthma|Completed||Phase 2|304|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:43:20.938331|2018-05-31 23:43:20.938331
NCT01136369|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer|Clinical Evaluation of LS-03M/LS-04R for the Detection of Sentinel Lymph Node Metastasis From Breast Cancer|Completed|||496|Actual|Sysmex America, Inc.|||1||f||||t||||||Samples With DNA|"~     Samples of the tissue homogenate will be retained and may be used for for further testing.~   "|||2018-05-31 23:43:21.612389|2018-05-31 23:43:21.612389
NCT01136356|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2016-04-14||2017-01-11|2010-06-02|2010-06-03|Estimate|2017-01-11|2017-03-03|Actual||||2017-01-11|2017-03-03|Actual|July 2010||2010-07-31|January 2017|2017-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals|A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals|Completed||Phase 1/Phase 2|12|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:43:21.713714|2018-05-31 23:43:21.713714
NCT01135290|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2013-09-30|2010-06-01|2010-06-02|Estimate|||||||2013-09-30|2013-10-01|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Post Treatment Care After Chemical Peel or Laser Resurfacing|Evaluation of HP828-101 for Post Treatment Care Following a Chemical Peel or Laser Resurfacing|Withdrawn||Early Phase 1|0|Actual|Healthpoint||2||Business decision, formulation will not be pursued.|f||||f||||||||||2018-05-31 23:43:42.621052|2018-05-31 23:43:42.621052
NCT01136343|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2010-12-01|2010-05-31|2010-06-03|Estimate|||||||2010-12-01|2010-12-03|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Comparison of Predictive Factors Related to Coronary Artery Disease Among Different Menopausal Status and Effect of a Life Style Management Program on Risk Factors Modification Among Middle-aged Women|Comparison of Predictive Factors Related to Coronary Artery Disease Among Different Menopausal Status and Effect of a Life Style Management Program on Risk Factors Modification Among Middle-aged Women|Unknown status|Recruiting|N/A|130|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-05-31 23:43:21.971907|2018-05-31 23:43:21.971907
NCT01136330|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-02-17|2010-06-02|2010-06-03|Estimate|||||||2012-02-17|2012-02-20|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|DM1-Heart-R||DM1 Heart Registry - DM1 Respiratory Registry|Cardiac and Respiratory Prognostic Factors in Patients With Myotonic Dystrophy Type 1|Completed|||914|Actual|Institut de Myologie, France|||||f||||f||||||||||2018-05-31 23:43:22.038882|2018-05-31 23:43:22.038882
NCT01136317|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-09-23|2010-06-02|2010-06-03|Estimate|||||||2010-09-23|2010-09-24|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|Oberab||Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects||Completed||Phase 2|||Nantes University Hospital||3|||f||||f||||||||||2018-05-31 23:43:22.177505|2018-05-31 23:43:22.177505
NCT01136304|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2015-05-29|2010-06-02|2010-06-03|Estimate|||||||2015-05-29|2015-06-01|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)|Retrospective and Prospective Validation of a Disease Severity Score System (DS3) for Adults With Type 1 Gaucher Disease (GD1)|Completed|||173|Actual|University Research Foundation for Lysosomal Storage Diseases, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood Buccal smears~   "|||2018-05-31 23:43:22.246249|2018-05-31 23:43:22.246249
NCT01136291|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2010-12-10||2011-03-20|2010-05-31|2010-06-03|Estimate|2011-01-25|2011-02-23|Estimate||||2011-03-20|2011-03-23|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Physical Exercise Influence Among Overweight and Obese Pregnant Women|Physical Exercise Influence on Maternal, Perinatal Outcomes and Quality of Life Among Overweight and Obese Pregnant Women:|Completed||N/A|82|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 23:43:22.32034|2018-05-31 23:43:22.32034
NCT01136278|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2013-01-24|2010-06-02|2010-06-03|Estimate|||||||2013-01-24|2013-01-25|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)|Pharmacological Interaction Between Clonidine and 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 23:43:22.555218|2018-05-31 23:43:22.555218
NCT01136265|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-01-10|2010-06-02|2010-06-03|Estimate|||||||2011-01-10|2011-01-11|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Observational|PETNode||PET/CT and Sentinel Node in Oral Cancer|Dual-time PET/CT and Sentinel Node Diagnostics Preoperatively in Patients With Oral Cancer|Unknown status|Active, not recruiting||70|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||Samples With DNA|"~     whole blood, primary cancer tissue, normal oral tissue~   "|||2018-05-31 23:43:22.674734|2018-05-31 23:43:22.674734
NCT01136252|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-03-16|2010-06-02|2010-06-03|Estimate|||||||2012-03-16|2012-03-19|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Open-label Clinical Trial to Evaluate Safety and Efficacy of Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Non-responders to the Conventional Treatment With Ranibizumab|Completed||Phase 2|5|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f||||||||||2018-05-31 23:43:22.739352|2018-05-31 23:43:22.739352
NCT01136239|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-04-08|2010-06-02|2010-06-03|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effect of High Dose N-acetylcysteine on Airtrapping and Airway Resistance of Chronic Obstructive Pulmonary disease-a Double Blinded Randomized Placebo Controlled Trial|Completed||Phase 4|133|Actual|Kwong Wah Hospital||2|||f||||t||||||||||2018-05-31 23:43:22.820826|2018-05-31 23:43:22.820826
NCT01136226|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|2013-04-12||2018-02-09|2010-06-02|2010-06-03|Estimate|2013-07-12|2013-07-16|Estimate||||2018-02-09|2018-03-09|Actual|October 2003||2003-10-31|February 2018|2018-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Eligard||Evaluate Recovery of Testosterone for Patients Using Eligard|A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer|Completed||Phase 4|42|Actual|Chesapeake Urology Research Associates||1|||f||||f||||||||||2018-05-31 23:43:22.923531|2018-05-31 23:43:22.923531
NCT01136213|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2017-08-03|2010-06-02|2010-06-03|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2010|Actual|2010-04-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|SEROTAMS||Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study|Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study|Completed|||53|Actual|University Hospital, Bordeaux|||3||f||||f||||||||||2018-05-31 23:43:23.112966|2018-05-31 23:43:23.112966
NCT01136200|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-07-28|2010-06-02|2010-06-03|Estimate|||||||2014-07-28|2014-07-29|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|ATBREFSURMED||Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Surgical and Medical Wards|Impact of Infectious Diseases Specialists on the Appropriateness of Antimicrobial Therapy in Surgical and Medical Wards: a Multicenter Randomized Controlled Trial.|Completed||N/A|264|Actual|Henri Mondor University Hospital||2|||f||||f||||||||||2018-05-31 23:43:23.200748|2018-05-31 23:43:23.200748
NCT01136187|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2012-12-20|2010-06-02|2010-06-03|Estimate|||||||2012-12-20|2012-12-21|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|STEMI-RADIAL||Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI)|ST Elevation Myocardial Infarction Treated by RADIAL or Femoral Approach - Randomized Multicenter Study Comparing Radial Versus Femoral Approach in Primary PCI. The STEMI-RADIAL Trial.|Completed||N/A|707|Actual|Charles University, Czech Republic||2|||f||||||||||||||2018-05-31 23:43:23.275796|2018-05-31 23:43:23.275796
NCT01136174|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|2014-11-14|2014-05-16|2014-12-15|2010-06-02|2010-06-03|Estimate|2014-12-15|2015-01-06|Estimate|2014-05-16|2014-05-29|Estimate|2014-12-15|2015-01-06|Estimate|May 2010||2010-05-31|December 2014|2014-12-31||||March 2011|Actual|2011-03-31||Interventional||Treated set: all patients who received study medication and were documented to have taken at least one dose of investigational treatment|Safety and PK Study of BIBF 1120 in Japanese Patients With IPF|A Double-blind, Randomised, Placebo-controlled (Within a Dose Group) Study to Evaluate Safety and Pharmacokinetics of Multiple Rising Doses of BIBF 1120 at 50 mg Bid (14 Days), 100 mg Bid (14 Days), and 150 mg Bid (28 Days) p.o., on Top of Standard Medical Care With Stratification According to Pirfenidone Use, in Japanese Patients With Idiopathic Pulmonary Fibrosis.|Completed||Phase 2|50|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:43:23.390842|2018-05-31 23:43:23.390842
NCT01136161|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2013-01-23|2010-06-02|2010-06-03|Estimate|||||||2013-01-23|2013-01-24|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection|Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection|Completed||Phase 2|95|Actual|Archivel Farma S.L.||8|||f||||t||||||||||2018-05-31 23:43:24.188022|2018-05-31 23:43:24.188022
NCT01136148|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-12-01|2010-06-02|2010-06-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|TEAM||Trial of a Medical and Mental Health Unit for Older People|Evaluation of a Medical and Mental Health Unit Compared With Standard Care for Older People Whose Emergency Admission to an Acute General Hospital is Complicated by Concurrent 'Confusion'.|Completed||N/A|600|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 23:43:24.343789|2018-05-31 23:43:24.343789
NCT01136135|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2015-08-31|2010-06-02|2010-06-03|Estimate|||||||2015-08-31|2015-09-01|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Observational|||Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection|Cardiac MRI for the Detection of Cellular Rejection in Patients With Heart Transplantation|Completed|||36|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 23:43:24.417146|2018-05-31 23:43:24.417146
NCT01136122|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2016-04-01|2010-06-02|2010-06-03|Estimate|||||||2016-04-01|2016-04-04|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|OSA-MRI||Effects of PAP Treatment of OSA in Patients With Heart Failure|Effects of Positive Airway Pressure (PAP) Treatment of Obstructive Sleep Apnea (OSA) in Patients With Heart Failure|Terminated||Phase 1|3|Actual|Ohio State University||2||The study was stopped due to low recruitment.|f||||f||||||||No||2018-05-31 23:43:24.470964|2018-05-31 23:43:24.470964
NCT01136109|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-01-15|2010-06-02|2010-06-03|Estimate|||||||2016-01-15|2016-01-18|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|IVCCI||A Study to Evaluate the Effect of Mechanical Ventilation on the Inferior Vena Cava Collapsibility Index|A Prospective Pilot Study to Evaluate the Effect of Mechanical Ventilation on the Inferior Vena Cava Collapsibility Index|Completed|||32|Actual|Ohio State University|||2||f||||f||||||||||2018-05-31 23:43:24.541773|2018-05-31 23:43:24.541773
NCT01136096|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-23|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|January 2004||2004-01-31|June 2010|2010-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Effects of Exercise Behavior Modification on Plasma Adiponectin and Insulin Resistance in High Risk Subjects of Diabetes|Effects of Exercise Behavior Modification on Plasma Adiponectin and Insulin Resistance in High Risk Subjects of Diabetes|Completed||N/A|216|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 23:43:24.597146|2018-05-31 23:43:24.597146
NCT01136083|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-08-12|2010-06-02|2010-06-03|Estimate|||||||2013-08-12|2013-08-13|Estimate|September 2010||2010-09-30|November 2011|2011-11-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients|Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients|Completed||N/A|60|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 23:43:24.767157|2018-05-31 23:43:24.767157
NCT01136070|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-10-12|2010-05-31|2010-06-03|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|||A Prospective Study of Body Image, Social Avoidance and Distress and Psychological Functioning in Burn Patients|A Prospective Study of Body Image, Social Avoidance and Distress and Psychological Functioning in Burn Patients|Withdrawn|||0|Actual|Saint Elizabeth Regional Medical Center|||1||f||||f||||||||||2018-05-31 23:43:24.912763|2018-05-31 23:43:24.912763
NCT01136057|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2017-12-14|2010-06-02|2010-06-03|Estimate|||||||2017-12-14|2017-12-18|Actual|April 2010||2010-04-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Blood and Plasma Collection For Use in Future Clinical Trials|A Pilot Study for Collection of High-Titer Anti-Influenza A Plasma|Active, not recruiting|||200|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||f||||||Samples With DNA|"~     Whole blood will be collected from participants.~   "|||2018-05-31 23:43:24.980053|2018-05-31 23:43:24.980053
NCT01136044|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Clinical Experience With a Tensor Fasciae Latae Perforator Flap Based on Septocutaneous Perforators|Clinical Experience With a Tensor Fasciae Latae Perforator Flap Based on Septocutaneous Perforators|Completed||N/A|14|Actual|Medical University of Graz|||||f||||f||||||||||2018-05-31 23:43:25.053216|2018-05-31 23:43:25.053216
NCT01136031|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2015-05-19|2010-05-31|2010-06-03|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|TI-2ndAGC||Paclitaxel and Irinotecan in Advanced Gastric Cancer|A Phase I/II Trial of Second-line Chemotherapy With Paclitaxel and Irinotecan in Fluoropyrimidine- and Platinum-Pretreated Advanced Gastric Cancer|Completed||Phase 1/Phase 2|42|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 23:43:25.162762|2018-05-31 23:43:25.162762
NCT01136018|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2011-04-18|2010-06-02|2010-06-03|Estimate|||||||2011-04-18|2011-04-19|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Observational|||A Prospective Evaluation of Iodinated Contrast Flow Patterns in Caudal Epidurography With Intentional Lateral Caudal Approach||Completed|||22|Actual|Yonsei University|||1||f||||||||||||||2018-05-31 23:43:25.28492|2018-05-31 23:43:25.28492
NCT01136005|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2017-11-08|2010-06-02|2010-06-03|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2010||2010-09-30|November 2017|2017-11-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|BeCet||Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)|Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of Papulopustular Eruption in Patients Receiving Epidermal Growth Factor Receptor Inhibitors (EGFRI): BeCet|Completed||Phase 3|160|Actual|Impaqtt Foundation||2|||f||||f||||||||||2018-05-31 23:43:25.362661|2018-05-31 23:43:25.362661
NCT01135992|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|2015-10-16|2011-02-24|2015-12-14|2010-05-31|2010-06-03|Estimate|2015-12-14|2016-01-22|Estimate|2011-03-09|2011-03-18|Estimate|2015-12-14|2016-01-22|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|BEGIN™|Full Analysis set (FAS)-Includes 129 subjects only as 13 subjects did not receive IDeg.|Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)|A Trial Assessing the Implications of Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™: SIMPLIFY)|Completed||Phase 3|143|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:43:25.561566|2018-05-31 23:43:25.561566
NCT01135979|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2013-03-05|2010-06-02|2010-06-03|Estimate|||||||2013-03-05|2013-03-06|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Assessment of the Sympathetic Nervous System Blockade of the Upper Limb After a Brachial Plexus Block in Patients With End Stage Renal Failure|Assessment of the Sympathetic Nervous System Blockade of the Upper Limb After a Brachial Plexus Block in Patients With End Stage Renal Failure|Withdrawn|||0|Actual|University of Nottingham|||1|Unable to recruit|f||||f||||||||||2018-05-31 23:43:26.02268|2018-05-31 23:43:26.02268
NCT01135966|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-12-09|2010-06-02|2010-06-03|Estimate|||||||2011-12-09|2011-12-12|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|REWORK||Resistance Training in Patients With Chronic Obstructive Lung Disease (COPD): Whole Body Vibration Versus Conventional Resistance Training|Resistance Training in Patients With Chronic Obstructive Lung Disease (COPD): Whole Body Vibration Versus Conventional Resistance Training|Completed||Phase 3|62|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:43:26.231925|2018-05-31 23:43:26.231925
NCT01135953|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-12-07|2010-06-02|2010-06-03|Estimate|||||||2010-12-07|2010-12-08|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Methods to Enhance Transcranial Direct Stimulation (tDCS)|Investigating Methods to Enhance the Excitatory Effects of Transcranial Direct Stimulation (tDCS)|Completed||N/A|24|Anticipated|The University of New South Wales||3|||f||||t||||||||||2018-05-31 23:43:26.682479|2018-05-31 23:43:26.682479
NCT01135940|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2016-05-30|2010-06-02|2010-06-03|Estimate|||||||2016-05-30|2016-06-01|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||The Use of Dermabond Versus Standard Staple for Wound Closure in Children With Neuromuscular Scoliosis Undergoing Spinal Deformity Correction Surgery|The Use of Dermabond vs. Standard Staple for Wound Closure in Children With Neuromuscular Scoliosis Undergoing Spinal Deformity Correction Surgery: A Phase II Study|Unknown status|Recruiting|Phase 2|80|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 23:43:26.756107|2018-05-31 23:43:26.756107
NCT01135927|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2017-01-19|2010-05-31|2010-06-03|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 1 Diabetes|Completed||Phase 1|22|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:43:26.858448|2018-05-31 23:43:26.858448
NCT01135914|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|2014-03-19||2014-10-22|2010-05-31|2010-06-03|Estimate|2014-10-22|2014-10-23|Estimate||||2014-10-22|2014-10-23|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|RESPOND|The Intent to Treat (ITT) population was defined as all patients receiving at least one dose of either study treatment for monotherapy treatment arms, or one of the two study treatments for the combination therapy arm, and having at least 1 post-baseline assessment. Patients from a center were excluded from ITT.|Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)|A Canadian 12-month, Prospective, Randomized, Open-label, Multicenter, Laser-controlled Phase IIIb Study Assessing the Efficacy, Safety and Cost-efficacy of Ranibizumab as Combination and Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema.|Completed||Phase 3|241|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:43:26.959178|2018-05-31 23:43:26.959178
NCT01135901|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2017-09-16|2010-05-31|2010-06-03|Estimate|||||||2017-09-16|2017-09-19|Actual|April 2010|Actual|2010-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VEND-RISK||Local Measures to Prevent Diabetes in the Værnes Region.|The VEND RISK-study. Preventing Diabetes Type 2 in Overweight Persons in the Værnes Region, Central-Norway.|Active, not recruiting||N/A|180|Actual|Norwegian University of Science and Technology||1|||f||||f|f|f||||||||2018-05-31 23:43:27.627942|2018-05-31 23:43:27.627942
NCT01135888|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-07-25|2010-06-02|2010-06-03|Estimate|||||||2011-07-25|2011-07-27|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Short Term Effects and Risks of Physical Exercise in Subjects With Hypohidrotic Ectodermal Dysplasia|Short Term Effects and Risks of Physical Exercise in Subjects With Hypohidrotic Ectodermal Dysplasia (Christ-Siemens-Touraine Syndrome)|Completed|||28|Actual|University Hospital Erlangen|||4||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:43:27.690115|2018-05-31 23:43:27.690115
NCT01135875|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-10-15|2010-06-02|2010-06-03|Estimate|||||||2013-10-15|2013-10-17|Estimate|October 2009||2009-10-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients|Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response|Completed|||130|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 23:43:27.762774|2018-05-31 23:43:27.762774
NCT01135862|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|June 2013|Anticipated|2013-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Platelet Administration To Patients With Traumatic Brain Injury Who Were Treated With Aspirin|Platelet Administration To Patients With Traumatic Brain Injury Who Were Treated With Aspirin|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 23:43:27.826676|2018-05-31 23:43:27.826676
NCT01135836|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|August 2009||2009-08-31|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Reducing Shoulder Tip Pain Following Laparoscopic Surgery|A Randomized, Controlled, Single Blind Study Comparing a Pulmonary Recruitment Maneuver Versus Intraperitoneal Infusion of Normal Saline to Reduce Shoulder Tip Pain After Gynecologic Laparoscopic Surgery|Unknown status|Recruiting|Phase 3|180|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f||||t||||||||||2018-05-31 23:43:27.987366|2018-05-31 23:43:27.987366
NCT01135823|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|July 2006||2006-07-31|June 2010|2010-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Symptom Assessment With Patient Surveys|Symptom Assessment With Patient Surveys|Completed|||100|Anticipated|Stanford University|||||f||||||||||||||2018-05-31 23:43:28.100309|2018-05-31 23:43:28.100309
NCT01135810|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2013-12-02|2010-06-02|2010-06-03|Estimate|||||||2013-12-02|2013-12-03|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Functional Magnetic Resonance Imaging (MRI) of Hypnosis and Mindfulness Meditation|Resting State Functional MRI Investigation of Hypnotic Trance and Mindfulness Meditation|Completed|||102|Actual|Stanford University|||||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-05-31 23:43:28.211039|2018-05-31 23:43:28.211039
NCT01135797|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2011-04-27|2010-06-02|2010-06-03|Estimate|||||||2011-04-27|2011-04-28|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|TALISMAN S||Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials|Retrospective Safety Survey In Patients Included In Phase I-II NV1FGF Clinical Trials|Completed|||164|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 23:43:28.341718|2018-05-31 23:43:28.341718
NCT01135784|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2011-06-13|2010-06-02|2010-06-03|Estimate|||||||2011-06-13|2011-06-14|Estimate|October 2011||2011-10-31|March 2011|2011-03-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|RZN||Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache|Human CT: Efficacy & Safety of MIGRA-ZEN RELIEF PLUS:Herbal Supp:Extracts Juniper Willow Goldenrod Dandelion Meadowsweet Whole Grape In Rx of Chronic Migraine Headache. Randomized, Double-Blind, Placebo Cont. Study P.II (PoC Study)|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|RZN Nutraceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:43:28.43523|2018-05-31 23:43:28.43523
NCT01135771|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Performance Study Using the OptiScanner on Healthy Diabetics|Performance Study Using the OptiScanner on Healthy Diabetics|Completed||Phase 1|60|Actual|Profil Institut für Stoffwechselforschung GmbH|||||f||||f||||||||||2018-05-31 23:43:28.584837|2018-05-31 23:43:28.584837
NCT01135758|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2015-12-04|2010-06-02|2010-06-03|Estimate|||||||2015-12-04|2015-12-07|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Study of Depression-Ketamine-Brain Function|Pilot Study Probing the Antidepressant Effects of 0.5 mg/kg Intravenous Ketamine in Drug-resistant Depressed Patients (Unipolar Depression): Efficacy, Safety, Brain Function|Terminated||Phase 2|10|Actual|University Hospital, Geneva||1||End of funding of study|f||||f||||||||||2018-05-31 23:43:28.653925|2018-05-31 23:43:28.653925
NCT01135745|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2018-01-18|2010-05-31|2010-06-03|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2010||2010-04-30|January 2018|2018-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF)|Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF)|Completed||Phase 4|32|Actual|MedtronicNeuro||1|||f||||t||||||||||2018-05-31 23:43:28.756733|2018-05-31 23:43:28.756733
NCT01135732|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-11-15|2010-06-02|2010-06-03|Estimate|||||||2010-11-15|2010-11-16|Estimate|October 2006||2006-10-31|October 2009|2009-10-31||||June 2010|Actual|2010-06-30||Observational|||Cytological Evaluation of Biliary Epithelium After Endoscopic Sphincterotomy|Cytological Evaluation of Biliary Epithelium After Previous Endoscopic Sphincterotomy for Benign Disease|Completed|||56|Anticipated|University of Athens|||2||f||||t||||||||||2018-05-31 23:43:28.878369|2018-05-31 23:43:28.878369
NCT01135719|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2018-04-22|2010-06-02|2010-06-03|Estimate|||||||2018-04-22|2018-04-24|Actual|April 2009||2009-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Comparison of Fellow Eyes Undergoing LASIK or PRK With a Wavefront-guided Excimer Laser Versus a Wavefront-optimized Excimer Laser|A Prospective Randomized Comparison of Fellow Eyes Undergoing LASIK or PRK With a Wavefront-guided Excimer Laser Versus a Wavefront-optimized Excimer Laser|Active, not recruiting||N/A|200|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 23:43:28.977955|2018-05-31 23:43:28.977955
NCT01135706|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2012-10-31|2010-06-02|2010-06-03|Estimate|||||||2012-10-31|2012-11-01|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Fractal Analysis of the Pulmonary Arterial Tree in Pulmonary Hypertension|Fractal Analysis of the Pulmonary Arterial Tree in Pulmonary Hypertension.|Completed|||6|Actual|Ohio State University|||2||f||||f||||||||||2018-05-31 23:43:29.10708|2018-05-31 23:43:29.10708
NCT01135693|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2010-06-02|2010-06-02|2010-06-03|Estimate|||||||2010-06-02|2010-06-03|Estimate|August 2010||2010-08-31|June 2010|2010-06-30|January 2011|Anticipated|2011-01-31|October 2010|Anticipated|2010-10-31||Observational|||Service Users' Perspective of Reasons for Detention Under Section 136 of the Mental Health Act 1983|A Qualitative Study of Service Users' Perspective of Reasons for Detention Under Section 136 of the Mental Health Act 1983 Using Grounded Theory|Unknown status|Not yet recruiting||20|Anticipated|South West Yorkshire Partnership NHS Foundation Trust|||||f||||t||||||||||2018-05-31 23:43:29.256449|2018-05-31 23:43:29.256449
NCT01135680|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2017-01-13|2010-05-31|2010-06-03|Estimate|||||||2017-01-13|2017-01-16|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100|Double-Blind Randomized Placebo-Control Trial to Evaluate Electrocardiogram Effects of HPN-100 as Defined by Clinical and Supratherapeutic Dose in Healthy Men and Women|Completed||Phase 1|98|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||f||||||||||2018-05-31 23:43:29.382085|2018-05-31 23:43:29.382085
NCT01135667|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2012-10-03|2010-06-02|2010-06-03|Estimate|||||||2012-10-03|2012-10-04|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|TAILOR||Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI|Thrombocytes And IndividuaLization of ORal Antiplatelet Treatment After Percutaneous Coronary Intervention|Completed||Phase 4|106|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 23:43:29.615668|2018-05-31 23:43:29.615668
NCT01135641|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2014-04-02|2010-06-02|2010-06-03|Estimate|||||||2014-04-02|2014-04-03|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|R-GVHD||Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)|Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab|Completed||Phase 2|25|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 23:43:29.96612|2018-05-31 23:43:29.96612
NCT01135628|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2014-08-18|2010-06-02|2010-06-03|Estimate|||||||2014-08-18|2014-08-20|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy|Hyperproteic and Fiber-rich Diet Plus Probiotics (Lactobacillus Reuteri) and Nitazoxanide in the Treatment of Minimal Hepatic Encephalopathy.|Completed||N/A|60|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||3|||f||||f||||||||||2018-05-31 23:43:30.072183|2018-05-31 23:43:30.072183
NCT01135615|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-07-20|2010-06-02|2010-06-03|Estimate|||||||2011-07-20|2011-07-22|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)|Sevelamer, FGF-23 and Endothelial Dysfunction in CKD|Completed||Phase 4|100|Actual|Gulhane School of Medicine||2|||f||||||||||||||2018-05-31 23:43:30.1708|2018-05-31 23:43:30.1708
NCT01135602|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-02|||2011-08-12|2010-06-02|2010-06-03|Estimate|||||||2011-08-12|2011-08-15|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|THoPA-O||Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study|Topiramate for Hospitalized Patients With Alcoholism: a 12-Week Open-Label Study|Unknown status|Recruiting|Phase 4|150|Anticipated|Chiang Mai University||1|||f||||f||||||||||2018-05-31 23:43:30.250992|2018-05-31 23:43:30.250992
NCT01135589|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-09-27|2010-06-02|2010-06-03|Estimate|||||||2010-09-27|2010-09-28|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation|Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 4|145|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 23:43:30.359483|2018-05-31 23:43:30.359483
NCT01135576|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2012-12-21|2010-06-02|2010-06-03|Estimate|||||||2012-12-21|2012-12-24|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|FeDrink||Iron Fortified Beverages and Application in Women Predisposed to Anemia||Completed||N/A|122|Actual|National Research Council, Spain||2|||f||||f||||||||||2018-05-31 23:43:30.472189|2018-05-31 23:43:30.472189
NCT01135563|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2013-12-02|2010-06-01|2010-06-02|Estimate|||||||2013-12-02|2013-12-03|Estimate|April 2010||2010-04-30|December 2013|2013-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including Central Nervous System Tumors|A Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including CNS Tumors|Completed||Phase 1|24|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 23:43:30.557074|2018-05-31 23:43:30.557074
NCT01135550|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2016-05-03|2010-06-01|2010-06-02|Estimate|||||||2016-05-03|2016-05-05|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation|A RANDOMIZED CONTROLLED MULTICENTER NON-INFERIORITY TRIAL OF TWICE DAILY LOW DOSE DEXAMETHASONE VERSUS USUAL DOSE DEXAMETHASONE FOR SYMPTOM CONTROL IN CHILDREN WITH A BRAIN TUMOUR UNDERGOING CRANIAL OR CRANIOSPINAL RADIATION|Terminated||Phase 3|25|Actual|The Hospital for Sick Children||2||premature closure due to lack of accrual|f||||f||||||||||2018-05-31 23:43:30.664341|2018-05-31 23:43:30.664341
NCT01135537|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2014-11-27|2010-06-01|2010-06-02|Estimate|||||||2014-11-27|2014-12-02|Estimate|November 2009||2009-11-30|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants|Pharmacokinetics and Pharmacodynamics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplant Recipients|Completed||Phase 2|30|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 23:43:30.797906|2018-05-31 23:43:30.797906
NCT01135524|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2010-07-15||2012-09-05|2010-06-01|2010-06-02|Estimate|2010-08-30|2010-09-23|Estimate||||2012-09-05|2012-09-10|Estimate|April 2004||2004-04-30|September 2012|2012-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase|A Randomized, Double-blind, Multicenter, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or OxyIR® Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain: A 52-Week Extension Phase|Terminated||Phase 3|196|Actual|Purdue Pharma LP|This study was terminated early for administrative reasons.|1||This study was terminated early for administrative reasons.|f||||f||||||||||2018-05-31 23:43:30.93283|2018-05-31 23:43:30.93283
NCT01135511|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2012-12-06|2012-02-14|2013-03-27|2010-06-01|2010-06-02|Estimate|2013-03-27|2013-05-07|Estimate|2012-02-14|2012-02-16|Estimate|2013-03-27|2013-05-07|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease|A Phase II, Prospective, Randomized, Double Masked/Investigator Masked, Vehicle And Comparator (Sodium Hyaluronate Eye Drops) Controlled, Dose Ranging Study Of CP-690,550 Eye Drops In Subjects With Dry Eye Disease|Completed||Phase 2|285|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 23:43:31.342834|2018-05-31 23:43:31.342834
NCT01135498|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2014-11-05||2015-01-22|2010-06-01|2010-06-02|Estimate|2015-01-22|2015-02-06|Estimate||||2015-01-22|2015-02-06|Estimate|November 2006||2006-11-30|January 2015|2015-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Intent-to-treat (ITT) population: all enrolled participants.|A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.|An Open-label Study of the Effect of First-line Treatment With Avastin+Xelox, Followed by Avastin+Tarceva, on Progression-free Survival in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|90|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:43:35.706261|2018-05-31 23:43:35.706261
NCT01135485|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-08-01|2010-06-01|2010-06-02|Estimate|||||||2017-08-01|2017-08-02|Actual|March 2010||2010-03-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome|Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome|Completed|||33|Actual|University of Pennsylvania|||3||f||||f||||||||||2018-05-31 23:43:36.279319|2018-05-31 23:43:36.279319
NCT01135459|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01||2013-09-09|2016-07-19|2010-06-01|2010-06-02|Estimate||||2013-09-09|2013-09-17|Estimate|2016-07-19|2016-07-21|Estimate|June 2010||2010-06-30|July 2016|2016-07-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate the Efficacy and Safety of CEP-33457 in Patients With Systemic Lupus Erythematosus|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus|Completed||Phase 2|183|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-05-31 23:43:36.44057|2018-05-31 23:43:36.44057
NCT01135446|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2016-10-14|2010-06-01|2010-06-02|Estimate|||||||2016-10-14|2016-10-17|Estimate|May 2010||2010-05-31|October 2016|2016-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ULDS||Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects|Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects|Completed||Phase 1|35|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 23:43:36.742508|2018-05-31 23:43:36.742508
NCT01135433|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2016-01-18|2010-06-01|2010-06-02|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients|A Phase 3, Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|Completed||Phase 3|168|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 23:43:36.844827|2018-05-31 23:43:36.844827
NCT01135420|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2015-07-21||2016-11-02|2010-06-01|2010-06-02|Estimate|2016-11-02|2016-12-29|Estimate||||2016-11-02|2016-12-29|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes|Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes|Completed||Phase 2|406|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:43:36.947443|2018-05-31 23:43:36.947443
NCT01135407|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-11-19|2010-06-01|2010-06-02|Estimate|||||||2010-11-19|2010-11-22|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|VSA-PD||Visual Selective Attention in Parkinson's Disease|Role of the Cortico-basal Ganglia Loops in Visual Attention: Effects of Dopaminergic and Subthalamic Nucleus Stimulation in Parkinson's Disease|Completed|||36|Actual|University Hospital, Grenoble|||3||f||||f||||||||||2018-05-31 23:43:37.129041|2018-05-31 23:43:37.129041
NCT01135394|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-09-11|2010-06-01|2010-06-02|Estimate|||||||2017-09-11|2017-09-13|Actual|March 2009||2009-03-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PPAR||Pharmacogenomics of Thiazolidinediones|Pharmacogenomics of Thiazolidinediones|Enrolling by invitation||N/A|134|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 23:43:37.211027|2018-05-31 23:43:37.211027
NCT01135381|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2013-04-10||2013-05-31|2010-06-01|2010-06-02|Estimate|2013-05-31|2013-06-03|Estimate||||2013-05-31|2013-06-03|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||A few patients were excluded from the final study groups. 6 patients died prior to discharge, 2 patients declined participation, and 4 patients became ineligible. After hospital discharge, 12 patients declined follow-up, we were unable to contact 5 for follow-up, and 4 became ineligible.|IVR-Enhanced Care Transition Support for Complex Patients|E-Coaching: IVR-Enhanced Care Transition Support for Complex Patients|Completed||N/A|511|Actual|University of Alabama at Birmingham|Limitations include generalizability. Our single healthcare system likely has unique characteristics. Readmission to the hospital is also a limited quality measure. There is currently no way to deem if readmissions are appropriate or avoidable.|4|||f||||t||||||||||2018-05-31 23:43:37.294834|2018-05-31 23:43:37.294834
NCT01135368|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2012-07-25||2012-07-25|2010-06-01|2010-06-02|Estimate|2012-07-25|2012-09-03|Estimate||||2012-07-25|2012-09-03|Estimate|June 2002||2002-06-30|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of Lansoprazole in Patients With Reflux Disease|Safety and Efficacy of Lansoprazole in Patients With Reflux Disease. An Open, Single Arm, Long-term Study|Completed||Phase 4|506|Actual|Takeda||1|||f||||f||||||||||2018-05-31 23:43:38.89004|2018-05-31 23:43:38.89004
NCT01135355|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-15|2010-06-01|2010-06-02|Estimate|||||||2010-06-15|2010-06-17|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|July 2011|Anticipated|2011-07-31|December 2010|Anticipated|2010-12-31||Observational|||Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients|Cytokine Assay for Early Identification of Pediatric Stem Cell Transplant Recipients at Risk for Respiratory Failure|Unknown status|Recruiting||50|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     blood~   "|||2018-05-31 23:43:42.146687|2018-05-31 23:43:42.146687
NCT01135342|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-05-31|2010-06-01|2010-06-02|Estimate|||||||2017-05-31|2017-06-01|Actual|July 2009||2009-07-31|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Adding Sleep Intervention to Traditional Diet and Exercise Approach to Weight Loss|Adding Sleep Intervention to Traditional Diet and Exercise Approach to Weight Loss|Completed||N/A|28|Actual|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 23:43:42.234764|2018-05-31 23:43:42.234764
NCT01135329|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2014-04-16|2010-06-01|2010-06-02|Estimate|||||||2014-04-16|2014-04-17|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers|Reduced-intensity, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies|Terminated||Phase 2|15|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||The stopping rule was met and hence the study was closed|f||||t||||||||||2018-05-31 23:43:42.356213|2018-05-31 23:43:42.356213
NCT01135316|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2014-05-05|2010-06-01|2010-06-02|Estimate|||||||2014-05-05|2014-05-07|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR|A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice|Completed|||2|Actual|Lantheus Medical Imaging|||||f||||f||||||Samples With DNA|"~     whole blood, tissue~   "|||2018-05-31 23:43:42.456169|2018-05-31 23:43:42.456169
NCT01135303|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-07-20|2010-05-31|2010-06-02|Estimate|||||||2011-07-20|2011-07-21|Estimate|February 2009||2009-02-28|July 2011|2011-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|VISTAO2||Effectiveness of VistaO2 Device in Screening of Sleep Apnea/Hypopnea Syndrome|Effectiveness of VistaO2 Device in Screening of Sleep Apnea/Hypopnea Syndrome|Completed||N/A|182|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 23:43:42.536153|2018-05-31 23:43:42.536153
NCT01135277|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-04-08|2010-06-01|2010-06-02|Estimate|||||||2016-04-08|2016-04-11|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|iVAP||Immune Suppression and Ventilator Associated Pneumonias|Immune Suppression and Ventilator Associated Pneumonias|Completed|||50|Actual|Ohio State University|||2||f||||f||||||Samples Without DNA|"~     Peripheral blood Bronchoalveolar lavage fluid~   "|||2018-05-31 23:43:42.706776|2018-05-31 23:43:42.706776
NCT01135264|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2017-01-12|2010-06-01|2010-06-02|Estimate|||||||2017-01-12|2017-03-24|Actual|August 2009||2009-08-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Cognitive-Motivational Behavior Therapy for Pathological Gamblers|Gambling Addiction: Treatment Mediators and Moderators|Completed||N/A|170|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 23:43:42.844556|2018-05-31 23:43:42.844556
NCT01135251|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-01|2010-06-01|2010-06-02|Estimate|||||||2010-06-01|2010-06-02|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy|A Double Blind, Parallel-group, Randomized Placebo Controlled, Multicentre Exploratory Study of Dimiracetam in Treatment Induced Painful Neuropathy in Patients With HIV Infection|Completed||Phase 2|116|Actual|Neurotune AG||2|||f||||f||||||||||2018-05-31 23:43:42.924395|2018-05-31 23:43:42.924395
NCT01135238|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2011-12-14|2010-06-01|2010-06-02|Estimate|||||||2011-12-14|2011-12-16|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Adrenalectomy for Solitary Adrenal Gland Metastases|The Use of Adrenalectomy in Patients With Solitary Adrenal Gland Metastases|Completed|||168|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 23:43:42.986022|2018-05-31 23:43:42.986022
NCT01135225|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2017-02-01|2010-06-01|2010-06-02|Estimate|||||||2017-02-01|2017-02-03|Estimate|July 2010||2010-07-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|August 2011|Actual|2011-08-31||Interventional|Evolve||Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent|EVOLVE: A Prospective Randomized Multicenter Single-blind Non-inferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System (Evolution Stent System) for the Treatment of a De Novo Atherosclerotic Lesion|Completed||N/A|291|Actual|Boston Scientific Corporation||3|||f||||t||||||||||2018-05-31 23:43:43.053072|2018-05-31 23:43:43.053072
NCT01135212|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2012-08-22|2010-06-01|2010-06-02|Estimate|||||||2012-08-22|2012-08-24|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb)|Completed||Phase 3|290|Actual|Boryung Pharmaceutical Co., Ltd||3|||f||||t||||||||||2018-05-31 23:43:43.191281|2018-05-31 23:43:43.191281
NCT01135199|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-04-07|2010-05-28|2010-06-02|Estimate|||||||2015-04-07|2015-04-08|Estimate||||April 2015|2015-04-30||||||||Interventional|||Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis|Safety and Efficacy of Pomalidomide in the Treatment of Refractory Cough in Patients With Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study|Withdrawn||Phase 2|0|Actual|Stanford University||||"The FDA did not accept the sponsor's additional animal toxicology data to support the proposed~   dosing in this protocol."|f||||||||||||||2018-05-31 23:43:43.294047|2018-05-31 23:43:43.294047
NCT01135186|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2016-10-13||2017-02-09|2010-06-01|2010-06-02|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|May 2010||2010-05-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.|Kuvan® (Sapropterin Dihydrochloride) for Improving Gastric Accommodation in Women With Diabetic Gastroparesis (KIGA-DG)|Completed||N/A|9|Actual|Stanford University|A larger sample size is required to confirm the efficacy of saproptetin in increasing gastric accommodation and decreasing gastroparesis symptoms. This would assist in optimal dosing and duration of therapy.|1|||f||||f||||||||||2018-05-31 23:43:43.378625|2018-05-31 23:43:43.378625
NCT01135173|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-09|2010-06-01|2010-06-02|Estimate|||||||2010-06-09|2010-06-10|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Waterpipe Cessation Intervention Study|Pilot Test of a Cessation Intervention for Waterpipe Smokers|Completed||Phase 1|50|Actual|University of Memphis||2|||f||||t||||||||||2018-05-31 23:43:43.601798|2018-05-31 23:43:43.601798
NCT01135160|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2016-08-30|2010-06-01|2010-06-02|Estimate|||||||2016-08-30|2016-08-31|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Weight Bearing After Total Hip and Knee Replacement|Evaluation of Weight Bearing in Patients After Total Hip and Knee Replacement|Recruiting|||100|Anticipated|Kantonsspital Münsterlingen|||1||f||||t||||||||||2018-05-31 23:43:43.699344|2018-05-31 23:43:43.699344
NCT01135147|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-31|||2010-06-01|2010-06-01|2010-06-02|Estimate|||||||2010-06-01|2010-06-02|Estimate|June 2010||2010-06-30|May 2010|2010-05-31||||June 2012|Anticipated|2012-06-30||Interventional|||Obesity and Obstructive Sleep Apnea (OSA) in Children|Dietary Therapy for Obesity-related Sleep-disordered Breathing in Children|Unknown status|Not yet recruiting|N/A|100|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 23:43:43.777385|2018-05-31 23:43:43.777385
NCT01135134|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2011-10-14||2017-03-16|2010-05-28|2010-06-02|Estimate|2011-10-14|2011-11-03|Estimate||||2017-03-16|2017-04-13|Actual|June 2010||2010-06-30|March 2017|2017-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)|Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No.P06332)|Completed||Phase 3|333|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:43:43.901422|2018-05-31 23:43:43.901422
NCT01135121|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-06-09|2010-06-01|2010-06-02|Estimate|||||||2015-06-09|2015-06-10|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Role of Diaphragm Fatigue in Weaning From Mechanical Ventilation|Pilot Study on the Role of Diaphragm Fatigue in Weaning From Mechanical Ventilation|Unknown status|Recruiting||20|Anticipated|University Medical Center Nijmegen|||2||f||||t||||||||||2018-05-31 23:43:44.12424|2018-05-31 23:43:44.12424
NCT01134146|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-07-17|2010-05-27|2010-05-31|Estimate|||||||2017-07-17|2017-07-21|Actual|May 27, 2010|Actual|2010-05-27|July 2017|2017-07-31|July 9, 2017|Actual|2017-07-09|July 9, 2017|Actual|2017-07-09||Interventional|||Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)|A Phase I Study of Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma After Radical Pleurectomy/Decortication (PD)|Completed||Phase 1|11|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:44:04.830008|2018-05-31 23:44:04.830008
NCT01135108|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2011-08-30|2010-06-01|2010-06-02|Estimate|||||||2011-08-30|2011-09-01|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Spinal Cord Injury|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Two-Period Crossover Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Spinal Cord Injury|Completed||Phase 2|5|Actual|KAI Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:43:44.246716|2018-05-31 23:43:44.246716
NCT01135095|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-04-23|2010-06-01|2010-06-02|Estimate|||||||2013-04-23|2013-04-24|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional|||Low Dose One-Day Tc99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera For Detection of Coronary Disease|Validation of a Low-Dose One-Day TC99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera for Detection of Coronary Artery Disease|Completed||Phase 4|101|Actual|Spectrum Dynamics||1|||f||||f||||||||||2018-05-31 23:43:44.312659|2018-05-31 23:43:44.312659
NCT01135082|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2014-09-03|2010-06-01|2010-06-02|Estimate|||||||2014-09-03|2014-09-04|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Pneumococcal Conjugate Vaccine (PCV) in HIV- Infected Children|The Immunogenicity and Safety of Pneumococcal Conjugate Vaccine in Human Immunodeficiency Virus - Infected Children|Completed||N/A|90|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-05-31 23:43:44.728962|2018-05-31 23:43:44.728962
NCT01135069|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2013-05-28||2014-10-15|2010-06-01|2010-06-02|Estimate|2014-10-09|2014-10-16|Estimate||||2014-10-15|2014-10-27|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo|Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo|Completed||Phase 3|480|Actual|Spear Pharmaceuticals|No unexpected problems.|3|||f||||f||||||||||2018-05-31 23:43:44.822177|2018-05-31 23:43:44.822177
NCT01135056|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2018-04-22|2010-05-30|2010-06-02|Estimate|||||||2018-04-22|2018-04-24|Actual|July 2010||2010-07-31|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|SIRveNIB||Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)|Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)|Active, not recruiting||Phase 3|360|Actual|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 23:43:45.149425|2018-05-31 23:43:45.149425
NCT01135043|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-05-28|2010-05-28|2010-06-02|Estimate|||||||2010-05-28|2010-06-02|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||Simple Verbal Intervention for Adequately Collecting Sputum|The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing|Unknown status|Recruiting|Phase 4|188|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:43:45.294905|2018-05-31 23:43:45.294905
NCT01135030|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-02-03|2010-06-01|2010-06-02|Estimate|||||||2012-02-03|2012-02-06|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|AR vs PR||Anterior Referencing Versus Posterior Referencing in Minimally Invasive Total Knee Arthroplasty|Anterior Referencing Vs. Posterior Referencing in Minimally Invasive Total Knee Arthroplasty|Completed||N/A|100|Actual|Heekin Orthopedic Research Institute||2|||f||||f||||||||||2018-05-31 23:43:45.381494|2018-05-31 23:43:45.381494
NCT01135017|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2013-02-21||2013-04-05|2010-05-28|2010-06-02|Estimate|2013-02-21|2013-04-01|Estimate||||2013-04-05|2013-04-11|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|HESTIA||Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers|A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers|Terminated||Phase 4|112|Actual|Sanofi|Due to smaller-than-planned number of participants (112 instead of 424), results should be cautiously interpreted. However, the power to detect large treatment effect remained high and the posthoc power to detect a 60% reduction in AF burden was 99%.|2|||f||||t||||||||||2018-05-31 23:43:45.582211|2018-05-31 23:43:45.582211
NCT01135004|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-30|||2010-06-01|2010-06-01|2010-06-02|Estimate|||||||2010-06-01|2010-06-02|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|February 2013|Anticipated|2013-02-28|February 2012|Anticipated|2012-02-29||Observational|||Pathogenesis of Primary Spontaneous Pneumothorax|Molecular Pathogenesis of Primary Spontaneous Pneumothorax|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     Thoracoscopic bullectomy will be performed in spontaneous pneumothorax patients. Part of the~     surgcal specimen (lung tissue) will be obtained for RNA and protein analyses.~   "|||2018-05-31 23:43:46.29766|2018-05-31 23:43:46.29766
NCT01134991|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2015-08-25|2010-06-01|2010-06-02|Estimate|||||||2015-08-25|2015-08-26|Estimate|June 2010||2010-06-30|August 2010|2010-08-31||||March 2014|Actual|2014-03-31||Interventional|||Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients|Pilot, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Moderate to Severe Rosacea Patients|Terminated||Phase 2|21|Actual|Foamix Ltd.||3||Difficulty in recruitment|f||||f||||||||||2018-05-31 23:43:46.388832|2018-05-31 23:43:46.388832
NCT01134978|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2011-11-04|2010-06-01|2010-06-02|Estimate|||||||2011-11-04|2011-11-07|Estimate|November 2007||2007-11-30|May 2011|2011-05-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|GRID12007||Neural Mechanisms of the Contextual Interference Effect: A fNIRs and EEG Study|Neural Mechanisms of the Contextual Interference Effect: A fNIRs and EEG Study|Completed||Phase 1|20|Anticipated|Drexel University||1|||f||||f||||||||||2018-05-31 23:43:46.496041|2018-05-31 23:43:46.496041
NCT01134965|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2011-04-07|2010-06-01|2010-06-02|Estimate|||||||2011-04-07|2011-04-08|Estimate|June 2010||2010-06-30|April 2011|2011-04-30||||July 2010|Actual|2010-07-31||Interventional|||to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers|An Open Two-way Cross-over Study to Evaluate the Effect of Multiple Doses of Flibanserin 100 mg Film-coated Tablets Given Once Daily on the Single Dose Pharmacokinetics of Digoxin 0.5 mg in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:43:46.612488|2018-05-31 23:43:46.612488
NCT01134133|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-06-21|2010-05-28|2010-05-31|Estimate|||||||2011-06-21|2011-06-23|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Can Hospital Acquired Pneumonia be Prevented in Patients Who Gurgle?|Can Hospital Acquired Pneumonia be Prevented in Patients Who Gurgle?|Withdrawn||Phase 1/Phase 2|50|Anticipated|Bridgeport Hospital||||Slow recruitment (preemptive treatment of gurglers, after association was published)|f||||f||||||||||2018-05-31 23:44:04.919972|2018-05-31 23:44:04.919972
NCT01134952|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2014-12-15||2015-02-06|2010-06-01|2010-06-02|Estimate|2015-01-10|2015-01-21|Estimate||||2015-02-06|2015-02-26|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)|A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection|Completed||Phase 4|11|Actual|London Health Sciences Centre|Greater than expected baseline variation; technical problems with laboratory measurement of HCV (two different platforms used); and poor recruitment over a long period make the results difficult to interpret.|1|||f||||f||||||||||2018-05-31 23:43:46.7412|2018-05-31 23:43:46.7412
NCT01134939|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|2014-12-31||2015-01-09|2010-06-01|2010-06-02|Estimate|2015-01-09|2015-01-21|Estimate||||2015-01-09|2015-01-21|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||Treated Set (TS): This patient set includes all HIV-1 infected patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment and of an antiretroviral combination partner.|Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data|Non-interventional Observational Study With Viramune® Plus Antiretroviral Backbone Combination in HIV-infected Women and Male Patients. Gender Specific Evaluation of Data.|Completed|||265|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:43:47.269124|2018-05-31 23:43:47.269124
NCT01134926|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-29|||2015-06-21|2010-06-01|2010-06-02|Estimate|||||||2015-06-21|2015-06-23|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Non Surgical Management for Uterine Residua After Pregnancy Termination, Abortion or Delivery|Phase Study Comparing Between Expectant Management and Misoprostol Treatment for Intra-uterine Residua After Pregnancy Termination, Abortion or Delivery|Terminated||Phase 2|23|Actual|HaEmek Medical Center, Israel||2||The principal investigator left the organization|f||||||||||||||2018-05-31 23:43:48.582666|2018-05-31 23:43:48.582666
NCT01134913|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-29|||2012-08-30|2010-06-01|2010-06-02|Estimate|||||||2012-08-30|2012-08-31|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|October 2010|Actual|2010-10-31||Observational|Midas 3||Multi-Markers In the Diagnosis of Acute Coronary Syndrome|Multi-Markers In the Diagnosis of Acute Coronary Syndrome - Sample Procurement Cohort 3|Completed|||621|Actual|Biosite|||||f||||f||||||Samples Without DNA|"~     EDTA Plasma Specimens~   "|||2018-05-31 23:43:48.650748|2018-05-31 23:43:48.650748
NCT01134900|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2012-01-25||2012-01-25|2010-06-01|2010-06-02|Estimate|2012-01-25|2012-02-27|Estimate||||2012-01-25|2012-02-27|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Achieving Medication Safety During Acute Kidney Injury|Achieving Medication Safety During Acute Kidney Injury: The Impact of Clinical Decision Support and Real-Time Pharmacy Surveillance|Completed||N/A|540|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 23:43:48.725949|2018-05-31 23:43:48.725949
NCT01134887|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2015-02-03||2017-06-26|2010-06-01|2010-06-02|Estimate|2016-03-15|2016-04-14|Estimate||||2017-06-26|2017-08-01|Actual|September 1, 2009|Actual|2009-09-01|June 2017|2017-06-30|January 30, 2017|Actual|2017-01-30|September 30, 2012|Actual|2012-09-30||Interventional|CHOICE||Controlling Hypertension Outcomes by Improved Communication & Engagement|Controlling Hypertension Outcomes by Improved Communication & Engagement (CHOICE)|Completed||N/A|26|Actual|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 23:43:49.009708|2018-05-31 23:43:49.009708
NCT01134874|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2015-08-04|2010-05-28|2010-06-02|Estimate|||||||2015-08-04|2015-08-05|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Comparison of a Technology-Based System and an In-Person Behavioral Weight Loss Intervention|The Comparison of a Technology-Based System and an In-Person Behavioral Weight Loss Intervention|Completed||Phase 2|51|Actual|University of Pittsburgh||3|||f||||f||||||||||2018-05-31 23:43:49.41311|2018-05-31 23:43:49.41311
NCT01134861|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-03-26|2010-05-29|2010-06-02|Estimate|||||||2015-03-26|2015-03-27|Estimate|July 1994||1994-07-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|October 1998|Actual|1998-10-31||Interventional|||Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|A Three-Arm Phase III Study of Concomitant Versus Sequential Chemotherapy and Thoracic Radiotherapy for Patients With Locally Advanced Inoperable Non-small Cell Lung Cancer|Completed||Phase 3|610|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-05-31 23:43:49.56592|2018-05-31 23:43:49.56592
NCT01134848|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-06-01|2010-06-01|2010-06-02|Estimate|||||||2010-06-01|2010-06-02|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers|A Randomised, Double Blind Cross-over Study of Serial MRCP Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers|Completed||Phase 4|10|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 23:43:49.680015|2018-05-31 23:43:49.680015
NCT01134835|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-12-01|2010-06-01|2010-06-02|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|||PPAR-gamma: a Novel Therapeutic Target for Asthma?|PPAR-gamma: a Novel Therapeutic Target in Asthma?|Terminated||Phase 4|68|Actual|University of Nottingham||2||safety concerns with pioglitazone|f||||f||||||||||2018-05-31 23:43:49.772613|2018-05-31 23:43:49.772613
NCT01134822|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2017-01-04|2010-06-01|2010-06-02|Estimate|||||||2017-01-04|2017-01-05|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|PROFILE||Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)|Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)|Active, not recruiting|||330|Anticipated|University of Nottingham|||1||f||||f||||||Samples With DNA|"~     Blood(serum, plasma) & Lavage Fluid~   "|No||2018-05-31 23:43:49.85282|2018-05-31 23:43:49.85282
NCT01134809|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-06-05|2010-06-01|2010-06-02|Estimate|||||||2015-06-05|2015-06-09|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|SIRSS||Skeletal Muscle Wasting and Insulin Resistance Following Surgical Stress|Does Surgical Stress Impair Skeletal Muscle Protein and Carbohydrate Metabolism?|Completed|||15|Actual|University of Nottingham|||1||f||||t||||||||||2018-05-31 23:43:49.929468|2018-05-31 23:43:49.929468
NCT01134796|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-12-01|2010-06-01|2010-06-02|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Assessment of GRASP Medical Device to Improve Arm Coordination After Stroke|Assessment of GRASP II Medical Device to Improve Arm Coordination After Stroke|Terminated|||10|Actual|University of Nottingham||||failure to recruit|f||||f||||||||||2018-05-31 23:43:50.020153|2018-05-31 23:43:50.020153
NCT01134783|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2015-08-24||2016-05-10|2010-05-28|2010-06-02|Estimate|2016-05-10|2016-06-17|Estimate||||2016-05-10|2016-06-17|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|CHOICES|The original study design was 4 arms (1 control & 3 intervention) that varied in the way the 4-month curriculum was delivered. Our formative work showed that students not being able to choose the course delivery method would limit interest in study participation. We changed the study design to 2 arms, which was approved by the EARLY trials DSMB.|Choosing Healthy Options in College Environments and Settings|Evaluating Innovative Weight Reduction Strategies for College Students|Completed||N/A|441|Actual|University of Minnesota - Clinical and Translational Science Institute|Because of sample size constraints we combined overweight and obese participants into one category. Additional insights might be gleaned from examining intervention impact and transitions between three categories of weight status.|2|||f||||t||||||||No||2018-05-31 23:43:50.09381|2018-05-31 23:43:50.09381
NCT01134770|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2017-10-13|2010-05-28|2010-06-02|Estimate|||||||2017-10-13|2017-10-16|Actual|July 2008||2008-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|PEEPS||Prenatal Exposure Effects Psychophysiology Study|Prenatal Cocaine and Neurobehavioral Factors Underlying Mother-Infant Interaction|Enrolling by invitation|||150|Anticipated|University of North Carolina, Chapel Hill|||3||f||||f||||||Samples With DNA|"~     Plasma from mothers and buccal cells from infants will be stored for possible DNA analysis of~     target genes pending additional funding.~   "|No||2018-05-31 23:43:50.674527|2018-05-31 23:43:50.674527
NCT01134757|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-03-16|2010-06-01|2010-06-02|Estimate|||||||2015-03-16|2015-03-17|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|||Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.|A Retrospective and Prospective, Diagnostic, Open-label, Single-center Study of the Safety of the Bronchial Allergen Challenge With House Dust Mite, Grass Pollen and Alternaria and Predictors for Positive Reaction.|Completed||N/A|425|Actual|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||||2018-05-31 23:43:50.826553|2018-05-31 23:43:50.826553
NCT01134744|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-06-18|2010-06-01|2010-06-02|Estimate|||||||2010-06-18|2010-06-22|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Evaluating Validity of Clinical Criteria for Requesting Chest X-Rays in Trauma Patients|Study of Accuracy of Clinical Examination for Chest Trauma|Completed|||385|Actual|Isfahan University of Medical Sciences|||1||f||||t||||||||||2018-05-31 23:43:50.951388|2018-05-31 23:43:50.951388
NCT01134731|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2015-05-26||2016-02-03|2010-06-01|2010-06-02|Estimate|2015-12-22|2016-01-29|Estimate||||2016-02-03|2016-03-03|Estimate|May 2010||2010-05-31|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|AFSP||Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation|Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation|Completed||Phase 4|54|Actual|University of Alabama at Birmingham|The inherent risk of the condition and concerns about the safety of the study, the high risk of impulsive and aggressive behavior, and high levels of distress making placebo-controlled studies difficult. Placebo arm terminated early due to dropout.|3|||f||||f||||||||No||2018-05-31 23:43:51.083933|2018-05-31 23:43:51.083933
NCT01134718|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2013-04-08|2010-05-28|2010-06-02|Estimate|||||||2013-04-08|2013-04-09|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration|Pilot BA Study With Phase III/Commercial Versus Phase IIB Formulation. A Phase I, Open Label, Randomized, Single Dose, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of Potential Phase III Formulations Compared to the Phase IIb Capsule|Completed||Phase 1|24|Actual|Tibotec Pharmaceuticals, Ireland||3|||f||||f||||||||||2018-05-31 23:43:51.433973|2018-05-31 23:43:51.433973
NCT01134705|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2012-04-23|2011-08-25|2012-04-23|2010-06-01|2010-06-02|Estimate|2012-04-23|2012-05-23|Estimate|2011-08-25|2011-08-29|Estimate|2012-04-23|2012-05-23|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older)|Completed||Phase 3|474|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 23:43:51.541541|2018-05-31 23:43:51.541541
NCT01134692|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2010-06-01|2010-06-01|2010-06-02|Estimate|||||||2010-06-01|2010-06-02|Estimate||||May 2010|2010-05-31||||||||Interventional|||Probiotics for Portal Hypertension|COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST|Unknown status|Recruiting|Phase 3|||Govind Ballabh Pant Hospital||3|||f||||f||||||||||2018-05-31 23:43:51.890335|2018-05-31 23:43:51.890335
NCT01134679|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-02-13|2010-06-01|2010-06-02|Estimate|||||||2012-02-13|2012-02-14|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|EASY-IMPACT||(EASY)-IMProving Adherence to Clopidogrel Trial (IMPACT))|Telephone Contacts to Improve Adherence to Dual Anti-Platelet Therapy Following Drug-Eluting Stent Implantation; A Randomized Controlled-Trial|Completed||N/A|300|Actual|Laval University||1|||f||||f||||||||||2018-05-31 23:43:52.076406|2018-05-31 23:43:52.076406
NCT01134666|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2017-06-08|2010-05-28|2010-06-02|Estimate|||||||2017-06-08|2017-06-09|Actual|November 30, 2009|Actual|2009-11-30|June 2017|2017-06-30|August 5, 2014|Actual|2014-08-05|July 31, 2013|Actual|2013-07-31||Observational|||An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer|An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer|Terminated|||165|Actual|Merck KGaA||||"The study was discontinued due to slow recruitment and subjects not completing follow up~   period."|f||||||||||Samples With DNA|"~     Whole Blood and Tissue~   "|||2018-05-31 23:43:52.163909|2018-05-31 23:43:52.163909
NCT01134653|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-02-02|2010-06-01|2010-06-02|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|||A Comparison of Early Mobilization Versus Traditional Treatment for Acute Ankle Sprains.|Efficacy of Stretch Band Ankle Traction Technique in the Treatment of Acute Ankle Sprains.|Completed||N/A|42|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 23:43:52.279301|2018-05-31 23:43:52.279301
NCT01132248|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2013-01-23|2010-05-27|2010-05-28|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Activity of Mefloquine Against Urinary Schistosomiasis|Activity of Mefloquine Against Urinary Schistosomiasis|Completed||Phase 2|65|Actual|Albert Schweitzer Hospital||2|||f||||f||||||||||2018-05-31 23:44:51.131966|2018-05-31 23:44:51.131966
NCT01134640|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-05-08|2010-05-28|2010-06-02|Estimate|||||||2014-05-08|2014-05-09|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment|A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment|Completed|||286|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:43:52.354272|2018-05-31 23:43:52.354272
NCT01134627|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2012-08-02||2013-12-02|2010-05-28|2010-06-02|Estimate|2012-08-02|2012-09-05|Estimate||||2013-12-02|2013-12-27|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|RECYCLINE||Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]|A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis|Terminated||Phase 2|305|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 23:43:52.482817|2018-05-31 23:43:52.482817
NCT01134614|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2015-03-23||2018-05-25|2010-05-28|2010-06-02|Estimate|2015-03-23|2015-04-02|Estimate||||2018-05-25|2018-05-30|Actual|December 28, 2010|Actual|2010-12-28|May 2018|2018-05-31||||February 15, 2013|Actual|2013-02-15||Interventional||All randomized patients are included in this analysis.|Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma|Active, not recruiting||Phase 2|245|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 23:43:53.012369|2018-05-31 23:43:53.012369
NCT01134601|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2018-05-23|2010-05-28|2010-06-02|Estimate|||||||2018-05-23|2018-05-24|Actual|May 24, 2010||2010-05-24|October 22, 2012|2012-10-22|October 22, 2012|Actual|2012-10-22|October 22, 2012|Actual|2012-10-22||Interventional|||A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum|A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum|Terminated||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:43:55.218088|2018-05-31 23:43:55.218088
NCT01134588|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2015-03-24|2010-06-01|2010-06-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|U-GYN-QOL||Assessment of Quality of Life in Disorders of the Pelvic Floor|Assessment of Quality of Life in Disorders of the Pelvic Floor|Completed||N/A|129|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 23:43:55.291564|2018-05-31 23:43:55.291564
NCT01134575|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2018-04-27|2010-05-28|2010-06-02|Estimate|||||||2018-04-27|2018-04-30|Actual|June 4, 2010|Actual|2010-06-04|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)|Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab|Completed||Phase 1|91|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:43:55.379872|2018-05-31 23:43:55.379872
NCT01134562|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2017-03-01||2017-05-26|2010-06-01|2010-06-02|Estimate|2017-05-26|2018-01-02|Actual||||2017-05-26|2018-01-02|Actual|September 7, 2010||2010-09-07|May 2017|2017-05-31|April 2, 2011|Actual|2011-04-02|April 2, 2011|Actual|2011-04-02||Interventional|||Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism|Completed||Phase 1|28|Actual|KAI Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:43:55.604485|2018-05-31 23:43:55.604485
NCT01134549|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2017-02-28||2017-02-28|2010-06-01|2010-06-02|Estimate|2017-02-28|2017-04-14|Actual||||2017-02-28|2017-04-14|Actual|June 9, 2010||2010-06-09|February 2017|2017-02-28|July 31, 2010|Actual|2010-07-31|July 31, 2010|Actual|2010-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Rising Single Intravenous Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of KAI-4169 in Healthy Male Volunteers|Completed||Phase 1|32|Actual|KAI Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:43:57.090637|2018-05-31 23:43:57.090637
NCT01134536|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-07-11|2010-05-28|2010-06-02|Estimate|||||||2014-07-11|2014-07-14|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents|Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentadol Oral Solution for the Treatment of Postsurgical Pain in Children and Adolescents Aged From 6 to Less Than 18 Years|Completed||Phase 2|45|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 23:43:58.464121|2018-05-31 23:43:58.464121
NCT01134523|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2013-03-14|2010-06-01|2010-06-02|Estimate|||||||2013-03-14|2013-03-15|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Regimens Comparison for Breast Cancers of Positive Lymph Nodes|Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes|Recruiting||Phase 3|1000|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 23:43:58.57957|2018-05-31 23:43:58.57957
NCT01134510|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2015-03-12||2017-02-16|2010-06-01|2010-06-02|Estimate|2015-07-28|2015-08-03|Estimate||||2017-02-16|2017-03-21|Actual|August 2011||2011-08-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection|"A Phase I/II Trial to Evaluate the Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Complement-Dependent, Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients"|Completed||Phase 1/Phase 2|20|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 23:43:58.746909|2018-05-31 23:43:58.746909
NCT01134497|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-05-18|2010-06-01|2010-06-02|Estimate|||||||2018-05-18|2018-05-22|Actual||||May 2018|2018-05-31|August 16, 2011|Actual|2011-08-16|August 16, 2011|Anticipated|2011-08-16||Interventional|PLANET||Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer|A Randomised Phase II Study of Carboplatin With or Without the Addition of the ETAR Inhibitor ZD4054 as Treatment for Patients With Metastatic Breast Cancer|Withdrawn||Phase 2|0|Actual|Cardiff University||2||New information on IMP affected the cost/benefit ratio|f||||t||||||||||2018-05-31 23:43:59.044668|2018-05-31 23:43:59.044668
NCT01134120|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-04-13|2010-05-28|2010-05-31|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2010||2010-04-30|April 2018|2018-04-30|February 22, 2018|Actual|2018-02-22|April 2014|Actual|2014-04-30||Interventional|||A Study in Myeloproliferative Disorders|A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders|Completed||Phase 1|80|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:44:05.011543|2018-05-31 23:44:05.011543
NCT01134484|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2012-07-19|2010-06-01|2010-06-02|Estimate|||||||2012-07-19|2012-07-20|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|December 2015|Anticipated|2015-12-31|August 2008|Actual|2008-08-31||Interventional|||VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)|A Phase 3, Prospective, Randomized Clinical Study of VELCADE-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) for Previously Untreated Multiple Myeloma (MM) Patients Who Are Candidates to Receive Double Autologous Transplantation|Unknown status|Active, not recruiting|Phase 3|480|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 23:43:59.114561|2018-05-31 23:43:59.114561
NCT01134471|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-06-01|2010-06-01|2010-06-02|Estimate|||||||2010-06-01|2010-06-02|Estimate|April 2009||2009-04-30|May 2010|2010-05-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Improvement of Hemostasis Techniques After Median Sternotomy|Improvement of Hemostasis Techniques After Median Sternotomy|Unknown status|Enrolling by invitation|Phase 4|75|Actual|Aarhus University Hospital||3|||f||||t||||||||||2018-05-31 23:43:59.210821|2018-05-31 23:43:59.210821
NCT01134458|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-07-18|2010-06-01|2010-06-02|Estimate|||||||2014-07-18|2014-07-22|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|November 2011|Actual|2011-11-30||Interventional|FIMDM_CVD||Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes|Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes|Completed||N/A|98|Actual|Duke University||2|||f||||f||||||||||2018-05-31 23:43:59.279944|2018-05-31 23:43:59.279944
NCT01134445|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2017-06-23|2010-06-01|2010-06-02|Estimate|||||||2017-06-23|2017-06-26|Actual|February 1, 2010|Actual|2010-02-01|June 2017|2017-06-30|June 1, 2016|Actual|2016-06-01|January 1, 2016|Actual|2016-01-01||Interventional|||An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement|Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy PROXIMA™ Hip in Subjects With Indications Suitable for a Primary Total Hip Arthroplasty|Terminated||Phase 4|42|Actual|DePuy International||1||Study terminated early for business reasons|f||||f||||||||||2018-05-31 23:43:59.369734|2018-05-31 23:43:59.369734
NCT01134432|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2013-09-09|2010-06-01|2010-06-02|Estimate|||||||2013-09-09|2013-09-10|Estimate|March 2005||2005-03-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia|Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial.|Completed||Phase 3|65|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-05-31 23:43:59.633482|2018-05-31 23:43:59.633482
NCT01134419|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2013-05-15|2010-06-01|2010-06-02|Estimate|||||||2013-05-15|2013-05-16|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Implementing a Comprehensive Handoff Program to Improve Pediatric Patient Safety|Implementing a Comprehensive Handoff Program to Improve Pediatric Patient Safety|Completed||N/A|84|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 23:43:59.725632|2018-05-31 23:43:59.725632
NCT01134406|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2011-11-02|2010-05-28|2010-06-02|Estimate|||||||2011-11-02|2011-11-03|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Hydros Joint Therapy and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis (OA)|A Prospective, Multi-center, Randomized, Double-blind Feasibility Study to Evaluate the Safety and Performance of Hydros Joint Therapy and Hydros-TA Joint Therapy for Management of Pain Associated With Osteoarthritis in the Knee|Completed||Phase 2|98|Actual|Carbylan Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 23:43:59.853895|2018-05-31 23:43:59.853895
NCT01134393|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2012-05-31||2013-12-13|2010-06-01|2010-06-02|Estimate|2012-05-31|2012-07-04|Estimate||||2013-12-13|2014-01-15|Estimate|May 2010||2010-05-31|December 2013|2013-12-31||||May 2011|Actual|2011-05-31||Interventional|||TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch|"A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension..."|Completed||Phase 3|502|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:43:59.962808|2018-05-31 23:43:59.962808
NCT01134380|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-10-07|2010-06-01|2010-06-02|Estimate|||||||2014-10-07|2014-10-08|Estimate|June 2010||2010-06-30|July 2011|2011-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|GIANT||Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment|Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment|Completed|||1500|Anticipated|Biotronik France|||2||f||||t||||||Samples With DNA|"~     DNA Samples from saliva to observe CYP2C19 genetic variants~   "|||2018-05-31 23:44:00.297562|2018-05-31 23:44:00.297562
NCT01134367|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2011-07-13|2010-06-01|2010-06-02|Estimate|||||||2011-07-13|2011-07-14|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease|An Epidemiological, Postmarketing Observational Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease (GERD) on Patients' Daily Life|Completed|||1000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:44:00.379454|2018-05-31 23:44:00.379454
NCT01134354|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-06-18|2010-06-01|2010-06-02|Estimate|||||||2014-06-18|2014-06-19|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||The Role of Patient Expectations in Traumatic Orthopedic Outcomes-TEFTOM EURASIA|The Role of Patient Expectations in Traumatic Orthopedic Outcomes TEFTOM: The Trauma Expectation Factor - Trauma Outcomes Measure TEFTOM EURASIA|Completed|||199|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 23:44:00.666225|2018-05-31 23:44:00.666225
NCT01134341|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2016-07-20|2010-06-01|2010-06-02|Estimate|||||||2016-07-20|2016-07-22|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma|A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma|Completed||Phase 1|34|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||||||||||||2018-05-31 23:44:00.74314|2018-05-31 23:44:00.74314
NCT01134328|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2017-06-22|2012-02-27|2017-09-13|2010-06-01|2010-06-02|Estimate|2017-09-13|2017-09-14|Actual|2012-02-27|2012-02-29|Estimate|2017-09-13|2017-09-14|Actual|May 2010||2010-05-31|September 2017|2017-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model|A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season|Completed||Phase 2|83|Actual|Aciex Therapeutics, Inc.||4|||f||||||||||||||2018-05-31 23:44:00.915524|2018-05-31 23:44:00.915524
NCT01134315|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2013-05-17||2013-05-17|2010-05-28|2010-06-02|Estimate|2013-05-17|2013-08-13|Estimate||||2013-05-17|2013-08-13|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice|A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice|Terminated|||61|Actual|AbbVie|||2|Terminated after FDA agreement.|f||||f||||||||||2018-05-31 23:44:02.18203|2018-05-31 23:44:02.18203
NCT01134302|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-05-27|2010-05-27|2010-05-31|Estimate|||||||2010-05-27|2010-05-31|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation|The Influence of Postoperative Systemic Oxygen Transport on Neurologic and Functional Outcomes in Infants Undergoing Single Ventricle Palliation With Norwood and Hybrid Management Strategies|Unknown status|Recruiting|Phase 3|50|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 23:44:03.208161|2018-05-31 23:44:03.208161
NCT01134289|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-06-04|2010-05-28|2010-05-31|Estimate|||||||2010-06-04|2010-06-07|Estimate|September 2009||2009-09-30|June 2010|2010-06-30||||February 2010|Anticipated|2010-02-28||Interventional|park001||Analysis of Photoplethysmographic Signal in Lumbar Sympathetic Block|An Analysis of Photoplethysmographic Signal in Diagnostic Lumbar Sympathetic Block for Complex Regional Pain Syndrome|Unknown status|Recruiting|Phase 3|25|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:44:03.398482|2018-05-31 23:44:03.398482
NCT01134276|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2014-04-07||2014-06-07|2010-05-27|2010-05-31|Estimate|2014-06-07|2014-06-11|Estimate||||2014-06-07|2014-06-11|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers|Prospective Study on the Comparison Between the Clinicopathological Outcomes According to the Methods of Preoperative Biliary Drainage in Periampullary Cancers Causing Obstructive Jaundice|Completed||N/A|211|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:44:03.528338|2018-05-31 23:44:03.528338
NCT01134263|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-01-09|2010-05-27|2010-05-31|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2010||2010-10-31|January 2018|2018-01-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia|Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia|Completed||Phase 3|712|Actual|Sanofi||5|||f||||t||||||||||2018-05-31 23:44:03.844159|2018-05-31 23:44:03.844159
NCT01134250|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-10-20|2010-05-28|2010-05-31|Estimate|||||||2014-10-20|2014-10-21|Estimate|June 2008||2008-06-30|October 2014|2014-10-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients|Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours|Unknown status|Recruiting|Phase 1/Phase 2|96|Anticipated|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:44:04.043541|2018-05-31 23:44:04.043541
NCT01134237|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-05-28|2010-05-28|2010-05-31|Estimate|||||||2010-05-28|2010-05-31|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|NTUH||Intrapleural Urokinase for Retained Hemothorax|Intrapleural Thrombolytic Treatment With Urokinase for Retained Hemothorax: A Prospective Double-blinded Randomized Multicenter Study|Unknown status|Active, not recruiting|Phase 3|32|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 23:44:04.143024|2018-05-31 23:44:04.143024
NCT01134224|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2013-11-26|2010-05-27|2010-05-31|Estimate|||||||2013-11-26|2013-11-27|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes|A Trial Investigating the Pharmacodynamic Response of NN5401 in Subjects With Type 2 Diabetes|Completed||Phase 1|39|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-05-31 23:44:04.21729|2018-05-31 23:44:04.21729
NCT01134211|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2016-11-17|2010-05-27|2010-05-31|Estimate|||||||2016-11-17|2016-11-21|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Clinical Comparison of Two Daily Disposable Lenses Among Daily Disposable Lens Wearers||Completed||N/A|316|Actual|Alcon Research||2|||f||||||||||||||2018-05-31 23:44:04.321033|2018-05-31 23:44:04.321033
NCT01134198|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2018-02-15|2010-05-28|2010-05-31|Estimate|||||||2018-02-15|2018-02-16|Estimate|May 2010||2010-05-31|February 2018|2018-02-28|February 14, 2018|Actual|2018-02-14|September 2016|Actual|2016-09-30||Interventional|||Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients|Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients|Completed||Phase 2/Phase 3|59|Actual|New York State Psychiatric Institute||2|||f||||t||||||||Yes|Data has been presented as an oral presentation at the annual meeting of the College on Drug Dependence in Palm Springs California on June 16th 2016. The data is presently being prepared for publication in a peer-reviewed publication.|2018-05-31 23:44:04.387336|2018-05-31 23:44:04.387336
NCT01134185|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2012-04-17|2010-05-28|2010-05-31|Estimate|||||||2012-04-17|2012-04-19|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|HI||Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment|Evaluation of Pharmacokinetics, Safety and Tolerability of a Single Dose of Prucalopride, in Subjects With Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects|Completed||Phase 1|24|Actual|Movetis||3|||f||||f||||||||||2018-05-31 23:44:04.47823|2018-05-31 23:44:04.47823
NCT01134172|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-05-01|2010-05-27|2010-05-31|Estimate|||||||2018-05-01|2018-05-03|Actual|May 2010|Actual|2010-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life|Breast Cancer and the Workforce: Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life (BCW)|Recruiting|||750|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 23:44:04.578525|2018-05-31 23:44:04.578525
NCT01134159|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2011-06-01|2010-05-28|2010-05-31|Estimate|||||||2011-06-01|2011-06-02|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|REWARDS TLX||Registry Experience at the Washington Hospital Center, Des - Taxus Liberte Versus Xience V|Registry Experience at the WAshington Hospital CenteR, DeS - Taxus Liberte vs Xience V|Completed|||1200|Anticipated|Medstar Health Research Institute|||2||f||||f||||||||||2018-05-31 23:44:04.734467|2018-05-31 23:44:04.734467
NCT01134107|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2012-09-27||2013-04-04|2010-05-27|2010-05-31|Estimate|2012-09-27|2012-10-26|Estimate||||2013-04-04|2013-04-11|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use|A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|133|Actual|Eli Lilly and Company|Input to primary endpoint measurements (SMBG) contained approximately 40% missing data. Several analyses to account for missing data were conducted and results from these additional analyses were consistent with results from the original analysis.|2|||f||||f||||||||||2018-05-31 23:44:05.147655|2018-05-31 23:44:05.147655
NCT01134094|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-06-22|2010-05-28|2010-05-31|Estimate|||||||2015-06-22|2015-06-24|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CROSSBAT||Combined Randomised and Observational Study of Type B Ankle Fracture Treatment|Combined Randomised and Observational Study of Type B Ankle Fracture Treatment|Completed||N/A|160|Actual|The University of New South Wales||2|||f||||t||||||||||2018-05-31 23:44:06.419987|2018-05-31 23:44:06.419987
NCT01134081|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2010-09-27||2017-07-19|2010-05-28|2010-05-31|Estimate|2017-06-20|2017-07-18|Actual||||2017-07-19|2017-08-21|Actual|January 2008||2008-01-31|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts|Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts|Completed||N/A|44|Actual|University of Michigan|Although the present study compared the differences in angiogenic biomarker expression between LCC and autograft, it is important to understand that both LCC and autograft heal by two different healing processes.|2|||f||||f||||||||No||2018-05-31 23:44:06.613382|2018-05-31 23:44:06.613382
NCT01134068|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2015-05-27|2010-05-28|2010-05-31|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|ADJUST||Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism|Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism: a Prospective Outcome Study.|Completed||Phase 4|3306|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 23:44:07.198827|2018-05-31 23:44:07.198827
NCT01134055|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2017-08-11|2013-04-11|2017-12-07|2010-05-27|2010-05-31|Estimate|2017-12-07|2018-01-08|Actual|2013-04-11|2013-04-18|Estimate|2017-12-07|2018-01-08|Actual|June 1, 2010|Actual|2010-06-01|December 2017|2017-12-31|October 1, 2012|Actual|2012-10-01|October 1, 2012|Actual|2012-10-01||Interventional|||Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration|MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration|Completed||Phase 2|510|Actual|GlaxoSmithKline||7|||f||||t||||||||||2018-05-31 23:44:07.608443|2018-05-31 23:44:07.608443
NCT01134042|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2013-06-06|2012-04-26|2016-11-23|2010-05-27|2010-05-31|Estimate|2013-06-06|2013-08-08|Estimate|2012-04-26|2012-04-30|Estimate|2016-11-23|2017-01-11|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics|HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents|Completed||Phase 3|587|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:44:14.423282|2018-05-31 23:44:14.423282
NCT01134029|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2014-12-03|2010-05-28|2010-05-31|Estimate|||||||2014-12-03|2014-12-05|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|Planned CORR||Planned CORR: Planned Care for Obesity and Risk Reduction|Planned CORR: Planned Care for Obesity and Risk Reduction|Completed||N/A|262|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 23:44:17.717382|2018-05-31 23:44:17.717382
NCT01134016|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2013-08-12||2016-05-17|2010-05-28|2010-05-31|Estimate|2014-01-10|2014-02-27|Estimate||||2016-05-17|2016-06-21|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Hocena|A total of 13 patients were enrolled in this study|Determine MTD and to Evaluate pk, Safety/Tolerability and Efficacy Profiles of Hocena® in NSCLC Subjects|Determine MTD and to Evaluate PK, Safety/Tolerability and Efficacy Profiles of Antroquinonol (Hocena®) in NSCLC Patients Refractory to Conventional Treatment Modalities|Completed||Phase 1|13|Actual|Golden Biotechnology Corporation||1|||f||||t||||||||No|There is not a plan to make individual participlant data(IPD).|2018-05-31 23:44:18.236385|2018-05-31 23:44:18.236385
NCT01134003|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-05-28|2010-05-28|2010-05-31|Estimate|||||||2010-05-28|2010-05-31|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||A Large Multi-Center Database of Women Who Have Had and Are Going to Have Surgical Correction of Their Pelvic Organ Prolapse Using the Gynecare Prolift System|A Large Multi-Center Database of Women Who Have Had and Are Going to Have Surgical Correction of Their Pelvic Organ Prolapse Using the Gynecare Prolift System|Completed|||||The Institute of Pelvic Medicine & Reconstructive Surgery, Allentown, Pennsylvania|||||f||||f||||||||||2018-05-31 23:44:19.972355|2018-05-31 23:44:19.972355
NCT01133990|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21||2013-05-21|2013-05-21|2010-05-28|2010-05-31|Estimate||||2013-05-21|2013-05-29|Estimate|2013-05-21|2013-05-29|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|5|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 23:44:20.141284|2018-05-31 23:44:20.141284
NCT01133977|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2015-03-13|2014-08-19|2016-08-16|2010-05-27|2010-05-31|Estimate|2016-08-16|2016-10-10|Estimate|2014-08-19|2014-08-21|Estimate|2016-08-16|2016-10-10|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional||A total of 40 participants were randomized in Dacarbazine (Phase 2) arm but only 39 participants received study drug and were included in the safety analysis set.|E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma.|Completed||Phase 1/Phase 2|97|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 23:44:20.314424|2018-05-31 23:44:20.314424
NCT01133951|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-01-03|2010-05-28|2010-05-31|Estimate|||||||2014-01-03|2014-01-06|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Helicobacter Pylori Eradication to Prevent Gastric Cancer|Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial|Active, not recruiting||N/A|3000|Actual|Second Military Medical University||2|||f||||t||||||||||2018-05-31 23:44:22.924165|2018-05-31 23:44:22.924165
NCT01133938|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-06-01|2010-05-28|2010-05-31|Estimate|||||||2010-06-01|2010-06-03|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Observational|||Predictive Factors for the Development of Osteonecrosis After the Treatment of the Developmental Dislocated Hip|Predictive Factors for the Development of Osteonecrosis After the Treatment of the Developmental Dislocated Hip. A Comparison of Early Open Reduction Versus Late Open Reduction With Combined Pemberton and Femoral Osteotomies|Completed|||79|Actual|Orthopedic Hospital Vienna Speising|||3||f||||f||||||||||2018-05-31 23:44:23.032028|2018-05-31 23:44:23.032028
NCT01133925|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-05-28|2010-05-28|2010-05-31|Estimate|||||||2010-05-28|2010-05-31|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|May 2011|Anticipated|2011-05-31|August 2009|Actual|2009-08-31||Interventional|LONG OCT||Optical Coherence Tomography in Long Lesions|Optical Coherence Tomography in Long Native Coronary Artery Lesions Treated With Multiple Novel Zotarolimus-eluting Stents: LONG OCT STUDY|Unknown status|Active, not recruiting|Phase 4|22|Actual|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-05-31 23:44:23.158562|2018-05-31 23:44:23.158562
NCT01133912|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-01-01|2010-05-28|2010-05-31|Estimate|||||||2012-01-01|2012-01-04|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|June 2010|Actual|2010-06-30||Interventional|PGT||Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT)|Phase Ib Study of Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) in Patients With HER2 Positive Operable Breast Cancer|Completed||Phase 1|13|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 23:44:23.294561|2018-05-31 23:44:23.294561
NCT01133899|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2011-12-18|2010-05-28|2010-05-31|Estimate|||||||2011-12-18|2011-12-20|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Guanidinoacetic Acid (GAA) Administration in Physically Active Men and Women|The Effects of Medium-term Oral Guanidinoacetic Acid (GAA) Administration on Human Performance, Body Composition, and Metabolic Outcomes in Physically Active Men and Women|Completed||Phase 1/Phase 2|40|Actual|Metropolitan University, Serbia||4|||f||||t||||||||||2018-05-31 23:44:23.39092|2018-05-31 23:44:23.39092
NCT01133886|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-09-02|2010-05-28|2010-05-31|Estimate|||||||2010-09-02|2010-09-03|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|DEC-MDS||Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure|Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure|Unknown status|Recruiting|Phase 2|50|Anticipated|King's College London||1|||f||||f||||||||||2018-05-31 23:44:23.596692|2018-05-31 23:44:23.596692
NCT01133873|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-04-12|2010-05-27|2010-05-31|Estimate|||||||2011-04-12|2011-04-13|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects|A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of Sequential Ascending Dose Levels to Assess the Safety, Tolerability and Electrocardiographic Effects of Propoxyphene Napsylate Capsules (and Its Metabolite Norpropoxyphene) When Administered Orally to Healthy Adult Subjects|Terminated||Phase 4|48|Anticipated|Xanodyne Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:44:23.787357|2018-05-31 23:44:23.787357
NCT01133860|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|2011-06-22||2011-07-22|2010-05-28|2010-05-31|Estimate|2011-06-22|2011-07-21|Estimate||||2011-07-22|2011-07-26|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease|An Exploratory Phase II Dose Escalation Study of Eltrombopag in MYH9 Related Disease|Completed||Phase 2|12|Actual|IRCCS Policlinico S. Matteo||1|||f||||t||||||||||2018-05-31 23:44:23.908661|2018-05-31 23:44:23.908661
NCT01133847|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2016-10-31||2017-02-27|2010-05-28|2010-05-31|Estimate|2017-02-27|2017-04-11|Actual||||2017-02-27|2017-04-11|Actual|November 2010||2010-11-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ICARD|Baseline characteristics are for our final analysis sample, consisting of all children randomized to each condition except for 1 in the ADHD arm, 1 in the Reading arm, and 4 in the Combined arm, who were excluded because upon ex post-facto review of records, they did not meet either ADHD, RD, or IQ inclusion criteria and had been included in error.|Interventions for Children With Attention and Reading Disorders|Reading ICARD: Interventions for Children With Attention and Reading Disorders|Completed||Phase 4|222|Actual|The University of Texas Health Science Center, Houston|There was some non-adherence, particularly for the ADHD treatment. Our oversampling of low income, African American children, although valuable in an understudied population, may limit generalizability.|3|||f||||t||||||||||2018-05-31 23:44:24.140963|2018-05-31 23:44:24.140963
NCT01133834|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2011-06-14|2010-05-28|2010-05-31|Estimate|||||||2011-06-14|2011-06-15|Estimate|March 2003||2003-03-31|February 2003|2003-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Correlation Between Cytokines and the Severity of Meningococcal Disease|Clinical and Laboratorial Factors Associated With the Severity of Meningococcal Disease|Completed|||100|Actual|University of Sao Paulo General Hospital|||1||f||||t||||||None Retained|"~     blood sample cerebral spinal fluid~   "|||2018-05-31 23:44:24.654181|2018-05-31 23:44:24.654181
NCT01133821|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2017-07-14||2017-12-07|2010-05-28|2010-05-31|Estimate|2017-07-14|2017-08-15|Actual||||2017-12-07|2018-01-09|Actual|August 2010||2010-08-31|December 2017|2017-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Acute Psychotherapy for Bipolar II Depression|Acute Psychotherapy for Bipolar II Depression|Completed||Phase 4|92|Actual|University of Pittsburgh|Limitations include absence of an inactive psychotherapy comparator, high dropouts, and poor remission rates. Power limitations could potentially leading to Type II errors.Our sample was predominantly white which may limit generalizability.|2|||f||||t||||||||||2018-05-31 23:44:24.717502|2018-05-31 23:44:24.717502
NCT01133808|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2011-09-08|2010-05-28|2010-05-31|Estimate|||||||2011-09-08|2011-09-09|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Effectiveness of Rotavirus Immunization in Nicaragua|Effectiveness of Rotavirus Immunization at the Community Level in Nicaragua|Completed|||667|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples Without DNA|"~     Stool samples obtained from children who develop diarrhea during the course of the study. In~     addition, stool samples will also be collected from normal children to serve as controls in~     laboratory analysis.~   "|||2018-05-31 23:44:24.975823|2018-05-31 23:44:24.975823
NCT01133795|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2016-08-17|2010-05-28|2010-05-31|Estimate|||||||2016-08-17|2016-08-18|Estimate|February 2010||2010-02-28|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MAFRI||Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment|Effect of Administration of Intravenous Albumin and Oral Midodrine on Renal Function in Patients With Cirrhosis and Functional Renal Impairment|Completed||Phase 2|7|Actual|Hospital Clinic of Barcelona||1|||f||||t||||||||||2018-05-31 23:44:25.213178|2018-05-31 23:44:25.213178
NCT01133782|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2010-05-28|2010-05-28|2010-05-31|Estimate|||||||2010-05-28|2010-05-31|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|luftvagsPCR||Clinical Application of PCR-based Diagnosis of Community-onset Viral Respiratory Infections.||Completed||N/A|406|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 23:44:25.302574|2018-05-31 23:44:25.302574
NCT01133769|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-01-19|2010-05-28|2010-05-31|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|||Operative Versus Non-Operative Treatment of Clavicle Fracture in PolyTrauma|Operative Versus Non-Operative Treatment For Clavicle Fracture in the PolyTrauma Patient With Associated Chest Injury. A Prospective, Randomized Clinical Trial|Withdrawn|||0|Actual|University of Kentucky|||1|Institutional issues Institution issues|f||||t||||||||||2018-05-31 23:44:25.36426|2018-05-31 23:44:25.36426
NCT01133756|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2016-02-16|2013-05-21|2016-10-11|2010-05-28|2010-05-31|Estimate|2016-10-11|2016-12-05|Estimate|2013-05-21|2013-05-29|Estimate|2016-10-11|2016-12-05|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Interventional|||E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125|An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125.|Terminated||Phase 1/Phase 2|7|Actual|Eisai Inc.|Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase 2.|2||poor accrual|f||||f||||||||||2018-05-31 23:44:25.44085|2018-05-31 23:44:25.44085
NCT01133743|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2017-05-01|2010-05-28|2010-05-31|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2010||2010-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia|An Open-Label Phase 2 Study of Lenalidomide (Revlimid) in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|31|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 23:44:25.833714|2018-05-31 23:44:25.833714
NCT01133730|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-12-13|2010-05-28|2010-05-31|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2010|Actual|2010-08-31|May 2010|2010-05-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft|The Analgesic Efficacy of the Transversalis Fascia Plane Block in Iliac Crest Bone Graft Harvesting|Completed||N/A|56|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:44:25.967109|2018-05-31 23:44:25.967109
NCT01133717|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-12-16|2010-05-28|2010-05-31|Estimate|||||||2014-12-16|2014-12-18|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Observational|||Cerebrovascular Reactivity in Obstructive Sleep Apnea (OSA) Subjects|Spatial and Temporal Response of Cerebrovascular Response in OSA|Unknown status|Recruiting||60|Anticipated|University Health Network, Toronto|||2||f||||f||||||||||2018-05-31 23:44:26.046181|2018-05-31 23:44:26.046181
NCT01133704|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2010-06-01||2010-09-02|2010-05-28|2010-05-31|Estimate|2010-08-17|2010-09-02|Estimate||||2010-09-02|2010-09-08|Estimate|May 2000||2000-05-31|September 2010|2010-09-30|May 2005|Actual|2005-05-31|March 2003|Actual|2003-03-31||Interventional|||Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer|A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer|Completed||Phase 3|98|Actual|Dendreon||2|||f||||||||||||||2018-05-31 23:44:26.165512|2018-05-31 23:44:26.165512
NCT01133691|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2012-01-16|2010-05-28|2010-05-31|Estimate|||||||2012-01-16|2012-01-18|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Examination of Gastric Emptying in Children|Examination of Gastric Emptying With Magnetic Resonance Imaging and Ultrasonography|Completed|||31|Actual|University Children's Hospital, Zurich|||1||f||||f||||||||||2018-05-31 23:44:26.576661|2018-05-31 23:44:26.576661
NCT01133678|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-10-09|2010-05-28|2010-05-31|Estimate|||||||2017-10-09|2017-10-11|Actual|May 4, 2010|Actual|2010-05-04|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck|Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck|Active, not recruiting||Phase 2|80|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 23:44:26.695444|2018-05-31 23:44:26.695444
NCT01133665|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2014-11-17||2014-11-17|2010-05-28|2010-05-31|Estimate|2014-11-17|2014-11-24|Estimate||||2014-11-17|2014-11-24|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Cetuximab and Lenalidomide in Head and Neck|Phase II Study of Cetuximab and Lenalidomide in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|42|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 23:44:26.846029|2018-05-31 23:44:26.846029
NCT01133652|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-08-23|2010-05-28|2010-05-31|Estimate|||||||2012-08-23|2012-08-24|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|VISION||Variation In Success of Intravenous (IV) Placement With Observation Using New Techniques|The VISION STUDY: Variation In Success of Intravenous (IV) Placement With Observation Using New Techniques|Completed||Phase 4|399|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 23:44:27.35967|2018-05-31 23:44:27.35967
NCT01133639|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-03-03|2010-05-27|2010-05-31|Estimate|||||||2017-03-03|2017-03-07|Actual|May 2010||2010-05-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Ketorolac Effects on Post-operative Pain and Bone Healing|Does Ketorolac Delay Bone Healing and Improve Post-operative Pain?: A Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial|Terminated||N/A|18|Actual|Beth Israel Deaconess Medical Center||2||Employment termination|f||||f||||||||||2018-05-31 23:44:27.430796|2018-05-31 23:44:27.430796
NCT01133626|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2012-04-23|2011-08-25|2012-05-31|2010-05-27|2010-05-31|Estimate|2012-05-31|2012-07-04|Estimate|2011-08-25|2011-08-29|Estimate|2012-05-31|2012-07-04|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP HFA Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis When Administered in Adolescent and Adult Subjects (12 to 45 Years of Age) With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|107|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 23:44:27.496697|2018-05-31 23:44:27.496697
NCT01133613|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2012-01-30|2010-05-28|2010-05-31|Estimate|||||||2012-01-30|2012-02-01|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee||Completed||Phase 1|51|Actual|Stryker Biotech||3|||f||||||||||||||2018-05-31 23:44:27.792533|2018-05-31 23:44:27.792533
NCT01133600|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2013-09-09|2010-05-28|2010-05-31|Estimate|||||||2013-09-09|2013-09-10|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens|Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens|Terminated||Phase 4|6|Actual|Clinical Alliance for Research & Education - Infectious Diseases, LLC.||2||Lack of patient enrollment|f||||t||||||||||2018-05-31 23:44:27.875745|2018-05-31 23:44:27.875745
NCT01133587|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2017-03-31|2010-05-28|2010-05-31|Estimate|||||||2017-03-31|2017-04-04|Actual|May 2010||2010-05-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Patient Guided Psychiatric Admissions|Patient Guided Psychiatric Admissions (Self-referral to Inpatient Beds)|Completed||N/A|53|Actual|St. Olavs Hospital||2|||f||||f|f|f||||||||2018-05-31 23:44:28.090162|2018-05-31 23:44:28.090162
NCT01133574|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-08-25|2010-05-27|2010-05-31|Estimate|||||||2011-08-25|2011-08-29|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||This is a Single Ascending Dose Tolerance Study|A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects|Terminated||Phase 1|47|Actual|Abbott||14||Part A completed successfully 22 July 2010, Part B will be separate PET study|f||||f||||||||||2018-05-31 23:44:28.192901|2018-05-31 23:44:28.192901
NCT01133561|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-02-22|2010-05-28|2010-05-31|Estimate|||||||2011-02-22|2011-02-23|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Pioglitazone in Psoriasis- A Clinical and Molecular Study.|The CLINICAL And MOLECULAR EFFECTS Of An INSULIN SENSITIZING DRUG: 'PIOGLITAZONE'On PSORIASIS TREATMENT|Completed||N/A|48|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 23:44:28.286208|2018-05-31 23:44:28.286208
NCT01133548|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-12-05|2010-05-28|2010-05-31|Estimate|||||||2017-12-05|2017-12-07|Actual|May 2010||2010-05-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males|A Multiple Dose Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of 5 g Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males|Completed||Phase 1|62|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:44:28.349966|2018-05-31 23:44:28.349966
NCT01133535|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-28|||2014-06-24|2010-05-28|2010-05-31|Estimate|||||||2014-06-24|2014-06-26|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Observational|IRAP||Idiopathic Recurrent Acute Pancreatitis (IRAP)|The IRAP Registry is a Multi-center Prospective, Collaborative Database Designed to Create a National Registry That Collects Information Concerning Episodes of Idiopathic Recurrent Acute Pancreatitis From Major 'Pancreas' Centers. Intent is to do a Comparative Effectiveness Study of Interventions.|Completed|||50|Actual|Aurora Health Care|||1||f||||t||||||||||2018-05-31 23:44:28.429162|2018-05-31 23:44:28.429162
NCT01133522|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2015-09-23||2015-09-23|2010-05-27|2010-05-31|Estimate|2015-09-23|2015-10-22|Estimate||||2015-09-23|2015-10-22|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Safety analysis set (all participants who received at least 1 dose of study drug).|Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 145 in Subjects With Hyperlipidemia on Stable Doses of a Statin|Completed||Phase 1|60|Actual|Amgen||2|||f||||f||||||||||2018-05-31 23:44:28.530948|2018-05-31 23:44:28.530948
NCT01133509|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2012-08-21|2010-05-28|2010-05-31|Estimate|||||||2012-08-21|2012-08-23|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study|A Model for the Implementation of the Cervical Cancer Screening and HPV Vaccination in the Emergency Department: a Pilot Study.|Unknown status|Recruiting|N/A|100|Anticipated|Eastern Virginia Medical School||1|||f||||t||||||||||2018-05-31 23:44:30.215346|2018-05-31 23:44:30.215346
NCT01133496|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-06-11|2010-05-27|2010-05-28|Estimate|||||||2010-06-11|2010-06-14|Estimate|December 2006||2006-12-31|June 2010|2010-06-30|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions|Open Label, Balanced, Randomized, Two-way, Single-dose, Crossover Bioequivalence Study of Alendronate Sodium 70 mg Tablets of Dr Reddy's, India and Fosamax® Tablets of Merck & Co., Inc., USA, in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|80|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:30.298164|2018-05-31 23:44:30.298164
NCT01133483|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-06-11|2010-05-27|2010-05-28|Estimate|||||||2010-06-11|2010-06-14|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fed Conditions|Completed||Phase 1|38|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:30.359807|2018-05-31 23:44:30.359807
NCT01133470|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-06-11|2010-05-27|2010-05-28|Estimate|||||||2010-06-11|2010-06-14|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|April 2007|Actual|2007-04-30|February 2007|Actual|2007-02-28||Interventional|||Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of Aventis, in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|54|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:30.423042|2018-05-31 23:44:30.423042
NCT01133457|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-05-27|2010-05-27|2010-05-28|Estimate|||||||2010-05-27|2010-05-28|Estimate|April 2002||2002-04-30|March 2002|2002-03-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia in Healthy Adult Males Under Fed Condition.|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:30.507987|2018-05-31 23:44:30.507987
NCT01133444|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-07-09|2010-05-27|2010-05-28|Estimate|||||||2010-07-09|2010-07-12|Estimate|April 2002||2002-04-30|May 2010|2010-05-31|May 2002|Actual|2002-05-31|April 2002|Actual|2002-04-30||Interventional|||Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition|Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia Under Fasting Condition.|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:30.704725|2018-05-31 23:44:30.704725
NCT01133431|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-12-09|2010-05-27|2010-05-28|Estimate|||||||2010-12-09|2010-12-10|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|CKD-501 DDI||The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea|Clinical Study to Assess the Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea (Glimepiride) in Healthy Male Subjects: Single-blinded, Randomized, Crossover Study|Completed||Phase 1|24|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 23:44:30.793565|2018-05-31 23:44:30.793565
NCT01133418|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2017-01-17||2017-04-28|2010-05-27|2010-05-28|Estimate|2017-04-27|2017-05-01|Actual||||2017-04-28|2017-05-30|Actual|September 2010||2010-09-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|August 2014|Actual|2014-08-31||Interventional|||Cognitive Training Trial|Efficacy of a Cognitive Training Intervention for Children With ADHD|Completed||N/A|72|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 23:44:30.869744|2018-05-31 23:44:30.869744
NCT01133405|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-11-04|2010-05-27|2010-05-28|Estimate|||||||2010-11-04|2010-11-05|Estimate|June 2010||2010-06-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Safety Study of LY2886721 Single Doses in Healthy Subjects|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects|Completed||Phase 1|0|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 23:44:31.224314|2018-05-31 23:44:31.224314
NCT01133392|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2014-10-10||2014-12-29|2010-05-27|2010-05-28|Estimate|2014-12-29|2014-12-30|Estimate||||2014-12-29|2014-12-30|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Bioequivalence of Two Lispro Formulations|Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects|Completed||Phase 1|41|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:44:31.340732|2018-05-31 23:44:31.340732
NCT01133379|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2015-05-28||2015-06-17|2010-05-27|2010-05-28|Estimate|2015-06-17|2015-07-09|Estimate||||2015-06-17|2015-07-09|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Tooth Sensitivity Relief by Two Mouthrinses|Evaluation of the Efficacy of Two Potassium Oxalate Containing Mouthrinses for Relieving Dentinal Hypersensitivity|Completed||N/A|174|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 23:44:31.703844|2018-05-31 23:44:31.703844
NCT01133366|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2016-08-01|2010-05-27|2010-05-28|Estimate|||||||2016-08-01|2016-08-03|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin|A Drug-Drug Interaction Study to Assess the Effects of Multiple Doses of Mipomersen (200 mg SC) on Single-Dose Warfarin (25 mg) Pharmacodynamics and Pharmacokinetics in Healthy Adult Subjects|Completed||Phase 1|18|Actual|Kastle Therapeutics, LLC||2|||f||||t||||||||||2018-05-31 23:44:33.214084|2018-05-31 23:44:33.214084
NCT01133353|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-11-17|2010-05-27|2010-05-28|Estimate|||||||2010-11-17|2010-11-18|Estimate|March 2011||2011-03-31|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|TBZ-MR||A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tetrabenazine MR in Subjects Aged 5 up to 17 Years With Tourette's Syndrome|Withdrawn||Phase 2|160|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||t||||||||||2018-05-31 23:44:33.313387|2018-05-31 23:44:33.313387
NCT01133340|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2014-10-01|2010-05-27|2010-05-28|Estimate|||||||2014-10-01|2014-10-02|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Feasibility Study to Compare the Benefits of Endoscopic Tumor Clip Placement and 3T-MRI Simulation for Accurate Target Volume Definition for Rectal Cancer Patients Undergoing Pre-operative Chemoradiation|A Feasibility Study to Compare the Benefits of Endoscopic Tumor Clip Placement and 3T-MRI Simulation for Accurate Target Volume Definition for Rectal Cancer Patients Undergoing Pre-operative Chemoradiation|Completed||N/A|10|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-05-31 23:44:33.394072|2018-05-31 23:44:33.394072
NCT01133327|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2012-08-03|2010-05-27|2010-05-28|Estimate|||||||2012-08-03|2012-08-06|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|ASTI||Adapt Monorail Carotid Stent System: A Postmarket Clinical Follow-up Study|Adapt™ Monorail™ Carotid Stent System: A Postmarket Clinical Follow-up Study|Completed||N/A|100|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 23:44:33.457602|2018-05-31 23:44:33.457602
NCT01133314|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-03-16|2010-05-27|2010-05-28|Estimate|||||||2013-03-16|2013-03-19|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|March 2014|Anticipated|2014-03-31|December 2012|Actual|2012-12-31||Observational|||Artemether-Lumefantrine Effectiveness in Guinea-Bissau 2|The Routine Use of Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Bissau - 2|Unknown status|Active, not recruiting||600|Anticipated|Bandim Health Project|||||f||||f||||||Samples Without DNA|"~     App 50 - 100 microliters blood on filterpaper for identification of parasite. Furthermore,~     whenever the health staff use a RDT this will be saved for the same analyses.~   "|||2018-05-31 23:44:33.565835|2018-05-31 23:44:33.565835
NCT01133301|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-26|2010-05-26|2010-05-28|Estimate|||||||2010-05-26|2010-05-28|Estimate|August 1998||1998-08-31|May 2010|2010-05-31|October 2001|Actual|2001-10-31|August 2001|Actual|2001-08-31||Interventional|||Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder|Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder|Completed||Phase 2|30|Actual|Central Institute of Mental Health, Mannheim||2|||f||||t||||||||||2018-05-31 23:44:33.716052|2018-05-31 23:44:33.716052
NCT01133288|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2011-07-11||2011-11-21|2010-05-27|2010-05-28|Estimate|2011-11-21|2011-12-23|Estimate||||2011-11-21|2011-12-23|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Yulex Glove Prospective Study in Spina Bifida|Yulex Glove Prospective Study|Terminated||N/A|7|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|The study was not completed because funding was never received. The two (2/7)enrolled participants who met screening eligibility criteria were terminated early without receiving the yulex glove intervention.|||The funder never paid for the study.|f||||f||||||||||2018-05-31 23:44:33.812168|2018-05-31 23:44:33.812168
NCT01133275|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2015-12-14||2018-01-09|2010-05-26|2010-05-28|Estimate|2015-12-14|2016-01-18|Estimate||||2018-01-09|2018-02-05|Actual|April 28, 2010|Actual|2010-04-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|January 31, 2015|Actual|2015-01-31||Interventional||All participants|Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS|A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients|Active, not recruiting||Phase 2|28|Actual|H. Lee Moffitt Cancer Center and Research Institute|The study was terminated at the end of step one, as no signal of higher response of the combination was observed compared to what was reported on the MDS-002 study.|1|||f||||t|t|f|||f|||||2018-05-31 23:44:34.001395|2018-05-31 23:44:34.001395
NCT01133262|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2015-03-09|2010-05-27|2010-05-28|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|December 2011|Anticipated|2011-12-31|||||Observational|||Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device|Effectiveness in Head and Neck Cancer Detection Using PET Insert Device|Withdrawn|||0|Actual|Washington University School of Medicine||||Feasibility/pilot study of 5 subjects registration not required|f||||t||||||||||2018-05-31 23:44:34.320174|2018-05-31 23:44:34.320174
NCT01133249|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-07-22|2010-05-27|2010-05-28|Estimate|||||||2016-07-22|2016-07-26|Estimate|July 2005||2005-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Total Hip Registry|Total Hip Registry|Enrolling by invitation|||942|Anticipated|Heekin Orthopedic Research Institute|||1||f||||f||||||||||2018-05-31 23:44:34.390215|2018-05-31 23:44:34.390215
NCT01133236|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-12-31|2010-05-27|2010-05-28|Estimate|||||||2013-12-31|2014-01-03|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Fluid and Salt Restriction in Decompensated Heart Failure Patients|Randomized Clinical Trial to Assess the Effect of Fluid and Salt Restriction on the Management of Patients Hospitalized Due to Decompensated Heart Failure|Completed||N/A|80|Actual|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-05-31 23:44:34.47049|2018-05-31 23:44:34.47049
NCT01133223|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2015-09-02|2010-05-27|2010-05-28|Estimate|||||||2015-09-02|2015-09-03|Estimate|May 2010||2010-05-31|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Efficacy of the Penumbra™ System in Acute Middle Cerebral Artery (MCA) Stroke|Randomized Clinical Trial Comparing Intravenous Thrombolysis With Thrombectomy by the Penumbra™ System in Patients With Middle Cerebral Artery Stem Occlusion - Pilot Study|Withdrawn||Phase 2|0|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 23:44:34.553935|2018-05-31 23:44:34.553935
NCT01133210|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2013-12-09|2010-05-26|2010-05-28|Estimate|||||||2013-12-09|2013-12-10|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)|Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)|Completed||Phase 1|27|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 23:44:34.626904|2018-05-31 23:44:34.626904
NCT01133197|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2015-06-26|2010-05-27|2010-05-28|Estimate|||||||2015-06-26|2015-06-29|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Impact of Thumb Carpometacarpal Osteoarthritis on General Health|The Impact of Thumb Carpometacarpal Osteoarthritis on General Health|Completed|||188|Actual|Washington University School of Medicine|||2||f||||t||||||||||2018-05-31 23:44:34.710165|2018-05-31 23:44:34.710165
NCT01133184|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-06-16|2010-05-27|2010-05-28|Estimate|||||||2010-06-16|2010-06-17|Estimate|September 2010||2010-09-30|January 2010|2010-01-31|September 2013|Anticipated|2013-09-30|March 2011|Anticipated|2011-03-31||Interventional|||Improved Prevention of Perinatal Hepatitis B Transmission|The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers|Unknown status|Not yet recruiting|Phase 4|6343|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-05-31 23:44:34.762301|2018-05-31 23:44:34.762301
NCT01133171|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2015-03-31||2015-10-28|2010-05-26|2010-05-28|Estimate|2015-10-28|2015-10-30|Estimate||||2015-10-28|2015-10-30|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Personalized Dashboard to Educate Veterans at Risk of Stroke|A Personalized Dashboard to Educate Veterans at Risk of Stroke|Completed||N/A|77|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-05-31 23:44:34.835263|2018-05-31 23:44:34.835263
NCT01133158|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2015-04-16|2010-05-27|2010-05-28|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|December 2013|Actual|2013-12-31||Interventional|||R-BMD GELTAMO Relapsed Lymphoma|Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||||2018-05-31 23:44:35.166453|2018-05-31 23:44:35.166453
NCT01133145|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-05-27|2010-05-27|2010-05-28|Estimate|||||||2010-05-27|2010-05-28|Estimate||||May 2010|2010-05-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|kneeTx||Allogeneic Vascularized Knee Transplantation|Allogenic Vascularized Knee and Femur Transplantation Clinical Evaluation|Unknown status|Enrolling by invitation|N/A|6|Actual|University of Jena||1|||f||||f||||||||||2018-05-31 23:44:35.356008|2018-05-31 23:44:35.356008
NCT01133132|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2018-02-08|2010-05-27|2010-05-28|Estimate|||||||2018-02-08|2018-02-12|Actual|February 2010||2010-02-28|February 2018|2018-02-28|September 18, 2017|Actual|2017-09-18|June 2013|Actual|2013-06-30||Interventional|||Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors|ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors|Completed||N/A|34|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 23:44:35.433467|2018-05-31 23:44:35.433467
NCT01133119|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2018-04-16|2010-05-26|2010-05-28|Estimate|||||||2018-04-16|2018-04-18|Actual|February 2010||2010-02-28|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Use of Local Anesthetic (0.25% Bupivacaine) for Pain Control in Pediatric Cardiac Catheterization|Use of Local Anesthetic (0.25% Bupivacaine) for Pain Control in Pediatric Cardiac Catheterization: A Randomized Controlled Trial.|Completed||Phase 2|140|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:44:35.510484|2018-05-31 23:44:35.510484
NCT01133106|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-05-19|2010-05-26|2010-05-28|Estimate|||||||2016-05-19|2016-05-23|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PSD2||Living Well With Stroke|Psychosocial/Behavioral Intervention in Post-Stroke Depression (PSD)|Completed||N/A|100|Actual|University of Washington||3|||f||||f||||||||Yes|de-identified data will be provided to qualified investigators, including students conducting secondary analysis|2018-05-31 23:44:35.594442|2018-05-31 23:44:35.594442
NCT01133093|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2016-05-05|2010-05-27|2010-05-28|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 2008||2008-03-31|May 2016|2016-05-31|October 2010|Actual|2010-10-31|June 2008|Actual|2008-06-30||Observational|ENRICA||Study on Nutrition and Cardiovascular Risk in Spain.|Study on Nutrition and Cardiovascular Risk in Spain.|Completed|||11991|Actual|Universidad Autonoma de Madrid|||||f||||t||||||Samples Without DNA|"~     Blood and urine samples~   "|Undecided||2018-05-31 23:44:35.67838|2018-05-31 23:44:35.67838
NCT01133080|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-01-04|2010-05-26|2010-05-28|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study||Unknown status|Recruiting|Phase 4|50|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 23:44:35.752207|2018-05-31 23:44:35.752207
NCT01133067|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2014-07-25|2010-05-27|2010-05-28|Estimate|||||||2014-07-25|2014-07-28|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|October 2013|Actual|2013-10-31||Observational|TELE001||Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients|A Prospective Study of Telephonic Contact and Subsequent Physical Follow up of Radically Treated Lung Cancer Patients|Unknown status|Active, not recruiting||200|Anticipated|Tata Memorial Hospital|||||f||||t||||||||||2018-05-31 23:44:35.838544|2018-05-31 23:44:35.838544
NCT01133054|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2013-12-01|2010-05-26|2010-05-28|Estimate|||||||2013-12-01|2013-12-03|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis|Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis|Completed||Phase 4|36|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:44:35.918497|2018-05-31 23:44:35.918497
NCT01133041|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2011-09-26|2010-05-27|2010-05-28|Estimate|||||||2011-09-26|2011-09-27|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps|Prospective Comparison of NBI and i-Scan in Real-time Histological Prediction of Diminutive Colonic Polyps|Completed||Phase 4|142|Actual|Soon Chun Hyang University||2|||f||||t||||||||||2018-05-31 23:44:35.992766|2018-05-31 23:44:35.992766
NCT01133028|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-26|2010-05-26|2010-05-28|Estimate|||||||2010-05-26|2010-05-28|Estimate|January 2011||2011-01-31|May 2010|2010-05-31|June 2012|Anticipated|2012-06-30|September 2011|Anticipated|2011-09-30||Interventional|||Classroom-Level Intervention to Promote Peers' Acceptance of Children With Attention Deficit Hyperactivity Disorder (ADHD)|Classroom-Level Intervention to Promote Peers' Acceptance of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|Unknown status|Not yet recruiting|N/A|102|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 23:44:36.076626|2018-05-31 23:44:36.076626
NCT01133015|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-07-20|2010-05-26|2010-05-28|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Comparison of Fractional Flow Reserve and Intravascular Ultrasound|Comparison of Fractional Flow Reserve and Minimal Luminal Area by Intravascular Ultrasound in Evaluating Intermediate Coronary Artery Stenosis in Each Coronary Artery|Unknown status|Recruiting|Phase 4|191|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 23:44:36.156601|2018-05-31 23:44:36.156601
NCT01133002|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-08-30|2010-05-27|2010-05-28|Estimate|||||||2010-08-30|2010-08-31|Estimate|August 2007||2007-08-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|RECOVERY||Canadian Outpatient VTE Management Registry|National, Prospective, Observational, Cohort Study of Venous Thromboembolism (VTE) Management With the Low Molecular Weight Heparin, Enoxaparin, in the Outpatient Setting in Canada|Completed|||915|Actual|Sanofi|||1||f||||||||||||||2018-05-31 23:44:36.235229|2018-05-31 23:44:36.235229
NCT01132989|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-27|2010-05-27|2010-05-28|Estimate|||||||2010-05-27|2010-05-28|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|REvMM2009||Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma|Open-label Phase 2 Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma|Unknown status|Recruiting|Phase 2|10|Anticipated|Florida Academic Dermatology Centers|||||f||||t||||||||||2018-05-31 23:44:36.289244|2018-05-31 23:44:36.289244
NCT01132976|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-09-19|2010-05-27|2010-05-28|Estimate|||||||2012-09-19|2012-09-21|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|PCI||The Personal Concerns Inventory Study (PCI)|The Addition of a Goal-based Motivational Interview to Standardised Treatment as Usual to Reduce Dropouts From a Service for Patients With Personality Disorder: A Feasibility Study|Completed||N/A|76|Actual|Nottinghamshire Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 23:44:36.356173|2018-05-31 23:44:36.356173
NCT01132963|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-05-27|2010-05-27|2010-05-28|Estimate|||||||2010-05-27|2010-05-28|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||The Effects of Footwear on Balance and Confidence in Older Inpatients|A Prospective Randomised Crossover Study to Evaluate the Effect Different Footwear Type Has on Measures of Balance and Confidence in Older Hospital Inpatients|Unknown status|Not yet recruiting|N/A|200|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 23:44:36.438858|2018-05-31 23:44:36.438858
NCT01132950|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-09-08|2010-05-27|2010-05-28|Estimate|||||||2010-09-08|2010-09-09|Estimate|February 2009||2009-02-28|September 2010|2010-09-30|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|CARE||Contraceptive Awareness and Reproductive Education|Empowering Women to Make Contraceptive Choices While Incarcerated|Unknown status|Recruiting|N/A|400|Anticipated|Memorial Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 23:44:36.532689|2018-05-31 23:44:36.532689
NCT01015209|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-09-24|2009-11-17|2009-11-18|Estimate|||||||2012-09-24|2012-09-25|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers||Completed||Phase 1|30|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:22:00.218733|2018-06-01 00:22:00.218733
NCT01132937|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-05-23|2010-05-27|2010-05-28|Estimate|||||||2018-05-23|2018-05-24|Actual|July 1, 2010||2010-07-01|October 10, 2017|2017-10-10||||||||Observational|||Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury|Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury|Recruiting|||1020|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:44:36.622075|2018-05-31 23:44:36.622075
NCT01132924|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-04-04|2010-05-27|2010-05-28|Estimate|||||||2018-04-04|2018-04-05|Actual|May 4, 2010||2010-05-04|February 2, 2018|2018-02-02||||||||Observational|||A Follow-up of the Early Pregnancy Study Cohort.|A Follow-up of the Early Pregnancy Study Cohort|Completed|||173|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:44:36.693215|2018-05-31 23:44:36.693215
NCT01132911|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-06-30|2010-05-27|2010-05-28|Estimate|||||||2017-06-30|2017-07-02|Actual|May 10, 2010||2010-05-10|April 13, 2011|2011-04-13|April 13, 2011|Actual|2011-04-13|April 13, 2011|Actual|2011-04-13||Interventional|||A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas|A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas|Completed||Phase 1|5|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:44:36.783435|2018-05-31 23:44:36.783435
NCT01132898|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-05-22|2010-05-27|2010-05-28|Estimate|||||||2018-05-22|2018-05-23|Actual|May 7, 2010||2010-05-07|May 10, 2018|2018-05-10||||||||Observational|||Long-term Clinical Correlates of Traumatic Brain Injury|Long Term Clinical Correlates of TBI: Imaging, Biomarkers, and Clinical Phenotyping Parameters|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:44:36.924908|2018-05-31 23:44:36.924908
NCT01132885|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-03-27|2010-05-27|2010-05-28|Estimate|||||||2018-03-27|2018-03-29|Actual|April 30, 2010||2010-04-30|January 25, 2018|2018-01-25||||||||Observational|||Defining the Brain Phenotype of Children With Williams Syndrome|Defining the Brain Phenotype of Children With Williams Syndrome|Recruiting|||415|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:44:37.006164|2018-05-31 23:44:37.006164
NCT01132872|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-06-30|2010-05-27|2010-05-28|Estimate|||||||2017-06-30|2017-07-02|Actual|April 30, 2010||2010-04-30|April 12, 2012|2012-04-12|April 12, 2012||2012-04-12|||||Observational|||PET Whole Body Distribution Studies Using [11C]CUMI|PET Whole Body Distribution Studies Using the 5-HT1A Agonist, [11C]CUMI|Completed|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:44:37.071953|2018-05-31 23:44:37.071953
NCT01132859|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2017-10-18|2010-05-27|2010-05-28|Estimate|||||||2017-10-18|2017-10-19|Actual|May 7, 2010||2010-05-07|August 17, 2017|2017-08-17||||||||Observational|||VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older|VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:44:37.14414|2018-05-31 23:44:37.14414
NCT01132846|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2014-07-07||2014-08-20|2010-05-27|2010-05-28|Estimate|2014-08-20|2014-08-21|Estimate||||2014-08-20|2014-08-21|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|ROSE/RED ROSE||Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study|Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study|Completed||Phase 2|360|Actual|Duke University||3|||f||||t||||||||||2018-05-31 23:44:37.242447|2018-05-31 23:44:37.242447
NCT01132833|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2016-08-18|2010-05-27|2010-05-28|Estimate|||||||2016-08-18|2016-08-22|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|December 2012|Actual|2012-12-31||Observational|||Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy|Chemotherapy and Anti-angiogenic Agents- Induced Thrombosis in Cancer.|Completed|||18|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 23:44:38.103458|2018-05-31 23:44:38.103458
NCT01132820|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|2016-12-15||2017-07-26|2010-05-27|2010-05-28|Estimate|2017-07-26|2017-08-28|Actual||||2017-07-26|2017-08-28|Actual|June 2010||2010-06-30|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|53|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:44:38.232725|2018-05-31 23:44:38.232725
NCT01132807|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-01-22|2010-05-27|2010-05-28|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2010||2010-05-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|February 2016|Actual|2016-02-29||Interventional|||Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma|Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma|Completed||Phase 2|164|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 23:44:38.723944|2018-05-31 23:44:38.723944
NCT01132794|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-06-15|2010-05-27|2010-05-28|Estimate|||||||2010-06-15|2010-06-16|Estimate||||May 2010|2010-05-31||||||||Interventional|||A Study to Assess the Analgesia and Sedation Using Intranasal Dexmedetomidine in Third Molar Surgery Under Local Anaesthesia||Completed||Phase 3|||The University of Hong Kong||2|||f||||||||||||||2018-05-31 23:44:39.049062|2018-05-31 23:44:39.049062
NCT01132781|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-08-22|2010-05-27|2010-05-28|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Theophylline in Rhinitis|The Effect of Theophylline in Patients With Allergic Rhinitis|Completed||Phase 2|28|Actual|University of East Anglia||2|||f||||f||||||||||2018-05-31 23:44:39.190577|2018-05-31 23:44:39.190577
NCT01132768|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-03-30|2010-05-26|2010-05-28|Estimate|||||||2012-03-30|2012-04-02|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CONFIRM||The Confirmatory Olmesartan Plaque Regression Study|Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study|Terminated||Phase 4|114|Actual|Daiichi Sankyo, Inc.||2||Low recruitment|f||||f||||||||||2018-05-31 23:44:39.450846|2018-05-31 23:44:39.450846
NCT01132755|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2017-08-17|2010-05-27|2010-05-28|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2010|Actual|2010-05-31|August 2017|2017-08-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage|Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage|Completed||Phase 2|112|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:44:39.588664|2018-05-31 23:44:39.588664
NCT01132742|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2013-01-10|2010-05-27|2010-05-28|Estimate|||||||2013-01-10|2013-01-11|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Malnutrition and Outcome in Hospitalized Children in Europe|Malnutrition and Outcome in Hospitalized Children in Europe (ESPEN Network Grant Project)|Completed|||2567|Actual|Ludwig-Maximilians - University of Munich|||1||f||||||||||||||2018-05-31 23:44:39.813258|2018-05-31 23:44:39.813258
NCT01132729|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-01-19|2010-05-27|2010-05-28|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2006||2006-09-30|January 2018|2018-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fasting Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:44:39.928919|2018-05-31 23:44:39.928919
NCT01132716|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-01-19|2010-05-27|2010-05-28|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2006||2006-09-30|January 2018|2018-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:44:40.04172|2018-05-31 23:44:40.04172
NCT01132703|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2014-06-03|2010-05-26|2010-05-28|Estimate|||||||2014-06-03|2014-06-04|Estimate|February 2010||2010-02-28|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers|A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of RP-1127 (Glyburide for Injection) in Healthy Male and Female Volunteers|Completed||Phase 1|34|Actual|Remedy Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:44:40.129199|2018-05-31 23:44:40.129199
NCT01132690|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2014-10-28|2014-04-25|2014-11-10|2010-05-26|2010-05-28|Estimate|2014-11-10|2014-11-11|Estimate|2014-04-25|2014-05-13|Estimate|2014-11-10|2014-11-11|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease|A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease|Completed||Phase 4|11|Actual|Protalix||2|||t||||t||||||||||2018-05-31 23:44:40.252045|2018-05-31 23:44:40.252045
NCT01132677|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2010-05-27|2010-05-27|2010-05-28|Estimate|||||||2010-05-27|2010-05-28|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|December 2011|Anticipated|2011-12-31|May 2011|Anticipated|2011-05-31||Interventional|||A Study Comparing Viscosupplementation and Corticosteroid Injections for Knee Osteoarthritis|A Randomized Clinical Trial Comparing Hyaluronic Acid (Hylan G-F 20) and Corticosteroid (Methylprednisolone Acetate) for Knee Osteoarthritis|Unknown status|Enrolling by invitation|N/A|78|Anticipated|LifeMark Health||2|||f||||f||||||||||2018-05-31 23:44:40.789799|2018-05-31 23:44:40.789799
NCT01132664|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2015-08-04||2016-08-09|2010-05-27|2010-05-28|Estimate|2015-09-29|2015-10-30|Estimate||||2016-08-09|2016-08-17|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer|A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab|Terminated||Phase 1/Phase 2|72|Actual|Novartis||2||Due to the rare patient population and challenges to enroll patients.|f||||f||||||||||2018-05-31 23:44:40.947679|2018-05-31 23:44:40.947679
NCT01132651|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2012-07-30||2014-12-11|2010-05-26|2010-05-28|Estimate|2012-12-10|2013-01-16|Estimate||||2014-12-11|2015-01-05|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cooling Pillow for Atopic Dermatitis|Novel Use of a Cooling Pillow for Treatment of Severe Hand and Neck Atopic Dermatitis|Completed||N/A|9|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 23:44:42.341392|2018-05-31 23:44:42.341392
NCT01132638|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2012-06-24|2010-05-27|2010-05-28|Estimate|||||||2012-06-24|2012-06-26|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PAMES 0109||Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease|Evaluation of Complete Remission of Erosive Gastroesophageal Reflux Disease Following Four-week Treatment With Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg With Eight-week Extension Treatment in Non-responding Patients - Multicenter, National, Prospective, Randomized, Double-blind, Parallel-group, Phase III|Completed||Phase 3|713|Actual|Takeda||2|||f||||||||||||||2018-05-31 23:44:42.735607|2018-05-31 23:44:42.735607
NCT01132625|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2013-02-21|2010-05-27|2010-05-28|Estimate|||||||2013-02-21|2013-02-22|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan|A Japanese Phase I, Multi-center, Open-label, Study of AUY922 Administered Intravenously on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies|Completed||Phase 1|37|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:44:42.874464|2018-05-31 23:44:42.874464
NCT01132612|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2017-10-17||2017-12-08|2010-05-26|2010-05-28|Estimate|2017-11-30|2017-12-05|Actual||||2017-12-08|2018-01-04|Actual|May 11, 2010|Actual|2010-05-11|December 2017|2017-12-31|October 18, 2016|Actual|2016-10-18|October 18, 2016|Actual|2016-10-18||Interventional|||AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis|A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 2|275|Actual|Novartis||3|||f||||f||||||||||2018-05-31 23:44:43.010982|2018-05-31 23:44:43.010982
NCT01132599|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-02-27|2010-05-26|2010-05-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|May 2010||2010-05-31|February 2012|2012-02-29||||June 2011|Actual|2011-06-30||Interventional|||Comparing PET-CT Using C-11 Choline and 18F-Fluoromethylcholine in Patients With Metastatic Prostate Cancer|A Cancer Research UK Phase II Trial to Compare [11C]Choline and [18F]Choline Each Given as a Single Administration Via Intravenous Injection for Imaging Patients With Metastatic Prostate Cancer|Withdrawn||Phase 2|0|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 23:44:43.881615|2018-05-31 23:44:43.881615
NCT01132586|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2014-12-22|2010-05-26|2010-05-28|Estimate|||||||2014-12-22|2014-12-23|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia|Phase I Study of Lenalidomide and Conventional Chemotherapy in Acute Myeloid Leukemia|Completed||Phase 1|61|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 23:44:43.996696|2018-05-31 23:44:43.996696
NCT01132573|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2014-07-16|2010-05-26|2010-05-28|Estimate|||||||2014-07-16|2014-07-17|Estimate|April 2010||2010-04-30|April 2014|2014-04-30||||June 2014|Actual|2014-06-30||Interventional|||Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia|A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995) Plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults With Relapsed and Refractory Disease|Completed||Phase 1|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:44:44.095253|2018-05-31 23:44:44.095253
NCT01132560|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2017-05-16|2010-05-26|2010-05-28|Estimate|||||||2017-05-16|2017-05-17|Actual|March 5, 2010|Actual|2010-03-05|May 2017|2017-05-31|April 5, 2010|Actual|2010-04-05|April 5, 2010|Actual|2010-04-05||Observational|||Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ|A Correlative Science Study for ECOG E5194|Completed|||500|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:44:44.178159|2018-05-31 23:44:44.178159
NCT01132547|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2015-01-12||2015-06-04|2010-05-26|2010-05-28|Estimate|2015-06-04|2015-07-02|Estimate||||2015-06-04|2015-07-02|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer|Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk|Terminated||Phase 3|22|Actual|University of South Florida||2||The study was terminated due to slow accrual.|f||||t||||||||||2018-05-31 23:44:44.267219|2018-05-31 23:44:44.267219
NCT01132534|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-15|2010-05-27|2010-05-28|Estimate|||||||2010-06-15|2010-06-16|Estimate|June 2007||2007-06-30|May 2010|2010-05-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Observational|CAFBI||A Randomized Study Comparing Autofluorescence Imaging(AFI) Followed by Narrow Band Imaging(NBI) With Videoendoscopy for the Detection of High Risk Lesions of Stomach|A Randomized Study Comparing Endoscopic Video-Autofluorescence Imaging Followed by Narrow Band Imaging With Standard Videoendoscopy for the Detection of High Risk Lesions of Stomach|Completed|||64|Actual|National University Hospital, Singapore|||2||f||||t||||||||||2018-05-31 23:44:44.550372|2018-05-31 23:44:44.550372
NCT01132521|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2018-01-16|2010-05-26|2010-05-28|Estimate|||||||2018-01-16|2018-01-17|Actual|June 2010|Actual|2010-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ulinastatin in Severe Acute Pancreatitis|Multicenter, Double-bind, Randomised, Placebo Controlled Study of Ulinastatin in Severe Acute Pancreatitis|Suspended||Phase 4|252|Actual|Techpool Bio-Pharma Co., Ltd.||2||Revised project|f||||t||||||||Undecided||2018-05-31 23:44:44.618793|2018-05-31 23:44:44.618793
NCT01132508|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2014-11-11||2015-05-26|2010-05-26|2010-05-28|Estimate|2015-05-26|2015-06-11|Estimate||||2015-05-26|2015-06-11|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational||All patients enrolled and treated with Norian Drillable Bone Void Filler.|Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures|Use of a Reinforced Injectable Calcium Phosphate Bone Cement in the Treatment of Tibial Plateau Fractures|Completed|||33|Actual|Synthes GmbH|||1||f||||f||||||||||2018-05-31 23:44:44.804067|2018-05-31 23:44:44.804067
NCT01132495|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2016-06-08||2016-12-08|2010-05-27|2010-05-28|Estimate|2016-10-13|2016-12-09|Estimate||||2016-12-08|2017-02-02|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|January 2014|Actual|2014-01-31||Interventional|||FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT|Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease|Completed||Phase 4|1170|Actual|St. Jude Medical||3|||f||||t||||||||||2018-05-31 23:44:46.764612|2018-05-31 23:44:46.764612
NCT01132482|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-08-29|2010-05-26|2010-05-28|Estimate|||||||2017-08-29|2017-08-31|Actual|October 2015||2015-10-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Effects of Sildenafil on CFTR-dependent Ion Transport Activity|Phase II Study of the Effects of Sildenafil on CFTR-dependent Ion Transport Activity|Completed||Phase 2|23|Actual|National Jewish Health||2|||f||||t||||||||||2018-05-31 23:44:47.113508|2018-05-31 23:44:47.113508
NCT01132469|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-05-26|2010-05-26|2010-05-28|Estimate|||||||2010-05-26|2010-05-28|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|ESD||Efficacy and Safety Study of Endoscopic Submucosal Dissection for Early Gastric Cancer|Long-term Follow-up After Endoscopic Submucosal Dissection for Early Gastric Cancer|Unknown status|Recruiting|N/A|1158|Anticipated|National Evidence-Based Healthcare Collaborating Agency||1|||f||||f||||||||||2018-05-31 23:44:47.207357|2018-05-31 23:44:47.207357
NCT01132456|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-06-09|2010-05-27|2010-05-28|Estimate|||||||2016-06-09|2016-06-13|Estimate|June 2010||2010-06-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|May 2013|Actual|2013-05-31||Interventional|R-A||RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia|RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia|Completed||N/A|312|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-05-31 23:44:47.284821|2018-05-31 23:44:47.284821
NCT01132443|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-06-14|2010-05-27|2010-05-28|Estimate|||||||2017-06-14|2017-06-16|Actual|May 6, 2010|Actual|2010-05-06|June 2017|2017-06-30|June 12, 2010|Actual|2010-06-12|June 12, 2010|Actual|2010-06-12||Interventional|||W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne|A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne Vulgaris|Completed||Phase 1|72|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:44:47.402748|2018-05-31 23:44:47.402748
NCT01132430|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2018-02-09|2010-05-27|2010-05-28|Estimate|||||||2018-02-09|2018-02-13|Actual|June 2008||2008-06-30|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Motivational Interviewing for Medication Adherence in Asthma|Impact of a Motivational Interviewing Intervention on Medication Adherence in Patients With Asthma|Completed||Phase 3|50|Actual|Hopital du Sacre-Coeur de Montreal||2|||f||||f||||||||||2018-05-31 23:44:47.481852|2018-05-31 23:44:47.481852
NCT01132417|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2011-06-21|2010-05-27|2010-05-28|Estimate|||||||2011-06-21|2011-06-23|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Observational|||In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance|In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance|Suspended|||500|Anticipated|King Faisal University|||1|researchers delay|f||||f||||||Samples Without DNA|"~     Sputum, whole blood, urine, tissue~   "|||2018-05-31 23:44:47.549792|2018-05-31 23:44:47.549792
NCT01132235|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-27|2010-05-26|2010-05-27|Estimate|||||||2010-05-27|2010-05-28|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|ENBRECAP2009||An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use|An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use|Unknown status|Recruiting|Phase 4|20|Anticipated|Florida Academic Dermatology Centers|||||f||||f||||||||||2018-05-31 23:44:51.201285|2018-05-31 23:44:51.201285
NCT01132404|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-01-26|2010-05-27|2010-05-28|Estimate|||||||2012-01-26|2012-01-31|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448|A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin|Terminated||Phase 1/Phase 2|9|Actual|Millennium Pharmaceuticals, Inc.||3||Developing new formulation of study drug. New study to open next year under a new protocol.|f||||f||||||||||2018-05-31 23:44:47.61662|2018-05-31 23:44:47.61662
NCT01132391|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2010-05-27|2010-05-27|2010-05-28|Estimate|||||||2010-05-27|2010-05-28|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Perianal Versus Endoanal Application of Glyceryl Trinitrate 0.4% Ointment for Chronic Anal Fissure|Perianal vs Endoanal Application of Glyceryl Trinitrate 0.4% Ointment in the Treatment of Chronic Anal Fissure: Results of a Randomized Controlled Trial.|Completed||Phase 3|60|Actual|Hospital General Universitario Elche||2|||f||||f||||||||||2018-05-31 23:44:47.682912|2018-05-31 23:44:47.682912
NCT01132378|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2013-03-19||2013-12-16|2010-05-27|2010-05-28|Estimate|2013-09-16|2013-11-19|Estimate||||2013-12-16|2014-01-17|Estimate|January 2006||2006-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Forty consecutive patients who underwent staged bilateral Total Knee Arthroplasty were prospectively randomised to receive mini MedialParapatellar Approach in one knee and mini-midvastus approach in the other knee (left or right)within no more than 7 days.|Midvastus Versus Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty|Mini-midvastus vs. Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty|Completed||N/A|40|Actual|Heekin Orthopedic Research Institute|The strength of the study is the standardized surgical protocol performed by a single surgeon and a prospectively randomized consecutive and blinded subjects|2|||f||||f||||||||||2018-05-31 23:44:47.777158|2018-05-31 23:44:47.777158
NCT01132365|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-07-22|2010-05-27|2010-05-28|Estimate|||||||2016-07-22|2016-07-26|Estimate|April 2005||2005-04-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Knee Arthroplasty Registry|Knee Arthroplasty Registry a. Function and Survival Stratified by BMI b. Return of Quadriceps Strength After Primary TKA|Enrolling by invitation|||7793|Anticipated|Heekin Orthopedic Research Institute|||1||f||||f||||||||||2018-05-31 23:44:48.058182|2018-05-31 23:44:48.058182
NCT01132352|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-27|2010-05-28|Estimate|||||||2010-06-11|2010-06-14|Estimate|September 2003||2003-09-30|June 2010|2010-06-30|November 2003|Actual|2003-11-30|October 2003|Actual|2003-10-31||Interventional|||Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Levetiracetam Tablets, 750 mg and Keppra® 750 mg Tablets of UCB Pharma in Healthy Adult Male Volunteers Under Fed Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:48.130862|2018-05-31 23:44:48.130862
NCT01132339|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-01-25|2010-05-27|2010-05-28|Estimate|||||||2014-01-25|2014-01-28|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Observational|||Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)|Prospective Clinical Trial to Investigate Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)|Completed|||1467|Actual|Copenhagen University Hospital at Herlev|||4||f||||t||||||||||2018-05-31 23:44:48.213616|2018-05-31 23:44:48.213616
NCT01132326|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2014-03-18|2013-03-27|2017-02-03|2010-05-26|2010-05-28|Estimate|2014-03-18|2014-04-21|Estimate|2013-03-27|2013-04-04|Estimate|2017-02-03|2017-03-15|Actual|January 2009||2009-01-31|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|NOH304||Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)|A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension|Completed||Phase 3|350|Actual|Chelsea Therapeutics||1|||f||||f||||||||||2018-05-31 23:44:48.311351|2018-05-31 23:44:48.311351
NCT01132313|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2015-10-29|2014-11-05|2015-12-22|2010-05-26|2010-05-28|Estimate|2015-12-22|2016-02-01|Estimate|2014-11-05|2014-11-18|Estimate|2015-12-22|2016-02-01|Estimate|May 2010||2010-05-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Treated set which included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment regardless of randomisation.|Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection|Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II)|Completed||Phase 2|488|Actual|Boehringer Ingelheim|There were only 3 patients entered in part 4 of the trial, therefore no formal analyses of efficacy data were performed.|12|||f||||||||||||||2018-05-31 23:44:48.767923|2018-05-31 23:44:48.767923
NCT01132300|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-05-26|2010-05-26|2010-05-28|Estimate|||||||2010-05-26|2010-05-28|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy Study Image Guided, Auto-Targeted Neurostimulation for the Treatment of Non-Specific Low Back Pain|An Open Trial Evaluating Efficacy of NeMa-st - A Computerized, Image Guided, Auto-Targeted Neurostimulation Device for the Treatment of Non Specific Low Back Pain|Completed||N/A|20|Actual|Bnai Zion Medical Center||1|||f||||f||||||||||2018-05-31 23:44:50.834041|2018-05-31 23:44:50.834041
NCT01132287|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-11-18|2010-05-27|2010-05-28|Estimate|||||||2016-11-18|2016-11-21|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||An Evaluation of a Marketed Lubricated Eye Drop in Soft Contact Lens Wearers Who Experience Ocular Dryness|An Evaluation of a Marketed Lubricated Eye Drop in Soft Contact Lens Wearers Who Experience Ocular Dryness|Completed||N/A|92|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:44:50.899781|2018-05-31 23:44:50.899781
NCT01132274|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-04-12|2010-05-27|2010-05-28|Estimate|||||||2013-04-12|2013-04-15|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|NO-PARTY||Radiation Exposure Reduction in Supraventricular Tachycardia Ablation|Near Zero Fluoroscopic Exposure During Catheter Ablation of Supraventricular Arrhythmias|Completed||Phase 4|210|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 23:44:50.981518|2018-05-31 23:44:50.981518
NCT01132261|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-27|2010-05-27|2010-05-28|Estimate|||||||2010-05-27|2010-05-28|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Trial of a Brain Preservation Diet in Preventing Cognitive Decline in Old Age Hostel Residents|A Randonized Control Trial of a Brain Preservation Diet in Preventing Congnitive Decline in Odl Age Hostel Residents|Completed||N/A|480|Anticipated|Chinese University of Hong Kong||2|||f||||||||||||||2018-05-31 23:44:51.066113|2018-05-31 23:44:51.066113
NCT01132222|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|September 2004||2004-09-30|June 2010|2010-06-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalence Study of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets Under Fed Conditions|A Randomized, Open Label, 2-treatment, Single Dose, Crossover, Bioequivalence Study of Ibuprofen 200 mg+Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare Under Fed Conditions.|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:51.276649|2018-05-31 23:44:51.276649
NCT01132209|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2014-07-31|2010-05-26|2010-05-27|Estimate|||||||2014-07-31|2014-08-01|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|STITCH||Suture Techniques to Reduce the Incidence of The inCisional Hernia|Suture Techniques to Reduce the Incidence of The inCisional Hernia|Completed||N/A|576|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 23:44:51.352388|2018-05-31 23:44:51.352388
NCT01132196|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|August 2006||2006-08-31|June 2010|2010-06-30|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence Study of Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, 2-treatment, 2-period, 2-sequence, Single Dose, Crossover, Bioequivalence Study of Divalproex Sodium DR 500 mg Tablets and Depakote® DR 500 mg Under Fed Conditions.|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:51.443609|2018-05-31 23:44:51.443609
NCT01132183|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Bioequivalence Study of Divalproex Sodium Capsules(Sprinkle),125 mg of Dr. Reddy's Under Fasting Condition (Apple Sauce)|An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Human Subjects Under Fasting Conditions.|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:51.620539|2018-05-31 23:44:51.620539
NCT01132170|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|August 2006||2006-08-31|June 2010|2010-06-30|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, 2-treatment, 2-period, 2-sequence, Single Dose, Crossover, Bioequivalence Study of Divalproex Sodium DR 500 mg Tablets and Depakote® DR 500 mg Under Fasting Conditions.|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:51.693466|2018-05-31 23:44:51.693466
NCT01132157|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-03-04|2010-05-26|2010-05-27|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of the Protective Effect of Desflurane and Propofol in Patients With Renal Transplantation|The Comparison of Preconditioning Effect of Desflurane and Antiapoptotic Effect of Propofol in Patients With Kidney Transplantation|Completed||Phase 4|99|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:44:51.762269|2018-05-31 23:44:51.762269
NCT01132144|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2013-06-18||2014-01-02|2010-05-26|2010-05-27|Estimate|2014-01-02|2014-02-17|Estimate||||2014-01-02|2014-02-17|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Endometrial Injury for Assisted Reproduction|Endometrial Injury Prior Ovulation Induction for Assisted Reproductive Techniques: a Randomized Controlled Trial|Terminated||Phase 3|158|Actual|University of Sao Paulo||2||Stopped after safety analysis because of significant benefit of intervention.|f||||f||||||||||2018-05-31 23:44:51.848239|2018-05-31 23:44:51.848239
NCT01132131|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2012-02-01|2010-05-26|2010-05-27|Estimate|||||||2012-02-01|2012-02-02|Estimate|August 2010||2010-08-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Management of Urinary Tract Infections in Primary Care Facilities.|Use of Standardized Delegation Form in Diagnosing and Treating Acute Cystitis in Primary Care Facilities.|Completed||Phase 4|443|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 23:44:52.167779|2018-05-31 23:44:52.167779
NCT01132118|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2014-08-08||2014-09-02|2010-05-26|2010-05-27|Estimate|2014-09-02|2014-09-03|Estimate||||2014-09-02|2014-09-03|Estimate|June 2010||2010-06-30|September 2014|2014-09-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|RA PLUS|Participants who were randomized to receive either HCQ or placebo.|Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis|Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis|Completed||Phase 3|30|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 23:44:52.272795|2018-05-31 23:44:52.272795
NCT01132105|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate||||May 2010|2010-05-31||||||||Observational|||Vestibular Evoked Myogenic Potential: A New Device Propose|Vestibular Evoked Myogenic Potential: A New Device Propose|Completed|||||Universidade Estadual de Ciências da Saúde de Alagoas|||1||f||||||||||||||2018-05-31 23:44:52.824859|2018-05-31 23:44:52.824859
NCT01132092|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate||||May 2010|2010-05-31||||||||Observational|||The Normal Standard of Brainstem Auditory Evoked Potential in Adults Using a New Device|The Normal Standard of Brainstem Auditory Evoked Potential in Adults Using a New Device|Completed|||||Universidade Estadual de Ciências da Saúde de Alagoas|||5||f||||||||||||||2018-05-31 23:44:52.999989|2018-05-31 23:44:52.999989
NCT01132079|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2005||2005-03-31|March 2005|2005-03-31||||||||Interventional|||Pimecrolimus and Epidermal Barrier Function|Role for Pimecrolimus in Restoring Skin Barrier Function and Normalizing Epidermal Lipid Content and Differentiation in Atopic Epidermis: a Randomized, Intra-patient, Double-blind (Right/Left Arm) Study in Adults With Atopic Dermatitis Treated With 1 % Pimecrolimus Cream and 0.1 % Betamethasone Cream as Treatment Control Twice Daily for 3 Weeks|Completed||N/A|15|Actual|University of Kiel||2|||f||||||||||||||2018-05-31 23:44:53.069816|2018-05-31 23:44:53.069816
NCT01132066|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-02-27|2010-05-26|2010-05-27|Estimate|||||||2014-02-27|2014-02-28|Estimate|April 2007||2007-04-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Transcranial Direct Current Stimulation (TDCS) for Facilitating Swallowing Improvement After an Acute Unilateral Hemispheric Stroke|Pilot Study of Transcranial Direct Current Stimulation for Facilitating Swallowing Improvement After an Acute Unilateral Hemispheric Infarction|Completed||Phase 1/Phase 2|19|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 23:44:53.147607|2018-05-31 23:44:53.147607
NCT01132053|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2018-03-07|2010-05-26|2010-05-27|Estimate|||||||2018-03-07|2018-03-08|Actual|June 2004||2004-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2016|Actual|2016-09-30||Observational|||Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)|Role of Inflammation in PML|Active, not recruiting|||126|Actual|Beth Israel Deaconess Medical Center|||2||f||||f||||||Samples With DNA|"~     Blood, Urine, CSF if needed for clinical management.~   "|||2018-05-31 23:44:53.239362|2018-05-31 23:44:53.239362
NCT01132040|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|August 2006||2006-08-31|May 2010|2010-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced. Randomized, Two-treatment, Two-period, Two-sequence, Single Dose,Crossover, Bioequivalence Study of Primidone 50 mg Tablets of Comparing With That of Mysoline® 50 mg Tablets Under Fasting Conditions.|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:53.312615|2018-05-31 23:44:53.312615
NCT01132027|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Bioavailability Study of Tacrolimus Capsules, 5 mg of Dr. Reddys's Laboratories Limited Under Non-Fasting Conditions|An Open Label, Two Way Crossover, Balanced, Single Dose, Comparative Evaluation of Relative Bioavailability of Tacrolimus Capsules 5 mg With That of 'Prograf' Capsules 5 mg in Healthy Subjects Under Non-fasting Conditions.|Completed||Phase 1|40|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:53.420462|2018-05-31 23:44:53.420462
NCT01132014|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2016-02-08|2010-05-26|2010-05-27|Estimate|||||||2016-02-08|2016-02-09|Estimate|May 2010||2010-05-31|February 2016|2016-02-29||||July 2015|Actual|2015-07-31||Interventional|||Autologous OC-DC Vaccine in Ovarian Cancer|A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Unknown status|Active, not recruiting|Early Phase 1|67|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:44:53.576488|2018-05-31 23:44:53.576488
NCT01132001|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-10-09|2010-05-26|2010-05-27|Estimate|||||||2012-10-09|2012-10-11|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Observational|||Ambulatory Versus Home Blood Pressure Measurement|EVALUATION OF BLOOD PRESSURE MEASUREMENTS OUTSIDE OFFICE: COMPARISON OF DIAGNOSIS BASED ON EITHER AMBULATORY OR HOME BLOOD PRESSURE MEASUREMENTS|Unknown status|Recruiting||200|Anticipated|University of Athens|||||f||||f||||||||||2018-05-31 23:44:53.663684|2018-05-31 23:44:53.663684
NCT01131988|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Bioavailability Study of Tacrolimus Capsules, 5 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Two Way Crossover, Balanced, Single Dose, Comparative Evaluation of Relative Bioavailability of Tacrolimus Capsules 5 mg With That of 'Prograf' Capsules 5 mg in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|40|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:53.727567|2018-05-31 23:44:53.727567
NCT01131975|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|January 2003||2003-01-31|June 2010|2010-06-30|March 2003|Actual|2003-03-31|February 2003|Actual|2003-02-28||Interventional|||Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition|Single Dose Two-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets With Lamictal 25 mg Chewable Tablets in Healthy Volunteers Under Fed Condition|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:53.897115|2018-05-31 23:44:53.897115
NCT01131962|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2014-12-03|2010-05-26|2010-05-27|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Interventional|||Comparing Two Methods to Stop Vomiting of Blood Using the Endoscope|Control of Acute Variceal Bleeding Using the Multi-shooter Band Ligator Compared to Injection Sclerotherapy.|Completed||Phase 3|200|Actual|Faculty of Medicine, University of Alexandria||2|||f||||f||||||||||2018-05-31 23:44:54.079094|2018-05-31 23:44:54.079094
NCT01131949|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|January 2003||2003-01-31|June 2010|2010-06-30|March 2003|Actual|2003-03-31|February 2003|Actual|2003-02-28||Interventional|||Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition|Single Dose Two-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets With Lamictal 25 mg Chewable Tablets in Healthy Volunteers Under Fasting Condition|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:54.145389|2018-05-31 23:44:54.145389
NCT01131936|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|August 2002||2002-08-31|June 2010|2010-06-30|November 2002|Actual|2002-11-30|September 2002|Actual|2002-09-30||Interventional|||Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fed Conditions|An Open-Label Randomized Single-Dose Bioequivalence Study of Amlodipine 10 mg Tablets and Norvasc ® 10 mg Tablets Under Fed Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:54.23242|2018-05-31 23:44:54.23242
NCT01131923|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|October 2002||2002-10-31|June 2010|2010-06-30|December 2002|Actual|2002-12-31|November 2002|Actual|2002-11-30||Interventional|||Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fasting Conditions|An Open-Label Randomized Single-Dose Bioequivalence Study of Amlodipine 10 mg Tablets and Norvasc ® 10 mg Tablets Under Fasting Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:54.3242|2018-05-31 23:44:54.3242
NCT01131910|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-05-24|2010-05-26|2010-05-27|Estimate|||||||2011-05-24|2011-05-25|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||TBE-vaccine to Patients With Rheumatoid Arthritis Who Are Using Immunosuppressive Drugs|Efficacy of TBE-vaccine to Patients With Rheumatic Disease Who Are Treated With Methotrexate and/or TNF-alfa Blocking Drugs|Completed||Phase 2|68|Actual|Sormland County Council, Sweden||1|||f||||t||||||||||2018-05-31 23:44:54.398743|2018-05-31 23:44:54.398743
NCT01131897|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|September 2003||2003-09-30|June 2010|2010-06-30|November 2003|Actual|2003-11-30|September 2003|Actual|2003-09-30||Interventional|||Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's Levetiracetam Tablets, 750 mg and Keppra® 750 mg Tablets of UCB Pharma in Healthy Adult Male Volunteers Under Fasting Conditions.|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:54.495075|2018-05-31 23:44:54.495075
NCT01131884|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2012-12-04||2015-12-25|2010-05-25|2010-05-27|Estimate|2013-09-12|2013-09-16|Estimate||||2015-12-25|2016-01-29|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pilot Study of Fosamax in Spinal Cord Injury|Double Blind Placebo Controlled Trial to Evaluate Preservation of Bone Mineral Density of the Hip and Distal Femur by Biphosphate Therapy (Fosamax) Following Spinal Cord Injury|Terminated||N/A|1|Actual|University of Rochester||2||Only 1 participant enrolled since the beginning of this study|f||||f||||||||||2018-05-31 23:44:54.564508|2018-05-31 23:44:54.564508
NCT01131871|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2015-08-04|2010-05-25|2010-05-27|Estimate|||||||2015-08-04|2015-08-05|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|IDEA||Innovative Approaches to Diet, Exercise and Activity|Enhanced Behavioral Intervention to Improve Long-Term Weight Loss in Young Adults|Completed||Phase 2|471|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 23:44:54.744095|2018-05-31 23:44:54.744095
NCT01131858|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2012-04-04|2010-05-26|2010-05-27|Estimate|||||||2012-04-04|2012-04-05|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|VITAPID||Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency|A Placebo Controlled Double Blinded Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency|Completed||Phase 1/Phase 2|140|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 23:44:54.809624|2018-05-31 23:44:54.809624
NCT01131845|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2012-05-16|2010-05-25|2010-05-27|Estimate|||||||2012-05-16|2012-05-17|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil|An Evaluation of the Pharmacokinetics and Safety of a Single Dose of UT-15C SR (Treprostinil Diethanolamine) in Subjects With Renal Impairment.|Completed||Phase 1|16|Actual|United Therapeutics||1|||f||||f||||||||||2018-05-31 23:44:54.869192|2018-05-31 23:44:54.869192
NCT01131832|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2017-05-05|2010-05-25|2010-05-27|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2010||2010-09-30|May 2017|2017-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols|Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols|Completed||Phase 4|71|Actual|University of Manitoba||1|||f||||||||||||||2018-05-31 23:44:54.94039|2018-05-31 23:44:54.94039
NCT01131819|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2018-05-25|2010-05-25|2010-05-27|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2010||2010-05-31|May 2018|2018-05-31|September 2012|Actual|2012-09-30|June 2011|Actual|2011-06-30||Interventional|||Use of an Interactive Video Game as Part of a New Amputee Rehabilitation Program|Use of an Interactive Video Game as Part of a New Amputee Rehabilitation Program|Completed||N/A|8|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 23:44:54.999999|2018-05-31 23:44:54.999999
NCT01131806|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-07-07|2010-05-26|2010-05-27|Estimate|||||||2010-07-07|2010-07-08|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|April 2011|Anticipated|2011-04-30|November 2010|Anticipated|2010-11-30||Interventional|||Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients|Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients|Unknown status|Recruiting|Phase 4|124|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 23:44:55.077939|2018-05-31 23:44:55.077939
NCT01131793|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-07-19|2010-05-25|2010-05-27|Estimate|||||||2011-07-19|2011-07-20|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|TOTAR||PowerAssert Radio-Frequency (RF) Guidewire Coronary In-Stent Chronic Total Occlusion (CTO)|Total Occlusion With Angioplasty After Using a Radiofrequency Guide Wire-Magnetic-Coronary|Completed||Phase 2|5|Actual|Stereotaxis||1|||f||||f||||||||||2018-05-31 23:44:55.304014|2018-05-31 23:44:55.304014
NCT01131780|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|October 2004||2004-10-31|June 2010|2010-06-30|November 2004|Actual|2004-11-30|October 2004|Actual|2004-10-31||Interventional|||Bioequivalency Study of Ibuprofen 200 mg and Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's Under Fasting Conditions|A Randomized, Open Label, 2-treatment, Single Dose, Crossover, Bioequivalence Study of Ibuprofen 200 mg+Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare Under Fasting Conditions.|Completed||Phase 1|32|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:55.370225|2018-05-31 23:44:55.370225
NCT01131767|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|July 2004||2004-07-31|June 2010|2010-06-30|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Naproxen Sodium 220 mg + Pseudoephedrine HCL 120 mg ER Tablets and Aleve Cold and Sinus® Under Fed Conditions.|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:55.448469|2018-05-31 23:44:55.448469
NCT01131754|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-13|2010-05-26|2010-05-27|Estimate|||||||2010-06-13|2010-06-15|Estimate|June 2007||2007-06-30|February 2007|2007-02-28|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Heparin 100U/L for Prevention of PVC Complications|STUDIO CLINICO RANDOMIZZATO SULL'UTILIZZO DI EPARINA PER LA PROFILASSI DELLA TROMBOFLEBITE DA CATETERE VENOSO PERIFERICO|Completed||Phase 3|214|Actual|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-05-31 23:44:55.521221|2018-05-31 23:44:55.521221
NCT01131741|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-23|||2011-02-13|2010-05-25|2010-05-27|Estimate|||||||2011-02-13|2011-02-15|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|April 2011|Anticipated|2011-04-30|July 2010|Anticipated|2010-07-31||Interventional|||Comparison of Perfusion Index, T Wave Amplitude, Systolic Blood Pressure and Heart Rate|Comparison of Perfusion Index, T Wave Amplitude, Systolic Blood Pressure and Heart Rate as an Indicator for Detecting Intravascular Injection of Epinephrine Containing Test Dose During Operation in Anesthetized Adults|Unknown status|Recruiting|N/A|50|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:44:55.593489|2018-05-31 23:44:55.593489
NCT01131728|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-11|2010-05-26|2010-05-27|Estimate|||||||2010-06-11|2010-06-14|Estimate|July 2004||2004-07-31|June 2010|2010-06-30|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fasting Conditions|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Naproxen Sodium 220 mg + Pseudoephedrine HCL 120 mg ER Tablets and Aleve Cold and Sinus® Under Fasting Conditions.|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 23:44:55.670908|2018-05-31 23:44:55.670908
NCT01131715|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||Pharmacist Follow-up, a Qualitative Study of Patient Experience|Pharmacist Follow-up of Patients With Coronary Heart Disease. A Qualitative Study of Patient Experience.|Unknown status|Active, not recruiting||4|Actual|Hospital Pharmacy of North Norway Trust|||1||f||||f||||||||||2018-05-31 23:44:55.735175|2018-05-31 23:44:55.735175
NCT01131702|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-06-08|2010-05-26|2010-05-27|Estimate|||||||2010-06-08|2010-06-09|Estimate|January 2003||2003-01-31|June 2010|2010-06-30|March 2003|Actual|2003-03-31|February 2003|Actual|2003-02-28||Interventional|||Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions|Randomized,2-way Crossover, Bioequivalence Study of Ranitidine 300 mg Tablets Zantac 300 mg Tablets Administered as 1 x 300 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 23:44:55.79229|2018-05-31 23:44:55.79229
NCT01131689|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2012-01-31|2010-05-26|2010-05-27|Estimate|||||||2012-01-31|2012-02-02|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma|Phase 1 Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1|20|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 23:44:55.913729|2018-05-31 23:44:55.913729
NCT01131676|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2016-04-07||2016-04-07|2010-05-26|2010-05-27|Estimate|2016-04-07|2016-05-16|Estimate||||2016-04-07|2016-05-16|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Treated set (TS): Consists of all randomised patients who received at least 1 dose of study medication. Patients were assigned to treatment groups according to the randomisation scheme.|BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).|A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk|Completed||Phase 3|7064|Actual|Boehringer Ingelheim|2 sets of duplicates(4 patients(pts)) were counted only once.652 sites were initiated and 611 enrolled.One site transferred all pts to other sites.27 pts randomised and 13 pts screened were excluded from analyses due to serious non-compliance|3|||f||||||||||||||2018-05-31 23:44:56.146871|2018-05-31 23:44:56.146871
NCT01131663|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-25|2010-05-25|2010-05-27|Estimate|||||||2010-05-25|2010-05-27|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|April 2012|Anticipated|2012-04-30|April 2011|Anticipated|2011-04-30||Observational|||Design and Development of an Infant's Oriented Face Mask|Design and Development of an Infant's Oriented Face Mask|Unknown status|Recruiting||200|Anticipated|Ziv Hospital|||||f||||f||||||||||2018-05-31 23:45:01.321263|2018-05-31 23:45:01.321263
NCT01131650|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Observational|||Prevalence of Diabetic Retinopathy in São José do Rio Preto-SP-Brazil|Prevalence of Diabetic Retinopathy in São José do Rio Preto-SP-Brazil|Completed|||710|Actual|Hospital do Olho Rio Preto|||2||f||||t||||||||||2018-05-31 23:45:01.401452|2018-05-31 23:45:01.401452
NCT01131637|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2017-12-19|2010-05-26|2010-05-27|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2010||2010-04-30|July 2012|2012-07-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure|Terminated||Phase 3|331|Actual|Zensun Sci. & Tech. Co., Ltd.||2||Sponsor has designed another study to replace the current study|f||||t||||||||||2018-05-31 23:45:01.551248|2018-05-31 23:45:01.551248
NCT01131624|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2015-05-27|2010-05-26|2010-05-27|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|ASAP||Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women|An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women|Completed||Phase 3|252|Actual|Vifor Inc.||2|||f||||t||||||||||2018-05-31 23:45:01.95236|2018-05-31 23:45:01.95236
NCT01131611|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-07-02|2010-05-25|2010-05-27|Estimate|||||||2014-07-02|2014-07-04|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CBPT||Cognitive-Behavioral Physical Therapy|Cognitive-Behavioral Based Physical Therapy: Improving Surgical Spine Outcomes|Completed||Phase 1/Phase 2|86|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 23:45:02.275686|2018-05-31 23:45:02.275686
NCT01131598|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-27|2010-05-26|2010-05-27|Estimate|||||||2010-05-27|2010-05-28|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2011|Anticipated|2011-01-31|June 2010|Anticipated|2010-06-30||Observational|ALIEN||Acute Lung Injury in Children: Epidemiology and Natural History. PEDIATRIC ALIEN.|Acute Lung Injury in Spanish Children|Unknown status|Recruiting||1|Anticipated|Hospital de Cruces|||||f||||f||||||||||2018-05-31 23:45:02.564088|2018-05-31 23:45:02.564088
NCT01131585|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2012-07-12||2012-08-20|2010-05-26|2010-05-27|Estimate|2012-07-12|2012-08-17|Estimate||||2012-08-20|2012-08-30|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|RELATION||Safety and Efficacy of Ranibizumab in Diabetic Macular Edema|A 12-month, Two-armed, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Laser Photocoagulation as Adjunctive to Ranibizumab Intravitreal Injections vs. Laser Photocoagulation Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema Followed by a 12 Month Follow up Period|Terminated||Phase 3|128|Actual|Novartis|Early study termination due to European drug approval.|2||European drug approval.|f||||||||||||||2018-05-31 23:45:02.802758|2018-05-31 23:45:02.802758
NCT01131572|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-05-08|2010-05-26|2010-05-27|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||N-acetylcysteine in Bulimia Nervosa||Terminated||Phase 2/Phase 3|11|Actual|Lindner Center of HOPE||1|||f||||||||||||||2018-05-31 23:45:03.418989|2018-05-31 23:45:03.418989
NCT01131559|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2014-03-04|2010-05-26|2010-05-27|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression|Adjunctive Lisdexamfetamine in Bipolar Depression|Terminated||Phase 3|50|Anticipated|Lindner Center of HOPE||2||Sponsor halted study.|f||||f||||||||||2018-05-31 23:45:03.600916|2018-05-31 23:45:03.600916
NCT01131546|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-05-30|2010-05-25|2010-05-27|Estimate|||||||2011-05-30|2011-06-01|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension|A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension|Completed||Phase 4|1080|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 23:45:03.719319|2018-05-31 23:45:03.719319
NCT01131533|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-09-14|2010-05-26|2010-05-27|Estimate|||||||2010-09-14|2010-09-15|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|July 2010|Actual|2010-07-31||Interventional|||Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human|Intraocular Pharmacokinetics of Erythropoietin After Single Intravitreal Injection in Human|Unknown status|Recruiting|N/A|5|Anticipated|Hallym University Medical Center||1|||f||||t||||||||||2018-05-31 23:45:03.80602|2018-05-31 23:45:03.80602
NCT01131507|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2014-01-27||2017-02-14|2010-05-26|2010-05-27|Estimate|2014-01-27|2014-03-07|Estimate||||2017-02-14|2017-03-21|Actual|July 2010||2010-07-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Safety population included all participants who received at least 1 dose of study drug.|PR-018: An Open-Label, Safety Extension of Study PR-011|A Multicenter, Open-Label, Safety Extension of Study PR-011 Titled: A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF)|Completed||Phase 4|15|Actual|Forest Laboratories||1|||f||||t||||||||||2018-05-31 23:45:04.762847|2018-05-31 23:45:04.762847
NCT01131494|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2011-05-05||2011-10-04|2010-05-26|2010-05-27|Estimate|2011-10-04|2011-11-08|Estimate||||2011-10-04|2011-11-08|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Swallowing Training in Parkinson`s Disease|Dysphagia Therapy for Parkinson`s Disease: the Role of the Oral Motor Exercises|Completed||N/A|17|Actual|Federal University of Bahia|"There was a delay because of faulty equipment that performs videofluoroscopy of swallowing.~Study limitations include small number of participants and no comparison group."|1|||f||||t||||||||||2018-05-31 23:45:05.048586|2018-05-31 23:45:05.048586
NCT01131481|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2015-09-14|2010-05-26|2010-05-27|Estimate|||||||2015-09-14|2015-09-15|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|AVS Vs MA50BM||Evaluation of Glistenings in Intraocular Lenses Implanted in Normal Patients Following Routine Cataract Extraction.|Evaluation of Glistenings in Intraocular Lenses AVS Model X-60 Vs AcrySof MA50-BM.|Withdrawn||Phase 4|0|Actual|Fry Eye Associates and Fry Eye Surgery Center||1||lack of recruitment|f||||t||||||||||2018-05-31 23:45:05.258558|2018-05-31 23:45:05.258558
NCT01131468|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Prevention of Drug Induced Ototoxicity in Peritoneal Dialysis Patients by N-Acetylcysteine|The Evaluation of the Protective Effect of N-Acetylcysteine Against Drug Induced Ototoxicity in Peritoneal Dialysis Patients|Completed||Phase 2|60|Actual|TC Erciyes University||2|||f||||||||||||||2018-05-31 23:45:05.325792|2018-05-31 23:45:05.325792
NCT01131455|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|2014-07-29||2014-11-12|2010-05-26|2010-05-27|Estimate|2014-11-12|2014-11-13|Estimate||||2014-11-12|2014-11-13|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||ACP for Local Application in Ankle Arthrodesis|Autologous Concentrated Platelet-rich Plasma (Arthrex ACP®) for Local Application in Ankle Arthrodesis: A Prospective Outcome Analysis.|Terminated||N/A|10|Actual|Columbia Orthopaedic Group, LLP||3||Study was terminated due to the untimely death of the investigator|f||||f||||||||||2018-05-31 23:45:05.464717|2018-05-31 23:45:05.464717
NCT01131442|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|November 2008||2008-11-30|May 2010|2010-05-31||||||||Observational|||Immunological Change and the Single Nucleotide Polymorphism (SNP) in Children With Irritable Bowel Syndrome (IBS)||Unknown status|Recruiting||40|Anticipated|Chang Gung Memorial Hospital|||2||f||||||||||||||2018-05-31 23:45:05.732702|2018-05-31 23:45:05.732702
NCT01131429|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|June 2015|Anticipated|2015-06-30|June 2013|Anticipated|2013-06-30||Interventional|||A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations|Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 23:45:05.813462|2018-05-31 23:45:05.813462
NCT01131416|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-06-27|2010-05-26|2010-05-27|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|GUM01||The Effects of Gum Chewing on Bowel Function Recovery Following Cesarean Section|The Effects of Gum Chewing on Bowel Function Recovery Following Cesarean Section: Randomized Controlled Trial|Completed||Phase 2/Phase 3|100|Anticipated|Chiang Mai University||2|||f||||f||||||||||2018-05-31 23:45:05.960015|2018-05-31 23:45:05.960015
NCT01131403|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2011-06-21|2010-05-26|2010-05-27|Estimate|||||||2011-06-21|2011-06-22|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|October 2007||2007-10-31|||||Observational|||Clinical Analysis of the Influence of Using the Skin Care Products on the Diaper Area in Comparison With Using a Cotton Wool Cloth, Moistened With Clear Water on the Skin Physiology of the Newborns From the 1st Day to the 4th Week of Life|Standardized Skin Care Regimen in the Diaper Area: a Prospective, Randomized Clinical Study on Skin Barrier Function and Epidermal IL-1α|Completed|||44||Charite University, Berlin, Germany|||2||f||||t||||||||||2018-05-31 23:45:06.038202|2018-05-31 23:45:06.038202
NCT01131390|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2011-06-21|2010-05-26|2010-05-27|Estimate|||||||2011-06-21|2011-06-22|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Ventilator Settings and Comfort|What Ventilator Settings Are Most Comfortable for Patients With COPD or Obesity.|Unknown status|Recruiting|Phase 3|20|Anticipated|Bridgeport Hospital|||||f||||f||||||||||2018-05-31 23:45:06.101321|2018-05-31 23:45:06.101321
NCT01131377|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-26|||2010-05-26|2010-05-26|2010-05-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Acetazolamide Facilitates Ventilator Weaning|Acetazolamide Facilitates Ventilator Weaning Multicenter, Prospective, Double Blinded, Randomised Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:45:06.178665|2018-05-31 23:45:06.178665
NCT01131364|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-02-24|2010-05-25|2010-05-26|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2008||2008-06-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients|A Dose-finding, Pharmacokinetic, Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours|Terminated||Phase 1/Phase 2|29|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:45:06.262828|2018-05-31 23:45:06.262828
NCT01131351|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25||2012-06-26|2012-06-26|2010-05-25|2010-05-26|Estimate||||2012-06-26|2012-07-02|Estimate|2012-06-26|2012-07-02|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis|A Phase 2, Multi-center, Non-controlled, Open-label Dose Escalation Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Orally Administered OPC-67683 Two Times Daily to Patients With Pulmonary Multidrug-Resistant Tuberculosis Refractory to Conventional Treatment|Completed||Phase 2|10|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-05-31 23:45:06.363395|2018-05-31 23:45:06.363395
NCT01131325|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2015-10-06|2010-05-25|2010-05-26|Estimate|||||||2015-10-06|2015-10-08|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MACS1148||Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations|A Multi-center, Single Arm Study of Nilotinib in Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Patients With Low Imatinib Trough Plasma Concentrations|Terminated||Phase 4|3|Actual|Novartis||1|||f||||f||||||||||2018-05-31 23:45:06.430572|2018-05-31 23:45:06.430572
NCT01131312|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2017-10-05|2010-05-25|2010-05-26|Estimate|||||||2017-10-05|2017-10-06|Actual|February 20, 2008||2008-02-20|July 18, 2017|2017-07-18|February 5, 2009|Actual|2009-02-05|February 5, 2009|Actual|2009-02-05||Interventional|||Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)|Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)|Completed||Phase 3|5060|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 23:45:06.508023|2018-05-31 23:45:06.508023
NCT01131299|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2016-04-18||2016-10-20|2010-05-25|2010-05-26|Estimate|2016-10-20|2016-10-21|Estimate||||2016-10-20|2016-10-21|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol|Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol|Completed||Phase 2|103|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||Undecided||2018-05-31 23:45:06.61701|2018-05-31 23:45:06.61701
NCT01131273|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2016-08-17|2010-05-25|2010-05-26|Estimate|||||||2016-08-17|2016-08-19|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||HIV Risk Reduction in Subutex Injectors in Tbilisi|Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors|Completed||Phase 3|68|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 23:45:06.846843|2018-05-31 23:45:06.846843
NCT01131260|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2015-10-19|2010-05-25|2010-05-26|Estimate|||||||2015-10-19|2015-10-21|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|STAN||Fetal ST Segment and T Wave Analysis in Labor|A Randomized Trial of Fetal ECG ST Segment and T Wave Analysis as an Adjunct to Electronic Fetal Heart Rate Monitoring (STAN)|Completed||Phase 3|11108|Actual|The George Washington University Biostatistics Center||2|||f||||t||||||||||2018-05-31 23:45:06.945782|2018-05-31 23:45:06.945782
NCT01131247|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-07-19|2010-05-25|2010-05-26|Estimate|||||||2011-07-19|2011-07-20|Estimate||||July 2011|2011-07-31||||||||Interventional|||PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab|PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB|Withdrawn||Phase 2|37|Anticipated|Nevada Cancer Institute||1||PI left institution|f||||t||||||||||2018-05-31 23:45:07.056772|2018-05-31 23:45:07.056772
NCT01131234|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-12-22|2010-05-25|2010-05-26|Estimate|||||||2014-12-22|2014-12-23|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors|A Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid Tumors|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:45:07.127921|2018-05-31 23:45:07.127921
NCT01131221|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-05-08|2010-05-25|2010-05-26|Estimate|||||||2014-05-08|2014-05-09|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma|Vitamin D Insufficiency and Follicular Lymphoma Prognosis|Completed|||196|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-05-31 23:45:07.218675|2018-05-31 23:45:07.218675
NCT01131208|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2017-05-16|2010-05-25|2010-05-26|Estimate|||||||2017-05-16|2017-05-17|Actual|April 21, 2010|Actual|2010-04-21|May 2017|2017-05-31|August 21, 2010|Actual|2010-08-21|August 21, 2010|Actual|2010-08-21||Observational|||Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab|Gene Expression Profiling Using Paraffin-embedded Tissues and the Nuclease Protection Assay in Diffuse Large B-cell Lymphoma (DLBCL) Treated With CHOP or R-CHOP: An ECOG and SWOG Correlative Study of E4494|Completed|||200|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:45:07.413073|2018-05-31 23:45:07.413073
NCT01131195|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-05-03|2010-05-25|2010-05-26|Estimate|||||||2018-05-03|2018-05-04|Actual|July 19, 2010|Actual|2010-07-19|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 14, 2012|Actual|2012-12-14||Interventional|||Metronomic Therapy in Metastatic Breast Cancer.|Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial.|Active, not recruiting||Phase 3|142|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-05-31 23:45:07.477386|2018-05-31 23:45:07.477386
NCT01131182|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2011-12-15|2011-11-02|2017-06-13|2010-05-25|2010-05-26|Estimate|2011-12-15|2012-01-20|Estimate|2011-11-02|2011-11-07|Estimate|2017-06-13|2017-07-06|Actual|June 13, 2010|Actual|2010-06-13|June 2017|2017-06-30|November 4, 2010|Actual|2010-11-04|November 4, 2010|Actual|2010-11-04||Interventional|||Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)|An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting|Completed||Phase 4|1147|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:45:07.621019|2018-05-31 23:45:07.621019
NCT01131169|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-05-30|2010-05-25|2010-05-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 2010|Actual|2010-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions|A Trial of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed or High-Risk Multiple Myeloma|Active, not recruiting||Phase 2|66|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 23:45:07.850344|2018-05-31 23:45:07.850344
NCT01131156|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-05-12|2010-05-25|2010-05-26|Estimate|||||||2014-05-12|2014-05-14|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Prevention of Postpartum Smoking Relapse in Mothers of Infants in the Neonatal Intensive Care Unit (NICU)|Prevention of Postpartum Smoking Relapse in Mothers of Infants in the Neonatal Intensive Care Unit|Completed||N/A|54|Actual|Loma Linda University|||||f||||t||||||||||2018-05-31 23:45:07.936426|2018-05-31 23:45:07.936426
NCT01131143|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-03-29|2010-05-25|2010-05-26|Estimate|||||||2013-03-29|2013-04-02|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|IVR||Trial of Provider-to-Patient Interactive Voice Response (IVR) Calls to Improve Weight Management in Community Health Centers (CHCs)|An RCT of Provider-to-Patient IVR Calls to Improve Weight Management in CHCs|Completed||N/A|1228|Actual|Indiana University||3|||f||||f||||||||||2018-05-31 23:45:08.089186|2018-05-31 23:45:08.089186
NCT01131130|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2014-03-28||2014-03-28|2010-05-25|2010-05-26|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||All eligible, dispensed participants|Feasibility of a New Silicone Hydrogel Lens|A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Lens|Completed||N/A|120|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-05-31 23:45:08.170339|2018-05-31 23:45:08.170339
NCT01131117|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-02-06|2010-05-25|2010-05-26|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2010|Actual|2010-04-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|September 2017|Actual|2017-09-30||Observational|||Fetal Programming of Obesity||Active, not recruiting|||320|Anticipated|Arkansas Children's Hospital Research Institute|||1||f||||f||||||Samples With DNA|"~     Blood, urine, stool, placenta, cord blood and umbilical cord may be collected from study~     participants.~   "|||2018-05-31 23:45:08.433589|2018-05-31 23:45:08.433589
NCT01131104|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2016-12-08||2017-09-05|2010-05-25|2010-05-26|Estimate|2017-09-05|2018-04-05|Actual||||2017-09-05|2018-04-05|Actual|May 2010||2010-05-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational||Participants with adjudication-confirmed NAION.|A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors|A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|Completed|||345|Actual|Eli Lilly and Company|||1||f||||f||||||||No||2018-05-31 23:45:08.533624|2018-05-31 23:45:08.533624
NCT01131091|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-02-09|2010-05-25|2010-05-26|Estimate|||||||2011-02-09|2011-02-10|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403|A Phase 1, Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403|Completed||Phase 1|30|Anticipated|Kowa Research Institute, Inc.||5|||f||||f||||||||||2018-05-31 23:45:08.827442|2018-05-31 23:45:08.827442
NCT01131078|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2014-12-19||2015-06-02|2010-05-25|2010-05-26|Estimate|2014-12-19|2014-12-31|Estimate||||2015-06-02|2015-06-04|Estimate|June 2005||2005-06-30|June 2015|2015-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||All enrolled participants were included in the Intent-to-Treat (ITT) population.|A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum|A Randomized, Open-label Study Comparing the Effect of 3 Chemotherapy Regimens Containing Avastin on Time to Disease Progression in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|306|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:45:08.986692|2018-05-31 23:45:08.986692
NCT01131065|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2015-12-28||2016-02-23|2010-05-25|2010-05-26|Estimate|2015-12-28|2016-02-01|Estimate||||2016-02-23|2016-02-25|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients|Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients.|Completed||Phase 3|15|Actual|Grifols Biologicals Inc.||1|||f||||f||||||||Undecided||2018-05-31 23:45:10.333703|2018-05-31 23:45:10.333703
NCT01131052|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2014-12-18||2014-12-18|2010-05-25|2010-05-26|Estimate|2014-12-18|2014-12-31|Estimate||||2014-12-18|2014-12-31|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DMElderly||Diabetes in the Elderly: Prospective Study|Diabetes Care in Nursing Home Residents: A Randomized Controlled Study|Completed||Phase 4|150|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:45:10.620988|2018-05-31 23:45:10.620988
NCT01131039|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-12-19|2010-05-25|2010-05-26|Estimate|||||||2013-12-19|2013-12-20|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer|A Phase II Trial of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Withdrawn||Phase 2|0|Actual|Emory University||1||PI left Emory|f||||t||||||||||2018-05-31 23:45:10.895027|2018-05-31 23:45:10.895027
NCT01131026|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2011-08-08|2010-05-25|2010-05-26|Estimate|||||||2011-08-08|2011-08-09|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication|A Monocentric, Open-label, Efficacy and Safety Evaluation Study of the Triple Therapy of 500 mg Levofloxacin, 1000 mg Amoxicillin and 30 mg Lansoprazole on Helicobacter Pylori Eradication in 60 Patients Infected With H. Pylori|Completed||Phase 3|60|Anticipated|Deva Holding A.S.|||||f||||f||||||||||2018-05-31 23:45:10.960495|2018-05-31 23:45:10.960495
NCT01131013|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2013-09-16|2010-05-25|2010-05-26|Estimate|||||||2013-09-16|2013-09-17|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Claudication|Completed||Phase 2|36|Anticipated|Cytokinetics||1|||f||||f||||||||||2018-05-31 23:45:11.056157|2018-05-31 23:45:11.056157
NCT01131000|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-05-25|2010-05-25|2010-05-26|Estimate|||||||2010-05-25|2010-05-26|Estimate|June 2002||2002-06-30|May 2010|2010-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients|A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial To Evaluate The Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Adult Febrile Patients|Completed||Phase 3|123|Actual|Cumberland Pharmaceuticals||2|||f||||t||||||||||2018-05-31 23:45:11.14735|2018-05-31 23:45:11.14735
NCT01130987|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2014-06-17|2010-05-25|2010-05-26|Estimate|||||||2014-06-17|2014-06-18|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Implementing a Comprehensive Handoff Program to Improve Patient Safety|Implementing a Comprehensive Handoff Program to Improve Patient Safety|Completed||N/A|92|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 23:45:12.294227|2018-05-31 23:45:12.294227
NCT01130974|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2013-03-15||2013-11-08|2010-05-25|2010-05-26|Estimate|2013-11-08|2013-12-10|Estimate||||2013-11-08|2013-12-10|Estimate|April 2010||2010-04-30|November 2013|2013-11-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional||All participants were randomized and dispensed lenses at the baseline visit.|A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens|A Study to Assess the Safety and Efficacy of a Daily Disposable Contact Lens|Completed||N/A|200|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 23:45:12.395347|2018-05-31 23:45:12.395347
NCT01130961|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-10-06|2010-05-25|2010-05-26|Estimate|||||||2010-10-06|2010-10-07|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand|Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand|Completed|||104|Actual|AstraZeneca|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 23:45:13.141581|2018-05-31 23:45:13.141581
NCT01130948|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2014-05-18|2010-05-25|2010-05-26|Estimate|||||||2014-05-18|2014-05-20|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects|Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects|Completed||N/A|51|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 23:45:13.288695|2018-05-31 23:45:13.288695
NCT01130935|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-02-23|2010-05-25|2010-05-26|Estimate|||||||2011-02-23|2011-02-24|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium|A National, Multicentre, Open-label, Non-comparative, Non-interventional Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium|Completed|||491|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:45:13.513098|2018-05-31 23:45:13.513098
NCT01130922|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2011-04-15|2010-05-25|2010-05-26|Estimate|||||||2011-04-15|2011-04-18|Estimate|March 2010||2010-03-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|DRUG10_MOXI||Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass|Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass.|Completed||Phase 4|12|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 23:45:13.622722|2018-05-31 23:45:13.622722
NCT01130909|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2014-10-10|2010-05-25|2010-05-26|Estimate|||||||2014-10-10|2014-10-13|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|AZD6765 EEG||A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765|A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo|Terminated||Phase 1|36|Actual|AstraZeneca||4||"The benefit of halting the study to analyze the available data outweighs the benefit of~   delaying the analysis to include data from remaining treatment periods"|f||||f||||||||||2018-05-31 23:45:13.709628|2018-05-31 23:45:13.709628
NCT01130896|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2017-03-22|2010-05-25|2010-05-26|Estimate|||||||2017-03-22|2017-03-24|Actual|May 2003|Actual|2003-05-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Clinically Indicated Magnetic Resonance Imaging in Patients With Cardiac Devices|Clinically Indicated Magnetic Resonance Imaging of Patients With Permanent Pacemakers (PPM) and Implantable Defibrillators (ICD)|Completed|||1000|Actual|Johns Hopkins University|||1||f||||t||||||||Yes||2018-05-31 23:45:13.836369|2018-05-31 23:45:13.836369
NCT01130883|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2011-07-25||2011-09-08|2010-05-25|2010-05-26|Estimate|2011-07-25|2011-08-23|Estimate||||2011-09-08|2011-09-12|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR|Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR in Patients With Upper Respiratory Infection, Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in the Czech Republic|Completed|||3130|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:45:13.994092|2018-05-31 23:45:13.994092
NCT01130870|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-11-09|2010-05-25|2010-05-26|Estimate|||||||2011-11-09|2011-11-10|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Dose Response Curve - Sacral Nerve Stimulation for Faecal Incontinence|Dose Response Curve - Sacral Nerve Stimulation for Faecal Incontinence|Completed||N/A|19|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:45:14.684739|2018-05-31 23:45:14.684739
NCT01130857|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-25|2010-05-25|2010-05-26|Estimate|||||||2010-05-25|2010-05-26|Estimate|July 2010||2010-07-31|January 2010|2010-01-31|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Observational|||Diagnostic Study of Temporal Arteritis|Diagnostic Tools in Temporal Arteritis - Towards the Development of a Diagnostic Algorithm|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:45:14.825559|2018-05-31 23:45:14.825559
NCT01130844|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2014-05-09||2015-06-15|2010-05-25|2010-05-26|Estimate|2015-06-15|2015-07-09|Estimate||||2015-06-15|2015-07-09|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis|A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis|Completed||Phase 1|52|Actual|Shire||3|||f||||f||||||||||2018-05-31 23:45:14.932551|2018-05-31 23:45:14.932551
NCT01130831|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-04-19||2013-07-09|2010-05-25|2010-05-26|Estimate|2013-04-19|2013-07-04|Estimate||||2013-07-09|2013-07-26|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational||Safety Analysis Set included all screened subjects who took at least 1 dose of lanthanum carbonate and for whom 1 follow-up assessment was completed (n = 61).|Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy|A Phase IV, Multi-Centre, Non-interventional Study Evaluating the Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium Based Phosphate Binder Therapy on Serum Phosphorous Control, Concomitant Vitamin D Therapy and Bone Related Biochemical Parameters in End Stage Renal Disease Patients on Hemodialysis|Completed|||66|Actual|Shire|||||f||||||||||||||2018-05-31 23:45:15.511132|2018-05-31 23:45:15.511132
NCT01130818|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-09-20|2010-05-25|2010-05-26|Estimate|||||||2010-09-20|2010-09-21|Estimate|May 2010||2010-05-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||First-in-Human Single Ascending Dose of GLPG0492|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of GLPG0492 in Healthy Subjects and Open Relative Bioavailability Study of Oral Solution Versus Solid Formulation, Fasted and Fed, in Elderly Subjects|Completed||Phase 1|28|Actual|Galapagos NV||5|||f||||f||||||||||2018-05-31 23:45:15.962121|2018-05-31 23:45:15.962121
NCT01130805|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2016-04-13|2010-05-25|2010-05-26|Estimate|||||||2016-04-13|2016-04-15|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||A Study of Pazopanib With CAPEOX in AGC Patients|A Phase II Study of Pazopanib in Combination With Capecitabine and Oxaliplatin (CAPEOX) in Patients With Advanced Gastric Cancer|Completed||Phase 2|66|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 23:45:16.023764|2018-05-31 23:45:16.023764
NCT01130792|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2015-02-02|2010-05-25|2010-05-26|Estimate|||||||2015-02-02|2015-02-04|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Probiotics for Infectious Diarrhea in Children in South India|Probiotics for Infectious Diarrhea in Children in South India|Completed||Phase 1/Phase 2|124|Actual|Christian Medical College, Vellore, India||2|||f||||t||||||||||2018-05-31 23:45:16.18964|2018-05-31 23:45:16.18964
NCT01130779|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-25|2010-05-25|2010-05-26|Estimate|||||||2010-05-25|2010-05-26|Estimate|August 2009||2009-08-31|May 2010|2010-05-31||||August 2010|Anticipated|2010-08-31||Interventional|||The Continuation of Erlotinib|The Continuation of Erlotinib Treatment in Non-small Cell Lung Cancer Patients Whose Brain Lesion is the Only Site of Progression : Pilot Study|Unknown status|Enrolling by invitation|Phase 2|23|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 23:45:16.266061|2018-05-31 23:45:16.266061
NCT01130766|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2010-05-25|2010-05-25|2010-05-26|Estimate|||||||2010-05-25|2010-05-26|Estimate|June 2008||2008-06-30|April 2010|2010-04-30||||May 2011|Anticipated|2011-05-31||Interventional|||Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)|Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC)|Unknown status|Enrolling by invitation|Phase 3|176|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 23:45:16.355776|2018-05-31 23:45:16.355776
NCT01130753|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-05-29|2010-05-25|2010-05-26|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer|A Phase II Trial of Neoadjuvant Erlotinib (Tarceva®) Followed by Surgery for Selected Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer|Completed||Phase 2|43|Anticipated|Samsung Medical Center|||||f||||||||||||||2018-05-31 23:45:16.425485|2018-05-31 23:45:16.425485
NCT01130740|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2014-11-26||2015-04-06|2010-05-25|2010-05-26|Estimate|2015-01-15|2015-01-26|Estimate||||2015-04-06|2015-04-28|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Patient and Provider Interventions for Managing Osteoarthritis in Primary Care|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care|Completed||N/A|300|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:45:16.507941|2018-05-31 23:45:16.507941
NCT01130727|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-04-17|2010-05-24|2010-05-26|Estimate|||||||2012-04-17|2012-04-19|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Effect of Green Tea or Cocoa Extracts in Endothelial Dysfunction in Patients With Diabetes Mellitus|Randomized Clinical Trial, Placebo Controlled, With Parallel Groups to Investigate Whether Green Tea or Cocoa Extracts Improves Endothelial Dysfunction in Patients With Diabetes Mellitus and Nephropathy and Hypertension|Completed||N/A|51|Actual|University of Campinas, Brazil||4|||f||||f||||||||||2018-05-31 23:45:17.046315|2018-05-31 23:45:17.046315
NCT01130714|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2015-08-19|2010-05-25|2010-05-26|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Resistance Training in Lung Cancer Patients on Chemotherapy|Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy|Completed||N/A|15|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 23:45:17.148385|2018-05-31 23:45:17.148385
NCT01130701|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2015-03-13|2010-05-25|2010-05-26|Estimate|||||||2015-03-13|2015-03-17|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PMABIIS||A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .|A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma|Withdrawn||Phase 2|0|Actual|University of Massachusetts, Worcester||||"Study never went beyond FDA application for an IND #. FDAA required institutional DSMC which~   this institution then lacked."|f||||f||||||||||2018-05-31 23:45:17.230722|2018-05-31 23:45:17.230722
NCT01130688|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2015-05-26|2010-05-25|2010-05-26|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|December 2014|Actual|2014-12-31|October 2012|Actual|2012-10-31||Interventional|||Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.|Phase I Study to Evaluate the Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in Patients With Chronic Myelogenous Leukemia|Terminated||Phase 1|2|Actual|University of Massachusetts, Worcester||1||Lack of enrollment|f||||f||||||||||2018-05-31 23:45:17.317453|2018-05-31 23:45:17.317453
NCT01130675|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-06-10|2010-05-25|2010-05-26|Estimate|||||||2013-06-10|2013-06-11|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Does Coffee Consumption Prevent or Shorten Postoperative Ileus After Colon Resection?|Does Coffee Consumption Prevent or Shorten Postoperative Ileus After Colon Resection? A Prospective Randomized Clinical Trial|Completed||Phase 3|44|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 23:45:17.423579|2018-05-31 23:45:17.423579
NCT01130662|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-03-25|2010-05-24|2010-05-26|Estimate|||||||2013-03-25|2013-03-26|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia|Phase I Open-Label Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients With Acute Myeloid Leukemia|Completed||Phase 1|16|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 23:45:17.490527|2018-05-31 23:45:17.490527
NCT01130649|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-05-01|2010-05-25|2010-05-26|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2010||2010-07-31|May 2017|2017-05-31|July 2013|Anticipated|2013-07-31|July 2011|Anticipated|2011-07-31||Observational|||Remote Tracking of Epilepsy Patients|Pilot Study of Real-time Automated Tracking System for Patients With Epilepsy|Withdrawn|||0|Actual|University of California, San Francisco|||2|not funded|f||||f||||||||||2018-05-31 23:45:17.619633|2018-05-31 23:45:17.619633
NCT01130636|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2012-10-04|2010-05-25|2010-05-26|Estimate|||||||2012-10-04|2012-10-08|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation|An Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation, Phase IV Trial|Completed||Phase 4|6|Actual|Pharmahungary Group||1|||f||||t||||||||||2018-05-31 23:45:17.726707|2018-05-31 23:45:17.726707
NCT01130623|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2017-06-30|2010-05-25|2010-05-26|Estimate|||||||2017-06-30|2017-07-02|Actual|May 10, 2010||2010-05-10|November 18, 2011|2011-11-18|November 18, 2011|Actual|2011-11-18|November 18, 2011|Actual|2011-11-18||Interventional|||A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors|A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:45:17.797613|2018-05-31 23:45:17.797613
NCT01130610|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-05-24|2010-05-24|2010-05-26|Estimate|||||||2010-05-24|2010-05-26|Estimate|September 2009||2009-09-30|May 2010|2010-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Pre-anesthetic Evaluation and Cost Reduction|Pre-anesthetic Evaluation and Cost Reduction Perioperative|Completed|||200|Actual|Santa Casa de Misericórdia de Belo Horizonte|||||f||||t||||||||||2018-05-31 23:45:17.868028|2018-05-31 23:45:17.868028
NCT01130597|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2015-11-11|2014-10-30|2015-12-21|2010-05-24|2010-05-26|Estimate|2015-12-21|2016-01-28|Estimate|2014-10-30|2014-11-06|Estimate|2015-12-21|2016-01-28|Estimate|May 2010||2010-05-31|December 2015|2015-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease|A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for Patiromer in Heart Failure Patients With Chronic Kidney Disease|Completed||Phase 2|63|Actual|Relypsa, Inc.||1|||f||||f||||||||||2018-05-31 23:45:17.956304|2018-05-31 23:45:17.956304
NCT01130584|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-12-10|2010-05-25|2010-05-26|Estimate|||||||2013-12-10|2013-12-11|Estimate|April 2010||2010-04-30|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer||Completed|||||National University Hospital, Singapore|||1||f||||||||||||||2018-05-31 23:45:18.265335|2018-05-31 23:45:18.265335
NCT01130571|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-01-21|2010-05-25|2010-05-26|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Establishment and Characterization of Patient-Derived Non-Small Cell Lung Cancer Xenografts and Cell Cultures||Unknown status|Recruiting||||National University Hospital, Singapore|||1||f||||||||||||||2018-05-31 23:45:18.340269|2018-05-31 23:45:18.340269
NCT01130558|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-05-24|2010-05-24|2010-05-26|Estimate|||||||2010-05-24|2010-05-26|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Structured Insulin Order|Efficacy of Structured Insulin Orders in Improving Glycemic Control|Completed||N/A|128|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:45:18.55541|2018-05-31 23:45:18.55541
NCT01130545|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-05-17|2010-05-25|2010-05-26|Estimate|||||||2018-05-17|2018-05-18|Actual|May 10, 2010||2010-05-10|October 24, 2017|2017-10-24||||||||Observational|||Imaging Techniques in MRI|Imaging Techniques in MRI|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:45:18.644638|2018-05-31 23:45:18.644638
NCT01130532|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2012-12-03||2012-12-03|2010-05-24|2010-05-26|Estimate|2012-12-03|2013-01-04|Estimate||||2012-12-03|2013-01-04|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study in Erectile Dysfunction|Tadalafil Once Daily Following As-Needed Phosphodiesterase Type 5 Inhibitor Treatment, an Assessment of Return to Normal Erectile Function|Completed||Phase 4|623|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:45:18.772912|2018-05-31 23:45:18.772912
NCT01130519|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2018-05-30|2010-05-25|2010-05-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 4, 2010||2010-05-04|May 2, 2018|2018-05-02|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer|A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer|Recruiting||Phase 2|85|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 23:45:20.721311|2018-05-31 23:45:20.721311
NCT01130506|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2017-08-01|2010-05-25|2010-05-26|Estimate|||||||2017-08-01|2017-08-02|Actual|May 17, 2010|Actual|2010-05-17|July 2017|2017-07-31||||November 19, 2012|Actual|2012-11-19||Interventional|||Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome|Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia|Completed||Phase 1|17|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:45:20.826857|2018-05-31 23:45:20.826857
NCT01130493|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2016-08-03|2013-09-27|2017-09-12|2010-05-24|2010-05-26|Estimate|2017-08-15|2017-09-13|Actual|2013-09-27|2013-10-28|Estimate|2017-09-12|2017-10-13|Actual|May 2010||2010-05-31|September 2017|2017-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Participants who completed the Dose Conversion period and were randomized into the double-blind crossover portion of the study.|A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066|A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 in Advanced Parkinson's Disease|Completed||Phase 3|110|Actual|IMPAX Laboratories, Inc.||2|||f||||f||||||||No||2018-05-31 23:45:20.960625|2018-05-31 23:45:20.960625
NCT01130480|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2017-04-03|2010-05-24|2010-05-26|Estimate|||||||2017-04-03|2017-04-04|Actual|May 31, 2010|Actual|2010-05-31|April 2017|2017-04-30|March 31, 2012|Actual|2012-03-31|March 31, 2012|Actual|2012-03-31||Interventional|||Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study|Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized Study|Completed||N/A|833|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:45:21.627677|2018-05-31 23:45:21.627677
NCT01130467|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-08-08|2010-05-25|2010-05-26|Estimate|||||||2010-08-08|2010-08-10|Estimate|September 2009||2009-09-30|May 2010|2010-05-31||||December 2011|Anticipated|2011-12-31||Observational|||Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder||Unknown status|Recruiting||150|Anticipated|Far Eastern Memorial Hospital|||3||f||||||||||||||2018-05-31 23:45:22.052109|2018-05-31 23:45:22.052109
NCT01130454|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-11-24|2010-05-25|2010-05-26|Estimate|||||||2010-11-24|2010-11-25|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||A Study for Evaluating the SCIO Biofeedback Device's Ability to Increase Body Wellness After One 45-minute Session|A Double-blind Placebo-controlled Study of the Application of the SCIO Universal Electrophysiological Biofeedback System for Statistical Evaluation of the SCIO's Ability to Increase Body Wellness After One 45-minute Session|Completed||Phase 2|151|Actual|Maitreya Kft.||2|||f||||f||||||||||2018-05-31 23:45:22.183744|2018-05-31 23:45:22.183744
NCT01130441|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-01-09|2010-05-25|2010-05-26|Estimate|||||||2013-01-09|2013-01-11|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Self-harming Behaviors Study of Adolescents in a Juvenile Detention House|Study on Self-harming Behaviors of Adolescents in a Juvenile Detention House|Completed|||277|Actual|Far Eastern Memorial Hospital|||2||f||||t||||||||||2018-05-31 23:45:22.351487|2018-05-31 23:45:22.351487
NCT01130428|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-04-19|2010-05-25|2010-05-26|Estimate|||||||2011-04-19|2011-04-20|Estimate|October 2010||2010-10-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Mechanical Bone Stimulation and Adenosine 5'-Triphosphate (ATP) Release in Humans|Pilot Study on the Effect of Mechanical Stimulation of Bone on ATP Release in Humans in Vivo|Completed||Phase 1/Phase 2|10|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 23:45:22.509069|2018-05-31 23:45:22.509069
NCT01130415|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-05-25|2010-05-25|2010-05-26|Estimate|||||||2010-05-25|2010-05-26|Estimate|May 2002||2002-05-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Observational|||Screening Method in Sacral Neuromodulation|Is the Method of Screening in Sacral Neuromodulation a Prognostic Factor for Long-term Success?|Completed|||64|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 23:45:22.589102|2018-05-31 23:45:22.589102
NCT01130402|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-05-25|2010-05-25|2010-05-26|Estimate|||||||2010-05-25|2010-05-26|Estimate|June 2009||2009-06-30|April 2009|2009-04-30|September 2009|Actual|2009-09-30|||||Observational|||A Real-time and Computerized Sonographic Reporting System in Predicting Malignant Cervical Lymphadenopathy|A Real-time and Computerized Sonographic Scoring System for Predicting Malignant Cervical Lymphadenopathy|Completed|||189|Actual|Far Eastern Memorial Hospital|||1||f||||t||||||||||2018-05-31 23:45:22.753239|2018-05-31 23:45:22.753239
NCT01130389|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-06-14|2010-05-24|2010-05-26|Estimate|||||||2011-06-14|2011-06-16|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||CONDOR Study of Osteonecrosis of the Jaws (TMJ)|Trans-PBRN Case-control Study of Osteonecrosis of the Jaws|Completed|||309|Actual|Dental Practice-Based Research Network|||||f||||f||||||||||2018-05-31 23:45:22.851568|2018-05-31 23:45:22.851568
NCT01130376|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2013-09-02|2010-05-25|2010-05-26|Estimate|||||||2013-09-02|2013-09-04|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|IMIRC1003||Novel Interventions in HIV-1 Infection|A Randomised, Open Labelled, Phase I, Safety, Toxicity, and Exploratory Immunogenicity Evaluation of Therapeutic Immunisation +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly Active Anti-retroviral Therapy|Terminated||Phase 1|12|Actual|Imperial College London||3||"Data from the 12 patients recruited has now been analysed, and it has been determined that it~   is sufficient to meet the study objectives."|f||||t||||||||||2018-05-31 23:45:22.968047|2018-05-31 23:45:22.968047
NCT01130363|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2012-06-29|2010-05-24|2010-05-26|Estimate|||||||2012-06-29|2012-07-02|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Fundic Gland Polyps and Proton Pump Inhibitor (PPI) Drugs|Determination of a Possible Association of Fundic Gland Polyps With the Use of Proton Pump Inhibitor Drugs|Terminated|||23|Actual|Columbia University|||3|Poor Enrollment|f||||t||||||Samples With DNA|"~     Blood draw: A fasting serum gastrin (FSG) level will be obtained to evaluate for~     hypergastrinemia at a follow-up visit after EGD. Approximately 4 cc's of blood is required.~     As many patients have been on long term PPI therapy, the FSG level is one method of~     determining whether the patient is on super-therapeutic levels of PPI which may need to be~     adjusted.~      Biopsy specimens: Gastric fundic gland polyps found during endoscopy will have biopsies taken~     of the polyp, adjacent normal gastric body or fundus, and from the antrum.~      Histological evaluation of biopsy specimens: Biopsies will be stained with H&E as well as~     neuroendocrine cell markers to assess for the presence of ECL cell hyperplasia.~     Paraffin-fixed tissue will be stored for future biological analysis. This will only be done~     after all clinically relevant analyses are completed and only if adequate tissue remains.~   "|||2018-05-31 23:45:23.091409|2018-05-31 23:45:23.091409
NCT01130337|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|2015-09-01||2015-09-01|2010-05-25|2010-05-26|Estimate|2015-09-01|2015-10-01|Estimate||||2015-09-01|2015-10-01|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Intent-to-treat (ITT) population included all enrolled participants.|A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer|An Open-label, Multi-center Study to Evaluate the Disease Free Survival Rate of a Perioperative Combination of Capecitabine (Xeloda), Trastuzumab (Herceptin) and Oxaliplatin (XELOX- Trastuzumab) in Patients With Resectable Gastric or Gastro-esophageal Junction Adenocarcinoma|Completed||Phase 2|36|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:45:23.177673|2018-05-31 23:45:23.177673
NCT01130324|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-07-18|2010-05-25|2010-05-26|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2009||2009-11-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|9 Months|Observational [Patient Registry]|||VIBATIV Pregnancy Registry|VIBATIV (Telavancin Hydrochloride) Pregnancy Exposure Registry|Recruiting|||300|Anticipated|Theravance Biopharma Antibiotics, Inc.|||1||f||||t||||||||Undecided||2018-05-31 23:45:23.515159|2018-05-31 23:45:23.515159
NCT01130311|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-25|||2011-06-27|2010-05-25|2010-05-26|Estimate|||||||2011-06-27|2011-06-28|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|SUCCINCT||Replacement of Vitamin D in Patients With Active Tuberculosis|A Randomized, Placebo-Controlled, Double-Blinded, 250-Subject Clinical Trial of Vitamin D Replacement in Patients With Pulmonary Tuberculosis|Completed||N/A|259|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 23:45:23.600174|2018-05-31 23:45:23.600174
NCT01130298|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-12-05|2010-05-25|2010-05-26|Estimate|||||||2017-12-05|2017-12-07|Actual|May 2010||2010-05-31|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier|An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier|Completed||Phase 1|24|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:45:23.69634|2018-05-31 23:45:23.69634
NCT01130285|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-12-06|2010-05-24|2010-05-25|Estimate|||||||2017-12-06|2017-12-08|Actual|May 2011||2011-05-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|August 2018|Anticipated|2018-08-31||Observational|||Validation of a Multi-gene Test for Lung Cancer Risk|Validation of a Multi-gene Test for Lung Cancer Risk|Active, not recruiting|||403|Actual|University of Toledo Health Science Campus|||1||f||||f||||||Samples With DNA|"~     Normal bronchial epithelial cell (NBEC) RNA. NBEC samples were obtained by bronchoscopic~     brushing after informed consent to this project was obtained. RNA was extracted and frozen in~     aliquots then archived. Two aliquots, were prepared for most subjects. In most cases, there~     were more than 1 microgram of RNA per aliquot.~   "|||2018-05-31 23:45:23.79666|2018-05-31 23:45:23.79666
NCT01129908|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-23|||2016-12-18|2010-05-24|2010-05-25|Estimate|||||||2016-12-18|2016-12-20|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Saliva Composition and Oral Hygiene in Children With Celiac Disease Before and After the Change in Diet|Saliva Composition and Oral Hygiene in Children With Celiac Disease Before and After the Change in Diet|Completed|||90|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-05-31 23:45:28.910792|2018-05-31 23:45:28.910792
NCT01130272|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24||2011-09-09|2012-06-11|2010-05-24|2010-05-25|Estimate||||2011-09-09|2011-09-21|Estimate|2012-06-11|2012-06-13|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea|Completed||Phase 2|807|Actual|Furiex Pharmaceuticals, Inc||5|||f||||f||||||||||2018-05-31 23:45:24.031085|2018-05-31 23:45:24.031085
NCT01130259|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-09-14|2010-05-24|2010-05-25|Estimate|||||||2013-09-14|2013-09-17|Estimate||||September 2013|2013-09-30||||||||Expanded Access|||An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer|An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in Patients With ER-, PR-, and HER2-Negative Metastatic Breast Cancer|No longer available|||||Sanofi|||||||||||||||||||2018-05-31 23:45:24.544826|2018-05-31 23:45:24.544826
NCT01130246|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2012-10-30|2010-05-24|2010-05-25|Estimate|||||||2012-10-30|2012-10-31|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|VISTA-16||VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome|VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes|Terminated||Phase 3|5189|Actual|Anthera Pharmaceuticals||2||Lack of efficacy|f||||t||||||||||2018-05-31 23:45:24.702765|2018-05-31 23:45:24.702765
NCT01130233|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-05-24|2010-05-24|2010-05-25|Estimate|||||||2010-05-24|2010-05-25|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Randomized Trial on Robotic Assisted Resection for Rectal Cancer|Randomized Controlled Trial Comparing the Bladder and Sexual Functions of Patients Who Undergo Laparoscopic and Robotic Assisted Resection for Rectal Cancer|Unknown status|Recruiting|Phase 3|98|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:45:25.183764|2018-05-31 23:45:25.183764
NCT01130220|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2012-07-24|2010-05-24|2010-05-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Study of the Health Information Needs of Brain Cancer Patients|Informed Brain Cancer Patients|Completed|||27|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 23:45:25.250775|2018-05-31 23:45:25.250775
NCT01130207|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-11-17|2010-05-24|2010-05-25|Estimate|||||||2014-11-17|2014-11-19|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Microbes and Bariatric Surgery|Effects of Bariatric Surgery on the Gastro-intestinal Microflora|Completed|||34|Actual|State University of New York - Upstate Medical University|||||f||||f||||||Samples With DNA|"~     Bacterial samples from dental plaque and feces, and serum~   "|||2018-05-31 23:45:25.397203|2018-05-31 23:45:25.397203
NCT01130194|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-05-09|2010-05-24|2010-05-25|Estimate|||||||2014-05-09|2014-05-12|Estimate|July 2006||2006-07-31|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MasterPlan||Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma|A Pilot Phase II Study Of Sequential Treatment With Chemotherapy, Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Follicular Lymphoma|Completed||Phase 2|29|Actual|St. Louis University||1|||f||||t||||||||||2018-05-31 23:45:25.458159|2018-05-31 23:45:25.458159
NCT01130181|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2014-05-23|2010-05-24|2010-05-25|Estimate|||||||2014-05-23|2014-05-28|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|VITdAL@ICU||VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients|"Correction of Vitamin D Deficiency in Critically Ill Patients: a Randomized, Double-blind, Placebo-controlled Trial (VITDAL@ICU)"|Completed||Phase 3|480|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 23:45:25.529407|2018-05-31 23:45:25.529407
NCT01130168|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2012-02-23||2015-10-08|2010-05-24|2010-05-25|Estimate|2012-04-26|2012-05-28|Estimate||||2015-10-08|2015-10-09|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Crossover Study to Evaluate the Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Subjects and Patients With Hypertension|Completed||Phase 1|38|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 23:45:25.634523|2018-05-31 23:45:25.634523
NCT01130155|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-06-22|2010-05-24|2010-05-25|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Observational|IMPACT2||IMPACT2: Monitoring Interventions to Improve Artemisinin-based Combination Therapy (ACT) Access and Targeting|IMPACT2: Monitoring Interventions to Improve ACT Access and Targeting|Unknown status|Active, not recruiting||33900|Anticipated|London School of Hygiene and Tropical Medicine|||3||f||||t||||||||||2018-05-31 23:45:26.120842|2018-05-31 23:45:26.120842
NCT01130142|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21||2013-06-13|2017-03-02|2010-05-24|2010-05-25|Estimate||||2013-06-13|2013-06-21|Estimate|2017-03-02|2017-03-06|Actual|April 2010||2010-04-30|March 2017|2017-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer|A Phase 1b/2 Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|122|Actual|Infinity Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:45:26.215368|2018-05-31 23:45:26.215368
NCT01130129|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2013-03-05|2010-05-24|2010-05-25|Estimate|||||||2013-03-05|2013-03-06|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effects of Plant Bioactives on Platelet Function|The Effects of Plant Bioactives on Platelet Function|Completed||N/A|15|Actual|Quadram Institute||1|||f||||f||||||||||2018-05-31 23:45:26.377031|2018-05-31 23:45:26.377031
NCT01130103|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|2012-07-09||2012-11-30|2010-05-24|2010-05-25|Estimate|2012-07-09|2012-08-14|Estimate||||2012-11-30|2012-12-04|Estimate|March 2004||2004-03-31|November 2012|2012-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack|Combination Treatment for PTSD After the WTC Attack|Completed||Phase 4|37|Actual|Research Foundation for Mental Hygiene, Inc.||2|||f||||f||||||||||2018-05-31 23:45:26.490852|2018-05-31 23:45:26.490852
NCT01130090|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-02-23|2010-05-24|2010-05-25|Estimate|||||||2011-02-23|2011-02-24|Estimate|September 2008||2008-09-30|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Patient-ventilator Interactions in Long Term Non-invasive Ventilation: Influence of Back-up Frequency|Patient-ventilator Interactions in Long Term Non-invasive Ventilation (NIV): Influence of Back-up Frequency|Completed||N/A|10|Anticipated|Ligue Pulmonaire Genevoise|||||f||||t||||||||||2018-05-31 23:45:26.930169|2018-05-31 23:45:26.930169
NCT01130077|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2018-01-12|2010-05-24|2010-05-25|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2009||2009-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas|A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas|Recruiting||N/A|60|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 23:45:27.014722|2018-05-31 23:45:27.014722
NCT01130064|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-02-20|2010-05-24|2010-05-25|Estimate|||||||2017-02-20|2017-02-23|Actual|May 2010||2010-05-31|February 2017|2017-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy of QAX576 in Asthma|A Multi-center, Randomized, Double Blind, Placebo-controlled, 'add-on' Study to Investigate the Efficacy and Safety of 24 Weeks Intravenous Treatment With QAX576 in Patients (≥18-75 Years) With Persistent Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting β2-agonists|Completed||Phase 2|259|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:45:27.135633|2018-05-31 23:45:27.135633
NCT01130051|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2011-04-05||2011-05-10|2010-05-24|2010-05-25|Estimate|2011-04-05|2011-05-11|Estimate||||2011-05-10|2011-05-12|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce|A Pilot Bioavailability Study of Colcrys® Tablet 0.6 mg Versus Colcrys® Tablets 0.6 mg Crushed and Sprinkled on Applesauce Under Fasting Conditions|Completed||Phase 1|16|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-05-31 23:45:27.324798|2018-05-31 23:45:27.324798
NCT01130038|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2011-08-27|2010-05-24|2010-05-25|Estimate|||||||2011-08-27|2011-08-30|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Characteristic of Play: Comparison Between Children With Development Coordination Disorder ( DCD) and Children With Typical Development||Completed|||64|Actual|Meir Medical Center|||2||f||||f||||||||||2018-05-31 23:45:27.596939|2018-05-31 23:45:27.596939
NCT01130025|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-06-13|2010-05-24|2010-05-25|Estimate|||||||2014-06-13|2014-06-16|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer|Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT|Completed||Phase 3|900|Actual|LEO Pharma||2|||f||||t||||||||||2018-05-31 23:45:27.734721|2018-05-31 23:45:27.734721
NCT01130012|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-12-14|2010-05-24|2010-05-25|Estimate|||||||2010-12-14|2010-12-15|Estimate|April 2005||2005-04-30|December 2010|2010-12-31|December 2006|Actual|2006-12-31|May 2006|Actual|2006-05-31||Interventional|||Prevention of Gestational Diabetes|Feasibility of a Lifestyle Intervention in Early Risk Pregnancy in Preventing Deterioration in Glucose Tolerance?|Completed||N/A|440|Actual|Kuopio University Hospital||2|||f||||||||||||||2018-05-31 23:45:27.884155|2018-05-31 23:45:27.884155
NCT01129999|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-02-03|2010-05-24|2010-05-25|Estimate|||||||2014-02-03|2014-02-04|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CBT-HT||Cognitive-Behavioral Therapy and Hypnotherapy for Smoking Cessation|The Comparative Efficacy of Cognitive-Behavioral Therapy (CBT) and Hypnotherapy (HT) for Smoking Cessation.|Completed||N/A|360|Actual|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 23:45:27.948239|2018-05-31 23:45:27.948239
NCT01129986|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-09-02|2010-05-24|2010-05-25|Estimate|||||||2013-09-02|2013-09-04|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|November 2011|Actual|2011-11-30|July 2010|Actual|2010-07-31||Interventional|||A Post Marketing Clinical Study Utilizing DermaStream and Saline in Venous Ulcers|A Post Marketing Clinical Study Utilizing DermaStream and Saline for Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremity|Completed||N/A|15|Actual|EnzySurge||1|||f||||||||||||||2018-05-31 23:45:28.048398|2018-05-31 23:45:28.048398
NCT01129973|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2010-05-24|2010-05-24|2010-05-25|Estimate|||||||2010-05-24|2010-05-25|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|Audiologist||Profile of Marketing Professional Audiologist Who Works in the Area of Audiology Clinic|Profile of Marketing Professional Audiologist Who Works in the Area of Audiology Clinic|Completed|||30|Actual|Fortaleza University|||||f||||t||||||None Retained|"~     no biospecimens are to be retained.~   "|||2018-05-31 23:45:28.123857|2018-05-31 23:45:28.123857
NCT01129960|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2014-01-10||2014-07-17|2010-05-24|2010-05-25|Estimate|2014-07-17|2014-07-18|Estimate||||2014-07-17|2014-07-18|Estimate|November 2010||2010-11-30|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain|A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain|Terminated||Phase 3|332|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 23:45:28.179347|2018-05-31 23:45:28.179347
NCT01129947|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-23|||2013-01-26|2010-05-24|2010-05-25|Estimate|||||||2013-01-26|2013-01-29|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Use of DHEA in Women With Premature Ovarian Failure|The Use of DHEA in Women With Premature Ovarian Failure|Withdrawn||Early Phase 1|0|Actual|Virginia Center for Reproductive Medicine||1||very poor patient recruitement|f||||t||||||||||2018-05-31 23:45:28.565571|2018-05-31 23:45:28.565571
NCT01129934|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-05-23|2010-05-23|2010-05-25|Estimate|||||||2010-05-23|2010-05-25|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|January 2013|Anticipated|2013-01-31|December 2011|Anticipated|2011-12-31||Interventional|||Morphine Versus Morphine-promethazine Combination for Acute Low Back Pain Relief in the Adult Emergency Department|Pharmacological Anxiolysis With Promethazine as an Adjunctive Therapy for Acute Low Back Pain in the Adult Emergency Department|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 23:45:28.62843|2018-05-31 23:45:28.62843
NCT01129921|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2013-01-07||2013-06-11|2010-05-23|2010-05-25|Estimate|2013-06-11|2013-07-16|Estimate||||2013-06-11|2013-07-16|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||ITT analysis includes all patients at weeks 6 to 12 post-treatment. Year 1 cohort analysis includes the 18 mild patients who reported outcomes at Year 1 and the 13 sham patients who reported outcomes at Year 1 after cross-over to mild.|Comparative Study of Sham Versus Mild® Procedure in Patients Diagnosed With Symptomatic Lumbar Central Canal Stenosis|Comparative Study of Sham Versus Mild® (Minimally Invasive Lumbar Decompression) Procedure in Patients Diagnosed With Symptomatic Moderate to Severe Lumbar Central Canal Stenosis|Completed||N/A|40|Actual|Napa Pain Institute|This was a small series with challenging patient retention, particularly in the sham arm.|2|||f||||f||||||||||2018-05-31 23:45:28.707039|2018-05-31 23:45:28.707039
NCT01129895|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-22|||2010-06-02|2010-05-24|2010-05-25|Estimate|||||||2010-06-02|2010-06-03|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|May 2011|Anticipated|2011-05-31|January 2011|Anticipated|2011-01-31||Interventional|PHASE||Promoting Health by Self Experience (PHASE) Randomized Controlled Trial|Promoting Health by Self Experience (PHASE) Randomized Controlled Trial|Unknown status|Recruiting|N/A|650|Anticipated|Unilever Israel||2|||f||||f||||||||||2018-05-31 23:45:28.956706|2018-05-31 23:45:28.956706
NCT01129882|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-22|||2017-07-27|2010-05-22|2010-05-25|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2010||2010-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ASPIRE||An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia|An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia|Active, not recruiting||Phase 3|709|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-05-31 23:45:29.959121|2018-05-31 23:45:29.959121
NCT01129869|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-22|||2018-04-04|2010-05-22|2010-05-25|Estimate|||||||2018-04-04|2018-04-05|Actual|May 13, 2010||2010-05-13|February 1, 2018|2018-02-01|February 1, 2018||2018-02-01|||||Observational|||Research Participant Perception of Care Project: Part II: Fielding and Validation of the Research Participant Perception Survey Derived From Focus Group-Identified Key Dimensions of the Research Participant Experience|Research Participant Perception of Care Project: Part II: Fielding and Validation of the Research Participant Perception Survey Derived From Focus Group-Identified Key Dimensions of the Research Participant Experience|Completed|||743|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:45:30.332462|2018-05-31 23:45:30.332462
NCT01129856|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-04-25|2010-05-22|2010-05-25|Estimate|||||||2011-04-25|2011-04-27|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye|Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for the Treatment of Dry Eye in the Controlled Adverse Environment (CAE) Model|Completed||Phase 3|198|Actual|Eyegate Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 23:45:30.401003|2018-05-31 23:45:30.401003
NCT01129843|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-22|||2011-05-28|2010-05-24|2010-05-25|Estimate|||||||2011-05-28|2011-06-01|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|DOHBIT||Directly Observed Iron Supplementation to Treat Anemia|A Cluster Randomized Trial for Lowering Prevalence of Anemia in Rural Hilly Villages With Directly Observed Home Based Daily Iron Therapy(DOHBIT)|Completed||N/A|1000|Anticipated|Build Healthy India Movement||2|||f||||t||||||||||2018-05-31 23:45:30.503762|2018-05-31 23:45:30.503762
NCT01129830|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2014-09-18|2010-05-24|2010-05-25|Estimate|||||||2014-09-18|2014-09-22|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve|The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve|Terminated||Early Phase 1|200|Actual|Virginia Center for Reproductive Medicine||1||Suboptimal recruitment|f||||t||||||||||2018-05-31 23:45:30.591281|2018-05-31 23:45:30.591281
NCT01129817|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-05-24|2010-05-24|2010-05-25|Estimate|||||||2010-05-24|2010-05-25|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy of Classification Based 'Cognitive Functional Therapy' in Patients With Non Specific Chronic Low Back Pain|Efficacy of Classification Based 'Cognitive Functional Therapy' in Patients With Non Specific Chronic Low Back Pain (NSCLBP) - A Randomized Controlled Trial|Completed||N/A|121|Actual|University of Bergen||2|||f||||t||||||||||2018-05-31 23:45:30.671652|2018-05-31 23:45:30.671652
NCT01129804|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-07-27|2010-05-24|2010-05-25|Estimate|||||||2017-07-27|2017-08-01|Actual|September 2009||2009-09-30|July 2017|2017-07-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|Net Support 2||Network Support for Alcohol Treatment 2|Network Support for Alcohol Treatment: Mechanisms and Effectiveness|Completed||N/A|193|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 23:45:30.740842|2018-05-31 23:45:30.740842
NCT01129791|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-05-31|2010-05-24|2010-05-25|Estimate|||||||2017-05-31|2017-06-01|Actual|February 2010||2010-02-28|May 2017|2017-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Raw Versus Other Milk Sources on Lactose Digestion|Comparison of Raw Milk Consumption vs. Other Milk Sources on Lactose Digestion in Healthy Individuals With Self-reported Lactose Intolerance|Completed||N/A|16|Actual|Stanford University||3|||f||||f|f|f||||||No||2018-05-31 23:45:30.809479|2018-05-31 23:45:30.809479
NCT01129778|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2017-01-07||2017-06-02|2010-05-24|2010-05-25|Estimate|2017-06-02|2017-06-06|Actual||||2017-06-02|2017-06-06|Actual|November 2009||2009-11-30|June 2017|2017-06-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional||21 participants who underwent pH testing were evaluable for Baseline Characteristics.|Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus|Assessment of the Effects of Zegerid Powder for Oral Suspension 40 mg on 24-Hour and Nocturnal Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease and Barrett's Esophagus|Terminated||N/A|27|Actual|Stanford University|The limitations included the small sample size, a cohort of patients with primarily short-segment BE, and the fact that the study relied on comparison of intraoesophageal pH levels on Ome-NaBic to other PPIs based on historical controls.|1||change in the business strategy of the sponsor|f||||||||||||||2018-05-31 23:45:30.894293|2018-05-31 23:45:30.894293
NCT01129765|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2010-06-02||2010-07-27|2010-05-24|2010-05-25|Estimate|2010-06-02|2010-07-05|Estimate||||2010-07-27|2010-08-03|Estimate|July 2009||2009-07-31|July 2010|2010-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Home Usability of a Nasal Lavage System in Children|Home Usability of a Nasal Lavage System in Children|Completed|||30|Actual|Aardvark Medical Company|||1||f||||f||||||||||2018-05-31 23:45:31.065769|2018-05-31 23:45:31.065769
NCT01129752|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-06-21|2010-05-24|2010-05-25|Estimate|||||||2011-06-21|2011-06-23|Estimate|February 2004||2004-02-29|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Mothers With a History of Depression and Their 10-14 Year Old Daughters|The Neural Correlates of Mood and Cognitive Bias in a Population at Risk for Depression: Maternal Cognitive and Emotional Functioning|Completed|||240|Actual|Stanford University|||1||f||||||||||Samples With DNA|"~     All participants are asked to submit saliva samples during their second session using sterile~     salivette containers in order to assess cortisol levels. There is no risk involved in giving~     these samples.~   "|||2018-05-31 23:45:31.392288|2018-05-31 23:45:31.392288
NCT01129739|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-24|2010-05-24|2010-05-25|Estimate|||||||2010-05-24|2010-05-25|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes|Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat RA and RARS of MDS|Unknown status|Recruiting|Phase 2|30|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 23:45:31.478504|2018-05-31 23:45:31.478504
NCT01129726|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-02-15|2010-05-24|2010-05-25|Estimate|||||||2012-02-15|2012-02-17|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Fiberoptic Intubation and Transillumination-guided Fiberoptic Intubation：Success Rate and Time in Untrained Medical Personnel|Fiberoptic Intubation and Transillumination-guided Fiberoptic Intubation：Time and Success Rate in Untrained Medical Personnel|Completed||N/A|100|Actual|Second Military Medical University||1|||f||||t||||||||||2018-05-31 23:45:31.570406|2018-05-31 23:45:31.570406
NCT01129713|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2014-08-04|2010-05-24|2010-05-25|Estimate|||||||2014-08-04|2014-08-05|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.|Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Effexus Pharmaceutical||2|||f||||f||||||||||2018-05-31 23:45:31.662381|2018-05-31 23:45:31.662381
NCT01129700|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2012-04-25|2010-05-24|2010-05-25|Estimate|||||||2012-04-25|2012-04-27|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer|Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer: Phase II Multi-institutional Study|Completed||Phase 2|73|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 23:45:31.7784|2018-05-31 23:45:31.7784
NCT01129687|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2017-04-24|2010-05-24|2010-05-25|Estimate|||||||2017-04-24|2017-04-26|Actual|March 2005||2005-03-31|April 2017|2017-04-30|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|||Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy|Multicenter Prospective Analysis of Treatment Outcome in Patients With Large Acoustic Neuromas|Recruiting|||200|Anticipated|Stanford University|||1||f||||||||||||||2018-05-31 23:45:31.86957|2018-05-31 23:45:31.86957
NCT01129674|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21||2013-01-11|2013-01-11|2010-05-21|2010-05-25|Estimate||||2013-01-11|2013-01-21|Estimate|2013-01-11|2013-01-21|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Long-Term, Open-Label, Study on Schizophrenia|A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia|Terminated||Phase 2/Phase 3|1210|Anticipated|Eli Lilly and Company||2||"The decision to stop the trial was based on efficacy results in the overall schizophrenia~   participant population."|f||||f||||||||||2018-05-31 23:45:32.029827|2018-05-31 23:45:32.029827
NCT01129661|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2011-01-20|2010-05-21|2010-05-25|Estimate|||||||2011-01-20|2011-01-24|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers|An Adaptive, Phase I, Single-Centre, Randomised, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics, of Intravenous CSL112 in Healthy Volunteers|Completed||Phase 1|57|Actual|CSL Limited||2|||f||||f||||||||||2018-05-31 23:45:32.233471|2018-05-31 23:45:32.233471
NCT01129648|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21||2012-01-18|2012-01-18|2010-05-24|2010-05-25|Estimate||||2012-01-18|2012-01-23|Estimate|2012-01-18|2012-01-23|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout|A Randomized, Double-Blind, Multi-center, Placebo-Controlled, Combination Study to Evaluate the Urate-Lowering Activity, Safety, and Potential Pharmacokinetic Interaction of Oral BCX4208 and Allopurinol Administered in Subjects With Gout|Completed||Phase 2|87|Actual|BioCryst Pharmaceuticals||16|||f||||f||||||||||2018-05-31 23:45:32.298862|2018-05-31 23:45:32.298862
NCT01129635|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2015-01-17|2010-05-21|2010-05-24|Estimate|||||||2015-01-17|2015-01-21|Estimate|June 2010||2010-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Optimal Coronary Sinus Lead Implantation Using Intracardiac Impedography and Magnetic Resonance Imaging|Real-Time Intracardiac Impedograms of Left Ventricular Leads to Locate Sites of Latest Mechanical Delay in Cardiac Resynchronization Therapy|Completed||N/A|38|Actual|Emory University||1|||f||||t||||||||||2018-05-31 23:45:32.413797|2018-05-31 23:45:32.413797
NCT01129622|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2012-03-03||2014-04-01|2010-05-21|2010-05-24|Estimate|2014-04-01|2014-05-01|Estimate||||2014-04-01|2014-05-01|Estimate|October 2008||2008-10-31|April 2014|2014-04-30|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|RFCLET2||Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)|Phase II Study of the Effect of Acute Aromatase Inhibition on Breast MRI Postmenopausal Women|Completed||Phase 2|16|Actual|Mount Sinai Hospital, Canada|The small sample size is a limitation.|1|||f||||f||||||||||2018-05-31 23:45:32.502424|2018-05-31 23:45:32.502424
NCT01129609|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2018-02-05|2010-05-21|2010-05-24|Estimate|||||||2018-02-05|2018-02-07|Actual|April 2010||2010-04-30|February 2018|2018-02-28|September 29, 2017|Actual|2017-09-29|June 2013|Actual|2013-06-30||Observational|||Talent Converter Post-Approval Study|Talent Converter Post-Approval Study|Completed|||20|Actual|Medtronic Endovascular|||1||f||||f||||||||||2018-05-31 23:45:32.93211|2018-05-31 23:45:32.93211
NCT01129596|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-02-23|2010-05-21|2010-05-24|Estimate|||||||2017-02-23|2017-02-27|Actual|June 10, 2010|Actual|2010-06-10|January 2017|2017-01-31|April 1, 2016|Actual|2016-04-01|September 25, 2015|Actual|2015-09-25||Observational|||Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-|Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-|Completed|||10238|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 23:45:33.127248|2018-05-31 23:45:33.127248
NCT01129583|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2010-06-16||2015-03-09|2010-05-21|2010-05-24|Estimate|2011-04-04|2011-05-02|Estimate||||2015-03-09|2015-03-27|Estimate|November 2003||2003-11-30|March 2015|2015-03-31|May 2010|Actual|2010-05-31|September 2009|Actual|2009-09-30||Interventional|||Botulinum Toxin as a Novel Treatment for Prevention of Post-Traumatic Elbow Stiffness|Intraoperative Injection of Botulinum Toxin A (Botox) for the Prevention of Post-Traumatic Elbow Stiffness: A Randomized Double Blind Placebo Controlled Study|Completed||N/A|18|Actual|Columbia University|"Limited statistical power: Limitations in time and funding as well as difficulties in recruiting~Blinding challenges: Weakness in the flexor muscles of patients receiving botulinum toxin injections was clinically apparent"|2|||f||||f||||||||||2018-05-31 23:45:34.383118|2018-05-31 23:45:34.383118
NCT01129570|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-11-21|2010-05-21|2010-05-24|Estimate|||||||2013-11-21|2013-11-25|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Siliphos in Advanced Hepatocellular Carcinoma|Phase I Trial of Siliphos in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1|3|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 23:45:34.643751|2018-05-31 23:45:34.643751
NCT01129557|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2014-02-10||2014-04-16|2010-05-21|2010-05-24|Estimate|2014-04-16|2014-05-15|Estimate||||2014-04-16|2014-05-15|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease|Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease|Terminated||Phase 4|46|Actual|Columbia University||3|||f||||t||||||||||2018-05-31 23:45:34.772496|2018-05-31 23:45:34.772496
NCT01129544|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2018-05-25|2010-05-21|2010-05-24|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 2010|Actual|2010-04-30|May 2018|2018-05-31|March 2033|Anticipated|2033-03-31|March 2018|Actual|2018-03-31||Interventional|||Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector|Multi-institutional Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer|Active, not recruiting||Phase 1/Phase 2|8|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 23:45:35.615037|2018-05-31 23:45:35.615037
NCT01129531|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2013-09-12|2012-10-22|2013-09-12|2010-05-21|2010-05-24|Estimate|2013-09-12|2013-11-15|Estimate|2012-10-22|2012-10-26|Estimate|2013-09-12|2013-11-15|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia||Completed||Phase 2|294|Actual|Allergan||3|||f||||t||||||||||2018-05-31 23:45:35.716737|2018-05-31 23:45:35.716737
NCT01129518|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2015-11-06|2010-05-21|2010-05-24|Estimate|||||||2015-11-06|2015-11-09|Estimate|June 2010||2010-06-30|November 2015|2015-11-30||||July 2013|Actual|2013-07-31||Interventional|MALTA||Can we Reduce the Number of Vaccine Injections for Children?|An Open Label Randomised Controlled Study to Evaluate the Induction of Immune Memory Following Infant Vaccination With a Glycoconjugate Neisseria Meningitidis Serogroup C Vaccine and to Assess the Immunological Impact of Administering Routine Infant Immunisations in Consistent Versus Alternating Limbs|Completed||Phase 4|404|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 23:45:36.344669|2018-05-31 23:45:36.344669
NCT01129505|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-12-17|2010-05-21|2010-05-24|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Preventing Childhood Obesity: A Two-pronged Approach Starting in Pregnancy and the First Year Postpartum|Preventing Childhood Obesity: Early Intervention During Pregnancy and First Year Postpartum for Overweight and Obese Women Using a Two-pronged Family-based Nutrition & Exercise Lifestyle Intervention Program (NELIP).|Completed||N/A|200|Actual|University of Western Ontario, Canada|||||f||||f||||||||||2018-05-31 23:45:36.434683|2018-05-31 23:45:36.434683
NCT01129492|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2010-05-21|2010-05-21|2010-05-24|Estimate|||||||2010-05-21|2010-05-24|Estimate|March 2006||2006-03-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis|Low-Level Laser Therapy in Chronic Autoimmune Thyroiditis: Randomized, Placebo Controlled Clinical Trial|Completed||Phase 2|43|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 23:45:36.524302|2018-05-31 23:45:36.524302
NCT01129479|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2010-05-21|2010-05-21|2010-05-24|Estimate|||||||2010-05-21|2010-05-24|Estimate|October 2004||2004-10-31|May 2010|2010-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Galantamine Treatment for Nonfluent Aphasia in Stroke Patients|Galantamine Treatment for Nonfluent Aphasia in Stroke Patients|Completed||N/A|8|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:45:36.697632|2018-05-31 23:45:36.697632
NCT01129466|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-02-13|2010-05-21|2010-05-24|Estimate|||||||2013-02-13|2013-02-15|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|Broccosprout||Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers|Effects of Sulforaphane Containing Supplements on Nasal Cell Phase 2 Gene Expression in Healthy Volunteers.|Completed||N/A|11|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:45:36.799589|2018-05-31 23:45:36.799589
NCT01129453|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-04-20|2010-05-21|2010-05-24|Estimate|||||||2017-04-20|2017-04-21|Actual|May 2010||2010-05-31|April 2017|2017-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection|Phase I Trial of a Live Oral Salmonella Enterica Serovar Paratyphi A Vaccine Harboring Mutations in guaBA and clpX|Completed||Phase 1|51|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 23:45:36.91037|2018-05-31 23:45:36.91037
NCT01129440|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2016-12-22|2010-05-21|2010-05-24|Estimate|||||||2016-12-22|2016-12-26|Estimate|June 2011||2011-06-30|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|GIFVT||Glass Ionomer Sealant and Fluoride Varnish Study to Prevent Early Childhood Caries|Glass Ionomer Sealant and Fluoride Varnish Randomized Clinical Trial|Completed||Phase 2|597|Actual|University of California, San Francisco||2|||f||||t||||||||Yes|Data will be shared on UCSF DataShare: http://datashare.ucsf.edu|2018-05-31 23:45:37.053056|2018-05-31 23:45:37.053056
NCT01129427|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-12-14|2010-05-21|2010-05-24|Estimate|||||||2011-12-14|2011-12-15|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Pantoprazole 80 mg/Day in Healthy Male Subjects|Completed||Phase 1|66|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:45:37.180391|2018-05-31 23:45:37.180391
NCT01129414|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-12-14|2010-05-21|2010-05-24|Estimate|||||||2011-12-14|2011-12-15|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (600 mg Loading Dose Followed by 150 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects|Completed||Phase 1|72|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:45:37.413044|2018-05-31 23:45:37.413044
NCT01129401|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-10-23|2010-05-21|2010-05-24|Estimate|||||||2014-10-23|2014-10-27|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|December 2012|Actual|2012-12-31||Interventional|STEP||Stonewall Treatment Evaluation Project|Evaluation of a Harm Reduction Treatment for Methamphetamine-Using Men Who Have Sex With Men (MSM)|Completed||Phase 1/Phase 2|150|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 23:45:37.612478|2018-05-31 23:45:37.612478
NCT01129388|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-12-14|2010-05-21|2010-05-24|Estimate|||||||2011-12-14|2011-12-15|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given With Omeprazole 80 mg/Day (12 Hours Apart on the Same Days) in Healthy Male and Female Subjects|Completed||Phase 1|72|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:45:37.829735|2018-05-31 23:45:37.829735
NCT01129375|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-12-14|2010-05-21|2010-05-24|Estimate|||||||2011-12-14|2011-12-15|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-period, Two-treatment, Two Sequence, Cross-over Pharmacodynamic and Pharmacokinetic Interaction Study After 5-days Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) Alone or Given Concomitantly With Omeprazole 80 mg/Day in Healthy Male and Female Subjects|Completed||Phase 1|72|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:45:38.117079|2018-05-31 23:45:38.117079
NCT01129362|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2018-02-05|2010-05-21|2010-05-24|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2010|Actual|2010-05-31|February 2018|2018-02-28|December 30, 2014|Actual|2014-12-30|December 30, 2014|Actual|2014-12-30||Observational|||Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines|Surveillance for Rates of Pertussis Disease Among Persons Birth Through 59 Months of Age Receiving Pentacel® or Other Pertussis Vaccines|Completed|||1538|Actual|Sanofi|||3||f||||f||||||||||2018-05-31 23:45:38.393217|2018-05-31 23:45:38.393217
NCT01129349|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2017-04-28|2010-05-21|2010-05-24|Estimate|||||||2017-04-28|2017-05-02|Actual|April 2010||2010-04-30|April 2017|2017-04-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors|A Phase 1, Open-label, Dose Escalation Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors|Completed||Phase 1|44|Actual|Amgen||1|||f||||f||||||||||2018-05-31 23:45:38.543295|2018-05-31 23:45:38.543295
NCT01129336|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-08-09||2014-05-09|2010-05-21|2010-05-24|Estimate|2014-01-16|2014-02-12|Estimate||||2014-05-09|2014-05-20|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|MACS1295||Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients|A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis|Completed||Phase 4|44|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:45:38.791828|2018-05-31 23:45:38.791828
NCT01129323|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-03-23|2010-05-21|2010-05-24|Estimate|||||||2012-03-23|2012-03-27|Estimate|November 2009||2009-11-30|March 2012|2012-03-31||||September 2011|Actual|2011-09-30||Interventional|||Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia|Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia|Withdrawn||N/A|0|Actual|City of Hope Medical Center||1||This study did not accrue any subjects and due to this will be closed.|f||||t||||||||||2018-05-31 23:45:39.356997|2018-05-31 23:45:39.356997
NCT01129310|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2016-01-06|2010-05-21|2010-05-24|Estimate|||||||2016-01-06|2016-01-08|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|IXOGoo1||First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.|A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma.|Unknown status|Active, not recruiting|Phase 2|47|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-05-31 23:45:39.445023|2018-05-31 23:45:39.445023
NCT01129297|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2016-11-23|2010-05-21|2010-05-24|Estimate|||||||2016-11-23|2016-11-25|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|ABOS||A Biological Atlas of Severe Obesity (Biological Tissue Collection)|Influence of the Glycemic and Ponderal Status on Tissues Gene Expression (Biological Tissue Collection)|Recruiting|||20000|Anticipated|University Hospital, Lille|||5||f||||f||||||Samples With DNA|"~     -  Liver samples before and at 1 and 5 years after bariatric surgery~        -  Muscle samples before and at 1 year after bariatric surgery~        -  Subcutaneous fat samples before and at 3 month and 1 year after bariatric surgery~        -  Visceral fat samples in the great omentum before bariatric surgery~        -  Intestinal samples during gastric by-pass surgery~        -  Blood samples~   "|Undecided||2018-05-31 23:45:39.517622|2018-05-31 23:45:39.517622
NCT01129284|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2014-02-05||2014-03-25|2010-05-21|2010-05-24|Estimate|2014-03-25|2014-04-24|Estimate||||2014-03-25|2014-04-24|Estimate|December 2009||2009-12-31|March 2014|2014-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)|The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)|Completed||Phase 4|15|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 23:45:39.605556|2018-05-31 23:45:39.605556
NCT01129271|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-12-14|2010-05-21|2010-05-24|Estimate|||||||2011-12-14|2011-12-15|Estimate|April 2009||2009-04-30|December 2011|2011-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects|A Randomized, Placebo-controlled, Two-sequence, Two-period Crossover Study, to Investigate a Potential Food Effect on the Pharmacodynamic and Bioavailability of Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) in Healthy Male Subjects|Completed||Phase 1|72|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:45:40.270039|2018-05-31 23:45:40.270039
NCT01129258|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-03-08|2010-05-21|2010-05-24|Estimate|||||||2011-03-08|2011-03-09|Estimate|June 2010||2010-06-30|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes|A Phase 1 Placebo-Controlled Trial to Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses of PF-04991532 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1|110|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:45:40.3619|2018-05-31 23:45:40.3619
NCT01129245|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2014-04-07||2017-09-22|2010-05-21|2010-05-24|Estimate|2014-06-02|2014-07-02|Estimate||||2017-09-22|2017-10-25|Actual|September 2009||2009-09-30|September 2017|2017-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||healthy reproductive-aged women with regular cycles, not currently using or needing hormonal contraception|The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation|The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation|Completed||N/A|11|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 23:45:40.471186|2018-05-31 23:45:40.471186
NCT01129232|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2018-05-14|2010-05-21|2010-05-24|Estimate|||||||2018-05-14|2018-05-17|Actual|January 2011||2011-01-31|May 2018|2018-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|DiViD||Diabetes Virus Detection Project, Intervention With GAD-alum|A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis|Terminated||Phase 2|6|Actual|Oslo University Hospital||2||Complications to procedure|f||||t||||||||||2018-05-31 23:45:40.715366|2018-05-31 23:45:40.715366
NCT01129219|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2010-05-21|2010-05-21|2010-05-24|Estimate|||||||2010-05-21|2010-05-24|Estimate|June 2007||2007-06-30|March 2007|2007-03-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Observation and Progressive Strength Training After Hip Fracture|Observation and Progressive Strength Training After Hip Fracture|Unknown status|Active, not recruiting|N/A|150|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 23:45:40.938556|2018-05-31 23:45:40.938556
NCT01129206|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2015-09-15||2016-04-25|2010-05-21|2010-05-24|Estimate|2015-09-15|2015-10-16|Estimate||||2016-04-25|2016-06-01|Estimate|July 2010||2010-07-31|April 2016|2016-04-30||||September 2012|Actual|2012-09-30||Interventional|||Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy|Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.|Completed||Phase 2|6|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:45:41.019669|2018-05-31 23:45:41.019669
NCT01129193|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-02-21|2010-05-21|2010-05-24|Estimate|||||||2017-02-21|2017-02-23|Actual|May 4, 2010|Actual|2010-05-04|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|January 7, 2017|Actual|2017-01-07||Interventional|||AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma|Phase I Study of AR-42 in Relapsed Myeloma, Chronic Lymphocytic Leukemia, and Lymphoma|Active, not recruiting||Phase 1|44|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 23:45:41.256323|2018-05-31 23:45:41.256323
NCT01129180|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-12-02|2010-05-21|2010-05-24|Estimate|||||||2013-12-02|2013-12-03|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma|Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma|Completed||Phase 1|8|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:45:41.359031|2018-05-31 23:45:41.359031
NCT01129167|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2018-02-06|2010-05-21|2010-05-24|Estimate|||||||2018-02-06|2018-02-08|Actual|September 15, 2009|Actual|2009-09-15|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma|Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma|Active, not recruiting|||1052|Actual|Columbia University|||||f||||t|f|f||||||No||2018-05-31 23:45:41.477947|2018-05-31 23:45:41.477947
NCT01129154|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2010-08-27|2010-05-21|2010-05-24|Estimate|||||||2010-08-27|2010-08-30|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|PASCE||Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)|An Open Label Multicentric Phase II Study of Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)|Unknown status|Recruiting|Phase 2|17|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 23:45:41.553168|2018-05-31 23:45:41.553168
NCT01129141|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2016-10-03||2016-11-30|2010-05-20|2010-05-24|Estimate|2016-10-03|2016-11-23|Estimate||||2016-11-30|2017-01-26|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Telephone Tinnitus Education for Patients With Traumatic Brain Injury (TBI)|Telehealth Tinnitus Intervention for Patients With TBI|Completed||N/A|205|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:45:41.63782|2018-05-31 23:45:41.63782
NCT01129128|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2012-05-04||2012-06-14|2010-05-20|2010-05-24|Estimate|2012-05-04|2012-06-05|Estimate||||2012-06-14|2012-06-21|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Three Arm Trial of Immune Effects of Echinacea|3-arm Randomized Controlled Trial Assessing the in Vivo Effect of an Echinacea Purpurea on Immune Markers in Adults|Completed||N/A|67|Actual|University of Washington|Levels of TNF alpha, IL-6, IL-2 and Interferon gamma varied widely limiting chance of detecting differences.|3|||f||||f||||||||||2018-05-31 23:45:42.293056|2018-05-31 23:45:42.293056
NCT01129115|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2015-11-04||2016-01-14|2010-05-20|2010-05-24|Estimate|2016-01-14|2016-02-15|Estimate||||2016-01-14|2016-02-15|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional||Participants were recruited as a convenience sample of volunteers through print and online advertising, community talks, and existing databases of individuals willing to be in research studies Participants had to be at least 65, sedentary or underactive a, and free of cognitive impairment.|Dose Response Study of Aerobic Exercise in Older Adults|Dose Response Study of Exercise for Age-related Cognitive Changes|Completed||Early Phase 1|101|Actual|University of Kansas Medical Center||4|||f||||t||||||||||2018-05-31 23:45:42.835753|2018-05-31 23:45:42.835753
NCT01129102|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2014-04-10||2014-05-15|2010-05-21|2010-05-24|Estimate|2014-05-15|2014-06-17|Estimate||||2014-05-15|2014-06-17|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Baseline analysis population was carried out based on FAS data set. 110, 50 and 55 pts were assigned to NPC-01, IKH-01 and placebo, respectively, and administered study drug 108, 47 and 54 pts. Safety and FAS analysis was carried out on 107, 47 and 54 pts/105, 47 and 54 pts due to 1 and 2 pts of NPC-01 have no available data respectively.|Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea|Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea|Completed||Phase 3|215|Actual|Nobelpharma||3|||f||||t||||||||||2018-05-31 23:45:43.468912|2018-05-31 23:45:43.468912
NCT01129089|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-05-20|2010-05-20|2010-05-24|Estimate|||||||2010-05-20|2010-05-24|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Acceptability of Nutrient Supplements Among Women and Children in Bangladesh|Acceptability of Lipid-based Nutrient Supplements (LNS) and Micronutrient Powder (MNP) for Women and Infants in Bangladesh|Completed||N/A|144|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 23:45:44.325292|2018-05-31 23:45:44.325292
NCT01129076|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2018-05-24|2010-05-21|2010-05-24|Estimate|||||||2018-05-24|2018-05-25|Actual|April 23, 2010||2010-04-23|January 7, 2016|2016-01-07|January 7, 2016||2016-01-07|||||Observational|||Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma|Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:45:44.461862|2018-05-31 23:45:44.461862
NCT01129063|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2010-08-27|2010-05-21|2010-05-24|Estimate|||||||2010-08-27|2010-08-30|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetic Study of Single Doses of Clopidogrel, 75 mg and 300 mg, in Healthy Subjects|An Open-label, Two-treatment Crossover Pharmacokinetic Study of Clopidogrel Hydrogen Sulfate in Healthy Male and Female Subjects|Completed||Phase 1|32|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:45:44.635039|2018-05-31 23:45:44.635039
NCT01129050|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2017-05-31|2010-05-21|2010-05-24|Estimate|||||||2017-05-31|2017-06-01|Actual|April 2007||2007-04-30|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Omega-3 Fatty Acids on Markers of Inflammation|Effects of Plant and Marine Omega-3 (w-3) Fatty Acids on Inflammatory Markers In Insulin Resistant Adults|Completed||N/A|102|Actual|Stanford University||5|||f||||f|f|f||||||No||2018-05-31 23:45:44.736541|2018-05-31 23:45:44.736541
NCT01129037|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2015-04-17|2010-05-21|2010-05-24|Estimate|||||||2015-04-17|2015-04-21|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional|||Goal Directed Fluid Therapy in Free Flap Reconstructive Surgery|Goal Directed Fluid Management and Patient Outcome in Free Flap Reconstructive Surgery for Head and Neck Oncology: a Feasibility Randomized, Controlled Trial|Completed||N/A|78|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 23:45:44.8417|2018-05-31 23:45:44.8417
NCT01129024|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07||2018-05-18|2018-05-21|2010-05-20|2010-05-24|Estimate||||2018-05-18|2018-05-22|Actual|2018-05-21|2018-05-23|Actual|March 2010||2010-03-31|May 2018|2018-05-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||An Open-label Safety Study of S-888711|An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy|Completed||Phase 2|19|Actual|Shionogi Inc.||1|||f||||f||||||||||2018-05-31 23:45:44.93649|2018-05-31 23:45:44.93649
NCT01129011|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2010-05-27||2010-11-29|2010-05-20|2010-05-24|Estimate|2010-11-29|2010-12-28|Estimate||||2010-11-29|2010-12-28|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen|6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers|Completed||Phase 3|420|Actual|POZEN||2|||f||||t||||||||||2018-05-31 23:45:45.066498|2018-05-31 23:45:45.066498
NCT01128998|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2015-10-16|2010-05-20|2010-05-24|Estimate|||||||2015-10-16|2015-10-19|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|October 2015|Actual|2015-10-31|November 2009|Actual|2009-11-30||Interventional|||Sorafenib Plus S-1 in Advanced Solid Tumors|An Open-Label Phase I Dose-Escalation Study of Sorafenib Plus S-1 in Advanced Solid Tumors|Completed||Phase 1|30|Actual|National Health Research Institutes, Taiwan||1|||f||||f||||||||||2018-05-31 23:45:45.493321|2018-05-31 23:45:45.493321
NCT01128985|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2013-05-27|2010-05-20|2010-05-24|Estimate|||||||2013-05-27|2013-05-29|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|July 2010|Actual|2010-07-31|||||Interventional|||A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|39|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||||||||||||2018-05-31 23:45:45.563458|2018-05-31 23:45:45.563458
NCT01128972|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2012-09-13||2014-12-11|2010-05-20|2010-05-24|Estimate|2013-03-14|2013-04-25|Estimate||||2014-12-11|2015-01-01|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion|Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion|Completed||Phase 2|36|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 23:45:45.686719|2018-05-31 23:45:45.686719
NCT01128959|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|2016-10-10|2014-04-11|2017-12-14|2010-05-21|2010-05-24|Estimate|2016-10-10|2016-12-05|Estimate|2014-04-11|2014-05-06|Estimate|2017-12-14|2018-01-16|Actual|June 2010||2010-06-30|December 2017|2017-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy|Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy|Completed||Phase 3|108|Actual|Lundbeck LLC||1|||f||||f||||||||||2018-05-31 23:45:46.010324|2018-05-31 23:45:46.010324
NCT01128946|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-03-21||2014-12-11|2010-05-21|2010-05-24|Estimate|2013-08-29|2013-11-04|Estimate||||2014-12-11|2015-01-01|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Enamel Remineralization Potential of Dentifrices in Situ|Comparison of Enamel Remineralization Potential of Dentifrices Incorporating Different Fluoride Salts Using an in Situ Caries Model|Completed||Phase 4|83|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 23:45:46.21838|2018-05-31 23:45:46.21838
NCT01128933|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2010-05-21|2010-05-21|2010-05-24|Estimate|||||||2010-05-21|2010-05-24|Estimate|June 2006||2006-06-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|PREFFER||Renal Fractional Flow Reserve in Renal Artery Stenting|Prognostic Value of Renal Fractional Flow Reserve in Hypertensive Patients With Renal Artery Stenosis Qualified to Renal Artery Stenting|Completed||N/A|45|Actual|Institute of Cardiology, Warsaw, Poland||1|||f||||f||||||||||2018-05-31 23:45:46.665629|2018-05-31 23:45:46.665629
NCT01128920|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2011-12-30|2010-05-21|2010-05-24|Estimate|||||||2011-12-30|2012-01-04|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Reducing Health Problems Associated With Injection Drug Use|Reduction of Medical Complications Associated With Injection Drug Use|Completed||N/A|87|Actual|University of Northern Colorado||2|||f||||f||||||||||2018-05-31 23:45:46.734747|2018-05-31 23:45:46.734747
NCT01128907|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2014-02-21|2010-05-21|2010-05-24|Estimate|||||||2014-02-21|2014-02-24|Estimate|October 2006||2006-10-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients|Galactomannan Antigen and Real Time - PCR for Aspergillus DNA Detection in Bronchoalveolar Lavage. Application in the Diagnosis of Invasive Aspergillosis in Neutropenic Patients|Completed|||200|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||||||2018-05-31 23:45:46.815085|2018-05-31 23:45:46.815085
NCT01128725|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2012-03-23|2010-05-21|2010-05-24|Estimate|||||||2012-03-23|2012-03-26|Estimate|September 2010||2010-09-30|May 2010|2010-05-31|December 2012|Anticipated|2012-12-31|September 2010|Actual|2010-09-30||Interventional|||Truncated and Extended Forms of Amyloid Beta Peptides in Alzheimer's Disease: Genesis, Toxicity and Identification as Biological Markers||Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 23:45:52.764662|2018-05-31 23:45:52.764662
NCT01128894|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2014-04-17|2012-07-26|2017-01-09|2010-05-21|2010-05-24|Estimate|2014-04-17|2014-05-20|Estimate|2012-07-26|2012-08-03|Estimate|2017-01-09|2017-02-23|Actual|May 2010||2010-05-31|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.|A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|841|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:45:46.906778|2018-05-31 23:45:46.906778
NCT01128881|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-10-19|2010-05-21|2010-05-24|Estimate|||||||2017-10-19|2017-10-23|Actual|May 2010||2010-05-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||IMMUNINE Pre-Treatment Study|IMMUNINE - Purified Factor IX Concentrate Virus-Inactivated: A Phase 4, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B Who Are Planned to Enter BAX 326 Study 250901 to Investigate a New Recombinant FIX Concentrate|Completed||Phase 4|57|Actual|Shire||1|||f||||t||||||||||2018-05-31 23:45:48.116247|2018-05-31 23:45:48.116247
NCT01128868|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2017-01-23|2010-05-21|2010-05-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|June 2013|Actual|2013-06-30||Interventional|||Proximal Femur Locking Compression Plates Versus Trochanteric Nails|Treatment of Reverse Oblique Intertrochanteric or Subtrochanteric Fractures With a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc) or Trochanteric Nails. A Multicenter Cohort Study|Completed||N/A|14|Actual|AO Clinical Investigation and Documentation||2|||f||||t||||||||||2018-05-31 23:45:48.212233|2018-05-31 23:45:48.212233
NCT01128855|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2017-07-13|2010-05-21|2010-05-24|Estimate|||||||2017-07-13|2017-07-18|Actual|July 12, 2010|Actual|2010-07-12|July 2017|2017-07-31|October 25, 2011|Actual|2011-10-25|October 25, 2011|Actual|2011-10-25||Interventional|DEMAND I||A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects|A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Subcutaneous Injections of GSK2402968 in Non-ambulant Subjects With Duchenne Muscular Dystrophy|Completed||Phase 1|20|Actual|GlaxoSmithKline||4|||f||||t||||||||||2018-05-31 23:45:48.321309|2018-05-31 23:45:48.321309
NCT01128842|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2012-05-10|2010-05-21|2010-05-24|Estimate|||||||2012-05-10|2012-05-14|Estimate|April 2010||2010-04-30|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor|A Phase 1, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Japanese Subject With Solid Tumors|Completed||Phase 1|7|Actual|Puma Biotechnology, Inc.||1|||f||||t||||||||||2018-05-31 23:45:48.445772|2018-05-31 23:45:48.445772
NCT01128829|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2014-06-02||2014-12-15|2010-05-21|2010-05-24|Estimate|2014-12-15|2014-12-22|Estimate||||2014-12-15|2014-12-22|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|October 2012|Actual|2012-10-31|February 2012|Actual|2012-02-29||Interventional|SIR||Sugar-replacement Sweeteners, and Blood Sugar Control|Regulation of Incretin Release by Non-nutritive Sweeteners in Humans|Completed||N/A|17|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 23:45:48.633137|2018-05-31 23:45:48.633137
NCT01128816|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2017-12-13|2010-05-21|2010-05-24|Estimate|||||||2017-12-13|2017-12-15|Actual|May 2010||2010-05-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|ADVENT-HF||Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure|A Multi-Centre, Randomized Study to Assess the Effects of Adaptive Servo Ventilation (ASV) on Survival and Frequency of Hospital Admissions in Patients With Heart Failure (HF) and Sleep Apnea (SA)-The ADVENT-HF Trial|Recruiting||Phase 4|860|Anticipated|Toronto Rehabilitation Institute||2|||f||||t||||||||||2018-05-31 23:45:48.783966|2018-05-31 23:45:48.783966
NCT01128803|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-11-06|2010-05-21|2010-05-24|Estimate|||||||2013-11-06|2013-11-07|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response|Phase I/II Multicenter: Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response|Terminated||Phase 1/Phase 2|1|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 23:45:49.048673|2018-05-31 23:45:49.048673
NCT01128790|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-12-20|2010-05-21|2010-05-24|Estimate|||||||2013-12-20|2013-12-23|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Pilot Study of Remote Ischemic Preconditioning in Heart Failure|Effect of Remote Ischemic Preconditioning on Exercise Capacity in Patients With Heart Failure: A Double Blind Randomized Control Trial|Completed||N/A|22|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:45:49.113053|2018-05-31 23:45:49.113053
NCT01128777|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-07-03|2010-05-21|2010-05-24|Estimate|||||||2013-07-03|2013-07-04|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Helping Hand||Teens Coping With Parental Military Deployment|Mental Health Intervention for Teens Coping With Parental Military Deployment|Terminated||Phase 1|6|Actual|Brown University||2||Terminated due to difficuly recruiting participants|f||||t||||||||||2018-05-31 23:45:49.181123|2018-05-31 23:45:49.181123
NCT01128764|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2014-07-28|2010-05-21|2010-05-24|Estimate|||||||2014-07-28|2014-07-29|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Integrated Treatment for Comorbid Depression and Obesity in Adolescents|Integrated Treatment for Comorbid Depression and Obesity in Adolescents|Completed||Phase 1|36|Actual|Brown University||2|||f||||t||||||||||2018-05-31 23:45:49.269986|2018-05-31 23:45:49.269986
NCT01128751|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2010-05-21|2010-05-21|2010-05-24|Estimate|||||||2010-05-21|2010-05-24|Estimate|March 2010||2010-03-31|May 2010|2010-05-31||||December 2011|Anticipated|2011-12-31||Interventional|ELMAR||Elimination of Microemboli During Aortic Valve Replacement|ELMAR - Elimination of Microemboli During Aortic Valve Replacement. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|University of Giessen||3|||f||||f||||||||||2018-05-31 23:45:49.408947|2018-05-31 23:45:49.408947
NCT01128738|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2012-03-29||2015-05-13|2010-05-20|2010-05-24|Estimate|2012-03-29|2012-04-25|Estimate||||2015-05-13|2015-06-08|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Including an Open-label Phase to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Axillary Hyperhidrosis|Completed||Phase 3|152|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:45:49.578348|2018-05-31 23:45:49.578348
NCT01128712|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2017-09-12|2010-05-21|2010-05-24|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2010||2010-04-30|September 2017|2017-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin|An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin|Terminated||Phase 4|4|Actual|Northeast Regional Epilepsy Group||2||lack of enrollment. terminated in 2014. no data analysis.|f||||f||||||||||2018-05-31 23:45:52.847229|2018-05-31 23:45:52.847229
NCT01128699|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2010-05-21|2010-05-21|2010-05-24|Estimate|||||||2010-05-21|2010-05-24|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|July 2011|Anticipated|2011-07-31|May 2011|Anticipated|2011-05-31||Interventional|||Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma|Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma: a Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 3|40|Anticipated|Vanak Eye Surgery Center||2|||f||||t||||||||||2018-05-31 23:45:52.915868|2018-05-31 23:45:52.915868
NCT01128686|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2016-09-12|2010-05-21|2010-05-24|Estimate|||||||2016-09-12|2016-09-13|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|LAMGR||Lamivudine(LAM) Good Responder Study|A Retrospective Cohort Study to Evaluate the Rate of Good Responses to Lamivudine (LAM) Treatment in naïve Chronic Hepatitis B (CHB) Patients With Certain Pre-treatment Characteristics|Completed|||1|Actual|ViiV Healthcare|||1||f||||f||||||||||2018-05-31 23:45:53.090944|2018-05-31 23:45:53.090944
NCT01128673|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2015-06-01|2010-05-21|2010-05-24|Estimate|||||||2015-06-01|2015-06-03|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE)|MRI Thermal Imaging of Infants Undergoing Cooling for HIE|Withdrawn|||0|Actual|Vanderbilt University|||2|No funding|f||||t||||||||||2018-05-31 23:45:53.179326|2018-05-31 23:45:53.179326
NCT01128660|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-02-01|2010-05-21|2010-05-24|Estimate|||||||2013-02-01|2013-02-04|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|||Assessment of the Prescriber's and the Pharmacies Overview of Patient Medication by Use of the Fidelity Coefficient.|Assessment of the Prescriber's and the Pharmacies Overview of Patient Medication by Use of the Fidelity Coefficient.|Completed|||283388|Actual|University of Southern Denmark|||1||f||||f||||||||||2018-05-31 23:45:53.283782|2018-05-31 23:45:53.283782
NCT01128647|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2013-02-12|2010-05-21|2010-05-24|Estimate|||||||2013-02-12|2013-02-13|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Observational|||Disposal of Oral Fructose During Exercise|Disposal of Oral Fructose During Exercise|Completed|||7|Actual|University of Lausanne|||||f||||f||||||||||2018-05-31 23:45:53.346291|2018-05-31 23:45:53.346291
NCT01128634|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2017-06-13|2010-05-20|2010-05-24|Estimate|||||||2017-06-13|2017-06-14|Actual|March 4, 2010|Actual|2010-03-04|June 2017|2017-06-30|April 26, 2010|Actual|2010-04-26|April 26, 2010|Actual|2010-04-26||Interventional|||Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects|A Single-Centre, Randomised, Open-label Study to Evaluate the Effects of Steady-State Verapamil, a Moderate P-Glycoprotein and CYP3A4 Inhibitor, on the Pharmacokinetics of GSK573719 and GSK573719 in Combination With GW642444|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:45:53.40278|2018-05-31 23:45:53.40278
NCT01128621|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2017-08-10|2012-03-29|2017-09-14|2010-05-20|2010-05-24|Estimate|2017-09-14|2017-10-16|Actual|2012-03-29|2012-04-02|Estimate|2017-09-14|2017-10-16|Actual|November 23, 2009|Actual|2009-11-23|August 2017|2017-08-31|April 12, 2010|Actual|2010-04-12|April 12, 2010|Actual|2010-04-12||Interventional|||A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263|A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263|Completed||Phase 2|66|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:45:53.67778|2018-05-31 23:45:53.67778
NCT01128608|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2010-07-20|2010-05-21|2010-05-24|Estimate|||||||2010-07-20|2010-07-21|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Interventional|PC02||The Effect of High PCO2 Solution on Esophageal Acid Sensation|The Effect of High PCO2 Solution on Esophageal Acid Sensation in Healthy Patients Versus Those With Non-Erosive Reflux Disease.|Unknown status|Recruiting|N/A|20|Anticipated|Southern Arizona VA Health Care System||2|||f||||f||||||||||2018-05-31 23:45:56.520574|2018-05-31 23:45:56.520574
NCT01128595|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-06-06|2012-02-16|2016-11-30|2010-05-20|2010-05-24|Estimate|2013-06-06|2013-08-09|Estimate|2012-02-16|2012-02-20|Estimate|2016-11-30|2017-01-18|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response|A Randomised, Double-blind, Placebo-controlled, Four-way Crossover, Repeat Dose Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination, GW642444M and Fluticasone Furoate on the Allergen-induced Asthmatic Response in Subjects With Mild Asthma|Completed||Phase 2|27|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:45:56.640734|2018-05-31 23:45:56.640734
NCT01128582|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2011-05-11|2010-05-21|2010-05-24|Estimate|||||||2011-05-11|2011-05-12|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|Rozerem||Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.|Effect of Rozerem on the Perception of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Chronic Insomnia.|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Southern Arizona VA Health Care System||2|||f||||f||||||||||2018-05-31 23:45:57.43224|2018-05-31 23:45:57.43224
NCT01128569|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-06-06|2012-03-15|2016-11-30|2010-05-20|2010-05-24|Estimate|2013-09-05|2013-09-11|Estimate|2012-03-15|2012-03-19|Estimate|2016-11-30|2017-01-18|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response|A Randomised, Double-blind, Placebo-controlled, Three-way Crossover, Repeat Dose Pilot Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination and Fluticasone Furoate on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma|Completed||Phase 2|52|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:45:57.541625|2018-05-31 23:45:57.541625
NCT01128556|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-21|||2010-07-07|2010-05-21|2010-05-24|Estimate|||||||2010-07-07|2010-07-08|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing|The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing|Completed||Phase 4|30|Anticipated|North Texas Institute for Clinical Trials||1|||f||||f||||||||||2018-05-31 23:45:58.043953|2018-05-31 23:45:58.043953
NCT01128543|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2012-11-15||2012-11-15|2010-05-21|2010-05-24|Estimate|2012-11-15|2012-12-12|Estimate||||2012-11-15|2012-12-12|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Lapatinib in Combination With Vinorelbine|A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer|Completed||Phase 2|29|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:45:58.240812|2018-05-31 23:45:58.240812
NCT01128530|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20||2011-01-25|2011-12-09|2010-05-20|2010-05-24|Estimate||||2011-01-25|2011-02-01|Estimate|2011-12-09|2011-12-16|Estimate|June 2010||2010-06-30|December 2011|2011-12-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)|A Randomized, Controlled, Double-Blind, Double Dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection|Completed||Phase 2|161|Actual|Furiex Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 23:45:58.967294|2018-05-31 23:45:58.967294
NCT01128517|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-21|2010-05-21|2010-05-24|Estimate|||||||2010-05-21|2010-05-24|Estimate|October 2008||2008-10-31|April 2010|2010-04-30|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Maternal Education on Complementary Feeding and Infant Outcome|Does Maternal Education on Complementary Feeding Have an Impact on Infant Nutritional Status in Low Middle-income Households? A Community Based Randomized Interventional Study in Karachi, Pakistan.|Completed||N/A|175|Actual|Aga Khan University||1|||f||||f||||||||||2018-05-31 23:45:59.471174|2018-05-31 23:45:59.471174
NCT01128478|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2013-01-05|2010-05-21|2010-05-24|Estimate|||||||2013-01-05|2013-01-08|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|MIMOSA||MIld to MOderate Acute Pancreatitis: Early naSogastric Tube Feeding Compared With pAncreas Rest (MIMOSA)|Early Enteral Tube Feeding Compared With Pancreas Rest in Patients With Acute Pancreatitis: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|35|Actual|University of Auckland, New Zealand||2|||f||||t||||||||||2018-05-31 23:45:59.561044|2018-05-31 23:45:59.561044
NCT01128465|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2011-03-16|2010-05-21|2010-05-24|Estimate|||||||2011-03-16|2011-03-17|Estimate|February 2010||2010-02-28|March 2011|2011-03-31||||||||Observational|||Pharmacokinetic and -Dynamic of Propofol During Awake Craniotomy|Investigation on the Pharmacokinetic and -Dynamic of Propofol During Awake Craniotomy|Completed|||10|Anticipated|University Hospital, Bonn|||||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 23:45:59.860016|2018-05-31 23:45:59.860016
NCT01128452|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19||2014-08-27|2016-03-01|2010-05-20|2010-05-21|Estimate||||2014-08-27|2014-08-28|Estimate|2016-03-01|2016-03-28|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy of EVT 101 in Treatment-Resistant Depression|A 4-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Efficacy of EVT 101 as Monotherapy in Patients With Treatment-Resistant Major Depression|Terminated||Phase 2|8|Actual|Janssen Research & Development, LLC||2||Evotec has indicated that this study was discontinued due to a clinical hold issued by the FDA|f||||t||||||||||2018-05-31 23:45:59.975899|2018-05-31 23:45:59.975899
NCT01128439|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2015-06-09|2010-05-20|2010-05-21|Estimate|||||||2015-06-09|2015-06-10|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease|A Postmarketing Observational Study Estimating The Impact Of Prevnar 13 (Trade Mark) (13vpnc) On Invasive Pneumococcal Disease Caused By Vaccine Serotypes Of Streptococcus Pneumoniae After Introduction Into Routine Pediatric Use|Completed|||1|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:46:00.082803|2018-05-31 23:46:00.082803
NCT01128426|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2014-05-14||2014-06-12|2010-05-20|2010-05-21|Estimate|2014-06-12|2014-07-14|Estimate||||2014-06-12|2014-07-14|Estimate|June 2010||2010-06-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||Analysis population included participants who started vaccination with 13vPnC within the first 6 months of life, were members of KPNC and received at least 1 dose of 13vPnC vaccine during the study observation period.|Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers|Postlicensure Observational Safety Study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Administered in Routine Use to Infants and Toddlers|Completed|||53902|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:46:00.464052|2018-05-31 23:46:00.464052
NCT01128413|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2016-02-06||2016-03-04|2010-05-20|2010-05-21|Estimate|2016-02-06|2016-03-07|Estimate||||2016-03-04|2016-04-01|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|EFFORT||Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)|Emergency Department (ED) Flow-directed Fluid Optimization Resuscitation Trial (EFFORT)|Terminated||N/A|22|Actual|Washington University School of Medicine|Trial terminated early due to lack of resources leading to small numbers of subjects analyzed.|2||lack of resources|f||||f||||||||No||2018-05-31 23:46:04.608916|2018-05-31 23:46:04.608916
NCT01128400|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2014-06-02||2014-06-02|2010-05-20|2010-05-21|Estimate|2014-06-02|2014-07-03|Estimate||||2014-06-02|2014-07-03|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|OT|Three groups of obese subjects (body mass index [BMI] >30 kg/m2) participated in this study. The three groups were matched on age, because there is a generic decline in taste perception with age.|Fat Perception in Humans (09-0873)|Inhibition of Lipolysis in Oral Cavity and Fat Perception in Humans|Completed|||40|Actual|Washington University School of Medicine|||3||f||||f||||||Samples With DNA|"~     whole blood will be collected and frozen~   "|||2018-05-31 23:46:05.013339|2018-05-31 23:46:05.013339
NCT01128387|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2017-11-08||2018-03-05|2010-05-20|2010-05-21|Estimate|2017-12-22|2018-01-23|Actual||||2018-03-05|2018-03-14|Actual|May 2010||2010-05-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer|A Phase I/II Study of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation Preoperatively for Patients With Locally Advanced Esophageal Cancer|Terminated||Phase 1/Phase 2|11|Actual|University of Wisconsin, Madison|The Standard of Care changed during this protocol, and the protocol was terminated prematurely.|2||slow accrual|f||||t||||||||||2018-05-31 23:46:05.340537|2018-05-31 23:46:05.340537
NCT01128374|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2013-01-14|2010-05-20|2010-05-21|Estimate|||||||2013-01-14|2013-01-15|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 Diabetes|The Effect of Non-Surgical Periodontal Therapy on Glycemic Control and Bacterial Levels in a Mexican-American Population With Type 2 DiabetesS|Completed||N/A|134|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 23:46:05.891145|2018-05-31 23:46:05.891145
NCT01128361|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2017-01-22||2017-01-22|2010-05-20|2010-05-21|Estimate|2017-01-22|2017-03-13|Actual||||2017-01-22|2017-03-13|Actual|May 2010||2010-05-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD)|Alzheimer's Disease Exercise Prevention Trial|Completed||N/A|76|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 23:46:05.973237|2018-05-31 23:46:05.973237
NCT01128348|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2013-03-19|2010-05-20|2010-05-21|Estimate|||||||2013-03-19|2013-03-20|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|HAP||A Patient Advocate and Literacy-Based Treatment of Asthma|A Patient Advocate and Literacy-Based Treatment of Asthma|Completed||N/A|100|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:46:06.277489|2018-05-31 23:46:06.277489
NCT01128335|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2016-11-17|2010-05-20|2010-05-21|Estimate|||||||2016-11-17|2016-11-18|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients|A 24-month Randomized Multicenter Study Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of Sotrastaurin and Tacrolimus vs. a Tacrolimus/Mycophenolate Mofetil-based Control Regimen in de Novo Liver Transplant Recipients|Completed||Phase 2|200|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:46:07.456841|2018-05-31 23:46:07.456841
NCT01128322|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-04-22|2010-05-20|2010-05-21|Estimate|||||||2011-04-22|2011-04-26|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||CKD-828 Primary Hypertension Trial(Dose-selection)|A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension|Completed||Phase 2|430|Anticipated|Chong Kun Dang Pharmaceutical||9|||f||||||||||||||2018-05-31 23:46:07.624204|2018-05-31 23:46:07.624204
NCT01128309|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2012-05-04|2010-05-20|2010-05-21|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain|Stress Reduction and Anxiety: Effects on the Function and Structure of the Brain|Completed||N/A|29|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:46:07.75551|2018-05-31 23:46:07.75551
NCT01128296|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2016-08-10||2017-06-06|2010-05-20|2010-05-21|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|October 2010||2010-10-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|April 2013|Actual|2013-04-30||Interventional|||Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas|Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas|Active, not recruiting||Phase 1/Phase 2|35|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 23:46:07.916065|2018-05-31 23:46:07.916065
NCT01128283|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-09-11|2010-05-20|2010-05-21|Estimate|||||||2014-09-11|2014-09-12|Estimate|January 2002||2002-01-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Indicators of Inflammation and Coagulation in Sepsis|Temporal Behavior of Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis|Completed|||500|Actual|University of Oklahoma|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:46:08.53862|2018-05-31 23:46:08.53862
NCT01128270|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-11-20||2014-04-08|2010-05-20|2010-05-21|Estimate|2014-04-08|2014-05-07|Estimate||||2014-04-08|2014-05-07|Estimate|April 2010||2010-04-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Withdrawals before their treatment was to begin, as all were scheduled to participate in all 4 participate.|Pharmacotoxicology of Trichloroethylene Metabolites|Pharmacotoxicology of Trichloroethylene Metabolites Aim 3|Completed||Phase 1/Phase 2|27|Actual|University of Florida|Subjects were asked to wait 30 days in between doses of medication. Some of the participants could not wait the entire 4 months to finish the study and thus dropped out before they completed the 4 arms. Ten were enrolled, screened, but did not start|4|||f||||f||||||||||2018-05-31 23:46:08.65009|2018-05-31 23:46:08.65009
NCT01128257|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2016-11-01|2010-05-20|2010-05-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis|Controllability and Real Life Efficacy of Bonviva 3 mg iv Quarterly vs. Oral Alendronate Generics|Completed|||6054|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 23:46:09.204725|2018-05-31 23:46:09.204725
NCT01128244|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2014-12-09||2016-12-13|2010-05-20|2010-05-21|Estimate|2014-12-09|2014-12-17|Estimate||||2016-12-13|2017-02-07|Estimate|April 2010||2010-04-30|December 2016|2016-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Vitamin B6 Effects for Women Taking Birth Control Pills|Vitamin B6 Effects on One-Carbon Metabolism|Completed||Phase 2/Phase 3|13|Actual|University of Florida|Secondary Outcome Measure(s): 5. Data Not Reported Exploratory Metabolite Profile and Metabolomics Analysis. The Analysis from the lab was delayed due to circumstance beyond our control.|1|||f||||f||||||||||2018-05-31 23:46:09.307599|2018-05-31 23:46:09.307599
NCT01128218|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2017-08-11|2010-05-20|2010-05-21|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2011|Actual|2011-03-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors|A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain|Completed||Phase 1/Phase 2|35|Actual|Southern Illinois University||1|||f||||t||||||||No||2018-05-31 23:46:09.579215|2018-05-31 23:46:09.579215
NCT01128205|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2011-06-14|2010-05-20|2010-05-21|Estimate|||||||2011-06-14|2011-06-15|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|3B||Nationwide Assessment of Cardiovascular Risk Factors: in Chinese Patients With Type 2 Diabetes|Nationwide Assessment of Cardiovascular Risk Factors: Blood Pressure, Blood Lipid, and Blood Glucose, in Chinese Patients With Type 2 Diabetes, A Study of China Cardiometabolic Registries (CCMR)|Completed|||25000|Anticipated|China Cardiometabolic Registries|||1||f||||f||||||||||2018-05-31 23:46:09.755202|2018-05-31 23:46:09.755202
NCT01128192|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2013-07-26||2014-12-23|2010-05-20|2010-05-21|Estimate|2014-12-23|2014-12-25|Estimate||||2014-12-23|2014-12-25|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|Pasireotide|Nondiabetic males, aged 18-50 years with body mass index (BMI) ≤ 25. Subjects were not to have any family history of diabetes and no diagnosis of impaired glucose tolerance or gallstone disease.|Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers|Phase 2, Double-Blind, Randomized, Single Center Trial to Assess the Mechanism(s) Responsible for the Effect of the Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers. Version #2 05/09/2009|Completed||Phase 2|45|Actual|Veterans Medical Research Foundation||3|||f||||f||||||||||2018-05-31 23:46:09.90614|2018-05-31 23:46:09.90614
NCT01128179|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2013-03-20||2014-06-16|2010-05-20|2010-05-21|Estimate|2013-03-25|2013-05-22|Estimate||||2014-06-16|2014-06-26|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||The Safety Analysis Set was defined as all randomized subjects who received at least 1 dose of investigational product. This population was used in all safety reporting.|Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD|A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease|Completed||Phase 2|35|Actual|Shire||2|||f||||||||||||||2018-05-31 23:46:10.894823|2018-05-31 23:46:10.894823
NCT01128166|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2015-10-19|2010-05-20|2010-05-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Observational|MultiSENSE||Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices|Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients|Completed|||975|Actual|Boston Scientific Corporation|||1||f||||t||||||||||2018-05-31 23:46:11.369172|2018-05-31 23:46:11.369172
NCT01128153|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2012-06-11||2012-08-07|2010-05-20|2010-05-21|Estimate|2012-06-28|2012-08-03|Estimate||||2012-08-07|2012-08-10|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Saxagliptin Triple Oral Therapy|A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea|Completed||Phase 3|257|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:46:11.668921|2018-05-31 23:46:11.668921
NCT01128140|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2015-05-26|2010-05-20|2010-05-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy Trial of Warrior Check-Up|Motivating Treatment Seeking and Behavior Change by Untreated Military Personnel Abusing Alcohol or Drugs|Completed||Phase 2|242|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:46:12.3321|2018-05-31 23:46:12.3321
NCT01128127|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2012-09-13|2010-05-20|2010-05-21|Estimate|||||||2012-09-13|2012-09-14|Estimate|January 2013||2013-01-31|September 2012|2012-09-30|June 2015|Anticipated|2015-06-30|November 2014|Anticipated|2014-11-30||Interventional|||Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription Associated to Non-steroidal Anti-inflammatory Drugs (NSAIDs)|Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription for Gastropathy Prevention Due to Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Primary Health Care|Withdrawn||N/A|0|Actual|Servicio Canario de Salud||3|||f||||f||||||||||2018-05-31 23:46:12.408977|2018-05-31 23:46:12.408977
NCT01128114|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2011-05-24||2012-04-11|2010-05-20|2010-05-21|Estimate|2012-03-16|2012-04-10|Estimate||||2012-04-11|2012-04-17|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|RELEASE||Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy|A 4-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Broad Clinical Benefit for Seroquel XR (Quetiapine Fumarate Extended Release) With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy|Terminated||Phase 4|32|Actual|AstraZeneca|In March 2011, considering the low patient inclusion rate (32 patients recruited so far whereas study objective was 125 patients for 85 completers), the study was ended prematurely earlier than the planned date. No analysis was conducted afterwards.|1||Poor recruitment|f||||f||||||||||2018-05-31 23:46:12.535765|2018-05-31 23:46:12.535765
NCT01128101|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-16|||2011-09-02|2010-05-20|2010-05-21|Estimate|||||||2011-09-02|2011-09-05|Estimate|March 2011||2011-03-31|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effects of Spironolactone in Dialysis|Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients|Unknown status|Recruiting|Phase 4|60|Anticipated|UPECLIN HC FM Botucatu Unesp||1|||f||||t||||||||||2018-05-31 23:46:12.748683|2018-05-31 23:46:12.748683
NCT01128088|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-05-20|2010-05-20|2010-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||The Stress Response in Laparoscopic Colorectal Surgery and Its Role in the Development of the Enhanced Recovery Program.|The Stress Response in Laparoscopic Colorectal Surgery and Its Role in the Development of the Enhanced Recovery Program.|Completed|||133|Actual|University of Surrey|||4||f||||f||||||||||2018-05-31 23:46:12.844992|2018-05-31 23:46:12.844992
NCT01128075|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-07-08|2010-05-20|2010-05-21|Estimate|||||||2014-07-08|2014-07-09|Estimate|August 2009||2009-08-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|MEASURE||Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects|Multi-center, Two-arm Non-comparative, Observational, 96-week Phase IV Study to Evaluate Treatment Adherence When Using RebiSmart™ for Self-injection of Rebif® in Multi-dose Cartridges in Subjects With Relapsing Multiple Sclerosis (RMS)|Completed|||198|Actual|Merck KGaA|||2||f||||f||||||||||2018-05-31 23:46:12.909978|2018-05-31 23:46:12.909978
NCT01128062|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-05-20|2010-05-20|2010-05-21|Estimate|||||||2010-05-20|2010-05-21|Estimate|December 1983||1983-12-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Observational|||Canthaxanthin Retinopathy: A Long-term Observation||Completed|||35|Actual|University of Cologne|||||f||||f||||||||||2018-05-31 23:46:12.992274|2018-05-31 23:46:12.992274
NCT01128049|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2015-05-25||2015-08-05|2010-05-20|2010-05-21|Estimate|2015-05-25|2015-06-11|Estimate||||2015-08-05|2015-08-07|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation|Non-invasive Tear Film Dynamic Measurements in Normal, MGD (Meibomium Gland Dysfunction) and Aqueous Deficient Dry Eye(ADDE) Subjects After Saline Instillation|Completed||N/A|15|Actual|University of Rochester||3|||f||||f||||||||||2018-05-31 23:46:13.067442|2018-05-31 23:46:13.067442
NCT01128036|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-08-08|2010-05-20|2010-05-21|Estimate|||||||2011-08-08|2011-08-09|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Comparison of Different Locations for Pulse Oximetry Probes in Cardiovascular (CV) Patients With Poor Peripheral Perfusion|Comparison of Different Locations for Pulse Oximetry Probes in Adult Cardiovascular Patients With Poor Peripheral Perfusion|Terminated|||51|Actual|Saint Luke's Health System|||1|Terminated due to software issues.|f||||f||||||||||2018-05-31 23:46:13.374019|2018-05-31 23:46:13.374019
NCT01128023|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2018-05-28|2010-05-19|2010-05-21|Estimate|||||||2018-05-28|2018-05-30|Actual|April 2010||2010-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Rb-ARMI||Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)|Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)|Active, not recruiting|||10000|Anticipated|Ottawa Heart Institute Research Corporation|||2||f||||f||||||||||2018-05-31 23:46:13.444278|2018-05-31 23:46:13.444278
NCT01128010|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-05-20|2010-05-20|2010-05-21|Estimate|||||||2010-05-20|2010-05-21|Estimate||||December 2002|2002-12-31||||||||Observational|||Role of CCL2 in Alcoholic Liver Diseases||Completed|||||Erasme University Hospital|||2||f||||||||||||||2018-05-31 23:46:13.550404|2018-05-31 23:46:13.550404
NCT01127997|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-08-20|2010-05-20|2010-05-21|Estimate|||||||2010-08-20|2010-08-23|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||The Effect and Mechanisms of the Second-meal Phenomenon in Type 2 Diabetic Patients|The Effect and Mechanisms of the Second-meal Phenomenon in Type 2 Diabetic|Completed|||12|Anticipated|The Catholic University of Korea|||2||f||||f||||||Samples Without DNA|"~     plasma, serum~   "|||2018-05-31 23:46:13.606452|2018-05-31 23:46:13.606452
NCT01127984|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2011-02-10|2010-05-20|2010-05-21|Estimate|||||||2011-02-10|2011-02-11|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|PHP||Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator. The PHP Study.|Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator (ICD) During Dual Antiplatelet or Anticoagulant Therapy. A Prospective Randomized Trial. The PHP Study.|Completed||Phase 4|100|Anticipated|Careggi Hospital||2|||f||||t||||||||||2018-05-31 23:46:13.659162|2018-05-31 23:46:13.659162
NCT01127971|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-10-22|2010-05-20|2010-05-21|Estimate|||||||2014-10-22|2014-10-23|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PBI Registry||Patient Registry: Partial Breast Irradiation|Patient Registry: A Study of the Use of Accelerated Partial Breast Irradiation to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities|Terminated|||145|Actual|Aurora Health Care||||administrative reasons (no impact/concern of subject rights, welfare, safety)|f||||f||||||None Retained|"~     No biospecimens collected~   "|||2018-05-31 23:46:13.726363|2018-05-31 23:46:13.726363
NCT01127958|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2017-02-16|2010-05-20|2010-05-21|Estimate|||||||2017-02-16|2017-02-17|Actual|May 2010||2010-05-31|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||DARE-trial: A Trial Studying the Effect of the SeQuent Please Drug-eluting Balloon Compared to the Xience Prime Drug-eluting Stent for the Treatment of Stenosis of an Earlier Implanted Stent.|DARE-Trial: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomized Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the Xience Prime Drug-eluting Stent for the Treatment of In-stent Restenosis.|Active, not recruiting||N/A|270|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 23:46:13.774806|2018-05-31 23:46:13.774806
NCT01127945|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2014-02-04|2010-05-20|2010-05-21|Estimate|||||||2014-02-04|2014-02-05|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients|A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Evaluate the Effectiveness of High Dose Statin Loading in Acute Heart Failure Patients|Completed||N/A|50|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:46:13.883142|2018-05-31 23:46:13.883142
NCT01127932|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2015-05-11|2010-05-20|2010-05-21|Estimate|||||||2015-05-11|2015-05-13|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Developing an Intervention to Address Suicide Risk During Substance Use Disorder||Completed||N/A|56|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 23:46:13.946998|2018-05-31 23:46:13.946998
NCT01127919|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2017-11-08|2010-05-20|2010-05-21|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2010||2010-07-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|May 2016|Actual|2016-05-31||Observational|TIGER||Training Interventions and Genetics of Exercise Response (TIGER)|Training Interventions and Genetics of Exercise Response (TIGER)|Completed|||3773|Actual|University of Texas at Austin|||3||f||||f||||||Samples With DNA|"~     Blood components and DNA~   "|||2018-05-31 23:46:14.023634|2018-05-31 23:46:14.023634
NCT01127906|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-09-22|2010-05-20|2010-05-21|Estimate|||||||2010-09-22|2010-09-23|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin|A Randomized, Double-Blind, Double-Dummy, Placebo And Active Comparator Controlled 4-Period Cross-Over Study To Assess The Effect Of PF-04531083 On Heat Pain In The UVB-Induced Pain Model In Healthy Volunteers|Completed||Phase 1|36|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:46:14.098191|2018-05-31 23:46:14.098191
NCT01127893|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20||2012-10-01|2012-10-08|2010-05-20|2010-05-21|Estimate||||2012-10-08|2012-10-11|Estimate|2012-10-08|2012-10-11|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis|A Phase 3, Multicenter, Randomized, Long Term Study Of The Safety Of The Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee|Terminated||Phase 3|1|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-05-31 23:46:14.254413|2018-05-31 23:46:14.254413
NCT01127880|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-05-20|2010-05-20|2010-05-21|Estimate|||||||2010-05-20|2010-05-21|Estimate|July 2005||2005-07-31|February 2009|2009-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax|The Role of Antibiotics in the Reduction of Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax: A Prospective, Double-Blinded Study|Completed||Phase 2/Phase 3|50|Actual|St. Luke's Hospital, Pennsylvania||2|||f||||f||||||||||2018-05-31 23:46:14.323344|2018-05-31 23:46:14.323344
NCT01126723|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2015-01-20||2015-02-04|2010-05-18|2010-05-20|Estimate|2015-01-20|2015-01-30|Estimate||||2015-02-04|2015-02-23|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of Tai Chi on Frailty in Elderly Adults|The Effects of Tai Chi on the Nonlinear Dynamics of Frailty in Elderly Adults|Completed||N/A|66|Actual|Hebrew Rehabilitation Center, Boston||2|||f||||f||||||||||2018-05-31 23:46:34.318832|2018-05-31 23:46:34.318832
NCT01127867|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2017-03-09|2010-05-20|2010-05-21|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2010||2010-05-31|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women|Docosahexaenoic Acid (DHA) Reduces Inflammation and Aromatase Expression in Subcutaneous Fat in Obese Postmenopausal Women: A Pilot Study|Completed||N/A|17|Actual|Rockefeller University|||||f||||f|f|f||||||Undecided||2018-05-31 23:46:14.446294|2018-05-31 23:46:14.446294
NCT01127854|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2018-03-20|2010-05-20|2010-05-21|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2009||2009-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pilot Study to Evaluate the Contribution of Gene Variants to Idiopathic Urolithiasis|Pilot Study to Evaluate the Contribution of Gene Variants to Idiopathic Urolithiasis|Enrolling by invitation|||900|Actual|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     Blood, Urine and DNA~   "|||2018-05-31 23:46:14.505552|2018-05-31 23:46:14.505552
NCT01127841|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2013-08-22|2010-05-20|2010-05-21|Estimate|||||||2013-08-22|2013-08-23|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line|Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas||1|||f||||f||||||||||2018-05-31 23:46:14.567572|2018-05-31 23:46:14.567572
NCT01127828|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-05-21|2010-05-20|2010-05-21|Estimate|||||||2010-05-21|2010-05-24|Estimate|September 2005||2005-09-30|May 2010|2010-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes|Effects of Cultura Yoghurt on Symptoms Intestinal Flora and Immunological Changes in Patients With Irritable Bowel Syndrome(IBS)|Completed||N/A|80|Actual|Good Food Practice, Sweden||2|||f||||f||||||||||2018-05-31 23:46:14.666727|2018-05-31 23:46:14.666727
NCT01127815|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-05-20|2010-05-20|2010-05-21|Estimate|||||||2010-05-20|2010-05-21|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|March 2011|Anticipated|2011-03-31||Observational|||Identify the Clinical Significance and Potential Implications of Peritoneal Washing Cytology (PWC) in Patients With Pancreatic Cancer|Identify the Clinical Significance and Potential Implications of PWC in Patients With Pancreatic Cancer|Unknown status|Active, not recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     peritoneal washing cells, postoperative drainage, and parts of tumor tissues~   "|||2018-05-31 23:46:14.735933|2018-05-31 23:46:14.735933
NCT01127802|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2010-05-20|2010-05-20|2010-05-21|Estimate|||||||2010-05-20|2010-05-21|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Changes of Functional Status, Symptoms Distress and Quality of Life in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|Changes of Functional Status, Symptoms Distress and Quality of Life in Patients Undergoing CABG Surgery|Unknown status|Enrolling by invitation||50|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 23:46:14.800632|2018-05-31 23:46:14.800632
NCT01127789|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-12-20|2010-05-20|2010-05-21|Estimate|||||||2012-12-20|2012-12-21|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|March 2011|Actual|2011-03-31||Interventional|||The Use of Transcranial Direct Current Stimulation (tDCS) to Study Implicit Motor Learning on Patients With Brain Injury|The Use of Transcranial Direct Current Stimulation (tDCS) to Study Implicit Motor Learning on Patients With Brain Injury|Withdrawn||Phase 1|0|Actual|National Taiwan University Hospital||1||test device not approved to be used|f||||t||||||||||2018-05-31 23:46:14.909796|2018-05-31 23:46:14.909796
NCT01127776|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-03-16|2010-05-20|2010-05-21|Estimate|||||||2012-03-16|2012-03-19|Estimate|October 2010||2010-10-31|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|March 2011|Actual|2011-03-31||Interventional|APOS-IL 001||Bi-trimalleolar Fracture and APOS System Treatment|APOS System Effects in Post-operation Bi-trimalleolar Fracture of Ankle Prospective, Comparative Randomize Trial Study|Unknown status|Recruiting|Phase 1|60|Anticipated|Meir Medical Center||2|||f||||||||||||||2018-05-31 23:46:14.982986|2018-05-31 23:46:14.982986
NCT01127763|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2014-01-24||2014-03-11|2010-05-20|2010-05-21|Estimate|2014-03-11|2014-04-09|Estimate||||2014-03-11|2014-04-09|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||RAD001 Plus Carboplatin in Breast Cancer Patients|Phase II Trial of RAD001 Plus Carboplatin in Patients With Triple-Negative Metastatic Breast Cancer|Completed||Phase 2|25|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 23:46:15.164442|2018-05-31 23:46:15.164442
NCT01127750|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2017-02-21|2010-05-19|2010-05-21|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2010||2010-05-31|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients|A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis|Completed||Phase 3|2417|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:46:15.62914|2018-05-31 23:46:15.62914
NCT01127737|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2011-04-13||2015-03-17|2010-05-20|2010-05-21|Estimate|2011-05-10|2011-06-01|Estimate||||2015-03-17|2015-04-03|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|SCCs in OTRs||Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients|Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients|Completed||N/A|75|Actual|Northwestern University|"Small sample at a single center for a limited period of follow-up~The dermatologists' assessment of the participants' concerning lesions was not performed"|2|||f||||f||||||||||2018-05-31 23:46:16.127574|2018-05-31 23:46:16.127574
NCT01127724|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-11-18|2010-05-20|2010-05-21|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis|Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis|Terminated||N/A|8|Actual|Meir Medical Center||3||difficulties in recruiting participants|f||||t||||||||||2018-05-31 23:46:16.964954|2018-05-31 23:46:16.964954
NCT01127711|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-02-27|2010-05-20|2010-05-21|Estimate|||||||2014-02-27|2014-02-28|Estimate|September 1997||1997-09-30|February 2014|2014-02-28||||December 1997|Actual|1997-12-31||Observational|COSM||Cohort of Swedish Men|Cohort of Swedish Men|Completed|||48850|Actual|Karolinska Institutet|||||f||||t||||||Samples With DNA|"~     Saliva Blood~   "|||2018-05-31 23:46:17.056045|2018-05-31 23:46:17.056045
NCT01127698|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|||2014-02-27|2010-05-20|2010-05-21|Estimate|||||||2014-02-27|2014-02-28|Estimate|March 1987||1987-03-31|February 2014|2014-02-28||||December 1990|Actual|1990-12-31||Observational|SMC||Swedish Mammography Cohort|Swedish Mammography Cohort|Completed|||61433|Anticipated|Karolinska Institutet|||||f||||t||||||Samples With DNA|"~     Saliva Blood~   "|||2018-05-31 23:46:17.253086|2018-05-31 23:46:17.253086
NCT01127685|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2011-08-29|2010-05-20|2010-05-21|Estimate|||||||2011-08-29|2011-08-30|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Weight-bearing Measuring Device Following Anterior Cruciate Ligament Reconstruction|The Use of a Biofeedback Insole Weight-bearing Measuring Device in Determining Weight-bearing Deficits Following Anterior Cruciate Ligament Reconstruction|Completed||Phase 1|30|Anticipated|Meir Medical Center|||||f||||||||||||||2018-05-31 23:46:17.522921|2018-05-31 23:46:17.522921
NCT01127672|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2014-04-15|2010-05-19|2010-05-21|Estimate|||||||2014-04-15|2014-04-16|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Treatment of Plantar Fasciitis With Platelet Rich Plasma|Platelet Rich Plasma Injection Compared to Corticosteroid Injection for Treatment of Plantar Fasciitis. A Prospective, Randomized Control Trial|Withdrawn||N/A|0|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 23:46:17.63327|2018-05-31 23:46:17.63327
NCT01127659|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-20|2017-01-13||2017-03-10|2010-05-20|2010-05-21|Estimate|2017-01-13|2017-03-07|Actual||||2017-03-10|2017-04-12|Actual|May 2010||2010-05-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Testosterone Replacement in Men With Diabetes and Obesity|Effect of Hypogonadotrophic Hypogonadism and Treatment With Testosterone on Insulin Sensitivity, Inflammation, Body Composition and Sexual Function in Obese and Type 2 Diabetic Men|Completed||Phase 4|144|Actual|University at Buffalo||6|||f||||f||||||||No||2018-05-31 23:46:17.777002|2018-05-31 23:46:17.777002
NCT01127646|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2012-04-30||2012-11-26|2010-05-19|2010-05-21|Estimate|2012-04-30|2012-06-04|Estimate||||2012-11-26|2012-11-28|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|EMD||A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents|Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study)|Terminated||Phase 4|23|Actual|Eli Lilly and Company|This study (Study LYEN) was terminated after enrolling 23 participants due to lack of availability of study participants to accommodate the study design.|2||Due to lack of availability of study participants to accommodate the study design|f||||f||||||||||2018-05-31 23:46:18.38315|2018-05-31 23:46:18.38315
NCT01127633|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2018-02-12|2014-09-29|2018-04-02|2010-05-19|2010-05-21|Estimate|2018-04-02|2018-05-03|Actual|2014-09-29|2014-10-08|Estimate|2018-04-02|2018-05-03|Actual|December 2010||2010-12-31|April 2018|2018-04-30|February 2017|Actual|2017-02-28|July 2014|Actual|2014-07-31||Interventional|EXPEDITION EXT|All randomized participants who received at least 1 dose of study drug.|Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease|Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease|Terminated||Phase 3|1457|Actual|Eli Lilly and Company||2||Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:46:19.193757|2018-05-31 23:46:19.193757
NCT01127620|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2012-09-25|2010-05-20|2010-05-21|Estimate|||||||2012-09-25|2012-09-26|Estimate|May 2004||2004-05-31|September 2012|2012-09-30|November 2006|Actual|2006-11-30|March 2006|Actual|2006-03-31||Interventional|||Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension|A Phase III, Comparative Study for the Efficacy and Safety of Bilastine 20 mg Versus Cetirizine 10 mg and Placebo in the Treatment of Perennial Allergic Rhinitis During 4 Weeks, Followed by a Long-term Safety Extension With Bilastine 20 mg|Completed||Phase 3|650|Actual|Faes Farma, S.A.||3|||f||||f||||||||||2018-05-31 23:46:22.084126|2018-05-31 23:46:22.084126
NCT01127607|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2014-01-06||2014-06-10|2010-05-20|2010-05-21|Estimate|2014-06-10|2014-06-13|Estimate||||2014-06-10|2014-06-13|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Adult participant was first stabilized on LDX during a 3 week open label titration. 11 participants dropped out during med titration phase (8 due to adverse events and 3 lost to follow-up; a 12th dropped out after group assignment but prior to receiving blinded phase II medication.|Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?|Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?|Completed||Phase 4|38|Actual|Florida International University|This study was limited by its small sample size. The validity and psychometrics of DPICS in adolescents is not well established, but removal of the adolescents had little impact on study results and actually strengthened some observed effects.|2|||f||||f||||||||||2018-05-31 23:46:22.247086|2018-05-31 23:46:22.247086
NCT01127594|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2015-03-06|2010-05-20|2010-05-21|Estimate|||||||2015-03-06|2015-03-09|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|||Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion|A Multi-Center Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-Arterial Temozolomide for Patients With Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion|Completed||Phase 1|29|Actual|Duke University|||||f||||f||||||||||2018-05-31 23:46:23.213026|2018-05-31 23:46:23.213026
NCT01127581|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2014-01-24|2013-04-12|2014-04-15|2010-05-20|2010-05-21|Estimate|2014-01-24|2014-03-07|Estimate|2013-04-12|2013-04-19|Estimate|2014-04-15|2014-05-01|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|EXPEDITE||Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery|Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy & Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term|Completed||Phase 3|1358|Actual|Ferring Pharmaceuticals||2|||f||||t||||||||||2018-05-31 23:46:23.517154|2018-05-31 23:46:23.517154
NCT01127568|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-05-20|2010-05-20|2010-05-21|Estimate|||||||2010-05-20|2010-05-21|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|June 2012|Anticipated|2012-06-30|September 2010|Anticipated|2010-09-30||Interventional|||A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol|A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Douglas Mental Health University Institute||2|||f||||t||||||||||2018-05-31 23:46:24.330644|2018-05-31 23:46:24.330644
NCT01126710|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-02-09|2010-05-18|2010-05-20|Estimate|||||||2012-02-09|2012-02-13|Estimate|May 2010||2010-05-31|February 2012|2012-02-29||||||||Observational|||Optical Detection of Intravenous Infiltration|Optical Detection of Intravenous Infiltration|Completed|||263|Actual|CW Optics, Inc.|||||f||||||||||||||2018-05-31 23:46:34.721354|2018-05-31 23:46:34.721354
NCT01127555|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-10-06|2010-05-20|2010-05-21|Estimate|||||||2013-10-06|2013-10-08|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|||Salvage mFOLFOX in BTC After Failure of Gemcitabine|Phase II Study of Salvage mFOLFOX(5-fluorouracil, Leucovorin, Oxaliplatin) in Patients With Unresectable Biliary Tract Cancer (BTC) Who Had Failed Gemcitabine|Completed||Phase 2|30|Actual|Chung-Ang University|||||f||||f||||||||||2018-05-31 23:46:24.43434|2018-05-31 23:46:24.43434
NCT01127542|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2011-12-02|2010-05-20|2010-05-21|Estimate|||||||2011-12-02|2011-12-05|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|||||Interventional|RESPeCT||RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial|A Single Arm Phase II Study to Investigate the Use of Lenalidomide in the Treatment of Patients With Early Stage CLL Associated With Poor Prognostic Factors|Terminated||Phase 2|1|Actual|The Christie NHS Foundation Trust||1||Potential safety issue of second primary malignancies in patients treated with lenalidomide.|f||||t||||||||||2018-05-31 23:46:24.511692|2018-05-31 23:46:24.511692
NCT01127529|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2018-01-16|2010-05-20|2010-05-21|Estimate|||||||2018-01-16|2018-01-18|Actual|June 23, 2010|Actual|2010-06-23|January 2018|2018-01-31|June 22, 2015|Actual|2015-06-22|June 22, 2015|Actual|2015-06-22||Observational|||Ceprotin Treatment Registry|Ceprotin Treatment Registry|Completed|||43|Actual|Shire|||1||f||||f||||||||||2018-05-31 23:46:24.604741|2018-05-31 23:46:24.604741
NCT01127516|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2014-07-08|2010-05-20|2010-05-21|Estimate|||||||2014-07-08|2014-07-09|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus|The Causes and Interpretation of Low-level Resistance in Staphylococcus Aureus to Vancomycin Among a Network of Academic Medical Center Hospitals|Completed|||45|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-05-31 23:46:24.706128|2018-05-31 23:46:24.706128
NCT01127503|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2017-12-19||2018-04-05|2010-05-20|2010-05-21|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|June 2010||2010-06-30|April 2018|2018-04-30|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Interventional|||Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome|A Double-Blind, Placebo-Controlled, Multi-Center, Randomized Trial of the Safety and Efficacy of Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velo-Cardio-Facial Syndrome|Terminated||Phase 2|2|Actual|Valeant Pharmaceuticals International, Inc.||2||Enrollment, study-design and execution challenges.|f||||f||||||||||2018-05-31 23:46:24.793807|2018-05-31 23:46:24.793807
NCT01127490|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2011-06-21|2010-05-20|2010-05-21|Estimate|||||||2011-06-21|2011-06-23|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study to Assess Mechanisms in Peripheral Tissue Innervation for Fibromyalgia|Duloxetine(Cymbalta) for Fibromyalgia: An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Duloxetine|Unknown status|Recruiting|N/A|30|Anticipated|Albany Medical College|||||f||||f||||||||||2018-05-31 23:46:25.057289|2018-05-31 23:46:25.057289
NCT01127477|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2012-06-25|2010-05-20|2010-05-21|Estimate|||||||2012-06-25|2012-06-26|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Obtain Volume Effect and Safety Data on 6 % Hydroxyethyl Starch 130/0.4 in Pediatric and Adult Patients Undergoing Major Elective Surgery|Examination of Volume Effect and Safety of 6 % Hydroxyethyl Starch 130/0.4 in Patients Undergoing Major Elective Surgery - an Uncontrolled, Open-labelled, Multi-centre Study|Completed||Phase 3|20|Actual|Fresenius Kabi||1|||f||||f||||||||||2018-05-31 23:46:25.116449|2018-05-31 23:46:25.116449
NCT01127464|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2014-05-07|2010-05-19|2010-05-20|Estimate|||||||2014-05-07|2014-05-08|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||DCVax Plus Poly ICLC in Healthy Volunteers|A Randomized, Placebo-controlled, Dose-escalating, Double-blinded Phase I Study to Evaluate the Safety and Immunogenicity of Anti-DEC-205 Monoclonal Antibody (Mab) Targeted HIV Gag p24 Vaccine (DCVax-001) With Poly ICLC (Hiltonol) as Adjuvant in HIV-uninfected Healthy Volunteers|Completed||Phase 1|43|Actual|Rockefeller University||5|||f||||t||||||||||2018-05-31 23:46:25.196838|2018-05-31 23:46:25.196838
NCT01127451|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19||2014-08-20|2017-12-15|2010-05-19|2010-05-20|Estimate||||2014-08-20|2014-08-22|Estimate|2017-12-15|2017-12-19|Actual|June 22, 2010|Actual|2010-06-22|December 2017|2017-12-31|March 30, 2018|Anticipated|2018-03-30|April 25, 2013|Actual|2013-04-25||Interventional|||Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma|A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma|Active, not recruiting||Phase 2|98|Actual|Eisai Inc.||1|||f||||f|t|||||||||2018-05-31 23:46:25.29865|2018-05-31 23:46:25.29865
NCT01127438|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2012-11-16||2013-02-06|2010-05-19|2010-05-20|Estimate|2013-02-06|2013-02-08|Estimate||||2013-02-06|2013-02-08|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations|A Double-blind, Randomized, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations|Completed||Phase 4|153|Actual|Eisai Inc.||6|||f||||f||||||||||2018-05-31 23:46:25.449507|2018-05-31 23:46:25.449507
NCT01127425|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-06-04|2010-05-19|2010-05-20|Estimate|||||||2010-06-04|2010-06-07|Estimate|July 2006||2006-07-31|June 2006|2006-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Length of Hospital Stay, Nursing Hours and Recovery After Laparoscopic Versus Open Colon Resection Without Fast Track|Length of Hospital Stay, Nursing Hours and Recovery After Laparoscopic Versus Open Colon Resection Without Fast Track|Terminated||N/A|18|Actual|University Hospital, Gentofte, Copenhagen||2||Due to reorganisation in the hospital structure|f||||t||||||||||2018-05-31 23:46:26.193395|2018-05-31 23:46:26.193395
NCT01127412|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-05-19|2010-05-19|2010-05-20|Estimate|||||||2010-05-19|2010-05-20|Estimate|December 2006||2006-12-31|May 2010|2010-05-31||||December 2009|Actual|2009-12-31||Interventional|||Early Obesity Intervention Program Within GECKO Drenthe; a Randomized Controlled Trial|Early Obesity Intervention Program Within GECKO Drenthe; a Randomized Controlled Trial|Completed||N/A|228|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 23:46:26.325483|2018-05-31 23:46:26.325483
NCT01127399|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2018-01-31|2010-05-19|2010-05-20|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2009|Actual|2009-09-30|January 2018|2018-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|BOLD II||Bariatric and Obstructive Lung Disease Study II|Effects of Obesity on Airway Caliber and Airway Smooth Muscle Tone|Terminated|||40|Actual|Johns Hopkins University|||4|Funding revoked|f||||f||||||Samples With DNA|"~     Blood samples.~   "|||2018-05-31 23:46:26.390195|2018-05-31 23:46:26.390195
NCT01127386|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2017-07-31|2010-05-19|2010-05-20|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2009||2009-03-31|July 2017|2017-07-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome|Effect of Lenalidomide (Revlimid®) in Solid Tumour Patients With Inflammatory Cancer Cachexia Syndrome on Lean Body Mass and Muscle Strength: A Multicenter, Proof-of-concept Study of Fixed Dose or CRP-response-guided Dose of Lenalidomide in Relation to New Standard Basic Cachexia Management (Receiving Placebo).|Completed||Phase 1/Phase 2|200|Actual|Cantonal Hospital of St. Gallen||3|||f||||t||||||||||2018-05-31 23:46:26.467421|2018-05-31 23:46:26.467421
NCT01127373|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2017-10-31|2010-05-19|2010-05-20|Estimate|||||||2017-10-31|2017-11-06|Actual|May 2010|Actual|2010-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer|Pilot Study of Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer Patients Requiring Treatment of the Internal Mammary Lymph Nodes|Active, not recruiting||N/A|120|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:46:26.617873|2018-05-31 23:46:26.617873
NCT01127360|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2015-01-15|2010-05-19|2010-05-20|Estimate|||||||2015-01-15|2015-01-16|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|LUCAS||LUCAS (Lucentis Compared to Avastin Study)|LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration|Completed||Phase 4|420|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 23:46:26.691382|2018-05-31 23:46:26.691382
NCT01127347|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-03-21|2010-05-19|2010-05-20|Estimate|||||||2013-03-21|2013-03-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:46:26.762708|2018-05-31 23:46:26.762708
NCT01127334|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2012-04-02|2010-05-19|2010-05-20|Estimate|||||||2012-04-02|2012-04-04|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Pilot Study Using Echocardiography to Evaluate Patients With Heart Failure and Dyssynchrony Who Have a CRT-D Device|Validation of a Robust Method for Kinematic Analysis of Ventricular Mechanical Dyssynchrony by Two Dimensional Echocardiography in Patients With Cardiac Resynchronization Devices for Chronic Systolic Heart Failure and Conduction System Disease|Withdrawn|||0|Actual|University of Mississippi Medical Center|||1|Principal Investigator terminated study|f||||f||||||||||2018-05-31 23:46:26.79822|2018-05-31 23:46:26.79822
NCT01127321|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2014-08-11||2014-08-11|2010-05-19|2010-05-20|Estimate|2014-08-11|2014-08-26|Estimate||||2014-08-11|2014-08-26|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Safety population included all participants who were randomized into the study and received at least 1 dose of investigational product.|A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus|A Phase 1, Double-blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in SLE|Terminated||Phase 1|44|Actual|MedImmune LLC|The study was terminated early by the sponsor due to business reasons.|5||Business reasons|f||||f||||||||||2018-05-31 23:46:26.874052|2018-05-31 23:46:26.874052
NCT01127308|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2016-03-22|2010-05-19|2010-05-20|Estimate|||||||2016-03-22|2016-03-23|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)|An Open Label, Single-Period, Phase 1 Study To Evaluate The Pharmacokinetics, Excretion Balance And Metabolism Of [14C]-PF04971729 In Healthy Adult Male Subjects|Completed||Phase 1|6|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 23:46:27.450873|2018-05-31 23:46:27.450873
NCT01127295|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2018-03-01|2010-05-19|2010-05-20|Estimate|||||||2018-03-01|2018-03-02|Actual|June 17, 2010|Actual|2010-06-17|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|PHACS||Pharmacology of Adjuvant Hormonotherapy in Breast Cancer|Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer|Completed||Phase 4|2000|Actual|Institut Claudius Regaud||1|||f||||t||||||||||2018-05-31 23:46:27.531933|2018-05-31 23:46:27.531933
NCT01127282|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-05-19|2010-05-19|2010-05-20|Estimate|||||||2010-05-19|2010-05-20|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|August 2010|Anticipated|2010-08-31|June 2010|Anticipated|2010-06-30||Interventional|||The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A|The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A: a Randomized-controlled Trial|Unknown status|Recruiting|Phase 4|180|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:46:27.694361|2018-05-31 23:46:27.694361
NCT01127269|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2014-07-16|2010-05-19|2010-05-20|Estimate|||||||2014-07-16|2014-07-17|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|AFICIONADO||Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes|Practical Implementation of ADA/EASD Consensus Algorithm in Patients With Type 2 Diabetes: Timely Insulin Initiation and Titration|Completed||Phase 4|178|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:46:27.797752|2018-05-31 23:46:27.797752
NCT01127256|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2010-08-02||2012-06-20|2010-05-19|2010-05-20|Estimate|2012-06-20|2012-07-26|Estimate||||2012-06-20|2012-07-26|Estimate|May 2006||2006-05-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation|Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation|Completed||Phase 4|200|Actual|Eisai Inc.|Early termination leading to small numbers of subjects analyzed|2|||f||||||||||||||2018-05-31 23:46:28.159063|2018-05-31 23:46:28.159063
NCT01127243|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-05-19|2010-05-19|2010-05-20|Estimate|||||||2010-05-19|2010-05-20|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Day-case Versus Inpatient Laparoscopic Supracervical Hysterectomy|Do Women Prefer to Stay in Hospital Following Hysterectomy? A Randomised Trial of Day-case Versus Inpatient Laparoscopic Supracervical Hysterectomy|Completed||N/A|49|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:46:28.535177|2018-05-31 23:46:28.535177
NCT01127230|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-07-16|2010-05-19|2010-05-20|Estimate|||||||2010-07-16|2010-07-19|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|COMPARE||Comparison Between Celution Preparation and Manual Preparation of Adipocyte Derived Regenerative Cells, Using Stromal Vascular Fraction Cell Counts (COMPARE)|Comparison Between Celution Preparation and Manual Preparation of Adipocyte Derived Regenerative Cells, Using Stromal Vascular Fraction Cell Counts (COMPARE)|Completed|||100|Anticipated|Novena Medical Center|||1||f||||t||||||Samples With DNA|"~     Lipoaspirate from liposuction.~   "|||2018-05-31 23:46:28.644017|2018-05-31 23:46:28.644017
NCT01127217|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-09-12|2010-05-19|2010-05-20|Estimate|||||||2010-09-12|2010-09-14|Estimate|May 2009||2009-05-31|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension|The Multicenter, Randomized, Double Blind Phase 3 Clinical Trial to Compare Efficacy and Safety of Combination of Amlodipine and Losartan Compared to Amlodipine Monotherapy in Patients With Stage 2 Hypertension|Completed||Phase 3|149|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 23:46:28.828602|2018-05-31 23:46:28.828602
NCT01127204|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2016-07-11|2010-05-19|2010-05-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age|Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, Côte d'Ivoire, Rwanda)|Completed||Phase 2/Phase 3|161|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 23:46:28.903223|2018-05-31 23:46:28.903223
NCT01127191|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2012-07-24|2010-05-19|2010-05-20|Estimate|||||||2012-07-24|2012-07-25|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Effect of Prolonged Military Exercises With High Load Carriage, on Neuromuscular Fatigue and Physiological/Biomechanical Responses||Completed|||10|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||t||||||Samples Without DNA|"~     Lactatemia, based on subject's arterialized capillary blood samples analysis.~   "|||2018-05-31 23:46:29.008621|2018-05-31 23:46:29.008621
NCT01127178|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2016-01-27|2010-05-19|2010-05-20|Estimate|||||||2016-01-27|2016-01-29|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors|Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors|Completed||Phase 1|12|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 23:46:29.095041|2018-05-31 23:46:29.095041
NCT01127165|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2010-07-29||2012-06-25|2010-05-19|2010-05-20|Estimate|2012-06-25|2012-07-31|Estimate||||2012-06-25|2012-07-31|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Low and High Dose Zonisamide in Children as Monotherapy|A Multi-center Comparative Trial of Low and High Dose Zonisamide in Children as Monotherapy|Completed||Phase 4|125|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 23:46:29.169642|2018-05-31 23:46:29.169642
NCT01127152|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-11-20|2010-05-19|2010-05-20|Estimate|||||||2012-11-20|2012-11-21|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|ARIBA||Assessment of Automatic Relays by Intensive Basis Advantage Compared With Manual Relays, on the Hypotension Risks, During Noradrenalin Administration|Assessment of Automatic Relays by Intensive Basis Advantage Compared With Manual Relays, on the Hypotension Risks, During Noradrenalin Administration|Completed||N/A|50|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 23:46:29.524543|2018-05-31 23:46:29.524543
NCT01127139|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|2012-03-30||2012-03-30|2010-05-19|2010-05-20|Estimate|2012-03-30|2012-05-01|Estimate||||2012-03-30|2012-05-01|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension|Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With VerapamilSR/ Trandolapril Fixed Combination (Tarka®) in Patients With Essential Hypertension in Routine Clinical Practice|Completed|||3828|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:46:29.639717|2018-05-31 23:46:29.639717
NCT01127126|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2012-01-18|2010-05-19|2010-05-20|Estimate|||||||2012-01-18|2012-01-19|Estimate|December 2010||2010-12-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Bryophyllum Versus Placebo for Overactive Bladder|Treatment of the Overactive Bladder in Postmenopausal Women With Bryophyllum Pinnatum Versus Placebo (a Multicenter, Prospective, Double-blind Randomised, Placebo-controlled Clinical Pilot Study, Phase II Drug Study)|Completed||Phase 2|22|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 23:46:30.058143|2018-05-31 23:46:30.058143
NCT01127113|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-12-03|2010-05-19|2010-05-20|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Interventional|||Inflammatory Cell Trafficking After Myocardial Infarction|Inflammatory Cell Labelling and Tracking With Magnetic Resonance Imaging After Myocardial Infarction|Suspended||N/A|66|Anticipated|University of Edinburgh||3|||f||||f||||||||||2018-05-31 23:46:30.129685|2018-05-31 23:46:30.129685
NCT01127100|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2016-07-23|2010-05-19|2010-05-20|Estimate|||||||2016-07-23|2016-07-26|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain|Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial|Completed||Phase 4|108|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:46:30.203434|2018-05-31 23:46:30.203434
NCT01127087|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2012-11-21||2012-11-21|2010-05-19|2010-05-20|Estimate|2012-11-21|2012-12-24|Estimate||||2012-11-21|2012-12-24|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Oxazyme in Patients With Hyperoxaluria|A Pilot Study to Evaluate the Safety and Efficacy of Oxazyme (OC4) in Patients With Hyperoxaluria|Completed||Phase 1/Phase 2|22|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:46:30.292896|2018-05-31 23:46:30.292896
NCT01127074|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2010-05-19|2010-05-19|2010-05-20|Estimate|||||||2010-05-19|2010-05-20|Estimate|March 2002||2002-03-31|May 2010|2010-05-31|January 2010|Actual|2010-01-31|July 2008|Actual|2008-07-31||Interventional|KS2422-vacc||Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422)|Phase 1 Study: Induction of Systemic Immune Responses in Metastatic Breast Cancer Patients by Vaccination With a CD80-modified, Devitalized HLA-*A0201+ Breast Cancer Cell Line (KS24.22)|Completed||Phase 1|15|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 23:46:30.84813|2018-05-31 23:46:30.84813
NCT01127061|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-03-10|2010-05-19|2010-05-20|Estimate|||||||2017-03-10|2017-03-14|Actual|April 2010|Actual|2010-04-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|September 2015|Actual|2015-09-30||Interventional|RESET-HCM||Study of Exercise Training in Hypertrophic Cardiomyopathy|A Randomized Trial of Moderate Intensity Exercise Training in Hypertrophic Cardiomyopathy|Completed||N/A|136|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 23:46:30.987654|2018-05-31 23:46:30.987654
NCT01127048|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-06-14|2010-05-19|2010-05-20|Estimate|||||||2011-06-14|2011-06-15|Estimate|October 2008||2008-10-31|May 2010|2010-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Prospan® Hustenzäpfchen - Investigation on Efficacy and Tolerability in Children|Investigation on Efficacy and Tolerability of Prospan® Hustenzäpfchen for the Symptomatic Treatment of Acute Bronchitis Accompanied by Coughing in Children|Unknown status|Recruiting|Phase 3|1400|Anticipated|Engelhard Arzneimittel GmbH & Co.KG||2|||f||||t||||||||||2018-05-31 23:46:31.080184|2018-05-31 23:46:31.080184
NCT01127035|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-06-04|2010-05-19|2010-05-20|Estimate|||||||2010-06-04|2010-06-07|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Sublingual Immunotherapy In Alternaria-Induced Rhinitis|STUDIO IN DOPPIO CIECO DISODIOCROMOGLICATO + PLACEBO vs DISODIOCROMOGLICATO + IMMUNOTERAPIA SPECIFICA SUBLINGUALE PER ALTERNARIA IN PAZIENTI CON RINITE ALLERGICA DOVUTA A SENSIBILIZZAZIONE AD ALTERNARIA|Completed||Phase 4|27|Actual|University of Genova||2|||f||||f||||||||||2018-05-31 23:46:31.158204|2018-05-31 23:46:31.158204
NCT01127022|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-09-17|2010-05-19|2010-05-20|Estimate|||||||2013-09-17|2013-09-18|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Maternal Choline Intake on Choline Status and Health Biomarkers During Pregnancy and Lactation|Effect of Maternal Choline Intake on Maternal/Fetal Biomarkers of Choline Status|Completed||N/A|82|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 23:46:31.231394|2018-05-31 23:46:31.231394
NCT01127009|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2015-08-12|2010-05-19|2010-05-20|Estimate|||||||2015-08-12|2015-08-13|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)|Completed||Phase 1|3|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:46:31.325819|2018-05-31 23:46:31.325819
NCT01126996|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2013-05-07|2010-05-19|2010-05-20|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Understanding the Persistence of Immunity After MenC Vaccines|An Observational Study Into the Maintenance of Seroprotection Against Meningococcal Serogroup C Disease Throughout Childhood Following a Single Dose of a Conjugated Meningococcal Serogroup C Vaccine Administered to Toddlers|Completed|||240|Anticipated|University of Oxford|||1||f||||f||||||||||2018-05-31 23:46:31.443611|2018-05-31 23:46:31.443611
NCT01126983|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-16|||2010-07-07|2010-05-18|2010-05-20|Estimate|||||||2010-07-07|2010-07-09|Estimate|May 2010||2010-05-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Lead Migration in Spinal Cord Stimulation Trials: Comparing Non-suture vs Suture and Lead Anchor|Lead Migration in Spinal Cord Stimulation Trials: Comparing Non-suture vs Suture and Lead Anchor Securing Methods: A Randomized Single Blind Clinical Trial for Better Outcomes.|Completed||N/A|50|Anticipated|Spine Care, Oklahoma||1|||f||||f||||||||||2018-05-31 23:46:31.534262|2018-05-31 23:46:31.534262
NCT01126970|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17||2018-04-25|2018-05-07|2010-05-18|2010-05-20|Estimate||||2018-04-25|2018-04-27|Actual|2018-05-07|2018-05-09|Actual|April 2010||2010-04-30|May 2018|2018-05-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects|A Double-Blind, Multi-Center, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of 400 mg of Velneperit (S-2367) and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day With a Reduced Calorie Diet (RCD) in Obese Subjects|Completed||Phase 2|486|Actual|Shionogi Inc.||4|||f||||t||||||||||2018-05-31 23:46:31.627715|2018-05-31 23:46:31.627715
NCT01126957|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2016-09-23||2017-04-19|2010-05-19|2010-05-20|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|May 2007||2007-05-31|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||107 participants signed the consent but 4 were found ineligible. 103 participants started and completed the study. Data were collected but not analyzed as the investigator left the institution prior to analysis and did not make data available for others to analyze.|Combined Ketamine/Propofol for Emergency Department Procedural Sedation|Combined Ketamine/Propofol for Emergency Department Procedural Sedation|Terminated||N/A|107|Actual|University of Missouri-Columbia|"107 participants were consented for the study. 4 were terminated by the investigator as they received surgery and were no longer eligible.~No data were analyzed/available as the target number of 200 was not reached; the PI has left the institution."|2||Investigator left institution.|f||||f||||||||Undecided||2018-05-31 23:46:31.767457|2018-05-31 23:46:31.767457
NCT01126944|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2011-07-01|2010-05-18|2010-05-20|Estimate|||||||2011-07-01|2011-07-04|Estimate|March 2010||2010-03-31|September 2010|2010-09-30|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|CHECKMATE||LVAD in Non Cardiac Transplant Candidates and Non Responders to Resynchronization|Study of Congestive Heart Failure Through the Evaluation of Cardiac Resynchronization Non-responders and Mechanical Assistance Therapy|Withdrawn||Phase 3|24|Anticipated|Rennes University Hospital||2||No patients recruted since recruiting is open|f||||t||||||||||2018-05-31 23:46:31.915334|2018-05-31 23:46:31.915334
NCT01126931|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-19|2010-05-19|2010-05-20|Estimate|||||||2010-05-19|2010-05-20|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Observational|||Wormwood in Chronic Progressive Disorders With Reduced Appetite|Pilot Trial With Wormwood to Improve Appetite in Cancer, Autoimmune Diseases, Depression and Old Age|Unknown status|Recruiting||300|Anticipated|University Hospital Freiburg|||||f||||f||||||||||2018-05-31 23:46:31.97479|2018-05-31 23:46:31.97479
NCT01126918|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2016-09-29|2010-05-18|2010-05-20|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students|Eating Disorders Prevention: An Effectiveness Trial for At-Risk College Students|Completed||N/A|432|Actual|Oregon Research Institute||2|||f||||t||||||||||2018-05-31 23:46:32.040169|2018-05-31 23:46:32.040169
NCT01126905|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2018-05-08|2010-05-19|2010-05-20|Estimate|||||||2018-05-08|2018-05-14|Actual|June 2010||2010-06-30|May 2018|2018-05-31|October 7, 2010|Actual|2010-10-07|October 7, 2010|Actual|2010-10-07||Observational|||Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal Patients|A Local Pilot Evaluation of Laboratory Monitoring of Renal Patients on Erythropoietin and /or Iron Therapy Using Mean Reticulated Haemoglobin Equivalent (RetHe) and Their Response to Therapy|Completed|||250|Actual|NHS Tayside|||||f||||t||||||||||2018-05-31 23:46:32.117174|2018-05-31 23:46:32.117174
NCT01124500|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-08-25|2010-05-13|2010-05-17|Estimate|||||||2010-08-25|2010-08-26|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Transdermal Methylphenidate for Cancer-Related Fatigue|Efficacy and Safety of Transdermal Methylphenidate for Cancer-Related Fatigue|Withdrawn||N/A|0|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:47:29.808496|2018-05-31 23:47:29.808496
NCT01126892|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2017-02-24|2010-05-18|2010-05-20|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2009||2009-01-31|February 2017|2017-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ENACT||A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|Completed||Phase 3|6|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:46:32.165128|2018-05-31 23:46:32.165128
NCT01126879|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2017-12-11|2010-05-18|2010-05-20|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2010||2010-05-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Genistein in Treating Patients With Prostate Cancer|Phase 2 Trial of Genistein in Men With Circulating Prostate Cancer Cells|Active, not recruiting||Phase 2|36|Anticipated|Northwestern University||2|||f||||t|t|f||||||||2018-05-31 23:46:32.228311|2018-05-31 23:46:32.228311
NCT01126866|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2011-07-14|2010-05-18|2010-05-20|Estimate|||||||2011-07-14|2011-07-15|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|APRIORI||Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy|Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab)|Terminated||Phase 2|35|Anticipated|National Center for Tumor Diseases, Heidelberg||1||recruiting inadequate|f||||t||||||||||2018-05-31 23:46:32.3032|2018-05-31 23:46:32.3032
NCT01126853|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-05-18|2010-05-18|2010-05-20|Estimate|||||||2010-05-18|2010-05-20|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders|A Pilot Study Evaluating the Combination Hepatitis A and B Vaccine (Twinrix®) in Healthy Healthcare Workers Who Meet the CDC Definition for Non-responders.|Unknown status|Recruiting|Phase 4|30|Anticipated|Mount Sinai Hospital, Canada||1|||f||||t||||||||||2018-05-31 23:46:32.397821|2018-05-31 23:46:32.397821
NCT01126840|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2017-10-06|2010-05-18|2010-05-20|Estimate|||||||2017-10-06|2017-10-09|Actual|June 20, 2010|Actual|2010-06-20|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Survivorship in Lynch Syndrome Families|Cancer Survivorship in Lynch Syndrome: Impact on Patients and Families|Active, not recruiting|||303|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 23:46:32.490014|2018-05-31 23:46:32.490014
NCT01126827|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-07-06|2010-05-18|2010-05-20|Estimate|||||||2011-07-06|2011-07-07|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|MBCT||Mindfulness-Based Cognitive Behavior Therapy for Bipolar Disorder|Mindfulness-Based Cognitive Behavior Therapy for Bipolar Disorder: A Randomized, Controlled Study|Completed||N/A|46|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:46:32.562208|2018-05-31 23:46:32.562208
NCT01126814|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-06-22|2010-05-19|2010-05-20|Estimate|||||||2015-06-22|2015-06-24|Estimate|July 2004||2004-07-31|June 2015|2015-06-30|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia|A Phase I-II Study Evaluating the Safety and Efficacy of Imatinib Mesylate (Gleevec) Combined With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|35|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 23:46:32.634098|2018-05-31 23:46:32.634098
NCT01126801|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2016-07-12||2017-09-19|2010-05-18|2010-05-20|Estimate|2016-07-12|2016-08-22|Estimate||||2017-09-19|2017-10-20|Actual|May 2010||2010-05-31|September 2017|2017-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women|Effects of Estrogen and Hot Flashes on Mood in Postmenopausal Women|Terminated||Phase 2|2|Actual|Massachusetts General Hospital|Due to the challenge of identifying eligible participants, we decided to stop enrolling subjects and not to analyze the 2 completed participants.|2||Stopped enrolling subjects due to challenge of identifying eligible participants|f||||t||||||||||2018-05-31 23:46:32.693929|2018-05-31 23:46:32.693929
NCT01126788|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2010-11-23|2010-05-19|2010-05-20|Estimate|||||||2010-11-23|2010-11-24|Estimate|December 2009||2009-12-31|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Comparative Physiologic Technology Study|Comparative Physiologic Technology Study|Unknown status|Recruiting||100|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 23:46:32.839775|2018-05-31 23:46:32.839775
NCT01126775|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2013-01-22|2010-05-19|2010-05-20|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2012||2012-04-30|January 2013|2013-01-31||||November 2013|Anticipated|2013-11-30||Observational|||Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie)|Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 Systematische Prävention Bei Hochrisikopatienten für Schlaganfall Und vaskulär (Mit)Bedingte Demenz: Identifizierung Und Behandlung Von Stummen Hirninfarkten.|Unknown status|Recruiting||1000|Anticipated|INVADE gGmbH|||2||f||||f||||||||||2018-05-31 23:46:32.892993|2018-05-31 23:46:32.892993
NCT01126762|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2012-03-20|2010-05-19|2010-05-20|Estimate|||||||2012-03-20|2012-03-22|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Trial of Fish Intake Advice in Pregnancy|A Pilot Randomized Controlled Trial to Promote Healthful Fish Consumption in Pregnancy|Completed||N/A|61|Actual|Harvard Pilgrim Health Care||3|||f||||f||||||||||2018-05-31 23:46:33.933128|2018-05-31 23:46:33.933128
NCT01126749|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-08-25|2010-05-19|2010-05-20|Estimate|||||||2017-08-25|2017-08-28|Actual|April 2010|Actual|2010-04-30|August 2017|2017-08-31|July 20, 2016|Actual|2016-07-20|May 9, 2015|Actual|2015-05-09||Interventional|||Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer|Completed||Phase 1/Phase 2|92|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 23:46:34.025477|2018-05-31 23:46:34.025477
NCT01126736|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2015-01-23|2010-05-18|2010-05-20|Estimate|||||||2015-01-23|2015-01-26|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|December 2012|Actual|2012-12-31||Interventional|||Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|150|Anticipated|Eisai Inc.||3|||f||||f||||||||||2018-05-31 23:46:34.184039|2018-05-31 23:46:34.184039
NCT01126697|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2016-06-13|2010-05-18|2010-05-20|Estimate|||||||2016-06-13|2016-06-14|Estimate|February 2010||2010-02-28|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies|PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies|Enrolling by invitation||Phase 2/Phase 3|120|Anticipated|Cooperative International Neuromuscular Research Group||4|||f||||t||||||||||2018-05-31 23:46:34.884851|2018-05-31 23:46:34.884851
NCT01126684|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-19|||2010-05-19|2010-05-19|2010-05-20|Estimate|||||||2010-05-19|2010-05-20|Estimate|June 2008||2008-06-30|April 2010|2010-04-30||||December 2009|Actual|2009-12-31||Interventional|||Effects of Atorvastatin on Blood Pressure and Urinary Albumin Excretion|EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL HYPERTENSION|Completed||N/A|50|Actual|Aristotle University Of Thessaloniki||2|||f||||||||||||||2018-05-31 23:46:35.026675|2018-05-31 23:46:35.026675
NCT01126671|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2013-03-08||2013-03-08|2010-05-18|2010-05-20|Estimate|2013-03-08|2013-04-19|Estimate||||2013-03-08|2013-04-19|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Vitamin D Supplementation in Healthy Adolescents|Clinical Trial of Vitamin D Supplementation in Healthy Adolescents|Completed||N/A|56|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 23:46:35.18403|2018-05-31 23:46:35.18403
NCT01126658|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2010-05-20|2010-05-18|2010-05-20|Estimate|||||||2010-05-20|2010-05-24|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|June 2010|Anticipated|2010-06-30|February 2010|Actual|2010-02-28||Observational|||Evaluation the Intracranial Volume Pressure Response in Increased Intracranial Pressure|Evaluation of the Intracranial Volume Pressure Relationship in Increased Intracranial Pressure Patients by a Mathematic Manner|Unknown status|Recruiting||41|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-05-31 23:46:35.603641|2018-05-31 23:46:35.603641
NCT01126645|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2016-12-02|2010-05-19|2010-05-20|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2010||2010-12-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|SORAMIC||Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer|Evaluation of Sorafenib in Combination With Local Micro-therapy Guided by Gd-EOB-DTPA Enhanced MRI in Patients With Inoperable Hepatocellular Carcinoma|Active, not recruiting||Phase 2|529|Actual|University of Magdeburg||2|||f||||t||||||||||2018-05-31 23:46:35.690289|2018-05-31 23:46:35.690289
NCT01126632|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-15|||2016-01-27|2010-05-18|2010-05-20|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|CAC||Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial|Will Cap-Assisted Colonoscopy Improve Performance of Colonoscopy: A Randomized Clinical Trial|Withdrawn|||0|Actual|Nova Scotia Health Authority|||2|Caps became unavailable by manufacturer|f||||f||||||||No|Study was terminated|2018-05-31 23:46:35.851868|2018-05-31 23:46:35.851868
NCT01126619|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2012-09-07||2012-10-19|2010-05-18|2010-05-20|Estimate|2012-09-07|2012-10-11|Estimate||||2012-10-19|2012-10-25|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis|To Observe the Effectiveness and Safety of Anti-TNFs in Patients With Moderate to Severe Psoriasis|Completed|||103|Actual|Abbott|||1||f||||||||||||||2018-05-31 23:46:35.976524|2018-05-31 23:46:35.976524
NCT01126606|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-12-01|2010-05-18|2010-05-19|Estimate|||||||2010-12-01|2010-12-02|Estimate|August 2010||2010-08-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparative Safety and Efficacy Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional|Single Center, Open, Cross-over, Phase III Study for Safety and Efficacy (Subjective and Instrumental) Comparative Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional for Intimate Use in Menopauses Woman.|Completed||Phase 3|70|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:46:36.370769|2018-05-31 23:46:36.370769
NCT01126593|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2013-11-06||2014-11-06|2010-05-18|2010-05-19|Estimate|2014-11-06|2014-11-07|Estimate||||2014-11-06|2014-11-07|Estimate|December 2008||2008-12-31|November 2014|2014-11-30|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion|Efficacy of Continuous Subacromial Bupivacaine Infusion for Postoperative Analgesia After Arthroscopic Rotator Cuff Repair.|Completed||N/A|96|Actual|Orlando Health, Inc.|It is possible that different catheter infusion rates, different bupivacaine concentrations, and pain modulation agents different from bupivacaine could result in different findings.|3|||f||||t||||||||||2018-05-31 23:46:36.452803|2018-05-31 23:46:36.452803
NCT01126580|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2014-10-03|2012-05-24|2015-01-15|2010-05-18|2010-05-19|Estimate|2015-01-15|2015-01-16|Estimate|2012-05-24|2012-06-01|Estimate|2015-01-15|2015-01-16|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional||Participants who received at least 1 dose of LY2189265 or Metformin.|A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)|The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)|Completed||Phase 3|807|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:46:36.833723|2018-05-31 23:46:36.833723
NCT01126567|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-05-18|2010-05-18|2010-05-19|Estimate|||||||2010-05-18|2010-05-19|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Observational|||Exploratory Biomarker Study of Cerebrospinal Fluid in Healthy Volunteers|A Study of the Effects of Sampling Rate on Cerebrospinal Fluid (CSF) Biomarker Levels in Healthy Subjects|Completed|||8|Actual|Abbott|||2||f||||||||||Samples With DNA|"~     Whole blood, plasma, cerebrospinal fluid~   "|||2018-05-31 23:46:38.941806|2018-05-31 23:46:38.941806
NCT01126554|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-04-28|2010-05-18|2010-05-19|Estimate|||||||2014-04-28|2014-04-29|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|Greenpep||ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill Patients|ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill|Completed|||110|Anticipated|University of Zurich|||1||f||||t||||||||||2018-05-31 23:46:39.024396|2018-05-31 23:46:39.024396
NCT01126541|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|2014-07-15||2014-09-10|2010-05-18|2010-05-19|Estimate|2014-09-10|2014-09-15|Estimate||||2014-09-10|2014-09-15|Estimate|September 2006||2006-09-30|September 2014|2014-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy|A Comparative Study to Assess the Effect of Retreatment With 2 Doses of MabThera on Disease Activity Score in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to antiTNF-alfa Therapy.(SMART)|Completed||Phase 3|224|Actual|Hoffmann-La Roche|Nonserious adverse events (AEs) presented in this record include all AEs reported during the study, not just nonserious events.|2|||f||||||||||||||2018-05-31 23:46:39.208421|2018-05-31 23:46:39.208421
NCT01126528|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-08-16|2010-05-18|2010-05-19|Estimate|||||||2012-08-16|2012-08-17|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|AViDD-2||Antenatal Vitamin D3 Supplementation in Bangladesh: Randomized Controlled Trial|The Effect of Antenatal Vitamin D Supplementation on Maternal-fetal Vitamin D Status and Neonatal Immune Function: a Randomized Controlled Trial in Bangladesh|Completed||Phase 2|160|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 23:46:41.837604|2018-05-31 23:46:41.837604
NCT01126515|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2011-03-15|2010-05-18|2010-05-19|Estimate|||||||2011-03-15|2011-03-17|Estimate|July 2007||2007-07-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|HYBOBI-MRI||Functional and Anatomical Magnetic Resonance Imaging (MRI) of Chronic Brain Injury and Hyperbaric Oxygen (HBO2) Study Subjects|MRI & CT Angiogram and Hyperbaric Oxygen in Chronic Stable Brain Injury|Completed|||20|Anticipated|Intermountain Health Care, Inc.|||1||f||||f||||||||||2018-05-31 23:46:41.902836|2018-05-31 23:46:41.902836
NCT01126502|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2015-11-03|2010-05-18|2010-05-19|Estimate|||||||2015-11-03|2015-11-04|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia|A Phase I Study of the Hsp90 Inhibitor 17-DMAG (Alvespimycin) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), and B-cell Prolymphocytic Leukemia (B-PLL)|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1||Administratively Complete.|f||||||||||||||2018-05-31 23:46:41.966357|2018-05-31 23:46:41.966357
NCT01126476|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-01-26|2010-05-18|2010-05-19|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2010||2010-02-28|September 2016|2016-09-30||||February 2017|Anticipated|2017-02-28||Interventional|||Proton Radiotherapy for Recurrent Tumors|Retreatment of Recurrent Tumors Using Proton Therapy|Recruiting||N/A|24|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:46:42.029457|2018-05-31 23:46:42.029457
NCT01126463|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2017-11-20|2010-05-18|2010-05-19|Estimate|||||||2017-11-20|2017-11-22|Actual|May 2010||2010-05-31|June 2016|2016-06-30|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|LIP-RE-I||188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas|Phase 1 Study of Hepatic Intra-Arterial Administration of 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas|Recruiting||Phase 1|24|Anticipated|Center Eugene Marquis||1|||f||||t||||||||||2018-05-31 23:46:42.184716|2018-05-31 23:46:42.184716
NCT01126450|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2012-03-16|2010-05-18|2010-05-19|Estimate|||||||2012-03-16|2012-03-20|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer|A Phase I, Open-Label Study To Determine The Maximum Tolerated Dose (Mtd) Of The Combination Of Lenalidomide And Cetuximab, And To Evaluate The Efficacy Of This Combination In Subjects With Wild Type K-Ras Metastatic Colorectal Carcinoma|Terminated||Phase 1|3|Actual|Case Comprehensive Cancer Center||1||low accrual,loss of funding and results from EU study showing drug ineffective.|f||||t||||||||||2018-05-31 23:46:42.258261|2018-05-31 23:46:42.258261
NCT01126437|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2014-05-20||2014-05-20|2010-05-18|2010-05-19|Estimate|2014-05-20|2014-06-20|Estimate||||2014-05-20|2014-06-20|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Treated set (TS): This analysis set included all randomized subjects without data irregularities who were documented to have taken at least one dose of investigational treatment.|Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease|A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)|Completed||Phase 3|17183|Actual|Boehringer Ingelheim|Prospectively defined outcome events, serious adverse events, adverse events leading to discontinuation, and investigator-determined drug-related adverse events were required for collection in this trial.|3|||f||||||||||||||2018-05-31 23:46:42.557498|2018-05-31 23:46:42.557498
NCT01126424|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2012-07-05|2011-12-12|2012-09-13|2010-05-18|2010-05-19|Estimate|2012-09-13|2012-10-15|Estimate|2011-12-12|2011-12-22|Estimate|2012-09-13|2012-10-15|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|SENIOR||A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability|A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study|Completed||Phase 4|26|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||f||||||||||2018-05-31 23:46:50.847224|2018-05-31 23:46:50.847224
NCT01126411|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2016-11-15|2010-05-18|2010-05-19|Estimate|||||||2016-11-15|2016-11-16|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Immunoadsorption in Patients With Pulmonary Hypertension|Randomized, Prospective Investigation on the Effects of Immunoadsorption on Pulmonary Vascular Resistance in Patients With Pulmonary Hypertension|Withdrawn||Phase 1/Phase 2|0|Actual|University Medicine Greifswald||2||PI left center|f||||f||||||||||2018-05-31 23:46:51.622274|2018-05-31 23:46:51.622274
NCT01126398|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-18|2010-05-18|2010-05-19|Estimate|||||||2010-05-18|2010-05-19|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Trauma Expectation Factor Trauma Outcome Measure|The Role of Patient Expectations in Traumatic Orthopedic Outcomes: the Development of the Trauma Expectation Factor Trauma Outcome Measure (TEFTOM)|Completed|||204|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 23:46:51.720069|2018-05-31 23:46:51.720069
NCT01126385|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2013-01-24|2010-05-18|2010-05-19|Estimate|||||||2013-01-24|2013-01-25|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Observational|DensiProbe||Pilot Study to Evaluate Feasibility of DensiProbe Spine Assessing Bone Strength in Spinal Surgery|A Prospective Case Series to Evaluate Handling and Feasibility of DensiProbe Spine Assessing Vertebral Bone Strength in Patients Undergoing Transpedicular Fixation of the Spine - a Pilot Study|Completed|||30|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 23:46:51.802802|2018-05-31 23:46:51.802802
NCT01126372|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-08-09|2010-05-18|2010-05-19|Estimate|||||||2013-08-09|2013-08-13|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease|Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease|Completed|||6|Actual|University of Utah|||||f||||f||||||||||2018-05-31 23:46:52.080995|2018-05-31 23:46:52.080995
NCT01126359|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2013-01-22||2014-05-21|2010-05-18|2010-05-19|Estimate|2014-05-21|2014-05-29|Estimate||||2014-05-21|2014-05-29|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Lidocaine Analgesia For Removal Of Wound Vac Dressings|Lidocaine Analgesia For Removal Of Wound Vacuum Assisted Closure Dressings: A Randomized Double Blinded Controlled Trial|Completed||N/A|11|Actual|University of Utah|Overall subjectivity of pain and dosing of narcotic medications, all male cohort, timing of wound VAC changes, did not define the ideal lidocaine dosing for VAC changes or dosing method.|2|||f||||f||||||||||2018-05-31 23:46:52.156637|2018-05-31 23:46:52.156637
NCT01126346|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2017-05-25|2010-05-18|2010-05-19|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2010||2010-05-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|April 2011|Actual|2011-04-30||Interventional|HOPE||Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HOPE Program: Quality of Life Enhancement and Survivorship Care|Completed||N/A|10|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 23:46:52.444168|2018-05-31 23:46:52.444168
NCT01126333|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-05-03|2010-05-18|2010-05-19|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2010||2010-06-30|May 2017|2017-05-31|June 30, 2015|Actual|2015-06-30|June 30, 2014|Actual|2014-06-30||Observational|STN||Long-term Follow-up of Spare the Nephron (STN) Patients|Long-term Follow-up of Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients.|Completed|||128|Actual|University of Maryland|||1||f||||f||||||||||2018-05-31 23:46:52.576103|2018-05-31 23:46:52.576103
NCT01126320|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-15|||2016-02-17|2010-05-18|2010-05-19|Estimate|||||||2016-02-17|2016-02-19|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated Patients Using the AnapnoGuard System|Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated ICU Patients Using the AnapnoGuard System|Completed||N/A|161|Actual|Hospitech Respiration||2|||f||||f||||||||||2018-05-31 23:46:52.77205|2018-05-31 23:46:52.77205
NCT01126307|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-18|2010-05-18|2010-05-19|Estimate|||||||2010-05-18|2010-05-19|Estimate|June 2010||2010-06-30|March 2010|2010-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study of Verapamil in Refractory Epilepsy||Unknown status|Not yet recruiting|N/A|16|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 23:46:52.922486|2018-05-31 23:46:52.922486
NCT01126294|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-18|2010-05-18|2010-05-19|Estimate|||||||2010-05-18|2010-05-19|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|September 2011|Anticipated|2011-09-30|July 2011|Anticipated|2011-07-31||Interventional|||Perioperative Melatonin in Lumbar Laminectomy|Perioperative Analgesic and Anxiolytic Effect of Melatonin in Patients Undergoing Lumbar Laminectomy|Unknown status|Recruiting|N/A|84|Anticipated|University Health Network, Toronto||3|||f||||f||||||||||2018-05-31 23:46:53.038606|2018-05-31 23:46:53.038606
NCT01126281|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-18|2010-05-18|2010-05-19|Estimate|||||||2010-05-18|2010-05-19|Estimate|August 2010||2010-08-31|May 2010|2010-05-31||||August 2013|Anticipated|2013-08-31||Interventional|GLA||Efficacy and Safety of Floseal for the Haemostasis During Laparoscopic Cholecystectomy in Acute Cholecystitis (GLA)|THE USE OF FLOSEAL GELATIN MATRIX FOR THE HAEMOSTASIS DURING LAPAROSCOPIC CHOLECYSTECTOMY FOR ACUTE CHOLECYSTITIS; EFFICACY AND SAFETY EVALUATED IN A MULTICENTER, PROSPECTIVE, OPEN LABEL TRIAL WITH AN HISTORICAL CONTROL GROUP. (G.L.A. STUDY: GELATIN Matrix in Laparoscopic Cholecystectomy for Acute Cholecystitis)|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|University of Bologna||1|||f||||||||||||||2018-05-31 23:46:53.259168|2018-05-31 23:46:53.259168
NCT01126268|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2015-12-14||2016-01-20|2010-05-18|2010-05-19|Estimate|2016-01-20|2016-02-17|Estimate||||2016-01-20|2016-02-17|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection|Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection|Completed||Phase 4|38|Actual|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 23:46:53.418253|2018-05-31 23:46:53.418253
NCT01126255|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2014-10-07|2010-05-17|2010-05-19|Estimate|||||||2014-10-07|2014-10-08|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Progesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus|Efficacy of a Topic Therapy With Progesterone Compared to the Conventional Therapy With Clobetasol Propionate in Patients With Vulvar Lichen Sclerosus. A Double Blind, Randomized Phase II Pilot Study.|Terminated||Phase 2|37|Actual|University Hospital Inselspital, Berne||2||Recruitment problems|f||||f||||||||||2018-05-31 23:46:54.233412|2018-05-31 23:46:54.233412
NCT01126242|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2016-02-12|2010-05-18|2010-05-19|Estimate|||||||2016-02-12|2016-02-15|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Tape Versus Semirigid Versus Lace-up Ankle Support in the Treatment of Acute Lateral Ankle Ligament Injury.|Tape Versus Semirigid Versus Lace-up Ankle Support in the Treatment of Acute Lateral Ankle Ligament Injury.|Completed||Phase 4|182|Actual|Gelre Hospitals||3|||f||||f||||||||||2018-05-31 23:46:54.332498|2018-05-31 23:46:54.332498
NCT01126229|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-12-10|2010-05-18|2010-05-19|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RIPE||Resveratrol for Improved Performance in the Elderly|A Pilot Study of Resveratrol Supplementation for Memory and Physical Performance|Completed||Phase 1|32|Actual|University of Florida||3|||f||||||||||||||2018-05-31 23:46:54.731671|2018-05-31 23:46:54.731671
NCT01126216|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-08-09|2010-05-17|2010-05-19|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2010||2010-05-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|February 2015|Actual|2015-02-28||Interventional|Paccis-RCT||Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer|Randomised Phase-III-trial of Simultaneous Radiochemotherapy (RCT) of Locally Advanced Head and Neck Cancer in the Stages III and IV A-B: Comparing Dose Reduced Radiotherapy (63,6 Gy) With Paclitaxel/Cisplatin to Standard Radiotherapy (70,2 Gy) With 5-Fluorouracil/Cisplatin|Active, not recruiting||Phase 3|542|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 23:46:54.834229|2018-05-31 23:46:54.834229
NCT01126203|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-21|2010-05-18|2010-05-19|Estimate|||||||2010-05-21|2010-05-24|Estimate|September 2006||2006-09-30|May 2010|2010-05-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|SLT||Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension|Randomized Multicentre Prospective Study of Selective Laser Trabeculoplasty (SLT) vs. Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension|Completed||Phase 3|25|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 23:46:54.993067|2018-05-31 23:46:54.993067
NCT01012648|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2011-03-15|2009-11-12|2009-11-13|Estimate|||||||2011-03-15|2011-03-16|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury||Unknown status|Recruiting|Phase 4|48|Anticipated|University of Zurich|||||f||||||||||||||2018-06-01 00:23:03.436452|2018-06-01 00:23:03.436452
NCT01126190|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04||2013-08-28|2016-07-19|2010-05-17|2010-05-19|Estimate||||2013-08-28|2013-09-13|Estimate|2016-07-19|2016-07-21|Estimate|June 2010||2010-06-30|July 2016|2016-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|NEUGR-003||Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)|A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Neugranin or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy|Completed||Phase 3|381|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 23:46:55.114024|2018-05-31 23:46:55.114024
NCT01126177|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2012-02-10|2010-05-18|2010-05-19|Estimate|||||||2012-02-10|2012-02-13|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Comparing Efficacy and Safety of Inhaled SNG001 to Placebo|A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses|Completed||Phase 2|300|Actual|Synairgen Research Ltd.||2|||f||||t||||||||||2018-05-31 23:46:55.325469|2018-05-31 23:46:55.325469
NCT01126164|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-12-18|2010-05-18|2010-05-19|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2005||2005-09-30|December 2017|2017-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|GOALS||Parent Intervention to Reduce Binge Drinking|Parent Intervention to Reduce Binge Drinking|Completed||N/A|800|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 23:46:55.420158|2018-05-31 23:46:55.420158
NCT01126151|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-12-13|2010-05-18|2010-05-19|Estimate|||||||2017-12-13|2017-12-15|Actual|July 2006||2006-07-31|December 2017|2017-12-31|September 2012|Actual|2012-09-30|October 2010|Actual|2010-10-31||Interventional|ACT||Parent Interventions to Prevent Student Drinking|Parent Interventions to Prevent Student Drinking|Completed||N/A|1900|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 23:46:55.515463|2018-05-31 23:46:55.515463
NCT01126138|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2011-05-03|2010-05-18|2010-05-19|Estimate|||||||2011-05-03|2011-05-04|Estimate|July 2010||2010-07-31|May 2010|2010-05-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|||Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)|A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.|Unknown status|Recruiting|Phase 3|200|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 23:46:55.596636|2018-05-31 23:46:55.596636
NCT01126125|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2012-11-07|2010-05-18|2010-05-19|Estimate|||||||2012-11-07|2012-11-08|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|INSIGHT||Study of the Effect of Iodized Oil Supplementation During Infancy|Iodized Oil Supplementation During Infancy|Completed||N/A|241|Actual|Swiss Federal Institute of Technology||2|||f||||t||||||||||2018-05-31 23:46:55.689971|2018-05-31 23:46:55.689971
NCT01126112|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2015-03-23|2010-05-18|2010-05-19|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|FRAIL||Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer|Phase II Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer|Completed||Phase 2|33|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-05-31 23:46:55.778216|2018-05-31 23:46:55.778216
NCT01126099|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2014-07-15||2015-05-19|2010-05-18|2010-05-19|Estimate|2015-05-19|2015-05-21|Estimate||||2015-05-19|2015-05-21|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease|Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease|Completed||N/A|20|Actual|Seattle Institute for Biomedical and Clinical Research||2|||f||||t||||||||||2018-05-31 23:46:55.895319|2018-05-31 23:46:55.895319
NCT01126086|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-05-07|2010-05-17|2010-05-19|Estimate|||||||2014-05-07|2014-05-08|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment|An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 μg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function.|Completed||Phase 1|25|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 23:46:56.208339|2018-05-31 23:46:56.208339
NCT01126073|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2011-10-05|2010-05-18|2010-05-19|Estimate|||||||2011-10-05|2011-10-06|Estimate|September 2010||2010-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Niacin/Laropiprant and Endothelial Function|A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin|Completed||Phase 4|60|Anticipated|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 23:46:56.295159|2018-05-31 23:46:56.295159
NCT01126060|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2011-09-06||2011-11-15|2010-05-18|2010-05-19|Estimate|2011-11-15|2011-12-19|Estimate||||2011-11-15|2011-12-19|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain|Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections|Completed||Phase 3|78|Actual|Samsung Medical Center|realtive small number of patients to retrieve significant difference between two groups|2|||f||||||||||||||2018-05-31 23:46:56.399426|2018-05-31 23:46:56.399426
NCT01126047|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-11-07|2010-05-18|2010-05-19|Estimate|||||||2011-11-07|2011-11-09|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Exhaled Carbon Monoxide (eCO) for Diffusing Capacity (DLCO) Correction|Validation of Exhaled Carbon Monoxide for DLCO Correction|Completed||N/A|100|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 23:46:56.809755|2018-05-31 23:46:56.809755
NCT01126034|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2015-12-03|2010-05-18|2010-05-19|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2007||2007-03-31|December 2015|2015-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention|Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention|Completed||N/A|85|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 23:46:57.00675|2018-05-31 23:46:57.00675
NCT01126021|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2016-12-01|2010-05-18|2010-05-19|Estimate|||||||2016-12-01|2016-12-02|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Using Technology to Promote Mental Acuity|Using Technology to Promote Mental Acuity|Completed||Phase 2/Phase 3|600|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 23:46:57.279568|2018-05-31 23:46:57.279568
NCT01126008|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2016-04-19|2010-05-18|2010-05-19|Estimate|||||||2016-04-19|2016-04-20|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|August 2013|Actual|2013-08-31||Interventional|||Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer|A Phase II Trial of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer|Unknown status|Active, not recruiting|Phase 2|44|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 23:46:57.571471|2018-05-31 23:46:57.571471
NCT01125995|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-05-29|2010-05-18|2010-05-19|Estimate|||||||2013-05-29|2013-05-30|Estimate|June 2003||2003-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|July 2011|Actual|2011-07-31||Interventional|||Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer|A Randomized Phase III Trial for Timing of Radiation in Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer|Completed||Phase 3|222|Actual|Samsung Medical Center||2|||f||||||||||||||2018-05-31 23:46:57.773614|2018-05-31 23:46:57.773614
NCT01125982|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2014-11-18|2010-05-18|2010-05-19|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Postoperative Fatigue and Nausea Related to Choice of Anaesthetic Regimens|Postanaesthetic Outcome and Assessment of Fatigue in Day-surgery Laparoscopic Cholecystectomy|Completed||Phase 4|130|Actual|Sykehuset Telemark||2|||f||||f||||||||||2018-05-31 23:46:57.848121|2018-05-31 23:46:57.848121
NCT01125969|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-08-18|2010-05-18|2010-05-19|Estimate|||||||2016-08-18|2016-08-22|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Trial of Incentives and Peer Mentors to Improve Diabetic Outcomes|A Randomized Trial of Incentives and Peer Mentors to Improve Diabetic Outcomes|Active, not recruiting||Phase 3|240|Anticipated|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 23:46:57.918411|2018-05-31 23:46:57.918411
NCT01125956|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2012-08-14|2010-05-18|2010-05-19|Estimate|||||||2012-08-14|2012-08-15|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Improving Diabetes Control Through Peer Counseling and Incentives|Improving Diabetes Control Through Peer Counseling and Incentives|Completed||Phase 2|160|Anticipated|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 23:46:58.045599|2018-05-31 23:46:58.045599
NCT01125943|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-01-08|2010-05-17|2010-05-19|Estimate|||||||2013-01-08|2013-01-10|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Bevacizumab and Endothelium Dependent Vasodilation|Bevacizumab and Endothelium Dependent Vasodilation|Completed||N/A|24|Actual|Radboud University||2|||f||||||||||||||2018-05-31 23:46:58.140114|2018-05-31 23:46:58.140114
NCT01125930|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2014-01-28||2014-07-15|2010-05-18|2010-05-19|Estimate|2014-07-15|2014-07-16|Estimate||||2014-07-15|2014-07-16|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Atralin Gel for the Treatment of Rosacea|Investigation of the Topical Retinoid, Atralin Gel 0.05% for the Treatment of Erythematotelangiectatic Rosacea|Terminated||Phase 3|68|Actual|University of Michigan|Early termination of study due to slow recruitment and sponsor request resulted in smaller number of subjects analyzed.|2||Due to slow recruitment and sponsor request study ended early|f||||f||||||||||2018-05-31 23:46:58.273049|2018-05-31 23:46:58.273049
NCT01125917|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2010-07-28||2012-08-27|2010-05-18|2010-05-19|Estimate|2010-08-25|2010-09-21|Estimate||||2012-08-27|2012-09-03|Estimate|June 2004||2004-06-30|August 2012|2012-08-31|January 2008|Actual|2008-01-31|September 2005|Actual|2005-09-30||Interventional|||Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015|A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release Vs Buprenorphine Transdermal System (BTDS) 5 in Subjects With Moderate to Severe Low Back Pain: A 52-Week Open-label Extension Phase of BUP3015|Terminated||Phase 3|354|Actual|Purdue Pharma LP|BUP3015S was terminated early due to administrative reasons unrelated to efficacy or safety. There was full evaluation of safety but no evaluation of efficacy.|1||Terminated early due to administrative reasons.|f||||f||||||||||2018-05-31 23:47:00.183062|2018-05-31 23:47:00.183062
NCT01125904|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-07-21|2010-05-17|2010-05-19|Estimate|||||||2010-07-21|2010-07-23|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers|A Study In Trained Taste Panel Healthy Adult Volunteers To Investigate The Palatability Of Select Formulations Of Crizotinib Oral Liquid|Completed||Phase 1|5|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:47:00.595789|2018-05-31 23:47:00.595789
NCT01125891|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-06-22|2010-05-17|2010-05-19|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2009||2009-01-31|June 2017|2017-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors|Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|39|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 23:47:00.668931|2018-05-31 23:47:00.668931
NCT01125878|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2018-03-15|2010-05-18|2010-05-19|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2010||2010-08-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|NST||Types of Resistant Starch and Their Effect on Appetite|Understanding Resistant Starch on Satiety in Premenopausal Women|Active, not recruiting||N/A|40|Actual|Institute for Food Safety and Health, United States||4|||f||||f||||||||||2018-05-31 23:47:00.747723|2018-05-31 23:47:00.747723
NCT01125865|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-03-09|2010-05-18|2010-05-19|Estimate|||||||2011-03-09|2011-03-10|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture|Uncovered Self-expandable Metal Stent Versus DoubleLayer Plastic Stent for Malignant Hilar Stricture: a Prospective Randomized Multicenter Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Soon Chun Hyang University||2|||f||||t||||||||||2018-05-31 23:47:00.837091|2018-05-31 23:47:00.837091
NCT01125852|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-05-13|2010-05-18|2010-05-19|Estimate|||||||2013-05-13|2013-05-14|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Supplementary Angiographic Embolization for Peptic Ulcer Bleeding|Supplementary Angiographic Embolization for Peptic Ulcer Bleeding: A Randomized Controlled Trial|Completed||N/A|105|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 23:47:01.029106|2018-05-31 23:47:01.029106
NCT01125839|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2014-02-24|2010-05-18|2010-05-19|Estimate|||||||2014-02-24|2014-02-25|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Characterization and Differential Diagnosis of Vertebral Osteomyelitis|Clinical Features, Microbiological-, Radiological Characteristics, and Differential Diagnosis of Vertebral Osteomyelitis|Completed|||100|Anticipated|Asan Medical Center|||1||f||||t||||||Samples With DNA|"~     CT guided biopsy specimen~   "|||2018-05-31 23:47:01.119278|2018-05-31 23:47:01.119278
NCT01125826|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-18|||2011-06-24|2010-05-18|2010-05-19|Estimate|||||||2011-06-24|2011-06-27|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Observational|||Cell Culture of Glioma Specimens for in Vitro Preclinical Studies|Primary Cell Culture of Surgical Glioma Specimens for Invitro Preclinical Studies|Unknown status|Recruiting||50|Anticipated|Albany Medical College|||||f||||f||||||Samples Without DNA|"~     All subjects will be give permission for specimen storage by signing a separate permission on~     the informed consent. All specimens will be stored at a tissue bank for an unspecified amount~     of time.~   "|||2018-05-31 23:47:01.183525|2018-05-31 23:47:01.183525
NCT01125813|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2013-01-21||2017-08-09|2010-05-17|2010-05-18|Estimate|2013-03-11|2013-04-22|Estimate||||2017-08-09|2017-09-11|Actual|June 2010||2010-06-30|August 2017|2017-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A|Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of Human-cl rhFVIII in Previously Treated Patients With Severe Hemophilia A|Completed||Phase 3|32|Actual|Octapharma||1|||f||||t||||||||||2018-05-31 23:47:01.261964|2018-05-31 23:47:01.261964
NCT01125800|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2015-09-29||2017-02-13|2010-05-17|2010-05-18|Estimate|2016-02-04|2016-03-02|Estimate||||2017-02-13|2017-03-20|Actual|February 2011||2011-02-28|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The analysis was performed in full analysis set population, defined as all the participants who received at least one dose of sonidegib.|A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB|A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma|Completed||Phase 1/Phase 2|76|Actual|Novartis|The Phase I and Phase II patients are pooled and summarized by dose levels. One pediatric patient enrolled in the Phase II portion at the 680 mg/m2 dose was pooled with 21 pediatric patients enrolled in Phase I at the same dose|5|||f||||f||||||||||2018-05-31 23:47:01.56482|2018-05-31 23:47:01.56482
NCT01125787|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-07-19|2010-05-17|2010-05-18|Estimate|||||||2011-07-19|2011-07-20|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|August 2010|Actual|2010-08-31||Interventional|||Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab|PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATION OF BENDAMUSTINE AND OFATUMUMAB|Terminated||Phase 2|1|Actual|Nevada Cancer Institute||1||Low enrollment|f||||t||||||||||2018-05-31 23:47:03.187106|2018-05-31 23:47:03.187106
NCT01125774|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2014-10-01||2017-05-26|2010-05-17|2010-05-18|Estimate|2014-10-01|2014-10-03|Estimate||||2017-05-26|2017-06-20|Actual|June 1, 2010|Actual|2010-06-01|May 2017|2017-05-31|April 8, 2011|Actual|2011-04-08|April 8, 2011|Actual|2011-04-08||Interventional||"All randomized participants, including those randomized at more than 1 site (duplicate participants). Participants randomized at more than 1 site resulting in randomization into both telcagepant 140 mg and placebo groups are allocated to the telcagepant 140 mg group."|Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)|A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine|Completed||Phase 2/Phase 3|4548|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 23:47:03.478508|2018-05-31 23:47:03.478508
NCT01125761|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-10-25|2010-05-17|2010-05-18|Estimate|||||||2010-10-25|2010-10-27|Estimate|November 2010||2010-11-30|April 2010|2010-04-30||||November 2010|Anticipated|2010-11-30||Interventional|||Efficacy and Safety of the Association of Dexamethasone 0.5 mg + Clemastine Fumarate 1 mg When Compared to Dexamethasone 0.5 mg in Patients With Allergic Dermatitis||Withdrawn||Phase 3|104|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-05-31 23:47:04.016479|2018-05-31 23:47:04.016479
NCT01125748|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2014-10-08||2014-10-08|2010-05-17|2010-05-18|Estimate|2014-10-08|2014-10-15|Estimate||||2014-10-08|2014-10-15|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|XPORT|Intent-to-treat population: All randomized participants.|A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy|A Phase IV, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Persistency of Response With or Without Xolair After Long-term Therapy (XPORT)|Completed||Phase 4|176|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 23:47:04.159364|2018-05-31 23:47:04.159364
NCT01125735|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-07-01|2010-05-17|2010-05-18|Estimate|||||||2013-07-01|2013-07-02|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|April 2014|Anticipated|2014-04-30|June 2012|Anticipated|2012-06-30||Interventional|Celleration||MIST Therapy's Effectiveness in Wound Bed Preparation and Role of Bacterial Biofilm in Chronic, Non-healing Wounds|A Prospective, Randomized, Controlled Study of MIST Therapy's Effectiveness in Wound Bed Preparation and the Role of Bacterial Biofilm in Subjects Presenting With Chronic, Non-healing Wounds|Withdrawn||Phase 4|0|Actual|Georgetown University||2||Contract negotiations were terminated and study never started.|f||||f||||||||||2018-05-31 23:47:05.711385|2018-05-31 23:47:05.711385
NCT01125722|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2012-04-09||2012-11-16|2010-05-17|2010-05-18|Estimate|2012-11-16|2012-12-17|Estimate||||2012-11-16|2012-12-17|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)|Pilot Clinical Trial to Study the Effectiveness of a Four-week Exposure to a Transcutaneous, High-frequency, Amplitude-modulated, Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence in Subjects With Idiopathic Overactive Bladder (OAB)|Completed||N/A|74|Actual|Ethicon Endo-Surgery||2|||f||||f||||||||||2018-05-31 23:47:05.814839|2018-05-31 23:47:05.814839
NCT01125709|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-01-10|2010-05-17|2010-05-18|Estimate|||||||2013-01-10|2013-01-11|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|||Comparative Study of Clinical Endpoint in DMD: Handheld Myometry (HHM) Versus CINRG Quantitative Measurement System (CQMS)|Comparative Study of Clinical Endpoint in DMD: HHM vs. CQMS|Completed|||30|Anticipated|Cooperative International Neuromuscular Research Group|||||f||||t||||||||||2018-05-31 23:47:06.1559|2018-05-31 23:47:06.1559
NCT01125696|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2015-02-02|2010-05-17|2010-05-18|Estimate|||||||2015-02-02|2015-02-03|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|August 2016|Anticipated|2016-08-31|May 2015|Anticipated|2015-05-31||Interventional|TiP||Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV|Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers|Unknown status|Recruiting|Phase 2|80|Anticipated|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 23:47:06.238703|2018-05-31 23:47:06.238703
NCT01125683|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2011-05-11|2010-05-17|2010-05-18|Estimate|||||||2011-05-11|2011-05-13|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease|A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD|Terminated||Phase 2|40|Anticipated|AstraZeneca||5||Poor recruitment.|f||||f||||||||||2018-05-31 23:47:06.342047|2018-05-31 23:47:06.342047
NCT01125670|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-24|2010-05-17|2010-05-18|Estimate|||||||2010-05-24|2010-05-25|Estimate|February 2010||2010-02-28|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet|Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet-|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:47:06.541195|2018-05-31 23:47:06.541195
NCT01125657|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-24|2010-05-17|2010-05-18|Estimate|||||||2010-05-24|2010-05-25|Estimate|February 2010||2010-02-28|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B|Pharmacokinetic Study of YM150 - The Verification ot the Bioequivalence Between YM150 Formulation-A and YM150 Formulation-B -|Completed||Phase 1|44|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:47:06.62806|2018-05-31 23:47:06.62806
NCT01125644|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2011-06-06|2010-05-17|2010-05-18|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis|Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study|Unknown status|Recruiting|Phase 3|10|Anticipated|Proaparts srl||1|||f||||t||||||||||2018-05-31 23:47:06.702721|2018-05-31 23:47:06.702721
NCT01125631|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2011-08-11|2010-05-17|2010-05-18|Estimate|||||||2011-08-11|2011-08-12|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease|A Phase 1, Randomized, Placebo-Controlled, Double Blind, Multicenter Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease|Completed||Phase 1|8|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:47:06.792727|2018-05-31 23:47:06.792727
NCT01125618|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2017-04-20|2010-05-17|2010-05-18|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2005|Actual|2005-01-31|April 2017|2017-04-30|June 25, 2016|Actual|2016-06-25|June 25, 2016|Actual|2016-06-25||Interventional|MVP||Millennium Villages Project in Sub-Saharan Africa|A Pair-matched Community Intervention Trial to Assess the Impact of an Integrated Health and Development Intervention on Child Survival and the Millennium Development Goals in 10 Sub- Saharan African Countries|Completed||N/A|65000|Actual|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 23:47:06.907973|2018-05-31 23:47:06.907973
NCT01125605|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2012-07-18||2015-03-24|2010-05-17|2010-05-18|Estimate|2012-07-18|2012-08-27|Estimate||||2015-03-24|2015-04-14|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|174||PASCONAL NERVENTROPFEN in the Treatment of Nervous Diseases|PASCONAL NERVENTROPFEN in the Treatment of Adults and Children Suffering From Nervous Diseases (e.g. Sleep Disorders Due to Nervousness)|Completed|||325|Actual|Pascoe Pharmazeutische Praeparate GmbH|||3||f||||f||||||||||2018-05-31 23:47:07.099019|2018-05-31 23:47:07.099019
NCT01125592|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-11-14|2010-05-17|2010-05-18|Estimate|||||||2011-11-14|2011-11-15|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Assessment of the Ability of Ionic Foot Bath (IonCleanse®) to Remove Heavy Metals Through the Feet and Its Potential Impact on Body Burden of Heavy Metals|Assessment of the Ability of Ionic Foot Bath (IonCleanse®) to Remove Heavy Metals Through the Feet and Its Potential Impact on Body Burden of Heavy Metals|Completed||Early Phase 1|6|Actual|The Canadian College of Naturopathic Medicine||1|||f||||f||||||||||2018-05-31 23:47:07.525377|2018-05-31 23:47:07.525377
NCT01125579|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2010-05-18|2010-05-17|2010-05-18|Estimate|||||||2010-05-18|2010-05-19|Estimate|March 2008||2008-03-31|May 2010|2010-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Effectiveness of NEURAPAS Balance in Children With Nervous Restlessness|NEURAPAS Balance in Children With Nervous Restlessness, e.g. Agitated Depression|Completed|||115|Actual|Pascoe Pharmazeutische Praeparate GmbH|||1||f||||f||||||||||2018-05-31 23:47:07.591229|2018-05-31 23:47:07.591229
NCT01125566|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2014-06-06||2018-03-07|2010-05-17|2010-05-18|Estimate|2014-08-05|2014-08-21|Estimate||||2018-03-07|2018-04-02|Actual|June 22, 2010|Actual|2010-06-22|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|June 8, 2013|Actual|2013-06-08||Interventional||Treated Set :The treated set included all randomised patients who were documented to have taken at least 1 dose of study medication (One centre was excluded from analysis due to serious non-compliance, thus data from 5 patients in AV arm and 1 patient in TV arm were excluded)|LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment|LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment|Active, not recruiting||Phase 3|508|Actual|Boehringer Ingelheim|The Data Monitoring Committee recommended termination of recruitment due to low likelihood of the study meeting its primary objectives.|2|||f||||||||||||||2018-05-31 23:47:07.752361|2018-05-31 23:47:07.752361
NCT01125553|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2015-09-24|2010-05-17|2010-05-18|Estimate|||||||2015-09-24|2015-09-25|Estimate|May 2010||2010-05-31|September 2015|2015-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Comparison Between Two Formulations of NN5401 in Healthy Subjects|A Trial to Test for Bioequivalence Between Two NN5401 Formulations in Healthy Subjects|Completed||Phase 1|26|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:47:09.07315|2018-05-31 23:47:09.07315
NCT01125540|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|June 2007||2007-06-30|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Role of Daily Disposable Contact Lenses in Ocular Allergy|The Role of Daily Disposable Contact Lenses in Ocular Allergy|Completed||N/A|10|Actual|Aston University|||||f||||f||||||||||2018-05-31 23:47:09.165579|2018-05-31 23:47:09.165579
NCT01125358|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17||2013-01-11|2013-01-11|2010-05-17|2010-05-18|Estimate||||2013-01-11|2013-01-21|Estimate|2013-01-11|2013-01-21|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study in Schizophrenic Patients|A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Patients With DSM-IV-TR Schizophrenia|Terminated||Phase 2|200|Anticipated|Eli Lilly and Company||4||"The decision to stop the trial was based on efficacy results in the overall schizophrenia~   participant population."|f||||t||||||||||2018-05-31 23:47:11.361619|2018-05-31 23:47:11.361619
NCT01125527|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2016-11-30|2010-05-17|2010-05-18|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children|A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose|Completed||Phase 3|700|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:47:09.275412|2018-05-31 23:47:09.275412
NCT01125514|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2012-08-09||2012-08-09|2010-05-17|2010-05-18|Estimate|2012-08-09|2012-09-10|Estimate||||2012-08-09|2012-09-10|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure|A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure|Completed||Phase 2|37|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:47:09.386091|2018-05-31 23:47:09.386091
NCT01125501|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-10-16|2010-05-17|2010-05-18|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2010||2010-04-30|July 2010|2010-07-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Protandim and the Metabolic Syndrome|Protandim and the Metabolic Syndrome: A Preliminary Study to Define Protein Signatures That Change Along With Lowered Oxidative Stress Measured as F2 Isoprostanes or TBARS and Inflammation Measured as hsCRP|Withdrawn||N/A|0|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||funding not available|f||||f||||||||||2018-05-31 23:47:10.269775|2018-05-31 23:47:10.269775
NCT01125488|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-06-06|2010-05-17|2010-05-18|Estimate|||||||2010-06-06|2010-06-08|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|March 2009|Anticipated|2009-03-31||Interventional|||Maintenance Therapy of Levonorgestrel-releasing Intrauterine System (LNG-IUS) to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery|Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial|Unknown status|Recruiting|Phase 3|80|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 23:47:10.363217|2018-05-31 23:47:10.363217
NCT01125475|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-07-15|2010-05-17|2010-05-18|Estimate|||||||2014-07-15|2014-07-16|Estimate|August 2010||2010-08-31|September 2012|2012-09-30||||March 2012|Actual|2012-03-31||Observational|SCANSMART||A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects|A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study|Completed|||61|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:47:10.526649|2018-05-31 23:47:10.526649
NCT01125462|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-07-15|2010-05-17|2010-05-18|Estimate|||||||2014-07-15|2014-07-16|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|POINT||A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) Cycles|Post Marketing Assessment of GONAL-f Solution for Injection in a Prefilled Pen for Follicular Stimulation in IVF-ET Cycles: An Observational Study|Completed|||61|Actual|Merck KGaA|||2||f||||||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:47:10.620509|2018-05-31 23:47:10.620509
NCT01125449|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-16|||2012-08-25|2010-05-17|2010-05-18|Estimate|||||||2012-08-25|2012-08-28|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease|Phase 2 Study of High Dose Ascorbic Acid in Solid Tumor Disease|Suspended||Phase 2|30|Anticipated|Situs Cancer Research Center||1||"Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche~   (Ireland)."|f||||t||||||||||2018-05-31 23:47:10.727666|2018-05-31 23:47:10.727666
NCT01125436|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2011-07-01|2010-05-17|2010-05-18|Estimate|||||||2011-07-01|2011-07-04|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||A Trial of Vitamin D Therapy in Patients With Heart Failure|A Randomized Placebo Controlled Trial of Vitamin D Therapy in Patients With Heart Failure|Unknown status|Active, not recruiting|N/A|64|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 23:47:10.833508|2018-05-31 23:47:10.833508
NCT01125423|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2011-06-23|2010-05-17|2010-05-18|Estimate|||||||2011-06-23|2011-06-27|Estimate|May 2010||2010-05-31|December 2010|2010-12-31||||May 2012|Anticipated|2012-05-31||Interventional|||Study of Fibromyalgia Treated With Milnacipran|An Open-Label Pilot Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therapeutic Responsiveness to Milnacipran|Unknown status|Recruiting|Phase 4|30|Anticipated|Albany Medical College|||||f||||f||||||||||2018-05-31 23:47:10.90014|2018-05-31 23:47:10.90014
NCT01125410|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis|Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis|Completed||Phase 3|321|Actual|Medinova AG||2|||f||||f||||||||||2018-05-31 23:47:10.972159|2018-05-31 23:47:10.972159
NCT01125397|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2013-05-08|2010-05-17|2010-05-18|Estimate|||||||2013-05-08|2013-05-10|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Behavior Therapy Prior to Bariatric Surgery|The Potential Effectiveness of Behavior Therapy on Weight Loss Following Bariatric Surgery|Completed||Phase 1|34|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:47:11.078619|2018-05-31 23:47:11.078619
NCT01125384|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|||2011-08-27|2010-05-17|2010-05-18|Estimate|||||||2011-08-27|2011-08-30|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparison Between Two Methods of Throat Swabbing|Comparison Between Two Methods of Throat Swabbing|Withdrawn||N/A|500|Anticipated|Meir Medical Center||2||stopped due to protocol mistakes|f||||||||||||||2018-05-31 23:47:11.141868|2018-05-31 23:47:11.141868
NCT01125371|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2017-12-05|2010-05-17|2010-05-18|Estimate|||||||2017-12-05|2017-12-07|Actual|October 2011||2011-10-31|December 2017|2017-12-31|June 7, 2016|Actual|2016-06-07|June 7, 2016|Actual|2016-06-07||Interventional|||Computerized Brief Alcohol Intervention (BI) for Binge Drinking HIV At-Risk and Infected Women|Computerized BI for Binge Drinking HIV At-Risk and Infected African-American Women|Completed||N/A|439|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 23:47:11.199474|2018-05-31 23:47:11.199474
NCT01125345|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-06-03|2010-05-17|2010-05-18|Estimate|||||||2010-06-03|2010-06-04|Estimate|January 2006||2006-01-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Posterior Capsule Opacification (PCO) With Single Piece Hydrophobic Versus Hydrophillic Intraocular Lens (IOL)|A Prospective Controlled Clinical Trial to Evaluate the Posterior Capsule Opacification in Contralateral Eyes Implanted With Single Piece Hydrophobic AcrySof IOL and Single Piece Hydrophilic Acrylic IOLs|Completed||Phase 4|60|Actual|Iladevi Cataract and IOL Research Center||3|||f||||t||||||||||2018-05-31 23:47:11.505121|2018-05-31 23:47:11.505121
NCT01125332|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-08-29|2010-05-17|2010-05-18|Estimate|||||||2014-08-29|2014-09-01|Estimate|February 2010||2010-02-28|August 2014|2014-08-31|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||Evaluation of Topic Anaesthesia for Laryngoscopy With Fibroscopy During Paediatric Ear Nose Throat (ENT)Consultation|Evaluation of Topic Anaesthesia for Laryngoscopy With Fibroscopy During Paediatric ENT Consultation|Terminated||Phase 3|1|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 23:47:11.65009|2018-05-31 23:47:11.65009
NCT01125319|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2015-06-30|2010-05-17|2010-05-18|Estimate|||||||2015-06-30|2015-07-01|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity|Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity|Completed||N/A|120|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 23:47:11.721958|2018-05-31 23:47:11.721958
NCT01125306|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-16|||2012-03-15|2010-05-17|2010-05-18|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|August 2011|Actual|2011-08-31||Interventional|||Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom||Unknown status|Recruiting|Phase 4|50|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:47:11.896511|2018-05-31 23:47:11.896511
NCT01125293|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-10-12|2010-05-17|2010-05-18|Estimate|||||||2017-10-12|2017-10-16|Actual|March 2010||2010-03-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia|Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia|Active, not recruiting||Phase 1/Phase 2|70|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 23:47:12.049936|2018-05-31 23:47:12.049936
NCT01125280|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|July 2010||2010-07-31|May 2010|2010-05-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Prospective Multicenter Validation of a Severity Score of Strangulated Small Bowel Occlusion|Prospective Multicenter Validation of a Clinicoradiological Score for Predicting the Severity of Strangulated Small Bowel Occlusion|Unknown status|Not yet recruiting|N/A|300|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 23:47:12.17731|2018-05-31 23:47:12.17731
NCT01125267|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|April 2003||2003-04-30|May 2010|2010-05-31|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Promoting Adherence to Treatment in Schizophrenia|Promoting Adherence to Treatment in Schizophrenia|Completed||N/A|174|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 23:47:12.38961|2018-05-31 23:47:12.38961
NCT01125254|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2015-01-02|2010-05-17|2010-05-18|Estimate|||||||2015-01-02|2015-01-05|Estimate|September 2008||2008-09-30|January 2015|2015-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|AnloThal||Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major|Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major|Completed||Phase 2/Phase 3|10|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 23:47:12.500627|2018-05-31 23:47:12.500627
NCT01125241|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2014-09-16|2010-05-15|2010-05-18|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression|A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression: a Muli-center, Randomized, Double-blinded, Placebo-controlled Superiority Clinical Trial|Completed||N/A|104|Actual|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 23:47:12.580253|2018-05-31 23:47:12.580253
NCT01125228|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-15|||2018-04-18|2010-05-17|2010-05-18|Estimate|||||||2018-04-18|2018-04-19|Actual|September 15, 1988||1988-09-15|December 11, 2017|2017-12-11||||||||Observational|||Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV|A Phase III Study With Long-Term Follow-Up of Zidovudine Versus Zidovudine and Alpha-Interferon Versus Alpha-Interferon in Patients With Early HIV Infection|Active, not recruiting|||180|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:47:12.717828|2018-05-31 23:47:12.717828
NCT01125215|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-15|||2013-04-10|2010-05-17|2010-05-18|Estimate|||||||2013-04-10|2013-04-11|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy|Study of Topical Preparation of Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy|Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 23:47:12.840561|2018-05-31 23:47:12.840561
NCT01125202|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2017-06-14||2017-08-14|2010-05-17|2010-05-18|Estimate|2017-08-14|2017-08-15|Actual||||2017-08-14|2017-08-15|Actual|September 2009||2009-09-30|August 2017|2017-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|BalanceWise-HD|One attention control participant was hospitalized after enrollment and did not have a baseline data collection form.|Intervention to Reduce Dietary Sodium in Hemodialysis|Intervention to Reduce Dietary Sodium in Hemodialysis|Completed||N/A|179|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 23:47:12.92957|2018-05-31 23:47:12.92957
NCT01125189|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|2015-08-13||2015-09-23|2010-05-17|2010-05-18|Estimate|2015-09-23|2015-10-23|Estimate||||2015-09-23|2015-10-23|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|HEPCAT||Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients|A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection|Completed||Phase 2|558|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 23:47:13.551308|2018-05-31 23:47:13.551308
NCT01125176|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2017-09-22|2010-05-17|2010-05-18|Estimate|||||||2017-09-22|2017-09-25|Actual|May 2012|Actual|2012-05-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|THRiL||Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL|A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL|Recruiting||Phase 2|24|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 23:47:14.365802|2018-05-31 23:47:14.365802
NCT01125163|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-11-29|2010-05-17|2010-05-18|Estimate|||||||2010-11-29|2010-11-30|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|May 2012|Anticipated|2012-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight (VLBW) Infants|Randomized Trial Comparing Iron Supplementation vs. Routine Iron Intake in Very Low Birth Weight (VLBW) Infants|Unknown status|Recruiting|N/A|150|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:47:14.435471|2018-05-31 23:47:14.435471
NCT01125150|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2012-09-04|2010-05-17|2010-05-18|Estimate|||||||2012-09-04|2012-09-06|Estimate|February 2009||2009-02-28|May 2010|2010-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia||Completed|||9|Actual|Henry Ford Health System|||||f||||t||||||||||2018-05-31 23:47:14.546947|2018-05-31 23:47:14.546947
NCT01125137|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2011-01-10|2010-05-17|2010-05-18|Estimate|||||||2011-01-10|2011-01-11|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar|Case-control Study on Matrix Metalloproteinase Levels in Tissue in Patients With Keloid Scar|Completed||N/A|20|Anticipated|Henry Ford Health System||1|||f||||t||||||||||2018-05-31 23:47:14.663484|2018-05-31 23:47:14.663484
NCT01125124|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-05-14|2010-05-14|2010-05-18|Estimate|||||||2010-05-14|2010-05-18|Estimate|August 2009||2009-08-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Safety and Effectiveness Study for Pleurodesis With Silver Nitrate in Malignant Pleural Effusion|Evaluation of Chest Pain, Effectiveness and Safety of Pleurodesis With Pleural Catheters and Silver Nitrate for Malignant Pleural Effusion.|Unknown status|Recruiting|Phase 2|60|Anticipated|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 23:47:14.760325|2018-05-31 23:47:14.760325
NCT01125111|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||The Clinical Study of Making the Evidence With Application of Da Vinci-Robot Assisted Low Anterior Resection in Rectal Cancer|The Clinical Study of Making the Evidence With Application of Da Vinci-Robot Assisted Low Anterior Resection in Rectal Cancer|Completed|||69|Actual|Yonsei University|||2||f||||||||||||||2018-05-31 23:47:14.83799|2018-05-31 23:47:14.83799
NCT01125098|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2014-12-09||2014-12-09|2010-05-17|2010-05-18|Estimate|2014-12-09|2014-12-17|Estimate||||2014-12-09|2014-12-17|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Observational|||Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD|Comparison of a Serum Procalcitonin (PRO-CT) Guided Treatment Plan With the Standard Guideline Recommended Antibiotic Treatment Plan for Patients Hospitalized With a Diagnosis of Exacerbation of COPD|Completed|||183|Actual|University of Modena and Reggio Emilia|||2||f||||f||||||Samples Without DNA|"~     Blood samples and sputum will be collected from COPD patients in order to measure serum~     PRO-CT levels and inflammatory markers (cells and mediators), respectively.~   "|||2018-05-31 23:47:14.922877|2018-05-31 23:47:14.922877
NCT01125085|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2014-02-24|2010-05-17|2010-05-18|Estimate|||||||2014-02-24|2014-02-25|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|||131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors|A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT) in Patients With Multiple Brain Metastases From Solid Tumors|Completed||Phase 2|32|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:47:15.234667|2018-05-31 23:47:15.234667
NCT01125072|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2017-11-08|2010-05-17|2010-05-18|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2005||2005-06-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Use of Echocardiography in the Evaluation of Chest Pain in the Emergency Department|Use of Echocardiography in the Evaluation of Chest Pain in the Emergency Department|Withdrawn|||0|Actual|New York University School of Medicine|||1|PI no longer with institution|f||||f|f|f||||||||2018-05-31 23:47:15.386487|2018-05-31 23:47:15.386487
NCT01125059|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2015-04-21|2010-05-17|2010-05-18|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Methadone Versus Placebo in Spine Fusion|The Effect of Methadone on Perioperative Analgesia After Posterior Lumbar Fusion - A Randomized, Placebo-controlled, Double-blinded Study|Withdrawn||N/A|0|Actual|Northwestern University||2||Unable to fulfill recruitment|f||||f||||||||||2018-05-31 23:47:15.499987|2018-05-31 23:47:15.499987
NCT01125046|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2018-04-11|2010-05-14|2010-05-18|Estimate|||||||2018-04-11|2018-04-12|Actual|July 2010||2010-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas|Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas|Active, not recruiting||Phase 2|50|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 23:47:15.702391|2018-05-31 23:47:15.702391
NCT01125033|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-06-16|2010-05-17|2010-05-18|Estimate|||||||2011-06-16|2011-06-17|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|ShirazUMS||Study of Vitamin C, Vitamin E and Their Combination to Treat Restless Legs Syndrome in Hemodialysis Patients|Efficacy of Vitamin C, Vitamin E and Their Combination for Treatment of Restless Legs Syndrome in Hemodialysis Patients: a Randomized Double-blind, Placebo-controlled Trial|Completed||Phase 2/Phase 3|60|Actual|Shiraz University of Medical Sciences||4|||f||||t||||||||||2018-05-31 23:47:15.801913|2018-05-31 23:47:15.801913
NCT01125020|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|May 2010|Anticipated|2010-05-31||Interventional|||Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation||Unknown status|Recruiting|N/A|150|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 23:47:15.916367|2018-05-31 23:47:15.916367
NCT01125007|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Capacity of Biofilm Removal and Gingival Abrasion After Utilization Medium and Soft Toothbrushes|Biofilm Capacity Removal and Gingival Abrasion After Utilization Medium and Soft Toothbrushes|Completed||Phase 1/Phase 2|25|Actual|Franciscan University Center||2|||f||||t||||||||||2018-05-31 23:47:16.012296|2018-05-31 23:47:16.012296
NCT01124994|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-17|||2014-01-22|2010-05-17|2010-05-18|Estimate|||||||2014-01-22|2014-01-23|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Confocal Laser Endomicroscopy and Endoscopic Mucosal Resection|Endomicroscopy-targeted Endoscopic Mucosa Resection for Barrett's Oesophagus-associated Neoplasia|Completed||N/A|38|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 23:47:16.086339|2018-05-31 23:47:16.086339
NCT01124981|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2014-12-15|2010-05-17|2010-05-18|Estimate|||||||2014-12-15|2014-12-16|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Haemocomplettan® P During Elective Complex Cardiac Surgery|Efficacy and Safety of Haemocomplettan® P in Patients Experiencing Microvascular Bleeding While Undergoing Elective Complex Cardiac Surgery|Completed||Phase 2/Phase 3|120|Anticipated|Isala||2|||f||||t||||||||||2018-05-31 23:47:16.192767|2018-05-31 23:47:16.192767
NCT01124968|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2011-02-07|2010-05-17|2010-05-18|Estimate|||||||2011-02-07|2011-02-08|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|eConsulta||eConculta: Impact of Virtual Visits in Primary Care|Before and After Study to Assess the Impact of the Use of Virtual Consultation on Frequency of Patient Attendance, and Satisfaction of Patients and Professionals|Completed||N/A|16720|Actual|Institut Catala de Salut||1|||f||||f||||||||||2018-05-31 23:47:16.282675|2018-05-31 23:47:16.282675
NCT01124955|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2010-08-09||2011-06-13|2010-05-17|2010-05-18|Estimate|2011-05-12|2011-06-13|Estimate||||2011-06-13|2011-06-15|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|ANLBP||Acupuncture Using Yamamoto's Method for the Treatment of Acute Nonspecific Low Back Pain|Acupuncture for Acute Nonspecific Low Back Pain: a Randomized, Controlled, Double-blind, Placebo Trial|Completed||N/A|80|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 23:47:16.437076|2018-05-31 23:47:16.437076
NCT01124942|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-05-17|2010-05-17|2010-05-18|Estimate|||||||2010-05-17|2010-05-18|Estimate|March 2010||2010-03-31|April 2010|2010-04-30|March 2013|Anticipated|2013-03-31|March 2011|Anticipated|2011-03-31||Interventional|GUARDIAN||MGuard Stent in ST-elevation Myocardial Infarction|MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial|Unknown status|Recruiting|Phase 4|350|Anticipated|Federico II University||2|||f||||f||||||||||2018-05-31 23:47:16.954846|2018-05-31 23:47:16.954846
NCT01124929|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-07-02|2010-05-17|2010-05-18|Estimate|||||||2015-07-02|2015-07-03|Estimate|July 2008||2008-07-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|July 2012|Actual|2012-07-31||Interventional|RNTCP-DOTS||Treatment Duration for Abdominal Tuberculosis|A Multi-centric Study on Treatment of Abdominal Tuberculosis (Intestinal or Peritoneal): A Randomized Controlled Trial to Compare the 6 Months of Cat I Treatment With 9 Months of Cat I Treatment (Extension for 3 Months) in Abdominal Tuberculosis Under the Revised National Tuberculosis Control Program|Completed||Phase 3|197|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 23:47:17.038836|2018-05-31 23:47:17.038836
NCT01124916|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2016-11-01||2016-11-01|2010-05-16|2010-05-17|Estimate|2016-11-01|2017-01-04|Estimate||||2016-11-01|2017-01-04|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ACCESS|The baseline analysis population comprises all randomized subjects|Abdominal Colpopexy: Comparison of Endoscopic Surgical Strategies|Abdominal Colpopexy: Comparison of Endoscopic Surgical Strategies|Completed||N/A|84|Actual|Loyola University|There are no limitations or caveats to specify.|2|||f||||t||||||||No||2018-05-31 23:47:17.116196|2018-05-31 23:47:17.116196
NCT01124903|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2012-02-29|2010-05-14|2010-05-17|Estimate|||||||2012-02-29|2012-03-01|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Human Hydration Status Monitoring|Human Hydration Status Monitoring: Phase I|Completed||Phase 2|31|Actual|United States Army Research Institute of Environmental Medicine||1|||f||||f||||||||||2018-05-31 23:47:17.816144|2018-05-31 23:47:17.816144
NCT01124890|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-05-14|2010-05-14|2010-05-17|Estimate|||||||2010-05-14|2010-05-17|Estimate|July 1998||1998-07-31|May 2010|2010-05-31|October 2009|Actual|2009-10-31|October 2001|Actual|2001-10-31||Interventional|SIAM III||Southwest German Interventional Study in Acute Myocardial Infarction III|Southwest German Interventional Study in Acute Myocardial Infarction III|Completed||Phase 4|197|Actual|University Hospital, Saarland||2|||f||||f||||||||||2018-05-31 23:47:17.915794|2018-05-31 23:47:17.915794
NCT01124877|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2013-01-17|2010-05-14|2010-05-17|Estimate|||||||2013-01-17|2013-01-18|Estimate|July 2010||2010-07-31|January 2013|2013-01-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)|26 Week Open Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)|Withdrawn||Phase 3|0|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 23:47:18.011883|2018-05-31 23:47:18.011883
NCT01124864|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2015-07-07||2016-02-02|2010-05-14|2010-05-17|Estimate|2016-02-02|2016-03-02|Estimate||||2016-02-02|2016-03-02|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The Full Analysis Set (FAS) consisted of all patients who received at least one dose of AUY922.|A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.|A Phase II, Multi-center, Open-label Study of AUY922 Administered IV on a Once-weekly Schedule in Patients With Advanced Non-small-cell Lung Cancer Who Have Received at Least Two Lines of Prior Chemotherapy|Completed||Phase 2|153|Actual|Novartis||5|||f||||f||||||||||2018-05-31 23:47:18.136768|2018-05-31 23:47:18.136768
NCT01124851|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2011-06-30|2010-05-14|2010-05-17|Estimate|||||||2011-06-30|2011-07-04|Estimate|August 2010||2010-08-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness|A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ABT-652 Administered Once Daily to Subjects With an Excessive Daytime Sleepiness Disorder|Completed||Phase 1|36|Actual|Abbott||3|||f||||f||||||||||2018-05-31 23:47:20.872115|2018-05-31 23:47:20.872115
NCT01124838|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2016-05-13||2016-07-11|2010-05-14|2010-05-17|Estimate|2016-05-13|2016-06-21|Estimate||||2016-07-11|2016-08-11|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Visual II||Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients|Completed||Phase 3|261|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 23:47:21.063519|2018-05-31 23:47:21.063519
NCT01124825|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2012-11-12|2010-05-13|2010-05-17|Estimate|||||||2012-11-12|2012-11-14|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|May 2012|Anticipated|2012-05-31||Interventional|||Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study|Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study|Withdrawn||Phase 4|0|Actual|University of Louisville||2||No subjects enrolled. Funding withdrawn by sponsor.|f||||f||||||||||2018-05-31 23:47:22.522846|2018-05-31 23:47:22.522846
NCT01124812|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2012-10-25|2010-05-14|2010-05-17|Estimate|||||||2012-10-25|2012-10-26|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|October 2012|Actual|2012-10-31|August 2011|Actual|2011-08-31||Interventional|||131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)|A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy in Patients With Inoperable, Locally-advanced (Stage III) NSCLC|Terminated||Phase 1|3|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 23:47:22.591459|2018-05-31 23:47:22.591459
NCT01124799|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2013-05-03|2010-05-13|2010-05-17|Estimate|||||||2013-05-03|2013-05-06|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light|Photosensitivity Trial. A Randomized, Double-blind, Double Dummy, Placebo- and Positive Controlled Phase I Trial to Evaluate the Photosensitizing Potential of TMC435 in Healthy Subjects.|Completed||Phase 1|49|Actual|Tibotec Pharmaceuticals, Ireland||3|||f||||||||||||||2018-05-31 23:47:22.71615|2018-05-31 23:47:22.71615
NCT01124786|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2013-11-12||2014-03-12|2010-05-14|2010-05-17|Estimate|2014-03-12|2014-04-17|Estimate||||2014-03-12|2014-04-17|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|November 2012|Actual|2012-11-30||Interventional||All randomized patients|A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)|A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|367|Actual|Clovis Oncology, Inc.|Due to Primary endpoint showing lack of efficacy, development of CO-1.01 was stopped and secondary endpoints were not analyzed. However, patient enrollment completed normally.|2|||f||||t||||||||||2018-05-31 23:47:22.917899|2018-05-31 23:47:22.917899
NCT01124773|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2017-11-02|2010-05-14|2010-05-17|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2009||2009-06-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|WHIMS-Y||Memory Study of Youngest Women Enrolled in the Women's Health Initiative Hormone Therapy (HT) Arm|Women's Health Initiative Memory Study of Younger Women|Completed|||1362|Actual|Wake Forest University Health Sciences|||1||f||||t||||||||Yes|WHIMS-Y will follow guidelines, methods and processes as set forth in the WHI 2015-2020 Data Sharing Plan. Limited data sets will be archived on the WHIMS-Y website. Accompanying the limited data sets, substantial electronic documentation will be provided in a standard format that is readable on a variety of platforms. Documentation will include data collection forms, a description of study protocol and procedures, description of all variable re-coding and a list of major study publications. These data will be available to users only under a data-sharing agreement that provides for: a commitment to using the data only for research purposes and not to identify any individual participant; a commitment to securing the data using appropriate computer technology; and a commitment to destroying or returning the data after analyses are completed. Data will be made available for timely release no later than the acceptance for publication of the main findings from the final dataset.|2018-05-31 23:47:24.493648|2018-05-31 23:47:24.493648
NCT01124760|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-08-02|2010-05-14|2010-05-17|Estimate|||||||2010-08-02|2010-08-03|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers|A Phase I, Single Center, Open Label, 2-consecutive-group, 2-period, 1-sequence Crossover Study to Assess the Effect of Diltiazem (Cardizem), a Moderate CYP3A4 Inhibitor, or Ketoconazole, a Potent CYP3A4 Inhibitor, on the Pharmacokinetics of a Single Intravenous Dose of 150mg of AZD9742.|Completed||Phase 1|28|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:47:24.605852|2018-05-31 23:47:24.605852
NCT01124747|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2014-05-02|2010-05-14|2010-05-17|Estimate|||||||2014-05-02|2014-05-05|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug|An Open-Label Study to Evaluate the Disposition of 14C-Labeled ASP1585 in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 23:47:24.686185|2018-05-31 23:47:24.686185
NCT01124734|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2016-09-12|2010-05-14|2010-05-17|Estimate|||||||2016-09-12|2016-09-14|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma|Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma|Active, not recruiting||Phase 2|40|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 23:47:24.767299|2018-05-31 23:47:24.767299
NCT01124721|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2017-05-26|2010-05-13|2010-05-17|Estimate|||||||2017-05-26|2017-05-31|Actual|January 2008||2008-01-31|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Cog-RAST||Effects of Cognitive Training on Academic Task Performance in Attention Deficit Hyperactivity Disorder (ADHD)|Pilot Testing of Cognitive Training on Academic Task Performance in Children With Attention-deficit/Hyperactivity Disorder|Completed||N/A|26|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 23:47:24.89667|2018-05-31 23:47:24.89667
NCT01124708|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05||2011-02-17|2013-09-03|2010-05-13|2010-05-17|Estimate||||2011-02-17|2011-02-23|Estimate|2013-09-03|2013-09-13|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)|A Double-blind, Randomized, Placebo-controlled, Multicenter, Fixed Dose Titration Study to Assess Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|134|Actual|Targacept Inc.||2|||f||||f||||||||||2018-05-31 23:47:25.03208|2018-05-31 23:47:25.03208
NCT01124695|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2012-12-06|2010-05-14|2010-05-17|Estimate|||||||2012-12-06|2012-12-07|Estimate|September 2010||2010-09-30|December 2012|2012-12-31||||July 2016|Anticipated|2016-07-31||Interventional|||Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer|A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen|Unknown status|Recruiting|Phase 2|240|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:47:25.277509|2018-05-31 23:47:25.277509
NCT01124682|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2013-08-23|2010-05-14|2010-05-17|Estimate|||||||2013-08-23|2013-08-26|Estimate|May 2009||2009-05-31|February 2011|2011-02-28||||April 2016|Anticipated|2016-04-30||Interventional|||3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder|Image Guided Dose Escalated Adaptive Bladder Radiotherapy|Unknown status|Recruiting|Phase 1|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:47:26.178675|2018-05-31 23:47:26.178675
NCT01124669|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2017-05-16|2010-05-14|2010-05-17|Estimate|||||||2017-05-16|2017-05-17|Actual|June 13, 2010|Actual|2010-06-13|May 2017|2017-05-31|July 13, 2010|Actual|2010-07-13|July 13, 2010|Actual|2010-07-13||Observational|||Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate|BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy|Completed|||80|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:47:26.272632|2018-05-31 23:47:26.272632
NCT01124656|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2012-05-18|2010-05-13|2010-05-17|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2006||2006-09-30|May 2012|2012-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes|A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of AD 4833-536 in Subjects With Type 2 Diabetes|Terminated||Phase 3|26|Actual|Takeda||1||Formulation issues.|f||||f||||||||||2018-05-31 23:47:26.351968|2018-05-31 23:47:26.351968
NCT01124643|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2014-03-25||2015-04-02|2010-05-13|2010-05-17|Estimate|2014-08-06|2014-08-22|Estimate||||2015-04-02|2015-04-24|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease|An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal® Enzyme Replacement Therapy Administered to Adult Patients With Fabry Disease|Completed||Phase 3|35|Actual|Shire||1|||f||||f||||||||||2018-05-31 23:47:26.593401|2018-05-31 23:47:26.593401
NCT01124630|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-12-02|2010-05-14|2010-05-17|Estimate|||||||2013-12-02|2013-12-03|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments|Pilot Study of CS-1008 in Combination With FOLFIRI (Irinotecan, Leucovorin, and 5-fluorouracil [5-FU]) in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Failed First-line Treatment That Was Not Irinotecan-based.|Completed||Phase 1|21|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 23:47:27.165991|2018-05-31 23:47:27.165991
NCT01124617|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2013-03-27||2013-12-11|2010-05-13|2010-05-17|Estimate|2013-06-25|2013-06-26|Estimate||||2013-12-11|2014-01-13|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia|Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia|Completed||Phase 2|91|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 23:47:27.363037|2018-05-31 23:47:27.363037
NCT01124604|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2013-03-06||2013-05-10|2010-05-13|2010-05-17|Estimate|2013-03-06|2013-04-17|Estimate||||2013-05-10|2013-05-14|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants|Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Osteoarthritis of the Knee or Low Back Pain|Completed||Phase 2|91|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 23:47:28.286734|2018-05-31 23:47:28.286734
NCT01124591|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-06-08|2010-05-13|2010-05-17|Estimate|||||||2015-06-08|2015-06-10|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|BIDMED||Brief Intervention for Drug Misuse in the Emergency Department|Clinical Trial to Determine the Effect of a Brief Behavioral Intervention in Reducing Drug Misuse Among an Emergency Department Population|Completed||Phase 2|1030|Actual|Rhode Island Hospital||1|||f||||t||||||||||2018-05-31 23:47:29.209923|2018-05-31 23:47:29.209923
NCT01124578|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2010-05-14|2010-05-14|2010-05-17|Estimate|||||||2010-05-14|2010-05-17|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Observational|||Study the Average Aerobic Bioburden Levels on Catheters After Use With Egret Catheter and the Predicate Device|Validate the Acceptability of Egret's Extended Use Product as Compared to the Existing Daily Change-out Product|Completed|||200|Actual|Egret Medical Products Inc.|||2||f||||f||||||||||2018-05-31 23:47:29.291514|2018-05-31 23:47:29.291514
NCT01124565|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12||2011-06-13|2013-12-16|2010-05-13|2010-05-17|Estimate||||2011-06-13|2011-06-27|Estimate|2013-12-16|2014-01-17|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|Completed||Phase 2|40|Actual|Revance Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 23:47:29.366618|2018-05-31 23:47:29.366618
NCT01124552|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06||2011-06-13|2013-12-24|2010-05-13|2010-05-17|Estimate||||2011-06-13|2011-06-27|Estimate|2013-12-24|2014-01-30|Estimate|April 2010||2010-04-30|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|A Phase 2, Double-Blind, Randomized, 4-Arm, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|Completed||Phase 2|180|Actual|Revance Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 23:47:29.442981|2018-05-31 23:47:29.442981
NCT01124539|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2014-12-08|2010-05-13|2010-05-17|Estimate|||||||2014-12-08|2014-12-09|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma|A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma|Unknown status|Active, not recruiting|Phase 2|58|Anticipated|Arno Therapeutics||1|||f||||f||||||||||2018-05-31 23:47:29.548343|2018-05-31 23:47:29.548343
NCT01124526|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2010-05-14|2010-05-14|2010-05-17|Estimate|||||||2010-05-14|2010-05-17|Estimate|September 2004||2004-09-30|May 2010|2010-05-31|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Interventional|||Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma|Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma|Completed||Phase 4|75|Actual|Asociacion Espanola de Hematologia y Hemoterapia||1|||f||||t||||||||||2018-05-31 23:47:29.63254|2018-05-31 23:47:29.63254
NCT01124513|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-03-17|2010-05-13|2010-05-17|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Melanin Index||Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI|A Prospective Study of Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI|Completed||N/A|270|Actual|Northwestern University||3|||f||||f||||||||||2018-05-31 23:47:29.736317|2018-05-31 23:47:29.736317
NCT01124487|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-14|2010-05-14|2010-05-17|Estimate|||||||2010-05-14|2010-05-17|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||The Acute Effects of Oleic Acid Enriched-diets on Lipids, Insulin Sensitivity and Serum Inflammatory Markers|The Acute Effects of Oleic Acid Enriched-diets on Lipids, Insulin Sensitivity and Serum Inflammatory Markers|Completed||N/A|10|Actual|Malaysia Palm Oil Board||3|||f||||t||||||||||2018-05-31 23:47:29.883616|2018-05-31 23:47:29.883616
NCT01124474|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2012-04-11|2010-05-14|2010-05-17|Estimate|||||||2012-04-11|2012-04-12|Estimate|December 2010||2010-12-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Spine Surgery|Evaluation of the Use of Arterial Pulse Waveform Contour Analysis for Goal Directed Therapy in Patients Undergoing Major Spine Surgery|Terminated||N/A|5|Actual|Loma Linda University||2||This study was stopped because of lack of posterior only major spine surgeries.|f||||f||||||||||2018-05-31 23:47:29.974583|2018-05-31 23:47:29.974583
NCT01124461|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2018-05-03|2010-05-14|2010-05-17|Estimate|||||||2018-05-03|2018-05-10|Estimate|January 2010|Actual|2010-01-31|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|CONDR||BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor|BIRN (Biomedical Informatics Research Network)Resources Facilitate the Personalization of Malignant Brain Tumor|Completed|||112|Actual|Washington University School of Medicine|||1||f||||t||||||Samples With DNA|"~     Brain tumor tissue, Whole Blood.~   "|||2018-05-31 23:47:30.024661|2018-05-31 23:47:30.024661
NCT01124448|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|2014-07-03||2014-08-19|2010-05-14|2010-05-17|Estimate|2014-08-19|2014-08-20|Estimate||||2014-08-19|2014-08-20|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|PROBIOLAC|This study was designed to evaluate a high number of microbiological, biochemical or immunological parameters before and after the administration of a probiotic to women with mastitis and to elucidate which of them can be useful as biomarkers in future studies. The number of participants was considered suitable for such purpose.|Global Effects of a Probiotic Strain on Lactating Women|Oral Administration of a Probiotic to Lactating Women: Microbiological, Immunological, Transcriptomics and Metabolomics Effects|Completed||N/A|40|Actual|Universidad Complutense de Madrid||2|||f||||f||||||||||2018-05-31 23:47:30.078449|2018-05-31 23:47:30.078449
NCT01124435|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2010-06-03|2010-05-14|2010-05-17|Estimate|||||||2010-06-03|2010-06-04|Estimate|October 2003||2003-10-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|September 2007|Actual|2007-09-30||Interventional|carbo-cox2||Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients|Phase II Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients|Completed||Phase 2|45|Actual|Catholic University of the Sacred Heart|||||f||||t||||||||||2018-05-31 23:47:30.355743|2018-05-31 23:47:30.355743
NCT01124422|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2011-11-17||2017-10-09|2010-05-13|2010-05-17|Estimate|2011-11-17|2011-12-21|Estimate||||2017-10-09|2017-11-08|Actual|July 19, 2010||2010-07-19|October 2017|2017-10-31|May 2, 2011|Actual|2011-05-02|May 1, 2011|Actual|2011-05-01||Interventional|ESWT||Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease|A Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 mcg Twice Daily Plus Tiotropium 18 mcg Daily Versus Placebo DISKUS Twice Daily Plus Tiotropium 18 mcg Daily on Exercise Time and Physiological Parameters in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|255|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:47:30.489161|2018-05-31 23:47:30.489161
NCT01124409|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2011-06-21|2010-05-14|2010-05-17|Estimate|||||||2011-06-21|2011-06-23|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.|Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma|Unknown status|Active, not recruiting|Phase 3|41|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 23:47:31.28149|2018-05-31 23:47:31.28149
NCT01124396|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2014-01-07|2010-05-13|2010-05-17|Estimate|||||||2014-01-07|2014-01-08|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|April 2012|Actual|2012-04-30|August 2010|Actual|2010-08-31||Observational|||DSP-3025 A Phase 1 Study of Healthy Male Volunteers|A Double-blind, Placebo-controlled, Randomised Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Repeated Weekly Doses of DSP-3025 Administered Intranasally to Healthy Male Volunteers|Completed|||24|Actual|Sumitomo Dainippon Pharma Co., Ltd.|||3||f||||||||||||||2018-05-31 23:47:31.376789|2018-05-31 23:47:31.376789
NCT01124383|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-05-13|2010-05-13|2010-05-17|Estimate|||||||2010-05-13|2010-05-17|Estimate|August 2008||2008-08-31|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Impact of Anesthesia on the Absorption of Glycine in Operative Hysteroscopy: a Randomized Controlled Trial|The Impact of Anesthesia on the Absorption of Glycine in Operative Hysteroscopy: a Randomized Controlled Trial|Completed||N/A|95|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 23:47:31.449768|2018-05-31 23:47:31.449768
NCT01124370|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2015-07-13||2016-04-12|2010-05-13|2010-05-17|Estimate|2015-08-10|2015-08-31|Estimate||||2016-04-12|2016-05-16|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||All subjects with an implant attempt.|Chronic Evaluation of Respicardia Therapy|Safety and Efficacy Evaluation of Respicardia Therapy for Central Sleep Apnea|Completed||Phase 2|57|Actual|Respicardia, Inc.||1|||f||||f||||||||||2018-05-31 23:47:31.558778|2018-05-31 23:47:31.558778
NCT01124357|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-05-14|2010-05-14|2010-05-17|Estimate|||||||2010-05-14|2010-05-17|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|COAT||A Study to Compare the Effectiveness of Two Different Outpatient Endometrial Ablation Techniques Used for Heavy Periods|A Randomised Control Trial To Compare the Effectiveness of Outpatient Endometrial Ablation Techniques (Novasure vs Thermachoice)in the Treatment of Menorhagia|Completed||N/A|81|Actual|Birmingham Women's NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 23:47:31.985621|2018-05-31 23:47:31.985621
NCT01124344|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2012-03-26|2010-05-13|2010-05-17|Estimate|||||||2012-03-26|2012-03-27|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Pharmacology Study of BMS-866949|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-866949 in Healthy Subjects|Terminated||Phase 1|47|Actual|Bristol-Myers Squibb||7|||f||||t||||||||||2018-05-31 23:47:32.081469|2018-05-31 23:47:32.081469
NCT01124331|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2015-02-03|2010-05-14|2010-05-17|Estimate|||||||2015-02-03|2015-02-05|Estimate|March 2005||2005-03-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NeOProM||Appropriate Oxygen Levels for Extremely Preterm Infants: a Prospective Meta-analysis|Appropriate Levels of Oxygen Saturation for Extremely Preterm Infants: Prospective Individual Patient Data Meta-analysis|Completed||N/A|4959|Actual|University of Sydney||2|||f||||t||||||||||2018-05-31 23:47:32.222298|2018-05-31 23:47:32.222298
NCT01124318|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-09-13|2010-05-13|2010-05-17|Estimate|||||||2010-09-13|2010-09-14|Estimate|May 2010||2010-05-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|LF-AD-09||A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults|Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Lactofiltrum, Orally Administered Tablets (Produced by AVVA RUS, JSC) to Treat Atopic Dermatitis in Adults|Completed||Phase 2/Phase 3|90|Anticipated|Avva Rus, JSC||2|||f||||t||||||||||2018-05-31 23:47:32.343974|2018-05-31 23:47:32.343974
NCT01124305|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2012-10-18||2013-11-25|2010-05-13|2010-05-17|Estimate|2012-12-12|2013-01-21|Estimate||||2013-11-25|2013-12-18|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|CPI||Knee Arthroplasty Performed With Conventional and Customized Instrumentation|A Prospective, Randomized Evaluation of Total Knee Arthroplasty Performed With Conventional and Customized Patient Instrumentation|Completed||Phase 4|70|Actual|Anderson Orthopaedic Research Institute||2|||f||||t||||||||||2018-05-31 23:47:32.460895|2018-05-31 23:47:32.460895
NCT01124292|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2013-05-02||2013-09-09|2010-05-14|2010-05-17|Estimate|2013-07-02|2013-09-10|Estimate||||2013-09-09|2013-09-18|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|TDS-1||Evaluation of a Tongue Operated Assistive Technology for Individuals With Severe Paralysis|Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals With Severe Neurological Disorders|Completed||Phase 1|61|Actual|Georgia Institute of Technology||3|||f||||t||||||||||2018-05-31 23:47:32.867923|2018-05-31 23:47:32.867923
NCT01124279|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2011-01-06|2010-05-13|2010-05-17|Estimate|||||||2011-01-06|2011-01-07|Estimate|May 2010||2010-05-31|January 2011|2011-01-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Single-dose, Pharmacokinetics of AMG 853 in Healthy Adult Subjects|A Phase I, Randomized, Open-Label, Single-Dose, 2-Part, 4-Treatment, 4-Way Crossover Study in Healthy Adult Subjects to Evaluate the Pharmacokinetics of Various AMG 853 Formulations When Administered Under Fasted and Fed Conditions|Completed||Phase 1|43|Actual|Amgen||1|||f||||||||||||||2018-05-31 23:47:35.624282|2018-05-31 23:47:35.624282
NCT01124266|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-14|||2011-02-16|2010-05-14|2010-05-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy|Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial|Completed||Phase 4|844|Actual|Soon Chun Hyang University||2|||f||||t||||||||||2018-05-31 23:47:35.704648|2018-05-31 23:47:35.704648
NCT01124253|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-14|2010-05-14|2010-05-17|Estimate|||||||2010-05-14|2010-05-17|Estimate|July 2007||2007-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|Dengshan||Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)|Phase III Study of Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer|Completed||Phase 3|250|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 23:47:35.808594|2018-05-31 23:47:35.808594
NCT01124240|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2011-07-25|2010-05-14|2010-05-17|Estimate|||||||2011-07-25|2011-07-26|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|January 2014|Anticipated|2014-01-31|November 2012|Anticipated|2012-11-30||Interventional|ExCentric||Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene|Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene|Unknown status|Recruiting|Phase 2|48|Anticipated|Northern Sydney and Central Coast Area Health Service|||||f||||t||||||||||2018-05-31 23:47:35.889081|2018-05-31 23:47:35.889081
NCT01124227|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2012-01-04|2010-05-14|2010-05-17|Estimate|||||||2012-01-04|2012-01-05|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|PDinCHF||Peritoneal Dialysis in Congestive Heart Failure|Symptomatic Improvement by Peritoneal Dialysis in Patients With End Stage Congestive Heart Failure|Unknown status|Recruiting|Phase 3|45|Anticipated|Martini Hospital Groningen||3|||f||||t||||||||||2018-05-31 23:47:35.961107|2018-05-31 23:47:35.961107
NCT01124214|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2018-02-13|2010-05-14|2010-05-17|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2010||2010-07-31|February 2018|2018-02-28|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|CEBE||Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study)|In Vivo Endomicroscopy (EM) for Improved Diagnosis of Barrett's Esophagus (BE) and Associated Neoplasia: A Multicenter Randomized Controlled Trial of Diagnostic Yield and Clinical Impact|Completed||N/A|68|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 23:47:36.033595|2018-05-31 23:47:36.033595
NCT01124201|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|February 2007||2007-02-28|March 2007|2007-03-31|June 2009|Actual|2009-06-30|March 2008|Actual|2008-03-31||Interventional|||Lumbar Stabilization, Strengthening and Stretching in Chronic Low Back Pain|Lumbar Segmental Stabilization, Strengthening and Stretching in Chronic Low Back Pain: a Comparative Study|Completed||N/A|45|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 23:47:36.101897|2018-05-31 23:47:36.101897
NCT01124188|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2016-12-15||2017-04-04|2010-05-13|2010-05-14|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|May 2010||2010-05-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ADAPT||ADAPT: Addressing Depression and Pain Together|Optimizing Care for Older Adults With Back Pain and Depression|Completed||Phase 4|263|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 23:47:36.20966|2018-05-31 23:47:36.20966
NCT01124175|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2010-06-21||2010-11-22|2010-05-13|2010-05-14|Estimate|2010-06-21|2010-07-19|Estimate||||2010-11-22|2010-12-08|Estimate|October 2003||2003-10-31|November 2010|2010-11-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Losartan 100 mg Tablet in Healthy Subjects Under Non-Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|80|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:47:36.588073|2018-05-31 23:47:36.588073
NCT01124162|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2010-06-21||2010-11-22|2010-05-13|2010-05-14|Estimate|2010-06-21|2010-07-19|Estimate||||2010-11-22|2010-12-08|Estimate|October 2003||2003-10-31|November 2010|2010-11-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Losartan 100 mg Tablets in Healthy Subjects Under Fasting Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Losartan 100 mg Tablets and Cozaar® Administered as 1 * 100 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|80|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-05-31 23:47:36.958731|2018-05-31 23:47:36.958731
NCT01124149|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2013-09-30||2014-06-06|2010-05-13|2010-05-14|Estimate|2013-09-30|2013-12-02|Estimate||||2014-06-06|2014-06-12|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||The Safety Population was used. Safety Population defined as all subjects who took at least 1 dose of investigational product during the Acute or Maintenance Phase (n=717).|Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis|A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis|Completed||Phase 4|722|Actual|Shire||1|||f||||||||||||||2018-05-31 23:47:37.33326|2018-05-31 23:47:37.33326
NCT01124136|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2018-01-10|2010-05-13|2010-05-14|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2010||2010-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|Neurostim||Neurostimulation of Spinal Nerves That Affect the Heart|Evaluation of the Effect of Neurostimulation in Patients With Symptomatic Heart Failure|Active, not recruiting||N/A|40|Actual|The Methodist Hospital System||2|||f||||t|f|t|f|f||||Undecided|to be determined|2018-05-31 23:47:38.939024|2018-05-31 23:47:38.939024
NCT01124123|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2012-09-25|2010-05-13|2010-05-14|Estimate|||||||2012-09-25|2012-09-26|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|BIOBI||Oral Bioavailability of Bilastine|Study to Assess Oral Bioavailability of Bilastine (Estudio de Biodisponibilidad Oral de Bilastina)|Completed||Phase 1|12|Actual|Faes Farma, S.A.||2|||f||||f||||||||||2018-05-31 23:47:39.103571|2018-05-31 23:47:39.103571
NCT01124110|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2014-11-17|2010-05-13|2010-05-14|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|March 2013|Actual|2013-03-31||Interventional|BCBSM-OE||Tobacco Tactics Website for Operating Engineers|Tobacco Tactics Website for Operating Engineers|Completed||Phase 3|232|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 23:47:39.387325|2018-05-31 23:47:39.387325
NCT01124097|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2014-01-10||2014-02-26|2010-05-13|2010-05-14|Estimate|2014-02-26|2014-04-07|Estimate||||2014-02-26|2014-04-07|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia|A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia|Terminated||Phase 3|240|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 23:47:39.559204|2018-05-31 23:47:39.559204
NCT01124084|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|||The Factors Affecting Intentions of Medical Staff to Use Personal Health Record in Northern Hospitals of Taiwan|The Factors Affecting Intentions of Medical Staff to Use Personal Health Record in Northern Hospitals of Taiwan|Completed|||1800|Actual|Taipei Medical University WanFang Hospital|||1||f||||f||||||||||2018-05-31 23:47:40.43114|2018-05-31 23:47:40.43114
NCT01124071|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|April 2011|Anticipated|2011-04-30|June 2010|Anticipated|2010-06-30||Interventional|||Korean Diet Efficacy Clinical Trial|A 13 Week Study to Examine the Effectiveness of the Korean Diet on Weight, Blood Pressure, Metabolic Parameters and Disease Control in an Australian Overweight and Obese Population.|Unknown status|Active, not recruiting|N/A|70|Actual|University of Sydney||2|||f||||f||||||||||2018-05-31 23:47:40.503728|2018-05-31 23:47:40.503728
NCT01124058|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2017-10-24|2010-05-13|2010-05-14|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2010|Actual|2010-07-31|October 2017|2017-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial|Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial.|Completed||Phase 1|39|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 23:47:40.63437|2018-05-31 23:47:40.63437
NCT01124045|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2013-04-30||2013-04-30|2010-05-13|2010-05-14|Estimate|2013-04-30|2013-06-19|Estimate||||2013-04-30|2013-06-19|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Baseline characteristics are presented for all patients who were exposed to the study drug.|Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery|A Phase IIIB, Multicenter, Randomized, Double-Masked, Parallel-Group, Active-Controlled Study of the Safety and Efficacy of Difluprednate Ophthalmic Emulsion, 0.05% (Durezol™) 4 Times Daily (QID) and Prednisolone Acetate Ophthalmic Suspension, 1.0% (Pred Forte™) QID for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age|Completed||Phase 3|80|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:47:40.937234|2018-05-31 23:47:40.937234
NCT01124032|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|May 2010||2010-05-31|May 2010|2010-05-31||||January 2011|Anticipated|2011-01-31||Interventional|||A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With ADHD Compared to Healthy Adults||Unknown status|Not yet recruiting|N/A|30|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 23:47:42.816657|2018-05-31 23:47:42.816657
NCT01124019|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2014-10-10|2010-05-13|2010-05-14|Estimate|||||||2014-10-10|2014-10-13|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography|SNP Panels and Risk Assessment in Women Undergoing Mammography|Completed|||1600|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||f||||||||||2018-05-31 23:47:42.898836|2018-05-31 23:47:42.898836
NCT01124006|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2015-12-18||2016-01-26|2010-05-13|2010-05-14|Estimate|2016-01-26|2016-02-24|Estimate||||2016-01-26|2016-02-24|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration||Completed||Phase 2|24|Actual|DePuy Spine||2|||f||||||||||||||2018-05-31 23:47:43.009855|2018-05-31 23:47:43.009855
NCT01123993|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|||2011-01-03|2010-05-13|2010-05-14|Estimate|||||||2011-01-03|2011-01-05|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||The Effect of Thai Traditional Music on Cognitive Function, Psychological Health and Quality of Sleep Among Thai Older Individuals With Dementia|The Effect of Thai Traditional Music on Cognitive Function, Psychological Health and Quality of Sleep Among Thai Older Individuals With Dementia.|Completed||Phase 3|60|Anticipated|Phramongkutklao College of Medicine and Hospital||1|||f||||t||||||||||2018-05-31 23:47:43.493768|2018-05-31 23:47:43.493768
NCT01123980|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2012-06-01||2017-01-10|2010-05-13|2010-05-14|Estimate|2012-06-01|2012-07-09|Estimate||||2017-01-10|2017-02-24|Actual|May 2010||2010-05-31|January 2017|2017-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|EasyMix||Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment|An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes|Completed||Phase 4|521|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:47:43.749479|2018-05-31 23:47:43.749479
NCT01123967|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-05-26|2010-05-13|2010-05-14|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2011||2011-02-28|May 2015|2015-05-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Offering Proactive Tobacco Treatment|Improved Effectiveness of Smoking Cessation Programs for Minnesota Priority Populations|Completed||N/A|2500|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 23:47:44.4062|2018-05-31 23:47:44.4062
NCT01123954|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2011-12-13|2010-05-13|2010-05-14|Estimate|||||||2011-12-13|2011-12-14|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers|Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers|Completed||Phase 2|33|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:47:44.501354|2018-05-31 23:47:44.501354
NCT01123941|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|2012-02-29||2013-12-16|2010-05-13|2010-05-14|Estimate|2012-05-14|2012-06-13|Estimate||||2013-12-16|2014-01-17|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)|A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.|Completed||Phase 1|50|Actual|Novartis||2|||f||||f||||||||||2018-05-31 23:47:44.633326|2018-05-31 23:47:44.633326
NCT01123928|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2011-12-28||2012-02-01|2010-05-13|2010-05-14|Estimate|2011-12-28|2012-02-02|Estimate||||2012-02-01|2012-02-03|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|GUSTO||Guangdong Uptake of Surgery Trial|The Effect of Counseling in Cataract Screening: Guangdong Uptake of Surgery Trial|Completed||N/A|434|Actual|Sun Yat-sen University|One of the six participating hospitals did not adhere to protocol, and thus total number of subjects analyzed was smaller than originally anticipated.|2|||f||||f||||||||||2018-05-31 23:47:44.91916|2018-05-31 23:47:44.91916
NCT01123915|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2018-03-20|2010-05-13|2010-05-14|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2010||2010-05-31|November 2011|2011-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People|A Phase 1, Dose Escalating, Single Centre, Double Blind Study of the Safety and Immunogenicity of Opal-HIV-Gag Clade C in HIV Positive Subjects|Terminated||Phase 1|22|Actual|Medicines Development Limited||2|||f||||t||||||||||2018-05-31 23:47:45.365723|2018-05-31 23:47:45.365723
NCT01123902|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|June 2006||2006-06-30|July 2006|2006-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effectiveness of a Hand-held Fan for Breathlessness|Effectiveness of a Hand-held Fan for Breathlessness: a Randomised Phase II Trial|Completed||Phase 2|109|Actual|King's College London||2|||f||||f||||||||||2018-05-31 23:47:45.503416|2018-05-31 23:47:45.503416
NCT01123889|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2013-10-31||2013-12-24|2010-05-12|2010-05-14|Estimate|2013-12-24|2014-02-11|Estimate||||2013-12-24|2014-02-11|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Treatment of the Rotator Cuff Disease With Platelet Rich Plasma Injection|Treatment of Rotator Cuff Syndrome With Injection of Autologous Platelet Rich Plasma|Completed||N/A|12|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 23:47:45.609736|2018-05-31 23:47:45.609736
NCT01123876|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2015-01-20|2010-05-13|2010-05-14|Estimate|||||||2015-01-20|2015-01-21|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor|A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors|Completed||Phase 1|60|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:47:45.899682|2018-05-31 23:47:45.899682
NCT01123863|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-06-12|2010-05-13|2010-05-14|Estimate|||||||2015-06-12|2015-06-16|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2|The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2|Completed|||248|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||||||2018-05-31 23:47:45.968499|2018-05-31 23:47:45.968499
NCT01123850|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2015-04-24||2015-05-11|2010-05-13|2010-05-14|Estimate|2015-05-11|2015-05-27|Estimate||||2015-05-11|2015-05-27|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||CopiOs Posterolateral Fusion Procedure|A Prospective Study Assessing Clinical Outcomes and Radiographic Results After the Use of CopiOs(R) Bone Void Filler (BVF)Sponge in a Posterolateral Fusion Procedure (PLF).|Terminated||Phase 2|45|Actual|Zimmer Biomet||1||Slow enrollment|f||||f||||||||||2018-05-31 23:47:46.097749|2018-05-31 23:47:46.097749
NCT01123837|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2014-01-20|2010-05-13|2010-05-14|Estimate|||||||2014-01-20|2014-01-22|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting|A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting|Completed||N/A|202|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 23:47:46.312917|2018-05-31 23:47:46.312917
NCT01123655|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-12-02|2010-05-12|2010-05-14|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients|Phase 1 Trial of CII APL A12 in Rheumatoid Arthritis Patients|Completed||Phase 1|22|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-05-31 23:47:47.636585|2018-05-31 23:47:47.636585
NCT01123824|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2011-12-14|2010-05-13|2010-05-14|Estimate|||||||2011-12-14|2011-12-15|Estimate|April 2009||2009-04-30|December 2011|2011-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects|A Randomized, Double-blind, Double-dummy, Two Period, Two Treatment Cross-over Pharmacodynamic and Pharmacokinetic Study of Clopidogrel Given as 5-day Repeated Oral Doses (300 mg Loading Dose Followed by 75 mg/Day and 600 mg Loading Dose Followed by 150 mg/Day) in 4 Different Groups of CYP2C19 Genotyped Healthy Male and Female Subjects|Completed||Phase 1|40|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:47:46.38907|2018-05-31 23:47:46.38907
NCT01123811|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2010-05-12|2010-05-12|2010-05-14|Estimate|||||||2010-05-12|2010-05-14|Estimate|May 2006||2006-05-31|March 2006|2006-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|GC-CIF-2005||Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer|An Open-label, Non-randomized Phase II Trial of Cetuximab in Combination With Irinotecan and 5-FU/FA for Patients With Metastatic Gastric Cancer|Completed||Phase 2|45|Actual|Johannes Gutenberg University Mainz||1|||f||||f||||||||||2018-05-31 23:47:46.570689|2018-05-31 23:47:46.570689
NCT01123798|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2011-06-14|2010-05-13|2010-05-14|Estimate|||||||2011-06-14|2011-06-15|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers|The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome in Injured Soldiers|Completed|||300|Anticipated|J&M Shuler|||3||f||||f||||||||||2018-05-31 23:47:46.724198|2018-05-31 23:47:46.724198
NCT01123785|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27||2012-04-27|2012-10-11|2010-05-12|2010-05-14|Estimate||||2012-10-11|2012-10-15|Estimate|2012-10-11|2012-10-15|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|A Phase I/II Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics (Efficacy) of Chronic Twice-Daily Topical Monocular Application of INO-8875 Ophthalmic Formulation in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|Completed||Phase 1/Phase 2|144|Actual|Inotek Pharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 23:47:46.820672|2018-05-31 23:47:46.820672
NCT01123772|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-04-27|2010-05-12|2010-05-14|Estimate|||||||2012-04-27|2012-04-30|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers|Phase I, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation Study to Evaluate Tolerability, Safety & PK of BID Topical Ocular Application of INO-8875 in Healthy Older-Adult Volunteers|Completed||Phase 1|70|Actual|Inotek Pharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 23:47:46.892551|2018-05-31 23:47:46.892551
NCT01123759|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Healthful Seafood Consumption for Sensitive Populations|Consuming Fish to Reduce Mercury Intake While Optimizing Omega-3 Fatty Acid Status|Completed||N/A|71|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 23:47:46.977469|2018-05-31 23:47:46.977469
NCT01123746|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-14|Estimate|||||||2010-05-12|2010-05-14|Estimate|October 2009||2009-10-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Observational|||Utility of Laboratory Testing for Children With Seizure in Emergency Department||Completed|||500|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:47:47.04715|2018-05-31 23:47:47.04715
NCT01123733|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-14|Estimate|||||||2010-05-12|2010-05-14|Estimate|October 2009||2009-10-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|May 2010|Anticipated|2010-05-31||Observational|||Breastfeeding Practice Evaluation in Taiwan|Breastfeeding Practice in Taiwan - Evaluation the Non-Baby-Friendly Hospitals Intervention Strategies to Breastfeeding Practice|Unknown status|Enrolling by invitation||1000|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:47:47.117667|2018-05-31 23:47:47.117667
NCT01123720|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-14|Estimate|||||||2010-05-12|2010-05-14|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Observational|||The Impact of Internationalize Medical Services to localPeople Seeking Medical Care|To Understand the Impacts of Internationalize Medical Services on Local People Seeking Medical Care, and to Establish Responsive Management Mechanism|Unknown status|Enrolling by invitation||100|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:47:47.175503|2018-05-31 23:47:47.175503
NCT01123707|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12||2012-08-17|2012-08-24|2010-05-13|2010-05-14|Estimate||||2012-08-24|2012-08-31|Estimate|2012-08-24|2012-08-31|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|ACES 257||To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|Terminated||Phase 3|170|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-05-31 23:47:47.231628|2018-05-31 23:47:47.231628
NCT01123694|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-14|Estimate|||||||2010-05-12|2010-05-14|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||Xeroderma Pigmentosum Patient Experiences|Xeroderma Pigmentosum: A Survey of Patient Experiences|Unknown status|Recruiting||15|Anticipated|Henry Ford Health System|||1||f||||t||||||||||2018-05-31 23:47:47.382616|2018-05-31 23:47:47.382616
NCT01123681|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2010-11-12|2010-05-13|2010-05-14|Estimate|||||||2010-11-12|2010-11-16|Estimate|May 2010||2010-05-31|November 2010|2010-11-30||||December 2010|Anticipated|2010-12-31||Observational|INDEX48||Intubation and Extubation Over 48 Hours Mechanical Ventilation|Observational Study of Intubation and Extubation Over 48 Hours Mechanical Ventilation|Unknown status|Active, not recruiting||200|Anticipated|Okayama Research Investigator Organizing Network|||2||f||||f||||||||||2018-05-31 23:47:47.479003|2018-05-31 23:47:47.479003
NCT01123668|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2014-09-05|2010-05-13|2010-05-14|Estimate|||||||2014-09-05|2014-09-08|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)|Neuropharmacology of Response Inhibition in Comorbid ADHD and Nicotine Dependence|Completed|||101|Actual|Duke University|||1||f||||f||||||Samples With DNA|"~     Samples With DNA~   "|||2018-05-31 23:47:47.579832|2018-05-31 23:47:47.579832
NCT01123642|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2015-06-04||2015-08-12|2010-05-12|2010-05-14|Estimate|2015-08-12|2015-08-14|Estimate||||2015-08-12|2015-08-14|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational||A total of 345 participants were enrolled (signed informed consent), of which 309 met final eligibility criteria. Results are analyzed using the 309 eligible enrolled participants.|Project SERVE: Post Deployment Functioning|Functional Outcomes in OEF/OIF Veterans With PTSD and Alcohol Misuse|Completed|||345|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-05-31 23:47:47.737459|2018-05-31 23:47:47.737459
NCT01123616|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-14|Estimate|||||||2010-05-12|2010-05-14|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|June 2010|Anticipated|2010-06-30|April 2010|Anticipated|2010-04-30||Interventional|||Abdominal Wall Closure With Triclosan-coated Suture (TCS09-10)|Abdomen Closure Using Triclosan Coated Absorbable Suture vs Uncoated Sutures of the Same Base Material|Unknown status|Active, not recruiting|Phase 2|1|Anticipated|University of Pecs||2|||f||||t||||||||||2018-05-31 23:47:47.933747|2018-05-31 23:47:47.933747
NCT01123603|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-01-13|2010-05-13|2010-05-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|LOTUS||Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata|Lower UTI Evaluation in Women With Uterine Leiomyomata|Completed|||860|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 23:47:48.062069|2018-05-31 23:47:48.062069
NCT01123590|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-11-21|2010-05-13|2010-05-14|Estimate|||||||2010-11-21|2010-11-23|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Observational|||Characteristics of Patients With Thymoma in Chulalongkorn Hospital|Characteristics of Patients With Thymoma Undergone Thymectomy in Chulalongkorn Hospital Between 2003-2007|Completed|||50|Actual|Chulalongkorn University|||2||f||||t||||||Samples Without DNA|"~     PBMC~   "|||2018-05-31 23:47:48.14255|2018-05-31 23:47:48.14255
NCT01123577|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2012-08-13|2010-05-13|2010-05-14|Estimate|||||||2012-08-13|2012-08-14|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|ESBPM||Evaluation of Integrating Self Blood Pressure Monitoring Into Urban Primary Care Practices|Evaluation of Integrating Self Blood Pressure Monitoring Into Urban Primary Care Practices to Improve Ethnic/ Racial Disparities in Hypertension|Completed||N/A|899|Actual|New York City Department of Health and Mental Hygiene||2|||f||||f||||||||||2018-05-31 23:47:48.26348|2018-05-31 23:47:48.26348
NCT01123564|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|BRAVO||Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion|A Randomized, Controlled, Two-center Phase II Study Assessing the Efficacy and Safety of Intravitreal Lucentis Injections in Patients With Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Pecs||2|||f||||f||||||||||2018-05-31 23:47:48.348871|2018-05-31 23:47:48.348871
NCT01123551|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2014-07-22|2010-05-13|2010-05-14|Estimate|||||||2014-07-22|2014-07-23|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy Study of Nebulized Morphine and Intravenous Morphine in Post Traumatic Pain|Nebulized Morphine Versus Intravenous Morphine in the Management of Post Traumatic Pain in Emergency Department (ED)|Completed||Phase 3|200|Actual|University of Monastir||2|||f||||f||||||||||2018-05-31 23:47:48.442405|2018-05-31 23:47:48.442405
NCT01123538|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-11-02|2010-05-12|2010-05-14|Estimate|||||||2011-11-02|2011-11-03|Estimate|December 2008||2008-12-31|November 2011|2011-11-30|October 2012|Anticipated|2012-10-31|October 2011|Actual|2011-10-31||Interventional|ProGEP||Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile|Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|University Hospital of North Norway||2|||f||||||||||||||2018-05-31 23:47:48.520195|2018-05-31 23:47:48.520195
NCT01123525|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-09-29|2010-05-12|2010-05-14|Estimate|||||||2011-09-29|2011-09-30|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Adenosine Cardioplegia; Improved Cardioprotection?|Adenosine Instead of Supranormal Potassium in Crystalloid Cardioplegia, a Randomized Clinical Study|Completed||Phase 1/Phase 2|60|Anticipated|University Hospital of North Norway||2|||f||||||||||||||2018-05-31 23:47:48.592946|2018-05-31 23:47:48.592946
NCT01123512|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2014-08-06||2014-10-01|2010-05-12|2010-05-14|Estimate|2014-08-06|2014-08-21|Estimate||||2014-10-01|2014-10-09|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|KAST|As-Treated population|The Kiva® System as a Vertebral Augmentation Treatment|The Kiva® System as a Vertebral Augmentation Treatment - A Safety and Effectiveness Trial|Completed||Phase 3|300|Actual|Benvenue Medical, Inc.||2|||f||||f||||||||||2018-05-31 23:47:48.733276|2018-05-31 23:47:48.733276
NCT01123499|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2018-05-02|2010-05-13|2010-05-14|Estimate|||||||2018-05-02|2018-05-03|Actual|April 28, 2010||2010-04-28|August 21, 2017|2017-08-21||||||||Observational|||Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers|Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Healthy Volunteers|Recruiting|||10|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:47:49.300241|2018-05-31 23:47:49.300241
NCT01123486|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-04-21|2010-05-13|2010-05-14|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint|A Hydromorphone High Resolution Pharmacokinetic-Pharmacodynamic Fingerprint as the Basis for Identifying Sex Differences in Opioid Pharmacokinetics and Pharmacodynamics|Withdrawn||N/A|0|Actual|Northwestern University||1||PI relocated to new university|f||||f||||||||||2018-05-31 23:47:49.418994|2018-05-31 23:47:49.418994
NCT01123473|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2016-10-11|2010-05-13|2010-05-14|Estimate|||||||2016-10-11|2016-10-12|Estimate|December 2010||2010-12-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|||Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer|Effectiveness of First Line Treatment With Lapatinib and ECF/X in Histologically Proven Adenocarcinoma of the Stomach or the Esophagogastric Junction, Metastatic or Not Amenable to Curative Surgery According to HER2 and EGFR Status: a Randomized Phase II Trial|Terminated||Phase 2|29|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||company withdrew interest|f||||||||||||||2018-05-31 23:47:49.530121|2018-05-31 23:47:49.530121
NCT01123460|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2017-05-16|2010-05-13|2010-05-14|Estimate|||||||2017-05-16|2017-05-17|Actual|April 12, 2010|Actual|2010-04-12|May 2017|2017-05-31|June 12, 2010|Actual|2010-06-12|June 12, 2010|Actual|2010-06-12||Observational|||Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride|Measurement of Potential Biomarkers Predicting Erlotinib Response|Completed|||127|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 23:47:49.633928|2018-05-31 23:47:49.633928
NCT01123447|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2016-08-22|2010-05-12|2010-05-14|Estimate|||||||2016-08-22|2016-08-23|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study Comparing Surgical Treatment Versus Non-surgical Treatment of Ulnar Fractures|A Prospective Randomized Trial Comparing Open Reduction and Internal Fixation With Non-operative Treatment for Ulnar Shaft Fractures|Recruiting||N/A|100|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 23:47:49.713798|2018-05-31 23:47:49.713798
NCT01123434|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-01-07|2010-05-12|2010-05-14|Estimate|||||||2015-01-07|2015-01-08|Estimate|April 2010||2010-04-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.|A Non-interventional Study of Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Chinese Prostate Cancer Patients.|Completed|||200|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:47:49.844698|2018-05-31 23:47:49.844698
NCT01123421|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2012-10-11|2010-05-13|2010-05-14|Estimate|||||||2012-10-11|2012-10-15|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|April 2011|Actual|2011-04-30||Observational|BUSS03||Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment|Portable Ultrasonometer for Osteoporosis Assessment: Retrospective Fracture Risk Validation Study, Version #1|Completed|||113|Actual|Artann Laboratories|||2||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 23:47:49.928466|2018-05-31 23:47:49.928466
NCT01123408|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|June 1999||1999-06-30|May 2010|2010-05-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Clozapine and Olanzapine Treatment of Aggression|Clozapine and Olanzapine in the Treatment of Violence in Schizophrenic Patients|Completed||N/A|110|Actual|Nathan Kline Institute for Psychiatric Research||3|||f||||f||||||||||2018-05-31 23:47:50.010045|2018-05-31 23:47:50.010045
NCT01123395|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2011-04-05||2011-04-29|2010-05-13|2010-05-14|Estimate|2011-04-05|2011-04-29|Estimate||||2011-04-29|2011-05-03|Estimate|May 2010||2010-05-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioavailability Study of Colcrys® in Apple Juice|A Pilot Bioavailability Study of Colcrys® Tablet 0.6 mg Versus Colcrys® Tablet 0.6 mg Crushed and Dissolved in Apple Juice Under Fasting Conditions|Completed||Phase 1|16|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-05-31 23:47:50.155463|2018-05-31 23:47:50.155463
NCT01123382|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|2017-09-15||2017-12-26|2010-05-12|2010-05-14|Estimate|2017-11-11|2017-12-12|Actual||||2017-12-26|2018-01-23|Actual|January 2010||2010-01-31|December 2017|2017-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Electrical Stimulation for Hemiplegic Shoulder Pain|Electrical Stimulation for Hemiplegic Shoulder Pain|Completed||N/A|25|Actual|MetroHealth Medical Center||2|||f||||f|f|||||||No||2018-05-31 23:47:50.459426|2018-05-31 23:47:50.459426
NCT01123369|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-09-13|2010-05-13|2010-05-14|Estimate|||||||2010-09-13|2010-09-14|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease|Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease|Completed|||8|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-05-31 23:47:50.951462|2018-05-31 23:47:50.951462
NCT01123356|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2015-04-21||2015-11-02|2010-05-13|2010-05-14|Estimate|2015-11-02|2015-12-03|Estimate||||2015-11-02|2015-12-03|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab|Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab|Completed||Phase 2|21|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 23:47:51.039109|2018-05-31 23:47:51.039109
NCT01123343|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-06-25|2010-05-12|2010-05-14|Estimate|||||||2015-06-25|2015-06-29|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Clinical Evaluation of TrueVision System: LRI and Capsulorhexis Templates|CLINICAL EVALUATION OF THE TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY: LRI AND CAPSULORHEXIS TEMPLATES|Completed||Phase 1|35|Actual|TrueVision Systems, Inc||2|||f||||f||||||||||2018-05-31 23:47:51.410377|2018-05-31 23:47:51.410377
NCT01123330|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-14|Estimate|||||||2010-05-12|2010-05-14|Estimate|October 2001||2001-10-31|May 2010|2010-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of a Brief Tailored Motivational Intervention to Prevent Early Childhood Caries|Detroit Research Center on Oral Health Disparities|Completed||Phase 2|2042|Actual|Temple University||2|||f||||||||||||||2018-05-31 23:47:51.567243|2018-05-31 23:47:51.567243
NCT01123317|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2017-04-20|2010-05-12|2010-05-14|Estimate|||||||2017-04-20|2017-04-21|Actual|July 2010||2010-07-31|April 2017|2017-04-30|January 2013|Anticipated|2013-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia|Brain Blood Flow Changes Elicited by Oxytocin in Healthy and Schizophrenic Volunteers, an Assessment Using Positron Emission Tomography and 15-Oxygen Labeled Water|Withdrawn||N/A|0|Actual|University of Maryland||1||Never started|f||||t||||||||||2018-05-31 23:47:51.710409|2018-05-31 23:47:51.710409
NCT01123304|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2014-07-16|2010-05-13|2010-05-14|Estimate|||||||2014-07-16|2014-07-17|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma|A Phase 1 Clinical Trial of Intra-Tumoral Injection of Human IgM Monoclonal Antibody (MORAb-028) to the Ganglioside GD2 in Subjects With Injectable Metastatic Melanoma|Terminated||Phase 1|18|Actual|Morphotek||1||This study has been terminated due to lack of availability of investigational product.|f||||f||||||||||2018-05-31 23:47:51.860144|2018-05-31 23:47:51.860144
NCT01123291|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2017-03-14|2010-05-13|2010-05-14|Estimate|||||||2017-03-14|2017-03-15|Actual|May 2010|Actual|2010-05-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ReACT||Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial|Randomized Evaluation of Routine Follow-up Coronary Angiography After Percutaneous Coronary Intervention Trial|Completed||Phase 4|700|Actual|Kyoto University, Graduate School of Medicine||2|||f||||t||||||||||2018-05-31 23:47:51.937629|2018-05-31 23:47:51.937629
NCT01123278|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2014-10-25|2010-05-11|2010-05-14|Estimate|||||||2014-10-25|2014-10-28|Estimate|January 2004||2004-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|TERMSINFAT||Testosterone Replacement in Metabolic Syndrome and Inflammation|Testosterone Replacement in Metabolic Syndrome and Inflammation of Fat Tissue|Completed||Phase 4|82|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 23:47:52.036525|2018-05-31 23:47:52.036525
NCT01122589|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-09-08|2010-05-12|2010-05-13|Estimate|||||||2010-09-08|2010-09-09|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|August 2011|Anticipated|2011-08-31|April 2011|Anticipated|2011-04-30||Interventional|WISE||Working Inside for Smoking Elimination|Sustaining Tobacco Abstinence After Incarceration|Unknown status|Recruiting|N/A|350|Anticipated|Memorial Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 23:48:04.700389|2018-05-31 23:48:04.700389
NCT01123265|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2015-09-17|2010-05-13|2010-05-14|Estimate|||||||2015-09-17|2015-09-21|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study|Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) as a Severity and Response Biomarker in Psoriatic Arthritis|Completed|||22|Actual|University of Rochester|||2||f||||f||||||||||2018-05-31 23:47:52.224172|2018-05-31 23:47:52.224172
NCT01123252|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2012-08-22|2010-05-12|2010-05-14|Estimate|||||||2012-08-22|2012-08-23|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|SAR||Seasonal Allergic Rhinitis Study|Evaluation of the Effect of Yoghurt-type Drink on Symptoms of Subjects Suffering Seasonal Allergic Rhinitis (SAR) [Rhinitis 2]|Completed||Phase 2|60|Actual|University of East Anglia||2|||f||||f||||||||||2018-05-31 23:47:52.305213|2018-05-31 23:47:52.305213
NCT01123239|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2015-05-26|2010-05-12|2010-05-14|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|R2D2C2||Understanding and Improving Diabetes Care for Ethnic Minorities|Reducing Racial Disparities in Diabetes Care - The Coached Care Study|Completed||N/A|540|Actual|University of California, Irvine||2|||f||||t||||||||||2018-05-31 23:47:52.411596|2018-05-31 23:47:52.411596
NCT01123226|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|September 2010||2010-09-30|May 2010|2010-05-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Trigger Point Therapy Versus Manipulation Correcting Thoracic Manipulable Lesion|Relative Effectiveness of Trigger Point Therapy Compared to Spinal Manipulation in Correcting a Thoracic Spinal Manipulable Lesion in Subjects With Mechanical Thoracic Back Pain: a Randomised Trial|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Anglo-European College of Chiropractic||2|||f||||f||||||||||2018-05-31 23:47:52.501672|2018-05-31 23:47:52.501672
NCT01123213|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2018-02-05|2010-05-13|2010-05-14|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2008||2008-01-31|February 2018|2018-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Characteristics Predictive of Pessary Success|Characteristics Predictive of Pessary Success|Completed|||158|Actual|University of California, Irvine|||||f||||t||||||||||2018-05-31 23:47:52.609201|2018-05-31 23:47:52.609201
NCT01123200|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2017-01-12||2017-03-14|2010-05-11|2010-05-14|Estimate|2017-03-14|2017-03-15|Actual||||2017-03-14|2017-03-15|Actual|January 2010||2010-01-31|March 2017|2017-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||An In-home Study of Brain Computer Interfaces|An In-home Study of Brain Computer Interfaces|Completed||N/A|1|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 23:47:52.680056|2018-05-31 23:47:52.680056
NCT01123187|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2018-01-08|2010-05-11|2010-05-14|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2003||2003-03-31|January 2018|2018-01-31|April 2016|Actual|2016-04-30|March 2014|Actual|2014-03-31||Interventional|||Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation|Phase 2 Study of Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation With Steroid Free Immunosuppression|Completed||N/A|14|Actual|University Hospital, Lille||1|||f||||t||||||||No||2018-05-31 23:47:52.841625|2018-05-31 23:47:52.841625
NCT01123174|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-06-17|2010-05-11|2010-05-14|Estimate|||||||2015-06-17|2015-06-18|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ALGOS||Effectiveness of a Case Management Algorithm: ALGOS After a Suicide Attempt|"Effectiveness of a Case Management Algorithm After a Suicide Attempt in Terms of Repetition of the Suicidal Behaviors and Medico-economic Impact"|Completed||N/A|1040|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 23:47:52.938403|2018-05-31 23:47:52.938403
NCT01123161|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2016-09-29||2017-02-18|2010-05-11|2010-05-14|Estimate|2017-02-18|2017-04-05|Actual||||2017-02-18|2017-04-05|Actual|June 2010||2010-06-30|February 2017|2017-02-28|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|ICTuS2/3|Patients enrolled and randomized|The Intravascular Cooling in the Treatment of Stroke 2/3 Trial|Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke|Terminated||Phase 2/Phase 3|120|Actual|University of California, San Diego||2||The ICTuS 2 portion of the trial has been halted and data will be analyzed.|f||||t||||||||Undecided||2018-05-31 23:47:53.085688|2018-05-31 23:47:53.085688
NCT01123148|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2016-03-04||2016-06-20|2010-05-11|2010-05-14|Estimate|2016-06-20|2016-08-01|Estimate||||2016-06-20|2016-08-01|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A P300 Brain Computer Interface to Operate Power Wheelchair Tilt|A P300 Brain Computer Interface to Operate Power Wheelchair Tilt|Completed||N/A|16|Actual|University of Michigan|This study only includes data from able-bodied individuals.|1|||f||||f||||||||No||2018-05-31 23:47:53.436874|2018-05-31 23:47:53.436874
NCT01123135|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-11-16|2010-05-12|2010-05-14|Estimate|||||||2010-11-16|2010-11-17|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence|The Effect of Vaginal Estrogen Cream on Subjective and Objective Symptoms of Urodynamic Stress Incontinence|Unknown status|Recruiting|N/A|108|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-05-31 23:47:53.556557|2018-05-31 23:47:53.556557
NCT01123122|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-13|||2015-03-31|2010-05-13|2010-05-14|Estimate|||||||2015-03-31|2015-04-01|Estimate|September 2011||2011-09-30|May 2011|2011-05-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation|A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation|Withdrawn||N/A|0|Actual|Vancouver Coastal Health||2|||f||||f||||||||||2018-05-31 23:47:53.634326|2018-05-31 23:47:53.634326
NCT01123109|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2018-02-05|2010-05-12|2010-05-14|Estimate|||||||2018-02-05|2018-02-07|Actual|December 2007||2007-12-31|February 2018|2018-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||3-D Endoanal Ultrasound: Normative Anatomy of the Anal Sphincter in Nulliparous Females|3-D Endoanal Ultrasound: Normative Anatomy of the Anal Sphincter in Nulliparous Females|Completed||N/A|75|Actual|University of California, Irvine||1|||f||||t||||||||||2018-05-31 23:47:53.799919|2018-05-31 23:47:53.799919
NCT01123096|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2013-06-27|2010-05-12|2010-05-14|Estimate|||||||2013-06-27|2013-07-01|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?|Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?|Completed|||60|Actual|University of California, Irvine|||1||f||||t||||||||||2018-05-31 23:47:53.929241|2018-05-31 23:47:53.929241
NCT01122394|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2016-07-15||2016-08-26|2010-05-10|2010-05-13|Estimate|2016-08-26|2016-10-20|Estimate||||2016-08-26|2016-10-20|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RRR||Reducing Risk of Recurrence|Reducing Risk of Recurrences: Issues in Maintenance and Stability in Stroke (CDA 08-009)|Completed||N/A|140|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:48:07.767428|2018-05-31 23:48:07.767428
NCT01123083|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2017-08-17|2012-11-15|2017-08-17|2010-05-13|2010-05-14|Estimate|2017-08-17|2017-09-15|Actual|2012-11-15|2012-11-20|Estimate|2017-08-17|2017-09-15|Actual|May 17, 2010|Actual|2010-05-17|August 2017|2017-08-31|March 9, 2012|Actual|2012-03-09|March 9, 2012|Actual|2012-03-09||Interventional|DEFEND-2||Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2|Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes|Completed||Phase 3|179|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:47:54.034907|2018-05-31 23:47:54.034907
NCT01123070|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2012-05-14|2010-05-13|2010-05-14|Estimate|||||||2012-05-14|2012-05-15|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||TL011 in Severe, Active Rheumatoid Arthritis Patients||Completed||Phase 1/Phase 2|48|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-05-31 23:47:54.676635|2018-05-31 23:47:54.676635
NCT01123057|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-13|2010-05-13|2010-05-14|Estimate|||||||2010-05-13|2010-05-14|Estimate|August 2008||2008-08-31|May 2010|2010-05-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia|Riboflavin-UVA Induced Collagen Crosslinking Treatment for Corneal Ectasia|Unknown status|Recruiting|N/A|30|Anticipated|Singapore National Eye Centre|||||f||||f||||||||||2018-05-31 23:47:54.753824|2018-05-31 23:47:54.753824
NCT01123044|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2011-07-07|2010-05-11|2010-05-14|Estimate|||||||2011-07-07|2011-07-08|Estimate|August 2011||2011-08-31|May 2010|2010-05-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|CLET||Transplantation of Cultivated Corneal Epithelial Sheet in Patients With Ocular Surface Disease|Transplantation of Cultivated Corneal Epithelial Sheet in Patients With Ocular Surface Disease|Unknown status|Not yet recruiting|Phase 3|42|Anticipated|Ministry of Health, Malaysia||2|||f||||f||||||||||2018-05-31 23:47:56.015009|2018-05-31 23:47:56.015009
NCT01123031|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-01-18|2010-05-13|2010-05-14|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|April 2011|Anticipated|2011-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)|Oral vs Intravenous Proton Pump Inhibitor（PPI） in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial|Unknown status|Active, not recruiting|Phase 4|65|Anticipated|Changhua Christian Hospital||2|||f||||f||||||||||2018-05-31 23:47:56.123684|2018-05-31 23:47:56.123684
NCT01123018|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2018-01-31|2010-05-12|2010-05-13|Estimate|||||||2018-01-31|2018-02-01|Actual|June 2007||2007-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Screening for Memory Studies|Screening for Memory Studies|Active, not recruiting|||2000|Anticipated|VA Palo Alto Health Care System|||1||f||||f||||||||Undecided||2018-05-31 23:47:56.202321|2018-05-31 23:47:56.202321
NCT01123005|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2017-11-01|2010-05-12|2010-05-13|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2010||2010-12-31|November 2017|2017-11-30|August 21, 2015|Actual|2015-08-21|August 21, 2015|Actual|2015-08-21||Interventional|||Imaging and Biomarkers of Hypoxia in Solid Tumors|Imaging and Biomarkers of Hypoxia in Solid Tumors|Terminated||Phase 1|28|Actual|Stanford University||2||Logistical|f||||t|t|f||||||No||2018-05-31 23:47:56.316678|2018-05-31 23:47:56.316678
NCT01122992|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-05-12|2010-05-12|2010-05-13|Estimate|||||||2010-05-12|2010-05-13|Estimate|November 2006||2006-11-30|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Prospective Evaluation of Limbal Relaxing Incision (LRI) in Conjunction With Phacoemulsification Surgery for Astigmatic Correction in Chinese Eyes|Prospective Evaluation of Limbal Relaxing Incision (LRI) in Conjunction With Phacoemulsification Surgery for Astigmatic Correction in Chinese Eyes|Unknown status|Recruiting|N/A|30|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-05-31 23:47:56.4573|2018-05-31 23:47:56.4573
NCT01122979|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2013-11-07|2010-05-12|2010-05-13|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|DINAMO||Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.|National (Brazil), Phase IV, Multicentric, Open Label, Parallel, Comparative Study of the Use of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.|Completed||Phase 4|72|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:47:56.591665|2018-05-31 23:47:56.591665
NCT01122966|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-05-25|2010-05-12|2010-05-13|Estimate|||||||2010-05-25|2010-05-26|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|March 2012|Anticipated|2012-03-31|March 2011|Anticipated|2011-03-31||Interventional|bevazicumab||The Effect of Bevacizumab on the Trabeculectomy|The Effect of Intracameral and Subconjunctival Injections of Bevacizumab in Trabeculectomy With Antimetabolite|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 23:47:56.810202|2018-05-31 23:47:56.810202
NCT01122953|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-07-15|2010-05-11|2010-05-13|Estimate|||||||2010-07-15|2010-07-16|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioequivalence Study Of PHENYTOIN Suspension Made By Pfizer, Versus EPAMIN® Made By McNeil LA LLC In Healthy Volunteers Under Fasting Conditions|Bioequivalence Study Of 5ml Dose Of PHENYTOIN 125mg/ 5ml Suspension Made By Laboratorios Pfizer, S.A. De C.V. Versus EPAMIN® 125 mg/5ml Made By McNeil LA LLC, Study In Healthy Volunteers Under Fasting Conditions|Completed||Phase 1|34|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:47:57.027299|2018-05-31 23:47:57.027299
NCT01122940|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2011-01-13|2010-05-12|2010-05-13|Estimate|||||||2011-01-13|2011-01-14|Estimate|July 2010||2010-07-31|January 2011|2011-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Bioequivalence Study Of Phenytoin Suspension Versus Epamin® In 34 Healthy Volunteers.|Bioequivalence Study Of 10ml Dose Of Phenytoin 0.75g/100ml Suspension Made By Laboratorios Pfizer, S.A. De C.V. Versus Epamin® 0.75g/100ml Made By McNeil LA LLC, Study In 34 Healthy Volunteers Under Fasting Conditions.|Completed||Phase 1|32|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:47:57.183722|2018-05-31 23:47:57.183722
NCT01122771|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2016-01-20|2010-05-11|2010-05-13|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh|A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh|Completed||Phase 3|602|Actual|Drugs for Neglected Diseases||4|||f||||t||||||||||2018-05-31 23:48:02.411549|2018-05-31 23:48:02.411549
NCT01122043|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2016-07-19|2010-05-11|2010-05-12|Estimate|||||||2016-07-19|2016-07-20|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Observational|||The SNEC DSAEK EndoGlide Clinical Trial|The SNEC DSAEK EndoGlide Clinical Trial|Completed|||100|Actual|Singapore Eye Research Institute|||1||f||||f||||||||||2018-05-31 23:48:15.433204|2018-05-31 23:48:15.433204
NCT01122927|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2015-08-05||2016-01-08|2010-05-12|2010-05-13|Estimate|2016-01-08|2016-02-08|Estimate||||2016-01-08|2016-02-08|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|ATTAIN 267||Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.|A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia or Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features|Terminated||Phase 3|524|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The study was terminated by the Sponsor as the European Medicines Agency P/99/2011Aripiprazole PIP which directed the sponsor to provide 2 years of safety data for at least 100 participants. The objective was met in April 2014.|1||"The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational~   Plan was met and provided 2 years of safety data."|f||||f||||||||||2018-05-31 23:47:57.394162|2018-05-31 23:47:57.394162
NCT01122914|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2018-05-17|2010-05-11|2010-05-13|Estimate|||||||2018-05-17|2018-05-18|Actual|April 14, 2010||2010-04-14|April 7, 2015|2015-04-07|April 7, 2015|Actual|2015-04-07|April 7, 2015|Actual|2015-04-07||Interventional|||A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis|A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis|Terminated||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:47:58.380717|2018-05-31 23:47:58.380717
NCT01122901|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2016-11-30||2017-03-22|2010-05-11|2010-05-13|Estimate|2017-03-22|2017-05-03|Actual||||2017-03-22|2017-05-03|Actual|December 2010||2010-12-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma|A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma|Terminated||Phase 2|47|Actual|National Cancer Institute (NCI)|Study terminated prematurely by Company due to their decision to terminate drug supply for further development of this drug. All CTEP-sponsored trials using RO4929097 were closed to accrual and all patients had to be off treatment by 7/31/12.|2||"Stopped prematurely by Company due to decision to terminate all CTEP supplied drug for further~   development of RO4929097."|f||||t||||||||No||2018-05-31 23:47:58.480362|2018-05-31 23:47:58.480362
NCT01122888|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-04-27|2010-05-11|2010-05-13|Estimate|||||||2015-04-27|2015-04-28|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|September 2012|Actual|2012-09-30||Interventional|||Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme|Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib|Terminated||Phase 1|41|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 23:47:58.929208|2018-05-31 23:47:58.929208
NCT01122875|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2016-11-01|2010-05-11|2010-05-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma|An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma|Completed||Phase 1|14|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 23:47:59.024102|2018-05-31 23:47:59.024102
NCT01122862|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2013-05-23||2013-08-22|2010-05-11|2010-05-13|Estimate|2013-07-25|2013-07-30|Estimate||||2013-08-22|2013-09-09|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth|A Clinical Study to Evaluate the Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth|Completed||Phase 2|23|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 23:47:59.155022|2018-05-31 23:47:59.155022
NCT01122849|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2017-03-16||2018-03-09|2010-05-11|2010-05-13|Estimate|2018-03-09|2018-04-09|Actual||||2018-03-09|2018-04-09|Actual|October 1, 2009||2009-10-01|January 2018|2018-01-31|February 1, 2010|Actual|2010-02-01|February 1, 2010|Actual|2010-02-01||Interventional|||Exploratory Subjective Sleep Study of a Prototype Nasal Dilator|Exploratory Subjective Sleep Study of a Prototype Nasal Dilator|Completed||Phase 2|61|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 23:47:59.629117|2018-05-31 23:47:59.629117
NCT01122836|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2017-10-11|2010-05-11|2010-05-13|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2010||2010-07-31|October 2017|2017-10-31|March 2014|Actual|2014-03-31|November 2011|Actual|2011-11-30||Interventional|||Dosing Study of Massage for Neck Pain|Dosing Study of Massage for Neck Pain|Completed||N/A|228|Anticipated|Kaiser Permanente||6|||f||||t||||||||||2018-05-31 23:48:01.91778|2018-05-31 23:48:01.91778
NCT01122823|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2017-10-11|2010-05-11|2010-05-13|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2009||2009-02-28|October 2017|2017-10-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluation of the Online Chronic Disease Self-Management Project at Group Health|Evaluation of the Online Chronic Disease Self-Management Project at Group Health|Completed||N/A|406|Actual|Kaiser Permanente||1|||f||||t||||||||||2018-05-31 23:48:02.015612|2018-05-31 23:48:02.015612
NCT01122810|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2011-03-08|2010-05-11|2010-05-13|Estimate|||||||2011-03-08|2011-03-09|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Scanner and Transplant Heart Patients Protocol|Head to Head Comparison of Multidetector Coronary Tomography and Conventional Coronary Angiogram in the Setting of Systematic Screening of Coronary Vasculopathy After Orthotopic Heart Transplantation.|Completed||N/A|102|Actual|French Cardiology Society|||||f||||f||||||||||2018-05-31 23:48:02.077744|2018-05-31 23:48:02.077744
NCT01122797|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-05-11|2010-05-11|2010-05-13|Estimate|||||||2010-05-11|2010-05-13|Estimate|January 2003||2003-01-31|December 2002|2002-12-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Observational|||Influence of Adiponutrin in Chronic Liver Disease|Study of Metabolism Influence in Human Alcoholic Liver Disease|Completed|||658|Actual|Erasme University Hospital|||2||f||||t||||||Samples With DNA|"~     DNA extraction from whole blood sample. Piece of liver tissue in the alcoholic liver disease~     group.~   "|||2018-05-31 23:48:02.14917|2018-05-31 23:48:02.14917
NCT01122784|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07||2013-08-14|2013-08-14|2010-05-11|2010-05-13|Estimate||||2013-08-14|2013-08-22|Estimate|2013-08-14|2013-08-22|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant|A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 µg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers|Completed||Phase 2|402|Actual|DynPort Vaccine Company LLC, A CSC Company||4|||f||||t||||||||||2018-05-31 23:48:02.207184|2018-05-31 23:48:02.207184
NCT01122758|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2012-11-27|2010-05-12|2010-05-13|Estimate|||||||2012-11-27|2012-11-28|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|January 2016|Anticipated|2016-01-31|January 2014|Anticipated|2014-01-31||Observational|CHAIN||Chronic Obstructive Pulmonary Disease (COPD) History Assessment In SpaiN (CHAIN)|"(COPD History Assessment In SpaiN): Estudio Sobre la Evolución Multidimensional de la Enfermedad Pulmonar Obstructiva Crónica (EPOC)."|Unknown status|Recruiting||2400|Anticipated|Cimera|||2||f||||f||||||Samples Without DNA|"~     complete blood and serum samples~   "|||2018-05-31 23:48:02.560646|2018-05-31 23:48:02.560646
NCT01122745|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2014-05-29|2010-05-12|2010-05-13|Estimate|||||||2014-05-29|2014-05-30|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Single Shot vs Continuous Interscalene Block for Rotator Cuff Repair|Comparison of Pain Relief After Single Shot Interscalene Block With Continuous Interscalene Block for Arthroscopic Rotator Cuff Shoulder Surgery: A Randomized Study|Completed|||88|Actual|University of Chicago|||2||f||||f||||||||||2018-05-31 23:48:02.712539|2018-05-31 23:48:02.712539
NCT01122732|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2016-10-31|2010-05-12|2010-05-13|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Comparison of Pain Relief After Non Stimulating Interscalene Catheter Placement vs Stimulating Catheter Placement in Total Shoulder Arthroplasty.|Comparison of Pain Relief After US Guided Non Stimulating Interscalene Catheter Placement vs Stimulating Catheter Placement in Total Shoulder Arthroplasty;a Randomized Study|Completed|||85|Actual|University of Chicago|||2||f||||f||||||||||2018-05-31 23:48:02.835235|2018-05-31 23:48:02.835235
NCT01122719|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2018-05-02|2010-05-11|2010-05-13|Estimate|||||||2018-05-02|2018-05-07|Actual|October 2010|Actual|2010-10-31|May 2018|2018-05-31|March 2013|Actual|2013-03-31|November 2011|Actual|2011-11-30||Interventional|BEST||Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen|The Best Trial - Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen|Terminated||N/A|16|Actual|CID - Carbostent & Implantable Devices||||"slow inclusion, due to difficulties in obtaining the patients consent for the 2 months invasive~   follow-up, as required by protocol design."|f||||t||||||||||2018-05-31 23:48:02.9649|2018-05-31 23:48:02.9649
NCT01122706|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-07-25|2010-05-11|2010-05-13|Estimate|||||||2011-07-25|2011-07-26|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Efficacy of Taiji Training as a Program for Stress Prevention|Efficacy of Taiji Training as a Program for Stress Prevention - a Randomized, Waiting List Controlled Longitudinal Study With Healthy Subjects|Completed||N/A|70|Actual|University of Bern||2|||f||||f||||||||||2018-05-31 23:48:03.137737|2018-05-31 23:48:03.137737
NCT01122693|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2016-02-03|2010-05-11|2010-05-13|Estimate|||||||2016-02-03|2016-02-04|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|eZono||Comparison Between Two Ultrasound Technologies for Ultrasound-guided Catheter Placement in Regional Anesthesia|A Prospective, Randomized Comparison Between Two Ultrasound Technologies for Ultrasound-guided Catheter Placement in Regional Anesthesia|Completed||N/A|90|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-05-31 23:48:03.353723|2018-05-31 23:48:03.353723
NCT01122680|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2012-04-10||2014-05-07|2010-05-11|2010-05-13|Estimate|2012-05-23|2012-06-27|Estimate||||2014-05-07|2014-05-16|Estimate|May 2010||2010-05-31|July 2012|2012-07-31||||April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma|A Phase II Randomised, Double-blind, Placebo-controlled, Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 µg, 2.5 µg and 5 µg) Delivered Via Respimat® Inhaler Once Daily in the Evening in Adolescents (12 to 17 Yrs Old) With Moderate Persistent Asthma|Completed||Phase 2|105|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:48:03.528815|2018-05-31 23:48:03.528815
NCT01122667|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2015-08-13|2010-05-11|2010-05-13|Estimate|||||||2015-08-13|2015-08-14|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)|A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 23:48:04.259651|2018-05-31 23:48:04.259651
NCT01122654|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2012-01-27|2010-05-12|2010-05-13|Estimate|||||||2012-01-27|2012-01-31|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Growth and Tolerance of Cow Milk-Based Infant Formulas|Growth and Tolerance of Cow Milk-Based Infant Formulas|Completed|||405|Anticipated|Mead Johnson Nutrition|||3||f||||f||||||||||2018-05-31 23:48:04.341489|2018-05-31 23:48:04.341489
NCT01122641|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2017-04-24|2010-05-12|2010-05-13|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2010||2010-05-31|April 2017|2017-04-30|August 1, 2014|Actual|2014-08-01|August 1, 2014|Actual|2014-08-01||Interventional|||The Vascular Effects of Vildagliptin in Insulin Resistant Individuals|Does Modulating the Gut Hormones, Incretins, Modify Vascular Function, Thereby Reducing the Risk of Vascular Complications in Insulin Resistant Individuals?|Completed||Phase 3|15|Actual|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 23:48:04.422834|2018-05-31 23:48:04.422834
NCT01122628|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-13|Estimate|||||||2010-05-12|2010-05-13|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Long Term Follow up of the DVR-A Locking Plate|Long Term Follow Up Study Into The Use Of The DVR-A Locking Plate In The Treatment Of Distal Radial Fractures|Unknown status|Enrolling by invitation||250|Anticipated|Norfolk and Norwich University Hospitals NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 23:48:04.493265|2018-05-31 23:48:04.493265
NCT01122615|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2015-11-16|2010-05-11|2010-05-13|Estimate|||||||2015-11-16|2015-11-18|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)|Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer|Completed||Phase 1|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:48:04.561376|2018-05-31 23:48:04.561376
NCT01122602|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2016-01-14|2010-05-12|2010-05-13|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|TAROT||Evaluate Analgesic Efficacy of Fast Release Aspirin|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 650 mg in Postsurgical Dental Pain|Completed||Phase 3|500|Actual|Bayer||3|||f||||f||||||||||2018-05-31 23:48:04.63573|2018-05-31 23:48:04.63573
NCT01012635|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2013-01-14|2009-11-12|2009-11-13|Estimate|||||||2013-01-14|2013-01-16|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Chronic Pain and Brain Activity in Spinal Cord Injury|Cortical Modulation of Chronic Pain|Completed|||36|Actual|University of Washington|||1||f||||t||||||||||2018-06-01 00:23:03.516997|2018-06-01 00:23:03.516997
NCT01122576|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2013-09-13||2014-02-12|2010-05-12|2010-05-13|Estimate|2014-02-12|2014-03-28|Estimate||||2014-02-12|2014-03-28|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of 3 Intraocular Lenses Following Lens Extraction|A Three Arm Prospective Clinical Evaluation of Three FDA Approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction.|Completed||Phase 4|78|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-05-31 23:48:04.903309|2018-05-31 23:48:04.903309
NCT01122563|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2011-01-11|2010-05-11|2010-05-13|Estimate|||||||2011-01-11|2011-01-13|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|RESORT-2||A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment|Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 2: Responsiveness|Completed|||55|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 23:48:06.310623|2018-05-31 23:48:06.310623
NCT01122550|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-08-23|2010-05-11|2010-05-13|Estimate|||||||2010-08-23|2010-08-24|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|RESORT-1||Reproducibility Study of Overactive Bladder Symptom Score [OABSS]|Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 1: Reproducibility -|Completed|||50|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 23:48:06.399602|2018-05-31 23:48:06.399602
NCT01122537|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2013-09-29|2010-05-11|2010-05-13|Estimate|||||||2013-09-29|2013-10-01|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Characterization and Differential Diagnosis of Postneurosurgical Meningitis|Clinical Features, Microbiological Characteristics, and Differential Diagnosis of Postneurosurgical Meningitis|Completed|||78|Actual|Asan Medical Center|||||f||||t||||||||||2018-05-31 23:48:06.462716|2018-05-31 23:48:06.462716
NCT01122524|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2011-10-06|2010-05-11|2010-05-13|Estimate|||||||2011-10-06|2011-10-10|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|MELISSA||MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy|A Prospective, Multi-center Observational Study With Blinded, Nested Case:Control Analyses to Evaluate the Performance of the Verinata Health Prenatal Aneuploidy Diagnostic Test|Completed|||10000|Anticipated|Verinata Health, Inc.|||2||f||||f|||||||"~     plasma~   "|||2018-05-31 23:48:06.519184|2018-05-31 23:48:06.519184
NCT01122511|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|2012-08-01|2012-05-25|2012-08-01|2010-05-11|2010-05-13|Estimate|2012-08-01|2012-09-05|Estimate|2012-05-25|2012-06-01|Estimate|2012-08-01|2012-09-05|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration||Terminated||Phase 2|4|Actual|Allergan|The study was terminated early due to difficulties with patient recruitment. No participants reached the 12 month time-point. Efficacy analyses were not performed.|2||The study was terminated early due to difficulties with patient recruitment.|f||||f||||||||||2018-05-31 23:48:06.622855|2018-05-31 23:48:06.622855
NCT01122498|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-02-20|2010-05-10|2010-05-13|Estimate|||||||2013-02-20|2013-02-22|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Rotator Cuff Tears|A Phase 1, Randomized, Open-Label, Standard Of Care Control, Dose-Escalating, Multicenter, Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Full-Thickness Rotator Cuff Tears Treated By Means Of An Open Surgical Repair|Terminated||Phase 1|23|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:48:06.834844|2018-05-31 23:48:06.834844
NCT01122485|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2011-06-13|2010-05-10|2010-05-13|Estimate|||||||2011-06-13|2011-06-14|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety Study of PG201 Tablet in Patients With Osteoarthritis|For an 8-week, Single Center, Randomized, Double Blind, Placebo Controlled Exploratory Clinical Study to Assess the Efficacy, Dose Response and Safety of PG201 Tablet in Patients With Osteoarthritis|Completed||Phase 2|82|Actual|ViroMed Co., Ltd.||3|||f||||f||||||||||2018-05-31 23:48:06.904962|2018-05-31 23:48:06.904962
NCT01122472|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2018-03-09|2010-05-12|2010-05-13|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2009||2009-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2016|Actual|2016-06-30||Interventional|REMARC||Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP|Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line|Active, not recruiting||Phase 3|650|Actual|The Lymphoma Academic Research Organisation||2|||f||||f||||||||||2018-05-31 23:48:07.070446|2018-05-31 23:48:07.070446
NCT01122459|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2011-07-20|2010-05-12|2010-05-13|Estimate|||||||2011-07-20|2011-07-21|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Evaluation of the Effect of Two Types of Fluid in the Recovery From Anaesthesia. Voluven 6% v Hartmanns|Evaluation of the Effects of Two Types of Fluid in the Recovery From Anaesthesia.|Completed||Phase 3|120|Actual|The Rotunda Hospital||2|||f||||t||||||||||2018-05-31 23:48:07.307351|2018-05-31 23:48:07.307351
NCT01122446|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2017-03-07|2010-05-12|2010-05-13|Estimate|||||||2017-03-07|2017-03-09|Actual|April 2009|Actual|2009-04-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DIAPREV-IT||Diabetes Prevention - Immune Tolerance|A Double-blind, Randomized Investigator-initiated Study to Determine the Safety and the Effect of Diamyd® on the Progression to Type 1 Diabetes in Children With Multiple Islet Cell Autoantibodies|Completed||Phase 2|50|Actual|Lund University||2|||f||||t|f|f||||||Undecided||2018-05-31 23:48:07.464736|2018-05-31 23:48:07.464736
NCT01122433|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2010-09-27|2010-05-12|2010-05-13|Estimate|||||||2010-09-27|2010-09-28|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Airway Management Study to Evaluate the C-MAC Video Laryngoscope as an Alternative to the Direct Laryngoscopy|Evaluation of the C-MAC Video Laryngoscope After Failed Direct Laryngoscopy|Completed||N/A|50|Anticipated|Johannes Gutenberg University Mainz||1|||f||||||||||||||2018-05-31 23:48:07.558472|2018-05-31 23:48:07.558472
NCT01122420|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-08-21|2010-05-10|2010-05-13|Estimate|||||||2013-08-21|2013-08-22|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Online Resources to Manage Obesity and Health Risks in an Employee Wellness Program|Online Resources to Manage Obesity and Health Risks in an Employee Wellness Program|Completed||N/A|12|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 23:48:07.632651|2018-05-31 23:48:07.632651
NCT01122407|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2017-01-16|2010-05-10|2010-05-13|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pathophysiology of Cardiometabolic Risk Factors in African Americans|Obesity, Hypertension in African American Women, Neuro-metabolic Mechanism|Completed||Phase 1|34|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 23:48:07.687646|2018-05-31 23:48:07.687646
NCT01122381|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2015-06-05||2015-08-11|2010-05-10|2010-05-13|Estimate|2015-08-11|2015-08-19|Estimate||||2015-08-11|2015-08-19|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Enrollees who completed baseline period and randomization.|Comparison of a Drug and Placebo in the Prevention of Migraine Headaches|Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine|Terminated||Phase 1/Phase 2|5|Actual|VA Office of Research and Development|Early termination occurred due to inadequate recruitment of episodic migraineurs in a population meeting too many exclusion criteria; resulting in no subjects available for analysis.|2||poor recruitment|f||||t||||||||||2018-05-31 23:48:09.058475|2018-05-31 23:48:09.058475
NCT01122368|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2017-08-31|2010-05-12|2010-05-13|Estimate|||||||2017-08-31|2017-09-01|Actual|July 13, 2010|Actual|2010-07-13|August 2017|2017-08-31|December 15, 2011|Actual|2011-12-15|December 15, 2011|Actual|2011-12-15||Interventional|INTENSE||A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects|An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis Versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Double-blind Study|Completed||Phase 2|252|Actual|Astellas Pharma Inc||2|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 23:48:09.427019|2018-05-31 23:48:09.427019
NCT01122355|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-28|2010-05-12|2010-05-13|Estimate|||||||2010-05-28|2010-05-31|Estimate|February 2009||2009-02-28|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol||Completed||Phase 4|240|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:48:09.724668|2018-05-31 23:48:09.724668
NCT01122342|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-13|Estimate|||||||2010-05-12|2010-05-13|Estimate|December 2006||2006-12-31|May 2010|2010-05-31|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|||Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.|Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.|Suspended||Phase 1/Phase 2|30|Anticipated|University of Vermont||1||Evaluating outcomes of current subjects pre further enrollment/dose reduction.|f||||t||||||||||2018-05-31 23:48:09.80637|2018-05-31 23:48:09.80637
NCT01122329|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2015-03-19|2010-05-12|2010-05-13|Estimate|||||||2015-03-19|2015-03-23|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|AD||A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease|A Single-site Positron Emission Tomography (PET) Study of the Cerebral Metabolic Effects of AC-1202 (Axona®) Treatment in Mild-to-Moderate Alzheimer's Disease (AD)|Completed||Phase 4|17|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:48:09.891282|2018-05-31 23:48:09.891282
NCT01122316|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2012-03-29|2010-05-12|2010-05-13|Estimate|||||||2012-03-29|2012-04-02|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Management of Diabetes With Metformin In Patients With Chronic Heart Failure|Management of Diabetes With Metformin In Patients With Chronic Heart Failure|Completed||N/A|9|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 23:48:09.997012|2018-05-31 23:48:09.997012
NCT01122303|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-01|||2010-05-11|2010-05-11|2010-05-13|Estimate|||||||2010-05-11|2010-05-13|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Observational|||Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye|Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye|Unknown status|Active, not recruiting||20|Actual|Mahidol University|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:48:10.088393|2018-05-31 23:48:10.088393
NCT01122290|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2010-05-12|2010-05-12|2010-05-13|Estimate|||||||2010-05-12|2010-05-13|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Inducing Children's Emotional Eating|Inducing Preschool Children's Emotional Eating: Relationships With Parental Feeding Practices.|Completed|||64|Actual|University of Birmingham|||2||f||||f||||||||||2018-05-31 23:48:10.16061|2018-05-31 23:48:10.16061
NCT01122277|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2011-07-07|2010-05-12|2010-05-13|Estimate|||||||2011-07-07|2011-07-08|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|October 2011|Anticipated|2011-10-31|May 2011|Actual|2011-05-31||Observational|RaFTinG||Rational Fluid Therapy in Germany|Klinisches Register RaFTinG - Rational Fluid Therapy in Germany|Unknown status|Active, not recruiting||4000|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||f||||||||||2018-05-31 23:48:10.237781|2018-05-31 23:48:10.237781
NCT01122264|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2012-06-11||2012-09-18|2010-05-11|2010-05-13|Estimate|2012-09-18|2012-10-19|Estimate||||2012-09-18|2012-10-19|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study in Patients With Erectile Dysfunction|Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors|Completed||Phase 4|770|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:48:10.396739|2018-05-31 23:48:10.396739
NCT01122251|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2011-02-17|2010-05-12|2010-05-13|Estimate|||||||2011-02-17|2011-02-18|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension|A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dose Combinations in Patients With Essential Hypertension|Completed||Phase 2|441|Anticipated|LG Life Sciences||3|||f||||f||||||||||2018-05-31 23:48:11.987912|2018-05-31 23:48:11.987912
NCT01122238|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2015-01-29||2015-11-12|2010-05-10|2010-05-13|Estimate|2015-03-13|2015-03-17|Estimate||||2015-11-12|2015-12-16|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Motivation|Adult smokers who consented to enroll in the treatment study.|Identifying Treatments to Motivate Smokers to Quit|Identifying Optimal, Translatable Smoking Cessation Intervention Components|Completed||Phase 4|517|Actual|University of Wisconsin, Madison||16|||f||||t||||||||||2018-05-31 23:48:12.208115|2018-05-31 23:48:12.208115
NCT01122225|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-28|2010-05-10|2010-05-13|Estimate|||||||2010-05-28|2010-05-31|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|June 2010|Anticipated|2010-06-30|May 2010|Actual|2010-05-31||Observational|NESAKI||Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury|Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury|Unknown status|Active, not recruiting||50|Actual|Université Victor Segalen Bordeaux 2|||1||f||||f||||||Samples Without DNA|"~     Blood Sample (350 µl) at inclusion and then 24 and 48 hours after~   "|||2018-05-31 23:48:13.622616|2018-05-31 23:48:13.622616
NCT01122212|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2015-04-17|2010-05-12|2010-05-13|Estimate|||||||2015-04-17|2015-04-21|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Observational|S100||Introduction of Protein S100 in Diagnostics in Minor Brain Injury Patients at Our Hospital|Introduction of Protein S100 in the Routine Diagnostics in Patients With Minor Head Injury|Completed|||128|Actual|Kantonsspital Münsterlingen|||||f||||t||||||Samples With DNA|"~     venous blood (Serum)~   "|||2018-05-31 23:48:13.738228|2018-05-31 23:48:13.738228
NCT01122199|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-05-09|2010-05-12|2010-05-13|Estimate|||||||2017-05-09|2017-05-10|Actual|May 14, 2010|Actual|2010-05-14|May 2017|2017-05-31|January 19, 2015|Actual|2015-01-19|January 19, 2015|Actual|2015-01-19||Interventional|||Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors|Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors|Completed||Phase 1|27|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 23:48:13.831267|2018-05-31 23:48:13.831267
NCT01122186|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2013-05-30|2010-05-12|2010-05-13|Estimate|||||||2013-05-30|2013-06-03|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ACE||Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)|Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men|Completed||N/A|210|Actual|Hunter College of City University of New York||2|||f||||t||||||||||2018-05-31 23:48:13.946447|2018-05-31 23:48:13.946447
NCT01122173|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2018-02-27|2010-05-11|2010-05-13|Estimate|||||||2018-02-27|2018-03-01|Actual|July 2013||2013-07-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Use of the Hansen Medical System in Patients With Paroxysmal Atrial Fibrillation|A Prospective, Single Arm Study of the Hansen System for Introducing and Positioning RF Ablation Catheters in Subjects With Paroxysmal Atrial Fibrillation|Terminated||N/A|150|Actual|Hansen Medical||1|||f||||t||||||||||2018-05-31 23:48:14.038028|2018-05-31 23:48:14.038028
NCT01122160|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2012-12-17||2013-07-23|2010-05-10|2010-05-13|Estimate|2013-07-23|2013-08-23|Estimate||||2013-07-23|2013-08-23|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Gastric pH and Anthocyanin Absorption|Gastric pH as a Possible Determinant of Anthocyanin Absorption|Completed||N/A|13|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 23:48:14.244054|2018-05-31 23:48:14.244054
NCT01122147|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2011-08-01|2010-05-10|2010-05-13|Estimate|||||||2011-08-01|2011-08-02|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Evaluation of Fluid Extract of Chamomilla Tincture for Oral Aphthae|Phase 1 Evaluation of Therapeutic Effect of Chamomilla Tincture Mouthwash on Oral Aphthae|Completed||Phase 1|30|Actual|Mashhad University of Medical Sciences||2|||f||||||||||||||2018-05-31 23:48:14.454962|2018-05-31 23:48:14.454962
NCT01122134|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-10|2010-05-10|2010-05-13|Estimate|||||||2010-05-10|2010-05-13|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Observational|||Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment|Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Treatment of Severe Malaria in Ugandan Patients|Unknown status|Not yet recruiting||20|Anticipated|Makerere University|||1||f||||f||||||Samples With DNA|"~     Blood samples collected for artesunate drug assays~   "|||2018-05-31 23:48:14.525758|2018-05-31 23:48:14.525758
NCT01122121|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2015-07-27|2010-05-10|2010-05-13|Estimate|||||||2015-07-27|2015-07-29|Estimate|March 2000||2000-03-31|July 2015|2015-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer|Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)|Completed||Phase 3|273|Actual|Takeda||2|||f||||t||||||||||2018-05-31 23:48:14.640271|2018-05-31 23:48:14.640271
NCT01122108|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2010-07-19||2010-09-22|2010-05-10|2010-05-13|Estimate|2010-09-22|2010-10-07|Estimate||||2010-09-22|2010-10-07|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale|A Randomized, Single-Blind, Single Research Site, Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale in Generally Healthy Subjects|Completed||Phase 4|42|Actual|Louisville Metabolic and Atherosclerosis Research Center|Used generally healthy subjects, for who lipid-altering medication may not be indicated; Compared the BAS on the same day; Evaluated estimated equal cholesterol lowering doses of each BAS, rather than same g amt of active drug|2|||f||||f||||||||||2018-05-31 23:48:14.745586|2018-05-31 23:48:14.745586
NCT01122095|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-05-28|2010-05-11|2010-05-12|Estimate|||||||2010-05-28|2010-05-31|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2011|Anticipated|2011-04-30|||||Observational|||Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis|Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis|Unknown status|Recruiting||100|Anticipated|University of California, San Diego|||2||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 23:48:15.011588|2018-05-31 23:48:15.011588
NCT01122082|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2017-08-22|2010-05-11|2010-05-12|Estimate|||||||2017-08-22|2017-08-24|Actual|October 2008||2008-10-31|August 2017|2017-08-31|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Respiratory Quotient and Food Liking, Food Wanting and Food Consumption|Influence of Respiratory Quotient on Food Liking, Food Wanting, Macronutrient Selection and Food Consumption in Humans|Completed||N/A|16|Actual|University of Burgundy|||||f||||f||||||||No||2018-05-31 23:48:15.09948|2018-05-31 23:48:15.09948
NCT01122069|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|March 2008||2008-03-31|December 2007|2007-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Contrast Echocardiography in Non-ST Elevation Myocardial Infarction|Contrast Echocardiography in Assessment of Myocardial Perfusion in Patients With Non-ST Elevation Myocardial Infarction|Completed|||110|Actual|University of Bergen|||1||f||||f||||||||||2018-05-31 23:48:15.211321|2018-05-31 23:48:15.211321
NCT01122056|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2017-03-01|2010-05-11|2010-05-12|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2010||2010-05-31|March 2017|2017-03-31|June 1, 2012|Actual|2012-06-01|June 1, 2012|Actual|2012-06-01||Interventional|||Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis|Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis|Completed||N/A|128|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:48:15.293272|2018-05-31 23:48:15.293272
NCT01122030|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2017-04-19||2017-04-19|2010-05-11|2010-05-12|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|May 19, 2010|Actual|2010-05-19|September 2011|2011-09-30|March 22, 2011|Actual|2011-03-22|February 23, 2011|Actual|2011-02-23||Interventional|||Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain|A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain|Completed||Phase 2|72|Actual|Shionogi Inc.||6|||f||||f||||||||||2018-05-31 23:48:15.589724|2018-05-31 23:48:15.589724
NCT01122017|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-05-12|2010-05-10|2010-05-12|Estimate|||||||2010-05-12|2010-05-13|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|November 2008|Actual|2008-11-30|February 2008|Actual|2008-02-29||Interventional|||A Modified (Retro-Tubercle) Opening Wedge High Tibial Osteotomy Versus the Conventional Technique|A Modified (Retro-Tubercle) Opening Wedge High Tibial Osteotomy Versus the Conventional Technique|Completed||N/A|72|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||f||||||||||2018-05-31 23:48:18.070663|2018-05-31 23:48:18.070663
NCT01122004|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-05-10|2010-05-10|2010-05-12|Estimate|||||||2010-05-10|2010-05-12|Estimate||||March 2010|2010-03-31||||||||Interventional|PRK||The Effect of Gabapentin (Neurentin) and Pregabalin (Lyrica) in Pain Reduction After Photorefractive Keratectomy||Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 23:48:18.142327|2018-05-31 23:48:18.142327
NCT01121991|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2011-02-17||2013-08-02|2010-05-11|2010-05-12|Estimate|2011-02-17|2011-03-18|Estimate||||2013-08-02|2013-08-07|Estimate|September 2004||2004-09-30|August 2013|2013-08-31||||September 2005|Actual|2005-09-30||Interventional|||A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies|A Phase III, Multicentre, Open-label Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone (Luveris) With r-hFSH on Follicular Development in Women Undergoing Ovarian Stimulation for ART|Completed||Phase 3|55|Actual|EMD Serono|||||f||||||||||||||2018-05-31 23:48:18.233143|2018-05-31 23:48:18.233143
NCT01121978|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-03-28|2010-05-10|2010-05-12|Estimate|||||||2011-03-28|2011-03-29|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|November 2012|Anticipated|2012-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Early Vitrectomy for Macular Tractional Maculopathy|Early Vitrectomy for Macular Tractional Maculopathy. Multicenter Clinical Trial|Unknown status|Recruiting|N/A|40|Anticipated|Seoul Retina Investigator Group||2|||f||||t||||||||||2018-05-31 23:48:18.546635|2018-05-31 23:48:18.546635
NCT01121965|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-03-28|2010-05-10|2010-05-12|Estimate|||||||2011-03-28|2011-03-29|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|November 2012|Anticipated|2012-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Early Vitrectomy for Impending Macular Hole|Early Vitrectomy for Impending Macular Hole. Multicenter Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|Seoul Retina Investigator Group||2|||f||||t||||||||||2018-05-31 23:48:18.685146|2018-05-31 23:48:18.685146
NCT01121952|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||The Effect of Manipulation on Dysfunction of the Talo-crural Joint|The Effect of Manipulation on Dysfunction of the Talo-crural Joint- a Clinical Randomised Trial|Unknown status|Active, not recruiting|N/A|19|Actual|Scandinavian College of Chiropractic||2|||f||||t||||||||||2018-05-31 23:48:18.797046|2018-05-31 23:48:18.797046
NCT01121939|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2015-02-26||2016-01-08|2010-05-10|2010-05-12|Estimate|2015-08-20|2015-09-23|Estimate||||2016-01-08|2016-02-05|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional||All Patients|Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers|Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers.|Completed||Phase 2|43|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 23:48:18.878308|2018-05-31 23:48:18.878308
NCT01121926|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2010-06-22||2012-04-25|2010-05-11|2010-05-12|Estimate|2010-07-21|2010-08-16|Estimate||||2012-04-25|2012-04-30|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady State|A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered Once Daily) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) at Steady State|Completed||Phase 1|30|Actual|Labopharm Inc.||2|||f||||||||||||||2018-05-31 23:48:19.265997|2018-05-31 23:48:19.265997
NCT01121913|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2010-06-22||2012-04-24|2010-05-10|2010-05-12|Estimate|2010-07-21|2010-08-16|Estimate||||2012-04-24|2012-04-27|Estimate|March 2005||2005-03-31|April 2012|2012-04-30||||April 2005|Actual|2005-04-30||Interventional|||Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers|A Randomized, Four-way Crossover Pilot Study to Compare the Relative Bioavailability of Two Prototype Once-a-day Trazodone Hydrochloride Products and Two Marketed Reference Products Following an Equivalent Daily Dose Administration Under Fasting Conditions in Healthy Volunteers|Completed||Phase 1|24|Actual|Labopharm Inc.||4|||f||||||||||||||2018-05-31 23:48:19.572351|2018-05-31 23:48:19.572351
NCT01121900|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2010-06-22||2012-04-24|2010-05-11|2010-05-12|Estimate|2010-07-21|2010-08-16|Estimate||||2012-04-24|2012-04-27|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)|A Randomized, Two-way Crossover Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets (Containing Contramid®) (Administered as a Single Dose) and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) Under Fasting Conditions|Completed||Phase 1|26|Actual|Labopharm Inc.||2|||f||||||||||||||2018-05-31 23:48:20.046194|2018-05-31 23:48:20.046194
NCT01121887|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Telephone-based Treatment for Smoking Cessation|Motivational Interviewing in Smoking Cessation: A Controlled Clinical Trial at the Swedish National Tobacco Quitline|Completed||Phase 3|1309|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 23:48:20.323826|2018-05-31 23:48:20.323826
NCT01121874|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2017-03-15|2010-05-11|2010-05-12|Estimate|||||||2017-03-15|2017-03-17|Actual|April 2010||2010-04-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Suture Fixation System Versus Tendonous Reconstruction in Carpometacarpal (CMC) Arthroplasty|Suture Fixation System Versus Tendonous Reconstruction in Thumb Carpometacarpal Arthroplasty: a Randomized Controlled Trial|Active, not recruiting||N/A|120|Anticipated|J&M Shuler||3|||f||||f||||||||||2018-05-31 23:48:20.413371|2018-05-31 23:48:20.413371
NCT01121861|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|June 2007||2007-06-30|May 2010|2010-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Prospective Comparative Study of Refractive Outcome of STAAR and Alcon Toric Intraocular Lenses|Prospective Comparative Study of the Efficacy, Predictability, Safety and Stability of the STAAR and Alcon Toric Intraocular Lenses Implanted in Asian Eyes During Phacoemulsification Surgery|Completed||N/A|100|Anticipated|Singapore National Eye Centre|||||f||||f||||||||||2018-05-31 23:48:20.661805|2018-05-31 23:48:20.661805
NCT01121848|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-10-23|2010-05-10|2010-05-12|Estimate|||||||2014-10-23|2014-10-27|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer|A Randomized Phase III Study of 5-Fluorouracil-based Regimen With or Without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have Previously Received Gemcitabine-based Chemotherapy|Completed||Phase 3|108|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:48:20.728435|2018-05-31 23:48:20.728435
NCT01121835|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2013-04-02|2010-05-11|2010-05-12|Estimate|||||||2013-04-02|2013-04-04|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|GALAPAGOS||Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study|A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents|Completed||Phase 4|934|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:48:20.84111|2018-05-31 23:48:20.84111
NCT01121822|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-10-05|2010-05-10|2010-05-12|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)|Completed||Phase 3|129|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:48:21.098072|2018-05-31 23:48:21.098072
NCT01121809|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-02-07|2010-05-10|2010-05-12|Estimate|||||||2011-02-07|2011-02-08|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|RAET||Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily|Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily (800 mg and 400 mg, Respectively) Compared With Standard Dosing (400 mg and 200 mg/12 h) in Patients With HIV Infection|Completed||Phase 4|16|Actual|Hospitales Universitarios Virgen del Rocío||2|||f||||t||||||||||2018-05-31 23:48:21.177464|2018-05-31 23:48:21.177464
NCT01121796|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-10|2010-05-10|2010-05-12|Estimate|||||||2010-05-10|2010-05-12|Estimate|June 2010||2010-06-30|May 2010|2010-05-31||||June 2011|Anticipated|2011-06-30||Interventional|||Influence of Vitamin D on Inflammatory Bowel Disease Remission||Unknown status|Not yet recruiting|N/A|90|Anticipated|Hillel Yaffe Medical Center||3|||f||||||||||||||2018-05-31 23:48:21.256222|2018-05-31 23:48:21.256222
NCT01121783|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-10|2010-05-10|2010-05-12|Estimate|||||||2010-05-10|2010-05-12|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||The Effect of Lactisole on the Responses to Glucose Solution|Study of the Effect of Lactisole on the Responses to Intragastric Glucose Solution|Unknown status|Recruiting|N/A|24|Anticipated|Salford Royal NHS Foundation Trust||4|||f||||||||||||||2018-05-31 23:48:21.330911|2018-05-31 23:48:21.330911
NCT01121770|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-08-29|2010-05-10|2010-05-12|Estimate|||||||2014-08-29|2014-09-01|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|FONDA PK||"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"|Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction|Completed||Phase 1|9|Actual|Duke University||1|||f||||f||||||||||2018-05-31 23:48:21.432778|2018-05-31 23:48:21.432778
NCT01121757|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2015-03-30||2016-08-01|2010-05-10|2010-05-12|Estimate|2015-05-05|2015-05-07|Estimate||||2016-08-01|2016-09-12|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|March 2013|Actual|2013-03-31||Interventional|||Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma|A Phase 2 Study Evaluating the Efficacy of Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma|Terminated||Phase 2|11|Actual|Duke University||2||"The study closed temporarily in February 2012 pending analysis of samples collected. In~   October, 2012, Celgene requested closure of the study."|f||||f||||||||No||2018-05-31 23:48:21.527905|2018-05-31 23:48:21.527905
NCT01121744|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2012-07-03|2010-05-11|2010-05-12|Estimate|||||||2012-07-03|2012-07-04|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Supralimus-Core™ Pharmacokinetic (PK) Study|Supralimus-Core™ Pharmacokinetic (PK) Study: Evaluation of Pharmacokinetic (PK) and Safety of the Supralimus-Core™ Sirolimus Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|Completed||N/A|20|Actual|Sahajanand Medical Technologies Pvt. Ltd.|||||f||||t||||||||||2018-05-31 23:48:22.08399|2018-05-31 23:48:22.08399
NCT01121731|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-02-04|2010-05-10|2010-05-12|Estimate|||||||2013-02-04|2013-02-05|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C|Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C|Completed||Phase 1/Phase 2|70|Actual|Digna Biotech S.L.||3|||f||||t||||||||||2018-05-31 23:48:22.18066|2018-05-31 23:48:22.18066
NCT01121718|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2017-02-02|2010-05-10|2010-05-12|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2010||2010-09-30|February 2017|2017-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||NIR-Guided Sentinel Lymph Node Mapping in Melanoma|Real-Time NIR-Guided Sentinel Lymph Node Mapping in Melanoma|Completed||Phase 1|26|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f|||f|||Undecided|At this time, a plan is not in place to make IPD available to other researchers.|2018-05-31 23:48:22.290473|2018-05-31 23:48:22.290473
NCT01121705|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-08-09|2010-05-10|2010-05-12|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|genotype-3||Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)|Multicenter Study on Efficacy of New Therapeutic Schedules With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV( Hepatitis C Virus) Infection|Completed||Phase 3|360|Actual|Casa Sollievo della Sofferenza IRCCS||2|||f||||f||||||||||2018-05-31 23:48:22.379555|2018-05-31 23:48:22.379555
NCT01121692|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-10-08|2010-05-11|2010-05-12|Estimate|||||||2015-10-08|2015-10-12|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Couples CoOp||Venue-Based Couples CoOp in South Africa|Venue-Based Recruitment and HIV Prevention for Alcohol and Other Drug (AOD) Using Couples in South Africa|Completed||Phase 2|600|Actual|RTI International||3|||f||||f||||||||||2018-05-31 23:48:22.474456|2018-05-31 23:48:22.474456
NCT01121679|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2012-06-15|2010-05-11|2010-05-12|Estimate|||||||2012-06-15|2012-06-18|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Observational|OCTOCARDIO||French Observatory on Hospitalizations in Cardiology of Patients of 80 Years and Over|French Observatory on Hospitalizations in Cardiology of Patients of 80 Years and Over|Completed|||534|Actual|French Cardiology Society|||1||f||||t||||||||||2018-05-31 23:48:22.541394|2018-05-31 23:48:22.541394
NCT01121666|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2016-02-17||2016-03-16|2010-05-11|2010-05-12|Estimate|2016-03-16|2016-04-15|Estimate||||2016-03-16|2016-04-15|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|March 2013|Actual|2013-03-31|December 2011|Actual|2011-12-31||Interventional|||Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment|A Phase III Assessor-blinded Randomized Parallel Group Multi-centre Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA Versus Gonal-f) in Women for Assisted Reproductive Treatment|Completed||Phase 3|460|Actual|Finox AG||2|||f||||f||||||||||2018-05-31 23:48:22.65926|2018-05-31 23:48:22.65926
NCT01121653|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-10|2010-05-10|2010-05-12|Estimate|||||||2010-05-10|2010-05-12|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Impact of Oral Magnesium on Neuropathic Pain|Impact of Oral Magnesium on Neuropathic Pain|Completed||Phase 4|50|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:48:23.532227|2018-05-31 23:48:23.532227
NCT01121640|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2017-08-16|2010-05-11|2010-05-12|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2009||2009-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2015|Actual|2015-06-30||Interventional|||A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women|A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women|Active, not recruiting||N/A|1208|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 23:48:23.63321|2018-05-31 23:48:23.63321
NCT01121627|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-08-21|2010-05-10|2010-05-12|Estimate|||||||2015-08-21|2015-08-24|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Computer-based Cognitive Training for Parkinson Disease|Effects of Computer-based Cognitive Training on Gait Function in Individuals With Parkinson Disease|Completed||N/A|30|Actual|Clalit Health Services||1|||f||||f||||||||||2018-05-31 23:48:23.712166|2018-05-31 23:48:23.712166
NCT01121614|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2012-07-05|2010-05-11|2010-05-12|Estimate|||||||2012-07-05|2012-07-09|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Mesenteric Vessel Sealing by Three Instruments|A Pilot Study to Compare Collateral Damage and Vessel Sealing Ability of LOTUS Ultrasonic Shears, Ethicon Harmonic Scalpel™ and LigaSure™ on Human Mesenteric Blood Vessels|Completed||N/A|18|Actual|University Hospital Plymouth NHS Trust||3|||f||||f||||||||||2018-05-31 23:48:23.892595|2018-05-31 23:48:23.892595
NCT01121601|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2015-08-04|2010-05-10|2010-05-12|Estimate|||||||2015-08-04|2015-08-06|Estimate|August 2011||2011-08-31|August 2015|2015-08-31||||||||Interventional|COLIBIS||CoSeal in Liver and Biliary Surgery in Prevention of Denovo Hepatic Adhesion|Effectiveness and Tolerance of CoSeal in the Prevention of Hepatic Adherences of Novo Post Operational Within the Framework of a Hepatic Surgery of Resection in Two Times for Hepatic Metastases: Study of Phase II/III.|Terminated||Phase 2/Phase 3|29|Actual|Centre Hospitalier Universitaire de Besancon||2||Practices in surgery have evolved and the study has not interest yet|f||||t||||||||||2018-05-31 23:48:23.976607|2018-05-31 23:48:23.976607
NCT01121588|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2018-01-25|2010-05-10|2010-05-12|Estimate|||||||2018-01-25|2018-01-29|Actual|March 22, 2011|Actual|2011-03-22|January 2018|2018-01-31|December 29, 2018|Anticipated|2018-12-29|December 29, 2018|Anticipated|2018-12-29||Interventional|||An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)|Phase 1b Open-label Study Of The Safety And Clinical Activity Of Crizotinib (Pf-02341066) In Tumors With Genetic Events Involving The Anaplastic Lymphoma Kinase (Alk ) Gene Locus|Active, not recruiting||Phase 1|44|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:48:24.081332|2018-05-31 23:48:24.081332
NCT01121575|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2015-02-11||2015-10-06|2010-05-10|2010-05-12|Estimate|2015-03-27|2015-03-30|Estimate||||2015-10-06|2015-10-28|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer|A Phase 1, Open-label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Combined Oral C-met/Alk Inhibitor (Pf-02341066) And Pan-her Inhibitor (Pf-00299804) In Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 1|70|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:48:24.321669|2018-05-31 23:48:24.321669
NCT01121562|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2012-07-01||2014-06-18|2010-05-10|2010-05-12|Estimate|2012-07-05|2012-08-27|Estimate||||2014-06-18|2014-06-30|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|July 2011|Actual|2011-07-31||Interventional|||Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors|A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors|Completed||Phase 2|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:48:26.897933|2018-05-31 23:48:26.897933
NCT01121549|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2013-12-04||2013-12-04|2010-05-11|2010-05-12|Estimate|2013-12-04|2014-01-22|Estimate||||2013-12-04|2014-01-22|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer|A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer In Postmenopausal Hormone Receptors Positive Patients Following Of 2-3 Years of Initial Adjuvant Tamoxifen Therapy|Terminated|||378|Actual|Pfizer|The study was prematurely terminated on 31 August 2012 due to unexpected high rate of participant withdrawal caused by Aromasin reimbursement policy change in Romania. There were no safety issues related to study termination.||1|See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:48:27.310376|2018-05-31 23:48:27.310376
NCT01121536|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2015-01-15|2014-03-04|2016-09-26|2010-05-10|2010-05-12|Estimate|2015-01-15|2015-01-26|Estimate|2014-03-04|2014-04-02|Estimate|2016-09-26|2016-10-28|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All participants|Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|Completed||Phase 3|867|Actual|Teva Pharmaceutical Industries||1|||f||||t||||||||||2018-05-31 23:48:28.786161|2018-05-31 23:48:28.786161
NCT01121523|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-10-19|2010-05-11|2010-05-12|Estimate|||||||2015-10-19|2015-10-21|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Cue-based Tactile Stimulation and Infant Stress Reactivity|Effect of Cue-based Tactile Stimulation on Premature, Low Birth Weight Infants: Stress Reactivity.Immune Functioning, and Parenting|Completed||N/A|56|Actual|Penn State University||2|||f||||t||||||||||2018-05-31 23:48:29.519062|2018-05-31 23:48:29.519062
NCT01121510|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-09-28|2010-05-10|2010-05-12|Estimate|||||||2010-09-28|2010-09-29|Estimate|May 2010||2010-05-31|September 2010|2010-09-30|May 2011|Anticipated|2011-05-31|July 2010|Anticipated|2010-07-31||Interventional|||Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose Design 9 System|The QuickClose Design 9 System Study|Withdrawn||Phase 1/Phase 2|50|Anticipated|CardioDex||||medical center difficulties in recruiting patients for the study in a timely fashion|f||||t||||||||||2018-05-31 23:48:29.621262|2018-05-31 23:48:29.621262
NCT01121497|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|July 2010||2010-07-31|April 2010|2010-04-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||The Effect of Physostigmine on Cognitive Functioning in the Immediate Period After Sedation for Colonoscopy||Unknown status|Not yet recruiting|N/A|160|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 23:48:29.696767|2018-05-31 23:48:29.696767
NCT01121484|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2012-02-16||2012-03-30|2010-05-10|2010-05-12|Estimate|2012-03-02|2012-03-30|Estimate||||2012-03-30|2012-04-04|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)|A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder|Completed||Phase 4|439|Actual|Pfizer|Baseline characteristics are available for all treated participants (434) and not all randomized participants (439).|2|||f||||f||||||||||2018-05-31 23:48:29.816608|2018-05-31 23:48:29.816608
NCT01121471|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-10|2010-05-10|2010-05-12|Estimate|||||||2010-05-10|2010-05-12|Estimate|December 2004||2004-12-31|May 2010|2010-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|WDS||Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)|Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)|Completed||N/A|55|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 23:48:30.228159|2018-05-31 23:48:30.228159
NCT01121458|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2013-06-07|2010-05-10|2010-05-12|Estimate|||||||2013-06-07|2013-06-10|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CARVE||Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed|Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE)|Completed||Phase 4|12|Actual|North Texas Veterans Healthcare System|||||f||||f||||||||||2018-05-31 23:48:30.385196|2018-05-31 23:48:30.385196
NCT01121445|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||The Impact of Daily Sinus Irrigation on Nasal Symptoms in Continuous Positive Airway Pressure (CPAP) Users - A Pilot Study||Unknown status|Recruiting|N/A|30|Anticipated|Bridgeport Hospital||1|||f||||f||||||||||2018-05-31 23:48:30.461239|2018-05-31 23:48:30.461239
NCT01121432|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)|Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     Mediastinal lymph nodes~   "|||2018-05-31 23:48:30.594977|2018-05-31 23:48:30.594977
NCT01121419|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-20|2010-05-11|2010-05-12|Estimate|||||||2010-05-20|2010-05-21|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||The Role of IMP3 Expression in Patients With Neuroblastoma|The Role of IMP3 Expression in Patients With Neuroblastoma|Completed|||||National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 23:48:30.66521|2018-05-31 23:48:30.66521
NCT01121406|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2015-07-17|2014-04-30|2015-07-17|2010-05-10|2010-05-12|Estimate|2015-07-17|2015-08-13|Estimate|2014-04-30|2014-05-16|Estimate|2015-07-17|2015-08-13|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Treated set (TS): The treated set consisted of all patients who received at least one administration of the trial drug.|BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer|Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy|Completed||Phase 2|110|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:48:30.829168|2018-05-31 23:48:30.829168
NCT01121393|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2014-12-27||2017-12-21|2010-05-11|2010-05-12|Estimate|2015-01-23|2015-01-26|Estimate||||2017-12-21|2017-12-22|Actual|April 19, 2010|Actual|2010-04-19|December 2017|2017-12-31|November 26, 2017|Actual|2017-11-26|December 23, 2013|Actual|2013-12-23||Interventional||The randomised set (RS) included all patients randomised to receive treatment, whether treated or not.|BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)|LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation|Completed||Phase 3|364|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:48:32.022371|2018-05-31 23:48:32.022371
NCT01121380|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2014-03-12|2010-05-11|2010-05-12|Estimate|||||||2014-03-12|2014-03-13|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021|A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single-Center Combined Single-Ascending Dose and Multiple-Ascending Dose, Parallel Groups, Study to Assess Safety, Tolerability and Pharmacokinetics of BL-1021 in Healthy Volunteers|Terminated||Phase 1|32|Actual|BioLineRx, Ltd.||8||Sponsor strategy change|f||||t||||||||||2018-05-31 23:48:33.058788|2018-05-31 23:48:33.058788
NCT01121367|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2011-06-23|2010-05-10|2010-05-12|Estimate|||||||2011-06-23|2011-06-27|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema|Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema|Completed|||82|Actual|Beijing Chao Yang Hospital|||5||f||||t||||||Samples Without DNA|"~     whole blood, serum, sputum~   "|||2018-05-31 23:48:33.143021|2018-05-31 23:48:33.143021
NCT01121354|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-07-15|2010-05-11|2010-05-12|Estimate|||||||2013-07-15|2013-07-16|Estimate|December 2009||2009-12-31|July 2013|2013-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|2 Cef||Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX|A Phase I Multiple-Dose Two-Arm Study to Evaluate the PK and Safety of Cefazolin 2g for Inj. USP and Dextrose Inj. USP in the DUPLEX® Drug Delivery System and Cefazolin for Inj. 1.5g in Daily Doses of 6g in Healthy Adult Subjects|Completed||Phase 1|24|Actual|B. Braun Medical Inc.||2|||f||||f||||||||||2018-05-31 23:48:33.209725|2018-05-31 23:48:33.209725
NCT01121341|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2010-05-19|2010-05-10|2010-05-12|Estimate|||||||2010-05-19|2010-05-20|Estimate|May 2010||2010-05-31|April 2010|2010-04-30||||June 2011|Anticipated|2011-06-30||Interventional|ESOS||ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial|ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial: a Prospective Randomized Trial for Coronary Artery Bypass Grafting (CABG) Surgery.|Unknown status|Recruiting|Phase 4|200|Anticipated|Azienda Ospedaliera San Giovanni Battista||2|||f||||t||||||||||2018-05-31 23:48:33.32514|2018-05-31 23:48:33.32514
NCT01121328|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-04-25|2010-05-10|2010-05-12|Estimate|||||||2013-04-25|2013-04-26|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|September 2014|Anticipated|2014-09-30|March 2014|Anticipated|2014-03-31||Interventional|||Autologous Umbilical Cord Blood Transfusion for Preterm Neonates|Autologous Umbilical Cord Blood Transfusion for Preterm and Low Birth Weight Neonates: A Pilot Feasibility Study|Unknown status|Recruiting|Phase 1|60|Anticipated|Ain Shams University||1|||f||||f||||||||||2018-05-31 23:48:33.422877|2018-05-31 23:48:33.422877
NCT01121315|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2012-05-10|2010-05-10|2010-05-12|Estimate|||||||2012-05-10|2012-05-11|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|ROSE||A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care|A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Glucose Lowering Drug Treatment in Primary Care|Completed|||58326|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:48:33.510159|2018-05-31 23:48:33.510159
NCT01121302|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2015-01-27|2010-05-11|2010-05-12|Estimate|||||||2015-01-27|2015-01-28|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects|A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability & PK of Single Ascending Dose (Part 1) & an Open-label Assessment of Effect of Food on the PK (Part 2)|Completed||Phase 1|88|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 23:48:33.595825|2018-05-31 23:48:33.595825
NCT01121289|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2013-12-09|2010-05-10|2010-05-12|Estimate|||||||2013-12-09|2013-12-10|Estimate|April 2010||2010-04-30|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Trial Investigating NN1218 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Type 1 Diabetes|Completed||Phase 1|26|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-05-31 23:48:33.671058|2018-05-31 23:48:33.671058
NCT01121276|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2017-01-16|2010-05-10|2010-05-12|Estimate|||||||2017-01-16|2017-01-18|Estimate|April 2010||2010-04-30|January 2017|2017-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 and Type 2 Diabetes|Completed||Phase 1|82|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-05-31 23:48:33.758248|2018-05-31 23:48:33.758248
NCT01121263|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2013-11-25||2014-02-07|2010-05-11|2010-05-12|Estimate|2013-11-25|2014-01-13|Estimate||||2014-02-07|2014-03-14|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Observational|||Hybrid Revascularization Observational Study|Hybrid Revascularization Observational Study|Completed|||298|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||t||||||||||2018-05-31 23:48:33.857355|2018-05-31 23:48:33.857355
NCT01121250|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2015-06-05|2010-05-11|2010-05-12|Estimate|||||||2015-06-05|2015-06-09|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|December 2013|Actual|2013-12-31||Interventional|Spouse READI||Spouse READI (Resilience Education And Deployment Information) Post Deployment Telephone Support Groups|Spouse READI (Resilience Education And Deployment Information) Post Deployment Telephone Support Groups|Completed||Phase 2/Phase 3|228|Actual|Memphis VA Medical Center||3|||f||||f||||||||||2018-05-31 23:48:34.265055|2018-05-31 23:48:34.265055
NCT01121237|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2016-04-05|2010-05-10|2010-05-12|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|MONITOR-CKD5||MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5|An International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Haemodialysis Patients With Anaemia Treated With Biosimilar Epoetin Alfa|Completed|||2086|Actual|Sandoz|||1||f||||t||||||||Undecided||2018-05-31 23:48:34.343628|2018-05-31 23:48:34.343628
NCT01121224|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2018-01-05||2018-02-07|2010-05-11|2010-05-12|Estimate|2018-01-05|2018-02-01|Actual||||2018-02-07|2018-03-08|Actual|January 2012||2012-01-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DIVA||Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty|CSP #571 - Drug-eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Angioplasty (DIVA)|Completed||Phase 4|597|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-05-31 23:48:34.667949|2018-05-31 23:48:34.667949
NCT01121211|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2017-01-25||2017-07-11|2010-05-11|2010-05-12|Estimate|2017-03-15|2017-04-26|Actual||||2017-07-11|2017-08-10|Actual|April 2010||2010-04-30|July 2017|2017-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Hormonal Factors in the Treatment of Anorexia Nervosa|Hormonal Factors in the Treatment of Anorexia Nervosa|Completed||Phase 2|90|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:48:35.194021|2018-05-31 23:48:35.194021
NCT01121198|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-10|2010-05-10|2010-05-12|Estimate|||||||2010-05-10|2010-05-12|Estimate|December 2006||2006-12-31|May 2010|2010-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects|ASP1941 Phase I Study —Placebo-controlled, Single-dose and Repeated-dose Oral Administration Study in Healthy Adult Male Subjects—|Completed||Phase 1|84|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 23:48:35.48996|2018-05-31 23:48:35.48996
NCT01121016|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|June 2010||2010-06-30|September 2009|2009-09-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|NAEB||Efficacy and Safety of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic Bronchitis|Randomized Double-blind Placebo-controlled Study of add-on Montelukast to Inhaled Budesonide in the Treatment of Nonasthmatic Eosinophilic Bronchitis|Unknown status|Not yet recruiting|Phase 4|63|Anticipated|Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 23:48:39.689024|2018-05-31 23:48:39.689024
NCT01121185|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2016-03-14|2013-10-23|2016-05-05|2010-05-11|2010-05-12|Estimate|2016-05-05|2016-06-14|Estimate|2013-10-23|2013-11-15|Estimate|2016-05-05|2016-06-14|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|MBL-HCV1|The eleven subjects who were randomized, initiated study infusions, and underwent liver transplantation were included in the analysis population.|Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C|A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation|Terminated||Phase 2|13|Actual|MassBiologics||2||The study was terminated due to slower than anticipated subject accrual.|f||||t||||||||||2018-05-31 23:48:35.618434|2018-05-31 23:48:35.618434
NCT01121172|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2016-03-15||2016-04-13|2010-05-11|2010-05-12|Estimate|2016-04-13|2016-05-19|Estimate||||2016-04-13|2016-05-19|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|June 2012|Actual|2012-06-30||Observational|||Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)|Serum Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ)in Obese Children and Adolescents.|Completed|||180|Actual|Aristotle University Of Thessaloniki|||2||f||||f||||||||||2018-05-31 23:48:37.386002|2018-05-31 23:48:37.386002
NCT01121159|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-08-14|2010-05-10|2010-05-12|Estimate|||||||2017-08-14|2017-08-16|Actual|June 2010||2010-06-30|August 2017|2017-08-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Observational|Orbita 3||Prospective Multicenter Trial to Compare Preformed vs Non Preformed Orbital Implants|A Prospective Multicenter Study to Compare the Accuracy of Posttraumatic Orbital Reconstruction of the Medial Orbital Wall and/or the Orbital Floor With Preoperatively Preformed Versus Non-preformed Orbital Plates|Completed|||185|Actual|AO Clinical Investigation and Documentation|||2||f||||f||||||||||2018-05-31 23:48:37.631369|2018-05-31 23:48:37.631369
NCT01121146|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|2013-07-31||2014-11-03|2010-05-11|2010-05-12|Estimate|2014-11-03|2014-11-05|Estimate||||2014-11-03|2014-11-05|Estimate|December 1998||1998-12-31|November 2014|2014-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty|A Prospective, Randomized Clinical Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty|Completed||N/A|236|Actual|Anderson Orthopaedic Research Institute||2|||f||||||||||||||2018-05-31 23:48:37.735861|2018-05-31 23:48:37.735861
NCT01121133|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2017-11-17|2010-05-10|2010-05-12|Estimate|||||||2017-11-17|2017-11-21|Actual|May 2010||2010-05-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax|A Phase I Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of ABT-263 (Navitoclax)|Completed||Phase 1|12|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:48:38.160865|2018-05-31 23:48:38.160865
NCT01121120|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2017-10-10|2010-05-09|2010-05-12|Estimate|||||||2017-10-10|2017-10-12|Actual|June 2010||2010-06-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|TXA127-PBSC||Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients|Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells|Active, not recruiting||Phase 2|75|Actual|Tarix Pharmaceuticals||2|||f||||t||||||||||2018-05-31 23:48:38.227772|2018-05-31 23:48:38.227772
NCT01121107|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05||2016-04-27|2016-05-31|2010-05-09|2010-05-12|Estimate||||2016-05-31|2016-06-06|Estimate|2016-05-31|2016-06-06|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|LAPTOP-HF||Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy|Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study|Completed||N/A|486|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 23:48:38.441771|2018-05-31 23:48:38.441771
NCT01121094|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2010-05-11|2010-05-11|2010-05-12|Estimate|||||||2010-05-11|2010-05-12|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Fetal Parenchymatic Evaluation (Liver, Spleen) Using T2* Sequences|Fetal Parenchymatic Evaluation (Liver, Spleen) Using T2* Sequences.|Unknown status|Not yet recruiting||50|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 23:48:38.805712|2018-05-31 23:48:38.805712
NCT01121081|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-11|||2013-01-23|2010-05-09|2010-05-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|||The Effect of Algae Dunaliella Bardawil on Psoriasis (2)|A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis Treated by Narrow Band UVB Therapy|Withdrawn||Phase 3|0|Actual|Sheba Medical Center||2||no patients enrolled|f||||f||||||||||2018-05-31 23:48:38.97097|2018-05-31 23:48:38.97097
NCT01121068|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2014-01-03|2010-05-11|2010-05-12|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Observational|||Monthly Follow up of Interferon Gamma Releasing Assay (IGRA) Among Health-care Workers Treating Tuberculosis (TB) Patients|Monthly Follow up of Interferon Gamma Releasing Assay Among Health-care Workers Treating TB Patients|Completed|||49|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 23:48:39.098459|2018-05-31 23:48:39.098459
NCT01121055|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2010-05-27|2010-05-09|2010-05-12|Estimate|||||||2010-05-27|2010-05-31|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Interventional|||Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy|Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy|Unknown status|Recruiting|Phase 4|372|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:48:39.240423|2018-05-31 23:48:39.240423
NCT01121042|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2016-03-01|2010-05-09|2010-05-12|Estimate|||||||2016-03-01|2016-03-02|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia|Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia|Unknown status|Recruiting|Phase 3|60|Anticipated|Bayside Health||2|||f||||t||||||||No||2018-05-31 23:48:39.393085|2018-05-31 23:48:39.393085
NCT01121029|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2012-12-06|2010-05-11|2010-05-12|Estimate|||||||2012-12-06|2012-12-10|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus|Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|15|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t||||||||||2018-05-31 23:48:39.580988|2018-05-31 23:48:39.580988
NCT01121003|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2011-10-18|2010-05-10|2010-05-11|Estimate|||||||2011-10-18|2011-10-19|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|FRUCTEXER||Effects of Fructose and Exercise on Hepatic Lipid Metabolism|Effects of a Weight Maintenance, High Fructose Diet and of Exercise on Hepatic Lipid Metabolism|Completed||N/A|8|Anticipated|University of Lausanne||3|||f||||f||||||||||2018-05-31 23:48:39.793355|2018-05-31 23:48:39.793355
NCT01120990|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2010-12-03||2012-04-14|2010-05-10|2010-05-11|Estimate|2012-02-04|2012-03-07|Estimate||||2012-04-14|2012-04-18|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|NISSEI||Hybrid Blood Pressure Monitor Validation|Validation of a Hybrid Blood Pressure Monitor to Replace the Mercury Standard for Validation Studies According to Modified Criteria of the European Society of Hypertension International Protocol 2010|Completed||Phase 4|51|Actual|University of Athens||1|||f||||f||||||||||2018-05-31 23:48:39.902163|2018-05-31 23:48:39.902163
NCT01120977|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2011-11-04|2010-05-10|2010-05-11|Estimate|||||||2011-11-04|2011-11-07|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|||Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study|Reference Values for Body Composition Parameters and IGF-I in the Adult NordiNet® International Outcome Study|Completed|||150|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Blood sample to measure Insulin like growth factor-1 (IGF-1)~   "|||2018-05-31 23:48:40.082904|2018-05-31 23:48:40.082904
NCT01120964|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06||2013-05-28|2017-01-23|2010-05-09|2010-05-11|Estimate||||2013-05-28|2013-06-06|Estimate|2017-01-23|2017-01-24|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol|Phase IB Double Blind, Randomized, Placebo Controlled Clinical Trial to Determine the Pharmacokinetics and Safety of a Revised Protocol of Intravenous L-Citrulline (Citrupress®) Versus Placebo in Children Undergoing Cardiopulmonary Bypass|Completed||Phase 1/Phase 2|22|Actual|Asklepion Pharmaceuticals, LLC||2|||f||||t||||||||||2018-05-31 23:48:40.198482|2018-05-31 23:48:40.198482
NCT01120951|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-09|||2010-05-17|2010-05-09|2010-05-11|Estimate|||||||2010-05-17|2010-05-18|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Clinical Assessment of the Use of the R8 Respiratory Rate Counter in Post-Operative Recovery in Adults and Adolescents|Clinical Assessment of the Use of the R8 Respiratory Rate Counter in Post-Operative Recovery in Adults and Adolescents|Completed|||220|Actual|Anaxsys Technology Ltd|||||f||||t||||||||||2018-05-31 23:48:40.305822|2018-05-31 23:48:40.305822
NCT01120938|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-08|||2010-05-25|2010-05-10|2010-05-11|Estimate|||||||2010-05-25|2010-05-26|Estimate|February 2010||2010-02-28|May 2010|2010-05-31|December 2012|Anticipated|2012-12-31|December 2010|Anticipated|2010-12-31||Observational|||Do Pacifiers Protect From Sudden Infant Death Syndrome (SIDS) Through an Increase in Upper Airway Patency?|Do Pacifiers Protect From Sudden Infant Death Syndrome (SIDS) Through an Increase in Upper Airway Patency?|Unknown status|Recruiting||30|Anticipated|Ziv Hospital|||||f||||f||||||||||2018-05-31 23:48:40.375861|2018-05-31 23:48:40.375861
NCT01120925|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-08|||2014-04-24|2010-05-08|2010-05-11|Estimate|||||||2014-04-24|2014-04-28|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Autologous Bone Marrow Derived Stem Cells in Decompensate Cirrhotic Patients|Comparison of Therapeutic Outcome of Twice Transplantation of CD133+ and MNC BM Derived Stem Cells in Cirrhotic Patients: Clinical Trial, Double Blind, Phase I/II|Completed||Phase 1/Phase 2|30|Actual|Royan Institute||3|||f||||t||||||||||2018-05-31 23:48:40.451875|2018-05-31 23:48:40.451875
NCT01120912|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-08|||2012-04-16|2010-05-10|2010-05-11|Estimate|||||||2012-04-16|2012-04-17|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients|A Single Center, Non-randomized, Single Blind, Placebo Controlled, Single Dose Study of the Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients - Phase 1 Study|Completed||Phase 1|8|Actual|Oshadi Drug Administration||1|||f||||f||||||||||2018-05-31 23:48:40.5406|2018-05-31 23:48:40.5406
NCT01120899|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-08|2012-08-02||2014-10-06|2010-05-08|2010-05-11|Estimate|2012-08-02|2012-09-06|Estimate||||2014-10-06|2014-10-17|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|February 2013|Actual|2013-02-28|August 2011|Actual|2011-08-31||Interventional|||A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema|A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema|Completed||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 23:48:40.660403|2018-05-31 23:48:40.660403
NCT01120886|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2013-04-19|2010-05-10|2010-05-11|Estimate|||||||2013-04-19|2013-04-22|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Post-mortem Genetic Testing|Post-mortem Genetic Testing for Cardiac Ion Channelopathy in Unexplained Still Births|Completed|||100|Anticipated|Thayyil, Sudhin|||||f||||f||||||Samples With DNA|"~     Skin and muscle~   "|||2018-05-31 23:48:41.069425|2018-05-31 23:48:41.069425
NCT01120873|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2010-05-10|2010-05-10|2010-05-11|Estimate|||||||2010-05-10|2010-05-11|Estimate|March 2007||2007-03-31|May 2010|2010-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of Metamin 3D on the Lipid and Glucose in Subjects With Metabolic Syndrome|Phase 3 Study of 3D in Metabolic Syndrome|Completed||Phase 3|110|Actual|Taichung Veterans General Hospital||1|||f||||f||||||||||2018-05-31 23:48:41.1277|2018-05-31 23:48:41.1277
NCT01120860|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-02-24|2010-05-10|2010-05-11|Estimate|||||||2017-02-24|2017-02-28|Actual|November 2002||2002-11-30|February 2017|2017-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance|MRI and Decline of Aging Aviator Performance|Completed|||67|Actual|Palo Alto Veterans Institute for Research|||||f||||f||||||Samples With DNA|"~     frozen genomic DNA~   "|||2018-05-31 23:48:41.278373|2018-05-31 23:48:41.278373
NCT01120847|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-02-09|2010-05-10|2010-05-11|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2004||2004-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Post Traumatic Stress Disorder (PTSD), Sleep Disordered Breathing And Genetics: Effects On Cognition|PTSD, Sleep Disordered Breathing And Genetics: Effects On Cognition|Active, not recruiting|||400|Anticipated|Stanford University|||2||f||||f||||||Samples With DNA|"~     blood or saliva~   "|||2018-05-31 23:48:41.34345|2018-05-31 23:48:41.34345
NCT01120834|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2017-02-23||2017-02-23|2010-05-10|2010-05-11|Estimate|2017-02-23|2017-04-10|Actual||||2017-02-23|2017-04-10|Actual|September 2010|Actual|2010-09-30|February 2017|2017-02-28|October 20, 2016|Actual|2016-10-20|April 2013|Actual|2013-04-30||Interventional|||Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)|Phase I/II Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory DLBCL|Completed||Phase 1/Phase 2|17|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 23:48:41.423102|2018-05-31 23:48:41.423102
NCT01120821|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2010-05-14|2010-05-07|2010-05-11|Estimate|||||||2010-05-14|2010-05-17|Estimate|August 2002||2002-08-31|May 2010|2010-05-31|June 2007|Actual|2007-06-30|January 2007|Actual|2007-01-31||Interventional|||Treatment of Polycythemia Vera With Gleevec|A Phase II Trial of the Treatment of Polycythemia Vera With Gleevec|Completed||Phase 2|36|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 23:48:41.561711|2018-05-31 23:48:41.561711
NCT01120808|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2016-07-23||2017-02-01|2010-05-10|2010-05-11|Estimate|2017-02-01|2017-03-24|Actual||||2017-02-01|2017-03-24|Actual|April 2010||2010-04-30|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Per protocol, participants completing the primary outcome measure were analyzable for baseline characteristics.|Prevention Trial Assessing Paper-Tape in Endurance Distances (PreTAPED)|Prevention Trial Assessing Paper-Tape in Endurance Distances (PreTAPED)|Completed||Phase 3|136|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 23:48:41.651553|2018-05-31 23:48:41.651553
NCT01120795|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-27|2010-05-10|2010-05-11|Estimate|||||||2010-05-27|2010-05-28|Estimate|February 2004||2004-02-29|May 2010|2010-05-31|July 2006|Actual|2006-07-31|January 2006|Actual|2006-01-31||Interventional|||Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy|Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes|Completed||Phase 4|55|Actual|Melbourne Health||1|||f||||f||||||||||2018-05-31 23:48:41.828016|2018-05-31 23:48:41.828016
NCT01120782|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2011-11-04||2017-09-26|2010-05-10|2010-05-11|Estimate|2011-11-04|2011-12-08|Estimate||||2017-09-26|2017-10-27|Actual|February 1, 2010|Actual|2010-02-01|September 2017|2017-09-30|February 1, 2010|Actual|2010-02-01|February 1, 2010|Actual|2010-02-01||Interventional|||Non-dispensing Study to Check Prescription Equivalence of Two Daily Disposable Toric Contact Lens Types||Completed||N/A|45|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 23:48:41.907438|2018-05-31 23:48:41.907438
NCT01120769|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-12-04|2010-05-07|2010-05-11|Estimate|||||||2015-12-04|2015-12-07|Estimate|July 2011||2011-07-31|December 2015|2015-12-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|APRIORI Pilot||Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction|Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction|Withdrawn||N/A|0|Actual|Vanderbilt University||2||Funding issue|f||||f||||||||||2018-05-31 23:48:43.070844|2018-05-31 23:48:43.070844
NCT01120756|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2018-03-09|2010-05-07|2010-05-11|Estimate|||||||2018-03-09|2018-03-12|Actual|October 1, 2011|Actual|2011-10-01|March 2018|2018-03-31|June 29, 2018|Anticipated|2018-06-29|September 30, 2017|Actual|2017-09-30||Interventional|||Neural Bases of Cognitive Rehabilitation for Brain Injury|Neural Bases of Cognitive Rehabilitation for Brain Injury|Active, not recruiting||N/A|210|Anticipated|VA Office of Research and Development||4|||f||||t|f|f|||f|||No||2018-05-31 23:48:43.156593|2018-05-31 23:48:43.156593
NCT01120743|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-11-21|2010-05-07|2010-05-11|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2008||2008-08-31|November 2017|2017-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Correlation Between Release of Cytokines From Liver Graft and Hemodynamic Instability|Correlation Between Release of Cytokines From Liver Graft and Hemodynamic Stability During Liver Transplantation|Completed|||17|Actual|Penn State University|||||f||||f||||||Samples Without DNA|"~     Blood samples were obtained. All blood samples were placed on ice and processed with~     centrifugation. The plasma supernatant was frozen at -80º Celsius.~   "|||2018-05-31 23:48:43.257282|2018-05-31 23:48:43.257282
NCT01120730|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-05-07|2010-05-07|2010-05-11|Estimate|||||||2010-05-07|2010-05-11|Estimate|April 1997||1997-04-30|May 2010|2010-05-31|March 2009|Actual|2009-03-31|September 1998|Actual|1998-09-30||Interventional|||Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury|Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury|Completed||Phase 3|28|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 23:48:43.316981|2018-05-31 23:48:43.316981
NCT01120717|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2012-12-13||2013-01-28|2010-05-10|2010-05-11|Estimate|2012-12-13|2013-01-21|Estimate||||2013-01-28|2013-01-31|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ENLIGHTEN||A Study to Assess the Long-term Safety of QVA149|A Multicener, Randomised, Double-blind, Placebo-controlled Study, to Assess the Long Term Safety of 52 Weeks Treatment With QVA149 (110 ug Indacaterol/50ug Glycopyrrolate) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|339|Actual|Novartis||2|||f||||t||||||||||2018-05-31 23:48:43.423805|2018-05-31 23:48:43.423805
NCT01120704|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2015-01-29||2015-11-12|2010-05-07|2010-05-11|Estimate|2015-01-29|2015-02-16|Estimate||||2015-11-12|2015-12-11|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Adherence||Evaluation of Treatments to Improve Smoking Cessation Medication Adherence|Project 3: Identifying Optimal Strategies of Increasing Smokers' Adherence to Cessation Medications|Completed||Phase 4|544|Actual|University of Wisconsin, Madison||32|||f||||t||||||||||2018-05-31 23:48:44.17693|2018-05-31 23:48:44.17693
NCT01120691|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2013-07-09||2013-10-29|2010-05-10|2010-05-11|Estimate|2013-07-09|2013-09-30|Estimate||||2013-10-29|2013-12-02|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SPARK|The modified safety set (mSAF set) includes all patients in the safety set except patients from a site who had major GCP issues.|Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations|A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|2224|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:48:45.914677|2018-05-31 23:48:45.914677
NCT01120678|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2011-03-04|2010-05-07|2010-05-11|Estimate|||||||2011-03-04|2011-03-07|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay|Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay|Completed|||250|Anticipated|University of Virginia|||1||f||||f||||||Samples Without DNA|"~     Samples of whole blood were obtained and processed to collect and retain only serum.~   "|||2018-05-31 23:48:48.295957|2018-05-31 23:48:48.295957
NCT01120665|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2012-06-21|2010-05-07|2010-05-11|Estimate|||||||2012-06-21|2012-06-22|Estimate|February 2002||2002-02-28|June 2012|2012-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|TRH01/989-7||Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women|Isolated and Associated Effects of Physical Exercise and Estrogen Therapy on Climactercs Women|Completed||N/A|62|Actual|University of Sao Paulo General Hospital||4|||f||||t||||||||||2018-05-31 23:48:48.377152|2018-05-31 23:48:48.377152
NCT01120652|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-11-30|2010-05-07|2010-05-11|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Reducing Depressive Symptoms in Systemic Lupus Erythematosus|Reducing Depressive Symptoms in Systemic Lupus Erythematosus|Completed||N/A|90|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 23:48:48.460732|2018-05-31 23:48:48.460732
NCT01120639|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2018-03-20|2010-05-07|2010-05-11|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2010||2010-04-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2016|Actual|2016-11-30||Interventional|Tx-Treatment||P1/2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform|A Phase 1/2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme|Active, not recruiting||Phase 1/Phase 2|30|Actual|Stanford University||2|||f||||t||||||||No||2018-05-31 23:48:48.547858|2018-05-31 23:48:48.547858
NCT01120626|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2015-11-19||2016-02-18|2010-05-07|2010-05-11|Estimate|2016-02-18|2016-03-17|Estimate||||2016-02-18|2016-03-17|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Randomized Controlled Study of Donepezil in Fragile X Syndrome|Augmentation of the Cholinergic System in Fragile X Syndrome: A Double-Blind Placebo-Controlled Randomized Study of Donepezil|Completed||Phase 2|45|Actual|Stanford University||2|||f||||t||||||||No||2018-05-31 23:48:48.704622|2018-05-31 23:48:48.704622
NCT01120613|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-05-29|2010-05-07|2010-05-11|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2010||2010-04-30|May 2013|2013-05-31||||August 2010|Anticipated|2010-08-31||Interventional|||Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study|Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study|Withdrawn||N/A|0|Actual|Northwell Health||1||primary investigator left institution; not enough patients|f||||f||||||||||2018-05-31 23:48:48.984688|2018-05-31 23:48:48.984688
NCT01120600|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2017-11-08||2017-11-08|2010-05-07|2010-05-11|Estimate|2017-11-08|2017-12-06|Actual||||2017-11-08|2017-12-06|Actual|June 9, 2010|Actual|2010-06-09|October 2017|2017-10-31|July 22, 2013|Actual|2013-07-22|July 22, 2013|Actual|2013-07-22||Interventional|||A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men With Osteoporosis Treated With Vitamin D and Calcium|Completed||Phase 3|294|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 23:48:49.088489|2018-05-31 23:48:49.088489
NCT01120587|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2010-05-10|2010-05-10|2010-05-11|Estimate|||||||2010-05-10|2010-05-11|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|VFD-IPP||Videofluoroscopic of Deglutition Study of the Initiation of Pharyngeal Phase in Young Adults|The Start of Pharyngeal Phase of Swallowing in Healthy Individuals|Completed|||40|Actual|Fortaleza University|||||f||||t||||||||||2018-05-31 23:48:49.589212|2018-05-31 23:48:49.589212
NCT01120574|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2017-03-21|2010-05-10|2010-05-11|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2005|Actual|2005-10-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Home Mechanical Ventilation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Hypercapnic Response|Home Mechanical Ventilation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Develop Nocturnal Hypercapnic Response Associated to Oxygen Therapy|Withdrawn||N/A|0|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 23:48:49.638368|2018-05-31 23:48:49.638368
NCT01120561|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-02-13|2010-05-07|2010-05-11|Estimate|||||||2017-02-13|2017-02-15|Actual|May 2010||2010-05-31|February 2017|2017-02-28||||||||Expanded Access|||A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer|An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer|No longer available|||||Genentech, Inc.|||||||||||||||||||2018-05-31 23:48:49.695328|2018-05-31 23:48:49.695328
NCT01120548|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-03-06|2010-05-07|2010-05-11|Estimate|||||||2015-03-06|2015-03-09|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|SATELIT-HF||Sleep Apnea Treatment During Cardiac Rehabilitation of Congestive Heart Failure Patients|SLEEP DISORDERED BREATHING DURING CARDIAC REHABILITATION A Study of the Improvement in Physical Performance of Patients With Heart Failure During Cardiac Rehabilitation Due to the Correction of Sleep Disordered Breathing|Completed||N/A|300|Actual|French Cardiology Society||2|||f||||f||||||||||2018-05-31 23:48:49.770402|2018-05-31 23:48:49.770402
NCT01120535|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-06-26|2010-05-10|2010-05-11|Estimate|||||||2014-06-26|2014-06-30|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|RETRIEVE 4||Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter 4|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 4 (RETRIEVE 4)|Completed||Phase 3|20|Actual|Crux Biomedical||1|||f||||t||||||||||2018-05-31 23:48:49.860482|2018-05-31 23:48:49.860482
NCT01120522|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-06-26|2010-05-10|2010-05-11|Estimate|||||||2014-06-26|2014-06-30|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|RETRIEVE 3||"Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 (RETRIEVE 3)"|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3|Completed||Phase 3|17|Actual|Crux Biomedical||1|||f||||t||||||||||2018-05-31 23:48:49.923296|2018-05-31 23:48:49.923296
NCT01120509|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-06-26|2010-05-07|2010-05-11|Estimate|||||||2014-06-26|2014-06-30|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|RETRIEVE 2||Crux Biomedical Vena Cava Filter Study - United States|Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 2|Completed||Phase 3|88|Actual|Crux Biomedical||1|||f||||t||||||||||2018-05-31 23:48:50.14303|2018-05-31 23:48:50.14303
NCT01120496|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2010-05-10|2010-05-10|2010-05-11|Estimate|||||||2010-05-10|2010-05-11|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Nebulized Hypertonic Saline Treatment in Hospitalized Children With Moderate to Severe Viral Bronchiolitis|A Randomized Controlled Trial of Nebulized Hypertonic Saline Treatment in Hospitalized Children With Moderate to Severe Viral Bronchiolitis|Completed||N/A|135|Actual|Chongqing Medical University||2|||f||||t||||||||||2018-05-31 23:48:50.241914|2018-05-31 23:48:50.241914
NCT01120483|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-10|2010-05-10|2010-05-11|Estimate|||||||2010-05-10|2010-05-11|Estimate|December 2006||2006-12-31|October 2006|2006-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Prevalence of Malnutrition in Oncologic Patients|Prevalence and Impact of Malnutrition in Hospitalised Patients|Completed|||400|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 23:48:50.312285|2018-05-31 23:48:50.312285
NCT01120470|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2016-07-28|2010-05-10|2010-05-11|Estimate|||||||2016-07-28|2016-08-01|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|October 2012|Actual|2012-10-31||Interventional|||OGX-427 in Castration Resistant Prostate Cancer Patients|A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease|Completed||Phase 2|74|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 23:48:50.37245|2018-05-31 23:48:50.37245
NCT01120457|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2015-03-05|2010-05-10|2010-05-11|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2010||2010-08-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers|A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects With Relapsed Acute Myelogenous Leukemia and Selected B-cell Malignancies|Completed||Phase 1|96|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 23:48:50.464787|2018-05-31 23:48:50.464787
NCT01120444|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2011-04-15|2010-05-10|2010-05-11|Estimate|||||||2011-04-15|2011-04-18|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients|A Single Center, Open-label, Randomized Study Examining the Glycemic Effects of ID vs SC Bolus Dosing of Insulin Lispro in Patients With Type 1 Diabetes|Completed||Phase 1/Phase 2|20|Anticipated|Becton, Dickinson and Company||2|||f||||f||||||||||2018-05-31 23:48:50.639014|2018-05-31 23:48:50.639014
NCT01120431|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-05-05|2010-05-10|2010-05-11|Estimate|||||||2017-05-05|2017-05-08|Actual|May 2010|Anticipated|2010-05-31|May 2017|2017-05-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|INFUSE-TM||Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)|The INcreased Flow Utilizing Subcutaneously-Enabled Time-Motion (INFUSE-TM) Study: A Randomized, Open-label, Parallel-group, Multicenter Study Evaluating Efficacy and Time and Resources in the Emergency Department for Hylenex-facilitated Subcutaneous Rehydration Versus Oral Rehydration Therapy in Pediatric Patients With Mild to Moderate Dehydration|Withdrawn||Phase 4|0|Actual|Baxter Healthcare Corporation||2||Strategic business decision (not related to safety or efficacy concerns)|f||||f||||||||||2018-05-31 23:48:50.73014|2018-05-31 23:48:50.73014
NCT01120418|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2012-08-10|2010-05-10|2010-05-11|Estimate|||||||2012-08-10|2012-08-13|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days|A Randomized, Contralateral Study To Evaluate Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered 0.6% ISV-403 Three Times Daily For Five Days|Completed||Phase 1|120|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 23:48:50.807681|2018-05-31 23:48:50.807681
NCT01120405|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2014-03-20||2014-05-20|2010-05-07|2010-05-11|Estimate|2014-05-20|2014-06-17|Estimate||||2014-05-20|2014-06-17|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CARVASAXe|Full analysis set (FAS): Randomised patients who started general anaesthesia induction. Patients were assigned to the treatment groups as randomised, i.e. the treatment groups were based on the treatment allocated by randomisation.|Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery|Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery: A Phase III Multicenter Randomized Controlled Study|Completed||Phase 3|600|Actual|Air Liquide Santé International||2|||f||||f||||||||||2018-05-31 23:48:50.907498|2018-05-31 23:48:50.907498
NCT01120392|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2011-12-06|2010-05-10|2010-05-11|Estimate|||||||2011-12-06|2011-12-07|Estimate|May 2011||2011-05-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease|Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease|Completed||Phase 2/Phase 3|40|Actual|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 23:48:51.494442|2018-05-31 23:48:51.494442
NCT01120379|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2013-08-02||2015-05-26|2010-05-07|2010-05-10|Estimate|2013-08-02|2013-10-11|Estimate||||2015-05-26|2015-06-22|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Observational|XVU-LTF|Baseline data was analyzed for 5020 patients as out of the enrolled 5034 patients 14 patients were transferred to the HCRI DAPT cohort, leaving 5020 in the XIENCE V USA LTF cohort.|XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)|Completed|||5034|Actual|Abbott Vascular|||1||f||||t||||||||||2018-05-31 23:48:51.613866|2018-05-31 23:48:51.613866
NCT01120366|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-01-23|2010-05-07|2010-05-10|Estimate|||||||2015-01-23|2015-01-26|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SURPRISE||Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation|Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation|Completed||Phase 4|233|Actual|SURPRISE Study Group||2|||f||||t||||||||||2018-05-31 23:48:52.439863|2018-05-31 23:48:52.439863
NCT01120353|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2017-10-05|2010-05-07|2010-05-10|Estimate|||||||2017-10-05|2017-10-06|Actual|January 5, 1995|Actual|1995-01-05|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Childhood Cancer Survivor Study|Childhood Cancer Survivor Study|Recruiting|||50000|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Blood, saliva and second tumor specimens~   "|||2018-05-31 23:48:52.719257|2018-05-31 23:48:52.719257
NCT01120340|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-09-17|2010-05-07|2010-05-10|Estimate|||||||2013-09-17|2013-09-18|Estimate|October 2005||2005-10-31|September 2013|2013-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|DIV-01/04||Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares||Completed||Phase 3|105|Actual|SOFAR S.p.A.||2|||f||||f||||||||||2018-05-31 23:48:52.926901|2018-05-31 23:48:52.926901
NCT01120327|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-05-07|2010-05-07|2010-05-10|Estimate|||||||2010-05-07|2010-05-10|Estimate|July 2010||2010-07-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|||A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients|A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients|Unknown status|Not yet recruiting|Phase 4|212|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:48:53.041788|2018-05-31 23:48:53.041788
NCT01120314|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-05-09|2010-05-07|2010-05-10|Estimate|||||||2014-05-09|2014-05-12|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment|An Open-label Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban Given as a Single 80 μg/kg Bolus Plus 100 µg/kg/h Continuous Infusion for 24 Hours in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function|Completed||Phase 1|48|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 23:48:53.206132|2018-05-31 23:48:53.206132
NCT01120301|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-11-14|2010-05-06|2010-05-10|Estimate|||||||2013-11-14|2013-11-15|Estimate|September 2010||2010-09-30|October 2012|2012-10-31||||September 2012|Actual|2012-09-30||Interventional|NEST-3||Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)|NeuroThera® Efficacy and Safety Trial - 3 (NEST-3) A Double-blind, Randomized, Sham-controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Efficacy of Transcranial Laser Therapy With the NeuroThera® Laser System for the Treatment of Acute Ischemic Stroke Within 24 Hours of Stroke Onset|Completed||Phase 3|1000|Anticipated|PhotoThera, Inc||2|||f||||t||||||||||2018-05-31 23:48:53.331144|2018-05-31 23:48:53.331144
NCT01120288|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-10-05|2010-05-07|2010-05-10|Estimate|||||||2017-10-05|2017-10-06|Actual|April 29, 2010||2010-04-29|March 6, 2014|2014-03-06|September 24, 2013|Actual|2013-09-24|||||Interventional|||A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases|A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:48:53.551311|2018-05-31 23:48:53.551311
NCT01120275|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2015-10-29||2016-05-06|2010-05-07|2010-05-10|Estimate|2016-05-06|2016-06-14|Estimate||||2016-05-06|2016-06-14|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|May 2013|Actual|2013-05-31||Interventional||Eligible patients who had received the protocol treatments were included in the baseline analysis.|Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma|Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma|Terminated||Phase 2|36|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-05-31 23:48:53.70396|2018-05-31 23:48:53.70396
NCT01120262|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2016-10-06|2010-05-07|2010-05-10|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin|Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy|Completed|||545|Actual|Southwest Oncology Group|||||f||||f||||||||Yes|https://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-05-31 23:48:54.532648|2018-05-31 23:48:54.532648
NCT01120249|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2017-12-06|2010-05-07|2010-05-10|Estimate|||||||2017-12-06|2017-12-08|Actual|April 2011||2011-04-30|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|S0931||S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery|EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study|Active, not recruiting||Phase 3|1545|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 23:48:54.71471|2018-05-31 23:48:54.71471
NCT01120236|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2016-04-18||2018-02-23|2010-05-07|2010-05-10|Estimate|2016-08-15|2016-10-06|Estimate||||2018-02-23|2018-02-26|Actual|December 2010||2010-12-31|February 2018|2018-02-28|August 23, 2017|Actual|2017-08-23|June 2015|Actual|2015-06-30||Interventional||One patient from Arm II (androgen deprivation therapy) was ineligible because of lack of a demonstrable radiographic metastasis. This patient was excluded from analyses.|Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer|A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone Sensitive Metastatic Prostate Cancer|Completed||Phase 2|211|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 23:48:58.548229|2018-05-31 23:48:58.548229
NCT01120223|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2014-09-26|2013-11-22|2015-03-25|2010-05-07|2010-05-10|Estimate|2014-11-27|2014-12-01|Estimate|2013-11-22|2013-12-17|Estimate|2015-03-25|2015-04-14|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis|Safety and Efficacy of Calcipotriol Plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis|Completed||Phase 2|78|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 23:49:00.244847|2018-05-31 23:49:00.244847
NCT01120210|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2012-09-06||2013-07-08|2010-05-07|2010-05-10|Estimate|2013-06-24|2013-06-25|Estimate||||2013-07-08|2013-07-19|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JNJ-39588146 in Subjects With Heart Failure|Completed||Phase 2|62|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Data from the extended infusion sub-study were exploratory; therefore, results for outcome measures from the sub-study are not reported.|2|||f||||t||||||||||2018-05-31 23:49:00.837946|2018-05-31 23:49:00.837946
NCT01120197|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2012-05-23||2016-09-26|2010-05-07|2010-05-10|Estimate|2014-05-05|2014-05-30|Estimate||||2016-09-26|2016-10-28|Estimate|May 2005||2005-05-31|September 2016|2016-09-30|November 2009|Actual|2009-11-30|January 2009|Actual|2009-01-31||Interventional|||Study of Effect of Exercise With Osteoporosis and Vertebral Fracture|Study of Effect of Exercise on Health-related Quality of Life, Mobility and Balance in Osteoporotic Women With a History of Vertebral Fracture.|Completed||N/A|89|Actual|Ostfold Hospital Trust|The numbers in our study were relatively small, and some caution is required in interpretation. Additionally, it cannot be ruled out that participants have become aware of the treatment allocation, and this could potentially have biased the results.|2|||f||||t||||||||No||2018-05-31 23:49:01.858655|2018-05-31 23:49:01.858655
NCT01120184|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2016-05-02||2017-11-03|2010-05-07|2010-05-10|Estimate|2017-01-03|2017-02-23|Actual||||2017-11-03|2017-11-07|Actual|July 31, 2010|Actual|2010-07-31|November 2017|2017-11-30|September 16, 2016|Actual|2016-09-16|September 30, 2014|Actual|2014-09-30||Interventional||Intent-to-Treat (ITT) Population: All participants randomized in the study.|A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)|A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer|Completed||Phase 3|1095|Actual|Hoffmann-La Roche||3|||f|||||t|f||||||||2018-05-31 23:49:02.317197|2018-05-31 23:49:02.317197
NCT01120171|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2015-10-06|2010-05-07|2010-05-10|Estimate|||||||2015-10-06|2015-10-07|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Myocet Plus Endoxan for Older Patients With Breast Cancer|Liposome-encapsulated Doxorubicin (Myocet) Plus Cyclophosphamide as First or Second Line Therapy for Older Patients With Metastatic Breast Cancer|Terminated||Phase 2|64|Actual|Hellenic Oncology Research Group||1||Due to poor accrual|f||||f||||||||||2018-05-31 23:49:05.63301|2018-05-31 23:49:05.63301
NCT01120158|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2017-02-22|2010-05-07|2010-05-10|Estimate|||||||2017-02-22|2017-02-23|Actual|September 2009||2009-09-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer|Biweekly Paclitaxel Plus Bevacizumab as First Line Treatment for Older Patients With Metastatic Breast Cancer|Terminated||Phase 2|46|Actual|Hellenic Oncology Research Group||1||Due to poor accrual|f||||f||||||||||2018-05-31 23:49:05.825427|2018-05-31 23:49:05.825427
NCT01120145|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-02-05|2010-05-07|2010-05-10|Estimate|||||||2013-02-05|2013-02-06|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Assessment of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi|Assessment of the Efficacy and Effectiveness of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi|Completed|||1410|Actual|Centers for Disease Control and Prevention|||3||f||||f||||||Samples With DNA|"~     Blood spots will be collected from parasitemic patients to look at malaria prasite molecular~     markers of resistance to sulphadoxine-pyrimethamine.~   "|||2018-05-31 23:49:05.988997|2018-05-31 23:49:05.988997
NCT01120132|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2012-03-08|2010-05-07|2010-05-10|Estimate|||||||2012-03-08|2012-03-09|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Administration of FOV1101-00 (Cyclosporine Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Mild Ongoing Ocular Allergic Inflammation|Completed||Phase 2|716|Actual|Fovea Pharmaceuticals SA||6|||f||||f||||||||||2018-05-31 23:49:06.070738|2018-05-31 23:49:06.070738
NCT01120119|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-07|2010-05-07|2010-05-10|Estimate|||||||2010-05-07|2010-05-10|Estimate||||March 2005|2005-03-31||||||||Interventional|IMDIABXIII||Efficacy of Calcitriol in Recent Onset Type 1 Diabetes|Clinical Study to Evaluate the Efficacy of 1,25(OH)2D3 (Calcitriol) Versus Placebo in Recent Onset Type 1 Diabetes(IMDIAB XIII)|Completed||Phase 2|||Campus Bio-Medico University||2|||f||||f||||||||||2018-05-31 23:49:06.156533|2018-05-31 23:49:06.156533
NCT01120106|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2012-06-22|2010-05-07|2010-05-10|Estimate|||||||2012-06-22|2012-06-26|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|||Levosimendan Administration in Neonates With Transposition of the Great Arteries|Perioperative Levosimendan Administration in Neonates With Transposition of the Great Arteries: Randomized Controlled Trial|Completed||Phase 2|63|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 23:49:06.238823|2018-05-31 23:49:06.238823
NCT01120093|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|2012-08-14||2016-11-17|2010-05-07|2010-05-10|Estimate|2012-08-14|2012-09-12|Estimate||||2016-11-17|2017-01-09|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.|Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator All Administered Twice Daily by Inhalation in Patients With Stable Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 2|79|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 23:49:06.336742|2018-05-31 23:49:06.336742
NCT01120080|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-01-18|2010-05-06|2010-05-10|Estimate|||||||2013-01-18|2013-01-21|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Alcohol Counseling for Telephone Quitline Callers|Advancing Tobacco and Cancer Control: Reducing Alcohol Use to Promote Smoking Cessation|Completed||Phase 1/Phase 2|1948|Actual|Yale University||2|||f||||t||||||||||2018-05-31 23:49:06.771738|2018-05-31 23:49:06.771738
NCT01120067|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2016-10-24||2017-03-13|2010-05-07|2010-05-10|Estimate|2016-10-24|2016-12-16|Estimate||||2017-03-13|2017-04-12|Actual|August 1, 2010|Actual|2010-08-01|March 2017|2017-03-31|December 29, 2016|Actual|2016-12-29|August 1, 2015|Actual|2015-08-01||Interventional|||Intensive Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)|Intensive Treatment of Chronic Pain and PTSD for OEF/OIF Veterans|Completed||N/A|23|Actual|VA Office of Research and Development|Small N due to challenges associated with recruitment.|2|||f||||f||||||||No||2018-05-31 23:49:06.885391|2018-05-31 23:49:06.885391
NCT01120054|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2017-05-11|2010-05-07|2010-05-10|Estimate|||||||2017-05-11|2017-05-12|Actual|May 2010||2010-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Traumatic Brain Injury Among Homeless Veterans|Traumatic Brain Injury Among Homeless Veterans|Active, not recruiting|||2000|Anticipated|VA Eastern Colorado Health Care System|||||f||||f||||||||||2018-05-31 23:49:07.131843|2018-05-31 23:49:07.131843
NCT01120041|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2011-01-10|2010-05-06|2010-05-10|Estimate|||||||2011-01-10|2011-01-12|Estimate|May 2010||2010-05-31|January 2011|2011-01-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|Baby Smiles||Community-based Intergenerational Oral Health Study|Community-based Intergenerational Oral Health Promotion In Rural America|Unknown status|Recruiting|Phase 3|400|Anticipated|University of Washington||4|||f||||t||||||||||2018-05-31 23:49:07.197909|2018-05-31 23:49:07.197909
NCT01120028|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2017-05-03|2010-05-06|2010-05-10|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2010||2010-09-30|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2014|Actual|2014-02-28||Interventional|3C||Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy|Open-label, Randomised Multicentre Study of CAMPATH-1H Versus Basiliximab Induction Treatment and Sirolimus Versus Tacrolimus Maintenance Treatment for the Preservation of Renal Function in Patients Receiving Kidney Transplants|Active, not recruiting||Phase 2/Phase 3|800|Anticipated|University of Oxford||4|||f||||t||||||||Undecided||2018-05-31 23:49:07.294645|2018-05-31 23:49:07.294645
NCT01120015|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2010-05-28|2010-05-07|2010-05-10|Estimate|||||||2010-05-28|2010-05-31|Estimate|January 2007||2007-01-31|May 2009|2009-05-31|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Diacerein as Adjuvant to Diclofenac Sodium in Indian Patients of Osteoarthritis (OA) Knee|Phase 4 Study of Diacerein as Adjuvant to Diclofenac Sodium in Indian Patients of OA Knee|Completed||Phase 4|84|Actual|Government Medical College, Amritsar||1|||f||||f||||||||||2018-05-31 23:49:07.396745|2018-05-31 23:49:07.396745
NCT01120002|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-07-21|2010-05-07|2010-05-10|Estimate|||||||2011-07-21|2011-07-22|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease||Unknown status|Recruiting|Phase 2|50|Anticipated|Osaka City University||2|||f||||||||||||||2018-05-31 23:49:07.485912|2018-05-31 23:49:07.485912
NCT01119989|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2018-05-01|2010-05-07|2010-05-10|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2010||2010-05-31|May 2018|2018-05-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|AMINOFRUCT||Effects of an Amino-acid Supplement on Hepatic Lipid Metabolism|Effects of a Supplementation With Amino-acids on Hepatic Lipid Metabolism|Completed||N/A|9|Actual|University of Lausanne||3|||f||||f||||||||||2018-05-31 23:49:07.721477|2018-05-31 23:49:07.721477
NCT01119976|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2012-12-06|2010-05-06|2010-05-10|Estimate|||||||2012-12-06|2012-12-07|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Association Between the Menstrual Cycle and Weight Loss|Evaluation of the Association Between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|Completed||N/A|20|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 23:49:07.790721|2018-05-31 23:49:07.790721
NCT01119963|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2018-03-20||2018-04-30|2010-05-06|2010-05-10|Estimate|2018-04-30|2018-05-30|Actual||||2018-04-30|2018-05-30|Actual|October 2011||2011-10-31|April 2018|2018-04-30|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|17PinPROM|Age, Continuous|Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)|17-alpha-Hydroxyprogesterone Caproate (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM), Double-blinded Randomized Clinical Trial|Completed||Phase 2/Phase 3|152|Actual|Mednax Center for Research, Education, Quality and Safety|One limitation is that we only studied one dose of 17OHPc (250mg) and only one frequency (once a week) however we did this to coincide with the study that showed benefits of 17OHPc in women with intact membranes with a history of preterm birth.|2|||f||||t||||||||||2018-05-31 23:49:07.892024|2018-05-31 23:49:07.892024
NCT01119950|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2013-01-23|2011-10-24|2015-03-03|2010-05-07|2010-05-10|Estimate|2014-03-19|2014-04-15|Estimate|2011-10-24|2011-10-26|Estimate|2015-03-03|2015-03-23|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Baseline/demographic measures are based on safety set|Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, 2-period, Cross-over Study to Assess the Efficacy and Safety of Differing Doses of NVA237 Administered Either Once Daily or Twice Daily, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|388|Actual|Novartis||8|||f||||||||||||||2018-05-31 23:49:08.389478|2018-05-31 23:49:08.389478
NCT01119937|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2012-11-20||2012-12-12|2010-05-07|2010-05-10|Estimate|2012-12-12|2013-01-18|Estimate||||2012-12-12|2013-01-18|Estimate|May 2010||2010-05-31|November 2012|2012-11-30||||November 2011|Actual|2011-11-30||Interventional|GLOW4||Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Tolerability of NVA237 (50µg o.d.) Using Tiotropium (18µg o.d.) as an Active Control in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|211|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:49:10.561493|2018-05-31 23:49:10.561493
NCT01119924|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2011-06-07|2010-05-07|2010-05-10|Estimate|||||||2011-06-07|2011-06-09|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain|Phase IV Study for Evaluation the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain|Completed||Phase 4|30|Anticipated|Nang Kuang Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 23:49:11.309032|2018-05-31 23:49:11.309032
NCT01119911|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2012-03-16|2010-05-07|2010-05-10|Estimate|||||||2012-03-16|2012-03-19|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|||||Observational|||Blood Sampling Through Peripheral Venous Catheter in Infants|Blood Sampling Through Peripheral Venous Catheter for Selected Basic Analytes in Infants|Unknown status|Recruiting||50|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:49:11.375456|2018-05-31 23:49:11.375456
NCT01119898|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2011-04-20|2010-05-07|2010-05-10|Estimate|||||||2011-04-20|2011-04-21|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Evaluation of the Safety and Efficacy of PENNSAID Gel in the Treatment of Osteoarthritis of the Knee|A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Clinical Study to Evaluate the Safety and Efficacy of PENNSAID Gel in the Symptomatic Treatment of Osteoarthritis of the Knee|Completed||Phase 2|260|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 23:49:11.516758|2018-05-31 23:49:11.516758
NCT01119885|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2014-04-24|2010-05-06|2010-05-10|Estimate|||||||2014-04-24|2014-04-28|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Observational Study Investigating the Effectiveness of Fentanyl Matrix in Relieving Pain and Improving Function in Patients With Osteoarthritis of the Knee or Hip|Fentanyl Matrix for the Treatment of Pain Caused by Osteoarthritis of the Knee or Hip: Improvement of Pain and Function: Multicenter, Open-label, Prospective, Observational Study|Completed|||742|Actual|Janssen Korea, Ltd., Korea|||2||f||||||||||||||2018-05-31 23:49:11.687009|2018-05-31 23:49:11.687009
NCT01119872|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-07|2010-05-07|2010-05-10|Estimate|||||||2010-05-07|2010-05-10|Estimate|January 2003||2003-01-31|December 2002|2002-12-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|PEEP-HUPA||Pilot Study of Positive-End Expiratory Pressure in Acute Respiratory Distress Syndrome|Randomized Controlled Pilot Study of Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome(ARDS): Individualized According to the Best Compliance or Fixed According to Fraction of Inspired Oxygen (FiO2) Applied|Completed||N/A|70|Actual|Hospital Universitario Principe de Asturias||2|||f||||f||||||||||2018-05-31 23:49:11.812752|2018-05-31 23:49:11.812752
NCT01119859|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2012-09-18||2013-01-10|2010-05-06|2010-05-10|Estimate|2013-01-10|2013-02-11|Estimate||||2013-01-10|2013-02-11|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis|A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis|Completed||Phase 4|326|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:49:11.953466|2018-05-31 23:49:11.953466
NCT01119846|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2017-09-21|2012-03-22|2017-12-18|2010-05-06|2010-05-10|Estimate|2017-12-18|2018-01-17|Actual|2012-03-22|2012-03-28|Estimate|2017-12-18|2018-01-17|Actual|June 5, 2009|Actual|2009-06-05|November 2017|2017-11-30|March 19, 2010|Actual|2010-03-19|March 19, 2010|Actual|2010-03-19||Interventional|||A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics|A Study in Type II Diabetic Subjects of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin or Metformin|Completed||Phase 2|100|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:49:12.814058|2018-05-31 23:49:12.814058
NCT01117922|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2015-03-11|2010-05-04|2010-05-06|Estimate|||||||2015-03-11|2015-03-12|Estimate|November 2004||2004-11-30|May 2010|2010-05-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|PPP||Philadelphia Preterm Prevention Project|Philadelphia Collaborative Preterm Prevention Project|Completed||N/A|1136|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 23:49:54.952058|2018-05-31 23:49:54.952058
NCT01119833|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05||2014-02-06|2014-02-06|2010-05-06|2010-05-10|Estimate||||2014-02-06|2014-03-10|Estimate|2014-02-06|2014-03-10|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis|Completed||Phase 2|76|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:49:16.273564|2018-05-31 23:49:16.273564
NCT01119820|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2013-07-18|2010-05-06|2010-05-10|Estimate|||||||2013-07-18|2013-07-22|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|February 2010|Actual|2010-02-28||Interventional|||Tissue Donation for Myoblast Culture|Tissue Donation for Myoblast Culture|Completed||N/A|24|Actual|University of California, Irvine||1|||f||||t||||||||||2018-05-31 23:49:16.408386|2018-05-31 23:49:16.408386
NCT01119807|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2012-08-03|2010-05-07|2010-05-10|Estimate|||||||2012-08-03|2012-08-07|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Intraosseous Versus Intravenous Vascular Access During Cardiac Arrest|Intraosseous Versus Intravenous Vascular Access During Cardiac Arrest|Completed||N/A|182|Actual|Carolinas Medical Center||3|||f||||t||||||||||2018-05-31 23:49:16.530748|2018-05-31 23:49:16.530748
NCT01119794|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2015-07-15||2015-08-12|2010-05-07|2010-05-10|Estimate|2015-07-17|2015-08-11|Estimate||||2015-08-12|2015-08-26|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab|Ofatumumab in Combination With Bortesomib in Patients With Relapsed or Refractory Low-Grade Non-Hodgkins Lymphoma|Terminated||Phase 2|10|Actual|Brown University||1||lack of accrual|f||||t||||||||||2018-05-31 23:49:16.692645|2018-05-31 23:49:16.692645
NCT01119781|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-05-29|2010-05-07|2010-05-10|Estimate|||||||2014-05-29|2014-06-02|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers|An Open-Label, Single-dose, Pharmacokinetic, Pharmacodynamic, and Safety Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Subjects and Subjects With Renal Impairment|Completed||Phase 1|35|Actual|Biogen||1|||f||||f||||||||||2018-05-31 23:49:17.085237|2018-05-31 23:49:17.085237
NCT01119768|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2012-06-01||2012-09-26|2010-05-07|2010-05-10|Estimate|2012-09-26|2012-09-28|Estimate||||2012-09-26|2012-09-28|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients|A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen|Completed||Phase 4|305|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:49:17.231053|2018-05-31 23:49:17.231053
NCT01119755|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2011-12-08||2011-12-08|2010-05-06|2010-05-10|Estimate|2011-12-08|2012-01-23|Estimate||||2011-12-08|2012-01-23|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Seasonal Variation of Ambulatory Blood Pressure|Seasonal Variation of 24hour Ambulatory Blood Pressure Monitoring in Treated Hypertensives|Completed|||80|Actual|University of Athens|||||f||||f||||||||||2018-05-31 23:49:17.681691|2018-05-31 23:49:17.681691
NCT01119742|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-05-05|2010-05-06|2010-05-10|Estimate|||||||2014-05-05|2014-05-06|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|BNF-0909||Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams to Lotrimin Ultra® Cream in Patients With Interdigital Tinea Pedis|Terminated||Phase 1|428|Actual|Taro Pharmaceuticals USA||5||Insufficient number of baseline eligible patient|f||||f||||||||||2018-05-31 23:49:17.932298|2018-05-31 23:49:17.932298
NCT01119729|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-07|||2010-05-07|2010-05-07|2010-05-10|Estimate|||||||2010-05-07|2010-05-10|Estimate||||May 2010|2010-05-31||||||||Observational|||Cardiovascular Diseases in HIV-infected Subjects (HIV-HEART Study)||Completed|||803|Actual|University Hospital, Essen|||1||f||||t||||||||||2018-05-31 23:49:18.027702|2018-05-31 23:49:18.027702
NCT01119716|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2013-12-13||2015-10-30|2010-05-06|2010-05-07|Estimate|2013-12-13|2014-01-30|Estimate||||2015-10-30|2015-11-26|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|RHYTHM-AF||International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)|International Registry on Cardioversion of Atrial Fibrillation|Completed|||4658|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:49:18.268142|2018-05-31 23:49:18.268142
NCT01119703|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2012-10-16||2015-11-30|2010-05-06|2010-05-07|Estimate|2012-10-16|2012-11-22|Estimate||||2015-11-30|2015-12-29|Estimate|July 2010||2010-07-31|November 2015|2015-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)|A Phase I, Open-Label Observational Study to Develop a Prospective Predictor of Vaccine Hyporesponse in Healthy Elderly Subjects|Completed|||174|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||Samples With DNA|"~     Cryopreserved peripheral blood mononuclear cells (PBMCs) obtained from whole blood samples.~   "|||2018-05-31 23:49:18.813512|2018-05-31 23:49:18.813512
NCT01119690|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-06|2010-05-06|2010-05-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|September 2004||2004-09-30|May 2010|2010-05-31|June 2008|Actual|2008-06-30|April 2005|Actual|2005-04-30||Interventional|HMS-03||Hämeenlinna Metabolic Syndrome Research Program: Effects of Rapeseed Oil on Serum Lipids and Platelet Function|Hämeenlinna Metabolic Syndrome Research Program (HMS): Effects of Dietary Cold-pressed Turnip Rapeseed Oil and Milk Fat on Serum Lipids, Oxidized LDL, Arterial Elasticity and Platelet Function|Completed||N/A|43|Actual|Central Hospital of Kanta-Hame||2|||f||||f||||||||||2018-05-31 23:49:19.203778|2018-05-31 23:49:19.203778
NCT01119677|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2017-11-15|2010-05-06|2010-05-07|Estimate|||||||2017-11-15|2017-11-17|Actual|May 5, 2010|Actual|2010-05-05|November 2017|2017-11-30|October 23, 2010|Actual|2010-10-23|October 23, 2010|Actual|2010-10-23||Interventional|||A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers|A Randomized, Three-Arm, Dose-Blinded, Parallel-Group Study to Determine the Effect of Avonex® Dose Titration on the Severity and Incidence of Interferon Beta-1a-Related Flu Like Symptoms in Healthy Volunteers|Completed||Phase 1|120|Actual|Biogen||3|||f||||f||||||||||2018-05-31 23:49:19.311118|2018-05-31 23:49:19.311118
NCT01119664|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2016-10-10|2010-05-06|2010-05-07|Estimate|||||||2016-10-10|2016-10-11|Estimate|April 2010||2010-04-30|October 2016|2016-10-31||||October 2013|Actual|2013-10-31||Interventional|||Combination Gene Transfer and Chemotherapy|A Pilot And Feasibility Trial Evaluating Two Different Chemotherapy Regimens In Combination With Intrapleural Adenoviral-Mediated Interferon-Alpha Gene Transfer For Malignant Pleural Mesothelioma|Active, not recruiting||Phase 1/Phase 2|40|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:49:19.424403|2018-05-31 23:49:19.424403
NCT01119651|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2017-06-12|2010-05-06|2010-05-07|Estimate|||||||2017-06-12|2017-06-14|Actual|June 14, 2010|Actual|2010-06-14|June 2017|2017-06-30|June 26, 2010|Actual|2010-06-26|June 26, 2010|Actual|2010-06-26||Interventional|||A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Photoallergic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Completed||Phase 1|59|Actual|GlaxoSmithKline||9|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:49:19.696248|2018-05-31 23:49:19.696248
NCT01119638|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-06-23|2010-05-06|2010-05-07|Estimate|||||||2015-06-23|2015-06-24|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|EscBPSD||Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone|Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients|Completed||Phase 4|40|Actual|Abarbanel Mental Health Center||2|||f||||t||||||||||2018-05-31 23:49:19.84117|2018-05-31 23:49:19.84117
NCT01119625|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2012-02-16|2011-04-01|2016-09-09|2010-05-06|2010-05-07|Estimate|2012-02-16|2012-03-22|Estimate|2011-04-01|2011-04-11|Estimate|2016-09-09|2016-10-20|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose|Evaluation of Immunological Persistence Following 3-dose Priming With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine in Study NCT00808444 and Safety and Immunogenicity Following a Booster Dose of the Same Vaccine|Completed||Phase 3|238|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:49:19.988576|2018-05-31 23:49:19.988576
NCT01119612|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2015-04-22|2010-05-06|2010-05-07|Estimate|||||||2015-04-22|2015-04-24|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|MAL1||Prenatal Iron Supplements: Safety and Efficacy in Tanzania|Prenatal Iron Supplements: Safety and Efficacy in Tanzania|Completed||N/A|1500|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 23:49:22.069372|2018-05-31 23:49:22.069372
NCT01119599|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-09-28|2010-05-06|2010-05-07|Estimate|||||||2015-09-28|2015-09-29|Estimate|May 2010||2010-05-31|June 2015|2015-06-30||||June 2013|Actual|2013-06-30||Interventional|||RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma|Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study|Completed||Phase 1|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:49:22.264467|2018-05-31 23:49:22.264467
NCT01119586|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2016-07-07|2010-05-06|2010-05-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2013||2013-02-28|July 2016|2016-07-31||||December 2015|Actual|2015-12-31||Observational|||Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia|Identifying Rare Genetic Variants Involved in High Risk Acute Lymphoblastic Leukemia (ALL) Via Pooled DNA Sequencing|Completed|||350|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-05-31 23:49:22.381623|2018-05-31 23:49:22.381623
NCT01119573|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-06-17|2010-05-06|2010-05-07|Estimate|||||||2010-06-17|2010-06-22|Estimate|May 2010||2010-05-31|May 2010|2010-05-31||||June 2010|Anticipated|2010-06-30||Observational|||Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer|Micro RNA's Associated With Lymph Node Metastasis in Endometrial Cancer|Unknown status|Not yet recruiting||100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:49:22.481385|2018-05-31 23:49:22.481385
NCT01119560|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2018-03-08|2010-05-06|2010-05-07|Estimate|||||||2018-03-08|2018-03-09|Actual|February 2012||2012-02-29|March 2018|2018-03-31|November 2032|Anticipated|2032-11-30|November 2032|Anticipated|2032-11-30||Observational|||Genetic Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])|Observational - Genetic Susceptibility Factors in the Etiology of Neuroblastoma Also Known as Neuroblastoma Epidemiology in North America (NENA)|Active, not recruiting|||700|Anticipated|Children's Oncology Group|||1||f||||t||||||Samples With DNA|"~     buccal cells~   "|||2018-05-31 23:49:22.56074|2018-05-31 23:49:22.56074
NCT01119547|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-05-06|2010-05-06|2010-05-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|September 2010||2010-09-30|April 2010|2010-04-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|PEPOA-E||Patient Education Program for Osteoarthritis With Exercise Included|The Effect of Including Exercise in an Education Program for Patients With Osteoarthritis in Primary Health Care|Unknown status|Not yet recruiting|N/A|100|Anticipated|Lund University||2|||f||||f||||||||||2018-05-31 23:49:22.700358|2018-05-31 23:49:22.700358
NCT01119534|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-01-27|2010-05-06|2010-05-07|Estimate|||||||2011-01-27|2011-01-28|Estimate|May 2011||2011-05-31|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin|Comparative Efficacy of the Suppository Composed by Guaiacol, Eucalyptol, Menthol and Camphor Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin|Unknown status|Not yet recruiting|Phase 3|270|Anticipated|Azidus Brasil||3|||f||||f||||||||||2018-05-31 23:49:22.810241|2018-05-31 23:49:22.810241
NCT01119521|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-01-05|2010-05-06|2010-05-07|Estimate|||||||2017-01-05|2017-01-09|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination|Phase I Study of Whether Preclearance of Latent M. Tuberculosis (MTB) Infection With Isoniazid (INH) Enhances Specific Immune Responses to MTB Following Subsequent BCG Revaccination in Healthy, HIV-Uninfected, Tuberculin Skin Test Positive Adults|Completed||Phase 1|82|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 23:49:22.943677|2018-05-31 23:49:22.943677
NCT01119508|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2016-08-16|2010-05-06|2010-05-07|Estimate|||||||2016-08-16|2016-08-17|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Ipilimumab + Temozolomide in Metastatic Melanoma|Phase II Study of Ipilimumab Plus Temozolomide in Patients With Metastatic Melanoma|Completed||Phase 2|64|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:49:23.086577|2018-05-31 23:49:23.086577
NCT01119482|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-04-18|2010-05-06|2010-05-07|Estimate|||||||2013-04-18|2013-04-19|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|MenAfriCar||Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage|The Impact of Vaccination With a Serogroup A Meningococcal Conjugate Vaccine on Carriage of Serogroup A Meningococci in Mali and Niger|Completed||Phase 4|33000|Actual|London School of Hygiene and Tropical Medicine||1|||f||||t||||||||||2018-05-31 23:49:23.191396|2018-05-31 23:49:23.191396
NCT01119469|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2014-08-05|2010-05-06|2010-05-07|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2010||2010-06-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis|Dysfunctional Illness-related Cognitions in Individuals With Hypochondriasis and Change Thereof|Completed||Phase 3|84|Actual|Goethe University||3|||f||||f||||||||||2018-05-31 23:49:23.297533|2018-05-31 23:49:23.297533
NCT01119456|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2014-01-08|2010-05-06|2010-05-07|Estimate|||||||2014-01-08|2014-01-09|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of IMC-RON8 in Advanced Solid Tumors|Phase 1 Study of the Anti-Ron Receptor Monoclonal Antibody IMC-RON8 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available|Completed||Phase 1|52|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:49:23.42861|2018-05-31 23:49:23.42861
NCT01119443|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2011-05-30||2014-06-03|2010-05-06|2010-05-07|Estimate|2011-05-30|2011-06-27|Estimate||||2014-06-03|2014-06-09|Estimate|April 2010||2010-04-30|May 2014|2014-05-31||||June 2010|Actual|2010-06-30||Interventional|||Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers|A Multiple Dose Study With Increasing Dose for Pramipexole Extended Release (ER) Tablet (0.375 mg q.d. to 1.5 mg q.d.) in Two-way Cross-over Comparison to Investigate the Bioequivalence of 1.5 mg ER x 1 Tablet q.d. Versus 0.375 mg ER x 4 Tablets q.d. Under Fasted and Fed Conditions in Japanese Healthy Male Volunteers|Completed||Phase 1|28|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:49:23.551225|2018-05-31 23:49:23.551225
NCT01119430|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-06|2010-05-06|2010-05-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|May 2004||2004-05-31|May 2010|2010-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Fluoxetine Versus Fluoxetine Plus DU125530 in Major Depressive Disorder|Fluoxetine Versus Fluoxetine Plus DU125530 in Latency of Antidepressant Response Shortening in Major Depressive Disorder|Terminated||Phase 2|50|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||interim analysis suggested no differences with whole sample|f||||t||||||||||2018-05-31 23:49:24.305092|2018-05-31 23:49:24.305092
NCT01119417|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2018-01-23|2010-05-05|2010-05-07|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2010||2010-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Role of Endothelin in the Supine Hypertension of Autonomic Failure|The Role of Endothelin in the Supine Hypertension of Autonomic Failure|Enrolling by invitation||Phase 1|12|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 23:49:24.419873|2018-05-31 23:49:24.419873
NCT01119404|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-05-10|2010-05-06|2010-05-07|Estimate|||||||2010-05-10|2010-05-11|Estimate|June 2003||2003-06-30|May 2010|2010-05-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|HMS-02||Hämeenlinna Metabolic Syndrome Research Program: Surrogate Indicators for Atherosclerosis|Hämeenlinna Metabolic Syndrome Research Program (HMS): Surrogate Indicators for Atherosclerosis in Men With Metabolic Syndrome, Coronary Heart Disease and Controls|Unknown status|Recruiting||300|Anticipated|Central Hospital of Kanta-Hame|||3||f||||f||||||Samples Without DNA|"~     serum, EDTA plasma, citrate plasma~   "|||2018-05-31 23:49:24.517661|2018-05-31 23:49:24.517661
NCT01119391|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2016-02-03|2010-05-06|2010-05-07|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||The Impact of Lifestyle Behaviors on In Vitro Fertilization (IVF) Outcome|The Impact of Lifestyle Behaviors on IVF Outcome|Completed|||118|Actual|Boston IVF|||1||f||||f||||||||No||2018-05-31 23:49:24.624598|2018-05-31 23:49:24.624598
NCT01119378|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2014-12-30|2010-05-05|2010-05-07|Estimate|||||||2014-12-30|2014-12-31|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study to Observe the Capability to Absorb Calcium as an Measure of Adequate Levels of Vitamin D|Calcium Absorption Efficiency As An Indicator For Vitamin D Sufficiency|Completed||N/A|76|Actual|Winthrop University Hospital||1|||f||||f||||||||||2018-05-31 23:49:24.704204|2018-05-31 23:49:24.704204
NCT01119365|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2018-01-03|2010-05-06|2010-05-07|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2011||2011-07-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Bright Light as a Countermeasure for Circadian Desynchrony|Bright Light as a Countermeasure for Circadian Desynchrony|Recruiting||N/A|80|Anticipated|VA Palo Alto Health Care System||1|||f||||f||||||||||2018-05-31 23:49:24.822853|2018-05-31 23:49:24.822853
NCT01119352|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2012-01-18|2010-05-06|2010-05-07|Estimate|||||||2012-01-18|2012-01-19|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||AZD7687 Multiple Ascending Dose Study|A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Multiple Ascending Doses in Overweight to Obese But Otherwise Healthy Male Subjects|Completed||Phase 1|45|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:49:24.952802|2018-05-31 23:49:24.952802
NCT01119339|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2015-05-28|2010-05-06|2010-05-07|Estimate|||||||2015-05-28|2015-05-29|Estimate|July 2010||2010-07-31|May 2015|2015-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis|An Investigator-blind, Controlled Study to Assess the Efficacy of Six Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test|Completed||Phase 2|20|Anticipated|Almirall, S.A.||8|||f||||f||||||||||2018-05-31 23:49:25.041486|2018-05-31 23:49:25.041486
NCT01119326|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2017-07-18|2010-05-06|2010-05-07|Estimate|||||||2017-07-18|2017-07-21|Actual|April 2010||2010-04-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Autologous Fat Transfer for Scar Prevention and Remodeling|A Phase I/II Study of Autologous Fat Transfer for Scar Prevention and Remodeling|Completed||Phase 1/Phase 2|14|Actual|University of Florida||2|||f||||t||||||||No||2018-05-31 23:49:25.141303|2018-05-31 23:49:25.141303
NCT01119313|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-07-09|2010-05-06|2010-05-07|Estimate|||||||2010-07-09|2010-07-12|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema|A Phase II, Single-center, Randomized, Controlled, Double-blind Study to Assess Effects on Skin Conditions and Patient Reported Outcome of a Topical Formulation Containing LAS41002 on Lesional Skin in Patients With Atopic Eczema|Completed||Phase 2|20|Actual|Almirall, S.A.||2|||f||||f||||||||||2018-05-31 23:49:25.238246|2018-05-31 23:49:25.238246
NCT01119300|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2014-12-02|2010-05-06|2010-05-07|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EU-PACT||EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin|EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin|Completed||Phase 4|455|Actual|Utrecht Institute for Pharmaceutical Sciences||2|||f||||t||||||||||2018-05-31 23:49:25.314032|2018-05-31 23:49:25.314032
NCT01119287|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2013-01-28||2014-02-27|2010-05-06|2010-05-07|Estimate|2013-03-04|2013-03-06|Estimate||||2014-02-27|2014-02-28|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis|A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model|Completed||Phase 4|180|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 23:49:25.43762|2018-05-31 23:49:25.43762
NCT01119274|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2013-06-17|2010-05-06|2010-05-07|Estimate|||||||2013-06-17|2013-06-18|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|EU-PACT||EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon|EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon|Completed||Phase 4|970|Anticipated|Utrecht Institute for Pharmaceutical Sciences||2|||f||||t||||||||||2018-05-31 23:49:25.843673|2018-05-31 23:49:25.843673
NCT01119261|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2013-06-17|2010-05-06|2010-05-07|Estimate|||||||2013-06-17|2013-06-18|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|EU-PACT||EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol|EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol|Completed||Phase 4|970|Anticipated|Utrecht Institute for Pharmaceutical Sciences||2|||f||||t||||||||||2018-05-31 23:49:25.937003|2018-05-31 23:49:25.937003
NCT01119248|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2013-01-24|2010-05-06|2010-05-07|Estimate|||||||2013-01-24|2013-01-25|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Pediatric Temperature Variation in the MRI Scanner Under General Anesthesia|Pediatric Temperature Variation in the MRI Scanner Under General Anesthesia|Completed|||121|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||||||2018-05-31 23:49:26.041295|2018-05-31 23:49:26.041295
NCT01119235|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-08-05|2010-05-05|2010-05-07|Estimate|||||||2010-08-05|2010-08-06|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.|A Phase 1, Open Label Study To Investigate The Pharmacokinetics Of Multiple Doses Of PF-04531083 Tablets In Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:49:26.215603|2018-05-31 23:49:26.215603
NCT01119222|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2010-10-12||2011-02-10|2010-05-06|2010-05-07|Estimate|2011-02-10|2011-03-07|Estimate||||2011-02-10|2011-03-07|Estimate|July 2008||2008-07-31|February 2011|2011-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers|A Randomised, Double-Blind, Double-Dummy, Placebo And Active Controlled, 4-Way Crossover Methodology Study To Assess The Effect Of Gabapentin, Diphenhydramine And Morphine On Cold Pain In Healthy Male Volunteers|Completed||Phase 1|19|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:49:26.325106|2018-05-31 23:49:26.325106
NCT01119209|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-03-15|2010-05-05|2010-05-07|Estimate|||||||2011-03-15|2011-03-16|Estimate|February 2008||2008-02-29|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Postoperative Analgesia With Local Infiltration After Hip Fracture Of Intertrochanteric Type|Postoperative Analgesia With Local Infiltration After Hip Fracture Of Intertrochanteric Type|Completed||Phase 4|74|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 23:49:26.893835|2018-05-31 23:49:26.893835
NCT01119196|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2016-09-22|2010-05-05|2010-05-07|Estimate|||||||2016-09-22|2016-09-26|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Measurement of Insulin Resistance in Peritoneal Dialysis Patients|The Measurement of Insulin Resistance in Peritoneal Dialysis Patients|Completed||N/A|10|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 23:49:27.013209|2018-05-31 23:49:27.013209
NCT01119183|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2011-07-22|2010-05-05|2010-05-07|Estimate|||||||2011-07-22|2011-07-26|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Improving Patient Understanding of Preeclampsia|Improving Patient Understanding of Preeclampsia|Completed||N/A|120|Anticipated|Northwestern University||3|||f||||f||||||||||2018-05-31 23:49:27.093713|2018-05-31 23:49:27.093713
NCT01119170|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-04-24|2010-05-05|2010-05-07|Estimate|||||||2012-04-24|2012-04-25|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Safety of D-lactate Producing Probiotics|Safety Assessment of a Starter Formula Containing D-lactate Producing Probiotics|Completed||N/A|88|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 23:49:27.187414|2018-05-31 23:49:27.187414
NCT01119157|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-06|2010-05-06|2010-05-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|August 2010|Anticipated|2010-08-31|March 2009|Actual|2009-03-31||Interventional|FLUSECUOEKH1||Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines|Comparison of the Cellular and the Humoral Immunogenicity as Well as the Safety of Different Trivalent Influenza Vaccines in Healthy Adults Between 18 and 60 Years of Age|Unknown status|Active, not recruiting|Phase 4|85|Actual|National Centre for Epidemiology, Hungary||2|||f||||t||||||||||2018-05-31 23:49:27.272006|2018-05-31 23:49:27.272006
NCT01119144|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2014-04-24|2010-05-06|2010-05-07|Estimate|||||||2014-04-24|2014-04-28|Estimate|April 2010||2010-04-30|April 2014|2014-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|PCL/TCP||Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial|Comparing the Reconstruction of the Orbit Fracture With a Poly Caprolactone / Tri-Calcium Phosphate ( PCL/TCP ) Implant vs. a Titanium Mesh Implant.|Unknown status|Recruiting|Phase 2|80|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 23:49:27.352353|2018-05-31 23:49:27.352353
NCT01119131|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2015-11-17||2016-02-08|2010-05-05|2010-05-07|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|May 2011||2011-05-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Vitamin D in Parkinson's Disease (PD)|The Effects of Vitamin D on Balance in Persons With PD|Completed||Phase 2|101|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 23:49:27.481466|2018-05-31 23:49:27.481466
NCT01119118|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2013-01-23||2013-03-18|2010-05-06|2010-05-07|Estimate|2013-03-18|2013-04-29|Estimate||||2013-03-18|2013-04-29|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer|Pharmacodynamic Response Assessment With PET/MRI Imaging in Patients With Metastatic Prostate CAncer to Bone Treated With ZD4054|Terminated||Phase 2|6|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 23:49:27.979126|2018-05-31 23:49:27.979126
NCT01119105|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05||2012-06-05|2012-07-02|2010-05-06|2010-05-07|Estimate||||2012-06-25|2012-07-02|Estimate|2012-07-02|2012-07-04|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|A Phase II, Multi-center, Randomized, Double-blind Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection|Completed||Phase 2|210|Actual|Nabriva Therapeutics AG||3|||f||||t||||||||||2018-05-31 23:49:28.183988|2018-05-31 23:49:28.183988
NCT01119092|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2011-05-26|2010-05-05|2010-05-07|Estimate|||||||2011-05-26|2011-05-30|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||The Effects of Gentle Movements at the Ankle in Individuals With Diminished Range of Motion|The Effects of Talocrural Joint Mobilizations in Individuals With Diminished Dorsiflexion Range of Motion After Ankle Sprain|Unknown status|Recruiting|N/A|40|Anticipated|University of Virginia||3|||f||||f||||||||||2018-05-31 23:49:28.255801|2018-05-31 23:49:28.255801
NCT01119079|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-04-23|2010-05-06|2010-05-07|Estimate|||||||2015-04-23|2015-04-24|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||Study to Determine Whether the Instillation of 10ml Normal Saline Improves Epidural Analgesia During Labor|A Randomized, Prospective Study to Establish Whether the Instillation of 10ml of Epidural Normal Saline Improves the Quality Of Epidural Analgesia During Labor|Withdrawn||Phase 3|0|Actual|Rutgers, The State University of New Jersey||2||PI unable to recruit appropriate patients|f||||f||||||||||2018-05-31 23:49:28.332742|2018-05-31 23:49:28.332742
NCT01119066|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2018-03-21|2010-05-05|2010-05-07|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2010||2010-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies|A Phase II Trial of Transplants From HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies and Other Lethal Hematologic Disorders|Recruiting||Phase 2|400|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 23:49:28.386316|2018-05-31 23:49:28.386316
NCT01119053|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2010-06-28|2010-05-06|2010-05-07|Estimate|||||||2010-06-28|2010-06-29|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|November 2012|Anticipated|2012-11-30|May 2012|Anticipated|2012-05-31||Interventional|Impuls-V||Effects of Vagus Nerve Stimulation (VNS) as a Treatment of Persistent Depression With Comorbid Personality Disorders (Impulse-VNS||Unknown status|Recruiting|N/A|40|Anticipated|University Medical Center Goettingen||2|||f||||f||||||||||2018-05-31 23:49:28.467743|2018-05-31 23:49:28.467743
NCT01119040|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|2010-10-14||2014-12-12|2010-05-06|2010-05-07|Estimate|2012-11-03|2012-12-03|Estimate||||2014-12-12|2015-01-05|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PEGRescue||"Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG Rescue"|"Prospective Evaluation of NOTES PEG Rescue"|Terminated||N/A|1|Actual|University Hospitals Cleveland Medical Center|Study terminated early due to difficulty with patient accrual due to lack of patient population.|1||Low accrual|f||||t||||||||||2018-05-31 23:49:28.630701|2018-05-31 23:49:28.630701
NCT01119027|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-12-12|2010-05-06|2010-05-07|Estimate|||||||2014-12-12|2014-12-15|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills|Assessing Effectiveness of Laparoscopic Colorectal Surgical Skills|Terminated|||83|Actual|University Hospitals Cleveland Medical Center|||2|slow accrual|f||||t||||||||||2018-05-31 23:49:28.76542|2018-05-31 23:49:28.76542
NCT01119014|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2014-10-02|2010-05-06|2010-05-07|Estimate|||||||2014-10-02|2014-10-03|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|February 2015|Anticipated|2015-02-28||Interventional|TEA||Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis|Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis|Unknown status|Active, not recruiting|Phase 4|300|Anticipated|University of Copenhagen||2|||f||||t||||||||||2018-05-31 23:49:28.849665|2018-05-31 23:49:28.849665
NCT01119001|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2015-05-27||2015-06-10|2010-05-05|2010-05-07|Estimate|2015-06-10|2015-06-12|Estimate||||2015-06-10|2015-06-12|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis|A P300 Brain Computer Interface Keyboard to Control Assistive Technology for People With Amyotrophic Lateral Sclerosis|Completed||N/A|13|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 23:49:28.949426|2018-05-31 23:49:28.949426
NCT01118988|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2016-02-10||2016-08-04|2010-05-06|2010-05-07|Estimate|2016-02-10|2016-03-09|Estimate||||2016-08-04|2016-09-30|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents|Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents|Completed||N/A|27|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 23:49:29.135338|2018-05-31 23:49:29.135338
NCT01118975|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2014-03-20||2017-04-19|2010-05-06|2010-05-07|Estimate|2014-03-20|2014-04-24|Estimate||||2017-04-19|2017-05-16|Actual|March 2010||2010-03-31|April 2017|2017-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers|GCC 0845: Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells|Terminated||Phase 1/Phase 2|12|Actual|University of Maryland|The most important limitation of this study is that the Phase II efficacy portion was terminated early by the sponsor.|2||Lost sponsorship for study drug|f||||t||||||||||2018-05-31 23:49:29.767332|2018-05-31 23:49:29.767332
NCT01118962|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2013-10-07||2018-03-09|2010-05-05|2010-05-07|Estimate|2013-10-07|2013-12-04|Estimate||||2018-03-09|2018-04-04|Actual|August 2010||2010-08-31|March 2018|2018-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||"Baseline measurements consist of the Safety Set (SS).~The Safety Set consists of all subjects that were dosed at least once with Lacosamide (LCM)."|Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy|An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy|Completed||Phase 2|39|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 23:49:30.077503|2018-05-31 23:49:30.077503
NCT01118949|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2012-08-08||2018-03-09|2010-05-06|2010-05-07|Estimate|2012-08-08|2012-09-07|Estimate||||2018-03-09|2018-04-04|Actual|May 2010||2010-05-31|March 2018|2018-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy|An Open-Label Pilot Study to Assess the Safety of Oral Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy|Completed||Phase 2|49|Actual|UCB Pharma||1|||f||||t||||||||||2018-05-31 23:49:30.308642|2018-05-31 23:49:30.308642
NCT01118936|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2013-09-03|2010-05-06|2010-05-07|Estimate|||||||2013-09-03|2013-09-04|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Daily Magnesium-treatment of Patients With Chronic Obstructive Pulmonary Disease|Daily Mablet-treatment of Patients With COPD|Completed||N/A|11|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:49:30.562596|2018-05-31 23:49:30.562596
NCT01118923|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2013-09-03|2010-05-06|2010-05-07|Estimate|||||||2013-09-03|2013-09-04|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Bronchial Challenge Test of Magnesium-treated Asthmatics|Metacholine-provocation of Mablet-treated Asthmatics|Completed||N/A|12|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:49:30.658247|2018-05-31 23:49:30.658247
NCT01118910|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2011-08-03|2010-05-06|2010-05-07|Estimate|||||||2011-08-03|2011-08-04|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of Intertrigo|Open-Label Pilot Study of the Efficacy and Safety of Vusion Ointment for the Treatment of Intertrigo|Completed||Early Phase 1|15|Anticipated|Image Dermatology P.C.||1|||f||||f||||||||||2018-05-31 23:49:30.752302|2018-05-31 23:49:30.752302
NCT01118897|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-08-05|2010-05-06|2010-05-07|Estimate|||||||2015-08-05|2015-08-07|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers|Concurrent Chemo-radiation Using Tomotherapy Based IMRT in Locally Advanced Gallbladder and Pancreatic Cancers :A Phase II Study|Completed||Phase 1/Phase 2|60|Actual|Tata Memorial Hospital||1|||f||||t||||||||||2018-05-31 23:49:30.822742|2018-05-31 23:49:30.822742
NCT01118884|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-05-06|2010-05-06|2010-05-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Interventional|||Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide for Uncooperative Children|Sedative Effects of Oral Midazolam in Comparison Promethazine With Nitrous Oxide/Oxygen on Behavior Management of Uncooperative Children Receiving Dental Treatment|Unknown status|Active, not recruiting|Phase 3|20|Anticipated|Shahid Beheshti University||1|||f||||t||||||||||2018-05-31 23:49:30.901574|2018-05-31 23:49:30.901574
NCT01118871|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2015-03-23|2010-05-06|2010-05-07|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2010||2010-05-31|July 2010|2010-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|FAST||The First Failure Study|A Randomised, Open Label, Prospective Study to Assess Two Different Therapeutic Strategies Following First Treatment Failure in HIV-1 Infected Subjects|Terminated||Phase 4|3|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 23:49:30.970274|2018-05-31 23:49:30.970274
NCT01118858|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2017-07-19|2010-05-06|2010-05-07|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2010||2010-04-30|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics|Exogenous and Endogenous Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics|Completed|||205|Actual|Children's Mercy Hospital Kansas City|||2||f||||f||||||Samples With DNA|"~     Blood or saliva for DNA testing. Blood samples will be obtained for safety labs throughout~     the study.~   "|||2018-05-31 23:49:31.04151|2018-05-31 23:49:31.04151
NCT01118845|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-01|2013-03-27||2013-05-29|2010-05-06|2010-05-07|Estimate|2013-05-29|2013-07-04|Estimate||||2013-05-29|2013-07-04|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma|A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma|Completed||Phase 2|63|Actual|SymBio Pharmaceuticals||1|||f||||t||||||||||2018-05-31 23:49:31.14072|2018-05-31 23:49:31.14072
NCT01118832|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2010-05-06|2010-05-06|2010-05-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|September 2009||2009-09-30|May 2010|2010-05-31||||||||Observational|||Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi|Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi|Unknown status|Recruiting||30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-05-31 23:49:32.196027|2018-05-31 23:49:32.196027
NCT01118819|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-01-19|2010-05-05|2010-05-07|Estimate|||||||2016-01-19|2016-01-20|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies|Phase I Safety Study of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies|Terminated||Phase 1|5|Actual|BioMed Valley Discoveries, Inc||1||"This study was terminated. An IT injection study of C. novyi-NT in patients with treatment~   refractory solid tumor malignancies may be viewed at NCT01924689."|f||||t||||||||||2018-05-31 23:49:32.339968|2018-05-31 23:49:32.339968
NCT01118806|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2011-11-21|2010-05-05|2010-05-07|Estimate|||||||2011-11-21|2011-11-23|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Vitamin D Levels in Residents in Medicine|Vitamin D Deficiency in Medical Residence in Israel|Completed|||106|Actual|Meir Medical Center|||2||f||||f||||||||||2018-05-31 23:49:32.511836|2018-05-31 23:49:32.511836
NCT01118793|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2010-05-06|2010-05-06|2010-05-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|PREDICT||Pilot Study on the Effect of High Clopidogrel Maintenance Dosing|PREDICT: Scripps Pilot Study on the Effect of High Clopidogrel Maintenance Dosing and Its Relationship to Cytochrome P450 2C19 Polymorphism Status|Completed|||41|Actual|Scripps Health|||1||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 23:49:32.581655|2018-05-31 23:49:32.581655
NCT01118780|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2013-06-25||2013-06-25|2010-05-05|2010-05-07|Estimate|2013-06-25|2013-09-02|Estimate||||2013-06-25|2013-09-02|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All randomized participants.|A Study of Duloxetine in Elderly Generalized Anxiety Disorder|Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder|Completed||Phase 4|291|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:49:32.770072|2018-05-31 23:49:32.770072
NCT01118767|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-06|||2010-06-15|2010-05-06|2010-05-07|Estimate|||||||2010-06-15|2010-06-16|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|Cell-POS||Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru|Evaluation of a Computer-Based System Using Cell Phones for HIV People in Peru|Unknown status|Recruiting|N/A|200|Anticipated|Universidad Peruana Cayetano Heredia||2|||f||||f||||||||||2018-05-31 23:49:34.239032|2018-05-31 23:49:34.239032
NCT01118754|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-11-01|2010-05-05|2010-05-07|Estimate|||||||2011-11-01|2011-11-03|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients|Phase I/II Prospective, Randomized, Double Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Compared to Placebo for the Treatment of Dry Eye Disease|Completed||Phase 1/Phase 2|132|Anticipated|Santen Inc.||3|||f||||f||||||||||2018-05-31 23:49:34.361165|2018-05-31 23:49:34.361165
NCT01118741|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2013-12-13||2017-09-12|2010-05-05|2010-05-07|Estimate|2014-05-15|2014-06-06|Estimate||||2017-09-12|2017-10-13|Actual|May 2010||2010-05-31|September 2017|2017-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)|A Multi-institutional Translational Clinical Trial of Disulfiram in Men With Recurrent Prostate Cancer as Evident by a Rising PSA|Completed||N/A|19|Actual|Johns Hopkins University|||||f||||t||||||||||2018-05-31 23:49:34.446996|2018-05-31 23:49:34.446996
NCT01118728|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2017-05-24|2013-01-11|2017-05-24|2010-05-06|2010-05-07|Estimate|2017-05-24|2017-06-21|Actual|2013-01-11|2013-01-21|Estimate|2017-05-24|2017-06-21|Actual|June 2010||2010-06-30|May 2017|2017-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SUSTAIN|All enrolled participants who received at least one dose of the study treatment after signature of the informed consent.|Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis|A Multicenter Uncontrolled Extension Study Evaluating the Long Term Safety and Efficacy of SAR153191 in Patients With Ankylosing Spondylitis (AS)|Terminated||Phase 2|223|Actual|Sanofi|The study was prematurely discontinued after approximately 1.5 years, when the ankylosing spondylitis development program was discontinued due to lack of efficacy in the DRI11073 study.|1||Lack of benefit on efficacy|f||||t||||||||||2018-05-31 23:49:34.747342|2018-05-31 23:49:34.747342
NCT01118715|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2016-02-23|2010-05-05|2010-05-07|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial|Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|139|Actual|J&M Shuler||2|||f||||f||||||||||2018-05-31 23:49:36.05848|2018-05-31 23:49:36.05848
NCT01118702|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2012-12-10|2010-05-05|2010-05-07|Estimate|||||||2012-12-10|2012-12-11|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|||||Interventional|||A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers|A Randomized, Open-label, Single-dose, Three-way Crossover Study to Determine the Relative Pharmacokinetic Profile of Oral Doses of CONCERTA Tablets, Ritalin-SR Tablets and Novo-Methylphenidate ER-CTablets Under Fasted Condition in Healthy Subjects|Completed||Phase 1|30|Actual|Janssen-Ortho Inc., Canada||3|||f||||||||||||||2018-05-31 23:49:36.172055|2018-05-31 23:49:36.172055
NCT01118689|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-07-31|2010-05-05|2010-05-07|Estimate|||||||2013-07-31|2013-08-02|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia|A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia|Completed||Phase 1|39|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:49:36.241027|2018-05-31 23:49:36.241027
NCT01118676|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2015-09-03|2010-05-05|2010-05-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer|Phase I Trial Evaluating Continuous Infusion of Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer|Completed||Phase 1|14|Actual|Institut Claudius Regaud||1|||f||||f||||||||||2018-05-31 23:49:36.324738|2018-05-31 23:49:36.324738
NCT01118663|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2014-04-15||2014-08-01|2010-05-05|2010-05-07|Estimate|2014-08-01|2014-08-04|Estimate||||2014-08-01|2014-08-04|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection|A Multi-center, Double-blind, Randomized, Controlled Study to Determine the Efficacy and Safety of a New Formulation of Acetylcysteine Injection|Terminated||Phase 3|17|Actual|Cumberland Pharmaceuticals||2|||f||||t||||||||||2018-05-31 23:49:36.419969|2018-05-31 23:49:36.419969
NCT01118650|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2012-04-17|2010-05-06|2010-05-07|Estimate|||||||2012-04-17|2012-04-18|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Concordance of the Quotient Attention Deficit Hyperactivity Disorder (ADHD) System Report With Teacher and Parent Assessments for Symptoms of ADHD|Concordance of the Quotient ADHD System Report With Teacher and Parent Assessments in School-Aged Children Receiving an Individualized Education Program (IEP) or 504 Accommodations in the Classroom Setting for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD)|Withdrawn|||0|Actual|BioBehavioral Diagnostics Company||||No interest from school district|f||||f||||||||||2018-05-31 23:49:36.971115|2018-05-31 23:49:36.971115
NCT01118637|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-05-23|2010-05-05|2010-05-07|Estimate|||||||2013-05-23|2013-05-27|Estimate|August 2010||2010-08-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Stepped Care in the Treatment of Trichotillomania|Stepped Care in the Treatment of Trichotillomania|Completed||Phase 2|60|Actual|American University||2|||f||||t||||||||||2018-05-31 23:49:37.068535|2018-05-31 23:49:37.068535
NCT01118624|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2014-02-24||2014-05-27|2010-05-05|2010-05-07|Estimate|2014-05-27|2014-06-05|Estimate||||2014-05-27|2014-06-05|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional||Patients enrolled and treated with study drug.|Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer|Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer|Completed||Phase 2|22|Actual|Spectrum Pharmaceuticals, Inc|Sufficient patients were enrolled.||||f||||||||||||||2018-05-31 23:49:37.160443|2018-05-31 23:49:37.160443
NCT01117909|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-05-26|2010-05-05|2010-05-06|Estimate|||||||2011-05-26|2011-05-30|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effects of Talocrural Joint Mobilizations in the Treatment of Subacute Lateral Ankle Sprains|Effects of Talocrural Joint Mobilizations in the Treatment of Subacute Lateral Ankle Sprains|Unknown status|Recruiting|N/A|60|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 23:49:55.046813|2018-05-31 23:49:55.046813
NCT01118611|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2013-04-30|2010-05-05|2010-05-06|Estimate|||||||2013-04-30|2013-05-01|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors|A Cancer Research UK Phase I Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Aurora B Inhibitor GSK1070916A in Patients With Advanced Solid Tumors|Completed||Phase 1|38|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 23:49:37.464536|2018-05-31 23:49:37.464536
NCT01118598|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2012-09-10|2010-05-05|2010-05-06|Estimate|||||||2012-09-10|2012-09-12|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome|To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS)|Completed||Phase 4|34|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 23:49:37.574779|2018-05-31 23:49:37.574779
NCT01118585|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2017-02-07|2010-05-05|2010-05-06|Estimate|||||||2017-02-07|2017-02-09|Estimate|May 2010||2010-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2015|Actual|2015-06-30||Interventional|||Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)|Prospective Outcome Evaluation of Transoral Incisionless Fundoplication (TIF) for the Treatment of Gastroesophageal Reflux Disease (GERD): The TIF Registry Study|Active, not recruiting||N/A|500|Anticipated|EndoGastric Solutions||1|||f||||f||||||||Undecided||2018-05-31 23:49:37.669218|2018-05-31 23:49:37.669218
NCT01118572|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2014-10-14|2010-05-05|2010-05-06|Estimate|||||||2014-10-14|2014-10-15|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients|A Phase III Study of YM177 (Postoperative Pain) -- An Etodolac- and Placebo-controlled, Multicenter, Double-blind, Group Comparison Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients --|Completed||Phase 3|616|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 23:49:37.765312|2018-05-31 23:49:37.765312
NCT01118559|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2010-05-05|2010-05-05|2010-05-06|Estimate|||||||2010-05-05|2010-05-06|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150|Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:49:37.849904|2018-05-31 23:49:37.849904
NCT01118546|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2016-09-28|2010-05-05|2010-05-06|Estimate|||||||2016-09-28|2016-09-29|Estimate|February 2007||2007-02-28|February 2015|2015-02-28|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Observational|||Physiopathology of Rapid Aspirin Desensitization|Physiopathology of Rapid Aspirin Desensitization in Patients With Coronary Artery Disease and a History of Hypersensitivity to Aspirin or NSAIDs|Completed|||86|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||Samples Without DNA|"~     plasma and urine~   "|||2018-05-31 23:49:37.914684|2018-05-31 23:49:37.914684
NCT01118533|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2016-06-09|2010-05-05|2010-05-06|Estimate|||||||2016-06-09|2016-06-10|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|MPLIT||Impact of Blades Used for Scheduled Orotracheal Intubation on Postoperative Sore Throat|A Prospective, Multicenter, Randomized and Single Bind Trial. Influence of Laryngoscope Blade Material on Postoperative PHARYNGEAL AND LARYNGEAL Morbidity Following Scheduled OroTracheal Intubation|Completed||N/A|712|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:49:38.025986|2018-05-31 23:49:38.025986
NCT01118520|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2015-08-04|2010-05-05|2010-05-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|September 2011||2011-09-30|October 2011|2011-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|AARDVARK||Evaluation of Effect of Angiotensin-converting Enzyme (ACE) Inhibitors on Small Aneurysm Growth Rate|An Evaluation of the Effect of an Angiotensin-converting Enzyme (ACE) Inhibitor on the Growth Rate of Small Abdominal Aortic Aneurysms. A Double Blind Comparison With Similar Blood Pressure Lowering Medication (Calcium Channel Blockade)and Placebo|Completed||Phase 2|227|Actual|Imperial College London||3|||f||||t||||||||||2018-05-31 23:49:38.21593|2018-05-31 23:49:38.21593
NCT01118507|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2014-01-02|2010-05-05|2010-05-06|Estimate|||||||2014-01-02|2014-01-03|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|SEQ21||Trisomy of Chromosome 21 Diagnosis by High Output Sequencing|Trisomy of Chromosome 21 Diagnosis by High Output Sequencing of Foetal Circulating DNA in Mother Blood at First Trimester of Pregnancy.|Completed|||976|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     fetal DNA in maternal blood~   "|||2018-05-31 23:49:38.34179|2018-05-31 23:49:38.34179
NCT01118494|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-05-05|2010-05-05|2010-05-06|Estimate|||||||2010-05-05|2010-05-06|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|June 2011|Anticipated|2011-06-30|February 2010|Anticipated|2010-02-28||Observational|||Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.||Unknown status|Recruiting||400|Anticipated|Fudan University|||1||f||||t||||||Samples With DNA|"~     serum plasma urine supernatant urine sediment~   "|||2018-05-31 23:49:38.426341|2018-05-31 23:49:38.426341
NCT01118481|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2017-02-06|2010-05-05|2010-05-06|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 2010||2010-01-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|ADVISE||Vasodilator Free Measure of Fractional Flow Reserve|ADenosine Vasodilator Independent Stenosis Evaluation Study (ADVISE)|Completed|||157|Actual|Imperial College London|||2||f||||t||||||||||2018-05-31 23:49:38.537969|2018-05-31 23:49:38.537969
NCT01118468|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2017-02-06|2010-05-05|2010-05-06|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2010||2010-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Systematic Assessment of Competitive Flow in Coronary Artery Bypass Grafts by Wave Intensity Analysis|Systematic Assessment of Competitive Flow in Coronary Artery Bypass Grafts by Wave Intensity Analysis|Recruiting|||40|Anticipated|Imperial College London|||||f||||t||||||||||2018-05-31 23:49:38.610561|2018-05-31 23:49:38.610561
NCT01118455|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2011-03-01||2014-06-25|2010-05-05|2010-05-06|Estimate|2014-06-25|2014-06-26|Estimate||||2014-06-25|2014-06-26|Estimate|October 2004||2004-10-31|June 2014|2014-06-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures|An Open Randomized Trial to Assess the Efficacy and Safety of Vagus Nerve Stimulation (VNS) Versus New Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures|Terminated||Phase 4|134|Actual|Cyberonics, Inc.|Study was terminated due to low enrollment.|2||Insufficient enrollment|f||||f||||||||||2018-05-31 23:49:38.720348|2018-05-31 23:49:38.720348
NCT01118442|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2017-02-06|2010-05-05|2010-05-06|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2009||2009-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Determination of the Acute Effects of Aortic Stenosis on Coronary Artery Haemodynamics|Determination of the Acute Effects of Aortic Stenosis on Coronary Artery Haemodynamics|Recruiting|||6|Anticipated|Imperial College London|||||f||||t||||||Samples With DNA|"~     Myocardial biopsy specimens~   "|||2018-05-31 23:49:39.512171|2018-05-31 23:49:39.512171
NCT01118429|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-05-05|2010-05-05|2010-05-06|Estimate|||||||2010-05-05|2010-05-06|Estimate|January 2007||2007-01-31|March 2010|2010-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Use of Oxybutynin to Treat Axillary Hyperhidrosis|Use of Oxybutynin to Treat Axillary Hyperhidrosis|Completed||N/A|100|Actual|Grupo de Cirurgia Vascular||2|||f||||t||||||||||2018-05-31 23:49:39.583113|2018-05-31 23:49:39.583113
NCT01118416|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-05-30|2010-05-05|2010-05-06|Estimate|||||||2013-05-30|2013-06-03|Estimate|June 2006||2006-06-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|September 2010|Actual|2010-09-30||Interventional|YMHP||Risk Reduction Intervention for Vulnerable Young Adult Males|Risk Reduction Intervention for Vulnerable Young Adult Males|Completed||N/A|317|Actual|Hunter College of City University of New York||2|||f||||t||||||||||2018-05-31 23:49:39.664598|2018-05-31 23:49:39.664598
NCT01118403|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2016-05-21|2010-05-05|2010-05-06|Estimate|||||||2016-05-21|2016-05-24|Estimate|March 2011||2011-03-31|May 2016|2016-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|NAVPRO||Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients|Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients: A Randomized Trial|Withdrawn||Phase 4|0|Actual|Hospital Pablo Tobón Uribe||2||He could not be started due to lack of funds|f||||t||||||||No||2018-05-31 23:49:39.834315|2018-05-31 23:49:39.834315
NCT01118390|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-05-05|2010-05-05|2010-05-06|Estimate|||||||2010-05-05|2010-05-06|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Treatment of Leg Telangiectasias With Nd:YAG 1064nm|Treatment of Leg Telangiectasias With Nd:YAG 1064nm|Unknown status|Enrolling by invitation|N/A|30|Actual|Grupo de Cirurgia Vascular||2|||f||||t||||||||||2018-05-31 23:49:39.933605|2018-05-31 23:49:39.933605
NCT01118377|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2013-09-30||2014-02-04|2010-05-05|2010-05-06|Estimate|2013-09-30|2013-12-03|Estimate||||2014-02-04|2014-02-06|Estimate|May 2007||2007-05-31|February 2014|2014-02-28|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional||Intent-to-treat population: All enrolled participants who received at least 1 dose of capecitabine. One of the 45 participants did not receive treatment and was not included in the intent-to-treat population (34 participants from study NO21125 and 10 participants from study NO18517).|A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas|A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas|Completed||Phase 2|45|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:49:40.065254|2018-05-31 23:49:40.065254
NCT01118364|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2014-08-27|2010-05-05|2010-05-06|Estimate|||||||2014-08-27|2014-08-28|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|||Effect of Cannabis on Simulated and Actual Driving in Healthy Subjects|Effect of Cannabis on Simulated and Actual Driving in Healthy Subjects|Completed||N/A|20|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 23:49:40.513682|2018-05-31 23:49:40.513682
NCT01118351|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2015-10-02|2010-05-05|2010-05-06|Estimate|||||||2015-10-02|2015-10-06|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|July 2012|Actual|2012-07-31||Interventional|||Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer|Phase II Single Arm, Open Label, Single Institution Study of Continuous Sunitinib (Sutent) in Patients With High-Risk (BCG-Refractory) Superficial Transitional Cell Carcinoma (TCC) of the Bladder|Completed||Phase 2|19|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:49:40.619946|2018-05-31 23:49:40.619946
NCT01118338|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2012-08-10|2010-05-05|2010-05-06|Estimate|||||||2012-08-10|2012-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:49:40.734203|2018-05-31 23:49:40.734203
NCT01118325|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2012-03-14|2011-02-23|2014-06-24|2010-05-05|2010-05-06|Estimate|2012-03-14|2012-04-09|Estimate|2011-06-01|2011-06-07|Estimate|2014-06-24|2014-07-08|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease|A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patients With Stable Coronary Artery Disease|Completed||Phase 2|146|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 23:49:40.803834|2018-05-31 23:49:40.803834
NCT01118312|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2015-09-24||2015-10-29|2010-05-05|2010-05-06|Estimate|2015-10-29|2015-11-30|Estimate||||2015-10-29|2015-11-30|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|STAN||Study of Asthma and Nasal Steroids|Study of Asthma and Nasal Steroids for the American Lung Association-Airways Clinical Research Centers|Completed||Phase 4|388|Actual|JHSPH Center for Clinical Trials||2|||f||||t||||||||||2018-05-31 23:49:41.429757|2018-05-31 23:49:41.429757
NCT01118299|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2017-12-12|2010-05-05|2010-05-06|Estimate|||||||2017-12-12|2017-12-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:49:41.797446|2018-05-31 23:49:41.797446
NCT01118286|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2012-06-26|2010-05-05|2010-05-06|Estimate|||||||2012-06-26|2012-06-27|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|||||Observational|||Treatment of Hypertension With Adalat® in Combination With Other Drugs|AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy|Completed|||4497|Actual|Bayer|||1||f||||f||||||||||2018-05-31 23:49:41.839052|2018-05-31 23:49:41.839052
NCT01118273|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2014-01-24|2012-05-30|2015-05-13|2010-05-05|2010-05-06|Estimate|2014-05-16|2014-06-17|Estimate|2012-05-30|2012-06-05|Estimate|2015-05-13|2015-06-08|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine|A Double-Blind, Randomized, Pilot Study Assessing the Analgesic and Hypnotic Effect of Naproxen Sodium and Diphenhydramine Combination in Dental Pain|Completed||Phase 4|162|Actual|Bayer||6|||f||||f||||||||||2018-05-31 23:49:42.009723|2018-05-31 23:49:42.009723
NCT01118260|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-05-05|2010-05-05|2010-05-06|Estimate|||||||2010-05-05|2010-05-06|Estimate|January 2006||2006-01-31|May 2010|2010-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|TURPS||Total Intravenous Anaesthesia (TIVA) Versus Spinal Anaesthesia in Patients Undergoing Transurethral Prostate Resection|TIVA Versus Spinal Anaesthesia in Patients Undergoing Transurethral Prostate Resection|Completed||Phase 4|101|Actual|Asker & Baerum Hospital||2|||f||||f||||||||||2018-05-31 23:49:46.052743|2018-05-31 23:49:46.052743
NCT01118247|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2017-08-14|2010-05-05|2010-05-06|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2004||2004-04-30|June 2015|2015-06-30|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Primary Uncemented Partly Ti-coated Total Hip Prosthesis With and Without HA, and Alumina-on-alumina Articulation|Primary Uncemented Total Hip Prosthesis With Pure Ti With and Without HA, and Alumina-on-alumina Articulation|Active, not recruiting||N/A|400|Anticipated|University Hospital of North Norway||2|||f||||t||||||||||2018-05-31 23:49:46.174814|2018-05-31 23:49:46.174814
NCT01118234|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-11-23|2010-05-05|2010-05-06|Estimate|||||||2017-11-23|2017-11-27|Actual|December 2009||2009-12-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)|International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 3|256|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||f||||||||||2018-05-31 23:49:46.272948|2018-05-31 23:49:46.272948
NCT01118221|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2014-11-19||2015-02-13|2010-05-04|2010-05-06|Estimate|2014-12-29|2015-01-16|Estimate||||2015-02-13|2015-03-04|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients|Rehabilitation of IPF Patients: Effects of Exercise and Oxidant Stress|Completed||N/A|25|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 23:49:46.469101|2018-05-31 23:49:46.469101
NCT01118208|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2017-10-18|2010-05-04|2010-05-06|Estimate|||||||2017-10-18|2017-10-20|Actual|September 2009||2009-09-30|October 2017|2017-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|BP||Blister Packaging Medication to Increase Treatment Adherence and Clinical Response|Blister Packaging Medication to Increase Treatment Adherence and Clinical Response: Impact on Suicide-Related Morbidity and Mortality|Completed||N/A|303|Actual|VA Eastern Colorado Health Care System||2|||f||||f||||||||||2018-05-31 23:49:47.136308|2018-05-31 23:49:47.136308
NCT01118195|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-04-21|2010-05-05|2010-05-06|Estimate|||||||2011-04-21|2011-04-26|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Executive Dysfunction & Suicide: An Exploration Of Risk Factors In Traumatically Brain Injured Veterans|Executive Dysfunction & Suicide: An Exploration Of Risk Factors In Traumatically Brain Injured Veterans|Completed|||54|Anticipated|VA Eastern Colorado Health Care System|||2||f||||f||||||||||2018-05-31 23:49:47.286832|2018-05-31 23:49:47.286832
NCT01118182|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2016-01-13|2010-05-05|2010-05-06|Estimate|||||||2016-01-13|2016-01-15|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|TBI||Use of a Traumatic Brain Injury (TBI) Screen in a Veteran Mental Health Population|Use of a Traumatic Brain Injury (TBI) Screen in a Veteran Mental Health Population: Prevalence, Validation, and Psychiatric Outcomes|Unknown status|Active, not recruiting||3000|Anticipated|VA Eastern Colorado Health Care System|||2||f||||f||||||||||2018-05-31 23:49:47.35544|2018-05-31 23:49:47.35544
NCT01118169|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-11-08|2010-05-04|2010-05-06|Estimate|||||||2011-11-08|2011-11-10|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Personal Values, Interpersonal Needs, and Suicidal Ideation in a Veteran Population|Examining the Relationship Between Personal Values, Interpersonal Needs, and Suicidal Ideation in a Veteran Population|Completed|||122|Actual|VA Eastern Colorado Health Care System|||1||f||||f||||||||||2018-05-31 23:49:47.526796|2018-05-31 23:49:47.526796
NCT01118156|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-05-01|2010-05-04|2010-05-06|Estimate|||||||2011-05-01|2011-05-03|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Suicide Classification System|Suicide Classification System|Completed|||74|Actual|VA Eastern Colorado Health Care System|||1||f||||t||||||||||2018-05-31 23:49:47.826532|2018-05-31 23:49:47.826532
NCT01118143|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2012-08-27||2015-03-26|2010-05-04|2010-05-06|Estimate|2015-03-12|2015-03-23|Estimate||||2015-03-26|2015-04-16|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Oral Health Literacy Tailored Communication|Effects of Communication Tailored to Oral Health Literacy Level of Adult Dental Patients: A Randomized Controlled Trial|Completed||N/A|179|Actual|University of Tromso||2|||f||||t||||||||||2018-05-31 23:49:47.905342|2018-05-31 23:49:47.905342
NCT01118130|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2017-11-02|2010-05-04|2010-05-06|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2010||2010-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pharmacogenomics of Drug Safety in Multiple Sclerosis|Canadian Pharmacogenomics Network for Drug Safety: Genetic Factors Associated With Multiple Sclerosis Treatment|Recruiting|||300|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 23:49:48.414821|2018-05-31 23:49:48.414821
NCT01118117|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2015-06-18|2014-04-22|2017-10-17|2010-05-04|2010-05-06|Estimate|2015-06-18|2015-07-14|Estimate|2014-07-07|2014-07-09|Estimate|2017-10-17|2017-11-20|Actual|July 2010||2010-07-31|October 2017|2017-10-31|April 2016|Actual|2016-04-30|July 2013|Actual|2013-07-31||Interventional|OSPREY||A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery|A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery|Completed||N/A|276|Actual|Terumo Medical Corporation||1|||f||||t||||||||||2018-05-31 23:49:48.590427|2018-05-31 23:49:48.590427
NCT01118104|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-05-14|2010-05-05|2010-05-06|Estimate|||||||2012-05-14|2012-05-15|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Sickness Absence Versus Physical, Mental, and Job-related Factors in Patients With Chronic Pulmonary Disease|Relationships Between Sickness Absence and Physical, Mental, and Job-related Factors in Patients With Chronic Pulmonary Disease|Completed||N/A|318|Actual|LHL Helse||1|||f||||f||||||||||2018-05-31 23:49:50.376956|2018-05-31 23:49:50.376956
NCT01118091|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2012-11-09||2015-10-06|2010-05-05|2010-05-06|Estimate|2013-05-29|2013-06-03|Estimate||||2015-10-06|2015-10-08|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...|Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-05-31 23:49:50.477597|2018-05-31 23:49:50.477597
NCT01117896|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2012-10-24|2010-05-04|2010-05-06|Estimate|||||||2012-10-24|2012-10-26|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|August 2008|Actual|2008-08-31||Interventional|||CPR Rescuer Fatigue on Chest Compression Effectiveness|Effect of Rescuer Fatigue on Chest Compression Effectiveness|Completed||N/A|106|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 23:49:55.145268|2018-05-31 23:49:55.145268
NCT01118078|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2016-05-17|2010-05-05|2010-05-06|Estimate|||||||2016-05-17|2016-05-19|Estimate|May 2010||2010-05-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor|Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Renal Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors|Completed|||185|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Archived tumor tissue samples~   "|||2018-05-31 23:49:50.988802|2018-05-31 23:49:50.988802
NCT01118065|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-08-09|2010-05-05|2010-05-06|Estimate|||||||2013-08-09|2013-08-12|Estimate|May 2010||2010-05-31|May 2010|2010-05-31||||May 2012|Anticipated|2012-05-31||Interventional|||Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer|A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor®, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma|Unknown status|Recruiting|Phase 2|42|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:49:51.103667|2018-05-31 23:49:51.103667
NCT01118052|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2017-11-02||2017-12-13|2010-05-05|2010-05-06|Estimate|2017-11-02|2017-11-30|Actual||||2017-12-13|2018-01-11|Actual|November 1, 2010|Actual|2010-11-01|August 2017|2017-08-31|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Interventional||Eligible and treated patients|EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 2|22|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 23:49:51.287173|2018-05-31 23:49:51.287173
NCT01118039|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-08-06|2010-05-05|2010-05-06|Estimate|||||||2013-08-06|2013-08-07|Estimate|July 2006||2006-07-31|September 2012|2012-09-30||||December 2010|Anticipated|2010-12-31||Interventional|||Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer|A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy|Unknown status|Recruiting|Phase 2|41|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:49:52.032024|2018-05-31 23:49:52.032024
NCT01118026|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2018-01-12|2010-05-05|2010-05-06|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2010|Actual|2010-09-30|January 2018|2018-01-31||||August 2020|Anticipated|2020-08-31||Interventional|||Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma|Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)|Active, not recruiting||Phase 2|101|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 23:49:52.250615|2018-05-31 23:49:52.250615
NCT01118013|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|2016-12-12||2017-02-06|2010-05-05|2010-05-06|Estimate|2017-02-06|2017-03-24|Actual||||2017-02-06|2017-03-24|Actual|December 2010||2010-12-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|March 2012|Actual|2012-03-31||Interventional|||Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant|Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients With Disease Relapse or Myelodysplasia After Prior Autologous Transplantation|Terminated||Phase 2|6|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 23:49:52.576243|2018-05-31 23:49:52.576243
NCT01118000|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-07-27|2010-05-04|2010-05-06|Estimate|||||||2010-07-27|2010-07-28|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Study on the Cardioprotection and Humoral Mechanism of Limb Ischemia Preconditioning|Study on the Cardioprotection and Humoral Mechanism of Limb Ischemia Preconditioning|Completed||N/A|60|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 23:49:52.946973|2018-05-31 23:49:52.946973
NCT01117987|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2015-04-02||2015-07-24|2010-05-04|2010-05-06|Estimate|2015-05-05|2015-05-21|Estimate||||2015-07-24|2015-08-13|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|IMPRES Extn||Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)|An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension|Terminated||Phase 3|144|Actual|Novartis|Within primary outcome measure (OM) #1, an additional death (>30 days post study completion) was included in the imatinib arm. The participant flow and secondary OM #2 reflect deaths that occurred up to and including 30 days post study completion.|2||"Novartis discontinued the development of imatinib in PAH due to requirement of regulatory~   authorities for additional data to secure marketing approval in PAH."|f||||t||||||||||2018-05-31 23:49:53.070649|2018-05-31 23:49:53.070649
NCT01117974|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2013-04-15|2010-05-04|2010-05-06|Estimate|||||||2013-04-15|2013-04-17|Estimate||||April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Neck Liposuction for the Treatment of Obstructive Sleep Apnea|Neck Liposuction With Tumescent Anesthesia for the Treatment of Obstructive Sleep Apnea - A Pilot Study|Withdrawn||N/A|0|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 23:49:54.298395|2018-05-31 23:49:54.298395
NCT01117961|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-04-30|2010-05-04|2010-05-06|Estimate|||||||2013-04-30|2013-05-01|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Promoting Healthy Weight Gain During Pregnancy|Promoting Healthy Weight Gain During Pregnancy|Completed||Phase 3|401|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 23:49:54.458323|2018-05-31 23:49:54.458323
NCT01117948|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2012-05-21||2013-02-01|2010-05-04|2010-05-06|Estimate|2012-10-30|2012-11-29|Estimate||||2013-02-01|2013-02-06|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.|A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.|Terminated||Phase 2|219|Actual|JSW Lifesciences||2||Lack of Efficacy|f||||t||||||||||2018-05-31 23:49:54.554268|2018-05-31 23:49:54.554268
NCT01117935|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2017-09-14|2010-05-05|2010-05-06|Estimate|||||||2017-09-14|2017-09-15|Actual|May 30, 2010||2010-05-30|September 2017|2017-09-30|May 31, 2018|Anticipated|2018-05-31|June 25, 2015|Actual|2015-06-25||Interventional|||Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer|Study of Hypofractionated Intensity Modulated External Beam Therapy for the Treatment of Patients With Adenocarcinoma of the Prostate|Active, not recruiting||N/A|55|Actual|Virginia Commonwealth University||1|||f||||t|f|f||||||||2018-05-31 23:49:54.883541|2018-05-31 23:49:54.883541
NCT01117883|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-07-13|2010-05-04|2010-05-06|Estimate|||||||2011-07-13|2011-07-14|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Sternal Wall Pressure in the Cath Lab|Effect of Gentle Sternal Chest Wall Pressure on Central Hemodynamic Measurements and Intrathoracic Pressure During Mechanical Ventilation in Children|Completed||N/A|20|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-05-31 23:49:55.230657|2018-05-31 23:49:55.230657
NCT01117870|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2016-06-06||2017-01-30|2010-05-04|2010-05-06|Estimate|2017-01-30|2017-03-21|Actual||||2017-01-30|2017-03-21|Actual|July 2010||2010-07-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional||Adult population both male and female >=18 years old|Assess the Effectiveness of Pulse RadioFrequency in Patients With Chronic Lumbar Radicular Pain|Randomized, Placebo Controlled, Double-blinded Trial to Assess the Effectiveness of Pulse RadioFrequency Treatment of Dorsal Root Ganglion in Patients With Chronic Lumbar Radicular Pain|Completed||N/A|31|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 23:49:55.323454|2018-05-31 23:49:55.323454
NCT01117857|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2014-07-03||2014-08-05|2010-05-04|2010-05-06|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Of 29 subjects who consented, 7 were ineligible at the screening visit. Out of the 22 remaining subjects, 19 received study medication.|Duloxetine for Menopausal Depression|Duloxetine for Menopausal Depression|Completed||Phase 4|29|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 23:49:55.697443|2018-05-31 23:49:55.697443
NCT01117844|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-09-23|2010-05-05|2010-05-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|February 2010||2010-02-28|September 2016|2016-09-30||||February 2017|Anticipated|2017-02-28||Interventional|||Proton Radiation For Meningiomas and Hemangiopericytomas|Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas|Recruiting||Phase 1/Phase 2|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 23:49:55.934558|2018-05-31 23:49:55.934558
NCT01117831|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2017-07-19|2010-05-05|2010-05-06|Estimate|||||||2017-07-19|2017-07-21|Actual|March 2010||2010-03-31|July 2017|2017-07-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Observational|||An Analysis of Diabetes Control in Puerto Rico|An Analysis of Variables That Affect Quality of Diabetes Control in Puerto Rico|Completed|||600|Actual|Center for Diabetes Control, Inc.|||||f||||f||||||||Yes|National Journal, Physician meeting, Press release|2018-05-31 23:49:55.997738|2018-05-31 23:49:55.997738
NCT01117818|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-12-10|2010-05-04|2010-05-06|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease|A Randomized, Controlled, Parallel Group, Double-blind, Multi-center, Phase II Study to Assess the Clinical- and Immunological Activity,as Well as the Safety and Tolerability of Different Doses/Formulations of AFFITOPE AD02 Administered Repeatedly to Patients With Early Alzheimer's Disease|Completed||Phase 2|335|Actual|Affiris AG||4|||f||||t||||||||||2018-05-31 23:49:56.059642|2018-05-31 23:49:56.059642
NCT01117805|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2016-06-09|2010-05-04|2010-05-05|Estimate|||||||2016-06-09|2016-06-10|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Women of Color and Asthma Control|Women of Color and Asthma Control|Completed||N/A|422|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 23:49:57.160728|2018-05-31 23:49:57.160728
NCT01117792|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-02-14|2010-05-04|2010-05-05|Estimate|||||||2017-02-14|2017-02-16|Actual|December 2008||2008-12-31|May 2010|2010-05-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation|Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation|Completed||N/A|55|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 23:49:57.37978|2018-05-31 23:49:57.37978
NCT01117779|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2017-10-06|2010-05-04|2010-05-05|Estimate|||||||2017-10-06|2017-10-09|Actual|May 2010||2010-05-31|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|TRACE||Tracking Renal Tumors After Cryoablation Evaluation|Tracking Renal Tumors After Cryoablation Evaluation (TRACE) Registry|Active, not recruiting|||250|Actual|Galil Medical|||1||f||||t||||||||No||2018-05-31 23:49:57.490915|2018-05-31 23:49:57.490915
NCT01117766|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2010-09-01||2011-02-14|2010-05-04|2010-05-05|Estimate|2010-09-01|2010-09-27|Estimate||||2011-02-14|2011-02-17|Estimate|December 2006||2006-12-31|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain|A Randomized, Double Blind, Placebo Controlled, 2-Way Crossover Methodology Study Designed To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing (QST) In Patients With Neuropathic Pain Treated With Pregabalin Vs Placebo|Completed||N/A|31|Actual|Pfizer||2|||f||||||||||||||2018-05-31 23:49:57.641452|2018-05-31 23:49:57.641452
NCT01117753|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2015-04-10|2010-05-04|2010-05-05|Estimate|||||||2015-04-10|2015-04-13|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Research on Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders|Stage II Research on Outpatient Treatment for Adolescents With Comorbidity|Completed||Phase 2|140|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 23:49:58.366537|2018-05-31 23:49:58.366537
NCT01117740|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2016-04-08|2010-05-04|2010-05-05|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Pleural Catheters Versus Thoracoscopic Pleurodesis|Comparative Effectiveness of Indwelling Pleural Catheters Versus Thoracoscopic Pleurodesis for Treatment of Malignant Pleural Effusions|Completed|||445|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 23:49:58.431478|2018-05-31 23:49:58.431478
NCT01117727|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2015-05-27||2015-06-11|2010-05-04|2010-05-05|Estimate|2015-06-11|2015-06-15|Estimate||||2015-06-11|2015-06-15|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology|Sensorimotor Rhythm Brain-Computer Interface Switch to Operate Assistive Technology|Terminated||Phase 1/Phase 2|1|Actual|University of Michigan||1||Performance of BCI switch insufficient in pilot testing.|f||||f||||||||||2018-05-31 23:49:58.507435|2018-05-31 23:49:58.507435
NCT01117714|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-05-10|2010-05-04|2010-05-05|Estimate|||||||2018-05-10|2018-05-16|Actual|September 2009||2009-09-30|May 2018|2018-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Surgical Versus Non-surgical Staging of Lung Cancer|A Prospective Multicenter Study Comparing Endobronchial and Endoscopic Ultrasound-Guided FNA to Mediastinoscopy/Thoracoscopy in the Staging and Early Detection of Metastases in Lung Cancer|Terminated||N/A|9|Actual|Medical University of South Carolina||2||"Accrual was poor at two other sites and manuscript was published which describing another study~   which accomplished the goals of this project."|f||||t||||||||||2018-05-31 23:49:58.68292|2018-05-31 23:49:58.68292
NCT01117701|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2015-03-17|2010-05-04|2010-05-05|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Does a Safety Guidewire Increase the Forces Needed to Move the Ureteroscope up and Down the Ureter?|Does a Safety Guidewire Adjacent to the Ureteroscope Increase the Forces Needed to Move the Ureteroscope up and Down the Ureter?|Completed||N/A|40|Anticipated|Helse-Bergen HF||2|||f||||f||||||||||2018-05-31 23:49:58.752692|2018-05-31 23:49:58.752692
NCT01117688|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2015-03-31|2010-05-04|2010-05-05|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Ureteroscopy With and Without Safety Guidewire|Ureteroscopy With and Without Safety Guidewire:. A Prospective, Randomized Study of the Results of Endoscopic Treatment of Urolithiasis.|Withdrawn||N/A|0|Actual|Helse-Bergen HF||2||Withdrawn. Not enough time to go through with the study.|f||||f||||||||||2018-05-31 23:49:58.827022|2018-05-31 23:49:58.827022
NCT01117675|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|January 2005||2005-01-31|April 2010|2010-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A New Telemedicine Approach for Chronic HIV/AIDS Patient Home Care|A New Telemedicine Approach for Chronic HIV/AIDS Patient Home Care|Completed||N/A|83|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 23:49:58.904509|2018-05-31 23:49:58.904509
NCT01117662|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-08-16|2010-05-04|2010-05-05|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2012||2012-05-31|October 2016|2016-10-31|August 23, 2016|Actual|2016-08-23|May 2016|Actual|2016-05-31||Interventional|RIACT||Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients|Efficacy of Rituximab in Acute Cellular Rejection With B-cell Infiltrates in Renal Transplant Patients - Randomized Placebo Controlled Double Blind Trial|Terminated||Phase 3|13|Actual|Hannover Medical School||2||The planned recruitment number of 180 Patient could not been achieved.|f||||t||||||||||2018-05-31 23:49:59.066145|2018-05-31 23:49:59.066145
NCT01117649|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-12-22|2010-05-04|2010-05-05|Estimate|||||||2016-12-22|2016-12-23|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Plasma Volume Replacement (PVR) Therapy With Colloid and Crystalloid Solutions|Prospective, Controlled, Double-blind, Randomized Multi-centric Study on the Efficacy and Safety of a Target Controlled PVR Therapy With a Hyperoncotic Balanced Hydroxyethyl Starch (HES) Solution Versus an Isooncotic Balanced HES Solution Compared to a Balanced Electrolyte Solution in Elective Surgery|Completed||Phase 4|63|Actual|B. Braun Melsungen AG||3|||f||||f||||||||||2018-05-31 23:49:59.169833|2018-05-31 23:49:59.169833
NCT01117636|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2016-02-16|2010-05-04|2010-05-05|Estimate|||||||2016-02-16|2016-02-18|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|TAROT||Evaluate Analgesic Efficacy of Fast Release Aspirin|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 1000 mg in Postsurgical Dental Pain|Completed||Phase 3|514|Actual|Bayer||3|||f||||f||||||||||2018-05-31 23:49:59.244424|2018-05-31 23:49:59.244424
NCT01117623|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2014-11-17||2015-11-16|2010-05-04|2010-05-05|Estimate|2015-01-15|2015-01-19|Estimate||||2015-11-16|2015-11-18|Estimate|February 2007||2007-02-28|November 2015|2015-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies|Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies|Completed||Phase 1|86|Actual|Bayer||8|||f||||f||||||||||2018-05-31 23:49:59.435183|2018-05-31 23:49:59.435183
NCT01117610|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||A Preemptive Epidural Ropivacaine for Postoperative Pain Relief in Degenerative Lumbar Spine Surgery|A Preemptive Epidural Ropivacaine for Postoperative Pain Relief in Degenerative Lumbar Spine Surgery: A Prospective Randomized Study|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||f||||||||||2018-05-31 23:50:02.155178|2018-05-31 23:50:02.155178
NCT01117597|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2016-08-24|2010-05-04|2010-05-05|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|TETRA||Terrestrial Trunked Radio (TETRA) and Cognitive Functions in Healthy Subjects|Experimental Study on Possible Effects of Radiofrequency (RF) Signal Characteristics Used for the TETRA Standard on Cognitive Functions in Healthy Subjects|Completed||N/A|32|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||Undecided||2018-05-31 23:50:02.270025|2018-05-31 23:50:02.270025
NCT01117584|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04||2012-04-29|2017-12-19|2010-05-04|2010-05-05|Estimate||||2012-04-29|2012-05-01|Estimate|2017-12-19|2017-12-20|Actual|April 6, 2010|Actual|2010-04-06|December 2017|2017-12-31|April 1, 2011|Actual|2011-04-01|April 1, 2011|Actual|2011-04-01||Interventional|BALANCE||A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus|Phase IIb, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment With ASP1941 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|Completed||Phase 2|343|Actual|Astellas Pharma Inc||5|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 23:50:02.368213|2018-05-31 23:50:02.368213
NCT01117571|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2017-09-19|2010-05-04|2010-05-05|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2010|Actual|2010-04-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Observational|iUni||Multi-Center Study to Evaluate the ConforMIS iUni Knee Implant|A Prospective, Multi-Center Study to Evaluate the ConforMIS iUni® G2 Unicompartmental Knee Resurfacing Device|Active, not recruiting|||120|Actual|ConforMIS, Inc.|||1||f||||f|f|t|f|f|t|||No||2018-05-31 23:50:02.534369|2018-05-31 23:50:02.534369
NCT01117558|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-09-10|2010-05-04|2010-05-05|Estimate|||||||2013-09-10|2013-09-11|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Observational|||Study of Metabolism and Cardiovascular Disease(CVD) in Women With Polycystic Ovary Syndrome (PCOS)|The Risk of Metabolic Syndrome and Cardiovascular Disease in Women With Polycystic Ovary Syndrome.|Completed|||300|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:50:02.654178|2018-05-31 23:50:02.654178
NCT01117545|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2018-04-23|2010-05-04|2010-05-05|Estimate|||||||2018-04-23|2018-04-25|Actual|May 2010|Actual|2010-05-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Psychological Symptom Change in Veterans After Six Sessions of EFT (Emotional Freedom Techniques)|Psychological Symptom Change in Veterans After Six Sessions of EFT (Emotional Freedom Techniques): A Randomized Controlled Trial|Completed||N/A|59|Actual|Soul Medicine Institute||2|||f||||f||||||||||2018-05-31 23:50:02.760817|2018-05-31 23:50:02.760817
NCT01117532|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2018-04-23|2010-05-04|2010-05-05|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2010||2010-04-30|April 2018|2018-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Brief Group Intervention Using EFT (Emotional Freedom Techniques) for Depression in College Students|Brief Group Intervention Using EFT (Emotional Freedom Techniques) for Depression in College Students: A Randomized Controlled Trial|Completed||Early Phase 1|70|Anticipated|Soul Medicine Institute||2|||f||||f||||||||||2018-05-31 23:50:02.887499|2018-05-31 23:50:02.887499
NCT01117519|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-11-15|2010-05-04|2010-05-05|Estimate|||||||2011-11-15|2011-11-16|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|HIPSTER||Impact of Fluid Management Within a Goal-directed Hemodynamic Protocol on Acid-base Balance in Elective Trauma Surgery|Impact of a Balanced Infusion Solution Compound of 50% Crystalloid and 50% Colloid Versus an Unbalanced Infusion Solution of 100% Crystalloid Within a Goal-directed Hemodynamic Protocol on Acid-base Balance|Completed||Phase 4|40|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:50:03.024216|2018-05-31 23:50:03.024216
NCT01117506|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2018-02-21|2010-05-04|2010-05-05|Estimate|||||||2018-02-21|2018-02-23|Actual|April 2010||2010-04-30|February 2018|2018-02-28|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Observational|COMPASS||Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)|A Blood-based Gene Expression Test (Corus CAD or ASGES) for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging.|Completed|||581|Actual|CardioDx|||||f||||f||||||Samples With DNA|"~     RNA PAXgene~   "|||2018-05-31 23:50:03.198265|2018-05-31 23:50:03.198265
NCT01117493|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|September 2006||2006-09-30|April 2010|2010-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis|Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis|Completed||N/A|64|Actual|Belfast Health and Social Care Trust||2|||f||||f||||||||||2018-05-31 23:50:03.314602|2018-05-31 23:50:03.314602
NCT01117480|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2015-12-11||2016-01-27|2010-05-04|2010-05-05|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|July 2005||2005-07-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|REACH|Baseline analyses accounts for Intention to treat (ITT) population (all participants who received at least 1 dose of study drug).|Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA|Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (REACH)|Completed|||1013|Actual|AbbVie|||1||f||||||||||||||2018-05-31 23:50:03.43826|2018-05-31 23:50:03.43826
NCT01117467|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2012-06-18|2010-05-04|2010-05-05|Estimate|||||||2012-06-18|2012-06-19|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Factors Affecting Medical Student Learning in Simulation Scenarios|Factors Affecting Medical Student Learning in Simulation Scenarios|Completed||N/A|76|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 23:50:03.832264|2018-05-31 23:50:03.832264
NCT01117454|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2017-02-22||2017-05-17|2010-05-04|2010-05-05|Estimate|2017-04-11|2017-05-17|Actual||||2017-05-17|2017-06-14|Actual|December 2011||2011-12-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia|A Prospective Randomized Crossover Trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia|Completed||N/A|14|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 23:50:03.928379|2018-05-31 23:50:03.928379
NCT01117441|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2018-05-22|2010-05-04|2010-05-05|Estimate|||||||2018-05-22|2018-05-23|Actual|June 2010||2010-06-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia|International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 3|4750|Anticipated|University of Schleswig-Holstein||6|||f||||t||||||||||2018-05-31 23:50:04.291006|2018-05-31 23:50:04.291006
NCT01117428|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2017-02-03||2018-02-13|2010-05-03|2010-05-05|Estimate|2017-06-23|2017-07-12|Actual||||2018-02-13|2018-03-13|Actual|March 2010|Actual|2010-03-31|February 2018|2018-02-28|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional||"Part A: Dose escalation in patients with refractory or recurrent advanced solid tumors.~Parts B, C, D, E and F: Dose expansion cohorts in patients wíth advanced anti-EGFR antibody refractory mCRC."|Sym004 in Patients With Advanced Solid Tumors|An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|111|Actual|Symphogen A/S|None reported|1|||f||||t|t|f||||||No||2018-05-31 23:50:04.862321|2018-05-31 23:50:04.862321
NCT01117415|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-06-04|2010-05-04|2010-05-05|Estimate|||||||2015-06-04|2015-06-08|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|NOTES||Cost Effectiveness Analysis of Cholecystectomy, Projected Long Term Outcomes and Complications Evaluation|Cost Effectiveness Analysis of Transgastric Cholecystectomy, Transvaginal Cholecystectomy, and Laparoscopic Cholecystectomy: Projected Long Term Outcomes and Complications Evaluation|Completed|||37|Actual|University Hospitals Cleveland Medical Center|||1||f||||t||||||||||2018-05-31 23:50:06.538837|2018-05-31 23:50:06.538837
NCT01117402|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Tomotherapy in Postsurgery Recurrent Carcinoma Cervix|Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix|Unknown status|Recruiting|Phase 2|90|Anticipated|Tata Memorial Hospital|||||f||||t||||||||||2018-05-31 23:50:06.622272|2018-05-31 23:50:06.622272
NCT01117389|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2015-08-26|2010-05-04|2010-05-05|Estimate|||||||2015-08-26|2015-08-27|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer|Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer|Completed|||587|Actual|St. Jude Children's Research Hospital|||2||f||||t||||||||||2018-05-31 23:50:06.711057|2018-05-31 23:50:06.711057
NCT01117376|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-03-30|2010-05-04|2010-05-05|Estimate|||||||2011-03-30|2011-03-31|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|August 2011|Anticipated|2011-08-31|June 2011|Anticipated|2011-06-30||Interventional|||Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients|Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients Intolerant to Enteral Feeding|Terminated||Phase 2|42|Anticipated|Shiraz University of Medical Sciences||2||"The study was prematurely terminated because of unavailibility of Methylnaltrexone in the~   region"|f||||f||||||||||2018-05-31 23:50:06.931639|2018-05-31 23:50:06.931639
NCT01117363|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Effect of Three Weeks Consumption of Rye Porridge Breakfast|Effect of Three Weeks Consumption of Rye Porridge Breakfast on 24 h Appetite Profile, and Acute Effect on OCTT and Breath Hydrogen|Unknown status|Active, not recruiting|N/A|26|Anticipated|Swedish University of Agricultural Sciences||2|||f||||f||||||||||2018-05-31 23:50:07.016828|2018-05-31 23:50:07.016828
NCT01117350|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2013-10-04||2014-03-05|2010-05-04|2010-05-05|Estimate|2013-12-11|2014-01-29|Estimate||||2014-03-05|2014-04-11|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|EAGLE|Modified-Intent-to-treat (mITT) population: all patients who were randomized, received at least one dose of Interventional Product (IP), and had at least one post-baseline assessment during comparative period of any primary or secondary efficacy variables|Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure|A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide|Completed||Phase 4|978|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:50:07.170604|2018-05-31 23:50:07.170604
NCT01117337|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2010-07-07||2010-08-09|2010-05-04|2010-05-05|Estimate|2010-08-09|2010-08-31|Estimate||||2010-08-09|2010-08-31|Estimate|September 2008||2008-09-30|July 2008|2008-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparing Non-fixation of Mesh to Mesh Fixation in Laparoscopic Inguinal Hernia Repair|Comparing Non-fixation of Mesh to Mesh Fixation in Laparoscopic Total Extraperitoneal Inguinal Hernia Repair Under Spinal Anesthesia- A Randomized Controlled Trial|Completed||Phase 4|104|Actual|Moulana Hospital||1|||f||||t||||||||||2018-05-31 23:50:08.140084|2018-05-31 23:50:08.140084
NCT01117324|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|June 2010||2010-06-30|May 2010|2010-05-31||||July 2011|Anticipated|2011-07-31||Observational|||Bone Density of Large Newborn Infants and Infants of Diabetic Mothers|Bone Density of Large Newborn Infants and Infants of Diabetic Mothers|Unknown status|Not yet recruiting||40|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 23:50:08.366976|2018-05-31 23:50:08.366976
NCT01117311|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2013-08-21||2013-11-14|2010-05-04|2010-05-05|Estimate|2013-11-14|2014-01-06|Estimate||||2013-11-14|2014-01-06|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Vagal Nerve Stimulation and Glucose Metabolism|The Effect of Vagal Nerve Stimulation on Enteroendocrine Secretion and Glucose Metabolism|Completed||N/A|9|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:50:08.411343|2018-05-31 23:50:08.411343
NCT01117298|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-07|2010-05-03|2010-05-05|Estimate|||||||2010-05-07|2010-05-10|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma|A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study|Completed||Phase 3|66|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||2|||f||||f||||||||||2018-05-31 23:50:08.605167|2018-05-31 23:50:08.605167
NCT01117285|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-20|2010-05-03|2010-05-05|Estimate|||||||2010-05-20|2010-05-21|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Implementation and Evaluation of the COTiD Program in the Netherlands|Implementation and Evaluation of an Effective Community Occupational Therapy in Dementia (COTiD) Program|Unknown status|Enrolling by invitation|N/A|180|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 23:50:08.886025|2018-05-31 23:50:08.886025
NCT01117272|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-11-13|2010-05-04|2010-05-05|Estimate|||||||2013-11-13|2013-11-14|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Observational|||The Relationship of PRL and Polycystic Ovary Syndrome (PCOS) in Taiwan's Women|Relationship of Metabolic Parameters, Endocrine and Prolactin Levels in Taiwan's Women With Polycystic Ovary Syndrome and Hyperprolactinemia.|Completed|||474|Actual|Taipei Medical University WanFang Hospital|||3||f||||f||||||||||2018-05-31 23:50:08.971996|2018-05-31 23:50:08.971996
NCT01117246|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2012-02-17|2010-05-03|2010-05-05|Estimate|||||||2012-02-17|2012-02-20|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Pilot Study for Palliation of Pain in Bone Metastases by MR-HIFU|Pilot Study for the Treatment of Bone Metastases by High Intensity Focused Ultrasound Guided by MRI to Perform Pain Palliation|Completed||Phase 1/Phase 2|2|Actual|Philips Healthcare||1|||f||||t||||||||||2018-05-31 23:50:09.057957|2018-05-31 23:50:09.057957
NCT01117233|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2012-01-17|2010-05-03|2010-05-05|Estimate|||||||2012-01-17|2012-01-18|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429|A Randomised, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 23:50:09.141618|2018-05-31 23:50:09.141618
NCT01117220|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-04-21|2010-05-03|2010-05-05|Estimate|||||||2015-04-21|2015-04-22|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)|Four Week, Double Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)|Withdrawn||Phase 3|0|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:50:09.300549|2018-05-31 23:50:09.300549
NCT01117194|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2012-12-20|2010-05-04|2010-05-05|Estimate|||||||2012-12-20|2012-12-21|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Effect on Shoulder Training Using Rehabilitation Robot for Stroke Patients|Rehabilitation Robot for Upper Limbs, Component Project 5: Effect on Shoulder Training Using Rehabilitation Robot for Stroke Patients|Unknown status|Recruiting|Phase 1|12|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 23:50:09.388813|2018-05-31 23:50:09.388813
NCT01117181|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|2013-02-11||2013-04-01|2010-05-04|2010-05-05|Estimate|2013-04-01|2013-05-10|Estimate||||2013-04-01|2013-05-10|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ADMET||Apathy in Dementia Methylphenidate Trial (ADMET)|Apathy in Dementia Methylphenidate Trial (ADMET)|Completed||Phase 2|60|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 23:50:09.583699|2018-05-31 23:50:09.583699
NCT01117168|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2017-10-05|2010-05-04|2010-05-05|Estimate|||||||2017-10-05|2017-10-06|Actual|April 30, 2010||2010-04-30|August 9, 2017|2017-08-09|August 9, 2017||2017-08-09|||||Observational|||Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group|Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group|Terminated|||4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:50:09.992952|2018-05-31 23:50:09.992952
NCT01117155|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2018-05-23|2010-05-04|2010-05-05|Estimate|||||||2018-05-23|2018-05-24|Actual|April 23, 2010||2010-04-23|October 22, 2012|2012-10-22|October 22, 2012||2012-10-22|||||Observational|||A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas|A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:50:10.077882|2018-05-31 23:50:10.077882
NCT01117142|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2018-03-27|2010-05-04|2010-05-05|Estimate|||||||2018-03-27|2018-03-29|Actual|April 28, 2010||2010-04-28|November 22, 2017|2017-11-22||||||||Observational|||A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers|A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers.|Recruiting|||105|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:50:10.154058|2018-05-31 23:50:10.154058
NCT01117129|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2014-03-27|2010-05-04|2010-05-05|Estimate|||||||2014-03-27|2014-03-28|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)|Efficacy of MabThera in Patients With Rheumatoid Arthritis, by Measurement of Disease Parameters Through Magnetic Resonance of the Hand (RESONAR Study)|Terminated||Phase 4|2|Actual|Hoffmann-La Roche||2||"This study was prematurely terminated as 2 patients were recruited and both of them withdrawn~   from the study before reaching the primary end point."|f||||||||||||||2018-05-31 23:50:10.243077|2018-05-31 23:50:10.243077
NCT01117116|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-03-27|2010-05-03|2010-05-05|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2010||2010-03-31|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Sub-Sensitivity to Long-Acting Bronchodilators (LABA)|Sub-Sensitivity to Long-Acting Bronchodilators (LABA)|Completed||N/A|21|Actual|National Jewish Health||2|||f||||f||||||||||2018-05-31 23:50:10.331224|2018-05-31 23:50:10.331224
NCT01117103|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2014-07-15|2010-05-03|2010-05-05|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes|A Prospective, Observational Study on the Use of Glucophage XR Therapy in the Management of Patients With Type 2 Diabetes|Completed|||3592|Actual|Merck KGaA|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:50:10.426657|2018-05-31 23:50:10.426657
NCT01117090|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2013-09-12||2017-04-20|2010-05-03|2010-05-05|Estimate|2013-09-12|2013-11-18|Estimate||||2017-04-20|2017-05-30|Actual|June 2010||2010-06-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|||Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery|Feasibility of Measuring Cerebrospinal Fluid (CSF) Signatures in Subjects With Intrathecal Catheter-Related Problems|Completed|||47|Actual|MedtronicNeuro|"Normal subjects who received intrathecal baclofen without experiencing catheter complications were not enrolled.~Subjects who received intrathecal drug delivery for chronic pain were not enrolled.~This was not a longitudinal study."||||f||||f||||||||||2018-05-31 23:50:10.502776|2018-05-31 23:50:10.502776
NCT01117077|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|May 2010||2010-05-31|May 2010|2010-05-31||||||||Observational|||The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis||Unknown status|Enrolling by invitation||50|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||||||||||||2018-05-31 23:50:10.865258|2018-05-31 23:50:10.865258
NCT01117064|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2013-05-26|2010-05-03|2010-05-05|Estimate|||||||2013-05-26|2013-05-29|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Neuromodulation Therapy Device for the Treatment of Sleep Apnea|Neuromodulation Therapy Device for the Treatment of Sleep Apnea|Completed||Phase 1|18|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 23:50:10.923811|2018-05-31 23:50:10.923811
NCT01117051|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2013-04-02||2014-06-06|2010-05-04|2010-05-05|Estimate|2013-05-17|2013-06-26|Estimate||||2014-06-06|2014-06-12|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|OIC|Safety Population was used which includes all subjects who were randomized into the study and who had received at least 1 dose of investigational product. 174 subjects were randomized but 5 were not treated (n = 169).|Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation|A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride in Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation|Terminated||Phase 3|174|Actual|Shire|Due to the early termination of the study, results should be interpreted with caution.|2||The study was stopped by the sponsor based on a non-safety related business priority decision|f||||f||||||||||2018-05-31 23:50:11.021695|2018-05-31 23:50:11.021695
NCT01117038|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2011-08-09|2010-05-04|2010-05-05|Estimate|||||||2011-08-09|2011-08-10|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Drug Interaction Study of Avanafil and Enalapril or Amlodipine|A Phase I, Double-Blind, Randomized, Placebo-Controlled, Two-Period, Two-Cohort Crossover Study to Assess the Potential Interaction of Avanafil on the Pharmacokinetic and/or Hemodynamic Effects of Enalapril or Amlodipine in Male Subjects|Completed||Phase 1|48|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-05-31 23:50:11.59196|2018-05-31 23:50:11.59196
NCT01117025|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2013-07-08|2010-05-04|2010-05-05|Estimate|||||||2013-07-08|2013-07-10|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Interventional|||Combined Treatment of Resistant Hypertension and Atrial Fibrillation|The Role of Renal Denervation in Improving Outcomes of Catheter Ablation in Patients With Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension|Completed||Phase 2|26|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 23:50:11.657334|2018-05-31 23:50:11.657334
NCT01116505|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2012-08-24|2010-05-04|2010-05-05|Estimate|||||||2012-08-24|2012-08-27|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Treatment of Screen-detected Celiac Disease|Treatment of Screen-detected Celiac Disease in Adults|Completed||N/A|40|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 23:50:19.351215|2018-05-31 23:50:19.351215
NCT01117012|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2015-06-01||2015-06-12|2010-05-03|2010-05-05|Estimate|2015-06-12|2015-07-07|Estimate||||2015-06-12|2015-07-07|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Full Analysis Set included all participants who were enrolled and received at least 1 dose of study drug during Study 105.|Rollover Study of VX-770 in Cystic Fibrosis Subjects|An Open-Label, Rollover Study to Evaluate the Long Term Safety and Efficacy of VX-770 in Subjects With Cystic Fibrosis|Completed||Phase 3|192|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||t||||||||||2018-05-31 23:50:12.032316|2018-05-31 23:50:12.032316
NCT01116999|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-09-25|2010-05-04|2010-05-05|Estimate|||||||2011-09-25|2011-09-27|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Retrograde Light Target Tracheal Intubation Technique:Clinical Comparison With Direct Pharyngoscopic Tracheal Intubation|Clinical Comparison of Direct Pharyngoscopic Tracheal Intubation Technique With Light-guided Tracheal Intubation|Completed||N/A|200|Actual|Second Military Medical University||1|||f||||t||||||||||2018-05-31 23:50:12.965521|2018-05-31 23:50:12.965521
NCT01116986|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2015-01-29||2015-11-12|2010-05-04|2010-05-05|Estimate|2015-03-13|2015-03-17|Estimate||||2015-11-12|2015-12-11|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Cessation||Identifying Optimal Smoking Cessation Intervention Components (Cessation)|Project 2: Identifying Optimal Smoking Cessation Intervention Components|Completed||Phase 4|637|Actual|University of Wisconsin, Madison||32|||f||||t||||||||||2018-05-31 23:50:13.096755|2018-05-31 23:50:13.096755
NCT01116973|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-05-01|2010-05-04|2010-05-05|Estimate|||||||2017-05-01|2017-05-04|Actual|September 2, 2009|Actual|2009-09-02|May 2017|2017-05-31|August 27, 2016|Actual|2016-08-27|August 27, 2016|Actual|2016-08-27||Interventional|CVP||Reliability of Central Venous Pressure Measurements|Reliability of Central Venous Pressure Measurements From Peripherally Inserted Central Catheters vs. Centrally Inserted Central Catheters|Terminated||N/A|17|Actual|University of Oklahoma||2||Change in guidelines by the manufacturer.|f||||f||||||||No||2018-05-31 23:50:14.620435|2018-05-31 23:50:14.620435
NCT01116960|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-05-01|2010-05-04|2010-05-05|Estimate|||||||2017-05-01|2017-05-04|Actual|April 2007||2007-04-30|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|P4P||How do Attitude About Pay for Performance Differ Among Different Anesthesia Care Provider and Over Time|How do Attitute About Pay for Performance Differ Among Different Anesthesia Care Provider and Over Time|Completed|||100|Actual|University of Oklahoma|||3||f||||f||||||||No||2018-05-31 23:50:14.686466|2018-05-31 23:50:14.686466
NCT01116947|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2012-02-27|2010-05-04|2010-05-05|Estimate|||||||2012-02-27|2012-02-29|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|FrEDI||Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study|Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study: An Investigator Initiated Study|Completed||N/A|108|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-05-31 23:50:14.74442|2018-05-31 23:50:14.74442
NCT01116934|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2015-06-01||2016-02-23|2010-05-03|2010-05-05|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|July 2006||2006-07-31|February 2016|2016-02-29|December 2009|Actual|2009-12-31|January 2007|Actual|2007-01-31||Observational|||Cytokines in Papillon-Lefèvre Syndrome|Observational Study on Cytokine Production by Leukocytes of Papillon-Lefèvre Syndrome Patients and Healthy Probands in Whole Blood Cultures|Completed|||17|Actual|Goethe University|||2||f||||f||||||||||2018-05-31 23:50:14.820744|2018-05-31 23:50:14.820744
NCT01116921|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2017-01-06||2017-01-06|2010-05-04|2010-05-05|Estimate|2017-01-06|2017-02-27|Actual||||2017-01-06|2017-02-27|Actual|February 2011||2011-02-28|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates|Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates|Completed||N/A|103|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 23:50:15.155624|2018-05-31 23:50:15.155624
NCT01116908|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-08-12|2010-05-04|2010-05-05|Estimate|||||||2011-08-12|2011-08-15|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SWIM||Safe Drinking Water For Households With Infants Born to HIV-Positive Mothers Pilot Study|Safe Drinking Water For Households With Infants Born to HIV-Positive Mothers in Zambia: Piloting a Household Water Treatment Intervention|Completed||N/A|120|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 23:50:15.562671|2018-05-31 23:50:15.562671
NCT01116895|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2011-09-12|2010-05-04|2010-05-05|Estimate|||||||2011-09-12|2011-09-13|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris|An International, Multi-centre, Prospective, Randomised, Double-blind, 4-arm, Placebo Controlled, Parallel Group Study With 12 Weeks Once Daily Oral Treatment in Subjects With Psoriasis Vulgaris|Completed||Phase 2|63|Actual|LEO Pharma||4|||f||||t||||||||||2018-05-31 23:50:15.660961|2018-05-31 23:50:15.660961
NCT01116882|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2014-06-06||2015-03-18|2010-05-04|2010-05-05|Estimate|2014-06-06|2014-07-08|Estimate||||2015-03-18|2015-04-07|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|MASS COMM||Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings|A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site|Completed||N/A|3691|Actual|Baim Institute for Clinical Research||2|||f||||t||||||||||2018-05-31 23:50:15.749565|2018-05-31 23:50:15.749565
NCT01116869|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2013-05-29|2010-05-04|2010-05-05|Estimate|||||||2013-05-29|2013-05-30|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|December 2011|Actual|2011-12-31||Observational|||China CellSearch Study|A Multi-Center, Prospective Study to Evaluate the Ability of CTC Enumeration Using the CellSearch® Circulating Tumor Cell Kit to Predict Prognosis and to Assess the Agreement Between CTC and Imaging Determined Response in MBC Patients 一项评价CellSearch® 循环肿瘤细胞检测试剂盒对复发转移性乳腺癌患者进行循环肿瘤细胞检测 以预测病人预后的能力及循环肿瘤细胞检测和影像学疗效判断之间一致性的多中心、前瞻性的研究|Unknown status|Active, not recruiting||500|Anticipated|Johnson & Johnson Medical, China|||3||f||||t||||||||||2018-05-31 23:50:16.389282|2018-05-31 23:50:16.389282
NCT01116856|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-09-29|2010-05-04|2010-05-05|Estimate|||||||2010-09-29|2010-09-30|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|January 2010|Anticipated|2010-01-31||Interventional|PRONAF||Nutrition and Physical Activity for Obesity|Nutrition and Physical Activity Programs for Obesity Treatment (PRONAF)|Unknown status|Recruiting|Phase 2|120|Anticipated|Universidad Politecnica de Madrid||4|||f||||f||||||||||2018-05-31 23:50:16.453248|2018-05-31 23:50:16.453248
NCT01116843|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-07-08|2010-05-04|2010-05-05|Estimate|||||||2015-07-08|2015-07-10|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2012|Actual|2012-02-29||Interventional|||Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment|A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804|Completed||Phase 1/Phase 2|13|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 23:50:16.61518|2018-05-31 23:50:16.61518
NCT01116830|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2016-11-01|2010-05-04|2010-05-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2010||2010-11-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder|A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder|Completed||Phase 1|29|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:50:16.764385|2018-05-31 23:50:16.764385
NCT01116817|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-07-13|2010-05-03|2010-05-05|Estimate|||||||2011-07-13|2011-07-14|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy|Exploratory, Cross-sectional Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy|Completed||Phase 4|35|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-05-31 23:50:16.866305|2018-05-31 23:50:16.866305
NCT01116804|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2014-12-04|2010-05-04|2010-05-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|||Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)|Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)|Unknown status|Recruiting|Phase 1|75|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 23:50:16.971055|2018-05-31 23:50:16.971055
NCT01116791|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-12-01|2010-05-03|2010-05-05|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer|Cytoreductive Surgery Plus Hyperthermic Intraoperative Peritoneal Chemotherapy With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer; the HIPCUpp-trial|Terminated||Phase 2|34|Actual|University Hospital, Gasthuisberg||1||Insufficient enrollment in Pancreatic & Biliary arm|f||||f||||||||||2018-05-31 23:50:17.059581|2018-05-31 23:50:17.059581
NCT01116778|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2015-08-31|2010-05-03|2010-05-05|Estimate|||||||2015-08-31|2015-09-02|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|PAR||the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis|A Phase III, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Efficacy and Safety of Probiotics eN-Lac® Capsules (Lactobacillus Paracasei GMNL-32) for the Treatment of Children With Perennial Allergic Rhinitis|Completed||Phase 3|236|Actual|GenMont Biotech Incorporation||2|||f||||t||||||||||2018-05-31 23:50:17.147185|2018-05-31 23:50:17.147185
NCT01116765|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-04-20|2010-05-04|2010-05-05|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|March 2014|Actual|2014-03-31||Interventional|||Impact of Early Oral Stimulation on Reducing Cardiorespiratory Events and Transition to Oral Feeding in Preterm Infants|Impact of Early Oral Stimulation on Reducing Cardiorespiratory Events and Transition to Oral Feeding in Preterm Infants|Unknown status|Active, not recruiting|N/A|62|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 23:50:17.238679|2018-05-31 23:50:17.238679
NCT01116752|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-08-28|2010-05-04|2010-05-05|Estimate|||||||2015-08-28|2015-08-31|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2013|Actual|2013-12-31||Interventional|PedETrol||Pediatric Intensive Care Units (ICUs) at Emory-Children's Center Glycemic Control: The PedETrol Trial|Pediatric ICUs at Emory-Children's Center Glycemic Control: The PedETrol Trial|Completed||Phase 3|153|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 23:50:17.315806|2018-05-31 23:50:17.315806
NCT01116739|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2018-05-08|2010-05-03|2010-05-05|Estimate|||||||2018-05-08|2018-05-10|Estimate|April 2011||2011-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs|Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs|Active, not recruiting||Phase 3|1040|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 23:50:17.583401|2018-05-31 23:50:17.583401
NCT01116726|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2018-01-16|2010-05-03|2010-05-05|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2011||2011-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Promoting Behavioral Change for Oral Health in American Indian Mothers and Children|Promoting Behavioral Change for Oral Health in American Indian Mothers and Children|Active, not recruiting||N/A|1134|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 23:50:17.66244|2018-05-31 23:50:17.66244
NCT01116713|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|dxt2010brca||Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer|Preoperative Dexamethasone Reduces Postoperative Pain, Nausea and Vomiting Following Mastectomy for Breast Cancer.|Completed||Phase 3|70|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 23:50:17.734063|2018-05-31 23:50:17.734063
NCT01116700|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-08-06|2010-05-04|2010-05-05|Estimate|||||||2013-08-06|2013-08-09|Estimate|December 2010||2010-12-31|August 2013|2013-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Dexmedetomidine in Seizure Patients|The Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Patients With Seizure Disorders|Completed||Phase 1|16|Actual|University of California, San Francisco|||||f||||f||||||||||2018-05-31 23:50:17.864191|2018-05-31 23:50:17.864191
NCT01116687|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2012-04-13||2014-05-02|2010-05-04|2010-05-05|Estimate|2012-05-10|2012-06-11|Estimate||||2014-05-02|2014-05-20|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||RO4929097 in Treating Patients With Metastatic Colorectal Cancer|A Phase 2 Open-Label Study of RO4929097 in Metastatic Colorectal Cancer|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:50:17.96638|2018-05-31 23:50:17.96638
NCT01116674|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-08-28|2010-05-03|2010-05-05|Estimate|||||||2015-08-28|2015-08-31|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Pediatric Critical Illness Hyperglycemia and Glycemic Control Registry|Pediatric Critical Illness Hyperglycemia and Glycemic Control Registry: A Project to Assist in the Improved Understanding of Hyperglycemia and Glycemic Control in Pediatric Critical Illness.|Completed|||206|Actual|Indiana University|||1||f||||t||||||||||2018-05-31 23:50:18.2662|2018-05-31 23:50:18.2662
NCT01116661|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-07-21|2010-05-04|2010-05-05|Estimate|||||||2017-07-21|2017-07-25|Actual|August 2010||2010-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ALA||Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain|Recruiting||Phase 2|300|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 23:50:18.338305|2018-05-31 23:50:18.338305
NCT01116648|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2018-05-23|2010-05-04|2010-05-05|Estimate|||||||2018-05-23|2018-05-24|Actual|March 25, 2010|Actual|2010-03-25|May 2018|2018-05-31||||October 31, 2018|Anticipated|2018-10-31||Interventional|||Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer|Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer|Active, not recruiting||Phase 1/Phase 2|162|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 23:50:18.434398|2018-05-31 23:50:18.434398
NCT01116635|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2014-03-14|2010-05-04|2010-05-05|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)|Phase I/II Study Examining Pharmacokinetics, Adverse Events, and Surgically Resected Histopathological Response Utilizing a Dose Escalation Model of Doxorubicin Loaded Drug Eluting Superabsorbent Polymer Microspheres in Surgically Resectable Hepatocellular Carcinoma in Humans|Completed||Phase 1/Phase 2|24|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 23:50:18.541331|2018-05-31 23:50:18.541331
NCT01116622|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2014-11-11|2010-05-03|2010-05-05|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2003||2003-04-30|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract|A Phase I Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract|Completed||Phase 1|24|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 23:50:18.622607|2018-05-31 23:50:18.622607
NCT01116609|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2011-11-04|2010-05-04|2010-05-05|Estimate|||||||2011-11-04|2011-11-07|Estimate|October 2004||2004-10-31|November 2011|2011-11-30|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Local Effects of Epinephrine on Lactate, Glucose, Lipid and Protein Metabolism in Bilaterally Perfused Human Legs|Local Effects of Epinephrine on Lactate, Glucose, Lipid and Protein Metabolism in Bilaterally Perfused Human Legs|Completed||N/A|10|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 23:50:18.694443|2018-05-31 23:50:18.694443
NCT01116596|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-04|2010-05-04|2010-05-05|Estimate|||||||2010-05-04|2010-05-05|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Paracetamol and Glutathion|Effect of Paracetamol on the Status in Glutathione for the Aged Person|Completed||Phase 1|18|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:50:18.757645|2018-05-31 23:50:18.757645
NCT01116583|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2014-08-04|2010-05-03|2010-05-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|GABATEA||The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy|The Effect of Gabapentin on Thoracic Epidural Analgesia Following Thoracotomy - A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 3|104|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 23:50:18.843108|2018-05-31 23:50:18.843108
NCT01116570|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2015-03-31|2010-05-04|2010-05-05|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FSHD1||Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients|Exercise and Myopathies. Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients: Functional, Tissue and Quality of Life Benefits.|Completed||N/A|15|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 23:50:18.930122|2018-05-31 23:50:18.930122
NCT01116557|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2014-10-01|2010-05-04|2010-05-05|Estimate|||||||2014-10-01|2014-10-02|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CLARITY-AF||Efficacy, Safety and Efficiency Study of CARTO® 3 System Guided THERMOCOOL® Catheter Ablation Versus Fluoroscopy Guided Ablation With the Pulmonary Vein Ablation Catheter® (PVAC®)|CARTO® 3 System-guided RF Ablation Using the THERMOCOOL® Catheter Versus Fluoroscopy-guided RF Ablation Using the Pulmonary Vein Ablation Catheter® (PVAC®) in Subjects With Paroxysmal Atrial Fibrillation: A Prospective, Multi-center, Randomized (2:1), Controlled, Two-arm, Unblinded Clinical Study|Terminated||Phase 4|79|Actual|Biosense Webster, Inc.||2||"Biosense stopped Study enrollment following publications that reported PVAC ablation is linked~   with a higher incidence of asymptomatic cerebral embolic lesions"|f||||t||||||||||2018-05-31 23:50:19.005724|2018-05-31 23:50:19.005724
NCT01116544|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2014-12-19|2010-05-03|2010-05-05|Estimate|||||||2014-12-19|2014-12-23|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2013|Actual|2013-12-31||Interventional|AMES||Treatment of Chronic Stroke With AMES + EMG Biofeedback|Treatment of Chronic Stroke With AMES + EMG Biofeedback|Unknown status|Active, not recruiting|Phase 1/Phase 2|64|Anticipated|AMES Technology||2|||f||||f||||||||||2018-05-31 23:50:19.13521|2018-05-31 23:50:19.13521
NCT01116531|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-05-30|2010-05-03|2010-05-05|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|December 2012|Anticipated|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin|Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain|Withdrawn||Phase 4|0|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 23:50:19.212739|2018-05-31 23:50:19.212739
NCT01116518|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-11-24|2010-05-04|2010-05-05|Estimate|||||||2013-11-24|2013-11-26|Estimate|February 2009||2009-02-28|May 2010|2010-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|toarcriep||Treatment of Atraumatic Rotator Cuff Rupture in Elderly Patients|Treatment of Atraumatic Rotator Cuff Rupture in Elderly Patients|Completed||N/A|180|Actual|Turku University Hospital||3|||f||||f||||||||||2018-05-31 23:50:19.284519|2018-05-31 23:50:19.284519
NCT01116492|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2010-05-20|2010-05-04|2010-05-05|Estimate|||||||2010-05-20|2010-05-21|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|Lap vs SILS||Study of the Inflammatory Reaction in Standard vs Single Port Cholecystectomy for Uncomplicated Cholelithiasis|Study of the Inflammatory Reaction in Standard vs Single Port Cholecystectomy for Uncomplicated Cholelithiasis|Completed||N/A|40|Actual|G. Hatzikosta General Hospital||2|||f||||t||||||||||2018-05-31 23:50:19.417341|2018-05-31 23:50:19.417341
NCT01116479|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2014-11-03|2010-05-04|2010-05-05|Estimate|||||||2014-11-03|2014-11-05|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|HaemOPtimal||Optimal Transfusion in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)|Randomised Feasibility Study of Optimal Transfusion Thresholds in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)|Terminated||Phase 2|180|Anticipated|Rigshospitalet, Denmark||2||low accrual|f||||f||||||||||2018-05-31 23:50:19.468576|2018-05-31 23:50:19.468576
NCT01116466|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2013-07-22||2014-11-06|2010-05-03|2010-05-05|Estimate|2014-11-06|2014-11-17|Estimate||||2014-11-06|2014-11-17|Estimate|August 2009||2009-08-31|November 2014|2014-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System|Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System|Completed||N/A|5|Actual|Otto Bock Healthcare Products GmbH||1|||f||||f||||||||||2018-05-31 23:50:19.535499|2018-05-31 23:50:19.535499
NCT01116453|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-03-05|2010-05-03|2010-05-05|Estimate|||||||2013-03-05|2013-03-07|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Randomized Controlled Trial of Acupuncture for Dysmenorrhea|Randomized Controlled Trial of Acupuncture on the Effect of Quality of Life and Clinical Efficacy for Dysmenorrhea Patients.|Completed||Phase 3|22|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 23:50:19.775035|2018-05-31 23:50:19.775035
NCT01116440|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-07-20|2010-05-03|2010-05-05|Estimate|||||||2011-07-20|2011-07-21|Estimate|April 2010||2010-04-30|July 2011|2011-07-31||||July 2011|Actual|2011-07-31||Interventional|||A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis|A Double Blind, Randomized, Controlled, Multicenter, Efficacy and Safety Study of Oral BGS649 vs. Placebo (Each Co-administered With a Combined Oral Contraceptive) Assessing Pain Response in Patients With Refractory Endometriosis|Terminated||Phase 2|68|Anticipated|Novartis||2|||f||||||||||||||2018-05-31 23:50:19.985199|2018-05-31 23:50:19.985199
NCT01116427|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2015-12-15|2014-08-12|2016-08-03|2010-05-03|2010-05-05|Estimate|2016-04-07|2016-04-08|Estimate|2014-08-13|2014-08-15|Estimate|2016-08-03|2016-09-15|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|ACCLAIM||A Cooperative Clinical Study of Abatacept in Multiple Sclerosis|A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|65|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.|2018-05-31 23:50:20.1557|2018-05-31 23:50:20.1557
NCT01116414|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2018-05-23|2010-05-03|2010-05-05|Estimate|||||||2018-05-23|2018-05-24|Actual|July 2009||2009-07-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Molecular Phenotypes for Cystic Fibrosis Lung Disease|Molecular Phenotypes for Cystic Fibrosis Lung Disease|Enrolling by invitation|||200|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 23:50:21.640667|2018-05-31 23:50:21.640667
NCT01116401|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2017-12-01||2017-12-26|2010-05-04|2010-05-05|Estimate|2017-12-01|2017-12-26|Actual||||2017-12-26|2018-01-23|Actual|November 3, 2009|Actual|2009-11-03|December 2017|2017-12-31|January 4, 2012|Actual|2012-01-04|December 29, 2011|Actual|2011-12-29||Interventional|||Impact of Hot Flashes on Sleep and Mood Disturbance|Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance|Completed||Phase 4|29|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:50:21.799532|2018-05-31 23:50:21.799532
NCT01116388|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2015-04-07|2010-05-03|2010-05-05|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|GFCF||A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders|A Study to Assess the Role of a Gluten Free-Casein Free Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders|Completed||N/A|65|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:50:22.200996|2018-05-31 23:50:22.200996
NCT01116375|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2018-03-07|2010-05-03|2010-05-05|Estimate|||||||2018-03-07|2018-03-09|Actual|June 2010|Actual|2010-06-30|March 2018|2018-03-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Observational|IMPACT Obesity||Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control?|Does Treating Obstructive Sleep Apnea in Obese Canadian Youth Improve Blood Sugar Control? A Multi-Centered Prospective Cohort Study|Completed|||27|Actual|Katz, Sherri Lynne, M.D.|||1||f||||f||||||||||2018-05-31 23:50:22.428258|2018-05-31 23:50:22.428258
NCT01116362|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-19|2010-05-03|2010-05-05|Estimate|||||||2010-05-19|2010-05-20|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparing Primary With Secondary Repair of Based on Electrodiagnostic Assessment and Clinical Examination|Study of Surgical Methods for Repair of Clean Transections in Peripheral Nerve Injuries|Completed||Phase 2|46|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:50:22.496616|2018-05-31 23:50:22.496616
NCT01116349|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2012-12-19|2010-05-03|2010-05-05|Estimate|||||||2012-12-19|2012-12-20|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|July 2014|Anticipated|2014-07-31|December 2012|Anticipated|2012-12-31||Interventional|||Conservative Treatment Versus the Surgical Treatment of Diaphyseal Fractures of Humerus|Diaphyseal Fractures of the Humerus: A Prospective Cohort Study Comparing the Conservative Treatment and the Surgical Treatment.|Terminated||N/A|4|Actual|Hopital de l'Enfant-Jesus||2||"Difficulties to recruit participants A similar Canadian multicentric study started at about the~   same."|f||||f||||||||||2018-05-31 23:50:22.566644|2018-05-31 23:50:22.566644
NCT01116336|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2017-11-29|2010-05-03|2010-05-05|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2010||2010-03-31|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck|Phase I Study of Chemoprevention With Green Tea Polyphenon E (PPE) and the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) in Patients With Premalignant Lesions of the Head and Neck|Active, not recruiting||Phase 1|25|Actual|Emory University||1|||f||||t||||||||||2018-05-31 23:50:22.6469|2018-05-31 23:50:22.6469
NCT01116323|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-09-20|2010-05-03|2010-05-04|Estimate|||||||2011-09-20|2011-09-21|Estimate|June 2010||2010-06-30|September 2011|2011-09-30|December 2013|Anticipated|2013-12-31|September 2012|Anticipated|2012-09-30||Observational|||Emergency Department Crowding in Relation to In-hospital Adverse Medical Events|Emergency Department Crowding in Relation to In-hospital Adverse Medical Events|Unknown status|Recruiting||104000|Anticipated|Katholieke Universiteit Leuven|||||f||||f||||||None Retained|"~     None Retained - no samples retained~   "|||2018-05-31 23:50:22.776219|2018-05-31 23:50:22.776219
NCT01116310|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-09-27|2010-05-03|2010-05-04|Estimate|||||||2011-09-27|2011-09-28|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|TRYSEM||Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause|Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Tolerability of the Combination of Soy Isoflavones and Red Clover Extract (FITOGYN) in the Treatment of the Hot Flushes in Menopausal Women.|Unknown status|Recruiting|Phase 4|166|Anticipated|Laboratorios Casen-Fleet S.L.U.||2|||f||||f||||||||||2018-05-31 23:50:23.050141|2018-05-31 23:50:23.050141
NCT01116297|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2013-02-14|2010-05-03|2010-05-04|Estimate|||||||2013-02-14|2013-02-18|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Tissue Oxygenation Measurements With Modulated Light (S-FLARE)|Tissue Oxygenation Measurements During Plastic Surgery Using Spatially Modulated Light (S-FLARE)|Completed||Phase 1|4|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-05-31 23:50:23.168184|2018-05-31 23:50:23.168184
NCT01116284|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2016-08-10|2010-05-03|2010-05-04|Estimate|||||||2016-08-10|2016-08-12|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Laparoscopic Revision of an Enlarged Gastric Outlet After Gastric Bypass|Laparoscopic Suture Plication of an Enlarged Gastric Stoma in the Gastric Bypass Patient|Terminated||N/A|5|Actual|Baystate Medical Center||1||no patients to recruit|f||||f||||||||No||2018-05-31 23:50:23.250489|2018-05-31 23:50:23.250489
NCT01116271|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2013-01-11|2010-05-03|2010-05-04|Estimate|||||||2013-01-11|2013-01-14|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec|A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination With Irinotecan, in 2nd Line Patients With K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer|Completed||Phase 2|32|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 23:50:23.350125|2018-05-31 23:50:23.350125
NCT01116258|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-10-08|2010-05-03|2010-05-04|Estimate|||||||2010-10-08|2010-10-11|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5847 Following Oral Administration to Healthy Male Subjects and Female Subjects of Non-childbearing Potential|Completed||Phase 1|60|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:50:23.469708|2018-05-31 23:50:23.469708
NCT01116245|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2016-07-26|2010-05-03|2010-05-04|Estimate|||||||2016-07-26|2016-07-27|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|December 2013|Actual|2013-12-31||Interventional|ADXS11-001||An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+|A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3|Terminated||Phase 2|81|Actual|Advaxis, Inc.||4||Study stopped due to lack of enrollment|f||||t||||||||||2018-05-31 23:50:23.541973|2018-05-31 23:50:23.541973
NCT01116232|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2013-10-22||2017-05-26|2010-05-03|2010-05-04|Estimate|2013-10-22|2013-12-13|Estimate||||2017-05-26|2017-06-21|Actual|August 2010||2010-08-31|May 2017|2017-05-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation|A Pilot Phase II Study of Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation|Terminated||Phase 2|4|Actual|Barbara Ann Karmanos Cancer Institute|Study terminated due to lack of funding. No analysis, patient data on this protocol due to the fact that only four patients was able to be accrued.|1||Lack of funding.|f||||t||||||||||2018-05-31 23:50:23.702743|2018-05-31 23:50:23.702743
NCT01116219|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2016-06-14|2010-05-03|2010-05-04|Estimate|||||||2016-06-14|2016-06-15|Estimate|June 2010||2010-06-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|July 2014|Actual|2014-07-31||Interventional|||Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).|Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).|Completed||Phase 2|149|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-05-31 23:50:24.050095|2018-05-31 23:50:24.050095
NCT01116206|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-03-17|2010-05-03|2010-05-04|Estimate|||||||2017-03-17|2017-03-21|Actual|May 2010||2010-05-31|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|Resolor||An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation|A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prucalopride (Resolor) Tablets in Participants With Chronic Constipation|Completed||Phase 3|507|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 23:50:24.15372|2018-05-31 23:50:24.15372
NCT01116193|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2017-09-13|2010-05-03|2010-05-04|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2010||2010-01-31|January 2011|2011-01-31|August 2013|Actual|2013-08-31|July 2012|Actual|2012-07-31||Interventional|RV-405 LAL||Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia|A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment|Completed||Phase 2|10|Actual|Institut de Cancérologie de la Loire|||||f||||t||||||||||2018-05-31 23:50:25.245042|2018-05-31 23:50:25.245042
NCT01116180|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2013-02-04|2010-05-03|2010-05-04|Estimate|||||||2013-02-04|2013-02-05|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Interventional|||Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System|Influence of Blockade of the Renin-angiotensin System for Preservation of Cognitive Function, Hormonal Counter-regulatory Response, Symptomatology and Cardiac Repolarisation During Hypoglycaemia in Patients With Type 1 Diabetes|Completed||N/A|9|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-05-31 23:50:25.317873|2018-05-31 23:50:25.317873
NCT01116167|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2013-05-17|2010-05-03|2010-05-04|Estimate|||||||2013-05-17|2013-05-20|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine|Letrozole and Berberine in Infertile PCOS Patients|Unknown status|Recruiting|N/A|660|Anticipated|Heilongjiang University of Chinese Medicine||3|||f||||f||||||||||2018-05-31 23:50:25.398039|2018-05-31 23:50:25.398039
NCT01116154|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-12-08|2010-05-03|2010-05-04|Estimate|||||||2010-12-08|2010-12-09|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma|A Phase I Study of the Combination of Lenalidomide With the Histone Deacetylase Inhibitor, Vorinostat in Hodgkin and Non Hodgkin's Lymphoma|Terminated||Phase 1|30|Anticipated|City of Hope Medical Center||1||Sponsor withdrew support for the study|f||||t||||||||||2018-05-31 23:50:25.503958|2018-05-31 23:50:25.503958
NCT01116141|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03||2013-03-27|2013-04-09|2010-05-03|2010-05-04|Estimate||||2013-03-27|2013-04-04|Estimate|2013-04-09|2013-04-15|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|MOTION||A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)|A Phase II, Multi-center, Randomized, Parallel Group, Double-blind, MTX Controlled Study to Assess the Clinical Efficacy, Safety and Tolerability of CH-4051 in Patients With Active RA Who Have Shown an Inadequate Response to MTX Monotherapy|Completed||Phase 2|250|Actual|Chelsea Therapeutics||5|||f||||t||||||||||2018-05-31 23:50:25.592535|2018-05-31 23:50:25.592535
NCT01116128|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2011-06-13|2010-05-03|2010-05-04|Estimate|||||||2011-06-13|2011-06-14|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|D-MP||Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients|A Multicenter, Open-label, Phase Ii Study of Dasatinib in Combination With Melphalan and Prednisone (D-MP) in Advanced, Relapsed / Refractory Multiple Myeloma Patients|Terminated||Phase 2|8|Actual|Fondazione Neoplasie Sangue Onlus||1||difficulty in enrolling patients|f||||t||||||||||2018-05-31 23:50:25.74644|2018-05-31 23:50:25.74644
NCT01116115|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-05-16|2010-05-03|2010-05-04|Estimate|||||||2011-05-16|2011-05-17|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effects of Dietary Palmitic Acid Triacylglyceride Position on Intestinal Parameters in Infants (InFat_005)|The Effects of Dietary Palmitic Acid Triacylglyceride Position on Intestinal Parameters, Anthropometric Parameters and Stool Characteristics in Term Infants|Completed||N/A|30|Actual|Enzymotec||3|||f||||f||||||||||2018-05-31 23:50:25.832739|2018-05-31 23:50:25.832739
NCT01116102|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2011-09-12||2011-10-17|2010-05-03|2010-05-04|Estimate|2011-09-12|2011-10-18|Estimate||||2011-10-17|2011-10-24|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|INFUSE-AT1A||Study of In-line Pressure Using Various Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase (INFUSE-AT1A)|The INcreased Flow Utilizing Subcutaneously-Enabled Fluids Administration Technique 1A Study (INFUSE-AT 1A): A Randomized, Parallel Group Study to Evaluate the In-line Pressure, Flow Rate, Safety and Tolerability of Hylenex-facilitated Subcutaneous Fluid Administration In Healthy Volunteers Using Various Subcutaneous Infusion Techniques|Terminated||Phase 4|20|Actual|Baxter Healthcare Corporation|Due to small numbers of subjects in each treatment arm, no conclusions can be drawn on the influence of any of the individual potential pressure-affecting factors or the combinations of these factors on in-line fluid pressure.|8||Strategic business decision (not related to safety or efficacy concerns)|f||||f||||||||||2018-05-31 23:50:25.966703|2018-05-31 23:50:25.966703
NCT01116089|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-11-16|2010-05-03|2010-05-04|Estimate|||||||2011-11-16|2011-11-17|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer|PHARMACOKINETIC STUDY OF BRAMITOB® ADMINISTERED FOR INHALATION BY PARI eFLOW® RAPID ELECTRONIC NEBULIZER VS PARI LC® PLUS NEBULIZER COUPLED WITH THE PARI TURBO BOY® N COMPRESSOR IN CYSTIC FIBROSIS PATIENTS INFECTED WITH PSEUDOMONAS AERUGINOSA|Completed||Phase 1|25|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 23:50:27.04749|2018-05-31 23:50:27.04749
NCT01116076|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-01-30|2010-05-03|2010-05-04|Estimate|||||||2013-01-30|2013-02-01|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|Decision+||DECISION+, a Training Program to Improve Optimal Drug Prescription|DECISION+: Une Formation Pour Les médecins de Famille Sur la Prise de décision partagée Afin d'Optimiser Les décisions Cliniques Concernant l'Utilisation d'Antibiotiques Pour Les Infections aiguës Des Voies Respiratoires (IAVR)|Completed||Phase 1|712|Actual|CHU de Quebec-Universite Laval||2|||f||||||||||||||2018-05-31 23:50:27.127308|2018-05-31 23:50:27.127308
NCT01116063|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-03|2010-05-03|2010-05-04|Estimate|||||||2010-05-03|2010-05-04|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|COPDVEN||Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)|Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease|Unknown status|Not yet recruiting|Phase 4|15|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 23:50:27.187868|2018-05-31 23:50:27.187868
NCT01116050|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-05-19|2010-05-03|2010-05-04|Estimate|||||||2011-05-19|2011-05-20|Estimate|January 2004||2004-01-31|May 2011|2011-05-31||||December 2007|Actual|2007-12-31||Interventional|HEMOSTOP||Intrarectal Misoprostol in Postpartum Haemorrhage|Second-line Treatment of Post-partum Haemorrhage With Intrarectal Misoprostol: a Multicentre, Double Blind, Randomized Placebo-controlled Trial|Completed||Phase 3|116|Actual|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 23:50:27.345499|2018-05-31 23:50:27.345499
NCT01116037|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2016-10-17||2017-04-24|2010-05-03|2010-05-04|Estimate|2017-04-24|2017-05-25|Actual||||2017-04-24|2017-05-25|Actual|September 2009||2009-09-30|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PAS||ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study|ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study|Terminated||N/A|26|Actual|Medtronic Cardiovascular||1||Business decision to end study due to limited enrollment and study population|f||||f||||||||||2018-05-31 23:50:27.425675|2018-05-31 23:50:27.425675
NCT01115855|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2016-09-05||2016-09-05|2010-04-30|2010-05-04|Estimate|2016-09-05|2016-10-27|Estimate||||2016-09-05|2016-10-27|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|J-EMPHASIS-HF|Full analysis set included all randomized participants.|Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure|The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure|Completed||Phase 3|221|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:50:30.383877|2018-05-31 23:50:30.383877
NCT01116024|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2016-05-26||2017-11-20|2010-05-03|2010-05-04|Estimate|2016-10-12|2016-12-05|Estimate||||2017-11-20|2017-12-19|Actual|May 2006||2006-05-31|October 2017|2017-10-31|August 2012|Actual|2012-08-31|December 2010|Actual|2010-12-31||Interventional|Enable|173 subjects were enrolled in the study. Of the 173 subjects enrolled, a cohort of 148 subjects were implanted with, and left the operating room with, the Model 6000 valve. As per protocol, only subjects who left the operating room with the device implanted were followed and included in the analysis.|ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000|ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000|Completed||N/A|173|Actual|Medtronic Cardiovascular|Of the 173 subjects enrolled, a cohort of 148 subjects were implanted, followed and included in the analysis. 25 of the 173 subjects enrolled were intraoperative exclusions due to surgeon’s discretion during the operative thoracotomy.|1|||f||||t||||||||||2018-05-31 23:50:27.65343|2018-05-31 23:50:27.65343
NCT01116011|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-12-14|2010-05-03|2010-05-04|Estimate|||||||2010-12-14|2010-12-15|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|JMAD||Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers|A Phase I, Single-Centre, Randomised, Double-Blind, Placebo-controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7268 When Given in Multiple Ascending Oral Doses in Japanese Healthy Male Subjects|Completed||Phase 1|30|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:50:28.123968|2018-05-31 23:50:28.123968
NCT01115998|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2009-03-19||2016-10-24|2010-05-03|2010-05-04|Estimate|2010-05-03|2010-05-04|Estimate||||2016-10-24|2016-12-05|Estimate|June 2002||2002-06-30|October 2016|2016-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Effect of Power Wheelchairs on the Development and Function of Young Children With Severe Physical Disabilities|Learning Early Travel Skills: Effects of Power Mobility on the Development of Young Children With Severe Motor Impairments|Completed||Phase 2|34|Actual|University of Oklahoma|Small sample limited power; matched pairs design limited sample size and analyses; not all children were independent using power wheelchair in 1 year; cognitive measure probably unresponsive to changes in children with physical limitations.|2|||f||||f||||||||||2018-05-31 23:50:28.215188|2018-05-31 23:50:28.215188
NCT01115985|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-26|2010-05-03|2010-05-04|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers|ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Atorvastatin -|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:50:28.534966|2018-05-31 23:50:28.534966
NCT01115972|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-26|2010-05-03|2010-05-04|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers|ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Valsartan -|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:50:28.605404|2018-05-31 23:50:28.605404
NCT01115959|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|||2014-06-11|2010-05-02|2010-05-04|Estimate|||||||2014-06-11|2014-06-12|Estimate|February 2003||2003-02-28|May 2010|2010-05-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Seizures Post Intracerebral Hemorrhage|Are Post Intracerebal Hemorrhage Prevented By Anti-Epileptic Treatment?|Completed||Phase 4|72|Actual|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 23:50:28.733741|2018-05-31 23:50:28.733741
NCT01115946|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-26|2010-05-03|2010-05-04|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers|ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Enalapril -|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 23:50:28.798198|2018-05-31 23:50:28.798198
NCT01115933|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|2013-08-06||2015-07-17|2010-05-03|2010-05-04|Estimate|2013-11-14|2014-01-03|Estimate||||2015-07-17|2015-08-13|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|August 2011|Actual|2011-08-31||Interventional|SV JAPAN|Based on number of patients who received XIENCE PRIME SV EECSS|A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population|SPIRIT PRIME JAPAN (SV JAPAN)|Completed||N/A|65|Actual|Abbott Vascular||1|||f||||f||||||||||2018-05-31 23:50:28.923883|2018-05-31 23:50:28.923883
NCT01115920|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-11-17|2010-05-03|2010-05-04|Estimate|||||||2010-11-17|2010-11-18|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults|A Phase I Study in Healthy Male and Healthy Female Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MTP-131 (Bendavia™) Using a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design|Completed||Phase 1|40|Actual|Stealth BioTherapeutics Inc.||5|||f||||t||||||||||2018-05-31 23:50:29.826758|2018-05-31 23:50:29.826758
NCT01115907|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2015-01-22|2010-04-30|2010-05-04|Estimate|||||||2015-01-22|2015-01-26|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SOLO||Freedom SOLO Stentless Heart Valve Study|Clinical Investigation of the Freedom SOLO Stentless Heart Valve in North America|Completed||Phase 3|251|Actual|Sorin Group USA, Inc.||1|||f||||t||||||||||2018-05-31 23:50:29.915306|2018-05-31 23:50:29.915306
NCT01115894|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2012-12-06|2010-05-03|2010-05-04|Estimate|||||||2012-12-06|2012-12-10|Estimate|February 2007||2007-02-28|December 2012|2012-12-31||||December 2010|Actual|2010-12-31||Interventional|ProjectSMART||Medication and Counseling for Controlled Drinking|Naltrexone and CBT for Problem-Drinking MSM|Unknown status|Active, not recruiting|Phase 3|200|Actual|Research Foundation for Mental Hygiene, Inc.||4|||f||||t||||||||||2018-05-31 23:50:30.044096|2018-05-31 23:50:30.044096
NCT01115881|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|||2016-09-26|2010-05-03|2010-05-04|Estimate|||||||2016-09-26|2016-09-27|Estimate|May 2010||2010-05-31|January 2010|2010-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Relationship Between Macular Thickness Measurement and Signal Strength in Optical Coherence Tomography|Relationship Between Macular Thickness Measurement and Signal Strength Using Stratus Optical Coherence Tomography|Completed|||40|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:50:30.153655|2018-05-31 23:50:30.153655
NCT01115868|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-02-09|2010-05-03|2010-05-04|Estimate|||||||2011-02-09|2011-02-10|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||Prevascar in African Continental Group Scarring|An Exploratory, Single Centre, Randomized, Placebo Controlled, Assessor Blind Clinical Trial to Assess the Effects of Intradermal Administrations of Prevascar on Scarring in Human Subjects of African Continental Ancestral Origin|Unknown status|Active, not recruiting|Phase 1|56|Anticipated|Renovo||4|||f||||f||||||||||2018-05-31 23:50:30.207971|2018-05-31 23:50:30.207971
NCT01115842|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|||2010-08-19|2010-05-03|2010-05-04|Estimate|||||||2010-08-19|2010-08-20|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|||Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI)|Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels|Unknown status|Recruiting|Phase 4|50|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 23:50:32.012091|2018-05-31 23:50:32.012091
NCT01115803|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2012-01-06|2010-05-03|2010-05-04|Estimate|||||||2012-01-06|2012-01-09|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of LY2584702 With Erlotinib or Everolimus in Patients With Solid Tumors|A Phase 1b Trial of LY2584702 in Combination With Erlotinib or Everolimus in Patients With Solid Tumors|Terminated||Phase 1|85|Anticipated|Eli Lilly and Company||2||Primary objective has been met; safety and pharmacokinetics have been characterized.|f||||f||||||||||2018-05-31 23:50:32.122207|2018-05-31 23:50:32.122207
NCT01115790|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-05-09|2010-05-03|2010-05-04|Estimate|||||||2016-05-09|2016-05-10|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Phase 1 Study in Participants With Advanced Cancer|A Phase 1 Study of LY2606368 in Patients With Advanced Cancer|Completed||Phase 1|150|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:50:32.205088|2018-05-31 23:50:32.205088
NCT01115777|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2018-05-03|2010-05-03|2010-05-04|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2005||2005-09-30|May 2018|2018-05-31|March 2029|Anticipated|2029-03-31|June 2025|Anticipated|2025-06-30||Observational|||Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies|Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-CNS Malignancies|Active, not recruiting|||600|Anticipated|Massachusetts General Hospital|||1||f||||||||||||||2018-05-31 23:50:32.276803|2018-05-31 23:50:32.276803
NCT01115764|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|||2010-05-02|2010-05-02|2010-05-04|Estimate|||||||2010-05-02|2010-05-04|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Observational|dd||LV Diastolic Dysfunction Among the Patients With Systolic Heart Failure-clinical Significance and Prognostic Importance.|LV Diastolic Dysfunction Among the Patients With Systolic Heart Failure|Unknown status|Not yet recruiting||200|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 23:50:32.338601|2018-05-31 23:50:32.338601
NCT01115751|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2012-07-30|2010-05-03|2010-05-04|Estimate|||||||2012-07-30|2012-07-31|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study in Patients With Advanced or Metastatic Cancer|A Phase I Trial of Single-Agent LY2780301 in Patients With Advanced or Metastatic Cancer|Completed||Phase 1|80|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:50:32.391488|2018-05-31 23:50:32.391488
NCT01115738|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2012-09-25||2012-11-15|2010-05-03|2010-05-04|Estimate|2012-09-25|2012-10-26|Estimate||||2012-11-15|2012-11-20|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients|TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET|Completed||Phase 2|282|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:50:32.481176|2018-05-31 23:50:32.481176
NCT01115725|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2014-07-16|2010-05-03|2010-05-04|Estimate|||||||2014-07-16|2014-07-17|Estimate|November 2005||2005-11-30|December 2012|2012-12-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)|Phase IV Study to Evaluate the Ease of Use, Local Tolerance Safety and Effectiveness of Gonal-f® (Filled-by-Mass in a Prefilled Pen)|Completed|||76|Actual|Merck KGaA|||1||f||||||||||||||2018-05-31 23:50:33.440488|2018-05-31 23:50:33.440488
NCT01115712|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2015-10-01|2010-05-03|2010-05-04|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)|A Randomized Clinical Trial to Measure the Effect of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males|Completed||Phase 1|35|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-05-31 23:50:33.5268|2018-05-31 23:50:33.5268
NCT01115699|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2013-10-23||2013-10-23|2010-04-30|2010-05-04|Estimate|2013-10-23|2013-12-13|Estimate||||2013-10-23|2013-12-13|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|rTMS||Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as Adjuvant Treatment for Depression|Pilot Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as Adjuvant Treatment in Patients With Non-remitting Depression: Third Stage of Citalopram/Escitalopram Study|Terminated||N/A|2|Actual|Mayo Clinic|This study was stopped early due to funding constraints and recruitment was slower than was expected.|1||Stopped due to funding constraints and recruitment was slower than was expected|f||||f||||||||||2018-05-31 23:50:33.619587|2018-05-31 23:50:33.619587
NCT01115686|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2012-12-04|2010-05-03|2010-05-04|Estimate|||||||2012-12-04|2012-12-05|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|ARSAS||Branched-chain Aminoacids in Sleep Apnea Syndromes (ARSAS)|Which Place for Branched-chain Aminoacids in the Treatment of Sleep Apnea Syndromes?|Withdrawn||Phase 3|0|Actual|University Hospital, Limoges||2|||f||||t||||||||||2018-05-31 23:50:33.752021|2018-05-31 23:50:33.752021
NCT01115673|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2012-01-04||2012-04-26|2010-05-03|2010-05-04|Estimate|2012-04-26|2012-05-28|Estimate||||2012-04-26|2012-05-28|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Safety and Efficacy Study of Acetaminophen 1000 mg and Acetaminophen 650 mg in Post Operative Dental Pain|Completed||Phase 3|540|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|Analysis is based on the Intent-to-Treat (ITT) set, which included all subjects who were randomized, took study medication, did not vomit within 60 minutes after dosing, and had a baseline pain score and at least one post-randomization assessment.|3|||f||||f||||||||||2018-05-31 23:50:33.858868|2018-05-31 23:50:33.858868
NCT01115660|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-02|2012-08-10||2015-10-11|2010-05-02|2010-05-04|Estimate|2012-12-14|2013-01-24|Estimate||||2015-10-11|2015-10-14|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|AVAIL II||Stroke Education Intervention Trial - Pilot|AVAIL interVention Trial (Adherence Evaluation After Ischemic Stroke - Longitudinal): Pilot Protocol|Completed||N/A|30|Actual|Duke University|Adverse events not collected|2|||f||||f||||||||||2018-05-31 23:50:35.597703|2018-05-31 23:50:35.597703
NCT01115647|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-11-21|2010-05-03|2010-05-04|Estimate|||||||2011-11-21|2011-11-22|Estimate|July 2010||2010-07-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|LUCOMA||Treating Moderate Malnutrition in 6-24 Months Old Children|Treating Moderate Malnutrition in 6-24 Months Old Children: Acceptability, Efficacy and Cost-effectiveness of a Local Soy-based RUTF vs. Enhanced Corn Soy Blend vs. Child-centered Counselling|Completed||N/A|2088|Actual|Institute of Tropical Medicine, Belgium||3|||f||||f||||||||||2018-05-31 23:50:35.852607|2018-05-31 23:50:35.852607
NCT01115634|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-01|||2016-07-20|2010-05-01|2010-05-04|Estimate|||||||2016-07-20|2016-07-21|Estimate|September 2008||2008-09-30|May 2010|2010-05-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Autologous Fibroblast Transplantation in Facial Deformities|Autologous Transplantation of Cultured Fibroblast for Facial Contour Deformities|Completed||Phase 2|60|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 23:50:35.925757|2018-05-31 23:50:35.925757
NCT01115621|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-04-30|2010-04-30|2010-05-04|Estimate|||||||2010-04-30|2010-05-04|Estimate|February 2001||2001-02-28|April 2010|2010-04-30|December 2016|Anticipated|2016-12-31|December 2009|Actual|2009-12-31||Interventional|||BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk|BABYDIET-Study - Primary Prevention of Type 1 Diabetes in Relatives at Increased Genetic Risk|Unknown status|Active, not recruiting|N/A|150|Actual|Institut fur Diabetesforschung, Munich, Germany||2|||f||||f||||||||||2018-05-31 23:50:35.992722|2018-05-31 23:50:35.992722
NCT01115608|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-05-03|2010-05-03|2010-05-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Pharmaceutical Follow-up of Coronary Heart Disease (CHD) Patients|Development of a Standardized Clinical Pharmacist Service for Patients Discharged From Hospital. Measurement of Drug Prescribing Quality in Secondary Prevention of Coronary Heart Disease Utilizing a Medication Assessment Tool (MAT-CHDsp)|Unknown status|Active, not recruiting|N/A|200|Anticipated|Hospital Pharmacy of North Norway Trust||2|||f||||f||||||||||2018-05-31 23:50:36.057975|2018-05-31 23:50:36.057975
NCT01115595|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-01|||2011-08-02|2010-05-03|2010-05-04|Estimate|||||||2011-08-02|2011-08-03|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Efficacy of Allergen Immunotherapy for Allergic Rhinitis in Thais|Efficacy of Mite Allergen Vaccine Among Thai Patients With Allergic Rhinitis|Unknown status|Recruiting|Phase 4|100|Anticipated|Mahidol University||1|||f||||t||||||||||2018-05-31 23:50:36.120774|2018-05-31 23:50:36.120774
NCT01115582|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2016-07-20|2013-05-21|2016-10-17|2010-05-01|2010-05-04|Estimate|2016-10-17|2016-12-09|Estimate|2013-05-21|2013-05-29|Estimate|2016-10-17|2016-12-09|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis|Open Label, Single Center, Nonrandomized Study Comparing Efficacy of To Be Marketed Cholic Acid With That of the Currently Used Formulation of Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis|Completed||Phase 3|16|Actual|Retrophin, Inc.||1|||f||||f||||||||||2018-05-31 23:50:36.218862|2018-05-31 23:50:36.218862
NCT01115569|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2014-02-04|2012-07-18|2014-03-25|2010-05-03|2010-05-04|Estimate|2014-03-25|2014-04-25|Estimate|2012-08-06|2012-08-15|Estimate|2014-03-25|2014-04-25|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain|A Long-Term Open-Label Safety Study of Hydrocodone Bitartrate Controlled-Release Capsules With Flexible Dosing to Treat Subjects With Moderate to Severe Chronic Pain|Completed||Phase 3|424|Actual|Zogenix, Inc.||1|||f||||f||||||||||2018-05-31 23:50:36.607353|2018-05-31 23:50:36.607353
NCT01115556|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2017-08-07||2018-05-01|2010-05-03|2010-05-04|Estimate|2017-09-07|2017-10-06|Actual||||2018-05-01|2018-05-03|Actual|May 2010||2010-05-31|May 2018|2018-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|LAST||A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)|This is a Single-masked Study to Compare Intravitreally Administered 0.5 mg Ranibizumab to 2.0 mg Ranibizumab in Subjects Who Manifest Persistent or Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy.|Completed||Phase 1/Phase 2|9|Actual|Vitreous -Retina- Macula Consultants of New York||2|||f||||||||||||||2018-05-31 23:50:37.207291|2018-05-31 23:50:37.207291
NCT01115543|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-01|||2010-05-01|2010-05-01|2010-05-04|Estimate|||||||2010-05-01|2010-05-04|Estimate|August 2008||2008-08-31|May 2010|2010-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism|A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients|Completed||Phase 4|32|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 23:50:37.375913|2018-05-31 23:50:37.375913
NCT01115530|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2012-04-11|2010-05-03|2010-05-04|Estimate|||||||2012-04-11|2012-04-13|Estimate|May 2011||2011-05-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Exercise and Nutritional Intervention for Deconditioned Older Adults|An Exercise and Nutritional Intervention for Deconditioned Older Adults|Withdrawn||N/A|0|Actual|VA Office of Research and Development||4||Insufficient subject recruitment.|f||||t||||||||||2018-05-31 23:50:37.44123|2018-05-31 23:50:37.44123
NCT01115517|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2016-03-02||2016-09-07|2010-05-03|2010-05-04|Estimate|2016-07-21|2016-09-02|Estimate||||2016-09-07|2016-10-21|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery|A Pilot Study to Assess Safety and Efficacy of Intraoperative Topical Mitomycin C and Bevacizumab (Avastin) Applied to Bare Sclera in Pterygium Surgery|Completed||Phase 2|51|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:50:37.515916|2018-05-31 23:50:37.515916
NCT01115504|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-12-22|2010-05-03|2010-05-04|Estimate|||||||2010-12-22|2010-12-23|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Thiamine Supplementation in Heart Failure Patients Receiving Full Medical Therapy|Thiamine Supplementation in Heart Failure Patients Receiving Full Medical Therapy|Completed||Phase 3|50|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:50:37.714799|2018-05-31 23:50:37.714799
NCT01115491|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2014-05-28||2014-12-03|2010-04-30|2010-05-04|Estimate|2014-12-03|2014-12-08|Estimate||||2014-12-03|2014-12-08|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Intent-to-treat (ITT) population: all enrolled participants.|A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme|A Single Arm Phase II Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|32|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 23:50:37.818037|2018-05-31 23:50:37.818037
NCT01115465|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2017-05-04|2010-04-30|2010-05-04|Estimate|||||||2017-05-04|2017-05-08|Actual|January 2008|Actual|2008-01-31|May 2017|2017-05-31|February 2022|Anticipated|2022-02-28|December 2021|Anticipated|2021-12-31||Interventional|ROSE||Study of Macroplastique Safety and Effectiveness in the Treatment of Female Stress Urinary Incontinence|Real-time Observation of Safety and Effectiveness in the Treatment of Female Stress Urinary Incontinence|Active, not recruiting||N/A|276|Actual|Uroplasty, Inc||1|||f||||f||||||||Undecided||2018-05-31 23:50:38.178777|2018-05-31 23:50:38.178777
NCT01115452|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2013-03-21||2015-01-22|2010-04-30|2010-05-04|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-22|2015-01-26|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity|A Proof of Principle Study Investigating the Effects of a Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity|Completed||Phase 2|32|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 23:50:38.299216|2018-05-31 23:50:38.299216
NCT01115439|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-07-11|2010-04-30|2010-05-04|Estimate|||||||2012-07-11|2012-07-12|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Observational|ASPF||Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria|Efficacy and Safety of Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Centers in Nangarhar, Kunar, Thakhar and Faryab Provinces of Afghanistan|Completed|||100|Actual|University of Oxford|||1||f||||f||||||||||2018-05-31 23:50:39.013354|2018-05-31 23:50:39.013354
NCT01115426|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-04-30|2010-04-30|2010-05-04|Estimate|||||||2010-04-30|2010-05-04|Estimate|January 1997||1997-01-31|January 1997|1997-01-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis|Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis|Completed||Phase 4|20|Actual|University Magna Graecia||1|||f||||t||||||||||2018-05-31 23:50:39.133689|2018-05-31 23:50:39.133689
NCT01115413|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2018-05-02|2010-05-03|2010-05-04|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2010||2010-04-30|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Effect of Teenage Maternity on Obstetrical and Perinatal Outcomes|Influence of Young Maternal Age on Pregnancy Outcome in Central Europe|Completed|||150|Actual|University of Luebeck|||2||f||||f||||||||||2018-05-31 23:50:39.212077|2018-05-31 23:50:39.212077
NCT01115400|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-03-15|2010-05-03|2010-05-04|Estimate|||||||2013-03-15|2013-03-19|Estimate|July 2007||2007-07-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Observational|QOL||Quality of Life Evaluations in Patients With Abdominal Wall Hernias|Quality of Life Evaluations in Patients With Abdominal Wall Hernias|Completed|||90|Actual|University Hospitals Cleveland Medical Center|||||f||||t||||||||||2018-05-31 23:50:39.27139|2018-05-31 23:50:39.27139
NCT01115387|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2017-11-08|2010-04-30|2010-05-04|Estimate|||||||2017-11-08|2017-11-13|Actual|August 2009||2009-08-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|February 2016|Actual|2016-02-29||Observational|||GARM II: A Study on the Genetics of Age-related Maculopathy|Genetics of Age Related Maculopathy|Active, not recruiting|||603|Actual|University of California, Los Angeles|||3||f||||f||||||Samples With DNA|"~     Saliva or blood~   "|||2018-05-31 23:50:39.392428|2018-05-31 23:50:39.392428
NCT01115374|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2016-02-03|2010-05-03|2010-05-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Lymphedema Therapy With Sound Wave Lymphatic Drainage|Efficacy of Low Frequency Sound Waves in the Treatment of Breast Cancer Related Lymphedema: a Cross-over Randomized Trial|Completed||N/A|34|Actual|Fundacion IMIM||2|||f||||f||||||||||2018-05-31 23:50:39.472627|2018-05-31 23:50:39.472627
NCT01115361|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2012-03-28|2010-05-03|2010-05-04|Estimate|||||||2012-03-28|2012-03-29|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|PPFP-IZ||Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services|Improving Access to and Uptake of Postpartum Family Planning Service Through Enhanced Family Planning in Immunization Services|Completed||N/A|800|Anticipated|FHI 360||2|||f||||f||||||||||2018-05-31 23:50:39.542805|2018-05-31 23:50:39.542805
NCT01115348|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-02-01|2010-05-03|2010-05-04|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 2009||2009-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2011|Actual|2011-12-31||Observational|SALGOT||SALGOT; Stroke Arm Longitudinal Study at the University of GOThenburg|Stroke Arm Longitudinal Study at the University of Gothenburg;SALGOT|Active, not recruiting|||120|Anticipated|Göteborg University|||||f||||f||||||||||2018-05-31 23:50:39.608593|2018-05-31 23:50:39.608593
NCT01115335|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2012-07-12|2010-05-03|2010-05-04|Estimate|||||||2012-07-12|2012-07-13|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|||Feasibility, Acceptability, and Safety of Neonatal Male Circumcision in Lusaka, Zambia|Feasibility, Acceptability, and Safety of Neonatal Male Circumcision at the University Teaching Hospital in Lusaka, Zambia and in the Lusaka District in Zambia Using Gomco; Plastibell; and Mogen Methods|Completed||Phase 4|661|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-05-31 23:50:39.665966|2018-05-31 23:50:39.665966
NCT01115322|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2017-06-19|2010-05-03|2010-05-04|Estimate|||||||2017-06-19|2017-06-20|Actual|April 1, 2010|Actual|2010-04-01|June 2017|2017-06-30|April 10, 2010|Actual|2010-04-10|April 10, 2010|Actual|2010-04-10||Interventional|||A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Completed||Phase 1|38|Actual|GlaxoSmithKline||9|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:50:39.741902|2018-05-31 23:50:39.741902
NCT01115309|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-05-20|2010-05-03|2010-05-04|Estimate|||||||2014-05-20|2014-05-22|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||XprESS Registry Study|XprESS Registry Study|Completed||N/A|175|Actual|Entellus Medical, Inc.||1|||f||||f||||||||||2018-05-31 23:50:39.850473|2018-05-31 23:50:39.850473
NCT01115296|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2012-08-16|2010-05-03|2010-05-04|Estimate|||||||2012-08-16|2012-08-17|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Control of Helicobacter Pylori Infection by Probiotics|Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri|Unknown status|Recruiting|N/A|100|Anticipated|University of Bari||2|||f||||t||||||||||2018-05-31 23:50:39.917474|2018-05-31 23:50:39.917474
NCT01115283|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2017-10-26|2010-05-03|2010-05-04|Estimate|||||||2017-10-26|2017-10-30|Actual|July 2015||2015-07-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||An Active Approach to Treat Amblyopia: Perceptual Learning and Video Games|Improving Spatial and Temporal Vision in Adult and Juvenile Amblyopia|Recruiting||Phase 1/Phase 2|50|Anticipated|University of California, Berkeley||3|||f||||f||||||||||2018-05-31 23:50:40.007435|2018-05-31 23:50:40.007435
NCT01115270|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2016-05-06|2010-05-03|2010-05-04|Estimate|||||||2016-05-06|2016-05-09|Estimate|February 2007||2007-02-28|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||A Study Comparing Shunt Placement Versus Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus|A Study Comparing Shunt Placement Versus Endoscopic Third Ventriculostomy in the Treatment of Hydrocephalus|Completed|||196|Actual|University of California, Los Angeles|||2||f||||t||||||||||2018-05-31 23:50:40.102925|2018-05-31 23:50:40.102925
NCT01115257|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2010-05-03|2010-05-03|2010-05-04|Estimate|||||||2010-05-03|2010-05-04|Estimate|October 2001||2001-10-31|October 2006|2006-10-31||||October 2006|Actual|2006-10-31||Interventional|||Severe Proliferative Diabetic Retinopathy|Severe Proliferative Diabetic Retinopathy Treated With Vitrectomy or Panretinal Photocoagulation: a Prospective Comparative Study|Completed||N/A|180|Actual|Universita degli Studi di Catania||2|||f||||f||||||||||2018-05-31 23:50:40.168416|2018-05-31 23:50:40.168416
NCT01115244|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2017-11-15||2017-11-15|2010-04-29|2010-05-04|Estimate|2017-11-15|2017-12-14|Actual||||2017-11-15|2017-12-14|Actual|July 2010|Actual|2010-07-31|November 2017|2017-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis|Dapsone Gel, 5% for Topical Treatment of Dermatitis Herpetiformis|Terminated||Phase 4|1|Actual|Vanderbilt University Medical Center||2||poor enrollment and lack of funding|f||||t|t|f|||f|||||2018-05-31 23:50:40.241781|2018-05-31 23:50:40.241781
NCT01115231|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2016-01-04|2010-04-29|2010-05-04|Estimate|||||||2016-01-04|2016-01-06|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Observational|CFH&AMD||Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration|Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration|Unknown status|Active, not recruiting||300|Anticipated|VA Office of Research and Development|||2||f||||f||||||Samples With DNA|"~     Whole blood will be collected into dipotassium ethylenediaminetetraacetic acid (EDTA) tubes~     resulting in a final EDTA concentration of 4.5 mM. Plasma will be separated from whole blood~     by centrifugation (10 minutes at 3000 RPM) and frozen at -80 degrees C until further use.~     Subjects will be genotyped for signal nucleotide polymorphisms for I62V and Y402H using~     TaqMan single nucleotide polymorphisms (SNP) genotyping assays. Complement pathway protein~     analysis will be performed by ELISAs.~   "|||2018-05-31 23:50:40.423747|2018-05-31 23:50:40.423747
NCT01115218|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-04-12|2010-05-03|2010-05-04|Estimate|||||||2013-04-12|2013-04-15|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|January 2010|Actual|2010-01-31||Observational|||The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy|The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy|Completed|||||University of Cologne|||1||f||||f||||||||||2018-05-31 23:50:40.493931|2018-05-31 23:50:40.493931
NCT01115205|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-05-03|2010-04-29|2010-05-04|Estimate|||||||2010-05-03|2010-05-05|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Supervised Walking Groups as a Model to Increase Physical Activity in Type 2 Diabetes|Assessment of Feasibility and Efficacy of a Project Aimed to Improve Metabolic Control in Type 2 Diabetes Through Lifestyle Changes and Self-monitoring of Blood Glucose|Completed||N/A|59|Actual|Universita di Verona||2|||f||||f||||||||||2018-05-31 23:50:40.554087|2018-05-31 23:50:40.554087
NCT01115192|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2013-04-23|2010-05-03|2010-05-04|Estimate|||||||2013-04-23|2013-04-24|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Blephacura Versus Baby Shampoo to Treat Blepharitis|Blephacura Versus Baby Shampoo to Treat Blepharitis|Completed||N/A|144|Actual|University of Cologne||2|||f||||f||||||||||2018-05-31 23:50:40.623158|2018-05-31 23:50:40.623158
NCT01115179|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-05-17|2010-05-03|2010-05-04|Estimate|||||||2010-05-17|2010-05-19|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Propofol and Perioperative Inflammation|Propofol and/or Its Solvent Modify the Course of Inflammatory Response After Surgical Stress: A Randomized, Controlled, Double-blind Study|Completed||Phase 4|79|Actual|University Hospital, Geneva||3|||f||||f||||||||||2018-05-31 23:50:40.680419|2018-05-31 23:50:40.680419
NCT01115166|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|2012-05-11||2012-09-06|2010-05-03|2010-05-04|Estimate|2012-09-06|2012-10-08|Estimate||||2012-09-06|2012-10-08|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|October 2010|Actual|2010-10-31||Observational|||Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation|Blood Volume and Fluid Kinetics in Patients Undergoing Extracorporal Circulation|Completed|||10|Actual|University Hospital, Linkoeping|The number of patients was small and it was not possible to use a reference method. Standardization was difficult due to the fact that it was a clinical study.||1||f||||f||||||||||2018-05-31 23:50:40.761722|2018-05-31 23:50:40.761722
NCT01115153|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-08-22|2010-05-03|2010-05-04|Estimate|||||||2011-08-22|2011-08-23|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||Prophylaxis With Single Versus Five Dose of Antibiotic Therapy as Treatment of Patients With Gangrenous Acute Appendicitis|Prophylaxis With Single Versus Five Dose of Antibiotic Therapy as Treatment of Patients With Gangrenous Acute Appendicitis (Randomized, Controlled Clinical Trial)|Completed||N/A|150|Actual|Universidad Industrial de Santander||2|||f||||f||||||||||2018-05-31 23:50:40.886199|2018-05-31 23:50:40.886199
NCT01115140|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-03|||2011-05-23|2010-05-03|2010-05-04|Estimate|||||||2011-05-23|2011-05-24|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Metformin and Folate in Pregnant Polycystic Ovary Syndrome(PCOS) Women|Effect of Metformin With or Without Folate Addiction on Uterine Blood Flow and Trophoblastic Invasion in Pregnant Patients With Polycystic Ovary Syndrome|Completed||Phase 4|50|Actual|University Magna Graecia||5|||f||||t||||||||||2018-05-31 23:50:40.958623|2018-05-31 23:50:40.958623
NCT01115127|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2012-03-01|2010-05-03|2010-05-04|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Myo-inositol and Melatonin in Pre-menopausal Women|Myo-inositol and Melatonin in Menopausal Transition. A Prospective, Randomized Trial|Completed||Phase 2/Phase 3|90|Actual|University of Messina||3|||f||||f||||||||||2018-05-31 23:50:41.031524|2018-05-31 23:50:41.031524
NCT01115114|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2015-02-09|2010-05-03|2010-05-04|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|December 2011|Actual|2011-12-31||Interventional|||Treatment of Metabolic Syndrome in a Community Mental Health Center|Treatment of Metabolic Syndrome in a Community Mental Health Center|Completed||N/A|130|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 23:50:41.097224|2018-05-31 23:50:41.097224
NCT01115101|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2012-02-21||2016-10-28|2010-05-03|2010-05-04|Estimate|2013-01-15|2013-02-15|Estimate||||2016-10-28|2016-12-12|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Superiority Study for Pain Treatment After Cesarean|A Randomized Controlled Trial: Pain Management After Cesarean Section: Oxycodon vs. Intravenous Piritramide|Completed||Phase 4|239|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 23:50:41.158508|2018-05-31 23:50:41.158508
NCT01115088|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2016-02-11|2010-05-03|2010-05-04|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2006||2006-01-31|February 2016|2016-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults|Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults: A Pilot Study|Completed||N/A|30|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 23:50:41.484422|2018-05-31 23:50:41.484422
NCT01115075|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-01-22|2010-05-03|2010-05-04|Estimate|||||||2016-01-22|2016-01-25|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|March 2011|Actual|2011-03-31||Interventional|Dietitian II||Oscillations of Dietary Fat/Carbohydrate Intake Over Interval of 3 to 4 Days|Oscillations in Dietary Fat Intake and Leptin Changes Among People Who Record Dietary Intake Accurately: the Dietitian Study II|Completed||N/A|16|Actual|Pennington Biomedical Research Center||1|||f||||f||||||||||2018-05-31 23:50:41.572803|2018-05-31 23:50:41.572803
NCT01115062|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2014-01-31|2010-05-03|2010-05-04|Estimate|||||||2014-01-31|2014-02-04|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparison of Synera Patch Versus LMX-4 Cream Versus Placebo Patch for Pain Reduction During Venipuncture in Children|Comparison of Lidocaine/Tetracaine Patch (SyneraTM), 4% Liposomal Lidocaine Cream (LMX-4) and Placebo for Pain Reduction During Venipuncture in Children|Completed||Phase 2|150|Actual|CAMC Health System||3|||f||||f||||||||||2018-05-31 23:50:41.647843|2018-05-31 23:50:41.647843
NCT01115049|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-04-30|2010-04-30|2010-05-03|Estimate|||||||2010-04-30|2010-05-03|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Hexetidine and Chlorobutanol for Lesions Due to Prostheses|Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial|Completed||Phase 4|44|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 23:50:41.730943|2018-05-31 23:50:41.730943
NCT01115036|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2013-06-17|2010-04-30|2010-05-03|Estimate|||||||2013-06-17|2013-06-19|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|April 2011|Anticipated|2011-04-30||Interventional|CLBH589C||A Panobinostat Presurgery|Phase II Study of Panobinostat (LBH589) for Recurrent Glioblastoma (GBM) Undergoing Planned Surgical Resection|Withdrawn||Phase 2|0|Actual|Duke University||1||No subjects were enrolled on this study, so study was closed and IND withdrawn.|f||||f||||||||||2018-05-31 23:50:41.805861|2018-05-31 23:50:41.805861
NCT01115023|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-04-30|2010-04-30|2010-05-03|Estimate|||||||2010-04-30|2010-05-03|Estimate|October 2003||2003-10-31|April 2010|2010-04-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|IDA||Effect of Consuming Food Cooked in Iron Utensils on Iron Status in Children With Iron Deficiency Anemia (IDA)|Randomized Controlled Trial to Study the Effect of Consuming Food Cooked in Iron Utensils on Iron Status in Children With Iron Deficiency Anemia (IDA)|Completed||N/A|36|Actual|Dhande, Leena Ajay, M.D.||2|||f||||f||||||||||2018-05-31 23:50:41.873114|2018-05-31 23:50:41.873114
NCT01115010|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-08-02|2010-04-30|2010-05-03|Estimate|||||||2011-08-02|2011-08-03|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effectiveness of Stiffening Wire in Colonoscopy With Pre-Owned Colonoscopes|Effectiveness of a Proprietary Intraluminal Stiffening Wire in Decreasing Procedure Time and Improving Cecal Intubation Rate With Pre-owned Colonoscopes; a Randomized, Controlled Trial|Terminated||N/A|112|Actual|Cornwall Regional Hospital||3||Colonoscope being used in study not repairable at economic cost.|f||||f||||||||||2018-05-31 23:50:41.942909|2018-05-31 23:50:41.942909
NCT01114997|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2016-05-16||2016-09-28|2010-04-30|2010-05-03|Estimate|2016-05-16|2016-06-23|Estimate||||2016-09-28|2016-11-03|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Lidocaine and Esmolol to Improve the Quality of Recovery|Effect of Lidocaine and Esmolol Alone or in Combination to Improve the Quality of Recovery, Maintaining Hemodynamic Stability During Abdominal Surgery|Terminated||Phase 4|32|Actual|Cedars-Sinai Medical Center||3||The early report didn't show any benefit.|f||||f||||||||Yes||2018-05-31 23:50:42.101593|2018-05-31 23:50:42.101593
NCT01114984|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-02-26|2010-04-30|2010-05-03|Estimate|||||||2015-02-26|2015-03-02|Estimate|July 2009||2009-07-31|February 2015|2015-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Post-Breast Procedure Pain Syndrome Study|A Prospective Cohort Study to Evaluate the Incidence and Characteristics of Post-Operative Pain Among Patients Undergoing Various Breast Surgeries|Withdrawn|||0|Actual|Cedars-Sinai Medical Center|||8|Bad design.|f||||f||||||||||2018-05-31 23:50:42.580282|2018-05-31 23:50:42.580282
NCT01114971|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2017-08-16|2010-04-30|2010-05-03|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2009||2009-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Labetalol and Esmolol: Vital Signs and Post Operative Pain Management|Randomized, Double-Blinded, Active-Controlled Study to Evaluate the Intraoperative Use of Labetalol vs. Esmolol for Maintaining Hemodynamic Stability During Laparoscopic Surgery: Effect on Recovery and Postoperative Pain|Recruiting||Phase 4|120|Anticipated|Cedars-Sinai Medical Center||3|||f||||t|t|f||||||||2018-05-31 23:50:42.689552|2018-05-31 23:50:42.689552
NCT01114958|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-05-04|2010-04-30|2010-05-03|Estimate|||||||2010-05-04|2010-05-05|Estimate|April 2010||2010-04-30|April 2010|2010-04-30||||October 2011|Anticipated|2011-10-31||Interventional|||Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases|A Phase I / Pilot Study of Intra-Arterial Supradose Cisplatin With Simultaneous Intravenous Thiosulfate Neutralization in Patients With Primary Lung Cancer or Lung Metastases|Unknown status|Recruiting|Phase 1|12|Anticipated|University of California, San Diego||1|||f||||||||||||||2018-05-31 23:50:42.860537|2018-05-31 23:50:42.860537
NCT01114945|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2015-09-03||2016-03-08|2010-04-30|2010-05-03|Estimate|2016-02-11|2016-03-09|Estimate||||2016-03-08|2016-04-06|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||"Obese patients (ASA II-III). In the Direct Macintosh group there is one more participant included, this is due that the last participant declined to complete with the last assessment.~Later changed his mind and completed the study (In that time we had enrolled another subject so we decided to use the data of both participants."|Comparative Effectiveness of Intubating Devices in the Morbidly Obese|A Prospective Study Comparing Video Laryngoscopy Devices to Direct Laryngoscopy for Tracheal Intubation of Patients Undergoing Bariatric Surgery|Completed||Phase 4|121|Actual|Cedars-Sinai Medical Center||4|||f||||t||||||||||2018-05-31 23:50:43.000897|2018-05-31 23:50:43.000897
NCT01114932|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2012-02-14|2010-04-30|2010-05-03|Estimate|||||||2012-02-14|2012-02-15|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||The Optimum Time for Preoxygenation Based on Body Mass Index|The Optimum Time for Preoxygenation Based on Body Mass Index|Completed|||75|Actual|Cedars-Sinai Medical Center|||3||f||||t||||||||||2018-05-31 23:50:43.414766|2018-05-31 23:50:43.414766
NCT01114906|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2011-09-16|2010-04-30|2010-05-03|Estimate|||||||2011-09-16|2011-09-19|Estimate|September 2010||2010-09-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia|Estimating the Use of Resources and the Costs of Treating Patients With Asthma in the Autonomous Community of Valencia|Completed|||292|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:50:43.559134|2018-05-31 23:50:43.559134
NCT01114893|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2011-05-26||2011-05-26|2010-04-30|2010-05-03|Estimate|2011-05-26|2011-06-23|Estimate||||2011-05-26|2011-06-23|Estimate|April 2010||2010-04-30|May 2011|2011-05-31||||May 2010|Actual|2010-05-31||Interventional|||Travoprost Five Day Posology Study||Completed||Phase 2|60|Actual|Alcon Research||5|||f||||f||||||||||2018-05-31 23:50:43.6233|2018-05-31 23:50:43.6233
NCT01114880|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2011-09-29||2011-11-22|2010-04-30|2010-05-03|Estimate|2011-09-29|2011-11-04|Estimate||||2011-11-22|2011-12-01|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis|A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis|Completed||Phase 3|344|Actual|Abbott||2|||f||||f||||||||||2018-05-31 23:50:43.977048|2018-05-31 23:50:43.977048
NCT01114867|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-03-26|2010-04-30|2010-05-03|Estimate|||||||2014-03-26|2014-03-27|Estimate|October 2010||2010-10-31|April 2010|2010-04-30||||||||Observational|||Fetal Penile Length and Corpus Cavernosum Length - Normal Measurement Via Ultrasound|Prospective Cross-sectional Study of Fetal Penis and Corpus Cavernosum Length|Unknown status|Not yet recruiting||200|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:50:44.947643|2018-05-31 23:50:44.947643
NCT01114854|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-05-16|2010-04-30|2010-05-03|Estimate|||||||2017-05-16|2017-05-18|Actual|June 2010||2010-06-30|May 2017|2017-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)|A Conversion Study to Determine the Relative Bioavailability of TPM MR vs TPM IR in Subjects With Epilepsy|Completed||Phase 1|69|Actual|Supernus Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:50:45.044569|2018-05-31 23:50:45.044569
NCT01114841|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-06-12|2010-04-30|2010-05-03|Estimate|||||||2017-06-12|2017-06-14|Actual|March 31, 2010|Actual|2010-03-31|June 2017|2017-06-30|June 26, 2010|Actual|2010-06-26|June 26, 2010|Actual|2010-06-26||Interventional|||A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Contact Sensitization Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Completed||Phase 1|254|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:50:45.131151|2018-05-31 23:50:45.131151
NCT01114828|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2013-12-15||2014-01-30|2010-04-30|2010-05-03|Estimate|2013-12-15|2014-01-31|Estimate||||2014-01-30|2014-03-04|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema|A Multi-center, Double-blind, Parallel-arm Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema|Completed||Phase 3|40|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 23:50:45.294283|2018-05-31 23:50:45.294283
NCT01114815|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-01-18|2010-04-30|2010-05-03|Estimate|||||||2013-01-18|2013-01-21|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)|Natural History of CADASIL: Migraine, Diagnosis and Misdiagnosis|Completed|||100|Actual|New York University School of Medicine|||||f||||t||||||||||2018-05-31 23:50:45.696356|2018-05-31 23:50:45.696356
NCT01114802|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-03-18|2010-04-30|2010-05-03|Estimate|||||||2014-03-18|2014-03-19|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|Onward||E-health Intervention for Cancer Survivors|Project Onward: an Innovative E-health Intervention for Cancer Survivors|Completed||Phase 1|31|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 23:50:45.817455|2018-05-31 23:50:45.817455
NCT01114789|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2011-01-25|2010-04-30|2010-05-03|Estimate|||||||2011-01-25|2011-01-26|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|IPOD||Impact on the Proteolysis of Obesity in Dialysis|Impact on the Proteolysis of Obesity in Dialysis|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:50:45.895717|2018-05-31 23:50:45.895717
NCT01114776|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2013-07-29|2010-04-30|2010-05-03|Estimate|||||||2013-07-29|2013-07-31|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|July 2013|Actual|2013-07-31||Observational|MCSIO||Multi-Center Study of Iron Overload: Pilot Study|Pilot Study Examining Mechanisms of Iron Trafficking and Extra-hepatic Iron Distribution in Sickle Cell Disease, Thalassemia, and Other Iron Loading Anemias|Unknown status|Active, not recruiting||20|Actual|Children's Hospital & Research Center Oakland|||4||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, and urine~   "|||2018-05-31 23:50:45.968394|2018-05-31 23:50:45.968394
NCT01114763|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2010-05-03|2010-04-30|2010-05-03|Estimate|||||||2010-05-03|2010-05-04|Estimate|June 2003||2003-06-30|April 2010|2010-04-30|September 2007|Actual|2007-09-30|November 2005|Actual|2005-11-30||Observational|HMS-01||Hämeenlinna Metabolic Syndrome Research Program: Oxidized LDL and Arterial Elasticity in Metabolic Syndrome and Controls (HMS-01)|Hämeenlinna Metabolic Syndrome Research Program (HMS): Comparison of Men With Metabolic Syndrome and Their Physically Active Controls - Circulating Oxidized LDL and Arterial Elasticity|Completed|||80|Actual|Central Hospital of Kanta-Hame|||2||f||||f||||||Samples Without DNA|"~     serum, EDTA plasma, citrate plasma~   "|||2018-05-31 23:50:47.027143|2018-05-31 23:50:47.027143
NCT01114750|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-10-03|2010-04-30|2010-05-03|Estimate|||||||2010-10-03|2010-10-05|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|ORA3||A Study to Determine the Absorption of Peroral Insulin in Dextran Matrix (ORA3)|A Placebo-controlled Study of Insulin Absorption in Healthy Volunteers After Single-dose Oral Administration of Insulin in Dextran Matrix|Suspended||Phase 1|8|Anticipated|Bows Pharmaceuticals AG||2|||f||||t||||||||||2018-05-31 23:50:47.098277|2018-05-31 23:50:47.098277
NCT01114568|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2016-03-16|2010-04-29|2010-05-03|Estimate|||||||2016-03-16|2016-03-17|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)|A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability Of Three Different Formulations Of PF-04971729 in Lean To Obese, Otherwise Healthy Adult Subjects|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 23:50:50.685216|2018-05-31 23:50:50.685216
NCT01114737|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2015-08-19||2015-12-24|2010-04-30|2010-05-03|Estimate|2015-12-24|2016-02-01|Estimate||||2015-12-24|2016-02-01|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients|A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Subjects With Phenylketonuria|Completed||Phase 3|206|Actual|BioMarin Pharmaceutical|As specified in the SAP, no multiplicity adjustment was made in the analyses; therefore, the family-wise error rate was not controlled in this study|2|||f||||t||||||||||2018-05-31 23:50:47.226088|2018-05-31 23:50:47.226088
NCT01114724|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2014-05-30||2018-04-30|2010-04-29|2010-05-03|Estimate|2014-05-30|2014-07-03|Estimate||||2018-04-30|2018-05-30|Actual|May 2010||2010-05-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|May 2013|Actual|2013-05-31||Interventional|||Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections|Valiant® Thoracic Stent Graft With the Captivia Delivery System. Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections|Completed||N/A|50|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-05-31 23:50:48.186077|2018-05-31 23:50:48.186077
NCT01114711|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2018-04-10|2010-04-29|2010-05-03|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2010||2010-04-30|April 2018|2018-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|FROVA||Frovatriptan and Menstrual Migraine|Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)|Terminated|||24|Actual|Mclean Hospital|||1|A sister study using Frova at a 10 mg dose had adverse effects.|f||||||||||||||2018-05-31 23:50:48.46793|2018-05-31 23:50:48.46793
NCT01114698|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22||2012-11-05|2013-02-11|2010-04-29|2010-05-03|Estimate||||2012-11-05|2012-11-07|Estimate|2013-02-11|2013-02-13|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder|A Randomized, Double-Blind, Parallel Group, Active- and Placebo-Controlled Study to Assess the Efficacy and Safety of JNJ26489112 in Adult Subjects With Treatment-Resistant Major Depressive Disorder|Terminated||Phase 2|12|Actual|Janssen Research & Development, LLC||3||Study was terminated due to sponsor portfolio decision.|f||||t||||||||||2018-05-31 23:50:48.522314|2018-05-31 23:50:48.522314
NCT01114685|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-30|2010-04-30|2010-05-03|Estimate|||||||2010-04-30|2010-05-03|Estimate|June 2006||2006-06-30|April 2010|2010-04-30|March 2010|Actual|2010-03-31|July 2008|Actual|2008-07-31||Interventional|||A Comparison of Changes in Bone Density With the Same Bone-health Plan, But With Different Bone-health Supplements|Bone Mineral Density (BMD) Changes in a Bone Health Plan Using Two Versions of a Bone Health Supplement: A Comparative Effectiveness Research (CER) Study|Completed||N/A|354|Actual|Integrative Health Technologies, Inc.||2|||f||||t||||||||||2018-05-31 23:50:48.711205|2018-05-31 23:50:48.711205
NCT01114672|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2013-01-08||2013-02-15|2010-04-30|2010-05-03|Estimate|2013-01-08|2013-02-12|Estimate||||2013-02-15|2013-02-21|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|CRN11||A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients|A Randomized Prospective, Double-Blind Placebo Controlled Study of Oral Ergocalciferol in the Treatment of Pruritis in Hemodialysis Patients|Completed||Phase 4|50|Actual|Winthrop University Hospital||2|||f||||f||||||||||2018-05-31 23:50:48.795622|2018-05-31 23:50:48.795622
NCT01114659|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-12-30|2010-04-30|2010-05-03|Estimate|||||||2013-12-30|2014-01-01|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Observational|||The Study of Polycystic Ovary Syndrome(PCOS) With Gene and Questionnaire|The Study of Metabolic and Cardiac Vascular Risk in Patients With Polycystic Ovary Syndrome|Completed|||169|Actual|Taipei Medical University WanFang Hospital|||2||f||||t||||||||||2018-05-31 23:50:49.069182|2018-05-31 23:50:49.069182
NCT01114646|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2012-02-09|2010-04-30|2010-05-03|Estimate|||||||2012-02-09|2012-02-10|Estimate|March 2005||2005-03-31|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Functional Status, Morbidity and Mortality in Cemented Versus Press-Fit Hemiarthroplasty|Functional Status, Morbidity and Mortality in Cemented Versus Uncemented Hemiarthroplasty for Subcapital Hip Fractures: A Prospective Randomized Trial|Completed||N/A|130|Actual|Hartford Hospital||2|||f||||f||||||||||2018-05-31 23:50:49.12894|2018-05-31 23:50:49.12894
NCT01114633|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-11-04|2010-04-30|2010-05-03|Estimate|||||||2013-11-04|2013-11-06|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||Obesity and Clinical Presentation of Hyperandrogenism|Obesity and Clinical Presentation of Hyperandrogenism|Completed|||46|Actual|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 23:50:49.207958|2018-05-31 23:50:49.207958
NCT01114620|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2017-05-08|2012-10-04|2017-05-08|2010-04-29|2010-05-03|Estimate|2017-05-08|2017-12-14|Actual|2012-10-11|2012-10-15|Estimate|2017-05-08|2017-12-14|Actual|May 1, 2010|Actual|2010-05-01|May 2017|2017-05-31|December 9, 2010|Actual|2010-12-09|November 5, 2010|Actual|2010-11-05||Interventional|||Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older|Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine Arepanrix™ (GSK2340274A) in Adults 65 Years of Age or Older|Completed||Phase 4|50|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:50:49.360068|2018-05-31 23:50:49.360068
NCT01114607|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-07-13|2010-04-29|2010-05-03|Estimate|||||||2017-07-13|2017-07-18|Actual|May 5, 2010|Actual|2010-05-05|July 2017|2017-07-31|June 29, 2010|Actual|2010-06-29|June 29, 2010|Actual|2010-06-29||Interventional|||A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects|A Single Dose, Randomized, Five-Period Crossover Study to Assess the Relative Bioavailability of Four New Formulations of the CCR9 Receptor Antagonist GSK1605786A (CCX282) in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||12|||f||||f||||||||||2018-05-31 23:50:50.238031|2018-05-31 23:50:50.238031
NCT01114594|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-08-09|2010-04-30|2010-05-03|Estimate|||||||2012-08-09|2012-08-10|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease|Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease|Completed|||42|Actual|The Rogosin Institute|||2||f||||f||||||Samples With DNA|"~     Plasma, serum, monocytes, urine~   "|||2018-05-31 23:50:50.366671|2018-05-31 23:50:50.366671
NCT01114581|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2012-03-15||2017-10-05|2010-04-29|2010-05-03|Estimate|2012-09-07|2012-10-08|Estimate||||2017-10-05|2017-11-06|Actual|April 2010||2010-04-30|October 2017|2017-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|MCC/CC||Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection||Completed||Phase 2|38|Actual|Reckitt Benckiser LLC||2|||f||||||||||||||2018-05-31 23:50:50.435569|2018-05-31 23:50:50.435569
NCT01114555|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2018-05-01|2010-04-30|2010-05-03|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2010||2010-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma|Combination of Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma: A Phase II Study|Active, not recruiting||Phase 2|63|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:50:50.791147|2018-05-31 23:50:50.791147
NCT01114542|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-10-06|2010-04-29|2010-05-03|Estimate|||||||2017-10-06|2017-10-09|Actual|May 3, 2010|Actual|2010-05-03|October 2017|2017-10-31|August 10, 2010|Actual|2010-08-10|August 10, 2010|Actual|2010-08-10||Interventional|||A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes|A Trial Evaluating the Pharmacodynamic Response of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes|Completed||Phase 1|66|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-05-31 23:50:50.872338|2018-05-31 23:50:50.872338
NCT01114529|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2015-10-26||2017-04-24|2010-04-29|2010-05-03|Estimate|2017-04-24|2017-05-30|Actual||||2017-04-24|2017-05-30|Actual|August 9, 2010|Actual|2010-08-09|April 2017|2017-04-30|October 30, 2014|Actual|2014-10-30|October 30, 2014|Actual|2014-10-30||Interventional|ELEVATE|Full analysis set (FAS), 24 month analysis|Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients|A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion|Completed||Phase 3|828|Actual|Novartis||2|||f||||t||||||||||2018-05-31 23:50:51.034032|2018-05-31 23:50:51.034032
NCT01114516|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2014-09-08||2014-11-05|2010-04-30|2010-05-03|Estimate|2014-10-05|2014-10-10|Estimate||||2014-11-05|2014-11-07|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|RECIA||Multifactorial Approach to Emergent Cerclage|Role in Emergent Cerclage of Indomethacin and Antibiotics|Completed||N/A|53|Actual|Northwestern University|Because this study was not adequately powered to detect differences in perinatal outcomes, whether this adjunctive therapy affects these outcomes remains uncertain.|2|||f||||f||||||||||2018-05-31 23:50:53.274826|2018-05-31 23:50:53.274826
NCT01114503|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2017-03-02||2017-04-21|2010-04-29|2010-05-03|Estimate|2017-04-21|2017-08-03|Actual||||2017-04-21|2017-08-03|Actual|July 7, 2010||2010-07-07|March 2017|2017-03-31|August 29, 2012|Actual|2012-08-29|August 1, 2011|Actual|2011-08-01||Interventional|||A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease|A Randomised, Comparator Controlled, Two Part, Open-label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Multiple Doses of Otelixizumab in Patients With Thyroid Orbitopathy|Terminated||Phase 2|2|Actual|GlaxoSmithKline|The study was terminated due to the need of better understanding of an efficacious dose with otelixizumab from other clinical studies.|3||"Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an~   efficacious dose with Otelixizumab from other clinical studies."|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:50:53.919002|2018-05-31 23:50:53.919002
NCT01114490|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2015-10-12|2010-04-30|2010-05-03|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)|A Single Dose Study to Investigate the Pharmacokinetics of MK0859 in Patients With Hepatic Insufficiency|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:50:54.738601|2018-05-31 23:50:54.738601
NCT01114477|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-11-11|2010-04-30|2010-05-03|Estimate|||||||2015-11-11|2015-11-13|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||NeuroStar TMS Therapy System: Utilization and Outcomes|NeuroStar TMS Therapy System: Data Management, Analysis and Reporting Format for Clinical Treatment Utilization and Outcomes (Protocol no. 19-50001-000,Rev D|Completed|||307|Actual|Neuronetics|||||f||||f||||||||||2018-05-31 23:50:54.901494|2018-05-31 23:50:54.901494
NCT01114464|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-08-05|2010-04-30|2010-05-03|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|Resova||Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer|Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer|Terminated|||250|Actual|Nantes University Hospital|||1|end of normal study|f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:50:55.02149|2018-05-31 23:50:55.02149
NCT01114451|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2012-03-16|2010-04-30|2010-05-03|Estimate|||||||2012-03-16|2012-03-19|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Early Versus Delayed Skin Staple Removal Following Cesarean Delivery in the Obese Patient|A Randomized Controlled Trial of Early Versus Delayed Skin Staple Removal Following Cesarean Delivery in the Obese Patient|Terminated||Phase 2/Phase 3|292|Actual|Greenville Health System||2||Funding limits exceeded prior to complete enrollment.|f||||f||||||||||2018-05-31 23:50:55.088862|2018-05-31 23:50:55.088862
NCT01114438|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2016-02-06||2017-04-21|2010-04-29|2010-05-03|Estimate|2016-12-29|2017-02-20|Actual||||2017-04-21|2017-04-24|Actual|October 2010||2010-10-31|April 2017|2017-04-30|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner|Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner|Completed||N/A|45|Actual|GI Dynamics||1|||f||||f||||||||Yes|De-identified individual subject data is on file at the Sponsor|2018-05-31 23:50:55.22628|2018-05-31 23:50:55.22628
NCT01114425|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-02-22|2010-04-30|2010-05-03|Estimate|||||||2017-02-22|2017-02-23|Actual|November 1, 2010|Actual|2010-11-01|February 2017|2017-02-28|December 1, 2012|Actual|2012-12-01|August 1, 2012|Actual|2012-08-01||Interventional|||Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection|Etude Observationnelle Multicentrique Relative à la tolérance de ISENTRESS® + TRUVADA® Prescrite en Prophylaxie Post-exposition de Personnes récemment Soumises au Risque de Transmission d'Une Infection Par le VIH|Completed||Phase 3|149|Actual|Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux|||||f||||f||||||||||2018-05-31 23:50:55.793749|2018-05-31 23:50:55.793749
NCT01114412|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-04-30|2010-04-30|2010-05-03|Estimate|||||||2010-04-30|2010-05-03|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Basic Sensations Coming From the Bladder|Description of Basic Visceral Sensations Coming From the Bladder|Completed|||11|Actual|Maastricht University Medical Center|||2||f||||f||||||||||2018-05-31 23:50:55.867827|2018-05-31 23:50:55.867827
NCT01114399|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2014-07-28|2010-04-30|2010-05-03|Estimate|||||||2014-07-28|2014-07-29|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BROCCOLI||Diet and Vascular Health Study|Diet and Vascular Health Study|Completed||N/A|48|Actual|Quadram Institute||3|||f||||f||||||||||2018-05-31 23:50:55.923361|2018-05-31 23:50:55.923361
NCT01114386|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2012-06-06|2010-04-30|2010-05-03|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Observational|||Clinical Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure (CHF)|Clinical, Functional and Biological Assessment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and/or Chronic Heart Failure(CHF) in Stable Conditions and During Exacerbation|Completed|||100|Actual|University of Modena and Reggio Emilia|||1||f||||f||||||Samples Without DNA|"~     Blood sampling for routine (haemachrome and differential cells blood count, bilirubin,~     cholesterol, high density lipoprotein, low density lipoprotein, glycemia, blood urea, blood~     electrolytes (sodium, potassium, chloride), glutamic-oxaloacetic transaminase,~     glutamic-pyruvic transaminase, γGT, triglycerides, creatinine, uric acid, creatine~     phosphokinase, glycosylated haemoglobin).~      Blood sampling for selected biomarkers: NTBNP, HS-PCR and IL-6, IL1-β, cellular receptor D6~     and TIR8, IL-1 decoy receptor PTX3.~      Measurement of arterial blood gases.~   "|||2018-05-31 23:50:55.98572|2018-05-31 23:50:55.98572
NCT01114373|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2015-09-15||2016-01-27|2010-04-30|2010-05-03|Estimate|2015-11-15|2015-12-18|Estimate||||2016-01-27|2016-02-26|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional||36 subjects completed the entire study.|Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study|Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study|Completed||Phase 2|40|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:50:56.09282|2018-05-31 23:50:56.09282
NCT01114360|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2015-09-15||2015-11-15|2010-04-30|2010-05-03|Estimate|2015-11-15|2015-12-18|Estimate||||2015-11-15|2015-12-18|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study|Melatonin and Nighttime Blood Pressure in African Americans- 8 mg Study|Completed||Phase 2|37|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:50:56.80928|2018-05-31 23:50:56.80928
NCT01114347|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|||2015-03-25|2010-04-30|2010-05-03|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|NosoPink||Prevention of Nosocomial E. Coli Infections After Placement of an Indwelling Catheter During Pelvic Surgery: an Evaluation of Cranberry Gel Capsules|Prevention of Nosocomial Escherichia Coli Infections After Placement of an Indwelling Catheter During Pelvic Surgery: a Randomized, Prospective, Double Blind Study for the Evaluation of Cranberry (Vaccinium Macrocarpon) Gel Capsules|Completed||Phase 2|270|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 23:50:57.291011|2018-05-31 23:50:57.291011
NCT01114334|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|2016-10-17||2017-03-09|2010-04-30|2010-05-03|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|April 2010||2010-04-30|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Motivational Interviews for Depression in Primary Care|Motivational Interviews Adapted to Improve Depression Treatment in Primary Care|Completed||N/A|168|Actual|Denver Health and Hospital Authority||2|||f||||t||||||||Undecided|We will be working in the coming year on a plan to share data. We have been able to share data in the past.|2018-05-31 23:50:57.380312|2018-05-31 23:50:57.380312
NCT01114321|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-01-18|2010-04-30|2010-05-03|Estimate|||||||2011-01-18|2011-01-19|Estimate|May 2010||2010-05-31|January 2011|2011-01-31|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Interventional|||Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease|Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 23:50:57.806566|2018-05-31 23:50:57.806566
NCT01114308|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27||2012-10-23|2017-06-12|2010-04-30|2010-05-03|Estimate||||2012-10-23|2012-10-30|Estimate|2017-06-12|2017-06-14|Actual|April 2010||2010-04-30|June 2017|2017-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction|A Randomized, Placebo and Active-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence|Completed||Phase 3|287|Actual|Braeburn Pharmaceuticals||3|||f||||t||||||||||2018-05-31 23:50:57.884563|2018-05-31 23:50:57.884563
NCT01114295|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-08-07|2010-04-30|2010-05-03|Estimate|||||||2013-08-07|2013-08-09|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||Computed Tomography Enterography (CTE) Versus Capsule Endoscopy for Overt, Obscure Gastrointestinal (GI) Bleeding|Comparative Effectiveness of Wireless Capsule Endoscopy and Dual Energy, Phase CT Enterography in the Evaluation of Overt Obscure GI Bleeding|Withdrawn||N/A|0|Actual|Brigham and Women's Hospital||1||"The study was stopped before the first patient was enetered due to logistical issues and lack~   of funding."|f||||t||||||||||2018-05-31 23:50:57.993172|2018-05-31 23:50:57.993172
NCT01114282|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2016-07-05|2010-04-30|2010-05-03|Estimate|||||||2016-07-05|2016-07-06|Estimate|August 2010||2010-08-31|July 2016|2016-07-31||||February 2014|Actual|2014-02-28||Interventional|||Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM|A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|11|Actual|Stanford University||1|||f||||||||||||||2018-05-31 23:50:58.133704|2018-05-31 23:50:58.133704
NCT01114269|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2018-05-16|2010-04-29|2010-05-03|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2007||2007-06-30|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||PRE-DETERMINE Cohort Study|PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study|Active, not recruiting|||5764|Actual|Brigham and Women's Hospital|||||f||||f||||||Samples With DNA|"~     plasma, buffy coat, and red blood cells~   "|No||2018-05-31 23:50:58.282387|2018-05-31 23:50:58.282387
NCT01114256|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2017-08-01|2010-04-29|2010-05-03|Estimate|||||||2017-08-01|2017-08-03|Actual|March 2010||2010-03-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||FNA Tumor Sampling for CD137 Modulation: A Pilot Study|FNA Tumor Sampling for CD137 Modulation: A Pilot Study|Terminated|||83|Actual|Stanford University|||1||f||||||||||Samples With DNA|"~     peripheral blood, fine needle aspiration biopsy~   "|||2018-05-31 23:50:58.549534|2018-05-31 23:50:58.549534
NCT01114243|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2011-11-10|2010-04-29|2010-05-03|Estimate|||||||2011-11-10|2011-11-11|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|||Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis|Pilot Study: Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis|Withdrawn|||0|Actual|Stanford University||||The PI has left Stanford University.|f||||f||||||||||2018-05-31 23:50:58.658562|2018-05-31 23:50:58.658562
NCT01114230|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2012-12-10|2010-04-30|2010-05-03|Estimate|||||||2012-12-10|2012-12-12|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer|A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma|Completed||Phase 1|26|Actual|Astellas Pharma Inc||9|||f||||f||||||||||2018-05-31 23:50:58.714927|2018-05-31 23:50:58.714927
NCT01114217|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29||2013-05-29|2013-05-29|2010-04-30|2010-05-03|Estimate||||2013-05-29|2013-06-06|Estimate|2013-05-29|2013-06-06|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|||Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia|A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia|Completed||Phase 3|634|Actual|AMAG Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 23:50:58.808276|2018-05-31 23:50:58.808276
NCT01114204|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29||2013-04-03|2013-04-03|2010-04-30|2010-05-03|Estimate||||2013-04-03|2013-04-10|Estimate|2013-04-03|2013-04-10|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia|A Phase III, Randomized, Open-label, Active-Controlled, Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia|Completed||Phase 3|605|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:50:58.890295|2018-05-31 23:50:58.890295
NCT01114191|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-07-22|2010-04-29|2010-05-03|Estimate|||||||2011-07-22|2011-07-26|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)|Ph I Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)|Completed||Phase 1|12|Actual|Abbott||1|||f||||f||||||||||2018-05-31 23:50:58.985865|2018-05-31 23:50:58.985865
NCT01114178|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-12-15|2010-04-30|2010-05-03|Estimate|||||||2016-12-15|2016-12-19|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|WELCH||Walking Impairment Questionnaire in PAD|Estimation de la capacité Fonctionnelle à la Marche Par Questionnaire Clinique Chez Des Patients adressés Pour un Test de Marche Sur Tapis Roulant|Terminated|||340|Actual|University Hospital, Angers|||1|recruitment problem due to administrative process being too long|f||||t||||||||||2018-05-31 23:50:59.247999|2018-05-31 23:50:59.247999
NCT01114165|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2012-12-04|2010-04-30|2010-05-03|Estimate|||||||2012-12-04|2012-12-05|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients|Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients|Completed||Phase 4|150|Actual|University Hospital Muenster||2|||f||||||||||||||2018-05-31 23:50:59.34715|2018-05-31 23:50:59.34715
NCT01114152|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-08-02|2010-04-29|2010-04-30|Estimate|||||||2010-08-02|2010-08-03|Estimate|April 2010||2010-04-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects|A Phase I, Single Center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous AZD9742 in Healthy Male and Female Japanese Subjects|Completed||Phase 1|35|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:50:59.47675|2018-05-31 23:50:59.47675
NCT01114139|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29||2013-04-03|2013-05-29|2010-04-29|2010-04-30|Estimate||||2013-04-03|2013-04-10|Estimate|2013-05-29|2013-06-06|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|February 2012|Actual|2012-02-29||Interventional|||A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia|A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia|Completed||Phase 3|812|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 23:50:59.580193|2018-05-31 23:50:59.580193
NCT01114126|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2011-04-06|2010-04-29|2010-04-30|Estimate|||||||2011-04-06|2011-04-07|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia|Randomized, Double-blind, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia|Completed||Phase 1|24|Anticipated|Neurim Pharmaceuticals Ltd.||5|||f||||t||||||||||2018-05-31 23:50:59.716089|2018-05-31 23:50:59.716089
NCT01114113|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-25|||2012-04-18|2010-04-29|2010-04-30|Estimate|||||||2012-04-18|2012-04-20|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Assessment of Gastric Emptying Speed in Patients Who Experience Diarrhea Following a Trigger Meal|Pilot Study: Assessment of Gastric and Intestinal Motility Following a Trigger Meal in Patients With Post Prandial Diarrhea|Withdrawn||N/A|0|Actual|Money, Mary E., M.D.||4||Lack of interest in participation by patients locally and lack of funding.|f||||f||||||||||2018-05-31 23:50:59.838376|2018-05-31 23:50:59.838376
NCT01114100|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-05-17|2010-04-29|2010-04-30|Estimate|||||||2010-05-17|2010-05-18|Estimate|January 2000||2000-01-31|May 2010|2010-05-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||The Effects of Treatment With Sertraline for Noncardiac Chest Pain|The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study|Completed||Phase 4|210|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 23:50:59.923535|2018-05-31 23:50:59.923535
NCT01114087|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2011-03-28|2010-04-29|2010-04-30|Estimate|||||||2011-03-28|2011-03-29|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|GLIFERTI||Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility|Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility|Completed||N/A|2|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:51:00.080782|2018-05-31 23:51:00.080782
NCT01114074|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2016-09-12|2010-04-29|2010-04-30|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|||Thrombus Formation Under Different Flow-conditions|The Influence of the Proteins of the Contact Activation System on Thrombus Formation Under Different Flow-conditions in Blood|Enrolling by invitation|||46|Anticipated|Maastricht University Medical Center|||5||f||||f||||||Samples Without DNA|"~     -  Whole blood~        -  Platelet poor plasma~   "|||2018-05-31 23:51:00.159948|2018-05-31 23:51:00.159948
NCT01114061|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2012-09-12|2010-04-29|2010-04-30|Estimate|||||||2012-09-12|2012-09-13|Estimate||||June 2011|2011-06-30||||||||Interventional|||Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the InsuPatch Device During Daily Life|Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the InsuPatch Device During Daily Life|Suspended||N/A|100|Anticipated|Insuline Medical Ltd.||1|||f||||f||||||||||2018-05-31 23:51:00.274606|2018-05-31 23:51:00.274606
NCT01114048|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2011-09-21|2010-04-29|2010-04-30|Estimate|||||||2011-09-21|2011-09-22|Estimate|March 2010||2010-03-31|September 2011|2011-09-30||||March 2012|Anticipated|2012-03-31||Interventional|KMM-97||Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)|Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) Who Are Eligible for Autologous Stem Cell Transplantation: Multicenter Phase 2 Study|Unknown status|Recruiting|Phase 2|78|Anticipated|Chonnam National University Hospital|||||f||||t||||||||||2018-05-31 23:51:00.345125|2018-05-31 23:51:00.345125
NCT01114035|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-08-01|2010-04-29|2010-04-30|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|DEI||Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or Tufting Enteropathy (TE)|Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or TE|Completed||N/A|41|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:51:00.433322|2018-05-31 23:51:00.433322
NCT01114022|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-08-25|2010-04-29|2010-04-30|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|Top-cuff||Prevention Inhalation of Bacterial by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane|Comparison of Prevention Bacterial Inhalation of Patients on Mechanical Ventilation by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane|Completed||N/A|620|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||t||||||||||2018-05-31 23:51:00.531529|2018-05-31 23:51:00.531529
NCT01114009|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-08-01|2010-04-29|2010-04-30|Estimate|||||||2013-08-01|2013-08-05|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Recruitment Maneuvers in Early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) Patients|Effects of Recruitment Maneuvers in Early ALI and ARDS Patients|Completed||N/A|120|Actual|Chi Mei Medical Hospital||2|||f||||t||||||||||2018-05-31 23:51:00.617476|2018-05-31 23:51:00.617476
NCT01113996|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2015-04-27|2010-04-29|2010-04-30|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PROMISE||Monitoring Patients Who Are Obese Surgery for Gastric By-pass Protein Supplementation and Physical Training (PROMISE)|Optimization of Monitoring Patients Who Are Obese Surgery for Gastric By-pass Protein Supplementation and Physical Training: Interventional Randomized Trial|Completed||Phase 3|78|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 23:51:00.686814|2018-05-31 23:51:00.686814
NCT01113983|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2014-02-19|2010-04-29|2010-04-30|Estimate|||||||2014-02-19|2014-02-21|Estimate|April 2010||2010-04-30|February 2014|2014-02-28|April 2016|Anticipated|2016-04-30|October 2011|Actual|2011-10-31||Interventional|PREVAIL JAPAN||Transfemoral & Transapical Placement of Aortic Balloon Expandable Transcatheter Valves Trial (JAPAN)|A Clinical Trial of a Transcatheter Bioprosthetic Valve for Patients With Aortic Stenosis|Unknown status|Active, not recruiting|N/A|69|Anticipated|Edwards Lifesciences|||||f||||t||||||||||2018-05-31 23:51:00.874194|2018-05-31 23:51:00.874194
NCT01113970|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2013-01-29|2010-04-29|2010-04-30|Estimate|||||||2013-01-29|2013-01-30|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer|Phase I/II Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|Ziopharm||1|||f||||f||||||||||2018-05-31 23:51:00.9321|2018-05-31 23:51:00.9321
NCT01113957|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26||2014-06-25|2014-06-25|2010-04-29|2010-04-30|Estimate||||2014-06-25|2014-06-27|Estimate|2014-06-25|2014-06-27|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer|A Phase 2 Randomized Clinical Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects With Recurrent High Grade Serous Ovarian Cancer|Completed||Phase 2|168|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 23:51:01.021351|2018-05-31 23:51:01.021351
NCT01113944|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2014-11-25|2010-04-28|2010-04-30|Estimate|||||||2014-11-25|2014-11-26|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Training in the Workplace|Training in the Workplace|Completed||N/A|75|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:51:01.161476|2018-05-31 23:51:01.161476
NCT01113931|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2011-11-09||2011-12-21|2010-04-29|2010-04-30|Estimate|2011-12-21|2012-01-27|Estimate||||2011-12-21|2012-01-27|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin|Safety and Efficacy of WC2031 Versus Vibramycin for the Treatment of Uncomplicated Urogenital Chlamydia Trachomatis Infection: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter Study|Completed||Phase 3|495|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 23:51:01.236899|2018-05-31 23:51:01.236899
NCT01113918|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2013-09-29|2010-04-29|2010-04-30|Estimate|||||||2013-09-29|2013-10-01|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Expression of CVD and HA Between Obesity and Non-obesity Polycystic Ovary Syndrome (PCOS) Women in Taiwan|A Study of Clinical Presentation and Cardiovascular Disease of Hyperandrogenism and Polycystic Ovary Syndrome in Obese and Non-obese Taiwanese Women|Completed|||627|Actual|Taipei Medical University WanFang Hospital|||2||f||||f||||||||||2018-05-31 23:51:01.759896|2018-05-31 23:51:01.759896
NCT01113905|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2014-08-05|2010-04-29|2010-04-30|Estimate|||||||2014-08-05|2014-08-07|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Observational|||Role of Beta-Endorphin in Cancer Therapy Fatigue|Beta-Endorphin as a Mediator of Cancer Therapy-Induced Fatigue|Terminated|||18|Actual|Massachusetts General Hospital|||2|Insufficient recruitment was obtained|f||||t||||||Samples Without DNA|"~     Blood samples to be measured for levels of beta-endorphin~   "|||2018-05-31 23:51:01.829375|2018-05-31 23:51:01.829375
NCT01113892|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2014-01-15|2010-04-29|2010-04-30|Estimate|||||||2014-01-15|2014-01-16|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|FINEST||Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.|Comparison of Safety and Primary Patency Between FUSION Vascular Graft With Bioline and EXXCEL Soft ePTFE (FINEST)|Completed||N/A|207|Actual|Maquet Cardiovascular||2|||f||||t||||||||||2018-05-31 23:51:01.903937|2018-05-31 23:51:01.903937
NCT01113879|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-02-06|2010-04-28|2010-04-30|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2009||2009-07-31|February 2017|2017-02-28|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Exercise as an Adjuvant to Aphasia Therapy|Exercise as an Adjuvant to Aphasia Therapy|Completed||Phase 1|100|Anticipated|VA Office of Research and Development||3|||f||||f||||||||||2018-05-31 23:51:02.003984|2018-05-31 23:51:02.003984
NCT01113866|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-05-03|2010-04-29|2010-04-30|Estimate|||||||2010-05-03|2010-05-04|Estimate|October 1998||1998-10-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|May 2003|Actual|2003-05-31||Observational|||Biomarkers for Prognosis of Ambulatory Chronic Heart Failure Patients|Circulating Biomarkers as Prognostic Indicators of Death in Ambulatory Heart Failure Patients|Completed|||124|Actual|University of Parma|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:51:02.08181|2018-05-31 23:51:02.08181
NCT01113840|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2017-11-06|2010-04-29|2010-04-30|Estimate|||||||2017-11-06|2017-11-08|Actual|July 1993||1993-07-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|December 2004|Actual|2004-12-31||Interventional|PARIS||Prospective Aerobic Reconditioning Intervention Study|Exercise Conditioning in Elderly Patients With Heart Failure|Completed||N/A|201|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 23:51:02.332861|2018-05-31 23:51:02.332861
NCT01113827|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2012-03-23|2010-04-29|2010-04-30|Estimate|||||||2012-03-23|2012-03-27|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|||Effects of Water-soluble Olive Extract Supplementation|Effects of Water-soluble Olive Extract on Antioxidant Status, Exercise Performance, Muscle Metabolism, Muscle Damage and Inflammation|Completed||N/A|61|Actual|University of Texas at Austin||3|||f||||t||||||||||2018-05-31 23:51:02.454081|2018-05-31 23:51:02.454081
NCT01113814|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-05-21|2010-04-29|2010-04-30|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31||||||||Interventional|||Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV|Performance of Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for the Non-invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C|Completed||N/A|||Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-05-31 23:51:02.54735|2018-05-31 23:51:02.54735
NCT01113801|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2017-09-27|2014-09-29|2017-11-17|2010-04-28|2010-04-30|Estimate|2017-11-17|2017-12-13|Actual|2014-09-29|2014-10-08|Estimate|2017-11-17|2017-12-13|Actual|July 2010||2010-07-31|November 2017|2017-11-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional||All participants who received at least 1 dose of study drug.|A Study in Participants With Diabetic Kidney Disease|A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes|Terminated||Phase 2|417|Actual|Eli Lilly and Company|Study was stopped early for efficacy futility per recommendation by the independent Data Safety Monitoring Committee.|4||Interim Assessment: Lack of Efficacy|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:51:02.806904|2018-05-31 23:51:02.806904
NCT01113788|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-04-29|2010-04-29|2010-04-30|Estimate|||||||2010-04-29|2010-04-30|Estimate|March 2010||2010-03-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Tricuspid Isthmus Imaged by CARTOsound, Patients With Typical Atrial Flutter|Tricuspid Isthmus Architecture as Imaged by CARTOsound, Determines Ablation Times in Patients With Typical Atrial Flutter|Unknown status|Recruiting||15|Anticipated|Lawson Health Research Institute|||1||f||||f||||||||||2018-05-31 23:51:04.605729|2018-05-31 23:51:04.605729
NCT01113775|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-05-14|2010-04-29|2010-04-30|Estimate|||||||2010-05-14|2010-05-17|Estimate|January 2007||2007-01-31|October 2009|2009-10-31||||||||Observational|PE-MAP||Pulmonary Embolism: Multifunctional Assessment of Prognosis|Right Ventricular Dysfunction in Acute Pulmonary Embolism as Assessed by Spiral CT Scan: Comparison With Transthoracic Echocardiography and Evaluation of Prognostic Value|Unknown status|Recruiting||400|Anticipated|University Of Perugia|||2||f||||||||||||||2018-05-31 23:51:04.670894|2018-05-31 23:51:04.670894
NCT01113762|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-12-17|2010-04-29|2010-04-30|Estimate|||||||2017-12-17|2017-12-19|Actual|February 2007||2007-02-28|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2009|Actual|2009-11-30||Interventional|||Metal-metal Articulations Versus Standard 28 mm Cementless Total Hip Arthroplasty|Metal-metal Articulations vs Standard 28 mm Cementless Total Hip Arthroplasty in Younger Patients. Randomized Studies|Active, not recruiting||Phase 2|71|Actual|University of Southern Denmark||4|||f||||f||||||||||2018-05-31 23:51:04.747031|2018-05-31 23:51:04.747031
NCT01113749|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2012-04-17||2012-07-03|2010-04-28|2010-04-30|Estimate|2012-07-03|2012-08-10|Estimate||||2012-07-03|2012-08-10|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Improving Decision Making About Feeding Options for Dementia|Improving Decision Making About Feeding Options for Dementia|Completed||N/A|256|Actual|University of North Carolina, Chapel Hill|Cluster randomization required, preventing double-blinding.|2|||f||||t||||||||||2018-05-31 23:51:04.838457|2018-05-31 23:51:04.838457
NCT01113736|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-12-12|2010-04-29|2010-04-30|Estimate|||||||2014-12-12|2014-12-15|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|AlloMem||Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy|Pilot Study Evaluating the Efficacy of AlloMEM in Prevention of Intraperitoneal Adhesions & Peritoneal Regeneration After Loop Ileostomy|Completed||N/A|10|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-05-31 23:51:05.030088|2018-05-31 23:51:05.030088
NCT01113723|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2015-09-03||2016-02-11|2010-04-28|2010-04-30|Estimate|2016-02-11|2016-03-09|Estimate||||2016-02-11|2016-03-09|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Intubation of Patients With an Unstable Cervical Spine Using the CMAC Device|A Randomized Prospective Study to Compare Tracheal Intubation With the CMAC Device to Fiberoptic Bronchoscopy in Patients With an Unstable Cervical Spine|Completed||Phase 4|140|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 23:51:05.093137|2018-05-31 23:51:05.093137
NCT01113710|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2012-07-06||2012-08-28|2010-04-29|2010-04-30|Estimate|2012-08-28|2012-09-28|Estimate||||2012-08-28|2012-09-28|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|RLS-Practise||Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise|Non-Interventional Study (NIS) in Patients With Restless Legs Syndrome (RLS) to Assess the Effectiveness and Safety of Neupro® in Daily Practise|Completed|||687|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 23:51:05.266625|2018-05-31 23:51:05.266625
NCT01113697|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2018-05-04|2010-04-29|2010-04-30|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 2009||2009-08-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Observational|||Genetics of the Early and Late Response to Allergen Challenge|Molecular Mechanisms Involved in the Early and Late Responses to Allergen Challenge, in Asthmatic and Allergic Rhinitis Cohorts|Recruiting|||520|Anticipated|University of British Columbia|||3||f||||f||||||Samples With DNA|"~     Whole blood, plasma, white cells~   "|||2018-05-31 23:51:06.590117|2018-05-31 23:51:06.590117
NCT01113684|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2018-05-09|2010-04-29|2010-04-30|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2010||2010-02-28|May 2018|2018-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)|Clinical and Neurophysiological Study of Subthalamic Brain Stimulation in PD|Completed|||175|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-05-31 23:51:06.690866|2018-05-31 23:51:06.690866
NCT01113671|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2011-01-10|2010-04-29|2010-04-30|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|IDEAL2||Type 2 Diabetes Haptoglobin Phenotype and Vitamin E|Evaluating the Effect of Vitamin E Treatment on HDL Function of Type 2 Diabetic Patients and the Correlation to Hp Phenotype. A Prospective, Double Blind, Randomized, Placebo Controlled Trial (IDEAL2 Study)|Completed||Phase 2/Phase 3|90|Anticipated|Technion, Israel Institute of Technology||2|||f||||f||||||||||2018-05-31 23:51:06.865469|2018-05-31 23:51:06.865469
NCT01113658|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-10-22|2010-04-29|2010-04-30|Estimate|||||||2010-10-22|2010-10-25|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|March 2013|Anticipated|2013-03-31|August 2012|Anticipated|2012-08-31||Interventional|||Clinical Evaluation of the SNaP Wound Care System|Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System|Unknown status|Recruiting|Phase 4|60|Anticipated|Spiracur, Inc.|||||f||||f||||||||||2018-05-31 23:51:06.972028|2018-05-31 23:51:06.972028
NCT01113645|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2013-04-30|2010-04-28|2010-04-30|Estimate|||||||2013-04-30|2013-05-01|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Observational|CCP||Impact of Cranioplasty On Cerebral Perfusion|The Impact of Cranioplasty on Local and Global Cerebral Blood Flow as Clinical Outcome Prognostic Factor in Patients Undergoing Decompressive Craniectomy for Severe Head Injury.|Completed|||20|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 23:51:07.069254|2018-05-31 23:51:07.069254
NCT01113632|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2015-05-18||2016-08-10|2010-04-29|2010-04-30|Estimate|2015-06-03|2015-06-04|Estimate||||2016-08-10|2016-09-20|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|March 2015|Actual|2015-03-31||Interventional|||Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Completed||Phase 2|77|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-05-31 23:51:07.189849|2018-05-31 23:51:07.189849
NCT01113619|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2011-12-06|2010-04-28|2010-04-30|Estimate|||||||2011-12-06|2011-12-08|Estimate|April 2011||2011-04-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effectiveness, Safety and Tolerability of RP-G28 in Subjects With Symptoms Associated With Lactose Intolerance|Completed||Phase 2|61|Actual|Ritter Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:51:07.689198|2018-05-31 23:51:07.689198
NCT01113606|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-04-29|2010-04-29|2010-04-30|Estimate|||||||2010-04-29|2010-04-30|Estimate||||April 2010|2010-04-30||||||||Interventional|SPAR||A Trial of Skin Care Protocols for Facial Resurfacing|A Double-Blind, Randomized, Controlled Trial to Assess the Effects of the Obagi Nu-Derm System on Re-Epithelialization After Chemical Peel or Ablative Laser Resurfacing.|Completed||Phase 4|||Plastic Surgery Educational Foundation||2|||f||||||||||||||2018-05-31 23:51:07.758544|2018-05-31 23:51:07.758544
NCT01113593|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27||2013-05-10|2013-05-17|2010-04-28|2010-04-30|Estimate||||2013-05-17|2013-05-27|Estimate|2013-05-17|2013-05-27|Estimate|May 2010||2010-05-31|May 2013|2013-05-31||||May 2010|Actual|2010-05-31||Interventional|||A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease|A Randomized, Multiple-Dose, Crossover Study Characterizing the Pharmacodynamic Profiles of Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler in Subjects With Stable Chronic Obstructive Pulmonary Disease|Completed||Phase 2|45|Actual|Dey||5|||f||||f||||||||||2018-05-31 23:51:07.823696|2018-05-31 23:51:07.823696
NCT01113580|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2012-06-13||2017-10-18|2010-04-28|2010-04-30|Estimate|2012-06-13|2012-07-18|Estimate||||2017-10-18|2017-11-21|Actual|May 2010||2010-05-31|October 2017|2017-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population|A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)|Completed||Phase 4|120|Actual|Seqirus||2|||f||||f||||||||||2018-05-31 23:51:07.912042|2018-05-31 23:51:07.912042
NCT01113567|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-08-09|2010-04-29|2010-04-30|Estimate|||||||2016-08-09|2016-08-10|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy|Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy. Double- Blind, Randomized, Controlled Clinical Trial|Suspended||N/A|18|Actual|Coordinación de Investigación en Salud, Mexico||2||We didn't find differences among both groups|f||||f||||||||||2018-05-31 23:51:08.338733|2018-05-31 23:51:08.338733
NCT01113554|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-10-31|2010-04-29|2010-04-30|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2010||2010-06-30|October 2017|2017-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors|A Pilot Study to Evaluate the Feasibility of a Breast Cancer Rehabilitation Program in Survivors of Breast Cancer|Completed||N/A|26|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 23:51:08.442706|2018-05-31 23:51:08.442706
NCT01113541|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2011-10-12||2012-06-05|2010-04-28|2010-04-30|Estimate|2012-06-05|2012-07-09|Estimate||||2012-06-05|2012-07-09|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome|A One-year, Phase III, Open-label, Non-comparative Trial of the Effect of Ziprasidone HCl on Metabolic Syndrome Risk Factors in Patients With Bipolar Disorder|Terminated||Phase 3|13|Actual|Pfizer|This study was terminated due to slow enrollment and changes in organizational strategy and resources; most of the planned analyses in the statistical analysis plan were not performed.|1||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:51:08.60159|2018-05-31 23:51:08.60159
NCT01113528|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2010-05-13|2010-04-29|2010-04-30|Estimate|||||||2010-05-13|2010-05-14|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|PR||Omega-3 and Aspirin in Periodontal Regeneration|The Effect of Host Response Modulation Therapy (Omega 3 Plus Low-dose Aspirin) as an Adjunctive Treatment of Chronic Periodontitis (Clinical and Biochemical Study)|Completed||Phase 2|40|Actual|October 6 University||2|||f||||t||||||||||2018-05-31 23:51:09.085265|2018-05-31 23:51:09.085265
NCT01113515|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2015-04-14|2010-04-28|2010-04-30|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers|An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax®) for the Treatment of Diabetic Foot Ulcer (DFU)|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Novalead Pharma Private Limited||4|||f||||f||||||||||2018-05-31 23:51:09.180641|2018-05-31 23:51:09.180641
NCT01113502|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2016-07-18|2010-04-29|2010-04-30|Estimate|||||||2016-07-18|2016-07-19|Estimate|April 2010||2010-04-30|July 2016|2016-07-31||||March 2013|Actual|2013-03-31||Interventional|||Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)|A Phase I/II Study of Eltrombopag in Elderly Patients With AML|Active, not recruiting||Phase 1/Phase 2|44|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:51:09.306468|2018-05-31 23:51:09.306468
NCT01113489|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-07-26|2010-04-29|2010-04-30|Estimate|||||||2010-07-26|2010-07-27|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone|Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone|Completed||Phase 3|32|Anticipated|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||f||||||||||2018-05-31 23:51:09.369259|2018-05-31 23:51:09.369259
NCT01113476|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2018-03-01|2010-04-28|2010-04-30|Estimate|||||||2018-03-01|2018-03-02|Actual|April 27, 2010|Actual|2010-04-27|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies|Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies|Active, not recruiting||Phase 1|176|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:51:09.489038|2018-05-31 23:51:09.489038
NCT01113463|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2016-06-08||2016-09-12|2010-04-28|2010-04-30|Estimate|2016-09-12|2016-10-31|Estimate||||2016-09-12|2016-10-31|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|December 2012|Actual|2012-12-31|June 2011|Actual|2011-06-30||Interventional||Insufficient enrollment to perform any meaningful statistical analysis, therefore study terminated early.|TPI 287 in Patients With Recurrent Glioblastoma Multiforme|A Phase 2 Open-Label Study of the Efficacy of TPI 287 in Patients With Glioblastoma Multiforme That Has Recurred or Progressed Following Prior Therapy With Radiation Plus Temozolomide|Terminated||Phase 2|17|Actual|M.D. Anderson Cancer Center|Not enough subjects were enrolled to perform any meaningful statistical analysis.|1||Low Accrual|f||||f||||||||||2018-05-31 23:51:09.654984|2018-05-31 23:51:09.654984
NCT01113450|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2010-04-29|2010-04-29|2010-04-30|Estimate|||||||2010-04-29|2010-04-30|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Results of a Program of Newborn Hearing Screening (NHS) in Cuiaba-Brazil|Results of a Program of Newborn Hearing Screening in Cuiaba-Brazil|Completed|||3148|Actual|Centro de Diagnostico Auditivo de Cuiaba|||||f||||t||||||||||2018-05-31 23:51:09.857229|2018-05-31 23:51:09.857229
NCT01113437|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2011-01-20|2010-04-28|2010-04-29|Estimate|||||||2011-01-20|2011-01-21|Estimate|April 2010||2010-04-30|April 2010|2010-04-30||||August 2012|Anticipated|2012-08-31||Interventional|||Omalizumab in Non-atopic Asthma|The Effect of a Humanised Monoclonal Anti-IgE Antibody,Omalizumab, on Disease Control and Bronchial Mucosal Inflammation in Non-atpic Asthma|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|King's College London||2|||f||||t||||||||||2018-05-31 23:51:09.901786|2018-05-31 23:51:09.901786
NCT01113424|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2012-07-06|2010-04-28|2010-04-29|Estimate|||||||2012-07-06|2012-07-10|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum|Bioequivalence Between Oral Nicotine Replacement Products and Nicorette® Gum - A Study in Healthy Smokers|Completed||N/A|88|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||||2018-05-31 23:51:10.127834|2018-05-31 23:51:10.127834
NCT01113411|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2012-12-19|2010-04-28|2010-04-29|Estimate|||||||2012-12-19|2012-12-20|Estimate|December 2009||2009-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effectiveness of Intensive Rehabilitation on Shoulder Function After Proximal Humerus Fracture|Effectiveness of Intensive Rehabilitation on Shoulder Function After a Fracture of the Proximal Humerus Treated by Locked Plate. A Prospective Randomized Study|Unknown status|Recruiting|N/A|80|Anticipated|Hopital de l'Enfant-Jesus||2|||f||||f||||||||||2018-05-31 23:51:10.217302|2018-05-31 23:51:10.217302
NCT01113398|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2015-10-21||2015-12-09|2010-04-28|2010-04-29|Estimate|2015-12-09|2015-12-10|Estimate||||2015-12-09|2015-12-10|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||AMG 102 and Avastin for Recurrent Malignant Glioma|Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma|Completed||Phase 2|36|Actual|Duke University|11/21/14 Amgen notified PI they stopped their own AMG102 studies due to increased risk found in the TX arm on a different study. Dr. Peters decided to stop TX on the 3 current subjects on her study at that time although no increased risks were found.|1|||f||||f||||||||||2018-05-31 23:51:10.335774|2018-05-31 23:51:10.335774
NCT01113385|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|2014-07-21||2014-09-08|2010-04-28|2010-04-29|Estimate|2014-09-08|2014-09-15|Estimate||||2014-09-08|2014-09-15|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome|Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study|Completed||N/A|7|Actual|Children's Research Institute||1|||f||||f||||||||||2018-05-31 23:51:10.783112|2018-05-31 23:51:10.783112
NCT01113372|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-12-17|2010-04-28|2010-04-29|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2010||2010-04-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|February 2013|Actual|2013-02-28||Interventional|OPTIMIZE||Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial|Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial|Completed||Phase 4|3119|Actual|Cardiovascular Research Center, Brazil||2|||f||||t||||||||||2018-05-31 23:51:11.068646|2018-05-31 23:51:11.068646
NCT01113359|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-04-28|2010-04-28|2010-04-29|Estimate|||||||2010-04-28|2010-04-29|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||The Link Between Human Cytomegalovirus (HCMV) and Hypertension|The Potential Link Between HCMV Infection and Essential Hypertension|Unknown status|Recruiting||300|Anticipated|Beijing Chao Yang Hospital|||2||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 23:51:11.190679|2018-05-31 23:51:11.190679
NCT01113346|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-07-13|2010-04-28|2010-04-29|Estimate|||||||2010-07-13|2010-07-14|Estimate|June 2010||2010-06-30|July 2010|2010-07-31|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|F-GE-09||A Pilot Study of Filtrum-STI in Children With Viral Gastroenteritis|Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Filtrum-STI, 0,4g Tablets (Produced by AVVA RUS) in Children With Viral Gastroenteritis|Unknown status|Recruiting|Phase 2/Phase 3|150|Anticipated|Avva Rus, JSC||2|||f||||t||||||||||2018-05-31 23:51:11.274556|2018-05-31 23:51:11.274556
NCT01113333|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2011-03-22|2010-04-28|2010-04-29|Estimate|||||||2011-03-22|2011-03-23|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis|A Double Blind, Placebo Controlled Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the IKK Inhibitor, SAR113945, Following Intra-articular Administration in Patients With Knee Osteoarthritis|Completed||Phase 1|40|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 23:51:11.373351|2018-05-31 23:51:11.373351
NCT01113320|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2013-03-28|2010-04-28|2010-04-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|Safinamide-LID||Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects|A Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose Escalation Trial to Explore the Potential Antidyskinetic Properties of Safinamide in Patients With Parkinson's Disease Suffering From Levodopa Induced Dyskinesias|Completed||Phase 2|26|Actual|Newron Pharmaceuticals SPA||2|||f||||f||||||||||2018-05-31 23:51:11.447458|2018-05-31 23:51:11.447458
NCT01113307|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2013-01-30|2010-04-28|2010-04-29|Estimate|||||||2013-01-30|2013-01-31|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Observational|||The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds|A Multi-Center Post- Marketing Study to Define Procedures for the Use of CureXcellTM in a Community Setting for the Treatment of Wounds|Completed|||131|Actual|Macrocure Ltd.|||1||f||||f||||||||||2018-05-31 23:51:11.554205|2018-05-31 23:51:11.554205
NCT01113294|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-04-27|2010-04-27|2010-04-29|Estimate|||||||2010-04-27|2010-04-29|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation|Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial|Unknown status|Recruiting|Phase 4|2040|Anticipated|Wuhan University||1|||f||||t||||||||||2018-05-31 23:51:11.641388|2018-05-31 23:51:11.641388
NCT01113281|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2011-11-18|2010-04-28|2010-04-29|Estimate|||||||2011-11-18|2011-11-21|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa|Phase Ib Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Volunteers in South Africa|Completed||Phase 1|24|Actual|Vakzine Projekt Management GmbH||2|||f||||f||||||||||2018-05-31 23:51:11.792802|2018-05-31 23:51:11.792802
NCT01113268|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-04-13|2010-04-28|2010-04-29|Estimate|||||||2017-04-13|2017-04-14|Actual|September 2010||2010-09-30|April 2017|2017-04-30|January 25, 2022|Anticipated|2022-01-25|July 25, 2017|Anticipated|2017-07-25||Interventional|PREGICA||PREdisposition Genetical in Cardiac Insufficiency = Genetic Predisposition to Heart Failure|Role of Candidate Genes/Signalling Pathways in the Progression Towards Heart Failure: Study in a Cohort of Patients With a First Myocardial Infarction (PREGICA Patient Collection : Genetic Predisposition to Heart Failure)|Active, not recruiting||N/A|750|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:51:11.92587|2018-05-31 23:51:11.92587
NCT01113255|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-11-05|2010-04-28|2010-04-29|Estimate|||||||2014-11-05|2014-11-06|Estimate|March 2009||2009-03-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|SIMULVENTI||Validation of a Simulated Clinical Evaluation of Ventilators|Validation of a Simulated Clinical Evaluation of Ventilators|Completed||Phase 2/Phase 3|54|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:51:11.994906|2018-05-31 23:51:11.994906
NCT01113242|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-11-30|2010-04-28|2010-04-29|Estimate|||||||2010-11-30|2010-12-01|Estimate|June 2010||2010-06-30|November 2010|2010-11-30|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Observational|||Neuropsychological Assessment of Cognitive Decline in Patients With a Definite Parkinson's Disease|Characteristics of Cognitive Decline During Parkinson's Disease in the Elderly|Unknown status|Recruiting||40|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-05-31 23:51:12.061923|2018-05-31 23:51:12.061923
NCT01113229|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2015-04-07|2010-04-28|2010-04-29|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|CYTOCINON||Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage|Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage|Terminated||Phase 4|1721|Actual|Assistance Publique - Hôpitaux de Paris||2||reason of halt prematurely: futility of the trial|f||||f||||||||||2018-05-31 23:51:12.136903|2018-05-31 23:51:12.136903
NCT01113216|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2017-12-05|2010-04-28|2010-04-29|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2008||2008-04-30|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Genetic Modifiers of Cystic Fibrosis Related Diabetes|Genetic Modifiers of Cystic Fibrosis Related Diabetes|Recruiting|||1500|Anticipated|Johns Hopkins University|||||f||||f||||||Samples With DNA|"~     Blood will be drawn from study participants and their parents. Two tablespoons of blood (one~     tablespoon in small children) will be drawn by standard techniques from a vein in the arm.~     Whenever possible, blood samples for this study will be collected at the same time that it is~     done for medically needed blood tests. This blood will be used to extract DNA and to~     establish cell lines that we will store as a permanent source of DNA. We will compare your~     clinical symptoms with your DNA to see if additional genes that affect CF symptoms can be~     found. Some serum and plasma will be stored for later testing, as additional knowledge~     becomes available. Any tests done in the future with your stored blood samples or your DNA~     will only be to answer questions about genes for CF.~   "|No||2018-05-31 23:51:12.234368|2018-05-31 23:51:12.234368
NCT01113203|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-04-28|2010-04-28|2010-04-29|Estimate|||||||2010-04-28|2010-04-29|Estimate|January 2008||2008-01-31|April 2010|2010-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|RTBP||Chronic and Acute Effects of Resistance Exercise on Older Subjects' Blood Pressure|Chronic and Acute Effects of Resistance Exercise on Older Subjects' Blood Pressure|Completed||N/A|25|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:51:12.320558|2018-05-31 23:51:12.320558
NCT01113190|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2016-04-06|2010-04-27|2010-04-29|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Healthier You: Optimizing Screening, Brief Interventions, and Referral to Treatment (SBIRT) in the Emergency Department|Optimizing SBIRT for Drug-Using Patients in an Inner-City Emergency Department|Completed||N/A|878|Actual|University of Michigan||6|||f||||f||||||||No||2018-05-31 23:51:12.508419|2018-05-31 23:51:12.508419
NCT01113177|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-11-08|2010-04-27|2010-04-29|Estimate|||||||2010-11-08|2010-11-09|Estimate|June 1994||1994-06-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|||Effect of Functional Treatment on Mandibular Asymmetric Growth|Effect of Functional Treatment on Mandibular Asymmetry Caused by Unilateral Temporomandibular Joint Involvement in Children With Juvenile Idiopathic Arthritis|Completed|||22|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 23:51:12.636828|2018-05-31 23:51:12.636828
NCT01113164|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-02-18|2010-04-28|2010-04-29|Estimate|||||||2012-02-18|2012-02-22|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Matching Genotypes and Serotonergic Medications for Alcoholism|Matching Genotypes and Serotonergic Medications for Alcoholism|Completed||Phase 1|79|Actual|Brown University||2|||f||||t||||||||||2018-05-31 23:51:12.708119|2018-05-31 23:51:12.708119
NCT01113151|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2013-09-03|2010-04-28|2010-04-29|Estimate|||||||2013-09-03|2013-09-04|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Daily Magnesium-supplement for Severe Asthmatics|Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics|Completed||N/A|5|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:51:12.793579|2018-05-31 23:51:12.793579
NCT01113138|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2014-01-10|2010-04-28|2010-04-29|Estimate|||||||2014-01-10|2014-01-13|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers|Pharmacokinetic Study of Mablet as Oral Supplement and Magnesium Sulfate as Infusion|Completed||N/A|10|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:51:12.897438|2018-05-31 23:51:12.897438
NCT01113125|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2014-02-11|2010-04-28|2010-04-29|Estimate|||||||2014-02-11|2014-02-12|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|July 2016|Anticipated|2016-07-31|August 2014|Anticipated|2014-08-31||Interventional|||Scars After Central Venous Catheters|Topical Treatment With Glucocorticoids to Prevent Hypertrophic Scars and Keloid Due to Central Venous Access in Children|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 23:51:12.993763|2018-05-31 23:51:12.993763
NCT01113112|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2017-02-24|2010-04-27|2010-04-29|Estimate|||||||2017-02-24|2017-02-28|Actual|August 2003|Actual|2003-08-31|February 2017|2017-02-28|December 31, 2025|Anticipated|2025-12-31|November 10, 2015|Actual|2015-11-10||Observational|VEGF||Biobehavioral-Cytokine Interactions in Ovarian Cancer|Biobehavioral-Cytokine Interactions in Ovarian Cancer|Active, not recruiting|||613|Actual|University of Iowa|||1||f||||f|f|f||||Samples With DNA|"~     serum, saliva, tissue, ascites~   "|No||2018-05-31 23:51:13.083856|2018-05-31 23:51:13.083856
NCT01113099|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-27|2010-04-27|2010-04-29|Estimate|||||||2010-04-27|2010-04-29|Estimate|June 2006||2006-06-30|April 2010|2010-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients|Assisted Detailing to Improve Guideline Adherence|Completed||N/A|247|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 23:51:13.145023|2018-05-31 23:51:13.145023
NCT01113086|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2017-03-17|2010-04-27|2010-04-29|Estimate|||||||2017-03-17|2017-03-21|Actual|December 2009||2009-12-31|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Use of Noninvasive Brain Stimulation in Parkinson's Disease|Selective Modulation of Cognitive, Affective, and Motor Function by Transcranial Direct Current Stimulation as Co-adjuvant Therapy in Parkinson's Disease.|Completed||N/A|12|Actual|Spaulding Rehabilitation Hospital||4|||f||||f|f|f||||||||2018-05-31 23:51:13.259255|2018-05-31 23:51:13.259255
NCT01113073|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-08-30|2010-04-28|2010-04-29|Estimate|||||||2010-08-30|2010-08-31|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||The Distribution of Pressure in the Thorax During Mechanical Ventilation and Its Effects on the Circulation|The Distribution of Pressure in the Thorax During Mechanical Ventilation and Its Effects on the Circulation|Unknown status|Recruiting|N/A|20|Anticipated|Radboud University||1|||f||||t||||||||||2018-05-31 23:51:13.367859|2018-05-31 23:51:13.367859
NCT01113060|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2016-12-16|2010-04-27|2010-04-29|Estimate|||||||2016-12-16|2016-12-19|Estimate|April 2010||2010-04-30|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Aspirin Effectiveness Study|Aspirin Effectiveness in Coronary Artery Disease Patients in Ireland|Recruiting|||500|Anticipated|Royal College of Surgeons, Ireland|||1||f||||f||||||||||2018-05-31 23:51:13.51105|2018-05-31 23:51:13.51105
NCT01113047|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2013-12-05|2010-04-28|2010-04-29|Estimate|||||||2013-12-05|2013-12-06|Estimate|May 2010||2010-05-31|December 2013|2013-12-31||||October 2010|Actual|2010-10-31||Interventional|AWESOME||Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Single Pill (SPC) Combination of Aliskiren 300 mg / Amlodipine 10 mg in Hypertensive Patients Not Adequately Respond to an Uptitrated 4 Week Therapy With the SPC of Olmesartan 40 mg / Amlodipine 10 mg, With a Potential Extension if Patients Still Not Adequately Respond With a 4 Week Therapy With the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg|Completed||Phase 3|347|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:51:13.594753|2018-05-31 23:51:13.594753
NCT01113034|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-07-29|2010-04-28|2010-04-29|Estimate|||||||2010-07-29|2010-08-02|Estimate|July 2010||2010-07-31|July 2010|2010-07-31||||December 2010|Anticipated|2010-12-31||Interventional|DAS181||A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis|A Phase 1 Randomized Double-Blind Placebo-Crossover Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis|Unknown status|Recruiting|Phase 1|24|Anticipated|Ansun Biopharma, Inc.||2|||t||||t||||||||||2018-05-31 23:51:13.670465|2018-05-31 23:51:13.670465
NCT01113021|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-28|||2010-04-28|2010-04-28|2010-04-29|Estimate|||||||2010-04-28|2010-04-29|Estimate||||August 2008|2008-08-31||||||||Interventional|||Study of Effects of Low Level Laser Therapy in the Physical Training and the Muscle Responses in Humans.|Phase 1. Muscle Genic Expression Under Strength Training and Photostimulated by Laser.|Completed||Phase 1|||Universidade Federal de Sao Carlos||1|||f||||||||||||||2018-05-31 23:51:13.754277|2018-05-31 23:51:13.754277
NCT01113008|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2015-01-11||2015-01-11|2010-04-28|2010-04-29|Estimate|2015-01-11|2015-01-21|Estimate||||2015-01-11|2015-01-21|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Remote Ischemic Postconditioning in Humans|Remote Ischemic Postconditioning. Can it Prevent Myocardial Injury During Percutaneous Coronary Intervention?|Completed||N/A|266|Actual|Hospital Universitario Virgen de la Victoria||2|||f||||t||||||||||2018-05-31 23:51:13.828669|2018-05-31 23:51:13.828669
NCT01112813|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2017-10-24|2010-04-27|2010-04-28|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2010||2010-04-30|October 2017|2017-10-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study|The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study|Completed||Phase 3|12|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 23:51:15.693014|2018-05-31 23:51:15.693014
NCT01112995|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2015-10-01|2010-04-27|2010-04-29|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2010||2010-01-31|April 2011|2011-04-30|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|PROSE||A Pilot Trial to Determine the Efficacy of Lactobacillus Rhamnosus for Reducing Colonization by Methicillin-resistant Staphylococcus Aureus (MRSA) (PROSE)|A Pilot Randomized Trial to Determine the Efficacy of a Probiotic, Lactobacillus Rhamnosus for Reducing Colonization by Methicillin-resistant Staphylococcus Aureus (MRSA)|Completed||Phase 2|49|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 23:51:14.019966|2018-05-31 23:51:14.019966
NCT01112982|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2015-07-17|2010-04-28|2010-04-29|Estimate|||||||2015-07-17|2015-07-20|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.|Shifting the Paradigm of Gout: An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.|Completed||Phase 4|76|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 23:51:14.120721|2018-05-31 23:51:14.120721
NCT01112969|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2015-07-22|2010-04-28|2010-04-29|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||OSCAR - An Internet-based Supportive Coaching for Informal Caregivers of Adult Individuals With an Acquired Brain Injury|OSCAR - An Internet-based Supportive Coaching for Informal Caregivers of Adult Individuals With an Acquired Brain Injury.|Terminated||Phase 2|40|Actual|University of Bern||2||Project end after 3 years; prolongation was rejected|f||||f||||||||||2018-05-31 23:51:14.255058|2018-05-31 23:51:14.255058
NCT01112956|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-03-22|2010-04-28|2010-04-29|Estimate|||||||2011-03-22|2011-03-23|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2|Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2: Development of Testing Strategies|Completed|||2500|Actual|Centers for Disease Control and Prevention|||3||f||||f||||||Samples Without DNA|"~     Serum specimens~   "|||2018-05-31 23:51:14.359459|2018-05-31 23:51:14.359459
NCT01112943|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-08-12|2010-04-28|2010-04-29|Estimate|||||||2012-08-12|2012-08-14|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Acupuncture Combined With Pulmonary Rehabilitation: Are There Additional Benefits?|The Impact of Acupuncture as an Adjunct to Pulmonary Rehabilitation|Completed||N/A|44|Actual|Beaumont Hospital||3|||f||||f||||||||||2018-05-31 23:51:14.423629|2018-05-31 23:51:14.423629
NCT01112930|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2015-04-14|2010-04-28|2010-04-29|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Essential Fatty Acid (EFA) Nutrition 5-Year-Olds X Section|n-3 Fatty Acids and Early Child Nutrition: 5-Year-Olds X-Section Study|Completed|||187|Actual|University of British Columbia|||||f||||f||||||Samples With DNA|"~     Plasma and blood cells~   "|||2018-05-31 23:51:14.54879|2018-05-31 23:51:14.54879
NCT01112917|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2016-04-18||2016-06-01|2010-04-27|2010-04-29|Estimate|2016-06-01|2016-07-11|Estimate||||2016-06-01|2016-07-11|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial|VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial|Completed||N/A|149|Actual|B. Braun Interventional Systems, Inc||1|||f||||t||||||||No||2018-05-31 23:51:14.617523|2018-05-31 23:51:14.617523
NCT01112904|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2015-04-14|2010-04-27|2010-04-29|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Essential Fatty Acid (EFA) Nutrition 5-Year-Olds Follow-Up Study|n-3 Fatty Acids and Early Child Nutrition: 5-Year-Olds Follow-Up Study|Completed|||98|Actual|University of British Columbia|||||f||||f||||||Samples With DNA|"~     Plasma and blood cells~   "|||2018-05-31 23:51:14.806852|2018-05-31 23:51:14.806852
NCT01112891|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2014-12-12|2010-04-27|2010-04-29|Estimate|||||||2014-12-12|2014-12-16|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Interventional|||Vitamin D in Pregnancy and Lactation|Vitamin D Dose-response Study Throughout Pregnancy and Lactation|Completed||Phase 4|225|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 23:51:14.85529|2018-05-31 23:51:14.85529
NCT01112878|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-09-10|2010-04-28|2010-04-29|Estimate|||||||2015-09-10|2015-09-14|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery|Randomized, Double-Blinded, Placebo-controlled Study to Evaluate the Analgesic Efficacy of Oral Clonidine and Gabapentin as Part of a Multi-modal Analgesic Regimen for Preventing Pain After Arthroscopic Shoulder or Knee Surgery|Withdrawn||Phase 4|0|Actual|Cedars-Sinai Medical Center||3||Several studies going on at the same time.|f||||t||||||||||2018-05-31 23:51:14.924689|2018-05-31 23:51:14.924689
NCT01112865|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2012-04-16||2012-05-15|2010-04-27|2010-04-28|Estimate|2012-04-16|2012-05-14|Estimate||||2012-05-15|2012-05-22|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CHOOSE||Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects|A Multicenter, Open-label, Randomized Two Arm Cross Over Study Assessing Dyad (Subject and Caregiver) and Adult Subject Perception of Convenience and Preference of the Newly Developed Genotropin Mark VII Pen.|Completed||Phase 3|120|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:51:15.004002|2018-05-31 23:51:15.004002
NCT01112852|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|December 2006||2006-12-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|EVL||EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding|A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding|Completed||Phase 4|118|Actual|National Science Council, Taiwan||2|||f||||t||||||||||2018-05-31 23:51:15.39931|2018-05-31 23:51:15.39931
NCT01112839|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2015-06-17|2010-04-27|2010-04-28|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ENERGY||Reducing Breast Cancer Recurrence With Weight Loss|Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial|Completed||N/A|692|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 23:51:15.49798|2018-05-31 23:51:15.49798
NCT01112826|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-09-08|2010-04-27|2010-04-28|Estimate|||||||2017-09-08|2017-09-11|Actual|April 2010||2010-04-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SYSUCC-001||Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer|Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast Cancer|Completed||Phase 3|432|Actual|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 23:51:15.601196|2018-05-31 23:51:15.601196
NCT01112800|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-06-18|2010-04-27|2010-04-28|Estimate|||||||2013-06-18|2013-06-19|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Markers of Anthracycline-Related Cardiac Muscle Injury|Markers of Anthracycline-Related Cardiac Muscle Injury|Withdrawn|||0|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples Without DNA|"~     A blood sample will be collected at baseline, prior to and at the end of each doxorubicin~     infusion (48- or 72-hour) and following completion of chemotherapy for osteosarcoma, ESFT,~     rhabdomyosarcoma or intermediate and high-risk non-rhabdomyosarcoma soft tissue~     sarcomas.cTn-T and NT-BNP will be measured at baseline, prior to and at the end of each~     doxorubicin infusion (48- or 72-hour) and following completion of chemotherapy for~     osteosarcoma, ESFT, rhabdomyosarcoma or intermediate and high-risk non-rhabdomyosarcoma soft~     tissue sarcomas.~   "|||2018-05-31 23:51:15.815063|2018-05-31 23:51:15.815063
NCT01112787|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2017-06-19|2010-04-27|2010-04-28|Estimate|||||||2017-06-19|2017-06-20|Actual|March 26, 2010|Actual|2010-03-26|June 2017|2017-06-30|April 26, 2010|Actual|2010-04-26|April 26, 2010|Actual|2010-04-26||Interventional|||A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers|A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled, Study To Evaluate The Cumulative Irritation Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers|Completed||Phase 1|39|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:51:15.925053|2018-05-31 23:51:15.925053
NCT01112774|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2017-03-17|2010-04-27|2010-04-28|Estimate|||||||2017-03-17|2017-03-21|Actual|April 2010||2010-04-30|March 2017|2017-03-31|August 14, 2013|Actual|2013-08-14|August 14, 2013|Actual|2013-08-14||Interventional|||Application of Transcranial Direct Current Stimulation (tDCS) in Patients With Chronic Pain After Spinal Cord Injury|Investigation of the Mechanisms of Transcranial Direct Current Stimulation of Motor Cortex for the Treatment of Chronic Pain in Spinal Cord Injury|Terminated||N/A|24|Actual|Spaulding Rehabilitation Hospital||2||Funding ended|f||||f|f|f||||||||2018-05-31 23:51:16.100263|2018-05-31 23:51:16.100263
NCT01112761|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2017-03-17|2010-04-27|2010-04-28|Estimate|||||||2017-03-17|2017-03-21|Actual|April 2010||2010-04-30|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Cortical Plasticity Assessment in Athletes With a History of Concussion|Cortical Plasticity Assessment in Athletes With a History of Concussion|Terminated||N/A|1|Actual|Spaulding Rehabilitation Hospital||2||Lack of resources to run the trial|f||||f|f|f||||||||2018-05-31 23:51:16.200289|2018-05-31 23:51:16.200289
NCT01112748|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2011-08-26|2010-04-27|2010-04-28|Estimate|||||||2011-08-26|2011-08-29|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Topical Lidocaine: Predictors of Response in Peripheral Nerve Injury|Evaluation of Predictors of Response for the Efficacy of Topical Lidocaine Patch (Versatis) on Chronic Neuropathic Pain After Peripheral Nerve Injury|Completed||Phase 4|24|Actual|Danish Pain Research Center|||||f||||t||||||||||2018-05-31 23:51:16.286516|2018-05-31 23:51:16.286516
NCT01112735|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27||2012-02-02|2012-02-03|2010-04-27|2010-04-28|Estimate||||2012-02-02|2012-02-06|Estimate|2012-02-03|2012-02-07|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty|A Randomized, Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of ARTISS (FS VH S/D 4 S-apr) for Flap Adherence in Subjects Undergoing Abdominoplasty|Completed||Phase 2|40|Actual|Baxter Healthcare Corporation||2|||f||||||||||||||2018-05-31 23:51:16.377223|2018-05-31 23:51:16.377223
NCT01112722|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-25|||2016-12-11|2010-04-27|2010-04-28|Estimate|||||||2016-12-11|2016-12-13|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis|A Multicenter, Randomized, Double Blind, Active Controlled, Parallel Group, Clinical Study, to Evaluate the Safety and Efficacy of Apitox vs Histamine in Subjects With Refractory Osteoarthritis Pain and Inflammation of the Knee|Completed||Phase 3|363|Actual|Apimeds, Inc.||2|||f||||t||||||||Undecided||2018-05-31 23:51:16.495911|2018-05-31 23:51:16.495911
NCT01112709|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-03-19|2010-04-27|2010-04-28|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Maintaining Resistance Training in Older Prediabetic Adults|Maintaining Resistance Training in Older Prediabetic Adults: Theoretical Approach|Completed||Phase 2|170|Actual|Virginia Polytechnic Institute and State University||2|||f||||t||||||||||2018-05-31 23:51:16.619901|2018-05-31 23:51:16.619901
NCT01112696|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2011-06-22||2017-12-18|2010-04-27|2010-04-28|Estimate|2012-07-23|2012-08-27|Estimate||||2017-12-18|2018-01-16|Actual|April 2010||2010-04-30|December 2017|2017-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor|An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor|Completed||N/A|100|Actual|Medtronic Diabetes||1|||f||||f||||||||||2018-05-31 23:51:16.720505|2018-05-31 23:51:16.720505
NCT01112683|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2012-07-25||2012-12-26|2010-04-27|2010-04-28|Estimate|2012-12-26|2013-02-01|Estimate||||2012-12-26|2013-02-01|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome|A Sixteen-Week, Randomized, Double Blind, Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Young Adults With Down Syndrome|Completed||Phase 4|42|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 23:51:16.925501|2018-05-31 23:51:16.925501
NCT01112670|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2012-10-07||2013-01-22|2010-04-27|2010-04-28|Estimate|2012-12-04|2013-01-08|Estimate||||2013-01-22|2013-01-24|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology|The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology|Completed||Phase 4|33|Actual|University of Colorado, Denver|Findings are only applicable to individuals with ABCB1 CGC/CGC, CGC/TTT, or TTT/TTT diplotypes.|3|||f||||f||||||||||2018-05-31 23:51:17.302865|2018-05-31 23:51:17.302865
NCT01112657|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2014-11-12|2010-04-27|2010-04-28|Estimate|||||||2014-11-12|2014-11-13|Estimate|November 2008||2008-11-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|NEO||An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year Period|A Prospective, Observational Study On The Progression Of Clinically Isolated Syndrome (CIS) To Multiple Sclerosis Over A 2-year Period|Completed|||154|Actual|Merck KGaA|||||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 23:51:17.67905|2018-05-31 23:51:17.67905
NCT01112449|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-07-08|2010-04-26|2010-04-28|Estimate|||||||2015-07-08|2015-07-10|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|July 2012|Actual|2012-07-31||Interventional|||Influence of Selenium on Prostate Cancer Related Biomarkers|Influence of Selenium on Prostate Cancer Related Biomarkers|Completed||N/A|130|Actual|Milton S. Hershey Medical Center||4|||f||||t||||||||||2018-05-31 23:51:20.437931|2018-05-31 23:51:20.437931
NCT01112644|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-04-09|2010-04-27|2010-04-28|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate Improvement of Symptoms of RLS in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms Who Take OXN PR Compared to Subjects Taking Placebo (PLA).|Completed||Phase 3|205|Actual|Mundipharma Research GmbH & Co KG||2|||f||||f||||||||||2018-05-31 23:51:17.744523|2018-05-31 23:51:17.744523
NCT01112631|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2011-09-19|2010-04-27|2010-04-28|Estimate|||||||2011-09-19|2011-09-20|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Prospective Study of Quality of Life in Non-small Cell Lung Cancer (NSCLC) Patients Treated With/Without Postoperative Radiotherapy|Prospective Comparison of Quality of Life and Cardiopulmonary Morbidity After Surgery in Non-small Cell Lung Cancer Patients Treated With and Without Postoperative Radiotherapy|Completed|||293|Actual|Maria Sklodowska-Curie Institute - Oncology Center|||2||f||||t||||||||||2018-05-31 23:51:17.838422|2018-05-31 23:51:17.838422
NCT01112618|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2014-07-15|2010-04-27|2010-04-28|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2008||2008-01-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in the Daily Practice|Pergoveris Non Interventional Study|Completed|||3247|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:51:17.900005|2018-05-31 23:51:17.900005
NCT01112605|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2011-07-16|2010-04-27|2010-04-28|Estimate|||||||2011-07-16|2011-07-19|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Standard Deviation of the Distance Between the Sural Nerve and Achilles Tendon by Ultrasound||Completed|||50|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 23:51:17.951799|2018-05-31 23:51:17.951799
NCT01112592|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2013-02-26|2010-04-27|2010-04-28|Estimate|||||||2013-02-26|2013-02-27|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Observational|NETs||NETs Formation in Patients With Recurrent Pyogenic Infections (NETS)|The Ability of Neutrophils From Patients With Recurrent Infections to Produce Neutrophil Extracellular Traps (NET).|Unknown status|Recruiting||100|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 23:51:18.006294|2018-05-31 23:51:18.006294
NCT01112579|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2015-10-01||2015-10-01|2010-04-27|2010-04-28|Estimate|2015-10-01|2015-10-29|Estimate||||2015-10-01|2015-10-29|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|January 2014|Actual|2014-01-31||Interventional|DEFEAT-HF||Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure|Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure|Completed||Phase 2|81|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-05-31 23:51:18.112909|2018-05-31 23:51:18.112909
NCT01112566|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2018-04-25|2010-04-27|2010-04-28|Estimate|||||||2018-04-25|2018-04-26|Actual|February 2013||2013-02-28|April 2018|2018-04-30|May 2017|Actual|2017-05-31|April 26, 2017|Actual|2017-04-26||Observational|||EASE MITRAL Expertise-based Assessment Study on Clinical Efficacy of Profile 3D in MITRAL Valve Annuloplasty|EASE MITRAL Expertise-based Assessment Study on Clinical Efficacy of Profile 3D in MITRAL Valve Annuloplasty|Completed|||152|Actual|Medtronic Cardiovascular|||||f||||f||||||||||2018-05-31 23:51:19.551346|2018-05-31 23:51:19.551346
NCT01112553|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-10-30|2010-04-27|2010-04-28|Estimate|||||||2012-10-30|2012-11-01|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|||||Observational|TREX||Treximet Migraine Brain Imaging Research Study|Evaluation of Brain Activation in Complete Responders and Partial Responders Following Acute Administration of Treximet (Sumatriptan and Naproxen)|Terminated|||2|Actual|Mclean Hospital|||1|Study was closed due to low enrollment numbers.|f||||||||||Samples With DNA|"~     Seven 5-mL blood samples will be drawn throughout the MRI session, and blood plasma will be~     analyzed for the concentration of Treximet.~   "|||2018-05-31 23:51:19.618923|2018-05-31 23:51:19.618923
NCT01112540|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate||||April 2010|2010-04-30||||||||Interventional|||Morphine in Acute Abdominal Pain||Completed||Phase 4|||Akdeniz University||2|||f||||||||||||||2018-05-31 23:51:19.677073|2018-05-31 23:51:19.677073
NCT01112527|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27||2016-10-27|2017-06-27|2010-04-27|2010-04-28|Estimate||||2016-10-27|2016-10-28|Estimate|2017-06-27|2017-07-02|Actual|April 2010||2010-04-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|September 2015|Actual|2015-09-30||Interventional|||PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma|An Open-Label, Phase 2 Trial of Orally Administered PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (GBM)|Active, not recruiting||Phase 2|58|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 23:51:19.740064|2018-05-31 23:51:19.740064
NCT01112514|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2013-08-06||2014-01-08|2010-04-27|2010-04-28|Estimate|2014-01-08|2014-02-24|Estimate||||2014-01-08|2014-02-24|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|April 2013|Actual|2013-04-30|December 2010|Actual|2010-12-31||Interventional||One participant withdrew from the study.|Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract|A Pilot Study of Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract|Completed||N/A|4|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:51:19.822378|2018-05-31 23:51:19.822378
NCT01112501|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|September 2006||2006-09-30|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|DEMSPET||SPECT/CT in the Diagnosis of Dementia|SPECT/CT in the Diagnosis of Dementia|Completed|||82|Actual|Kuopio University Hospital|||||f||||||||||||||2018-05-31 23:51:20.180971|2018-05-31 23:51:20.180971
NCT01112488|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|PEPS||Patient Engagement Program for Stroke - Pilot Study|Patient Engagement Program for Stroke - Pilot Study|Unknown status|Not yet recruiting|N/A|30|Anticipated|Kowloon Hospital, Hong Kong||2|||f||||t||||||||||2018-05-31 23:51:20.236912|2018-05-31 23:51:20.236912
NCT01112475|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-05-13|2010-04-27|2010-04-28|Estimate|||||||2010-05-13|2010-05-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:51:20.318806|2018-05-31 23:51:20.318806
NCT01112462|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-07-06|2010-04-27|2010-04-28|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||To Test Bioequivalence Between Two Formulations of Paracetamol/Phenylephrine|A Single-dose, Randomized, Crossover Bioequivalence Study to Compare Two Formulations of Paracetamol/Phenylephrine|Completed||Phase 1|40|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 23:51:20.360819|2018-05-31 23:51:20.360819
NCT01112436|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2011-06-23|2010-04-27|2010-04-28|Estimate|||||||2011-06-23|2011-06-27|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement|The Effect of Periarticular Injection of Multi-drug Regimen on Pain in Patient Receiving Partial Hip Replacement:Randomized Prospective Study.|Unknown status|Recruiting|Phase 4|258|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||f||||||||||2018-05-31 23:51:20.541026|2018-05-31 23:51:20.541026
NCT01112423|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23||2012-04-25|2015-09-23|2010-04-27|2010-04-28|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety Study of BMS-823778 in Subjects With Hypercholesterolemia|A Double-Blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Non-Diabetic Subjects With Primary Hypercholesterolemia on a Stable Dose of Statin Therapy With or Without Ezetimibe|Completed||Phase 2|60|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 23:51:20.651138|2018-05-31 23:51:20.651138
NCT01112410|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis|A Randomised Double Blind 13 Week Crossover Trial of Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Patients With Bronchiectasis.|Unknown status|Recruiting|Phase 2|20|Anticipated|Belfast Health and Social Care Trust|||||f||||f||||||||||2018-05-31 23:51:20.783371|2018-05-31 23:51:20.783371
NCT01112397|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-07-19|2010-04-27|2010-04-28|Estimate|||||||2013-07-19|2013-07-22|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours|A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.|Terminated||Phase 1|72|Actual|AstraZeneca||2||Decision to stop development of AZD1480|f||||f||||||||||2018-05-31 23:51:20.864705|2018-05-31 23:51:20.864705
NCT01112384|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-11-25|2010-04-27|2010-04-28|Estimate|||||||2016-11-25|2016-11-28|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|IND200||A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas|A Phase II Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas|Completed||Phase 2|24|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-05-31 23:51:20.945029|2018-05-31 23:51:20.945029
NCT01112371|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-04-07|2010-04-26|2010-04-28|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ConMex||Contractubex Treatment in Scars After Abdominal Caesarean Section|A Prospective, Single-center, Randomized, Parallel Group Trial to Investigate the Efficacy of Contractubex® Gel, Containing Extractum Cepae, Allantoin, and Heparin, in Scars After Abdominal Caesarean Section|Completed||Phase 4|61|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-05-31 23:51:21.020385|2018-05-31 23:51:21.020385
NCT01112358|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2016-11-18|2010-04-27|2010-04-28|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2005||2005-11-30|April 2010|2010-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||An Exploratory Trial to Assess the Efficacy and Safety of Luveris in Women at Risk of Poor Response Undergoing Controlled Ovarian Stimulation (COS) Prior to Intracytoplasmic Sperm Injection (ICSI) With Gonal-f and Cetrotide|Lutropin Alfa (Luveris®) in Women at Risk of Poor Response Suppressed With Cetrorelix: an Exploratory Trial|Completed||Phase 2|60|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 23:51:21.084252|2018-05-31 23:51:21.084252
NCT01112345|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2014-07-15|2010-04-26|2010-04-28|Estimate|||||||2014-07-15|2014-07-16|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters|A Multicentre, Non Interventional, Non Randomized, Observational Study for the Assessment of Compliance and Persistence With Rebif® Therapy of Patients With Relapsing-Remitting Multiple Sclerosis as Well as for the Evaluation of Potential Factors Influencing These Parameters, in Real Life Clinical Practice|Completed|||133|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:51:21.168941|2018-05-31 23:51:21.168941
NCT01112332|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-08-09|2010-04-26|2010-04-28|Estimate|||||||2012-08-09|2012-08-10|Estimate|March 2010||2010-03-31|August 2012|2012-08-31||||||||Expanded Access|SSW001||Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics|: Use of an Innovative Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics in Different Physiologic Conditions|Available|||||Meir Medical Center|||||||||f||||||||||2018-05-31 23:51:21.351119|2018-05-31 23:51:21.351119
NCT01112319|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-09-06|2010-04-27|2010-04-28|Estimate|||||||2012-09-06|2012-09-07|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|May 2012|Anticipated|2012-05-31|March 2011|Actual|2011-03-31||Interventional|||The Effects of the Electro, Heat and Cold -Therapy During Physiotherapy Treatment in Osteoarthritis(OA) of KNEE|The Effects of the Electro, Heat and Cold -Therapy During Physiotherapy Treatment in OA of KNEE - Prospective Randomize Trial|Withdrawn||Phase 1|0|Actual|Meir Medical Center||2||not patient recruitment|f||||||||||||||2018-05-31 23:51:21.431859|2018-05-31 23:51:21.431859
NCT01112306|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2018-03-12|2010-04-27|2010-04-28|Estimate|||||||2018-03-12|2018-03-13|Actual|December 1, 2009||2009-12-01|March 2018|2018-03-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||ACT-293987 in Pulmonary Arterial Hypertension|Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of Selexipag (ACT-293987) in Patients With Pulmonary Arterial Hypertension|Active, not recruiting||Phase 3|670|Anticipated|Actelion||1|||f||||t||||||||||2018-05-31 23:51:21.57156|2018-05-31 23:51:21.57156
NCT01112293|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2017-07-31|2010-04-27|2010-04-28|Estimate|||||||2017-07-31|2017-08-02|Actual|April 2010||2010-04-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|October 2012|Actual|2012-10-31||Interventional|||Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma|A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM))|Completed||Phase 2|14|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:51:21.868335|2018-05-31 23:51:21.868335
NCT00977964|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-11-24|2009-09-15|2009-09-16|Estimate|||||||2010-11-24|2010-11-25|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Tolerance of Healthy Term Infants Fed Infant Formulas #3|Tolerance of Healthy Term Infants Fed Infant Formulas|Completed||Phase 3|270|Actual|Abbott Nutrition||6|||f||||t||||||||||2018-06-01 00:34:47.235406|2018-06-01 00:34:47.235406
NCT01112280|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2016-02-22|2010-04-27|2010-04-28|Estimate|||||||2016-02-22|2016-02-24|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|CapACE||Efficacy of Cap-assisted Chromoendoscopy as a Screening Test for Colorectal Neoplasm Using Web-based Research Network|Prospective Randomized Controlled Trial of Cap-Assisted ChromoEndoscopy(CapACE) Versus Conventional Colonoscopy(CC) for the Detection and 3-year Recurrence Rate of Colorectal Neoplasia|Unknown status|Recruiting|N/A|2000|Anticipated|Korean Association for the Study of Intestinal Diseases||2|||f||||t||||||||Undecided||2018-05-31 23:51:21.943552|2018-05-31 23:51:21.943552
NCT01112267|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2013-04-01||2013-06-20|2010-04-26|2010-04-28|Estimate|2013-06-20|2013-07-24|Estimate||||2013-06-20|2013-07-24|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain|A Randomized, Placebo-Controlled, Parallel Group, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Tramadol HCl/Acetaminophen Extended Release Tablet in Subjects With Chronic Low Back Pain|Completed||Phase 3|248|Actual|Janssen Korea, Ltd., Korea||2|||f||||f||||||||||2018-05-31 23:51:22.071026|2018-05-31 23:51:22.071026
NCT01112254|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2016-01-25|2010-04-27|2010-04-28|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|IRCIS||Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer|Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer|Completed||Phase 3|360|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||||||||||||2018-05-31 23:51:22.46324|2018-05-31 23:51:22.46324
NCT01112241|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|2010-11-30||2011-02-28|2010-04-27|2010-04-28|Estimate|2011-01-26|2011-02-23|Estimate||||2011-02-28|2011-03-02|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|BD-OB||Bronchodilator Responsiveness in Obliterative Bronchiolitis|Acute Bronchodilator Responsiveness in Obliterative Bronchiolitis (OB) Following Hematopoietic Stem Cell Transplantation|Completed||Phase 4|17|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||1|||f||||f||||||||||2018-05-31 23:51:22.54547|2018-05-31 23:51:22.54547
NCT01112228|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-09-17|2010-04-26|2010-04-28|Estimate|||||||2010-09-17|2010-09-20|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|COST||Clinical Obesity Staging Tools|Assessing Clinical Staging Tools for Tracking the Impacts of Obesity on Individuals|Completed|||600|Actual|Imperial College London|||1||f||||||||||||||2018-05-31 23:51:22.822243|2018-05-31 23:51:22.822243
NCT01112215|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2016-10-03|2010-04-27|2010-04-28|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations|Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations|Completed||Phase 4|240|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 23:51:22.911155|2018-05-31 23:51:22.911155
NCT01112202|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2012-06-05|2010-04-27|2010-04-28|Estimate|||||||2012-06-05|2012-06-06|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Observational|||Effect of Dabigatran on Coagulation parameters-an ex Vivo Study|Effect of Dabigatran on Coagulation Parameters in Patients Undergoing Elective Orthopaedic Surgery|Completed|||70|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-05-31 23:51:22.990554|2018-05-31 23:51:22.990554
NCT01112189|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2011-03-23|2010-04-26|2010-04-28|Estimate|||||||2011-03-23|2011-03-24|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|SCL||Use of Stem Cells in Lymphedema Post Mastectomy|Postoperative Lymphedema Treatment in Upper Extremities Following Axillary Lymphadenectomy by Transplanting Autologous Endothelial Progenitor Cells (EPC)|Completed||Phase 1/Phase 2|20|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t||||||||||2018-05-31 23:51:23.062862|2018-05-31 23:51:23.062862
NCT01112176|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Effect of Heart Rate on Left Ventricular Performance|Effect of Heart Rate on Left Ventricular Performance|Unknown status|Recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-05-31 23:51:23.204438|2018-05-31 23:51:23.204438
NCT01112163|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||The Effect of Enhanced External Counter Pulsation on Left Ventricular Systolic and Diastolic Function|The Effect of Enhanced External Counter Pulsation on Left Ventricular Systolic and Diastolic Function|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Herning Hospital||1|||f||||f||||||||||2018-05-31 23:51:23.281077|2018-05-31 23:51:23.281077
NCT01112150|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Interventional|||Effect of Normatec Pump for Relief of Leg Edema|Effect of Normatec Pump for Relief of Leg Edema: Short- Intermediate- and Longer-term Outcomes|Unknown status|Recruiting|N/A|20|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||||2018-05-31 23:51:23.350756|2018-05-31 23:51:23.350756
NCT01112137|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|January 2005||2005-01-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Effects of Clopidogrel on Blood Pressure|Phase IV Study of the Effects of Clopidogrel on Soluble CD40 Ligand, Endothelial Function and Blood Pressure|Completed||Phase 4|46|Actual|University of Cologne||4|||f||||f||||||||||2018-05-31 23:51:23.431521|2018-05-31 23:51:23.431521
NCT01112124|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-09-04|2010-04-27|2010-04-28|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2007||2007-09-30|September 2013|2013-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Behaviors of Children Ages 15 Months to Five Years Around Microwave Ovens|Behaviors of Children Ages 15 Months to Five Years Around Microwave Ovens|Completed|||40|Actual|University of Chicago|||||f||||f||||||||||2018-05-31 23:51:23.497243|2018-05-31 23:51:23.497243
NCT01112111|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-04-26|2010-04-26|2010-04-28|Estimate|||||||2010-04-26|2010-04-28|Estimate|May 2010||2010-05-31|April 2010|2010-04-30||||September 2010|Anticipated|2010-09-30||Observational|||A Novel Stimulation Protocol and the Conventional Low Dose Step-up and Step Down Regimens|Conventional Step-up, Step Down and a Novel Stimulation Regime in Controlled Ovarian Stimulation of Older Than 30 Years PCOS Patients Undergoing IVF- A Prospective Randomized Study.|Unknown status|Enrolling by invitation||225|Anticipated|Genesis Center for Fertility & Human Pre-Implantation Genetics|||3||f||||t||||||||||2018-05-31 23:51:23.565731|2018-05-31 23:51:23.565731
NCT01112098|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2011-05-06|2010-04-27|2010-04-28|Estimate|||||||2011-05-06|2011-05-10|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Improving Quality of Osteoporosis Care Through Patient Storytelling|Randomized Trial of a Mailed Intervention and Self-Scheduling to Improve Osteoporosis Screening in Postmenopausal Women|Completed||N/A|2997|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 23:51:23.633855|2018-05-31 23:51:23.633855
NCT01112085|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2014-06-13|2010-04-26|2010-04-28|Estimate|||||||2014-06-13|2014-06-16|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|MINIMA-2||MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)|Phase 2 Study of Microdoses of Ranibizumab in Diabetic Macular Edema - the MINIMA 2 Study|Completed||Phase 2|72|Actual|Especialistas en Retina Medica y Quirurgica Grupo de Investigacion||2|||f||||t||||||||||2018-05-31 23:51:23.719118|2018-05-31 23:51:23.719118
NCT01112072|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2018-01-23|2010-04-27|2010-04-28|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2010||2010-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CXL||Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia|Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia|Active, not recruiting||Phase 3|160|Anticipated|Cornea and Laser Eye Institute||2|||f||||t||||||||||2018-05-31 23:51:23.830839|2018-05-31 23:51:23.830839
NCT01112059|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2016-11-04|2013-12-19|2017-01-11|2010-04-27|2010-04-28|Estimate|2017-01-11|2017-03-06|Actual|2013-12-19|2014-01-27|Estimate|2017-01-11|2017-03-06|Actual|November 2008||2008-11-30|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|DOXY||Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients|A Randomized Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult CF Patients Hospitalized for Pulmonary Exacerbations|Completed||N/A|40|Actual|University of Alabama at Birmingham|Although the study has a relatively large number of subjects, this was a single center trial. In addition, it is possible that the protein readouts are mediated by modulating the dysregulated protease activity in the airway.|2|||f||||t||||||||No||2018-05-31 23:51:23.929031|2018-05-31 23:51:23.929031
NCT01112046|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2014-02-10|2010-04-27|2010-04-28|Estimate|||||||2014-02-10|2014-02-11|Estimate|April 2010||2010-04-30|February 2014|2014-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Endoscopic Submucosal Dissection Versus Laparoscopic Resection for Early Colorectal Neoplasms|Endoscopic Submucosal Dissection Versus Laparoscopic Resection for Early Colorectal Neoplasms: A Prospective Randomized Trial|Unknown status|Recruiting|Phase 3|124|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:51:24.214353|2018-05-31 23:51:24.214353
NCT01112033|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-08-05|2010-04-26|2010-04-28|Estimate|||||||2015-08-05|2015-08-07|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Observational|||Biliverdin Reductase A in Chronic Hepatitis C Virus Infection|Biliverdin Reductase A in Chronic Hepatitis C Virus Infection|Completed|||113|Actual|Charles University, Czech Republic|||1||f||||f||||||Samples With DNA|"~     peripheral blood, liver biopsy~   "|||2018-05-31 23:51:24.296703|2018-05-31 23:51:24.296703
NCT01112020|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-03-21|2010-04-27|2010-04-28|Estimate|||||||2013-03-21|2013-03-22|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Components of Chlorhexidine Gluconate Dressing|Components & Tolerability of Chlorhexidine Gluconate Dressing Patch Compared to BioPatch & Tegaderm Chlorhexidine Gluconate Securement Dressing After Application to Healthy Subjects Over a 7-day Period|Completed||Phase 1|45|Actual|CareFusion||3|||f||||f||||||||||2018-05-31 23:51:24.365859|2018-05-31 23:51:24.365859
NCT01112007|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2011-12-05|2010-04-27|2010-04-28|Estimate|||||||2011-12-05|2011-12-06|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Accomplices of Insulin Resistance in Prehypertension: Aldosterone?|Searching for Accomplices in the Transgression of Insulin Resistance in Prehypertension: Aldosterone?|Completed|||43|Actual|Taipei Veterans General Hospital, Taiwan|||1||f||||f||||||||||2018-05-31 23:51:24.442774|2018-05-31 23:51:24.442774
NCT01111994|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-05-19|2010-04-26|2010-04-28|Estimate|||||||2010-05-19|2010-05-20|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Efficacy & Safety of Clindamycin and Tretinoin in Acne|Efficacy & Safety of Clindamycin Phosphase 1.2% and Tretinoin 0.025% Gel vs. Vehicle for the Treatment of Acne and Acne-Induced Post Inflammatory Hyperpigmentation in Patients With Skin of Color|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Callender Center for Clinical Research|||||f||||f||||||||||2018-05-31 23:51:24.496958|2018-05-31 23:51:24.496958
NCT01111981|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-04-27|2010-04-27|2010-04-28|Estimate|||||||2010-04-27|2010-04-28|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|October 2010|Anticipated|2010-10-31|February 2010|Anticipated|2010-02-28||Interventional|||Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia|Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia|Unknown status|Recruiting|Phase 4|30|Anticipated|Callender Center for Clinical Research|||||f||||f||||||||||2018-05-31 23:51:24.558878|2018-05-31 23:51:24.558878
NCT01111968|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2013-02-05|2010-04-27|2010-04-28|Estimate|||||||2013-02-05|2013-02-06|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines|Evaluation of Safety, Tolerability and Immunogenicity of Adjuvanted Candidate Vaccines Against Pandemic Influenza A (H1N1)|Completed||Phase 1|266|Actual|Butantan Institute||10|||f||||t||||||||||2018-05-31 23:51:24.656127|2018-05-31 23:51:24.656127
NCT01111955|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26||2012-04-25|2015-09-23|2010-04-27|2010-04-28|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety Study of BMS-823778 in Subjects With Type 2 Diabetes|A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin|Completed||Phase 2|62|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 23:51:24.740415|2018-05-31 23:51:24.740415
NCT01111942|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2015-08-04|2010-04-26|2010-04-28|Estimate|||||||2015-08-04|2015-08-05|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer|A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer|Terminated||Early Phase 1|4|Actual|Southern Illinois University||2||lack of enrollment|f||||t||||||||||2018-05-31 23:51:24.822539|2018-05-31 23:51:24.822539
NCT00976742|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-11|2009-09-11|2009-09-14|Estimate|||||||2009-09-11|2009-09-14|Estimate|June 1998||1998-06-30|September 2009|2009-09-30||||December 2004|Actual|2004-12-31||Interventional|GERS||Gene - Exercise Research Study|Impact of Common Genetic Polymorphisms on CV Disease Risk Factor Changes With Endurance Exercise Training|Completed||N/A|225|Actual|University of Maryland||1|||f||||f||||||||||2018-06-01 00:35:29.84971|2018-06-01 00:35:29.84971
NCT01111929|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2017-11-20|2010-04-27|2010-04-28|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2009|Actual|2009-01-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|ECLAM||Emergency Contraception as a Back up of Lactational Amenorrhea Method(LAM)|Emergency Contraception as a Back up of Lactational Amenorrhea Method of Contraception|Completed||N/A|1174|Anticipated|Assiut University||2|||f||||t||||||||||2018-05-31 23:51:24.936977|2018-05-31 23:51:24.936977
NCT01111916|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2014-02-24|2010-04-26|2010-04-28|Estimate|||||||2014-02-24|2014-02-25|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Development Study Using Vaginal Tactile Imager|A Development Study Using Vaginal Tactile Imager to Assess the Elasticity Properties of the Vaginal Wall and Surrounding Connective Tissue|Completed|||31|Actual|Artann Laboratories|||||f||||f||||||||||2018-05-31 23:51:25.075513|2018-05-31 23:51:25.075513
NCT01111903|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2016-03-15|2010-04-27|2010-04-28|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2009||2009-05-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|REV||A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse|A Two Stage Trial of lénalidomide (Revlimid®) : a Phase II Study of lénalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lénalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.|Completed||Phase 1/Phase 2|67|Actual|ARCAGY/ GINECO GROUP||1|||f||||t||||||||||2018-05-31 23:51:25.138281|2018-05-31 23:51:25.138281
NCT01111890|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2015-07-27|2010-04-26|2010-04-28|Estimate|||||||2015-07-27|2015-07-29|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension||Completed||Phase 4|70|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:51:25.215848|2018-05-31 23:51:25.215848
NCT01111877|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-01-31|2010-04-27|2010-04-28|Estimate|||||||2012-01-31|2012-02-02|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Natural History Study of Incidence of Otorrhea Following Tympanostomy Tube Insertion in Children 6 Months to 12 Years||Terminated|||1389|Actual|Alcon Research||||Management Decision|f||||f||||||||||2018-05-31 23:51:25.317554|2018-05-31 23:51:25.317554
NCT01111864|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-06-06|2010-04-26|2010-04-28|Estimate|||||||2013-06-06|2013-06-07|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Changes in Microbiota and Iron Status After Iron Fortification of Complementary Foods|The Effect of Iron Fortification of Complementary Foods on Iron Status and Infant Gut Microbiota in Kenya|Completed||N/A|160|Actual|Swiss Federal Institute of Technology||4|||f||||t||||||||||2018-05-31 23:51:25.374626|2018-05-31 23:51:25.374626
NCT01111851|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2011-09-29||2015-02-06|2010-04-26|2010-04-28|Estimate|2011-09-29|2011-11-03|Estimate||||2015-02-06|2015-02-25|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)|MK0869 and MK0517 Time-on-Target PET Study|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 23:51:25.453537|2018-05-31 23:51:25.453537
NCT01111838|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2015-10-19||2015-10-19|2010-04-26|2010-04-28|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Clinical and Translational Study of STA-9090|A Phase II Clinical and Translational Study of STA-9090 in Patients With Refractory Metastatic Colorectal Cancer|Completed||Phase 2|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:51:25.790492|2018-05-31 23:51:25.790492
NCT01111825|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2017-08-10|2016-10-05|2017-10-06|2010-04-26|2010-04-28|Estimate|2017-10-06|2017-11-07|Actual|2016-10-05|2016-10-07|Estimate|2017-10-06|2017-11-07|Actual|April 2010|Actual|2010-04-30|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer|A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer|Completed||Phase 1/Phase 2|99|Actual|Puma Biotechnology, Inc.||1|||f|||||t|f||||||||2018-05-31 23:51:26.081803|2018-05-31 23:51:26.081803
NCT01111812|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2017-11-19|2010-04-26|2010-04-28|Estimate|||||||2017-11-19|2017-11-21|Actual|January 2011||2011-01-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Observational|||Prediction of Weight Gain by Children and Adolescents|Prediction of Weight Gain by Children and Adolescents That Participate in a Multi-disciplinary Intervention Program for Treatment of Overweight and Obese|Completed|||530|Actual|Meir Medical Center|||1||f||||f||||||||||2018-05-31 23:51:27.426809|2018-05-31 23:51:27.426809
NCT01111799|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-03-15|2010-04-26|2010-04-28|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Does Local Injury of the Endometrium Improve Controlled Ovarian Hyperstimulation (COH) + Intrauterine Insemination (IUI) Outcome?|Exploration of the Possibility That Local Injury of the Endometrium Has the Same Beneficial Effect on IUI Outcome as Demonstrated in IVF Treatment|Unknown status|Recruiting|N/A|600|Anticipated|Meir Medical Center||6|||f||||f||||||||||2018-05-31 23:51:27.50886|2018-05-31 23:51:27.50886
NCT01111786|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2014-06-24|2010-04-26|2010-04-28|Estimate|||||||2014-06-24|2014-06-26|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Finger Hardness Measure in Scleroderma|Durometer Skin Assessment in Scleroderma: a Study to Validate This New Tool in the Digital Tufts|Completed|||60|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 23:51:27.630215|2018-05-31 23:51:27.630215
NCT01111773|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26||2012-03-14|2012-03-14|2010-04-26|2010-04-28|Estimate||||2012-03-14|2012-03-16|Estimate|2012-03-14|2012-03-16|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Study Evaluating a Heated Lidocaine and Tetracaine Topical Patch in the Treatment of Patients With Patellar Tendinopathy|An Open-label Pilot Study Evaluating Synera® in the Treatment of Patients With Patellar Tendinopathy|Completed||Phase 2|13|Actual|ZARS Pharma Inc.||1|||f||||f||||||||||2018-05-31 23:51:27.724117|2018-05-31 23:51:27.724117
NCT01111760|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-04-03|2010-04-26|2010-04-28|Estimate|||||||2013-04-03|2013-04-05|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational|FLASH||Radiation Dose From Computed Tomography Before and After Implementation of a High Pitch Dual Spiral Technique|Radiation Dose From Computed Tomography Before and After Implementation of a High Pitch Dual Spiral Technique|Completed|||334|Actual|William Beaumont Hospitals|||||f||||f||||||||||2018-05-31 23:51:27.810195|2018-05-31 23:51:27.810195
NCT01111747|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-03-13|2010-04-26|2010-04-28|Estimate|||||||2012-03-13|2012-03-14|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Patellar Tendon Regeneration With Platelet-rich Plasma|Regeneration of the Patellar Tendon After Harvesting Its Central Third With Platelet-rich Plasma. Prospective and Randomized Study.|Completed||Phase 4|27|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 23:51:27.940629|2018-05-31 23:51:27.940629
NCT01111734|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2015-06-09|2010-04-26|2010-04-28|Estimate|||||||2015-06-09|2015-06-11|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents|N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study|Completed||Phase 1|67|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 23:51:28.042458|2018-05-31 23:51:28.042458
NCT01111721|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2013-03-13|2010-04-26|2010-04-28|Estimate|||||||2013-03-13|2013-03-14|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|POWER||Project POWER, Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners|Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners|Completed||N/A|598|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:51:28.283944|2018-05-31 23:51:28.283944
NCT01111708|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|April 2010||2010-04-30|January 2010|2010-01-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|CR-IPAA||Clinical Outcome After Close Rectal Ileo Pouch Anal Anastomosis for Colitis Ulcerosa(CU)|Clinical Outcome After Close Rectal Ileo Pouch Anal Anastomosis for Colitis Ulcerosa Compared to the Ileo Neo Rectal Anastomosis and the Ileo Pouch Anal Anastomosis|Unknown status|Recruiting|N/A|90|Anticipated|University Medical Center Nijmegen||3|||f||||t||||||||||2018-05-31 23:51:28.731383|2018-05-31 23:51:28.731383
NCT01111695|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2011-09-29|2010-04-26|2010-04-27|Estimate|||||||2011-09-29|2011-09-30|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Evaluation of a Ionic Silver and Honey Preparation to Treat Chronic Wounds of the Lower Legs|Open Label Study (Phase 2) to Evaluate the Safety, Tolerance and Efficacy of a Ionic Silver and Honey Preparation to Treat Chronic Wounds of the Lower Legs|Completed||Phase 2|30|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 23:51:29.020854|2018-05-31 23:51:29.020854
NCT01111682|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2013-03-04|2010-04-26|2010-04-27|Estimate|||||||2013-03-04|2013-03-05|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure|Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure|Terminated||Phase 3|5|Actual|University of Cincinnati||2||"A significant reduction in head injuries coupled with more frequent use of crainectomy reduced~   the number of potential subjects."|f||||f||||||||||2018-05-31 23:51:29.125999|2018-05-31 23:51:29.125999
NCT01111669|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2012-04-25|2010-04-26|2010-04-27|Estimate|||||||2012-04-25|2012-04-27|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery|Intravenous Tranexamic Acid and Intraoperative Visualization During Functional Endoscopic Sinus Surgery: A Double Blind Randomized Controlled Trial|Completed||N/A|28|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 23:51:29.230287|2018-05-31 23:51:29.230287
NCT01111656|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2011-09-06|2010-04-25|2010-04-27|Estimate|||||||2011-09-06|2011-09-07|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b|"SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study)"|Completed||Phase 2|28|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 23:51:29.333974|2018-05-31 23:51:29.333974
NCT01111643|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-25|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|April 2008||2008-04-30|April 2010|2010-04-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Longitudinal Strain in Addition to Visual Assessment of Wall Motion for Ruling in Ischemia in the Emergency Room||Unknown status|Recruiting||500|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-05-31 23:51:29.408554|2018-05-31 23:51:29.408554
NCT01111630|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-25|||2014-05-12|2010-04-26|2010-04-27|Estimate|||||||2014-05-12|2014-05-14|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Study of Erythropoietin (EPO) Administration Schedule|Compare the Hemoglobin and Hematocrit Variability Between Once & Three Times Weekly Erythropoietin Therapy for the Anemia in Patients With Maintenance Dialysis|Completed||Phase 4|60|Anticipated|JW Pharmaceutical||2|||f||||t||||||||||2018-05-31 23:51:29.474582|2018-05-31 23:51:29.474582
NCT01111617|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2018-04-16|2010-04-26|2010-04-27|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Applications of Realtime Functional Magnetic Resonance Imaging (fMRI )|Applications of Realtime fMRI Phase II|Active, not recruiting||N/A|400|Anticipated|Stanford University||1|||f||||||||||||||2018-05-31 23:51:29.628601|2018-05-31 23:51:29.628601
NCT01111604|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08||2010-08-30|2014-04-28|2010-04-26|2010-04-27|Estimate||||2010-08-30|2010-09-01|Estimate|2014-04-28|2014-05-14|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer|An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy|Completed||Phase 2|157|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 23:51:29.886984|2018-05-31 23:51:29.886984
NCT01111591|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2016-10-27|2010-04-26|2010-04-27|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer|Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer.|Enrolling by invitation||Phase 4|220|Anticipated|Seoul National University Hospital||4|||f||||t||||||||Undecided||2018-05-31 23:51:30.026555|2018-05-31 23:51:30.026555
NCT01111578|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-11-29|2010-04-26|2010-04-27|Estimate|||||||2010-11-29|2010-11-30|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Evaluation of a New Enteral Feeding Tube for the Measurement of Esophageal and Gastric Pressure|Evaluation of a New Enteral Feeding Tube for the Measurement of Esophageal and Gastric Pressure|Completed|||30|Anticipated|Policlinico Hospital|||1||f||||f||||||||||2018-05-31 23:51:30.16079|2018-05-31 23:51:30.16079
NCT01111409|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2014-10-10|2010-04-26|2010-04-27|Estimate|||||||2014-10-10|2014-10-13|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||A Pilot Study to Evaluate the Clinical Effectiveness and Safety of the VFIX Device as Treatment for Apical Prolapse|A Prospective, Multi-Centre Pilot Study to Evaluate the Clinical Effectiveness and Safety of the VFIX Device as Treatment for Apical Prolapse|Completed||N/A|20|Actual|Ethicon, Inc.||1|||f||||f||||||||||2018-05-31 23:51:32.945781|2018-05-31 23:51:32.945781
NCT01111565|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22||2012-08-17|2012-08-24|2010-04-26|2010-04-27|Estimate||||2012-08-24|2012-08-31|Estimate|2012-08-24|2012-08-31|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|ACES 263||Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|Terminated||Phase 3|45|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||||||||||||2018-05-31 23:51:30.274063|2018-05-31 23:51:30.274063
NCT01111552|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22||2012-08-17|2012-08-24|2010-04-26|2010-04-27|Estimate||||2012-08-24|2012-08-31|Estimate|2012-08-24|2012-08-31|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|ACES 256||Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|Terminated||Phase 3|66|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-05-31 23:51:30.522775|2018-05-31 23:51:30.522775
NCT01111539|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22||2012-08-17|2012-08-24|2010-04-26|2010-04-27|Estimate||||2012-08-24|2012-08-31|Estimate|2012-08-24|2012-08-31|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|ACES 255||Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)|A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder|Terminated||Phase 3|84|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-05-31 23:51:30.777873|2018-05-31 23:51:30.777873
NCT01111526|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2016-08-30||2018-05-11|2010-04-23|2010-04-27|Estimate|2016-10-27|2016-12-22|Estimate||||2018-05-11|2018-05-15|Actual|April 2010||2010-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional||All participants. All participants received study treatment.|Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)|A Phase I/II Trial Evaluating the Use of Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease|Completed||Phase 1/Phase 2|22|Actual|H. Lee Moffitt Cancer Center and Research Institute|The discontinuation of the IV Formulation of LBH589 required a treatment plan change to Oral Formulation LBH589, after the first 4 participants were treated. The study accrued fewer participants than investigators had planned to evaluate.|1|||f||||t||||||||||2018-05-31 23:51:31.086026|2018-05-31 23:51:31.086026
NCT01111513|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-12-19|2010-04-23|2010-04-27|Estimate|||||||2012-12-19|2012-12-20|Estimate|November 2007||2007-11-30|December 2012|2012-12-31|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|||The Influence of the Femoral Nerve Block on Quadriceps Strength|The Influence of the Femoral Nerve Block on the Quadriceps Strength After Total Knee Replacement|Completed||N/A|135|Actual|Hopital de l'Enfant-Jesus||3|||f||||f||||||||||2018-05-31 23:51:31.532259|2018-05-31 23:51:31.532259
NCT01111500|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2012-12-19|2010-04-23|2010-04-27|Estimate|||||||2012-12-19|2012-12-20|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|February 2015|Anticipated|2015-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Immobilization After an Anterior Glenohumeral Joint Dislocation With a Bankart Lesion|First Time Anterior Glenohumeral Joint Dislocation With a Bankart Lesion in Young Patients: Which Type of Immobilization Should be Chosen? A Prospective Randomized Study|Unknown status|Recruiting|N/A|50|Anticipated|Hopital de l'Enfant-Jesus||2|||f||||f||||||||||2018-05-31 23:51:31.660557|2018-05-31 23:51:31.660557
NCT01111487|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2011-09-25|2010-04-26|2010-04-27|Estimate|||||||2011-09-25|2011-09-27|Estimate|November 2009||2009-11-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Activity of Inspiratory Muscles With the Use of Positive Pressure in Patients With Chronic Obstructive Pulmonary Disease|Inspiratory Muscle Recruitment in COPD Patients With the Use of Expiratory Positive Airways Pressure|Completed||N/A|40|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 23:51:31.791238|2018-05-31 23:51:31.791238
NCT01111474|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|Cyano-laser||Cyanoacrylate and Laser and Dentin Sensitivity|Effectiveness of Cyanoacrylate and of the Laser in the Treatment of Cervical Dentin Sensitivity|Completed||Phase 3|17|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 23:51:31.917114|2018-05-31 23:51:31.917114
NCT01111461|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2015-03-13||2016-11-23|2010-04-23|2010-04-27|Estimate|2016-04-07|2016-04-18|Estimate||||2016-11-23|2017-01-20|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|May 2012|Actual|2012-05-31||Interventional|||Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression|An Open-Label, Single-Arm, Multicenter Phase II Study of E7080 (Lenvatinib) in Subjects With Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy|Completed||Phase 2|133|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 23:51:32.122907|2018-05-31 23:51:32.122907
NCT01111448|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-02-12|2010-04-26|2010-04-27|Estimate|||||||2015-02-12|2015-02-13|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|TEMDS||Temsirolimus in Myelodysplastic Syndrome (MDS)|Treatment of MDS Patients With Single Agent Temsirolimus - a Pilot Study|Terminated||Phase 2|20|Actual|Technische Universität Dresden||1||Unfavourable Risk-Benefit-Ratio|f||||t||||||||||2018-05-31 23:51:32.685908|2018-05-31 23:51:32.685908
NCT01111435|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-03-02|2010-04-26|2010-04-27|Estimate|||||||2012-03-02|2012-03-05|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Observational|||A Prospective Study of Spasticity in Individuals With Multiple Sclerosis|A Prospective Study of Spasticity in Individuals With Multiple Sclerosis in Transition From Interferon to Glatiramer Acetate (Copaxone®)|Unknown status|Active, not recruiting||110|Anticipated|Fraser, Cira, Ph.D., RN, ACNS-BC|||1||f||||f||||||||||2018-05-31 23:51:32.782856|2018-05-31 23:51:32.782856
NCT01111422|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients|A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis|Unknown status|Recruiting|Phase 4|66|Anticipated|Ewha Womans University||2|||f||||f||||||||||2018-05-31 23:51:32.849714|2018-05-31 23:51:32.849714
NCT01111396|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|February 2010||2010-02-28|April 2010|2010-04-30||||||||Observational|HIF-ALL||Longitudinal Investigation of Hippocampal Function and Morphology in Acute Lymphatic Leukemia (ALL) Patients Treated With Chemotherapy|Longitudinal Investigation of Hippocampal Function and Morphology in ALL Patients Treated With Chemotherapy: A Monocentric, Interdisciplinary Pilot Study|Unknown status|Recruiting||10|Anticipated|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 23:51:33.057706|2018-05-31 23:51:33.057706
NCT01111383|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2018-04-12|2010-04-26|2010-04-27|Estimate|||||||2018-04-12|2018-04-13|Actual|September 2009||2009-09-30|April 2018|2018-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|CT03Ext||A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®|A Single Arm 48-Week Follow-on Safety Study to the Core Study (A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa)|Completed||Phase 3|209|Actual|Chiesi Farmaceutici S.p.A.|||||f||||f||||||||||2018-05-31 23:51:33.152319|2018-05-31 23:51:33.152319
NCT01111370|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2015-08-04||2017-02-07|2010-04-26|2010-04-27|Estimate|2017-02-07|2017-03-27|Actual||||2017-02-07|2017-03-27|Actual|February 2010||2010-02-28|August 2015|2015-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System|Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System|Completed||N/A|60|Actual|DexCom, Inc.||1|||f||||f||||||||No||2018-05-31 23:51:33.262989|2018-05-31 23:51:33.262989
NCT01111357|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-12-20|2010-04-23|2010-04-27|Estimate|||||||2010-12-20|2010-12-21|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|HLAPRPA||Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis|Study of HLA Polymorphisms in French West-Indian Patients With Rheumatoid Arthritis : A Case Control Study|Completed|||200|Anticipated|University Hospital Center of Martinique|||||f||||f||||||Samples With DNA|"~     whole blood : collect of 10 ml of peripheric blood~   "|||2018-05-31 23:51:33.407302|2018-05-31 23:51:33.407302
NCT01111344|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2012-05-06|2010-04-26|2010-04-27|Estimate|||||||2012-05-06|2012-05-08|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Glizigen-Viudid-External Anogenital Warts in Children and Adolescents|Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents.|Completed||Phase 3|76|Actual|Catalysis SL||2|||f||||t||||||||||2018-05-31 23:51:33.462248|2018-05-31 23:51:33.462248
NCT01111331|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2014-05-16||2014-06-25|2010-04-26|2010-04-27|Estimate|2014-06-25|2014-07-23|Estimate||||2014-06-25|2014-07-23|Estimate|May 2010||2010-05-31|June 2014|2014-06-30||||July 2010|Actual|2010-07-31||Interventional|||Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers|Relative Bioavailability of Both BI 10773 and Warfarin and Pharmacodynamics of Warfarin After Co-administration Compared to Multiple Oral Doses of BI 10773 (25 mg Once Daily) and a Single Oral Dose of Warfarin (25 mg) Alone in Healthy Male Volunteers (an Open-label, Crossover, Clinical Phase I Study)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:51:33.584746|2018-05-31 23:51:33.584746
NCT01111318|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|2014-05-16||2014-05-16|2010-04-26|2010-04-27|Estimate|2014-05-16|2014-06-13|Estimate||||2014-05-16|2014-06-13|Estimate|July 2010||2010-07-31|May 2014|2014-05-31||||November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function|Pharmacokinetics, Safety and Tolerability of BI 10773 50 mg Single Dose in Male and Female Subjects With Different Degrees of Liver Impairment (Child-Pugh Classification A, B and C) as Compared to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 23:51:34.449336|2018-05-31 23:51:34.449336
NCT01111305|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-24|2017-04-27||2017-10-30|2010-04-24|2010-04-27|Estimate|2017-04-27|2017-06-01|Actual||||2017-10-30|2017-12-05|Actual|April 2010||2010-04-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|January 2016|Actual|2016-01-31||Interventional|||Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis|A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection|Completed||Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f||||||No||2018-05-31 23:51:35.147599|2018-05-31 23:51:35.147599
NCT01111292|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-24|2016-01-29||2016-06-01|2010-04-24|2010-04-27|Estimate|2016-06-01|2016-07-12|Estimate||||2016-06-01|2016-07-12|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia|Myo-Inositol Chemoprevention in Colitis-Associated Dysplasia|Terminated||Phase 1/Phase 2|5|Actual|National Cancer Institute (NCI)||2||The study was closed prematurely due to poor accrual.|f||||t||||||||||2018-05-31 23:51:35.699363|2018-05-31 23:51:35.699363
NCT01111279|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2011-02-28|2010-04-26|2010-04-27|Estimate|||||||2011-02-28|2011-03-01|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis|Clinical Safety and Tolerability of gpASIT+TM Administered Subcutaneously in Absence or in Presence of DnaK Immunoregulating Adjuvant for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis|Completed||Phase 1|27|Anticipated|BioTech Tools S.A.||3|||f||||f||||||||||2018-05-31 23:51:36.134623|2018-05-31 23:51:36.134623
NCT01111266|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2012-03-13|2010-04-26|2010-04-27|Estimate|||||||2012-03-13|2012-03-14|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||Determination of in Vivo Ultrafiltration Coefficient (KUF) in Patients With Chronic Kidney Disease (CKD)|Evaluation of Performance and Safety Profile of Xevonta High Flux Dialyzer With Special Focus on Determination of in Vivo Ultrafiltration Coefficient in Patients With CKD|Completed||N/A|12|Actual|B.Braun Avitum AG|||||f||||f||||||||||2018-05-31 23:51:36.223092|2018-05-31 23:51:36.223092
NCT01111253|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2012-10-26|2010-04-26|2010-04-27|Estimate|||||||2012-10-26|2012-10-29|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|October 2014|Anticipated|2014-10-31|April 2013|Anticipated|2013-04-30||Interventional|DIABOLO||Diverticulitis: Antibiotics or Close Observation?|DIABOLO Trial: A Multicenter Randomized Clinical Trial Investigating the Cost-effectiveness of Treatment Strategies With or Without Antibiotics for Uncomplicated Acute Diverticulitis.|Unknown status|Active, not recruiting|Phase 4|533|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 23:51:36.288774|2018-05-31 23:51:36.288774
NCT01111240|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2014-12-09||2014-12-29|2010-04-26|2010-04-27|Estimate|2014-12-29|2014-12-30|Estimate||||2014-12-29|2014-12-30|Estimate|August 2005||2005-08-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice|A Long Term Documentation to Demonstrate Long Term Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis Under Conditions of Daily Practice|Completed|||4635|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:51:36.717532|2018-05-31 23:51:36.717532
NCT01111227|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|March 2008||2008-03-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Inflammatory Cytokines Profile in Individuals Subjected to Surgical Procedures Using Propofol or Isoflurane|Inflammatory Cytokines Profile in Individuals Subjected to Surgical Procedures Using Propofol or Isoflurane.|Completed||Phase 4|40|Actual|UPECLIN HC FM Botucatu Unesp|||||f||||t||||||||||2018-05-31 23:51:39.418915|2018-05-31 23:51:39.418915
NCT01111214|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-01-09|2010-04-26|2010-04-27|Estimate|||||||2013-01-09|2013-01-10|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Child Pneumococcal Serotype Epidemiology In Greece|Incidence And Serotypes Of Invasive Pneumococcal Disease, After The Introduction Of The Heptavalent Conjugated Vaccine In Greece|Completed|||457|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:51:39.497523|2018-05-31 23:51:39.497523
NCT01111201|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2012-05-30|2010-04-26|2010-04-27|Estimate|||||||2012-05-30|2012-06-01|Estimate|April 2010||2010-04-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients|Pilot Survey to Assess International Travel Patterns and Risk Behaviour of Breast Cancer, Lymphoma Patients and Bone Marrow Transplant Recipients at Memorial Sloan-Kettering Cancer Center|Completed|||26|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 23:51:39.596304|2018-05-31 23:51:39.596304
NCT01111188|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-01-29|2010-04-26|2010-04-27|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2010||2010-06-30|January 2018|2018-01-31|January 15, 2024|Anticipated|2024-01-15|January 15, 2023|Anticipated|2023-01-15||Interventional|||Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma|Phase I Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma|Active, not recruiting||Phase 1|20|Actual|Weill Medical College of Cornell University||1|||f||||t|t|f||||||Undecided||2018-05-31 23:51:39.68038|2018-05-31 23:51:39.68038
NCT01111175|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2013-07-19|2010-04-26|2010-04-27|Estimate|||||||2013-07-19|2013-07-23|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Triple Negative Breast Cancer Biomarker Study|Triple Negative Breast Cancer Biomarker Study|Completed|||14|Actual|US Oncology Research|||||f||||f||||||Samples With DNA|"~     Whole blood and tumor tissue~   "|||2018-05-31 23:51:39.805528|2018-05-31 23:51:39.805528
NCT01111162|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2016-06-05||2016-06-07|2010-04-26|2010-04-27|Estimate|2016-06-07|2016-07-12|Estimate||||2016-06-07|2016-07-12|Estimate|December 2009||2009-12-31|June 2016|2016-06-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients|Evaluating the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Infected Patients|Completed||Phase 4|120|Actual|University of Pennsylvania|Single Arm Study|1|||f||||f||||||||||2018-05-31 23:51:39.918571|2018-05-31 23:51:39.918571
NCT01111149|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2013-12-16||2014-07-08|2010-04-26|2010-04-27|Estimate|2014-06-02|2014-07-03|Estimate||||2014-07-08|2014-07-17|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|VSCS||Varenicline and Smoking Cessation in Schizophrenia|Varenicline and Smoking Cessation in Schizophrenia|Completed||Phase 2|24|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 23:51:40.258223|2018-05-31 23:51:40.258223
NCT01111136|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2010-11-23|2010-04-26|2010-04-27|Estimate|||||||2010-11-23|2010-11-25|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Stress Intervention for Chronic Urticaria|Effect of Psychological Stress Intervention for Patients With Chronic Urticaria|Completed||N/A|4|Actual|University of Mississippi Medical Center||1|||f||||f||||||||||2018-05-31 23:51:41.763514|2018-05-31 23:51:41.763514
NCT01111123|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2011-06-15||2016-05-25|2010-04-23|2010-04-27|Estimate|2016-05-25|2016-06-24|Estimate||||2016-05-25|2016-06-24|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis|A Randomized, Double-blind Study to Evaluate the Efficacy of Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis.|Completed||Phase 4|55|Actual|Icahn School of Medicine at Mount Sinai|The maintenance phase did not have a long enough study duration to capture clinically significant changes in disease status in the steroid group since >50 percent of the patients at the end of the 24 weeks still remained in the study.|2|||f||||t||||||||||2018-05-31 23:51:41.849749|2018-05-31 23:51:41.849749
NCT01111110|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2012-01-10||2012-05-14|2010-04-26|2010-04-27|Estimate|2012-05-14|2012-06-19|Estimate||||2012-05-14|2012-06-19|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|April 2009|Actual|2009-04-30||Interventional|||Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm|Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm|Completed||N/A|88|Actual|University of Florida|Nocturnal asthma model is a very sensitive model, but very labor intensive and to get more completed subjects, we might need to do multicenter trial|2|||f||||f||||||||||2018-05-31 23:51:42.084514|2018-05-31 23:51:42.084514
NCT01111097|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2015-09-18|2010-04-26|2010-04-27|Estimate|||||||2015-09-18|2015-09-22|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors|Phase 1, Open-Label, Single-Arm, Clinical and Metabolomics Study of Dichloroacetate (DCA) in Adults With Recurrent Malignant Brain Tumors|Completed||Phase 1|15|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 23:51:42.299129|2018-05-31 23:51:42.299129
NCT01111084|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2014-07-15|2010-04-23|2010-04-27|Estimate|||||||2014-07-15|2014-07-16|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Observational|P450||A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α|Prospective Multi-centre Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin α|Completed|||410|Actual|Merck KGaA|||||f||||||||||Samples With DNA|"~     Serum~   "|||2018-05-31 23:51:42.360916|2018-05-31 23:51:42.360916
NCT01111071|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2016-05-11|2010-04-23|2010-04-27|Estimate|||||||2016-05-11|2016-05-12|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study|Variation Between Hospitals in Short-term Mortality After Acute Coronary Syndromes: A CALIBER Study|Completed|||316648|Actual|University College, London|||3||f||||t||||||||No|permissions to use anonymised data from data owners do not allow further sharing.|2018-05-31 23:51:42.507762|2018-05-31 23:51:42.507762
NCT01111058|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2017-05-22|2010-04-26|2010-04-27|Estimate|||||||2017-05-22|2017-05-23|Actual|April 2010||2010-04-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Everolimus Versus Placebo in Head and Neck Cancer|Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)|Active, not recruiting||Phase 2|160|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 23:51:42.616298|2018-05-31 23:51:42.616298
NCT01111045|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2012-01-30|2010-04-26|2010-04-27|Estimate|||||||2012-01-30|2012-02-01|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee|A Phase 2, Double Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee|Completed||Phase 2|355|Actual|Stryker Biotech||4|||f||||t||||||||||2018-05-31 23:51:42.721113|2018-05-31 23:51:42.721113
NCT01111032|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-26|||2013-09-29|2010-04-26|2010-04-27|Estimate|||||||2013-09-29|2013-10-01|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||Comparison of Two-treadmill Test Protocols to Evaluate Endurance in People With Cancer|Comparison of Two-treadmill Test Protocols to Evaluate Endurance in People With Cancer.|Completed|||12|Actual|McMaster University|||1||f||||f||||||||||2018-05-31 23:51:42.932876|2018-05-31 23:51:42.932876
NCT01111019|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2017-12-01|2010-04-26|2010-04-27|Estimate|||||||2017-12-01|2017-12-04|Actual|March 21, 2006|Actual|2006-03-21|November 2017|2017-11-30|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children|Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated Over a Period of 3 Years or 5 Years if Applicable, in Comparison With a Historic Cohort of Non-treated Children With Hypochondroplasia|Completed||Phase 2|19|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:51:43.067769|2018-05-31 23:51:43.067769
NCT01111006|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-04|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effect of Electronic Cleansing Toilet System (Bidet) on Anal Resting Pressure|The Effect of Electronic Cleansing Toilet System (Bidet) on Anal Resting Pressure in Normal Healthy Volunteers|Completed||Early Phase 1|20|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 23:51:43.204693|2018-05-31 23:51:43.204693
NCT01110993|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-01-31|2010-04-23|2010-04-27|Estimate|||||||2014-01-31|2014-02-03|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|MusiClock||An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)|Prospective, Non-interventional, Multicenter Study to Evaluate QoL and Influence of Cognitive Status on QoL in Patients With RRMS During 2 Years Treatment With RNF|Completed|||65|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:51:43.325499|2018-05-31 23:51:43.325499
NCT01110980|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-05-21|2010-04-26|2010-04-27|Estimate|||||||2013-05-21|2013-05-22|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FOCISD||Normalcy of Food Intake in Head and Neck Cancer Patients|Normalcy of Food Intake in Head and Neck Cancer Patients Receiving (Chemo)Radiotherapy Supported by Swallowing Therapy and Individual Dietary Counselling. (Supportive Care)|Completed||N/A|120|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 23:51:43.406246|2018-05-31 23:51:43.406246
NCT01110967|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2014-05-13||2016-01-26|2010-04-23|2010-04-27|Estimate|2014-07-14|2014-08-07|Estimate||||2016-01-26|2016-01-28|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Satellite™ PEEK Nucleus Replacement Retrospective Analysis|Satellite™ PEEK Nucleus Replacement Retrospective Analysis|Completed|||40|Actual|Medtronic Spinal and Biologics|Due to the retrospective design, it was not possible to report on SF-36 results and Modic endplate changes results as limited data was available in the patient records.||||f||||f||||||||||2018-05-31 23:51:43.553976|2018-05-31 23:51:43.553976
NCT01110954|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-04-03|2010-04-23|2010-04-27|Estimate|||||||2017-04-03|2017-04-04|Actual|May 31, 2010|Actual|2010-05-31|April 2017|2017-04-30|December 20, 2012|Actual|2012-12-20|July 19, 2012|Actual|2012-07-19||Interventional|||Fluorescence-guided Resection in Breast Cancer|Evaluation of the Suitability of PD L 506 for Intraoperative Visualisation of Palpable and Nonpalpable Breast Cancer Tissue|Terminated||Phase 2|8|Actual|photonamic GmbH & Co. KG||2||Insufficient recruitment|f||||f||||||||||2018-05-31 23:51:43.964944|2018-05-31 23:51:43.964944
NCT01110941|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2015-05-17|2010-04-26|2010-04-27|Estimate|||||||2015-05-17|2015-05-19|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|SCI-101||Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China|A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|20|Actual|Peking University||1|||f||||||||||||||2018-05-31 23:51:44.049866|2018-05-31 23:51:44.049866
NCT01110928|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2017-11-02|2010-04-26|2010-04-27|Estimate|||||||2017-11-02|2017-11-06|Actual|November 26, 2009|Actual|2009-11-26|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate on Long-term Safety and Efficacy of Norditropin® Formulation in Patients With SGA Short Stature Without Closure of Epiphyseal Discs|Active, not recruiting|||360|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 23:51:44.160364|2018-05-31 23:51:44.160364
NCT01110915|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2013-02-20||2013-04-23|2010-04-23|2010-04-27|Estimate|2013-02-20|2013-04-04|Estimate||||2013-04-23|2013-04-30|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Advisa MRI Clinical Study|Advisa MRI™ System Clinical Investigation|Completed||N/A|269|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-05-31 23:51:44.317997|2018-05-31 23:51:44.317997
NCT01110902|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23||2012-07-24|2012-09-19|2010-04-26|2010-04-27|Estimate||||2012-07-24|2012-08-01|Estimate|2012-09-19|2012-09-26|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)|A 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD)|Completed||Phase 3|589|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:51:45.07068|2018-05-31 23:51:45.07068
NCT01110889|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23||2013-02-18|2013-02-21|2010-04-26|2010-04-27|Estimate||||2013-02-18|2013-02-22|Estimate|2013-02-21|2013-02-28|Estimate|May 2010||2010-05-31|February 2013|2013-02-28||||July 2011|Actual|2011-07-31||Interventional|||Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder|An 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients With Major Depressive Disorder (MDD)|Completed||Phase 3|582|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:51:45.284008|2018-05-31 23:51:45.284008
NCT01110876|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-11-07|2010-04-23|2010-04-27|Estimate|||||||2014-11-07|2014-11-10|Estimate|June 2011||2011-06-30|November 2014|2014-11-30||||July 2014|Actual|2014-07-31||Interventional|||Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)|Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme|Terminated||Phase 1/Phase 2|21|Actual|M.D. Anderson Cancer Center||4||Unanticipated Toxicities|f||||t||||||||||2018-05-31 23:51:45.465324|2018-05-31 23:51:45.465324
NCT01110863|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-12-13|2010-04-23|2010-04-27|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2005||2005-12-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects|Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects|Active, not recruiting|||90|Anticipated|Northwell Health|||1||f||||f||||||Samples With DNA|"~     Blood cells, Bone Marrow~   "|||2018-05-31 23:51:45.566652|2018-05-31 23:51:45.566652
NCT01110850|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-06-02|2010-04-23|2010-04-27|Estimate|||||||2017-06-02|2017-06-05|Actual|June 2001||2001-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water|Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia Using Deuterated Water (GAC 0004)|Active, not recruiting|||50|Anticipated|Northwell Health|||1||f||||f||||||Samples With DNA|"~     Blood Cells, Bone MArrow~   "|||2018-05-31 23:51:45.635408|2018-05-31 23:51:45.635408
NCT01110837|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2012-10-31|2010-04-26|2010-04-27|Estimate|||||||2012-10-31|2012-11-01|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Repeat Dose Nasal Allergen Challenge|Repeat Dose Nasal Allergen Challenge: Development of a Model to Investigate the Cellular and Inflammatory Changes That Occur in Allergic Rhinitis|Unknown status|Recruiting|N/A|30|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 23:51:45.692663|2018-05-31 23:51:45.692663
NCT01110824|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-11-14|2010-04-23|2010-04-27|Estimate|||||||2013-11-14|2013-11-15|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|OVERCOME||Prevention of Left Ventricular Dysfunction During Chemotherapy|Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies|Completed||Phase 3|90|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 23:51:45.773507|2018-05-31 23:51:45.773507
NCT01110811|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2016-08-11|2010-04-26|2010-04-27|Estimate|||||||2016-08-11|2016-08-15|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|September 2015|Actual|2015-09-30||Interventional|||Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD)|A Randomized Controlled Trial Comparing Transoral Incisionless Fundoplication (TIF) Using EsophyX With Sham Procedure for the Treatment of PPI Dependent GERD: the TIF vs. Sham Study|Active, not recruiting||Phase 4|60|Anticipated|EndoGastric Solutions||2|||f||||f||||||||||2018-05-31 23:51:45.864095|2018-05-31 23:51:45.864095
NCT01110798|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-09-16|2010-04-23|2010-04-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 2009||2009-10-31|February 2011|2011-02-28||||October 2011|Anticipated|2011-10-31||Interventional|||J-Pouch Colorectal Anastomosis or Straight Colorectal Anastomosis in Treating Patients With Rectal Cancer Who Have Undergone Surgery to Remove the Tumor|Colonic J-Pouch Reconstruction Versus Straight Colorectal Anastomosis After Low Anterior Resection for Rectal Cancer: Impact on Anastomotic Leak, Bowel Function and Quality of Life|Unknown status|Recruiting|N/A|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:51:45.951275|2018-05-31 23:51:45.951275
NCT01110785|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-09-16|2010-04-23|2010-04-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2010||2010-04-30|April 2011|2011-04-30||||April 2012|Anticipated|2012-04-30||Interventional|||Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer|Safety and Efficacy of the Addition of Simvastatin to Panitumumab in K-ras Mutant Advanced or Metastatic Colorectal Cancer Patients. A Single-Arm, Multicenter, Phase II Study Using a Simon Two Stage Design.|Unknown status|Recruiting|Phase 2|46|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:51:46.071503|2018-05-31 23:51:46.071503
NCT01110772|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2010-04-26|2010-04-26|2010-04-27|Estimate|||||||2010-04-26|2010-04-27|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Comparison of Iodine + Isopropyl Alcohol Versus Iodine + Antimicrobial Sealant for Skin Preparation|Comparative Study of a Iodine + Cyanoacrylate (Integuseal) vs. Iodine and Isopropyl Alcohol in Skin Preparation for Prevention of Surgical Site Infections in Oncologic Surgery|Unknown status|Recruiting|Phase 4|1200|Anticipated|National Institute of Cancerología||2|||f||||f||||||||||2018-05-31 23:51:46.209248|2018-05-31 23:51:46.209248
NCT01110759|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-10-30|2010-04-26|2010-04-27|Estimate|||||||2013-10-30|2013-11-01|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Medical Review: Hand Surgery After Local Block Versus Non-block|Retrospective Chart-review Study Involving Outpatients Who Underwent Hand Surgery With Local Anesthesia: Comparing Outcome With a Peripheral Nerve Block vs. Local Infiltration Alone|Completed|||200|Actual|Cedars-Sinai Medical Center|||2||f||||f||||||||||2018-05-31 23:51:46.330778|2018-05-31 23:51:46.330778
NCT01110252|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2011-11-03||2012-02-22|2010-04-22|2010-04-26|Estimate|2012-02-22|2012-03-26|Estimate||||2012-02-22|2012-03-26|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|October 2010|Actual|2010-10-31||Interventional|COPD-01||Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease|Unicentric Study Protocol of Cell Therapy in Chronic Obstructive Pulmonary Disease|Completed||N/A|4|Actual|UPECLIN HC FM Botucatu Unesp|small number of subjects analyzed|2|||f||||f||||||||||2018-05-31 23:51:56.760492|2018-05-31 23:51:56.760492
NCT01110746|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13||2015-07-30|2015-07-30|2010-04-26|2010-04-27|Estimate||||2015-07-30|2015-08-03|Estimate|2015-07-30|2015-08-03|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy|A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy|Completed||Phase 3|20|Actual|Biodel||2|||f||||f||||||||||2018-05-31 23:51:46.395396|2018-05-31 23:51:46.395396
NCT01110733|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2018-04-30|2010-04-26|2010-04-27|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2010||2010-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|COMPLETE||Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry|Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma|Active, not recruiting|||3000|Anticipated|Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-05-31 23:51:46.478863|2018-05-31 23:51:46.478863
NCT01110720|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-01-15|2010-04-26|2010-04-27|Estimate|||||||2013-01-15|2013-01-17|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy|A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy|Completed||Phase 2/Phase 3|313|Actual|Allon Therapeutics||2|||f||||t||||||||||2018-05-31 23:51:46.660614|2018-05-31 23:51:46.660614
NCT01110707|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2017-08-28||2017-08-28|2010-04-26|2010-04-27|Estimate|2017-08-28|2018-03-27|Actual||||2017-08-28|2018-03-27|Actual|January 10, 2005|Actual|2005-01-10|August 2017|2017-08-31|November 15, 2006|Actual|2006-11-15|November 15, 2006|Actual|2006-11-15||Interventional|||A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve|Lutropin Alpha in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve: Comparative Study, in Phase II, With Parallel Control|Completed||Phase 2|131|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 23:51:46.826863|2018-05-31 23:51:46.826863
NCT01110694|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-06-19|2010-04-26|2010-04-27|Estimate|||||||2017-06-19|2017-06-20|Actual|September 2010|Actual|2010-09-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|PROFILE||Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study|Prospective Observation of Fibrosis in the Lung Clinical Endpoints (PROFILE_Brompton)Study|Active, not recruiting|||230|Actual|Royal Brompton & Harefield NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, bronchoalveolar lavage, surgical lung biopsy (when clinically indicated)~   "|||2018-05-31 23:51:47.416597|2018-05-31 23:51:47.416597
NCT01110681|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2012-11-22|2010-04-22|2010-04-27|Estimate|||||||2012-11-22|2012-11-27|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Study to Evaluate Solesta for Treatment of Fecal Incontinence|An Open, Non-comparative, Post-marketing, Multi-center Study to Evaluate Efficacy and Safety of SolestaTM for the Treatment of Fecal Incontinence|Completed||N/A|115|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 23:51:47.548744|2018-05-31 23:51:47.548744
NCT01110668|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-02-24|2010-04-26|2010-04-27|Estimate|||||||2017-02-24|2017-02-28|Actual|September 2008||2008-09-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)|Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Previously Treated With Imatinib|Completed||Phase 2|2|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:51:47.683538|2018-05-31 23:51:47.683538
NCT01110655|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2010-04-23|2010-04-23|2010-04-26|Estimate|||||||2010-04-23|2010-04-26|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||The Efficacy of Oral Versus Intravenous Hypertonic Saline Administration in Runners With Exercise-Associated Hyponatremia|Incidence and Cause of Hyponatremia in Endurance Runners, Also to Determine if Oral Hypertonic Saline is as Efficacious as Intravenous Hypertonic Saline in the Correction of Below Normal Blood Sodium Concentrations in Runners With Hyponatremia Without Neurological Symptoms|Unknown status|Recruiting|N/A|100|Anticipated|Western States Endurance Run Research Foundation||2|||f||||f||||||||||2018-05-31 23:51:47.781559|2018-05-31 23:51:47.781559
NCT01110642|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-05-15|2010-04-23|2010-04-26|Estimate|||||||2015-05-15|2015-05-19|Estimate|July 2011||2011-07-31|May 2015|2015-05-31||||||||Interventional|||Novel Treatment for Syndromic Ichthyoses|Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses|Withdrawn||Phase 2|0|Actual|Northwestern University||1||Study was withdrawn due to lack of eligible population for study|f||||f||||||||||2018-05-31 23:51:48.013298|2018-05-31 23:51:48.013298
NCT01110629|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2014-10-12|2010-04-23|2010-04-26|Estimate|||||||2014-10-12|2014-10-15|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study in Chronic Kidney Disease (CKD) Not on Dialysis|Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Lanthanum Carbonate 750 to 2250 mg in Patients With Chronic Kidney Disease Not on Dialysis Who Develop Hyperphosphatemia|Completed||Phase 3|143|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:51:48.130903|2018-05-31 23:51:48.130903
NCT01110616|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-10-30|2010-04-22|2010-04-26|Estimate|||||||2015-10-30|2015-11-02|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)|A Double Blind, Randomized, Crossover Study to Assess EEG Platform Standardization in Healthy Male Subjects|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||12|||f||||f||||||||||2018-05-31 23:51:48.372324|2018-05-31 23:51:48.372324
NCT01110603|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2016-05-04|2010-04-23|2010-04-26|Estimate|||||||2016-05-04|2016-05-05|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)|A Phase Ib Dose Escalation Study of MK-4827 in Combination With Carboplatin, Carboplatin/Paclitaxel and Carboplatin/Liposomal Doxorubicin in Patients With Advanced Solid Tumors|Terminated||Phase 1|12|Actual|Tesaro, Inc.||3|||f||||f||||||||||2018-05-31 23:51:48.637618|2018-05-31 23:51:48.637618
NCT01110291|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-26|2010-04-22|2010-04-26|Estimate|||||||2010-04-26|2010-04-27|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|March 2009|Actual|2009-03-31|January 2004|Actual|2004-01-31||Observational|Docetaxel||Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events|Activity of CYP3A and Genotypes of CYP3A5 and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients|Completed|||20|Actual|University of Turku|||1||f||||f||||||Samples With DNA|"~     Blood samples for genotyping and phenotyping as well as analysis of docetaxel concentrations.~   "|||2018-05-31 23:51:56.529645|2018-05-31 23:51:56.529645
NCT01110590|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2013-02-21|2010-04-23|2010-04-26|Estimate|||||||2013-02-21|2013-02-22|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Multiple Dose Escalation Study (14 Days) to Investigate Safety, Tolerability, PK and PD of Vardenafil and BAY60-4552|Randomized, Double-blind, Placebo-controlled, Group-comparison, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administration of Different Doses of Vardenafil (2 Dose Strengths) and BAY60-4552 (4 Dose Strengths) Given Once-daily (od) Over 14 Days in Patients With Erectile Dysfunction (ED).|Completed||Phase 1|37|Actual|Bayer||4|||f||||f||||||||||2018-05-31 23:51:48.817778|2018-05-31 23:51:48.817778
NCT01110577|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-04-08|2010-04-23|2010-04-26|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)|Inter-Center Reproducibility Study of Magnetic Resonance Imaging (MRI) for Quantification of Hepatic Fat Fraction in Diabetic and Pre-Diabetic Patients|Completed|||10|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:51:48.952299|2018-05-31 23:51:48.952299
NCT01110564|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2011-01-27|2010-04-23|2010-04-26|Estimate|||||||2011-01-27|2011-01-28|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Study to Investigate Daily Symptom Variability, Symptom Effects on Morning Activities of Chronic Obstructive Disease|A Cross-sectional Observational Study to Investigate Daily Symptom Variability, Effects of Symptom on Morning Activities and Therapeutic Expectations of Patients and Physicians in Chronic Obstructive Pulmonary Disease - SUNRISE Study|Completed|||515|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 23:51:49.055078|2018-05-31 23:51:49.055078
NCT01110551|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2013-01-31|2010-04-22|2010-04-26|Estimate|||||||2013-01-31|2013-02-04|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Tetravalent Chimeric Dengue Vaccine Trial|A Double-Blind Randomized, Placebo-Controlled, Phase I Dose Escalation Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Adult Volunteers|Completed||Phase 1|72|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 23:51:49.209608|2018-05-31 23:51:49.209608
NCT01110538|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2016-11-23|2010-04-23|2010-04-26|Estimate|||||||2016-11-23|2016-11-25|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||The Massachusetts General Hospital Optical Coherence Tomography Registry|The Massachusetts General Hospital Optical Coherence Tomography Registry|Active, not recruiting|||2714|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 23:51:49.311407|2018-05-31 23:51:49.311407
NCT01110525|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-11-17|2010-04-23|2010-04-26|Estimate|||||||2010-11-17|2010-11-18|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives|A Phase I, Double-blind, Randomised, Placebo-controlled, Two-cycle Crossover, Drug-drug Interaction Study to Investigate the Effects of AZD1981 Tablets 400 mg Twice Daily on the PK and PD of Oral Contraceptives in Healthy Female Volunteers|Completed||Phase 1|28|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:51:49.413469|2018-05-31 23:51:49.413469
NCT01110512|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-10-26|2010-04-23|2010-04-26|Estimate|||||||2010-10-26|2010-10-27|Estimate|October 2010||2010-10-31|April 2010|2010-04-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)||Unknown status|Not yet recruiting|Phase 3|140|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-05-31 23:51:49.52531|2018-05-31 23:51:49.52531
NCT01110499|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|2013-05-31|2012-05-25|2014-07-10|2010-04-23|2010-04-26|Estimate|2014-07-10|2014-08-05|Estimate|2012-05-25|2012-06-01|Estimate|2014-07-10|2014-08-05|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 2|163|Actual|Allergan||8|||f||||f||||||||||2018-05-31 23:51:49.723611|2018-05-31 23:51:49.723611
NCT01110486|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2013-11-04|2010-04-23|2010-04-26|Estimate|||||||2013-11-04|2013-11-06|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors|Completed||Phase 1|102|Actual|AbbVie||5|||f||||f||||||||||2018-05-31 23:51:50.960015|2018-05-31 23:51:50.960015
NCT01110473|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2017-11-16|2010-04-23|2010-04-26|Estimate|||||||2017-11-16|2017-11-20|Actual|April 2010||2010-04-30|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies|Completed||Phase 1|52|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 23:51:51.053933|2018-05-31 23:51:51.053933
NCT01110460|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2011-01-31|2010-04-23|2010-04-26|Estimate|||||||2011-01-31|2011-02-01|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|October 2009|Actual|2009-10-31||Observational|PRISMA||Prospective Study on Asthma Control|Cross-sectional and Prospective Observational Study Aimed to Assess the Prevalence of Uncontrolled and Partially Controlled Asthmatics in Italy and the Prevalence of Uncontrolled/Partially Controlled Patients Achieved Asthma Control After 12 Months|Completed|||2875|Actual|Chiesi Farmaceutici S.p.A.|||||f||||t||||||||||2018-05-31 23:51:51.149969|2018-05-31 23:51:51.149969
NCT01110447|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-23|||2013-12-26|2010-04-23|2010-04-26|Estimate|||||||2013-12-26|2013-12-30|Estimate|April 2010||2010-04-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|VSL#3||Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation|Secondary Prophylaxis of Hepatic Encephalopathy: A Double Blind, Randomized, Placebo Controlled Study With Supplementation With a Probiotic Preparation|Completed||Phase 2/Phase 3|130|Actual|CD Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 23:51:51.287941|2018-05-31 23:51:51.287941
NCT01110434|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-07-11|2010-04-23|2010-04-26|Estimate|||||||2012-07-11|2012-07-12|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents|Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents|Completed||Phase 2|64|Actual|Brown University||2|||f||||t||||||||||2018-05-31 23:51:51.363969|2018-05-31 23:51:51.363969
NCT01110421|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2014-05-30|2013-12-02|2014-07-02|2010-04-23|2010-04-26|Estimate|2014-05-30|2014-07-02|Estimate|2013-12-02|2013-12-27|Estimate|2014-07-02|2014-07-15|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia|Terminated||Phase 3|7|Actual|Janssen Research & Development, LLC|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with cefepime.|2||Trial terminated early per business decision|f||||t||||||||||2018-05-31 23:51:51.457354|2018-05-31 23:51:51.457354
NCT01110408|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2014-05-30||2014-07-02|2010-04-23|2010-04-26|Estimate|2014-05-30|2014-07-02|Estimate||||2014-07-02|2014-07-15|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections|Terminated||Phase 3|41|Actual|Janssen Research & Development, LLC|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with cefepime.|2||Trial terminated early per business decision|f||||t||||||||||2018-05-31 23:51:52.095302|2018-05-31 23:51:52.095302
NCT01110395|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2016-05-25|2010-04-22|2010-04-26|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Phosphorous Magnetic Resonance Spectroscopy of Heart|31P Magnetic Resonance Spectroscopy of Heart|Unknown status|Recruiting||15|Anticipated|Washington University School of Medicine|||1||f||||t||||||||||2018-05-31 23:51:52.741112|2018-05-31 23:51:52.741112
NCT01110382|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2014-05-30||2014-07-02|2010-04-23|2010-04-26|Estimate|2014-05-30|2014-07-02|Estimate||||2014-07-02|2014-07-15|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections|A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infections|Terminated||Phase 3|41|Actual|Janssen Research & Development, LLC|This study was terminated early due to business reasons and not related to safety concerns or issues. As such, the limited enrollment precludes a meaningful conclusion about the efficacy and safety of doripenem compared with meropenem.|2||Trial terminated early per business decision|f||||t||||||||||2018-05-31 23:51:52.981374|2018-05-31 23:51:52.981374
NCT01110369|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2012-01-30|2010-04-22|2010-04-26|Estimate|||||||2012-01-30|2012-01-31|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ProMuscle||A Protein Supplementation and Exercise Strategy to Promote Muscle Protein Anabolism in Frail Elderly People|A Protein Supplementation and Exercise Strategy to Promote Muscle Protein Anabolism in Frail Elderly People|Completed||N/A|62|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 23:51:55.189198|2018-05-31 23:51:55.189198
NCT01110356|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2012-11-13|2010-04-22|2010-04-26|Estimate|||||||2012-11-13|2012-11-15|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|Prefer||Ferric Carboxymaltose Treatment to Improve Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age|A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Fatigue Symptoms in Iron-deficient Non-anaemic Women of Child Bearing Age|Completed||Phase 4|294|Actual|Vifor Inc.||2|||f||||f||||||||||2018-05-31 23:51:55.289245|2018-05-31 23:51:55.289245
NCT01110343|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2015-06-02|2010-04-22|2010-04-26|Estimate|||||||2015-06-02|2015-06-04|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PSIP||Conventional vs Mindfulness Intervention in Parents of Children With Disabilities|Conventional Versus Mindfulness Intervention in Parents of Children With Disabilities|Completed||N/A|243|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 23:51:55.36666|2018-05-31 23:51:55.36666
NCT01110330|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2013-02-26||2014-04-10|2010-04-22|2010-04-26|Estimate|2013-05-01|2013-06-06|Estimate||||2014-04-10|2014-04-29|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot|A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis|Terminated||Phase 3|583|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|The study was terminated prematurely by the sponsor due to significant discrepancies between potassium hydroxide and mycological culture results.|3||"Unexpected discordant results between the KOH microscopy and mycological culture tests at three~   study sites in the UK."|f||||f||||||||||2018-05-31 23:51:55.470844|2018-05-31 23:51:55.470844
NCT01110317|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-26|2010-04-22|2010-04-26|Estimate|||||||2010-04-26|2010-04-27|Estimate|July 2005||2005-07-31|April 2010|2010-04-30|March 2006|Actual|2006-03-31|||||Interventional|||A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate|Open-Label, Parallel, Randomized, Multiple-Dose Pharmacokinetic Study of Paliperidone After Intramuscular Injection of Paliperidone Palmitate in the Deltoid or Gluteal Muscle in Subjects With Schizophrenia|Completed||Phase 1|49|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-05-31 23:51:56.292831|2018-05-31 23:51:56.292831
NCT01110304|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-12-19|2010-04-23|2010-04-26|Estimate|||||||2012-12-19|2012-12-20|Estimate|May 2007||2007-05-31|December 2012|2012-12-31|February 2015|Anticipated|2015-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Acromio-clavicular Dislocation Type III - Conservative Treatment Versus Surgical Hook Plate Treatment|Acromio-clavicular Joint Dislocation Type III. Conservative Treatment Compared to Surgical Management With 3.5mm Clavicle Hook Plate. A Prospective Randomized Study|Unknown status|Recruiting|N/A|56|Anticipated|Hopital de l'Enfant-Jesus||2|||f||||f||||||||||2018-05-31 23:51:56.402908|2018-05-31 23:51:56.402908
NCT01110278|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-08-17|2010-04-23|2010-04-26|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2010||2010-05-31|August 2017|2017-08-31|June 22, 2012|Actual|2012-06-22|June 22, 2012|Actual|2012-06-22||Observational|||Examining Bladder Control Using Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI)|Examining the Brain's Control Systems in Normal and Overactive Bladder Using DTI and Functional MRI|Completed|||47|Actual|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 23:51:56.597932|2018-05-31 23:51:56.597932
NCT01110239|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2011-08-09||2017-05-05|2010-04-23|2010-04-26|Estimate|2013-01-31|2013-03-11|Estimate||||2017-05-05|2017-06-09|Actual|November 2008||2008-11-30|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Preconditioning for Aneurismal Subarachnoid Hemorrhage|Remote Ischemic Preconditioning to Ameliorate Delayed Ischemic Neurological Deficit After Aneurismal Subarachnoid Hemorrhage|Completed||N/A|34|Actual|University of Miami||1|||f||||t||||||||||2018-05-31 23:51:57.13691|2018-05-31 23:51:57.13691
NCT01110226|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2015-02-23|2010-04-22|2010-04-26|Estimate|||||||2015-02-23|2015-02-25|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|0805 GCC||Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies|Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies|Unknown status|Recruiting|Phase 1|15|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 23:51:57.517317|2018-05-31 23:51:57.517317
NCT01110213|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-04-22|2010-04-22|2010-04-26|Estimate|||||||2010-04-22|2010-04-26|Estimate|August 2006||2006-08-31|April 2010|2010-04-30|August 2007|Actual|2007-08-31|March 2007|Actual|2007-03-31||Interventional|GSDB||Goal Setting and Lifestyle|Goal Setting and Decisional Balance Applied to Physical Activity and Fruit & Vegetable Consumption|Completed||N/A|43|Actual|University of Hawaii||2|||f||||t||||||||||2018-05-31 23:51:57.669122|2018-05-31 23:51:57.669122
NCT01110200|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2012-12-13||2017-10-09|2010-04-22|2010-04-26|Estimate|2012-12-13|2013-01-18|Estimate||||2017-10-09|2017-11-08|Actual|April 30, 2010||2010-04-30|October 2017|2017-10-31|May 8, 2012|Actual|2012-05-08|April 1, 2012|Actual|2012-04-01||Interventional|||Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study|A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of COPD Following Hospitalization|Completed||Phase 4|639|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:51:57.84352|2018-05-31 23:51:57.84352
NCT01110187|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2013-06-19||2014-03-26|2010-04-22|2010-04-26|Estimate|2014-03-26|2014-04-28|Estimate||||2014-03-26|2014-04-28|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Traumatic Brain Injury|A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide|A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide|Terminated||N/A|11|Actual|University of Alabama at Birmingham|Early termination due to lack of enrollment. Statistical comparisons between groups are not possible and were not performed.|2||Lack of enrollement|f||||t||||||||||2018-05-31 23:51:58.862497|2018-05-31 23:51:58.862497
NCT01110174|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-09-22|2010-04-23|2010-04-26|Estimate|||||||2017-09-22|2017-09-26|Actual|March 2010||2010-03-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ENIGMA||Assessing Response to Neoadjuvant Chemotherapy With HD PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms|Assessing Response to Neoadjuvant Chemotherapy With Dedicated Breast High Definition PET/CT, Serum Glycomic Markers and Tissue Muc-1 Isoforms|Completed||N/A|20|Actual|University of California, Davis||1|||f||||f|f|t||||||||2018-05-31 23:51:59.397546|2018-05-31 23:51:59.397546
NCT01110161|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-12-06|2010-04-22|2010-04-26|Estimate|||||||2010-12-06|2010-12-08|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Technical Validation of Lunar iDXA Visceral Fat Tool|Technical Validation of Lunar iDXA Visceral Fat Tool|Completed|||148|Actual|GE Healthcare|||1||f||||f||||||||||2018-05-31 23:51:59.551746|2018-05-31 23:51:59.551746
NCT01110148|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-23|2010-04-23|2010-04-26|Estimate|||||||2010-04-23|2010-04-26|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Use of Portable Technology in Patient Education of Shave/Punch Biopsies|Use of MP3 Portable Technology in Patient Education and Informed Consent of Shave and Punch Biopsies|Completed||N/A|84|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 23:51:59.692547|2018-05-31 23:51:59.692547
NCT01110135|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2017-04-14||2017-04-14|2010-04-23|2010-04-26|Estimate|2017-04-14|2017-05-24|Actual||||2017-04-14|2017-05-24|Actual|August 2010||2010-08-31|April 2017|2017-04-30||||November 2013|Actual|2013-11-30||Interventional|||Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma|A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)|Completed||Phase 2|43|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:51:59.805504|2018-05-31 23:51:59.805504
NCT01110122|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-22|2010-04-22|2010-04-26|Estimate|||||||2010-04-22|2010-04-26|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Effect of Whey Protein on Soccer Performance|The Effect of Post-exercise Supplementation With Whey Protein Versus Carbohydrate on Soccer Performance.|Unknown status|Recruiting|N/A|50|Anticipated|VU University of Amsterdam|||||f||||f||||||||||2018-05-31 23:52:00.112812|2018-05-31 23:52:00.112812
NCT01110109|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-10-25|2010-04-23|2010-04-26|Estimate|||||||2010-10-25|2010-10-26|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|||Removing Fluid Above Breathing Tubes in the Operating Room|EVAC Use in the OR: A Randomized Clinical Study to Evaluate the Content of Fluid Extracted From the Endotracheal Tube Cuff Using Intermittent and Continuous Suctioning During Surgery|Completed|||48|Actual|Medtronic - MITG|||2||f||||f||||||Samples Without DNA|"~     Suction secretions~   "|||2018-05-31 23:52:00.231024|2018-05-31 23:52:00.231024
NCT01110096|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2017-06-02|2010-04-22|2010-04-26|Estimate|||||||2017-06-02|2017-06-05|Actual|April 2010||2010-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|May 2013|Actual|2013-05-31||Interventional|||Family Based Intervention in Childhood obesitY|Randomised Controlled Clinical Trial Comparing Two Family Interventions to Treat Obesity in Children Between 7 and 12 Years.|Active, not recruiting||N/A|100|Actual|Sykehuset i Vestfold HF||2|||f||||f||||||||||2018-05-31 23:52:00.315576|2018-05-31 23:52:00.315576
NCT01110083|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-10-21|2010-04-22|2010-04-26|Estimate|||||||2013-10-21|2013-10-22|Estimate|April 2010||2010-04-30|October 2013|2013-10-31||||March 2012|Actual|2012-03-31||Interventional|||First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors|A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors|Terminated||Phase 1|38|Actual|EMD Serono||1||"Please see Purpose statement below."|f||||f||||||||||2018-05-31 23:52:00.425343|2018-05-31 23:52:00.425343
NCT01110070|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-07-06|2010-04-23|2010-04-26|Estimate|||||||2017-07-06|2017-07-07|Actual|July 2010||2010-07-31|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||ChonDux for Filling Full Thickness Cartilage Defects in the Femoral Condyle of the Knee|Pivotal Study in Europe for CE Mark|Terminated||N/A|21|Actual|Zimmer Biomet||2||Enrollment suspended; follow up continue|f||||f||||||||||2018-05-31 23:52:00.518832|2018-05-31 23:52:00.518832
NCT01110057|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-06-07|2010-04-22|2010-04-23|Estimate|||||||2017-06-07|2017-06-08|Actual|January 7, 2010|Actual|2010-01-07|June 2017|2017-06-30|August 23, 2010|Actual|2010-08-23|August 23, 2010|Actual|2010-08-23||Interventional|||Efficacy Study in Lumbosacral Radiculopathy|A Randomised, Double Blind Study to Evaluate the Safety and Efficacy of the p38 Kinase Inhibitor, GW856553, in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy|Completed||Phase 2|142|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:52:00.637635|2018-05-31 23:52:00.637635
NCT01110044|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-03-26|2010-04-22|2010-04-23|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine|Immunogenicity and Safety of a Birth Dose of GlaxoSmithKline Biologicals' Reduced-antigen-content Tri-component Pertussis (251154) Vaccine|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|f||||||||||||||2018-05-31 23:52:00.933711|2018-05-31 23:52:00.933711
NCT01110031|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-11-08|2010-04-22|2010-04-23|Estimate|||||||2017-11-08|2017-11-13|Actual|May 13, 2010|Actual|2010-05-13|November 2017|2017-11-30|June 26, 2012|Actual|2012-06-26|April 12, 2012|Actual|2012-04-12||Interventional|||Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects|An Open-Label, Single-Arm, Phase I Study to Evaluate the Effect of Ofatumumab on Cardiac Repolarization (QTc Duration) in Patients With Fludarabine-Refractory B-cell Chronic Lymphocytic Leukemia|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:52:01.052842|2018-05-31 23:52:01.052842
NCT01110018|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2017-06-26|2010-04-22|2010-04-23|Estimate|||||||2017-06-26|2017-06-27|Actual|April 28, 2010|Actual|2010-04-28|June 2017|2017-06-30|June 9, 2010|Actual|2010-06-09|June 9, 2010|Actual|2010-06-09||Interventional|||GSK573719 IV Enabling Study|A Single-centre, Open-label, Sequential, Cross-over Study to Examine the Safety, Tolerability and Pharmacokinetics of 3 Ascending Single Intravenous Doses, a Single 1000μg Oral Dose and a Single 1000μg Inhaled Dose of GSK573719 in Healthy Male Volunteers.|Completed||Phase 1|10|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:52:01.168008|2018-05-31 23:52:01.168008
NCT01110005|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2017-01-24||2017-01-24|2010-04-22|2010-04-23|Estimate|2017-01-24|2017-03-14|Actual||||2017-01-24|2017-03-14|Actual|April 2010||2010-04-30|January 2017|2017-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|RARHY|A total of 318 subjects were randomized for the study but nine were excluded from analysis entirely: 3 were deemed ineligible, 5 did not have adequate documentation of informed consent, and 1 subject withdrew consent.|A Trial of Intravenous Fluids During Labor|A Multi-Center, Two-Arm, Single-Blind Randomized Trial of IV Fluids During Labor|Completed||N/A|318|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||No||2018-05-31 23:52:01.332144|2018-05-31 23:52:01.332144
NCT01109992|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-07-11|2010-04-22|2010-04-23|Estimate|||||||2017-07-11|2017-07-13|Actual|February 2011||2011-02-28|July 2017|2017-07-31|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|IDEALPET||Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET|Integrated Dual Exercise and Lexiscan PET: IDEAL PET|Completed||Phase 4|41|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:52:01.734861|2018-05-31 23:52:01.734861
NCT01109979|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2013-02-28||2016-06-10|2010-04-22|2010-04-23|Estimate|2013-04-30|2013-05-03|Estimate||||2016-06-10|2016-07-12|Estimate|December 2009||2009-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|January 2012|Actual|2012-01-31||Interventional|||Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function|Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study|Completed||Phase 4|24|Actual|Brigham and Women's Hospital|There may have been an order effect of E+DRSP on FMD. For this, however, we would expect %FMD to be lower in the 2nd treatment period, regardless of specific treatment. It is unclear whether this was true cross-over effect or due to the study size.|2|||f||||t||||||||||2018-05-31 23:52:01.817652|2018-05-31 23:52:01.817652
NCT01109966|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2017-05-04|2010-04-22|2010-04-23|Estimate|||||||2017-05-04|2017-05-08|Actual|June 2010|Actual|2010-06-30|May 2017|2017-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||An Elimination Diet Using a New Amino Acid Based Formula: Immunological and Clinical Effects in Cow's Milk Allergy|A Prospective, Double Blind Randomised Controlled Trial to Evaluate the Immunological Benefits and Clinical Effects of an Elimination Diet Using an Amino Acid Based Formula (AAF)|Terminated||N/A|34|Actual|Nutricia Research||2|||f||||f||||||||No||2018-05-31 23:52:02.184142|2018-05-31 23:52:02.184142
NCT01109953|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-03-15|2010-04-22|2010-04-23|Estimate|||||||2012-03-15|2012-03-16|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images|Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images|Terminated|||6|Actual|Memorial Sloan Kettering Cancer Center|||1|Lack of accrual|f||||||||||||||2018-05-31 23:52:02.268061|2018-05-31 23:52:02.268061
NCT01109940|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2016-11-15|2010-04-22|2010-04-23|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis|An Open Label Non-randomized Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti Interleukin-17 Monoclonal Antibody) in Patients With Moderate to Severe Ankylosing Spondylitis|Completed||Phase 2|39|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:52:02.374808|2018-05-31 23:52:02.374808
NCT01109927|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-22|2010-04-22|2010-04-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|February 1995||1995-02-28|February 1995|1995-02-28|May 2005|Actual|2005-05-31|April 2002|Actual|2002-04-30||Interventional|||Early Insulin Treatment in Patients With Latent Autoimmune Diabetes|Early Insulin Treatment in Patients With Latent Autoimmune Diabetes (LADA)|Completed||Phase 4|42|Actual|Lund University Hospital||2|||f||||f||||||||||2018-05-31 23:52:02.55365|2018-05-31 23:52:02.55365
NCT01109914|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-03-25|2010-04-22|2010-04-23|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MICH||Mucosal Response in Immunocompromised Host|Immune Response After Inactivated Oral Cholera Vaccine (Dukoral) in Renal Transplant Recipients|Completed||Phase 4|51|Actual|Leiden University Medical Center||3|||f||||f||||||||||2018-05-31 23:52:02.699081|2018-05-31 23:52:02.699081
NCT01109901|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-22|2010-04-22|2010-04-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Comparison of Effect of Anterior Subcutaneous and Submuscular Transposition on Cubital Tunnel Syndrome|Study of Surgical Methods for Cubital Tunnel Syndrome|Completed||Phase 2|48|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:52:02.84557|2018-05-31 23:52:02.84557
NCT01109888|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2016-03-29|2010-04-22|2010-04-23|Estimate|||||||2016-03-29|2016-03-30|Estimate||||April 2010|2010-04-30||||||||Interventional|||Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)|Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian During Controlled Ovarian Stimulation(COH) for In Vitro Fertilisation(IVF)|Withdrawn||Phase 1/Phase 2|0|Actual|Wolfson Medical Center||1||there was no percipitant enrolled|f||||t||||||||||2018-05-31 23:52:03.011466|2018-05-31 23:52:03.011466
NCT01109875|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-06-11|2010-04-22|2010-04-23|Estimate|||||||2014-06-11|2014-06-12|Estimate|May 2010||2010-05-31|June 2014|2014-06-30||||December 2014|Anticipated|2014-12-31||Interventional|||Screening for Fabry Disease Among Young Stroke Patients in an Israeli Stroke Clinic||Unknown status|Active, not recruiting|N/A|1000|Anticipated|Wolfson Medical Center|||||f||||||||||||||2018-05-31 23:52:03.130479|2018-05-31 23:52:03.130479
NCT01109862|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2011-06-16|2010-04-22|2010-04-23|Estimate|||||||2011-06-16|2011-06-17|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Prospective Randomized Comparison of Bipolar Hemiarthroplasty and Total Hip Arthroplasty With Large Femoral Heads for the Treatment of Displaced Intracapsular Femoral Neck Fractures in the Elderly|Prospective Randomized Comparison of Bipolar Hemiarthroplasty and Total Hip Arthroplasty With Large Femoral Heads for the Treatment of Displaced Intracapsular Femoral Neck Fractures in the Elderly|Unknown status|Recruiting|Phase 1|80|Anticipated|Wolfson Medical Center||2|||f||||||||||||||2018-05-31 23:52:03.227927|2018-05-31 23:52:03.227927
NCT01109849|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2017-04-21||2017-06-16|2010-04-22|2010-04-23|Estimate|2017-06-16|2017-07-14|Actual||||2017-06-16|2017-07-14|Actual|November 2010||2010-11-30|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||all participants assigned to treatment Note that initial randomization was to med or behavior. Those meeting criteria were then adaptively rerandomized to 1 of 3 weight recovery arms.|Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth|Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth|Completed||Phase 3|230|Actual|Florida International University||5|||f||||t||||||||||2018-05-31 23:52:03.3734|2018-05-31 23:52:03.3734
NCT01109836|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2015-01-12|2010-04-22|2010-04-23|Estimate|||||||2015-01-12|2015-01-13|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ASPIS||Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke|ASPIS-Austrian Polyintervention Study to Prevent Cognitive Decline After Ischemic Stroke|Completed||Phase 4|202|Actual|Danube University Krems||2|||f||||t||||||||||2018-05-31 23:52:04.289705|2018-05-31 23:52:04.289705
NCT01109823|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-12-04|2010-04-22|2010-04-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration|Pharmacokinetic Evaluation of Fluoroquinolone Antibiotics Administered Intravenously in Intensive Care Patients With Normal Renal Function and With Renal Hyperfiltration|Unknown status|Recruiting|Phase 3|40|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 23:52:04.37627|2018-05-31 23:52:04.37627
NCT01109810|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2018-05-08|2010-04-22|2010-04-23|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2010||2010-08-31|May 2018|2018-05-31|August 2025|Anticipated|2025-08-31|August 2020|Anticipated|2020-08-31||Observational|IDEaL||Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)|Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)|Recruiting|||500|Anticipated|Coram Clinical Trials|||1||f||||f||||||||||2018-05-31 23:52:04.454403|2018-05-31 23:52:04.454403
NCT01109797|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2014-05-23|2010-04-22|2010-04-23|Estimate|||||||2014-05-23|2014-05-26|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care|A Comparison of Two Models for Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care|Completed||N/A|28|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 23:52:04.54401|2018-05-31 23:52:04.54401
NCT01109784|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-08-23|2010-04-22|2010-04-23|Estimate|||||||2010-08-23|2010-08-24|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).|Phase 3 Study of Prasugrel vs High Dose (150 mg) Clopidogrel in Clopidogrel Resistant Patients Post Coronary Angioplasty.|Completed||Phase 3|70|Anticipated|University of Patras||2|||f||||f||||||||||2018-05-31 23:52:04.61624|2018-05-31 23:52:04.61624
NCT01109771|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-12-04|2010-04-22|2010-04-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|SORBET||Absorbable Versus Permanent Mesh Fixation Trial in Laparoscopic Midline Ventral Hernia Repair|Absorbable Versus Permanent Mesh Fixation Trial in Laparoscopic Midline Ventral Hernia Repair (SORBET Trial)|Unknown status|Recruiting|Phase 4|440|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 23:52:04.685701|2018-05-31 23:52:04.685701
NCT01109758|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-22|2010-04-22|2010-04-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|March 2008||2008-03-31|April 2010|2010-04-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Fenofibrate on Gene Expression in Healthy Volunteers|Effects of Fenofibrate on Gene Expression Activity and DNA Methylation Profile in Circulating Monocytes of Healthy Volunteers|Completed||Phase 1|26|Actual|Solvay Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:52:04.783127|2018-05-31 23:52:04.783127
NCT01109745|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-03-17|2010-04-22|2010-04-23|Estimate|||||||2014-03-17|2014-03-18|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|PELICANII||Effectiveness of the Pelican Instrument in Medical Care|Effectiveness of the Paediatric Electronic Quality of Life Instrument for Childhood Asthma in the Netherlands (Pelican) in Medical Care.|Completed||N/A|120|Actual|Radboud University||4|||f||||f||||||||||2018-05-31 23:52:04.847119|2018-05-31 23:52:04.847119
NCT01109732|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2016-11-01|2010-04-22|2010-04-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional|||Physical Activity, Function and Quality of Life in Patients After Endovascular Treatment|Physical Activity, Function and Quality of Life in Patients After Endovascular Treatment|Completed||N/A|50|Actual|Oslo University Hospital||2|||f||||t||||||||No||2018-05-31 23:52:04.933533|2018-05-31 23:52:04.933533
NCT01109719|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-08-23|2010-04-22|2010-04-23|Estimate|||||||2010-08-23|2010-08-25|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Observational|CIOS||Critical Illness Outcomes Study|The Association of ICU Organization and Structure on in Patient Mortality|Unknown status|Active, not recruiting||6000|Anticipated|National Institute of General Medical Sciences (NIGMS)|||||f||||f||||||||||2018-05-31 23:52:04.998497|2018-05-31 23:52:04.998497
NCT01109706|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-11-16|2010-04-22|2010-04-23|Estimate|||||||2012-11-16|2012-11-19|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|PC-SCA-9||Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.|Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.|Unknown status|Recruiting||200|Anticipated|Nantes University Hospital|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 23:52:05.065953|2018-05-31 23:52:05.065953
NCT01109693|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2016-09-29|2010-04-22|2010-04-23|Estimate|||||||2016-09-29|2016-10-03|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|SUN(^_^)D||Strategic Use of New Generation Antidepressants for Depression|Strategic Use of New Generation Antidepressants for Depression|Completed||Phase 4|2011|Actual|Kyoto University||3|||f||||t||||||||||2018-05-31 23:52:05.174261|2018-05-31 23:52:05.174261
NCT01109680|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2011-02-07|2010-04-22|2010-04-23|Estimate|||||||2011-02-07|2011-02-08|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects|A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects|Completed||Phase 1|8|Anticipated|Merz Pharmaceuticals GmbH||1|||f||||||||||||||2018-05-31 23:52:05.245947|2018-05-31 23:52:05.245947
NCT01109667|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-22|2010-04-22|2010-04-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Differences in Coagulation Test Kits|The Effects of Different Reagents on Coagulation Tests: Innovin Versus Thromborel-S.|Completed|||350|Anticipated|Yuksek Ihtisas Hospital|||2||f||||f||||||||||2018-05-31 23:52:05.300423|2018-05-31 23:52:05.300423
NCT01109654|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2014-07-15|2010-04-22|2010-04-23|Estimate|||||||2014-07-15|2014-07-16|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)|A Prospective, Observational Study on the Use of Cetrotide (GnRH Antagonist) With GONAL-f in Assisted Reproductive Technologies (ART)|Completed|||2175|Actual|Merck KGaA|||||f||||f||||||Samples Without DNA|"~     Plasma, Serum, Tissue, Urine~   "|||2018-05-31 23:52:05.43748|2018-05-31 23:52:05.43748
NCT01109641|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-10-06|2010-04-22|2010-04-23|Estimate|||||||2010-10-06|2010-10-07|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|PING-EP||PhrenIc Nerve mappinG and Stimulation EP Catheter Study: PING-EP Study|PhrenIc Nerve mappinG and Stimulation EP Catheter Study: PING-EP Study|Completed||Phase 4|40|Actual|Medtronic Italia|||||f||||f||||||||||2018-05-31 23:52:05.534719|2018-05-31 23:52:05.534719
NCT01109628|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2012-01-30|2010-04-21|2010-04-23|Estimate|||||||2012-01-30|2012-01-31|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ProMuscle||Protein Supplementation to Promote Muscle Protein Anabolism in Frail Elderly People|Protein Supplementation to Promote Muscle Protein Anabolism in Frail Elderly People|Completed||N/A|65|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 23:52:05.619627|2018-05-31 23:52:05.619627
NCT01109615|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-04-17|2010-04-21|2010-04-23|Estimate|||||||2012-04-17|2012-04-19|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|PG||Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations|Phase II Study of Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations|Terminated||Phase 2|40|Actual|Vejle Hospital||1||Lacking effect of treatment|f||||t||||||||||2018-05-31 23:52:05.712899|2018-05-31 23:52:05.712899
NCT01109602|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|2015-10-05||2015-11-04|2010-04-21|2010-04-23|Estimate|2015-11-04|2015-11-23|Estimate||||2015-11-04|2015-11-23|Estimate|July 2010||2010-07-31|November 2015|2015-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|HEALTHY||Strength, Flexibility, And Balance Therapy After Stroke|Yoga as a Complex Intervention for Vets With Stroke|Completed||Phase 1/Phase 2|47|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-05-31 23:52:05.804152|2018-05-31 23:52:05.804152
NCT01109589|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2010-04-22|2010-04-22|2010-04-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|December 2004||2004-12-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Observational|||Respiratory Tract Infections and Prescription Drugs in Children and in Pregnancy|Respiratory Tract Infections and Prescription Drugs in Children and in Pregnancy - a Study From Norwegian General Practice|Completed|||60000|Anticipated|University of Oslo|||2||f||||f||||||||||2018-05-31 23:52:06.275577|2018-05-31 23:52:06.275577
NCT01109576|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2015-06-04||2015-08-28|2010-04-22|2010-04-23|Estimate|2015-08-28|2015-09-29|Estimate||||2015-08-28|2015-09-29|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|August 2013|Actual|2013-08-31|July 2012|Actual|2012-07-31||Interventional|DSLW||Workshops for Veterans With Vision and Hearing Loss|Pilot Study: Self Management Groups for Veterans With Dual Sensory Loss|Completed||Early Phase 1|13|Actual|VA Office of Research and Development|The sample size was too small to draw any definitive conclusion from the data.|1|||f||||f||||||||||2018-05-31 23:52:06.345653|2018-05-31 23:52:06.345653
NCT01109563|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2016-10-25|2010-04-22|2010-04-23|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Teen Marijuana Check-Up|Reaching and Motivating Change in Teen Marijuana Smokers|Completed||Phase 3|252|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 23:52:06.517047|2018-05-31 23:52:06.517047
NCT01109550|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-12-07|2010-04-22|2010-04-23|Estimate|||||||2012-12-07|2012-12-10|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Observational|||Biliary Candidiasis - Optimization of Diagnostics and Therapy|Biliary Candidiasis - Evaluation of Risk Factors, Implementation of an Algorithm in Diagnostics and Therapy|Unknown status|Recruiting||80|Anticipated|University Hospital Muenster|||2||f||||f||||||Samples Without DNA|"~     bile samples, buccal smears, stool samples, blood samples, transpapillary biopsies (bile~     duct)~   "|||2018-05-31 23:52:06.607163|2018-05-31 23:52:06.607163
NCT01109537|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2015-01-06|2010-04-22|2010-04-23|Estimate|||||||2015-01-06|2015-01-07|Estimate|April 2010||2010-04-30|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|RLS||Altered Brain GABA and Glutamate in Restless Legs Syndrome|Thalamic and Anterior Cingulate Cortex GABA and Glutamate in Restless Legs Syndrome: A 1-HMRS Study|Completed|||75|Actual|Brigham and Women's Hospital|||2||f||||f||||||||||2018-05-31 23:52:06.709866|2018-05-31 23:52:06.709866
NCT01109342|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-08-28|2010-04-21|2010-04-23|Estimate|||||||2013-08-28|2013-08-29|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Extended Follow-Up of Participants in Preventive HIV Vaccine Studies in Uganda|Extended Follow-Up for Participants in VRC HIV-1 Recombinant Adenovirus-5 Vector Vaccine Studies in Uganda|Completed|||||National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 23:52:08.50944|2018-05-31 23:52:08.50944
NCT01109524|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|2013-09-12||2015-11-24|2010-04-22|2010-04-23|Estimate|2013-11-15|2013-12-10|Estimate||||2015-11-24|2015-12-24|Estimate|July 2010||2010-07-31|November 2015|2015-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||All treated participants.|Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer|Cisplatin and Vinorelbine in Combination With Cetuximab as First Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): a Single Arm Multicenter Safety Phase 2 Study|Completed||Phase 2|72|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 23:52:06.814298|2018-05-31 23:52:06.814298
NCT01109511|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2011-07-20|2010-04-22|2010-04-23|Estimate|||||||2011-07-20|2011-07-21|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|July 2011|Anticipated|2011-07-31|April 2010|Actual|2010-04-30||Interventional|||A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy||Unknown status|Recruiting|Phase 4|||Oslo University Hospital||2|||f||||||||||||||2018-05-31 23:52:07.36184|2018-05-31 23:52:07.36184
NCT01109498|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2011-09-29|2010-04-22|2010-04-23|Estimate|||||||2011-09-29|2011-09-30|Estimate|August 2007||2007-08-31|April 2010|2010-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]|A Study to Determine the Safety and Efficacy in Lipoprotein Lipase-Deficient Subjects After Intramuscular Administration of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein LipaseS447X|Unknown status|Active, not recruiting|Phase 2/Phase 3|14|Actual|Amsterdam Molecular Therapeutics||3|||f||||t||||||||||2018-05-31 23:52:07.437868|2018-05-31 23:52:07.437868
NCT01109485|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-05-11|2010-04-22|2010-04-23|Estimate|||||||2015-05-11|2015-05-12|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients||Completed||Phase 4|42|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:52:07.522561|2018-05-31 23:52:07.522561
NCT01109472|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-12-20|2010-04-21|2010-04-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Improving Osteoporosis Care in a Home Health Setting||Completed||N/A|1009|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 23:52:07.595183|2018-05-31 23:52:07.595183
NCT01109459|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-04-22|2010-04-22|2010-04-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|September 2004||2004-09-30|April 2010|2010-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|EPPICC||Multimodal Physician Intervention to Detect Amblyopia|"Multimodal Physician Intervention to Detect Amblyopia (Recruiting Title Equipping Primary Care Physicians to Improve Care for Children)"|Completed||N/A|136|Actual|University of Alabama at Birmingham||3|||f||||f||||||||||2018-05-31 23:52:07.658266|2018-05-31 23:52:07.658266
NCT01109446|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-02-13|2010-04-22|2010-04-23|Estimate|||||||2012-02-13|2012-02-14|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Treatment of Lateral Epicondylitis: Platelet Rich Plasma Versus Steroid Versus Saline Solution|Treatment of Lateral Epicondylitis. Platelet Rich Plasma vs. Steroid vs. Saline Solution|Completed||N/A|60|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 23:52:07.746608|2018-05-31 23:52:07.746608
NCT01109433|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2018-03-27|2010-04-22|2010-04-23|Estimate|||||||2018-03-27|2018-03-29|Actual|April 15, 2010||2010-04-15|December 22, 2017|2017-12-22||||||||Observational|||Immunogenetic Mechanisms in Behcet's Disease|Immunogenetic Mechanisms in Behcet's Disease|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:52:07.826846|2018-05-31 23:52:07.826846
NCT01109420|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2018-04-26|2010-04-22|2010-04-23|Estimate|||||||2018-04-26|2018-04-27|Actual|May 1, 2010||2010-05-01|April 25, 2018|2018-04-25||||||||Observational|||Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer|Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:52:07.900801|2018-05-31 23:52:07.900801
NCT01109407|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2018-02-13|2010-04-22|2010-04-23|Estimate|||||||2018-02-13|2018-02-14|Actual|April 15, 2010||2010-04-15|July 10, 2017|2017-07-10||||||||Observational|||Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)|Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)|Completed|||225|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:52:07.960116|2018-05-31 23:52:07.960116
NCT01109394|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2018-05-26|2010-04-22|2010-04-23|Estimate|||||||2018-05-26|2018-05-30|Actual|April 19, 2010||2010-04-19|May 24, 2018|2018-05-24||||||||Observational|||Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies|Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies|Recruiting|||6035|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:52:08.037818|2018-05-31 23:52:08.037818
NCT01109381|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2013-05-23||2014-03-04|2010-04-21|2010-04-23|Estimate|2014-03-04|2014-04-02|Estimate||||2014-03-04|2014-04-02|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori|A Single-centre, Open-label, Non-controlled, Exploratory Safety and Efficacy Clinical Trial of GT08 in Volunteers and Patients Who Are Infected With Helicobacter Pylori|Terminated||Phase 1/Phase 2|33|Actual|Synergy Pharmaceuticals Pte. Ltd.|The trial has no control group. All participants had current H.pylori infection at study entry. Only two participants had this infection eradicated, making an efficacy control group unnecessary.|1||Poor efficacy (2 of 31 completing participants with H.pylori eradication)|f||||f||||||||||2018-05-31 23:52:08.104366|2018-05-31 23:52:08.104366
NCT01109368|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2018-04-09|2010-04-22|2010-04-23|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2010||2010-06-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository|The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository|Recruiting|||60|Anticipated|The Rogosin Institute|||||f||||f||||||Samples With DNA|"~     Plasma, serum, monocytes~   "|||2018-05-31 23:52:08.239628|2018-05-31 23:52:08.239628
NCT01109355|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-22|2010-04-22|2010-04-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Positive and Expiratory Pressure and Hemorrhagic Stroke|Effect of Positive End Expiratory Pressure on Cerebral Perfusion Pressure in Adult Patients With Hemorrhagic Stroke|Completed||N/A|25|Actual|Universidade Federal de Pernambuco|||||f||||t||||||||||2018-05-31 23:52:08.409641|2018-05-31 23:52:08.409641
NCT01109160|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-07-03|2010-04-22|2010-04-23|Estimate|||||||2013-07-03|2013-07-04|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|October 2012|Actual|2012-10-31||Interventional|AZI002||Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation|A Prospective, Open-label Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation|Completed||Phase 4|15|Actual|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 23:52:11.290032|2018-05-31 23:52:11.290032
NCT01109329|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-12-31|2010-04-21|2010-04-23|Estimate|||||||2012-12-31|2013-01-03|Estimate|June 2010||2010-06-30|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults|Phase 1 Inpatient Study of rHMPV-SHs, a Human Metapneumovirus Challenge Strain, Administered to Healthy Adults in Isolation|Completed||Phase 1|21|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-05-31 23:52:08.616156|2018-05-31 23:52:08.616156
NCT01109316|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2012-08-08||2012-09-27|2010-04-21|2010-04-23|Estimate|2012-09-27|2012-10-30|Estimate||||2012-09-27|2012-10-30|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use|An Open-Label, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|132|Actual|Eli Lilly and Company|Input to primary endpoint measurements (SMBG) contained approximately 40% missing data. Several analyses to account for missing data have been conducted and results from these additional analyses were consistent with results of original analysis.|3|||f||||f||||||||||2018-05-31 23:52:08.84694|2018-05-31 23:52:08.84694
NCT01109303|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-12-19|2010-04-21|2010-04-23|Estimate|||||||2012-12-19|2012-12-20|Estimate|October 2008||2008-10-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional|||Static Implant Versus Dynamic Implant in the Surgical Treatment on Ankle Syndesmosis Rupture|Prospective Randomized Multicentric Trial Comparing a Static Implant and a Dynamic Implant in the Surgical Treatment of Ankle Syndesmosis Rupture|Completed||N/A|70|Actual|Hopital de l'Enfant-Jesus||2|||f||||f||||||||||2018-05-31 23:52:10.144514|2018-05-31 23:52:10.144514
NCT01109290|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2011-09-13|2010-04-22|2010-04-23|Estimate|||||||2011-09-13|2011-09-14|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Observational|||Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia|Validation of Non-invasive Technologies for the Characterization of Sweat Gland Function in Patients With Recessively Inherited Hypohidrotic Ectodermal Dysplasia, Their Heterozygous Family Members and Healthy Controls|Completed|||65|Actual|University Hospital Erlangen|||4||f||||||||||||||2018-05-31 23:52:10.224862|2018-05-31 23:52:10.224862
NCT01109277|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2011-01-18|2010-04-22|2010-04-23|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|2010ICTPAGR||Prediction of Neonatal Hyperbilirubinemia|An Evidence-based Strategy for Assessing the Risk of Significant Neonatal Hyperbilirubinemia|Completed|||3500|Anticipated|University of Patras|||1||f||||f||||||||||2018-05-31 23:52:10.282004|2018-05-31 23:52:10.282004
NCT01109264|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-08-21|2010-04-22|2010-04-23|Estimate|||||||2013-08-21|2013-08-23|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia|Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients|Completed||Phase 2|147|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 23:52:10.338387|2018-05-31 23:52:10.338387
NCT01109251|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2013-11-12|2010-04-22|2010-04-23|Estimate|||||||2013-11-12|2013-11-13|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|Hippocrate||Post CVA Persistent Hypertension Caring|Post CVA Persistent Hypetension, Interest of Caring by Tensional Auto-measures|Unknown status|Recruiting|N/A|240|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 23:52:10.413409|2018-05-31 23:52:10.413409
NCT01109238|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-07-19|2010-04-22|2010-04-23|Estimate|||||||2013-07-19|2013-07-22|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma|Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma|Completed|||5|Actual|Spectrum Health Hospitals|||1||f||||f||||||||||2018-05-31 23:52:10.488443|2018-05-31 23:52:10.488443
NCT01109225|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-22|||2017-05-12|2010-04-22|2010-04-23|Estimate|||||||2017-05-12|2017-05-16|Actual|April 2010|Actual|2010-04-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|March 2014|Actual|2014-03-31||Interventional|REMI||Relation Between Aldosterone and Cardiac Remodeling After Myocardial Infarction|Multiparametric Study of Cardiac Remodeling After Myocardial Infarction Revascularized in Acute Phase : Relation With the Serum Concentrations in Aldosterone|Active, not recruiting||N/A|145|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 23:52:10.572356|2018-05-31 23:52:10.572356
NCT01109212|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2016-03-29|2010-04-22|2010-04-23|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2007||2007-03-31|March 2016|2016-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||The Effects of Bindarit in Diabetic Nephropathy|The Effects of the Association Bindarit + Irbesartan Versus Irbesartan Alone on Albuminuria on Patients With Diabetic Nephropathy. Placebo-controlled Study|Completed||Phase 2|100|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f||||||||||2018-05-31 23:52:10.685487|2018-05-31 23:52:10.685487
NCT01109199|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2015-09-30|2010-04-22|2010-04-23|Estimate|||||||2015-09-30|2015-10-02|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effects of a Dietary Fibre Supplementation of a Low Calorie Diet on Appetite and Body Weight|A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a High Viscosity Dietary Fibre (PGX) Supplementation of a Low Calorie Diet on Appetite and Body Weight, in Overweight and Moderately Obese Females|Completed||Phase 3|20|Actual|Canadian Center for Functional Medicine||2|||f||||||||||||||2018-05-31 23:52:10.786221|2018-05-31 23:52:10.786221
NCT01109186|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-11-16|2010-04-22|2010-04-23|Estimate|||||||2012-11-16|2012-11-19|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|BKv||Anti-BK Virus Immune Response and Kidney Transplantation|Role of Specific Immune Cellular Response in the Control of BK Virus Infection: Prospective Study, Monocentric and Longitudinal During the First Nine Months After a Kidney Transplantation|Unknown status|Recruiting||120|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 23:52:10.869882|2018-05-31 23:52:10.869882
NCT01109173|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2012-11-01|2012-07-17|2012-11-29|2010-04-22|2010-04-23|Estimate|2012-11-29|2012-11-30|Estimate|2012-07-17|2012-07-25|Estimate|2012-11-29|2012-11-30|Estimate|June 2010||2010-06-30|November 2012|2012-11-30||||May 2011|Actual|2011-05-31||Interventional|||Confirmatory Study Nepafenac 0.3%|Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery|Completed||Phase 3|2120|Actual|Alcon Research|This study excluded patients who were under the age of 18, had uncontrolled glaucoma, were at risk of developing macular edema (eg, diabetic retinopathy), or of childbearing potential. Therefore, results may not be generalizable to these populations.|4|||f||||f||||||||||2018-05-31 23:52:10.958212|2018-05-31 23:52:10.958212
NCT01109147|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2013-08-29||2014-03-03|2010-04-22|2010-04-23|Estimate|2014-03-03|2014-04-09|Estimate||||2014-03-03|2014-04-09|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional||The number of participants was calculated as an estimation, due to no previous known results in this field of research.|Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients|Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients During Emotional Tasks and With Reference to Controls|Completed||Phase 4|67|Actual|Qualissima||3|||f||||f||||||||||2018-05-31 23:52:12.423431|2018-05-31 23:52:12.423431
NCT01109134|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-04-21|2010-04-21|2010-04-22|Estimate|||||||2010-04-21|2010-04-22|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|||Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients|Prospective Randomized Controlled Clinical Study to Compare Tirofiban Intracoronary Bolus-Only vs Intravenous Bolus Plus Infusion in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Completed||Phase 3|49|Actual|Kosuyolu Heart Hospital||2|||f||||t||||||||||2018-05-31 23:52:12.720426|2018-05-31 23:52:12.720426
NCT01109121|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2011-01-05|2010-04-21|2010-04-22|Estimate|||||||2011-01-05|2011-01-06|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Tranilast Plus Allopurinol in Patients With Moderate to Severe Gout (TAnGO)|A Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Tranilast in Combination With Allopurinol in Patients With Moderate to Severe Gout (TAnGO)|Completed||Phase 2|112|Actual|Nuon Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 23:52:12.818017|2018-05-31 23:52:12.818017
NCT01109108|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2017-01-25||2017-01-25|2010-04-21|2010-04-22|Estimate|2017-01-25|2017-03-14|Actual||||2017-01-25|2017-03-14|Actual|April 2010||2010-04-30|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage|Streptococcus Pneumonia: Herd Effects and Emergence of Potentially Virulent Serotypes PCV13_Impact of NP Colonization, Herd Effects and Emergence of Potentially Virulent Serotypes of Pneumococci|Completed|||9000|Actual|Boston Medical Center|||2||f||||f||||||Samples With DNA|"~     NP specimens and bacterial isolates of S. pneuomoniae and nontypable Haemophilus~   "|||2018-05-31 23:52:12.992206|2018-05-31 23:52:12.992206
NCT01109095|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2018-03-09|2010-04-21|2010-04-22|Estimate|||||||2018-03-09|2018-03-13|Actual|October 2010||2010-10-31|March 2018|2018-03-31|November 2028|Anticipated|2028-11-30|June 2014|Actual|2014-06-30||Interventional|HERT-GBM||CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM|Administration of HER2 Chimeric Antigen Receptor Expressing CMV-Specific Cytotoxic T Cells Ins Patients With Glioblastoma Multiforme (HERT-GBM)|Active, not recruiting||Phase 1|16|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 23:52:13.59417|2018-05-31 23:52:13.59417
NCT01109082|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-03-18|2010-04-21|2010-04-22|Estimate|||||||2013-03-18|2013-03-19|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Gait and Postural Stability Assessment in Children With Idiopathic Scoliosis Undergoing Posterior Spine Instrumentation|Gait and Postural Stability Assessment in Children With Idiopathic Scoliosis Undergoing Posterior Spine Instrumentation|Completed|||42|Actual|Shriners Hospitals for Children|||1||f||||t||||||||||2018-05-31 23:52:13.687947|2018-05-31 23:52:13.687947
NCT01109069|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-04-03|2010-04-21|2010-04-22|Estimate|||||||2018-04-03|2018-04-04|Actual|June 2010||2010-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia|A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia.|Enrolling by invitation||Phase 2|200|Anticipated|Pharmacyclics LLC.||1|||f||||f||||||||||2018-05-31 23:52:13.798584|2018-05-31 23:52:13.798584
NCT01109056|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2012-05-22||2012-05-22|2010-04-21|2010-04-22|Estimate|2012-05-22|2012-06-25|Estimate||||2012-05-22|2012-06-25|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium||Completed||Phase 2|115|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:52:13.928503|2018-05-31 23:52:13.928503
NCT01109043|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2014-07-30|2010-04-21|2010-04-22|Estimate|||||||2014-07-30|2014-07-31|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart Rate|b. p. m Study (Beats Per Minute): Heart Rate Development Whilst Treating Patients With Hypertension With Concor or Concor Plus|Completed|||351|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:52:14.265657|2018-05-31 23:52:14.265657
NCT01109030|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-17|||2012-05-08|2010-04-21|2010-04-22|Estimate|||||||2012-05-08|2012-05-09|Estimate|April 2010||2010-04-30|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder|Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder|Completed||Phase 2/Phase 3|50|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:52:14.350988|2018-05-31 23:52:14.350988
NCT01109017|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2015-01-07|2010-04-21|2010-04-22|Estimate|||||||2015-01-07|2015-01-08|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency|A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Long-term Safety and Efficacy of Norditropin® Formulation in Patients With AGHD|Completed|||387|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 23:52:14.452977|2018-05-31 23:52:14.452977
NCT01109004|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2018-03-27|2010-04-21|2010-04-22|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2010|Actual|2010-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|January 15, 2017|Actual|2017-01-15||Interventional|||Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)|A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients With Multiple Myeloma (BMT CTN 0702)|Active, not recruiting||Phase 3|758|Actual|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 23:52:14.612428|2018-05-31 23:52:14.612428
NCT01108991|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2015-12-24|2010-04-21|2010-04-22|Estimate|||||||2015-12-24|2015-12-29|Estimate|April 2010||2010-04-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|COPD-SMART||Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD|Randomized Trial of Physical Activity Self-Management Intervention for Patients With COPD|Completed||N/A|325|Actual|The University of Texas Health Science Center at Tyler||2|||f||||t||||||||||2018-05-31 23:52:14.839309|2018-05-31 23:52:14.839309
NCT01108978|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2011-06-07|2010-04-21|2010-04-22|Estimate|||||||2011-06-07|2011-06-09|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease|Phase IV Study for Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease|Terminated||Phase 4|60|Anticipated|Nang Kuang Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 23:52:15.051753|2018-05-31 23:52:15.051753
NCT01108965|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2016-05-25|2010-04-21|2010-04-22|Estimate|||||||2016-05-25|2016-05-27|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Study of Shunt Flow Sensor Accuracy in Extra-ventricular Drains.|A Flow Monitor for Pediatric Hydrocephalic Shunts|Completed|||16|Actual|Transonic Systems Inc.|||1||f||||f||||||Samples With DNA|"~     Cerebrospinal fluid samples are to be retained~   "|||2018-05-31 23:52:15.150606|2018-05-31 23:52:15.150606
NCT01108952|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-04-21|2010-04-21|2010-04-22|Estimate|||||||2010-04-21|2010-04-22|Estimate|January 2011||2011-01-31|April 2010|2010-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Impact of Chemotherapy on Memory Function and the Development of Traumatic Symptoms in Children With Cancer|The Impact of Chemotherapy on Memory Function and the Development of Traumatic Symptoms in Children With Cancer|Unknown status|Not yet recruiting||45|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 23:52:15.235662|2018-05-31 23:52:15.235662
NCT01108939|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-06-06|2010-04-21|2010-04-22|Estimate|||||||2013-06-06|2013-06-07|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||Study of Iron Absorption and Utilization in Asymptomatic Malaria|The Effect of Asymptomatic Malaria on Iron Absorption and Utilization From a Sorghum-based Meal in Adult Women in Benin|Completed||Early Phase 1|23|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 23:52:15.314769|2018-05-31 23:52:15.314769
NCT01108926|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-10-29|2010-04-21|2010-04-22|Estimate|||||||2010-10-29|2010-11-01|Estimate|June 2010||2010-06-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers|Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Efavirenz Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers|Completed||Phase 1|19|Actual|St Stephens Aids Trust||1|||f||||f||||||||||2018-05-31 23:52:15.425536|2018-05-31 23:52:15.425536
NCT01108913|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2011-05-06|2010-04-21|2010-04-22|Estimate|||||||2011-05-06|2011-05-09|Estimate||||May 2011|2011-05-31||||||||Interventional|||Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Phase II Study to Evaluate the Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe COPD|Completed||Phase 2|60|Anticipated|Revotar Biopharmaceuticals AG||2|||f||||||||||||||2018-05-31 23:52:15.544862|2018-05-31 23:52:15.544862
NCT01108900|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2011-12-16|2010-04-21|2010-04-22|Estimate|||||||2011-12-16|2011-12-20|Estimate|July 2010||2010-07-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|SURE||A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil|Non-Interventional, Prospective Study Of the Evaluation Of Patients Population With ED, Treated With Sildenafil|Completed|||100|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:52:15.613872|2018-05-31 23:52:15.613872
NCT01108887|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-09-16|2010-04-21|2010-04-22|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|SMART||An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.|Assessment of Adherence, Effectiveness & Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.|Completed|||912|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:52:15.686192|2018-05-31 23:52:15.686192
NCT01108874|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-09-30|2010-04-21|2010-04-22|Estimate|||||||2010-09-30|2010-10-01|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Cesarean Section|Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Elective Cesarean Section|Completed||Phase 2|48|Anticipated|Federal University of São Paulo|||||f||||||||||||||2018-05-31 23:52:15.76281|2018-05-31 23:52:15.76281
NCT01108861|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2014-09-01|2010-04-21|2010-04-22|Estimate|||||||2014-09-01|2014-09-03|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|RELINE||GORE VIABAHN® Versus Plain Old Balloon Angioplasty (POBA) for Superficial Femoral Artery (SFA) In-Stent Restenosis|The GORE VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Versus Plain Old Balloon Angioplasty (POBA) for the Treatment of Superficial Femoral Artery (SFA) In-Stent Restenosis|Completed||Phase 4|100|Actual|Flanders Medical Research Program||2|||f||||f||||||||||2018-05-31 23:52:15.852349|2018-05-31 23:52:15.852349
NCT01108848|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-06-05|2010-04-21|2010-04-22|Estimate|||||||2014-06-05|2014-06-09|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Patient Registry Study of Berinert® in Normal Clinical Practice|Patient Registry for Berinert®, a C1-Esterase Inhibitor|Completed|||318|Actual|CSL Behring|||1||f||||f||||||||||2018-05-31 23:52:15.964379|2018-05-31 23:52:15.964379
NCT01108835|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2016-07-21||2017-07-21|2010-04-21|2010-04-22|Estimate|2017-02-12|2017-03-30|Actual||||2017-07-21|2017-08-23|Actual|April 2010||2010-04-30|July 2017|2017-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease|A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|180|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 23:52:16.147349|2018-05-31 23:52:16.147349
NCT01108822|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2011-06-30|2010-04-21|2010-04-22|Estimate|||||||2011-06-30|2011-07-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:52:16.459539|2018-05-31 23:52:16.459539
NCT01108809|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2012-07-04||2014-02-28|2010-04-21|2010-04-22|Estimate|2012-09-21|2012-09-24|Estimate||||2014-02-28|2014-03-28|Estimate|April 2010||2010-04-30|February 2014|2014-02-28||||January 2011|Actual|2011-01-31||Observational|||Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients|Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg; 80/25 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients|Completed|||295|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:52:16.543656|2018-05-31 23:52:16.543656
NCT01108627|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2012-05-02|2010-04-20|2010-04-22|Estimate|||||||2012-05-02|2012-05-04|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists||Terminated||Phase 4|4|Actual|Nemours Children's Clinic||2|||f||||t||||||||||2018-05-31 23:52:19.545281|2018-05-31 23:52:19.545281
NCT01108796|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2011-09-01||2014-02-28|2010-04-21|2010-04-22|Estimate|2011-11-25|2011-12-30|Estimate||||2014-02-28|2014-04-10|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan|Additional Effect of a Life Style Program on Antihypertensive Treatment With Telmisartan|Completed|||1856|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:52:16.981105|2018-05-31 23:52:16.981105
NCT01108783|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-04-04|2010-04-21|2010-04-22|Estimate|||||||2012-04-04|2012-04-05|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|February 2004|Actual|2004-02-29|August 2003|Actual|2003-08-31||Interventional|||A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine|Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 3|720|Actual|Faes Farma, S.A.||3|||f||||f||||||||||2018-05-31 23:52:17.81613|2018-05-31 23:52:17.81613
NCT01108770|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2012-08-20|2010-04-21|2010-04-22|Estimate|||||||2012-08-20|2012-08-21|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Observational|||Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia|Evaluation of Phenotypic and Genetic Properties in Male Subjects With Hypohidrotic Ectodermal Dysplasia and Their Family Members|Completed|||62|Actual|Edimer Pharmaceuticals|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 23:52:17.962962|2018-05-31 23:52:17.962962
NCT01108757|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|2017-01-11||2017-10-17|2010-04-21|2010-04-22|Estimate|2017-10-17|2017-10-18|Actual||||2017-10-17|2017-10-18|Actual|April 2010||2010-04-30|October 2017|2017-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|PRECAUTION||Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients|Prevention of Catheter-Associated Urinary Tract Infections in Patients Undergoing Incontinence and Reconstructive Pelvic Surgery: A Randomized Controlled Trial|Terminated||N/A|52|Actual|The Cleveland Clinic||2||Unfeasible because of low accrual|f||||f||||||||||2018-05-31 23:52:18.047377|2018-05-31 23:52:18.047377
NCT01108744|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-03-14|2010-04-21|2010-04-22|Estimate|||||||2017-03-14|2017-03-16|Actual|January 2012||2012-01-31|March 2017|2017-03-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).|Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center||2||Timeline to consent prior to intervention start was unfeasible.|f||||t||||||||No||2018-05-31 23:52:18.262286|2018-05-31 23:52:18.262286
NCT01108731|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2014-07-07||2016-05-31|2010-04-21|2010-04-22|Estimate|2014-10-13|2014-10-15|Estimate||||2016-05-31|2016-06-30|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Had to report widespread pain and to have at least 11 of 18 tender points [rated on a 0 to 10 pain intensity scale at 2 or higher].|The Effect of Milnacipran in Patients With Fibromyalgia|"The Effect of Milnacipran or Placebo on Ventricular Lactate Levels and Fibromyalgia Induced Brain Fog."|Completed||Phase 2/Phase 3|37|Actual|Beth Israel Medical Center||2|||f||||f||||||||No||2018-05-31 23:52:18.389523|2018-05-31 23:52:18.389523
NCT01108718|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2012-02-03||2017-01-30|2010-04-21|2010-04-22|Estimate|2013-04-25|2013-05-31|Estimate||||2017-01-30|2017-03-10|Actual|July 2009||2009-07-31|January 2017|2017-01-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Study of Mattress Type in Fibromyalgia|Study of Mattress Type in Fibromyalgia|Completed||N/A|12|Actual|Beth Israel Medical Center||2|||f||||f||||||||No||2018-05-31 23:52:18.698523|2018-05-31 23:52:18.698523
NCT01108705|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15||2015-09-23|2015-09-23|2010-04-21|2010-04-22|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|May 2010||2010-05-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|BRISK-APS||Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment|A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib|Terminated||Phase 3|87|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 23:52:18.898328|2018-05-31 23:52:18.898328
NCT01108692|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2013-12-05|2010-04-21|2010-04-22|Estimate|||||||2013-12-05|2013-12-06|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|SETAM||Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM)|Investigation on Early Detection and Active Management of Supra-ventricular Arrhythmia With Telecardiology|Completed||N/A|602|Actual|Biotronik France||2|||f||||t||||||||||2018-05-31 23:52:18.996819|2018-05-31 23:52:18.996819
NCT01108679|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-21|||2010-05-06|2010-04-21|2010-04-22|Estimate|||||||2010-05-06|2010-05-07|Estimate|December 2009||2009-12-31|April 2010|2010-04-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users|Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users|Unknown status|Recruiting||100|Anticipated|Albert Einstein College of Medicine, Inc.|||1||f||||t||||||Samples With DNA|"~     Whole blood, Urine~   "|||2018-05-31 23:52:19.221567|2018-05-31 23:52:19.221567
NCT01108666|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2016-07-15|2010-04-21|2010-04-22|Estimate|||||||2016-07-15|2016-07-18|Estimate|March 2010||2010-03-31|July 2016|2016-07-31||||August 2014|Actual|2014-08-31||Interventional|||Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)|Phase I Dose Escalation Trial of Proton Beam Radiotherapy With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III NSCLC|Active, not recruiting||Phase 1|72|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 23:52:19.302382|2018-05-31 23:52:19.302382
NCT01108653|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-05-06|2010-04-20|2010-04-22|Estimate|||||||2010-05-06|2010-05-07|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Structuralised Sick-leave Program Compared to Usual Care Sick Leave Management in Patients After an Acute Myocardial Infarction|A Structuralised Sick-leave Program Compared to Usual Care Sick Leave Management in Patients After an Acute Myocardial Infarction|Unknown status|Recruiting|N/A|120|Anticipated|Oslo University Hospital||2|||f||||||||||||||2018-05-31 23:52:19.383914|2018-05-31 23:52:19.383914
NCT01108640|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2014-06-13|2010-04-21|2010-04-22|Estimate|||||||2014-06-13|2014-06-16|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Continuous Glucose Monitoring in Critically Ill Surgical Patients|Continuous Glucose Monitoring in Critically Ill Surgical Patients|Completed|||24|Actual|Yale University|||3||f||||f||||||||||2018-05-31 23:52:19.468973|2018-05-31 23:52:19.468973
NCT01108614|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2010-05-06|2010-04-20|2010-04-22|Estimate|||||||2010-05-06|2010-05-07|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Injecting Drug Use Community Intervention Trial|A Randomized Community Intervention Trial on Reducing HIV Infection Among Drug Users Attending Methadone Maintenance Treatment(MMT) and Preventing Secondary Transmission From HIV Positive Clients to Their Sexual Partners in China|Unknown status|Recruiting|Phase 3|12000|Anticipated|National Center for AIDS/STD Control and Prevention, China CDC||2|||f||||t||||||||||2018-05-31 23:52:19.631216|2018-05-31 23:52:19.631216
NCT01108601|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-20|2010-04-20|2010-04-22|Estimate|||||||2010-04-20|2010-04-22|Estimate|April 2008||2008-04-30|April 2010|2010-04-30||||April 2011|Anticipated|2011-04-30||Interventional|||Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity|Transtympanic Administration of Lactate: An Innovative Otoprotection for Patients Receiving Cisplatin or Carboplatin Chemotherapy|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|McGill University Health Center||1|||f||||f||||||||||2018-05-31 23:52:19.776469|2018-05-31 23:52:19.776469
NCT01108588|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2015-08-11|2010-04-20|2010-04-22|Estimate|||||||2015-08-11|2015-08-13|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)|A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study Using Aspirin and Clopidogrel to Assess Reproducibility and Compare Platelet Function Assays|Completed||Phase 1|15|Anticipated|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 23:52:19.85596|2018-05-31 23:52:19.85596
NCT01108575|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2013-12-10|2010-04-21|2010-04-22|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Inspiratory Muscle Training on Duration of Mechanical Ventilation Support|Inspiratory Muscle Strength Training in Ventilator Dependent Patients|Completed||Phase 1/Phase 2|76|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 23:52:19.938519|2018-05-31 23:52:19.938519
NCT01108562|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2015-04-02|2010-04-20|2010-04-22|Estimate|||||||2015-04-02|2015-04-06|Estimate|February 2008||2008-02-29|April 2015|2015-04-30||||August 2008|Anticipated|2008-08-31||Interventional|||Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion|Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion in Combination With Patient Controlled Analgesia: a Prospective Randomized, Double-blinded, Placebo-controlled Study|Withdrawn||Phase 1/Phase 2|0|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 23:52:20.009299|2018-05-31 23:52:20.009299
NCT01108549|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2010-04-20|2010-04-20|2010-04-22|Estimate|||||||2010-04-20|2010-04-22|Estimate|April 2009||2009-04-30|April 2010|2010-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study|Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study|Completed||N/A|257|Actual|Kona Research Center|||||f||||f||||||||||2018-05-31 23:52:20.089704|2018-05-31 23:52:20.089704
NCT01108536|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2012-07-30|2010-04-21|2010-04-22|Estimate|||||||2012-07-30|2012-08-01|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|August 2012|Anticipated|2012-08-31|June 2012|Actual|2012-06-30||Interventional|SMARTsocket-||Dynamic Management of Excess Residual Limb Pressure With New Smart Socket Technology/Intelligent Prosthetic Socket With Variable Volume and Elevated Vacuum Systems|Dynamic Management of Excess Residual Limb Pressure With New Smart Socket Technology/Intelligent Amputee Sockets Employing Real Time Advanced Photonic Sensors for Optimum Fit and Pressure Relief Through Active Controls/Intelligent Prosthetic Socket With Variable Volume and Elevated Vacuum Systems|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Wisconsin, Milwaukee||1|||f||||t||||||||||2018-05-31 23:52:20.174571|2018-05-31 23:52:20.174571
NCT01108523|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2013-10-09||2013-10-09|2010-04-21|2010-04-22|Estimate|2013-10-09|2013-12-06|Estimate||||2013-10-09|2013-12-06|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|February 2012|Actual|2012-02-29|July 2010|Actual|2010-07-31||Interventional|||Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage|Open Label Evaluation of the Effects of HP828-101 in the Management of Moisture Associated Skin Damage in Adults|Terminated||Early Phase 1|7|Actual|Healthpoint||1||Business decision|f||||f||||||||||2018-05-31 23:52:20.265985|2018-05-31 23:52:20.265985
NCT01108510|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2014-10-23|2011-08-23|2016-04-15|2010-04-20|2010-04-22|Estimate|2014-10-23|2014-10-28|Estimate|2011-08-23|2011-08-25|Estimate|2016-04-15|2016-05-23|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|November 2011|Actual|2011-11-30||Interventional||Safety Analysis Set: participants who were randomized and received at least on dose of study drug|Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Completed||Phase 3|698|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t||||||||||2018-05-31 23:52:20.508698|2018-05-31 23:52:20.508698
NCT01108497|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2016-06-22|2010-04-21|2010-04-22|Estimate|||||||2016-06-22|2016-06-24|Estimate|July 2001||2001-07-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia|Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia|Terminated|||235|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     bone marrow~   "|||2018-05-31 23:52:22.109698|2018-05-31 23:52:22.109698
NCT01108484|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2016-05-14|2010-04-20|2010-04-22|Estimate|||||||2016-05-14|2016-05-17|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|EDICOS||Program of Exercise, Diet and Control of Psychological Stress in Cancer Survivors|Evaluation of the Effects of Exercise, Diet and Control of Psychological Stress in Cancer Survivors|Completed||Phase 3|120|Actual|Grupo de Investigación en Actividad Física y Salud||4|||f||||t||||||||||2018-05-31 23:52:22.276632|2018-05-31 23:52:22.276632
NCT01108471|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2011-08-25|2010-04-21|2010-04-22|Estimate|||||||2011-08-25|2011-08-26|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|||Non-Invasive Measurement of Hemoglobin (Using Pulse Co-Oximetry) in Patients Undergoing Elective Cesarean Delivery|Study Comparing Non-Invasive Measurement of Hemoglobin (Using Pulse Co-Oximetry) With Laboratory Measurement in Patients Undergoing Elective Cesarean Delivery|Completed|||50|Actual|Stanford University|||||f||||f||||||||||2018-05-31 23:52:22.387102|2018-05-31 23:52:22.387102
NCT01108458|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2017-01-12||2017-01-12|2010-04-21|2010-04-22|Estimate|2017-01-12|2017-03-03|Actual||||2017-01-12|2017-03-03|Actual|July 2010||2010-07-31|January 2017|2017-01-31|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|||A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma|A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma|Terminated||Phase 2|1|Actual|Stanford University||1||Extreme toxicity of Pertuzumab and Erlotinib combination|f||||t||||||||No||2018-05-31 23:52:22.499091|2018-05-31 23:52:22.499091
NCT01108445|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2016-02-16||2017-12-15|2010-04-20|2010-04-22|Estimate|2016-05-11|2016-06-20|Estimate||||2017-12-15|2018-01-16|Actual|September 2010||2010-09-30|September 2017|2017-09-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|ASPEN||Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma|A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)|Completed||Phase 2|131|Actual|Duke University||2|||f||||t||||||||||2018-05-31 23:52:22.998172|2018-05-31 23:52:22.998172
NCT01108432|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2013-01-24|2010-04-20|2010-04-22|Estimate|||||||2013-01-24|2013-01-25|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|HiQuit||DPBRN Hygienists Internet Quality Improvement in Tobacco Cessation (HiQuit)|Hygienists Internet Tobacco Cessation Study (HiQuit)|Completed||Early Phase 1|80|Actual|Dental Practice-Based Research Network||2|||f||||t||||||||||2018-05-31 23:52:24.400524|2018-05-31 23:52:24.400524
NCT01108419|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2017-01-05|2010-04-20|2010-04-22|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2010||2010-03-31|January 2017|2017-01-31|June 2012|Actual|2012-06-30|June 2010|Actual|2010-06-30||Interventional|||Evaluation of Dose-effect of a New Fermented Food in Healthy Adults|Evaluation of the Safety and Tolerance of a New Fermented Food in Healthy Adults|Completed||N/A|96|Actual|Danone Research||4|||f||||||||||||||2018-05-31 23:52:24.469175|2018-05-31 23:52:24.469175
NCT01108406|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2013-06-01||2014-10-10|2010-04-20|2010-04-22|Estimate|2014-10-07|2014-10-10|Estimate||||2014-10-10|2014-10-20|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Long Term Safety of the Sonitus SoundBite System|Long Term Safety of the Sonitus SoundBite System|Completed||N/A|22|Actual|Sonitus Medical Inc||1|||f||||t||||||||||2018-05-31 23:52:24.571436|2018-05-31 23:52:24.571436
NCT01108393|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2018-04-10|2010-04-21|2010-04-22|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2010||2010-05-31|April 2018|2018-04-30|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional|||Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder|Efficacy of Agomelatine 25mg/Day (With Possible Increase to 50mg/Day After 8 Weeks of Treatment) Given Orally During 16 Weeks in Patients With Obsessive-Compulsive Disorder. A Randomised, Double-blind, Placebo-controlled, Parallel Groups, International Study|Completed||Phase 2|74|Actual|Servier||2|||f||||f||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies in patients:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 23:52:24.775757|2018-05-31 23:52:24.775757
NCT01108380|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2010-12-14|2010-04-21|2010-04-22|Estimate|||||||2010-12-14|2010-12-15|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells|Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells Transplantation in the Patient Needed Extensive Hepatectomy|Unknown status|Recruiting|N/A|30|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 23:52:24.842976|2018-05-31 23:52:24.842976
NCT01108367|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2011-05-09|2010-04-21|2010-04-22|Estimate|||||||2011-05-09|2011-05-10|Estimate|November 2009||2009-11-30|May 2011|2011-05-31||||March 2010|Actual|2010-03-31||Observational|||Transient Urinary Incontinence After Holmium Laser Enucleation of the Prostate (HoLEP)|Predictor of Transient Urinary Incontinence Following Holmium Laser Enucleation of the Prostate|Completed|||204|Actual|Seoul National University Hospital|||||f||||||||||||||2018-05-31 23:52:24.988474|2018-05-31 23:52:24.988474
NCT01108354|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2014-01-02|2010-04-21|2010-04-22|Estimate|||||||2014-01-02|2014-01-03|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||The Serotonin Transporter in Attention Deficit Hyperactivity Disorder|The Serotonin Transporter in Attention Deficit Hyperactivity Disorder Investigated With Positron Emission Tomography|Completed|||44|Actual|Medical University of Vienna|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 23:52:25.033551|2018-05-31 23:52:25.033551
NCT01108341|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2012-07-24||2012-07-24|2010-04-20|2010-04-22|Estimate|2012-07-24|2012-08-28|Estimate||||2012-07-24|2012-08-28|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)|An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 2|50|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 23:52:25.150194|2018-05-31 23:52:25.150194
NCT01108328|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2015-09-30|2010-04-20|2010-04-22|Estimate|||||||2015-09-30|2015-10-02|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Evaluation of Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX)|A Prospective, Single Crossover, Randomized, Double Blind Placebo Controlled Trial Evaluating Subjective Ratings of Appetite and Glucoregulation of a Low Calorie Diet Supplemented With a High Viscosity Polysaccharide (PolyGlycopleX - PGX) vs. Rice Flour Control, in Overweight and Moderately Obese Females.|Completed||Phase 3|35|Actual|Canadian Center for Functional Medicine||2|||f||||||||||||||2018-05-31 23:52:26.95791|2018-05-31 23:52:26.95791
NCT01108315|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-02-02|2010-04-20|2010-04-22|Estimate|||||||2012-02-02|2012-02-06|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice|Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice|Completed||Phase 1/Phase 2|138|Actual|BrightOutcome||2|||f||||f||||||||||2018-05-31 23:52:27.168902|2018-05-31 23:52:27.168902
NCT01108302|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2012-01-06|2010-04-20|2010-04-21|Estimate|||||||2012-01-06|2012-01-09|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India|Assessing the Effectiveness, Safety and Feasibility of Expanding Use of Oxytocin in Uniject™ by Auxiliary Nurse Midwives to Prevent Postpartum Hemorrhage: A Community-based Cluster Randomized Trial in Bagalkot, India|Withdrawn||N/A|0|Actual|Johns Hopkins Bloomberg School of Public Health||2||PATH withdrew IRB approval|f||||t||||||||||2018-05-31 23:52:27.329964|2018-05-31 23:52:27.329964
NCT00943332|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2015-06-10|2009-07-21|2009-07-22|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|December 2014|Actual|2014-12-31||Observational|||Pediatric Femur Research Project|Pediatric Femur Research Project|Unknown status|Active, not recruiting||145|Anticipated|Washington University School of Medicine|||3||f||||f||||||||||2018-06-01 00:46:16.252554|2018-06-01 00:46:16.252554
NCT01108289|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2013-07-01|2010-04-20|2010-04-21|Estimate|||||||2013-07-01|2013-07-02|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Prophylactic Administration of Oxytocin in Uniject™ on Postpartum Hemorrhage at Home Births in Ghana|The Oxytocin Initiative: Determining the Effect of Prophylactic Administration of Oxytocin in Uniject™ by a Community Health Officer on Postpartum Hemorrhage at Home Births in Four Districts in Ghana|Completed||N/A|1586|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 23:52:27.516704|2018-05-31 23:52:27.516704
NCT01108276|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-03-08|2010-04-20|2010-04-21|Estimate|||||||2012-03-08|2012-03-09|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|November 2011|Anticipated|2011-11-30|May 2011|Anticipated|2011-05-31||Interventional|||Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy Device to Moist Wound Therapy|A Prospective, Randomized, Controlled Study Comparing the Efficacy of the ConvaTec Engenex® Negative Pressure Wound Therapy (NPWT) Device to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Wounds|Withdrawn||Phase 4|0|Actual|Georgetown University||||Study never started and therefore terminated.|f||||f||||||||||2018-05-31 23:52:27.864679|2018-05-31 23:52:27.864679
NCT01108263|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2013-07-01||2014-02-03|2010-04-20|2010-04-21|Estimate|2014-02-03|2014-03-17|Estimate||||2014-02-03|2014-03-17|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers|The Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers in High Risk Populations: A Prospective, Randomized, Controlled Trial|Terminated||Phase 4|5|Actual|Georgetown University||2||Sponsor Terminated|f||||f||||||||||2018-05-31 23:52:28.249346|2018-05-31 23:52:28.249346
NCT01108250|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-08-28|2010-04-20|2010-04-21|Estimate|||||||2011-08-28|2011-08-30|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|PCV||LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population|LOC387715/HTRA1 Variants in Polypoidal Choroidal Vasculopathy in a Korean Population|Completed||N/A|215|Actual|Kyungpook National University||2|||f||||t||||||||||2018-05-31 23:52:29.142197|2018-05-31 23:52:29.142197
NCT01108237|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2012-03-27||2013-12-18|2010-04-20|2010-04-21|Estimate|2012-04-19|2012-05-21|Estimate||||2013-12-18|2014-01-24|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Alignment Comparison Between TruMatch™ Personalized Solutions and Conventional Total Knee Replacement Instrumentation|Comparison of In Vivo Alignment With TruMatch™ Personalized Solutions Compared to Conventional Instrumentation in Total Knee Replacement (TKR)|Completed||N/A|78|Actual|DePuy Orthopaedics||2|||f||||f||||||||||2018-05-31 23:52:29.30948|2018-05-31 23:52:29.30948
NCT01108224|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-04-20|2010-04-20|2010-04-21|Estimate|||||||2010-04-20|2010-04-21|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Psychotherapy to Patients With Primary Breast Cancer - Psycho-social and Survival Outcome From a Randomised Trial|Psychosocial Group Intervention to Patients With Primary Breast Cancer - Psychosocial and Survival Outcome From a Randomised Study|Completed||N/A|210|Actual|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 23:52:30.404851|2018-05-31 23:52:30.404851
NCT01108211|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2015-07-28|2010-04-20|2010-04-21|Estimate|||||||2015-07-28|2015-07-29|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Improving Low Bone Mass With Vibration Therapy in Adolescent Idiopathic Scoliosis (AIS)|Improving Low Bone Mass With Vibration Therapy for Girls With Adolescent Idiopathic Scoliosis (AIS) - A Randomized Controlled Trial|Completed||Phase 3|149|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 23:52:30.646996|2018-05-31 23:52:30.646996
NCT01108198|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2010-04-20|2010-04-20|2010-04-21|Estimate|||||||2010-04-20|2010-04-21|Estimate|October 2006||2006-10-31|April 2010|2010-04-30||||June 2011|Anticipated|2011-06-30||Interventional|||Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study|Treatment of Phimosis With Topical Steroid Cream -Double-blind, Randomized, Placebo-controlled Study in 98 Boys|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Oulu||2|||f||||||||||||||2018-05-31 23:52:30.815976|2018-05-31 23:52:30.815976
NCT01108185|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2011-07-26||2011-09-09|2010-04-20|2010-04-21|Estimate|2011-07-26|2011-08-25|Estimate||||2011-09-09|2011-09-13|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection|Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis or Mild Community-acquired Bronchopneumonia in Common Clinical Practice in the Slovak Republic|Completed|||3181|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:52:31.290461|2018-05-31 23:52:31.290461
NCT01108172|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2013-12-06|2010-04-19|2010-04-21|Estimate|||||||2013-12-06|2013-12-09|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||A Virtual Ward to Reduce Readmissions After Hospital Discharge|A Virtual Ward to Reduce Readmissions After Hospital Discharge|Unknown status|Active, not recruiting|N/A|1928|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 23:52:32.752241|2018-05-31 23:52:32.752241
NCT01108159|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-05-29|2010-04-20|2010-04-21|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 2009||2009-09-30|May 2018|2018-05-31|August 2, 2013|Actual|2013-08-02|August 2, 2013|Actual|2013-08-02||Observational|||Integrated Whole-Genome Analysis of Hematologic Disorders|Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies|Completed|||35|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     blood, bone marrow, skin biopsy~   "|||2018-05-31 23:52:33.090992|2018-05-31 23:52:33.090992
NCT01108146|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-01-29|2010-04-20|2010-04-21|Estimate|||||||2013-01-29|2013-01-30|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Hydrocortisone in the Treatment of Intrusions in Patients With Posttraumatic Stress Disorder|Monocentric, Double-blind Placebo-Controlled, Randomized Cross-Sectional Clinical Trial of Hydrocortisone (10 and 30 mg/d) in Outpatients With Posttraumatic-Stress-Disorder (PTSD)|Completed||N/A|30|Actual|Central Institute of Mental Health, Mannheim||2|||f||||t||||||||||2018-05-31 23:52:33.211755|2018-05-31 23:52:33.211755
NCT01108133|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2017-06-28|2010-04-20|2010-04-21|Estimate|||||||2017-06-28|2017-07-02|Actual|October 2010||2010-10-31|July 2016|2016-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Neural and Pharmacological Correlates of Intrusions in Patients With Posttraumatic Stress Disorder|Neural and Pharmacological Correlates of Intrusions in Patients With Posttraumatic Stress Disorder|Completed||N/A|13|Actual|Central Institute of Mental Health, Mannheim||3|||f||||t||||||||No||2018-05-31 23:52:33.35526|2018-05-31 23:52:33.35526
NCT00938834|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-10-31|2009-07-13|2009-07-14|Estimate|||||||2012-10-31|2012-11-01|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Qigong For Treatment Of Fibromyalgia|A Randomized Controlled Trial Of Qigong For Treatment Of Fibromyalgia|Completed||N/A|100|Actual|Nova Scotia Health Authority||1|||f||||||||||||||2018-06-01 00:47:27.297743|2018-06-01 00:47:27.297743
NCT01108120|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-07-04|2010-04-20|2010-04-21|Estimate|||||||2013-07-04|2013-07-08|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers|The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers|Unknown status|Recruiting|Phase 2|200|Anticipated|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 23:52:33.636783|2018-05-31 23:52:33.636783
NCT01108107|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2015-05-20|2010-04-20|2010-04-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|March 2015|Actual|2015-03-31|September 2013|Actual|2013-09-30||Interventional|||Neoadjuvant Treatment of Colon Cancer|Neoadjuvant Chemotherapy and Biological Treatment for Patients With Locally Advanced Colon Cancer|Completed||Phase 2|76|Actual|Vejle Hospital||2|||f||||t||||||||||2018-05-31 23:52:33.86673|2018-05-31 23:52:33.86673
NCT01108094|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2016-06-30|2010-04-20|2010-04-21|Estimate|||||||2016-06-30|2016-07-01|Estimate|April 2010||2010-04-30|June 2016|2016-06-30|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|||Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas|Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas|Completed||Phase 2|15|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 23:52:34.04908|2018-05-31 23:52:34.04908
NCT01108081|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2016-12-19||2016-12-19|2010-04-20|2010-04-21|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|October 2010||2010-10-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Telemedicine Interventions for Obstructive Sleep Apnea (OSA)|An RCT of Telemedicine Interventions for OSA|Completed||Phase 3|169|Actual|VA Office of Research and Development||4|||f||||f||||||||Undecided||2018-05-31 23:52:34.284594|2018-05-31 23:52:34.284594
NCT01108068|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2017-04-21||2018-04-24|2010-04-20|2010-04-21|Estimate|2018-04-24|2018-04-27|Actual||||2018-04-24|2018-04-27|Actual|July 2010||2010-07-31|April 2018|2018-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All participants were from the Old Order Mennonite community from PA|Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome|Trial of Lithium Carbonate for Treatment of Osteoporosis Pseudoglioma Syndrome|Completed||N/A|26|Actual|University of Maryland||2|||f||||t||||||||No||2018-05-31 23:52:34.876392|2018-05-31 23:52:34.876392
NCT01108055|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2017-01-18||2017-05-08|2010-04-20|2010-04-21|Estimate|2017-05-08|2017-06-09|Actual||||2017-05-08|2017-06-09|Actual|April 2010||2010-04-30|May 2017|2017-05-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|||Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer|A Phase II Study of Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer|Completed||Phase 2|43|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 23:52:35.427959|2018-05-31 23:52:35.427959
NCT01108042|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-05-17|2010-04-20|2010-04-21|Estimate|||||||2016-05-17|2016-05-18|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer|Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer|Completed||Phase 1/Phase 2|71|Actual|University of Jena||1|||f||||t||||||||No||2018-05-31 23:52:37.173847|2018-05-31 23:52:37.173847
NCT01108029|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-03-23|2010-04-20|2010-04-21|Estimate|||||||2012-03-23|2012-03-26|Estimate|October 2009||2009-10-31|July 2009|2009-07-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|FOGG-I||Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease|Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial|Completed||Phase 4|28|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 23:52:37.413927|2018-05-31 23:52:37.413927
NCT01108016|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2010-12-02|2010-04-19|2010-04-21|Estimate|||||||2010-12-02|2010-12-06|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Expanding Rural Access: Distance Delivery of Support Groups (Main Study)|Expanding Rural Access: Distance Delivery of Support Groups (Main Study)|Completed||Phase 3|100|Anticipated|Stanford University|||||f||||||||||||||2018-05-31 23:52:37.570883|2018-05-31 23:52:37.570883
NCT01108003|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2016-05-16||2017-05-31|2010-04-20|2010-04-21|Estimate|2016-05-16|2016-06-23|Estimate||||2017-05-31|2017-06-26|Actual|April 2010||2010-04-30|May 2017|2017-05-31|October 2015|Actual|2015-10-31|September 2014|Actual|2014-09-30||Interventional||All treated and eligible patients|Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery|Pilot Pre-cystectomy Trial of Broccoli Extract in Patients With Superficial or Locally Advanced Bladder Cancer|Terminated||N/A|7|Actual|Roswell Park Cancer Institute|Due to the study's early termination and low accrual, data were not collected for all study objectives assessment.|2||low accrual|f||||t||||||||||2018-05-31 23:52:37.693396|2018-05-31 23:52:37.693396
NCT01107990|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2010-04-20|2010-04-20|2010-04-21|Estimate|||||||2010-04-20|2010-04-21|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|January 2011|Anticipated|2011-01-31|October 2010|Anticipated|2010-10-31||Observational|||Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques|Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques|Unknown status|Recruiting||30|Anticipated|University of California, San Francisco|||2||f||||t||||||||||2018-05-31 23:52:38.289537|2018-05-31 23:52:38.289537
NCT01107977|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2016-11-23|2010-04-20|2010-04-21|Estimate|||||||2016-11-23|2016-11-28|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Iyengar Yoga for Young People With Irritable Bowel Syndrome|Iyengar Yoga for Young People With Irritable Bowel Syndrome|Completed||N/A|58|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:52:38.408646|2018-05-31 23:52:38.408646
NCT01107964|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2017-10-17||2017-11-29|2010-04-20|2010-04-21|Estimate|2017-11-29|2017-12-22|Actual||||2017-11-29|2017-12-22|Actual|July 2010||2010-07-31|November 2017|2017-11-30|June 15, 2015|Actual|2015-06-15|August 2014|Actual|2014-08-31||Interventional|||Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome|Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome|Completed||N/A|27|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 23:52:38.874455|2018-05-31 23:52:38.874455
NCT01107951|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-03-21|2010-04-20|2010-04-21|Estimate|||||||2013-03-21|2013-03-22|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|April 2010|Actual|2010-04-30||Interventional|||Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP|Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for Adult Patients With Immune Thrombocytopenic Purpura.|Completed||Phase 2|21|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||f||||||||||2018-05-31 23:52:39.420284|2018-05-31 23:52:39.420284
NCT01106261|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-05-23|2010-04-16|2010-04-19|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2010|Actual|2010-04-30|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|PulMiCC||A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer|A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer|Active, not recruiting||N/A|93|Actual|University College, London||2|||f||||t||||||||||2018-05-31 23:53:25.51818|2018-05-31 23:53:25.51818
NCT01107938|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-20|2010-04-20|2010-04-21|Estimate|||||||2010-04-20|2010-04-21|Estimate|May 2010||2010-05-31|April 2010|2010-04-30||||June 2010|Anticipated|2010-06-30||Interventional|||Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients|Efficacy and Safety of Ilaprazole for GERD: A Randomized,Double-Blind, Esomeprazole-Controlled,Phase2,Multicenter Trial in China|Unknown status|Not yet recruiting|Phase 2|330|Anticipated|Livzon Pharmaceutical Group Inc.||3|||f||||t||||||||||2018-05-31 23:52:39.495557|2018-05-31 23:52:39.495557
NCT01107925|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2012-07-27||2012-07-27|2010-04-19|2010-04-21|Estimate|2012-07-27|2012-08-30|Estimate||||2012-07-27|2012-08-30|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|FEATHER||Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease|A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease|Completed||Phase 1|72|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:52:39.600644|2018-05-31 23:52:39.600644
NCT01107912|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2012-09-27||2012-09-27|2010-04-19|2010-04-21|Estimate|2012-09-27|2012-10-26|Estimate||||2012-09-27|2012-10-26|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|GENERATIONS||Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease|A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease|Completed||Phase 1|155|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 23:52:40.517307|2018-05-31 23:52:40.517307
NCT01107899|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2011-12-01||2012-03-07|2010-04-19|2010-04-21|Estimate|2011-12-01|2012-01-12|Estimate||||2012-03-07|2012-03-09|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes|Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary Syndromes|Terminated||Phase 1|29|Actual|Eli Lilly and Company|Trial was terminated early due to enrollment futility which resulted in limited data and the inability to analyze some outcome measures.|3||Terminated due to Enrollment futility|f||||f||||||||||2018-05-31 23:52:41.939938|2018-05-31 23:52:41.939938
NCT01107886|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2014-05-15||2014-07-09|2010-04-20|2010-04-21|Estimate|2014-05-15|2014-06-13|Estimate||||2014-07-09|2014-07-17|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SAVOR- TIMI 53||Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications|A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes|Completed||Phase 4|18206|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 23:52:43.317938|2018-05-31 23:52:43.317938
NCT01107873|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-10-06|2010-04-19|2010-04-21|Estimate|||||||2010-10-06|2010-10-07|Estimate|May 2010||2010-05-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Changes of Dorsalis Pedis Artery Flow Pattern After Caudal Block in Children: Observational Study Using a Duplex Sonography||Completed|||20|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 23:52:48.193264|2018-05-31 23:52:48.193264
NCT01107860|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2013-06-14|2010-04-20|2010-04-21|Estimate|||||||2013-06-14|2013-06-18|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||Cone Beam Computed Tomography for Breast Imaging|Cone Beam Computed Tomography for Breast Imaging|Completed|||401|Actual|Koning Corporation|||2||f||||t||||||||||2018-05-31 23:52:48.248662|2018-05-31 23:52:48.248662
NCT01107847|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-20|2010-04-20|2010-04-21|Estimate|||||||2010-04-20|2010-04-21|Estimate||||March 2010|2010-03-31||||||||Interventional|||Regional Lung Opening and Closing Pressures in Patients With Acute Lung Injury|Measurement of Regional Lung Opening and Closing Pressures in Patients With Acute Lung Injury Using Electrical Impedance Tomography|Unknown status|Recruiting|N/A|25|Anticipated|University of Schleswig-Holstein|||||f||||f||||||||||2018-05-31 23:52:48.30454|2018-05-31 23:52:48.30454
NCT01107834|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2013-12-16||2016-06-08|2010-04-19|2010-04-21|Estimate|2016-06-08|2016-07-20|Estimate||||2016-06-08|2016-07-20|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Heart Function in HIV-Negative Children Exposed to HIV and HAART|Left Ventricular Function in HIV-Negative Children Exposed to HIV and HAART In Utero|Completed|||60|Actual|Washington University School of Medicine|||2||f||||t||||||||||2018-05-31 23:52:48.560775|2018-05-31 23:52:48.560775
NCT01107821|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-06-02|2010-04-20|2010-04-21|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation|Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation|Unknown status|Recruiting|Phase 4|15|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 23:52:48.997483|2018-05-31 23:52:48.997483
NCT01107808|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2015-03-09|2010-04-20|2010-04-21|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2009||2009-06-30|March 2011|2011-03-31|March 2011|Anticipated|2011-03-31|September 2010|Anticipated|2010-09-30||Interventional|||Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females|Calcium, Vitamin D and Metformin to Treat Insulin Resistance in Obese African American Adolescent Females.|Withdrawn||N/A|0|Actual|University of Alabama at Birmingham||3||Poor recruitment to the study|f||||f||||||||||2018-05-31 23:52:49.071576|2018-05-31 23:52:49.071576
NCT01107795|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2017-09-01|2010-04-20|2010-04-21|Estimate|||||||2017-09-01|2017-09-05|Actual|March 2010||2010-03-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Prospective Study to Evaluate Outcomes From Trans-oral Base of Tongue Resection for Obstructive Sleep Apnea Hypopnea Syndrome|Prospective Study to Evaluate Outcomes From Trans-oral Base of Tongue Resection for Obstructive Sleep Apnea Hypopnea Syndrome|Recruiting|||75|Anticipated|University of Alabama at Birmingham|||||f||||t||||||||||2018-05-31 23:52:49.158087|2018-05-31 23:52:49.158087
NCT01107782|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2011-02-22|2010-04-20|2010-04-21|Estimate|||||||2011-02-22|2011-02-23|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|January 2012|Anticipated|2012-01-31|June 2010|Anticipated|2010-06-30||Interventional|||Sildenafil and Uteroplacental Perfusion|Phase 2 Study of Fetal Growth Retardation Treatment by Sildenafil|Unknown status|Recruiting|Phase 2/Phase 3|70|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:52:49.2142|2018-05-31 23:52:49.2142
NCT01107769|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2011-11-18|2010-04-20|2010-04-21|Estimate|||||||2011-11-18|2011-11-21|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||VISIONAIRE™ Value Study|A Single-center, Randomized, Value Study of VISIONAIRE™ Patient Matched Technology vs. Standard Surgical Instrumentation|Completed|||38|Actual|Smith & Nephew, Inc.|||2||f||||f||||||||||2018-05-31 23:52:49.369354|2018-05-31 23:52:49.369354
NCT01107756|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2012-10-04|2010-04-20|2010-04-21|Estimate|||||||2012-10-04|2012-10-05|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Grano-Tax||A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen|A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen|Completed||Phase 4|403|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:52:49.44105|2018-05-31 23:52:49.44105
NCT01107743|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2013-04-09||2013-06-10|2010-04-20|2010-04-21|Estimate|2013-04-09|2013-05-30|Estimate||||2013-06-10|2013-06-20|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Caduet® Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Completed|||1291|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:52:49.579538|2018-05-31 23:52:49.579538
NCT01107730|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|2015-04-28||2015-09-28|2010-04-20|2010-04-21|Estimate|2015-04-28|2015-05-13|Estimate||||2015-09-28|2015-10-19|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures|Randomized Double Blind Study of Administration of Vitamin C for Prophylaxis of Post-operative Atrial Fibrillation in On-pump Cardiac Surgery Procedures|Completed||Phase 3|33|Actual|Attikon Hospital||3|||f||||f||||||||||2018-05-31 23:52:50.443742|2018-05-31 23:52:50.443742
NCT01107717|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2017-08-11|2010-04-20|2010-04-21|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2009||2009-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM|Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes|Recruiting||N/A|600|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 23:52:50.796001|2018-05-31 23:52:50.796001
NCT01107704|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2014-01-23|2010-04-19|2010-04-21|Estimate|||||||2014-01-23|2014-01-27|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Family Support Intervention in Intensive Care Units (The Four Supports Study)|A Randomized Controlled Trial to Test the Effectiveness of a Multi-faceted Communication Intervention for Family Members of Critically Ill Patients.|Completed||N/A|159|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 23:52:50.871634|2018-05-31 23:52:50.871634
NCT01107691|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2015-05-28|2010-04-19|2010-04-21|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Comparison of 1 vs 3 Sets of Resistance Training on Muscular Hypertrophy|Resistance Training Energy Balance & Weight Management|Completed||N/A|169|Actual|University of Kansas||3|||f||||t||||||||||2018-05-31 23:52:50.937175|2018-05-31 23:52:50.937175
NCT01107678|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2014-01-08|2010-04-19|2010-04-21|Estimate|||||||2014-01-08|2014-01-09|Estimate|July 2007||2007-07-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|May 2011|Actual|2011-05-31||Interventional|YMCA-PAN||YMCA-Physical Activity and Nutrition|The YMCA After School Program of Physical Activity and Nutrition|Completed||N/A|966|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 23:52:51.224688|2018-05-31 23:52:51.224688
NCT01107665|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-01-12|2010-04-20|2010-04-21|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2010||2010-08-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma|A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma|Active, not recruiting||Phase 2|60|Actual|University of California, Irvine||1|||f||||t||||||||||2018-05-31 23:52:51.308267|2018-05-31 23:52:51.308267
NCT01107639|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2017-10-30|2010-04-20|2010-04-21|Estimate|||||||2017-10-30|2017-10-31|Actual|May 18, 2010|Actual|2010-05-18|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|October 6, 2016|Actual|2016-10-06||Interventional|||Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery|Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial|Active, not recruiting||Phase 3|297|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t|f|f||||||No||2018-05-31 23:52:51.423833|2018-05-31 23:52:51.423833
NCT01107626|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2017-02-06|2010-04-20|2010-04-21|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 2010||2010-08-31|February 2017|2017-02-28|April 1, 2018|Anticipated|2018-04-01|April 2018|Anticipated|2018-04-30||Interventional|||Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC|Active, not recruiting||Phase 3|1282|Anticipated|Eastern Cooperative Oncology Group||3|||f||||t|f|f||||||Undecided||2018-05-31 23:52:51.677162|2018-05-31 23:52:51.677162
NCT01107613|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-05-04|2010-04-19|2010-04-21|Estimate|||||||2010-05-04|2010-05-05|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Interventional|TLAL||The Role of Opinion Leaders in Enhancing Evidence-based Care After Chronic Obstructive Pulmonary Disease (COPD) Emergency Department (ED) Visits|The Lung Attack Alert Study|Unknown status|Not yet recruiting|Phase 4|110|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 23:52:52.627945|2018-05-31 23:52:52.627945
NCT01107600|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-20|2010-04-20|2010-04-21|Estimate|||||||2010-04-20|2010-04-21|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Study on Immediate Loading of Immediately Placed Single Implants.|Study on Immediate Loading of Immediately Placed Single Implants in Extraction Sockets With Nobel Active™ Implants and Bio-oss®.|Unknown status|Not yet recruiting|N/A|10|Anticipated|Hospital San Pietro Fatebenefratelli||2|||f||||t||||||||||2018-05-31 23:52:52.730592|2018-05-31 23:52:52.730592
NCT01107587|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2017-05-18|2010-04-20|2010-04-21|Estimate|||||||2017-05-18|2017-05-19|Actual|April 13, 2010|Actual|2010-04-13|May 2017|2017-05-31|June 28, 2010|Actual|2010-06-28|June 28, 2010|Actual|2010-06-28||Interventional|||Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants|Reactogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine 444563, in Healthy Infants|Completed||Phase 1|50|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:52:52.822921|2018-05-31 23:52:52.822921
NCT01107574|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-08-27|2010-04-20|2010-04-21|Estimate|||||||2013-08-27|2013-08-28|Estimate|April 2004||2004-04-30|August 2013|2013-08-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|FTTGO||Fibromyalgia Treatment Trial With Gabapentin and Osteopathic Manipulative Medicine|Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia|Completed||Phase 3|41|Actual|Good Samaritan Regional Medical Center, Oregon||3|||f||||t||||||||||2018-05-31 23:52:52.922658|2018-05-31 23:52:52.922658
NCT01107561|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-10-13|2010-04-19|2010-04-21|Estimate|||||||2011-10-13|2011-10-14|Estimate|April 2010||2010-04-30|October 2011|2011-10-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|CRIC||Different Techniques for Emergency Cricothyroidotomy|Incision-first Versus Classic Seldinger Technique for Emergency Cricothyroidotomy|Completed||N/A|50|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 23:52:53.036578|2018-05-31 23:52:53.036578
NCT01107548|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2012-02-16|2010-04-19|2010-04-21|Estimate|||||||2012-02-16|2012-02-20|Estimate|January 2001||2001-01-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|December 2008|Actual|2008-12-31||Interventional|INVADE||Prevention of Stroke and Dementia in Primary Care|Intervention Project of Cerebrovascular Diseases and Dementia in the District of Ebersberg|Terminated||N/A|3908|Actual|Technische Universität München||1|||f||||f||||||||||2018-05-31 23:52:53.180072|2018-05-31 23:52:53.180072
NCT01107535|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-20|2012-02-07||2012-10-26|2010-04-20|2010-04-21|Estimate|2012-03-22|2012-04-23|Estimate||||2012-10-26|2012-10-31|Estimate|September 2007||2007-09-30|October 2012|2012-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|INSPIRA||Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection|Observational Study of the Effectiveness of Synagis Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus Infection|Completed|||82|Actual|Abbott|||1||f||||||||||||||2018-05-31 23:52:53.280547|2018-05-31 23:52:53.280547
NCT01107522|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2018-04-23|2010-04-20|2010-04-21|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2010||2010-05-31|April 2018|2018-04-30||||June 2018|Anticipated|2018-06-30||Interventional|||Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas|A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas|Active, not recruiting||Phase 1|100|Anticipated|Tactical Therapeutics, Inc.||3|||f||||||||||||||2018-05-31 23:52:53.537772|2018-05-31 23:52:53.537772
NCT01107509|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2018-04-02|2010-04-20|2010-04-21|Estimate|||||||2018-04-02|2018-04-04|Actual|October 1, 2010|Actual|2010-10-01|April 2018|2018-04-30|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers|A Pilot Study of Neo-Adjuvant Everolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy - Analysis of Serum and Tissue Biomarkers|Completed||N/A|20|Actual|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||||2018-05-31 23:52:53.646043|2018-05-31 23:52:53.646043
NCT01107496|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19||2012-12-17|2017-05-04|2010-04-19|2010-04-21|Estimate||||2012-12-21|2012-12-28|Estimate|2017-05-04|2017-05-05|Actual|June 2010||2010-06-30|May 2017|2017-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD|A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 1/Phase 2|52|Actual|Supernus Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 23:52:53.744754|2018-05-31 23:52:53.744754
NCT01107483|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2010-05-06|2010-04-19|2010-04-21|Estimate|||||||2010-05-06|2010-05-07|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Observational|OCEHBV||Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic Hepatitis B Virus (HBV) Infection|Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic HBV Infection|Completed|||140|Actual|Sun Yat-sen University|||5||f||||f||||||||||2018-05-31 23:52:53.924626|2018-05-31 23:52:53.924626
NCT01107470|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2012-03-22|2010-04-20|2010-04-21|Estimate|||||||2012-03-22|2012-03-26|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in ART|Age-related Variability of the Efficacy and Tolerability of Alternative Pituitary Suppression Regimens in Follicular Stimulation for Assisted Reproduction Purposes. A Randomised, Prospective, Multi-centre Clinical Trial|Unknown status|Recruiting||2000|Anticipated|Shandong University|||4||f||||t||||||||||2018-05-31 23:52:54.068085|2018-05-31 23:52:54.068085
NCT01107457|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2016-04-20|2011-04-05|2017-06-26|2010-04-20|2010-04-21|Estimate|2017-06-26|2017-07-25|Actual|2011-04-05|2011-04-13|Estimate|2017-06-26|2017-07-25|Actual|April 2010||2010-04-30|June 2017|2017-06-30|July 2016|Actual|2016-07-31|January 2011|Actual|2011-01-31||Interventional||All randomized participants who received at least 1 dose of study drug.|A Study in Participants With Moderate to Severe Psoriasis|A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis|Completed||Phase 2|142|Actual|Eli Lilly and Company||7|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:52:54.282912|2018-05-31 23:52:54.282912
NCT01107444|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15||2012-05-24|2012-08-09|2010-04-20|2010-04-21|Estimate||||2012-05-24|2012-06-01|Estimate|2012-08-09|2012-08-17|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer|A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy|Completed||Phase 2|150|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 23:52:56.643087|2018-05-31 23:52:56.643087
NCT01107431|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-05-11|2010-04-20|2010-04-21|Estimate|||||||2011-05-11|2011-05-13|Estimate|December 2008||2008-12-31|May 2011|2011-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|L-Arabinose||Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin|A Combination of L-Arabinose and Chromium Lowers Circulating Glucose and Insulin Levels After Acute Oral Sucrose Challenge|Completed||N/A|70|Actual|Integrative Health Technologies, Inc.||2|||f||||f||||||||||2018-05-31 23:52:56.855141|2018-05-31 23:52:56.855141
NCT01107418|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2015-07-29||2015-07-29|2010-04-19|2010-04-21|Estimate|2015-07-29|2015-08-26|Estimate||||2015-07-29|2015-08-26|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Safety population included all participants who received at least one dose of vemurafenib.|A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma|A Phase I, Randomized, Open-label, Multi-center, Multiple Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO5185426 Administered as 240 mg Tablets to Previously Treated BRAF V600E Positive Metastatic Melanoma Patients|Completed||Phase 1|52|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:52:56.99126|2018-05-31 23:52:56.99126
NCT01107405|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2011-09-21||2012-02-14|2010-04-19|2010-04-21|Estimate|2012-02-14|2012-03-21|Estimate||||2012-02-14|2012-03-21|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge|Efficacy of Loteprednol Etabonate Ophthalmic Base Compared to Loteprednol Etabonate Ophthalmic Suspension vs Placebo in a Modified Conjunctival Allergen Challenge(CAC) Model|Completed||Phase 2|101|Actual|Bausch & Lomb Incorporated||5|||f||||f||||||||||2018-05-31 23:52:58.708928|2018-05-31 23:52:58.708928
NCT01107392|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2014-02-24|2013-03-14|2014-02-24|2010-04-19|2010-04-21|Estimate|2014-02-24|2014-04-04|Estimate|2013-03-14|2013-03-20|Estimate|2014-02-24|2014-04-04|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia||Completed||Phase 2|315|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:52:59.546934|2018-05-31 23:52:59.546934
NCT01107379|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2014-05-28||2014-09-13|2010-04-20|2010-04-21|Estimate|2014-09-13|2014-09-18|Estimate||||2014-09-13|2014-09-18|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Observational|ORIOS 2||Optimization and Refinement of Technique in In-Office Sinus Dilation 2|Optimization and Refinement of Technique in In-Office Sinus Dilation 2 (ORIOS 2)|Completed|||203|Actual|Acclarent|||1||f||||f||||||||||2018-05-31 23:52:59.874008|2018-05-31 23:52:59.874008
NCT01107366|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-20|||2011-06-27|2010-04-20|2010-04-21|Estimate|||||||2011-06-27|2011-06-28|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|ATLANTIS||ATLANTIS:Extensive Type A Dissections and Thoracic/ Thoraco-Abdominal Aneurysms Repair With LupiAe Hybrid TechNique|Extensive Type A Dissections and Thoracic/ Thoraco-Abdominal|Withdrawn||Phase 4|120|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||||The study never started since our Medical Ethic Commeettee did not approved it|f||||f||||||||||2018-05-31 23:53:00.095959|2018-05-31 23:53:00.095959
NCT01107353|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2013-11-26||2018-01-19|2010-04-19|2010-04-20|Estimate|2013-11-26|2014-01-15|Estimate||||2018-01-19|2018-02-05|Actual|August 2008||2008-08-31|January 2018|2018-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Normal healthy volunteers|Bioequivalency Study of Imipramine Pamoate 75 mg Capsules Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Imipramine Pamoate Capsules, 75 mg, Under Fasted Conditions|Completed||N/A|39|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 23:53:00.169308|2018-05-31 23:53:00.169308
NCT01107340|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2018-05-02|2010-04-19|2010-04-20|Estimate|||||||2018-05-02|2018-05-08|Actual|February 2010||2010-02-28|May 2018|2018-05-31|February 2028|Anticipated|2028-02-29|February 2028|Anticipated|2028-02-29||Interventional|||AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study|AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study|Active, not recruiting||N/A|500|Anticipated|Medacta International SA||1|||f||||||||||||||2018-05-31 23:53:00.589241|2018-05-31 23:53:00.589241
NCT01107327|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2014-10-29|2010-04-19|2010-04-20|Estimate|||||||2014-10-29|2014-10-31|Estimate|August 2006||2006-08-31|October 2014|2014-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated Venothromboembolism|FDG PET in Cancer Associated Venothromboembolism|Completed|||26|Actual|University of Utah|||||f||||t||||||||||2018-05-31 23:53:00.678366|2018-05-31 23:53:00.678366
NCT01107314|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-01-12|2010-04-19|2010-04-20|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2010||2010-02-28|March 2012|2012-03-31|April 30, 2011|Actual|2011-04-30|April 30, 2011|Actual|2011-04-30||Observational|||Vasopressin Deficiency in Hemorrhagic Shock|Vasopressin Deficiency in Hemorrhagic Shock|Completed|||81|Actual|The University of Texas Health Science Center at San Antonio|||1||f||||f||||||||||2018-05-31 23:53:00.755857|2018-05-31 23:53:00.755857
NCT01107301|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2014-09-04|2010-04-19|2010-04-20|Estimate|||||||2014-09-04|2014-09-05|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Vascular Effects of Attention Deficit Hyperactivity Disorder (ADHD) Medications in Youth|Vascular Consequences of ADHD Medication Use in Children and Adolescents|Completed|||138|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 23:53:00.838418|2018-05-31 23:53:00.838418
NCT01107288|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2014-02-21|2010-04-19|2010-04-20|Estimate|||||||2014-02-21|2014-02-24|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of a Music-Based Multitask Exercises Program on Gait, Balance and Fall Risk in the Elderly|A Randomized Controlled Trial of Music-Based Multitask Exercises (Jaques-Dalcroze Eurhythmics) on Gait, Balance and Fall Risk in the Elderly|Completed||N/A|134|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 23:53:00.917872|2018-05-31 23:53:00.917872
NCT01107275|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|November 2002||2002-11-30|April 2010|2010-04-30|November 2008|Actual|2008-11-30|November 2004|Actual|2004-11-30||Interventional|I49P1||Early Rabies Vaccine Immunization in Primary School Children|Compare Immunogenicity, Safety and Long-term Booster Response After Primary Vaccination With 2 Intradermal Doses Versus 3 Intradermal Doses of PCEC Rabies Vaccine (Rabipur) in Healthy School Children in Thailand (5-8 Years of Age)|Completed||Phase 3|703|Actual|Provincial Public Health Office, Phetchabun||2|||f||||t||||||||||2018-05-31 23:53:01.00639|2018-05-31 23:53:01.00639
NCT01107262|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-10-26|2010-04-19|2010-04-20|Estimate|||||||2011-10-26|2011-10-27|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Avian Influenza Studies In Lebanon|Avian Influenza Studies In Lebanon|Completed|||250|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||Samples Without DNA|"~     A trained phlebotomist will collect a tube of blood (7.5ml) in serum separator tubes. The~     blood will be allowed to clot at room temperature then centrifuged on the same day. Serum~     specimens will be aliqouted into multiple cryovials, labelled and preserved at -20°C until~     ready for laboratory study.~   "|||2018-05-31 23:53:01.092933|2018-05-31 23:53:01.092933
NCT01105910|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2016-11-17|2010-04-15|2010-04-19|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2010||2010-02-28|January 2012|2012-01-31||||December 2010|Actual|2010-12-31||Interventional|||Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye||Completed||Phase 4|70|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:53:37.602188|2018-05-31 23:53:37.602188
NCT01107249|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2016-03-15|2010-04-19|2010-04-20|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ESO-stent||A Trial of Esophageal and Gastric Stenting for Leak or Perforation|A Phase II Trial of Esophageal and Gastric Stenting for Leak or Perforation|Completed||Phase 2|10|Actual|The Methodist Hospital System||1|||f||||f||||||||No|No plan to share data at this time. The PI has relocated to another institution and closed the IDE.|2018-05-31 23:53:01.167273|2018-05-31 23:53:01.167273
NCT01107236|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2013-12-17|2010-04-19|2010-04-20|Estimate|||||||2013-12-17|2013-12-19|Estimate|June 2010||2010-06-30|December 2013|2013-12-31||||August 2010|Actual|2010-08-31||Interventional|||Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction|A Phase 2, Single-center, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study of a Single Dose of IW-6118, in Patients Undergoing Third Molar Extraction|Completed||Phase 2|90|Actual|Ironwood Pharmaceuticals, Inc.||3|||f||||||||||||||2018-05-31 23:53:01.23908|2018-05-31 23:53:01.23908
NCT01107223|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|September 2004||2004-09-30|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|April 2009|Actual|2009-04-30||Interventional|PAAIR2||Long Term Effect of General Practitioner Education on Antibiotic Prescribing|Long Term Effect of General Practitioner Education on Antibiotic Prescribing: a Large Scale Randomized Study|Unknown status|Active, not recruiting|N/A|170|Actual|Henri Mondor University Hospital||2|||f||||t||||||||||2018-05-31 23:53:01.312828|2018-05-31 23:53:01.312828
NCT01107210|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-06-22|2010-04-19|2010-04-20|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2006||2006-05-31|April 2010|2010-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Evaluation of Physical Fitness After Stroke|Evaluation of Physical Fitness After Stroke: Evolution and Determinants|Completed|||50|Anticipated|Katholieke Universiteit Leuven|||1||f||||t||||||||||2018-05-31 23:53:01.400244|2018-05-31 23:53:01.400244
NCT01107197|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2013-03-10||2014-01-16|2010-04-19|2010-04-20|Estimate|2014-01-16|2014-02-12|Estimate||||2014-01-16|2014-02-12|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|OEST|Principal analysis were conducted according to the intention-to-treat (ITT) principle. ITT analyses were based on 157 patients. All patients who have been assessed at baseline and at least at 4 weeks will be included in the ITT population.|Nutritional Support in Pressure Ulcer Patients|Nutritional Support in Malnourished Pressure Ulcer Patients: the Oligoelement Sore Trial (OEST)|Completed||N/A|200|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita|Limited to specific settings: long-term care and home-care services Limited to malnourished patients|2|||f||||t||||||||||2018-05-31 23:53:01.506731|2018-05-31 23:53:01.506731
NCT01107184|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-01-30|2010-04-19|2010-04-20|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2010||2010-01-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|RICO||Remote Ischemic Conditioning and Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG)|A Clinical Study on the Effect of Remote Ischemic Conditioning on Atrial Fibrillation and Outcome After Coronary Artery Bypass Grafting|Terminated||N/A|191|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||4||slow recruitment|f||||f||||||||||2018-05-31 23:53:01.879228|2018-05-31 23:53:01.879228
NCT01107171|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-04-20|2010-04-19|2010-04-20|Estimate|||||||2010-04-20|2010-04-21|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes|Multi-center Randomized Controled and Double Blind Trial of Tang-min-ling Pills in the Treatment of Type 2 Diabetes|Completed||Phase 2|210|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||3|||f||||t||||||||||2018-05-31 23:53:01.969774|2018-05-31 23:53:01.969774
NCT01107158|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2015-11-19|2010-04-19|2010-04-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||LXRs, Cholesterol Metabolism and Uterine Dystocia|The Role of Two Nuclear Receptors for Oxysterols as a Molecular Cause of Uterine Dystocia: LXR Alpha and LXR Beta|Terminated|||58|Actual|Centre Hospitalier Universitaire de Nīmes|||2|Inclusion curve too slow.|f||||f||||||Samples With DNA|"~     A whole blood sample is taken and DNA extracted using Qiagen kits.~   "|||2018-05-31 23:53:02.098376|2018-05-31 23:53:02.098376
NCT01107145|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2012-04-12|2010-04-19|2010-04-20|Estimate|||||||2012-04-12|2012-04-13|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PAACT-PV||Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)|A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil|Terminated||Phase 4|16|Actual|Centers for Disease Control and Prevention||3||Extremely slow enrollment|f||||t||||||||||2018-05-31 23:53:02.173108|2018-05-31 23:53:02.173108
NCT01107132|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-18|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|May 2010||2010-05-31|April 2010|2010-04-30||||||||Observational|||Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus|Blood-retinal Barrier Imaging in Type 2 Diabetes Mellitus: a Window for Blood-brain Barrier Breakdown and Neuropsychiatric Sequela|Unknown status|Not yet recruiting||100|Anticipated|Soroka University Medical Center|||1||f||||t||||||Samples Without DNA|"~     • Fluorescein Angiography~        1. Investigation and documentation of the retinal and choroidal vascular systems integrity~          by intravenous administration of sodium fluorescein~        2. FA images are recorded in a central database with restricted accesses and are routinely~          analyzed by the eye specialist~   "|||2018-05-31 23:53:02.297186|2018-05-31 23:53:02.297186
NCT01107119|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-18|||2017-04-19|2010-04-19|2010-04-20|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2009||2009-10-31|April 2017|2017-04-30|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Integrated Care Pathways in a Community Setting|Enabling Elderly Patients to Manage Their Own Lives - A Systematic Management Program for Home Care Services.|Completed||N/A|304|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 23:53:02.377064|2018-05-31 23:53:02.377064
NCT01107106|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-05-14|2010-04-19|2010-04-20|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Observational|||Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women|Prospective Observational Single Arm Open-Label Multicenter Study to Assess the Safety, Tolerability and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Adult Women|Completed|||579|Actual|HRA Pharma|||2||f||||f||||||||||2018-05-31 23:53:02.46553|2018-05-31 23:53:02.46553
NCT00936299|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2013-05-28|2009-07-08|2009-07-10|Estimate|||||||2013-05-28|2013-05-30|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Bupropion for ADHD in Adolescents With Substance Use Disorder|Bupropion for ADHD in Adolescents With Substance Use Disorder|Completed||Phase 4|105|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 00:48:29.156183|2018-06-01 00:48:29.156183
NCT01107093|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-08-24|2010-04-19|2010-04-20|Estimate|||||||2010-08-24|2010-08-25|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of CDB-2914 Versus Placebo in the Prevention of Follicular Rupture Post-luteinizing Hormone (LH) Surge|A Prospective, Randomized, Double-blind, Cross-Over Study to Compare the Capacity to Prevent Follicular Rupture of CDB-2914 With Placebo, When Administered After the Ovulatory Process Has Been Triggered by the LH Surge|Completed||Phase 2|35|Actual|HRA Pharma||2|||f||||f||||||||||2018-05-31 23:53:02.727207|2018-05-31 23:53:02.727207
NCT01107080|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-18|||2013-02-06|2010-04-18|2010-04-20|Estimate|||||||2013-02-06|2013-02-07|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Fast Spectral Imaging Device for Tumor Margin Mapping|Fast Spectral Imaging Device for Tumor Margin Mapping|Completed|||54|Actual|Duke University|||2||f||||t||||||||||2018-05-31 23:53:02.8524|2018-05-31 23:53:02.8524
NCT01107067|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|June 2008||2008-06-30|May 2008|2008-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism|Phase IV Study to Investigate the Effect of Testosterone Treatment on Paraoxonase Level in Male Patients With Hypogonadotrophic Hypogonadism|Completed||Phase 4|32|Actual|Gulhane School of Medicine||1|||f||||f||||||||||2018-05-31 23:53:02.965237|2018-05-31 23:53:02.965237
NCT01107054|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-01-12|2010-04-19|2010-04-20|Estimate|||||||2011-01-12|2011-01-13|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers|A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects|Completed||Phase 1|48|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:53:03.134748|2018-05-31 23:53:03.134748
NCT01107041|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2017-03-21|2010-04-19|2010-04-20|Estimate|||||||2017-03-21|2017-03-24|Actual|December 2014||2014-12-31|October 2015|2015-10-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Mobile Phone Sensing and Outreach as Adjuncts to Internet-Based Behavioral Intervention for Depression|Technology Assisted Intervention for the Treatment and Prevention of Depression|Completed||N/A|2010|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 23:53:03.354423|2018-05-31 23:53:03.354423
NCT01107028|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-03-27|2010-04-19|2010-04-20|Estimate|||||||2017-03-27|2017-03-29|Actual|February 2010||2010-02-28|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis|Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis|Completed|||41|Actual|National Jewish Health|||2||f||||f||||||||||2018-05-31 23:53:03.567756|2018-05-31 23:53:03.567756
NCT01107015|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-17|2017-09-29||2018-02-27|2010-04-19|2010-04-20|Estimate|2018-02-27|2018-03-01|Actual||||2018-02-27|2018-03-01|Actual|June 2008||2008-06-30|February 2018|2018-02-28|September 2011|Actual|2011-09-30|August 2010|Actual|2010-08-31||Interventional|||Mobile Diabetes Management|Mobile Diabetes Management|Completed||N/A|213|Actual|University of Maryland||4|||f||||t||||||||||2018-05-31 23:53:03.804142|2018-05-31 23:53:03.804142
NCT01107002|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-17|||2011-07-14|2010-04-19|2010-04-20|Estimate|||||||2011-07-14|2011-07-15|Estimate|July 2008||2008-07-31|April 2010|2010-04-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of 5 Day Embryo Transfer With 2-3 Day Transfer in Patients With Previous In Vitro Fertilization Failure|Comparison of 5 Day Embryo Transfer With 2-3 Day Transfer in Patients Who Failed to Conceive in Two or More Day 2-3 Embryo Transfer Cycle in Royan Institute|Completed||Phase 1/Phase 2|200|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 23:53:04.528948|2018-05-31 23:53:04.528948
NCT01106989|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16||2012-03-14|2012-03-14|2010-04-19|2010-04-20|Estimate||||2012-03-14|2012-03-16|Estimate|2012-03-14|2012-03-16|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points|An Open-label Pilot Study Evaluating Synera® in the Treatment of Patients With Pain Associated With Myofascial Trigger Points|Completed||Phase 2|20|Actual|ZARS Pharma Inc.||1|||f||||f||||||||||2018-05-31 23:53:04.628178|2018-05-31 23:53:04.628178
NCT01106976|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2015-11-06||2015-12-23|2010-04-19|2010-04-20|Estimate|2015-12-23|2016-02-01|Estimate||||2015-12-23|2016-02-01|Estimate|May 2010||2010-05-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Observational||Parkinson disease, minimum age of 50.|Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease|Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease|Completed|||67|Actual|VA Office of Research and Development|Observational study.||1||f||||f||||||None Retained|"~     Saliva~   "|||2018-05-31 23:53:04.727883|2018-05-31 23:53:04.727883
NCT01106963|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Anterior Knee Pain After Tibial Nailing|Nail Position Has an Influence on Anterior Knee Pain After Tibial Intramedullary Nailing|Completed|||50|Actual|University of Zagreb|||1||f||||f||||||||||2018-05-31 23:53:04.901309|2018-05-31 23:53:04.901309
NCT01106950|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|2013-05-06||2017-12-03|2010-04-19|2010-04-20|Estimate|2013-05-06|2013-06-26|Estimate||||2017-12-03|2017-12-28|Actual|July 2010||2010-07-31|December 2017|2017-12-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)|Adoptive Transfer of Haploidentical Natural Killer Cells to Treat Refractory or Relapsed AML MT2010-02|Terminated||Phase 2|15|Actual|Masonic Cancer Center, University of Minnesota||1||study drug (Ontak) no longer available|f||||t||||||||||2018-05-31 23:53:04.98324|2018-05-31 23:53:04.98324
NCT01106937|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Factor XIII and Pulmonary Embolism in Neurosurgical Patients|Risk Factors for Perioperative Pulmonary Embolism in Neurosurgical Patients in Respect of Factor XIII Activity|Unknown status|Recruiting||130|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||||2018-05-31 23:53:06.522813|2018-05-31 23:53:06.522813
NCT01106924|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2012-05-25|2010-04-19|2010-04-20|Estimate|||||||2012-05-25|2012-05-28|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Effects of a Probiotic on Body Weight|Effects of Consumption of a Probiotic Formulation on Weight Control in Obese Subjects|Completed||N/A|120|Actual|Laval University||2|||f||||f||||||||||2018-05-31 23:53:06.613644|2018-05-31 23:53:06.613644
NCT01106911|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2016-01-25||2016-02-24|2010-04-19|2010-04-20|Estimate|2016-02-24|2016-03-25|Estimate||||2016-02-24|2016-03-25|Estimate|May 2010||2010-05-31|February 2016|2016-02-29||||September 2014|Actual|2014-09-30||Interventional||Participants who completed research procedures|Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment|Assessment of Digital Breast Tomosynthesis (DBT) in the Screening Environment: a Prospective Study|Completed||N/A|1080|Actual|University of Pittsburgh|||||f||||f||||||||||2018-05-31 23:53:06.68694|2018-05-31 23:53:06.68694
NCT01106898|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2018-04-30||2018-04-30|2010-04-16|2010-04-20|Estimate|2018-04-30|2018-05-31|Estimate||||2018-04-30|2018-05-31|Estimate|March 2010||2010-03-31|October 2017|2017-10-31|September 28, 2015|Actual|2015-09-28|September 28, 2015|Actual|2015-09-28||Interventional|||Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery|A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients|Completed||Phase 2|112|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 23:53:06.947558|2018-05-31 23:53:06.947558
NCT01106885|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2015-04-24|2010-04-16|2010-04-20|Estimate|||||||2015-04-24|2015-04-28|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|April 2011|Actual|2011-04-30|October 2009|Actual|2009-10-31||Interventional|||Effective Care Management of Depressed Diabetes Patients (The Positive Steps Study)|Effective Care Management of Depressed Diabetes Patients|Completed||N/A|339|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 23:53:08.134075|2018-05-31 23:53:08.134075
NCT01106872|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2017-08-22|2010-04-19|2010-04-20|Estimate|||||||2017-08-22|2017-08-24|Actual|September 2010||2010-09-30|August 2017|2017-08-31|August 22, 2017|Actual|2017-08-22|July 2017|Actual|2017-07-31||Interventional|||Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas|A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas|Completed||Phase 1/Phase 2|47|Actual|University of Iowa||1|||f||||t||||||||||2018-05-31 23:53:08.268345|2018-05-31 23:53:08.268345
NCT01106859|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2011-12-15||2012-02-10|2010-04-19|2010-04-20|Estimate|2011-12-15|2012-01-20|Estimate||||2012-02-10|2012-02-14|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet|Assessment of Next-Morning Driving Performance After Middle of the Night Administration of Zolpidem Tartrate Sublingual Tablet 3.5 mg in Healthy Adult Volunteers: Single-center, Double-blind, Randomized, Placebo-controlled, Four-way Crossover Study|Completed||Phase 1|40|Actual|Transcept Pharmaceuticals|No studies directly connect SDLP thresholds with an increased risk of an accident for an individual. Nor has a SDLP threshold been adopted by a regulatory body. Based on published literature, an SDLP change of 2.5 cm was used in the primary outcome.|4|||f||||f||||||||||2018-05-31 23:53:08.374871|2018-05-31 23:53:08.374871
NCT01106846|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2015-06-18||2015-07-20|2010-04-19|2010-04-20|Estimate|2015-07-16|2015-07-20|Estimate||||2015-07-20|2015-08-07|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery|Analgesic Effect of Ketamine in Patients Undergoing Hysteroscopic Endometrial Thermal Ablation Surgery|Terminated||N/A|22|Actual|Northwestern University|Study was terminated early.|2||Resources not available to complete.|f||||f||||||||||2018-05-31 23:53:09.119504|2018-05-31 23:53:09.119504
NCT01106833|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2018-01-30|2010-04-16|2010-04-20|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2010|Actual|2010-04-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)|A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN Protocol #0801)|Active, not recruiting||Phase 2/Phase 3|161|Actual|Medical College of Wisconsin||2|||f||||t||||||||Yes|Findings will be published in a manuscript|2018-05-31 23:53:09.377797|2018-05-31 23:53:09.377797
NCT01106820|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-12-16|2010-04-19|2010-04-20|Estimate|||||||2016-12-16|2016-12-19|Estimate|April 2010||2010-04-30|December 2016|2016-12-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|BEATE||Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and Effects on Fatigue and Quality of Life|Progressive Resistance Training vs. Relaxation for Breast Cancer Patients During Chemotherapy: A Randomized Controlled Intervention Trial to Evaluate the Biological Mechanisms and Effects of Resistance Training on Fatigue and Quality of Life|Completed||N/A|101|Actual|German Cancer Research Center||2|||f||||f||||||||||2018-05-31 23:53:09.503657|2018-05-31 23:53:09.503657
NCT01106807|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19||2011-01-19|2012-04-18|2010-04-19|2010-04-20|Estimate||||2011-01-19|2011-01-28|Estimate|2012-04-18|2012-04-20|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne|Exploratory Study to Evaluate the Efficacy and Safety of CD07223 1.5% Gel and 0.5% Gel in Subjects With Acne|Completed||Phase 2|73|Actual|Galderma||3|||f||||f||||||||||2018-05-31 23:53:09.585597|2018-05-31 23:53:09.585597
NCT01106794|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-01-11|2010-04-19|2010-04-20|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2010||2010-04-30|January 2018|2018-01-31|April 2030|Anticipated|2030-04-30|April 2025|Anticipated|2025-04-30||Observational|||Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma|Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma|Recruiting|||100|Anticipated|Children's Research Institute|||1||f||||f||||||Samples With DNA|"~     Cerebrospinal fluid, serum, urine, brainstem tumor and constitutional tissue from patients~     with diffuse intrinsic pontine glioma or brainstem glioma will be collected.~   "|||2018-05-31 23:53:09.676011|2018-05-31 23:53:09.676011
NCT01106781|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2014-03-17|2010-04-19|2010-04-20|Estimate|||||||2014-03-17|2014-03-18|Estimate|August 2010||2010-08-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|ICAN||A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology|A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology|Completed|||591|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 23:53:09.754184|2018-05-31 23:53:09.754184
NCT01106768|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2012-06-28|2010-04-19|2010-04-20|Estimate|||||||2012-06-28|2012-07-02|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|April 2013|Anticipated|2013-04-30||Observational|||Evaluation of Oral Needs of Children With Disorder Attention Deficit/Hyperactivity Disorder|Evaluation of Oral Needs of Children With Disorder Attention Deficit/Hyperactivity Disorder|Unknown status|Recruiting||140|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-05-31 23:53:09.945941|2018-05-31 23:53:09.945941
NCT01106755|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Effects of Ground Level Gait Training With Body Weight Support (BWS) and Functional Electrical Stimulation (FES)|Ground-level Gait Training Combining Body Weight Support and Functional Electrical Stimulation in People Following Chronic Stroke|Completed||N/A|12|Actual|Universidade Federal de Sao Carlos||1|||f||||t||||||||||2018-05-31 23:53:10.026711|2018-05-31 23:53:10.026711
NCT01106742|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2011-07-18|2010-04-19|2010-04-20|Estimate|||||||2011-07-18|2011-07-19|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)|Potential Anti-inflammatory Effect of Mushroom Extract From Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)|Completed||Phase 2|20|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 23:53:10.11105|2018-05-31 23:53:10.11105
NCT01106729|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2011-10-01|2010-04-19|2010-04-20|Estimate|||||||2011-10-01|2011-10-04|Estimate|July 2011||2011-07-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Tracing the Path of an Ingested Plant Pigment Through the Human Body|Tracing the Path of the Plant Pigment Cyanidin-3-glucoside, Through the Human Body After Consumption|Completed||N/A|8|Anticipated|University of East Anglia||1|||f||||f||||||||||2018-05-31 23:53:10.176366|2018-05-31 23:53:10.176366
NCT01106716|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2011-08-30|2010-04-19|2010-04-20|Estimate|||||||2011-08-30|2011-09-01|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia|A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia|Completed||Phase 2|23|Actual|KAI Pharmaceuticals||3|||f||||f||||||||||2018-05-31 23:53:10.255981|2018-05-31 23:53:10.255981
NCT01106703|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-07-23|2010-04-19|2010-04-20|Estimate|||||||2010-07-23|2010-07-27|Estimate|December 2006||2006-12-31|July 2010|2010-07-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||The Effects of PG102, a Water Soluble Extract From Actinidia Arguta, on Serum Total IgE Levels|The Effects of PG102 on Allergy-related Risk Factors: A Randomized, Double Blind, Placebo Controlled Study|Completed||Phase 2|90|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:53:10.340243|2018-05-31 23:53:10.340243
NCT01106690|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2013-04-02|2012-03-30|2013-06-26|2010-04-16|2010-04-20|Estimate|2013-04-02|2013-05-21|Estimate|2012-04-24|2012-04-25|Estimate|2013-06-26|2013-07-15|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|||The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy|Completed||Phase 3|344|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 23:53:10.490998|2018-05-31 23:53:10.490998
NCT01106677|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2013-04-04|2012-03-30|2013-07-25|2010-04-19|2010-04-20|Estimate|2013-07-25|2013-07-30|Estimate|2012-04-24|2012-04-25|Estimate|2013-07-25|2013-07-30|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)|A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|1284|Actual|Janssen Research & Development, LLC||4|||f||||t||||||||||2018-05-31 23:53:11.659411|2018-05-31 23:53:11.659411
NCT01106664|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2012-06-12|2010-04-19|2010-04-20|Estimate|||||||2012-06-12|2012-06-14|Estimate|April 2010||2010-04-30|June 2012|2012-06-30||||November 2010|Actual|2010-11-30||Interventional|||ONO-7746 Study in Healthy Adult Subject|A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Healthy Adult Subjects|Completed||Phase 1|72|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-05-31 23:53:13.91683|2018-05-31 23:53:13.91683
NCT01106651|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2013-04-01|2012-03-30|2014-10-27|2010-04-16|2010-04-20|Estimate|2013-04-01|2013-05-29|Estimate|2012-04-24|2012-04-25|Estimate|2014-10-27|2014-11-04|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|May 2013|Actual|2013-05-31|November 2011|Actual|2011-11-30||Interventional|||A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy|Completed||Phase 3|716|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 23:53:14.031763|2018-05-31 23:53:14.031763
NCT01106638|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-04-25|2010-04-19|2010-04-20|Estimate|||||||2018-04-25|2018-04-27|Actual|December 2009|Actual|2009-12-31|April 2018|2018-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)|A Trial to Test the Efficacy of a Tailored Intensive Smoking Cessation Intervention in Persons With HIV (PWHs)|Completed||Phase 3|147|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 23:53:16.057965|2018-05-31 23:53:16.057965
NCT01106625|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2013-04-10|2012-03-30|2013-06-12|2010-04-19|2010-04-20|Estimate|2013-04-10|2013-05-29|Estimate|2012-06-29|2012-07-02|Estimate|2013-06-12|2013-06-20|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy|Completed||Phase 3|469|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 23:53:16.186366|2018-05-31 23:53:16.186366
NCT01106612|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-04-07|2010-04-19|2010-04-20|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PROSPECT-CAD||Study Comparing CT Scan and Stress Test in Patients With Known Coronary Artery Disease Hospitalized for Chest Pain|A Randomized Controlled Trial Comparing Coronary CT Angiography and Radionuclide Stress Myocardial Perfusion Imaging in Symptomatic Inpatients With Known Coronary Artery Disease|Terminated||N/A|7|Actual|Montefiore Medical Center||2||low recruitment|f||||t||||||||||2018-05-31 23:53:17.272876|2018-05-31 23:53:17.272876
NCT01106599|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2016-11-01|2010-04-16|2010-04-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors|An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0623 Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|61|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 23:53:17.367594|2018-05-31 23:53:17.367594
NCT01106586|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2012-09-20|2011-08-23|2015-10-09|2010-04-19|2010-04-20|Estimate|2012-09-20|2012-10-22|Estimate|2011-08-23|2011-08-25|Estimate|2015-10-09|2015-11-11|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2011|Actual|2011-09-30||Interventional||Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug|Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Completed||Phase 3|708|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t||||||||||2018-05-31 23:53:17.479232|2018-05-31 23:53:17.479232
NCT01106573|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2010-04-19|2010-04-19|2010-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Associations Between Diabetes, Arterial Stiffness and Fibulin-1 in Patients Undergoing Heart- and Vascular Surgery?|Is There an Association Between the Presence of Diabetes, the Degree of Arterial Stiffness and a New Plasma Marker for Vascular Elasticity, Fibulin-1 in Patients Undergoing Heart- and Vascular Surgery?|Unknown status|Not yet recruiting||1400|Anticipated|Odense University Hospital|||||f||||t||||||Samples With DNA|"~     In this study we will collect serum, whole blood and urine~   "|||2018-05-31 23:53:18.818634|2018-05-31 23:53:18.818634
NCT01106560|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2016-04-11|2010-04-19|2010-04-20|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Randomised Trial Comparing Anterior Versus Posterior Approach in Total Hip Replacement|A Single Centre Prospective Randomised Controlled Clinical Trial Comparing Total Hip Arthroplasty Performed Either Through a Posterior Approach or a Direct Anterior Approach|Completed||N/A|50|Actual|Medacta International SA||2|||f||||||||||||||2018-05-31 23:53:18.874502|2018-05-31 23:53:18.874502
NCT01106547|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2011-10-12|2010-04-19|2010-04-20|Estimate|||||||2011-10-12|2011-10-13|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy|The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy: A Prospective, Double Blinded, Placebo Controlled Study|Completed||Phase 4|55|Anticipated|Holbaek Sygehus||2|||f||||t||||||||||2018-05-31 23:53:18.939492|2018-05-31 23:53:18.939492
NCT01106534|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2015-07-31|2015-01-20|2016-05-12|2010-04-19|2010-04-20|Estimate|2016-05-12|2016-06-28|Estimate|2015-04-08|2015-05-14|Estimate|2016-05-12|2016-06-28|Estimate|August 2009||2009-08-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|XVU-AV DAPT|Baseline characteristics are provided for 2997 patients recruited in the second enrollment phase.|XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort|XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)|Completed||Phase 4|870|Actual|Abbott Vascular|The participants enrolled in this study will be followed by Abbott Vacular but their data will not be independently analyzed; they will only be analyzed as part of the DAPT study (NCT00977938) which is sufficiently powered for the outcomes.|2|||f||||t||||||||||2018-05-31 23:53:19.057551|2018-05-31 23:53:19.057551
NCT01106521|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-02-28|2010-04-19|2010-04-20|Estimate|||||||2013-02-28|2013-03-01|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|March 2024|Anticipated|2024-03-31|March 2014|Anticipated|2014-03-31||Interventional|||A Registry Study of Permanent Breast Seed Implant|A Multicentre Registry Study of Permanent Breast Seed Implant (PBSI) for Early Stage Breast Cancers.|Recruiting||N/A|420|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 23:53:19.503028|2018-05-31 23:53:19.503028
NCT01106508|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2016-01-11|2010-04-19|2010-04-20|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors|A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors|Completed||Phase 1|57|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:53:19.601743|2018-05-31 23:53:19.601743
NCT01106495|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-19|||2018-04-18|2010-04-19|2010-04-20|Estimate|||||||2018-04-18|2018-04-20|Actual|May 2010|Actual|2010-05-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SESA||Effect of Enhanced External Counterpulsation (EECP) on Subclinical Atherosclerosis|Study of the Effect of EECP on Subclinical Atherosclerosis|Recruiting||N/A|150|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 23:53:19.679568|2018-05-31 23:53:19.679568
NCT01106482|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-12-07|2010-04-19|2010-04-20|Estimate|||||||2011-12-07|2011-12-08|Estimate|May 2009||2009-05-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE|A Phase IV, Open-label, Multi-center Follow-up Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE|Completed||Phase 4|126|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:53:19.773362|2018-05-31 23:53:19.773362
NCT01106469|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2014-04-07|2010-04-19|2010-04-20|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|July 2010|Actual|2010-07-31|||||Interventional|||Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants|Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male Subjects|Completed||Phase 1|74|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||7|||f||||||||||||||2018-05-31 23:53:19.848464|2018-05-31 23:53:19.848464
NCT01106456|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2017-03-14||2017-03-14|2010-04-16|2010-04-19|Estimate|2017-03-14|2017-04-26|Actual||||2017-03-14|2017-04-26|Actual|September 2010||2010-09-30|March 2017|2017-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Smoking Cessation for American Indians|Culturally-Tailored Smoking Cessation for American Indians|Completed||Phase 3|463|Actual|University of Kansas Medical Center|Significant loss to follow-up, lower than expected salivary collection rates, lower long-term retention of participants, and higher than expected drop off from randomization to enrollment.|2|||f||||t|t|f|||f|||No||2018-05-31 23:53:19.929449|2018-05-31 23:53:19.929449
NCT01106443|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-12-13|2010-04-16|2010-04-19|Estimate|||||||2016-12-13|2016-12-14|Estimate|February 2010||2010-02-28|December 2016|2016-12-31|October 2016|Actual|2016-10-31|July 2013|Actual|2013-07-31||Interventional|||Central Compartment Neck Dissection With Thyroidectomy|Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial|Terminated||N/A|128|Anticipated|University of Alberta||4||Poor patient accrual|f||||f||||||||||2018-05-31 23:53:20.32942|2018-05-31 23:53:20.32942
NCT01106430|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2013-05-03||2014-06-06|2010-04-16|2010-04-19|Estimate|2013-05-03|2013-06-24|Estimate||||2014-06-06|2014-06-12|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional||Safety Population was used for baseline characteristics (n = 262). Defined as all subjects who were randomized and who had taken at least 1 dose of investigational product. Five randomized subjects did not take any investigational product.|Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate|A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel Group Study to Assess the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy|Completed||Phase 3|267|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:53:20.444016|2018-05-31 23:53:20.444016
NCT01106417|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2016-12-15|2010-04-16|2010-04-19|Estimate|||||||2016-12-15|2016-12-19|Estimate|June 2010||2010-06-30|December 2016|2016-12-31|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion|Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation|Completed||Phase 2|12|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-05-31 23:53:21.115394|2018-05-31 23:53:21.115394
NCT01106404|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|2012-01-12||2012-08-17|2010-04-16|2010-04-19|Estimate|2012-06-25|2012-08-01|Estimate||||2012-08-17|2012-08-30|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||RestoreSensor Study|RestoreSensor Study|Completed||N/A|79|Actual|MedtronicNeuro||2|||f||||f||||||||||2018-05-31 23:53:21.209752|2018-05-31 23:53:21.209752
NCT01106391|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2013-09-23||2016-11-16|2010-04-16|2010-04-19|Estimate|2013-09-23|2013-11-26|Estimate||||2016-11-16|2017-01-04|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2011|Actual|2011-08-31||Interventional|INNOVATION||A MULTICENTER, OPEN LABEL, PROSPECTIVE, NON-RANDOMIZED STUDY OF INCRAFT™ IN SUBJECTS WITH ABDOMINAL AORTIC ANEURYSMS (INNOVATION)|A Multicenter, Open Label, Prospective, Non-Randomized Study Of INCRAFT™ In Subjects With Abdominal Aortic Aneurysms|Completed||Phase 2|60|Actual|Cordis Corporation||1|||f||||t||||||||Undecided||2018-05-31 23:53:21.601625|2018-05-31 23:53:21.601625
NCT01106378|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2011-07-11|2010-04-16|2010-04-19|Estimate|||||||2011-07-11|2011-07-12|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|July 2011|Actual|2011-07-31||Observational|CYNERGY||Cynergy: the CYPHER-NEVO Registry|Cynergy - The CYPHER-NEVO Registry. An Observational Registry, to Evaluate the Safety and Performance of the NEVO™ Sirolimus-eluting Coronary Stent in Routine Clinical Practice, and to Compare Its Safety and Performance With the CYPHER Select® Plus Sirolimus-eluting Coronary Stent (SES)|Terminated|||14000|Anticipated|Cordis Corporation|||2|Early termination of patient enrollment based on business decision|f||||f||||||||||2018-05-31 23:53:21.896974|2018-05-31 23:53:21.896974
NCT01106365|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-12-21|2010-04-16|2010-04-19|Estimate|||||||2017-12-21|2017-12-22|Actual|February 2010||2010-02-28|December 2017|2017-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|rTMS in MS||Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis|Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis - A Pilot Study to Evaluate Safety and Efficacy of Deep rTMS on Fatigue and Depressivity in Patients With Multiple Sclerosis|Completed||N/A|36|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 23:53:21.973426|2018-05-31 23:53:21.973426
NCT01106352|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2016-06-14||2016-11-11|2010-04-16|2010-04-19|Estimate|2016-09-20|2016-11-09|Estimate||||2016-11-11|2017-01-04|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)|A Phase I/IIa Study of Safety and Efficacy of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer|Completed||Phase 1/Phase 2|70|Actual|Bayer|The radium 223 dichloride treatment was calculated as 50 kBq per NIST 2010, and would be approximately 55 kBq per NIST 2015 standard. Pharmacokinetic endpoint was deleted as no PK variables were evaluated in the study.|2|||f||||f||||||||||2018-05-31 23:53:22.144336|2018-05-31 23:53:22.144336
NCT01106339|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-04-03|2010-04-16|2010-04-19|Estimate|||||||2013-04-03|2013-04-05|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|IPPPDIV||Immune Patterns in Pain Patients DSM-IV|Phase 1 Study of Immune, Psychometric and Sociodemographic Patterns in Pain Patients Classified by DSM-IV|Completed|||52|Actual|University of Ulm|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, and white cells will be retained.~   "|||2018-05-31 23:53:24.63114|2018-05-31 23:53:24.63114
NCT01106326|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2011-06-15||2014-07-25|2010-04-16|2010-04-19|Estimate|2011-08-02|2011-09-02|Estimate||||2014-07-25|2014-08-01|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|September 2012|Actual|2012-09-30|June 2010|Actual|2010-06-30||Interventional|||A Pilot Study to Improve Preventive Asthma Care for Urban Adolescents|A Pilot Study to Improve Preventive Asthma Care for Urban Adolescents|Completed||N/A|30|Actual|University of Rochester||1|||f||||f||||||||||2018-05-31 23:53:24.696465|2018-05-31 23:53:24.696465
NCT01106313|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-10-03|2010-04-16|2010-04-19|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2009||2009-07-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Insulin Resistance in Patients With Major Depression|Insulin Resistance in Patients With Major Depression|Completed|||57|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     Optional buffy coat sample~   "|||2018-05-31 23:53:24.833013|2018-05-31 23:53:24.833013
NCT01106300|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2015-12-17|2010-04-16|2010-04-19|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MUSCLE||Musculoskeletal Ultrasound Study in Critical Care: Longitudinal Evaluation|Assessment of Peripheral Muscle and Bone Mass in the Critically Ill and Its Response to External Muscle Stimulation|Completed|||63|Actual|University College, London|||2||f||||t||||||Samples With DNA|"~     quadricep muscle biopsy, blood and urine samples~   "|||2018-05-31 23:53:24.880917|2018-05-31 23:53:24.880917
NCT01106287|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|2012-07-03||2016-02-03|2010-04-16|2010-04-19|Estimate|2012-11-15|2012-12-13|Estimate||||2016-02-03|2016-02-04|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)|A Study of Higher Single Doses of MK-0941 in Type 2 Diabetics|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:53:24.941211|2018-05-31 23:53:24.941211
NCT01106274|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2010-04-16|2010-04-16|2010-04-19|Estimate|||||||2010-04-16|2010-04-19|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|September 2009|Actual|2009-09-30|||||Interventional|C3R||The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy|Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking|Completed||N/A|20|Actual|Mashhad University of Medical Sciences|||||f||||f||||||||||2018-05-31 23:53:25.46631|2018-05-31 23:53:25.46631
NCT01106248|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2011-12-22||2012-03-19|2010-04-16|2010-04-19|Estimate|2012-03-19|2012-04-13|Estimate||||2012-03-19|2012-04-13|Estimate|March 2009||2009-03-31|March 2012|2012-03-31||||September 2010|Actual|2010-09-30||Interventional|||QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors|An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors|Completed||Phase 1|26|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 23:53:25.662251|2018-05-31 23:53:25.662251
NCT01106235|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-12-20|2010-04-16|2010-04-19|Estimate|||||||2011-12-20|2011-12-21|Estimate|April 2010||2010-04-30|December 2011|2011-12-31||||November 2011|Actual|2011-11-30||Interventional|||Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma|Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous IL-21 Modulated CD8+ Antigen-Specific T Cells For Patients With Metastatic Melanoma|Terminated||Phase 1|12|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 23:53:26.021041|2018-05-31 23:53:26.021041
NCT01106222|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-04-16|2010-04-16|2010-04-19|Estimate|||||||2010-04-16|2010-04-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:53:26.107739|2018-05-31 23:53:26.107739
NCT01106209|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2017-10-25|2010-04-15|2010-04-19|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2010||2010-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Necrotizing Enterocolitis|Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Necrotizing Enterocolitis|Suspended|||60|Anticipated|University of Utah|||3|Seeking further funding|f||||f||||||Samples With DNA|"~     blood and intestinal tissue samples~   "|||2018-05-31 23:53:26.137275|2018-05-31 23:53:26.137275
NCT01106196|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2014-12-01|2010-04-16|2010-04-19|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||The Role of Influenza as a Trigger for Acute Myocardial Infarction: a CALIBER Study|The Role of Influenza as a Trigger for Acute Myocardial Infarction: a Self-controlled Case Series Analysis of Linked Data From the Myocardial Ischaemia National Audit Project (MINAP) and the General Practice Research Database (GPRD)|Completed|||11208|Actual|University College, London|||1||f||||t||||||||||2018-05-31 23:53:26.198494|2018-05-31 23:53:26.198494
NCT01106183|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2011-11-14|2010-04-15|2010-04-19|Estimate|||||||2011-11-14|2011-11-16|Estimate|January 2010||2010-01-31|November 2011|2011-11-30||||March 2010|Actual|2010-03-31||Interventional|||Efficacy of Transfer Factor to Prevent Upper Respiratory Tract Infections in Healthy Adults|A Double Blind Study on the Efficacy of a Colostrum and Egg Yolk Supplement vs. Placebo to Reduce Frequency and Duration of Upper Respiratory Tract Infections in Healthy Adults|Completed||N/A|49|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 23:53:26.254512|2018-05-31 23:53:26.254512
NCT01106170|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2015-01-13|2010-04-15|2010-04-19|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure|A Double-Blind, Placebo-Controlled, Crossover Evaluation of a Grape Seed Extract and Quercetin Supplement (Provex CV) to Reduce Markers of Inflammatory Cytokines and Blood Pressure in Subjects With Metabolic Syndrome|Completed||Phase 1|20|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 23:53:26.319027|2018-05-31 23:53:26.319027
NCT01106157|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2015-10-14||2018-02-07|2010-04-15|2010-04-19|Estimate|2016-01-19|2016-01-20|Estimate||||2018-02-07|2018-03-08|Actual|April 2010|Actual|2010-04-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|January 2015|Actual|2015-01-31||Interventional|||Reversing Type 1 Diabetes After it is Established|Reversing Type 1 Diabetes After it is Established: A Pilot Safety and Feasibility Study of Anti-Thymocyte Globulin (Thymoglobulin®)and Pegylated GCSF (Neulasta®) in Established Type 1 Diabetes|Active, not recruiting||Phase 1/Phase 2|25|Actual|University of Florida||2|||f||||t|t|f||||||||2018-05-31 23:53:26.385567|2018-05-31 23:53:26.385567
NCT01106144|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2011-05-23|2010-04-15|2010-04-19|Estimate|||||||2011-05-23|2011-05-24|Estimate|May 2010||2010-05-31|May 2011|2011-05-31||||||||Observational|||Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia|Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia|Unknown status|Recruiting||500|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     Preserved bone marrow sample from the adult patients with acute myeloid leukemia~   "|||2018-05-31 23:53:27.016712|2018-05-31 23:53:27.016712
NCT01106131|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2013-02-13|2010-04-16|2010-04-19|Estimate|||||||2013-02-13|2013-02-15|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin|Efficacy and Safety of CKD-501 or Pioglitazone Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: Multi Center, Randomized, Double Blind, Therapeutic Confirmatory Study|Completed||Phase 3|253|Actual|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-05-31 23:53:27.072469|2018-05-31 23:53:27.072469
NCT01106118|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2016-10-14|2010-04-16|2010-04-19|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Observational|REVITALISE||Therapeutic Effectiveness of Vardenafil in Patients With Erectile Dysfunction and Metabolic Syndrome in Daily Clinical Practice|Therapeutic Effectiveness of Vardenafil in ED Patients With the Metabolic Syndrome in Daily Clinical Practice|Completed|||2289|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-05-31 23:53:27.148762|2018-05-31 23:53:27.148762
NCT01106105|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2010-04-16|2010-04-16|2010-04-19|Estimate|||||||2010-04-16|2010-04-19|Estimate|April 2010||2010-04-30|April 2010|2010-04-30||||||||Observational|||Impact of Obesity on Postural Control||Completed|||||Université Joseph Fourier|||2||f||||f||||||||||2018-05-31 23:53:27.246921|2018-05-31 23:53:27.246921
NCT01106092|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2017-03-01|2010-12-10|2017-04-19|2010-04-14|2010-04-19|Estimate|2017-03-01|2017-04-12|Actual|2010-12-10|2010-12-16|Estimate|2017-04-19|2017-05-17|Actual|May 1, 2010||2010-05-01|March 2017|2017-03-31|September 2, 2010|Actual|2010-09-02|September 2, 2010|Actual|2010-09-02||Interventional|||Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers|Immunogenicity and Reactogenicity of a Booster Dose of GlaxoSmithKline Biologicals' GSK2036874A Vaccine in Healthy Toddlers|Completed||Phase 2|312|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:53:27.345243|2018-05-31 23:53:27.345243
NCT01106079|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2015-05-27|2010-04-16|2010-04-19|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|TICOPA||TIght COntrol of Psoriatic Arthritis|A Randomised Controlled Trial to Compare Intensive Management vs Standard Care in Early Psoriatic Arthritis|Completed||Phase 3|206|Actual|University of Leeds||2|||f||||t||||||||||2018-05-31 23:53:28.284049|2018-05-31 23:53:28.284049
NCT01106066|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-06-12|2010-04-15|2010-04-19|Estimate|||||||2013-06-12|2013-06-14|Estimate|March 2009||2009-03-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT|A Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer|Terminated||Phase 1/Phase 2|30|Actual|Samsung Medical Center||1||Difficulties in recruiting patients|f||||f||||||||||2018-05-31 23:53:28.367036|2018-05-31 23:53:28.367036
NCT01106053|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-05-03|2010-04-15|2010-04-19|Estimate|||||||2013-05-03|2013-05-06|Estimate|April 2010||2010-04-30|May 2013|2013-05-31||||July 2011|Actual|2011-07-31||Interventional|||Pramipexole for Binge Eating Disorder|An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder|Withdrawn||Phase 3|0|Actual|Neuropsychiatric Research Institute, Fargo, North Dakota||1||No participants were recruited and study has been closed.|f||||f||||||||||2018-05-31 23:53:28.440368|2018-05-31 23:53:28.440368
NCT01106040|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2013-04-13|2012-03-28|2013-06-06|2010-04-15|2010-04-19|Estimate|2013-04-13|2013-06-03|Estimate|2012-03-28|2012-03-30|Estimate|2013-06-06|2013-06-17|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Of the 163 participants who enrolled in the trial, 153 were administered the study agent, Lymphoseek, and therefore this participant number is used for the baseline analysis.|Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes|A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping|Completed||Phase 3|163|Actual|Navidea Biopharmaceuticals||1|||f||||f||||||||||2018-05-31 23:53:28.513221|2018-05-31 23:53:28.513221
NCT01106027|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|2017-10-12||2018-01-08|2010-04-15|2010-04-19|Estimate|2017-10-12|2017-11-14|Actual||||2018-01-08|2018-01-31|Actual|March 2010|Actual|2010-03-31|January 2018|2018-01-31|August 19, 2016|Actual|2016-08-19|August 19, 2016|Actual|2016-08-19||Interventional|||Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant|A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Acute Humoral Rejection (AHR) in Positive Crossmatch Deceased Donor Kidney Transplantation|Terminated||Phase 1/Phase 2|2|Actual|Mayo Clinic|The study was terminated early due to difficulty enrolling and competing industry-funded multi-center clinical trial.|1||Difficulty enrolling; competing industry-funded multi-center clinical trial|f||||f|t|f|||t|||||2018-05-31 23:53:28.686415|2018-05-31 23:53:28.686415
NCT01106014|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|2016-02-02||2017-12-13|2010-04-16|2010-04-19|Estimate|2016-02-02|2016-03-01|Estimate||||2017-12-13|2018-01-11|Actual|December 1, 2009||2009-12-01|December 2017|2017-12-31|October 1, 2014|Actual|2014-10-01|April 1, 2014|Actual|2014-04-01||Interventional|GRIPHON||Selexipag (ACT-293987) in Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension|Completed||Phase 3|1156|Actual|Actelion||2|||f||||t||||||||||2018-05-31 23:53:29.067815|2018-05-31 23:53:29.067815
NCT01106001|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-16|2010-04-16|2010-04-19|Estimate|||||||2010-04-16|2010-04-19|Estimate|September 2008||2008-09-30|July 2008|2008-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study to Test the Efficacy of Periarticular Levo Bupivicaine Injection Following Primary Hip Arthroplasty|A Double Blind Randomized Control Trial on the Efficacy of Periarticular Levo Bupivicaine Injection Following Primary Hip Arthroplasty|Completed||Phase 4|91|Actual|Orthopaedic Research and Innovation Foundation||2|||f||||t||||||||||2018-05-31 23:53:30.772485|2018-05-31 23:53:30.772485
NCT01105988|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2012-01-04|2010-04-15|2010-04-19|Estimate|||||||2012-01-04|2012-01-06|Estimate|May 2011||2011-05-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluating Tumor Pseudoprogression With FLT-PET and MRI|A Pilot Study to Evaluate Tumor Pseudoprogression With FLT-PET and MRI|Terminated||Early Phase 1|2|Actual|Massachusetts General Hospital||||Funding ended|f||||t||||||||||2018-05-31 23:53:30.842461|2018-05-31 23:53:30.842461
NCT01105975|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2018-02-18|2011-09-20|2018-02-18|2010-04-15|2010-04-19|Estimate|2018-02-18|2018-03-22|Actual|2011-09-20|2011-09-26|Estimate|2018-02-18|2018-03-22|Actual|April 2010||2010-04-30|February 2018|2018-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of LY2484595 in Patients With High LDL-C or Low HDL-C|A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C|Completed||Phase 2|398|Actual|Eli Lilly and Company||10|||f||||t||||||||||2018-05-31 23:53:31.185478|2018-05-31 23:53:31.185478
NCT01105962|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2016-09-17|2010-04-15|2010-04-19|Estimate|||||||2016-09-17|2016-09-20|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|NBIRR-1||Hyperbaric Oxygen Therapy in Chronic Traumatic Brain Injury or Post-Traumatic Stress Disorder|Multicenter Observational Study of Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post-Concussion Syndrome (PCS) and/or TBI/Post-Traumatic Stress Disorder (PTSD)|Terminated|||133|Actual|International Hyperbaric Medical Foundation||||new regulatory requirements will require funding for restart as a new study|f||||t||||||||||2018-05-31 23:53:36.761025|2018-05-31 23:53:36.761025
NCT01105949|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2012-01-25|2010-04-15|2010-04-19|Estimate|||||||2012-01-25|2012-01-30|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||An Evaluation of Two Novel Nasal Strip Prototypes on Nasal Patency|An Evaluation of Two Novel Breathe Right Nasal Strip Prototypes on Nasal Patency|Completed||Phase 1|50|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 23:53:36.888202|2018-05-31 23:53:36.888202
NCT01105936|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2013-06-20||2017-05-29|2010-04-15|2010-04-19|Estimate|2015-03-12|2015-03-24|Estimate||||2017-05-29|2017-06-21|Actual|September 1, 2010||2010-09-01|May 2017|2017-05-31|August 1, 2011|Actual|2011-08-01|August 1, 2011|Actual|2011-08-01||Interventional|||Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)|A Randomised, Double-blind, Evaluation of the Effects of Paracetamol on the BOLD fMRI Response to Painful Stimuli in Subjects With Osteoarthritis|Completed||Phase 4|31|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 23:53:37.001126|2018-05-31 23:53:37.001126
NCT01105923|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2015-01-30|2010-04-16|2010-04-19|Estimate|||||||2015-01-30|2015-02-02|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|November 2017|Anticipated|2017-11-30|November 2010|Actual|2010-11-30||Interventional|MAPLE||Study of an Intervention to Improve Problem List Accuracy and Use|Making Accurate Problem Lists in the EHR|Unknown status|Active, not recruiting|N/A|140|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:53:37.432532|2018-05-31 23:53:37.432532
NCT01105897|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2012-08-30|2010-04-16|2010-04-19|Estimate|||||||2012-08-30|2012-08-31|Estimate|January 2005||2005-01-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Prospective Study of the Outcomes of the Surgical Treatment of Deeply Infiltrating Endometriosis|Incidence of Deeply Infiltrating Endometriosis in Surgically Treated Endometriosis Patients and Long-term Results of Surgical Treatment in Terms of Pain, Quality of Life and Sexual Functioning|Unknown status|Active, not recruiting||201|Actual|PaijatHame Central Hospital|||1||f||||f||||||||||2018-05-31 23:53:37.691144|2018-05-31 23:53:37.691144
NCT01105884|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2012-04-21|2010-04-16|2010-04-19|Estimate|||||||2012-04-21|2012-04-24|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers||Unknown status|Recruiting|N/A|50|Anticipated|M.V. Hospital for Diabetes||5|||f||||f||||||||||2018-05-31 23:53:37.766895|2018-05-31 23:53:37.766895
NCT01105871|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2012-08-17|2010-04-16|2010-04-19|Estimate|||||||2012-08-17|2012-08-21|Estimate|August 2010||2010-08-31|August 2012|2012-08-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|Narcan||Subjective Analgesic Effects of Naloxone and Virtual Reality|Subjective Analgesic Effects of Naloxone and Virtual Reality|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 23:53:37.864078|2018-05-31 23:53:37.864078
NCT01105858|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2017-10-26|2010-04-16|2010-04-19|Estimate|||||||2017-10-26|2017-10-27|Actual|April 1, 2010||2010-04-01|October 24, 2017|2017-10-24||||||||Observational|||Molecular and Clinical Profile of Diabetes Mellitus and Its Complications|Molecular and Clinical Profile of Diabetes Mellitus and Its Complications|Recruiting|||999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:53:37.94276|2018-05-31 23:53:37.94276
NCT01105845|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-16|||2018-05-22|2010-04-16|2010-04-19|Estimate|||||||2018-05-22|2018-05-23|Actual|April 14, 2010||2010-04-14|December 21, 2015|2015-12-21|December 21, 2015||2015-12-21|||||Observational|||Genetics of Motor Learning|Genetics of Motor Learning|Terminated|||5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:53:38.032696|2018-05-31 23:53:38.032696
NCT01105832|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-12-09|2010-04-16|2010-04-19|Estimate|||||||2014-12-09|2014-12-10|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?|Påskyndar PTH läkningen av Konservativt Behandlade Humerusfrakturer?|Completed||Phase 4|40|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 23:53:38.103613|2018-05-31 23:53:38.103613
NCT01105819|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2018-05-13|2010-04-16|2010-04-19|Estimate|||||||2018-05-13|2018-05-17|Actual|April 2010||2010-04-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2016|Actual|2016-01-31||Interventional|||Chlorhexidine vs Lactobacillus Plantarum for Oral Care in Intubated ICU Patients|A Study Comparing a Suspension of Lactobacillus Plantarum 299 With Chlorhexidine for Oral Care in Intubated Mechanically Ventilated Patients in Intensive Care|Completed||N/A|100|Actual|Region Skane||2|||f||||t||||||||Yes|Results are under review and are planned for publishing in a scientific journal|2018-05-31 23:53:38.243824|2018-05-31 23:53:38.243824
NCT01105806|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2015-07-15|2010-04-16|2010-04-19|Estimate|||||||2015-07-15|2015-07-16|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Cardiopulmonary Resuscitation (CPR) Video to Enhance Advance Care Planning in Advanced Upper Gastrointestinal Cancer Patients|The Use of a CPR Video to Enhance Advance Care Planning in Advanced Upper Gastrointestinal Cancer Patients: A Randomized Controlled Pilot Tria|Completed|||57|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 23:53:38.339981|2018-05-31 23:53:38.339981
NCT01105793|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-10-25|2010-04-15|2010-04-16|Estimate|||||||2011-10-25|2011-10-26|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia||Completed||Phase 2|20|Anticipated|FemmePharma Global Healthcare, Inc.|||||f||||f||||||||||2018-05-31 23:53:38.720549|2018-05-31 23:53:38.720549
NCT01105780|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2014-04-07|2010-04-15|2010-04-16|Estimate|||||||2014-04-07|2014-04-08|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|August 2010|Actual|2010-08-31|||||Interventional|||JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study|Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male and Female Caucasian and Male Japanese Subjects|Completed||Phase 1|32|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-05-31 23:53:38.781844|2018-05-31 23:53:38.781844
NCT01105767|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2014-03-06||2014-11-02|2010-04-15|2010-04-16|Estimate|2014-11-02|2014-11-04|Estimate||||2014-11-02|2014-11-04|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Participants that developed SSTI.|Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees|Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees|Completed||N/A|30209|Actual|Uniformed Services University of the Health Sciences||3|||f||||f||||||||||2018-05-31 23:53:38.866978|2018-05-31 23:53:38.866978
NCT01105754|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2015-09-15||2016-01-15|2010-04-15|2010-04-16|Estimate|2015-09-15|2015-10-16|Estimate||||2016-01-15|2016-02-08|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Interventional|PAIR-UP||A Multifaceted Prompting Intervention for Urban Children With Asthma|A Multifaceted Prompting Intervention for Urban Children With Asthma|Completed||N/A|638|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 23:53:39.195038|2018-05-31 23:53:39.195038
NCT01105741|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-02-04|2010-04-15|2010-04-16|Estimate|||||||2014-02-04|2014-02-05|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Observational|MB||Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)|Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)|Completed|||25|Actual|University of Calgary|||1||f||||f||||||Samples Without DNA|"~     Serum, plasma and urine~   "|||2018-05-31 23:53:39.476642|2018-05-31 23:53:39.476642
NCT01105728|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2012-04-23|2010-04-15|2010-04-16|Estimate|||||||2012-04-23|2012-04-24|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|EndoResect||Endoscopic Resection of Gastric Subepithelial Masses, EndoResect Study|Endoscopic Resection of Gastric Subepithelial Masses, EndoResect Study|Completed||Phase 1|38|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 23:53:39.620979|2018-05-31 23:53:39.620979
NCT01105377|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2013-08-29||2014-07-30|2010-04-15|2010-04-16|Estimate|2013-08-29|2013-11-01|Estimate||||2014-07-30|2014-08-01|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|March 2012|Actual|2012-03-31||Interventional||All participants accrued to this study are included in the description of baseline patient demographics.|Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of Azacitadine and Entinostat in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|47|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:53:44.082346|2018-05-31 23:53:44.082346
NCT01105715|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-06-18|2010-04-15|2010-04-16|Estimate|||||||2013-06-18|2013-06-19|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|cLDL in RA||Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis|cLDL as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis|Completed|||100|Anticipated|University of Arkansas|||2||f||||f||||||Samples With DNA|"~     If a subject consents, any blood samples remaining after the tests planned for this study~     will be stored indefinitely for potential future new studies. Any future new studies using~     these blood samples will require prior approval by the UAMS Institutional Review Board (IRB).~     A subject may request destruction of the stored samples at any time.~   "|||2018-05-31 23:53:39.725259|2018-05-31 23:53:39.725259
NCT01105702|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2015-10-05||2016-07-06|2010-04-15|2010-04-16|Estimate|2015-10-05|2015-11-06|Estimate||||2016-07-06|2016-08-04|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional||All patients enrolled|Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma|Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study|Terminated||Phase 2|28|Actual|New York University School of Medicine||1||Due to slow accrual|f||||t||||||||||2018-05-31 23:53:39.812713|2018-05-31 23:53:39.812713
NCT01105689|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2011-09-08|2010-04-15|2010-04-16|Estimate|||||||2011-09-08|2011-09-09|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers|Utility of the Urine Calcium Creatinine Ratio as a Screening Tool for Vitamin D Deficiency in Infants and Toddlers|Completed|||60|Actual|Nemours Children's Clinic|||||f||||f||||||Samples Without DNA|"~     Whole Blood will be obtained from which we will collect serum and fresh urine which will be~     used for study labs. Urine and serum may be stored for future studies.~   "|||2018-05-31 23:53:40.264873|2018-05-31 23:53:40.264873
NCT01105676|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2014-01-06|2010-04-15|2010-04-16|Estimate|||||||2014-01-06|2014-01-07|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Vascular Malformations and Abnormalities of Growth|Vascular Malformations and Abnormalities of Growth|Completed||N/A|50|Anticipated|Medical College of Wisconsin||1|||f||||f||||||||||2018-05-31 23:53:40.391824|2018-05-31 23:53:40.391824
NCT01105663|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-01-26|2010-04-15|2010-04-16|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2010|Actual|2010-03-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PISA||Pharmacologic Impact on Sedation Assessments|Pharmacologic Impact on Sedation Assessment|Completed|||175|Actual|Children's Hospital of Philadelphia|||2||f||||t||||||Samples With DNA|"~     The primary evaluation will be the assessment of morphine/midazolam pharmacokinetics (PK) and~     pharmacodynamics (PD). Data from all fully evaluable subjects will be included in the~     analysis. Analyses will be model based.~   "|||2018-05-31 23:53:40.471922|2018-05-31 23:53:40.471922
NCT01105650|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2017-01-04||2017-12-03|2010-04-15|2010-04-16|Estimate|2017-01-04|2017-02-24|Actual||||2017-12-03|2017-12-28|Actual|July 2010||2010-07-31|December 2017|2017-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer|Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)|Completed||Phase 2|13|Actual|Masonic Cancer Center, University of Minnesota||4|||f||||t||||||||||2018-05-31 23:53:40.577285|2018-05-31 23:53:40.577285
NCT01105637|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2016-06-21|2010-04-15|2010-04-16|Estimate|||||||2016-06-21|2016-06-23|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|AEP||A Trial of an Augmented Exercise Program in the Prevention of Deconditioning Among Survivors of Severe Burns|A Trial of an Augmented Exercise Program in the Prevention of Deconditioning Among Survivors of Severe Burns|Completed||N/A|20|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 23:53:40.998702|2018-05-31 23:53:40.998702
NCT01105624|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15||2011-03-24|2011-09-20|2010-04-15|2010-04-16|Estimate||||2011-03-30|2011-04-01|Estimate|2011-09-20|2011-09-26|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)||Completed||Phase 4|50|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 23:53:41.074963|2018-05-31 23:53:41.074963
NCT01105611|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2011-07-20|2010-04-15|2010-04-16|Estimate|||||||2011-07-20|2011-07-21|Estimate|August 2010||2010-08-31|March 2010|2010-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users|An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone|Unknown status|Recruiting|Phase 4|40|Anticipated|St. James's Hospital, Ireland||2|||f||||t||||||||||2018-05-31 23:53:41.193287|2018-05-31 23:53:41.193287
NCT01105598|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-11-16|2010-04-15|2010-04-16|Estimate|||||||2010-11-16|2010-11-18|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia|A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ETC-1002 in Subjects With Mild Dyslipidemia|Completed||Phase 1|53|Actual|Esperion Therapeutics||5|||f||||f||||||||||2018-05-31 23:53:41.495134|2018-05-31 23:53:41.495134
NCT01105585|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2012-11-27|2010-04-15|2010-04-16|Estimate|||||||2012-11-27|2012-11-29|Estimate|April 2010||2010-04-30|November 2012|2012-11-30||||June 2011|Actual|2011-06-30||Interventional|||A Comparative Pilot Study Of High-Order Aberrations With Aspheric IOL Models SN60WF and ZCB00|A Comparative Pilot Study Of High-Order Aberrations With Aspheric Intraocular Lens (IOL) Models SN60WF And ZCB00|Completed||N/A|20|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:53:41.728759|2018-05-31 23:53:41.728759
NCT01105572|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-04-15|2010-04-15|2010-04-16|Estimate|||||||2010-04-15|2010-04-16|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Aetna_Intel Medicare Home Biomonitoring Study|Study of Impact of Home Biomonitoring With Nurse Case Manager Support for a Congestive Heart Failure Cohort, Compared to Case Manager Support Without Biomonitoring|Completed||N/A|316|Actual|Aetna, Inc.||2|||f||||f||||||||||2018-05-31 23:53:41.827245|2018-05-31 23:53:41.827245
NCT01105559|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2011-12-12|2010-04-15|2010-04-16|Estimate|||||||2011-12-12|2011-12-13|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine|Antibody Persistence in Healthy South African Children After Primary Series and Booster Vaccination With an Investigational (DTaP-IPV-Hep B-PRP-T) or Control Vaccines|Completed|||455|Actual|Sanofi|||3||f||||f||||||||||2018-05-31 23:53:41.917564|2018-05-31 23:53:41.917564
NCT01105546|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-04-05|2010-04-15|2010-04-16|Estimate|||||||2013-04-05|2013-04-08|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Interventional|ENJOIH||rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors|An Investigator-initiated Study on rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors - European Initiative to Prevent Joint Damage in Hemophilia A Children With Inhibitors|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||t||||||||||2018-05-31 23:53:41.996806|2018-05-31 23:53:41.996806
NCT01105533|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2012-12-20||2013-02-13|2010-04-15|2010-04-16|Estimate|2013-02-13|2013-03-19|Estimate||||2013-02-13|2013-03-19|Estimate|May 2006||2006-05-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|October 2010|Actual|2010-10-31||Interventional|||A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors|Phase I, Open-Label, Multi-Center, Accelerated Dose Escalation Study Of The Anti-Angiogenesis Agent PF-00337210 In Patients With Advanced Solid Tumors|Completed||Phase 1|46|Actual|Pfizer|Designation of outcomes as primary and secondary was based on study team input as study did not specify primary or secondary outcome measures.|10|||f||||f||||||||||2018-05-31 23:53:42.173797|2018-05-31 23:53:42.173797
NCT01105520|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-04-15|2010-04-15|2010-04-16|Estimate|||||||2010-04-15|2010-04-16|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|December 2015||2015-12-31|||||Observational|||Neurologic and Neurophysiologic Assessment of Clinical Course in Patients With Intraspinal Processes||Unknown status|Recruiting||100|Anticipated|University of Zurich|||1||f||||||||||||||2018-05-31 23:53:43.205968|2018-05-31 23:53:43.205968
NCT01105507|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2017-03-17|2010-04-15|2010-04-16|Estimate|||||||2017-03-17|2017-03-21|Actual|August 2010||2010-08-31|March 2017|2017-03-31|May 12, 2012|Actual|2012-05-12|May 12, 2012|Actual|2012-05-12||Interventional|||The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada|An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada|Completed||Phase 3|4|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:53:43.276389|2018-05-31 23:53:43.276389
NCT01105494|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2012-09-12|2010-04-15|2010-04-16|Estimate|||||||2012-09-12|2012-09-13|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia|Prospective Study Evaluating the Quality of Life in Dialysis Patients With End Stage Renal Disease|Completed|||6000|Actual|Hoffmann-La Roche|||||f||||||||||||||2018-05-31 23:53:43.358572|2018-05-31 23:53:43.358572
NCT01105481|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-04-14|2010-04-14|2010-04-16|Estimate|||||||2010-04-14|2010-04-16|Estimate|May 2006||2006-05-31|April 2010|2010-04-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|M1106||Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients|Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients: A 14-week Randomized, Double-blind and Placebo-controlled Trial|Completed||Phase 4|273|Actual|National Health Research Institutes, Taiwan||2|||f||||f||||||||||2018-05-31 23:53:43.426487|2018-05-31 23:53:43.426487
NCT01105468|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2013-01-11|2010-04-15|2010-04-16|Estimate|||||||2013-01-11|2013-01-14|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|April 2017|Anticipated|2017-04-30|April 2013|Anticipated|2013-04-30||Observational|||Breath Gas Analysis for the Diagnosis of Breast Cancer|Leistungsbewertungsprüfung: Atemluftanalyse für Die Diagnose Von Brustkrebs, für Die Überwachung Der Therapie Und für Die Voraussage Des Metastasenrisikos|Terminated|||202|Actual|Ionimed Analytik GmbH|||3|"Sponsor quit partnership in Oncotyrol-Center for Personalized Medicine, and consequential loss~   of public funding."|f||||f||||||||||2018-05-31 23:53:43.535689|2018-05-31 23:53:43.535689
NCT01105455|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-03-11|2010-04-15|2010-04-16|Estimate|||||||2013-03-11|2013-03-12|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Pregnant Women at Risk for Gestational Diabetes|The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Pregnant Women at Risk for Gestational Diabetes|Completed||N/A|103|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 23:53:43.600612|2018-05-31 23:53:43.600612
NCT01105442|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2011-07-20|2010-04-15|2010-04-16|Estimate|||||||2011-07-20|2011-07-21|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Observational|||Local Anaesthesia Used During Fast-track Colonic Surgery: Evaluation of Bupivacaine and Levobupivacaine in Practice|Local Anaesthesia Used During Fast-track Colonic Surgery: Evaluation of Bupivacaine and Levobupivacaine in Practice|Completed|||14|Actual|Martini Hospital Groningen|||2||f||||t||||||||||2018-05-31 23:53:43.668501|2018-05-31 23:53:43.668501
NCT01105429|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-03-08|2010-04-15|2010-04-16|Estimate|||||||2011-03-08|2011-03-09|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes on Background Therapy of Metformin|Completed||Phase 1|56|Actual|Bristol-Myers Squibb||9|||f||||f||||||||||2018-05-31 23:53:43.732525|2018-05-31 23:53:43.732525
NCT01105416|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2014-11-03|2010-04-15|2010-04-16|Estimate|||||||2014-11-03|2014-11-05|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Emergency Department (ED) Adolescent Alcohol Prevention Intervention|Emergency Department Based Prevention Intervention to Delay Alcohol Use by Young Adolescents|Completed||N/A|196|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 23:53:43.848426|2018-05-31 23:53:43.848426
NCT01105403|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-04-22|2010-04-15|2010-04-16|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Exploratory Study on POL6326 in Stem Cell Mobilization|A Phase IIa, Proof of Concept Study is to Determine the Degree of Mobilisation of CD34+ Cells Following Administration of POL6326 in Patients With Multiple Myeloma|Completed||Phase 2|21|Actual|Polyphor Ltd.||1|||f||||t||||||||||2018-05-31 23:53:43.92253|2018-05-31 23:53:43.92253
NCT01105390|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-08-01|2010-04-15|2010-04-16|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2010||2010-04-30|January 2013|2013-01-31||||May 2011|Actual|2011-05-31||Interventional|||AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma|A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1||withdrawn|f||||||||||||||2018-05-31 23:53:43.98808|2018-05-31 23:53:43.98808
NCT01105364|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-08-09|2010-04-15|2010-04-16|Estimate|||||||2013-08-09|2013-08-12|Estimate|December 2007||2007-12-31|September 2011|2011-09-30||||March 2012|Anticipated|2012-03-31||Interventional|||Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer|Early Assessment of Anti-Angiogenic Treatment Efficacy in Advanced Renal Cancer by Using Contrast-Enhanced Sonography|Unknown status|Recruiting|N/A|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:53:44.657533|2018-05-31 23:53:44.657533
NCT01105351|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2018-05-07|2010-04-15|2010-04-16|Estimate|||||||2018-05-07|2018-05-14|Actual|June 2010||2010-06-30|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Folic Acid on Primary Folate Forms in Relation to MTHFR|Effect of Mild Increase in Folic Acid Intake on the Distribution of Folate Forms in Relation to a Common Polymorphism in One Folate Catabolising Enzyme|Completed||N/A|75|Actual|Saarland University||2|||f||||f||||||||||2018-05-31 23:53:44.770092|2018-05-31 23:53:44.770092
NCT01105338|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2018-01-19|2010-04-15|2010-04-16|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2009||2009-08-31|January 2018|2018-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|ProDiet||Lycopene or Green Tea for Men at Risk of Prostate Cancer|Lycopene or Green Tea a Feasibility Study in Men at Risk of Prostate Cancer|Completed||Phase 2/Phase 3|126|Actual|University of Bristol||6|||f||||f||||||||||2018-05-31 23:53:44.875822|2018-05-31 23:53:44.875822
NCT01105325|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-10-01|2010-04-15|2010-04-16|Estimate|||||||2010-10-01|2010-10-04|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|SCAVANCE||Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care|Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care (CIC) - Electronic Measurement of Compliance|Terminated|||1000|Anticipated|AstraZeneca||||due to poor patient recruitment|f||||f||||||||||2018-05-31 23:53:45.042636|2018-05-31 23:53:45.042636
NCT01105312|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2017-02-28||2017-05-23|2010-04-15|2010-04-16|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|September 2010|Actual|2010-09-30|May 2017|2017-05-31|September 3, 2013|Actual|2013-09-03|August 2013|Actual|2013-08-31||Interventional||All phase I and phase II patients were used for baseline analysis|Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer|Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer|Completed||Phase 1/Phase 2|28|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 23:53:45.313382|2018-05-31 23:53:45.313382
NCT01105299|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-04-15|2010-04-15|2010-04-16|Estimate|||||||2010-04-15|2010-04-16|Estimate|June 2008||2008-06-30|April 2010|2010-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Bioequivalence Study of Anastrozole 1 mg Tablet|Bioequivalence Study of CJ Anastrozole 1mg Tablet and Arimidex® 1 mg Tablet|Completed||N/A|24|Actual|Asan Medical Center|||||f||||t||||||||||2018-05-31 23:53:46.163933|2018-05-31 23:53:46.163933
NCT01105286|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2013-10-24|2010-04-15|2010-04-16|Estimate|||||||2013-10-24|2013-10-25|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis||Completed||Phase 1|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 23:53:46.225353|2018-05-31 23:53:46.225353
NCT01105273|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2012-12-30|2010-04-15|2010-04-16|Estimate|||||||2012-12-30|2013-01-03|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia|HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia After Conditioning of Fludarabine, Cyclophosphamide and Antithymocyte Globulin|Completed||Phase 1/Phase 2|12|Actual|Asan Medical Center||1|||f||||||||||||||2018-05-31 23:53:46.285683|2018-05-31 23:53:46.285683
NCT01105260|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2015-07-27|2010-04-15|2010-04-16|Estimate|||||||2015-07-27|2015-07-28|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|||Effects of an Early Wheelchair Reconditionong Program on Functional Independence in Spinal Cord-inured Individuals|Effects of an Early Wheelchair Reconditionong Program on Functional Independence in Spinal Cord-inured Individuals|Terminated|||20|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2|Difficulty to include patients|f||||t||||||||||2018-05-31 23:53:46.359622|2018-05-31 23:53:46.359622
NCT01105247|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2013-12-16||2014-02-13|2010-04-14|2010-04-16|Estimate|2014-02-13|2014-03-31|Estimate||||2014-02-13|2014-03-31|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Safety of PCI-32765 in Chronic Lymphocytic Leukemia|A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|133|Actual|Pharmacyclics LLC.||1|||f||||f||||||||||2018-05-31 23:53:46.43671|2018-05-31 23:53:46.43671
NCT01105234|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-03-25|2010-04-15|2010-04-16|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects|An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects|Completed||Phase 1|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 23:53:47.217732|2018-05-31 23:53:47.217732
NCT01105221|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-01-07|2010-04-15|2010-04-16|Estimate|||||||2011-01-07|2011-01-10|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Acupuncture for Dry Eye|Acupuncture for Dry Eye: a Multicenter Randomized Controlled Trial With Active Comparison Intervention (Artificial Tear Drop) Using a Mixed Method Approach|Completed||Phase 3|150|Anticipated|Korea Institute of Oriental Medicine||2|||f||||t||||||||||2018-05-31 23:53:47.293692|2018-05-31 23:53:47.293692
NCT01105208|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-05-19|2010-04-15|2010-04-16|Estimate|||||||2014-05-19|2014-05-20|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension|Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef From Bayer (Cephalexin Suspension 250 mg/5 mL and Equivalent Concentration of Keflex Pediatrico From Eli Lilly (Cephalexin Suspension 125 mg/5mL) in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|26|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:53:47.378649|2018-05-31 23:53:47.378649
NCT01105195|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-11-16|2010-04-15|2010-04-16|Estimate|||||||2010-11-16|2010-11-17|Estimate|January 2010||2010-01-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy of Surgical Preparations in Lumbar Spine Surgery|Efficacy of Surgical Preparations in Lumbar Spine Surgery|Completed||N/A|100|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 23:53:47.43621|2018-05-31 23:53:47.43621
NCT01105182|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-15|2010-04-15|2010-04-16|Estimate|||||||2010-04-15|2010-04-16|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Observational|FACPT||Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors|A Prospective Study of Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors|Unknown status|Recruiting||48|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||1||f||||t||||||||||2018-05-31 23:53:47.537344|2018-05-31 23:53:47.537344
NCT01104818|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2014-02-10|2010-04-14|2010-04-15|Estimate|||||||2014-02-10|2014-02-12|Estimate|May 2010||2010-05-31|April 2010|2010-04-30||||April 2014|Anticipated|2014-04-30||Interventional|SIBS||Siblings in Foster Care|Evaluation of Intervention for Siblings in Foster Care|Unknown status|Not yet recruiting|N/A|480|Anticipated|Portland State University|||||f||||f||||||||||2018-05-31 23:53:54.79944|2018-05-31 23:53:54.79944
NCT01105169|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2017-08-10|2010-04-14|2010-04-16|Estimate|||||||2017-08-10|2017-08-14|Actual|August 2010||2010-08-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Personalized Prevention of Colorectal Cancer Trial|Investigational Nutrigenetic Studies for Cancer Prevention|Active, not recruiting||N/A|250|Actual|Vanderbilt University Medical Center||4|||f||||||||||||||2018-05-31 23:53:47.635577|2018-05-31 23:53:47.635577
NCT01105156|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-15|2010-04-15|2010-04-16|Estimate|||||||2010-04-15|2010-04-16|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Observational|||Outcomes of Gastric Band Fills as Found With a Patient Self-reported Questionnaire: The Vomiting, Eating, and Weight Loss (VEW) Questionnaire|Outcomes of Gastric Band Fills as Found With a Patient Self-reported Questionnaire. The VEW [Vomiting, Eating, and Weight Loss] Questionnaire|Unknown status|Not yet recruiting||361|Anticipated|North Eastern Weight Loss Surgery|||1||f||||f||||||||||2018-05-31 23:53:47.701379|2018-05-31 23:53:47.701379
NCT01105143|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2017-12-18|2010-04-15|2010-04-16|Estimate|||||||2017-12-18|2017-12-20|Actual|March 2012|Actual|2012-03-31|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Negative Energy Balance on Muscle Mass Regulation|Effects of Negative Energy Balance on Muscle Mass Regulation|Completed||N/A|81|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 23:53:47.767026|2018-05-31 23:53:47.767026
NCT01105130|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2015-01-12||2017-05-25|2010-04-14|2010-04-16|Estimate|2015-07-15|2015-07-21|Estimate||||2017-05-25|2017-06-20|Actual|October 2010||2010-10-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||All randomized participants|L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors|A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated With Radiotherapy|Completed||N/A|140|Actual|Wake Forest University Health Sciences||3|||f||||t|f|f||||||||2018-05-31 23:53:47.848036|2018-05-31 23:53:47.848036
NCT01105117|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2012-07-20||2012-11-29|2010-04-15|2010-04-16|Estimate|2012-07-20|2012-08-23|Estimate||||2012-11-29|2012-12-03|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|EPITOME-1 Ext||Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401|An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 4|2|Actual|Actelion||2|||f||||f||||||||||2018-05-31 23:53:49.401618|2018-05-31 23:53:49.401618
NCT01105104|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2011-11-07|2010-04-15|2010-04-16|Estimate|||||||2011-11-07|2011-11-08|Estimate|September 2011||2011-09-30|November 2011|2011-11-30|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|||An Enhanced Medication Monitoring Program|An Enhanced Medication Monitoring Program|Unknown status|Recruiting|Phase 1|150|Anticipated|MedMinder Systems Inc.||2|||f||||t||||||||||2018-05-31 23:53:49.632538|2018-05-31 23:53:49.632538
NCT01105091|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|2012-07-20||2012-11-29|2010-04-15|2010-04-16|Estimate|2012-07-20|2012-08-23|Estimate||||2012-11-29|2012-12-03|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|EPITOME-1||Epoprostenol for Injection in Pulmonary Arterial Hypertension|A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 4|30|Actual|Actelion|The EPITOME-1 study is an open label study without a primary endpoint. The sample size was determined based on feasibility and not a power calculation.|2|||f||||f||||||||||2018-05-31 23:53:49.756679|2018-05-31 23:53:49.756679
NCT01105078|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2014-08-05|2010-04-15|2010-04-16|Estimate|||||||2014-08-05|2014-08-06|Estimate|May 2010||2010-05-31|August 2014|2014-08-31||||December 2015|Anticipated|2015-12-31||Interventional|||Optimal Flow Rate During Cardiopulmonary Bypass|Optimal Flow Rate During Cardiopulmonary Bypass|Unknown status|Recruiting|N/A|60|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||||2018-05-31 23:53:51.239222|2018-05-31 23:53:51.239222
NCT01105065|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2014-12-07||2017-03-31|2010-04-15|2010-04-16|Estimate|2016-10-26|2016-10-27|Estimate||||2017-03-31|2017-04-04|Actual|March 2010||2010-03-31|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma|Effect of Brimonidine 0.15% on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Tension Glaucoma|Completed||N/A|46|Actual|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||No||2018-05-31 23:53:51.378017|2018-05-31 23:53:51.378017
NCT01105052|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-14|2010-04-14|2010-04-16|Estimate|||||||2010-04-14|2010-04-16|Estimate|February 2008||2008-02-29|April 2010|2010-04-30|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|||Self-help Cognitive Behavioral Therapy (CBT) for Insomnia|Cognitive Behavioral Therapy as Guided Self-help for Insomnia - a Randomized Controlled Trial|Completed||N/A|133|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 23:53:51.746917|2018-05-31 23:53:51.746917
NCT01105039|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-04-15|2010-04-14|2010-04-16|Estimate|||||||2011-04-15|2011-04-18|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||Detailed Pain Pattern After Laparoscopic Inguinal Hernia Repair|Early Pain Pattern and Its Components After Laparoscopic Inguinal Hernia Repair|Completed|||50|Actual|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 23:53:51.863765|2018-05-31 23:53:51.863765
NCT01105026|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-15|||2010-04-15|2010-04-15|2010-04-16|Estimate|||||||2010-04-15|2010-04-16|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Clinical Investigation to Evaluate the Healing of Tooth Extraction Sites Filled With BioRestore™|Bone Regeneration by Means of a Bioactive Glass Scaffold.|Completed||Phase 1|14|Actual|University of Trieste||1|||f||||t||||||||||2018-05-31 23:53:51.986298|2018-05-31 23:53:51.986298
NCT01105013|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2012-04-11|2010-04-15|2010-04-16|Estimate|||||||2012-04-11|2012-04-12|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|Tonaftato||Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections|"Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body"|Unknown status|Not yet recruiting|Phase 3|90|Anticipated|Laboratório Teuto Brasileiro S/A||1|||f||||t||||||||||2018-05-31 23:53:52.05239|2018-05-31 23:53:52.05239
NCT01105000|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-04-22|2010-04-15|2010-04-16|Estimate|||||||2016-04-22|2016-04-25|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity|The Role of Socioeconomic Status and Ethnicity in Influencing HPV Vaccine Knowledge and Attitudes in Adult Women|Completed|||160|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 23:53:52.182012|2018-05-31 23:53:52.182012
NCT01104987|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-08-08|2010-04-15|2010-04-16|Estimate|||||||2016-08-08|2016-08-09|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS)|Treatment With Alendronate in Patients With Ankylosing Spondylitis (AS), an Open Label Prospective Trial|Completed|||16|Actual|Göteborg University|||1||f||||t||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 23:53:52.235459|2018-05-31 23:53:52.235459
NCT01104974|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-01-20|2010-04-15|2010-04-16|Estimate|||||||2016-01-20|2016-01-22|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||HIV Physician's Survey|Canadian Health Care Providers' Attitudes of Pregnancy, Fertility Care, and Assisted Reproductive Technologies for HIV-Positive Individuals|Completed|||167|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 23:53:52.31532|2018-05-31 23:53:52.31532
NCT01104961|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-10-13|2010-04-14|2010-04-16|Estimate|||||||2010-10-13|2010-10-15|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Studying the Relationship Between Contact Lens Packaging Solutions and Bacterial Binding to Surface Eye Cells|A Masked, Randomized, Prospective, Single Center Crossover Clinical Trial on the Relationship Between Chemically Preserved Contact Lens Packaging Solutions and Bacterial Binding to Corneal Epithelial Cells|Completed||N/A|20|Anticipated|University of Texas Southwestern Medical Center||3|||f||||||||||||||2018-05-31 23:53:52.364941|2018-05-31 23:53:52.364941
NCT01104948|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2012-07-10|2010-04-15|2010-04-16|Estimate|||||||2012-07-10|2012-07-11|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Characterize the Pharmacokinetics of DA-8031 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of DA-8031 After Oral Administration in Healthy Male Subjects|Completed||Phase 1|106|Actual|Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-05-31 23:53:52.446218|2018-05-31 23:53:52.446218
NCT01104935|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2018-01-09|2010-04-15|2010-04-16|Estimate|||||||2018-01-09|2018-01-10|Actual|October 28, 2009|Actual|2009-10-28|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|October 31, 2017|Actual|2017-10-31||Interventional|RESPECT||National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]|Evaluation of Trastuzumab Without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled Trial|Active, not recruiting||Phase 3|275|Actual|Comprehensive Support Project for Oncology Research||2|||f||||t||||||||||2018-05-31 23:53:52.542331|2018-05-31 23:53:52.542331
NCT01104922|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2018-04-25|2010-04-14|2010-04-16|Estimate|||||||2018-04-25|2018-04-27|Actual|July 2007||2007-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck|Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 2|59|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-05-31 23:53:52.660102|2018-05-31 23:53:52.660102
NCT01104909|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-14|2010-04-14|2010-04-16|Estimate|||||||2010-04-14|2010-04-16|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|January 2010|Actual|2010-01-31|May 2008|Actual|2008-05-31||Interventional|||How to Get a Better Dry Weight in End-stage Renal Disease (ESRD) Population for Improving Blood Pressure Control|Randomized Clinical Trial Evaluating Different Protocols for Improving the Way of Getting the Best Dry Weight for Hemodialysis Patients, Looking for Blood Pressure Control, Measured by ABPM|Completed||N/A|100|Anticipated|Universidade de Passo Fundo||2|||f||||t||||||||||2018-05-31 23:53:52.734746|2018-05-31 23:53:52.734746
NCT01104896|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-14|2010-04-14|2010-04-16|Estimate|||||||2010-04-14|2010-04-16|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|NICOREA||Effect of Daily Nicotine Patch Application on Mechanical Ventilation Weaning in Smoking Patients|Multicentric Evaluation of a Daily Nicotine Patch Administration on Mechanical Ventilation Weaning in Smoking Patients Hospitalized in Intensive Care Unit|Unknown status|Recruiting|Phase 4|600|Anticipated|University of Paris 5 - Rene Descartes||2|||f||||t||||||||||2018-05-31 23:53:52.831919|2018-05-31 23:53:52.831919
NCT01104883|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-04-12|2010-04-14|2010-04-16|Estimate|||||||2011-04-12|2011-04-13|Estimate|August 2010||2010-08-31|April 2010|2010-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Efficacy of Adductor-Canal-Blockade on Morphine Consumption, Pain and Mobilisation After Total Knee Arthroplasty|The Efficacy of Adductor-Canal-Blockade on Morphine Consumption, Pain and Mobilisation After Total Knee Arthroplasty|Completed||Phase 4|70|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 23:53:52.923544|2018-05-31 23:53:52.923544
NCT01104870|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2015-11-24||2016-05-25|2010-04-14|2010-04-16|Estimate|2015-11-24|2015-12-30|Estimate||||2016-05-25|2016-05-27|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension|A 12-Week, Randomized, Dose Response Study of UT-15C (Treprostinil Diethanolamine) SR in Patients With Exercise-Induced Pulmonary Hypertension|Completed||Phase 2|50|Actual|United Therapeutics||3|||f||||f||||||||||2018-05-31 23:53:53.155211|2018-05-31 23:53:53.155211
NCT01104857|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-06-09|2010-04-14|2010-04-16|Estimate|||||||2015-06-09|2015-06-10|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Respiratory Muscle Dysfunction in Critically Ill Patients||Unknown status|Active, not recruiting|N/A|30|Anticipated|University Medical Center Nijmegen||2|||f||||f||||||||||2018-05-31 23:53:54.496825|2018-05-31 23:53:54.496825
NCT01104844|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2013-07-11|2010-04-15|2010-04-16|Estimate|||||||2013-07-11|2013-07-12|Estimate||||July 2013|2013-07-31||||||||Interventional|||Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain|Multicentre, Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Analgesic Effects of Different Maxigesic Doses Versus Acetaminophen, Ibuprofen and Placebo for the Teeth Extraction Pain|Withdrawn||Phase 2|0|Actual|AFT Pharmaceuticals, Ltd.||7||The study was withdrawn due to administrative reason|f||||f||||||||||2018-05-31 23:53:54.630714|2018-05-31 23:53:54.630714
NCT01104831|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2017-05-03|2010-04-14|2010-04-16|Estimate|||||||2017-05-03|2017-05-08|Actual|April 2010||2010-04-30|April 2011|2011-04-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|ARCTIC CAT||The Efficacy and Cost Effectiveness of Preoperative and Postoperative Cryotherapy in Proximal Tibia Fractures|The Efficacy and Cost Effectiveness of Preoperative and Postoperative Cryotherapy in Proximal Tibia Fractures|Terminated||Phase 3|20|Actual|University of Manitoba||2||Inadequate recruitment.|f||||t||||||||||2018-05-31 23:53:54.72869|2018-05-31 23:53:54.72869
NCT01104805|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2017-07-06|2010-04-14|2010-04-15|Estimate|||||||2017-07-06|2017-07-11|Actual|April 2010||2010-04-30|July 2017|2017-07-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|CTN-0044||Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders|NIDA-CTN-0044: Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders Using the Therapeutic Education System (TES)|Completed||N/A|507|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 23:53:54.890353|2018-05-31 23:53:54.890353
NCT01104792|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12||2014-03-28|2014-03-28|2010-04-14|2010-04-15|Estimate||||2011-06-24|2011-06-29|Estimate|2014-03-28|2014-04-25|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Long-term Study of Cariprazine in Patients With Schizophrenia|Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients With Schizophrenia|Completed||Phase 3|588|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 23:53:55.096135|2018-05-31 23:53:55.096135
NCT01104779|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14||2012-12-06|2012-12-06|2010-04-14|2010-04-15|Estimate||||2012-12-06|2012-12-10|Estimate|2012-12-06|2012-12-10|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of Cariprazine in Schizophrenia|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia|Completed||Phase 3|459|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 23:53:55.281271|2018-05-31 23:53:55.281271
NCT01104766|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09||2011-12-30|2012-01-09|2010-04-14|2010-04-15|Estimate||||2011-12-30|2012-01-04|Estimate|2012-01-09|2012-01-11|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of Cariprazine in Patients With Schizophrenia|A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia|Completed||Phase 3|617|Actual|Forest Laboratories||4|||f||||f||||||||||2018-05-31 23:53:55.425544|2018-05-31 23:53:55.425544
NCT01104753|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2011-04-06|2010-04-14|2010-04-15|Estimate|||||||2011-04-06|2011-04-07|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Observational|||A Study of Pentasa in Patients With Ulcerative Colitis|Non-interventional Post Marketing Safety Study Confirming Efficacy and Safety of Pentasa Slow Release Tablets in Patients With Ulcerative Colitis in Common Clinical Practice|Completed|||338|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 23:53:55.779977|2018-05-31 23:53:55.779977
NCT01104740|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2010-04-14|2010-04-14|2010-04-15|Estimate|||||||2010-04-14|2010-04-15|Estimate|June 2010||2010-06-30|April 2010|2010-04-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|DengSeroprevAn||Dengue Seroprevalence Study in Blood Donors in the French West Indies|Dengue Seroprevalence Study in Blood Donors in the French West Indies|Unknown status|Not yet recruiting||770|Anticipated|Etablissement Français du Sang, Martinique|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 23:53:55.893658|2018-05-31 23:53:55.893658
NCT01104727|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2016-01-20|2010-04-14|2010-04-15|Estimate|||||||2016-01-20|2016-01-22|Estimate|April 2011||2011-04-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|MUSIC||Multi-Port Versus Single-port Cholecystectomy|Multi-Port vs. Single-port Cholecystectomy|Completed||Phase 4|600|Actual|European Association for Endoscopic Surgery||2|||f||||t||||||||||2018-05-31 23:53:55.971543|2018-05-31 23:53:55.971543
NCT01104714|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2015-03-25|2010-04-14|2010-04-15|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|APPROCHE ORL||Pharmacogenetic Response to Chemotherapy Induction for ORL Cancers|Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers|Completed|||90|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples With DNA|"~     Surplus blood, tumor tissue from biopsies, and DNA will be stocked in the Biothèque of the~     Nîmes University Hospital~   "|||2018-05-31 23:53:56.054474|2018-05-31 23:53:56.054474
NCT01104701|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2014-06-17|2013-03-06|2015-07-31|2010-04-14|2010-04-15|Estimate|2014-07-16|2014-07-17|Estimate|2013-03-06|2013-03-14|Estimate|2015-07-31|2015-08-20|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||All participants who were randomized and received at least one dose of study study drug were analyzed in the intent to treat (ITT) population.|A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension|A Randomized, Multi-dose, Controlled Trial Investigating the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension.|Completed||Phase 2|121|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 23:53:56.262201|2018-05-31 23:53:56.262201
NCT01104688|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2015-01-12|2010-04-14|2010-04-15|Estimate|||||||2015-01-12|2015-01-14|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Non Invasive Imaging of Abdominal Aorta Aneurysm Hemodynamics and Wall Structure|Non Invasive in Vivo Evaluation of Abdominal Aorta Aneurysm Hemodynamics, Wall Stress, and Inflammation Using Magnetic Resonance Imaging|Completed|||20|Actual|Aarhus University Hospital|||||f||||f||||||||||2018-05-31 23:53:57.358263|2018-05-31 23:53:57.358263
NCT01104675|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2014-08-04|2010-04-14|2010-04-15|Estimate|||||||2014-08-04|2014-08-06|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|August 2011|Actual|2011-08-31||Interventional|||Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer|A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer|Completed||Phase 2|64|Actual|CASI Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:53:57.438795|2018-05-31 23:53:57.438795
NCT01104662|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|2015-04-28||2017-02-22|2010-04-14|2010-04-15|Estimate|2015-04-28|2015-05-13|Estimate||||2017-02-22|2017-03-24|Actual|April 2010||2010-04-30|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|RENSE|All participants who received at least 1 dose of study drug.|Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment|A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Staphylococcus Aureus Bacteremia Among Subjects With Moderate or Severe Renal Impairment|Terminated||Phase 4|92|Actual|Cubist Pharmaceuticals LLC||8||"Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can~   stop."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:53:57.576659|2018-05-31 23:53:57.576659
NCT01104649|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2015-04-20|2010-04-14|2010-04-15|Estimate|||||||2015-04-20|2015-04-21|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Efficacy of Riluzole in Hereditary Cerebellar Ataxia|Efficacy of Riluzole in Hereditary Cerebellar Ataxia: a Randomized Double-blind Placebo-controlled Trial.|Completed||Phase 2/Phase 3|60|Actual|S. Andrea Hospital||2|||f||||t||||||||||2018-05-31 23:53:59.331056|2018-05-31 23:53:59.331056
NCT01104636|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2012-01-17||2012-03-01|2010-04-14|2010-04-15|Estimate|2012-01-17|2012-02-24|Estimate||||2012-03-01|2012-03-02|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|VIBRATIONS||"VIBRATIONS - A Study In Smokers Who Are Willing And Motivated To Stop Smoking With The Aid Of Varenicline Which Will Be Prescribed According To Usual Clinical Practice In Germany"|"VIBRATIONS: Varenicline In Patients Ambitioned To Terminate Smoking - A Non-Interventional Study"|Completed|||1177|Actual|Pfizer|It is highly likely that Adverse Events were under reported for this study as it was a Non Interventional study.||1||f||||f||||||||||2018-05-31 23:53:59.42165|2018-05-31 23:53:59.42165
NCT01104623|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2012-02-07|2010-04-14|2010-04-15|Estimate|||||||2012-02-07|2012-02-08|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Observational|ADHD||ADHD - Voice Analysis, Vocal Acoustic Biomarkers in Attention Deficit Hyperactivity Disorder|Phase 1 Study of Vocal Acoustic Biomarkers in Attention Deficit Hyperactivity Disorder (ADHD)|Unknown status|Recruiting||400|Anticipated|Charite University, Berlin, Germany|||2||f||||t||||||||||2018-05-31 23:53:59.622275|2018-05-31 23:53:59.622275
NCT01104610|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2017-07-11|2010-04-14|2010-04-15|Estimate|||||||2017-07-11|2017-07-13|Actual|May 2009||2009-05-31|July 2017|2017-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|OVO||Target Volume Mode Controlled Ventilator in Obesity Hypoventilation Syndrome|Target Volume With a Pressure Controlled Ventilator in Obesity Hypoventilation Syndrome With Persistent Oxygen Desaturations With Continuous Positive Airway Pressure|Withdrawn||N/A|0|Actual|Breas Medical S.A.R.L.||3||Stopped by the sponsor|f||||f||||||||||2018-05-31 23:53:59.698687|2018-05-31 23:53:59.698687
NCT01104597|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-06-10|2010-04-14|2010-04-15|Estimate|||||||2013-06-10|2013-06-12|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study to Evaluate Subclinical Atherosclerosis (an Early Sign of Heart Disease) in Healthy Adult Immigrant Asian Indians|Assessment of Subclinical Atherosclerosis in Healthy Adult Immigrant Asian Indians Using Flow Mediated Endothelial Dysfunction Method|Withdrawn||N/A|0|Actual|Northwell Health||||No subjects were enrolled into the study|f||||f||||||||||2018-05-31 23:53:59.779751|2018-05-31 23:53:59.779751
NCT01104584|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2014-07-10|2012-09-13|2014-11-10|2010-04-14|2010-04-15|Estimate|2014-11-10|2014-11-11|Estimate|2012-09-13|2012-09-17|Estimate|2014-11-10|2014-11-11|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|GEMMA 2||Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)|An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI|Completed||Phase 3|460|Actual|Bayer||1|||f||||f||||||||||2018-05-31 23:53:59.869329|2018-05-31 23:53:59.869329
NCT01104571|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-05-27|2010-04-13|2010-04-15|Estimate|||||||2014-05-27|2014-05-28|Estimate|April 2010||2010-04-30|May 2014|2014-05-31||||December 2014|Anticipated|2014-12-31||Interventional|EPHOS-B||Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer|Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study - Biological Phase (EPHOS-B)|Unknown status|Recruiting|Phase 3|250|Anticipated|Institute of Cancer Research, United Kingdom||6|||f||||t||||||||||2018-05-31 23:54:01.007863|2018-05-31 23:54:01.007863
NCT01104558|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2012-03-13||2014-01-20|2010-04-13|2010-04-15|Estimate|2012-03-13|2012-04-10|Estimate||||2014-01-20|2014-02-13|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ABBA||Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients.|Association Between Beta-1 and Beta-2 Adrenergic Receptor Polymorphism and Beta-blocker (Bisoprolol) Therapy in Heart Failure|Completed||Phase 4|100|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:54:01.186282|2018-05-31 23:54:01.186282
NCT01104545|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-13|2010-04-13|2010-04-15|Estimate|||||||2010-04-13|2010-04-15|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Single Dose Study of MK3614|A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK3614|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 23:54:02.131449|2018-05-31 23:54:02.131449
NCT01104532|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2010-04-15|2010-04-14|2010-04-15|Estimate|||||||2010-04-15|2010-04-16|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects|A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Sitagliptin After Separate and Concomitant Administration to Healthy Adult Subjects|Completed||Phase 1|64|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 23:54:02.188935|2018-05-31 23:54:02.188935
NCT01104519|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2015-07-29|2010-04-13|2010-04-15|Estimate|||||||2015-07-29|2015-07-30|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effects of Multiple Oral Doses of 2000 mg of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity in Subjects With Hypercholesterolemia|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 23:54:02.252669|2018-05-31 23:54:02.252669
NCT01104506|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-12-13|2010-04-14|2010-04-15|Estimate|||||||2010-12-13|2010-12-14|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|CCPB||Elaboration of a Pre-surgery Mapping Protocol of Primary Motor Cortex, Prior to an Implementation of a Stimulation of Primary Motor Cortex for Patients With Deafferentiation of Brachial Plexus Pain|Elaboration of a Pre-surgery Mapping Protocol of Primary Motor Cortex, Prior to an Implementation of a Stimulation of Primary Motor Cortex for Patients With Deafferentiation of Brachial Plexus Pain|Terminated||N/A|13|Actual|Nantes University Hospital||3|||f||||f||||||||||2018-05-31 23:54:02.307227|2018-05-31 23:54:02.307227
NCT01104493|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2011-06-14||2011-07-14|2010-04-13|2010-04-15|Estimate|2011-06-14|2011-07-14|Estimate||||2011-07-14|2011-07-18|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||A Clinical Study to Assess the Safety of a New Influenza Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety of a New 6:2 Influenza Virus Reassortant|Completed||Phase 4|300|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 23:54:02.389299|2018-05-31 23:54:02.389299
NCT01104480|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-05-12|2010-04-13|2010-04-15|Estimate|||||||2014-05-12|2014-05-13|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|May 2012|Anticipated|2012-05-31|July 2010|Anticipated|2010-07-31||Interventional|||Tocilizumab for Relapsing Polychondritis|Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis|Withdrawn||Phase 2|0|Actual|McMaster Children's Hospital||||Tocilizumab was licenced in Canada for children, so the study was not necessary|f||||f||||||||||2018-05-31 23:54:03.070564|2018-05-31 23:54:03.070564
NCT01104467|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-10-14|2010-04-13|2010-04-15|Estimate|||||||2015-10-14|2015-10-16|Estimate|August 2010||2010-08-31|October 2015|2015-10-31||||August 2013|Actual|2013-08-31||Interventional|DIAS-J||Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke|Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke|Completed||Phase 2|48|Actual|Lundbeck Japan K. K.||3|||f||||t||||||||||2018-05-31 23:54:03.195512|2018-05-31 23:54:03.195512
NCT01104454|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2018-02-06|2010-04-14|2010-04-15|Estimate|||||||2018-02-06|2018-02-07|Actual|March 2010|Actual|2010-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|January 2012|Actual|2012-01-31||Observational|||Placenta and Cord Blood Analyses|Placenta and Cord Blood Analyses|Active, not recruiting|||60|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||Samples With DNA|"~     placenta, umbilical cord and cord blood~   "|||2018-05-31 23:54:03.373847|2018-05-31 23:54:03.373847
NCT01104441|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2012-12-04|2010-04-13|2010-04-15|Estimate|||||||2012-12-04|2012-12-05|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Observational|Aspirine||Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia|Cardiovascular Events at One Year of Patients Hospitalized for Critical Limb Ischaemia and Aspirin Resistant Using the VerifyNow®. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia|Unknown status|Recruiting||153|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 23:54:03.493309|2018-05-31 23:54:03.493309
NCT01104428|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-09-07|2010-04-13|2010-04-15|Estimate|||||||2010-09-07|2010-09-08|Estimate|November 2009||2009-11-30|September 2010|2010-09-30||||December 2011|Anticipated|2011-12-31||Interventional|||Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura|Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura|Unknown status|Recruiting|Phase 2|256|Anticipated|Liaoning University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 23:54:03.752534|2018-05-31 23:54:03.752534
NCT01104415|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2017-03-27|2016-02-04|2018-03-05|2010-04-13|2010-04-15|Estimate|2018-03-05|2018-04-06|Actual|2016-02-04|2016-03-03|Estimate|2018-03-05|2018-04-06|Actual|May 2010||2010-05-31|March 2018|2018-03-31|February 12, 2014|Actual|2014-02-12|February 2014|Actual|2014-02-28||Interventional|||Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome|A Phase 2, Open-Label, Multi-Center, Serial Ascending Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome|Completed||Phase 2|15|Actual|Lexicon Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:54:03.950253|2018-05-31 23:54:03.950253
NCT01104402|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2017-07-19||2017-09-22|2010-04-13|2010-04-15|Estimate|2017-09-22|2017-10-23|Actual||||2017-09-22|2017-10-23|Actual|October 2011||2011-10-31|September 2017|2017-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|eICE||Early Intervention in Cystic Fibrosis Exacerbation|Early Intervention in Cystic Fibrosis Exacerbation|Completed||N/A|267|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 23:54:04.809912|2018-05-31 23:54:04.809912
NCT01104389|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2015-08-24|2010-04-13|2010-04-15|Estimate|||||||2015-08-24|2015-08-26|Estimate|May 2010||2010-05-31|August 2015|2015-08-31||||July 2010|Anticipated|2010-07-31||Interventional|||Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging|A Prospective Investigation of the Use of the Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging of Renal Cortical Tumors|Withdrawn||N/A|0|Actual|Intuitive Surgical||||Study was never started|f||||f||||||||||2018-05-31 23:54:05.148635|2018-05-31 23:54:05.148635
NCT01104376|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2014-12-08||2014-12-16|2010-04-14|2010-04-15|Estimate|2014-12-16|2014-12-17|Estimate||||2014-12-16|2014-12-17|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2011|Actual|2011-04-30||Interventional|||Determine the Effects of Gene Differences and Voriconazole on Enzyme CYP2B6 Activity in the Liver in Healthy Volunteers|Effect of Cytochrome P450 2B6 Genetic Polymorphism and Voriconazole on CYP2B6 Activity in Healthy Volunteers|Completed||N/A|61|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 23:54:05.224692|2018-05-31 23:54:05.224692
NCT01104363|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2010-04-13|2010-04-13|2010-04-15|Estimate|||||||2010-04-13|2010-04-15|Estimate|June 2010||2010-06-30|March 2010|2010-03-31|May 2011|Anticipated|2011-05-31|September 2010|Anticipated|2010-09-30||Interventional|||Enhancing Prosthetic Results by Predictable Impression Technique and Reliable NobelProcera™ Systems|Heavy Vinyl PolySiloxane and Splinted Implants Impression Technique in Edentulous Patients Rehabilitated With the All-on-4 Concept and Procera® Implant Bridge|Suspended||N/A|12|Anticipated|Hospital San Pietro Fatebenefratelli||3||Pending approval of the Ethics Committee|f||||t||||||||||2018-05-31 23:54:05.504969|2018-05-31 23:54:05.504969
NCT01104350|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2018-03-07|2010-04-14|2010-04-15|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2010|Actual|2010-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy|Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy|Active, not recruiting||Phase 1|19|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:54:05.590947|2018-05-31 23:54:05.590947
NCT01104337|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-13|2010-04-13|2010-04-15|Estimate|||||||2010-04-13|2010-04-15|Estimate|March 2007||2007-03-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|November 2008|Actual|2008-11-30||Interventional|INPAWA2||Drug Interaction Between Paracetamol and Warfarin|Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial|Completed||Phase 4|45|Actual|Hopital Lariboisière||3|||f||||f||||||||||2018-05-31 23:54:05.667417|2018-05-31 23:54:05.667417
NCT01104324|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-14|2010-04-14|2010-04-15|Estimate|||||||2010-04-14|2010-04-15|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Osteonecrosis in Children With Acute Lymphoblastic Leukemia|Steroid Induced Osteoporosis in the Pediatric Population Ancillary Study- Osteonecrosis in Children With Acute Lymphoblastic Leukemia|Unknown status|Recruiting||130|Anticipated|Halton, Jacqueline, M.D.|||||f||||f||||||Samples With DNA|"~     Platlet free plasma~   "|||2018-05-31 23:54:05.74914|2018-05-31 23:54:05.74914
NCT01104311|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2016-02-11||2017-01-17|2010-04-14|2010-04-15|Estimate|2017-01-17|2017-03-07|Actual||||2017-01-17|2017-03-07|Actual|April 2010||2010-04-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|April 2014|Actual|2014-04-30||Interventional|STABLE-ICAS|The overall number of baseline participatns are analyzed by ITTpopulation ITT Population (Aggressive BP Lowring: 66, Modest BP Lowering: 63)|Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis|Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis|Terminated||Phase 4|132|Actual|Asan Medical Center||2||"The enrollment was not done actively even though enrollment period was extended due to poor~   enrollment."|f||||f||||||||Undecided|There is no plan to share data yet. It will be discussed with investigators who have been participating in this study.|2018-05-31 23:54:05.901941|2018-05-31 23:54:05.901941
NCT01104298|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2015-10-26|2010-04-14|2010-04-15|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|May 2014|Actual|2014-05-31|December 2012|Actual|2012-12-31||Interventional|||Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS|Randomized, Open, Multicenter, Prospective, Phase II Clinical Trial of Doxorubicin vs. Trabectedin Plus Doxorubicin in the First Line Treatment of Patients With Advanced Non Operable and/or Metastatic Soft Tissue Sarcomas|Terminated||Phase 2|115|Actual|Grupo Espanol de Investigacion en Sarcomas||2||Interim analysis did not show good results for main objective|f||||t||||||||||2018-05-31 23:54:06.40865|2018-05-31 23:54:06.40865
NCT01104285|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|2011-11-16||2012-04-18|2010-04-14|2010-04-15|Estimate|2012-04-18|2012-05-23|Estimate||||2012-04-18|2012-05-23|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Chest Tube Drainage of Transudative Pleural Effusions Hastens Liberation From Mechanical Ventilation|Chest Tube Drainage of Transudative Pleural Effusions Hastens Liberation From Mechanical Ventilation|Completed|||198|Actual|Maimonides Medical Center|||2||f||||f||||||||||2018-05-31 23:54:06.676945|2018-05-31 23:54:06.676945
NCT01104272|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2011-01-17|2010-04-14|2010-04-15|Estimate|||||||2011-01-17|2011-01-19|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Subcutaneous Contouring Using High Intensity Focused Ultrasound|An Evaluation of the Treatment of Adipose Tissue Using a Focused Ultrasound Device in Subjects With Fitzpatrick IV-VI Skin Types|Completed||N/A|36|Anticipated|Medicis Technologies Corporation||1|||f||||f||||||||||2018-05-31 23:54:06.903965|2018-05-31 23:54:06.903965
NCT01104259|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-08-08|2010-04-13|2010-04-15|Estimate|||||||2017-08-08|2017-08-10|Actual|July 2010|Actual|2010-07-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|February 2015|Actual|2015-02-28||Interventional|||Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer|Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer|Completed||Phase 1|50|Actual|University of Washington||1|||f||||t||||||||||2018-05-31 23:54:06.992443|2018-05-31 23:54:06.992443
NCT01104246|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2011-02-01||2012-10-02|2010-04-14|2010-04-15|Estimate|2011-02-01|2011-02-23|Estimate||||2012-10-02|2012-10-05|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men|An Open Label, Dose-Titration Investigation of the Pharmacokinetics, Metabolism and Safety of Testosterone Transdermal Systems in Hypogonadal Men|Completed||Phase 1|40|Actual|Watson Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:54:07.113553|2018-05-31 23:54:07.113553
NCT01104233|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-13|2010-04-13|2010-04-15|Estimate|||||||2010-04-13|2010-04-15|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Observational|||Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) With LAP Protector|Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) With Rigid Spreading Versus Soft Spreading (Using LAP Protector)|Unknown status|Recruiting||80|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||2||f||||t||||||||||2018-05-31 23:54:07.345407|2018-05-31 23:54:07.345407
NCT01104220|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-08-29|2010-04-14|2010-04-15|Estimate|||||||2017-08-29|2017-08-30|Actual|April 2010|Actual|2010-04-30|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)|Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk (201102127)|Active, not recruiting|||144|Anticipated|Washington University School of Medicine|||4||f||||f|f|f||||Samples With DNA|"~     Plasma and subcutaneous fat~   "|||2018-05-31 23:54:07.440616|2018-05-31 23:54:07.440616
NCT01104207|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2017-01-04||2017-02-27|2010-04-13|2010-04-15|Estimate|2017-01-04|2017-02-23|Actual||||2017-02-27|2017-03-29|Actual|March 2011||2011-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Transcranial Magnetic Stimulation for Tinnitus|Clinical Trial of Transcranial Magnetic Stimulation for Relief of Tinnitus|Completed||Phase 1/Phase 2|70|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 23:54:07.531402|2018-05-31 23:54:07.531402
NCT01104194|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-07-08|2010-04-14|2010-04-15|Estimate|||||||2011-07-08|2011-07-11|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Fish-oil on Mood and Cognitive Functions of Healthy Individuals|The Effects of Omega-3 Fatty Acids Dietary Supplements (Fish-oil) on Mood and Cognitive Functions of Healthy Individuals|Completed||N/A|60|Anticipated|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 23:54:07.912951|2018-05-31 23:54:07.912951
NCT01104181|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2011-06-21|2010-04-14|2010-04-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test|Collection of Anal Specimens for Assessment of Anal Cancer Using the HC2 High-Risk DNA Test (QIAGEN)|Completed||N/A|300|Actual|Laser Surgery Care||1|||f||||t||||||||||2018-05-31 23:54:08.004699|2018-05-31 23:54:08.004699
NCT01104168|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-11-12|2010-04-14|2010-04-15|Estimate|||||||2013-11-12|2013-11-14|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Diabetes in the Elderly: Retrospective Study|Diabetes Care in Nursing Home Residents|Completed|||1409|Anticipated|Emory University|||1||f||||f||||||||||2018-05-31 23:54:08.118433|2018-05-31 23:54:08.118433
NCT01104155|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2016-12-22||2018-01-31|2010-04-13|2010-04-15|Estimate|2016-12-22|2017-02-14|Actual||||2018-01-31|2018-02-28|Actual|February 22, 2010|Actual|2010-02-22|January 2018|2018-01-31|January 18, 2017|Actual|2017-01-18|April 7, 2011|Actual|2011-04-07||Interventional|||Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer|The Purpose of This Study is to Investigate Two Different Dose Regimens of Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer.|Completed||Phase 2|123|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 23:54:08.274201|2018-05-31 23:54:08.274201
NCT01104142|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-14|2010-04-14|2010-04-15|Estimate|||||||2010-04-14|2010-04-15|Estimate|April 2009||2009-04-30|April 2010|2010-04-30||||||||Observational|||Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy|Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy|Completed|||120|Anticipated|DexCom, Inc.|||2||f||||f||||||||||2018-05-31 23:54:08.864078|2018-05-31 23:54:08.864078
NCT01103973|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2016-09-01||2017-12-19|2010-04-14|2010-04-15|Estimate|2016-09-01|2016-10-24|Estimate||||2017-12-19|2018-01-18|Actual|March 2007||2007-03-31|December 2017|2017-12-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||The Impact of Distress on the IVF Outcome|The Impact of Distress on the IVF Outcome|Completed||N/A|143|Actual|Boston IVF||2|||f||||f||||||||No||2018-05-31 23:54:10.223249|2018-05-31 23:54:10.223249
NCT01104129|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2018-02-06|2010-04-14|2010-04-15|Estimate|||||||2018-02-06|2018-02-08|Actual|July 9, 2009|Actual|2009-07-09|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Stool Testing for Pancreatic Cancer|Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study|Active, not recruiting|||158|Actual|Columbia University|||2||f||||t|f|f||||Samples With DNA|"~     -  Tissue Collection: Fresh frozen resected tumor and IPMN tissue will be obtained whenever~          possible. All resected specimens, cancer and IPMN, will have histologic review to~          confirm the diagnosis. Ten slices of 10 microns each from each specimen will be prepared~          and sent to Mayo Clinic on dry ice.~        -  Stool Collection: Prior to any surgery, stool will be collected from both study and~          control patients. Collection containers and mailing materials will be provided to~          subjects at time of their recruitment. Stool specimens will be mailed directly to Mayo~          Clinic within 48 hours of collection. Stool will be stored at 80 °C until assayed.~        -  Stool DNA extraction: After stool is homogenized, crude stool DNA will be extracted and~          purified.~        -  Digital melt curve mutation analysis: Target gene copies in captured stool DNA and~          tissue DNA will be quantified with real-time PCR. To target the mutations detected in~          tumor specimens, we will utilize PCR primers that scan for specific gene abnormalities.~   "|No||2018-05-31 23:54:08.921019|2018-05-31 23:54:08.921019
NCT01104116|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2016-07-27||2016-07-27|2010-04-14|2010-04-15|Estimate|2016-07-27|2016-09-15|Estimate||||2016-07-27|2016-09-15|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|May 2011|Actual|2011-05-31||Interventional|||Use of PET Imaging to Distinguish Malignant From Benign IPMN|Utility of [18F]-FDG PET Imaging to Distinguish Malignant From Benign Intrapapillary Mucinous Neoplasms|Terminated||N/A|1|Actual|Columbia University||1||Poor enrollment; PI left the institution|f||||t||||||||No||2018-05-31 23:54:08.986825|2018-05-31 23:54:08.986825
NCT01104103|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2012-07-16||2012-07-16|2010-04-13|2010-04-15|Estimate|2012-07-16|2012-08-20|Estimate||||2012-07-16|2012-08-20|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effectiveness Study of the BOA(R)-Constricting IV Band|The BOA(R)-Constricting IV Band: A Single Blind, Cohort Study of Effectiveness|Terminated||N/A|467|Actual|The University of Texas Health Science Center, Houston|There was a significant disparity between subjective opinion and objective results. Nurses and paramedics who used the BOA were uniformly positive in their comments about the device.|2||"Pre-determined stopping point met with signficant difference between intervention and control~   groups."|f||||f||||||||||2018-05-31 23:54:09.130271|2018-05-31 23:54:09.130271
NCT01104090|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2013-06-17|2010-04-14|2010-04-15|Estimate|||||||2013-06-17|2013-06-19|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|February 2012|Actual|2012-02-29|September 2010|Actual|2010-09-30||Interventional|C-MAC||Initial Experience With Storz C-MAC Video Intubation System|Initial Experience With Storz C-MAC Video Intubation System|Completed||Phase 4|50|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 23:54:09.523025|2018-05-31 23:54:09.523025
NCT01104077|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2018-02-06|2010-04-14|2010-04-15|Estimate|||||||2018-02-06|2018-02-08|Actual|November 17, 2008|Actual|2008-11-17|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Family and Personal History of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)|Family and Personal History of Pancreatic and Other Malignancies in Patients With Intraductal Papillary Mucinous Neoplasms|Recruiting|||400|Anticipated|Columbia University|||||f||||t||||||||No||2018-05-31 23:54:09.60395|2018-05-31 23:54:09.60395
NCT01104064|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2013-08-16|2010-04-14|2010-04-15|Estimate|||||||2013-08-16|2013-08-19|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pediatric Hemiplegia: Synergistic Treatment Using rTMS and CIT|Pediatric Hemiplegia: Synergistic Treatment Using rTMS and CIT|Completed||Phase 1|19|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 23:54:09.681822|2018-05-31 23:54:09.681822
NCT01104051|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2015-07-27|2010-04-14|2010-04-15|Estimate|||||||2015-07-27|2015-07-29|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Radiofrequency Nerve Ablation Versus Sham to Treat Chronic Low Back Pain Caused by Sacroiliac Joint Dysfunction|A Prospective, Single Center, Double Blind, Randomized, Sham Controlled, Crossover Study to Evaluate the Clinical Efficacy of Radiofrequency Nerve Ablation Using Simplicity III Versus Sham for the Treatment of Chronic Low Back Pain Associated With Sacroiliac Joint Dysfunction|Completed|||28|Actual|Coastal Orthopedics & Sports Medicine|||2||f||||f||||||||||2018-05-31 23:54:09.763981|2018-05-31 23:54:09.763981
NCT01104038|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-05-22|2010-04-14|2010-04-15|Estimate|||||||2014-05-22|2014-05-26|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|EXCEL||EXCEL: Change in Cardiometabolic Disease Risk Factors During an Interactive Fitness Program|EXCEL: Change in Cardiometabolic Disease Risk Factors During an Interactive Fitness Program|Completed||Phase 1|60|Actual|University of Massachusetts, Boston||2|||f||||t||||||||||2018-05-31 23:54:09.829342|2018-05-31 23:54:09.829342
NCT01104025|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-11-15|2010-04-14|2010-04-15|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|||Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis|An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH|Completed||Phase 2|31|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 23:54:09.910547|2018-05-31 23:54:09.910547
NCT01104012|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-03-26|2010-04-13|2010-04-15|Estimate|||||||2015-03-26|2015-03-27|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|VAPARA||Validation of Proteomic Analyses for Allergic Asthma and Rhinitis|The VAPARA Study: Validation of Proteomic Analyses for Allergic Asthma and Rhinitis|Completed|||133|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma samples are taken on patient inclusion. For the purposes of this study, only~     proteomic profiles via SELDI-TOF will be characterized. Excess serum and plasma will be~     stored in the CHU de Nîmes Biothèque.~   "|||2018-05-31 23:54:10.027727|2018-05-31 23:54:10.027727
NCT01103999|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-03-25|2010-04-14|2010-04-15|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Prospective Evaluation of Spleen Injury Treatments in Languedoc Roussillon|Prospective Evaluation of Spleen Injury Treatments in Languedoc Roussilon, France|Completed|||93|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||||2018-05-31 23:54:10.096544|2018-05-31 23:54:10.096544
NCT01103986|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2011-06-22|2010-04-13|2010-04-15|Estimate|||||||2011-06-22|2011-06-27|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Assessing the Effectiveness of a Health Literacy Intervention in the Workplace|Assessing the Effectiveness of a Health Literacy Intervention in the Workplace: A Quasi-experimental Pre-post Randomized Controlled Study|Completed||N/A|184|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 23:54:10.154702|2018-05-31 23:54:10.154702
NCT01103960|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2012-08-21||2014-06-17|2010-04-13|2010-04-15|Estimate|2012-08-21|2012-09-20|Estimate||||2014-06-17|2014-06-27|Estimate|July 2010||2010-07-31|December 2013|2013-12-31||||August 2011|Actual|2011-08-31||Interventional|||An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy|8 Week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg+ Amlodipine 5 mg vs. Amlodipine 5mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy|Completed||Phase 3|324|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:54:10.435949|2018-05-31 23:54:10.435949
NCT01103947|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-04-06|2010-04-14|2010-04-15|Estimate|||||||2017-04-06|2017-04-07|Actual|April 2010||2010-04-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||EcoAnaesthesia Facemask Versus Standard Facemask During Anesthesia Induction|A Comparison of the Efficiency of the New EcoAnaesthesia Facemask With a Standard Facemask During Induction of Anesthesia|Withdrawn||N/A|0|Actual|University of Louisville||2||Not able to finalize funding|f||||f||||||||||2018-05-31 23:54:11.938525|2018-05-31 23:54:11.938525
NCT01103934|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2014-10-06||2014-10-06|2010-04-14|2010-04-15|Estimate|2014-10-06|2014-10-09|Estimate||||2014-10-06|2014-10-09|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Vitamin D Plus Fluticasone Propionate|The Addition of Vitamin D to Fluticasone Propionate in the Management of Seasonal Allergic Rhinitis|Completed||Phase 4|35|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 23:54:12.016825|2018-05-31 23:54:12.016825
NCT01103921|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-05-25|2010-04-13|2010-04-15|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2008||2008-10-31|May 2017|2017-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|DRS||The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks|Effects of 2-weeks Fructose & HFCS Consumption on Dyslipidemia & Insulin Resistance|Completed||N/A|214|Actual|University of California, Davis||4|||f||||t||||||||||2018-05-31 23:54:12.251373|2018-05-31 23:54:12.251373
NCT01103908|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-05-25|2010-04-14|2010-04-15|Estimate|||||||2016-05-25|2016-05-27|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Observational|||Cardiac Output Measurement at the Conclusion of Cardiopulmonary Bypass|Ultrasound Dilution Cardiac Output at the Conclusion of Cardiopulmonary Bypass in Pediatric Patients|Terminated|||3|Actual|Transonic Systems Inc.|||1|Site PI left position and lack of a suitable replacement PI.|f||||f||||||||No||2018-05-31 23:54:12.347548|2018-05-31 23:54:12.347548
NCT01103895|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-05-25|2010-04-13|2010-04-15|Estimate|||||||2016-05-25|2016-05-27|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Measurement of Cardiac Output Before and After Cardiopulmonary Bypass.|Ultrasound Dilution Measurement of Cardiac Output Before and After Adult Cardiopulmonary Bypass|Terminated|||14|Actual|Transonic Systems Inc.||||Lack of enrollment|f||||f||||||||No||2018-05-31 23:54:12.519242|2018-05-31 23:54:12.519242
NCT01103882|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-03-20|2010-04-13|2010-04-15|Estimate|||||||2017-03-20|2017-03-21|Actual|May 2010||2010-05-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|August 2014|Actual|2014-08-31||Observational|||Short-Term Clinical Outcome of Total Hip Arthroplasty Using Larger Diameter of 4th Generation Ceramic Bearing|Short-Term Clinical Outcome Including Dislocation Rate and Ceramic Fracture of Total Hip Arthroplasty Using Larger Diameter of 4th Generation Ceramic Bearing|Active, not recruiting|||277|Anticipated|Zimmer Biomet|||||f||||f||||||||Yes||2018-05-31 23:54:12.596771|2018-05-31 23:54:12.596771
NCT01103869|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-12-14|2010-04-14|2010-04-15|Estimate|||||||2010-12-14|2010-12-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:54:12.673118|2018-05-31 23:54:12.673118
NCT01103856|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-06-20|2010-04-13|2010-04-15|Estimate|||||||2016-06-20|2016-06-22|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||Test of an Intervention to Improve HIV Care|Test of an Intervention to Improve HIV Care|Completed||N/A|460|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 23:54:12.714784|2018-05-31 23:54:12.714784
NCT01103843|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-14|||2010-04-14|2010-04-14|2010-04-15|Estimate|||||||2010-04-14|2010-04-15|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|PPD||Plavix, Prasugrel and Drug Eluting Stents Pilot Trial|PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents|Unknown status|Recruiting|N/A|1000|Anticipated|St. Francis Hospital, New York||2|||f||||t||||||||||2018-05-31 23:54:12.803301|2018-05-31 23:54:12.803301
NCT01103830|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-06-16|2010-04-13|2010-04-15|Estimate|||||||2011-06-16|2011-06-17|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers|Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers|Completed||Phase 1|287|Actual|sigma-tau i.f.r. S.p.A.||6|||f||||f||||||||||2018-05-31 23:54:12.939814|2018-05-31 23:54:12.939814
NCT01103817|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2016-05-30|2010-04-14|2010-04-15|Estimate|||||||2016-05-30|2016-06-01|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Influence of Vitamin D on Vascular Function in Adolescents and Young Adults With Type 1 Diabetes|Influence of Vitamin D on Vascular Function in Adolescents and Young Adults With Type 1 Diabetes|Completed||Phase 2|33|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:54:13.074384|2018-05-31 23:54:13.074384
NCT01103804|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-01-10|2010-04-13|2010-04-15|Estimate|||||||2011-01-10|2011-01-11|Estimate|March 2010||2010-03-31|January 2011|2011-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment|A Prospective, Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Systematic Treatment With PPIs in GERD Patients in Primary Care Setting in Romania, Using the Validated GerdQ Questionnaire.|Completed|||952|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:54:13.162564|2018-05-31 23:54:13.162564
NCT01103791|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2017-05-02|2010-04-14|2010-04-15|Estimate|||||||2017-05-02|2017-05-05|Actual|April 2010|Actual|2010-04-30|May 2017|2017-05-31|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies|A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies|Completed||Phase 1|19|Actual|Samyang Biopharmaceuticals Corporation||6|||f||||t||||||||||2018-05-31 23:54:13.282083|2018-05-31 23:54:13.282083
NCT01103765|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-06-14|2010-04-14|2010-04-15|Estimate|||||||2011-06-14|2011-06-16|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|PODIUM||Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis|A Prospective Randomized Multicenter Study of the Efficacy and Safety of Systematic Post -Dilatation With Noncompliant Balloon After Successful Drug-eluting Stent Implantation. IVUS Analysis.|Unknown status|Recruiting|Phase 4|220|Anticipated|Recherches et etudes en sciences sociales et sante, France||2|||f||||f||||||||||2018-05-31 23:54:13.432979|2018-05-31 23:54:13.432979
NCT01103752|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-12-13|2010-04-13|2010-04-15|Estimate|||||||2011-12-13|2011-12-14|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Postoperative Cognitive Dysfunction After Total Knee or Hip Replacement Surgery in Fast-track Set-up|Postoperative Cognitive Dysfunction After Total Knee or Hip Replacement Surgery in Fast-track Set-up|Completed|||225|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 23:54:13.514598|2018-05-31 23:54:13.514598
NCT01103739|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2010-06-03|2010-04-13|2010-04-15|Estimate|||||||2010-06-03|2010-06-04|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||To Explore The Potential For PF-04531083 To Effect The Blood Concentrations Of Simvastatin And Its Main Acid Metabolite Following Co-Administration Of Both Medications|A Phase 1, Open Label, Fixed Sequence Study To Investigate The Effect Of Multiple Doses Of PF-04531083 On Simvastatin And Simvastatin Acid Pharmacokinetics Following Single Dose Of Simvastatin in Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:54:13.569737|2018-05-31 23:54:13.569737
NCT01103726|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-11-11|2010-04-14|2010-04-15|Estimate|||||||2011-11-11|2011-11-16|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects|Evaluation Of Regional Glucose Metabolism In Striatum As Measured By [18f]-Fluorodeoxyglucose Positron Emission Tomography Following Single Oral Dose Administration Of PF-02545920 In Healthy Subjects|Completed||Phase 1|34|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 23:54:13.656784|2018-05-31 23:54:13.656784
NCT01103713|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2014-07-16||2015-01-22|2010-04-13|2010-04-15|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-22|2015-01-26|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa|An Open Label, Non-comparative Study To Evaluate Parasitological Clearance Rates And Pharmacokinetics Of Azithromycin And Chloroquine Following Administration Of A Fixed Dose Combination Of Azithromycin And Chloroquine (Azcq) In Asymptomatic Pregnant Women With Plasmodium Falciparum Parasitemia In Sub-saharan Africa|Terminated||Phase 3|168|Actual|Pfizer||1||See termination reason in detailed description.|f||||t||||||||||2018-05-31 23:54:13.904547|2018-05-31 23:54:13.904547
NCT01103700|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-04-14|2010-04-14|2010-04-15|Estimate|||||||2010-04-14|2010-04-15|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|August 2010|Anticipated|2010-08-31|July 2010|Anticipated|2010-07-31||Observational|||Evaluation of Multidisciplinary Palliative Care on Terminal Cancer Patients in Taiwan|Evaluation of Multidisciplinary Palliative Care on Terminal Cancer Patients in Taiwan|Unknown status|Not yet recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 23:54:14.540357|2018-05-31 23:54:14.540357
NCT01103687|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-09-05|2010-04-13|2010-04-15|Estimate|||||||2017-09-05|2017-09-08|Actual|July 2010||2010-07-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|September 2012|Actual|2012-09-30||Interventional|||Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults|A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety, Mucosal Immunogenicity and Innate Immune Responses of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad26.ENVA.01 (rAd26) HIV-1 Mucosal/IPCAVD-003 Vaccine Study)|Completed||Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 23:54:14.616753|2018-05-31 23:54:14.616753
NCT01103674|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-04-02|2010-04-13|2010-04-15|Estimate|||||||2014-04-02|2014-04-03|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|CAP STOPS AF||Safety and Efficacy Study of the Combined Ablation Procedure to Treat Paroxysmal Atrial Fibrillation|Feasibility Study For Safety and Efficacy Evaluation Of The Combined Ablation Procedure For The Treatment Of Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation|Terminated||N/A|1|Actual|nContact Surgical Inc.||1||enrollment challenges, only one patient enrolled|f||||t||||||||||2018-05-31 23:54:14.708059|2018-05-31 23:54:14.708059
NCT01103661|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-04-02|2010-04-14|2010-04-15|Estimate|||||||2014-04-02|2014-04-03|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|CAPstopsLSPAF||Safety and Efficacy Study of The Combined Ablation Procedure To Treat Longstanding Persistent Atrial Fibrillation|Feasibility Study For Safety and Efficacy Evaluation Of The Combined Ablation Procedure For The Treatment Of LongStanding Persistent Atrial Fibrillation|Terminated||N/A|7|Actual|nContact Surgical Inc.||1|||f||||t||||||||||2018-05-31 23:54:14.80415|2018-05-31 23:54:14.80415
NCT01103648|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-14|2010-04-14|2010-04-15|Estimate|||||||2010-04-14|2010-04-15|Estimate|June 2005||2005-06-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|May 2006|Actual|2006-05-31||Interventional|||Effect of Simvastatin and Ezetimibe on Lipid and Inflammation|Synergistic Effect of Simvastatin and Ezetimibe on Lipid and Pro-inflammatory Profiles in Pre-diabetic Subjects|Completed||N/A|50|Actual|Federal University of São Paulo||3|||f||||f||||||||||2018-05-31 23:54:14.907414|2018-05-31 23:54:14.907414
NCT01103635|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2016-07-15|2010-04-13|2010-04-14|Estimate|||||||2016-07-15|2016-07-18|Estimate|February 2010||2010-02-28|July 2016|2016-07-31||||October 2014|Actual|2014-10-31||Interventional|||Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma|A Phase 1 Dose-Escalation Trial To Evaluate Safety, Tolerability And Immune Pharmacodynamics Of Combined Administration Of Tremelimumab (Blocking Anti-CTLA-4 Antibody) And CP-870,893 (Agonist Anti-CD40 Antibody) In Patients With Metastatic Melanoma|Active, not recruiting||Phase 1|32|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 23:54:14.990733|2018-05-31 23:54:14.990733
NCT01103622|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-01-04|2010-04-13|2010-04-14|Estimate|||||||2011-01-04|2011-01-05|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients|An Open-label, Randomised, Placebo Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics of Digoxin During Co-administration With AZD1656|Completed||Phase 1|20|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 23:54:15.062578|2018-05-31 23:54:15.062578
NCT01103609|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2010-11-05|2010-04-13|2010-04-14|Estimate|||||||2010-11-05|2010-11-08|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients|An Open-Label, Randomised, Placebo-Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Warfarin During Co-administration With AZD1656|Completed||Phase 1|16|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:54:15.15382|2018-05-31 23:54:15.15382
NCT01103596|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2011-12-13|2010-04-13|2010-04-14|Estimate|||||||2011-12-13|2011-12-14|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|EOLE||Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)|Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to ARVs - EOLE|Completed|||94|Actual|Abbott|||2||f||||f||||||Samples Without DNA|"~     Frozen plasma for determination of Lopinavir/ritonavir (LPV/r) Cmin~   "|||2018-05-31 23:54:15.223857|2018-05-31 23:54:15.223857
NCT01103583|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2014-02-10|2010-04-13|2010-04-14|Estimate|||||||2014-02-10|2014-02-11|Estimate|July 2011||2011-07-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Interventional|||Hydroxyurea in Primary Progressive Multiple Sclerosis||Terminated||Phase 2/Phase 3|33|Actual|S. Andrea Hospital||2||No efficacy (interim.analysis)|f||||t||||||||||2018-05-31 23:54:15.396051|2018-05-31 23:54:15.396051
NCT01103570|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-04-13|2010-04-13|2010-04-14|Estimate|||||||2010-04-13|2010-04-14|Estimate|March 2009||2009-03-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Cholecyst- Versus Cystic Duct Cholangiography During Laparoscopic Cholecystectomy|Cholecystocholangiography Versus Cystic Duct Cholangiography During Laparoscopic Cholecystectomy: A Prospective Controlled Randomized Trial|Completed||Phase 4|60|Actual|Theodor Bilharz Research Institute||2|||f||||t||||||||||2018-05-31 23:54:15.483599|2018-05-31 23:54:15.483599
NCT01103557|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-13|2010-04-13|2010-04-14|Estimate|||||||2010-04-13|2010-04-14|Estimate||||January 2010|2010-01-31||||||||Interventional|||Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma|The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis|Completed||N/A|62|Actual|Pusan National University Hospital|||||f||||t||||||||||2018-05-31 23:54:15.562053|2018-05-31 23:54:15.562053
NCT01103544|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-11|||2015-05-12|2010-04-13|2010-04-14|Estimate|||||||2015-05-12|2015-05-13|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|September 2011|Actual|2011-09-30||Observational|JONAS-1||JAVLOR® Online Non-Interventional Trial|Usage of Vinflunine i.v. (JAVLOR®) for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in Adult Patients After Failure of a Cisplatinum-containing Therapy|Completed|||200|Anticipated|Pierre Fabre Pharma GmbH|||1||f||||f||||||||||2018-05-31 23:54:15.621353|2018-05-31 23:54:15.621353
NCT01103531|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2015-11-30|2010-04-13|2010-04-14|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Exercise to Improve Outcomes of Treatment for Methamphetamine Users|Aerobic Exercise to Improve Outcomes of Treatment for Methamphetamine Dependence|Completed||N/A|135|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:54:15.700861|2018-05-31 23:54:15.700861
NCT01103518|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-08-05|2010-04-13|2010-04-14|Estimate|||||||2010-08-05|2010-08-06|Estimate|December 2009||2009-12-31|April 2010|2010-04-30|January 2011|Anticipated|2011-01-31|November 2010|Anticipated|2010-11-30||Interventional|||Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation|Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Fundação Educacional Serra dos Órgãos||2|||f||||f||||||||||2018-05-31 23:54:15.790867|2018-05-31 23:54:15.790867
NCT01103505|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-10-02|2010-04-13|2010-04-14|Estimate|||||||2014-10-02|2014-10-03|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|AREDS||HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device|The HOME Study: HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device - (HOme Monitoring of the Eye)|Completed||Phase 3|1520|Actual|Notal Vision Ltd||2|||f||||t||||||||||2018-05-31 23:54:15.885596|2018-05-31 23:54:15.885596
NCT01103492|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2011-03-29||2014-12-12|2010-04-13|2010-04-14|Estimate|2011-03-29|2011-04-27|Estimate||||2014-12-12|2015-01-05|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatment of Hemorrhagic Radiation Proctitis Using the Halo System|Treatment of Hemorrhagic Radiation Proctitis Using the Halo System|Completed||N/A|1|Actual|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-05-31 23:54:16.022866|2018-05-31 23:54:16.022866
NCT01103479|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2014-08-28||2015-04-14|2010-04-13|2010-04-14|Estimate|2014-08-28|2014-09-09|Estimate||||2015-04-14|2015-05-06|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional||Participants had to reach randomization, complete both pre and post-tests, and be eligible for colorectal cancer screening (verified by chart review).|Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening|Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening|Completed||Phase 2/Phase 3|569|Actual|Northwestern University||3|||f||||t||||||||||2018-05-31 23:54:16.182652|2018-05-31 23:54:16.182652
NCT01103466|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2012-01-09||2013-02-22|2010-04-13|2010-04-14|Estimate|2013-02-22|2013-04-04|Estimate||||2013-02-22|2013-04-04|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||2 subjects were excluded from the ITT and PP population, and therefore not included in the baseline measurements|Investigation of the Performance of Ostomy Base Plate|A Randomised Controlled Cross-over Study Investigating the Performance and Safety of the Ostomy Base Plate SSH|Completed||N/A|41|Actual|Coloplast A/S||3|||f||||f||||||||||2018-05-31 23:54:16.879392|2018-05-31 23:54:16.879392
NCT01103453|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-07-20|2010-04-13|2010-04-14|Estimate|||||||2011-07-20|2011-07-21|Estimate|November 2010||2010-11-30|July 2011|2011-07-31|May 2012|Anticipated|2012-05-31|November 2011|Anticipated|2011-11-30||Interventional|EF-VAPS||Change in Executive Function and IADL Using a Virtual Supermarket Environment Among People With MCI|Change in Executive Functions and in Instrumental Activities of Daily Living as a Result of Intervention by Virtual Supermarket Environment Among People With Mild Cognitive Impairment.|Unknown status|Recruiting|Phase 1|10|Anticipated|Carmel Medical Center||1|||f||||t||||||||||2018-05-31 23:54:17.064615|2018-05-31 23:54:17.064615
NCT01103297|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2014-09-18|2010-04-13|2010-04-14|Estimate|||||||2014-09-18|2014-09-19|Estimate|June 2010||2010-06-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|VALCP2010||2.4 mm Variable Angle LCP Two-Column Volar Distal Radius|A Prospective Multicenter Case-series of Patients Treated With the 2.4 mm Variable Angle LCP Two-Column Volar Distal Radius Plate ®|Completed||Phase 4|74|Actual|AO Clinical Investigation and Documentation||1|||f||||f||||||||||2018-05-31 23:54:20.834606|2018-05-31 23:54:20.834606
NCT01103440|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2018-01-18||2018-01-18|2010-04-13|2010-04-14|Estimate|2018-01-18|2018-02-14|Actual||||2018-01-18|2018-02-14|Actual|April 2007||2007-04-30|January 2018|2018-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|RESIST||Aspirin Resistance and Percutaneous Coronary Intervention (PCI)|A Randomized, Pilot, Single-center Study, Investigator-Initiated Study to Look at an Aggressive Therapeutic Approach in Aspirin Resistant Patients Comparing to Standard for Patient Undergoing Percutaneous Coronary Intervention|Completed||Phase 2|36|Actual|Icahn School of Medicine at Mount Sinai|Small pilot study with a limited sample size and not powered to detect differences in individual ischemic endpoints. Study does not delineate an optimal dose of aspirin. Antiplatelet effect of aspirin may fluctuate in patients at the same dosage.|2|||f||||t|t|f||||||||2018-05-31 23:54:17.171247|2018-05-31 23:54:17.171247
NCT01103427|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2013-12-16|2010-04-13|2010-04-14|Estimate|||||||2013-12-16|2013-12-17|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Usefulness of Supportive SMS in Addition to an Internet Based Quit Smoking Program (Www.Slutta.no)|Mobile Text Messaging as an Adjunct Function to an Internet-based Smoking Cessation Intervention Implemented in the General Population and in a Health Care Setting|Completed||N/A|4300|Actual|University of Tromso||4|||f||||f||||||||||2018-05-31 23:54:17.372123|2018-05-31 23:54:17.372123
NCT01103414|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2013-02-15||2015-04-06|2010-04-13|2010-04-14|Estimate|2013-02-15|2013-03-22|Estimate||||2015-04-06|2015-04-28|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional||All randomized patients who received at least 1 dose of randomized study medication|Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients|Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients|Completed||Phase 2|356|Actual|Metabolic Solutions Development Company||5|||f||||f||||||||||2018-05-31 23:54:17.46978|2018-05-31 23:54:17.46978
NCT01103401|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2015-04-14|2010-04-13|2010-04-14|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery|Ketorolac Plus Tobramycin/Dexamethasone vs. Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery|Completed||N/A|145|Actual|Veroia General Hospital||2|||f||||t||||||||||2018-05-31 23:54:18.322921|2018-05-31 23:54:18.322921
NCT01103388|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2012-07-27|2010-04-12|2010-04-14|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 2003||2003-08-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2006|Actual|2006-04-30||Interventional|||Rituximab Maintenance After Autologous Transplantation|Maintenance Therapy With Rituximab After Autologous Transplantation for Non-Hodgkin's Lymphoma|Terminated||Phase 3|4|Actual|M.D. Anderson Cancer Center||2||Closed early due to slow patient accrual and sponsor's withdrawal of support.|f||||f||||||||||2018-05-31 23:54:18.422028|2018-05-31 23:54:18.422028
NCT01103375|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2017-05-25|2010-04-13|2010-04-14|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2010||2010-05-31|February 2017|2017-02-28|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma|A Phase I Single Arm Open Label Study of Erlotinib and 13-cis-Retinoic Acid (CRA) in Patients With Recurrent Malignant Gliomas|Terminated||Phase 1|5|Actual|Wake Forest University Health Sciences||1||Slow accrual|f||||f|t|f||||||||2018-05-31 23:54:18.509506|2018-05-31 23:54:18.509506
NCT01103362|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2014-04-11||2014-04-11|2010-04-13|2010-04-14|Estimate|2014-04-11|2014-05-12|Estimate||||2014-04-11|2014-05-12|Estimate|April 2010||2010-04-30|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder|Open-label Extension Trial for Pre- and Postmenopausal Women With HSDD|Terminated||Phase 3|596|Actual|Sprout Pharmaceuticals, Inc||1||administrative reasons|f||||t||||||||||2018-05-31 23:54:18.642078|2018-05-31 23:54:18.642078
NCT01103349|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19||2014-04-30|2014-04-30|2010-04-13|2010-04-14|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|March 2010||2010-03-31|December 2011|2011-12-31||||August 2011|Actual|2011-08-31||Interventional|||BI671800 in Asthmatic Patients on Inhaled Corticosteroids|Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)|Completed||Phase 2|243|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:54:18.941408|2018-05-31 23:54:18.941408
NCT01103336|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2012-02-02|2010-04-13|2010-04-14|Estimate|||||||2012-02-02|2012-02-06|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study)|Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study): A Investigator-initiated, Control- Randomized, Phase IV Multicenter Study|Completed||Phase 4|173|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:54:19.080086|2018-05-31 23:54:19.080086
NCT01103323|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2012-10-19||2015-05-28|2010-04-13|2010-04-14|Estimate|2012-10-19|2012-11-19|Estimate||||2015-05-28|2015-06-24|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|July 2011|Actual|2011-07-31||Interventional|||Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy|A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy|Completed||Phase 3|760|Actual|Bayer|At 2nd IA, pre-specified O’Brien-Fleming-type efficacy boundary was crossed. DMC concluded OS result positive and after positive risk benefit assessment, recommended unblinding of study. OS from 2nd IA are the final formal and definitive results.|2|||f||||t||||||||||2018-05-31 23:54:19.322128|2018-05-31 23:54:19.322128
NCT01103310|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2014-11-11|2010-04-13|2010-04-14|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation|Open-label, Multi Center Study for an Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY94-9392 Following a Single Intravenous Administration of 300 MBq (Corresponding to ≤ 100 µg Total Quantity) in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability, Pharmacokinetics, and Diagnostic Performance of the Tracer in PET/CT in Cancer Patients or Patients With Inflammation.|Completed||Phase 1|46|Actual|Piramal Imaging SA||2|||f||||f||||||||||2018-05-31 23:54:20.74876|2018-05-31 23:54:20.74876
NCT01103284|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|2015-11-16||2016-04-19|2010-04-13|2010-04-14|Estimate|2016-04-19|2016-05-26|Estimate||||2016-04-19|2016-05-26|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|DIA-AID2|All patients randomized into the study are included in presentation of baseline results|Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults|A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Clinical Efficacy and Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Subjects|Completed||Phase 3|475|Actual|Andromeda Biotech Ltd.||2|||f||||t||||||||||2018-05-31 23:54:20.963434|2018-05-31 23:54:20.963434
NCT01103271|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2012-05-02||2013-01-08|2010-04-12|2010-04-14|Estimate|2013-01-08|2013-01-14|Estimate||||2013-01-08|2013-01-14|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pilot Study of Open-label Placebo to Treat Major Depressive Disorder|Harnessing the Placebo Effect in Major Depressive Disorder|Completed||Phase 2|20|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 23:54:21.618065|2018-05-31 23:54:21.618065
NCT01103258|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-12|2010-04-12|2010-04-14|Estimate|||||||2010-04-12|2010-04-14|Estimate|February 2006||2006-02-28|April 2010|2010-04-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||FOAM-study, Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins|FOAM-study Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins: a Randomized Controlled Study|Completed||N/A|460|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 23:54:21.812559|2018-05-31 23:54:21.812559
NCT01103245|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-08-04|2010-04-13|2010-04-14|Estimate|||||||2011-08-04|2011-08-05|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Aldosterone and the Metabolic Syndrome|Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism|Unknown status|Recruiting|N/A|168|Anticipated|Vanderbilt University||3|||f||||t||||||||||2018-05-31 23:54:21.941052|2018-05-31 23:54:21.941052
NCT01103232|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2011-08-13||2012-06-20|2010-04-13|2010-04-14|Estimate|2012-02-24|2012-03-26|Estimate||||2012-06-20|2012-06-25|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Cross-Education Of Contralateral Antagonists|Cross-Education Of Muscular Strength: Is Cross-Training Effects Confined To Untrained Contralateral Homologous Muscle|Completed||N/A|30|Actual|Vakif Gureba Training and Research Hospital|This study has small sample size.|2|||f||||t||||||||||2018-05-31 23:54:22.043914|2018-05-31 23:54:22.043914
NCT01103219|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2017-05-02|2010-04-12|2010-04-14|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2010||2010-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|December 2012|Actual|2012-12-31||Interventional|PRENU||Nutrition, Growth and Development Among Very Preterm Infants|Nutrition, Growth and Development Among Very Preterm Infants|Terminated||Phase 3|50|Actual|University of Oslo||2||A planned interim-analysis revealed increased number of infections in the intervention arm.|f||||t||||||||||2018-05-31 23:54:22.244648|2018-05-31 23:54:22.244648
NCT01103206|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-10-15|2010-04-13|2010-04-14|Estimate|||||||2013-10-15|2013-10-16|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of a Cincalcet Suppression Test|Evaluation of a Parathyroid Hormone Suppression Test With Cinacalcet. Comparison: 1- With the Results of the Intravenous Calcium Suppression Test in Healthy Controls; 2- Between Healthy Controls and Patients With Primary Hyperparathyroidism.|Completed||Phase 4|36|Actual|University Hospital, Rouen||3|||f||||t||||||||||2018-05-31 23:54:22.345152|2018-05-31 23:54:22.345152
NCT01103193|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2012-05-07|2010-04-12|2010-04-14|Estimate|||||||2012-05-07|2012-05-08|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Nitrous Oxide - Sevoflurane-Remifentanil Interaction|Nitrous Oxide - Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance.|Terminated||Phase 4|4|Actual|University Hospital, Ghent||2||"Need of change to the protocol. As the Principal Investigator has left the University Hospital~   Ghent end 2010, the change of protocol was never submitted."|f||||f||||||||||2018-05-31 23:54:22.458994|2018-05-31 23:54:22.458994
NCT01103180|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-04-07|2010-04-13|2010-04-14|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder|SSRIs and Self-harm in Borderline Personality Disorder|Completed||Phase 2|80|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 23:54:22.557025|2018-05-31 23:54:22.557025
NCT01103167|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-04-13|2010-04-13|2010-04-14|Estimate|||||||2010-04-13|2010-04-14|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Body Composition Monitor in Hemodialysis Patients|The Association Between Body Composition and Biomarkers in Hemodialysis Patients|Unknown status|Recruiting|Phase 4|160|Anticipated|Gachon University Gil Medical Center|||||f||||f||||||||||2018-05-31 23:54:22.646348|2018-05-31 23:54:22.646348
NCT01103154|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-10-24|2010-04-12|2010-04-14|Estimate|||||||2010-10-24|2010-10-26|Estimate|March 2005||2005-03-31|October 2010|2010-10-31|January 2010||2010-01-31|January 2010|Actual|2010-01-31||Interventional|Carvedilol||A Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding|A Controlled Trial of Nadolol Plus Isosorbide Mononitrate vs. Carvedilol for the Prevention of Variceal Rebleeding|Completed||Phase 4|121|Actual|E-DA Hospital||2|||f||||t||||||||||2018-05-31 23:54:22.726931|2018-05-31 23:54:22.726931
NCT01103141|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2017-02-17||2017-04-05|2010-04-13|2010-04-14|Estimate|2017-02-17|2017-04-04|Actual||||2017-04-05|2017-05-11|Actual|June 2010||2010-06-30|April 2017|2017-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|FEMORIS||Femoral Micropuncture or Routine Introducer Study||Terminated||N/A|143|Actual|Cook Group Incorporated||2||This original design is no longer consistent with current clinical practice.|f||||||||||||||2018-05-31 23:54:22.80301|2018-05-31 23:54:22.80301
NCT01102998|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-11-15|2010-04-12|2010-04-13|Estimate|||||||2013-11-15|2013-11-18|Estimate|April 2010||2010-04-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Observational|||Assessment of Sleep Complaints in Brain Tumor Survivors|Assessment of Sleep Complaints in Brain Tumor Survivors|Completed|||153|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 23:54:25.670525|2018-05-31 23:54:25.670525
NCT01102985|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2015-06-30|2010-04-12|2010-04-13|Estimate|||||||2015-06-30|2015-07-01|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Women With Cancer: An Exercise Study to Promote Health|An Exercise Intervention to Improve Health in Postmenopausal Cancer Survivors|Completed||N/A|154|Actual|Yale University||2|||f||||f||||||||||2018-05-31 23:54:25.858042|2018-05-31 23:54:25.858042
NCT01103128|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-06-22|2010-04-13|2010-04-14|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Validation of a Mouse Model of Pancreatic Carcinogenesis|BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis|Terminated|||450|Anticipated|Columbia University|||||f||||t||||||Samples With DNA|"~     -  Peripheral Blood Specimens: Three tubes of blood will be collected from each study~          participant. Two tubes will be EDTA-whole blood and one tube will be serum. Each tube~          will contain ~4-5 ml. A portion of the blood will be utilized to extract white blood~          cells that will be immortalized by EBV infection.~        -  Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or~          elsewhere, will be requested after obtaining consent for study participation.~        -  Fresh Tissue Collection: At the time of surgery for tumor resection, tumor and adjacent~          normal tissue will be requested from the Pathology Department. At the time of endoscopy,~          aspirated fluid or biopsied tissue will be requested. No additional tissue will be~          resected beyond that required for surgical or endoscopic management.~        -  Genetic Testing: All genetic testing will be performed in a research laboratory. Test~          results from research laboratories will not be disclosed to patients.~   "|||2018-05-31 23:54:23.090565|2018-05-31 23:54:23.090565
NCT01103115|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2015-02-02|2010-04-13|2010-04-14|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Calcium + Vitamin D Supplementation for Low Bone Mass in Adolescent Idiopathic Scoliosis (AIS)|Can Calcium and Vitamin D Supplementation Improve Bone Mineral Density and Curve Progression in Girls With Adolescent Idiopathic Scoliosis?|Completed||Phase 3|330|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 23:54:23.154636|2018-05-31 23:54:23.154636
NCT01103102|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-01-27|2010-04-13|2010-04-14|Estimate|||||||2013-01-27|2013-01-29|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Dose-Response Study of Iocide Oral Rinse|Phase II Study: Evaluate Dose-Response of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects of Biological Markers Indicative of Systemic Disease|Completed||Phase 2|97|Actual|Biomedical Development Corporation||4|||f||||t||||||||||2018-05-31 23:54:23.265372|2018-05-31 23:54:23.265372
NCT01103089|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2011-10-11|2010-04-13|2010-04-14|Estimate|||||||2011-10-11|2011-10-12|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)|Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)|Completed|||10|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 23:54:23.341152|2018-05-31 23:54:23.341152
NCT01103076|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-13|||2011-07-06|2010-04-13|2010-04-14|Estimate|||||||2011-07-06|2011-07-07|Estimate|April 2011||2011-04-30|March 2010|2010-03-31|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease|Effects of High Cut-off Hemodialysis on Central Memory CD4+ T Cells and Regulatory T Cells in Patients With End-stage Kidney Disease|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Centre Hospitalier du Centre du Valais||2|||f||||t||||||||||2018-05-31 23:54:23.613059|2018-05-31 23:54:23.613059
NCT01103063|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2014-08-25||2015-05-14|2010-04-12|2010-04-13|Estimate|2014-08-25|2014-09-05|Estimate||||2015-05-14|2015-06-16|Estimate|October 2010||2010-10-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa|A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa|Terminated||Phase 3|2891|Actual|Pfizer|This program was terminated by Pfizer based on the results of the pre-planned interim analysis for this pivotal study. The interim analysis showed no benefit of the study drug (AZCQ) compared to standard of care (SP).|2||See termination reason in detailed description.|f||||t||||||||||2018-05-31 23:54:23.789793|2018-05-31 23:54:23.789793
NCT01103050|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2017-02-20|2010-04-12|2010-04-13|Estimate|||||||2017-02-20|2017-02-23|Actual|March 22, 2010|Actual|2010-03-22|February 2017|2017-02-28|July 28, 2010|Actual|2010-07-28|July 28, 2010|Actual|2010-07-28||Interventional|||A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine|A Randomized, Double-blind, Double-dummy, Placebo Controlled Three-period Incomplete Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine on Total Nasal Symptom Score in Allergic Rhinitis Patients in an Environmental Exposure Chamber|Completed||Phase 2|60|Actual|Novartis||4|||f||||||||||||||2018-05-31 23:54:25.341214|2018-05-31 23:54:25.341214
NCT01103037|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12||2012-05-02|2012-05-02|2010-04-12|2010-04-13|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma|A Randomized, Double-blind, Parallel Group Study to Compare the Pharmacodynamics/Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Moderate Persistent Asthma|Terminated||Phase 2|8|Actual|Novartis||2||Terminated by sponsor|f||||||||||||||2018-05-31 23:54:25.412352|2018-05-31 23:54:25.412352
NCT01103024|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09||2012-05-02|2012-05-02|2010-04-12|2010-04-13|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|December 2010||2010-12-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|INSURE||Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis|A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study)|Terminated||Phase 3|27|Actual|Novartis||4||"Core study in non-infectious active uveitis was terminated. Patients came only for the planned~   safety follow-up visit in this extension study."|f||||||||||||||2018-05-31 23:54:25.489041|2018-05-31 23:54:25.489041
NCT01103011|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-10-03|2010-04-12|2010-04-13|Estimate|||||||2010-10-03|2010-10-05|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611|A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuously Delivered ND0611|Completed||Phase 1|8|Anticipated|NeuroDerm Ltd.||1|||f||||||||||||||2018-05-31 23:54:25.572708|2018-05-31 23:54:25.572708
NCT01102972|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2012-11-28||2013-10-24|2010-04-12|2010-04-13|Estimate|2012-11-28|2012-12-31|Estimate||||2013-10-24|2013-11-19|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|ASSURE||A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)|A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects|Completed||Phase 4|297|Actual|ViiV Healthcare|This study consists of a 35-day Screening Period, a 48-week Treatment Period, and a Follow-up Period (contact ~2-4 weeks after the Week 48/Withdrawal Visit). Data from Week 24 (primary endpoint) and Week 48 (final data) are presented in this summary.|2|||f||||f||||||||||2018-05-31 23:54:26.030321|2018-05-31 23:54:26.030321
NCT01102959|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||The Effectiveness of Photographic Educational Material on Carbohydrate Counting for Adolescents With Diabetes|The Effectiveness of Photographic Educational Material on Carbohydrate Counting for Adolescents With Diabetes|Unknown status|Recruiting|N/A|50|Anticipated|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-05-31 23:54:27.216694|2018-05-31 23:54:27.216694
NCT01102946|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2011-08-03|2010-04-12|2010-04-13|Estimate|||||||2011-08-03|2011-08-04|Estimate|February 2009||2009-02-28|January 2011|2011-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|IRaHi||Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy|Panretinal Photocoagulation Versus Panretinal Photocoagulation Plus Intravitreous Ranibizumab for High Risk Proliferative Diabetic Retinopathy|Completed||Phase 2|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:54:27.354525|2018-05-31 23:54:27.354525
NCT01102933|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-03-22|2010-04-12|2010-04-13|Estimate|||||||2014-03-22|2014-03-26|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|REBUS||RElevance of Biomarkers for Future Risk of Thromboembolic Events in UnSelected Post-myocardial Infarction Patients|RElevance of Biomarkers for Future Risk of Thromboembolic Events in UnSelected Post-myocardial Infarction Patients - an Observational Study (REBUS)|Completed|||425|Actual|Uppsala University|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected for analysis of biomarkers and platelets. At the first visit~     after the hospital stay blood for DNA analysis will also be collected.~   "|||2018-05-31 23:54:27.444377|2018-05-31 23:54:27.444377
NCT01102920|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2017-11-06|2010-04-12|2010-04-13|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2010||2010-05-31|November 2017|2017-11-30|September 2014|Actual|2014-09-30|March 2012|Actual|2012-03-31||Interventional|||Life-style Changes in Obstructive Sleep Apnea|Health Behaviour Modifications in Obstructive Sleep Apnea. Tailored Behavioural Medicine Strategies to Promote Physical Activity and Weight Loss.|Completed||N/A|86|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 23:54:27.50394|2018-05-31 23:54:27.50394
NCT01102907|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2012-03-28|2010-04-12|2010-04-13|Estimate|||||||2012-03-28|2012-03-29|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Effect of Food Form on Satiety and Gastric Emptying|Beverages and Obesity: Effect of Food Form on Satiety and Hunger|Completed|||10|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 23:54:27.600643|2018-05-31 23:54:27.600643
NCT01102894|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2013-02-07||2014-10-27|2010-04-12|2010-04-13|Estimate|2014-10-15|2014-10-27|Estimate||||2014-10-27|2014-11-04|Estimate|August 2009||2009-08-31|October 2014|2014-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pilot Study Using a Wireless Motility Capsule|Measurement of Whole Gut Transit Time After a Dietary Fiber Treatment Using a Wireless Motility Capsule|Completed||N/A|10|Actual|University of Minnesota - Clinical and Translational Science Institute|The study interventions were not randomized, which doesn't allow for period effect calculations. The SmartPill can reside in the stomach for longer than a few hours, which can skew results.|1|||f||||f||||||||||2018-05-31 23:54:27.713167|2018-05-31 23:54:27.713167
NCT01102881|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-09-08|2010-04-12|2010-04-13|Estimate|||||||2010-09-08|2010-09-09|Estimate|August 2009||2009-08-31|September 2010|2010-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Laxation and Satiety Response of Novel Dietary Fibers|Laxation and Satiety Response of Novel Dietary Fibers|Completed||N/A|36|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 23:54:27.886311|2018-05-31 23:54:27.886311
NCT01102868|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-01-20|2010-04-12|2010-04-13|Estimate|||||||2012-01-20|2012-01-23|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||IMS-treatment and Canalis Carpi Syndrome|An Randomized Controlled Trial of IMS-treatment Versus Scam for Canalis Carpi Syndrome|Completed||N/A|75|Actual|Uni Research||2|||f||||f||||||||||2018-05-31 23:54:27.951922|2018-05-31 23:54:27.951922
NCT01102855|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-08-10|2010-04-12|2010-04-13|Estimate|||||||2011-08-10|2011-08-11|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Endomicroscopy and Crohn´s Disease|Confocal Laser Endomicroscopy in Patients With Crohn´s Disease|Completed|||40|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||t||||||||||2018-05-31 23:54:28.028796|2018-05-31 23:54:28.028796
NCT01102842|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2013-09-04|2010-04-12|2010-04-13|Estimate|||||||2013-09-04|2013-09-05|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Unattended In-home Sleep Recording: A Pilot Study|Unattended In-home Sleep Recording: A Pilot Study|Completed|||165|Actual|University of Chicago|||||f||||||||||||||2018-05-31 23:54:28.250238|2018-05-31 23:54:28.250238
NCT01102829|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|September 2007||2007-09-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|ROCC||Early Migration in a High Congruent Rotating Platform Total Knee Prosthesis Design|Early Migration in a High Congruent Rotating Platform Total Knee Prosthesis Design. A Synchronised Motion Analysis Study With Fluoroscopy and RSA|Completed|||11|Actual|Leiden University Medical Center|||||f||||f||||||||||2018-05-31 23:54:28.304012|2018-05-31 23:54:28.304012
NCT01102816|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2011-01-25|2010-04-12|2010-04-13|Estimate|||||||2011-01-25|2011-01-26|Estimate|May 2010||2010-05-31|January 2011|2011-01-31|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Interventional|||Acupuncture for Pain Management of Hemodialysis Patients|Acupuncture for Pain Management of Hemodialysis Patients: a Randomized, Controlled Pilot Study|Terminated||N/A|1|Actual|Korea Institute of Oriental Medicine||2||"We failed to recruit enough patients by regular recruitment methods (i.e., newspaper ads,~   hospital postings, radios and television ads)."|f||||t||||||||||2018-05-31 23:54:28.364225|2018-05-31 23:54:28.364225
NCT00898040|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|July 6, 2006|Actual|2006-07-06|May 2017|2017-05-31|January 1, 2007|Actual|2007-01-01|January 1, 2007|Actual|2007-01-01||Observational|||Study of DNA Samples From Patients With Multiple Myeloma|Proposal for Combining ECOG Myeloma Trial SNP Data|Completed|||600|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:28.397316|2018-06-01 00:59:28.397316
NCT01102803|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2012-12-12||2013-01-18|2010-04-12|2010-04-13|Estimate|2013-01-18|2013-02-21|Estimate||||2013-01-18|2013-02-21|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia|Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes|Completed||Phase 3|40|Actual|Southern Methodist University|Sample may not have been severe enough to see an effect of DCS; there may have been a ceiling effect; there was no pre-session pill administration; assessors were blind but not independent; only one dose of DCS was examined|2|||f||||f||||||||||2018-05-31 23:54:28.454879|2018-05-31 23:54:28.454879
NCT01102790|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-04-14|2010-04-12|2010-04-13|Estimate|||||||2010-04-14|2010-04-15|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|October 2010|Anticipated|2010-10-31|September 2010|Anticipated|2010-09-30||Observational|||Generation of Heparin-induced Thrombocytopenia (HIT)-Antibodies Without Prior Heparin Exposure|Generation of HIT-antibodies Without Prior Heparin Exposure Following Orthopedic Surgery (Subgroup Study) (Change of Coagulation Parameters Under Exposition With New Anticoagulants [Title of the Main Study])|Unknown status|Recruiting||160|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples With DNA|"~     serum citrated blood edta blood~   "|||2018-05-31 23:54:28.933842|2018-05-31 23:54:28.933842
NCT01102777|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2015-07-09||2016-04-28|2010-04-12|2010-04-13|Estimate|2016-04-28|2016-06-07|Estimate||||2016-04-28|2016-06-07|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)|Effectiveness of an Automated Walking Program Targeting Veterans With COPD|Completed||N/A|307|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 23:54:29.018653|2018-05-31 23:54:29.018653
NCT01102764|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2016-04-14||2016-07-20|2010-04-12|2010-04-13|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional||There were 150 participants enrolled in the study, and 132 completed at least one session and were thus analyzed. The numbers here reflect those participants who were analyzed because they completed at least 1 treatment session.|Prolonged Exposure (PE) for Post Traumatic Stress Disorder (PTSD): Telemedicine Versus In Person|Prolonged Exposure (PE) for PTSD: Telemedicine vs. In Person|Completed||N/A|150|Actual|VA Office of Research and Development|"The study lacked a third group of participants receiving an alternative intervention to compare PE-HBT with a standard control-group.~The achieved effect sizes were less than those typically evident in PE treatment outcome studies"|2|||f||||f||||||||||2018-05-31 23:54:29.529397|2018-05-31 23:54:29.529397
NCT01102751|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate||||August 2009|2009-08-31||||||||Observational|||Serum FGF-23 and Vitamin D Deficiency|Effects Of Vitamin D Replacement Therapy on Serum FGF-23 Concentrations in Vitamin D Deficient Women In Short Term|Completed|||||Istanbul University|||3||f||||f||||||||||2018-05-31 23:54:29.934455|2018-05-31 23:54:29.934455
NCT01102738|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2015-03-25|2010-04-12|2010-04-13|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2011||2011-01-31|February 2011|2011-02-28|June 2014|Actual|2014-06-30|January 2013|Actual|2013-01-31||Observational|||Defining the Intestinal Microbiota in Premature Neonates|The Microbiota of the Premature Neonatal Gastrointestinal Tract: Its Development and Relation to Necrotizing Enterocolitis and Bloodstream Infection|Completed|||369|Actual|Imperial College London|||1||f||||t||||||Samples Without DNA|"~     Faecal samples, surplus gut tissue samples (if patient requires bowel resection due to~     Necrotizing Enterocolitis).~   "|||2018-05-31 23:54:29.999459|2018-05-31 23:54:29.999459
NCT01102725|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-12-12|2010-04-12|2010-04-13|Estimate|||||||2014-12-12|2014-12-16|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|NOTES||Assessing Infectious Risk and Visceral Closure in Natural Orifice Translumenal Endoscopic Surgery (NOTES)|The Challenge of Assessing Infectious Risk and Visceral Closure in NOTES: A Prospective Study Examining Routine Colorectal Surgery as a Model in Humans|Completed|||12|Actual|University Hospitals Cleveland Medical Center|||1||f||||t||||||||||2018-05-31 23:54:30.068107|2018-05-31 23:54:30.068107
NCT01102712|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2012-02-21|2010-04-12|2010-04-13|Estimate|||||||2012-02-21|2012-02-23|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|BTVA||Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction|Evaluation Study of Unilateral Bronchoscopic Thermal Vapor Ablation (BTVA) in Patients With Heterogeneous Emphysema and Upper Lobe Predominance|Completed||N/A|34|Actual|Uptake Medical Corp||1|||f||||f||||||||||2018-05-31 23:54:30.15078|2018-05-31 23:54:30.15078
NCT01102699|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-08-30|2010-04-12|2010-04-13|Estimate|||||||2013-08-30|2013-09-02|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|GCSF-DM||Bone Marrow Progenitor Cell Mobilization in Diabetes|Bone Marrow Responsiveness to Pharmacologic Mobilization of Progenitor Cells in Diabetic Versus Non-diabetic Patients|Completed||Phase 4|48|Anticipated|University of Padova||1|||f||||f||||||||||2018-05-31 23:54:30.233445|2018-05-31 23:54:30.233445
NCT01102686|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2012-02-22|2010-04-12|2010-04-13|Estimate|||||||2012-02-22|2012-02-23|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)|Proposed Investigator-Initiated Clinical Trial of Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)|Completed||Phase 1/Phase 2|20|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 23:54:30.306816|2018-05-31 23:54:30.306816
NCT01102673|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-08-03|2010-04-12|2010-04-13|Estimate|||||||2010-08-03|2010-08-05|Estimate|April 2010||2010-04-30|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Single Dose Study of PF-04991532 in Healthy Subjects|A Phase 1 Placebo-Controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Food Effect of Single Escalating Oral Doses of PF-04991532 in Healthy Adult Subjects|Completed||Phase 1|18|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 23:54:30.400629|2018-05-31 23:54:30.400629
NCT01102660|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12||2012-10-01|2014-08-20|2010-04-12|2010-04-13|Estimate||||2012-10-01|2012-10-05|Estimate|2014-08-20|2014-08-22|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee|A Randomized, Double-Blind, Double-Dummy, Placebo And Active Controlled Two Period Four Treatment Cross-Over Clinical Trial To Examine The Pain Relief Of PH-797804 Alone Or With Naproxen In Subjects With Flare-Enriched Osteoarthritis Of The Knee|Completed||Phase 2|172|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 23:54:30.476329|2018-05-31 23:54:30.476329
NCT01102647|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-04-28|2010-04-12|2010-04-13|Estimate|||||||2011-04-28|2011-05-02|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Cholesterol Metabolism in Heterozygous Phytosterolemia|Assessment of Cholesterol Metabolism in Heterozygous Phytosterolemia|Completed||Phase 1|26|Anticipated|University of Manitoba||1|||f||||t||||||||||2018-05-31 23:54:30.571707|2018-05-31 23:54:30.571707
NCT01102634|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|April 2010||2010-04-30|April 2010|2010-04-30||||August 2010|Anticipated|2010-08-31||Interventional|||Effects of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Blood Lactate and Excessive Post-exercise Oxygen Consumption (EPOC)||Unknown status|Recruiting|N/A|20|Anticipated|The Hong Kong Polytechnic University||2|||f||||||||||||||2018-05-31 23:54:30.633498|2018-05-31 23:54:30.633498
NCT01102621|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|January 2005||2005-01-31|March 2010|2010-03-31|July 2007|Actual|2007-07-31|January 2007|Actual|2007-01-31||Observational|||Hearing Loss and Complaint in Patients With Head and Neck Cancer Treated With Radiotherapy|Hearing Loss and Complaint in Patients With Head and Neck Cancer Treated With Radiotherapy|Completed|||282|Actual|Hospital A.C. Camargo|||2||f||||f||||||||||2018-05-31 23:54:30.697408|2018-05-31 23:54:30.697408
NCT01102608|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2012-03-19|2010-04-12|2010-04-13|Estimate|||||||2012-03-19|2012-03-20|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma|Phase II Study of Neoadyuvant High-dose Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma and Identification of Response Predictors|Completed||Phase 2|32|Actual|Grupo Espanol de Investigacion en Sarcomas||1|||f||||f||||||||||2018-05-31 23:54:30.755086|2018-05-31 23:54:30.755086
NCT01102595|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2015-08-25|2010-04-12|2010-04-13|Estimate|||||||2015-08-25|2015-08-26|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|October 2013|Actual|2013-10-31||Interventional|||Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma|A Phase II Open Label Randomised Multicentric Study in Patients With Unresectable Glioblastoma Using Neo-adjuvant Treatment With Two Cycles of Temozolomide Previous Temozolomide Plus Radiation Therapy and Adjuvant Temozolomide vs. Neo-adjuvant Treatment With Two Cycles of Temozolomide Plus Bevacizumab Previous Temozolomide, Bevacizumab and Radiation Therapy and Adjuvant Temozolomide.|Completed||Phase 2|102|Actual|Grupo Español de Investigación en Neurooncología||2|||f||||f||||||||||2018-05-31 23:54:30.833578|2018-05-31 23:54:30.833578
NCT01102582|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-02-02|2010-04-12|2010-04-13|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia|A Six-month Observational Study to Investigate Prevalence of Neuropsychiatric Symptom in Korean Patients With Parkinson's Disease Dementia|Completed|||48|Actual|The Catholic University of Korea|||||f||||t||||||||||2018-05-31 23:54:31.056226|2018-05-31 23:54:31.056226
NCT01102569|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-07-02|2010-04-12|2010-04-13|Estimate|||||||2015-07-02|2015-07-03|Estimate|January 2008||2008-01-31|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Observational|||Pancreatic Cancer Genetics|Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients|Unknown status|Recruiting||100|Anticipated|Columbia University|||1||f||||t||||||Samples With DNA|"~     -  Peripheral Blood Specimens: Three tubes of blood will be collected from each study~          participant. A portion of the blood will be utilized to extract white blood cells that~          will be immortalized by Epstein-Barr virus (EBV) infection.~        -  Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or~          elsewhere, will be requested after obtaining consent for study participation.~        -  Fresh Tissue Collection: At the time of surgery for tumor resection, tumor and adjacent~          normal tissue will be requested from the Pathology Department. At the time of endoscopy,~          aspirated fluid or biopsied tissue will be requested. No additional tissue will be~          resected beyond that required for surgical or endoscopic management.~        -  Genetic Testing: Genetic testing will be performed in a New York State certified~          research laboratory . Test results from research laboratories will not be disclosed to~          patients.~   "|||2018-05-31 23:54:31.123732|2018-05-31 23:54:31.123732
NCT01102556|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2017-08-10|2010-04-12|2010-04-13|Estimate|||||||2017-08-10|2017-08-11|Actual|July 2004||2004-07-31|August 2017|2017-08-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|1 Year|Observational [Patient Registry]|||PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease|PREDICT: Pancreatic Disease Cohort. A Registry and Biospecimen Bank To Better Understand Pancreatic Disease.|Recruiting|||1000|Anticipated|Columbia University|||1||f||||t||||||Samples With DNA|"~     -  Peripheral Blood Specimens: Three tubes of blood will be collected from each study~          participant.~        -  Archived Fixed Tissue Samples: Tissue blocks from surgery performed at CUMC or~          elsewhere, will be requested after obtaining consent for study participation.~        -  Fresh Tissue Collection: At the time of surgery for any tumor resection, tumor tissue~          and adjacent normal tissue will be requested from the Pathology Department. At the time~          of endoscopy, aspirated fluid or biopsied tissue will be requested. No additional tissue~          will be resected beyond that required for surgical or endoscopic management. In no~          circumstance will tissue be obtained solely for the purpose of the study.~   "|No||2018-05-31 23:54:31.203634|2018-05-31 23:54:31.203634
NCT01102543|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2012-04-05|2010-04-12|2010-04-13|Estimate|||||||2012-04-05|2012-04-06|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Observational|||Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)|Observational Study in Neonatal Intensive Care Units (NICU) on the Real Life Use of Curosurf in Prophylaxis of RDS in Premature Babies.|Completed|||972|Actual|Chiesi Farmaceutici S.p.A.|||2||f||||t||||||||||2018-05-31 23:54:31.279956|2018-05-31 23:54:31.279956
NCT01102530|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-06-27|2010-04-12|2010-04-13|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Observational|||Diabetes Prevention in Women With a Recent History of Gestational Diabetes (Focus Groups)|Diabetes Prevention in Women With a Recent History of Gestational Diabetes|Completed|||29|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-05-31 23:54:31.346011|2018-05-31 23:54:31.346011
NCT01102517|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2018-02-27|2010-04-12|2010-04-13|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2010||2010-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial on Video-assisted Thoracoscopic Surgery and Axillary Thoracotomy for Resection of Early-stage Non-small Cell Lung Cancer||Active, not recruiting||N/A|500|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 23:54:31.400005|2018-05-31 23:54:31.400005
NCT01102504|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2015-04-02|2010-04-12|2010-04-13|Estimate|||||||2015-04-02|2015-04-06|Estimate|August 2015||2015-08-31|April 2015|2015-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|SOLANUM||Supplementation of Lycopene in Carotid Atheroma|Supplementation of Lycopene on Carotid Atheroma: Neovascularisation and Morphology (SOLANUM) Study|Withdrawn||N/A|0|Actual|Cambridge University Hospitals NHS Foundation Trust||2||lack of funding|f||||t||||||||||2018-05-31 23:54:31.473639|2018-05-31 23:54:31.473639
NCT01102491|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2010-04-26||2012-06-03|2010-04-09|2010-04-13|Estimate|2010-04-26|2010-05-21|Estimate||||2012-06-03|2012-06-08|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty|The Effect of Multimodal Anti-emetic Protocol on Postoperative Nausea and Vomiting After Total Knee Arthroplasty|Completed||Phase 4|153|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:54:31.6237|2018-05-31 23:54:31.6237
NCT01102478|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2018-01-19|2010-04-12|2010-04-13|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2005||2005-02-28|January 2018|2018-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide Tablets 100 mg/25 mg Under Fasting Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:54:31.916306|2018-05-31 23:54:31.916306
NCT01102465|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2018-01-19|2010-04-12|2010-04-13|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2005||2005-02-28|January 2018|2018-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide Tablets 100 mg/25 mg Under Fed Conditions|Completed||N/A|25|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-05-31 23:54:32.005232|2018-05-31 23:54:32.005232
NCT01102452|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2012-12-24|2010-04-12|2010-04-13|Estimate|||||||2012-12-24|2012-12-27|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Evaluate the Blood Glucose Regulation and Safety of PPB-R-203-02 Based Noodle Versus Commercially Available Wet Noodle in Patients With Diabetes|A Randomized, Two-Regimen, Crossover, Comparative Study to Evaluate the Blood Glucose Regulation and Safety of PPB-R-203-02 Based Noodle Versus Commercially Available Wet Noodle in 24 Patients With Diabetes|Completed||N/A|24|Actual|Pharma Power Biotec Co., Ltd.||2|||f||||||||||||||2018-05-31 23:54:32.074241|2018-05-31 23:54:32.074241
NCT01102439|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-04-27|2010-04-12|2010-04-13|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|February 2013|Actual|2013-02-28|December 2010|Actual|2010-12-31||Interventional|INTERACTION||Clopidogrel/Aspirin Interaction Study|Randomized, Factorial Study to Explore Interaction Between Aspirin and Clopidogrel in Stable Patients With Previous Myocardial Infarction or Coronary Artery Stent|Completed||Phase 4|82|Actual|Population Health Research Institute||4|||f||||f||||||||||2018-05-31 23:54:32.210363|2018-05-31 23:54:32.210363
NCT01102426|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2018-01-02|2010-04-12|2010-04-13|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2010||2010-06-30|January 2017|2017-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|ADMYRE||Aplidin - Dexamethasone in Relapsed/Refractory Myeloma|Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma|Completed||Phase 3|250|Anticipated|PharmaMar||2|||f||||t||||||||||2018-05-31 23:54:32.353974|2018-05-31 23:54:32.353974
NCT01102413|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2015-09-21||2015-11-02|2010-04-12|2010-04-13|Estimate|2015-11-02|2015-12-03|Estimate||||2015-11-02|2015-12-03|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia|A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia|Completed||Phase 3|351|Actual|Pharmacosmos A/S||2|||f||||t||||||||||2018-05-31 23:54:32.586459|2018-05-31 23:54:32.586459
NCT01102400|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2013-02-05|2010-04-12|2010-04-13|Estimate|||||||2013-02-05|2013-02-06|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of MEDI-575 in Patients With Advanced Solid Malignancies|A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid Malignancies|Completed||Phase 1|22|Actual|AstraZeneca||1|||f||||t||||||||||2018-05-31 23:54:32.916805|2018-05-31 23:54:32.916805
NCT01102387|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-07-03|2010-04-12|2010-04-13|Estimate|||||||2012-07-03|2012-07-04|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections|Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at the Trunk|Completed||Phase 2|137|Actual|Almirall, S.A.||3|||f||||f||||||||||2018-05-31 23:54:33.034815|2018-05-31 23:54:33.034815
NCT01102374|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-11|2016-10-28||2017-04-18|2010-04-12|2010-04-13|Estimate|2017-04-18|2017-04-21|Actual||||2017-04-18|2017-04-21|Actual|May 2010||2010-05-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|August 2014|Actual|2014-08-31||Interventional|||Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents|Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents|Completed||Phase 2|107|Actual|University of Colorado, Denver||2|||f||||t|t|f||||||No||2018-05-31 23:54:33.136377|2018-05-31 23:54:33.136377
NCT01102361|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-11|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Interventional|BxB||Ultrasound Based Transperineal Robotic Biopsy of the the Prostate|Study of Prostate Cancer Detection With in House Developed Robot|Unknown status|Recruiting|Phase 1/Phase 2|250|Anticipated|Singapore General Hospital||1|||f||||f||||||||||2018-05-31 23:54:33.698427|2018-05-31 23:54:33.698427
NCT01102348|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-04-13|2010-04-09|2010-04-13|Estimate|||||||2010-04-13|2010-04-14|Estimate|May 2008||2008-05-31|April 2010|2010-04-30||||April 2009|Actual|2009-04-30||Interventional|PEP-uP||Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients|Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients: A Single Center Feasibility Trial of The PEP uP Protocol|Completed||N/A|50|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||f||||||||||2018-05-31 23:54:33.795718|2018-05-31 23:54:33.795718
NCT01102335|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|TACEHBV||Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy|The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy|Unknown status|Recruiting|Phase 4|80|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 23:54:33.894666|2018-05-31 23:54:33.894666
NCT01102322|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2011-02-18|2010-04-12|2010-04-13|Estimate|||||||2011-02-18|2011-02-21|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|||Factors Associated With the Use of Lung Protective Ventilation Strategy (LPV) in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients in Intensive Care Unit (ICU)|Factors Associated With the Use of Lung Protective Ventilation Strategy (LPV) in ALI/ARDS Patients in ICU|Completed|||111|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 23:54:33.979849|2018-05-31 23:54:33.979849
NCT01102309|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-06-23|2010-04-12|2010-04-13|Estimate|||||||2011-06-23|2011-06-27|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Robot-assisted Rehabilitation of the Upper Limb in Acute and Subacute Post-stroke Patients|Clinical and Social-economic Impact Assessment of Robot-assisted Rehabilitation of the Upper Limb in Acute and Subacute Post-stroke Patients|Completed||N/A|27|Actual|Eremo Hospital, Arco||2|||f||||f||||||||||2018-05-31 23:54:34.048589|2018-05-31 23:54:34.048589
NCT01102296|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2012-12-25|2010-04-12|2010-04-13|Estimate|||||||2012-12-25|2012-12-27|Estimate|June 2009||2009-06-30|December 2012|2012-12-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection|Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital|Completed||N/A|582|Actual|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 23:54:34.12909|2018-05-31 23:54:34.12909
NCT01102283|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2013-09-16|2010-04-12|2010-04-13|Estimate|||||||2013-09-16|2013-09-18|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Observational|||Treatment of Colonic Obstruction With Cook Evolution® Colonic Stent System|Treatment of Colonic Obstruction With Cook Evolution® Colonic Stent System|Completed|||80|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 23:54:34.222929|2018-05-31 23:54:34.222929
NCT01102270|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|2013-04-29||2017-04-14|2010-04-12|2010-04-13|Estimate|2017-04-14|2017-04-18|Actual||||2017-04-14|2017-04-18|Actual|January 2009||2009-01-31|April 2017|2017-04-30|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional||although 28 were screened, only 17 were randomized since 11 did not qualify for the randomization portion of the study|The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome|A Double-Blind Randomized Physiological Study Examining the Effects of Eszopiclone on the Arousal Threshold and Obstructive Sleep Apnea Severity|Completed||Early Phase 1|17|Actual|Brigham and Women's Hospital|We excluded patients with blood arterial oxygen saturations <70% as we wanted to avoid any potential risks associated with this group.|2|||f||||f||||||||No|published|2018-05-31 23:54:34.297275|2018-05-31 23:54:34.297275
NCT01102257|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2011-04-29||2012-07-20|2010-04-09|2010-04-13|Estimate|2012-07-20|2012-08-23|Estimate||||2012-07-20|2012-08-23|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|July 2010|Actual|2010-07-31||Interventional|DREAM||Dry Eye Assessment and Management: Feasibility Study|Clinical Trial of Essential Fatty Acids for Dry Eye Disease: Feasibility Study|Completed||Phase 2/Phase 3|23|Actual|Asbell, Penny, M.D.|DREAM: Feasibility Study, is labeled “feasibility” because its primary end-point is to demonstrate an ability to execute the protocol rather than generate statistically relevant data on the safety and efficacy of omega-3 EFA in patients with DED.|2|||f||||t||||||||||2018-05-31 23:54:34.482526|2018-05-31 23:54:34.482526
NCT01102244|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2012-06-07|2010-04-12|2010-04-13|Estimate|||||||2012-06-07|2012-06-11|Estimate|April 2010||2010-04-30|January 2011|2011-01-31||||June 2010|Actual|2010-06-30||Interventional|||A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis||Completed||Phase 3|122|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:54:34.733327|2018-05-31 23:54:34.733327
NCT01102231|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-10|||2017-03-01|2010-04-12|2010-04-13|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2010|Actual|2010-03-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)|Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|106|Actual|Intergroupe Francophone de Cancerologie Thoracique||1|||f||||f||||||||||2018-05-31 23:54:34.794059|2018-05-31 23:54:34.794059
NCT01102218|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|2012-01-18||2012-03-26|2010-04-12|2010-04-13|Estimate|2012-02-23|2012-03-26|Estimate||||2012-03-26|2012-03-28|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Safety Study of Pentoxifylline for the Treatment of Anemia|A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis|Terminated||Phase 2|48|Actual|Fresenius Medical Care North America|Release of new FDA guidelines re target Hgb values impacted EPO dosing.|2||Lack of statistical difference between both arms of the trial.|f||||t||||||||||2018-05-31 23:54:36.127616|2018-05-31 23:54:36.127616
NCT01102205|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-06-11|2010-04-12|2010-04-13|Estimate|||||||2013-06-11|2013-06-13|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Observational|||Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease|Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease|Completed|||130|Actual|Vakif Gureba Training and Research Hospital|||3||f||||t||||||Samples Without DNA|"~     after overnight fasting state,venous blood will be taken to obtain serum.speciemens stored~     -70 cantigrade celcius untillanalysing.~   "|||2018-05-31 23:54:36.427683|2018-05-31 23:54:36.427683
NCT01102192|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2018-02-01|2010-04-12|2010-04-13|Estimate|||||||2018-02-01|2018-02-02|Estimate|August 2007||2007-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Role of the Thymus in Myasthenia Gravis||Active, not recruiting|||80|Anticipated|Charite University, Berlin, Germany|||4||f||||f||||||Samples Without DNA|"~     Blood sample (serum, plasma), Thymoma tissue~   "|||2018-05-31 23:54:36.49462|2018-05-31 23:54:36.49462
NCT01102179|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2014-11-06|2010-04-12|2010-04-13|Estimate|||||||2014-11-06|2014-11-07|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease (CKD) Patients in Singapore|Prevalence of Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease Patients in Singapore|Completed|||196|Actual|National University, Singapore|||1||f||||f||||||||||2018-05-31 23:54:36.666686|2018-05-31 23:54:36.666686
NCT01102166|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|August 2005||2005-08-31|October 2009|2009-10-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Acapella With Nebulization in Normal Subjects|Effect of the Use the Acapella Device in Regional Lung Deposition of Radio-aerosol|Completed||N/A|10|Actual|Universidade Federal de Pernambuco|||||f||||t||||||||||2018-05-31 23:54:36.743517|2018-05-31 23:54:36.743517
NCT01102153|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-04-12|2010-04-12|2010-04-13|Estimate|||||||2010-04-12|2010-04-13|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Neuron Specific Enolase (NSE) as Outcome Parameter of Cooling Therapy After Survived Sudden Cardiac Death|NSE as an Outcome Predictor of Therapeutical Hypothermia After Survived Sudden Cardiac Death|Completed|||108|Actual|University of Leipzig|||2||f||||f||||||||||2018-05-31 23:54:36.827628|2018-05-31 23:54:36.827628
NCT01102140|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|2017-05-18||2017-06-13|2010-04-12|2010-04-13|Estimate|2017-06-13|2017-07-14|Actual||||2017-06-13|2017-07-14|Actual|July 2010||2010-07-31|June 2017|2017-06-30|May 31, 2013|Actual|2013-05-31|May 31, 2013|Actual|2013-05-31||Interventional|ImPrOVE||The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study|The Impact of Pomegranate (Punica Granatum) Polyphenol Extract on Oxidative Stress, Ventricular Remodeling and Endothelial Function in Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study|Terminated||Phase 2|20|Actual|University of Michigan||2||Investigator left University of Michigan|f||||f|f|||||||Undecided||2018-05-31 23:54:36.956675|2018-05-31 23:54:36.956675
NCT01102127|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-12|||2011-05-24|2010-04-12|2010-04-13|Estimate|||||||2011-05-24|2011-05-25|Estimate|February 2010||2010-02-28|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Elastography in Thyroid Nodules|Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease.|Completed|||128|Actual|Castilla-León Health Service|||1||f||||f||||||Samples Without DNA|"~     Thyroid cells~   "|||2018-05-31 23:54:37.450859|2018-05-31 23:54:37.450859
NCT01102114|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2012-05-08|2010-04-09|2010-04-12|Estimate|||||||2012-05-08|2012-05-09|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation|A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation|Completed||Phase 3|1000|Actual|Nabi Biopharmaceuticals||2|||f||||t||||||||||2018-05-31 23:54:37.544619|2018-05-31 23:54:37.544619
NCT01102101|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-09|2010-04-09|2010-04-12|Estimate|||||||2010-04-09|2010-04-12|Estimate|August 2010||2010-08-31|April 2010|2010-04-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|VHPRG-HDRPH||Effect of Opioids in Neuropathic Pain in Postherpetic Patients|Effect of Opioids in Neuropathic Pain in Postherpetic Patients|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-05-31 23:54:37.669539|2018-05-31 23:54:37.669539
NCT01102088|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2017-06-19|2010-04-09|2010-04-12|Estimate|||||||2017-06-19|2017-06-20|Actual|April 2010|Actual|2010-04-30|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Simultaneous Integrated Boost (SIB) in Esophageal Cancer|Phase I/II Study of Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients With Esophageal Cancer|Active, not recruiting||Phase 1/Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:54:37.757916|2018-05-31 23:54:37.757916
NCT01102075|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-09|2010-04-09|2010-04-12|Estimate|||||||2010-04-09|2010-04-12|Estimate|January 2010||2010-01-31|September 2009|2009-09-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||The Effect of Electroacupuncture on Obesity|The Effect of Low Frequency Electroacupuncture on Waist Circumference in Obesity-Three Arm Randomized Controlled Trial, Pilot Study|Unknown status|Active, not recruiting|Phase 2|39|Anticipated|Kyunghee University Medical Center||3|||f||||t||||||||||2018-05-31 23:54:37.864875|2018-05-31 23:54:37.864875
NCT01102062|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2016-11-04|2010-04-09|2010-04-12|Estimate|||||||2016-11-04|2016-11-07|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Human Urinary Biomarker for Orange Juice Consumption|Human Urinary Biomarker for Orange Juice Consumption|Completed||N/A|6|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 23:54:37.963167|2018-05-31 23:54:37.963167
NCT01102049|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2016-11-04|2010-04-09|2010-04-12|Estimate|||||||2016-11-04|2016-11-07|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Food-related Differences in Human Metabolite Profiles|Food-related Differences in Human Metabolite Profiles|Completed||N/A|7|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 23:54:38.050834|2018-05-31 23:54:38.050834
NCT01102036|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-08-25|2010-04-09|2010-04-12|Estimate|||||||2011-08-25|2011-08-26|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Effects of Cultura Yoghurt in Relation to Transit Time and Digestive Discomfort in Healthy Women and Men|Effects of Cultura Yoghurt in Relation to Transit Time and Digestive Discomfort During 2 Weeks of Treatment in Comparison to Placebo in Healthy Women and Men|Completed||N/A|50|Anticipated|Good Food Practice, Sweden||2|||f||||f||||||||||2018-05-31 23:54:38.227625|2018-05-31 23:54:38.227625
NCT01102023|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-09|2010-04-09|2010-04-12|Estimate|||||||2010-04-09|2010-04-12|Estimate||||March 2010|2010-03-31||||||||Interventional|||Effect of Solar Salt Diet in Elderly Hypertensive Patients||Completed||Phase 3|||Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||||||||||||2018-05-31 23:54:38.349069|2018-05-31 23:54:38.349069
NCT01102010|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-07-16|2010-04-09|2010-04-12|Estimate|||||||2015-07-16|2015-07-20|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Postoperative Blood Transfusion for Frail Elderly With Hip Fracture|Postoperative Blood Transfusion for Frail Elderly With Hip Fracture - a Clinical Randomized Controlled Trial|Completed||Early Phase 1|284|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 23:54:38.414534|2018-05-31 23:54:38.414534
NCT01101997|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2011-06-16|2010-04-09|2010-04-12|Estimate|||||||2011-06-16|2011-06-20|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|JUNO||Non-Invasive Reduction of Abdominal Fat|Non-Invasive Reduction of Abdominal Fat Utilizing the JUNO Applicator|Completed||N/A|50|Anticipated|Zeltiq Aesthetics|||||f||||f||||||||||2018-05-31 23:54:38.494208|2018-05-31 23:54:38.494208
NCT01101984|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2012-11-11|2010-04-08|2010-04-12|Estimate|||||||2012-11-11|2012-11-14|Estimate|February 2010||2010-02-28|November 2012|2012-11-30|April 2012|Actual|2012-04-30|||||Interventional|||Study of DE-089 Ophthalmic Solution in Patients With Dry Eye|A Randomized, Parallel- Group Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Comparison With 0.1% Sodium Hyaluronate Ophthalmic Solution) － A Multinational Study －|Completed||N/A|400|Anticipated|Santen Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 23:54:38.569123|2018-05-31 23:54:38.569123
NCT01101971|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2017-04-03||2017-04-03|2010-04-08|2010-04-12|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|April 2010||2010-04-30|April 2017|2017-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Preparing Medical Students to Undertake a First Female Pelvic Exam.|Can a MEdTech E-learning Module Adequately Prepare Medical Students to Undertake a First Female Pelvic Exam?|Completed||N/A|45|Actual|Queen's University||1|||f||||f||||||||No||2018-05-31 23:54:38.653319|2018-05-31 23:54:38.653319
NCT01101958|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2013-12-04||2017-04-06|2010-04-08|2010-04-12|Estimate|2013-12-04|2014-01-23|Estimate||||2017-04-06|2017-05-12|Actual|January 2012||2012-01-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)|A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) in Subjects With Heterogeneous Emphysema|Completed||N/A|96|Actual|Pulmonx, Inc.||1|||f||||||||||||||2018-05-31 23:54:38.815744|2018-05-31 23:54:38.815744
NCT01101945|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-08-10|2010-04-08|2010-04-12|Estimate|||||||2010-08-10|2010-08-11|Estimate|July 2007||2007-07-31|August 2010|2010-08-31|March 2010|Anticipated|2010-03-31|January 2010|Anticipated|2010-01-31||Interventional|||Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus|An Open Label, Multi-Center, Long-Term Follow-up Study to Evaluate the Safety of PHX1149T in Subjects With Type 2 Diabetes Mellitus - Extension to Protocol PHX1149-PROT202|Terminated||Phase 2|339|Actual|Phenomix|||||f||||||||||||||2018-05-31 23:54:39.120699|2018-05-31 23:54:39.120699
NCT01101932|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2011-07-21|2010-04-08|2010-04-12|Estimate|||||||2011-07-21|2011-07-25|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers|A Phase 1, Placebo-Controlled, Multiple-Dose Escalation Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04308515 (Part 1), And A Single Dose Pharmacokinetic Assessment Of A PF-04308515 Tablet Formulation (Part 2), In Healthy Volunteers|Completed||Phase 1|58|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 23:54:39.282218|2018-05-31 23:54:39.282218
NCT01101919|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2011-11-11|2010-04-08|2010-04-12|Estimate|||||||2011-11-11|2011-11-16|Estimate|October 2010||2010-10-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||CP-690,550 Pharmacokinetics In Healthy Chinese Subjects|An Open Label, Single And Multiple Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Healthy Chinese Subjects|Completed||Phase 1|12|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 23:54:39.359466|2018-05-31 23:54:39.359466
NCT01101906|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08||2012-12-10|2012-12-10|2010-04-08|2010-04-12|Estimate||||2012-12-10|2012-12-12|Estimate|2012-12-10|2012-12-12|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC|A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib|Terminated||Phase 2|23|Actual|Astellas Pharma Inc||2||"Company decided not to pursue the development of this drug in this patient population at this~   time"|f||||t||||||||||2018-05-31 23:54:39.458681|2018-05-31 23:54:39.458681
NCT01101893|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2017-09-08|2010-04-09|2010-04-12|Estimate|||||||2017-09-08|2017-09-11|Actual|April 2010||2010-04-30|September 2017|2017-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects|A Phase I, Open Label, Single Sequence, Drug Interaction Study Evaluating Plasma GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects.|Completed||Phase 1|15|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 23:54:39.651043|2018-05-31 23:54:39.651043
NCT01101880|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2017-03-04||2017-09-18|2010-04-09|2010-04-12|Estimate|2017-09-18|2017-10-19|Actual||||2017-09-18|2017-10-19|Actual|August 2010||2010-08-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|June 2013|Actual|2013-06-30||Interventional|||Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm|Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Less Than Age 65 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome and/or Advanced Myeloproliferative Neoplasm|Completed||Phase 2|50|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:54:39.787289|2018-05-31 23:54:39.787289
NCT01101867|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2013-04-09||2018-01-03|2010-04-08|2010-04-12|Estimate|2013-05-28|2013-07-02|Estimate||||2018-01-03|2018-01-31|Actual|June 2010||2010-06-30|January 2018|2018-01-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|ICHO||Prandial Insulin Dosing in Hospitalized Patients|Prandial Insulin Dosing Using the Carbohydrate Counting Technique in Hospitalized Patients With Diabetes|Completed||Phase 4|126|Actual|Ohio State University|Miscalculation of meal doses, mistimed doses, lack of complete documentation of carbohydrate intake, and dosing conducted by an experienced clinician may have contributed to the findings.|2|||f||||f||||||||||2018-05-31 23:54:40.282426|2018-05-31 23:54:40.282426
NCT01101854|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2017-07-20|2010-04-09|2010-04-12|Estimate|||||||2017-07-20|2017-07-24|Actual|December 2004||2004-12-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|WHGS1||Gene Expression Profiles in Healing and Non-Healing Wounds|Gene Expression Profiles in Healing and Non-Healing Wounds|Recruiting|||1300|Anticipated|Ohio State University|||2||f||||f|f|f||||Samples With DNA|"~     Tissue~   "|No||2018-05-31 23:54:40.697113|2018-05-31 23:54:40.697113
NCT01101841|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2013-07-16|2012-02-23|2015-10-14|2010-04-09|2010-04-12|Estimate|2014-03-20|2014-04-21|Estimate|2012-02-23|2012-02-24|Estimate|2015-10-14|2015-10-15|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms|A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|570|Actual|Noven Therapeutics||2|||f||||f||||||||||2018-05-31 23:54:40.87221|2018-05-31 23:54:40.87221
NCT01101828|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-02-10|2010-04-08|2010-04-12|Estimate|||||||2011-02-10|2011-02-14|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|DRY||Self-collected Swabs for HPV Testing in 18-24 Year Old Women|Self-collected Swabs for HPV Testing in 18-24 Year Old Women|Completed|||150|Anticipated|University of Washington|||||f||||f||||||Samples With DNA|"~     Self-collected vaginal samples for HPV testing~   "|||2018-05-31 23:54:42.09664|2018-05-31 23:54:42.09664
NCT01101815|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2016-08-17|2010-04-08|2010-04-12|Estimate|||||||2016-08-17|2016-08-19|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Adherence to HIV Therapy in Heroin Addicts|Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone|Recruiting||Phase 3|200|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 23:54:42.152281|2018-05-31 23:54:42.152281
NCT01101802|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2011-09-27|2010-04-09|2010-04-12|Estimate|||||||2011-09-27|2011-09-28|Estimate|March 2006||2006-03-31|May 2005|2005-05-31|October 2008|Actual|2008-10-31|March 2008|Actual|2008-03-31||Interventional|MISSILE||Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)|A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE.|Completed||Phase 4|71|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 23:54:42.23732|2018-05-31 23:54:42.23732
NCT01101789|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-10-11|2010-04-08|2010-04-12|Estimate|||||||2015-10-11|2015-10-14|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Triclosan Coated Suture Wound Closure for Peripheral Vascular Surgery: a Prospective Multicenter Study|Triclosan Coated Suture Wound Closure for Peripheral Vascular Surgery: a Prospective Multicenter Study|Completed||N/A|276|Actual|North Karelia Central Hospital||2|||f||||f||||||||||2018-05-31 23:54:42.308921|2018-05-31 23:54:42.308921
NCT01101776|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2014-08-12|2010-04-08|2010-04-12|Estimate|||||||2014-08-12|2014-08-13|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|ReNew||Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.|Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting|Completed|||49|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:54:42.37794|2018-05-31 23:54:42.37794
NCT01101763|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-04-21|2010-04-08|2010-04-12|Estimate|||||||2015-04-21|2015-04-22|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Observational|||A Study of the Kinetics of a 13C-Cholesterol Infusate in Healthy Male Subjects (0000-108)(COMPLETED)|A Pilot Study to Evaluate the Plasma Enrichment Kinetics of a 13C-Cholesterol Infusate in Healthy Male Subjects|Completed|||20|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 23:54:42.463558|2018-05-31 23:54:42.463558
NCT01101750|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2011-02-09|2010-04-08|2010-04-12|Estimate|||||||2011-02-09|2011-02-10|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?|Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients.|Unknown status|Recruiting|Phase 4|60|Anticipated|Medstar Health Research Institute|||||f||||f||||||||||2018-05-31 23:54:42.610607|2018-05-31 23:54:42.610607
NCT01101737|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-04-09|2010-04-09|2010-04-12|Estimate|||||||2010-04-09|2010-04-12|Estimate|February 2008||2008-02-29|April 2010|2010-04-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Trial of a Nurse Led Hypertension Clinic in Inner City General Practices|Evaluation of a Nurse-led Hypertension Clinic in Two Inner City General Practices: Randomised Controlled Trial|Completed||N/A|353|Actual|St George's, University of London||2|||f||||f||||||||||2018-05-31 23:54:42.700471|2018-05-31 23:54:42.700471
NCT01101724|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2013-11-01|2010-04-08|2010-04-12|Estimate|||||||2013-11-01|2013-11-05|Estimate|April 2010||2010-04-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Early Rest on Recovery From Pediatric Concussion|Effect of Early Rest on Recovery From Pediatric Concussion|Completed||N/A|99|Actual|Medical College of Wisconsin||2|||f||||t||||||||||2018-05-31 23:54:42.764333|2018-05-31 23:54:42.764333
NCT01101711|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2012-09-06|2010-04-08|2010-04-12|Estimate|||||||2012-09-06|2012-09-07|Estimate|November 2006||2006-11-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|February 2011|Actual|2011-02-28||Observational|||Endocrine Dysfunction and Quality of Life After Subarachnoid Hemorrhage|Endocrine Dysfunction and Quality of Life After Subarachnoid Hemorrhage|Completed|||50|Anticipated|Lund University Hospital|||1||f||||f||||||None Retained|"~     Blood and urine samples~   "|||2018-05-31 23:54:42.841351|2018-05-31 23:54:42.841351
NCT01101698|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2010-04-12|2010-04-09|2010-04-12|Estimate|||||||2010-04-12|2010-04-13|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|CACSK2||Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients|Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease|Unknown status|Recruiting|Phase 4|60|Anticipated|Medical Universtity of Lodz||2|||f||||t||||||||||2018-05-31 23:54:42.909048|2018-05-31 23:54:42.909048
NCT01101685|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2011-06-06|2010-04-08|2010-04-12|Estimate|||||||2011-06-06|2011-06-07|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Neural Responses and Dysphoria: Modulation by a Pharmacological Probe|Blood Oxygen Level Dependent (BOLD) Responses During Emotional and Cognitive Processing in Dysphoric and Non-dysphoric Participants and Their Modulation by a Pharmacological Probe of Serotonin Function|Completed||Phase 4|160|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 23:54:43.023373|2018-05-31 23:54:43.023373
NCT01101672|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-09|2010-04-09|2010-04-12|Estimate|||||||2010-04-09|2010-04-12|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Interventional|||Trial for Single Port Versus Conventional Laparoscopic Colectomy|A Randomized Controlled Trial Comparing the Outcomes of Patients Who Undergo Single Port Laparoscopic Colectomy and Conventional Laparoscopic Colectomy for Colonic Neoplasia|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 23:54:43.138517|2018-05-31 23:54:43.138517
NCT01101659|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2014-04-07|2010-04-08|2010-04-12|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|July 2010|Actual|2010-07-31|||||Interventional|||Ketamine Challenge Study With JNJ-40411813|A Double-Blind, 2-Way Crossover Study to Investigate the Effects of JNJ-40411813 on Ketamine-Induced Alterations in Neuropsychiatric Performance|Completed||Phase 1|40|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-05-31 23:54:43.240814|2018-05-31 23:54:43.240814
NCT01101646|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2014-05-26|2010-04-08|2010-04-12|Estimate|||||||2014-05-26|2014-05-28|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers|A Phase 1, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Rabeprazole Phase 3 Pediatric Bead Formulation Versus the Phase 1 Pediatric Bead Formulation and Effect of Food on the Pharmacokinetics of Rabeprazole Phase 3 Pediatric Bead Formulation in Healthy Subjects|Completed||Phase 1|36|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||||||||||||2018-05-31 23:54:43.330171|2018-05-31 23:54:43.330171
NCT01101633|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-04-09|2010-04-09|2010-04-12|Estimate|||||||2010-04-09|2010-04-12|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|B247Algobes||The Effect of Sodium Alginate on Appetite Sensation|The Effect of Sodium Alginate Containing Beverage on Appetite and Body Weight Regulation|Completed||Phase 1|20|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 23:54:43.430524|2018-05-31 23:54:43.430524
NCT01101620|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2011-01-19|2010-04-09|2010-04-12|Estimate|||||||2011-01-19|2011-01-20|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|LSD1||Effect of Levosimendan on Respiratory Muscle Function in Healthy Subjects|Pilot Study on the Effects of Levosimendan on in Vivo Respiratory Muscle Function in Healthy Subjects|Completed||N/A|30|Actual|University Medical Center Nijmegen||2|||f||||t||||||||||2018-05-31 23:54:43.549649|2018-05-31 23:54:43.549649
NCT01101607|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-08|2010-04-08|2010-04-12|Estimate|||||||2010-04-08|2010-04-12|Estimate|April 2008||2008-04-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Interventional|||Closed Reduction of Distal Forearm Fractures by Pediatric Emergency Medicine Physicians: A Prospective Study|Closed Reduction and Cast Immobilization of Distal Radius Fractures by Pediatric Emergency Medicine|Completed||N/A|104|Actual|InMotion Orthopaedic Research Center||2|||f||||f||||||||||2018-05-31 23:54:43.652999|2018-05-31 23:54:43.652999
NCT01101594|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2015-10-09|2010-04-09|2010-04-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma|A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|17|Actual|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 23:54:43.743833|2018-05-31 23:54:43.743833
NCT01101581|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2015-03-02|2010-04-08|2010-04-12|Estimate|||||||2015-03-02|2015-03-03|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL|Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|70|Anticipated|Immunomedics, Inc.||2|||f||||f||||||||||2018-05-31 23:54:43.851364|2018-05-31 23:54:43.851364
NCT01101568|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2017-06-12|2010-04-08|2010-04-12|Estimate|||||||2017-06-12|2017-06-14|Actual|April 14, 2010|Actual|2010-04-14|June 2017|2017-06-30|June 24, 2010|Actual|2010-06-24|June 24, 2010|Actual|2010-06-24||Interventional|||A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects|A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects|Completed||Phase 1|28|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:54:43.975577|2018-05-31 23:54:43.975577
NCT01101555|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2017-06-09|2010-04-09|2010-04-12|Estimate|||||||2017-06-09|2017-06-12|Actual|May 12, 2010|Actual|2010-05-12|June 2017|2017-06-30|November 29, 2012|Actual|2012-11-29|September 16, 2011|Actual|2011-09-16||Interventional|||Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study|A Randomised, Single-blind, Placebo-controlled, Study Toevaluate the Safety, Tolerability, Pharmacodynamics Andpharmacokinetics of Repeat Subcutaneous Administration Ofotelixizumab in Subjects With Rheumatoid Arthritis|Completed||Phase 1|28|Actual|GlaxoSmithKline||7|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:54:44.068908|2018-05-31 23:54:44.068908
NCT01101542|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2011-11-10||2015-10-29|2010-04-08|2010-04-12|Estimate|2011-11-10|2011-12-19|Estimate||||2015-10-29|2015-11-02|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females|Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix® When Administered to Healthy Females According to the Prescribing Information in Korea|Completed|||3091|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 23:54:44.185824|2018-05-31 23:54:44.185824
NCT01101529|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2012-12-12|2010-04-09|2010-04-12|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Treatment of Chemotherapy-induced Nausea and Vomiting|A Randomized Controlled Study to Compare (EMEND®)to Standard Treatment as Prevention for Delayed Chemotherapy-induced Nausea and Vomiting (CINV) After Myeloablative Therapy for Patients Undergoing Autologous Stem Cell Transplantation.|Completed||Phase 2|90|Anticipated|Uppsala University Hospital||2|||f||||f||||||||||2018-05-31 23:54:44.53903|2018-05-31 23:54:44.53903
NCT01101503|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2013-07-04|2010-04-09|2010-04-12|Estimate|||||||2013-07-04|2013-07-08|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Effect of Intensive Multifactorial Therapy on Endothelial Function in Newly Diagnosed Type 2 Diabetes|The Metabolic Memorial Effect of Early Intensive Multifactorial Treatment in Diabetes|Recruiting||Phase 2|1000|Anticipated|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 23:54:44.738253|2018-05-31 23:54:44.738253
NCT01101490|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-04-21|2010-04-09|2010-04-12|Estimate|||||||2011-04-21|2011-04-22|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Changes of Right and Left Cerebral Oxygen Saturation and Blood Flow During Nephrectomy in Lateral Decubitus Position||Completed|||20|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 23:54:44.839216|2018-05-31 23:54:44.839216
NCT01101477|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2011-11-05||2011-11-05|2010-04-08|2010-04-12|Estimate|2011-11-05|2011-12-08|Estimate||||2011-11-05|2011-12-08|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation|Target-Controlled Infusion of Propofol for Flexible Bronchoscopy Sedation: Determining the Optimal Titrating Regimen|Terminated||N/A|144|Actual|Chang Gung Memorial Hospital|Early termination leading to small numbers of subjects analyzed.|3||Hypoxemia(SPaO2<80%) episodes occured significantly in the arm titration by 0.5ug/ml|f||||f||||||||||2018-05-31 23:54:44.934327|2018-05-31 23:54:44.934327
NCT01101464|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2010-06-03||2015-10-30|2010-04-09|2010-04-12|Estimate|2010-09-23|2010-10-13|Estimate||||2015-10-30|2015-11-02|Estimate|October 2002||2002-10-31|October 2015|2015-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)|A Single-center, Open-label, 2-way Crossover Relative Bioavailability and Safety Trial With Two Differing Strength Tablets (3 x 5 mg vs. 1 x 15 mg) of Sublingually Administered Org 5222 in Subjects With Schizophrenia or Schizoaffective Disorder.|Completed||Phase 2|8|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 23:54:45.376875|2018-05-31 23:54:45.376875
NCT01101451|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2017-08-23|2010-04-09|2010-04-12|Estimate|||||||2017-08-23|2017-08-24|Actual|April 12, 2010|Actual|2010-04-12|August 2017|2017-08-31||||December 31, 2020|Anticipated|2020-12-31||Interventional|||Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery|Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy|Recruiting||Phase 3|534|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 23:54:45.937563|2018-05-31 23:54:45.937563
NCT00888992|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2015-04-02|2009-04-27|2009-04-28|Estimate|||||||2015-04-02|2015-04-03|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|January 2013|Actual|2013-01-31||Interventional|TEQ||Technology-Enhanced Quitline Services to Prevent Smoking Relapse|Technology-Enhanced Quitline Services to Prevent Smoking Relapse|Completed||N/A|1785|Actual|Indiana University||3|||f||||f||||||||||2018-06-01 01:02:10.741956|2018-06-01 01:02:10.741956
NCT01101438|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2018-03-27|2010-04-09|2010-04-12|Estimate|||||||2018-03-27|2018-03-29|Actual|June 25, 2010|Actual|2010-06-25|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer|A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer|Active, not recruiting||Phase 3|3649|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 23:54:49.057346|2018-05-31 23:54:49.057346
NCT01101425|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2017-09-07|2010-04-09|2010-04-12|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2010||2010-12-31|September 2017|2017-09-30|March 2027|Anticipated|2027-03-31|February 2027|Anticipated|2027-02-28|10 Years|Observational [Patient Registry]|||Male Breast Cancer: Understanding the Biology for Improved Patient Care|Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.|Active, not recruiting|||200|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||f||||||||||2018-05-31 23:54:51.039829|2018-05-31 23:54:51.039829
NCT01101412|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-02-13|2010-04-09|2010-04-12|Estimate|||||||2013-02-13|2013-02-15|Estimate||||February 2013|2013-02-28||||||||Interventional|||Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies|Multi-Center, Prospective, Randomized, Double-Blinded, Controlled Clinical Trial to Evaluate the Safety and Effectiveness of an Antimicrobial Catheter Lock Solution in Maintaining Catheter Patency and Preventing Catheter Related Blood Stream Infections (CRBSI)|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||2||Study was not opened.|f||||t||||||||||2018-05-31 23:54:51.526809|2018-05-31 23:54:51.526809
NCT01101399|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2013-12-16|2010-04-08|2010-04-09|Estimate|||||||2013-12-16|2013-12-18|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|FID-CHEMO||Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy|Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Lymphoid Malignancies & Functional Iron Deficiency Receiving Chemotherapy|Completed||Phase 3|19|Actual|Vifor Inc.||2|||f||||f||||||||||2018-05-31 23:54:52.033497|2018-05-31 23:54:52.033497
NCT01101386|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-05-20|2010-04-08|2010-04-09|Estimate|||||||2014-05-20|2014-05-22|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Study of Cyclodextrin (SBECD) and Voriconazole Blood Concentrations During Continuous Dialysis|Evaluation of Sulfobutylether-ß-cyclodextrin Sodium (SBECD) Accumulation and Voriconazole Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy|Completed|||10|Actual|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, urine, effluent fluid from dialysis machine~   "|||2018-05-31 23:54:52.518283|2018-05-31 23:54:52.518283
NCT01101373|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|October 2000||2000-10-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Observational|||Treatment of Severe Depressive Illness by Targeted Brain Surgery|Bilateral Anterior Capsulotomy For Intractable Depression|Completed|||||University of British Columbia|||1||f||||f||||||||||2018-05-31 23:54:52.830278|2018-05-31 23:54:52.830278
NCT01101360|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2014-11-30|2010-04-08|2010-04-09|Estimate|||||||2014-11-30|2014-12-02|Estimate|March 2010||2010-03-31|November 2014|2014-11-30||||September 2011|Actual|2011-09-30||Interventional|||Port Wine Stains Treatment Matrix RF Study|Evaluation of Fractional Radiofrequency (Matrix RF) Stand Alone and Combined With PDL Treatment on Port Wine Stains|Completed||N/A|10|Actual|Syneron Medical||1|||f||||f||||||||||2018-05-31 23:54:52.979698|2018-05-31 23:54:52.979698
NCT01101347|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-11-26|2010-04-08|2010-04-09|Estimate|||||||2010-11-26|2010-11-30|Estimate||||November 2010|2010-11-30||||||||Interventional|||A Feasibility Study of the Surpass Aneurysm-Embolization System in Intracranial Arteries|A Feasibility Study of the Surpass Aneurysm-Embolization System in Intracranial Arteries|Withdrawn||Phase 1|10|Anticipated|Surpass Medical Ltd.||1||Product received Approval for Commercial Distribution|f||||t||||||||||2018-05-31 23:54:53.087434|2018-05-31 23:54:53.087434
NCT01101334|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07||2014-05-07|2014-05-07|2010-04-08|2010-04-09|Estimate||||2014-05-07|2014-05-23|Estimate|2014-05-07|2014-05-23|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer|Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy|Completed||Phase 2|90|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 23:54:53.258418|2018-05-31 23:54:53.258418
NCT01101321|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2010-04-14||2015-10-19|2010-04-08|2010-04-09|Estimate|2010-04-14|2010-05-12|Estimate||||2015-10-19|2015-11-18|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities|A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets Manufactured at the Totowa, NJ Facility to Oxycodone Tamper Resistant (OTR) 80-mg Tablets Manufactured at the Wilson, NC Facility|Completed||Phase 1|58|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:54:53.440042|2018-05-31 23:54:53.440042
NCT01101308|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2010-04-14||2010-05-17|2010-04-08|2010-04-09|Estimate|2010-04-14|2010-05-11|Estimate||||2010-05-17|2010-05-25|Estimate|July 2008||2008-07-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities|A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets Manufactured at the Totowa, NJ Facility to Oxycodone Tamper Resistant (OTR) 10-mg Tablets Manufactured at the Wilson, NC Facility|Completed||Phase 1|55|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:54:54.419205|2018-05-31 23:54:54.419205
NCT01101295|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2012-03-20|2010-04-08|2010-04-09|Estimate|||||||2012-03-20|2012-03-21|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|April 2017|Anticipated|2017-04-30|April 2012|Anticipated|2012-04-30||Observational|ITP-RITUX||The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.|The ITP-RITUX Cohort: An Observational Study on Rituximab Off-label Use for Immune ThrombocytoPenia.|Unknown status|Recruiting||250|Anticipated|Henri Mondor University Hospital|||||f||||t||||||||||2018-05-31 23:54:54.879299|2018-05-31 23:54:54.879299
NCT01101282|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2013-02-13|2010-04-08|2010-04-09|Estimate|||||||2013-02-13|2013-02-15|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Does Positive Expiratory Pressure Mask Therapy Improve Recovery From Acute Exacerbations of Chronic Obstructive Pulmonary Disease?|Does the Addition of Positive Expiratory Pressure (PEP) Mask Therapy to Usual Medical Care Improve Patients' Symptoms, Quality or Life and Risk of Future Exacerbations in Individuals With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)?|Completed||N/A|92|Actual|La Trobe University||2|||f||||f||||||||||2018-05-31 23:54:55.01226|2018-05-31 23:54:55.01226
NCT01101269|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2017-05-10|2010-04-08|2010-04-09|Estimate|||||||2017-05-10|2017-05-12|Actual|February 2010||2010-02-28|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease|Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease (KXK005).|Terminated||N/A|6|Actual|University of Virginia||2||Slow Recruitment|f||||f||||||||||2018-05-31 23:54:55.13366|2018-05-31 23:54:55.13366
NCT01101256|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-04-12|2010-04-08|2010-04-09|Estimate|||||||2010-04-12|2010-04-13|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|October 2010|Anticipated|2010-10-31|September 2010|Anticipated|2010-09-30||Observational|||Determination of Residual Anticoagulatory Effects of Fondaparinux|Determination of Residual Anticoagulatory Effects of Prophylactic or Therapeutic Treatment With Fondaparinux|Unknown status|Recruiting||110|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     Citrated blood~   "|||2018-05-31 23:54:55.225398|2018-05-31 23:54:55.225398
NCT01101243|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|October 2008||2008-10-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|March 2009|Actual|2009-03-31||Interventional|||Maintenance of Vitamin D Level by UVB Radiation|How Much UVB Radiation is Necessary to Maintain Summer Vitamin D Level During Winter?|Completed||N/A|75|Actual|Bispebjerg Hospital||5|||f||||f||||||||||2018-05-31 23:54:55.300163|2018-05-31 23:54:55.300163
NCT01101230|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2013-11-14|2010-04-08|2010-04-09|Estimate|||||||2013-11-14|2013-11-18|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|ALD||Effects of Almonds on Cardiovascular Risk Factors|Effects of a Diet Rich in Almonds on LDL Cholesterol, LDL Particle Size, Abdominal Adiposity and Vascular Health|Completed||N/A|61|Actual|Penn State University||2|||f||||f||||||||||2018-05-31 23:54:55.394444|2018-05-31 23:54:55.394444
NCT01101217|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|September 2009|Actual|2009-09-30|||||Interventional|||Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients||Completed||N/A|100|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:54:55.52174|2018-05-31 23:54:55.52174
NCT01101204|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2012-07-05|2010-04-08|2010-04-09|Estimate|||||||2012-07-05|2012-07-09|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|MSF||The Effects of Hypolipemic and Antidiabetic Treatment on Cytokines|Effects of High and Low Doses of Metformin, Fenofibrate and Simvastatin, Administered Together and in Sequence With Lifestyle Intervention on Lipid Profile, Glucose Metabolism, Low-grade Inflammation and Hemostasis in Patient's Blood Plasma in Type 2 Diabetic Patients With Serious Mixed Dyslipidemia|Unknown status|Not yet recruiting|N/A|200|Anticipated|Medical University of Silesia||9|||f||||f||||||||||2018-05-31 23:54:55.725334|2018-05-31 23:54:55.725334
NCT01101191|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2010-04-14||2010-05-17|2010-04-08|2010-04-09|Estimate|2010-04-14|2010-05-11|Estimate||||2010-05-17|2010-05-25|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets to OxyContin® 80-mg Tablets|Completed||Phase 1|84|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:54:55.866248|2018-05-31 23:54:55.866248
NCT01101178|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2010-04-14||2011-10-07|2010-04-08|2010-04-09|Estimate|2010-04-14|2010-05-10|Estimate||||2011-10-07|2011-10-10|Estimate|August 2007||2007-08-31|October 2011|2011-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 80-mg Tablets to OxyContin® 80-mg Tablets|Completed||Phase 1|79|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:54:56.241274|2018-05-31 23:54:56.241274
NCT01101165|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2010-04-13||2010-05-06|2010-04-08|2010-04-09|Estimate|2010-04-13|2010-05-06|Estimate||||2010-05-06|2010-05-11|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|July 2007|Actual|2007-07-31|April 2007|Actual|2007-04-30||Interventional|||To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 40-mg Tablets to OxyContin® 40-mg Tablets|Completed||Phase 1|92|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:54:56.579719|2018-05-31 23:54:56.579719
NCT01101152|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-08-04|2010-04-08|2010-04-09|Estimate|||||||2011-08-04|2011-08-08|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|DVS||Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers|Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Females and Males|Unknown status|Recruiting|Phase 1|20|Anticipated|University of Ottawa||2|||f||||f||||||||||2018-05-31 23:54:56.980274|2018-05-31 23:54:56.980274
NCT01101139|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2012-12-14|2010-04-08|2010-04-09|Estimate|||||||2012-12-14|2012-12-17|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery|Small Dose of Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery (TOF 0.9)|Completed||Phase 4|300|Actual|Technische Universität München||2|||f||||||||||||||2018-05-31 23:54:57.14861|2018-05-31 23:54:57.14861
NCT01101126|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-01-20|2010-04-08|2010-04-09|Estimate|||||||2015-01-20|2015-01-21|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|ACDM-Maccabi||Disease Management in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Patients|Disease Management Program for Chronic Obstructive Pulmonary Diseases in Maccabi Health Services|Terminated||N/A|492|Actual|Sheba Medical Center||2||An excess of all-cause acute health services utilization in the intervention arm|f||||t||||||||||2018-05-31 23:54:57.274822|2018-05-31 23:54:57.274822
NCT01101113|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-04|||2012-06-06|2010-04-08|2010-04-09|Estimate|||||||2012-06-06|2012-06-08|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|CUPID||Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level|Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients|Completed||Phase 4|66|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 23:54:57.404341|2018-05-31 23:54:57.404341
NCT01101100|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2015-10-20|2010-04-08|2010-04-09|Estimate|||||||2015-10-20|2015-10-22|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis|A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Psoriasis|Terminated||Phase 2|181|Actual|Amgen||1||Sponsor Decision|f||||f||||||||||2018-05-31 23:54:57.509812|2018-05-31 23:54:57.509812
NCT01101087|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-12-17|2010-04-08|2010-04-09|Estimate|||||||2015-12-17|2015-12-18|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Taurolock for Preventing Bacterial Peritonitis During Renal Insufficiency|Efficacity of Taurolock in Preventing Primary Bacterial Peritonitis in Patients Undergoing Peritoneal Dialysis for Renal Insufficiency: a Randomized, Multicenter, Double Blind Study With Placebo|Completed||N/A|150|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||t||||||||||2018-05-31 23:54:57.633068|2018-05-31 23:54:57.633068
NCT01101074|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2011-10-07|2010-04-08|2010-04-09|Estimate|||||||2011-10-07|2011-10-12|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|January 2010|Actual|2010-01-31||Observational|||Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine|A Prospective Observational Study of Safety and Effectiveness Following Administration of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine|Completed|||135469|Actual|Novartis|||6||f||||||||||||||2018-05-31 23:54:57.744395|2018-05-31 23:54:57.744395
NCT01101061|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-03-31|2010-04-08|2010-04-09|Estimate|||||||2011-03-31|2011-04-01|Estimate|May 2010||2010-05-31|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Single-dose Study Evaluating AMG 785 in Healthy Postmenopausal Japanese Women|A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Postmenopausal Japanese Women|Completed||Phase 1|31|Actual|Amgen||2|||f||||||||||||||2018-05-31 23:54:57.813733|2018-05-31 23:54:57.813733
NCT01101048|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2012-10-15|2010-04-08|2010-04-09|Estimate|||||||2012-10-15|2012-10-17|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 1|74|Actual|Amgen||2|||f||||f||||||||||2018-05-31 23:54:57.875076|2018-05-31 23:54:57.875076
NCT01101035|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2017-08-10|2010-04-07|2010-04-09|Estimate|||||||2017-08-10|2017-08-11|Actual|April 30, 2010|Actual|2010-04-30|August 2017|2017-08-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|CARES||Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities|A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities|Completed||Phase 3|6198|Actual|Takeda||2|||f||||t||||||||||2018-05-31 23:54:57.966684|2018-05-31 23:54:57.966684
NCT01101022|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2011-09-06||2014-01-07|2010-04-07|2010-04-09|Estimate|2012-01-09|2012-02-13|Estimate||||2014-01-07|2014-02-06|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-controlled, Parallel Group Study Evaluating the Safety and Efficacy of SPD489 on Executive Function (Self-Regulation) Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Reporting Clinically Significant Impairment of Real-World Executive Function Behavior.|Completed||Phase 4|161|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:54:58.493878|2018-05-31 23:54:58.493878
NCT01101009|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2013-01-14|2010-04-07|2010-04-09|Estimate|||||||2013-01-14|2013-01-15|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure|Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-|Completed||Phase 4|486|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 23:54:59.518686|2018-05-31 23:54:59.518686
NCT01100996|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-06-06|2010-04-08|2010-04-09|Estimate|||||||2011-06-06|2011-06-07|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|VIHE||Anti-inflammatory Effects of Enriched Enteral Nutrition During Human Experimental Endotoxemia|The Effect of Enriched Enteral Nutrition on Inflammation and Sub-clinical Organ Dysfunction During Human Endotoxemia|Completed||N/A|36|Anticipated|Radboud University||3|||f||||t||||||||||2018-05-31 23:54:59.625226|2018-05-31 23:54:59.625226
NCT01100983|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-04-19|2010-04-08|2010-04-09|Estimate|||||||2015-04-19|2015-04-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:54:59.704197|2018-05-31 23:54:59.704197
NCT01100970|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2011-01-30|2010-04-08|2010-04-09|Estimate|||||||2011-01-30|2011-02-01|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Cortisol Levels in Infants Born by C-section - Electric Unipolar Needle Versus Electric Bipolar Needle|Cortisol Levels in Infants Born by C-section - A Comparison of Using an Electric Unipolar Needle and Electric Bipolar Needle|Unknown status|Active, not recruiting||90|Anticipated|Hadassah Medical Organization|||3||f||||f||||||Samples Without DNA|"~     Bouth umbilical Blood samples and saliva samples will be kept in a -20C freezer utill~     assayed.~   "|||2018-05-31 23:54:59.74858|2018-05-31 23:54:59.74858
NCT01100957|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2011-08-23|2010-04-07|2010-04-09|Estimate|||||||2011-08-23|2011-08-24|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of the Single Use Flexible Optical Scope Versus Multiple Use Flexible Optical Scopes for Intubation|Evaluation and Comparison of the New Single Use Ambu aScope With Olympus BF 160 Multiple Use Scope for Securing the Airway of the Anaesthetised/Awake Patients' Normal or Difficult Airway|Completed||N/A|60|Anticipated|Rigshospitalet, Denmark||2|||f||||||||||||||2018-05-31 23:55:00.080084|2018-05-31 23:55:00.080084
NCT01100762|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2011-12-19||2012-06-13|2010-04-08|2010-04-09|Estimate|2012-04-10|2012-05-07|Estimate||||2012-06-13|2012-06-15|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) and Parkinson's Disease|Can Transcranial Direct Current Stimulation (tDCS)Modulate Protective Stepping and Gait Performance of People With Parkinson's Disease|Completed||Phase 1/Phase 2|10|Actual|University of Maryland|"The absence of a placebo CES~Limiting the stimulation to only one region of interest (Right M1)~Non-random order of intervention~CES for only one 20 minute session"|1|||f||||t||||||||||2018-05-31 23:55:04.282309|2018-05-31 23:55:04.282309
NCT01100944|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2016-07-26||2017-07-11|2010-04-08|2010-04-09|Estimate|2016-11-14|2016-11-15|Estimate||||2017-07-11|2017-08-10|Actual|March 4, 2010|Actual|2010-03-04|July 2017|2017-07-31|October 21, 2015|Actual|2015-10-21|October 21, 2015|Actual|2015-10-21||Interventional||Per protocol, two group results, as well as single arm results are reported throughout the results data.|A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies|A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic Malignancies|Terminated||Phase 1/Phase 2|26|Actual|National Institutes of Health Clinical Center (CC)||1||Principal investigator left the National Institutes of Health (NIH).|f||||f|t|f||||||No||2018-05-31 23:55:00.328286|2018-05-31 23:55:00.328286
NCT01100931|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|2013-02-21||2015-09-29|2010-04-08|2010-04-09|Estimate|2013-02-21|2013-04-04|Estimate||||2015-09-29|2015-10-19|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)|A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)|Completed||Phase 1/Phase 2|42|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 23:55:01.448292|2018-05-31 23:55:01.448292
NCT01100918|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2014-08-12|2010-04-08|2010-04-09|Estimate|||||||2014-08-12|2014-08-13|Estimate|February 2007||2007-02-28|August 2014|2014-08-31|December 2010|Actual|2010-12-31|||||Interventional|TIBI-HF||Utility of Tissue Doppler Echocardiography for Selecting Patients for Cardiac Resynchronisation Therapy|Utility of Tissue Doppler Echocardiography for Selecting Patients for Cardiac Resynchronisation Therapy in Heart Failure|Completed||Phase 4|80|Actual|Barts & The London NHS Trust||3|||f||||f||||||||||2018-05-31 23:55:02.403547|2018-05-31 23:55:02.403547
NCT01100905|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-04-23|2010-04-08|2010-04-09|Estimate|||||||2010-04-23|2010-04-26|Estimate||||April 2010|2010-04-30||||||||Interventional|||An Iron-containing Food Product for the Prevention of Diminished Iron Status in Soldiers|Utility of an Iron-containing Food Product for the Prevention of Diminished Iron Status During Basic Combat Training|Completed||N/A|||United States Army Research Institute of Environmental Medicine|||||f||||f||||||||||2018-05-31 23:55:02.4877|2018-05-31 23:55:02.4877
NCT01100892|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-10-03|2010-04-08|2010-04-09|Estimate|||||||2017-10-03|2017-10-04|Actual|December 2010||2010-12-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|CF-IDEA||Cystic Fibrosis - Insulin Deficiency, Early Action|Cystic Fibrosis - Insulin Deficiency, Early Action|Recruiting||Phase 3|100|Anticipated|Sydney Children's Hospitals Network||2|||f||||t||||||||No||2018-05-31 23:55:02.576078|2018-05-31 23:55:02.576078
NCT01100879|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2011-10-11|2010-04-08|2010-04-09|Estimate|||||||2011-10-11|2011-10-12|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|AOC-MM||Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy|Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy|Terminated||Phase 4|40|Anticipated|Vifor Inc.||2||Lack of Recruitment|f||||f||||||||||2018-05-31 23:55:02.744246|2018-05-31 23:55:02.744246
NCT01100866|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2014-03-10|2010-04-08|2010-04-09|Estimate|||||||2014-03-10|2014-03-11|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of POMELLA™ Extract to Treat Prostate Cancer|Randomized Controlled Trial of POMELLA™ Extract in Prostate Cancer Patients Scheduled for Surgery|Terminated||N/A|1|Actual|Vancouver Coastal Health||2||due to slow enrollment|f||||f||||||||||2018-05-31 23:55:02.901638|2018-05-31 23:55:02.901638
NCT01100853|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2013-07-09||2018-03-02|2010-04-07|2010-04-09|Estimate|2013-11-25|2014-01-13|Estimate||||2018-03-02|2018-03-06|Actual|May 2010||2010-05-31|March 2018|2018-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland|Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland|Completed||Phase 3|100|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 23:55:03.018404|2018-05-31 23:55:03.018404
NCT01100840|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-12-10|2010-04-07|2010-04-09|Estimate|||||||2013-12-10|2013-12-11|Estimate|April 2009||2009-04-30|December 2013|2013-12-31||||April 2014|Anticipated|2014-04-30||Observational|||A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer|A Retrospective Study of Biomarkers in Non-small Cell Lung Cancer|Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 23:55:03.615009|2018-05-31 23:55:03.615009
NCT01100827|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2013-12-10|2010-04-08|2010-04-09|Estimate|||||||2013-12-10|2013-12-11|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status||Unknown status|Recruiting||||National University Hospital, Singapore|||1||f||||||||||||||2018-05-31 23:55:03.691059|2018-05-31 23:55:03.691059
NCT01100814|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2014-01-21|2010-04-07|2010-04-09|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer|Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer|Unknown status|Active, not recruiting||||National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 23:55:03.779343|2018-05-31 23:55:03.779343
NCT01100801|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2016-06-21|2010-04-08|2010-04-09|Estimate|||||||2016-06-21|2016-06-22|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|3G||A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients|A Phase II Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients|Recruiting||Phase 2|90|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 23:55:03.865751|2018-05-31 23:55:03.865751
NCT01100788|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|March 2009||2009-03-31|April 2010|2010-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Satiety Response of Short Chain Fructooligosaccharide|Satiety Response of Short Chain Fructooligosaccharide|Completed||Early Phase 1|20|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 23:55:04.007103|2018-05-31 23:55:04.007103
NCT01100775|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2018-02-15|2010-04-07|2010-04-09|Estimate|||||||2018-02-15|2018-02-19|Actual|May 2010||2010-05-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Galantamine on Cognition|Effects of Galantamine on Cognition|Active, not recruiting||Phase 2|24|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 23:55:04.14357|2018-05-31 23:55:04.14357
NCT01100749|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2015-05-27|2010-04-07|2010-04-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada|Demography, Clinical Characteristics, Metabolic Status, Viral Subtype and Genetics of Infection With Hepatitis C Genotype 3 in Canada|Terminated|||25|Actual|University Health Network, Toronto||||Low recruitment|f||||f||||||Samples With DNA|"~     Saliva samples will be collected for DNA extraction. Also, blood specimens will be collected~     for genotype subtype analysis and HOMA score calculation.~   "|||2018-05-31 23:55:04.69592|2018-05-31 23:55:04.69592
NCT01100736|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-07-20|2010-04-08|2010-04-09|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)|Characterisation of the Role of ETA and ETB Receptors in Regulating Plasma ET-1 and the Vasodilator Response to ET-3 in Man|Completed||Early Phase 1|10|Anticipated|University of Edinburgh||3|||f||||t||||||||||2018-05-31 23:55:04.772837|2018-05-31 23:55:04.772837
NCT01100723|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2013-01-23||2016-11-04|2010-04-08|2010-04-09|Estimate|2016-11-04|2017-01-02|Estimate||||2016-11-04|2017-01-02|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Trial to Optimize Mineral Outcomes in Dialysis Patients|Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients|Completed||Phase 4|92|Actual|University of Colorado, Denver|No adverse events reported. Dose titration limited by hypocalcemia and subject non-adherent to oral medications.|1|||f||||f||||||||No||2018-05-31 23:55:04.885307|2018-05-31 23:55:04.885307
NCT01100710|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|March 2007||2007-03-31|February 2007|2007-02-28|December 2009|Actual|2009-12-31|March 2007|Actual|2007-03-31||Observational|||Age Gender Left Ventricular Mass and Cardiac Troponin T|Relative Contribution of Age, Gender and Left Ventricular Mass as Quantified by Cardiac Magnetic Resonance Tomography to Detectable Levels of Cardiac Troponin T in a Healthy Reference Population Aged Below 70 Years|Completed|||116|Actual|Heidelberg University|||1||f||||f||||||||||2018-05-31 23:55:05.207964|2018-05-31 23:55:05.207964
NCT01100697|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2018-05-02|2010-04-08|2010-04-09|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2009||2009-12-31|May 2018|2018-05-31|October 1, 2015|Actual|2015-10-01|October 2014|Actual|2014-10-31||Observational|||Outcome of Fetal Spina Bifida|Fetal Spina Bifida -Prenatal Course and Outcome in 103 Cases A Single Center Experience.|Completed|||103|Actual|University of Luebeck|||3||f||||f||||||||||2018-05-31 23:55:05.308333|2018-05-31 23:55:05.308333
NCT01100684|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2013-12-17|2010-04-08|2010-04-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)|A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of Asimadoline in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)|Completed||Phase 3|611|Actual|Tioga Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:55:05.464244|2018-05-31 23:55:05.464244
NCT01100671|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2018-03-12|2010-04-08|2010-04-09|Estimate|||||||2018-03-12|2018-03-14|Actual|April 2010||2010-04-30|March 2018|2018-03-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|||Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation|Comparison of 18F-fluorodeoxyglucose Positron Emission Tomography and Coronary Computed Tomography in Assessing Vascular Inflammation in Healthy Population|Completed|||120|Actual|Korea University|||1||f||||t||||||Samples Without DNA|"~     plasam and serum~   "|||2018-05-31 23:55:05.894606|2018-05-31 23:55:05.894606
NCT01100658|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2011-07-28||2015-03-16|2010-04-07|2010-04-09|Estimate|2011-10-11|2011-11-22|Estimate||||2015-03-16|2015-03-27|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors|Effects of Methylphenidate on Neuropsychological Functioning in Children With Attention Deficits Secondary to Childhood Cancer|Terminated||N/A|1|Actual|University of Minnesota - Clinical and Translational Science Institute|Only 1 patient was enrolled in this study, no analysis/outcome data can be reported. This patient completed baseline assessment, but withdrew from the study before beginning the medication trial. No medications/placebo were administered.|2||Due to slow accrual|f||||t||||||||||2018-05-31 23:55:06.003182|2018-05-31 23:55:06.003182
NCT01100645|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-10-26|2010-04-08|2010-04-09|Estimate|||||||2010-10-26|2010-10-28|Estimate|October 2010||2010-10-31|April 2010|2010-04-30|February 2011|Anticipated|2011-02-28|January 2011|Anticipated|2011-01-31||Interventional|||Efficacy and Safety of the Herbal Medicine Sominex ® (Passiflora Incarnata L., Valeriana Officinalis L. and Crataegus Oxyacantha L.), Manufactured by the Laboratory EMS S / A in Patients With Psychophysiological Insomnia||Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 23:55:06.248044|2018-05-31 23:55:06.248044
NCT01100632|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-10-26|2010-04-08|2010-04-09|Estimate|||||||2010-10-26|2010-10-27|Estimate|September 2010||2010-09-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Effectiveness Evaluation of Panax Ginseng, Vitamins and Minerals in Improvement of Stress and Fatigue||Suspended||Phase 3|300|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 23:55:06.378667|2018-05-31 23:55:06.378667
NCT01100619|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2013-09-17|2010-04-07|2010-04-09|Estimate|||||||2013-09-17|2013-09-19|Estimate|April 2010||2010-04-30|September 2013|2013-09-30||||August 2012|Actual|2012-08-31||Interventional|||A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors|A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors|Completed||Phase 1|40|Actual|Exelixis||1|||f||||f||||||||||2018-05-31 23:55:06.470971|2018-05-31 23:55:06.470971
NCT01100606|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|2014-03-05||2014-03-05|2010-04-07|2010-04-09|Estimate|2014-03-05|2014-04-10|Estimate||||2014-03-05|2014-04-10|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Safety analysis population included all participants who received at least 1 dose of study medication.|A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age|A Multicenter, Randomized, Open-Label, Crossover Study to Evaluate the Mode of Administration and Safety of EUR-1008 in Infants 1 to 12 Months of Age With Exocrine Pancreatic Insufficiency (EPI) Associated With Cystic Fibrosis (CF)|Completed||Phase 4|15|Actual|Forest Laboratories||2|||f||||t||||||||||2018-05-31 23:55:06.627711|2018-05-31 23:55:06.627711
NCT01100593|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2012-11-01|2010-04-07|2010-04-09|Estimate|||||||2012-11-01|2012-11-02|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Ultrasound IV Study|Optimal Catheter Length for Ultrasound-Guided Peripheral Vascular Access|Completed||N/A|22|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-05-31 23:55:07.313874|2018-05-31 23:55:07.313874
NCT01100580|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|May 2012|Anticipated|2012-05-31|May 2011|Anticipated|2011-05-31||Interventional|||The Links Between Water and Salt Intake, Body Weight, Hypertension and Kidney Stones: a Difficult Puzzle|The Links Between Water and Salt Intake, Body Weight, Hypertension and Kidney Stones: a Difficult Puzzle|Unknown status|Not yet recruiting|N/A|350|Anticipated|University of Parma||2|||f||||t||||||||||2018-05-31 23:55:07.407166|2018-05-31 23:55:07.407166
NCT01100567|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2016-11-29||2017-04-07|2010-04-08|2010-04-09|Estimate|2017-04-07|2017-05-17|Actual||||2017-04-07|2017-05-17|Actual|April 2009||2009-04-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia Nervosa|EFFECT OF BIOMECHANICAL STIMULATION ON SKELETAL HEALTH IN ADOLESCENT AND YOUNG WOMEN WITH ANOREXIA NERVOSA|Completed||N/A|101|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 23:55:07.585725|2018-05-31 23:55:07.585725
NCT01100554|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-04-11|2010-04-08|2010-04-09|Estimate|||||||2010-04-11|2010-04-13|Estimate|October 2009||2009-10-31|April 2010|2010-04-30||||June 2010|Anticipated|2010-06-30||Interventional|||Upper Airway Collapsibility Evaluation in Different Sedative Levels by Sleep Endoscopy|Upper Airway Collapsibility Evaluation in Different Sedative Levels by Sleep Endoscopy|Unknown status|Recruiting|N/A|120|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 23:55:08.280908|2018-05-31 23:55:08.280908
NCT01100541|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Evaluation of a Polymeric Plate Derived From Castor Oil to Thermotherapy|Evaluation of a Polymeric Plate Derived From Castor Oil to Thermotherapy|Completed||N/A|30|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:55:08.487638|2018-05-31 23:55:08.487638
NCT01100528|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2017-04-24|2010-04-07|2010-04-09|Estimate|||||||2017-04-24|2017-04-25|Actual|November 11, 2009|Actual|2009-11-11|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|July 25, 2015|Actual|2015-07-25||Interventional|||Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance|Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance|Active, not recruiting||Phase 2|38|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 23:55:08.880031|2018-05-31 23:55:08.880031
NCT01100515|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|October 1989||1989-10-31|April 2010|2010-04-30|February 2000|Actual|2000-02-29|January 2000|Actual|2000-01-31||Interventional|||Hyperbaric Oxygen Therapy for Acute Domestic Carbon Monoxide (CO) Poisoning|Phase 3 Study of Hyperbaric Oxygen Therapy in Non-Comatose Patients With Acute Domestic Carbon Monoxide Poisoning|Terminated||Phase 3|179|Actual|University of Versailles||2||this study was suspended for futility|f||||f||||||||||2018-05-31 23:55:09.016598|2018-05-31 23:55:09.016598
NCT01100502|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2015-07-31||2018-03-13|2010-04-08|2010-04-09|Estimate|2015-10-07|2015-11-11|Estimate||||2018-03-13|2018-03-15|Actual|April 2010||2010-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|August 2014|Actual|2014-08-31||Interventional||Intention-to-Treat analysis set|A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant|Active, not recruiting||Phase 3|329|Actual|Seattle Genetics, Inc.|Patients are currently being followed for survival; final overall survival data are not available and will be reported upon study closure.|2|||t||||t||||||||||2018-05-31 23:55:09.31408|2018-05-31 23:55:09.31408
NCT01100489|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-12-07|2010-04-07|2010-04-09|Estimate|||||||2011-12-07|2011-12-08|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer|A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center||1||No accrual|f||||t||||||||||2018-05-31 23:55:10.610255|2018-05-31 23:55:10.610255
NCT01100476|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2013-02-12|2010-04-08|2010-04-09|Estimate|||||||2013-02-12|2013-02-15|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Mynx||Mynx M5 One Hour Ambulation Study|Single-center, Post Market, Prospective, Consecutive, Single-arm Study Compared to Historical Control (Diagnostic Arm of the Mynx 6/7F Study)|Completed||Phase 4|200|Actual|Cardiovascular Associates of the Delaware Valley|||||f||||t||||||||||2018-05-31 23:55:10.738918|2018-05-31 23:55:10.738918
NCT01100463|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-08|2010-04-08|2010-04-09|Estimate|||||||2010-04-08|2010-04-09|Estimate|December 2009||2009-12-31|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome|A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Cahaba Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:55:10.903353|2018-05-31 23:55:10.903353
NCT01100450|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2017-03-22|2010-04-07|2010-04-09|Estimate|||||||2017-03-22|2017-03-24|Actual|September 2009||2009-09-30|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Progressive Resistance Training in Patients With Class III Obesity|Pilot Study to Determine Feasibility, Acceptance, and Efficacy of a 12-week Progressive Resistance Training Exercise Protocol in Patients With Class III Obesity Preparing for Bariatric Surgery.|Completed||N/A|6|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-05-31 23:55:12.195522|2018-05-31 23:55:12.195522
NCT01100437|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2012-02-27||2012-07-05|2010-04-07|2010-04-09|Estimate|2012-02-27|2012-03-28|Estimate||||2012-07-05|2012-07-13|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients|A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA¿|Terminated||Phase 4|14|Actual|Pfizer|Sponsor terminated study early on 10-Mar-2011.|2||See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:55:12.353509|2018-05-31 23:55:12.353509
NCT01100424|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2012-10-19|2010-04-08|2010-04-09|Estimate|||||||2012-10-19|2012-10-23|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Assessment of Tear Film-Based Proteins Associated With Care Solution Induced Corneal Staining|Assessment of Tear Film-Based Proteins Associated With Care Solution Induced Corneal Staining|Completed||N/A|60|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 23:55:13.344481|2018-05-31 23:55:13.344481
NCT01100411|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2012-07-17|2010-04-07|2010-04-09|Estimate|||||||2012-07-17|2012-07-18|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Changes in Invitro and ex Vivo Lens Metrology With Daily Wear Contact Lenses|Changes in Invitro and ex Vivo Lens Metrology With Experienced Daily Wear Contact Lens Wearers|Completed||N/A|35|Actual|Alcon Research||6|||f||||f||||||||||2018-05-31 23:55:13.448839|2018-05-31 23:55:13.448839
NCT01100398|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2010-12-23|2010-04-08|2010-04-09|Estimate|||||||2010-12-23|2010-12-24|Estimate|January 2007||2007-01-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy|Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Utilizing Ultrasound and Percutaneous Liver Biopsy: A Prospective Cohort Study|Completed|||400|Actual|Brooke Army Medical Center|||1||f||||t||||||Samples Without DNA|"~     liver biopsies and serum blood samples may be obtained~   "|||2018-05-31 23:55:13.573142|2018-05-31 23:55:13.573142
NCT01100385|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-08|||2015-06-23|2010-04-08|2010-04-09|Estimate|||||||2015-06-23|2015-06-25|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|TomVasc||TomVasc - Vascular Effects of Tomato Extract|Vascular Effects of Nutritional Supplementation With a Standardised Preparation of Tomato Extract (Ateronon) in Vivo in Man|Completed||N/A|72|Actual|Cambridge University Hospitals NHS Foundation Trust||4|||f||||f||||||||||2018-05-31 23:55:13.699823|2018-05-31 23:55:13.699823
NCT01100372|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2013-08-23|2010-04-07|2010-04-08|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2009||2009-07-31|April 2010|2010-04-30||||May 2014|Anticipated|2014-05-31||Interventional|||Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|Randomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the Peritoneum|Unknown status|Recruiting|Phase 2|154|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:55:13.80376|2018-05-31 23:55:13.80376
NCT01100359|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2013-08-06|2010-04-07|2010-04-08|Estimate|||||||2013-08-06|2013-08-07|Estimate|November 2007||2007-11-30|February 2011|2011-02-28||||October 2010|Anticipated|2010-10-31||Interventional|||Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer|Phase II Multicenter Trial of the Austrian AGO With the Combination of Liposomal Doxorubicin (Myocet®) and Carboplatin in Primary Advanced or Metastatic and Recurrent Endometrial Cancer|Unknown status|Recruiting|Phase 2|39|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:55:13.934534|2018-05-31 23:55:13.934534
NCT01100346|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2014-03-17|2010-04-07|2010-04-08|Estimate|||||||2014-03-17|2014-03-18|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen|A Prospective, Single Center, Observational Study on the Predictive Factors of Ovarian Response in Ovulation Induction (OI) With Intrauterine Insemination (IUI) of a Gonal-f Low-dose Step-up Regimen|Terminated|||30|Actual|Merck KGaA|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:55:14.045617|2018-05-31 23:55:14.045617
NCT01100333|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-07-30|2010-04-07|2010-04-08|Estimate|||||||2014-07-30|2014-07-31|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)|Observational Study GONAL-f® Consort|Completed|||2552|Actual|Merck KGaA|||||f||||||||||Samples Without DNA|"~     Whole Blood~   "|||2018-05-31 23:55:14.126983|2018-05-31 23:55:14.126983
NCT01100320|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2010-04-13||2010-05-06|2010-04-07|2010-04-08|Estimate|2010-04-13|2010-05-06|Estimate||||2010-05-06|2010-05-11|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|July 2007|Actual|2007-07-31|March 2007|Actual|2007-03-31||Interventional|||A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 40-mg Tablets to OxyContin® 40-mg Tablets|Completed||Phase 1|88|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:55:14.209599|2018-05-31 23:55:14.209599
NCT01100307|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|2013-05-15||2013-08-16|2010-04-07|2010-04-08|Estimate|2013-05-15|2013-07-15|Estimate||||2013-08-16|2013-08-23|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema|A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium, With Sham Injections, And Open Study (For 30 Weeks) To Confirm The Safety Of 0.3 MG Pegaptanib Sodium In Subjects With Diabetic Macular Edema (DME)|Completed||Phase 3|243|Actual|Pfizer|During the study, an issue was reported concerning proper maintenance of treatment masking. Due to this masking process issue, the study results cannot be interpreted as that arising from a well-controlled double-masked trial.|2|||f||||f||||||||||2018-05-31 23:55:14.559633|2018-05-31 23:55:14.559633
NCT01100294|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-05-18|2010-04-07|2010-04-08|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children|Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children|Completed||N/A|10|Actual|Fluart Innovative Vaccine Ltd, Hungary||1|||f||||t||||||||||2018-05-31 23:55:15.922034|2018-05-31 23:55:15.922034
NCT01100281|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-12-08|2010-04-07|2010-04-08|Estimate|||||||2011-12-08|2011-12-09|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|April 2011|Actual|2011-04-30|||||Observational|||Prefrontal Cortex and Abstract Thinking|Neuropsychological and Anatomical Study of Concept Formation in Frontal Patients|Completed|||69|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||f||||||||||2018-05-31 23:55:16.028567|2018-05-31 23:55:16.028567
NCT01100268|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|2013-06-04||2014-09-10|2010-04-07|2010-04-08|Estimate|2013-06-04|2013-08-15|Estimate||||2014-09-10|2014-09-18|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Individuals with Hoarding Disorder|Enhancing Attention in Adults With Compulsive Hoarding|Enhancing Attention in Adults With Compulsive Hoarding: A Pilot Study|Completed||Phase 2|4|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 23:55:16.104849|2018-05-31 23:55:16.104849
NCT01100255|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|2016-05-19||2017-01-03|2010-04-07|2010-04-08|Estimate|2016-09-06|2016-10-27|Estimate||||2017-01-03|2017-02-20|Actual|April 2010||2010-04-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||This was a cross over trial.|Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)|Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine|Completed||Phase 2|15|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 23:55:16.357839|2018-05-31 23:55:16.357839
NCT01100242|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2015-06-15||2015-08-14|2010-04-07|2010-04-08|Estimate|2015-08-14|2015-09-17|Estimate||||2015-08-14|2015-09-17|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Interventional|||Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma|Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma|Terminated||Phase 2|17|Actual|New Mexico Cancer Care Alliance||1||Low accrual|f||||t||||||||||2018-05-31 23:55:16.799109|2018-05-31 23:55:16.799109
NCT01100216|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-12-09|2010-04-07|2010-04-08|Estimate|||||||2014-12-09|2014-12-10|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Human Laboratory Study of Smokeless Tobacco Products|Human Laboratory Study of Smokeless Tobacco Products|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||4||Funding expired prior to implementing subject recruitment.|f||||f||||||||||2018-05-31 23:55:17.168561|2018-05-31 23:55:17.168561
NCT01100203|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2012-02-07|2010-04-07|2010-04-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|ALBLOCK-2||Aldosterone Blockade in Chronic Kidney Disease: Influence on Arterial Stiffness and Kidney Function|Aldosterone Blockade in Chronic Kidney Disease. Influence on Arterial Stiffness and Kidney Function|Terminated||Phase 3|54|Actual|Herlev Hospital||2||It was not possible within the time frame to recruit the planned no. of patients.|f||||t||||||||||2018-05-31 23:55:17.344439|2018-05-31 23:55:17.344439
NCT01100190|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2017-08-10|2010-04-07|2010-04-08|Estimate|||||||2017-08-10|2017-08-11|Actual|March 1, 2010|Actual|2010-03-01|August 2017|2017-08-31|March 1, 2014|Actual|2014-03-01|April 1, 2011|Actual|2011-04-01||Interventional|||A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures|A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures|Terminated||N/A|100|Anticipated|Ethicon, Inc.||1||Change in business priorities.|f||||f|f|f||||||No|Not an applicable trial, product manufactured outside of US and all study sites outside US.|2018-05-31 23:55:17.601286|2018-05-31 23:55:17.601286
NCT01100177|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2013-03-08|2010-04-07|2010-04-08|Estimate|||||||2013-03-08|2013-03-11|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients|An Open Label Non- Randomized Multicentric Phase II Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients|Completed||Phase 2|12|Actual|Grupo Español de Investigación en Neurooncología||1|||f||||f||||||||||2018-05-31 23:55:17.753901|2018-05-31 23:55:17.753901
NCT01100164|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2015-07-24|2010-04-07|2010-04-08|Estimate|||||||2015-07-24|2015-07-27|Estimate|March 2011||2011-03-31|March 2010|2010-03-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|Eszo||A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia|A Phase III, Non-inferiority, Double-blind, Unicenter Clinical Trial With Two Treatment Arms - Test Group With Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia|Completed||Phase 3|263|Actual|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-05-31 23:55:17.837322|2018-05-31 23:55:17.837322
NCT01100151|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07||2011-08-18|2011-08-18|2010-04-07|2010-04-08|Estimate||||2011-08-18|2011-08-23|Estimate|2011-08-18|2011-08-23|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)|A Phase 2 Study of the Effects of RDC-1036 Administered to Subjects With Opioid-induced Constipation During Treatment With Opioids for Chronic Pain|Completed||Phase 2|60|Anticipated|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 23:55:17.940225|2018-05-31 23:55:17.940225
NCT01100125|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2013-10-24|2010-04-06|2010-04-08|Estimate|||||||2013-10-24|2013-10-25|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|November 2012|Actual|2012-11-30|January 2012|Actual|2012-01-31||Interventional|||Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment|Comparison Between Sitagliptin Add-on Therapy and Insulin Dose Increase Therapy for Uncontrolled Type 2 Diabetes on Insulin Therapy|Completed||Phase 4|140|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 23:55:18.126668|2018-05-31 23:55:18.126668
NCT01100112|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2014-03-28|2012-02-09|2014-05-30|2010-04-06|2010-04-08|Estimate|2014-05-30|2014-06-05|Estimate|2012-02-09|2012-02-13|Estimate|2014-05-30|2014-06-05|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional||All patients who received at least 1 dose of study drug were considered Evaluable patients. Total evaluable population was 60.|(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets|Multicenter, Open-Label Efficacy and Safety Study of Oral Budesonide-MMX 9mg Extended Release Tablets in Patients With Mild to Moderate, Active Ulcerative Colitis|Completed||Phase 3|61|Actual|Valeant Pharmaceuticals International, Inc.|This was an open label study. There was no reference therapy for statistical analysis.|1|||f||||f||||||||||2018-05-31 23:55:18.271365|2018-05-31 23:55:18.271365
NCT01100099|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2012-09-18|2010-04-07|2010-04-08|Estimate|||||||2012-09-18|2012-09-19|Estimate|September 2006||2006-09-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|December 2009|Actual|2009-12-31||Interventional|||HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease||Completed||Phase 2/Phase 3|100|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 23:55:18.50235|2018-05-31 23:55:18.50235
NCT01100086|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2010-04-13||2010-05-17|2010-04-07|2010-04-08|Estimate|2010-04-13|2010-05-06|Estimate||||2010-05-17|2010-05-25|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fasting Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin® 10-mg Tablets|Completed||Phase 1|84|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:55:18.639402|2018-05-31 23:55:18.639402
NCT01100073|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2010-07-30||2014-03-14|2010-04-07|2010-04-08|Estimate|2010-08-30|2010-09-20|Estimate||||2014-03-14|2014-04-11|Estimate|February 2008||2008-02-29|March 2014|2014-03-31||||August 2009|Actual|2009-08-31||Observational||Treated set (TS) (31 patients were missing age and 17 patients were missing gender)|Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life|Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life|Completed|||1703|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:55:19.304321|2018-05-31 23:55:19.304321
NCT01099904|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2016-11-01|2010-04-06|2010-04-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048|The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048|Completed||Phase 1|30|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:55:22.026735|2018-05-31 23:55:22.026735
NCT01100060|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2010-08-24|2010-04-06|2010-04-08|Estimate|||||||2010-08-24|2010-08-25|Estimate|April 2010||2010-04-30|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|AZCQ||A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects|A Phase 1, Open-Label, Randomized, Single Dose, Parallel Design Study To Estimate The Relative Bioavailability Of Co Administered Formulations Of Azithromycin Microsphere (AZ) And Chloroquine Test Formulation (CQ) Compared With Co Administered Immediate Release Individual AZ And CQ Tablets In Healthy Adult Subjects|Completed||Phase 1|40|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:55:20.084984|2018-05-31 23:55:20.084984
NCT01100047|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2015-06-24|2010-04-07|2010-04-08|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|JSMAD||Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 in Healthy Japanese Subjects After Single and Multiple Ascending Doses|Completed||Phase 1|63|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:55:20.196966|2018-05-31 23:55:20.196966
NCT01100034|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2018-03-22|2010-04-07|2010-04-08|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2010|Actual|2010-11-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|PURPOSE||Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis|A Long-term, Prospective, Observational Cohort Study Of The Safety And Effectiveness Of Etanercept In The Treatment Of Paediatric Psoriasis Patients In A Naturalistic Setting: A Post-authorization Safety Study (Pass)|Active, not recruiting|||72|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:55:20.304318|2018-05-31 23:55:20.304318
NCT01100021|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-01-05|2010-04-06|2010-04-08|Estimate|||||||2011-01-05|2011-01-07|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin|A Phase 1, Single-centre, Double-blind, Randomized, Placebo-controlled, Two-cohort, Two-period Crossover Study of the Hemodynamic Interactions Between Avanafil and Two α-Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle-aged Healthy Male Subjects|Completed||Phase 1|48|Actual|VIVUS, Inc.||2|||f||||||||||||||2018-05-31 23:55:20.787442|2018-05-31 23:55:20.787442
NCT01100008|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2016-03-11|2010-04-07|2010-04-08|Estimate|||||||2016-03-11|2016-03-14|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|||Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion|Cardiac Magnetic Resonance Imaging and Pulmonary Perfusion: Its Role in the Diagnosis of the Severity of Pulmonary Hypertension in Adults and in the Follow-up. Preliminary Study.|Completed||N/A|29|Actual|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 23:55:20.890219|2018-05-31 23:55:20.890219
NCT01099995|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2010-04-07|2010-04-07|2010-04-08|Estimate|||||||2010-04-07|2010-04-08|Estimate|October 1989||1989-10-31|April 2010|2010-04-30|February 2000|Actual|2000-02-29|January 2000|Actual|2000-01-31||Interventional|||Hyperbaric Oxygen Therapy for Comatose Patients With Acute Carbon Monoxide Poisoning|Phase 3 Study of Hyperbaric Oxygen Therapy for Comatose Patients With Acute Domestic Carbon Monoxide Poisoning|Terminated||Phase 3|170|Actual|University of Versailles||2||"the study was halted after the first interim analysis as there were significantly more patients~   who recovered at one month in the control arm"|f||||f||||||||||2018-05-31 23:55:20.990316|2018-05-31 23:55:20.990316
NCT01099982|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2017-10-25|2010-04-06|2010-04-08|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2008||2008-09-30|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease|Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease, Effects of Mechanical Unloading on Myocardial Function and Structure in Humans|Recruiting|||300|Anticipated|University of Utah|||2||f||||t||||||Samples With DNA|"~     Serum and myocardial tissue.~   "|||2018-05-31 23:55:21.111094|2018-05-31 23:55:21.111094
NCT01099969|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-10-14|2010-04-07|2010-04-08|Estimate|||||||2010-10-14|2010-10-15|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|March 2011|Anticipated|2011-03-31|September 2010|Anticipated|2010-09-30||Interventional|||Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy|Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy|Unknown status|Active, not recruiting|N/A|60|Anticipated|The University of Texas Health Science Center, Houston||4|||f||||f||||||||||2018-05-31 23:55:21.30322|2018-05-31 23:55:21.30322
NCT01099956|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2011-10-24|2010-04-06|2010-04-08|Estimate|||||||2011-10-24|2011-10-25|Estimate|April 2010||2010-04-30|October 2011|2011-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|Coccinelle||Low Grade Inflammation in Type 1 Diabetes Children|Low Grade Inflammation in Type 1 Diabetes Children|Completed|||80|Actual|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 23:55:21.421468|2018-05-31 23:55:21.421468
NCT01099943|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2015-10-05|2010-04-06|2010-04-08|Estimate|||||||2015-10-05|2015-10-06|Estimate|August 2009||2009-08-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians|Reducing Inappropriate Antibiotic Prescribing by Primary Care Clinicians|Completed||N/A|8|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 23:55:21.482309|2018-05-31 23:55:21.482309
NCT01099930|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2016-09-27|2010-04-06|2010-04-08|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2001||2001-08-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|November 2012|Actual|2012-11-30||Interventional|MS/BMT||Autologous Stem Cell Transplant for Multiple Sclerosis|Targeting Multiple Sclerosis as an Autoimmune Disease With Intensive Immunoablative Therapy and Immunological Reconstitution: A Potential Curative Therapy for Patients With a Predicted Poor Prognosis|Completed||Phase 2|24|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 23:55:21.543593|2018-05-31 23:55:21.543593
NCT01099917|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|2015-12-28||2016-04-11|2010-04-06|2010-04-08|Estimate|2016-04-11|2016-05-19|Estimate||||2016-04-11|2016-05-19|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?|Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients? A Phase II Trial|Completed||Phase 2|45|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:55:21.64743|2018-05-31 23:55:21.64743
NCT01099891|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-08-01|2010-04-06|2010-04-08|Estimate|||||||2014-08-01|2014-08-04|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients||Unknown status|Active, not recruiting|Phase 3|300|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 23:55:23.184997|2018-05-31 23:55:23.184997
NCT01099878|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-06|2010-04-06|2010-04-08|Estimate|||||||2010-04-06|2010-04-08|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||Cycling Exercise With Functional Electrical Stimulation Improves Postural Control in Stroke Patients|Institutional Review Board of Chung Shan Medical University Hospital|Completed||Phase 1/Phase 2|20|Anticipated|Chung Shan Medical University||2|||f||||t||||||||||2018-05-31 23:55:23.425931|2018-05-31 23:55:23.425931
NCT01099865|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2010-04-07|2010-04-07|2010-04-08|Estimate|||||||2010-04-07|2010-04-08|Estimate|December 2009||2009-12-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes|High-sensitivity C-reactive Protein and UKPDS Risk Score in Type 2 Diabetes: Nalysis With 18F-Fluorodeoxyglucose Positron Emission Tomography|Completed|||56|Actual|Korea University|||||f||||t||||||||||2018-05-31 23:55:23.517209|2018-05-31 23:55:23.517209
NCT01099852|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2016-10-26|2010-04-06|2010-04-08|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Observational|CARBO||Cohort of Patients Infected by an Arbovirus|Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r|Recruiting|||1377|Anticipated|University Hospital Center of Martinique|||||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells, plasma, DNA, Urine~   "|Undecided||2018-05-31 23:55:23.611028|2018-05-31 23:55:23.611028
NCT01099839|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2010-06-08|2010-04-06|2010-04-08|Estimate|||||||2010-06-08|2010-06-09|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol|A Phase I Study to Assess Drug-Drug Interaction Between ASP1941 and Miglitol.|Completed||Phase 1|30|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 23:55:24.041204|2018-05-31 23:55:24.041204
NCT01099826|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-07|2010-04-07|2010-04-08|Estimate|||||||2010-04-07|2010-04-08|Estimate|October 2004||2004-10-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Increasing Colorectal Cancer (CRC) Screening In Primary Care|Increasing CRC Screening in Primary Care Settings|Completed||Phase 3|511|Actual|Arizona State University||3|||f||||t||||||||||2018-05-31 23:55:24.688569|2018-05-31 23:55:24.688569
NCT01099813|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2014-05-21|2010-04-07|2010-04-08|Estimate|||||||2014-05-21|2014-05-23|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|SPOT(Light)||Sepsis Pathophysiological & Organisational Timing|The Effect of Pathophysiological and Organisational Lead Times to Critical Care on Survival and Resource Utilisation|Completed|||15602|Actual|Intensive Care National Audit & Research Centre|||1||f||||t||||||||||2018-05-31 23:55:25.252472|2018-05-31 23:55:25.252472
NCT01099800|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2011-06-22|2010-04-07|2010-04-08|Estimate|||||||2011-06-22|2011-06-23|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|August 2014|Anticipated|2014-08-31|December 2013|Anticipated|2013-12-31||Observational|||Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM|Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM|Unknown status|Enrolling by invitation||600|Anticipated|Arizona State University|||2||f||||t||||||||||2018-05-31 23:55:26.079118|2018-05-31 23:55:26.079118
NCT01099787|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-07|||2011-06-21|2010-04-07|2010-04-08|Estimate|||||||2011-06-21|2011-06-22|Estimate|April 2010||2010-04-30|June 2011|2011-06-30||||||||Observational|||Pediatric Alliance for International Neurogastrointestinal Functional Research|Pediatric Alliance for International Neurogastrointestinal Functional Research Registry|Unknown status|Recruiting||300|Anticipated|Nationwide Children's Hospital|||1||f||||||||||||||2018-05-31 23:55:27.309328|2018-05-31 23:55:27.309328
NCT01099774|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2012-04-03||2012-04-03|2010-04-06|2010-04-08|Estimate|2012-04-03|2012-04-27|Estimate||||2012-04-03|2012-04-27|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|597|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:55:27.745113|2018-05-31 23:55:27.745113
NCT01099761|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|2016-05-10|2013-01-24|2017-03-08|2010-04-06|2010-04-08|Estimate|2016-08-22|2016-10-14|Estimate|2013-01-31|2013-02-04|Estimate|2017-03-08|2017-04-05|Actual|April 2010||2010-04-30|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACE-031 (ActRIIB-IgG1) in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 2|24|Actual|Acceleron Pharma, Inc.||3||Based on preliminary safety data.|f||||t||||||||No|Abstract summarizing trial data has been published online in Muscle & Nerve 23-Dec-2016 https://www.ncbi.nlm.nih.gov/pubmed/27462804 The Sponor currently has no plans to make IPD available for a number of reasons; (i) the study was terminated by the Sponsor prematurely based upon concerns for potential adverse drug reactions following long-term use, which were identified in chronic toxicity studies in animals, (ii) the study population was one with a rare disease, in a groups of subjects with a relatively narrow age range, across a small number of study sites. The Sponsor believes that these factors, taken together, make patient anonymity a significant challenge.|2018-05-31 23:55:28.392681|2018-05-31 23:55:28.392681
NCT01099748|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2010-08-26|2010-04-06|2010-04-07|Estimate|||||||2010-08-26|2010-08-30|Estimate|May 2010||2010-05-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone|Open Label, Single-Sequence Study To Estimate The Effect Of Lersivirine (UK-453,061) On S- And R-Methadone In Subjects Receiving Chronic Methadone Treatment|Completed||Phase 1|13|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:55:30.730054|2018-05-31 23:55:30.730054
NCT01099735|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2011-01-27|2010-04-06|2010-04-07|Estimate|||||||2011-01-27|2011-01-28|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Observational|||Effect of Continuous Positive Airway Pressure (CPAP) on Lower Esophageal Sphincter Pressure in Morbidly Obese Patients|Effect of Continuous Positive Airway Pressure On Lower Esophageal Sphincter Pressure in Subjects Undergoing Bariatric Surgery|Unknown status|Enrolling by invitation||50|Anticipated|Oregon Health and Science University|||1||f||||t||||||||||2018-05-31 23:55:31.352211|2018-05-31 23:55:31.352211
NCT01099722|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-08-12|2010-04-06|2010-04-07|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2010||2010-04-30|August 2014|2014-08-31||||November 2010|Actual|2010-11-30||Interventional|||Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma||Completed||Phase 3|261|Actual|Mundipharma Research Limited||2|||f||||f||||||||||2018-05-31 23:55:31.516727|2018-05-31 23:55:31.516727
NCT01099709|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2010-04-13||2010-04-13|2010-04-06|2010-04-07|Estimate|2010-04-13|2010-05-06|Estimate||||2010-04-13|2010-05-06|Estimate|January 2007||2007-01-31|April 2010|2010-04-30|August 2007|Actual|2007-08-31|March 2007|Actual|2007-03-31||Interventional|||A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets|A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin® 10-mg Tablets|Completed||Phase 1|85|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-05-31 23:55:31.770488|2018-05-31 23:55:31.770488
NCT01099696|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2012-12-19|2010-04-06|2010-04-07|Estimate|||||||2012-12-19|2012-12-20|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and Bloating|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Benefit of a Probiotic (Bifidobacterium Infantis 35624) in Healthy Subjects With a History of Abdominal Discomfort and Bloating|Completed||N/A|302|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 23:55:32.263521|2018-05-31 23:55:32.263521
NCT01099683|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-12-23|2010-04-06|2010-04-07|Estimate|||||||2010-12-23|2010-12-24|Estimate|April 2010||2010-04-30|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects|A Double-blind, Randomised, Placebo-controlled Study in Elderly Subjects to Evaluate the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in a 2 g Suppository|Completed||Phase 1|26|Actual|Norgine||2|||f||||f||||||||||2018-05-31 23:55:32.403519|2018-05-31 23:55:32.403519
NCT01099670|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-12-23|2010-04-06|2010-04-07|Estimate|||||||2010-12-23|2010-12-24|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days|A Double-blind, Placebo-controlled, Randomised, Parallel-group, Dose-escalating, Repeat Dose Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of the Once Daily Rectal Application of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days|Completed||Phase 1|48|Anticipated|Norgine||4|||f||||t||||||||||2018-05-31 23:55:32.478473|2018-05-31 23:55:32.478473
NCT01099657|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2017-05-10|2010-04-06|2010-04-07|Estimate|||||||2017-05-10|2017-05-12|Actual|June 2007||2007-06-30|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|VRHChP||Virtual Reality Hypnosis for Chronic Pain Reduction|Virtual Reality Hypnosis for Chronic Pain Reduction|Completed||N/A|10|Actual|University of Washington||2|||f||||t||||||||Undecided||2018-05-31 23:55:32.675156|2018-05-31 23:55:32.675156
NCT01099644|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2018-05-03|2010-04-06|2010-04-07|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2010|Actual|2010-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum|Phase I Study of Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum|Recruiting||Phase 1|45|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:55:32.783091|2018-05-31 23:55:32.783091
NCT01099631|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2017-11-29|2010-04-06|2010-04-07|Estimate|||||||2017-11-29|2017-12-02|Actual|April 2010||2010-04-30|November 2017|2017-11-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread|A Phase 1 Study of an IL-2 Expressing, Attenuated Salmonella Typhimurium in Patients With Unresectable Hepatic Spread From Any Non-Hematologic Primary|Completed||Phase 1|22|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 23:55:32.931431|2018-05-31 23:55:32.931431
NCT01099618|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2015-05-09||2015-05-30|2010-04-06|2010-04-07|Estimate|2015-05-30|2015-06-18|Estimate||||2015-05-30|2015-06-18|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional||AA patient with new-onset DM presenting with BG > 400 or DKA|Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment|Ketosis-Prone Diabetes in African Americans: Predictive Markers, Underlying Mechanisms, and Treatment Outcomes: The Effects of Metformin vs. Sitagliptin on Beta-Cell Preservation in Obese Subjects With Ketosis-Prone Type 2 Diabetes Mellitus|Completed||Phase 4|48|Actual|Emory University||3|||f||||t||||||||||2018-05-31 23:55:33.082569|2018-05-31 23:55:33.082569
NCT01099605|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-06|2010-04-06|2010-04-07|Estimate|||||||2010-04-06|2010-04-07|Estimate|April 2010||2010-04-30|April 2010|2010-04-30||||April 2012|Anticipated|2012-04-30||Interventional|||Continuous Infusion of Local Anesthetic for Optimal Post Operative Pain Control Following Hemorrhoidectomy|Continuous Infusion of Local Anesthetic for Optimal Post Operative Pain Control Following Hemorrhoidectomy: A Randomized Double-blind Controlled Trial|Unknown status|Recruiting|Phase 4|42|Anticipated|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-05-31 23:55:33.471866|2018-05-31 23:55:33.471866
NCT01099592|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2016-01-27|2010-04-06|2010-04-07|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ARCADE||Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression|Predictors of Depression Treatment Response Following an Acute Coronary Syndrome|Terminated||Phase 4|7|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||||inability to recruit|f||||f||||||||||2018-05-31 23:55:33.572837|2018-05-31 23:55:33.572837
NCT01099579|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|2013-11-14||2018-04-26|2010-04-06|2010-04-07|Estimate|2014-01-07|2014-02-06|Estimate||||2018-04-26|2018-05-24|Actual|October 13, 2010|Actual|2010-10-13|April 2018|2018-04-30|September 11, 2017|Actual|2017-09-11|October 4, 2012|Actual|2012-10-04||Interventional|PRINCE1||PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)|A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)|Completed||Phase 3|82|Actual|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 23:55:33.738853|2018-05-31 23:55:33.738853
NCT01099566|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2011-07-08|2010-04-06|2010-04-07|Estimate|||||||2011-07-08|2011-07-11|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation|The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation|Completed||Phase 4|20|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 23:55:37.342841|2018-05-31 23:55:37.342841
NCT01099553|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2012-08-29|2010-04-06|2010-04-07|Estimate|||||||2012-08-29|2012-08-31|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Improving Bowel Preparation With an Educational Video|Improving Bowel Preparation With an Education Video|Completed||Phase 3|2000|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 23:55:37.517077|2018-05-31 23:55:37.517077
NCT01099540|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2015-12-28|2010-04-06|2010-04-07|Estimate|||||||2015-12-28|2015-12-29|Estimate|April 2010||2010-04-30|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor|Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor|Completed||Phase 2|37|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 23:55:37.585289|2018-05-31 23:55:37.585289
NCT01099527|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2015-12-28|2010-04-06|2010-04-07|Estimate|||||||2015-12-28|2015-12-29|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||A Trial of RAD001/Capecitabine in Refractory Gastric Cancer|A Phase I/II Trial of RAD001/Capecitabine in Refractory Gastric Cancer|Completed||Phase 1/Phase 2|59|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 23:55:37.655116|2018-05-31 23:55:37.655116
NCT01099514|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2015-12-28|2010-04-06|2010-04-07|Estimate|||||||2015-12-28|2015-12-29|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Interventional|||Study of Nilotinib in Metastatic Melanoma With KIT Aberrations|Phase II Study of Nilotinib in Metastatic Melanoma With KIT Aberrations|Completed||Phase 2|33|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 23:55:37.731078|2018-05-31 23:55:37.731078
NCT01099501|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2013-11-21|2010-04-06|2010-04-07|Estimate|||||||2013-11-21|2013-11-25|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31||Interventional|OMT||Oxepa in Multiple Trauma|Oxepa in Multiple Trauma: Prospective, Randomized, Comparative, Double-blind, Controlled Clinical Study|Unknown status|Recruiting|Phase 4|120|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 23:55:37.825225|2018-05-31 23:55:37.825225
NCT01099488|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2017-06-26|2010-04-06|2010-04-07|Estimate|||||||2017-06-26|2017-06-27|Actual|April 1, 2010||2010-04-01|June 2017|2017-06-30|December 7, 2010|Actual|2010-12-07|December 7, 2010|Actual|2010-12-07||Interventional|||A Study in Healthy Adults Having Received a Single Vaccine Administration to Support the Development of Immunological Assays|A Study in Healthy Adults Having Received a Single Vaccine Administration to Support the Development of Immunological Assays|Completed||N/A|46|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 23:55:38.009463|2018-05-31 23:55:38.009463
NCT01099475|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2014-01-18||2014-10-13|2010-04-06|2010-04-07|Estimate|2014-10-13|2014-10-17|Estimate||||2014-10-13|2014-10-17|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|April 2011|Actual|2011-04-30|July 2009|Actual|2009-07-31||Interventional|||Effect of Intermittent Pedicle Clamping on Hepatocellular Injury During Liver Surgery|Randomized Controlled Trial on the Effect of Intermittent Pedicle Clamping Using 15 or 30 Minutes Ischemic Intervals During Liver Surgery|Completed||N/A|20|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 23:55:38.118185|2018-05-31 23:55:38.118185
NCT01099462|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2010-04-06|2010-04-06|2010-04-07|Estimate|||||||2010-04-06|2010-04-07|Estimate|June 2007||2007-06-30|March 2010|2010-03-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Observational|||Ibuprofen Concentration in Cerebro Spinal Fluid (CSF) of Infants and Children||Unknown status|Recruiting||30|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||Samples Without DNA|"~     Whole blood CSF~   "|||2018-05-31 23:55:38.397366|2018-05-31 23:55:38.397366
NCT01099449|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2016-08-11|2010-04-06|2010-04-07|Estimate|||||||2016-08-11|2016-08-12|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy|A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity|Completed||Phase 3|362|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-05-31 23:55:38.691471|2018-05-31 23:55:38.691471
NCT01099436|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2014-07-15|2010-04-06|2010-04-07|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|April 2012|Actual|2012-04-30||Interventional|NEO-ZOTAC||Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients|A Phase III Randomized Trial With NEOadjuvant Chemotherapy (TAC) With or Without ZOledronic Acid for Patients With HER2- Negative Large Resectable or Locally Advanced Breast Cancer(NEO-ZOTAC)|Completed||Phase 3|250|Actual|Borstkanker Onderzoek Groep||2|||f||||t||||||||||2018-05-31 23:55:39.898662|2018-05-31 23:55:39.898662
NCT01099423|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-06|||2017-02-07|2010-04-06|2010-04-07|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 2010|Actual|2010-04-30|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|April 2016|Actual|2016-04-30||Interventional|SURTIME||Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer|Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 3|99|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-05-31 23:55:40.372345|2018-05-31 23:55:40.372345
NCT01099410|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2016-01-04|2010-04-05|2010-04-07|Estimate|||||||2016-01-04|2016-01-06|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Apoptotic Cell (AC) Uptake by Human Alveolar Macrophages (AM)|Apoptotic Cell Ingestion by Normal Human Alveolar Macrophages|Completed|||17|Actual|VA Office of Research and Development|||1||f||||f||||||None Retained|"~     whole blood, white blood cells, serum, bronchoalveolar lavage fluid~   "|||2018-05-31 23:55:41.143567|2018-05-31 23:55:41.143567
NCT01099397|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2012-05-10||2018-03-30|2010-04-06|2010-04-07|Estimate|2012-08-29|2012-09-03|Estimate||||2018-03-30|2018-04-03|Actual|May 2009||2009-05-31|March 2018|2018-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study|Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study|Completed|||26|Actual|University of Florida|This was a pilot study to evaluate two glucose phenotypes in a small sample from a larger trial. As such, our sample size was small. Further, if participants were withdrawn from the parent trial, they were also withdrawn from the sub-study.||1||f||||f||||||Samples With DNA|"~     Serum and plasma~   "|||2018-05-31 23:55:41.58313|2018-05-31 23:55:41.58313
NCT01099384|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2013-05-21|2010-04-06|2010-04-07|Estimate|||||||2013-05-21|2013-05-23|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Tobacco Cessation Treatment for Alaska Native Youth|Tobacco Cessation Treatment for Alaska Native Youth|Completed||Phase 1|100|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 23:55:42.564945|2018-05-31 23:55:42.564945
NCT01099371|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-05-06|2010-04-05|2010-04-07|Estimate|||||||2010-05-06|2010-05-07|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|February 2011|Anticipated|2011-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Resistance Training in Knee Osteoarthritis|Progressive Resistance Training in Women With Knee Osteoarthritis|Unknown status|Active, not recruiting|Phase 2/Phase 3|70|Anticipated|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 23:55:42.823047|2018-05-31 23:55:42.823047
NCT01099358|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2016-10-20||2016-10-20|2010-04-06|2010-04-07|Estimate|2016-10-20|2016-12-13|Estimate||||2016-10-20|2016-12-13|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional||All participants who received at least one dose of study drug.|Study in Advanced Solid Tumors|Phase 2 Study to Evaluate the Pharmacokinetics and Drug-Drug Interaction of Cetuximab and Cisplatin in Patients With Advanced Solid Tumors|Completed||Phase 2|47|Actual|Eli Lilly and Company|Due to protocol amendment in Sep 2011,any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment June 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only.|4|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:55:43.232833|2018-05-31 23:55:43.232833
NCT01099345|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2014-06-02|2010-04-06|2010-04-07|Estimate|||||||2014-06-02|2014-06-04|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)|A Pilot, Overactive Bladder Syndrome Study Utilizing a Sleep Laboratory Setting to Compare Detrusor Positive Nocturia Female Subjects to Detrusor Negative Nocturia Female Subjects|Terminated|||15|Actual|Astellas Pharma Inc|||2|Slow Enrollment|f||||f||||||||||2018-05-31 23:55:45.669935|2018-05-31 23:55:45.669935
NCT01099332|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2011-01-27|2010-04-05|2010-04-07|Estimate|||||||2011-01-27|2011-01-28|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease|CopperProof-2: Prospective, Randomized, Double-Blind Placebo-Controlled Clinical Trial Comparing the Effects of a Novel Once-Daily Oral Zinc Cysteine Preparation on Zinc and Copper Parameters in Mild Cognitive Impairment and Alzheimer's Disease|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|Adeona Pharmaceuticals||2|||f||||t||||||||||2018-05-31 23:55:45.993689|2018-05-31 23:55:45.993689
NCT01099319|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2012-05-06|2010-04-05|2010-04-06|Estimate|||||||2012-05-06|2012-05-08|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Renalof in the Treatment of Elderly Patients With Gallstones|Efficacy and Safety of Renalof Administration in the Treatment of Elderly Patients With Gallstones|Completed||Phase 3|40|Actual|Catalysis SL||2|||f||||t||||||||||2018-05-31 23:55:46.346584|2018-05-31 23:55:46.346584
NCT01099306|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2010-04-05|2010-04-05|2010-04-06|Estimate|||||||2010-04-05|2010-04-06|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome|Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome|Completed||N/A|199|Actual|University of Jordan||2|||f||||t||||||||||2018-05-31 23:55:46.629676|2018-05-31 23:55:46.629676
NCT01099293|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-05-17|2010-04-05|2010-04-06|Estimate|||||||2012-05-17|2012-05-21|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Observational|||Cerebrovascular Reactivity in Hepatic Encephalopathy|Correlation Between Cerebrovascular Reactivity and Hepatic Encephalopathy in Patients With Cirrhosis|Completed|||90|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||4||f||||f||||||Samples Without DNA|"~     1. Patients with cirrhosis without hepatic encephalopathy.~        2. Patients with cirrhosis and minimal hepatic encephalopathy.~        3. Patients with cirrhosis and hepatic encephalopathy stage 1.~        4. Healthy subjects willing to participate.~   "|||2018-05-31 23:55:46.922619|2018-05-31 23:55:46.922619
NCT01099280|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2011-04-08|2010-04-05|2010-04-06|Estimate|||||||2011-04-08|2011-04-11|Estimate|November 2009||2009-11-30|March 2010|2010-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Induction of Labor in Term Premature Rupture of Membranes: A Comparison Between Oxytocin and Dinoprostone Followed Six Hours Later by Oxytocin||Completed||Phase 3|225|Anticipated|Erzincan Military Hospital||2|||f||||||||||||||2018-05-31 23:55:47.17768|2018-05-31 23:55:47.17768
NCT01099267|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|2011-10-05||2016-10-28|2010-04-05|2010-04-06|Estimate|2011-10-05|2011-11-18|Estimate||||2016-10-28|2016-12-12|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003|Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003|Completed|||54|Actual|Celgene Corporation|||1||f||||t||||||||||2018-05-31 23:55:47.471246|2018-05-31 23:55:47.471246
NCT01099254|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-04-05|2010-04-05|2010-04-06|Estimate|||||||2010-04-05|2010-04-06|Estimate|August 2007||2007-08-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Internal Jugular Vein Cross Sectional Area|Effect of Position on Cross Sectional Area of IJV|Completed|||38|Actual|University of Iowa|||||f||||f||||||||||2018-05-31 23:55:47.983079|2018-05-31 23:55:47.983079
NCT01099241|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2010-04-05|2010-04-05|2010-04-06|Estimate|||||||2010-04-05|2010-04-06|Estimate|August 2007||2007-08-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Central Venous Pressure (CVP) Assessment by Ultrasound and Physical Examination|Use of Ultrasound to Determine Central Venous Pressure in Critically Ill Patients|Completed|||38|Actual|University of Iowa|||||f||||f||||||||||2018-05-31 23:55:48.044397|2018-05-31 23:55:48.044397
NCT01099228|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2016-07-19|2010-04-05|2010-04-06|Estimate|||||||2016-07-19|2016-07-21|Estimate|September 2006||2006-09-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|April 2008|Actual|2008-04-30||Interventional|||Combination Targeted Radiotherapy in Neuroendocrine Tumors|Combination Targeted Radiotherapy in Neuroendocrine Tumors|Completed||N/A|2|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 23:55:48.223281|2018-05-31 23:55:48.223281
NCT01099215|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2013-06-28||2014-01-02|2010-04-05|2010-04-06|Estimate|2014-01-02|2014-02-04|Estimate||||2014-01-02|2014-02-04|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|TRIUMPH||Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)|An Open-Label Dose Escalation Safety Study of PVS-10200 for the Treatment of Restenosis in Patients Undergoing Minimally Invasive Peripheral Revascularization (TRIUMPH)|Completed||Phase 1/Phase 2|21|Actual|Shire Regenerative Medicine, Inc.|Small patient number, no control arm|1|||f||||t||||||||||2018-05-31 23:55:48.343507|2018-05-31 23:55:48.343507
NCT01099059|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-03|||2010-11-17|2010-04-05|2010-04-06|Estimate|||||||2010-11-17|2010-11-18|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|June 2010|Anticipated|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)|Amantadine VS Ritalin in the Treatment of ADHD: a Double Blind Randomized Trial|Unknown status|Recruiting|Phase 2|40|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:55:50.435666|2018-05-31 23:55:50.435666
NCT01099202|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|2012-06-12||2012-07-24|2010-04-05|2010-04-06|Estimate|2012-07-24|2012-08-27|Estimate||||2012-07-24|2012-08-27|Estimate|March 2003||2003-03-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy|A Randomized Study of Procrit Versus No Procrit in Patients With Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy|Completed||N/A|109|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 23:55:48.897332|2018-05-31 23:55:48.897332
NCT01099189|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2010-04-05|2010-04-05|2010-04-06|Estimate|||||||2010-04-05|2010-04-06|Estimate|July 2010||2010-07-31|March 2010|2010-03-31|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Observational|||Vein Histology in Arteriovenous Fistulas and Its Effect on Fistula Surgery Success|A Cohort Study of the Histopathological Changes Evident in Vein Wall at the Time of Arteriovenous Dialysis Access Fistulas and the Effects of Such Changes on Biomechanical Compliance and Patient's Clinical Outcomes in a University Teaching Hospital.|Unknown status|Not yet recruiting||30|Anticipated|University of Hull|||1||f||||f||||||Samples Without DNA|"~     vein samples collected at time of fistula formation~   "|||2018-05-31 23:55:49.18644|2018-05-31 23:55:49.18644
NCT01099176|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2010-04-08|2010-04-05|2010-04-06|Estimate|||||||2010-04-08|2010-04-09|Estimate|May 2008||2008-05-31|March 2006|2006-03-31|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Effects of Hypolipemic Treatment on Adipokines|The Effects of 90-day Monotherapies With Atorvastatin, Fenofibrate and Combined Therapy With Atorvastatin and Fenofibrate on Lipid Profile, Fasting Plasma Glucose, Proinflammatory Cytokines and Adipokines|Completed||N/A|78|Actual|Medical University of Silesia||4|||f||||t||||||||||2018-05-31 23:55:49.272847|2018-05-31 23:55:49.272847
NCT01099163|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2011-06-14|2010-04-05|2010-04-06|Estimate|||||||2011-06-14|2011-06-15|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E in Patients With Type 2 Diabetes Mellitus|Effect of Conjugated Linoleic Acid Alone and in Conjunction With Vitamin E on Insulin Sensitivity, Beta Cell Function, Markers of Inflammation, Body Fat Mass and Other Biochemical Indicators in Patients With Type 2 Diabetes Mellitus|Completed||N/A|60|Actual|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-05-31 23:55:49.39247|2018-05-31 23:55:49.39247
NCT01099150|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2012-04-15|2010-04-05|2010-04-06|Estimate|||||||2012-04-15|2012-04-17|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|November 2009|Actual|2009-11-30||Interventional|||Dark Chocolate and Platelet Function in Humans|Acute Effects of the Consumption of Dark Chocolate Enriched in Flavan-3-ols on Platelet Function and the Platelet Proteome|Completed||N/A|42|Actual|University of Aberdeen||1|||f||||t||||||||||2018-05-31 23:55:49.477344|2018-05-31 23:55:49.477344
NCT01099137|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-05|||2014-05-26|2010-04-05|2010-04-06|Estimate|||||||2014-05-26|2014-05-28|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin|The Study About Glucose Lowering Effect of Vildagliptin in Type 2 Diabetes Patients Who Are Uncontrolled With Metformin and a Sulphonylurea|Completed||Phase 4|344|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 23:55:49.57912|2018-05-31 23:55:49.57912
NCT01099124|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-01-28|2010-04-05|2010-04-06|Estimate|||||||2013-01-28|2013-01-29|Estimate|December 2009||2009-12-31|April 2010|2010-04-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)|Single-center, Open Trail of Phase 1 of M2ES With TC Regimen in Advanced NSCLC|Completed||N/A|25|Actual|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||||2018-05-31 23:55:49.653381|2018-05-31 23:55:49.653381
NCT01099111|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2014-03-22||2014-04-24|2010-04-05|2010-04-06|Estimate|2014-04-24|2014-05-22|Estimate||||2014-04-24|2014-05-22|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|||Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders|Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic Gastrointestinal Disorders (IBS, IBD, CRC)|Completed|||225|Actual|King Fahad Medical City|After completing recruitment, the colonic mucosal washing sampling did not result in enough DNA extract and we had to drop some of the participants for analysis.||5||f||||t||||||Samples With DNA|"~     Colonic washing samples from 4 specific segments (cecum, transverse, proximal sigmoid and~     rectum) of every subject will be retained for 16S rRNA analysis for the study purpose, and~     more samples will be retained for further analysis later on.~      Samples from the unified colonic segments (each collected as 15 cc in each of four 20 cc~     tubes and stored in -70 Freezer) were completely recruited from 50 normal subjects, 50 IBS,~     50 UC, 46 CD and only 29 CRC.~      One to two tubes from each segment sample of all subjects have been utilized for DNA~     extraction and accepted if identified sufficient according to lab. Hence submitted for 16S~     rRNA analysis. Currently we are waiting for intra-cohort comparison of samples, then~     inter-cohort comparisons among different study groups will be done.~   "|||2018-05-31 23:55:49.779221|2018-05-31 23:55:49.779221
NCT01099098|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-04|||2011-05-11|2010-04-05|2010-04-06|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Observational|||Prevalence of Latent Tuberculosis (TB) Infection Diagnosed by Interferon-gamma Release Assay and Tuberculin Skin Tests in Patients With Old Healed TB||Completed|||480|Anticipated|Seoul National University Hospital|||2||f||||f||||||||||2018-05-31 23:55:50.197824|2018-05-31 23:55:50.197824
NCT01099085|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-04|||2017-02-15|2010-04-05|2010-04-06|Estimate|||||||2017-02-15|2017-02-17|Actual|February 2009|Actual|2009-02-28|February 2017|2017-02-28|January 2015|Actual|2015-01-31|June 2013|Actual|2013-06-30||Interventional|||Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients|Placebo-controlled, Double-blinded Phase III Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients|Completed||Phase 3|207|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 23:55:50.256236|2018-05-31 23:55:50.256236
NCT01099072|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-03|||2012-12-06|2010-04-05|2010-04-06|Estimate|||||||2012-12-06|2012-12-07|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder|Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder Children and Adolescents in the Placebo Control Double -Blind Randomized Clinical Trail|Unknown status|Enrolling by invitation|Phase 2|40|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:55:50.345184|2018-05-31 23:55:50.345184
NCT01097824|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-03-31|2010-03-31|2010-04-02|Estimate|||||||2010-03-31|2010-04-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:56:13.909702|2018-05-31 23:56:13.909702
NCT01099046|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-27|||2010-04-03|2010-04-03|2010-04-06|Estimate|||||||2010-04-03|2010-04-06|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|January 2020|Anticipated|2020-01-31|January 2015|Anticipated|2015-01-31||Interventional|SMT||Stress Management Therapy for Meniere's Disease|Reduction of Plasma Vasopressin Level in Patients With Meniere's Disease|Recruiting||N/A|200|Anticipated|Osaka University||4|||f||||t||||||||||2018-05-31 23:55:50.544645|2018-05-31 23:55:50.544645
NCT01099033|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2018-05-07|2010-04-05|2010-04-06|Estimate|||||||2018-05-07|2018-05-14|Actual|August 2007||2007-08-31|May 2018|2018-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||The Biologic Basis of Hernia Formation|The Biologic Basis of Hernia Formation|Completed|||151|Actual|Washington University School of Medicine|||2||f||||f||||||Samples With DNA|"~     small tissue biopsies of gastrohepatic, gastrophrenic, and phrenoesophageal ligaments~   "|||2018-05-31 23:55:50.68027|2018-05-31 23:55:50.68027
NCT01099020|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2015-05-29|2010-04-05|2010-04-06|Estimate|||||||2015-05-29|2015-06-02|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Temporal Pattern of Circulating DNA for Patients Receiving Irradiation|Temporal Pattern of Circulating DNA for Patients Receiving Total Body Irradiation|Terminated|||13|Actual|University of Rochester||||Funding for project was withdrawn|f||||f||||||||||2018-05-31 23:55:50.75483|2018-05-31 23:55:50.75483
NCT01099007|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2014-05-20|2010-04-05|2010-04-06|Estimate|||||||2014-05-20|2014-05-22|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|HBHH||Healthy Bodies, Healthy Hearts: A Physical Activity Intervention Trial|Phase II: Healthy Bodies, Hearts After Menopause|Completed||Phase 1|99|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 23:55:50.813163|2018-05-31 23:55:50.813163
NCT01098994|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-06-02|2010-04-02|2010-04-06|Estimate|||||||2014-06-02|2014-06-03|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|HAP-E||Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes|Pilot and Feasibility Study for a Pharmacogenomic Trial in Type 1 Diabetes|Completed||N/A|87|Actual|University of Pittsburgh||3|||f||||f||||||||||2018-05-31 23:55:50.916195|2018-05-31 23:55:50.916195
NCT01098981|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2015-04-03|2010-04-05|2010-04-06|Estimate|||||||2015-04-03|2015-04-07|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CLOTBUST-ER||Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke|A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke|Terminated||Phase 3|675|Actual|Cerevast Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 23:55:51.029213|2018-05-31 23:55:51.029213
NCT01098968|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2011-09-07|2010-04-02|2010-04-05|Estimate|||||||2011-09-07|2011-09-08|Estimate|January 2007||2007-01-31|September 2010|2010-09-30|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|EDUFIT||Education and Fitness: EDUFIT Study|Effects of a Physical Education Program Focused on Improving Physical Fitness in Adolescents Aged 12-14 Years|Completed||N/A|70|Actual|Universidad de Granada||3|||f||||f||||||||||2018-05-31 23:55:51.098209|2018-05-31 23:55:51.098209
NCT01098955|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2017-09-19|2010-04-02|2010-04-05|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2010|Actual|2010-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Smoking Cessation Treatment for Head & Neck Cancer Patients|Smoking Cessation Treatment for Head & Neck Cancer Patients: Acceptance and Commitment Therapy|Active, not recruiting||N/A|108|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 23:55:51.203287|2018-05-31 23:55:51.203287
NCT01098942|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2018-03-20|2010-04-02|2010-04-05|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2009||2009-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|August 2012|Actual|2012-08-31||Observational|||Bariatric Surgery and Skeletal Health|Effects of Bariatric Surgery on Skeletal Health|Completed|||50|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 23:55:51.4654|2018-05-31 23:55:51.4654
NCT01098929|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2015-12-16|2010-04-02|2010-04-05|Estimate|||||||2015-12-16|2015-12-17|Estimate|July 2002||2002-07-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia|Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia|Unknown status|Recruiting||1000|Anticipated|Massachusetts General Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood, tissue, saliva, urine~   "|||2018-05-31 23:55:51.531388|2018-05-31 23:55:51.531388
NCT01098916|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-04-02|2010-04-02|2010-04-05|Estimate|||||||2010-04-02|2010-04-05|Estimate|June 2008||2008-06-30|May 2008|2008-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|RHP||The RAD-HOME Project: a Pilot Study of Domiciliary Teleradiology|The RAD-HOME Project: a Randomized Pilot Study of a Domiciliary Teleradiology Program for Frail Elderly Patients|Completed||N/A|69|Actual|Azienda Ospedaliera San Giovanni Battista||2|||f||||f||||||||||2018-05-31 23:55:51.602992|2018-05-31 23:55:51.602992
NCT01098903|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-07-11|2010-04-02|2010-04-05|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Observational|CLEARSUN||Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients|Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib (Sutent, SU11248) in Patients With Cancer|Completed|||52|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 23:55:51.672342|2018-05-31 23:55:51.672342
NCT01098890|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-11-10|2010-04-02|2010-04-05|Estimate|||||||2010-11-10|2010-11-11|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|April 2012|Anticipated|2012-04-30|October 2011|Anticipated|2011-10-31||Interventional|||Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage|Intraventricular Tissue Plasminogen Activator in the Management of Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Pilot Study|Unknown status|Recruiting|Phase 2|12|Anticipated|University of Calgary||2|||f||||||||||||||2018-05-31 23:55:51.734561|2018-05-31 23:55:51.734561
NCT01098877|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2010-10-12|2010-04-01|2010-04-05|Estimate|||||||2010-10-12|2010-10-13|Estimate|April 2010||2010-04-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||First In Human Study Of Increasing Oral Doses Of PF-04634817|A Double Blind, Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Pharmacokinetics (In The Fed And Fasted State), Safety And Toleration Of Single Oral Doses Of PF-04634817 In Healthy Volunteers|Completed||Phase 1|27|Actual|Pfizer||11|||f||||f||||||||||2018-05-31 23:55:51.827579|2018-05-31 23:55:51.827579
NCT01095900|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate||||March 2010|2010-03-31||||||||Observational|||Comparison of Botulinum Toxin and Sphincterotomy in the Treatment of Chronic Anal Fissure||Completed|||40|Anticipated|Theodor Bilharz Research Institute|||2||f||||t||||||||||2018-05-31 23:56:43.55541|2018-05-31 23:56:43.55541
NCT01098864|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2015-03-03|2010-04-02|2010-04-05|Estimate|||||||2015-03-03|2015-03-04|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting.|Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting.|Withdrawn||N/A|0|Actual|University of Arkansas||||"Study was withdrawn prior to the first subject being enrolled due to the Co-Investigator~   leaving the university"|f||||t||||||||||2018-05-31 23:55:51.996798|2018-05-31 23:55:51.996798
NCT01098851|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|2010-12-16||2014-08-05|2010-04-02|2010-04-05|Estimate|2011-06-03|2011-06-29|Estimate||||2014-08-05|2014-08-07|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Oxygen Saturation Monitoring During Surgery|Saturation Pattern Detection Prevalence Study Protocol|Completed|||21|Actual|Medtronic - MITG|Small numbers of subjects analyzed.||2||f||||f||||||||||2018-05-31 23:55:52.064116|2018-05-31 23:55:52.064116
NCT01098838|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2012-08-02|2010-04-01|2010-04-05|Estimate|||||||2012-08-02|2012-08-03|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy of LCL161 in Patients With Solid Tumors|A Phase I, Multi-center, Open-label, Dose-escalation Study of Oral LCL161 in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|71|Actual|Novartis||3|||f||||||||||||||2018-05-31 23:55:52.279232|2018-05-31 23:55:52.279232
NCT01098825|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2011-06-22|2010-04-01|2010-04-05|Estimate|||||||2011-06-22|2011-06-27|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Vaccine Hesitancy: A Survey of Pediatric Clinicians|Vaccine Hesitancy: A Survey of District VI Pediatric Clinicians|Completed|||1000|Anticipated|Children's Mercy Hospital Kansas City|||1||f||||f||||||||||2018-05-31 23:55:52.352671|2018-05-31 23:55:52.352671
NCT01098812|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|2013-05-02|2013-01-03|2013-06-28|2010-04-02|2010-04-05|Estimate|2013-06-28|2013-07-02|Estimate|2013-01-04|2013-01-09|Estimate|2013-06-28|2013-07-02|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Evaluation of a 1-Piece Intraocular Lens|Clinical Evaluation of the TECNIS® Toric 1-Piece Intraocular Lens|Completed||Phase 3|269|Actual|Abbott Medical Optics||3|||f||||f||||||||||2018-05-31 23:55:52.436554|2018-05-31 23:55:52.436554
NCT01098799|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2013-06-12|2010-04-02|2010-04-05|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Urotensin II in Chronic Kidney Diseases and Kidney Transplants|Urotensin II in Chronic Kidney Diseases|Completed|||110|Actual|Vakif Gureba Training and Research Hospital|||3||f||||t||||||||||2018-05-31 23:55:52.776703|2018-05-31 23:55:52.776703
NCT01098786|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-03-13|2010-04-02|2010-04-05|Estimate|||||||2017-03-13|2017-03-14|Actual|February 2010||2010-02-28|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Drug Use Investigation for Cell-culture Derived Influenza A (H1N1) Emulsion HA Vaccine|Observational Study to Evaluate Safety of Cell-derived A/H1N1 Influenza HA Vaccine in Healthy Japanese Subjects|Completed|||556|Actual|Novartis|||1||f||||||||||||||2018-05-31 23:55:52.879783|2018-05-31 23:55:52.879783
NCT01098773|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-07-04|2010-04-02|2010-04-05|Estimate|||||||2014-07-04|2014-07-08|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|PULCO||Pulmonary and Cardiac Ultrasound During Weaning From Mechanical Ventilation|Pulmonary and Cardiac Ultrasound During Weaning From Mechanical Ventilation|Completed|||100|Actual|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 23:55:52.950135|2018-05-31 23:55:52.950135
NCT01098760|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2013-10-30|2010-04-02|2010-04-05|Estimate|||||||2013-10-30|2013-10-31|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Interventional|HATT||Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients|A Phase IV, Single-arm, Open-label Study of Sorafenib (Nexavar®) in Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 4|151|Actual|Bayer||1|||f||||f||||||||||2018-05-31 23:55:53.035049|2018-05-31 23:55:53.035049
NCT01098747|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2012-07-12|2011-05-25|2012-07-12|2010-04-01|2010-04-05|Estimate|2012-07-12|2012-08-17|Estimate|2011-05-25|2011-06-02|Estimate|2012-07-12|2012-08-17|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain|Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain: Study I|Completed||Phase 3|335|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:55:53.200248|2018-05-31 23:55:53.200248
NCT01098734|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2011-06-09|2010-04-01|2010-04-05|Estimate|||||||2011-06-09|2011-06-13|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream|A 12-week Efficacy Evaluation of WBI-1001 Cream in Patients With Atopic Dermatitis: A Multi-centered, Double-blinded Study (6-week Placebo-controlled Phase Followed by a 6-week Non-placebo Controlled Phase).|Completed||Phase 2|148|Actual|Welichem Biotech Inc.||3|||f||||t||||||||||2018-05-31 23:55:54.97047|2018-05-31 23:55:54.97047
NCT01098721|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2012-12-18|2010-04-02|2010-04-05|Estimate|||||||2012-12-18|2012-12-20|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|134993||A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks|A Double-blinded, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Topically Applied 1.0% WBI-1001 Cream for 12 Weeks, in the Treatment of Mild to Moderate Plaque Psoriasis.|Completed||Phase 2|61|Actual|Welichem Biotech Inc.||2|||f||||t||||||||||2018-05-31 23:55:55.135042|2018-05-31 23:55:55.135042
NCT01098708|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2017-01-17|2010-04-01|2010-04-05|Estimate|||||||2017-01-17|2017-01-18|Estimate|March 2010||2010-03-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|DMD||This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy|Clinical Outcomes Validation in Non Ambulatory and Young Boys/Men With Duchenne Muscular Dystrophy (DMD)|Completed|||50|Actual|Washington University School of Medicine|||||f||||f||||||||No||2018-05-31 23:55:55.220512|2018-05-31 23:55:55.220512
NCT01098695|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-02|2010-04-02|2010-04-05|Estimate|||||||2010-04-02|2010-04-05|Estimate|March 2003||2003-03-31|April 2010|2010-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|Early Steps||Early Family-Centered Prevention of Drug Use Risk (Aka Early Steps)|Early Family-Centered Prevention of Drug Use Risk|Unknown status|Active, not recruiting|N/A|731|Actual|University of Oregon||2|||f||||f||||||||||2018-05-31 23:55:55.297938|2018-05-31 23:55:55.297938
NCT01098682|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2017-04-21|2010-04-01|2010-04-05|Estimate|||||||2017-04-21|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:55:55.39461|2018-05-31 23:55:55.39461
NCT01098669|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2017-04-06|2010-04-02|2010-04-05|Estimate|||||||2017-04-06|2017-04-07|Actual|December 2009||2009-12-31|April 2017|2017-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Impact of Secondary Lymphedema on Symptoms, Functional Status, and Quality of Life After Treatment in Patients With Head and Neck Cancer|The Impact of Secondary Lymphedema After Head and Neck Cancer Treatment on Symptoms, Functional Status, and Quality of Life|Completed|||103|Actual|Vanderbilt University|||||f||||f||||||||||2018-05-31 23:55:55.440489|2018-05-31 23:55:55.440489
NCT01098656|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2016-07-06|2010-04-02|2010-04-05|Estimate|||||||2016-07-06|2016-07-07|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Lenalidomide Maintenance Post-debulking in Advanced CTCL|A Phase III Study of Lenalidomide Maintenance After Debulking Therapy in Patients With Advanced Cutaneous T-Cell Lymphoma|Terminated||Phase 3|21|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||"recruitment prematurely halted following company's decision to stop financial support to the~   study"|f||||t||||||||||2018-05-31 23:55:55.509432|2018-05-31 23:55:55.509432
NCT01098643|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2017-03-30|2010-04-02|2010-04-05|Estimate|||||||2017-03-30|2017-04-04|Actual|October 2009|Actual|2009-10-31|March 2010|2010-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Satisfaction With Placement of Implantable Venous Access Devices in Patients With Solid Tumors|Patient Satisfaction With Placement of Implantable Venous Access Devices|Terminated||N/A|88|Actual|Vanderbilt University Medical Center||||not enough pts for available to reach goal|f||||f||||||||No|never published, terminated|2018-05-31 23:55:55.646593|2018-05-31 23:55:55.646593
NCT01098630|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2018-04-11|2010-04-02|2010-04-05|Estimate|||||||2018-04-11|2018-04-12|Actual|July 2010||2010-07-31|April 2018|2018-04-30|January 27, 2018|Actual|2018-01-27|May 2012|Actual|2012-05-31||Observational|||Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer|Patient, Physician And Nurse Factors Associated With Entry Onto Clinical Trials And Completion Of Treatment For Women With Primary Or Recurrent Invasive Cancer Of The Uterine Corpus Or Uterine Cervix, All Stages|Completed|||778|Actual|Gynecologic Oncology Group|||2||f||||||||||||||2018-05-31 23:55:55.768025|2018-05-31 23:55:55.768025
NCT01098617|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-02|2010-04-02|2010-04-05|Estimate|||||||2010-04-02|2010-04-05|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Observational|||Antihemostatic Therapy and Endoscopic Biliary Sphincterotomy Induced Bleeding|The Effect of Antiaggregant, Anticoagulant and Nonsteroidal Antiinflammatory Therapy on Endoscopic Biliary Sphincterotomy Induced Bleeding|Unknown status|Recruiting||350|Anticipated|Yuksek Ihtisas Hospital|||1||f||||t||||||||||2018-05-31 23:55:56.124823|2018-05-31 23:55:56.124823
NCT01098604|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-03-19|2010-04-02|2010-04-05|Estimate|||||||2014-03-19|2014-03-20|Estimate|May 2006||2006-05-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|November 2007|Actual|2007-11-30||Interventional|THA||The Comparison of 32mm and 28mm Head Components in Alumina-alumina Total Hip Arthroplasty|The Comparison of 32mm and 28mm Head Components in Alumina-alumina Total Hip Arthroplasty: A Randomized Clinical Trial|Completed||Phase 4|120|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 23:55:56.18493|2018-05-31 23:55:56.18493
NCT01098591|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-03-01|2010-04-02|2010-04-05|Estimate|||||||2015-03-01|2015-03-03|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|ACCRUE||Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE|Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE|Unknown status|Recruiting||1000|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 23:55:56.253969|2018-05-31 23:55:56.253969
NCT01098578|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2013-06-04||2015-01-21|2010-04-01|2010-04-02|Estimate|2015-01-21|2015-01-26|Estimate||||2015-01-21|2015-01-26|Estimate|April 2010||2010-04-30|January 2015|2015-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Floseal Treatment for Posterior Epistaxis Study|Floseal Posterior Epistaxis Pilot Study (PEPIS)|Completed||N/A|20|Actual|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-05-31 23:55:56.379161|2018-05-31 23:55:56.379161
NCT01098565|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2013-08-01|2010-04-01|2010-04-02|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Deep Brain Stimulation Effects Study|Deep Brain Stimulation Effects: Human Proof-of-Concept Study|Terminated||Phase 1|6|Actual|MedtronicNeuro||1||"The goal of collecting proof-of-concept information was met through additional modeling~   studies, new published evidence and information collected from the study"|f||||t||||||||||2018-05-31 23:55:56.56588|2018-05-31 23:55:56.56588
NCT01098552|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2013-01-09|2010-04-01|2010-04-02|Estimate|||||||2013-01-09|2013-01-11|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up|Participation in Procurement of Tissue, Serum, Plasma, Cell Bank, DNA and RNA Samples, and Urine for Biological Studies Related to Prostate Cancer and Prostate Cancer Treatment Follow Up|Completed|||4900|Actual|Mayo Clinic|||6||f||||f||||||Samples With DNA|"~     Blood, urine, prostate tissue~   "|||2018-05-31 23:55:56.621647|2018-05-31 23:55:56.621647
NCT01098539|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2014-04-17|2012-11-21|2017-01-16|2010-04-01|2010-04-02|Estimate|2014-04-17|2014-05-16|Estimate|2012-11-21|2012-11-27|Estimate|2017-01-16|2017-02-28|Actual|May 2010||2010-05-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.|A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment|Completed||Phase 3|507|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:55:56.916104|2018-05-31 23:55:56.916104
NCT01098526|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-09-21|2010-04-01|2010-04-02|Estimate|||||||2017-09-21|2017-09-25|Actual|March 16, 2010|Actual|2010-03-16|September 2017|2017-09-30|May 26, 2010|Actual|2010-05-26|May 26, 2010|Actual|2010-05-26||Interventional|||GSK1349572 Drug Interaction Study With Efavirenz|A Phase 1, Open Label, Single Sequence, Three Period Study to Evaluate the Single Dose Pharmacokinetics of GSK1349572 100mg Versus 50mg and the Effect of Efavirenz 600mg Once Daily on the Pharmacokinetics, Safety and Tolerability of GSK1349572 50mg Once Daily in Healthy Adult Subjects (ING114005)|Completed||Phase 1|12|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 23:55:59.343259|2018-05-31 23:55:59.343259
NCT01098513|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2017-06-08|2010-04-01|2010-04-02|Estimate|||||||2017-06-08|2017-06-09|Actual|April 2010||2010-04-30|February 2011|2011-02-28|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||GSK1349572 Relative Bioavailability Study|Relative Bioavailability Study of Three Different Tablet Formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in Healthy Male and Female Volunteers (ING113674)|Completed||Phase 1|24|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 23:55:59.519153|2018-05-31 23:55:59.519153
NCT01098500|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2011-05-02||2017-05-25|2010-04-01|2010-04-02|Estimate|2011-06-09|2011-07-07|Estimate||||2017-05-25|2017-05-30|Actual|February 2009||2009-02-28|May 2017|2017-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs|Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs Using the LabRx Database|Completed|||3800|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 23:56:00.544423|2018-05-31 23:56:00.544423
NCT01098487|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2015-01-05||2015-02-26|2010-04-01|2010-04-02|Estimate|2015-02-26|2015-03-12|Estimate||||2015-02-26|2015-03-12|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||All Treated Subjects (ATS) Population: all participants who received at least one dose of study medication excluding the 5 participants from Center 082877.|A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Completed||Phase 4|167|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:56:00.927664|2018-05-31 23:56:00.927664
NCT01098474|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18||2012-07-26|2016-10-12|2010-04-01|2010-04-02|Estimate||||2012-07-26|2012-08-03|Estimate|2016-10-12|2016-10-13|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|April 2011|Actual|2011-04-30||Interventional|||Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants|Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants|Completed||Phase 2|302|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 23:56:01.73711|2018-05-31 23:56:01.73711
NCT01098461|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2014-04-24|2012-02-16|2016-11-29|2010-04-01|2010-04-02|Estimate|2014-05-29|2014-07-01|Estimate|2012-02-16|2012-02-20|Estimate|2016-11-29|2017-01-13|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Dose Ranging Study of Albiglutide in Japanese Subjects|A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus|Completed||Phase 2|215|Actual|GlaxoSmithKline||4|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:56:01.912693|2018-05-31 23:56:01.912693
NCT01098448|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-01|2010-04-01|2010-04-02|Estimate|||||||2010-04-01|2010-04-02|Estimate|September 1999||1999-09-30|April 2010|2010-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Control of Periodontal Infections|Control of Periodontal Infections|Completed||Phase 3|187|Actual|The Forsyth Institute||8|||f||||f||||||||||2018-05-31 23:56:02.844063|2018-05-31 23:56:02.844063
NCT01098435|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01||2011-08-18|2011-08-18|2010-04-01|2010-04-02|Estimate||||2011-08-18|2011-08-23|Estimate|2011-08-18|2011-08-23|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Pilot Study of the Safety and Efficacy of RDC-0313 in Adults With Binge Eating Disorder|Completed||Phase 2|69|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 23:56:02.976064|2018-05-31 23:56:02.976064
NCT01098422|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2015-06-04|2010-04-01|2010-04-02|Estimate|||||||2015-06-04|2015-06-08|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver|A Phase II Study of Yttrium-90 Radioactive Resin Microspheres in the Treatment of Colorectal Adenocarcinoma Metastatic to the Liver After Failure of First-Line Combination Chemotherapy|Terminated||Phase 2|10|Actual|University of California, San Diego||1||Halted due to slow enrollment|f||||t||||||||||2018-05-31 23:56:03.129666|2018-05-31 23:56:03.129666
NCT01098409|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2010-04-01|2010-04-01|2010-04-02|Estimate|||||||2010-04-01|2010-04-02|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|||Nitrite Mediated Cardioprotection During Coronary Artery Bypass Surgery|Mechanisms of Nitrite Mediated Cardioprotection in Coronary Artery Bypass Surgery|Unknown status|Recruiting|Phase 2|50|Anticipated|University Hospital Birmingham NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 23:56:03.253825|2018-05-31 23:56:03.253825
NCT01098396|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-01|2010-04-01|2010-04-02|Estimate|||||||2010-04-01|2010-04-02|Estimate|May 2010||2010-05-31|September 2009|2009-09-30||||||||Observational|||Rasagiline for Gait Treatment|Rasagiline for the Treatment of Gait Disturbances in Patients With Parkinson´S Disease (PD): an Open Label Study|Unknown status|Not yet recruiting||10|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-05-31 23:56:03.355339|2018-05-31 23:56:03.355339
NCT01098383|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-10-13|2010-04-01|2010-04-02|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders|Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism|Recruiting||Phase 4|84|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:56:03.43128|2018-05-31 23:56:03.43128
NCT01098357|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-12-12|2010-04-01|2010-04-02|Estimate|||||||2014-12-12|2014-12-15|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Interventional|||Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer|A Phase I/II, Multicentre, Randomised, Controlled, and Open-label Trial Comparing the Efficacy and Safety of Three Dose Regimens of BioChaperone PDGF-BB to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer|Completed||Phase 1/Phase 2|192|Actual|Virchow Group||4|||f||||f||||||||||2018-05-31 23:56:03.531561|2018-05-31 23:56:03.531561
NCT01098344|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2015-10-13|2010-04-01|2010-04-02|Estimate|||||||2015-10-13|2015-10-14|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery|A Cancer Research UK Phase I Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage III and IV Pancreatic Cancer|Completed||Phase 1|44|Actual|Cancer Research UK|||||f||||||||||||||2018-05-31 23:56:03.644485|2018-05-31 23:56:03.644485
NCT01098331|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2011-02-18|2010-04-01|2010-04-02|Estimate|||||||2011-02-18|2011-02-21|Estimate|May 2009||2009-05-31|March 2010|2010-03-31||||November 2011|Anticipated|2011-11-30||Interventional|||Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer|Surgery and Brachytherapy: A Randomized Evaluation. Randomized Controlled Trial of Brachytherapy Versus Radical Prostatectomy in Good Risk Prostate Cancer: A Feasibility Study|Unknown status|Recruiting|N/A|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:56:03.734668|2018-05-31 23:56:03.734668
NCT00888251|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2011-09-21|2009-04-24|2009-04-27|Estimate|||||||2011-09-21|2011-09-23|Estimate|March 2009||2009-03-31|September 2011|2011-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Evaluation of a Weight Management Program|A Multicenter, Retrospective Study to Evaluate the Effectiveness of the OPTIFAST Weight Management Program|Completed|||153|Actual|Nestlé|||1||f||||f||||||||||2018-06-01 01:02:22.817407|2018-06-01 01:02:22.817407
NCT01098318|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2015-07-20||2018-01-24|2010-04-01|2010-04-02|Estimate|2016-04-11|2016-05-18|Estimate||||2018-01-24|2018-02-21|Estimate|June 2010||2010-06-30|January 2018|2018-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Rhodiola Rosea Therapy of Major Depressive Disorder|Rhodiola Rosea Therapy of Major Depressive Disorder|Completed||Phase 3|58|Actual|University of Pennsylvania|Subjects refuse to answer measures such as the RUSH sexual inventory and the CSSR. Therefore, no statistical analysis was performed on these. In addition, suicidal ideation (measured by CSSR) was captured in the AE form during the study peiod.|3|||f||||t||||||||||2018-05-31 23:56:03.817056|2018-05-31 23:56:03.817056
NCT01098305|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2015-05-26||2015-07-09|2010-04-01|2010-04-02|Estimate|2015-05-26|2015-06-09|Estimate||||2015-07-09|2015-07-30|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy of Varenicline for Smokeless Tobacco Use in India|Efficacy of Varenicline for Smokeless Tobacco Use in India|Completed||Phase 2|237|Actual|University of Pennsylvania|Sample size and reduced power; lack of long-term assessments; a priori inclusion of covariates in prediction models; adherence to medication was low.|2|||f||||f||||||||||2018-05-31 23:56:04.26197|2018-05-31 23:56:04.26197
NCT01098292|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-12-08|2010-04-01|2010-04-02|Estimate|||||||2014-12-08|2014-12-10|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Observational|MAPP-Control||Observational Study of Control Participants for the MAPP Research Network|Multidisciplinary Approach to the Study of Chronic Pelvic Pain: Trans-MAPP Control Study|Completed|||615|Actual|University of Pennsylvania|||2||f||||t||||||Samples With DNA|"~     DNA Blood Urine~   "|||2018-05-31 23:56:04.491829|2018-05-31 23:56:04.491829
NCT01098279|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-12-08|2010-04-01|2010-04-02|Estimate|||||||2014-12-08|2014-12-10|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Observational|MAPP-EP||Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis|Multidisciplinary Approach to the Study of Chronic Pelvic Pain: Trans-MAPP Epidemiology and Phenotyping (EP) Study|Completed|||424|Actual|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     DNA Blood Urine~   "|||2018-05-31 23:56:04.570727|2018-05-31 23:56:04.570727
NCT01098266|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-12-20|2010-04-01|2010-04-02|Estimate|||||||2017-12-20|2017-12-22|Actual|March 2010||2010-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed|NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM)|Completed||Phase 3|400|Actual|MolMed S.p.A.||2|||f||||t||||||||||2018-05-31 23:56:04.677183|2018-05-31 23:56:04.677183
NCT01098253|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2011-11-29||2012-02-08|2010-04-01|2010-04-02|Estimate|2012-02-08|2012-03-09|Estimate||||2012-02-08|2012-03-09|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Integrating Depression Services Into DM Management|Integrating Depression Services Into Type 2 Diabetes Mellitus Management|Completed||N/A|182|Actual|University of Pennsylvania|Our primary care sites might not be representative of most primary care practices. Patients in the usual care group did not have the same number of in person contacts as those in the integrated care intervention to control for attention.|2|||f||||t||||||||||2018-05-31 23:56:04.817187|2018-05-31 23:56:04.817187
NCT01098240|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2012-09-18||2013-07-18|2010-04-01|2010-04-02|Estimate|2013-05-17|2013-06-26|Estimate||||2013-07-18|2013-07-26|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression|A Randomized Phase 2a, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression|Terminated||Phase 2|297|Actual|Pfizer||2||See termination reason in detailed description.|f||||t||||||||||2018-05-31 23:56:05.09048|2018-05-31 23:56:05.09048
NCT01098227|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-12-23|2010-04-01|2010-04-02|Estimate|||||||2015-12-23|2015-12-28|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Exhaled Nitric Oxide Levels in Infants and Young Children Infected With RSV or Other Viral Infections|A Prospective Study Measuring Exhaled Nitric Oxide Levels in Infants and Young Children Admitted to the Hospital for Respiratory Syncytial Virus (RSV) or Other Viral Lower Respiratory Tract Infections|Withdrawn|||0|Actual|Winthrop University Hospital|||3|The equipment to be used for the study was inoperable and not repairable.|f||||t||||||None Retained|"~     Exhaled air for Nitric Oxide measurement~   "|||2018-05-31 23:56:06.17225|2018-05-31 23:56:06.17225
NCT01098214|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-12-09|2010-04-01|2010-04-02|Estimate|||||||2014-12-09|2014-12-11|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||The Role of Cytokines in Apparently Normal Pregnancies|The Role of Cytokines (and Other Biomarkers) in Apparently Normal Pregnancies|Withdrawn|||0|Actual|Winthrop University Hospital||||Decided not to pursue study at this time. Resources not available|f||||f||||||Samples With DNA|"~     Amniotic fluid samples from patients undergoing amniocentesis with an apparently normal~     pregnancy will have a small aliquot of fluid stored for future analysis, including the~     cytokine profile, proteomics, metabolomics, etc.~   "|||2018-05-31 23:56:06.243064|2018-05-31 23:56:06.243064
NCT01098201|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-09-17|2010-04-01|2010-04-02|Estimate|||||||2015-09-17|2015-09-21|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)|The Effect of Certolizumab on Lower Extremity Lymph Flow in Rheumatoid Arthritis|Completed|||5|Actual|University of Rochester|||||f||||f||||||||||2018-05-31 23:56:06.29375|2018-05-31 23:56:06.29375
NCT01098188|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2012-04-27|2010-04-01|2010-04-02|Estimate|||||||2012-04-27|2012-04-30|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia|Open, Non-controlled, Multicentre, First-in-man Study Using Escalating Doses of LFB-R603 in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia|Completed||Phase 1|33|Actual|Laboratoire français de Fractionnement et de Biotechnologies|||||f||||||||||||||2018-05-31 23:56:06.366922|2018-05-31 23:56:06.366922
NCT01098175|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-01|2010-04-01|2010-04-02|Estimate|||||||2010-04-01|2010-04-02|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Peritoneal Cavity Conditioning During Open Surgery.|Peritoneal Cavity Conditioning During Open Surgery Decreases Postoperative Pain and Inflammation and Decreases Time to Restore Transit|Unknown status|Not yet recruiting||40|Anticipated|Katholieke Universiteit Leuven|||2||f||||f||||||||||2018-05-31 23:56:06.447952|2018-05-31 23:56:06.447952
NCT01098162|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2014-06-24||2014-08-22|2010-04-01|2010-04-02|Estimate|2014-06-24|2014-07-22|Estimate||||2014-08-22|2014-09-03|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|VITOBA|Baseline characteristics refer to the Full Analysis Set (FAS) which comprises all patients who have been treated with Vimpat® at least once and for whom a valid value of seizure frequency is available.|Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug|A Non-interventional Post-marketing Study, Evaluating Seizure Control and Tolerability of Vimpat® as Adjunctive Therapy to One Baseline Antiepileptic Drug in Epilepsy Patients With Partial-onset Seizures With or Without Secondary Generalization in Daily Clinical Practice in Germany|Completed|||576|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 23:56:06.55359|2018-05-31 23:56:06.55359
NCT01098149|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-04-01|2010-04-01|2010-04-02|Estimate|||||||2010-04-01|2010-04-02|Estimate|March 2006||2006-03-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|THIRD||Tolerance to Hemodialysis in Insulin-Requiring Diabetic Patients: BD vs AFB With Blood Volume Biofeedback|Tolerance to Hemodialysis in Insulin-Requiring Diabetic Patients: a Prospective Randomized,Cross-over Multicenter Study Between Bicarbonate Dialysis (BD) and Blood Volume Controlled Acetate-Free Biofiltration (BVC-AFB)|Completed||N/A|55|Actual|Università degli Studi di Brescia||2|||f||||t||||||||||2018-05-31 23:56:07.112641|2018-05-31 23:56:07.112641
NCT01098136|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2012-08-30|2010-04-01|2010-04-02|Estimate|||||||2012-08-30|2012-08-31|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Pelvic Girdle Pain in a Pregnant Population in Western Norway.|A Study of Pelvic Girdle Pain in a Pregnant Population in Western Norway - Incidence, Cumulative Prevalence, Course and Intervention.|Completed||N/A|650|Actual|Helse Stavanger HF||3|||f||||f||||||||||2018-05-31 23:56:07.200416|2018-05-31 23:56:07.200416
NCT01098123|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-01|2010-04-01|2010-04-02|Estimate|||||||2010-04-01|2010-04-02|Estimate|April 2006||2006-04-30|February 2006|2006-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Metabolic Effects of Rowing Multi-races Events|Nutritional and Metabolic Context in Rowers|Completed|||45|Actual|University of Paris 5 - Rene Descartes|||2||f||||t||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 23:56:07.277568|2018-05-31 23:56:07.277568
NCT01098110|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2015-04-02||2017-06-01|2010-04-01|2010-04-02|Estimate|2015-04-02|2015-04-17|Estimate||||2017-06-01|2017-07-02|Actual|May 25, 2010|Actual|2010-05-25|June 2017|2017-06-30|April 14, 2014|Actual|2014-04-14|April 14, 2014|Actual|2014-04-14||Interventional||Participants who received at least one dose of trial medication.|6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)|A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)|Completed||Phase 3|532|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:56:07.377241|2018-05-31 23:56:07.377241
NCT01098097|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2012-10-17||2014-11-14|2010-04-01|2010-04-02|Estimate|2012-10-17|2012-11-20|Estimate||||2014-11-14|2014-11-26|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|POMOSCH||Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)|Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin|Completed|||963|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-05-31 23:56:07.953|2018-05-31 23:56:07.953
NCT01098084|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2014-03-19|2010-04-01|2010-04-02|Estimate|||||||2014-03-19|2014-03-20|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)|A Phase II Study of Decitabine in Patients With Chronic Myelomonocytic Leukemia|Completed||Phase 2|41|Actual|Groupe Francophone des Myelodysplasies||1|||f||||t||||||||||2018-05-31 23:56:08.18601|2018-05-31 23:56:08.18601
NCT01098071|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2011-06-13||2017-09-15|2010-04-01|2010-04-02|Estimate|2011-10-20|2011-11-29|Estimate||||2017-09-15|2017-10-17|Actual|August 1, 2008|Actual|2008-08-01|September 2017|2017-09-30|September 1, 2009|Actual|2009-09-01|September 1, 2009|Actual|2009-09-01||Interventional|NAHCh||Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)|Open Label Pilot Trial, Evaluating the Role of Nasonex in the Management of Nasal Obstruction Secondary to Adenoids Hypertrophy in Children|Completed||Phase 4|34|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 23:56:08.415692|2018-05-31 23:56:08.415692
NCT01098058|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2016-04-18|2010-04-01|2010-04-02|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Cognitive-Behavioural Therapy (CBT) for Adult Attention Deficit Hyperactivity Disorder (ADHD)|A Proof of Concept Randomised Controlled Trial to Examine the Potential Efficacy, Patient Acceptability and Feasibility of Cognitive-behavioural Therapy for Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|60|Actual|South London and Maudsley NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 23:56:08.693767|2018-05-31 23:56:08.693767
NCT01098045|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2016-03-14|2010-04-01|2010-04-02|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|June 2014|Actual|2014-06-30||Observational|||HIV Fat Redistribution and the Evaluation of Brown Fat|FDG/PET Imaging for the Assessment of Brown Adipose Tissue in HIV Lipodystrophy|Completed|||27|Actual|Massachusetts General Hospital|||4||f||||f||||||Samples With DNA|"~     Blood tests will include a complete blood count, creatinine, SGPT TSH and Free T4,~     triglyceride, total, HDL and LDL cholesterol, HIV test, CD4 count (for HIV+ subjects only),~     HIV viral load (for HIV+ subjects only), fasting glucose, 2 hour OGTT, as well as tissue~     samples from fat biopsy.~   "|||2018-05-31 23:56:08.797006|2018-05-31 23:56:08.797006
NCT01098032|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2015-02-05||2017-02-08|2010-04-01|2010-04-02|Estimate|2015-03-07|2015-03-10|Estimate||||2017-02-08|2017-03-16|Actual|January 2009||2009-01-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|REMEDIALII||RenalGuard System and Contrast Media|Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury|Completed||Phase 3|292|Actual|Clinica Mediterranea||2|||f||||t||||||||||2018-05-31 23:56:08.902123|2018-05-31 23:56:08.902123
NCT01098019|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2012-04-20|2010-04-01|2010-04-02|Estimate|||||||2012-04-20|2012-04-23|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Treatment of Notalgia Paresthetica With Xeomin|Efficacy and Safety of Xeomin for the Treatment of Notalgia Paresthetica|Completed||Phase 3|20|Actual|Innovaderm Research Inc.||2|||f||||f||||||||||2018-05-31 23:56:09.215849|2018-05-31 23:56:09.215849
NCT01098006|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2017-05-24||2017-05-24|2010-04-01|2010-04-02|Estimate|2017-05-24|2017-12-18|Actual||||2017-05-24|2017-12-18|Actual|April 29, 2010|Actual|2010-04-29|May 2017|2017-05-31|February 20, 2012|Actual|2012-02-20|February 20, 2012|Actual|2012-02-20||Interventional|||A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays|A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays|Completed||N/A|99|Actual|GlaxoSmithKline||4|||f|||||f|f||||||||2018-05-31 23:56:09.467809|2018-05-31 23:56:09.467809
NCT01097993|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2017-01-18|2010-04-01|2010-04-02|Estimate|||||||2017-01-18|2017-01-20|Estimate|February 2010||2010-02-28|January 2017|2017-01-31|January 2014|Actual|2014-01-31|June 2012|Actual|2012-06-30||Interventional|||A Single-centre, Randomised, Double-blind, Controlled, Parallel-group Study to Evaluate the Effect of a Fermented Dairy Product on Abdominal Distension, Digestive Symptoms and Rectal Sensitivity in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)||Completed||N/A|120|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 23:56:11.308791|2018-05-31 23:56:11.308791
NCT01097980|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2012-04-23|2010-04-01|2010-04-02|Estimate|||||||2012-04-23|2012-04-24|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|T-SSRI-SD||Trazodone for SSRI-sexual Dsyfunction|The Efficacy of Trazodone for Selective Serotonin Reuptake Inhibitor-induced Sexual Dysfunction|Completed||N/A|56|Actual|Beitou Armed Forces Hospital, Taipei, Taiwan||2|||f||||t||||||||||2018-05-31 23:56:11.364103|2018-05-31 23:56:11.364103
NCT01097967|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2015-10-23|2010-04-01|2010-04-02|Estimate|||||||2015-10-23|2015-10-26|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|SAS-CARE||Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy|Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm|Unknown status|Active, not recruiting|Phase 4|246|Actual|Ospedale Civico, Lugano||3|||f||||f||||||||||2018-05-31 23:56:12.436298|2018-05-31 23:56:12.436298
NCT01097954|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2013-06-13|2010-04-01|2010-04-02|Estimate|||||||2013-06-13|2013-06-14|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma|A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma|Completed|||22|Actual|Winthrop University Hospital|||||f||||t||||||||||2018-05-31 23:56:12.53201|2018-05-31 23:56:12.53201
NCT01097941|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-09-22|2010-04-01|2010-04-02|Estimate|||||||2015-09-22|2015-09-24|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|H1N1Children||Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children|Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated A/California/07/09 H1N1 Influenza Vaccines in Children|Withdrawn||Phase 4|0|Actual|University of Rochester||3||Live H1N1 vaccine expired and unable to get new supply|f||||f||||||||||2018-05-31 23:56:12.600229|2018-05-31 23:56:12.600229
NCT01097928|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2018-04-16|2010-03-31|2010-04-02|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2010||2010-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: PERFECT|Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: The PERFECT Registry|Recruiting|||100|Anticipated|Stanford University|||1||f||||||||||||||2018-05-31 23:56:12.691285|2018-05-31 23:56:12.691285
NCT01097915|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|2016-07-19||2017-11-06|2010-04-01|2010-04-02|Estimate|2016-10-26|2016-12-21|Estimate||||2017-11-06|2017-12-15|Actual|October 2009||2009-10-31|November 2017|2017-11-30|June 2016|Actual|2016-06-30|December 2009|Actual|2009-12-31||Observational|gustinprop|Caucasian and were originally from Sardinia, Italy. Participants between 20-30 years were eligible for the study.|Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste|Sensitivity to 6-n-propylthiouracil (PROP) Association With Gustin (CA6) Gene Polymorphism, Salivary Zinc and BMI in Humans|Completed|||170|Actual|University of Cagliari|||1||f||||f||||||Samples With DNA|"~     DNA and zinc analyses in saliva~   "|Undecided|Data of this study are available from the principal investigator of this study upon request|2018-05-31 23:56:12.784565|2018-05-31 23:56:12.784565
NCT01097902|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2013-06-18|2010-04-01|2010-04-02|Estimate|||||||2013-06-18|2013-06-19|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of Experimental Models of Pain and Inflammation.|Experimental Inflammatory and Micro-incisional Pain Model Analysis by Gene Expression and Interstitial Fluid Proteomics of Skin Tissue|Completed||Phase 1|15|Actual|Stanford University||2|||f||||||||||||||2018-05-31 23:56:13.272548|2018-05-31 23:56:13.272548
NCT01097889|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-03-31|2010-03-31|2010-04-02|Estimate|||||||2010-03-31|2010-04-02|Estimate|April 2009||2009-04-30|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|November 2009|Actual|2009-11-30||Interventional|||Evaluating the Relative Effectiveness of Two Feeding Interventions for the Treatment of Moderate Acute Malnutrition|Evaluating the Relative Effectiveness of Two Feeding Interventions for the Treatment of Moderate Acute Malnutrition in Children 6-60 Months of Age in Southern Ethiopia|Unknown status|Active, not recruiting|N/A|2600|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:56:13.357868|2018-05-31 23:56:13.357868
NCT01097876|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-08-03|2010-03-31|2010-04-02|Estimate|||||||2010-08-03|2010-08-04|Estimate|April 2010||2010-04-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Of PF-04447943 When Administered With Donepezil To Healthy Volunteer Subjects|A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Healthy Volunteers When Combined With Donepezil|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:56:13.440446|2018-05-31 23:56:13.440446
NCT01097863|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|2011-05-27||2012-06-26|2010-03-31|2010-04-02|Estimate|2011-05-27|2011-06-27|Estimate||||2012-06-26|2012-07-10|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Clinical Validation of the New Print on Focus DAILIES Toric||Completed||N/A|280|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 23:56:13.54371|2018-05-31 23:56:13.54371
NCT01097850|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2014-12-11|2010-04-01|2010-04-02|Estimate|||||||2014-12-11|2014-12-12|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Topical Henna Preparation for the Treatment of Hand Foot Skin Syndrome|Prospective Randomized Controlled Open-label Trial of a Topical Henna Preparation for the Treatment of Hand-Foot Skin Syndrome and Its Associated Symptoms|Withdrawn||Phase 2|0|Actual|Northwestern University||2||No subject accrual.|f||||t||||||||||2018-05-31 23:56:13.763742|2018-05-31 23:56:13.763742
NCT01097837|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2015-10-14|2010-04-01|2010-04-02|Estimate|||||||2015-10-14|2015-10-16|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|EBCR||Epilepsy Birth Control Registry|Epilepsy Birth Control Registry|Unknown status|Recruiting||1000|Anticipated|Neuroendocrine Associates P.C.|||1||f||||f||||||||||2018-05-31 23:56:13.83088|2018-05-31 23:56:13.83088
NCT01097811|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-04-27|2010-03-31|2010-04-02|Estimate|||||||2010-04-27|2010-04-28|Estimate|June 2008||2008-06-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy|Erythromycin Versus Neomycin Treatment for Overt Hepatic Encephalopathy: a Double-blind, Randomised, Controlled Trial.|Unknown status|Active, not recruiting|N/A|20|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||||2018-05-31 23:56:13.950041|2018-05-31 23:56:13.950041
NCT01097798|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-15|2010-04-01|2010-04-02|Estimate|||||||2010-04-15|2010-04-16|Estimate|June 2010||2010-06-30|February 2010|2010-02-28|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|LBB-ALI-01/09||To Evaluate the Efficacy and Safety Aliviador Compared to Gelol in Patients With Contusions, Sprains, Trauma and Muscle Injury.|Multicenter, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety Aliviador Compared to Gelol in the Relief in Patients With Contusons, Sprains,Trauma and Muscle Injury.|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Laboratorio Brasileiro de Biologia||2|||f||||t||||||||||2018-05-31 23:56:14.029802|2018-05-31 23:56:14.029802
NCT01097785|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2015-08-20||2016-09-29|2010-03-31|2010-04-02|Estimate|2016-09-29|2016-11-21|Estimate||||2016-09-29|2016-11-21|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Quality muscle sympathteic nerve activity recordings obtained in 6 patients.|Targeting Sympathetic Overactivity in Heart Failure Patients With Statins|Targeting Sympathetic Overactivity in Heart Failure Patients With Statins|Completed||N/A|12|Actual|University of Missouri-Columbia||2|||f||||t||||||||||2018-05-31 23:56:14.123421|2018-05-31 23:56:14.123421
NCT01097772|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2015-11-04|2010-03-31|2010-04-02|Estimate|||||||2015-11-04|2015-11-06|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2010|Actual|2010-09-30||Interventional|||TriVascular European Union (EU) Abdominal Stent Graft Trial|A Clinical Study to Evaluate the Safety and Performance of the TriVascular Ovation™ Abdominal Stent Graft System|Completed||Phase 2|30|Actual|TriVascular, Inc.||1|||f||||t||||||||||2018-05-31 23:56:14.317926|2018-05-31 23:56:14.317926
NCT01097759|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2010-04-01|2010-04-01|2010-04-02|Estimate|||||||2010-04-01|2010-04-02|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Observational|||LigaSure Hemorrhoidectomy Versus Stapled Hemorrhoidopexy|LigaSure Hemorrhoidectomy vs Stapled Hemorrhoidopexy: a Prospective Randomized Clinical Trial|Completed|||115|Actual|Kuwait Oil Company Ahmadi Hospital|||2||f||||t||||||||||2018-05-31 23:56:14.381366|2018-05-31 23:56:14.381366
NCT01097746|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-10-25|2010-04-01|2010-04-02|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2010|Actual|2010-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer|A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma|Active, not recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:56:14.541364|2018-05-31 23:56:14.541364
NCT01097733|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2014-06-22|2010-03-31|2010-04-02|Estimate|||||||2014-06-22|2014-06-24|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|September 2016|Anticipated|2016-09-30|September 2014|Anticipated|2014-09-30||Observational|DIRECT||Dual-Source Computed Tomography to Improve Prediction of Response to Cardiac Resynchronization Therapy|Dual-Source Computed Tomography to Improve Prediction of Response to Cardiac Resynchronization Therapy|Unknown status|Active, not recruiting||60|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 23:56:14.632908|2018-05-31 23:56:14.632908
NCT01097720|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-03-31|2010-03-31|2010-04-02|Estimate|||||||2010-03-31|2010-04-02|Estimate|March 2005||2005-03-31|March 2010|2010-03-31|September 2010|Anticipated|2010-09-30|January 2010|Actual|2010-01-31||Observational|||Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine|Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine, Sodium Valproate, or Carbamazepine|Unknown status|Active, not recruiting||298|Actual|Massachusetts General Hospital|||3||f||||f||||||||||2018-05-31 23:56:14.704442|2018-05-31 23:56:14.704442
NCT01097707|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31||2012-02-10|2012-02-10|2010-03-31|2010-04-02|Estimate||||2012-02-10|2012-02-14|Estimate|2012-02-10|2012-02-14|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study in Men With Benign Prostatic Hyperplasia|A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)|Terminated||Phase 2|414|Actual|Eli Lilly and Company||5||Terminated due to insufficient efficacy|f||||t||||||||||2018-05-31 23:56:14.794034|2018-05-31 23:56:14.794034
NCT01097694|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2017-04-04||2017-05-15|2010-03-31|2010-04-02|Estimate|2017-05-15|2017-05-19|Actual||||2017-05-15|2017-05-19|Actual|November 2010||2010-11-30|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|KIA|severe asthmatics ages 18-65|Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)|A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)|Completed||Phase 2|176|Actual|Brigham and Women's Hospital||2|||f||||t||||||||Undecided||2018-05-31 23:56:15.05319|2018-05-31 23:56:15.05319
NCT01097681|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2016-01-18|2010-03-31|2010-04-02|Estimate|||||||2016-01-18|2016-01-20|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment|An Open-Label Study to Assess the Effect of Different Grades of Renal Impairment in Japanese Patients With Type 2 Diabetes Mellitus on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP1941 Relative to Type 2 Diabetes Mellitus Patients With Normal Renal Function|Completed||Phase 1|25|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 23:56:15.922242|2018-05-31 23:56:15.922242
NCT01097668|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|2014-12-23||2015-02-03|2010-03-31|2010-04-02|Estimate|2015-02-03|2015-02-16|Estimate||||2015-02-03|2015-02-16|Estimate|March 2010||2010-03-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||>=18 and <=55 years Gender, female and male|ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis|SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).|Completed||Phase 1|43|Actual|Apitope Technology (Bristol) Ltd.||2|||f||||t||||||||||2018-05-31 23:56:16.00297|2018-05-31 23:56:16.00297
NCT01097655|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2017-01-18||2017-05-18|2010-03-31|2010-04-02|Estimate|2017-05-18|2017-05-23|Actual||||2017-05-18|2017-05-23|Actual|August 2006||2006-08-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet|Use of KALETRA® Tablets in Adult HIV-infected Patients: Data From the Multicenter Star/Stella Cohort|Completed|||3049|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:56:16.405908|2018-05-31 23:56:16.405908
NCT01097642|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2016-09-12|2010-03-31|2010-04-01|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ICE||Neo-Adjuvant Study in Triple Negative Breast Cancer Patients|Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cetuximab (IC) in Triple Negative Breast Cancer Patients|Active, not recruiting||Phase 2|40|Actual|The Methodist Hospital System||2|||f||||t||||||||Undecided|Plan to share data to be determined|2018-05-31 23:56:16.955789|2018-05-31 23:56:16.955789
NCT01097629|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2014-08-19||2017-06-01|2010-03-31|2010-04-01|Estimate|2014-08-19|2014-09-01|Estimate||||2017-06-01|2017-07-02|Actual|May 3, 2010|Actual|2010-05-03|June 2017|2017-06-30|November 8, 2011|Actual|2011-11-08|November 8, 2011|Actual|2011-11-08||Interventional|||Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study B|Completed||Phase 3|1020|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 23:56:17.083595|2018-05-31 23:56:17.083595
NCT01097616|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2014-08-19||2017-06-01|2010-03-31|2010-04-01|Estimate|2014-08-19|2014-09-01|Estimate||||2017-06-01|2017-07-02|Actual|May 5, 2010|Actual|2010-05-05|June 2017|2017-06-30|December 7, 2011|Actual|2011-12-07|September 9, 2011|Actual|2011-09-09||Interventional|||Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study A|Completed||Phase 3|1023|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 23:56:18.157443|2018-05-31 23:56:18.157443
NCT01097603|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-03-31|2010-03-31|2010-04-01|Estimate|||||||2010-03-31|2010-04-01|Estimate||||March 2010|2010-03-31||||||||Observational|||Larsen & Toubro (L&T) Noninvasive Blood Pressure Module Performance Validation|L&T Noninvasive Blood Pressure Module Performance Validation|Completed|||||Larsen & Toubro Limited|||||f||||f||||||||||2018-05-31 23:56:19.606185|2018-05-31 23:56:19.606185
NCT01097590|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2013-08-20|2010-03-31|2010-04-01|Estimate|||||||2013-08-20|2013-08-21|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||A Study to Evaluate a Leukapheresis Treatment in Patients With Ulcerative Colitis|A Randomized Placebo Controlled, Single Centre Study to Evaluate a Novel Leukapheresis Treatment in Patients With Ulcerative Colitis.|Completed||Phase 1|23|Actual|IBD Column Therapies International AB||2|||f||||f||||||||||2018-05-31 23:56:19.655686|2018-05-31 23:56:19.655686
NCT01097577|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-06-21|2010-03-31|2010-04-01|Estimate|||||||2010-06-21|2010-06-22|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Comparison of Pregabalin (Lyrica®) to Placebo in Pain Relief After Photorefractive Keratectomy (PRK) Surgery|A Comparison of Pregabalin (Lyrica®) to Placebo in Postoperative Pain Relief of Patients Status-post Photorefractive Keratectomy: A Double-masked Randomized Prospective Study|Completed||N/A|150|Anticipated|Wilford Hall Medical Center||2|||f||||t||||||||||2018-05-31 23:56:19.731042|2018-05-31 23:56:19.731042
NCT01097564|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-01-14|2010-03-31|2010-04-01|Estimate|||||||2016-01-14|2016-01-15|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|COL4A1||COL4A1 Gene Related Cerebra-retinal Angiopathy|COL4A1 Gene Related Cerebra-retinal Angiopathy : Clinical Spectrum From Children to Adult, Mutational Spectrum and Application to Routine Management of Affected Patients : a Prospective Cohort Study|Completed|||132|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 23:56:19.818084|2018-05-31 23:56:19.818084
NCT01097551|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2012-07-02|2010-03-31|2010-04-01|Estimate|||||||2012-07-02|2012-07-03|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|DENDI||Endothelial Dysfunction and Diabetes|Assessment of Endothelial Dysfunction in Retinal and Peripheral Retinal Vessels in Diabetes|Completed|||38|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 23:56:19.890117|2018-05-31 23:56:19.890117
NCT01097538|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2011-08-11|2010-03-31|2010-04-01|Estimate|||||||2011-08-11|2011-08-12|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Study of Alternative Exercise Therapies for Progressive Multiple Sclerosis (MS)|Total Body Recumbent Stepper Training in Progressive MS: An Alternative Training Therapy for Patients With Impaired Mobility|Completed||N/A|10|Actual|Hicks, Audrey, Ph.D.||2|||f||||f||||||||||2018-05-31 23:56:19.973286|2018-05-31 23:56:19.973286
NCT01097525|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2015-03-12|2010-03-31|2010-04-01|Estimate|||||||2015-03-12|2015-03-13|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery|Optical Quality, Threshold Target Identification, and Military Target Task Performance After Advanced Keratorefractive Surgery|Completed||N/A|224|Actual|Fort Belvoir Community Hospital||4|||f||||t||||||||||2018-05-31 23:56:20.045907|2018-05-31 23:56:20.045907
NCT01097512|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2014-01-29|2010-03-31|2010-04-01|Estimate|||||||2014-01-29|2014-01-30|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|February 2011|Actual|2011-02-28|July 2010|Actual|2010-07-31||Interventional|||AS703569 and Gemcitabine Combination in Advanced Malignancies|A Phase I, Dose-escalation Study of a Combination AS703569 and Gemcitabine Given to Subjects With Advanced Malignancies|Completed||Phase 1|66|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:56:20.129344|2018-05-31 23:56:20.129344
NCT01097499|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-03-31|2010-03-31|2010-04-01|Estimate|||||||2010-03-31|2010-04-01|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|||Low Level Laser (LED) Use to Increase Dental Implant Stability and Post Operative Analgesia|Role of Light Emitting Diode on Implant Stability, Bone Resorption and Analgesia Post Dental Implant Placement|Unknown status|Not yet recruiting|N/A|60|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-05-31 23:56:20.21467|2018-05-31 23:56:20.21467
NCT01097486|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2016-12-15|2010-03-31|2010-04-01|Estimate|||||||2016-12-15|2016-12-19|Estimate|June 2010||2010-06-30|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy|Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation|Completed||Phase 2|24|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-05-31 23:56:20.291027|2018-05-31 23:56:20.291027
NCT01097473|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-03-31|2010-03-31|2010-04-01|Estimate|||||||2010-03-31|2010-04-01|Estimate|April 1996||1996-04-30|March 2010|2010-03-31|March 1998|Actual|1998-03-31|January 1998|Actual|1998-01-31||Interventional|||Long Term Physical Training in Asthma|Effects of Long Term Physical Training Once a Week on Fitness and Quality of Life in Elderly Asthmatics|Completed||N/A|24|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 23:56:20.450033|2018-05-31 23:56:20.450033
NCT01097460|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2014-12-01||2014-12-18|2010-03-31|2010-04-01|Estimate|2014-12-01|2014-12-04|Estimate||||2014-12-18|2015-01-07|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer|MM-111-02-12-02: A Phase 1 Study of MM-111 in Combination With Herceptin in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Breast Cancer|Completed||Phase 1|16|Actual|Merrimack Pharmaceuticals||1|||f||||f||||||||||2018-05-31 23:56:20.522905|2018-05-31 23:56:20.522905
NCT01097447|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2017-02-01|2010-03-31|2010-04-01|Estimate|||||||2017-02-01|2017-02-03|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Recruiting|||500|Anticipated|Cxlusa|||3||f||||f||||||||||2018-05-31 23:56:20.739665|2018-05-31 23:56:20.739665
NCT01097434|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2012-01-12|2010-03-31|2010-04-01|Estimate|||||||2012-01-12|2012-01-13|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|TEST-6-OCT||Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence Tomography|Randomized Comparison of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coating Regarding Stent Coverage Assessed by Optical Coherence Tomography|Completed||Phase 4|48|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 23:56:20.800115|2018-05-31 23:56:20.800115
NCT01097421|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2012-09-14||2014-03-14|2010-03-31|2010-04-01|Estimate|2012-10-25|2012-11-26|Estimate||||2014-03-14|2014-04-11|Estimate|March 2010||2010-03-31|March 2014|2014-03-31||||September 2011|Actual|2011-09-30||Observational||Full analysis set (FAS)|Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease|Influence of Pramipexole Extended Release on Medication Adherence in Real Life Care of Parkinson's Disease|Completed|||329|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 23:56:20.933686|2018-05-31 23:56:20.933686
NCT01097408|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2010-08-06|2010-03-31|2010-04-01|Estimate|||||||2010-08-06|2010-08-09|Estimate|March 2010||2010-03-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Pharmacokinetics of AZD7295 Capsules|A Randomised, Double-Blind, Placebo-Controlled Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD7295 Capsules in Healthy Volunteers|Completed||Phase 1|12|Actual|Arrow Therapeutics||2|||f||||t||||||||||2018-05-31 23:56:21.137414|2018-05-31 23:56:21.137414
NCT01097395|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2017-06-19|2010-03-31|2010-04-01|Estimate|||||||2017-06-19|2017-06-21|Actual|February 2010||2010-02-28|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection|Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection|Completed||Phase 4|15|Actual|University of Colorado, Denver||2|||f||||f|t|f|||f|||||2018-05-31 23:56:21.199876|2018-05-31 23:56:21.199876
NCT01097382|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2012-07-16|2010-03-31|2010-04-01|Estimate|||||||2012-07-16|2012-07-17|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|MORFEO CR||Sleep Satisfaction and Psychomotor Performance of Adults|National, Multicenter, Open Label, Phase IV, Before-after Design Study, in Adult Patients With Primary Insomnia to Evaluate Sleep Satisfaction and Psychomotor Performance After 1 Month of Treatment With Zolpidem CR (Ambien®CR) in 6 Sites in Argentina|Completed||Phase 4|30|Actual|Sanofi||1|||f||||||||||||||2018-05-31 23:56:21.271205|2018-05-31 23:56:21.271205
NCT01097369|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2013-01-30|2010-03-31|2010-04-01|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Elitek (Rasburicase) Immuno-Monitoring Study|A Multicenter Registry Study of Anti-rasburicase Antibodies in Patients Retreated With Rasburicase (SR29142) in the Context of Relapsing Leukemia/Lymphoma Who Experienced Subsequent Hypersensitivity Reaction(s) or Loss of Uricolytic Activity: An Immuno-Monitoring Observational Study|Terminated|||1|Actual|Sanofi|||1|business decision due to low subject recruitment|f||||||||||||||2018-05-31 23:56:21.337624|2018-05-31 23:56:21.337624
NCT01097356|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-04-22|2010-03-31|2010-04-01|Estimate|||||||2010-04-22|2010-04-23|Estimate|April 2010||2010-04-30|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Effect of Probiotics on the Clearance of the Human Papillomavirus and on Cytological Lesions Caused by the Virus||Unknown status|Recruiting|N/A|60|Anticipated|Universiteit Antwerpen||2|||f||||f||||||||||2018-05-31 23:56:21.395953|2018-05-31 23:56:21.395953
NCT01097343|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2012-07-09||2017-11-14|2010-03-31|2010-04-01|Estimate|2014-02-26|2014-03-26|Estimate||||2017-11-14|2017-12-12|Actual|March 2010||2010-03-31|February 2014|2014-02-28|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Clopidogrel Pharmacogenomics Project|Clopidogrel Pharmacogenomics Project|Completed||Phase 2|50|Actual|University of North Carolina, Chapel Hill||2|||f||||||||||||||2018-05-31 23:56:21.457387|2018-05-31 23:56:21.457387
NCT01097330|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2011-08-04|2010-03-31|2010-04-01|Estimate|||||||2011-08-04|2011-08-05|Estimate|August 2010||2010-08-31|August 2011|2011-08-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|CEASE-VT||Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia|Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia: A Multi-center Randomized Trial|Terminated||Phase 3|12|Actual|Population Health Research Institute||2||Anticipated non-feasibility of recruitment objectives|f||||f||||||||||2018-05-31 23:56:21.647795|2018-05-31 23:56:21.647795
NCT01097317|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2011-08-05|2010-03-31|2010-04-01|Estimate|||||||2011-08-05|2011-08-08|Estimate|September 2009||2009-09-30|September 2010|2010-09-30||||September 2011|Anticipated|2011-09-30||Interventional|||First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer|NMES for Patients With NSCLC Receiving Palliative Chemotherapy. Is Neuromuscular Electrical Stimulation an Acceptable and Feasible Supportive Therapy for Patients With Non-Small Cell Lung Cancer Receiving Palliative Chemotherapy?|Unknown status|Recruiting|Phase 2|52|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:56:22.003526|2018-05-31 23:56:22.003526
NCT01097304|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|2015-04-29||2017-11-22|2010-03-31|2010-04-01|Estimate|2015-04-29|2015-05-15|Estimate||||2017-11-22|2017-12-19|Actual|April 2010||2010-04-30|November 2017|2017-11-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia|Clinical Study of Ursodeoxycholic Acid in Barrett's Patients|Completed||Phase 2|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:56:22.13541|2018-05-31 23:56:22.13541
NCT01097278|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2017-11-21|2010-03-31|2010-04-01|Estimate|||||||2017-11-21|2017-11-24|Actual|November 1, 2011|Actual|2011-11-01|November 2017|2017-11-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer|Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer|Completed||N/A|208|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 23:56:22.46055|2018-05-31 23:56:22.46055
NCT01097265|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2013-08-09|2010-03-31|2010-04-01|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2010||2010-07-31|September 2011|2011-09-30||||January 2015|Anticipated|2015-01-31||Interventional|||Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery|The Influence of Micrometastases on Prognosis and Survival in Stage I-II Colon Cancer Patients: The EnRoute+ Study|Unknown status|Recruiting|Phase 2/Phase 3|1500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:56:23.063283|2018-05-31 23:56:23.063283
NCT01097252|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2014-05-07|2010-03-31|2010-04-01|Estimate|||||||2014-05-07|2014-05-09|Estimate|January 2002||2002-01-31|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2004|Actual|2004-12-31||Interventional|||Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer|Randomized Trial of Concurrent Chemoradiation With Weekly Versus Three-week Cisplatin in Patients With Advanced Cervical Cancer|Completed||Phase 3|104|Actual|Korea Cancer Center Hospital||2|||f||||f||||||||||2018-05-31 23:56:23.29049|2018-05-31 23:56:23.29049
NCT01097239|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2016-09-15|2010-03-31|2010-04-01|Estimate|||||||2016-09-15|2016-09-16|Estimate|November 2009||2009-11-30|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer|A Phase I/II Feasibility/Efficacy Study of HIFU in Otherwise Untreatable Pelvic Rectal Cancer|Recruiting||Phase 1/Phase 2|50|Anticipated|Imperial College London||1|||f||||t||||||||||2018-05-31 23:56:23.36973|2018-05-31 23:56:23.36973
NCT01097226|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2013-03-05|2010-03-31|2010-04-01|Estimate|||||||2013-03-05|2013-03-06|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|POLYMALUS||Bioavailability and Vascular Effects of Apple Polyphenols|Bioavailability and Vascular Effects of Apple Polyphenols|Completed||N/A|12|Actual|Quadram Institute||1|||f||||f||||||||||2018-05-31 23:56:23.473402|2018-05-31 23:56:23.473402
NCT01097213|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-03-11|2010-03-31|2010-04-01|Estimate|||||||2013-03-11|2013-03-12|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Neural Mechanisms Underlying Alcohol Induced Disinhibition|Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 2: To Examine the Effect of Acute Alcohol Administration on Forebrain Disinhibition Using Functional Magnetic Resonance Imaging (fMRI)|Completed|||50|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-05-31 23:56:23.549498|2018-05-31 23:56:23.549498
NCT01097200|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2018-03-17|2010-03-31|2010-04-01|Estimate|||||||2018-03-17|2018-03-20|Actual|May 2010||2010-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|November 2016|Actual|2016-11-30||Interventional|||Sacrocolpopexy Versus Vaginal Mesh Procedure for Pelvic Prolapse|Anatomic and Functional Outcomes of Vaginal Mesh ( ELEVATE) Compared With Laparoscopic Sacrocolpopexy for Pelvic Organ Prolapse|Active, not recruiting||N/A|60|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||Yes|First article has been submitted to the European Urology on feb 13th 2017|2018-05-31 23:56:23.632081|2018-05-31 23:56:23.632081
NCT01097174|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2017-05-12|2010-03-30|2010-04-01|Estimate|||||||2017-05-12|2017-05-15|Actual|December 2009||2009-12-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|CyCLE||CyPass Clinical Experience Study|A Multicenter Registry Study to Capture Data With Respect to CyPass Clinical Experience|Completed|||555|Actual|Alcon Research|||1||f||||f||||||||||2018-05-31 23:56:23.721688|2018-05-31 23:56:23.721688
NCT01097161|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-04-01|2010-03-31|2010-04-01|Estimate|||||||2010-04-01|2010-04-02|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|June 2008|Actual|2008-06-30|October 2007|Actual|2007-10-31||Interventional|SAS:EIP||Stuttering and Apraxia of Speech: the Efficacy of an Intervention Program|The Speech Prosody of People With Stuttering and Developmental Apraxia: the Efficacy of an Intervention Program|Completed||N/A|4|Actual|Federal University of Minas Gerais||1|||f||||t||||||||||2018-05-31 23:56:23.889599|2018-05-31 23:56:23.889599
NCT01097148|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-31|||2010-10-12|2010-03-31|2010-04-01|Estimate|||||||2010-10-12|2010-10-13|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|POP-II||Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients|Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients|Completed||Phase 4|20|Actual|St. Antonius Hospital||2|||f||||||||||||||2018-05-31 23:56:23.997492|2018-05-31 23:56:23.997492
NCT01097135|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2013-09-16|2010-03-30|2010-04-01|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||Evaluating the Effectiveness of 2 Surgical Skin Preparation Methods in Reducing Surgical Wound Drainage After Total Hip or Knee Replacement|Prospective, Randomized Clinical Study to Evaluate the Efficacy of 2 Surgical Skin Preparations in Reducing Wound Drainage Following Total Joint Arthroplasty|Completed||N/A|600|Anticipated|Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 23:56:24.083804|2018-05-31 23:56:24.083804
NCT01097122|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-27|||2012-02-24|2010-03-31|2010-04-01|Estimate|||||||2012-02-24|2012-02-27|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|BMRR3||Effects Of Unilateral Vibration On Contralateral Forearm Muscle Activity|Effects Of Unilateral Forearm Vibration On Electrical Activity Of Untrained Contralateral Forearm Muscle|Completed||N/A|90|Actual|Vakif Gureba Training and Research Hospital||1|||f||||t||||||||||2018-05-31 23:56:24.158692|2018-05-31 23:56:24.158692
NCT01097109|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-04-21|2010-03-30|2010-04-01|Estimate|||||||2012-04-21|2012-04-24|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||The Effect of Somatic Dysfunction of the Pelvis, Sacrum and Lower Lumbar Spine on Weight Bearing|The Effect of Somatic Dysfunction of the Pelvis, Sacrum and Lower Lumbar Spine on Weight Bearing|Completed|||111|Actual|Nova Southeastern University|||||f||||f||||||||||2018-05-31 23:56:24.235975|2018-05-31 23:56:24.235975
NCT01097096|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29||2016-03-22|2016-03-22|2010-03-30|2010-04-01|Estimate||||2016-03-22|2016-04-25|Estimate|2016-03-22|2016-04-25|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients|A 90-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study in Patients With Mild Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Abeta-specific Antibody Response Following Repeated i.m. Injections of Adjuvanted CAD106|Completed||Phase 2|177|Actual|Novartis||9|||f||||||||||||||2018-05-31 23:56:24.311243|2018-05-31 23:56:24.311243
NCT01097083|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2014-01-13|2010-03-31|2010-04-01|Estimate|||||||2014-01-13|2014-01-14|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma|A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy|Terminated||Phase 2|20||National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 23:56:24.455034|2018-05-31 23:56:24.455034
NCT01097070|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-30|2010-03-30|2010-04-01|Estimate|||||||2010-03-30|2010-04-01|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days|A Phase II Multicenter, Open-label, Randomized, Parrallel Group Study to Assess the Pharmacokinetics of Bevirimat (BVM) 100 mg Tablets Administered to HIV-1 Positive Patients for 15 Days|Completed||Phase 2|35|Actual|Myrexis Inc.||3|||f||||f||||||||||2018-05-31 23:56:24.526195|2018-05-31 23:56:24.526195
NCT01097057|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2017-03-26||2017-12-28|2010-03-30|2010-04-01|Estimate|2017-06-01|2017-07-02|Actual||||2017-12-28|2018-01-23|Actual|November 9, 2010|Actual|2010-11-09|December 2017|2017-12-31|December 26, 2017|Actual|2017-12-26|September 2013|Actual|2013-09-30||Interventional|||Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells|Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor|Completed||Phase 2|20|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||No||2018-05-31 23:56:24.608424|2018-05-31 23:56:24.608424
NCT01097044|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2013-03-21|2010-03-30|2010-04-01|Estimate|||||||2013-03-21|2013-03-25|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)|A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)|Completed||Phase 2|77|Actual|Clinuvel Pharmaceuticals Limited||2|||f||||t||||||||||2018-05-31 23:56:24.823989|2018-05-31 23:56:24.823989
NCT01097031|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2010-03-31|2010-03-31|2010-04-01|Estimate|||||||2010-03-31|2010-04-01|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|April 2009|Actual|2009-04-30|||||Observational|UP4061||Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomized Clinical Trial|Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomized Clinical Trial|Completed|||140|Actual|Instituto de Cardiologia do Rio Grande do Sul|||3||f||||f||||||||||2018-05-31 23:56:24.900807|2018-05-31 23:56:24.900807
NCT01097018|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30||2013-06-18|2013-06-25|2010-03-30|2010-04-01|Estimate||||2013-06-18|2013-06-26|Estimate|2013-06-25|2013-07-02|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|X-PECT||Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer|A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer|Completed||Phase 3|468|Actual|AEterna Zentaris||2|||f||||t||||||||||2018-05-31 23:56:24.970063|2018-05-31 23:56:24.970063
NCT01097005|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2015-06-17||2016-07-28|2010-03-30|2010-04-01|Estimate|2016-07-28|2016-09-19|Estimate||||2016-07-28|2016-09-19|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections|Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections|Completed|||466|Actual|Mylan Inc.|||1||f||||f||||||||Yes|Please contact the investigator, and discuss with us.|2018-05-31 23:56:25.105225|2018-05-31 23:56:25.105225
NCT01096992|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2017-04-03|2010-03-30|2010-03-31|Estimate|||||||2017-04-03|2017-04-05|Actual|April 19, 2010|Actual|2010-04-19|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)|A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 1/Phase 2|54|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 23:56:25.650841|2018-05-31 23:56:25.650841
NCT01096979|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16||2015-03-05|2015-03-05|2010-03-30|2010-03-31|Estimate||||2015-03-05|2015-03-26|Estimate|2015-03-05|2015-03-26|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity|A Double-Masked, Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity|Completed||Phase 2|60|Actual|Neothetics, Inc||3|||f||||f||||||||||2018-05-31 23:56:25.745745|2018-05-31 23:56:25.745745
NCT01096966|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30||2011-08-16|2012-05-24|2010-03-30|2010-03-31|Estimate||||2011-08-16|2011-08-23|Estimate|2012-05-24|2012-06-01|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Bupivacaine TTS (Bupivacaine Patch) in Patients With Chronic Low Back Pain|Completed||Phase 2|263|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:56:25.904289|2018-05-31 23:56:25.904289
NCT01096953|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2010-03-30|2010-03-30|2010-03-31|Estimate|||||||2010-03-30|2010-03-31|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Telepsychiatry in Rural Youth|A Randomized Exploratory Study of Telepsychiatry Outcomes in Rural Youth|Unknown status|Not yet recruiting|N/A|50|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 23:56:26.032218|2018-05-31 23:56:26.032218
NCT01096940|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2010-11-05|2010-03-30|2010-03-31|Estimate|||||||2010-11-05|2010-11-08|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin|A Randomized, Open-label, 3-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Simvastatin During Coadministration With AZD1656 and to Evaluate the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin|Completed||Phase 1|44|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 23:56:26.139567|2018-05-31 23:56:26.139567
NCT01096927|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2011-07-26|2010-03-30|2010-03-31|Estimate|||||||2011-07-26|2011-07-27|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|NOTA||Non Operative Treatment for Acute Appendicitis|Non Operative Treatment for Acute Appendicitis: Study on Efficacy and Safety of Antibiotic Treatment (Amoxicillin and Clavulanic Acid) in Patients With Right Sided Lower Abdominal Pain|Completed||Phase 4|160|Actual|Maggiore Bellaria Hospital, Bologna||1|||f||||f||||||||||2018-05-31 23:56:26.239953|2018-05-31 23:56:26.239953
NCT01096914|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2014-01-28|2010-03-30|2010-03-31|Estimate|||||||2014-01-28|2014-01-30|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|September 2012|Actual|2012-09-30||Interventional|||Radiofrequency Versus Laser Ablation for Hepatocellular Carcinoma|Radiofrequency Ablation Versus Laser Ablation for the Treatment of Small Hepatocellular Carcinoma: a Randomized Controlled Trial|Completed||N/A|140|Actual|Cardarelli Hospital||2|||f||||f||||||||||2018-05-31 23:56:26.380563|2018-05-31 23:56:26.380563
NCT01096901|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-10-26|2010-03-30|2010-03-31|Estimate|||||||2015-10-26|2015-10-28|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CTL||Choose to Lose for Women-Weight Loss to Reduce Breast Cancer Risk Factors|Weight Loss to Reduce Breast Cancer Risk Factors|Completed||Early Phase 1|19|Actual|California Polytechnic State University-San Luis Obispo||2|||f||||f||||||||||2018-05-31 23:56:26.478616|2018-05-31 23:56:26.478616
NCT01096888|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-10-26|2010-03-30|2010-03-31|Estimate|||||||2015-10-26|2015-10-28|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|FM||Fit Moms- an Internet-based Postpartum Weight Loss Program|FFit Moms- an Internet-based Postpartum Weight Loss Program|Completed||Early Phase 1|25|Actual|California Polytechnic State University-San Luis Obispo||2|||f||||f||||||||||2018-05-31 23:56:26.557697|2018-05-31 23:56:26.557697
NCT01096875|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|2013-02-10||2014-07-04|2010-03-30|2010-03-31|Estimate|2014-07-04|2014-07-09|Estimate||||2014-07-04|2014-07-09|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery|Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial|Completed||Phase 4|60|Actual|Ankara University|The major limitation of this study is lack of functional assessment of EPCs using in vitro analysis of colony forming units because of the financial constraints.|2|||f||||t||||||||||2018-05-31 23:56:26.663561|2018-05-31 23:56:26.663561
NCT01096862|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18||2012-07-18|2012-07-18|2010-03-30|2010-03-31|Estimate||||2012-07-18|2012-07-25|Estimate|2012-07-18|2012-07-25|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis|A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|124|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 23:56:27.051117|2018-05-31 23:56:27.051117
NCT01096849|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12||2013-07-09|2013-07-09|2010-03-30|2010-03-31|Estimate||||2013-07-09|2013-07-12|Estimate|2013-07-09|2013-07-12|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Study of Plazomicin (ACHN-490) Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis|A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis|Completed||Phase 2|145|Actual|Achaogen, Inc.||3|||f||||f||||||||||2018-05-31 23:56:27.159924|2018-05-31 23:56:27.159924
NCT01096836|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-30|2010-03-30|2010-03-31|Estimate|||||||2010-03-30|2010-03-31|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|August 2008|Actual|2008-08-31|January 2008|Actual|2008-01-31||Interventional|LCD-RT||Low Carbohydrate and Conventional Diets Associated to Resistance Training on Muscle Fitness and Health Markers|Combined Effects of Resistance Training and Low Carbohydrate or Conventional Diets on Strength, Muscle Mass, Body Composition, Blood Lipids and Endothelium Function|Completed||N/A|21|Actual|Universidade Gama Filho||2|||f||||t||||||||||2018-05-31 23:56:27.265936|2018-05-31 23:56:27.265936
NCT01096823|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2016-02-11||2016-03-24|2010-03-30|2010-03-31|Estimate|2016-03-24|2016-04-27|Estimate||||2016-03-24|2016-04-27|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Iyengar Yoga for Young People With Rheumatoid Arthritis|Iyengar Yoga for Young People With Rheumatoid Arthritis|Completed||N/A|30|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:56:27.336547|2018-05-31 23:56:27.336547
NCT01096810|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2016-03-24||2016-06-14|2010-03-30|2010-03-31|Estimate|2016-06-14|2016-07-22|Estimate||||2016-06-14|2016-07-22|Estimate|September 2008||2008-09-30|June 2016|2016-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma|A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma|Terminated||Phase 2|20|Actual|Jagannath, Sundar, M.D.||1||The research is permanently closed to enrollment.|f||||f||||||||No||2018-05-31 23:56:27.566604|2018-05-31 23:56:27.566604
NCT01096797|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-30|2010-03-30|2010-03-31|Estimate|||||||2010-03-30|2010-03-31|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|e-PONB ENT||Correlation Between Pain and Emergence Delirium After Adenotonsillectomy in Preschool Children|Prospective Cohort Study Evaluating Incidence and Correlation Between Pain and Emergence Delirium After Adenotonsillectomy in Preschool Children|Completed||Phase 4|150|Actual|San Gerardo Hospital||1|||f||||f||||||||||2018-05-31 23:56:27.709476|2018-05-31 23:56:27.709476
NCT01096784|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2016-09-28||2017-05-04|2010-03-30|2010-03-31|Estimate|2017-05-04|2017-06-07|Actual||||2017-05-04|2017-06-07|Actual|June 1, 2010||2010-06-01|May 2017|2017-05-31|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Interventional||Intent-to-Treat (ITT) set included all enrolled participants for whom a randomization number was assigned.|IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity|Determination of the rhIGF-1/rhIGFBP-3 Dose, Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-1 Levels Within Physiological Levels in Premature Infants, to Prevent Retinopathy of Prematurity A Phase 2, Randomized Controlled, Assessor-blind, Dose Confirming, Pharmacokinetic, Safety and Efficacy, Multicenter Study|Completed||Phase 2|121|Actual|Shire||2|||f||||t||||||||||2018-05-31 23:56:27.796609|2018-05-31 23:56:27.796609
NCT01096771|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2014-03-26||2014-04-25|2010-03-30|2010-03-31|Estimate|2014-04-25|2014-05-26|Estimate||||2014-04-25|2014-05-26|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)|The Effect of Intravenous Lipid Emulsions on Lung Function in ARDS: A Pilot Study|Terminated||Phase 2|14|Actual|Methodist Research Institute, Indianapolis||2||Unable to secure product from international source, low recruitment rate.|f||||t||||||||||2018-05-31 23:56:28.746981|2018-05-31 23:56:28.746981
NCT01096758|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2013-09-09|2010-03-30|2010-03-31|Estimate|||||||2013-09-09|2013-09-10|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Observational|||Follow-up of Adult Phenylketonuria (PKU) Patients|5-year Follow-up of the Comparison of Life and Physical Health in Adult Patients With PKU and Healthy Age Matched Controls|Completed|||40|Actual|Ludwig-Maximilians - University of Munich|||2||f||||f||||||Samples With DNA|"~     blood cheek cells~   "|||2018-05-31 23:56:29.219017|2018-05-31 23:56:29.219017
NCT01096745|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2011-06-21|2010-03-30|2010-03-31|Estimate|||||||2011-06-21|2011-06-23|Estimate|July 2010||2010-07-31|June 2011|2011-06-30|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Interventional|||Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer|Randomized Phase II Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer Patients|Terminated||Phase 2|78|Anticipated|Gyeongsang National University Hospital||2||Planning for randomized phase III trial for this issue.|f||||f||||||||||2018-05-31 23:56:29.311552|2018-05-31 23:56:29.311552
NCT01096732|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2014-01-07|2010-03-30|2010-03-31|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HIPPoS||Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)|Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period|Terminated||Phase 2|3|Actual|Cambridge University Hospitals NHS Foundation Trust||1||Slow recruitment|f||||f||||||||||2018-05-31 23:56:29.544415|2018-05-31 23:56:29.544415
NCT01096719|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2018-04-03|2010-03-30|2010-03-31|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2010||2010-01-31|April 2018|2018-04-30|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|HEC4L||The Healthy Eating Choices for Life Program|The Effect of Diets Targeting Energy Density and Energy Restriction on Weight Loss and Feelings of Deprivation, Satisfaction, and Hunger During Behavioral Weight Loss Treatment.|Completed||N/A|45|Actual|The University of Tennessee, Knoxville||3|||f||||f||||||||||2018-05-31 23:56:29.756526|2018-05-31 23:56:29.756526
NCT01096706|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-05-14|2010-03-30|2010-03-31|Estimate|||||||2012-05-14|2012-05-15|Estimate|July 2011||2011-07-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 3)|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers|Completed||N/A|10|Actual|University of Edinburgh||5|||f||||f||||||||||2018-05-31 23:56:29.852691|2018-05-31 23:56:29.852691
NCT01096693|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-05-10|2010-03-30|2010-03-31|Estimate|||||||2012-05-10|2012-05-11|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 2)|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers|Suspended||N/A|12|Anticipated|University of Edinburgh||2||Awaiting supply of peptide from a different company|f||||f||||||||||2018-05-31 23:56:29.940802|2018-05-31 23:56:29.940802
NCT01096680|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2011-05-25||2012-04-11|2010-03-30|2010-03-31|Estimate|2011-05-25|2011-06-23|Estimate||||2012-04-11|2012-04-17|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss|A Phase 2, Randomized, Double-Blind, Single Center, Parallel Group, Placebo and Active Comparator, Controlled Study to Evaluate the Pharmacodynamic Profile of Single Doses of SPD489 in Healthy Adult Male Subjects Undergoing a Nocturnal Period of Acute Sleep Loss|Completed||Phase 2|135|Actual|Shire||5|||f||||f||||||||||2018-05-31 23:56:30.110739|2018-05-31 23:56:30.110739
NCT01096667|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2017-11-15|2013-04-10|2017-11-15|2010-03-30|2010-03-31|Estimate|2017-11-15|2017-12-13|Actual|2013-04-10|2013-04-16|Estimate|2017-11-15|2017-12-13|Actual|May 17, 2010|Actual|2010-05-17|November 2017|2017-11-30|February 25, 2011|Actual|2011-02-25|February 9, 2011|Actual|2011-02-09||Interventional||Baseline analysis population includes participants who received at least 1 dose of blinded treatment regimen.|Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)|A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic And Blood Pressure Control|Completed||Phase 2|194|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 23:56:31.439911|2018-05-31 23:56:31.439911
NCT01096654|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-07-15|2010-03-30|2010-03-31|Estimate|||||||2015-07-15|2015-07-16|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|SPARTACUS||SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan.|Towards Cost-effective Management of Patients With Hypertension Due to Primary Aldosteronism: Adrenal Vein Sampling or Ct-scan?|Completed||Phase 3|200|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 23:56:34.056408|2018-05-31 23:56:34.056408
NCT01096641|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-06-21|2010-03-30|2010-03-31|Estimate|||||||2012-06-21|2012-06-22|Estimate|April 2010||2010-04-30|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||An Explorative Study on Physiological and Neurophysiological Determinants of Fatigue in Cancer Survivors|An Explorative Study on Physiological and Neurophysiological Determinants of Fatigue in Cancer Survivors|Unknown status|Active, not recruiting|N/A|57|Anticipated|Radboud University||3|||f||||f||||||||||2018-05-31 23:56:34.134081|2018-05-31 23:56:34.134081
NCT01096628|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2014-01-30|2010-03-30|2010-03-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Chiropractic and Exercise for Low Back Pain in Adolescents|Chiropractic and Exercise for Low Back Pain in Adolescents|Completed||Phase 2/Phase 3|185|Actual|Northwestern Health Sciences University||2|||f||||t||||||||||2018-05-31 23:56:34.213047|2018-05-31 23:56:34.213047
NCT01096615|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-07-25|2010-03-30|2010-03-31|Estimate|||||||2012-07-25|2012-07-26|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|BionAtlanta||Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens|Evaluation of the Effect of Probiotic Lactobacillus Paracasei Lp-33 for the Management of Rhinitis in People Sensitized to Allergens. A Double Blind Randomized Parallel Placebo Controlled Study. (GA2LEN STUDY) BIONATLANTA Project|Completed||Phase 3|500|Actual|Merck Medication Familiale||2|||f||||f||||||||||2018-05-31 23:56:34.334212|2018-05-31 23:56:34.334212
NCT01096602|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2018-05-10|2010-03-30|2010-03-31|Estimate|||||||2018-05-10|2018-05-11|Actual|May 2010||2010-05-31|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission|Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission|Active, not recruiting||Phase 2|63|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 23:56:34.716998|2018-05-31 23:56:34.716998
NCT01096589|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|2012-07-20||2012-11-26|2010-03-30|2010-03-31|Estimate|2012-11-26|2012-11-27|Estimate||||2012-11-26|2012-11-27|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Assessment of 3M Oedema Reduction System in the Treatment of Lymphoedema Compared to Commercial Short-stretch Bandage|Preliminary Study to Assess the Effectiveness of 3M Oedema Reduction System in the Treatment of Lymphoedema Treatment Compared to Comprilan Short-stretch Bandage Compression Therapy|Completed||N/A|82|Actual|3M||4|||f||||f||||||||||2018-05-31 23:56:34.831054|2018-05-31 23:56:34.831054
NCT01096576|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2016-11-01|2010-03-30|2010-03-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Balapiravir in Patients With Dengue Virus Infection|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Dengue Virus Polymerase Inhibitor (Balapiravir) in Male Patients With Confirmed Dengue Virus Infection|Completed||Phase 1|64|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:56:35.416684|2018-05-31 23:56:35.416684
NCT01096563|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-12-02|2010-03-30|2010-03-31|Estimate|||||||2010-12-02|2010-12-03|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|JSMAD||A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD9164 After Administration of Single and Multiple Ascending Doses for 13 Days in Healthy Male and Female Japanese Subjects|Terminated||Phase 1|27|Anticipated|AstraZeneca||2||Sponsor has taken the decision to terminate further development of the compound|f||||f||||||||||2018-05-31 23:56:35.482983|2018-05-31 23:56:35.482983
NCT01096550|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2013-08-13||2015-03-25|2010-03-30|2010-03-31|Estimate|2013-08-13|2013-10-17|Estimate||||2015-03-25|2015-04-15|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||21 were from the discontinued site, 2 dropped because participant was non-regular treatment track, 1 voluntarily withdrew from the study, 1 was erroneously re-enrolled after being re-admitted to the same clinic, and 1 was erroneously re-enrolled, and 19 were not African American.|Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans|Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans|Completed||Phase 4|319|Actual|Friends Research Institute, Inc.|OP condition participants received more counseling services at the clinics as part of their regular care than was initially expected and IOP condition participants received slightly less that 9 hours of counseling, on average.|2|||f||||t||||||||||2018-05-31 23:56:35.559503|2018-05-31 23:56:35.559503
NCT01096537|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2016-07-04|2010-03-30|2010-03-31|Estimate|||||||2016-07-04|2016-07-06|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Observational|ABCD||Early Incidence of Occupational Asthma Among Bakers, Pastry-makers and Hairdressers|Evolution of the Incidence of Occupational Asthma at the Beginning of the Activity of Young Bakers, Pastry-makers and Hairdressers, and Exploration of Its Risk Factors|Completed|||866|Actual|Central Hospital, Nancy, France|||1||f||||f||||||Samples Without DNA|"~     whole blood, serum, plasma~   "|||2018-05-31 23:56:35.881474|2018-05-31 23:56:35.881474
NCT01096524|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-07-18|2010-03-30|2010-03-31|Estimate|||||||2014-07-18|2014-07-21|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|KneehabTKA||Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty|Phase III Study Investigating the Effects of 6-weeks of Neuromuscular Electrical Stimulation (NMES) Peri-total Knee Arthroplasty (TKA).|Completed||Phase 3|200|Anticipated|Bio-Medical Research, Ltd.||2|||f||||f||||||||||2018-05-31 23:56:35.962435|2018-05-31 23:56:35.962435
NCT01096511|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-06-20|2010-03-30|2010-03-31|Estimate|||||||2013-06-20|2013-06-21|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)|Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)|Completed|||1001|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-05-31 23:56:36.070217|2018-05-31 23:56:36.070217
NCT01096498|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2013-06-08|2010-03-30|2010-03-31|Estimate|||||||2013-06-08|2013-06-11|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|LEVEQ-2||Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel|Open-label, Randomized, Crossover Study to Prove Bioequivalence Between Opxion® (Levonorgestrel 0.75 mg From Bayer de Mexico) and Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers|Completed||Phase 1|24|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:56:36.161063|2018-05-31 23:56:36.161063
NCT01096485|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2013-06-09|2010-03-30|2010-03-31|Estimate|||||||2013-06-09|2013-06-11|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|LEVEQ-1||Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel|Open-label, Randomized, Crossover Study to Compare the Bioavailability of One Coated Tablet of Opxion® (Levonorgestrel 1.5 mg From Bayer de Mexico) vs. Two Tablets of Postday® (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers|Completed||Phase 1|24|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:56:36.236746|2018-05-31 23:56:36.236746
NCT01096472|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-07-05|2010-03-30|2010-03-31|Estimate|||||||2012-07-05|2012-07-09|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis|Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis|Completed||Phase 2|120|Actual|Almirall, S.A.||3|||f||||f||||||||||2018-05-31 23:56:36.355496|2018-05-31 23:56:36.355496
NCT01096459|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2013-07-31|2010-03-30|2010-03-31|Estimate|||||||2013-07-31|2013-08-02|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Nerve Rerouting Treatment for Neurogenic Bladder in Spina Bifida|Safety and Efficacy of Nerve Rerouting for Treating Neurogenic Bladder in Spina Bifida|Withdrawn||N/A|0|Actual|William Beaumont Hospitals||||Protocol as presented by investigator was not approved by the NIDDK.|f||||t||||||||||2018-05-31 23:56:36.445397|2018-05-31 23:56:36.445397
NCT01096446|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2013-11-25||2014-11-19|2010-03-30|2010-03-31|Estimate|2014-11-19|2014-11-20|Estimate||||2014-11-19|2014-11-20|Estimate|April 2008||2008-04-30|November 2014|2014-11-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional||Twelve infants were randomized into the experimental arm and 10 infants were randomized into the control arm.|Intravenous Fat Emulsions and Premature Infants|Tolerance of Higher Infusion Rates of Intravenous Fat Emulsions in Extremely Low Birthweight Infants During the First Week of Life|Terminated||N/A|19|Actual|OSF Healthcare System|This study was terminated early because 100% of the infants in the experimental grouped developed hypertriglyceridemia (>200 gm/dl), which did not support our primary hypothesis.|2||To many infants in the experimental group developed hypertriglyceridemia|f||||t||||||||||2018-05-31 23:56:36.518191|2018-05-31 23:56:36.518191
NCT01096433|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-01-24|2010-03-30|2010-03-31|Estimate|||||||2012-01-24|2012-01-26|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Circadian Variations of Prostaglandin in Sleep Apnea|Association of Circadian Variations,Sleep Architecture, Hypertension, and Prostaglandin in Sleep Apnea|Completed||N/A|64|Actual|Kyoto University||1|||f||||t||||||||||2018-05-31 23:56:36.801106|2018-05-31 23:56:36.801106
NCT01096420|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2013-08-12|2010-03-30|2010-03-31|Estimate|||||||2013-08-12|2013-08-14|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Acupuncture in Chronic Migraine: A Randomized Controlled Trial|Acupuncture in Chronic Migraine: A Randomized Controlled Trial|Completed||N/A|68|Actual|Kuang Tien General Hospital||2|||f||||f||||||||||2018-05-31 23:56:36.907091|2018-05-31 23:56:36.907091
NCT01096407|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2013-04-01|2010-03-30|2010-03-31|Estimate|||||||2013-04-01|2013-04-04|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel|The Role of COX-2 Mediated Prostaglandin Production on Paclitaxel-Induced Myalgias and Arthralgias.|Terminated|||5|Actual|Vanderbilt-Ingram Cancer Center|||1|slow accrual|f||||f||||||||||2018-05-31 23:56:37.004506|2018-05-31 23:56:37.004506
NCT01096394|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2015-12-09|2010-03-30|2010-03-31|Estimate|||||||2015-12-09|2015-12-10|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer|Orthotopic Propagation of Primary Human Ovarian Tumors for Preclinical Investigation of Novel Anti-Tumor Agents.|Completed|||20|Actual|Vanderbilt University|||1||f||||f||||||Samples With DNA|"~     Metastatic and primary tumor tissue.~   "|||2018-05-31 23:56:37.08888|2018-05-31 23:56:37.08888
NCT01096381|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2012-02-23|2010-03-30|2010-03-31|Estimate|||||||2012-02-23|2012-02-27|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Observational|||Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor|A Prospective Clinical Trial Evaluating Potential Biomarkers for Bevacizumab Induced Hypertension|Terminated|||8|Actual|Vanderbilt-Ingram Cancer Center|||2|funding withdrawn due to fellow's departure from VICC|f||||t||||||||||2018-05-31 23:56:37.162029|2018-05-31 23:56:37.162029
NCT01096368|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2017-09-08|2010-03-30|2010-03-31|Estimate|||||||2017-09-08|2017-09-12|Actual|March 2010||2010-03-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma|Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years|Recruiting||Phase 3|400|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 23:56:37.336536|2018-05-31 23:56:37.336536
NCT01096355|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2014-04-01|2010-03-30|2010-03-31|Estimate|||||||2014-04-01|2014-04-02|Estimate|February 2010||2010-02-28|December 2013|2013-12-31||||July 2012|Actual|2012-07-31||Interventional|||Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies|A Phase I Study of Various Administration Schedules of RO4929097 With Multi-parameter Assessment (Biomarkers, Pharmacokinetics, Pharmacodynamics) in Patients With Advanced Solid Cancers|Completed||Phase 1|28|Actual|National Cancer Institute (NCI)||6|||f||||||||||||||2018-05-31 23:56:38.07245|2018-05-31 23:56:38.07245
NCT01096342|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|2013-01-18||2014-06-02|2010-03-30|2010-03-31|Estimate|2013-01-18|2013-02-25|Estimate||||2014-06-02|2014-06-18|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional||A total of sixteen participants were accrued to the 50 mg/m^2 after the December 30, 2009 amendment (6 at MTD plus 10 phase II) and were grouped together as Phase II. Of these 16 particpants, one participant was excluded due to a major treatment violation.|Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:56:38.196605|2018-05-31 23:56:38.196605
NCT01096329|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2011-06-06|2010-03-30|2010-03-31|Estimate|||||||2011-06-06|2011-06-08|Estimate|February 2010||2010-02-28|June 2011|2011-06-30||||April 2010|Actual|2010-04-30||Interventional|||A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®|A Phase 1, Open-label, Randomized, Three-cohort, Two-period Crossover Study to Determine the Relative Bioavailability of Testosterone Following Application of Two Testosterone Transdermal Spray (TTS) Formulations Once Daily and Intrinsa® Patch Twice Weekly in Healthy, Surgically and Naturally Post-menopausal Women Receiving Estrogen Replacement Therapy|Terminated||Phase 1|16|Actual|VIVUS, Inc.||3|||f||||f||||||||||2018-05-31 23:56:38.443625|2018-05-31 23:56:38.443625
NCT01096316|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2014-06-27||2016-01-06|2010-03-29|2010-03-31|Estimate|2014-08-25|2014-08-27|Estimate||||2016-01-06|2016-02-04|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|DAWN|Baseline data from the intervention arms were examined for statistically significant differences using t tests, chi squares and logistic regression analyses.|Depression Attention for Women Now (The DAWN Study)|Reducing Disparities and Improving Care for Depression in OB-GYN Clinics: Depression Attention for Women Now (The DAWN Study)|Completed||N/A|205|Actual|University of Washington|Patients were recruited from university-affiliated OB/GYN clinics, which potentially limits generalizability to other OB/GYN populations; non-English speaking women were not included; and antidepressant adherence was based on self-report data.|2|||f||||t||||||||||2018-05-31 23:56:38.545097|2018-05-31 23:56:38.545097
NCT01096303|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2017-05-12|2010-03-30|2010-03-31|Estimate|||||||2017-05-12|2017-05-15|Actual|November 2010||2010-11-30|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Effects of Marijuana Used on Lung Function in Persons With Chronic Obstructive Pulmonary Disease (COPD)|Effects of Marijuana Smoking on Pulmonary Function in Patients With COPD|Completed|||200|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 23:56:38.819546|2018-05-31 23:56:38.819546
NCT01096290|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2013-06-26|2010-03-29|2010-03-31|Estimate|||||||2013-06-26|2013-06-28|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications|Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications|Completed||Phase 4|23|Actual|University of South Alabama||2|||f||||t||||||||||2018-05-31 23:56:38.895132|2018-05-31 23:56:38.895132
NCT01096277|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2010-03-30|2010-03-30|2010-03-31|Estimate|||||||2010-03-30|2010-03-31|Estimate|October 2010||2010-10-31|March 2010|2010-03-31|December 2012|Anticipated|2012-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Vascular Effects of Sitagliptin in Diabetes Mellitus|Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus|Unknown status|Not yet recruiting|Phase 4|70|Anticipated|Hannover Medical School||3|||f||||f||||||||||2018-05-31 23:56:38.999287|2018-05-31 23:56:38.999287
NCT01096264|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2015-03-06|2010-03-30|2010-03-31|Estimate|||||||2015-03-06|2015-03-09|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|ULTRAFASTECHO||Non-Invasive Quantitative Imaging of Human Local Arterial Wall Elasticity Using Supersonic Shear Imaging|Establishment of Local Arterial Stiffness Normal Values (Carotid and Femoral) on Healthy Volunteers Using Supersonic Shear Imaging|Completed||N/A|145|Actual|French Cardiology Society||2|||f||||f||||||||||2018-05-31 23:56:39.078204|2018-05-31 23:56:39.078204
NCT00883389|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2011-07-31||2014-12-01|2009-04-16|2009-04-17|Estimate|2012-07-17|2012-08-21|Estimate||||2014-12-01|2014-12-16|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Med-alert Bracelet in Chronic Kidney Disease|Safe Kidney Care Med-Alert Bracelet/Keytag|Completed|||26|Actual|University of Maryland|||1||f||||f||||||||||2018-06-01 01:04:20.767308|2018-06-01 01:04:20.767308
NCT01096251|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-30|||2010-03-30|2010-03-30|2010-03-31|Estimate|||||||2010-03-30|2010-03-31|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|STRATOB||STRATOB: a Randomized Controlled Clinical Trial of Cognitive Behavioural Therapy and Brief Strategic Therapy With Telecare for Binge-eating Disorder|Systemic and STRATegic Psychotherapy for OBesity|Unknown status|Active, not recruiting|N/A|100|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 23:56:39.171614|2018-05-31 23:56:39.171614
NCT01096238|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-04-11|2010-03-30|2010-03-31|Estimate|||||||2010-04-11|2010-04-13|Estimate|March 2010||2010-03-31|April 2010|2010-04-30||||||||Observational|||Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months|Follow-up of Immunogenicity of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers After 6 Months|Unknown status|Enrolling by invitation||185|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 23:56:39.234229|2018-05-31 23:56:39.234229
NCT01096225|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-04-09|2010-03-30|2010-03-31|Estimate|||||||2010-04-09|2010-04-12|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|August 2010|Anticipated|2010-08-31|April 2010|Anticipated|2010-04-30||Observational|||Immunogenicity Study of S-OIV H1N1 Influenza Vaccine|Study of Humoral and Cellular Immunogenicity of Split-vaccine to Swine-origin H1N1 Influenza|Unknown status|Active, not recruiting||20|Anticipated|Chinese Academy of Sciences|||1||f||||f||||||Samples Without DNA|"~     Serum Peripheral Blood Mononuclear Cell (PBMC)~   "|||2018-05-31 23:56:39.283822|2018-05-31 23:56:39.283822
NCT01096212|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-30|2010-03-30|2010-03-31|Estimate|||||||2010-03-30|2010-03-31|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia|A Multi-center, Open-Label, Randomized, Active-controlled, Parallel, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia|Completed||Phase 4|178|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 23:56:39.348039|2018-05-31 23:56:39.348039
NCT01096199|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2014-01-21|2010-03-30|2010-03-31|Estimate|||||||2014-01-21|2014-01-22|Estimate||||January 2014|2014-01-31||||September 2012|Actual|2012-09-30||Interventional|||A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)|A Phase I Study of TS-1, Cisplatin & RAD001 (Everolimus)|Terminated||Phase 1|35||National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 23:56:39.421132|2018-05-31 23:56:39.421132
NCT01096186|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2015-12-09|2013-09-27|2017-01-30|2010-03-30|2010-03-31|Estimate|2016-02-04|2016-03-03|Estimate|2013-09-27|2013-10-28|Estimate|2017-01-30|2017-03-10|Actual|March 2010||2010-03-31|January 2017|2017-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||All enrolled subjects|An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease|An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease|Completed||Phase 3|617|Actual|IMPAX Laboratories, Inc.||1|||f||||f||||||||No||2018-05-31 23:56:39.520446|2018-05-31 23:56:39.520446
NCT01096173|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2011-04-07|2010-03-29|2010-03-30|Estimate|||||||2011-04-07|2011-04-11|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Observational|||Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum|Determination of the in Vitro Effects of CALM on COPD Sputum|Completed|||10|Anticipated|Pulmatrix Inc.|||||f||||f||||||None Retained|"~     Sputum samples~   "|||2018-05-31 23:56:40.007066|2018-05-31 23:56:40.007066
NCT01096160|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2015-03-17|2010-03-29|2010-03-30|Estimate|||||||2015-03-17|2015-03-18|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 (8266-002)(COMPLETED)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 23:56:40.061632|2018-05-31 23:56:40.061632
NCT01096147|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2013-11-01|2010-03-29|2010-03-30|Estimate|||||||2013-11-01|2013-11-04|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Interventional|||Efficacy Study of the Octapolar Lead in Patients With Failed Back Surgery Syndrome (FBSS) With Chronic Pain|Octad Study: Evaluation of the Effectiveness of the Octopolar Lead in Patients With Failed Back Surgery Syndrome With Low Back and/or Leg Pain During a One Year Follow-up Period|Completed||Phase 4|80|Actual|Medtronic Neuromodulation Europe||1|||f||||t||||||||||2018-05-31 23:56:40.161718|2018-05-31 23:56:40.161718
NCT01096134|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2015-10-09|2010-03-29|2010-03-30|Estimate|||||||2015-10-09|2015-10-12|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|MDI||Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention|Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention|Completed||N/A|8000|Actual|Jhpiego||1|||f||||f||||||||||2018-05-31 23:56:40.281272|2018-05-31 23:56:40.281272
NCT01096121|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-07-25|2010-03-29|2010-03-30|Estimate|||||||2012-07-25|2012-07-26|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|MADREPIEC||Angiotensin-converting Enzyme Inhibitors and Early Sickle Cell Renal Disease in Children|Interest of Angiotensin-converting Enzyme Inhibitors on Early Sickle Cell Renal Disease in Children. A Randomized, Double-blind Trial Enalapril vs Placebo.|Terminated||N/A|5|Actual|Assistance Publique - Hôpitaux de Paris||2||Not enough inclusions|f||||t||||||||||2018-05-31 23:56:40.366211|2018-05-31 23:56:40.366211
NCT01096108|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2014-08-21|2010-03-29|2010-03-30|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Quit and Win Contests to Improve Smoking Cessation Among College Students|Enhancing Quit and Win Contests to Improve Smoking Cessation Among College Students|Completed||N/A|1318|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 23:56:40.450906|2018-05-31 23:56:40.450906
NCT01096095|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-08-15|2010-03-29|2010-03-30|Estimate|||||||2012-08-15|2012-08-17|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|July 2011|Anticipated|2011-07-31|December 2010|Anticipated|2010-12-31||Interventional|||Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3|Phenylbutyrate in SCA3: a Double-blind, Placebo-controlled Study to Determine Safety and Efficacy of Sodium Phenylbutyrate in Patients With SCA3|Withdrawn||Phase 2|0|Actual|Hospital de Clinicas de Porto Alegre||2||Regulatory authorities did not allow the entrance of the study drug in the country|f||||f||||||||||2018-05-31 23:56:40.538626|2018-05-31 23:56:40.538626
NCT01096082|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2013-01-29|2010-03-29|2010-03-30|Estimate|||||||2013-01-29|2013-01-30|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3|Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3|Completed||Phase 2/Phase 3|62|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||||||||||||2018-05-31 23:56:40.625965|2018-05-31 23:56:40.625965
NCT01096069|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|June 2010||2010-06-30|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Complement Regulatory Proteins Expression and Clinical Response in Rheumatoid Arthritis (RA) Patients Treated With Rituximab|Expressão de Cregs e a Resposta clínica em Pacientes AR Tratada Com Rituximabe|Unknown status|Not yet recruiting||10|Anticipated|Hospital de Clinicas de Porto Alegre|||1||f||||t||||||||||2018-05-31 23:56:40.702518|2018-05-31 23:56:40.702518
NCT01096056|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|2012-04-12||2016-09-22|2010-03-29|2010-03-30|Estimate|2012-04-12|2012-05-10|Estimate||||2016-09-22|2016-10-20|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children|Safety and Immunogenicity of GSK2186877A Candidate Seasonal Influenza Vaccine in Healthy Children 6 to 35 Months of Age.|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:56:40.782103|2018-05-31 23:56:40.782103
NCT01096043|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2016-11-14|2010-03-29|2010-03-30|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure|A Phase IIa, 3 Strata Dose-Defining Study Evaluating the Hemodynamic Effects, Safety and Tolerability of CXL-1020 in Patients With Systolic Heart Failure|Completed||Phase 2|69|Actual|Bristol-Myers Squibb||4|||f||||t||||||||||2018-05-31 23:56:41.449422|2018-05-31 23:56:41.449422
NCT01096030|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2013-11-18|2010-03-29|2010-03-30|Estimate|||||||2013-11-18|2013-11-19|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors|Uncontrolled, Open-label, Non-randomized, Phase 1 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors|Completed||Phase 1|33|Actual|Bayer||1|||f||||f||||||||||2018-05-31 23:56:41.544534|2018-05-31 23:56:41.544534
NCT01096017|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2011-10-03||2012-07-27|2010-03-29|2010-03-30|Estimate|2012-07-27|2012-08-31|Estimate||||2012-07-27|2012-08-31|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study|A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler® 0.4 mg and Salbutamol Pressurized Metered Dose Inhaler (pMDI) 200 μg - a Single Blind, Single Dose, Randomized, Crossover, Phase III Study in Japanese Adult Asthma Patients|Completed||Phase 3|24|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:56:41.621426|2018-05-31 23:56:41.621426
NCT01096004|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-12-09|2010-03-29|2010-03-30|Estimate|||||||2010-12-09|2010-12-10|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue|A Randomised, Single-blind, Placebo-controlled, Single-centre, Phase I Study in Abdominally Obese Healthy Volunteers to Evaluate Methods to Assess 11-βHSD1 Activity in Adipose Tissue and Related Downstream Biomarkers After Single and Repeated Oral Doses of AZD4017 for 10 Days|Completed||Phase 1|15|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:56:41.954317|2018-05-31 23:56:41.954317
NCT01095991|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-06-30|2010-03-29|2010-03-30|Estimate|||||||2010-06-30|2010-07-01|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus|A Randomised, Open, Phase I Study in Patients With Type 2 Diabetes Mellitus Treated With Metformin to Evaluate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin and Vice Versa|Completed||Phase 1|12|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 23:56:42.093041|2018-05-31 23:56:42.093041
NCT01095978|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|2011-05-17||2011-06-29|2010-03-29|2010-03-30|Estimate|2011-05-17|2011-06-15|Estimate||||2011-06-29|2011-07-11|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|KLARAINE||Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine|Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine|Completed|||2822|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:56:42.262793|2018-05-31 23:56:42.262793
NCT01095965|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2015-01-09|2010-03-29|2010-03-30|Estimate|||||||2015-01-09|2015-01-12|Estimate|April 2010||2010-04-30|January 2015|2015-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Nutrition Education Intervention in Adults With Type 2 Diabetes Mellitus in a Resource Poor Setting|Implementation and Evaluation of a Nutrition Education Programme for Adults With Type 2 Diabetes Mellitus in a Resource Poor Setting of the Moretele Sub-District, North West Province, South Africa|Completed||N/A|82|Actual|University of Pretoria||1|||f||||t||||||||||2018-05-31 23:56:43.111602|2018-05-31 23:56:43.111602
NCT01095952|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2014-02-14|2010-03-26|2010-03-30|Estimate|||||||2014-02-14|2014-02-17|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|AVNS||AV-node Stimulation Clinical Download Study to Reduce Ventricular Rate During AF|"Reduction of Ventricular Rate During Atrial Fibrillation by AV Node Stimulation AVNS Download Study"|Completed||N/A|45|Actual|Medtronic BRC||1|||f||||f||||||||||2018-05-31 23:56:43.194194|2018-05-31 23:56:43.194194
NCT01095939|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2018-04-30|2010-03-29|2010-03-30|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2010||2010-04-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2015|Actual|2015-12-31||Interventional|RPPEC||Post-preeclampsia Renal Project: Study of Nephroprotection in Women Having Suffered Preeclampsia|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Benazepril (ATC N° C09AA07) in the Treatment of Persistent Renal Dysfunction in Pre-eclamptic Women|Completed||Phase 3|120|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 23:56:43.283615|2018-05-31 23:56:43.283615
NCT01095926|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2013-06-27|2010-03-29|2010-03-30|Estimate|||||||2013-06-27|2013-06-28|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|Doxo||Pharmacokinetic Study of Doxorubicin in Children With Cancer|Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia|Completed||Phase 2|101|Actual|University Hospital Muenster||1|||f||||t||||||||||2018-05-31 23:56:43.367127|2018-05-31 23:56:43.367127
NCT01095913|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2015-01-07|2010-03-26|2010-03-30|Estimate|||||||2015-01-07|2015-01-08|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Fluorescent Dyes for Lymph Node Mapping|Near-Infrared Imaging of Fluorescent Dyes for Lymph Node Mapping|Completed||Phase 1|30|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-05-31 23:56:43.488307|2018-05-31 23:56:43.488307
NCT01095887|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2015-06-03||2015-06-26|2010-03-29|2010-03-30|Estimate|2015-06-03|2015-06-19|Estimate||||2015-06-26|2015-07-20|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ABOi||Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation|A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in ABO Blood Group Incompatible Living Donor Kidney Transplantation (ABOi LDKTx)|Terminated||Phase 1/Phase 2|6|Actual|Mayo Clinic|The study was terminated early due to poor enrollment.|1||Poor enrollment|f||||f||||||||||2018-05-31 23:56:43.626831|2018-05-31 23:56:43.626831
NCT01095874|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2014-01-17|2010-03-29|2010-03-30|Estimate|||||||2014-01-17|2014-01-20|Estimate|January 2008||2008-01-31|January 2014|2014-01-31||||January 2014|Actual|2014-01-31||Observational|ONIalloMDS||Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study|Allogeneic Hematopoietic Stem Cell Transplantation Evaluation in High Risk Myelodysplasia: an Observational Non-interventional Study Comparing Outcome of Patients Aged From 50 to 70 Years With or Without Donor|Completed|||164|Actual|Saint-Louis Hospital, Paris, France|||||f||||f||||||||||2018-05-31 23:56:43.797317|2018-05-31 23:56:43.797317
NCT01095861|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-08-04|2010-03-26|2010-03-30|Estimate|||||||2011-08-04|2011-08-05|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparison of Parker Flex-Tip Endotracheal Tube to Standard Endotracheal Tube|Comparison of Parker Flex-Tip Endotracheal Tube to Standard Endotracheal Tube: A Randomized Controlled Trial|Completed||N/A|200|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:56:43.884939|2018-05-31 23:56:43.884939
NCT01095848|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2015-12-14|2010-03-26|2010-03-30|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|||A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer|A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer|Completed||Phase 1|23|Actual|ImmunoVaccine Technologies, Inc.||2|||f||||t||||||||||2018-05-31 23:56:43.959582|2018-05-31 23:56:43.959582
NCT01095835|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2016-09-15||2016-09-15|2010-03-26|2010-03-30|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|February 2005||2005-02-28|March 2016|2016-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||The ITT population included all participants randomized who received at least one dose of study medication.|A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)|A Multicenter, Randomized, Controlled Study Comparing the Efficacy and Safety of 48 Weeks of 40kD Branched Pegylated Interferon Alfa-2a (PEG-IFN, RO 25-8310) Versus 96 Weeks of PEG-IFN, Alone or in Combination With 100 mg Lamivudine for 48 Weeks in Patients With HBeAg-Negative Chronic Hepatitis B|Completed||Phase 3|131|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 23:56:44.074074|2018-05-31 23:56:44.074074
NCT01095822|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics|A Randomized Evaluation of the Effects of Valsartan and Aliskiren in Combination Versus Tekturna Alone on Hemostatic Biomarkers in Patients With Newly Diagnosed Mild to Moderate Hypertension and Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|HeartDrug Research LLC||2|||f||||t||||||||||2018-05-31 23:56:45.655865|2018-05-31 23:56:45.655865
NCT01095809|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-03-22|2010-03-29|2010-03-30|Estimate|||||||2012-03-22|2012-03-23|Estimate|April 2010||2010-04-30|December 2010|2010-12-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|EBEV||Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema|Open , Randomized Study About Efficacy, Safety and Tolerability od Repeated Dosis of Intravitreous Bevacizumab in Patients With Uveitic Macular Oedema|Terminated||Phase 3|5|Actual|Hospital Clinic of Barcelona||2||New intraocular steroid in the market. Recruitment no longer ethical.|f||||f||||||||||2018-05-31 23:56:45.736713|2018-05-31 23:56:45.736713
NCT01095796|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2012-09-20|2011-08-23|2015-10-15|2010-03-26|2010-03-30|Estimate|2012-09-20|2012-10-22|Estimate|2011-08-23|2011-08-25|Estimate|2015-10-15|2015-11-11|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|August 2011|Actual|2011-08-31||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study medication.|Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Completed||Phase 3|707|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t||||||||||2018-05-31 23:56:45.872003|2018-05-31 23:56:45.872003
NCT01095783|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2015-08-10|2010-03-29|2010-03-30|Estimate|||||||2015-08-10|2015-08-11|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Treatment of Low Back Pain in Patients With End-stage Renal Disease on Hemodialysis||Withdrawn||Phase 3|0|Actual|Federal University of São Paulo||2||My main collaborator got sick and cannot continue the project. The study ended.|f||||||||||||||2018-05-31 23:56:47.286716|2018-05-31 23:56:47.286716
NCT01095770|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|November 2012|Anticipated|2012-11-30|April 2012|Anticipated|2012-04-30||Interventional|LAAPITUP||Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP|Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP|Unknown status|Not yet recruiting|N/A|50|Anticipated|Eastbourne General Hospital||4|||f||||f||||||||||2018-05-31 23:56:47.40802|2018-05-31 23:56:47.40802
NCT01095757|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2013-10-22||2014-09-16|2010-03-29|2010-03-30|Estimate|2014-09-05|2014-09-12|Estimate||||2014-09-16|2014-09-29|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|May 2012|Actual|2012-05-31||Interventional|||Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection|Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization|Completed||Phase 2|45|Actual|Emory University||1|||f||||t||||||||||2018-05-31 23:56:47.501231|2018-05-31 23:56:47.501231
NCT01095588|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2011-01-05|2010-03-29|2010-03-30|Estimate|||||||2011-01-05|2011-01-07|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects|A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm Study of the Effects of Avanafil on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects|Completed||Phase 1|24|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-05-31 23:56:50.164511|2018-05-31 23:56:50.164511
NCT01095744|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2012-10-08|2010-03-29|2010-03-30|Estimate|||||||2012-10-08|2012-10-10|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|BIOMAGE||Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease|Influence of Age on amyloïd Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease Like Posterior Cortical Atrophy (PCA) and Logopenic Progressive Aphasia (LPA)Using Positron Emitting Tomography (PET) Imaging|Completed|||60|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||5||f||||f||||||Samples With DNA|"~     DNA sample immortalized blood cell cultures csf aliquots for patients who beneficiated from a~     lumbar puncture.~   "|||2018-05-31 23:56:47.809605|2018-05-31 23:56:47.809605
NCT01095731|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25||2014-01-28|2016-06-15|2010-03-26|2010-03-30|Estimate||||2014-01-28|2014-02-28|Estimate|2016-06-15|2016-07-11|Estimate|April 2010||2010-04-30|June 2016|2016-06-30|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage|Phase II Study of the Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage|Completed||Phase 2|60|Actual|Columbia University||4|||f||||t||||||||||2018-05-31 23:56:48.050942|2018-05-31 23:56:48.050942
NCT01095718|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2012-03-23|2010-03-29|2010-03-30|Estimate|||||||2012-03-23|2012-03-26|Estimate|March 2010||2010-03-31|December 2011|2011-12-31||||March 2012|Anticipated|2012-03-31||Interventional|C3LM-ILAD||Comparison of 3 Learning Methods to Improve Independent Activities of Daily Living (IADLs) in Alzheimer Disease|Comparison of 3 Learning Methods and Their Underlying Mechanisms to Improve Independent Living in the Activities of Daily Living in Alzheimer's Dementia: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|300|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 23:56:48.179463|2018-05-31 23:56:48.179463
NCT01095705|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2013-12-18|2010-03-29|2010-03-30|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|I-SLEPT||Hypnosis for Transesophageal Echocardiography|Utility of Hypnosis for Transesophageal Echocardiography|Completed||N/A|101|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:56:48.295003|2018-05-31 23:56:48.295003
NCT01095692|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2014-06-05|2010-03-29|2010-03-30|Estimate|||||||2014-06-05|2014-06-06|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ATHENA||Evaluating the Necessity of TOT Implantation in Women With Pelvic Organ Prolapse and Occult Stress Urinary Incontinence|Evaluating the Necessity of TOT Implantation in Women With Pelvic Organ Prolapse and Occult Stress Urinary Incontinence|Completed||N/A|21|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 23:56:48.406768|2018-05-31 23:56:48.406768
NCT01095679|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-10-30|2010-03-29|2010-03-30|Estimate|||||||2012-10-30|2012-10-31|Estimate|March 2010||2010-03-31|December 2009|2009-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PERIODIBAC||Baclofen and Hypoxia-induced Periodic Ventilation|Assessment of the Effect of the GABA-B Receptor Agonist, Baclofen, on Hypoxia-induced Periodic Ventilation, in Healthy Subjects|Completed||Phase 1|53|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:56:48.50595|2018-05-31 23:56:48.50595
NCT01095666|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2016-10-03||2017-09-04|2010-03-26|2010-03-30|Estimate|2017-09-04|2017-09-11|Actual||||2017-09-04|2017-09-11|Actual|June 2010||2010-06-30|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All randomized participants who received at least 1 dose of study medication|A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone|Completed||Phase 3|1484|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 23:56:48.632019|2018-05-31 23:56:48.632019
NCT01095653|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2016-09-30||2016-12-13|2010-03-26|2010-03-30|Estimate|2016-12-13|2017-02-06|Estimate||||2016-12-13|2017-02-06|Estimate|June 2010||2010-06-30|December 2016|2016-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||All randomized participants who received at least 1 dose of study medication|A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 3|1179|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 23:56:49.186717|2018-05-31 23:56:49.186717
NCT01095640|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Comparing 0.3% Adapalene Topical Gel to Differin® 0.3% Adapalene Topical Gel|A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study Comparing 0.3% Adapalene Topical Gel (Actavis Mid Atlantic LLC) to Differin® (0.3 % Adapalene Topical Gel) (Galderma Laboratories, L.P.) and Both Active Treatments to a Vehicle Control (Actavis Mid Atlantic LLC) in the Treatment of Mild to Moderate Acne Vulgaris|Completed||N/A|1159|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 23:56:49.743732|2018-05-31 23:56:49.743732
NCT01095627|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-02-08|2010-03-29|2010-03-30|Estimate|||||||2011-02-08|2011-02-09|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Characterization of Aerosol Generation and Transport in the Human Lung|Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Mild Intermittent Allergic Asthma Before and After Methacholine Challenge|Completed||N/A|10|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f||||f||||||||||2018-05-31 23:56:49.826113|2018-05-31 23:56:49.826113
NCT01095614|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2011-01-18|2010-03-29|2010-03-30|Estimate|||||||2011-01-18|2011-01-19|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Substrate Utilization and Hormonal Status in Women|Impact of Women Hormonal Status (Oral Contraception vs no Contraception) on Substrate Utilization During Exercise|Completed|||24|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 23:56:49.985139|2018-05-31 23:56:49.985139
NCT01095601|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2011-01-05|2010-03-29|2010-03-30|Estimate|||||||2011-01-05|2011-01-07|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Assess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects|A Phase I, Single-Centre, Open-Label, Randomized, Four-Period Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Avanafil, to Determine The Relative Bioavailability of Two Avanafil Tablet Formulations and to Investigate Dose Proportionality in Healthy Male Subjects|Completed||Phase 1|24|Actual|VIVUS, Inc.||4|||f||||||||||||||2018-05-31 23:56:50.076022|2018-05-31 23:56:50.076022
NCT01095575|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2010-04-09|2010-03-29|2010-03-30|Estimate|||||||2010-04-09|2010-04-12|Estimate|January 2006||2006-01-31|March 2010|2010-03-31|January 2008|Actual|2008-01-31|||||Interventional|||Pre- Versus Post-Incisional Epidural Morphine: Higher Postoperative Pain Perception and Extra Morphine Consumption|Pre- vs. Post-Incisional Epidural Morphine: Higher Postoperative Pain Perception and Extra Morphine Consumption|Completed||N/A|40|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 23:56:50.241581|2018-05-31 23:56:50.241581
NCT01095562|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26||2012-08-30|2013-01-02|2010-03-26|2010-03-30|Estimate||||2012-08-30|2012-09-05|Estimate|2013-01-02|2013-01-07|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)|Completed||Phase 2|207|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 23:56:50.316097|2018-05-31 23:56:50.316097
NCT01095549|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2010-05-25|2010-03-29|2010-03-30|Estimate|||||||2010-05-25|2010-05-27|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||April 2011|Anticipated|2011-04-30||Interventional|||Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients|Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy|Unknown status|Recruiting|Phase 4|300|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 23:56:50.442721|2018-05-31 23:56:50.442721
NCT01095536|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2010-10-04|2010-03-29|2010-03-30|Estimate|||||||2010-10-04|2010-10-06|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Risk Factors for Shoulder Pain and Emesis After Laparoscopic Cholecystectomy|The Observational Cohort Study to Identify Risk Factors for Shoulder Pain and Emesis After Laparoscopic Cholecystectomy Under General Anesthesia|Unknown status|Recruiting||380|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||t||||||||||2018-05-31 23:56:50.55456|2018-05-31 23:56:50.55456
NCT01095523|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-27|||2017-06-30|2010-03-27|2010-03-30|Estimate|||||||2017-06-30|2017-07-02|Actual|January 14, 2010||2010-01-14|February 9, 2012|2012-02-09|February 9, 2012|Actual|2012-02-09|February 9, 2012|Actual|2012-02-09||Interventional|||Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases|Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:56:50.62326|2018-05-31 23:56:50.62326
NCT01095510|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2014-06-26||2015-07-14|2010-03-26|2010-03-30|Estimate|2014-06-26|2014-07-25|Estimate||||2015-07-14|2015-08-05|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12|Open-Label, Single-Dose Study to Evaluate the Response and Pharmacokinetics/Pharmacodynamics of Different Doses of CINRYZE® [C1 Inhibitor (Human)] For Treatment of Acute Angioedema Attacks in Children Less Than 12 Years of Age With Hereditary Angioedema|Completed||Phase 2|9|Actual|Shire|Change in C1 INH antigen and functional C1 INH concentrations endpoint was not analyzed as no participants agreed to additional and optional blood sampling. As a result, no PK parameters were calculated for this study.|4|||f||||f||||||||||2018-05-31 23:56:50.705555|2018-05-31 23:56:50.705555
NCT01095497|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2011-12-23||2014-04-24|2010-03-26|2010-03-30|Estimate|2012-02-07|2012-03-08|Estimate||||2014-04-24|2014-05-09|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration|An Open-Label Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Versus Intravenous (IV) Administration of CINRYZE in Adolescents and Adults With Hereditary Angioedema (HAE)|Completed||Phase 2|26|Actual|Shire||2|||f||||f||||||||||2018-05-31 23:56:51.051686|2018-05-31 23:56:51.051686
NCT01095484|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2014-10-17|2010-03-29|2010-03-30|Estimate|||||||2014-10-17|2014-10-20|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Named Patient Program With Rotigotine Transdermal System|Named Patient Program With Rotigotine Transdermal System|Completed|||520|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 23:56:51.298638|2018-05-31 23:56:51.298638
NCT01095471|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2011-03-21|2010-03-29|2010-03-30|Estimate|||||||2011-03-21|2011-03-22|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study|A follow-on, Multi-centre, Open-label, Clinical, Phase 4 Trial to Investigate the Persistence of Serotype-specific Antibodies at 40 Months of Age in Children Who Have Received Either the 7-valent or the 13-valent Pneumococcal Conjugate Vaccine at 2, 4 and 12 Months of Age and Assessing the Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Booster Dose Given at 40 Months of Age|Completed||Phase 4|100|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 23:56:51.434974|2018-05-31 23:56:51.434974
NCT01095458|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2014-04-03|2010-03-29|2010-03-30|Estimate|||||||2014-04-03|2014-04-04|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|July 2011|Actual|2011-07-31||Interventional|||Phone Versus Clinical Approach to Weight Loss|Equivalent Weight Loss for Phone and Clinic Weight Management Programs|Completed||N/A|395|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 23:56:51.519859|2018-05-31 23:56:51.519859
NCT01095445|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2011-09-27|2010-03-29|2010-03-30|Estimate|||||||2011-09-27|2011-09-29|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|EXACT-R(3)||EXtended Therapy in Hepatitis C Genotype 3 Infected Patients|EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR)|Terminated||Phase 3|2|Actual|University Health Network, Toronto||2||Unlikely to recruit the adequate number of patients within a reasonable timeline|f||||t||||||||||2018-05-31 23:56:51.623337|2018-05-31 23:56:51.623337
NCT01095432|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2016-05-20|2010-03-26|2010-03-30|Estimate|||||||2016-05-20|2016-05-23|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|Brushings||Partial Wave Spectroscopic Detection of Colon Cancer Risk|Partial Wave Spectroscopic Detection of Colon Cancer Risk|Completed|||40|Actual|University of Chicago|||1||f||||f||||||Samples Without DNA|"~     A sample of rectal mucosa will be collected during the subject's standard of care colonoscopy~     or flexible sigmoidoscopy.~   "|||2018-05-31 23:56:51.726603|2018-05-31 23:56:51.726603
NCT01095419|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|May 2008||2008-05-31|March 2010|2010-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|MT and CABG||Effects of Massage Therapy on Sleep After Heart Surgery|Effects of Massage Therapy on Sleep Quality After Coronary Artery Bypass Graft Surgery|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:56:51.787501|2018-05-31 23:56:51.787501
NCT01095406|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2012-09-18|2010-03-29|2010-03-30|Estimate|||||||2012-09-18|2012-09-19|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|CloserPed||Safety and Feasibility Study of a Mechanical Ventilation Computerized Protocol: Intellivent|Safety, Feasibility and Efficacy of Ventilation Weaning in Children With a Computerized Protocol: a Pilot Study on S1 Ventilator With Intellivent(Hamilton Medical).|Completed||Phase 2/Phase 3|19|Actual|St. Justine's Hospital||2|||f||||t||||||||||2018-05-31 23:56:51.855963|2018-05-31 23:56:51.855963
NCT01095393|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2017-11-15|2010-03-29|2010-03-30|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2009||2009-09-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|December 2016|Actual|2016-12-31||Observational|||National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)|National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies|Enrolling by invitation|||12500|Anticipated|UCB Pharma|||2||f||||f||||||||||2018-05-31 23:56:51.928463|2018-05-31 23:56:51.928463
NCT01095380|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|November 2003||2003-11-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Comparison of Post-pinal Cord Injury (SCI) Locomotor Training Techniques|Comparison of Post-SCI Locomotor Training Techniques|Completed||Phase 2/Phase 3|74|Actual|University of Miami||4|||f||||f||||||||||2018-05-31 23:56:51.983324|2018-05-31 23:56:51.983324
NCT01095367|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2014-09-25|2010-03-26|2010-03-30|Estimate|||||||2014-09-25|2014-09-26|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|October 2012|Actual|2012-10-31||Interventional|||Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer|Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer|Terminated||N/A|15|Actual|University of British Columbia||2||"due to company changes and lack of funding-unlikely to have sufficient numbers to analyze~   meaningfully"|f||||f||||||||||2018-05-31 23:56:52.04779|2018-05-31 23:56:52.04779
NCT01095354|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2018-05-01|2010-03-29|2010-03-30|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2009||2009-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Investigation of Lung Ventilation Inhomogeneity in Pediatric Asthma|Investigation of Lung Ventilation Inhomogeneity in Pediatric Asthma: Multiple Breath Washout and Asthma|Active, not recruiting|||49|Actual|The Hospital for Sick Children|||1||f||||f||||||Samples Without DNA|"~     samples will be processed and divided into two categories: eosinophilic (% eosinophils >2.5%)~     and non-eosinophilic (<2.5% eosinophils). The two categories of asthmatics will be used to~     categorize asthmatics for comparison on parameters such as SnIII analysis of SF6, LCI etc. In~     addition, % eosinophilia will be considered as a continuous measure in those with %~     eosinophils > 2% and correlated with LCI.~   "|Yes|scientific journal articles|2018-05-31 23:56:52.21376|2018-05-31 23:56:52.21376
NCT01095341|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|April 2008||2008-04-30|March 2010|2010-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Postoperative Hyperthyroidism|Postoperative Hyperthyroidism After Parathyroidectomy|Completed|||57|Actual|Heidelberg University|||2||f||||f||||||||||2018-05-31 23:56:52.30086|2018-05-31 23:56:52.30086
NCT01095328|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-06-30|2010-03-29|2010-03-30|Estimate|||||||2010-06-30|2010-07-01|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|February 2011|Anticipated|2011-02-28||Interventional|||A Screening Strategy for Q Fever Among Pregnant Women|Cost-effectiveness of a Screening Strategy for Q Fever Among Pregnant Women in Risk Areas: a Clustered Randomized Controlled Trial|Unknown status|Recruiting|N/A|4000|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 23:56:52.382581|2018-05-31 23:56:52.382581
NCT01095315|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-04-09|2010-03-29|2010-03-30|Estimate|||||||2010-04-09|2010-04-12|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Delayed Positioning in Cesarean Section||Completed||N/A|86|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 23:56:52.489525|2018-05-31 23:56:52.489525
NCT01095302|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2013-10-12|2010-03-29|2010-03-30|Estimate|||||||2013-10-12|2013-10-16|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors|An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Docetaxel and Cisplatin Every 3 Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|11|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:56:52.569724|2018-05-31 23:56:52.569724
NCT01095289|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Electromyographic Activity of Masseter Muscle During Deglutition in Total Laryngectomized Subjects|Electromyographic Activity of Masseter Muscle During Deglutition in Total Laryngectomized Subjects|Completed|||16|Actual|Universidade Federal de Pernambuco|||1||f||||t||||||||||2018-05-31 23:56:52.651658|2018-05-31 23:56:52.651658
NCT01095276|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|November 2005||2005-11-30|March 2010|2010-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients|Inhaled Dnase (Pulmozyme®) as a Non-Invasive Treatment of Atelectasis in Mechanically Ventilated Patients|Completed||N/A|30|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 23:56:52.71121|2018-05-31 23:56:52.71121
NCT01095263|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-08-21|2010-03-29|2010-03-30|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|FORESEE||Effects of Deep Brain Stimulation in Treatment Resistant Major Depression|Assessment of Efficacy, Safety and Effects on Quality of Life of Deep Brain Stimulation to the Medial Forebrain Bundle in Patients With Treatment Resistant Major Depression (FORESEE: FOREbrain Stimulation dEprEssion)|Unknown status|Active, not recruiting|Phase 1|7|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 23:56:52.7993|2018-05-31 23:56:52.7993
NCT01095094|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|2013-04-24||2013-04-24|2010-03-26|2010-03-29|Estimate|2013-04-24|2013-06-10|Estimate||||2013-04-24|2013-06-10|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|November 2011|Actual|2011-11-30|June 2010|Actual|2010-06-30||Interventional|||Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma|Phase II Trial of Ritonavir/Lopinavir in Patients With Progressive of Recurrent High-Grade Gliomas|Terminated||Phase 2|19|Actual|Case Comprehensive Cancer Center||1||Study did not meet its primary objective|f||||t||||||||||2018-05-31 23:56:54.686972|2018-05-31 23:56:54.686972
NCT01095250|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2015-02-12|2012-05-02|2015-10-05|2010-03-26|2010-03-30|Estimate|2015-10-05|2015-11-03|Estimate|2012-05-02|2012-05-04|Estimate|2015-10-05|2015-11-03|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|INSURE||Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis|A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)|Terminated||Phase 3|30|Actual|Novartis|Study CAIN457C2302 was terminated to avoid continuing patients on a study with a low probability of success. Since patients did not reach the endpoint of analysis there can be no meaningful interpretation of data and data will be not provided.|4||"Terminated: Study in Behcet's disease with mostly active uveitis did not meet its primary~   endpoint."|f||||||||||||||2018-05-31 23:56:52.911306|2018-05-31 23:56:52.911306
NCT01095237|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-07-08|2010-03-29|2010-03-30|Estimate|||||||2014-07-08|2014-07-09|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Clinical Pilot-Study of ProEndoTecc Vascular Grafts as Superficial Femoral Artery Bypass / Interponate|Multicenter, Clinical Pilot-Study of ProEndoTecc Vascular Grafts (6, 7 or 8 mm Diameter) as Superficial Femoral Artery Bypass/Interponate|Terminated||N/A|33|Actual|NonWoTecc Medical GmbH||||Study has been halted due to safety reasons|f||||t||||||||||2018-05-31 23:56:53.619926|2018-05-31 23:56:53.619926
NCT01095224|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2017-08-15|2010-03-26|2010-03-30|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2010||2010-09-30|April 2017|2017-04-30|February 2016|Actual|2016-02-29|October 2012|Actual|2012-10-31||Interventional|||Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Regimens Utilizing Recombinant Adenovirus Serotype 35 (rAd35) With HIV-1 Clade A Env Insert and Recombinant Adenovirus Serotype 5 (rAd5) With HIV-1 Clade A or B Env Inserts in Healthy, HIV-1-Uninfected Adults|Completed||Phase 1|180|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 23:56:53.720176|2018-05-31 23:56:53.720176
NCT01095211|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2018-05-07|2010-03-29|2010-03-30|Estimate|||||||2018-05-07|2018-05-11|Actual|January 2003||2003-01-31|May 2018|2018-05-31|December 2009|Actual|2009-12-31|September 2005|Actual|2005-09-30||Interventional|||B-vitamins Treatment for Improvement of Cognitive Function|Effect of B-Vitamins on Cognitive Function in Elderly People|Completed||N/A|79|Actual|Saarland University||2|||f||||f|f|f||||||||2018-05-31 23:56:53.824287|2018-05-31 23:56:53.824287
NCT01095198|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2011-07-19|2010-03-29|2010-03-30|Estimate|||||||2011-07-19|2011-07-21|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|January 2013|Anticipated|2013-01-31|November 2012|Anticipated|2012-11-30||Interventional|||Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)|Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation|Unknown status|Enrolling by invitation|Phase 2/Phase 3|1440|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 23:56:53.915573|2018-05-31 23:56:53.915573
NCT01095185|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2015-03-18|2010-03-29|2010-03-30|Estimate|||||||2015-03-18|2015-03-19|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding|A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding|Completed||Phase 3|150|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 23:56:54.00211|2018-05-31 23:56:54.00211
NCT01095172|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2016-08-18|2010-03-29|2010-03-30|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|ReMIND||RituxiMab INDuction in Renal Transplantation|A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation|Recruiting||Phase 4|612|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 23:56:54.121584|2018-05-31 23:56:54.121584
NCT01095159|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2018-05-28|2010-03-29|2010-03-30|Estimate|||||||2018-05-28|2018-05-30|Actual|February 2009||2009-02-28|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|TVTOxTVTS||TVTO™ X TVTS ™ for Treatment of Stress Urinary Incontinence|Comparative Study of TVTO™ X TVTS ™ for Treatment of Stress Urinary Incontinence|Completed||Phase 4|124|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 23:56:54.377417|2018-05-31 23:56:54.377417
NCT01095146|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-29|||2010-03-29|2010-03-29|2010-03-30|Estimate|||||||2010-03-29|2010-03-30|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|MAS-D||New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome|Comparison of Predictive Ability of New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome|Unknown status|Enrolling by invitation||50|Anticipated|Amrita Institute of Medical Sciences & Research Center|||||f||||f||||||||||2018-05-31 23:56:54.440944|2018-05-31 23:56:54.440944
NCT01095133|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2012-09-18|2010-03-29|2010-03-30|Estimate|||||||2012-09-18|2012-09-20|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Do Acid Sensing Ion Channels Contribute to Heartburn?|Do Acid Sensing Ion Channels (ASICs) Contribute to Heartburn in Proton Pump Inhibitor (PPI)-Complete Responders or PPI-Partial Responders With Nonerosive Reflux Disease (NERD)?|Completed||Phase 1|24|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:56:54.497077|2018-05-31 23:56:54.497077
NCT01095120|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2012-03-14|2010-03-26|2010-03-29|Estimate|||||||2012-03-14|2012-03-15|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer|A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|27|Anticipated|Genta Incorporated|||||f||||f||||||||||2018-05-31 23:56:54.565953|2018-05-31 23:56:54.565953
NCT01095107|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2018-01-11|2010-03-26|2010-03-29|Estimate|||||||2018-01-11|2018-01-16|Actual|January 2010||2010-01-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Food Energy Density in Eating Disorders|Relationship of Energy Density of Foods Within a Nutritional Insufficiency Patient's Diet to Inpatient Hospital Stay Duration, Body Image, Mood and Gastrointestinal Symptoms|Enrolling by invitation||N/A|20|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 23:56:54.622246|2018-05-31 23:56:54.622246
NCT01094899|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2012-01-27|2010-03-26|2010-03-29|Estimate|||||||2012-01-27|2012-01-31|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|September 2011|Actual|2011-09-30||Interventional|||Abnormal Structure and Bone Density in Diabetes|Study of Abnormal Structure and Bone Density at the Feet of Diabetic Patients|Unknown status|Recruiting|N/A|80|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||t||||||||||2018-05-31 23:56:57.067852|2018-05-31 23:56:57.067852
NCT01095081|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2015-01-19|2010-03-26|2010-03-29|Estimate|||||||2015-01-19|2015-01-21|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|GARDIAN||GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients|GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients|Completed|||23775|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-05-31 23:56:54.992481|2018-05-31 23:56:54.992481
NCT01095068|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2017-10-04|2010-03-26|2010-03-29|Estimate|||||||2017-10-04|2017-10-05|Actual|March 2010||2010-03-31|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Physical Exercise in Type 2 Diabetics|Beneficial Effects of Exercise Training on Physical Capacity in Type 2 Diabetics: Improvement in Skeletal Muscle Energetic Capacity, Endothelial Dysfunction and Glycemic Control|Terminated||N/A|15|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 23:56:55.136264|2018-05-31 23:56:55.136264
NCT01095055|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2011-03-25|2010-03-26|2010-03-29|Estimate|||||||2011-03-25|2011-03-28|Estimate|March 2010||2010-03-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of AdCh63 AMA1 Alone and With MVA AMA1|A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 AMA1 Alone and With MVA AMA1|Completed||Phase 1|16|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 23:56:55.240321|2018-05-31 23:56:55.240321
NCT01095042|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-01-27|2010-03-26|2010-03-29|Estimate|||||||2014-01-27|2014-01-28|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|EMOTION||Cognition and Emotion in the SII and IBD|Etude de la réactivité émotionnelle Des Patients MICI ou SII|Completed||N/A|120|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 23:56:55.340636|2018-05-31 23:56:55.340636
NCT01095029|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2014-07-03|2010-03-26|2010-03-29|Estimate|||||||2014-07-03|2014-07-04|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|July 2014|Actual|2014-07-31|August 2012|Actual|2012-08-31||Interventional|||Cerebral Responses During Bilateral/Unilateral Sacral Nerve Stimulation for Idiopathic Faecal Incontinence|Cerebral Responses During Bilateral/Unilateral Sacral Nerve Stimulation for Idiopathic Faecal Incontinence - Assessed With Positron Emission Tomography Scan (PET-scan)|Completed||N/A|10|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 23:56:55.497766|2018-05-31 23:56:55.497766
NCT01095016|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2013-01-15|2010-03-26|2010-03-29|Estimate|||||||2013-01-15|2013-01-16|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients|An Open-label, Randomized, Cross-over, Active-controlled Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients|Completed||Phase 3|32|Anticipated|Taiwan Otsuka Pharm. Co., Ltd||2|||f||||f||||||||||2018-05-31 23:56:55.590052|2018-05-31 23:56:55.590052
NCT01095003|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2015-10-30|2010-03-26|2010-03-29|Estimate|||||||2015-10-30|2015-11-02|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|October 2015|Actual|2015-10-31|December 2011|Actual|2011-12-31||Interventional|||Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer|A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.|Completed||Phase 3|770|Actual|Pierre Fabre Medicament||2|||f||||t||||||||||2018-05-31 23:56:55.746429|2018-05-31 23:56:55.746429
NCT01094990|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2012-01-09|2010-03-26|2010-03-29|Estimate|||||||2012-01-09|2012-01-11|Estimate|April 2011||2011-04-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy|Efficacy of Dexamethasone for The Prevention of Nausea and Vomiting Associated With Intrathecal Chemotherapy and Ketamine Sedation in Children With Leukemia|Completed||Phase 4|32|Anticipated|Phramongkutklao College of Medicine and Hospital|||||f||||t||||||||||2018-05-31 23:56:56.065158|2018-05-31 23:56:56.065158
NCT01094977|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2013-08-27|2010-03-26|2010-03-29|Estimate|||||||2013-08-27|2013-08-28|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid|Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid Undergoing Craniosynostosis Reconstruction: A Randomized Placebo-Controlled Double Blind Study of Low and High Dose Therapy|Unknown status|Recruiting|Phase 3|90|Anticipated|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 23:56:56.234791|2018-05-31 23:56:56.234791
NCT01094964|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2013-08-09|2010-03-26|2010-03-29|Estimate|||||||2013-08-09|2013-08-12|Estimate|October 2009||2009-10-31|March 2010|2010-03-31||||October 2013|Anticipated|2013-10-31||Interventional|||Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer|HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy|Unknown status|Recruiting|Phase 3|242|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:56:56.360035|2018-05-31 23:56:56.360035
NCT01094951|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2017-11-06|2010-03-26|2010-03-29|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2010||2010-03-31|November 2017|2017-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ENGAGE||Engaging Depressed Low-Income Seniors in Mental Health Services|Engaging Depressed Low-Income Seniors in Mental Health Services|Completed||N/A|12|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 23:56:56.576961|2018-05-31 23:56:56.576961
NCT01094938|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2010-03-26|2010-03-26|2010-03-29|Estimate|||||||2010-03-26|2010-03-29|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Observational|||Cardiac Output Monitoring in Aortic Aneurysm Surgery||Completed|||30|Actual|NHS Lothian|||1||f||||f||||||||||2018-05-31 23:56:56.700667|2018-05-31 23:56:56.700667
NCT01094925|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2011-02-22|2010-03-25|2010-03-29|Estimate|||||||2011-02-22|2011-02-23|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||The Effectiveness of Gabapentin for Post-operative Pain Following Cesarean Section|The Effectiveness of a Pre-operative Single Dose Administration of Gabapentin for Management of Post-operative Pain Following Cesarean Section: a Randomised, Double-blind, Placebo-controlled, Dose-finding Study|Completed||N/A|126|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||3|||f||||f||||||||||2018-05-31 23:56:56.780336|2018-05-31 23:56:56.780336
NCT01094912|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2015-08-31|2010-03-26|2010-03-29|Estimate|||||||2015-08-31|2015-09-01|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|TALViSoP||Procedures of Locoregional Analgesia and Quality of Life in Palliative Care Units|Procedures of Locoregional Analgesia and Quality of Life in Palliative Care|Suspended||N/A|38|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 23:56:56.962238|2018-05-31 23:56:56.962238
NCT01094886|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2011-12-01||2017-02-08|2010-03-25|2010-03-29|Estimate|2012-01-25|2012-02-27|Estimate||||2017-02-08|2017-03-17|Actual|March 2010||2010-03-31|February 2017|2017-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement|A Open-Label Study of the Transition to Rivaroxaban From Low-Molecular Weight Heparin for Venous Thromboembolism Prophylaxis After Total Joint Replacement: The Safe Simple Transitions Study|Completed||Phase 3|56|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|There were 56 subjects enrolled in the study, but only 53 of them were treated with study medication.|1|||f||||t||||||||||2018-05-31 23:56:57.170715|2018-05-31 23:56:57.170715
NCT01094873|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2015-04-22|2010-03-25|2010-03-29|Estimate|||||||2015-04-22|2015-04-23|Estimate|November 2009||2009-11-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of a Novel Therapeutic Vaccine for Hepatitis C Virus|A Phase I Study to Assess the Safety and Immunogenicity of Ad6NSmut and AdCh3NSmut in Patients With Hepatitis C Virus Infection|Completed||Phase 1|35|Actual|ReiThera Srl||9|||f||||t||||||||||2018-05-31 23:56:57.603247|2018-05-31 23:56:57.603247
NCT01094860|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-01-09|2010-03-26|2010-03-29|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2010|Actual|2010-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies|A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies|Active, not recruiting||Phase 1|29|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 23:56:57.710509|2018-05-31 23:56:57.710509
NCT01094847|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2011-05-19|2010-03-26|2010-03-29|Estimate|||||||2011-05-19|2011-05-20|Estimate|April 2010||2010-04-30|May 2011|2011-05-31||||May 2010|Actual|2010-05-31||Interventional|||Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine|Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine|Completed||Phase 1|30|Anticipated|Daewoong Pharmaceutical Co. LTD.||3|||f||||||||||||||2018-05-31 23:56:57.839314|2018-05-31 23:56:57.839314
NCT01094834|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2011-02-08|2010-03-26|2010-03-29|Estimate|||||||2011-02-08|2011-02-09|Estimate|April 2010||2010-04-30|February 2011|2011-02-28||||October 2010|Actual|2010-10-31||Interventional|||A Multiple Dose Study of DWP05195 in Healthy Adult Subjects|A Multiple Dose Study To Determine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP05195 in Healthy Adult Subjects|Completed||Phase 1|40|Anticipated|Daewoong Pharmaceutical Co. LTD.||1|||f||||t||||||||||2018-05-31 23:56:57.945622|2018-05-31 23:56:57.945622
NCT01094821|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2010-03-26|2010-03-26|2010-03-29|Estimate|||||||2010-03-26|2010-03-29|Estimate|January 2005||2005-01-31|March 2010|2010-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Effect of ATI-7505 on Gastric Emptying and Small Bowel and Colonic Transit in Healthy Volunteers|Completed||Phase 1/Phase 2|48|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 23:56:58.037413|2018-05-31 23:56:58.037413
NCT01094808|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2012-01-26||2012-03-05|2010-03-25|2010-03-29|Estimate|2012-02-02|2012-03-06|Estimate||||2012-03-05|2012-03-07|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Pregabalin and Colonic Function|Effect of Pregabalin on Colonic Sensorimotor Function in Healthy Adults.|Completed||Phase 4|62|Actual|Mayo Clinic||3|||f||||t||||||||||2018-05-31 23:56:58.134298|2018-05-31 23:56:58.134298
NCT01094795|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2018-01-10|2010-03-26|2010-03-29|Estimate|||||||2018-01-10|2018-01-12|Actual|March 31, 2011|Actual|2011-03-31|January 2018|2018-01-31|June 24, 2019|Anticipated|2019-06-24|June 24, 2019|Anticipated|2019-06-24||Observational|||Safety Study of Abatacept in Sweden|A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Sweden Using the ARTIS Register|Active, not recruiting|||100000|Anticipated|Bristol-Myers Squibb|||5||f||||f||||||||||2018-05-31 23:56:58.974278|2018-05-31 23:56:58.974278
NCT01094782|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2016-10-25|2010-03-26|2010-03-29|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluating the Effect of Acupuncture on Pain Relief Using Quantitative Sensory Testing (QST)|Evaluating the Effect of Acupuncture on Pain Relief Using QST|Active, not recruiting||N/A|254|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 23:57:00.079131|2018-05-31 23:57:00.079131
NCT01094769|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2013-12-16|2010-03-26|2010-03-29|Estimate|||||||2013-12-16|2013-12-18|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|April 2015|Anticipated|2015-04-30|January 2015|Anticipated|2015-01-31||Interventional|||Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease|Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy|Unknown status|Recruiting|Phase 4|48|Anticipated|Baker IDI Heart and Diabetes Institute||2|||f||||f||||||||||2018-05-31 23:57:00.20224|2018-05-31 23:57:00.20224
NCT01094756|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2016-10-31|2010-03-25|2010-03-29|Estimate|||||||2016-10-31|2016-11-02|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2015|Actual|2015-06-30||Interventional|BODY||Brain, Obesity, Dopamine and You Study|Central Dopamine Receptors In Obesity|Completed||N/A|82|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 23:57:00.320492|2018-05-31 23:57:00.320492
NCT01094743|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2011-11-07||2017-09-20|2010-03-25|2010-03-29|Estimate|2011-12-19|2012-01-25|Estimate||||2017-09-20|2017-10-20|Actual|February 1, 2010|Actual|2010-02-01|September 2017|2017-09-30|March 1, 2010|Actual|2010-03-01|March 1, 2010|Actual|2010-03-01||Interventional|||Dispensing Evaluation of a Prototype Contact Lens and a Marketed Contact Lens||Completed||N/A|52|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 23:57:00.463589|2018-05-31 23:57:00.463589
NCT01094730|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2011-11-04||2017-08-31|2010-03-26|2010-03-29|Estimate|2013-09-13|2013-11-19|Estimate||||2017-08-31|2017-10-02|Actual|February 1, 2010|Actual|2010-02-01|August 2017|2017-08-31|April 1, 2010|Actual|2010-04-01|April 1, 2010|Actual|2010-04-01||Interventional||Baseline summary was conducted on all enrolled subjects who have the demographic data. Two enrolled subjects were excluded from the Baseline summary for age and gender categories due to missing demographic data, reducing the count from 185 to 183; one subject was ineligible and the other one withdrew their consent.|Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens|A Multi-site Dispensing Evaluation Comparing a New Galyfilcon A Prototype Lens With a Marketed Galyfilcon A Contact Lens|Completed||N/A|185|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 23:57:00.792015|2018-05-31 23:57:00.792015
NCT01094717|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2012-03-06|2010-03-25|2010-03-29|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis|A Comparison of Treatment of Psoriasis With Acitretin or Tazarotene Gel 0.1% and Active or Sham Treatments With the 308 nm Excimer Laser|Terminated||N/A|13|Actual|University of Utah||2||lack of efficacy and lack of funding|f||||f||||||||||2018-05-31 23:57:01.194108|2018-05-31 23:57:01.194108
NCT01094704|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2011-09-26||2012-07-17|2010-03-25|2010-03-29|Estimate|2012-07-17|2012-08-21|Estimate||||2012-07-17|2012-08-21|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis|Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis|Completed||Phase 1|16|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:57:01.304476|2018-05-31 23:57:01.304476
NCT01094691|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-05-02|2010-03-25|2010-03-29|Estimate|||||||2018-05-02|2018-05-08|Actual|November 2008||2008-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Haufen Diagnostic Biomarkers of BK Renal Disease|Polyomavirus Aggregates, Haufen, in Voided Urine Samples as Diagnostic Biomarkers of Intra Renal BK-virus Disease: a Prospective Proof-of-concept Study|Enrolling by invitation||N/A|10|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 23:57:01.53417|2018-05-31 23:57:01.53417
NCT01094678|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2014-09-09|2010-03-26|2010-03-29|Estimate|||||||2014-09-09|2014-09-11|Estimate|April 2006||2006-04-30|September 2014|2014-09-30|April 2011|Actual|2011-04-30|January 2009|Actual|2009-01-31||Interventional|||Zilver® PTX™ Global Registry|Evaluation of the Safety and Performance of the Zilver® PTX™ Drug-Eluting Stent for Treating De Novo or Restenotic Lesions of the Above-the-knee Femoropopliteal Artery|Completed||N/A|788|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 23:57:01.604708|2018-05-31 23:57:01.604708
NCT01094665|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-03-07|2010-03-25|2010-03-29|Estimate|||||||2018-03-07|2018-03-09|Actual|November 2009||2009-11-30|March 2018|2018-03-31|October 8, 2015|Actual|2015-10-08|October 8, 2015|Actual|2015-10-08||Interventional|FLTT002||MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer|Phase 1 Study of MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer|Completed||N/A|54|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 23:57:01.700469|2018-05-31 23:57:01.700469
NCT01094652|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2012-08-01|2010-03-25|2010-03-29|Estimate|||||||2012-08-01|2012-08-02|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||The Addition of Whole Grains to the Diets of Middle-school Children|The Addition of Whole Grains to the Diets of Middle-school Children: A Study of Digestive Health and Immune Defenses|Completed||N/A|83|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 23:57:01.763393|2018-05-31 23:57:01.763393
NCT01094639|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2016-10-24|2010-03-25|2010-03-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|PeriRen||Periodontal Infection and Systemic Inflammation in Renal Patients|Periodontal Infection and Systemic Inflammation in Renal Patients|Completed||N/A|52|Actual|UConn Health||2|||f||||t||||||||Undecided||2018-05-31 23:57:01.831879|2018-05-31 23:57:01.831879
NCT01094626|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2016-06-08|2010-03-26|2010-03-29|Estimate|||||||2016-06-08|2016-06-10|Estimate|April 2010||2010-04-30|June 2016|2016-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Secretin-enhanced Magnetic Resonance Imaging (S-MRI) for Pancreatic Cancer Detection|MRI With Secretin Enhancement to Increase Conspicuity of Pancreatic Cancer|Withdrawn||N/A|0|Actual|Columbia University||2||Pharmaceutical company did not decide to renew contract|f||||t||||||||No||2018-05-31 23:57:01.906753|2018-05-31 23:57:01.906753
NCT01094613|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2013-03-06|2010-03-25|2010-03-29|Estimate|||||||2013-03-06|2013-03-07|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease|MultiCTR Randomized Double-Blind Double-Dummy Study to Evaluate Clinical Efficacy/Safety of DR 6MP for Targeted Ileal Delivery vs Purinethol in Patients w/Moderately Active Crohn's Disease|Terminated||Phase 1/Phase 2|70|Actual|Teva GTC||2||Sponsor withdrew support of study due to reorganization and project prioritization|f||||f||||||||||2018-05-31 23:57:01.993323|2018-05-31 23:57:01.993323
NCT01094600|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2012-06-29|2010-03-26|2010-03-29|Estimate|||||||2012-06-29|2012-07-02|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency|Comparison of Secretin Enhanced MRCP to Endoscopic Pancreatic Function Testing in Diagnosing Exocrine Insufficiency in Patients Who Have Undergone Pancreas Cancer Resection|Withdrawn||N/A|0|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 23:57:02.098544|2018-05-31 23:57:02.098544
NCT01094587|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2017-10-12|2010-03-25|2010-03-29|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2009|Actual|2009-11-30|October 2017|2017-10-31|June 24, 2015|Actual|2015-06-24|June 24, 2015|Actual|2015-06-24||Interventional|||Sutureless vs Sutured Gastroschisis Closure|Sutureless vs Sutured Gastroschisis Closure|Terminated||N/A|39|Actual|Stanford University||2||Enrollment difficulty|f||||||||||||||2018-05-31 23:57:02.163362|2018-05-31 23:57:02.163362
NCT01094574|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2016-06-28||2017-01-04|2010-03-25|2010-03-29|Estimate|2017-01-04|2017-02-24|Actual||||2017-01-04|2017-02-24|Actual|January 2010||2010-01-31|January 2017|2017-01-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Evaluation of Propranolol's Effect on Pain and Inflammation.|Investigation of Analgesic and Anti-inflammatory Effects of Beta-adrenergic Antagonist Propranolol|Completed||N/A|10|Actual|Stanford University||3|||f||||f||||||||No|Individual participant data will not be shared.|2018-05-31 23:57:02.349006|2018-05-31 23:57:02.349006
NCT01094561|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2016-05-14||2016-07-25|2010-03-26|2010-03-29|Estimate|2016-07-25|2016-09-09|Estimate||||2016-07-25|2016-09-09|Estimate|July 2006||2006-07-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients|Secretin-Stimulated MRCP as an Early Screening Modality for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot Study|Completed||N/A|23|Actual|Columbia University||1|||f||||t||||||||Undecided||2018-05-31 23:57:03.175696|2018-05-31 23:57:03.175696
NCT01094548|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2015-10-15||2016-01-24|2010-03-26|2010-03-29|Estimate|2016-01-24|2016-02-22|Estimate||||2016-01-24|2016-02-22|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional||Safety analysis set included all the randomized participants who received at least 1 dose of trial treatment.|Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy|A Randomized, Open-label, Phase II Study With Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Either Chemotherapy-naïve, Slowly Progressive, Asymptomatic Multiple Myeloma or With Stage II/III Multiple Myeloma in Stable Response/Plateau Phase Following Anti-tumor Therapy|Completed||Phase 2|34|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 23:57:03.49223|2018-05-31 23:57:03.49223
NCT01094353|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2017-06-19|2010-03-25|2010-03-26|Estimate|||||||2017-06-19|2017-06-21|Actual|June 2008|Actual|2008-06-30|June 2017|2017-06-30|July 2015|Actual|2015-07-31|December 2011|Actual|2011-12-31||Interventional|sui||A Comparative Study Minisling Versus Transobturator (TOT)Sling|Randomised Trial of Ophira™ Minisling System and Unitape™ for the Treatment of Stress Urinary Incontinence in Women|Completed||Phase 4|145|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 23:57:05.737388|2018-05-31 23:57:05.737388
NCT01094535|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2015-04-03|2010-03-26|2010-03-29|Estimate|||||||2015-04-03|2015-04-06|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery|MRCP With Secretin Stimulation for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic Adenocarcinoma|Withdrawn||N/A|0|Actual|Columbia University||1||Poor enrollment|f||||t||||||||||2018-05-31 23:57:04.280332|2018-05-31 23:57:04.280332
NCT01094522|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2017-07-11||2017-08-17|2010-03-25|2010-03-29|Estimate|2017-07-11|2017-08-09|Actual||||2017-08-17|2017-09-18|Actual|March 2010||2010-03-31|August 2017|2017-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Measuring the Amount of Methadone or Morphine in the Blood of Neonates, Infants & Children After Cardiac Surgery.|A Randomized, Double-blind, Controlled, Multi-site Study of the Pharmacokinetics and Pharmacodynamics of Methadone vs. Morphine During Mechanical Ventilation Following Cardiac Surgery in Neonates, Infants and Children|Completed||Phase 1/Phase 2|47|Actual|Stanford University||2|||f||||||||||||||2018-05-31 23:57:04.351328|2018-05-31 23:57:04.351328
NCT01094509|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2014-11-18|2010-03-26|2010-03-29|Estimate|||||||2014-11-18|2014-11-20|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional|ACE-Seniors||Activities for Cognitive Enhancement of Seniors|Tai Chi and Guided Autobiography for Remediation of Age-related Cognitive Decline|Completed||N/A|175|Actual|Stanford University||6|||f||||f||||||||||2018-05-31 23:57:04.696342|2018-05-31 23:57:04.696342
NCT01094496|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25||2016-02-16|2016-02-16|2010-03-26|2010-03-29|Estimate||||2016-02-16|2016-03-15|Estimate|2016-02-16|2016-03-15|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|July 2011|Actual|2011-07-31||Interventional|||"A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The N-ABLE Study)"|A Phase II, Open-Label Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-β|Terminated||Phase 2|30|Actual|Celldex Therapeutics||1||Portfolio prioritization due to slow enrollment|f||||f||||||||||2018-05-31 23:57:04.80357|2018-05-31 23:57:04.80357
NCT01094483|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-12-06|2010-03-26|2010-03-29|Estimate|||||||2010-12-06|2010-12-07|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin|A Phase I Prospective, Randomized, Double-blind, Placebo-controlled Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN 400 and Low Dose Aspirin|Completed||Phase 1|40|Anticipated|AstraZeneca||2|||f||||||||||||||2018-05-31 23:57:04.904719|2018-05-31 23:57:04.904719
NCT01094470|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-03-26|2010-03-26|2010-03-29|Estimate|||||||2010-03-26|2010-03-29|Estimate|August 2007||2007-08-31|July 2006|2006-07-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|BWSGR||Body Weight Support Training on Ground Level|Ground-level Partial Body Weight Support Gait Training for Individuals With Chronic Stroke|Completed||N/A|12|Actual|Universidade Federal de Sao Carlos|||||f||||f||||||||||2018-05-31 23:57:04.985623|2018-05-31 23:57:04.985623
NCT01094457|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2012-06-13|2010-03-26|2010-03-29|Estimate|||||||2012-06-13|2012-06-14|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation||Completed||Phase 4|840|Actual|Shenyang Northern Hospital||2|||f||||t||||||||||2018-05-31 23:57:05.066717|2018-05-31 23:57:05.066717
NCT01094444|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-01-20|2010-03-26|2010-03-29|Estimate|||||||2015-01-20|2015-01-21|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional|||Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis|Placebo-controlled Trial Investigating the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis|Completed||Phase 2|30|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 23:57:05.148723|2018-05-31 23:57:05.148723
NCT01094431|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2014-12-02|2010-03-26|2010-03-29|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|RDTNEG||Etiology of Uncomplicated Fever in Children <5 in Rural Zanzibar|Infectious Disease Etiologies of Uncomplicated Febrile Illness in Children <5 Years of Age in Rural Zanzibar|Completed|||690|Actual|Karolinska University Hospital|||||f||||t||||||Samples Without DNA|"~     Urine collected in deep ager Frozen Nasopharyngeal secretions~   "|||2018-05-31 23:57:05.227287|2018-05-31 23:57:05.227287
NCT01094418|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-03-26|2010-03-26|2010-03-29|Estimate|||||||2010-03-26|2010-03-29|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Electrodiagnostic Parameters in Patients With Impaired Glucose Tolerance and Diabetes Mellitus|A Observational Cross Sectional Study to Evaluate the Sensory Nerve Conduction Parameters of the Distal Sensory Nerves in Patients With Impaired Glucose Tolerance and Diabetes Mellitus|Completed|||150|Actual|The Catholic University of Korea|||3||f||||f||||||||||2018-05-31 23:57:05.296801|2018-05-31 23:57:05.296801
NCT01094405|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-26|||2018-01-10|2010-03-26|2010-03-29|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2010||2010-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy|Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy|Active, not recruiting||Phase 2|25|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 23:57:05.383776|2018-05-31 23:57:05.383776
NCT01094392|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2016-03-03|2010-03-26|2010-03-29|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Hemostasis During Asparaginase Treatment in Acute Lymphoblastic Leukemia(ALL)|Influence on Hemostasis During Prolonged Asparaginase Treatment in Childhood and Adolescent ALL|Recruiting|||250|Anticipated|Aarhus University Hospital|||2||f||||f||||||||||2018-05-31 23:57:05.462104|2018-05-31 23:57:05.462104
NCT01094379|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-06-24|2010-03-25|2010-03-26|Estimate|||||||2010-06-24|2010-06-25|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||A Randomised Comparison Between Single Incision Laparoscopic Cholecystectomy and Standard Laparoscopic Cholecystectomy|A Randomised Comparison of Postoperative Pain and Recovery Between Single Incision Laparoscopic Cholecystectomy Using One Port and Standard Laparoscopic Cholecystectomy Using Four Ports|Unknown status|Recruiting|N/A|40|Anticipated|University of Athens||2|||f||||t||||||||||2018-05-31 23:57:05.54358|2018-05-31 23:57:05.54358
NCT01094366|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2011-03-25|2010-03-25|2010-03-26|Estimate|||||||2011-03-25|2011-03-28|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|October 2010|Actual|2010-10-31||Interventional|||Paracervical Block for Pain Control in First Trimester Abortion|An Evaluation of the Paracervical Block for Pain Control in First Trimester Surgical Abortion|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 23:57:05.643739|2018-05-31 23:57:05.643739
NCT01094340|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2012-08-06|2010-03-25|2010-03-26|Estimate|||||||2012-08-06|2012-08-08|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Thalidomide for Patients With Mild to Moderate Alzheimer's Disease|"Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease"|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Banner Health||1|||f||||t||||||||||2018-05-31 23:57:05.826062|2018-05-31 23:57:05.826062
NCT01094327|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-02-07|2010-03-25|2010-03-26|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2008||2008-02-29|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Proteinuria in Pre and Post Transplant|Evaluation of Recipients With and Without Proteinuria, Pre and Post Kidney Transplantation|Recruiting|||100|Anticipated|University of Miami|||||f||||f||||||||||2018-05-31 23:57:05.89939|2018-05-31 23:57:05.89939
NCT01094314|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-03-25|2010-03-25|2010-03-26|Estimate|||||||2010-03-25|2010-03-26|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Impact of Culture Medium on Embryo Quality||Completed||N/A|790|Anticipated|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-05-31 23:57:05.961529|2018-05-31 23:57:05.961529
NCT01094301|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-04-03|2010-03-25|2010-03-26|Estimate|||||||2018-04-03|2018-04-04|Actual|April 2010||2010-04-30|April 2018|2018-04-30|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain|A Prospective Multi-Center Pilot Study of the SPR™ System for the Treatment of Post-Stroke Shoulder Pain|Completed||N/A|28|Actual|SPR Therapeutics, LLC||1|||f||||||||||||||2018-05-31 23:57:06.119078|2018-05-31 23:57:06.119078
NCT01094288|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-01-31|2010-03-25|2010-03-26|Estimate|||||||2017-01-31|2017-02-02|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen|A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen|Completed||Phase 1|41|Actual|Takeda||1|||f||||f||||||||||2018-05-31 23:57:06.205748|2018-05-31 23:57:06.205748
NCT01094275|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2018-01-29|2010-03-25|2010-03-26|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2010||2010-01-31|January 2018|2018-01-31|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30|6 Months|Observational [Patient Registry]|||Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole|Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole|Completed|||75|Actual|The Methodist Hospital System|||4||f||||f||||||None Retained|"~     Cheek swabs for DNA, blood samples for drug metabolite estimation and platelet function~     study.~   "|Undecided|Plan to share data to be determined.|2018-05-31 23:57:06.304044|2018-05-31 23:57:06.304044
NCT01094262|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25||2012-04-26|2016-03-29|2010-03-25|2010-03-26|Estimate||||2012-04-26|2012-04-30|Estimate|2016-03-29|2016-05-02|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis|A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis|Terminated||Phase 2|196|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4||Logistic reasons associated with the FDA-imposed clinical hold.|f||||t||||||||||2018-05-31 23:57:06.390905|2018-05-31 23:57:06.390905
NCT01094249|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2014-04-07|2010-03-25|2010-03-26|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder|An Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Paliperidone Extended-Release on the Steady-State Pharmacokinetics of Valproic Acid in Clinically Stable Subjects With Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder|Completed||Phase 1|9|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 23:57:06.586407|2018-05-31 23:57:06.586407
NCT01094236|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2010-03-25|2010-03-25|2010-03-26|Estimate|||||||2010-03-25|2010-03-26|Estimate|August 2005||2005-08-31|March 2010|2010-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|Playground_2||Interactive Program for Effective Playground Supervision|Interactive Program for Effective Playground Supervision|Completed||N/A|2316|Actual|Oregon Center for Applied Science, Inc.||6|||f||||f||||||||||2018-05-31 23:57:06.694396|2018-05-31 23:57:06.694396
NCT01094223|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2015-12-17|2010-03-25|2010-03-26|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2010||2010-04-30|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|April 2012|Actual|2012-04-30||Interventional|MBRP||Mindfulness Based Relapse Prevention for Stimulant Users|Mindfulness Based Relapse Prevention for Stimulant Users|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:57:06.814339|2018-05-31 23:57:06.814339
NCT01094210|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2015-03-23|2010-03-25|2010-03-26|Estimate|||||||2015-03-23|2015-03-25|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Evaluation of a Low-fluoride Anticaries Toothpaste|Evaluation of a Low-fluoride Anticaries Toothpaste Containing an Innovative Calcium Technology|Completed|||30|Actual|Indiana Nanotech, LLC|||2||f||||t||||||||||2018-05-31 23:57:06.881044|2018-05-31 23:57:06.881044
NCT01094197|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2013-04-11|2010-03-25|2010-03-26|Estimate|||||||2013-04-11|2013-04-12|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Observational|||Detailed Evaluation of Microchimerism|Evaluation to Determine Whether Transfusion-associated Microchimerism Involves Engraftment With Hematopoietic Progenitor Cells|Withdrawn|||0|Actual|Blood Systems Research Institute|||1|Investigators could not identify subjects who met all inclusion criteria.|f||||f||||||Samples With DNA|"~     Leukapheresis filtrate and/or whole blood samples~   "|||2018-05-31 23:57:06.961081|2018-05-31 23:57:06.961081
NCT01094184|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|2016-12-19||2017-08-25|2010-03-25|2010-03-26|Estimate|2017-08-25|2018-03-22|Actual||||2017-08-25|2018-03-22|Actual|March 2010||2010-03-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|BATMAN|Safety analysis population included all participants who received at least one dose of study medication (taxane [paclitaxel/ docetaxel] or bevacizumab).|A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer|Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-Line Treatment of Patients With Advanced Triple Negative Breast Cancer|Completed||Phase 4|49|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:57:07.171865|2018-05-31 23:57:07.171865
NCT01094171|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2013-10-24||2017-03-09|2010-03-25|2010-03-26|Estimate|2013-11-07|2013-12-30|Estimate||||2017-03-09|2017-04-06|Actual|December 2010||2010-12-31|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia|A Phase IV (Not Interventional), Open-label, Multicentre Study to Evaluate the Reactogenicity and Safety of Co-administration of GlaxoSmithKline Biologicals' DTPa (Infanrix) and IPV (Poliorix) Vaccines Administered as Three-dose Primary Immunisation Course at 3, 4.5 and 6 Months of Age in Healthy Children in Russian Federation|Completed||Phase 4|400|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 23:57:09.793507|2018-05-31 23:57:09.793507
NCT01094158|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-01-30|2010-03-25|2010-03-26|Estimate|||||||2012-01-30|2012-01-31|Estimate|November 2010||2010-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|Aramchol003||Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis|A Phase II Placebo Controlled Randomised Study of Aramchol on Liver Triglyceride in Patients With Steatosis Due to NAFLD or NASH|Completed||Phase 2|60|Anticipated|Galmed Medical Reserch||3|||f||||t||||||||||2018-05-31 23:57:10.056497|2018-05-31 23:57:10.056497
NCT01094145|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2013-06-06|2010-03-25|2010-03-26|Estimate|||||||2013-06-06|2013-06-07|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MeynD-DBS||Deep Brain Stimulation (DBS) of the Nucleus Basalis Meynert (NBM) to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease|Deep Brain Stimulation of the Nucleus Basalis Meynert to Treat Cognitive Deficits in Light to Moderate Alzheimer's Disease|Completed||N/A|6|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 23:57:10.170589|2018-05-31 23:57:10.170589
NCT01094132|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-02-02|2010-03-25|2010-03-26|Estimate|||||||2018-02-02|2018-02-05|Actual|December 2012||2012-12-31|January 2018|2018-01-31|November 9, 2016|Actual|2016-11-09|September 1, 2016|Actual|2016-09-01||Interventional|MDC_Algo||Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection|Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.|Completed||Phase 2|551|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 23:57:10.260292|2018-05-31 23:57:10.260292
NCT01094119|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|2016-11-29||2017-03-08|2010-03-25|2010-03-26|Estimate|2017-03-08|2017-04-19|Actual||||2017-03-08|2017-04-19|Actual|March 2010||2010-03-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||Most baseline characteristics were well balanced be- tween the randomized groups. However, patients assigned to resistive heating were more likely to have higher ASA physical status classification. Thus, ASA status was adjusted for in all analyses. Patients in each warming group were given comparable doses of volatile anesthesia and opioid.|A Randomized Comparison of Intraoperative Warming With the LMA PerfecTemp and Forced-air|A Randomized Comparison of Intraoperative Warming With the LMA PerfecTemp and Forced-air|Completed||N/A|70|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 23:57:10.379191|2018-05-31 23:57:10.379191
NCT01094106|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2012-01-01|2010-03-25|2010-03-26|Estimate|||||||2012-01-01|2012-01-04|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Infiltration Analgesia After Caesarean Section|Local Infiltration Analgesia for Postoperative Pain After Caesarean Section. A Prospective, Randomised, Controlled Trial|Completed||Phase 4|70|Actual|North Karelia Central Hospital||2|||f||||f||||||||||2018-05-31 23:57:10.687765|2018-05-31 23:57:10.687765
NCT01094093|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2017-05-18|2010-03-25|2010-03-26|Estimate|||||||2017-05-18|2017-05-19|Actual|April 11, 2010|Actual|2010-04-11|May 2017|2017-05-31|July 26, 2011|Actual|2011-07-26|July 26, 2011|Actual|2011-07-26||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|73|Actual|Allergan||2|||f||||||||||||||2018-05-31 23:57:10.75259|2018-05-31 23:57:10.75259
NCT01094080|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2018-05-30|2010-03-25|2010-03-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 2010||2010-02-28|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|September 2011|Actual|2011-09-30||Interventional|BEMIM||Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health|Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health|Active, not recruiting||N/A|505|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-05-31 23:57:10.823421|2018-05-31 23:57:10.823421
NCT01094067|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25||2012-07-13|2017-08-24|2010-03-25|2010-03-26|Estimate||||2012-07-13|2012-07-23|Estimate|2017-08-24|2017-08-25|Actual|September 1, 2010||2010-09-01|August 2017|2017-08-31|September 1, 2011|Actual|2011-09-01|December 1, 2010|Actual|2010-12-01||Interventional|||Tezosentan in Patients With Pulmonary Arterial Hypertension|Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.|Terminated||Phase 2|2|Actual|Actelion||2||Due to slow recruitment, the study was prematurely discontinued.|f||||f||||||||||2018-05-31 23:57:10.891378|2018-05-31 23:57:10.891378
NCT01094054|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2013-05-08|2010-03-25|2010-03-26|Estimate|||||||2013-05-08|2013-05-10|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Adjustable Gastric Banding and Its Effects on Postprandial Glucose Metabolism Independent of Weight Loss|Adjustable Gastric Banding and Its Effects on Postprandial Glucose Metabolism Independent of Weight Loss|Completed||Phase 4|29|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:57:10.97275|2018-05-31 23:57:10.97275
NCT01094041|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2013-05-08|2010-03-25|2010-03-26|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|||Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome|Gluten Intolerance in Irritable Bowel Syndrome With Diarrhea: The Role of HLA-DQ2|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:57:11.055533|2018-05-31 23:57:11.055533
NCT01094028|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-03-25|2010-03-25|2010-03-26|Estimate|||||||2010-03-25|2010-03-26|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Intraumbilical Vein Injection of Oxytocin in Routine Practice for Active Management of the Third Stage of Labor||Completed||Phase 3|412|Actual|Erzincan Military Hospital||1|||f||||t||||||||||2018-05-31 23:57:11.128073|2018-05-31 23:57:11.128073
NCT01094015|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-04-08|2010-03-25|2010-03-26|Estimate|||||||2010-04-08|2010-04-09|Estimate|July 2007||2007-07-31|March 2006|2006-03-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|HISTEROS-07||Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysteroscopy Practice|Lidocaine-Prilocaine (EMLA) Cream as Analgesia in Hysteroscopy Practice: a Prospective Randomized Clinical Trial|Completed||Phase 4|92|Actual|Consorci Sanitari de Terrassa||2|||f||||t||||||||||2018-05-31 23:57:11.272859|2018-05-31 23:57:11.272859
NCT01094002|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-04-09|2010-03-25|2010-03-26|Estimate|||||||2010-04-09|2010-04-12|Estimate|November 2002||2002-11-30|February 2010|2010-02-28|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Effects of a Structured Occupational Therapy Intervention in an Acute Geriatric Unit|Effects of a Structured Occupational Therapy Intervention in an Acute Geriatric Unit. A Randomised Clinical Trial|Completed||N/A|400|Actual|Complejo Hospitalario Universitario de Albacete||2|||f||||f||||||||||2018-05-31 23:57:11.35319|2018-05-31 23:57:11.35319
NCT01093989|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2015-05-28|2010-03-24|2010-03-26|Estimate|||||||2015-05-28|2015-06-01|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition|Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition|Completed||N/A|239|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 23:57:11.414928|2018-05-31 23:57:11.414928
NCT01093976|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2012-03-01||2013-08-06|2010-03-25|2010-03-26|Estimate|2013-08-06|2013-09-27|Estimate||||2013-08-06|2013-09-27|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Marinol in Trichotillomania or Obsessive Compulsive Disorder|An Open-Label Study of Dronabinol, a Cannabinoid Agonist, for Obsessive Compulsive Disorder and the Obsessive-Compulsive Spectrum Disorders Trichotillomania and Pathological Skin Picking|Completed||Phase 2|14|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 23:57:11.54172|2018-05-31 23:57:11.54172
NCT01093963|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2015-08-31|2010-03-25|2010-03-26|Estimate|||||||2015-08-31|2015-09-02|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression|Adjunctive Lisdexamfetamine in Bipolar Depression|Terminated||Phase 3|25|Actual|Lindner Center of HOPE||2||Enrollment goals not met|f||||f||||||||||2018-05-31 23:57:11.829504|2018-05-31 23:57:11.829504
NCT01093950|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2014-10-07|2010-03-25|2010-03-26|Estimate|||||||2014-10-07|2014-10-09|Estimate|January 2005||2005-01-31|October 2014|2014-10-31|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Observational|||White Light Scanning to Aid Body Contouring: A Pilot Project|White Light Scanning to Aid Body Contouring: A Pilot Project|Recruiting|||500|Anticipated|Eastern Virginia Medical School|||1||f||||f||||||||||2018-05-31 23:57:11.899215|2018-05-31 23:57:11.899215
NCT01093937|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2011-06-22|2010-03-25|2010-03-26|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolar Disorder|A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder|Completed||N/A|30|Anticipated|Centre for Addiction and Mental Health|||||f||||t||||||||||2018-05-31 23:57:11.964995|2018-05-31 23:57:11.964995
NCT01093924|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2013-11-13|2010-03-24|2010-03-26|Estimate|||||||2013-11-13|2013-11-15|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Partnerships to Overcome Obesity Disparities in Hawaii: 18-month CBPR Study|Partnerships to Overcome Obesity Disparities in Hawaii|Completed||N/A|240|Actual|University of Hawaii||3|||f||||t||||||||||2018-05-31 23:57:12.04303|2018-05-31 23:57:12.04303
NCT01093911|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2013-01-03|2010-03-24|2010-03-26|Estimate|||||||2013-01-03|2013-01-04|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity and to Explore the Pharmacodynamics of CDP7657 Administered in Healthy Subjects and in SLE Patients.|Completed||Phase 1|44|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 23:57:12.11338|2018-05-31 23:57:12.11338
NCT01093898|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2018-03-15|2010-03-24|2010-03-26|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2010||2010-04-30|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|Imaging||The Neuroeconomics of Behavioral Therapies for Adolescent Substance Abuse|The Neuroeconomics of Behavioral Therapies for Adolescent Substance Abuse|Completed|||51|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||f||||||||No||2018-05-31 23:57:12.21319|2018-05-31 23:57:12.21319
NCT01093885|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2017-05-01|2010-03-24|2010-03-26|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2010||2010-02-28|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis|An Open Label Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Treatment of Diffuse Systemic Sclerosis|Completed||N/A|15|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 23:57:12.322522|2018-05-31 23:57:12.322522
NCT01093872|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2012-12-06|2010-03-24|2010-03-26|Estimate|||||||2012-12-06|2012-12-10|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Tinnitus Treatment|Repetitive Transcranial Magnetic Stimulation for Tinnitus Treatment|Unknown status|Recruiting|N/A|100|Anticipated|Singapore General Hospital|||||f||||f||||||||||2018-05-31 23:57:13.477292|2018-05-31 23:57:13.477292
NCT01093859|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2012-09-04|2010-03-24|2010-03-26|Estimate|||||||2012-09-04|2012-09-05|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||An Exploratory Phase 1 Microdose Study of PRX-105|An Exploratory Phase 1 Study to Assess the Safety and Pharmacokinetics of PRX-105, Administered as a Single, Microdose, Intravenous Slow Bolus Injection to Healthy Volunteers|Completed||Early Phase 1|10|Actual|Protalix||1|||f||||f||||||||||2018-05-31 23:57:13.539161|2018-05-31 23:57:13.539161
NCT01093846|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2015-02-12|2012-05-02|2016-01-22|2010-03-24|2010-03-26|Estimate|2016-01-22|2016-02-22|Estimate|2012-05-02|2012-05-04|Estimate|2016-01-22|2016-02-22|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SHIELD||38 Week Extension Study to CAIN457C2303|A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study)|Terminated||Phase 3|59|Actual|Novartis|Due to early termination of the study AIN457C2303E1, the analysis of extension period was changed. No efficacy analyses were completed, the safety analyses were reduced to summary of AEs occurred during the extension and safety follow-up periods.|3||Core Study in Behcet's disease with mostly active uveitis did not meet its primary endpoint|f||||||||||||||2018-05-31 23:57:13.661344|2018-05-31 23:57:13.661344
NCT01093833|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2016-05-04|2010-03-25|2010-03-26|Estimate|||||||2016-05-04|2016-05-06|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces|A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces|Completed||Phase 1|40|Actual|Becton, Dickinson and Company||1|||f||||f||||||||No||2018-05-31 23:57:14.174528|2018-05-31 23:57:14.174528
NCT01093820|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-02-28|2010-03-25|2010-03-26|Estimate|||||||2012-02-28|2012-02-29|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|BEATSTEMIPi||Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction|Documentation of Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEAT-STEMI Pilot)|Completed||Phase 2|8|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 23:57:14.333039|2018-05-31 23:57:14.333039
NCT01093807|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2011-04-28|2010-03-25|2010-03-26|Estimate|||||||2011-04-28|2011-04-29|Estimate|March 2010||2010-03-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|FELT||Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension|Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension|Completed||Phase 2|1039|Actual|Recordati Industria Chimica e Farmaceutica S.p.A.||9|||f||||f||||||||||2018-05-31 23:57:14.441252|2018-05-31 23:57:14.441252
NCT01093794|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2011-06-03||2015-07-17|2010-03-24|2010-03-26|Estimate|2011-06-03|2011-06-27|Estimate||||2015-07-17|2015-07-28|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)|A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet|Completed||Phase 1|28|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:57:14.581671|2018-05-31 23:57:14.581671
NCT01093781|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2013-03-12|2010-03-24|2010-03-26|Estimate|||||||2013-03-12|2013-03-13|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Aliskiren in Patients With Idiopathic Membranous Nephropathy|A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy|Withdrawn||N/A|0|Actual|Mayo Clinic||1||Manufacturer asked to close study due to AEs experienced by subjects in other studies.|f||||t||||||||||2018-05-31 23:57:14.943626|2018-05-31 23:57:14.943626
NCT01093768|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2018-05-23|2010-03-25|2010-03-26|Estimate|||||||2018-05-23|2018-05-24|Actual|February 19, 2010||2010-02-19|April 11, 2013|2013-04-11|April 11, 2013|Actual|2013-04-11|April 11, 2013|Actual|2013-04-11||Interventional|||Brain Imaging Study of Adults With Autism Spectrum Disorders|Effects of Prosocial Neuropeptides on Human Brain Function in Healthy Volunteers and Individuals With Autism Spectrum Disorders|Completed||Phase 1|38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:57:15.033557|2018-05-31 23:57:15.033557
NCT01093755|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2016-02-19||2016-02-19|2010-03-25|2010-03-26|Estimate|2016-02-19|2016-03-17|Estimate||||2016-02-19|2016-03-17|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?|Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?: A Randomized Controlled Trial|Completed||Phase 4|30|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 23:57:15.142622|2018-05-31 23:57:15.142622
NCT01093742|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2014-02-06|2010-03-25|2010-03-26|Estimate|||||||2014-02-06|2014-02-07|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of HM10560A in Healthy Male Subject|A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM10560A After S.C. Administration in Healthy Male Subjects|Completed||Phase 1|32|Actual|Hanmi Pharmaceutical Company Limited||4|||f||||f||||||||||2018-05-31 23:57:15.644237|2018-05-31 23:57:15.644237
NCT01093729|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-02-06|2010-03-25|2010-03-26|Estimate|||||||2014-02-06|2014-02-07|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of HM11260C in Healthy Male Subject|A Dose Block-randomized, Double-blind, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM11260C After Subcutaneous Administration in Healthy Male Subjects|Completed||Phase 1|41|Actual|Hanmi Pharmaceutical Company Limited||5|||f||||f||||||||||2018-05-31 23:57:15.7174|2018-05-31 23:57:15.7174
NCT01093716|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-03-25|2010-03-25|2010-03-26|Estimate|||||||2010-03-25|2010-03-26|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Anti-craving Efficacy of Right and Left Prefrontal High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Alcohol Dependence|Comparison of Anti-craving Efficacy of Right and Left Prefrontal High Frequency rTMS in Alcohol Dependence: a Randomized Double-blind Study|Completed||N/A|22|Actual|Central Institute of Psychiatry, Ranchi, India||1|||f||||t||||||||||2018-05-31 23:57:15.79168|2018-05-31 23:57:15.79168
NCT01093703|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2013-05-28|2010-03-24|2010-03-26|Estimate|||||||2013-05-28|2013-05-30|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients|Randomized Trial to Explore the Effect of Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern and Improve Allograft Function in Kidney Transplant Recipients|Completed||N/A|99|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 23:57:15.852553|2018-05-31 23:57:15.852553
NCT01093690|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2010-10-10||2010-11-04|2010-03-24|2010-03-26|Estimate|2010-11-04|2010-12-02|Estimate||||2010-11-04|2010-12-02|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis After Receiving Cisplatin|Randomized, Placebo-controlled Trial of Ondansetron Plus Dexamethasone With or Without Metoclopramide as Antiemetic Prophylaxis in Patients Receiving High Dose Cisplatin in Routine Medical Practice|Completed||N/A|162|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 23:57:16.014544|2018-05-31 23:57:16.014544
NCT01093677|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-06-04|2010-03-25|2010-03-26|Estimate|||||||2010-06-04|2010-06-08|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|LIM||Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance|A Single-Blind,Randomized,Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance|Withdrawn||Phase 1|30|Anticipated|Limerick BioPharma||2||no subjects enrolled|f||||f||||||||||2018-05-31 23:57:16.341695|2018-05-31 23:57:16.341695
NCT01093352|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2017-05-31|2010-03-24|2010-03-25|Estimate|||||||2017-05-31|2017-06-01|Actual|January 2010||2010-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Alveolar-decortication on Velocity of Tooth Movement|The Efficacy of Surgical Exposure With Alveolar-decortication vs. Conventional Surgical Exposure to Reduce Treatment Time for Orthodontic Alignment of Palatally Impacted Canines|Active, not recruiting||N/A|30|Anticipated|University of Birmingham||2|||f||||f||||||||||2018-05-31 23:57:26.660003|2018-05-31 23:57:26.660003
NCT01093664|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2010-10-18|2010-03-25|2010-03-26|Estimate|||||||2010-10-18|2010-10-19|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02|Phase IB Follow-up Study to Assess a Boost Immunization With AFFITOPE AD02 With Regard to Safety/Tolerability, Immunological and Clinical Activity in Alzheimer Patients Who Have Received the Vaccine Within the Clinical Study AFF002|Completed||Phase 1|20|Actual|Affiris AG||1|||f||||t||||||||||2018-05-31 23:57:16.549448|2018-05-31 23:57:16.549448
NCT01093651|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2013-05-13||2014-01-22|2010-03-24|2010-03-26|Estimate|2013-12-17|2014-01-23|Estimate||||2014-01-22|2014-02-17|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|DPPIVinHIV||Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV|A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women|Completed||Phase 2/Phase 3|20|Actual|Washington University School of Medicine|Potential for type 2 error given small sample size. But, study was powered to detect significant decline in CD4 count. Measures of monocyte and lymphocyte activation should be conducted.|2|||f||||t||||||||||2018-05-31 23:57:16.672981|2018-05-31 23:57:16.672981
NCT01093638|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2016-08-09|2010-03-24|2010-03-26|Estimate|||||||2016-08-09|2016-08-11|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|August 2013|Actual|2013-08-31||Interventional|||Oral Formulation of Insulin for Preterm Infants|A Multi-center, Randomized, Double-blinded Clinical Study to Assess the Effect of Insulin Enriched Formula on Gastrointestinal Tract Maturation in Pre-term Infants.|Terminated||Phase 2|33|Actual|Nutrinia||2|||f||||t||||||||No||2018-05-31 23:57:17.338261|2018-05-31 23:57:17.338261
NCT01093625|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2013-10-30||2015-05-05|2010-03-24|2010-03-26|Estimate|2014-02-12|2014-02-13|Estimate||||2015-05-05|2015-05-21|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Baseline participants were those who were randomly assigned to a study arm and started the study.|Assessment of Daily Disposable Silicone Hydrogel Lens Wear||Completed||N/A|157|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 23:57:17.474531|2018-05-31 23:57:17.474531
NCT01093612|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2018-05-04|2010-03-25|2010-03-26|Estimate|||||||2018-05-04|2018-05-08|Actual|March 14, 2011||2011-03-14|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer|64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer|Active, not recruiting||N/A|18|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 23:57:18.132357|2018-05-31 23:57:18.132357
NCT01093599|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2014-05-17||2015-09-30|2010-03-25|2010-03-26|Estimate|2015-01-28|2015-02-16|Estimate||||2015-09-30|2015-10-20|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MTS|total enrolled|Trial on the Effectiveness of Mindfulness Training for Smokers|Phase 2 Randomized Trial on the Effectiveness of Mindfulness Training for Smokers, a Novel Intervention Designed to Help Smokers Quit Smoking|Completed||N/A|196|Actual|University of Wisconsin, Madison|A principal limitation of this study is that it is designed to compare MTS to a less intensive usual care therapy and as such lacks a time/intensity matched control.|2|||f||||t||||||||||2018-05-31 23:57:18.339818|2018-05-31 23:57:18.339818
NCT01093586|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2015-12-18|2010-03-25|2010-03-26|Estimate|||||||2015-12-18|2015-12-21|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies|Completed||Phase 2|14|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:57:19.146623|2018-05-31 23:57:19.146623
NCT01093573|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2016-06-08|2010-03-25|2010-03-26|Estimate|||||||2016-06-08|2016-06-10|Estimate|July 2009||2009-07-31|June 2016|2016-06-30||||June 2016|Actual|2016-06-30||Interventional|||Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia|A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.|Active, not recruiting||Phase 1/Phase 2|34|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 23:57:19.519436|2018-05-31 23:57:19.519436
NCT01093560|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2011-08-03|2010-03-24|2010-03-26|Estimate|||||||2011-08-03|2011-08-05|Estimate|March 2010||2010-03-31|August 2011|2011-08-31|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Interventional|FEMMES II||Fat Effects in Women With Metabolic Syndrome|Fat Effects in Women With Metabolic Syndrome|Unknown status|Active, not recruiting|N/A|10|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 23:57:19.827527|2018-05-31 23:57:19.827527
NCT01093547|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2017-10-18|2010-03-24|2010-03-26|Estimate|||||||2017-10-18|2017-10-20|Actual|February 2010|Anticipated|2010-02-28|October 2017|2017-10-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|ECOS||Open-label, Randomized Trial to Determine the Effect of Icodextrin Versus Dextrose (Dianeal 2.5%) in HOMA IR|Multi-centre, Open-label, Randomized Trial to Determine the Effect of Icodextrin (Extraneal) Versus Dextrose (Dianeal 2.5%) Used in Long-dwell Exchange, Measuring the HOMA Index in Non-diabetic Prevalent CAPD Patients|Withdrawn||Phase 4|0|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 23:57:20.132541|2018-05-31 23:57:20.132541
NCT01093534|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2014-02-26|2012-07-18|2017-02-15|2010-03-24|2010-03-26|Estimate|2014-02-26|2014-04-07|Estimate|2012-08-31|2012-09-06|Estimate|2017-02-15|2017-03-21|Actual|January 2010||2010-01-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SHRINK|Safety analysis set: all randomized participants who took at least 1 dose of the randomized study medication and for whom any data was reported after the first dose of study drug.|Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.|A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and Urinary Nerve Growth Factor in Female Subjects With Overactive Bladder and a Diagnosis of Detrusor Overactivity - A Double-blind, Randomised, Placebo-controlled, Parallel Group, Multi-centre Study.|Completed||Phase 4|547|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.|3|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 23:57:20.708127|2018-05-31 23:57:20.708127
NCT01093339|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-08-18|2010-03-24|2010-03-25|Estimate|||||||2010-08-18|2010-08-19|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|IRUSESOM0428||To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure|To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure, and if This Effect is Mediated in Gastroesophageal Reflux Disease (GERD)Patients by Altering Appetite Regulation|Completed|||50|Actual|Southern Arizona VA Health Care System|||1||f||||f||||||Samples Without DNA|"~     Serum samples collected and stored -80 freezer in GI lab.~   "|||2018-05-31 23:57:26.719816|2018-05-31 23:57:26.719816
NCT01093521|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2014-09-15||2017-04-10|2010-03-25|2010-03-26|Estimate|2015-12-08|2016-01-12|Estimate||||2017-04-10|2017-05-15|Actual|April 2010||2010-04-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|April 2012|Actual|2012-04-30||Interventional||Patients were adults age 18 years but less than 55 years of age with CF and chronic Pseudomonal infection. Patient had to have a baseline FEV1% of predicted greater than or equal to 30%. They had to have been at least 14 days from the end of treatment with intravenous antibiotics for exacerbation. They could not be lactating or pregnant.|A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients|A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients|Active, not recruiting||Phase 1|20|Actual|University of Washington|The primary limitation of our study was that it was uncontrolled without a blinded placebo. Thus, subjective endpoints could have been biased by either the subjects or the investigators.|2|||f||||t||||||||||2018-05-31 23:57:23.846095|2018-05-31 23:57:23.846095
NCT01093508|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-11-01|2010-03-24|2010-03-26|Estimate|||||||2010-11-01|2010-11-02|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Single-dose Safety Study of APD916 in Healthy Volunteers|Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability and Pharmacokinetics of APD916 Administered to Healthy Adult Subjects|Completed||Phase 1|72|Anticipated|Arena Pharmaceuticals|||||f||||f||||||||||2018-05-31 23:57:24.207082|2018-05-31 23:57:24.207082
NCT01093495|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|January 2009||2009-01-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Weaning Preterm Neonates From Nasal Continuous Positive Airway Pressure|A Randomized Controlled Trial on Weaning Preterm Neonates From Nasal Continuous Positive Airway Pressure|Completed||N/A|60|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 23:57:24.285523|2018-05-31 23:57:24.285523
NCT01093482|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2017-02-27||2018-02-01|2010-03-24|2010-03-25|Estimate|2017-06-24|2018-01-26|Actual||||2018-02-01|2018-03-01|Actual|April 2010||2010-04-30|February 2018|2018-02-28|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Observational|ISMV||Third International Study on Mechanical Ventilation|Third Prospective, Observational, International, Multicenter Study on Mechanical Ventilation|Completed|||8151|Actual|Hospital Universitario Getafe|||1||f||||f|f|f||||||Undecided||2018-05-31 23:57:24.462134|2018-05-31 23:57:24.462134
NCT01093469|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2017-01-26||2017-04-11|2010-03-24|2010-03-25|Estimate|2017-04-11|2017-05-18|Actual||||2017-04-11|2017-05-18|Actual|September 2009||2009-09-30|February 2017|2017-02-28|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis|An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis|Completed||N/A|39|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||No||2018-05-31 23:57:25.438108|2018-05-31 23:57:25.438108
NCT01093456|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2016-05-12|2010-03-24|2010-03-25|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Diurnal Variation of Uremic Solutes in Peritoneal Dialysis|Diurnal Variation of Mineral Metabolism and Protein Fermentation Metabolites in Peritoneal Dialysis Patients and Healthy Volunteers|Completed|||18|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples Without DNA|"~     whole blood, serum, urine and dialysate~   "|No||2018-05-31 23:57:25.78609|2018-05-31 23:57:25.78609
NCT01093443|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-10-08|2010-03-24|2010-03-25|Estimate|||||||2010-10-08|2010-10-11|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days|Administration of a GnRH Antagonist During 3 Days at Initiation of the Cycle: Impact on the Stimulation in IVF/ICSI|Completed||Phase 4|70|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 23:57:25.840105|2018-05-31 23:57:25.840105
NCT01093430|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Is the Anterior Superior Iliac Spine a Useful Landmark at Laparoscopy?|Anterior Superior Iliac Spine - A Useful Surface Anatomical Landmark for Safe and Symmetric Accessory Laparoscopic Port Entry|Unknown status|Recruiting|N/A|160|Anticipated|Royal Free Hampstead NHS Trust||2|||f||||f||||||||||2018-05-31 23:57:25.962342|2018-05-31 23:57:25.962342
NCT01093417|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2012-01-28||2016-06-14|2010-03-24|2010-03-25|Estimate|2012-01-28|2012-02-29|Estimate||||2016-06-14|2016-07-14|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study of Vitamin D and Effect on Heart Disease and Insulin Resistance|The Effect of Vitamin D Supplementation on Endothelial Function, Inflammation and Insulin Resistance in HIV|Completed||Phase 2|45|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 23:57:26.054319|2018-05-31 23:57:26.054319
NCT01093404|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2016-07-07|2010-03-24|2010-03-25|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|TASTE||Thrombus Aspiration in Myocardial Infarction|Thrombus Aspiration in ST- Elevation Myocardial Infarction in Scandinavia|Completed||N/A|7243|Actual|Region Örebro County||2|||f||||t||||||||||2018-05-31 23:57:26.298002|2018-05-31 23:57:26.298002
NCT01093391|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-07-20|2010-03-24|2010-03-25|Estimate|||||||2015-07-20|2015-07-22|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|INSPIRON||A Trial of Bare Metal Stent - Cobalt Chromium Versus Stent Coating With Sirolimus|A Randomized Trial of Bare Metal Stent (Cronus®) - Cobalt Chromium Versus Stent Coating With Sirolimus (DES)|Completed||Phase 3|63|Actual|Scitech Produtos Medicos Ltda||2|||f||||t||||||||||2018-05-31 23:57:26.423883|2018-05-31 23:57:26.423883
NCT01093378|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2015-08-28|2010-03-24|2010-03-25|Estimate|||||||2015-08-28|2015-08-31|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|October 2013|Actual|2013-10-31||Observational|ALIFERT||Diet and Its Relationship With Couple Infertility|Impact of the Diet Fertility : A Case-control Multicentric Study|Completed|||400|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Impact of genetic polymorphism on clinical and biological phenotypes linked to food behaviour~     in infertility context~   "|||2018-05-31 23:57:26.508848|2018-05-31 23:57:26.508848
NCT01093365|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2016-08-25|2010-03-24|2010-03-25|Estimate|||||||2016-08-25|2016-08-26|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia|Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia|Completed||Phase 2|58|Actual|Centre for Addiction and Mental Health||1|||f||||t||||||||||2018-05-31 23:57:26.575622|2018-05-31 23:57:26.575622
NCT01093326|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2018-03-02|2010-03-24|2010-03-25|Estimate|||||||2018-03-02|2018-03-05|Actual|May 12, 2010|Actual|2010-05-12|March 2018|2018-03-31|December 15, 2021|Anticipated|2021-12-15|December 15, 2021|Anticipated|2021-12-15||Interventional|||Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis|Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis|Active, not recruiting||Phase 2|353|Actual|Actelion||3|||f||||t||||||||||2018-05-31 23:57:26.782874|2018-05-31 23:57:26.782874
NCT01093313|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|August 2006||2006-08-31|March 2010|2010-03-31|March 2008|Actual|2008-03-31|April 2007|Actual|2007-04-30||Interventional|||Attention Training and Cognitive Therapy|Comparison of Attention Training and Cognitive Therapy in the Treatment of Social Phobia: a Randomized Controlled Trial|Completed||N/A|46|Actual|University of Sydney||2|||f||||t||||||||||2018-05-31 23:57:27.076289|2018-05-31 23:57:27.076289
NCT01093300|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate||||March 2010|2010-03-31||||||||Interventional|||Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -||Unknown status|Not yet recruiting|Phase 4|264|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:57:27.135982|2018-05-31 23:57:27.135982
NCT01093287|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2012-06-10|2010-03-24|2010-03-25|Estimate|||||||2012-06-10|2012-06-12|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Predictors for Responsiveness to Corticosteroid in Patients With Early Acute Respiratory Distress Syndrome|Predictors for Responsiveness to Corticosteroid in Patients With Early Acute Respiratory Distress Syndrome|Terminated|||20|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 23:57:27.207522|2018-05-31 23:57:27.207522
NCT01093274|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate||||February 2010|2010-02-28||||||||Interventional|||Efficacy and Safety of Polyethylene Glycol Compared With Sodium Picosulphate for Bowel Preparation Before Colonoscopy|Efficacy and Safety of Polyethylene Glycol Compared With Sodium Picosulphate for Bowel Preparation Before Colonoscopy, a Prospective Randomized, Controlled Study|Unknown status|Not yet recruiting|N/A|200|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 23:57:27.277622|2018-05-31 23:57:27.277622
NCT01093261|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2017-09-13|2010-03-24|2010-03-25|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2010||2010-08-31|September 2017|2017-09-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|Corti-TC||Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury|Phase 3 Study of Hydrocortisone and Fludrocortisone in Glucocorticoid Insufficiency Related to Traumatic Brain Injury|Completed||Phase 3|336|Actual|Nantes University Hospital||3|||f||||t||||||||||2018-05-31 23:57:27.357262|2018-05-31 23:57:27.357262
NCT01093248|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2012-08-14|2010-03-24|2010-03-25|Estimate|||||||2012-08-14|2012-08-15|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|M0508||Methadone Maintenance Treatment Outcome Study in Taiwan|Methadone Maintenance Treatment Outcome Study in Taiwan|Unknown status|Recruiting||300|Anticipated|National Health Research Institutes, Taiwan|||1||f||||f||||||||||2018-05-31 23:57:27.512414|2018-05-31 23:57:27.512414
NCT01093235|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|April 2009||2009-04-30|March 2010|2010-03-31||||April 2012|Anticipated|2012-04-30||Interventional|||Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer|ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer|Unknown status|Recruiting|Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:57:27.601966|2018-05-31 23:57:27.601966
NCT01093222|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2013-11-01||2015-06-03|2010-03-24|2010-03-25|Estimate|2013-12-23|2014-01-29|Estimate||||2015-06-03|2015-06-30|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2012|Actual|2012-09-30||Interventional||Eligible patients who began protocol therapy|Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma|Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)|The first stage of accrual was met with 40 registered patients. Insufficient number of patients were alive and free from progression at four months to warrant accruing to a second stage.|1|||f||||||||||||||2018-05-31 23:57:27.769324|2018-05-31 23:57:27.769324
NCT01093209|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2011-06-27|2010-03-24|2010-03-25|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy of the Interferential Laser Therapy in Pain Reduction in Carpal Tunnel Syndrome|Efficacy of the Interferential Laser Therapy in Pain Reduction in Carpal Tunnel Syndrome|Completed||Phase 2|100|Anticipated|Hospital Universitario Ramon y Cajal||2|||f||||t||||||||||2018-05-31 23:57:28.345679|2018-05-31 23:57:28.345679
NCT01093196|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2018-02-26|2010-03-24|2010-03-25|Estimate|||||||2018-02-26|2018-02-27|Actual|October 2009||2009-10-31|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|November 2012|Actual|2012-11-30||Interventional|||Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients|A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects|Active, not recruiting||Phase 3|660|Anticipated|Fondazione Neoplasie Sangue Onlus||3|||f||||t||||||||||2018-05-31 23:57:28.419406|2018-05-31 23:57:28.419406
NCT01093183|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-04-03|2010-03-24|2010-03-25|Estimate|||||||2014-04-03|2014-04-04|Estimate|March 2010||2010-03-31|April 2014|2014-04-30||||February 2014|Actual|2014-02-28||Interventional|||Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer|A Phase I/II Clinical Trial of Lenalidomide in Combination With Oral Cyclophosphamide in Patients With Previously Treated Hormone Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|53|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 23:57:28.486237|2018-05-31 23:57:28.486237
NCT01093170|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2018-01-15|2010-03-24|2010-03-25|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2011||2011-03-31|January 2018|2018-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy|A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy|Withdrawn||Phase 1|0|Actual|University of Kentucky||1||Study was not conducted, no subjects recruited.|f||||f||||||||||2018-05-31 23:57:28.578742|2018-05-31 23:57:28.578742
NCT01093157|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2017-05-02|2010-03-24|2010-03-25|Estimate|||||||2017-05-02|2017-05-04|Actual|February 2010||2010-02-28|January 2013|2013-01-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy|A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN)|Completed||Phase 1/Phase 2|10|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 23:57:28.631517|2018-05-31 23:57:28.631517
NCT01093144|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Assessment of Pelvis Diameters as a Predictor for the Mode of Delivery ,Using Non-invasive, Ultrasound Based Measurements|Assessment of Pelvis Diameters as a Predictor for the Mode of Delivery ,Using Non-invasive, Ultrasound Based Measurements.|Unknown status|Not yet recruiting|N/A|100|Anticipated|Trig Medical Inc|||||f||||f||||||||||2018-05-31 23:57:28.690631|2018-05-31 23:57:28.690631
NCT01093131|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2016-11-29|2010-03-23|2010-03-25|Estimate|||||||2016-11-29|2016-11-30|Estimate|February 2005||2005-02-28|November 2016|2016-11-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|HYDRATE||Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy|Oral Hydration and Alkalinization is Non-Inferior to Intravenous Therapy for Prevention of Contrast Induced Nephropathy in Patients With Chronic Kidney Disease.|Completed||Phase 4|91|Actual|The Western Pennsylvania Hospital||4|||f||||t||||||||||2018-05-31 23:57:28.741257|2018-05-31 23:57:28.741257
NCT01093118|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2011-01-14|2010-03-24|2010-03-25|Estimate|||||||2011-01-14|2011-01-17|Estimate|September 2009||2009-09-30|January 2011|2011-01-31||||April 2011|Anticipated|2011-04-30||Interventional|||A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis|A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TMI-358 in the Treatment of Distal Subungual Onychomycosis of the Toenail|Terminated||Phase 2|120|Anticipated|Talima Therapeutics, Inc.||2||Business decision|f||||f||||||||||2018-05-31 23:57:28.923165|2018-05-31 23:57:28.923165
NCT01093105|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-02-19|2010-03-24|2010-03-25|Estimate|||||||2014-02-19|2014-02-21|Estimate||||February 2014|2014-02-28||||||||Observational|||An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)|A Multicenter, Prospective, Longitudinal, Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (Krabbe Disease)|Withdrawn|||0|Actual|Shire||||Study halted prior to enrollment of first participant|f||||f||||||||||2018-05-31 23:57:28.998202|2018-05-31 23:57:28.998202
NCT01093092|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2016-01-11|2010-03-24|2010-03-25|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery|A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors|Terminated||Phase 1|14|Actual|Roswell Park Cancer Institute||1||Study transferring to INOVA Health|f||||f||||||||||2018-05-31 23:57:29.062764|2018-05-31 23:57:29.062764
NCT01093079|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|September 2009||2009-09-30|July 2009|2009-07-31||||||||Observational|LapVsOpen prtn||Laparoscopic Versus Open Partial Nephrectomy - Surgical and Oncological Outcomes||Unknown status|Recruiting||100|Anticipated|Rabin Medical Center|||2||f||||||||||||||2018-05-31 23:57:29.189269|2018-05-31 23:57:29.189269
NCT01093066|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2017-07-26|2010-03-24|2010-03-25|Estimate|||||||2017-07-26|2017-07-28|Actual|September 2010||2010-09-30|September 2016|2016-09-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|ReChiVe||Prospective Multicentric Evaluation of a Bladder Preservation Strategy|Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma|Recruiting||Phase 2|77|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||t|f|f||||||||2018-05-31 23:57:29.319658|2018-05-31 23:57:29.319658
NCT01093053|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-01-27|2010-03-24|2010-03-25|Estimate|||||||2014-01-27|2014-01-29|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations|A Randomized Controlled Study of Mind-Body Skills Groups for Treatment of War Zone Stress in Military and Veteran Populations|Completed||N/A|108|Actual|The Center for Mind-Body Medicine||2|||f||||f||||||||||2018-05-31 23:57:29.591485|2018-05-31 23:57:29.591485
NCT01093040|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2012-08-29|2010-03-24|2010-03-25|Estimate|||||||2012-08-29|2012-08-30|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects|A Phase I, Single-Center, Single-blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of CAT-354 Following Subcutaneous Administration in Healthy Male and Female Japanese Subjects|Completed||Phase 1|30|Actual|MedImmune LLC||3|||f||||f||||||||||2018-05-31 23:57:29.677433|2018-05-31 23:57:29.677433
NCT01093027|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|2012-02-01||2012-12-14|2010-03-24|2010-03-25|Estimate|2012-03-06|2012-04-03|Estimate||||2012-12-14|2012-12-19|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor|Electrophysiological Study of the Effects of Limb Cooling on Essential Tremor|Completed||N/A|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:57:29.773631|2018-05-31 23:57:29.773631
NCT01093014|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2016-01-07||2016-02-09|2010-03-24|2010-03-25|Estimate|2016-01-07|2016-02-05|Estimate||||2016-02-09|2016-03-10|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Novel Intervention to Influence Muscle Plasticity in Veterans|Novel Intervention to Influence Muscle Plasticity in Veterans|Completed||N/A|33|Actual|VA Office of Research and Development||3|||f||||f||||||||No||2018-05-31 23:57:29.981277|2018-05-31 23:57:29.981277
NCT01093001|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2016-11-02|2010-03-24|2010-03-25|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Interventional|||Tricuspid Regurgitation Study|The Effect of Cardiac Pacing Leads on Tricuspid Regurgitation|Completed||Phase 4|119|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 23:57:30.238572|2018-05-31 23:57:30.238572
NCT01092988|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2012-02-19|2010-03-24|2010-03-25|Estimate|||||||2012-02-19|2012-02-22|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids|A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids|Completed||N/A|40|Anticipated|InSightec||1|||f||||f||||||||||2018-05-31 23:57:30.332699|2018-05-31 23:57:30.332699
NCT01092975|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2015-07-22|2010-03-24|2010-03-25|Estimate|||||||2015-07-22|2015-07-23|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|||Safety of Phenylephrine for Oral Mucositis Prevention|A Phase I Safety Study of Phenylephrine Applied Topically to the Oral Mucosa in Cancer Patients Receiving Radiation to Sub-mandibular Lymph Nodes|Terminated||Phase 1|1|Actual|University of Wisconsin, Madison||8||formulation/dose changes; planned changes to safety monitoring/reporting|f||||t||||||||||2018-05-31 23:57:30.400987|2018-05-31 23:57:30.400987
NCT01092962|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2015-03-25|2010-03-24|2010-03-25|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|NEPHROMYCY||Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children|Cyclophosphamide Versus Mycophenolate Mofetil for Children With Steroid-dependent Idiopathic Nephrotic Syndrome : a Multicenter Randomized Controlled Trial|Completed||Phase 3|70|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:57:30.475576|2018-05-31 23:57:30.475576
NCT01092949|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2016-04-18|2010-03-24|2010-03-25|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|March 2016|Actual|2016-03-31||Observational|||Reference Ranges for Placental Perfusion Using Magnetic Resonance Imaging (MRI)PLACENTIMAGE|Reference Ranges for Placental Perfusion Using Magnetic Resonance Imaging (MRI)PLACENTIMAGE|Unknown status|Active, not recruiting||135|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 23:57:30.546742|2018-05-31 23:57:30.546742
NCT01092936|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|IRIS||Italian Validation of the Revised MDS-Unified Parkinson's Disease Rating Scale|Italian Validation of the Revised MDS-Unified Parkinson's Disease Rating Scale|Unknown status|Not yet recruiting||350|Anticipated|Fondazione Neureca|||||f||||t||||||||||2018-05-31 23:57:30.622124|2018-05-31 23:57:30.622124
NCT01092923|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2012-02-16||2012-09-11|2010-03-24|2010-03-25|Estimate|2012-09-11|2012-10-12|Estimate||||2012-09-11|2012-10-12|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Physiological Effects of Nitrous Oxide on Anaesthesia|Nitrous Oxide and Inhalational Agent Pharmacokinetics During Anaesthetic Induction and Emergence|Completed||Phase 4|20|Actual|Austin Health||2|||f||||t||||||||||2018-05-31 23:57:30.705448|2018-05-31 23:57:30.705448
NCT01092910|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2016-01-26||2016-01-26|2010-03-24|2010-03-25|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|August 2010|Actual|2010-08-31|July 2009|Actual|2009-07-31||Interventional|||Esteem Totally Implantable Hearing System|Esteem Totally Implantable Hearing System Clinical Trial U.S. Pivotal Trial|Completed||N/A|57|Actual|Envoy Medical Corporation||1|||f||||t||||||||No||2018-05-31 23:57:31.037607|2018-05-31 23:57:31.037607
NCT01092897|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-02-03|2010-03-24|2010-03-25|Estimate|||||||2014-02-03|2014-02-04|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Pulmonary Hypertension and Imatinib|Biomarkers in Pulmonary Arterial Hypertension Treated With Imatinib|Completed|||130|Anticipated|The Cleveland Clinic|||1||f||||f||||||||||2018-05-31 23:57:31.246425|2018-05-31 23:57:31.246425
NCT01092884|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2012-07-23|2010-03-23|2010-03-25|Estimate|||||||2012-07-23|2012-07-25|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Polypodium Leucotomos Extract for the Treatment of Melasma|Polypodium Leucotomos Extract as an Adjunct to Sunscreen for the Treatment of Melasma|Completed||N/A|40|Actual|University of Texas Southwestern Medical Center||2|||f||||||||||||||2018-05-31 23:57:31.344271|2018-05-31 23:57:31.344271
NCT01092871|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-12-18|2010-03-24|2010-03-25|Estimate|||||||2014-12-18|2014-12-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 23:57:31.412406|2018-05-31 23:57:31.412406
NCT01092858|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-24|||2014-11-03|2010-03-24|2010-03-25|Estimate|||||||2014-11-03|2014-11-05|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)|Effect of Exercise Alone or in Combination With Testosterone Replacement on Muscle Strength and Quality of Life in Older Men With Low Testosterone Concentrations: a Randomized Double-blind, Placebo Controlled Study|Terminated||Phase 4|4|Actual|Bayer||2|||f||||f||||||||||2018-05-31 23:57:31.441508|2018-05-31 23:57:31.441508
NCT01092845|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-07-14|2010-03-23|2010-03-25|Estimate|||||||2010-07-14|2010-07-15|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers|Double-Blind, Randomized, Multiple-Dose, Placebo-Controlled, 2-Way Crossover Study To Study Effects of PF-04457845 On Polysomnographic Endpoints In Healthy Volunteers|Completed||Phase 1|30|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 23:57:31.522837|2018-05-31 23:57:31.522837
NCT01092832|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2014-06-02||2016-05-17|2010-03-23|2010-03-25|Estimate|2015-08-10|2015-08-17|Estimate||||2016-05-17|2016-06-23|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional||Safety population: all participants who received at least 1 dose of study medication.|A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients|A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects|Terminated||Phase 3|23|Actual|Pfizer|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.|1||"This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any~   safety issues or concerns."|f||||t||||||||||2018-05-31 23:57:31.598608|2018-05-31 23:57:31.598608
NCT01092819|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2016-09-26|2010-03-24|2010-03-25|Estimate|||||||2016-09-26|2016-09-28|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|FIRST||A Clinical Trial to Assess the Acute Safety and Functional Outcome and Recovery After STROKE: The FIRST Trial|Functional Outcome and Recovery After STROKE: The FIRST Trial|Active, not recruiting|||150|Anticipated|Penumbra Inc.|||1||f||||f||||||||||2018-05-31 23:57:31.934482|2018-05-31 23:57:31.934482
NCT01092806|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-12-02|2010-03-24|2010-03-25|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|ADVA-09||Insulin Secretion and Advagraf|Effects on Insulin Secretion and Sensitivity of Two Different Formulations Tacrolimus - Prograf® and Advagraf®|Completed||Phase 4|20|Actual|University of Oslo School of Pharmacy||2|||f||||f||||||||||2018-05-31 23:57:32.880534|2018-05-31 23:57:32.880534
NCT01092793|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-25|Estimate|||||||2010-03-23|2010-03-25|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease|Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease|Unknown status|Recruiting|N/A|60||Oslo University Hospital||3|||f||||f||||||||||2018-05-31 23:57:32.990835|2018-05-31 23:57:32.990835
NCT01092780|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2016-02-18||2016-03-22|2010-03-23|2010-03-25|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)|An Active-Comparator Controlled Single Dose Study to Evaluate the Pharmacodynamics/Efficacy of MK-7288 in Sleep Apnea Patients|Completed||Phase 1|56|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:57:33.094397|2018-05-31 23:57:33.094397
NCT01092767|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|2014-02-13||2018-02-05|2010-03-23|2010-03-25|Estimate|2014-02-13|2014-03-28|Estimate||||2018-02-05|2018-02-07|Actual|April 2010|Actual|2010-04-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|April 2012|Actual|2012-04-30||Interventional|RESCUE||Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury|Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System for the Endovascular Treatment of Blunt Thoracic Aortic Injuries (RESCUE)|Completed||N/A|50|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-05-31 23:57:33.478138|2018-05-31 23:57:33.478138
NCT01092754|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2017-07-31|2010-03-24|2010-03-25|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2002||2002-05-31|July 2017|2017-07-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients|An Open-Label, Multicenter, Phase 4 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark(R) in Pediatric Patients (2-11 & 12-18 Yrs) Referred for Contrast-Enhanced MRI|Completed||Phase 4|100|Actual|Guerbet||2|||f||||f||||||||||2018-05-31 23:57:33.756517|2018-05-31 23:57:33.756517
NCT01092741|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2016-05-09|2010-03-23|2010-03-25|Estimate|||||||2016-05-09|2016-05-11|Estimate|July 2001||2001-07-31|May 2016|2016-05-31|September 2013|Actual|2013-09-30|December 2006|Actual|2006-12-31||Interventional|||Late Chronic Phase Chronic Myelogenous Leukemia|Therapy of Late Chronic Phase Chronic Myelogenous Leukemia (CML) With High-Dose Gleevec (STI571)|Completed||Phase 2|47|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 23:57:33.850726|2018-05-31 23:57:33.850726
NCT01092728|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2016-05-13||2016-07-20|2010-03-23|2010-03-25|Estimate|2016-07-20|2016-09-05|Estimate||||2016-07-20|2016-09-05|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||One participant was screen-failed prior to study group entry.|Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma|A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma|Terminated||Phase 2|19|Actual|M.D. Anderson Cancer Center||2||Slow accrual.|f||||t||||||||||2018-05-31 23:57:33.940228|2018-05-31 23:57:33.940228
NCT01092715|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|June 2003||2003-06-30|March 2010|2010-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Cervical Mobilization vs. Standard Physical Therapy for Chronic Neck Pain|"A Comparison of Cervical Spine Mobilization and Standard Physical Therapy Intervention in the Treatment of Chronic Neck Pain, A Pilot Study"|Completed||Phase 2|23|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:57:34.24019|2018-05-31 23:57:34.24019
NCT01092702|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2010-10-28||2011-04-15|2010-03-23|2010-03-25|Estimate|2010-10-28|2010-11-30|Estimate||||2011-04-15|2011-04-19|Estimate|April 2008||2008-04-30|April 2011|2011-04-30|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Varenicline For Smokers In Recovery From Alcohol Dependence|A Pilot Study of Varenicline for Tobacco Dependence Treatment in Recovering Alcoholic Smokers: the Clinical Trial|Completed||Phase 2/Phase 3|32|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 23:57:34.323276|2018-05-31 23:57:34.323276
NCT01092689|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-01-22|2010-03-23|2010-03-25|Estimate|||||||2014-01-22|2014-01-23|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Role of Meat-borne Carcinogens in Pancreatic Cancer|Understanding the Role of Meat-Borne Carcinogen in Pancreatic Cancer Etiology|Withdrawn||Phase 1|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||Needed New IND per FDA|f||||t||||||||||2018-05-31 23:57:34.462056|2018-05-31 23:57:34.462056
NCT01092676|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-06-02|2010-03-23|2010-03-25|Estimate|||||||2010-06-02|2010-06-04|Estimate|February 2010||2010-02-28|June 2010|2010-06-30||||February 2012|Anticipated|2012-02-29||Interventional|||Regular vs Intermittent Dose Ibuprofen for the Treatment of Ankle Sprains in Children|Regular vs Intermittent Dose Ibuprofen for the Treatment of Ankle Sprains in Children|Unknown status|Recruiting|N/A|90|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:57:34.521364|2018-05-31 23:57:34.521364
NCT01092663|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2012-11-12||2013-01-15|2010-03-23|2010-03-25|Estimate|2013-01-15|2013-01-17|Estimate||||2013-01-15|2013-01-17|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus|The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Patients With Type 2 Diabetes|Completed||N/A|61|Actual|KineMed||2|||f||||t||||||||||2018-05-31 23:57:34.644215|2018-05-31 23:57:34.644215
NCT01092650|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-10-24|2010-03-24|2010-03-25|Estimate|||||||2014-10-24|2014-10-27|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine|Determining Levels of [D10] Phenanthrene Tetraol in Smokers' Urine|Completed||Phase 1|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 23:57:35.481748|2018-05-31 23:57:35.481748
NCT01092637|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2015-03-04||2015-12-15|2010-03-23|2010-03-25|Estimate|2015-12-15|2016-01-21|Estimate||||2015-12-15|2016-01-21|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Observational||96 children died before school age assessment could take place. 184 children were included in the 6-7 year follow-up study, 98 cooled and 86 non-cooled.|The TOBY Children Study|School Age Outcomes Following a Newborn Cooling Trial|Completed|||280|Actual|Imperial College London|||2||f||||f||||||||||2018-05-31 23:57:35.569996|2018-05-31 23:57:35.569996
NCT01092624|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2011-11-03|2010-03-23|2010-03-25|Estimate|||||||2011-11-03|2011-11-04|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|PESSARY||Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse|"A Randomized, Placebo-Controlled Parallel-Design Trial of the Effect of Solifenacin Treatment for Overactive Bladder in Women With Anterior Vaginal Wall Prolapse Managed With a Pessary (the PESSARY Study)"|Terminated||Phase 4|94|Anticipated|Hartford Hospital||2||sponsor closed study due to poor enrollment|f||||f||||||||||2018-05-31 23:57:35.774726|2018-05-31 23:57:35.774726
NCT01092611|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2018-03-01|2010-03-23|2010-03-25|Estimate|||||||2018-03-01|2018-03-02|Actual|March 22, 2010|Actual|2010-03-22|March 2018|2018-03-31|May 19, 2014|Actual|2014-05-19|March 17, 2014|Actual|2014-03-17||Interventional|||Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine|Long-term Follow-up of Participants From Studies Evaluating the HIV Vaccine 732462|Completed||Phase 1|190|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 23:57:35.859642|2018-05-31 23:57:35.859642
NCT01092598|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2015-05-26|2010-03-24|2010-03-25|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|June 2012|Actual|2012-06-30||Observational|||Factors Association With Poor Physical Function in Older Adults With Schizophrenia|The Impact of Neurocognition and Symptomatology on Physical Function Among Older Adults With Schizophrenia|Completed|||46|Actual|University of California, San Francisco|||||f||||t||||||||||2018-05-31 23:57:36.017347|2018-05-31 23:57:36.017347
NCT01092585|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2011-11-04|2010-03-24|2010-03-25|Estimate|||||||2011-11-04|2011-11-08|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH|A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH|Unknown status|Recruiting|Phase 2|27|Anticipated|Genta Incorporated|||||f||||f||||||||||2018-05-31 23:57:36.068241|2018-05-31 23:57:36.068241
NCT01092572|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-01-29|2010-03-24|2010-03-25|Estimate|||||||2014-01-29|2014-01-30|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|CFStatin||Statins To Treat Adult Cystic Fibrosis|The Effect of Simvastatin on Systemic Inflammation in Adult Cystic Fibrosis Subjects: A Pilot Study|Withdrawn||Phase 1/Phase 2|0|Actual|University of British Columbia||2||Lack of funding|f||||f||||||||||2018-05-31 23:57:36.128641|2018-05-31 23:57:36.128641
NCT01092559|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2013-04-18||2013-04-18|2010-03-23|2010-03-25|Estimate|2013-04-18|2013-06-04|Estimate||||2013-04-18|2013-06-04|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PILOT||Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide|An Open Label Pilot Study Evaluating Preliminary Safety and Performance of the GeNO Nitrosyl Delivery System|Completed||Phase 2|10|Actual|Geno LLC||1|||f||||f||||||||||2018-05-31 23:57:36.203307|2018-05-31 23:57:36.203307
NCT01092546|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2013-09-05||2013-11-20|2010-03-23|2010-03-25|Estimate|2013-09-05|2013-11-19|Estimate||||2013-11-20|2013-12-13|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||4 of the 16 Subjects were withdrawn prior to study dosing.|Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus|A Principal, Prospective, Open-label Biopsy Study to Validate Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Normal Pressure Hydrocephalus (NPH) Subjects.|Terminated||Phase 3|12|Actual|GE Healthcare||1||Changed focus of the program|f||||t||||||||||2018-05-31 23:57:36.356322|2018-05-31 23:57:36.356322
NCT01092533|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2017-05-05|2010-03-24|2010-03-25|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2010||2010-03-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|MYCUV-IIT02||Myfortic for the Treatment of Non-infectious Intermediate Uveitis|Myfortic (Enteric-coated Mycophenolate Sodium) for the Treatment of Non-infectious Intermediate Uveitis - a Prospective, Controlled, Randomized Multicenter Trial|Completed||Phase 3|44|Actual|STZ eyetrial||2|||f||||t||||||||||2018-05-31 23:57:36.494462|2018-05-31 23:57:36.494462
NCT01092520|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2013-08-19|2010-03-24|2010-03-25|Estimate|||||||2013-08-19|2013-08-20|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children|Open Label Pilot Study of Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children|Withdrawn||Phase 1|0|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 23:57:36.650932|2018-05-31 23:57:36.650932
NCT01092507|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2013-09-30||2013-11-30|2010-03-24|2010-03-25|Estimate|2013-09-30|2013-12-02|Estimate||||2013-11-30|2013-12-25|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers|A Controlled Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Comparison With SA14-14-2 Vaccine in Infants and Toddlers in Thailand|Completed||Phase 3|300|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:57:36.738684|2018-05-31 23:57:36.738684
NCT01092494|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-24|2010-03-24|2010-03-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Observational|||Postoperative Cyclic Oral Contraceptive Use for the Prevention of Endometrioma Recurrence|Efficacy of Postoperative Cyclic Oral Contraceptive Use After Gonadotropin-releasing Hormone Agonist for the Prevention of Endometrioma Recurrence|Unknown status|Not yet recruiting||232|Anticipated|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 23:57:37.227584|2018-05-31 23:57:37.227584
NCT01092481|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2018-01-15|2010-03-24|2010-03-25|Estimate|||||||2018-01-15|2018-01-17|Actual|January 26, 2010|Actual|2010-01-26|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy|A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer|Recruiting||Phase 3|2660|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 23:57:37.309673|2018-05-31 23:57:37.309673
NCT01092468|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2011-10-02|2010-03-24|2010-03-25|Estimate|||||||2011-10-02|2011-10-04|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of Harmonic Scalpel to Conventional Diathermy in Perforator Flap Elevation for Head and Neck Reconstruction|Prospective, Randomised, Single-blinded Study : Comparison of Harmonic Scalpel to Conventional Diathermy in Perforator Flap|Completed||Phase 2|20|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 23:57:37.464532|2018-05-31 23:57:37.464532
NCT01092455|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2011-08-31|2010-03-24|2010-03-25|Estimate|||||||2011-08-31|2011-09-02|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Observational|||Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment|Citrasate® Effect On Heparin N Requirements During Hemodialysis Treatment: A Phase IV,Study to Investigate the Effects of Citrasate on Heparin N Requirements During Hemodialysis Treatment in Subjects Maintained on Thrice Weekly Hemodialysis|Completed|||300|Anticipated|Fresenius Medical Care North America|||1||f||||f||||||||||2018-05-31 23:57:37.529771|2018-05-31 23:57:37.529771
NCT01092442|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2015-11-02||2016-08-26|2010-03-24|2010-03-25|Estimate|2015-11-02|2015-12-09|Estimate||||2016-08-26|2016-10-06|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SGPV||CryoValve SG Pulmonary Human Heart Valve Post Clearance Study|CryoValve SG Pulmonary Human Heart Valve Post Clearance Study|Completed|||140|Actual|CryoLife, Inc.|||2||f||||f||||||||||2018-05-31 23:57:37.638829|2018-05-31 23:57:37.638829
NCT01092429|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-07-28|2010-03-23|2010-03-25|Estimate|||||||2014-07-28|2014-07-29|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|TDI||2D and Tissue Doppler Imaging Echocardiography Analysis of Left Ventricular Regional Wall Motion and Prognosis||Unknown status|Recruiting||500|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-05-31 23:57:37.954103|2018-05-31 23:57:37.954103
NCT01092416|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2015-09-01||2017-01-27|2010-03-23|2010-03-25|Estimate|2015-12-01|2016-01-06|Estimate||||2017-01-27|2017-03-09|Actual|May 2010||2010-05-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2013|Actual|2013-01-31||Interventional|ORBIT II||Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions|Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°® Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II)|Completed||N/A|443|Actual|Cardiovascular Systems Inc|||||f||||t||||||||||2018-05-31 23:57:38.091596|2018-05-31 23:57:38.091596
NCT01092403|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2012-01-25|2010-03-23|2010-03-25|Estimate|||||||2012-01-25|2012-01-26|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Inhalation Once Daily to Subjects With Mild Allergic Asthma|Completed||Phase 2|24|Actual|Asmacure Ltée||2|||f||||f||||||||||2018-05-31 23:57:38.638287|2018-05-31 23:57:38.638287
NCT01092390|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2012-04-27|2010-03-23|2010-03-24|Estimate|||||||2012-04-27|2012-04-30|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease|"Go FishOmega-3 Fatty Acid Supplementation in Diabetic Kidney Disease"|Completed||Phase 3|31|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 23:57:38.799846|2018-05-31 23:57:38.799846
NCT01092377|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2011-01-13|2010-03-23|2010-03-24|Estimate|||||||2011-01-13|2011-01-14|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|FeFA||The Effects of Iron and Omega-3 Fatty Acid Supplementation on Cognition and Immune Function in Iron Deficient Children|The Effects of Iron and Omega-3 Fatty Acid Supplementation, Alone and in Combination, on Cognition, Immune System and Gut Microbiota: a Randomized, Double-blind, 2x2 Intervention Trial in Iron Deficient South African Children|Completed||N/A|320|Actual|North-West University, South Africa||4|||f||||t||||||||||2018-05-31 23:57:39.004866|2018-05-31 23:57:39.004866
NCT01092364|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2017-08-21||2017-11-01|2010-03-23|2010-03-24|Estimate|2017-11-01|2017-11-13|Actual||||2017-11-01|2017-11-13|Actual|November 2010||2010-11-30|November 2017|2017-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CITY||Cell Phone Intervention in Young Adults|Cell Phone Intervention in Young Adults|Completed||N/A|365|Actual|Duke University||3|||f||||t||||||||||2018-05-31 23:57:39.085487|2018-05-31 23:57:39.085487
NCT01092351|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-03-22|2010-03-22|2010-03-24|Estimate|||||||2010-03-22|2010-03-24|Estimate|January 2007||2007-01-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults|Open Label Study on the Bacteriological and Clinical Efficacy and Safety of a Nitrofurantoin Formulation Given Twice Daily (Bid) for Seven Days in Uncomplicated Urinary Tract Infection in Adults|Completed||Phase 4|37|Actual|Mepha Ltd.||1|||f||||f||||||||||2018-05-31 23:57:39.548597|2018-05-31 23:57:39.548597
NCT01092338|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|2013-01-07||2013-08-01|2010-03-23|2010-03-24|Estimate|2013-08-01|2013-09-18|Estimate||||2013-08-01|2013-09-18|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Vitamin D Dose Finding Study|Safe and Effective Vitamin D Supplementation in HIV|Completed||Phase 2|44|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 23:57:39.650879|2018-05-31 23:57:39.650879
NCT01092325|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2016-06-30|2010-03-23|2010-03-24|Estimate|||||||2016-06-30|2016-07-01|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure|A Phase I/IIa Dose-Escalation Study Evaluating the Safety and Tolerability of CXL-1020 and Specific Effects on Electrocardiographic and Non-Invasive Hemodynamic Parameters in Patients With Chronic Heart Failure|Completed||Phase 1/Phase 2|28|Actual|Bristol-Myers Squibb||6|||f||||t||||||||||2018-05-31 23:57:39.915829|2018-05-31 23:57:39.915829
NCT01092312|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2017-08-31|2010-03-23|2010-03-24|Estimate|||||||2017-08-31|2017-09-05|Actual|March 2010|Actual|2010-03-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Signature Personalised Patient Care System With the Vanguard Knee System Study|Study on the Signature Personalised Patient Care System With the Vanguard Knee System|Terminated||N/A|325|Actual|Zimmer Biomet||2||No difference in outcome between the two groups|f||||f||||||||||2018-05-31 23:57:40.022523|2018-05-31 23:57:40.022523
NCT01092299|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-08-26|2010-03-23|2010-03-24|Estimate|||||||2010-08-26|2010-08-27|Estimate|February 2010||2010-02-28|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions|A Phase I Study to Investigate the Relative Bioavailability of Modified-release Formulations of AZD1446 Compared to an Immediate-release Capsule Under Fed and Fasting Conditions Following Single and Repeated Dose Administration to Young and Elderly Healthy Volunteers|Completed||Phase 1|62|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 23:57:40.106924|2018-05-31 23:57:40.106924
NCT01092286|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2018-01-23|2010-03-23|2010-03-24|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2006||2006-07-31|January 2018|2018-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Neuromuscular Warm-up on Injuries in Female Athletes|Effect of Neuromuscular Warm-up on Injuries in Female Athletes in Urban Public High Schools: A Cluster-randomized Controlled Trial|Completed||N/A|1653|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 23:57:40.199234|2018-05-31 23:57:40.199234
NCT01092273|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate||||January 2008|2008-01-31||||||||Observational|||Bimatoprost Versus Travoprost at Cairo University|Bimatoprost Versus Travoprost in an Egyptian Population: A Hospital-Based Prospective Randomized Study.|Completed|||||Cairo University|||1||f||||t||||||||||2018-05-31 23:57:40.275366|2018-05-31 23:57:40.275366
NCT01092260|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2012-01-03|2010-03-23|2010-03-24|Estimate|||||||2012-01-03|2012-01-05|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Renal Function Measurements in Children|Glomerular Filtration Rate in Children - a Methodological Study With Iohexol Clearance|Completed|||96|Actual|Haukeland University Hospital|||||f||||||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 23:57:40.339031|2018-05-31 23:57:40.339031
NCT01092234|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2017-09-28|2010-03-23|2010-03-24|Estimate|||||||2017-09-28|2017-10-02|Actual|March 2010|Actual|2010-03-31|September 2017|2017-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effectiveness of an Observational Unit at St. Olavs Hospital|An Open Randomized Trial of the Effectiveness of an Observational Unit at St. Olavs Hospital|Completed||N/A|105|Actual|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 23:57:40.459585|2018-05-31 23:57:40.459585
NCT01092221|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2012-05-06|2010-03-23|2010-03-24|Estimate|||||||2012-05-06|2012-05-08|Estimate|May 2010||2010-05-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode|Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode.|Completed||Phase 3|180|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 23:57:40.528862|2018-05-31 23:57:40.528862
NCT01092208|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2018-05-19|2010-03-23|2010-03-24|Estimate|||||||2018-05-19|2018-05-22|Actual|March 17, 2010||2010-03-17|September 24, 2013|2013-09-24|September 24, 2013||2013-09-24|||||Observational|||Studies of Autistic Patients: Gene Networks and Clinical Subtypes|Studies of Autistic Patients: Gene Networks and Clinical Subtypes|Terminated|||11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:57:40.636283|2018-05-31 23:57:40.636283
NCT01092195|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2018-03-16|2010-03-23|2010-03-24|Estimate|||||||2018-03-16|2018-03-19|Actual|March 18, 2010||2010-03-18|July 18, 2017|2017-07-18|July 19, 2016|Actual|2016-07-19|July 19, 2016|Actual|2016-07-19||Interventional|||A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression|A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression|Completed||Phase 1|65|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:57:40.687012|2018-05-31 23:57:40.687012
NCT01092182|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2018-05-17|2010-03-23|2010-03-24|Estimate|||||||2018-05-17|2018-05-18|Actual|February 24, 2010||2010-02-24|January 23, 2018|2018-01-23|February 28, 2023|Anticipated|2023-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma|Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma|Active, not recruiting||Phase 2|194|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 23:57:40.748231|2018-05-31 23:57:40.748231
NCT01092169|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate||||March 2010|2010-03-31||||||||Observational|||Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia||Unknown status|Not yet recruiting||||Hillel Yaffe Medical Center|||1||f||||||||||||||2018-05-31 23:57:40.911818|2018-05-31 23:57:40.911818
NCT01092156|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-06-21|2010-03-23|2010-03-24|Estimate|||||||2010-06-21|2010-06-22|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|BEST||Prenatal Breastfeeding Education to Reduce Nipple Pain|Prenatal Breastfeeding Education to Reduce Nipple Pain|Completed||N/A|200|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 23:57:41.011004|2018-05-31 23:57:41.011004
NCT01092143|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19||2014-04-30|2014-04-30|2010-03-23|2010-03-24|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|March 2010||2010-03-31|April 2014|2014-04-30||||April 2011|Actual|2011-04-30||Interventional|||BI 671800 ED in Steroid-naive Asthmatic Patients|A Randomized, Double Blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of 6-week Treatment With Oral Doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in Steroid-naïve Patients With Persistent Asthma|Completed||Phase 2|389|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 23:57:41.110642|2018-05-31 23:57:41.110642
NCT01092130|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2013-02-13|2010-03-23|2010-03-24|Estimate|||||||2013-02-13|2013-02-15|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|VitD-CHF||Study to Investigate the Effects of Vitamin D Administration on Plasma Renin Activity in Patients With Stable Chronic Heart Failure|An Open-label, Blinded-endpoint, Randomized, Prospective Trial Investigating the Effects of Vitamin D Administration on Plasma Renin Activity in Patients With Stable Chronic Heart Failure|Completed||Phase 2|101|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 23:57:41.460725|2018-05-31 23:57:41.460725
NCT01092117|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-05-01|2010-03-22|2010-03-24|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2010||2010-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Clinical Study of the TriVascular Ovation™ Abdominal Stent Graft System|A Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the Ovation™ Abdominal Stent Graft System|Active, not recruiting||Phase 3|188|Actual|TriVascular, Inc.||1|||f||||t||||||||Undecided||2018-05-31 23:57:41.622196|2018-05-31 23:57:41.622196
NCT01092104|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22||2013-06-19|2013-07-03|2010-03-22|2010-03-24|Estimate||||2013-07-03|2013-07-10|Estimate|2013-07-03|2013-07-10|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients|A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients|Completed||Phase 1/Phase 2|52|Actual|Tobira Therapeutics, Inc.||6|||f||||t||||||||||2018-05-31 23:57:41.727766|2018-05-31 23:57:41.727766
NCT01092091|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2012-03-13|2010-03-23|2010-03-24|Estimate|||||||2012-03-13|2012-03-14|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|BCT-100-002||Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)|Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 1/Phase 2|20|Actual|Bio-Cancer Treatment International Limited||1|||f||||t||||||||||2018-05-31 23:57:41.829305|2018-05-31 23:57:41.829305
NCT01092078|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-04-20|2010-03-23|2010-03-24|Estimate|||||||2015-04-20|2015-04-22|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MISTER-B||Community-based Approaches to Treating Hypertension and Colon Cancer Prevention|Community-based Approaches to Treating Hypertension and Colon Cancer Prevention|Completed||N/A|740|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 23:57:42.034866|2018-05-31 23:57:42.034866
NCT01091181|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2018-05-17|2010-03-22|2010-03-23|Estimate|||||||2018-05-17|2018-05-22|Actual|October 2009|Actual|2009-10-31|May 2018|2018-05-31|October 31, 2017|Actual|2017-10-31|December 1, 2016|Actual|2016-12-01||Interventional|||The Effect of Hysterotomy Technique on the Rate of Large Defects in the Hysterotomy Scar|The Effect of Hysterotomy Technique on the Rate of Large Defects in the Hysterotomy Scar|Completed||N/A|122|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 23:57:52.914934|2018-05-31 23:57:52.914934
NCT01092065|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22||2013-02-18|2013-03-06|2010-03-23|2010-03-24|Estimate||||2013-02-18|2013-02-22|Estimate|2013-03-06|2013-03-14|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia|A 6-week, Double-blind, Placebo-controlled, Randomized, Multicenter Study to Explore the Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With OFF Time and Moderate-severe L-dopa Induced Dyskinesia|Completed||Phase 2|23|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:57:42.190484|2018-05-31 23:57:42.190484
NCT01092052|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2012-09-06|2010-03-22|2010-03-24|Estimate|||||||2012-09-06|2012-09-07|Estimate|January 2010||2010-01-31|September 2012|2012-09-30||||July 2012|Actual|2012-07-31||Interventional|||Study of NMS-1116354 in Advanced/Metastatic Solid Tumors|A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced/Metastatic Solid Tumors|Terminated||Phase 1|24|Actual|Nerviano Medical Sciences||1||Discontinuation of clinical investigation with NMS-1116354|f||||f||||||||||2018-05-31 23:57:42.308639|2018-05-31 23:57:42.308639
NCT01092039|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2012-07-23|2010-03-22|2010-03-24|Estimate|||||||2012-07-23|2012-07-24|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy Study of Oral XIGO Tablets to Treat The Common Cold|XIGO Effectiveness Study: An Investigation of the Safety and Efficacy of Oral XIGO Tablets on Patients Diagnosed With the Common Cold|Completed||N/A|140|Anticipated|Xigo Health LLC||2|||f||||t||||||||||2018-05-31 23:57:42.390443|2018-05-31 23:57:42.390443
NCT01092026|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2016-06-03|2010-03-23|2010-03-24|Estimate|||||||2016-06-03|2016-06-06|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells|A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 23:57:42.508804|2018-05-31 23:57:42.508804
NCT01092013|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-08-03|2010-03-22|2010-03-24|Estimate|||||||2010-08-03|2010-08-04|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Comparative Evaluation of Simulator Based and Traditional In-surgery Laparoscopic Camera Training's Efficiency in Novices||Completed||N/A|24|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 23:57:42.604163|2018-05-31 23:57:42.604163
NCT01092000|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2018-04-03|2010-03-22|2010-03-24|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||The Nutrition Challenge: A Health Promotion Campaign|The Nutrition Challenge: A Health Promotion Campaign|Completed|||56|Actual|The University of Tennessee, Knoxville|||3||f||||t||||||||||2018-05-31 23:57:42.691552|2018-05-31 23:57:42.691552
NCT01091987|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2011-06-07|2010-03-22|2010-03-24|Estimate|||||||2011-06-07|2011-06-08|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Non-pharmacological Treatment of Insomnia in Nursing Homes.|Pilot Study on the Feasibility of Non-pharmacological Treatment of Insomnia in Nursing Homes.|Completed||N/A|45|Anticipated|University Ghent||1|||f||||f||||||||||2018-05-31 23:57:42.771514|2018-05-31 23:57:42.771514
NCT01091974|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2015-02-05||2016-12-16|2010-03-22|2010-03-24|Estimate|2015-03-11|2015-03-13|Estimate||||2016-12-16|2017-02-09|Estimate|February 2008||2008-02-29|December 2016|2016-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy|Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy|Completed||Phase 2|138|Actual|University of Rochester||4|||f||||t||||||||||2018-05-31 23:57:43.075364|2018-05-31 23:57:43.075364
NCT01091961|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2017-08-24|2010-03-23|2010-03-24|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2010|Actual|2010-01-31|August 2017|2017-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|PASS||Study of Preoperative Management of Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin Receptor Blocker (ARB) Medications|Pre-Operative Inhibition of the Angiotensin System Study: A Prospective Randomized Single-Blinded Trial of Pre-Operative Management of Medications That Inhibit the Renin-Angiotensin System|Completed||N/A|200|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 23:57:43.520703|2018-05-31 23:57:43.520703
NCT01091948|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2016-06-20||2016-10-26|2010-03-23|2010-03-24|Estimate|2016-10-26|2016-12-20|Estimate||||2016-10-26|2016-12-20|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||GlideScope Video Laryngoscope Versus Fiberoptic Intubation|GlideScope Video Laryngoscope vs Fiberoptic Intubation|Completed||N/A|75|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 23:57:43.620698|2018-05-31 23:57:43.620698
NCT01091935|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Safety of Intravenous Lidocaine Infusions|Safety of Intravenous Lidocaine Infusions for Chronic Neuropathic Pain|Completed|||70|Actual|Lawson Health Research Institute|||1||f||||f||||||||||2018-05-31 23:57:44.021736|2018-05-31 23:57:44.021736
NCT01091922|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|January 2008||2008-01-31|March 2008|2008-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Impact of Dietary Flavanols on the Gut Microflora|Prebiotic Evaluation of Cocoa-derived Flavanols in Healthy Humans Using a Randomized, Double Blind, Crossover, Placebo-controlled Intervention Study|Completed||N/A|22|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 23:57:44.102369|2018-05-31 23:57:44.102369
NCT01091909|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-07-16|2010-03-23|2010-03-24|Estimate|||||||2014-07-16|2014-07-17|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|PEWHPD||Post-extraction Wound Healing in Patients With Type 2 Diabetes|Post-extraction Wound Healing in Patients With Type 2 Diabetes|Completed||N/A|82|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 23:57:44.185652|2018-05-31 23:57:44.185652
NCT01091896|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|March 2011|Anticipated|2011-03-31|September 2010|Anticipated|2010-09-30||Interventional|||Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage|Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage Secondary to Diabetic Retinopathy|Unknown status|Recruiting|Phase 2|1|Anticipated|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 23:57:44.252753|2018-05-31 23:57:44.252753
NCT01091168|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2016-10-12|2010-03-19|2010-03-23|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer||Completed||Phase 3|594|Actual|Pierre Fabre Medicament||2|||f||||t||||||||||2018-05-31 23:57:52.994036|2018-05-31 23:57:52.994036
NCT01091883|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2016-03-07|2010-03-23|2010-03-24|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma|Phase IIIA Study Comparing the Safety and Effectiveness of MR Guided Focused Ultrasound and External Beam Radiation for Treatment of Metastatic Bone Tumors and Multiple Myeloma|Unknown status|Recruiting|Phase 3|60|Anticipated|InSightec||2|||f||||f||||||||||2018-05-31 23:57:44.327763|2018-05-31 23:57:44.327763
NCT01091870|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2015-03-24|2010-03-22|2010-03-24|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2010||2010-03-31|March 2015|2015-03-31||||December 2012|Anticipated|2012-12-31||Interventional|SIPCEVA||Sildenafil for Prevention of Cerebral Vasospasm|Sildenafil for Prevention of Cerebral Vasospasm Secondary to Subarachnoid Haemorrhage - Phase II Randomized Clinical Trial|Withdrawn||Phase 2|0|Actual|Hospital de Clinicas de Porto Alegre||3||Absence of inclusion criteria|f||||t||||||||||2018-05-31 23:57:44.392926|2018-05-31 23:57:44.392926
NCT01091857|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-03-22|2010-03-22|2010-03-24|Estimate|||||||2010-03-22|2010-03-24|Estimate|September 2004||2004-09-30|March 2010|2010-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|COSTRIDE||Mediators and Moderators of Exercise Behavior Change|Mediators and Moderators of Exercise Behavior Change|Completed||N/A|238|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 23:57:44.471049|2018-05-31 23:57:44.471049
NCT01091844|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-10-12|2010-03-23|2010-03-24|Estimate|||||||2010-10-12|2010-10-13|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||Efficacy of Retrograde Fill Vs Spontaneous Fill to Assess Voiding Function|Efficacy of Retrograde Fill Vs Spontaneous FIll to Assess Voiding Function|Completed||N/A|50|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 23:57:44.521219|2018-05-31 23:57:44.521219
NCT01091831|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2017-09-05|2010-03-23|2010-03-24|Estimate|||||||2017-09-05|2017-09-06|Actual|July 2009||2009-07-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects|A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects|Active, not recruiting||Phase 3|389|Actual|Fondazione Neoplasie Sangue Onlus||2|||f||||t||||||||||2018-05-31 23:57:44.621206|2018-05-31 23:57:44.621206
NCT01091818|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2011-07-20|2010-03-23|2010-03-24|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children|A Prospective, Double-blind Study of Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children|Unknown status|Recruiting|Phase 3|40|Anticipated|Oslo University Hospital||2|||f||||||||||||||2018-05-31 23:57:44.683692|2018-05-31 23:57:44.683692
NCT01091805|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2017-04-11|2010-03-23|2010-03-24|Estimate|||||||2017-04-11|2017-04-13|Actual|December 2008|Actual|2008-12-31|March 2013|2013-03-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|Pepsin||Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux|Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux|Completed|||143|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-05-31 23:57:45.64328|2018-05-31 23:57:45.64328
NCT01091792|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2018-05-24|2010-03-23|2010-03-24|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2010||2010-03-31|May 2018|2018-05-31|April 2, 2015|Actual|2015-04-02|April 2, 2015|Actual|2015-04-02||Interventional|||Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)|DMS 0947 Exploratory Study of the Modulation of the Immune System by Vascular Endothelial Growth Factor (VEGF) Blockade in Patients With Glioblastoma Multiforme (GBM)|Completed||Early Phase 1|13|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 23:57:45.696027|2018-05-31 23:57:45.696027
NCT01091779|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2012-01-26|2010-03-23|2010-03-24|Estimate|||||||2012-01-26|2012-01-31|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Changes of Upper and Lower Limb Blood Flow and Vascular Resistance in Hyperbaric Spinal Anesthesia for Transurethral Resection of the Prostate (TURP) Using Duplex Ultrasonography: Comparison of Normotensive and Hypertensive Patients||Completed|||40|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 23:57:45.779504|2018-05-31 23:57:45.779504
NCT01091766|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2012-07-23|2010-03-23|2010-03-24|Estimate|||||||2012-07-23|2012-07-24|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine|Sensitivity of Electrocardiogram on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine: a Study in Children of Different Age|Completed||Phase 4|150|Actual|University Children's Hospital, Zurich||3|||f||||f||||||||||2018-05-31 23:57:45.833403|2018-05-31 23:57:45.833403
NCT01091753|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-10-07|2010-03-23|2010-03-24|Estimate|||||||2010-10-07|2010-10-08|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers|Effect of Nocturnal Administration of Anti-hypertensive Medications in NoN-dippers|Completed||Phase 4|28|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 23:57:45.909758|2018-05-31 23:57:45.909758
NCT01091740|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2012-01-26|2010-03-23|2010-03-24|Estimate|||||||2012-01-26|2012-01-31|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|COVER OCT-II||ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months|ComparisiOn of Neointimal coVerage betwEen zotaRolimus Eluting Stent and Everolimus Eluting Stent Using Optical Coherence Tomography at 3 Months|Completed||Phase 4|40|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:57:45.981052|2018-05-31 23:57:45.981052
NCT01091727|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-03-22|2010-03-22|2010-03-24|Estimate|||||||2010-03-22|2010-03-24|Estimate|October 2006||2006-10-31|March 2010|2010-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity|Prospective Randomized Double-blind Trial of Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Spinal Cord Injury or Multiple Sclerosis|Completed||Phase 3|57|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 23:57:46.057153|2018-05-31 23:57:46.057153
NCT01091714|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2011-10-04|2010-03-22|2010-03-24|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2010||2010-10-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?|Is Omega-3 Fatty Acid RBC Saturation Product Dependent?|Completed||Phase 4|60|Actual|Bucci Laser Vision Institute||3|||f||||f||||||||||2018-05-31 23:57:46.231094|2018-05-31 23:57:46.231094
NCT01091701|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2016-05-11|2010-03-23|2010-03-24|Estimate|||||||2016-05-11|2016-05-12|Estimate|December 2011||2011-12-31|June 2011|2011-06-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke|A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase -I/ II Study Assessing The Safety And Efficacy Of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells In Patients With Ischemic Cerebral Stroke|Withdrawn||Phase 1/Phase 2|0|Actual|Stempeutics Research Pvt Ltd||2||Business reasons|f||||t||||||||||2018-05-31 23:57:46.323937|2018-05-31 23:57:46.323937
NCT01091688|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-07-24|2010-03-23|2010-03-24|Estimate|||||||2015-07-24|2015-07-27|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Impact of Just-in-time Information on Neonatal Intensive Care Unit (NICU) Discharges|"The Impact of Just-in-time Information on NICU Discharges"|Completed||N/A|229|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 23:57:46.436356|2018-05-31 23:57:46.436356
NCT01091675|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|2015-05-06||2015-08-12|2010-03-23|2010-03-24|Estimate|2015-05-26|2015-06-10|Estimate||||2015-08-12|2015-08-25|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs|Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to ≥2 Nonsteroidal Antiinflammatory Drug (NSAID)|Completed||Phase 3|58|Actual|Spanish Foundation of Rheumatology||1|||f||||t||||||||||2018-05-31 23:57:46.52428|2018-05-31 23:57:46.52428
NCT01091662|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2015-10-02|2014-05-14|2016-09-13|2010-03-22|2010-03-24|Estimate|2015-11-16|2015-12-21|Estimate|2014-05-14|2014-05-28|Estimate|2016-09-13|2016-10-24|Estimate|June 2010||2010-06-30|September 2016|2016-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic|Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs|Completed||Phase 3|172|Actual|Sunovion||2|||f||||f||||||||||2018-05-31 23:57:46.822685|2018-05-31 23:57:46.822685
NCT01091649|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2010-12-17|2010-03-22|2010-03-24|Estimate|||||||2010-12-17|2010-12-21|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450|An Open-label, Randomized, Crossover Study to Evaluate the Bioavailability of Two Candidate Tablet Formulations of ABT-450 With Reference to the Hard Gelatin Capsule Formulation|Completed||Phase 1|40|Actual|Abbott||5|||f||||||||||||||2018-05-31 23:57:47.610632|2018-05-31 23:57:47.610632
NCT01091636|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2014-09-24|2010-03-23|2010-03-24|Estimate|||||||2014-09-24|2014-09-26|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|February 2016|Anticipated|2016-02-29||Interventional|||Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer|The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer|Unknown status|Enrolling by invitation|Phase 2/Phase 3|170|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 23:57:47.787147|2018-05-31 23:57:47.787147
NCT01091623|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|June 2005||2005-06-30|May 2005|2005-05-31||||January 2010|Actual|2010-01-31||Interventional|||Effects of Strength Training in Combination With Endurance Training on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Completed||N/A|36|Actual|Medical University of Vienna||3|||f||||||||||||||2018-05-31 23:57:47.860269|2018-05-31 23:57:47.860269
NCT01091610|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-21|||2015-07-09|2010-03-23|2010-03-24|Estimate|||||||2015-07-09|2015-07-10|Estimate|May 2010||2010-05-31|March 2011|2011-03-31||||||||Observational|||Work Related Injuries Among Prehospital Emergency Medical Staff, an Observational Study|Work Related Injuries Among Prehospital Emergency Medical Staff, a Retrospective, Observational Study|Withdrawn|||0|Actual|University Hospital Inselspital, Berne|||2|no collaboration|f||||f||||||||||2018-05-31 23:57:47.9227|2018-05-31 23:57:47.9227
NCT01091597|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|June 2007||2007-06-30|March 2010|2010-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pulmonary Vein (PV) Isolation Versus Box Isolation for the Treatment of Atrial Fibrillation|PV Isolation Versus Box Isolation for the Treatment of Atrial Fibrillation|Completed||N/A|30|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 23:57:47.995222|2018-05-31 23:57:47.995222
NCT01091584|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2016-12-02|2010-03-22|2010-03-24|Estimate|||||||2016-12-02|2016-12-05|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|February 2013|Actual|2013-02-28||Interventional|VIP||Nurse Intervention Project|A Randomized Trial to Assess the (Cost) Effectiveness of the Use of the Distress Thermometer by a Nurse in Addition to Usual Care for Patients Treated With Curative Intent for Breast Cancer.|Completed||N/A|193|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 23:57:48.07039|2018-05-31 23:57:48.07039
NCT01091571|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-11-04|2010-03-23|2010-03-24|Estimate|||||||2010-11-04|2010-11-05|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia|The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia.|Completed||Phase 4|30|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 23:57:48.133911|2018-05-31 23:57:48.133911
NCT01091558|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2017-03-30|2010-03-19|2010-03-24|Estimate|||||||2017-03-30|2017-03-31|Actual|September 2009||2009-09-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Study of Effects of L-Arginine in Colitis and Colon Cancer|Immunomodulary Effects of Arginine Supplementation in Colitis and Colon Cancer|Completed|||204|Actual|Vanderbilt University Medical Center|||2||f||||t||||||Samples Without DNA|"~     blood, urine and tissue~   "|No||2018-05-31 23:57:48.218715|2018-05-31 23:57:48.218715
NCT01091545|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2018-05-17|2010-03-23|2010-03-24|Estimate|||||||2018-05-17|2018-05-22|Actual|February 1, 2010|Actual|2010-02-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MBTST||Malmö Breast Tomosynthesis Screening Trial|Malmö Breast Tomosynthesis Screening Trial|Active, not recruiting||N/A|15000|Actual|Region Skane||1|||f||||f||||||||||2018-05-31 23:57:48.301815|2018-05-31 23:57:48.301815
NCT01091532|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2010-07-27|2010-03-22|2010-03-24|Estimate|||||||2010-07-27|2010-07-28|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.|A Double Blind, Randomized 3rd Party Open, Placebo Controlled, Parallel Group Multiple Oral Escalating Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UK-396,082 In Healthy Subjects|Completed||Phase 1|48|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:57:48.386564|2018-05-31 23:57:48.386564
NCT01091519|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2013-01-29||2013-01-29|2010-03-22|2010-03-24|Estimate|2013-01-29|2013-03-07|Estimate||||2013-01-29|2013-03-07|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy|Facts Study (Fakten-studie): Non-interventional Study to Investigate Whether Information Provided to Patients Influences Satisfaction With Toviaz Therapy As Perceived by the Patient|Terminated|||781|Actual|Pfizer|This was an open label observational study in Germany, which was stopped early due to low participant recruitment rates. The results should therefore be interpreted with caution due to the lower than planned sample size.||2|See termination reason in detailed description.|f||||f||||||||||2018-05-31 23:57:48.48202|2018-05-31 23:57:48.48202
NCT01091506|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2016-08-02|2010-03-23|2010-03-24|Estimate|||||||2016-08-02|2016-08-03|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients|A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients|Completed||N/A|55|Actual|Pamlab, Inc.||2|||f||||f||||||||||2018-05-31 23:57:48.9048|2018-05-31 23:57:48.9048
NCT01091493|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2018-04-11|2010-03-23|2010-03-24|Estimate|||||||2018-04-11|2018-04-13|Actual|July 2010||2010-07-31|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|AEPOC-ATB||Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy|Utility of Antibiotic Treatment in Acute Non-purulent Exacerbations of COPD: a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy|Active, not recruiting||Phase 4|224|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||t||||||||||2018-05-31 23:57:48.986419|2018-05-31 23:57:48.986419
NCT01091480|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2017-11-21|2010-03-23|2010-03-24|Estimate|||||||2017-11-21|2017-11-24|Actual|January 2010||2010-01-31|November 2017|2017-11-30|December 2028|Anticipated|2028-12-31|December 2023|Anticipated|2023-12-31||Observational|REMY||French Hypertrophic Cardiomyopathy Observatory|French Hypertrophic Cardiomyopathy Observatory|Recruiting|||600|Anticipated|French Cardiology Society|||1||f||||f||||||Samples With DNA|"~     Systematic search for predisposition genes and Fabry disease in patients with hypertrophic~     cardiomyopathy (GE-REMY) with blood sampling at baseline or during a consultation normally~     scheduled as part of the management of this pathology~   "|||2018-05-31 23:57:49.061682|2018-05-31 23:57:49.061682
NCT01091467|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2017-11-21|2010-03-23|2010-03-24|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2008||2008-10-31|November 2017|2017-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|KaRen||Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction|Prospective Study of Heart Failure With Preserved Left Ventricular Ejection Fraction: Prevalence, Characterisation and Prognostic Significance of Cardiac Desynchrony|Completed|||362|Actual|French Cardiology Society|||1||f||||t||||||||||2018-05-31 23:57:49.117424|2018-05-31 23:57:49.117424
NCT01091454|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2016-12-07||2018-04-06|2010-03-23|2010-03-24|Estimate|2017-01-31|2017-03-20|Actual||||2018-04-06|2018-05-08|Actual|June 2010|Actual|2010-06-30|April 2018|2018-04-30|November 1, 2014|Actual|2014-11-01|June 2012|Actual|2012-06-30||Interventional|||Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Cancer|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 23:57:49.319645|2018-05-31 23:57:49.319645
NCT01091441|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2017-11-21|2010-03-23|2010-03-24|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2007||2007-02-28|November 2017|2017-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|ODIN||Permanent Observatory of Heart Failure|Permanent Observatory of Heart Failure|Completed|||3248|Actual|French Cardiology Society|||1||f||||t||||||||||2018-05-31 23:57:49.992976|2018-05-31 23:57:49.992976
NCT01091428|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17||2017-02-08|2017-02-09|2010-03-19|2010-03-24|Estimate||||2017-02-08|2017-02-09|Estimate|2017-02-09|2017-02-10|Actual|May 2010||2010-05-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|June 2015|Actual|2015-06-30||Interventional|||MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer|Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer|Active, not recruiting||Phase 2|59|Actual|Takeda||2|||f||||f||||||||||2018-05-31 23:57:50.059266|2018-05-31 23:57:50.059266
NCT01091415|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|March 2007||2007-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparison of Volar Locking Plate Fixation Alone and Volar Locking Plate Fixation Plus Calcium Phosphate Bone Cement Augmentation for Distal Radius Fractures Patients Aged More Than 65|Comparison of Volar Locking Plate Fixation Alone and Volar Locking Plate Fixation Plus Calcium Phosphate Bone Cement Augmentation for Distal Radius Fractures Patients Aged More Than 65|Completed||N/A|41|Actual|Ewha Womans University||1|||f||||t||||||||||2018-05-31 23:57:50.142772|2018-05-31 23:57:50.142772
NCT01091402|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2010-03-23|2010-03-23|2010-03-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|January 2009||2009-01-31|January 2009|2009-01-31||||||||Observational|||Autologous Serum Skin Test and Serum IL-18 Levels in Chronic Idiopathic Urticaria and Respiratory Allergic Diseases||Completed|||||Eskisehir Osmangazi University|||4||f||||||||||||||2018-05-31 23:57:50.199352|2018-05-31 23:57:50.199352
NCT01091389|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-23|||2017-04-24|2010-03-23|2010-03-24|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2010||2010-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|February 23, 2015|Actual|2015-02-23||Interventional|AFACT||Atrial Fibrillation Ablation and Autonomic Modulation Via Thorascopic Surgery|A Randomized Single Center Study to Prospectively Investigate the Effect of Ablation of the Autonomic Ganglia in Addition to Minimally Invasive Surgical Isolation of Pulmonary Veins in Patients With Atrial Fibrillation|Completed||Phase 4|240|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 23:57:50.256804|2018-05-31 23:57:50.256804
NCT01091376|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-05-13|2010-03-21|2010-03-24|Estimate|||||||2010-05-13|2010-05-17|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|March 2013|Anticipated|2013-03-31|December 2010|Anticipated|2010-12-31||Interventional|RT0901||Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)|A Phase II Study of Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|75|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 23:57:50.352253|2018-05-31 23:57:50.352253
NCT01091363|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-21|||2014-05-29|2010-03-22|2010-03-24|Estimate|||||||2014-05-29|2014-05-30|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Tobacco Dependence Treatment for Asian Americans|A Randomized Controlled Clinical Trial of a Combination of Pharmacotherapy and Culturally Tailored Cognitive Behavior Therapy With Korean Americans|Completed||Phase 1/Phase 2|131|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 23:57:50.426461|2018-05-31 23:57:50.426461
NCT01091350|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-14|||2013-05-29|2010-03-22|2010-03-24|Estimate|||||||2013-05-29|2013-05-31|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Influence of Equilibration Rate Constant (ke0) of Propofol on the Effect Site Concentration for Loss of Consciousness|Influence of Equilibration Rate Constant (ke0) of Propofol on the Effect-site Concentration for Loss of Consciousness|Completed||N/A|60|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 23:57:50.542138|2018-05-31 23:57:50.542138
NCT01091337|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-22|2010-03-22|2010-03-24|Estimate|||||||2010-03-22|2010-03-24|Estimate|May 2006||2006-05-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room|Comparative Study on the Efficacy and Safety of Procaterol vs Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room|Completed||Phase 4|96|Actual|Otsuka Pharmaceutical, Inc., Philippines||2|||f||||f||||||||||2018-05-31 23:57:50.617368|2018-05-31 23:57:50.617368
NCT01091324|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-03-22|2010-03-22|2010-03-24|Estimate|||||||2010-03-22|2010-03-24|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|CKD||Dextromethorphan and Silymarin in Chronic Kidney Disease (CKD) Patients|The Reno-protective and Cardiovascular Effect of Dextromethorphan and Silymarin in Patients With Chronic Kidney Disease|Unknown status|Active, not recruiting|Phase 3|45|Anticipated|National Cheng-Kung University Hospital||3|||f||||t||||||||||2018-05-31 23:57:50.709983|2018-05-31 23:57:50.709983
NCT01091311|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2011-06-07|2010-03-21|2010-03-24|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ESPOIR||Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases|Phase IV Multicentric Study, 30 Patients Suffering of Meibomian Glands Dysfunction.|Completed||Phase 4|30|Actual|Laboratoires Thea|||||f||||f||||||||||2018-05-31 23:57:50.881338|2018-05-31 23:57:50.881338
NCT01091298|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2011-06-07|2010-03-20|2010-03-24|Estimate|||||||2011-06-07|2011-06-08|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers|Phase I Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Tolerability of a Single Administration (10e6.25 FFU of Each Constituent Serotype Per 0.5 ml) of Live Attenuated Tetravalent (G1-G4) Bovine-human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Adult Males|Completed||Phase 1|20|Anticipated|Shantha Biotechnics Limited||2|||f||||f||||||||||2018-05-31 23:57:50.968158|2018-05-31 23:57:50.968158
NCT01091285|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-20|||2011-08-16|2010-03-22|2010-03-24|Estimate|||||||2011-08-16|2011-08-17|Estimate|March 2010||2010-03-31|April 2010|2010-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Induction of Labor With Single and Double Balloon Catheters, a Randomized Controlled Study|Induction of Labor With Single and Double Balloon Catheters, a Randomized Controlled Study|Completed||Phase 4|180|Actual|Haukeland University Hospital||2|||f||||||||||||||2018-05-31 23:57:51.044408|2018-05-31 23:57:51.044408
NCT01091272|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-09-17|2010-03-19|2010-03-24|Estimate|||||||2010-09-17|2010-09-20|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers|A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04995274 After Administration Of Single Oral Doses To Healthy Adult Subjects|Completed||Phase 1|28|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 23:57:51.111165|2018-05-31 23:57:51.111165
NCT01091259|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2015-08-21||2015-10-26|2010-03-22|2010-03-23|Estimate|2015-09-22|2015-10-19|Estimate||||2015-10-26|2015-11-24|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|February 2014|Actual|2014-02-28||Interventional|||Irinotecan and Bevacizumab for Recurrent Ovarian Cancer|Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.|Completed||Phase 2|29|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 23:57:51.218687|2018-05-31 23:57:51.218687
NCT01091246|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2011-07-20||2011-09-22|2010-03-22|2010-03-23|Estimate|2011-08-17|2011-09-22|Estimate||||2011-09-22|2011-09-26|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|LAIV||A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children|A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children|Completed||Phase 3|2312|Actual|MedImmune LLC||3|||f||||t||||||||||2018-05-31 23:57:51.685081|2018-05-31 23:57:51.685081
NCT01091233|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2015-06-03|2010-03-22|2010-03-23|Estimate|||||||2015-06-03|2015-06-04|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2012|Actual|2012-12-31||Observational|||The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study|The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study|Suspended|||20|Anticipated|University Hospital, Ghent|||1|logistical problems|f||||f||||||||||2018-05-31 23:57:52.602635|2018-05-31 23:57:52.602635
NCT01091220|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2011-09-02|2010-03-22|2010-03-23|Estimate|||||||2011-09-02|2011-09-05|Estimate|March 2010||2010-03-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers|A Randomized, Single-center, Double-blind, Placebo-controlled Study to Explore the Effect of a Single Dose of Certolizumab Pegol 400 mg on Semen Quality in Healthy Male Volunteers|Completed||Phase 1|20|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 23:57:52.685297|2018-05-31 23:57:52.685297
NCT01091207|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-01-18|2010-03-22|2010-03-23|Estimate|||||||2012-01-18|2012-01-20|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Sorafenib for Imatinib/Sunitinib-failed GIST|A Phase II Study of Sorafenib in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors Who Failed to Imatinib and Sunitinib|Completed||Phase 2|39|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 23:57:52.755692|2018-05-31 23:57:52.755692
NCT01091194|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2013-02-18|2010-03-22|2010-03-23|Estimate|||||||2013-02-18|2013-02-20|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|TEX||Effect of Exercise After Heart Transplantation|Effect of High Intensity Interval-based Aerobic Exercise 1-8 Years After Heart Transplantation. 1 Year Follow Up.|Completed||Phase 2|51|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 23:57:52.849503|2018-05-31 23:57:52.849503
NCT01091155|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2013-06-04||2013-08-20|2010-03-22|2010-03-23|Estimate|2013-08-20|2013-10-25|Estimate||||2013-08-20|2013-10-25|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|COMPRES||COMPRES - COMpression Anastomosis Ring (CAR™ 27/ColonRing™) Post maRketing Evaluation Study|COMPRES - COMpression Anastomosis Ring (CAR™ 27/ColonRing™) Post maRketing Evaluation Study|Completed||Phase 4|288|Actual|novoGI|The study had acceptable rate of AE, and technical problems.|1|||f||||t||||||||||2018-05-31 23:57:53.34005|2018-05-31 23:57:53.34005
NCT01091142|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2010-10-04|2010-03-22|2010-03-23|Estimate|||||||2010-10-04|2010-10-06|Estimate|July 2010||2010-07-31|October 2010|2010-10-31||||September 2010|Actual|2010-09-30||Interventional|||Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)|Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 1|56|Anticipated|Neuraltus Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:57:53.657218|2018-05-31 23:57:53.657218
NCT01091129|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2014-12-05|2010-03-22|2010-03-23|Estimate|||||||2014-12-05|2014-12-09|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis|Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis|Completed||N/A|31|Actual|Miramar Labs||1|||f||||f||||||||||2018-05-31 23:57:53.777469|2018-05-31 23:57:53.777469
NCT01091116|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2012-11-08||2013-01-16|2010-03-19|2010-03-23|Estimate|2013-01-16|2013-02-18|Estimate||||2013-01-16|2013-02-18|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|ALBATROSS||A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS|Intra-articular Treatment With MEN16132 in Patients With Symptomatic Primary Osteoarthritis of the Knee: A Randomized, Multi-centre, Double Blind, Placebo Controlled, Five Parallel Group, Dose Finding Study|Completed||Phase 2|423|Actual|Menarini Group||5|||f||||f||||||||||2018-05-31 23:57:54.043546|2018-05-31 23:57:54.043546
NCT01091103|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2014-11-10||2017-08-24|2010-03-22|2010-03-23|Estimate|2014-11-10|2014-11-17|Estimate||||2017-08-24|2017-09-25|Actual|February 18, 2010|Actual|2010-02-18|August 2017|2017-08-31|August 31, 2013|Actual|2013-08-31|February 29, 2012|Actual|2012-02-29||Interventional|||Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide|A Study Of Continuous Oral Dosing Of A Novel Antiandrogen Mdv3100, In Castration-resistant Bone Metastatic Prostate Cancer Patients Evaluating The Tumor Micro-enviroment|Completed||Phase 2|60|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 23:57:55.345652|2018-05-31 23:57:55.345652
NCT01091090|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2012-05-23|2010-03-19|2010-03-23|Estimate|||||||2012-05-23|2012-05-25|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Cognitive Behavioral Smoking Cessation Intervention for Adults With Chronic Pain|Cognitive Behavioral Smoking Cessation Intervention for Adults With Chronic Pain|Completed||N/A|26|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:57:55.749164|2018-05-31 23:57:55.749164
NCT01091077|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2015-09-21|2010-03-19|2010-03-23|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection|A Pilot Study of the Grapefruit Flavonoid Naringenin for the Treatment of HCV Infection|Completed||Phase 1|7|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 23:57:55.807375|2018-05-31 23:57:55.807375
NCT01091064|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2015-09-04|2010-03-22|2010-03-23|Estimate|||||||2015-09-04|2015-09-07|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|April 2014|Anticipated|2014-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Impact Of A Health Care Protocol For Patients Suffering Symptoms Of Mild Acute Viral Bronchiolitis On Early Release In The Emergency Department|IMPACT OF A HEALTH CARE PROTOCOL FOR PATIENTS SUFFERING SYMPTOMS OF MILD ACUTE VIRAL BRONCHIOLITIS ON EARLY DISCHARGE IN THE EMERGENCY DEPARTMENT.|Withdrawn||Phase 2|0|Actual|Laval University||2||The study was stopped because it was not approved for funding|f||||t||||||||||2018-05-31 23:57:55.876388|2018-05-31 23:57:55.876388
NCT01091051|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2013-06-10|2010-03-22|2010-03-23|Estimate|||||||2013-06-10|2013-06-11|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis|Safety and Efficacy of Ustekinumab in the Treatment of Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis|Terminated||Phase 3|33|Actual|Innovaderm Research Inc.||2||Manufacturer ceased to produce vials used for this study.|f||||f||||||||||2018-05-31 23:57:55.945409|2018-05-31 23:57:55.945409
NCT01091038|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2010-04-01|2010-03-22|2010-03-23|Estimate|||||||2010-04-01|2010-04-05|Estimate|August 2001||2001-08-31|March 2010|2010-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Improving Safety by Basic Computerizing Outpatient Prescribing|Improving Safety by Basic Computerizing Outpatient Prescribing|Completed||Phase 2/Phase 3|228|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 23:57:56.056642|2018-05-31 23:57:56.056642
NCT01091025|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2017-12-20|2010-03-19|2010-03-23|Estimate|||||||2017-12-20|2017-12-22|Actual|March 2009||2009-03-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|CFRD||Comparing Two Different Approaches in the Screening of Cystic Fibrosis Related Diabetes|A Comparative Analysis of the Clinical Efficacy of Two Approaches in the Screening for Cystic Fibrosis Related Diabetes in Adult With Cystic Fibrosis: i) a Selective Approach; ii) an Unselected Annual Oral Glucose Tolerance Test|Completed||N/A|100|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 23:57:56.166146|2018-05-31 23:57:56.166146
NCT01091012|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-09-10|2010-03-22|2010-03-23|Estimate|||||||2012-09-10|2012-09-11|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension|Study About Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension, at Last Moderate and Secondary at Valve Disease(Corrected With a Normally Functioning Prosthesis).|Unknown status|Recruiting|Phase 3|30|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 23:57:56.231485|2018-05-31 23:57:56.231485
NCT01090999|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2017-03-21|2010-03-22|2010-03-23|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2006||2006-10-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Long - Term Respiratory Rehabilitation Programs in Chronic Obstructive Pulmonary Disease.|Long - Term Respiratory Rehabilitation Programs in Chronic Obstructive Pulmonary Disease (COPD) Patients: Study of Cost- Effectiveness.|Completed||N/A|116|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 23:57:57.216924|2018-05-31 23:57:57.216924
NCT00874653|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2014-06-20|2009-04-01|2009-04-02|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2008||2008-04-30|June 2014|2014-06-30|December 2008|Actual|2008-12-31|||||Observational|||Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding|Levonorgestrel Releasing Intrauterine System (MIRENA) in Idiopathic Menorrhagia|Completed|||78|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:08:37.645219|2018-06-01 01:08:37.645219
NCT01090986|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2014-02-21|2010-03-22|2010-03-23|Estimate|||||||2014-02-21|2014-02-24|Estimate|June 2006||2006-06-30|February 2014|2014-02-28||||July 2013|Actual|2013-07-31||Observational|||Home Mechanical Ventilation Effectiveness and Air Leaks|Prediction of Home Mechanical Ventilation Effectiveness by Means of Non-controlled Air Leaks Estimation.|Completed|||20|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||||||2018-05-31 23:57:57.297242|2018-05-31 23:57:57.297242
NCT01090973|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2012-01-27||2013-11-21|2010-03-19|2010-03-23|Estimate|2012-02-28|2012-03-28|Estimate||||2013-11-21|2013-12-16|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)|Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma|Terminated||Phase 2|1|Actual|H. Lee Moffitt Cancer Center and Research Institute|"The study was abandoned after only one patient due to low accrual and the sponsor losing interest in the single-agent.~The one patient had disease progression requiring more aggressive treatment and did not complete the study."|1||Pharmaceutical company request.|f||||t||||||||||2018-05-31 23:57:57.37326|2018-05-31 23:57:57.37326
NCT01090960|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2016-07-01|2010-03-22|2010-03-23|Estimate|||||||2016-07-01|2016-07-04|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors|An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors|Completed||Phase 1|52|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 23:57:57.560918|2018-05-31 23:57:57.560918
NCT01090947|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-03-16|2010-03-19|2010-03-23|Estimate|||||||2015-03-16|2015-03-17|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Data Aquisition for Optimization of Coronary Artery Disease Algorithm|Data Aquisition for Optimization of Coronary Artery Disease Algorithm|Completed|||729|Actual|Coloplast A/S|||1||f||||f||||||||||2018-05-31 23:57:57.630345|2018-05-31 23:57:57.630345
NCT01090934|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2016-01-26|2010-03-19|2010-03-23|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|EEG-HR||Localizing the Epileptogenic Zone With High Resolution Electroencephalography|Etude de la Performance Diagnostique de l'EEG-Haute Résolution Sur la Localisation de la Zone épileptogène Pour le Traitement Chirurgical Des épilepsies Partielles Pharmaco-résistantes|Completed||N/A|115|Actual|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 23:57:57.691721|2018-05-31 23:57:57.691721
NCT01090921|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2016-02-01|2010-03-19|2010-03-23|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma|Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma|Completed||Phase 2|50|Actual|Boston VA Research Institute, Inc.||1|||f||||t||||||||No||2018-05-31 23:57:57.852593|2018-05-31 23:57:57.852593
NCT01090908|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2012-08-27|2010-03-19|2010-03-23|Estimate|||||||2012-08-27|2012-08-29|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Observational|||Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. Aeruginosa|A Multi-Center, Open Label Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Ciprofloxacin For Inhalation (CFI) Given Daily For 14 Days To Stable Cystic Fibrosis Patients Ages 6 To 17 With Pseudomonas Aeruginosa|Withdrawn|||0|Actual|Aradigm Corporation|||2||f||||f||||||||||2018-05-31 23:57:57.943623|2018-05-31 23:57:57.943623
NCT01090895|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2016-03-08|2010-03-22|2010-03-23|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|TREVI||Treatment of Reperfusion Event by Vitamin C Infusion|Effect of Vitamin C Infusion on Coronary Reperfusion Indexes|Recruiting||Phase 4|80|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||No||2018-05-31 23:57:58.016392|2018-05-31 23:57:58.016392
NCT01090882|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-03-22|2010-03-22|2010-03-23|Estimate|||||||2010-03-22|2010-03-23|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Intraperitoneal Techniques of Local Anaesthesia During Laparoscopic Cholecystectomy|Efficacy of Intraperitoneal Local Anaesthetic Techniques During Laparoscopic Cholecystectomy: A Double Blind Randomized Controlled Trial|Completed||N/A|128|Actual|University Hospitals Coventry and Warwickshire NHS Trust||3|||f||||f||||||||||2018-05-31 23:57:58.140132|2018-05-31 23:57:58.140132
NCT01090869|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-22|2010-03-22|2010-03-23|Estimate|||||||2010-03-22|2010-03-23|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TPS||Physical Training Per se|Physical Activity is Healthy - Effect of Weight Loss or Physical Training Per se?|Completed||N/A|60|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 23:57:58.221245|2018-05-31 23:57:58.221245
NCT01090856|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2014-12-04|2010-03-22|2010-03-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Predilation of Side Branch During Percutaneous Treatment of Bifurcation Lesions With Provisional T Stenting|Predilation of Side Branch During Percutaneous Treatment of Bifurcation Lesions With Provisional T Stenting.|Completed||Phase 4|420|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||||2018-05-31 23:57:58.300308|2018-05-31 23:57:58.300308
NCT01090843|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2011-10-03|2010-03-22|2010-03-23|Estimate|||||||2011-10-03|2011-10-05|Estimate|April 2010||2010-04-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Video Capsule Endoscopy (VCE) Comparison Study|Comparison Study of IntroMedic®'s MiroCam® and Olympus®' Enteropro EndoCapsule®|Completed||N/A|50|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 23:57:58.383343|2018-05-31 23:57:58.383343
NCT01090830|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2018-02-21|2010-03-22|2010-03-23|Estimate|||||||2018-02-21|2018-02-23|Actual|April 2010||2010-04-30|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|HCH003||Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer|Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.|Terminated||Phase 1/Phase 2|7|Actual|Holy Cross Hospital, Florida||1||Principal Investigator has left institution. IND withdrawn.|f||||f||||||||||2018-05-31 23:57:58.46341|2018-05-31 23:57:58.46341
NCT01090648|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2012-12-10|2010-03-18|2010-03-22|Estimate|||||||2012-12-10|2012-12-11|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients|A Study to Survey the Swallowability of Uncoated 200-mg Tablets of Etravirine in HIV-1 Infected Subjects|Completed||Phase 1|49|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||||||||||||2018-05-31 23:58:02.759517|2018-05-31 23:58:02.759517
NCT01090817|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2015-06-07|2010-03-22|2010-03-23|Estimate|||||||2015-06-07|2015-06-09|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease|A Multicentre Australian Phase 2 Study to Evaluate Safety and Efficacy of Mesenchymal Stromal Cells for Treating Biologic Refractory Crohn's Disease|Completed||Phase 2|21|Actual|Royal Perth Hospital||1|||f||||t||||||||||2018-05-31 23:57:58.541443|2018-05-31 23:57:58.541443
NCT01090804|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-03-22|2010-03-22|2010-03-23|Estimate|||||||2010-03-22|2010-03-23|Estimate|August 2009||2009-08-31|January 2010|2010-01-31||||December 2009|Actual|2009-12-31||Interventional|ESMOSC||The Effectiveness of BreatheMAX Breathing Device on Secretion Clearance|The Effectiveness of BreatheMAX Breathing Device on Airway Secretion Clearance in Patients With Ventilatory Dependence|Unknown status|Recruiting|Phase 2/Phase 3|14|Anticipated|Khon Kaen University||1|||f||||t||||||||||2018-05-31 23:57:58.6327|2018-05-31 23:57:58.6327
NCT01090791|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2016-09-07|2010-03-22|2010-03-23|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|FLOVAC||FLOTRAC/VIGILEO in Acute Circulatory Failure|Assessment of the FLOTRAC/VIGILEO Third Generation Software to Predict Fluid Responsiveness in Critically Ill Patient With Acute Circulatory Failure|Terminated|||1|Actual|Hôpital Européen Marseille||||Major change in protocol anticipated|f||||f||||||||||2018-05-31 23:57:58.702059|2018-05-31 23:57:58.702059
NCT01090778|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-22|||2014-01-08|2010-03-22|2010-03-23|Estimate|||||||2014-01-08|2014-01-09|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)|Pharmacokinetic Profiles of GH Using Two Different Administration Regimes; a Bolus and an Infusion Both With and Without Exercise, in Adults With Growth Hormone Deficiency|Completed||Phase 2|8|Actual|Aarhus University Hospital||4|||f||||t||||||||||2018-05-31 23:57:58.759013|2018-05-31 23:57:58.759013
NCT01090765|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2015-01-29||2018-04-13|2010-03-19|2010-03-22|Estimate|2015-01-29|2015-02-13|Estimate||||2018-04-13|2018-05-22|Actual|February 23, 2010|Actual|2010-02-23|April 2018|2018-04-30|April 17, 2015|Actual|2015-04-17|April 1, 2014|Actual|2014-04-01||Interventional|||A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)|A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)|Completed||Phase 1/Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||f|t|f||||||No||2018-05-31 23:57:58.882723|2018-05-31 23:57:58.882723
NCT01090752|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2010-03-24||2010-03-24|2010-03-19|2010-03-22|Estimate|2010-03-24|2010-04-08|Estimate||||2010-03-24|2010-04-08|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Renal and Hormonal Effects of Pioglitazone|Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects|Completed||Phase 4|16|Actual|University Hospital, Geneva|The sample size may seem small but the cross over design of the study increased the statistical power. Each of 16 individuals was examined 4 times after the 4 different phases (pioglitazone-low salt, and high salt, placebo low salt and high salt).|2|||f||||f||||||||||2018-05-31 23:58:00.769808|2018-05-31 23:58:00.769808
NCT01090739|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|2016-04-19|2015-01-15|2016-08-25|2010-03-19|2010-03-22|Estimate|2016-08-25|2016-08-26|Estimate|2015-01-15|2015-01-27|Estimate|2016-08-25|2016-08-26|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|November 2013|Actual|2013-11-30||Interventional|TRANSFORM|All subjects who met the study inclusion/exclusion criteria and were implanted with the TOPAS device.|Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence|An Investigation of the Treatment of Fecal Incontinence Using the TOPAS Sling System For Women (TRANSFORM)|Completed||N/A|207|Actual|ASTORA Women's Health|Study was a single arm trial with no control group. Study was done with a very specialized group of clinical investigators from two medical sub-specialties, Colorectal Surgeons and Urogynecologists. Study population was primarily Caucasian (90%).|1|||f||||t||||||||Yes|Each site was provided with their individual participant data|2018-05-31 23:58:01.052748|2018-05-31 23:58:01.052748
NCT01090726|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-12-10|2010-03-19|2010-03-22|Estimate|||||||2010-12-10|2010-12-13|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Intubation With Storz Videolaryngoscope® Versus Airtraq® - in an Infant Population|Intubation With Storz Videolaryngoscope® Versus Airtraq® - in an Infant Population|Completed||N/A|10|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 23:58:02.002316|2018-05-31 23:58:02.002316
NCT01090713|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2016-07-13|2010-03-19|2010-03-22|Estimate|||||||2016-07-13|2016-07-15|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder|Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity|Completed||Phase 3|50|Actual|Lindner Center of HOPE||2|||f||||f||||||||||2018-05-31 23:58:02.063445|2018-05-31 23:58:02.063445
NCT01090700|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-04-08|2010-03-18|2010-03-22|Estimate|||||||2013-04-08|2013-04-09|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||TMC435-TiDP16-C112 - Interaction Trial With Antidepressants|A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state|Completed||Phase 1|20|Actual|Tibotec Pharmaceuticals, Ireland||3|||f||||||||||||||2018-05-31 23:58:02.141345|2018-05-31 23:58:02.141345
NCT01090687|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-07-31|2010-03-18|2010-03-22|Estimate|||||||2013-07-31|2013-08-01|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Role of 3D Tomography in Breast Cancer|Role of 3D Tomography in Breast Cancer|Completed|||150|Actual|University of Rochester|||2||f||||t||||||||||2018-05-31 23:58:02.23871|2018-05-31 23:58:02.23871
NCT01090674|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2014-02-21|2010-03-19|2010-03-22|Estimate|||||||2014-02-21|2014-02-24|Estimate|June 2007||2007-06-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases|Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases.|Completed|||5|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||||||2018-05-31 23:58:02.516764|2018-05-31 23:58:02.516764
NCT01090661|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2016-08-01|2010-03-19|2010-03-22|Estimate|||||||2016-08-01|2016-08-03|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects|A Randomized Double-Blinded Crossover Trial to Define the ECG Effects of Mipomersen (ISIS 301012) Using a Therapeutic and Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial|Completed||Phase 1|60|Actual|Kastle Therapeutics, LLC||4|||f||||t||||||||||2018-05-31 23:58:02.580463|2018-05-31 23:58:02.580463
NCT01090622|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2012-03-14|2010-03-18|2010-03-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)|Phase 2a, Double-blind, Placebo-controlled, 2-period, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients With Inherited Erythromelalgia.|Completed||Phase 1/Phase 2|4|Actual|Xenon Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 23:58:02.968835|2018-05-31 23:58:02.968835
NCT01090609|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-11-13|2010-03-19|2010-03-22|Estimate|||||||2014-11-13|2014-11-14|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|September 2012|Actual|2012-09-30||Interventional|CRONUS||Study to Evaluate the Safety of Cronus® - Cobalt Chromium Coronary Stent|Multicenter, Prospective, Non-randomized Study to Evaluate the Safety of Cronus® Cobalt Chromium Coronary Stent - Study After 9 Months|Completed||Phase 4|263|Actual|Scitech Produtos Medicos Ltda||1|||f||||t||||||||||2018-05-31 23:58:03.050376|2018-05-31 23:58:03.050376
NCT01090596|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-18|2010-03-18|2010-03-22|Estimate|||||||2010-03-18|2010-03-22|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|Lesions3||Changes in mRNA Expression Following Exposure to Naproxen|Changes in mRNA Expression Following Exposure to Naproxen|Completed||N/A|48|Actual|Research Associates of New York, LLP||2|||f||||f||||||||||2018-05-31 23:58:03.180204|2018-05-31 23:58:03.180204
NCT01090583|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-12-08|2010-03-19|2010-03-22|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Observational|||Can Non-invasive Sampling Determine the Inflammatory Status of the Intra-uterine Environment?|Can Non-invasive Sampling Determine the Inflammatory Status of the Intra-uterine Environment?|Completed|||20|Actual|Winthrop University Hospital|||1||f||||f|||||||"~     observational study, no specimens required.~   "|||2018-05-31 23:58:03.330345|2018-05-31 23:58:03.330345
NCT01090570|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2015-03-13|2010-03-18|2010-03-22|Estimate|||||||2015-03-13|2015-03-17|Estimate|May 2010||2010-05-31|March 2015|2015-03-31||||December 2010|Anticipated|2010-12-31||Interventional|||Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate||Withdrawn||Phase 1|0|Actual|Plexxikon||6|||f||||f||||||||||2018-05-31 23:58:03.409918|2018-05-31 23:58:03.409918
NCT01090557|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2010-03-19|2010-03-19|2010-03-22|Estimate|||||||2010-03-19|2010-03-22|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study|A Prospective, Pilot Study Measuring Exhaled Nitric Oxide Levels in Infants and Young Children Admitted to the Hospital for Respiratory Syncytial Virus (RSV) or Other Viral Lower Respiratory Tract Infections|Completed|||60|Anticipated|Winthrop University Hospital|||3||f||||t||||||||||2018-05-31 23:58:03.494699|2018-05-31 23:58:03.494699
NCT01090544|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2010-09-29|2010-03-19|2010-03-22|Estimate|||||||2010-09-29|2010-09-30|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|TNICOPD||Transnasal Insufflation (TNI) and Chronic Obstructive Pulmonary Disease|Transnasal Insufflation for Patients With COPD GOLD IV and Hypercapnia|Completed||N/A|21|Actual|Helios Klinik Ambrock|||||f||||f||||||||||2018-05-31 23:58:03.575905|2018-05-31 23:58:03.575905
NCT01090531|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-19|||2012-05-21|2010-03-19|2010-03-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|August 2009||2009-08-31|May 2012|2012-05-31||||August 2019|Anticipated|2019-08-31||Observational|||Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy|A Multicenter, Prospective, Observational, Long-Term Follow-Up Study of Subjects With Chronic Hepatitis B and Low Viremia Who Do Not Receive Antiviral Therapy|Recruiting|||600|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 23:58:03.684596|2018-05-31 23:58:03.684596
NCT01090518|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-02-04|2010-03-19|2010-03-22|Estimate|||||||2013-02-04|2013-02-05|Estimate|February 2010||2010-02-28|February 2013|2013-02-28||||November 2013|Anticipated|2013-11-30||Interventional|||Cortisol Augmentation of a Psychological Treatment in Warfighters With Post Traumatic Stress Disorder (PTSD)|Cortisol Augmentation of a Psychological Treatment in Warfighters With Post Traumatic Stress Disorder (PTSD)|Unknown status|Recruiting|N/A|50|Anticipated|Bronx VA Medical Center||2|||f||||f||||||||||2018-05-31 23:58:03.786561|2018-05-31 23:58:03.786561
NCT01090505|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-19|2010-03-19|2010-03-22|Estimate|||||||2010-03-19|2010-03-22|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|December 2015|Anticipated|2015-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer|Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced|Unknown status|Recruiting|Phase 2|160|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 23:58:03.883237|2018-05-31 23:58:03.883237
NCT01090492|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2017-08-15|2012-11-09|2018-04-16|2010-03-18|2010-03-22|Estimate|2018-04-16|2018-05-16|Actual|2012-11-09|2012-11-16|Estimate|2018-04-16|2018-05-16|Actual|August 4, 2010|Actual|2010-08-04|April 2018|2018-04-30|May 31, 2011|Actual|2011-05-31|May 31, 2011|Actual|2011-05-31||Interventional|||PF-00489791 For The Treatment Of Raynaud's|A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon|Completed||Phase 2|243|Actual|Pfizer|Plasma concentration of PF-00489791 metabolites was not intended as secondary endpoint in the protocol and was considered as an exploratory endpoint.|8|||f||||f||||||||||2018-05-31 23:58:04.040746|2018-05-31 23:58:04.040746
NCT01090479|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2012-07-09||2013-04-30|2010-03-19|2010-03-22|Estimate|2012-07-09|2012-08-14|Estimate||||2013-04-30|2013-05-06|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Pre-operative Preparation Using 2% Chlorhexidine Cloth For Shoulder Surgery|Efficacy of Home Pre-Operative Use of 2% Chlorhexidine Cloths Prior to Shoulder Surgery|Completed||N/A|100|Actual|Northwestern University|No specific limitations other than the study was underpowered to detect a difference in the clinical infection rate between the chlorhexidine and control groups.|2|||f||||t||||||||||2018-05-31 23:58:05.761624|2018-05-31 23:58:05.761624
NCT01090466|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2018-02-02|2010-03-18|2010-03-22|Estimate|||||||2018-02-02|2018-02-06|Actual|February 2008||2008-02-29|February 2018|2018-02-28|March 16, 2016|Actual|2016-03-16|January 2010|Actual|2010-01-31||Interventional|||Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium|A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium|Completed||Phase 1/Phase 2|15|Actual|Cardiff University|||||f||||t||||||||||2018-05-31 23:58:06.32402|2018-05-31 23:58:06.32402
NCT01090453|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2014-06-19|2011-11-17|2016-08-29|2010-03-18|2010-03-22|Estimate|2014-07-24|2014-08-15|Estimate|2011-11-17|2011-11-21|Estimate|2016-08-29|2016-10-07|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants|Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 4 and 12 Months of Age|Completed||Phase 2|480|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:58:06.55319|2018-05-31 23:58:06.55319
NCT01090440|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-06-21|2010-03-18|2010-03-22|Estimate|||||||2017-06-21|2017-06-22|Actual|September 1, 2009|Actual|2009-09-01|June 2017|2017-06-30|October 9, 2009|Actual|2009-10-09|October 9, 2009|Actual|2009-10-09||Interventional|MNK112891||Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects|An Open Label, Randomised, Three-way Cross-over Study to Evaluate the Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Male and Female Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 23:58:07.571262|2018-05-31 23:58:07.571262
NCT01090427|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2014-12-10|2014-01-24|2015-01-16|2010-03-18|2010-03-22|Estimate|2014-12-10|2014-12-18|Estimate|2014-01-24|2014-02-24|Estimate|2015-01-16|2015-01-29|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the of Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type Psoriasis (CADMUS)|Completed||Phase 3|110|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 23:58:07.672129|2018-05-31 23:58:07.672129
NCT01090414|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2018-04-03|2010-03-18|2010-03-22|Estimate|||||||2018-04-03|2018-04-05|Actual|March 22, 2010|Actual|2010-03-22|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study|An Extension Study to Investigate the Safety and Durability of Clinical Activity of Idelalisib in Subjects With Hematologic Malignancies|Active, not recruiting||Phase 1|202|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 23:58:08.673389|2018-05-31 23:58:08.673389
NCT01090401|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2011-11-15|2010-03-18|2010-03-22|Estimate|||||||2011-11-15|2011-11-16|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Linox Smart S DX PME/Master Study|PME/Master Study of the Linoxsmart S DX ICD Leads|Completed||Phase 4|116|Actual|Biotronik SE & Co. KG||1|||f||||t||||||||||2018-05-31 23:58:08.76604|2018-05-31 23:58:08.76604
NCT01090388|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2016-11-07|2010-03-19|2010-03-22|Estimate|||||||2016-11-07|2016-11-09|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2011|Actual|2011-08-31||Observational|||Bladder Cancer Patient-Reported Outcomes|A Cross-Sectional Study Of Patient-Reported Outcomes For Bladder Cancer Patients With Non-Invasive Disease|Completed|||108|Actual|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 23:58:08.821302|2018-05-31 23:58:08.821302
NCT01090375|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|August 2008||2008-08-31|March 2010|2010-03-31||||March 2009|Actual|2009-03-31||Interventional|||Regulation of Intraarticular and Synovium-related Biomarkers of Osteoarthritis. Effect of Acute Mechanical Joint Loading||Completed||Early Phase 1|||Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 23:58:08.876877|2018-05-31 23:58:08.876877
NCT01090362|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-12-04|2010-03-18|2010-03-19|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|GARFIELD-AF||Global Anticoagulant Registry in the Field|Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.|Recruiting|||55000|Anticipated|Thrombosis Research Institute|||5||f||||t||||||||||2018-05-31 23:58:08.940272|2018-05-31 23:58:08.940272
NCT01090349|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2015-10-21|2010-03-18|2010-03-19|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2012|Actual|2012-04-30||Interventional|REACT||Clinical Evaluation Of Remote Monitoring With Direct Alerts To Reduce Time From Event To Clinical Decision|CLINICAL EVALUATION OF REMOTE MONITORING WITH DIRECT ALERTS TO REDUCE TIME FROM EVENT TO CLINICAL DECISION. (REACT Study)|Completed||N/A|220|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 23:58:09.154372|2018-05-31 23:58:09.154372
NCT01090336|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2011-04-15|2010-03-18|2010-03-19|Estimate|||||||2011-04-15|2011-04-18|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|||||Observational|||Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)|Prevalence of Inadequate Platelet Inhibition After Oral Loading With Prasugrel/Clopidogrel in Patients With an Acute Coronary Syndrome Undergoing Early PCI|Unknown status|Recruiting||26|Anticipated|Heidelberg University|||2||f||||f||||||||||2018-05-31 23:58:09.227523|2018-05-31 23:58:09.227523
NCT01090323|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2010-12-21||2011-05-03|2010-03-18|2010-03-19|Estimate|2010-12-21|2011-01-20|Estimate||||2011-05-03|2011-06-06|Estimate|July 2004||2004-07-31|May 2011|2011-05-31||||July 2009|Actual|2009-07-31||Interventional|||Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).|A One Year Open Label, Non-comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration (LIC) of Repeated Doses of 5-30mg/kg/Day ICL670 Relative to Deferoxamine (DFO) in Sickle Cell Disease (SCD) Patients With Transfusional Hemosideresis (THS) [Amendment 3: Extension Prolonged to 4-years]|Completed||Phase 2|185|Actual|Novartis||1|||f||||t||||||||||2018-05-31 23:58:09.319589|2018-05-31 23:58:09.319589
NCT01090310|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2015-02-12|2013-07-25|2015-12-08|2010-03-18|2010-03-19|Estimate|2015-12-08|2016-01-14|Estimate|2013-07-25|2013-08-01|Estimate|2015-12-08|2016-01-14|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ENDURE||Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis|A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis|Terminated||Phase 3|86|Actual|Novartis||4|||f||||t||||||||||2018-05-31 23:58:10.219601|2018-05-31 23:58:10.219601
NCT01090297|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2013-02-14|2010-03-18|2010-03-19|Estimate|||||||2013-02-14|2013-02-15|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|AgirSASadom||Continuous Positive Airway Pressure (CPAP) Mode Impact on Clinical Blood Arterial Pressure|CPAP Treatment : Fixed Versus Auto-adjusting Mode Impact on Clinical Blood Arterial Pressure. Randomised, Controlled and Double Blinded Trial in SAOS Patients|Completed||N/A|322|Actual|AGIR à Dom||2|||f||||f||||||||||2018-05-31 23:58:10.866568|2018-05-31 23:58:10.866568
NCT01090284|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-03-22|2010-03-18|2010-03-19|Estimate|||||||2010-03-22|2010-03-23|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Observational|||The Immunologic Reaction to Polypropylene Mesh in Inguinal Hernioplasty|The Immunologic Reaction to Polypropylene Mesh Implantation: a Comparison Between Heavyweight and Lightweight Mesh.|Unknown status|Recruiting||60|Anticipated|University Hospital, Catania|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 23:58:10.964804|2018-05-31 23:58:10.964804
NCT01090271|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|October 2007||2007-10-31|September 2007|2007-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effects of Eccentric Training for Shoulder Abductors in Subjects With Shoulder Impingement Syndrome|Eccentric Training for Shoulder Abductors Improves Pain, Function and Isokinetic Performance Steadiness in Subjects With Shoulder Impingement Syndrome|Completed||N/A|25|Actual|Universidade Federal de Sao Carlos||1|||f||||t||||||||||2018-05-31 23:58:11.147609|2018-05-31 23:58:11.147609
NCT01090258|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-02-24|2010-03-18|2010-03-19|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|CLOSER1||Pilot Evaluation of Closed Loop Ventilation and Oxygen Controller|Pilot Evaluation of Closed Loop Ventilation and Oxygen Controller|Completed||N/A|60|Actual|Laval University||2|||f||||f||||||||||2018-05-31 23:58:11.212116|2018-05-31 23:58:11.212116
NCT01090245|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-05-09|2010-03-18|2010-03-19|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2010||2010-04-30|May 2017|2017-05-31|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional|PIP||Using Incentives to Improve Parolee Participation and Attendance in Community Treatment|Using Incentives to Improve Parolee Participation and Attendance in Community Tx|Completed||N/A|202|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 23:58:11.27332|2018-05-31 23:58:11.27332
NCT01090232|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-08-29|2010-03-18|2010-03-19|Estimate|||||||2014-08-29|2014-09-01|Estimate|February 2010||2010-02-28|August 2014|2014-08-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection|Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection|Completed||N/A|17|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 23:58:11.359963|2018-05-31 23:58:11.359963
NCT01090219|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|July 2010|Anticipated|2010-07-31|February 2010|Anticipated|2010-02-28||Interventional|||Polypropylene Meshes in Hernia Repair|Morphofunctional Evaluations of Heavyweight and Ultralightweight Polypropylene Meshes in Men Inguinal Hernia Repair|Unknown status|Recruiting|N/A|32|Anticipated|Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude||1|||f||||t||||||||||2018-05-31 23:58:11.540491|2018-05-31 23:58:11.540491
NCT01090206|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2016-04-27|2010-03-17|2010-03-19|Estimate|||||||2016-04-27|2016-04-29|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2013|Actual|2013-03-31||Interventional|||Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia|Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia|Completed||N/A|20|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-05-31 23:58:11.62718|2018-05-31 23:58:11.62718
NCT01090193|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Human Kidney Histopathology in Obstructive Jaundice|Phase 4 Study :Human Kidney Histopathology in Acute Obstructive Jaundice: a Prospective Study|Completed||Phase 4|20|Actual|Turkish Ministry of Health Izmir Teaching Hospital||1|||f||||f||||||||||2018-05-31 23:58:11.700547|2018-05-31 23:58:11.700547
NCT01090180|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2016-08-08||2016-10-04|2010-03-18|2010-03-19|Estimate|2016-10-04|2016-11-25|Estimate||||2016-10-04|2016-11-25|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|VA CORT|Male veterans with combat-related PTSD|Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD|Extinction of Fear Memories With Glucocorticoids in Veterans With PTSD|Completed||N/A|129|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 23:58:11.796305|2018-05-31 23:58:11.796305
NCT01090167|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-03-17|2010-03-18|2010-03-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)|A Phase I, Open-label, Multi-center Study of Clofarabine (JC0707) in Japanese Patients With Acute Myeloid Leukemia (AML)|Completed||Phase 1|14|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 23:58:12.070616|2018-05-31 23:58:12.070616
NCT01090154|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2018-04-30|2010-03-17|2010-03-19|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2010||2010-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|UC CIMZIA||Study of Cimzia for the Treatment of Ulcerative Colitis|Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study|Active, not recruiting||Phase 2|25|Anticipated|University of Washington||1|||f||||t||||||||No||2018-05-31 23:58:12.212443|2018-05-31 23:58:12.212443
NCT01090141|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2014-09-12|2010-03-18|2010-03-19|Estimate|||||||2014-09-12|2014-09-15|Estimate|November 2009||2009-11-30|March 2010|2010-03-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|Micafungin||Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers|Pharmacokinetic Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers|Completed||Phase 4|36|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 23:58:12.305929|2018-05-31 23:58:12.305929
NCT01090128|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-03-29|2010-03-18|2010-03-19|Estimate|||||||2017-03-29|2017-03-31|Actual|September 2008||2008-09-30|March 2017|2017-03-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|NAC||Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer|Phase I Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer|Terminated||Phase 1|27|Actual|University of Utah||1||Drug Manufacturer withdrew support for studies not in metastatic breast cancer|f||||f||||||||||2018-05-31 23:58:12.394121|2018-05-31 23:58:12.394121
NCT01090102|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2014-05-20||2014-08-08|2010-03-18|2010-03-19|Estimate|2014-07-17|2014-08-11|Estimate||||2014-08-08|2014-08-13|Estimate|June 2010||2010-06-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Mesalamine to Reduce T Cell Activation in HIV Infection|Mesalamine to Reduce T Cell Activation in HIV Infection|Completed||Phase 4|33|Actual|University of California, San Francisco||2|||f||||||||||||||2018-05-31 23:58:12.486086|2018-05-31 23:58:12.486086
NCT01086878|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-02-24|2010-03-12|2010-03-15|Estimate|||||||2011-02-24|2011-02-25|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety of Cotrimoxazole in HIV- and HAART-exposed Infants|Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana|Completed||Phase 4|222|Anticipated|Harvard School of Public Health||1|||f||||f||||||||||2018-05-31 23:59:12.246616|2018-05-31 23:59:12.246616
NCT01090089|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2017-09-05|2010-03-18|2010-03-19|Estimate|||||||2017-09-05|2017-09-08|Actual|March 1, 2010|Actual|2010-03-01|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|DSM XIII||Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma|The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma|Recruiting||Phase 3|348|Anticipated|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||2|||f||||f|f|f||||||||2018-05-31 23:58:12.743427|2018-05-31 23:58:12.743427
NCT01090076|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2013-02-13||2013-06-14|2010-03-18|2010-03-19|Estimate|2013-05-20|2013-06-06|Estimate||||2013-06-14|2013-06-24|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates- A Placebo Controlled Trial|The Use of Specialised Amino Acid Mixture in Pressure Ulcer Wound Healing Rates-A Placebo Controlled Trial|Completed||N/A|26|Actual|Changi General Hospital|Limitations of trial include small sample size and it was difficult to standardise wound care regimen as the pressure ulcers were of different stages and locations.|2|||f||||f||||||||||2018-05-31 23:58:12.92452|2018-05-31 23:58:12.92452
NCT01090063|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2012-08-13||2016-09-26|2010-03-18|2010-03-19|Estimate|2013-01-31|2013-03-11|Estimate||||2016-09-26|2016-10-28|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|PPP||Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis|An Investigator-Initiated, Open-label Study Evaluating the Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis|Completed||N/A|26|Actual|Tufts Medical Center|||||f||||f||||||||No||2018-05-31 23:58:13.215943|2018-05-31 23:58:13.215943
NCT01090050|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|2013-02-05||2013-05-29|2010-03-18|2010-03-19|Estimate|2013-05-29|2013-07-03|Estimate||||2013-05-29|2013-07-03|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Treximet in the Treatment of Chronic Migraine|Treximet in the Treatment of Chronic Migraine|Completed||Phase 4|56|Actual|Cady, Roger, M.D.||2|||f||||f||||||||||2018-05-31 23:58:13.439575|2018-05-31 23:58:13.439575
NCT01090037|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2015-02-03|2010-03-17|2010-03-19|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2010||2010-03-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)|TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)|Completed||Phase 2/Phase 3|892|Actual|Toray Industries, Inc||2|||f||||t||||||||||2018-05-31 23:58:13.857139|2018-05-31 23:58:13.857139
NCT01090024|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18||2014-04-30|2014-04-30|2010-03-18|2010-03-19|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|March 2010||2010-03-31|April 2014|2014-04-30||||February 2011|Actual|2011-02-28||Interventional|||Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids|A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI|Completed||Phase 2|108|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 23:58:13.939428|2018-05-31 23:58:13.939428
NCT01090011|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2014-01-09||2015-08-29|2010-03-18|2010-03-19|Estimate|2014-06-20|2014-07-21|Estimate||||2015-08-29|2015-10-02|Estimate|March 2010||2010-03-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|January 2013|Actual|2013-01-31||Interventional||Treated set which includeed all patients enrolled in the trial who were documented to have taken at least one dose of study medication.|Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer|A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small Cell Lung Cancer With Progression Following Prior Erlotinib (Tarceva®) or Gefitinib (Iressa®)|Completed||Phase 1|171|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:58:14.072196|2018-05-31 23:58:14.072196
NCT01089998|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2013-01-18|2010-03-18|2010-03-19|Estimate|||||||2013-01-18|2013-01-21|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations|Open-label, Multicenter Study of the 18F-labeled PET/CT (Positron Emission Tomography / Computed Tomography) Tracer BAY86-9596 Following a Single Intravenous Administration of 200 or 300 MBq (Corresponding to ≤ 18 µg Mass Dose) for Evaluation of Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers (200 MBq) as Well as Investigation of Safety, Tolerability and Diagnostic Performance in Patients (300 MBq) With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and in Patients With Inflammation.|Completed||Phase 1|35|Actual|Piramal Imaging SA||4|||f||||f||||||||||2018-05-31 23:58:15.550654|2018-05-31 23:58:15.550654
NCT01089985|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-01-15|2010-03-18|2010-03-19|Estimate|||||||2012-01-15|2012-01-18|Estimate|July 2010||2010-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye|Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye|Completed||Phase 1|10|Actual|Singapore National Eye Centre||1|||f||||f||||||||||2018-05-31 23:58:15.656034|2018-05-31 23:58:15.656034
NCT01089972|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2011-03-31|2010-03-18|2010-03-19|Estimate|||||||2011-03-31|2011-04-01|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Ultrasonographic Evaluation of the Radial and Ulnar Blood Flow After Radial Arterial Cannulation||Completed|||80|Actual|Severance Hospital|||2||f||||||||||||||2018-05-31 23:58:15.731658|2018-05-31 23:58:15.731658
NCT01089959|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-08-18|2010-03-18|2010-03-19|Estimate|||||||2010-08-18|2010-08-19|Estimate|March 2010||2010-03-31|August 2010|2010-08-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|ISS||Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD|The Effect of Esomeprazole 40 mg. Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With Gastroesophageal Reflux Disease (GERD).|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Southern Arizona VA Health Care System||1|||f||||f||||||||||2018-05-31 23:58:15.787689|2018-05-31 23:58:15.787689
NCT01089946|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2012-10-09|2010-03-18|2010-03-19|Estimate|||||||2012-10-09|2012-10-10|Estimate|March 2010||2010-03-31|October 2012|2012-10-31||||June 2010|Actual|2010-06-30||Observational|||Cardiovascular Changes and Changes in Tissue Oxygenation During Early Postoperative Mobilization in Total Hip Arthroplasty (THA) Patients|Cardiovascular Changes and Changes in Tissue Oxygenation During Early Postoperative Mobilization After Primary Total Hip Arthroplasty|Completed|||26|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 23:58:15.94536|2018-05-31 23:58:15.94536
NCT01089933|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-05-09|2010-03-18|2010-03-19|Estimate|||||||2017-05-09|2017-05-11|Actual|September 2009||2009-09-30|May 2017|2017-05-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|RELIeF||Reducing Pain and Disability After Breast Cancer Surgery|Efficacy of Thoracic Paravertebral Block in Reducing Chronic Pain and Disability After Breast Cancer Surgery With Axillary Lymph Node Dissection|Completed||N/A|145|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 23:58:16.026471|2018-05-31 23:58:16.026471
NCT01089920|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2014-06-04|2010-03-18|2010-03-19|Estimate|||||||2014-06-04|2014-06-05|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans|Dose Response Bioavailability of Coffee and Green Tea Antioxidants in Humans|Completed||N/A|23|Actual|Nestlé||6|||f||||f||||||||||2018-05-31 23:58:17.382426|2018-05-31 23:58:17.382426
NCT01089907|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Observational|||Genomic Changes in Childhood Acute Lymphoblastic Leukemia|Genomics Evolution in Childhood Acute Lymphoblastic Leukemia|Unknown status|Not yet recruiting||400|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     bone marrow, peripheral blood~   "|||2018-05-31 23:58:17.598373|2018-05-31 23:58:17.598373
NCT01089894|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|August 2008||2008-08-31|March 2010|2010-03-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Clinical Application of 18F-3'-Fluoro-3'-Deoxy-L-thymidine (18F-FLT) Positron Emission Tomography (PET) in Lung Tumors|Clinical Application of 18F-FLT PET in Lung Tumors|Unknown status|Recruiting||90|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 23:58:17.721784|2018-05-31 23:58:17.721784
NCT01089881|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer|The Effectiveness of 18F-fluorocholine PET in Detecting, Staging and Following-up Prostate Cancer|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 23:58:17.789136|2018-05-31 23:58:17.789136
NCT01089868|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2012-08-05|2010-03-18|2010-03-19|Estimate|||||||2012-08-05|2012-08-07|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Observational|||Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients|Quantification of Therapy Effects After Microsurgery, Percutaneous Irradiation and Chemotherapy by FET-PET Analysis|Completed|||79|Actual|Ludwig-Maximilians - University of Munich|||2||f||||f||||||Samples With DNA|"~     DNA and RNA samples for MGMT methylation and LOH 1p and 19q status analysis~   "|||2018-05-31 23:58:17.853926|2018-05-31 23:58:17.853926
NCT01089855|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-07-10|2010-03-18|2010-03-19|Estimate|||||||2017-07-10|2017-07-13|Actual|December 2009||2009-12-31|February 2011|2011-02-28||||July 2010|Actual|2010-07-31||Interventional|||Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain|Phase IV Open Non Comparative Trial to Evaluate Efficacy and Safety of Tegretol® in Diabetes Neuropathy Pain.|Completed||Phase 4|123|Actual|Novartis||1|||f||||||||||||||2018-05-31 23:58:17.956534|2018-05-31 23:58:17.956534
NCT01089842|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|January 2012|Anticipated|2012-01-31|June 2011|Anticipated|2011-06-30||Interventional|||Health Coaching to Promote Physical Activity for Coronary Heart Disease Prevention|Randomized Clinical Trial to Assess the Efficacy and Cost-efficacy of Health Coaching to Promote Physical Activity in Secondary Prevention of Coronary Heart Disease|Unknown status|Recruiting|N/A|262|Anticipated|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 23:58:18.043413|2018-05-31 23:58:18.043413
NCT01089829|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-03-18|2010-03-18|2010-03-19|Estimate|||||||2010-03-18|2010-03-19|Estimate|April 2010||2010-04-30|January 2010|2010-01-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||Risk Factors for Foot Ulceration in the Chronic Kidney Disease (CKD) Population|The Pathological Relationships Between Chronic Kidney Disease (CKD)and the Development of Lower Limb Threatening Complications|Unknown status|Not yet recruiting||200|Anticipated|Cardiff University|||2||f||||t||||||||||2018-05-31 23:58:18.887634|2018-05-31 23:58:18.887634
NCT01089816|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2015-04-17|2010-03-18|2010-03-19|Estimate|||||||2015-04-17|2015-04-21|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Observational|||Rapid Diagnostic Test for Influenza|Clinical Validation of the Point-of-Care MSD Influenza Test in Asia|Completed|||569|Actual|Meso Scale Diagnostics, LLC.|||1||f||||f||||||Samples With DNA|"~     Viral transport media containing nasal swab extract.~   "|||2018-05-31 23:58:19.007098|2018-05-31 23:58:19.007098
NCT01089803|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2015-12-03|2010-03-18|2010-03-19|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer|Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer|Completed|||279|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 23:58:19.195619|2018-05-31 23:58:19.195619
NCT01089790|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17||2011-09-14|2011-09-14|2010-03-18|2010-03-19|Estimate||||2011-09-14|2011-09-21|Estimate|2011-09-14|2011-09-21|Estimate|March 2010||2010-03-31|September 2011|2011-09-30||||August 2010|Actual|2010-08-31||Interventional|REDWOOD403||Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone|A Phase III, Multicenter, Double-blind, Active-Controlled, 52 Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone|Terminated||Phase 3|141|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 23:58:19.308368|2018-05-31 23:58:19.308368
NCT01089777|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2014-08-02|2010-03-18|2010-03-19|Estimate|||||||2014-08-02|2014-08-05|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|||Monitoring and Characterization of Coronary Flow By Transthoracic Parametric Doppler (TPD) During Exercise Stress Test||Terminated|||60|Actual|Echosense Ltd.|||||f||||f||||||||||2018-05-31 23:58:19.67352|2018-05-31 23:58:19.67352
NCT01089764|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2013-08-13|2010-03-18|2010-03-19|Estimate|||||||2013-08-13|2013-08-14|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|couplelinks||Couplelinks.ca - An Online Intervention for Couples Affected by Breast Cancer|A Randomized Controlled Trials of Couplelinks.ca: The First Online Couples Intervention for Young Women Dealing With Breast Cancer and Their Male Partners|Unknown status|Recruiting|Phase 3|260|Anticipated|Canadian Breast Cancer Research Alliance||2|||f||||f||||||||||2018-05-31 23:58:19.741627|2018-05-31 23:58:19.741627
NCT01089751|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2013-06-12||2013-09-24|2010-03-18|2010-03-19|Estimate|2013-09-24|2013-09-26|Estimate||||2013-09-24|2013-09-26|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily||Completed||Phase 4|322|Actual|Allergan||2|||f||||f||||||||||2018-05-31 23:58:19.938357|2018-05-31 23:58:19.938357
NCT01089738|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-07-06|2010-03-17|2010-03-18|Estimate|||||||2010-07-06|2010-07-07|Estimate|November 2010||2010-11-30|July 2010|2010-07-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals|An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of PF-03382792 In Healthy Elderly Subjects|Withdrawn||Phase 1|40|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 23:58:20.64647|2018-05-31 23:58:20.64647
NCT01089725|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11||2012-01-27|2013-06-27|2010-03-17|2010-03-18|Estimate||||2012-08-20|2012-08-29|Estimate|2013-06-27|2013-07-03|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee|Terminated||Phase 3|385|Actual|Pfizer||5||See termination reason in detailed description.|f||||t||||||||||2018-05-31 23:58:20.735799|2018-05-31 23:58:20.735799
NCT01089712|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2014-04-04|2010-03-17|2010-03-18|Estimate|||||||2014-04-04|2014-04-08|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|September 2011|Actual|2011-09-30||Observational|||Management Practices and the Risk of Infection Following Cardiac Surgery|Management Practices and the Risk of Infection Following Cardiac Surgery|Completed|||5158|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||t||||||||||2018-05-31 23:58:21.103536|2018-05-31 23:58:21.103536
NCT01089699|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-17|2010-03-17|2010-03-18|Estimate|||||||2010-03-17|2010-03-18|Estimate|April 2010||2010-04-30|November 2009|2009-11-30|March 2015|Anticipated|2015-03-31|March 2013|Anticipated|2013-03-31||Interventional|CBCRA09||A Trial Testing Professional and Peer-led Support Online Support Groups for Young Canadian Breast Cancer Survivors|A Randomized Control Trial Testing the Efficacy of Professional and Peer-Led Online Support Groups for Young Canadian Breast Cancer Survivors|Unknown status|Not yet recruiting|Early Phase 1|210|Anticipated|British Columbia Cancer Agency||3|||f||||t||||||||||2018-05-31 23:58:21.222207|2018-05-31 23:58:21.222207
NCT01089686|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2012-03-06|2010-03-17|2010-03-18|Estimate|||||||2012-03-06|2012-03-07|Estimate|August 2010||2010-08-31|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients|Utility of Chronic Cerebrospinal Venous Insufficiency Percutaneous Angioplasty for Multiple Sclerosis: The Albany Vascular Group Study (Liberation Study)|Terminated||N/A|2|Actual|The Vascular Group, PLLC||2|||f||||f||||||||||2018-05-31 23:58:21.303786|2018-05-31 23:58:21.303786
NCT01089673|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2011-09-06|2010-03-17|2010-03-18|Estimate|||||||2011-09-06|2011-09-07|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Retrospective Study of the Effects of Molecular Diagnostics on Wound Care Outcomes|A Retrospective Study of the Effects of Molecular Diagnostics on Wound Care Outcomes|Completed|||600|Anticipated|Southwest Regional Wound Care Center|||1||f||||f||||||||||2018-05-31 23:58:21.377136|2018-05-31 23:58:21.377136
NCT01089660|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2014-01-10|2010-03-17|2010-03-18|Estimate|||||||2014-01-10|2014-01-14|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults|Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects|Completed||Phase 2|202|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:58:21.432977|2018-05-31 23:58:21.432977
NCT01089647|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2013-05-29|2010-03-17|2010-03-18|Estimate|||||||2013-05-29|2013-05-30|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)|Montelukast and Nasa ICS for Treatment of Mild Obstructive Sleep Apnea in Adults|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Romaker & Associates||2|||f||||t||||||||||2018-05-31 23:58:21.510208|2018-05-31 23:58:21.510208
NCT01089634|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2018-04-24|2010-03-17|2010-03-18|Estimate|||||||2018-04-24|2018-04-26|Actual|October 2007||2007-10-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Observational|LEARN||Left Ventricular Capture Management Study|Left Ventricular Capture Management (LEARN) Study|Completed|||151|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-05-31 23:58:21.60937|2018-05-31 23:58:21.60937
NCT01089621|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-08-23|2010-03-17|2010-03-18|Estimate|||||||2010-08-23|2010-08-24|Estimate|March 2010||2010-03-31|August 2010|2010-08-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||A Study for Adolescents With Fibromyalgia Syndrome|An Open-label Feasibility Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome: A Pilot Study|Terminated||Phase 4|0|Actual|Eli Lilly and Company||1||Terminated due to study design changes; zero patients randomized to treatment|f||||f||||||||||2018-05-31 23:58:21.673693|2018-05-31 23:58:21.673693
NCT01089608|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2014-10-07||2014-11-03|2010-03-17|2010-03-18|Estimate|2014-11-03|2014-11-04|Estimate||||2014-11-03|2014-11-04|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis|Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis (Pilot Phase II Clinical Study, Multicentre, Randomised, Double Masked, Comparative, 2 X 40 Patients)|Completed||Phase 2|93|Actual|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 23:58:21.772941|2018-05-31 23:58:21.772941
NCT01089595|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2013-05-07||2017-01-25|2010-03-17|2010-03-18|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|February 2009||2009-02-28|January 2017|2017-01-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)|Open Label Phase II Randomized Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or in Combination With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced GIST That Have Progressed on High Dose Imatinib|Terminated||Phase 2|5|Actual|Fox Chase Cancer Center|Trial ended early due to industry support of provision of nilotinib was discontinued.|2||Novartis is ending their research program for Nilotinib in GIST.|f||||t||||||||||2018-05-31 23:58:21.974698|2018-05-31 23:58:21.974698
NCT01089582|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2010-06-29||2011-04-25|2010-03-17|2010-03-18|Estimate|2010-06-29|2010-08-03|Estimate||||2011-04-25|2011-04-28|Estimate|November 2007||2007-11-30|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|QUEST||Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets|Quality Of Life Assessment In AD Patients Receiving Aricept Tablets (Donepezil Hydrochloride)|Completed|||628|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 23:58:22.295525|2018-05-31 23:58:22.295525
NCT01089569|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2016-10-28||2017-04-19|2010-03-17|2010-03-18|Estimate|2017-04-19|2017-05-23|Actual||||2017-04-19|2017-05-23|Actual|April 2010||2010-04-30|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine|Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis|Completed||N/A|60|Actual|HealthPartners Institute||3|||f||||f||||||||No||2018-05-31 23:58:23.52072|2018-05-31 23:58:23.52072
NCT01089556|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2012-10-30||2013-01-17|2010-03-17|2010-03-18|Estimate|2012-10-30|2012-12-04|Estimate||||2013-01-17|2013-01-24|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|COMBO-DN||A Study in Painful Diabetic Neuropathy|"Use of Duloxetine or Pregabalin in Monotherapy Versus Combination Therapy of Both Drugs in Patients With Painful Diabetic Neuropathy The COMBO - DN (COmbination vs Monotherapy of pregaBalin and dulOxetine in Diabetic Neuropathy) Study"|Completed||Phase 3|811|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 23:58:24.272185|2018-05-31 23:58:24.272185
NCT01089543|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2013-09-17||2013-11-27|2010-03-17|2010-03-18|Estimate|2013-09-17|2013-11-19|Estimate||||2013-11-27|2013-12-24|Estimate|April 2010||2010-04-30|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Per Protocol Set (PPS): was defined as those participants who complied with the study protocol. N= 338 participants were enrolled at study start. However, a total of 307 participants were included in PPS for efficacy evaluation.|A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)|A Multi-Center, Randomized, Double-Blind Study of E3810 for Japanese Subjects With Functional Dyspepsia|Completed||Phase 2|338|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 23:58:26.782089|2018-05-31 23:58:26.782089
NCT01089530|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-03-17|2010-03-17|2010-03-18|Estimate|||||||2010-03-17|2010-03-18|Estimate|January 2003||2003-01-31|March 2010|2010-03-31|December 2006||2006-12-31|||||Interventional|EFAP||Clinical Intervention Study in the Primary Care Setting of Patients With High Plasma Fibrinogen (EFAP)|Clinical Intervention Study in the Primary Care Setting of Patients With High Plasma Fibrinogen in Primary Prevention of Cardiovascular Disease|Completed||N/A|436||Jordi Gol i Gurina Foundation||1|||f||||t||||||||||2018-05-31 23:58:27.133656|2018-05-31 23:58:27.133656
NCT01089517|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|2013-11-13||2017-04-06|2010-03-17|2010-03-18|Estimate|2013-11-13|2014-01-03|Estimate||||2017-04-06|2017-05-12|Actual|March 2010||2010-03-31|April 2017|2017-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration|A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 2|449|Actual|Ophthotech Corporation||3|||f||||f||||||||||2018-05-31 23:58:27.200238|2018-05-31 23:58:27.200238
NCT01089504|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2016-01-04||2016-01-04|2010-03-17|2010-03-18|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PROPHENO||Prophylactic Phenobarbital After Neonatal Seizures|Prophylactic Phenobarbital After Resolution of Neonatal Seizures|Terminated||Phase 4|13|Actual|University of Rochester|Due to low enrollment, there was limited data available for analysis and therefore insufficient power to provide meaningful results for our primary analysis.|2||Inadequate rate of enrollment|f||||t||||||||||2018-05-31 23:58:27.71971|2018-05-31 23:58:27.71971
NCT01089491|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2015-05-11|2010-03-17|2010-03-18|Estimate|||||||2015-05-11|2015-05-12|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Study of Cells From Spinal Cavity of Patients With Low Back Pain|Localization and Characterization of Cells in the Lumbar Epidural Cavity of Patients With Low Back Pain With or Without Radiculopathy|Withdrawn|||0|Actual|Texas Tech University Health Sciences Center||||PI chose not to conduct the study; no data collected.|f||||f||||||Samples Without DNA|"~     Up to two (2) cell samples will be collected from different sites in the epidural space~   "|||2018-05-31 23:58:28.00177|2018-05-31 23:58:28.00177
NCT01089478|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2018-01-17|2010-03-17|2010-03-18|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2005||2005-04-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|||Cytology Study of Cells From Patients With Low Back Pain|Cells in the Lumbar Epidural Space of Patients With Low Back Pain and/or Radiculopathy|Active, not recruiting|||605|Actual|Texas Tech University Health Sciences Center|||||f||||f||||||Samples Without DNA|"~     During epiduroscopy up to five (5) specimen samples will be collected from different sites in~     the epidural space~   "|||2018-05-31 23:58:28.084276|2018-05-31 23:58:28.084276
NCT01089465|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-12-07|2010-03-17|2010-03-18|Estimate|||||||2011-12-07|2011-12-08|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||March 2012|Anticipated|2012-03-31||Interventional|||Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role|Cimex Lectularius or Bed Bugs : Vector of Infectious Agents and Pathogenic Role|Unknown status|Recruiting|N/A|135|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-05-31 23:58:28.142988|2018-05-31 23:58:28.142988
NCT01089452|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2015-06-02|2010-03-17|2010-03-18|Estimate|||||||2015-06-02|2015-06-03|Estimate||||June 2015|2015-06-30||||||||Interventional|ACCESS||Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study|ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy.|Withdrawn||Phase 4|0|Actual|Monash University||3||Study not started due to administrative reasons.|f||||f||||||||||2018-05-31 23:58:28.216959|2018-05-31 23:58:28.216959
NCT01089439|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2014-12-03|2010-03-17|2010-03-18|Estimate|||||||2014-12-03|2014-12-04|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|INNOSTAPED||Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children|Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children: Randomized, Double Blind Placebo-controlled Concept-proof Trial|Completed||Phase 2|21|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 23:58:28.326361|2018-05-31 23:58:28.326361
NCT01086189|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|February 2010|Actual|2010-02-28|||||Observational|||Does Green Tea Affect Postprandial Glucose, Insulin and Satiety in Healthy Subjects||Completed|||14|Actual|Skane University Hospital|||||f||||||||||||||2018-05-31 23:59:24.651848|2018-05-31 23:59:24.651848
NCT01089426|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2018-01-18|2010-03-17|2010-03-18|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2008||2008-09-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury|Research Study of an Intravenous Fat Emulsion Comprised of Fish Oils (Omegaven) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury|Recruiting||N/A|90|Anticipated|Children's Hospital Los Angeles||2|||f||||t||||||||||2018-05-31 23:58:28.406353|2018-05-31 23:58:28.406353
NCT01089413|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2015-11-13||2015-11-13|2010-03-17|2010-03-18|Estimate|2015-11-13|2015-12-16|Estimate||||2015-11-13|2015-12-16|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||Full analysis population (FAS) included all participants who received bevacizumab in first line mCRC. Baseline characteristics were reported by age groups.|Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)|A Multicenter, Non-interventional, Post-authorization Study to Observe in Daily Clinical Practice the Treatment Duration of Patients Treated With Avastin (Bevacizumab) in 1st Line mCRC in Belgium|Completed|||201|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 23:58:28.546394|2018-05-31 23:58:28.546394
NCT01089400|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2012-01-27|2010-03-17|2010-03-18|Estimate|||||||2012-01-27|2012-01-31|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|||||Observational|FluBAL||Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage|Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage in Patients Requiring Mechanical Ventilation in Intensive Care Unit|Completed|||30|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||Samples Without DNA|"~     Bronchoalveolar lavage fuid Nasal sample Peripheral mononuclear blood cells Plasma Serum~   "|||2018-05-31 23:58:29.692874|2018-05-31 23:58:29.692874
NCT01089387|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2016-11-17|2010-03-17|2010-03-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|May 2010||2010-05-31|April 2011|2011-04-30|March 2015|Actual|2015-03-31|May 2012|Actual|2012-05-31||Interventional|INSTIN||Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction|Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction|Completed||Phase 1/Phase 2|18|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 23:58:29.759429|2018-05-31 23:58:29.759429
NCT01089374|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2017-12-20|2010-03-17|2010-03-18|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2010||2010-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Phyllodes Tumor Partial Breast Radiation Study|A Prospective Study of Partial Breast Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors|Recruiting||N/A|50|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 23:58:29.829592|2018-05-31 23:58:29.829592
NCT01089361|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|2015-12-22||2017-07-21|2010-03-17|2010-03-18|Estimate|2017-07-21|2017-08-21|Actual||||2017-07-21|2017-08-21|Actual|December 2009||2009-12-31|July 2017|2017-07-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Immunomodulatory Properties of Ketamine in Sepsis|Immunomodulatory Properties of Ketamine in Sepsis|Completed||Phase 1/Phase 2|19|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 23:58:29.907494|2018-05-31 23:58:29.907494
NCT01089348|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-07-20|2010-03-17|2010-03-18|Estimate|||||||2010-07-20|2010-07-21|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|LF-BV-09||A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis|Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis|Unknown status|Recruiting|Phase 2/Phase 3|90|Anticipated|Avva Rus, JSC||2|||f||||t||||||||||2018-05-31 23:58:30.228165|2018-05-31 23:58:30.228165
NCT01089335|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-04-11|2010-03-17|2010-03-18|Estimate|||||||2017-04-11|2017-04-12|Actual|March 2010||2010-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SNTC||Sentinel Lymphnode in Patients With Papillary Thyroid Carcinoma and in Patients With Suspected Thyroid Neoplasia|Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential|Recruiting|||200|Anticipated|Region Skane|||2||f||||f||||||||||2018-05-31 23:58:30.304992|2018-05-31 23:58:30.304992
NCT01089322|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2017-02-14|2010-03-16|2010-03-18|Estimate|||||||2017-02-14|2017-02-16|Actual|December 9, 2005|Actual|2005-12-09|February 2017|2017-02-28|May 13, 2009|Actual|2009-05-13|April 3, 2009|Actual|2009-04-03||Interventional|||Risk Factors Associated to Difficult-to-control Asthma|Risk Factors Associated to Difficult-to-control Asthma: Characterization of Clinical, Structural and Inflammatory Factors Related to Treatment Response|Completed||Phase 4|74|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 23:58:30.390416|2018-05-31 23:58:30.390416
NCT01089309|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2010-03-26|2010-03-17|2010-03-18|Estimate|||||||2010-03-26|2010-03-29|Estimate|May 2004||2004-05-31|March 2010|2010-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|RAAS LAEI SAEI||Effect of Aldosterone Blockade on Arterial Compliance|Effect of Aldosterone Blockade on Metabolic Parameters and Arterial Compliance|Completed||Phase 4|51|Actual|Wolfson Medical Center||1|||f||||t||||||||||2018-05-31 23:58:30.454564|2018-05-31 23:58:30.454564
NCT01089296|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-04-04|2010-03-17|2010-03-18|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2010||2010-03-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Norwegian Physical Therapy Study in Preterm Infants|Parental Participation in Individually Customized Physiotherapy for Preterm Infants in the Neonatal Intensive Care Unit: Effects and Experiences. The Pragmatic Randomized Controlled Part.|Active, not recruiting||N/A|150|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 23:58:30.499175|2018-05-31 23:58:30.499175
NCT01089283|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-17|2010-03-17|2010-03-18|Estimate|||||||2010-03-17|2010-03-18|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||March 2011|Anticipated|2011-03-31||Observational|||Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics|I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic|Unknown status|Not yet recruiting||80|Anticipated|Tel-Aviv Sourasky Medical Center|||4||f||||t||||||||||2018-05-31 23:58:30.559424|2018-05-31 23:58:30.559424
NCT01089270|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2010-03-17|2010-03-17|2010-03-18|Estimate|||||||2010-03-17|2010-03-18|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||March 2011|Anticipated|2011-03-31||Observational|||Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives||Unknown status|Not yet recruiting||80|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-05-31 23:58:30.62371|2018-05-31 23:58:30.62371
NCT01086176|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-04-26|2010-03-11|2010-03-12|Estimate|||||||2010-04-26|2010-04-27|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||The Impact of Post-tetanic Count on Subsequent Train-of-four During Recovery From Rocuronium||Completed|||22|Anticipated|Maisonneuve-Rosemont Hospital|||1||f||||||||||||||2018-05-31 23:59:24.704642|2018-05-31 23:59:24.704642
NCT01089257|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2016-03-04|2010-03-16|2010-03-18|Estimate|||||||2016-03-04|2016-03-07|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|January 2021|Anticipated|2021-01-31|November 2007|Actual|2007-11-30||Observational|INFRASAS||Cardiovascular Impairments and Obstructive Sleep Apnea Syndrome|Subclinical Cardiovascular Impairments in Patients With Obstructive Sleep Apnea Syndrome|Recruiting|||580|Anticipated|University Hospital, Grenoble|||||f||||f||||||||||2018-05-31 23:58:30.684139|2018-05-31 23:58:30.684139
NCT01089244|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2015-09-18|2010-03-17|2010-03-18|Estimate|||||||2015-09-18|2015-09-22|Estimate|June 2008||2008-06-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma|Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas|Unknown status|Active, not recruiting||38|Actual|Ludwig-Maximilians - University of Munich|||2||f||||f||||||Samples With DNA|"~     High molecular wight DNA and RNA speciments for MGMT promoter methylation, IDH1/IDH2 and p53~     mutation, LOH 1p and 19q analysis~   "|||2018-05-31 23:58:30.88127|2018-05-31 23:58:30.88127
NCT01089231|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2011-10-27||2011-12-12|2010-03-17|2010-03-18|Estimate|2011-10-27|2011-12-02|Estimate||||2011-12-12|2011-12-19|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Omega-3 Fatty Acids on the Human Gene Expression|Effects of Omega-3 Fatty Acids From Fish Oil on the Gene Expression in Healthy Humans and Humans With Hypertriglyceridemia|Completed||Phase 4|40|Actual|Gottfried Wilhelm Leibniz Universität Hannover|"A higher number of participants would be better to compensate drop outs~two pre-screening procedures of lipid levels are generally desirable~CO is not an optimal placebo control"|4|||f||||f||||||||||2018-05-31 23:58:30.952337|2018-05-31 23:58:30.952337
NCT01089218|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-14|||2011-07-19|2010-03-17|2010-03-18|Estimate|||||||2011-07-19|2011-07-21|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|February 2010|Actual|2010-02-28|January 2009|Actual|2009-01-31||Interventional|||The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines|The Impact of Antibiotic Prophylaxis on Incidence of Post-bronchoscopy Fever and Change of Serum Cytokines|Completed||Phase 4|241|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 23:58:31.298817|2018-05-31 23:58:31.298817
NCT01089205|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-07-28|2010-03-17|2010-03-18|Estimate|||||||2010-07-28|2010-07-29|Estimate||||March 2010|2010-03-31||||||||Interventional|||Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.|An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fed Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited||2|||f||||||||||||||2018-05-31 23:58:31.363951|2018-05-31 23:58:31.363951
NCT01089192|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-10-13|2010-03-17|2010-03-18|Estimate|||||||2010-10-13|2010-10-14|Estimate||||March 2010|2010-03-31||||||||Interventional|||Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.|An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fasting Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited||2|||f||||||||||||||2018-05-31 23:58:31.410909|2018-05-31 23:58:31.410909
NCT01089179|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-05-06|2010-03-17|2010-03-18|Estimate|||||||2010-05-06|2010-05-07|Estimate||||March 2010|2010-03-31||||||||Interventional|||Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions|An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 500 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 23:58:31.461318|2018-05-31 23:58:31.461318
NCT01089166|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-06-18|2010-03-17|2010-03-18|Estimate|||||||2010-06-18|2010-06-22|Estimate||||March 2010|2010-03-31||||||||Interventional|||Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition|To Compare the Bioavailability of Extended Release Metformin HCl Tablet(Test Formulation, Torrent Pharmaceuticals Ltd.,India) Versus Glucophage XR® Tablets ( Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers Under Fasting Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited||2|||f||||||||||||||2018-05-31 23:58:31.582665|2018-05-31 23:58:31.582665
NCT01089153|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2011-09-06|2010-03-16|2010-03-18|Estimate|||||||2011-09-06|2011-09-07|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research|Obtaining and Storing Human Blood, Urine, and Fecal Samples for Spirochete-Related Epidemiological Research|Completed|||35|Actual|Southwest Regional Wound Care Center|||||f||||f||||||Samples With DNA|"~     human blood, urine and fecal samples~   "|||2018-05-31 23:58:31.641778|2018-05-31 23:58:31.641778
NCT01089140|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-08-27|2010-03-16|2010-03-18|Estimate|||||||2013-08-27|2013-08-28|Estimate|November 2014||2014-11-30|August 2013|2013-08-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Non-Idiopathic Scoliosis Treated With Tranexamic Acid|Blood Loss and Transfusion Requirement in Pediatric Patients With Non-Idiopathic Scoliosis Treated With Tranexamic Acid Undergoing Posterior Spinal Instrumentation and Fusion.|Suspended||Phase 2|2|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 23:58:31.686556|2018-05-31 23:58:31.686556
NCT01089127|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2011-07-22||2011-07-22|2010-03-17|2010-03-18|Estimate|2011-07-22|2011-08-19|Estimate||||2011-07-22|2011-08-19|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease, Using Salmeterol as an Active Control|Completed||Phase 3|552|Actual|Novartis||6|||f||||||||||||||2018-05-31 23:58:31.794346|2018-05-31 23:58:31.794346
NCT01089114|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2018-02-13|2010-03-17|2010-03-18|Estimate|||||||2018-02-13|2018-02-14|Actual|March 8, 2010||2010-03-08|August 7, 2015|2015-08-07|August 7, 2015||2015-08-07|||||Observational|||Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology|Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology|Completed|||168|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:58:32.269395|2018-05-31 23:58:32.269395
NCT01089101|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2018-04-09|2010-03-17|2010-03-18|Estimate|||||||2018-04-09|2018-04-10|Actual|April 19, 2010|Actual|2010-04-19|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma|A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma|Recruiting||Phase 1/Phase 2|180|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:58:32.340699|2018-05-31 23:58:32.340699
NCT01089088|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2013-02-28|2010-03-17|2010-03-18|Estimate|||||||2013-02-28|2013-03-01|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|July 2013|Anticipated|2013-07-31||Interventional|||Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium|A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium|Unknown status|Active, not recruiting|Phase 2|63|Anticipated|Wales Cancer Trials Unit|||||f||||t||||||||||2018-05-31 23:58:32.44077|2018-05-31 23:58:32.44077
NCT01089075|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2015-04-07|2010-03-17|2010-03-18|Estimate|||||||2015-04-07|2015-04-08|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CSMünchen01||Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency|Phase IV Study to Evaluate the Neuropsychological Effects of Hydrocortisone Substitution in Patients With Partial Adrenal Insufficiency After Traumatic Brain Injury or Subarachnoidal Haemorrhage|Terminated||Phase 4|32|Actual|Max-Planck-Institute of Psychiatry||2||Insufficient recruitment of suitable patients.|f||||f||||||||||2018-05-31 23:58:32.536346|2018-05-31 23:58:32.536346
NCT01089062|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2013-08-19||2013-12-09|2010-03-17|2010-03-18|Estimate|2013-08-19|2013-10-22|Estimate||||2013-12-09|2014-01-09|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure|A Randomized, Double Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of Intravenous Dihydroergotamine (DHE) and Orally Inhaled DHE (MAP0004) on Pulmonary Arterial Pressure and Tolerability in Healthy Adults|Completed||Phase 1|24|Actual|Allergan||6|||f||||f||||||||||2018-05-31 23:58:32.632469|2018-05-31 23:58:32.632469
NCT01089049|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2012-03-23|2010-03-17|2010-03-18|Estimate|||||||2012-03-23|2012-03-26|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Effect of a Natural Health Product on Urinary Estrogen Metabolites|A Clinical Trial to Assess the Efficacy of a Supplemental Formula Targeting Breast Health in Beneficially Altering Urinary Estrogen Metabolites Levels in Both Pre- and Post-menopausal Women|Completed||Phase 1/Phase 2|98|Actual|Nutrasource Diagnostics Inc.||2|||f||||f||||||||||2018-05-31 23:58:33.160863|2018-05-31 23:58:33.160863
NCT01089036|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2013-10-18|2010-03-17|2010-03-18|Estimate|||||||2013-10-18|2013-10-21|Estimate|March 2010||2010-03-31|October 2013|2013-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|ECMO||Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in Extracorporeal Membrane Oxygenation (ECMO) Patients|Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in ECMO Patients|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     serum,plasma, and cells for study. Once the study is completed, biospecimen will be~     discarded.~   "|||2018-05-31 23:58:33.234453|2018-05-31 23:58:33.234453
NCT01089023|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2014-06-23||2014-06-23|2010-03-17|2010-03-18|Estimate|2014-06-23|2014-07-22|Estimate||||2014-06-23|2014-07-22|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||All the participants who were administered treatment at each visit were considered during the analysis.|A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis|Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and the Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti- TNF Therapy.|Completed||Phase 4|95|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-05-31 23:58:33.337036|2018-05-31 23:58:33.337036
NCT01089010|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2011-05-11|2010-03-17|2010-03-18|Estimate|||||||2011-05-11|2011-05-13|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|67|Actual|Cytokinetics||1|||f||||f||||||||||2018-05-31 23:58:33.872144|2018-05-31 23:58:33.872144
NCT01088997|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|2015-05-20||2016-06-02|2010-03-16|2010-03-18|Estimate|2016-06-02|2016-07-12|Estimate||||2016-06-02|2016-07-12|Estimate|June 2010||2010-06-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|February 2013|Actual|2013-02-28||Interventional|||Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn|Milrinone Pharmacokinetics and Pharmacodynamics in Newborns With Persistent Pulmonary Hypertension of the Newborn - a Pilot Study to Enable a Randomized Trial of Intervention|Terminated||N/A|12|Actual|Children's Hospital of Philadelphia|Study enrollment was terminated early resulting in a small number of evaluable subjects for analysis.|2||Inadequate enrollment|f||||t||||||||||2018-05-31 23:58:34.005013|2018-05-31 23:58:34.005013
NCT01088984|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|2014-09-24|2013-03-20|2016-04-21|2010-03-16|2010-03-18|Estimate|2014-09-24|2014-10-01|Estimate|2013-03-20|2013-03-28|Estimate|2016-04-21|2016-05-23|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Includes 5 participants treated with bendamustine at 90 mg/m2 in Phase 1, and 6 participants treated with bendamustine at 120 mg/m2 in Phase 1, and 32 participants treated with the recommended phase II dose (RP2D) of bendamustine (120 mg/m2) in Phase 2.|Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia|An Open-Label Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia|Completed||Phase 1/Phase 2|43|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-05-31 23:58:34.42167|2018-05-31 23:58:34.42167
NCT01088971|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2011-12-22|2010-03-16|2010-03-18|Estimate|||||||2011-12-22|2011-12-23|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Duolac 7S Administration on Improving Symptom in Irritable Bowel Syndrome||Completed||Phase 3|60|Actual|Cell Biotech Co., Ltd.||2|||f||||||||||||||2018-05-31 23:58:35.041046|2018-05-31 23:58:35.041046
NCT01088958|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2015-07-28|2010-03-16|2010-03-18|Estimate|||||||2015-07-28|2015-07-30|Estimate|January 2007||2007-01-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|January 2012|Actual|2012-01-31||Interventional|NICHE||Effectiveness of Selling Micronutrient Sprinkles in Rural Kenya|Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project|Completed||Phase 4|7200|Actual|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 23:58:35.121053|2018-05-31 23:58:35.121053
NCT01088945|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-07-24|2010-03-17|2010-03-18|Estimate|||||||2015-07-24|2015-07-27|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safe Passages: Ensuring Quality Transitions From NICU (Neonatal Intensive Care Unit) to Ambulatory Care|Safe Passages: Ensuring Quality Transitions From NICU to Ambulatory Care|Completed||Phase 3|229|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 23:58:35.208217|2018-05-31 23:58:35.208217
NCT01088932|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-07-17|2010-03-16|2010-03-18|Estimate|||||||2010-07-17|2010-07-20|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|AVN007||Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Multiple-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Azevan Pharmaceuticals||2|||f||||f||||||||||2018-05-31 23:58:35.271276|2018-05-31 23:58:35.271276
NCT01088919|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-04-15|2010-03-16|2010-03-18|Estimate|||||||2010-04-15|2010-04-16|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects|A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride After Separate and Concomitant Administration to Healthy Adult Subjects|Completed||Phase 1|64|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 23:58:35.339141|2018-05-31 23:58:35.339141
NCT01088906|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2015-07-03|2010-03-16|2010-03-17|Estimate|||||||2015-07-03|2015-07-07|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Phalcis||Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC|Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial|Terminated||Phase 2|57|Actual|Spanish Lung Cancer Group||1||No safety reasons. Low recruitment.|f||||t||||||||||2018-05-31 23:58:35.423906|2018-05-31 23:58:35.423906
NCT01088893|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2012-05-22|2010-03-16|2010-03-17|Estimate|||||||2012-05-22|2012-05-24|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy|A Randomized Study of mTOR Inhibition by RAD001 (Everolimus) in Invasive Breast Cancer Patients After Pre-operative Use of Anthracycline and/or Taxane-based Chemotherapy|Unknown status|Recruiting|Phase 2|50|Anticipated|Organisation for Oncology and Translational Research||2|||f||||||||||||||2018-05-31 23:58:35.493646|2018-05-31 23:58:35.493646
NCT01088880|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-04-27|2010-03-16|2010-03-17|Estimate|||||||2012-04-27|2012-05-01|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever|An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever|Completed||Phase 2|10|Anticipated|Novartis||1|||f||||||||||||||2018-05-31 23:58:35.557825|2018-05-31 23:58:35.557825
NCT01088867|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2013-06-17|2010-03-16|2010-03-17|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Using Diffuse Noxious Inhibitory Control (DNIC) to Predict Acupuncture Therapy Outcome: A Pilot Study|Using DNIC to Predict Acupuncture Therapy Outcome: A Pilot Study|Completed||N/A|10|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 23:58:35.615439|2018-05-31 23:58:35.615439
NCT01088854|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2015-06-19|2010-03-16|2010-03-17|Estimate|||||||2015-06-19|2015-06-23|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|||Acute Effect of Continuous Positive Airway Pressure in Heart Failure|Acute Effect of Continuous Positive Airway Pressure on Left Ventricular Diastolic Function and Exercise Tolerance in Compensated Heart Failure|Completed||Phase 2|2|Actual|UPECLIN HC FM Botucatu Unesp||1|||f||||f||||||||||2018-05-31 23:58:35.702362|2018-05-31 23:58:35.702362
NCT01088841|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2011-02-22|2010-03-16|2010-03-17|Estimate|||||||2011-02-22|2011-02-23|Estimate|April 2009||2009-04-30|February 2011|2011-02-28|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY|The Functional Significance of Gut-expressed Taste Receptors in the Secretion of Glucagon-like Peptide-1 and Peptide YY|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||4|||f||||f||||||||||2018-05-31 23:58:35.762116|2018-05-31 23:58:35.762116
NCT01088828|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2015-11-04|2010-03-16|2010-03-17|Estimate|||||||2015-11-04|2015-11-05|Estimate|May 2010||2010-05-31|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Exploring the Causes of Clubfoot Using Magnetic Resonance Imaging, MRI|The Pma Mouse and the Developmental Basis of Clubfoot: MRI Anatomical Modelling of Human ICTEV (Clubfoot)|Completed|||35|Actual|University of Aberdeen|||5||f||||t||||||||||2018-05-31 23:58:35.831998|2018-05-31 23:58:35.831998
NCT01088815|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2015-05-27|2010-03-16|2010-03-17|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas|A Phase II Study of Gemcitabine and Nab-Paclitaxel in Combination With GDC-0449 (Hedgehog Inhibitor) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 23:58:35.891264|2018-05-31 23:58:35.891264
NCT01088802|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2018-04-04|2010-03-16|2010-03-17|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2010||2010-01-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Interventional|||Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx|A Phase II Study on Treatment De-Intensification in Favorable Squamous Cell Carcinoma of the Oropharynx|Active, not recruiting||Phase 2|60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 23:58:36.077486|2018-05-31 23:58:36.077486
NCT01088477|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2014-05-20|2010-03-16|2010-03-17|Estimate|||||||2014-05-20|2014-05-21|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer|Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer|Completed|||21|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 23:58:41.964122|2018-05-31 23:58:41.964122
NCT01088789|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2018-04-17|2010-03-16|2010-03-17|Estimate|||||||2018-04-17|2018-04-19|Actual|April 2010||2010-04-30|April 2018|2018-04-30|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine|A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene|Recruiting||Phase 2|72|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||No|Data entry and analysis is still ongoing.|2018-05-31 23:58:36.160061|2018-05-31 23:58:36.160061
NCT01088776|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2016-10-19|2010-03-16|2010-03-17|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|February 2012|Actual|2012-02-29||Interventional|||Omega-3 Fatty Acid Supplementation in Children|Omega-3 Fatty Acid Supplementation to Treat Hypertriglyceridemia in Children With Chronic Kidney Disease|Completed||Phase 2|4|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 23:58:36.248468|2018-05-31 23:58:36.248468
NCT01088763|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2014-11-04|2010-03-16|2010-03-17|Estimate|||||||2014-11-04|2014-11-05|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia|A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA|Terminated||Phase 1|129|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 23:58:36.339547|2018-05-31 23:58:36.339547
NCT01088750|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2016-12-02|2010-03-16|2010-03-17|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma|First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents|Recruiting||Phase 4|200|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 23:58:36.450064|2018-05-31 23:58:36.450064
NCT01088737|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-10-26|2010-03-16|2010-03-17|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2011||2011-01-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna|An Open Monocentric Pilot Study to Investigate the Potential of Imiquimod 5% Cream to Detect Residual and to Prevent Recurrence of Lentigo Maligna After Surgical Excision|Active, not recruiting||Phase 2/Phase 3|60|Actual|Medical University of Graz|||||f||||f||||||||||2018-05-31 23:58:36.536733|2018-05-31 23:58:36.536733
NCT01088724|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|February 2002||2002-02-28|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|FCD-R||Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)|Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)|Completed||Phase 4|4|Actual|A.O. Ospedale Papa Giovanni XXIII||1|||f||||f||||||||||2018-05-31 23:58:36.620645|2018-05-31 23:58:36.620645
NCT01088711|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|2015-09-29||2017-06-01|2010-03-16|2010-03-17|Estimate|2015-11-20|2015-12-24|Estimate||||2017-06-01|2017-06-29|Actual|March 11, 2010|Actual|2010-03-11|June 2017|2017-06-30|May 11, 2010|Actual|2010-05-11|May 11, 2010|Actual|2010-05-11||Interventional|||Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes|Completed||Phase 1|32|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 23:58:36.738163|2018-05-31 23:58:36.738163
NCT01088698|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2014-06-23|2010-03-16|2010-03-17|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Golimumab Plus UVB-311nm in Psoriasis|Prospective Study of the Combination of Golimumab and UVB-311nm Phototherapy in Patients With Psoriatic Arthritis and Psoriatic Skin Lesions|Terminated||N/A|20|Anticipated|Medical University of Graz||||Difficulties in recruiting patients;|f||||f||||||||||2018-05-31 23:58:37.129654|2018-05-31 23:58:37.129654
NCT01088685|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2011-10-04|2010-03-16|2010-03-17|Estimate|||||||2011-10-04|2011-10-06|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Hydrogel Blister Patch Prototype Treatment for Foot Blisters on the Heel|Feasibility Study to Evaluate the Safety and Performance of a Hydrogel Blister Patch Prototype for the Treatment of Foot Blisters|Completed||N/A|93|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 23:58:37.183972|2018-05-31 23:58:37.183972
NCT01088672|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2015-02-12||2015-07-13|2010-03-16|2010-03-17|Estimate|2015-07-13|2015-07-17|Estimate||||2015-07-13|2015-07-17|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|TREVO||Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)|Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)|Completed||Phase 4|60|Actual|Stryker Neurovascular||1|||f||||f||||||||||2018-05-31 23:58:37.258967|2018-05-31 23:58:37.258967
NCT01088659|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2018-01-11|2010-03-16|2010-03-17|Estimate|||||||2018-01-11|2018-01-12|Actual|February 16, 2010|Actual|2010-02-16|January 2018|2018-01-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|||A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.|A Multicenter Randomised Study Comparing the Antiviral Efficacy of Pegylated Interferon-alfa-2a Plus Placebo vs. Pegylated Interferon-alfa-2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis|Completed||Phase 3|50|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:58:38.469932|2018-05-31 23:58:38.469932
NCT01088646|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2012-03-27||2012-05-06|2010-03-16|2010-03-17|Estimate|2012-04-03|2012-05-02|Estimate||||2012-05-06|2012-05-08|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|RD-300||Evaluation of PillCam® Express Capsule Endoscopy Delivery System|Evaluation of PillCam® Express Capsule Endoscopy Delivery System|Completed||N/A|25|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-05-31 23:58:38.565742|2018-05-31 23:58:38.565742
NCT01088633|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-02-08|2010-03-16|2010-03-17|Estimate|||||||2011-02-08|2011-02-09|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease|Completed||N/A|70|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f||||f||||||||||2018-05-31 23:58:38.724036|2018-05-31 23:58:38.724036
NCT01088620|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2013-03-13|2010-03-16|2010-03-17|Estimate|||||||2013-03-13|2013-03-14|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|January 2014|Anticipated|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer|CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With Particular Regard to the KRAS Status|Suspended||Phase 2|134|Anticipated|WiSP Wissenschaftlicher Service Pharma GmbH||2||"the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has~   not yet been verified"|f||||t||||||||||2018-05-31 23:58:38.786478|2018-05-31 23:58:38.786478
NCT01088607|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2017-10-24|2010-03-16|2010-03-17|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2010|Actual|2010-10-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis|Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinstitution Trial|Completed||Phase 1|27|Actual|University of Tennessee||1|||f||||t||||||||||2018-05-31 23:58:38.969169|2018-05-31 23:58:38.969169
NCT01088594|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers|A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers|Completed||Phase 1|12|Actual|Solvay Pharmaceuticals||3|||f||||||||||||||2018-05-31 23:58:39.088367|2018-05-31 23:58:39.088367
NCT01088581|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-01-31|2010-03-16|2010-03-17|Estimate|||||||2012-01-31|2012-02-02|Estimate|January 2006||2006-01-31|January 2012|2012-01-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Adjuvant Hepatic Arterial Infusional Chemotherapy After Curative Resection of Hepatocellular Carcinoma|Adjuvant Hepatic Arterial Infusional Chemotherapy With 5-fluorouracil and Cisplatin After Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Study|Completed||Phase 3|101|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 23:58:39.192803|2018-05-31 23:58:39.192803
NCT01088568|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|March 2010|Anticipated|2010-03-31|December 2008|Actual|2008-12-31||Interventional|||Randomized, Prospective Comparison of the Outcome of Toric Implantable Contact Lens (TICL) and Q-LASIK for the Correction of Myopia With Astigmatism|Randomized, Prospective Comparison of the Outcome of TICL and Q Value Customized LASIK for the Correction of Myopia With Astigmatism|Unknown status|Active, not recruiting|N/A|30|Actual|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 23:58:39.269524|2018-05-31 23:58:39.269524
NCT01088555|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2013-12-23|2010-03-16|2010-03-17|Estimate|||||||2013-12-23|2013-12-24|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers|Pilot Study : Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers|Completed||N/A|10|Actual|VA New York Harbor Healthcare System||2|||f||||f||||||||||2018-05-31 23:58:39.368059|2018-05-31 23:58:39.368059
NCT01088542|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2017-05-16|2010-03-15|2010-03-17|Estimate|||||||2017-05-16|2017-05-18|Actual|October 2003||2003-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CYDS III||The Community Youth Development Study: A Test of Communities That Care|Long-term Effects of Communities That Care on Young Adults From Small Towns|Completed||N/A|52323|Actual|University of Washington||2|||f||||t||||||||Yes|We support the goal of making datasets available to researchers in a timely manner to expedite translation of research results into knowledge, products, and procedures to improve human health. With these goals in mind, we have entered into data-sharing collaborations many times with outside researchers. To ensure that the use of these data stay within the legal and ethical constraints of the consent agreement under which they were collected, we have developed a Fair Use Agreement, available upon request, that is signed by the Principal Investigator, Dr. Oesterle, and by the collaborating researcher when agreement has been reached to share study data. As part of the Fair Use Agreement, we ask researchers to abide by the same Data and Safety Monitoring Plan (DSMP) that we adhere to. We will continue to share data with other researchers who meet the terms of our Fair Use Agreement (and DSMP) and share our strong commitment to protection of the rights and privacy of study participants.|2018-05-31 23:58:39.456513|2018-05-31 23:58:39.456513
NCT01088529|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2014-03-04||2014-05-01|2010-03-16|2010-03-17|Estimate|2014-03-04|2014-04-09|Estimate||||2014-05-01|2014-05-15|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer|A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone|Completed||Phase 2|66|Actual|Cougar Biotechnology, Inc.||2|||f||||t||||||||||2018-05-31 23:58:39.577852|2018-05-31 23:58:39.577852
NCT01088516|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-06-22|2010-03-16|2010-03-17|Estimate|||||||2015-06-22|2015-06-24|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa|Use of an Aluvia Based Highly Active Antiretroviral Therapy (HAART) Regimen in the Prevention of Mother to Child HIV Transmission (PMTCT) Antepartum, Intrapartum and Postpartum in Africa|Completed||Phase 4|280|Actual|University of Zambia||1|||f||||t||||||||||2018-05-31 23:58:39.968775|2018-05-31 23:58:39.968775
NCT01088503|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2015-01-29||2015-12-22|2010-03-15|2010-03-17|Estimate|2015-12-22|2016-01-29|Estimate||||2015-12-22|2016-01-29|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|TRANSLATE-ACS|All enrolled participants.|Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome|The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome|Completed|||12227|Actual|Eli Lilly and Company|||1||f||||t||||||||||2018-05-31 23:58:40.266781|2018-05-31 23:58:40.266781
NCT01088490|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2014-12-03|2010-03-16|2010-03-17|Estimate|||||||2014-12-03|2014-12-05|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2012|Actual|2012-01-31||Observational|H2S-1||Hydrogen Sulfide as Prognostic Factor|Hydrogen Sulfide as Prognostic Factor|Completed|||50|Actual|University Medical Centre Ljubljana|||1||f||||t||||||||||2018-05-31 23:58:41.876725|2018-05-31 23:58:41.876725
NCT01088464|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|2015-12-21||2016-12-09|2010-03-16|2010-03-17|Estimate|2016-12-09|2017-02-03|Estimate||||2016-12-09|2017-02-03|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||All enrolled participants who received any quantity of study drug.|Study of IMC-11F8 in Participants With Advanced Solid Tumors|A Phase 1 Study of IMC-11F8 in Patients With Advanced Solid Tumors|Completed||Phase 1|15|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 23:58:42.055935|2018-05-31 23:58:42.055935
NCT01088451|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|December 2009||2009-12-31|February 2010|2010-02-28|September 2010|Anticipated|2010-09-30|March 2010|Anticipated|2010-03-31||Interventional|CPIT||Joint Application of Human Insulin and Rapid Insulin Analogue in Control of Postprandial Glycemia|Joint Application of Human Insulin and Rapid Insulin Analogue in Control of Postprandial Glycemia|Unknown status|Active, not recruiting|N/A|20|Anticipated|University Hospital Hradec Kralove|||||f||||f||||||||||2018-05-31 23:58:43.078195|2018-05-31 23:58:43.078195
NCT01088438|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|2011-03-14||2011-04-11|2010-03-16|2010-03-17|Estimate|2011-04-11|2011-05-06|Estimate||||2011-04-11|2011-05-06|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Measuring Quality of Medical Student Performance at Contextualizing Care|Measuring Quality of Medical Student Performance at Contextualizing Care|Completed||N/A|189|Actual|University of Illinois at Chicago|Small number of cases and variants. Alternating assignment of site to intervention/control. Substantial drop-out (sensitivity analysis finds results robust to conservative imputation for drop-outs).|2|||f||||f||||||||||2018-05-31 23:58:43.175076|2018-05-31 23:58:43.175076
NCT01088425|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-03-12|2010-03-16|2010-03-17|Estimate|||||||2017-03-12|2017-03-14|Actual|March 2010||2010-03-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Vitrification Versus Spontaneous Conception and Slow- Rate Freezing|Maternal Pregnancy and Neonatal Outcome After Assisted Reproduction. Comparison of Vitrification vs. Spontaneous Conception|Completed|||850|Anticipated|University of Luebeck|||3||f||||t||||||||||2018-05-31 23:58:43.481757|2018-05-31 23:58:43.481757
NCT01088412|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-10-23|2010-03-16|2010-03-17|Estimate|||||||2015-10-23|2015-10-26|Estimate|April 1999||1999-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|GeNeSIS||Observational Study of Somatropin Treatment in Children|The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)|Completed|||22929|Actual|Eli Lilly and Company|||2||f||||f||||||Samples With DNA|"~     If patient consented a DNA sample is kept until the end of the study~   "|||2018-05-31 23:58:43.587526|2018-05-31 23:58:43.587526
NCT01088399|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2014-01-13||2014-03-25|2010-03-16|2010-03-17|Estimate|2014-03-25|2014-04-21|Estimate||||2014-03-25|2014-04-21|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|HypoCCS||A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults|The Global Hypopituitary Control and Complications Study|Completed|||10673|Actual|Eli Lilly and Company|||2||f||||f||||||Samples With DNA|"~     DNA Addendum - implemented in Germany only. Germany: DNA sample is kept, if participant~     consented to German DNA Addendum~   "|||2018-05-31 23:58:43.846938|2018-05-31 23:58:43.846938
NCT01088386|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2017-12-06|2010-03-16|2010-03-17|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2010||2010-03-31|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Zyprexa® Relprevv™ Patient Care Program|Zyprexa® Relprevv™ Patient Care Program|Enrolling by invitation|||4000|Anticipated|Eli Lilly and Company|||1||f||||f||||||||||2018-05-31 23:58:49.111097|2018-05-31 23:58:49.111097
NCT01088373|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-12-14|2010-03-16|2010-03-17|Estimate|||||||2017-12-14|2017-12-15|Actual|March 25, 2010|Actual|2010-03-25|December 2017|2017-12-31|July 25, 2016|Actual|2016-07-25|July 25, 2016|Actual|2016-07-25||Interventional|GFM-AZA-REV-09||Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q|A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q|Completed||Phase 2|50|Actual|Groupe Francophone des Myelodysplasies||1|||f||||t||||||||||2018-05-31 23:58:49.18595|2018-05-31 23:58:49.18595
NCT01088360|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2018-01-10|2010-03-16|2010-03-17|Estimate|||||||2018-01-10|2018-01-12|Actual|March 31, 2005|Actual|2005-03-31|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)|An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies|Active, not recruiting|||20000|Anticipated|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 23:58:49.299052|2018-05-31 23:58:49.299052
NCT01088347|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-04-21|2010-03-16|2010-03-17|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer|A Phase 1b/2 Study With the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination With Cisplatin and Radiotherapy as a First Line Therapy in Patients With Advanced Cervical Cancer.|Completed||Phase 1/Phase 2|9|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 23:58:49.361367|2018-05-31 23:58:49.361367
NCT01088334|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-03-26|2010-03-16|2010-03-17|Estimate|||||||2010-03-26|2010-03-29|Estimate|December 2002||2002-12-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Observational|Trousseau||Mortality Due to Malignancy in Patients With Idiopathic Venous Thromboembolism|Trousseau Studie, Mortaliteit Door Maligniteit Bij patiënten Met Idiopatische Veneuze Tromboembolie|Terminated|||630|Actual|Slotervaart Hospital|||2|Terminated because of futility to continue, after planned interim analysis.|f||||t||||||||||2018-05-31 23:58:49.445501|2018-05-31 23:58:49.445501
NCT01088321|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2016-12-07|2010-03-16|2010-03-17|Estimate|||||||2016-12-07|2016-12-08|Estimate|March 2005||2005-03-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)|Safety of Disease Modifying Antirheumatic Drug (DMARD) and Biologic Treatment of Rheumatoid Arthritis|Completed|||81332|Actual|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 23:58:49.549821|2018-05-31 23:58:49.549821
NCT01088308|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-07-08|2010-03-16|2010-03-17|Estimate|||||||2016-07-08|2016-07-11|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion|Hemodynamic Differentiation of Tachycardia Episodes Using Tissue Perfusion|Terminated||N/A|18|Actual|Medtronic BRC||1||No enrollements for more than 6 months in Phase II|f||||f||||||||Undecided||2018-05-31 23:58:49.603223|2018-05-31 23:58:49.603223
NCT01088282|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Visual and Economic Profits of ReSTOR® Multifocal Intraocular Lenses (IOL) on Public Health Patients in Spain|Visual Function, Non-dependence on Glasses and Global Economic Cost in Patients Undergoing Lens Surgery With ReSTOR® Multifocal Aspheric Iol Implants|Unknown status|Not yet recruiting|N/A|120|Anticipated|University of Barcelona||2|||f||||f||||||||||2018-05-31 23:58:49.913558|2018-05-31 23:58:49.913558
NCT01088269|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2017-09-13|2010-03-16|2010-03-17|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2010||2010-03-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Blood Pressure Assessment in Atrial Fibrillation|Evaluation of the Oscillometric Blood Pressure Measurement in Atrial Fibrillation and Relation of Blood Pressure With Serum Biomarkers and Echocardiographic Indexes|Recruiting|||100|Anticipated|University of Athens|||2||f||||f||||||||||2018-05-31 23:58:49.998872|2018-05-31 23:58:49.998872
NCT01088256|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-08-23|2010-03-16|2010-03-17|Estimate|||||||2012-08-23|2012-08-24|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy of Etoricoxib on Peripheral Hyperalgesia|Efficacy of Etoricoxib in Patients With Neuropathic Pain With and Without Peripheral Hyperalgesia - A Prove of Concept Trial|Terminated||Phase 2|9|Actual|Ruhr University of Bochum||4|||f||||f||||||||||2018-05-31 23:58:50.069047|2018-05-31 23:58:50.069047
NCT01088243|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2017-09-14||2017-12-12|2010-03-16|2010-03-17|Estimate|2017-11-09|2017-12-12|Actual||||2017-12-12|2018-01-10|Actual|March 2010||2010-03-31|December 2017|2017-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Targeting Oxidative Stress in Chronic Beryllium Disease|Targeting Oxidative Stress in Chronic Beryllium Disease|Completed||Phase 1/Phase 2|18|Actual|National Jewish Health||2|||f||||t||||||||||2018-05-31 23:58:50.192074|2018-05-31 23:58:50.192074
NCT01088230|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2011-04-22|2010-03-16|2010-03-17|Estimate|||||||2011-04-22|2011-04-26|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke|The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke: A Double Blind, Placebo-Controlled Pilot Study|Completed||Phase 1/Phase 2|12|Actual|New York Presbyterian Hospital||2|||f||||f||||||||||2018-05-31 23:58:50.485435|2018-05-31 23:58:50.485435
NCT01088217|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2018-03-27|2010-03-16|2010-03-17|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2008||2008-07-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|GWAS||Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)|Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)|Recruiting|||8000|Anticipated|National Jewish Health|||||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, lung tissue, DNA, RNA~   "|||2018-05-31 23:58:50.59274|2018-05-31 23:58:50.59274
NCT01088204|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2015-10-05|2010-03-16|2010-03-17|Estimate|||||||2015-10-05|2015-10-07|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2011|Actual|2011-12-31||Interventional|COACT_1001||Feasibility Study of Laparoscopy-assisted D2 Distal Gastrectomy to Treat Advanced Gastric Cancer|A Multicenter Randomized Phase II Clinical Trial of Laparoscopy Assisted Versus Open Distal Gastrectomy With D2 Lymph Node Dissection for Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|204|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 23:58:50.690831|2018-05-31 23:58:50.690831
NCT01088191|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-12-15|2010-03-16|2010-03-17|Estimate|||||||2016-12-15|2016-12-19|Estimate|March 2009||2009-03-31|December 2016|2016-12-31|October 2014|Actual|2014-10-31|November 2013|Actual|2013-11-30||Interventional|||Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction|Phase 2 Study to Assess Safety & Tolerability of a Single Injection Into the Knee Joint of Two Different Doses of MSB-CAR001 Combined With Hyaluronan Compared to Hyaluronan Alone in Patients Who Have Undergone an ACL Reconstruction|Completed||Phase 1/Phase 2|17|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-05-31 23:58:50.777233|2018-05-31 23:58:50.777233
NCT01088178|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-09-29|2010-03-16|2010-03-17|Estimate|||||||2010-09-29|2010-09-30|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|July 2010|Anticipated|2010-07-31|May 2010|Anticipated|2010-05-31||Interventional|||Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period|Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period: A Prospective, Randomized Pilot Study of Three Time Intervals|Unknown status|Recruiting|N/A|45|Anticipated|United States Naval Medical Center, Portsmouth||3|||f||||t||||||||||2018-05-31 23:58:51.124874|2018-05-31 23:58:51.124874
NCT01088165|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-01-18|2010-03-16|2010-03-17|Estimate|||||||2012-01-18|2012-01-20|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|May 2014|Anticipated|2014-05-31|May 2013|Anticipated|2013-05-31||Interventional|CASTIP||The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis|The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris|Unknown status|Recruiting|Phase 4|66|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 23:58:51.206527|2018-05-31 23:58:51.206527
NCT01088152|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|August 2008||2008-08-31|January 2001|2001-01-31|March 2010|Anticipated|2010-03-31|January 2009|Actual|2009-01-31||Interventional|CDST||Celiac Disease School for Women Living on a Gluten-free Diet|Structured Education of Swedish Celiac Women Living on a Gluten-free Diet for Years|Unknown status|Recruiting|N/A|106|Anticipated|Medical Research Council of Southeast Sweden||2|||f||||t||||||||||2018-05-31 23:58:51.291475|2018-05-31 23:58:51.291475
NCT01088139|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2011-05-03|2010-03-16|2010-03-17|Estimate|||||||2011-05-03|2011-05-04|Estimate|November 2008||2008-11-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|March 2010|Actual|2010-03-31||Interventional|||Nutritional Intervention for Geriatric Hip Fracture Patients|A Randomized Controlled Study of Nutritional Intervention for Geriatric Hip Fracture Patients and Its Effect on Rehabilitation Outcomes|Completed||N/A|126|Actual|Kowloon Hospital, Hong Kong||2|||f||||f||||||||||2018-05-31 23:58:51.384488|2018-05-31 23:58:51.384488
NCT01088126|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2018-03-19|2010-03-16|2010-03-17|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2010||2010-01-31|January 2010|2010-01-31|March 2, 2017|Actual|2017-03-02|June 2011|Actual|2011-06-30||Interventional|||Linear Ablation Versus Focal Ablation of Complex Fractionated Atrial Electrograms in Persistent Atrial Fibrillation|Comparison of Linear Ablation Versus Focal Ablation of Complex Fractionated Atrial Electrograms After Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation: A Prospective & Randomized Controlled Study|Withdrawn||N/A|0|Actual|Korea University Anam Hospital||2||It was difficult to enrol patients.|f||||||||||||||2018-05-31 23:58:51.473457|2018-05-31 23:58:51.473457
NCT01088113|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate||||August 2008|2008-08-31||||||||Observational|||The Relationship Between Cranial Near-InfraRed Oxygenation(NIRO) and Heart Rate Variability During Mental Exercise|The Relationship Between Cranial Near-InfraRed Oxygenation(NIRO) and Heart Rate Variability During Mental Exercise|Completed|||||The Hong Kong Polytechnic University|||2||f||||||||||||||2018-05-31 23:58:51.543052|2018-05-31 23:58:51.543052
NCT01088100|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-01-07|2010-03-16|2010-03-17|Estimate|||||||2011-01-07|2011-01-10|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Study of the Correlation Between Specific Genes and Cognitive Dysfunction After Surgery|The Correlation Between Certain Clock-gene Genotypes and POCD (Post-operative Cognitive Dysfunction)|Completed|||279|Actual|Herlev Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood on filter paper~   "|||2018-05-31 23:58:51.604502|2018-05-31 23:58:51.604502
NCT01088087|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|March 2010||2010-03-31|November 2009|2009-11-30|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Effect of Colostrum on Gut Permeability and Endotoxin Level in Chronic Alcoholic Disease|Effect of Colostrum Administration on Improving Gut Permeability and Serum Endotoxin Level in Chronic Alcohol Drinkers With Hepatic Dysfunction|Unknown status|Recruiting|Phase 2/Phase 3|34|Anticipated|Gangnam Severance Hospital||2|||f||||t||||||||||2018-05-31 23:58:51.741775|2018-05-31 23:58:51.741775
NCT01088074|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-08-21|2010-03-16|2010-03-17|Estimate|||||||2012-08-21|2012-08-22|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||A Comparative Study of Incision Closure Methods for Total Knee Replacement|A Comparative Study of Incision Closure Methods for Total Knee Arthroplasty|Completed||N/A|75|Actual|Foundation for Southwest Orthopedic Research||4|||f||||t||||||||||2018-05-31 23:58:51.831922|2018-05-31 23:58:51.831922
NCT01088061|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2011-10-27|2010-03-16|2010-03-17|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Adipose Expression of Leptin, Adiponectin and IL-6 and Plasma Levels of Adipocytokines in Women With and Without Polycystic Ovary Syndrome (PCOS)|Adipocytokines in Lean and Obese Women With and Without PCOS|Completed|||65|Actual|Copenhagen University Hospital, Hvidovre|||4||f||||t||||||Samples With DNA|"~     Fat biopsies, plasma~   "|||2018-05-31 23:58:51.963626|2018-05-31 23:58:51.963626
NCT01088048|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2015-05-11|2010-03-15|2010-03-17|Estimate|||||||2015-05-11|2015-05-13|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia|A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia|Completed||Phase 1|241|Actual|Gilead Sciences||10|||f||||f||||||||||2018-05-31 23:58:52.033255|2018-05-31 23:58:52.033255
NCT01088035|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2015-02-27|2010-03-16|2010-03-17|Estimate|||||||2015-02-27|2015-03-02|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|April 2015|Anticipated|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma|A Phase II Multi-Institutional Trial of Focal Radiotherapy With Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children With Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively|Terminated||Phase 2|75|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||1||Poor accrual|f||||f||||||||||2018-05-31 23:58:52.170094|2018-05-31 23:58:52.170094
NCT01088022|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2010-03-16|2010-03-16|2010-03-17|Estimate|||||||2010-03-16|2010-03-17|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|PG-APRE1||Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting|Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting: a Phase III, Double-blind, Randomized, Placebo-controlled Trial in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Azienda Ospedaliera di Perugia||2|||f||||t||||||||||2018-05-31 23:58:52.240563|2018-05-31 23:58:52.240563
NCT01088009|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2013-10-28|2010-03-15|2010-03-16|Estimate|||||||2013-10-28|2013-10-30|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|EXPLORE||Efficacy Optimizing Research of Lamivudine Therapy|A Prospective, Randomised, Open-label, Multi-centre Study to Compare Three Chronic Hepatitis B (CHB) Treatment Strategies Over a 2year Period in Chinese HBeAg Positive CHB Patients|Completed||Phase 4|366|Actual|Nanfang Hospital of Southern Medical University||3|||f||||t||||||||||2018-05-31 23:58:52.342557|2018-05-31 23:58:52.342557
NCT01087996|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2013-08-30||2015-05-21|2010-03-15|2010-03-16|Estimate|2015-05-21|2015-05-27|Estimate||||2015-05-21|2015-05-27|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional|||The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)|A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction|Completed||Phase 1/Phase 2|31|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 23:58:52.474782|2018-05-31 23:58:52.474782
NCT01087983|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2015-11-09|2010-03-15|2010-03-16|Estimate|||||||2015-11-09|2015-11-11|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Lapatinib With Sirolimus or Metformin|A Phase 1 Trial of Lapatinib in Combination With 1) Sirolimus or 2) Metformin in Advanced Cancer|Completed||Phase 1|111|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 23:58:53.044645|2018-05-31 23:58:53.044645
NCT01087970|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2014-04-18||2014-04-18|2010-03-15|2010-03-16|Estimate|2014-04-18|2014-05-19|Estimate||||2014-04-18|2014-05-19|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All enrolled participants who received at least 1 dose of study drug.|A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer|Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|69|Actual|Eli Lilly and Company|Efficacy populations excluded data from a noncompliant site (11 participants).|1|||f||||f||||||||||2018-05-31 23:58:53.153085|2018-05-31 23:58:53.153085
NCT01087957|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2014-02-25||2014-04-14|2010-03-15|2010-03-16|Estimate|2014-04-14|2014-05-13|Estimate||||2014-04-14|2014-05-13|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|February 2012|Actual|2012-02-29||Interventional|||WalkAide Compared to Ankle-Foot Orthosis (AFO) in Stroke Patients|Randomized Trial of the Innovative Neurotronics WalkAide Compared to Conventional Ankle-Foot Orthosis (AFO) in Stroke Patients (INSTRIDE)|Completed||N/A|495|Actual|Innovative Neurotronics||2|||f||||t||||||||||2018-05-31 23:58:54.079111|2018-05-31 23:58:54.079111
NCT01087944|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2015-11-17||2016-01-11|2010-03-15|2010-03-16|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||The intent-to-treat (ITT) population included all participants who received at least one injection.|A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C|Tolerability and User Handling Study of an Autoinjector to Administer 180 µg/0.5 mL Peginterferon Alfa-2a (Pegasys, PEG-IFN)|Completed||Phase 1|60|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 23:58:54.936312|2018-05-31 23:58:54.936312
NCT01087931|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2011-01-11|2010-03-15|2010-03-16|Estimate|||||||2011-01-11|2011-01-12|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|||Pain Relief at Iliac Crest Bone Harvest Sites in Spine Surgery Using Bupivacaine|Local Anesthetic Use at Iliac Crest Bone Graft Site in Spinal Reconstructive Surgery|Unknown status|Recruiting|N/A|100|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-05-31 23:58:55.640498|2018-05-31 23:58:55.640498
NCT01087918|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2012-05-10||2012-10-22|2010-03-15|2010-03-16|Estimate|2012-09-18|2012-10-19|Estimate||||2012-10-22|2012-10-29|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Lokomat Versus Strength Training in Chronic Incomplete Spinal Cord Injury|Effects of Automated Treadmill Training and Lower Extremity Strength Training on Walking-related and Other Outcomes in Subjects With Chronic Incomplete Spinal Cord Injury|Completed||Phase 1/Phase 2|9|Actual|University of Zurich|Issues to find participants led to small numbers of subjects analyzed. Ambulatory activity besides our interventions was not controlled for.|2|||f||||f||||||||||2018-05-31 23:58:55.769108|2018-05-31 23:58:55.769108
NCT01087905|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2013-01-30||2016-10-26|2010-03-15|2010-03-16|Estimate|2013-04-22|2013-04-24|Estimate||||2016-10-26|2016-12-08|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|November 2011|Actual|2011-11-30|February 2011|Actual|2011-02-28||Interventional||Baseline sample=987 adult smokers (at least 18 years of age) who called the Wisconsin Tobacco Quit Line (WTQL) from April 1, 2010 to June 15, 2010.|Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines|Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines|Completed||Phase 4|987|Actual|University of Wisconsin, Madison||8|||f||||f||||||||Yes|Upon request, clinical trial data will be shared with other investigators in the form of de-identified datasets. Requests can be sent to Stevens S. Smith, Ph.D., at sss@ctri.wisc.edu|2018-05-31 23:58:56.496698|2018-05-31 23:58:56.496698
NCT01087892|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2014-07-21|2010-03-15|2010-03-16|Estimate|||||||2014-07-21|2014-07-22|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|NU278||Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection|Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection|Completed||N/A|1126|Actual|University of Sussex||2|||f||||t||||||||||2018-05-31 23:58:57.400579|2018-05-31 23:58:57.400579
NCT01087879|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2011-09-06|2010-03-15|2010-03-16|Estimate|||||||2011-09-06|2011-09-07|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effect of Hormonal Contraceptives on Androgens and Glucose Metabolism|The Impact of Different Administration Routes of Hormonal Contraceptives on Androgen Synthesis, Glucose Metabolism and Inflammation. A Prospective Randomized Trial.|Completed||N/A|45|Anticipated|University of Oulu||3|||f||||f||||||||||2018-05-31 23:58:57.93717|2018-05-31 23:58:57.93717
NCT01087866|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate|June 2005||2005-06-30|March 2010|2010-03-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus|Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus: a Randomized Controlled Study|Completed||Phase 2/Phase 3|97|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 23:58:58.053349|2018-05-31 23:58:58.053349
NCT01087853|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2011-05-31|2010-03-15|2010-03-16|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Effect of Crystalloids and Colloids on Visceral Blood Flow|The Effects of Balanced and Unbalanced Crystalloids and Colloids on Serum Biochemistry and Visceral Blood Flow: A Two Phase, Double Blind, Randomised Crossover Study|Completed||Phase 1/Phase 2|25|Actual|University of Nottingham||4|||f||||f||||||||||2018-05-31 23:58:58.146447|2018-05-31 23:58:58.146447
NCT01087840|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2014-04-15|2010-03-15|2010-03-16|Estimate|||||||2014-04-15|2014-04-17|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|RAL-NPEP||Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men|Safety, Tolerability, and Adherence to a Raltegravir-based Antiretroviral Regimen for HIV Non-occupational Postexposure Prophylaxis|Completed||Phase 4|120|Actual|St Vincent's Hospital, Sydney||1|||f||||f||||||||||2018-05-31 23:58:58.231025|2018-05-31 23:58:58.231025
NCT01087827|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-11-06|2010-03-15|2010-03-16|Estimate|||||||2012-11-06|2012-11-07|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Observational|||Body Structures Determining Differences in Forearm and Upper Arm Blood Pressures|Anatomical Determinants of Forearm and Upper Arm Oscillometric Blood Pressure Differences|Completed|||51|Actual|Christiana Care Health Services|||||f||||f||||||||||2018-05-31 23:58:58.340178|2018-05-31 23:58:58.340178
NCT01087814|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2011-11-07||2017-01-26|2010-03-15|2010-03-16|Estimate|2014-09-05|2014-09-12|Estimate||||2017-01-26|2017-03-09|Actual|February 2010||2010-02-28|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||Sustiva Levels With Use of a Gel Capsule|Effect of Encapsulation Upon Efavirenz Pharmacokinetics|Completed||Phase 4|16|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 23:58:58.41067|2018-05-31 23:58:58.41067
NCT01087801|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2011-06-07||2011-12-02|2010-03-15|2010-03-16|Estimate|2011-10-26|2011-12-02|Estimate||||2011-12-02|2011-12-06|Estimate|October 2007||2007-10-31|December 2011|2011-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|CRC2006-05||A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers|A Placebo Controlled, Double-Blind, Parallel, Multicenter Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers|Completed||Phase 3|64|Actual|ChiRhoClin, Inc.||2|||f||||f||||||||||2018-05-31 23:58:58.701415|2018-05-31 23:58:58.701415
NCT01087619|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2017-11-21|2010-03-15|2010-03-16|Estimate|||||||2017-11-21|2017-11-22|Actual|August 2010|Actual|2010-08-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up|Primary Hyperparathyroidism in Patients Older Than 65 Years: A Prospective Randomized Trial of Surgical Treatment Compared With Follow-up|Recruiting||N/A|100|Anticipated|Region Skane||2|||f||||f||||||||||2018-05-31 23:59:05.427587|2018-05-31 23:59:05.427587
NCT01087788|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2013-10-25|2012-08-09|2018-04-23|2010-03-15|2010-03-16|Estimate|2014-01-07|2014-02-25|Estimate|2012-08-09|2012-08-17|Estimate|2018-04-23|2018-05-22|Actual|March 2010||2010-03-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|November 2011|Actual|2011-11-30||Interventional||409 subjects are included in Randomized Set (RS) shown in Baseline Characteristics, which is an Intention-to-Treat (ITT) dataset.|Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis|Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)|Completed||Phase 3|409|Actual|UCB Pharma||7|||f||||f||||||||||2018-05-31 23:58:58.974554|2018-05-31 23:58:58.974554
NCT01087775|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2014-08-25|2010-03-15|2010-03-16|Estimate|||||||2014-08-25|2014-08-27|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Enhancing Cognitive Function and Reintegration in Iraq and Afghanistan Veterans With Post Traumatic Stress Disorder (PTSD) Using Computer-Based Cognitive Training|Enhancing Cognitive Function and Reintegration in Iraq and Afghanistan Veterans With PTSD Using Computer-Based Cognitive Training|Unknown status|Active, not recruiting|N/A|50|Anticipated|San Francisco Veterans Affairs Medical Center||1|||f||||t||||||||||2018-05-31 23:59:00.006437|2018-05-31 23:59:00.006437
NCT01087762|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2013-11-06|2012-08-09|2016-11-17|2010-03-15|2010-03-16|Estimate|2013-11-06|2013-12-25|Estimate|2012-08-09|2012-08-17|Estimate|2016-11-17|2017-01-13|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|October 2011|Actual|2011-10-31||Interventional||Baseline Characteristics refer to the Randomized Set (RS), which is an Intention-to-Treat (ITT) dataset.|Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis|Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis|Completed||Phase 3|325|Actual|UCB Pharma||7|||f||||f||||||||||2018-05-31 23:59:00.127376|2018-05-31 23:59:00.127376
NCT01087749|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2013-05-28|2010-03-15|2010-03-16|Estimate|||||||2013-05-28|2013-05-30|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CKD||Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers|Pharmacokinetic Study of Propranolol, Losartan, and Eprosartan in Healthy Volunteers and Patients With Chronic Kidney Disease|Completed||Phase 1|24|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:59:02.745597|2018-05-31 23:59:02.745597
NCT01087736|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2014-01-28||2014-05-01|2010-03-15|2010-03-16|Estimate|2014-05-01|2014-06-03|Estimate||||2014-05-01|2014-06-03|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional|TAP||Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy|Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy|Completed||Phase 4|30|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 23:59:03.009393|2018-05-31 23:59:03.009393
NCT01087723|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|2016-01-13||2016-01-13|2010-03-15|2010-03-16|Estimate|2016-01-13|2016-02-12|Estimate||||2016-01-13|2016-02-12|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional|EUROMAX|Participants who were randomized and signed an ICF; ITT population|European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial|Multi-centre, Multi-national, Prospective, Randomised, Open-label, Comparison of Bivalirudin to Other Guideline Based Current Therapies (Excluding Bivalirudin)|Completed||Phase 3|2198|Actual|The Medicines Company||2|||f||||t||||||||||2018-05-31 23:59:03.795583|2018-05-31 23:59:03.795583
NCT01087710|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||Effect of Medical Food on Reducing Asthma Symptoms in Asthmatic Children|Effect of Novel Medical Food on Reducing the Frequency and Severity of Asthma Symptoms and Airway Hyper-responsiveness in Children With Mild to Moderate Persistent Asthma|Completed||Phase 2|43|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 23:59:04.86201|2018-05-31 23:59:04.86201
NCT01087697|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2014-12-09|2010-03-15|2010-03-16|Estimate|||||||2014-12-09|2014-12-10|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit|A Phase 1 Open Label Exploratory Study of an Autologous Neo-Urinary Conduit in Subjects Requiring Incontinent Urinary Diversion Following Radical Cystectomy|Completed||Phase 1|8|Actual|Tengion||1|||f||||t||||||||||2018-05-31 23:59:04.946756|2018-05-31 23:59:04.946756
NCT01087684|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2013-10-08|2010-03-15|2010-03-16|Estimate|||||||2013-10-08|2013-10-10|Estimate|December 2004||2004-12-31|October 2013|2013-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Response to SLT vs. ALT in Patients Under 60 Years of Age|A Prospective, Randomized, Clinically Based Study on the Response to Selective Laser Trabeculoplasty Versus Argon Laser Trabeculoplasty in Patients Who Are Under 60 Years of Age|Completed||N/A|42|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 23:59:05.026717|2018-05-31 23:59:05.026717
NCT01087671|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2013-05-30|2010-03-15|2010-03-16|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops|Ocular Signs and Symptoms in Patients With Ocular Hypertension or Open-angle Glaucoma Switched From Preserved Latanoprost 0.005% Eye Drops to Preservative Free Tafluprost Eye Drops|Completed||Phase 3|185|Actual|Santen Oy||1|||f||||f||||||||||2018-05-31 23:59:05.105237|2018-05-31 23:59:05.105237
NCT01087658|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2013-06-20|2010-03-15|2010-03-16|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|GLUTOX||Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity|A Multicentre, Randomized, Open-label, Phase III Study Comparing the Efficacy of Oral Glutamine and Calcium-magnesium With Calcium-magnesium Alone in the Prevention of Oxaliplatin-induced Neurotoxicity in Patients With Colorectal Cancer Treated With Oxaliplatin in Adjuvant or 1st Line Metastatic Settings.|Completed||Phase 3|200|Actual|Sanofi||2|||f||||||||||||||2018-05-31 23:59:05.174516|2018-05-31 23:59:05.174516
NCT01087645|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2017-02-24|2010-03-15|2010-03-16|Estimate|||||||2017-02-24|2017-02-28|Actual|March 12, 2010|Actual|2010-03-12|February 2017|2017-02-28|September 16, 2010|Actual|2010-09-16|September 16, 2010|Actual|2010-09-16||Interventional|||A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects|Investigation of Safety, Tolerability and Bioavailability of NN9925 in Healthy Male Subjects|Completed||Phase 1|70|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:59:05.256771|2018-05-31 23:59:05.256771
NCT01087632|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-09-01|2010-03-15|2010-03-16|Estimate|||||||2010-09-01|2010-09-02|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Armolipid Plus and Metabolic Syndrome|Effects of Armolipid Plus on Indices of Insulin Resistance in Patients With Metabolic Syndrome|Completed||N/A|66|Actual|Rottapharm||2|||f||||f||||||||||2018-05-31 23:59:05.325405|2018-05-31 23:59:05.325405
NCT01087593|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate|August 2001||2001-08-31|September 2001|2001-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia|Hormonal Replacement Therapy Does Not Affect Self-estimated Pain or Experimental Pain Responses in Postmenopausal Women Suffering From Fibromyalgia: A Double-blind, Randomized, Placebo-controlled Trial|Terminated||N/A|29|Actual|Ostergotland County Council, Sweden||2||Due to ethical concerns regard to the results from the WHI study|f||||f||||||||||2018-05-31 23:59:05.511851|2018-05-31 23:59:05.511851
NCT01087580|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2017-03-01|2010-03-15|2010-03-16|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2011||2011-03-31|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer|A Randomized Phase-II Pilot Trial of Docetaxel and Prednisone Versus Radiation Therapy Plus Docetaxel and Prednisone in Patients With Nonmetastatic and Oligometastatic Castrate Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 23:59:05.663385|2018-05-31 23:59:05.663385
NCT01087567|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2014-04-16|2010-03-15|2010-03-16|Estimate|||||||2014-04-16|2014-04-21|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|INSPIRE||INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes|A Pilot Study of Intensive Insulin Regimen as a Primary Treatment of New Onset of Type 2 DM|Completed||Phase 4|23|Actual|Ohio University||2|||f||||t||||||||||2018-05-31 23:59:05.747116|2018-05-31 23:59:05.747116
NCT01087554|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2017-11-08|2010-03-15|2010-03-16|Estimate|||||||2017-11-08|2017-11-13|Actual|March 2010|Actual|2010-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer|A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer|Active, not recruiting||Phase 1|249|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 23:59:05.841948|2018-05-31 23:59:05.841948
NCT01087541|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2010-05-31||2011-03-27|2010-03-15|2010-03-16|Estimate|2011-02-24|2011-03-24|Estimate||||2011-03-27|2011-03-29|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|December 2008|Actual|2008-12-31||Interventional|SEGUDIAB||SEGUDIAB Study: Evaluation of Safety in the Diabetic Patients|SEGUDIAB Study: Safety in Diabetic Patients. Evaluation of an Educational Program for the Professionals to Improve the Safety in Diabetic Patients|Completed||N/A|6830|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 23:59:05.956055|2018-05-31 23:59:05.956055
NCT01087528|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2012-04-03||2012-06-10|2010-03-15|2010-03-16|Estimate|2012-05-06|2012-06-08|Estimate||||2012-06-10|2012-06-13|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of PillCam™ Colon 2 in Visualization of the Colon|Evaluation of PillCam™ Colon 2 in Visualization of the Colon|Completed||Phase 3|51|Actual|Given Imaging Ltd.||1|||f||||f||||||||||2018-05-31 23:59:06.235976|2018-05-31 23:59:06.235976
NCT01087515|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-11-08|2010-03-15|2010-03-16|Estimate|||||||2011-11-08|2011-11-09|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pilot Study for Cell Based Therapies in Patients With Asthma|Development and Validation of Magnetic Cell Separations Techniques Using a Good Manufacturing Practice (GMP) Grade Manufacturing Process for Clinical Applications and Generation of Pre-clinical Data|Completed||N/A|20|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f||||f||||||||||2018-05-31 23:59:06.376371|2018-05-31 23:59:06.376371
NCT01087502|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2013-05-17||2014-06-17|2010-03-15|2010-03-16|Estimate|2013-08-12|2013-10-17|Estimate||||2014-06-17|2014-06-27|Estimate|March 2010||2010-03-31|May 2014|2014-05-31||||May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment|A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control|Completed||Phase 3|241|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 23:59:06.484779|2018-05-31 23:59:06.484779
NCT01087489|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|2012-04-28||2012-11-19|2010-03-15|2010-03-16|Estimate|2012-11-19|2012-11-20|Estimate||||2012-11-19|2012-11-20|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye|Clinical Comparison of Two Anesthetic Preparations for Intravitreal Injection|Completed||N/A|53|Actual|Miami VA Healthcare System|discomfort One hour after injection was assessed the next day via telephone and might be affected by recall bias.|2|||f||||f||||||||||2018-05-31 23:59:07.358356|2018-05-31 23:59:07.358356
NCT01087476|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|February 2013|Anticipated|2013-02-28|June 2011|Anticipated|2011-06-30||Interventional|||Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate|Phase 2 Double-blind, Randomized, Placebo Controlled Clinical Trial for the Prevention of Oral Mucositis Using Sub-microbial Doses of Doxycycline Hyclate in Patients With Acute Leukemia Receiving Induction Chemotherapy|Unknown status|Not yet recruiting|Phase 2|164|Anticipated|Metropolitan Autonomous University||1|||f||||t||||||||||2018-05-31 23:59:07.553631|2018-05-31 23:59:07.553631
NCT01087463|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-14|||2010-03-14|2010-03-14|2010-03-16|Estimate|||||||2010-03-14|2010-03-16|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|April 2012|Anticipated|2012-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Intramedullary Fixation of Humerus Fractures Without Intramedullary Reaming|Composite Nailing System for the Intramedullary Fixation of Humerus Fractures Without Intramedullary Reaming|Unknown status|Not yet recruiting|N/A|20|Anticipated|N.M.B. Medical Applications Ltd||1|||f||||f||||||||||2018-05-31 23:59:07.624642|2018-05-31 23:59:07.624642
NCT01087450|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2018-03-09|2010-03-15|2010-03-16|Estimate|||||||2018-03-09|2018-03-13|Actual|August 12, 2009|Actual|2009-08-12|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Observational|||The Effect of Erythropietin on Microcircualtory Alteration in Intensive Care Unit Patients With Severe Sepsis|The Effect of rHuEPO on Microcircualtory Alteration in ICU Patients With Severre Sepsis and Septic Shock|Terminated|||22|Actual|London Health Sciences Centre|||2|Lack of recruitment|f||||t||||||||||2018-05-31 23:59:07.68703|2018-05-31 23:59:07.68703
NCT01087437|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-14|||2014-03-30|2010-03-15|2010-03-16|Estimate|||||||2014-03-30|2014-04-01|Estimate|January 2011||2011-01-31|March 2014|2014-03-31||||||||Interventional|||Testing the Effect of Crustacean's Gastrolith Nutraceutical on Mineralization Rate During Distraction Osteogenesis||Unknown status|Recruiting|Phase 1|||Hadassah Medical Organization||1|||f||||t||||||||||2018-05-31 23:59:07.74029|2018-05-31 23:59:07.74029
NCT01087424|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate|April 2006||2006-04-30|March 2010|2010-03-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Mini-CHOP and Rituximab in Patients Aged Over 80 Years|Phase II Study of Mini-CHOP Plus Rituximab in Non Previously Treated Patients Aged Over 80 Years With CD 20+ Diffuse Large B-Cell Lymphoma|Unknown status|Active, not recruiting|Phase 2|150|Actual|Lymphoma Study Association||1|||f||||f||||||||||2018-05-31 23:59:07.885666|2018-05-31 23:59:07.885666
NCT01087411|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2011-05-13|2010-03-15|2010-03-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|October 2008||2008-10-31|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|STOPP-8||Intervention Study to Prevent Obesity in Sedentary 8 Year Old Swedish Children|A Controlled Study Aiming to Increase Physical Activity and Decrease Risk Bio-markers in Sedentary 8 Year Old Swedish Children Via Physical Activity and Fish Liver Oil Supplementation|Terminated||N/A|240|Anticipated|Karolinska Institutet||4||2010 represented complications recruiting. The team suffered from sick-leave.|f||||f||||||||||2018-05-31 23:59:07.950981|2018-05-31 23:59:07.950981
NCT01087398|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2012-05-31|2010-03-15|2010-03-16|Estimate|||||||2012-05-31|2012-06-04|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis|Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-05-31 23:59:08.048052|2018-05-31 23:59:08.048052
NCT01087385|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2015-04-14|2010-03-15|2010-03-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Troponin T as Risk Stratification Tool in Peripheral Arterial Occlusive Disease|Troponin T as Risk Stratification Tool in Patients With Peripheral Arterial Occlusive Disease|Completed|||1000|Actual|Heart Center Bad Krozingen|||2||f||||f||||||||||2018-05-31 23:59:08.132616|2018-05-31 23:59:08.132616
NCT01087372|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-06-07|2010-03-15|2010-03-16|Estimate|||||||2010-06-07|2010-06-08|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Stress Hyperglycemia. Potential Role of Incretin Analogs|Stress Hyperglycemia in Critically Ill Patients. Potential Role of Incretin Analogs. A Preliminary Study|Completed|||60|Anticipated|Hospital Universitari Son Dureta|||||f||||f||||||Samples Without DNA|"~     Plasma and serum samples to analyze glucorregulatory hormones.~   "|||2018-05-31 23:59:08.192555|2018-05-31 23:59:08.192555
NCT01087359|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2011-06-17|2010-03-15|2010-03-16|Estimate|||||||2011-06-17|2011-06-20|Estimate|June 2010||2010-06-30|October 2010|2010-10-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Antiinflammatoric and Antioxidative Effect of Melatonin in Human Endotoxaemia|Antiinflammatoric and Antioxidative Effect of Melatonin in Human Endotoxaemia|Completed||Phase 4|12|Anticipated|Herlev Hospital||6|||f||||t||||||||||2018-05-31 23:59:08.248044|2018-05-31 23:59:08.248044
NCT01087346|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2018-05-23|2010-03-13|2010-03-16|Estimate|||||||2018-05-23|2018-05-24|Actual|March 4, 2010||2010-03-04|April 19, 2018|2018-04-19||||||||Observational|||Parents Thoughts About Kids and Eating|Parents Thoughts About Kids and Eating|Recruiting|||1100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:08.311253|2018-05-31 23:59:08.311253
NCT01087333|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2018-02-13|2010-03-13|2010-03-16|Estimate|||||||2018-02-13|2018-02-14|Actual|February 16, 2010||2010-02-16|January 19, 2018|2018-01-19||||||||Observational|||Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment|Collection of Human Samples to Study Hairy Cell and Other Leukemias and to Develop Recombinant Immunotoxins for Cancer Treatment|Recruiting|||1263|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:08.382732|2018-05-31 23:59:08.382732
NCT01087320|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2018-05-26|2010-03-13|2010-03-16|Estimate|||||||2018-05-26|2018-05-30|Actual|February 17, 2010||2010-02-17|May 21, 2018|2018-05-21||||||||Observational|||Whole Genome Medical Sequencing for Genome Discovery|Whole Genome Medical Sequencing for Gene Discovery|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:08.478583|2018-05-31 23:59:08.478583
NCT01087307|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2018-05-26|2010-03-13|2010-03-16|Estimate|||||||2018-05-26|2018-05-30|Actual|February 16, 2010||2010-02-16|May 23, 2018|2018-05-23||||||||Observational|||Sample Collection Registry for Quality Control of Biological and Environmental Specimens and Assay Development and Testing|Sample Collection Registry for Quality Control of Biological and Environmental Specimens and Assay Development and Testing|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:08.558851|2018-05-31 23:59:08.558851
NCT01087294|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2018-04-18|2010-03-13|2010-03-16|Estimate|||||||2018-04-18|2018-04-19|Actual|February 5, 2010||2010-02-05|January 31, 2018|2018-01-31|March 1, 2024|Anticipated|2024-03-01|March 1, 2023|Anticipated|2023-03-01||Interventional|||Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation|Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T-cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation|Recruiting||Phase 1|150|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 23:59:08.638256|2018-05-31 23:59:08.638256
NCT01087281|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2018-05-17|2010-03-13|2010-03-16|Estimate|||||||2018-05-17|2018-05-18|Actual|February 22, 2010||2010-02-22|April 16, 2018|2018-04-16||||||||Observational|||Top-Down Attentional Control of Visual-Processing|Top-Down Attentional Control of Visual-Processing|Recruiting|||102|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:08.743621|2018-05-31 23:59:08.743621
NCT01087268|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-13|||2011-07-14|2010-03-13|2010-03-16|Estimate|||||||2011-07-14|2011-07-15|Estimate|January 2009||2009-01-31|March 2010|2010-03-31||||December 2011|Anticipated|2011-12-31||Interventional|||Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer|Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II)|Unknown status|Recruiting|Phase 3|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:59:08.838769|2018-05-31 23:59:08.838769
NCT01087255|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2011-06-21|2010-03-15|2010-03-16|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2009||2009-11-30|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Caregivers and Electronic Medication Monitoring in Chronic Kidney Disease|Caregivers and Internet Based Monitoring to Improve Medication Use in HPHC Enrollees With Chronic Kidney Disease|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Harvard Pilgrim Health Care||2|||f||||f||||||||||2018-05-31 23:59:08.938101|2018-05-31 23:59:08.938101
NCT01087242|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|June 2010|Anticipated|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Clinical Trail of Tang-min-Ling Pills in Type 2 Diabetes Mellitus|Randomized，Double-blind，Dose Parallel Controlled, Multicentre Clinical Trail of Tang-min-Ling Pills and Placebo in Diabetes Mellitus(Liver-stomach Heat Retention Syndrome) (Phase Ⅲ)|Unknown status|Active, not recruiting|Phase 3|480|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 23:59:09.052533|2018-05-31 23:59:09.052533
NCT01087229|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2015-03-26|2010-03-15|2010-03-16|Estimate|||||||2015-03-26|2015-03-27|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|MEOPA||Effectiveness of an Oxygen-nitrous Oxide Mixture During Physical Therapy for Frozen Shoulder|Comparative Study of the Effectiveness of an Equimolar Oxygen-nitrous Oxide Mixture During Physical Therapy for Adhesive Shoulder Capsulitis|Completed||Phase 4|75|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 23:59:09.145952|2018-05-31 23:59:09.145952
NCT01087216|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-15|||2012-03-23|2010-03-15|2010-03-16|Estimate|||||||2012-03-23|2012-03-26|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo||Completed||Phase 2/Phase 3|20|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 23:59:09.241299|2018-05-31 23:59:09.241299
NCT01087203|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11||2012-01-27|2012-08-23|2010-03-12|2010-03-16|Estimate||||2012-08-23|2012-08-30|Estimate|2012-08-23|2012-08-30|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy|Terminated||Phase 2|73|Actual|Pfizer||2||See termination reason in detailed description.|f||||t||||||||||2018-05-31 23:59:09.326709|2018-05-31 23:59:09.326709
NCT01087190|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-12-11|2010-03-15|2010-03-16|Estimate|||||||2013-12-11|2013-12-12|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Isoniazid (INH) Treatment Based on ELISPOT Assay|A Prospective, Randomized, Open Labeled Trial of Isoniazid Treatment Based on ELISPOT Assay to Prevent Tuberculosis in a Kidney Transplant Recipient|Completed||N/A|831|Actual|Asan Medical Center||3|||f||||t||||||||||2018-05-31 23:59:09.470475|2018-05-31 23:59:09.470475
NCT01087177|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2012-03-21|2010-03-12|2010-03-16|Estimate|||||||2012-03-21|2012-03-22|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effectiveness of Pedialink CEASE Module|Evaluating Online Clinical Office-Systems Training to Address SHS Exposure of Children|Completed||N/A|647|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 23:59:09.546474|2018-05-31 23:59:09.546474
NCT01087164|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2014-02-06|2010-03-15|2010-03-16|Estimate|||||||2014-02-06|2014-02-10|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers|Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers in Adolescents|Unknown status|Active, not recruiting|N/A|600|Anticipated|Indiana University||2|||f||||f||||||||||2018-05-31 23:59:09.647688|2018-05-31 23:59:09.647688
NCT01087151|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11||2013-08-20|2016-11-01|2010-03-12|2010-03-16|Estimate||||2013-08-20|2013-08-28|Estimate|2016-11-01|2016-11-02|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)|A Phase II, Multicenter, Randomized, Controlled, Open-label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-intensive Rituximab, or Dose-intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|118|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 23:59:09.750843|2018-05-31 23:59:09.750843
NCT01087138|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate||||March 2010|2010-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|Exkids||Study to Determine How Exercise and Calcium Affect Pubertal Bone|Effect of Exercise and Calcium Foods on Pubertal Bone Gain|Completed||Phase 3|134|Actual|Creighton University||3|||f||||f||||||||||2018-05-31 23:59:10.012246|2018-05-31 23:59:10.012246
NCT01087125|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2018-03-26|2010-03-15|2010-03-16|Estimate|||||||2018-03-26|2018-03-29|Actual|September 30, 2006|Actual|2006-09-30|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Abatacept Pregnancy Exposure Registry|Abatacept Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project: An Extension Study|Recruiting|||240|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 23:59:10.071993|2018-05-31 23:59:10.071993
NCT01087112|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2010-03-15|2010-03-15|2010-03-16|Estimate|||||||2010-03-15|2010-03-16|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|MIPPS-02||Mother-Infant Psychoanalysis Project of Stockholm (MIPPS)- Follow-up at 4½ Years|A Follow-up Study of a Randomized Controlled Trial of Mother-Infant Psychoanalytic Treatment and Treatment As Usual at Child Health Centres|Unknown status|Recruiting|Early Phase 1|71|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 23:59:10.204717|2018-05-31 23:59:10.204717
NCT01087099|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-07-30|2010-03-12|2010-03-15|Estimate|||||||2011-07-30|2011-08-02|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|WORMCON||A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children|A Multinational Trial of the Efficacy of Albendazole Against Soil-transmitted Nematode Infections in Children|Completed||Phase 4|1750|Anticipated|University Ghent||1|||f||||f||||||||||2018-05-31 23:59:10.3312|2018-05-31 23:59:10.3312
NCT01087086|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-05-11|2010-03-12|2010-03-15|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Interventional|RESMENA-S||Reduction of the Metabolic Syndrome in Navarra-Spain|Reduction of the Metabolic Syndrome in Navarra-Spain (RESMENA-S) Through an Innovative Multidisciplinary Strategy Based on the Crononutrition and Dietary Training Concepts, in Addition to Both Dietary and Psychological Control|Completed||N/A|109|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-05-31 23:59:10.421784|2018-05-31 23:59:10.421784
NCT01087073|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2016-08-25|2010-03-12|2010-03-15|Estimate|||||||2016-08-25|2016-08-26|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Improving Diabetes Care and Outcomes on the South Side of Chicago|Improving Diabetes Care and Outcomes on the South Side of Chicago|Active, not recruiting||N/A|5000|Anticipated|University of Chicago||5|||f||||f||||||||||2018-05-31 23:59:10.556786|2018-05-31 23:59:10.556786
NCT01087060|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-12|2010-03-12|2010-03-15|Estimate|||||||2010-03-12|2010-03-15|Estimate|January 1997||1997-01-31|March 2010|2010-03-31|May 2009|Actual|2009-05-31|March 2008|Actual|2008-03-31||Observational|||Detection of Renal Malignancy of Complicated Renal Cysts|Does Hounsfield Unit (HU) Predict the Detection of Cystic Renal Malignancy of Complicated Renal Cysts?|Completed|||269|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 23:59:10.69246|2018-05-31 23:59:10.69246
NCT01087047|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2012-06-11|2010-03-12|2010-03-15|Estimate|||||||2012-06-11|2012-06-12|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|MAVAG||Upper Airways in Pregnancy: Evaluation by the Acoustic Reflection Method|Upper Airways in Pregnancy: Evaluation by the Acoustic Reflection Method|Completed|||50|Actual|Club d'Anesthésie-Réanimation Pédiatrique Armand Trousseau|||2||f||||t||||||||||2018-05-31 23:59:10.764277|2018-05-31 23:59:10.764277
NCT01087034|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2012-06-11|2010-03-12|2010-03-15|Estimate|||||||2012-06-11|2012-06-12|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Observational|MASI||Bracing During Infantile Scoliosis: Airways Study|Bracing During Infantile Scoliosis: Airways Study by Acoustic Method, EOS™ Acquisition and Noninvasive Respiratory Muscles Assessment|Completed|||15|Actual|Club d'Anesthésie-Réanimation Pédiatrique Armand Trousseau|||2||f||||f||||||||||2018-05-31 23:59:10.848572|2018-05-31 23:59:10.848572
NCT01087021|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-12-15|2010-03-12|2010-03-15|Estimate|||||||2011-12-15|2011-12-16|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|QT-Cab||Effect of Cabazitaxel on the QTc Interval in Cancer Patients|QT-Cab: An Open-Label Study to Investigate the Effect of Cabazitaxel on the QTc Interval in Cancer Patients|Completed||Phase 1|45|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:59:10.970396|2018-05-31 23:59:10.970396
NCT01087008|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2017-10-25|2010-03-12|2010-03-15|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2010||2010-04-30|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2013|Actual|2013-05-31||Interventional|AZABACHE||Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse|Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group|Active, not recruiting||Phase 4|103|Anticipated|PETHEMA Foundation||2|||f||||t||||||||||2018-05-31 23:59:11.087352|2018-05-31 23:59:11.087352
NCT01086995|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2017-07-05|2010-03-12|2010-03-15|Estimate|||||||2017-07-05|2017-07-07|Actual|November 2007||2007-11-30|July 2017|2017-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|WAVE||Weaning And Variability Evaluation (WAVE)|Weaning And Variability Evaluation|Completed|||60|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 23:59:11.209687|2018-05-31 23:59:11.209687
NCT01086982|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-10-26|2010-03-12|2010-03-15|Estimate|||||||2010-10-26|2010-10-28|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||May 2010|Anticipated|2010-05-31||Interventional|||Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A.||Suspended||Phase 1|16|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 23:59:11.271566|2018-05-31 23:59:11.271566
NCT01086969|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2012-01-03||2012-02-02|2010-03-12|2010-03-15|Estimate|2012-01-03|2012-02-03|Estimate||||2012-02-02|2012-02-06|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India|Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects 2-55 Years of Age in India|Completed||Phase 3|300|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 23:59:11.359735|2018-05-31 23:59:11.359735
NCT01086956|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-11-10|2010-03-12|2010-03-15|Estimate|||||||2010-11-10|2010-11-11|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy|Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy|Completed||N/A|60|Actual|Yonsei University|||||f||||f||||||||||2018-05-31 23:59:11.779185|2018-05-31 23:59:11.779185
NCT01086943|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2012-01-27|2010-03-12|2010-03-15|Estimate|||||||2012-01-27|2012-01-31|Estimate||||January 2012|2012-01-31||||||||Interventional|||Clinical Safety Study on an Eyelid Warming Device to Evaluate the Eyelid and Cornea Temperature in Healthy Volunteers|Clinical Safety Study on an Eyelid Warming Device, Moist Heat Technology BLEPHASTEAM®, to Evaluate the Eyelid and Cornea Temperature in Healthy Volunteers|Completed||Phase 1|25|Actual|Laboratoires Thea||1|||f||||f||||||||||2018-05-31 23:59:11.832228|2018-05-31 23:59:11.832228
NCT01086930|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2011-08-04|2010-03-12|2010-03-15|Estimate|||||||2011-08-04|2011-08-05|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|SCIPA Hands-On||SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury|SCIPA (Spinal Cord Injury and Physical Activity) Hands-On: Early Intensive Hand Rehabilitation After Spinal Cord Injury|Unknown status|Recruiting|Phase 3|78|Anticipated|University of Melbourne||2|||f||||t||||||||||2018-05-31 23:59:11.882117|2018-05-31 23:59:11.882117
NCT01086917|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2015-04-17|2010-03-12|2010-03-15|Estimate|||||||2015-04-17|2015-04-21|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Experimental Human Malaria Infection by PfSPZ|Experimental Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites (PfSPZ Challenge)|Completed||Phase 1|18|Actual|Sanaria Inc.||3|||f||||t||||||||||2018-05-31 23:59:12.048646|2018-05-31 23:59:12.048646
NCT01086904|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-12-29|2010-03-12|2010-03-15|Estimate|||||||2011-12-29|2012-01-02|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|Transfluvac||Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients|Etude de Phase II évaluant l'immunogénicité et la tolérance d'un Vaccin inactivé Non adjuvanté Contre la Grippe A (H1N1) après Transplantation rénale|Completed||Phase 2|120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-05-31 23:59:12.119467|2018-05-31 23:59:12.119467
NCT01086891|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2013-08-29|2010-03-12|2010-03-15|Estimate|||||||2013-08-29|2013-08-30|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Efficacy of Two Liquid Oxygen Devices in Deambulation|Efficacy of Two Liquid Oxygen Devices in Deambulation|Completed||N/A|60|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 23:59:12.184606|2018-05-31 23:59:12.184606
NCT01086865|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-05-18|2010-03-12|2010-03-15|Estimate|||||||2010-05-18|2010-05-19|Estimate|August 2010||2010-08-31|March 2009|2009-03-31|January 2011|Anticipated|2011-01-31|November 2010|Anticipated|2010-11-30||Interventional|Apetiviton BC||Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.|Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|Cifarma Cientifica Farmaceutica Ltda||2|||f||||t||||||||||2018-05-31 23:59:12.338628|2018-05-31 23:59:12.338628
NCT01086852|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2015-01-12||2017-01-30|2010-03-12|2010-03-15|Estimate|2015-07-02|2015-07-03|Estimate||||2017-01-30|2017-03-10|Actual|March 2011||2011-03-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Ten03||Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery|A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL's High Purity FACTOR X in the Treatment of Factor X Deficient Subjects Undergoing Surgery|Terminated||Phase 3|4|Actual|Bio Products Laboratory|none reported|1||Closed early due to difficulties in enrolling the target number of 10 surgical procedures.|f||||f||||||||||2018-05-31 23:59:12.406995|2018-05-31 23:59:12.406995
NCT01086839|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2014-11-28|2010-03-12|2010-03-15|Estimate|||||||2014-11-28|2014-12-02|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial|Completed||N/A|69|Actual|University of Jena||2|||f||||f||||||||||2018-05-31 23:59:12.647677|2018-05-31 23:59:12.647677
NCT01086826|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2015-01-23|2010-03-12|2010-03-15|Estimate|||||||2015-01-23|2015-01-26|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|H&N07||Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study.|Completed||Phase 3|320|Actual|Associazione Volontari Pazienti Oncologici||4|||f||||f||||||||||2018-05-31 23:59:12.73048|2018-05-31 23:59:12.73048
NCT01086813|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2012-12-19|2010-03-12|2010-03-15|Estimate|||||||2012-12-19|2012-12-20|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|AZD3043||Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043|Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly (=65 Years) Healthy Volunteers|Withdrawn||Phase 1|0|Actual|AstraZeneca||1||The compound is being re-evaluated|f||||f||||||||||2018-05-31 23:59:13.850917|2018-05-31 23:59:13.850917
NCT01086800|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2013-02-21|2010-03-12|2010-03-15|Estimate|||||||2013-02-21|2013-02-25|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|HeartBEAT||Heart Biomarker Evaluation in Apnea Treatment|Phase II Trial of Sleep Apnea Treatment to Reduce Cardiovascular Morbidity|Completed||Phase 2|318|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 23:59:13.922661|2018-05-31 23:59:13.922661
NCT01086787|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-06-10|2010-03-12|2010-03-15|Estimate|||||||2010-06-10|2010-06-11|Estimate|August 2010||2010-08-31|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Observational|BM-CHF||Paracrine Mechanisms of Bone Marrow Stem Cell Signalling in Chronic Heart Failure|Paracrine Mechanisms of Bone Marrow Stem Cell Signalling in Chronic Heart Failure|Unknown status|Not yet recruiting||125|Anticipated|University Medical Center Groningen|||3||f||||f||||||Samples With DNA|"~     Whole blood, serum, white cells, urine, bone marrow~   "|||2018-05-31 23:59:14.021517|2018-05-31 23:59:14.021517
NCT01086774|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2012-01-31|2010-03-12|2010-03-15|Estimate|||||||2012-01-31|2012-02-02|Estimate|July 2010||2010-07-31|January 2012|2012-01-31||||November 2010|Actual|2010-11-30||Interventional|||Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects||Completed||Phase 4|10|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 23:59:14.100753|2018-05-31 23:59:14.100753
NCT01086761|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2014-04-14||2014-04-14|2010-03-12|2010-03-15|Estimate|2014-04-14|2014-05-12|Estimate||||2014-04-14|2014-05-12|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration|A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)|Terminated||Phase 1|32|Actual|Allergan||6||The study was terminated due to a company decision following completion of Part A.|f||||t||||||||||2018-05-31 23:59:14.194542|2018-05-31 23:59:14.194542
NCT01086748|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12||2012-09-18|2012-09-18|2010-03-12|2010-03-15|Estimate||||2012-09-18|2012-09-25|Estimate|2012-09-18|2012-09-25|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study in Schizophrenia Patients|A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 Versus Placebo in Patients With DSM-IV-TR Schizophrenia|Completed||Phase 2|880|Anticipated|Eli Lilly and Company||4|||f||||t||||||||||2018-05-31 23:59:14.907569|2018-05-31 23:59:14.907569
NCT01086735|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2013-01-11|2010-03-12|2010-03-15|Estimate|||||||2013-01-11|2013-01-14|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ILD-TK01||Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation|Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation: a Phase I/II Clinical Study|Completed||Phase 1/Phase 2|11|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 23:59:15.03244|2018-05-31 23:59:15.03244
NCT01086722|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2015-10-14|2010-03-12|2010-03-15|Estimate|||||||2015-10-14|2015-10-16|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|FAROBE/1||Pharmacokinetics in Morbid Obesity After Bariatric Surgery|Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques in Drugs Metabolism.|Completed||Phase 1/Phase 2|52|Actual|Fundacion IMIM||1|||f||||f||||||||||2018-05-31 23:59:15.110499|2018-05-31 23:59:15.110499
NCT01086709|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2018-04-04|2010-03-12|2010-03-15|Estimate|||||||2018-04-04|2018-04-05|Actual|January 27, 2010||2010-01-27|March 17, 2015|2015-03-17|March 17, 2015||2015-03-17|||||Observational|||Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191|Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191(NCI)/IC-200403(INCIENSA)|Completed|||5444|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:15.1736|2018-05-31 23:59:15.1736
NCT01086696|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2018-05-22|2010-03-12|2010-03-15|Estimate|||||||2018-05-22|2018-05-23|Actual|March 9, 2010||2010-03-09|May 11, 2016|2016-05-11|May 11, 2016|Actual|2016-05-11|August 20, 2014|Actual|2014-08-20||Interventional|||A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers|A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers|Terminated||Early Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 23:59:15.233282|2018-05-31 23:59:15.233282
NCT01086683|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2010-03-12|2010-03-12|2010-03-15|Estimate|||||||2010-03-12|2010-03-15|Estimate|May 2004||2004-05-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course|Rehabilitation of Cancer Survivors in Denmark: A Randomized Controlled Trial on the Effect of a Multi-focused Psychosocial Rehabilitation Course|Completed||Phase 2/Phase 3|513|Actual|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 23:59:15.323518|2018-05-31 23:59:15.323518
NCT01086670|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2018-05-08|2010-03-12|2010-03-15|Estimate|||||||2018-05-08|2018-05-09|Actual|March 5, 2010||2010-03-05|May 4, 2018|2018-05-04|May 9, 2016|Actual|2016-05-09|May 9, 2016|Actual|2016-05-09||Interventional|||Physical, Functional and Neural Effects of Two Lower Extremity Exercise Protocols in Children With Cerebral Palsy|Physical, Functional and Neurological Effects of Two Lower Extremity Exercise Programs in Children With Cerebral Palsy|Completed||Phase 1/Phase 2|55|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:15.533112|2018-05-31 23:59:15.533112
NCT01086657|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2017-06-30|2010-03-12|2010-03-15|Estimate|||||||2017-06-30|2017-07-02|Actual|February 25, 2010||2010-02-25|December 12, 2011|2011-12-12|December 12, 2011|Actual|2011-12-12|December 12, 2011|Actual|2011-12-12||Interventional|||An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...|VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine|Completed||Phase 1|64|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-05-31 23:59:15.660953|2018-05-31 23:59:15.660953
NCT01086631|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2017-10-05|2010-03-12|2010-03-15|Estimate|||||||2017-10-05|2017-10-06|Actual|January 22, 2010||2010-01-22|July 8, 2014|2014-07-08|July 8, 2014|Actual|2014-07-08|||||Interventional|||Rituximab for Autoimmune Retinopathy|Rituximab for Autoimmune Retinopathy|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 23:59:15.755932|2018-05-31 23:59:15.755932
NCT01086618|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2013-08-23|2010-03-12|2010-03-15|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Chemotherapy With or Without Surgery in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery|A Randomized Trial of Initial Surgery in Advanced Asymptomatic Colorectal Cancer Patients Receiving Chemotherapy for Metastatic Disease|Completed||Phase 2/Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:59:15.868441|2018-05-31 23:59:15.868441
NCT01086605|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|2016-12-12||2018-04-06|2010-03-12|2010-03-15|Estimate|2017-01-04|2017-02-23|Actual||||2018-04-06|2018-05-08|Actual|May 2010|Actual|2010-05-31|April 2018|2018-04-30|November 15, 2014|Actual|2014-11-15|January 2012|Actual|2012-01-31||Interventional|||Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer|Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer|Completed||Phase 2|46|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 23:59:16.010742|2018-05-31 23:59:16.010742
NCT01086592|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-07-02|2010-03-12|2010-03-15|Estimate|||||||2010-07-02|2010-07-05|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects of a Program of Physical Exercise and Electrotherapy on Muscle Strength in Subjects of the Fourth Age|Effects of a Program of Physical Exercise and Electrotherapy on Muscle Strength in Subjects of the Fourth Age|Completed||Early Phase 1|118|Actual|Cardenal Herrera University||4|||f||||f||||||||||2018-05-31 23:59:16.942396|2018-05-31 23:59:16.942396
NCT01086579|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-08-13|2010-03-12|2010-03-15|Estimate|||||||2013-08-13|2013-08-14|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|May 2014|Anticipated|2014-05-31|March 2012|Actual|2012-03-31||Interventional|BELLO||Balloon Elution and Late Loss Optimization (BELLO) Study|Balloon Elution and Late Loss Optimization (BELLO) Study: A Multicentre Randomized Study of the IN.PACT Falcon™ Paclitaxel Drug-eluting Balloon to Reduce Restenosis in Small Coronary Vessels|Unknown status|Active, not recruiting|N/A|182|Actual|Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS||2|||f||||t||||||||||2018-05-31 23:59:17.030989|2018-05-31 23:59:17.030989
NCT01086566|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2015-12-31|2010-03-11|2010-03-15|Estimate|||||||2015-12-31|2016-01-01|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines|Evaluation of the Safety and Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines Representing Different Clades|Completed||Phase 1|95|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-05-31 23:59:17.118532|2018-05-31 23:59:17.118532
NCT01086553|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2014-10-29|2010-03-12|2010-03-15|Estimate|||||||2014-10-29|2014-10-30|Estimate|November 2009||2009-11-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease|Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease|Completed||Phase 3|471|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-05-31 23:59:17.200292|2018-05-31 23:59:17.200292
NCT01086540|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2018-05-08|2010-03-11|2010-03-15|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2010||2010-08-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)|A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)|Active, not recruiting||Phase 2|57|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 23:59:17.28856|2018-05-31 23:59:17.28856
NCT01086527|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2014-01-23|2010-03-11|2010-03-15|Estimate|||||||2014-01-23|2014-01-24|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|GSPOM||Genotype Stratified Pharmacokinetic Study of Montelukast|Genotype Stratified Pharmacokinetic Study of Montelukast|Unknown status|Recruiting|Phase 1|6|Anticipated|Nemours Children's Clinic||1|||f||||f||||||||||2018-05-31 23:59:17.41314|2018-05-31 23:59:17.41314
NCT01086514|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2015-09-28|2010-03-12|2010-03-15|Estimate|||||||2015-09-28|2015-09-30|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Digital Mammography for the Detection and Preoperative Staging of Breast Cancer|Dual Energy Contrast Enhanced Digital Mammography for the Detection and Preoperative Staging of Breast Cancer|Completed||N/A|82|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 23:59:17.500945|2018-05-31 23:59:17.500945
NCT01086501|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-12|||2013-02-28|2010-03-12|2010-03-15|Estimate|||||||2013-02-28|2013-03-01|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|October 2012|Actual|2012-10-31|July 2011|Actual|2011-07-31||Observational|||ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients|Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters|Completed|||225|Actual|Desitin Arzneimittel GmbH|||||f||||||||||||||2018-05-31 23:59:17.567013|2018-05-31 23:59:17.567013
NCT01086488|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2011-07-07|2010-03-11|2010-03-15|Estimate|||||||2011-07-07|2011-07-08|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|FOSCAN||Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma|A Phase II, Randomized Controlled Trial of Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Recurrent or Persistent Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|66|Anticipated|Ministry of Health, Malaysia||1|||f||||f||||||||||2018-05-31 23:59:17.623521|2018-05-31 23:59:17.623521
NCT01086475|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2015-08-28||2016-03-15|2010-03-11|2010-03-15|Estimate|2016-03-15|2016-04-14|Estimate||||2016-03-15|2016-04-14|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||D-Cycloserine and Social Skills Training in Autism Spectrum Disorders|A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders|Completed||Phase 3|68|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 23:59:17.714647|2018-05-31 23:59:17.714647
NCT01086462|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-07-13|2010-03-11|2010-03-15|Estimate|||||||2017-07-13|2017-07-18|Actual|January 21, 2010|Actual|2010-01-21|July 2017|2017-07-31|February 22, 2010|Actual|2010-02-22|February 22, 2010|Actual|2010-02-22||Interventional|||Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633|A Microdose Study to Describe the Intravenous Pharmacokinetics of [14C]-GSK2239633 in Healthy Male Subjects|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:59:17.978509|2018-05-31 23:59:17.978509
NCT01086449|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2018-03-08|2010-03-11|2010-03-15|Estimate|||||||2018-03-08|2018-03-09|Actual|March 4, 2010|Actual|2010-03-04|March 2018|2018-03-31|November 25, 2010|Actual|2010-11-25|June 25, 2010|Actual|2010-06-25||Interventional|||Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults|Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults|Completed||Phase 1|20|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:59:18.154222|2018-05-31 23:59:18.154222
NCT01086436|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2017-05-18|2010-03-11|2010-03-15|Estimate|||||||2017-05-18|2017-05-19|Actual|March 13, 2010|Actual|2010-03-13|May 2017|2017-05-31|April 16, 2010|Actual|2010-04-16|April 16, 2010|Actual|2010-04-16||Interventional|||Study to Evaluate the Safety of Rotarix™ in Chinese Children|Reactogenicity and Safety of a Single Dose of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Children|Completed||Phase 1|50|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:59:18.26253|2018-05-31 23:59:18.26253
NCT01086423|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2017-02-24|2010-12-23|2017-04-13|2010-03-11|2010-03-15|Estimate|2017-02-24|2017-04-10|Actual|2010-12-23|2010-12-30|Estimate|2017-04-13|2017-05-23|Actual|March 1, 2010||2010-03-01|February 2017|2017-02-28|November 19, 2010|Actual|2010-11-19|November 19, 2010|Actual|2010-11-19||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine|Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib™) in Infants|Completed||Phase 3|985|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 23:59:18.41356|2018-05-31 23:59:18.41356
NCT01086410|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2013-06-06|2012-03-15|2016-11-30|2010-03-11|2010-03-15|Estimate|2013-06-06|2013-08-08|Estimate|2012-03-15|2012-03-19|Estimate|2016-11-30|2017-01-18|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis|Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 Versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics|Completed||Phase 3|185|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:59:19.353957|2018-05-31 23:59:19.353957
NCT01086397|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2012-03-14|2010-03-12|2010-03-15|Estimate|||||||2012-03-14|2012-03-15|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia|Distribution Of PCV13 Serotype Streptococcus Pneumoniae In Adults 50 Years And Older Presenting To Select US Hospitals With Radiographically-Confirmed Community-Acquired Pneumonia (CAP)|Completed|||782|Actual|Pfizer|||1||f||||f||||||Samples Without DNA|"~     urine serum and potentially blood isolates~   "|||2018-05-31 23:59:20.595197|2018-05-31 23:59:20.595197
NCT01086384|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2013-05-30|2012-07-26|2018-01-18|2010-03-11|2010-03-15|Estimate|2013-09-05|2013-09-11|Estimate|2012-07-26|2012-08-03|Estimate|2018-01-18|2018-01-24|Actual|February 22, 2010||2010-02-22|January 2018|2018-01-31|September 15, 2011|Actual|2011-09-15|September 1, 2011|Actual|2011-09-01||Interventional|||Asthma Exacerbation Study|A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma|Completed||Phase 3|2020|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 23:59:20.91546|2018-05-31 23:59:20.91546
NCT01086371|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2012-01-18|2010-03-11|2010-03-15|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Rhythmic Auditory Stimulation and Walking Performance in Multiple Sclerosis (MS) Patients|Rhythmic Auditory Stimulation and Walking Performance in MS Patients|Withdrawn||Phase 2|0|Actual|The Cleveland Clinic||3||Study being redesigned in anticipation of new study protocol.|f||||f||||||||||2018-05-31 23:59:21.803773|2018-05-31 23:59:21.803773
NCT01086358|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2017-12-21||2018-03-29|2010-03-11|2010-03-15|Estimate|2018-03-29|2018-05-01|Actual||||2018-03-29|2018-05-01|Actual|September 2009|Actual|2009-09-30|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?|A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan|Completed||Phase 4|60|Actual|The Cleveland Clinic|Unusually high number of subjects lost to follow-up.|2|||f||||f|t|||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 23:59:21.896799|2018-05-31 23:59:21.896799
NCT01086345|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2015-08-12|2010-03-12|2010-03-15|Estimate|||||||2015-08-12|2015-08-13|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Radiosurgery Plus Bevacizumab in Glioblastoma|Phase I/II Trial of Radiosurgery Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma|Terminated||Phase 1/Phase 2|9|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||t||||||||||2018-05-31 23:59:22.166132|2018-05-31 23:59:22.166132
NCT01086332|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2018-01-04|2010-03-12|2010-03-15|Estimate|||||||2018-01-04|2018-01-08|Actual|May 2009||2009-05-31|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluation of Nelfinavir and Chemoradiation for Pancreatic Cancer|A Phase I/II Trial of the HIV Protease Inhibitor Nelfinavir and Concurrent Radiation and Chemotherapy in Patients With Locally Advanced Pancreatic Cancer|Terminated||Phase 1|7|Actual|University of Iowa||1||Toxicities, lack of funding|f||||t||||||||Yes|Data will be shared through clinicaltrials.gov|2018-05-31 23:59:22.243477|2018-05-31 23:59:22.243477
NCT01086319|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-09-19|2010-03-12|2010-03-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments|Comparison of Risk of Hospitalization for Severe Hypersensitivity (Including Severe Cutaneous Reactions) Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments|Completed|||113505|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:59:22.317751|2018-05-31 23:59:22.317751
NCT01086306|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-09-19|2010-03-12|2010-03-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment|Comparison of Risk of Hospitalization for Infections Between Patients With Type 2 Diabetes Exposed to Saxagliptin and Those Exposed to Other Oral Anti-Diabetic Treatments|Completed|||113505|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:59:22.403871|2018-05-31 23:59:22.403871
NCT01086293|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-09-19|2010-03-12|2010-03-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments|Comparison of Risk of Hospitalization With Acute Liver Failure Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments|Completed|||113505|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:59:22.478169|2018-05-31 23:59:22.478169
NCT01086280|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-09-19|2010-03-12|2010-03-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments|Comparison of Risk of Major Cardiovascular Events Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments|Completed|||113505|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:59:22.53459|2018-05-31 23:59:22.53459
NCT01086267|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11||2015-09-23|2016-06-23|2010-03-11|2010-03-15|Estimate||||2015-09-23|2015-10-12|Estimate|2016-06-23|2016-06-27|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer|A Phase 1/2 Study of BMS-908662 (XL281) Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|17|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 23:59:22.595036|2018-05-31 23:59:22.595036
NCT01086254|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-09-23|2010-03-12|2010-03-15|Estimate|||||||2013-09-23|2013-09-24|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer|Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer|Completed||Phase 2|119|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 23:59:22.776193|2018-05-31 23:59:22.776193
NCT01086241|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-03-10|2010-03-11|2010-03-15|Estimate|||||||2016-03-10|2016-03-11|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Tomosynthesis in Screening Mammography|A Study to Determine Patient Benefit of Tomosynthesis in Screening Mammography|Completed||N/A|500|Actual|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-05-31 23:59:22.864983|2018-05-31 23:59:22.864983
NCT01086228|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2017-02-13||2017-08-16|2010-03-11|2010-03-15|Estimate|2017-08-16|2018-02-19|Actual||||2017-08-16|2018-02-19|Actual|March 2010||2010-03-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|June 2012|Actual|2012-06-30||Observational||Baseline characteristics were analyzed for 2,009 patients (XIENCE V:1,159 ; PROMUS : 850).|XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan|XIENCE V/PROMUS Everolimus-Eluting Stent System Japan Post-marketing Surveillance Protocol|Completed|||2010|Actual|Abbott Vascular|||1||f||||f||||||||||2018-05-31 23:59:22.995635|2018-05-31 23:59:22.995635
NCT01086215|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2014-10-29||2014-11-03|2010-03-12|2010-03-15|Estimate|2014-10-29|2014-11-03|Estimate||||2014-11-03|2014-11-10|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|PEARLII|Descriptive Analysis|Registry of AngioJet Use in the Peripheral Vascular System|PEARL II: PEripheral Use of AngioJet® Rheolytic Thrombectomy With a Variety of Catheter Lengths|Completed|||500|Actual|Boston Scientific Corporation|||4||f||||f||||||||||2018-05-31 23:59:24.003847|2018-05-31 23:59:24.003847
NCT01086202|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-09-14|2010-03-12|2010-03-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Clinical Outcome Comparison Between Medial and Lateral Offset Reverse Shoulder Arthroplasty|Clinical Outcome Comparison Between Medial and Lateral Offset Reverse Shoulder Arthroplasty|Completed|||37|Actual|Loma Linda University|||2||f||||t||||||||||2018-05-31 23:59:24.591376|2018-05-31 23:59:24.591376
NCT01086163|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|October 2010||2010-10-31|March 2010|2010-03-31|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Observational|OMPA-CAD||Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia|Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD)|Unknown status|Not yet recruiting||30|Anticipated|HeartDrug Research LLC|||1||f||||t||||||Samples Without DNA|"~     Serial blood samples - at baseline, day 7, and day 14 after treatment assignment~   "|||2018-05-31 23:59:24.764354|2018-05-31 23:59:24.764354
NCT01086150|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2011-06-21|2010-03-11|2010-03-12|Estimate|||||||2011-06-21|2011-06-23|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy|Use of Topical Lidocaine (Lidoderm 5% Patch) to Reduce Pain in Patients With Diabetic Neuropathy: Does the Density and Subtype of Sodium Channels Affect Response?|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Albany Medical College||3|||f||||f||||||||||2018-05-31 23:59:24.960875|2018-05-31 23:59:24.960875
NCT01086137|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-08-05|2010-03-11|2010-03-12|Estimate|||||||2013-08-05|2013-08-07|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Biomarkers of Metabolic Syndrome and Prediabetes|Assessing Salivary Biomarkers for Risk Stratification in Metabolic Syndrome|Completed|||102|Actual|West Virginia School of Osteopathic Medicine|||||f||||||||||Samples With DNA|"~     saliva~   "|||2018-05-31 23:59:25.082445|2018-05-31 23:59:25.082445
NCT01086124|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-07-03|2010-03-11|2010-03-12|Estimate|||||||2013-07-03|2013-07-08|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|ROSE||Objective Systolic Function Recuperation Assessed by Echocardiography|Objective Systolic Function Recuperation Assessed by Echocardiography|Completed|||42|Actual|Université de Sherbrooke|||1||f||||f||||||||||2018-05-31 23:59:25.135621|2018-05-31 23:59:25.135621
NCT01086111|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-12-03|2010-03-11|2010-03-12|Estimate|||||||2015-12-03|2015-12-04|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient|Mechanisms of Type 2 Diabetes Improvement, Besides Weightloss After Gastric Bypass|Completed|||30|Actual|University Hospital, Gasthuisberg|||3||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 23:59:25.248401|2018-05-31 23:59:25.248401
NCT01086098|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|PACE30||PACE30: 30 Years in Cardiac Pacing|Trends in Cardiac Pacing - 30 Years of Implants|Unknown status|Active, not recruiting||5000|Anticipated|University of Dundee|||1||f||||f||||||||||2018-05-31 23:59:25.397738|2018-05-31 23:59:25.397738
NCT01086085|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-11-01|2010-03-11|2010-03-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive|A Study on Optimizing the Treatment in HBeAg Positive CHB Patients With Response Guide Treatment (RGT) Method.|Completed||Phase 4|265|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 23:59:25.43913|2018-05-31 23:59:25.43913
NCT01086072|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2018-05-09|2010-03-11|2010-03-12|Estimate|||||||2018-05-09|2018-05-15|Actual|March 1, 2010|Actual|2010-03-01|March 2010|2010-03-31|March 1, 2011|Actual|2011-03-01|March 1, 2011|Actual|2011-03-01||Observational|||Survival Trends in Myocardial Infarction 1994 - 2010|Survival Trends in Myocardial Infarction 1994 - 2010|Completed|||8000|Anticipated|University of Dundee|||2||f||||f||||||||||2018-05-31 23:59:25.649236|2018-05-31 23:59:25.649236
NCT01086059|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2017-03-22|2010-03-11|2010-03-12|Estimate|||||||2017-03-22|2017-03-24|Actual|November 2003||2003-11-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|August 2016|Actual|2016-08-31||Observational|||OTIS Autoimmune Diseases in Pregnancy Project|Humira (Adalimumab) Pregnancy Exposure Registry: OTIS Rheumatoid Arthritis in Pregnancy Project|Active, not recruiting|||554|Anticipated|University of California, San Diego|||4||f||||t||||||||||2018-05-31 23:59:25.715456|2018-05-31 23:59:25.715456
NCT01086046|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-01-18|2010-03-11|2010-03-12|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Study of Blood Clotting After Transcatheter Atrial Septal Defect Closure|A Multicentre, Randomized Controlled Study of Blood Clotting After Transcatheter Atrial Septal Defect Closure|Unknown status|Recruiting|N/A|450|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 23:59:25.788212|2018-05-31 23:59:25.788212
NCT01086033|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2013-07-17||2013-09-24|2010-03-11|2010-03-12|Estimate|2013-09-24|2013-09-26|Estimate||||2013-09-24|2013-09-26|Estimate|May 2006||2006-05-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece|A 3-year Post-marketing Observational Study Following up Patients With Moderate to Severe RA Treated With Humira in Greece|Completed|||566|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:59:25.895812|2018-05-31 23:59:25.895812
NCT01086020|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2011-04-01|2010-03-11|2010-03-12|Estimate|||||||2011-04-01|2011-04-04|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|AEPP||Atorvastatin Plus Ezetimibe on Coronary Plaque Progression|Same Lipid Lowering by Atorvastatin Versus Atorvastatin Plus Ezetimibe on Coronary Plaque Progression|Unknown status|Recruiting|Phase 4|400|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 23:59:26.616775|2018-05-31 23:59:26.616775
NCT01086007|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2015-10-29|2010-03-11|2010-03-12|Estimate|||||||2015-10-29|2015-10-30|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Pain Related Sexual Dysfunction After Laparoscopic Inguinal Hernia Repair|Pain Related Sexual Dysfunction After Laparoscopic Inguinal Hernia Repair|Completed|||1172|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 23:59:26.706213|2018-05-31 23:59:26.706213
NCT01085994|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-10-06|2010-03-11|2010-03-12|Estimate|||||||2010-10-06|2010-10-07|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Observational|||Procalcitonin Monitoring May Decrease Antibiotic Use in the Intensive Care Unit|Procalcitonin-guided Algorithms of Antibiotic Stewardship in the Intensive Care Unit: Systematic Review and Meta-analysis|Unknown status|Enrolling by invitation||||University of Athens|||2||f||||f||||||||||2018-05-31 23:59:26.767986|2018-05-31 23:59:26.767986
NCT01085981|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow|The Quantitative Analysis of Clitoral Blood Before and After a Topically Applied Vasodilating Cream Using Sonographic Doppler Flow Plethysmography|Unknown status|Not yet recruiting|N/A|30|Anticipated|East Suburban Ob Gyn||2|||f||||f||||||||||2018-05-31 23:59:26.856776|2018-05-31 23:59:26.856776
NCT01085968|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2016-07-05||2016-08-16|2010-03-10|2010-03-12|Estimate|2016-08-16|2016-10-11|Estimate||||2016-08-16|2016-10-11|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Multivariate Analysis of Variance was performed to identify differences across groups in baseline characteristics|Cognitive Rehabilitation in Parkinson's Disease|PC-based Rehabilitation of Motor Planning Deficits in Parkinson Disease|Completed||Early Phase 1|54|Actual|VA Office of Research and Development||2|||f||||f||||||||Yes|De-identified individual participant data will be available upon request.|2018-05-31 23:59:26.969917|2018-05-31 23:59:26.969917
NCT01085955|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2016-01-14|2010-03-10|2010-03-12|Estimate|||||||2016-01-14|2016-01-15|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|IPAC||Investigation in Pregnancy Associate Cardiomyopathy|Immune Activation and Myocardial Recovery in Peripartum Cardiomyopathy|Completed|||100|Actual|University of Pittsburgh|||4||f||||t||||||Samples With DNA|"~     Specimens for cellular analysis, complete blood count, DNA banking and genotyping, RNA~     analysis and banking, serum banking and for mediator analysis.~   "|||2018-05-31 23:59:27.33305|2018-05-31 23:59:27.33305
NCT01085942|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2018-01-19|2010-03-11|2010-03-12|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2008||2008-10-31|January 2018|2018-01-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Observational|||Longitudinal Study of Asymptomatic Rotator Cuff Tears|Longitudinal Study of Asymptomatic Rotator Cuff Tears. A Eight Year Follow-up of Symptomatic Status and Tear Characteristics Like Tear Size, Muscle Atrophy and Fatty Degeneration|Completed|||50|Actual|Martina Hansen's Hospital|||1||f||||f||||||||||2018-05-31 23:59:27.430605|2018-05-31 23:59:27.430605
NCT01085929|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|August 2008||2008-08-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses|Ultrasound Guided Needle Drainage Versus Formal Incision and Drainage of Superficial Soft Tissue Abscesses in the Emergency Department Setting|Completed||Phase 3|101|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 23:59:27.496515|2018-05-31 23:59:27.496515
NCT01085916|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Observational|||Prevalence of Asthma and Rhinitis Symptoms Among Secondary School Students in Saudi Arabia|Prevalence of Asthma and Rhinitis Symptoms Among Secondary School Students in Saudi Arabia|Unknown status|Enrolling by invitation||4000|Anticipated|King Abdulaziz Medical City|||||f||||t||||||||||2018-05-31 23:59:27.645619|2018-05-31 23:59:27.645619
NCT01085903|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2016-07-25||2016-10-17|2010-03-11|2010-03-12|Estimate|2016-10-17|2016-10-18|Estimate||||2016-10-17|2016-10-18|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia|Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia|Completed||Phase 2|28|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 23:59:27.722369|2018-05-31 23:59:27.722369
NCT01085890|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Hypertension in Primary Health Care: Lifestyle Change and Blood Pressure Goals|Hypertension in Primary Health Care: Can More Intensive Work With Lifestyle Change Help Patients Achieve Blood Pressure Goals?|Completed||N/A|141|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 23:59:28.075599|2018-05-31 23:59:28.075599
NCT01085877|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2014-06-25|2010-03-11|2010-03-12|Estimate|||||||2014-06-25|2014-06-26|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis|An Open Randomized Two-Way Cross-Over Comparative Bioavailability Study to Compare the Extent of Systemic Absorption of Estradiol After a Single Dose Treatment With Two 25 mcg Estradiol Vaginal Tablet Formulations Administered in Postmenopausal Women With Vaginal Atrophy|Completed||Phase 1|70|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 23:59:28.13905|2018-05-31 23:59:28.13905
NCT01085864|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2017-08-29|2010-03-11|2010-03-12|Estimate|||||||2017-08-29|2017-08-31|Actual|March 2010||2010-03-31|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|Nodule||Biomarkers for Diagnosis of Lung Nodules|Biomarkers for Diagnosis of Lung Nodules|Recruiting|||500|Anticipated|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     Blood specimen, a sputum sample, a urine sample, and an exhaled breath sample.~   "|||2018-05-31 23:59:28.201453|2018-05-31 23:59:28.201453
NCT01085851|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate||||October 2009|2009-10-31||||||||Interventional|||Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Sunburn Related Symptoms|Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Lotion) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Sunburn Related Symptoms|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||t||||||||||2018-05-31 23:59:28.257992|2018-05-31 23:59:28.257992
NCT01085838|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-11-07|2010-03-11|2010-03-12|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Erlotinib in Higher Risk Myelodysplastic Syndrome|Phase I-II Trial of Erlotinib in Higher Risk Myelodysplastic Syndrome|Completed||Phase 1/Phase 2|30|Actual|Groupe Francophone des Myelodysplasies||3|||f||||t||||||||No||2018-05-31 23:59:28.328573|2018-05-31 23:59:28.328573
NCT01085825|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2015-04-15||2016-12-06|2010-03-10|2010-03-12|Estimate|2015-05-20|2015-06-08|Estimate||||2016-12-06|2017-02-01|Estimate|April 2010||2010-04-30|December 2016|2016-12-31||||October 2011|Actual|2011-10-31||Interventional|||Study of the Sensitivity of Manual vs Electric Aspiration to Detect Completed Early Abortion|The Sensitivity of Manual Versus Electric Vacuum Aspiration to Detect Completed Abortion at Less Than Six Weeks of Pregnancy|Completed||N/A|500|Actual|Planned Parenthood of New York City, Inc.||2|||f||||||||||||||2018-05-31 23:59:28.415289|2018-05-31 23:59:28.415289
NCT01085812|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10||2011-12-29|2011-12-29|2010-03-11|2010-03-12|Estimate||||2011-12-29|2012-01-04|Estimate|2011-12-29|2012-01-04|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder|Completed||Phase 3|348|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 23:59:28.597219|2018-05-31 23:59:28.597219
NCT01085448|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2013-11-04|2010-03-10|2010-03-11|Estimate|||||||2013-11-04|2013-11-05|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||Clinical Prediction Rule for Clinical Lumbar Instability|Identifying the Subgroup of Patient With Mechanical Low Back Pain Who Have Clinical Lumbar Instability|Terminated||N/A|20|Actual|Drexel University||1||lack of timely recruitment of subjects|f||||f||||||||||2018-05-31 23:59:34.705248|2018-05-31 23:59:34.705248
NCT01085799|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2011-03-15|2010-03-11|2010-03-12|Estimate|||||||2011-03-15|2011-03-16|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Education Intervention to Reduce Helminth Infections and Absenteeism in Grade 5 School-children|Effectiveness of a Post-deworming Education Intervention to Reduce Soil-transmitted Helminth Infections and Absenteeism in Grade 5 School-children in a Community of Extreme Poverty, Peruvian Amazon|Completed||N/A|1101|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 23:59:28.719856|2018-05-31 23:59:28.719856
NCT01085786|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2011-04-12||2015-09-06|2010-03-11|2010-03-12|Estimate|2011-04-12|2011-05-06|Estimate||||2015-09-06|2015-09-21|Estimate|August 2008||2008-08-31|September 2015|2015-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Sequential and Hybrid Therapies for H Pylori Infection|Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection|Completed||Phase 4|240|Actual|Kaohsiung Veterans General Hospital.|The trial was performed in a single country.|2|||f||||t||||||||||2018-05-31 23:59:29.71156|2018-05-31 23:59:29.71156
NCT01085773|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|February 2005||2005-02-28|January 2005|2005-01-31|December 2007|Actual|2007-12-31|October 2006|Actual|2006-10-31||Interventional|||Effects of Nordic Walking and Exercise on Glucose Metabolism in Type 2 Diabetes Mellitus: A Randomized Controlled Trial|Effects of Nordic Walking and Exercise on Prescription on Glucose Metabolism in Type 2 Diabetes Mellitus: A Randomized Controlled Trial|Completed||Phase 2|68|Actual|Hospital of South West Denmark||3|||f||||f||||||||||2018-05-31 23:59:29.927159|2018-05-31 23:59:29.927159
NCT01085760|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2012-11-02||2013-07-12|2010-03-10|2010-03-12|Estimate|2013-07-12|2013-09-19|Estimate||||2013-07-12|2013-09-19|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|PSC||A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis|A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis|Completed||Phase 1|35|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 23:59:30.007594|2018-05-31 23:59:30.007594
NCT01085747|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2013-08-14|2010-03-11|2010-03-12|Estimate|||||||2013-08-14|2013-08-15|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|May 2015|Anticipated|2015-05-31|May 2013|Actual|2013-05-31||Observational|||Endoscopic Treatment of Biliary Stricture Caused by Chronic Pancreatitis|Covered Self-expandable Metal Stents Versus Multiple Plastic Stents for Benign Biliary Stricture Caused by Chronic Pancreatitis: a Prospective Randomized Study|Unknown status|Active, not recruiting||60|Anticipated|Helsinki University Central Hospital|||2||f||||f||||||||||2018-05-31 23:59:30.408813|2018-05-31 23:59:30.408813
NCT01085734|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2013-04-24||2014-03-13|2010-03-11|2010-03-12|Estimate|2014-03-13|2014-04-21|Estimate||||2014-03-13|2014-04-21|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion|A 6-Month, Single Site, Masked, Randomized,Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion|Completed||Phase 4|30|Actual|Maturi, Raj K., M.D., P.C.||2|||f||||f||||||||||2018-05-31 23:59:30.588247|2018-05-31 23:59:30.588247
NCT01085721|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-10|2010-03-10|2010-03-12|Estimate|||||||2010-03-10|2010-03-12|Estimate||||March 2010|2010-03-31||||||||Interventional|||Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections|Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in the Relief of Allergic Symptoms in Rhinitic Patients With Viral Upper Respiratory Tract Infections and Productive Cough|Unknown status|Not yet recruiting|Phase 3|170|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||t||||||||||2018-05-31 23:59:30.928711|2018-05-31 23:59:30.928711
NCT01085708|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-05-09|2010-03-11|2010-03-12|Estimate|||||||2013-05-09|2013-05-13|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)|A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)|Completed||Phase 1|16|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 23:59:30.997122|2018-05-31 23:59:30.997122
NCT01085695|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-05-09|2010-03-11|2010-03-12|Estimate|||||||2013-05-09|2013-05-13|Estimate|April 2010||2010-04-30|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of E3810 for Healthy Japanese Male (Under Fasting Condition)|A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Fasting Condition)|Completed||Phase 1|16|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 23:59:31.066686|2018-05-31 23:59:31.066686
NCT01085682|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2014-09-08||2014-09-08|2010-03-11|2010-03-12|Estimate|2014-09-08|2014-09-12|Estimate||||2014-09-08|2014-09-12|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program|Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program|Completed||Phase 4|59|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 23:59:31.143139|2018-05-31 23:59:31.143139
NCT01085669|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|May 2012|Anticipated|2012-05-31|December 2011|Anticipated|2011-12-31||Observational|||Infection Rate of Vertical Expandable Prosthetic Titanium Rib Implants (VEPTR)|Infection Rate of VEPTR-Implants in Children With Severe Spinal and Thoracic Deformities|Unknown status|Recruiting||50|Anticipated|Centre Hospitalier Universitaire Vaudois|||1||f||||f||||||||||2018-05-31 23:59:31.317192|2018-05-31 23:59:31.317192
NCT01085656|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2017-08-07|2010-03-11|2010-03-12|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2011||2011-02-28|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS|A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)|Terminated||Phase 1|18|Actual|University of Florida||1|||f||||t|t|f||||||||2018-05-31 23:59:31.411383|2018-05-31 23:59:31.411383
NCT01085643|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2011-06-22||2011-11-08|2010-03-11|2010-03-12|Estimate|2011-11-08|2011-12-12|Estimate||||2011-11-08|2011-12-12|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)|The Effect of Lubiprostone on Patterns of Contractions in the Small Bowel in Female Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)|Completed||N/A|4|Actual|Cedars-Sinai Medical Center|Limited time period resulting in recruitment of only 4 patients.|2|||f||||f||||||||||2018-05-31 23:59:31.496336|2018-05-31 23:59:31.496336
NCT01085630|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2018-01-24|2010-03-11|2010-03-12|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2010||2010-04-30|January 2018|2018-01-31||||July 2017|Actual|2017-07-31||Interventional|||Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy|Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy|Active, not recruiting||Phase 2|68|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 23:59:31.702063|2018-05-31 23:59:31.702063
NCT01085617|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-08-23|2010-03-11|2010-03-12|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2010||2010-01-31|June 2011|2011-06-30||||January 2016|Anticipated|2016-01-31||Interventional|||Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 3|720|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 23:59:32.044651|2018-05-31 23:59:32.044651
NCT01085604|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-08-03|2010-03-10|2010-03-12|Estimate|||||||2015-08-03|2015-08-05|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|||Recurrent Low Back Pain:Linking Mechanisms to Outcomes|Recurrent Low Back Pain:Linking Mechanisms to Outcomes|Completed|||69|Actual|Drexel University|||1||f||||f||||||||||2018-05-31 23:59:32.141402|2018-05-31 23:59:32.141402
NCT01085591|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2015-04-21||2016-08-22|2010-03-10|2010-03-12|Estimate|2015-06-12|2015-06-16|Estimate||||2016-08-22|2016-09-28|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional||All randomized participants who gave proper informed consent.|Study of CB-183,315 in Participants With Clostridium Difficile Infection|A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.|Completed||Phase 2|210|Actual|Cubist Pharmaceuticals LLC||3|||f||||t||||||||||2018-05-31 23:59:32.281179|2018-05-31 23:59:32.281179
NCT01085578|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2013-02-13|2010-03-11|2010-03-12|Estimate|||||||2013-02-13|2013-02-15|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||CG400549 Single Ascending Dose Study|Evaluation of Safety,Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers|Completed||Phase 1|18|Actual|CrystalGenomics, Inc.||3|||f||||f||||||||||2018-05-31 23:59:33.261335|2018-05-31 23:59:33.261335
NCT01085565|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2016-03-07|2010-03-11|2010-03-12|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System|Phase II Study to Evaluate the Safety and Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System|Completed||Phase 2|50|Anticipated|InSightec||1|||f||||f||||||||||2018-05-31 23:59:33.395087|2018-05-31 23:59:33.395087
NCT01085552|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2010-03-11|2010-03-11|2010-03-12|Estimate|||||||2010-03-11|2010-03-12|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta in Healthy Japanese and Caucasian Male Subjects|A Phase I Single Centre Open Label Trial to Investigate the Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta (NeoRecormon®) in Healthy Japanese and Caucasian Male Subjects|Completed||Phase 1|23|Actual|InCROM Europe Clinical Research||1|||f||||f||||||||||2018-05-31 23:59:33.475969|2018-05-31 23:59:33.475969
NCT01085539|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2012-05-02||2014-08-05|2010-03-11|2010-03-12|Estimate|2012-07-31|2012-09-05|Estimate||||2014-08-05|2014-08-07|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||Oxygen Saturation Alarms in the Neonatal Intensive Care Unit|Oxygen Saturation Monitoring in the Neonatal Intensive Care Unit (NICU): An Observational Study of Response to Alarms|Completed|||50|Actual|Medtronic - MITG|The study oximeter's detection could have been 60 seconds before or after the recorded clinical intervention because of sampling bias. There were many desaturations that led to alarms that had no interventions.||||f||||f||||||||||2018-05-31 23:59:33.538255|2018-05-31 23:59:33.538255
NCT01085526|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-02-16|2010-03-11|2010-03-12|Estimate|||||||2015-02-16|2015-02-18|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis|Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Patients With Allergic Rhinitis Due to Grass Pollen Allergy - a Prospective Randomized Controlled Study|Completed||N/A|30|Actual|Aarhus University Hospital||3|||f||||t||||||||||2018-05-31 23:59:33.779228|2018-05-31 23:59:33.779228
NCT01085513|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|2014-02-25||2014-05-21|2010-03-11|2010-03-12|Estimate|2014-05-21|2014-06-23|Estimate||||2014-05-21|2014-06-23|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional||no analysis has been performd since study was premature terminated|Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy|Intestinal Motility Evaluation by Endoluminal Image Analysis Using Capsule Endoscopy (CE-EIA): a Multi-center Clinical Trial|Terminated||Phase 2|143|Actual|Given Imaging Ltd.||2|||f||||f||||||||||2018-05-31 23:59:33.893431|2018-05-31 23:59:33.893431
NCT01085500|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2011-05-16||2016-09-26|2010-03-11|2010-03-12|Estimate|2011-05-16|2011-06-10|Estimate||||2016-09-26|2016-10-28|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||Mastery Learning Inguinal Hernia Repair|Mastery Learning Totally Extraperitoneal Inguinal Hernia Repair: Linking Surgical Simulation to Patient Level Outcomes|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 23:59:34.20112|2018-05-31 23:59:34.20112
NCT01085487|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2012-04-09|2010-03-11|2010-03-12|Estimate|||||||2012-04-09|2012-04-10|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|June 2011|Actual|2011-06-30|||||Observational|||MiCo - Mirena or Conventional Medical Treatment for Menorrhagia|MiCo - Mirena or Conventional Medical Treatment for Menorrhagia (MA0901)|Completed|||1211|Actual|Bayer|||3||f||||f||||||None Retained|"~     n.a.~   "|||2018-05-31 23:59:34.47799|2018-05-31 23:59:34.47799
NCT01085474|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-11|||2013-01-25|2010-03-11|2010-03-12|Estimate|||||||2013-01-25|2013-01-28|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient|Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient|Completed|||384|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 23:59:34.57436|2018-05-31 23:59:34.57436
NCT01085461|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2012-03-01|2010-03-10|2010-03-11|Estimate|||||||2012-03-01|2012-03-05|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|||||Observational|ASERT||Assessment of Suicidality in Epilepsy - Rating Tools|Assessment of Suicidality in Epilepsy - Rating Tools|Completed|||200|Anticipated|The Epilepsy Study Consortium|||||f||||f||||||||||2018-05-31 23:59:34.642371|2018-05-31 23:59:34.642371
NCT01085435|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2018-03-20|2010-03-10|2010-03-11|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2010|Actual|2010-10-31|August 2017|2017-08-31|December 2023|Anticipated|2023-12-31|November 24, 2019|Anticipated|2019-11-24||Observational|EFFORTLESS||Boston Scientific Post Market S-ICD Registry|Evaluation oF Factors ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD (The EFFORTLESS S-ICD Registry)|Enrolling by invitation|||1000|Anticipated|Boston Scientific Corporation|||1||f||||t|f|t|f|f|t|||||2018-05-31 23:59:34.776645|2018-05-31 23:59:34.776645
NCT01085422|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2017-11-17|2010-03-10|2010-03-11|Estimate|||||||2017-11-17|2017-11-21|Actual|April 2010||2010-04-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer|A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies|Completed||Phase 1|35|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 23:59:34.946876|2018-05-31 23:59:34.946876
NCT01085409|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2013-05-06|2010-03-10|2010-03-11|Estimate|||||||2013-05-06|2013-05-07|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|MOMENTUM||The Q in the Quality Adjusted Life Years (QALY): Exploring New Methods|The Q in the QALY: Exploring New Methods|Completed|||139|Actual|Maastricht University Medical Center|||4||f||||f||||||||||2018-05-31 23:59:35.019505|2018-05-31 23:59:35.019505
NCT01085396|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-05-26|2010-03-10|2010-03-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin|Optical Spectroscopy for Non-invasive Diagnosis of Melanoma and Assessment of Impact of UV Exposure on Skin|Terminated|||16|Actual|University of Pittsburgh||||Ran out of funding|f||||t||||||Samples With DNA|"~     A pigmented lesion is removed as part of the subjects routine care when it is felt to be~     suspicious for severe atypica or early malignancy, and sometimes because the patient desires~     removal of lesions for cosmetic reasons, or because the lesion is irritated or located in a~     zone of traum.~      For this research study, samples of the tumor tissue from these clinical care biopsies will~     be studied.~      Researchers will look at markers and search for additional characteristics that may help them~     better understand Melanoma. This will be optional to subjects. If subjects do not agree to~     have their tissue kept for future research purposes they can still participate in the rest of~     this study.~   "|||2018-05-31 23:59:35.083011|2018-05-31 23:59:35.083011
NCT01085383|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2015-05-27|2010-03-10|2010-03-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|APS||Aripiprazole and Prolactin Study|Aripiprazole Treatment for Antipsychotic Induced Hyperprolactinaemia in Patients With Severe Mental Illness and Learning Disabilities|Completed||Phase 4|15|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 23:59:35.138316|2018-05-31 23:59:35.138316
NCT01085370|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2014-03-17|2010-03-10|2010-03-11|Estimate|||||||2014-03-17|2014-03-18|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|PICARTA-B||Psychological Interventions in Children After Road Traffic Accidents or Burns|Psychological Interventions in Children After Road Traffic Accidents or Burns: a Randomized Controlled Study|Completed||N/A|108|Actual|University Children's Hospital, Zurich||2|||f||||f||||||||||2018-05-31 23:59:35.197665|2018-05-31 23:59:35.197665
NCT01085357|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2016-08-25|2016-02-24|2017-05-12|2010-03-10|2010-03-11|Estimate|2016-08-25|2016-10-20|Estimate|2016-02-24|2016-03-24|Estimate|2017-05-12|2017-05-15|Actual|September 2009||2009-09-30|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|COMPASS|All randomized participants (Intent-to-Treat)|Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery|A Prospective, Randomized, Comparative, MultiCenter Clinical Study to Assess the Safety and Effectiveness of the Transcend CyPass Glaucoma Implant in Patients With Open Angle Glaucoma Undergoing Cataract Surgery|Completed||N/A|897|Actual|Alcon Research||2|||f||||t||||||||||2018-05-31 23:59:35.323327|2018-05-31 23:59:35.323327
NCT01085344|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2015-06-04|2010-03-10|2010-03-11|Estimate|||||||2015-06-04|2015-06-08|Estimate|July 1997||1997-07-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|CHPS||Canadian Hemophilia Prophylaxis Study|Moderate Term Musculoskeletal Outcomes With Escalating Dose Prophylaxis: the Canadian Hemophilia Prophylaxis Study Follow-up Study|Completed||Phase 4|56|Actual|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 23:59:35.719494|2018-05-31 23:59:35.719494
NCT01085331|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2016-08-24||2016-08-24|2010-03-10|2010-03-11|Estimate|2016-08-24|2016-10-19|Estimate||||2016-08-24|2016-10-19|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||The safety analysis set included all subjects who received at least one (non-zero) administration of the trial medication (any of the 3 FOLFIRI drugs and pimasertib).|MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)|A Double-blind, Randomized, Comparative, Multicenter, Exploratory, and Placebo-controlled Phase II Trial of FOLFIRI Plus MSC1936369B or Placebo With a Safety run-in Part as Second-line Treatment of Metastatic K Ras Mutated Colorectal Cancer Subjects|Terminated||Phase 1/Phase 2|16|Actual|EMD Serono|During the trial, the decision was made not to perform the Phase 2 part of the study due to the achieved MTD for pimasertib (45mg/day) in combination with FOLFIRI, so that no further dose escalation was possible as per the protocol.|3||"Conduct the randomized Phase 2 part not recommended due to the achieved MTD for pimasertib~   (45mg/day) in combination with FOLFIRI"|f||||f||||||||||2018-05-31 23:59:35.884225|2018-05-31 23:59:35.884225
NCT01085318|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2013-02-11||2018-01-25|2010-03-10|2010-03-11|Estimate|2013-04-30|2013-05-03|Estimate||||2018-01-25|2018-02-23|Actual|June 30, 2010|Actual|2010-06-30|January 2018|2018-01-31|March 31, 2012|Actual|2012-03-31|February 29, 2012|Actual|2012-02-29||Interventional|||Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial|A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group|Completed||Phase 4|38|Actual|EMD Serono||2|||f||||||||||||||2018-05-31 23:59:36.636575|2018-05-31 23:59:36.636575
NCT01085305|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2016-09-14|2010-03-10|2010-03-11|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2006||2006-09-30|September 2016|2016-09-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||The Effectiveness of Parent-Child Interaction Therapy (PCIT)|The Effectiveness of Parent-Child Interaction Therapy (PCIT) in Treating Behavior Problems in Young Children|Completed||N/A|63|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 23:59:37.022714|2018-05-31 23:59:37.022714
NCT01085292|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2013-02-12|2010-03-10|2010-03-11|Estimate|||||||2013-02-12|2013-02-13|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus|NOX-E36 - A Phase Ib, Multiple Intravenous Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties in Healthy Subjects and Then in Three Groups of Patients With Type 2 Diabetes Mellitus to Compare Three Ascending Dose Regimens in a Double-blind and Placebo-controlled Manner|Completed||Phase 1/Phase 2|47|Actual|NOXXON Pharma AG||2|||f||||t||||||||||2018-05-31 23:59:37.109065|2018-05-31 23:59:37.109065
NCT01085279|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Fractional Laser as Treatment Option for Various Pigment Disorders (Fractional-3)|Non-ablative 1,550 nm Fractional Laser Therapy Versus Triple Topical Therapy for the Treatment of Melasma: a Randomized Controlled Split-face Study|Completed||Phase 2|29|Actual|Netherlands Institute for Pigment Disorders||2|||f||||t||||||||||2018-05-31 23:59:37.189652|2018-05-31 23:59:37.189652
NCT01085266|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10||2016-10-11|2016-10-11|2010-03-10|2010-03-11|Estimate||||2016-10-11|2016-10-12|Estimate|2016-10-11|2016-10-12|Estimate|February 2010||2010-02-28|October 2016|2016-10-31||||June 2011|Actual|2011-06-30||Interventional|HORIZON PLUS||An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease|HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease|Terminated||Phase 3|362|Actual|Medivation, Inc.||1|||f||||||||||||||2018-05-31 23:59:37.300694|2018-05-31 23:59:37.300694
NCT01085253|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2012-09-27|2010-03-10|2010-03-11|Estimate|||||||2012-09-27|2012-09-28|Estimate|April 2010||2010-04-30|January 2012|2012-01-31||||||||Observational|Nucleipark||Nucleipark:High Field MR Imaging (7T and 3T) of the Brainstem, the Deep Nuclei and Their Connections in the Parkinsonian Syndromes. Applications to Prognosis, Pathophysiology and Improvement of Therapeutic Strategies|High Field MR Imaging (7T and 3T) of the Brainstem, the Deep Nuclei and Their Connections in the Parkinsonian Syndromes. Applications to Prognosis, Pathophysiology and Improvement of Therapeutic Strategies|Unknown status|Recruiting||85|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||f||||||||||2018-05-31 23:59:37.369083|2018-05-31 23:59:37.369083
NCT01085240|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2017-04-25|2010-03-10|2010-03-11|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2008||2008-09-30|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Getting on With the Rest of Your Life After a Stroke|Getting on With the Rest of Your Life After Stroke: A Cross-Canada Program Aimed at Enhanced Life Participation, Prevention of Deterioration and Optimization of Health Care Utilization|Completed||N/A|240|Actual|McGill University||2|||f||||f||||||||||2018-05-31 23:59:37.561089|2018-05-31 23:59:37.561089
NCT01085227|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2012-09-26|2010-03-10|2010-03-11|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2008||2008-04-30|January 2012|2012-01-31||||||||Observational|LRRK2||Clinical, Molecular and by Neuroimaging of LRRK2 Mutations|Clinical, Molecular and by Neuroimaging Characterization of Monogenic Forms of Parkinsonism Syndromes: Mutations of the LRRK2 Gene.|Unknown status|Recruiting||50|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||||||2018-05-31 23:59:37.691638|2018-05-31 23:59:37.691638
NCT01085214|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2015-07-24||2015-07-24|2010-03-10|2010-03-11|Estimate|2015-07-24|2015-08-19|Estimate||||2015-07-24|2015-08-19|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||All participants enrolled.|AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma|A Phase 2 Study of AZD6244 in Multiple Myeloma|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 23:59:37.831464|2018-05-31 23:59:37.831464
NCT01085201|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2013-05-02||2014-02-05|2010-03-10|2010-03-11|Estimate|2014-02-05|2014-03-07|Estimate||||2014-02-05|2014-03-07|Estimate|April 2010||2010-04-30|February 2014|2014-02-28|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||The number of participants was determined per protocol following a 3+3 design. In Stages 2b and 4, we received permission from the FDA, IRB, and DSMB to study only 3 subjects because we did not observe any prior DLT. One patient enrolled in Stage 2b withdrew consent during the infusion due to an unrelated toothache, and was excluded from analysis.|Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease|Safety of Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease|Completed||Phase 1|39|Actual|Dana-Farber Cancer Institute|The highest dose we examined (dose level 2, 1.44 mcg/kg/hr) may not be the maximally tolerated dose. No toxicities definitely or probably attributable to the drug occurred, so it is possible that there is a higher dose that can be tolerated safely.|5|||f||||t||||||||||2018-05-31 23:59:38.202772|2018-05-31 23:59:38.202772
NCT01085188|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|January 2003||2003-01-31|March 2010|2010-03-31||||January 2008|Actual|2008-01-31||Interventional|||Effectiveness of Assertive Continuing Care for Youth||Completed||Phase 3|342|Actual|Chestnut Health Systems||4|||f||||||||||||||2018-05-31 23:59:38.680128|2018-05-31 23:59:38.680128
NCT01085175|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2015-10-12|2010-03-10|2010-03-11|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|LMI1195-201||Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing|A Multicenter, Phase II, Open Label Trial to Determine Optimal Imaging Parameters and Assess the Safety of LMI 1195 in Low Risk Patients and Heart Failure Patients With a History of Firing of an Implantable Cardioverter-Defibrillator|Withdrawn||Phase 2|0|Actual|Lantheus Medical Imaging||2||Sponsor is re-evaluating the clinical development path|f||||t||||||||||2018-05-31 23:59:38.765054|2018-05-31 23:59:38.765054
NCT01085162|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2013-04-02|2010-03-10|2010-03-11|Estimate|||||||2013-04-02|2013-04-04|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)|An Open-Label Prospective, Non-Randomized, International, Multi-center, Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) in Patients Suspected of Coronary Artery Disease (CAD)|Withdrawn|||0|Actual|Lantheus Medical Imaging|||||f||||t||||||||||2018-05-31 23:59:38.839866|2018-05-31 23:59:38.839866
NCT01085149|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|May 2010||2010-05-31|March 2010|2010-03-31||||October 2010|Anticipated|2010-10-31||Interventional|||The Effect Of Simvastatin On Bone Remodeling In Socket Of Mandibular Teeth||Unknown status|Not yet recruiting|N/A|20|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 23:59:38.911197|2018-05-31 23:59:38.911197
NCT01085136|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2014-10-01||2017-02-15|2010-03-10|2010-03-11|Estimate|2014-10-01|2014-10-03|Estimate||||2017-02-15|2017-04-04|Actual|February 2010||2010-02-28|February 2017|2017-02-28|January 2016|Actual|2016-01-31|October 2013|Actual|2013-10-31||Interventional||Treated set, i.e. all patients who were documented to have taken at least 1 dose of afatinib 50 mg in Part A of the trial and all patients who received at least 1 dose of trial medication in Part B.|LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib|Phase III Randomized Trial of BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Previous Erlotinib or Gefitinib Treatment (LUX Lung 5)|Completed||Phase 3|1154|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:59:39.120996|2018-05-31 23:59:39.120996
NCT01085123|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-11-02|2010-03-10|2010-03-11|Estimate|||||||2010-11-02|2010-11-03|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers|An Open Label, Positron Emission Tomography (PET) Study With [11C]AZ10419369 to Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers|Completed||Phase 1|10|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 23:59:40.837668|2018-05-31 23:59:40.837668
NCT01085110|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2012-05-29|2010-03-10|2010-03-11|Estimate|||||||2012-05-29|2012-05-30|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|||Persistent Pain After Laparoscopic Inguinal Hernia Repair|Neurophysiological Characterization of Persistent Pain After Laparoscopic Inguinal Hernia Repair|Completed|||11|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 23:59:40.949605|2018-05-31 23:59:40.949605
NCT01085097|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04||2014-02-12|2016-07-20|2010-03-09|2010-03-11|Estimate||||2014-02-12|2014-03-14|Estimate|2016-07-20|2016-07-22|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids)|Completed||Phase 2|47|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 23:59:41.015071|2018-05-31 23:59:41.015071
NCT01085084|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09||2013-09-23|2016-07-18|2010-03-09|2010-03-11|Estimate||||2013-09-23|2013-10-01|Estimate|2016-07-18|2016-07-20|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus Arthritis|Completed||Phase 2|82|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-05-31 23:59:41.175871|2018-05-31 23:59:41.175871
NCT01085071|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2013-01-18|2010-03-10|2010-03-11|Estimate|||||||2013-01-18|2013-01-21|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|GRIP-COMPASS||Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients|GRIP-COMPASS Trial: Computer-driven Glucose and Potassium Regulation Program in Intensive Care Patients With COMparison of PotASSium Targets Within normokAlemic Range|Completed||Phase 4|1225|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 23:59:41.308133|2018-05-31 23:59:41.308133
NCT01085058|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|May 2003||2003-05-31|March 2010|2010-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|CU01||"Predictive Value of the Cytocapacity Test Patients With Lymphoproliferative Diseases and High-dose Therapy"|"Predictive Value of the Cytocapacity Test Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy"|Completed||Phase 2/Phase 3|169|Actual|WiSP Wissenschaftlicher Service Pharma GmbH||1|||f||||f||||||||||2018-05-31 23:59:41.44529|2018-05-31 23:59:41.44529
NCT01085045|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2016-05-24|2012-09-11|2017-03-14|2010-03-09|2010-03-11|Estimate|2017-03-14|2017-04-26|Actual|2012-09-11|2012-09-13|Estimate|2017-03-14|2017-04-26|Actual|March 2010||2010-03-31|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Analysis Population included all randomized participants. 118 plus 4 sentinel patients to make 122.|Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (7 Days), Four-Period, Eight-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Two Doses of PT003, Two Doses of PT005 and One Dose of PT001 in Patients With Moderate to Very Severe COPD, Compared With Foradil® Aerolizer® (12 μg, Open-Label) and Spiriva® Handihaler® (18 μg, Open-Label) as Active Controls|Completed||Phase 2|118|Actual|Pearl Therapeutics, Inc.||8|||f||||f||||||||||2018-05-31 23:59:41.602289|2018-05-31 23:59:41.602289
NCT01085032|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|August 2006||2006-08-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Nicotine Patch Trial in Syrian Primary Care Settings|Transdermal Nicotine Therapy as an Adjunct to Behavioral Smoking Cessation Counseling in Syrian Primary Care Settings|Completed||Phase 2|269|Actual|University of Memphis||2|||f||||t||||||||||2018-05-31 23:59:43.128052|2018-05-31 23:59:43.128052
NCT01085019|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2012-06-26|2010-03-09|2010-03-11|Estimate|||||||2012-06-26|2012-06-28|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Impact of Spices and Herbs on Endothelial Function|Investigation of the Impact of Spices and Herbs on Endothelial Function and Other CVD Risk Factors in Men and Women.|Completed||N/A|224|Actual|Laval University||6|||f||||f||||||||||2018-05-31 23:59:43.230598|2018-05-31 23:59:43.230598
NCT01085006|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|2011-01-02||2011-01-02|2010-03-10|2010-03-11|Estimate|2011-01-02|2011-01-25|Estimate||||2011-01-02|2011-01-25|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery|The Effect of Tranexamic Acid Administration on Postpartum Hemorrhage During and After Cesarean Delivery|Completed||Phase 1/Phase 2|100|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 23:59:43.358934|2018-05-31 23:59:43.358934
NCT01084993|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2018-01-29|2010-03-10|2010-03-11|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2010||2010-03-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|EASY-B2B||EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding|EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding: Bivalirudin to Reduce Bleeding EASY-B2B Study|Recruiting||Phase 4|2000|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 23:59:43.571511|2018-05-31 23:59:43.571511
NCT01084980|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2011-08-12|2010-03-10|2010-03-11|Estimate|||||||2011-08-12|2011-08-16|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|MCNS||Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome|A Pilot Study for Comparative Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap®) in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome|Completed||Phase 2/Phase 3|20|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 23:59:43.70662|2018-05-31 23:59:43.70662
NCT01084967|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2016-04-25|2010-03-10|2010-03-11|Estimate|||||||2016-04-25|2016-04-26|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|GOCY||Genetics of Obesity in Chinese Youngs|Study of Clinical Characteristics and Genetic Susceptibility in Chinese Obese Youngs|Recruiting|||3000|Anticipated|Shanghai Jiao Tong University School of Medicine|||2||f||||f||||||Samples With DNA|"~     Whole blood,fasting serum and morning urine~   "|||2018-05-31 23:59:43.803138|2018-05-31 23:59:43.803138
NCT01084954|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2016-06-15|2010-03-10|2010-03-11|Estimate|||||||2016-06-15|2016-06-16|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection|Validation of a Simple and Cost-Effective Nucleic Acid Test for HIV Detection|Completed|||153|Actual|George Washington University|||||f||||f||||||||No||2018-05-31 23:59:43.906488|2018-05-31 23:59:43.906488
NCT01084941|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2013-11-20|2010-03-10|2010-03-11|Estimate|||||||2013-11-20|2013-11-21|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Lifestyle Intervention to Limit Excessive Weight Gain During Pregnancy in Minority Women|Lifestyle Intervention to Limit Excessive Weight Gain During Pregnancy in Minority Women|Completed||Phase 4|57|Actual|Emory University||2|||f||||t||||||||||2018-05-31 23:59:43.969253|2018-05-31 23:59:43.969253
NCT01084928|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2013-09-24|2010-03-09|2010-03-11|Estimate|||||||2013-09-24|2013-09-25|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SHAPE||A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians|A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians|Completed||N/A|16|Actual|Emory University||1|||f||||t||||||||||2018-05-31 23:59:44.030798|2018-05-31 23:59:44.030798
NCT01084915|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2014-03-05|2010-03-10|2010-03-11|Estimate|||||||2014-03-05|2014-03-06|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|ROS||The Results and Outcomes of the Modified Swedish Adjustable Gastric Band (SAGB-VC)|The Results and Outcomes of the SAGB-VC in a High Volume Bariatric Centre|Completed|||840|Actual|Rijnstate Hospital|||1||f||||f||||||||||2018-05-31 23:59:44.101268|2018-05-31 23:59:44.101268
NCT01084902|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Efficacy Comparison of Xalatan and Azopt on POAG and OH|Comparison of the Effects of Latanoprost(0.005%) and Brinzolamide(1.0%) on Intraocular Pressure in Primary Open-angle Glaucoma and Ocular Hypertension|Unknown status|Active, not recruiting|N/A|130|Actual|Peking University First Hospital||2|||f||||||||||||||2018-05-31 23:59:44.154901|2018-05-31 23:59:44.154901
NCT01084889|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2017-06-22|2010-03-10|2010-03-11|Estimate|||||||2017-06-22|2017-06-23|Actual|April 2010|Actual|2010-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|January 2014|Actual|2014-01-31||Observational|||Anterior Pelvic Prolapse Reconstruction With TiLOOP® Total 6|National, Multicentre Post-marketing Surveillance Study on Anterior Pelvic Prolapse Reconstruction With Titanium-coated Polypropylene Mesh (TiLOOP® Total 6)|Completed|||292|Actual|pfm medical ag|||1||f||||t||||||||No||2018-05-31 23:59:44.213218|2018-05-31 23:59:44.213218
NCT01084876|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2015-02-11|2010-03-09|2010-03-11|Estimate|||||||2015-02-11|2015-02-12|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2011|Actual|2011-12-31||Interventional|Compare||Demonstrate Efficacy and Safety of Metastatic Breast Cancer|Double-blind, Randomised, Parallel Group, Phase III Study|Unknown status|Active, not recruiting|Phase 3|383|Actual|Celltrion||2|||f||||t||||||||||2018-05-31 23:59:44.284699|2018-05-31 23:59:44.284699
NCT01084863|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2015-02-11|2010-03-09|2010-03-11|Estimate|||||||2015-02-11|2015-02-12|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2011|Actual|2011-12-31||Interventional|Compare||Evaluate Safety, Efficacy and Pharmacokinetics|Double-blind Randomised Phase I/IIb Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|174|Actual|Celltrion||2|||f||||t||||||||||2018-05-31 23:59:44.398508|2018-05-31 23:59:44.398508
NCT01084850|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Observational|||Corneal Endothelium Morphology and Central Thickness in Type II Diabetes Mellitus and Normal Subjects|Corneal Endothelium Morphology and Central Thickness in Type II Diabetes Mellitus and Normal Subjects|Unknown status|Recruiting||300|Anticipated|Frederiksberg University Hospital|||2||f||||f||||||||||2018-05-31 23:59:44.473462|2018-05-31 23:59:44.473462
NCT01084837|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2015-09-16|2010-03-10|2010-03-11|Estimate|||||||2015-09-16|2015-09-17|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional|RENVEL||Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure|A National, Multicentric, Open-label Study of Induction Treatment With VELCADE and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure|Completed||Phase 2|60|Actual|PETHEMA Foundation|||||f||||t||||||||||2018-05-31 23:59:44.564574|2018-05-31 23:59:44.564574
NCT01084824|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2010-03-10|2010-03-10|2010-03-11|Estimate|||||||2010-03-10|2010-03-11|Estimate|June 2007||2007-06-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin|A Randomized Clinical Trial Examining the Efficacy of Treatment of Cutaneous Verruca Vulgaris in Adult Patients With Combined Liquid Nitrogen Cryotherapy and Topically Applied Cantharidin|Completed||N/A|70|Actual|North Idaho Dermatology||2|||f||||||||||||||2018-05-31 23:59:44.63677|2018-05-31 23:59:44.63677
NCT01084811|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2011-07-06|2010-03-10|2010-03-11|Estimate|||||||2011-07-06|2011-07-07|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Chronic Rhinosinusitis: Biochemical Markers and Biofilm||Unknown status|Recruiting||230|Anticipated|University Hospital, Akershus|||3||f||||f||||||Samples With DNA|"~     Nasal mucosa and nasal polyps~   "|||2018-05-31 23:59:44.701304|2018-05-31 23:59:44.701304
NCT01084798|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2014-07-30|2010-03-10|2010-03-11|Estimate|||||||2014-07-30|2014-07-31|Estimate|August 2008||2008-08-31|March 2010|2010-03-31|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Observational|||A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years|A Retrospective Study On The Management of Multiple Sclerosis (MS) Over The Last 10 Years|Completed|||123|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 23:59:44.763583|2018-05-31 23:59:44.763583
NCT01084785|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-10|||2016-05-23|2010-03-10|2010-03-11|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2003||2003-01-31|May 2016|2016-05-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|Biobank||Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer|Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic|Recruiting|||10000|Anticipated|Maastricht Radiation Oncology|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 23:59:44.811945|2018-05-31 23:59:44.811945
NCT01084772|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-09-22|2010-03-09|2010-03-10|Estimate|||||||2016-09-22|2016-09-23|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Visionaire™ Versus Standard Instrumentation Safety and Efficacy in Total Knee Arthroplasty (TKA)|A Multicenter, Randomized, Clinical Outcome of VISIONAIRE™ Patient Matched Technology vs. Standard Surgical Instrumentation in Total Knee Arthroplasty|Terminated||N/A|196|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-05-31 23:59:44.885524|2018-05-31 23:59:44.885524
NCT01084759|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2015-12-17||2016-04-05|2010-03-09|2010-03-10|Estimate|2016-04-05|2016-05-09|Estimate||||2016-04-05|2016-05-09|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer|A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer|Completed||N/A|16|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||Undecided||2018-05-31 23:59:44.952392|2018-05-31 23:59:44.952392
NCT01084746|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2018-05-03|2010-03-09|2010-03-10|Estimate|||||||2018-05-03|2018-05-10|Estimate|January 2005||2005-01-31|May 2018|2018-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|PCCaSO||Tailored Interactive Intervention to Increase CRCS|Tailored Interactive Intervention to Increase CRCS|Completed||N/A|1224|Actual|The University of Texas Health Science Center, Houston||3|||f||||t||||||||||2018-05-31 23:59:45.197106|2018-05-31 23:59:45.197106
NCT01084733|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2017-07-05|2010-03-09|2010-03-10|Estimate|||||||2017-07-05|2017-07-06|Actual|August 2007||2007-08-31|July 2017|2017-07-31||||November 15, 2019|Anticipated|2019-11-15||Observational|||Nicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer|Correlative Study of Nicotine Levels With Response Rates to Therapy Using Radiation Alone or in Combination With Chemotherapy in Head and Neck Cancer|Active, not recruiting|||114|Actual|University of Kentucky|||||f||||t||||||Samples Without DNA|"~     Blood will be obtained weekly during the treatment phase. Serum will be collected and~     aliquoted into eppendorf tubes. Serum samples will be stored in -20C freezer until assayed~     for cotinine levels using Immulite immunoassay for cotinine (Immulite 2000 Assay, DPC, United~     States, Technical Services 800-372-1782).~   "|||2018-05-31 23:59:46.246083|2018-05-31 23:59:46.246083
NCT01084720|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|December 2002||2002-12-31|March 2010|2010-03-31|December 2003|Actual|2003-12-31|||||Interventional|||Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients With Uremic Xerosis|Efficacy, Local Tolerance and Patient Acceptability of a Moisturizing Emollient in Patients Undergoing Maintenance Renal Dialysis With Uremic Xerosis (MRD)|Completed||Phase 3|100|Actual|Orfagen|||||f||||f||||||||||2018-05-31 23:59:46.301749|2018-05-31 23:59:46.301749
NCT01084707|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2010-04-16||2012-07-06|2010-03-09|2010-03-10|Estimate|2010-10-01|2010-10-19|Estimate||||2012-07-06|2012-07-13|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product.|Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product. A Study in Healthy Smokers.|Completed||N/A|40|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||5|||f||||f||||||||||2018-05-31 23:59:46.371734|2018-05-31 23:59:46.371734
NCT01084694|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2018-03-27|2010-03-09|2010-03-10|Estimate|||||||2018-03-27|2018-03-29|Actual|April 19, 2010|Actual|2010-04-19|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|September 29, 2017|Actual|2017-09-29||Observational|||Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant|The Impact of Hematopoeitic Stem Cell Transplantation on Primary Caregiver Level of Burden and Distress|Active, not recruiting|||100|Actual|Northside Hospital, Inc.|||||f||||f||||||||||2018-05-31 23:59:46.741956|2018-05-31 23:59:46.741956
NCT01084681|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2011-06-07|2010-03-09|2010-03-10|Estimate|||||||2011-06-07|2011-06-08|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Efficacy Trial of Intracranial Aneurysm Treatment Using Two Different Endovascular Techniques|Multicenter Randomized Trial on Selective Endovascular Aneurysm Occlusion With Coils Versus Parent Vessel Reconstruction Using the SILK Flow Diverter (MARCO POLO Post-Market Clinical Investigation)|Unknown status|Recruiting|N/A|160|Anticipated|Balt International||2|||f||||f||||||||||2018-05-31 23:59:46.812759|2018-05-31 23:59:46.812759
NCT01084668|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|2012-04-26||2012-06-25|2010-03-09|2010-03-10|Estimate|2012-04-26|2012-05-30|Estimate||||2012-06-25|2012-06-29|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|QUALITY||Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs|A Post-marketing Observational Study of the Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic DMARDs Over a Period of 1 Year (QUALITY)|Completed|||46|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:59:46.99335|2018-05-31 23:59:46.99335
NCT01084655|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09||2016-03-04|2016-03-04|2010-03-09|2010-03-10|Estimate||||2016-03-04|2016-04-04|Estimate|2016-03-04|2016-04-04|Estimate|July 2010||2010-07-31|March 2016|2016-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer|An Open-label Phase 1/2 Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 1/Phase 2|38|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 23:59:47.282364|2018-05-31 23:59:47.282364
NCT01084642|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2017-07-05|2010-03-09|2010-03-10|Estimate|||||||2017-07-05|2017-07-06|Actual|March 4, 2010|Actual|2010-03-04|April 2017|2017-04-30|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Observational|||Female Cancer Patients' Preference For Sexual Health Interventions|A Pilot Study Surveying Female Cancer Patients' Preference For Sexual Health Interventions|Completed|||229|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 23:59:47.356933|2018-05-31 23:59:47.356933
NCT01084629|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2017-08-02|2010-03-09|2010-03-10|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2010||2010-01-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||The Role of the Fujinon Intelligent Chromo Endoscopy (FICE™) in Barrett's Esophagus|The Role of the Fujinon Intelligent Chromo Endoscopy (FICE™) for the Detection of Dysplasia in Barrett's Esophagus and in Post Ablation Barrett's Esophagus|Suspended|||150|Anticipated|Mayo Clinic|||2|"This voluntary action is being taken by Fujinon in response to an inquiry by the US FDA~   regarding the potential use of FICE"|f||||f||||||||||2018-05-31 23:59:47.413698|2018-05-31 23:59:47.413698
NCT01084616|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-12-16|2010-03-09|2010-03-10|Estimate|||||||2010-12-16|2010-12-17|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Vaginal Microbiota Among Postmenopausal Women|The Role of Vaginal Microbiota in Symptoms of Vaginal Dryness in Postmenopausal Women|Completed|||16|Actual|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 23:59:47.488135|2018-05-31 23:59:47.488135
NCT01084603|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2010-04-16||2012-07-06|2010-03-09|2010-03-10|Estimate|2010-06-10|2010-07-08|Estimate||||2012-07-06|2012-07-13|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product|Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product. A Study in Healthy Smokers|Completed||N/A|45|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||5|||f||||f||||||||||2018-05-31 23:59:47.571461|2018-05-31 23:59:47.571461
NCT01084590|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2015-03-25|2010-03-09|2010-03-10|Estimate|||||||2015-03-25|2015-03-27|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|HHHK_5-9||Healthy Homes/Healthy Kids_5-9|Healthy Homes/Healthy Kids: Pediatric Primary Care-based Obesity Prevention|Completed||N/A|421|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 23:59:47.932786|2018-05-31 23:59:47.932786
NCT01084577|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2011-02-17|2010-03-09|2010-03-10|Estimate|||||||2011-02-17|2011-02-21|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers|A Prospective, Multi-centre, Randomized, Open-label, Parallel, Comparative Study to Evaluate Effects of AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers|Completed||Phase 4|266|Anticipated|ConvaTec Inc.||2|||f||||||||||||||2018-05-31 23:59:48.018107|2018-05-31 23:59:48.018107
NCT01084564|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|EconoHeart||Economic Evaluation of Heart Failure Management in Colombian Clinics|Economic Evaluation of Heart Failure Management in Colombian Clinics|Completed|||300|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 23:59:48.263718|2018-05-31 23:59:48.263718
NCT01084551|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2014-02-03||2014-05-28|2010-03-08|2010-03-10|Estimate|2014-05-28|2014-06-05|Estimate||||2014-05-28|2014-06-05|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)|A Phase 3 Multi-Center, Placebo-Controlled, Double Blind, 3-Armed Parallel Group, Comparative Study of SPM 962 4.5 and 6.75 mg/Day to Investigate Superiority to Placebo in Patients With Restless Legs Syndrome|Completed||Phase 3|284|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 23:59:48.354513|2018-05-31 23:59:48.354513
NCT01084538|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2011-06-30||2011-09-19|2010-03-09|2010-03-10|Estimate|2011-08-09|2011-09-12|Estimate||||2011-09-19|2011-09-21|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis|A One-year, Multicountry, Multicenter Study of Zemplar Injections in Patients With End Stage Chronic Kidney Disease, Undergoing Hemodialysis, Not Adequately Controlled With Oral Vitamin D Receptor Activator (Calcitriol or Alfacalcidol)|Completed|||181|Actual|Abbott|||1||f||||f||||||||||2018-05-31 23:59:48.965765|2018-05-31 23:59:48.965765
NCT01084525|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2011-06-07|2010-03-08|2010-03-10|Estimate|||||||2011-06-07|2011-06-08|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||OTO-104 for Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 1B Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease|Completed||Phase 1|44|Actual|Otonomy, Inc.||3|||f||||t||||||||||2018-05-31 23:59:49.220808|2018-05-31 23:59:49.220808
NCT01084512|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|July 2005||2005-07-31|February 2010|2010-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|SCI||Chest Wall Kinematics and Respiratory Muscle Action During Supine Breathing in Individuals With and Without Spinal Cord Injury|Phase 0 Study of Chest Wall Kinematics and Respiratory Muscle Action During Supine Breathing in Individuals With and Without Spinal Cord Injury.|Completed|||50|Anticipated|National Taiwan University Hospital|||3||f||||t||||||||||2018-05-31 23:59:49.294519|2018-05-31 23:59:49.294519
NCT01084499|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2014-07-09|2010-03-09|2010-03-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Bioequivalence Study of Letrozole 2.5 mg Tablets|Bioequivalence Study of YUHAN Letrozole 2.5 mg Tablets|Completed||N/A|26|Actual|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 23:59:49.356817|2018-05-31 23:59:49.356817
NCT01084486|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate||||March 2010|2010-03-31||||||||Interventional|||Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease||Completed||Phase 1/Phase 2|||Wolfson Medical Center||1|||f||||||||||||||2018-05-31 23:59:49.418821|2018-05-31 23:59:49.418821
NCT01084473|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-06-03|2010-03-09|2010-03-10|Estimate|||||||2010-06-03|2010-06-04|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|GADEX||Effect of Dexmedetomidine on Gastric Emptying and Gastrointestinal Transit|Effect of Dexmedetomidine Infusion on Gastric Emptying and Gastrointestinal Transit in Healthy Volunteers|Completed||Phase 1|12|Actual|University of Turku||3|||f||||f||||||||||2018-05-31 23:59:49.472373|2018-05-31 23:59:49.472373
NCT01084460|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|January 1997||1997-01-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Follow-up of the Natural Course of the Small EUS-suspected Gastric Gastointestinal Stromal Tumors||Completed|||||National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 23:59:49.562637|2018-05-31 23:59:49.562637
NCT01084447|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|January 2004||2004-01-31|March 2010|2010-03-31|August 2005|Actual|2005-08-31|August 2004|Actual|2004-08-31||Interventional|||Inspiratory Muscle Training After Gastroplasty|Effect of Inspiratory Muscle Training on Muscular and Pulmonary Function Following Gastroplasty in Obese Patients|Completed||Phase 1|30|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 23:59:49.662118|2018-05-31 23:59:49.662118
NCT01084434|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Interventional|||Probiotic, Prebiotic and Synbiotic Effect on Immunity|Double-blind, Placebo Controlled Randomized Parallel Study to Determine the Effects of Pre-pro and Synbiotic Administration on the Immune Response to Influenza Vaccination and Faecal Microbiota in Healthy Adults|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Reading||4|||f||||f||||||||||2018-05-31 23:59:49.809836|2018-05-31 23:59:49.809836
NCT01084421|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2016-08-29|2010-03-09|2010-03-10|Estimate|||||||2016-08-29|2016-08-31|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|June 2010|Actual|2010-06-30|September 2008|Actual|2008-09-30||Interventional|||A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos|A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos|Completed||N/A|260|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 23:59:49.897981|2018-05-31 23:59:49.897981
NCT01084408|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2016-05-11|2010-03-09|2010-03-10|Estimate|||||||2016-05-11|2016-05-12|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|PEPCAD-DEBonly||Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™|Randomized Trial on the Treatment of Coronary De-novo Lesions With a Drug Eluting Stent or a Drug Coated Balloon|Active, not recruiting||Phase 3|90|Anticipated|University Hospital, Saarland||2|||f||||f||||||||||2018-05-31 23:59:49.988771|2018-05-31 23:59:49.988771
NCT01084395|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-17|2010-03-09|2010-03-10|Estimate|||||||2010-03-17|2010-03-19|Estimate|September 2002||2002-09-30|March 2010|2010-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Reducing HIV Risk Among Mexican Youth|Reducing HIV Risk Among Mexican Youth|Completed||N/A|1620|Actual|University of Michigan||4|||f||||f||||||||||2018-05-31 23:59:50.084666|2018-05-31 23:59:50.084666
NCT01084382|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|September 2010||2010-09-30|June 2010||2010-06-30||Interventional|||" Arthrospira Platensis as Nutrition Supplementation for Female Adult Patients Infected by HIV in Yaoundé Cameroon"||Unknown status|Enrolling by invitation|N/A|70|Actual|University of Giessen||2|||f||||t||||||||||2018-05-31 23:59:50.173828|2018-05-31 23:59:50.173828
NCT01084369|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2014-01-03|2010-03-09|2010-03-10|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism|Phase IV: Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism|Unknown status|Recruiting|Phase 4|40|Anticipated|Tameside Hospital NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 23:59:50.247148|2018-05-31 23:59:50.247148
NCT01084356|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||March 2011|Anticipated|2011-03-31||Observational|||Evaluation of a New CZT System|Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||4||f||||f||||||||||2018-05-31 23:59:50.325404|2018-05-31 23:59:50.325404
NCT01084343|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2012-07-12|2010-03-09|2010-03-10|Estimate|||||||2012-07-12|2012-07-13|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects|A Dose Escalating Phase I Study, Double-blind, Randomized, Placebo-controlled for Examining the Safety and Tolerability to a Prophylactic HIV-1 Vaccine Called MYM-V101, Administered i.m. in Combination With i.n. Administrations to Healthy Female Subjects.|Completed||Phase 1|24|Actual|Mymetics Corporation||2|||f||||f||||||||||2018-05-31 23:59:50.397308|2018-05-31 23:59:50.397308
NCT01084330|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2017-02-21|2010-03-08|2010-03-10|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2010||2010-04-30|February 2017|2017-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer|A Randomized, Open-label, Multi-center Phase II Study to Compare AUY922 With Docetaxel or Irinotecan in Adult Patients With Advanced Gastric Cancer, Who Have Progressed After One Line of Chemotherapy|Completed||Phase 2|68|Actual|Novartis||2|||f||||||||||||||2018-05-31 23:59:50.478245|2018-05-31 23:59:50.478245
NCT01084317|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2013-02-06|2010-03-09|2010-03-10|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Evaluation of the Delay in Asthma Diagnosis in Children From the Lodz Region|Evaluation of the Delay in Asthma Diagnosis in Children From the Lodz Region After the Program for Prevention of Allergic Diseases|Completed|||907|Actual|Medical Universtity of Lodz|||1||f||||t||||||||||2018-05-31 23:59:50.609032|2018-05-31 23:59:50.609032
NCT01084304|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2017-03-21|2010-03-09|2010-03-10|Estimate|||||||2017-03-21|2017-03-24|Actual|February 2010||2010-02-28|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Assessment of Stress Levels in Consumers Using Ovulation Tests in Order to Conceive|Assessment of Stress Levels in Consumers Using Ovulation Tests in Order to Conceive|Completed|||150|Anticipated|SPD Development Company Limited|||2||f||||f||||||Samples Without DNA|"~     Urine samples~   "|||2018-05-31 23:59:50.702595|2018-05-31 23:59:50.702595
NCT01084291|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-12-31|2010-03-08|2010-03-10|Estimate|||||||2012-12-31|2013-01-03|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine|A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects|Completed||Phase 1|18|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 23:59:50.77941|2018-05-31 23:59:50.77941
NCT01084278|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2012-09-11|2012-03-12|2012-09-11|2010-03-08|2010-03-10|Estimate|2012-09-11|2012-10-12|Estimate|2012-03-16|2012-03-20|Estimate|2012-09-11|2012-10-12|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)|Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease|Completed||Phase 4|40|Actual|Takeda||5|||f||||f||||||||||2018-05-31 23:59:50.885801|2018-05-31 23:59:50.885801
NCT01084265|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2012-02-06||2013-12-02|2010-03-08|2010-03-10|Estimate|2012-04-19|2012-05-22|Estimate||||2013-12-02|2013-12-27|Estimate|February 2004||2004-02-29|December 2013|2013-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism|Clinical Trial on Application of Injectable Recombinant Human Luteinizing Hormone (Luveris®) in the Treatment of Chinese Female Patients With Hypogonadotropic Hypogonadism: A Multi-center, Open, Prospective Drug Clinical Trial for Registration|Completed||Phase 3|31|Actual|Merck KGaA|||||f||||||||||||||2018-05-31 23:59:51.888169|2018-05-31 23:59:51.888169
NCT01084252|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2018-03-27|2010-03-09|2010-03-10|Estimate|||||||2018-03-27|2018-03-29|Actual|May 11, 2010||2010-05-11|March 2018|2018-03-31|February 13, 2019|Anticipated|2019-02-13|February 13, 2019|Anticipated|2019-02-13||Interventional|||Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies|A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies|Recruiting||Phase 1/Phase 2|341|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 23:59:52.084361|2018-05-31 23:59:52.084361
NCT01084239|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2013-09-09||2014-04-08|2010-03-08|2010-03-10|Estimate|2014-04-08|2014-05-07|Estimate||||2014-04-08|2014-05-07|Estimate|April 2010||2010-04-30|April 2014|2014-04-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|ROMICAT-II||Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography|Rule Out Myocardial Ischemia/Infarction by Computer Assisted Tomography|Completed||Phase 3|1000|Actual|Massachusetts General Hospital|"Enrollment occurred only during weekday hours.~Lack of blinding to the intervention.~Results may not be applicable to populations we did not study (i.e. patients younger than 40 years of age and those older than 74 years of age)."|2|||f||||t||||||||||2018-05-31 23:59:52.348127|2018-05-31 23:59:52.348127
NCT01084226|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|February 2010||2010-02-28|April 2009|Actual|2009-04-30||Interventional|Rye-2008||Rye Bread Trial; Antioxidative and Cholesterol Lowering Effects|Dietary Intervention Trial of Alkylresorcinols and Plant Sterols in High-Fibre Rye Bread and Their Effects on Serum Lipids in Normo- and Mildly Hypercholesterolemic Subjects|Completed||Phase 2|68|Actual|Helsinki University||2|||f||||||||||||||2018-05-31 23:59:52.657868|2018-05-31 23:59:52.657868
NCT01084213|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2014-04-10|2010-03-08|2010-03-10|Estimate|||||||2014-04-10|2014-04-11|Estimate|June 2010||2010-06-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|IPTp_IST||Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy|A Trial of Intermittent Preventive Treatment With Sulfadoxine-pyrimethamine Versus Intermittent Screening and Treatment of Malaria in Pregnancy|Completed||Phase 4|5354|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 23:59:52.743347|2018-05-31 23:59:52.743347
NCT01084200|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-08-09|2010-03-09|2010-03-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparison of Sevoflurane, Propofol, and Sevoflurane Plus Propofol for Maintenance of Anaesthesia|Comparison of Postoperative Pain of Sevoflurane, Propofol, and Sevoflurane Plus Propofol in Maintenance of Anaesthesia for Gynaecological Laparoscopic Surgery|Completed||Phase 4|90|Actual|Huazhong University of Science and Technology||3|||f||||t||||||||||2018-05-31 23:59:52.839498|2018-05-31 23:59:52.839498
NCT01084187|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2011-04-15|2010-03-09|2010-03-10|Estimate|||||||2011-04-15|2011-04-18|Estimate|January 2010||2010-01-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Correlation Study of Vascular Parameters in Hypertensive Men With Erectile Dysfunction|Correlation of Flow Mediated Dilation of Brachial Artery and Carotid Intima Media Thickness With Erectile Dysfunction Severity and Clinical Response to PDE 5 Inhibitor in Hypertensive Men|Completed||Phase 4|100|Actual|Hospital Universitario Pedro Ernesto||3|||f||||f||||||||||2018-05-31 23:59:52.963997|2018-05-31 23:59:52.963997
NCT01084174|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2017-02-23||2017-02-23|2010-03-09|2010-03-10|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|March 2010||2010-03-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy|Completed||Phase 1/Phase 2|21|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 23:59:53.067821|2018-05-31 23:59:53.067821
NCT01084161|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05||2011-06-24|2011-11-28|2010-03-09|2010-03-10|Estimate||||2011-11-28|2011-12-02|Estimate|2011-11-28|2011-12-02|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study to Evaluate the Efficacy, Safety and Tolerability of N1539|A Randomized Double-Blind, Placebo- and Active-Controlled, Dose-Ranging Study to Evaluate the Analgesic, Efficacy, Safety and Tolerability of Intravenous N1539 in Subjects After Open Abdominal Hysterectomy|Completed||Phase 2|486|Actual|Alkermes, Inc.||7|||f||||f||||||||||2018-05-31 23:59:53.491215|2018-05-31 23:59:53.491215
NCT01084148|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2014-01-31||2017-11-24|2010-03-09|2010-03-10|Estimate|2014-01-31|2014-03-18|Estimate||||2017-11-24|2017-12-20|Actual|January 2007||2007-01-31|November 2017|2017-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional||"1 patient not randomised~1 patient in V0034 CR 01B vehicle group not treated"|Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis|Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis|Completed||Phase 3|237|Actual|Orfagen||2|||f||||f||||||||||2018-05-31 23:59:53.586526|2018-05-31 23:59:53.586526
NCT01084135|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2015-02-27||2015-03-17|2010-03-09|2010-03-10|Estimate|2015-02-27|2015-03-12|Estimate||||2015-03-17|2015-04-06|Estimate|November 2009||2009-11-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|DS-Riv||Rivastigmine Study in Adolescents With Down Syndrome|A 20-Week Double-Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Rivastigmine in Children (Ages 10-18) With Down Syndrome|Completed||Phase 1/Phase 2|42|Actual|Duke University||2|||f||||f||||||||||2018-05-31 23:59:53.978922|2018-05-31 23:59:53.978922
NCT01084122|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|May 2010||2010-05-31|January 2010|2010-01-31||||December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia|Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia|Unknown status|Not yet recruiting|Phase 4|360|Anticipated|Hospital Clinic of Barcelona|||||f||||f||||||||||2018-05-31 23:59:54.551527|2018-05-31 23:59:54.551527
NCT01084109|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2013-11-22|2010-03-09|2010-03-10|Estimate|||||||2013-11-22|2013-11-25|Estimate|July 2008||2008-07-31|November 2013|2013-11-30|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|First Bites||First Bites: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial|Complementary Feeding - A Global Network Cluster Randomized Controlled Trial|Completed||Phase 3|1236|Actual|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-05-31 23:59:54.613137|2018-05-31 23:59:54.613137
NCT01084096|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2014-07-29|2010-03-09|2010-03-10|Estimate|||||||2014-07-29|2014-07-31|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|ACT||Trial of the Use of Antenatal Corticosteroids in Developing Countries|Trial of the Use of Antenatal Corticosteroids in Developing Countries|Completed||Phase 3|6214|Actual|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-05-31 23:59:54.6875|2018-05-31 23:59:54.6875
NCT01084083|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2015-08-17||2015-09-22|2010-03-09|2010-03-10|Estimate|2015-09-22|2015-10-28|Estimate||||2015-09-22|2015-10-28|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Eligible and treated patients|Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer|A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx|Completed||Phase 2|90|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-05-31 23:59:54.781334|2018-05-31 23:59:54.781334
NCT01084070|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|||2012-06-11|2010-03-09|2010-03-10|Estimate|||||||2012-06-11|2012-06-12|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Early Oral Feeding Versus Traditional Postoperative Care in Emergency Abdominal Surgery|Randomized Clinical Trial of Early Oral Feeding Versus Traditional Postoperative Care in Emergency Abdominal Surgery|Completed||Phase 3|336|Actual|Hospital General de Agudos “Dr. Cosme Argerich”||2|||f||||f||||||||||2018-05-31 23:59:55.340601|2018-05-31 23:59:55.340601
NCT01084057|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2018-04-04|2010-03-08|2010-03-10|Estimate|||||||2018-04-04|2018-04-05|Actual|May 17, 2010||2010-05-17|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer|Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer|Active, not recruiting||Phase 1|56|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 23:59:55.425622|2018-05-31 23:59:55.425622
NCT01084044|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-01-31|2010-03-09|2010-03-10|Estimate|||||||2012-01-31|2012-02-02|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery|Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery|Completed||Phase 4|80|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 23:59:55.519106|2018-05-31 23:59:55.519106
NCT01084031|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2014-02-17|2010-03-09|2010-03-10|Estimate|||||||2014-02-17|2014-02-19|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|March 2011|Actual|2011-03-31|February 2010|Actual|2010-02-28||Interventional|||Dose Titration of Propofol for Tracheal Intubation in Children With Sevoflurane Inhalation Induction|Dose Titration of Propofol for Tracheal Intubation in Children With Sevoflurane Inhalation Induction|Completed||N/A|50|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 23:59:55.591783|2018-05-31 23:59:55.591783
NCT01084018|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-09-14|2010-03-09|2010-03-10|Estimate|||||||2010-09-14|2010-09-15|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|SOULAGETAVIE||Development and Evaluation of a Nursing Virtual Intervention Tailored for Pain After Cardiac Surgery|Development and Evaluation of a Nursing Virtual Intervention Tailored for Pain After Cardiac Surgery-SOULAGETAVIE|Completed||Phase 1/Phase 2|60|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||t||||||||||2018-05-31 23:59:55.655942|2018-05-31 23:59:55.655942
NCT01084005|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2012-06-14||2013-12-11|2010-03-09|2010-03-10|Estimate|2012-06-14|2012-07-18|Estimate||||2013-12-11|2014-01-29|Estimate|March 2010||2010-03-31|December 2013|2013-12-31||||June 2011|Actual|2011-06-30||Interventional|||Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes|A Phase III Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin (5 mg) Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients (Age >= 70 Years) With Insufficient Glycaemic Control( HbA1c >= 7.0) Despite Metformin and/or Sulphonylurea and/or Insulin Therapy|Completed||Phase 3|241|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 23:59:55.745395|2018-05-31 23:59:55.745395
NCT01083992|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2011-04-27|2010-03-09|2010-03-10|Estimate|||||||2011-04-27|2011-04-28|Estimate|April 2012||2012-04-30|March 2010|2010-03-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|||Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|Unknown status|Not yet recruiting|N/A|60|Anticipated|Ziv Hospital||2|||f||||t||||||||||2018-05-31 23:59:56.265907|2018-05-31 23:59:56.265907
NCT01083979|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2013-12-24||2016-12-14|2010-03-09|2010-03-10|Estimate|2016-12-14|2017-02-08|Estimate||||2016-12-14|2017-02-08|Estimate|August 2010||2010-08-31|December 2016|2016-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Intravesical Liposomes for Ulcerative Cystitis|Intravesical Liposomes for Ulcerative Cystitis|Completed||N/A|1|Actual|William Beaumont Hospitals|This was a single-subject treatment study. Therefore the data analysis and results are limited and are not generalizable.|1|||f||||f||||||||No|No plan to make individual participant data available|2018-05-31 23:59:56.3466|2018-05-31 23:59:56.3466
NCT01083966|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2018-02-28|2010-03-09|2010-03-10|Estimate|||||||2018-02-28|2018-03-01|Actual|August 2011||2011-08-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma|Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma (Acoustic Neuroma)|Suspended||Phase 1|30|Anticipated|Northwell Health||1||In the process of transferring IRB to PI's current institution.|f||||f||||||||||2018-05-31 23:59:56.490308|2018-05-31 23:59:56.490308
NCT01083953|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2015-12-02|2010-03-09|2010-03-10|Estimate|||||||2015-12-02|2015-12-03|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Optimal End-Tidal (ET) Sevoflurane and Desflurane Concentration for Extubation of Supreme Laryngeal Mask Airway (LMA) in Adults|Optimal End-Tidal Concentration of Sevoflurane and Desflurane for Removal of Supreme Laryngeal Mask Airway in Anaesthetized Adults|Completed||N/A|54|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 23:59:56.559046|2018-05-31 23:59:56.559046
NCT01083940|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2011-06-22|2010-03-08|2010-03-10|Estimate|||||||2011-06-22|2011-06-27|Estimate|October 2010||2010-10-31|June 2011|2011-06-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Impact of Computerized Decision Support on Racial/Ethnic Disparities in Hypertension Outcomes|Evaluating the Impact of Computerized Decision Support on Racial/Ethnic Disparities in Hypertension Outcomes|Unknown status|Active, not recruiting|Early Phase 1|3600|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 23:59:56.630254|2018-05-31 23:59:56.630254
NCT01083927|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||Rotational Narrow Strip Versus Full Conjunctival Graft in Pterygium Excision|Rotational Narrow Strip Versus Full Conjunctival Graft in Pterygium Excision|Completed||N/A|94|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 23:59:56.686367|2018-05-31 23:59:56.686367
NCT01083914|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2013-08-22|2010-03-09|2010-03-10|Estimate|||||||2013-08-22|2013-08-23|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Comparing Blood Loss, RBC Transfusions and Inflammatory Marker Changes Among Methods of CPB|Investigation of the Ability of the MECC System to Provide Reduced Risk Over the Existing CECC System and Equivalent Risk to Off-Pump CABG Surgery: The IMPROVE TRIAL|Completed|||102|Actual|Baylor Research Institute|||3||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 23:59:56.750022|2018-05-31 23:59:56.750022
NCT01080170|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2016-05-11|2010-03-02|2010-03-03|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|Silhouette||The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer||Completed|||20|Actual|University of Pittsburgh|||2||f||||f||||||Samples With DNA|"~     Frozen serum samples. No further testing planned at the moment.~   "|||2018-06-01 00:01:18.986149|2018-06-01 00:01:18.986149
NCT01083901|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2013-02-04||2013-06-17|2010-03-09|2010-03-10|Estimate|2013-02-04|2013-03-08|Estimate||||2013-06-17|2013-06-24|Estimate|May 2006||2006-05-31|June 2013|2013-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training|Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training|Completed||N/A|34|Actual|University of Colorado, Denver|This was a preliminary study that was limited by small sample size, exclusion of women, and the duration of intervention which was too brief to measure changes in bone mineral density.|3|||f||||f||||||||||2018-05-31 23:59:56.820041|2018-05-31 23:59:56.820041
NCT01083888|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-06-16|2010-03-08|2010-03-10|Estimate|||||||2010-06-16|2010-06-22|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||ASP1517 Pharmacokinetics Study in Anemia Patients on Hemodialysis|ASP1517 Clinical Pharmacology Study - PK/PD Study in Renal Anemia Patients on Hemodialysis|Completed||Phase 1|12|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 23:59:57.128564|2018-05-31 23:59:57.128564
NCT01083875|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-16|2010-03-09|2010-03-10|Estimate|||||||2010-03-16|2010-03-18|Estimate|February 2000||2000-02-29|March 2010|2010-03-31|June 2001|Actual|2001-06-30|||||Interventional|||Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region|A Double-blind, Randomized, Vehicle-controlled Phase II Study to Determine the Effects of Concomitant Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region|Completed||Phase 2|58|Actual|Access Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 23:59:57.194822|2018-05-31 23:59:57.194822
NCT01083862|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|October 2005||2005-10-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|October 2007|Actual|2007-10-31||Interventional|||Impact of Health Literacy on Outcomes and Effectiveness of Shared Decision Making Programs in Patients With Chronic Diseases||Completed||N/A|187|Actual|University of Cincinnati||2|||f||||f||||||||||2018-05-31 23:59:57.275323|2018-05-31 23:59:57.275323
NCT01083849|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2014-12-11||2014-12-11|2010-03-08|2010-03-10|Estimate|2014-12-11|2014-12-19|Estimate||||2014-12-11|2014-12-19|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|TOP|A total of 761 participants were enrolled in the study, however 2 participants lacked information necessary for assignment to one of the analysis groups. Hence, analysis was conducted with 759 participants.|Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice|Long-Term Therapy Outcomes When Treating CKD-patients With Paricalcitol in German Clinical Practice (TOP Study)|Completed|||761|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 23:59:57.381088|2018-05-31 23:59:57.381088
NCT01083823|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-04-19|2010-03-08|2010-03-10|Estimate|||||||2012-04-19|2012-04-20|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Calling for Care: Cell Phones for Mood Telemetry in Teens|Calling for Care: Cell Phones for Mood Telemetry|Completed||N/A|33|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 23:59:58.608201|2018-05-31 23:59:58.608201
NCT01083810|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2011-06-30||2011-08-09|2010-03-08|2010-03-10|Estimate|2011-06-30|2011-07-29|Estimate||||2011-08-09|2011-08-11|Estimate|June 2001||2001-06-30|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Evaluation of Kaletra Therapy Over the Long-term|Evaluation of Kaletra Therapy Over the Long-term|Completed|||284|Actual|Abbott|||3||f||||f||||||||||2018-05-31 23:59:58.743526|2018-05-31 23:59:58.743526
NCT01083797|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2013-10-24|2010-03-09|2010-03-10|Estimate|||||||2013-10-24|2013-10-25|Estimate|December 2009||2009-12-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Interventional|||Sedation to Electroencephalography With Dexmedetomidine or Chloral Hydrate|Sedation to Electroencephalography With Dexmedetomidine or Chloral Hydrate: a Comparative Study of the Qualitative and Quantitative Electroencephalogram Pattern|Completed||Phase 3|25|Actual|Federal University of Minas Gerais||1|||f||||t||||||||||2018-05-31 23:59:59.627341|2018-05-31 23:59:59.627341
NCT01083784|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2011-07-21|2010-03-08|2010-03-10|Estimate|||||||2011-07-21|2011-07-25|Estimate|March 2010||2010-03-31|July 2011|2011-07-31||||December 2012|Anticipated|2012-12-31||Interventional|||The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia|The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia|Unknown status|Enrolling by invitation|Phase 4|60|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 23:59:59.704255|2018-05-31 23:59:59.704255
NCT01083771|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-09|2015-06-09||2015-07-21|2010-03-09|2010-03-10|Estimate|2015-07-21|2015-07-23|Estimate||||2015-07-21|2015-07-23|Estimate|February 2009||2009-02-28|July 2015|2015-07-31|August 2012|Actual|2012-08-31|September 2010|Actual|2010-09-30||Interventional|||Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer|Eight Week Plant-based Mediterranean Diet as Prevention of Metabolic Syndrome in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A BrUOG Pilot Study|Completed||N/A|21|Actual|Brown University||1|||f||||t||||||||||2018-06-01 00:00:00.990155|2018-06-01 00:00:00.990155
NCT01083758|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2014-09-26|2013-11-22|2015-09-07|2010-03-09|2010-03-10|Estimate|2015-09-07|2015-10-12|Estimate|2013-11-22|2013-12-17|Estimate|2015-09-07|2015-10-12|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis|Effect of Calcipotriol Plus Betamethasone Dipropionate Topical Suspension on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 17 Years) With Scalp Psoriasis|Completed||Phase 2|31|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 00:00:01.384572|2018-06-01 00:00:01.384572
NCT01083745|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-16|2010-03-09|2010-03-10|Estimate|||||||2010-03-16|2010-03-18|Estimate||||March 2010|2010-03-31||||||||Observational|||Assessment of Blood and Follicular Fluid Immune Cell Constitution in Patients Undergoing in Vitro Fertilization||Unknown status|Not yet recruiting||||Hillel Yaffe Medical Center|||2||f||||||||||||||2018-06-01 00:00:02.765831|2018-06-01 00:00:02.765831
NCT01083732|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2016-08-17||2016-11-02|2010-03-08|2010-03-10|Estimate|2016-11-02|2016-12-28|Estimate||||2016-11-02|2016-12-28|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Treated set (TS): This patient set included all subjects who were dispensed study medication and were documented to have taken at least 1 dose of trial medication.|Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age|Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Successive Groups of Children Aged 2 Years to Less Than 12 Years Followed by 1 Year to Less Than 2 Years|Completed||Phase 2|18|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:00:03.084694|2018-06-01 00:00:03.084694
NCT00874484|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2011-10-17|2009-04-01|2009-04-02|Estimate|||||||2011-10-17|2011-10-18|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Enoxaparin as Treatment for Vulvodynia|Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia|Completed||Phase 2|40|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-06-01 01:08:41.884104|2018-06-01 01:08:41.884104
NCT01083719|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-06|||2010-03-09|2010-03-09|2010-03-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.|Phase II Study Comparing FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.|Unknown status|Not yet recruiting|Phase 2|15|Anticipated|Medanta Institute of Clinical Research||1|||f||||f||||||||||2018-06-01 00:00:05.494969|2018-06-01 00:00:05.494969
NCT01083706|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2017-04-17||2017-04-17|2010-03-08|2010-03-10|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|April 2010||2010-04-30|April 2017|2017-04-30||||December 2013|Actual|2013-12-31||Interventional|||Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant|Treatment of Post-Transplant Relapse and Persistent Disease in Patients With MDS, CMML and AML With Azacitidine|Completed||Phase 2|43|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 00:00:05.633843|2018-06-01 00:00:05.633843
NCT01083693|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|2011-06-28||2011-08-09|2010-03-08|2010-03-10|Estimate|2011-06-28|2011-07-26|Estimate||||2011-08-09|2011-08-11|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs|An Open Label Multicenter Post Marketing Observational Study for the Evaluation of Quality of Life Outcomes and Tolerability of HUMIRA in Routine Clinical Use in Patients With RA PsA AS After Unsustainable Response to Disease Modifying Antirheumatic Drugs and or Biologicals|Completed|||162|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:00:06.208159|2018-06-01 00:00:06.208159
NCT01083680|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2016-12-13||2017-03-30|2010-03-08|2010-03-10|Estimate|2017-03-30|2017-04-04|Actual||||2017-03-30|2017-04-04|Actual|May 2007||2007-05-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational||Baseline analyses accounts for safety analysis set population (all participants who received at least 1 dose of study drug).|Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine|Post-marketing Observational Study to Evaluate the Safety and Efficacy of HUMIRA® (Adalimumab SC) for the Treatment of Moderate to Severe Crohn's Disease in Daily Clinical Practice|Completed|||4107|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:00:08.841395|2018-06-01 00:00:08.841395
NCT01083667|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2017-02-17||2017-05-19|2010-03-08|2010-03-10|Estimate|2017-05-19|2017-06-19|Actual||||2017-05-19|2017-06-19|Actual|November 2009||2009-11-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional|||SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)|Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS|Completed||Phase 1/Phase 2|32|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||Undecided||2018-06-01 00:00:10.967942|2018-06-01 00:00:10.967942
NCT01083654|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2015-12-29||2016-05-16|2010-03-08|2010-03-10|Estimate|2015-12-29|2016-02-01|Estimate||||2016-05-16|2016-06-17|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|START|Adult American Indian smokers eligible for services at the Menominee Tribal Clinic.|Menominee Stop Tobacco Abuse Renew Tradition Study|Menominee Smoking Cessation Clinical Trial|Completed||N/A|103|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:00:11.745691|2018-06-01 00:00:11.745691
NCT01083641|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2017-01-13||2017-03-06|2010-03-08|2010-03-10|Estimate|2017-01-13|2017-03-07|Actual||||2017-03-06|2017-04-04|Actual|January 2010||2010-01-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|June 2013|Actual|2013-06-30||Interventional||Adult women with measurable advanced TNBC.|Estrogen for Triple Negative Breast Cancer|A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer|Terminated||Phase 2|17|Actual|University of Wisconsin, Madison||1||did not meet efficacy goals after interim analysis|f||||t||||||||||2018-06-01 00:00:13.388357|2018-06-01 00:00:13.388357
NCT01083628|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2015-05-13|2010-03-08|2010-03-10|Estimate|||||||2015-05-13|2015-05-15|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|Txt4CBT||Text Messaging and Cognitive Behavioral Therapy for Depression|Using Text Messaging to Enhance Cognitive Behavioral Therapy (CBT) for Depression|Unknown status|Enrolling by invitation|Phase 1/Phase 2|30|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:00:15.521802|2018-06-01 00:00:15.521802
NCT01083615|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26||2015-11-04|2016-10-07|2010-03-08|2010-03-10|Estimate||||2015-11-04|2015-12-01|Estimate|2016-10-07|2016-10-12|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)|A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer|Terminated||Phase 3|14|Actual|Achieve Life Sciences||2||Unable to enroll due to criteria for stable baseline pain|f||||t||||||||||2018-06-01 00:00:16.132476|2018-06-01 00:00:16.132476
NCT01083602|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2015-02-23||2017-11-27|2010-03-08|2010-03-10|Estimate|2015-03-11|2015-03-27|Estimate||||2017-11-27|2017-12-21|Actual|June 2010||2010-06-30|November 2017|2017-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|MACS1271|The study population consisted of adult patients with relapsed and bortezomib-refractory MM who had received at least 2 prior lines of therapy and had been exposed to an IMiD (thalidomide or lenalidomide). Bortezomib-refractory was defined as demonstrated disease progression on or within 60 days of the last bortezomib -containing line of therapy.|Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma|A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma|Completed||Phase 2|55|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:00:16.726645|2018-06-01 00:00:16.726645
NCT01083589|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-01-09|2010-03-08|2010-03-10|Estimate|||||||2012-01-09|2012-01-11|Estimate|January 2005||2005-01-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|October 2007|Actual|2007-10-31||Interventional|||Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)|Phase II Study of Imatinib Mesylate and Docetaxel in Pretreated Patients With Metastatic NSCLC|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:00:18.022814|2018-06-01 00:00:18.022814
NCT01083420|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2012|Anticipated|2012-03-31|March 2011|Anticipated|2011-03-31||Interventional|||The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus|The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 00:00:24.936453|2018-06-01 00:00:24.936453
NCT01083576|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2013-11-20||2015-06-23|2010-03-08|2010-03-09|Estimate|2014-04-14|2014-05-15|Estimate||||2015-06-23|2015-07-16|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional||All randomized subjects were included in the mITT Analysis. All subjects met criteria for the evaluable subset.|Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama|Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama|Completed||Phase 2|30|Actual|U.S. Army Medical Research and Materiel Command|There are no PK tables for gentamicin due to low sample size; only 2 individuals with measureable gentamicin.|2|||f||||f||||||||||2018-06-01 00:00:18.567345|2018-06-01 00:00:18.567345
NCT01083563|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2015-04-07|2010-03-08|2010-03-09|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy|The Morphologic and Functional Relationship Between the Draining PLN and Synovial Inflammation in the Knee Joints of RA Patients Before and After Anti-TNF or B Cell Depletion Therapy|Terminated|||7|Actual|University of Rochester|||2|Funding has ended prior to complete enrollment|f||||f||||||||||2018-06-01 00:00:20.576757|2018-06-01 00:00:20.576757
NCT01083550|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2016-11-28|2010-03-08|2010-03-09|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer|Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial)|Completed||Phase 2/Phase 3|74|Actual|University Health Network, Toronto||2|||f||||f||||||||No|No plan to share individual participant data|2018-06-01 00:00:20.678731|2018-06-01 00:00:20.678731
NCT01083537|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2012-06-07|2010-03-08|2010-03-09|Estimate|||||||2012-06-07|2012-06-08|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction|Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction|Terminated||Phase 1/Phase 2|1|Actual|University Health Network, Toronto||2||Slow accrual|f||||f||||||||||2018-06-01 00:00:21.471156|2018-06-01 00:00:21.471156
NCT01083524|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2014-05-30|2010-03-08|2010-03-09|Estimate|||||||2014-05-30|2014-06-03|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension|A Phase I, Open-Label, Two Centre Study to Evaluate Dichloroacetate(DCA) in Advanced Pulmonary Arterial Hypertension.|Completed||Phase 1|30|Actual|University of Alberta||3|||f||||t||||||||||2018-06-01 00:00:21.708933|2018-06-01 00:00:21.708933
NCT01083511|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2014-05-13|2010-03-08|2010-03-09|Estimate|||||||2014-05-13|2014-05-14|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Collection and Extraction of Respiratory Specimens|Collection & Extraction of Respiratory Specimens for the Validation of the Artus Influenza RG PCR Test|Completed|||600|Actual|QIAGEN Gaithersburg, Inc|||1||f||||f||||||Samples With DNA|"~     Extracted nucleic acid, Residual Universal Transport Medium.~   "|||2018-06-01 00:00:21.971721|2018-06-01 00:00:21.971721
NCT01083498|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|fractional-2||Fractional Laser as Treatment Option for Various Pigment Disorders|Ablative Fractional Laser Therapy as Treatment for Becker's Nevus; a Pilot Study|Completed||Phase 2|11|Actual|Netherlands Institute for Pigment Disorders||2|||f||||f||||||||||2018-06-01 00:00:22.183856|2018-06-01 00:00:22.183856
NCT01083485|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2011-06-10||2012-02-15|2010-03-08|2010-03-09|Estimate|2012-02-15|2012-02-16|Estimate||||2012-02-15|2012-02-16|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|OXN4505||OXN PR Compared to OXY PR in Subjects With Postoperative Pain After Knee Arthroplasty|A Randomised, Double-blind, Parallel Group Multicentre Study to Demonstrate Non-inferiority of the Analgesic Efficacy of Oxycodone/Naloxone 10/5 or 20/10 mg Prolonged Release Tablets (OXN PR) BID Compared to Oxycodone 10 or 20 mg Prolonged Release Tablets (OXY PR) BID in Subjects With Postoperative Pain After Knee Arthroplasty|Completed||Phase 4|137|Actual|Mundipharma Oy||2|||f||||f||||||||||2018-06-01 00:00:22.426436|2018-06-01 00:00:22.426436
NCT01083472|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2013-09-18||2013-09-18|2010-03-08|2010-03-09|Estimate|2013-09-18|2013-11-19|Estimate||||2013-09-18|2013-11-19|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|StAR||Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair (StAR)|A Multicenter, Prospective, Single-Blind, Randomized, Controlled Study of the Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair|Terminated||Phase 4|37|Actual|LifeCell||2||"Surgical practice evolution changed acceptable standard of care and lead to potential~   enrollment bias."|f||||t||||||||||2018-06-01 00:00:23.145005|2018-06-01 00:00:23.145005
NCT01083459|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2015-01-16|2010-03-08|2010-03-09|Estimate|||||||2015-01-16|2015-01-19|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Impact of PCV on Disease and Colonization Among Native American Communities|Impact of PCV on Disease and Colonization Among Native American Communities|Completed|||6628|Actual|Johns Hopkins Bloomberg School of Public Health|||2||f||||f||||||Samples With DNA|"~     Nasopharyngeal swab Blood~   "|||2018-06-01 00:00:23.866558|2018-06-01 00:00:23.866558
NCT01083446|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|August 2010|Anticipated|2010-08-31|July 2010|Anticipated|2010-07-31||Interventional|||A Nutritional Approach to Minimal Hepatic Encephalopathy|A Nutritional Approach to Minimal Hepatic Encephalopathy|Unknown status|Recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:00:24.388087|2018-06-01 00:00:24.388087
NCT01083433|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-06-12|2010-03-08|2010-03-09|Estimate|||||||2012-06-12|2012-06-13|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Study to Find Out if Intensive Diabetes Clinic and Continuous Glucose Monitors Help Teenagers With Diabetes|Intensive Diabetes Clinic and Intermittent Continuous Glucose Monitoring in Adolescents With Type 1 Diabetes Mellitus in Poor Glycemic Control|Completed||N/A|62|Actual|University Hospitals Cleveland Medical Center||3|||f||||f||||||||||2018-06-01 00:00:24.677079|2018-06-01 00:00:24.677079
NCT00874471|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2014-04-07|2009-04-01|2009-04-02|Estimate|||||||2014-04-07|2014-04-09|Estimate|June 2005||2005-06-30|April 2014|2014-04-30||||July 2010|Actual|2010-07-31||Observational|||Uveitis Gene-Expression Profiling||Completed|||280|Actual|Oregon Health and Science University|||10||f||||f||||||||||2018-06-01 01:08:41.952487|2018-06-01 01:08:41.952487
NCT01083407|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|June 2005||2005-06-30|March 2009|2009-03-31|June 2008|Actual|2008-06-30|June 2006|Actual|2006-06-30||Interventional|||Oral Care Interventions and Ventilator Associated Pneumonia in Critically Ill Children|Oral Care Interventions With 0.12% Chlorhexidine and Ventilator Associated Pneumonia in Critically Ill Children: Prospective, Randomic and Double Blind Study|Completed||Phase 1|146|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 00:00:25.058574|2018-06-01 00:00:25.058574
NCT01083394|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-03-07|2010-03-08|2010-03-09|Estimate|||||||2014-03-07|2014-03-10|Estimate|March 2010||2010-03-31|April 2010|2010-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|ISAR-PEBIS||Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery|Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS)|Unknown status|Recruiting|Phase 4|70|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-06-01 00:00:25.213031|2018-06-01 00:00:25.213031
NCT01083381|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|April 2011|Anticipated|2011-04-30|October 2010|Anticipated|2010-10-31||Interventional|||Is MS14 Helpful in Schizophrenia?|The Effect of MS14 in Association With Risperidone in Treatment of Schizophrenia: A Double Blind Randomized Control Trial|Unknown status|Recruiting|Phase 2|50|Anticipated|Farzan Institute||2|||f||||t||||||||||2018-06-01 00:00:25.359409|2018-06-01 00:00:25.359409
NCT01083368|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2015-08-12|2010-03-08|2010-03-09|Estimate|||||||2015-08-12|2015-08-14|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|December 2011|Actual|2011-12-31||Interventional|||Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy|Phase I-II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Avastin in Patients With Chemotherapy Refractory Castrate Resistant Prostate Cancer (CRPC)|Completed||Phase 1/Phase 2|22|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:00:25.504653|2018-06-01 00:00:25.504653
NCT01083355|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-03-28|2010-03-08|2010-03-09|Estimate|||||||2016-03-28|2016-03-30|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury (ALI)|Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury|Withdrawn|||0|Actual|Boston Medical Center|||1|No participants were enrolled, no funding obtained to perform study|f||||f||||||||||2018-06-01 00:00:25.819795|2018-06-01 00:00:25.819795
NCT01083342|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-05-22|2010-03-08|2010-03-09|Estimate|||||||2012-05-22|2012-05-24|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study|Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study|Completed||Phase 2|36|Actual|Samsung Medical Center|||||f||||||||||||||2018-06-01 00:00:26.014274|2018-06-01 00:00:26.014274
NCT01083329|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2012-10-22|2010-03-08|2010-03-09|Estimate|||||||2012-10-22|2012-10-23|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2010|Actual|2010-06-30||Interventional|ANITA||Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects|Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects|Completed||Phase 2|24|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 00:00:26.106263|2018-06-01 00:00:26.106263
NCT01083316|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2016-12-13||2018-04-09|2010-03-08|2010-03-09|Estimate|2016-12-13|2017-02-06|Estimate||||2018-04-09|2018-05-08|Actual|September 2009|Actual|2009-09-30|April 2018|2018-04-30|December 2040|Anticipated|2040-12-31|August 2013|Actual|2013-08-31||Interventional|||Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis|Phase II Trial of Induction Therapy With Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation in Patients With AL Amyloidosis|Active, not recruiting||Phase 2|35|Actual|Boston Medical Center||1|||f||||t|t|f|||t|||No||2018-06-01 00:00:26.235791|2018-06-01 00:00:26.235791
NCT01083303|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-08-01|2010-03-08|2010-03-09|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2005||2005-05-31|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Weaning Preterm Infants at 1500 Grams From Incubators|A Randomized Trial of Weaning Preterm Infants at 1500g From Incubators: Effect on Failure to Wean, Weight Gain and Energy Expenditure|Completed||N/A|21|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:00:26.605326|2018-06-01 00:00:26.605326
NCT01083290|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-05-07|2010-03-08|2010-03-09|Estimate|||||||2010-05-07|2010-05-10|Estimate|April 2010||2010-04-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets|Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|14|Actual|Orion Corporation, Orion Pharma||3|||f||||f||||||||||2018-06-01 00:00:26.76619|2018-06-01 00:00:26.76619
NCT01083277|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2017-07-06|2010-03-08|2010-03-09|Estimate|||||||2017-07-06|2017-07-11|Actual|September 2012||2012-09-30|July 2017|2017-07-31|December 23, 2016|Actual|2016-12-23|July 2016|Actual|2016-07-31||Interventional|||Variable Ventilation During Acute Respiratory Failure|Variable Ventilation During Acute Respiratory Failure|Terminated||N/A|7|Actual|Boston Medical Center||2||Slow enrollment|f||||t|f|t|f|f||||No||2018-06-01 00:00:26.922088|2018-06-01 00:00:26.922088
NCT01083264|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2014-06-20|2010-03-08|2010-03-09|Estimate|||||||2014-06-20|2014-06-23|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Relative Bioavailability, Transdermally Administered EE and GSD, 3 Applications Sites|Open-label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Transdermally Administered Ethinylestradiol (EE) and Gestodene (GSD) After Repeated Applications of a Fertility Control Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene to 3 Different Application Sites (Buttocks, Arm Versus Abdomen) in Healthy Young Female Subjects|Completed||Phase 1|43|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:00:27.072465|2018-06-01 00:00:27.072465
NCT01083251|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-01-17|2010-03-08|2010-03-09|Estimate|||||||2011-01-17|2011-01-19|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|December 2012|Anticipated|2012-12-31|February 2012|Anticipated|2012-02-29||Interventional|||The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection|The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic HBV Viral Infection|Unknown status|Recruiting|N/A|120|Anticipated|Ziv Hospital||4|||f||||t||||||||||2018-06-01 00:00:27.241388|2018-06-01 00:00:27.241388
NCT01083238|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-06-24|2010-03-08|2010-03-09|Estimate|||||||2015-06-24|2015-06-25|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose|A Phase I, Two-part Study to Investigate the Effects of Food on the PK, Safety and Tolerability of a Single Oral Dose of AZD5069 (120 mg) in Healthy Adult Volunteers (Part A) and to Compare the PK of AZD5069 in Adult and Elderly Healthy Volunteers (Part B)|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:00:27.45607|2018-06-01 00:00:27.45607
NCT01083225|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2015-08-18|2010-03-08|2010-03-09|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Patient Participation in Mental Health Care|Randomised Controlled Trial on the Effect of Individual User Involvement in a Mental Health Center|Completed||N/A|75|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 00:00:27.586394|2018-06-01 00:00:27.586394
NCT01083212|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-06-30|2010-03-08|2010-03-09|Estimate|||||||2010-06-30|2010-07-01|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656|A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656|Completed||Phase 1|19|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:00:27.68379|2018-06-01 00:00:27.68379
NCT01083199|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2016-03-14||2016-03-14|2010-03-08|2010-03-09|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Global Performance Evaluation of the AMS CONTINUUM™ Device|Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy|Completed||Phase 4|10|Actual|American Medical Systems||1|||f||||f||||||||||2018-06-01 00:00:27.793754|2018-06-01 00:00:27.793754
NCT01083186|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-20|2013-01-31||2013-03-11|2010-03-08|2010-03-09|Estimate|2013-01-31|2013-03-07|Estimate||||2013-03-11|2013-03-12|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|PROTECT||Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience|Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience|Completed|||500|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:00:28.152857|2018-06-01 00:00:28.152857
NCT01083173|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2015-10-30||2016-01-25|2010-03-08|2010-03-09|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Surveillance of Kaletra in Korean Patients|"Post-Marketing Surveillance of Safety and Efficacy of Kaletra® Tablet in Korean Patients Under the New Drug Re-Examination"|Completed|||595|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:00:29.231176|2018-06-01 00:00:29.231176
NCT01083160|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2011-11-23||2012-01-17|2010-03-08|2010-03-09|Estimate|2011-11-23|2012-01-02|Estimate||||2012-01-17|2012-01-19|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|FALLA||Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use|Clinical Outcomes,Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab. A Multicenter Post-Marketing Observational Study in Routine Clinical Use|Terminated|||82|Actual|Abbott|||1|The study was terminated due to low enrollment because inclusion criteria are obsolete.|f||||||||||||||2018-06-01 00:00:29.807508|2018-06-01 00:00:29.807508
NCT01083147|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2010-09-22|2010-03-08|2010-03-09|Estimate|||||||2010-09-22|2010-09-23|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Observational|AMD||Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment|Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment|Completed|||50|Actual|Notal Vision Ltd|||1||f||||t||||||||||2018-06-01 00:00:30.114535|2018-06-01 00:00:30.114535
NCT01083134|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-07|||2014-07-28|2010-03-08|2010-03-09|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|March 2020|Anticipated|2020-03-31|March 2015|Anticipated|2015-03-31||Observational|||The Correlation of Heart Hemodynamic Status Between 320 Multidetector Computed Tomography, Echocardiography and Cardiac Catheterization in Patients With Coronary Artery Disease||Recruiting|||100|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-06-01 00:00:30.204228|2018-06-01 00:00:30.204228
NCT01083121|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2013-06-13||2013-08-20|2010-03-08|2010-03-09|Estimate|2013-06-13|2013-08-20|Estimate||||2013-08-20|2013-08-21|Estimate|April 2007||2007-04-30|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational||Safety analysis population|Surveillance of Humira Injection in Korean Patients|"Post-Marketing Surveillance of Humira Injection in Korean Patients Under the New-Drug Re-examination"|Completed|||1779|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:00:30.456934|2018-06-01 00:00:30.456934
NCT01083108|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-06|||2018-05-23|2010-03-06|2010-03-09|Estimate|||||||2018-05-23|2018-05-24|Actual|February 22, 2010||2010-02-22|April 9, 2018|2018-04-09|May 22, 2013|Actual|2013-05-22|May 22, 2013|Actual|2013-05-22||Interventional|||Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus|Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus|Completed||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:00:30.987059|2018-06-01 00:00:30.987059
NCT01083095|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-06|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|January 2005||2005-01-31|December 2006|2006-12-31|December 2006|Actual|2006-12-31|March 2005|Actual|2005-03-31||Interventional|ChallengeII||Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers|Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers|Completed||Early Phase 1|18|Actual|Malaria Vaccine and Drug Development Center||3|||f||||t||||||||||2018-06-01 00:00:31.142588|2018-06-01 00:00:31.142588
NCT01083082|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-06|||2016-08-30|2010-03-08|2010-03-09|Estimate|||||||2016-08-30|2016-08-31|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|EVIDENT||Lifestyles and Endothelial Dysfunction|Physical Exercise, Fitness and Dietary Pattern and Theirs Relationship With Blood Pressure Circadian Pattern, Augmentation Index and Endothelial Dysfunction Biological Markers. (EVIDENT Study)|Completed|||1500|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|||||f||||f||||||||||2018-06-01 00:00:31.340859|2018-06-01 00:00:31.340859
NCT01080157|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2012-12-03|2010-03-02|2010-03-03|Estimate|||||||2012-12-03|2012-12-04|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ENGINE||Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes|An Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes|Completed|||509|Actual|VeraLight, Inc.|||1||f||||f||||||||||2018-06-01 00:01:19.168914|2018-06-01 00:01:19.168914
NCT01083069|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Observational|||Follow up After Survived Therapy With Mild Induced Hypothermia (MIH) After Restoration of Spontaneous Circulation (ROSC)|Neurological Outcome After Mild Induced Hypothermia (MIH) After Restoration of Spontaneous Circulation|Unknown status|Recruiting||150|Anticipated|University of Leipzig|||2||f||||f||||||||||2018-06-01 00:00:31.521541|2018-06-01 00:00:31.521541
NCT01083056|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2014-07-30|2010-03-08|2010-03-09|Estimate|||||||2014-07-30|2014-07-31|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Observational Study - ILM Peeling|Observational Study On Retinal Structure And Function Before And After Epimacular Membrane Peeling|Completed|||10|Actual|University Hospital Tuebingen|||2||f||||f||||||||||2018-06-01 00:00:31.65386|2018-06-01 00:00:31.65386
NCT01083043|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2013-01-15|2010-03-05|2010-03-09|Estimate|||||||2013-01-15|2013-01-16|Estimate|December 2006||2006-12-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Continuous Glucose Monitoring in Type 2 Diabetes Mellitus|Glycemic Variability Predicts Endothelial Dysfunction|Completed|||28|Actual|Winthrop University Hospital|||1||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-06-01 00:00:31.861489|2018-06-01 00:00:31.861489
NCT01083030|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-07-25|2010-03-08|2010-03-09|Estimate|||||||2013-07-25|2013-07-26|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|August 2011|Actual|2011-08-31||Interventional|PACIFIER||Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis|Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis|Completed||Phase 4|90|Anticipated|University Hospital, Saarland||2|||f||||t||||||||||2018-06-01 00:00:32.014706|2018-06-01 00:00:32.014706
NCT01083017|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2011-08-26|2010-03-08|2010-03-09|Estimate|||||||2011-08-26|2011-08-30|Estimate|April 2011||2011-04-30|August 2011|2011-08-31|April 2018|Anticipated|2018-04-30|June 2013|Anticipated|2013-06-30||Observational|RAHyCo||Resistant Arterial Hypertension Cohort Study|Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.|Unknown status|Recruiting||200|Anticipated|University Hospital, Geneva|||3||f||||f||||||Samples With DNA|"~     serum, DNA, urine~   "|||2018-06-01 00:00:32.202297|2018-06-01 00:00:32.202297
NCT01083004|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2011-04-15|2010-03-08|2010-03-09|Estimate|||||||2011-04-15|2011-04-18|Estimate|January 2008||2008-01-31|October 2007|2007-10-31||||May 2011|Anticipated|2011-05-31||Interventional|||Brilliant Blue Versus Indocyanine Green|A Randomized Study Comparing Brilliant Blue and Indocyanine Green as Intravitreal Dye in Macular Pucker and Macular Hole|Unknown status|Recruiting|Phase 3|50|Anticipated|University of Cologne||2|||f||||||||||||||2018-06-01 00:00:32.328323|2018-06-01 00:00:32.328323
NCT01082991|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2016-04-06|2010-03-08|2010-03-09|Estimate|||||||2016-04-06|2016-04-07|Estimate|October 2009||2009-10-31|April 2016|2016-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|PAR||Patient Acuity Rating: a Tool to Prevent In-Hospital Cardiac Arrest|Strategies to Predict and Prevent In-Hospital Cardiac Arrest|Withdrawn||Early Phase 1|0|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 00:00:32.483022|2018-06-01 00:00:32.483022
NCT01082978|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2017-07-31|2010-03-08|2010-03-09|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2010|Actual|2010-03-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|PHF-RCT||Portable Health Files Improve Quality of Care and Health Outcomes: a Randomized Controlled Trial|A Randomized Controlled Trial of Portable Electronic(USB)and Paper Medical Records as an Adjunct to Usual Care (Portable Health File RCT): an Evaluation of Short Term Quality Measures and Long-term Clinical Outcomes|Active, not recruiting||N/A|382|Anticipated|St George Hospital, Australia||3|||f||||t|f|||||||||2018-06-01 00:00:32.60868|2018-06-01 00:00:32.60868
NCT01082965|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2013-07-03||2013-07-03|2010-03-05|2010-03-09|Estimate|2013-07-03|2013-09-12|Estimate||||2013-07-03|2013-09-12|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease|A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease|Terminated||N/A|18|Actual|Pfizer|The study was terminated because of the prohibitively low recruitment rate and the reassessment of the Neuroscience Research Unit portfolio. The decision to terminate the study was not based on any safety or efficacy concerns.|2||"The study was terminated because of slow enrollment. The decision to terminate the trial was~   not based on any safety or efficacy concerns."|f||||f||||||||||2018-06-01 00:00:32.85875|2018-06-01 00:00:32.85875
NCT01082952|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2011-07-20||2011-10-11|2010-03-08|2010-03-09|Estimate|2011-10-11|2011-11-18|Estimate||||2011-10-11|2011-11-18|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Role of Eosinophils in the Proliferation of Airway Smooth Muscle (ASM) Cells|Role of Eosinophils in the Proliferation of ASM Cells in Asthma|Completed|||12|Actual|King Saud University|||2||f||||t||||||||||2018-06-01 00:00:33.94008|2018-06-01 00:00:33.94008
NCT01082939|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2011-07-26||2012-02-17|2010-03-08|2010-03-09|Estimate|2011-09-13|2011-10-21|Estimate||||2012-02-17|2012-02-20|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|80|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:00:34.354737|2018-06-01 00:00:34.354737
NCT01082926|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2015-06-03|2010-03-08|2010-03-09|Estimate|||||||2015-06-03|2015-06-08|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2|Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2|Completed||Phase 1|6|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 00:00:34.544807|2018-06-01 00:00:34.544807
NCT01082913|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|SSE||The Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology|Study of the Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Shiga University||2|||f||||f||||||||||2018-06-01 00:00:34.63725|2018-06-01 00:00:34.63725
NCT01082900|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2015-10-05|2010-03-08|2010-03-09|Estimate|||||||2015-10-05|2015-10-06|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Prophylactic Continuous Positive Airway Pressure (CPAP) in Delivery Room, in the Prevention of Transient Tachypnea of Newborn (TTN): A Randomized Controlled Trial|Prophylactic CPAP/PEEP in Delivery Room (DR) Resuscitation, Effects on Natriuretic Peptide in the Prevention of Transient Tachypnea of Newborn (TTN): A Randomized Controlled Trial|Completed||N/A|138|Actual|New York Hospital Queens||2|||f||||t||||||||||2018-06-01 00:00:35.633328|2018-06-01 00:00:35.633328
NCT01082887|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2016-08-05|2010-03-08|2010-03-09|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)|A Phase I/II Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)|Terminated||Phase 1/Phase 2|18|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-06-01 00:00:35.699963|2018-06-01 00:00:35.699963
NCT01082874|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|2016-07-14||2016-07-14|2010-03-08|2010-03-09|Estimate|2016-07-14|2016-08-25|Estimate||||2016-07-14|2016-08-25|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|March 2014|Actual|2014-03-31||Interventional|POISE-2||PeriOperative ISchemic Evaluation-2 Trial|A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event|Completed||Phase 3|10010|Actual|McMaster University||4|||f||||t||||||||||2018-06-01 00:00:35.83547|2018-06-01 00:00:35.83547
NCT01082861|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-18|2010-03-08|2010-03-09|Estimate|||||||2010-03-18|2010-03-19|Estimate|September 2010||2010-09-30|March 2010|2010-03-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|TANGO||Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination|A Phase 4, Randomized, Open Label Clinical Trial to Determine Efficacy and Immunomodulation of Simultaneous HPV/HBV Vaccination Tango-trial)|Terminated||Phase 4|0|Actual|National Institute for Public Health and the Environment (RIVM)||3||"Due to recent strategic policy developments in the national vaccination program it is uncertain~   preadolescent girls will receive the HBV vaccin."|f||||f||||||||||2018-06-01 00:00:37.363444|2018-06-01 00:00:37.363444
NCT01082848|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2013-02-21|2010-03-08|2010-03-09|Estimate|||||||2013-02-21|2013-02-22|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|ARIANE||ARIpiprazole in Anorexia NErvosa|Efficacy of Aripiprazole in the Treatment of Anorexia Nervosa in Teenagers: a Pilot, Randomised, Double Blind, Placebo-controlled Clinical Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 00:00:37.439165|2018-06-01 00:00:37.439165
NCT01082835|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-15|2010-03-08|2010-03-09|Estimate|||||||2010-03-15|2010-03-16|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|August 2010|Anticipated|2010-08-31|July 2010|Anticipated|2010-07-31||Observational|JZQG||Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat)Clinical Study|Jiangzhuo Qinggan Prescription and Irbesartan in the Treatment of Essential Hypertension(Hepatogastric Damp-heat), Randomized, Parallel-controlled, Multi-center Clinical Study|Unknown status|Not yet recruiting||240|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|||2||f||||t||||||||||2018-06-01 00:00:37.518224|2018-06-01 00:00:37.518224
NCT01082822|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|January 2012|Anticipated|2012-01-31|November 2011|Anticipated|2011-11-30||Interventional|||Periodontal Ligament Stem Cell Implantation in the Treatment of Periodontitis|Periodontal Ligament Stem Cell Implantation in the Treatment of Periodontitis|Unknown status|Active, not recruiting|Phase 1/Phase 2|80|Anticipated|Fourth Military Medical University||3|||f||||t||||||||||2018-06-01 00:00:37.598107|2018-06-01 00:00:37.598107
NCT01082809|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2014-05-13|2010-03-08|2010-03-09|Estimate|||||||2014-05-13|2014-05-14|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma|Phase II Study of Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma: Multicenter, Multinational Study|Completed||Phase 2|59|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 00:00:37.671056|2018-06-01 00:00:37.671056
NCT01082796|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|January 2010|Actual|2010-01-31|||||Interventional|||Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects|Investigate the Relationship Between CYP2C19 Genetic Polymorphisms and Pharmacokinetics of Glipizide in Healthy Chinese Subjects|Completed||N/A|14|Actual|Chinese Academy of Sciences||2|||f||||t||||||||||2018-06-01 00:00:37.738121|2018-06-01 00:00:37.738121
NCT01082783|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2018-02-01|2010-03-08|2010-03-09|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2009||2009-12-31|February 2018|2018-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|ARIMIS||Autoimmune Phenomena After Acute Stroke|Autoimmune Phenomena After Acute Stroke - the Role of Stroke-induced Immunodepression|Completed|||28|Actual|Charite University, Berlin, Germany|||2||f||||f||||||Samples Without DNA|"~     blood samples (serum and plasma)~   "|||2018-06-01 00:00:37.813599|2018-06-01 00:00:37.813599
NCT01082770|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2010-03-08|2010-03-08|2010-03-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|March 2010||2010-03-31|January 2010|2010-01-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|TEGO||Randomised Controlled Trial of Needle Free Access Devices in Preventing Hemodialysis Blood Stream Infection|A Randomised Controlled Trial Comparing Bacteraemia Rates in Closed Luer Lock Access Devices(TEGO) With Standard Devices in the Outpatient Haemodialysis Population|Unknown status|Enrolling by invitation|Phase 4|106|Anticipated|Beaumont Hospital||2|||f||||t||||||||||2018-06-01 00:00:37.904972|2018-06-01 00:00:37.904972
NCT01082757|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2014-07-30|2010-03-08|2010-03-09|Estimate|||||||2014-07-30|2014-07-31|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients|Prevalence of the Mutational Status of KRAS in mCRC in Argentine Patients|Completed|||1524|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 00:00:38.123306|2018-06-01 00:00:38.123306
NCT01082575|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2012-02-08||2014-08-05|2010-03-05|2010-03-08|Estimate|2012-09-04|2012-10-04|Estimate||||2014-08-05|2014-08-07|Estimate|February 2010||2010-02-28|August 2014|2014-08-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Oxygen Monitoring of Patients After Surgery on the Hospital General Care Floor|Oxygen Saturation Monitoring in the General Care Floor (GCF): An Observational Study of Repetitive Reductions in Airflow|Completed|||100|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-06-01 00:00:41.123353|2018-06-01 00:00:41.123353
NCT01082744|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2015-03-18|2010-03-08|2010-03-09|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|PARAVI||Thoracic Paravertebral Block for Postoperative Analgesia After Video-assisted Thoracic Surgery.|Thoracic Paravertebral Block: a Comparative Study of Ropivacaine With Ropivacaine and Sufentanil for Treating Pain After Video-assisted Thoracic Surgery.|Completed||Phase 3|90|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 00:00:38.188506|2018-06-01 00:00:38.188506
NCT01082731|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-04-12|2010-03-08|2010-03-09|Estimate|||||||2012-04-12|2012-04-13|Estimate|November 2010||2010-11-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PAACT-PF||Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil|A Multi-center, Open-label, Randomized, Phase 4, Trial of Artemether-Lumefantrine and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Falciparum Malaria Parasitemia in Pregnant Women in Brazil|Terminated||Phase 4|6|Actual|Centers for Disease Control and Prevention||2||Extremely slow enrollment|f||||t||||||||||2018-06-01 00:00:38.265777|2018-06-01 00:00:38.265777
NCT01082718|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-04-12|2010-03-08|2010-03-09|Estimate|||||||2012-04-12|2012-04-13|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection|Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection|Withdrawn||Phase 2/Phase 3|0|Actual|Centers for Disease Control and Prevention||2||Logistical difficulties|f||||t||||||||||2018-06-01 00:00:38.355437|2018-06-01 00:00:38.355437
NCT01082705|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-08|||2012-01-27|2010-03-08|2010-03-09|Estimate|||||||2012-01-27|2012-01-31|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children|Impact Tanzania in Vivo Efficacy 2010: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children Aged 6-59 Months|Completed||Phase 3|323|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 00:00:38.468026|2018-06-01 00:00:38.468026
NCT01082692|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2012-11-08|2010-03-05|2010-03-08|Estimate|||||||2012-11-08|2012-11-09|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HIV-001||Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants|A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants|Completed||Phase 1|12|Actual|Inovio Pharmaceuticals||1|||f||||t||||||||||2018-06-01 00:00:38.546774|2018-06-01 00:00:38.546774
NCT01082679|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-05|2010-03-05|2010-03-08|Estimate|||||||2010-03-05|2010-03-08|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Treatment for Opioid Dependent Offenders|Treatment for Opioid Dependent Offenders|Unknown status|Active, not recruiting|Phase 2/Phase 3|16|Actual|University of Wisconsin, Madison||3|||f||||f||||||||||2018-06-01 00:00:38.633725|2018-06-01 00:00:38.633725
NCT01082666|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2015-06-17|2010-03-05|2010-03-08|Estimate|||||||2015-06-17|2015-06-18|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Continuous Control of Tracheal Cuff Pressure and Microaspiration in Critically Ill Patients|Phase 4 Study of Continuous Control of Tracheal Cuff Pressure and Microaspiration in Critically Ill Patients|Completed||Phase 4|122|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-06-01 00:00:38.703125|2018-06-01 00:00:38.703125
NCT01082653|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-05-07|2010-03-05|2010-03-08|Estimate|||||||2014-05-07|2014-05-09|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|ALS||Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis|Phase I, Single Center, Prospective, Non-randomized, Open Label, Safety/Efficacy Study of the Infusion of Autologous Bone Marrow-derived Stem Cells, in Patients With Amyotrophic Lateral Sclerosis|Suspended||Phase 1|6|Anticipated|TCA Cellular Therapy||1||Suspended due to lack of funding.|f||||t||||||||||2018-06-01 00:00:38.780708|2018-06-01 00:00:38.780708
NCT01082640|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2013-05-31||2013-09-23|2010-03-05|2010-03-08|Estimate|2013-09-23|2013-09-25|Estimate||||2013-09-23|2013-09-25|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment|A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment|Completed||Phase 2|96|Actual|Takeda||3|||f||||t||||||||||2018-06-01 00:00:38.874279|2018-06-01 00:00:38.874279
NCT01082627|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-08-02|2010-03-05|2010-03-08|Estimate|||||||2011-08-02|2011-08-03|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction|Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction|Completed||Phase 4|44|Anticipated|Nanjing PLA General Hospital||2|||f||||t||||||||||2018-06-01 00:00:40.28688|2018-06-01 00:00:40.28688
NCT01082614|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2015-03-17||2018-03-05|2010-03-05|2010-03-08|Estimate|2015-03-23|2015-04-02|Estimate||||2018-03-05|2018-03-30|Actual|August 2009||2009-08-31|March 2018|2018-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Abdominal Surgery|Evaluation of the Use of Arterial Pulse Waveform Contour Analysis for Early Goal Directed Therapy in Patients Undergoing Major Abdominal Surgery|Completed||N/A|46|Actual|Loma Linda University||2|||f||||f||||||||||2018-06-01 00:00:40.375644|2018-06-01 00:00:40.375644
NCT01082601|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2012-10-15|2010-03-05|2010-03-08|Estimate|||||||2012-10-15|2012-10-17|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Catheter Ablation for Atrial Fibrillation and Heart Failure|Pulmonary Vein Isolation for Rhythm Control in Patients With Atrial Fibrillation and Left Ventricular Dysfunction: A Pilot Study|Withdrawn|||0|Actual|St. Luke's-Roosevelt Hospital Center|||1|no enrollment|f||||t||||||||||2018-06-01 00:00:40.662551|2018-06-01 00:00:40.662551
NCT01082588|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2013-11-20||2014-03-26|2010-03-05|2010-03-08|Estimate|2014-03-26|2014-04-28|Estimate||||2014-03-26|2014-04-28|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia|Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia|Completed||Phase 4|60|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 00:00:40.780546|2018-06-01 00:00:40.780546
NCT01082562|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-01-25|2010-03-05|2010-03-08|Estimate|||||||2011-01-25|2011-01-26|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study of BMS-844421 for Treatment of Hypercholesterolemia|Randomized, Double-blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study to Evaluate the Safety , Pharmacokinetics and Pharmacodynamics of BMS-844421 in Healthy Subjects and in Subjects With Elevated Cholesterol|Terminated||Phase 1|40|Actual|Bristol-Myers Squibb||16|||f||||f||||||||||2018-06-01 00:00:41.26914|2018-06-01 00:00:41.26914
NCT01082549|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05||2016-02-17|2016-02-17|2010-03-05|2010-03-08|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ECLIPSE||Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)|Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 3|780|Actual|Sanofi||2|||t||||t||||||||||2018-06-01 00:00:41.355427|2018-06-01 00:00:41.355427
NCT01082536|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2014-12-01|2010-03-05|2010-03-08|Estimate|||||||2014-12-01|2014-12-02|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||Prospective Analysis of Cerebral Perfusion Using Head Ultrasound and Multi-source-detector Near Infrared Spectroscopy (NIRS) Imaging|Prospective Analysis of Regional Cerebral Perfusion Using Head Ultrasound and Multi-source-detector Near Infrared Spectroscopy (NIRS) Imaging|Unknown status|Active, not recruiting||70|Anticipated|University of Texas Southwestern Medical Center|||6||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:00:41.753244|2018-06-01 00:00:41.753244
NCT01082523|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-05|2010-03-05|2010-03-08|Estimate|||||||2010-03-05|2010-03-08|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"|"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"|Unknown status|Recruiting|N/A|40|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 00:00:41.823979|2018-06-01 00:00:41.823979
NCT01082510|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-03-22|2010-03-05|2010-03-08|Estimate|||||||2011-03-22|2011-03-24|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)|Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study|Recruiting||Phase 3|288|Anticipated|Urological Oncology Council of Northern Tokyo||2|||f||||f||||||||||2018-06-01 00:00:41.955151|2018-06-01 00:00:41.955151
NCT01082497|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2012-04-11|2010-03-05|2010-03-08|Estimate|||||||2012-04-11|2012-04-12|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|MTS||Mindfulness Training for Staff (MTS)|Mindfulness Training and Developing the Ability of Empathy at an Inpatient Ward for Dual Diagnoses|Completed||Early Phase 1|53|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 00:00:42.020397|2018-06-01 00:00:42.020397
NCT01082484|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-10-05|2010-03-05|2010-03-08|Estimate|||||||2011-10-05|2011-10-06|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|INFLUX-IT-VS||Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers|Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers|Completed||Phase 1/Phase 2|20|Anticipated|University Hospital, Grenoble||3|||f||||||||||||||2018-06-01 00:00:42.086728|2018-06-01 00:00:42.086728
NCT01082471|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-05|2010-03-05|2010-03-08|Estimate|||||||2010-03-05|2010-03-08|Estimate|November 2005||2005-11-30|March 2010|2010-03-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours|A Randomised Double-blind Study to Compare the Analgesic Efficacy and Safety Profiles of M6G and Morphine, as a Loading Dose Followed by PCA, in Patients Suffering Moderate to Severe Post-operative Pain Requiring PCA for at Least 24 Hours|Completed||Phase 3|517|Actual|Paion UK Ltd.||2|||f||||f||||||||||2018-06-01 00:00:42.154958|2018-06-01 00:00:42.154958
NCT01082458|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-11-18|2010-03-05|2010-03-08|Estimate|||||||2010-11-18|2010-11-19|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia|Comparison of Lidocaine and Remifentanil for the Effect on Responses to the Endotracheal Tube During Emergence From General Anesthesia|Completed||N/A|67|Actual|Yonsei University|||||f||||t||||||||||2018-06-01 00:00:42.239195|2018-06-01 00:00:42.239195
NCT01082445|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-03-07|2010-03-05|2010-03-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effects of N-acetylcysteine on Diabetic Foot Oxygenation|Effects of Prolonged N-acetylcysteine Administration on Foot Ulcer Oxygenation in Diabetic Patients|Completed||Phase 3|100|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-06-01 00:00:42.294298|2018-06-01 00:00:42.294298
NCT01082432|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-05|2010-03-05|2010-03-08|Estimate|||||||2010-03-05|2010-03-08|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Observational|||Electrical Stimulation to Recover Greater Range of Motion After Surgery|Superimposed Electrical Stimulation Real-time Effects on Repeated Muscle Contractions Enable to Increase Recovery From Thumb Joint Stiffness After Surgery of the Ulnar Collateral Ligament|Completed|||25|Actual|Université Joseph Fourier|||||f||||f||||||||||2018-06-01 00:00:42.374875|2018-06-01 00:00:42.374875
NCT01082419|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2014-11-06|2010-03-05|2010-03-08|Estimate|||||||2014-11-06|2014-11-07|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|NARFI||Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity|Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity - Norms in ARFI: Distribution and Reproducibility of ARFI Values in Disease-free Livers or Pathological Livers.|Completed||N/A|109|Actual|University Hospital, Bordeaux||7|||f||||f||||||||||2018-06-01 00:00:42.451794|2018-06-01 00:00:42.451794
NCT01082406|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2016-09-20|2010-03-05|2010-03-08|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects|A Single Centre, Randomised, Double-blind, Cross-over Trial in Healthy Male Subjects Investigating Bioequivalence and Pharmacokinetics of rFXIII (Avecia DS) to rFXIII (Novo Nordisk DS)|Completed||Phase 1|51|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:00:42.54101|2018-06-01 00:00:42.54101
NCT01082393|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-12-04|2010-03-05|2010-03-08|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Koebner||Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)|Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)|Unknown status|Recruiting|Phase 4|10|Anticipated|University Hospital, Ghent||4|||f||||f||||||||||2018-06-01 00:00:42.629496|2018-06-01 00:00:42.629496
NCT01082380|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2011-09-12||2012-02-28|2010-03-05|2010-03-08|Estimate|2011-09-12|2011-10-26|Estimate||||2012-02-28|2012-02-29|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-02341066 In Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:00:42.738355|2018-06-01 00:00:42.738355
NCT01082367|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2015-12-22||2016-06-06|2010-03-05|2010-03-08|Estimate|2016-03-24|2016-04-27|Estimate||||2016-06-06|2016-07-15|Estimate|April 2010||2010-04-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EARLY||Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years|A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years|Completed||Phase 3|50|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:00:43.106667|2018-06-01 00:00:43.106667
NCT01082354|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2016-02-11|2010-03-05|2010-03-08|Estimate|||||||2016-02-11|2016-02-12|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|SEPAGE||A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)|Non Interventional Study on the Follow-up, by Specialists, of Short Children Born Small for Gestational Age and Treated With SAIZEN®- SEPAGE Study|Completed|||150|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:00:43.790618|2018-06-01 00:00:43.790618
NCT01082341|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2018-03-21|2010-03-05|2010-03-08|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2012||2012-06-30|March 2018|2018-03-31|September 2017|Actual|2017-09-30|May 2015|Actual|2015-05-31||Interventional|SPZ-Irrad||Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites|Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites|Completed||Phase 1/Phase 2|27|Actual|Malaria Vaccine and Drug Development Center||3|||f||||t||||||||||2018-06-01 00:00:43.925859|2018-06-01 00:00:43.925859
NCT01082328|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2013-05-31||2014-01-26|2010-03-05|2010-03-08|Estimate|2013-05-31|2013-08-01|Estimate||||2014-01-26|2014-02-27|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|ENDURE||Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period|ENDURE: A Phase IV, Prospective, Open-label, Uncontrolled, Multi-centre Cohort Trial to Assess the Responsiveness of Subjects With Phenylketonuria (PKU) to Treatment With Kuvan® 20 mg/kg/Day for 28 Days|Completed||Phase 4|59|Actual|Merck KGaA||1|||f||||f||||||||||2018-06-01 00:00:44.093054|2018-06-01 00:00:44.093054
NCT01082315|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2014-08-28|2010-03-05|2010-03-08|Estimate|||||||2014-08-28|2014-08-29|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment|A Korean Post-Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer|Completed|||730|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:00:44.422961|2018-06-01 00:00:44.422961
NCT01082302|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-09-07|2010-03-05|2010-03-08|Estimate|||||||2010-09-07|2010-09-08|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage|An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage|Completed||Phase 4|43|Actual|MediGene||2|||f||||f||||||||||2018-06-01 00:00:44.491122|2018-06-01 00:00:44.491122
NCT01082289|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-09-06|2010-03-05|2010-03-08|Estimate|||||||2011-09-06|2011-09-08|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Digoxin Drug-Drug Interaction With Lurasidone HCl|A Phase 1, Open-Label, Drug-Drug Interaction Study to Determine the Effect of Repeated Dose Lurasidone 120 mg Administration on the Pharmacokinetics of Orally Administered Digoxin 0.25 mg in Patients With Schizophrenia or Schizoaffective Disorder.|Completed||Phase 1|24|Actual|Sunovion|||||f||||||||||||||2018-06-01 00:00:44.573253|2018-06-01 00:00:44.573253
NCT01082276|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-09-06|2010-03-05|2010-03-08|Estimate|||||||2011-09-06|2011-09-08|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Rifampin Drug-Drug Interaction Study With Lurasidone HCl||Completed||Phase 1|20|Actual|Sunovion||1|||f||||t||||||||||2018-06-01 00:00:44.635853|2018-06-01 00:00:44.635853
NCT01082263|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-09-06|2010-03-05|2010-03-08|Estimate|||||||2011-09-06|2011-09-08|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Midazolam Drug-Drug Interaction Study With Lurasidone HCl||Completed||Phase 1|24|Anticipated|Sunovion||1|||f||||t||||||||||2018-06-01 00:00:44.704739|2018-06-01 00:00:44.704739
NCT01082250|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2011-09-06|2010-03-05|2010-03-08|Estimate|||||||2011-09-06|2011-09-08|Estimate|July 2008||2008-07-31|September 2011|2011-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Bioequivalence Of Two Different Lurasidone Formulations In Patients|AN OPEN-LABEL, RANDOMIZED, THREE-PERIOD, TWO-SEQUENCE CROSSOVER, REPEATED-DOSE, REPLICATE DESIGN STUDY TO DETERMINE THE BIOEQUIVALENCE OF TWO DIFFERENT LURASIDONE FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE, OR SCHIZOPHRENIFORM DISORDER|Completed||Phase 1|52|Anticipated|Sunovion||2|||f||||t||||||||||2018-06-01 00:00:44.773531|2018-06-01 00:00:44.773531
NCT01082237|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2013-04-15|2010-03-05|2010-03-08|Estimate|||||||2013-04-15|2013-04-16|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|BOLD||Biomarkers for Outcomes In Late-life Depression (BOLD)|Biomarkers for Outcomes In Late-life Depression|Completed||Phase 4|80|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-06-01 00:00:44.844784|2018-06-01 00:00:44.844784
NCT01082224|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2017-03-16|2010-03-05|2010-03-08|Estimate|||||||2017-03-16|2017-03-20|Actual|December 2010||2010-12-31|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|ACRIN6690||Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy|A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation|Active, not recruiting||N/A|440|Anticipated|American College of Radiology Imaging Network||1|||f||||t||||||||Yes|Data sharing plan is available on-line at https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx|2018-06-01 00:00:44.922299|2018-06-01 00:00:44.922299
NCT01082211|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|2017-05-03||2017-05-03|2010-03-05|2010-03-08|Estimate|2017-05-03|2017-06-08|Actual||||2017-05-03|2017-06-08|Actual|June 2010||2010-06-30|May 2017|2017-05-31||||November 2014|Actual|2014-11-30||Interventional||All eligible patients|Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery|A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma|Active, not recruiting||Phase 2|65|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 00:00:45.079639|2018-06-01 00:00:45.079639
NCT01082198|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2013-08-23|2010-03-05|2010-03-08|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2002||2002-10-31|March 2010|2010-03-31||||April 2010|Anticipated|2010-04-30||Interventional|||Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes|Adjuvant Vaccination With Melanoma Antigen Pulsed Dendritic Cells (DCs) in Stage III Melanoma Patients|Unknown status|Recruiting|Phase 1/Phase 2|22|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:00:45.373473|2018-06-01 00:00:45.373473
NCT01082185|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2016-10-17|2010-03-05|2010-03-08|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|February 2011|Actual|2011-02-28||Interventional|||South American Abdominal Stent Graft Trial|A Clinical Study to Evaluate the Safety and Performance of the TriVascular Modular Abdominal Stent Graft System|Completed||Phase 1|20|Actual|TriVascular, Inc.||1|||f||||t||||||||||2018-06-01 00:00:45.436742|2018-06-01 00:00:45.436742
NCT01082172|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-11-08|2010-03-05|2010-03-08|Estimate|||||||2012-11-08|2012-11-09|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||South American Thoracic Stent-Graft Study|A Pilot Trial to Evaluate the Performance of the TriVascular Thoracic Stent Graft System|Completed||Phase 1|2|Actual|TriVascular, Inc.|||||f||||f||||||||||2018-06-01 00:00:45.499415|2018-06-01 00:00:45.499415
NCT01082159|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2013-02-15||2013-02-21|2010-03-05|2010-03-08|Estimate|2013-02-21|2013-04-01|Estimate||||2013-02-21|2013-04-01|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|Completed||Phase 4|55|Actual|Vertos Medical, Inc.||1|||f||||t||||||||||2018-06-01 00:00:45.581558|2018-06-01 00:00:45.581558
NCT01082146|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2014-04-01|2010-03-05|2010-03-08|Estimate|||||||2014-04-01|2014-04-03|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [Issthiazolyl-3-14C]-Lurasidone Following Postprandial Single Oral Dose Administration in Health Male Subjects|Completed||Phase 1|6|Actual|Sunovion||1|||f||||t||||||||||2018-06-01 00:00:45.75416|2018-06-01 00:00:45.75416
NCT01082133|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2016-06-28|2010-03-05|2010-03-08|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2009||2009-10-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Multicenter Transplant Study for Fanconi Anemia|A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|Completed||Phase 2|45|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 00:00:45.819639|2018-06-01 00:00:45.819639
NCT01082120|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-07-09|2010-03-05|2010-03-08|Estimate|||||||2010-07-09|2010-07-12|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus|Open, Randomized, Phase I Study in Subjects With Type 2 Diabetes Mellitus Treated With Metformin to Evaluate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa|Completed||Phase 1|28|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:00:45.890336|2018-06-01 00:00:45.890336
NCT01082107|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-05|||2010-03-05|2010-03-05|2010-03-08|Estimate|||||||2010-03-05|2010-03-08|Estimate|October 2006||2006-10-31|June 2009|2009-06-30|August 2009|Actual|2009-08-31|||||Interventional|SODISWATER||Solar Disinfection of Drinking Water|Solar Disinfection of Drinking Water for Use in Developing Countries or in Emergency Situations|Completed||N/A|800|Actual|Council for Scientific and Industrial Research, South Africa||1|||f||||||||||||||2018-06-01 00:00:45.96266|2018-06-01 00:00:45.96266
NCT01082094|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-06-05|2010-03-04|2010-03-08|Estimate|||||||2012-06-05|2012-06-06|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure|An Open Label Dose Escalation Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure|Completed||Phase 1|17|Actual|Juventas Therapeutics, Inc.||1|||f||||t||||||||||2018-06-01 00:00:46.046395|2018-06-01 00:00:46.046395
NCT01082081|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2013-06-20||2015-04-27|2010-03-04|2010-03-08|Estimate|2015-01-12|2015-01-22|Estimate||||2015-04-27|2015-05-13|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Post-operative Dental Pain Study Comparing Analgesic Efficacy|A Study to Compare the Analgesic Efficacy of Two Different Paracetamol Doses as Measured by Post-operative Dental Pain Relief|Completed||Phase 4|300|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 00:00:46.149819|2018-06-01 00:00:46.149819
NCT01082068|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04||2016-05-09|2016-05-09|2010-03-05|2010-03-08|Estimate||||2016-05-09|2016-06-03|Estimate|2016-05-09|2016-06-03|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer|A Phase 1/2 Dose-Escalation Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Hormone Receptor-Positive and HER2-Negative Breast Cancer Refractory to a Nonsteroidal Aromatase Inhibitor|Completed||Phase 1/Phase 2|72|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:00:46.784663|2018-06-01 00:00:46.784663
NCT01074190|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2017-01-31|2010-02-23|2010-02-24|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of Neuraxial Analgesia on Maternal Breastfeeding|The Effect of Neuraxial Analgesia on Maternal Breastfeeding|Completed||N/A|345|Actual|Northwestern University||3|||f||||f||||||||No||2018-06-01 00:03:39.371181|2018-06-01 00:03:39.371181
NCT01082055|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2018-05-08|2010-03-04|2010-03-05|Estimate|||||||2018-05-08|2018-05-14|Actual|March 1, 2010||2010-03-01|March 2010|2010-03-31|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|||Antiarrythmic Drugs - Long-term Follow-up in the Modern Era|Retrospective Record Linkage Study to Investigate the Incidence of Complications and Follow-up Associated With Anti-arrythmic Drug Therapy|Completed|||5000|Anticipated|University of Dundee|||1||f||||f||||||||||2018-06-01 00:00:46.874692|2018-06-01 00:00:46.874692
NCT01082042|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|EXCELL||Exercising With Computers in Later Life|Exercising With Computers in Later Life (EXCELL) - Pilot and Feasibility Study of the Nintendo® WiiFit in Community-dwelling Fallers|Completed|||21|Actual|NHS Grampian|||2||f||||f||||||||||2018-06-01 00:00:46.92738|2018-06-01 00:00:46.92738
NCT01082029|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2015-04-12|2010-03-04|2010-03-05|Estimate|||||||2015-04-12|2015-04-14|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children|Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study|Completed||Phase 4|65|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 00:00:46.988283|2018-06-01 00:00:46.988283
NCT01082016|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-09-17|2010-03-04|2010-03-05|Estimate|||||||2010-09-17|2010-09-20|Estimate|April 2010||2010-04-30|March 2010|2010-03-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|||Sleep Promotion in Critically Ill and Injured Patients Cared for in the Intensive Care Unit||Unknown status|Enrolling by invitation|N/A|75|Anticipated|University of Arizona||2|||f||||t||||||||||2018-06-01 00:00:47.151355|2018-06-01 00:00:47.151355
NCT01082003|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-08-27|2010-03-04|2010-03-05|Estimate|||||||2013-08-27|2013-08-28|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|June 2014|Anticipated|2014-06-30|August 2013|Anticipated|2013-08-31||Interventional|||Prevention of Capsular Contracture Using Trental and Vitamin E|A Single Center, Prospective Treatment Trial to Assess Prophylactic Use of Trental (Pentoxifylline) and Vitamin E to Prevent Capsular Contracture After Implant Reconstruction in Patients Requiring Adjuvant Radiation Therapy|Unknown status|Active, not recruiting|N/A|30|Actual|Legacy Health System||2|||f||||t||||||||||2018-06-01 00:00:47.251946|2018-06-01 00:00:47.251946
NCT01081990|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-07-23|2010-03-04|2010-03-05|Estimate|||||||2013-07-23|2013-07-24|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Use of Cyclobenzaprine After Vaginal Surgery|The Short-term Use of Cyclobenzaprine in Patients Undergoing Vaginal Surgery|Unknown status|Recruiting|N/A|60|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||t||||||||||2018-06-01 00:00:47.346897|2018-06-01 00:00:47.346897
NCT01081977|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-08-01|2010-03-04|2010-03-05|Estimate|||||||2012-08-01|2012-08-02|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants|Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants at Birth and Three Months of Age|Completed||Phase 2|340|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 00:00:47.468117|2018-06-01 00:00:47.468117
NCT01081964|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-05-04|2010-03-04|2010-03-05|Estimate|||||||2012-05-04|2012-05-07|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia|A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity|Terminated||Phase 2|48|Actual|IASO Pharma Inc.||3||Financial considerations|f||||f||||||||||2018-06-01 00:00:47.563509|2018-06-01 00:00:47.563509
NCT01081951|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2012-11-12||2018-02-27|2010-03-04|2010-03-05|Estimate|2012-11-12|2012-12-10|Estimate||||2018-02-27|2018-03-01|Actual|February 4, 2010|Actual|2010-02-04|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|October 10, 2011|Actual|2011-10-10||Interventional|||Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer|A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer|Active, not recruiting||Phase 2|162|Actual|AstraZeneca||2|||t||||f||||||||||2018-06-01 00:00:47.73127|2018-06-01 00:00:47.73127
NCT01081938|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-03-26|2010-03-04|2010-03-05|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition|National, Phase IV, Multicentric, Open Label, Comparative Study to Evaluate the Efficacy and Safety of Insulin Glargine Plus Glulisine and Sliding Scale Plus Glulisine in Hospitalized Patients With Diabetes Metabolism Type II Under Enteral Nutrition.|Terminated||Phase 4|15|Actual|Sanofi||2||Recruitment challenges|f||||f||||||||||2018-06-01 00:00:48.382701|2018-06-01 00:00:48.382701
NCT01081925|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Congestive Heart Failure: Causes of Sudden Worsening|Congestive Heart Failure: Causes of Sudden Worsening|Unknown status|Recruiting||100|Anticipated|University Hospital Hradec Kralove|||1||f||||f||||||||||2018-06-01 00:00:48.503583|2018-06-01 00:00:48.503583
NCT01081912|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2014-02-04|2012-07-18|2014-03-25|2010-03-04|2010-03-05|Estimate|2014-03-25|2014-04-21|Estimate|2012-08-06|2012-08-15|Estimate|2014-03-25|2014-04-21|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Out of 510 subjects treated with Hydrocodone Bitartrate Extended Release (HC-ER) capsules in the Conversion/Titration Phase, 208 subjects discontinued early and 151 subjects were randomized into each of the two treatment groups (Maintenance HC-ER Treatment and Placebo Treatment).|Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain|A Randomized Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Tolerability and Safety of Hydrocodone Bitartrate Controlled-Release Capsules in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain|Completed||Phase 3|510|Actual|Zogenix, Inc.||2|||f||||f||||||||||2018-06-01 00:00:48.582853|2018-06-01 00:00:48.582853
NCT01081899|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-01-11|2010-03-04|2010-03-05|Estimate|||||||2013-01-11|2013-01-14|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effectiveness of the LCP in Improving End of Life Care for Dying Cancer Patients in Hospital.|The Effectiveness of the Liverpool Care Pathway in Improving End of Life Care for Dying Cancer Patients in Hospital. A Cluster Randomised Trial.|Completed||Phase 3|308|Actual|Regional Palliative Care Network||2|||f||||f||||||||||2018-06-01 00:00:49.045477|2018-06-01 00:00:49.045477
NCT01081886|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2012-11-29||2013-01-03|2010-03-04|2010-03-05|Estimate|2012-11-29|2013-01-03|Estimate||||2013-01-03|2013-01-08|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PRECISE||PEAK PlasmaBlade 4.0 Versus Traditional Electrosurgery in Total Knee Replacement.|A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade 4.0 in Total Knee Replacement|Terminated||N/A|24|Actual|Medtronic Surgical Technologies|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.|2||Termination due to acquisition of PEAK Surgical by Medtronic|f||||f||||||||||2018-06-01 00:00:49.13566|2018-06-01 00:00:49.13566
NCT01081873|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|2011-12-22||2012-10-26|2010-03-04|2010-03-05|Estimate|2012-02-22|2012-03-26|Estimate||||2012-10-26|2012-10-31|Estimate|June 2004||2004-06-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer|A Post-Marketing Observational Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatment of Advanced Prostate Cancer|Completed|||2717|Actual|Abbott|||1||f||||||||||||||2018-06-01 00:00:49.431609|2018-06-01 00:00:49.431609
NCT01081860|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-04-26|2010-03-04|2010-03-05|Estimate|||||||2010-04-26|2010-04-27|Estimate|May 2010||2010-05-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Observational|STIF-CTS||Stiffness of the Skin and Joints in Relation to Carpal Tunnel Syndrome|Correlation of Joint Stiffness and Stiffness of the Skin and the Prevelation of Carpal Tunnel Syndrome (CTS)|Unknown status|Not yet recruiting||40|Anticipated|St. Antonius Hospital|||4||f||||f||||||||||2018-06-01 00:00:51.35956|2018-06-01 00:00:51.35956
NCT01081847|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2010-03-05|2010-03-04|2010-03-05|Estimate|||||||2010-03-05|2010-03-08|Estimate|July 2005||2005-07-31|March 2010|2010-03-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|Fase1B||Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants|Malaria Vaccine Phase IB Clinical Trial: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants|Completed||Phase 1|40|Actual|Malaria Vaccine and Drug Development Center||5|||f||||t||||||||||2018-06-01 00:00:51.445303|2018-06-01 00:00:51.445303
NCT01081834|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2013-04-15|2012-04-24|2017-02-15|2010-03-04|2010-03-05|Estimate|2013-04-15|2013-06-03|Estimate|2012-04-24|2012-04-26|Estimate|2017-02-15|2017-02-23|Actual|March 2010||2010-03-31|June 2013|2013-06-30|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise|Completed||Phase 3|678|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-06-01 00:00:51.735478|2018-06-01 00:00:51.735478
NCT01081821|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-09-05|2010-03-04|2010-03-05|Estimate|||||||2013-09-05|2013-09-06|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent|A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Investigate the Safety and Pharmacokinetics of JNJ-39758979 in Healthy Japanese and Caucasian Adult Male Subjects|Completed||Phase 1|61|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 00:00:53.329489|2018-06-01 00:00:53.329489
NCT01081808|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2015-03-24|2010-03-04|2010-03-05|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors|A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors|Terminated||Phase 1|2|Actual|Roger Williams Medical Center||1||Funding ended|f||||t||||||||||2018-06-01 00:00:53.422872|2018-06-01 00:00:53.422872
NCT01081795|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2013-03-19||2013-06-20|2010-03-04|2010-03-05|Estimate|2013-03-19|2013-05-06|Estimate||||2013-06-20|2013-07-02|Estimate|April 2007||2007-04-30|June 2013|2013-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine|A Placebo-Controlled Dose-Finding Study of JNS019 (Topiramate) in Migraine Patients|Completed||Phase 2|387|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 00:00:53.617802|2018-06-01 00:00:53.617802
NCT01081782|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04||2013-11-30|2013-11-30|2010-03-04|2010-03-05|Estimate||||2013-11-30|2013-12-25|Estimate|2013-11-30|2013-12-25|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|DreaMS||A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis|A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|407|Actual|Ono Pharmaceutical Co. Ltd||4|||f||||t||||||||||2018-06-01 00:00:54.649208|2018-06-01 00:00:54.649208
NCT01081769|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2014-11-17||2015-02-17|2010-03-04|2010-03-05|Estimate|2015-02-17|2015-02-18|Estimate||||2015-02-17|2015-02-18|Estimate|February 2010||2010-02-28|February 2015|2015-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PROSIPAL|Whole Intent-to-Treat population: All randomized patients who received at least 1 dose of study medication during the screening or treatment phase|Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics|A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia|Completed||Phase 3|769|Actual|Janssen-Cilag International NV||2|||f||||f||||||||||2018-06-01 00:00:54.926914|2018-06-01 00:00:54.926914
NCT01081756|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2014-07-30|2010-03-04|2010-03-05|Estimate|||||||2014-07-30|2014-07-31|Estimate|December 2003||2003-12-31|March 2010|2010-03-31|September 2004|Actual|2004-09-30|||||Interventional|||A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)|An Open, Randomized, Comparative Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)|Completed||Phase 3|218|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 00:00:56.187858|2018-06-01 00:00:56.187858
NCT01080183|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|||2016-01-13|2010-03-02|2010-03-03|Estimate|||||||2016-01-13|2016-01-15|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Functional Assessment Screening Tablets - Patient Reported Measures|Functional Assessment Screening Tablets - Patient Reported Measures Translating Research Into Practice Pilot|Completed||N/A|150|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:01:18.931922|2018-06-01 00:01:18.931922
NCT01081743|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-08-25|2010-03-04|2010-03-05|Estimate|||||||2017-08-25|2017-08-28|Actual|November 24, 2009|Actual|2009-11-24|August 2017|2017-08-31|October 2, 2013|Actual|2013-10-02|October 2, 2013|Actual|2013-10-02||Interventional|AIDALZ||Effectiveness of Care Management in Alzheimer Patients|Evaluation de la Mise en Place d'un Auxiliaire d'évaluation Dans la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées en France|Completed||N/A|270|Actual|Institut de Sante Publique, d'Epidemiologie et de Developpement||2|||f||||t||||||||||2018-06-01 00:00:56.27928|2018-06-01 00:00:56.27928
NCT01081730|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2018-03-28|2010-03-04|2010-03-05|Estimate|||||||2018-03-28|2018-03-30|Actual|February 9, 2010|Actual|2010-02-09|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database|A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Psoriasis Treated With Ustekinumab and Other Types of Biological and Systemic Non-biological Treatments|Active, not recruiting|||2000|Anticipated|Janssen Biotech, Inc.|||5||f||||f|f|||||||||2018-06-01 00:00:56.361707|2018-06-01 00:00:56.361707
NCT01081717|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-11-24|2010-03-04|2010-03-05|Estimate|||||||2017-11-24|2017-11-28|Actual|April 14, 2009|Actual|2009-04-14|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Golimumab Safety and Surveillance Program Using the Ingenix NHI Database|A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments|Active, not recruiting|||400|Anticipated|Janssen Biotech, Inc.|||5||f||||f||f||||||||2018-06-01 00:00:56.443922|2018-06-01 00:00:56.443922
NCT01081704|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-05-26|2010-03-04|2010-03-05|Estimate|||||||2014-05-26|2014-05-28|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects|A Study to Evaluate the Pharmacokinetics of Ustekinumab Following a Single Subcutaneous Administration of 45 mg or 90 mg to Healthy, Chinese, Male Subjects|Completed||Phase 1|24|Actual|Centocor, Inc.||2|||f||||f||||||||||2018-06-01 00:00:56.530517|2018-06-01 00:00:56.530517
NCT01081691|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-09-30|2010-03-04|2010-03-05|Estimate|||||||2010-09-30|2010-10-01|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|September 2010|Actual|2010-09-30|||||Interventional|||A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 5825 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects|Completed||Phase 1|64|Actual|Centocor, Inc.||7|||f||||||||||||||2018-06-01 00:00:56.604613|2018-06-01 00:00:56.604613
NCT01081678|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04||2014-01-15|2014-01-15|2010-03-04|2010-03-05|Estimate||||2014-01-15|2014-02-12|Estimate|2014-01-15|2014-02-12|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Study To Assess Fracture Healing With Sclerostin Antibody|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults With a Fresh Unilateral Hip Fracture, Status Post Surgical Fixation|Completed||Phase 2|332|Actual|Amgen||4|||f||||||||||||||2018-06-01 00:00:56.709216|2018-06-01 00:00:56.709216
NCT01081665|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|2012-02-07||2012-03-26|2010-03-04|2010-03-05|Estimate|2012-02-07|2012-03-12|Estimate||||2012-03-26|2012-03-27|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism|A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism|Completed|||237|Actual|Abbott|||1||f||||||||||||||2018-06-01 00:00:56.908321|2018-06-01 00:00:56.908321
NCT01081652|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2014-07-30|2010-03-04|2010-03-05|Estimate|||||||2014-07-30|2014-07-31|Estimate|May 2004||2004-05-31|March 2010|2010-03-31|May 2005|Actual|2005-05-31|||||Interventional|||A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)|An Open, Randomized, Comparative, Phase III Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)|Completed||Phase 3|238|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 00:00:57.424589|2018-06-01 00:00:57.424589
NCT01081639|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-07-30|2010-03-04|2010-03-05|Estimate|||||||2014-07-30|2014-07-31|Estimate|November 2003||2003-11-30|November 2010|2010-11-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid Pen|Phase III Study on the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Formulation Applied by a Pen Versus Follitropin Beta Liquid Formulation Applied by Pen|Completed||Phase 3|34|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 00:00:57.499189|2018-06-01 00:00:57.499189
NCT01081626|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|2012-09-03||2014-01-20|2010-03-04|2010-03-05|Estimate|2012-10-08|2012-11-07|Estimate||||2014-01-20|2014-02-13|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction|A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II)|Completed||Phase 4|310|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:00:57.595301|2018-06-01 00:00:57.595301
NCT01081613|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-09-05|2010-03-04|2010-03-05|Estimate|||||||2012-09-05|2012-09-06|Estimate|February 2010||2010-02-28|September 2012|2012-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)|Imaging the Effect of HSP90 Inhibitor AUY922 on VEGF by Means of 89Zr-bevacizumab PET|Completed|||7|Actual|University Medical Center Groningen|||1||f||||t||||||||||2018-06-01 00:00:57.986352|2018-06-01 00:00:57.986352
NCT01081600|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-05-13|2010-03-04|2010-03-05|Estimate|||||||2013-05-13|2013-05-14|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|AUY922||89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition|Imaging the Effect of HSP90 Inhibitor AUY922 on HER2 Expression by Means of 89Zr-trastuzumab PET. Side Study to Phase I-II Study With AUY922 in Either HER2 or ER Positive Locally Advanced or Metastatic Breast Cancer: Protocol CAUY922A2101|Completed|||7|Actual|University Medical Center Groningen|||1||f||||t||||||||||2018-06-01 00:00:58.070244|2018-06-01 00:00:58.070244
NCT01081587|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2013-05-14|2010-03-04|2010-03-05|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|PREDIRE||Preventing Malnutrition and Restoring Nutritional Status in Hospitalized Children|Developing an Organization to Improve the Screening and Care of Starved Children in Hospital|Completed||N/A|1457|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 00:00:58.134689|2018-06-01 00:00:58.134689
NCT01081574|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-09-25|2010-03-04|2010-03-05|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)|A Multicentre, International, Adaptive, Open-label, Repeated Administration Pharmacokinetic Study of Bilastine in Children From 2 to <12 Years of Age With Allergic Rhinoconjunctivitis or Chronic Urticaria|Completed||Phase 1/Phase 2|36|Actual|Faes Farma, S.A.||1|||f||||f||||||||||2018-06-01 00:00:58.201834|2018-06-01 00:00:58.201834
NCT01081561|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-12-17|2010-03-04|2010-03-05|Estimate|||||||2012-12-17|2012-12-18|Estimate|June 2009||2009-06-30|December 2012|2012-12-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs|Randomized Study of Corneal Collagen Cross-Linking With the UV-X System for the Treatment of Keratectasia in Eyes With Intacs Compared to Eyes Without Intacs|Unknown status|Recruiting|Phase 2/Phase 3|400|Anticipated|Cornea Genetic Eye Institute||2|||f||||t||||||||||2018-06-01 00:00:58.284725|2018-06-01 00:00:58.284725
NCT01081548|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Clinical Trial Study to Evaluate Efficacy and Safety of Atorvastatin in Korean Patients With Hypercholesterolemia|A Multi-center, Randomized, Open-labeled Clinical Trial to Evaluate Efficacy and Safety of Lipinon® 20mg Versus Lipitor® 20mg in Korean Patients With Hypercholesterolemia|Completed||Phase 4|17|Actual|Yonsei University||2|||f||||||||||||||2018-06-01 00:00:58.358603|2018-06-01 00:00:58.358603
NCT01081535|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|May 2009||2009-05-31|January 2010|2010-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effect of Intravenous (IV) Patient Controlled Analgesic (PCA) With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy|The Effect of IV PCA With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy|Completed||N/A|50|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 00:00:58.426359|2018-06-01 00:00:58.426359
NCT01081522|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds|A Preliminary, Non-comparative Study to Evaluate a Bioresorbable Wound Scaffold in Acute Wounds|Completed|||12|Actual|ConvaTec Inc.|||||f||||||||||Samples With DNA|"~     tissue (3mm punch biopsy)~   "|||2018-06-01 00:00:58.491056|2018-06-01 00:00:58.491056
NCT01081509|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2011-11-15|2010-03-04|2010-03-05|Estimate|||||||2011-11-15|2011-11-16|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|ARIADNE||Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence|Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex|Completed|||1077|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:00:58.553143|2018-06-01 00:00:58.553143
NCT01081496|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2011-03-15|2010-03-04|2010-03-05|Estimate|||||||2011-03-15|2011-03-16|Estimate|March 2010||2010-03-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Observational|Spanish REASON||Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)|Epidemiological Study to Evaluate the Prevalence of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)|Completed|||1000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 00:00:58.642993|2018-06-01 00:00:58.642993
NCT01081483|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-10-22|2010-03-04|2010-03-05|Estimate|||||||2010-10-22|2010-10-25|Estimate|March 2010||2010-03-31|September 2010|2010-09-30||||June 2010|Actual|2010-06-30||Interventional|||A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults|A Blinded, Randomized, Placebo-controlled Phase 1 Study in Healthy Male Adults to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Doses of ABT-072|Completed||Phase 1|24|Actual|Abbott||2|||f||||f||||||||||2018-06-01 00:00:58.724444|2018-06-01 00:00:58.724444
NCT01081457|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-02-06|2010-03-04|2010-03-05|Estimate|||||||2012-02-06|2012-02-07|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SCP-Comodig||Effect of Deep Brain Stimulation on Gastrointestinal (GI) Motility|Effect of Deep Brain Stimulation on Voluntary and Involuntary Gastrointestinal Motility in Parkinson's Disease|Completed||N/A|16|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-06-01 00:00:58.786103|2018-06-01 00:00:58.786103
NCT01081444|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-03-22|2010-03-04|2010-03-05|Estimate|||||||2012-03-22|2012-03-23|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|rTMS AVC||Repetitive Transcranial Stimulation (rTMS) in Post Stroke Dysphagia|Effect of Pharyngeal Inhibition Induced by Repetitive Transcranial Stimulation in Post Stroke Dysphagia|Completed||Phase 4|30|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-06-01 00:00:58.844527|2018-06-01 00:00:58.844527
NCT01081431|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2017-09-06|2010-03-04|2010-03-05|Estimate|||||||2017-09-06|2017-09-11|Actual|March 2010||2010-03-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|MDS-LE-MON-5||Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q|A Multicenter, Single-arm, Open-label Phase II Study of the Safety of Lenalidomide Monotherapy and Markers for Disease Progression in Patients With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Associated With an Isolated Deletion 5q Cytogenetic Abnormality (Del 5q)|Active, not recruiting||Phase 2|91|Actual|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||1|||f||||t||||||||||2018-06-01 00:00:58.913482|2018-06-01 00:00:58.913482
NCT01081418|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|April 2005||2005-04-30|March 2010|2010-03-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|ACCESS||Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders|Assertive Community Treatment (ACT) as Part of Integrated Care Versus Standard Care: a 12-month Trial in Patients With First- and Negatively Selected Multiple-episode Schizophrenia-spectrum Disorders Treated With Quetiapine IR|Completed||Phase 4|120|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-06-01 00:00:58.997912|2018-06-01 00:00:58.997912
NCT01074177|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2018-01-24||2018-03-05|2010-02-22|2010-02-24|Estimate|2018-03-05|2018-03-09|Actual||||2018-03-05|2018-03-09|Actual|February 2011||2011-02-28|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Understanding Mechanisms of Acquired Resistance to BIBW2992|Understanding Mechanisms of Acquired Resistance to BIBW2992|Completed||N/A|24|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:03:39.476054|2018-06-01 00:03:39.476054
NCT01081405|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2017-09-05|2010-03-04|2010-03-05|Estimate|||||||2017-09-05|2017-09-06|Actual|November 2007||2007-11-30|September 2017|2017-09-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|TLI||Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients With Hematologic Malignancies|Recruiting||Phase 2|20|Anticipated|Fondazione Neoplasie Sangue Onlus||1|||f||||t||||||||||2018-06-01 00:00:59.060088|2018-06-01 00:00:59.060088
NCT01081392|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Interventional|||Inflammatory Markers in Sputum After LPS Inhalation|The Role of Inhaled Particle Size on the Inflammatory Response Induced by Endotoxin Inhalation|Unknown status|Active, not recruiting|N/A|12|Actual|Centre Hospitalier Universitaire Brugmann||6|||f||||f||||||||||2018-06-01 00:00:59.128896|2018-06-01 00:00:59.128896
NCT01081379|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-02-20|2010-03-04|2010-03-05|Estimate|||||||2012-02-20|2012-02-22|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|August 2014|Anticipated|2014-08-31|February 2014|Anticipated|2014-02-28||Observational|||The Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection|The Relation Between the Maternal Cellular Immune System and Cytomegalovirus Intrauterine Infection|Unknown status|Not yet recruiting||100|Anticipated|Shaare Zedek Medical Center|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:00:59.205704|2018-06-01 00:00:59.205704
NCT01081366|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2016-01-21|2010-03-04|2010-03-05|Estimate|||||||2016-01-21|2016-01-22|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|||Drug Eluting Pantera Lux Catheter Registry|Evaluation of the Safety Profile of the Pantera Lux Paclitaxel Releasing Balloon for Coronary Arteries in Daily Clinical Practice|Completed|||1064|Actual|Biotronik AG|||||f||||t||||||||No||2018-06-01 00:00:59.265928|2018-06-01 00:00:59.265928
NCT01081353|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2014-06-25|2010-03-04|2010-03-05|Estimate|||||||2014-06-25|2014-06-26|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin|An Open Label 4-Way Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Effervescent Aspirin in Healthy Adult Subjects|Completed||Phase 1|26|Actual|Bayer||4|||f||||t||||||||||2018-06-01 00:00:59.322707|2018-06-01 00:00:59.322707
NCT01081340|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2017-11-02|2010-03-03|2010-03-05|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2010||2010-05-31|January 2017|2017-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Building Social Networks to Enhance Postpartum Weight Loss and Appropriate Infant Feeding Practices|Building Social Networks to Enhance Postpartum Weight Loss and Appropriate Infant Feeding Practices|Completed||N/A|41|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-06-01 00:00:59.42713|2018-06-01 00:00:59.42713
NCT01081327|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-06-24|2010-03-04|2010-03-05|Estimate|||||||2010-06-24|2010-06-25|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Warfarin - How Good Are we at Maintaining Target Range ?|Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.|Unknown status|Active, not recruiting||5000|Anticipated|University of Dundee|||1||f||||f||||||||||2018-06-01 00:00:59.4904|2018-06-01 00:00:59.4904
NCT01081314|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2015-11-20|2010-03-03|2010-03-05|Estimate|||||||2015-11-20|2015-11-23|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Treating PTSD in Patients With Borderline Personality Disorder|Treating PTSD in Patients With Borderline Personality Disorder|Completed||Phase 1/Phase 2|39|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 00:00:59.622563|2018-06-01 00:00:59.622563
NCT01081301|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2013-11-06||2014-07-22|2010-03-03|2010-03-05|Estimate|2014-07-22|2014-07-23|Estimate||||2014-07-22|2014-07-23|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|LWH||Living With Hope Program for Rural Women Caregivers|Living With Hope: Developing a Psychosocial Supportive Program for Rural Older Women Caregivers of Spouses With Advanced Cancer|Completed||Phase 2|36|Actual|University of Saskatchewan||1|||f||||f||||||||||2018-06-01 00:00:59.713123|2018-06-01 00:00:59.713123
NCT01081288|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2018-05-03|2010-03-04|2010-03-05|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2009||2009-06-30|May 2018|2018-05-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|AgeX||Extending the National Health Service (NHS) Breast Screening Age Range|Nationwide Cluster-randomised Trial of Extending the NHS Breast Screening Age Range in England|Enrolling by invitation||N/A|6000000|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 00:01:00.129136|2018-06-01 00:01:00.129136
NCT01081275|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2015-04-14|2010-03-04|2010-03-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Improving Hand Use in Multiple Sclerosis|Rehabilitating Extremity Use After Multiple Sclerosis|Unknown status|Active, not recruiting|Phase 2|66|Anticipated|National Multiple Sclerosis Society||2|||f||||t||||||||||2018-06-01 00:01:00.237022|2018-06-01 00:01:00.237022
NCT01081262|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-08-21|2010-03-04|2010-03-05|Estimate|||||||2017-08-21|2017-08-22|Actual|October 12, 2010|Actual|2010-10-12|August 2017|2017-08-31||||February 25, 2015|Actual|2015-02-25||Interventional|||Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer|A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)|Active, not recruiting||Phase 3|16|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-06-01 00:01:00.419275|2018-06-01 00:01:00.419275
NCT01081249|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2014-09-16||2014-10-13|2010-03-04|2010-03-05|Estimate|2014-10-13|2014-10-16|Estimate||||2014-10-13|2014-10-16|Estimate|December 2008||2008-12-31|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|OT-PT||Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting|Physiologic Correlates of Perceived [Therapist] Empathy and Social-Emotional Process During Psychotherapy: Testing Oxytocin in a Cross-Over Design Pilot Study|Completed||Phase 4|18|Actual|MacDonald, Kai, M.D.||2|||f||||f||||||||||2018-06-01 00:01:00.867188|2018-06-01 00:01:00.867188
NCT01081236|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2010-12-15|2010-03-04|2010-03-05|Estimate|||||||2010-12-15|2010-12-16|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|||Intestinal Barrier Function and Liver Cirrhosis|The Role of the Intestinal Barrier Function in Liver Cirrhosis|Unknown status|Recruiting||62|Anticipated|Maastricht University Medical Center|||2||f||||f||||||||||2018-06-01 00:01:01.022784|2018-06-01 00:01:01.022784
NCT01081223|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2013-06-04|2010-03-03|2010-03-05|Estimate|||||||2013-06-04|2013-06-06|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma|Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma|Completed||Phase 1/Phase 2|14|Actual|TVAX Biomedical||1|||f||||f||||||||||2018-06-01 00:01:01.09647|2018-06-01 00:01:01.09647
NCT01081210|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-03-29|2010-03-04|2010-03-05|Estimate|||||||2011-03-29|2011-03-30|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|||Screening of Patients Admitted to a Local Hospital With Pocket-sized Ultrasound|Screening With Pocket-sized Ultrasound of Patients Admitted to Department of Medicine at a Local Hospital|Completed|||400|Anticipated|Levanger Hospital|||1||f||||t||||||Samples Without DNA|"~     Serum blood samples including; hematology, electrolytes, creatinine, liver enzymes and~     cholestasis parametres, brain natriuretic peptides etc.~   "|||2018-06-01 00:01:01.191333|2018-06-01 00:01:01.191333
NCT01081197|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-05-02|2010-03-04|2010-03-05|Estimate|||||||2013-05-02|2013-05-03|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|||Somatic Disease Among Alcohol Abusers in an Out-day Patients' Clinic|Somatic Disease Among Alcohol Abusers in an Out-day Patients' Clinic. A Neglected Area|Completed|||150|Actual|Levanger Hospital|||2||f||||f||||||Samples Without DNA|"~     Conventional blood samples including i.e. glycosylated haemoglobin, serum ferritin, serum~     gamma-GT, B-type natriuretic peptide.~   "|||2018-06-01 00:01:01.266196|2018-06-01 00:01:01.266196
NCT01081184|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2013-04-16|2010-03-04|2010-03-05|Estimate|||||||2013-04-16|2013-04-17|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Observational|Neuro-SGSp||Neurotrophins Implications in Primary Sjögren Syndrome|Neurotrophins Implications in Primary Sjögren Syndrome|Completed|||40|Actual|University Hospital, Limoges|||2||f||||f||||||||||2018-06-01 00:01:01.378369|2018-06-01 00:01:01.378369
NCT01081158|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2015-02-06|2010-03-03|2010-03-05|Estimate|||||||2015-02-06|2015-02-09|Estimate|July 2007||2007-07-31|February 2015|2015-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)|Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)|Completed||Phase 1|41|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 00:01:01.451209|2018-06-01 00:01:01.451209
NCT01081145|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2014-05-09||2014-11-25|2010-03-04|2010-03-05|Estimate|2014-05-09|2014-06-09|Estimate||||2014-11-25|2014-12-15|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Open-label Safety Population defined as all subjects who took at least 1 dose of any investigational product during the study. Two subjects did not receive investigational product, therefore n = 526.|Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)|A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised Withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention Deficit/Hyperactivity Disorder|Completed||Phase 3|528|Actual|Shire||2|||f||||||||||||||2018-06-01 00:01:01.556445|2018-06-01 00:01:01.556445
NCT01081132|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2014-03-26||2014-06-06|2010-03-04|2010-03-05|Estimate|2014-04-28|2014-05-23|Estimate||||2014-06-06|2014-06-13|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Used Safety Population which is defined as all randomized subjects who took at least 1 dose of investigational product. Two subjects did not take investigational product, therefore n = 312.|Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl|A Phase 3, Double-blind, Randomized, Multi-center, Placebo Controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Adolescents Aged 13-17 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|314|Actual|Shire|For the secondary outcomes, the p-values are not controlled for multiplicity, therefore they should be considered as descriptive not inferential.|2|||f||||f||||||||||2018-06-01 00:01:03.166031|2018-06-01 00:01:03.166031
NCT01081119|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2014-07-09|2010-03-03|2010-03-05|Estimate|||||||2014-07-09|2014-07-10|Estimate|September 2008||2008-09-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|CHOICE||Brief Voluntary Alcohol and Drug Intervention for Middle School Youth|Brief Voluntary Alcohol and Drug Intervention for Middle School Youth|Completed||Phase 2|6455|Actual|RAND||2|||f||||f||||||||||2018-06-01 00:01:04.006926|2018-06-01 00:01:04.006926
NCT01081106|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-07-30|2010-03-04|2010-03-05|Estimate|||||||2012-07-30|2012-07-31|Estimate||||July 2012|2012-07-31||||||||Interventional|||Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer|Low Level Laser Therapy for Hair Preservation With Chemotherapy for Breast Cancer|Withdrawn||N/A|0|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 00:01:04.088878|2018-06-01 00:01:04.088878
NCT01081093|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2014-08-05|2010-03-04|2010-03-05|Estimate|||||||2014-08-05|2014-08-06|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|BIVENT||Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement|Biventricular Pacing in Hypertrophic Cardiomyopathy After Aortic Valve Replacement|Completed||N/A|72|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||||2018-06-01 00:01:04.194432|2018-06-01 00:01:04.194432
NCT01081080|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-01-10|2010-03-04|2010-03-05|Estimate|||||||2013-01-10|2013-01-11|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Cardiac Magnetic Resonance in Children With Muscular Dystrophy|PITT0110 - Cardiac Magnetic Resonance: A Parallel Protocol to Cardiac Outcome Measures in Children With Muscular Dystrophy|Completed|||20|Anticipated|Cooperative International Neuromuscular Research Group|||||f||||t||||||||||2018-06-01 00:01:04.270516|2018-06-01 00:01:04.270516
NCT01081067|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-01-03|2010-03-03|2010-03-05|Estimate|||||||2011-01-03|2011-01-05|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Assessment of Efficiency and Safety of an Infant Formula Containing a Probiotic in Children|Assessment of Efficiency and Safety of an Infant Formula Containing a Probiotic in Children|Completed|||134|Anticipated|Mead Johnson Nutrition|||2||f||||f||||||||||2018-06-01 00:01:04.329636|2018-06-01 00:01:04.329636
NCT01081054|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-06-10|2010-03-04|2010-03-05|Estimate|||||||2012-06-10|2012-06-12|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|01DIVER||Hospitalization or Ambulatory Treatment of Acute Diverticulitis|Randomized Trial Comparing Two Treatment Strategies for Acute Diverticulitis. Hospitalization or Ambulatory Antibiotic Treatment|Completed||Phase 4|132|Actual|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-06-01 00:01:04.3861|2018-06-01 00:01:04.3861
NCT01081041|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2014-06-12||2017-03-14|2010-03-03|2010-03-05|Estimate|2014-06-12|2014-07-14|Estimate||||2017-03-14|2017-04-12|Actual|June 2010||2010-06-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|August 2013|Actual|2013-08-31||Interventional||Participants who received at least 1 dose of any study drug (cetuximab, cisplatin, carboplatin, or 5-FU).|A Study in Head and Neck Cancer|A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone Versus Boehringer Ingelheim Manufacturing Processes, in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients With Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|187|Actual|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 00:01:04.520425|2018-06-01 00:01:04.520425
NCT01081028|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2017-12-20|2010-03-04|2010-03-05|Estimate|||||||2017-12-20|2017-12-22|Actual|September 1, 2009||2009-09-01|December 2017|2017-12-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Observational|||Connect® MM- The Multiple Myeloma Disease Registry|Connect® MM- The Multiple Myeloma Disease Registry|Active, not recruiting|||3011|Actual|Celgene|||2||f||||f||||||||||2018-06-01 00:01:05.930149|2018-06-01 00:01:05.930149
NCT01081015|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2018-03-27|2010-03-04|2010-03-05|Estimate|||||||2018-03-27|2018-03-29|Actual|March 19, 2010|Actual|2010-03-19|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry|Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry|Completed|||1494|Actual|Celgene|||||f||||f||||||||||2018-06-01 00:01:06.379625|2018-06-01 00:01:06.379625
NCT01081002|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2014-12-02|2010-03-04|2010-03-05|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Propofol Sedation During Upper Endoscopy With and Without Topical Pharyngeal Anesthesia|Study of Propofol Sedation During Upper Endoscopy With and Without Topical Pharyngeal Anesthesia|Completed||Phase 4|294|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 00:01:06.775235|2018-06-01 00:01:06.775235
NCT01080989|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-30|||2017-05-07|2010-03-03|2010-03-05|Estimate|||||||2017-05-07|2017-05-09|Actual|March 2009||2009-03-31|April 2011|2011-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands|The Sero-prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands|Completed||N/A|1477|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||||2018-06-01 00:01:06.860571|2018-06-01 00:01:06.860571
NCT01080976|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2017-03-27||2018-02-01|2010-03-04|2010-03-05|Estimate|2018-02-01|2018-02-07|Actual||||2018-02-01|2018-02-07|Actual|March 2010||2010-03-31|February 2018|2018-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Comparing Google With A Focused Diabetes Search Engine|Comparing Google With A Focused Diabetes Search Engine|Completed|||10|Actual|Beth Israel Deaconess Medical Center|||2||f||||||||||||||2018-06-01 00:01:06.932409|2018-06-01 00:01:06.932409
NCT01080963|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2012-04-16|2010-03-04|2010-03-05|Estimate|||||||2012-04-16|2012-04-17|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DaPro||Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections|Prospective Randomised Study of Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections After Median Sternotomy|Completed||Phase 4|650|Actual|Hannover Medical School||2|||f||||||||||||||2018-06-01 00:01:07.17376|2018-06-01 00:01:07.17376
NCT01080950|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2010-03-04|2010-03-04|2010-03-05|Estimate|||||||2010-03-04|2010-03-05|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Vitamin D Zinc Fever|Vitamin d and Zinc Levels in Patients With Fever|Unknown status|Not yet recruiting||200|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||Samples Without DNA|"~     blood drawn for vitamin d will be freezed and stored until all samples have been collected~     and only than will it be analyzed.~   "|||2018-06-01 00:01:07.274796|2018-06-01 00:01:07.274796
NCT01080937|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2017-11-21|2010-03-04|2010-03-05|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2009||2009-03-31|November 2017|2017-11-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|OFICA||French Observatory of Acute Heart Failure|French Observatory of Acute Heart Failure|Completed|||1818|Actual|French Cardiology Society|||1||f||||f||||||||||2018-06-01 00:01:07.353174|2018-06-01 00:01:07.353174
NCT01080924|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-06-23|2010-03-04|2010-03-05|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|Pabes||Demonstration of Broncholytic Effects in Subjects With Obstructive Airway Diseases by Low Frequency Ultrasound||Completed||N/A|50|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f||||f||||||||||2018-06-01 00:01:07.426928|2018-06-01 00:01:07.426928
NCT01080911|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-09-05|2010-03-03|2010-03-04|Estimate|||||||2011-09-05|2011-09-07|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||0.05 mg Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy|0.05 vs. 0.1 Milligram Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy With/Without Anterior and Posterior Vaginoplasty|Unknown status|Recruiting|Phase 4|72|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 00:01:07.490869|2018-06-01 00:01:07.490869
NCT01080898|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2012-07-20|2010-03-03|2010-03-04|Estimate|||||||2012-07-20|2012-07-23|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|ESSO||Evaluation of Optical Coherence Tomography.|Evaluation of the Sensitivity and Specificity of Optical Coherence Tomography Combined With Fundus Color Photos for Diagnosis of Choroidal Neovessels in Age-related Macular Degeneration|Completed|||151|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-06-01 00:01:07.578349|2018-06-01 00:01:07.578349
NCT01080885|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2012-04-20|2010-03-03|2010-03-04|Estimate|||||||2012-04-20|2012-04-23|Estimate|July 2010||2010-07-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|HHHK||Healthy Homes/Healthy Kids Preschool|Linking Home Environments and Primary Care: Obesity Prevention for 2-5 Year Olds|Completed||N/A|60|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-06-01 00:01:07.644269|2018-06-01 00:01:07.644269
NCT01080872|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-05-04|2010-03-03|2010-03-04|Estimate|||||||2011-05-04|2011-05-05|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|BASE-CFR||Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome|Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome|Completed|||40|Anticipated|The Hospital District of Satakunta|||2||f||||t||||||||||2018-06-01 00:01:07.740409|2018-06-01 00:01:07.740409
NCT01080859|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-05-04|2010-03-03|2010-03-04|Estimate|||||||2011-05-04|2011-05-05|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|BASE-OCT||Vessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Assessed By Optical Coherence Tomography|Early Coverage and Vessel Wall Response of the Bio-Active-stent and Everolimus-Eluting Stent Implanted in Acute Coronary Syndrome Assessed By Optical Coherence Tomography (BASE-OCT)|Completed|||40|Anticipated|The Hospital District of Satakunta|||2||f||||t||||||||||2018-06-01 00:01:07.838042|2018-06-01 00:01:07.838042
NCT01080846|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-11-09|2010-03-03|2010-03-04|Estimate|||||||2010-11-09|2010-11-11|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage|Assessment of Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage|Completed||N/A|50|Actual|Gynuity Health Projects||1|||f||||t||||||||||2018-06-01 00:01:07.929843|2018-06-01 00:01:07.929843
NCT01080833|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-18|2010-03-03|2010-03-04|Estimate|||||||2010-03-18|2010-03-19|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|ERCP||Effect of ERCP Mechanical Simulator (EMS) Practice on Endoscopic Retrograde Cholangiopancreatography (ERCP) Training|Effect of Simulator Practice on Trainees' ERCP (Endoscopic Retrograde Cholangiopancreatography) Performance in the Early Learning Period: a Multi-center Randomized Controlled Observational Study|Completed||N/A|16|Actual|East Bay Institute for Research and Education||2|||f||||t||||||||||2018-06-01 00:01:08.01325|2018-06-01 00:01:08.01325
NCT01080820|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-06-30|2010-03-03|2010-03-04|Estimate|||||||2011-06-30|2011-07-04|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of CMX157 in Healthy Adult Volunteers.|Completed||Phase 1|36|Anticipated|Chimerix||3|||f||||f||||||||||2018-06-01 00:01:08.100653|2018-06-01 00:01:08.100653
NCT01080807|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2011-10-21||2012-05-17|2010-03-03|2010-03-04|Estimate|2012-05-17|2012-06-20|Estimate||||2012-05-17|2012-06-20|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Armodafinil Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated With Shift Work Disorder|Completed||Phase 4|385|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 00:01:08.201366|2018-06-01 00:01:08.201366
NCT01080794|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2016-01-12||2017-03-02|2010-03-03|2010-03-04|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|May 2010||2010-05-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MASTER-PD||rTMS for Motor and Mood Symptoms of Parkinson's Disease|Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial|Completed||N/A|61|Actual|Beth Israel Deaconess Medical Center|The study did not reach the enrollment goal of 120 patients reducing the statistical power of the study. Additionally, patients with mild and advanced disease with variable years of drug exposure were enrolled, which may obscure effects in subgroups.|4|||f||||t||||||||No||2018-06-01 00:01:08.975483|2018-06-01 00:01:08.975483
NCT01080781|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2013-01-22|2010-03-03|2010-03-04|Estimate|||||||2013-01-22|2013-01-24|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Observational|REBORD||Ephrin B1 Regulation in Human Right Appendage|Ephrin B1 Regulation in Human Right Appendage|Completed|||30|Actual|University Hospital, Toulouse|||2||f||||f||||||Samples With DNA|"~     right appendage~   "|||2018-06-01 00:01:09.851697|2018-06-01 00:01:09.851697
NCT01080768|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|2011-11-22||2011-11-22|2010-03-03|2010-03-04|Estimate|2011-11-22|2011-12-26|Estimate||||2011-11-22|2011-12-26|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension|A Double Blind, Randomized, Parallel Study to Assess the Effects of Aliskiren/Amlodipine and Amlodipine Monotherapy on Ankle Foot Volume (AFV) in Patients naïve to Trial Drugs With Mild to Moderate Hypertension|Terminated||Phase 2|31|Actual|Novartis||2||Publication of data from a similar study made the current study redundant.|f||||||||||||||2018-06-01 00:01:09.927953|2018-06-01 00:01:09.927953
NCT01080755|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2014-03-10|2010-03-03|2010-03-04|Estimate|||||||2014-03-10|2014-03-11|Estimate|December 2003||2003-12-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|MEGHA FRANCE||Metabolic Endocrinology and Growth Hormone in Adults|Study on the Prescription of the Growth Hormone Saizen® for Adults in France and Follow-up of Treated Patients|Completed|||90|Actual|Merck KGaA|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 00:01:10.172086|2018-06-01 00:01:10.172086
NCT01080742|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2014-08-04|2010-03-03|2010-03-04|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Observational|Lodoz OS||An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients|A Prospective Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive Patients|Completed|||1007|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:01:10.229369|2018-06-01 00:01:10.229369
NCT01080729|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2014-07-01|2010-03-03|2010-03-04|Estimate|||||||2014-07-01|2014-07-02|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM Pen|A Prospective, Observational and Multicentric Study to Compare the Dose of GONAL-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of GONAL-fTM FbM Pen|Terminated|||25|Actual|Merck KGaA|||||f||||f||||||Samples Without DNA|"~     Blood Serum~   "|||2018-06-01 00:01:10.306326|2018-06-01 00:01:10.306326
NCT01080716|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23||2015-06-02|2015-06-02|2010-03-02|2010-03-04|Estimate||||2015-06-02|2015-06-30|Estimate|2015-06-02|2015-06-30|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate|Safety, Immunogenicity, and Efficacy Studies of WRSS1, a Live Attenuated Shigella Sonnei Vaccine Candidate, in Healthy Thai Adults|Completed||Phase 1/Phase 2|40|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-06-01 00:01:10.381171|2018-06-01 00:01:10.381171
NCT01080703|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2014-12-03|2010-03-02|2010-03-04|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Resistance||To Determine if a Lower Extremity Strengthening Program Improve Quadriceps Muscle Strength|Does The Lower Extremity Resistance Program Improve Quadriceps Strength, Endurance, And Quality Life In Pre-Lung Transplant Patients?|Completed||N/A|40|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 00:01:10.484337|2018-06-01 00:01:10.484337
NCT01080690|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|EFRAIM||Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)|Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)|Unknown status|Recruiting|N/A|240|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 00:01:10.551414|2018-06-01 00:01:10.551414
NCT01080677|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2015-01-28||2017-01-04|2010-03-02|2010-03-04|Estimate|2017-01-04|2017-02-24|Actual||||2017-01-04|2017-02-24|Actual|January 2007||2007-01-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional||Thirty females, thirty males, agews ranged from 18-50 years old. All had an established history of migraines for at least 1 year. All met the diagnostic criteria of the International Classification of Headache Disorders.|Caffeine/Propranolol Intervention for Acute Migraine|Randomized Double-Blind Study to Evaluate the Dose-Related Efficacy and Safety of Caffeine/Propranolol in the Treatment of Acute Migraine|Completed||Phase 2|60|Actual|Stanford University||3|||f||||f||||||||||2018-06-01 00:01:10.644417|2018-06-01 00:01:10.644417
NCT01080664|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2013-10-21|2010-03-02|2010-03-04|Estimate|||||||2013-10-21|2013-10-22|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|August 2011|Actual|2011-08-31|March 2010|Actual|2010-03-31||Interventional|||A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies|A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies|Terminated||Phase 1|124|Actual|EMD Serono||2||Please see Purpose Statement below|f||||f||||||||||2018-06-01 00:01:10.946777|2018-06-01 00:01:10.946777
NCT01080651|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2011-08-17|2010-03-02|2010-03-04|Estimate|||||||2011-08-17|2011-08-19|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole|Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part B)|Completed||Phase 1|12|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:01:11.029521|2018-06-01 00:01:11.029521
NCT01080638|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-03-02|2010-03-02|2010-03-04|Estimate|||||||2010-03-02|2010-03-04|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.||Unknown status|Recruiting|Phase 4|150|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:01:11.210985|2018-06-01 00:01:11.210985
NCT01080625|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2012-02-13||2012-05-01|2010-03-02|2010-03-04|Estimate|2012-03-17|2012-04-12|Estimate||||2012-05-01|2012-05-03|Estimate|April 2010||2010-04-30|May 2012|2012-05-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Effect of Epinephrine/ Phenylephrine for Preventing the Postreperfusion Syndrome During Reperfusion in Liver Transplantation|Effect of Preventive Medicine on the Postreperfusion Syndrome|Completed||N/A|96|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-06-01 00:01:11.323604|2018-06-01 00:01:11.323604
NCT01080612|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2015-03-04|2010-03-02|2010-03-04|Estimate|||||||2015-03-04|2015-03-05|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation|An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Pregabalin Controlled Release Formulation Administered Following Various Caloric Intakes As Compared To The Immediate Release Formulation|Completed||Phase 1|24|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:01:11.695945|2018-06-01 00:01:11.695945
NCT01080599|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Comparison of the Success Rate of Two Approaches for Obturator Nerve Block in TURB (Conventional Pubic Approach [Labat Technique] and Inguinal Approach)|Comparison of the Success Rate of Two Approaches for Obturator Nerve Block in TURB (Conventional Pubic Approach [Labat Technique] and Inguinal Approach)|Completed||N/A|100|Actual|Yonsei University||2|||f||||||||||||||2018-06-01 00:01:11.775545|2018-06-01 00:01:11.775545
NCT01080586|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Bioequivalence Study of Cyclosporine 100mg Capsule Under Fed Condition|A Randomized Single Dose Open Label Bioequivalence Study of Cyclosporine Capsules USP (Modified)100mg in Normal Healthy Male Subjects Under Fed Condition|Completed||N/A|36|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:11.828048|2018-06-01 00:01:11.828048
NCT01080573|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2014-07-30|2010-03-03|2010-03-04|Estimate|||||||2014-07-30|2014-07-31|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|AIMS||Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis|A Questionnaire Based Survey to Identify Issues With Patient Compliance and to Develop Solutions to Improve Rebif Compliance and Improve Patient Outcomes|Completed|||1257|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:01:11.911909|2018-06-01 00:01:11.911909
NCT01080560|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|August 2007||2007-08-31|March 2010|2010-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Bioequivalence Study of Cyclosporine 100mg Capsule Under Fasting Condition|A Randomized Single Dose Open Label Bioequivalence Study of Cyclosporine Capsules USP (Modified)100mg in Normal Healthy Male Subjects Under Fasting Condition|Completed||N/A|36|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:12.029857|2018-06-01 00:01:12.029857
NCT01080547|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2017-04-04|2010-03-03|2010-03-04|Estimate|||||||2017-04-04|2017-04-06|Actual|March 2010||2010-03-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Study Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer|Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer|Completed||Phase 3|374|Actual|Zhejiang University||4|||f||||t||||||||||2018-06-01 00:01:12.10764|2018-06-01 00:01:12.10764
NCT01080534|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 5 mg in Normal Healthy Male Subjects Under Fed Condition|Completed||N/A|36|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:12.202301|2018-06-01 00:01:12.202301
NCT01080521|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2018-04-11|2010-03-03|2010-03-04|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2010||2010-04-30|April 2018|2018-04-30|January 27, 2018|Actual|2018-01-27|January 2012|Actual|2012-01-31||Observational|||Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy|A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Completed|||247|Actual|Gynecologic Oncology Group|||1||f||||||||||||||2018-06-01 00:01:12.313784|2018-06-01 00:01:12.313784
NCT01080508|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2010-10-25|2010-03-03|2010-03-04|Estimate|||||||2010-10-25|2010-10-26|Estimate|December 2009||2009-12-31|October 2009|2009-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Spirometry in Esophageal Intubation|Analysis of the Spirometry Pattern in Esophageal Intubation|Completed|||40|Anticipated|University Medical Center Groningen|||1||f||||f||||||||||2018-06-01 00:01:12.857322|2018-06-01 00:01:12.857322
NCT01080495|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|Strain||Evaluation of Radial Strain for Assessment of Left Ventricular Function in Transesophageal Echocardiography|Evaluation of Radial Strain Versus Fractional Shortening and Fractional Area Change for Assessment of Left Ventricular Function in Transesophageal Echocardiography|Unknown status|Recruiting|Phase 4|33|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-06-01 00:01:12.927146|2018-06-01 00:01:12.927146
NCT01080482|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fasting Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 5 mg in Normal Healthy Male Subjects Under Fasting Condition|Completed||N/A|36|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:13.029605|2018-06-01 00:01:13.029605
NCT01080469|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 1 mg in Normal Healthy Male Subjects Under Fed Condition|Completed||N/A|36|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:13.105304|2018-06-01 00:01:13.105304
NCT01080456|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study of Tacrolimus Capsules 1 mg in Normal Healthy Male Subjects Under Fasting Condition|Completed||N/A|36|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:13.178107|2018-06-01 00:01:13.178107
NCT01080443|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-11|2010-03-03|2010-03-04|Estimate|||||||2010-03-11|2010-03-12|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fasting Condition|Open Label Balanced Randomized Two-treatment Two-period Two-sequence Single Dose Two-way Crossover Oral Bioequivalence Study of Mycophenolate Mofetil Capsules 250 mg in Normal Healthy Adult Human Subjects Under Fasting Conditions|Completed||N/A|56|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:13.317378|2018-06-01 00:01:13.317378
NCT01080430|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of a Vestibular Rehabilitation Maneuver|Short-term and Long-term Effects of the Rotational Maneuver in Patients With Chronic Vestibular Imbalance|Completed||N/A|23|Actual|Day General Hospital.|||||f||||t||||||||||2018-06-01 00:01:13.390485|2018-06-01 00:01:13.390485
NCT01080417|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fed Condition|Open Label Balanced Randomized Two-treatment Two-period Two-sequence Single Dose Two-way Crossover Oral Bioequivalence Study of Mycophenolate Mofetil Capsules 250 mg in Normal Healthy Adult Human Subjects Under Fed Conditions|Completed||N/A|84|Actual|Panacea Biotec Ltd||2|||f||||f||||||||||2018-06-01 00:01:13.456842|2018-06-01 00:01:13.456842
NCT01080404|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2018-04-26|2010-03-03|2010-03-04|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2010||2010-05-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of Surgical Weight Loss to Treat Obstructive Sleep Apnea|Obesity, Metabolism and Obstructive Sleep Apnea: Prevalence and the Effect of Bariatric Surgery|Recruiting||N/A|100|Anticipated|Kuopio University Hospital||3|||f||||f||||||||||2018-06-01 00:01:13.552022|2018-06-01 00:01:13.552022
NCT01080391|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2015-06-08||2017-12-11|2010-03-02|2010-03-04|Estimate|2015-06-12|2015-07-08|Estimate||||2017-12-11|2018-01-09|Actual|August 6, 2010|Actual|2010-08-06|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|June 16, 2014|Actual|2014-06-16||Interventional|||Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma|A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma|Completed||Phase 3|792|Actual|Amgen||2|||f||||t||||||||||2018-06-01 00:01:13.785436|2018-06-01 00:01:13.785436
NCT01080378|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|||2010-03-03|2010-03-03|2010-03-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|April 2010||2010-04-30|March 2010|2010-03-31||||||||Interventional|SAMS-2||Metabolic Effects of Birth Weight on Overweight and Obese Chinese Adults and Their Responses to Weight Loss|Developmental Pathways to Metabolic Diseases: To Investigate the Metabolic Effects of Birth Weight on Overweight and Obese Chinese Adults and Their Responses to Weight Loss Over 16 Weeks|Unknown status|Not yet recruiting|N/A|180|Anticipated|National University Hospital, Singapore||3|||f||||f||||||||||2018-06-01 00:01:15.425335|2018-06-01 00:01:15.425335
NCT01080365|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-09-03|2010-03-03|2010-03-04|Estimate|||||||2010-09-03|2010-09-06|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions|A Single Dose Bioequivalence Study Comparing The Commercial Tablet Formulation To The Clinical Tablet Of Bosutinib In Healthy Subjects|Completed||Phase 1|31|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 00:01:15.508755|2018-06-01 00:01:15.508755
NCT01080352|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2015-03-25|2010-03-03|2010-03-04|Estimate|||||||2015-03-25|2015-03-26|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Vitamin C as an Anti-cancer Drug|Evaluation of Cytotoxicity and Genetic Changes of High Dose Vitamin C Infusions in Castration Resistant Metastatic Human Prostate Cancer|Completed||Phase 2|31|Actual|Copenhagen University Hospital at Herlev||1|||f||||t||||||||||2018-06-01 00:01:15.589314|2018-06-01 00:01:15.589314
NCT01080339|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2011-06-22|2010-03-03|2010-03-04|Estimate|||||||2011-06-22|2011-06-23|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|EXCEL||Substudy of Change in Cardiometabolic Disease (CMD) Risk Factors During an Interactive Fitness Program|Change in Cardiometabolic Risk Factors During an Interactive Fitness Program: An Exploratory Sub-study|Terminated|||3|Actual|Boston Children’s Hospital|||2|Unable to recruit participants.|f||||f||||||||||2018-06-01 00:01:15.66621|2018-06-01 00:01:15.66621
NCT01080326|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2015-04-01||2015-04-01|2010-03-02|2010-03-04|Estimate|2015-04-01|2015-04-14|Estimate||||2015-04-01|2015-04-14|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||This includes only those participants for whom ulcer repair was attempted. Participants who were excluded in the operating room (OR) for previously unknown complications were not included.|Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus|Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus|Completed||N/A|7|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:01:15.733874|2018-06-01 00:01:15.733874
NCT01080313|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-02-10|2010-03-02|2010-03-04|Estimate|||||||2012-02-10|2012-02-13|Estimate|August 2005||2005-08-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|LORHAN||Head and Neck Cancer Registry (LORHAN)|Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Cancer|Completed|||26000|Anticipated|Eli Lilly and Company|||1||f||||f||||||||||2018-06-01 00:01:15.882112|2018-06-01 00:01:15.882112
NCT01080300|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2013-11-13||2014-02-07|2010-03-03|2010-03-04|Estimate|2014-02-07|2014-03-26|Estimate||||2014-02-07|2014-03-26|Estimate|August 2010||2010-08-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Breeze3|Intent-to-treat (ITT) Population|Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER_ Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 3|600|Actual|Depomed||2|||f||||f||||||||||2018-06-01 00:01:15.969093|2018-06-01 00:01:15.969093
NCT01080287|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-02-20|2010-03-03|2010-03-04|Estimate|||||||2012-02-20|2012-02-22|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras|The Identification and Characterization of Autonomic Dysfunction in Migraineurs With and Without Auras|Completed|||60|Actual|The Cleveland Clinic|||2||f||||f||||||||||2018-06-01 00:01:16.518142|2018-06-01 00:01:16.518142
NCT01080274|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-03|||2010-04-06|2010-03-03|2010-03-04|Estimate|||||||2010-04-06|2010-04-07|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test|Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test|Unknown status|Active, not recruiting||200|Anticipated|Assaf-Harofeh Medical Center|||3||f||||f||||||Samples Without DNA|"~     blood will be collected for vit d and zinc , stored until all samples are collected and only~     than the laboratoty will analyze it.~   "|||2018-06-01 00:01:16.578783|2018-06-01 00:01:16.578783
NCT01080261|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2012-03-19||2016-03-01|2010-03-02|2010-03-04|Estimate|2012-03-19|2012-04-12|Estimate||||2016-03-01|2016-03-29|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Interventional|||PROMUS Element Japan Small Vessel Trial|A Prospective Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of a Small Vessel De Novo Coronary Artery Lesion in Japan|Completed||Phase 3|60|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-06-01 00:01:16.695699|2018-06-01 00:01:16.695699
NCT01080248|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2015-05-04||2015-05-22|2010-03-03|2010-03-04|Estimate|2015-05-22|2015-06-09|Estimate||||2015-05-22|2015-06-09|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer|A Phase II Study of Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer|Terminated||Phase 2|2|Actual|Washington University School of Medicine||1||Closed due to delay by GSK|f||||f||||||||||2018-06-01 00:01:17.204937|2018-06-01 00:01:17.204937
NCT01080235|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-02|2010-03-02|2010-03-04|Estimate|||||||2010-03-02|2010-03-04|Estimate|October 2006||2006-10-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|MacyCoVE||Improving Quality of Care for Elderly Patients in the Educational Setting|Improving Quality of Care for Elderly Patients in the Educational Setting: A Multicenter Exploratory Study of Quality Improvement|Completed||N/A|42|Actual|American Board of Internal Medicine||2|||f||||t||||||||||2018-06-01 00:01:17.386879|2018-06-01 00:01:17.386879
NCT01080222|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-02-28|2010-03-02|2010-03-04|Estimate|||||||2014-02-28|2014-03-03|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection|A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C|Terminated||Phase 2|152|Actual|Vertex Pharmaceuticals Incorporated||6||Study discontinued|f||||f||||||||||2018-06-01 00:01:17.458259|2018-06-01 00:01:17.458259
NCT01080209|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2015-02-05||2015-02-05|2010-03-03|2010-03-04|Estimate|2015-02-05|2015-02-20|Estimate||||2015-02-05|2015-02-20|Estimate|February 2010||2010-02-28|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System||Completed||Phase 2|215|Actual|Allergan||7|||f||||f||||||||||2018-06-01 00:01:17.596294|2018-06-01 00:01:17.596294
NCT01080196|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2016-03-22||2017-12-07|2010-03-02|2010-03-03|Estimate|2017-12-07|2018-01-10|Actual||||2017-12-07|2018-01-10|Actual|April 2008||2008-04-30|December 2017|2017-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Reducing Falls With RENEW in Older Adults Who Have Fallen|Reducing Falls With RENEW in Older Adults Who Have Fallen|Completed||N/A|134|Actual|University of Utah||2|||f||||t||||||||No||2018-06-01 00:01:18.72913|2018-06-01 00:01:18.72913
NCT01080144|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2017-05-10|2010-03-02|2010-03-03|Estimate|||||||2017-05-10|2017-05-11|Actual|October 2009||2009-10-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Feasibility of Critical Flicker Frequency Procedure for the Diagnosis of Minimal Encephalopathy|A Pilot Study Aiming to Assess the Feasibility of Critical Flicker Frequency for the Diagnosis of Minimal Encephalopathy in Patients With Cirrhosis|Completed||N/A|30|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-06-01 00:01:19.249205|2018-06-01 00:01:19.249205
NCT01080131|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2011-08-30||2013-12-24|2010-03-02|2010-03-03|Estimate|2011-11-21|2011-12-26|Estimate||||2013-12-24|2014-01-30|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Interventional|β-RELIEVED-II||Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.|A Randomized, Controlled Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective Including a 12 Weeks Extension Study and a 1 Year Open-label Extension Study|Completed||Phase 3|226|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:01:19.410712|2018-06-01 00:01:19.410712
NCT01080118|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2012-03-02||2013-10-29|2010-03-02|2010-03-03|Estimate|2013-06-20|2013-09-04|Estimate||||2013-10-29|2013-12-02|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||The 15 in each group represents the medical student/ interns who are being studied.|Effectiveness of Video System in Improving Learning of Tracheal Intubation Using Standard Laryngoscopy Among Novices|A Clinical Trial on the Effectiveness of Video System in Improving Learning of Tracheal Intubation Using Standard Laryngoscopy Among Novices|Completed||N/A|90|Actual|Northwestern University|The intubating laryngeal mask airway the optical laryngoscope device used in this study does not allow for ventilation of the patient if intubation fails. We did not study retention of airway management skills between the groups.|2|||f||||f||||||||||2018-06-01 00:01:20.780006|2018-06-01 00:01:20.780006
NCT01080105|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-06-29|2010-03-02|2010-03-03|Estimate|||||||2012-06-29|2012-07-03|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|AIM||Internet Intervention for the Prevention of Depression - Approaches to Improving Mood|Technology Assisted Behavioral Intervention for the Prevention of Depression|Withdrawn||Phase 1|0|Actual|Northwestern University||3||This is withdrawn because we started working on studies that are funded.|f||||f||||||||||2018-06-01 00:01:21.007462|2018-06-01 00:01:21.007462
NCT01080092|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2011-12-01|2010-03-02|2010-03-03|Estimate|||||||2011-12-01|2011-12-02|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Stress-management and Biofeedback on Craving in Smoking Abstinence: A Pilot Study|Effect of Stress-management and Biofeedback on Craving in Smoking Abstinence: A Pilot Study|Completed||Phase 2|40|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 00:01:21.076849|2018-06-01 00:01:21.076849
NCT01080079|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2012-10-18|2010-03-02|2010-03-03|Estimate|||||||2012-10-18|2012-10-19|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis|A Subject Blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail|Completed||Phase 2|168|Actual|Nitric BioTherapeutics, Inc||6|||f||||f||||||||||2018-06-01 00:01:21.143568|2018-06-01 00:01:21.143568
NCT01080066|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2014-07-07|2010-03-02|2010-03-03|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)|A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)|Completed|||215|Actual|Merck KGaA|||1||f||||f||||||||||2018-06-01 00:01:21.226559|2018-06-01 00:01:21.226559
NCT01080053|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2013-10-13|2010-03-02|2010-03-03|Estimate|||||||2013-10-13|2013-10-16|Estimate|November 2008||2008-11-30|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)|Observational Study to Determine the Relationship Between the Degree of Disability and the Presence of Sexual Dysfunction and Between Sexual Dysfunction and the Quality of Life in Patients With Multiple Sclerosis (RRMS)|Completed|||306|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 00:01:21.290835|2018-06-01 00:01:21.290835
NCT01080040|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2013-10-13|2010-03-02|2010-03-03|Estimate|||||||2013-10-13|2013-10-16|Estimate|August 2008||2008-08-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients|Observational Study to Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Patients With Multiple Sclerosis in Argentina|Completed|||150|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 00:01:21.490219|2018-06-01 00:01:21.490219
NCT01080027|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2014-07-30|2010-03-02|2010-03-03|Estimate|||||||2014-07-30|2014-07-31|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|STAR||Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)|An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings|Completed|||254|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 00:01:21.551111|2018-06-01 00:01:21.551111
NCT01080014|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-10-13|2010-03-02|2010-03-03|Estimate|||||||2013-10-13|2013-10-16|Estimate|August 2008||2008-08-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina|The Multiple Sclerosis Functional Composite (MSFC) in the Follow-up of MS Patients: Correlation With the Expanded Disability Status Scale (EDSS) Among Different Clinical Forms in Argentina|Completed|||252|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 00:01:21.633073|2018-06-01 00:01:21.633073
NCT01080001|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2014-03-06|2010-03-02|2010-03-03|Estimate|||||||2014-03-06|2014-03-07|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|December 2010|Actual|2010-12-31||Observational|||A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina|Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina|Completed|||71|Actual|Merck KGaA|||||f||||t||||||||||2018-06-01 00:01:21.701337|2018-06-01 00:01:21.701337
NCT01079988|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2010-04-12||2014-01-26|2010-03-02|2010-03-03|Estimate|2010-04-12|2010-05-11|Estimate||||2014-01-26|2014-02-27|Estimate|February 2004||2004-02-29|January 2014|2014-01-31|April 2005|Actual|2005-04-30|December 2004|Actual|2004-12-31||Interventional|||Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence|A Phase IV Open Label, Multicentre, Investigational Study of the Therapeutic Options for Subjects Discontinuing Efalizumab Therapy and Experiencing Inflammatory Disease Recurrence|Completed||Phase 4|41|Actual|Merck KGaA||5|||f||||f||||||||||2018-06-01 00:01:21.77939|2018-06-01 00:01:21.77939
NCT01079975|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2014-07-30|2010-03-02|2010-03-03|Estimate|||||||2014-07-30|2014-07-31|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|October 2010|Actual|2010-10-31||Observational|||To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis|Predicting Factors for Depression in Patients With MS in Argentina|Completed|||301|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:01:22.273485|2018-06-01 00:01:22.273485
NCT01079962|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2012-08-30||2014-01-20|2010-03-02|2010-03-03|Estimate|2012-08-30|2012-10-02|Estimate||||2014-01-20|2014-02-13|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])|A Prospective, Multi-center, Randomized, Open-label, Clinical Trial to Compare the Aortic Pulse Pressure Effects of Bisoprolol and Atenolol in 12 Weeks Treatment of Hypertension|Completed||Phase 4|209|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:01:22.357681|2018-06-01 00:01:22.357681
NCT01079949|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2012-11-12||2014-01-26|2010-03-02|2010-03-03|Estimate|2013-01-17|2013-02-20|Estimate||||2014-01-26|2014-02-27|Estimate|November 2007||2007-11-30|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age|Lutropin Alfa (Luveris®) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age: Phase II Clinical Trial|Terminated||Phase 2|93|Actual|Merck KGaA||2||Trial was terminated due to low recruitment rate|f||||f||||||||||2018-06-01 00:01:23.050385|2018-06-01 00:01:23.050385
NCT01079936|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2016-03-31||2016-05-05|2010-03-02|2010-03-03|Estimate|2016-05-05|2016-06-06|Estimate||||2016-05-05|2016-06-06|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Two participants were not eligible for study, and another two were eligible but did not receive required stem cell transplant therefore all appear in participation flow but two ineligible are not in baseline analysis population demographics.|Lenalidomide and High-Dose Melphalan|Phase I/II Study Of The Combination Of Lenalidomide With High-Dose Melphalan For Autologous Transplant in Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|61|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 00:01:23.549576|2018-06-01 00:01:23.549576
NCT01079923|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-11-16|2010-03-02|2010-03-03|Estimate|||||||2012-11-16|2012-11-20|Estimate|February 2010||2010-02-28|November 2012|2012-11-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation|Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation|Completed||N/A|40|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:01:23.948378|2018-06-01 00:01:23.948378
NCT01079910|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-03-15|2010-03-02|2010-03-03|Estimate|||||||2012-03-15|2012-03-19|Estimate||||March 2012|2012-03-31||||||||Interventional|||Clinical Efficacy of an Experimental Toothpaste|Clinical Efficacy of an Experimental Toothpaste|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:01:24.023244|2018-06-01 00:01:24.023244
NCT01079897|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2011-10-17|2010-03-02|2010-03-03|Estimate|||||||2011-10-17|2011-10-18|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis|A Randomized, Comparator-controlled, Double-blind, Multicenter Intra-individual Clinical Trial to Evaluate the Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis|Completed||N/A|64|Actual|Bitop AG||2|||f||||f||||||||||2018-06-01 00:01:24.085137|2018-06-01 00:01:24.085137
NCT01079884|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-02-21|2010-03-02|2010-03-03|Estimate|||||||2012-02-21|2012-02-22|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance|Gastroesophageal Reflux Disease, Sleep, and the Relationship to Driving Simulator Performance|Completed||N/A|18|Actual|Digestive & Liver Disease Specialists|||||f||||f||||||||||2018-06-01 00:01:24.306986|2018-06-01 00:01:24.306986
NCT01079871|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-01-31|2010-03-02|2010-03-03|Estimate|||||||2012-01-31|2012-02-02|Estimate|February 2010||2010-02-28|January 2012|2012-01-31||||June 2010|Actual|2010-06-30||Interventional|||Evaluation of FID 114657 in Sjogren's Syndrome Subjects||Completed||N/A|50|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:01:24.374327|2018-06-01 00:01:24.374327
NCT01079858|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-01-31|2010-03-02|2010-03-03|Estimate|||||||2012-01-31|2012-02-02|Estimate|February 2010||2010-02-28|January 2012|2012-01-31||||April 2010|Actual|2010-04-30||Interventional|||Evaluation of FID 114657 in Dry Eye Subjects||Completed||N/A|49|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:01:24.433501|2018-06-01 00:01:24.433501
NCT01079845|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2015-02-04|2010-03-02|2010-03-03|Estimate|||||||2015-02-04|2015-02-05|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ACES||A Cooking and Eating Study|Low-glycemic Load vs. Low-fat Diet for Treating PCOS in Obese Adolescents and Young Adults|Terminated||N/A|19|Actual|Boston Children’s Hospital||2||"For this pilot, we constructed conditional power curves and noted that we would not~   substantially enhance power by enrolling additional participants."|f||||f||||||||||2018-06-01 00:01:24.491977|2018-06-01 00:01:24.491977
NCT01079832|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2013-07-19||2013-09-27|2010-03-02|2010-03-03|Estimate|2013-09-27|2013-11-28|Estimate||||2013-09-27|2013-11-28|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies|A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies|Completed||Phase 2|50|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:01:24.576553|2018-06-01 00:01:24.576553
NCT01079819|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2011-02-04|2010-03-02|2010-03-03|Estimate|||||||2011-02-04|2011-02-07|Estimate|April 2010||2010-04-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163|Randomized, Placebo-controlled, Double-blind, Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163 in Healthy Young Male and Elderly Male and Female Chinese Subjects|Completed||Phase 1|32|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 00:01:24.793106|2018-06-01 00:01:24.793106
NCT01079806|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2014-03-17||2017-12-06|2010-03-02|2010-03-03|Estimate|2014-03-17|2014-04-21|Estimate||||2017-12-06|2017-12-29|Actual|June 30, 2010|Actual|2010-06-30|December 2017|2017-12-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2013|Actual|2013-03-31||Interventional||All participants who received study drug|A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection|A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) Versus Placebo in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive|Active, not recruiting||Phase 3|180|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-06-01 00:01:24.887814|2018-06-01 00:01:24.887814
NCT01079793|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-06-11|2010-03-02|2010-03-03|Estimate|||||||2010-06-11|2010-06-14|Estimate|May 2010||2010-05-31|May 2010|2010-05-31||||March 2012|Anticipated|2012-03-31||Interventional|||Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery|A Phase I/II Study of Adjuvant Prostate Irradiation and Ixabepilone For High Risk Prostate Cancer Post-Prostatectomy|Unknown status|Recruiting|Phase 1/Phase 2|54|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:01:26.507944|2018-06-01 00:01:26.507944
NCT01079780|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2017-12-12|2010-03-02|2010-03-03|Estimate|||||||2017-12-12|2017-12-14|Actual|October 8, 2010|Actual|2010-10-08|December 2017|2017-12-31|July 1, 2023|Anticipated|2023-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy|A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy|Active, not recruiting||Phase 2|135|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 00:01:26.661606|2018-06-01 00:01:26.661606
NCT01079767|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2014-03-03|2010-03-02|2010-03-03|Estimate|||||||2014-03-03|2014-03-04|Estimate|January 2010||2010-01-31|March 2010|2010-03-31||||December 2010|Actual|2010-12-31||Interventional|||Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis|Advanced Hepatocellular Carcinoma on Child B Cirrhosis: Tolerance and Efficacy of Torisel® (Temsirolimus)|Terminated||Phase 2|6|Actual|Federation Francophone de Cancerologie Digestive||1||The study treminated early according to DSMB recommendantions|f||||t||||||||||2018-06-01 00:01:27.165681|2018-06-01 00:01:27.165681
NCT01079754|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2011-09-10|2010-03-02|2010-03-03|Estimate|||||||2011-09-10|2011-09-13|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||0.05 Versus 0.1 mg Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy|The Comparison of 0.05 vs. 0.1 Milligram Spinal Morphine for Reducing Morphine Requirement After Vaginal Hysterectomy With/Without Anterior and Posterior Vaginoplasty|Unknown status|Recruiting|Phase 4|72|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 00:01:27.241814|2018-06-01 00:01:27.241814
NCT01079741|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2017-04-08||2018-01-16|2010-03-02|2010-03-03|Estimate|2018-01-16|2018-02-13|Actual||||2018-01-16|2018-02-13|Actual|September 2010||2010-09-30|November 2017|2017-11-30|March 11, 2013|Actual|2013-03-11|March 11, 2013|Actual|2013-03-11||Interventional|||Safety Study of Adjuvant Vaccine to Treat Melanoma Patients|Phase I/Phase II Open Label Study of the TLR3 Agonist Poly-ICLC as an Adjuvant for NY-ESO-1 Protein Vaccination With or Without Montanide ® ISA-51 VG in Patients With High Risk Melanoma in Complete Clinical Remission|Completed||Phase 1/Phase 2|34|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 00:01:27.366987|2018-06-01 00:01:27.366987
NCT01079728|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2018-02-01|2010-03-02|2010-03-03|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2010||2010-02-28|February 2018|2018-02-28|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Observational|PREDICT||Prediction of Stroke-associated Pneumonia|Prediction of Stroke-associated Pneumonia|Completed|||486|Actual|Charite University, Berlin, Germany|||1||f||||f||||||Samples Without DNA|"~     Blood sample (serum, plasma)~   "|||2018-06-01 00:01:28.169104|2018-06-01 00:01:28.169104
NCT01079715|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-11-24|2010-03-02|2010-03-03|Estimate|||||||2012-11-24|2012-11-27|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PROP-ROP||Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity|Safety and Efficacy of Treatment With Propranolol in Newborns With Retinopathy of Prematurity: a Pilot Study|Completed||Phase 2/Phase 3|52|Actual|Azienda Ospedaliero, Universitaria Meyer||2|||f||||t||||||||||2018-06-01 00:01:28.262656|2018-06-01 00:01:28.262656
NCT01079702|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate|April 2008||2008-04-30|January 2008|2008-01-31|January 2011|Anticipated|2011-01-31|April 2010|Anticipated|2010-04-30||Interventional|m-TOR||Everolimus and Capecitabine in Patients With Advanced Malignancy|A Phase I/II, Non-randomized, Multi-center, Dose-escalating, Two-stage Efficacy and Feasibility Study of the Combination of Everolimus and Capecitabine in Patients With Advanced Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|35|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||t||||||||||2018-06-01 00:01:28.346197|2018-06-01 00:01:28.346197
NCT01079689|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-07-09|2010-03-02|2010-03-03|Estimate|||||||2012-07-09|2012-07-10|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|BANS||Brain Activity Changes Measured by EEG and fMRI on Healthy Volunteers After Complex Somatosensory Stimulation|Brain Activity Changes Measured by EEG and fMRI on Healthy Volunteers After Complex Somatosensory Stimulation With Acupuncture Needles|Completed||N/A|20|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 00:01:28.46128|2018-06-01 00:01:28.46128
NCT01079676|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-10-15|2010-03-02|2010-03-03|Estimate|||||||2012-10-15|2012-10-16|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional|||A Non-inferiority Study Comparing Two Filgrastim Preparations in Breast Cancer|A Phase III, Non-inferiority Study Comparing Two Filgrastim Preparations in Preventing Chemotherapy Induced Neutropenia in Breast Cancer|Completed||Phase 3|220|Actual|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-06-01 00:01:28.534093|2018-06-01 00:01:28.534093
NCT01079663|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2011-11-14|2010-03-02|2010-03-03|Estimate|||||||2011-11-14|2011-11-15|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis|The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis|Completed||Phase 2|||Dexcel Pharma Technologies Ltd.||2|||f||||f||||||||||2018-06-01 00:01:28.614311|2018-06-01 00:01:28.614311
NCT01079650|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate|May 2010||2010-05-31|March 2010|2010-03-31||||May 2012|Anticipated|2012-05-31||Observational|||Diagnosis of Acute Appendicitis, Ovary Torsion and Inflammation, and Testicular Torsion and Inflammation by Infrared Thermography||Unknown status|Not yet recruiting||50|Anticipated|Assaf-Harofeh Medical Center|||1||f||||||||||||||2018-06-01 00:01:28.682216|2018-06-01 00:01:28.682216
NCT01079637|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2015-06-22|2010-03-02|2010-03-03|Estimate|||||||2015-06-22|2015-06-23|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MFB||Midfoot Fusion Bolt (MFB) in the Early Stage of Diabetic-neuropathic Charcot Feet|Midfoot Fusion Bolt (MFB). A Randomized Controlled Multicenter Study to Assess the Effectiveness of Surgical Treatment With Midfoot Fusion Bolt in the Early Stage of Diabetic-neuropathic Charcot Feet|Terminated||N/A|1|Actual|AO Clinical Investigation and Documentation||2||The study was stopped because there were not enough eligible patients to complete the study.|f||||||||||||||2018-06-01 00:01:28.747685|2018-06-01 00:01:28.747685
NCT01079624|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate|August 2006||2006-08-31|July 2009|2009-07-31|November 2009|Actual|2009-11-30|January 2008|Actual|2008-01-31||Interventional|GIP-GLP-gas||GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose|Effects of GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose Homeostasis|Completed||Phase 1|15|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 00:01:28.827944|2018-06-01 00:01:28.827944
NCT01079611|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2012-06-19|2010-03-02|2010-03-03|Estimate|||||||2012-06-19|2012-06-20|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Observational|||Non-invasive Assessments of Central Venous Pressure|Non-invasive Assessments of Central Venous Pressure by Ultrasound and Clinical Examination: a Prospective Comparative Study|Completed|||81|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 00:01:28.911233|2018-06-01 00:01:28.911233
NCT01079598|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2017-01-31||2017-03-24|2010-03-01|2010-03-03|Estimate|2017-03-24|2017-05-05|Actual||||2017-03-24|2017-05-05|Actual|March 2010||2010-03-31|March 2017|2017-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|TRIPLE||RFS (Radiofrequency Stylet) - Radiofrequency Perforator Vein Treatment Study|A Prospective Multicenter Study on the Treatment of Incompetent Perforators With the VNUS® Closure Radiofrequency Stylet|Terminated||N/A|8|Actual|Medtronic Endovascular|Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data.|1||Low enrollment|f||||f||||||||No|Out of a planned 225 patient subject size, a total of 8 subjects were enrolled with 10 limbs treated. As a result of stagnant enrollment in the study, a decision was made to terminate the study.|2018-06-01 00:01:28.970044|2018-06-01 00:01:28.970044
NCT01079585|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||The Effect of 40gr Okara on Gastric Emptying||Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 00:01:29.118096|2018-06-01 00:01:29.118096
NCT01079572|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2013-02-06|2010-03-02|2010-03-03|Estimate|||||||2013-02-06|2013-02-07|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Cost-Effectiveness of Web-Based Follow Ups|Cost-Effectiveness of Web-Based Follow Up Following Total Joint Arthroplasty|Completed||N/A|260|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-06-01 00:01:29.176282|2018-06-01 00:01:29.176282
NCT01079559|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2013-02-06|2010-03-02|2010-03-03|Estimate|||||||2013-02-06|2013-02-07|Estimate||||February 2013|2013-02-28||||||||Interventional|ABC||The Effectiveness of Antibiotic Cement (ABC) Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Trial|The Effectiveness of Antibiotic Cement Compared to Regular Cement in Reducing the Rate of Infection Following Total Knee Arthroplasty: The ABC Feasibility Study|Withdrawn||Phase 3|0|Actual|University of Western Ontario, Canada||2|||f||||t||||||||||2018-06-01 00:01:29.24263|2018-06-01 00:01:29.24263
NCT01079546|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|January 2011|Anticipated|2011-01-31|June 2010|Anticipated|2010-06-30||Observational|HPV||Human Papillomavirus (HPV) in Squamous Cell Carcinoma of the Head and Neck|Retrospective Trial to Assess HPV Epidemiology in Squamous Cell Carcinoma of Head and Neck|Unknown status|Enrolling by invitation||100|Anticipated|Tel-Aviv Sourasky Medical Center|||7||f||||t||||||Samples With DNA|"~     Parafin blocks from squamous cell carcinoma of head and neck~   "|||2018-06-01 00:01:29.310676|2018-06-01 00:01:29.310676
NCT01079533|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2017-05-02|2010-03-02|2010-03-03|Estimate|||||||2017-05-02|2017-05-03|Actual|July 2008|Actual|2008-07-31|May 2017|2017-05-31|July 31, 2014|Actual|2014-07-31|November 3, 2011|Actual|2011-11-03||Interventional|SSN||"Initiation of Colon Cancer Screening in Veterans or Start Screening Now"|Initiation of Colon Cancer Screening in Veterans|Completed||N/A|1892|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 00:01:29.370058|2018-06-01 00:01:29.370058
NCT01079520|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2012-10-31|2010-03-02|2010-03-03|Estimate|||||||2012-10-31|2012-11-01|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)|A Prospective Trial of Endobronchial Ultrasound- Transbronchial Needle Aspiration Compared to Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer|Completed||N/A|138|Actual|Samsung Medical Center|||||f||||||||||||||2018-06-01 00:01:29.435717|2018-06-01 00:01:29.435717
NCT01079507|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate|February 2010||2010-02-28|March 2010|2010-03-31||||||||Observational|||Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia|Genome-wide Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Lymphoblastic Leukemia|Unknown status|Recruiting||200|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     Stored bone marrow specimens of patients with acute lymphoblastic leukemia~   "|||2018-06-01 00:01:29.539863|2018-06-01 00:01:29.539863
NCT01079494|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-04-06|2010-03-02|2010-03-03|Estimate|||||||2010-04-06|2010-04-07|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Clinical Pharmacists Role in the Management of Hypertension in Jordan|Clinical Pharmacists Role in the Management of Hypertension in Jordan|Completed||N/A|266|Actual|University of Jordan||2|||f||||t||||||||||2018-06-01 00:01:29.66523|2018-06-01 00:01:29.66523
NCT01079481|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2013-05-29|2010-03-02|2010-03-03|Estimate|||||||2013-05-29|2013-05-30|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|May 2012|Actual|2012-05-31||Interventional|||Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer|A Phase I Study of Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer|Completed||Phase 1|21|Actual|Samsung Medical Center||1|||f||||||||||||||2018-06-01 00:01:29.738077|2018-06-01 00:01:29.738077
NCT01079468|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2011-11-07|2010-03-02|2010-03-03|Estimate|||||||2011-11-07|2011-11-08|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Cognition in Postoperative Total Hip Arthroplasty and Total Hip Resurfacing Patients|Cognition in Postoperative Total Hip Arthroplasty and Total Hip Resurfacing Patients|Completed|||100|Anticipated|Rothman Institute Orthopaedics|||2||f||||f||||||||||2018-06-01 00:01:29.822684|2018-06-01 00:01:29.822684
NCT01079455|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|December 2013|Anticipated|2013-12-31|July 2012|Anticipated|2012-07-31||Interventional|||Comparison of Hyaluronic Acid and Corticosteroid Intra-articular Injections for the Treatment of Osteoarthritis of the Hip|Comparison of Hyaluronic Acid and Corticosteroid Intra-articular Injections for the Treatment of Osteoarthritis of the Hip Controlled With Intra-articular Injections With Bupivacaine|Unknown status|Not yet recruiting|Phase 3|489|Anticipated|University Hospital Pellenberg||3|||f||||f||||||||||2018-06-01 00:01:29.903434|2018-06-01 00:01:29.903434
NCT01079442|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2011-09-29|2010-03-02|2010-03-03|Estimate|||||||2011-09-29|2011-09-30|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Coffee Trial - Does Coffee Intake Reduce Postoperative Ileus After Elective Colectomy?|Does Coffee Intake Reduce Postoperative Ileus After Elective Colectomy?|Completed||N/A|80|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 00:01:30.009528|2018-06-01 00:01:30.009528
NCT01079429|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2017-08-28|2010-03-02|2010-03-03|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2010||2010-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|GENOMGUS||Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.|Large Scale Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From Monoclonal Gammopathy of Undetermined Significance (MGUS) and Indolent Myeloma (SMM).|Active, not recruiting|||1200|Anticipated|Rennes University Hospital|||1||f||||t||||||Samples With DNA|"~     Whole blood Plasma Urine Bone marrow~   "|||2018-06-01 00:01:30.09376|2018-06-01 00:01:30.09376
NCT01079416|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2013-01-31|2010-03-02|2010-03-03|Estimate|||||||2013-01-31|2013-02-01|Estimate|June 2006||2006-06-30|January 2013|2013-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Study of Capsule Endoscopy to Determine the Accuracy for Detection of Esophageal Varices|Is Capsule Endoscopy Accurate and Cost-effective Enough to Screen Cirrhotic Patients for Varices & Other Lesions?|Completed|||65|Actual|University of California, Los Angeles|||2||f||||f||||||||||2018-06-01 00:01:30.195607|2018-06-01 00:01:30.195607
NCT01079390|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2014-03-25||2017-07-12|2010-03-02|2010-03-03|Estimate|2017-07-12|2017-08-10|Actual||||2017-07-12|2017-08-10|Actual|January 2010||2010-01-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|January 2013|Actual|2013-01-31||Interventional|||An Acupuncture Functional Magnetic Resonance Imaging (fMRI) Study on Chronic Pain: Response Reliability and Dose Effect|An Acupuncture fMRI Study on Chronic Pain: Response Reliability and Dose Effect|Completed||N/A|44|Actual|Massachusetts General Hospital|Limitations of the study are the small sample size as well as the effects of factors such as age, gender, and chronic duration of pain.|3|||f||||t||||||||||2018-06-01 00:01:30.275156|2018-06-01 00:01:30.275156
NCT01079377|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2017-03-30|2010-03-02|2010-03-03|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2010||2010-01-31|March 2017|2017-03-31|January 5, 2017|Actual|2017-01-05|January 2017|Actual|2017-01-31||Observational|||Psychological Symptoms Among Adolescents Enrolled in a Bariatric Surgery Program|Psychological Symptoms Among Adolescents Enrolled in a Bariatric Surgery Program|Completed|||150|Actual|New York State Psychiatric Institute|||3||f||||f||||||||||2018-06-01 00:01:30.57422|2018-06-01 00:01:30.57422
NCT01079364|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-05-27|2010-03-02|2010-03-03|Estimate|||||||2013-05-27|2013-05-29|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|BASAAL PLUS||Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting|Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting|Terminated||Phase 4|52|Actual|Sanofi||2||Slow recruitment|f||||||||||||||2018-06-01 00:01:30.638306|2018-06-01 00:01:30.638306
NCT01079351|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-04-22|2010-03-02|2010-03-03|Estimate|||||||2010-04-22|2010-04-23|Estimate|April 2007||2007-04-30|April 2010|2010-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy|A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy|Completed||Phase 1|98|Actual|Lundbeck LLC|||||f||||t||||||||||2018-06-01 00:01:30.715772|2018-06-01 00:01:30.715772
NCT01079338|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2010-03-02|2010-03-02|2010-03-03|Estimate|||||||2010-03-02|2010-03-03|Estimate||||February 2010|2010-02-28||||||||Interventional|PROTAMER||Salivary Proteome and Sensitivity to Bitterness||Completed||N/A|||Institut National de la Recherche Agronomique||1|||f||||f||||||||||2018-06-01 00:01:30.784089|2018-06-01 00:01:30.784089
NCT01079325|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2016-04-18|2010-03-02|2010-03-03|Estimate|||||||2016-04-18|2016-04-19|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Interventional|||Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy|A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderately Severe Diabetic Neuropathy|Completed||Phase 2|170|Actual|Sangamo Therapeutics||2|||f||||f||||||||||2018-06-01 00:01:30.853386|2018-06-01 00:01:30.853386
NCT01079312|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2012-07-04|2010-03-02|2010-03-03|Estimate|||||||2012-07-04|2012-07-06|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Patient-controlled Sedation With Propofol and Remifentanyl for Endoscopic Retrograde Cholangiopancreatography (ERCP)|Patient-controlled Sedation vs Propofol Infusion for ERCP:a Randomized Controlled Study|Completed||Phase 4|80|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-06-01 00:01:30.984761|2018-06-01 00:01:30.984761
NCT01079299|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2011-08-18||2012-01-09|2010-03-02|2010-03-03|Estimate|2012-01-09|2012-02-10|Estimate||||2012-01-09|2012-02-10|Estimate|December 2007||2007-12-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema|Intermittent, Gradient, Pneumatic Compression Plus Standard Compression for Hard-To-Heal Venous Ulcers in Subjects With Secondary Lymphedema and Chronic Venous Insufficiency|Completed||N/A|52|Actual|Calvary Hospital, Bronx, NY||2|||f||||f||||||||||2018-06-01 00:01:31.086553|2018-06-01 00:01:31.086553
NCT01079286|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-07-12|2010-03-02|2010-03-03|Estimate|||||||2013-07-12|2013-07-15|Estimate|June 2009||2009-06-30|July 2013|2013-07-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|I-NET||Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers|Phase I Study of Nelfinavir in Combination With Temsirolimus in the Treatment of Patients With Advanced Cancers, Including Second Line Renal Cell Cancer|Completed||Phase 1|18|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-06-01 00:01:31.279494|2018-06-01 00:01:31.279494
NCT01079273|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2012-05-31|2010-03-02|2010-03-03|Estimate|||||||2012-05-31|2012-06-01|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects|An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 to 60 Years|Completed||Phase 4|7|Actual|Opera Srl||1|||f||||f||||||||||2018-06-01 00:01:31.344317|2018-06-01 00:01:31.344317
NCT01079260|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-11-12|2010-03-02|2010-03-03|Estimate|||||||2014-11-12|2014-11-13|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||An Investigation of the Efficacy of Oral Nutritional Supplements in Participants at Risk of Malnutrition|An Investigation of the Efficacy of High Energy, Low Volume Oral Nutritional Supplements in Participants at Risk of Malnutrition|Completed||N/A|60|Actual|Nutricia UK Ltd||2|||f||||f||||||||||2018-06-01 00:01:31.410598|2018-06-01 00:01:31.410598
NCT01079247|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2016-12-08|2010-03-01|2010-03-03|Estimate|||||||2016-12-08|2016-12-12|Estimate|February 2010||2010-02-28|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A Trial of Restrictive Versus Traditional Blood Transfusion Practices in Burn Patients|A Randomized Clinical Trial of Restrictive vs. Traditional Blood Transfusion Practices in Burn Patients|Active, not recruiting||Phase 3|347|Actual|American Burn Association||2|||f||||t||||||||||2018-06-01 00:01:31.485559|2018-06-01 00:01:31.485559
NCT01079234|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|2015-10-12|2011-12-08|2016-12-16|2010-03-02|2010-03-03|Estimate|2015-11-27|2015-12-31|Estimate|2011-12-08|2011-12-22|Estimate|2016-12-16|2017-02-09|Estimate|March 2010||2010-03-31|December 2016|2016-12-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|BEGIN™||Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes|A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin™: Flex T1)|Completed||Phase 3|493|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 00:01:31.708621|2018-06-01 00:01:31.708621
NCT01079221|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2016-08-01|2010-03-02|2010-03-03|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2009||2009-02-28|August 2016|2016-08-31|December 2012|Actual|2012-12-31|June 2010|Actual|2010-06-30||Interventional|||Effects of Knee-extensor Exercise Training in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of Knee-extensor Exercise Training in Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||N/A|12|Actual|Norwegian University of Science and Technology||1|||f||||t||||||||||2018-06-01 00:01:32.279478|2018-06-01 00:01:32.279478
NCT01079208|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-02|||2014-12-02|2010-03-02|2010-03-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2010||2010-03-31|October 2013|2013-10-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|||Growth of Infants Fed New Starter Formula|Assessment of Growth of Infants Fed Starter Formulas With Modified Protein and Synbiotics|Completed||N/A|297|Anticipated|Nestlé||3|||f||||f||||||||||2018-06-01 00:01:32.358001|2018-06-01 00:01:32.358001
NCT01079195|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2011-03-04||2011-04-15|2010-03-02|2010-03-03|Estimate|2011-04-15|2011-05-09|Estimate||||2011-04-15|2011-05-09|Estimate|October 2007||2007-10-31|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|TARDIA||Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus|Effectiveness and Tolerability of Tarka in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus, Not Controlled on Single-drug Therapy: A Multicountry, Multicenter, Post-marketing Observational Study in the Routine Clinical Use|Completed|||15436|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:01:32.56616|2018-06-01 00:01:32.56616
NCT01079182|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2015-05-13||2015-06-10|2010-03-02|2010-03-03|Estimate|2015-05-13|2015-06-01|Estimate||||2015-06-10|2015-07-09|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||A total of 4681 participants enrolled in the study, but the complete set of parameters was not available for each participant (Age and gender, N=4680; duration of AS symptoms, N=4521; HLA-B27 positive, N=3807).|Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)|Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice|Completed|||4681|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:01:34.239051|2018-06-01 00:01:34.239051
NCT01079169|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-05-13|2010-03-02|2010-03-03|Estimate|||||||2016-05-13|2016-05-16|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Cranberry Capsules on Urinary Infection Rates in Spinal Cord Injured Patients During Post Acute Rehabilitation|Evaluation of the Effect of Cranberry Capsules on the Occurrence of Urinary Tract Infections During Post-acute Rehabilitation of Spinal Cord Injured Patients|Terminated||N/A|3|Actual|Uppsala University||2||Terminated early due to recruitment difficulties|f||||f||||||||||2018-06-01 00:01:37.138716|2018-06-01 00:01:37.138716
NCT01079143|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2013-06-27||2014-01-31|2010-03-01|2010-03-02|Estimate|2014-01-31|2014-03-18|Estimate||||2014-01-31|2014-03-18|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CERTITEM||Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients|Prospective, Multicenter, Randomized Open Study to Evaluate the Progression of Renal Graft Fibrosis According to the Epithelial-mesenchymal Transition (EMT) in de Novo Renal Transplant Recipients Treated Either by a CNI Free Immunosuppressive Regimen With Everolimus and Enteric-coated Mycophenolate Sodium or a CNI Based Regimen With Cyclosporine and Enteric-coated Mycophenolate Sodium|Completed||Phase 3|194|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:01:37.29227|2018-06-01 00:01:37.29227
NCT01079130|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2011-07-22||2011-07-22|2010-03-01|2010-03-02|Estimate|2011-07-22|2011-08-19|Estimate||||2011-07-22|2011-08-19|Estimate|February 2010||2010-02-28|July 2011|2011-07-31||||July 2010|Actual|2010-07-31||Interventional|||Efficacy and Safety of Different Doses of Indacaterol|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Different Doses of Indacaterol in Adult Patients With Persistent Asthma, Using Salmeterol as an Active Control|Completed||Phase 3|511|Actual|Novartis||6|||f||||||||||||||2018-06-01 00:01:38.767876|2018-06-01 00:01:38.767876
NCT01079117|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-03-27|2010-03-01|2010-03-02|Estimate|||||||2014-03-27|2014-03-28|Estimate|October 2006||2006-10-31|March 2014|2014-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Morphine Slow-release Capsules in Substitution Therapy|Randomised, Controlled Clinical Study Regarding the Feasibility of Converting Opiate Dependents From Methadone Substitutes to Slow Release Morphine Sulphate (Sevre-Long™)|Completed||Phase 3|276|Actual|Mundipharma Medical Company||2|||f||||f||||||||||2018-06-01 00:01:39.32254|2018-06-01 00:01:39.32254
NCT01079104|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-12-30|2010-03-01|2010-03-02|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|HEPATICUS-2||Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units|Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units|Terminated||N/A|7|Actual|Hepa Wash GmbH||2||The foundations of our pilotstudy planning has changed.|f||||t||||||||||2018-06-01 00:01:39.401468|2018-06-01 00:01:39.401468
NCT01079091|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-12-30|2010-03-01|2010-03-02|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|HEPATICUS-1||Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units|Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units|Terminated||N/A|6|Actual|Hepa Wash GmbH||2||The foundations of our pilotstudy planning has changed.|f||||t||||||||||2018-06-01 00:01:39.473851|2018-06-01 00:01:39.473851
NCT01079078|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fed Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gelcaps (Containing Acetaminophen 650 mg) of OHM Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals Inc.) With TylenolÒ Arthritis Pain Extended Release Caplets (Containing Acetaminophen 650 mg) of McNeil-PPC Inc. in Healthy, Adult, Human, Male Subjects Under Fed Condition.|Completed||N/A|26|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-06-01 00:01:39.5459|2018-06-01 00:01:39.5459
NCT01079065|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Famotidine 20 mg Tablets of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With PEPCID AC Tablets (Containing Famotidine 20 mg) of Johnson & Johnson Merck Consumer Pharmaceutical Co. in Healthy, Adult, Human, Male Subjects Under Fasting Condition.|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-06-01 00:01:39.611972|2018-06-01 00:01:39.611972
NCT01079052|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition||Completed||N/A|24|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-06-01 00:01:39.681233|2018-06-01 00:01:39.681233
NCT01079026|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|March 2008||2008-03-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Outcome After Lumbar Epidural Steroid Injection|Functional Outcome After Lumbar Epidural Steroid Injection|Completed|||26|Actual|Scuderi, Gaetano J., M.D.|||||f||||t||||||Samples With DNA|"~     lavage fluid from epidural space~   "|||2018-06-01 00:01:39.755378|2018-06-01 00:01:39.755378
NCT01079013|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2016-04-19|2010-03-01|2010-03-02|Estimate|||||||2016-04-19|2016-04-20|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies|Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:01:39.806901|2018-06-01 00:01:39.806901
NCT01079000|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2016-11-17|2010-03-01|2010-03-02|Estimate|||||||2016-11-17|2016-11-21|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Emergency Department (ED)-Directed Interventions to Improve Asthma Outcomes|Emergency Department (ED)-Directed Interventions to Improve Outcomes After Asthma Exacerbations|Completed||N/A|367|Actual|University of Alberta||3|||f||||f||||||||No||2018-06-01 00:01:39.868595|2018-06-01 00:01:39.868595
NCT01078987|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2014-11-19|2010-03-01|2010-03-02|Estimate|||||||2014-11-19|2014-11-21|Estimate|February 2002||2002-02-28|November 2014|2014-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|NFD||Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)|Use of Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) and Understanding Its Etiology|Terminated||Phase 4|12|Actual|Loma Linda University||4||Insufficient recruitment|f||||f||||||||||2018-06-01 00:01:39.943852|2018-06-01 00:01:39.943852
NCT01078974|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2016-02-04||2016-06-13|2010-03-01|2010-03-02|Estimate|2016-06-13|2016-07-25|Estimate||||2016-06-13|2016-07-25|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia|Phase I Study of Pomalidomide, Dexamethasone and Rituximab (PDR) in Relapsed or Refractory Waldenstrom's Macroglobulinemia|Terminated||Phase 1|7|Actual|Dana-Farber Cancer Institute|Pomalidomide and rituximab could have a synergistic effect on serum IgM levels and produce an IgM flare. The highest dose of pomalidomide in this trial was 1mg. The study was permanently closed to accrual given the safety concerns with the IgM flare.|1||Safety concerns (IgM Flare)|f||||t||||||||||2018-06-01 00:01:40.129045|2018-06-01 00:01:40.129045
NCT01078961|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2016-06-07|2010-03-01|2010-03-02|Estimate|||||||2016-06-07|2016-06-08|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|June 2016|Actual|2016-06-30|February 2013|Actual|2013-02-28||Interventional|||An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma|A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma|Completed||Phase 1|11|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:01:40.430903|2018-06-01 00:01:40.430903
NCT01078948|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2012-02-09|2010-03-01|2010-03-02|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) in the Treatment of Major Depressive Disorder (MDD)|A Double-blind Sham Controlled Trial of Transcranial Direct Current Stimulation (tDCS) in Treating Refractory Major Depressive Disorder (MDD)|Completed||N/A|24|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 00:01:40.510866|2018-06-01 00:01:40.510866
NCT01078935|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2011-08-10|2010-03-01|2010-03-02|Estimate|||||||2011-08-10|2011-08-11|Estimate|December 2012||2012-12-31|March 2010|2010-03-31||||April 2014|Anticipated|2014-04-30||Interventional|||The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation|The Effect of Probiotics on Bowel Disease|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||f||||||||||2018-06-01 00:01:40.577549|2018-06-01 00:01:40.577549
NCT01078922|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2014-04-01||2014-07-02|2010-03-01|2010-03-02|Estimate|2014-04-01|2014-05-02|Estimate||||2014-07-02|2014-07-16|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas|A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas|Terminated||Phase 2|11|Actual|Oncology Specialists, S.C.||1||Study terminated due to slow acrual|f||||f||||||||||2018-06-01 00:01:40.643785|2018-06-01 00:01:40.643785
NCT01078909|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2015-09-16||2017-09-29|2010-03-01|2010-03-02|Estimate|2017-05-16|2017-06-14|Actual||||2017-09-29|2017-11-01|Actual|October 2011||2011-10-31|September 2017|2017-09-30|April 2014|Actual|2014-04-30|November 2012|Actual|2012-11-30||Interventional|||Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation|Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation|Completed||Phase 3|125|Actual|Penn State University||5|||f||||t||||||||||2018-06-01 00:01:40.919848|2018-06-01 00:01:40.919848
NCT01078883|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|||2011-01-06|2010-03-01|2010-03-02|Estimate|||||||2011-01-06|2011-01-10|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Respiratory Muscle Performance and Functional Capacity in Primary Stage IIIb and IV Lung Cancer|Association Between Respiratory Muscle Performance and Functional Capacity in Patients With Primary Stage IIIb & IV Lung Cancer|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 00:01:41.25112|2018-06-01 00:01:41.25112
NCT01078870|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|||2010-03-09|2010-03-01|2010-03-02|Estimate|||||||2010-03-09|2010-03-10|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|TANESN||Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype|A Double-blind, Randomized, Placebo Controlled Clinical Trial on Comparing Escitalopram and Duloxetine add-on for Negative Symptoms in Schizophrenic Subjects With Neuregulin-1 (NRG1) Risk Genotype|Unknown status|Active, not recruiting|Phase 4|75|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||||2018-06-01 00:01:41.424936|2018-06-01 00:01:41.424936
NCT01078857|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|February 2009||2009-02-28|February 2010|2010-02-28||||August 2012|Anticipated|2012-08-31||Interventional|||Small-fiber Neuropathy in Chronic Kidney Disease|Small-fiber Neuropathy in Chronic Kidney Disease|Unknown status|Recruiting|N/A|120|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 00:01:41.507075|2018-06-01 00:01:41.507075
NCT01078844|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2017-05-17||2017-06-27|2010-03-01|2010-03-02|Estimate|2017-06-27|2017-07-26|Actual||||2017-06-27|2017-07-26|Actual|February 2010|Actual|2010-02-28|June 2017|2017-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Memantine in Adult Autism Spectrum Disorder|Memantine in Adult Autism Spectrum Disorder|Terminated||N/A|4|Actual|Johns Hopkins University||2||Sponsor withdrew funds|f||||t||||||||||2018-06-01 00:01:41.586549|2018-06-01 00:01:41.586549
NCT01078831|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-11-10|2010-03-01|2010-03-02|Estimate|||||||2010-11-10|2010-11-11|Estimate|March 2002||2002-03-31|November 2010|2010-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Intrabronchial Airway Pressures in Intubated Patients During Bronchoscopy|Intrabronchial Airway Pressures in Intubated Patients During Bronchoscopy Under Volume Controlled (VC) and Pressure Controlled (PC) Ventilation|Completed|||20|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples Without DNA|"~     Arterial blood gases~   "|||2018-06-01 00:01:41.718647|2018-06-01 00:01:41.718647
NCT01078818|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-02|2010-03-01|2010-03-02|Estimate|||||||2010-03-02|2010-03-03|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation|A Phase IV, Unicenter, Randomized, Double-Blind, Parallel-Group, Comparaty Study of Intravenous and Oral Iron vs Placebo in Patient Under Extracorporeal Circulation in Cardiovascular Surgery|Completed||Phase 4|159|Actual|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||3|||f||||f||||||||||2018-06-01 00:01:41.786825|2018-06-01 00:01:41.786825
NCT01078805|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2012-01-30||2012-05-16|2010-03-01|2010-03-02|Estimate|2012-05-16|2012-06-26|Estimate||||2012-05-16|2012-06-26|Estimate|August 2003||2003-08-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|DANCE||Study of FORTEO Use in Subjects in the Community Setting|Direct Assessment of Non-Vertebral Fractures in Community Experience (DANCE)|Completed|||4167|Actual|Eli Lilly and Company|||1||f||||f||||||||||2018-06-01 00:01:41.91158|2018-06-01 00:01:41.91158
NCT01078792|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate||||March 2010|2010-03-31||||||||Observational|||Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence||Unknown status|Not yet recruiting||||Hillel Yaffe Medical Center|||1||f||||||||||||||2018-06-01 00:01:42.720784|2018-06-01 00:01:42.720784
NCT01078779|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|||2010-02-28|2010-02-28|2010-03-02|Estimate|||||||2010-02-28|2010-03-02|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|August 2010|Anticipated|2010-08-31|May 2010|Anticipated|2010-05-31||Interventional|CHIP||The Chloroquine for Influenza Prevention Trial|A Randomised, Double-blind, Placebo Controlled Trial of Chloroquine for the Prevention of Influenza|Unknown status|Active, not recruiting|Phase 2|1516|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 00:01:42.780174|2018-06-01 00:01:42.780174
NCT01078766|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|||2016-04-07|2010-03-01|2010-03-02|Estimate|||||||2016-04-07|2016-04-08|Estimate|August 2009||2009-08-31|June 2015|2015-06-30||||March 2010|Actual|2010-03-31||Interventional|||Constraint-induced Movement Therapy and Hand Arm Bimanual Training in Children With Hemiplegic Cerebral Palsy (CP)|Constraint-induced Movement Therapy and Hand Arm Bimanual Training in Children With Hemiplegic CP|Unknown status|Enrolling by invitation|N/A|9|Actual|Alyn Pediatric & Adolecent Rehabilitation Center||1|||f||||f||||||||||2018-06-01 00:01:42.848617|2018-06-01 00:01:42.848617
NCT01078753|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2011-09-27||2011-09-27|2010-03-01|2010-03-02|Estimate|2011-09-27|2011-11-02|Estimate||||2011-09-27|2011-11-02|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PNE||Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis|A Double-blind, Placebo-controlled, Phase III Comparative Study With FE992026 in Children and Adolescents With Reduced Night-time Urinary Osmolarity-type Nocturnal Enuresis|Completed||Phase 3|89|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:01:42.915109|2018-06-01 00:01:42.915109
NCT01078740|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2013-03-05|2010-03-01|2010-03-02|Estimate|||||||2013-03-05|2013-03-07|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects|Detection of Cystic Fibrosis Transmembrane Conductance Regulator CFTR) Activity in Rectal Tissues From Human Subjects|Completed|||57|Actual|CF Therapeutics Development Network Coordinating Center|||2||f||||t||||||Samples With DNA|"~     Rectal biopsy~   "|||2018-06-01 00:01:43.365262|2018-06-01 00:01:43.365262
NCT01078727|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|August 2007||2007-08-31|February 2008|2008-02-29|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|||Safety Study of Thermal Stimulation on Upper Extremity Motor Recovery to Stroke|Thermal Stimulation on Upper Extremity Movement and Function in Patients With Stroke|Completed||Phase 1/Phase 2|25|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-06-01 00:01:43.428159|2018-06-01 00:01:43.428159
NCT01078714|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2011-12-20|2010-03-01|2010-03-02|Estimate|||||||2011-12-20|2011-12-21|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|BUMEA||Efficiency of Bumetanide in Autistic Children|Study of the Efficiency of a Treatment by Bumetanide in a Population of Autistic Children|Completed||Phase 3|60|Actual|University Hospital, Brest||2|||f||||f||||||||||2018-06-01 00:01:43.487549|2018-06-01 00:01:43.487549
NCT01078701|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2011-01-04|2010-03-01|2010-03-02|Estimate|||||||2011-01-04|2011-01-05|Estimate|December 2009||2009-12-31|January 2011|2011-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|GHB-CS07||Dose Finding Study of Single Dose GHB11L1 in Healthy Adults|Randomised, Double-blind, Placebo-controlled, Phase IIa Dose Finding Study of Single Dose GHB11L1 in Healthy Adults|Completed||Phase 2|49|Actual|AVIR Green Hills Biotechnology AG||2|||f||||f||||||||||2018-06-01 00:01:43.556244|2018-06-01 00:01:43.556244
NCT01078688|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-01-28|2010-03-01|2010-03-02|Estimate|||||||2013-01-28|2013-01-29|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|ASMAVIE||Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma|Evaluation of the Frequency of Limitation of Activity, Depending on Gender and Age-group, in Patients With Persistent Asthma Consulting a General Practitioner|Completed|||1942|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:01:43.692418|2018-06-01 00:01:43.692418
NCT01078675|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2014-02-06||2015-03-19|2010-03-01|2010-03-02|Estimate|2015-01-30|2015-02-02|Estimate||||2015-03-19|2015-04-07|Estimate|February 2010||2010-02-28|March 2015|2015-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Rosuvastatin; All treated patients. Healthy siblings; All patient who started this study|An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia|An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (Aged From 6 to Less Than 18 Years) With Familial Hypercholesterolaemia|Completed||Phase 3|315|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:01:44.936093|2018-06-01 00:01:44.936093
NCT01078662|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2015-01-13|2013-05-09|2018-02-27|2010-03-01|2010-03-02|Estimate|2015-05-21|2015-05-22|Estimate|2013-05-09|2013-05-16|Estimate|2018-02-27|2018-03-01|Actual|February 21, 2010|Actual|2010-02-21|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|July 31, 2012|Actual|2012-07-31||Interventional|||Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats|A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation|Active, not recruiting||Phase 2|299|Actual|AstraZeneca||1|||t||||f||||||||||2018-06-01 00:01:45.608728|2018-06-01 00:01:45.608728
NCT01078649|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-10-21|2010-03-01|2010-03-02|Estimate|||||||2014-10-21|2014-10-22|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas|A Phase I, Open Label, Multi-Center, Dose Escalation Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Properties of Orally Administered AT-406 in Patients With Advanced Solid Tumors and Lymphomas|Completed||Phase 1|51|Actual|Debiopharm International SA||1|||f||||f||||||||||2018-06-01 00:01:46.181476|2018-06-01 00:01:46.181476
NCT01078636|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2014-09-15|2010-03-01|2010-03-02|Estimate|||||||2014-09-15|2014-09-16|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|ADNI-GO||Alzheimer's Disease Neuroimaging Initiative Grand Opportunity|Alzheimer's Disease Neuroimaging Initiative Grand Opportunity|Completed|||342|Actual|Alzheimer's Disease Cooperative Study (ADCS)|||3||f||||t||||||Samples With DNA|"~     blood, urine, cerebrospinal fluid~   "|||2018-06-01 00:01:46.416762|2018-06-01 00:01:46.416762
NCT01078623|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2016-09-27||2017-01-05|2010-03-01|2010-03-02|Estimate|2016-09-27|2016-11-15|Estimate||||2017-01-05|2017-02-23|Actual|February 2010||2010-02-28|December 2016|2016-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|ALIGHT-COPD||Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate|Efficacy, Safety and Tolerability of Two Fixed-Dose Combinations of Aclidinium Bromide With Two Doses of Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo All Administered Twice Daily in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease Patients.|Completed||Phase 2|176|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 00:01:46.645387|2018-06-01 00:01:46.645387
NCT01078610|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2012-08-08|2010-03-01|2010-03-02|Estimate|||||||2012-08-08|2012-08-10|Estimate||||June 2012|2012-06-30||||||||Observational|ELAN||Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine|Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Psoriatic Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice|Withdrawn|||0|Actual|Abbott|||1|Study stopped prior to enrollment.|f||||f||||||||||2018-06-01 00:01:47.17856|2018-06-01 00:01:47.17856
NCT01078597|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2013-08-16|2010-03-01|2010-03-02|Estimate|||||||2013-08-16|2013-08-20|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA|A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA|Completed|||35|Actual|AbbVie|||1||f||||f||||||None Retained|"~     There are no biospecimens specifically retained for the purposes of the study. Routine blood~     samples may be retained as per routine practice of the participating centre.~   "|||2018-06-01 00:01:47.245915|2018-06-01 00:01:47.245915
NCT01078584|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2012-09-07||2012-10-19|2010-03-01|2010-03-02|Estimate|2012-09-07|2012-10-11|Estimate||||2012-10-19|2012-10-25|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|in-MAU-tion||Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients|A Prospective, Non-interventional, Observational Study To Describe the Effectiveness of Trandolapril (Mavik®) in the Management of Patients Requiring Angiotensin Converting Enzyme Inhibitor Treatment (In-MAU-tion)|Completed|||7993|Actual|Abbott|||1||f||||||||||||||2018-06-01 00:01:47.432018|2018-06-01 00:01:47.432018
NCT01078571|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2011-05-27||2011-10-26|2010-03-01|2010-03-02|Estimate|2011-09-15|2011-10-25|Estimate||||2011-10-26|2011-10-28|Estimate|May 2006||2006-05-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|DALI||Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis|Safety and Effectiveness of Adalimumab (HUMIRA®) in Patients Diagnosed With Rheumatoid Arthritis (DALI Study)|Completed|||705|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:01:49.342693|2018-06-01 00:01:49.342693
NCT01078558|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2018-01-15|2010-03-01|2010-03-02|Estimate|||||||2018-01-15|2018-01-17|Actual|May 13, 2004||2004-05-13|January 2018|2018-01-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Observational|ProAct||A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis or Psoriatic Arthritis Who Are Treated With HUMIRA (Adalimumab)|Completed|||5832|Actual|AbbVie|||1||f||||f|f|f|||f|||No||2018-06-01 00:01:49.826581|2018-06-01 00:01:49.826581
NCT01078545|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|2011-11-29||2012-01-12|2010-02-28|2010-03-02|Estimate|2011-11-29|2012-01-06|Estimate||||2012-01-12|2012-01-16|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|LEMON||Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)|Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms. International, Multicenter Post-marketing Observational Study.|Completed|||729|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:01:50.06529|2018-06-01 00:01:50.06529
NCT01078532|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|||2014-05-20|2010-03-01|2010-03-02|Estimate|||||||2014-05-20|2014-05-21|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|SMART PHR||Self Management and Reminders With Technology: SMART Appraisal of an Integrated Personal Health Record (PHR)|Self Management & Reminders With Technology: SMART Appraisal of an Integrated Personal Health Record (SMART PHR)|Completed||N/A|1815|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:01:50.782685|2018-06-01 00:01:50.782685
NCT01078519|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-07-14|2010-03-01|2010-03-02|Estimate|||||||2010-07-14|2010-07-15|Estimate|January 2010||2010-01-31|December 2007|2007-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|feveranalg||Combined Anesthesia for Labor and Maternal Temperature|Combined Spinal and Epidural Anesthesia and Maternal Intrapartum Temperature During Vaginal Delivery: a Randomized Clinical Trial|Completed||Phase 3|70|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-06-01 00:01:50.953003|2018-06-01 00:01:50.953003
NCT01078506|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2013-04-22|2010-03-01|2010-03-02|Estimate|||||||2013-04-22|2013-04-23|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Prevalence of Intracranial Aneurysm in Hong Kong Chinese|Prevalence of Intracranial Aneurysm in Hong Kong Chinese|Completed|||200|Actual|Chinese University of Hong Kong|||1||f||||t||||||||||2018-06-01 00:01:51.050742|2018-06-01 00:01:51.050742
NCT01078493|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|||2016-09-23|2010-03-01|2010-03-02|Estimate|||||||2016-09-23|2016-09-26|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|WIPES||Wrinkle Injection With Autologous Platelet Rich Plasma Study|Phase 1 Study of Intradermal Injection of Autologous Platelet Rich Plasma for Facial Wrinkles|Withdrawn||Phase 1|0|Actual|Novena Medical Center||||Protocol revision necessary.|f||||f||||||||||2018-06-01 00:01:51.235378|2018-06-01 00:01:51.235378
NCT01078480|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|||2016-01-21|2010-03-01|2010-03-02|Estimate|||||||2016-01-21|2016-01-22|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Conservative Treatment Compared to Osteosynthesis in Patients With a Fractured Collar Bone|Conservative Treatment Versus Plate Osteosynthesis Using Angular Stabile Screws and Precontoured Plates in Displaced Midshaft Clavicular Fractures. A Prospective Randomized Multicenter Study|Completed||N/A|140|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-06-01 00:01:51.334528|2018-06-01 00:01:51.334528
NCT01078467|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|||2018-05-23|2010-02-27|2010-03-02|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2, 2010||2010-02-02|February 27, 2018|2018-02-27||||||||Observational|||The Molecular Anatomy of Oral Wound Healing|The Molecular Anatomy of Oral Wound Healing|Completed|||53|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:01:51.406827|2018-06-01 00:01:51.406827
NCT01078454|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|2014-11-20||2014-11-20|2010-02-27|2010-03-02|Estimate|2014-11-20|2014-11-26|Estimate||||2014-11-20|2014-11-26|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||All enrolled patients are included in this analysis.|Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis|A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-Chain (AL) Amyloidosis Ineligible for Autologous Stem-Cell Transplantation|Completed||Phase 3|11|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 00:01:51.506152|2018-06-01 00:01:51.506152
NCT01078441|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|2015-01-05||2015-01-05|2010-02-27|2010-03-02|Estimate|2015-01-05|2015-01-12|Estimate||||2015-01-05|2015-01-12|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional||All patients enrolled are included in this analysis.|Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant|A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients With Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant|Terminated||Phase 2|2|Actual|National Cancer Institute (NCI)||1||The study was closed early due to weak accrual on June 26, 2012.|f||||f||||||||||2018-06-01 00:01:52.198813|2018-06-01 00:01:52.198813
NCT01078428|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|||2014-01-24|2010-03-01|2010-03-02|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars|Effect of Transparent, Self-drying Silicone Gel on the Treatment of Hypertrophic Abdominal Scars|Completed||Phase 4|38|Actual|Mahidol University||2|||f||||t||||||||||2018-06-01 00:01:52.778163|2018-06-01 00:01:52.778163
NCT01078415|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2016-11-07|2010-03-01|2010-03-02|Estimate|||||||2016-11-07|2016-11-08|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)|A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)|Completed||N/A|26|Actual|Angiodynamics, Inc.|||||f||||f||||||||||2018-06-01 00:01:52.90631|2018-06-01 00:01:52.90631
NCT01073852|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-01-21|2010-02-22|2010-02-23|Estimate|||||||2013-01-21|2013-01-23|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Hydroxychloroquine Efficacy in Chronic Urticaria|Hydroxychloroquine Efficacy in Chronic Urticaria|Withdrawn||N/A|0|Actual|Vanderbilt University||2||withdrawn, not funded|f||||t||||||||||2018-06-01 00:03:52.874224|2018-06-01 00:03:52.874224
NCT01078402|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|2012-11-19||2013-02-08|2010-02-27|2010-03-02|Estimate|2013-01-09|2013-02-07|Estimate||||2013-02-08|2013-02-12|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|EviraEAST||EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries|Evaluation of Clinical Outcome, Treatment Compliance and Tolerability of humIRA (Adalimumab) in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries; EviraEAST - a Multi-country, Multi-Center Post Marketing Observational Study in Routine Clinical Use|Completed|||809|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:01:53.051943|2018-06-01 00:01:53.051943
NCT01078389|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2014-09-03||2014-09-03|2010-03-01|2010-03-02|Estimate|2014-09-03|2014-09-10|Estimate||||2014-09-03|2014-09-10|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout|A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout|Completed||Phase 2|314|Actual|Takeda||2|||f||||t||||||||||2018-06-01 00:01:54.856728|2018-06-01 00:01:54.856728
NCT01078376|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2014-06-26||2014-06-26|2010-03-01|2010-03-02|Estimate|2014-06-26|2014-07-25|Estimate||||2014-06-26|2014-07-25|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults|A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults|Terminated||Phase 1|29|Actual|Takeda|The study was discontinued without complete enrollment of Cohort 3. Therefore, PK modeling will be used to determine the appropriate doses in children 1 to <6 years of age, in lieu of completing Cohort 3.|4||Business Decision (see below)|f||||t||||||||||2018-06-01 00:01:55.847085|2018-06-01 00:01:55.847085
NCT01078363|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2016-06-17||2016-12-02|2010-03-01|2010-03-02|Estimate|2016-06-17|2016-07-27|Estimate||||2016-12-02|2017-01-26|Estimate|June 2009||2009-06-30|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy|ACE Inhibition and Cardiac Allograft Vasculopathy|Completed||N/A|96|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 00:01:56.79942|2018-06-01 00:01:56.79942
NCT01078350|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2017-11-16|2010-03-01|2010-03-02|Estimate|||||||2017-11-16|2017-11-20|Actual|May 2004|Actual|2004-05-31|November 2017|2017-11-30|December 4, 2015|Actual|2015-12-04|December 4, 2015|Actual|2015-12-04||Observational|||Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy|Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy|Completed|||93|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     tissues sample~   "|||2018-06-01 00:01:57.025265|2018-06-01 00:01:57.025265
NCT01078337|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|November 2002||2002-11-30|February 2010|2010-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis|T-cell MRD Evaluation Using Flow Cytometric Analysis|Completed|||15|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     blood and bone marrow~   "|||2018-06-01 00:01:57.133731|2018-06-01 00:01:57.133731
NCT01078324|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2016-08-17|2010-03-01|2010-03-02|Estimate|||||||2016-08-17|2016-08-19|Estimate|December 1997||1997-12-31|August 2016|2016-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Study of Ischemic Colitis Compared to Other Diagnoses in Patients With Lower Gastrointestinal Bleeding|Ischemic Colitis Is a Common Cause of Severe Hematochezia and Patient Outcomes Are Worse Than With Other Colonic Diagnoses|Completed|||550|Actual|University of California, Los Angeles|||1||f||||f||||||||||2018-06-01 00:01:57.184412|2018-06-01 00:01:57.184412
NCT01078311|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2014|Anticipated|2014-02-28|February 2012|Anticipated|2012-02-29||Observational|DOSE-HEP||Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Phase 2 Study of Measurement of Trough Levels of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting||100|Anticipated|South West Sydney Local Health District|||1||f||||t||||||||||2018-06-01 00:01:58.21667|2018-06-01 00:01:58.21667
NCT01078298|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2013-01-17||2013-03-06|2010-02-26|2010-03-02|Estimate|2013-03-06|2013-04-16|Estimate||||2013-03-06|2013-04-16|Estimate|March 2010||2010-03-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression|A Phase 4 12-week, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555) 1mg BID For Smoking Cessation In Subjects With Depression|Completed||Phase 4|525|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:01:58.408261|2018-06-01 00:01:58.408261
NCT01078285|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-07-30|2010-02-26|2010-03-02|Estimate|||||||2015-07-30|2015-07-31|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor|Impact Of An Integrated Intervention Program On Adherence To Atorvastatin|Completed|||500|Actual|Pfizer|||2||f||||f||||||||||2018-06-01 00:02:00.388993|2018-06-01 00:02:00.388993
NCT01078272|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|SaFR||The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)|The Saint Francis Remote Ischemic Preconditioning Trial (SaFR)|Unknown status|Not yet recruiting|N/A|500|Anticipated|St. Francis Hospital, New York||2|||f||||f||||||||||2018-06-01 00:02:00.463213|2018-06-01 00:02:00.463213
NCT01078246|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2016-03-09||2017-06-09|2010-03-01|2010-03-02|Estimate|2016-03-09|2016-04-07|Estimate||||2017-06-09|2017-07-11|Actual|August 31, 2009|Actual|2009-08-31|June 2017|2017-06-30|December 9, 2014|Actual|2014-12-09|December 9, 2014|Actual|2014-12-09||Observational|||Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)|Post-Licensure Safety Study of ISENTRESS™ in a US Managed Care Network|Completed|||7124|Actual|Merck Sharp & Dohme Corp.|||7||f||||t||||||||||2018-06-01 00:02:00.574306|2018-06-01 00:02:00.574306
NCT01078233|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2015-06-15||2017-06-08|2010-03-01|2010-03-02|Estimate|2015-08-17|2015-09-17|Estimate||||2017-06-08|2017-07-11|Actual|May 5, 2008|Actual|2008-05-05|June 2017|2017-06-30|March 6, 2014|Actual|2014-03-06|March 6, 2014|Actual|2014-03-06||Observational|||Observational Data Analysis in EuroSIDA (MK-0518-058)|Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period|Completed|||6617|Actual|Merck Sharp & Dohme Corp.|||3||f||||t||||||||||2018-06-01 00:02:01.156028|2018-06-01 00:02:01.156028
NCT00872846|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-28|||2012-01-23|2009-03-30|2009-03-31|Estimate|||||||2012-01-23|2012-01-24|Estimate|February 2009||2009-02-28|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Balance System Study in Type 2 Diabetic Patients|Evaluation of the BALANCE System in Type 2 Diabetic Patients|Completed||Phase 1|20|Actual|Beta-Stim Ltd.|||||f||||t||||||||||2018-06-01 01:09:21.043654|2018-06-01 01:09:21.043654
NCT01078220|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2011-11-23||2017-06-09|2010-03-01|2010-03-02|Estimate|2011-11-23|2012-01-09|Estimate||||2017-06-09|2017-07-11|Actual|February 6, 2007|Actual|2007-02-06|June 2017|2017-06-30|December 13, 2010|Actual|2010-12-13|December 13, 2010|Actual|2010-12-13||Observational|||Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)|A Post-licensure Surveillance Program for the Safety of GARDASIL™ in a Managed Care Organization Setting|Completed|||189629|Actual|Merck Sharp & Dohme Corp.|Details of syncope and cellulitis findings and null findings for hundreds of other general safety analyses will be described in future publications.||4||f||||t||||||||||2018-06-01 00:02:01.470902|2018-06-01 00:02:01.470902
NCT01078207|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2012-05-14||2014-08-05|2010-03-01|2010-03-02|Estimate|2012-06-27|2012-08-01|Estimate||||2014-08-05|2014-08-07|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Oxygen Saturation Patterns in Post-Op Patients at Risk for Obstructive Sleep Apnea|A Prospective Non-Randomized Study of Pulse Oximetry Saturation Patterns in Postoperative Patients at High Risk of Obstructive Sleep Apnea|Completed|||100|Actual|Medtronic - MITG|||||f||||t||||||||||2018-06-01 00:02:01.662544|2018-06-01 00:02:01.662544
NCT01078194|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-05-24|2010-03-01|2010-03-02|Estimate|||||||2010-05-24|2010-05-25|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Secondary Bypass Banding for Weight Regain or Weight Loss Failure After Lap. Gastric Bypass|Observational Study on the Secondary Placement of the A.M.I. Soft Gastric Band in Weight Regain or Weight Loss Failure After Lap. Gastric Bypass|Unknown status|Recruiting||20|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-06-01 00:02:01.798036|2018-06-01 00:02:01.798036
NCT01078181|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-06-23|2010-03-01|2010-03-02|Estimate|||||||2010-06-23|2010-06-24|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Banded Versus Non-banded Roux-en-Y Gastric Bypass|A Prospective Randomized Comparison on Weight Loss After Gastric Bypass and Banded Gastric Bypass Using the A.M.I B-Band (Soft Gastric Bypass Band)|Unknown status|Recruiting|N/A|100|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:02:01.884938|2018-06-01 00:02:01.884938
NCT01078168|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|2016-03-14||2017-07-18|2010-03-01|2010-03-02|Estimate|2017-07-18|2018-02-02|Estimate||||2017-07-18|2018-02-02|Estimate|March 2010||2010-03-31|July 2017|2017-07-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|ADAM||Alzheimer`s Disease Acitretin Medication|Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study|Completed||Phase 2|22|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-06-01 00:02:01.969497|2018-06-01 00:02:01.969497
NCT01078155|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2015-05-12||2015-05-29|2010-02-26|2010-03-02|Estimate|2015-05-12|2015-05-29|Estimate||||2015-05-29|2015-06-26|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis|Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis|Completed|||131|Actual|AbbVie|||1||f||||f||||||Samples With DNA|"~     osteocalcin (OC), C-terminal type I procollagen peptide (CICP), C-telopeptide of type I~     collagen (CTX-I), whole blood (serum)~   "|||2018-06-01 00:02:02.448307|2018-06-01 00:02:02.448307
NCT01078142|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-09-08|2010-03-01|2010-03-02|Estimate|||||||2017-09-08|2017-09-11|Actual|February 2, 2010|Actual|2010-02-02|May 2017|2017-05-31|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|BERT||Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma|A Phase I/II Trial to Evaluate the Safety, Feasibility and Efficacy of the Addition of Temsirolimus to a Regimen of Bendamustine and Rituximab for the Treatment of Patients With Follicular Lymphoma or Mantle Cell Lymphoma in First to Third Relapse|Completed||Phase 1/Phase 2|39|Actual|Johannes Gutenberg University Mainz||1|||f||||t||||||||No||2018-06-01 00:02:02.823038|2018-06-01 00:02:02.823038
NCT01078129|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-02-24|2010-03-01|2010-03-02|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2006||2006-01-31|February 2014|2014-02-28|December 2010|Actual|2010-12-31|March 2008|Actual|2008-03-31||Interventional|||Cognitive Remediation Therapy and Schizophrenia|Efficacy of Hierarchized Computer-assisted Cognitive Remediation Therapy in Schizophrenia|Completed||N/A|77|Actual|Hôpital le Vinatier||2|||f||||f||||||||||2018-06-01 00:02:02.97379|2018-06-01 00:02:02.97379
NCT01078116|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2011-06-24||2011-08-09|2010-02-26|2010-03-02|Estimate|2011-06-24|2011-07-25|Estimate||||2011-08-09|2011-08-11|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|HEOR||Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)|Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis|Completed|||124|Actual|Abbott|Study NCT 01078116 (P10-159) is a substudy of NCT 01086033(GREC-2004-06). Adverse events were not recorded in this study but will be reported in the main study upon completion. Only adverse events leading to withdrawal are reported in this substudy.||1||f||||f||||||||||2018-06-01 00:02:03.112796|2018-06-01 00:02:03.112796
NCT01078103|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes Mellitus Type II|Corneal Endothelial Changes Associated With Phacoemulsification in Diabetes|Completed|||60|Actual|Frederiksberg University Hospital|||||f||||f||||||||||2018-06-01 00:02:03.436332|2018-06-01 00:02:03.436332
NCT01078090|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2014-03-19||2014-04-23|2010-02-26|2010-03-02|Estimate|2014-03-19|2014-04-23|Estimate||||2014-04-23|2014-05-08|Estimate|April 2003||2003-04-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice|Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice|Completed|||5745|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:02:03.596499|2018-06-01 00:02:03.596499
NCT01078077|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2012-03-01|2010-03-01|2010-03-02|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|March 2012|Actual|2012-03-31||Observational|TVConFSD||The Impact of a Topical Vasodilating Cream on Female Sexual Experience|The Impact of a Topical Vasodilating Cream (When Applied to the Clitoris) on the Female Sexual Experience Using a Standard 7 Part Female Sexual Dysfunction Questionnaire|Unknown status|Recruiting||200|Anticipated|East Suburban Ob Gyn|||||f||||f||||||||||2018-06-01 00:02:05.198313|2018-06-01 00:02:05.198313
NCT01078064|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-03-01|2010-03-01|2010-03-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|November 2010|Anticipated|2010-11-30|September 2010|Anticipated|2010-09-30||Observational|||Gastric Accommodation and Gastroesophageal Reflux|Gastric Accommodation as a Factor Influencing the Number of Reflux Episodes in Children and Adolescents|Unknown status|Not yet recruiting||33|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||||2018-06-01 00:02:05.263454|2018-06-01 00:02:05.263454
NCT01078051|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2016-12-21|2010-03-01|2010-03-02|Estimate|||||||2016-12-21|2016-12-22|Estimate|March 2010||2010-03-31|December 2016|2016-12-31|December 2030|Anticipated|2030-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)|Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients|Recruiting||Phase 4|1284|Anticipated|CardioVascular Research Foundation, Korea||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-06-01 00:02:05.339702|2018-06-01 00:02:05.339702
NCT01078038|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2012-08-07|2010-03-01|2010-03-02|Estimate|||||||2012-08-07|2012-08-08|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|LONG-DES-III||Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)|Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III: Sirolimus vs. Everolimus-eluting Stent|Completed||Phase 4|451|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 00:02:05.612709|2018-06-01 00:02:05.612709
NCT01078025|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2010-12-09|2010-03-01|2010-03-02|Estimate|||||||2010-12-09|2010-12-10|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|NOBACT||Evaluation of Microbial Colonisation and Contamination Caused by the Transvaginal and Transabdominal Access for Cholecystectomy||Completed|||30|Anticipated|Cantonal Hospital of St. Gallen|||2||f||||f||||||||||2018-06-01 00:02:05.742324|2018-06-01 00:02:05.742324
NCT01078012|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-01|||2015-12-29|2010-03-01|2010-03-02|Estimate|||||||2015-12-29|2015-12-30|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SIMOHpilot||Short Intervention for Medication Overuse Headache (MOH) - Pilot|Pilot Study of Short Intervention for Medication Overuse Headache in General Practice|Completed||N/A|5|Actual|University Hospital, Akershus||1|||f||||f||||||||||2018-06-01 00:02:05.806825|2018-06-01 00:02:05.806825
NCT01077999|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-08-26|2010-03-01|2010-03-02|Estimate|||||||2014-08-26|2014-08-27|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|April 2012|Actual|2012-04-30|February 2011|Actual|2011-02-28||Interventional|||Chemoradiation and Panitumumab for Esophageal Cancer|Chemoradiation Combined With Panitumumab Followed by Surgery for Patients With Operable Esophageal Cancer|Completed||Phase 2|78|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-06-01 00:02:05.889941|2018-06-01 00:02:05.889941
NCT01077986|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-05-19|2010-03-01|2010-03-02|Estimate|||||||2014-05-19|2014-05-20|Estimate|August 2009||2009-08-31|September 2010|2010-09-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer|A Phase I/ II, Non-randomized, Feasibility/ Safety and Efficacy Study of the Combination of Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|35|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||t||||||||||2018-06-01 00:02:05.996478|2018-06-01 00:02:05.996478
NCT01077973|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2012-07-12||2012-07-13|2010-02-26|2010-03-01|Estimate|2012-07-13|2012-08-20|Estimate||||2012-07-13|2012-08-20|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache|Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Episodic Tension-Type Headache|Completed||Phase 3|200|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:02:06.125096|2018-06-01 00:02:06.125096
NCT01077960|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2010-05-25||2013-08-04|2010-02-26|2010-03-01|Estimate|2010-05-25|2010-06-23|Estimate||||2013-08-04|2013-08-07|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome|Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS)|Completed||Phase 3|126|Actual|EMD Serono||1|||f||||f||||||||||2018-06-01 00:02:07.102727|2018-06-01 00:02:07.102727
NCT01077947|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2016-09-09|2010-02-26|2010-03-01|Estimate|||||||2016-09-09|2016-09-13|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Value of Functional Anesthetic and Provocative Discography in the Surgical Treatment of Discogenic Pain|Comparing the Value of Functional Anesthetic and Provocative Discography in the Surgical Treatment of Discogenic Pain|Withdrawn||Phase 4|0|Actual|Northwestern University||2||Internal|f||||f||||||||||2018-06-01 00:02:07.392709|2018-06-01 00:02:07.392709
NCT01077934|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2015-04-24|2010-02-26|2010-03-01|Estimate|||||||2015-04-24|2015-04-27|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Assessment of Near Infrared Spectroscopy as a Diagnostic Tool in Acute Compartment Syndrome|Assessment of Near Infrared Spectroscopy as a Diagnostic Tool in Acute Compartment Syndrome|Completed|||8|Actual|J&M Shuler|||2||f||||t||||||||||2018-06-01 00:02:07.457023|2018-06-01 00:02:07.457023
NCT01077921|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2014-12-30||2015-01-19|2010-02-26|2010-03-01|Estimate|2015-01-19|2015-01-22|Estimate||||2015-01-19|2015-01-22|Estimate|June 2010||2010-06-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)|Phase II Study of Propranolol as Anti-Adhesive Therapy for Sickle Cell Disease|Completed||Phase 2|31|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:02:07.538027|2018-06-01 00:02:07.538027
NCT01077908|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2018-01-23|2010-02-26|2010-03-01|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2008||2008-07-31|January 2018|2018-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|CMV-IMPACT||Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study|A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant|Completed||Phase 3|89|Actual|Cell Medica Ltd||2|||f||||t||||||||||2018-06-01 00:02:08.150378|2018-06-01 00:02:08.150378
NCT01077895|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-06-02|2010-02-26|2010-03-01|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Influence of Fluid Removal Using Continuous Venovenous Hemofiltration (CVVH) on Intra-abdominal Pressure and Kidney Function|The Influence of Fluid Removal Using Continuous Venovenous Hemofiltration (CVVH) on Intra-abdominal Pressure and Kidney Function in Critically Ill Adults With Intra-abdominal Hypertension and Acute Kidney Injury|Unknown status|Recruiting|Phase 3|30|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 00:02:08.261175|2018-06-01 00:02:08.261175
NCT01077726|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-11-01|2010-02-26|2010-03-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression|A Single Arm, Open-label Trial Assessing the Effect of Capecitabine (Xeloda® ) on Progression-free Survival Rate at Four Months in Breast Cancer Patients With CNS Progression After Whole Brain Radiotherapy|Completed||Phase 2|3|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:02:11.695214|2018-06-01 00:02:11.695214
NCT01077882|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2012-07-04|2010-02-26|2010-03-01|Estimate|||||||2012-07-04|2012-07-06|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|OnderHUIDs||Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis|Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis|Completed||Phase 4|50|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 00:02:08.360483|2018-06-01 00:02:08.360483
NCT01077869|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-05-25|2010-02-26|2010-03-01|Estimate|||||||2011-05-25|2011-05-26|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis|A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis|Terminated|||10|Anticipated|University Hospital, Ghent||||poor recruitment rate|f||||f||||||||||2018-06-01 00:02:08.428085|2018-06-01 00:02:08.428085
NCT01077856|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2015-11-05||2017-06-08|2010-02-26|2010-03-01|Estimate|2015-11-05|2015-12-10|Estimate||||2017-06-08|2017-07-11|Actual|May 29, 2007|Actual|2007-05-29|June 2017|2017-06-30|December 2, 2014|Actual|2014-12-02|December 2, 2014|Actual|2014-12-02||Observational|VIP|Participants who took the first survey given before Gardasil licensure|GARDASIL™ Vaccine Impact in Population Study (V501-033)|GARDASIL™ Vaccine Impact in Population Study|Completed|||54516|Actual|Merck Sharp & Dohme Corp.|||2||f||||t||||||Samples With DNA|"~     Tissue, cervical cells~   "|||2018-06-01 00:02:08.580725|2018-06-01 00:02:08.580725
NCT01077843|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2017-06-05|2010-02-26|2010-03-01|Estimate|||||||2017-06-05|2017-06-07|Actual|August 17, 2009|Actual|2009-08-17|June 2017|2017-06-30|July 1, 2015|Actual|2015-07-01|July 1, 2015|Actual|2015-07-01||Observational|||Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)|A Nested Case-control Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in a Cohort of Patients With Ankylosing Spondylitis (AS) in the UK, France and Germany|Completed|||27381|Actual|Merck Sharp & Dohme Corp.|||2||f||||f|f|f||||||||2018-06-01 00:02:09.751483|2018-06-01 00:02:09.751483
NCT01077830|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2013-12-16||2015-10-30|2010-02-26|2010-03-01|Estimate|2013-12-16|2014-02-04|Estimate||||2015-10-30|2015-11-02|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Observational|||An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)|A Multinational, Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS Trial|Completed|||1392|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 00:02:09.838826|2018-06-01 00:02:09.838826
NCT01077817|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2012-11-01||2017-06-08|2010-02-26|2010-03-01|Estimate|2013-03-14|2013-05-01|Estimate||||2017-06-08|2017-07-11|Actual|February 26, 2010|Actual|2010-02-26|June 2017|2017-06-30|February 16, 2012|Actual|2012-02-16|February 16, 2012|Actual|2012-02-16||Observational|||Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)|The Risk of Esophageal Cancer in Relation to the Treatment and Prevention of Osteoporosis in Women|Completed|||684815|Actual|Merck Sharp & Dohme Corp.|||8||f||||f||||||||||2018-06-01 00:02:10.076275|2018-06-01 00:02:10.076275
NCT01077804|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2011-09-29||2017-08-17|2010-02-26|2010-03-01|Estimate|2011-09-29|2011-11-03|Estimate||||2017-08-17|2017-09-15|Actual|June 1, 1995|Actual|1995-06-01|August 2017|2017-08-31|November 1, 2010|Actual|2010-11-01|September 1, 2010|Actual|2010-09-01||Observational|||A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)|Fifteen Year Follow-up to Evaluate Long-term Effectiveness of VARIVAX Among Children and Adolescents|Completed|||7585|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:02:10.306103|2018-06-01 00:02:10.306103
NCT01077791|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2013-10-07|2010-02-26|2010-03-01|Estimate|||||||2013-10-07|2013-10-08|Estimate|July 2008||2008-07-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|REMEDCOG||A Study of a Remediation Program of Social Cognition in Schizophrenia|Cognitive Remediation of the Ability to Infer Intention of Others in Schizophrenic Patients - A Controlled, Randomized Trial (Phase IIb)|Terminated||Phase 2|26|Actual|Assistance Publique - Hôpitaux de Paris||2||no reponse of the of the treatment|f||||f||||||||||2018-06-01 00:02:10.458225|2018-06-01 00:02:10.458225
NCT01077778|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2016-01-22|2010-02-26|2010-03-01|Estimate|||||||2016-01-22|2016-01-25|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|February 2010|Actual|2010-02-28|September 2007|Actual|2007-09-30||Observational|IRM-EP||Magnetic Resonance Diagnosis of Pulmonary Embolism|Magnetic Resonance Diagnosis of Pulmonary Embolism: Prospective Evaluation in 280 Patients, With Comparison to Multi-slice CT Angiography|Terminated|||300|Actual|Assistance Publique - Hôpitaux de Paris||||the number of patients will be included is reach|f||||f||||||||||2018-06-01 00:02:10.520828|2018-06-01 00:02:10.520828
NCT01077765|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2010-02-26|2010-02-26|2010-03-01|Estimate|||||||2010-02-26|2010-03-01|Estimate|November 2005||2005-11-30|January 2010|2010-01-31|September 2009|Actual|2009-09-30|July 2008|Actual|2008-07-31||Interventional|LIPOPHILL||Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy|Open Label, Multicenter, Single Arm Trial of the Safety and Efficacy of Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus-Related Facial Lipoatrophy : THE LIPOPHILL TRIAL|Completed||Phase 3|100|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:02:10.589454|2018-06-01 00:02:10.589454
NCT01077752|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-01-20|2010-02-26|2010-03-01|Estimate|||||||2014-01-20|2014-01-22|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|February 2013|Actual|2013-02-28|June 2012|Actual|2012-06-30||Interventional|CATCH||Local Anesthetic Continuous Preperitoneal Infiltration and Wound Hyperalgesia|Effect of Local Anesthetic Continuous Preperitoneal Wound Infiltration on Incisional Hyperalgesia Following Colorectal Laparoscopic Surgery|Completed||Phase 3|95|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-06-01 00:02:10.837436|2018-06-01 00:02:10.837436
NCT01077739|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2014-07-15||2014-12-08|2010-02-26|2010-03-01|Estimate|2014-07-15|2014-08-07|Estimate||||2014-12-08|2014-12-15|Estimate|July 2009||2009-07-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Intent-to-treat (ITT) population: all enrolled participants who received at least 1 dose of the investigational and non-investigational products.|A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin|A Single-arm Open-label Phase II Study: Treatment Beyond Progression by Adding Bevacizumab to XELOX or FOLFOX Chemotherapy in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI + Bevacizumab Combination|Completed||Phase 2|75|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:02:10.973032|2018-06-01 00:02:10.973032
NCT00872638|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-28|||2015-05-28|2009-03-30|2009-03-31|Estimate|||||||2015-05-28|2015-06-01|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||The Effect of Wound Edge Eversion on Cosmesis|The Effect of Wound Edge Eversion on Cosmesis|Withdrawn||N/A|0|Actual|Stony Brook University||2||lack of participation|f||||f||||||||||2018-06-01 01:09:24.114459|2018-06-01 01:09:24.114459
NCT01077713|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2015-09-09||2015-09-09|2010-02-26|2010-03-01|Estimate|2015-09-09|2015-10-08|Estimate||||2015-09-09|2015-10-08|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All participants randomized set (RND) included all participants who provided informed consent and who were randomized to study medication.|A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer|Randomised Phase II Trial of Bevacizumab (AVASTIN®) in Combination With Gemcitabine or Attenuated Doses of Cisplatin and Gemcitabine as First-line Treatment of Elderly Patients With Advanced Non-squamous Non-small Cell Lung Cancer - EAGLES|Completed||Phase 2|86|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:02:11.801845|2018-06-01 00:02:11.801845
NCT01077700|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26||2012-07-12|2013-03-29|2010-02-26|2010-03-01|Estimate||||2012-07-12|2012-07-23|Estimate|2013-03-29|2013-04-05|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-288 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)|Completed||Phase 2|214|Actual|AbbVie||3|||f||||t||||||||||2018-06-01 00:02:12.242878|2018-06-01 00:02:12.242878
NCT01077687|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-26|2010-02-26|2010-03-01|Estimate|||||||2010-02-26|2010-03-01|Estimate|July 2009||2009-07-31|November 2008|2008-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|S-TOGET||Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan|Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan|Unknown status|Recruiting||1050|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood.~   "|||2018-06-01 00:02:12.34695|2018-06-01 00:02:12.34695
NCT01077674|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2013-10-08|2010-02-26|2010-03-01|Estimate|||||||2013-10-08|2013-10-09|Estimate|December 2009||2009-12-31|October 2013|2013-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Comparison of Two Electroencephalogram (EEG)-Derived Indices With Electroencephalogram Signals|Comparison of Bispectral Index and Entropy With Electroencephalogram During Sevoflurane Anaesthesia|Completed|||65|Actual|Tampere University Hospital|||1||f||||f||||||||||2018-06-01 00:02:12.407854|2018-06-01 00:02:12.407854
NCT01077661|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-05-25|2010-02-25|2010-03-01|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2009||2009-10-31|May 2017|2017-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|Nebilet PMS||Regulatory Nebilet PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Nebilet Administered in Korean Patients According to the Prescribing Information|Completed|||743|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:02:12.4668|2018-06-01 00:02:12.4668
NCT01077648|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-05-22|2010-02-25|2010-03-01|Estimate|||||||2014-05-22|2014-05-26|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Brain Metastasis in Breast Cancer Patients|Occurrence of Brain Metastasis in Breast Cancer Patients Diagnosed at Advanced Stages of the Disease|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:02:12.542119|2018-06-01 00:02:12.542119
NCT01077635|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-05-31|2010-02-25|2010-03-01|Estimate|||||||2017-05-31|2017-06-01|Actual|October 2008||2008-10-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||PENTA Fosamprenavir Study|An Observational Multi-cohort Study on the Use of Fosamprenavir-Ritonavir Among HIV-infected Children and Adolescents in Europe|Completed|||1|Actual|ViiV Healthcare|||1||f||||f||||||||||2018-06-01 00:02:12.60754|2018-06-01 00:02:12.60754
NCT01077622|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2011-12-21||2017-04-28|2010-02-25|2010-03-01|Estimate|2011-12-21|2012-01-27|Estimate||||2017-04-28|2017-05-30|Actual|September 1, 2009||2009-09-01|October 2013|2013-10-31|April 1, 2011|Actual|2011-04-01|April 1, 2011|Actual|2011-04-01||Interventional|||A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia|A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia|Completed||Phase 2|10|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 00:02:12.917459|2018-06-01 00:02:12.917459
NCT01077609|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-07-30|2010-02-25|2010-03-01|Estimate|||||||2013-07-30|2013-07-31|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Flixonase Safety in Patients With Allergic Rhinitis (AR)|Fluticasone Propionate Nasal Spray (Flixonase) Safety in Patients With Allergic Rhinitis Registered in the UK General Practice Research Database|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-06-01 00:02:14.236962|2018-06-01 00:02:14.236962
NCT01077596|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2011-01-21||2017-05-25|2010-02-25|2010-03-01|Estimate|2011-01-21|2011-02-10|Estimate||||2017-05-25|2017-05-30|Actual|June 2008||2008-06-30|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Carcinogenicity Study of Bupropion|Post-marketing Carcinogenicity Study of Bupropion|Completed|||50430|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:02:14.351486|2018-06-01 00:02:14.351486
NCT01077583|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2011-09-27|2010-02-26|2010-03-01|Estimate|||||||2011-09-27|2011-09-28|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Performance Evaluation Study for Clearblue Pregnancy Test|Performance Evaluation Study for Clearblue Pregnancy Test|Completed|||800|Anticipated|SPD Development Company Limited|||||f||||f||||||Samples Without DNA|"~     Daily early morning urine samples~   "|||2018-06-01 00:02:15.573204|2018-06-01 00:02:15.573204
NCT01077570|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-06-25|2010-02-26|2010-03-01|Estimate|||||||2014-06-25|2014-06-26|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|SAFE||An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients|The Clinical Safety and Effectiveness of Repaglinide in Treatment-naive Type 2 Diabetes Subjects in China. A 16-week Multicentre, Prospective, Open Label, Non-interventional Study.|Completed|||2033|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 00:02:15.630339|2018-06-01 00:02:15.630339
NCT01077557|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-05-31|2010-02-25|2010-03-01|Estimate|||||||2017-05-31|2017-06-01|Actual|November 2006||2006-11-30|May 2017|2017-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status|Fractures Over Time Stratified by HIV Infection and Antiretroviral Therapy (ART) Exposure|Completed|||1|Actual|ViiV Healthcare|||3||f||||f||||||||||2018-06-01 00:02:15.693381|2018-06-01 00:02:15.693381
NCT01077427|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-11-14|2010-02-26|2010-03-01|Estimate|||||||2017-11-14|2017-11-17|Actual|March 2012||2012-03-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|HEAT||Hyperthermia European Adjuvant Trial|A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)|Recruiting||Phase 3|336|Anticipated|Klinikum der Universitaet Muenchen, Grosshadern||2|||f||||t||||||||||2018-06-01 00:02:17.322983|2018-06-01 00:02:17.322983
NCT01077544|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2015-12-18||2015-12-18|2010-02-26|2010-03-01|Estimate|2015-12-18|2016-01-27|Estimate||||2015-12-18|2016-01-27|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Full analysis set (FAS): consists of all patients who passed the screening and are enrolled into the study. Patients may or may not have taken study drug.|A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)|A Multi-center, Open-label, Pharmacokinetic Study of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Chronic Phase (CP) Ph+ CML, With CP or Accelerated Phase (AP) Ph+ CML Resistant/Intolerant to Imatinib and/or Dasatinib, or With Refractory/Relapsed Ph+ ALL|Completed||Phase 1|15|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:02:15.785285|2018-06-01 00:02:15.785285
NCT01077531|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-06-07|2010-02-25|2010-03-01|Estimate|||||||2017-06-07|2017-06-08|Actual|April 28, 2010|Actual|2010-04-28|June 2017|2017-06-30|March 19, 2013|Actual|2013-03-19|March 19, 2013|Actual|2013-03-19||Interventional|||Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis|A Randomized, Placebo-controlled, Single-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Otelixizumab in Rheumatoid Arthritis Subjects|Terminated||Phase 1|12|Actual|GlaxoSmithKline||2||"The risk-benefit ratio for patients has changed since we initiated the study, and that the~   study in its current form cannot be justified"|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:02:16.405035|2018-06-01 00:02:16.405035
NCT01077518|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2018-01-12|2010-02-25|2010-03-01|Estimate|||||||2018-01-12|2018-01-17|Actual|August 26, 2010|Actual|2010-08-26|January 2018|2018-01-31|December 20, 2024|Anticipated|2024-12-20|January 3, 2018|Actual|2018-01-03||Interventional|COMPLEMENT A+B||Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen|A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment|Active, not recruiting||Phase 3|346|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 00:02:16.533847|2018-06-01 00:02:16.533847
NCT01077505|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-06-13|2010-02-25|2010-03-01|Estimate|||||||2017-06-13|2017-06-14|Actual|March 15, 2010|Actual|2010-03-15|June 2017|2017-06-30|November 24, 2010|Actual|2010-11-24|November 24, 2010|Actual|2010-11-24||Interventional|||An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .|An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK716155 in Healthy Adult Female Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:02:16.815954|2018-06-01 00:02:16.815954
NCT01077492|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2012-11-01|2010-02-26|2010-03-01|Estimate|||||||2012-11-01|2012-11-02|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Virtual Bronchoscopy Transbronchial Needle Aspiration(TBNA): a Proof of Concept Study|CT-PET Virtual Bronchoscopy Guided Transbronchial Needle Aspiration for Mediastinal Lymph Node Staging in Suspected Lung Cancer|Terminated|||80|Actual|VU University Medical Center|||1||f||||f||||||||||2018-06-01 00:02:16.914132|2018-06-01 00:02:16.914132
NCT01077479|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-05-13|2010-02-26|2010-03-01|Estimate|||||||2014-05-13|2014-05-15|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MVENT||Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome|Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome|Completed||Phase 2|28|Actual|Western Sydney Local Health District||1|||f||||t||||||||||2018-06-01 00:02:16.985695|2018-06-01 00:02:16.985695
NCT01077466|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2012-02-15|2010-02-26|2010-03-01|Estimate|||||||2012-02-15|2012-02-17|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|NAPMS||Natalizumab Treatment of Progressive Multiple Sclerosis|Natalizumab Treatment of Progressive Multiple Sclerosis|Completed||Phase 2|24|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-06-01 00:02:17.06187|2018-06-01 00:02:17.06187
NCT01077453|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-10-17|2010-02-26|2010-03-01|Estimate|||||||2014-10-17|2014-10-20|Estimate|March 2010||2010-03-31|October 2014|2014-10-31||||June 2014|Actual|2014-06-30||Interventional|||Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer|Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer|Completed||Phase 1|112|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 00:02:17.152201|2018-06-01 00:02:17.152201
NCT01077440|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2014-12-08|2010-02-26|2010-03-01|Estimate|||||||2014-12-08|2014-12-10|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant|Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants|Terminated|||24|Actual|Vanderbilt University|||1|PI leaving institution|f||||f||||||Samples With DNA|"~     Your sample will only be used for research at Vanderbilt University and will not be sold.~     Health insurance companies and group health plans may not request your genetic information~     that comes from this research. As part of this study, we ask that the data from the semen~     analysis can be put into a databank at Vanderbilt and kept with data from other people in the~     study. Your data will be given a special code and will not identify you directly. We ask you~     to select yes or no to allow/disallow us to:~        -  Use your semen sample for gene research.~        -  Store/share your semen sample for future gene research in hematopoietic stem cell~          transplantation.~        -  Store/share your semen sample for future gene research for other health problems (such~          as cancer, heart disease, etc).~   "|||2018-06-01 00:02:17.236271|2018-06-01 00:02:17.236271
NCT01076062|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-04-22|2010-02-24|2010-02-25|Estimate|||||||2013-04-22|2013-04-24|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Elective Induction of Nulliparous Labor|Elective Induction of Nulliparous Labor: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|200|Anticipated|Madigan Army Medical Center||2|||f||||t||||||||||2018-06-01 00:02:58.85297|2018-06-01 00:02:58.85297
NCT01077414|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2018-05-24|2010-02-26|2010-03-01|Estimate|||||||2018-05-24|2018-05-25|Actual|September 4, 2009||2009-09-04|November 2, 2016|2016-11-02|November 2, 2016||2016-11-02|||||Observational|||Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness|Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness|Completed|||37|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:02:17.404325|2018-06-01 00:02:17.404325
NCT01077401|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|2016-08-30||2017-03-20|2010-02-26|2010-03-01|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|February 2010||2010-02-28|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|READ 3||Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study|Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study|Completed||Phase 2|152|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:02:17.45746|2018-06-01 00:02:17.45746
NCT01077388|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-10-11|2010-02-25|2010-03-01|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2010||2010-05-31|October 2017|2017-10-31|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|e-Compare||e-Care for Heart Wellness|Collaborative Behavioral e-Care to Decrease Cardiovascular Risk (e-Compare)|Completed||Phase 3|100|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 00:02:17.87241|2018-06-01 00:02:17.87241
NCT01077375|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2011-12-21||2011-12-21|2010-02-25|2010-03-01|Estimate|2011-12-21|2012-01-26|Estimate||||2011-12-21|2012-01-26|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Switch Study to Evaluate the Safety, Tolerability and Efficacy of Milnacipran in Patients With an Inadequate Response to Duloxetine for the Treatment of Fibromyalgia|Completed||Phase 4|107|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:02:17.956546|2018-06-01 00:02:17.956546
NCT01077362|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2013-10-11|2013-03-14|2014-01-22|2010-02-26|2010-03-01|Estimate|2014-01-22|2014-02-27|Estimate|2013-03-14|2013-03-21|Estimate|2014-01-22|2014-02-27|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|March 2012|Actual|2012-03-31||Interventional|||A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s)|Completed||Phase 3|312|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-06-01 00:02:18.283483|2018-06-01 00:02:18.283483
NCT01077349|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2017-02-08|2010-02-26|2010-03-01|Estimate|||||||2017-02-08|2017-02-09|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|HEROICS||High Volume Veno-venous Hemofiltration Versus Standard Care for Post-cardiac Surgery Shock|Early Continuous High Volume Veno-venous Hemofiltration vs. Standard Care for Post-cardiac Surgery Shock Requiring High Doses Catecholamines. The HEROICS Study: HEmofiltration to Rescue Severe shOck followIng Cardiac Surgery|Completed||N/A|226|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:02:19.983266|2018-06-01 00:02:19.983266
NCT01077336|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-07-15|2010-02-26|2010-03-01|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility|Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility|Completed|||450|Actual|University of Houston|||1||f||||f||||||||||2018-06-01 00:02:20.060523|2018-06-01 00:02:20.060523
NCT01077323|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2010-08-12||2015-03-25|2010-02-26|2010-03-01|Estimate|2010-09-10|2010-10-06|Estimate||||2015-03-25|2015-04-15|Estimate|September 2004||2004-09-30|March 2015|2015-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents|A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Byetta (Exenatide) and Other Antidiabetic Agents|Completed|||363766|Actual|AstraZeneca|||3||f||||f||||||||||2018-06-01 00:02:20.12784|2018-06-01 00:02:20.12784
NCT01077310|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2016-08-04||2017-04-25|2010-02-25|2010-03-01|Estimate|2016-10-04|2016-11-25|Estimate||||2017-04-25|2017-05-30|Actual|August 2010||2010-08-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|INSPIRE||Alcohol Pharmacotherapy for HIV+ Prisoners|Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking|Completed||N/A|100|Actual|Yale University||2|||f||||f||||||||No||2018-06-01 00:02:21.339254|2018-06-01 00:02:21.339254
NCT01077297|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25||2012-07-13|2012-07-13|2010-02-26|2010-03-01|Estimate||||2012-07-13|2012-07-23|Estimate|2012-07-13|2012-07-23|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Interventional|||Tezosentan in Pulmonary Arterial Hypertension|Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines|Terminated||Phase 2|3|Actual|Actelion||1||Due to slow recruitment, the study was prematurely discontinued|f||||f||||||||||2018-06-01 00:02:21.704177|2018-06-01 00:02:21.704177
NCT01077284|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2012-10-15||2013-01-14|2010-02-26|2010-03-01|Estimate|2013-01-14|2013-02-15|Estimate||||2013-01-14|2013-02-15|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones|A Multicenter, Randomized, Double-Blind, Placebo and Allopurinol Controlled, Phase 2 Study to Evaluate Febuxostat in the Medical Management of Subjects With Hyperuricosuria and Calcium Oxalate Stones|Completed||Phase 2|99|Actual|Takeda||3|||f||||t||||||||||2018-06-01 00:02:21.81644|2018-06-01 00:02:21.81644
NCT01077271|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2012-05-17||2012-08-20|2010-02-25|2010-03-01|Estimate|2012-08-20|2012-08-21|Estimate||||2012-08-20|2012-08-21|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA|PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA Over 3 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria|Completed|||124|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:02:22.842856|2018-06-01 00:02:22.842856
NCT01077258|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2014-02-28||2014-04-09|2010-02-25|2010-03-01|Estimate|2014-02-28|2014-04-08|Estimate||||2014-04-09|2014-04-25|Estimate|April 2004||2004-04-30|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice|Effectiveness and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice|Completed|||4208|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:02:23.900281|2018-06-01 00:02:23.900281
NCT01077245|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-11-08|2010-02-25|2010-03-01|Estimate|||||||2013-11-08|2013-11-11|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections|A Phase 2 Study to Evaluate the Safety and Potential Efficacy of Clostridium Butyricum MIYAIRI 588 Strain (MIYA-BM Fine Granules) for the Prevention of Recurrent Clostridium Difficile Infections|Withdrawn||Phase 2|0|Actual|Osel, Inc.||2||Lack of enrollment|f||||t||||||||||2018-06-01 00:02:25.521956|2018-06-01 00:02:25.521956
NCT01077232|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2018-05-04|2010-02-25|2010-03-01|Estimate|||||||2018-05-04|2018-05-10|Estimate|January 4, 2008|Actual|2008-01-04|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Observational|LOTOS||Documentation of Humira in Psoriasis Patients in Routine Clinical Practice|Long Term Documentation of the Safety and Efficacy as Well as the Effects on Work Productivity in Patients With Moderate to Severe Plaque Psoriasis Treated With HUMIRA (Adalimumab) in Routine Clinical Practice (LOTOS)|Recruiting|||3000|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-06-01 00:02:25.742182|2018-06-01 00:02:25.742182
NCT01077219|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-26|2010-02-26|2010-03-01|Estimate|||||||2010-02-26|2010-03-01|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Study on Energy Cost Prediction of Cycle Ergometer||Completed|||40|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 00:02:27.245159|2018-06-01 00:02:27.245159
NCT01077206|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-26|||2015-02-02|2010-02-26|2010-03-01|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|HDS-SAH||High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage|High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage: Is it Better?|Completed||Phase 2/Phase 3|255|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 00:02:27.297946|2018-06-01 00:02:27.297946
NCT01077193|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2013-07-09||2014-01-08|2010-02-26|2010-03-01|Estimate|2013-07-09|2013-09-13|Estimate||||2014-01-08|2014-02-07|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Intent-to-Treat Population: All subjects who underwent the gastric plication surgery.|Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication|Surgical Intervention in Bariatric Patients: Excess Weight Loss in the Morbidly Obese Following Gastric Plication|Terminated||N/A|44|Actual|Ethicon Endo-Surgery||1||"Study was terminated due to commercial considerations and potential patient attrition at 3~   years. There were no patient safety or procedure efficacy reasons."|f||||f||||||||||2018-06-01 00:02:27.415576|2018-06-01 00:02:27.415576
NCT01077180|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2016-10-18|2010-02-25|2010-02-26|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|October 2010|Actual|2010-10-31|December 2007|Actual|2007-12-31||Interventional|||Rheos Feasibility Trial|Rheos Feasibility Trial- A Study of Baroreflex Hypertension TherapyTM in Refractory Hypertension|Completed||Phase 2|16|Actual|CVRx, Inc.||2|||f||||t||||||||||2018-06-01 00:02:27.778807|2018-06-01 00:02:27.778807
NCT01077167|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-05-26|2010-02-25|2010-02-26|Estimate|||||||2011-05-26|2011-05-30|Estimate|July 2010||2010-07-31|May 2011|2011-05-31|May 2011|Anticipated|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients|An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart Failure|Withdrawn||Phase 2|0|Actual|Amgen||1||Study cancelled due to sponsor's decision to redesign the study|f||||||||||||||2018-06-01 00:02:27.853073|2018-06-01 00:02:27.853073
NCT01077154|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2018-04-20|2010-02-25|2010-02-26|Estimate|||||||2018-04-20|2018-04-24|Actual|June 2, 2010|Actual|2010-06-02|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|August 31, 2017|Actual|2017-08-31||Interventional|||Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)|Terminated||Phase 3|4509|Actual|Amgen||2||Terminated: Amgen decision following Primary Analysis. Not due to safety reason|f||||t||||||||||2018-06-01 00:02:28.054989|2018-06-01 00:02:28.054989
NCT01077141|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-12-22|2010-02-25|2010-02-26|Estimate|||||||2010-12-22|2010-12-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:02:28.980055|2018-06-01 00:02:28.980055
NCT01077128|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2013-09-13||2014-02-19|2010-02-25|2010-02-26|Estimate|2014-02-19|2014-02-21|Estimate||||2014-02-19|2014-02-21|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab|[E S] A Greek, Post-marketing, Observational Study of the quAlity of Life in Patients With Psoriasis Treated With Adalimumab - GOAL Study|Completed|||500|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:02:29.067871|2018-06-01 00:02:29.067871
NCT01077115|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|June 2003||2003-06-30|February 2010|2010-02-28|September 2006|Actual|2006-09-30|June 2004|Actual|2004-06-30||Interventional|ESTOLC||Extent of Surgical Trauma in Open and Laparoscopic Cholecystectomy|Extent of Surgical Trauma in Open and Laparoscopic Cholecystectomy|Completed||N/A|120|Actual|Ministry of Health, Montenegro||2|||f||||t||||||||||2018-06-01 00:02:29.684495|2018-06-01 00:02:29.684495
NCT01077102|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-12-04|2010-02-25|2010-02-26|Estimate|||||||2015-12-04|2015-12-07|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Eccentric Exercise Training as Novel Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD)|Eccentric Training as Novel Rehabilitation for COPD|Completed||N/A|24|Actual|McGill University Health Center||2|||f||||t||||||||||2018-06-01 00:02:29.76153|2018-06-01 00:02:29.76153
NCT01077089|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-02-22|2010-02-25|2010-02-26|Estimate|||||||2013-02-22|2013-02-25|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Effects of Transport on Patients With Traumatic Brain Injury|Effects of Transport on Patients With Traumatic Brain Injury|Completed|||14|Actual|University of Cincinnati|||1||f||||f||||||||||2018-06-01 00:02:29.840875|2018-06-01 00:02:29.840875
NCT01077076|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2010-03-11||2015-02-20|2010-02-25|2010-02-26|Estimate|2010-03-11|2010-04-02|Estimate||||2015-02-20|2015-03-11|Estimate|December 2008||2008-12-31|February 2015|2015-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole (P07812) (COMPLETED)|Randomized, Placebo-Controlled, Crossover Pharmacodynamic Study Comparing the Effects of Two Different Forms of Omeprazole|Completed||Phase 3|30|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:02:29.917583|2018-06-01 00:02:29.917583
NCT01070511|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2013-08-19|2010-02-17|2010-02-18|Estimate|||||||2013-08-19|2013-08-20|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Tadalafil in Becker Muscular Dystrophy|Functional Muscle Ischemia and PDE5A Inhibition in Becker Muscular Dystrophy|Completed||Phase 4|48|Anticipated|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-06-01 00:04:58.735843|2018-06-01 00:04:58.735843
NCT01077063|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2014-09-15||2015-10-06|2010-02-25|2010-02-26|Estimate|2014-09-15|2014-09-22|Estimate||||2015-10-06|2015-10-29|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||subjects with malignant ascites|An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites|An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites|Terminated||N/A|7|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The study was closed by investigator due to low enrollment. Subject JH006 S-B did have abdominal pain, post Pleurx placement, so it was removed and she was taken out of the study.|2||Study was closed by PI because of low enrollment.|f||||t||||||||||2018-06-01 00:02:30.274036|2018-06-01 00:02:30.274036
NCT01077050|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2013-06-12||2013-11-08|2010-02-25|2010-02-26|Estimate|2013-11-08|2013-12-30|Estimate||||2013-11-08|2013-12-30|Estimate|April 2010||2010-04-30|November 2013|2013-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional||All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.|SciBase International Melanoma Pivotal Study|SciBase International Melanoma Pivotal Study|Completed||N/A|1951|Actual|SciBase AB||1|||f||||||||||||||2018-06-01 00:02:30.811595|2018-06-01 00:02:30.811595
NCT01077037|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2015-05-05|2010-02-25|2010-02-26|Estimate|||||||2015-05-05|2015-05-06|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Impact of a Decision Aid on Patient Decision Making in Emergency Department Chest Pain Patients|Impact of a Decision Aid on Patient Participation in Decision Making and Resource Use in Low Risk Chest Pain Patients: A Randomized Trial|Completed||N/A|204|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:02:31.018437|2018-06-01 00:02:31.018437
NCT01077024|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2014-04-24||2014-07-31|2010-02-25|2010-02-26|Estimate|2014-07-31|2014-08-20|Estimate||||2014-07-31|2014-08-20|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|S-CAST|The baseline analysis was performed on the Intent-to-Treat population, which was the population of randomized participants|Smoking-Cessation and Stimulant Treatment (S-CAST)|Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes|Completed||Phase 3|538|Actual|University of Cincinnati|Stimulant use was relatively low throughout the study; this may have limited our ability to make inferences about the treatment.|2|||f||||t||||||||||2018-06-01 00:02:31.229907|2018-06-01 00:02:31.229907
NCT01077011|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2016-11-18|2010-02-25|2010-02-26|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2010||2010-01-31|January 2012|2012-01-31||||January 2010|Actual|2010-01-31||Interventional|||Acute Comfort and Blur Profile of a Lubricant Eye Drop Versus a Marketed Lubricant Eye Gel||Completed||N/A|25|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:02:32.519012|2018-06-01 00:02:32.519012
NCT01076998|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-01-31|2010-02-25|2010-02-26|Estimate|||||||2012-01-31|2012-02-02|Estimate|January 2010||2010-01-31|January 2012|2012-01-31||||January 2010|Actual|2010-01-31||Interventional|||Acute Comfort and Blur Profile of a Lubricant Eye Drop Versus a Marketed Eye Ointment||Completed||N/A|24|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:02:32.592709|2018-06-01 00:02:32.592709
NCT01076985|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2011-12-09||2011-12-09|2010-02-25|2010-02-26|Estimate|2011-12-09|2012-01-18|Estimate||||2011-12-09|2012-01-18|Estimate|December 2000||2000-12-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Special Investigation of Kaletra in Pregnant Women|Special Investigation of Kaletra in Pregnant Women|Completed|||24|Actual|Abbott|||1||f||||||||||||||2018-06-01 00:02:32.686373|2018-06-01 00:02:32.686373
NCT01076972|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2011-12-09||2012-01-31|2010-02-25|2010-02-26|Estimate|2012-01-31|2012-03-01|Estimate||||2012-01-31|2012-03-01|Estimate|December 2000||2000-12-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Drug Use Investigation of Kaletra|Drug Use Investigation of Kaletra|Completed|||1184|Actual|Abbott|||1||f||||||||||||||2018-06-01 00:02:33.01908|2018-06-01 00:02:33.01908
NCT01076959|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2012-06-29||2012-08-27|2010-02-25|2010-02-26|Estimate|2012-06-29|2012-08-07|Estimate||||2012-08-27|2012-08-28|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis|Humira 40 mg/0.8 mL for Subcutaneous Injection - Drug Use Investigation (All Patient Investigation) for Rheumatoid Arthritis|Completed|||7972|Actual|Abbott|||1||f||||||||||||||2018-06-01 00:02:33.746615|2018-06-01 00:02:33.746615
NCT01076946|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|March 2010||2010-03-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Observational|||Insights in the Pathophysiology of Transient Left Ventricular Ballooning Syndrome (TLVBS)|Insights in the Pathophysiology of Transient Left Ventricular Ballooning Syndrome (TLVBS)|Unknown status|Not yet recruiting||30|Anticipated|University Hospital, Gasthuisberg|||1||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 00:02:38.880163|2018-06-01 00:02:38.880163
NCT01076933|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2017-05-10|2010-02-25|2010-02-26|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2010||2010-01-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|SiMaT-B||Transcranial Magnetic Stimulation for Borderline Personality Disorder|Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Borderline Personality Disorder (BPD)|Completed||N/A|13|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 00:02:38.972954|2018-06-01 00:02:38.972954
NCT01076920|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2014-09-18|2010-02-25|2010-02-26|Estimate|||||||2014-09-18|2014-09-19|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|MESAMI||Mesenchymal Stem Cells and Myocardial Ischemia|Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy|Completed||Phase 1/Phase 2|10|Actual|University Hospital, Toulouse||1|||f||||t||||||||||2018-06-01 00:02:39.41797|2018-06-01 00:02:39.41797
NCT01076907|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-12-14|2010-02-25|2010-02-26|Estimate|||||||2015-12-14|2015-12-15|Estimate|December 2007||2007-12-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Techniques to Enhance Patient Comfort in Sedation-risk Free Colonoscopy|Can Simple and Inexpensive Techniques Enhance Patient Comfort in Sedation-risk Free Screening and Surveillance Colonoscopy?|Terminated||Phase 1/Phase 2|85|Actual|VA Greater Los Angeles Healthcare System||2||Necessary equipment to perform the study arms was removed by the medical center administration.|f||||f||||||||||2018-06-01 00:02:39.518995|2018-06-01 00:02:39.518995
NCT01076894|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|February 2007||2007-02-28|February 2010|2010-02-28|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Thoracotomy: Intercostal Nerve Block Versus Epidural Anesthesia|Analgesia and Pulmonary Function After Thoracic Surgery: is an Intercostal Nerve Block Plus Intravenous Morphine as Effective as Epidural Anesthesia? A Prospective Randomized Clinical Study.|Completed||N/A|83|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 00:02:39.72023|2018-06-01 00:02:39.72023
NCT01076881|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|December 2008||2008-12-31|February 2010|2010-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Combined Resistance and Aerobic Exercise is Better Than Resistance Training Alone to Improve Functional Performance of Hemodialysis Patients - Results of a Randomized Trial|Combined Resistance and Aerobic Exercise is Better Than Resistance Training Alone to Improve Functional Performance of Hemodialysis Patients - Results of a Randomized Trial|Completed||N/A|26|Actual|Universidade Católica de Pelotas||2|||f||||f||||||||||2018-06-01 00:02:39.80442|2018-06-01 00:02:39.80442
NCT01076868|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-08-28|2010-02-25|2010-02-26|Estimate|||||||2013-08-28|2013-08-29|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|VHC||Incidence of Vivax Along the Thai Burma Border|Determining the Incidence of New Plasmodium Vivax Infections After Radical Treatment Following Vivax Malaria Along the Thai Burma Border|Unknown status|Recruiting|N/A|200|Anticipated|University of Oxford||1|||f||||f||||||||||2018-06-01 00:02:40.0683|2018-06-01 00:02:40.0683
NCT01076855|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-06-02|2010-02-25|2010-02-26|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|BOCS||Guidance for Elderly With Cognitive Disorders|Guidance Programme for Elderly With Cognitive Disorders|Unknown status|Recruiting||100|Anticipated|University Hospital, Ghent|||1||f||||f||||||||||2018-06-01 00:02:40.197413|2018-06-01 00:02:40.197413
NCT01076842|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-06-24|2010-02-25|2010-02-26|Estimate|||||||2011-06-24|2011-06-27|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment|The Effect of Detemir Compared to Exenatide and/or the Combination of Detemir and Exenatide on Glycemic Control and Weight in Patients With Type 2 Diabetes Mellitus Who Have Failed Oral Hypoglycemic Agents|Completed||Phase 4|75|Anticipated|Walter Reed Army Medical Center||3|||f||||t||||||||||2018-06-01 00:02:40.328844|2018-06-01 00:02:40.328844
NCT01076829|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-06-09|2010-02-25|2010-02-26|Estimate|||||||2014-06-09|2014-06-10|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes|Inhibition of Absorption of Cytoxic Lipid Peroxidation Products and Abnormalities of Postprandial Endothelial Function by Spice Polyphenols Fed Together With High Fat Meat Patty in Men With Type 2 Diabetes Mellitus or Impaired Glucose Tolerance|Completed||N/A|10|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:02:40.596663|2018-06-01 00:02:40.596663
NCT01076816|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-10-03|2010-02-25|2010-02-26|Estimate|||||||2011-10-03|2011-10-04|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure||Terminated||Phase 3|1|Actual|University Hospital, Ghent||||Poor inclusion rate.|f||||t||||||||||2018-06-01 00:02:40.69542|2018-06-01 00:02:40.69542
NCT01076803|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-12-04|2010-02-25|2010-02-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients|Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients|Completed||Phase 2|40|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 00:02:40.790744|2018-06-01 00:02:40.790744
NCT01076790|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-10-08|2010-02-25|2010-02-26|Estimate|||||||2013-10-08|2013-10-09|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Dexmedetomidine-propofol-remifentanil Anaesthesia and Reactivity to Noxious Stimuli|The Effect of Dexmedetomidine on Reactivity to Noxious Stimuli During Propofol-remifentanil Anaesthesia and Surgery|Completed||Phase 4|44|Actual|Tampere University Hospital||1|||f||||f||||||||||2018-06-01 00:02:40.925009|2018-06-01 00:02:40.925009
NCT01076777|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|May 2007||2007-05-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial|Effects of Physical Exercise on Anxiety and Co-morbid Emotional Disturbances: A Clinical Trail in a Day Care Unit|Completed||Phase 2|36|Actual|University of Bergen||2|||f||||f||||||||||2018-06-01 00:02:41.076434|2018-06-01 00:02:41.076434
NCT01076764|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25||2016-04-04|2016-04-04|2010-02-25|2010-02-26|Estimate||||2016-04-04|2016-05-04|Estimate|2016-04-04|2016-05-04|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TAO||Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy|Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban With Unfractionated Heparin + Eptifibatide, in Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy|Completed||Phase 3|13220|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 00:02:41.322627|2018-06-01 00:02:41.322627
NCT01076751|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-02-11|2010-02-25|2010-02-26|Estimate|||||||2011-02-11|2011-02-14|Estimate|February 2010||2010-02-28|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|PORTREAT||Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients|Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen|Terminated|||82|Actual|Sanofi|||1|delay in recruitment|f||||||||||||||2018-06-01 00:02:42.582541|2018-06-01 00:02:42.582541
NCT01076738|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-09-10|2010-02-25|2010-02-26|Estimate|||||||2010-09-10|2010-09-13|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Screening DIVA - Diffuse Vascular Disease|The Value of Routine Screening for Diffuse Vascular Disease in the Canadian Post-Acute Coronary Syndrome/Ischemic Stroke/Transient Ischemic Attack General Practice Population With Previously Undocumented Peripheral Arterial Disease|Completed|||2233|Anticipated|Sanofi|||1||f||||||||||||||2018-06-01 00:02:42.718661|2018-06-01 00:02:42.718661
NCT01076725|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|PLMA||Rotation Technique for the Insertion of the ProSeal Laryngeal Mask Airway in Pediatric Patients|Insertion of the ProSeal Laryngeal Mask Airway is More Successful With the 90 Degree Rotation Technique in Pediatric Patients: a Randomized Controlled Trial|Completed||N/A|63|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:02:42.901849|2018-06-01 00:02:42.901849
NCT01076712|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-03-09|2010-02-25|2010-02-26|Estimate|||||||2010-03-09|2010-03-10|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Effectiveness of Physiotherapy Interventions for Patients With Parkinson's Disease|The Effectiveness of Physiotherapy Interventions in Patients With Parkinson's Disease, a Randomized Controlled Trial|Unknown status|Recruiting|N/A|112|Anticipated|Queen Elizabeth Hospital, Hong Kong||2|||f||||f||||||||||2018-06-01 00:02:43.035804|2018-06-01 00:02:43.035804
NCT01076699|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-07-16|2010-02-25|2010-02-26|Estimate|||||||2010-07-16|2010-07-19|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)|A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Four-Arm Trial to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo for the Treatment of Abdominal Pain in Patients With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)|Suspended||Phase 2|192|Anticipated|Revogenex, Inc.||4||recruiting/enrolling participants has halted prematurely but potentially will resume Oct|f||||f||||||||||2018-06-01 00:02:43.109187|2018-06-01 00:02:43.109187
NCT01076686|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2011-11-06||2012-04-15|2010-02-25|2010-02-26|Estimate|2012-04-15|2012-05-14|Estimate||||2012-04-15|2012-05-14|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Observational Study to Assess Long-Term Follow-Up of Breast Augmentation Subjects|An Observational Study to Assess the Long-Term Follow-Up of Subjects Who Had Participated in SKY0402 Breast Augmentation Studies|Completed|||94|Actual|Pacira Pharmaceuticals, Inc|||4||f||||f||||||||||2018-06-01 00:02:43.219424|2018-06-01 00:02:43.219424
NCT01076673|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2015-03-12|2010-02-25|2010-02-26|Estimate|||||||2015-03-12|2015-03-17|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Autologous Peripheral Blood Stem Cell Treatment on Articular Cartilage Regeneration|Articular Cartilage Regeneration With Autologous Peripheral Blood Stem Cells Versus Hyaluronic Acid: A Randomized, Controlled Trial|Completed||Phase 2|50|Actual|Kuala Lumpur Sports Medicine Centre||2|||f||||f||||||||||2018-06-01 00:02:43.581346|2018-06-01 00:02:43.581346
NCT01076660|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2017-12-06|2010-02-25|2010-02-26|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2003||2003-10-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Left Ventricular Structural Predictors of Sudden Cardiac Death|Left Ventricular Structural Predictors of Sudden Cardiac Death [Substudy of: Functional Energetics and Imaging for Phenotypic Characterization of Patients at Risk for Sudden Cardiac Death, See Also NCT000181233]|Recruiting|||400|Anticipated|Johns Hopkins University|||||f||||f||||||||No||2018-06-01 00:02:43.672015|2018-06-01 00:02:43.672015
NCT01076647|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2015-10-13|2011-02-23|2017-01-20|2010-02-25|2010-02-26|Estimate|2015-10-13|2015-11-10|Estimate|2011-02-23|2011-03-01|Estimate|2017-01-20|2017-03-06|Actual|March 2010||2010-03-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|BEGIN™||Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes|A 26-week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA 200 U/ml Three Times Weekly Injected in the Evening and Insulin Glargine Once Daily in a Population of Insulin naïve Subjects With Type 2 Diabetes Mellitus Currently Treated With OADs Qualifying for Intensified Treatment (BEGIN™: EASY™)|Completed||Phase 3|467|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:02:43.794313|2018-06-01 00:02:43.794313
NCT01076634|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2017-01-20|2010-02-25|2010-02-26|Estimate|||||||2017-01-20|2017-01-23|Estimate|February 2010||2010-02-28|January 2017|2017-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1250 in Subjects With Type 1 Diabetes|Completed||Phase 1|33|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:02:45.14353|2018-06-01 00:02:45.14353
NCT01076621|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-10-24|2010-02-25|2010-02-26|Estimate|||||||2014-10-24|2014-10-27|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months|A 12 Month Non-interventional (Observational), International, Multi-centre, Prospective Study to Evaluate the Bleeding Pattern of Ultra-low Dose Continuous Combined Hormone Replacement Therapy Containing 0.5 mg Estradiol and 0.1 mg Norethisterone Acetate (Eviana®)|Completed|||176|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 00:02:45.393928|2018-06-01 00:02:45.393928
NCT01076608|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|September 2003||2003-09-30|February 2010|2010-02-28|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|DETECT||DETECT-Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment|Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of Treatment (DETECT)|Completed|||55518|Actual|Technische Universität Dresden|||||f||||t||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-06-01 00:02:45.531286|2018-06-01 00:02:45.531286
NCT01076595|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-07-02|2010-02-25|2010-02-26|Estimate|||||||2015-07-02|2015-07-03|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|November 2013|Actual|2013-11-30||Observational|SEPLUS||Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period|Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program|Completed|||73|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 00:02:45.624169|2018-06-01 00:02:45.624169
NCT01076582|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-10-27|2010-02-25|2010-02-26|Estimate|||||||2014-10-27|2014-10-28|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparative Trial in Hormone Withdrawal Associated Symptoms|A Multi-centre, Randomized, Double-blind, Active Control, Parallel-group, 2-arm Study to Investigate the Effect of Ethinylestradiol / Drospirenone (0.02 mg/3 mg) Oral Contraception in a 24/4 Regimen Compared to Ethinylestradiol / Desogestrel (0.02 mg/0.15 mg) Oral Contraception in a 21/7 Regimen on Hormone Withdrawal Associated Symptoms in Otherwise Healthy Women After 4 Cycles of Treatment|Completed||Phase 3|592|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:02:45.74321|2018-06-01 00:02:45.74321
NCT01076569|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2016-05-17|2010-02-25|2010-02-26|Estimate|||||||2016-05-17|2016-05-19|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia|Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis|Completed|||250|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     bone marrow~   "|||2018-06-01 00:02:45.913167|2018-06-01 00:02:45.913167
NCT01076556|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2015-11-10|2010-02-25|2010-02-26|Estimate|||||||2015-11-10|2015-11-11|Estimate|April 2010||2010-04-30|November 2015|2015-11-30||||July 2010|Actual|2010-07-31||Interventional|||Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I Feasibility Trial of Cyclophosphamide, Alvocidib (Flavopiridol) and Rituximab (CAR) in Patients With High Risk B-cell CLL/SLL|Terminated||Phase 1|9|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:02:45.998422|2018-06-01 00:02:45.998422
NCT01076543|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2018-04-10|2010-02-25|2010-02-26|Estimate|||||||2018-04-10|2018-04-11|Actual|April 15, 2010|Actual|2010-04-15|January 2018|2018-01-31||||December 31, 2017|Actual|2017-12-31||Interventional|||Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma|Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas|Active, not recruiting||Phase 1/Phase 2|110|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 00:02:46.237992|2018-06-01 00:02:46.237992
NCT01076530|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2013-05-01|2010-02-25|2010-02-26|Estimate|||||||2013-05-01|2013-05-03|Estimate|February 2010||2010-02-28|May 2013|2013-05-31||||October 2012|Actual|2012-10-31||Interventional|||Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors|A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors|Completed||Phase 1|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:02:46.999659|2018-06-01 00:02:46.999659
NCT01076517|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2018-04-16|2010-02-24|2010-02-26|Estimate|||||||2018-04-16|2018-04-18|Actual||||April 2018|2018-04-30||||||||Expanded Access|||A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma|A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma|Available|||||Stanford University|||||f||||||||||||||2018-06-01 00:02:47.173151|2018-06-01 00:02:47.173151
NCT01076504|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2015-04-30||2016-04-01|2010-02-24|2010-02-26|Estimate|2015-11-06|2015-12-10|Estimate||||2016-04-01|2016-05-05|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2012|Actual|2012-03-31||Interventional||81 patients were enrolled but 1 patient was hospitalized prior to receiving any protocol treatment and was never treated. 80 patients included in the analysis|A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer|A Phase II Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|81|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 00:02:47.282609|2018-06-01 00:02:47.282609
NCT01076491|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2010-02-24|2010-02-24|2010-02-26|Estimate|||||||2010-02-24|2010-02-26|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||High Dose Inhaled Mannitol Study|A Pilot Study to Investigate the Feasibility and Tolerability of Inhaling a High Dose of Dry Powder Mannitol (IDPM) Per Breath Administered Via a Dry Powder Inhaler Loaded With a Single Capsule in Subjects With Bronchiectasis|Completed||Phase 1/Phase 2|10|Anticipated|Pharmaxis|||||f||||f||||||||||2018-06-01 00:02:47.838006|2018-06-01 00:02:47.838006
NCT01076478|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|March 2004||2004-03-31|February 2010|2010-02-28|November 2009|Actual|2009-11-30|||||Interventional|ASCEND||Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines||Completed||Phase 4|47|Actual|Otsuka Pharmaceutical, Inc., Philippines||3|||f||||f||||||||||2018-06-01 00:02:47.928628|2018-06-01 00:02:47.928628
NCT01076465|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2016-04-16|2010-02-25|2010-02-26|Estimate|||||||2016-04-16|2016-04-19|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy of a Disease Management Program in Very Old Patients With Heart Failure|Efficacy of a Disease Management Program in Very Old Patients With Heart Failure and Significant Comorbidity: a Multicenter Randomized Trial|Completed||N/A|700|Actual|Hospital de Meixoeiro||2|||f||||f||||||||||2018-06-01 00:02:48.033948|2018-06-01 00:02:48.033948
NCT01076452|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2013-09-11||2014-06-27|2010-02-25|2010-02-26|Estimate|2013-11-26|2014-01-15|Estimate||||2014-06-27|2014-07-14|Estimate|April 2002||2002-04-30|June 2014|2014-06-30|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional|||Phase II Subthalamic Nucleus (STN) vs. Globus Pallidus (GPi) Trial|CSP #468 Phase II - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease, Phase II|Completed||Phase 3|299|Actual|VA Office of Research and Development|We observed differences between STN and GPi DBS groups on several secondary measures but these findings should be interpreted cautiously. We did not adjust for repeated significance tests and the differences may have limited clinical significance.|2|||f||||t||||||||||2018-06-01 00:02:48.231436|2018-06-01 00:02:48.231436
NCT01076439|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2012-02-21|2010-02-24|2010-02-26|Estimate|||||||2012-02-21|2012-02-22|Estimate||||February 2012|2012-02-29||||||||Interventional|||An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo|A Pilot Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo Nasal Spray in Reducing Nasal Allergic Symptoms Following Ragweed Exposure in the Allergen BioCube (ABC)|Withdrawn||Phase 4|0|Actual|ORA, Inc.||3|||f||||||||||||||2018-06-01 00:02:48.968275|2018-06-01 00:02:48.968275
NCT01076426|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-25|2010-02-25|2010-02-26|Estimate|||||||2010-02-25|2010-02-26|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Probiotics Use in the Chronic Peritoneal Dialysis Patients|The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis|Unknown status|Recruiting|Phase 4|100|Anticipated|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-06-01 00:02:49.042867|2018-06-01 00:02:49.042867
NCT01076413|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2016-01-21|2010-02-25|2010-02-26|Estimate|||||||2016-01-21|2016-01-25|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|PRIME||Comparison of Two Exercise Interventions to Improve Gait in Older Persons|Comparison of Two Exercise Interventions to Improve Gait in Older Persons: The PRIME (Program to Improve Mobility in The Elderly) Study|Completed||N/A|40|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 00:02:49.177403|2018-06-01 00:02:49.177403
NCT01076400|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2017-10-13||2017-11-17|2010-02-24|2010-02-26|Estimate|2017-11-17|2017-12-14|Actual||||2017-11-17|2017-12-14|Actual|May 31, 2010|Actual|2010-05-31|November 2017|2017-11-30|June 13, 2011|Actual|2011-06-13|June 13, 2011|Actual|2011-06-13||Interventional|||A Study of MK-1775 in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)|A Two Part, Phase I-IIa Study Evaluating MK1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer|Terminated||Phase 1/Phase 2|7|Actual|Merck Sharp & Dohme Corp.||3||"The sponsor permanently suspended new enrollment into the trial and discontinued the study;~   which was not related to any concerns over product safety."|f||||f|t|f||||||||2018-06-01 00:02:49.292824|2018-06-01 00:02:49.292824
NCT01076387|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2018-02-23|2010-02-24|2010-02-26|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2010|Actual|2010-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Randomized Trial Comparing Robotic and Open Radical Cystectomy|A Prospective, Randomized Trial Comparing Robotic and Open Radical Cystectomy|Active, not recruiting||Phase 3|124|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 00:02:49.524161|2018-06-01 00:02:49.524161
NCT01076374|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2018-04-24|2010-02-25|2010-02-26|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2008||2008-07-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|||MEDTRONIC ADAPTA, VERSA AND SENSIA nEw3 POST APPROVAL STUDY|Medtronic Adapta/Versa/Sensia Long Term Reliability Study|Completed|||2927|Actual|Medtronic|||||f||||f||||||||||2018-06-01 00:02:49.607193|2018-06-01 00:02:49.607193
NCT01076361|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2013-06-28||2014-10-24|2010-02-25|2010-02-26|Estimate|2014-10-24|2014-10-27|Estimate||||2014-10-24|2014-10-27|Estimate|September 1999||1999-09-30|October 2014|2014-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30|5 Years|Observational [Patient Registry]|4968|A total of 631 leads were implanted in 370 subjects. 22 leads in 21 patients were not included in the analysis due to missing data. The final number of leads analyzed was 609.|Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study|Medtronic Model 4968 CapSure Epi® Steroid-Eluting Bipolar Epicardial Pacing Lead Post-approval Study|Completed|||370|Actual|Medtronic|||||f||||f||||||||||2018-06-01 00:02:49.820211|2018-06-01 00:02:49.820211
NCT01076348|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2012-05-16||2018-02-28|2010-02-25|2010-02-26|Estimate|2012-07-09|2012-08-23|Estimate||||2018-02-28|2018-03-29|Actual|September 1996||1996-09-30|February 2018|2018-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Model 4965 Post-Approval Study|Medtronic Model 4965 Capsure Epi® Steroid-eluting Unipolar Epicardial Pacing Lead Post Approval Study|Completed|||73|Actual|Medtronic|The study cohort was limited to subjects >19 years of age at the time of implant, limiting the survival analysis of the Model 4965 lead in a pediatric population.||||f||||f||||||||||2018-06-01 00:02:50.256079|2018-06-01 00:02:50.256079
NCT01076335|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2016-06-28||2016-08-08|2010-02-25|2010-02-26|Estimate|2016-06-28|2016-08-08|Estimate||||2016-08-08|2016-09-19|Estimate|May 2005||2005-05-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||One participant declined presurgical therapy after enrollment and was excluded from analysis.|Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer|Phase II Study of Neoadjuvant Hormonal Therapy Plus Docetaxel Followed by Radical Prostatectomy for Men With Proven or Suspected Node-positive Prostate Cancer|Completed||Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:02:50.628718|2018-06-01 00:02:50.628718
NCT01076322|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-08-10|2010-02-25|2010-02-26|Estimate|||||||2010-08-10|2010-08-12|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients||Completed||Phase 3|17|Anticipated|Taiwan Otsuka Pharm. Co., Ltd||2|||f||||f||||||||||2018-06-01 00:02:50.813135|2018-06-01 00:02:50.813135
NCT01076309|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2011-07-19|2010-02-25|2010-02-26|Estimate|||||||2011-07-19|2011-07-21|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Corneal Endothelium Cell Loss After Cataract Extraction in Patients Taking Tamsulosin|Corneal Endothelium Cell Loss After Cataract Extraction in Patients Taking Systemic Sympathetic Alfa-1-a-antagonist Medication (Tamsulosin)|Completed|||60|Actual|Frederiksberg University Hospital|||2||f||||f||||||||||2018-06-01 00:02:50.940156|2018-06-01 00:02:50.940156
NCT01076296|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2015-12-16||2016-02-08|2010-02-25|2010-02-26|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System|A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System|Completed|||1000|Actual|GE Healthcare|||||f||||f||||||||||2018-06-01 00:02:50.999966|2018-06-01 00:02:50.999966
NCT01076283|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|2013-05-05||2013-10-15|2010-02-25|2010-02-26|Estimate|2013-10-15|2013-10-17|Estimate||||2013-10-15|2013-10-17|Estimate|December 2009||2009-12-31|October 2013|2013-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking|A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking|Completed||Phase 2|14|Actual|Brown University|Very small sample. This pilot trial was primarily aimed to determine a power analysis for future larger trials.|2|||f||||f||||||||||2018-06-01 00:02:51.222172|2018-06-01 00:02:51.222172
NCT01076270|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2017-02-15||2017-06-26|2010-02-24|2010-02-26|Estimate|2017-02-15|2017-03-31|Actual||||2017-06-26|2017-06-28|Actual|June 2010||2010-06-30|June 2017|2017-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Pilot Study of Combined Plerixafor + Filgrastim for Mobilization of Peripheral Blood Stem Cells From Normal Donors|Terminated||N/A|1|Actual|Fred Hutchinson Cancer Research Center|Only one patient was enrolled in this trial.|1||Funding withdrawal|f||||f||||||||||2018-06-01 00:02:51.52996|2018-06-01 00:02:51.52996
NCT01076257|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2012-07-30|2010-02-24|2010-02-26|Estimate|||||||2012-07-30|2012-07-31|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage|Efficacy of Modified Constraint-induced Movement Therapy in Children With Brain Damage: Evidence of Kinematic Study|Completed||N/A|48|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:02:51.772351|2018-06-01 00:02:51.772351
NCT01076244|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2013-02-22||2013-02-22|2010-02-25|2010-02-26|Estimate|2013-02-22|2013-04-02|Estimate||||2013-02-22|2013-04-02|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Vertos Mild - Post Market Patient Outcomes|Single - Center, Prospective, Patient Outcomes Assessment of Minimally Invasive Lumbar Decompression With the Mild Devices in Patients With Symptomatic Central Canal Stenosis.|Completed||N/A|46|Actual|The Center for Pain Relief, Inc.||1|||f||||t||||||||||2018-06-01 00:02:51.854525|2018-06-01 00:02:51.854525
NCT01076231|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2016-04-11|2010-02-24|2010-02-26|Estimate|||||||2016-04-11|2016-04-13|Estimate|January 2010||2010-01-31|April 2016|2016-04-30||||July 2017|Anticipated|2017-07-31||Interventional|||Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery|Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC|Unknown status|Recruiting|Phase 1/Phase 2|72|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:02:52.019701|2018-06-01 00:02:52.019701
NCT01076218|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-24|2010-02-24|2010-02-26|Estimate|||||||2010-02-24|2010-02-26|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|FSNQS||Navigator 1.5 Accuracy Study|In Clinic Evaluation of the FreeStyle Navigator® Continuous Glucose Monitoring System Version 1.5|Completed|||57|Actual|Abbott Diabetes Care|||1||f||||f||||||||||2018-06-01 00:02:52.106822|2018-06-01 00:02:52.106822
NCT01076205|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2017-10-10|2010-02-24|2010-02-26|Estimate|||||||2017-10-10|2017-10-12|Actual|September 8, 2009||2009-09-08|October 2017|2017-10-31|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Observational|AGIL||Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis|Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice (AGIL)|Completed|||7199|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:02:52.197205|2018-06-01 00:02:52.197205
NCT01076192|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2015-09-25||2015-12-01|2010-02-24|2010-02-26|Estimate|2015-12-01|2016-01-06|Estimate||||2015-12-01|2016-01-06|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|PROMISE|Baseline analyses accounts for Intention to treat (ITT) population (all participants who received at least 1 dose of study drug and had at least 1 follow-up visit).|Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)|Post-authorization, Observational Study to Evaluate the Effectiveness of Adalimumab (HUMIRA®) on Moderate-severe Psoriasis Under Conditions of Routine Clinical Practice in Spain.|Completed|||547|Actual|AbbVie|||1||f||||||||||||||2018-06-01 00:02:52.908262|2018-06-01 00:02:52.908262
NCT01076179|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2017-01-18||2017-05-18|2010-02-24|2010-02-26|Estimate|2017-05-18|2017-05-19|Actual||||2017-05-18|2017-05-19|Actual|September 2008||2008-09-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|PROTEKT||Kaletra in Combination With Antiretroviral Agents|KALETRA in Combination With New Substances (PROTEKT)|Completed|||502|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:02:53.68586|2018-06-01 00:02:53.68586
NCT01076166|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2011-01-07||2011-04-07|2010-02-24|2010-02-26|Estimate|2011-02-10|2011-03-07|Estimate||||2011-04-07|2011-04-11|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid® Granules for Oral Suspension.|A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid Granules for Oral Suspension.|Completed|||337|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:02:54.419271|2018-06-01 00:02:54.419271
NCT01076153|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2011-04-22||2011-07-01|2010-02-24|2010-02-26|Estimate|2011-06-03|2011-06-29|Estimate||||2011-07-01|2011-07-12|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR|A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR|Completed|||760|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:02:54.714494|2018-06-01 00:02:54.714494
NCT01076140|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2012-04-05|2010-02-24|2010-02-25|Estimate|||||||2012-04-05|2012-04-06|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|August 2011|Anticipated|2011-08-31|January 2011|Anticipated|2011-01-31||Interventional|||Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab|Comparative Blood Pressure Effects of Nebivolol Versus Lisinopril in Patients With New Onset or Exacerbated Hypertension Induced by Bevacizumab: a Crossover Study|Withdrawn||N/A|0|Actual|University of Mississippi Medical Center||2||No participants enrolled|f||||f||||||||||2018-06-01 00:02:55.086642|2018-06-01 00:02:55.086642
NCT01076127|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-12-12|2010-02-24|2010-02-25|Estimate|||||||2010-12-12|2010-12-14|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Effect of Kettlebell Training on Musculoskeletal and Cardiovascular Health|Effect of Kettlebell Training on Musculoskeletal and Cardiovascular Health|Completed||N/A|40|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-06-01 00:02:55.372638|2018-06-01 00:02:55.372638
NCT01076114|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2011-03-14|2010-02-24|2010-02-25|Estimate|||||||2011-03-14|2011-03-15|Estimate|February 2010||2010-02-28|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Comparison of Critical Flicker Fusion Versus Automated Visual Fields in the Detection of Early Glaucoma|Comparison of Critical Flicker Fusion vs. Automated Visual Fields in the Detection of Early Glaucoma|Completed|||58|Actual|Northwell Health|||2||f||||t||||||||||2018-06-01 00:02:57.48904|2018-06-01 00:02:57.48904
NCT01076101|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2017-02-02|2010-02-24|2010-02-25|Estimate|||||||2017-02-02|2017-02-06|Estimate|February 2009||2009-02-28|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|7 Years|Observational [Patient Registry]|SisSLE||Autoimmunity in Sisters of Lupus Patients|Mapping Autoimmune Phenotypes in Multiplex Families (MADGC 2)|Completed|||817|Actual|Northwell Health|||2||f||||f|f|f||||Samples With DNA|"~     We will use your DNA blood sample to study the function of genes and biomarkers and gain~     understanding of their role in protection against disease or the role they play in increasing~     the risk factors of developing lupus. No, you will not get test results since the information~     we gather is only useful for research and is not diagnostic. Participation in this study is~     not a substitute for regular medical care.~      The information and blood sample that is collected for research will be analyzed for many~     years and it is not possible to know how long this analysis and follow-up will take.~     Therefore, participation allows the information and banking of your blood sample to be~     indefinite.~   "|No||2018-06-01 00:02:57.559686|2018-06-01 00:02:57.559686
NCT01076088|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2013-12-17||2017-04-27|2010-02-24|2010-02-25|Estimate|2013-12-17|2014-02-06|Estimate||||2017-04-27|2017-05-23|Actual|November 15, 2010|Actual|2010-11-15|April 2017|2017-04-30|December 24, 2012|Actual|2012-12-24|December 24, 2012|Actual|2012-12-24||Interventional|||Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)|A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial in China to Study the Safety and Efficacy of Co-administration of Sitagliptin and Metformin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|744|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:02:57.661538|2018-06-01 00:02:57.661538
NCT01076075|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2012-06-28||2017-05-04|2010-02-24|2010-02-25|Estimate|2012-06-28|2012-08-07|Estimate||||2017-05-04|2017-06-05|Actual|June 3, 2010|Actual|2010-06-03|May 2017|2017-05-31|January 19, 2012|Actual|2012-01-19|July 11, 2011|Actual|2011-07-11||Interventional|||A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)|A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylurea in Combination With Metformin|Completed||Phase 3|427|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:02:58.457657|2018-06-01 00:02:58.457657
NCT01076049|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2013-06-12|2010-02-24|2010-02-25|Estimate|||||||2013-06-12|2013-06-14|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|USF||Evaluation of IrriSept for Irrigation of Skin and Soft Tissue Infections in the Emergency Room Setting|Evaluation of a Novel Solution, IrriSept, Containing a Long-Acting Antimicrobial Agent for Irrigation of Skin and Soft Tissue Infections in the Emergency Setting|Terminated||Phase 2|114|Actual|Irrimax Corporation||2||suboptimal recruitment|f||||t||||||||||2018-06-01 00:02:58.949056|2018-06-01 00:02:58.949056
NCT01076036|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2012-07-31||2015-08-06|2010-02-24|2010-02-25|Estimate|2015-08-06|2015-09-07|Estimate||||2015-08-06|2015-09-07|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)|CorPath™ 200 System: Coronary Remote Catheterization Feasibility Study|Completed||Phase 2|8|Actual|Corindus Inc.||1|||f||||t||||||||||2018-06-01 00:02:59.024529|2018-06-01 00:02:59.024529
NCT01076023|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-02-13|2010-02-24|2010-02-25|Estimate|||||||2013-02-13|2013-02-15|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|March 2013|Anticipated|2013-03-31|October 2012|Actual|2012-10-31||Observational|CCDC||Cohort Study in Type 2 Diabetes in China|Comprehensive Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Disease in China|Unknown status|Active, not recruiting||1000|Anticipated|China Cardiometabolic Registries|||||f||||f||||||||||2018-06-01 00:02:59.159968|2018-06-01 00:02:59.159968
NCT01076010|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2015-06-22|2010-02-24|2010-02-25|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)|An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)|Completed||Phase 3|350|Anticipated|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:02:59.238428|2018-06-01 00:02:59.238428
NCT01075997|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|November 2007||2007-11-30|June 2009|2009-06-30|October 2010|Anticipated|2010-10-31|July 2010|Anticipated|2010-07-31||Interventional|||The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus|The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus|Unknown status|Active, not recruiting|N/A|170|Anticipated|Walter Reed Army Medical Center||2|||f||||f||||||||||2018-06-01 00:02:59.468573|2018-06-01 00:02:59.468573
NCT01075984|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2013-09-10||2017-10-11|2010-02-24|2010-02-25|Estimate|2013-09-10|2013-11-15|Estimate||||2017-10-11|2017-11-13|Actual|February 23, 2010|Actual|2010-02-23|October 2017|2017-10-31|November 20, 2012|Actual|2012-11-20|November 20, 2012|Actual|2012-11-20||Interventional|||Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)|Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05520)|Completed||Phase 1|279|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:02:59.600158|2018-06-01 00:02:59.600158
NCT01075971|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2010-03-26||2011-04-14|2010-02-24|2010-02-25|Estimate|2010-03-26|2010-04-13|Estimate||||2011-04-14|2011-04-19|Estimate|September 2005||2005-09-30|April 2010|2010-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)|Evaluation of Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy|Completed||Phase 2|52|Actual|Indivior Inc.||1|||f||||f||||||||||2018-06-01 00:03:00.946913|2018-06-01 00:03:00.946913
NCT01075958|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2011-02-23||2011-08-02|2010-02-24|2010-02-25|Estimate|2011-08-02|2011-09-02|Estimate||||2011-08-02|2011-09-02|Estimate|July 2007||2007-07-31|August 2011|2011-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Polyunsaturated Fatty Acids (PUFA) Status and Cognitive Function in Healthy Young Adults|The Relationship Between Serum PUFAs and Cognitive Function in Healthy Young Adults|Completed|||283|Actual|Northumbria University|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 00:03:01.075518|2018-06-01 00:03:01.075518
NCT01075945|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan||Unknown status|Recruiting|Phase 4|140|Anticipated|University of Khartoum||2|||f||||t||||||||||2018-06-01 00:03:01.360155|2018-06-01 00:03:01.360155
NCT01075932|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Effects of Docosahexaenoic Acid (DHA)-Rich Fish Oil on Cerebral Haemodynamics|The Cognitive And Cerebral Hemodynamic Effects Of DHA-Rich Fish Oil: A Dose-Ranging Study|Completed||N/A|65|Actual|Northumbria University||3|||f||||f||||||||||2018-06-01 00:03:01.491648|2018-06-01 00:03:01.491648
NCT01075919|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|December 2007||2007-12-31|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cognitive and Mood Effects of Docosahexaenoic Acid (DHA)-Rich and Eicosapentaenoic Acid (EPA)-Rich Fish Oil in Healthy Young Adults|Cognitive and Mood Effects of DHA-rich and EPA-rich Fish Oil in Healthy Young Adults|Completed||N/A|159|Actual|Northumbria University||3|||f||||f||||||||||2018-06-01 00:03:01.560581|2018-06-01 00:03:01.560581
NCT01075906|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2012-01-09|2010-02-24|2010-02-25|Estimate|||||||2012-01-09|2012-01-10|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients|An Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMF|Completed||Phase 1|75|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||t||||||||||2018-06-01 00:03:01.649244|2018-06-01 00:03:01.649244
NCT01075893|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2017-10-27|2010-02-24|2010-02-25|Estimate|||||||2017-10-27|2017-10-31|Actual|February 2010||2010-02-28|March 2016|2016-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer|Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer|Completed|||11|Actual|Newcastle University|||3||f||||f||||||Samples Without DNA|"~     Rectal pinch biopsies - x 9 (10 cm from anal verge)~   "|||2018-06-01 00:03:01.771712|2018-06-01 00:03:01.771712
NCT01075880|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-09-05|2010-02-24|2010-02-25|Estimate|||||||2013-09-05|2013-09-06|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|SKORE||Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®|Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif|Completed|||300|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:03:01.842418|2018-06-01 00:03:01.842418
NCT01075867|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-03-17|2010-02-24|2010-02-25|Estimate|||||||2014-03-17|2014-03-18|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Multi-dimensional Prevention Program After Acute Coronary Syndrome (ELIPS) (SPUM-ACS- SP1)||Unknown status|Recruiting||3500|Anticipated|University Hospital, Geneva|||2||f||||||||||||||2018-06-01 00:03:01.965834|2018-06-01 00:03:01.965834
NCT01075854|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-07-30|2010-02-24|2010-02-25|Estimate|||||||2014-07-30|2014-07-31|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)|A Prospective, Multi-center, Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to IVF/ICSI|Completed|||1539|Actual|Merck KGaA|||||f||||||||||Samples Without DNA|"~     Serum samples~   "|||2018-06-01 00:03:02.091829|2018-06-01 00:03:02.091829
NCT01075841|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-07-01|2010-02-24|2010-02-25|Estimate|||||||2014-07-01|2014-07-02|Estimate|March 2009||2009-03-31|December 2010|2010-12-31||||March 2009|Actual|2009-03-31||Observational|||A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck|A Korean Post-Marketing Surveillance Study On Erbitux (Cetuximab) In Patients With Recurrent And/Or Metastatic Squamous Cell Carcinoma Of The Head And Neck|Withdrawn|||0|Actual|Merck KGaA||||"After loss of orphan drug status in Korea, study was withdrawn due to Regulatory Authority~   request. Patients will be enrolled into NCT01075828 instead."|f||||f||||||||||2018-06-01 00:03:02.167667|2018-06-01 00:03:02.167667
NCT01075828|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-08-28|2010-02-24|2010-02-25|Estimate|||||||2014-08-28|2014-08-29|Estimate|March 2009||2009-03-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea|A Korean Post Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck (SCCHN)|Completed|||221|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:03:02.227731|2018-06-01 00:03:02.227731
NCT01075815|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2012-08-29||2014-01-20|2010-02-24|2010-02-25|Estimate|2012-11-19|2012-11-20|Estimate||||2014-01-20|2014-02-13|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age|Exploratory Study to Determine the Effect of Lutropin Alfa on Embryo Quality and Their Implantation in Women of Advanced Reproductive Age|Terminated||Phase 2|76|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:03:02.313177|2018-06-01 00:03:02.313177
NCT01075802|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-05-03|2010-02-24|2010-02-25|Estimate|||||||2013-05-03|2013-05-06|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|TADE||Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms|A Multi-Centre Study of Tamoxifen Dose Escalation Study in Breast Cancer Patients With CYP2D6 Polymorphisms|Completed||N/A|121|Actual|Western Sydney Local Health District||1|||f||||t||||||||||2018-06-01 00:03:02.916072|2018-06-01 00:03:02.916072
NCT01075789|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2016-03-30|2010-02-24|2010-02-25|Estimate|||||||2016-03-30|2016-03-31|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|NGTIPPS||Using Lignocaine Spray and Gel to Reduce the Pain Associated With Nasogastric Tube Insertion in Children|The Combined Use of Intranasal Lignocaine Spray and Oral Lignocaine Gel to Reduce the Pain and Trauma Associated With Nasogastric Tube Insertion in Hospitalised Children.|Terminated||N/A|13|Actual|Queensland Children's Medical Research Institute||3||Failure to recruit|f||||f||||||||||2018-06-01 00:03:03.002758|2018-06-01 00:03:03.002758
NCT01075776|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2016-10-26|2010-02-24|2010-02-25|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of C-type Natriuretic Peptide on Human Forearm Blood Vessels|The Effects of C-type Natriuretic Peptide on Endothelial Function Following Ischaemia-Reperfusion in the Human Forearm|Not yet recruiting||N/A|20|Anticipated|Queen Mary University of London||2|||f||||t||||||||||2018-06-01 00:03:03.079445|2018-06-01 00:03:03.079445
NCT01075763|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|2012-03-07||2014-01-20|2010-02-24|2010-02-25|Estimate|2012-03-07|2012-04-04|Estimate||||2014-01-20|2014-02-13|Estimate|November 2004||2004-11-30|January 2014|2014-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|REAL||A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease|Pilot Trial of Interferon Beta-1a in Alzheimer's Disease|Completed||Phase 2|42|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 00:03:03.160557|2018-06-01 00:03:03.160557
NCT01075750|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2013-02-10|2010-02-24|2010-02-25|Estimate|||||||2013-02-10|2013-02-12|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants|Perioperative Fluid Management in Patients Receiving Cadaveric Renal Transplants - Effects of Normal Saline Versus Balanced Infusates on the Incidence of Electrolyte and Acid-base Disturbances|Completed|||150|Actual|Medical University of Vienna|||2||f||||t||||||||||2018-06-01 00:03:03.703477|2018-06-01 00:03:03.703477
NCT01075737|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-02-14|2010-02-24|2010-02-25|Estimate|||||||2014-02-14|2014-02-17|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|||An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers|Observational Study to Assess the Quality of Life of the Caregivers of Patients With Multiple Sclerosis|Completed|||141|Actual|Merck KGaA|||2||f||||f||||||||||2018-06-01 00:03:03.77814|2018-06-01 00:03:03.77814
NCT01075724|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-01-14|2010-02-24|2010-02-25|Estimate|||||||2015-01-14|2015-01-15|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of a New Patient Warming System Using a Polymer Conductive Warming Under-body and Upper-body Blanket With Forced Air Warming|Comparison of a New Patient Warming System Using a Polymer Conductive Warming Under-body and Upper-body Blanket With Forced Air Warming During Surgery|Completed||Phase 3|40|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:03:03.872195|2018-06-01 00:03:03.872195
NCT01075711|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-02-16|2010-02-24|2010-02-25|Estimate|||||||2014-02-16|2014-02-19|Estimate|April 2009||2009-04-30|February 2014|2014-02-28|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|LODOTRA||Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)|Non-interventional Study for Determining the Improvement in the Activity Status / Life Quality of Patients With Rheumatoid Arthritis Being Treated With the Tempus Tablet|Completed|||2728|Actual|Merck KGaA|||2||f||||||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 00:03:03.964015|2018-06-01 00:03:03.964015
NCT01075698|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2016-09-03|2010-02-24|2010-02-25|Estimate|||||||2016-09-03|2016-09-07|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|ATTEMPT-CVD||A Trial of Telmisartan Prevention of Cardiovascular Disease|A Trial of Telmisartan Prevention of Cardiovascular Disease|Completed||Phase 4|1228|Actual|Kumamoto University||2|||f||||t||||||||||2018-06-01 00:03:04.066714|2018-06-01 00:03:04.066714
NCT01075685|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2010-08-19||2010-10-15|2010-02-24|2010-02-25|Estimate|2010-10-15|2010-11-10|Estimate||||2010-10-15|2010-11-10|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of an Internet-based Intervention for Hazardous Drinkers||Completed||Phase 2|1157|Actual|Institut national de prevention et d'education pour la sante|High rate of loss to follow-up lead to small number of subjects analyzed. Some participants were lost to follow-up even before completing baseline measures.|2|||f||||f||||||||||2018-06-01 00:03:04.22255|2018-06-01 00:03:04.22255
NCT01075672|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2018-05-04|2010-02-24|2010-02-25|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2010||2010-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals|Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting|Active, not recruiting||N/A|250|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:03:04.647926|2018-06-01 00:03:04.647926
NCT01075659|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2012-07-06|2010-02-24|2010-02-25|Estimate|||||||2012-07-06|2012-07-10|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge|Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge: A Study in Healthy Smokers|Completed||Phase 2|200|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-06-01 00:03:04.72864|2018-06-01 00:03:04.72864
NCT01075646|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2016-02-20||2017-02-23|2010-02-24|2010-02-25|Estimate|2016-09-27|2016-11-18|Estimate||||2017-02-23|2017-03-27|Actual|March 2009||2009-03-31|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CATROP-2007||Local Anesthesia Versus Saline Serum in Surgical Incision of Colorectal or Hepatic Surgery|Randomised and Double-blind Clinical Trial on Post-operative Analgesic Efficacy in Colorectal Surgery and Hepatic Surgery With Continuous Infusion of Local Anesthesia vs Saline Serum in the Surgical Incision.|Completed||Phase 4|225|Actual|Hospital Universitari de Bellvitge|A limitation of the study is the high number of recruited patients who were excluded before ranodmization.|2|||f||||f||||||||Undecided||2018-06-01 00:03:04.825083|2018-06-01 00:03:04.825083
NCT01075633|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-01-07|2010-02-24|2010-02-25|Estimate|||||||2014-01-07|2014-01-08|Estimate|January 2006||2006-01-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|December 2011|Actual|2011-12-31||Interventional|COLONFAM||Colorectal Cancer Screening in Familiar-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy|Colorectal Cancer Screening in Familiar-Risk Population: a Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy|Completed||Phase 3|1501|Actual|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||2|||f||||f||||||||||2018-06-01 00:03:06.001145|2018-06-01 00:03:06.001145
NCT01075620|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|May 2002||2002-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|December 2002|Actual|2002-12-31||Interventional|||Comparison of Nonposterior- and Posterior-Stabilized Mobile-Bearing Total Knee Arthroplasty|Comparison of Nonposterior- and Posterior-Stabilized Mobile-Bearing Total Knee Arthroplasty A Prospective, Randomized Study|Completed||Phase 4|126|Actual|Ewha Womans University||2|||f||||t||||||||||2018-06-01 00:03:06.26109|2018-06-01 00:03:06.26109
NCT01075607|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2012-03-27|2010-02-24|2010-02-25|Estimate|||||||2012-03-27|2012-03-28|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Observational|||Lymph Fluid and Blood Collection for Identification of Novel Biomarkers|The Comparison of Lymph Fluid and Blood From Metastatic and Non-metastatic Invasive Breast Cancer Patients for Identification of Novel Biomarkers|Terminated|||50|Anticipated|Indiana University||||Halted prematurely due to lack of funding.|f||||f||||||||||2018-06-01 00:03:06.346027|2018-06-01 00:03:06.346027
NCT01075594|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-09-09|2010-02-24|2010-02-25|Estimate|||||||2010-09-09|2010-09-10|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|CEPHEUS||Study of Undertreatment of Patients With Dyslipidemia in Bulgaria|Centralized Pan-Bulgarian Survey on the Undertreatment of Hypercholesterolemia|Completed|||2500|Actual|AstraZeneca|||1||f||||f||||||None Retained|"~     whole blood, serum~   "|||2018-06-01 00:03:06.426564|2018-06-01 00:03:06.426564
NCT01075581|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Intranasal Injection Versus Topical Administration of Epinephrin During Endoscopic Sinus Surgery|Hemostatic and Hemodynamic Effects of Intranasal Injection Compared to Topical Administration of Epinephrin in Endoscopic Sinus Surgery|Unknown status|Not yet recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:03:06.686829|2018-06-01 00:03:06.686829
NCT01075568|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-03-02|2010-02-24|2010-02-25|Estimate|||||||2010-03-02|2010-03-03|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||The Satiety Effect After Okara Compared to Porridge Eating||Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 00:03:06.85187|2018-06-01 00:03:06.85187
NCT01075555|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2016-05-26|2010-02-24|2010-02-25|Estimate|||||||2016-05-26|2016-05-27|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis|Randomized Phase III Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma|Completed||Phase 3|323|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||||2018-06-01 00:03:06.991955|2018-06-01 00:03:06.991955
NCT00862524|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16||2012-01-23|2012-09-28|2009-03-16|2009-03-17|Estimate||||2012-01-23|2012-01-27|Estimate|2012-09-28|2012-10-04|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer||Completed||Phase 1/Phase 2|20|Actual|Array BioPharma||1|||f||||||||||||||2018-06-01 01:12:23.472326|2018-06-01 01:12:23.472326
NCT01075542|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2014-01-13|2010-02-24|2010-02-25|Estimate|||||||2014-01-13|2014-01-14|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Astigmatism Management in Cataract Surgery With the AcrySof Toric Intraocular Lens|Efficacy and Cost-effectiveness of Toric Intraocular Lenses in Correcting Astigmatism in Cataract Surgery: a Randomised Clinical Trial|Completed||N/A|86|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:03:07.19119|2018-06-01 00:03:07.19119
NCT01075529|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|March 2007||2007-03-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Early Prediction of Fluoxetine Response|Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine|Completed||Phase 4|140|Actual|Kaohsiung Kai-Suan Psychiatric Hospital||1|||f||||t||||||||||2018-06-01 00:03:07.281848|2018-06-01 00:03:07.281848
NCT01075516|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2014-01-30|2010-02-24|2010-02-25|Estimate|||||||2014-01-30|2014-02-03|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|March 2012|Actual|2012-03-31||Observational|TARIFF||Health Economic Evaluation of Remote Follow up for Implantable Cardioverter Defibrillator (ICD) Patients|TARIFF Health Economics Evaluation Registry for Remote Follow up|Completed|||200|Actual|St. Jude Medical|||2||f||||f||||||||||2018-06-01 00:03:07.563592|2018-06-01 00:03:07.563592
NCT01075503|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|RIBPA||Clinical Research of Retrograde Infraclavicular Brachial Plexus Blockade|New Approach for Brachial Plexus Block: Clinical Research of Retrograde Infraclavicular Brachial Plexus Blockade|Completed||N/A|90|Actual|Beijing Jishuitan Hospital||3|||f||||t||||||||||2018-06-01 00:03:07.992783|2018-06-01 00:03:07.992783
NCT01075490|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|November 2006|Actual|2006-11-30||Interventional|||Neonatal Spinal Anesthesia: Effects of the Addition of Clonidine|Neonatal Spinal Anesthesia: Effects of the Addition of Clonidine|Unknown status|Recruiting|Phase 4|120|Anticipated|University Hospital, Montpellier||4|||f||||t||||||||||2018-06-01 00:03:08.460231|2018-06-01 00:03:08.460231
NCT01075477|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2016-11-01|2010-02-24|2010-02-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)|Naturalistic Prospective Non-interventional Study on Rheumatoid Arthritis (RA) Patients Treated With Rituximab According to Local Treatment Guidelines|Completed|||151|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-06-01 00:03:08.674075|2018-06-01 00:03:08.674075
NCT01075464|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2016-11-01|2010-02-24|2010-02-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, a Human IgG1 Antibody, in Combination With Bevacizumab and Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|64|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 00:03:09.011418|2018-06-01 00:03:09.011418
NCT01075451|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2013-05-17|2010-02-24|2010-02-25|Estimate|||||||2013-05-17|2013-05-20|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Antimicrobial Drug Use and Resistant Staphylococcus Aureus|Antimicrobial Drug Use and Resistant Staphylococcus Aureus in a Network of Academic Medical Center Hospitals.|Completed|||41|Actual|Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 00:03:09.277336|2018-06-01 00:03:09.277336
NCT01075438|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-03-15|2010-02-24|2010-02-25|Estimate|||||||2010-03-15|2010-03-16|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients|Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar®, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax® Aventis Pasteur MSD) in Ataxia-telangiectasia Patients|Unknown status|Not yet recruiting||20|Anticipated|Sheba Medical Center|||||f||||f||||||Samples Without DNA|"~     Serum for specific anti-pneumococcal antibody levels and Immunoglobulin levels.~   "|||2018-06-01 00:03:09.363476|2018-06-01 00:03:09.363476
NCT01075425|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2016-04-13|2010-02-23|2010-02-25|Estimate|||||||2016-04-13|2016-04-15|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome|Phase I Study of Belinostat (PXD-101) and Velcade (Bortezomib) in Relapsed or Refractory Acute Leukemia/ Myelodysplastic Syndrome|Completed||Phase 1|41|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 00:03:09.681845|2018-06-01 00:03:09.681845
NCT01075412|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2017-08-03||2017-10-25|2010-02-23|2010-02-25|Estimate|2017-10-25|2017-12-02|Actual||||2017-10-25|2017-12-02|Actual|September 2009|Actual|2009-09-30|October 2017|2017-10-31|April 11, 2016|Actual|2016-04-11|March 3, 2016|Actual|2016-03-03||Interventional|||FLT PET Imaging for Cervical Cancer|`F-18 Fluorothymidine ([18F]FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Cervical Cancer|Terminated||Phase 2|6|Actual|University of Iowa|The results of this pilot study were merged with NCT01717391 for analysis and resultant publication.|2||Study was closed and reopened as NCT01717391|f||||t||||||||Yes|Yes, data will be shared utilizing clinicaltrials.gov results|2018-06-01 00:03:10.060094|2018-06-01 00:03:10.060094
NCT01075399|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2013-02-14||2013-07-26|2010-02-23|2010-02-25|Estimate|2013-07-26|2013-08-30|Estimate||||2013-07-26|2013-08-30|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|February 2012|Actual|2012-02-29|May 2011|Actual|2011-05-31||Interventional|HX4-200|A total of 50 patients were enrolled. A total of 42 patients received at least one dose of [F-18]HX4. Thirty-nine (39) patients completed two pre-treatment [F-18]HX4 PET/CT scans. Thirty (30) patients had an evaluable tumor response assessment 3 (±1) months after treatment start|Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors|A Pilot, Phase II , Open Label, Nonrandomized, Multi- Center Study of [F 18]HX4 Positron Emission Tomography (PET) to Detect Hypoxia in Tumors|Completed||Phase 2|50|Actual|Siemens Molecular Imaging||1|||f||||f||||||||||2018-06-01 00:03:11.10597|2018-06-01 00:03:11.10597
NCT01075386|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2018-04-03|2010-02-24|2010-02-25|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2009|Actual|2009-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2011|Actual|2011-08-31||Observational|Ghrelin||The Effects of the Endocrine System on Endometrial Cancer|Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer|Active, not recruiting|||80|Anticipated|Queensland Centre for Gynaecological Cancer|||4||f||||f||||||Samples Without DNA|"~     Endometrial tissue~   "|||2018-06-01 00:03:11.540015|2018-06-01 00:03:11.540015
NCT01075373|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-03-04|2010-02-23|2010-02-25|Estimate|||||||2010-03-04|2010-03-08|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|SONPOS||A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations|A Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological Differentiations|Unknown status|Enrolling by invitation||360|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:03:11.70599|2018-06-01 00:03:11.70599
NCT01075360|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Observational|||The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression|The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression|Completed|||||National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 00:03:11.762029|2018-06-01 00:03:11.762029
NCT01075347|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2010-07-14||2010-09-07|2010-02-24|2010-02-25|Estimate|2010-08-12|2010-09-02|Estimate||||2010-09-07|2010-09-14|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries|Clinical Study: Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries|Completed||Phase 1|165|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 00:03:11.819457|2018-06-01 00:03:11.819457
NCT01075334|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|December 2012|Anticipated|2012-12-31|February 2010|Actual|2010-02-28||Interventional|||Is a Carnitine Based Food Supplement (PorimoreTM) for Infertile Men Superior to Folate and Zinc With Regard to Pregnancy Rates in Intrauterine Insemination Cycles?||Unknown status|Recruiting|N/A|100|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 00:03:12.330382|2018-06-01 00:03:12.330382
NCT01075321|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2018-02-07|2010-02-23|2010-02-25|Estimate|||||||2018-02-07|2018-02-09|Actual|January 2011|Actual|2011-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma|A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy|Active, not recruiting||Phase 1/Phase 2|59|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:03:12.896127|2018-06-01 00:03:12.896127
NCT01075308|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-24|||2015-07-10|2010-02-24|2010-02-25|Estimate|||||||2015-07-10|2015-07-13|Estimate|February 2010||2010-02-28|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer|A Phase II Study of SB939 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer|Completed||Phase 2|32|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-06-01 00:03:13.540995|2018-06-01 00:03:13.540995
NCT01075295|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2017-07-23|2010-02-24|2010-02-25|Estimate|||||||2017-07-23|2017-07-25|Actual|February 2010||2010-02-28|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prevention of Weight Gain in Early Psychoses|Prevention of Weight Gain in Early Psychoses|Completed||N/A|70|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 00:03:13.69618|2018-06-01 00:03:13.69618
NCT01075282|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2014-10-03|2012-09-18|2015-01-15|2010-02-23|2010-02-25|Estimate|2015-01-15|2015-01-16|Estimate|2012-09-18|2012-09-25|Estimate|2015-01-15|2015-01-16|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|AWARD-2|Participants who were randomized and received at least 1 dose of LY2189265 or Insulin Glargine.|A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)|A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride|Completed||Phase 3|810|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 00:03:13.982999|2018-06-01 00:03:13.982999
NCT01075269|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-24|2010-02-24|2010-02-25|Estimate|||||||2010-02-24|2010-02-25|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|May 2010|Anticipated|2010-05-31|February 2010|Actual|2010-02-28||Observational|Robot1||Postoperative Distress and Cosmetic Outcomes After Open Versus Robotic Thyroidectomy|Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report.|Unknown status|Active, not recruiting||84|Actual|Korean Association of Endocrine Surgeons|||2||f||||t||||||||||2018-06-01 00:03:17.9908|2018-06-01 00:03:17.9908
NCT01075256|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2011-09-23||2013-04-25|2010-02-23|2010-02-25|Estimate|2013-04-25|2013-06-03|Estimate||||2013-04-25|2013-06-03|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dose Response of a Tubule Occlusion Agent|An Exploratory Clinical Study to Evaluate the Efficacy of Two Currently Marketed Toothpastes Containing Different Concentrations of a Tubule Occlusion Agent|Completed||Phase 4|195|Actual|GlaxoSmithKline|An issue with study product packaging was discovered post-study completion. The nature indicated that subject response was likely to have been liable to a positive bias. Efficacy cannot be considered as valid and no reliable conclusions possible.|3|||f||||f||||||||||2018-06-01 00:03:18.188054|2018-06-01 00:03:18.188054
NCT01075243|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2013-06-20||2015-04-27|2010-02-23|2010-02-25|Estimate|2015-04-27|2015-04-29|Estimate||||2015-04-27|2015-04-29|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy|A Study to Compare the Analgesic Efficacy of Two Different Paracetamol Doses as Measured by Post-operative Pain Relief|Completed||Phase 4|401|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 00:03:18.962007|2018-06-01 00:03:18.962007
NCT01075230|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2013-11-20|2010-02-24|2010-02-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)|A Prospective, Randomized, Single-blind, Multi-center Clinical Study to Evaluate the Effect of Platelet Rich Plasma (PRP) on Short-term Patient Outcomes Following Total Knee Replacement.|Terminated||N/A|50|Actual|Exactech||2||"Intended as multi-center. 1 of 2 sites could not participate. Enrollment discontinued after~   50/100. Subjects followed per protocol."|f||||f||||||||||2018-06-01 00:03:20.061461|2018-06-01 00:03:20.061461
NCT01075061|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2016-02-23|2010-02-23|2010-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|MOMIC||"Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification PROJET  MOMIC "|Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification : MOMIC|Completed||N/A|40|Actual|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||||2018-06-01 00:03:28.504731|2018-06-01 00:03:28.504731
NCT01075217|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2013-02-25||2013-05-23|2010-02-24|2010-02-25|Estimate|2013-04-15|2013-05-23|Estimate||||2013-05-23|2013-05-30|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Patients who received study agent comprised the baseline population. Four patients assigned to Isovue 250 and 1 assigned to Visipaque 270 did not receive study agent because they did not meet all entry criteria or withdrew before study agent was adminstered|Isovue in Peripheral Digital Subtraction Angiography (DSA)|A Phase IV Multi-Center Study to Compare ISOVUE -250 and VISIPAQUE 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)|Completed||Phase 4|174|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-06-01 00:03:20.407494|2018-06-01 00:03:20.407494
NCT01075204|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2012-12-20||2013-02-06|2010-02-23|2010-02-25|Estimate|2012-12-20|2013-01-30|Estimate||||2013-02-06|2013-02-12|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|CLOSER||Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)|Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)|Completed|||335|Actual|Abbott|||1||f||||f||||||||||2018-06-01 00:03:21.161396|2018-06-01 00:03:21.161396
NCT01075191|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2012-09-28||2013-01-14|2010-02-23|2010-02-25|Estimate|2012-09-28|2012-10-30|Estimate||||2013-01-14|2013-01-18|Estimate|January 2004||2004-01-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Kaletra: Therapy With Double Protease Inhibitors|PMOS: Kaletra Double Protease Inhibitors|Completed|||65|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:03:22.815488|2018-06-01 00:03:22.815488
NCT01075178|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2011-01-28||2011-03-18|2010-02-23|2010-02-25|Estimate|2011-01-28|2011-02-24|Estimate||||2011-03-18|2011-03-23|Estimate|July 2006||2006-07-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease|Palivizumab (Synagis®) Post-marketing Surveillance Cohort Study in Children < 24 Months of Age With Hemodynamically Significant Congenital Heart Disease|Completed|||2036|Actual|Abbott|Only serious adverse events of infection and arrhythmia as well as deaths were collected in this study. The criterion for non-inferiority was not met for death, most likely because the reported mortality rates were lower than expected in both groups.||2||f||||f||||||||||2018-06-01 00:03:23.631729|2018-06-01 00:03:23.631729
NCT01075165|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2015-02-02|2010-02-23|2010-02-24|Estimate|||||||2015-02-02|2015-02-04|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy of Spray Silicone in Alteration of Burn Scar|The Efficacy of Spray Silicone in the Alteration of Physical Burn Scar Characteristics: A Double Blinded Randomized Controlled Trial|Withdrawn||N/A|0|Actual|United States Army Institute of Surgical Research||2||IRB closed study due to no enrollment over 4 yrs|f||||f||||||||||2018-06-01 00:03:25.567385|2018-06-01 00:03:25.567385
NCT01075152|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2014-06-27||2015-08-13|2010-02-23|2010-02-24|Estimate|2014-07-31|2014-08-20|Estimate||||2015-08-13|2015-08-26|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|COAT|HIV-infected persons not previously receiving HIV therapy with first episode of cryptococcal meningitis diagnosed by CSF culture and/or CSF cryptococcal antigen testing.|Cryptococcal Optimal ART Timing Trial|Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis|Completed||Phase 4|177|Actual|University of Minnesota - Clinical and Translational Science Institute|The differences in mortality in the two arms were of sufficient magnitude that trial enrollment was stopped early by the Data and Safety Monitoring Board. Historically, trials stopped early routinely over-estimate the magnitude of benefit or harm.|2|||f||||t||||||||||2018-06-01 00:03:25.682064|2018-06-01 00:03:25.682064
NCT01075139|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2011-09-20|2010-02-23|2010-02-24|Estimate|||||||2011-09-20|2011-09-22|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Brief Motivational Intervention to Increase Physical Activity and Fruit/Vegetable Intake|Pilot Trial of a Brief Motivational Intervention to Increase Physical Activity and Fruit/Vegetable Intake Among College Students|Completed||Phase 2|70|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-06-01 00:03:26.58512|2018-06-01 00:03:26.58512
NCT01075126|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|December 2006||2006-12-31|February 2010|2010-02-28|December 2006|Anticipated|2006-12-31|December 2006|Anticipated|2006-12-31||Interventional|||Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder|Depakote Vs. Lithium in African Americans With Bipolar Disorder|Withdrawn||Phase 4|50|Anticipated|Lawson, William B., M.D., PhD, DFAPA||||key investigator relocated.|f||||||||||||||2018-06-01 00:03:26.66524|2018-06-01 00:03:26.66524
NCT01075113|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2017-09-11|2010-02-23|2010-02-24|Estimate|||||||2017-09-11|2017-09-12|Actual|August 10, 2010||2010-08-10|September 2017|2017-09-30|January 31, 2023|Anticipated|2023-01-31|February 2, 2017|Actual|2017-02-02||Interventional|||Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer|A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 1|16|Actual|Virginia Commonwealth University||2|||f||||t|t|f||||||||2018-06-01 00:03:26.764298|2018-06-01 00:03:26.764298
NCT01075100|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2016-01-12||2016-10-14|2010-02-23|2010-02-24|Estimate|2016-10-14|2016-12-07|Estimate||||2016-10-14|2016-12-07|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||ITT population|Ixabepilone + Carboplatin Metastatic Breast Cancer|Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPSE Study|Completed||Phase 2|103|Actual|US Oncology Research||1|||f||||t||||||||||2018-06-01 00:03:26.893723|2018-06-01 00:03:26.893723
NCT01075087|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2014-05-23||2014-05-23|2010-02-23|2010-02-24|Estimate|2014-05-23|2014-06-26|Estimate||||2014-05-23|2014-06-26|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Pre-Operative Transversus Abdominis Plane (TAP) Block in the Post Operative Opioid Consumption in Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery: A Prospective,Randomized, Blinded Study|TAP) Block in Morbid Obese Patients Undergoing Laparoscopic Gastric Bypass Surgery: A Prospective,Randomized, Blinded Study|Completed||N/A|19|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 00:03:27.614294|2018-06-01 00:03:27.614294
NCT01075074|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2012-03-06||2013-10-29|2010-02-23|2010-02-24|Estimate|2012-03-06|2012-04-03|Estimate||||2013-10-29|2013-11-21|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pre Operative Transversus Abdominis Plane Block Laparoscopic Gynecological Surgery|The Effect of Pre Operative Transversus Abdominis Plane (TAP) Block in the Quality of Recovery of Patients Undergoing Outpatient Laparoscopic Gynecological Surgery: A Prospective, Randomized Blinded Study|Completed||N/A|75|Actual|Northwestern University|We did not obtain local anesthetic levels to compare safety profile. We were underpowered to detect a difference in the physical comfort dimension of the QOR questionnaire between the ropivacaine groups and the saline group.|3|||f||||f||||||||||2018-06-01 00:03:27.964343|2018-06-01 00:03:27.964343
NCT01075048|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17||2015-10-22|2018-02-23|2010-02-23|2010-02-24|Estimate||||2015-10-22|2015-11-16|Estimate|2018-02-23|2018-02-26|Actual|January 2010||2010-01-31|February 2018|2018-02-28|September 2014|Actual|2014-09-30|January 2013|Actual|2013-01-31||Interventional|||ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer|A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy|Completed||Phase 1/Phase 2|150|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-06-01 00:03:28.589669|2018-06-01 00:03:28.589669
NCT01075035|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2015-12-09|2010-02-23|2010-02-24|Estimate|||||||2015-12-09|2015-12-11|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|SANIC||Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder|Evidence Based Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder at the Saint Louis University Advanced Neurosurgical Innovation Center (SANIC)|Completed|||224|Actual|St. Louis University|||3||f||||t||||||||||2018-06-01 00:03:28.741716|2018-06-01 00:03:28.741716
NCT01075022|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Effect of a Single Colecalciferol Dose on Insulin Resistance|Effect of a Single Colecalciferol Dose on Insulin Resistance: A Prospective Randomized Trial|Unknown status|Enrolling by invitation|N/A|136|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:03:28.812897|2018-06-01 00:03:28.812897
NCT01075009|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2014-07-08|2010-02-23|2010-02-24|Estimate|||||||2014-07-08|2014-07-09|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Predictors of Rates of Resistant Gram-Negative Bacteria|Predictors of Rates of Resistant Gram-Negative Bacteria in a Consortium of Academic Medical Center Hospitals.|Completed|||36|Actual|Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 00:03:28.893823|2018-06-01 00:03:28.893823
NCT01074996|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2014-01-15|2010-02-23|2010-02-24|Estimate|||||||2014-01-15|2014-01-16|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|October 2013|Actual|2013-10-31||Interventional|APC-S1||Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers|A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers|Unknown status|Active, not recruiting|Phase 2|92|Actual|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||t||||||||||2018-06-01 00:03:28.961512|2018-06-01 00:03:28.961512
NCT01074983|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2015-12-08|2010-02-23|2010-02-24|Estimate|||||||2015-12-08|2015-12-10|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Observational|||Pre-hospital Hypoxemia in Trauma Patients|Prevalence of Pre-hospital Hypoxemia in Trauma Patients: Do Trauma Patients Need Oxygen?|Completed|||224|Actual|University of Cincinnati|||2||f||||f||||||||||2018-06-01 00:03:29.071297|2018-06-01 00:03:29.071297
NCT01074970|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2018-02-20|2010-02-23|2010-02-24|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2010||2010-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations|PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146|Active, not recruiting||Phase 2|135|Actual|Hoosier Cancer Research Network||2|||f||||t||||||||||2018-06-01 00:03:29.160075|2018-06-01 00:03:29.160075
NCT01074957|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Effects of Physical Therapy on Cardiac Surgery|Effects of Physical Therapy on Pulmonary Volumes|Completed||N/A|35|Actual|Centro Universitário Augusto Motta||3|||f||||f||||||||||2018-06-01 00:03:29.281722|2018-06-01 00:03:29.281722
NCT01074944|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2016-10-07||2016-12-12|2010-02-23|2010-02-24|Estimate|2016-10-07|2016-12-02|Estimate||||2016-12-12|2017-02-06|Estimate|June 2010||2010-06-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||All treated (AT) analysis set included all participants who received at least 1 dose of eliglustat during LIP.|A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)|A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once Daily Versus Twice Daily Dosing of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638|Completed||Phase 3|170|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:03:29.444963|2018-06-01 00:03:29.444963
NCT01074931|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2011-05-20||2011-07-07|2010-02-23|2010-02-24|Estimate|2011-07-07|2011-08-03|Estimate||||2011-07-07|2011-08-03|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China|Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China: A Multicenter Post-Marketing Observational Study|Completed|||98|Actual|Abbott|The location of lipodystrophy was not summarized as there was not a place to record the information on the case report form. Too few participants withdrew from treatment to conduct planned analyses of duration to adverse event(s)/discontinuation.||1||f||||f||||||||||2018-06-01 00:03:30.809938|2018-06-01 00:03:30.809938
NCT01074918|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2018-05-18|2010-02-23|2010-02-24|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2009||2009-09-30|May 2018|2018-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients|Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients; Role of Natriuresis|Completed||Phase 1/Phase 2|35|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:03:31.267991|2018-06-01 00:03:31.267991
NCT01074905|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2013-08-27|2010-02-23|2010-02-24|Estimate|||||||2013-08-27|2013-08-28|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|VHX||Study on the Treatment of Vivax Malaria|A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border|Completed||Phase 3|655|Actual|University of Oxford||3|||f||||t||||||||||2018-06-01 00:03:31.337668|2018-06-01 00:03:31.337668
NCT01074892|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2012-05-11|2010-02-23|2010-02-24|Estimate|||||||2012-05-11|2012-05-14|Estimate|May 2005||2005-05-31|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|Mirena||A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia|A Multicenter Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia|Unknown status|Active, not recruiting|Phase 4|170|Actual|University Hospital of North Norway||3|||f||||f||||||||||2018-06-01 00:03:31.443851|2018-06-01 00:03:31.443851
NCT01074879|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|IceProQualita||Protein Ingestion and Resistance Exercise in Elderly|Effects of Protein Quantity and Quality in Combination With Resistance Exercise on Muscle Mass and -Strength in Icelandic Elderly.|Completed||N/A|220|Actual|University of Iceland||3|||f||||f||||||||||2018-06-01 00:03:31.55294|2018-06-01 00:03:31.55294
NCT01074866|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2012-09-20|2010-02-23|2010-02-24|Estimate|||||||2012-09-20|2012-09-21|Estimate|July 2010||2010-07-31|January 2010|2010-01-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Neurally Adjusted Ventilatory Assist for Non Invasive Ventilation and Patient-ventilator Interaction|The Effects of Neurally Adjusted Ventilatory Assist (NAVA) on Improving Patient-ventilator Interaction in Patients Undergoing Ventilation for Acute Respiratory Failure|Completed||N/A|13|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 00:03:31.622477|2018-06-01 00:03:31.622477
NCT01074853|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2013-02-06|2010-02-23|2010-02-24|Estimate|||||||2013-02-06|2013-02-07|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Beta Blockers for the Treatment of Asthma|Evaluation of Beta Blockers for the Treatment of Asthma. A Randomised Controlled Trial of Propranolol|Completed||Phase 2|18|Actual|University of Dundee||2|||f||||t||||||||||2018-06-01 00:03:31.714196|2018-06-01 00:03:31.714196
NCT01074840|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2014-12-01|2010-02-23|2010-02-24|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|DCOIT||Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy|Dendritic Cell Responses to Viral Stimulation in Peanut Allergic Subjects Undergoing Peanut Oral Immunotherapy|Completed||N/A|12|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:03:31.778869|2018-06-01 00:03:31.778869
NCT01074827|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2015-07-06|2010-02-23|2010-02-24|Estimate|||||||2015-07-06|2015-07-08|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Improving Gait in Multiple Sclerosis (MS) - Strength Training or Treadmill Walking?|Strength Training or Treadmill Walking? A Randomized Control Study on the Effect on Gait in Multiple Sclerosis|Completed||N/A|28|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-06-01 00:03:31.855615|2018-06-01 00:03:31.855615
NCT01074814|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-08-27|2010-02-23|2010-02-24|Estimate|||||||2013-08-27|2013-08-28|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Side-Out||Pilot Study Using Molecular Profiling to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.|A Pilot Study Utilizing Molecular Profiling by IHC, FISH, DNA Microarray, and Reverse Phase Protein Microarray (RPMA) of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer.|Completed||N/A|25|Actual|Translational Drug Development|||||f||||f||||||||||2018-06-01 00:03:31.958314|2018-06-01 00:03:31.958314
NCT01074801|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2011-04-05|2010-02-23|2010-02-24|Estimate|||||||2011-04-05|2011-04-06|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes|An Open-label, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of 36-hour Closed-loop Glucose Control in Comparison With Conventional Subcutaneous Insulin Pump Treatment in Adolescents With Type 1 Diabetes|Completed||Phase 2|12|Anticipated|University of Cambridge||2|||f||||f||||||||||2018-06-01 00:03:32.027452|2018-06-01 00:03:32.027452
NCT01074788|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|November 2009||2009-11-30|February 2010|2010-02-28||||November 2010|Anticipated|2010-11-30||Interventional|||Mind Body Therapy During Geriatric Rehabilitation||Unknown status|Active, not recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-06-01 00:03:32.092981|2018-06-01 00:03:32.092981
NCT01074775|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|September 2006||2006-09-30|February 2010|2010-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|UBC-INNATE01||Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection|An Investigation Of In Vivo Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection|Completed||N/A|7|Actual|St George's, University of London||1|||f||||f||||||||||2018-06-01 00:03:32.147034|2018-06-01 00:03:32.147034
NCT01074762|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|March 1989||1989-03-31|July 2003|2003-07-31|February 1996|Actual|1996-02-29|February 1996|Actual|1996-02-29||Interventional|DCGP||Randomised Controlled Trial of Structured Personal Care of Type 2 Diabetes Mellitus|The Diabetes Care in General Practice Study: Randomised Controlled Trial of Structured Personal Care of Type 2 Diabetes Mellitus|Completed||N/A|1470|Actual|Research Unit Of General Practice, Copenhagen||1|||f||||f||||||||||2018-06-01 00:03:32.21141|2018-06-01 00:03:32.21141
NCT01074749|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-07-07|2010-02-23|2010-02-24|Estimate|||||||2015-07-07|2015-07-08|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|OSAT||Optimal Sensing in Atrial Tachyarrhythmia's Study|OSAT: Optimal Sensing in Atrial Tachyarrhythmia's Study|Terminated||N/A|111|Actual|St. Jude Medical||2||Interim analysis indicated that endpoints can not be analysed with current dataset.|f||||t||||||||||2018-06-01 00:03:32.556458|2018-06-01 00:03:32.556458
NCT01074736|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-11-03|2010-02-23|2010-02-24|Estimate|||||||2010-11-03|2010-11-04|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Observational|||Host Genetic Susceptibility to Avian Influenza A/H5N1|Host Genetic Susceptibility to Avian Influenza A/H5N1 in Vietnam, Thailand, Indonesia and Singapore|Completed|||500|Actual|South East Asia Infectious Disease Clinical Research Network|||||f||||t||||||Samples With DNA|"~     -  whole blood in tubes containing EDTA~        -  mouth wash.~        -  buffy coat; cell pellet from centrifuged blood, nucleic acid extracted for diagnostic~          purposes, serum, throat, nose or endotracheal swabs~   "|||2018-06-01 00:03:32.633588|2018-06-01 00:03:32.633588
NCT01074723|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2014-02-07|2010-02-23|2010-02-24|Estimate|||||||2014-02-07|2014-02-10|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|December 2012|Actual|2012-12-31|July 2010|Actual|2010-07-31||Interventional|||B-cryptoxanthin and Phytosterols on Bone Remodeling and Cardiovascular Risk Factors|Bioavailability of Added B-cryptoxanthin and Phytosterols; In Vitro and in Vivo Interactions and Effect on Bone Remodelling and Cardiovascular Risk Markers|Completed||Phase 1|36|Actual|Puerta de Hierro University Hospital||3|||f||||f||||||||||2018-06-01 00:03:32.765163|2018-06-01 00:03:32.765163
NCT01074710|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-07-16|2010-02-23|2010-02-24|Estimate|||||||2010-07-16|2010-07-19|Estimate|February 2010||2010-02-28|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers|A Phase I, Double-Blind, Placebo-Controlled, Randomized, 3-Period, Safety and Pharmacokinetic Study of 13C-uracil in a Semi-solid Meal at Single Oral Doses of 50, 100, and 200 mg in Healthy Volunteers|Completed||Phase 1|8|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:03:32.834333|2018-06-01 00:03:32.834333
NCT01074697|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2015-04-23|2010-02-23|2010-02-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|GAND-emesis||Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin|A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin.|Completed||Phase 3|246|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 00:03:32.893263|2018-06-01 00:03:32.893263
NCT01074684|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2015-11-27|2010-02-23|2010-02-24|Estimate|||||||2015-11-27|2015-11-30|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|TIR-2009-01||Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer|Defining Predictive Factors of Clinical, Laboratory and Imaging Criteria Routinely Used in the Diagnosis of Thyroid Cancer: Observational, Prospective Multicentered Study|Unknown status|Active, not recruiting||959|Actual|National Cancer Institute, Naples|||||f||||f||||||||||2018-06-01 00:03:33.250636|2018-06-01 00:03:33.250636
NCT01074671|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2015-10-28|2010-02-23|2010-02-24|Estimate|||||||2015-10-28|2015-10-29|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||CG Future® Annuloplasty Ring/Band Clinical Trial|Colvin-Galloway Future® Annuloplasty Ring/Band Clinical Trial: Interventional Multi-center Prospective Clinical Outcome Study|Completed||Phase 4|77|Actual|Medtronic Cardiovascular||1|||f||||f||||||||||2018-06-01 00:03:33.347288|2018-06-01 00:03:33.347288
NCT01074658|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|2016-07-13||2017-10-25|2010-02-23|2010-02-24|Estimate|2016-08-30|2016-10-21|Estimate||||2017-10-25|2017-12-02|Actual|March 2010||2010-03-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|November 2011|Actual|2011-11-30||Observational|||CoreValve Advance International Post Market Study|"CoreValve Advance International Post Market Study: Evaluation of the Medtronic CoreValve System in a Real-World Patient Population."|Completed|||1015|Actual|Medtronic Cardiovascular|||1||f||||f||||||||||2018-06-01 00:03:33.444082|2018-06-01 00:03:33.444082
NCT01074645|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|ACLF||Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure|Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial|Completed||Phase 4|27|Actual|Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-06-01 00:03:33.744546|2018-06-01 00:03:33.744546
NCT01074632|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2011-09-06|2010-02-23|2010-02-24|Estimate|||||||2011-09-06|2011-09-08|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl|A Phase 1, Open-Label Study to Determine the Effect of Calories and Fat Content on the Pharmacokinetics of Repeated Dose Lurasidone 120 mg in Subjects With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.|Completed||Phase 1|26|Actual|Sunovion|||||f||||||||||||||2018-06-01 00:03:33.838097|2018-06-01 00:03:33.838097
NCT01074619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-08-31|2010-02-23|2010-02-24|Estimate|||||||2012-08-31|2012-09-03|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||Study on Cognitive Disorders of Multiple Sclerosis|Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis|Completed||Phase 3|90|Actual|University Hospital, Caen||2|||f||||||||||||||2018-06-01 00:03:33.938659|2018-06-01 00:03:33.938659
NCT01074606|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2012-09-18|2010-02-23|2010-02-24|Estimate|||||||2012-09-18|2012-09-19|Estimate|January 2010||2010-01-31|August 2011|2011-08-31||||March 2011|Actual|2011-03-31||Interventional|||Visual Function After Implantation of AcrySof® Toric Lens||Terminated||Phase 4|56|Actual|Alcon Research||1||The study was terminated based on a business decision.|f||||f||||||||||2018-06-01 00:03:34.073851|2018-06-01 00:03:34.073851
NCT01074593|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2013-02-22|2010-02-23|2010-02-24|Estimate|||||||2013-02-22|2013-02-25|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects|Clinical Study of Pharmacokinetics and Pharmacodynamics of the Drug Interferon Beta-1a Produced By Laboratorio Quimico Farmaceutico Bergamo Compared To Interferon Beta-1a (Rebif - Merck Serono) In Healthy Subjects|Completed||Phase 1|20|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:03:34.133792|2018-06-01 00:03:34.133792
NCT01074580|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2016-01-25|2010-02-23|2010-02-24|Estimate|||||||2016-01-25|2016-01-26|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease|High Frequency Ultrasound and Contrast Enhanced Ultrasound of Patients Treated for Deterioration of Crohn's Disease|Terminated|||20|Actual|Haukeland University Hospital|||1|Did not get enough patients|f||||f||||||Samples With DNA|"~     Mucosal biopsies from the colon and terminal ileum.~   "|||2018-06-01 00:03:34.193253|2018-06-01 00:03:34.193253
NCT01074567|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2011-04-04|2010-02-23|2010-02-24|Estimate|||||||2011-04-04|2011-04-05|Estimate|December 2009||2009-12-31|March 2010|2010-03-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||DMSO Efficacy in IC/PBS Patients During and After Treatment|Efficacy of DMSO Cocktail Treatment in Interstitial Cystitis Patients During and After Treatment|Unknown status|Recruiting|N/A|50|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-06-01 00:03:34.249138|2018-06-01 00:03:34.249138
NCT01074554|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2012-10-26||2016-10-27|2010-02-23|2010-02-24|Estimate|2016-09-03|2016-10-27|Estimate||||2016-10-27|2016-12-12|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|CLEAR||Trial of Antimycobacterial Therapy in Sarcoidosis|Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis|Completed||Phase 1/Phase 2|30|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 00:03:34.334141|2018-06-01 00:03:34.334141
NCT01074541|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|January 2008||2008-01-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|March 2008|Actual|2008-03-31||Interventional|||The Vitamin D Dose-Response Relationship|Vitamin D Production Depends on Ultraviolet-B Dose But Not on UV-intensity. A Randomized Controlled Trial|Completed||N/A|55|Actual|Bispebjerg Hospital||4|||f||||f||||||||||2018-06-01 00:03:34.550399|2018-06-01 00:03:34.550399
NCT01074528|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-07-13|2010-02-23|2010-02-24|Estimate|||||||2017-07-13|2017-07-17|Actual|April 2010||2010-04-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Mindfulness Based Stress Reduction: Supportive Treatment for Adult Patients With Cancer and Their Partners|Mindfulness Based Stress Reduction: Supportive Treatment for Adult Patients With Cancer and Their Partners|Completed||N/A|150|Actual|Belgian Federal Public Service, Food Chain Safety and Environment||2|||f||||f||||||||||2018-06-01 00:03:34.635783|2018-06-01 00:03:34.635783
NCT01074515|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2015-12-01|2010-02-22|2010-02-24|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|CASCADE||Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)|Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation|Unknown status|Active, not recruiting||350|Anticipated|University of Washington|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:03:34.820025|2018-06-01 00:03:34.820025
NCT01074502|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2011-10-06||2017-02-01|2010-02-23|2010-02-24|Estimate|2012-03-08|2012-03-12|Estimate||||2017-02-01|2017-03-13|Actual|February 2010||2010-02-28|February 2017|2017-02-28|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Apremilast in the Treatment of Moderate to Severe Acne|An Open-label, Single-arm Pilot Study of the Safety and Efficacy of an Oral PDE4-inhibitor Agent, Apremilast, in the Treatment of Moderate to Severe Acne|Terminated||Phase 2|3|Actual|University of North Carolina, Chapel Hill||1||lack of funding due to Celgene administrative decision|f||||t||||||||||2018-06-01 00:03:34.912986|2018-06-01 00:03:34.912986
NCT01074489|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-08-21|2010-02-23|2010-02-24|Estimate|||||||2015-08-21|2015-08-25|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Challenging the Gold Standard: Pilot Study Comparing Continuous Glucose Monitoring System (CGMS), Capillary Glucose Monitors and 3 Hour Glucose Tolerance Test (GTT) to Diagnose Gestational Diabetes Mellitus (GDM)|Challenging the Gold Standard: A Pilot Study Comparing CGMS and Capillary Glucose Monitors Versus 3 Hour GTT to Diagnose Gestational Diabetes Mellitus|Completed|||7|Actual|University of Cincinnati|||||f||||f||||||||||2018-06-01 00:03:35.133934|2018-06-01 00:03:35.133934
NCT01074476|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2016-06-28|2010-02-23|2010-02-24|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Glucosamine on Joint Fluid in Osteoarthritis Patients|Investigation of Oral Glucosamine Effects on Synovial Fluid Viscosity and Viscoelasticity in Osteoarthritis Patients|Active, not recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:03:35.229983|2018-06-01 00:03:35.229983
NCT01074463|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2010-04-08||2010-04-08|2010-02-23|2010-02-24|Estimate|2010-04-08|2010-04-30|Estimate||||2010-04-08|2010-04-30|Estimate|February 2005||2005-02-28|April 2010|2010-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 0.25 mg Pramipexole Dihydrochloride Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 00:03:35.323859|2018-06-01 00:03:35.323859
NCT01074450|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2010-04-08||2010-04-08|2010-02-23|2010-02-24|Estimate|2010-04-08|2010-04-30|Estimate||||2010-04-08|2010-04-30|Estimate|February 2005||2005-02-28|April 2010|2010-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 0.25 mg Pramipexole Dihydrochloride Tablets Under Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 00:03:35.685067|2018-06-01 00:03:35.685067
NCT01074437|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2013-07-22||2013-12-11|2010-02-23|2010-02-24|Estimate|2013-07-22|2013-09-26|Estimate||||2013-12-11|2014-01-13|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Interventional|||Corticosteroids With Placebo Versus Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)|A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)|Terminated||Phase 2|9|Actual|Seattle Children's Hospital|Trial limited by lack of patient family to have randomization, which limited the number of participants and made the project nonviable.|2||Insufficient enrollment|f||||t||||||||||2018-06-01 00:03:36.010127|2018-06-01 00:03:36.010127
NCT01074424|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|February 2010||2010-02-28|February 2010|2010-02-28||||March 2010|Anticipated|2010-03-31||Observational|||Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer|Development of a Serum Proteomic Profile for Cervical Cancer With Potential Prognostic Value|Unknown status|Not yet recruiting||84|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:03:36.244699|2018-06-01 00:03:36.244699
NCT01074411|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2018-05-23|2010-02-23|2010-02-24|Estimate|||||||2018-05-23|2018-05-24|Actual|April 5, 2010|Actual|2010-04-05|May 2018|2018-05-31||||April 4, 2014|Actual|2014-04-04||Interventional|||Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Active, not recruiting||Phase 1|33|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:03:36.318743|2018-06-01 00:03:36.318743
NCT01074398|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-23|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|February 2010||2010-02-28|February 2010|2010-02-28||||March 2010|Anticipated|2010-03-31||Observational|||Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182|ERCC1 Expression as a Predictor of Progression Free and Overall Survival in Patients With Epithelial Ovarian Cancer Treated on GOG Protocols 0172 and 0182|Unknown status|Not yet recruiting||513|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:03:36.468033|2018-06-01 00:03:36.468033
NCT01074385|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-09-13|2010-02-23|2010-02-24|Estimate|||||||2013-09-13|2013-09-16|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Dignity Therapy in mCRC to Increase Peaceful Awareness & Impact Goals of Care Decision-Making|Use of Dignity Therapy in Stage IV Colorectal Cancer Patients Receiving Chemotherapy to Increase Peaceful Awareness and Impact Goals of Care Decision-Making|Completed||N/A|24|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 00:03:36.528912|2018-06-01 00:03:36.528912
NCT01074372|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-01-24|2010-02-23|2010-02-24|Estimate|||||||2015-01-24|2015-01-27|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers|A Randomized, Double-Blind,Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of Subcutaneously Administered REGN727 in Healthy Volunteers|Completed||Phase 1|32|Actual|Regeneron Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:03:36.597382|2018-06-01 00:03:36.597382
NCT01074203|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2012-07-27|2010-02-22|2010-02-24|Estimate|||||||2012-07-27|2012-07-31|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation|A Pilot Study to Explore a Potential Role of Nitazoxanide (NTZ) in the Prevention of Recurrent Hepatitis C Virus (HCV) Infection After Orthotopic Liver Transplantation|Completed||Phase 1|8|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:03:39.30517|2018-06-01 00:03:39.30517
NCT01074359|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2011-04-21|2010-02-23|2010-02-24|Estimate|||||||2011-04-21|2011-04-22|Estimate|February 2010||2010-02-28|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation|A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 Day, Two-arm, Parallel Group Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitochondrial Function|Terminated||Phase 2|30|Anticipated|Penwest Pharmaceuticals Co.||2||"Terminated for Commercial Reasons. There were no safety issues involved in the decision to~   terminate the study."|f||||f||||||||||2018-06-01 00:03:36.665993|2018-06-01 00:03:36.665993
NCT01074346|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-02-16|2010-02-22|2010-02-24|Estimate|||||||2014-02-16|2014-02-19|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis|A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif®) Therapy for Korean Patients With Multiple Sclerosis|Completed|||60|Actual|Merck KGaA|||||f||||f||||||||||2018-06-01 00:03:36.747261|2018-06-01 00:03:36.747261
NCT01074333|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-06-16|2010-02-22|2010-02-24|Estimate|||||||2014-06-16|2014-06-17|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment|Prospective, Multicenter, Observational Study on Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer|Terminated|||146|Actual|Merck KGaA||||This study was terminated due to low recruitment|f||||f||||||||||2018-06-01 00:03:36.803981|2018-06-01 00:03:36.803981
NCT01074320|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-12-15|2010-02-23|2010-02-24|Estimate|||||||2015-12-15|2015-12-16|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|AIMS||Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors|Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors|Completed|||150|Actual|HealthPartners Institute|||1||f||||f||||||||||2018-06-01 00:03:36.868869|2018-06-01 00:03:36.868869
NCT01074307|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2013-07-30||2014-01-13|2010-02-22|2010-02-24|Estimate|2014-01-13|2014-02-14|Estimate||||2014-01-13|2014-02-14|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PRISM|Intention-to-treat (ITT) population included all the randomized participants who had at least one dose of the investigational product. Baseline data has been provided for 159 participants (ITT population).|A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea|Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM)|Completed||Phase 4|180|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:03:36.943193|2018-06-01 00:03:36.943193
NCT01074294|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22||2012-10-23|2012-10-23|2010-02-23|2010-02-24|Estimate||||2012-10-23|2012-10-30|Estimate|2012-10-23|2012-10-30|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|STEP-A||Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/ Hyperactivity Disorder|Completed||Phase 2|740|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-06-01 00:03:37.442594|2018-06-01 00:03:37.442594
NCT01074281|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-02-16|2010-02-22|2010-02-24|Estimate|||||||2014-02-16|2014-02-19|Estimate|June 2008||2008-06-30|February 2014|2014-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)|Examination of Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With ENEAS®.|Completed|||2065|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 00:03:37.55167|2018-06-01 00:03:37.55167
NCT01074268|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2015-10-15|2011-02-25|2017-01-20|2010-02-22|2010-02-24|Estimate|2015-10-15|2015-11-16|Estimate|2011-02-25|2011-03-11|Estimate|2017-01-20|2017-03-06|Actual|February 2010||2010-02-28|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|BEGIN™||Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes|NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen / NN1250-3725: An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN™: BB T1)|Completed||Phase 3|456|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:03:37.649851|2018-06-01 00:03:37.649851
NCT01074255|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2012-08-31||2015-04-02|2010-02-22|2010-02-24|Estimate|2012-08-31|2012-10-05|Estimate||||2015-04-02|2015-04-21|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Re-examination Study of EMEND (Aprepitant) (MK-0869-184)|Re-examination Study For General Drug Use to Assess the Safety and Efficacy Profile of EMEND in Usual Practice|Completed|||3546|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:03:38.332756|2018-06-01 00:03:38.332756
NCT01074242|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2014-02-11||2017-03-16|2010-02-22|2010-02-24|Estimate|2014-02-11|2014-03-27|Estimate||||2017-03-16|2017-04-13|Actual|September 2007||2007-09-30|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||Baseline characteristics were reported for all enrolled participants who received at least 1 dose of study vaccine|ROTATEQ Reexamination Study (V260-037)|Re-examination Study for General Vaccine Use to Assess the Safety Profile of ROTATEQ in Usual Practice|Completed|||3798|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:03:38.540607|2018-06-01 00:03:38.540607
NCT01074229|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2013-04-04||2014-04-09|2010-02-23|2010-02-24|Estimate|2014-04-09|2014-05-08|Estimate||||2014-04-09|2014-05-08|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|TAP HYS||Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy|The Effect of Pre-operative Transversus Abdominis Plane (TAP) Block in the Quality of Recovery of Patients Undergoing Laparoscopic Hysterectomy: a Prospective, Randomized, Blinded Study|Completed||N/A|75|Actual|Northwestern University|Ropivacaine blood levels were not obtained. Distribution of study drug unable to gauge due to general anesthesia. Study underpowered to detect a difference in opioid consumption or global QoR-40 between the ropivacaine 0.25% and 0.5% groups.|3|||f||||f||||||||||2018-06-01 00:03:38.691272|2018-06-01 00:03:38.691272
NCT01074216|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2016-01-04||2016-01-04|2010-02-22|2010-02-24|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Vitamin D Levels in Stage IV Colorectal Cancer Patients|Vitamin D Levels in Stage IV Colorectal Cancer Patients: A Phase II Study|Completed||Phase 2|45|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:03:39.10165|2018-06-01 00:03:39.10165
NCT01074164|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2012-07-30||2014-12-11|2010-02-23|2010-02-24|Estimate|2012-12-10|2013-01-16|Estimate||||2014-12-11|2015-01-05|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Acupressure in Pruritus for Atopic Dermatitis|Evaluating the Effectiveness of Acupressure in Relieving Pruritus Related to Atopic Dermatitis|Completed||N/A|15|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 00:03:39.847577|2018-06-01 00:03:39.847577
NCT01074151|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2017-12-06|2010-02-22|2010-02-24|Estimate|||||||2017-12-06|2017-12-08|Actual|July 2009||2009-07-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Cymbalta Pregnancy Registry|The Cymbalta Pregnancy Registry|Recruiting|||484|Anticipated|Eli Lilly and Company|||1||f||||t||||||||||2018-06-01 00:03:40.210361|2018-06-01 00:03:40.210361
NCT01074138|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2016-11-14|2010-02-22|2010-02-24|Estimate|||||||2016-11-14|2016-11-15|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy|A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy|Completed||Phase 2|31|Actual|Athenex, Inc.||1|||f||||f||||||||||2018-06-01 00:03:40.29368|2018-06-01 00:03:40.29368
NCT01074125|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2014-10-04||2014-12-03|2010-02-22|2010-02-24|Estimate|2014-12-03|2014-12-04|Estimate||||2014-12-03|2014-12-04|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Intent-to-treat|A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease|A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period|Completed||Phase 3|154|Actual|Keryx Biopharmaceuticals||3|||f||||t||||||||||2018-06-01 00:03:40.416343|2018-06-01 00:03:40.416343
NCT01074112|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-23|2010-02-23|2010-02-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|March 2010||2010-03-31|February 2010|2010-02-28||||||||Observational|||Keller Prehospital Ultrasound Study|Keller Fire Rescue Study of Prehospital Ultrasound Use|Unknown status|Not yet recruiting||30|Anticipated|Keller Fire Rescue|||10||f||||f||||||||||2018-06-01 00:03:42.294221|2018-06-01 00:03:42.294221
NCT01074099|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2014-08-18||2015-12-14|2010-02-22|2010-02-24|Estimate|2015-12-14|2016-01-18|Estimate||||2015-12-14|2016-01-18|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Feasibility Study of BMAC Enhanced CABG|Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery|Terminated||Phase 1/Phase 2|5|Actual|Harvest Technologies|The study was terminated early. Only 5 subjects were enrolled and they were followed for a year for safety data only. One efficacy data was collected.|2||Pilot results in change to protocol, new study needed.|f||||f||||||||||2018-06-01 00:03:42.505635|2018-06-01 00:03:42.505635
NCT01074086|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2012-12-21|2010-02-23|2010-02-24|Estimate|||||||2012-12-21|2012-12-24|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase I Study in RAD 001 Patients With Relapse AML|Multicentric Study of GOELAMS Phase I Evaluation of RAD001 in Association With Aracytine and Daunorubicine in AML Treatment in Patients Less Than 65 Years in Relapse More Than One Year After First Complete Remission|Completed||Phase 1|31|Actual|French Innovative Leukemia Organisation||1|||f||||t||||||||||2018-06-01 00:03:42.879907|2018-06-01 00:03:42.879907
NCT01074073|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2011-09-06|2010-02-22|2010-02-24|Estimate|||||||2011-09-06|2011-09-08|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Lithium Drug-Drug Interaction Study With Lurasidone HCl|A Phase 1, Open-Label, 2-Period, Sequential, Drug-Drug Interaction Study To Determine The Effect Of Lithium 600 Mg BID On The Safety And Pharmacokinetics Of Lurasidone 120 Mg QD In Patients With Schizophrenia Or Schizoaffective Disorder|Completed||Phase 1|24|Actual|Sunovion||1|||f||||t||||||||||2018-06-01 00:03:43.18555|2018-06-01 00:03:43.18555
NCT01074060|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2013-02-13|2010-02-22|2010-02-24|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma|A Phase I/Pilot Study of Intravenous PLERIXAFOR Following Cyclophosphamide Mobilization in Patients With Multiple Myeloma|Completed||Phase 1|18|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 00:03:43.340224|2018-06-01 00:03:43.340224
NCT01074047|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2015-01-22||2017-08-25|2010-02-22|2010-02-24|Estimate|2015-02-10|2015-02-26|Estimate||||2017-08-25|2017-08-29|Actual|June 1, 2010|Actual|2010-06-01|August 2017|2017-08-31|July 25, 2016|Actual|2016-07-25|January 22, 2014|Actual|2014-01-22||Interventional||The intent-to-treat (ITT) population is defined as all participants who were randomized, independent of whether they received study treatment or not.|Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)|A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 3|488|Actual|Celgene||2|||f||||t|t|f||||||||2018-06-01 00:03:43.712995|2018-06-01 00:03:43.712995
NCT01074034|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2017-03-17||2017-07-05|2010-02-22|2010-02-24|Estimate|2017-05-17|2017-06-14|Actual||||2017-07-05|2017-08-01|Actual|April 2006||2006-04-30|July 2017|2017-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|REASSURE||REASSURE AV Registry|Clinical Research Evaluation of the ASSURE Device Atrial and Ventricular Tachyarrhythmia Therapies Registry|Completed||N/A|211|Actual|Boston Scientific Corporation||1|||f||||f||||||||No||2018-06-01 00:03:47.188323|2018-06-01 00:03:47.188323
NCT01074021|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-21|||2015-10-28|2010-02-22|2010-02-24|Estimate|||||||2015-10-28|2015-10-30|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer|A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer|Unknown status|Active, not recruiting|Phase 3|480|Anticipated|Biotech Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-06-01 00:03:47.460966|2018-06-01 00:03:47.460966
NCT01073839|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2015-09-17|2010-02-22|2010-02-23|Estimate|||||||2015-09-17|2015-09-18|Estimate|August 2008||2008-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.|Adjuvant Treatment of Resectable Cholangiocellular Carcinoma (CCC) With Cisplatin Plus Gemcitabine. A Prospective Single Center Phase Ib-II Study.|Completed||Phase 1/Phase 2|33|Actual|University of Zurich||1|||f||||t||||||||||2018-06-01 00:03:52.957988|2018-06-01 00:03:52.957988
NCT01074008|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2014-12-29|2012-06-25|2014-12-29|2010-02-22|2010-02-24|Estimate|2014-12-29|2015-01-08|Estimate|2012-06-25|2012-07-02|Estimate|2014-12-29|2015-01-08|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|Champion2|All participants who recieved at least one dose of study drug were included in the baseline characteristic analaysis.|A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072|A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|74|Actual|AbbVie||9|||f||||f||||||||||2018-06-01 00:03:47.660129|2018-06-01 00:03:47.660129
NCT01073995|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2016-09-28|2010-02-22|2010-02-24|Estimate|||||||2016-09-28|2016-09-29|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery|The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery in Patients With Lumbar Disc Herniations|Completed||Phase 3|54|Actual|Horizon Health Network||2|||f||||t||||||||Yes|Manuscript preparation in progress|2018-06-01 00:03:50.017876|2018-06-01 00:03:50.017876
NCT01073982|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2011-01-19|2010-02-22|2010-02-24|Estimate|||||||2011-01-19|2011-01-20|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Tart Cherry Juice to Reduce Pain and Inflammation Among Patients With Inflammatory Osteoarthritis|Efficacy of Tart Cherry Juice to Reduce Pain and Inflammation Among Patients With Inflammatory Osteoarthritis|Completed||Phase 4|20|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 00:03:50.103854|2018-06-01 00:03:50.103854
NCT01073969|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Study to Determine the Digestive and Physiological Effects of an Extract From Bran in Healthy Men and Women|A Double-blind, Randomized, Controlled Crossover Trial to Assess the Digestive and Physiological Effects of a Wheat Bran Extract in Healthy Men and Women|Completed||Phase 4|65|Actual|Kellogg Company||3|||f||||f||||||||||2018-06-01 00:03:50.192987|2018-06-01 00:03:50.192987
NCT01073956|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2011-07-06|2010-02-22|2010-02-23|Estimate|||||||2011-07-06|2011-07-07|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Electrotherapy in Subacromial Impingement Syndrome|Efficacy of Electrotherapy in Subacromial Impingement Syndrome: Randomised Placebo-controlled Clinical Trial|Unknown status|Active, not recruiting|N/A|92|Actual|Fundacio Espai Salut||3|||f||||||||||||||2018-06-01 00:03:50.287676|2018-06-01 00:03:50.287676
NCT01073943|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2012-08-10|2011-10-28|2012-10-23|2010-02-22|2010-02-23|Estimate|2012-08-10|2012-09-11|Estimate|2011-10-28|2011-10-31|Estimate|2012-10-23|2012-10-30|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep|"A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety and Tolerability of Day Before PicoPrep™ for Oral Administration Versus HalfLytely® for Colon Cleansing in Preparation for Colonoscopy"|Completed||Phase 3|603|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:03:50.405831|2018-06-01 00:03:50.405831
NCT01073930|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2012-08-10|2011-10-28|2013-02-11|2010-02-22|2010-02-23|Estimate|2012-08-10|2012-09-11|Estimate|2011-10-28|2011-10-31|Estimate|2013-02-11|2013-02-12|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep|"A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety and Tolerability of Split-Dose PicoPrep™ for Oral Administration Versus HalfLytely® for Colon Cleansing in Preparation for Colonoscopy"|Completed||Phase 3|608|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:03:51.094076|2018-06-01 00:03:51.094076
NCT01073917|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-10-28|2010-02-22|2010-02-23|Estimate|||||||2010-10-28|2010-10-29|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|SBAFGA||Effects of Spontaneous Breathing Activity on Atelectasis Formation During General Anaesthesia|Effects of Spontaneous Breathing Activity on Atelectasis Formation During General Anaesthesia: A Randomized Clinical Trial|Completed||N/A|30|Anticipated|Technische Universität Dresden||3|||f||||f||||||||||2018-06-01 00:03:51.644937|2018-06-01 00:03:51.644937
NCT01073904|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-04-01|2010-02-22|2010-02-23|Estimate|||||||2014-04-01|2014-04-03|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|LEVEQ-3||Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg|Open-label, Randomized, Crossover Study to Prove the Bioequivalence Between Opxion® (Levonorgestrel 1.5 mg Coated Tablet From Bayer de Mexico) and Postinor 2® (Levonorgestrel 1.5 mg Tablet From Biofarma Natural CMD) in Healthy Volunteers|Completed||Phase 1|32|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:03:51.731616|2018-06-01 00:03:51.731616
NCT01073891|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-06-30|2010-02-22|2010-02-23|Estimate|||||||2015-06-30|2015-07-01|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults|Single-dose, Open-label, Randomized, Non-blinded, Three-fold Crossover Study in Healthy Subjects to Compare the Bioavailability of Moxifloxacin (BAY12-8039) 400 mg Tablet and 400 mg Oral Suspension Under Fasting Conditions, and to Investigate the Effect of Food on the Bioavailability of 400 mg Suspension.|Completed||Phase 1|24|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:03:51.793209|2018-06-01 00:03:51.793209
NCT01073878|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2011-07-13|2010-02-22|2010-02-23|Estimate|||||||2011-07-13|2011-07-14|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|DUETS||Athena Pelvic Muscle Trainer - DUETS Trial|"Athena PMT - Device to Treat Urinary Incontinence - Effectiveness, Tolerability and Satisfaction Athena D.U.E.T.S. Trial"|Completed||Phase 4|462|Actual|Athena Feminine Technologies, Inc.|||||f||||f||||||||||2018-06-01 00:03:51.871807|2018-06-01 00:03:51.871807
NCT01073865|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2013-08-19||2018-02-05|2010-02-22|2010-02-23|Estimate|2013-12-09|2014-01-10|Estimate||||2018-02-05|2018-03-01|Actual|February 26, 2010|Actual|2010-02-26|January 2018|2018-01-31|November 20, 2017|Actual|2017-11-20|September 19, 2012|Actual|2012-09-19||Interventional|||Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer|An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer.|Completed||Phase 3|222|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:03:52.350786|2018-06-01 00:03:52.350786
NCT01073826|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2016-10-31|2010-02-22|2010-02-23|Estimate|||||||2016-10-31|2016-11-01|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|Exil-6||Role of Interleukin-6 in Exercise|A Lifestyle Intervention Study Investigating the Role of Interleukin-6 in the Beneficial Effect of Exercise on Beta-cell Function in Obese People and Patients With Type 2 Diabetes|Completed||N/A|56|Actual|University of Zurich||3|||f||||t||||||||||2018-06-01 00:03:53.080383|2018-06-01 00:03:53.080383
NCT01073813|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-01-21|2010-02-22|2010-02-23|Estimate|||||||2013-01-21|2013-01-23|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional|Mino in ON||Neuroprotection and Repair in Optic Neuritis|Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON)|Terminated||Phase 2|6|Actual|University of Calgary||2||Lack of recruitment|f||||f||||||||||2018-06-01 00:03:53.155744|2018-06-01 00:03:53.155744
NCT01073800|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2011-12-15|2010-02-22|2010-02-23|Estimate|||||||2011-12-15|2011-12-16|Estimate|April 2009||2009-04-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|August 2009|Actual|2009-08-31||Interventional|VASTVALUS||Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill|Using AtorVASTatin to Prevent VAscular Inflammatory OccLUSion in the Critically Ill|Completed||Phase 2/Phase 3|100|Anticipated|University of Alberta||2|||f||||t||||||||||2018-06-01 00:03:53.227212|2018-06-01 00:03:53.227212
NCT01073787|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2016-11-03|2010-02-22|2010-02-23|Estimate|||||||2016-11-03|2016-11-07|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|EDMigraine3||Intravenous Fluid for Pediatric Migraine in the Emergency Department|Single-blind, Placebo-challenge Study of Intravenous Fluid Hydration in the Management of Pediatric Migraine in the Emergency Department|Completed||Phase 1/Phase 2|46|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 00:03:53.317534|2018-06-01 00:03:53.317534
NCT01073774|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|February 2006||2006-02-28|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Side by Side||Side by Side - Prediction of Couples' Adjustment to Breast or Gynecological Cancer|Side by Side - Prediction of Couples' Adjustment to Breast or Gynecological Cancer|Completed||Phase 2|||Technical University of Braunschweig||2|||f||||f||||||||||2018-06-01 00:03:53.431592|2018-06-01 00:03:53.431592
NCT01073761|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-08-13|2010-02-22|2010-02-23|Estimate|||||||2010-08-13|2010-08-16|Estimate|April 2010||2010-04-30|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study|Pharmacokinetics of Darunavir/Ritonavir Once Daily and Atazanavir/Ritonavir Once Daily Over 72 Hours Following Drug Intake Cessation|Completed||Phase 1|25|Anticipated|St Stephens Aids Trust||1|||f||||f||||||||||2018-06-01 00:03:53.485682|2018-06-01 00:03:53.485682
NCT01073748|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2011-01-23|2010-02-22|2010-02-23|Estimate|||||||2011-01-23|2011-01-25|Estimate|March 2010||2010-03-31|January 2011|2011-01-31||||March 2011|Anticipated|2011-03-31||Interventional|||The Effect of Single Dose Paracetamol on the Lower Airways of Asthmatic and Healthy Children|The Effect of Paracetamol on Lower Airway Obstruction in Asthmatic Versus Non Asthmatic Children|Unknown status|Recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:03:53.557779|2018-06-01 00:03:53.557779
NCT01073735|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2012-02-08|2010-02-22|2010-02-23|Estimate|||||||2012-02-08|2012-02-09|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience|Investigating the Needs of Childhood Cancer Survivors: The Unreported Experience|Completed|||1178|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 00:03:53.67416|2018-06-01 00:03:53.67416
NCT01073722|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2011-04-29|2010-02-22|2010-02-23|Estimate|||||||2011-04-29|2011-05-02|Estimate|February 2010||2010-02-28|August 2010|2010-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||EZ Blocker Versus Left Sided Double-lumen Tube|Endobronchial EZ Blocker Compared to Left Sided Double-lumen Tube for One-lung Ventilation|Completed||Phase 4|100|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 00:03:53.73355|2018-06-01 00:03:53.73355
NCT01073709|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Relative Bioavailability Study of Acetaminophen 650 mg Extended Release Gelcaps Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioavailability Study Comparing Acetaminophen 650 mg Extended Release Gelcaps of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc.), With Tylenol® Arthritis Pain Extended Release Caplets (Containing Acetaminophen 650 mg) of Mc Neil-PPC Inc., in Healthy, Adult, Human, Male Subjects Under Fasting Condition.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-06-01 00:03:53.796818|2018-06-01 00:03:53.796818
NCT01073696|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-09-24|2010-02-22|2010-02-23|Estimate|||||||2010-09-24|2010-09-27|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects|A Phase I Study to Evaluate the Effect of External Heat on the Pharmacokinetics of a Transdermal Granisetron Patch in Healthy Subjects|Completed||Phase 1|16|Actual|Prostrakan Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:03:53.883214|2018-06-01 00:03:53.883214
NCT01073683|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-03-03|2010-02-22|2010-02-23|Estimate|||||||2010-03-03|2010-03-05|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer|Phase II Organ Preservation Trial Using Cisplatin Concomitant With Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to Induction Chemotherapy With Taxotere, Cisplatin, and 5-Fluorouracil (TPF)|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-06-01 00:03:53.954941|2018-06-01 00:03:53.954941
NCT01073670|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|August 2000||2000-08-31|February 2010|2010-02-28|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Indomethacin and Cardiac Bypass Surgery|Quantification of Postoperative Coagulation Following Administration of Indomethacin to Expedite Fast-tracking of Cardiac Surgical Patients|Completed||Phase 4|82|Actual|Queen's University||3|||f||||f||||||||||2018-06-01 00:03:54.050952|2018-06-01 00:03:54.050952
NCT01073657|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2014-12-10||2015-04-06|2010-02-22|2010-02-23|Estimate|2015-02-13|2015-02-18|Estimate||||2015-04-06|2015-04-28|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|SEd||Supported Education Pilot|Supporting Education Goals of OIF/OEF Veterans With PTSD: Pilot Process & Outcome|Completed||Early Phase 1|33|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:03:54.199024|2018-06-01 00:03:54.199024
NCT01073644|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-07-03|2010-02-22|2010-02-23|Estimate|||||||2013-07-03|2013-07-04|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients|Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients|Terminated|||3|Actual|Pfizer|||1|"The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were~   no safety concerns that led to the decision to terminate."|f||||f||||||||||2018-06-01 00:03:54.516496|2018-06-01 00:03:54.516496
NCT01073631|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2010-08-16||2012-05-31|2010-02-22|2010-02-23|Estimate|2010-08-16|2010-09-13|Estimate||||2012-05-31|2012-06-07|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea|Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet|Completed|||543|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:03:54.609427|2018-06-01 00:03:54.609427
NCT01073618|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2010-08-20||2012-05-31|2010-02-22|2010-02-23|Estimate|2010-08-20|2010-09-16|Estimate||||2012-05-31|2012-06-07|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV|Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV|Completed|||692|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:03:55.176847|2018-06-01 00:03:55.176847
NCT01073605|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2010-05-06||2010-11-08|2010-02-22|2010-02-23|Estimate|2010-08-04|2010-08-31|Estimate||||2010-11-08|2010-11-18|Estimate|July 1993||1993-07-31|February 2010|2010-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation|A Two Years Multicentre Study of Genotropin Treatment of Short Prepubertal Children With Intra-Uterine Growth Retardation|Completed||Phase 3|208|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:03:55.655542|2018-06-01 00:03:55.655542
NCT01073592|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-05-16|2010-02-22|2010-02-23|Estimate|||||||2013-05-16|2013-05-17|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||Comparison Between Foresee Home and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)|Comparison Between Home Macular Perimeter (FORESEE HOME) and OCT Visual Field Defects in Patients With CNV|Completed|||10|Actual|Notal Vision Ltd|||1||f||||f||||||||||2018-06-01 00:03:56.622498|2018-06-01 00:03:56.622498
NCT01073579|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2016-07-28|2010-02-22|2010-02-23|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 2009||2009-08-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Sabril Patient Registry|Sabril Patient Registry|Completed|||9423|Actual|Lundbeck LLC|||1||f||||t||||||||||2018-06-01 00:03:56.687861|2018-06-01 00:03:56.687861
NCT01073566|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2012-02-09||2012-03-13|2010-02-22|2010-02-23|Estimate|2012-03-13|2012-04-09|Estimate||||2012-03-13|2012-04-09|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections|The Effects of Finesse on Glycemic Control in Adults With Diabetes Using MDI: Finesse vs. Pen or Syringe and Vial as Bolus Prandial Insulin Device|Completed||Phase 2|38|Actual|Calibra Medical, Inc.|The short duration of the study precludes comments on longer-term outcomes.|2|||f||||f||||||||||2018-06-01 00:03:56.842597|2018-06-01 00:03:56.842597
NCT01073553|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-04-02|2010-02-22|2010-02-23|Estimate|||||||2015-04-02|2015-04-03|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules|Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef (Cephalexin 500 mg Capsules) From Bayer and Keflex (Cephalexin 250 mg Capsules) From Eli Lilly po in Healthy Subjects Using Equivalent Concentrations|Completed||Phase 1|26|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:03:57.24518|2018-06-01 00:03:57.24518
NCT01073540|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2014-04-01|2010-02-22|2010-02-23|Estimate|||||||2014-04-01|2014-04-03|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension|Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef Suspension From Bayer (Cephalexin Suspension 250 mg/5 mL) and Equivalent Concentration of Keflex Pediatrico From Eli Lilly (Cephalexin Suspension 125 mg/5mL) in Healthy Subjects|Completed||Phase 1|26|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:03:57.384269|2018-06-01 00:03:57.384269
NCT01073527|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2011-08-07|2010-02-22|2010-02-23|Estimate|||||||2011-08-07|2011-08-09|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Hypertonic Saline as Add on Therapy in Preschool Children With Acute Wheezing Attack.|"Interventional Study: Hypertonic Saline as Add on Treatment to the Usual Therapy for Preschool Children With Acute Asthmatic Attack Presenting to the ER: A Double Blind Control Study"|Completed||N/A|41|Actual|Wolfson Medical Center||2|||f||||f||||||||||2018-06-01 00:03:57.555725|2018-06-01 00:03:57.555725
NCT01073514|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-21|||2015-12-21|2010-02-22|2010-02-23|Estimate|||||||2015-12-21|2015-12-22|Estimate|December 2009||2009-12-31|February 2010|2010-02-28|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|MBO—IR||Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction|Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction|Unknown status|Recruiting||300|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||||f||||t||||||Samples With DNA|"~     bile,blood and urine specimen~   "|||2018-06-01 00:03:57.688506|2018-06-01 00:03:57.688506
NCT01073501|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus|Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus|Unknown status|Not yet recruiting|Phase 4|36|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-06-01 00:03:57.790823|2018-06-01 00:03:57.790823
NCT01073488|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-21|||2013-11-15|2010-02-21|2010-02-23|Estimate|||||||2013-11-15|2013-11-18|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|EmONC||Emergency Obstetric and Neonatal Care: The EmONC Trial|Evaluation of an Emergency Obstetric and Neonatal Care (EmONC) Intervention Package to Reduce Adverse Pregnancy Outcomes in Low Resource Settings (The EmONC Trial)|Completed||N/A|267181|Actual|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-06-01 00:03:57.915616|2018-06-01 00:03:57.915616
NCT01073475|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-21|||2018-04-02|2010-02-21|2010-02-23|Estimate|||||||2018-04-02|2018-04-04|Actual|May 2008||2008-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|MNH||Maternal Newborn Health Registry|Global Network for Women's and Children's Health Research Maternal Newborn Health Registry|Recruiting|||600000|Anticipated|NICHD Global Network for Women's and Children's Health|||2||f||||t||||||||||2018-06-01 00:03:58.134942|2018-06-01 00:03:58.134942
NCT01073462|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-20|2014-06-09||2014-06-09|2010-02-22|2010-02-23|Estimate|2014-06-09|2014-07-10|Estimate||||2014-06-09|2014-07-10|Estimate|December 2008||2008-12-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years|Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.|Completed|||67|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 00:03:58.26987|2018-06-01 00:03:58.26987
NCT01073449|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|2011-01-10||2011-02-02|2010-02-22|2010-02-23|Estimate|2011-02-02|2011-02-28|Estimate||||2011-02-02|2011-02-28|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|ATHENS||Actions Elicited by In-hospital Follow-up of Cardiac Devices|Action Elicited By Scheduled In-Hospital Follow-Up of Cardiac Devices|Completed|||3362|Actual|Cliniche Humanitas Gavazzeni|||1||f||||f||||||||||2018-06-01 00:03:58.562717|2018-06-01 00:03:58.562717
NCT01073436|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-11-11|2010-02-22|2010-02-23|Estimate|||||||2016-11-11|2016-11-15|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha|Discontinuation of Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myeloid Leukemia, Previously Treated With Interferon-Alpha|Terminated|||7|Actual|University of Michigan Cancer Center|||1|Closed prematurely due to low accrual.|f||||t||||||||||2018-06-01 00:03:59.79558|2018-06-01 00:03:59.79558
NCT01073423|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-06-22|2010-02-22|2010-02-23|Estimate|||||||2010-06-22|2010-06-23|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|R&R||Improving Sleep and Quality of Life in Adults With HIV Disease|Improving Sleep and Quality of Life in Adults With HIV Disease: A Pilot Study|Completed||N/A|20|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:03:59.866809|2018-06-01 00:03:59.866809
NCT01073410|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2017-07-18|2010-02-22|2010-02-23|Estimate|||||||2017-07-18|2017-07-19|Actual|February 2010||2010-02-28|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|February 2017|Actual|2017-02-28||Observational|AADCRC||Chitinases and Transforming Growth Factor Beta (TGFB) in Human Asthma|Chitinases and TGFB in Human Asthma|Active, not recruiting|||23|Actual|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     sputum, blood, saliva, DNA, RNA, Plasma~   "|||2018-06-01 00:03:59.928666|2018-06-01 00:03:59.928666
NCT01073397|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2017-11-02|2010-02-22|2010-02-23|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2010||2010-01-31|November 2013|2013-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|GLAM||Effect of Yoga on Objective and Subjective Menopausal Hot Flashes|Effectiveness of Integral Yoga on Objective and Subjective Menopausal Hot Flashes|Completed||N/A|54|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||||2018-06-01 00:03:59.996662|2018-06-01 00:03:59.996662
NCT01073384|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-12-12|2010-02-22|2010-02-23|Estimate|||||||2012-12-12|2012-12-17|Estimate|December 2009||2009-12-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|January 2012|Actual|2012-01-31||Interventional|||A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer|A Phase 1/2 Study to Evaluate Escalating Doses of SGX201 [Delayed Release Oral Beclomethasone Dipropionate (BDP)] for Prevention of Signs and Symptoms of Acute Enteritis in Patients With Rectal Cancer Treated With Combined Chemotherapy and Radiation Therapy|Completed||Phase 1/Phase 2|16|Actual|Soligenix||4|||f||||f||||||||||2018-06-01 00:04:00.065934|2018-06-01 00:04:00.065934
NCT01073371|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia|Local Anesthetics New Formulations: From Development to Clinical Tests|Completed||Phase 1|32|Actual|University of Campinas, Brazil||3|||f||||t||||||||||2018-06-01 00:04:00.146154|2018-06-01 00:04:00.146154
NCT01073358|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2017-10-26|2010-02-22|2010-02-23|Estimate|||||||2017-10-26|2017-10-27|Actual|March 9, 2010|Actual|2010-03-09|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|July 2019|Anticipated|2019-07-31||Interventional|RELY||Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy|Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy - A Randomized Controlled Trial|Enrolling by invitation||N/A|166|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-06-01 00:04:00.310723|2018-06-01 00:04:00.310723
NCT01073345|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Portal Venous Hemodynamic Changes After Hepatectomy|Portal Venous Hemodynamic Changes After Hepatectomy and the Incidence of Postoperative Ascites|Unknown status|Enrolling by invitation||110|Actual|Heidelberg University|||3||f||||f||||||Samples Without DNA|"~     Blood samples for liver function tests and cytokine levels~   "|||2018-06-01 00:04:00.383264|2018-06-01 00:04:00.383264
NCT01073332|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2015-05-06|2010-02-22|2010-02-23|Estimate|||||||2015-05-06|2015-05-08|Estimate|October 2004||2004-10-31|February 2010|2010-02-28|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||"The Effects of a Dietary Supplement on Exercise Performance in Healthy Older Adults"|Arginine and Antioxidant Supplement on Performance in Elderly Male Cyclists: A Randomized Controlled Trial|Completed||N/A|16|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:04:00.460376|2018-06-01 00:04:00.460376
NCT01073319|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-07-25|2010-02-19|2010-02-23|Estimate|||||||2012-07-25|2012-07-27|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Rivastigmine as a Treatment for Methamphetamine Dependence|Rivastigmine as a Treatment for Methamphetamine Dependence|Completed||Phase 1|17|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 00:04:00.53804|2018-06-01 00:04:00.53804
NCT01073306|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-12-31|2010-02-19|2010-02-23|Estimate|||||||2012-12-31|2013-01-03|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Immune Response to an Investigational Dengue Type 2 Vaccine|A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects|Completed||Phase 1|18|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 00:04:00.648349|2018-06-01 00:04:00.648349
NCT01073111|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2013-03-18|2010-02-22|2010-02-23|Estimate|||||||2013-03-18|2013-03-20|Estimate|April 2010||2010-04-30|March 2013|2013-03-31||||October 2011|Actual|2011-10-31||Interventional|ASSESS||Assessment of Stent Strut Coverage and Endothelial Function After Drug-Eluting Stents|Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems|Unknown status|Recruiting|Phase 4|60|Anticipated|Hyogo College of Medicine||3|||f||||||||||||||2018-06-01 00:04:03.411788|2018-06-01 00:04:03.411788
NCT01073293|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2014-12-12||2017-03-20|2010-02-19|2010-02-23|Estimate|2014-12-12|2014-12-22|Estimate||||2017-03-20|2017-04-17|Actual|April 22, 2010|Actual|2010-04-22|March 2017|2017-03-31|June 16, 2011|Actual|2011-06-16|June 16, 2011|Actual|2011-06-16||Interventional|||A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)|A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds)|Completed||Phase 3|1054|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:04:00.783726|2018-06-01 00:04:00.783726
NCT01073280|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|October 2010|Anticipated|2010-10-31|January 2010|Anticipated|2010-01-31||Observational|||Cerebral, Meningeal Biopsy by Flexible Endoscopy in Patients Without Neurological Diagnosis|Cerebral, Meningeal Biopsy by Flexible Endoscopy in Patients Without Neurological Diagnosis|Unknown status|Recruiting||40|Anticipated|Universidad Autonoma de San Luis Potosí|||1||f||||f||||||||||2018-06-01 00:04:01.229982|2018-06-01 00:04:01.229982
NCT01073267|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2015-11-25||2015-11-25|2010-02-19|2010-02-23|Estimate|2015-11-25|2015-12-31|Estimate||||2015-11-25|2015-12-31|Estimate|February 2010||2010-02-28|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides|A Phase II Study of Total Skin Electron Beam Therapy (TSEBT) to Dose of 12 Gy in Stage IB-IIIA Mycosis Fungoides|Completed||Phase 2|4|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:04:01.309985|2018-06-01 00:04:01.309985
NCT01073241|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-03-12|2010-02-22|2010-02-23|Estimate|||||||2010-03-12|2010-03-15|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate|Transurethral Ventral Wall of Urethra-preserving Enucleation of Prostate|Unknown status|Active, not recruiting|N/A|200|Anticipated|Southwest Hospital, China||2|||f||||f||||||||||2018-06-01 00:04:01.437492|2018-06-01 00:04:01.437492
NCT01073228|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19||2013-02-19|2014-03-28|2010-02-22|2010-02-23|Estimate||||2013-02-19|2013-02-22|Estimate|2014-03-28|2014-04-25|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease|Completed||Phase 2|409|Actual|FORUM Pharmaceuticals Inc||4|||f||||f||||||||||2018-06-01 00:04:01.610729|2018-06-01 00:04:01.610729
NCT01073215|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-02-17|2010-02-22|2010-02-23|Estimate|||||||2012-02-17|2012-02-20|Estimate|July 2006||2006-07-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TEENS||Primary Care Research Network for the Treatment of Adolescent Obesity|Primary Care Research Network for the Treatment of Adolescent Obesity|Completed||N/A|173|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 00:04:01.77616|2018-06-01 00:04:01.77616
NCT01073202|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-12-29|2010-02-22|2010-02-23|Estimate|||||||2010-12-29|2010-12-30|Estimate|May 2005||2005-05-31|December 2009|2009-12-31|January 2009|Actual|2009-01-31|April 2008|Actual|2008-04-30||Interventional|||Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation||Completed||N/A|112|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-06-01 00:04:01.853533|2018-06-01 00:04:01.853533
NCT01073189|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2016-03-25|2010-02-22|2010-02-23|Estimate|||||||2016-03-25|2016-03-28|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|IR-FTA||Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury|Effect of Combination Intra-Renal Infusion of Fenoldopam Mesylate and High Dose Diuretics on Peak Serum Creatinine and Incidence of Renal Replacement Therapy in Patients With Early Acute Kidney Injury|Withdrawn||Phase 4|0|Actual|Southeast Renal Research Institute||2||withdrew due to funding|f||||f||||||||||2018-06-01 00:04:01.956277|2018-06-01 00:04:01.956277
NCT01073176|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2011-09-13|2010-02-22|2010-02-23|Estimate|||||||2011-09-13|2011-09-14|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|TEAMS||Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies|Training Executive, Attention and Motor Skills (TEAMS): Preliminary Studies|Completed||Phase 1|30|Anticipated|Queens College, The City University of New York||1|||f||||f||||||||||2018-06-01 00:04:02.145909|2018-06-01 00:04:02.145909
NCT01073163|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2014-02-25|2013-03-26|2014-04-07|2010-02-19|2010-02-23|Estimate|2014-02-25|2014-04-04|Estimate|2013-03-26|2013-04-02|Estimate|2014-04-07|2014-04-24|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)|A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)|Completed||Phase 3|54|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 00:04:02.323166|2018-06-01 00:04:02.323166
NCT01073150|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-02-19|2010-02-19|2010-02-23|Estimate|||||||2010-02-19|2010-02-23|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Tea Tree Oil in the Treatment of Chronic Blepharitis|Tea Tree Oil in the Treatment of Chronic Blepharitis|Completed||Phase 2|34|Actual|Federal University of São Paulo|||||f||||t||||||||||2018-06-01 00:04:03.097486|2018-06-01 00:04:03.097486
NCT01073137|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2010-02-22|2010-02-22|2010-02-23|Estimate|||||||2010-02-22|2010-02-23|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|||Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions|Noninvasive Blood Glucose Monitoring Using Otoacoustic Emissions|Unknown status|Recruiting||44|Anticipated|Portland VA Medical Center|||2||f||||t||||||||||2018-06-01 00:04:03.207343|2018-06-01 00:04:03.207343
NCT01073124|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2016-08-17|2010-02-22|2010-02-23|Estimate|||||||2016-08-17|2016-08-19|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Sensitivity Diagnosing Traumatic Knee Injuries With and Without Injection of Blue Dye Into the Knee Joint|Sensitivity of the Saline Load Test With and Without Methylene Blue Dye in the Diagnosis of Traumatic Knee Arthrotomies|Completed||N/A|60|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||No||2018-06-01 00:04:03.330194|2018-06-01 00:04:03.330194
NCT01072760|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2010-02-19|2010-02-19|2010-02-22|Estimate|||||||2010-02-19|2010-02-22|Estimate|May 2003||2003-05-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Kirschner Wire and Pull-out Wire Fixation for the Treatment of Bony Mallet Finger|Kirschner Wire and Pull-out Wire Fixation for the Treatment of Bony Mallet Finger|Completed||N/A|54|Actual|The Second Hospital of Qinhuangdao||1|||f||||t||||||||||2018-06-01 00:04:08.210192|2018-06-01 00:04:08.210192
NCT01073098|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-22|||2012-03-23|2010-02-22|2010-02-23|Estimate|||||||2012-03-23|2012-03-26|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Evaluation of Muscle StO2 as a Prognostic Factor After Out of Hospital Cardiac Arrest|Evaluation of Muscle StO2 as a Prognostic Factor After Out of Hospital Cardiac Arrest|Unknown status|Recruiting|N/A|51|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-06-01 00:04:03.590211|2018-06-01 00:04:03.590211
NCT01073085|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2014-01-16|2010-02-22|2010-02-23|Estimate|||||||2014-01-16|2014-01-17|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|Stamp||Effectiveness of a French Automated Web-based Smoking Cessation Program|Effectiveness of a French Automated Web-based Smoking Cessation Program : a Randomized Controlled Trial|Completed||N/A|2478|Actual|Institut national de prevention et d'education pour la sante||2|||f||||f||||||||||2018-06-01 00:04:03.779156|2018-06-01 00:04:03.779156
NCT01073072|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-03-15|2010-02-22|2010-02-23|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|Tutomesh||Study Comparing Tutomesh® Repair to Conventional Surgical Techniques in Potentially Contaminated Hernia Repair and Abdominal Wall Reconstruction|Multicentric Prospective Randomized Study Comparing Technique of Tension-free Repair With Placement of a Bovine Pericardium Bioprosthesis (Tutopatch® and Tutomesh®) to Current Conventional Surgical Techniques in Potentially Contaminated Hernia Repair and Abdominal Wall Reconstruction|Completed||Phase 3|134|Actual|Centre Hospitalier Régional Universitaire Montpellier||2|||f||||f||||||||||2018-06-01 00:04:03.878196|2018-06-01 00:04:03.878196
NCT01073059|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-12-07|2010-02-22|2010-02-23|Estimate|||||||2010-12-07|2010-12-08|Estimate|August 2009||2009-08-31|February 2010|2010-02-28||||||||Interventional|||Pharmacokinetic Interactions in Combination Treatment of Valproic Acid and Ertapenem in Normal Subjects|Open-label, Two-period, One Sequence, Multiple Dose, Crossover Study, A Study to Investigate Pharmacokinetic Interactions in Combination Treatment of Valproic Acid and Ertapenem in Normal Healthy Male Subjects|Completed||Phase 1|10|Actual|Chonbuk National University||1|||f||||t||||||||||2018-06-01 00:04:03.998233|2018-06-01 00:04:03.998233
NCT01073046|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-08-01|2010-02-22|2010-02-23|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Gastric Decompression After Sub-total Gastrectomy|Naso-gastric/Jejunal Tube Placement After Sub-total Gastrectomy. A Multicenter Prospective Randomized Trial|Completed|||276|Actual|Catholic University, Italy|||2||f||||f||||||||||2018-06-01 00:04:04.087083|2018-06-01 00:04:04.087083
NCT01073033|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-09-25|2010-02-19|2010-02-22|Estimate|||||||2012-09-25|2012-09-27|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Oral Supplement for Pregnant and Lactating Mothers|Oral Supplement for Pregnant and Lactating Mothers to Promote Infant Immune Maturation and Protection Against Early Life Infections|Completed||N/A|234|Actual|Nestlé||3|||f||||f||||||||||2018-06-01 00:04:04.179751|2018-06-01 00:04:04.179751
NCT01073020|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2018-02-14|2010-02-19|2010-02-22|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2010||2010-01-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|December 2014|Actual|2014-12-31||Interventional|SLIMM-T2D||Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes|Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D)|Active, not recruiting||N/A|88|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-06-01 00:04:04.272104|2018-06-01 00:04:04.272104
NCT01073007|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2016-12-20|2010-02-19|2010-02-22|Estimate|||||||2016-12-20|2016-12-21|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Stroke Treatment With Acute Reperfusion and Simvastatin|Multicentric, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy of Simvastatin in the Acute Phase of Ischemic Stroke|Completed||Phase 4|104|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-06-01 00:04:04.391173|2018-06-01 00:04:04.391173
NCT01072994|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-07-28|2010-02-19|2010-02-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|March 2012|Actual|2012-03-31|April 2011|Anticipated|2011-04-30||Interventional|FOHMC||Fish Oil In Heart Transplantation|Fish Oil Effect on Heart Muscle Cells in Heart Transplant Patients (FOHMC)|Unknown status|Not yet recruiting|N/A|50|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t||||||||||2018-06-01 00:04:04.517443|2018-06-01 00:04:04.517443
NCT01072981|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2016-09-20|2010-02-19|2010-02-22|Estimate|||||||2016-09-20|2016-09-21|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Immunotherapy Study for Surgically Resected Pancreatic Cancer|A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer|Completed||Phase 3|722|Actual|NewLink Genetics Corporation||2|||f||||t||||||||||2018-06-01 00:04:04.604274|2018-06-01 00:04:04.604274
NCT01072968|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2015-01-20|2010-02-19|2010-02-22|Estimate|||||||2015-01-20|2015-01-21|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|HAROSA2||BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.|Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy|Completed||Phase 3|268|Actual|Bioprojet||2|||f||||t||||||||||2018-06-01 00:04:04.789332|2018-06-01 00:04:04.789332
NCT01072955|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2011-01-27|2010-02-19|2010-02-22|Estimate|||||||2011-01-27|2011-01-28|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|October 2011|Anticipated|2011-10-31|August 2010|Anticipated|2010-08-31||Interventional|||Efficacy And Safety Of Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass||Unknown status|Recruiting|Phase 3|104|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:04:04.867923|2018-06-01 00:04:04.867923
NCT01072942|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2014-04-01|2010-02-19|2010-02-22|Estimate|||||||2014-04-01|2014-04-02|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)|Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD; GOLD II-III), Following Multiple Inhalation of Ciprofloxacin PulmoSphere Inhalation Powder|Completed||Phase 1|16|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:04:04.936172|2018-06-01 00:04:04.936172
NCT01072253|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-19|2010-02-19|2010-02-22|Estimate|||||||2010-02-19|2010-02-22|Estimate|February 2008||2008-02-29|February 2010|2010-02-28||||May 2008|Actual|2008-05-31||Observational|||Quality of Life of Eye Amputated Patients in Denmark|Quality of Life of Eye Amputated Patients in Denmark|Completed|||152|Actual|University of Copenhagen|||1||f||||||||||||||2018-06-01 00:04:17.957154|2018-06-01 00:04:17.957154
NCT01072929|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2015-01-15|2013-02-19|2016-04-26|2010-02-19|2010-02-22|Estimate|2015-01-15|2015-01-26|Estimate|2013-02-22|2013-02-28|Estimate|2016-04-26|2016-04-27|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Randomized participants|A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|Completed||Phase 3|433|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 00:04:05.060069|2018-06-01 00:04:05.060069
NCT01072916|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2016-03-10|2010-02-19|2010-02-22|Estimate|||||||2016-03-10|2016-03-11|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)|The Role of Serine-Proteases in Gastrointestinal Function and Irritable Bowel Syndrome|Completed|||60|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples Without DNA|"~     Urine and Stool.~   "|||2018-06-01 00:04:06.402488|2018-06-01 00:04:06.402488
NCT01072903|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2013-12-11|2010-02-19|2010-02-22|Estimate|||||||2013-12-11|2013-12-12|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|K23||The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)|The Role of Intestinal Inflammation in the Pathophysiology of IBS|Completed|||78|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples Without DNA|"~     8 rectosigmoidal intestinal biopsies, stool, and blood~   "|||2018-06-01 00:04:06.518976|2018-06-01 00:04:06.518976
NCT01072890|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2012-03-26|2010-02-19|2010-02-22|Estimate|||||||2012-03-26|2012-03-28|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors|Phase I Study of the Combination of Temsirolimus (CCI-779) and Pazopanib (GW786034) in Patients With Advanced Solid Tumors|Completed||Phase 1|8|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 00:04:06.617485|2018-06-01 00:04:06.617485
NCT01072877|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2014-01-15|2013-07-23|2015-02-19|2010-02-19|2010-02-22|Estimate|2014-04-15|2014-05-16|Estimate|2013-12-09|2014-01-09|Estimate|2015-02-19|2015-03-10|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional|VANISH-1|Safety population|Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence|A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Polidocanol Injectable Foam 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence|Completed||Phase 3|279|Actual|BTG International Inc.||5|||f||||t||||||||||2018-06-01 00:04:06.763003|2018-06-01 00:04:06.763003
NCT01072864|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-10-28|2010-02-19|2010-02-22|Estimate|||||||2010-10-28|2010-11-01|Estimate|June 2010||2010-06-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Effects of California Walnuts on Vascular Function in Postmenopausal Women|Effects of California Walnuts on Vascular Function in Postmenopausal Women|Completed||Phase 1|5|Actual|University of California, Davis||4|||f||||f||||||||||2018-06-01 00:04:07.363552|2018-06-01 00:04:07.363552
NCT01072851|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-09-06|2010-02-19|2010-02-22|Estimate|||||||2012-09-06|2012-09-07|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Tools for Improving Colorectal Cancer Screening Rates: Multimedia Versus Print|Tools for Improving Colorectal Cancer Screening Rates: Multimedia vs Print|Completed||Phase 3|920|Actual|Saint Francis Care||3|||f||||f||||||||||2018-06-01 00:04:07.453084|2018-06-01 00:04:07.453084
NCT01072838|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2013-06-14|2010-02-19|2010-02-22|Estimate|||||||2013-06-14|2013-06-17|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB|Safety and Feasibility of Short-Course, Accelerated, Hypofractionated Partial Breast Radiotherapy in Women With Early Stage Breast Cancer Using the Contura MLB Breast Brachytherapy Catheter: A Phase II Trial|Terminated||Phase 2|60|Actual|SenoRx, Inc.||1|||f||||t||||||||||2018-06-01 00:04:07.544637|2018-06-01 00:04:07.544637
NCT01072825|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2015-06-02|2010-02-19|2010-02-22|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|January 2020|Anticipated|2020-01-31|January 2016|Anticipated|2016-01-31||Observational|ENIGI||A European Network for the Investigation of Gender Incongruence|A European Network for the Investigation of Gender Incongruence|Recruiting|||125|Anticipated|University Hospital, Ghent|||1||f||||f||||||||||2018-06-01 00:04:07.637154|2018-06-01 00:04:07.637154
NCT01072812|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2015-04-20|2010-02-19|2010-02-22|Estimate|||||||2015-04-20|2015-04-22|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment|An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment|Terminated||Phase 1|5|Actual|QR Pharma Inc.||1||Business decision based on funding|f||||f||||||||||2018-06-01 00:04:07.725566|2018-06-01 00:04:07.725566
NCT01072799|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-04-23|2010-02-19|2010-02-22|Estimate|||||||2012-04-23|2012-04-25|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine|A Phase 2 Study to Assess the Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine|Completed||Phase 2|4560|Actual|Novavax||4|||f||||t||||||||||2018-06-01 00:04:07.80511|2018-06-01 00:04:07.80511
NCT01072786|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-12-31|2010-02-19|2010-02-22|Estimate|||||||2012-12-31|2013-01-03|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects|Completed||Phase 1|141|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-06-01 00:04:07.880392|2018-06-01 00:04:07.880392
NCT01072773|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2012-11-07||2014-03-05|2010-02-19|2010-02-22|Estimate|2012-11-07|2012-12-05|Estimate||||2014-03-05|2014-04-02|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional|||Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis|Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Light Chain Amyloidosis|Completed||Phase 2|2|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:04:07.980284|2018-06-01 00:04:07.980284
NCT01072747|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2011-01-27|2010-02-19|2010-02-22|Estimate|||||||2011-01-27|2011-01-28|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|November 2011|Anticipated|2011-11-30|August 2011|Anticipated|2011-08-31||Interventional|||Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass|Randomized, Blind and Comparative Clinical Trial of Efficacy and Security of Unfractioned Heparin Sodium of Bovine Origin in Patients Submitted to Cardiovascular Surgery With Cardiopulmonary Bypass|Unknown status|Recruiting|Phase 3|104|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:04:08.371229|2018-06-01 00:04:08.371229
NCT01072734|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-10-11|2010-02-19|2010-02-22|Estimate|||||||2010-10-11|2010-10-13|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|GRIPLUP||Auto-immunity in Lupus Patients After Influenza Vaccine|Role of CXCR4/CXCL12 Axis on the Control of Humoral Immunity and Auto-immunity in Lupus Patients After Influenza Vaccine Challenge|Completed||Phase 2|28|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 00:04:08.472607|2018-06-01 00:04:08.472607
NCT01072721|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2017-12-07|2010-02-19|2010-02-22|Estimate|||||||2017-12-07|2017-12-08|Actual|January 19, 2010||2010-01-19|December 2017|2017-12-31|December 31, 2017|Anticipated|2017-12-31|July 11, 2017|Actual|2017-07-11||Interventional|PEDISCAN||Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis|Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of FIBROSCANN.|Active, not recruiting||N/A|264|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:04:08.567038|2018-06-01 00:04:08.567038
NCT01072708|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-03-24|2010-02-19|2010-02-22|Estimate|||||||2016-03-24|2016-03-25|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|DIAMUCO||Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients|Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients (Study DIAMUCO)|Completed||N/A|230|Actual|Hospices Civils de Lyon|||||f||||t||||||||||2018-06-01 00:04:08.661715|2018-06-01 00:04:08.661715
NCT01072695|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-05-30|2010-02-19|2010-02-22|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|January 2012|Actual|2012-01-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection|A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112)|Completed||Phase 2|46|Actual|Gilead Sciences||3|||f||||f||||||||||2018-06-01 00:04:08.752841|2018-06-01 00:04:08.752841
NCT01072682|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2011-08-31|2010-02-19|2010-02-22|Estimate|||||||2011-08-31|2011-09-02|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety Study of a Selective Cytopheric Device (SCD) in Patients With Acute Renal Failure|A Multi-Center Pilot Study to Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) Treatments In Patients With Acute Renal Failure (ARF)|Completed||Phase 1|35|Actual|CytoPherx, Inc|||||f||||f||||||||||2018-06-01 00:04:08.885472|2018-06-01 00:04:08.885472
NCT01072669|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2012-08-31||2013-03-22|2010-02-19|2010-02-22|Estimate|2013-03-22|2013-05-03|Estimate||||2013-03-22|2013-05-03|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ambrisentan||Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet|Evaluation of the Effect of Ambrisentan on Digital Microvascular Flow in Patients With Systemic Sclerosis Using Laser Doppler Perfusion Imaging|Completed||N/A|20|Actual|The Cleveland Clinic|Small sample size and short duration of study Some patients had hand contractures which made the LDPI images somewhat inaccurate Could not adjust for all variables in final analysis Placebo effect reflected in patient responses to questionnaires|2|||f||||t||||||||||2018-06-01 00:04:08.955923|2018-06-01 00:04:08.955923
NCT01072656|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2016-07-20||2017-05-01|2010-02-19|2010-02-22|Estimate|2016-07-20|2016-08-30|Estimate||||2017-05-01|2017-06-09|Actual|May 2010||2010-05-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|August 2014|Actual|2014-08-31||Interventional|DBS||Safety Study of Deep Brain Stimulation to Manage Thalamic Pain Syndrome|Deep Brain Stimulation for Thalamic Pain Syndrome|Completed||N/A|10|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 00:04:09.219881|2018-06-01 00:04:09.219881
NCT01072643|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2014-07-16||2014-09-05|2010-02-19|2010-02-22|Estimate|2014-09-05|2014-09-08|Estimate||||2014-09-05|2014-09-08|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional||Children with PHTN who received Dex sedation for cardiac catheterization.|Sedation With Dexmedetomidine During Cardiac Catheterization|The Pharmacodynamics, Safety, and Pharmacokinetics of Sedation With Dexmedetomidine in Children Undergoing Hemodynamic Cardiac Catheterization With Special Reference to the Pulmonary Vascular Bed|Completed||Phase 2/Phase 3|4|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-06-01 00:04:09.692776|2018-06-01 00:04:09.692776
NCT01072630|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2015-01-15|2013-03-20|2016-04-26|2010-02-19|2010-02-22|Estimate|2015-01-15|2015-01-26|Estimate|2013-03-20|2013-03-28|Estimate|2016-04-26|2016-04-27|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Randomized participants|Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|Completed||Phase 3|492|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 00:04:09.967572|2018-06-01 00:04:09.967572
NCT01072617|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2017-01-20||2017-04-28|2010-02-19|2010-02-22|Estimate|2017-04-28|2017-06-05|Actual||||2017-04-28|2017-06-05|Actual|February 2008||2008-02-29|April 2017|2017-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Cerebellar rTMS for the Treatment of Schizophrenic Patients|Safety and Therapeutic Efficacy of Cerebellar Repetitive Transcranial Magnetic Stimulation in Patients With Schizophrenia|Completed||N/A|8|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-06-01 00:04:11.280954|2018-06-01 00:04:11.280954
NCT01072604|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2014-04-18|2010-02-19|2010-02-22|Estimate|||||||2014-04-18|2014-04-21|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetic Study Comparing Aspirin and Aspirin Granules|An Open Label Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Aspirin Tablets and Aspirin Dry Granules in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Bayer||4|||f||||f||||||||||2018-06-01 00:04:11.546809|2018-06-01 00:04:11.546809
NCT01071603|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2018-04-04|2010-02-18|2010-02-19|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2, 2010||2010-02-02|January 29, 2018|2018-01-29|January 29, 2018||2018-01-29|||||Observational|||Tuberculosis in China|A Natural History Study of Tuberculosis in China; Correlates of a Successful Response to Treatment|Completed|||199|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:04:34.705684|2018-06-01 00:04:34.705684
NCT01072591|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2013-01-28|2010-02-19|2010-02-22|Estimate|||||||2013-01-28|2013-01-29|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee|A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee|Terminated||Phase 1|108|Actual|AstraZeneca||2||Amended clinical development plan.|f||||t||||||||||2018-06-01 00:04:11.648311|2018-06-01 00:04:11.648311
NCT01072578|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-05-31|2010-02-19|2010-02-22|Estimate|||||||2012-05-31|2012-06-01|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose|An Open-label, Randomised, Two-period Crossover Study to Assess the Effect of Dapagliflozin on Percent Inhibition of Glucose Re-absorption When Administered Once a Day (10 mg OD) Versus Twice a Day (5 mg BID) in Healthy Male and Female Volunteers|Completed||Phase 1|16|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:04:11.732975|2018-06-01 00:04:11.732975
NCT01072565|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-11-25|2010-02-19|2010-02-22|Estimate|||||||2015-11-25|2015-11-26|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring|Optimization of SMBG Employing Modal Day Analysis: Examining Clinical Decision-making Processes Using Blinded FreeStyle Navigator Continuous Glucose Monitoring System (CGM)|Completed||N/A|91|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-06-01 00:04:11.812539|2018-06-01 00:04:11.812539
NCT01072552|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2012-04-01|2010-02-19|2010-02-22|Estimate|||||||2012-04-01|2012-04-03|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Observational|||Effect of Palivizumab on Later Recurrent Wheezing in Preterm Infants|Effect of Palivizumab Treatment on Subsequent Recurrent Wheezing in Preterm Infants: Case-control Study by Scientific Committee of Recurrent Wheezing (SCREW)|Completed|||444|Actual|Tokyo Women's Medical University|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:04:11.896093|2018-06-01 00:04:11.896093
NCT01072539|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2016-04-21||2016-04-21|2010-02-19|2010-02-22|Estimate|2016-04-21|2016-05-30|Estimate||||2016-04-21|2016-05-30|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational||Safety Analysis Set: participants who received at least one dose of Tygacil and had related safety endpoints evaluated at least once.|Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment|A Post-marketing Surveillance (Pms) Study Of Safety And Effectiveness In Patients With Tigecycline Treatment|Completed|||3172|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:04:12.006033|2018-06-01 00:04:12.006033
NCT01072526|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|2014-09-04||2016-11-15|2010-02-19|2010-02-22|Estimate|2016-11-15|2017-01-12|Estimate||||2016-11-15|2017-01-12|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease|Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease|Terminated||Phase 2|7|Actual|University of Missouri-Columbia|Early termination leading to small numbers of subjects analyzed|2||Study personnel left institution before study completion|f||||f||||||||||2018-06-01 00:04:12.647995|2018-06-01 00:04:12.647995
NCT01072513|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2016-04-05|2010-02-19|2010-02-22|Estimate|||||||2016-04-05|2016-04-06|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|PR08||Semen Analysis After Proton Therapy for Prostate Cancer|Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone|Completed||N/A|31|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 00:04:12.841988|2018-06-01 00:04:12.841988
NCT01072500|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2015-12-08||2018-04-04|2010-02-19|2010-02-22|Estimate|2016-03-21|2016-04-18|Estimate||||2018-04-04|2018-05-07|Actual|February 2010||2010-02-28|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|LIFE|Baseline characteristics were similar in the 2 groups.|The LIFE Study - Lifestyle Interventions and Independence for Elders|The LIFE Study - Lifestyle Interventions and Independence for Elders|Completed||Phase 3|1635|Actual|University of Florida||2|||f||||t||||||||Yes|"If an investigator outside of a LIFE study team would like access to the LIFE coded dataset, this individual must go through the following steps:~Request access to the LIFE website for the purposes of submitting a P&P proposal to obtain access to the Coded Datasets by going to the LIFE website (www.thelifestudy.org) and clicking on the button Request for Non-LIFE investigator Access and completing the request form.~Access would be granted to the LIFE website where access to would be provided to the data dictionary, data documentation, and protocol, in addition to the Manuscript Proposal Submission Form.~A proposal would be submitted (per current guidelines) to LIFE and reviewed through the usual channels.~If approved the Investigator would be sent a Coded Data Use Agreement document to be signed and sent back to the DMAQC for filing.~Access to the Coded Datasets would be granted for a period of 10 days."|2018-06-01 00:04:12.999686|2018-06-01 00:04:12.999686
NCT01072487|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2011-02-02|2010-02-19|2010-02-22|Estimate|||||||2011-02-02|2011-02-03|Estimate|February 2010||2010-02-28|February 2011|2011-02-28||||February 2011|Actual|2011-02-28||Interventional|ColoCap||Capnography During Colonoscopy|Capnography as an Adjunct to Standard Monitoring During Midazolam and Propofol Sedation for Colonoscopy|Completed||Phase 3|760|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 00:04:14.055462|2018-06-01 00:04:14.055462
NCT01072474|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-08-23|2010-02-19|2010-02-22|Estimate|||||||2012-08-23|2012-08-24|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional|EndoBreath||Capnography During ERCP|Capnography as an Adjunct to Standard Monitoring During Midazolam and Propofol Sedation for ERCP|Completed||Phase 3|242|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 00:04:14.121307|2018-06-01 00:04:14.121307
NCT01072461|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2015-10-06|2010-02-19|2010-02-22|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2013|Actual|2013-03-31||Interventional|||Optimizing Hand Rehabilitation Post-Stroke Using Interactive Virtual Environments|Optimizing Hand Rehabilitation Post-Stroke Using Interactive Virtual Environments|Completed||Phase 1|55|Actual|New Jersey Institute of Technology||3|||f||||f||||||||||2018-06-01 00:04:14.191073|2018-06-01 00:04:14.191073
NCT01072448|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2011-07-22||2011-07-22|2010-02-19|2010-02-22|Estimate|2011-07-22|2011-08-19|Estimate||||2011-07-22|2011-08-19|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||12-week Efficacy of Indacaterol|A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|323|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:04:14.280836|2018-06-01 00:04:14.280836
NCT01072435|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2012-07-13|2010-02-19|2010-02-22|Estimate|||||||2012-07-13|2012-07-16|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Target-controlled Infusion Versus Patient-controlled Sedation With Propofol in Endoscopic Retrograde Cholangiopancreatography (ERCP)|Target-controlled Infusion vs Patient-controlled Sedation With Propofol in ERCP. A Randomized Prospective Clinical Trial|Completed||Phase 4|82|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-06-01 00:04:15.554847|2018-06-01 00:04:15.554847
NCT01072422|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|||2010-02-19|2010-02-19|2010-02-22|Estimate|||||||2010-02-19|2010-02-22|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|May 2011|Anticipated|2011-05-31|February 2011|Anticipated|2011-02-28||Interventional|||Smoking Cessation in Primary Health Care Patients With Obstructive Pulmonary Disease|Smoking Cessation in Primary Health Care Patients With Obstructive Pulmonary Disease|Unknown status|Not yet recruiting|N/A|400|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 00:04:15.638245|2018-06-01 00:04:15.638245
NCT01072409|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2014-09-18||2016-09-23|2010-02-19|2010-02-22|Estimate|2014-09-18|2014-09-25|Estimate||||2016-09-23|2016-10-27|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Clinical Evaluation of the Nucleus 5 Cochlear Implant (CI) System|Clinical Evaluation of the Nucleus 5 Cochlear Implant System|Completed||N/A|49|Actual|Cochlear||1|||f||||f||||||||||2018-06-01 00:04:15.735459|2018-06-01 00:04:15.735459
NCT01072396|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-19|2012-11-22||2013-11-27|2010-02-19|2010-02-22|Estimate|2013-04-04|2013-05-15|Estimate||||2013-11-27|2013-12-24|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo-controlled, 6-week, Crossover Study to Examine the Effects of Tiotropium (Spiriva® HandiHaler®, 18 µg Once Daily) on Dynamic Hyperinflation and Physical Exercise Capacity in Patients With Early Stage Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|126|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 00:04:15.894713|2018-06-01 00:04:15.894713
NCT01072383|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-03-12|2010-02-19|2010-02-22|Estimate|||||||2012-03-12|2012-03-13|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis|A Randomized, Placebo-controlled, Double-blind, Multicentre, Multiple Dose, Cohort Study With Escalating Doses to Evaluate the Safety and Efficacy of the Humanized Monoclonal Antibody BT061 Administered to Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|49|Actual|Biotest||2|||f||||t||||||||||2018-06-01 00:04:16.33283|2018-06-01 00:04:16.33283
NCT01072370|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2018-01-16|2010-02-18|2010-02-22|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2010||2010-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children|A Placebo-Controlled, Observer-Blinded, Crossover Study to Evaluate the Safety and Effectiveness of a Single, Autologous, Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children|Recruiting||Phase 1/Phase 2|40|Anticipated|Augusta University||2|||f||||t||||||||||2018-06-01 00:04:16.437747|2018-06-01 00:04:16.437747
NCT01072357|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2017-03-27||2017-05-08|2010-02-19|2010-02-22|Estimate|2017-05-08|2017-05-15|Actual||||2017-05-08|2017-05-15|Actual|December 2009||2009-12-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival|Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival|Completed||Phase 1/Phase 2|30|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||No||2018-06-01 00:04:16.544154|2018-06-01 00:04:16.544154
NCT01072344|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2017-04-28||2017-06-06|2010-02-18|2010-02-22|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|February 2010||2010-02-28|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Long Term Chamomile Therapy for Anxiety|Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)|Completed||Phase 3|180|Actual|University of Pennsylvania||2|||f||||t||||||||No||2018-06-01 00:04:16.873299|2018-06-01 00:04:16.873299
NCT01072331|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2012-11-20||2013-04-02|2010-02-18|2010-02-22|Estimate|2012-11-20|2012-12-19|Estimate||||2013-04-02|2013-04-09|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus|Pharmacokinetic/Pharmacodynamic Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|99|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-06-01 00:04:17.169267|2018-06-01 00:04:17.169267
NCT01072318|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-14|||2010-02-18|2010-02-18|2010-02-22|Estimate|||||||2010-02-18|2010-02-22|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|LEXTOP||Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene|Evaluate Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Have Completed 5 Years of Toremifene|Unknown status|Enrolling by invitation|Phase 4|495|Anticipated|Korean Breast Cancer Study Group||1|||f||||t||||||||||2018-06-01 00:04:17.463292|2018-06-01 00:04:17.463292
NCT01072305|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-19|2010-02-19|2010-02-22|Estimate|||||||2010-02-19|2010-02-22|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Pneumatic Compression of the Legs to Reduce Fluid Demand in Minor Surgery|Einfluss Der Intermittierenden Pneumatischen Kompression Der Unteren Extremitäten Auf Den Intraoperativen Flüssigkeitsbedarf|Completed||N/A|70|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-06-01 00:04:17.531628|2018-06-01 00:04:17.531628
NCT01072292|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2014-06-01|2010-02-19|2010-02-22|Estimate|||||||2014-06-01|2014-06-03|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Cognitive Behavioral Therapy for Insomnia in People With Chronic Obstructive Pulmonary Disease(COPD)|Nurse Managed Cognitive Behavioral Therapy for Insomnia in People With Chronic Obstructive Pulmonary Disease|Completed||N/A|54|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-06-01 00:04:17.644279|2018-06-01 00:04:17.644279
NCT01072279|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2016-02-23|2010-02-19|2010-02-22|Estimate|||||||2016-02-23|2016-02-25|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Preventing Malnutrition in Children Under Two Years of Age Approach|"Strengthening and Evaluating the Preventing Malnutrition in Children Under Two Years of Age Approach (PM2A) in Guatemala and Burundi"|Completed||N/A|16895|Actual|International Food Policy Research Institute||10|||f||||f||||||||||2018-06-01 00:04:17.783404|2018-06-01 00:04:17.783404
NCT01072266|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-11-20|2010-02-19|2010-02-22|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2010||2010-01-31|November 2017|2017-11-30|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||A Dose-escalation Study in Subjects With Advanced Malignancies|A Phase 1, Open-label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB028060 in Subjects With Advanced Malignancies|Completed||Phase 1|45|Actual|Incyte Corporation||1|||f||||f||||||||||2018-06-01 00:04:17.875538|2018-06-01 00:04:17.875538
NCT01072240|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2016-10-29|2010-02-18|2010-02-22|Estimate|||||||2016-10-29|2016-11-01|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia|An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.|Completed|||92|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-06-01 00:04:18.045718|2018-06-01 00:04:18.045718
NCT01072227|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-05-25|2010-02-18|2010-02-22|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2010||2010-07-31|May 2017|2017-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Taiwan|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Taiwan|Terminated|||10|Actual|GlaxoSmithKline|||1|The study was terminated for logistic reasons|f||||||||||Samples With DNA|"~     Tissue~   "|||2018-06-01 00:04:18.148319|2018-06-01 00:04:18.148319
NCT01072214|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-11-10|2010-02-18|2010-02-22|Estimate|||||||2017-11-10|2017-11-14|Actual|March 9, 2010|Actual|2010-03-09|November 2017|2017-11-30|June 28, 2010|Actual|2010-06-28|June 28, 2010|Actual|2010-06-28||Interventional|||A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers|A Randomized, Placebo-controlled, Double-masked, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Repeat Doses of Pazopanib Eye Drops in Healthy Adult Subjects|Completed||Phase 1|37|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 00:04:18.219569|2018-06-01 00:04:18.219569
NCT01072201|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2010-09-29|2010-02-09|2010-02-19|Estimate|2010-02-09|2010-02-19|Estimate||||2010-09-29|2010-10-05|Estimate|June 2007||2007-06-30|September 2010|2010-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|implantitis||To Access the Effects of Mucositis in Adults With Dental Implants|To Access the Effects of Mucositis in Adults With Dental Implants|Completed||Phase 3|60|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 00:04:18.302288|2018-06-01 00:04:18.302288
NCT01072188|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2011-06-10|2010-02-09|2010-02-19|Estimate|2010-02-09|2010-02-19|Estimate||||2011-06-10|2011-06-14|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste|Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste|Completed||Phase 3|45|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 00:04:18.567858|2018-06-01 00:04:18.567858
NCT01072175|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2013-06-27||2018-02-22|2010-02-18|2010-02-19|Estimate|2013-09-19|2013-11-21|Estimate||||2018-02-22|2018-02-26|Actual|March 26, 2010||2010-03-26|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|May 31, 2012|Actual|2012-05-31||Interventional|||Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212|An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma|Active, not recruiting||Phase 2|430|Actual|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 00:04:19.127092|2018-06-01 00:04:19.127092
NCT01072162|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2017-11-10|2010-02-18|2010-02-19|Estimate|||||||2017-11-10|2017-11-14|Actual|January 12, 2010|Actual|2010-01-12|November 2017|2017-11-30|April 7, 2010|Actual|2010-04-07|April 7, 2010|Actual|2010-04-07||Interventional|||Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect|A Randomized, Open-label, Five-period, Balanced Crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag Powder for Oral Suspension (PfOS) Formulation Relative to the Commercial 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in Healthy Adult Subjects|Completed||Phase 1|40|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-06-01 00:04:27.405111|2018-06-01 00:04:27.405111
NCT01072149|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2013-05-30|2011-03-17|2017-10-09|2010-02-18|2010-02-19|Estimate|2013-11-07|2013-12-25|Estimate|2011-03-17|2011-03-28|Estimate|2017-10-09|2017-11-09|Actual|January 1, 2010||2010-01-01|October 2017|2017-10-31|July 1, 2010|Actual|2010-07-01|July 1, 2010|Actual|2010-07-01||Interventional|||A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo|A Three-way Incomplete Block Crossover Study to Investigate the 24-hour Pulmonary Function of Three Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder vs. Placebo, in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|54|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:04:27.531672|2018-06-01 00:04:27.531672
NCT01072136|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2012-09-20||2014-12-04|2010-02-18|2010-02-19|Estimate|2012-09-20|2012-10-25|Estimate||||2014-12-04|2014-12-24|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Empiric Therapy of Mucopurulent Cervicitis (MPC)|A Randomized Trial to Evaluate the Need for Empiric Therapy for Mucopurulent Cervicitis of Unknown Etiology|Terminated||Phase 3|87|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study closed early due to slow accrual with 11% of the targeted sample size enrolled. Therefore, precision and power were low.|2|||f||||||||||||||2018-06-01 00:04:28.253942|2018-06-01 00:04:28.253942
NCT01072123|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2016-01-13|2010-02-18|2010-02-19|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Asthma Education Using Child Life Services and an Asthma-based Computer Game|Innovative Asthma Education Using a Unique Blend of Child Life Services and an Asthma-based Computer Game in the Pediatric Emergency Room|Completed||N/A|27|Actual|Winthrop University Hospital|||||f||||f||||||||||2018-06-01 00:04:28.617868|2018-06-01 00:04:28.617868
NCT01072110|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2013-01-23|2010-02-18|2010-02-19|Estimate|||||||2013-01-23|2013-01-24|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Observational|||Confocal Laser Endomicroscopy (CLE) in Patients With Diarrhea|Confocal Laser Endomicroscopy in Patients With Diarrhea|Unknown status|Recruiting||200|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-06-01 00:04:28.696999|2018-06-01 00:04:28.696999
NCT01072097|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2011-09-06|2010-02-18|2010-02-19|Estimate|||||||2011-09-06|2011-09-07|Estimate|September 2006||2006-09-30|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women|The Effect of Atorvastatin on Androgen Synthesis, Glucose Metabolism and Inflammation in Women With Polycystic Ovary Syndrome (PCOS). A Placebo Controlled Trial|Completed||N/A|30|Anticipated|University of Oulu||2|||f||||f||||||||||2018-06-01 00:04:28.77645|2018-06-01 00:04:28.77645
NCT01072084|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-18|2010-02-18|2010-02-19|Estimate|||||||2010-02-18|2010-02-19|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|||Endomicroscopy in Patients With Food Allergy: a New Diagnostic Option|Endomicroscopy in Patients With Food Allergy: a New Diagnostic Option|Unknown status|Not yet recruiting||50|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-06-01 00:04:28.858847|2018-06-01 00:04:28.858847
NCT01072071|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-19|2010-02-18|2010-02-19|Estimate|||||||2010-02-19|2010-02-22|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Critically Ill Patients|The Influence of Furosemide on Fluid Balance and Intra-abdominal Pressure in Mechanically Ventilated Critically Ill Patients With Secondary Intra-abdominal Hypertension|Unknown status|Recruiting|N/A|30|Anticipated|Ziekenhuis Netwerk Antwerpen (ZNA)||2|||f||||f||||||||||2018-06-01 00:04:28.936729|2018-06-01 00:04:28.936729
NCT01072058|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2013-06-05|2010-02-18|2010-02-19|Estimate|||||||2013-06-05|2013-06-07|Estimate|February 2008||2008-02-29|June 2013|2013-06-30||||February 2011|Actual|2011-02-28||Interventional|||Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker|Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-06-01 00:04:29.280052|2018-06-01 00:04:29.280052
NCT01072045|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2014-12-01|2010-02-18|2010-02-19|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma|A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma|Completed||Phase 2|50|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:04:29.368347|2018-06-01 00:04:29.368347
NCT01072032|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2016-04-12||2016-05-23|2010-02-17|2010-02-19|Estimate|2016-05-23|2016-06-30|Estimate||||2016-05-23|2016-06-30|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|AbotMot||Cortical and Biomechanical Dynamics of Ankle Robotics Training in Stroke|Cortical and Biomechanical Dynamics of Ankle Robotics Training in Stroke|Completed||N/A|27|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-06-01 00:04:29.461239|2018-06-01 00:04:29.461239
NCT01072019|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2014-09-02|2010-02-18|2010-02-19|Estimate|||||||2014-09-02|2014-09-03|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Cutting Block||A Randomized Prospective Trial of Total Knee Arthroplasty Options Comparing Standard Knee Cutting Guides and MRI Generated Patient Specific Custom Cutting Guides|Comparative Clinical Study of the Vanguard® Knee System Using Signature™ Custom Guides & Conventional Techniques|Completed||N/A|25|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:04:29.722032|2018-06-01 00:04:29.722032
NCT01072006|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2017-01-03||2017-08-11|2010-02-18|2010-02-19|Estimate|2017-03-09|2017-04-24|Actual||||2017-08-11|2017-09-12|Actual|June 7, 2011|Actual|2011-06-07|August 2017|2017-08-31|April 21, 2017|Actual|2017-04-21|December 1, 2015|Actual|2015-12-01||Observational|||Top-Down Executive Control in Traumatic Brain Injury (TBI), PTSD and Combined|Top-Down Executive Control in TBI, PTSD and Combined TBI/PTSD|Completed|||30|Actual|VA Office of Research and Development|||4||f||||f|f|f|||f|||No||2018-06-01 00:04:29.803633|2018-06-01 00:04:29.803633
NCT01071993|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2017-04-07||2017-10-27|2010-02-18|2010-02-19|Estimate|2017-08-14|2017-09-13|Actual||||2017-10-27|2017-12-04|Actual|March 2010||2010-03-31|October 2017|2017-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SCIN|Participants signed consent; however, study was terminated prior to randomization.|Efficacy of Statins In Prevention of CIN|Efficacy Of Statins In The Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Insufficiency (SCIN Trial): A Double-Blind, Placebo-Controlled Trial|Terminated||N/A|21|Actual|University of Oklahoma|Study Sponsor no longer supplied study drug/placebo.|2||Sponsor can not supply drugs anymore.|f||||t||||||||No|No data was collected; therefore, a plan is not applicable.|2018-06-01 00:04:30.217095|2018-06-01 00:04:30.217095
NCT01071980|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-10-10|2010-02-18|2010-02-19|Estimate|||||||2012-10-10|2012-10-11|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|VIMS||Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Industrial Workers|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS) - Industrial Workers|Completed||N/A|522|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||||||||||||2018-06-01 00:04:30.368109|2018-06-01 00:04:30.368109
NCT01071967|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2013-09-06|2010-02-18|2010-02-19|Estimate|||||||2013-09-06|2013-09-10|Estimate|April 2002||2002-04-30|September 2013|2013-09-30|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of a Community-based Nursing Intervention on Mortality in Chronically Ill Older Adults|Effect of a Longitudinal, Multifactorial Community-based Nursing Intervention on Mortality in Chronically Ill Older Adults|Unknown status|Enrolling by invitation|N/A|2000|Anticipated|Health Quality Partners||2|||f||||f||||||||||2018-06-01 00:04:30.445929|2018-06-01 00:04:30.445929
NCT01071954|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17||2017-07-27|2017-07-27|2010-02-18|2010-02-19|Estimate||||2017-07-27|2017-07-31|Actual|2017-07-27|2017-07-31|Actual|December 30, 2009|Actual|2009-12-30|July 2017|2017-07-31|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura|An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)|Completed||Phase 3|66|Actual|Amgen||1|||f||||f||||||||||2018-06-01 00:04:30.560602|2018-06-01 00:04:30.560602
NCT01071941|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-05-16|2010-02-18|2010-02-19|Estimate|||||||2018-05-16|2018-05-17|Actual|October 2010||2010-10-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors|rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors|Recruiting||Phase 1|40|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:04:30.702851|2018-06-01 00:04:30.702851
NCT01071928|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-08-17|2010-02-18|2010-02-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma|A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144|Withdrawn||Phase 2|0|Actual|Hoosier Cancer Research Network||1||Lack of efficacy of experimental treatment|f||||t||||||||||2018-06-01 00:04:30.803676|2018-06-01 00:04:30.803676
NCT01071915|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2012-10-29||2013-01-08|2010-02-18|2010-02-19|Estimate|2013-01-08|2013-02-12|Estimate||||2013-01-08|2013-02-12|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer|An Open-label, Multi-Centre Trial, Bridging Efficacy and Safety of Degarelix One-Month Dosing Regimen in Korean Patients With Prostate Cancer Requiring Androgen Ablation Therapy|Completed||Phase 3|157|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:04:30.950567|2018-06-01 00:04:30.950567
NCT01071902|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18||2012-11-28|2012-11-29|2010-02-18|2010-02-19|Estimate||||2012-11-28|2012-11-30|Estimate|2012-11-29|2012-12-03|Estimate|February 2010||2010-02-28|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of Moxidex Otic|Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media With Otorrhea in Tympanostomy Tubes|Terminated||Phase 3|400|Actual|Alcon Research||3||Management decision|f||||f||||||||||2018-06-01 00:04:31.303376|2018-06-01 00:04:31.303376
NCT01071889|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2015-01-29|2010-02-18|2010-02-19|Estimate|||||||2015-01-29|2015-01-30|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|August 2012|Actual|2012-08-31||Interventional|||Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults|Double-blind, Randomized, Placebo and Active Controlled Study to Assess the Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults(Zolpidem or Brotizolam)|Completed||Phase 1/Phase 2|10|Actual|Coeruleus Ltd.||2|||f||||t||||||||||2018-06-01 00:04:31.373915|2018-06-01 00:04:31.373915
NCT01071876|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-01-20|2010-02-18|2010-02-19|Estimate|||||||2015-01-20|2015-01-21|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|HAROSA1||BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS|BF2.649 in Patients With Obstructive Sleep Apnea Syndrome (OSA) and Treated by Nasal Continuous Positive Airway Pressure (nCPAP), But Still Complaining of Excessive Daytime Sleepiness (EDS)|Completed||Phase 3|244|Actual|Bioprojet||2|||f||||t||||||||||2018-06-01 00:04:31.442407|2018-06-01 00:04:31.442407
NCT01071863|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-19|2010-02-18|2010-02-19|Estimate|||||||2010-02-19|2010-02-22|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|||Association of Fear of Falling and Physical Activity in Rheumatoid Arthritis Comparison Before and After Biological Therapy|Association of Fear of Falling and Physical Activity in Rheumatoid Arthritis Comparison Before and After Biological Therapy|Unknown status|Not yet recruiting||40|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust|||2||f||||f||||||||||2018-06-01 00:04:31.530741|2018-06-01 00:04:31.530741
NCT01071850|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18||2012-04-29|2017-11-20|2010-02-18|2010-02-19|Estimate||||2012-04-29|2012-05-01|Estimate|2017-11-20|2017-11-21|Actual|March 3, 2010|Actual|2010-03-03|November 2017|2017-11-30|April 11, 2011|Actual|2011-04-11|April 11, 2011|Actual|2011-04-11||Interventional|||A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|412|Actual|Astellas Pharma Inc||6|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:04:31.764669|2018-06-01 00:04:31.764669
NCT01071837|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-06-15|2010-02-18|2010-02-19|Estimate|||||||2015-06-15|2015-06-16|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||APG101 in Glioblastoma|A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma|Completed||Phase 2|84|Actual|Apogenix GmbH||2|||f||||t||||||||||2018-06-01 00:04:31.926846|2018-06-01 00:04:31.926846
NCT01071824|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-08-29|2010-02-18|2010-02-19|Estimate|||||||2017-08-29|2017-08-31|Actual|June 2009||2009-06-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Limb Size of Transverse Coloplasty Pouch|Prospective Randomised Study for Comparison of the Size of Limb of Transverse Coloplasty Pouch After Low Rectal Resection With Total Mesorectal Excision|Recruiting||N/A|52|Anticipated|Kantonsspital Liestal||2|||f||||t||||||||||2018-06-01 00:04:32.029184|2018-06-01 00:04:32.029184
NCT01071811|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-19|2010-02-18|2010-02-19|Estimate|||||||2010-02-19|2010-02-22|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Effect After 12 Weeks of Having Received a Pedometer and a Pedometer Program on Physical Activity and Health|The Effect After 12 Weeks of Having Received a Pedometer and a Pedometer Program on Physical Activity, Health Measurements, Self-rated Health, Stress, and Sleep Quality: a Randomized Controlled Trial|Completed||Phase 3|668|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-06-01 00:04:32.173059|2018-06-01 00:04:32.173059
NCT01071798|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2015-11-12||2016-01-25|2010-02-18|2010-02-19|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational||Main analysis population|An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis|A Prospective, Multi-center, Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months (in Case of Re-therapy the First 12 Months) of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care|Completed|||1653|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-06-01 00:04:32.31919|2018-06-01 00:04:32.31919
NCT01071785|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2010-02-25|2010-02-18|2010-02-19|Estimate|||||||2010-02-25|2010-03-01|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Dietetic Intervention With Soluble Fiber in Type 2 Diabetes Mellitus (DM) Patients With Metabolic Syndrome (MS)|Dietetic Intervention With Soluble Fiber in Type 2 Diabetes Mellitus (DM) Patients With Metabolic Syndrome (MS)|Completed||N/A|42|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:04:33.498222|2018-06-01 00:04:33.498222
NCT01071590|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2018-05-10|2010-02-18|2010-02-19|Estimate|||||||2018-05-10|2018-05-11|Actual|February 1, 2010||2010-02-01|January 3, 2014|2014-01-03|January 3, 2014||2014-01-03|||||Observational|||The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait|The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait|Completed|||45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:04:34.773226|2018-06-01 00:04:34.773226
NCT01071772|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2011-06-08|2010-02-18|2010-02-19|Estimate|||||||2011-06-08|2011-06-09|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|METAMOD||The Effect of Hyperglycemia on LV Function and Exercise Capacity in Diabetics With and Without Heart Failure.|Metabolic Substrate Modulation in Insulin Treated Diabetics With and Without Heart Failure: The Effect of Hyperglycemia on Left Ventricular Function and Exercise Capacity.|Completed||Phase 2|18|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:04:33.571378|2018-06-01 00:04:33.571378
NCT01071759|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-18|2010-02-18|2010-02-19|Estimate|||||||2010-02-18|2010-02-19|Estimate|February 2009||2009-02-28|February 2010|2010-02-28||||||||Observational|||Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes|Effects of Dietary Heme/Non-heme Iron and Hp Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes - a Perinatal Longitudinal Study|Unknown status|Recruiting||140|Anticipated|E-DA Hospital|||1||f||||t||||||||||2018-06-01 00:04:33.630357|2018-06-01 00:04:33.630357
NCT01071746|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-18|2010-02-18|2010-02-19|Estimate|||||||2010-02-18|2010-02-19|Estimate|September 2008||2008-09-30|April 2008|2008-04-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|DASIMAR||Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)|The Predictive Utility of the Dimethylarginines and Ischemia Modified Albumin as Prognostic Biomarkers in Patients With Acute-on-chronic Liver Failure|Unknown status|Recruiting||700|Anticipated|University College London Hospitals|||1||f||||f||||||Samples With DNA|"~     RNA~   "|||2018-06-01 00:04:33.694952|2018-06-01 00:04:33.694952
NCT01071733|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-11-17|2010-02-18|2010-02-19|Estimate|||||||2017-11-17|2017-11-20|Actual|December 2009||2009-12-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Observational|FREEUS||Fracture Evaluated in Emergency Room by Ultra Sound|Fracture Evaluated in Emergency Room by Ultra Sound|Withdrawn|||0|Actual|University of Aarhus|||3|study was never initiated due to logistic causes|f||||f||||||||||2018-06-01 00:04:33.880241|2018-06-01 00:04:33.880241
NCT01071720|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-12-09|2010-02-18|2010-02-19|Estimate|||||||2010-12-09|2010-12-10|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|CKD-501 FDI||The Effect of Food on the Pharmacokinetic Characteristics of CKD-501|Clinical Study to Assess the Effect of Food on the Pharmacokinetic Characteristics of CKD-501 in Healthy Subjects|Completed||Phase 1|24|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-06-01 00:04:33.949231|2018-06-01 00:04:33.949231
NCT01071707|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-10-16|2010-02-18|2010-02-19|Estimate|||||||2012-10-16|2012-10-17|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Observational|COMET||Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)|COMET: Correlating Outcomes With Biochemical Markers to Estimate Time-progression in IPF. A Prospective, Multi-Center, Longitudinal Follow up Study of Subjects With Idiopathic Pulmonary Fibrosis|Completed|||108|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     whole blood, tissue~   "|||2018-06-01 00:04:34.014866|2018-06-01 00:04:34.014866
NCT01071694|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-04-12|2010-02-18|2010-02-19|Estimate|||||||2012-04-12|2012-04-16|Estimate|January 2011||2011-01-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea|QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea|Withdrawn|||0|Actual|Bayer|||1|Study Manager could not embark on it during the timeline.|f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 00:04:34.120419|2018-06-01 00:04:34.120419
NCT01071681|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2011-11-01|2010-02-18|2010-02-19|Estimate|||||||2011-11-01|2011-11-02|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Survey to Assess Why People Are Not Responding to Treatment in Hypertension|Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.|Completed|||1589|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 00:04:34.193353|2018-06-01 00:04:34.193353
NCT01071668|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-05-11|2010-02-18|2010-02-19|Estimate|||||||2015-05-11|2015-05-12|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|GEM-2||Onset of Labor and Metabolomics (GEM-2)|Feasibility Study to Develop the Analysis of the Metabolome During the Onset of Labor During Pregnancy|Unknown status|Active, not recruiting||80|Anticipated|Université de Sherbrooke|||1||f||||f||||||Samples Without DNA|"~     Vaginal secretions, whole blood and urine are collected~   "|||2018-06-01 00:04:34.265068|2018-06-01 00:04:34.265068
NCT01071655|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2015-03-23|2010-02-18|2010-02-19|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|SETICC||Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer|Selecting Treatment in Colorectal Cancer: Capecitabine or 5-fluorouracil Selection According to Polymorphisms in TS-3'UTR and ERCC1-118 to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer|Completed||Phase 2|195|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-06-01 00:04:34.322817|2018-06-01 00:04:34.322817
NCT01071642|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2017-06-20|2010-02-18|2010-02-19|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2010||2010-03-31|June 2017|2017-06-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography||Completed||N/A|100|Actual|Soroka University Medical Center||3|||f||||||||||||||2018-06-01 00:04:34.469908|2018-06-01 00:04:34.469908
NCT01071629|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-03-12|2010-02-18|2010-02-19|Estimate|||||||2015-03-12|2015-03-13|Estimate|November 2004||2004-11-30|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|April 2010|Actual|2010-04-30||Interventional|||Exercise Training Effects in Patients With Heart Failure|Aerobic Interval Training Versus Combined Aerobic Interval Training and Strength Training Effects in Patients With Heart Failure|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Athens||2|||f||||f||||||||||2018-06-01 00:04:34.553815|2018-06-01 00:04:34.553815
NCT01071616|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2018-04-04|2010-02-18|2010-02-19|Estimate|||||||2018-04-04|2018-04-05|Actual|January 22, 2010||2010-01-22|November 29, 2013|2013-11-29|November 29, 2013|Actual|2013-11-29|||||Interventional|||Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis|Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked Cannabis|Completed||Phase 1|45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:04:34.634742|2018-06-01 00:04:34.634742
NCT01071577|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2018-05-30|2010-02-18|2010-02-19|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 27, 2010||2010-01-27|May 29, 2018|2018-05-29||||||||Observational|||Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products|Collection of Bone Marrow From Healthy Volunteers and Patients for the Production of Clinical Bone Marrow Stromal Cell (BMSC) Products|Completed|||65|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:04:34.852542|2018-06-01 00:04:34.852542
NCT01071564|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-04-14|2010-02-18|2010-02-19|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery|A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC # 749225) Administered in Patients With Advanced Breast Cancer|Terminated||Phase 1|13|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:04:34.923859|2018-06-01 00:04:34.923859
NCT01071551|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-18|2010-02-18|2010-02-19|Estimate|||||||2010-02-18|2010-02-19|Estimate|September 2008||2008-09-30|November 2009|2009-11-30|September 2011|Anticipated|2011-09-30|December 2009|Actual|2009-12-31||Interventional|NEHLM||"The Impact of the Nutrition Enrichment and Healthy Living Model ( NEHLM) on Diet Quality, Physical Activity and Dental Health Among Children From Socioeconomically Disadvantaged Families in Beer Sheva"|"The Impact of the Nutrition Enrichment and Healthy Living Model ( NEHLM) on Diet Quality."|Unknown status|Active, not recruiting|N/A|258|Actual|Soroka University Medical Center||2|||f||||f||||||||||2018-06-01 00:04:35.02309|2018-06-01 00:04:35.02309
NCT01071538|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2016-01-07||2018-02-09|2010-02-18|2010-02-19|Estimate|2016-02-18|2016-03-17|Estimate||||2018-02-09|2018-03-09|Actual|May 2010||2010-05-31|February 2018|2018-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|BUILD||Buprenorphine for Late-Life Treatment Resistant Depression|Buprenorphine for Late-Life Treatment Resistant Depression|Completed||Phase 2|15|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-06-01 00:04:35.095308|2018-06-01 00:04:35.095308
NCT01071525|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-25|2010-02-18|2010-02-19|Estimate|||||||2010-02-25|2010-03-01|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|||The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker||Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-06-01 00:04:35.30181|2018-06-01 00:04:35.30181
NCT01071512|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2017-06-15||2017-09-22|2010-02-18|2010-02-19|Estimate|2017-08-04|2017-09-06|Actual||||2017-09-22|2017-10-25|Actual|April 2010||2010-04-30|September 2017|2017-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Includes patients that completed treatment|Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis|Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis|Completed||N/A|20|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 00:04:35.665218|2018-06-01 00:04:35.665218
NCT01071499|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2017-06-30|2010-02-17|2010-02-19|Estimate|||||||2017-06-30|2017-07-05|Actual|March 2010||2010-03-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population Presenting for Elective Surgery|Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population (2 - 6 Years of Age) Presenting for Elective Surgery|Completed||Phase 2/Phase 3|43|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 00:04:36.866985|2018-06-01 00:04:36.866985
NCT01071486|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-11-08|2010-02-18|2010-02-19|Estimate|||||||2015-11-08|2015-11-10|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation|Busulfan Pharmacokinetic Analysis and Glutathione S-transferase (GST)Genetic Polymorphism (A1,T1,M1,P1)in Adults Undergoing Hematological Bone Marrow Transplantation (HSCT).|Withdrawn||Phase 4|0|Actual|Rambam Health Care Campus||||lack of participants|f||||f||||||||||2018-06-01 00:04:36.940879|2018-06-01 00:04:36.940879
NCT01071473|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2014-02-06|2010-02-18|2010-02-19|Estimate|||||||2014-02-06|2014-02-10|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy|Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy|Completed||N/A|22|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 00:04:37.008913|2018-06-01 00:04:37.008913
NCT01071460|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-11-08|2010-02-18|2010-02-19|Estimate|||||||2012-11-08|2012-11-09|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Evaluation of Efficacy and Safety of the FlexStent Self-Expanding Stent System|The FlexStent-Registry, Evaluation of Efficacy and Safety of the FlexStent Femoropopliteal Self-Expanding Stent System|Completed||Phase 3|100|Actual|Provascular GmbH||1|||f||||t||||||||||2018-06-01 00:04:37.101574|2018-06-01 00:04:37.101574
NCT01071447|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-08-17|2010-02-18|2010-02-19|Estimate|||||||2010-08-17|2010-08-18|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment|Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment:a Randomized Controlled Trial Comparing Nurse-led Clinic Versus Rheumatologist Clinic|Unknown status|Recruiting|N/A|100|Anticipated|Spenshult Hospital||2|||f||||t||||||||||2018-06-01 00:04:37.198453|2018-06-01 00:04:37.198453
NCT01071434|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2012-12-05|2010-02-18|2010-02-19|Estimate|||||||2012-12-05|2012-12-07|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors|Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors|Terminated|||5|Actual|Stanford University||||PI left|f||||||||||||||2018-06-01 00:04:37.320192|2018-06-01 00:04:37.320192
NCT01071421|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-18|2010-02-18|2010-02-19|Estimate|||||||2010-02-18|2010-02-19|Estimate|April 2006||2006-04-30|February 2006|2006-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|NEBULOSA||Sleep Apnea Syndrome and Community Acquired Pneumonia|Prevalence of Sleep Apnea-hypopnea Syndrome in Patients With Community Acquired Pneumonia, Prospective and Comparative Case-control Study|Completed|||123|Actual|Hospital Universitario San Juan de Alicante|||2||f||||t||||||||||2018-06-01 00:04:37.380724|2018-06-01 00:04:37.380724
NCT01071408|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2012-05-14|2010-02-17|2010-02-19|Estimate|||||||2012-05-14|2012-05-16|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Trial of a Secondary Stroke Prevention Program|Development of a Stroke Prevention Program for an Underserved Minority Community|Completed||N/A|54|Actual|Sepulveda Research Corporation||2|||f||||f||||||||||2018-06-01 00:04:37.471456|2018-06-01 00:04:37.471456
NCT01071395|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2014-11-17||2015-05-07|2010-02-18|2010-02-19|Estimate|2015-05-07|2015-05-28|Estimate||||2015-05-07|2015-05-28|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|April 2012|Actual|2012-04-30||Interventional|||Validation of Dyskinesia Rating Scales|Validation of Dyskinesia Rating Scales|Completed||Phase 4|68|Actual|Rush University Medical Center|Study limitations include the patient population universally derived from university centers and the short duration of the program.|2|||f||||t||||||||||2018-06-01 00:04:37.667921|2018-06-01 00:04:37.667921
NCT01071382|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2012-10-15|2010-02-18|2010-02-19|Estimate|||||||2012-10-15|2012-10-16|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Epidemiology of Aeromedical Evacuation|Epidemiology of Aeromedical Evacuation|Completed|||504|Actual|Ruhr University of Bochum|||||f||||f||||||||||2018-06-01 00:04:38.410398|2018-06-01 00:04:38.410398
NCT01071369|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2017-04-25|2010-02-18|2010-02-19|Estimate|||||||2017-04-25|2017-04-27|Actual|February 2008|Actual|2008-02-29|April 2017|2017-04-30|June 2012|Actual|2012-06-30|February 2008|Actual|2008-02-29||Interventional|||Treatment of Chronic Thoracic and Neck and Upper Extremity Pain|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Cervical and Thoracic Interlaminar Epidural Injections in Thoracic and Cervical Disc Herniation, Discogenic Pain, and Post-Cervical Laminectomy Syndrome|Completed||Phase 4|120|Actual|Pain Management Center of Paducah||2|||f||||f|t|f|||t|||No||2018-06-01 00:04:38.476989|2018-06-01 00:04:38.476989
NCT01071356|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2015-05-11||2018-04-27|2010-02-18|2010-02-19|Estimate|2018-04-27|2018-05-24|Actual||||2018-04-27|2018-05-24|Actual|February 2009||2009-02-28|April 2018|2018-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Intensive Motivational Interviewing for Methamphetamine Dependence|Intensive Motivational Interviewing for Methamphetamine Dependence|Completed||Phase 2|217|Actual|Public Health Institute, California||2|||f||||f||||||||No|There is no plan to share IPD|2018-06-01 00:04:38.60716|2018-06-01 00:04:38.60716
NCT01071343|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-02-18|2010-02-18|2010-02-19|Estimate|||||||2010-02-18|2010-02-19|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Transcutaneous Electric Muscle Stimulation (TEMS) in Septic Patients|Effect of Transcutaneous Electric Muscle Stimulation on Muscle Volume in Patients With Septic Shock|Completed||N/A|8|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 00:04:39.005925|2018-06-01 00:04:39.005925
NCT01071317|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-04-26|2010-02-18|2010-02-19|Estimate|||||||2012-04-26|2012-04-30|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Trial of Comprehensive Migraine Intervention|An RCT of a Comprehensive Migraine Intervention at the Time of Discharge From the ED After Treatment for Acute Migraine|Completed||Phase 4|50|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 00:04:39.078719|2018-06-01 00:04:39.078719
NCT01071304|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2015-04-09|2010-02-18|2010-02-19|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|February 2012|Actual|2012-02-29|September 2010|Actual|2010-09-30||Interventional|||Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)|A Study to Evaluate the Effect of Multiple Doses of Ridaforolimus (AP23573; MK-8669) on the Single Dose Pharmacokinetics of Midazolam.|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:04:39.202792|2018-06-01 00:04:39.202792
NCT01071291|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2015-10-09|2010-02-18|2010-02-19|Estimate|||||||2015-10-09|2015-10-12|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effects of Niaspan™ on Reverse Cholesterol Transport in Healthy Male Subjects|Completed||Phase 1|37|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:04:39.288485|2018-06-01 00:04:39.288485
NCT01071278|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2012-02-01||2015-07-21|2010-02-17|2010-02-19|Estimate|2012-02-01|2012-03-07|Estimate||||2015-07-21|2015-08-11|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Lipid Management in Clinical Practice (MK-0524A-115)|Lipid Management in Clinical Practice|Completed|||2390|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 00:04:39.408307|2018-06-01 00:04:39.408307
NCT01071265|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2015-09-24|2010-02-18|2010-02-19|Estimate|||||||2015-09-24|2015-09-28|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Interventional|Remote IMPACT||Remote Ischemic Preconditioning in Cardiac Surgery Trial|Remote Ischemic Preconditioning in Cardiac Surgery: a Pilot Randomized Controlled Trial|Completed||N/A|250|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 00:04:39.72047|2018-06-01 00:04:39.72047
NCT01071252|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2015-01-28|2012-05-31|2015-02-12|2010-02-18|2010-02-19|Estimate|2015-02-12|2015-02-16|Estimate|2012-05-31|2012-06-06|Estimate|2015-02-12|2015-02-16|Estimate|March 2010||2010-03-31|February 2015|2015-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|A Randomized, Double-blind, Placebo Controlled, Multicenter Dose Ranging Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 2|125|Actual|Novartis||5|||f||||||||||||||2018-06-01 00:04:39.960839|2018-06-01 00:04:39.960839
NCT01071239|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20||2018-03-20|2018-03-23|2010-02-18|2010-02-19|Estimate||||2018-03-21|2018-03-23|Actual|2018-03-23|2018-03-26|Estimate|April 2009||2009-04-30|March 2018|2018-03-31|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional|FA||Hematopoietic Stem Cell Transplant for Fanconi Anemia|A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|Completed||Phase 2|1|Actual|Medical College of Wisconsin||1|||f||||t||||||||||2018-06-01 00:04:40.892933|2018-06-01 00:04:40.892933
NCT01071226|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17||2018-03-22|2018-03-26|2010-02-18|2010-02-19|Estimate||||2018-03-22|2018-03-26|Estimate|2018-03-26|2018-03-29|Actual|May 2008||2008-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|August 2016|Actual|2016-08-31||Interventional|||Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device|CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With The CliniMACS Device for T and B Cell Depletion|Active, not recruiting||N/A|60|Actual|Medical College of Wisconsin||2|||f||||t||||||||||2018-06-01 00:04:41.011457|2018-06-01 00:04:41.011457
NCT01071044|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2012-10-29||2015-03-17|2010-02-17|2010-02-18|Estimate|2014-05-23|2014-06-26|Estimate||||2015-03-17|2015-04-03|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome|Use of Lisdexamfetamine Dimesylate in Treatment of Cognitive Impairment (Chronic Fatigue Syndrome): A Double Blind, Placebo Controlled Study|Completed||Phase 4|26|Actual|Rochester Center for Behavioral Medicine|Relatively small sample size, imbalance of participants in active vs. placebo group due to pre-randomization, heterogenous sample (only one male participant in the study, who was in the control group and not the treatment group).|2|||f||||f||||||||||2018-06-01 00:04:44.197319|2018-06-01 00:04:44.197319
NCT01071200|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|2012-05-14||2013-12-02|2010-02-18|2010-02-19|Estimate|2012-06-28|2012-08-14|Estimate||||2013-12-02|2013-12-27|Estimate|March 2005||2005-03-31|December 2013|2013-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|Luveris in ART||Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle|A Phase III, Multicentric, Randomized, Open, Comparative Study to Evaluate if the Addition of Recombinant Human Luteinising Hormone [r-hLH (Luveris®)] to Follicle Stimulating Hormone (FSH) From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing Assisted Reproduction Technology (ART), Who Required High FSH Dose in a Previous Cycle|Terminated||Phase 3|133|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 00:04:41.191823|2018-06-01 00:04:41.191823
NCT01071187|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2010-09-14|2010-02-18|2010-02-19|Estimate|||||||2010-09-14|2010-09-15|Estimate|March 2010||2010-03-31|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Varenicline for Alcohol Dependence|Investigation of the Efficacy and Safety of Varenicline in the Postacute Treatment of Alcohol Dependence - a Prospective, Double-blind, Placebo-controlled, Randomised Phase-II Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-06-01 00:04:41.721851|2018-06-01 00:04:41.721851
NCT01071174|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2011-08-01|2010-02-18|2010-02-19|Estimate|||||||2011-08-01|2011-08-02|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||A Safety Study of Dapivirine Vaginal Ring in Africa|A Double-Blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety of an Intravaginal Matrix Ring With Dapivirine in Healthy, HIV-Negative Women.|Completed||Phase 1/Phase 2|280|Actual|International Partnership for Microbicides, Inc.||2|||f||||t||||||||||2018-06-01 00:04:41.837139|2018-06-01 00:04:41.837139
NCT01071161|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2015-09-17|2010-02-18|2010-02-19|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|CACTUS||The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough|Phase III (c) The Effect of Azithromycin in Patients With COPD and Chronic Productive Cough|Completed||Phase 3|84|Actual|Isala||2|||f||||t||||||||||2018-06-01 00:04:41.928611|2018-06-01 00:04:41.928611
NCT01071148|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2014-05-02|2010-02-18|2010-02-19|Estimate|||||||2014-05-02|2014-05-05|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth|A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth.|Completed|||166|Actual|Merck KGaA|||2||f||||f||||||||||2018-06-01 00:04:42.037124|2018-06-01 00:04:42.037124
NCT01071135|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2011-11-10|2010-02-18|2010-02-19|Estimate|||||||2011-11-10|2011-11-11|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Quetiapine XR in Schizophrenic Patients|Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study-|Terminated||Phase 3|5|Actual|Hannover Medical School||1||Planned number of 30 subjects could not be recruited during recruitment phase.|f||||f||||||||||2018-06-01 00:04:42.111853|2018-06-01 00:04:42.111853
NCT01071122|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-18|||2014-01-24|2010-02-18|2010-02-19|Estimate|||||||2014-01-24|2014-01-27|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)|A Prospective, Open-label, Active-controlled, Randomized Study Comparing Nifedipine GITS Versus Valsartan Versus a Combination of Both on Central Blood Pressure in Inadequately Controlled Essential Hypertension.|Completed||Phase 4|365|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:04:42.1862|2018-06-01 00:04:42.1862
NCT01071109|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-17|2010-02-17|2010-02-19|Estimate|||||||2010-02-17|2010-02-19|Estimate|November 2010||2010-11-30|February 2010|2010-02-28|April 2012|Anticipated|2012-04-30|October 2011|Anticipated|2011-10-31||Interventional|RTTM301||The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy|The Clinical and Biochemical Effect of Therapeutic Massage on Fatigue and Insomnia in Women With Breast Cancer Receiving Radiation Therapy|Unknown status|Not yet recruiting|N/A|48|Anticipated|Floyd Memorial Hospital and Health Services||2|||f||||f||||||||||2018-06-01 00:04:42.284024|2018-06-01 00:04:42.284024
NCT01071096|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2012-01-16||2013-02-06|2010-02-18|2010-02-19|Estimate|2012-01-16|2012-02-17|Estimate||||2013-02-06|2013-02-12|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Calcitonin Gene-related Peptide Levels in Chronic Migraine|Calcitonin Gene-related Peptide (CGRP) Levels in the Pathogenesis of Chronic Migraine|Completed||Phase 4|20|Actual|Cady, Roger, M.D.|Due to identified lab errors related to processing of samples for CGRP and cytokine levels, samples are currently being re-processed. Results will be posted following re-analysis of all study data related to sample values.|2|||f||||f||||||||||2018-06-01 00:04:42.387852|2018-06-01 00:04:42.387852
NCT01071083|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2012-10-25||2013-09-12|2010-02-17|2010-02-19|Estimate|2012-12-20|2013-01-30|Estimate||||2013-09-12|2013-09-19|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|RESTORE||Treatment Interruption of Natalizumab|Randomized Treatment Interruption of Natalizumab|Completed||Phase 2|175|Actual|Biogen||3|||f||||||||||||||2018-06-01 00:04:42.881071|2018-06-01 00:04:42.881071
NCT01071070|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2011-11-07||2011-12-20|2010-02-17|2010-02-19|Estimate|2011-12-20|2012-01-26|Estimate||||2011-12-20|2012-01-26|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease|A Phase 3b, Randomized, Active-Controlled, Single-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Injection in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects Receiving Hemodialysis|Completed||Phase 3|216|Actual|Abbott||2|||f||||||||||||||2018-06-01 00:04:43.665438|2018-06-01 00:04:43.665438
NCT01071057|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2017-10-24|2010-02-17|2010-02-18|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2010||2010-12-31|October 2017|2017-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Naloxone for the Treatment of Opioid-Induced Pruritus|Naloxone for the Treatment of Opioid-Induced Pruritus: A Double-Blind, Prospective, Randomized, Controlled Study|Completed||Phase 2/Phase 3|92|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:04:44.101122|2018-06-01 00:04:44.101122
NCT01071031|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-09-25|2010-02-17|2010-02-18|Estimate|||||||2012-09-25|2012-09-26|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||HIV Vaccine Study in HIV Positive Patients|A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v|Completed||Phase 1|54|Actual|PepTcell Limited||5|||f||||f||||||||||2018-06-01 00:04:44.650628|2018-06-01 00:04:44.650628
NCT01071018|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2015-09-04|2010-02-17|2010-02-18|Estimate|||||||2015-09-04|2015-09-07|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)|A Phase I Study of MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:04:44.751662|2018-06-01 00:04:44.751662
NCT01071005|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2013-02-22|2010-02-17|2010-02-18|Estimate|||||||2013-02-22|2013-02-25|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ® (Leuprorelin Acetate - Abbot)|Randomized Clinical Trial of the Pharmacodynamics of Lorelin Depot 3.75Mg (Leuprorelin Acetate) Produced by Laboratório Químico Farmacêutico Bergamo LTDA. Compared to Lupron Depot ® 3.75 Mg Produced by Abbott in Healthy Subjects|Completed||Phase 1|58|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:04:44.835881|2018-06-01 00:04:44.835881
NCT01070992|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-17|2010-02-17|2010-02-18|Estimate|||||||2010-02-17|2010-02-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:04:44.919472|2018-06-01 00:04:44.919472
NCT01070979|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2011-02-14||2013-04-15|2010-02-17|2010-02-18|Estimate|2011-03-09|2011-04-08|Estimate||||2013-04-15|2013-04-22|Estimate|February 2003||2003-02-28|April 2013|2013-04-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.|A Multicenter, Double-Blind, Controlled, Randomized Study to Compare the Efficacy in Relief of Hot Flushes in Women Receiving Oral Estradiol Acetate Tablets, Oral Estradiol Tablets or Oral Conjugated Equine Estrogens|Completed||Phase 3|249|Actual|Warner Chilcott||3|||f||||f||||||||||2018-06-01 00:04:44.991593|2018-06-01 00:04:44.991593
NCT01070966|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2011-04-14||2015-10-30|2010-02-17|2010-02-18|Estimate|2011-04-14|2011-05-10|Estimate||||2015-10-30|2015-11-02|Estimate|July 2005||2005-07-31|October 2015|2015-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Vytorin Reexamination Study (0653A-174)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of VYTORIN in Usual Practice|Completed|||2089|Actual|Merck Sharp & Dohme Corp.|||4||f||||f||||||||||2018-06-01 00:04:45.442615|2018-06-01 00:04:45.442615
NCT01070953|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2011-07-28||2015-10-12|2010-02-17|2010-02-18|Estimate|2011-09-26|2011-11-04|Estimate||||2015-10-12|2015-10-14|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||EZETROL® Re-examination Study (MK0653-175)(COMPLETED)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of EZETROL® in Usual Practice|Completed|||4467|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:04:45.771198|2018-06-01 00:04:45.771198
NCT01070940|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2011-02-18|2010-02-17|2010-02-18|Estimate|||||||2011-02-18|2011-02-21|Estimate|February 2010||2010-02-28|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||L-NMMA Dose-response Study in Healthy Subjects|L-NMMA's Effect on Renal and Cardiovascular Variables in Healthy Subjects. A Randomized, Placebo-controlled Crossover Study.|Completed||Phase 1|12|Actual|Regional Hospital Holstebro||4|||f||||t||||||||||2018-06-01 00:04:46.181002|2018-06-01 00:04:46.181002
NCT01070927|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2016-11-01|2010-02-17|2010-02-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer|An Exploratory Study on Anti-tumour Activity of Orally Administered RO4929097, a Gamma-secretase Inhibitor, as a Single Agent in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer (NSCLC).|Completed||Phase 2|7|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:04:46.246451|2018-06-01 00:04:46.246451
NCT01070914|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-06|||2012-05-07|2010-02-17|2010-02-18|Estimate|||||||2012-05-07|2012-05-08|Estimate|June 2011||2011-06-30|May 2012|2012-05-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|||Early Detection and Characterization of Primary Ciliary Dyskinesia|The Israeli National Consortium for Early Detection and Characterization of Primary Ciliary Dyskinesia|Unknown status|Recruiting||130|Anticipated|Ziv Hospital|||||f||||f||||||||||2018-06-01 00:04:46.303219|2018-06-01 00:04:46.303219
NCT01070901|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2013-02-04|2010-02-17|2010-02-18|Estimate|||||||2013-02-04|2013-02-05|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Immune Status in Solid Organ Transplantation|Evaluation of Predictors of Immune Status in Solid Organ Transplantation|Completed|||20|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||f||||||||||2018-06-01 00:04:46.364162|2018-06-01 00:04:46.364162
NCT01070888|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2014-11-19||2014-12-17|2010-02-17|2010-02-18|Estimate|2014-12-17|2014-12-30|Estimate||||2014-12-17|2014-12-30|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma|A Randomized, Double-blind, Double Dummy Crossover Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma in Patients With Persistent Asthma|Terminated||Phase 4|6|Actual|Boston Children’s Hospital||2||Unable to reach target goal|f||||t||||||||||2018-06-01 00:04:46.55138|2018-06-01 00:04:46.55138
NCT01070875|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2016-01-14|2010-02-17|2010-02-18|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Partial Thromboplastin Time During the First 24 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin (UFH)|Partial Thromboplastin Time During the First 24 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin: Comparison of a 2 Times Per Day Versus Per 3 Times a Day Dosage|Completed||N/A|53|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 00:04:46.786058|2018-06-01 00:04:46.786058
NCT01070862|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-17|2010-02-17|2010-02-18|Estimate|||||||2010-02-17|2010-02-18|Estimate|May 2003||2003-05-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|||||Interventional|MAG 2002||Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.|Multiple Myeloma Treatment With Thalidomide. Three Randomized Studies on Thalidomide as Induction Treatment Before Autotransplant (MY-TAG) or With a Conventional Chemotherapy (MY-DECT) and as Consolidation/Maintenance at Plateau Phase (MY-PLAT).|Completed||Phase 3|||University Hospital, Caen||6|||f||||f||||||||||2018-06-01 00:04:46.860501|2018-06-01 00:04:46.860501
NCT01070849|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-08-17|2010-02-17|2010-02-18|Estimate|||||||2012-08-17|2012-08-20|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|RÜCKGEWINN||A Bio-psycho-social Exercise Program (RÜCKGEWINN) for Chronic Low Back Pain in Rehabilitation Aftercare|Effect and Sustainability of a Bio-psycho-social Exercise Program (RÜCKGEWINN) for Chronic Low Back Pain in Rehabilitation Aftercare - a Randomised Controlled Trial|Completed||Phase 2/Phase 3|299|Actual|University of Erlangen-Nürnberg||3|||f||||f||||||||||2018-06-01 00:04:46.940786|2018-06-01 00:04:46.940786
NCT01070836|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2016-09-27|2010-02-17|2010-02-18|Estimate|||||||2016-09-27|2016-09-29|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|STRATIFY-2||JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab|JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2|Completed|||35895|Actual|Biogen|||1||f||||f||||||Samples With DNA|"~     Plasma, Serum, Urine, Whole Blood, Peripheral blood mononuclear cell (PBMC)~   "|||2018-06-01 00:04:47.082679|2018-06-01 00:04:47.082679
NCT01070823|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2016-10-04|2010-02-17|2010-02-18|Estimate|||||||2016-10-04|2016-10-05|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|STRATIFY-1||JC-Virus (JCV) Antibody Program|JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri®: STRATIFY-1|Completed|||1096|Actual|Biogen|||1||f||||f||||||Samples Without DNA|"~     Serum, Urine and Plasma~   "|||2018-06-01 00:04:49.333048|2018-06-01 00:04:49.333048
NCT01070810|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2016-01-20||2017-04-29|2010-02-17|2010-02-18|Estimate|2017-04-29|2017-05-15|Actual||||2017-04-29|2017-05-15|Actual|February 2010||2010-02-28|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Thiamine as a Metabolic Resuscitator in Septic Shock|Thiamine as a Metabolic Resuscitator in Septic Shock|Completed||Phase 1/Phase 2|88|Actual|Beth Israel Deaconess Medical Center||2|||f||||||||||||||2018-06-01 00:04:49.446361|2018-06-01 00:04:49.446361
NCT01070797|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-09-02|2010-02-17|2010-02-18|Estimate|||||||2014-09-02|2014-09-04|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|||Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)|Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes for the Prophylaxis and Treatment of EBV, CMV, and Adenovirus Infection Post Allogeneic Stem Cell Transplant (VIRAGE)|Completed||Phase 1|10|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 00:04:49.816983|2018-06-01 00:04:49.816983
NCT01070784|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2012-10-08||2014-04-14|2010-02-17|2010-02-18|Estimate|2013-10-07|2013-12-05|Estimate||||2014-04-14|2014-04-29|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan|An Open-label Phase III, Multi-centre 52-week , Parallel-group Study Evaluating the Safety and Efficacy of Symbicort Turbuhaler 320/9 Twice Daily Compared With Standard Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|328|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:04:49.965535|2018-06-01 00:04:49.965535
NCT01070771|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2015-05-29||2015-10-12|2010-02-17|2010-02-18|Estimate|2015-10-12|2015-11-11|Estimate||||2015-10-12|2015-11-11|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|RIPCORD||Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?|Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?|Completed||N/A|203|Actual|University Hospital Southampton NHS Foundation Trust|||||f||||t||||||||||2018-06-01 00:04:51.24545|2018-06-01 00:04:51.24545
NCT01070758|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-12-12|2010-02-17|2010-02-18|Estimate|||||||2012-12-12|2012-12-13|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy|Treatment With Lanreotide Autogel (Somatostatin Analogue) in Patients With Congenital Hyperinsulinism of Infancy Already Treated With Somatostatin Analog by Pump|Unknown status|Recruiting|Phase 4|10|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 00:04:51.672294|2018-06-01 00:04:51.672294
NCT01070745|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-06-06|2010-02-17|2010-02-18|Estimate|||||||2012-06-06|2012-06-07|Estimate|June 2010||2010-06-30|February 2010|2010-02-28||||June 2012|Anticipated|2012-06-30||Interventional|||Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA)|Ibuprofen vs. Indomethacin as Second Course of Therapy for Resistant PDA in Low Birth Weight Neonates|Withdrawn||Phase 2|0|Actual|Shaare Zedek Medical Center||2||Changes in approach to PDA therapy|f||||t||||||||||2018-06-01 00:04:51.889059|2018-06-01 00:04:51.889059
NCT01070732|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-17|2010-02-17|2010-02-18|Estimate|||||||2010-02-17|2010-02-18|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|APOTEL01||Paracetamol as Antipyretic and Analgesic Medication|An Open-label Non-randomized Phase IV Trial of the Clinical Efficacy of Intravenously Administered 1000mg Paracetamol as Antipyretic and Analgesic Medication|Completed||Phase 4|100|Actual|University of Athens||1|||f||||f||||||||||2018-06-01 00:04:52.058005|2018-06-01 00:04:52.058005
NCT01070719|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-02-28|2010-02-17|2010-02-18|Estimate|||||||2012-02-28|2012-03-01|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort|Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort|Completed|||270|Actual|Rocky Mountain MS Research Group, LLC|||1||f||||t||||||Samples Without DNA|"~     Serum will be collected, and spun for specific tests. The back-up specimens (plasma)will be~     held in case of a laboratory error.~   "|||2018-06-01 00:04:52.209801|2018-06-01 00:04:52.209801
NCT01070706|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-01-01|2010-02-17|2010-02-18|Estimate|||||||2012-01-01|2012-01-04|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|December 2009|Actual|2009-12-31||Interventional|PGS||Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib|Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib in Patients With HER2-negative Stage II/III Breast Cancer|Completed||Phase 1/Phase 2|15|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 00:04:52.30555|2018-06-01 00:04:52.30555
NCT01070693|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|2013-12-02||2013-12-02|2010-02-17|2010-02-18|Estimate|2013-12-02|2014-01-16|Estimate||||2013-12-02|2014-01-16|Estimate|September 2001||2001-09-30|December 2013|2013-12-31|December 2009|Actual|2009-12-31|January 2005|Actual|2005-01-31||Interventional|||Lichtenstein Patch or Prolene Hernia System (PHS) for Inguinal Hernia Repair|Randomized Clinical Trial of Lichtenstein Patch or Prolene Hernia System for Inguinal Hernia Repair|Completed||N/A|300|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-06-01 00:04:52.539375|2018-06-01 00:04:52.539375
NCT01070680|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-07-13|2010-02-17|2010-02-18|Estimate|||||||2012-07-13|2012-07-16|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation|Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study|Completed||Phase 4|50|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-06-01 00:04:52.850601|2018-06-01 00:04:52.850601
NCT01070667|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-19|2010-02-17|2010-02-18|Estimate|||||||2010-02-19|2010-02-22|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|DROPPAF||Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation|Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Eastbourne General Hospital||2|||f||||f||||||||||2018-06-01 00:04:52.938429|2018-06-01 00:04:52.938429
NCT01070654|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-07-06|2010-02-17|2010-02-18|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2010||2010-06-30|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Inflammatory Effects of a Lung Recruitment Manoeuvre|Prospective, Open, Uncontrolled, Non-randomized and Monocentric Trial on the Efficacy and the Inflammatory Effects of a Lung Recruitment Manoeuvre in Mechanical Ventilated Patients With Respiratory Failure|Unknown status|Recruiting|N/A|10|Anticipated|Azienda Ospedaliero, Universitaria Pisana||1|||f||||t||||||||||2018-06-01 00:04:53.157361|2018-06-01 00:04:53.157361
NCT01070641|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-17|2010-02-17|2010-02-18|Estimate|||||||2010-02-17|2010-02-18|Estimate|June 2002||2002-06-30|February 2010|2010-02-28|July 2011|Anticipated|2011-07-31|February 2011|Anticipated|2011-02-28||Interventional|||RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage|RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage|Unknown status|Recruiting|Phase 4|148|Anticipated|Aga Khan University||2|||f||||t||||||||||2018-06-01 00:04:53.314311|2018-06-01 00:04:53.314311
NCT01070628|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2010-08-12|2010-02-17|2010-02-18|Estimate|||||||2010-08-12|2010-08-13|Estimate|December 2009||2009-12-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|NEWSTA||Levodopa Concentration Profile With Stalevo 75/125 mg|Levodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel Groups|Completed||Phase 1|20|Anticipated|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 00:04:53.5258|2018-06-01 00:04:53.5258
NCT01070615|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-03-01|2010-02-17|2010-02-18|Estimate|||||||2010-03-01|2010-03-02|Estimate|June 1998||1998-06-30|February 2010|2010-02-28||||November 2000|Actual|2000-11-30||Interventional|||Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic Constipation|A Study to Evaluate the Long-Term Tolerability and Safety of Oral Prucalopride Administered to Patients With Chronic Constipation|Completed||Phase 3|693|Actual|Movetis|||||f||||f||||||||||2018-06-01 00:04:53.677121|2018-06-01 00:04:53.677121
NCT01070602|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2013-06-27|2010-02-17|2010-02-18|Estimate|||||||2013-06-27|2013-07-01|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||The Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients||Unknown status|Recruiting|N/A|40|Anticipated|Meir Medical Center||1|||f||||||||||||||2018-06-01 00:04:53.730477|2018-06-01 00:04:53.730477
NCT01070589|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2012-03-16|2010-02-17|2010-02-18|Estimate|||||||2012-03-16|2012-03-19|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise|The Effect of Obesity on Growth Hormone Response to Anaerobic Exercise|Unknown status|Recruiting||24|Anticipated|Meir Medical Center|||2||f||||t||||||||||2018-06-01 00:04:53.930032|2018-06-01 00:04:53.930032
NCT01070576|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-04-06|2010-02-17|2010-02-18|Estimate|||||||2010-04-06|2010-04-07|Estimate|March 2010||2010-03-31|April 2010|2010-04-30||||March 2012|Anticipated|2012-03-31||Observational|||Arginine and Nitric Oxide (NO) Early Prognostic Markers for Non-union Development|Arginine and Nitric Oxide (NO) Metabolism During Bone Healing and Non-union Development- Early Prognostic Markers|Unknown status|Recruiting||100|Anticipated|Maastricht University Medical Center|||3||f||||f||||||Samples With DNA|"~     bone debris and bloodsamples for amino acid determination~   "|||2018-06-01 00:04:54.39092|2018-06-01 00:04:54.39092
NCT01070563|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2011-06-30|2010-02-17|2010-02-18|Estimate|||||||2011-06-30|2011-07-04|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Transcranial Doppler Ultrasonography and Brain Death|Evaluation of Transcranial Doppler Ultrasonography to Guide the Time of Cerebral Angiography for the Brain Death Diagnosis|Completed|||44|Anticipated|Institut d'Anesthesiologie des Alpes Maritimes|||2||f||||f||||||||||2018-06-01 00:04:54.600704|2018-06-01 00:04:54.600704
NCT01070550|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2016-05-09||2016-05-09|2010-02-17|2010-02-18|Estimate|2016-05-09|2016-06-15|Estimate||||2016-05-09|2016-06-15|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational||All enrolled population included every participant for whom there was any data available in the PROPHESYS 1 database.|PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naïve HCV-infected Patients Treated With Pegylated Interferons.|Completed|||4680|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-06-01 00:04:54.845423|2018-06-01 00:04:54.845423
NCT01070537|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-02-17|2010-02-17|2010-02-18|Estimate|||||||2010-02-17|2010-02-18|Estimate|February 2008||2008-02-29|February 2010|2010-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|INVIBO||Evaluation of the Bonfils Fiberscope for Predicted Difficult Intubation in Awake Patients With Ear, Nose, and Throat (ENT) Cancer (INVIBO)|INVIBO: Evaluation of the Feasibility and Tolerance of an Intubation Procedure Performed by Means of the Bonfils Fiberscope in Awake Patients With Predicted Difficult Intubation in the Context of ENT Cancer Surgery|Completed||Phase 2|41|Actual|Centre Leon Berard|||||f||||f||||||||||2018-06-01 00:04:58.413752|2018-06-01 00:04:58.413752
NCT01070524|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2017-03-28|2010-02-17|2010-02-18|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2010||2010-01-31|March 2017|2017-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma|A Randomised, Double-blind, Active-controlled, 3 Way Cross-over Study to Evaluate the Effect on Trough FEV1 After 4 Weeks Treatment With CHF 5188 pMDI qd (Fixed Combination Budesonide / Carmoterol) in Adult Patients With Moderate or Severe Persistent Asthma|Completed||Phase 2|113|Anticipated|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-06-01 00:04:58.634614|2018-06-01 00:04:58.634614
NCT01070498|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2017-02-02|2010-02-17|2010-02-18|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2010||2010-02-28|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Trichuris Suis Ova in Peanut and Tree Nut Allergy|Trichuris Suis Ova Therapy for Mild to Moderate Peanut and Tree Nut Allergy in Adults and Children|Completed||Phase 1|18|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-06-01 00:04:58.87211|2018-06-01 00:04:58.87211
NCT01070485|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2014-06-24|2010-02-17|2010-02-18|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|||BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease|An Open-label Phase IIa, Non-randomized Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy|Completed||Phase 2|23|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:04:58.941411|2018-06-01 00:04:58.941411
NCT01070472|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-12-09|2010-02-17|2010-02-18|Estimate|||||||2013-12-09|2013-12-10|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy and Safety of Titrated Oral Misoprostol Solution for Labor Induction at Term|Efficacy and Safety of Titrated Oral Misoprostol Solution for Labor Induction at Term|Completed||N/A|250|Anticipated|University of Manitoba|||||f||||t||||||||||2018-06-01 00:04:59.077346|2018-06-01 00:04:59.077346
NCT01070459|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-04-13|2010-02-17|2010-02-18|Estimate|||||||2010-04-13|2010-04-14|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Effect of an Aerobic Exercise Programme in Stroke Patients|The Effect of an Aerobic Training Programme on the Aerobic Capacity, Functional Behavior and the Cardiovascular Risk Factors in Stroke Patients|Unknown status|Enrolling by invitation|Phase 3|50|Actual|University College of Antwerp||5|||f||||t||||||||||2018-06-01 00:04:59.156127|2018-06-01 00:04:59.156127
NCT01070446|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-02-17|2010-02-17|2010-02-18|Estimate|||||||2010-02-17|2010-02-18|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|||Choline Nutrition in Children With Cystic Fibrosis|Choline Nutrition in Children With Cystic Fibrosis|Completed||N/A|34|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 00:04:59.451354|2018-06-01 00:04:59.451354
NCT01070433|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16||2015-05-18|2018-04-16|2010-02-17|2010-02-18|Estimate||||2015-05-18|2015-06-11|Estimate|2018-04-16|2018-04-18|Actual|September 2012||2012-09-30|April 2018|2018-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers|A Phase II, Randomized, Controlled, Multi-Center Study of the Safety and Efficacy of Topically Applied MEBO Wound Ointment Compared to Standard of Care in Subjects With Diabetic Foot Ulcers|Completed||Phase 2|75|Actual|Skingenix, Inc.||2|||f||||f||||||||No||2018-06-01 00:04:59.559715|2018-06-01 00:04:59.559715
NCT01070420|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-10|||2011-07-15|2010-02-16|2010-02-18|Estimate|||||||2011-07-15|2011-07-18|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement||Completed||Phase 4|66|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:04:59.672014|2018-06-01 00:04:59.672014
NCT01070407|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2015-04-22|2010-02-17|2010-02-18|Estimate|||||||2015-04-22|2015-04-23|Estimate|July 2007||2007-07-31|April 2015|2015-04-30|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Interventional|||A Study of a New Candidate Vaccine Against Hepatitis C Virus (HCV)|A Phase I Study to Assess the Safety and Immunogenicity of New Hepatitis C Virus Vaccine Candidates AdCh3NSmut and Ad6NSmut|Completed||Phase 1|41|Actual|ReiThera Srl||9|||f||||t||||||||||2018-06-01 00:04:59.759724|2018-06-01 00:04:59.759724
NCT01070394|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2013-04-11||2018-03-05|2010-02-17|2010-02-18|Estimate|2016-10-04|2016-11-25|Estimate||||2018-03-05|2018-04-03|Actual|February 2010||2010-02-28|March 2018|2018-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Eligibility was determined by meeting all inclusion criteria and not meeting any of the exclusion criteria. Of the 40 who initially enrolled, 33 completed the full treatment.|Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)|Evaluation of Pharmacokinetics and Profile of Clinical Response of Subacute Lisdexamfetamine Dimesylate (Vyvanse) Treatment vs. Clinical Response to Subacute Immediate Release Mixed Amphetamine Salt Therapy in Adult ADHD|Completed||Phase 4|40|Actual|New York University School of Medicine||1|||f||||t|t|f||||||||2018-06-01 00:04:59.910311|2018-06-01 00:04:59.910311
NCT01070381|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2011-02-25||2013-11-19|2010-02-17|2010-02-18|Estimate|2011-02-25|2011-03-24|Estimate||||2013-11-19|2013-12-13|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Daily Disposable Toric Comparative Trial in Europe||Completed||N/A|220|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 00:05:00.175443|2018-06-01 00:05:00.175443
NCT01070368|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-02-27|2010-02-17|2010-02-18|Estimate|||||||2013-02-27|2013-02-28|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Accuracy Of Skin Prick Test Using In-house Wheat Extract For The Diagnosis Of IgE-mediated Wheat Allergy: A Pilot Study|Accuracy Of Skin Prick Test Using In-house Wheat Extract For The Diagnosis Of IgE-mediated Wheat Allergy: A Pilot Study|Completed||N/A|30|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 00:05:00.576618|2018-06-01 00:05:00.576618
NCT01070355|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2011-10-20|2010-02-17|2010-02-18|Estimate|||||||2011-10-20|2011-10-21|Estimate|April 2010||2010-04-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|EMT||Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases|The Effects of Eicosapentaenoic Acid (EPA) on Biomarkers of Growth and Vascularity in Human Colorectal Cancer Liver Metastases (The EPA for Metastasis Trial)|Completed||Phase 2|88|Actual|University of Leeds||2|||f||||t||||||||||2018-06-01 00:05:00.659286|2018-06-01 00:05:00.659286
NCT01070342|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-17|||2010-02-17|2010-02-17|2010-02-18|Estimate|||||||2010-02-17|2010-02-18|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|May 2012|Anticipated|2012-05-31|February 2011|Anticipated|2011-02-28||Observational|ABPM||Ambulatory Blood Pressure Monitoring in Children|Methodological Improvement in Measuring Efficacy Outcome in Antihypertensive Trials in Children|Unknown status|Not yet recruiting||170|Anticipated|University Hospitals Cleveland Medical Center|||1||f||||f||||||||||2018-06-01 00:05:00.761164|2018-06-01 00:05:00.761164
NCT01070329|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2012-01-10||2012-01-10|2010-02-16|2010-02-18|Estimate|2012-01-10|2012-02-13|Estimate||||2012-01-10|2012-02-13|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study in Depression and Associated Painful Physical Symptoms|Duloxetine Versus Placebo in the Acute Treatment of Patients With Major Depressive Disorder and Associated Painful Physical Symptoms|Completed||Phase 4|527|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:05:00.900456|2018-06-01 00:05:00.900456
NCT01070316|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2016-08-01||2017-02-01|2010-02-16|2010-02-18|Estimate|2016-08-01|2016-09-23|Estimate||||2017-02-01|2017-03-13|Actual|January 2010||2010-01-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||20 study subjects were consented, screened, enrolled, and received study drug|Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)|Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex|Completed||Phase 1/Phase 2|20|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||Undecided||2018-06-01 00:05:01.862269|2018-06-01 00:05:01.862269
NCT01070303|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2010-03-11||2011-04-07|2010-02-16|2010-02-18|Estimate|2010-04-19|2010-05-07|Estimate||||2011-04-07|2011-04-11|Estimate|August 2002||2002-08-31|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CLASSICII||Remission in Subjects With Crohn's Disease, Open Label Extension|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease, Open Label Extension|Completed||Phase 3|177|Actual|Abbott||1|||f||||f||||||||||2018-06-01 00:05:02.271514|2018-06-01 00:05:02.271514
NCT01070290|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-01-06|2010-02-17|2010-02-18|Estimate|||||||2014-01-06|2014-01-07|Estimate||||January 2014|2014-01-31||||||||Interventional|||A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen|A Randomized Phase 2 Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen|Withdrawn||Phase 2|0|Actual|ArQule||2|||f||||t||||||||||2018-06-01 00:05:03.375497|2018-06-01 00:05:03.375497
NCT01070277|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2014-08-26|2010-02-17|2010-02-18|Estimate|||||||2014-08-26|2014-08-27|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Antiparasitic Treatment for Returning Travelers With Chronic Diarrhea||Unknown status|Recruiting|N/A|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 00:05:03.451408|2018-06-01 00:05:03.451408
NCT01070264|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|March 2006||2006-03-31|February 2007|2007-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Pilot Observational Clinical Survey: Impacts of Tahitian Noni Juice on the Quality of Life of Patients With Osteoarthritis|A Pilot Observational Clinical Survey: Impacts of Tahitian Noni Juice on the Quality of Life of Patients With Osteoarthritis|Completed||N/A|||University of Illinois at Chicago||1|||f||||f||||||||||2018-06-01 00:05:03.528646|2018-06-01 00:05:03.528646
NCT01070251|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2012-07-31|2010-02-16|2010-02-17|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||Effects of a Multimodal Preference-based Parental Intervention on Preschoolers' Physical Activity Behaviour - a Cluster-randomized Trial|Effects of a Multimodal Preference-based Parental Intervention on Preschoolers' Physical Activity Behaviour - a Cluster-randomized Trial|Completed||N/A|826|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 00:05:03.595992|2018-06-01 00:05:03.595992
NCT01070238|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate||||November 2002|2002-11-30||||||||Interventional|||Metabolic Response of Slow Released Carbohydrates in Diabetes Mellitus|Explorative, Pilot Study With Cross-over Design on the Metabolic Response of Orally Applied Slow Released Carbohydrates in Diabetes Type 2 Patients|Completed||Phase 1/Phase 2|||University of Giessen|||||f||||f||||||||||2018-06-01 00:05:03.759496|2018-06-01 00:05:03.759496
NCT01070225|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2018-04-20|2010-02-16|2010-02-17|Estimate|||||||2018-04-20|2018-04-24|Actual|March 2010||2010-03-31|April 2018|2018-04-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Reversal of Acute β-Blocker Induced Bronchoconstriction|Reversal of Acute β-Blocker Induced Bronchoconstriction|Completed||Phase 4|14|Actual|University of Dundee||2|||f||||t||||||||||2018-06-01 00:05:03.816499|2018-06-01 00:05:03.816499
NCT01070212|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-05-28|2010-02-16|2010-02-17|Estimate|||||||2013-05-28|2013-05-30|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Gum Chewing on Appetite and Digestion|Effects of Gum Chewing on Appetite and Digestion|Completed||N/A|60|Actual|Purdue University||3|||f||||f||||||||||2018-06-01 00:05:03.885561|2018-06-01 00:05:03.885561
NCT01070199|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2011-07-22|2010-02-16|2010-02-17|Estimate|||||||2011-07-22|2011-07-25|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Food Form and Fitness on Appetite and Digestion.|Effects of Food Form and Fitness on Appetite and Digestion.|Completed||N/A|81|Actual|Purdue University||4|||f||||f||||||||||2018-06-01 00:05:03.956587|2018-06-01 00:05:03.956587
NCT01070186|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2012-07-27|2010-02-16|2010-02-17|Estimate|||||||2012-07-27|2012-07-31|Estimate|October 2010||2010-10-31|July 2012|2012-07-31||||||||Interventional|||Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma|Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||1||No participants were enrolled.|f||||t||||||||||2018-06-01 00:05:04.082581|2018-06-01 00:05:04.082581
NCT01070173|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2012-12-08||2013-01-15|2010-02-16|2010-02-17|Estimate|2013-01-15|2013-02-18|Estimate||||2013-01-15|2013-02-18|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Ghrelin Levels in Children With Poor Growth|Ghrelin Levels in Children With Gastrointestinal Symptoms and/or Poor Growth|Completed|||52|Actual|Tripler Army Medical Center|||3||f||||f||||||||||2018-06-01 00:05:04.234555|2018-06-01 00:05:04.234555
NCT01070160|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-06-13|2010-02-16|2010-02-17|Estimate|||||||2014-06-13|2014-06-16|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)|Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)|Completed|||14|Actual|Yale University|||3||f||||f||||||Samples With DNA|"~     blood, endometrium tissue biopsy~   "|||2018-06-01 00:05:04.479644|2018-06-01 00:05:04.479644
NCT01070147|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2011-03-21|2010-02-16|2010-02-17|Estimate|||||||2011-03-21|2011-03-22|Estimate|October 2010||2010-10-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Computerized Asthma Management System in the Pediatric Emergency Department|A Computerized Asthma Management System in the Pediatric Emergency Department|Completed||N/A|2400|Anticipated|Vanderbilt University||1|||f||||f||||||||||2018-06-01 00:05:04.549682|2018-06-01 00:05:04.549682
NCT01069783|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2016-10-12|2010-02-16|2010-02-17|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of A3309 in Patients With Dyslipidemia|A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients With Dyslipidemia|Completed||Phase 2|36|Actual|Albireo||3|||f||||f||||||||||2018-06-01 00:05:11.0667|2018-06-01 00:05:11.0667
NCT01070134|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2011-06-06|2010-02-16|2010-02-17|Estimate|||||||2011-06-06|2011-06-08|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|Mipsy||Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial|Mindfulness-based Behavioural Therapy (MIBT) Versus Psychodynamic Therapy for Patients With Major Depressive Disorder in Psychotherapeutic Day Treatment. A Randomised Clinical Pilot Trial|Unknown status|Recruiting|N/A|84|Anticipated|Psychiatry Roskilde||2|||f||||t||||||||||2018-06-01 00:05:04.623779|2018-06-01 00:05:04.623779
NCT01070121|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2015-10-12|2010-02-16|2010-02-17|Estimate|||||||2015-10-12|2015-10-14|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|TETRAD||Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository|Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository|Completed|||200|Actual|University of Alabama at Birmingham|||1||f||||f||||||Samples With DNA|"~     Whole blood, red blood cells, white blood cells, plasma, serum, DNA, RNA~   "|||2018-06-01 00:05:04.688377|2018-06-01 00:05:04.688377
NCT01070108|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Escalating Ketamine Doses and Pre-emption|EARLY PREOPERATIVE ESCALATING DOSES OF KETAMINE ATTENUATE POSTOPERATIVE PAIN AND REDUCE MORPHINE CONSUMPTION IN HUMANS|Completed||N/A|120|Actual|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-06-01 00:05:04.762539|2018-06-01 00:05:04.762539
NCT01070095|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-11-25|2010-02-16|2010-02-17|Estimate|||||||2014-11-25|2014-11-26|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|eAAPS||The Electronic Asthma Action Plan System for Implementation in Primary Care|The Electronic Asthma Action Plan System for Implementation in Primary Care|Completed||Phase 2|19|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-06-01 00:05:04.82505|2018-06-01 00:05:04.82505
NCT01070082|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2011-08-17|2010-02-16|2010-02-17|Estimate|||||||2011-08-17|2011-08-18|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|Europain®||Europain®: A Study of Procedural Pain|Pain Associated With ICU Procedures: An International Study|Completed|||5150|Actual|Saint-Louis Hospital, Paris, France|||1||f||||f||||||||||2018-06-01 00:05:04.887171|2018-06-01 00:05:04.887171
NCT01070069|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-01-27|2010-02-16|2010-02-17|Estimate|||||||2014-01-27|2014-01-29|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|PEVAR||Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial|Prospective, Multicenter, Randomized Controlled Trial of Endovascular Aneurysm Repair Using a Bilateral Percutaneous Approach (PEVAR) vs. Standard Approach (SEVAR) Using the IntuiTrak Endovascular AAA Delivery System and the Prostar XL or Perclose ProGlide Suture-Mediated Closure System|Completed||Phase 2|150|Actual|Endologix||3|||f||||t||||||||||2018-06-01 00:05:04.947455|2018-06-01 00:05:04.947455
NCT01070056|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-11-12|2010-02-16|2010-02-17|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|TLC-Clinic||Practice-based Trial of Blood Pressure Control in African Americans|Practice-based Trial of Blood Pressure Control in African Americans|Completed||Phase 3|194|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 00:05:05.050083|2018-06-01 00:05:05.050083
NCT01070043|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-06|2011-09-13||2011-09-13|2010-02-16|2010-02-17|Estimate|2011-09-13|2011-10-19|Estimate||||2011-09-13|2011-10-19|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone|A Single Center, Randomized, Double-blind, Active Controlled, Parallel Group Study to Demonstrate Non-inferiority of a Fixed Dose Combination of 5 mg Amlodipine and 80 mg Valsartan to 160 mg Valsartan in the Treatment of Hypertension|Completed||Phase 4|60|Actual|Novartis||3|||f||||f||||||||||2018-06-01 00:05:05.129274|2018-06-01 00:05:05.129274
NCT01070030|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2017-02-21|2010-02-16|2010-02-17|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2010||2010-01-31|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|ACADEMY||Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension|Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT|Completed||Phase 4|230|Actual|Novartis|||||f||||||||||||||2018-06-01 00:05:06.417707|2018-06-01 00:05:06.417707
NCT01070017|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2017-10-24|2010-02-16|2010-02-17|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2010||2010-02-28|October 2017|2017-10-31|August 2014|Actual|2014-08-31|July 31, 2012|Actual|2012-07-31||Interventional|CASA||Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru|Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru|Completed||Phase 3|1244|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 00:05:06.499909|2018-06-01 00:05:06.499909
NCT01070004|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2012-06-13|2010-02-16|2010-02-17|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|KILLSLEEP||Effect of Countermeasures on Nocturnal Driving Performance|Countermeasures for Sleepiness at the Wheel and Prediction of Inter- Individual Differences to Their Responses (KillSleep)|Completed||N/A|72|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 00:05:06.570828|2018-06-01 00:05:06.570828
NCT01069991|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-02-11|2010-02-16|2010-02-17|Estimate|||||||2013-02-11|2013-02-12|Estimate|January 2002||2002-01-31|February 2013|2013-02-28|February 2007|Actual|2007-02-28|April 2006|Actual|2006-04-30||Interventional|ASMA||Asthma Self-Management For Adolescents|Educating Adolescents To Preventively Manage Their Asthma|Completed||Phase 2|345|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 00:05:06.65603|2018-06-01 00:05:06.65603
NCT01069965|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-09-26|2010-02-16|2010-02-17|Estimate|||||||2014-09-26|2014-09-29|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy of BGP-15 in Patients With Type 2 Diabetes Mellitus|Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety & Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin & Sulfonylurea or Metformin in T2 Diabetic Patients|Terminated||Phase 2|196|Actual|N-Gene Research Laboratories, Inc.||6||Funding support withdrawn.|f||||f||||||||||2018-06-01 00:05:06.838413|2018-06-01 00:05:06.838413
NCT01069952|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2012-07-23|2010-02-16|2010-02-17|Estimate|||||||2012-07-23|2012-07-24|Estimate|December 2002||2002-12-31|July 2012|2012-07-31||||May 2004|Actual|2004-05-31||Interventional|||Electrical Stimulation of the Internal Capsule for Intractable Depression|Electrical Stimulation of the Internal Capsule for Intractable Depression|Completed||Phase 2|5|Actual|Butler Hospital||1|||f||||t||||||||||2018-06-01 00:05:07.23054|2018-06-01 00:05:07.23054
NCT01069939|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2012-10-24||2012-10-24|2010-02-16|2010-02-17|Estimate|2012-10-24|2012-11-22|Estimate||||2012-10-24|2012-11-22|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin|A Phase III Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for Prevention of Gastric and/or Duodenal Ulcers Associated With Continuous Low-dose Aspirin (LDA) Use|Completed||Phase 3|427|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 00:05:07.428172|2018-06-01 00:05:07.428172
NCT01069926|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-12-08|2010-02-16|2010-02-17|Estimate|||||||2010-12-08|2010-12-09|Estimate|March 2010||2010-03-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients|A Phase I, Multi-center, Open-label, Single Dose Study, to Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients With or Without Renal Impairment|Completed||Phase 1|21|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:05:08.27768|2018-06-01 00:05:08.27768
NCT01069913|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient|A Pharmacokinetics Profile Determination of BG00012 Standard Formulation and the BG00012 Active Pharmaceutical Ingredient (API) After a Single Oral Dose Administered to Healthy Male Volunteers|Completed||Phase 1|14|Actual|Biogen||2|||f||||f||||||||||2018-06-01 00:05:08.352609|2018-06-01 00:05:08.352609
NCT01069900|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2015-11-04||2018-02-22|2010-02-16|2010-02-17|Estimate|2015-11-04|2015-12-08|Estimate||||2018-02-22|2018-03-20|Actual|July 21, 2010|Actual|2010-07-21|February 2018|2018-02-28|January 21, 2015|Actual|2015-01-21|January 21, 2015|Actual|2015-01-21||Interventional|MOXIPEDIA||Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection|A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection|Completed||Phase 3|458|Actual|Bayer||2|||f||||t||||||||||2018-06-01 00:05:08.521928|2018-06-01 00:05:08.521928
NCT01069887|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-23|2010-02-16|2010-02-17|Estimate|||||||2010-02-23|2010-02-24|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|||||Observational|HEMA E-CHART||A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoietic Stem Cell Transplant|A Non-interventional Multicentre Prospective Registry to Monitor the Incidence of Invasive Fungal Infections and to Monitor the Diagnostic and Therapeutic Management of Suspected Fungal-related Febrile Episodes in Patients With Malignant Hemopathies or Subjected to Haematopoietic Cell Transplant for the Treatment of Onco-haematological Diseases (HEMA E-CHART REGISTRY)|Completed|||3000|Actual|Catholic University of the Sacred Heart|||4||f||||f||||||||||2018-06-01 00:05:09.73043|2018-06-01 00:05:09.73043
NCT01069874|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-02-03|2010-02-16|2010-02-17|Estimate|||||||2014-02-03|2014-02-04|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ViDiFlu||Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections (ViDiFlu)|Cluster-randomised, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation for the Prevention of Influenza and Other Respiratory Infections in Sheltered Accommodation (ViDiFlu)|Completed||Phase 2/Phase 3|240|Actual|Barts & The London NHS Trust||2|||f||||t||||||||||2018-06-01 00:05:09.804995|2018-06-01 00:05:09.804995
NCT01069861|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2012-11-01||2012-11-01|2010-02-15|2010-02-17|Estimate|2012-11-01|2012-12-03|Estimate||||2012-11-01|2012-12-03|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)|A Single Arm Single Centre Study To Investigate Safety And Efficacy Of Sildenafil In Near Term And Term Newborns With Persistent Pulmonary Hypertension Of The Newborn (PPHN)|Terminated||Phase 2|4|Actual|Pfizer|The study was prematurely discontinued, therefore not all data was analyzed.|1||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:05:09.919703|2018-06-01 00:05:09.919703
NCT01069848|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2015-06-22|2010-02-16|2010-02-17|Estimate|||||||2015-06-22|2015-06-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:05:10.214304|2018-06-01 00:05:10.214304
NCT01069835|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2015-05-18|2010-02-16|2010-02-17|Estimate|||||||2015-05-18|2015-05-19|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|EPICLIN||Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN)|Epidemiological Study to Describe NSCLC Clinical Management Patterns in Central Eastern Europe and Russia. Lung-EPICLIN|Completed|||840|Actual|AstraZeneca|||1||f||||f||||||Samples With DNA|"~     Paraffin embedded tumour tissue samples~   "|||2018-06-01 00:05:10.292086|2018-06-01 00:05:10.292086
NCT01069822|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2014-10-10|2010-02-16|2010-02-17|Estimate|||||||2014-10-10|2014-10-13|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels|A Phase I Open-label, Fixed Sequence Study to Determine the Effect of Multiple Intravenous Doses of AZD6765 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Substrate) in Healthy Subjects|Completed||Phase 1|46|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:05:10.514013|2018-06-01 00:05:10.514013
NCT01069809|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2017-01-23|2010-02-16|2010-02-17|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2010|Actual|2010-07-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|August 2014|Actual|2014-08-31||Interventional|||Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption|A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption|Completed||Phase 2|53|Actual|Argos Therapeutics||2|||f||||t||||||||No||2018-06-01 00:05:10.601455|2018-06-01 00:05:10.601455
NCT01069796|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2016-03-15|2010-02-16|2010-02-17|Estimate|||||||2016-03-15|2016-03-17|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|March 2012|Actual|2012-03-31||Interventional|||Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer|A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer|Terminated||Phase 2|64|Actual|ARCAGY/ GINECO GROUP||1||The number of inclusion was reached normally|f||||t||||||||||2018-06-01 00:05:10.8066|2018-06-01 00:05:10.8066
NCT00862329|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2012-03-21|2009-03-13|2009-03-16|Estimate|||||||2012-03-21|2012-03-22|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|November 2010|Actual|2010-11-30|June 2009|Actual|2009-06-30||Interventional|||Influence of Protein Source on Satiety and Metabolism||Completed||N/A|120|Actual|Institut National de la Recherche Agronomique||4|||f||||t||||||||||2018-06-01 01:12:27.833519|2018-06-01 01:12:27.833519
NCT01069770|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2011-06-21|2010-02-16|2010-02-17|Estimate|||||||2011-06-21|2011-06-23|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)|Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma Patients: a Prospective Study|Unknown status|Recruiting|Phase 2|32|Anticipated|Korean Urological Oncology Society|||||f||||t||||||||||2018-06-01 00:05:11.318166|2018-06-01 00:05:11.318166
NCT01069757|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2017-03-14|2010-02-16|2010-02-17|Estimate|||||||2017-03-14|2017-03-15|Actual|February 2010||2010-02-28|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of ARQ 197 in Combination With Erlotinib|A Phase I Study of ARQ 197 in Combination With Erlotinib in Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer|Completed||Phase 1|16|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-06-01 00:05:11.559588|2018-06-01 00:05:11.559588
NCT01069744|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Oral Entrainment on Suck Development of Preterm Infants Born 23 to 34 Weeks Gestational Age (GA)|Randomized Control Trial Evaluating The Effect Of Patterned Oral Somatosensory Entrainment Stimulation Program (NTrainer System) On Suck Development and Feeding Performance of Preterm Infants Born Between 23 And 34 Weeks Gestational Age|Completed|||71|Actual|KC BioMediX, Inc|||2||f||||f||||||||||2018-06-01 00:05:11.703249|2018-06-01 00:05:11.703249
NCT01069731|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2008||2008-01-31|February 2010|2010-02-28|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|||Comparison of Non-nutritive Suck (NNS) Measures to Clinical Estimates of Suck and Feeding Readiness in Preterm Infants|Comparison of NNS Performance Measures to Clinical Estimates of Suck and Feeding Readiness in Preterm Infants Using the NTrainer Device|Completed|||70|Actual|KC BioMediX, Inc|||1||f||||f||||||||||2018-06-01 00:05:11.845702|2018-06-01 00:05:11.845702
NCT01069718|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|||Evaluating Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance|Evaluating the Effect of Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance in Infants With Feeding Dysfunction|Completed|||24|Actual|KC BioMediX, Inc|||2||f||||f||||||||||2018-06-01 00:05:11.980038|2018-06-01 00:05:11.980038
NCT01069705|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2017-02-21|2010-02-16|2010-02-17|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2010||2010-02-28|February 2017|2017-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Second Open Label Extension to Bridging Study CTBM100C2303|A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Completed Participation in Study CTBM100C2303E1.|Completed||Phase 3|49|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:05:12.089284|2018-06-01 00:05:12.089284
NCT01069692|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2011-07-20|2010-02-16|2010-02-17|Estimate|||||||2011-07-20|2011-07-21|Estimate|February 2010||2010-02-28|July 2011|2011-07-31||||October 2010|Actual|2010-10-31||Interventional|SBR759||Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients|A Double-blind, Randomized, Placebo-controlled Multi-center Trial to Compare the Phosphate Lowering Efficacy of Different Doses of SBR759 to Placebo|Completed||Phase 3|115|Actual|Novartis||5|||f||||||||||||||2018-06-01 00:05:12.408472|2018-06-01 00:05:12.408472
NCT01069666|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-05-03|2010-02-16|2010-02-17|Estimate|||||||2010-05-03|2010-05-04|Estimate|July 2008||2008-07-31|May 2010|2010-05-31|December 2008||2008-12-31|||||Observational|||Knowledge Base in the Treatment of Atopic Dermatitis Among Thai Pediatricians||Completed|||||Siriraj Hospital|||||f||||f||||||||||2018-06-01 00:05:12.597583|2018-06-01 00:05:12.597583
NCT01069653|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-09-16|2010-02-16|2010-02-17|Estimate|||||||2013-09-16|2013-09-18|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer|Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*24 (CDCA1,KIF20A) in Patients With Small Cell Lung Cancer Refractory to Standard Therapy|Unknown status|Recruiting|Phase 1|9|Anticipated|Shiga University||3|||f||||t||||||||||2018-06-01 00:05:12.689831|2018-06-01 00:05:12.689831
NCT01069640|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-09-16|2010-02-16|2010-02-17|Estimate|||||||2013-09-16|2013-09-18|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer|Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy|Unknown status|Recruiting|Phase 1|9|Anticipated|Shiga University||3|||f||||t||||||||||2018-06-01 00:05:12.969939|2018-06-01 00:05:12.969939
NCT01069627|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2014-05-23||2014-05-23|2010-02-15|2010-02-17|Estimate|2014-05-23|2014-06-25|Estimate||||2014-05-23|2014-06-25|Estimate||||May 2014|2014-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Safety Population: all participants who signed the informed consent form, were assigned a study patient number, and took at least one dose of each drug of study combination.|A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma|An Open-label Study to Assess the Anti-tumor Activity of Avastin in Combination With Fotemustine as First-line Therapy in Patients With Metastatic Melanoma|Completed||Phase 2|20|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-06-01 00:05:13.448351|2018-06-01 00:05:13.448351
NCT01069614|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-07|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate||||February 2010|2010-02-28||||||||Interventional|||A Skin Stretching Wound Closure System||Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Hillel Yaffe Medical Center||1|||f||||||||||||||2018-06-01 00:05:14.039082|2018-06-01 00:05:14.039082
NCT01069601|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2012-04-13|2010-02-16|2010-02-17|Estimate|||||||2012-04-13|2012-04-16|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||H1N1sw Vaccine in Adult Transplant Recipients|A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers|Terminated||Phase 2|13|Actual|HepNet Study House, German Liverfoundation||1||End of H1N1 Swine Flu Pandemic|f||||t||||||||||2018-06-01 00:05:14.122661|2018-06-01 00:05:14.122661
NCT01069588|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2017-11-28|2010-02-16|2010-02-17|Estimate|||||||2017-11-28|2017-11-30|Actual|December 2009||2009-12-31|November 2017|2017-11-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Observational|||Anterior Cruciate Ligament (ACL) Reconstruction- Bioabsorbable Screw|ACL Reconstruction - Bioabsorbable Screws- 2 Year Follow-up|Completed|||67|Actual|Vanderbilt University Medical Center|||2||f||||t||||||||||2018-06-01 00:05:14.224791|2018-06-01 00:05:14.224791
NCT01069575|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-09-16|2010-02-16|2010-02-17|Estimate|||||||2013-09-16|2013-09-18|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer|Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy|Unknown status|Recruiting|Phase 1|18|Anticipated|Shiga University||3|||f||||t||||||||||2018-06-01 00:05:14.331526|2018-06-01 00:05:14.331526
NCT01069562|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2010-08-02||2011-01-24|2010-02-16|2010-02-17|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Closed Loop Isoflurane Administration With Bispectral Index in Open Heart Surgery|Comparison of Isoflurane Anaesthesia by Closed Loop Controlled Administration Versus Manually Controlled Administration Using Bispectral Index in Open Heart Surgery|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-06-01 00:05:14.456628|2018-06-01 00:05:14.456628
NCT01069549|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2015-10-23|2010-02-16|2010-02-17|Estimate|||||||2015-10-23|2015-10-26|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Observational|||Association of AGTR1 and ACACB Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes|Study of the Association of AGTR1 and ACACB Gene Polymorphism and Susceptibility of Diabetic Nephropathy in North Indian Type 2 Diabetic Patients|Completed|||476|Actual|Postgraduate Institute of Medical Education and Research|||2||f||||f||||||Samples With DNA|"~     4 ml of whole blood sample.~   "|||2018-06-01 00:05:14.858905|2018-06-01 00:05:14.858905
NCT01069536|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|May 2008|Actual|2008-05-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy and Akathisia Incidence of Slow Infusion Metoclopramide||Completed||N/A|140|Actual|Pamukkale University||2|||f||||||||||||||2018-06-01 00:05:15.006615|2018-06-01 00:05:15.006615
NCT01069523|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2012-06-14||2012-08-01|2010-02-16|2010-02-17|Estimate|2012-08-01|2012-09-03|Estimate||||2012-08-01|2012-09-03|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)|Electrophysiological Effects of Guanfacine Extended-Release (GXR) on Inhibitory Control in Children With Attention Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|42|Actual|The University of Texas Health Science Center at San Antonio|The intent of the study was to examine ERP waveforms associated with impulse control. Unfortuanately, the Stop signal task and EEG proved very difficult for this young group of subjects. The ERP data could not be fully analyzed and is not reported.|2|||f||||t||||||||||2018-06-01 00:05:15.07265|2018-06-01 00:05:15.07265
NCT01069510|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2017-04-05|2010-02-16|2010-02-17|Estimate|||||||2017-04-05|2017-04-06|Actual|February 2010||2010-02-28|April 2017|2017-04-30|March 2017|Actual|2017-03-31|June 2016|Actual|2016-06-30||Interventional|||Spironolactone in Adult Congenital Heart Disease|Heart Failure in Congenital Heart Disease: the Role of Myocardial Fibrosis. Treatment Sub-Study: Spironolactone vs. Placebo|Completed||Phase 2|160|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 00:05:15.341938|2018-06-01 00:05:15.341938
NCT01069497|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|ENLIL||Preventability of Infections in Residents of French Nursing Homes|Impact of a Multifaceted Intervention on the Preventability of Infections in Residents of French Nursing Homes: Cluster-randomised Controlled Trial (ENLIL Study)|Unknown status|Active, not recruiting|N/A|3500|Anticipated|Observatoire du Risque Infectieux en Gériatrie||2|||f||||t||||||||||2018-06-01 00:05:15.436916|2018-06-01 00:05:15.436916
NCT01069484|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|2015-04-27||2016-10-07|2010-02-16|2010-02-17|Estimate|2016-10-07|2016-12-01|Estimate||||2016-10-07|2016-12-01|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional||Assuming a similar difference among comparison groups as found by Mørkved and Bø (1997), a two-sided significance of < 0.05 and a power of 0.90 requiered a total of 62 women. For applying stratified analysis on major levator ani (LA) muscle defects, the statistical advice was to aim for 80 women with- and 80 women without major LA muscle defects.|Postpartum Pelvic Floor Muscle Training in Women With and Without Injured Pelvic Floor Muscles|The Effect of Postpartum Pelvic Floor Muscle Training in Women With Injured and Non-injured Pelvic Floor Muscles. A Single Blind Randomized Controlled Trial|Completed||N/A|175|Actual|Norwegian School of Sport Sciences||2|||f||||t||||||||Undecided||2018-06-01 00:05:15.513647|2018-06-01 00:05:15.513647
NCT01069471|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-10-11|2010-02-16|2010-02-17|Estimate|||||||2010-10-11|2010-10-13|Estimate|February 2010||2010-02-28|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella|Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults|Completed||Phase 1|40|Actual|GlycoVaxyn AG||4|||f||||t||||||||||2018-06-01 00:05:15.889306|2018-06-01 00:05:15.889306
NCT01069458|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2017-06-28|2010-02-15|2010-02-17|Estimate|||||||2017-06-28|2017-06-29|Actual|January 2010||2010-01-31|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of a High Protein Diet Versus a Low Fat Diet on Body Weight After Smoking Cessation|The Effect of a High Protein Diet Versus a Low Fat Diet on Body Weight and Composition, Total Energy Expenditure, Metabolic Risk Factors and Eating Behavior After Smoking Cessation|Completed||N/A|122|Actual|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-06-01 00:05:15.970004|2018-06-01 00:05:15.970004
NCT01069445|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2011-05-31|2010-02-16|2010-02-17|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|RISTOMED||Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene|Open Label, Randomized Study of the Impact of Diet on Gut Microbiota, Inflammageing and Oxidative Stress in Elderly People. Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene. French Part of a Multicentric European Study|Completed||N/A|48|Anticipated|University Hospital, Bordeaux||4|||f||||f||||||||||2018-06-01 00:05:16.055761|2018-06-01 00:05:16.055761
NCT01069432|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2018-03-15|2010-02-16|2010-02-17|Estimate|||||||2018-03-15|2018-03-19|Actual|May 2010||2010-05-31|March 2018|2018-03-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia|Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia|Withdrawn|||0|Actual|Dartmouth-Hitchcock Medical Center|||2|"IRB delayed their review for an extensive period of time. Funding for this protocol is no~   longer available."|f||||t||||||Samples With DNA|"~     10cc of peripheral blood.~   "|||2018-06-01 00:05:16.168345|2018-06-01 00:05:16.168345
NCT01069419|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2015-08-27||2015-10-06|2010-02-15|2010-02-17|Estimate|2015-08-27|2015-09-29|Estimate||||2015-10-06|2015-10-29|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|FasT|Baseline Characteristics refer to the Enrolled Set.|Observation of Treatment With Certolizumab Pegol in Daily Practice|A Multicenter, Observational, Non-interventional Study to Evaluate the Safety and Efficacy of Anti-TNF (Anti-Tumor Necrosis Factor) Alpha Therapy With Certolizumab Pegol Observed in Daily Practice in Adult Rheumatoid Arthritis (RA) Patients|Completed|||1117|Actual|UCB Pharma|||1||f||||f||||||||||2018-06-01 00:05:16.296907|2018-06-01 00:05:16.296907
NCT01069406|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2015-05-18|2010-02-16|2010-02-17|Estimate|||||||2015-05-18|2015-05-20|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||The Association Between Uterine Artery Notch and First Trimester Bleeding|The Association Between Uterine Artery Notch and First Trimester Bleeding|Completed|||200|Actual|Soroka University Medical Center|||1||f||||f||||||||||2018-06-01 00:05:16.931002|2018-06-01 00:05:16.931002
NCT01069393|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2014-11-18|2010-02-15|2010-02-17|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Alternative Delivery of Dose Adjustment For Normal Eating (DAFNE) Trial in Patients With Type 1 Diabetes|Improving Management of Type 1 Diabetes in the UK: The DAFNE Programme as a Research Test-bed - 5 x 1 Day RCT|Completed||N/A|170|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:05:16.984592|2018-06-01 00:05:16.984592
NCT01069380|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Observational|RMR||Resting Metabolic Rate in Chronic Bed-Ridden Patients|Resting Metabolic Rate in Chronic Bed-Ridden Patients|Unknown status|Recruiting||70|Anticipated|Reuth Medical Center|||||f||||f||||||||||2018-06-01 00:05:17.071214|2018-06-01 00:05:17.071214
NCT01069367|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2016-11-30|2010-02-16|2010-02-17|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects|Open-label, Uncontrolled Postmarketing Study to Evaluate Immunogenicity, Safety and Tolerability of Cell-derived A/H1N1 Influenza HA Vaccine in Healthy Japanese Elderly Subjects|Completed||Phase 4|100|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:05:17.235879|2018-06-01 00:05:17.235879
NCT01069354|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2016-09-08||2017-09-18|2010-02-15|2010-02-17|Estimate|2017-09-18|2018-05-30|Actual||||2017-09-18|2018-05-30|Actual|November 2012||2012-11-30|September 2017|2017-09-30|February 2014|Actual|2014-02-28|May 2013|Actual|2013-05-31||Interventional|||Evaluation of Pain With Radiesse® With Lidocaine for Nasolabial Folds|Evaluation of Pain With the Use of Radiesse® With Lidocaine for the Treatment of Nasolabial Folds|Completed||N/A|102|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-06-01 00:05:17.342911|2018-06-01 00:05:17.342911
NCT01069341|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|2012-07-25||2012-09-04|2010-02-16|2010-02-17|Estimate|2012-09-04|2012-10-04|Estimate||||2012-09-04|2012-10-04|Estimate|July 2007||2007-07-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery|Ranibizumab in Subjects With Dense Cataract and Rubeosis Due to Proliferative Diabetic Retinopathy (PDR)|Completed||Phase 1|4|Actual|Bhagat, Neelakshi, M.D., M.P.H.|Uncontrolled pilot study with a small sample size.|1|||f||||f||||||||||2018-06-01 00:05:17.846435|2018-06-01 00:05:17.846435
NCT01069328|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2013-11-12|2010-02-16|2010-02-17|Estimate|||||||2013-11-12|2013-11-13|Estimate|July 2006||2006-07-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)|Study of BAY43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|33|Actual|Bayer||6|||f||||f||||||||||2018-06-01 00:05:18.206684|2018-06-01 00:05:18.206684
NCT01069315|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|July 2006||2006-07-31|February 2010|2010-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|FLOW||Fluid Lavage of Open Wounds (FLOW): Pilot Trial|Fluid Lavage of Open Wounds (FLOW): A Multi-Center, Blinded, Factorial Pilot Trial Comparing Alternative Irrigating Solutions and Pressures in Patients With Open Fractures|Completed||Phase 3|111|Actual|McMaster University||4|||f||||f||||||||||2018-06-01 00:05:18.320585|2018-06-01 00:05:18.320585
NCT01069302|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2016-01-07|2010-02-16|2010-02-17|Estimate|||||||2016-01-07|2016-01-11|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|CHOICE||Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan|Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan|Completed||Phase 4|106|Actual|Kyoto University, Graduate School of Medicine||4|||f||||t||||||||||2018-06-01 00:05:18.444232|2018-06-01 00:05:18.444232
NCT01069289|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2012-03-21||2012-09-25|2010-02-16|2010-02-17|Estimate|2012-09-25|2012-10-25|Estimate||||2012-09-25|2012-10-25|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SUMIRE||Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler® 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis® Turbuhaler® 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1293|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:05:18.639916|2018-06-01 00:05:18.639916
NCT01069276|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2012-06-12|2010-02-16|2010-02-17|Estimate|||||||2012-06-12|2012-06-13|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Observational|||Prehospital Transcranial Duplex in Patients With Acute Stroke|Prehospital Transcranial Duplex in Patients With Acute Stroke|Terminated|||30|Anticipated|Johannes Gutenberg University Mainz|||1|"Changes in preclinical treatment of stroke patients, no more emergency physician will met this~   patients"|f||||f||||||||||2018-06-01 00:05:19.27969|2018-06-01 00:05:19.27969
NCT01069263|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-10|||2011-04-04|2010-02-15|2010-02-17|Estimate|||||||2011-04-04|2011-04-05|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Interventional|||Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis|Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial|Unknown status|Recruiting|N/A|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 00:05:19.371778|2018-06-01 00:05:19.371778
NCT01069250|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2013-08-21|2010-02-16|2010-02-17|Estimate|||||||2013-08-21|2013-08-22|Estimate|August 2001||2001-08-31|August 2013|2013-08-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|||Dynamic and Static Autoregulation After Brain Injury|Serial Measurement of Static and Dynamic Cerebrovascular Autoregulation After Brain Injury|Completed|||16|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-06-01 00:05:19.516708|2018-06-01 00:05:19.516708
NCT01069237|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2012-01-30|2010-02-16|2010-02-17|Estimate|||||||2012-01-30|2012-02-01|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Compliance and Contamination in Soft Contact Lens Wearers|Compliance and Contamination in Soft Contact Lens Wearers|Completed|||40|Actual|Alcon Research|||2||f||||f||||||||||2018-06-01 00:05:19.584985|2018-06-01 00:05:19.584985
NCT01069224|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Analysis of Proinflammatory Factors in the Synovial Fluid In Patients With Rotator Cuff Disease||Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||||||||Samples Without DNA|"~     Synovial fluid lavages will be collected at the time of arthroscopic RC reconstruction or~     other shoulder arthroscopy that will be performed for therapeutic goals (instability repair,~     SLAP lesion).~   "|||2018-06-01 00:05:19.687181|2018-06-01 00:05:19.687181
NCT01069211|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-14|||2011-05-10|2010-02-16|2010-02-17|Estimate|||||||2011-05-10|2011-05-11|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|LETTER||Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women|Assessment of Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|Unknown status|Recruiting||876|Anticipated|Korean Breast Cancer Study Group|||3||f||||t||||||Samples Without DNA|"~     Breast Cancer Tissue~   "|||2018-06-01 00:05:19.742947|2018-06-01 00:05:19.742947
NCT01069198|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-14|||2012-11-12|2010-02-16|2010-02-17|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||A Community Trial for Visceral Leishmaniasis (VL)|A Randomized, Double Blind, Community Trial to Assess the Efficacy of a Combination of Anti-helminth, and Vitamin A, Zinc and Iron Supplementation in Preventing Visceral Leishmaniasis (VL) Disease Among Asymptomatic Individuals With VL|Completed||N/A|200|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 00:05:19.807734|2018-06-01 00:05:19.807734
NCT01069185|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2017-02-24||2017-09-04|2010-02-16|2010-02-17|Estimate|2017-09-04|2017-09-11|Actual||||2017-09-04|2017-09-11|Actual|February 2010||2010-02-28|September 2017|2017-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Differences in Morbidity Between a Necessity Endotracheal Suctioning Protocol Versus a Routine Endotracheal Suctioning|Differences in Morbidity Frequency Between a Necessity Endotracheal Suctioning Protocol Versus a Routine Endotracheal Suctioning Protocol in Hospital Pablo Tobon Uribe´s Pediatric Intensive Care Unit (PICU). A Randomized Controlled Trial|Completed||N/A|92|Actual|Hospital Pablo Tobón Uribe||2|||f||||t||||||||No||2018-06-01 00:05:19.87874|2018-06-01 00:05:19.87874
NCT01069172|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-13|2014-06-17||2014-08-25|2010-02-16|2010-02-17|Estimate|2014-08-25|2014-09-04|Estimate||||2014-08-25|2014-09-04|Estimate|February 2010||2010-02-28|August 2014|2014-08-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional||Baseline analysis population consists of the 29 subjects that had both eyes enrolled. Of these 29 subjects, all had FS laser surgery in one eye (29 FS surgery eyes) and CCC with U/S surgery in their fellow eye (29 CCC surgery eyes).|Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery|A Prospective, Randomized Study of Cataract Surgery With the Assistance of the OptiMedica Femtosecond Laser System Compared to Standard Surgical Procedure of Continuous Curvilinear Capsulorhexis and Ultrasonic Phacoemulsification|Completed||Phase 3|30|Actual|Abbott Medical Optics|This evaluation was performed on a relatively small number of patients; assessment of CDE should be repeated in a larger number of subjects.|2|||f||||f||||||||||2018-06-01 00:05:21.050842|2018-06-01 00:05:21.050842
NCT01069159|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-13|||2011-06-19|2010-02-16|2010-02-17|Estimate|||||||2011-06-19|2011-06-21|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|PTTM||Propranolol Treatment of Traumatic Memories (PTTM)|Propranolol Treatment of Traumatic Memories (PTTM)|Unknown status|Recruiting|N/A|66|Anticipated|Mela, Mansfield, M.D.||2|||f||||f||||||||||2018-06-01 00:05:21.203827|2018-06-01 00:05:21.203827
NCT01069146|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-13|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2002||2002-01-31|February 2010|2010-02-28|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Mild Therapeutic Hypothermia During Severe Sepsis|Mild Therapeutic Hypothermia During Severe Sepsis|Completed||N/A|20|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-06-01 00:05:21.291956|2018-06-01 00:05:21.291956
NCT01069133|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2012-12-10|2010-02-16|2010-02-17|Estimate|||||||2012-12-10|2012-12-11|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Study of Rifaximin in Minimal Hepatic Encephalopathy|Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy,Diffusion Tensor Imaging Microbiome and Metabolome: a Prospective Trial|Completed||Phase 1/Phase 2|20|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||1|||f||||f||||||||||2018-06-01 00:05:21.412579|2018-06-01 00:05:21.412579
NCT01069120|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2014-06-25||2014-08-05|2010-02-16|2010-02-17|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated|Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids|A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304|Terminated||Phase 3|27|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|2||Repros stopped study due to safety and FDA placed study on hold|f||||t||||||||||2018-06-01 00:05:21.490238|2018-06-01 00:05:21.490238
NCT01069107|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2016-02-17|2010-02-16|2010-02-17|Estimate|||||||2016-02-17|2016-02-19|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|April 2013|Actual|2013-04-30||Interventional|||Acute Admission to Hallingdal Sjukestugu|Acute Admission to Hallingdal Sjukestugu. Can Acute Admissions to a Community Hospital be a Realistic Alternative to General Hospital Admissions?|Completed||N/A|140|Anticipated|Helse Sor-Ost||1|||f||||f||||||||||2018-06-01 00:05:21.748664|2018-06-01 00:05:21.748664
NCT01069094|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2014-06-27|2010-02-16|2010-02-17|Estimate|||||||2014-06-27|2014-06-30|Estimate|July 2004||2004-07-31|June 2014|2014-06-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata|A Single Dose lead-in PK Followed by a Randomized, Double-blinded, Controlled, Multiple Dose Study of the Selective Progesterone Receptor Modulator Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata|Completed||Phase 1/Phase 2|29|Actual|Repros Therapeutics Inc.||5|||f||||f||||||||||2018-06-01 00:05:21.838601|2018-06-01 00:05:21.838601
NCT01069081|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-03-04|2010-02-16|2010-02-17|Estimate|||||||2015-03-04|2015-03-06|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer|Phase II Study of Docetaxel and Cisplatin Chemotherapy Versus Docetaxel and Cisplatin Chemotherapy Combined With High Dose Proton Pump Inhibitor in Metastatic Breast Cancer|Completed||Phase 2|94|Actual|Fudan University||3|||f||||t||||||||||2018-06-01 00:05:21.943035|2018-06-01 00:05:21.943035
NCT01069068|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2011-12-07|2010-02-16|2010-02-17|Estimate|||||||2011-12-07|2011-12-09|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Assessment of the Impact of a Stepped Mouthpiece on the Upper Airways Measured Through Acoustic Pharyngometry|Assessment of the Impact of a Stepped Mouthpiece on the Upper Airways Measured Through Acoustic Pharyngometry|Completed|||60|Actual|Doctor's Directive Strategies Inc.|||||f||||f||||||||||2018-06-01 00:05:22.026489|2018-06-01 00:05:22.026489
NCT01069055|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-23|2010-02-16|2010-02-17|Estimate|||||||2010-02-23|2010-02-24|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Comparison of Lornoxicam and Paracetamol for Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair|Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair: Prospective Randomized Double-blinded Placebo Controlled Comparison of Lornoxicam and Paracetamol|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Diskapi Teaching and Research Hospital||3|||f||||t||||||||||2018-06-01 00:05:22.096224|2018-06-01 00:05:22.096224
NCT01069042|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2010-02-23|2010-02-16|2010-02-17|Estimate|||||||2010-02-23|2010-02-25|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|November 2010|Anticipated|2010-11-30|August 2010|Anticipated|2010-08-31||Interventional|||Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human|A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement|Unknown status|Recruiting|Phase 4|60|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-06-01 00:05:22.188698|2018-06-01 00:05:22.188698
NCT01069029|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2010-02-16|2010-02-16|2010-02-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Combined Versus Successive Macular Hole and Cataract Surgery|Macular Hole and Cataract Extraction: Combined Surgery Versus Two Times Surgery|Completed|||120|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||f||||||||||2018-06-01 00:05:22.480097|2018-06-01 00:05:22.480097
NCT01069016|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2017-07-20|2010-02-16|2010-02-17|Estimate|||||||2017-07-20|2017-07-21|Actual|February 2010|Actual|2010-02-28|July 2017|2017-07-31|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Interventional|||Comparison of Sacral Nerve Modulation and Pudendal Nerve Stimulation in Treatment of Fecal Incontinence|Comparison of Sacral Nerve Modulation and Pudendal Nerve Stimulation in Treatment of Fecal Incontinence|Completed||N/A|30|Actual|Cantonal Hospital of St. Gallen||2|||f||||f||||||||||2018-06-01 00:05:22.565418|2018-06-01 00:05:22.565418
NCT01069003|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2015-06-29||2015-12-11|2010-02-16|2010-02-17|Estimate|2015-12-11|2016-01-20|Estimate||||2015-12-11|2016-01-20|Estimate|April 2010||2010-04-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|EDUCATE|The intent to treat arm contains non randomized subjects followed through 24 months|EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events|EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen|Completed||Phase 4|2272|Actual|Medtronic Vascular||3|||f||||t||||||||||2018-06-01 00:05:22.747811|2018-06-01 00:05:22.747811
NCT01068990|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2018-01-08|2010-02-16|2010-02-17|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2010||2010-03-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Detection and Characterization of Lower Respiratory Infections in Critically Ill Patients|Detection and Characterization of Lower Respiratory Infections in Critically Ill Patients|Recruiting|||300|Anticipated|Asan Medical Center|||||f||||t||||||||||2018-06-01 00:05:23.546354|2018-06-01 00:05:23.546354
NCT01068977|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2017-05-18|2010-02-12|2010-02-17|Estimate|||||||2017-05-18|2017-05-19|Actual|August 2007|Actual|2007-08-31|May 2017|2017-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|44|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 00:05:23.694596|2018-06-01 00:05:23.694596
NCT01068964|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2011-12-16||2014-09-15|2010-02-12|2010-02-17|Estimate|2011-12-16|2012-01-20|Estimate||||2014-09-15|2014-09-16|Estimate|February 2010||2010-02-28|September 2014|2014-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension||Completed||N/A|235|Actual|Allergan||2|||f||||||||||||||2018-06-01 00:05:23.865279|2018-06-01 00:05:23.865279
NCT01068951|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2014-02-04|2010-02-16|2010-02-17|Estimate|||||||2014-02-04|2014-02-05|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells|Open Study to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells in Treatment of Recently Diagnosed Patients With Type 1 Diabetes Mellitus|Completed||N/A|20|Actual|Uppsala University Hospital||2|||f||||||||||||||2018-06-01 00:05:24.210034|2018-06-01 00:05:24.210034
NCT01068938|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-16|||2016-12-19|2010-02-16|2010-02-17|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2013|Actual|2013-12-31||Observational|X-SCOPE||Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter|Detection of Visual Field Defects and Scotoma Progression in Glaucomatous Optic Neuropathy, Using Short-term Intervals With Automated Scotoma-oriented Perimetry (SCOPE) and the Fast Thresholding Strategy GATE (German Adaptive Threshold Estimation)|Active, not recruiting|||30|Anticipated|University Hospital Tuebingen|||1||f||||f||||||||||2018-06-01 00:05:24.334034|2018-06-01 00:05:24.334034
NCT01068925|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2011-01-22|2010-02-12|2010-02-15|Estimate|||||||2011-01-22|2011-01-25|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|ING||Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers|An Open-Label, Single Sequence, Three-Period Drug Interaction Study of GSK1349572 and Tipranavir/Ritonavir in Healthy Adult Subjects (ING113096)|Completed||Phase 1|18|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 00:05:24.426871|2018-06-01 00:05:24.426871
NCT01068912|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2014-02-11||2015-10-20|2010-02-12|2010-02-15|Estimate|2014-02-11|2014-03-27|Estimate||||2015-10-20|2015-11-18|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional||The Safety Population, defined as all patients who received study drug, was used for demographic and baseline characteristics and safety analyses, unless otherwise indicated.|Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Favipiravir in Adult Patients With Uncomplicated Influenza|Completed||Phase 2|530|Actual|MDVI, LLC||3|||f||||t||||||||||2018-06-01 00:05:24.640226|2018-06-01 00:05:24.640226
NCT01068899|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2011-05-16|2010-02-12|2010-02-15|Estimate|||||||2011-05-16|2011-05-18|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Energy Expenditure|Energy Expenditure|Completed|||30|Anticipated|Arkansas Children's Hospital Research Institute|||2||f||||t||||||||||2018-06-01 00:05:26.452443|2018-06-01 00:05:26.452443
NCT01068886|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-02-12|2010-02-12|2010-02-15|Estimate|||||||2010-02-12|2010-02-15|Estimate|January 2006||2006-01-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||External Pancreatic Duct Stent After Pancreaticoduodenectomy|External Pancreatic Duct Stent After Pancreaticoduodenectomy: a Prospective Randomized Multicenter Trial|Completed||Phase 3|150|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-06-01 00:05:26.55237|2018-06-01 00:05:26.55237
NCT01068873|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2014-06-05|2010-02-12|2010-02-15|Estimate|||||||2014-06-05|2014-06-06|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|KALMAR||Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)|Kaletra and Maraviroc in Antiretroviral Therapy-Naïve Patients - KALMAR Study -Version 1.0 Amendment 2|Terminated||Phase 4|1|Actual|Temple University||1||Poor enrollment|f||||f||||||||||2018-06-01 00:05:26.693655|2018-06-01 00:05:26.693655
NCT01068860|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2011-08-03||2011-08-03|2010-02-12|2010-02-15|Estimate|2011-08-03|2011-09-05|Estimate||||2011-08-03|2011-09-05|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies|A Multi-center, Double-blind, Placebo-controlled, Randomized Study to Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes Treated With Differing Baseline Diabetes Therapies|Completed||Phase 2|246|Actual|Novartis||10|||f||||f||||||||||2018-06-01 00:05:26.866035|2018-06-01 00:05:26.866035
NCT01068847|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2013-03-06|2010-02-12|2010-02-15|Estimate|||||||2013-03-06|2013-03-07|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|OMDD3||Drug Discrimination in Methadone-Maintained Humans Study 3|Drug Discrimination in Methadone-Maintained Humans Study 3|Completed||Phase 1|9|Actual|University of Arkansas||1|||f||||t||||||||||2018-06-01 00:05:28.892369|2018-06-01 00:05:28.892369
NCT01068834|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2012-01-30|2010-02-12|2010-02-15|Estimate|||||||2012-01-30|2012-02-01|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|AKROBATS||Additional KIF6 Risk Offers Better Adherence to Statins|Additional KIF6 Risk Offers Better Adherence to Statins|Completed|||1282|Actual|Medco Health Solutions, Inc.|||2||f||||f||||||Samples With DNA|"~     DNA samples~   "|||2018-06-01 00:05:28.96613|2018-06-01 00:05:28.96613
NCT01068821|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2011-08-15||2012-04-16|2010-02-12|2010-02-15|Estimate|2012-04-16|2012-05-15|Estimate||||2012-04-16|2012-05-15|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SPS||Trendelenburg's Slide Prevention Study|Randomized Controlled Trial Comparing Commonly Used Techniques to Prevent Slippage During Steep Trendelenburg's Position|Completed||N/A|60|Actual|Mayo Clinic|Evaluation of postoperative outcomes was non-systematic using chart review for all participants except for one participant whose identity was not listed on data abstraction sheet.|2|||f||||f||||||||||2018-06-01 00:05:29.067314|2018-06-01 00:05:29.067314
NCT01068808|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2013-02-18|2010-02-12|2010-02-15|Estimate|||||||2013-02-18|2013-02-20|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Observational|||The Development of Allergic Rhinitis in Children Previously Diagnosed as Nonallergic Rhinitis|The Development of Allergic Rhinitis in Children Previously Diagnosed as Nonallergic Rhinitis|Completed|||175|Actual|Mahidol University|||1||f||||t||||||||||2018-06-01 00:05:29.403205|2018-06-01 00:05:29.403205
NCT01068795|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2016-02-20|2010-02-12|2010-02-15|Estimate|||||||2016-02-20|2016-02-23|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome|Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome|Completed||N/A|144|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-06-01 00:05:29.539687|2018-06-01 00:05:29.539687
NCT01068782|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2014-07-28|2010-02-12|2010-02-15|Estimate|||||||2014-07-28|2014-07-30|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|May 2011|Actual|2011-05-31||Interventional|||Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse|A Phase 2 Non-Comparative Randomized Open-Label Study of Multiple Regimens of Single-Agent XL184 in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse|Completed||Phase 2|19|Actual|Exelixis||4|||f||||t||||||||||2018-06-01 00:05:29.628991|2018-06-01 00:05:29.628991
NCT01068769|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2014-01-09||2018-02-01|2010-02-12|2010-02-15|Estimate|2014-01-09|2014-02-24|Estimate||||2018-02-01|2018-03-01|Actual|February 2010||2010-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2012|Actual|2012-06-30||Interventional||Eligible patients were included in the baseline analysis population|Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor|A Multi-center Phase II Study Evaluating the Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST), Resistent or Intolerant to at Least Imatinib and Sunitinib|Active, not recruiting||Phase 2|34|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:05:29.806198|2018-06-01 00:05:29.806198
NCT01068756|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2016-10-14|2010-02-12|2010-02-15|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects|Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects|Terminated||Phase 1|14|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:05:30.310946|2018-06-01 00:05:30.310946
NCT01068743|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2012-01-09||2015-04-21|2010-02-12|2010-02-15|Estimate|2012-01-09|2012-02-08|Estimate||||2015-04-21|2015-05-08|Estimate|February 2010||2010-02-28|March 2015|2015-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 850 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 850 mg Metformin (Glucophage Marketed by Merck Serono) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed Conditions|Completed||Phase 1|24|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:05:30.494451|2018-06-01 00:05:30.494451
NCT01068730|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2012-01-20||2015-04-21|2010-02-12|2010-02-15|Estimate|2012-02-29|2012-03-29|Estimate||||2015-04-21|2015-05-08|Estimate|February 2010||2010-02-28|March 2015|2015-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects|Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets Manufactured by Bristol-Myers Squibb Relative to 500 mg and 1000 mg Diabex (Metformin) Tablets Marketed in Australia by Alphapharm Administered to Healthy Subjects in the Fed State|Completed||Phase 1|28|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:05:32.01426|2018-06-01 00:05:32.01426
NCT01068717|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2011-08-10||2015-04-22|2010-02-12|2010-02-15|Estimate|2011-09-15|2011-10-21|Estimate||||2015-04-22|2015-05-12|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Tablet Relative to a 2.5 mg Saxagliptin (Onglyza) Tablet and a 500 mg Metformin (Glucophage Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States|Completed||Phase 1|27|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:05:32.720028|2018-06-01 00:05:32.720028
NCT01068704|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12||2012-03-24|2015-09-23|2010-02-12|2010-02-15|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer|An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole With Lapatinib + Letrozole in Recurrent and Metastatic Breast Cancer Patients Who Are Hormone Receptor Positive Despite HER2 Status And Who Relapsed While Receiving or After Completing Adjuvant Antiendocrine Therapy|Completed||Phase 2|4|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 00:05:33.53281|2018-06-01 00:05:33.53281
NCT01068691|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-02-12|2010-02-12|2010-02-15|Estimate|||||||2010-02-12|2010-02-15|Estimate|May 2008||2008-05-31|February 2010|2010-02-28|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|ao_diss||Arterial Properties of Thoracic Aorta Disease|Blood Pressure Control and Arterial Properties After Surgical Treatment of Type A Thoracic Aortic Dissection or Haematoma|Unknown status|Recruiting||180|Anticipated|University Hospital, Grenoble|||||f||||t||||||Samples Without DNA|"~     Plasma samples for inflammation, oxidative stress and collagen markers~   "|||2018-06-01 00:05:33.68261|2018-06-01 00:05:33.68261
NCT01068678|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2015-10-12|2011-02-24|2017-01-20|2010-02-12|2010-02-15|Estimate|2015-11-19|2015-12-28|Estimate|2011-02-24|2011-03-09|Estimate|2017-01-20|2017-03-06|Actual|February 2010||2010-02-28|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|BEGIN™|Full Analysis Set (FAS)- included all randomised subjects. 1 subject was randomised despite being a screening failure|Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: EASY AM)|Completed||Phase 3|460|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:05:33.784081|2018-06-01 00:05:33.784081
NCT01068665|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2015-10-12|2011-02-23|2017-01-20|2010-02-12|2010-02-15|Estimate|2015-10-12|2015-11-13|Estimate|2011-02-23|2011-03-01|Estimate|2017-01-20|2017-03-06|Actual|March 2010||2010-03-31|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|BEGIN™|The Full Analysis Set (FAS) included all randomised subjects.|Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: LOW VOLUME)|Completed||Phase 3|460|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:05:34.318764|2018-06-01 00:05:34.318764
NCT01068652|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2013-02-26||2016-11-23|2010-02-12|2010-02-15|Estimate|2013-02-26|2013-04-08|Estimate||||2016-11-23|2017-01-13|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs|Effect of 50-week Treatment With Stepwise Insulin Intensification of Basal-bolus Insulin Analogues (Insulin Detemir and Aspart) or Biphasic Insulin Aspart 30 (NovoMix 30) All in Combination With Fixed Dose of Metformin on Glycaemic Control (Measured as HbA1c) in Subjects With Type 2 Diabetes. Open Labelled, Randomized, Two-arm, Parallel Group, Multi-centre, Multi-national Trial|Completed||Phase 4|403|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:05:35.000442|2018-06-01 00:05:35.000442
NCT01068639|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2014-06-25|2010-02-12|2010-02-15|Estimate|||||||2014-06-25|2014-06-26|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Observational|IMPACT||An Observational Study on Treatment Compliance by Children Treated With Growth Hormone|IMprove PAtient Compliance sTudy: An Observational, Cross-sectional Study on Children Treated With Growth Hormone in France|Withdrawn|||0|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 00:05:35.704361|2018-06-01 00:05:35.704361
NCT01068626|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2011-02-07||2015-08-06|2010-02-12|2010-02-15|Estimate|2011-02-07|2011-03-02|Estimate||||2015-08-06|2015-08-24|Estimate|May 2006||2006-05-31|August 2015|2015-08-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|RIVIERA||Rosuvastatin in Visceral Adiposity|A 26-week, Single Center, Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Evaluate the Effect of Rosuvastatin on Visceral Adipose Tissue in Male Patients With Abdominal Obesity|Completed||Phase 3|54|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 00:05:35.810927|2018-06-01 00:05:35.810927
NCT01068106|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2012-05-07|2010-02-11|2010-02-12|Estimate|||||||2012-05-07|2012-05-08|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|ISAR-TEST6||Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents|Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings|Unknown status|Active, not recruiting|Phase 4|2010|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 00:05:44.135512|2018-06-01 00:05:44.135512
NCT01068613|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12||2012-05-02|2012-05-02|2010-02-12|2010-02-15|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-blind, Double-dummy, Three Period Incomplete Cross-over Study to Evaluate the Safety and Efficacy of Multiple Daily Doses of QAX028 as Compared to Tiotropium Bromide (Positive Control) and Placebo in COPD Patients|Completed||Phase 2|62|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:05:36.363206|2018-06-01 00:05:36.363206
NCT01068600|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|2011-07-22||2011-07-22|2010-02-12|2010-02-15|Estimate|2011-07-22|2011-08-19|Estimate||||2011-07-22|2011-08-19|Estimate|January 2010||2010-01-31|July 2011|2011-07-31||||June 2010|Actual|2010-06-30||Interventional|||Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks|A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|318|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:05:36.563428|2018-06-01 00:05:36.563428
NCT01068587|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2017-11-28|2010-02-12|2010-02-15|Estimate|||||||2017-11-28|2017-11-29|Actual|December 2009||2009-12-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|March 2014|Actual|2014-03-31||Interventional|||MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy|A Phase I/II Study of Foretinib in Patients With Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy|Completed||Phase 1/Phase 2|31|Actual|Canadian Cancer Trials Group||2|||f||||f||||||||||2018-06-01 00:05:37.078022|2018-06-01 00:05:37.078022
NCT01068574|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2010-08-02|2010-02-12|2010-02-15|Estimate|||||||2010-08-02|2010-08-03|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|||Evaluation of the Basic Assessment of Severity of Illness in Children (BASIC) Scale|Evaluation of the BASIC Scale (Basic Assessment of Severity of Illness in Children): A Simple Triage Tool for Resource-limited Settings|Unknown status|Recruiting||2500|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||||2018-06-01 00:05:37.217722|2018-06-01 00:05:37.217722
NCT01068561|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2011-09-19|2010-02-12|2010-02-15|Estimate|||||||2011-09-19|2011-09-20|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa|Phase 1 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa|Completed||Phase 1|5|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 00:05:37.30638|2018-06-01 00:05:37.30638
NCT01068548|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2014-11-07||2015-04-06|2010-02-12|2010-02-15|Estimate|2014-11-07|2014-11-17|Estimate||||2015-04-06|2015-04-28|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Reducing Length of Stay for Veterans Hospitalized With Pneumonia|Reducing Length of Stay for Veterans Hospitalized With Pneumonia|Completed||N/A|129|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:05:37.417905|2018-06-01 00:05:37.417905
NCT01068535|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2012-09-12|2010-02-12|2010-02-15|Estimate|||||||2012-09-12|2012-09-14|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|July 2013|Anticipated|2013-07-31|July 2012|Actual|2012-07-31||Observational|||Early Vascular Wall Changes by Magnetic Resonance Imaging (MRI) in Metabolic Syndrome Versus Metabolically Normal Pre-Menopausal Women: A Pilot Study|Early Vascular Wall Changes by MRI in Metabolic Syndrome vs. Metabolically Normal Pre-Menopausal Women: A Pilot Study|Unknown status|Active, not recruiting||43|Actual|University of Washington|||2||f||||f||||||Samples Without DNA|"~     Lipids, LDL-Buoyancy, Apo-B, Apo-A1 Inflammatory markers: hs-CRP, SAA, IL-6, & TNF-α Vascular~     Adhesion Markers: VCAM, sICAM~   "|||2018-06-01 00:05:37.706019|2018-06-01 00:05:37.706019
NCT01068522|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2012-10-31|2010-02-12|2010-02-15|Estimate|||||||2012-10-31|2012-11-01|Estimate|July 2007||2007-07-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|April 2012|Actual|2012-04-30||Interventional|||Study to Improve Outcomes for Survivors of Traumatic Brain Injury in Latin America|Traumatic Brain Injury in Latin America: Lifespan Analysis|Unknown status|Active, not recruiting|Phase 3|324|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 00:05:37.796262|2018-06-01 00:05:37.796262
NCT01068509|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2016-03-29||2017-04-04|2010-02-11|2010-02-15|Estimate|2016-06-23|2016-08-04|Estimate||||2017-04-04|2017-05-11|Actual|July 2010||2010-07-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|August 2013|Actual|2013-08-31||Interventional||All participants: All participants enrolled in the study.|Ovarian Cancer Vaccine for Patients in Remission|A Randomized, Open-label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (Cvac™) for Epithelial Ovarian Cancer Patients in First or Second Remission|Completed||Phase 2|63|Actual|Prima BioMed Ltd||3|||f||||t||||||||||2018-06-01 00:05:37.920243|2018-06-01 00:05:37.920243
NCT01068496|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-12|||2015-05-18|2010-02-12|2010-02-15|Estimate|||||||2015-05-18|2015-05-20|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium|Risk Factors and Biomarkers Associated With Recurrence After Excision of Primary Pterygium|Terminated|||1|Actual|Singapore National Eye Centre||||Other and future studies on lipiview in pterygium will cover this current trial sufficiently.|f||||f||||||Samples With DNA|"~     Pterygium and conjunctival tissue samples~   "|||2018-06-01 00:05:38.495564|2018-06-01 00:05:38.495564
NCT01068483|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2013-04-09|2010-02-11|2010-02-15|Estimate|||||||2013-04-09|2013-04-11|Estimate|November 2008||2008-11-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|September 2011|Actual|2011-09-30||Interventional|||Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients|A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies|Completed||Phase 1|107|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:05:38.560004|2018-06-01 00:05:38.560004
NCT01068470|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2014-05-28|2010-02-12|2010-02-15|Estimate|||||||2014-05-28|2014-05-29|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|March 2012|Actual|2012-03-31|December 2010|Actual|2010-12-31||Observational|LAK||Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy|Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy|Terminated|||11|Actual|Loma Linda University|||1|PI left the institution|f||||f||||||||||2018-06-01 00:05:38.637936|2018-06-01 00:05:38.637936
NCT01068457|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-07-13|2010-02-12|2010-02-15|Estimate|||||||2010-07-13|2010-07-14|Estimate|December 2009||2009-12-31|July 2010|2010-07-31||||April 2010|Actual|2010-04-30||Observational|||Chronic Pain After Thoracotomy (Video Assisted Thoracic Surgery - VATS)|Chronic Pain After Thoracotomy (VATS)|Completed|||48|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-06-01 00:05:38.694077|2018-06-01 00:05:38.694077
NCT01068444|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2018-03-07|2010-02-12|2010-02-15|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2009||2009-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis|A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis|Recruiting||Phase 2|90|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:05:38.751558|2018-06-01 00:05:38.751558
NCT01068431|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-12-04|2010-02-12|2010-02-15|Estimate|||||||2012-12-04|2012-12-05|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Short Term Effectiveness Study of Juxta-Fit Versus Trico Bandages in the Treatment of Leg Lymphedema|Prospective, Randomized Controlled Trial Comparing the Effect of CircAid(R) Juxta-Fit(tm) Versus Trico Bandages in the Treatment of Leg Lymphedema|Completed||Phase 4|30|Actual|Nij Smellinghe Hosptial||2|||f||||f||||||||||2018-06-01 00:05:38.840342|2018-06-01 00:05:38.840342
NCT01068418|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2016-12-22||2017-03-01|2010-02-12|2010-02-15|Estimate|2016-12-22|2017-02-14|Actual||||2017-03-01|2017-03-30|Actual|February 2010||2010-02-28|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity|Vitamin D Deficiency Augments Renin-Angiotensin System Activity in Obesity|Completed||N/A|26|Actual|Brigham and Women's Hospital|"This was a small physiologic study intended to provide insights on the influence of vitamin D3 on the renin-angiotensin system and vascular function. It is not generalizable to clinical practice. This is not a standard clinical trial."|1|||f||||f||||||||||2018-06-01 00:05:38.934337|2018-06-01 00:05:38.934337
NCT01068405|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-12-08|2010-02-12|2010-02-15|Estimate|||||||2011-12-08|2011-12-09|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|ADEM||Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo|Erosive Osteoarthritis of the Hands: Treatment by Methotrexate Versus Placebo - Assessment of Structural and Clinical Action of Magnetic Resonance Imaging|Unknown status|Recruiting|Phase 3|64|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 00:05:39.115699|2018-06-01 00:05:39.115699
NCT01068392|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2014-11-02|2010-02-11|2010-02-12|Estimate|||||||2014-11-02|2014-11-04|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)|A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma|Completed||Phase 2|42|Actual|Dong-A University Hospital||1|||f||||t||||||||||2018-06-01 00:05:39.19393|2018-06-01 00:05:39.19393
NCT01068379|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-05-24|2010-02-11|2010-02-12|Estimate|||||||2010-05-24|2010-05-26|Estimate|July 2006||2006-07-31|May 2010|2010-05-31||||January 2009|Actual|2009-01-31||Interventional|||Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation|Randomized Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery|Completed||Phase 3|86|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-06-01 00:05:39.27625|2018-06-01 00:05:39.27625
NCT01068366|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2013-05-14|2010-02-11|2010-02-12|Estimate|||||||2013-05-14|2013-05-15|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|NASAH||Nickel Allergy With Septal Closure Devices|Nickel Allergy With Septal Occluder Using Amplatzer and Helex Devices (NASAH) Trial|Terminated|||4|Actual|University of Utah||||PI re-located.|f||||t||||||||||2018-06-01 00:05:39.358859|2018-06-01 00:05:39.358859
NCT01068353|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2014-04-22|2010-02-11|2010-02-12|Estimate|||||||2014-04-22|2014-04-23|Estimate|January 2011||2011-01-31|April 2014|2014-04-30||||December 2013|Actual|2013-12-31||Interventional|STEADI-09||Safety and Tolerability of Etanercept in Alzheimer's Disease|A Phase 2, Double-blind, Placebo-controlled Study of the Safety and Tolerability of Etanercept in Patients With Alzheimer's Disease|Completed||Phase 2|41|Actual|University of Southampton||2|||f||||t||||||||||2018-06-01 00:05:39.427872|2018-06-01 00:05:39.427872
NCT01068340|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2016-05-11|2010-02-11|2010-02-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||Early Small Bowel Obstruction Following Laparotomy For Trauma|Retrospective Review of the Incidence of Early Small Bowel Obstruction in Patients Undergoing an Exploratory Laparotomy Following Trauma|Completed|||571|Actual|University of Southern California|||2||f||||f||||||||||2018-06-01 00:05:40.698278|2018-06-01 00:05:40.698278
NCT01068327|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2018-04-24|2010-02-11|2010-02-12|Estimate|||||||2018-04-24|2018-04-25|Actual|November 2007||2007-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|August 2013|Actual|2013-08-31||Interventional|||Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer|Active, not recruiting||Phase 1|46|Actual|University of Nebraska||1|||f||||||||||||||2018-06-01 00:05:40.785917|2018-06-01 00:05:40.785917
NCT01068314|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2014-02-25|2010-02-11|2010-02-12|Estimate|||||||2014-02-25|2014-02-27|Estimate|January 2007||2007-01-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|May 2008|Actual|2008-05-31||Interventional|||Effect of Exercise on Endothelial Function and Vascular Compliance in Chronic Kidney Disease|Effect of Forearm Exercise on Flow Mediated Vasodilation Prior to Arteriovenous Fistula Placement for Hemodialysis|Completed||N/A|12|Actual|University of Iowa||2|||f||||f||||||||||2018-06-01 00:05:40.935591|2018-06-01 00:05:40.935591
NCT01068301|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2013-12-31|2010-02-11|2010-02-12|Estimate|||||||2013-12-31|2014-01-01|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation|A Phase I Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation|Completed||Phase 1|12|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 00:05:41.021682|2018-06-01 00:05:41.021682
NCT01068288|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2015-05-29|2010-02-11|2010-02-12|Estimate|||||||2015-05-29|2015-06-01|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Perforated Appendicitis With Delayed Presentation|Perforated Appendicitis With Delayed Presentation: Laparoscopic Appendectomy vs Expectant Management. A Randomized Clinical Trial (The PADLE Trial)|Unknown status|Recruiting|Phase 2|60|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 00:05:41.128377|2018-06-01 00:05:41.128377
NCT01067911|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2016-05-31|2010-02-10|2010-02-12|Estimate|||||||2016-05-31|2016-06-01|Estimate|July 2009||2009-07-31|May 2016|2016-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Optimizing Dietary Fatty Acids to Lower Metabolic Risk Factors Among Canadians|Optimizing Dietary Fatty Acids to Lower Metabolic Risk Factors Among Canadians|Terminated||N/A|12|Actual|University of British Columbia||4||Not enough enrollment, study needs to be revised|f||||f||||||||||2018-06-01 00:05:50.305454|2018-06-01 00:05:50.305454
NCT01068275|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-08-24|2010-02-11|2010-02-12|Estimate|||||||2010-08-24|2010-08-26|Estimate|April 2010||2010-04-30|August 2010|2010-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Lumbar Plexus Catheter Versus Femoral Nerve Catheter for Postoperative Pain After Anterior Cruciate Ligament (ACL) Repair|Lumbar Plexus Catheter Versus Femoral Nerve Catheter Versus Single-shot Femoral Block for Postoperative Pain Control After Anterior Cruciate Ligament Reconstruction|Unknown status|Recruiting|N/A|114|Anticipated|Seattle Children's Hospital||3|||f||||f||||||||||2018-06-01 00:05:41.265672|2018-06-01 00:05:41.265672
NCT01068262|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2017-02-06||2017-03-30|2010-02-11|2010-02-12|Estimate|2017-03-30|2017-06-16|Actual||||2017-03-30|2017-06-16|Actual|December 8, 2009|Actual|2009-12-08|March 2017|2017-03-31|May 2, 2010|Actual|2010-05-02|April 26, 2010|Actual|2010-04-26||Interventional|||Safety and Tolerability of Odanacatib (0822-059)|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Odanacatib (MK0822) in Healthy Male and Postmenopausal Female Subjects|Completed||Phase 1|44|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 00:05:41.415478|2018-06-01 00:05:41.415478
NCT01068249|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2018-02-20|2010-02-11|2010-02-12|Estimate|||||||2018-02-20|2018-02-22|Actual|April 2010|Actual|2010-04-30|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer|A Phase II Study of Letrozole and RAD001 (Everolimus) in Patients With Advanced or Recurrent Endometrial Cancer|Active, not recruiting||Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:05:42.226529|2018-06-01 00:05:42.226529
NCT01068236|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-03-23|2010-02-11|2010-02-12|Estimate|||||||2010-03-23|2010-03-24|Estimate|August 2005||2005-08-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SHINE||Primary Care Treatment for Overweight Adolescent Females (SHINE)|Primary Care Treatment for Overweight Adolescent Females|Completed||Phase 2|215|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 00:05:42.356475|2018-06-01 00:05:42.356475
NCT01068223|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2013-09-03|2010-02-11|2010-02-12|Estimate|||||||2013-09-03|2013-09-04|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|May 2010|Actual|2010-05-31|||||Interventional|||A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers|A Single-Center, Single-Dose, Double-Blind, Modified-Double-Dummy, Placebo and Active-Controlled, Randomized, Three-Way, Six-Sequence Cross-Over Study to Investigate the Effect of JNJ-39758979 on Histamine Induced Pruritus in Healthy Male Subjects|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||||||||||||2018-06-01 00:05:42.465968|2018-06-01 00:05:42.465968
NCT01068210|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2017-11-01|2010-02-11|2010-02-12|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Lung Cancer Exercise Training Study|Lung Cancer Exercise Training Study: A Randomized Trial of Aerobic Training, Resistance Training, or Both in Lung Cancer Patients|Recruiting||N/A|82|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||t||||||||||2018-06-01 00:05:42.5853|2018-06-01 00:05:42.5853
NCT01068197|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2014-09-08|2010-02-11|2010-02-12|Estimate|||||||2014-09-08|2014-09-09|Estimate|October 2003||2003-10-31|September 2014|2014-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|COOL Kids||Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes|Low Glycemic Load Diets in Latino Children at Risk for Type 2 Diabetes|Completed||Phase 2/Phase 3|113|Actual|Children's Research Institute||2|||f||||t||||||||||2018-06-01 00:05:42.734095|2018-06-01 00:05:42.734095
NCT01068184|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-09-22|2010-02-11|2010-02-12|Estimate|||||||2010-09-22|2010-09-24|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase I, Randomised, Double-Blind, Placebo-Controlled, 3-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD6553 in Healthy Volunteers (Parts A and B) and Patients (Part C) With Chronic Obstructive Pulmonary Disease|Terminated||Phase 1|109|Anticipated|AstraZeneca||2||"temporary hold in May 2010 due to an emerging PK profile that could not be aligned to the known~   pharmaceutical properties of the IMP (AZD6553)."|f||||f||||||||||2018-06-01 00:05:42.842666|2018-06-01 00:05:42.842666
NCT01068171|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-12-03|2010-02-11|2010-02-12|Estimate|||||||2010-12-03|2010-12-06|Estimate|May 2010||2010-05-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Developing a Diabetic Foot Ulcer Protocol|Developing a Diabetic Foot Ulcer Protocol in a Multi-ethnic, Underserved Population|Unknown status|Recruiting|N/A|180|Anticipated|The University of Texas Health Science Center, Houston||6|||f||||f||||||||||2018-06-01 00:05:42.932069|2018-06-01 00:05:42.932069
NCT01068158|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2012-03-07|2011-03-15|2012-04-04|2010-02-11|2010-02-12|Estimate|2012-03-07|2012-04-04|Estimate|2011-03-15|2011-03-25|Estimate|2012-04-04|2012-04-06|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|LICE OUT||A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects|A Double-Blind Randomized Study to Compare the Efficacy, Safety, and Local Tolerability of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation|Completed||Phase 3|371|Actual|Topaz Pharmaceuticals Inc||2|||f||||f||||||||||2018-06-01 00:05:43.194606|2018-06-01 00:05:43.194606
NCT01068145|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2015-03-25|2010-02-11|2010-02-12|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2010||2010-02-28|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)|Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled, Incomplete Crossover, Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and COPD Patients|Terminated||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||9|||f||||f||||||||||2018-06-01 00:05:43.745123|2018-06-01 00:05:43.745123
NCT01068132|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2014-05-09|2010-02-11|2010-02-12|Estimate|||||||2014-05-09|2014-05-12|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.|Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. An Italian Trial|Completed||Phase 2|54|Actual|Regione Lombardia||1|||f||||t||||||||||2018-06-01 00:05:43.885209|2018-06-01 00:05:43.885209
NCT01068119|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2013-09-20|2010-02-11|2010-02-12|Estimate|||||||2013-09-20|2013-09-23|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|GREECE||Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)|Feasibility and Safety of Same-Day Discharge of Troponin Negative Patients After Coronary PTCA Via the Transfemoral Approach|Terminated||Phase 4|57|Actual|Piedmont Healthcare||1||Slow enrollment and high number of screen failures|f||||f||||||||||2018-06-01 00:05:44.015986|2018-06-01 00:05:44.015986
NCT01068093|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-10-21|2010-02-11|2010-02-12|Estimate|||||||2010-10-21|2010-10-22|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||The Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome|Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome|Unknown status|Recruiting|Phase 4|120|Anticipated|Yokohama City University Medical Center|||||f||||f||||||||||2018-06-01 00:05:44.734955|2018-06-01 00:05:44.734955
NCT01068080|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-02-11|2010-02-11|2010-02-12|Estimate|||||||2010-02-11|2010-02-12|Estimate|January 2001||2001-01-31|October 2000|2000-10-31|December 2004|Actual|2004-12-31|||||Observational|CD_HD_FAIR||Involvement of FFA Metabolism and Insulin Resistance in Cardiac Death|Prediction of Impaired Myocardial Fatty Acid Metabolism and Insulin Resistance for Cardiac Death of Hemodialysis Patients With Normal Coronary Arteries|Completed|||155|Actual|Toujinkai Hospital|||1||f||||f||||||||||2018-06-01 00:05:44.84122|2018-06-01 00:05:44.84122
NCT01068067|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-07-26|2010-02-11|2010-02-12|Estimate|||||||2010-07-26|2010-07-28|Estimate|March 2010||2010-03-31|January 2010|2010-01-31||||December 2012|Anticipated|2012-12-31||Interventional|||Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Recipients|Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Chinese Renal Transplant Recipients: A Prospective Randomized Controlled Study|Unknown status|Recruiting|N/A|60|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-06-01 00:05:44.957204|2018-06-01 00:05:44.957204
NCT01068054|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-02-11|2010-02-11|2010-02-12|Estimate|||||||2010-02-11|2010-02-12|Estimate|June 2003||2003-06-30|June 2003|2003-06-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC)|A Double-blind Comparison of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drops in the Treatment of Vernal Keratoconjunctivits (VKC)|Completed||Phase 2/Phase 3|24|Actual|Siriraj Hospital||2|||f||||t||||||||||2018-06-01 00:05:45.072465|2018-06-01 00:05:45.072465
NCT01068041|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2015-11-03|2010-02-11|2010-02-12|Estimate|||||||2015-11-03|2015-11-04|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|PH3||Effects of PH3 in Diabetic Nephropathy|Effects of PH3 in Diabetic Nephropathy|Completed||Phase 2|100|Actual|PhytoHealth Corporation||4|||f||||f||||||||||2018-06-01 00:05:45.356962|2018-06-01 00:05:45.356962
NCT01068028|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-08-13|2010-02-11|2010-02-12|Estimate|||||||2010-08-13|2010-08-16|Estimate|February 2010||2010-02-28|August 2010|2010-08-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741|Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of ORM-12741|Completed||Phase 1|49|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-06-01 00:05:45.634166|2018-06-01 00:05:45.634166
NCT01068015|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-04-07|2010-02-11|2010-02-12|Estimate|||||||2010-04-07|2010-04-08|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||(Men Who Have Sex With Men) MSM Community Intervention Trial|A COMMUNITY-BASED, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF COMPREHENSIVE HIV/STIs INTERVENTION AMONG MEN WHO HAVE SEX WITH MEN IN 8 CITIES IN CHINA|Unknown status|Active, not recruiting|Phase 3|3214|Actual|National Center for AIDS/STD Control and Prevention, China CDC||2|||f||||t||||||||||2018-06-01 00:05:45.93276|2018-06-01 00:05:45.93276
NCT01068002|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-02-11|2010-02-11|2010-02-12|Estimate|||||||2010-02-11|2010-02-12|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|CREATION-P||Cardiovascular an Echocardiographic Assessment in Hypertension During Pregnancy|Hypertension During Pregnancy: Cardiovascular & Echocardiographic Assessment: CREATION - P (01)|Unknown status|Recruiting||80|Anticipated|HaEmek Medical Center, Israel|||3||f||||f||||||||||2018-06-01 00:05:46.255145|2018-06-01 00:05:46.255145
NCT01067989|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2015-07-06|2010-02-11|2010-02-12|Estimate|||||||2015-07-06|2015-07-08|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer|Antiangiogenic Treatment Strategy With Metronomic Chemotherapy Regimen Combined With a Cox-2 Inhibitor and a Bisphosphonate for Patients With Metastatic Breast Cancer|Terminated||Phase 2|22|Actual|HaEmek Medical Center, Israel||1||No satisfactory acrual|f||||f||||||||||2018-06-01 00:05:46.774856|2018-06-01 00:05:46.774856
NCT01067976|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|2014-07-10|2012-09-05|2014-11-10|2010-02-11|2010-02-12|Estimate|2014-11-10|2014-11-11|Estimate|2012-09-13|2012-09-17|Estimate|2014-11-10|2014-11-11|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI|An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI|Completed||Phase 3|446|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:05:47.190934|2018-06-01 00:05:47.190934
NCT01067963|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-06-05|2010-02-11|2010-02-12|Estimate|||||||2015-06-05|2015-06-09|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|SMaRT||Self-Management and Resourceful Transition of Type 2 Diabetes With Stage 3 Kidney Disease|Self-management of Type 2 Diabetes and Chronic Kidney Disease|Terminated||N/A|80|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 00:05:49.814455|2018-06-01 00:05:49.814455
NCT01067950|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2010-06-01|2010-02-11|2010-02-12|Estimate|||||||2010-06-01|2010-06-02|Estimate|March 2010||2010-03-31|March 2010|2010-03-31||||||||Interventional|PANCREAS||Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study|International, Multicenter, Prospective, Randomized, Parallel Group, Open Label Protocol to Evaluate Safety and Efficacy of Isolated Pancreas Transplantation Compared to Intensive Insulin Therapy in Type 1 Diabetic Patients With Overt Diabetic Nephropathy and Mildly Reduced Renal Function|Unknown status|Recruiting|Phase 3|180|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-06-01 00:05:49.984571|2018-06-01 00:05:49.984571
NCT01067937|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2013-02-06|2010-02-11|2010-02-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ALGAP||Study for a Rational Management of Appendicitis in Children|Multicenter Prospective Study for a Rational Management of Appendicitis in Children|Completed||N/A|891|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 00:05:50.099919|2018-06-01 00:05:50.099919
NCT01067924|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2014-07-17|2010-02-11|2010-02-12|Estimate|||||||2014-07-17|2014-07-21|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|April 2012|Actual|2012-04-30||Interventional|||Motivational Interviewing to Promote Maintenance of Physical Activity in People With Type 2 Diabetes|Motivational Interviewing to Promote Maintenance of Physical Activity in People With Type 2 Diabetes|Completed||N/A|55|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 00:05:50.200553|2018-06-01 00:05:50.200553
NCT01067898|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2012-03-26|2010-02-11|2010-02-12|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study on Oral Vitamin D Megadoses|A Randomized, Double-blind, Placebo-controlled Study on Oral Vitamin D Megadoses - 100 000 or 200 000 IU Vitamin D3 Every Three Months|Completed||Phase 4|60|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-06-01 00:05:50.37562|2018-06-01 00:05:50.37562
NCT01067885|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11|||2012-04-11|2010-02-11|2010-02-12|Estimate|||||||2012-04-11|2012-04-12|Estimate|April 2006||2006-04-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MARIS||A Post-market Registry of the MARIS-stent (Invatec) Implanted in the Superficial Femoral Artery|MARIS - Prospective, Multicenter Registry|Completed||N/A|1051|Actual|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|||||f||||f||||||||||2018-06-01 00:05:50.563697|2018-06-01 00:05:50.563697
NCT01067859|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-11||2015-09-23|2015-09-23|2010-02-11|2010-02-12|Estimate||||2015-09-23|2015-10-08|Estimate|2015-09-23|2015-10-08|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|COMPOSE 2||A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY58-2667 (25 µg/h, 10 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|Terminated||Phase 2|5|Actual|Bayer||3|||f||||t||||||||||2018-06-01 00:05:50.822067|2018-06-01 00:05:50.822067
NCT01067846|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2013-06-11||2013-10-31|2010-02-11|2010-02-12|Estimate|2013-10-31|2013-11-26|Estimate||||2013-10-31|2013-11-26|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||These numbers include participants that were eligible after the initial intake assessment and were assigned to a group.|Cognitive Enhancement and Relapse Prevention in Cocaine Addiction|The Clinical and Neural Response of Cocaine Addicts to Combination Treatment With a Cognitive Enhancer and Extinction-Based Psychotherapy|Completed||N/A|85|Actual|University of Arkansas||2|||f||||t||||||||||2018-06-01 00:05:50.965205|2018-06-01 00:05:50.965205
NCT01067833|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2011-05-13|2010-02-10|2010-02-12|Estimate|||||||2011-05-13|2011-05-16|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|ARCTIC-AF||Phase 2 Study of Oral K201 for Prevention of AF Recurrence|A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary EffiCacy Study of K201 Oral for the Prevention of ATrial FIbrillation (AF) Recurrence in Subjects Post-Conversion From AF|Terminated||Phase 2|300|Anticipated|Sequel Pharmaceuticals, Inc||4|||f||||t||||||||||2018-06-01 00:05:51.474743|2018-06-01 00:05:51.474743
NCT01067820|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2013-06-03|2010-02-11|2010-02-12|Estimate|||||||2013-06-03|2013-06-04|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|ASSURE I||ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation|Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound|Completed||Phase 2|324|Actual|Resverlogix Corp||2|||f||||t||||||||||2018-06-01 00:05:51.754312|2018-06-01 00:05:51.754312
NCT01067807|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2014-07-03|2010-02-10|2010-02-12|Estimate|||||||2014-07-03|2014-07-08|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Proellex Pharmacokinetics Bridging Study|Proellex Pharmacokinetics Bridging Study|Completed||Phase 1|21|Actual|Repros Therapeutics Inc.||4|||f||||f||||||||||2018-06-01 00:05:51.998057|2018-06-01 00:05:51.998057
NCT01067794|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-08-23|2010-02-10|2010-02-12|Estimate|||||||2012-08-23|2012-08-24|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|FRAME||Chemotherapy in Treating Patients With Lung Cancer|First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study on Overall Survival|Completed|||1610|Anticipated|Eli Lilly and Company|||5||f||||f||||||||||2018-06-01 00:05:52.171132|2018-06-01 00:05:52.171132
NCT01067781|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2014-01-30||2018-03-20|2010-02-11|2010-02-12|Estimate|2014-01-30|2014-03-13|Estimate||||2018-03-20|2018-04-17|Actual|February 2010||2010-02-28|March 2018|2018-03-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional||safety population: includes all study subjects that were consented and received investigational study material (i.e., at least one vaccination)|Gender-Stratified Safety and Immunogenicity Study|A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Two Vaccination Regimen With the Travelers' Diarrhea Vaccine System in Healthy Adults|Completed||Phase 2|600|Actual|Intercell USA, Inc.||4|||f||||f||||||||||2018-06-01 00:05:52.251206|2018-06-01 00:05:52.251206
NCT01067768|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2011-07-11||2014-03-02|2010-02-10|2010-02-12|Estimate|2011-07-11|2011-08-04|Estimate||||2014-03-02|2014-03-28|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Reduction of Catheter-associated Urinary Tract Infection With a Daily Nursing Review of the Indication|Reduction of Catheter-associated Urinary Tract Infection With a Daily Nursing Review of the Indication. Randomized Controlled Trial|Completed||Phase 3|1209|Actual|Hospital Pablo Tobón Uribe||2|||f||||f||||||||||2018-06-01 00:05:52.917075|2018-06-01 00:05:52.917075
NCT01067755|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-02-10|2010-02-10|2010-02-12|Estimate|||||||2010-02-10|2010-02-12|Estimate|July 2009||2009-07-31|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Observational|||Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System|Clinical Product Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System|Unknown status|Recruiting||60|Anticipated|Broncus Technologies|||1||f||||f||||||||||2018-06-01 00:05:53.432951|2018-06-01 00:05:53.432951
NCT01067742|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2016-01-12|2010-02-10|2010-02-12|Estimate|||||||2016-01-12|2016-01-13|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Observational|||The Natural History of Mucolipidosis Type IV|The Natural History of Mucolipidosis Type IV|Recruiting|||35|Anticipated|Baylor Research Institute|||1||f||||f||||||Samples With DNA|"~     blood, urine and skin~   "|||2018-06-01 00:05:53.647488|2018-06-01 00:05:53.647488
NCT01067729|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-01-23|2010-02-11|2010-02-12|Estimate|||||||2015-01-23|2015-01-26|Estimate|November 2009||2009-11-30|February 2010|2010-02-28||||June 2011|Actual|2011-06-30||Interventional|||A Postmarket Randomized Study of the Treatment of Superficial Partial-Thickness Burns Using Two Dressings|A Multi-Center, Randomized, Prospective Study of the Treatment of Superficial Partial-Thickness Burns: AWBAT™ vs. Biobrane®|Terminated||N/A|||Aubrey Inc.|||||f||||f||||||||||2018-06-01 00:05:53.782124|2018-06-01 00:05:53.782124
NCT01065701|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-07|||2017-10-24|2010-02-08|2010-02-09|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2009||2009-07-31|October 2017|2017-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children|Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children - a Double-blinded Randomized Controlled Trial|Completed||Phase 3|104|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:06:32.37674|2018-06-01 00:06:32.37674
NCT01067716|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2013-03-28||2013-10-07|2010-02-10|2010-02-12|Estimate|2013-03-28|2013-05-22|Estimate||||2013-10-07|2013-10-31|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Performance and Acceptability of VSS-R|A Prospective Study to Evaluate the Performance and Acceptability of Advanced Variable Spot Scanning (AVSS) Ablations With the STAR S4 IR® Excimer Laser System|Completed||N/A|150|Actual|Abbott Medical Optics||1|||f||||f||||||||||2018-06-01 00:05:54.110649|2018-06-01 00:05:54.110649
NCT01067703|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-12-01|2010-02-10|2010-02-11|Estimate|||||||2015-12-01|2015-12-03|Estimate|December 2010||2010-12-31|September 2014|2014-09-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Remote Ischaemic Preconditioning for Heart Surgery (RIPHeart-Study)|Remote Ischaemic Preconditioning for Heart Surgery|Terminated||Phase 3|1400|Actual|University of Schleswig-Holstein||2|||f||||t||||||||||2018-06-01 00:05:54.826533|2018-06-01 00:05:54.826533
NCT01067690|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2016-08-29|2010-02-10|2010-02-11|Estimate|||||||2016-08-29|2016-08-30|Estimate|June 2008||2008-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|||Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma|Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy|Completed||Phase 2|25|Actual|Istituto Superiore di Sanità|||||f||||||||||||||2018-06-01 00:05:54.92745|2018-06-01 00:05:54.92745
NCT01067677|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2017-11-12|2010-02-10|2010-02-11|Estimate|||||||2017-11-12|2017-11-14|Actual|February 2010||2010-02-28|November 2017|2017-11-30|February 2014|Anticipated|2014-02-28|February 2012|Anticipated|2012-02-29||Interventional|RETCHES||Rescue Emetic Therapy for Children Having Elective Surgery|Rescue Emetic Therapy for Children Having Elective Therapy|Withdrawn||N/A|0|Actual|University of Pittsburgh||4||We do not have the funding or resources to complete the study at this time|f||||f||||||||||2018-06-01 00:05:55.042288|2018-06-01 00:05:55.042288
NCT01067664|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2013-10-17|2010-02-10|2010-02-11|Estimate|||||||2013-10-17|2013-10-18|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|PROG2||Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome|The Effect of Serum Progesterone Levels on the Day of hCG Administration on the Probability of Pregnancy in Patients Treated by IVF Using GnRH Antagonists and Recombinant Gonadotrophins|Completed|||130|Actual|Aristotle University Of Thessaloniki|||1||f||||f||||||Samples Without DNA|"~     6ml of serum will be frozen and stored for later analysis~   "|||2018-06-01 00:05:55.179166|2018-06-01 00:05:55.179166
NCT01067651|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-02-10|2010-02-10|2010-02-11|Estimate|||||||2010-02-10|2010-02-11|Estimate||||April 2007|2007-04-30||||||||Interventional|||Comparison of Casting Materials for the Treatment of Clubfoot Using the Ponseti Method|Comparison of Two Different Cast Materials for the Treatment of Congenital Idiopathic Clubfoot Using the Ponseti Method: A Prospective Randomized Controlled Trial|Completed||N/A|30|Actual|Alberta Children's Hospital||2|||f||||f||||||||||2018-06-01 00:05:55.318611|2018-06-01 00:05:55.318611
NCT01067638|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-12-03|2010-02-10|2010-02-11|Estimate|||||||2010-12-03|2010-12-06|Estimate|November 2009||2009-11-30|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Tranexamic Acid on Postoperative Blood Loss and Coagulation in Patients With Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft; Double Blind Randomized Control Study||Completed||Phase 4|90|Actual|Yonsei University||1|||f||||t||||||||||2018-06-01 00:05:55.52579|2018-06-01 00:05:55.52579
NCT01067625|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-02-10|2010-02-10|2010-02-11|Estimate|||||||2010-02-10|2010-02-11|Estimate|February 2006||2006-02-28|February 2010|2010-02-28||||December 2015|Anticipated|2015-12-31||Interventional|TOGA®||Endoscopic Bariatric Stapling Pilot Study||Unknown status|Enrolling by invitation|Phase 1|200|Anticipated|Satiety, Inc.||1|||f||||||||||||||2018-06-01 00:05:55.629317|2018-06-01 00:05:55.629317
NCT01067599|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2018-02-22|2010-02-10|2010-02-11|Estimate|||||||2018-02-22|2018-02-26|Actual|March 2012|Actual|2012-03-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|August 2015|Actual|2015-08-31||Interventional|||Novel Determinants and Measures of Smokeless Tobacco Use: Study 2|Novel Determinants and Measures of Smokeless Tobacco Use: Study 2 Effects of Switching Levels of Nicotine and TSNA in Products on Smokeless Tobacco Use|Completed||N/A|278|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-06-01 00:05:55.781208|2018-06-01 00:05:55.781208
NCT01067586|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-12-11|2010-02-10|2010-02-11|Estimate|||||||2015-12-11|2015-12-15|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Novel Determinants and Measures of Smokeless Tobacco Use: Study 1|Toxicant Exposure Across Brands of Smokeless Tobacco|Completed|||359|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||Samples Without DNA|"~     Urine, buccal cells and blood will be collected from subjects in this study.~   "|||2018-06-01 00:05:55.889056|2018-06-01 00:05:55.889056
NCT01067573|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2012-06-14|2010-02-10|2010-02-11|Estimate|||||||2012-06-14|2012-06-18|Estimate|December 2009||2009-12-31|February 2010|2010-02-28|July 2011|Actual|2011-07-31|||||Observational|Leptin||The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment|The Role of Leptin Levels in Multiple Sclerosis|Completed|||20|Actual|University of South Florida|||||f||||t||||||||||2018-06-01 00:05:55.951684|2018-06-01 00:05:55.951684
NCT01067560|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-11-08|2010-02-10|2010-02-11|Estimate|||||||2010-11-08|2010-11-10|Estimate|January 2010||2010-01-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Measuring Cerebrospinal Fluid (CSF) Glucose Levels in Patients Under Going an Elective Cesarean Section With Spinal Anesthesia|Measurement of CSF Glucose Levels Using Three Different Glucose Meters in Parturients Undergoing Spinal Anesthesia for Elective Cesarean Section|Completed|||30|Actual|University of British Columbia|||||f||||f||||||Samples With DNA|"~     Whole blood, CSF~   "|||2018-06-01 00:05:56.035121|2018-06-01 00:05:56.035121
NCT01067547|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2015-04-28|2010-02-10|2010-02-11|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||A Trial of Iron Replacement in Patients With Iron Deficiency.|A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency.|Completed||Phase 4|130|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 00:05:56.234289|2018-06-01 00:05:56.234289
NCT01067534|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2011-01-18|2010-02-10|2010-02-11|Estimate|||||||2011-01-18|2011-01-19|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bronchodilator Responsiveness in Healthy Young Adults Using Forced Oscillations Technique (FOT)|Assessment of Bronchodilator Responsiveness in Healthy Young Adults Using Forced Oscillations|Completed||N/A|100|Anticipated|University of Patras|||||f||||f||||||||||2018-06-01 00:05:56.392308|2018-06-01 00:05:56.392308
NCT01065181|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-06|||2018-03-24|2010-02-08|2010-02-09|Estimate|||||||2018-03-24|2018-03-27|Actual|January 2008|Actual|2008-01-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|Safethrow||Youth Throwers Respond to Stretching|Shoulder Posterior Capsular Contracture in Youth Baseball Players: It Can be Improved by Stretching|Active, not recruiting|||1261|Actual|Metzger, Charles, M.D.|||||f||||f||||||||||2018-06-01 00:06:40.122054|2018-06-01 00:06:40.122054
NCT01067521|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2017-11-15|2010-02-10|2010-02-11|Estimate|||||||2017-11-15|2017-11-17|Actual|May 31, 2010|Actual|2010-05-31|November 2017|2017-11-30|May 12, 2017|Actual|2017-05-12|May 7, 2012|Actual|2012-05-07||Interventional|GALA||A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo|A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design|Completed||Phase 3|1404|Actual|Teva Pharmaceutical Industries||2|||f||||t|t|f||||||||2018-06-01 00:05:56.607332|2018-06-01 00:05:56.607332
NCT01067508|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2013-05-08|2010-02-10|2010-02-11|Estimate|||||||2013-05-08|2013-05-13|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Effects of Naturally Silicon-Rich Water on Bone Metabolism in Women|Effects of Naturally Occurring Silicon in Drinking Water on Bone Metabolism|Completed||N/A|15|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-06-01 00:05:57.002494|2018-06-01 00:05:57.002494
NCT01067495|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-10|2010-02-10|2010-02-11|Estimate|||||||2010-02-10|2010-02-11|Estimate|January 2006||2006-01-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Adapted Cardiac Rehabilitation After Stroke|Feasibility and Effects of Cardiac Rehabilitation for Individuals After Stroke|Completed||Phase 1|43|Actual|Toronto Rehabilitation Institute||1|||f||||f||||||||||2018-06-01 00:05:57.094604|2018-06-01 00:05:57.094604
NCT01067482|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-03-22|2010-02-10|2010-02-11|Estimate|||||||2010-03-22|2010-03-23|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|cirrusOCT||The Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous Eyes|The Performances of Spectral Domain Optical Coherence Tomography for Distinguishing Between Normal Eyes, Glaucoma Suspect and Glaucomatous Eyes|Completed|||80|Anticipated|Prince of Songkla University|||3||f||||t||||||||||2018-06-01 00:05:57.180686|2018-06-01 00:05:57.180686
NCT01067469|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2016-10-27|2010-02-10|2010-02-11|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)|Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) In Adults With Recurrent Glioblastoma Multiforme|Completed||Phase 2|83|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:05:57.270731|2018-06-01 00:05:57.270731
NCT01067456|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2014-04-08||2017-11-27|2010-02-10|2010-02-11|Estimate|2014-10-14|2014-10-20|Estimate||||2017-11-27|2017-12-22|Actual|May 2008||2008-05-31|November 2017|2017-11-30|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|CAPTURE||Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain|Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain|Completed||Phase 4|59|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:05:57.424115|2018-06-01 00:05:57.424115
NCT01067443|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2017-04-21|2010-02-10|2010-02-11|Estimate|||||||2017-04-21|2017-04-24|Actual|March 2010||2010-03-31|April 2017|2017-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa|A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Primary Visceral Leishmaniasis in Eastern Africa|Completed||Phase 2|151|Actual|Drugs for Neglected Diseases||3|||f||||t||||||||||2018-06-01 00:05:57.884418|2018-06-01 00:05:57.884418
NCT01067430|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-02-10|2010-02-10|2010-02-11|Estimate|||||||2010-02-10|2010-02-11|Estimate|April 2010||2010-04-30|January 2010|2010-01-31|April 2011|Anticipated|2011-04-30|October 2010|Anticipated|2010-10-31||Interventional|||Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)|Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis.|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Northumbria Healthcare NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:05:58.079617|2018-06-01 00:05:58.079617
NCT01067417|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-07-29|2010-02-10|2010-02-11|Estimate|||||||2010-07-29|2010-07-30|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|HCQ-01||Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients|Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients|Unknown status|Active, not recruiting|Phase 2|83|Actual|Medical Research Council||2|||f||||t||||||||||2018-06-01 00:05:58.443533|2018-06-01 00:05:58.443533
NCT01067404|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2010-02-10|2010-02-10|2010-02-11|Estimate|||||||2010-02-10|2010-02-11|Estimate|February 2010||2010-02-28|February 2010|2010-02-28||||||||Observational|TITRE II||TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B|TIV Infant/Toddler Response Evaluation (TITRE)- Follow-up & Focus on Influenza B|Unknown status|Enrolling by invitation||50|Anticipated|British Columbia Centre for Disease Control|||1||f||||f||||||||||2018-06-01 00:05:58.679568|2018-06-01 00:05:58.679568
NCT01067391|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-07-16|2010-02-10|2010-02-11|Estimate|||||||2015-07-16|2015-07-17|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males|A Randomized, Double-blind, Placebo-controlled Cross-over Trial Assessing the Effect of Tadalafil (Cialis) on the Cardiovascular System in Men With Complete Spinal Cord Injury (SCI) at or Above the Sixth Thoracic Level|Completed||Phase 4|20|Actual|University of Manitoba||2|||f||||f||||||||||2018-06-01 00:05:58.944822|2018-06-01 00:05:58.944822
NCT01067378|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2015-11-16|2010-02-10|2010-02-11|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PICS||Peer Debriefing Versus Instructor Debriefing for Interprofessional Simulation Based Education|Peer Debriefing Versus Instructor Debriefing for Interprofessional Simulation Based Education (PICS|Completed||N/A|120|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 00:05:59.238608|2018-06-01 00:05:59.238608
NCT01067365|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2014-06-26|2010-02-10|2010-02-11|Estimate|||||||2014-06-26|2014-06-27|Estimate|March 2006||2006-03-31|June 2014|2014-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|ZA-003Ext||Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism|An Open-Label, Multiple Center Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism Who Completed ZA-003|Completed||Phase 3|104|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-06-01 00:05:59.422678|2018-06-01 00:05:59.422678
NCT01067352|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|2011-10-05||2013-12-02|2010-02-10|2010-02-11|Estimate|2011-11-09|2011-12-14|Estimate||||2013-12-02|2013-12-27|Estimate|February 2004||2004-02-29|December 2013|2013-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|SAIZEN in SGA||A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)|An Open, Multicenter, Randomized, Controlled Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)|Terminated||Phase 3|25|Actual|Merck KGaA|The primary and secondary efficacy objectives were not met because of poor participant enrollment and no quality RNA samples obtained to evaluate (RNA degradation in nearly all of the blood samples).|3||This study was discontinued prematurely due to difficulty in participant recruitment.|f||||||||||||||2018-06-01 00:05:59.668756|2018-06-01 00:05:59.668756
NCT01067339|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2017-01-25||2017-03-22|2010-02-10|2010-02-11|Estimate|2017-01-25|2017-03-15|Actual||||2017-03-22|2017-04-18|Actual|February 4, 2010||2010-02-04|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||The baseline characteristics table only includes subjects who completed the study.|Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans|Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III|Completed||Phase 3|70|Actual|Mayo Clinic||2|||f||||t|t|f||||||No||2018-06-01 00:06:00.436842|2018-06-01 00:06:00.436842
NCT01067326|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2013-01-09||2013-01-09|2010-02-10|2010-02-11|Estimate|2013-01-09|2013-02-13|Estimate||||2013-01-09|2013-02-13|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis|The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis|Terminated||Phase 3|22|Actual|Mayo Clinic|The study was terminated early due to safety concerns from the ALTITUDE trial; there was an unexpected increase in adverse events (non-fatal stroke, renal complications, hyperkalemia and hypotension). Novartis ended all studies regarding Aliskiren.|2||Novartis ended all studies regarding Aliskiren.|f||||f||||||||||2018-06-01 00:06:01.078168|2018-06-01 00:06:01.078168
NCT01067313|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2011-03-28|2010-02-10|2010-02-11|Estimate|||||||2011-03-28|2011-03-29|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane|Evaluation of Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane in Intensive Care|Completed||Phase 2/Phase 3|24|Actual|Fresenius Medical Care France||2|||f||||f||||||||||2018-06-01 00:06:02.752325|2018-06-01 00:06:02.752325
NCT01067300|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-09-29|2010-02-10|2010-02-11|Estimate|||||||2015-09-29|2015-10-01|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission|A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission|Unknown status|Active, not recruiting|Phase 3|198|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 00:06:02.856446|2018-06-01 00:06:02.856446
NCT01067287|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2018-05-10|2010-02-10|2010-02-11|Estimate|||||||2018-05-10|2018-05-11|Actual|March 2010||2010-03-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation|Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation|Active, not recruiting||Phase 2|35|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 00:06:03.042723|2018-06-01 00:06:03.042723
NCT01067274|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-12-29|2010-02-10|2010-02-11|Estimate|||||||2015-12-29|2015-12-30|Estimate|April 2010||2010-04-30|February 2010|2010-02-28||||April 2016|Anticipated|2016-04-30||Interventional|ALFA-0703||ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)|A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination With Induction Chemotherapy, or Azacitidine and Idarubicin as Salvage Therapy and Idarubicin With Cytarabine or Azacitidine as Maintenance Therapy in Older Patients With Acute Myeloblastic Leukemia (AML)|Withdrawn||Phase 3|0|Actual|Acute Leukemia French Association||6||Study abandoned|f||||||||||||||2018-06-01 00:06:03.304426|2018-06-01 00:06:03.304426
NCT01067261|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2013-05-23|2010-02-10|2010-02-11|Estimate|||||||2013-05-23|2013-05-24|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Preservation and Restoration of Urinary Continence and Erectile Function and in the Treatment of Erectile Dysfunction and Urinary Incontinence in Conjunction With Nerve Sparing Radical Prostatectomy|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Preservation and Restoration of Urinary Continence and Erectile Function and in the Treatment of Erectile Dysfunction and Urinary Incontinence in Conjunction With Nerve Sparing Radical Prostatectomy|Completed||Phase 3|68|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-06-01 00:06:03.46887|2018-06-01 00:06:03.46887
NCT01067248|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2015-07-28|2010-02-10|2010-02-11|Estimate|||||||2015-07-28|2015-07-29|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Chronic Obstructive Pulmonary Disease (COPD) and Osteoporosis|Patho-physiology of Osteoporosis in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||120|Actual|Catharina Ziekenhuis Eindhoven|||1||f||||f||||||Samples With DNA|"~     Markers of ageing, such as telomere length and sirtuin 1.~   "|||2018-06-01 00:06:03.566727|2018-06-01 00:06:03.566727
NCT01067235|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2013-02-08|2010-02-10|2010-02-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|Harmony2||Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy|Prospective, Randomized, Double-blind Study, Parallel-group, Multi-center Trial Assessing the Effects of Escalating Doses of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolepsy|Completed||Phase 3|14|Actual|Bioprojet||2|||f||||f||||||||||2018-06-01 00:06:04.089645|2018-06-01 00:06:04.089645
NCT01067222|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2012-06-08|2010-02-10|2010-02-11|Estimate|||||||2012-06-08|2012-06-11|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|Harmony1||Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy|Prospective, Randomized, Double-blind Study, Placebo-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in Treatment of Excessive Daytime Sleepiness in Narcolepsy|Completed||Phase 3|110|Actual|Bioprojet||3|||f||||f||||||||||2018-06-01 00:06:04.349581|2018-06-01 00:06:04.349581
NCT01067209|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2018-02-06|2010-02-10|2010-02-11|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2010||2010-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|DRTC||Reversal of Obese/Diabetic Cardiomyopathy After Gastric Bypass Surgery|Reversal of Obesity- and Diabetes-related Cardiomyopathy in Patients Who Have Undergone Gastric Bypass Surgery.|Active, not recruiting|||45|Anticipated|Washington University School of Medicine|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 00:06:04.816134|2018-06-01 00:06:04.816134
NCT01067196|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2017-07-20|2010-02-09|2010-02-11|Estimate|||||||2017-07-20|2017-07-21|Actual|February 2010||2010-02-28|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CN01||Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck|A Study of Late Effects After Proton Radiotherapy for Pediatric Tumors of the Brain, Head, and Neck|Completed|||442|Actual|University of Florida|||1||f||||f||||||||||2018-06-01 00:06:04.98764|2018-06-01 00:06:04.98764
NCT01067183|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-17|2010-02-09|2010-02-11|Estimate|||||||2010-02-17|2010-02-19|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Does a Portable Biofeedback Tool Reduce Physician Stress?|Does a Portable Biofeedback Tool Reduce Physician Stress?|Completed||N/A|40|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 00:06:05.115297|2018-06-01 00:06:05.115297
NCT01067170|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2012-12-12|2010-02-09|2010-02-11|Estimate|||||||2012-12-12|2012-12-13|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|August 2012|Actual|2012-08-31|February 2011|Actual|2011-02-28||Interventional|||Pneumatic Compression Stockings During Hemodialysis|The Effect of Pneumatic Compression Stockings on Hemodynamic Parameters in Hemodialysis Patients: A Randomized Crossover Trial|Completed||N/A|51|Actual|University of Calgary||1|||f||||f||||||||||2018-06-01 00:06:05.339196|2018-06-01 00:06:05.339196
NCT01067157|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2017-09-27|2010-02-10|2010-02-11|Estimate|||||||2017-09-27|2017-09-29|Actual|January 1, 2006|Actual|2006-01-01|September 2017|2017-09-30|July 2022|Anticipated|2022-07-31|December 31, 2013|Actual|2013-12-31||Interventional|LOGIC||Long-term Effects of Lifestyle Intervention in Obesity and Genetic Influence|Long-term Effects of Lifestyle Intervention in Obesity and Genetic Influence in Children - LOGIC-Study|Active, not recruiting||N/A|1500|Actual|Technische Universität München||1|||f||||f||||||||||2018-06-01 00:06:05.479582|2018-06-01 00:06:05.479582
NCT01067144|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2016-06-22|2010-02-10|2010-02-11|Estimate|||||||2016-06-22|2016-06-24|Estimate|May 2010||2010-05-31|June 2016|2016-06-30|May 2024|Anticipated|2024-05-31|July 2016|Anticipated|2016-07-31||Interventional|||Stanford Accelerated Recovery Trial (START)|Stanford Accelerated Recovery Trial (START)|Active, not recruiting||Phase 3|560|Anticipated|Stanford University||2|||f||||t||||||||||2018-06-01 00:06:05.860221|2018-06-01 00:06:05.860221
NCT01067131|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-10|||2012-12-21|2010-02-10|2010-02-11|Estimate|||||||2012-12-21|2012-12-24|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection|A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers|Completed||Phase 1|48|Actual|Pevion Biotech Ltd||4|||f||||t||||||||||2018-06-01 00:06:06.049976|2018-06-01 00:06:06.049976
NCT01067118|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2017-02-09|2010-02-09|2010-02-11|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2010||2010-04-30|February 2017|2017-02-28|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Interventional|||A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.|Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Glycemia|Withdrawn||Phase 2|0|Actual|Stanford University||2||The study was suspended due to lack of study drug|f||||t||||||||||2018-06-01 00:06:06.52457|2018-06-01 00:06:06.52457
NCT01067105|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2012-02-15|2011-11-08|2012-06-08|2010-02-09|2010-02-11|Estimate|2012-05-07|2012-06-11|Estimate|2011-11-08|2011-11-16|Estimate|2012-06-08|2012-06-13|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older|A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older|Completed||Phase 3|824|Actual|Sunovion|Open label study investigating a dose higher than the US FDA approved dose (74 mcg once daily) for allergic rhinitis subjects. Publication references to 148 mcg is equivalent to 160 mcg.|1|||f||||f||||||||||2018-06-01 00:06:06.746639|2018-06-01 00:06:06.746639
NCT01067092|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-11-30|2010-02-09|2010-02-11|Estimate|||||||2011-11-30|2011-12-02|Estimate|May 2005||2005-05-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MATCH||MATCH: The Mexican-American Trial of Community Health Workers|MATCH: The Mexican-American Trial of Community Health Workers|Completed||N/A|144|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-06-01 00:06:07.639006|2018-06-01 00:06:07.639006
NCT01067079|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-12-27|2010-02-10|2010-02-11|Estimate|||||||2011-12-27|2011-12-30|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen|A Phase III, Single Center, Open Label, Follow-up Immunogenicity Study in Subjects Who Previously Received Post-exposure Rabies Vaccine According to the Essen or 2:1:1 (Zagreb) Schedule|Terminated|||200|Actual|Novartis|||1||f||||||||||||||2018-06-01 00:06:07.803054|2018-06-01 00:06:07.803054
NCT01067066|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2017-07-17|2010-02-10|2010-02-11|Estimate|||||||2017-07-17|2017-07-21|Actual|February 3, 2010|Actual|2010-02-03|July 2017|2017-07-31|July 6, 2016|Actual|2016-07-06|July 6, 2016|Actual|2016-07-06||Interventional|||A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma|A Phase I/II Open-Label Study TPI 287 in Combination With Temozolomide in Patients With Metastatic Melanoma|Terminated||Phase 1|21|Actual|M.D. Anderson Cancer Center||1||Phase I/II study halted as Phase I, Low Response Rate|f||||f||||||||||2018-06-01 00:06:07.972655|2018-06-01 00:06:07.972655
NCT01067053|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2014-01-08|2010-02-10|2010-02-11|Estimate|||||||2014-01-08|2014-01-09|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|November 2010|Actual|2010-11-30||Interventional|BECOX||Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.|A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment|Unknown status|Active, not recruiting|Phase 2|69|Anticipated|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f||||||||||2018-06-01 00:06:08.206593|2018-06-01 00:06:08.206593
NCT01067040|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-02-09|2010-02-09|2010-02-11|Estimate|||||||2010-02-09|2010-02-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:06:08.483544|2018-06-01 00:06:08.483544
NCT01067027|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-06-28|2010-02-10|2010-02-11|Estimate|||||||2011-06-28|2011-06-29|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri|Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri|Unknown status|Recruiting|Phase 4|50|Anticipated|Children's Investigational Research Program, LLC|||||f||||t||||||||||2018-06-01 00:06:08.531781|2018-06-01 00:06:08.531781
NCT01067014|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2013-09-19|2010-02-09|2010-02-11|Estimate|||||||2013-09-19|2013-09-23|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||The iO-Flex® Study: Evaluation of the Baxano iO-Flex® System for Decompressive Lumbar Surgery|The iO-Flex® Study: Evaluation of the Baxano iO-Flex® System for Decompressive Lumbar Surgery|Unknown status|Active, not recruiting||75|Anticipated|Baxano Surgical, Inc.|||1||f||||f||||||||||2018-06-01 00:06:08.717177|2018-06-01 00:06:08.717177
NCT01067001|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-11|Estimate|||||||2010-02-09|2010-02-11|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|Minocycline||Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study|Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover, Bioequivalence Study in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.|Completed|||18|Actual|Amneal Pharmaceuticals Co. India Private Limited|||2||f||||f||||||||||2018-06-01 00:06:08.86298|2018-06-01 00:06:08.86298
NCT01066988|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2016-11-17|2010-02-09|2010-02-11|Estimate|||||||2016-11-17|2016-11-18|Estimate|January 2010||2010-01-31|February 2012|2012-02-29||||February 2010|Actual|2010-02-28||Interventional|||Evaluation of an Investigational Lubricant Eye Drop on Lipid Layer Thickness||Completed||N/A|40|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:06:08.972352|2018-06-01 00:06:08.972352
NCT01066975|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Observational|||Mechanical Load on the Shoulders While Carrying a Backpack- Towards a Knowledge-Based Backpack Design|Mechanical Load on the Shoulders While Carrying a Backpack- Towards a Knowledge-Based Backpack Design|Unknown status|Not yet recruiting||5|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 00:06:09.089786|2018-06-01 00:06:09.089786
NCT01066962|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2013-11-05|2010-02-09|2010-02-10|Estimate|||||||2013-11-05|2013-11-06|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|ANRS 143||Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects|An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir (ANRS 143/NEAT 001)|Completed||Phase 3|800|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 00:06:09.18899|2018-06-01 00:06:09.18899
NCT01066949|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2015-05-26|2010-02-09|2010-02-10|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2006||2006-06-30|May 2015|2015-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Behavioral Intervention and Adherence in Dialysis|Behavioral Intervention and Adherence in Dialysis|Completed||Phase 2|119|Actual|University of Iowa||2|||f||||f||||||||||2018-06-01 00:06:09.563724|2018-06-01 00:06:09.563724
NCT01066936|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2018-05-15|2010-02-09|2010-02-10|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2009||2009-08-31|May 2018|2018-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|MISDexa||Mini Stem DEXA (Dual Energy X-ray Absorptiometry)|"Bone Density by Dual Energy X-ray Absorptiometry (DEXA) Following Total Hip Arthroplasty With the Short Mini Stem"|Completed|||20|Actual|Smith & Nephew, Inc.|||||f||||f||||||||||2018-06-01 00:06:09.734866|2018-06-01 00:06:09.734866
NCT01066923|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2016-03-18||2017-10-10|2010-02-09|2010-02-10|Estimate|2016-07-05|2016-08-17|Estimate||||2017-10-10|2017-11-13|Actual|February 2010||2010-02-28|October 2017|2017-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|EFFoRT||Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation|Enhanced Firefighter Rehab Trial: Aspirin Versus Placebo|Completed||N/A|124|Actual|University of Pittsburgh|Detailed results at Olafiranye et al. (2015) Vascular Medicine 20:230-236 and at Hostler et al. (2014) Prehospital Emergency Care 18: 359-367 These papers are linked in the Reference Section|8|||f||||f||||||||No||2018-06-01 00:06:10.164848|2018-06-01 00:06:10.164848
NCT01066910|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2012-07-09|2010-02-09|2010-02-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|PAAC||Parents As The Agent Of Change For Childhood Obesity (PAAC)|Parents As The Agent Of Change For Childhood Obesity (PAAC)|Completed||N/A|80|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 00:06:10.973046|2018-06-01 00:06:10.973046
NCT01066897|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2016-10-11||2017-04-11|2010-02-09|2010-02-10|Estimate|2017-04-11|2017-05-16|Actual||||2017-04-11|2017-05-16|Actual|February 2010||2010-02-28|April 2017|2017-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole|Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole|Terminated||Phase 4|16|Actual|Stanford University|The sample size is really too small for statistical analyses. Lack of funding prevented further recruitment.|2||Lack of funding prevented further recruitment|f||||f||||||||||2018-06-01 00:06:11.130148|2018-06-01 00:06:11.130148
NCT01066884|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2016-08-22|2010-02-09|2010-02-10|Estimate|||||||2016-08-22|2016-08-24|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer||Completed||Phase 4|5|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:06:11.998968|2018-06-01 00:06:11.998968
NCT01066871|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2016-02-22||2016-02-22|2010-02-09|2010-02-10|Estimate|2016-02-22|2016-03-23|Estimate||||2016-02-22|2016-03-23|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||The intention-to-treat (ITT) population included all participants randomized to a trial treatment.|Sprifermin (AS902330) in Cartilage Injury Repair (CIR)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Trial to Investigate the Efficacy and Safety of Weekly Intra-articular (i.a.) Injections of 10, 30, and 100 µg of AS902330 for Three Consecutive Weeks in Patients With Acute Cartilage Injury of the Knee|Terminated||Phase 2|74|Actual|Merck KGaA|The study was discontinued due to low recruitment.|4||The study was discontinued due to low recruitment.|f||||f||||||||||2018-06-01 00:06:12.186489|2018-06-01 00:06:12.186489
NCT01059734|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2015-03-05|2010-01-29|2010-02-01|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia|Topoisomerase 2 Expression and Acute Myeloid Leukemia (AML)|Completed|||357|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:08:22.198648|2018-06-01 00:08:22.198648
NCT01066858|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2016-01-13|2010-02-09|2010-02-10|Estimate|||||||2016-01-13|2016-01-14|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding|Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)|Completed|||1765|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||t||||||||||2018-06-01 00:06:14.235934|2018-06-01 00:06:14.235934
NCT01066845|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2015-10-23|2010-02-09|2010-02-10|Estimate|||||||2015-10-23|2015-10-26|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension|Safety and Effectiveness of Adcirca (Tadalafil) in Japanese Patients With Pulmonary Arterial Hypertension: Open-label, Non-interventional Observational Study in Japan|Completed|||1809|Actual|Eli Lilly and Company|||1||f||||f||||||||||2018-06-01 00:06:14.38651|2018-06-01 00:06:14.38651
NCT01066832|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-06-16|2010-02-09|2010-02-10|Estimate|||||||2011-06-16|2011-06-17|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||The Valentines Trial|The Valentines Trial|Completed||Phase 4|276|Actual|Eurocor GmbH|||||f||||||||||||||2018-06-01 00:06:14.47227|2018-06-01 00:06:14.47227
NCT01066819|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2016-05-09||2016-06-27|2010-02-09|2010-02-10|Estimate|2016-06-27|2016-08-08|Estimate||||2016-06-27|2016-08-08|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational||The All Patient Enrolled Population included every participant of whom there was any data in the PROPHESYS database.|PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naïve HCV-infected Patients Treated With Pegylated Interferons|Completed|||1656|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-06-01 00:06:14.673428|2018-06-01 00:06:14.673428
NCT01066806|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2016-09-21|2010-02-09|2010-02-10|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|DQ||Adequate Dairy Intake on Weight Change in Girls|Efficacy of Optimal Levels of Dietary Dairy on Modulation of Adolescent Weight|Completed||N/A|274|Actual|Creighton University||2|||f||||t||||||||||2018-06-01 00:06:17.084948|2018-06-01 00:06:17.084948
NCT01066793|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2016-04-04||2016-04-04|2010-02-09|2010-02-10|Estimate|2016-04-04|2016-05-09|Estimate||||2016-04-04|2016-05-09|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Observational||The all patient enrolled population included every participant for whom there was any data available in the PROPHESYS database.|PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b|Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naïve HCV-infected Patients Treated With Pegylated Interferons.|Completed|||2343|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-06-01 00:06:17.278935|2018-06-01 00:06:17.278935
NCT01066780|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2012-05-01|2011-09-01|2012-10-23|2010-02-09|2010-02-10|Estimate|2012-10-23|2012-10-25|Estimate|2011-09-01|2011-09-12|Estimate|2012-10-23|2012-10-25|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||ClearVoice Sound-processing Strategy for AB HiRes 120 Cochlear Implant Users|Evaluation of the ClearVoice™ Strategy in Adults Using HiResolution® Fidelity 120® Sound Processing|Completed||N/A|48|Actual|Advanced Bionics||2|||f||||f||||||||||2018-06-01 00:06:19.703099|2018-06-01 00:06:19.703099
NCT01066767|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|April 2002||2002-04-30|February 2010|2010-02-28|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:06:19.923554|2018-06-01 00:06:19.923554
NCT01066754|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|April 2002||2002-04-30|February 2010|2010-02-28|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Fexofenadine Hydrochloride 180 mg Tablets and Allegra® 180 mg Tablets Administered as 1 x 180 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:06:20.021157|2018-06-01 00:06:20.021157
NCT01066741|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2012-10-31|2010-02-09|2010-02-10|Estimate|||||||2012-10-31|2012-11-01|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer|Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer|Terminated||Phase 3|78|Actual|Centre Leon Berard||2||insufficient recruitment, the planed sample size appears not achievable|f||||f||||||||||2018-06-01 00:06:20.12696|2018-06-01 00:06:20.12696
NCT01066728|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-03-01|2010-02-09|2010-02-10|Estimate|||||||2010-03-01|2010-03-03|Estimate|August 2001||2001-08-31|January 2010|2010-01-31|March 2007|Actual|2007-03-31|September 2005|Actual|2005-09-30||Interventional|||CO2 Inhalation as a New Treatment Modality for Apnea of Prematurity||Completed||Phase 2/Phase 3|87|Actual|University of Manitoba||2|||f||||t||||||||||2018-06-01 00:06:20.234164|2018-06-01 00:06:20.234164
NCT01066715|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-09-30|2010-02-08|2010-02-10|Estimate|||||||2011-09-30|2011-10-04|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy|Completed||Phase 2|421|Actual|XOMA (US) LLC||2|||f||||t||||||||||2018-06-01 00:06:20.342194|2018-06-01 00:06:20.342194
NCT01066702|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2017-06-30|2010-02-09|2010-02-10|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2010||2010-05-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Confirmatory Study of NeoCart in Knee Cartilage Repair|A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee|Active, not recruiting||Phase 3|245|Actual|Histogenics Corporation||2|||f||||t||||||||||2018-06-01 00:06:20.539389|2018-06-01 00:06:20.539389
NCT01066689|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|October 2008||2008-10-31|February 2010|2010-02-28|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|RITUX-ERAH||Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation|Phase III Study of Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation.|Unknown status|Recruiting|Phase 3|64|Anticipated|University Hospital, Tours||2|||f||||f||||||||||2018-06-01 00:06:20.661776|2018-06-01 00:06:20.661776
NCT01066676|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2012-07-09|2010-02-09|2010-02-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee|Prospective, Clinical Trial to Investigate Safety, Tolerability and Efficacy of Dexibuprofen Gebro 400 mg Powder for Oral Suspension (Test) Compared to Ibuprofen 400 mg Powder for Oral Suspension (Reference) in Patients Suffering From Osteoarthritis of the Hip or Knee|Completed||Phase 4|482|Actual|Gebro Pharma GmbH||2|||f||||f||||||||||2018-06-01 00:06:20.879469|2018-06-01 00:06:20.879469
NCT01066663|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2017-05-17|2010-02-09|2010-02-10|Estimate|||||||2017-05-17|2017-05-18|Actual|March 2010||2010-03-31|May 2017|2017-05-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Recruiting||Phase 1/Phase 2|26|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:06:20.952125|2018-06-01 00:06:20.952125
NCT01066650|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2015-07-27|2010-02-09|2010-02-10|Estimate|||||||2015-07-27|2015-07-28|Estimate|June 2008||2008-06-30|July 2015|2015-07-31|September 2012|Actual|2012-09-30|August 2010|Actual|2010-08-31||Interventional|TWENTE||The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente|The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario|Completed||Phase 4|1391|Actual|Cardio Research Enschede BV||2|||f||||t||||||||||2018-06-01 00:06:21.060778|2018-06-01 00:06:21.060778
NCT01066637|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2018-02-05|2010-02-08|2010-02-10|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2009|Actual|2009-09-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|F-NOS||iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.|Imaging iNOS Activity Using [18F] (+/-) NOS With Positron Emission Tomography (PET) in Cellular Inflammation.|Completed||Early Phase 1|26|Actual|Washington University School of Medicine||2|||f||||t||||||||Yes||2018-06-01 00:06:21.142604|2018-06-01 00:06:21.142604
NCT01066624|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2015-06-04||2015-07-16|2010-02-09|2010-02-10|Estimate|2015-07-16|2015-07-23|Estimate||||2015-07-16|2015-07-23|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation|A Prospective, Randomized, Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation.|Completed||N/A|117|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||f||||||||||2018-06-01 00:06:21.221681|2018-06-01 00:06:21.221681
NCT01066611|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2011-05-04|2010-02-09|2010-02-10|Estimate|||||||2011-05-04|2011-05-05|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-263 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge|Completed||Phase 1|48|Anticipated|Gilead Sciences||2|||f||||f||||||||||2018-06-01 00:06:21.635223|2018-06-01 00:06:21.635223
NCT01066598|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-09-06|2010-02-08|2010-02-10|Estimate|||||||2011-09-06|2011-09-07|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)|A Phase II Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease|Terminated||Phase 2|1|Actual|University Health Network, Toronto||1||Poor Accrual|f||||f||||||||||2018-06-01 00:06:21.739081|2018-06-01 00:06:21.739081
NCT01066585|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2012-03-07|2011-03-15|2012-04-04|2010-02-09|2010-02-10|Estimate|2012-03-07|2012-04-04|Estimate|2011-03-15|2011-03-25|Estimate|2012-04-04|2012-04-06|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|LICE OUT||A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation|A Double-Blind Randomized Study to Compare the Efficacy, Safety and Local Tolerability of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation|Completed||Phase 3|410|Actual|Topaz Pharmaceuticals Inc||2|||f||||f||||||||||2018-06-01 00:06:21.901392|2018-06-01 00:06:21.901392
NCT01066572|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2017-03-29|2010-02-09|2010-02-10|Estimate|||||||2017-03-29|2017-03-30|Actual|October 2010||2010-10-31|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PIL-FAST||Paramedic Initiated Lisinopril For Acute Stroke Treatment|Paramedic Initiated Lisinopril For Acute Stroke Treatment: a Pilot Randomised Controlled Trial|Completed||Phase 1|14|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||f||||||||No|No IPD were shared, nor will be, from this trial.|2018-06-01 00:06:22.290607|2018-06-01 00:06:22.290607
NCT01066559|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2015-06-24|2010-02-09|2010-02-10|Estimate|||||||2015-06-24|2015-06-25|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HEPADIAL||Improvement of Humoral Immune Response With Hemodialysis on BK-F Membrane: Correlation to Soluble CD40 Clearing|Multicentric Randomized Trial of the Impact of Hemodialysis With Polymethylmetacrylate Membrane on the Improvement of Humoral Immune Response in the Hemodialyzed Patients: Application to Hepatitis B Vaccination and Correlation to sCD40 Clearing|Completed||N/A|27|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 00:06:22.59378|2018-06-01 00:06:22.59378
NCT01066390|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2014-05-05|2010-02-09|2010-02-10|Estimate|||||||2014-05-05|2014-05-06|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma||Completed||Phase 1|18|Anticipated|Universitair Ziekenhuis Brussel|||||f||||f||||||||||2018-06-01 00:06:24.247771|2018-06-01 00:06:24.247771
NCT01066546|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2012-07-30|2011-09-08|2012-08-30|2010-02-09|2010-02-10|Estimate|2012-08-30|2012-10-02|Estimate|2011-09-08|2011-09-12|Estimate|2012-08-30|2012-10-02|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease|An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease|Terminated||Phase 3|5|Actual|Pfizer|Results are not summarized because of early termination of the study due to modification in the development plan of the study treatment following lack of demonstration of efficacy in the completed DIM14 CONNECTION (B1451002/NCT00675623) study.|1||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:06:22.704013|2018-06-01 00:06:22.704013
NCT01066533|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|October 2009||2009-10-31|July 2009|2009-07-31|February 2010|Anticipated|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Immunohistochemical Study of Human Teeth Pulp Capped With Mineral Trioxide Aggregate (MTA) and Novel Endodontic Cement (NEC)|Histologic and Immunohistochemical Study of Fibronectin and Tenascin in Human Teeth Pulp Capped With MTA and NEC|Terminated||Phase 4|32|Actual|Mashhad University of Medical Sciences||2||immunohistochemistry markers are not recieved yet|f||||t||||||||||2018-06-01 00:06:22.964086|2018-06-01 00:06:22.964086
NCT01066520|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2013-02-18||2013-12-09|2010-02-09|2010-02-10|Estimate|2013-10-15|2013-12-09|Estimate||||2013-12-09|2014-01-09|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|TAASS|Analyzed ITT population|TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain|A Randomized, Controlled, Multi-center Study on the Effectiveness of Traumeel S (Both Ointment and Gel) in Terms of Pain and Function Compared With a Topical NSAID in Athletes With Acute Ankle Sprain|Completed||Phase 3|449|Actual|Biologische Heilmittel Heel GmbH||3|||f||||f||||||||||2018-06-01 00:06:23.088669|2018-06-01 00:06:23.088669
NCT01066507|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|Her2F test||Detection of Amplification of Her2 Fluorescent in Situ Hybridization (FISH) in Breast Tissue Sections|Concordance Study for Amplification Detection of Her2 FISH in Breast Tissue Sections|Completed|||126|Actual|Applied Spectral Imaging Ltd.|||1||f||||f||||||Samples Without DNA|"~     Paraffin embedded tissue sections~   "|||2018-06-01 00:06:23.517519|2018-06-01 00:06:23.517519
NCT01066494|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-01-14|2010-02-09|2010-02-10|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|January 2011|Anticipated|2011-01-31|September 2010|Anticipated|2010-09-30||Interventional|||A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)|A Phase IIa Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Adult Patients With Acute Myeloid Leukemia (AML)|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Antisoma Research||1|||f||||f||||||||||2018-06-01 00:06:23.587682|2018-06-01 00:06:23.587682
NCT01066481|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-06-28|2010-02-09|2010-02-10|Estimate|||||||2010-06-28|2010-06-29|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Interventional|||A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease|A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled Safety And Efficacy Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease|Withdrawn||Phase 2|0|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 00:06:23.667562|2018-06-01 00:06:23.667562
NCT01066468|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2012-03-12|2010-02-09|2010-02-10|Estimate|||||||2012-03-12|2012-03-13|Estimate|October 2010||2010-10-31|March 2012|2012-03-31||||May 2011|Actual|2011-05-31||Interventional|||Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.|A Non-randomized, Open-label Study to Characterize the Pharmacokinetics (PK) of Glivec/Gleevec® (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) or Other Glivec/ Gleevec® Indicated Hematological Disorders (HES, CEL, MDS/ MPN)|Terminated||Phase 1|3|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:06:23.740371|2018-06-01 00:06:23.740371
NCT01066455|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2013-01-10|2010-02-09|2010-02-10|Estimate|||||||2013-01-10|2013-01-11|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Cardiac Outcome Measures in Children With Muscular Dystrophy|PITT1109: Cardiac Outcome Measures in Children With Muscular Dystrophy|Completed|||48|Actual|Cooperative International Neuromuscular Research Group|||||f||||t||||||None Retained|"~     Prospective collection of blood sample for BNP measurements.~   "|||2018-06-01 00:06:23.818327|2018-06-01 00:06:23.818327
NCT01066442|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2013-04-11|2010-02-09|2010-02-10|Estimate|||||||2013-04-11|2013-04-12|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HARPS2||Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease|A Randomised, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38 Week Open Label Extension Phase|Completed||Phase 3|273|Actual|Bioprojet||2|||f||||f||||||||||2018-06-01 00:06:23.873278|2018-06-01 00:06:23.873278
NCT01066429|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-11|2010-02-09|2010-02-10|Estimate|||||||2010-02-11|2010-02-12|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2012|Anticipated|2012-12-31|December 2010|Anticipated|2010-12-31||Interventional|||DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma|Treatment With Infusional Dose-adjusted Etoposide/Vincristine/Doxorubicin/Bolus Cyclophosphamide/Dexamethasone and Rituximab (DA-EDOCH14-R) in Patients With Poor-prognosis Diffuse Large B-cell Lymphoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Hospital Universitario Principe de Asturias||1|||f||||f||||||||||2018-06-01 00:06:23.976214|2018-06-01 00:06:23.976214
NCT01066416|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|July 2009||2009-07-31|February 2010|2010-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Endoscopic Sinus Surgery for Chronic Sinusitis on Asthma Control|Effects of Endoscopic Sinus Surgery for Chronic Sinusitis on Asthma Control|Unknown status|Recruiting|N/A|40|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||t||||||||||2018-06-01 00:06:24.089347|2018-06-01 00:06:24.089347
NCT01066403|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|October 2003||2003-10-31|December 2008|2008-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia|Dopaminergic Modulation of Prefrontal Functions in Schizophrenic Patients: Adjuvant Therapy With Pergolide|Completed||N/A|28|Actual|Heidelberg University||1|||f||||f||||||||||2018-06-01 00:06:24.159821|2018-06-01 00:06:24.159821
NCT01066377|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-07-12|2010-02-09|2010-02-10|Estimate|||||||2011-07-12|2011-07-13|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|January 2013|Anticipated|2013-01-31|July 2011|Actual|2011-07-31||Interventional|PRIMAGE||PRIMAGE (Probiotics, Immunity and Ageing)|A Randomised, Controlled, Parallel Study to Determine the Immunomodulatory Effects of Pre- and Probiotics Upon the Immune Response to Influenza Vaccination in Young and Older Volunteers|Unknown status|Active, not recruiting|N/A|120|Anticipated|University of Reading||2|||f||||f||||||||||2018-06-01 00:06:24.32918|2018-06-01 00:06:24.32918
NCT01066364|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis|Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis|Unknown status|Enrolling by invitation|Phase 2|54|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 00:06:24.410301|2018-06-01 00:06:24.410301
NCT01066351|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Interventional|||Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery|Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery|Unknown status|Enrolling by invitation|Phase 3|200|Anticipated|Thammasat University||2|||f||||t||||||||||2018-06-01 00:06:24.491447|2018-06-01 00:06:24.491447
NCT01066338|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-17|2010-02-09|2010-02-10|Estimate|||||||2010-02-17|2010-02-19|Estimate|February 2010||2010-02-28|February 2010|2010-02-28||||||||Observational|||Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype|Genome-wide Pharmacogenetic Candidate Gene SNP Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype|Unknown status|Recruiting||500|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     The stored bone marrow specimens of patients with normal karyotype AML who were treated with~     chemotherapy~   "|||2018-06-01 00:06:24.567779|2018-06-01 00:06:24.567779
NCT01066325|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2017-06-16|2010-02-09|2010-02-10|Estimate|||||||2017-06-16|2017-06-20|Actual|March 2010||2010-03-31|June 2017|2017-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Improving Flexibility With a Mindbody Approach|Improving Flexibility With a Mindbody Approach|Completed||Early Phase 1|45|Actual|Parker Research Institute||3|||f||||t||||||||||2018-06-01 00:06:24.638561|2018-06-01 00:06:24.638561
NCT01066312|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2017-06-16|2010-02-09|2010-02-10|Estimate|||||||2017-06-16|2017-06-19|Actual|March 2010|Actual|2010-03-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||The Accuracy of Manual Muscle Testing|Investigating the Accuracy of Manual Muscle Testing for Distinguishing Congruent From Incongruent Statements Under Varying Levels of Blinding|Completed|||160|Actual|Parker Research Institute|||2||f||||t||||||||||2018-06-01 00:06:24.758657|2018-06-01 00:06:24.758657
NCT01066299|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2011-11-28|2010-02-09|2010-02-10|Estimate|||||||2011-11-28|2011-11-29|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Influence of Oxytocin on the Startle Reflex and on Its Modulation|A Randomized, Double-blind, Placebo-controlled Single-center Study on the Influence of Oxytocin on the Startle Reflex and on Its Modulation in Healthy Male Subjects|Unknown status|Recruiting|N/A|50|Anticipated|University of Zurich||2|||f||||t||||||||||2018-06-01 00:06:24.829075|2018-06-01 00:06:24.829075
NCT01066286|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|February 2010||2010-02-28|February 2010|2010-02-28||||||||Observational|||Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia|Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia|Unknown status|Recruiting||100|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     Stored bone marrow specimens of patient with core binding factor positive acute myeloid~     leukemia treated with chemotherapy between 1995 and 2008 at Samsung Medical Center and Hwasun~     Chonnam National University Hospital~   "|||2018-06-01 00:06:24.974123|2018-06-01 00:06:24.974123
NCT01066273|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2016-12-29|2010-02-09|2010-02-10|Estimate|||||||2016-12-29|2016-12-30|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Somatosensory Based Treatments for Tinnitus|Somatosensory Based Treatments for Tinnitus|Withdrawn||N/A|0|Actual|Massachusetts Eye and Ear Infirmary||1||Principal Investigator no longer at institution|f||||f||||||||No||2018-06-01 00:06:25.068541|2018-06-01 00:06:25.068541
NCT01066260|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2013-06-03|2010-02-09|2010-02-10|Estimate|||||||2013-06-03|2013-06-04|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Efficacy of a Probiotic Formulation on Energy Balance in Overweight Subjects|Efficacy of a Probiotic Formulation on Energy Balance in Overweight Subjects|Completed||N/A|80|Actual|Nestlé||2|||f||||t||||||||||2018-06-01 00:06:25.258669|2018-06-01 00:06:25.258669
NCT01066247|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-07-25|2010-02-09|2010-02-10|Estimate|||||||2011-07-25|2011-07-26|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Premedication and Haemodynamics After Spinal Anesthesia|The Influence of HRV-changing Premedication on Hemodynamic Parameters After Spinal Anesthesia|Completed||N/A|60|Anticipated|Medical University of Gdansk||2|||f||||f||||||||||2018-06-01 00:06:25.366064|2018-06-01 00:06:25.366064
NCT01066234|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2016-04-19|2010-02-09|2010-02-10|Estimate|||||||2016-04-19|2016-04-20|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2014|Actual|2014-03-31||Interventional|||Adjuvant CCRT vs CT in Minimal N2 NSCLC|A Randomized Phase II Study of Adjuvant Concurrent Chemoradiotherapy vs Chemotherapy Alone in Completely Resected Microscopic N2 Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-06-01 00:06:25.447716|2018-06-01 00:06:25.447716
NCT01066221|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-07-19|2010-02-09|2010-02-10|Estimate|||||||2011-07-19|2011-07-20|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|||Comparative Study of Three Different Testing Mechanisms for Clostridium Difficile|Comparative Study of Enzyme Immunoassays:Techlab Toxins A&B, C Diff Quick Check for Glutamate Dehydrogenase (GDH);3 PCRs,and Cytotoxin Assay (CTA) for the Detection of Clostridium Difficile Toxin in Adult Stool Specimens|Completed|||470|Actual|McMaster University|||1||f||||f||||||||||2018-06-01 00:06:25.527613|2018-06-01 00:06:25.527613
NCT00842608|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2016-11-11||2017-02-03|2009-02-10|2009-02-12|Estimate|2017-02-03|2017-03-24|Actual||||2017-02-03|2017-03-24|Actual|February 2009||2009-02-28|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PMD||Pharmacological Management of Delirium|Pharmacological Management of Delirium|Completed||N/A|551|Actual|Indiana University||4|||f||||t||||||||||2018-06-01 01:18:54.661776|2018-06-01 01:18:54.661776
NCT01066208|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2016-08-18|2010-02-09|2010-02-10|Estimate|||||||2016-08-18|2016-08-19|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|DCVAS||American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis|ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis|Recruiting|||3588|Anticipated|University of Oxford|||14||f||||t||||||Samples With DNA|"~     Patients may be given the option of having blood, urine or other tissue obtained as part of~     their routine care retained for use in future ethically approved studies. They may also be~     asked to provide additional blood to be stored for this purpose. This component is an~     optional extra, and does not form part of the main study.~   "|||2018-06-01 00:06:25.656032|2018-06-01 00:06:25.656032
NCT01066195|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|May 2008||2008-05-31|February 2010|2010-02-28||||October 2010|Anticipated|2010-10-31||Interventional|||Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy|A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy|Unknown status|Enrolling by invitation|Phase 3|129|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-06-01 00:06:26.243868|2018-06-01 00:06:26.243868
NCT01066182|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2011-10-27|2010-02-09|2010-02-10|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DOLAB||The DHA (Docosahexaenoic Acid) Oxford Learning and Behaviour (DOLAB) Study|A Randomised Controlled Trial of DHA (Docosahexaenoic Acid)for Learning and Behaviour in Children Aged 7 - 9 Years|Completed||Phase 2|360|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 00:06:26.332482|2018-06-01 00:06:26.332482
NCT01066169|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2012-01-27|2010-02-09|2010-02-10|Estimate|||||||2012-01-27|2012-01-30|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|RICH-3||Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza|Immune Response After Vaccination Against Pandemic A/H1N1 Influenza in the Immunocompromised Host. Vaccination Response in ImmunoCompromised Host|Completed|||104|Actual|Leiden University Medical Center|||2||f||||t||||||Samples Without DNA|"~     Serum, Plasma, Peripheral blood mononuclear cells~   "|||2018-06-01 00:06:26.419312|2018-06-01 00:06:26.419312
NCT01066156|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2017-03-03||2017-04-18|2010-02-08|2010-02-10|Estimate|2017-04-18|2017-05-30|Actual||||2017-04-18|2017-05-30|Actual|February 2010||2010-02-28|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Post-Traumatic Stress Disorder (PTSD) and Seroquel|Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes|Completed||N/A|34|Actual|Cambridge Health Alliance||1|||f||||t||||||||No||2018-06-01 00:06:26.516413|2018-06-01 00:06:26.516413
NCT01066143|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2017-04-07||2017-04-07|2010-02-08|2010-02-10|Estimate|2017-04-07|2017-05-17|Actual||||2017-04-07|2017-05-17|Actual|February 2010||2010-02-28|April 2017|2017-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|GAD|8 subjects signed the consent but were later found to be ineligible; therefore the study didn't start|Generalized Anxiety and Seroquel|Pharmacotherapy of Generalized Anxiety Disorder With Seroquel: Normalization of Brain Stress and Reward Function|Terminated||N/A|8|Actual|Mclean Hospital|8 subjects signed the consent but were later found to be ineligible; the study didn't start|1||The underwriter stopped the funding|f||||t||||||||||2018-06-01 00:06:26.663668|2018-06-01 00:06:26.663668
NCT01066130|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|January 2001||2001-01-31|February 2010|2010-02-28|December 2005|Actual|2005-12-31|||||Interventional|||Psychosocial Treatment Intervention in Persons Newly Diagnosed With Rheumatoid Arthritis or Diabetes|Psychosocial Treatment Intervention in Persons Newly Diagnosed With Rheumatoid Arthritis or Diabetes|Completed||N/A|200|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-06-01 00:06:26.816014|2018-06-01 00:06:26.816014
NCT01066117|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Effectiveness of PeeRelease - a Gel Absorbent Pad in Moderate to Severe Urinary Incontinence|Effectiveness of PeeRelease - a Gel Absorbent Pad in Moderate to Severe Urinary Incontinence Over Existing Solutions|Unknown status|Not yet recruiting|N/A|90|Anticipated|Tisteron Ltd.|||||f||||f||||||||||2018-06-01 00:06:26.885156|2018-06-01 00:06:26.885156
NCT01066104|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2017-02-24||2017-05-19|2010-02-09|2010-02-10|Estimate|2017-04-14|2017-05-19|Actual||||2017-05-19|2017-06-14|Actual|December 2009||2009-12-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis|Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis|Completed||Phase 2|27|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-06-01 00:06:26.962748|2018-06-01 00:06:26.962748
NCT01066091|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2015-03-24|2010-02-09|2010-02-10|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2010||2010-03-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Postprandial Inflammatory Response in Healthy Men: Effect of Dietary Fat Source, Obesity and Age|Postprandial Inflammatory Response in Healthy Men: Effect of Dietary Fat Source, Obesity and Age|Completed||N/A|32|Actual|Institut National de la Recherche Agronomique||3|||f||||f||||||||||2018-06-01 00:06:27.373427|2018-06-01 00:06:27.373427
NCT01066078|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-03-04|2010-02-09|2010-02-10|Estimate|||||||2010-03-04|2010-03-05|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Echocardiography and Peak Endocardial Acceleration (PEA) Measurements in Cardiac Resynchronization Therapy (CRT)|Echocardiography and PEA Measurements in CRT Therapy|Completed|||216|Actual|LivaNova|||1||f||||f||||||||||2018-06-01 00:06:27.464931|2018-06-01 00:06:27.464931
NCT01066065|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-06-24|2010-02-09|2010-02-10|Estimate|||||||2010-06-24|2010-06-25|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Observational|||Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients|Metabolic Profile and Cardiovascular Biomarker Pattern Compared in naíve Patients Initiating HAART With TDF-FTC and Raltegravir 400mg BID Vs Darunavir 800 mg Plus Ritonavir 100 mg QD; a One Year Follow-up Observational Study|Unknown status|Recruiting||120|Anticipated|Hospital Carlos III, Madrid|||2||f||||f||||||||||2018-06-01 00:06:27.559923|2018-06-01 00:06:27.559923
NCT01065883|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-08-13|2010-02-08|2010-02-09|Estimate|||||||2012-08-13|2012-08-15|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Project CURA||The Community United to Challenge Asthma|A Family Intervention for Pediatric Asthma Self-Management in Puerto Ricans|Completed||N/A|50|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 00:06:30.372579|2018-06-01 00:06:30.372579
NCT01066052|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2014-07-30|2010-02-09|2010-02-10|Estimate|||||||2014-07-30|2014-07-31|Estimate|February 1992||1992-02-29|August 2011|2011-08-31|August 2010|Actual|2010-08-31|March 1999|Actual|1999-03-31||Interventional|||Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years|"Collaborative Study to Assess the Effects of Treatment With Recombinant Growth Hormone Saizen® in the Prevention of Short Stature in Young Girls Suffering From Turner Syndrome Before the Age of 4 Years. Original French Title:  Etude Collaborative Pour apprécier Les Effets du Traitement Par l'Hormone de Croissance Recombinante SAIZEN® Dans le Retard de Croissance de la Fillette Atteinte de Syndrome de Turner Avant l'âge de 4 Ans "|Completed||Phase 4|64|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:06:27.632731|2018-06-01 00:06:27.632731
NCT01066039|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2014-06-04||2014-06-04|2010-02-09|2010-02-10|Estimate|2014-06-04|2014-07-04|Estimate||||2014-06-04|2014-07-04|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|GIANT|Analysis population included all the participants who were enrolled in this study.|Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control|A Prospective, Multi-center, Open-label, Single Arm Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II DIAbetic patieNTs With Suboptimal Blood Pressure Control (GIANT Study)|Completed||Phase 4|202|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 00:06:27.758623|2018-06-01 00:06:27.758623
NCT01066026|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-11-22|2010-02-09|2010-02-10|Estimate|||||||2010-11-22|2010-11-23|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Comparison of Safety and Efficacy of a Metallic Cannula Versus a Standard Needle to Inject Hyaluronic Acid for Nasolabial Fold|Double-blind, Randomized and Controlled Clinical Trial to Compare Safety and Efficacy of a Metallic Cannula vs a Standard Needle for the Injection of Hyaluronic Acid Gel Dermal Filler (Restylane®) to Treat Nasolabial Folds|Completed||Phase 2|25|Anticipated|Brazilan Center for Studies in Dermatology||2|||f||||f||||||||||2018-06-01 00:06:28.113222|2018-06-01 00:06:28.113222
NCT01066013|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-08-17|2010-02-08|2010-02-10|Estimate|||||||2010-08-17|2010-08-18|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Antimicrobial De-escalation Strategy in Medical Patients|Antimicrobial De-escalation Strategy in Medical Patients|Unknown status|Active, not recruiting|N/A|100|Anticipated|Fraser Health||2|||f||||f||||||||||2018-06-01 00:06:28.227968|2018-06-01 00:06:28.227968
NCT01066000|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|2016-02-18||2017-11-02|2010-02-09|2010-02-10|Estimate|2016-04-11|2016-05-13|Estimate||||2017-11-02|2017-11-13|Actual|October 31, 2009|Actual|2009-10-31|November 2017|2017-11-30|September 30, 2011|Actual|2011-09-30|September 30, 2011|Actual|2011-09-30||Interventional|||A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia|A Single Arm Open Label Interventional Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous Methoxy-polyethylene Glycol-epoetin Beta for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia|Terminated||Phase 4|33|Actual|Hoffmann-La Roche|"This was an open-label, single arm study with no control arms for comparison of results from this study.~The study was prematurely terminated due to high screening failures and low recruitment rate. Therefore, the data only showed a trend."|1|||f||||||||||||||2018-06-01 00:06:28.293992|2018-06-01 00:06:28.293992
NCT01065987|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-08|2010-02-08|2010-02-10|Estimate|||||||2010-02-08|2010-02-10|Estimate|September 2001||2001-09-30|February 2010|2010-02-28|November 2001|Actual|2001-11-30|September 2001|Actual|2001-09-30||Interventional|||Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions|Randomized, 2-way Crossover, Bioequivalence Study of Tizanidine Hydrochloride 4mg Tablets and Zanaflex® 4mg Tablets Administered As 1 x 4mg Tablet in Healthy Adult Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:06:29.702211|2018-06-01 00:06:29.702211
NCT01065974|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2017-10-05|2010-02-09|2010-02-10|Estimate|||||||2017-10-05|2017-10-09|Actual|October 2009||2009-10-31|October 2017|2017-10-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||A Test of Nutritional Interventions to Enhance Weight Loss Maintenance|A Test of Nutritional Interventions to Enhance Weight Loss Maintenance|Completed||N/A|262|Actual|Drexel University||3|||f||||t||||||||||2018-06-01 00:06:29.773754|2018-06-01 00:06:29.773754
NCT01065961|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-09|||2010-02-09|2010-02-09|2010-02-10|Estimate|||||||2010-02-09|2010-02-10|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Randomized Controlled Trials of the Effects of Decadron on Swallowing, Airway, and Arthrodesis|Prospective Randomized Controlled Trail of the Effects of Steroids on Swallowing, Airway and Arthrodesis Related to Myulti-Level Anterior Cervical Reconstruction|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Albany Medical College||2|||f||||f||||||||||2018-06-01 00:06:29.850985|2018-06-01 00:06:29.850985
NCT01065948|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2016-02-03|2010-02-09|2010-02-10|Estimate|||||||2016-02-03|2016-02-04|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|FAS||A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours|A Feasibility Study to Assess Critical Aspects of FAS Performance and Safety Over Several Hours|Completed||Phase 1|12|Actual|BioTex, Inc.||1|||f||||t||||||||Yes||2018-06-01 00:06:29.91718|2018-06-01 00:06:29.91718
NCT01065935|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05||2018-01-24|2018-01-31|2010-02-08|2010-02-10|Estimate||||2018-01-31|2018-02-02|Estimate|2018-01-31|2018-02-02|Estimate|February 2010||2010-02-28|January 2018|2018-01-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)|A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)|Completed||Phase 2|87|Actual|Alnylam Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:06:29.999218|2018-06-01 00:06:29.999218
NCT01065909|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-10-02|2010-02-08|2010-02-09|Estimate|||||||2014-10-02|2014-10-03|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||"Observatory on Elderly Patients Les S.AGES"|National Observatory on the Therapeutic Management in Ambulatory Care Patients Aged 65 and Over, With Diabetes Type 2, Chronic Pain or Atrial Fibrillation|Completed|||3491|Actual|Sanofi|||3||f||||||||||||||2018-06-01 00:06:30.230734|2018-06-01 00:06:30.230734
NCT01065896|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2012-10-02|2010-02-08|2010-02-09|Estimate|||||||2012-10-02|2012-10-03|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Observational|||Coronary Computed Tomography (CT) to Measure Coronary Calcification in Spinal Cord Injury (SCI)|The Use of Non-invasive Multidetector Coronary Computed Tomography Imaging for the Assessment of Coronary Calcification in Persons With Spinal Cord Injury|Completed|||150|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 00:06:30.304308|2018-06-01 00:06:30.304308
NCT01065870|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-01-27|2010-02-08|2010-02-09|Estimate|||||||2014-01-27|2014-01-29|Estimate|December 2009||2009-12-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)|Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma|Unknown status|Recruiting|Phase 2/Phase 3|64|Anticipated|Columbia University||2|||f||||t||||||||||2018-06-01 00:06:30.447715|2018-06-01 00:06:30.447715
NCT01065857|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-04-14|2010-02-08|2010-02-09|Estimate|||||||2011-04-14|2011-04-15|Estimate|January 2010||2010-01-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.|Phase III, Multicenter, Randomized, Assessor-blind Study to Evaluate the Safety and Efficacy of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.|Completed||Phase 3|547|Anticipated|Laboratorios Casen-Fleet S.L.U.||3|||f||||f||||||||||2018-06-01 00:06:30.550288|2018-06-01 00:06:30.550288
NCT01065844|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2016-10-25||2017-11-09|2010-02-08|2010-02-09|Estimate|2016-10-25|2016-12-19|Estimate||||2017-11-09|2017-12-11|Actual|October 2009||2009-10-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|May 2015|Actual|2015-05-31||Interventional|||Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck|A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck|Completed||Phase 2|15|Actual|University of Iowa|Favorable selection criteria were used in study design. RECIST assessed at a median interval of 12 weeks - this difference in methods may have artificially prolonged the progression free survival observed in this study.|1|||f||||t||||||||||2018-06-01 00:06:30.678056|2018-06-01 00:06:30.678056
NCT01065831|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2016-02-29|2010-02-08|2010-02-09|Estimate|||||||2016-02-29|2016-03-01|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|FAITH||Faith-based Approaches in the Treatment of Hypertension (FAITH)|Faith-based Approaches in the Treatment of Hypertension (FAITH)|Completed||N/A|373|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 00:06:30.863105|2018-06-01 00:06:30.863105
NCT01065818|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2017-07-28||2017-08-28|2010-02-08|2010-02-09|Estimate|2017-08-28|2017-09-26|Actual||||2017-08-28|2017-09-26|Actual|August 2009||2009-08-31|August 2017|2017-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET|Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET|Terminated||N/A|6|Actual|Columbia University|Enrollment was very slow and poor, resulting in inadequate data collection. As a result, data was not analyzed.|1||Lack of funding|f||||t||||||||||2018-06-01 00:06:30.936899|2018-06-01 00:06:30.936899
NCT01065805|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2014-06-10|2010-02-08|2010-02-09|Estimate|||||||2014-06-10|2014-06-12|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma|A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-L-fluorothymidine (18F-FLT)in Patients With Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and With Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|170|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||||2018-06-01 00:06:31.069918|2018-06-01 00:06:31.069918
NCT01065792|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2015-07-20|2010-02-08|2010-02-09|Estimate|||||||2015-07-20|2015-07-21|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Stocrin Re-examination Study (0831-028)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of STOCRIN in Usual Practice|Completed|||728|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:06:31.149814|2018-06-01 00:06:31.149814
NCT01065779|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2011-06-21||2015-07-17|2010-02-08|2010-02-09|Estimate|2011-08-09|2011-09-13|Estimate||||2015-07-17|2015-07-28|Estimate|March 2006||2006-03-31|July 2015|2015-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of FOSAMAX PLUS and FOSAMAX PLUS D in Usual Practice|Completed|||880|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:06:31.224365|2018-06-01 00:06:31.224365
NCT01065766|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2014-03-11||2015-02-18|2010-02-08|2010-02-09|Estimate|2014-03-11|2014-04-17|Estimate||||2015-02-18|2015-03-06|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational||Baseline characteristics were only reported for the Safety Population (4033) who qualified for the study and not for the 4065 participants from whom CRFs were collected.|Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of JANUMET in Usual Practice|Completed|||4065|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:06:31.665448|2018-06-01 00:06:31.665448
NCT01065753|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-08|2010-02-08|2010-02-09|Estimate|||||||2010-02-08|2010-02-09|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Multi-faceted Evaluations Following Weight Reduction in Subjects With Metabolic Syndrome|Study of Wight Reduction by Life-style Modification|Completed||N/A|40|Actual|Taichung Veterans General Hospital||1|||f||||f||||||||||2018-06-01 00:06:31.95061|2018-06-01 00:06:31.95061
NCT01065740|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2016-06-24|2010-02-08|2010-02-09|Estimate|||||||2016-06-24|2016-06-27|Estimate|February 2010||2010-02-28|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|POPART||Optimized Supervised Education Program for Peripheral Arterial Disease|Optimized Supervised Education Program for Peripheral Arterial Disease: Ambulatory Management With Patient Education|Terminated||N/A|64|Actual|Rennes University Hospital||2||Recruitment Difficulties and Financing Limited and exhausted|f||||t||||||||||2018-06-01 00:06:32.034628|2018-06-01 00:06:32.034628
NCT01065727|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2012-11-30|2010-02-08|2010-02-09|Estimate|||||||2012-11-30|2012-12-03|Estimate|February 2010||2010-02-28|November 2012|2012-11-30|February 2019|Anticipated|2019-02-28|February 2016|Anticipated|2016-02-29||Interventional|IQUALYSEP||Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis|Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis|Recruiting||N/A|250|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 00:06:32.110842|2018-06-01 00:06:32.110842
NCT01065714|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2012-03-30||2013-04-22|2010-02-08|2010-02-09|Estimate|2013-04-22|2013-04-25|Estimate||||2013-04-22|2013-04-25|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis|Transepidermal Water Loss (TEWL) and Corneometry With Hydrogel Vehicle in the Treatment of Atopic Dermatitis - A Randomized, Investigator-Blind Pilot Study|Completed||Phase 4|20|Actual|Derm Research, PLLC|Small number of participants, pilot study, short term|2|||f||||f||||||||||2018-06-01 00:06:32.203756|2018-06-01 00:06:32.203756
NCT01065688|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-09-08|2010-02-08|2010-02-09|Estimate|||||||2010-09-08|2010-09-09|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer|A Prospective Randomized Controlled Trial Comparing Billroth-I Reconstruction With Roux-en Y Reconstruction After Distal Gastrectomy for Gastric Cancer|Unknown status|Recruiting|Phase 3|120|Anticipated|Wakayama Medical University||2|||f||||t||||||||||2018-06-01 00:06:32.443033|2018-06-01 00:06:32.443033
NCT01065675|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-12-26|2010-02-08|2010-02-09|Estimate|||||||2012-12-26|2012-12-28|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|May 2011|Actual|2011-05-31|April 2010|Actual|2010-04-30||Interventional|||Medication Histories Conducted by Nurses (RNs), Pharmacy Techs (CPhTs) & Pharmacists (RPhs)|Electronic Patient Triage Development and Implementation Involving Nurse (RN), Pharmacy Technician (CPhT), and Pharmacist (RPh) Obtained Medication Histories in the Emergency Department (ED)and Impact on Medication Reconciliation|Terminated||N/A|153|Actual|Wesley Medical Center||||"Statistical analysis of 153 enrolled Phase 1 patients showed that specific patients could not~   be targeted for medication histories by discipline."|f||||f||||||||||2018-06-01 00:06:32.535439|2018-06-01 00:06:32.535439
NCT01065662|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2017-05-04|2010-02-08|2010-02-09|Estimate|||||||2017-05-04|2017-05-08|Actual|February 2010||2010-02-28|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|September 2013|Actual|2013-09-30||Interventional|||AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies|A Phase I/IB Study fo AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies|Active, not recruiting||Phase 1|50|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:06:32.611863|2018-06-01 00:06:32.611863
NCT01065649|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2012-07-14|2010-02-08|2010-02-09|Estimate|||||||2012-07-14|2012-07-17|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|NORGERD||Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients|Effect of Nortriptyline in the Cortical Representation of Heartburn in Patients With Nonerosive Reflux Disease|Completed||Phase 3|20|Actual|Universidade de Passo Fundo||2|||f||||f||||||||||2018-06-01 00:06:32.722325|2018-06-01 00:06:32.722325
NCT01065636|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2017-08-25|2010-02-08|2010-02-09|Estimate|||||||2017-08-25|2017-08-28|Actual|February 2010||2010-02-28|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|January 2016|Actual|2016-01-31||Interventional|LITOE||Lifestyle Intervention Trial in Obese Elderly|Exercise Interventions During Voluntary Weight Loss in Obese Older Adults|Active, not recruiting||N/A|160|Anticipated|Biomedical Research Institute of New Mexico||4|||f||||t||||||||||2018-06-01 00:06:32.825595|2018-06-01 00:06:32.825595
NCT01065623|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-09-30|2010-02-08|2010-02-09|Estimate|||||||2014-09-30|2014-10-01|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors|An Open Label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY79-4620 Administered as an Intravenous Infusion Once Every 2 Weeks in Patients With Advanced Solid Tumors|Terminated||Phase 1|2|Actual|Bayer||1||The study was terminated due to safety reasons|f||||f||||||||||2018-06-01 00:06:32.894918|2018-06-01 00:06:32.894918
NCT01065610|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-08|2010-02-08|2010-02-09|Estimate|||||||2010-02-08|2010-02-09|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Oxytocin Buffers Stress Response in Individuals With Impaired Coping Abilities|Oxytocin Buffers Cortisol Responses to Stress in Individuals With Impaired Coping Abilities|Completed||N/A|||University of Osnabrueck||2|||f||||||||||||||2018-06-01 00:06:32.967141|2018-06-01 00:06:32.967141
NCT01065597|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2015-06-12||2015-08-21|2010-02-08|2010-02-09|Estimate|2015-07-10|2015-08-10|Estimate||||2015-08-21|2015-08-28|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Nonconvulsive Electrotherapy: a Proof-of-concept Trial|Nonconvulsive Electrotherapy: a Proof-of-concept Trial|Completed||Phase 1|13|Actual|University of Maryland||1|||f||||f||||||||||2018-06-01 00:06:33.032931|2018-06-01 00:06:33.032931
NCT01065584|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-09-14|2010-02-08|2010-02-09|Estimate|||||||2011-09-14|2011-09-15|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|April 2012|Anticipated|2012-04-30|February 2012|Anticipated|2012-02-29||Observational|OSCITT||An Observational Study to Assess the Effect of Calcineurin Inhibitors on Markers of Transplant Tolerance|An Observational Study to Assess the Effect of Calcineurin Inhibitors on Markers of Transplant Tolerance|Unknown status|Recruiting||58|Anticipated|University Medical Center Goettingen|||2||f||||t||||||Samples Without DNA|"~     Blood cells for fluorescence activated cell sorting and leukocytes for ImmuKnow/Cylex assay~   "|||2018-06-01 00:06:33.239448|2018-06-01 00:06:33.239448
NCT01065571|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2013-08-06|2010-02-08|2010-02-09|Estimate|||||||2013-08-06|2013-08-09|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity|Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity|Unknown status|Recruiting|N/A|40|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||||2018-06-01 00:06:33.296947|2018-06-01 00:06:33.296947
NCT01065558|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-06|2012-12-18||2013-04-17|2010-02-08|2010-02-09|Estimate|2013-04-17|2013-04-18|Estimate||||2013-04-17|2013-04-18|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional||Lesch-Nyhan patients with moderate to severe self-injurious behaviors at the start of the study|Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease|A Safety and Pilot Activity Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease|Completed||Phase 1|5|Actual|Psyadon Pharma|This was an open label trial of oral ecopipam in pediatric, adolescent and adult patients with Lesch-Nyhan Disease.In this population, ecopipam's safety and PK was similar to non-LND subjects.|1|||f||||f||||||||||2018-06-01 00:06:33.40739|2018-06-01 00:06:33.40739
NCT01065545|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2015-04-09|2010-02-08|2010-02-09|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2011||2011-06-30|April 2015|2015-04-30||||||||Interventional|||The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia|A Phase I Feasibility Study Assessing the Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia|Withdrawn||Phase 1|0|Actual|Northwestern University||1||Due to funding issues.|f||||t||||||||||2018-06-01 00:06:33.638313|2018-06-01 00:06:33.638313
NCT01065532|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-09|2010-02-08|2010-02-09|Estimate|||||||2010-02-09|2010-02-10|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|December 2015|Anticipated|2015-12-31|December 2010|Anticipated|2010-12-31||Interventional|SEDUCE||SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study|Healing Responses After Treatment of Bare Metal Stent Restenosis With Implantation of an Everolimus-eluting Xience V Stent Versus Use of a Paclitaxel-eluting Balloon: Optical Coherence Tomography Study|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-06-01 00:06:33.750627|2018-06-01 00:06:33.750627
NCT01065519|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-08|2010-02-08|2010-02-09|Estimate|||||||2010-02-08|2010-02-09|Estimate|June 2009||2009-06-30|April 2009|2009-04-30|June 2015|Anticipated|2015-06-30|June 2010|Anticipated|2010-06-30||Interventional|STACCATO||STACCATO: Stent sTrut Apposition and Coverage in Coronary ArTeries: an Optical Coherence Tomography (OCT) Study|Assessment of Vessel Healing After DES Implantation With STEMI, NSTEMI and Stable/Unstable Angina Patients: a Randomized Study Between Everolimus and Biolimus A9-eluting Stents: an Optical Coherence Tomography (OCT) and Intravascular Ultrasound Tissue Characterisation (IVUS-TC) Study|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-06-01 00:06:33.834787|2018-06-01 00:06:33.834787
NCT01065506|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2015-11-20||2016-01-04|2010-02-08|2010-02-09|Estimate|2016-01-04|2016-02-04|Estimate||||2016-01-04|2016-02-04|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|STEP||Smoking Termination Enhancement Project (STEP)|Smoking Termination Enhancement Project (STEP)|Completed||Phase 3|150|Actual|Southern Methodist University||2|||f||||t||||||||||2018-06-01 00:06:33.955214|2018-06-01 00:06:33.955214
NCT01065493|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-11-18|2010-02-08|2010-02-09|Estimate|||||||2014-11-18|2014-11-19|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||QuitAdvisorMD: A Point-of-care Tool for Brief Smoking Cessation Interventions|QuitAdvisorMD: A Point-of-care Tool for Brief Smoking Cessation Interventions|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Silverchair Science & Communications, LLC||2|||f||||f||||||||||2018-06-01 00:06:34.233171|2018-06-01 00:06:34.233171
NCT01065480|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2017-06-29||2017-10-03|2010-02-08|2010-02-09|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|March 1, 2010|Actual|2010-03-01|October 2017|2017-10-31|December 1, 2015|Actual|2015-12-01|June 1, 2015|Actual|2015-06-01||Interventional|MITraining||Training Clinicians in Motivational Interviewing|Training Motivational Interviewing Using Live Supervision|Completed||N/A|91|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-06-01 00:06:34.317643|2018-06-01 00:06:34.317643
NCT01065467|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2017-03-27|2010-02-08|2010-02-09|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2010|Actual|2010-02-28|March 2017|2017-03-31|March 13, 2017|Actual|2017-03-13|March 2013|Actual|2013-03-31||Interventional|||Panobinostat (LBH589) in Patients With Metastatic Melanoma|A Pilot/Phase I Study of Panobinostat (LBH589) in Patients With Metastatic Melanoma|Completed||Phase 1|16|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:06:34.599413|2018-06-01 00:06:34.599413
NCT01065454|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2013-11-06||2018-01-26|2010-02-08|2010-02-09|Estimate|2013-11-06|2013-12-25|Estimate||||2018-01-26|2018-01-29|Actual|April 14, 2010|Actual|2010-04-14|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|June 6, 2012|Actual|2012-06-06||Interventional|LEPHT||A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction|Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction|Active, not recruiting||Phase 2|201|Actual|Bayer|Subjects had advanced disease and were heavily pretreated. Baseline values were not comparable between treatment groups.|4|||f||||t|t|f||||||||2018-06-01 00:06:34.815124|2018-06-01 00:06:34.815124
NCT01065441|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-07|||2012-11-29|2010-02-07|2010-02-09|Estimate|||||||2012-11-29|2012-11-30|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer|A Phase I/II Study of an Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancers|Withdrawn||Phase 1/Phase 2|0|Actual|Immunovative Therapies, Ltd.||||Protocol withdrawn for lack of financial support|f||||f||||||||||2018-06-01 00:06:37.491652|2018-06-01 00:06:37.491652
NCT01065428|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2010-10-18||2011-08-29|2010-02-08|2010-02-09|Estimate|2010-10-18|2010-11-16|Estimate||||2011-08-29|2011-08-31|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Extubation Readiness and Neuroventilatory Efficiency After Acute Respiratory Failure|Department of Critical Care Medicine, Nanjing Zhong-Da Hospital, Southeast University School of Medicine, China; Department of Critical Care Medicine St. Michaels's Hospital, University of Toronto, Canada|Completed|||52|Actual|Southeast University, China|Early termination leading to small numbers of subjects analyzed||2||f||||t||||||Samples Without DNA|"~     Parameters of arterial blood gases, haemodynamic and mechanics of breathing~   "|||2018-06-01 00:06:37.594462|2018-06-01 00:06:37.594462
NCT01065415|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-12-25|2010-02-08|2010-02-09|Estimate|||||||2011-12-25|2011-12-29|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|October 2011|Actual|2011-10-31|||||Observational|||Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC)|The Efficacy of Coregistered Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer|Completed|||272|Actual|Samsung Medical Center|||2||f||||f||||||||||2018-06-01 00:06:37.823253|2018-06-01 00:06:37.823253
NCT01065402|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2010-02-08|2010-02-08|2010-02-09|Estimate|||||||2010-02-08|2010-02-09|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||A Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With Diabetes|A Randomized, Two-Regimen, Crossover, Comparative Study to Evaluate the Efficacy and Safety of PPB-R-203-Based Meal Versus TK9-Based Meal in 20 Patients With Diabetes|Unknown status|Recruiting|N/A|20|Anticipated|Pharma Power Biotec Co., Ltd.||2|||f||||||||||||||2018-06-01 00:06:37.888615|2018-06-01 00:06:37.888615
NCT01065389|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2013-09-08|2010-02-08|2010-02-09|Estimate|||||||2013-09-08|2013-09-10|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|August 2016|Anticipated|2016-08-31|April 2015|Anticipated|2015-04-30||Interventional|DIAPRE||Resistance Training in Intradialysis Patients|Phase 1 RCT of Progressive Resistance Training on Small Solute Clearance, Functional Capacity and Quality of Life in Intradialysis Patients|Unknown status|Active, not recruiting|Phase 2|46|Anticipated|Sikkim Manipal University||2|||f||||t||||||||||2018-06-01 00:06:38.006931|2018-06-01 00:06:38.006931
NCT01065376|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-07-20|2010-02-08|2010-02-09|Estimate|||||||2011-07-20|2011-07-21|Estimate|January 2010||2010-01-31|April 2011|2011-04-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation|The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation in Women Undergoing Assisted Reproduction|Completed||Phase 4|120|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:06:38.219293|2018-06-01 00:06:38.219293
NCT01065363|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-08|2010-02-08|2010-02-09|Estimate|||||||2010-02-08|2010-02-09|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Health Promotion and Management for Hepatitis B Carriers|Project of Health Promotion and Management for Hepatitis B Carriers in NTU Campus|Unknown status|Active, not recruiting|N/A|160|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:06:38.299527|2018-06-01 00:06:38.299527
NCT01065350|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-07|2013-02-15||2013-03-21|2010-02-08|2010-02-09|Estimate|2013-03-21|2013-05-03|Estimate||||2013-03-21|2013-05-03|Estimate|December 2010||2010-12-31|March 2013|2013-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters|A Comparison of Ketofol (Ketamine and Propofol Admixture) vs. Propofol as Induction Agents on Hemodynamic Parameters|Completed||N/A|85|Actual|Mayo Clinic|The dose ratio implemented was not ideal. Enrollment was limited to ASA I and II patients only.|2|||f||||t||||||||||2018-06-01 00:06:38.391492|2018-06-01 00:06:38.391492
NCT01065337|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2012-05-24|2010-02-08|2010-02-09|Estimate|||||||2012-05-24|2012-05-25|Estimate|August 2005||2005-08-31|May 2012|2012-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Induced Wound Healing by Application of Expanded Bone Marrow Stem Cells in Diabetic Patients With Critical Limb Ischemia|Study on Induced Wound Healing Through Application of Expanded Autologous Bone Marrow Stem Cells in Diabetic Patients With Ischemia-induced Chronic Tissue Ulcers Affecting the Lower Limbs|Completed||Phase 2|30|Actual|Ruhr University of Bochum||5|||f||||f||||||||||2018-06-01 00:06:38.956078|2018-06-01 00:06:38.956078
NCT01065324|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-08|2010-02-08|2010-02-09|Estimate|||||||2010-02-08|2010-02-09|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|December 2012|Anticipated|2012-12-31|||||Observational|||Balloon-assisted Enteroscopy and Bacteria|Intestinal Barrier Permeability Defects, Recovery, and Risk of Bacterial Translocation Induced After Deep Intestinal Manipulation by Balloon-assisted Enteroscopy: From Basic to Clinical Research|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     Bacterial DNA, host DNA~   "|||2018-06-01 00:06:39.036071|2018-06-01 00:06:39.036071
NCT01065311|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-05-14|2010-02-08|2010-02-09|Estimate|||||||2014-05-14|2014-05-15|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Mindfulness-based Cognitive Therapy for Chronic Depression|Mindfulness-based Cognitive Therapy for Chronic Depression|Completed||Phase 2|106|Actual|Ruhr University of Bochum||3|||f||||f||||||||||2018-06-01 00:06:39.109063|2018-06-01 00:06:39.109063
NCT01065298|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2015-10-19|2010-02-08|2010-02-09|Estimate|||||||2015-10-19|2015-10-21|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus|Completed|||30|Actual|Postgraduate Institute of Medical Education and Research|||2||f||||t||||||||||2018-06-01 00:06:39.19418|2018-06-01 00:06:39.19418
NCT01065285|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2016-01-05|2010-02-08|2010-02-09|Estimate|||||||2016-01-05|2016-01-06|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|MAIVAX||Vaccination Against Influenza in Autoimmune Diseases|Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX)|Completed||Phase 4|234|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:06:39.287788|2018-06-01 00:06:39.287788
NCT01065272|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2016-08-09|2010-02-08|2010-02-09|Estimate|||||||2016-08-09|2016-08-10|Estimate|February 2010||2010-02-28|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|#9105||Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma|Dexamethasone Versus Placebo in the Treatment of Viral Bronchiolitis in Patients With Either Eczema and or Parental or Sibling History of Asthma.A Randomized Controlled Trial.|Completed||Phase 1|200|Actual|Hamad Medical Corporation||2|||f||||t||||||||||2018-06-01 00:06:39.37296|2018-06-01 00:06:39.37296
NCT01065259|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-07-20|2010-02-08|2010-02-09|Estimate|||||||2011-07-20|2011-07-22|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children|Randomized Control Study of Concerta and Strattera on the Improvement of Executive Function in Attention Deficit Hyperactivity Disorder Children|Completed||Phase 4|262|Actual|Peking University||3|||f||||t||||||||||2018-06-01 00:06:39.448479|2018-06-01 00:06:39.448479
NCT01065246|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2012-10-02|2010-02-08|2010-02-09|Estimate|||||||2012-10-02|2012-10-03|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|SECIMAS||Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites|Phase II Open Label Study to Evaluate the Safety of a Second I.P. Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Due to Carcinoma, Requiring Their First Therapeutic Puncture After Treatment in the CASIMAS Study|Completed||Phase 2|8|Actual|Neovii Biotech||1|||f||||t||||||||||2018-06-01 00:06:39.519611|2018-06-01 00:06:39.519611
NCT01065233|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-08-12|2010-02-08|2010-02-09|Estimate|||||||2011-08-12|2011-08-15|Estimate|May 2008||2008-05-31|April 2010|2010-04-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|CDCHC||Pangenomic Study During Alcoholic Cirrhosis|Genetical Predisposition in Hepatocellular Carcinoma : Pangenomic Link Study During Alcoholic Cirrhosis|Unknown status|Recruiting||600|Anticipated|Nantes University Hospital|||2||f||||||||||Samples With DNA|"~     2 blood samples of 5ml for DNA extraction~   "|||2018-06-01 00:06:39.720871|2018-06-01 00:06:39.720871
NCT01065220|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-01-02|2010-02-08|2010-02-09|Estimate|||||||2014-01-02|2014-01-03|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Sex Steroids and the Serotonin Transporter|The Influence of Sex Steroid Hormones on Serotonin Transporter Binding in the Human Brain Investigated by Positron Emission Tomography|Completed||Phase 4|32|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:06:39.806298|2018-06-01 00:06:39.806298
NCT01065207|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2012-12-26|2010-02-08|2010-02-09|Estimate|||||||2012-12-26|2012-12-27|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|ANRS CO18||Patients Infected With HIV Since More Than 10 Years With a Plasma Viral RNA <400 Copies / mL in the Absence of Any Treatment: Study Mechanisms Involved in Controlling the Infection|ANRS HIV CONTROLLERS NATIONAL OBSERVATORY|Completed||N/A|250|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-06-01 00:06:39.919935|2018-06-01 00:06:39.919935
NCT01065194|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-08-27|2010-02-08|2010-02-09|Estimate|||||||2010-08-27|2010-08-30|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|LevoRep||Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure|Efficacy and Safety of Pulsed Infusions of Levosimendan in Outpatients With Advanced Heart Failure - A Multicenter, Double-blind, Placebo Controlled Prospective Trial With Two Arms|Unknown status|Recruiting|Phase 3|120|Anticipated|Medical University Innsbruck||2|||f||||t||||||||||2018-06-01 00:06:40.018609|2018-06-01 00:06:40.018609
NCT01065168|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-06|||2010-02-16|2010-02-08|2010-02-09|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|March 2010|Anticipated|2010-03-31|January 2010|Anticipated|2010-01-31||Observational|||Serial Measurement of Serum Antimullerian Hormone in Women Undergoing Laparoscopic Cystectomy of Endometrioma|Serial Measurement of Serum Antimullerian Hormone in Women Undergoing Laparoscopic Cystectomy of Endometrioma|Unknown status|Active, not recruiting||43|Actual|Mahidol University|||1||f||||t||||||||||2018-06-01 00:06:40.1809|2018-06-01 00:06:40.1809
NCT01065155|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-06|||2014-03-04|2010-02-08|2010-02-09|Estimate|||||||2014-03-04|2014-03-05|Estimate|February 2010||2010-02-28|March 2011|2011-03-31|March 2014|Anticipated|2014-03-31|February 2010|Actual|2010-02-28||Observational|LOD-DIABETES||Relationship of Central Blood Pressure and Pulse Wave Velocity With Target Organ Damage|Central Blood Pressure and Pulse Wave Velocity: Relationship to Target Organ Damage and Cardiovascular Morbidity-mortality in Diabetic Patients. An Observational Prospective Study. LOD-DIABETES: Study Protocol|Unknown status|Active, not recruiting||110|Anticipated|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|||1||f||||t||||||Samples Without DNA|"~     blood and urine).~   "|||2018-06-01 00:06:40.300265|2018-06-01 00:06:40.300265
NCT01065142|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-03-27|2010-02-08|2010-02-09|Estimate|||||||2014-03-27|2014-03-28|Estimate|April 2011||2011-04-30|March 2014|2014-03-31||||July 2014|Anticipated|2014-07-31||Interventional|ETIC||ETIC (Therapeutic Education in Heart Failure)|Does Therapeutic Education Improve Heart Failure Patient Quality of Life?|Unknown status|Active, not recruiting|N/A|200|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:06:40.357804|2018-06-01 00:06:40.357804
NCT01065129|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2017-03-16|2010-02-08|2010-02-09|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2, 2010|Actual|2010-09-02|March 2017|2017-03-31|October 18, 2016|Actual|2016-10-18|July 2014|Actual|2014-07-31||Interventional|MDS||Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)|A Phase I Trial Evaluating the Effects of Plerixafor (AMD3100) and G-CSF in Combination With Azacitidine (Vidaza) for the Treatment of MDS|Completed||Phase 1|28|Actual|Washington University School of Medicine||4|||f||||t|t|f|||f|||No||2018-06-01 00:06:40.432983|2018-06-01 00:06:40.432983
NCT01065116|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2011-07-20|2010-02-08|2010-02-09|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2010||2010-03-31|May 2010|2010-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs|Effectiveness and Treatment Adherence to Artemether/Lumefantrine Pre-packs Versus Blister Packs in the Treatment of Uncomplicated Malaria in Uganda|Completed||Phase 3|920|Actual|Malaria Consortium, Uganda||2|||f||||t||||||||||2018-06-01 00:06:40.528385|2018-06-01 00:06:40.528385
NCT01065103|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2014-09-08|2010-02-08|2010-02-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI)|Fractional Flow Reserve Stability Study of Non-culprit Vessels in Patients With ST Elevation Myocardial Infarction|Completed||N/A|48|Actual|Cardiology Research UBC||1|||f||||t||||||||||2018-06-01 00:06:40.604182|2018-06-01 00:06:40.604182
NCT01065090|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2015-04-09|2010-02-08|2010-02-09|Estimate|||||||2015-04-09|2015-04-13|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|ACTIMS||A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis|A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis|Completed|||38|Actual|Biogen|||2||f||||t||||||||||2018-06-01 00:06:40.688194|2018-06-01 00:06:40.688194
NCT01065077|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08||2015-09-23|2015-09-23|2010-02-08|2010-02-09|Estimate||||2015-09-23|2015-10-08|Estimate|2015-09-23|2015-10-08|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|COMPOSE 1||BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|Terminated||Phase 2|12|Actual|Bayer||4|||f||||t||||||||||2018-06-01 00:06:40.773682|2018-06-01 00:06:40.773682
NCT01065064|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-02-08|2010-02-08|2010-02-09|Estimate|||||||2010-02-08|2010-02-09|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|||Visual Performance After RESTOR Implantation|Visual Performance After Implantation of an Aspheric Multifocal Diffractive Intraocular Lens|Completed||Phase 4|50|Actual|Hospital Oftalmologico de Brasilia||1|||f||||t||||||||||2018-06-01 00:06:40.940672|2018-06-01 00:06:40.940672
NCT01065051|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2013-11-04||2013-12-31|2010-02-08|2010-02-09|Estimate|2013-12-31|2014-01-06|Estimate||||2013-12-31|2014-01-06|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|HEARTWORK||Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)|Terminated||Phase 2|1|Actual|Bayer|The study was terminated prematurely due to low recruitment (one subject enrolled only). No statistical analyses of efficacy parameters were performed. Therefore, no clinically meaningful conclusions can be drawn from the data generated.|2|||f||||f||||||||||2018-06-01 00:06:41.02171|2018-06-01 00:06:41.02171
NCT01065038|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2010-10-05|2010-02-08|2010-02-09|Estimate|||||||2010-10-05|2010-10-06|Estimate|September 2002||2002-09-30|September 2005|2005-09-30||||||||Interventional|ANAHYDRET||Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia|A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia|Completed||Phase 3|||AOP Orphan Pharmaceuticals AG||2|||f||||t||||||||||2018-06-01 00:06:41.300428|2018-06-01 00:06:41.300428
NCT01065025|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2015-04-10|2010-02-08|2010-02-09|Estimate|||||||2015-04-10|2015-04-13|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|AEGIS||Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies|Open Label, Dose Escalation Trial of Oral 4SC-205 in Patients With Advanced Malignancies: First-In-Man Study of a Newly Developed, Oral Inhibitor of Kinesin-spindle Protein, Eg5|Completed||Phase 1|60|Anticipated|4SC AG||1|||f||||t||||||||||2018-06-01 00:06:41.383969|2018-06-01 00:06:41.383969
NCT01065012|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05||2012-04-11|2015-03-30|2010-02-05|2010-02-09|Estimate||||2012-04-11|2012-04-16|Estimate|2015-03-30|2015-04-20|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Treatment of Erectile Dysfunction - Long Term Safety and Efficacy|Open-Label Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction|Completed||Phase 3|1027|Actual|Warner Chilcott||4|||f||||f||||||||||2018-06-01 00:06:41.456595|2018-06-01 00:06:41.456595
NCT01064999|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2012-03-12|2010-02-08|2010-02-09|Estimate|||||||2012-03-12|2012-03-14|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|March 2012|Actual|2012-03-31||Interventional|||A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer|An Open Label, Randomized, Multi-center, Phase II/III Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy With Intensity-modified Radiation Therapy (IMRT) in Local Advanced Rectal Cancer|Unknown status|Recruiting|Phase 2/Phase 3|240|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 00:06:41.618148|2018-06-01 00:06:41.618148
NCT01064986|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2014-05-20|2010-02-08|2010-02-09|Estimate|||||||2014-05-20|2014-05-22|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers|The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers|Completed||Phase 1|12|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 00:06:41.687211|2018-06-01 00:06:41.687211
NCT01064973|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2012-12-19|2010-02-05|2010-02-09|Estimate|||||||2012-12-19|2012-12-20|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders|An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders|Terminated||Phase 2|32|Actual|Seaside Therapeutics, Inc.||1||all active subjects were rolled into study 209AS209/NCT01706523|f||||f||||||||||2018-06-01 00:06:41.759625|2018-06-01 00:06:41.759625
NCT01064960|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2012-12-03|2010-02-08|2010-02-09|Estimate|||||||2012-12-03|2012-12-04|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner|Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner|Completed||Phase 3|7|Actual|Philips Healthcare||1|||f||||t||||||||||2018-06-01 00:06:41.947071|2018-06-01 00:06:41.947071
NCT01064947|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|2013-04-24||2016-08-15|2010-02-08|2010-02-09|Estimate|2013-04-24|2013-07-04|Estimate||||2016-08-15|2016-09-22|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Baseline characteristics are provided only for those subjects with a positive culture|Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis|Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study|Completed||Phase 4|29|Actual|Derm Research, PLLC|small number of subjects/short duration of study treatment||||f||||f||||||||||2018-06-01 00:06:42.107694|2018-06-01 00:06:42.107694
NCT01064934|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2015-06-03|2010-02-08|2010-02-09|Estimate|||||||2015-06-03|2015-06-04|Estimate|September 2010||2010-09-30|May 2010|2010-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|ELAILa||Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a)|Randomized Controlled Trial of Efficacy and Safety of Lipid Apheresis for the Prevention of Cardiovasc. Events in Patients With Progr. Cardiovasc. Disease, Lp(a)≥ 60 mg/dl and LDL-C <130 mg/dl on Maximally Tolerated Lipid-lowering Therapy|Withdrawn||N/A|0|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 00:06:42.281992|2018-06-01 00:06:42.281992
NCT01064921|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2018-02-15|2010-02-08|2010-02-09|Estimate|||||||2018-02-15|2018-02-19|Actual|January 19, 2010|Actual|2010-01-19|February 2018|2018-02-28|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|||Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma|A Phase I Trial Of Vorinostat In The Treatment Of Advanced Laryngeal, Hypopharyngeal, Nasopharyngeal And Oropharyngeal Squamous Cell Carcinoma Of The Head And Neck.|Completed||Phase 1|27|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:06:42.366023|2018-06-01 00:06:42.366023
NCT01064908|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2013-08-07|2010-02-08|2010-02-09|Estimate|||||||2013-08-07|2013-08-09|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||A New Oxygen Mask for Carotid Endarterectomy Under Local Anaesthesia|A Study To Determine The Effectiveness Of A New Oxygen Mask At Increasing Arterial Oxygen Content During Carotid Endarterectomy Under Local Anaesthesia|Completed|||25|Actual|Brighton and Sussex University Hospitals NHS Trust|||1||f||||f||||||||||2018-06-01 00:06:42.470101|2018-06-01 00:06:42.470101
NCT01064895|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2016-11-07|2010-02-05|2010-02-09|Estimate|||||||2016-11-07|2016-11-08|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|PROVIDE||Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)|Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)|Terminated|||||Angiodynamics, Inc.|||1||f||||f||||||||||2018-06-01 00:06:42.54268|2018-06-01 00:06:42.54268
NCT01064882|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2011-08-18||2011-11-07|2010-02-05|2010-02-09|Estimate|2011-11-07|2011-12-09|Estimate||||2011-11-07|2011-12-09|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence||Completed||Phase 2|104|Actual|Allergan||3|||f||||||||||||||2018-06-01 00:06:42.72506|2018-06-01 00:06:42.72506
NCT01064869|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-08|||2016-03-14|2010-02-08|2010-02-09|Estimate|||||||2016-03-14|2016-03-15|Estimate|January 2005||2005-01-31|March 2016|2016-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Nurse Led Programme to Improve Adherence in Difficult Asthma|Evaluation of the Benefits of an Individualised Menu Driven Nurse Led Programme to Improve Adherence in Difficult Asthma|Completed||N/A|20|Actual|Belfast Health and Social Care Trust||2|||f||||f||||||||||2018-06-01 00:06:43.221249|2018-06-01 00:06:43.221249
NCT01064856|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2016-05-31|2012-08-10|2016-10-04|2010-02-05|2010-02-09|Estimate|2016-10-04|2016-11-25|Estimate|2012-08-10|2012-08-20|Estimate|2016-10-04|2016-11-25|Estimate|February 2010||2010-02-28|August 2016|2016-08-31|May 2014|Actual|2014-05-31|August 2011|Actual|2011-08-31||Interventional||Efficacy analyses included all participants who were randomized and received at least 1 dose of double-blind study drug (ITT).|Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis|Completed||Phase 3|165|Actual|AbbVie||4|||f||||f||||||||||2018-06-01 00:06:43.355132|2018-06-01 00:06:43.355132
NCT01064843|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2014-05-29|2010-02-08|2010-02-09|Estimate|||||||2014-05-29|2014-05-30|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Clinical Evaluation of the Mandibular Mini-Implant Overdenture|Clinical Evaluation of the Mandibular Mini-Implant Overdenture|Completed|||80|Actual|3M|||1||f||||f||||||||||2018-06-01 00:06:44.13394|2018-06-01 00:06:44.13394
NCT01064323|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2017-06-20||2017-07-18|2010-02-05|2010-02-08|Estimate|2017-07-18|2017-08-17|Actual||||2017-07-18|2017-08-17|Actual|January 2009|Actual|2009-01-31|July 2017|2017-07-31|January 2014|Actual|2014-01-31|June 2010|Actual|2010-06-30||Interventional|||Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study|Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study|Completed||N/A|10|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 00:06:58.212382|2018-06-01 00:06:58.212382
NCT01064830|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2012-10-02||2017-02-01|2010-02-05|2010-02-08|Estimate|2012-11-01|2012-12-03|Estimate||||2017-02-01|2017-03-13|Actual|February 2010||2010-02-28|February 2017|2017-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Topical Cyclosporine Suspension for the Treatment of Brittle Nails|A Single Center, Investigator-blinded Study of the Efficacy of Topical Cyclosporine 0.05% Ophthalmic Suspension (RESTASIS®) Under Occlusion Versus Vehicle in the Treatment of Brittle Nail Syndrome|Completed||Phase 2|21|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:06:44.201271|2018-06-01 00:06:44.201271
NCT01064817|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2014-04-14||2014-07-14|2010-02-05|2010-02-08|Estimate|2014-07-14|2014-08-07|Estimate||||2014-07-14|2014-08-07|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional||All subjects screened and enrolled in study|PRM-151 in the Prevention of Scarring Following Trabeculectomy|A Randomized, Double-Masked, Placebo-Controlled Study of PRM-151 in the Prevention of Postoperative Scarring in Glaucoma Patients Following Primary Trabeculectomy|Completed||Phase 2|124|Actual|Promedior, Inc.||2|||f||||t||||||||||2018-06-01 00:06:44.536873|2018-06-01 00:06:44.536873
NCT01064804|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2010-02-05|2010-02-05|2010-02-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||To Test The Relative Bioavailability Of PF-04191834 When Dosed As An Immediate Release Tablet Compared With Solution Following Single And Multiple Dosing|An Open Randomised 4-Way Crossover Single Dose And A Parallel Group Multiple Dose Comparative Pharmacokinetic Study Of The PF-04191834 Phase 2 Tablet And The Phase 1 Dispersion Formulations.|Completed|||20|Anticipated|Pfizer|||1||f||||f||||||Samples With DNA|"~     whole blood, plasma, urine, saliva~   "|||2018-06-01 00:06:45.008998|2018-06-01 00:06:45.008998
NCT01064791|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2016-11-16|2010-02-05|2010-02-08|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients|A Partially Blinded, Prospective, Randomized Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral Sotrastaurin Plus Standard or Reduced Exposure Tacrolimus vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients|Completed||Phase 2|298|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:06:45.100195|2018-06-01 00:06:45.100195
NCT01064778|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2012-02-01|2010-02-05|2010-02-08|Estimate|||||||2012-02-01|2012-02-02|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Glycemic Index and Brain Function|The Effects of Dietary Glycemic Index on Brain Function|Completed||N/A|12|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 00:06:45.265535|2018-06-01 00:06:45.265535
NCT01064765|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2013-09-04|2010-02-05|2010-02-08|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|ACT-HF||ACT-HF: Attention, Cognition and Self-Management in Heart Failure|ACT-HF: Attention, Cognition and Self-Management in Heart Failure|Completed|||72|Actual|University of Chicago|||1||f||||f||||||||||2018-06-01 00:06:45.34901|2018-06-01 00:06:45.34901
NCT01064752|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2010-02-05|2010-02-05|2010-02-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|April 2005||2005-04-30|April 2009|2009-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection|A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection|Completed|||7|Actual|University of California, San Francisco|||1||f||||t||||||Samples With DNA|"~     Samples of both cerebrospinal fluid and blood will also be frozen and stored.~   "|||2018-06-01 00:06:45.417227|2018-06-01 00:06:45.417227
NCT01064739|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2013-03-01||2016-04-26|2010-02-05|2010-02-08|Estimate|2013-06-18|2013-07-31|Estimate||||2016-04-26|2016-05-26|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration|Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration|Completed||Early Phase 1|14|Actual|Vanderbilt University||1|||f||||f||||||||No||2018-06-01 00:06:45.516504|2018-06-01 00:06:45.516504
NCT01064726|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2010-06-01|2010-02-05|2010-02-08|Estimate|||||||2010-06-01|2010-06-02|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.|A Double Blind (3rd Party Open), 3-Way Crossover Study To Explore The Reproducibility Of Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis (Out Of Season) And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:06:46.967357|2018-06-01 00:06:46.967357
NCT01064713|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2014-11-03|2010-02-05|2010-02-08|Estimate|||||||2014-11-03|2014-11-04|Estimate|February 2010||2010-02-28|November 2014|2014-11-30||||October 2014|Actual|2014-10-31||Interventional|||Phase II Study of Tesetaxel in Metastatic Melanoma|A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH|Completed||Phase 2|17|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:06:47.066345|2018-06-01 00:06:47.066345
NCT01064700|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-05|2010-02-05|2010-02-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|October 2006||2006-10-31|February 2010|2010-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Bright Light: A Novel Treatment for Anxiety|Bright Light: A Novel Treatment for Anxiety|Completed||Phase 1|33|Actual|University of South Carolina||2|||f||||f||||||||||2018-06-01 00:06:47.158512|2018-06-01 00:06:47.158512
NCT01064687|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2014-10-03|2012-02-10|2015-01-15|2010-02-05|2010-02-08|Estimate|2015-01-15|2015-01-26|Estimate|2012-02-10|2012-02-14|Estimate|2015-01-15|2015-01-26|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|AWARD-1|Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.|A Study in Participants With Type 2 Diabetes Mellitus|A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)|Completed||Phase 3|978|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 00:06:47.425375|2018-06-01 00:06:47.425375
NCT01064674|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2010-02-05|2010-02-05|2010-02-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Observational|||Cardiovascular Evaluation Before Renal Transplantation|Cardiovascular Diagnostic Before Renal Transplantation: a Prospective Study to Assess Cardiovascular Morbidity Before Renal Transplantation and to Improve Standard Diagnostic Procedures.|Unknown status|Recruiting||100|Anticipated|University Hospital Muenster|||1||f||||f||||||||||2018-06-01 00:06:50.818078|2018-06-01 00:06:50.818078
NCT01064661|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2013-12-11|2010-02-05|2010-02-08|Estimate|||||||2013-12-11|2013-12-12|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pilot Study Studying Physiological Effects of Probiotic Pills in Patients With Abdominal Pain/Discomfort and Bloating|Physiological Effects of Probiotic Bacteria Lactobacillus Acidophilus NCFM Alone Versus a Combination With Bifidobacterium Lactids - LBi07 in Patients With Mild to Moderate Abdominal Pain/Discomfort and Bloating|Completed||N/A|22|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:06:50.905731|2018-06-01 00:06:50.905731
NCT01064648|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2018-05-10|2010-02-05|2010-02-08|Estimate|||||||2018-05-10|2018-05-11|Actual|March 15, 2010|Actual|2010-03-15|May 2018|2018-05-31||||June 1, 2018|Anticipated|2018-06-01||Interventional|||Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma|A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma|Active, not recruiting||Phase 1/Phase 2|116|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 00:06:51.095121|2018-06-01 00:06:51.095121
NCT01064635|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2018-05-08|2010-02-05|2010-02-08|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2005||2005-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2015|Actual|2015-08-31||Interventional|GIM4||Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)|Letrozole Adjuvant Therapy Duration (LEAD) Study: Standard Versus Long Treatment. A Phase III Trial in Post-Menopausal Women With Early Breast Cancer.|Active, not recruiting||Phase 3|2056|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||||||||||||2018-06-01 00:06:51.494385|2018-06-01 00:06:51.494385
NCT01064622|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|2015-01-29||2015-07-20|2010-02-05|2010-02-08|Estimate|2015-01-29|2015-02-13|Estimate||||2015-07-20|2015-08-14|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer|A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)|Completed||Phase 1/Phase 2|118|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:06:51.789745|2018-06-01 00:06:51.789745
NCT01064609|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2013-01-21|2010-02-05|2010-02-08|Estimate|||||||2013-01-21|2013-01-23|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||"Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps."|"Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps:a Randomized Clinical Trial"|Completed||N/A|75|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-06-01 00:06:52.918977|2018-06-01 00:06:52.918977
NCT01064596|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-09-25|2010-02-05|2010-02-08|Estimate|||||||2014-09-25|2014-09-26|Estimate|February 2010||2010-02-28|September 2014|2014-09-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery|Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery|Completed|||40|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     4 blood samples to measure anti-Xa activity~   "|||2018-06-01 00:06:52.988601|2018-06-01 00:06:52.988601
NCT01064583|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2013-11-12|2010-02-05|2010-02-08|Estimate|||||||2013-11-12|2013-11-13|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Cocoa Flavanols and Painfree Walking Distance|Long-term Effect of Dietary Intervention With Flavanol-containing Cocoa on Vascular Function of Diabetic Patients|Completed||Phase 1/Phase 2|62|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-06-01 00:06:53.087854|2018-06-01 00:06:53.087854
NCT01064570|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2018-02-20|2010-02-05|2010-02-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2000||2000-05-31|February 2018|2018-02-28||||||||Interventional|||AIDA 2000 Guidelines|Guidelines for Treatment of Acute Promyelocytic Leukemia|Recruiting||Phase 2|600|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 00:06:53.164082|2018-06-01 00:06:53.164082
NCT01064557|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2018-02-20|2010-02-05|2010-02-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 1993||1993-10-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||"AIDA Protocol (LAP 0493)"|Guideline for the Treatment of Newly Diagnosed Patients Eith Acutypromyelocytic Leukemia, Aged > 12 Months (1 Year) and <75 Years, Using All-trans Retinoic Acid in Combination With Idarubicin|Recruiting||N/A|1068|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 00:06:53.254756|2018-06-01 00:06:53.254756
NCT01064544|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-07-19|2010-02-05|2010-02-08|Estimate|||||||2011-07-19|2011-07-20|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|SHINE||Study on Hemodialysis: Illumination Effects|Effects of Light Therapy on Sleep, Melatonin Rhythm and Mood in Hemodialysis Patients|Completed||Phase 3|14|Actual|Meander Medical Center||2|||f||||f||||||||||2018-06-01 00:06:53.571244|2018-06-01 00:06:53.571244
NCT01064531|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2016-10-17|2010-02-05|2010-02-08|Estimate|||||||2016-10-17|2016-10-18|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|MISRSA||Mini Stem Radiostereometric Analysis Study|A Randomized Controlled Trial to Compare Implant Migration of the MIS Stem Versus The Synergy Total Hip Systems by Radiostereometric Analysis|Completed|||41|Actual|Smith & Nephew, Inc.|||2||f||||f||||||||||2018-06-01 00:06:53.648044|2018-06-01 00:06:53.648044
NCT01064518|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04||2011-06-13|2013-08-12|2010-02-04|2010-02-08|Estimate||||2011-06-13|2011-06-27|Estimate|2013-08-12|2013-08-21|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|Completed||Phase 2|90|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 00:06:53.72067|2018-06-01 00:06:53.72067
NCT01064505|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2013-05-09|2010-02-04|2010-02-08|Estimate|||||||2013-05-09|2013-05-13|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients|A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)|Completed||Phase 1|48|Actual|Quark Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:06:53.80088|2018-06-01 00:06:53.80088
NCT01064492|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-03-16|2010-02-04|2010-02-08|Estimate|||||||2010-03-16|2010-03-18|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects|A Phase 1, Cross-Over, Single-Dose, Open-Label Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:06:53.925417|2018-06-01 00:06:53.925417
NCT01064479|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2018-05-01|2010-02-05|2010-02-08|Estimate|||||||2018-05-01|2018-05-03|Actual|February 2010|Actual|2010-02-28|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck|A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel And Cisplatin With Or Without Erlotinib In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of the Head And Neck|Active, not recruiting||Phase 2|120|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 00:06:54.063794|2018-06-01 00:06:54.063794
NCT01064466|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2017-11-20|2010-02-04|2010-02-08|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|Drugs-SNPs||Discovery Stage IND EXEMPT Clinical Study - Etoposide and Single Nucleotide Polymorphisms|Personalize Etoposide Chemotherapy Toward Small Cell Lung Cancer (SCLC) With Maximizing Effectiveness and Minimizing Risk Via Assay Single Nucleotide Polymorphisms (SNPs) of Relative Etoposide Targets, Topoisomerase II and CYP4503A4|Active, not recruiting||Phase 3|600|Anticipated|Medicine Invention Design, Inc||2|||f||||t||||||||No||2018-06-01 00:06:54.264957|2018-06-01 00:06:54.264957
NCT01064453|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2013-11-18|2010-02-05|2010-02-08|Estimate|||||||2013-11-18|2013-11-19|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|Angeliq rPMS||Angeliq Regulatory Post Marketing Surveillance|Angeliq Regulatory Post Marketing Surveillance|Completed|||4078|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:06:54.402587|2018-06-01 00:06:54.402587
NCT01064440|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04||2015-01-16|2015-10-14|2010-02-04|2010-02-08|Estimate||||2015-01-19|2015-01-29|Estimate|2015-10-14|2015-11-06|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subject With Critical Limb Ischemia|Completed||Phase 2|52|Actual|ViroMed Co., Ltd.||3|||f||||t||||||||||2018-06-01 00:06:54.484358|2018-06-01 00:06:54.484358
NCT01064427|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2010-02-05|2010-02-05|2010-02-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|FATSEIN||Factors Correlated With Fatigue in Breast Cancer|Factors Correlated With Fatigue in Breast Cancer Patients Before, During and After Adjuvant Chemotherapy|Unknown status|Recruiting||557|Anticipated|Central Hospital, Nancy, France|||2||f||||f||||||||||2018-06-01 00:06:54.591803|2018-06-01 00:06:54.591803
NCT01064414|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2013-04-02|2012-06-27|2013-08-02|2010-02-04|2010-02-08|Estimate|2013-04-02|2013-05-27|Estimate|2012-04-24|2012-04-25|Estimate|2013-08-02|2013-08-14|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment|A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment|Completed||Phase 3|272|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-06-01 00:06:54.705679|2018-06-01 00:06:54.705679
NCT01064401|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-05-31|2015-08-21|2016-05-31|2010-02-05|2010-02-08|Estimate|2016-05-31|2016-07-11|Estimate|2015-08-21|2015-09-04|Estimate|2016-05-31|2016-07-11|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|(DECIDE)||Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis|Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|1841|Actual|Biogen||2|||f||||t||||||||||2018-06-01 00:06:56.156974|2018-06-01 00:06:56.156974
NCT01064388|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-06-05|2010-02-05|2010-02-08|Estimate|||||||2012-06-05|2012-06-06|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days|A Phase I, Single Center, Double-blind Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects|Completed||Phase 1|36|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:06:57.490954|2018-06-01 00:06:57.490954
NCT01064375|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2015-05-05|2010-02-05|2010-02-08|Estimate|||||||2015-05-05|2015-05-06|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|October 2017|Anticipated|2017-10-31|February 2017|Anticipated|2017-02-28||Interventional|El-porCEA||Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer|Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Karolinska University Hospital||3|||f||||t||||||||||2018-06-01 00:06:57.55553|2018-06-01 00:06:57.55553
NCT01064362|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2011-01-25||2015-04-23|2010-02-04|2010-02-08|Estimate|2011-01-25|2011-02-11|Estimate||||2015-04-23|2015-05-12|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Hemorrhage Risk Prescribed Arixtra|Risk of Hemorrhage in Patients Prescribed Arixtra Compared to LMWH|Completed|||13442|Actual|GlaxoSmithKline|Differences among hospitals in the registration of events (not all events were captured), the presence of policlinical pharmacy, and different drug usage patterns in each hospital did not enable a valid comparison of the risk of haemorrhage.||1||f||||f||||||||||2018-06-01 00:06:57.65055|2018-06-01 00:06:57.65055
NCT01064349|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2015-04-14|2010-02-04|2010-02-08|Estimate|||||||2015-04-14|2015-04-15|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Breast Cancer With Over-expression of erbB2-BRAINSTORM|Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)|Completed|||144|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:06:58.078033|2018-06-01 00:06:58.078033
NCT01064336|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2016-07-22|2010-02-04|2010-02-08|Estimate|||||||2016-07-22|2016-07-25|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31|6 Years|Observational [Patient Registry]|||Promacta Pregnancy Registry|Promacta Pregnancy Registry|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-06-01 00:06:58.145929|2018-06-01 00:06:58.145929
NCT01064310|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2012-06-07||2017-03-05|2010-02-04|2010-02-08|Estimate|2012-07-19|2012-08-23|Estimate||||2017-03-05|2017-04-17|Actual|May 17, 2010|Actual|2010-05-17|March 2017|2017-03-31|November 23, 2015|Actual|2015-11-23|October 19, 2011|Actual|2011-10-19||Interventional|PISCES||Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer|A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma.|Completed||Phase 3|169|Actual|Novartis|The study remained open to allow subjects currently on treatment continued access to treatment with open label pazopanib.|2|||f||||f||||||||||2018-06-01 00:06:58.753639|2018-06-01 00:06:58.753639
NCT01064297|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2010-06-14||2013-02-21|2010-02-04|2010-02-08|Estimate|2010-09-09|2010-10-11|Estimate||||2013-02-21|2013-02-25|Estimate|November 2001||2001-11-30|February 2013|2013-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Lamotrigine Pregnancy Registry (LAM05)|Lamotrigine Pregnancy Registry (LAM05)|Completed|||3416|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:07:00.07635|2018-06-01 00:07:00.07635
NCT01064284|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2016-12-02||2017-07-26|2010-02-05|2010-02-08|Estimate|2017-02-23|2017-04-07|Actual||||2017-07-26|2017-08-25|Actual|January 2010||2010-01-31|July 2017|2017-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SIPPET|"It is considered as Baseline Analysis Population only the one actually analyzed at the end of the study."|Survey of Inhibitors in Plasma-Product Exposed Toddlers|Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial|Completed||Phase 4|303|Actual|Fondazione Angelo Bianchi Bonomi|Enrollment early termination,because on September2014 WFH stated:with other safe clotting-factor concentrates available,consider not to use Kogenate FS/Helixate NexGen(CSL Behring)for newly diagnosed Severe Haemophilia A patients not treated before.|2|||f||||t||||||||Yes|Individual participant data (IPD) are available to other researchers through the publication of an article.|2018-06-01 00:07:00.977091|2018-06-01 00:07:00.977091
NCT01064271|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-08|Estimate|||||||2010-02-04|2010-02-08|Estimate|October 2006||2006-10-31|February 2010|2010-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition|A Relative Bioavailability Study of Two Risperidone 1 mg Tablet Formulations Under Fed Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:07:01.764717|2018-06-01 00:07:01.764717
NCT01064258|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-15|2010-02-05|2010-02-08|Estimate|||||||2010-02-15|2010-02-16|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Trial of Auto Continuous Positive Airway Pressure (CPAP)|Reliability of Automatic CPAP Devices. A Double Blind Dummy Controlled Phase 1 Study|Completed||Phase 1|1|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-06-01 00:07:01.836694|2018-06-01 00:07:01.836694
NCT01064245|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2017-04-04|2010-02-05|2010-02-08|Estimate|||||||2017-04-04|2017-04-05|Actual|February 2010||2010-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests|Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests|Active, not recruiting||N/A|24|Anticipated|Queen's University||2|||f||||f||||||||||2018-06-01 00:07:01.916053|2018-06-01 00:07:01.916053
NCT01064232|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-08|Estimate|||||||2010-02-04|2010-02-08|Estimate|October 2006||2006-10-31|February 2010|2010-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Risperidone Tablets, 1 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition|A Relative Bioavailability Study of Two Risperidone 1 mg Tablet Formulations Under Fasting Conditions|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:07:02.027101|2018-06-01 00:07:02.027101
NCT01064219|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2013-11-02|2010-02-05|2010-02-08|Estimate|||||||2013-11-02|2013-11-05|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Intrauterine Human Chorionic Gonadotrophins (hCG) and Endometrial Treg Cells|The Effect of Intrauterine Injection of Human Chorionic Gonadotrophins (hCG) on the Endometrial T-regulatory Cells and the Electronmicroscopic Endometrial Characteristics|Completed||N/A|20|Actual|The Egyptian IVF-ET Center||1|||f||||f||||||||||2018-06-01 00:07:02.105639|2018-06-01 00:07:02.105639
NCT01064206|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2016-11-09|2010-02-05|2010-02-08|Estimate|||||||2016-11-09|2016-11-10|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|ADDICTAO||ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease|Study of Psychological and Addictive Profile of Patients With Buerger's Disease|Completed|||224|Actual|University Hospital, Lille|||2||f||||f||||||Samples Without DNA|"~     urine~   "|No||2018-06-01 00:07:02.212251|2018-06-01 00:07:02.212251
NCT01064193|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2015-04-07|2010-02-05|2010-02-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|NIDABRECHE||Impact of Local Biopsy to the Endometrium Prior to Controlled Ovarian Stimulation on Clinical Pregnancy|Influence of Local Biopsy of the Endometrium Prior to Controlled Ovarian Stimulation for IVF or ICSI Procedure on the Rates of Embryo Implantation, Clinical Pregnancy and Live Birth in ART|Completed||Phase 3|190|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 00:07:03.330097|2018-06-01 00:07:03.330097
NCT01064180|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-08|Estimate|||||||2010-02-04|2010-02-08|Estimate|May 2002||2002-05-31|February 2010|2010-02-28|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed Conditions|Randomized,2-way Crossover, Bioequivalence Study of Carvedilol 25 mg Film-coated Tablets and COREG® 25 mg Film-coated Tablets Administered as 1 x 25 mg Film-coated Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:07:03.418168|2018-06-01 00:07:03.418168
NCT01064167|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2010-08-30||2011-01-11|2010-02-05|2010-02-08|Estimate|2011-01-11|2011-02-03|Estimate||||2011-01-11|2011-02-03|Estimate|February 2009||2009-02-28|February 2010|2010-02-28|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|TAOPCAB||Tranexamic Acid in Off-pump Coronary Surgery|Tranexamic Acid Reduces Blood Loss After Off-pump Coronary Artery Bypass Grafting|Completed||N/A|231|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-06-01 00:07:03.492837|2018-06-01 00:07:03.492837
NCT01063686|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2015-10-27|2010-02-04|2010-02-05|Estimate|||||||2015-10-27|2015-10-28|Estimate||||October 2015|2015-10-31||||||||Interventional|||The Cervical Cap in the Diagnosis of Rupture of Membranes in the Second Trimester|Use of a Cervical Cap as an Aid in Uncertain Rupture of Membranes in the Second Trimester|Withdrawn||N/A|0|Actual|Rabin Medical Center||1||Insufficient Funding|f||||t||||||||||2018-06-01 00:07:13.664927|2018-06-01 00:07:13.664927
NCT01064154|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-08|Estimate|||||||2010-02-04|2010-02-08|Estimate|May 2002||2002-05-31|February 2010|2010-02-28|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions|Randomized,2-way Crossover, Bioequivalence Study of Carvedilol 25 mg Film-coated Tablets and COREG® 25 mg Film-coated Tablets Administered as 1 x 25 mg Film-coated Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:07:03.760049|2018-06-01 00:07:03.760049
NCT01064141|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2013-02-05|2010-02-05|2010-02-08|Estimate|||||||2013-02-05|2013-02-06|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines|Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines|Completed||Phase 2|210|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 00:07:03.841253|2018-06-01 00:07:03.841253
NCT01064128|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2011-07-18|2010-02-05|2010-02-08|Estimate|||||||2011-07-18|2011-07-20|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy|Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy|Completed||Phase 3|40|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:07:03.934901|2018-06-01 00:07:03.934901
NCT01064115|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-08|Estimate|||||||2010-02-04|2010-02-08|Estimate|January 2006||2006-01-31|February 2010|2010-02-28|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition|A Two Way, Open Label, Single Dose, Cross Over, Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects Under Fed Conditions.|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:07:04.091754|2018-06-01 00:07:04.091754
NCT01064102|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-05|2010-02-05|2010-02-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|January 2006||2006-01-31|February 2010|2010-02-28|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition|Experimental Evaluation of Relative Bioavailabilities of Two Formulations of Cetirizine Hydrochloride Tablets 10 mg in Healthy Adult Human Male Subjects Under Fasting Conditions.|Completed||Phase 1|30|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:07:04.161462|2018-06-01 00:07:04.161462
NCT01064089|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-12-17|2010-02-05|2010-02-08|Estimate|||||||2012-12-17|2012-12-19|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Dose Escalation of HSP990 in Japan/Korea|A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally Once Weekly in Adult Japanese and Korea Patients With Advanced Solid Malignancies|Terminated||Phase 1|17|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:07:04.232411|2018-06-01 00:07:04.232411
NCT01064076|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2014-11-19||2017-02-07|2010-02-04|2010-02-08|Estimate|2017-02-07|2017-03-27|Actual||||2017-02-07|2017-03-27|Actual|January 2010||2010-01-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|October 2011|Actual|2011-10-31||Interventional||All patients with an attempted implant of the S-ICD System.|S-ICD® System IDE Clinical Study|S-ICD® System Clinical Investigation|Completed||N/A|330|Actual|Boston Scientific Corporation|The major limitation of this study is the lack of a control group and the relatively short follow-up time.|1|||f||||t||||||||||2018-06-01 00:07:04.338218|2018-06-01 00:07:04.338218
NCT01064063|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2017-03-09|2010-02-04|2010-02-08|Estimate|||||||2017-03-09|2017-03-13|Actual|February 15, 2011|Actual|2011-02-15|March 2017|2017-03-31|June 2023|Anticipated|2023-06-30|February 2022|Anticipated|2022-02-28||Interventional|Vanguard||Randomized Controlled Clinical Evaluation to Compare Vanguard Cruciate Retaining and AGC Total Condylar Knee Implants|Randomized Controlled Clinical Evaluation to Compare Vanguard Cruciate Retaining and AGC Total Condylar Knee Implants|Active, not recruiting||N/A|150|Actual|Zimmer Biomet||2|||f||||f|f|f||||||Undecided|To be confirmed.|2018-06-01 00:07:04.638246|2018-06-01 00:07:04.638246
NCT01064050|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2015-07-27|2010-02-05|2010-02-08|Estimate|||||||2015-07-27|2015-07-28|Estimate|November 2008||2008-11-30|July 2015|2015-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|SPOC||Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers|Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence After Therapeutic Bronchoscopy in Lung Cancers (SPOC Study)|Terminated||Phase 4|75|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||Difficulty to include patient|f||||f||||||||||2018-06-01 00:07:04.715786|2018-06-01 00:07:04.715786
NCT01064037|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04||2015-09-23|2015-09-23|2010-02-05|2010-02-08|Estimate||||2015-09-23|2015-10-08|Estimate|2015-09-23|2015-10-08|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|COMPOSE EARLY||A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)|A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) Within 12 Hours After Hospital Admission (Pulmonary Artery Catheter eg, Swan-Ganz Not Required)|Terminated||Phase 2|62|Actual|Bayer||4|||f||||t||||||||||2018-06-01 00:07:04.813721|2018-06-01 00:07:04.813721
NCT01064024|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04||2013-01-24|2013-01-24|2010-02-05|2010-02-08|Estimate||||2013-01-24|2013-01-29|Estimate|2013-01-24|2013-01-29|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo|A Double Blind, Randomized, Parallel Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo as a Urinary Analgesic for Short Term Treatment in Female Subjects Suffering From Pain or Burning When Passing Urine Associated With Uncomplicated Urinary Tract Infections (uUTI)|Completed||Phase 3|233|Actual|Amneal Pharmaceuticals, LLC||2|||f||||t||||||||||2018-06-01 00:07:04.964824|2018-06-01 00:07:04.964824
NCT01064011|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2011-06-24|2010-02-05|2010-02-08|Estimate|||||||2011-06-24|2011-06-27|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|IVH||Prospective Randomized, Controlled Trial for Treatment of Intraventricular Hemorrhage|A Prospective Randomized, Controlled Trial for Treatment of Intraventricular Hemorrhage: External Ventricular Drainage and Intraventricular Thrombolysis vs. External Ventricular Drainage and Endoscopic Evacuation|Unknown status|Recruiting|N/A|34|Anticipated|Albany Medical College||2|||f||||f||||||||||2018-06-01 00:07:05.128192|2018-06-01 00:07:05.128192
NCT01063998|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2013-11-06|2010-02-04|2010-02-05|Estimate|||||||2013-11-06|2013-11-08|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma|A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma|Terminated|||23|Actual|William Beaumont Hospitals|||2|Preliminary data did not show expected outcomes.|f||||f||||||Samples With DNA|"~     Renal tumor.~   "|||2018-06-01 00:07:05.20834|2018-06-01 00:07:05.20834
NCT01063985|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2011-07-25|2010-02-04|2010-02-05|Estimate|||||||2011-07-25|2011-07-27|Estimate|May 2010||2010-05-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Comparison of Skin Prick Tests, Clinical Symptoms, and Nasal Challenge Using a New Mouse Extract|A Comparison of Skin Prick Tests, Clinical Symptoms and Nasal Challenge Using a New Mouse Extract|Completed|||39|Actual|Vanderbilt University|||||f||||t||||||||||2018-06-01 00:07:05.301187|2018-06-01 00:07:05.301187
NCT01063972|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2015-04-18|2010-02-04|2010-02-05|Estimate|||||||2015-04-18|2015-04-21|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Smoking Cessation in Rural Hospitals|Centralized Disease Management for Rural Hospitalized Smokers|Completed||N/A|606|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 00:07:05.366727|2018-06-01 00:07:05.366727
NCT01063959|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2015-12-17|2010-02-04|2010-02-05|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Sleeve Gastrectomy Versus Gastric Bypass for Private Pay Patients Seeking Obesity Surgery|Advantages of Sleeve Gastrectomy Over Gastric Bypass for Private Pay Patients Seeking Obesity Surgery|Withdrawn||N/A|0|Actual|Pennington Biomedical Research Center||3||No Enrollment|f||||f||||||||||2018-06-01 00:07:05.448288|2018-06-01 00:07:05.448288
NCT01063946|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2011-12-20|2010-02-04|2010-02-05|Estimate|||||||2011-12-20|2011-12-21|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor|A Phase I, Open Label Study Investigating the Disposition of 25 mg/m² [14C]-AVE8062 (1.85 MBq, 50 µCi) Administered at Cycle 1 as a 30-minute Intravenous Infusion to Patients With Advanced Solid Tumors|Completed||Phase 1|3|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:07:05.539536|2018-06-01 00:07:05.539536
NCT01063933|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2011-11-10|2010-02-04|2010-02-05|Estimate|||||||2011-11-10|2011-11-11|Estimate||||January 2010|2010-01-31|December 2012|Anticipated|2012-12-31|August 2011|Anticipated|2011-08-31||Interventional|||Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza|A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Investigational Intravenous Peramivir in Children With Influenza Disease (CASG 117)|Withdrawn||Phase 1/Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 00:07:05.627332|2018-06-01 00:07:05.627332
NCT01063920|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2011-01-20|2010-02-04|2010-02-05|Estimate|||||||2011-01-20|2011-01-24|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®|A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Non-Inferiority Study of LT-NS001 Versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates|Completed||Phase 2/Phase 3|534|Anticipated|Logical Therapeutics||2|||f||||f||||||||||2018-06-01 00:07:05.783563|2018-06-01 00:07:05.783563
NCT01063907|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2014-09-25||2014-12-01|2010-02-04|2010-02-05|Estimate|2014-11-03|2014-11-05|Estimate||||2014-12-01|2014-12-16|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||A total of up to 101 male and female subjects at least 18 years of age with a confirmed diagnosis of MM, who failed at least 1 and no more than 3 prior chemotherapy regimens and met other inclusion criteria and none of exclusion criteria, were to be enrolled in this study over a period of 22 months (up to 24 subject in P1 and 77 subjects in P2).|A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma|An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|95|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||5|||f||||f||||||||||2018-06-01 00:07:06.050662|2018-06-01 00:07:06.050662
NCT01063894|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|December 2009||2009-12-31|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Effects of Breakfast on Cognitive Processes in Children|A Randomized, Controlled, Parallel Trial to Evaluate the Effects of Breakfast on Cognitive Processes in Children|Unknown status|Recruiting|N/A|280|Anticipated|Kellogg Company||2|||f||||f||||||||||2018-06-01 00:07:08.257128|2018-06-01 00:07:08.257128
NCT01063881|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2012-08-01|2012-06-08|2013-01-31|2010-02-04|2010-02-05|Estimate|2012-10-01|2012-10-31|Estimate|2012-06-08|2012-06-11|Estimate|2013-01-31|2013-02-04|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy|The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy|Completed||Phase 3|285|Actual|Johnson & Johnson Pte Ltd|“Subgroup by dosage” was categorized based on dose-titration patterns observed during the course of the treatment period. Patients were not randomized to treatment by dosage group, disease type, or Intravaginal Ejaculation Latency Time.|1|||f||||||||||||||2018-06-01 00:07:08.364037|2018-06-01 00:07:08.364037
NCT01063868|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2011-04-14||2014-01-30|2010-02-04|2010-02-05|Estimate|2011-04-14|2011-05-10|Estimate||||2014-01-30|2014-03-04|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)|A One-Year, Randomized, Open-Label, Parallel-Group, Multiple-Dose Long-Term Safety Study With Controlled Adjustment of Dose of Tapentadol Extended-Release (ER) and Oxycodone Controlled-Release (CR) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN)|Terminated||Phase 3|47|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Early termination, due to sponsor's discretion, lead to only 47 patients out of the 800 planned (5.9%) being available for analysis. The data should be interpreted with caution.|2||Business decision|f||||f||||||||||2018-06-01 00:07:08.998035|2018-06-01 00:07:08.998035
NCT01063673|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2015-04-09|2010-02-04|2010-02-05|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||The Relation Between Running Patterns and Overuse Injuries in Runners|The Relation Between Running Patterns and Overuse Injuries in Runners|Completed|||940|Actual|Northern Orthopaedic Division, Denmark|||1||f||||t||||||||||2018-06-01 00:07:13.746055|2018-06-01 00:07:13.746055
NCT01063855|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2012-10-04||2013-01-16|2010-02-04|2010-02-05|Estimate|2012-10-04|2012-11-05|Estimate||||2013-01-16|2013-01-24|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|COUPLE||Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a Phosphodiesterase-5 Inhibitor|Completed||Phase 3|495|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 00:07:09.341326|2018-06-01 00:07:09.341326
NCT01063842|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|August 2005||2005-08-31|February 2010|2010-02-28|May 2006|Actual|2006-05-31|||||Interventional|||A Study of the Tolerability of Titrated Dose Tramadol/Acetaminophen Combination Tablet in Korean Patients With Osteoarthritis|Tolerability Improvement of Tramadol/Acetaminophen (Ultracet) by Titration in Korean OA Patients:Multicenter, Randomized, Double-blind Study|Completed||Phase 4|250|Actual|Janssen Korea, Ltd., Korea||2|||f||||||||||||||2018-06-01 00:07:10.156925|2018-06-01 00:07:10.156925
NCT01063829|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2017-12-06|2013-01-24|2018-01-15|2010-02-04|2010-02-05|Estimate|2018-01-15|2018-02-13|Actual|2013-01-28|2013-01-30|Estimate|2018-01-15|2018-02-13|Actual|March 2010||2010-03-31|December 2010|2010-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients|A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug|Completed||Phase 2|133|Actual|AiCuris Anti-infective Cures GmbH||4|||f||||t||||||||||2018-06-01 00:07:10.310951|2018-06-01 00:07:10.310951
NCT01063816|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2017-11-17|2010-02-04|2010-02-05|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2010||2010-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors|A Phase 1 Study of Veliparib in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors|Completed||Phase 1|79|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 00:07:12.0082|2018-06-01 00:07:12.0082
NCT01063803|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02||2013-01-30|2016-03-10|2010-02-04|2010-02-05|Estimate||||2013-01-30|2013-01-31|Estimate|2016-03-10|2016-04-11|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis|An Open-Label Extension Study To Assess The Long-term Safety And Tolerability Of ATN-103 In Subjects With Rheumatoid Arthritis|Completed||Phase 2|266|Actual|Ablynx||2|||f||||f||||||||||2018-06-01 00:07:12.085418|2018-06-01 00:07:12.085418
NCT01063790|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2012-07-13|2010-02-04|2010-02-05|Estimate|||||||2012-07-13|2012-07-16|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|HREI||The Effect of an Individualized Education Intervention on Pain Following Inguinal Hernia Repair Surgery|The Effect of an Individualized Education Intervention Versus Usual Care on Pain Following Ambulatory Inguinal Hernia Repair|Completed||Early Phase 1|82|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 00:07:12.344535|2018-06-01 00:07:12.344535
NCT01063777|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2012-08-17|2010-02-04|2010-02-05|Estimate|||||||2012-08-17|2012-08-20|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis. Long-term Follow-up.|Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis. Long-term Follow-up of a Prospective, Randomized Controlled Intervention Study.|Unknown status|Active, not recruiting|N/A|109|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 00:07:12.425876|2018-06-01 00:07:12.425876
NCT01063764|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2012-03-28||2015-02-16|2010-02-04|2010-02-05|Estimate|2012-05-15|2012-06-19|Estimate||||2015-02-16|2015-03-05|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|April 2011|Actual|2011-04-30||Interventional||Baseline Characteristics refer to the Full Analysis Set (FAS). FAS includes all subjects taking at least one dose of study medication.|An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures|An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 Anti-Epileptic Drugs|Completed||Phase 3|73|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 00:07:12.537896|2018-06-01 00:07:12.537896
NCT01063751|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2017-12-13|2010-02-04|2010-02-05|Estimate|||||||2017-12-13|2017-12-15|Actual|July 2011||2011-07-31|December 2017|2017-12-31|November 2026|Anticipated|2026-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Tritanium® Primary Acetabular Shell Study|A Prospective, Post-market, Multi-center Study of the Tritanium® Acetabular Shell|Active, not recruiting||N/A|240|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:07:13.02745|2018-06-01 00:07:13.02745
NCT01063738|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2015-01-02|2010-02-04|2010-02-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|August 2010||2010-08-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Interventional|REMAIC||Rehabilitating Muscle After Intensive Care|Rehabilitating Muscle After Intensive Care|Completed||N/A|93|Actual|St Helens & Knowsley Teaching Hospitals NHS Trust||4|||f||||f||||||||||2018-06-01 00:07:13.106258|2018-06-01 00:07:13.106258
NCT01063725|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2011-10-09|2010-02-04|2010-02-05|Estimate|||||||2011-10-09|2011-10-12|Estimate|August 2011||2011-08-31|February 2010|2010-02-28|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms|A Multi-center, Randomized, Placebo-controlled Double Blind Clinical Study Assessing the Efficacy and Safety of Femarelle® in Menopausal Women With Vasomotor Syndrome|Unknown status|Recruiting|N/A|200|Anticipated|Se-cure Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 00:07:13.187652|2018-06-01 00:07:13.187652
NCT01063712|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2011-02-23||2012-05-22|2010-02-04|2010-02-05|Estimate|2012-05-22|2012-05-24|Estimate||||2012-05-22|2012-05-24|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||"Safety and Effectiveness of the Device Nit-Occlud® PDA-R"|"Safety and Effectiveness of the Device Nit-Occlud® PDA-R for Percutaneous Closure of Patent Arterial Duct Between 2 and 8 mm in Patients Treated Interventionally in Specialized Centers"|Completed||Phase 2|29|Actual|pfm S.R.L.|The number of participants is small, because the participants were recruited in high altitude cities over 2700m above the sea level. At this altitude bigger defects are more frequent to find than little ones, so is pulmonary hypertension.|1|||f||||t||||||||||2018-06-01 00:07:13.306874|2018-06-01 00:07:13.306874
NCT01063699|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|August 2003||2003-08-31|December 2009|2009-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Survival With Own Liver of Conventional Versus Laparoscopic Kasai for Biliary Atresia|Prospective Trial on Survival With Own Liver After Conventional Versus Laparoscopic Kasai for Biliary Atresia|Completed||N/A|56|Actual|Hannover Medical School||1|||f||||t||||||||||2018-06-01 00:07:13.552385|2018-06-01 00:07:13.552385
NCT01063660|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|March 2004||2004-03-31|February 2010|2010-02-28|July 2007|Actual|2007-07-31|||||Interventional|||Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)|Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukaemia|Completed||Phase 2|75|Actual|medac GmbH||1|||f||||f||||||||||2018-06-01 00:07:13.837102|2018-06-01 00:07:13.837102
NCT01063647|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|November 2001||2001-11-30|February 2010|2010-02-28|June 2006|Actual|2006-06-30|June 2005|Actual|2005-06-30||Interventional|||Dose-range Finding Treosulfan-based Conditioning|Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Advanced Hematological Malignancies After Treosulfan-based Conditioning Therapy - A Clinical Phase II Study|Completed||Phase 1/Phase 2|56|Actual|medac GmbH||3|||f||||t||||||||||2018-06-01 00:07:13.924283|2018-06-01 00:07:13.924283
NCT01063634|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Observational|VIADUCT||Comparison of a Plastic Stent Without Central Lumen With Self Expandable Metal Stents in Patients With Malignant Distal Biliary Obstruction|Comparison of a Plastic Stent Without Central Lumen With Self Expandable Metal Stents in Patients With Malignant Distal Biliary Obstruction. A Randomized, Controlled Trial|Unknown status|Recruiting||76|Anticipated|Kliniken Ludwigsburg-Bietigheim gGmbH|||||f||||f||||||||||2018-06-01 00:07:14.26541|2018-06-01 00:07:14.26541
NCT01063621|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2017-03-14|2010-02-04|2010-02-05|Estimate|||||||2017-03-14|2017-03-15|Actual|January 2010||2010-01-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|6500-005||Extended Long-Term Safety Study of KW-6500|Phase 3 Study of KW-6500 (Safety Study for Extended Long-Term Self-Injection at Home in Patients With Parkinson's Disease)|Completed||Phase 3|27|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-06-01 00:07:14.399556|2018-06-01 00:07:14.399556
NCT01063608|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-03-15|2010-02-04|2010-02-05|Estimate|||||||2010-03-15|2010-03-16|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|FLU-HOP||Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.|Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Clinical Staff (FLU-HOP)|Unknown status|Active, not recruiting|Phase 4|147|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-06-01 00:07:14.495284|2018-06-01 00:07:14.495284
NCT01063595|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2014-03-31||2014-05-12|2010-02-04|2010-02-05|Estimate|2014-03-31|2014-05-01|Estimate||||2014-05-12|2014-05-20|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||Safety population: All participants who received at least 1 of the study treatments in any study period.|A Trial to Investigate the Relative Efficacy, Safety, and Tolerability of Octaplas LG Versus Octaplas SD|A Comparative, Open-label, Randomized, Cross-over Phase I Trial in Healthy Volunteers to Investigate the Relative Efficacy, Safety and Tolerability of Octaplas LG™ vs. Octaplas®|Completed||Phase 1|63|Actual|Octapharma||2|||f||||||||||||||2018-06-01 00:07:14.581125|2018-06-01 00:07:14.581125
NCT01063582|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|February 2005||2005-02-28|January 2007|2007-01-31|December 2010|Anticipated|2010-12-31|September 2005|Anticipated|2005-09-30||Observational|||Noise, a Risk for Heart in Airplane Pilots|Noise of Airplanes a Factor of Risk for the Health of the Heart in Pilots and Crew in Operations of the F16 Airplane|Unknown status|Enrolling by invitation||16|Actual|Universidad Politecnica de Madrid|||2||f||||t||||||||||2018-06-01 00:07:14.83636|2018-06-01 00:07:14.83636
NCT01063569|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-03-19|2010-02-04|2010-02-05|Estimate|||||||2013-03-19|2013-03-20|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Glucocorticoid Treatment in Addison's Disease|Glucocorticoid Treatment in Addison's Disease|Completed||Phase 2/Phase 3|33|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 00:07:15.074525|2018-06-01 00:07:15.074525
NCT01063556|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2013-05-13|2010-02-04|2010-02-05|Estimate|||||||2013-05-13|2013-05-14|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.|Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.|Completed||Phase 4|6|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 00:07:15.332088|2018-06-01 00:07:15.332088
NCT01063543|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|September 2004||2004-09-30|February 2010|2010-02-28|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Observational|POP-A-RIX||Pharmacokinetics of Fondaparinux in Patients With Major Orthopedic Surgery|Population Pharmacokinetics of Fondaparinux Administered at Prophylactic Doses After Major Orthopedic Surgery in Everyday Practice|Completed|||997|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     blood sample for anti-Xaactivity measure~   "|||2018-06-01 00:07:15.447404|2018-06-01 00:07:15.447404
NCT01063530|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Effects of DIammine SIlver Fluoride on Tooth Sensitivity|Effects of DIammine SIlver Fluoride Placed Over Cervical Lesions of Permanent Teeth to Reduce Tooth Sensitivity|Unknown status|Not yet recruiting|N/A|144|Anticipated|Universidad Peruana Cayetano Heredia||2|||f||||t||||||||||2018-06-01 00:07:15.522266|2018-06-01 00:07:15.522266
NCT01063517|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|2015-01-13|2013-07-12|2018-05-28|2010-02-04|2010-02-05|Estimate|2015-04-14|2015-04-30|Estimate|2013-07-12|2013-07-15|Estimate|2018-05-28|2018-05-30|Actual|February 2, 2010|Actual|2010-02-02|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|May 11, 2012|Actual|2012-05-11||Interventional|||Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients|A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy|Active, not recruiting||Phase 2|124|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:07:15.703498|2018-06-01 00:07:15.703498
NCT01063504|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2013-06-17|2010-02-04|2010-02-05|Estimate|||||||2013-06-17|2013-06-19|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Teriparatide for Improved Knee Prosthesis Fixation||Completed||Phase 2|60|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-06-01 00:07:16.887378|2018-06-01 00:07:16.887378
NCT01063309|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2018-03-27|2010-02-04|2010-02-05|Estimate|||||||2018-03-27|2018-03-29|Actual|December 11, 2009||2009-12-11|March 14, 2018|2018-03-14||||||||Observational|||Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System|Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System|Recruiting|||550|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:07:18.967981|2018-06-01 00:07:18.967981
NCT01063491|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2013-10-31|2010-02-04|2010-02-05|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|CABG-PRO||Cardiac CAtheterization for Bypass Graft Patency Rate Optimization: the CABG-PRO Randomized-controlled Pilot Study|Cardiac CAtheterization for Bypass Graft Patency Rate Optimization: the CABG-PRO Randomized-controlled Pilot Study|Unknown status|Active, not recruiting|Phase 3|170|Anticipated|North Texas Veterans Healthcare System||2|||f||||t||||||||||2018-06-01 00:07:17.057673|2018-06-01 00:07:17.057673
NCT01063478|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2014-01-16|2010-02-04|2010-02-05|Estimate|||||||2014-01-16|2014-01-17|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|RAD001||Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC|A Phase I Dose Escalation Study of RAD001 in Combination With Chemotherapy and Radiation in Patients With NSCLC|Terminated||Phase 1|3|Actual|University of Chicago||1||Poor accrual|f||||t||||||||||2018-06-01 00:07:17.164693|2018-06-01 00:07:17.164693
NCT01063465|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|February 2009||2009-02-28|January 2009|2009-01-31||||December 2010|Anticipated|2010-12-31||Interventional|||Measurement of Mechanical Properties of the Healing Achilles Tendon With or Without Early Weightbearing|Measurement of Mechanical Properties of the Healing Achilles Tendon With or Without Early Weightbearing in a Clinical Randomized Trial|Unknown status|Recruiting|N/A|35|Anticipated|Linkoeping University||2|||f||||f||||||||||2018-06-01 00:07:17.284929|2018-06-01 00:07:17.284929
NCT01063452|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-01-04|2010-02-04|2010-02-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2010||2010-02-28|January 2017|2017-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Impact of Atkinson Product Design Urinary Slide Valve Versus Standard Catheter Drainage System on Social Functioning|Impact of Atkinson Product Design Urinary Slide Valve Versus Standard Catheter Drainage System on Social Functioning|Withdrawn||Phase 4|0|Actual|The Cleveland Clinic||2||This trial was never initiated due to inability to obtain the device|f||||f||||||||||2018-06-01 00:07:17.508932|2018-06-01 00:07:17.508932
NCT01063439|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-12-01|2010-02-04|2010-02-05|Estimate|||||||2010-12-01|2010-12-02|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|February 2015|Anticipated|2015-02-28|August 2014|Anticipated|2014-08-31||Interventional|||BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)|Busulfan, Etoposide, Cytarabine and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With Diffuse Large B Cell Lymphoma (DLCBL) Previously Treated With Rituximab Based Regimen|Unknown status|Recruiting|Phase 2|42|Anticipated|Inje University||1|||f||||f||||||||||2018-06-01 00:07:17.596329|2018-06-01 00:07:17.596329
NCT01063426|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|Re-STOP DVT||Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users|Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|180|Anticipated|Hallym University Medical Center||2|||f||||f||||||||||2018-06-01 00:07:17.866829|2018-06-01 00:07:17.866829
NCT01063413|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-11-02|2010-02-04|2010-02-05|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2010||2010-02-28|January 2017|2017-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Physical Activity, Weight and Fitness Outcomes in Children in After-Care|Impact Analysis of Metro Parks' After-School Programming on Physical Activity, Weight and Fitness Outcomes|Completed|||97|Actual|Wake Forest University Health Sciences|||2||f||||t||||||||Yes|These data have been shared with researchers who have contacted the PI, Dr. Sabina Gesell at sgesell@wakehealth.edu.|2018-06-01 00:07:17.97023|2018-06-01 00:07:17.97023
NCT01063400|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-02-10|2010-02-04|2010-02-05|Estimate|||||||2012-02-10|2012-02-14|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors|OS09328 Feasibility Study: Comparison of Performance Status With Objective Physical Activity Monitors|Terminated|||6|Actual|University of Wisconsin, Madison|||1|lack of funding|f||||t||||||||||2018-06-01 00:07:18.073751|2018-06-01 00:07:18.073751
NCT01063387|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Prophylactic Irradiation of the Para-Aortic Lymph Nodes and Supraclavicular Lymph Nodes in Locally Advanced Uterine Cervical Cancer|Molecular Markers in Lymph Node Metastasis of Cervical Cancer and Prophylactic Irradiation of the Para-Aortic Lymph Nodes and Supraclavicular Lymph Nodes in Locally Advanced Uterine Cervical Cancer|Unknown status|Active, not recruiting|Phase 1|200|Anticipated|Huazhong University of Science and Technology||4|||f||||t||||||||||2018-06-01 00:07:18.183109|2018-06-01 00:07:18.183109
NCT01063374|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2016-09-12|2010-02-04|2010-02-05|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Low Glycemic Index Diet for Type 2 Diabetics|Low Glycemic Index Diets to Improve Glycemic Control and Cardiovascular Disease in Type 2 Diabetics|Completed||Phase 2|169|Actual|University of Toronto||2|||f||||t||||||||No||2018-06-01 00:07:18.257585|2018-06-01 00:07:18.257585
NCT01063361|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2015-12-07|2010-02-03|2010-02-05|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2011|Actual|2011-08-31||Interventional|||Low Glycemic Index Diets (With Pulses) in Type 2 Diabetes|Effect of Low Glycemic Index Diets (With Pulses) on Glucose Control in Non-Insulin Dependent Diabetics|Completed||Phase 2|131|Actual|University of Toronto||2|||f||||t||||||||||2018-06-01 00:07:18.408899|2018-06-01 00:07:18.408899
NCT01063348|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2016-04-19||2016-09-14|2010-02-04|2010-02-05|Estimate|2016-09-14|2016-10-31|Estimate||||2016-09-14|2016-10-31|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||N-Acetyl Cysteine in Pathologic Skin Picking|A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Pathologic Skin Picking|Completed||Phase 2|66|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 00:07:18.534853|2018-06-01 00:07:18.534853
NCT01063335|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2018-02-13|2010-02-04|2010-02-05|Estimate|||||||2018-02-13|2018-02-14|Actual|February 1, 2010||2010-02-01|September 20, 2012|2012-09-20|September 20, 2012||2012-09-20|||||Observational|||Imaging Cannabinoid CB1 Receptors in Schizophrenia|Imaging Cannabinoid CB1 Receptors in Schizophrenia|Terminated|||1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:07:18.820728|2018-06-01 00:07:18.820728
NCT01063322|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2018-05-24|2010-02-04|2010-02-05|Estimate|||||||2018-05-24|2018-05-25|Actual|February 1, 2010||2010-02-01|April 11, 2018|2018-04-11|April 11, 2018||2018-04-11|||||Observational|||New Techniques to Evaluate Mitral Regurgitation|New Techniques to Evaluate Mitral Regurgitation|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:07:18.895033|2018-06-01 00:07:18.895033
NCT01063296|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2010-02-08|2010-02-04|2010-02-05|Estimate|||||||2010-02-08|2010-02-09|Estimate|March 2010||2010-03-31|January 2010|2010-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Effects of Chemotherapy on Circulating Tumor Cells and Recurrences in Cervical Cancer Patients|Effects of Chemotherapy on Circulating Tumor Cells and Recurrences in IB-IIA Cervical Cancer Patients With Intermediate Risk Factors After Radical Surgery|Unknown status|Not yet recruiting||400|Anticipated|Huazhong University of Science and Technology|||||f||||t||||||Samples With DNA|"~     sampling of peripheral blood~   "|||2018-06-01 00:07:19.098214|2018-06-01 00:07:19.098214
NCT01063283|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-05-30|2010-02-04|2010-02-05|Estimate|||||||2017-05-30|2017-06-01|Actual|March 2010||2010-03-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|AVF4759||Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC|A Randomized, Open-Label, Dose Escalation Study of Bevacizumab With Ambulatory Blood Pressure Monitoring in Previously Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer|Completed||N/A|70|Anticipated|University of Chicago||2|||f||||t||||||||||2018-06-01 00:07:19.209977|2018-06-01 00:07:19.209977
NCT01063270|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2013-03-27|2010-02-04|2010-02-05|Estimate|||||||2013-03-27|2013-03-29|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|July 2011|Actual|2011-07-31||Interventional|||Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa|Randomized Control Trial Comparing Efficacy of Antibiotic Therapy Alone Versus Antibiotic Therapy in Conjunction With Quadruple Pulse Therapy Using NdYag Laser in Treatment of Hidradenitis Suppurativa|Unknown status|Active, not recruiting|N/A|18|Actual|Henry Ford Health System||2|||f||||t||||||||||2018-06-01 00:07:19.386331|2018-06-01 00:07:19.386331
NCT01063257|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2014-03-18|2010-02-04|2010-02-05|Estimate|||||||2014-03-18|2014-03-19|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Clofarabine in High Risk Myelodysplastic Syndrome (MDS)|A Phase I/II Multicenter Study of IV Clofarabine in Patients With High-Risk Myelodysplastic Syndrome Who Have Failed Therapy With Azacitidine: the NIDEVOL Study|Completed||Phase 1/Phase 2|76|Actual|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||||2018-06-01 00:07:19.54056|2018-06-01 00:07:19.54056
NCT01063244|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2016-04-14|2010-02-04|2010-02-05|Estimate|||||||2016-04-14|2016-04-18|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Foley Balloon With or Without Traction for the Cervical Ripening|Comparison of Foley Balloon With or Without Traction for the Cervical Ripening|Completed||Phase 3|65|Actual|St. Luke's Hospital, Pennsylvania||2|||f||||t||||||||No||2018-06-01 00:07:19.641769|2018-06-01 00:07:19.641769
NCT01063231|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2010-11-25|2010-02-04|2010-02-05|Estimate|||||||2010-11-25|2010-11-29|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Evaluation of PillCam™ Colon 2 in Visualization of the Colon|Evaluation of PillCam™ Colon 2 in Visualization of the Colon|Completed||Phase 3|119|Actual|Given Imaging Ltd.||1|||f||||f||||||||||2018-06-01 00:07:19.727047|2018-06-01 00:07:19.727047
NCT01063218|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2012-03-09|2010-02-04|2010-02-05|Estimate|||||||2012-03-09|2012-03-12|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application|Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application|Completed||Phase 4|74|Anticipated|Galderma Brasil Ltda.||1|||f||||f||||||||||2018-06-01 00:07:19.945467|2018-06-01 00:07:19.945467
NCT01063205|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-07-25|2010-02-03|2010-02-05|Estimate|||||||2012-07-25|2012-07-27|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||NAC as a Potential Treatment for Methamphetamine Dependence|N-AcetylCysteine as a Potential Treatment of Methamphetamine Dependence|Completed||Phase 1|10|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 00:07:20.010947|2018-06-01 00:07:20.010947
NCT01063192|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2010-02-04|2010-02-04|2010-02-05|Estimate|||||||2010-02-04|2010-02-05|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|September 2016|Anticipated|2016-09-30|September 2013|Anticipated|2013-09-30||Interventional|||A Study of Locally Advanced Pancreatic Cancer|A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer|Unknown status|Enrolling by invitation|Phase 2|73|Anticipated|National Health Research Institutes, Taiwan||2|||f||||t||||||||||2018-06-01 00:07:20.112227|2018-06-01 00:07:20.112227
NCT01063179|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2017-09-05|2010-02-04|2010-02-05|Estimate|||||||2017-09-05|2017-09-06|Actual|May 2006||2006-05-31|September 2017|2017-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients|A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS|Completed||Phase 3|511|Actual|Fondazione Neoplasie Sangue Onlus||2|||f||||t||||||||||2018-06-01 00:07:20.185107|2018-06-01 00:07:20.185107
NCT01063166|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2016-01-20|2010-02-04|2010-02-05|Estimate|||||||2016-01-20|2016-01-21|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|March 2012|Actual|2012-03-31||Observational|||Prospective Assessment of Adolescent Drinking Trajectories With Computer-Assisted Self-administration of Ethanol (CASE)|Collaboration on Alcohol Self Administration in Adolescents and Young Adults - Specific Aim 1: Assess the Initial Slope of Adolescent Drinking Trajectories, Beginning at the Age of Eighteen|Completed|||96|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 00:07:20.259364|2018-06-01 00:07:20.259364
NCT01063153|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2013-06-12||2017-03-30|2010-02-04|2010-02-05|Estimate|2013-10-21|2013-12-09|Estimate||||2017-03-30|2017-05-03|Actual|September 2009||2009-09-30|March 2017|2017-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials|Diagnostic Utility of ADHD by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials|Completed||Phase 4|71|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 00:07:20.368349|2018-06-01 00:07:20.368349
NCT01063140|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2015-09-03|2010-02-04|2010-02-05|Estimate|||||||2015-09-03|2015-09-07|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Rabies Immune Plasma Booster Study|Rabies Immune Plasma Booster Program - A Clinical Study Conducted as an Investigational New Drug Study|Completed|||491|Actual|CSL Behring|||2||f||||||||||||||2018-06-01 00:07:21.024693|2018-06-01 00:07:21.024693
NCT01062776|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-08-18|2010-02-03|2010-02-04|Estimate|||||||2010-08-18|2010-08-19|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Kinetic Method to Detect Dehydration|New Method to Detect Dehydration|Completed||Phase 1|10|Actual|Sodertalje Hospital||4|||f||||f||||||||||2018-06-01 00:07:26.817319|2018-06-01 00:07:26.817319
NCT01063127|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-02-14|2010-02-04|2010-02-05|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Observational|||A Longitudinal Study on Short-term Effects of Gastric Bypass on Glucose Homeostasis in Obesity|A Longitudinal, Open-label Study on the Short-term Effects of Roux-en-Y Gastric Bypass Surgery vs. Gastric Banding on Glucose Homeostasis in Obese Subjects|Completed|||23|Actual|Catholic University of the Sacred Heart|||2||f||||f||||||None Retained|"~     Blood sampling~   "|||2018-06-01 00:07:21.181757|2018-06-01 00:07:21.181757
NCT01063114|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2018-05-03|2010-02-03|2010-02-05|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2010|Actual|2010-04-30|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma|Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma: An Assessment of Acute Toxicity and Long Term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes|Active, not recruiting||N/A|90|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:07:21.262821|2018-06-01 00:07:21.262821
NCT01063101|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2018-01-23|2010-02-04|2010-02-05|Estimate|||||||2018-01-23|2018-01-25|Actual|January 29, 2010|Actual|2010-01-29|January 2018|2018-01-31|August 1, 2010|Actual|2010-08-01|July 22, 2010|Actual|2010-07-22||Interventional|||Phase 1 Dosing Study of BAX 513 in Healthy Volunteers|A Phase 1 Study to Evaluate the Effects of BAX 513 on Hemostatic Parameters in Healthy Volunteers|Completed||Phase 1|30|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:07:21.338405|2018-06-01 00:07:21.338405
NCT01063088|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2015-10-07|2010-02-04|2010-02-05|Estimate|||||||2015-10-07|2015-10-09|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine|An Open Label, Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population|Completed||Phase 3|211|Actual|Ology Bioservices||1|||f||||f||||||||||2018-06-01 00:07:21.410164|2018-06-01 00:07:21.410164
NCT01063075|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2016-05-09||2016-07-15|2010-02-03|2010-02-05|Estimate|2016-05-09|2016-06-15|Estimate||||2016-07-15|2016-08-15|Estimate|June 2010||2010-06-30|July 2016|2016-07-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional||All participants who received at least one dose of study drug.|A Study in Advanced Solid Tumors|Phase 2 Study to Evaluate the Pharmacokinetics and Drug-Drug Interaction of Cetuximab and Carboplatin in Patients With Advanced Solid Tumors|Completed||Phase 2|34|Actual|Eli Lilly and Company|Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin(C) arm only. After protocol amendment February 2014, any newly enrolled participants were placed into Group D arm only.|4|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 00:07:21.529978|2018-06-01 00:07:21.529978
NCT01063062|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2014-07-08||2017-07-17|2010-02-03|2010-02-05|Estimate|2014-07-08|2014-08-04|Estimate||||2017-07-17|2017-08-21|Actual|February 28, 2010|Actual|2010-02-28|July 2017|2017-07-31|January 17, 2011|Actual|2011-01-17|January 17, 2011|Actual|2011-01-17||Interventional|||A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)|A Single-arm, Open-label, Multicenter Study of Tocilizumab Monotherapy or in Combination With Methotrexate to Assess Safety and the Efficacy in Reducing Disease Activity in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs (PICTURE)|Completed||Phase 3|107|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:07:22.662803|2018-06-01 00:07:22.662803
NCT01063049|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2013-08-20||2013-11-15|2010-02-04|2010-02-05|Estimate|2013-11-15|2013-11-18|Estimate||||2013-11-15|2013-11-18|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation|Gatorade/Miralax With or Without Bisacodyl vs NuLytely for Colonoscopy Preparation|Completed||Phase 4|600|Actual|Gastroenterology Services, Ltd.|Both the BBPS and OPS suffer from poorly designed scoring systems that are not easily converted into the poor/fair/good/excellent subjective rating scale, which is often used by gastroenterologists in their colonoscopy reports.|3|||f||||t||||||||||2018-06-01 00:07:23.659202|2018-06-01 00:07:23.659202
NCT01063036|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2013-11-05||2014-11-25|2010-02-04|2010-02-05|Estimate|2013-12-30|2014-02-13|Estimate||||2014-11-25|2014-12-15|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|November 2012|Actual|2012-11-30||Interventional||All participants who were treated with study drug.|Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment|A Study of the Safety and Efficacy of Entecavir Plus Tenofovir in Adults With Chronic Hepatitis B Virus Infection With Previous Nucleoside/Nucleotide Treatment Failure|Completed||Phase 3|144|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:07:24.034697|2018-06-01 00:07:24.034697
NCT01063023|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-01-24|2010-02-03|2010-02-05|Estimate|||||||2011-01-24|2011-01-25|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Drug Interaction Oral Contraceptive Pill (OCP)|Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:07:24.517203|2018-06-01 00:07:24.517203
NCT01063010|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-03-14|2010-02-04|2010-02-05|Estimate|||||||2017-03-14|2017-03-16|Actual|February 2010||2010-02-28|March 2017|2017-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock|Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center||2||no participants enrolled|f||||t||||||||||2018-06-01 00:07:24.595528|2018-06-01 00:07:24.595528
NCT01062997|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-04|||2016-08-06|2010-02-04|2010-02-05|Estimate|||||||2016-08-06|2016-08-09|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|||Volar Locked Plating Versus Bridging External Fixation|Volar Locked Plating Versus Bridging External Fixation|Completed|||166|Actual|University Hospital, Akershus|||||f||||||||||||||2018-06-01 00:07:24.688052|2018-06-01 00:07:24.688052
NCT01062984|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2016-10-24|2010-02-03|2010-02-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2015|Actual|2015-09-30||Interventional|||Continuous Venovenous Hemofiltration Versus Continuous Venovenuous Hemodialysis|A Comparison of the Efficacy of Continuous Venovenous Hemofiltration Versus Continuous Venovenous Hemodialysis for Renal Replacement Therapy in Acute Kidney Injury|Active, not recruiting||N/A|20|Anticipated|University of Chicago||2|||f||||f||||||||||2018-06-01 00:07:24.764956|2018-06-01 00:07:24.764956
NCT01062971|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2018-04-27|2010-02-03|2010-02-04|Estimate|||||||2018-04-27|2018-05-01|Actual|February 2006||2006-02-28|April 2018|2018-04-30|June 2008|Actual|2008-06-30|August 2007|Actual|2007-08-31||Interventional|||Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide|Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination of Timolol-Brimonidine-Dorzolamide In Patients With Open Angle Glaucoma Or Ocular Hypertension|Completed||Phase 2|100|Actual|Laboratorios Sophia S.A de C.V.||2|||f||||t||||||||||2018-06-01 00:07:24.843619|2018-06-01 00:07:24.843619
NCT01062958|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2013-04-12|2010-02-03|2010-02-04|Estimate|||||||2013-04-12|2013-04-16|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||A Retrospective Analysis of Neevo®/Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy|A Retrospective Analysis of Neevo® and Neevo®DHA Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy (N-001)|Completed|||100|Actual|Pamlab, Inc.|||2||f||||f||||||||||2018-06-01 00:07:24.927857|2018-06-01 00:07:24.927857
NCT01062945|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-07-25|2010-02-03|2010-02-04|Estimate|||||||2012-07-25|2012-07-27|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine|The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine|Completed||Phase 1|13|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 00:07:25.020327|2018-06-01 00:07:25.020327
NCT01062932|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-07-25|2010-02-03|2010-02-04|Estimate|||||||2012-07-25|2012-07-27|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Investigation of Cycloserine as a Smoking Cessation Treatment|Cycloserine Enhancement of Extinction Learning|Completed||Phase 1|34|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 00:07:25.100236|2018-06-01 00:07:25.100236
NCT01062919|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2015-08-03|2010-02-03|2010-02-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Local Anesthetic Wound Infusion and Functional Recovery After Colon Surgery|Postoperative Determinants of Functional Recovery Following Colon Surgery: The Effect of Wound Infiltration With Local Anesthetics|Terminated||N/A|10|Actual|McGill University Health Center||2||Low recruitment rate - >70% of colorectal procedures are done laparoscopically|f||||t||||||||||2018-06-01 00:07:25.172203|2018-06-01 00:07:25.172203
NCT01062906|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-01-12|2010-02-03|2010-02-04|Estimate|||||||2011-01-12|2011-01-13|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Intravenous Lidocaine for Laparoscopic Cholecystectomy|The Effect of Intravenous Lidocaine on Short-term Outcomes After Laparoscopic Cholecystectomy|Completed||N/A|80|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-06-01 00:07:25.251132|2018-06-01 00:07:25.251132
NCT01062893|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2017-11-06|2010-02-03|2010-02-04|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2009||2009-08-31|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Combined Spinal/Epidural (CSE) Saline Duration/Spread|Effect of Epidural Saline on Duration and Spread of Subsequent Spinal Analgesia/Anesthesia Using a CSE Technique|Terminated||N/A|60|Actual|Wake Forest University Health Sciences||2||lack of subjects and manpower issues|f||||t||||||||||2018-06-01 00:07:25.332722|2018-06-01 00:07:25.332722
NCT01062880|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|February 2010||2010-02-28|October 2009|2009-10-31|May 2012|Anticipated|2012-05-31|May 2011|Anticipated|2011-05-31||Interventional|Neuropattern||Neuropattern - Assessment of a Translational Diagnostic Tool for Depression, Adjustment- and Somatoform-disorders|Neuropattern - Clinical Trial of a Psychobiological Stress Diagnostic Tool (Neuropattern - Erprobung Einer Psychobiologischen Stressdiagnostik)|Unknown status|Recruiting|N/A|2000|Anticipated|University of Trier|||||f||||t||||||||||2018-06-01 00:07:25.581536|2018-06-01 00:07:25.581536
NCT01062867|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|January 2000||2000-01-31|January 2010|2010-01-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||First Administration to Man Of Org 25435 a New Intravenous Anesthetic|First Administration to Man Of Org 25435 a New Intravenous Anesthetic|Completed||Phase 1|26|Actual|University of Plymouth||1|||f||||f||||||||||2018-06-01 00:07:25.653598|2018-06-01 00:07:25.653598
NCT01062854|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2016-12-03|2010-02-03|2010-02-04|Estimate|||||||2016-12-03|2016-12-06|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Earplugs on Sleep and Sleep Apnea|Effects of Earplugs on Sleep and Sleep Apnea|Completed||N/A|407|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:07:25.744219|2018-06-01 00:07:25.744219
NCT01062841|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2015-11-30||2016-08-05|2010-02-03|2010-02-04|Estimate|2016-08-05|2016-09-29|Estimate||||2016-08-05|2016-09-29|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Residents enrolled with >1 follow-up visit|Targeted Infection Control in Long-term Care|Targeted Infection Control Program (TIP) to Reduce Resistant Pathogens and Infections|Completed||N/A|418|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:07:25.873319|2018-06-01 00:07:25.873319
NCT01062828|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-08-24|2010-02-03|2010-02-04|Estimate|||||||2017-08-24|2017-08-28|Actual|July 2009||2009-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants|Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants|Terminated|||60|Actual|University of Miami|||1|Terminated: participants are no longer being enrolled|f||||f||||||||No||2018-06-01 00:07:26.511772|2018-06-01 00:07:26.511772
NCT01062815|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2015-11-20|2010-02-03|2010-02-04|Estimate|||||||2015-11-20|2015-11-23|Estimate|February 2009||2009-02-28|November 2015|2015-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants|Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants|Terminated||N/A|48|Actual|University of Miami||2||Difficulty in recruiting patients|f||||f||||||||||2018-06-01 00:07:26.577568|2018-06-01 00:07:26.577568
NCT01062802|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Statin Use in Abdominal Aortic Aneurysm Repair|Randomised Controlled Trial of Effect of Pre-operative Statin Use on Matrix Metalloproteinases (MMP) & Tissue Inhibitors of Matrix Metalloproteinases (TIMP) in Abdominal Aortic Aneurysm (AAA).|Completed||Phase 4|40|Actual|University of Hull||2|||f||||||||||||||2018-06-01 00:07:26.65284|2018-06-01 00:07:26.65284
NCT01062789|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-05-16|2010-02-03|2010-02-04|Estimate|||||||2011-05-16|2011-05-17|Estimate|February 2010||2010-02-28|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|OBC||Optical Breath-hold Control System for Image-guided Procedures|Use of an Optical Breath-hold Control (OBC) System for Image-guided Interventional Radiology Procedures: A Feasibility Study|Withdrawn||Early Phase 1|0|Actual|Mayo Clinic||1||Closed due to funding and never enrolled a subject|f||||f||||||||||2018-06-01 00:07:26.721839|2018-06-01 00:07:26.721839
NCT01062763|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2013-06-27||2014-04-08|2010-02-03|2010-02-04|Estimate|2014-04-08|2014-05-08|Estimate||||2014-04-08|2014-05-08|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|SDHDS||The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension|South Danish Hypertension and Diabetes Study|Completed||Phase 3|119|Actual|Odense University Hospital||2|||f||||f||||||||||2018-06-01 00:07:26.902471|2018-06-01 00:07:26.902471
NCT01062750|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2015-09-04|2010-02-03|2010-02-04|Estimate|||||||2015-09-04|2015-09-07|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells|Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells|Completed||N/A|4|Actual|Kanazawa University||1|||f||||f||||||||||2018-06-01 00:07:27.138993|2018-06-01 00:07:27.138993
NCT01062737|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|December 1999||1999-12-31|February 2010|2010-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|ERADIAS||Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis|Evaluation of the Structure-modifying Effect and Safety of Avocado-Soybean Unsaponifiable (Piascledine 300) in Hip Osteoarthritis (OA) a 3 Years Multicenter Randomized, Double Blind, Placebo Controlled Trial|Completed||Phase 3|||Laboratoires Expanscience S.A.||1|||f||||f||||||||||2018-06-01 00:07:27.201796|2018-06-01 00:07:27.201796
NCT01062724|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-06-08|2010-02-03|2010-02-04|Estimate|||||||2017-06-08|2017-06-09|Actual|May 2011|Actual|2011-05-31|February 2016|2016-02-29|July 2016|Actual|2016-07-31|November 2015|Actual|2015-11-30||Interventional|TPNAC||Total Parenteral Nutrition Associated Cholestasis (TPNAC) and Plasma Amino Acid Levels in Neonates|Effect of Two Amino Acid Solutions on Blood Amino Acid Levels and Frequency of Cholestasis in Neonates|Terminated||Phase 3|94|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||Undecided||2018-06-01 00:07:27.263327|2018-06-01 00:07:27.263327
NCT01062711|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-07-19|2010-02-03|2010-02-04|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|NDC||Dose Response of Whey and Soy Protein Ingestion With and Without Resistance Exercise in Elderly Men|Responses of Muscle and Whole-body Protein Turnover to Ingestion of Differing Doses of Whey and Soy Protein With and Without Resistance Exercise in Elderly Men|Completed||N/A|81|Anticipated|McMaster University||7|||f||||f||||||||||2018-06-01 00:07:27.38129|2018-06-01 00:07:27.38129
NCT01062698|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-07-20|2010-02-03|2010-02-04|Estimate|||||||2017-07-20|2017-07-21|Actual|June 2010||2010-06-30|July 2017|2017-07-31|March 2016||2016-03-31|December 2015||2015-12-31||Interventional|THRACE||Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke|The Contribution of Intra-arterial Thrombectomy in Acute Ischemic Stroke in Patients Treated With Intravenous Thrombolysis|Terminated||N/A|412|Actual|Central Hospital, Nancy, France||2||Efficacy|f||||||||||||||2018-06-01 00:07:27.459535|2018-06-01 00:07:27.459535
NCT01062685|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-04-25|2010-02-03|2010-02-04|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2009|Actual|2009-01-31|April 2017|2017-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|St02||Near Infrared Spectroscopy (St02)|Near Infrared Spectroscopy (NIRS) to Measure Tissue Oxygen Saturation (St02)|Completed|||186|Actual|Beth Israel Deaconess Medical Center|||3||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum~   "|Undecided||2018-06-01 00:07:27.534002|2018-06-01 00:07:27.534002
NCT01062672|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2016-01-26|2010-02-03|2010-02-04|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Functional Neuroimaging of Cortical Plasticity in the Human Visual System|Functional Neuroimaging of Cortical Plasticity in the Human Visual System|Unknown status|Recruiting||200|Anticipated|Baylor College of Medicine|||||f||||f||||||||||2018-06-01 00:07:27.605269|2018-06-01 00:07:27.605269
NCT01062659|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2014-03-31|2010-02-03|2010-02-04|Estimate|||||||2014-03-31|2014-04-01|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Observational|||Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients|Characterization of Cellular Immune Responses in the Liver in Patients With Chronic Hepatitis C Virus Infection|Withdrawn|||0|Actual|University of Ulm|||1|Lack of funding|f||||f||||||||||2018-06-01 00:07:27.658873|2018-06-01 00:07:27.658873
NCT01062646|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|||Multimodal Music Therapy for Children With Anxiety Disorders|A Randomized Controlled Trial of Multimodal Music Therapy for Children With Anxiety Disorders|Completed||Phase 3|36|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 00:07:27.707669|2018-06-01 00:07:27.707669
NCT01062633|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|November 2011|Anticipated|2011-11-30|February 2011|Anticipated|2011-02-28||Interventional|||Effect of Erythritol and Xylitol on Dental Caries Prevention in Children|Effect of Erythritol and Xylitol on Dental Caries Prevention in Children|Unknown status|Recruiting|Phase 2/Phase 3|450|Anticipated|University of Tartu||3|||f||||t||||||||||2018-06-01 00:07:27.759505|2018-06-01 00:07:27.759505
NCT01062620|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-09-14|2010-02-03|2010-02-04|Estimate|||||||2011-09-14|2011-09-15|Estimate|April 2008||2008-04-30|September 2011|2011-09-30||||May 2011|Actual|2011-05-31||Interventional|||A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer|A Dose Escalating Phase Ia-b Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer: A Prospective, Single Armed, Open Label, Dose-finding Phase Ia-b Study|Completed||Phase 1|49|Actual|Axelar AB||1|||f||||t||||||||||2018-06-01 00:07:27.845777|2018-06-01 00:07:27.845777
NCT01062607|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2012-05-22|2010-02-03|2010-02-04|Estimate|||||||2012-05-22|2012-05-23|Estimate|April 2010||2010-04-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|WAVE bd||Study of the Clinical Management of Bipolar Disease|Multinational Ambispective Study of the Clinical Management and Burden of Bipolar Disorder (WAVE bd Study)|Completed|||2965|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 00:07:27.917271|2018-06-01 00:07:27.917271
NCT01062594|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2014-12-03|2010-02-03|2010-02-04|Estimate|||||||2014-12-03|2014-12-04|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Pre-operative Exercise in Abdominal Aortic Aneurysms (AAA) Patients.|A Randomised Controlled Trial to Assess the Effect of a Pre-operative Supervised Exercise Programme on Outcome Following Intervention for Abdominal Aortic Aneurysms.|Completed||N/A|124|Actual|University of Hull||2|||f||||t||||||||||2018-06-01 00:07:28.466961|2018-06-01 00:07:28.466961
NCT01062581|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2018-02-12|2010-02-03|2010-02-04|Estimate|||||||2018-02-12|2018-02-13|Actual|March 1997||1997-03-31|February 2018|2018-02-28|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31||Observational|||University of Minnesota Transplant Registry|University of Minnesota Transplant Registry|Recruiting|||10000|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t||||||||||2018-06-01 00:07:28.547567|2018-06-01 00:07:28.547567
NCT01062568|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2014-12-09|2010-02-03|2010-02-04|Estimate|||||||2014-12-09|2014-12-11|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Adrenal Contribution to Androgen Production in Girls During Puberty|The Adrenal Contribution to Androgen Production in Girls During Puberty|Completed||Phase 3|24|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 00:07:28.619935|2018-06-01 00:07:28.619935
NCT01062555|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2018-02-12|2010-02-03|2010-02-04|Estimate|||||||2018-02-12|2018-02-13|Actual|October 2006||2006-10-31|February 2018|2018-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CNI-Sparing||Calcineurin Inhibitor Sparing After Kidney Transplantation|Calcineurin-Sparing in a Steroid-free Maintenance Immunosuppression Protocol After Kidney Transplantation|Completed||Phase 1/Phase 2|527|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t||||||||||2018-06-01 00:07:28.70999|2018-06-01 00:07:28.70999
NCT01062542|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2017-09-19|2010-02-03|2010-02-04|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2008||2008-09-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Assessment of Ovarian Reserve in Female Cancer Survivors|Fertility in Female Cancer Survivors - Novel Assessment of Ovarian Reserve|Active, not recruiting|||210|Anticipated|University Health Network, Toronto|||3||f||||f||||||||||2018-06-01 00:07:28.812391|2018-06-01 00:07:28.812391
NCT01062529|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2013-01-18|2010-02-03|2010-02-04|Estimate|||||||2013-01-18|2013-01-21|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Peripheral Metabolic Effects of Somatostatin|Peripheral Metabolic Effects of Intra Arterial Somatostatin Infusion in Healthy Controls|Completed||N/A|8|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 00:07:28.89449|2018-06-01 00:07:28.89449
NCT01062516|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-10-02|2010-02-03|2010-02-04|Estimate|||||||2010-10-02|2010-10-05|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin|Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin|Completed||Phase 4|100|Anticipated|Ruttonjee Hospital||2|||f||||t||||||||||2018-06-01 00:07:28.993859|2018-06-01 00:07:28.993859
NCT01062503|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2015-04-24|2010-02-03|2010-02-04|Estimate|||||||2015-04-24|2015-04-27|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|SubDueP||Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC|Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer|Completed|||48|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 00:07:29.06641|2018-06-01 00:07:29.06641
NCT01062490|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|November 2004||2004-11-30|February 2010|2010-02-28|October 2009|Actual|2009-10-31|July 2008|Actual|2008-07-31||Interventional|||Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)|Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS)|Completed||Phase 2|45|Actual|medac GmbH||1|||f||||f||||||||||2018-06-01 00:07:29.126815|2018-06-01 00:07:29.126815
NCT01062477|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-12-12|2010-02-03|2010-02-04|Estimate|||||||2011-12-12|2011-12-13|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants|Safety and Immunogenicity of the Sanofi Pasteur's DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Hib Conjugate (Act-HIB) Monovalent Vaccine as a Three-dose Primary and Booster Vaccination in Healthy Infants in China|Completed||Phase 3|1056|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 00:07:29.197142|2018-06-01 00:07:29.197142
NCT01062464|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-06-13|2010-02-03|2010-02-04|Estimate|||||||2012-06-13|2012-06-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:07:29.272824|2018-06-01 00:07:29.272824
NCT01062451|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-07-11|2010-02-03|2010-02-04|Estimate|||||||2017-07-11|2017-07-12|Actual|May 2009||2009-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence|An ACE Inhibitor or an Angiotensin Receptor Blocker as a Treatment for Methamphetamine Dependence|Active, not recruiting||Phase 1|80|Anticipated|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 00:07:29.305057|2018-06-01 00:07:29.305057
NCT01062438|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2015-05-05|2010-02-03|2010-02-04|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma|Genomic Study of Metastatic Osteosarcoma Using Next-Generation Sequencing Technology|Completed|||99|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tumor Tissue~   "|||2018-06-01 00:07:29.377507|2018-06-01 00:07:29.377507
NCT01062425|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2016-07-28||2018-05-23|2010-02-03|2010-02-04|Estimate|2016-07-28|2016-09-19|Estimate||||2018-05-23|2018-05-24|Actual|February 26, 2010|Actual|2010-02-26|May 2018|2018-05-31||||December 6, 2015|Actual|2015-12-06||Interventional||All randomized and eligible patients.|Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma|Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients With Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 2|261|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 00:07:29.478198|2018-06-01 00:07:29.478198
NCT01062412|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:07:30.338174|2018-06-01 00:07:30.338174
NCT01062399|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2017-11-13||2017-12-19|2010-02-03|2010-02-04|Estimate|2017-12-19|2018-01-23|Actual||||2017-12-19|2018-01-23|Actual|December 2010||2010-12-31|December 2017|2017-12-31||||June 2016|Actual|2016-06-30||Interventional|RTOG 0913|Eligible randomized patients|Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1/Phase 2|279|Actual|Radiation Therapy Oncology Group||5|||f||||t||||||||||2018-06-01 00:07:30.40276|2018-06-01 00:07:30.40276
NCT01062048|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2016-02-03|2010-02-02|2010-02-04|Estimate|||||||2016-02-03|2016-02-05|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Januvia Re-examination Study (MK-0431-181)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of Januvia in Usual Practice|Completed|||3483|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:07:37.010879|2018-06-01 00:07:37.010879
NCT01062386|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2011-08-11|2010-02-03|2010-02-04|Estimate|||||||2011-08-11|2011-08-12|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Observational|||Malaria Survey in Mbarara District, Uganda 2010|The Epidemiology of Malaria Among Children Under Five in Mbarara District, Uganda - A Cross-sectional Population-based Survey 2010|Completed|||2320|Actual|Epicentre|||||f||||f||||||Samples With DNA|"~     Blood sample for:~      Malaria rapid diagnostic test, Malaria Blood smear, Malaria PCR, Anopheles mosquitoes~     anti-saliva antibodies~   "|||2018-06-01 00:07:32.71788|2018-06-01 00:07:32.71788
NCT01062373|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2012-09-26|2010-02-03|2010-02-04|Estimate|||||||2012-09-26|2012-09-27|Estimate|February 2010||2010-02-28|January 2012|2012-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|DHARMA||Effect of Docosahexaenoic Acid (DHA)-Enriched Human Milk in Premature Newborns|Improvement of Polyunsaturated Fatty Acids Status in Premature Newborns Following Docosahexaenoic Acid Enrichment of Human Milk|Terminated||N/A|2|Actual|Institut National de la Santé Et de la Recherche Médicale, France||3||difficulties of recruitement|f||||t||||||||||2018-06-01 00:07:32.777872|2018-06-01 00:07:32.777872
NCT01062360|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2017-08-31|2010-02-03|2010-02-04|Estimate|||||||2017-08-31|2017-09-01|Actual|December 23, 2005|Actual|2005-12-23|August 2017|2017-08-31|May 14, 2007|Actual|2007-05-14|May 14, 2007|Actual|2007-05-14||Interventional|||Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine|A Pivotal, Placebo Controlled, Phase III Study to Compare Efficacy and Tolerability of a Fixed Combination, Containing 500 mg ASA and 30 mg Pseudoephedrine, in Comparison to Its Single Components in Patients With Sore Throat and Nasal Congestion|Completed||Phase 3|1016|Actual|Bayer||4|||f||||f||||||||||2018-06-01 00:07:32.866705|2018-06-01 00:07:32.866705
NCT01062347|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2017-06-06|2010-02-03|2010-02-04|Estimate|||||||2017-06-06|2017-06-07|Actual|July 1, 2007|Actual|2007-07-01|February 2010|2010-02-28|December 31, 2010|Actual|2010-12-31|December 31, 2010|Actual|2010-12-31||Interventional|||A Novel Bio-marker of Zinc Status|Exploring the Possibility of Using Intestinal mRNA Levels of Zinc Transporter Genes, and Changes in Their Expression Levels in Response to Zinc Supplementation as a Bio-marker for Zinc Status|Completed||Phase 1|||International Centre for Diarrhoeal Disease Research, Bangladesh||1|||f||||||||||||||2018-06-01 00:07:33.053003|2018-06-01 00:07:33.053003
NCT01062334|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2014-02-04|2010-02-03|2010-02-04|Estimate|||||||2014-02-04|2014-02-05|Estimate|March 2010||2010-03-31|February 2014|2014-02-28||||March 2015|Anticipated|2015-03-31||Interventional|||Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer|Intraperitoneal Microdialysis Monitoring of Patients During the Early Postoperative Period After LAR With Reference to Early Diagnosis of Anastomotic Leakage Ore Other Complications|Unknown status|Recruiting|N/A|150|Anticipated|Odense University Hospital||1|||f||||||||||||||2018-06-01 00:07:33.117481|2018-06-01 00:07:33.117481
NCT01062321|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2015-04-10|2010-02-03|2010-02-04|Estimate|||||||2015-04-10|2015-04-13|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Role of Cytokines in Hepatitis E Virus Infection During Pregnancy|Role of Cytokines in Hepatitis E Virus Infection During Pregnancy|Completed|||491|Actual|Maulana Azad Medical College|||1||f||||f||||||||||2018-06-01 00:07:33.185026|2018-06-01 00:07:33.185026
NCT01062308|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|2012-06-18||2013-03-07|2010-02-03|2010-02-04|Estimate|2013-01-31|2013-03-07|Estimate||||2013-03-07|2013-03-12|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|STRIPS||STRIPS: Shoulder Taping Reduces Injury and Pain in Stroke|The Effectiveness of Taping Technique Versus Conventional Techniques in Prevention of Shoulder Injuries in Patients With Acute Stroke-A Prospective, Randomized, Interventional, Outcome Blinded (PROBE Design), Parallel Design Trial|Completed||Phase 3|162|Actual|Christian Medical College and Hospital, Ludhiana, India|Follow up period was short. Secondly, X rays of the shoulder were not done to document other shoulder injuries.|2|||f||||t||||||||||2018-06-01 00:07:33.267978|2018-06-01 00:07:33.267978
NCT01062295|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of the Device Siesta-SystemTM for Inducing Objective Sleep and re Rest|Efficacy and Safety of the Device Siesta-SystemTM for Inducing Objective Sleep and re Rest.|Completed||N/A|40|Actual|Basque Health Service||2|||f||||f||||||||||2018-06-01 00:07:33.573675|2018-06-01 00:07:33.573675
NCT01062282|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2011-04-01|2010-02-03|2010-02-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|July 2006||2006-07-31|April 2011|2011-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)|VENIS - Prospective Observational Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension|Completed|||41|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 00:07:33.684375|2018-06-01 00:07:33.684375
NCT01062269|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2010-05-18||2011-07-01|2010-02-03|2010-02-04|Estimate|2010-07-14|2010-08-10|Estimate||||2011-07-01|2011-07-12|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study|A Randomized Single Blind Placebo Controlled Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study in Generally Healthy Subjects|Completed||Phase 4|42|Actual|Louisville Metabolic and Atherosclerosis Research Center|(1)It was performed in generally healthy subjects, for whom lipid-altering medication may not be indicated.(2)The subjects’ preference or dislike of the 1st or 2nd powder mixture might have influenced their ratings of the 2nd or 3rd powder.|3|||f||||f||||||||||2018-06-01 00:07:33.862858|2018-06-01 00:07:33.862858
NCT01062256|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2011-02-09||2013-02-20|2010-02-02|2010-02-04|Estimate|2011-02-09|2011-03-04|Estimate||||2013-02-20|2013-02-25|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections|A Methodology Study to Assess Cough Counts in Subjects With Acute Upper Respiratory Tract Infections|Completed||N/A|265|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 00:07:34.172611|2018-06-01 00:07:34.172611
NCT01062243|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-07-29|2010-02-03|2010-02-04|Estimate|||||||2013-07-29|2013-07-31|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|BIIG-FACS||Brain Injury Inpatient Educational Intervention for Families and Caregivers|Brain Injury Inpatient Educational Intervention for Families and Caregivers (a Research Project Within the Traumatic Brain Injury Model System)|Completed||N/A|110|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-06-01 00:07:34.912833|2018-06-01 00:07:34.912833
NCT01061346|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2016-01-22|2010-02-02|2010-02-03|Estimate|||||||2016-01-22|2016-01-25|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Fructose||Effect of Dietary Fat When Eaten With Fructose Versus Glucose|Effect of Dietary Fat When Eaten With Fructose vs. Glucose on Insulin Resistance and Liver Fat|Completed||N/A|19|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-06-01 00:07:50.626266|2018-06-01 00:07:50.626266
NCT01062230|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2014-09-24||2015-04-02|2010-02-03|2010-02-04|Estimate|2015-04-02|2015-04-06|Estimate||||2015-04-02|2015-04-06|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 2|6|Actual|University of Arkansas|Complete data was not received from the primary institution for all six patients enrolled. Data available is represented.|1||Slow accrual; PI left primary institution|f||||t||||||||||2018-06-01 00:07:34.992749|2018-06-01 00:07:34.992749
NCT01062217|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:07:35.156778|2018-06-01 00:07:35.156778
NCT01062204|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|May 2008||2008-05-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Altrazeal™ Versus Aquacel® Ag for Partial Thickness Skin Donor Sites|A Randomized Comparison Study of a Flexible HydrogelNanoparticle Wound Dressing (Altrazeal) Versus a Sodium Carboxymethylcellulose Dressing (Aquacel Ag) as Dressings for Partial Thickness Skin Graft Donor Sites|Completed||N/A|40|Anticipated|ULURU|||||f||||t||||||||||2018-06-01 00:07:35.190521|2018-06-01 00:07:35.190521
NCT01062191|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2011-06-07|2010-02-03|2010-02-04|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ROM||Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl|Flexible Hydrogel Nanoparticle Wound Dressing Allows Greater Joint Range of Motion Compared to Typical Sodium Carboxymethylcellulose Dressing|Terminated||N/A|3|Actual|ULURU||2||Lack of enrollment|f||||t||||||||||2018-06-01 00:07:35.261068|2018-06-01 00:07:35.261068
NCT01062178|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2016-03-07|2010-02-03|2010-02-04|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy of Ultrasound Contrast Agent to Assess Renal Masses|The Comparison of Accuracy of Contrast Enhanced Ultrasound on Diagnosis of Small Renal Masses and Distinguishing Renal Cell Carcinomas From Other Renal Masses, With Biopsy|Completed||Phase 2|167|Actual|University Health Network, Toronto||1|||f||||t||||||||No||2018-06-01 00:07:35.329195|2018-06-01 00:07:35.329195
NCT01062165|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2012-12-13||2016-12-21|2010-02-03|2010-02-04|Estimate|2012-12-13|2013-01-21|Estimate||||2016-12-21|2017-02-10|Actual|February 2010||2010-02-28|December 2016|2016-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Weight and/or Obesity on Caspofungin Drug Concentrations|Population Pharmacokinetic Analysis of Caspofungin in Overweight and Obese Volunteers|Completed||Phase 4|18|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||||2018-06-01 00:07:35.395435|2018-06-01 00:07:35.395435
NCT01062152|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2013-06-04|2010-02-03|2010-02-04|Estimate|||||||2013-06-04|2013-06-06|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 1|19|Actual|Telik||1|||f||||f||||||||||2018-06-01 00:07:35.568634|2018-06-01 00:07:35.568634
NCT01062139|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-03|2010-02-03|2010-02-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|October 2009||2009-10-31|February 2010|2010-02-28||||April 2010|Anticipated|2010-04-30||Interventional|||Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy|A Randomized, Parallel, Double-blind, Multi-center, Comparative Study to Exploratively Evaluate the Efficacy and Safety of Cosalin® Monotherapy vs. Cosalin® and Xarlin® Combination Therapy in Patients With Allergic Rhinitis|Unknown status|Enrolling by invitation|Phase 4|100|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-06-01 00:07:35.8069|2018-06-01 00:07:35.8069
NCT01062126|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2012-12-12|2010-02-03|2010-02-04|Estimate|||||||2012-12-12|2012-12-17|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|BRADYCARE||BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes|Advanced Bradycardia Device Feature Utilization and Clinical Outcomes|Completed|||3389|Actual|St. Jude Medical|||||f||||f||||||||||2018-06-01 00:07:35.873731|2018-06-01 00:07:35.873731
NCT01062113|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2011-08-01||2012-10-17|2010-02-02|2010-02-04|Estimate|2012-10-17|2012-11-19|Estimate||||2012-10-17|2012-11-19|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain|A Randomized, Double-Blind, Multicenter, Comparative Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In The Treatment Of Acute Pain After Oral Surgery Lateral Mandibular Impacted Third Molar Tooth Extraction|Completed||Phase 2|255|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:07:35.933273|2018-06-01 00:07:35.933273
NCT01062100|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2013-02-15|2010-02-03|2010-02-04|Estimate|||||||2013-02-15|2013-02-18|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|THORN||Study To Investigate the Feasibility and Safety of A Dedicated High Resolution Nuclear Breast Imaging Camera|The Hamilton Prospective Pilot Study To Investigate the Feasibility and Safety of A Dedicated High Resolution Nuclear Breast Imaging Camera|Completed||N/A|42|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||f||||||||||2018-06-01 00:07:36.392857|2018-06-01 00:07:36.392857
NCT01062087|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2012-05-01|2010-02-03|2010-02-04|Estimate|||||||2012-05-01|2012-05-03|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Observational|||Pain Perception After Tubal Ligation|Retrospective Investigation of Postoperative Pain Perception After Laparoscopic Tubal Sterilization|Completed|||62|Actual|Oklahoma State University Center for Health Sciences|||2||f||||f||||||||||2018-06-01 00:07:36.497337|2018-06-01 00:07:36.497337
NCT01062074|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2014-02-07||2017-03-20|2010-02-02|2010-02-04|Estimate|2014-02-07|2014-03-27|Estimate||||2017-03-20|2017-04-17|Actual|September 28, 2007|Actual|2007-09-28|March 2017|2017-03-31|May 7, 2013|Actual|2013-05-07|May 7, 2013|Actual|2013-05-07||Observational|||GARDASIL Reexamination Study (V501-059)|Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice|Completed|||3605|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:07:36.612643|2018-06-01 00:07:36.612643
NCT01062061|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2013-04-16||2015-09-03|2010-02-02|2010-02-04|Estimate|2013-04-16|2013-07-03|Estimate||||2015-09-03|2015-09-04|Estimate|June 2007||2007-06-30|September 2015|2015-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Re-examination Study For Varivax (V210-059 AM2)|Re-examination Study for General Vaccine Use to Assess the Safety Profile of Varivax in Usual Practice|Completed|||754|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:07:36.784158|2018-06-01 00:07:36.784158
NCT01062035|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2014-06-24|2010-02-02|2010-02-04|Estimate|||||||2014-06-24|2014-06-26|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Study of a Screening Blood Test to Determine Patients' Potential Risk of Adenomatous or Advanced Colon Polyps (ACPs)|Peripheral Blood Telomere Length as a Biomarker of Advanced Colorectal Adenomas|Completed|||72|Actual|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     The only specimens obtained will be blood for PBL DNA. For all subjects two 10 cc EDTA tubes~     will be obtained and processed into DNA.~   "|||2018-06-01 00:07:37.081483|2018-06-01 00:07:37.081483
NCT01062022|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2016-08-16|2010-02-02|2010-02-04|Estimate|||||||2016-08-16|2016-08-18|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|FOCUS-CI||FOCUS-CI: A Preventive Intervention With Children and Families of the Combat Injured|FOCUS-CI: A Preventive Intervention With Children and Families of the Combat Injured|Terminated||N/A|23|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2||Loss of funding|f||||f||||||||Undecided|study ended - no data|2018-06-01 00:07:37.147569|2018-06-01 00:07:37.147569
NCT01062009|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2015-01-26|2010-02-02|2010-02-04|Estimate|||||||2015-01-26|2015-01-28|Estimate|November 2008||2008-11-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children|A Safety and Dose-escalation Study of Zinc Supplementation in Pediatric Critical Illness|Completed||Phase 1/Phase 2|24|Actual|Children's Hospital & Research Center Oakland||4|||f||||t||||||||||2018-06-01 00:07:37.263373|2018-06-01 00:07:37.263373
NCT01061996|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-02|2010-02-02|2010-02-04|Estimate|||||||2010-02-02|2010-02-04|Estimate|July 2007||2007-07-31|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Basiliximab Maintenance in Ulcerative Colitis|An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis|Terminated||Phase 2|88|Actual|Cerimon Pharmaceuticals||1||lack of efficacy|f||||f||||||||||2018-06-01 00:07:37.32982|2018-06-01 00:07:37.32982
NCT01061983|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2013-02-21|2010-02-03|2010-02-04|Estimate|||||||2013-02-21|2013-02-25|Estimate|January 2001||2001-01-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|April 2004|Actual|2004-04-30||Interventional|||Electrical Stimulation of the Internal Capsule for Intractable Obsessive-compulsive Disorder (OCD)|Electrical Stimulation of the Internal Capsule for Intractable OCD|Completed||Phase 2|5|Actual|Butler Hospital||1|||f||||t||||||||||2018-06-01 00:07:37.408965|2018-06-01 00:07:37.408965
NCT01061970|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-02|2010-02-02|2010-02-03|Estimate|||||||2010-02-02|2010-02-03|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|October 2007|Actual|2007-10-31|||||Interventional|||Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy|Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy: A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 2|15|Anticipated|QuatRx Pharmaceuticals Company|||||f||||||||||||||2018-06-01 00:07:37.487366|2018-06-01 00:07:37.487366
NCT01061957|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-03|2010-02-02|2010-02-03|Estimate|||||||2010-02-03|2010-02-04|Estimate|January 2006||2006-01-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Observational|||Raltegravir Treatment in Patients Failing Highly Active Antiretroviral Therapy (HAART) in Denmark|Clinical, Virological and Immunological Course in Danish Patients With Triple Class Failure Receiving Raltegravir as Part of a Salvage Regimen.|Completed|||96|Actual|Rigshospitalet, Denmark|||2||f||||t||||||||||2018-06-01 00:07:37.564149|2018-06-01 00:07:37.564149
NCT01061944|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2018-01-24|2010-02-02|2010-02-03|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2010||2010-02-28|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2016|Actual|2016-12-31||Observational|||Biopsies of Cancer Patients for Tumor Molecular Characterization|Biopsies of Cancer Patients for Tumor Molecular Characterization|Completed|||188|Actual|Massachusetts General Hospital|||||f||||t||||||Samples With DNA|"~     Tumor biopsy~   "|||2018-06-01 00:07:37.638192|2018-06-01 00:07:37.638192
NCT01061931|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2014-06-23|2010-02-02|2010-02-03|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|MACPAF||Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation|HD Mesh Ablator Versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation - Efficiency and Safety of PV Ablation Systems|Terminated||Phase 4|108|Anticipated|Charite University, Berlin, Germany||2||reason|f||||f||||||||||2018-06-01 00:07:37.695599|2018-06-01 00:07:37.695599
NCT01061918|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2011-02-16|2010-02-02|2010-02-03|Estimate|||||||2011-02-16|2011-02-17|Estimate|August 2009||2009-08-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses|Evaluation Of Bilateral Tecnis Multifocal Versus ReSTOR 3D Intraocular Lenses|Completed||Phase 4|40|Anticipated|Innovative Medical||2|||f||||f||||||||||2018-06-01 00:07:37.756588|2018-06-01 00:07:37.756588
NCT01061905|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2011-11-11|2010-02-02|2010-02-03|Estimate|||||||2011-11-11|2011-11-16|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Behavioral Economics and Food Choice|Behavioral Economics Concepts Influencing Healthy Food Choice - Pilot 2|Completed||N/A|4|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 00:07:37.816254|2018-06-01 00:07:37.816254
NCT01061879|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2012-12-28|2010-02-02|2010-02-03|Estimate|||||||2012-12-28|2013-01-03|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Expansion of Umbilical Cord Blood Using a Unique Bio-system|Ex Vivo Expansion of Umbilical Cord Blood Using a Unique Bio-system|Completed|||8|Actual|University of Kansas Medical Center|||||f||||f||||||Samples With DNA|"~     umbilical cord~   "|||2018-06-01 00:07:37.921064|2018-06-01 00:07:37.921064
NCT01061866|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2009-02-17||2010-02-05|2010-01-07|2010-02-03|Estimate|2010-01-07|2010-02-03|Estimate||||2010-02-05|2010-02-18|Estimate|June 2006||2006-06-30|December 2009|2009-12-31|January 2008|Actual|2008-01-31|June 2007|Actual|2007-06-30||Interventional|||Thalidomide Low Threshold in Epilepsy|Treatment of Refractory Epilepsy With Thalidomide: an Open Trial|Completed||Phase 1/Phase 2|7|Actual|National Institute of Neurology and Neurosurgery, Mexico||1|||f||||f||||||||||2018-06-01 00:07:38.047729|2018-06-01 00:07:38.047729
NCT01061853|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2013-10-15|2010-02-02|2010-02-03|Estimate|||||||2013-10-15|2013-10-16|Estimate|February 2008||2008-02-29|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|RALIB||Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen|Efficacy of Topical Rapamycin in Treatment of Chronic Erosive Oral Lichen Planus. Double Blind Randomised Controlled Trial Rapamycin vs Topical Steroids|Terminated||Phase 3|76|Actual|University Hospital, Tours||2||Per protocol intermediate analyses of 76 patients and enrollment difficulties.|f||||t||||||||||2018-06-01 00:07:38.22736|2018-06-01 00:07:38.22736
NCT01061840|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2018-04-09|2010-02-02|2010-02-03|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2009||2009-12-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer|Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer|Active, not recruiting||Phase 1|100|Anticipated|Gradalis, Inc.||3|||f||||t||||||||||2018-06-01 00:07:38.323001|2018-06-01 00:07:38.323001
NCT01061827|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2017-01-13|2010-02-02|2010-02-03|Estimate|||||||2017-01-13|2017-01-16|Estimate|June 2008||2008-06-30|January 2017|2017-01-31|November 2013|Actual|2013-11-30|June 2008|Actual|2008-06-30||Observational|GMS-Package||Validation of the French Version of the Geriatric Mental State (GMS)|Validation of the French Version of the Geriatric Mental State: a Structured and Standardized Interview for Diagnosis of Psychiatric Disorders in the Elderly|Completed|||96|Actual|University Hospital, Tours|||3||f||||t||||||||||2018-06-01 00:07:38.415265|2018-06-01 00:07:38.415265
NCT01061814|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2016-08-01|2010-02-02|2010-02-03|Estimate|||||||2016-08-01|2016-08-03|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Relative Bioavailability, Pharmacokinetics, Safety, and Tolerability of Daily, Thrice Weekly, and Weekly Dosing Regimens of Mipomersen Administered Subcutaneously to Healthy Volunteers|Completed||Phase 1|84|Actual|Kastle Therapeutics, LLC||2|||f||||t||||||||||2018-06-01 00:07:38.485962|2018-06-01 00:07:38.485962
NCT01061801|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-04|2010-02-02|2010-02-03|Estimate|||||||2010-02-04|2010-02-08|Estimate|August 2006||2006-08-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Spouses/Partners Expressing Their Thoughts After Transplant|Emotional Expression and Cancer Caregivers|Completed||N/A|122|Actual|Fred Hutchinson Cancer Research Center||3|||f||||f||||||||||2018-06-01 00:07:38.563866|2018-06-01 00:07:38.563866
NCT01061788|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2018-02-09|2010-02-02|2010-02-03|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2010||2010-04-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|RAP||A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007|A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination With Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer (The RAP Trial)|Active, not recruiting||Phase 1|100|Anticipated|Duke University||1|||f||||t||||||||||2018-06-01 00:07:38.651743|2018-06-01 00:07:38.651743
NCT01061775|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2015-02-25||2017-07-28|2010-02-02|2010-02-03|Estimate|2016-02-22|2016-03-21|Estimate||||2017-07-28|2017-08-28|Actual|January 2010||2010-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Exenatide on Hypothalamic Obesity|Effects of Exenatide on Hypothalamic Obesity|Active, not recruiting||Phase 1/Phase 2|19|Actual|Children's Hospitals and Clinics of Minnesota||1|||f||||t||||||||No|We do not plan to share individual participant data.|2018-06-01 00:07:38.729117|2018-06-01 00:07:38.729117
NCT01061762|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2013-06-14|2010-02-02|2010-02-03|Estimate|||||||2013-06-14|2013-06-17|Estimate|February 2008||2008-02-29|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Adherence Intervention for People With Low-literacy|HIV Treatment Adherence Intervention for People With Poor Literacy Skills|Completed||Phase 2|450|Actual|University of Connecticut||3|||f||||f||||||||||2018-06-01 00:07:39.029044|2018-06-01 00:07:39.029044
NCT01061749|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2016-01-22|2010-02-02|2010-02-03|Estimate|||||||2016-01-22|2016-01-25|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|April 2013|Actual|2013-04-30||Interventional|||Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies|A Phase I, Single-Institution Open Label, Dose-Escalation Trial With an Expansion Trial Cohort Evaluating the Safety and Tolerability of AZD6244 and IMC-A12 in Subjects With Advanced Solid Malignancies|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:07:39.119024|2018-06-01 00:07:39.119024
NCT01061736|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2017-05-23|2014-11-19|2017-06-27|2010-02-02|2010-02-03|Estimate|2017-06-27|2017-06-28|Actual|2014-11-19|2014-12-09|Estimate|2017-06-27|2017-06-28|Actual|March 2010||2010-03-31|June 2017|2017-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|RA-MOBILITY||Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Placebo-controlled, Multicenter, Two-part, Dose Ranging and Confirmatory Study With an Operationally Seamless Design, Evaluating Efficacy and Safety of SAR153191 on Top of Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy|Completed||Phase 2/Phase 3|1675|Actual|Sanofi||10|||f||||t||||||||||2018-06-01 00:07:39.342025|2018-06-01 00:07:39.342025
NCT01061723|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2017-05-24|2012-08-02|2017-07-07|2010-02-02|2010-02-03|Estimate|2017-07-07|2017-08-08|Actual|2012-08-02|2012-08-07|Estimate|2017-07-07|2017-08-08|Actual|February 2010||2010-02-28|July 2017|2017-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|ALIGN||Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis|A Randomized Double Blind-placebo Controlled Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 in Participants With Ankylosing Spondylitis (AS)|Completed||Phase 2|301|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 00:07:42.522238|2018-06-01 00:07:42.522238
NCT01061710|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2015-01-27||2015-01-27|2010-02-02|2010-02-03|Estimate|2015-01-27|2015-02-11|Estimate||||2015-01-27|2015-02-11|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational||A total of 20 participants were enrolled in this survey. Of the 20 participants, 14 participants were excluded from the baseline analysis due to a protocol violation.|Varenicline (Champix®) Special Investigation (Regulatory Post Marketing Commitment Plan)|Champix Tablets Special Investigation -Retrospective Survey For Subjects Who Have Been Retreated With Champix.-(Regulatory Post Marketing Commitment Plan).|Completed|||20|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:07:43.570965|2018-06-01 00:07:43.570965
NCT01061697|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2011-07-04|2010-02-02|2010-02-03|Estimate|||||||2011-07-04|2011-07-06|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|PARPS||Pregabalin and Radicular Pain Study (PARPS)|Open Labelled Study of Pregabalin in the Treatment of Neuropathic Pain in Cervical Myeloradiculopathy (Pregabalin and Radicular Pain Study (PARPS))|Completed||Phase 4|50|Actual|Singapore General Hospital|||||f||||f||||||||||2018-06-01 00:07:44.761122|2018-06-01 00:07:44.761122
NCT01061684|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2018-03-12|2010-02-02|2010-02-03|Estimate|||||||2018-03-12|2018-03-14|Actual|December 2009||2009-12-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|NAFLD Peds DB2||NAFLD Pediatric Database 2|Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Database 2|Recruiting|||850|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||1||f||||t||||||Samples With DNA|"~     plasma, serum, liver tissue~   "|Yes|Data will be uploaded to www.niddkrepository.org at the end of the funding.|2018-06-01 00:07:44.874781|2018-06-01 00:07:44.874781
NCT01061671|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2015-01-29||2017-12-08|2010-02-02|2010-02-03|Estimate|2015-03-12|2015-03-26|Estimate||||2017-12-08|2018-01-02|Actual|March 2010||2010-03-31|December 2017|2017-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|STATCOPE||Simvastatin Therapy for Moderate and Severe COPD|Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)|Terminated||Phase 3|885|Actual|University of Minnesota - Clinical and Translational Science Institute|Early termination by the Data and Safety Monitoring Board due to futility in respect to a treatment effect. The original study population goal was 1200 and the study was terminated at 885 participants.|2||Futility|f||||t||||||||||2018-06-01 00:07:45.036023|2018-06-01 00:07:45.036023
NCT01061658|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-10-01|2010-02-02|2010-02-03|Estimate|||||||2010-10-01|2010-10-04|Estimate|July 2010||2010-07-31|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine|Phase I/II, Randomized, Double-blind, Placebo-controlled, Dosage Selection (10e5.5 or 10e6.25 FFU of Each Constituent Serotype Per 0.5 mL) Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Infants|Unknown status|Recruiting|Phase 1/Phase 2|90|Anticipated|Shantha Biotechnics Limited||3|||f||||t||||||||||2018-06-01 00:07:46.242251|2018-06-01 00:07:46.242251
NCT01061645|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2012-05-03|2010-02-02|2010-02-03|Estimate|||||||2012-05-03|2012-05-04|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of MOC31-PE in Antigen Positive Carcinomas|Phase I Study of MOC31-PE in Antigen Positive Carcinomas|Completed||Phase 1|30|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-06-01 00:07:46.314104|2018-06-01 00:07:46.314104
NCT01061632|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2013-03-07|2010-02-02|2010-02-03|Estimate|||||||2013-03-07|2013-03-08|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Interventional|||High(Deadlift) Versus Low Intensity Motor Control Exercises on Low Back Pain|Effects of High(Deadlift) Versus Low Intensity Motor Control Exercises on Patients With Peripherally Mediated Low Back Pain|Completed||Phase 2|70|Actual|Luleå Tekniska Universitet|||||f||||f||||||||||2018-06-01 00:07:46.578766|2018-06-01 00:07:46.578766
NCT01061619|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2017-03-27|2010-02-02|2010-02-03|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2010||2010-01-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|April 2016|Actual|2016-04-30||Observational|MITO-12||Pathway to Diagnosis of Ovarian Cancer|Pathway to Diagnosis of Ovarian Cancer: Observational Retrospective Multicenter Study|Active, not recruiting|||400|Anticipated|National Cancer Institute, Naples|||||f||||f||||||||||2018-06-01 00:07:46.730048|2018-06-01 00:07:46.730048
NCT01061606|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2016-09-21||2016-09-21|2010-02-02|2010-02-03|Estimate|2016-09-21|2016-11-09|Estimate||||2016-09-21|2016-11-09|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus|Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus|Terminated||Phase 2|8|Actual|National Cancer Institute (NCI)||1||Poor accrual|f||||t||||||||||2018-06-01 00:07:46.863233|2018-06-01 00:07:46.863233
NCT01061593|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2015-05-18|2010-02-02|2010-02-03|Estimate|||||||2015-05-18|2015-05-20|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV|Phase III, Double-blind, Placebo-controlled, Randomized, 1-month Clinical Trial of Immunoxel Combined With Anti-TB Therapy Versus Anti-TB Therapy With Placebo|Completed||Phase 3|269|Actual|Lisichansk Regional Tuberculosis Dispensary||2|||f||||f||||||||||2018-06-01 00:07:47.147645|2018-06-01 00:07:47.147645
NCT01061580|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2014-06-25|2010-02-02|2010-02-03|Estimate|||||||2014-06-25|2014-06-26|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||BMAC Enhanced Coronary Artery Bypass Grafting (CABG)|Dose Response Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting (CABG) Surgery|Terminated||Phase 1/Phase 2|20|Anticipated|Harvest Technologies||1|||f||||f||||||||||2018-06-01 00:07:47.251165|2018-06-01 00:07:47.251165
NCT01061567|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|2014-06-06||2014-06-06|2010-02-02|2010-02-03|Estimate|2014-06-06|2014-07-08|Estimate||||2014-06-06|2014-07-08|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||Patients from Treated Set (TS) who were documented to have taken at least one dose of study treatment.|Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice|Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice|Completed|||1814|Actual|Boehringer Ingelheim|There was no PI assigned for the overall study.||1||f||||||||||||||2018-06-01 00:07:47.411746|2018-06-01 00:07:47.411746
NCT01061554|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-02|2010-02-02|2010-02-03|Estimate|||||||2010-02-02|2010-02-03|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Bioavailability Study of Long Chain Omega-3 Fatty Acids From a Gastric Stable Emulsion|Correlation Between Level of Polyunsaturated Fatty Acid EPA and DHA in Blood After Digestion of ProBios Omega-3 Concordix™ Compared With Omega-3 Soft Capsules - a Pilot|Completed||Phase 1|27|Actual|Ayanda AS||3|||f||||f||||||||||2018-06-01 00:07:48.191992|2018-06-01 00:07:48.191992
NCT01061541|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2016-09-08|2010-02-02|2010-02-03|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2003||2003-08-31|September 2016|2016-09-30|August 2004|Actual|2004-08-31|January 2004|Actual|2004-01-31||Interventional|||Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™|A Phase II, Double-blind, Randomized Study to Compare the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB/Hib2.5 to GSK Biologicals' Tritanrix™-HepB/Hiberix™ When Administered as a Three-dose Primary Vaccination Course to Healthy Infants at 6, 10 and 14 Weeks of Age. A Dose of Unconjugated Hib Vaccine (Plain PRP Booster) Will be Administered at the Age of 10 Months to 50% of the Subjects|Completed||Phase 2|192|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:07:48.278739|2018-06-01 00:07:48.278739
NCT01061528|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2016-07-25|2010-02-02|2010-02-03|Estimate|||||||2016-07-25|2016-07-27|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|Project-WIN||Coping Skills Treatment for Smoking Cessation|Distress Tolerance Treatment for Smoking Cessation|Completed||N/A|128|Actual|Butler Hospital||2|||f||||t||||||||No||2018-06-01 00:07:48.368035|2018-06-01 00:07:48.368035
NCT01059760|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2016-12-21||2017-04-18|2010-01-29|2010-02-01|Estimate|2017-04-18|2017-07-17|Actual||||2017-04-18|2017-07-17|Actual|January 2010||2010-01-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|FEELGOOD||Expression of Longevity Genes in Response to Extended Fasting|Expression of Longevity Genes in Response to Extended Fasting|Completed||N/A|30|Actual|Intermountain Health Care, Inc.||2|||f||||f||||||||||2018-06-01 00:08:21.391654|2018-06-01 00:08:21.391654
NCT01061515|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2018-01-04|2010-02-02|2010-02-03|Estimate|||||||2018-01-04|2018-01-08|Actual|May 10, 2011|Actual|2011-05-10|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer|A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer|Recruiting||Phase 1|24|Anticipated|Washington University School of Medicine||5|||f||||t|t|f|||f|||No||2018-06-01 00:07:48.458327|2018-06-01 00:07:48.458327
NCT01061502|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-12-09|2010-02-02|2010-02-03|Estimate|||||||2010-12-09|2010-12-10|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds|Efficacy of the PROCELLERA Wound Dressing in the Healing of Skin Graft Donor Sites|Completed||Phase 1/Phase 2|17|Actual|Vomaris Innovations||2|||f||||t||||||||||2018-06-01 00:07:48.745952|2018-06-01 00:07:48.745952
NCT01061489|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2016-07-13|2010-02-02|2010-02-03|Estimate|||||||2016-07-13|2016-07-14|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment|Computer-based Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease (AD)|Completed||N/A|65|Actual|University of Konstanz||3|||f||||f||||||||||2018-06-01 00:07:48.812189|2018-06-01 00:07:48.812189
NCT01061476|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|2012-09-20||2013-07-09|2010-02-02|2010-02-03|Estimate|2013-05-31|2013-07-08|Estimate||||2013-07-09|2013-07-19|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SATER||Sleep Apnea Treatment With Expiratory Resistance(Provent™)|Sleep Apnea Treatment With Expiratory Resistance(Provent™)|Completed||Phase 1/Phase 2|12|Actual|Johns Hopkins University|"Small sample size and limited power for analysis.~Oral breathing during expiratory nasal resistance (ENR) confounds the mechanism of action."|1|||f||||f||||||||||2018-06-01 00:07:48.899251|2018-06-01 00:07:48.899251
NCT01061463|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2015-04-03|2010-02-02|2010-02-03|Estimate|||||||2015-04-03|2015-04-06|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Observational|||Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study|Study of the Occupational Risk of Radiation-induced Cataracts Among Cardiologists|Completed|||250|Actual|Institut de Radioprotection et de Surete Nucleaire|||2||f||||t||||||||||2018-06-01 00:07:49.187691|2018-06-01 00:07:49.187691
NCT01061450|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-02|2010-02-02|2010-02-03|Estimate|||||||2010-02-02|2010-02-03|Estimate|November 2006||2006-11-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Simvastatin and Diastolic Dysfunction|Effect of the Addition of Simvastatin to Enalapril in Hypertensive Individuals With Average Cholesterol Levels and Diastolic Dysfunction|Completed||Phase 4|55|Actual|Brasilia Heart Study Group||2|||f||||t||||||||||2018-06-01 00:07:49.283363|2018-06-01 00:07:49.283363
NCT01061437|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-09-24|2010-02-02|2010-02-03|Estimate|||||||2012-09-24|2012-09-26|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)|A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori|Completed||Phase 3|1859|Actual|Southwest Oncology Group||3|||f||||t||||||||||2018-06-01 00:07:49.424753|2018-06-01 00:07:49.424753
NCT01061424|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-08-13|2010-02-02|2010-02-03|Estimate|||||||2012-08-13|2012-08-15|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Project CURA||The Community United to Challenge Asthma|A Community-Academic Partnership to Improve Asthma Management in Latino Children|Completed||N/A|51|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 00:07:49.557028|2018-06-01 00:07:49.557028
NCT01061411|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2017-04-25|2010-02-01|2010-02-03|Estimate|||||||2017-04-25|2017-04-26|Actual|February 6, 2010|Actual|2010-02-06|April 2017|2017-04-30|April 21, 2017|Actual|2017-04-21|October 14, 2015|Actual|2015-10-14||Interventional|||Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery|Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1|16|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 00:07:49.639229|2018-06-01 00:07:49.639229
NCT01061398|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2012-06-27|2010-02-02|2010-02-03|Estimate|||||||2012-06-27|2012-06-28|Estimate|November 2007||2007-11-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|CT-FIRST||CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification|CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification|Unknown status|Active, not recruiting|N/A|240|Actual|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 00:07:49.803387|2018-06-01 00:07:49.803387
NCT01061385|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2015-08-07|2013-06-10|2016-04-06|2010-02-02|2010-02-03|Estimate|2015-11-02|2015-12-07|Estimate|2013-06-17|2013-06-25|Estimate|2016-04-06|2016-05-13|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional||Participants meeting study inclusion/exclusion criteria|The Safety and Efficacy of the ReShape Intragastric Balloon in Obese Subjects|IDE G090121 A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Intragastric Balloon (RIBTM) in Obese Subjects|Completed||N/A|30|Actual|ReShape Lifesciences|Given the small sample size of this feasibility cohort, it was not expected to show significant effectiveness.|2|||f||||t||||||||||2018-06-01 00:07:49.921008|2018-06-01 00:07:49.921008
NCT01061372|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-06-28|2010-02-01|2010-02-03|Estimate|||||||2010-06-28|2010-06-29|Estimate|May 2010||2010-05-31|June 2010|2010-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects|Randomized Double-Blind, 12-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome|Withdrawn||Phase 3|0|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:07:50.206578|2018-06-01 00:07:50.206578
NCT01061359|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2010-10-14||2010-12-16|2010-02-02|2010-02-03|Estimate|2010-10-14|2010-11-18|Estimate||||2010-12-16|2010-12-29|Estimate|January 1999||1999-01-31|December 2010|2010-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer|Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))|Completed|||1981|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:07:50.314714|2018-06-01 00:07:50.314714
NCT01059747|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-01-29|2010-01-29|2010-02-01|Estimate|||||||2010-01-29|2010-02-01|Estimate|December 2008||2008-12-31|January 2010|2010-01-31||||||||Observational|M0108||Therapeutic Drug Monitoring and Pharmacogenomics Study of Methadone Therapy||Unknown status|Recruiting||500|Anticipated|National Health Research Institutes, Taiwan|||1||f||||f||||||||||2018-06-01 00:08:22.113453|2018-06-01 00:08:22.113453
NCT01061333|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2012-04-26||2015-09-03|2010-02-02|2010-02-03|Estimate|2012-04-26|2012-05-28|Estimate||||2015-09-03|2015-09-04|Estimate|June 2010||2010-06-30|September 2015|2015-09-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Early Airway Response to Allergen in Asthmatics (MK-0000-176)|A Two-Part, Randomized, Placebo-Controlled, Crossover Trial to Evaluate the Differential Effects of Inhaled Nedocromil, Oral Montelukast, and Inhaled Mometasone on Markers of the Early Airway Response to Allergen in Asthmatics|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 00:07:50.721786|2018-06-01 00:07:50.721786
NCT01061320|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-02-02|2010-02-02|2010-02-03|Estimate|||||||2010-02-02|2010-02-03|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients|Efficacy of Alpha Tocopherol and New Biomarker (Urine NGAL) for Prevention and Early Diagnosis of Contrast-induced Nephropathy in CKD Patients Undergoing Elective Coronary Procedures|Unknown status|Enrolling by invitation|Phase 3|200|Anticipated|Thammasat University||2|||f||||t||||||||||2018-06-01 00:07:51.181214|2018-06-01 00:07:51.181214
NCT01061307|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2016-01-05|2010-02-02|2010-02-03|Estimate|||||||2016-01-05|2016-01-06|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand|An Efficacy Trial of Fe, Zn and Vitamin A Fortified Rice in Children in Satun, Thailand|Completed||Early Phase 1|203|Actual|Swiss Federal Institute of Technology||1|||f||||f||||||||||2018-06-01 00:07:51.266216|2018-06-01 00:07:51.266216
NCT01061294|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2011-01-12|2010-02-02|2010-02-03|Estimate|||||||2011-01-12|2011-01-13|Estimate|December 2009||2009-12-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure|Evaluation of Outcomes Using the AMO Advanced Customvue™ iLasik Procedure (Wavescan Wavefront® System, Star S4 IR™ Excimer Laser System and Intralse™ FS System)|Completed||Phase 4|20|Anticipated|Innovative Medical||1|||f||||f||||||||||2018-06-01 00:07:51.325099|2018-06-01 00:07:51.325099
NCT01061281|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-01-13|2010-02-02|2010-02-03|Estimate|||||||2012-01-13|2012-01-18|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses|Evaluation of the Tecnis™ Multifocal and Crystalens™ Accommodating Intraocular Lenses|Completed||Phase 4|40|Actual|Innovative Medical||2|||f||||f||||||||||2018-06-01 00:07:51.47431|2018-06-01 00:07:51.47431
NCT01061268|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-02-15|2010-02-02|2010-02-03|Estimate|||||||2012-02-15|2012-02-17|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens|A Randomized Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens|Completed||Phase 4|25|Actual|Innovative Medical||2|||f||||f||||||||||2018-06-01 00:07:51.652198|2018-06-01 00:07:51.652198
NCT01061255|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2010-07-22|2010-02-02|2010-02-03|Estimate|||||||2010-07-22|2010-07-23|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Stress and Clinical Reasoning in Medical Students|Physiological and Psychological Responses to Stress in Year 6 Medical Students Faced to Ambulatory Symptomatic Patients|Completed||N/A|62|Actual|Nantes University Hospital|||||f||||f||||||||||2018-06-01 00:07:51.759581|2018-06-01 00:07:51.759581
NCT01061242|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2011-06-22|2010-02-02|2010-02-03|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Intensive Care Unit (ICU) Sleep Quality and Neurocognitive Performance|Post-ICU Neurocognitive Performance and Sleep Quality Ratings Following Exposure to a Medical ICU Sleep Quality Improvement Project|Completed||N/A|88|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 00:07:51.836057|2018-06-01 00:07:51.836057
NCT01061229|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-02|||2012-07-09|2010-02-02|2010-02-03|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|HAMSV||Homeopathic Drug Proving Trial|Homeopathic Drug Proving Trial|Completed||Phase 1|29|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 00:07:51.923784|2018-06-01 00:07:51.923784
NCT01061216|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-03-09|2010-02-01|2010-02-03|Estimate|||||||2010-03-09|2010-03-10|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously|A Mono-center, Open Label, Randomised 2-period Crossover Study to Compare the Pharmacokinetics and Pharmacodynamics of Continuous Insulin Infusion Administered Either Intradermally or Subcutaneously in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|20|Actual|Becton, Dickinson and Company||2|||f||||f||||||||||2018-06-01 00:07:52.023945|2018-06-01 00:07:52.023945
NCT01061203|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2016-09-07|2010-02-01|2010-02-03|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|GAP||Grazax Asthma Prevention|Grazax Asthma Prevention|Completed||Phase 3|812|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-06-01 00:07:52.117921|2018-06-01 00:07:52.117921
NCT01061190|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2015-10-12|2010-02-02|2010-02-03|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|October 2011|Actual|2011-10-31||Interventional|BIAS||Beta Blockers In Acute Ischemic Stroke|Beta-Blocker in Acute Ischemic Stroke - a Prospective, Randomized, Double-blinded, Placebo-controlled Safety and Efficacy Trial of Early Treatment|Completed||Phase 2/Phase 3|20|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 00:07:52.212312|2018-06-01 00:07:52.212312
NCT01061177|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2015-08-03||2017-01-04|2010-02-01|2010-02-02|Estimate|2017-01-04|2017-02-24|Actual||||2017-01-04|2017-02-24|Actual|May 2010||2010-05-31|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|`MACS1252|The intent-to-treat (ITT) population consisted of all participants who received at least one dose of study drug.|Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase|A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase|Completed||Phase 4|1090|Actual|Novartis||1|||f||||t||||||||||2018-06-01 00:07:52.433452|2018-06-01 00:07:52.433452
NCT01061164|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2015-03-23|2010-02-01|2010-02-02|Estimate|||||||2015-03-23|2015-03-25|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Observational|||IMPAACT P1074: Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents|A Prospective Surveillance Study of Long-Term Outcomes in HIV-Infected Infants, Children and Adolescents|Completed|||1207|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||1||f||||t||||||||||2018-06-01 00:07:54.473621|2018-06-01 00:07:54.473621
NCT01061151|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|2017-09-28||2018-01-12|2010-02-01|2010-02-02|Estimate|2018-01-12|2018-02-09|Actual||||2018-01-12|2018-02-09|Actual|March 2011||2011-03-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PROMISE||Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries|Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)|Completed||Phase 3|3747|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-06-01 00:07:54.885632|2018-06-01 00:07:54.885632
NCT01061138|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-12-03|2010-02-01|2010-02-02|Estimate|||||||2012-12-03|2012-12-04|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Xpress Digital Mammography System Images for Computer Aided Detection Development|A Multi-Center Clinical Study to Acquire Xpress Digital Mammography System Images for Computer Aided Detection Development|Completed|||597|Actual|Konica Minolta Medical Imaging, USA|||2||f||||f||||||||||2018-06-01 00:08:01.14933|2018-06-01 00:08:01.14933
NCT01061125|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2017-02-09|2010-02-01|2010-02-02|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2010|Actual|2010-01-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|RPAF-A||Implantable Loop Recorders in Post-atrial Fibrillation (AF) Ablation: RPAF-A|Implantable Loop Recorders in Post-AF Ablation: RPAF-A|Completed|||68|Actual|The Cleveland Clinic|||2||f||||f|f|f||||||No||2018-06-01 00:08:01.226647|2018-06-01 00:08:01.226647
NCT01061112|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-11-12|2010-02-01|2010-02-02|Estimate|||||||2013-11-12|2013-11-13|Estimate|December 2009||2009-12-31|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Effects of Genotype on CYP2C9 Drug Interactions|Effects of Genotype on CYP2C9 Drug Interactions|Unknown status|Active, not recruiting||23|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||||2018-06-01 00:08:01.315548|2018-06-01 00:08:01.315548
NCT01061099|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2015-04-23|2010-02-01|2010-02-02|Estimate|||||||2015-04-23|2015-04-24|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|February 2014|Actual|2014-02-28|March 2013|Actual|2013-03-31||Interventional|STOD3||Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta|A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta|Completed||Phase 1|5|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-06-01 00:08:01.393805|2018-06-01 00:08:01.393805
NCT01061086|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2011-12-20|2010-02-01|2010-02-02|Estimate|||||||2011-12-20|2011-12-21|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Observational|TARGET||An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study|An Epidemiological Study of Acute Coronary Syndromes in The Greek Population|Completed|||418|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:08:01.483443|2018-06-01 00:08:01.483443
NCT01061073|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2016-10-10|2010-02-01|2010-02-02|Estimate|||||||2016-10-10|2016-10-11|Estimate|January 2010||2010-01-31|October 2016|2016-10-31||||October 2012|Actual|2012-10-31||Interventional|||Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial|Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial|Completed||Phase 3|73|Actual|Poitiers University Hospital||2|||f||||f||||||||||2018-06-01 00:08:01.58952|2018-06-01 00:08:01.58952
NCT01061060|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2016-02-11|2010-02-01|2010-02-02|Estimate|||||||2016-02-11|2016-02-15|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients|The Effect of Prostaglandin I2 (Beraprost Na), Administered Orally for Eight Weeks, on the Endothelial Cell Functional Disorder in Type II Diabetes Mellitus Patients With Symptoms of a Minute Peripheral Blood Flow Disorder|Completed||Phase 4|110|Actual|Yonsei University||2|||f||||f||||||||||2018-06-01 00:08:01.847324|2018-06-01 00:08:01.847324
NCT01061047|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2012-08-28|2010-02-01|2010-02-02|Estimate|||||||2012-08-28|2012-08-29|Estimate||||January 2010|2010-01-31||||||||Interventional|||Comparison of Ertapenem Distribution in the Muscle of Six Healthy Volunteers and Six Critically Ill Patients by Microdialysis||Completed||Phase 1|||Poitiers University Hospital|||||f||||f||||||||||2018-06-01 00:08:01.987424|2018-06-01 00:08:01.987424
NCT01061034|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-03|2009-05-03||2010-01-02|2010-01-02|2010-02-02|Estimate|2010-01-02|2010-02-02|Estimate||||2010-01-02|2010-02-02|Estimate|March 2007||2007-03-31|November 2009|2009-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Pharmacological Study That Measures Omeprazole Effect on Aspirins Absorption in Healthy Volunteers|The Effect of Proton Pump Inhibitor (Omeprazole) on Acetosalisylic Acid Absorption.|Completed||N/A|9|Actual|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 00:08:02.056548|2018-06-01 00:08:02.056548
NCT01061021|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-11-15|2010-02-01|2010-02-02|Estimate|||||||2010-11-15|2010-11-17|Estimate|March 2005||2005-03-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|October 2009|Actual|2009-10-31||Interventional|||HIV Prevention Intervention for People Living With HIV/AIDS|HIV Treatment Adherence/Risk Reduction Integrated|Completed||Phase 2|490|Actual|University of Connecticut||2|||f||||f||||||||||2018-06-01 00:08:02.292315|2018-06-01 00:08:02.292315
NCT01061008|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2013-02-15||2014-06-11|2010-02-01|2010-02-02|Estimate|2014-06-11|2014-07-15|Estimate||||2014-06-11|2014-07-15|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Handgrip Exercise for Arteriovenous Fistula Maturation|The Effects of Progressive Handgrip Exercise Training on Arteriovenous Fistula Maturation in Chronic Kidney Disease|Completed||N/A|31|Actual|Bangor University||2|||f||||f||||||||||2018-06-01 00:08:02.414191|2018-06-01 00:08:02.414191
NCT01060995|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2018-05-01|2010-02-01|2010-02-02|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2009||2009-01-31|May 2018|2018-05-31|March 26, 2013|Actual|2013-03-26|July 2009|Actual|2009-07-31||Observational|SmartConsent||SmartConsent: A Computerized Informed Consent for Patients|SmartConsent: A Computerized Informed Consent for Patients|Completed|||50|Actual|The University of Texas Health Science Center, Houston|||2||f||||t||||||||||2018-06-01 00:08:02.722223|2018-06-01 00:08:02.722223
NCT01060982|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2014-05-05|2010-02-01|2010-02-02|Estimate|||||||2014-05-05|2014-05-06|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure|Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU)Treatment Procedure: A Monocentre, Open, Uncontrolled Study|Completed||N/A|5|Actual|Theraclion||1|||f||||f||||||||||2018-06-01 00:08:02.786669|2018-06-01 00:08:02.786669
NCT01060969|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2012-09-07|2010-02-01|2010-02-02|Estimate|||||||2012-09-07|2012-09-10|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention|Tadalafil and Acetazolamide Versus Acetazolamide in Acute Mountain Sickness Prevention|Completed||N/A|55|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 00:08:02.886512|2018-06-01 00:08:02.886512
NCT01060956|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2011-07-26|2010-02-01|2010-02-02|Estimate|||||||2011-07-26|2011-07-27|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Clinical Impact of Isolation of Two Different Bacteria in Urinary Cultures|The Clinical Impact of Isolation of Two Different Bacteria in Urinary Cultures|Completed||N/A|81|Actual|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-06-01 00:08:03.008958|2018-06-01 00:08:03.008958
NCT01060943|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|May 2008||2008-05-31|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds|A Randomized, Multicenter, Prospective, Paired Comparison of the Efficacy and Safety of TheraFill® Versus KOKEN for 3 Months on Nasolabial Folds|Completed||Phase 3|73|Actual|Sewon Cellontech Co., Ltd.||2|||f||||t||||||||||2018-06-01 00:08:03.387119|2018-06-01 00:08:03.387119
NCT01060930|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-12-15|2010-02-01|2010-02-02|Estimate|||||||2011-12-15|2011-12-16|Estimate|March 2010||2010-03-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|DISCO||Diesel Exhaust Inhalation, Systemic Nitric Oxide Inhibition and Cardiac Output|Diesel Exhaust Inhalation, Systemic Nitric Oxide Inhibition and Cardiac Output|Completed||N/A|14|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:08:03.510859|2018-06-01 00:08:03.510859
NCT01060917|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2003||2003-01-31|January 2010|2010-01-31|May 2003|Actual|2003-05-31|March 2003|Actual|2003-03-31||Interventional|||Glucose Clamp Study to Prove Hypo- and Hyperglycemic Episodes Using a Non-invasive Glucose Monitoring Device|A Single Center, Open Study in Order to Prove Hypo- and Hyperglycaemic Episodes Using a Non-invasive Glucose Measuring Method in Healthy Volunteers and in Type 1 Diabetic Patients|Completed||Phase 1/Phase 2|21|Actual|Profil Institut für Stoffwechselforschung GmbH|||||f||||f||||||||||2018-06-01 00:08:03.632161|2018-06-01 00:08:03.632161
NCT01060904|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2014-12-17|2010-01-29|2010-02-02|Estimate|||||||2014-12-17|2014-12-18|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma|A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With Multi-Agent Chemotherapy as Frontline Therapy in Patients With Hodgkin Lymphoma|Completed||Phase 1|51|Actual|Seattle Genetics, Inc.||2|||t||||f||||||||||2018-06-01 00:08:03.738646|2018-06-01 00:08:03.738646
NCT01060891|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2016-10-10|2010-02-01|2010-02-02|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2009||2009-05-31|October 2016|2016-10-31||||April 2015|Actual|2015-04-30||Interventional|||Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria||Completed||Phase 1|200|Actual|Poitiers University Hospital|||||f||||f||||||||||2018-06-01 00:08:03.852779|2018-06-01 00:08:03.852779
NCT01060878|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2013-03-01|2010-02-01|2010-02-02|Estimate|||||||2013-03-01|2013-03-04|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CONFIDENT-PD||Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)|Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks|Completed||Phase 2|425|Actual|Phytopharm||4|||f||||t||||||||||2018-06-01 00:08:03.956212|2018-06-01 00:08:03.956212
NCT01060865|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2017-01-10|2010-02-01|2010-02-02|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|REALITY||Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements|Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation|Terminated||Phase 4|50|Actual|Meir Medical Center||1||The participants signed an old version of the informed consent.|f||||t||||||||Undecided||2018-06-01 00:08:04.284796|2018-06-01 00:08:04.284796
NCT01060852|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2014-04-10|2010-02-01|2010-02-02|Estimate|||||||2014-04-10|2014-04-11|Estimate|March 2006||2006-03-31|April 2014|2014-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|MD||Evaluation of the Media Detective Program for Elementary School-Aged Children to Prevention Substance Use|Randomized Controlled Trial Efficacy Study of a Media Literacy Education Substance Use Prevention Program for Elementary School-Aged Children|Completed||N/A|679|Actual|Innovation Research & Training||1|||f||||t||||||||||2018-06-01 00:08:04.37013|2018-06-01 00:08:04.37013
NCT01060839|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|April 2006||2006-04-30|February 2010|2010-02-28|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|PN||Evaluation of Counseling for Partner Notification|Evaluation of Partner Notification for Sexually Transmitted Infections in Bangladesh|Completed||Phase 1/Phase 2|1339|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 00:08:04.499122|2018-06-01 00:08:04.499122
NCT01060826|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-06-21|2010-02-01|2010-02-02|Estimate|||||||2011-06-21|2011-06-22|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|crepsmt1||Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Randomized, Double-blind Study to Evaluate the Efficacy of Administration With Intravenous Bolus Followed by a Continuous Infusion of Somatostatin in the Prevention of Post-ERCP Pancreatitis|Unknown status|Recruiting|Phase 3|510|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-06-01 00:08:04.62258|2018-06-01 00:08:04.62258
NCT01060813|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2015-08-20|2010-02-01|2010-02-02|Estimate|||||||2015-08-20|2015-08-21|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Study of the Benefit of Exercise and Aminoacid Supplements in Cirrhotic Patients|Study of the Benefit of Exercise and Aminoacid Supplements in Cirrhotic Patients|Completed||N/A|17|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-06-01 00:08:04.749469|2018-06-01 00:08:04.749469
NCT01060800|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2018-04-17|2010-02-01|2010-02-02|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2009||2009-06-30|April 2018|2018-04-30|August 2025|Anticipated|2025-08-31|August 2025|Anticipated|2025-08-31||Observational|||The Genetics of Chiari Type I Malformation|The Genetics of Chiari Type I Malformation (CMI) With or Without Syringomyelia|Active, not recruiting|||2000|Anticipated|Duke University|||||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum, DNA~   "|No||2018-06-01 00:08:04.853911|2018-06-01 00:08:04.853911
NCT01060787|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2017-04-24|2010-02-01|2010-02-02|Estimate|||||||2017-04-24|2017-04-25|Actual|February 4, 2016|Actual|2016-02-04|April 2017|2017-04-30|May 5, 2018|Anticipated|2018-05-05|March 6, 2018|Anticipated|2018-03-06||Observational|||Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant|An Observational Bilateral Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant for at Least One Year|Recruiting|||100|Anticipated|Bausch & Lomb Incorporated|||2||f||||f||||||||||2018-06-01 00:08:04.980502|2018-06-01 00:08:04.980502
NCT01060774|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|||2018-05-29|2010-02-01|2010-02-02|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2008||2008-07-31|May 2018|2018-05-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Bupivacaine Versus Lidocaine on Inflammatory Regulation|Comparison of Bupivacaine vs Lidocaine on Inflammatory Regulation Following Endodontic Surgery: A Double-Blind, Randomized, Controlled Clinical Trial|Completed||Phase 4|11|Actual|University of Maryland||2|||f||||f||||||||||2018-06-01 00:08:05.265027|2018-06-01 00:08:05.265027
NCT01060761|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2017-11-02|2010-02-01|2010-02-02|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2010||2010-03-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|KRIPP||Involvement of Patients and Relatives in the Course of Cancer Disease|Involvement of Patients and Relatives in the Course of Cancer Disease With a Particular View to Rehabilitation and the Life With Cancer|Completed||N/A|42|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-06-01 00:08:05.365921|2018-06-01 00:08:05.365921
NCT01060748|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-03-04|2010-02-01|2010-02-02|Estimate|||||||2011-03-04|2011-03-07|Estimate|March 2010||2010-03-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea|Development of a Polyvalent Vaccine Against Enterotoxigenic Escherichia Coli (ETEC)Protective Efficacy of the Deletion-Attenuated, Multi-valent ACE527 Against Challenge With a Prototype Strain of Enterotoxigenic E.Coli Expressing LT and ST Enterotoxins and CFA/I (Strain H10407) in Human Challenge Model.|Completed||Phase 2|70|Actual|TD Vaccines A/S||2|||f||||t||||||||||2018-06-01 00:08:05.432106|2018-06-01 00:08:05.432106
NCT01060735|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|||2011-07-21|2010-02-01|2010-02-02|Estimate|||||||2011-07-21|2011-07-22|Estimate|November 2010||2010-11-30|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Vitamin D Supplementation During Pregnancy and Bone Status in Children at Birth and at One Year of Age|The Effect of Different Doses of Vitamin D Supplementation During Pregnancy on Bone and Vitamin D Status in Children at Birth and at One Year Age|Unknown status|Recruiting|N/A|120|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 00:08:05.508423|2018-06-01 00:08:05.508423
NCT01060722|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|||2015-04-05|2010-02-01|2010-02-02|Estimate|||||||2015-04-05|2015-04-07|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||MOD-4023 Study in Healthy Male Volunteers|A Phase I, Randomized, Double-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of a Long Acting Human Growth Hormone (hGH) Product (MOD-4023), in Healthy Volunteers|Completed||Phase 1|24|Actual|Opko Biologics||3|||f||||f||||||||||2018-06-01 00:08:05.581675|2018-06-01 00:08:05.581675
NCT01060709|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-10-25|2010-02-01|2010-02-02|Estimate|||||||2010-10-25|2010-10-26|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Transcutaneous Measurement of Carbon Dioxide Versus Current Sedation Practices in Sedated Patients|Does Transcutaneous Carbon Dioxide Partial Pressure (TcCO2) Monitoring Detect Hypoventilation Prior to Current Sedation Monitoring Practices?|Completed|||250|Anticipated|University Medical Center Groningen|||1||f||||f||||||||||2018-06-01 00:08:05.646896|2018-06-01 00:08:05.646896
NCT01060696|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2009||2009-01-31|January 2010|2010-01-31|May 2010|Anticipated|2010-05-31|March 2010|Anticipated|2010-03-31||Interventional|||Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile Women|Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile Women. A Double Blind Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|138|Anticipated|Mahidol University||1|||f||||f||||||||||2018-06-01 00:08:05.703499|2018-06-01 00:08:05.703499
NCT01060683|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2016-10-24|2010-02-01|2010-02-02|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2010||2010-01-31|August 2009|2009-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Non-invasive Measurement of Hemoglobin Concentration With Pulse Co-oximetry|Liver Resection and Non-invasive Measurement of Hemoglobin Concentration With Pulse Co-oximetry|Completed|||30|Actual|University Medical Center Groningen|||2||f||||f||||||Samples Without DNA|"~     laboratory hemoglobin, Coagulation variables,blood chemistry,Blood gas analysis~   "|||2018-06-01 00:08:05.899811|2018-06-01 00:08:05.899811
NCT01060670|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|2016-03-23||2016-07-29|2010-01-31|2010-02-02|Estimate|2016-07-29|2016-09-22|Estimate||||2016-07-29|2016-09-22|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers|A Multi-Center, Randomized, Controlled Clinical Trial to Evaluate The Safety and Effectiveness of Integra® Dermal Regeneration Template for the Treatment of Neuropathic Diabetic Foot Ulcers|Completed||N/A|545|Actual|Integra LifeSciences Corporation||2|||f||||f||||||||||2018-06-01 00:08:06.045577|2018-06-01 00:08:06.045577
NCT01060657|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|December 2011|Anticipated|2011-12-31|May 2011|Anticipated|2011-05-31||Observational|||Clinical Values of Dose Reduction Techniques in Computed Tomography (CT) Coronary Artery Imaging With 64-row Multi-Slice Helical CT||Unknown status|Active, not recruiting||500|Anticipated|General Hospital of Chinese Armed Police Forces|||2||f||||t||||||||||2018-06-01 00:08:06.775517|2018-06-01 00:08:06.775517
NCT01060644|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|||2013-11-20|2010-02-01|2010-02-02|Estimate|||||||2013-11-20|2013-11-21|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Maxillary Sinus Floor Elevation Following Simultaneous Implant Installation Without Graft Material|Maxillary Sinus Floor Elevation Following Simultaneous Implant Installation Without Graft Material|Completed|||15|Actual|Carmel Medical Center|||||f||||f||||||||||2018-06-01 00:08:06.842743|2018-06-01 00:08:06.842743
NCT01060631|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2011-06-29|2010-02-01|2010-02-02|Estimate|||||||2011-06-29|2011-07-01|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Influence of Intracranial Lesions on Bispectral Index|"Assessment of the Influence of Intracranial Space Occupying Lesions on the Reliability Off Monitoring of the Bispectral Index for Detection of Return of Consciousness."|Completed|||40|Actual|University Medical Center Groningen|||2||f||||f||||||Samples Without DNA|"~     plasma blood~   "|||2018-06-01 00:08:06.905636|2018-06-01 00:08:06.905636
NCT01060618|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-31|||2013-02-27|2010-02-01|2010-02-02|Estimate|||||||2013-02-27|2013-02-28|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TROPISMVC||Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term|Estudio Comparativo de Dos métodos Para Predecir el Uso de Co-receptores Por el Virus de la Inmunodeficiencia 1 (HIV-1): el Ensayo fenotípico (Trofile ESTA®) y la Respuesta virológica a Corto Plazo a un Antagonista de CCR5|Completed||Phase 2/Phase 3|58|Actual|Asociacion para el Estudio de las Enfermedades Infecciosas||1|||f||||f||||||||||2018-06-01 00:08:06.992239|2018-06-01 00:08:06.992239
NCT01060605|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|October 2001||2001-10-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|December 2005|Actual|2005-12-31||Interventional|ITA-Rp||Pre Transplant Rapamycin Treatment in Islet Transplantation Alone|Effects of Pre-transplant Rapamycin Treatment and Tacrolimus Levels on the Outcome of Islet Transplantation Alone in Patients Receiving Edmonton Protocol.|Completed||Phase 3|11|Actual|IRCCS San Raffaele||1|||f||||t||||||||||2018-06-01 00:08:07.076628|2018-06-01 00:08:07.076628
NCT01060592|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-30|2013-02-20||2013-04-04|2010-01-30|2010-02-02|Estimate|2013-03-26|2013-04-04|Estimate||||2013-04-04|2013-04-08|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||LapBand Adjustment to Improve Early Weight Loss|Effect on Early Weight Loss by Adjusting Gastric Band During Surgery|Completed||Phase 2/Phase 3|35|Actual|Crospon||2|||f||||f||||||||||2018-06-01 00:08:07.188515|2018-06-01 00:08:07.188515
NCT01060579|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-30||2014-02-17|2014-04-18|2010-02-01|2010-02-02|Estimate||||2014-03-25|2014-04-21|Estimate|2014-04-18|2014-05-08|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure|A Phase 2, Double-masked, Randomized, Active-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure|Completed||Phase 2|217|Actual|Aerie Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:08:07.463323|2018-06-01 00:08:07.463323
NCT01060566|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-04-15|2010-02-01|2010-02-02|Estimate|||||||2010-04-15|2010-04-16|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770|An Open-Label Phase 1 Study to Examine the Effect of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770 in Healthy Subjects|Completed||Phase 1|24|Anticipated|Vertex Pharmaceuticals Incorporated||4|||f||||f||||||||||2018-06-01 00:08:07.579607|2018-06-01 00:08:07.579607
NCT01060553|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2014-10-15||2015-04-06|2010-02-01|2010-02-02|Estimate|2014-11-07|2014-11-19|Estimate||||2015-04-06|2015-04-28|Estimate|July 2010||2010-07-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pilot of Acupuncture to Improve Quality of Life in Veterans With TBI and PTSD|Pilot of Acupuncture to Improve Quality of Life in Veterans With TBI and PTSD|Completed||N/A|34|Actual|VA Office of Research and Development|very small numbers of subjects due to dropout and loss to followup. data from the wait list subjects who completed the intervention were combined with those initially assigned to treatment for a pre/post single group analysis|2|||f||||f||||||||||2018-06-01 00:08:07.660593|2018-06-01 00:08:07.660593
NCT01060540|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2014-04-16||2015-04-06|2010-02-01|2010-02-02|Estimate|2014-07-11|2014-08-04|Estimate||||2015-04-06|2015-04-24|Estimate|August 2010||2010-08-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Baseline characteristics were calculated for all participants who attended the baseline session, where consent and baseline measures were obtained, regardless of whether they attended the intervention (risk counseling session).|Genetic Testing for Type 2 Diabetes|The Impact of Genetic Testing for Type 2 Diabetes on Health Behaviors|Completed||N/A|601|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:08:07.84597|2018-06-01 00:08:07.84597
NCT01060527|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2010||2010-01-31|January 2010|2010-01-31||||||||Observational|||Altered Faecal Protease Activity in Irritable Bowel Syndrome Patients in China||Unknown status|Enrolling by invitation||60|Anticipated|Health Science Center of Xi’an Jiaotong University|||3||f||||||||||||||2018-06-01 00:08:08.336862|2018-06-01 00:08:08.336862
NCT01060514|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-10-28|2010-02-01|2010-02-02|Estimate|||||||2013-10-28|2013-10-30|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|September 2013|Actual|2013-09-30|February 2012|Actual|2012-02-29||Interventional|||Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer|Phase I Study of Pazopanib in Combination With Vinorelbine in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer|Terminated||Phase 1|8|Actual|Northwestern University||1||Lack of timely accrual.|f||||t||||||||||2018-06-01 00:08:08.379283|2018-06-01 00:08:08.379283
NCT01060501|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|July 1992||1992-07-31|July 1991|1991-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|FOGT1||Modulation of Adjuvant 5-FU by Folinic Acid and Interferon-alpha in Colon Cancer|Phase 3 Study of Adjuvant Chemoradiotherapy of Advanced Resectable Rectal Cancer Comparing Modulation of 5-FU With Folinic Acid or With Interferon-alpha|Completed||Phase 3|796|Actual|University of Ulm||3|||f||||t||||||||||2018-06-01 00:08:08.44541|2018-06-01 00:08:08.44541
NCT01060488|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2014-08-04|2010-02-01|2010-02-02|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2004||2004-01-31|July 2011|2011-07-31||||November 2005|Actual|2005-11-30||Interventional|||Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency|A Phase III, Multicentric, Open-label, Randomised, Comparative, Parallel Group Study of (GHRH + Arginine) Combination Test vs. Insulin Tolerance Test (ITT) in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)|Completed||Phase 3|69|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:08:08.512992|2018-06-01 00:08:08.512992
NCT01060475|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-06-04|2010-02-01|2010-02-02|Estimate|||||||2010-06-04|2010-06-07|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|LIM||Safety and Tolerability of LIM-0705 in Healthy Male Subjects|A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of LIM-0705 Given With or Without Tacrolimus in Healthy Male Subjects|Completed||Phase 1|44|Actual|Limerick BioPharma||4|||f||||t||||||||||2018-06-01 00:08:08.583902|2018-06-01 00:08:08.583902
NCT01060462|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2014-05-14|2010-01-29|2010-02-02|Estimate|||||||2014-05-14|2014-05-15|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients|Efficacy According to Treatment Timing in Immunocompromised Patients Treated With Itraconazole Injection as an Empiric Antifungal Therapy|Completed|||438|Actual|Janssen Korea, Ltd., Korea|||1||f||||t||||||||||2018-06-01 00:08:08.645632|2018-06-01 00:08:08.645632
NCT01060449|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-12-15|2010-02-01|2010-02-02|Estimate|||||||2013-12-15|2013-12-17|Estimate|August 2008||2008-08-31|December 2013|2013-12-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|SILVeR-CRT||Stimulus Intensity in Left Ventricular Leads|Stimulus Intensity in Left Ventricular Leads and Response to Cardiac Resynchronization Therapy|Completed||N/A|60|Actual|Emory University||2|||f||||t||||||||||2018-06-01 00:08:08.857638|2018-06-01 00:08:08.857638
NCT01060436|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2016-12-03|2010-02-01|2010-02-02|Estimate|||||||2016-12-03|2016-12-06|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Observational|Face||Face of Sleepiness|The Face of Sleepiness|Completed|||30|Actual|University of Michigan|||||f||||f||||||||||2018-06-01 00:08:08.926288|2018-06-01 00:08:08.926288
NCT01060423|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2016-10-25|2010-02-01|2010-02-02|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|May 2015|Actual|2015-05-31|December 2012|Actual|2012-12-31||Interventional|DEBIRITUX||TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer|A Randomized Phase II Trial of Irinotecan Drug-eluting Beads Administered by Hepatic Chemoembolization With Intravenous Cetuximab (DEBIRITUX) Versus Systemic Treatment With Intravenous Cetuximab and Irinotecan in Patients With Refractory Metastatic Colorectal Cancer and K-ras Wild-type Tumours|Terminated||Phase 2|8|Actual|Martin-Luther-Universität Halle-Wittenberg||2||Terminated due to poor subject enrolment|f||||f||||||||||2018-06-01 00:08:08.993023|2018-06-01 00:08:08.993023
NCT01060410|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2012-06-18|2010-02-01|2010-02-02|Estimate|||||||2012-06-18|2012-06-20|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment|Exploration of Genetic Polymorphisms Related to Individual Variations of Side Effects of Cyclophosphamide in Systemic Lupus Erythematosus Treatment|Completed|||222|Actual|Sun Yat-sen University|||1||f||||f||||||Samples With DNA|"~     Whole blood for DNA extraction as well as for pharmacokinetic studies~   "|||2018-06-01 00:08:09.091446|2018-06-01 00:08:09.091446
NCT01060397|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2014-11-25|2010-02-01|2010-02-02|Estimate|||||||2014-11-25|2014-11-26|Estimate|November 2009||2009-11-30|January 2010|2010-01-31|November 2013|Actual|2013-11-30|July 2011|Actual|2011-07-31||Interventional|ADPAC||A Controlled Trial of Extended Brief Interventions in Alcohol Dependent Patients|A Randomized Controlled Trial of Extended Brief Interventions for Alcohol-dependent Patients in an Acute Care Setting|Completed||N/A|267|Actual|Southport and Ormskirk Hospital NHS Trust||2|||f||||t||||||||||2018-06-01 00:08:09.282268|2018-06-01 00:08:09.282268
NCT01060384|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2017-09-01|2010-02-01|2010-02-02|Estimate|||||||2017-09-01|2017-09-05|Actual|March 2010||2010-03-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-06-01 00:08:09.393203|2018-06-01 00:08:09.393203
NCT01060371|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2017-08-16|2010-01-29|2010-02-02|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2010||2010-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias|Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) to Study Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias (SCA)|Recruiting|||800|Anticipated|University of Florida|||4||f||||t||||||Samples With DNA|"~     Blood samples collection for DNA analysis and genetic modifier study~   "|||2018-06-01 00:08:09.473711|2018-06-01 00:08:09.473711
NCT01060358|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-02-05|2010-01-29|2010-02-02|Estimate|||||||2013-02-05|2013-02-07|Estimate|August 2009||2009-08-31|January 2010|2010-01-31|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Observational|||Assessment of Spinal Stability|Neuromuscular Neutral Zones in Humans: A New Method to Assess Spinal Stability|Completed|||25|Actual|University of Colorado, Denver|||1||f||||t||||||||||2018-06-01 00:08:09.649349|2018-06-01 00:08:09.649349
NCT01060345|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2016-01-06|2010-01-29|2010-02-02|Estimate|||||||2016-01-06|2016-01-07|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ|A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS)|Terminated||N/A|32|Actual|University of Chicago||1||Drug no longer available|f||||f||||||||||2018-06-01 00:08:09.721981|2018-06-01 00:08:09.721981
NCT01060332|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-03-25|2010-02-01|2010-02-02|Estimate|||||||2010-03-25|2010-03-26|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Observational|||The Body Constitution and Quality of Life of Diabetic|The Body Constitution and Quality of Life of Diabetic|Unknown status|Recruiting||500|Anticipated|Taichung Veterans General Hospital|||1||f||||t||||||||||2018-06-01 00:08:09.79677|2018-06-01 00:08:09.79677
NCT01060319|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-10-10|2010-02-01|2010-02-02|Estimate|||||||2013-10-10|2013-10-14|Estimate|December 2013||2013-12-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies|A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies|Unknown status|Not yet recruiting||40|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     Bladder cancer specimens~   "|||2018-06-01 00:08:09.875786|2018-06-01 00:08:09.875786
NCT01060306|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2011|Anticipated|2011-01-31|||||Observational|PONTINA||Optical Coherence Tomography Evaluation of a Biodegradable Polymer-based Drug-eluting Stent|Prospective Optical cohereNce Tomography Evaluation of neoINtimal Coverage of a biodegrAdable Polymer-based Drug-eluting Stent|Unknown status|Recruiting||30|Anticipated|Ospedale Santa Maria Goretti|||3||f||||f||||||||||2018-06-01 00:08:09.935826|2018-06-01 00:08:09.935826
NCT01060293|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2013-09-10|2010-02-01|2010-02-02|Estimate|||||||2013-09-10|2013-09-11|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|DAD-HF II||Dopamine in Acute Decompensated Heart Failure II|Comparison of High-dose Furosemide, Low-dose Furosemide, and the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure|Terminated||Phase 4|161|Actual|Larissa University Hospital||3||Safety issues in the LDFD-group (higher heart rate with dopamine)|f||||f||||||||||2018-06-01 00:08:10.000364|2018-06-01 00:08:10.000364
NCT01060280|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2014-08-15|2010-02-01|2010-02-02|Estimate|||||||2014-08-15|2014-08-18|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Effectiveness of Group GDS and Individual GDS for Treatment of Low Back Pain in Primary Care|The Effectiveness of the Physiotherapy Techniques Group GDS and Individual GDS for the Treatment of Nonspecific Low Back Pain in Primary Care. A Cluster, Randomized, Controlled Trial.|Completed||N/A|461|Actual|Kovacs Foundation||3|||f||||t||||||||||2018-06-01 00:08:10.076189|2018-06-01 00:08:10.076189
NCT01060267|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Intravenous Erythromycin Before Endoscopy in Patients With Variceal Bleeding: A Randomized, Double-Blind Trial|Effect of Intravenous Bolus Infusion of Erythromycin Prior to Endoscopy in Patients Presenting With Variceal Bleeding: A Prospective, Randomized, Double- Blind ,Placebo Controlled, Trial|Completed||N/A|102|Actual|King Abdulaziz Medical City||2|||f||||t||||||||||2018-06-01 00:08:10.152994|2018-06-01 00:08:10.152994
NCT01060254|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29||2012-04-26|2015-11-30|2010-01-29|2010-02-02|Estimate||||2012-04-26|2012-04-30|Estimate|2015-11-30|2015-12-30|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome|Terminated||Phase 2|31|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Logistic reasons associated with the FDA-imposed clinical hold.|f||||t||||||||||2018-06-01 00:08:10.225029|2018-06-01 00:08:10.225029
NCT01060241|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2011-06-28|2010-02-01|2010-02-02|Estimate|||||||2011-06-28|2011-06-29|Estimate|February 2010||2010-02-28|January 2010|2010-01-31||||||||Interventional|||Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM) on Combination Oral Therapy|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus on Combination Oral Therapy|Suspended||N/A|50|Anticipated|Endocrine Research Society||2||Other projects warranted more attention|f||||f||||||||||2018-06-01 00:08:10.336322|2018-06-01 00:08:10.336322
NCT01060228|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2012-12-21|2010-01-29|2010-02-02|Estimate|||||||2012-12-21|2012-12-24|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|February 2009|Actual|2009-02-28|||||Interventional|||A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men|An Open-Label, Drug-Drug Interaction Study Between Steady-State Valproic Acid and Single-Dose Paliperidone Extended-Release in Healthy Men|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 00:08:10.396391|2018-06-01 00:08:10.396391
NCT01060215|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-02-01|2010-02-01|2010-02-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|May 2009||2009-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effects of Joint Effusion on Proprioception|Clinical Trial for the Effects of Joint Effusion on Proprioception|Completed||N/A|40|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-06-01 00:08:10.455679|2018-06-01 00:08:10.455679
NCT01060202|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-07-16|2010-01-29|2010-02-02|Estimate|||||||2013-07-16|2013-07-17|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib|A Prospective, Open-label, Multicenter Observational Study to Evaluate the QoL of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib|Completed|||60|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-06-01 00:08:10.51172|2018-06-01 00:08:10.51172
NCT01060189|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2015-04-09|2010-02-01|2010-02-02|Estimate|||||||2015-04-09|2015-04-13|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery|Hemostatic and Anti-Inflammatory Effects of Ulinastatin and Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery|Unknown status|Recruiting|N/A|350|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||4|||f||||t||||||||||2018-06-01 00:08:10.57139|2018-06-01 00:08:10.57139
NCT01060176|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2015-04-09|2010-02-01|2010-02-02|Estimate|||||||2015-04-09|2015-04-13|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Tranexamic Acid on Blood Loss and Transfusion in Cardiac Surgery|A Multicenter Clinical Trial of Tranexamic Acid on Blood Loss and Allogeneic Transfusions in Cardiopulmonary Bypass Cardiac Surgery|Unknown status|Recruiting|N/A|1200|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||4|||f||||t||||||||||2018-06-01 00:08:10.637299|2018-06-01 00:08:10.637299
NCT01060163|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-11-21|2010-02-01|2010-02-02|Estimate|||||||2011-11-21|2011-11-22|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|TRACED||Tranexamic Acid in Clopidogrel Exposure to Decrease Hemorrhage and Transfusion|Effects of Antifibrinolytics on Bleeding and Transfusion Outcomes in Patients Receiving Coronary Artery Bypass Surgery With Preoperative Clopidogrel Exposure|Completed||N/A|552|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||6|||f||||t||||||||||2018-06-01 00:08:10.706112|2018-06-01 00:08:10.706112
NCT01060150|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2013-03-19||2013-08-14|2010-01-29|2010-02-02|Estimate|2013-06-26|2013-07-31|Estimate||||2013-08-14|2013-08-23|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)|Efficacy and Learning Skill After OROS Methylphenidate Treatment in Adolescents With Attention-Deficit/Hyperactivity Disorder: A 12-week, Multi-center, Open-label Study|Completed||Phase 4|115|Actual|Janssen Korea, Ltd., Korea||1|||f||||f||||||||||2018-06-01 00:08:10.791025|2018-06-01 00:08:10.791025
NCT01060137|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-02-04|2010-01-29|2010-02-02|Estimate|||||||2010-02-04|2010-02-05|Estimate|May 2006||2006-05-31|February 2010|2010-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Fentanyl Matrix in Lung Cancer Pain|Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients|Completed||Phase 4|268|Actual|Janssen Korea, Ltd., Korea||1|||f||||||||||||||2018-06-01 00:08:11.063679|2018-06-01 00:08:11.063679
NCT01060124|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2013-03-14||2014-04-10|2010-01-29|2010-02-02|Estimate|2013-03-14|2013-04-26|Estimate||||2014-04-10|2014-04-29|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics|Use of Durogesic D-TRANS in Cancer Pain Patients With Inadequately Controlled Pain Relief From Weak Opioids|Completed||Phase 4|103|Actual|Janssen Korea, Ltd., Korea||1|||f||||f||||||||||2018-06-01 00:08:11.133902|2018-06-01 00:08:11.133902
NCT01060111|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2013-03-26||2013-08-14|2010-01-29|2010-02-02|Estimate|2013-07-03|2013-08-06|Estimate||||2013-08-14|2013-08-22|Estimate|July 2006||2006-07-31|August 2013|2013-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Baseline characteristics were measured for Intent-to-treat (ITT) population which was defined as participants who took topiramate at least once and had migraine improvement data at the Week 6.|An Efficacy and Tolerability Study of Topiramate in Participants With Migraine|Adequate Therapy of Topiramate in Migraine|Completed||Phase 4|250|Actual|Janssen Korea, Ltd., Korea||3|||f||||f||||||||||2018-06-01 00:08:11.338735|2018-06-01 00:08:11.338735
NCT01060098|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2015-03-23|2010-01-29|2010-02-02|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||T Cells and TNF: The Impact of TNF Blockade|T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents|Completed|||52|Actual|Imperial College London|||3||f||||f||||||||||2018-06-01 00:08:11.859568|2018-06-01 00:08:11.859568
NCT01060085|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2017-02-20|2010-02-01|2010-02-02|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2009||2009-02-28|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging|A Comparison of the Diagnostic Accuracy of Adjunctive Digital Breast Tomosynthesis Versus Adjunctive Contrast Enhanced Breast Magnetic Resonance Imaging in the Preoperative Assessment of Breast Cancer|Completed|||51|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||||No||2018-06-01 00:08:11.930054|2018-06-01 00:08:11.930054
NCT01060072|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2011-09-20||2011-12-08|2010-02-01|2010-02-02|Estimate|2011-12-08|2012-01-13|Estimate||||2011-12-08|2012-01-13|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery|A Randomized, Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate, 0.5% Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery|Completed||Phase 3|407|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:08:12.00785|2018-06-01 00:08:12.00785
NCT01060059|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2013-07-31||2015-03-20|2010-01-29|2010-02-02|Estimate|2013-11-27|2014-01-16|Estimate||||2015-03-20|2015-04-09|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes|EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients With Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment|Completed|||888|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 00:08:12.353998|2018-06-01 00:08:12.353998
NCT01060046|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2018-05-07|2010-01-28|2010-02-01|Estimate|||||||2018-05-07|2018-05-14|Actual|August 2007||2007-08-31|May 2018|2018-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Analysis and Characterization of Biologic Implants|Analysis and Characterization of in Vivo Tissue Remodeling in Routine Biologic Mesh Explants From Patients Undergoing Reoperation for Recurrent Hernia or Revision of a Prior Surgical Site|Completed|||241|Actual|Washington University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Biopsy samples of previously implanted biologic meshes, biopsy samples of native abdominal~     wall fascia~   "|||2018-06-01 00:08:13.111953|2018-06-01 00:08:13.111953
NCT01060033|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-04-12|2010-01-29|2010-02-01|Estimate|||||||2017-04-12|2017-04-14|Actual|November 2010||2010-11-30|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|MRI||MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer|A Study of Novel Magnetic Resonance Imaging Sequences for Target Delineation and Prognostication in Cervical Cancer|Completed||N/A|9|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 00:08:13.177163|2018-06-01 00:08:13.177163
NCT01060020|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2018-01-25||2018-04-16|2010-01-28|2010-02-01|Estimate|2018-04-16|2018-04-25|Actual||||2018-04-16|2018-04-25|Actual|January 2010||2010-01-31|April 2018|2018-04-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis|Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis|Completed||Phase 4|20|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 00:08:13.247193|2018-06-01 00:08:13.247193
NCT01060007|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2015-01-23||2017-01-24|2010-01-29|2010-02-01|Estimate|2015-01-23|2015-02-10|Estimate||||2017-01-24|2017-03-08|Actual|November 2009||2009-11-30|January 2017|2017-01-31|September 2014|Actual|2014-09-30|April 2013|Actual|2013-04-30||Interventional|||Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer|A Phase II Evaluation of Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer|Completed||Phase 2|80|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 00:08:13.438672|2018-06-01 00:08:13.438672
NCT01059994|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2015-09-25||2015-11-18|2010-01-29|2010-02-01|Estimate|2015-11-18|2015-12-23|Estimate||||2015-11-18|2015-12-23|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability|Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability|Completed||N/A|12|Actual|The University of Texas Medical Branch, Galveston||4|||f||||f||||||||||2018-06-01 00:08:13.924655|2018-06-01 00:08:13.924655
NCT01059981|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2010-07-06|2010-01-28|2010-02-01|Estimate|||||||2010-07-06|2010-07-08|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Analysis of Emergency Department (ED) Volumes During Natural Disasters|Analysis of Emergency Department Volumes During Natural Disasters|Completed|||1000|Anticipated|The University of Texas Health Science Center, Houston|||3||f||||f||||||||||2018-06-01 00:08:14.154763|2018-06-01 00:08:14.154763
NCT01059968|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2011-06-22|2010-01-28|2010-02-01|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|||Low Energy Availability, Menstrual Irregularity, and Low Bone Mass|The Role of Low Energy Availability and the H-P-A Axis, Menstrual Irregularity, and Low Bone Mass|Completed|||45|Actual|USDA, Western Human Nutrition Research Center|||1||f||||f||||||||||2018-06-01 00:08:14.205231|2018-06-01 00:08:14.205231
NCT01059955|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2016-04-20|2010-01-28|2010-02-01|Estimate|||||||2016-04-20|2016-04-21|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study|Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study|Completed||Phase 1|18|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:08:14.258049|2018-06-01 00:08:14.258049
NCT01059942|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-09-04|2010-01-28|2010-02-01|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|August 2011|Actual|2011-08-31||Observational|||Development and Validation of a Tool to Measure Hand-off Quality|Development and Validation of a Tool to Evaluate Hand-off Quality|Completed|||27|Actual|University of Chicago|||1||f||||f||||||||||2018-06-01 00:08:14.326564|2018-06-01 00:08:14.326564
NCT01059929|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2014-12-02|2010-01-28|2010-02-01|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)|A Double-blinded Randomized Controlled Trial of Dexmedetomidine Versus Propofol for Sedation in Mechanically Ventilated Medical Intensive Care Unit Patients.|Unknown status|Active, not recruiting|Phase 4|210|Anticipated|University of Chicago||2|||f||||t||||||||||2018-06-01 00:08:14.380806|2018-06-01 00:08:14.380806
NCT01059903|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2011-02-04||2012-05-15|2010-01-28|2010-02-01|Estimate|2011-02-04|2011-03-03|Estimate||||2012-05-15|2012-05-22|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body|Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) Comparing Two Different Formulations|Completed||Phase 1|50|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 00:08:14.485797|2018-06-01 00:08:14.485797
NCT01059890|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2016-10-10|2010-01-29|2010-02-01|Estimate|||||||2016-10-10|2016-10-11|Estimate|September 2009||2009-09-30|October 2016|2016-10-31||||June 2013|Actual|2013-06-30||Interventional|||Cerebral Antibiotics Distribution After Acute Brain Injury||Completed||Phase 1|18|Actual|Poitiers University Hospital||4|||f||||f||||||||||2018-06-01 00:08:15.863558|2018-06-01 00:08:15.863558
NCT01059877|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2012-02-23|2010-01-29|2010-02-01|Estimate|||||||2012-02-23|2012-02-24|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia|Assessing the Effect of 1072nm Infrared (IR) Phototherapy on the Behavioral and Cognitive Symptoms Associated With Early and Mid-stage Dementia: a Randomized Placebo-controlled Clinical Trial.|Completed||Phase 1/Phase 2|11|Actual|Quietmind Foundation|||||f||||t||||||||||2018-06-01 00:08:15.925626|2018-06-01 00:08:15.925626
NCT01059864|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2012-11-14|2012-11-05|2012-11-14|2010-01-28|2010-02-01|Estimate|2012-11-14|2012-12-13|Estimate|2012-11-05|2012-11-07|Estimate|2012-11-14|2012-12-13|Estimate|February 2010||2010-02-28|November 2012|2012-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550|Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis|Completed||Phase 2|111|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:08:16.060431|2018-06-01 00:08:16.060431
NCT01059851|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2014-08-19||2017-06-01|2010-01-28|2010-02-01|Estimate|2014-08-19|2014-08-29|Estimate||||2017-06-01|2017-07-02|Actual|May 24, 2010|Actual|2010-05-24|June 2017|2017-06-30|July 15, 2010|Actual|2010-07-15|July 15, 2010|Actual|2010-07-15||Interventional||Baseline characteristics were only presented for participants in Part I of the study (N=16). No participants were enrolled in Part II of the study.|Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4305 in Patients With Impaired Renal Function|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:08:17.078604|2018-06-01 00:08:17.078604
NCT01059838|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-09-07|2010-01-28|2010-02-01|Estimate|||||||2017-09-07|2017-09-08|Actual|October 2009||2009-10-31|September 2017|2017-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Speech Perception for Children With Cochlear Implants|Speech Perception in Noise for Children With Cochlear Implants|Completed||N/A|30|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:08:17.297516|2018-06-01 00:08:17.297516
NCT01059825|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2017-09-08|2012-11-12|2018-04-10|2010-01-29|2010-02-01|Estimate|2017-09-08|2017-10-04|Actual|2012-11-12|2012-11-19|Estimate|2018-04-10|2018-04-11|Actual|February 24, 2010|Actual|2010-02-24|April 2018|2018-04-30|January 20, 2011|Actual|2011-01-20|January 20, 2011|Actual|2011-01-20||Interventional||Of the 375 enrolled participants included in the metformin run-in period, 328 participants were randomized to 1 of 6 treatment groups.|Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)|A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Completed||Phase 2|375|Actual|Merck Sharp & Dohme Corp.||6|||f||||f|t|f||||||||2018-06-01 00:08:17.476627|2018-06-01 00:08:17.476627
NCT01059812|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2015-10-19|2011-02-23|2018-03-06|2010-01-29|2010-02-01|Estimate|2015-10-19|2015-11-20|Estimate|2011-02-23|2011-03-01|Estimate|2018-03-06|2018-04-02|Actual|February 1, 2010|Actual|2010-02-01|March 2018|2018-03-31|December 23, 2010|Actual|2010-12-23|December 23, 2010|Actual|2010-12-23||Interventional|BOOST™|Baseline characterises are presented for full analysis set (FAS), which included all randomized subjects. In exceptional cases subjects from the FAS were eliminated; 2 subjects in the IDegAsp group were excluded from the FAS because the subjects were randomized in error in spite of being screening failures.|A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes|A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™: INTENSIFY ALL)|Completed||Phase 3|424|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:08:19.340973|2018-06-01 00:08:19.340973
NCT01059799|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|2015-10-12|2011-02-23|2017-02-28|2010-01-29|2010-02-01|Estimate|2015-10-12|2015-11-13|Estimate|2011-02-23|2011-03-01|Estimate|2017-02-28|2017-03-30|Actual|February 1, 2010|Actual|2010-02-01|February 2017|2017-02-28|December 16, 2010|Actual|2010-12-16|December 16, 2010|Actual|2010-12-16||Interventional|BEGIN™|"Full analysis set (FAS) included all randomised subjects and missing data is imputed using last observation carried forward (LOCF).~Safety analysis set includes all subjects who received at least one dose of the investigational product or its comparator."|Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes|A Pan Asian Trial Comparing Efficacy and Safety of Insulin NN1250 and Insulin Glargine as Add on to OAD(s) in Subjects With Type 2 Diabetes (BEGIN™: ONCE ASIA)|Completed||Phase 3|435|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:08:19.836177|2018-06-01 00:08:19.836177
NCT01059786|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2018-03-17|2010-01-29|2010-02-01|Estimate|||||||2018-03-17|2018-03-20|Actual|December 18, 2009||2009-12-18|December 14, 2017|2017-12-14|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia|Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia|Recruiting||Phase 2|74|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:08:20.273216|2018-06-01 00:08:20.273216
NCT01059773|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2011-12-22||2014-11-13|2010-01-28|2010-02-01|Estimate|2011-12-22|2012-01-30|Estimate||||2014-11-13|2014-11-24|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|August 2011|Actual|2011-08-31|November 2010|Actual|2010-11-30||Interventional|TRANSIT||A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate|An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT)|Completed||Phase 4|490|Actual|Janssen-Cilag International NV||2|||f||||t||||||||||2018-06-01 00:08:20.414716|2018-06-01 00:08:20.414716
NCT00834470|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2012-08-03|2009-02-01|2009-02-03|Estimate|||||||2012-08-03|2012-08-06|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Adjunctive Atropine During Ketamine Sedation|Is Atropine Needed With Ketamine Sedation?|Completed||Phase 4|140|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 01:21:07.41209|2018-06-01 01:21:07.41209
NCT01059721|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2012-02-07|2010-01-29|2010-02-01|Estimate|||||||2012-02-07|2012-02-08|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Outcome After Soft Tissue Realignment of the Tibial Insertion of the Patella Tendon|Treatment of Patella Dislocation in Childhood and Adolescence. Soft Tissue Realignment of the Tibial Insertion of the Patella Tendon. Long-term Outcome.|Completed||N/A|43|Actual|Medical University of Graz||1|||f||||f||||||||||2018-06-01 00:08:22.26184|2018-06-01 00:08:22.26184
NCT01059708|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-03-15|2010-01-28|2010-02-01|Estimate|||||||2011-03-15|2011-03-17|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|CO PED||Outcome Following Carbon Monoxide Poisoning in Children|Outcome Following Carbon Monoxide Poisoning in Children|Terminated|||40|Anticipated|Intermountain Health Care, Inc.|||1|Low enrollment.|f||||f||||||Samples With DNA|"~     DNA will be obtained by mouthwash, spit collection, or buccal swab,~   "|||2018-06-01 00:08:22.320487|2018-06-01 00:08:22.320487
NCT01059695|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2015-01-13|2010-01-29|2010-02-01|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Observational|CervixLimburg||Analysis of the Results of Treatment for Cervical Carcinoma in Limburg|Retrospective Analysis of Treatment and Quality of Life of Women Treated for Cervical Carcinoma FIGO Stage IB-1 to IVb From 2000-2008 in Limburg, a Province in the South of the Netherlands.|Completed|||220|Actual|Maastricht Radiation Oncology|||||f||||f||||||||||2018-06-01 00:08:22.381297|2018-06-01 00:08:22.381297
NCT01059682|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29||2016-07-26|2016-08-08|2010-01-29|2010-02-01|Estimate||||2016-07-26|2016-07-28|Estimate|2016-08-08|2016-08-10|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease|A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography|Terminated||Phase 3|936|Actual|Hoffmann-La Roche||2||Termination of the clinical development program by the Sponsor|f||||||||||||||2018-06-01 00:08:22.443797|2018-06-01 00:08:22.443797
NCT01059669|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2016-08-17|2010-01-29|2010-02-01|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2009||2009-08-31|August 2016|2016-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||The Diagnosis of Chronic Pancreatitis|A Multimodal Approach to Diagnose Patients With Chronic Pancreatitis|Recruiting|||100|Anticipated|Haukeland University Hospital|||2||f||||f||||||Samples With DNA|"~     Pankreatic juice Duodenal tissue Blood~   "|||2018-06-01 00:08:22.623457|2018-06-01 00:08:22.623457
NCT01059656|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2016-06-30|2010-01-28|2010-02-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|DFSP-PAZO||Phase II Pazopanib Study in Advanced Dermatofibrosarcomas|A Phase IIa Open Multicenter, Trial, of Treatment With Pazopanib (Multi Tyrosine Kinase Inhibitor) in Dermatofibrosarcomas (DFSP), Unresectable Locally Advanced (Potentially Mutilating Surgery), Primary or Relapsing , Transformed or Not.|Terminated||Phase 2|23|Actual|Assistance Publique - Hôpitaux de Paris||1||Decision of Study Principal Investigator|f||||f||||||||||2018-06-01 00:08:22.691069|2018-06-01 00:08:22.691069
NCT01059643|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2017-09-27|2013-04-30|2017-10-28|2010-01-29|2010-02-01|Estimate|2017-10-28|2017-12-04|Actual|2013-04-30|2013-05-08|Estimate|2017-10-28|2017-12-04|Actual|April 2011||2011-04-30|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All enrolled participants.|A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Indication Identification Study of LY2523355 in Patients With Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|103|Actual|Eli Lilly and Company||1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 00:08:22.769573|2018-06-01 00:08:22.769573
NCT01059630|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2016-09-27|2015-09-01|2018-03-28|2010-01-28|2010-02-01|Estimate|2016-09-27|2016-11-17|Estimate|2015-11-08|2015-12-07|Estimate|2018-03-28|2018-03-30|Actual|April 30, 2010|Actual|2010-04-30|March 2018|2018-03-31|February 19, 2019|Anticipated|2019-02-19|September 30, 2014|Actual|2014-09-30||Interventional||Intent to treat (ITT) population included all participants who were randomized in the study.|A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)|An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 3|396|Actual|Genentech, Inc.||2|||f||||t||||||||||2018-06-01 00:08:23.297752|2018-06-01 00:08:23.297752
NCT01059617|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2012-01-31||2018-01-08|2010-01-28|2010-02-01|Estimate|2012-05-03|2012-06-07|Estimate||||2018-01-08|2018-02-01|Actual|February 9, 2010|Actual|2010-02-09|January 2018|2018-01-31|October 21, 2011|Actual|2011-10-21|January 14, 2011|Actual|2011-01-14||Interventional|||Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults|A Study to Evaluate Immune Responses Following A/California/7/2009 (H1N1)V-like Virus Vaccination Given 4 Months Following Seasonal Influenza Vaccination in Adults 19 to 40 Years of Age|Completed||Phase 1|133|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:08:24.969217|2018-06-01 00:08:24.969217
NCT01059604|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2014-10-30|2010-01-29|2010-02-01|Estimate|||||||2014-10-30|2014-11-03|Estimate|December 2001||2001-12-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30|12 Years|Observational [Patient Registry]|||Sumatriptan and Naratriptan Pregnancy Registry|The Sumatriptan and Naratriptan Pregnancy Registry|Completed|||868|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:08:32.299576|2018-06-01 00:08:32.299576
NCT01059591|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-08-10|2010-01-29|2010-02-01|Estimate|||||||2017-08-10|2017-08-11|Actual|May 25, 2006|Actual|2006-05-25|August 2017|2017-08-31|January 25, 2007|Actual|2007-01-25|January 25, 2007|Actual|2007-01-25||Interventional|||First Study in Humans With GSK424887|A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK424887 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin- Receceptor Occupancy|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:08:32.377833|2018-06-01 00:08:32.377833
NCT01059578|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-08-09|2010-01-28|2010-02-01|Estimate|||||||2017-08-09|2017-08-10|Actual|May 23, 2006|Actual|2006-05-23|August 2017|2017-08-31|December 18, 2006|Actual|2006-12-18|December 18, 2006|Actual|2006-12-18||Interventional|NSB101909||First Study in Humans With GSK206136|A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK206136 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin-1 Receptor Occupancy|Completed||Phase 1|33|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:08:32.453541|2018-06-01 00:08:32.453541
NCT01059565|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2013-03-08||2014-02-07|2010-01-29|2010-02-01|Estimate|2014-02-07|2014-03-11|Estimate||||2014-02-07|2014-03-11|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional||Full Analysis Set: participants were randomized and received at least one dose of study drug.|Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection|Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects With Cystic Fibrosis (CF) and Chronic Burkholderia Species Infection|Completed||Phase 3|102|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 00:08:32.590206|2018-06-01 00:08:32.590206
NCT01059552|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2018-02-13|2010-01-29|2010-02-01|Estimate|||||||2018-02-13|2018-02-14|Actual|December 16, 2009|Actual|2009-12-16|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|July 22, 2015|Actual|2015-07-22||Interventional|NSCLC||Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|18|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-06-01 00:08:33.790588|2018-06-01 00:08:33.790588
NCT01059539|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27||2012-12-06|2012-12-06|2010-01-28|2010-02-01|Estimate||||2012-12-06|2012-12-10|Estimate|2012-12-06|2012-12-10|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder|A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder|Completed||Phase 3|403|Actual|Forest Laboratories||1|||f||||f||||||||||2018-06-01 00:08:33.868095|2018-06-01 00:08:33.868095
NCT01059526|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2014-09-10||2018-01-22|2010-01-28|2010-02-01|Estimate|2014-10-02|2014-10-06|Estimate||||2018-01-22|2018-02-20|Actual|February 1, 2010||2010-02-01|January 2018|2018-01-31|June 1, 2014|Actual|2014-06-01|September 1, 2013|Actual|2013-09-01||Observational||Safety population; defined as all patients who received at least 1 treatment dose of KALBITOR|Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema|A Phase 4, Long-Term Observational Safety Study to Evaluate Immunogenicity and Hypersensitivity With Exposure to KALBITOR (Ecallantide) for the Treatment of Acute Attacks of HAE|Completed|||81|Actual|Shire|44 patients (out of 200 planned) received treatment in this study. Additionally, the collection of evaluable efficacy data for the secondary endpoint was limited by a lack of response data collected for HAE attacks treated at alternate sites.||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:08:33.986048|2018-06-01 00:08:33.986048
NCT01059513|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2018-04-26|2010-01-29|2010-02-01|Estimate|||||||2018-04-26|2018-04-30|Actual|January 26, 2010|Actual|2010-01-26|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer|Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer|Recruiting|||60|Anticipated|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 00:08:34.397184|2018-06-01 00:08:34.397184
NCT01059500|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2016-02-15|2010-01-28|2010-02-01|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional|QUAADRICs||Assessment of Acute Disease to Reduce Imaging Costs|Quantitative Pretest Probability to Reduce Cardiopulmonary Imaging in the ED|Completed||N/A|850|Actual|Carolinas Healthcare System||2|||f||||t||||||||||2018-06-01 00:08:34.52265|2018-06-01 00:08:34.52265
NCT01059487|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2010-02-01|2010-01-29|2010-02-01|Estimate|||||||2010-02-01|2010-02-02|Estimate|September 2010||2010-09-30|January 2010|2010-01-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine|Bringing Acute and Wellness Care to Underserved Populations Using Traditional Chinese Medicine: A Pragmatic Clinical Trial Using Quality of Life Measures in a Community Health Care Setting|Unknown status|Not yet recruiting|Early Phase 1|||Chicago College of Oriental Medicine||1|||f||||f||||||||||2018-06-01 00:08:34.603163|2018-06-01 00:08:34.603163
NCT01059474|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-06-21|2010-01-29|2010-02-01|Estimate|||||||2011-06-21|2011-06-22|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion|Transdermal Absorption of DMPS and Its Effect on Urinary Mercury Excretion|Completed||Phase 1|9|Actual|Banner Health||1|||f||||f||||||||||2018-06-01 00:08:34.673784|2018-06-01 00:08:34.673784
NCT01059461|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-29|||2013-09-12|2010-01-29|2010-02-01|Estimate|||||||2013-09-12|2013-09-13|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CerebroHIE||Study of Cerebrolysin for Treatment of Infants With History of Neonatal Hypoxic Ischemic Encephalopathy|Phase 2 Nerve Growth Factor (Cerebrolysin®) for Treatment of Neonatal Hypoxic Ischemic Encephalopathy|Completed||Phase 2|40|Anticipated|Ain Shams University||1|||f||||t||||||||||2018-06-01 00:08:34.750899|2018-06-01 00:08:34.750899
NCT01059448|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28||2015-04-06|2015-08-14|2010-01-28|2010-02-01|Estimate||||2015-04-06|2015-04-27|Estimate|2015-08-14|2015-09-02|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy of AMG 827 in Subjects With RA|A Long-Term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects With Rheumatoid Arthritis|Terminated||Phase 2|211|Actual|Amgen||1||Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)|f||||||||||||||2018-06-01 00:08:34.842622|2018-06-01 00:08:34.842622
NCT01059435|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2013-05-01|2010-01-29|2010-02-01|Estimate|||||||2013-05-01|2013-05-03|Estimate|December 2006||2006-12-31|May 2013|2013-05-31|August 2008|Actual|2008-08-31|July 2007|Actual|2007-07-31||Interventional|||A First-in-human Study Evaluating AMG 785 in Healthy Men and Postmenopausal Women|A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women|Completed||Phase 1|74|Actual|Amgen||2|||f||||||||||||||2018-06-01 00:08:35.044872|2018-06-01 00:08:35.044872
NCT01059253|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2012-06-14|2010-01-28|2010-01-29|Estimate|||||||2012-06-14|2012-06-15|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|AdvanStep||Pilot Study of AdvanStep in Improving Balance in at Risk Elderly|Feasibility and Pilot Study of AdvanStep in Improving Balance in Elderly at Risk for Falls|Withdrawn||Phase 1/Phase 2|0|Actual|Sheba Medical Center||1||equipment not functional|f||||f||||||||||2018-06-01 00:08:36.898365|2018-06-01 00:08:36.898365
NCT01059422|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-05-05|2010-01-28|2010-01-29|Estimate|||||||2011-05-05|2011-05-06|Estimate|October 2010||2010-10-31|May 2011|2011-05-31||||October 2011|Anticipated|2011-10-31||Interventional|||Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients|Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naïve, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy|Unknown status|Recruiting|Phase 4|10|Anticipated|Central Institute of Epidemiology, Moscow, Russia|||||f||||f||||||||||2018-06-01 00:08:35.128544|2018-06-01 00:08:35.128544
NCT01059409|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2016-05-09|2010-01-28|2010-01-29|Estimate|||||||2016-05-09|2016-05-10|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ERAM||Study of Meniscal Allografts|The Clinical and Medico-economical Evaluation of Meniscal Allografts in the Sequelae of Total or Sub-total Meniscectomy.|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:08:35.228725|2018-06-01 00:08:35.228725
NCT01059396|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-08-21|2010-01-28|2010-01-29|Estimate|||||||2017-08-21|2017-08-22|Actual|January 28, 2010|Actual|2010-01-28|January 2017|2017-01-31|July 15, 2015|Actual|2015-07-15|July 15, 2015|Actual|2015-07-15||Interventional|PREDESCI||Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal|Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension|Completed||Phase 4|201|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||3|||f||||f||||||||||2018-06-01 00:08:35.314684|2018-06-01 00:08:35.314684
NCT01059383|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2012-07-27|2010-01-28|2010-01-29|Estimate|||||||2012-07-27|2012-07-30|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms|Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms|Completed||Phase 2|52|Actual|Vecta Ltd.||2|||f||||||||||||||2018-06-01 00:08:35.395758|2018-06-01 00:08:35.395758
NCT01059370|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-10-15|2010-01-28|2010-01-29|Estimate|||||||2012-10-15|2012-10-16|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Autonomic Dysreflexia in Spinal Cord Injury|Autonom Dysrefleksi Ved Rygmarvsskade|Completed||N/A|12|Actual|University of Aarhus||1|||f||||t||||||||||2018-06-01 00:08:35.466674|2018-06-01 00:08:35.466674
NCT01059357|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2017-07-31|2010-01-28|2010-01-29|Estimate|||||||2017-07-31|2017-08-02|Actual|June 2010|Actual|2010-06-30|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|TORS||Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Lesions Using Da Vinci Robotic Surgical System|A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System|Completed||Early Phase 1|58|Actual|Wake Forest University Health Sciences||1|||f||||t|f|t||||||||2018-06-01 00:08:35.540777|2018-06-01 00:08:35.540777
NCT01059344|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2016-10-24||2017-06-27|2010-01-28|2010-01-29|Estimate|2017-03-13|2017-04-24|Actual||||2017-06-27|2017-08-02|Actual|November 2009||2009-11-30|June 2017|2017-06-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis|A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis|Completed||Phase 3|281|Actual|Tillotts Pharma AG|Investigator endoscopy scores resultet in 31% patients with insuficient disease severity at baseline. Central reader scores were used for a post hoc analysis of the primary endpoint, including patients with pre-specified disease severity only.|2|||f||||f||||||||No||2018-06-01 00:08:35.616657|2018-06-01 00:08:35.616657
NCT01059331|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2014-03-20|2010-01-28|2010-01-29|Estimate|||||||2014-03-20|2014-03-21|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Postoperative Analgesia After Laparoscopic Living Donor Nephrectomy|Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study|Completed||Phase 4|80|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 00:08:36.211813|2018-06-01 00:08:36.211813
NCT01059318|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2012-10-22|2010-01-28|2010-01-29|Estimate|||||||2012-10-22|2012-10-24|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis|An Exploratory, Open Label, Non-randomized, Within-patient Multiple Dose-escalation Safety, Tolerability, PK and Efficacy Trial of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis|Completed||Phase 2|22|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:08:36.312232|2018-06-01 00:08:36.312232
NCT01059305|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|2017-02-16||2017-02-16|2010-01-28|2010-01-29|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|February 2011||2011-02-28|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin|Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin|Terminated||Phase 2|10|Actual|M.D. Anderson Cancer Center||1||Lack of primary outcome efficacy.|f||||f||||||||||2018-06-01 00:08:36.457371|2018-06-01 00:08:36.457371
NCT01059292|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-01-28|2010-01-28|2010-01-29|Estimate|||||||2010-01-28|2010-01-29|Estimate|October 2009||2009-10-31|October 2009|2009-10-31||||||||Observational|TIPE2||TIPE2 Associated With Kidney Transplant|Department of Renal Transplantation, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|Suspended|||93|Anticipated|Health Science Center of Xi’an Jiaotong University|||||f||||||||||||||2018-06-01 00:08:36.651049|2018-06-01 00:08:36.651049
NCT01059279|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-07-19|2010-01-28|2010-01-29|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2009||2009-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Heat Intolerance in the Group of FMF Patients|Heat Intolerance in the Group of FMF Patients|Enrolling by invitation|||15|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-06-01 00:08:36.692991|2018-06-01 00:08:36.692991
NCT01059266|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2012-02-09|2010-01-28|2010-01-29|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||PURETHAL Grasses Rush Study|A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis|Completed||Phase 4|150|Actual|HAL Allergy||2|||f||||f||||||||||2018-06-01 00:08:36.752987|2018-06-01 00:08:36.752987
NCT01059227|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-10-05|2010-01-28|2010-01-29|Estimate|||||||2017-10-05|2017-10-06|Actual|January 22, 2010||2010-01-22|August 14, 2015|2015-08-14|August 14, 2015||2015-08-14|||||Observational|||Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers|Effects of a CRF1 Receptor Antagonist on Human Startle in Normal Female Volunteers|Completed|||39|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:08:37.0392|2018-06-01 00:08:37.0392
NCT01059214|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2018-04-04|2010-01-28|2010-01-29|Estimate|||||||2018-04-04|2018-04-05|Actual|December 10, 2009||2009-12-10|October 11, 2012|2012-10-11|October 11, 2012||2012-10-11|||||Observational|||Cardiac MRI for Patients Enrolled in INFUSE-AMI|Cardiac MRI for Patients Enrolled in INFUSE-AMI|Completed|||455|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:08:37.106303|2018-06-01 00:08:37.106303
NCT01059201|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2018-05-17|2010-01-28|2010-01-29|Estimate|||||||2018-05-17|2018-05-18|Actual|January 21, 2010||2010-01-21|May 15, 2017|2017-05-15|May 15, 2017||2017-05-15|||||Observational|||Exome Sequencing in Autistic Spectrum Disorder|Exome Sequencing in Autistic Spectrum Disorder Patients With Altered Cholesterol Homeostasis|Completed|||322|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:08:37.342562|2018-06-01 00:08:37.342562
NCT01059188|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2017-07-21|2010-01-28|2010-01-29|Estimate|||||||2017-07-21|2017-07-25|Actual|May 3, 2010|Actual|2010-05-03|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|December 9, 2016|Actual|2016-12-09||Interventional|||Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)|Preoperative Chemotherapy and Radiotherapy Concomitant to Cetuximab in Non-Small Cell Lung Cancer (NSCLC) Patients With IIIB Disease - A Multicenter Phase II Trial|Active, not recruiting||Phase 2|69|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-06-01 00:08:37.603101|2018-06-01 00:08:37.603101
NCT01059175|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-05-25||2017-04-18|2010-01-28|2010-01-29|Estimate|2017-04-18|2017-04-21|Actual||||2017-04-18|2017-04-21|Actual|September 2010||2010-09-30|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|V3|One patient of the V3 group was not included in the ITT analysis of efficacy results as he did not meet inclusion criteria so 83 pts were analyzed|Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial|Dual-Site LV Pacing in CRT Non Responders Multicenter Randomized V3 Trial|Completed||N/A|84|Actual|Medtronic Bakken Research Center||2|||f||||t||||||||||2018-06-01 00:08:38.004532|2018-06-01 00:08:38.004532
NCT01059162|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-06-07|2010-01-28|2010-01-29|Estimate|||||||2011-06-07|2011-06-08|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery|Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma Surgery|Unknown status|Active, not recruiting|N/A|60|Anticipated|IOPtima Ltd.||1|||f||||f||||||||||2018-06-01 00:08:39.291706|2018-06-01 00:08:39.291706
NCT01059149|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2015-01-15|2010-01-28|2010-01-29|Estimate|||||||2015-01-15|2015-01-16|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|RAICup||Safety and Long-term Effectiveness of High Frequency Repetitive Transcranial Magnetic Stimulation of Stroke (RAICup)|Safety and Long-term Effectiveness of High Frequency Repetitive Transcranial Magnetic Stimulation at the Subacute Phase of Ischaemic Stroke|Terminated||Phase 2|2|Actual|Assistance Publique - Hôpitaux de Paris||2||sponsor decision|f||||f||||||||||2018-06-01 00:08:39.553318|2018-06-01 00:08:39.553318
NCT01059136|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2015-06-10|2010-01-28|2010-01-29|Estimate|||||||2015-06-10|2015-06-11|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|ALBATROSS||Aldosterone Blockade Early After Acute Myocardial Infarction|Aldosterone Lethal Effects Blocked in AMI Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up: THE ALBATROSS TRIAL|Completed||Phase 3|1603|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:08:39.831419|2018-06-01 00:08:39.831419
NCT01059123|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2014-02-06|2010-01-28|2010-01-29|Estimate|||||||2014-02-06|2014-02-07|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SHARE||Short Course of Amoxicillin for Erysipelas|Randomized Non Inferiority Study Comparing Short Course of Oral Amoxicillin to One of the Usual Treatments of Lower Leg Erysipelas|Terminated||Phase 4|10|Actual|Assistance Publique - Hôpitaux de Paris||2||Insufficient number of inclusion|f||||f||||||||||2018-06-01 00:08:40.102447|2018-06-01 00:08:40.102447
NCT01059110|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-01-10|2010-01-28|2010-01-29|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2010||2010-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|January 2015|Actual|2015-01-31||Interventional|VRAIE||Comparison of Five Treatments in Patients With Plantar Warts|Comparison of Occlusive Dressings, Salicylate Ointment, Cryotherapy, Topical 5-fluoro-uracil and Imiquimod in Immunocompetent Patients Presenting Plantar Warts in Office-based Settings: a Randomized Clinical Trial|Terminated||Phase 4|358|Actual|Assistance Publique - Hôpitaux de Paris||4||Difficulty to enrollment patients|f||||t||||||||||2018-06-01 00:08:40.426822|2018-06-01 00:08:40.426822
NCT01059097|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-28|2010-01-28|2010-01-29|Estimate|||||||2010-01-28|2010-01-29|Estimate|August 2001||2001-08-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Surgeon Volume on Outcome of Pancreaticoduodenectomy|Effect of Surgeon Volume on Outcome of Pancreaticoduodenectomy in a High Volume Hospital.|Completed||N/A|610|Actual|Università Vita-Salute San Raffaele||2|||f||||f||||||||||2018-06-01 00:08:40.760705|2018-06-01 00:08:40.760705
NCT01059084|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2012-12-04|2010-01-28|2010-01-29|Estimate|||||||2012-12-04|2012-12-05|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons|An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons|Withdrawn||N/A|0|Actual|University of Washington||||We were unable to enroll any participants into this study.|f||||t||||||||||2018-06-01 00:08:41.011817|2018-06-01 00:08:41.011817
NCT01059071|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-05-11||2016-09-08|2010-01-28|2010-01-29|Estimate|2016-05-11|2016-06-20|Estimate||||2016-09-08|2016-10-27|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide|A Phase I Trial for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide|Completed||Phase 1|21|Actual|Spectrum Health Hospitals||1|||f||||t||||||||||2018-06-01 00:08:41.304238|2018-06-01 00:08:41.304238
NCT01059058|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2015-08-13|2010-01-27|2010-01-29|Estimate|||||||2015-08-13|2015-08-17|Estimate|March 2010||2010-03-31|August 2015|2015-08-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|||Study of Treatments Used for White Spot Lesions After Orthodontic Treatment.|Treatment of White Spot Lesions After Orthodontic Treatment: A Practice-based Randomized Controlled Trial|Completed||N/A|240|Anticipated|University of Washington||3|||f||||t||||||||||2018-06-01 00:08:41.561112|2018-06-01 00:08:41.561112
NCT01059045|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-06-25|2010-01-28|2010-01-29|Estimate|||||||2010-06-25|2010-06-28|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|December 2009|Actual|2009-12-31|||||Interventional|||Prospective Controlled Study Evaluating Cryocontact Therapy of Infantile Hemangiomas of Preterm Infants|Prospective Controlled Study Evaluating Cryocontact Therapy of Infantile Hemangiomas of Preterm Infants|Terminated||N/A|14|Actual|University Hospital Tuebingen||2||Recruitement was much slower than anticipated.|f||||t||||||||||2018-06-01 00:08:41.649595|2018-06-01 00:08:41.649595
NCT01059032|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2015-06-01|2010-01-28|2010-01-29|Estimate|||||||2015-06-01|2015-06-02|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Enhancement and Restoring of Low Dose Abdominal CT Images|Enhancement and Restoring of Low Dose Abdominal CT Images by a Novel Adaptive Nonlinear 3D Post Processing Filter - a Prospective Blinded Interventional Study|Completed||Phase 1|12|Actual|University of Oslo||2|||f||||f||||||||||2018-06-01 00:08:41.70433|2018-06-01 00:08:41.70433
NCT01059019|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2013-06-19|2010-01-28|2010-01-29|Estimate|||||||2013-06-19|2013-06-21|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|Omega-3||Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery|Epithelial Healing and Visual Outcomes of Patients Using Omega-3 Supplements as an Adjunct Therapy Before and After Photorefractive Keratectomy (PRK) Surgery|Completed||N/A|17|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 00:08:41.772169|2018-06-01 00:08:41.772169
NCT01059006|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-08-04|2010-01-28|2010-01-29|Estimate|||||||2011-08-04|2011-08-05|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Peripheral PresbyLASIK Using the Allegretto Wavelight System For The Treatment of Presbyopia|Peripheral PresbyLASIK Using the Allegretto Wavelight System For The Treatment of Presbyopia|Withdrawn||N/A|0|Actual|University of California, San Diego||1||Lead researcher completed fellowship and never got study off ground|f||||f||||||||||2018-06-01 00:08:41.855813|2018-06-01 00:08:41.855813
NCT01058993|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2011-08-03||2012-05-16|2010-01-28|2010-01-29|Estimate|2012-05-16|2012-06-15|Estimate||||2012-05-16|2012-06-15|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||AMD 3100 for Treatment of Myelokathexis|A Phase I Study of the CXCR-4 Inhibitor AMD3100 for the Treatment of Neutropenia Due to Mutations of CXCR-4, the Myelokathexis Syndrome|Completed||Phase 1|6|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 00:08:41.99532|2018-06-01 00:08:41.99532
NCT01058980|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2014-04-01|2010-01-28|2010-01-29|Estimate|||||||2014-04-01|2014-04-03|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|ADVICE||ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial|ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial|Completed||Phase 4|550|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-06-01 00:08:42.213163|2018-06-01 00:08:42.213163
NCT01058967|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-07-22|2010-01-27|2010-01-29|Estimate|||||||2010-07-22|2010-07-23|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|November 2010|Anticipated|2010-11-30|September 2010|Anticipated|2010-09-30||Observational|||Prospective Evaluation of Aeromedical EMS Ultrasound in Major Trauma Victims|UTHSC-H Proposal for Prospective Evaluation of Aeromedical EMS Ultrasound in Major Trauma Victims.|Unknown status|Active, not recruiting||500|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-06-01 00:08:42.324844|2018-06-01 00:08:42.324844
NCT01058941|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2017-03-01||2017-03-01|2010-01-28|2010-01-29|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|September 2010||2010-09-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease|Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease|Completed||Phase 1/Phase 2|67|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 00:08:42.410225|2018-06-01 00:08:42.410225
NCT01058928|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-01-28|2010-01-28|2010-01-29|Estimate|||||||2010-01-28|2010-01-29|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Observational|||Effects of Tracheal Tube Size on Pulmonary Aspiration|Effects of Tracheal Tube Size on Pulmonary Aspiration Different Endotracheal Tube Size Influences Pulmonary Aspiration|Unknown status|Not yet recruiting||36|Anticipated|Seoul National University Bundang Hospital|||2||f||||t||||||||||2018-06-01 00:08:42.872707|2018-06-01 00:08:42.872707
NCT01058915|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-01-28|2010-01-28|2010-01-29|Estimate|||||||2010-01-28|2010-01-29|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|VIRHISTAMI||Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI)|Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition Assessed by Virtual Histology in Patients With ST-Segment Elevation Acute Myocardial Infarction (VIRHISTAMI)|Completed||N/A|87|Actual|Odense University Hospital||2|||f||||f||||||||||2018-06-01 00:08:42.941639|2018-06-01 00:08:42.941639
NCT01058902|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-03-04|2010-01-28|2010-01-29|Estimate|||||||2016-03-04|2016-03-07|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|August 2020|Anticipated|2020-08-31|August 2015|Anticipated|2015-08-31||Interventional|||The Effect Of Aspirin On Survival in Lung Cancer|The Effect Of Aspirin On Survival Following Potentially Curative Resection Of Non Small Cell Carcinoma Of The Lung The Big A Trial|Withdrawn||Phase 3|0|Actual|Liverpool Heart and Chest Hospital NHS Foundation Trust||4||failed to achive funding|f||||t||||||||||2018-06-01 00:08:43.027574|2018-06-01 00:08:43.027574
NCT01058889|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-08-04|2010-01-28|2010-01-29|Estimate|||||||2011-08-04|2011-08-05|Estimate|November 2009||2009-11-30|August 2011|2011-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|Tele-Diab||Tele-Diab: Electronic Diary for Patients With Type 2 Diabetes Mellitus|Tele-Diab: Electronic Diary for Patients With Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 3|50|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:08:43.123938|2018-06-01 00:08:43.123938
NCT01058876|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-05-23|2010-01-27|2010-01-29|Estimate|||||||2013-05-23|2013-05-24|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|6162-AAPK2||Comparison of Low Yield Cigarettes in African Americans vs. Whites|Nicotine Regulation/Response to Low Yield Cigarettes in African-Americans vs. Whites|Completed||Phase 1|43|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:08:43.195552|2018-06-01 00:08:43.195552
NCT01058694|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-01-28|2010-01-28|2010-01-29|Estimate|||||||2010-01-28|2010-01-29|Estimate|June 2007||2007-06-30|January 2010|2010-01-31|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|CAPS||The Impact of Short Message Services (SMS) on ARV Adherence in Western Kenya|Adherence to ARV Treatment and Its Effects on Medium Run Socio-Economic Outcomes: Evidence From Western Kenya|Completed||N/A|720|Actual|Georgetown University||5|||f||||f||||||||||2018-06-01 00:08:44.65769|2018-06-01 00:08:44.65769
NCT01058863|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2015-05-19|2011-08-25|2016-04-26|2010-01-28|2010-01-29|Estimate|2015-05-19|2015-06-08|Estimate|2011-08-25|2011-08-29|Estimate|2016-04-26|2016-05-26|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Randomized and treated|A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma|A Double-blind, Randomized, Placebo-controlled, 5-way Crossover, Multicenter, Single-dose, Dose-ranging Study to Compare the Efficacy and Safety of Albuterol Spiromax® and ProAir® HFA in Adult and Adolescent Subjects Ages 12 and Older With Persistent Asthma|Completed||Phase 2|72|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-06-01 00:08:43.278646|2018-06-01 00:08:43.278646
NCT01058850|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-10-22|2010-01-27|2010-01-29|Estimate|||||||2013-10-22|2013-10-24|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas|A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas|Terminated||Phase 1|3|Actual|Stanford University||1||Resources can be better spent on higher enrolling studies|f||||t||||||||||2018-06-01 00:08:43.566082|2018-06-01 00:08:43.566082
NCT01058837|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-02-09|2010-01-27|2010-01-29|Estimate|||||||2010-02-09|2010-02-11|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|SCD-HeFT10 Yr||SCD-HeFT 10 Year Follow-up|Sudden Cardiac Death in Heart Failure Trial 10 Year Follow-up (SCD-HeFT 10 Year)|Unknown status|Active, not recruiting||1855|Anticipated|Seattle Institute for Cardiac Research|||||f||||f||||||||||2018-06-01 00:08:43.651851|2018-06-01 00:08:43.651851
NCT01058824|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2011-04-25|2010-01-27|2010-01-29|Estimate|||||||2011-04-25|2011-04-26|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule|Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule 500 Mg Formulations, In Healthy Volunteers Using Formulations (Frademicina®) Manufactured By Pfizer Laboratories Ltd|Completed||Phase 1|36|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:08:43.705864|2018-06-01 00:08:43.705864
NCT01058811|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-01-27|2010-01-27|2010-01-29|Estimate|||||||2010-01-27|2010-01-29|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|||||Observational|||Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue|Established Lung Cancer Cell Line and Stroma Cell From Surgical Tissue: Find Lung Cancer Stem Cells and Test Its Chemotherapy Drug Resistance; Compare Stroma Cell Between Tumor Part and Surrounding Part|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Routine Surgical resection of lung tumor~   "|||2018-06-01 00:08:43.769998|2018-06-01 00:08:43.769998
NCT01058798|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-01-27|2010-01-27|2010-01-29|Estimate|||||||2010-01-27|2010-01-29|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|April 2009|Actual|2009-04-30|February 2008|Actual|2008-02-29||Observational|||The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma|The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma|Completed|||||National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 00:08:43.818016|2018-06-01 00:08:43.818016
NCT01058785|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-07-28|2010-01-28|2010-01-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|March 2003||2003-03-31|January 2010|2010-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer|Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer|Completed||Phase 2|75|Actual|NovaRx Corporation||1|||f||||f||||||||||2018-06-01 00:08:43.856078|2018-06-01 00:08:43.856078
NCT01058772|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2015-04-29|2010-01-28|2010-01-29|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|GINEXMAL||Gestational Diabetes: Induction Versus Expectant Management of Labour|GINEXMAL RCT: Induction of Labour Versus Expectant Management in Gestational Diabetes Pregnancies|Completed||N/A|425|Actual|IRCCS Burlo Garofolo||2|||f||||t||||||||||2018-06-01 00:08:44.08892|2018-06-01 00:08:44.08892
NCT01058759|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-11-10|2010-01-28|2010-01-29|Estimate|||||||2011-11-10|2011-11-11|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Taxotere-Enoxaparin-(ENOXA)-Study|Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as Single Therapy or in Combination With Enoxaparin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, a Phase III Study|Terminated||Phase 3|14|Actual|Hannover Medical School||2||"The external funding (pharmaceutical company) was stopped and could not be substituded by~   internal funding."|f||||f||||||||||2018-06-01 00:08:44.198722|2018-06-01 00:08:44.198722
NCT01058746|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2018-01-19|2010-01-27|2010-01-29|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2010|Actual|2010-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Randomized Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection|A Prospective Randomized Controlled Clinical Trial of Restrictive Versus Liberal Perioperative Fluid Management for Patients Undergoing Pancreatic Resection|Active, not recruiting||N/A|331|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 00:08:44.266294|2018-06-01 00:08:44.266294
NCT01058733|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2010-01-28|2010-01-28|2010-01-29|Estimate|||||||2010-01-28|2010-01-29|Estimate|October 2006||2006-10-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|SARS||Semi-automatic Response System(SARS)in Type 2 Diabetes|Seoul St. Mary's Hospital College of Medicine The Catholic University of Korea, Seoul, Korea|Completed||N/A|79|Actual|The Catholic University of Korea||1|||f||||t||||||||||2018-06-01 00:08:44.335349|2018-06-01 00:08:44.335349
NCT01058720|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2015-12-30|2010-01-28|2010-01-29|Estimate|||||||2015-12-30|2016-01-01|Estimate|December 2009||2009-12-31|December 2015|2015-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents|A Pilot Study to Evaluate the Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents|Completed||Phase 4|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:08:44.404514|2018-06-01 00:08:44.404514
NCT01058707|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2018-01-30|2010-01-27|2010-01-29|Estimate|||||||2018-01-30|2018-02-01|Actual|January 4, 2010|Actual|2010-01-04|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|July 31, 2015|Actual|2015-07-31||Interventional|||Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies|A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies Followed by an Expansion in Subjects With Measurable Disease|Active, not recruiting||Phase 1|116|Actual|Takeda||1|||f||||f|t|f||||||||2018-06-01 00:08:44.475681|2018-06-01 00:08:44.475681
NCT00833950|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2009-03-02|2009-01-30|2009-02-02|Estimate|||||||2009-03-02|2009-03-03|Estimate|March 2008||2008-03-31|December 2008|2008-12-31||||March 2009|Actual|2009-03-31||Interventional|||Phase Out in Tinnitus Patients|Phase Out Treatment for Tinnitus|Completed||Phase 4|40|Anticipated|University Hospital, Antwerp||1|||f||||f||||||||||2018-06-01 01:21:17.642544|2018-06-01 01:21:17.642544
NCT01058681|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-28|||2011-08-02|2010-01-28|2010-01-29|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Impacts of Metabolic Variation on Neuroendocrine Control of Reproduction|Impacts of Metabolic Variation on the Activity of Neuroendocrine Reproductive Axis in Healthy Volunteers|Completed||N/A|9|Actual|Centre Hospitalier Universitaire Vaudois||3|||f||||f||||||||||2018-06-01 00:08:44.754256|2018-06-01 00:08:44.754256
NCT01058668|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2017-03-01|2011-12-30|2017-03-01|2010-01-27|2010-01-29|Estimate|2017-03-01|2017-04-12|Actual|2011-12-30|2012-01-04|Estimate|2017-03-01|2017-04-12|Actual|February 2010||2010-02-28|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Safety Population included all participants who received at least 1 dose of study drug.|Safety and Efficacy of Cariprazine for Bipolar I Disorder|A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder|Completed||Phase 3|497|Actual|Forest Laboratories|All participants from 1 investigative site were excluded due to Good Clinical Practice (GCP) Violations.|3|||f||||f||||||||||2018-06-01 00:08:44.874026|2018-06-01 00:08:44.874026
NCT01058655|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2017-02-23||2017-04-11|2010-01-27|2010-01-29|Estimate|2017-02-23|2017-04-07|Actual||||2017-04-11|2017-04-13|Actual|February 2010||2010-02-28|February 2017|2017-02-28|April 2015|Actual|2015-04-30|September 2013|Actual|2013-09-30||Interventional||The analysis dataset is comprised of all enrolled patients.|RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer|A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|56|Actual|Dana-Farber Cancer Institute||4|||f||||t||||||||No||2018-06-01 00:08:45.527322|2018-06-01 00:08:45.527322
NCT01058642|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2015-04-23||2015-07-08|2010-01-27|2010-01-29|Estimate|2015-06-12|2015-07-08|Estimate||||2015-07-08|2015-07-30|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||All randomized participants.|Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia|A Phase 2A, Randomized, Blinded, Placebo- and Active-controlled, 2-Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of ADL5747 in Subjects With Postherpetic Neuralgia|Terminated||Phase 2|41|Actual|Cubist Pharmaceuticals LLC|On the basis of the interim analysis, the results indicated that ADL5747 did not show sufficient efficacy to continue the study; therefore, formal and final efficacy analyses were not generated for this study.|3|||f||||f||||||||||2018-06-01 00:08:46.343731|2018-06-01 00:08:46.343731
NCT01058629|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-08-24|2010-01-26|2010-01-28|Estimate|||||||2010-08-24|2010-08-25|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses|A 180 Day, Multicenter Study to Evaluate the Clinical Performance of SynergEyes A2 Hybrid Contact Lenses for Daily Wear Use in the Correction of Refractive Error With or Without Astigmatism in Non-diseased Eyes|Unknown status|Active, not recruiting|N/A|125|Anticipated|SynergEyes, Inc.||1|||f||||f||||||||||2018-06-01 00:08:46.845231|2018-06-01 00:08:46.845231
NCT01058616|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-02-08|2010-01-27|2010-01-28|Estimate|||||||2013-02-08|2013-02-11|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour|Phase 1 Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour|Completed||Phase 1|14|Actual|Lytix Biopharma AS|||||f||||t||||||||||2018-06-01 00:08:46.926187|2018-06-01 00:08:46.926187
NCT01058603|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-02-03|2010-01-27|2010-01-28|Estimate|||||||2010-02-03|2010-02-04|Estimate|February 2008||2008-02-29|February 2010|2010-02-28||||||||Interventional|||Efficacy of Endocell® vs Conventional Medium in the Treatment of Infertility|Multicentre, Randomised, Controlled Clinical Study on the Efficacy in Terms of Clinical Pregnancy Rate of 1 Embryo Transfer at Day 5 After Co-culture on Autologous Endometrial Cells(ENDOCELL®) Versus 1 Embryo Transfer at Day 3 After Culture on Conventional Medium.|Unknown status|Recruiting|Phase 3|720|Anticipated|Laboratoires Genévrier||2|||f||||f||||||||||2018-06-01 00:08:46.986218|2018-06-01 00:08:46.986218
NCT01058590|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-01-27|2010-01-27|2010-01-28|Estimate|||||||2010-01-27|2010-01-28|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|February 2012|Anticipated|2012-02-29|February 2011|Anticipated|2011-02-28||Observational|||Inflammatory Markers in Infants With Obstructive Sleep Apnea|Inflammatory Markers in Infants With Obstructive Sleep Apnea|Unknown status|Not yet recruiting||100|Anticipated|Soroka University Medical Center|||||f||||||||||Samples Without DNA|"~     Serum and urine will be obtained before therapy (T%A) snd 3 months afterwards. The serum will~     be stored at -70 throughout the study in the PI's Lab (DR.Goldbart) At the end of the study~     the sampled will be assessed for the presence of inflammatory markers (cytokines).~   "|||2018-06-01 00:08:47.049801|2018-06-01 00:08:47.049801
NCT01058577|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-01-27|2010-01-27|2010-01-28|Estimate|||||||2010-01-27|2010-01-28|Estimate|December 2001||2001-12-31|January 2010|2010-01-31|August 2002|Actual|2002-08-31|May 2002|Actual|2002-05-31||Interventional|||Changes in Serum Electrolytes at Different Glucose Concentrations + Impact on a Non-invasive Glucose Monitoring Method|A Single Center, Open Study to Evaluate Changes in Serum Electrolytes at Different Glucose Concentrations and Their Impact on a Non-invasive Glucose Monitoring Method|Completed||Phase 1|20|Actual|Profil Institut für Stoffwechselforschung GmbH|||||f||||f||||||||||2018-06-01 00:08:47.112335|2018-06-01 00:08:47.112335
NCT01058564|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-11-22|2010-01-27|2010-01-28|Estimate|||||||2013-11-22|2013-11-25|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter|A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter|Completed||Phase 1/Phase 2|4|Actual|Torax Medical Incorporated||1|||f||||f||||||||||2018-06-01 00:08:47.180069|2018-06-01 00:08:47.180069
NCT01058551|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2018-03-07|2010-01-27|2010-01-28|Estimate|||||||2018-03-07|2018-03-09|Actual|June 2011||2011-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study|Incidence of New Onset Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study|Active, not recruiting||N/A|31|Actual|Queen's University||1|||f||||f||||||||||2018-06-01 00:08:47.242875|2018-06-01 00:08:47.242875
NCT01058538|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2014-02-24|2010-01-27|2010-01-28|Estimate|||||||2014-02-24|2014-02-25|Estimate|November 2005||2005-11-30|February 2014|2014-02-28|November 2009|Actual|2009-11-30|April 2008|Actual|2008-04-30||Interventional|||A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours|A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours|Completed||Phase 1/Phase 2|33|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-06-01 00:08:47.303391|2018-06-01 00:08:47.303391
NCT01058525|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2016-09-22|2010-01-27|2010-01-28|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Hydro-Echo||Influence of Ultrasonographic Hydro-dissection With Glucose 5% on Nerve Block Efficiency|Influence of Ultrasonographic Hydro-dissection With Glucose 5% Solution on Median Nerve Block Efficiency: a Prospective and Randomized Study|Completed||Phase 4|100|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 00:08:47.366675|2018-06-01 00:08:47.366675
NCT01058512|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-07-09|2010-01-27|2010-01-28|Estimate|||||||2013-07-09|2013-07-11|Estimate|March 2010||2010-03-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|NOV-205||A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy|A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin|Completed||Phase 2|40|Anticipated|Cellectar Biosciences, Inc.||1|||f||||f||||||||||2018-06-01 00:08:47.421244|2018-06-01 00:08:47.421244
NCT01058499|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2016-03-17|2010-01-27|2010-01-28|Estimate|||||||2016-03-17|2016-03-21|Estimate|February 2010||2010-02-28|March 2016|2016-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Mindfulness Based Stress Reduction in COPD|Mindfulness Based Stress Reduction in COPD|Completed||Phase 1|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:08:47.493039|2018-06-01 00:08:47.493039
NCT01058486|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2016-09-28|2010-01-27|2010-01-28|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Multicomponent Intervention to Decrease Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations|Multicomponent Intervention to Decrease COPD-related Hospitalizations|Completed||N/A|215|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:08:47.550161|2018-06-01 00:08:47.550161
NCT01058473|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-07-29|2010-01-26|2010-01-28|Estimate|||||||2013-07-29|2013-07-30|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain|Psychometric Evaluation of the Inpatient Pediatric Physical Activity Questionnaire (IPPAQ) in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain|Completed|||159|Actual|Connecticut Children's Medical Center|||1||f||||f||||||||||2018-06-01 00:08:47.607192|2018-06-01 00:08:47.607192
NCT01058460|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2011-05-31|2010-01-27|2010-01-28|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|COCY||HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN|A Randomized Controlled Trial Comparing Concomitant HPV-cytology Testing With Conventional Cytology Testing for the Detection of High Grade Cervical Intraepithelial Neoplasia in Primary Cervical Cancer Screening in Hong Kong|Unknown status|Recruiting|N/A|12000|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-06-01 00:08:48.823303|2018-06-01 00:08:48.823303
NCT01058447|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-11-17|2010-01-27|2010-01-28|Estimate|||||||2010-11-17|2010-11-18|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|ADME||Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers|An Open, Single-Dose, Single-Centre, Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers|Completed||Phase 1|4|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:08:48.915293|2018-06-01 00:08:48.915293
NCT01058434|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-11-15|2010-01-26|2010-01-28|Estimate|||||||2016-11-15|2016-11-16|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation|A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation|Completed||Phase 2|43|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:08:48.98371|2018-06-01 00:08:48.98371
NCT01058421|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-07-22||2017-03-16|2010-01-27|2010-01-28|Estimate|2017-03-16|2017-04-27|Actual||||2017-03-16|2017-04-27|Actual|September 2009||2009-09-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|May 2014|Actual|2014-05-31||Interventional|Do-It-Now||Treatment of Critical Illness Polyneuromyopathy|Randomized Trial of Intensive Physical Therapy for Patients With Acute Respiratory Failure|Completed||N/A|120|Actual|University of Colorado, Denver||2|||f||||t||||||||Yes|We have created a de-identified data set that is available to other investigators upon request.|2018-06-01 00:08:49.156076|2018-06-01 00:08:49.156076
NCT01058408|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-02-20|2010-01-26|2010-01-28|Estimate|||||||2013-02-20|2013-02-22|Estimate|February 2010||2010-02-28|February 2013|2013-02-28||||February 2012|Actual|2012-02-29||Interventional|||RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer|A Phase I Trial Using RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer|Terminated||Phase 1|3|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:08:49.590344|2018-06-01 00:08:49.590344
NCT01058395|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-08-16|2010-01-27|2010-01-28|Estimate|||||||2017-08-16|2017-08-21|Actual|February 2010||2010-02-28|April 2016|2016-04-30|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|TBI||Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)|Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans|Completed||Phase 1/Phase 2|15|Actual|Wayne State University||2|||f||||t|t|f||||||No||2018-06-01 00:08:49.676223|2018-06-01 00:08:49.676223
NCT01058382|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-05-08|2010-01-27|2010-01-28|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|FETProg||Progesterone Support of FET|Progesterone Support for Frozen Embryo Transfer: Intramuscular Versus Vaginal Suppository - A Prospective, Randomized, Controlled Trial|Completed|||57|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 00:08:49.815581|2018-06-01 00:08:49.815581
NCT01058369|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2015-05-29|2010-01-27|2010-01-28|Estimate|||||||2015-05-29|2015-06-01|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Exjade-Early-Trial|Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study -|Terminated||Phase 2|2|Actual|University of Erlangen-Nürnberg Medical School||1||Insufficient patient recruitment (only 2 patients)|f||||||||||||||2018-06-01 00:08:49.893927|2018-06-01 00:08:49.893927
NCT01058356|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2010-03-08||2010-04-15|2010-01-27|2010-01-28|Estimate|2010-03-08|2010-03-31|Estimate||||2010-04-15|2010-04-20|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Observational|||Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea|Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea: Prospective, Randomized Double-blind, Multicenter Study|Completed|||214|Actual|Pharmbio Korea Co., Ltd.|||1||f||||t||||||||||2018-06-01 00:08:49.992366|2018-06-01 00:08:49.992366
NCT01058343|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2017-03-27|2010-01-27|2010-01-28|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2010||2010-03-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|April 2011|Actual|2011-04-30||Interventional|||Safety of IFNa Kinoid in Systemic Lupus Erythematosus|A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.|Completed||Phase 1/Phase 2|28|Actual|Neovacs||5|||f||||t||||||||||2018-06-01 00:08:50.267048|2018-06-01 00:08:50.267048
NCT01058330|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2014-11-17|2010-01-27|2010-01-28|Estimate|||||||2014-11-17|2014-11-19|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1|Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With Neurofibromatosis Type 1|Completed||N/A|35|Actual|Shriners Hospitals for Children||2|||f||||f||||||||||2018-06-01 00:08:50.367856|2018-06-01 00:08:50.367856
NCT01058317|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-11-19|2010-01-27|2010-01-28|Estimate|||||||2013-11-19|2013-11-21|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis|Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis|Withdrawn||Phase 2/Phase 3|0|Actual|Massachusetts Eye and Ear Infirmary||1||No participants enrolled|f||||f||||||||||2018-06-01 00:08:50.436033|2018-06-01 00:08:50.436033
NCT01058304|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2015-03-12||2015-03-23|2010-01-27|2010-01-28|Estimate|2015-03-12|2015-03-24|Estimate||||2015-03-23|2015-04-14|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional||All enrolled, randomized participants|Group Physical Therapy for Knee Osteoarthritis|Group Physical Therapy for Veterans With Knee Osteoarthritis|Completed||N/A|320|Actual|VA Office of Research and Development|Because the target recruitment goal could not be met, a new sample size target was calculated, with a goal of being able to detect an effect size of 0.35. This translated into a target of n=226, which we exceeded by enrolling n=320.|2|||f||||f||||||||||2018-06-01 00:08:50.511251|2018-06-01 00:08:50.511251
NCT01058291|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2017-02-28|2010-01-27|2010-01-28|Estimate|||||||2017-02-28|2017-03-03|Actual|January 2010||2010-01-31|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|6500-004||Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500|Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)|Completed||Phase 3|31|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||||||||||||2018-06-01 00:08:50.782444|2018-06-01 00:08:50.782444
NCT01058278|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2016-02-26|2010-01-27|2010-01-28|Estimate|||||||2016-02-26|2016-02-29|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2012|Actual|2012-06-30||Interventional|SLT||Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma|Impact of the Post-operative Treatment on the Intraocular Pressure Post Selective Laser Trabeculoplasty (SLT) on Patients With Primary Open-angle Glaucoma|Completed||N/A|67|Actual|CHU de Quebec-Universite Laval||3|||f||||f||||||||||2018-06-01 00:08:50.836822|2018-06-01 00:08:50.836822
NCT01058265|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2011-12-15||2012-01-23|2010-01-27|2010-01-28|Estimate|2012-01-23|2012-02-24|Estimate||||2012-01-23|2012-02-24|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Integrative Medicine Consultation for Patients With Pain or Fatigue|Effect of an Integrative Medicine Consultation on Outcome for Patients With Pain or Fatigue|Completed||N/A|47|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:08:51.00981|2018-06-01 00:08:51.00981
NCT01058252|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2011-02-06|2010-01-27|2010-01-28|Estimate|||||||2011-02-06|2011-02-08|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Observational|MSP-IVC||Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF|A Scientific & Clinical Review of Minimal Stimulation Protocol Using AROMEK (Letrozole) and Follitrope (Recombinant FSH)Combined With INVOCell(Intravaginal Culturing) - Effectiveness as Low Cost IVF|Unknown status|Recruiting||100|Anticipated|Galaxy Pharma (Pvt) Limited|||1||f||||f||||||||||2018-06-01 00:08:51.360637|2018-06-01 00:08:51.360637
NCT01058239|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2017-11-03||2018-01-18|2010-01-27|2010-01-28|Estimate|2018-01-18|2018-02-15|Actual||||2018-01-18|2018-02-15|Actual|November 2011|Actual|2011-11-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|December 2016|Actual|2016-12-31||Interventional|||Bortezomib Plus Rituximab for EBV+ PTLD|Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD)|Completed||Phase 2|7|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:08:51.503338|2018-06-01 00:08:51.503338
NCT01058226|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2011-03-29|2010-01-27|2010-01-28|Estimate|||||||2011-03-29|2011-03-31|Estimate|February 2010||2010-02-28|March 2011|2011-03-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Reproducibility of Malaria Challenge in Healthy Volunteers|Reproducibility of Malaria Challenge in Healthy Volunteers|Completed||Phase 1|6|Anticipated|Seattle Biomedical Research Institute|||||f||||t||||||||||2018-06-01 00:08:51.834514|2018-06-01 00:08:51.834514
NCT01058213|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-12-17|2010-01-27|2010-01-28|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Nurse Managed Sequential Strength Training and Bicycle Training in Chronic Obstructive Pulmonary Disease (COPD)|Nurse Managed Sequential Resistance Then Aerobic Training in COPD|Completed||Phase 2|354|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-06-01 00:08:51.923302|2018-06-01 00:08:51.923302
NCT01058200|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-07-19|2010-01-27|2010-01-28|Estimate|||||||2013-07-19|2013-07-22|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ICUP||"a Randomized Multicenter Trial Comparing Vacuum Assisted Delivery With the New Device iCUP Versus the Reference Cup."|"Assess the Risk-benefit Balance of the New Vacuum Assisted-delivery Device iCUP Versus the Reference Vacuum. Multicenter Prospective Randomized Controlled Study"|Completed||Phase 3|668|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 00:08:51.993948|2018-06-01 00:08:51.993948
NCT01058187|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2014-03-10|2010-01-27|2010-01-28|Estimate|||||||2014-03-10|2014-03-12|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Observational|||Assessment of Fatty Acids in Infants' Blood Cells When Consuming Infant Formula Containing Long-Chain Polyunsaturated Fatty Acids|Assessment of Fatty Acids in Infants' Blood Cells When Consuming Infant Formula Containing Long-Chain Polyunsaturated Fatty Acids|Completed|||86|Anticipated|Mead Johnson Nutrition|||3||f||||||||||||||2018-06-01 00:08:52.066787|2018-06-01 00:08:52.066787
NCT01057836|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-01-26|2010-01-26|2010-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate||||January 2010|2010-01-31||||||||Interventional|||Effect of Neck Strength Training on Health-related Quality of Life in Females With Neck Pain|Effect of Neck Strength Training on Health-related Quality of Life in Females With Chronic Neck Pain: A Randomized Controlled 1-year Follow-up Study|Completed||N/A|180|Actual|Jyväskylä Central Hospital||3|||f||||f||||||||||2018-06-01 00:08:55.92854|2018-06-01 00:08:55.92854
NCT01058174|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-11-20|2010-01-26|2010-01-28|Estimate|||||||2017-11-20|2017-11-22|Actual|December 15, 2009|Actual|2009-12-15|November 2017|2017-11-30|May 3, 2012|Actual|2012-05-03|May 3, 2012|Actual|2012-05-03||Interventional|TENPIN||Liver Transplant European Study Into the Prevention of Fungal Infection|Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients|Completed||Phase 3|350|Actual|Astellas Pharma Inc||2|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:08:52.125265|2018-06-01 00:08:52.125265
NCT01058161|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2014-08-27|2010-01-27|2010-01-28|Estimate|||||||2014-08-27|2014-08-28|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||High-Field MRI Characterization of Wrist and Hand Cartilage Abnormalities in Inflammatory and Chronic Rheumatisms|High-Field MRI Characterization of Wrist and Hand Cartilage Abnormalities in Inflammatory and Chronic Rheumatisms|Completed||N/A|34|Actual|Assistance Publique Hopitaux De Marseille||5|||f||||f||||||||||2018-06-01 00:08:52.246937|2018-06-01 00:08:52.246937
NCT01058148|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2017-06-30|2010-01-27|2010-01-28|Estimate|||||||2017-06-30|2017-07-02|Actual|December 22, 2009||2009-12-22|April 13, 2011|2011-04-13|April 13, 2011||2011-04-13|||||Observational|||A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening|A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening|Completed|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:08:52.310587|2018-06-01 00:08:52.310587
NCT01058135|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-04-20|2010-01-27|2010-01-28|Estimate|||||||2016-04-20|2016-04-21|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Hi-maize Resistant Starch on Insulin Sensitivity|A Randomized, Controlled, Double-blind Crossover Study to Assess the Effects of a Dietary Fiber Ingredient, at Two Doses, on Insulin Sensitivity|Completed||N/A|32|Actual|Ingredion Incorporated|||||f||||f||||||||||2018-06-01 00:08:52.359089|2018-06-01 00:08:52.359089
NCT01058122|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2018-05-03|2010-01-27|2010-01-28|Estimate|||||||2018-05-03|2018-05-10|Estimate|August 2007|Actual|2007-08-31|May 2018|2018-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Collection, Evaluation and Assessment of Adverse Drug Reactions on the Oncology Ward|Collection, Evaluation and Assessment of Adverse Drug Reactions on the Oncology Ward|Completed|||129|Actual|University of Zurich|||1||f||||t||||||||||2018-06-01 00:08:52.502399|2018-06-01 00:08:52.502399
NCT01058109|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2016-03-24|2010-01-27|2010-01-28|Estimate|||||||2016-03-24|2016-03-28|Estimate|September 1997||1997-09-30|March 2016|2016-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|Calkids||Study of the Effect of a Calcium-rich Diet on Bone Health in Girls|Effect of Calcium Foods on Bone Quality in Pubertal Females|Completed||Phase 3|65|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 00:08:52.576093|2018-06-01 00:08:52.576093
NCT01058096|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2017-03-01|2011-08-02|2017-03-01|2010-01-27|2010-01-28|Estimate|2017-03-01|2017-04-17|Actual|2011-08-02|2011-08-08|Estimate|2017-03-01|2017-04-17|Actual|February 2010||2010-02-28|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Safety Population included all randomized participants who took at least 1 dose of double-blind investigational product.|Safety and Efficacy of Cariprazine for Mania|A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder|Completed||Phase 3|323|Actual|Forest Laboratories|All participants from 1 investigative site are excluded due to GCP violations.|2|||f||||f||||||||||2018-06-01 00:08:52.672403|2018-06-01 00:08:52.672403
NCT01058083|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-04-18|2010-01-26|2010-01-28|Estimate|||||||2012-04-18|2012-04-19|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety Study of BMS-770767 in Subjects With Hypercholesterolemia|A Double-blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Primary Hypercholesterolemia|Completed||Phase 2|81|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:08:53.108586|2018-06-01 00:08:53.108586
NCT01058070|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2014-03-03||2014-05-07|2010-01-27|2010-01-28|Estimate|2014-05-07|2014-06-02|Estimate||||2014-05-07|2014-06-02|Estimate|February 2007||2007-02-28|May 2014|2014-05-31|August 2013|Actual|2013-08-31|July 2009|Actual|2009-07-31||Interventional|||An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter|An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter|Completed||Phase 1/Phase 2|44|Actual|Torax Medical Incorporated||1|||f||||f||||||||||2018-06-01 00:08:53.220844|2018-06-01 00:08:53.220844
NCT01058057|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2010-02-02|2010-01-27|2010-01-28|Estimate|||||||2010-02-02|2010-02-03|Estimate|February 2008||2008-02-29|January 2008|2008-01-31||||June 2010|Anticipated|2010-06-30||Interventional|TIPS-2||Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention (PCI) Study 2|Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study 2|Unknown status|Recruiting|Phase 3|200|Anticipated|University Hospital, Motol||1|||f||||f||||||||||2018-06-01 00:08:53.386694|2018-06-01 00:08:53.386694
NCT01058044|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2012-08-08|2010-01-27|2010-01-28|Estimate|||||||2012-08-08|2012-08-09|Estimate|July 2009||2009-07-31|August 2012|2012-08-31||||January 2011|Actual|2011-01-31||Interventional|||Adherence to Oral Anticancer Treatment Using Electronic Monitoring System|A Pilot Study of Adherence to Oral Anticancer Treatment Using Electronic Monitoring System|Completed||N/A|33|Actual|Centre Jean Perrin||1|||f||||f||||||||||2018-06-01 00:08:53.463582|2018-06-01 00:08:53.463582
NCT01058031|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-11-04|2010-01-27|2010-01-28|Estimate|||||||2013-11-04|2013-11-05|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|||Neural Correlates of PTSD Prevention With Mindfulness Based Stress Reduction (MBSR) in Iraqi Veterans|Neural Correlates of PTSD Prevention With MBSR in Iraqi Veterans|Completed||N/A|30|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 00:08:53.52269|2018-06-01 00:08:53.52269
NCT01058018|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26||2013-10-23|2016-07-20|2010-01-27|2010-01-28|Estimate||||2013-10-23|2013-11-15|Estimate|2016-07-20|2016-07-22|Estimate|December 2009||2009-12-31|July 2016|2016-07-31||||June 2010|Actual|2010-06-30||Interventional|ASSERT||Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease|Phase II Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for Dose-finding and Safety Study of RVX000222 in Subjects With Stable Coronary Artery Disease|Completed||Phase 2|299|Actual|Resverlogix Corp||4|||f||||t||||||||||2018-06-01 00:08:53.586363|2018-06-01 00:08:53.586363
NCT01057823|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-12-05|2010-01-26|2010-01-27|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2010||2010-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Understanding Sleep in Hospitalized Older Patients|Environment and Perceived Control: Improving Sleep in Hospitalized Older Patients|Recruiting|||800|Anticipated|University of Chicago|||1||f||||f||||||||||2018-06-01 00:08:55.985984|2018-06-01 00:08:55.985984
NCT01058005|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2014-07-23||2014-08-18|2010-01-27|2010-01-28|Estimate|2014-07-23|2014-08-13|Estimate||||2014-08-18|2014-09-03|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SURPASS|Participants who received at least 1 dose of study medication.|Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis|A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis|Terminated||Phase 3|84|Actual|Biogen|Due to early termination of the study and the small size of the study population, there was insufficient power for efficacy and safety analyses. Only serious adverse events were to be captured and reported under the protocol.|3||"Due to significantly slower than expected enrollment, the Sponsor decided to terminate the~   study."|f||||||||||||||2018-06-01 00:08:53.703236|2018-06-01 00:08:53.703236
NCT01057992|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-11-22|2010-01-27|2010-01-28|Estimate|||||||2013-11-22|2013-11-25|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|October 2009|Actual|2009-10-31||Interventional|||A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter|A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter|Completed||Phase 1/Phase 2|31|Actual|Torax Medical Incorporated||1|||f||||f||||||||||2018-06-01 00:08:54.171175|2018-06-01 00:08:54.171175
NCT01057979|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-05-08|2010-01-27|2010-01-28|Estimate|||||||2012-05-08|2012-05-09|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|MILE||Motivational Interventions for Lifestyle and Exercise in College Students|Motivational Interventions for Exercise in Hazardous Drinking College Students|Completed||Phase 1|72|Actual|University of Connecticut||2|||f||||t||||||||||2018-06-01 00:08:54.317427|2018-06-01 00:08:54.317427
NCT01057966|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2012-01-31|2010-01-27|2010-01-28|Estimate|||||||2012-01-31|2012-02-02|Estimate|February 2010||2010-02-28|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Bioavailability of Nutrients Contained in Softgel Capsules vs Tablets||Completed||Phase 4|15|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 00:08:54.372221|2018-06-01 00:08:54.372221
NCT01057953|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-10-15|2010-01-27|2010-01-28|Estimate|||||||2013-10-15|2013-10-16|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|DOCC||Oligogenic Determinism of Colorectal Cancer|Oligogenic Determinism of Colorectal Cancer|Completed||N/A|1550|Actual|University Hospital, Rouen||1|||f||||t||||||||||2018-06-01 00:08:54.426346|2018-06-01 00:08:54.426346
NCT01057940|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2013-06-26|2010-01-27|2010-01-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Pilot to Assess DBE as a Rescue Technique for Failed PEJ|A Pilot Study to Assess the Feasibility of Double Balloon Enteroscopy as a Rescue Technique for Failed Direct Percutaneous Endoscopic Jejunostomy Tube Placement|Completed|||20|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 00:08:54.490975|2018-06-01 00:08:54.490975
NCT01057927|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-27|2010-01-27|2010-01-28|Estimate|||||||2010-01-27|2010-01-28|Estimate|January 2007||2007-01-31|January 2010|2010-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects|Parallel Group, Randomised, Placebo Controlled, Double Blind Oral Assessment of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects|Completed||Phase 2|132|Actual|Oxagen Ltd||2|||f||||t||||||||||2018-06-01 00:08:54.542443|2018-06-01 00:08:54.542443
NCT01057914|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|||2017-05-18|2010-01-27|2010-01-28|Estimate|||||||2017-05-18|2017-05-19|Actual|February 2010||2010-02-28|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Nutritional Supplementation and Dietary Advice in Elderly Patients After Hospital Discharge.|Effects of Six Months Treatment With Nutritional Supplements or Dietary Advice, Alone or in Combination on Mortality, Health-related Quality of Life and Health-care Consumption for Elderly Patients at Risk of Malnutrition.|Active, not recruiting||N/A|800|Anticipated|Uppsala University||4|||f||||f||||||||||2018-06-01 00:08:54.704122|2018-06-01 00:08:54.704122
NCT01057901|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2014-04-14||2014-06-16|2010-01-27|2010-01-28|Estimate|2014-06-16|2014-06-17|Estimate||||2014-06-16|2014-06-17|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America|24 - Week Flibanserin 100mg for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Noth America|Terminated||Phase 3|748|Actual|Sprout Pharmaceuticals, Inc||2||Study terminated for administrative reasons.|f||||t||||||||||2018-06-01 00:08:54.805558|2018-06-01 00:08:54.805558
NCT01057888|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2012-10-18||2015-12-16|2010-01-26|2010-01-27|Estimate|2012-10-18|2012-11-16|Estimate||||2015-12-16|2016-01-20|Estimate|December 2009||2009-12-31|December 2015|2015-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients|Randomized Controlled Trial of an Automated, Managed Care-based Reminder/Recall System on Improving Rates of Immunization and Preventive Care Visits for Publically Insured Adolescents|Completed||N/A|10599|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-06-01 00:08:55.251696|2018-06-01 00:08:55.251696
NCT01057875|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-10-05|2010-01-26|2010-01-27|Estimate|||||||2010-10-05|2010-10-07|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.|The Effects of Caffeine on Exhaled Nitric Oxide Levels and Methacholine PC20|Completed||N/A|15|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 00:08:55.535586|2018-06-01 00:08:55.535586
NCT01057862|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2017-01-11||2017-09-12|2010-01-26|2010-01-27|Estimate|2017-08-11|2017-09-12|Actual||||2017-09-12|2017-10-13|Actual|February 2009|Actual|2009-02-28|August 2017|2017-08-31|January 2017|Actual|2017-01-31|February 2016|Actual|2016-02-29||Interventional|||Investigation of Naltrexone for Pathological Gambling|Double-Blind Placebo-Controlled Investigation of Naltrexone for Pathological Gambling|Completed||Phase 2|9|Actual|Yale University|Enrollment was lower than expected and due to the low numbers of subjects completing the study (7 subjects completed all interventions) the numbers were not powerful enough to conduct a full analysis or provide any meaningful statistical analyses.|2|||f||||t||||||||||2018-06-01 00:08:55.618791|2018-06-01 00:08:55.618791
NCT01057849|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-01-26|2010-01-26|2010-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|September 2008||2008-09-30|September 2008|2008-09-30||||March 2011|Anticipated|2011-03-31||Interventional|||Standard Comprehensive Intervention to Treat First-episode Schizophrenia|Sequenced Atypical Antipsychotics Therapy With Intensive or Basic Psychosocial Intervention for First-episode Schizophrenia: An Effectiveness Study|Unknown status|Recruiting|N/A|600|Anticipated|Peking University||6|||f||||t||||||||||2018-06-01 00:08:55.834517|2018-06-01 00:08:55.834517
NCT01057810|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-03-07||2016-07-11|2010-01-26|2010-01-27|Estimate|2016-07-11|2016-08-18|Estimate||||2016-07-11|2016-08-18|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional||All randomized participants|Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer|Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer|Completed||Phase 3|837|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 00:08:56.129434|2018-06-01 00:08:56.129434
NCT01057797|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-01-26|2010-01-26|2010-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|September 2003||2003-09-30|January 2010|2010-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD)|Nurse Managed Upper Body Strength Training in COPD|Completed||Phase 2|208|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-06-01 00:08:57.503775|2018-06-01 00:08:57.503775
NCT01057784|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2014-12-05|2010-01-26|2010-01-27|Estimate|||||||2014-12-05|2014-12-08|Estimate|March 2010||2010-03-31|January 2010|2010-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Bariatric Surgery Outcomes|Bariatric Surgery Outcomes: Quality of Life / Reproductive-Age Women|Withdrawn|||0|Actual|University of California, Los Angeles|||2||f||||f||||||Samples With DNA|"~     The subgroup of 10 reproductive-age women will have coded bloods samples retained for DNA and~     RNA analysis.~   "|||2018-06-01 00:08:57.587758|2018-06-01 00:08:57.587758
NCT01057771|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2015-10-09|2010-01-22|2010-01-27|Estimate|||||||2015-10-09|2015-10-12|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MEPARI||Meditation and Exercise for Prevention of Acute Respiratory Infection|Meditation and Exercise for Prevention of Acute Respiratory Infection|Completed||Phase 2/Phase 3|154|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-06-01 00:08:57.672564|2018-06-01 00:08:57.672564
NCT01057758|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-10-29|2010-01-26|2010-01-27|Estimate|||||||2013-10-29|2013-10-30|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||STATIN-VAP STATIN-VAP - STATINs and Ventilator-Associated Pneumonia|Effect of the Association of a Statin to Antibiotics on the Prognosis of Patients Presenting With a Suspicion of Ventilator-associated Pneumonia|Terminated||Phase 3|300|Actual|Assistance Publique Hopitaux De Marseille||2||stopped for futility|f||||t||||||||||2018-06-01 00:08:57.747542|2018-06-01 00:08:57.747542
NCT01057745|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-06-20|2010-01-26|2010-01-27|Estimate|||||||2017-06-20|2017-06-21|Actual|June 12, 2007|Actual|2007-06-12|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Observational|||Ovarian Freezing Before Cancer Treatment|Ovarian Tissue Freezing Prior to Chemotherapy or Radiation Therapy: a Study by the Oncofertility Consortium|Enrolling by invitation|||150|Anticipated|University of Pennsylvania|||||f||||f||||||Samples Without DNA|"~     ovarian tissue~   "|||2018-06-01 00:08:57.814177|2018-06-01 00:08:57.814177
NCT01057732|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-25|2010-01-25|2010-01-27|Estimate|||||||2010-01-25|2010-01-27|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Observational|||Effects of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism|The Effect of Parathyroidectomy on Cardiovascular Risk Factors in Patients With Primary Hyperparathyroidism|Completed|||76|Actual|HaEmek Medical Center, Israel|||2||f||||f||||||Samples Without DNA|"~     serum, urine~   "|||2018-06-01 00:08:57.868965|2018-06-01 00:08:57.868965
NCT01057719|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-01-26|2010-01-26|2010-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|June 2006||2006-06-30|January 2010|2010-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|CIOPIMS||Climate Influence on Physiotherapy in Multiple Sclerosis|Climate Influence on Physiotherapy in Multiple Sclerosis|Completed||N/A|60|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 00:08:57.925467|2018-06-01 00:08:57.925467
NCT01057706|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2015-05-05|2010-01-26|2010-01-27|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional|||Chiropractic and Exercise Management of Spinal Dysfunction in Seniors|Chiropractic and Exercise Management of Spinal Dysfunction in Seniors|Completed||Phase 2/Phase 3|200|Actual|Northwestern Health Sciences University||2|||f||||t||||||||||2018-06-01 00:08:57.990927|2018-06-01 00:08:57.990927
NCT01057693|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2013-01-18||2013-01-18|2010-01-26|2010-01-27|Estimate|2013-01-18|2013-02-22|Estimate||||2013-01-18|2013-02-22|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy|A Phase 3b Multicenter, Double-Blind, Efficacy And Safety Study Of Pregabalin In The Treatment Of Patients With Inadequately Treated Painful Diabetic Peripheral Neuropathy|Completed||Phase 3|665|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:08:58.23098|2018-06-01 00:08:58.23098
NCT01057680|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-12-26|2010-01-26|2010-01-27|Estimate|||||||2012-12-26|2012-12-27|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone|Potential of Resistance-Exercise and Creatine Supplementation on Aging Musculoskeletal Health|Completed||Phase 3|90|Actual|University of Saskatchewan||2|||f||||t||||||||||2018-06-01 00:09:00.868379|2018-06-01 00:09:00.868379
NCT01057667|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26||2016-07-07|2016-11-01|2010-01-26|2010-01-27|Estimate||||2016-07-07|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4|A Randomized, Double-blinded, Multicenter Study to Evaluate the Antiviral Efficacy and Safety of Adding the HCV Polymerase Inhibitor Prodrug (RO5024048) for 24 Weeks to the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 or 4|Completed||Phase 2|168|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:09:00.961176|2018-06-01 00:09:00.961176
NCT01057654|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-01-26|2010-01-26|2010-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|January 1996||1996-01-31|January 2010|2010-01-31|June 1998|Actual|1998-06-30|April 1996|Actual|1996-04-30||Interventional|||A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin|A Stable-isotope Study in Healthy Normolipidemic Volunteers Comparing the Mechanisms of Action of Lifibrol and Pravastatin|Completed||Phase 3|18|Actual|University Hospital, Bonn||2|||f||||t||||||||||2018-06-01 00:09:01.051416|2018-06-01 00:09:01.051416
NCT01057641|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-11-04|2010-01-26|2010-01-27|Estimate|||||||2016-11-04|2016-11-07|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|May 2016|Actual|2016-05-31||Interventional|||Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant|A Clinical Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant in Comparison With the Best Non-operative Treatment of Lumbar Spine Stenosis|Terminated||Phase 4|22|Actual|University of Cologne||2||low enrollment|f||||t||||||||||2018-06-01 00:09:01.116412|2018-06-01 00:09:01.116412
NCT01057628|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2016-01-18|2010-01-25|2010-01-27|Estimate|||||||2016-01-18|2016-01-20|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients|A Phase 3, Double-Blind, Placebo-Controlled, Monotherapy Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|130|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 00:09:01.181253|2018-06-01 00:09:01.181253
NCT01057615|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2011-01-28|2010-01-26|2010-01-27|Estimate|||||||2011-01-28|2011-01-31|Estimate|March 2010||2010-03-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Fish Oil and Vitamin C on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Comparative and Additive Effects of Fish Oil and Ascorbic Acid Supplementation on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma|Completed||Phase 1|14|Actual|Indiana University||3|||f||||f||||||||||2018-06-01 00:09:01.332094|2018-06-01 00:09:01.332094
NCT01057602|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-23|||2010-02-07|2010-01-26|2010-01-27|Estimate|||||||2010-02-07|2010-02-09|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|September 2010|Anticipated|2010-09-30|May 2010|Anticipated|2010-05-31||Observational|||Further Validation of the Memory Orientation Screening Test (MOST):A 5-minute Screening Test for Dementia in Primary Care Practice|Further Validation of the Memory Orientation Screening Test (MOST): A 5-minute Screening Test for Dementia in Primary Care Practice|Unknown status|Recruiting||300|Anticipated|Clionsky, Mitchell, Ph.D., ABPP(CN)|||1||f||||t||||||||||2018-06-01 00:09:01.416162|2018-06-01 00:09:01.416162
NCT01057589|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2013-02-06||2013-09-05|2010-01-26|2010-01-27|Estimate|2013-02-06|2013-03-19|Estimate||||2013-09-05|2013-09-18|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|October 2012|Actual|2012-10-31|February 2012|Actual|2012-02-29||Interventional|||A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer|Phase 2 Study of Pemetrexed in Combination With Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|66|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:09:01.523442|2018-06-01 00:09:01.523442
NCT01057576|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2016-04-07|2010-01-26|2010-01-27|Estimate|||||||2016-04-07|2016-04-08|Estimate|March 2006||2006-03-31|April 2016|2016-04-30|October 2008|Actual|2008-10-31|March 2007|Actual|2007-03-31||Interventional|5011||Safety and Efficacy Study of Tarragon on Insulin Action in Humans|The Effect of Artemisia Dracunculus L. on Insulin Sensitivity in Obese, Insulin-Resistant Human Subjects|Completed||Phase 1/Phase 2|28|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 00:09:01.970641|2018-06-01 00:09:01.970641
NCT01057563|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-01-26|2010-01-26|2010-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|November 2009||2009-11-30|January 2010|2010-01-31||||November 2010|Anticipated|2010-11-30||Interventional|IN-PACT CORO||Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent|IN-PACT CORO INtimal hyPerplasia evAluated by oCT in de Novo COROnary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent|Unknown status|Recruiting|Phase 4|30|Anticipated|Catholic University of the Sacred Heart||3|||f||||t||||||||||2018-06-01 00:09:02.029825|2018-06-01 00:09:02.029825
NCT01057550|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-01-26|2010-01-26|2010-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|October 2001||2001-10-31|March 2004|2004-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Randomised Controlled Trial Comparing Tension-Free Vaginal Tape (TVT), Pelvicol & Autologous Slings for Stress Urinary Incontinence(SUI)|A Randomised Controlled Trial Comparing TVT, Pelvicol and Autologous Fascial Slings for the Treatment of Stress Urinary Incontinence in Women|Completed||Phase 3|201|Actual|Abertawe Bro Morgannwg University NHS Trust||3|||f||||t||||||||||2018-06-01 00:09:02.218866|2018-06-01 00:09:02.218866
NCT01057537|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-11-26|2010-01-26|2010-01-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|UMPIRE||UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events|A Randomised Controlled Trial of a Fixed-dose Combination Polypill Medication (the Red Heart Pill) and Usual Care in Those at High Risk of Cardiovascular Disease.|Completed||Phase 3|2004|Actual|Imperial College London||2|||f||||t||||||||||2018-06-01 00:09:02.293747|2018-06-01 00:09:02.293747
NCT01057524|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-11-10|2010-01-26|2010-01-27|Estimate|||||||2016-11-10|2016-11-11|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||High Frequency Chest Wall Oscillation and Cystic Fibrosis|The Use of High Frequency Chest Wall Oscillation During an Acute Infective Pulmonary Exacerbation of Cystic Fibrosis|Completed||Phase 3|56|Actual|Imperial College London||2|||f||||t||||||||||2018-06-01 00:09:02.383674|2018-06-01 00:09:02.383674
NCT01057511|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-04-01|2010-01-26|2010-01-27|Estimate|||||||2012-04-01|2012-04-03|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|||Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration|Investigation of the Differences of Progesterone Concentration in Serum and Endometrium After Administration With Vaginal and Intramuscular Progesterone|Completed||Phase 1/Phase 2|51|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-06-01 00:09:02.451428|2018-06-01 00:09:02.451428
NCT01057498|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-01-11|2010-01-25|2010-01-27|Estimate|||||||2012-01-11|2012-01-12|Estimate|May 2010||2010-05-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Safety Study of Nebulized RNS60 to Treat Asthma.|A Phase I Study of Nebulized RNS60 in Adult Healthy Subjects and Patients With Mild to Moderate Asthma.|Completed||Phase 1|36|Actual|Revalesio Corporation||3|||f||||f||||||||||2018-06-01 00:09:02.515024|2018-06-01 00:09:02.515024
NCT01057485|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-05-25|2010-01-26|2010-01-27|Estimate|||||||2010-05-25|2010-05-26|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|NAFAPAF||Node and Atrial Fibrillation Ablation for Persistent Atrial Fibrillation|Node and Atrial Fibrillation Ablation for Persistent Atrial Fibrillation|Unknown status|Recruiting|N/A|50|Anticipated|Eastbourne General Hospital||2|||f||||f||||||||||2018-06-01 00:09:02.577723|2018-06-01 00:09:02.577723
NCT01057472|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-01-24|2010-01-26|2010-01-27|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Repeatability and Feasibility of Infant Spirometry|Repeatability and Feasibility of Infant Spirometry|Completed|||30|Actual|Haukeland University Hospital|||3||f||||f||||||||||2018-06-01 00:09:02.702337|2018-06-01 00:09:02.702337
NCT01057459|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-06-26|2010-01-26|2010-01-27|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2010|Actual|2010-02-28|June 2017|2017-06-30|June 23, 2014|Actual|2014-06-23|June 23, 2014|Actual|2014-06-23||Observational|||DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701|Natural Killer Cell KIR and HLA Genotypes May Predict Response to Antibody Therapy in Follicular Lymphoma|Completed|||78|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:09:02.761167|2018-06-01 00:09:02.761167
NCT01057433|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2012-03-23||2012-07-05|2010-01-25|2010-01-27|Estimate|2012-07-05|2012-08-13|Estimate||||2012-07-05|2012-08-13|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin|Drug-Drug Interaction Study to Assess the Effects of Steady-State Lopinavir/Ritonavir on Pitavastatin in Healthy Adult Volunteers|Completed||Phase 4|24|Actual|Kowa Research Institute, Inc.||1|||f||||f||||||||||2018-06-01 00:09:02.954569|2018-06-01 00:09:02.954569
NCT01057420|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-08-23|2010-01-26|2010-01-27|Estimate|||||||2010-08-23|2010-08-24|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Hyperoxemia on Platelet Function in Healthy Volunteers|Effect of Hyperoxemia on Platelet Function in Healthy Volunteers|Completed||Phase 4|50|Anticipated|University of Zurich||1|||f||||f||||||||||2018-06-01 00:09:03.138444|2018-06-01 00:09:03.138444
NCT01057407|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-04-30|2010-01-25|2010-01-27|Estimate|||||||2015-04-30|2015-05-04|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis|A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis|Completed||Phase 3|110|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:09:03.214369|2018-06-01 00:09:03.214369
NCT01057394|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-04-18||2016-07-27|2010-01-26|2010-01-27|Estimate|2016-07-27|2016-08-01|Estimate||||2016-07-27|2016-08-01|Estimate|December 2009||2009-12-31|July 2016|2016-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|En-GARDE||Post-Market Randomized Trial: Endoscopically- Guided Ablation vs. Radiofrequency Ablation|Post-Market Randomized Controlled Trial: Endoscopically- Guided Ablation vs. Radiofrequency Ablation GuideD by Electroanatomical Mapping to Achieve Permanent Pulmonary Vein Isolation (En-GARDE)|Terminated||Phase 4|21|Actual|CardioFocus||2||Sponsor stopped study for business reasons; not for clinical or clinical outcomes reasons.|f||||f||||||||||2018-06-01 00:09:03.294541|2018-06-01 00:09:03.294541
NCT01057381|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-08-09|2010-01-26|2010-01-27|Estimate|||||||2012-08-09|2012-08-10|Estimate|August 2005||2005-08-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Dexmedetomidine in Pediatric Tonsillectomy|Dose Response Relationship of Dexmedetomidine in Decreasing Post Operative Analgesic Requirements in the Pediatric Tonsillectomy Patient|Completed||Phase 4|109|Actual|Baylor College of Medicine||4|||f||||t||||||||||2018-06-01 00:09:03.432664|2018-06-01 00:09:03.432664
NCT01057368|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2014-06-03|2010-01-22|2010-01-27|Estimate|||||||2014-06-03|2014-06-05|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effects of Well-being Interventions on Affect, Attention, Sleep, Social Stress and Pain Regulation|The Effects of Well-being Interventions on Affect, Attention, Sleep, Social Stress and Pain Regulation|Completed||N/A|161|Actual|University of Wisconsin, Madison||4|||f||||t||||||||||2018-06-01 00:09:03.50877|2018-06-01 00:09:03.50877
NCT01057355|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2014-09-17|2010-01-26|2010-01-27|Estimate|||||||2014-09-17|2014-09-19|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms|Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms|Withdrawn||Phase 1|0|Actual|Mayo Clinic||1||slow accural|f||||t||||||||||2018-06-01 00:09:03.581928|2018-06-01 00:09:03.581928
NCT01057342|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-04-09|2010-01-26|2010-01-27|Estimate|||||||2013-04-09|2013-04-10|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|May 2011|Actual|2011-05-31||Interventional|||Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Carboplatin and Paclitaxel Plus ASA404 as First Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial|Completed||Phase 2|17|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-06-01 00:09:03.65471|2018-06-01 00:09:03.65471
NCT01057329|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-09-28|2010-01-26|2010-01-27|Estimate|||||||2017-09-28|2017-10-02|Actual|January 2010||2010-01-31|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|TDMKJP||Therapeutic Drug Monitoring in Child and Adolescent Psychiatry|Therapeutic Drug Monitoring (TDM) in Child & Adolescent Psychiatry|Recruiting|||200|Anticipated|Medical University of Vienna|||4||f||||f||||||||||2018-06-01 00:09:03.753969|2018-06-01 00:09:03.753969
NCT01057316|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2017-06-30|2010-01-25|2010-01-27|Estimate|||||||2017-06-30|2017-07-02|Actual|February 2010||2010-02-28|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|January 2014|Actual|2014-01-31||Interventional|||Formula PTX Renal Stent Clinical Study|Evaluation of Safety and Effectiveness of the Formula PTX Balloon-Expandable Stent for Renal Artery Stenosis|Active, not recruiting||N/A|120|Actual|Cook Group Incorporated||3|||f||||||||||||||2018-06-01 00:09:03.830527|2018-06-01 00:09:03.830527
NCT01057303|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2015-05-05|2010-01-26|2010-01-27|Estimate|||||||2015-05-05|2015-05-06|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Studying Gene Expression in Tissue Samples From Young Patients With Acute Myeloid Leukemia|EVI-1 Expression in Pediatric AML With 11q23 Abnormalities|Completed|||20|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-06-01 00:09:03.896508|2018-06-01 00:09:03.896508
NCT01057290|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-05-17|2010-01-26|2010-01-27|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2012||2012-09-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia|Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML|Completed|||75|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     cell samples~   "|||2018-06-01 00:09:03.946543|2018-06-01 00:09:03.946543
NCT01057277|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2015-07-08||2015-07-08|2010-01-26|2010-01-27|Estimate|2015-07-08|2015-08-04|Estimate||||2015-07-08|2015-08-04|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer|BrUOG-H&N-229-RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer: A PHASE I STUDY- Novartis CRAD001CUS134T|Terminated||Phase 1|3|Actual|Brown University||1||Pharmaceutical co- re aligned their specialties- no longer will fund H&N ca|f||||t||||||||||2018-06-01 00:09:04.006121|2018-06-01 00:09:04.006121
NCT01057264|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-11-16|2010-01-25|2010-01-27|Estimate|||||||2015-11-16|2015-11-18|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||HAI Abraxane With Gemcitabine and Bevacizumab|A Phase I Study of Hepatic Arterial Infusion (HAI) of Abraxane in Combination With Gemcitabine and Bevacizumab for Patients With Advanced Cancers Metastatic to the Liver|Completed||Phase 1|78|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:09:04.25843|2018-06-01 00:09:04.25843
NCT00832013|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-08-17|2009-01-28|2009-01-29|Estimate|||||||2009-08-17|2009-08-18|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Safe Administration of Propofol for Sedation in Children|Safe Administration of Propofol for Sedation in Children|Completed||N/A|120|Anticipated|University of British Columbia||2|||f||||||||||||||2018-06-01 01:21:58.472955|2018-06-01 01:21:58.472955
NCT01057251|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2011-12-06||2011-12-06|2010-01-26|2010-01-27|Estimate|2011-12-06|2012-01-11|Estimate||||2011-12-06|2012-01-11|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|NEB-MD-20||Nebivolol in Patients With Systolic Stage 2 Hypertension|Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of 5 mg or 20 mg Nebivolol Once Daily on Blood Pressure in Patients With Systolic Stage 2 Hypertension|Completed||Phase 4|433|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:09:04.353022|2018-06-01 00:09:04.353022
NCT01057238|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-07-25|2010-01-26|2010-01-27|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2005||2005-11-30|July 2016|2016-07-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Intensive Communication for Chronically Critically Ill|Intensive Communication for Chronically Critically Ill|Completed||N/A|571|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-06-01 00:09:04.599603|2018-06-01 00:09:04.599603
NCT01057225|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-08-02||2017-11-14|2010-01-26|2010-01-27|Estimate|2016-08-02|2016-09-23|Estimate||||2017-11-14|2017-12-12|Actual|March 2010||2010-03-31|November 2017|2017-11-30|September 5, 2017|Actual|2017-09-05|March 2014|Actual|2014-03-31||Interventional||All patients that were eligible and treated for the study were evaluated.|Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma|A Phase I/II Trial of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone (CYCLONE) in Patients With Newly Diagnosed Active Multiple Myeloma|Completed||Phase 1/Phase 2|64|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:09:04.734476|2018-06-01 00:09:04.734476
NCT01057212|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-09-04|2010-01-25|2010-01-27|Estimate|||||||2015-09-04|2015-09-07|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Phase II Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Progressive After First-line Therapy|Terminated||Phase 2|6|Actual|Providence Health & Services||1||Lack of support from pharmaceutical collaborator.|f||||f||||||||||2018-06-01 00:09:05.223588|2018-06-01 00:09:05.223588
NCT01057199|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2015-05-05|2010-01-26|2010-01-27|Estimate|||||||2015-05-05|2015-05-07|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia|Critical Role of MicroRNA-34a and MicroRNA-194 in Acute Myeloid Leukemia With CEBPA Mutations|Completed|||6|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     cell samples~   "|||2018-06-01 00:09:05.306347|2018-06-01 00:09:05.306347
NCT01057186|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-08-30|2010-01-26|2010-01-27|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2009||2009-12-31|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Observational|||Hypophosphatemic Rickets in Norway|Hypophosphatemic Rickets in Norway|Active, not recruiting|||80|Anticipated|Haukeland University Hospital|||2||f||||f||||||Samples With DNA|"~     EDTA plasma, serum, urine~   "|||2018-06-01 00:09:05.368584|2018-06-01 00:09:05.368584
NCT01057173|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-05-16|2010-01-26|2010-01-27|Estimate|||||||2017-05-16|2017-05-18|Actual|December 2009|Actual|2009-12-31|May 2017|2017-05-31|April 2023|Anticipated|2023-04-30|April 2014|Actual|2014-04-30||Interventional|NOTION||The Nordic Aortic Valve Intervention Trial|Transcatheter Versus Surgical Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis|Active, not recruiting||N/A|280|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 00:09:05.432527|2018-06-01 00:09:05.432527
NCT01057160|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-01-25|2010-01-26|2010-01-27|Estimate|||||||2013-01-25|2013-01-28|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|Rinotama||Rizatriptan 10 MG RPD in the Treatment of Acute Migraine|A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment|Completed||Phase 4|195|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-06-01 00:09:05.509073|2018-06-01 00:09:05.509073
NCT01057147|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25||2012-01-09|2012-01-09|2010-01-25|2010-01-27|Estimate||||2012-01-09|2012-01-11|Estimate|2012-01-09|2012-01-11|Estimate|February 2010||2010-02-28|January 2012|2012-01-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea|A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo in Clearing of Fluorescein Staining of the Central Cornea in Subjects With Keratoconjunctivitis Sicca (Dry Eye)|Completed||Phase 2|116|Actual|Acucela Inc.||2|||f||||||||||||||2018-06-01 00:09:05.57976|2018-06-01 00:09:05.57976
NCT01057134|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2013-06-21|2010-01-26|2010-01-27|Estimate|||||||2013-06-21|2013-06-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:09:05.659332|2018-06-01 00:09:05.659332
NCT01057121|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|2016-03-04||2016-06-07|2010-01-26|2010-01-27|Estimate|2016-06-07|2016-07-21|Estimate||||2016-06-07|2016-07-21|Estimate|August 2010||2010-08-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma|A Phase I/II Study of Lenalidomide in Patients With AIDS-Associated Kaposi's Sarcoma|Completed||Phase 1/Phase 2|38|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:09:05.711867|2018-06-01 00:09:05.711867
NCT01057108|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-01-05|2010-01-26|2010-01-27|Estimate|||||||2011-01-05|2011-01-07|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia|A Double Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of FOSTRAP Chewing Gum in Patients With Chronic Kidney Disease and Hyperphosphatemia.|Completed||Phase 1|121|Actual|Denver Nephrologists, P.C.||4|||f||||f||||||||||2018-06-01 00:09:06.40583|2018-06-01 00:09:06.40583
NCT01057095|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2015-09-30|2010-01-26|2010-01-27|Estimate|||||||2015-09-30|2015-10-02|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia|Mechanisms of PLAGL2-Induced Leukaemogenesis|Completed|||20|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-06-01 00:09:06.520684|2018-06-01 00:09:06.520684
NCT01057082|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-03-16|2010-01-26|2010-01-27|Estimate|||||||2012-03-16|2012-03-19|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dietary Supplements and Aging Muscle|Dietary Supplements and Aging Muscle: Specific Amino Acids to Combat Sarcopenia|Completed||N/A|36|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 00:09:06.601218|2018-06-01 00:09:06.601218
NCT01055665|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2012-05-01|2010-01-22|2010-01-25|Estimate|||||||2012-05-01|2012-05-03|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Cognitive Behavioral Therapy, Self-Efficacy, and Depression in Persons With Chronic Pain|Cognitive Behavioral Therapy, Self-Efficacy, and Depression in Persons With Chronic Pain|Completed|||138|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 00:09:28.757205|2018-06-01 00:09:28.757205
NCT01057069|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2017-04-13|2010-01-26|2010-01-27|Estimate|||||||2017-04-13|2017-04-17|Actual|January 2010||2010-01-31|April 2017|2017-04-30|December 2029|Anticipated|2029-12-31|December 2019|Anticipated|2019-12-31||Interventional|neo-TN||Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer|Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors|Active, not recruiting||Phase 2/Phase 3|310|Actual|The Netherlands Cancer Institute||5|||f||||f||||||||||2018-06-01 00:09:06.811483|2018-06-01 00:09:06.811483
NCT01057056|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2010-02-04|2010-01-26|2010-01-27|Estimate|||||||2010-02-04|2010-02-05|Estimate|January 2010||2010-01-31|January 2010|2010-01-31||||||||Interventional|||The Role of Mind Body Therapy in Geriatric Rehabilitation||Unknown status|Not yet recruiting|Phase 1/Phase 2|||Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-06-01 00:09:06.908478|2018-06-01 00:09:06.908478
NCT01057043|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2012-10-22|2010-01-26|2010-01-27|Estimate|||||||2012-10-22|2012-10-23|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Cupping in Osteoarthritis of the Knee|Randomised Controlled Clinical Trial on Pulsatile Cupping in Patients With Osteoarthritis of the Knee.|Completed||N/A|40|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:09:06.981562|2018-06-01 00:09:06.981562
NCT01057030|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2011-01-24|2010-01-26|2010-01-27|Estimate|||||||2011-01-24|2011-01-25|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Multiple Dose Japanese Bridging Study|Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 125 mg in Healthy Japanese and Non-Japanese Subjects|Completed||Phase 1|22|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 00:09:07.088212|2018-06-01 00:09:07.088212
NCT01057017|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2013-05-09||2014-06-18|2010-01-26|2010-01-27|Estimate|2013-10-09|2013-11-04|Estimate||||2014-06-18|2014-06-27|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras|Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras|Terminated||Phase 2|5|Actual|Brown University||1||possible lack of efficacy|f||||t||||||||||2018-06-01 00:09:07.179553|2018-06-01 00:09:07.179553
NCT01057004|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2016-06-23|2010-01-26|2010-01-27|Estimate|||||||2016-06-23|2016-06-24|Estimate|February 2009||2009-02-28|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|EVITA-HF||EVIdence Based TreAtment - Heart Failure (EVITA-HF)|EVIdence Based TreAtment - Heart Failure (EVITA-HF)|Completed|||4560|Actual|Stiftung Institut fuer Herzinfarktforschung|||1||f||||f||||||||No||2018-06-01 00:09:07.328011|2018-06-01 00:09:07.328011
NCT01056991|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2014-06-11|2010-01-26|2010-01-27|Estimate|||||||2014-06-11|2014-06-12|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Prevention of IPH: Electric Warming Mattress vs Forced Air Warming Blanket|A Study to Determine if Modern Under-patient Warming Mattresses Are as Effective as Forced-air Warming Blankets in Preventing Peri-operative Hypothermia|Completed||N/A|120|Actual|Brighton and Sussex University Hospitals NHS Trust||2|||f||||f||||||||||2018-06-01 00:09:07.480821|2018-06-01 00:09:07.480821
NCT01056978|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-26|||2013-08-06|2010-01-26|2010-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|RHESO||Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliative Care Unit|Predictive Factors for Major Bleeding Risk in Patients Admitted in a Palliativecare Unit - Etude RHESO - Etude Monocentrique|Completed|||1230|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||t||||||||||2018-06-01 00:09:07.563881|2018-06-01 00:09:07.563881
NCT01056965|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2018-03-23|2010-01-25|2010-01-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 2010||2010-01-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Davunetide (AL-108) in Predicted Tauopathies - Pilot Study|A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies|Completed||Phase 2|12|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:09:07.667215|2018-06-01 00:09:07.667215
NCT01056952|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2012-06-13|2010-01-25|2010-01-26|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure (OPTIFLOW)|Physiologic Effects of High Flow Nasal Therapy in Patients With Acute Hypoxemic Respiratory Failure|Completed||N/A|12|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 00:09:07.777081|2018-06-01 00:09:07.777081
NCT01056939|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-05-24|2010-01-25|2010-01-26|Estimate|||||||2012-05-24|2012-05-25|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Neurally Adjusted Ventilatory Assist (NAVA) in Pediatric Patients|Neurally Adjusted Ventilatory Assist (NAVA) in Pediatric Patients|Completed||N/A|170|Actual|University of Oulu||2|||f||||f||||||||||2018-06-01 00:09:07.860904|2018-06-01 00:09:07.860904
NCT01056926|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2017-01-30|2010-01-24|2010-01-26|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|NNN||Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction|Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction|Completed||Phase 1|147|Actual|Duke University||4|||f||||f||||||||||2018-06-01 00:09:07.929226|2018-06-01 00:09:07.929226
NCT01056913|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|2013-12-11||2013-12-11|2010-01-25|2010-01-26|Estimate|2013-12-11|2014-01-29|Estimate||||2013-12-11|2014-01-29|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery|Compression Anastomosis: Initial Clinical Experience With the ColonRingTM|Completed||Phase 4|62|Actual|St John of God Hospital, Vienna||1|||f||||f||||||||||2018-06-01 00:09:08.051166|2018-06-01 00:09:08.051166
NCT01056900|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-24|2010-01-24|2010-01-26|Estimate|||||||2010-01-24|2010-01-26|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Observational|||Observation of the Result After Chondron (Autologous Chondrocytes) Treatment|An Investigator-sponsored Trial for Observation of the Result After Chondron (Autologous Chondrocytes) Treatment|Completed|||127|Actual|Sewon Cellontech Co., Ltd.|||1||f||||f||||||||||2018-06-01 00:09:08.202172|2018-06-01 00:09:08.202172
NCT01056887|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-04-22|2010-01-25|2010-01-26|Estimate|||||||2011-04-22|2011-04-25|Estimate|March 2008||2008-03-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Copeptin in Differentiation of Polyuria and Polydipsia||Completed|||50|Anticipated|University of Wuerzburg|||1||f||||t||||||||||2018-06-01 00:09:08.271222|2018-06-01 00:09:08.271222
NCT01054950|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2016-06-29|2010-01-21|2010-01-22|Estimate|||||||2016-06-29|2016-06-30|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Quality of Life in Food Allergic Families|Quality of Life in Food Allergic Families|Completed||N/A|58|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:09:41.25038|2018-06-01 00:09:41.25038
NCT01056874|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2011-04-06|2010-01-22|2010-01-26|Estimate|||||||2011-04-06|2011-04-07|Estimate|March 2010||2010-03-31|April 2011|2011-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect Of Maraviroc On The Pharmacokinetics Of Digoxin|Open-Label, Fixed Sequence, Crossover Study To Estimate The Effect Of Multiple Dose Maraviroc On Single Dose Digoxin Pharmacokinetics In Healthy Subjects|Completed||Phase 1|12|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-06-01 00:09:08.326127|2018-06-01 00:09:08.326127
NCT01056861|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-04-16|2010-01-25|2010-01-26|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Effects of Botulinum Toxin in Cervical Dystonia|Effects of Botulinum on the Afferent Input Modulation of Neuronal Circuits Involved in Cervical Dystonia|Completed|||7|Actual|Henry Ford Health System|||2||f||||f||||||||||2018-06-01 00:09:08.402703|2018-06-01 00:09:08.402703
NCT01056848|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2011-06-20|2010-01-25|2010-01-26|Estimate|||||||2011-06-20|2011-06-21|Estimate|January 2010||2010-01-31|June 2011|2011-06-30||||June 2011|Actual|2011-06-30||Observational|||International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430|International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430|Completed|||135|Actual|CardioKine Inc.|||3||f||||||||||||||2018-06-01 00:09:08.476403|2018-06-01 00:09:08.476403
NCT01056835|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2015-05-24|2010-01-24|2010-01-26|Estimate|||||||2015-05-24|2015-05-27|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy|Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy|Completed||Phase 3|40|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-06-01 00:09:08.554055|2018-06-01 00:09:08.554055
NCT01056822|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2014-04-10||2014-12-02|2010-01-25|2010-01-26|Estimate|2014-12-02|2014-12-03|Estimate||||2014-12-02|2014-12-03|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MAXIMIZA|The intention-to-treat (ITT) population consisted of all randomised patients who gave signed informed consent and received at least one dose of the study medicinal product and have at least one baseline visit and one post-baseline visit (containing data to allow the primary endpoint to be calculated) Standard Deviation|Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.|Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.|Completed||Phase 4|89|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:09:08.674186|2018-06-01 00:09:08.674186
NCT01056809|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-05-30|2010-01-25|2010-01-26|Estimate|||||||2012-05-30|2012-05-31|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PGC||Treatment Strategies for Primarily Generalized Colorectal Cancer|Treatment Strategies for Primarily Generalized Colorectal Cancer Prospective Randomized Comparison Between Two Treatment Strategies|Terminated||N/A|15|Actual|Vrinnevi Hospital||2||Too slow recruitment|f||||f||||||||||2018-06-01 00:09:09.537684|2018-06-01 00:09:09.537684
NCT01056796|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-06-29|2010-01-25|2010-01-26|Estimate|||||||2011-06-29|2011-06-30|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27|Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27|Unknown status|Recruiting|Phase 2|10|Anticipated|Niti Medical Technologies Ltd.||1|||f||||f||||||||||2018-06-01 00:09:09.644058|2018-06-01 00:09:09.644058
NCT01056783|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-01-04|2010-01-25|2010-01-26|Estimate|||||||2012-01-04|2012-01-05|Estimate|August 2010||2010-08-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Proof of Concept Study of OC000459 in Eosinophilic Esophagitis|A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis|Completed||Phase 2|26|Actual|Oxagen Ltd||2|||f||||f||||||||||2018-06-01 00:09:09.729822|2018-06-01 00:09:09.729822
NCT01056770|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2013-12-05|2010-01-24|2010-01-26|Estimate|||||||2013-12-05|2013-12-06|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers|An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers|Completed||Phase 3|88|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-06-01 00:09:09.792681|2018-06-01 00:09:09.792681
NCT01056757|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-11-03|2010-01-25|2010-01-26|Estimate|||||||2015-11-03|2015-11-04|Estimate|December 2009||2009-12-31|November 2015|2015-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Treatment With Ribavirin for Patients With Metastatic Breast Cancer|A Phase I/II Exploratory Study of Ribavirin in Metastatic Breast Cancer Expressing Elevated eIF4E|Terminated||Phase 1/Phase 2|4|Actual|Jewish General Hospital||1||Study closed because of new overlapping study with ribavirin.|f||||f||||||||||2018-06-01 00:09:09.85885|2018-06-01 00:09:09.85885
NCT01056744|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2013-02-25|2010-01-25|2010-01-26|Estimate|||||||2013-02-25|2013-02-26|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|May 2011|Actual|2011-05-31||Interventional|OCTOPUS||Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents|Endothelial Stent Coverage and Neointimal Proliferation at 6 Months After Implantation of a Coronary Everolimus-Eluting Stent Compared With a Bare Metal Stent Postdilated With a Paclitaxel-Eluting Balloon: A Randomised Study Using Optical Coherence Tomography|Completed||Phase 4|90|Actual|University of Jena||2|||f||||t||||||||||2018-06-01 00:09:09.931206|2018-06-01 00:09:09.931206
NCT01056731|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2017-02-21|2010-01-25|2010-01-26|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2010||2010-02-28|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ANDROMEDA||A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.|A 16-week, Prospective, Open Label, Multicenter Study to Evaluate the Effectiveness and Safety of Rasilez® (Aliskiren) Monotherapy or in Addition With Hydrochlorothiazide 12.5 mg or 25 mg in Patients With Hypertension Stage I and II|Completed||Phase 4|253|Actual|Novartis||1|||f||||t||||||||||2018-06-01 00:09:09.996925|2018-06-01 00:09:09.996925
NCT01056562|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2015-04-24|2010-01-25|2010-01-26|Estimate|||||||2015-04-24|2015-04-27|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|TADS||An Alternative to A Fixed Schedule In Management Of Prostate Cancer|Testosterone-Guided Schedule of Androgen Deprivation Therapy (ADT) as an Alternative to A Fixed Schedule In Management Of Prostate Cancer|Completed|||82|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 00:09:14.347761|2018-06-01 00:09:14.347761
NCT01056718|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2015-12-16||2017-03-21|2010-01-25|2010-01-26|Estimate|2016-02-19|2016-03-21|Estimate||||2017-03-21|2017-04-18|Actual|November 2009||2009-11-30|March 2017|2017-03-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function|Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function|Completed||N/A|53|Actual|Mercy Research|There was no placebo control. All patients received nebivolol and served as their own control before and after treatment. This study had a small study population and short duration.|1|||f||||f||||||||No||2018-06-01 00:09:10.083744|2018-06-01 00:09:10.083744
NCT01056705|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2016-07-31|2010-01-25|2010-01-26|Estimate|||||||2016-07-31|2016-08-02|Estimate|July 2009||2009-07-31|July 2016|2016-07-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|Sabin IPV||The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)|The Phase Ⅱ Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|Completed||Phase 2|500|Actual|Chinese Academy of Medical Sciences||5|||f||||t||||||||||2018-06-01 00:09:11.587213|2018-06-01 00:09:11.587213
NCT01056692|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|February 2006||2006-02-28|January 2010|2010-01-31||||||||Interventional|||OC000459 Bronchial Allergen Challenge|A Phase II Study of oc000459 in Subjects With Allergic Asthma; a Randomised, Double Blind, Two Way Balanced Crossover Comparing oc000459 With Placebo|Completed||Phase 2|20|Actual|Oxagen Ltd||2|||f||||f||||||||||2018-06-01 00:09:11.673158|2018-06-01 00:09:11.673158
NCT01056679|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2018-03-21|2010-01-25|2010-01-26|Estimate|||||||2018-03-21|2018-03-22|Actual|April 2010||2010-04-30|March 2018|2018-03-31|February 2016|Actual|2016-02-29|April 2014|Actual|2014-04-30||Interventional|AVD-Rev||Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients|Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients|Completed||Phase 1|30|Anticipated|University of Cologne||1|||f||||t||||||||||2018-06-01 00:09:11.750197|2018-06-01 00:09:11.750197
NCT01056666|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-09-16|2010-01-25|2010-01-26|Estimate|||||||2011-09-16|2011-09-19|Estimate|June 2007||2007-06-30|April 2007|2007-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Conveen Optima Urisheaths With Collecting Bags Versus Absorbents|Evaluation de l'Impact Sur la qualité de Vie de l'Utilisation d'un système Collecteur Conveen( étuis pénien Conveen Optima Avec Poches de Recueil Conveen) Chez Des Hommes Souffrant d'Une Incontinence Urinaire modérée ou sévère, Comparativement à Leur Protection Absorbante Habituelle|Completed||Phase 4|61|Actual|Coloplast A/S||2|||f||||f||||||||||2018-06-01 00:09:11.822535|2018-06-01 00:09:11.822535
NCT01056653|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2016-08-08||2017-02-27|2010-01-25|2010-01-26|Estimate|2017-01-04|2017-02-23|Actual||||2017-02-27|2017-03-29|Actual|December 2008||2008-12-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|FLPTB|Sociodemographic and health data were collected with the first home visit.|Fathers and Late Preterm Babies Study|Fathers and Late Preterm Babies Study: Effects of an Educational Intervention on Fathers' Interactions With Infants Born Between 34 and 36 Weeks Gestation|Completed||N/A|113|Actual|University of Calgary|"Challenges recruiting first-time fathers of late preterm infants; recruiting challenges led to a smaller sample than planned.~Limited inter-rater reliability."|3|||f||||f||||||||No||2018-06-01 00:09:12.701555|2018-06-01 00:09:12.701555
NCT01056640|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2012-11-06||2013-01-07|2010-01-25|2010-01-26|Estimate|2013-01-07|2013-02-08|Estimate||||2013-01-07|2013-02-08|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Telemonitoring Versus Usual Care|A Randomized Controlled Trial of Telemonitoring Versus Usual Care in a High Risk Elderly Population.|Completed||Phase 2/Phase 3|205|Actual|Mayo Clinic|Patients in the usual care group had access to a tertiary care hospital and to some case management for treatment of heart failure and diabetes. These services may have biased the results to show no difference between the groups.|2|||f||||f||||||||||2018-06-01 00:09:13.562368|2018-06-01 00:09:13.562368
NCT01056627|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|December 2006||2006-12-31|January 2010|2010-01-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Bioequivalence Study of Dr. Reddy's Divalproex Sodium Coated Particles in Capsules, 125 mg, Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Human Subjects Under Fed Conditions.|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:09:13.836099|2018-06-01 00:09:13.836099
NCT01056614|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2016-05-04|2010-01-22|2010-01-26|Estimate|||||||2016-05-04|2016-05-06|Estimate|September 2004||2004-09-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|August 2005|Actual|2005-08-31||Interventional|||Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies|Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies|Completed||Phase 2|23|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 00:09:13.902602|2018-06-01 00:09:13.902602
NCT01056601|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2011-07-28||2017-12-03|2010-01-25|2010-01-26|Estimate|2011-07-28|2011-08-26|Estimate||||2017-12-03|2017-12-28|Actual|September 2010||2010-09-30|November 2017|2017-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy|Phase II Study of Panobinostat (LBH589) Given in Combination With Bortezomib (Velcade) in Patients With Pancreatic Cancer Progressing on Gemcitabine Therapy Alone or Gemcitabine in Combination|Terminated||Phase 2|7|Actual|Masonic Cancer Center, University of Minnesota|Study was terminated early leading to small numbers of subjects analyzed; no solid conclusion can be derived.|1||Funding not available|f||||t||||||||||2018-06-01 00:09:14.021198|2018-06-01 00:09:14.021198
NCT01056588|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-06-21|2010-01-25|2010-01-26|Estimate|||||||2011-06-21|2011-06-23|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|CM||Contingency Management for Smoking Abstinence With Adolescent Smokers|Predictors of Smoking Outcomes During Treatment Programs|Unknown status|Recruiting|N/A|126|Anticipated|Nationwide Children's Hospital||2|||f||||t||||||||||2018-06-01 00:09:14.209684|2018-06-01 00:09:14.209684
NCT01056575|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-09-01|2010-01-25|2010-01-26|Estimate|||||||2010-09-01|2010-09-02|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4|An Open Label Balanced Study in Healthy Subjects to Evaluate the Potential for Cytochrome P 450 3A4 Induction by Oral OC000459 Using Oral Midazolam as a Probe|Completed||Phase 1|20|Anticipated|Oxagen Ltd||1|||f||||f||||||||||2018-06-01 00:09:14.283019|2018-06-01 00:09:14.283019
NCT01056549|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-06-21|2010-01-25|2010-01-26|Estimate|||||||2012-06-21|2012-06-22|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans|Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans.|Completed||N/A|15|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 00:09:14.408099|2018-06-01 00:09:14.408099
NCT01056536|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2014-08-20|2010-01-25|2010-01-26|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2006||2006-01-31|August 2014|2014-08-31|November 2011|Actual|2011-11-30|December 2008|Actual|2008-12-31||Interventional|||Efficacy of a Brief Intervention and/or Distribution of Free Condoms During Pre-travel Consultation on Sexual Behaviour Abroad|Efficacy of a Brief Intervention and/or Distribution of Free Condoms During Pre-travel Consultation on Sexual Behaviour Abroad: a Randomized Controlled Trial|Completed||N/A|1000|Actual|University of Lausanne Hospitals||3|||f||||f||||||||||2018-06-01 00:09:14.472129|2018-06-01 00:09:14.472129
NCT01056523|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2015-10-19||2016-12-02|2010-01-25|2010-01-26|Estimate|2016-12-02|2017-01-30|Estimate||||2016-12-02|2017-01-30|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia|A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression|Completed||Phase 1/Phase 2|29|Actual|Jewish General Hospital|There were no limitations or caveats|1|||f||||f||||||||||2018-06-01 00:09:14.560218|2018-06-01 00:09:14.560218
NCT01056510|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2015-06-02||2015-06-24|2010-01-25|2010-01-26|Estimate|2015-06-24|2015-06-25|Estimate||||2015-06-24|2015-06-25|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Intent-to-Treat (ITT) Population: all randomized participants|A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)|A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia|Completed||Phase 4|357|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:09:14.981666|2018-06-01 00:09:14.981666
NCT01056497|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-09-28|2010-01-22|2010-01-26|Estimate|||||||2012-09-28|2012-10-02|Estimate|February 2010||2010-02-28|September 2012|2012-09-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion|The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion|Completed||Phase 4|15|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 00:09:16.09893|2018-06-01 00:09:16.09893
NCT01056484|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2014-04-30||2014-10-24|2010-01-22|2010-01-26|Estimate|2014-08-01|2014-08-04|Estimate||||2014-10-24|2014-11-06|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Mindfulness Meditation for Health|Mindfulness Meditation For Alcohol Relapse Prevention|Completed||Phase 2|123|Actual|University of Wisconsin, Madison|Lack of blinding of study staff to group status (except the statistician who was blinded during initial primary analyses); conducting most study related activities by the same core group of research staff may have introduced bias and placebo effect.|2|||f||||t||||||||||2018-06-01 00:09:16.173749|2018-06-01 00:09:16.173749
NCT01056471|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-08-04|2010-01-25|2010-01-26|Estimate|||||||2015-08-04|2015-08-07|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|June 2015|Actual|2015-06-30|June 2012|Actual|2012-06-30||Interventional|||Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis|Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment|Completed||Phase 1/Phase 2|30|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||3|||f||||f||||||||||2018-06-01 00:09:16.423315|2018-06-01 00:09:16.423315
NCT01056458|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-05-28|2010-01-25|2010-01-26|Estimate|||||||2010-05-28|2010-05-31|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|AAA||Auricular Acupressure for Perimenopausal Women With Anxiety|Effect of Auricular Acupressure on Perimenopausal and Early Postmenopausal Women With Anxiety: a Double Blinded, Randomized and Controlled Study|Unknown status|Recruiting|N/A|90|Anticipated|Chang-Hua Hospital||2|||f||||t||||||||||2018-06-01 00:09:16.527211|2018-06-01 00:09:16.527211
NCT01056445|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Hemodynamic Instability Following Carotid Artery Stenting|Hemodynamic Instability Following Carotid Artery Stenting|Completed||N/A|27|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:09:16.70932|2018-06-01 00:09:16.70932
NCT01056432|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2014-03-28|2010-01-24|2010-01-26|Estimate|||||||2014-03-28|2014-03-31|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|BUSS||Bone UltraSonic Scanner (BUSS) Clinical Optimization Study|Phase I Study of Portable Bone Ultrasonometer for Osteoporosis Assessment|Completed|||100|Actual|Artann Laboratories|||||f||||f||||||||||2018-06-01 00:09:16.790034|2018-06-01 00:09:16.790034
NCT01056419|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|August 2010|Anticipated|2010-08-31|June 2010|Anticipated|2010-06-30||Interventional|||The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy||Unknown status|Recruiting|Phase 4|40|Anticipated|Ankara University||2|||f||||||||||||||2018-06-01 00:09:16.85779|2018-06-01 00:09:16.85779
NCT01056406|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2016-03-18|2010-01-22|2010-01-26|Estimate|||||||2016-03-18|2016-03-21|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Nutrition Intervention for the Promotion of Healthy Weight Gain During Pregnancy|Nutrition Intervention for the Promotion of Healthy Weight Gain During Pregnancy: The Revere Pregnancy Weight Management Study|Completed||N/A|300|Actual|Massachusetts General Hospital||2|||f||||f||||||||Yes|in process|2018-06-01 00:09:16.938806|2018-06-01 00:09:16.938806
NCT01056393|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22||2018-04-11|2018-04-12|2010-01-25|2010-01-26|Estimate||||2018-04-11|2018-04-13|Actual|2018-04-12|2018-04-17|Actual|November 2009||2009-11-30|April 2018|2018-04-30|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Investigator-Sponsored Protocol - Continued Use of Ibalizumab|Investigator-Sponsored Protocol - Continued Use of Ibalizumab|Completed||Phase 2|5|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 00:09:17.021081|2018-06-01 00:09:17.021081
NCT01056224|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|May 2005||2005-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Remifentanil Boluses on Hemodynamics in Skull Pin Insertion|The Dose Effects of Remifentanil Boluses on the Hemodynamic Response to Skull Pin Insertion.|Completed||N/A|72|Actual|University Health Network, Toronto||9|||f||||f||||||||||2018-06-01 00:09:21.313065|2018-06-01 00:09:21.313065
NCT01056380|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-23|2013-11-18||2018-04-03|2010-01-25|2010-01-26|Estimate|2017-07-07|2017-08-08|Actual||||2018-04-03|2018-04-05|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza|Terminated||Phase 2|79|Actual|Romark Laboratories L.C.|Early termination leading to small numbers of subjects analyzed.|2||Insufficient enrollment during 2009-2010 flu season, new study initiated.|f||||f||||||||||2018-06-01 00:09:17.111279|2018-06-01 00:09:17.111279
NCT01056367|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-10-09|2010-01-25|2010-01-26|Estimate|||||||2011-10-09|2011-10-12|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Observational|RESIST||Resistant Hypertension in Patients With Type-II-Diabetes Mellitus|Resistant Hypertension in Patients With Type-II-Diabetes Mellitus: Prevalence, Characterization and Treatment|Completed|||180|Actual|Svendborg Hospital|||||f||||f||||||Samples Without DNA|"~     Only serum and plasma samples are used and saved for later analysis.~   "|||2018-06-01 00:09:17.479233|2018-06-01 00:09:17.479233
NCT01056354|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2017-08-15|2010-01-25|2010-01-26|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2009||2009-08-31|August 2017|2017-08-31|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Observational|||Respiratory Virus Outpatient Study (FLU 002 Plus)|An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses|Completed|||11719|Actual|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||Samples With DNA|"~     Upper respiratory tract specimen~      Serum and plasma~      For participants with a confirmed targeted non-influenza respiratory virus, attempts will be~     made to obtain a sample of the local specimen used to confirm diagnosis.~      Whole blood for human genomics (only at FLU 002 Plus sites opting to also participate in~     INSIGHT Genomics and participant has signed an additional consent)~   "|||2018-06-01 00:09:17.557488|2018-06-01 00:09:17.557488
NCT01056341|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|2014-04-09|2013-03-27|2015-11-12|2010-01-24|2010-01-26|Estimate|2014-05-21|2014-06-24|Estimate|2013-03-28|2013-04-04|Estimate|2015-11-12|2015-12-10|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|May 2012|Actual|2012-05-31||Interventional||Among the 460 randomized patients, 4 were not treated: 2 because of parent(s)'/guardian's decision (1 in 1mg/kg/day 6 months arm,1 in 3 mg/kg/day 3 months arm), 2 because of absence of adequate treatment on site (1 in 1 mg/kg/day 3 months arm and 1 in 3mg/kg/day 6 months arm).|Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy|A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind).|Completed||Phase 2/Phase 3|512|Actual|Pierre Fabre Dermatology||2|||f||||t||||||||||2018-06-01 00:09:17.7601|2018-06-01 00:09:17.7601
NCT01056328|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2014-01-28||2014-04-28|2010-01-22|2010-01-26|Estimate|2014-04-28|2014-05-23|Estimate||||2014-04-28|2014-05-23|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|IRASE-AF||Irrigated Ablation System Evaluation for Atrial Fibrillation (AF)|Irrigated Ablation System Evaluation for AF|Completed||N/A|324|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 00:09:19.254312|2018-06-01 00:09:19.254312
NCT01056315|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|2012-04-05||2013-04-19|2010-01-25|2010-01-26|Estimate|2012-04-05|2012-05-03|Estimate||||2013-04-19|2013-04-30|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Analgesic Efficacy and Safety of a New Analgesic Compared to Placebo in Subjects With Painful Diabetic Peripheral Neuropathy|Terminated||Phase 2|553|Actual|Grünenthal GmbH|No participants were analyzed as the study was terminated|2||Trial was stopped due to difficult enrolment|f||||f||||||||||2018-06-01 00:09:19.708387|2018-06-01 00:09:19.708387
NCT01056302|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2014-12-12|2010-01-22|2010-01-26|Estimate|||||||2014-12-12|2014-12-15|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Advanced Visuohaptic Surgical Planning for Trauma Surgery|Advanced Visuohaptic Surgical Planning for Trauma Surgery|Unknown status|Active, not recruiting||15|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 00:09:20.148094|2018-06-01 00:09:20.148094
NCT01056289|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2012-01-31||2012-02-25|2010-01-22|2010-01-26|Estimate|2012-01-31|2012-02-17|Estimate||||2012-02-25|2012-02-28|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)|A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation|Completed||Phase 4|480|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:09:20.257961|2018-06-01 00:09:20.257961
NCT01056276|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2017-02-08||2017-03-30|2010-01-25|2010-01-26|Estimate|2017-02-08|2017-03-28|Actual||||2017-03-30|2017-05-03|Actual|May 2010||2010-05-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|August 2015|Actual|2015-08-31||Interventional||All patients enrolled in either the original treatment regimen or the modified treatment regimen.|Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy|Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy|Completed||Phase 2|59|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 00:09:20.547523|2018-06-01 00:09:20.547523
NCT01056263|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2012-02-25||2012-04-18|2010-01-25|2010-01-26|Estimate|2012-02-25|2012-03-28|Estimate||||2012-04-18|2012-04-20|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012|Retrospective Observational Study Of Subjects With Cytokine-Refractory Metastatic Renal Cancer Treated With Axitinib (AG-013736) To Estimate 5-Yr Survival|Completed|||52|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:09:21.060911|2018-06-01 00:09:21.060911
NCT01056250|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2011-05-08|2010-01-25|2010-01-26|Estimate|||||||2011-05-08|2011-05-10|Estimate|September 2009||2009-09-30|July 2010|2010-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||SILS Cholecystectomy: Cholangiography of the Biliary Tract|Performing Cholangiography During SILS Cholecystectomy: is it Feasible?|Completed||N/A|20|Anticipated|St John of God Hospital, Vienna||1|||f||||f||||||||||2018-06-01 00:09:21.192935|2018-06-01 00:09:21.192935
NCT01056237|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2015-07-30|2010-01-25|2010-01-26|Estimate|||||||2015-07-30|2015-07-31|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis|Research Institute of Nephrology, Jinling Hospital,|Completed||N/A|206|Actual|Nanjing University School of Medicine||2|||f||||t||||||||||2018-06-01 00:09:21.250653|2018-06-01 00:09:21.250653
NCT01056211|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2014-12-04|2010-01-25|2010-01-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||1540nm Non Ablative Fractional Laser Treatment of Scars|1540nm Non Ablative Fractional Laser Treatment of Scars : a Prospective Single Blinded Within Patient Controlled Randomized Trial.|Completed||Phase 4|90|Actual|University Hospital, Ghent||6|||f||||f||||||||||2018-06-01 00:09:21.378538|2018-06-01 00:09:21.378538
NCT01056198|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2012-03-15||2012-10-23|2010-01-25|2010-01-26|Estimate|2012-10-23|2012-11-21|Estimate||||2012-10-23|2012-11-21|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Santyl vs. Sharp Debridement of Diabetic Foot Wounds|Comparison of Sharp Surgical Debridement Versus Collagenase Santyl Ointment in the Care of Diabetic Foot Wounds|Completed||Phase 4|48|Actual|Healthpoint||2|||f||||f||||||||||2018-06-01 00:09:21.546261|2018-06-01 00:09:21.546261
NCT01056185|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2018-02-22|2010-01-25|2010-01-26|Estimate|||||||2018-02-22|2018-02-23|Actual|August 2009|Actual|2009-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Respiratory Virus Hospitalization Study (FLU 003 Plus)|An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses|Recruiting|||1000|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, respiratory for all participants. For participants with a confirmed targeted~     non-influenza respiratory virus, attempts will be made to obtain a sample of the local~     specimen used to confirm diagnosis.~      Whole blood for human genomics (only for FLU 003 Plus sites opting to also participate in~     INSIGHT Genomics and participant has signed an additional consent)~   "|||2018-06-01 00:09:21.961236|2018-06-01 00:09:21.961236
NCT01056172|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-04-18|2010-01-25|2010-01-26|Estimate|||||||2012-04-18|2012-04-20|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)|A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response|Unknown status|Recruiting|Phase 4|164|Anticipated|Pusan National University Yangsan Hospital||2|||f||||t||||||||||2018-06-01 00:09:22.269069|2018-06-01 00:09:22.269069
NCT01056159|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2012-05-11|2010-01-22|2010-01-26|Estimate|||||||2012-05-11|2012-05-14|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)|Cumulative Dose Comparison of the Efficacy and Safety of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler) in Adult Patients With Asthma|Completed||Phase 1|47|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 00:09:22.383595|2018-06-01 00:09:22.383595
NCT01056146|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2014-10-27|2010-01-22|2010-01-26|Estimate|||||||2014-10-27|2014-10-28|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|I-InTERACT||"Interacting Together Everyday: Recovery After Childhood Traumatic Brain Injury (TBI) I-InTERACT"|An Online Intervention for Families of Young Children With TBI: I-InTERACT|Completed||N/A|41|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-06-01 00:09:22.469911|2018-06-01 00:09:22.469911
NCT01056133|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2016-05-10|2010-01-25|2010-01-26|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH)|A Pilot Study to Determine the Effect of Omega-3 Polyunsaturated Fatty Acids From Fish Oil on Patients With Non-Alcoholic Steatohepatitis (NASH)|Completed||Phase 2|20|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 00:09:22.551303|2018-06-01 00:09:22.551303
NCT01056120|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2016-01-29|2010-01-25|2010-01-26|Estimate|||||||2016-01-29|2016-02-01|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Observational|ENERGY||Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice|Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice Multinational, Prospective, Non-randomized, Multi-centre, Non-interventional Trial|Completed|||1026|Actual|Biotronik AG|||1||f||||f||||||||||2018-06-01 00:09:22.636253|2018-06-01 00:09:22.636253
NCT01056107|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2013-02-21||2013-04-24|2010-01-25|2010-01-26|Estimate|2013-04-24|2013-05-31|Estimate||||2013-04-24|2013-05-31|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients|Effect of ROSE-010 on Gastrointestinal Motor Functions in Female Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)|Completed||Phase 1/Phase 2|52|Actual|Mayo Clinic||4|||f||||f||||||||||2018-06-01 00:09:22.783334|2018-06-01 00:09:22.783334
NCT01056094|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-06-21|2010-01-25|2010-01-26|Estimate|||||||2012-06-21|2012-06-25|Estimate|April 2010||2010-04-30|April 2009|2009-04-30|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers|Effects of Lutein Supplementation on Oxidative Stress and Inflammation in Healthy Nonsmokers|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Peking University||3|||f||||t||||||||||2018-06-01 00:09:23.266287|2018-06-01 00:09:23.266287
NCT01056081|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|April 2006||2006-04-30|March 2006|2006-03-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Inspiratory Muscle Training in Chronic Obstructive Pulmonary Disease|Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disease Undergoing a Pulmonary Rehabilitation Program|Completed||Phase 3|19|Actual|Faculdade Evangelica do Parana||1|||f||||t||||||||||2018-06-01 00:09:23.32192|2018-06-01 00:09:23.32192
NCT01056055|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|February 2007||2007-02-28|March 2007|2007-03-31|December 2009|Actual|2009-12-31|December 2007|Actual|2007-12-31||Observational|||Outcomes of the Modified-Brostrom Procedure Using Suture Anchor for Chronic Lateral Ankle Instability|Outcomes of the Modified-Brostrom Procedure Using Suture Anchor for Chronic Lateral Ankle Instability - A Prospective, Randomized Comparison With the Bone Tunnel Technique|Completed|||40|Actual|Chonbuk National University Hospital|||1||f||||t||||||||||2018-06-01 00:09:23.374123|2018-06-01 00:09:23.374123
NCT01056042|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2014-10-28|2010-01-25|2010-01-26|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2007||2007-06-30|October 2014|2014-10-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Efficacy of Injectable Contraceptive and Oral Contraceptive Administered After Surgical Treatment of Endometriosis With Pain|Postoperative Intramuscular Depot Medroxyprogesterone Acetate Versus Continuous Oral Contraceptive for Pelvic Pain Associated With Endometriosis : Randomized Comparative Trial.|Completed||Phase 4|112|Anticipated|Prince of Songkla University||2|||f||||f||||||||||2018-06-01 00:09:23.423921|2018-06-01 00:09:23.423921
NCT01056029|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2015-12-08|2010-01-25|2010-01-26|Estimate|||||||2015-12-08|2015-12-10|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors|An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors|Completed||Phase 1|30|Anticipated|GenSpera, Inc.||1|||f||||f||||||||||2018-06-01 00:09:23.490197|2018-06-01 00:09:23.490197
NCT01056016|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2016-07-25||2016-10-31|2010-01-25|2010-01-26|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Disseminating a Model Intervention to Promote Improved Attention-deficit Hyperactivity Disorder (ADHD) Care in the Community|Disseminating a Model Intervention to Promote Improved ADHD Care in the Community|Completed||N/A|49|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-06-01 00:09:23.584293|2018-06-01 00:09:23.584293
NCT01056003|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2010-01-24|2010-01-24|2010-01-26|Estimate|||||||2010-01-24|2010-01-26|Estimate|June 2010||2010-06-30|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Prevalence of Gastric Inlet Patches of the Cervical Esophagus.|Gastric Inlet Patches of the Cervical Esophagus. Incidental Finding or Underrated Cause of Globus Sensations.|Unknown status|Not yet recruiting||4000|Anticipated|Technische Universität München|||1||f||||t||||||||||2018-06-01 00:09:23.735742|2018-06-01 00:09:23.735742
NCT01055990|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Interventional|||Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients|Phase1 An Observational Clinical Trial With an Influenza A (H1N1) 2009 Monovalent,Split-virion Vaccine in Healthy Adults, Aged 18-60 Years Phase2 Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients|Unknown status|Active, not recruiting|Phase 2|7|Anticipated|Shanghai Public Health Clinical Center||2|||f||||t||||||||||2018-06-01 00:09:23.802933|2018-06-01 00:09:23.802933
NCT01055977|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-08-29|2010-01-25|2010-01-26|Estimate|||||||2011-08-29|2011-08-30|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|STEP||Statin Therapy Results in the Real World Practice in the Czech Republic|Statin Therapy Results in the Real World Practice in the Czech Republic|Completed|||3253|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 00:09:23.896143|2018-06-01 00:09:23.896143
NCT01055964|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2015-05-24|2010-01-24|2010-01-26|Estimate|||||||2015-05-24|2015-05-27|Estimate|September 2008||2008-09-30|May 2015|2015-05-31||||December 2014|Actual|2014-12-31||Interventional|||a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients|a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients|Completed||Phase 3|80|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:09:24.990475|2018-06-01 00:09:24.990475
NCT01055951|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2011-06-01|2010-01-24|2010-01-26|Estimate|||||||2011-06-01|2011-06-02|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Feasibility Study of the Solo™ Insulin Pump|Feasibility Study of the Solo™ Insulin Pump|Completed||Phase 1|90|Anticipated|Medingo Ltd||1|||f||||f||||||||||2018-06-01 00:09:25.046682|2018-06-01 00:09:25.046682
NCT01055938|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|December 2006||2006-12-31|January 2010|2010-01-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Bioequivalence Study of Dr. Reddy's Divalproex Sodium Capsules (Sprinkle), 125 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Human Subjects Under Fasting Conditions.|Completed||Phase 1|34|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:09:25.113286|2018-06-01 00:09:25.113286
NCT01055925|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate||||January 2010|2010-01-31||||||||Interventional|||Clinical Comparative Trial of a Modified Polyurethane Dressing and Aquacel||Completed||N/A|||Klinik Bogenhausen||2|||f||||f||||||||||2018-06-01 00:09:25.18041|2018-06-01 00:09:25.18041
NCT01055912|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22||2011-06-20|2011-06-20|2010-01-25|2010-01-26|Estimate||||2011-06-20|2011-06-28|Estimate|2011-06-20|2011-06-28|Estimate|January 2010||2010-01-31|November 2010|2010-11-30||||September 2010|Actual|2010-09-30||Interventional|||Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure|Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Efficacy and Safety Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure|Completed||Phase 2|170|Actual|CardioKine Inc.||2|||f||||t||||||||||2018-06-01 00:09:25.246089|2018-06-01 00:09:25.246089
NCT01055899|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2013-09-27|2010-01-25|2010-01-26|Estimate|||||||2013-09-27|2013-09-30|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate|Completed||Phase 1|15|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:09:25.435943|2018-06-01 00:09:25.435943
NCT01055886|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|2014-12-09||2014-12-16|2010-01-25|2010-01-26|Estimate|2014-12-09|2014-12-15|Estimate||||2014-12-16|2015-01-06|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||65 participants were randomized and began study procedures.|Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)|Supplemental Nicotine Administration for Smoking Cessation in PTSD|Completed||N/A|69|Actual|Duke University||2|||f||||t||||||||||2018-06-01 00:09:25.528784|2018-06-01 00:09:25.528784
NCT01055873|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2010-11-17|2010-01-25|2010-01-26|Estimate|||||||2010-11-17|2010-11-18|Estimate|February 2007||2007-02-28|November 2010|2010-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|EP38||Immunology of the Infection Perinatal|Immunology of the Infection Perinatal|Completed|||93|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||f||||||||||2018-06-01 00:09:25.79453|2018-06-01 00:09:25.79453
NCT01055860|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2011-03-21|2010-01-25|2010-01-26|Estimate|||||||2011-03-21|2011-03-22|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Observational|||One Year Outcome After Robotic Assisted Laparoscopic Sacral Colpopexy, a Case Series Review|One Year Outcome After Robotic Assisted Laparoscopic Sacral Colpopexy, a Case Series Review|Completed|||75|Anticipated|Atlantic Health System|||1||f||||f||||||||||2018-06-01 00:09:25.863231|2018-06-01 00:09:25.863231
NCT01055678|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2012-12-14|2010-01-24|2010-01-26|Estimate|||||||2012-12-14|2012-12-17|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||To Evaluate the Characteristics of a Breast Cancer|Pilot Study to Characterize the HRHV Axis in the Microenvironment of Breast Cancers|Withdrawn||Early Phase 1|0|Actual|Duke University||1||PI left Duke|f||||f||||||||||2018-06-01 00:09:28.688559|2018-06-01 00:09:28.688559
NCT01055847|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-23|||2010-01-25|2010-01-25|2010-01-26|Estimate|||||||2010-01-25|2010-01-26|Estimate|June 2003||2003-06-30|January 2010|2010-01-31|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection|A Blinded, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam for Inhalation (AI) in Cystic Fibrosis Patient With Lung Disease Due to P. Aeruginosa Infection|Completed||Phase 2|105|Actual|Gilead Sciences||3|||f||||t||||||||||2018-06-01 00:09:25.942215|2018-06-01 00:09:25.942215
NCT01055834|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|2013-01-10||2013-01-10|2010-01-25|2010-01-26|Estimate|2013-01-10|2013-02-12|Estimate||||2013-01-10|2013-02-12|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)|A Bioequivalence Study of Different Formulations of SEP-190 and Food Effect Study in Japanese Healthy Adult Males|Completed||Phase 1|42|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 00:09:26.058243|2018-06-01 00:09:26.058243
NCT01055821|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2013-08-09|2010-01-25|2010-01-26|Estimate|||||||2013-08-09|2013-08-13|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|HCVac||Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients|A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naïve Patients With Chronic Genotype 1 Hepatitis C.|Completed||Phase 2|140|Actual|Transgene||3|||f||||t||||||||||2018-06-01 00:09:26.337633|2018-06-01 00:09:26.337633
NCT01055808|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-23|||2010-12-09|2010-01-23|2010-01-26|Estimate|||||||2010-12-09|2010-12-10|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|INSIGHTS||Observational Study in Japanese Type 2 Diabetes Patients|A Prospective, Non-safety Observational Study in Japanese Type 2 Diabetes Patients(INSIGHTS)|Completed|||677|Actual|Eli Lilly and Company|||1||f||||f||||||||||2018-06-01 00:09:26.444783|2018-06-01 00:09:26.444783
NCT01055795|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|||2012-12-21|2010-01-24|2010-01-26|Estimate|||||||2012-12-21|2012-12-24|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|BEL||Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors|Phase I Study of the Combination of Bevacizumab, Everolimus and LBH589 (BEL) for the Treatment of Advanced Solid Tumors|Completed||Phase 1|14|Actual|Duke University||1|||f||||t||||||||||2018-06-01 00:09:26.569072|2018-06-01 00:09:26.569072
NCT01055782|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-24|2012-03-23||2012-06-06|2010-01-25|2010-01-26|Estimate|2012-04-26|2012-05-28|Estimate||||2012-06-06|2012-06-11|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|April 2011|Actual|2011-04-30||Interventional|||Colonoscopy Endoguide in Specialist Practice|Kan Anvendelse af Endoskopisk Positioneringsudstyr Ved coloskopiundersøgelsen (kikkertundersøgelse af Tarmen) i en højt Specialiseret Praksis Forbedre Patientens Subjektive Kvalitetsoplevelse (Smerteperception)?|Completed||N/A|1004|Actual|The Specialist Doctors at Rolighedsvej|Early termination due to higher than expected eligible patients|2|||f||||f||||||||||2018-06-01 00:09:26.650377|2018-06-01 00:09:26.650377
NCT01055769|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2011-03-04||2012-01-30|2010-01-22|2010-01-26|Estimate|2011-03-04|2011-04-05|Estimate||||2012-01-30|2012-02-01|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects|An Open Label, Single Dose, 2-Way, Randomized Cross-Over Bioequivalence Study Comparing Linezolid 600 Mg Oral Suspension With 600 Mg Tablet In Chinese Healthy Male Subjects|Completed||Phase 1|20|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:09:27.055147|2018-06-01 00:09:27.055147
NCT01055756|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2010-10-26|2010-01-25|2010-01-26|Estimate|||||||2010-10-26|2010-10-28|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|June 2010|Anticipated|2010-06-30|April 2010|Anticipated|2010-04-30||Interventional|||Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis||Withdrawn||Phase 3|32|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-06-01 00:09:27.362949|2018-06-01 00:09:27.362949
NCT01055743|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-24|2010-01-24|2010-01-26|Estimate|||||||2010-01-24|2010-01-26|Estimate|August 2009||2009-08-31|January 2010|2010-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma|A Randomized, Controlled Trial of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|250|Anticipated|Simcere Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-06-01 00:09:27.457142|2018-06-01 00:09:27.457142
NCT01055730|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2013-11-19|2010-01-25|2010-01-26|Estimate|||||||2013-11-19|2013-11-21|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|PR-ILD||The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease|The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease: A Prospective Cohort Study|Completed|||54|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-06-01 00:09:27.733128|2018-06-01 00:09:27.733128
NCT01055717|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2013-05-23|2010-01-25|2010-01-26|Estimate|||||||2013-05-23|2013-05-27|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults|Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults|Completed||N/A|12|Actual|Tufts University||2|||f||||t||||||||||2018-06-01 00:09:27.836135|2018-06-01 00:09:27.836135
NCT01055704|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2011-07-08||2012-06-20|2010-01-25|2010-01-26|Estimate|2011-07-08|2011-08-08|Estimate||||2012-06-20|2012-06-25|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect of Methylnaltrexone on GI Transit in Healthy Volunteers|Effect of Methylnaltrexone on Gastrointestinal and Colonic Transit in Health|Completed||Phase 4|48|Actual|Mayo Clinic|We did not evaluate dose-response. A higher dosage of MNTX may be needed to produce a detectable effect on GI and colonic transit as well as bowel pattern in healthy subjects who are naive to opioid agonists during MNTX initiation.|4|||f||||f||||||||||2018-06-01 00:09:27.948762|2018-06-01 00:09:27.948762
NCT01055691|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-25|||2012-05-31|2010-01-25|2010-01-26|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets|A Two Part, Open Label, Randomized, Phase I Bioequivalence Study Comparing the Fixed Dose Combination Dapagliflozin/Metformin IR Tablet (2.5 mg/850 mg or 5 mg/1000 mg) vs. the Free Combination of Dapagliflozin and Metformin IR Tablets, in Healthy Volunteers, in the Fed State|Completed||Phase 1|120|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:09:28.606049|2018-06-01 00:09:28.606049
NCT01055652|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2011-10-14|2010-01-22|2010-01-25|Estimate|||||||2011-10-14|2011-10-17|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients|An Open-label, Multi-centre, Drug-drug Interaction Study to Assess the Effect of Voglibose (0.2 mg Tid) on the Pharmacokinetics, Safety and Tolerability of Single Oral Administration of Dapagliflozin (10 mg) in Japanese Patients With Type 2 Diabetes|Completed||Phase 1|28|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:09:28.81941|2018-06-01 00:09:28.81941
NCT01055639|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2015-06-19||2016-06-30|2010-01-21|2010-01-25|Estimate|2016-06-30|2016-08-12|Estimate||||2016-06-30|2016-08-12|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|TTCP||Telehealth Therapy for Chronic Pain: Comparison of In-person vs. Video-administered ACT for Pain|Telehealth Therapy for Chronic Pain|Completed||Phase 2|126|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:09:28.899289|2018-06-01 00:09:28.899289
NCT01055626|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2016-10-24|2010-01-22|2010-01-25|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||New Body Mass Index (BMI) Cut-offs for the Diagnosis of Obesity and Comorbidities|Usefulness of the Determination of Body Composition for Establishing New Cut-offs for the Diagnosis and Follow-up of Obesity and Comorbidities|Recruiting|||6000|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra|||||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|No||2018-06-01 00:09:29.45006|2018-06-01 00:09:29.45006
NCT01055613|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2016-06-07||2016-07-18|2010-01-22|2010-01-25|Estimate|2016-07-18|2016-08-31|Estimate||||2016-07-18|2016-08-31|Estimate|November 2009||2009-11-30|July 2016|2016-07-31||||May 2010|Actual|2010-05-31||Interventional||All subjects that were dispensed a study lens.|Investigational Multi-purpose Contact Lens Care Solution.||Completed||N/A|312|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 00:09:29.552459|2018-06-01 00:09:29.552459
NCT01055600|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2015-05-11|2010-01-21|2010-01-25|Estimate|||||||2015-05-11|2015-05-13|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|July 2014|Anticipated|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Milk-only Lactation Study for Patients on Eltrombopag|A Phase IV Study Evaluating Eltrombopag Concentrations in Breast Milk of Nursing Mothers Taking Eltrombopag|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||1||"Protocol opened to recruitment in Nov 2009. No potential subjects identified in 5 years;~   therefore, study was terminated in Jul 2014 due to lack of feasibility"|f||||f||||||||||2018-06-01 00:09:29.886729|2018-06-01 00:09:29.886729
NCT01055587|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2017-02-07|2010-01-22|2010-01-25|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2009||2009-09-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|Earlygnost||Diagnostic of Infections Following Major Abdominal Surgery and Burn Injury|Impact of Biomarkers for Early Diagnostic of Infections Following Major Abdominal Surgery and Severe Burn Injuries|Completed|||120|Actual|Klinikum St. Georg gGmbH|||2||f||||f||||||Samples Without DNA|"~     plasma samples~   "|||2018-06-01 00:09:29.987313|2018-06-01 00:09:29.987313
NCT01055574|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2011-09-08|2010-01-22|2010-01-25|Estimate|||||||2011-09-08|2011-09-09|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Observational|||Physical Capability Outcomes After Single-Level PD-L vs Single-Level ALIF: a Multi-Center Clinical Trial|Physical Capability Outcomes After Single-Level ProDisc-L Total Disc Replacement or Single-Level Anterior Lumbar Interbody Fusion: a Multi-Center Clinical Trial|Terminated|||45|Actual|Gundersen Lutheran Medical Foundation|||2|Unanticipated study design flaw; PCO evaluator interrater reliability was not performed.|f||||t||||||||||2018-06-01 00:09:30.079283|2018-06-01 00:09:30.079283
NCT01055561|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2016-05-27|2010-01-22|2010-01-25|Estimate|||||||2016-05-27|2016-05-30|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||A Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia|An Open-label Multi-center Safety and Tolerability Study of Acupuncture for Patients With Behavioural and Psychological Symptoms of Dementia & Healthy Volunteers|Completed||Phase 1|30|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:09:30.179063|2018-06-01 00:09:30.179063
NCT01055548|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2015-06-02|2010-01-22|2010-01-25|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|PPrime||PPrime: Parents Views on Diagnosis and Information-giving in Neonatal Care (Pilot Study)|Parents Views on Diagnosis and Information-giving in Neonatal Care (Pilot Study)|Completed|||20|Actual|Imperial College London|||1||f||||t||||||||||2018-06-01 00:09:30.25364|2018-06-01 00:09:30.25364
NCT01055535|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2014-04-04|2010-01-22|2010-01-25|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|MIVI-8||Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion|An Open Label, Single Centre Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion|Completed||Phase 2|17|Actual|ThromboGenics||1|||f||||||||||||||2018-06-01 00:09:30.307229|2018-06-01 00:09:30.307229
NCT01055522|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2014-02-24|2010-01-22|2010-01-25|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma|Dose Definition and Activity Evaluation Study of the Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Combination With Dacarbazine in Patients With Metastatic Melanoma|Terminated||Phase 2|102|Actual|Philogen S.p.A.||3|||f||||f||||||||||2018-06-01 00:09:30.370155|2018-06-01 00:09:30.370155
NCT01055509|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2013-06-27|2010-01-22|2010-01-25|Estimate|||||||2013-06-27|2013-06-28|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|CAT-Denmark||Compensatory Strategies Applied to Cognitive Impairment in Schizophrenia|Effectiveness of Cognitive Adaptation Training Applied to Cognitive Impairment in Schizophrenia - A Randomised Trial|Completed||N/A|65|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-06-01 00:09:30.466898|2018-06-01 00:09:30.466898
NCT01055496|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2014-03-31|2010-01-21|2010-01-25|Estimate|||||||2014-03-31|2014-04-01|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma|An Open-Label, Phase 1 Study Of R-CVP Or R-GDP In Combination With Inotuzumab Ozogamicin In Subjects With CD22-Positive Non-Hodgkin's Lymphoma|Completed||Phase 1|104|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:09:30.561369|2018-06-01 00:09:30.561369
NCT01054768|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2013-07-29|2010-01-20|2010-01-22|Estimate|||||||2013-07-29|2013-07-31|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease|Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease|Completed||Phase 2|42|Actual|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-06-01 00:09:47.913839|2018-06-01 00:09:47.913839
NCT01055483|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2013-02-14|2010-01-21|2010-01-25|Estimate|||||||2013-02-14|2013-02-15|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia|A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia|Completed||Phase 1|59|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:09:30.693504|2018-06-01 00:09:30.693504
NCT01055470|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-22|2010-01-22|2010-01-25|Estimate|||||||2010-01-22|2010-01-25|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparative Clinical Trial of Lornoxicam to Diclofenac in Patients of Osteoarthritis of Knee Joint.|Open, Randomized, Controlled Clinical Trial of Lornoxicam as Compared to Diclofenac in Osteoarthritis of Knee Joint in Patients of Tertiary Care Hospital of Gujarat.|Completed||N/A|40|Actual|Government Medical College, Bhavnagar||2|||f||||||||||||||2018-06-01 00:09:30.763245|2018-06-01 00:09:30.763245
NCT01055457|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2016-08-10||2017-08-21|2010-01-22|2010-01-25|Estimate|2016-11-28|2017-01-24|Estimate||||2017-08-21|2017-09-19|Actual|November 1, 2009|Actual|2009-11-01|August 2017|2017-08-31|May 1, 2010|Actual|2010-05-01|May 1, 2010|Actual|2010-05-01||Interventional||All subjects that were dispensed a study lens and solution.|Vistakon Investigational Multi-purpose Contact Lens Care Solution.||Completed||N/A|315|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||||2018-06-01 00:09:30.84793|2018-06-01 00:09:30.84793
NCT01055444|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21||2012-03-14|2012-03-14|2010-01-22|2010-01-25|Estimate||||2012-03-14|2012-03-16|Estimate|2012-03-14|2012-03-16|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome|An Open-Label Pilot Study Evaluating Synera® in the Treatment of Patients With Shoulder Impingement Syndrome|Completed||Phase 2|20|Actual|ZARS Pharma Inc.||1|||f||||f||||||||||2018-06-01 00:09:31.480132|2018-06-01 00:09:31.480132
NCT01055431|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2014-07-29|2010-01-22|2010-01-25|Estimate|||||||2014-07-29|2014-07-30|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Functional Food for the Prevention of Iron-deficiency Anemia|Teff (Eragrostis Tef) as a Functional Food for the Prevention of Pregnancy Iron-deficiency Anemia|Completed||Phase 1|55|Actual|Manchester Metropolitan University||2|||f||||t||||||||||2018-06-01 00:09:31.54954|2018-06-01 00:09:31.54954
NCT01055418|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2013-05-01|2010-01-22|2010-01-25|Estimate|||||||2013-05-01|2013-05-03|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Cognitive and Cerebral Blood Flow Effects of Vitamin C|Cognitive and Cerebral Blood Flow Effects of Vitamin C|Completed||Phase 4|24|Actual|Northumbria University||2|||f||||f||||||||||2018-06-01 00:09:31.733899|2018-06-01 00:09:31.733899
NCT01055405|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2012-04-03|2010-01-22|2010-01-25|Estimate|||||||2012-04-03|2012-04-04|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|SIL-COPD-02||Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary Hypertension|Phase IV Study on the Effects of Sildenafil in Combination With Pulmonary Rehabilitation Program on Exercise Tolerance in Patients With COPD and Pulmonary Hypertension|Completed||Phase 4|65|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 00:09:31.805804|2018-06-01 00:09:31.805804
NCT01055392|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-22|2010-01-22|2010-01-25|Estimate|||||||2010-01-22|2010-01-25|Estimate|March 2007||2007-03-31|December 2009|2009-12-31||||March 2009|Actual|2009-03-31||Interventional|||Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease|Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease: a Double-blind, Placebo-controlled Prevention Study in Elderly Patients With Mild Cognitive Impairment|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:09:31.879783|2018-06-01 00:09:31.879783
NCT01055379|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2017-01-05|2010-01-22|2010-01-25|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2010||2010-03-31|January 2017|2017-01-31||||July 2012|Actual|2012-07-31||Interventional|ACCORDO||Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn|A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study|Completed||Phase 4|121|Actual|Lundbeck Italia S.p.A.||2|||f||||f||||||||||2018-06-01 00:09:31.976232|2018-06-01 00:09:31.976232
NCT01055366|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2012-12-13|2010-01-22|2010-01-25|Estimate|||||||2012-12-13|2012-12-17|Estimate|March 2010||2010-03-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||ELAZOP Switching Study in Korea||Completed||Phase 4|96|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:09:32.080748|2018-06-01 00:09:32.080748
NCT01055353|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-05-11|2010-01-22|2010-01-25|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|PreVENT-A GP||Evaluation of Target Organs Damage in Hypertensive Patients|Evaluation of Target Organs Damage in Hypertensive Patients Followed in General Practice With no Known Cardiovascular (CV) or Renal Disease, Stratified According to Blood Pressure Control|Completed|||1857|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:09:32.238752|2018-06-01 00:09:32.238752
NCT01055340|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2015-05-28|2010-01-22|2010-01-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)|A Randomized Clinical Trial to Study Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:09:33.568195|2018-06-01 00:09:33.568195
NCT01055327|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2014-09-29|2010-01-21|2010-01-25|Estimate|||||||2014-09-29|2014-10-01|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT)|Monitoring of Specific Birth Defects Associated With Exposure to Lamotrigine in Pregnancy Through the EUROCAT Network|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:09:33.72619|2018-06-01 00:09:33.72619
NCT01055314|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2016-08-18||2017-07-31|2010-01-22|2010-01-25|Estimate|2017-06-30|2017-07-28|Actual||||2017-07-31|2017-08-29|Actual|January 2010||2010-01-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||175 patients were enrolled on the study.|Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma|A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma|Completed||Phase 2|175|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 00:09:33.893047|2018-06-01 00:09:33.893047
NCT01055301|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2015-03-05|2010-01-22|2010-01-25|Estimate|||||||2015-03-05|2015-03-06|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma|S0833, Modified Total Therapy 3 (TT3) for Newly Diagnosed Patients With Multiple Myeloma (MM): A Phase II SWOG Trial for Patients Aged ≤ 65 Years|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||1||lack of accrual|f||||t||||||||||2018-06-01 00:09:35.16125|2018-06-01 00:09:35.16125
NCT01055275|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2013-06-19|2010-01-22|2010-01-25|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Cook Iliac Branch Graft Post-market Registry|Cook Iliac Branch Graft Post-market Registry|Terminated|||2|Actual|Cook Group Incorporated|||1|Terminated due to low enrollment.|f||||||||||||||2018-06-01 00:09:35.275289|2018-06-01 00:09:35.275289
NCT01055262|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2012-05-07||2012-05-07|2010-01-22|2010-01-25|Estimate|2012-05-07|2012-06-19|Estimate||||2012-05-07|2012-06-19|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back|An Open Label Study To Evaluate The Safety, Tolerability And On-Body Temperature Of A Disposable Heatwrap Device For The Lower Back|Completed||Phase 3|169|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:09:35.355337|2018-06-01 00:09:35.355337
NCT01055249|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-07-12|2010-01-22|2010-01-25|Estimate|||||||2010-07-12|2010-07-13|Estimate|January 2010||2010-01-31|July 2010|2010-07-31||||June 2010|Actual|2010-06-30||Interventional|||UVB Model Validation Study|Single Centre, Subject and Observer Blinded, Placebo Controlled, Cross-over Study of the Effect of Oral Ibuprofen and Topical Hydrocortisone-21-acetate on Ultraviolet Radiation (UVR) Induced Pain and Inflammation in Healthy Volunteers|Completed||Phase 1|24|Anticipated|X-pert Med GmbH||2|||f||||f||||||||||2018-06-01 00:09:35.619337|2018-06-01 00:09:35.619337
NCT01055236|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-03-26|2010-01-22|2010-01-25|Estimate|||||||2010-03-26|2010-03-29|Estimate|August 2007||2007-08-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|TAH||Hydroxyzine for the Prevention of Pruritus From Spinal Morphine in Transabdominal Hysterectomy Patients|Hydroxyzine for the Prevention of Pruritus and Nausea Vomiting From Spinal Morphine in Patients Having Transabdominal Hysterectomy Under Combined Spinal-general Anesthesia: A Randomized Control Trial|Completed||Phase 4|80|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 00:09:35.704089|2018-06-01 00:09:35.704089
NCT01055223|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2010-12-16||2017-05-25|2010-01-21|2010-01-25|Estimate|2011-03-16|2011-04-18|Estimate||||2017-05-25|2017-05-30|Actual|May 2009||2009-05-31|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Fracture Risk With Thiazolidinediones|The Association Between Exposure to Spironolactone or Amiloride and Fracture Risk Among Subjects Treated With Thiazolidinediones|Completed|||98483|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:09:35.799198|2018-06-01 00:09:35.799198
NCT01055210|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-22|2010-01-22|2010-01-25|Estimate|||||||2010-01-22|2010-01-25|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|CHOICE2||Optimisation of Cardiac Resynchronisation Therapy by Non-invasive Cardiac Output - The CHOICE2 Study|Optimisation of Cardiac Resynchronisation Therapy by Non-invasive Cardiac Output - The CHOICE2 Study|Unknown status|Not yet recruiting|N/A|40|Anticipated|University of Dundee|||||f||||f||||||||||2018-06-01 00:09:36.17216|2018-06-01 00:09:36.17216
NCT01055197|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2016-08-26||2016-12-30|2010-01-22|2010-01-25|Estimate|2016-08-26|2016-10-21|Estimate||||2016-12-30|2017-02-17|Actual|March 2010||2010-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2015|Actual|2015-03-31||Interventional||All randomized and eligible patients|Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer|Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)|Completed||Phase 2|97|Actual|Radiation Therapy Oncology Group|At the first interim analysis of overall survival the data monitoring committee determined that due to the lack of evidence of potential efficacy and a higher than acceptable toxicity profile for the PCI+RT arm, study accrual would close early.|2|||f||||t||||||||||2018-06-01 00:09:36.247494|2018-06-01 00:09:36.247494
NCT01055184|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2015-09-22||2016-04-26|2010-01-21|2010-01-25|Estimate|2016-04-26|2016-05-30|Estimate||||2016-04-26|2016-05-30|Estimate|March 2010||2010-03-31|April 2016|2016-04-30||||April 2011|Actual|2011-04-30||Interventional|||Effects of Age on Response to the 2009 H1N1 Virus Vaccine|Assessment of the Effect of Age on the Immunological and Virological Response to a Live Attenuated Influenza Vaccine for the 2009 H1N1 Virus|Completed||Phase 1/Phase 2|34|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 00:09:37.573561|2018-06-01 00:09:37.573561
NCT01055171|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2014-04-18||2016-02-08|2010-01-22|2010-01-25|Estimate|2014-04-18|2014-05-19|Estimate||||2016-02-08|2016-03-08|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Urn randomization was used to assign participants to the propranolol vs. placebo condition while balancing treatment assignment on gender and age (less than 35 or equal to or greater than 35 years of age).|Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence|Treatment Implications of Trauma Memory Modulation for PTSD & Alcohol Dependence|Completed||Phase 2|44|Actual|Medical University of South Carolina|Lack of a “no retrieval” control group. Lack of determination of plasma propranolol levels following the medicated retrieval session. The sample size was insufficient to assess the more distal effects at 1-week follow-up.|2|||f||||t||||||||||2018-06-01 00:09:37.927114|2018-06-01 00:09:37.927114
NCT01055158|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2017-03-29|2010-01-22|2010-01-25|Estimate|||||||2017-03-29|2017-03-31|Actual|January 2010||2010-01-31|March 2017|2017-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Telephone Based Cognitive Behavioral Therapy for HIV Related Depression|Connect: A Pilot Study of Telephone Based Cognitive Behavioral Therapy for HIV Related Depression|Completed||N/A|38|Actual|University of Maryland||2|||f||||f||||||||||2018-06-01 00:09:38.311645|2018-06-01 00:09:38.311645
NCT01055145|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2012-11-22|2010-01-22|2010-01-25|Estimate|||||||2012-11-22|2012-11-27|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients|Comparison of the Effect Between Levofloxacin and Moxifloxacin on the Culture Conversion After 3 Months Treatment Among MDR-TB Patients; Prospective Multicenter Randomized Open Label Phase III Trial|Terminated||Phase 3|182|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:09:38.404599|2018-06-01 00:09:38.404599
NCT01055132|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|2011-11-03||2015-05-05|2010-01-22|2010-01-25|Estimate|2013-01-04|2013-02-07|Estimate||||2015-05-05|2015-05-21|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Dispensing Evaluation of New Daily Disposable Toric Soft Contact Lens.|Dispensing Evaluation of New Daily Disposable Toric Soft Contact Lens.|Completed||N/A|70|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 00:09:38.526218|2018-06-01 00:09:38.526218
NCT01055119|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2013-05-02|2010-01-22|2010-01-25|Estimate|||||||2013-05-02|2013-05-03|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|EFA||Effect of Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder|Effect of Supplementation With Long Chain Polyunsaturated Fatty Acids on Behavior and Cognition in Children With Attention Deficit Hyperactivity Disorder|Completed||N/A|95|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 00:09:38.78877|2018-06-01 00:09:38.78877
NCT01055106|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21||2011-06-14|2011-06-28|2010-01-21|2010-01-25|Estimate||||2011-06-28|2011-07-01|Estimate|2011-06-28|2011-07-01|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis|A Multicenter, Randomized, Investigator-Blinded, Phase 2, Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis|Completed||Phase 2|255|Actual|Graceway Pharmaceuticals, LLC||4|||f||||f||||||||||2018-06-01 00:09:38.867774|2018-06-01 00:09:38.867774
NCT01055093|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2017-09-11|2010-01-22|2010-01-25|Estimate|||||||2017-09-11|2017-09-12|Actual|September 2005|Actual|2005-09-30|September 2017|2017-09-30|September 2035|Anticipated|2035-09-30|September 2025|Anticipated|2025-09-30||Observational|GDC||Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients|Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients|Recruiting|||2000|Anticipated|German Diabetes Center|||2||f||||||||||Samples With DNA|"~     Whole blood, PBMC, serum, plasma, urine, stool~   "|||2018-06-01 00:09:38.965956|2018-06-01 00:09:38.965956
NCT01055080|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-22|2010-01-22|2010-01-25|Estimate|||||||2010-01-22|2010-01-25|Estimate|May 2002||2002-05-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|June 2006|Actual|2006-06-30||Interventional|FINDIA||Insulin-free Cow Milk Formula in Prevention of Type 1 Diabetes Associated Autoimmunity - FINDIA Pilot Study|Pilot Study of Dietary Prevention of Type 1 Diabetes Associated Beta-cell Autoimmunity in Children at Genetic Risk|Completed||N/A|987|Actual|National Institute for Health and Welfare, Finland||3|||f||||f||||||||||2018-06-01 00:09:39.043236|2018-06-01 00:09:39.043236
NCT01055067|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21||2013-09-30|2018-02-22|2010-01-22|2010-01-25|Estimate||||2013-09-30|2013-10-28|Estimate|2018-02-22|2018-02-26|Actual|January 2010||2010-01-31|February 2018|2018-02-28|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|||ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors|Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors|Completed||Phase 2|41|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 00:09:39.104025|2018-06-01 00:09:39.104025
NCT01055054|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2017-08-25|2010-01-21|2010-01-25|Estimate|||||||2017-08-25|2017-08-28|Actual|July 1980||1980-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Bariatric Surgery Registry|Analysis Bariatric Surgery Data|Enrolling by invitation|||5042|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 00:09:39.191928|2018-06-01 00:09:39.191928
NCT01055041|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2010-01-22|2010-01-22|2010-01-25|Estimate|||||||2010-01-22|2010-01-25|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Controller Medications in the Management of Bronchial Asthma|A Randomized, Open Labeled Comparative Study to Assess the Efficacy and Safety of Controller Medications as Add on to Inhaled Steroid and Long Acting β2 Agonist in Treatment of Moderate to Severe Persistent Bronchial Asthma|Completed||N/A|50|Actual|Government Medical College, Bhavnagar||3|||f||||f||||||||||2018-06-01 00:09:39.351752|2018-06-01 00:09:39.351752
NCT01055028|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2016-12-19||2018-02-23|2010-01-22|2010-01-25|Estimate|2018-02-23|2018-03-26|Estimate||||2018-02-23|2018-03-26|Estimate|February 2010||2010-02-28|May 2017|2017-05-31|June 24, 2016|Actual|2016-06-24|March 2016|Actual|2016-03-31||Interventional|||Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma|Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma|Terminated||Phase 2|18|Actual|Stanford University||2||Poor accrual|f||||t|t|f||||||No||2018-06-01 00:09:39.457198|2018-06-01 00:09:39.457198
NCT01055015|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22||2011-05-10|2012-05-15|2010-01-22|2010-01-25|Estimate||||2011-05-10|2011-05-17|Estimate|2012-05-15|2012-05-17|Estimate|February 2010||2010-02-28|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty|A Randomized, Double-Blind, Study of the Analgesic Efficacy and Safety of Flexible Dose Q8003 Versus Low Dose Q8003 in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty|Completed||Phase 3|141|Actual|QRxPharma Inc.||2|||f||||f||||||||||2018-06-01 00:09:40.337706|2018-06-01 00:09:40.337706
NCT01055002|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-06-23|2010-01-22|2010-01-25|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers|A Pilot Phase II Study of the Efficacy of Antimalarial Drugs Against Plasmodium Falciparum by Experimental Challenge With a Low Dose of Blood Stage Parasites in Healthy Male Volunteers|Completed||Phase 1/Phase 2|16|Anticipated|Medicines for Malaria Venture||2|||f||||f||||||||||2018-06-01 00:09:40.447996|2018-06-01 00:09:40.447996
NCT01054989|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-22|||2012-07-12|2010-01-22|2010-01-25|Estimate|||||||2012-07-12|2012-07-13|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|September 2011|Actual|2011-09-30||Interventional|FIRE||Fat, Inflammation and Insulin Resistance|Fat, Inflammation and Insulin Resistance (FIRE-Study)|Unknown status|Active, not recruiting|Phase 4|16|Actual|German Diabetes Center||4|||f||||t||||||||||2018-06-01 00:09:40.524121|2018-06-01 00:09:40.524121
NCT01054976|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2012-05-04||2012-11-23|2010-01-21|2010-01-22|Estimate|2012-11-23|2012-12-24|Estimate||||2012-11-23|2012-12-24|Estimate|October 2006||2006-10-31|November 2012|2012-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease|The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease|Completed||Phase 4|99|Actual|Janssen Korea, Ltd., Korea|A relatively low number of patients finished the study, which may have had an impact on the statistical power of data analysis. Difficulties in performing computer-based tests for elderly patients may have hampered detection of changes in attention.|1|||f||||||||||||||2018-06-01 00:09:40.620632|2018-06-01 00:09:40.620632
NCT01054963|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-12-23|2010-01-21|2010-01-22|Estimate|||||||2011-12-23|2011-12-29|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis - Peer Mentor Training|Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis - Peer Mentor Training|Completed||N/A|10|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 00:09:41.105498|2018-06-01 00:09:41.105498
NCT01054937|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-01-12|2010-01-21|2010-01-22|Estimate|||||||2011-01-12|2011-01-13|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Single Dose Study With 4SC-203 in Healthy Volunteers|First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers|Completed||Phase 1|60|Actual|4SC AG||2|||f||||||||||||||2018-06-01 00:09:41.341237|2018-06-01 00:09:41.341237
NCT01054924|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate|November 2009||2009-11-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening|Clinical Study to Assess the Performance of the Invendo C20 Colonoscope System in Persons Undergoing Colorectal Cancer Screening at Average Risk for CRC|Completed|||||Invendo Medical GmbH|||1||f||||||||||||||2018-06-01 00:09:41.649337|2018-06-01 00:09:41.649337
NCT01054911|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2016-01-26||2016-08-02|2010-01-21|2010-01-22|Estimate|2016-04-26|2016-06-03|Estimate||||2016-08-02|2016-09-22|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional||Gastrointestinal stromal tumor comprise 1% of gastrointestinal tumors. There are 6000 new cases per year in the United States without apparent geographic, ethnic, or gender prevalence.|Evaluation of Patients With Bulky GIST Using Sunitinib|Pilot Trial of Neoadjuvant Sunitinib in Patients With Bulky GIST|Terminated||N/A|5|Actual|University of Alabama at Birmingham|This Pilot trial was terminated early due sluggish accrual; thereby, resulting in much smaller numbers.|1||poor accrual|f||||t||||||||No||2018-06-01 00:09:41.73503|2018-06-01 00:09:41.73503
NCT01054898|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2015-05-26|2010-01-20|2010-01-22|Estimate|||||||2015-05-26|2015-05-28|Estimate|February 2007||2007-02-28|May 2015|2015-05-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Effectiveness of a Telephone Intervention to Improve the Mental Health of Abused Women|A RCT to Test the Effectiveness of a Telephone Intervention to Improve the Mental Health of Community Dwelling Women Abused by Their Intimate Partners|Completed||N/A|200|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:09:41.966741|2018-06-01 00:09:41.966741
NCT01054885|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2013-06-12|2012-02-16|2018-01-18|2010-01-21|2010-01-22|Estimate|2013-06-12|2013-08-15|Estimate|2012-02-16|2012-02-20|Estimate|2018-01-18|2018-01-24|Actual|October 19, 2009||2009-10-19|January 2018|2018-01-31|February 8, 2011|Actual|2011-02-08|February 1, 2011|Actual|2011-02-01||Interventional|||Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1226|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:09:42.10429|2018-06-01 00:09:42.10429
NCT01054872|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2016-06-20|2010-01-21|2010-01-22|Estimate|||||||2016-06-20|2016-06-21|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|November 2012|Actual|2012-11-30||Interventional|||Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins|A Phase 1B Clinical Trial to Examine the Role of Host Genetics in Determining the Immune Response to HIV Vaccination (With VRC-HIVDNA016-00-VP and VRC-HIVADV014-00-VP) in Twin Pairs|Completed||Phase 1|8|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 00:09:44.816723|2018-06-01 00:09:44.816723
NCT01054859|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-01-05|2010-01-21|2010-01-22|Estimate|||||||2011-01-05|2011-01-07|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.|A PHASE I, A SINGLE-CENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, THREE-PERIOD, THREE-WAY CROSSOVER STUDY OF THE HEMODYNAMIC INTERACTIONS OF AVANAFIL AND ALCOHOL IN HEALTHY MALE SUBJECTS|Completed||Phase 1|15|Actual|VIVUS, Inc.||3|||f||||||||||||||2018-06-01 00:09:45.166518|2018-06-01 00:09:45.166518
NCT01054846|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2016-11-09||2017-02-07|2010-01-21|2010-01-22|Estimate|2016-11-09|2016-11-18|Estimate||||2017-02-07|2017-02-09|Estimate|May 2008||2008-05-31|February 2017|2017-02-28|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Impact of Helmet Use in Preschool Children|The Impact of Helmet Use in Preschool Children From Low-income Families in Northeastern Indiana|Completed||N/A|609|Actual|Parkview Health||2|||f||||f||||||||||2018-06-01 00:09:45.398002|2018-06-01 00:09:45.398002
NCT01054833|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2013-05-29|2010-01-21|2010-01-22|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Clinical Evaluation of the Needleless® Sling|A Clinical Evaluation of the Needleless® Sling for the Treatment of Female Stress Urinary Incontinence|Completed||N/A|50|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 00:09:45.939404|2018-06-01 00:09:45.939404
NCT01054820|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2012-07-10||2012-07-10|2010-01-20|2010-01-22|Estimate|2012-07-10|2012-08-16|Estimate||||2012-07-10|2012-08-16|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain|Multicenter, Open-Label Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain|Completed||Phase 4|123|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:09:46.188227|2018-06-01 00:09:46.188227
NCT01054807|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21||2017-06-16|2017-06-16|2010-01-21|2010-01-22|Estimate||||2017-06-16|2017-06-20|Actual|2017-06-16|2017-06-20|Actual|November 1, 2009|Actual|2009-11-01|June 2017|2017-06-30|March 1, 2010|Actual|2010-03-01|March 1, 2010|Actual|2010-03-01||Interventional|||Non-Dispensing Evaluation of an Investigational Galyfilcon A Soft Contact Lens||Completed||N/A|32|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||f|f|t|f|f|t|||No||2018-06-01 00:09:46.960118|2018-06-01 00:09:46.960118
NCT01054794|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2015-06-19|2010-01-19|2010-01-22|Estimate|||||||2015-06-19|2015-06-22|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Temporary Gastric Electrical Stimulation for Gastroparesis|Temporary Gastric Neurostimulation for Gastroparesis|Completed||N/A|30|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 00:09:47.160953|2018-06-01 00:09:47.160953
NCT01054781|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2012-09-26|2010-01-20|2010-01-22|Estimate|||||||2012-09-26|2012-09-27|Estimate|January 2009||2009-01-31|September 2012|2012-09-30||||November 2010|Actual|2010-11-30||Interventional|||Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)|Open-labelled, Multicenter Phase II Study of Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)|Completed||Phase 2|91|Actual|Samsung Medical Center|||||f||||f||||||||||2018-06-01 00:09:47.653562|2018-06-01 00:09:47.653562
NCT01054742|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2012-05-15||2015-01-07|2010-01-21|2010-01-22|Estimate|2012-07-18|2012-08-22|Estimate||||2015-01-07|2015-01-16|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)|PREDICT (Part 2)- Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With HCV Genotype 1 Low Viral Load (HCV LVL 1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24|Completed|||2|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||None Retained|"~     Blood sample for polymerase chain reaction (PCR) Assay~   "|||2018-06-01 00:09:48.120596|2018-06-01 00:09:48.120596
NCT01054729|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2014-01-06|2012-05-24|2014-03-31|2010-01-21|2010-01-22|Estimate|2014-01-06|2014-02-19|Estimate|2012-05-24|2012-05-31|Estimate|2014-03-31|2014-04-17|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|August 2011|Actual|2011-08-31|April 2010|Actual|2010-04-30||Interventional||Participants who were randomized and treated were analyzed for Baseline Characteristics|Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients|A Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Standard of Care (Pegylated Interferon and Ribavirin) in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1|Completed||Phase 2|64|Actual|Gilead Sciences||4|||f||||f||||||||||2018-06-01 00:09:48.525923|2018-06-01 00:09:48.525923
NCT01054716|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-09-01|2010-01-21|2010-01-22|Estimate|||||||2011-09-01|2011-09-05|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|IRIS||Evaluation of a Noninvasive Fetal RHD Genotyping Test|Evaluation of a Noninvasive Fetal RHD Genotyping Test|Completed|||500|Anticipated|Sequenom, Inc.|||||f||||f||||||Samples With DNA|"~     Whole blood collected, processed to plasma and buffy coat for DNA extraction.~   "|||2018-06-01 00:09:53.43152|2018-06-01 00:09:53.43152
NCT01054703|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2010-02-08||2017-06-29|2010-01-21|2010-01-22|Estimate|2010-02-08|2010-02-24|Estimate||||2017-06-29|2017-08-07|Actual|April 1, 2007|Actual|2007-04-01|June 2017|2017-06-30|November 1, 2007|Actual|2007-11-01|November 1, 2007|Actual|2007-11-01||Interventional|SPACER||Clinical Evaluation of the Ethmoid Sinus Spacer|Clinical Evaluation of the Safety and Feasibility of the Ethmoid Sinus Spacer and Access System With Drug (SPACER)|Terminated||N/A|14|Actual|Acclarent||1||"Interim assessment performed after 14 patients provided evidence that further enrollment was~   not required to achieve intended endpoints of the study."|f||||f|f|t|f|||||No||2018-06-01 00:09:54.042954|2018-06-01 00:09:54.042954
NCT01054690|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-20|2010-01-20|2010-01-22|Estimate|||||||2010-01-20|2010-01-22|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Silver Alloyed Urinary Catheters and Incidence of Catheter Acquired Urinary Tract Infections (UTI)|A Comparative Study to Investigate if Silver Alloyed Urinary Catheters Can Reduce the Incidence of Catheter Acquired Urinary Tract Infections in Patients Undergoing Elective Surgery|Completed||N/A|511|Actual|Region Skane||2|||f||||f||||||||||2018-06-01 00:09:54.243929|2018-06-01 00:09:54.243929
NCT01054677|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate||||May 2003|2003-05-31||||||||Interventional|SANT||Swedish Antibiotic Nursing Home Trial||Completed||N/A|||Karolinska Institutet||2|||f||||||||||||||2018-06-01 00:09:54.453757|2018-06-01 00:09:54.453757
NCT01054664|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate|February 2010||2010-02-28|January 2010|2010-01-31||||||||Observational|||The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances||Unknown status|Not yet recruiting||30|Anticipated|Meir Medical Center|||3||f||||||||||||||2018-06-01 00:09:54.660487|2018-06-01 00:09:54.660487
NCT01054651|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni|Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children|Completed||Phase 3|212|Actual|Kenya Medical Research Institute||2|||f||||f||||||||||2018-06-01 00:09:54.770399|2018-06-01 00:09:54.770399
NCT01054638|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-07-26|2010-01-21|2010-01-22|Estimate|||||||2011-07-26|2011-07-27|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||HIV Treatment and CVD Events|HIV Treatment and CVD Events - Ingenix. Retrospective Database Analysis of Patients With Human Immunodeficiency Virus (HIV) Treatment and Cardiovascular Disease (CVD) Events|Completed|||0|Actual|ViiV Healthcare|||2||f||||f||||||||||2018-06-01 00:09:54.906309|2018-06-01 00:09:54.906309
NCT01054625|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2013-08-08||2013-11-13|2010-01-21|2010-01-22|Estimate|2013-11-13|2014-01-03|Estimate||||2013-11-13|2014-01-03|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional||Thirty of the 31 enrolled patients were included in the full analysis set (FAS) population. One patient was excluded from the FAS because he died before the first infusion of trial drug.|Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)|An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic Profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Non-curable Patients With SCCHN|Completed||Phase 1/Phase 2|31|Actual|Genmab||3|||f||||f||||||||||2018-06-01 00:09:55.03966|2018-06-01 00:09:55.03966
NCT01054612|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-03-03|2010-01-20|2010-01-22|Estimate|||||||2015-03-03|2015-03-04|Estimate|March 2002||2002-03-31|March 2015|2015-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Tissue Sectioning by Electro-Dissociation|Tissue Sectioning by Electro-Dissociation|Withdrawn|||0|Actual|University of Arkansas||||The study was closed due to the departure of several of the co-investigators.|f||||||||||||||2018-06-01 00:09:56.271988|2018-06-01 00:09:56.271988
NCT01054599|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2017-03-23||2017-06-11|2010-01-21|2010-01-22|Estimate|2017-06-11|2017-07-11|Actual||||2017-06-11|2017-07-11|Actual|January 2009||2009-01-31|June 2017|2017-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?|Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||N/A|29|Actual|American Academy of Neurology||2|||f||||f||||||||||2018-06-01 00:09:56.54982|2018-06-01 00:09:56.54982
NCT01054586|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2011-01-14||2013-05-02|2010-01-21|2010-01-22|Estimate|2011-06-02|2011-06-28|Estimate||||2013-05-02|2013-05-07|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Fosamprenavir in Pts With Hepatic Impairment|HI FPV Study: Using Observational Cohorts to Monitor Safety of Fosamprenavir in Patients With Mild/Moderate Hepatic Impairment|Completed|||167|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:09:58.360229|2018-06-01 00:09:58.360229
NCT01054573|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2013-03-08||2013-05-06|2010-01-21|2010-01-22|Estimate|2013-03-08|2013-04-19|Estimate||||2013-05-06|2013-05-08|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo|An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX- 950-TiDP24-C216 Trial Who Failed Therapy for Virologic Reasons|Completed||Phase 3|90|Actual|Janssen Infectious Diseases BVBA||1|||f||||f||||||||||2018-06-01 00:10:00.391236|2018-06-01 00:10:00.391236
NCT01054560|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2012-04-24||2016-08-31|2010-01-20|2010-01-22|Estimate|2016-08-31|2016-10-26|Estimate||||2016-08-31|2016-10-26|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SWIFT||SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study|SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study|Completed||N/A|144|Actual|Medtronic Neurovascular Clinical Affairs||2|||f||||t||||||||||2018-06-01 00:10:01.743105|2018-06-01 00:10:01.743105
NCT01054547|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate|September 2006||2006-09-30|May 2006|2006-05-31|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||Topical Formulations of Liposomal Local Anesthetics|Local Anesthetic Activity of Liposomal Formulations in Dentistry|Completed||Phase 1|80|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-06-01 00:10:02.926116|2018-06-01 00:10:02.926116
NCT01054534|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2015-04-10|2010-01-21|2010-01-22|Estimate|||||||2015-04-10|2015-04-13|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads|Real-time Ultrasound Guided Placement of Sacral Quadripolar Leads With Ultrasound Image Fusion of Acquired Magnetic Resonance Scan (MRI)|Terminated||N/A|1|Actual|Mayo Clinic||1||Sponsor withdrew funding|f||||f||||||||||2018-06-01 00:10:03.002361|2018-06-01 00:10:03.002361
NCT01054521|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2014-05-29|2010-01-21|2010-01-22|Estimate|||||||2014-05-29|2014-06-02|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CompareRFIT||A Randomized Study of Temperature-controlled and Bipolar Radiofrequency for Inferior Turbinate Reduction|A Randomized Comparison Study of Temperature-controlled and Bipolar Radiofrequency for Inferior Turbinate Reduction in Patients With Chronic Rhinitis|Completed||N/A|84|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 00:10:03.110411|2018-06-01 00:10:03.110411
NCT01054508|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2012-10-10|2010-01-21|2010-01-22|Estimate|||||||2012-10-10|2012-10-12|Estimate|June 2010||2010-06-30|January 2011|2011-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Tredaptive on Serum Lipoproteins and Inflammatory Markers|Effect of Tredaptive on Serum Lipoproteins, Lipoproteins Metabolism, Oxidative Stress and HDL Antioxidant Function|Completed||Phase 4|38|Actual|Manchester University NHS Foundation Trust||1|||f||||f||||||||||2018-06-01 00:10:03.175125|2018-06-01 00:10:03.175125
NCT01054495|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-28|2010-01-21|2010-01-22|Estimate|||||||2010-01-28|2010-01-29|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Placebo in Acupuncture|Evaluating Placebo Interventions in Acupuncture Research|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|National Research Centre of Complementary and Alternative Medicine, Norway||3|||f||||t||||||||||2018-06-01 00:10:03.260395|2018-06-01 00:10:03.260395
NCT01054482|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-02-01|2010-01-21|2010-01-22|Estimate|||||||2010-02-01|2010-02-02|Estimate|February 2007||2007-02-28|January 2007|2007-01-31|December 2011|Anticipated|2011-12-31|January 2011|Anticipated|2011-01-31||Interventional|||Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer|A Randomized Phase II Study Preoperative Chemotherapy Versus Preoperative Concurrent Chemoradiotherapy for Patients With Locally Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|120|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-06-01 00:10:03.349848|2018-06-01 00:10:03.349848
NCT01054469|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2012-06-20|2010-01-20|2010-01-22|Estimate|||||||2012-06-20|2012-06-21|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Transversus Abdominus Plane Block|Ultrasound Guided Transversus Abdominus Plane Block for Patients Undergoing Laparoscopic Hand-assisted Nephrectomy.|Completed||N/A|21|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:10:03.426944|2018-06-01 00:10:03.426944
NCT01054456|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-01-05|2010-01-20|2010-01-22|Estimate|||||||2011-01-05|2011-01-06|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)|A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)|Completed||Phase 2|100|Anticipated|Eisai Inc.||1|||f||||f||||||||||2018-06-01 00:10:03.633209|2018-06-01 00:10:03.633209
NCT01054443|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20||2018-05-18|2018-05-18|2010-01-20|2010-01-22|Estimate||||2018-05-18|2018-05-22|Actual|2018-05-18|2018-05-22|Actual|January 2010||2010-01-31|May 2018|2018-05-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy|Terminated||Phase 2|19|Actual|Shionogi Inc.||4||The study objectives became unachievable as a result of the termination of 0913M0621|f||||f||||||||||2018-06-01 00:10:03.917904|2018-06-01 00:10:03.917904
NCT01054430|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-01-05|2010-01-20|2010-01-22|Estimate|||||||2011-01-05|2011-01-07|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|avanafil||To Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.|A PHASE I, OPEN LABEL, NON-RANDOMIZED, SINGLE-DOSE, PARALLEL-COHORT, MATCHED-CONTROL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF AVANAFIL (TA-1790) IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY CONTROL MALE SUBJECTS|Completed||Phase 1|27|Actual|VIVUS, Inc.||3|||f||||||||||||||2018-06-01 00:10:04.031363|2018-06-01 00:10:04.031363
NCT01054417|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-11-16|2010-01-21|2010-01-22|Estimate|||||||2011-11-16|2011-11-17|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Observational|APPEL||APPEndicitis and Laparoscopic Criteria; APPEL Study|A Prospective Evaluation to Determine Laparoscopic Criteria for the Diagnosis Appendicitis During a Diagnostic Laparoscopy|Completed|||142|Actual|University Medical Center Groningen|||1||f||||f||||||Samples Without DNA|"~     Slices of the appendix fixed for pathologic examnination will be retained (standard~     procedure).~   "|||2018-06-01 00:10:04.110819|2018-06-01 00:10:04.110819
NCT01054404|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2013-05-08||2013-06-27|2010-01-20|2010-01-22|Estimate|2013-06-27|2013-08-02|Estimate||||2013-06-27|2013-08-02|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Furosemide vs Placebo for Brain Relaxation|The Effect of Furosemide Versus Placebo on Brain Relaxation and Incidence of Significant Intravascular Volume Depletion in Human Subjects Receiving Mannitol|Terminated||N/A|23|Actual|Northwestern University|Recruitment was stopped at 23 subjects because of concern that the administration of furosemide was producing such a large diuresis that clinically significant and potentially unsafe hypovolemia and electrolyte abnormalities were developing.|2||Concern for volume depletion and electrolyte abnormalities in furosemide arm.|f||||f||||||||||2018-06-01 00:10:04.19045|2018-06-01 00:10:04.19045
NCT01054391|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-22|Estimate|||||||2010-01-20|2010-01-22|Estimate|October 2008||2008-10-31|January 2010|2010-01-31||||December 2010|Anticipated|2010-12-31||Interventional|||Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae|NEC Trial - Nfocus - Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae - A Non-Randomized Pilot Study|Unknown status|Recruiting|N/A|10|Anticipated|Nfocus Neuromedical||1|||f||||||||||||||2018-06-01 00:10:04.421806|2018-06-01 00:10:04.421806
NCT01054378|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-12-06|2010-01-21|2010-01-22|Estimate|||||||2010-12-06|2010-12-07|Estimate|January 2010||2010-01-31|December 2010|2010-12-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Diaphragmatic Movement Before and After Stellate Ganglion Block : A Ultrasonographic Study||Completed||Phase 4|43|Actual|Yonsei University|||||f||||||||||||||2018-06-01 00:10:04.510849|2018-06-01 00:10:04.510849
NCT01054365|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-03-31|2010-01-21|2010-01-22|Estimate|||||||2017-03-31|2017-04-04|Actual|December 2009||2009-12-31|January 2010|2010-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Same Day Discharge After Coronary Stenting Trial|Same Day Discharge After Coronary Stenting Trial|Completed|||100|Actual|University of Southern California|||2||f||||t||||||||||2018-06-01 00:10:04.565455|2018-06-01 00:10:04.565455
NCT01054352|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2013-09-03|2010-01-21|2010-01-22|Estimate|||||||2013-09-03|2013-09-04|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|March 2011|Actual|2011-03-31|||||Interventional|||A Single and Multiple Dose Study to Explore the Safety of JNJ-38224342 in Healthy Patients and Patients With Seasonal Allergies|A Double-blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics and Pharmacodynamics of JNJ-38224342 in Healthy Patients and in Healthy Patients With Seasonal Allergic Rhinitis|Completed||Phase 1|182|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-06-01 00:10:04.621466|2018-06-01 00:10:04.621466
NCT01054339|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2012-08-14||2016-07-13|2010-01-21|2010-01-22|Estimate|2012-08-14|2012-09-14|Estimate||||2016-07-13|2016-08-12|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|November 2011|Actual|2011-11-30||Interventional|||Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency|A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin Deficiency|Completed||Phase 2|9|Actual|Applied Genetic Technologies Corp|Study results based on small number of subjects.|3|||f||||t||||||||||2018-06-01 00:10:04.703543|2018-06-01 00:10:04.703543
NCT01054326|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate|January 2003||2003-01-31|January 2006|2006-01-31|January 2007|Actual|2007-01-31|January 2006|Actual|2006-01-31||Interventional|||Effects of Supervised Physical Therapy With Early Activation of the Rotator Cuff Versus Home Exercises in Patients After Arthroscopic Subacromial Decompression|Effects of Supervised Physical Therapy With Early Activation of the Rotator Cuff Versus Home Exercises in Patients After Arthroscopic Subacromial Decompression|Completed||N/A|45|Actual|Linkoeping University||2|||f||||f||||||||||2018-06-01 00:10:05.099546|2018-06-01 00:10:05.099546
NCT01054313|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2015-10-05|2010-01-20|2010-01-22|Estimate|||||||2015-10-05|2015-10-07|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Docetaxel and Sirolimus in Patients With Advanced Malignancies|A Phase I Trial of Docetaxel and Sirolimus in Patients With Advanced Malignancies|Completed||Phase 1|103|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:10:06.183024|2018-06-01 00:10:06.183024
NCT01054300|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2016-05-20|2010-01-20|2010-01-22|Estimate|||||||2016-05-20|2016-05-23|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|52|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 00:10:06.266879|2018-06-01 00:10:06.266879
NCT01054287|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate||||January 2010|2010-01-31||||||||Interventional|PRECEPT||Falls Prevention in Acute Care Hospital|Falls Prevention Program in Acute Care Hospital|Unknown status|Not yet recruiting|N/A|||Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-06-01 00:10:06.349834|2018-06-01 00:10:06.349834
NCT01054274|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2012-03-30|2010-01-21|2010-01-22|Estimate|||||||2012-03-30|2012-04-02|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||December 2012|Anticipated|2012-12-31||Interventional|||a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent|Self-Expandable Esophageal Radiation Stent:a Multicentric Randomized Controlled Trial in Patients With Advanced Esophageal Cancer|Unknown status|Recruiting|Phase 3|180|Anticipated|Southeast University, China||2|||f||||t||||||||||2018-06-01 00:10:06.417728|2018-06-01 00:10:06.417728
NCT01054261|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-01-05|2010-01-21|2010-01-22|Estimate|||||||2011-01-05|2011-01-07|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.|A Phase I, Open-Label, Parallel-Group, Single Dose, Non-Randomized Study to Compare the Pharmacokinetics of Avanafil in Male Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function|Completed||Phase 1|24|Actual|VIVUS, Inc.||3|||f||||f||||||||||2018-06-01 00:10:06.500223|2018-06-01 00:10:06.500223
NCT01054248|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2016-09-13|2010-01-21|2010-01-22|Estimate|||||||2016-09-13|2016-09-14|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|DMA||Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy|A Randomised Open Label Trial Comparing Standard Dose of Dihydroartemisinin-piperaquine, Standard Fixed Artesunate-mefloquine Regimen and a Longer Regimen of Artemether-lumefantrine in the Treatment of Uncomplicated Malaria in Pregnancy|Completed||Phase 3|499|Actual|University of Oxford||3|||f||||t||||||||||2018-06-01 00:10:06.561091|2018-06-01 00:10:06.561091
NCT01054222|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2012-12-17||2013-04-02|2010-01-20|2010-01-22|Estimate|2013-04-02|2013-05-15|Estimate||||2013-04-02|2013-05-15|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder|A Local, Multicentre, Open-Label, Extension Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder|Completed||Phase 4|31|Actual|Pfizer|Due to the small sample size and that this is a single country study (Portugal) the results should be interpreted with caution.|2|||f||||f||||||||||2018-06-01 00:10:06.957766|2018-06-01 00:10:06.957766
NCT01054209|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2012-12-06|2010-01-21|2010-01-22|Estimate|||||||2012-12-06|2012-12-07|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|ObsIPH||A Study to Determine the Effectiveness of a Warming Mattress in Preventing Inadvertent Peri-operative Hypothermia and Shivering in Patients Undergoing Elective Cesarean Section|A Study to Determine the Effectiveness of a Warming Mattress in Preventing Inadvertent Peri-operative Hypothermia and Shivering in Patients Undergoing Elective Cesarean Section|Completed||N/A|116|Actual|Brighton and Sussex University Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 00:10:07.702427|2018-06-01 00:10:07.702427
NCT01054196|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2018-02-27|2010-01-19|2010-01-22|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2010|Actual|2010-08-31|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study|Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study|Recruiting||Phase 1/Phase 2|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 00:10:07.784217|2018-06-01 00:10:07.784217
NCT01054183|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2012-11-28||2015-02-04|2010-01-21|2010-01-22|Estimate|2015-01-22|2015-02-05|Estimate||||2015-02-04|2015-02-23|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||The Use of the GlideScope Ranger in Pediatric Critical Care Transport|The Use of the GlideScope Ranger in Pediatric Critical Care Transport|Completed||N/A|22|Actual|Akron Children's Hospital|The biggest limitation was slow patient enrollment, prompting the study to be closed prior to reaching the full study power. All data were reliably reported.|2|||f||||t||||||||||2018-06-01 00:10:07.867436|2018-06-01 00:10:07.867436
NCT01054170|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2012-01-24||2012-08-14|2010-01-21|2010-01-22|Estimate|2012-06-19|2012-07-25|Estimate||||2012-08-14|2012-08-20|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 12-week, Phase II, Double-blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60mg AZD9668 Administered Orally Twice Daily on Structural Changes in the Airways by Multi-Slice Computed Tomography in Patients With Chronic Obstructive Pulmonary Disease.|Completed||Phase 2|52|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 00:10:08.258558|2018-06-01 00:10:08.258558
NCT01054157|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate|February 2010||2010-02-28|January 2010|2010-01-31||||||||Observational|||Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues|Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues|Unknown status|Not yet recruiting||50|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-06-01 00:10:08.865879|2018-06-01 00:10:08.865879
NCT01054144|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2018-02-26|2010-01-21|2010-01-22|Estimate|||||||2018-02-26|2018-02-28|Actual|January 14, 2010|Actual|2010-01-14|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma|Phase II Study of Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults With Newly Diagnosed, Standard Risk Multiple Myeloma|Active, not recruiting||Phase 2|27|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 00:10:08.922801|2018-06-01 00:10:08.922801
NCT01054131|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-12-23|2010-01-21|2010-01-22|Estimate|||||||2011-12-23|2011-12-29|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program|Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program|Completed||N/A|10|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 00:10:09.008858|2018-06-01 00:10:09.008858
NCT01054118|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2013-09-03|2010-01-21|2010-01-22|Estimate|||||||2013-09-03|2013-09-04|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|February 2010|Actual|2010-02-28|||||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin|Sitagliptin Combo Study|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-06-01 00:10:09.075052|2018-06-01 00:10:09.075052
NCT01054105|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2016-02-10|2010-01-21|2010-01-22|Estimate|||||||2016-02-10|2016-02-11|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|PILGRIM||Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension|The Prevalence of BMPR-2 Gene Mutations in Korean Patients With Pulmonary Arterial Hypertension (PAH) and the Effects of Gene Mutations on Hemodynamic Response by Drug Therapy|Unknown status|Recruiting|Phase 4|48|Anticipated|Gachon University Gil Medical Center||2|||f||||f||||||||||2018-06-01 00:10:09.171212|2018-06-01 00:10:09.171212
NCT01054092|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2016-01-18|2010-01-20|2010-01-22|Estimate|||||||2016-01-18|2016-01-20|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients|A Phase 3, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-Term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|182|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 00:10:09.385647|2018-06-01 00:10:09.385647
NCT01054079|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|2015-08-14||2018-04-10|2010-01-21|2010-01-22|Estimate|2015-09-29|2015-10-29|Estimate||||2018-04-10|2018-05-11|Actual|September 2011||2011-09-30|April 2018|2018-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer|A Phase II Trial to Assess the Effect of Cinacalcet Hydrochloride on PSA Levels in Patients With Biochemically Recurrent Prostate Cancer After Failed Definitive Local Therapy|Completed||Phase 2|20|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-06-01 00:10:09.48198|2018-06-01 00:10:09.48198
NCT01054053|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2012-03-22|2010-01-21|2010-01-22|Estimate|||||||2012-03-22|2012-03-23|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Observational|EFFIVAC||Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®|Phase 3, Vaccinal Activity Assessment of MenBVac Against Nesseiria Menigitidis B:14,P1.7,16 Strain in Child.|Completed|||218|Actual|University Hospital, Rouen|||1||f||||t||||||Samples Without DNA|"~     blood samples~   "|||2018-06-01 00:10:09.77426|2018-06-01 00:10:09.77426
NCT01054040|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-22|Estimate|||||||2010-01-20|2010-01-22|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||The Impact of Portion Plates for Weight Loss on Cardiac Rehabilitation Patients|The Impact of Portion Plates for Weight Loss on Cardiac Rehabilitation Patients|Unknown status|Not yet recruiting|N/A|90|Anticipated|Richmond Health Services||1|||f||||f||||||||||2018-06-01 00:10:09.824255|2018-06-01 00:10:09.824255
NCT01054027|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2010-01-21|2010-01-21|2010-01-22|Estimate|||||||2010-01-21|2010-01-22|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Study on Effective Mydriasis in Premature Infants|A Randomized Controlled Trial to Determine the Lowest Effective Dose for Adequate Mydriasis in Premature Infants|Completed||N/A|15|Actual|Georgetown University||4|||f||||f||||||||||2018-06-01 00:10:09.896155|2018-06-01 00:10:09.896155
NCT01054014|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2013-09-03|2010-01-21|2010-01-22|Estimate|||||||2013-09-03|2013-09-04|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|January 2011|Actual|2011-01-31|||||Interventional|||A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers|A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-40346527 in Healthy Subjects|Completed||Phase 1|120|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 00:10:10.050269|2018-06-01 00:10:10.050269
NCT01054001|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-08-18|2010-01-21|2010-01-22|Estimate|||||||2011-08-18|2011-08-22|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|SILRALP||Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy|Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy|Unknown status|Recruiting|N/A|124|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:10:10.128736|2018-06-01 00:10:10.128736
NCT01053988|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2013-06-12|2012-02-16|2017-05-01|2010-01-21|2010-01-22|Estimate|2013-06-12|2013-08-15|Estimate|2012-02-16|2012-02-20|Estimate|2017-05-01|2017-06-01|Actual|October 5, 2009||2009-10-05|May 2017|2017-05-31|April 14, 2011|Actual|2011-04-14|February 1, 2011|Actual|2011-02-01||Interventional|||A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1031|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:10:10.255552|2018-06-01 00:10:10.255552
NCT01053975|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-11-05|2010-01-20|2010-01-22|Estimate|||||||2010-11-05|2010-11-08|Estimate|February 2010||2010-02-28|November 2010|2010-11-30||||||||Observational|SCORE||SPIROCOR Coronary Outcome by Respiratory Stress Examination|SPIROCOR Coronary Outcome by Respiratory Stress Examination - SCORE Study|Terminated|||1000|Anticipated|Spirocor||||"Based on analyses of studies separately of the SCORE study, sponsor has decided to discontinue~   the Study. Data collected during the study will not be analyzed"|f||||t||||||||||2018-06-01 00:10:11.406539|2018-06-01 00:10:11.406539
NCT01053962|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-11-16|2010-01-21|2010-01-22|Estimate|||||||2010-11-16|2010-11-17|Estimate|February 2010||2010-02-28|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|CIC||SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation|A Phase IIa Randomized, Double-Blind, Placebo-Controlled, 14-Day Repeat, Oral, Dose Ranging Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of SP-304 in Patients With Chronic Idiopathic Constipation|Completed||Phase 2|80|Anticipated|Synergy Pharmaceuticals Inc.||5|||f||||f||||||||||2018-06-01 00:10:11.546199|2018-06-01 00:10:11.546199
NCT01053949|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2015-11-03|2010-01-21|2010-01-22|Estimate|||||||2015-11-03|2015-11-04|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|IFM2009-02||IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma|A Multicenter Randomized Open Label Phase II Study of Pomalidomide and Dexamethasone in Relapse and Refractory Multiple Myeloma Patients Who Are Progressive and Did Not Achieve at Least a Partial Response to Bortezomib and Lenalidomide|Completed||Phase 2|84|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-06-01 00:10:11.639542|2018-06-01 00:10:11.639542
NCT01053936|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20||2012-05-31|2012-06-12|2010-01-20|2010-01-22|Estimate||||2012-06-12|2012-06-14|Estimate|2012-06-12|2012-06-14|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease|A Multi-Center, Open-Label, Randomized, Parallel Group, Dose-Ranging, Pharmacodynamic Phase II Trial to Determine the Effects of Bardoxolone Methyl (RTA 402, Amorphous Dispersion) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease (eGFR 15-45 mL/Min/1.73m2)|Completed||Phase 2|129|Actual|Reata Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-06-01 00:10:11.749803|2018-06-01 00:10:11.749803
NCT01053923|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2013-06-11|2010-01-21|2010-01-22|Estimate|||||||2013-06-11|2013-06-13|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||MRI for Tumor During Chemoradiation for Anal Canal and Perianal Cancer|A Feasibility Study of MRI in Assessment of Primary Tumor During Chemoradiation for Anal Canal and Perianal Cancer|Withdrawn|||0|Actual|University Health Network, Toronto|||1|"Patient eligibility has limited accrual and patient sample has changed with the change in~   referral patients."|f||||f||||||||||2018-06-01 00:10:11.944857|2018-06-01 00:10:11.944857
NCT01053910|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-20|2010-01-20|2010-01-22|Estimate|||||||2010-01-20|2010-01-22|Estimate|October 2003||2003-10-31|February 2009|2009-02-28||||July 2005|Actual|2005-07-31||Interventional|||Ramipril 10 mg/Day Prevention|A Multicentre Open, Non Comparative Study of the Safety of Ramipril (Tritace) 10 mg/Day in Prevention of Cardiovascular Events in High-risk Patients|Completed||Phase 4|1012|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:10:12.028621|2018-06-01 00:10:12.028621
NCT00824096|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-01-15|2009-01-15|2009-01-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|December 2006||2006-12-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Use Bronchoscopy to Predict Post-Extubation Stridor in Critical Ill Patients||Unknown status|Recruiting|N/A|100|Anticipated|Chimei Medical Center|||||f||||f||||||||||2018-06-01 01:24:17.269423|2018-06-01 01:24:17.269423
NCT01053897|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2013-03-11||2013-08-19|2010-01-20|2010-01-22|Estimate|2013-08-19|2013-10-24|Estimate||||2013-08-19|2013-10-24|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery|A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery|Completed||Phase 2|5|Actual|Garnet BioTherapeutics, Inc.|Study was discontinued early due to difficulty in identifying and enrolling eligible subjects.|2|||f||||f||||||||||2018-06-01 00:10:12.107413|2018-06-01 00:10:12.107413
NCT01053884|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2012-03-01|2010-01-21|2010-01-22|Estimate|||||||2012-03-01|2012-03-02|Estimate|October 2009||2009-10-31|July 2009|2009-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ECALTA||Anidulafungin in Patients With Hematologic Malignancies|Anidulafungin in Patients With Hematologic Malignancies - An Open-label, Prospective Study to Evaluate the Safety Profile at Prophylactic and Therapeutic Dosages|Terminated||Phase 2|10|Actual|Elisabethinen Hospital||1||reduced recruitment rate due to non infectious, but competitive trials at our institution|f||||f||||||||||2018-06-01 00:10:12.37687|2018-06-01 00:10:12.37687
NCT01053871|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-21|||2011-06-13|2010-01-21|2010-01-22|Estimate|||||||2011-06-13|2011-06-14|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Propofol Versus Midazolam With Fentanyl for EGD Endomicroscopy||Completed||N/A|104|Anticipated|Shandong University||2|||f||||t||||||||||2018-06-01 00:10:12.471224|2018-06-01 00:10:12.471224
NCT01053858|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-20|2010-01-20|2010-01-22|Estimate|||||||2010-01-20|2010-01-22|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|||Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision||Completed||N/A|38|Actual|Hallym University Medical Center||2|||f||||t||||||||||2018-06-01 00:10:12.556594|2018-06-01 00:10:12.556594
NCT01053845|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2014-07-04|2010-01-19|2010-01-21|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PhyDoNe||Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain|Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain|Completed||Phase 1|20|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:10:12.626085|2018-06-01 00:10:12.626085
NCT01053832|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-10-24|2010-01-20|2010-01-21|Estimate|||||||2011-10-24|2011-10-25|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|VpS||Ventricular Pace Suppression Study|Ventricular Pace Suppression Study With the EVIA/ENTOVIS DR-T/DR Pacemaker|Completed||N/A|84|Anticipated|Biotronik SE & Co. KG||2|||f||||||||||||||2018-06-01 00:10:12.701597|2018-06-01 00:10:12.701597
NCT01053819|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2012-05-01||2018-01-29|2010-01-20|2010-01-21|Estimate|2012-08-21|2012-08-22|Estimate||||2018-01-29|2018-02-23|Actual|September 2007||2007-09-30|January 2018|2018-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Can We Miss Pigmented Lesions in Psoriasis Patients?|Can We Miss Pigmented Lesions in Psoriasis Patients?|Completed||Phase 4|6|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 00:10:12.780826|2018-06-01 00:10:12.780826
NCT01053806|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-09-23|2010-01-20|2010-01-21|Estimate|||||||2012-09-23|2012-09-25|Estimate|August 2011||2011-08-31|September 2012|2012-09-30||||March 2014|Anticipated|2014-03-31||Interventional|ViLen 001||Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome|A PHASE 2, SINGLE ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF AZACITIDINE, AND LENALIDOMIDE IN HIGHER RISK MYELODYSPLASTIC SYNDROME|Unknown status|Recruiting|Phase 2|6|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 00:10:12.947082|2018-06-01 00:10:12.947082
NCT01053793|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-01-14|2010-01-20|2010-01-21|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|GI||Glycemic Index and Polyphenol Bioavailability of Potatoes|A Trial to Measure the Glycemic Index and Polyphenol Bioavailability of Four Different Varieties of Potato.|Completed||N/A|10|Anticipated|Guelph Food Research Centre||2|||f||||t||||||||||2018-06-01 00:10:13.02951|2018-06-01 00:10:13.02951
NCT01053780|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-20|2010-01-20|2010-01-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|January 2010|Actual|2010-01-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Remote Intercessory Prayer|Effects of Remote Intercessory Prayer in Outcomes of Pregnants Women: a Randomized Controlled Trial|Completed||N/A|565|Actual|Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude|||||f||||f||||||||||2018-06-01 00:10:13.111137|2018-06-01 00:10:13.111137
NCT01053767|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-12-07|2010-01-19|2010-01-21|Estimate|||||||2011-12-07|2011-12-08|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine|A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotypes Ib and III Antibodies in Women Previously Immunized With a GBS Ib and III Crm-Glycoconjugate Vaccine|Completed||Phase 1|95|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:10:13.161394|2018-06-01 00:10:13.161394
NCT01053754|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2014-08-28|2010-01-18|2010-01-21|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Optimization of the Evaluation of the Adrenal Function After Discontinuation of a Prolonged Therapy With Corticosteroids|Optimization of the Evaluation of the Adrenal Function After Discontinuation of a Prolonged Therapy With Corticosteroids|Terminated||N/A|10|Actual|Assistance Publique Hopitaux De Marseille|||||f||||||||||||||2018-06-01 00:10:13.216752|2018-06-01 00:10:13.216752
NCT01053741|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2017-03-02||2017-04-24|2010-01-20|2010-01-21|Estimate|2017-04-24|2017-05-25|Actual||||2017-04-24|2017-05-25|Actual|March 2008||2008-03-31|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission|The Effect of Seminal Fluid on Distal Colon Mucosal Permeability and Susceptibility to HIV Infection|Completed||N/A|11|Actual|Johns Hopkins University||2|||f||||t||||||||No|This is an exploratory physiologic study.|2018-06-01 00:10:13.29232|2018-06-01 00:10:13.29232
NCT01053728|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-07-25|2010-01-19|2010-01-21|Estimate|||||||2011-07-25|2011-07-26|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)|Randomized, Double-blind, Euglycemic Glucose Clamp Study of Four Formulations of SAR161271, in Single Doses in Healthy Subjects and Single Ascending Doses in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|46|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 00:10:13.487454|2018-06-01 00:10:13.487454
NCT01050439|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-04-14|2010-01-14|2010-01-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2002||2002-11-30|April 2015|2015-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Unrelated Donor Transplant for Malignant and Non-Malignant Disorders|Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders|Terminated||Phase 2|22|Actual|Columbia University||1||PI left the institution|f||||t||||||||||2018-06-01 00:10:57.846483|2018-06-01 00:10:57.846483
NCT01053715|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2015-03-18|2010-01-20|2010-01-21|Estimate|||||||2015-03-18|2015-03-20|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Quality of Life Study of Helixate NexGen|A European, Prospective, Non-Interventional Study to Assess Health Related Quality of Life and to Identify Key Transitional Life Events in Patients With Moderate or Severe Haemophilia A Using Helixate NexGen|Completed|||78|Actual|CSL Behring|||||f||||f||||||||||2018-06-01 00:10:13.649462|2018-06-01 00:10:13.649462
NCT01053702|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-04-17|2010-01-19|2010-01-21|Estimate|||||||2011-04-17|2011-04-19|Estimate||||April 2011|2011-04-30||||||||Interventional|||Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury||Withdrawn||Phase 2|0|Actual|Regeneron Pharmaceuticals||3||Sponsor decision|f||||t||||||||||2018-06-01 00:10:13.757761|2018-06-01 00:10:13.757761
NCT01053689|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-21|Estimate|||||||2010-01-19|2010-01-21|Estimate|December 2003||2003-12-31|January 2010|2010-01-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Bioequivalence Study of Dr.Reddys Laboratories Limited, Glimepiride 1 mg Tablets in Healthy Subjects Under Fed Condition|Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fed Condition|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-06-01 00:10:13.825108|2018-06-01 00:10:13.825108
NCT01053676|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2014-06-20|2010-01-20|2010-01-21|Estimate|||||||2014-06-20|2014-06-23|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Bioequivalence Study of BAY77-1931 Granule|Bioequivalence Study of BAY77-1931 Granule - Randomized, Non-blind, Two-way, Crossover Study to Establish the Bioequivalence Between BAY77-1931 Granule 500 mg and Fosrenol Chewable Tablet 500 mg in Japanese Healthy Male Adult Subjects|Completed||Phase 1|59|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:10:13.906134|2018-06-01 00:10:13.906134
NCT01053663|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|2016-01-15||2016-06-16|2010-01-20|2010-01-21|Estimate|2016-06-16|2016-07-27|Estimate||||2016-06-16|2016-07-27|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||All-participants population included all participants who were enrolled in the study.|A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza|An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection|Terminated||Phase 1|9|Actual|Hoffmann-La Roche|Low number of participants enrolled in the study at the time that the study was terminated limits conclusions that can be derived from the study data.|1||The study was terminated prematurely after three influenza seasons.|f||||||||||||||2018-06-01 00:10:14.009962|2018-06-01 00:10:14.009962
NCT01053650|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-01-26|2010-01-19|2010-01-21|Estimate|||||||2012-01-26|2012-01-30|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|HOP||Placebo Effect of Paracetamol in Healthy Volunteers|Placebo Effect of Paracetamol in Healthy Volunteers|Completed||Phase 1|40|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:10:14.652792|2018-06-01 00:10:14.652792
NCT01053637|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2015-05-11|2010-01-20|2010-01-21|Estimate|||||||2015-05-11|2015-05-13|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|January 2012|Actual|2012-01-31||Interventional|||Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair|Randomized Control Trial of Oral Narcotic Medication for Pain and Anxiety Management During Laceration Repair in the Pediatric Emergency Department|Completed||N/A|85|Actual|Texas Children's Hospital||2|||f||||f||||||||||2018-06-01 00:10:14.742814|2018-06-01 00:10:14.742814
NCT01053624|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-01-18|2010-01-20|2010-01-21|Estimate|||||||2011-01-18|2011-01-19|Estimate|October 2001||2001-10-31|January 2011|2011-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Concomitant Tracheostomy and Lung Resection|Concomitant Tracheostomy and Lung Resection in Patient With Low Postoperative Pulmonary Function|Unknown status|Recruiting|Phase 3|60|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:10:14.837351|2018-06-01 00:10:14.837351
NCT01053611|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-03-24|2010-01-20|2010-01-21|Estimate|||||||2011-03-24|2011-03-25|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Composite Variability Index Versus Bispectral Index (BIS)|Changes in a Composite Variability Index (CVI) and Bispectral Index (BIS) in Response to Standardized Pain Stimuli During Propofol Remifentanil Infusion|Completed||N/A|140|Actual|University Medical Center Groningen||12|||f||||f||||||||||2018-06-01 00:10:14.909679|2018-06-01 00:10:14.909679
NCT01053598|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2013-02-16|2010-01-20|2010-01-21|Estimate|||||||2013-02-16|2013-02-20|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|NRA RETA||Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting|EVALUATION OF THE PERFORMANCE OF THE NITRATE REDUCTASE AND RESAZURIN TITRE ASSAY FOR THE DETECTION OF MYCOBACTERIUM TUBERCULOSIS COMPLEX FROM SPUTUM IN A HIGH TB AND HIV SETTING|Completed|||600|Anticipated|Epicentre|||||f||||f||||||||||2018-06-01 00:10:15.001063|2018-06-01 00:10:15.001063
NCT01053585|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2011-06-01|2010-01-20|2010-01-21|Estimate|||||||2011-06-01|2011-06-02|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Structure and Function of the Gastro-esophageal Junction|Combined Magnetic Resonance Imaging and High Resolution Manometry Studies|Completed||N/A|24|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 00:10:15.073564|2018-06-01 00:10:15.073564
NCT01053572|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-04-24|2010-01-19|2010-01-21|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2010|Actual|2010-02-28|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2012|Actual|2012-01-31||Interventional|||Role of Steroids and 10% Hypertonic Sodium Chloride in Adhesiolysis in Post Lumbar Surgery Syndrome Patients|Evaluation of the Role of Steroids and 10% Hypertonic Sodium Chloride in Adhesiolysis in Post Lumbar Surgery Syndrome Patients: A Prospective, Randomized, Double-Blind, Equivalence, Controlled Trial of Percutaneous Lumbar Adhesiolysis|Completed||N/A|240|Actual|Pain Management Center of Paducah||4|||f||||t|f|f||||||No||2018-06-01 00:10:15.149787|2018-06-01 00:10:15.149787
NCT01053559|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2014-04-23|2010-01-20|2010-01-21|Estimate|||||||2014-04-23|2014-04-24|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy|Open Label Investigator Initiated, Single Site Study of Mucosal Healing in Patients With Small Bowel Crohn's Disease Treated With Certolizumab Pegol (Cimzia) Assessed by Wireless Capsule Endoscopy|Completed||N/A|15|Actual|Shafran Gastroenterology Center||1|||f||||f||||||||||2018-06-01 00:10:15.234404|2018-06-01 00:10:15.234404
NCT01042990|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-05|2010-01-05|2010-01-06|Estimate|||||||2010-01-05|2010-01-06|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|TAPAS||Testing Adaptive Physical Activity in Stroke|Testing Adaptive Physical Activity in Stroke|Unknown status|Recruiting|N/A|54|Anticipated|Baltimore VA Medical Center||3|||f||||t||||||||||2018-06-01 00:12:57.829272|2018-06-01 00:12:57.829272
NCT01053546|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2017-05-25|2010-01-20|2010-01-21|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2010||2010-11-30|February 2017|2017-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer|Effects of Early vs Late Onset of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer|Terminated||N/A|14|Actual|Wake Forest University Health Sciences||2||slow accrual|f||||t|f|f||||||||2018-06-01 00:10:15.311176|2018-06-01 00:10:15.311176
NCT01053533|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-06-07|2010-01-20|2010-01-21|Estimate|||||||2010-06-07|2010-06-08|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|200907001-2A||A Pragmatic Randomized Controlled Trial of Chinese Herbal Medicine for Severe Pandemic H1N1 Influenza||Unknown status|Recruiting|N/A|1100|Anticipated|Beijing Ditan Hospital||2|||f||||t||||||||||2018-06-01 00:10:15.392389|2018-06-01 00:10:15.392389
NCT01053520|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2010-11-08|2010-01-19|2010-01-21|Estimate|||||||2010-11-08|2010-11-09|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects||Completed||Phase 1|12|Anticipated|Abbott||3|||f||||f||||||||||2018-06-01 00:10:15.474269|2018-06-01 00:10:15.474269
NCT01053507|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2014-01-28||2014-01-28|2010-01-20|2010-01-21|Estimate|2014-01-28|2014-03-10|Estimate||||2014-01-28|2014-03-10|Estimate|May 2010||2010-05-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction|Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction|Terminated||Phase 4|23|Actual|Cady, Roger, M.D.||2||Enrollment rate was slower than anticipated.|f||||f||||||||||2018-06-01 00:10:15.568247|2018-06-01 00:10:15.568247
NCT01053494|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2018-05-24|2010-01-20|2010-01-21|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2010||2010-04-30|May 2018|2018-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer|The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer|Completed||N/A|80|Actual|Wake Forest University Health Sciences||3|||f||||f|f|f||||||||2018-06-01 00:10:15.828788|2018-06-01 00:10:15.828788
NCT01053481|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2013-11-21|2010-01-20|2010-01-21|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health|Using Ca-41 Methodology to Assess the Impact of Different Vitamin D Supplementation Levels on Postmenopausal Bone Health|Completed||Early Phase 1|25|Actual|Swiss Federal Institute of Technology||1|||f||||t||||||||||2018-06-01 00:10:15.930915|2018-06-01 00:10:15.930915
NCT01053468|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2011-06-30|2010-01-20|2010-01-21|Estimate|||||||2011-06-30|2011-07-01|Estimate|August 2010||2010-08-31|January 2010|2010-01-31|April 2013|Anticipated|2013-04-30|April 2012|Anticipated|2012-04-30||Interventional|PROACTIVE||Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy|Facilitating Physical Activity Behavior and Health Outcomes in Breast Cancer Patients Receiving Chemotherapy|Unknown status|Recruiting|Phase 2|150|Anticipated|Athabasca University||2|||f||||f||||||||||2018-06-01 00:10:16.00569|2018-06-01 00:10:16.00569
NCT01053455|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2012-06-21|2010-01-20|2010-01-21|Estimate|||||||2012-06-21|2012-06-22|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Observational Crossover Study Comparing Oxygenation and Ventilation Using SiPAP Versus CPAP in LBW Infants|Observational Crossover Study Comparing Oxygenation and Ventilation Using Biphasic CPAP (SiPAP) Versus CPAP to Treat Respiratory Distress in Low Birth Weight Infants|Completed|||20|Actual|Children's Hospitals and Clinics of Minnesota|||2||f||||t||||||||||2018-06-01 00:10:16.085947|2018-06-01 00:10:16.085947
NCT01053442|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2012-04-04|2010-01-20|2010-01-21|Estimate|||||||2012-04-04|2012-04-05|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|SIA||Absorption, Stable Isotope Appearance and Non-transferrin-bound Iron (NTBI) Profile From NaFeEDTA and Ferrous Sulphate|Absorption, Stable Isotope Appearance and NTBI Profile From NaFeEDTA and Ferrous Sulphate|Completed||N/A|17|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-06-01 00:10:16.232341|2018-06-01 00:10:16.232341
NCT01053429|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2010-12-21||2010-12-21|2010-01-20|2010-01-21|Estimate|2010-12-21|2011-01-07|Estimate||||2010-12-21|2011-01-07|Estimate|June 2005||2005-06-30|December 2010|2010-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule|Post-Marketing Surveillance (PMS) Study to Evaluate Safety and Efficacy of Zeldox Capsule|Completed|||3391|Actual|Pfizer|Per the Statistical Analysis Plan Amendment CGI-S and CGI-I endpoints analyzed as frequency counts (categorical) rather than the planned CGI-S mean change from baseline and CGI-I mean scores (continuous); any additional analyses would be exploratory.||1||f||||f||||||||||2018-06-01 00:10:16.327054|2018-06-01 00:10:16.327054
NCT01053416|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-21|2010-01-20|2010-01-21|Estimate|||||||2010-01-21|2010-01-22|Estimate|January 1993||1993-01-31|January 2003|2003-01-31|December 2003|Actual|2003-12-31|April 2003|Actual|2003-04-30||Interventional|||Pigment Dispersion Syndrome: Natural History and Possible Protective Effect of a YAG Laser Iridotomy|10-year Follow up of Patients With Pigment Dispersion Syndrome: Risk Factors for Conversion to Pigmentary Glaucoma and Potential Protective Effect of a Yag-laser Iridotomy in High Risk Eye|Completed||N/A|72|Actual|University of Parma||2|||f||||f||||||||||2018-06-01 00:10:16.687248|2018-06-01 00:10:16.687248
NCT01053403|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2013-05-29|2010-01-19|2010-01-21|Estimate|||||||2013-05-29|2013-05-31|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|2C||Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.|The Effects of MDMA on Sleep Architecture, Water Homeostasis and Cognitive Function|Completed||N/A|12|Actual|California Pacific Medical Center Research Institute||1|||f||||f||||||||||2018-06-01 00:10:16.751156|2018-06-01 00:10:16.751156
NCT01053390|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2013-12-18|2010-01-20|2010-01-21|Estimate|||||||2013-12-18|2013-12-20|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma|A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma|Completed||Phase 3|216|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 00:10:16.894754|2018-06-01 00:10:16.894754
NCT01052844|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2010-09-24||2014-01-18|2010-01-19|2010-01-20|Estimate|2014-01-18|2014-03-07|Estimate||||2014-01-18|2014-03-07|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy|Clinical Trial of Gabapentin in the Prevention of Nausea Ond Vomiting Induced by Chemotherapy, a Randomized, Double-blind, Placebo Controled Study|Completed||Phase 3|80|Actual|Faculdade de Medicina do ABC||2|||f||||t||||||||||2018-06-01 00:10:22.415437|2018-06-01 00:10:22.415437
NCT01053377|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-20|2010-01-20|2010-01-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|PEPpIE||A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes|A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes|Unknown status|Enrolling by invitation|Phase 4|900|Anticipated|National Institute for Public Health and the Environment (RIVM)||2|||f||||t||||||||||2018-06-01 00:10:17.0216|2018-06-01 00:10:17.0216
NCT01053364|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-01-04|2010-01-19|2010-01-21|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Feasibility Study of NL-Prow Interspinous Spacer to Treat Lumbar Spinal Stenosis|Feasibility Study of NL-Prow Interspinous Spacer Device and Procedure|Unknown status|Active, not recruiting|N/A|6|Actual|Non-Linear Technologies||1|||f||||||||||||||2018-06-01 00:10:17.099135|2018-06-01 00:10:17.099135
NCT01053338|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fed Condition|Open Label,Balanced,Randomized,Two-treatment,Two-sequence,Two Period,Single-dose,Crossover Oral Bioequivalence Study of Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets of Dr.Reddy's and Advil®PM of Wyeth in Normal,Healthy,Adult,Human Subjects Under Fed Conditions.|Completed||Phase 1|40|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:10:17.162674|2018-06-01 00:10:17.162674
NCT01053325|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2013-10-23|2010-01-20|2010-01-21|Estimate|||||||2013-10-23|2013-10-24|Estimate|September 2010||2010-09-30|October 2013|2013-10-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy|A Clinical Trial to Establish The Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy|Completed||Phase 3|848|Actual|Institute of Tropical Medicine, Belgium||5|||f||||t||||||||||2018-06-01 00:10:17.246314|2018-06-01 00:10:17.246314
NCT01053312|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2012-03-28||2012-06-07|2010-01-19|2010-01-21|Estimate|2012-05-02|2012-06-05|Estimate||||2012-06-07|2012-06-11|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus|A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied|Completed||Phase 3|7|Actual|GE Healthcare||1|||f||||t||||||||||2018-06-01 00:10:17.371653|2018-06-01 00:10:17.371653
NCT01053299|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-27|2010-01-20|2010-01-21|Estimate|||||||2010-01-27|2010-01-28|Estimate|March 2010||2010-03-31|January 2010|2010-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Universal Ultrasound-screening for Developmental Dysplasia of the Hip in Newborn|Universal Ultrasound-screening for Developmental Dysplasia of the Hip. 5-12 Years Followup of 4 200 Newborns|Unknown status|Enrolling by invitation|N/A|4200|Anticipated|Vestre VikenHF Kongsberg Sykehus||1|||f||||t||||||||||2018-06-01 00:10:17.713132|2018-06-01 00:10:17.713132
NCT01053286|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2017-05-25|2010-01-19|2010-01-21|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2009||2009-10-31|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin|Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin|Completed|||19|Actual|University of California, Davis|||||f||||f||||||||||2018-06-01 00:10:17.785693|2018-06-01 00:10:17.785693
NCT01053273|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-04-24|2010-01-20|2010-01-21|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2010|Actual|2010-02-28|April 2017|2017-04-30|January 27, 2014|Actual|2014-01-27|January 2012|Actual|2012-01-31||Interventional|||A Randomized, Equivalence Trial of Percutaneous Lumbar Adhesiolysis and Caudal Epidural Steroid Injections|Comparative Effectiveness of Percutaneous Adhesiolysis and Caudal Epidural Steroid Injections in Low Back and/or Lower Extremity Pain: A Randomized, Equivalence Trial|Completed||N/A|120|Actual|Pain Management Center of Paducah||2|||f||||t|f|f||||||No||2018-06-01 00:10:17.849046|2018-06-01 00:10:17.849046
NCT01053260|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-06-14|2010-01-19|2010-01-21|Estimate|||||||2012-06-14|2012-06-18|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|WeLCoMe||Contingency Management for Promoting Weight Loss in University Students|Contingency Management for Promoting Weight Loss in University Students|Completed||Phase 2|47|Actual|UConn Health||2|||f||||t||||||||||2018-06-01 00:10:17.919334|2018-06-01 00:10:17.919334
NCT01053247|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2014-09-30|2014-06-16|2014-09-30|2010-01-20|2010-01-21|Estimate|2014-09-30|2014-10-03|Estimate|2014-06-16|2014-06-19|Estimate|2014-09-30|2014-10-03|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of 0416 Ointment in the Treatment of Atopic Dermatitis|Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0416 Ointment.|Completed||Phase 3|793|Actual|Fougera Pharmaceuticals Inc.||3|||f||||f||||||||||2018-06-01 00:10:17.993223|2018-06-01 00:10:17.993223
NCT01053234|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|February 2007||2007-02-28|January 2010|2010-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Different Insulin Regimens and Postprandial Coagulation Activation|Effects of Standardised Meals on Postprandial Coagulation Activation in Patients With Type 2 Diabetes Treated With Two Different Insulin Regimens|Completed||N/A|78|Actual|Hospital of South West Denmark||2|||f||||f||||||||||2018-06-01 00:10:18.230728|2018-06-01 00:10:18.230728
NCT01053221|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-02-16|2010-01-20|2010-01-21|Estimate|||||||2017-02-16|2017-02-20|Actual|March 2006||2006-03-31|February 2017|2017-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation|Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation|Terminated||N/A|30|Actual|University of Wisconsin, Madison||2||Funding loss|f||||t||||||||||2018-06-01 00:10:18.289999|2018-06-01 00:10:18.289999
NCT01053208|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bioequivalence Study of Dr.Reddy's Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets Under Fasting Condition|Open Label,Balanced,Randomized,Two-treatment,Two-sequence,Two Period,Single-dose,Crossover Oral Bioequivalence Study of Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets of Dr.Reddy's and Advil®PM of Wyeth in Normal,Healthy,Adult,Human Subjects Under Fasting Conditions.|Completed||Phase 1|40|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:10:18.353319|2018-06-01 00:10:18.353319
NCT01053195|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2016-08-25|2010-01-20|2010-01-21|Estimate|||||||2016-08-25|2016-08-29|Estimate|December 2005||2005-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|QDDPP||Qingdao Diabetes Prevention Project|A Community-based Lifestyle Intervention to Reduce the Risk of Diabetes in Qingdao, China----Qingdao Diabetes Prevention Project (2005-2012)|Completed||N/A|276793|Actual|Helsinki University||2|||f||||t||||||||||2018-06-01 00:10:18.419566|2018-06-01 00:10:18.419566
NCT01053182|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches|A Phase Ⅲ Study of Respiratory Complications Associated With Esophagectomy Through Either Ivor-Lewis or Sweet Approach for the Treatment of Middle or Lower Third Intrathoracic Esophageal Carcinoma|Unknown status|Recruiting|Phase 3|320|Anticipated|Sichuan University||2|||f||||t||||||||||2018-06-01 00:10:18.49465|2018-06-01 00:10:18.49465
NCT01053169|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2017-10-02|2010-01-20|2010-01-21|Estimate|||||||2017-10-02|2017-10-03|Actual|May 2010||2010-05-31|October 2017|2017-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)|Non-interventional Observational Study of Beriplex® P/N in Prophylaxis and Treatment of Acute Bleeding Perioperatively (Diagnostic Intervention or Surgery)|Completed|||445|Actual|CSL Behring|||2||f||||f||||||||||2018-06-01 00:10:18.577938|2018-06-01 00:10:18.577938
NCT01053156|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2013-02-08||2017-05-25|2010-01-20|2010-01-21|Estimate|2014-06-30|2014-07-30|Estimate||||2017-05-25|2017-05-30|Actual|January 2010||2010-01-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||The baseline participants are different in number from those started in the participant flow module because in our intent to treat analysis, only those who completed one or more treatment periods were included in the analysis.|Trial of Minocycline to Treat Children With Fragile X Syndrome|Randomized Double-Blind Controlled Cross Over Trial of Minocycline in Children With Fragile X Syndrome|Completed||N/A|66|Actual|University of California, Davis|Results may be potentially biased by study design weaknesses, including unblinding of subjects when they completed the study, drug-related side effects unblinding and preliminary efficacy analysis results known to investigators.|2|||f||||t||||||||||2018-06-01 00:10:18.750469|2018-06-01 00:10:18.750469
NCT01053143|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2014-01-10|2010-01-19|2010-01-21|Estimate|||||||2014-01-10|2014-01-14|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India|Bridging Study on Safety and Immunogenicity of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India|Completed||Phase 3|100|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:10:19.143534|2018-06-01 00:10:19.143534
NCT01053130|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2016-06-08|2010-01-20|2010-01-21|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Weight Loss Interventions in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial|The Effect of Weight Loss Surgery on Preservation of Kidney Function and Cardiovascular Disease Risk Factors in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial|Completed||N/A|16|Actual|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-06-01 00:10:19.206339|2018-06-01 00:10:19.206339
NCT01053117|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2014-04-16|2010-01-20|2010-01-21|Estimate|||||||2014-04-16|2014-04-17|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Reducing Hemodialysis Catheter Use in Prevalent Hemodialysis Patients|Reducing Hemodialysis Catheter Use in in a Prevalent Hemodialysis Population; A Pilot Randomized Control Trial|Terminated||Phase 2|3|Actual|University of Manitoba||2||Unable to enrol patients|f||||f||||||||||2018-06-01 00:10:19.263867|2018-06-01 00:10:19.263867
NCT01053104|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-03|||2012-07-24|2010-01-19|2010-01-21|Estimate|||||||2012-07-24|2012-07-25|Estimate|November 2009||2009-11-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Observational|DATACAP||Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring|Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring Pilot Study of Optimal Dose Scheduling of Capecitabine for Patients With Metastatic Colorectal or Metastatic Breast Cancer|Completed|||26|Actual|University of Oxford|||4||f||||f||||||||||2018-06-01 00:10:19.322204|2018-06-01 00:10:19.322204
NCT01053091|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2015-02-25|2010-01-20|2010-01-21|Estimate|||||||2015-02-25|2015-02-26|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Exercise-based Rehabilitation on Circulatory Functions in Patients With Diastolic Heart Failure|Effect of Exercise-based Rehabilitation on Circulatory Functions in Patients With Diastolic Heart Failure|Completed||N/A|120|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:10:19.381218|2018-06-01 00:10:19.381218
NCT01053078|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2014-09-04||2018-01-22|2010-01-20|2010-01-21|Estimate|2014-09-04|2014-09-12|Estimate||||2018-01-22|2018-01-24|Actual|October 2009||2009-10-31|January 2018|2018-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Naltrexone||Naltrexone and Hypoglycemia in Type 1 Diabetes|Study of the Effect of Naltrexone on Cerebral Blood Flow and Hypoglycemia in Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|29|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 00:10:19.447848|2018-06-01 00:10:19.447848
NCT01053065|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-25|2010-01-20|2010-01-21|Estimate|||||||2010-01-25|2010-01-26|Estimate||||January 2005|2005-01-31||||||||Interventional|MAPS||The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study|The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study|Completed||N/A|60|Actual|University of Padua||3|||f||||f||||||||||2018-06-01 00:10:19.675485|2018-06-01 00:10:19.675485
NCT01053052|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2017-05-08|2010-01-20|2010-01-21|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2010||2010-01-31|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of FemVue(TM) Sono Tubal Evaluation System Method Comparison to HSG|A Comparative Study of Methods for Tubal Patency Determination and Uterine Cavity Evaluation: Sonography With the FemVue(TM) Catheter System vs. Hysterosalpingography (HSG)|Withdrawn||N/A|0|Actual|Femasys Inc.||1||Study cancelled without recruitment|f||||f|f|t|f|f|f|||No||2018-06-01 00:10:19.749541|2018-06-01 00:10:19.749541
NCT01053039|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2015-12-15|2010-01-19|2010-01-21|Estimate|||||||2015-12-15|2015-12-16|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|ITMP||The Use of Intrathecal Morphine in the Management of Acute Pain Following Decompressive Lumbar Spinal Surgery|The Use of Intrathecal Morphine in the Management of Acute Pain Following Decompressive Lumbar Spinal Surgery: A Randomized Controlled Trial|Completed||Phase 4|150|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 00:10:19.806521|2018-06-01 00:10:19.806521
NCT01053026|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2012-11-15|2010-01-20|2010-01-21|Estimate|||||||2012-11-15|2012-11-16|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Evaluation of Effects of Exercise Training and ARB in DM Patients|Evaluation of Vascular Function, Effects of Exercise Training and Angiotensin Receptor II Antagonist in Patients With Type II Diabetes and Hypertension by Using Near-infrared Spectroscopy, Rapid Laser Doppler Blood Flow Imaging and Circulating Biomarkers|Completed|||15|Actual|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:10:19.865194|2018-06-01 00:10:19.865194
NCT01053013|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2018-04-30|2010-01-20|2010-01-21|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2010||2010-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Macrobead||Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer|An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma|Recruiting||Phase 2|60|Anticipated|The Rogosin Institute||1|||f||||t||||||||||2018-06-01 00:10:20.865314|2018-06-01 00:10:20.865314
NCT01053000|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2014-05-16||2015-07-21|2010-01-19|2010-01-21|Estimate|2015-06-23|2015-07-22|Estimate||||2015-07-21|2015-08-11|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses|Photodynamic Therapy With Levulan® Topical Solution And Blue Light +/- Topical Retinoid Pre-Treatment In The Treatment Of Dorsal Hand/Forearm Actinic Keratoses|Completed||N/A|10|Actual|Stewart, Roger H., M.D., P.A.||2|||f||||f||||||||||2018-06-01 00:10:20.966089|2018-06-01 00:10:20.966089
NCT01052987|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-01-05|2010-01-19|2010-01-21|Estimate|||||||2011-01-05|2011-01-06|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia|A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Allopurinol Compared With Tranilast Alone and Allopurinol Alone in Healthy Subjects With Hyperuricemia|Completed||Phase 2|24|Anticipated|Nuon Therapeutics, Inc.||5|||f||||f||||||||||2018-06-01 00:10:21.139868|2018-06-01 00:10:21.139868
NCT01052974|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-10-30|2010-01-20|2010-01-21|Estimate|||||||2017-10-30|2017-11-01|Actual|March 26, 2009|Actual|2009-03-26|January 2010|2010-01-31|November 9, 2010|Actual|2010-11-09|May 2010|Actual|2010-05-31||Interventional|KTcol||Perioperative Analgesia by Femoral Perineural Catheter for Femoral Neck Fracture - Study KTcol|Perioperative Analgesia by Femoral Perineural Catheter for Femoral Neck Fracture - Study KTcol -|Completed||Phase 4|60|Actual|University Hospital, Angers||2|||f||||f||||||||||2018-06-01 00:10:21.217482|2018-06-01 00:10:21.217482
NCT01052961|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-07-19|2010-01-20|2010-01-21|Estimate|||||||2012-07-19|2012-07-20|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza|Initiating Oseltamivir in Adults Hospitalized With Influenza -- a Study on the Impact of Virological Clearance and Clinical Recovery for Higher-dose Treatment Started Within 96 Hours|Completed||Phase 4|157|Actual|Chinese University of Hong Kong||2|||f||||||||||||||2018-06-01 00:10:21.295941|2018-06-01 00:10:21.295941
NCT01052948|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2010-12-28||2011-03-17|2010-01-19|2010-01-21|Estimate|2011-02-15|2011-03-11|Estimate||||2011-03-17|2011-03-23|Estimate|January 2007||2007-01-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events|The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events|Completed|||86939|Actual|Pfizer|||4||f||||t||||||||||2018-06-01 00:10:21.393898|2018-06-01 00:10:21.393898
NCT01052935|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-06-09|2010-01-19|2010-01-21|Estimate|||||||2017-06-09|2017-06-14|Actual|January 2010||2010-01-31|June 2017|2017-06-30|October 2010|Actual|2010-10-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine|A Phase I Extension Study to Assess the Long-Term Persistence of GBS Serotype Ia Antibodies in Women Previously Immunized With a GBS Ia Crm-Glycoconjugate Vaccine|Completed||Phase 1|50|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:10:21.770193|2018-06-01 00:10:21.770193
NCT01052922|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-10-11|2010-01-19|2010-01-21|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2009||2009-08-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement|Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement|Completed||N/A|2260|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-06-01 00:10:21.842458|2018-06-01 00:10:21.842458
NCT01052909|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-21|Estimate|||||||2010-01-19|2010-01-21|Estimate|December 2003||2003-12-31|January 2010|2010-01-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Bioequivalence Study of Dr.Reddy's Laboratories Limited, Glimepiride Tablets 1 mg Under Fasting Condition|Randomized, 2-way Crossover, Bioequivalence Study of Glimepiride 1 mg Tablets and Amaryl 1 mg Tablets in Healthy Subjects Under Fasting Condition|Completed||Phase 1|44|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:10:21.928625|2018-06-01 00:10:21.928625
NCT01052896|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-20|||2010-01-20|2010-01-20|2010-01-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|March 2010||2010-03-31|January 2010|2010-01-31|May 2011|Anticipated|2011-05-31|March 2011|Anticipated|2011-03-31||Interventional|||Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition|Gabapentin in Functional Dyspepsia Refractory to Proton Pump Inhibition|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Wilford Hall Medical Center||2|||f||||f||||||||||2018-06-01 00:10:22.01217|2018-06-01 00:10:22.01217
NCT01052883|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2013-09-03|2010-01-19|2010-01-20|Estimate|||||||2013-09-03|2013-09-04|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions|A Phase I, Open Label, Randomized, Single Dose, Crossover Study in Healthy Subjects to Compare the Oral Bioavailability of a Prototype Tablet Formulation of Darunavir 800mg(G002) to That of the Commercial 400mg(F030) Tablet Formulation Under Fed & Fasted Conditions, in Presence of Low-dose Ritonavir|Completed||Phase 1|32|Actual|Tibotec Pharmaceuticals, Ireland||4|||f||||||||||||||2018-06-01 00:10:22.126661|2018-06-01 00:10:22.126661
NCT01052870|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-16|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia|Study Evaluating the Association of CAG Repeat Polymorphisms and Finasteride Response in Women With Androgenetic Alopecia|Completed||Phase 1|12|Actual|HairDx, LLC||2|||f||||f||||||||||2018-06-01 00:10:22.225707|2018-06-01 00:10:22.225707
NCT01052857|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|November 2007||2007-11-30|December 2007|2007-12-31|January 2009|Actual|2009-01-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy of Acupuncture on Induction of Labor|Efficacy of Acupuncture on Induction of Labor|Completed||Early Phase 1|80|Actual|University of Modena and Reggio Emilia||2|||f||||t||||||||||2018-06-01 00:10:22.331937|2018-06-01 00:10:22.331937
NCT01052831|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2015-03-10||2015-07-13|2010-01-15|2010-01-20|Estimate|2015-05-22|2015-06-22|Estimate||||2015-07-13|2015-08-06|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Naltrexone for Impulse Control Disorders in Parkinson's Disease|Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease|Completed||Phase 4|50|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:10:22.681636|2018-06-01 00:10:22.681636
NCT01052818|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2010-01-18|2010-01-18|2010-01-20|Estimate|||||||2010-01-18|2010-01-20|Estimate|July 2007||2007-07-31|January 2010|2010-01-31||||August 2008|Anticipated|2008-08-31||Observational|||Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer||Unknown status|Recruiting||200|Anticipated|National Institute of Cancerología|||1||f||||f||||||Samples With DNA|"~     Peripheral blood samples are collected were the cell pellet are collected from~     centrifugation, lysed by TRIzol method to get RNA. The RNA is retrotranscribed to cDNA in~     order to quantify cytokeratin (CK) 19, 18 and carcinoembrionic antigen which are markers of~     epithelial cells presumambly coming form the tumor.~   "|||2018-06-01 00:10:22.954999|2018-06-01 00:10:22.954999
NCT01052805|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2011-10-20|2010-01-19|2010-01-20|Estimate|||||||2011-10-20|2011-10-21|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Anatomy Study in Control Nerve From Normal Human|Anatomy Study in Control Nerve From Normal Human|Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||1||f||||f|||||||"~     nerve from cadaveric donor nerve from nerve graft operation patient~   "|||2018-06-01 00:10:23.033428|2018-06-01 00:10:23.033428
NCT01052792|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|May 2006||2006-05-31|January 2010|2010-01-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions|Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fed Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:10:23.190348|2018-06-01 00:10:23.190348
NCT01052779|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2018-03-26|2013-04-03|2018-05-10|2010-01-19|2010-01-20|Estimate|2018-05-10|2018-05-15|Actual|2013-04-03|2013-04-10|Estimate|2018-05-10|2018-05-15|Actual|March 1, 2010|Actual|2010-03-01|May 2018|2018-05-31|April 19, 2012|Actual|2012-04-19|July 19, 2011|Actual|2011-07-19||Interventional|FIRST|Intent-to-Treat (ITT) Population: Any randomized participant who had any exposure to study drug (IV ferumoxytol or IV iron sucrose).|A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease|Ferumoxytol Compared to Iron Sucrose Trial (FIRST): A Randomized, Multicenter, Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease|Completed||Phase 2|162|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 00:10:23.289317|2018-06-01 00:10:23.289317
NCT01052766|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2012-03-15|2010-01-18|2010-01-20|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis|The Use of Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung and Liver Lesions and Assessment of Tumor Glycolysis|Terminated||N/A|11|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-06-01 00:10:23.825224|2018-06-01 00:10:23.825224
NCT01052753|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2010||2010-08-31|January 2010|2010-01-31|July 2013|Anticipated|2013-07-31|||||Observational|||The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD)|The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention-deficit Hyperactivity Disorder|Unknown status|Not yet recruiting||300|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-06-01 00:10:23.936834|2018-06-01 00:10:23.936834
NCT01052740|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-16|||2017-06-30|2010-01-16|2010-01-20|Estimate|||||||2017-06-30|2017-07-02|Actual|December 30, 2009||2009-12-30|September 20, 2011|2011-09-20|September 20, 2011||2011-09-20|||||Observational|||X-Ray Mammography Standard of Care Protocol|X-Ray Mammography Standard of Care Protocol|Completed|||108|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:10:24.020074|2018-06-01 00:10:24.020074
NCT01052727|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate||||December 2009|2009-12-31||||||||Interventional|DOLCE||Day-care Versus Overnight-stay Laparoscopic Cholecystectomy Randomized Controlled Trial.|DOLCE Study: Day-care Versus Overnight-stay Laparoscopic Cholecystectomy Randomized, Controlled Trial|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|St. Orsola Hospital||2|||f||||f||||||||||2018-06-01 00:10:24.081196|2018-06-01 00:10:24.081196
NCT01052714|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2017-07-11||2018-02-12|2010-01-15|2010-01-20|Estimate|2017-09-07|2017-10-06|Actual||||2018-02-12|2018-03-12|Actual|September 1, 2010|Actual|2010-09-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2017|Actual|2017-06-30||Interventional|MAMAO2||Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2|Management of Antipsychotic Medication Associated Obesity - 2|Active, not recruiting||N/A|121|Actual|VA Office of Research and Development||3|||f||||t|f|f|||f|||No||2018-06-01 00:10:24.225974|2018-06-01 00:10:24.225974
NCT01052701|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2017-02-07||2017-04-27|2010-01-19|2010-01-20|Estimate|2017-04-25|2017-04-27|Actual||||2017-04-27|2017-05-01|Actual|December 2009||2009-12-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment|Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment|Completed||Phase 1|26|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-06-01 00:10:25.186688|2018-06-01 00:10:25.186688
NCT01052688|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-04-18|2010-01-19|2010-01-20|Estimate|||||||2016-04-18|2016-04-20|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|CHARMM-AP||Noninvasive Screening for Affected Pregnancies: Assay Development & Optimization in Affected Pregnancies|Noninvasive Screening for Fetal Chromosomal Aneuploidy and Abnormality: Assay Development & Optimization in Affected Pregnancies|Unknown status|Recruiting||300|Anticipated|Sequenom, Inc.|||1||f||||f||||||Samples With DNA|"~     Plasma, white blood cells~   "|No|Samples and data are used in research and development of a noninvasive prenatal test. However, sample data used in publications will be shared as per requirements of the journal.|2018-06-01 00:10:25.485914|2018-06-01 00:10:25.485914
NCT01052675|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-01-31|2010-01-19|2010-01-20|Estimate|||||||2012-01-31|2012-02-02|Estimate|January 2008||2008-01-31|January 2010|2010-01-31||||||||Observational|||Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation|Pharmacological, Clinical and Statistical Assessment of a New Tool Available for Pharmacodependence Report Evaluation|Unknown status|Recruiting||5000|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-06-01 00:10:25.629178|2018-06-01 00:10:25.629178
NCT01052662|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|2015-01-14||2015-03-11|2010-01-19|2010-01-20|Estimate|2015-02-13|2015-03-06|Estimate||||2015-03-11|2015-04-01|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional||Intent-to-treat sample|Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults|Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults|Completed||Phase 2/Phase 3|87|Actual|University of Massachusetts, Worcester|Rapid discontinuation of buprenorphine was associated with dropout that may have limited the statistical power to evaluate some variables. Memantine for 7 weeks may have been too short, and a longer exposure may have yielded better results.|3|||f||||t||||||||||2018-06-01 00:10:25.740914|2018-06-01 00:10:25.740914
NCT01052649|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2008||2008-08-31|July 2009|2009-07-31||||||||Observational|||Gene Expression Monitoring of Mononuclear Cells (MNC) Subpopulations and Immunological Status and Metabolome Defining of Healthy Population|Gene Expression Monitoring of Peripheral Blood Mononuclear Cells Subpopulations (CD4+ Cells, CD56+ Cells and CD4+CD25+ Cells) and Immunological Status and Metabolome Defining of Healthy Population|Completed|||||Blood Transfusion Centre of Slovenia|||1||f||||f||||||||||2018-06-01 00:10:26.267183|2018-06-01 00:10:26.267183
NCT01052636|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-17|||2017-02-02|2010-01-17|2010-01-20|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2001||2001-01-31|February 2017|2017-02-28|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Intervention Program for Elderly Patients With Hip Fracture|Intervention Program for Elderly Patients With Hip Fracture|Completed||N/A|162|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-06-01 00:10:26.332795|2018-06-01 00:10:26.332795
NCT01052623|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-07-02|2010-01-19|2010-01-20|Estimate|||||||2010-07-02|2010-07-05|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|September 2012|Anticipated|2012-09-30|December 2011|Anticipated|2011-12-31||Interventional|GHAT||Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)|Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia|Unknown status|Recruiting|Phase 4|24|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||||2018-06-01 00:10:26.418064|2018-06-01 00:10:26.418064
NCT01052610|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2013-02-06|2010-01-19|2010-01-20|Estimate|||||||2013-02-06|2013-02-07|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites|Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites|Unknown status|Recruiting|Phase 4|100|Anticipated|Medical Universtity of Lodz||2|||f||||f||||||||||2018-06-01 00:10:26.527463|2018-06-01 00:10:26.527463
NCT01052597|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|July 2009||2009-07-31|August 2007|2007-08-31|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|||Curcumin for Type 2 Diabetic Patients|Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients|Unknown status|Recruiting|Phase 4|200|Anticipated|Srinakharinwirot University||2|||f||||f||||||||||2018-06-01 00:10:26.632606|2018-06-01 00:10:26.632606
NCT01052584|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-17|||2010-11-17|2010-01-17|2010-01-20|Estimate|||||||2010-11-17|2010-11-18|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Ethiopia Malaria Therapeutic Efficacy Study|Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection|Completed||N/A|354|Actual|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-06-01 00:10:26.735139|2018-06-01 00:10:26.735139
NCT01052571|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2015-10-20|2010-01-18|2010-01-20|Estimate|||||||2015-10-20|2015-10-21|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|August 2014|Actual|2014-08-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of the Effectiveness of Transforaminal Epidural Injections in Lumbar Disc Herniation or Radiculitis|A Randomized, Prospective, Double-Blind, Equivalence, Controlled Evaluation of the Effectiveness of Transforaminal Epidural Injections in Lumbar Disc Herniation or Radiculitis With or Without Steroids|Completed||N/A|120|Actual|Pain Management Center of Paducah||2|||f||||t||||||||||2018-06-01 00:10:26.814625|2018-06-01 00:10:26.814625
NCT01052558|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-05-18|2010-01-19|2010-01-20|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma|A Prospective, Randomized, Controlled, Parallel Groupos, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 in Conjunction With Cataract Surgery|Completed||Phase 3|164|Actual|Glaukos Corporation||2|||f||||t||||||||||2018-06-01 00:10:26.889115|2018-06-01 00:10:26.889115
NCT01052545|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2014-10-20||2015-04-17|2010-01-15|2010-01-20|Estimate|2014-10-29|2014-11-06|Estimate||||2015-04-17|2015-05-07|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ABU||Asymptomatic Bacteriuria Guideline Implementation Study|Guideline Implementation to Decrease Inappropriate Bacteriuria Treatment|Completed||N/A|1598|Actual|VA Office of Research and Development|Modification may be necessary for private sector facilities. We do not know what aspect of our intervention had the biggest impact, and whether the entire bundle is necessary.|2|||f||||f||||||||||2018-06-01 00:10:26.989316|2018-06-01 00:10:26.989316
NCT01052532|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-12-01|2010-01-19|2010-01-20|Estimate|||||||2010-12-01|2010-12-02|Estimate|June 2005||2005-06-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|P1A2||Molecular Mechanisms of Mitral Regurgitation—Aim 2|The Study to Define the Unique Molecular Mechanisms of Mitral Regurgitation in Order to Find New Targeted Therapy to Attenuate the Remodeling and Delay the Need for Surgery and Improve Surgical Outcomes.|Completed|||65|Actual|University of Alabama at Birmingham|||1||f||||f||||||Samples With DNA|"~     Plasma, myocyte tissue~   "|||2018-06-01 00:10:27.30487|2018-06-01 00:10:27.30487
NCT01052519|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2014-11-18|2010-01-19|2010-01-20|Estimate|||||||2014-11-18|2014-11-19|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Obesity and Goal-directed Intraoperative Fluid Therapy|Intraoperative Goal-directed Fluid Management in Non-Obese and Obese Patients Undergoing Laparoscopic Surgery|Completed||N/A|90|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-06-01 00:10:27.369986|2018-06-01 00:10:27.369986
NCT01052506|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-01-05|2010-01-19|2010-01-20|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects|A Randomized, Blinded, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Adult Volunteers|Completed||Phase 1|72|Actual|Biogen||2|||f||||f||||||||||2018-06-01 00:10:27.434567|2018-06-01 00:10:27.434567
NCT01052493|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-01-31|2010-01-19|2010-01-20|Estimate|||||||2011-01-31|2011-02-01|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects|A First Time in Human, Double Blind, Randomised, Placebo Controlled Dose Escalation Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects.|Completed||Phase 1|12|Anticipated|Imperial College London|||||f||||t||||||||||2018-06-01 00:10:27.496331|2018-06-01 00:10:27.496331
NCT01052480|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-16|2017-04-19||2017-08-03|2010-01-16|2010-01-20|Estimate|2017-04-19|2017-05-23|Actual||||2017-08-03|2017-09-05|Actual|December 2010|Actual|2010-12-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|IRC002||Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza|A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational Anti-Influenza Immune Plasma for the Treatment of Influenza (IRC002)|Completed||Phase 2|98|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-06-01 00:10:27.702157|2018-06-01 00:10:27.702157
NCT01052467|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2014-02-18|2010-01-19|2010-01-20|Estimate|||||||2014-02-18|2014-02-19|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)|Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)|Completed|||724|Actual|LEO Pharma|||||f||||f||||||||||2018-06-01 00:10:28.542635|2018-06-01 00:10:28.542635
NCT01052454|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|September 2005||2005-09-30|January 2010|2010-01-31||||May 2009|Actual|2009-05-31||Interventional|||Mindfulness-Based Stress Reduction for Hot Flashes|Pilot Study to Assess the Feasibility of MBSR for Hot Flashes|Completed||Early Phase 1|110|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 00:10:28.604545|2018-06-01 00:10:28.604545
NCT01052441|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2012-12-08|2010-01-19|2010-01-20|Estimate|||||||2012-12-08|2012-12-11|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|ICARUS||Iodine Content for Diagnostic AccuRacy and Patient Comfort For Individuals Undergoing Cardiac Computed Tomography (CT) Scanning|Iodine Content for Diagnostic AccuRacy and Patient Comfort For Individuals Undergoing Cardiac CT Scanning: The Multicenter ICARUS Trial|Completed|||250|Anticipated|MDDX LLC|||1||f||||f||||||||||2018-06-01 00:10:28.671997|2018-06-01 00:10:28.671997
NCT01052428|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2011-07-29||2012-11-16|2010-01-19|2010-01-20|Estimate|2012-03-20|2012-04-16|Estimate||||2012-11-16|2012-11-22|Estimate|August 2004||2004-08-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|P1A1||Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)|Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)|Completed||Phase 2/Phase 3|38|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 00:10:28.77734|2018-06-01 00:10:28.77734
NCT01052415|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2016-11-23|2010-01-19|2010-01-20|Estimate|||||||2016-11-23|2016-11-28|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||POL and Access Intervention to Reduce HIV Stigma Among Service Providers in China|POL and Access Intervention to Reduce HIV Stigma Among Service Providers in China|Completed||N/A|5400|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:10:29.28044|2018-06-01 00:10:29.28044
NCT01052402|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2015-10-07|2010-01-19|2010-01-20|Estimate|||||||2015-10-07|2015-10-09|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents|A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years|Completed||Phase 1/Phase 2|684|Actual|Ology Bioservices||2|||f||||t||||||||||2018-06-01 00:10:29.367422|2018-06-01 00:10:29.367422
NCT01052389|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2014-04-09|2010-01-19|2010-01-20|Estimate|||||||2014-04-09|2014-04-10|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|GiSAS||Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia|GiSAS Trial: Aripiprazole, Olanzapine, and Haloperidol in the Long Term Treatment of Schizophrenia.|Completed||Phase 4|300|Actual|Mario Negri Institute for Pharmacological Research||3|||f||||t||||||||||2018-06-01 00:10:29.45808|2018-06-01 00:10:29.45808
NCT01052376|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-05-22|2010-01-19|2010-01-20|Estimate|||||||2012-05-22|2012-05-23|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|January 2011|Actual|2011-01-31|||||Interventional|||Endomicrocancer: Confocal Endomicroscopy in Patients With High Risk of Colorectal Cancer|Confocal Endomicroscopy in Patients With High Risk of Colorectal Cancer: Potential for Diagnosis of Early Neoplasia|Terminated||N/A|73|Actual|Nantes University Hospital|||||f||||t||||||||||2018-06-01 00:10:29.553513|2018-06-01 00:10:29.553513
NCT01052363|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-02-07|2010-01-19|2010-01-20|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2010||2010-01-31|February 2017|2017-02-28||||||||Interventional|||OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas|OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas|Withdrawn||Phase 1|0|Actual|West Virginia University||2||No funding|f||||t||||||||No||2018-06-01 00:10:29.62795|2018-06-01 00:10:29.62795
NCT01052350|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-11-01|2010-01-15|2010-01-20|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2006||2006-08-31|November 2017|2017-11-30|July 2030|Anticipated|2030-07-31|July 2030|Anticipated|2030-07-31||Observational|||PET Imaging in Parkinson Disease Dementia|Investigations of Dementia in Parkinson Disease|Active, not recruiting|||320|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 00:10:29.708743|2018-06-01 00:10:29.708743
NCT01052337|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|April 2009||2009-04-30|December 2009|2009-12-31||||March 2010|Anticipated|2010-03-31||Interventional|Blade runner||Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy|Anesthesia Induction With Propofol or Sevoflurane in Patients Undergoing Fiberoptic Intubation for Cervical Myelopathy: Effects on Heamodynamics|Unknown status|Recruiting|Phase 4|116|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-06-01 00:10:29.759628|2018-06-01 00:10:29.759628
NCT01052324|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2011-05-12|2010-01-19|2010-01-20|Estimate|||||||2011-05-12|2011-05-13|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation|The Effect Site Concentration of Remifentanil for Conscious Sedation During Awake Nasotracheal Fiberoptic Intubation|Completed||Phase 4|19|Actual|Yonsei University|||||f||||t||||||||||2018-06-01 00:10:29.819691|2018-06-01 00:10:29.819691
NCT01052311|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-16|||2016-10-18|2010-01-16|2010-01-20|Estimate|||||||2016-10-18|2016-10-19|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients|The Impact of Tredaptive (ER Niacin/Laropiprant) Compared to Placebo on Brachial Artery Endothelial Function in Patients With Stable Coronary Artery Disease on Statin Therapy|Terminated||Phase 4|8|Actual|Sheba Medical Center||2||The sponsor decided to withdraw study drug from market|f||||f||||||||No||2018-06-01 00:10:29.866467|2018-06-01 00:10:29.866467
NCT01052298|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-05-29|2010-01-19|2010-01-20|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)|Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (GOLD I - II), Following Inhalation of Ciprofloxacin PulmoSphere Inhalation Powder.|Completed||Phase 1|25|Actual|Bayer||4|||f||||f||||||||||2018-06-01 00:10:29.930926|2018-06-01 00:10:29.930926
NCT01052285|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-11-17|2010-01-19|2010-01-20|Estimate|||||||2011-11-17|2011-11-18|Estimate|June 2010||2010-06-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||The Efficacy of Transversus Abdominis Plane Block After Groin Hernia Repair|The Efficacy of Transversus Abdominis Plane Block Versus Placebo Versus Local Infiltration in Patients Undergoing Groin Hernia Repair in Day Case Surgery.|Completed||Phase 4|90|Actual|Glostrup University Hospital, Copenhagen||3|||f||||t||||||||||2018-06-01 00:10:30.082559|2018-06-01 00:10:30.082559
NCT01052272|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2012-03-20||2012-11-16|2010-01-19|2010-01-20|Estimate|2012-11-16|2012-12-17|Estimate||||2012-11-16|2012-12-17|Estimate|July 2005||2005-07-31|November 2012|2012-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|P3||Impact of Diabetes on Left Ventricular Remodeling|Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.|Completed||Phase 2/Phase 3|72|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-06-01 00:10:30.193956|2018-06-01 00:10:30.193956
NCT01052259|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2014-01-07|2010-01-19|2010-01-20|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection|Pilot Study of Cycling Treatment of Deoxyspergualin in Biopsy-proven Chronic Rejection of Kidney Transplantation|Terminated||N/A|35|Actual|Nippon Kayaku Co.,Ltd.||1||Insufficient patient enrollment|f||||f||||||||||2018-06-01 00:10:31.140048|2018-06-01 00:10:31.140048
NCT01052246|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Pulsed Dye Laser Treatment of Acne Vulgaris|The Pulsed Dye Laser as an Adjuvant Treatment Modality in Acne Vulgaris - a Randomized Controlled Single Blinded Trial|Completed||N/A|80|Actual|Laserklinik Karlsruhe||2|||f||||f||||||||||2018-06-01 00:10:31.221752|2018-06-01 00:10:31.221752
NCT01052233|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2015-01-20|2010-01-19|2010-01-20|Estimate|||||||2015-01-20|2015-01-21|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|January 2024|Anticipated|2024-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Development of Knee Osteoarthritis After Arthroscopic Partial Resection of Degenerative Meniscus Tear|Effect of Arthroscopic Partial Resection of Degenerative Meniscus Tear on Development of Knee Osteoarthritis: Which is the Chicken and the Egg?|Enrolling by invitation||Phase 4|160|Anticipated|University of Tampere||2|||f||||t||||||||||2018-06-01 00:10:31.297845|2018-06-01 00:10:31.297845
NCT01052220|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2017-11-01|2010-01-19|2010-01-20|Estimate|||||||2017-11-01|2017-11-06|Actual|June 2009||2009-06-30|November 2017|2017-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention|Improving Blood Pressure Control in End-Stage Renal Disease Through a Supportive-Educative Nursing Intervention|Completed||N/A|118|Actual|Wayne State University||2|||f||||t||||||||||2018-06-01 00:10:31.378139|2018-06-01 00:10:31.378139
NCT01052207|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2013-12-09||2015-05-11|2010-01-15|2010-01-20|Estimate|2014-09-19|2014-09-22|Estimate||||2015-05-11|2015-06-04|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|OxStress||Pilot Study Assessing Oxidative Stress in Children|Prevalence of Oxidative Stress in Critically Ill Children and Its Relationship to Adrenal Insufficiency; a Pilot Study|Completed|||102|Actual|Emory University|||2||f||||f||||||Samples Without DNA|"~     Serum from critically ill patients~   "|||2018-06-01 00:10:31.483731|2018-06-01 00:10:31.483731
NCT01052194|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18||2012-12-12|2012-12-12|2010-01-18|2010-01-20|Estimate||||2012-12-12|2012-12-13|Estimate|2012-12-12|2012-12-13|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis|A 12-week, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|206|Actual|Vertex Pharmaceuticals Incorporated||5|||f||||t||||||||||2018-06-01 00:10:31.79773|2018-06-01 00:10:31.79773
NCT01052181|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-16|||2012-06-05|2010-01-19|2010-01-20|Estimate|||||||2012-06-05|2012-06-06|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|LongtermVitD||A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity|A Double Blind Randomized Control Trial to Study the Effect of Long Term Vitamin D Supplementation on Peripheral Insulin Sensitivity in Apparently Healthy Middle Aged Centrally Obese Adults|Unknown status|Active, not recruiting|Phase 4|300|Anticipated|Sitaram Bhartia Institute of Science and Research||2|||f||||t||||||||||2018-06-01 00:10:31.951288|2018-06-01 00:10:31.951288
NCT01052168|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2013-03-22|2010-01-18|2010-01-20|Estimate|||||||2013-03-22|2013-03-25|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Do Motion Metrics Lead to Improved Skill Acquisition on Simulators?|Do Motion Metrics Lead to Improved Skill Acquisition on Simulators?|Completed||N/A|42|Actual|Carolinas Healthcare System||3|||f||||t||||||||||2018-06-01 00:10:32.062334|2018-06-01 00:10:32.062334
NCT01052155|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2011-03-11|2010-01-18|2010-01-20|Estimate|||||||2011-03-11|2011-03-14|Estimate|February 2010||2010-02-28|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients|Accuracy of Point of Care (POC) or In-office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective Analysis of Immunoassay and Liquid Chromatography Tandem Mass Spectometry (LC/MS/MS)|Completed|||1000|Anticipated|Pain Management Center of Paducah|||||f||||t||||||||||2018-06-01 00:10:32.149874|2018-06-01 00:10:32.149874
NCT01052142|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2012-04-10|2010-01-18|2010-01-20|Estimate|||||||2012-04-10|2012-04-11|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma|A Phase I Open-label Study of the Safety and Immunogenicity of Escalating Doses of Lipovaxin-MM, a Novel Melanoma Immunotherapeutic, in Patients With Metastatic Melanoma|Completed||Phase 1|12|Actual|Lipotek Pty Ltd||1|||f||||t||||||||||2018-06-01 00:10:32.257592|2018-06-01 00:10:32.257592
NCT01052129|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-05-26|2010-01-19|2010-01-20|Estimate|||||||2010-05-26|2010-05-27|Estimate|May 2006||2006-05-31|May 2010|2010-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fasting Condition|Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:10:32.327604|2018-06-01 00:10:32.327604
NCT01052116|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2015-12-10||2015-12-10|2010-01-19|2010-01-20|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|SOYA||The Study of Soy Isoflavones in Asthma|The Study of Soy Isoflavones in Asthma|Completed||Phase 4|386|Actual|American Lung Association Asthma Clinical Research Centers||2|||f||||t||||||||||2018-06-01 00:10:32.412285|2018-06-01 00:10:32.412285
NCT01052103|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13||2012-09-18|2012-09-18|2010-01-19|2010-01-20|Estimate||||2012-09-18|2012-09-25|Estimate|2012-09-18|2012-09-25|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms|A 17-Week, Phase 2, Multicenter, Randomized, Double-Blind Study of Treatment With LY2140023 Combined With Standard of Care Compared to Placebo Combined With Standard of Care in the Treatment of Patients With Prominent Negative Symptoms of Schizophrenia|Completed||Phase 2|280|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 00:10:32.657135|2018-06-01 00:10:32.657135
NCT01052090|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-17|||2013-11-24|2010-01-19|2010-01-20|Estimate|||||||2013-11-24|2013-11-26|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|ENCHAMP||Safety and Efficacy Study in Hepatitis C Patients With PHN121|Safety and Efficacy Study in Non-Responder Hepatitis C Genotype 1 Patients With PHN121|Terminated||Phase 1/Phase 2|12|Actual|PhytoHealth Corporation||1|||f||||t||||||||||2018-06-01 00:10:32.732054|2018-06-01 00:10:32.732054
NCT01052077|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2015-08-04|2012-11-01|2015-09-30|2010-01-15|2010-01-20|Estimate|2015-09-30|2015-11-02|Estimate|2012-11-01|2012-11-05|Estimate|2015-09-30|2015-11-02|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|STEP-D222||Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPDC-34712 (1 to 3 mg/Day) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder.|Completed||Phase 2|773|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 00:10:32.81605|2018-06-01 00:10:32.81605
NCT01052064|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|April 2009||2009-04-30|January 2010|2010-01-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Transcranial Magnetic Stimulation in Children With Attention Deficit Hyperactivity Disorder (ADHD). A Safety Study|Therapy With rTMS in Children With Attention Deficit and Hyperactivity Disorder. Phase 1 Study.|Unknown status|Recruiting|Phase 1|20|Anticipated|International Center for Neurological Restoration, Cuba||1|||f||||t||||||||||2018-06-01 00:10:33.715235|2018-06-01 00:10:33.715235
NCT01052051|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2016-09-09|2010-01-19|2010-01-20|Estimate|||||||2016-09-09|2016-09-13|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|CAPS||Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women|Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women|Completed||Phase 3|2303|Actual|Creighton University||2|||f||||t||||||||||2018-06-01 00:10:33.809186|2018-06-01 00:10:33.809186
NCT01052038|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2011-10-31||2012-04-05|2010-01-19|2010-01-20|Estimate|2012-04-05|2012-05-02|Estimate||||2012-04-05|2012-05-02|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Post Operative Sore Throat and Dexamethasone|The Effect of Systemic Prophylactic Dexamethasone on the Incidence of Postoperative Sore Throat in Patients Undergoing Ambulatory Laparoscopic Gynecologic Surgery: A Prospective, Randomized, Double Blinded, Placebo Controlled Trial|Completed||Phase 4|120|Actual|Northwestern University|Study was limited to 2 doses of dexamethasone and was underpowered to assess side effects such as hyperglycemia or delayed wound healing. Study was limited to a single type of surgery and results may differ in different types of surgery.|3|||f||||f||||||||||2018-06-01 00:10:33.915078|2018-06-01 00:10:33.915078
NCT01052025|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2009||2009-08-31|March 2009|2009-03-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance|Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance|Unknown status|Recruiting|Phase 4|200|Anticipated|Srinakharinwirot University||2|||f||||f||||||||||2018-06-01 00:10:34.354281|2018-06-01 00:10:34.354281
NCT01052012|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18||2011-12-20|2011-12-20|2010-01-18|2010-01-20|Estimate||||2011-12-20|2011-12-22|Estimate|2011-12-20|2011-12-22|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|BESST||Bupivacaine Effectiveness and Safety in SABER™ Trial|Bupivacaine Effectiveness and Safety in SABER™ Trial (BESST)|Completed||Phase 3|305|Actual|Durect||3|||f||||f||||||||||2018-06-01 00:10:34.449871|2018-06-01 00:10:34.449871
NCT01051999|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2015-01-13|2010-01-19|2010-01-20|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|CFG||Glutamine Supplementation in Cystic Fibrosis|Glutamine Supplementation and Immunity in Adults With Cystic Fibrosis|Completed||Phase 2|17|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:10:34.567954|2018-06-01 00:10:34.567954
NCT01051986|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-17|2013-05-29||2013-11-21|2010-01-17|2010-01-20|Estimate|2013-11-21|2014-01-10|Estimate||||2013-11-21|2014-01-10|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SAVERITA||A Prospective Randomized Study for Comparison of Y-Composite Grafts|A Randomized Comparison of the SAphenous VEin Versus Right Internal Thoracic Artery as a Y-Composite Graft (SAVE-RITA Trial)|Completed||N/A|224|Actual|Seoul National University Hospital|"the current study is not a multicenter “all-comers” study, although it is a prospective, randomized, controlled trial.~The 1-year graft patency rates and clinical outcomes of 34 months do not provide sufficient data to reach a definite conclusion"|2|||f||||f||||||||||2018-06-01 00:10:34.641436|2018-06-01 00:10:34.641436
NCT01051973|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2012-01-03|2010-01-19|2010-01-20|Estimate|||||||2012-01-03|2012-01-05|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cognitive Behavior Therapy (CBT) Compared to Stress Management for Irritable Bowel Syndrome|Internet-delivered Cognitive Behavior Therapy Compared to Stress Management in the Treatment of Irritable Bowel Syndrome - A Randomized Controlled Study.|Completed||N/A|200|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 00:10:34.897041|2018-06-01 00:10:34.897041
NCT01051960|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2018-03-05|2010-01-19|2010-01-20|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2009|Actual|2009-03-31|March 2018|2018-03-31|January 2011|Actual|2011-01-31|June 2010|Actual|2010-06-30||Interventional|||Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan|Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study|Completed||Phase 4|15|Actual|University of California, Los Angeles||1|||f||||f||||||||No||2018-06-01 00:10:34.962026|2018-06-01 00:10:34.962026
NCT01051947|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2011-07-29|2010-01-19|2010-01-20|Estimate|||||||2011-07-29|2011-08-01|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Impact of Nebivolol on Central Aortic Pressure|Impact of Nebivolol on Central Aortic Pressure|Withdrawn||N/A|0|Actual|Creighton University||2||Similar study already published|f||||f||||||||||2018-06-01 00:10:35.056282|2018-06-01 00:10:35.056282
NCT01051934|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-16|||2017-06-30|2010-01-16|2010-01-20|Estimate|||||||2017-06-30|2017-07-02|Actual|December 29, 2009||2009-12-29|September 28, 2011|2011-09-28|September 28, 2011|Actual|2011-09-28|September 28, 2011|Actual|2011-09-28||Interventional|||A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma|A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma|Completed||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:10:35.1179|2018-06-01 00:10:35.1179
NCT01051921|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|2012-03-13||2012-04-10|2010-01-19|2010-01-20|Estimate|2012-03-14|2012-04-10|Estimate||||2012-04-10|2012-04-16|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|CTS-1027-04||Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders|An Open-Label Trial of Pegylated Interferon Plus Ribavirin in Combination With CTS-1027 in HCV Null-Responders|Completed||Phase 2|67|Actual|Conatus Pharmaceuticals Inc.|Although this study was completed, the entire CTS-1027 program was discontinued prior to database lock. Hence, only a safety analysis was carried out for this study. Analysis of the primary and secondary efficacy measures was not completed.|1|||f||||t||||||||||2018-06-01 00:10:35.188227|2018-06-01 00:10:35.188227
NCT01051895|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2017-08-04|2010-01-19|2010-01-20|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2010||2010-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|September 2015|Actual|2015-09-30||Interventional|CoHIPP||Colposcopy Versus HPV Testing to Identify Persistent Cervical Precancers|Randomized Controlled Trial Comparing Routine Colposcopy to HPV Testing to Identify Persistent or Recurrent High Grade Cervical Cancer Precursors|Active, not recruiting||N/A|2253|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-06-01 00:10:35.397333|2018-06-01 00:10:35.397333
NCT01051882|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-17|||2013-11-06|2010-01-19|2010-01-20|Estimate|||||||2013-11-06|2013-11-07|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.|A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.|Completed||Phase 1/Phase 2|12|Actual|Hadassah Medical Organization||1|||f||||||||||||||2018-06-01 00:10:35.466113|2018-06-01 00:10:35.466113
NCT01051869|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2017-11-23|2010-01-19|2010-01-20|Estimate|||||||2017-11-23|2017-11-27|Actual|September 2010||2010-09-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Simple Decompression Versus Anterior Transposition of the Ulnar Nerve|A Multicentre, Randomized Trial of Simple Decompression Versus Anterior Transposition of the Ulnar Nerve for Acute, Displaced Fractures of the Distal Humerus Treated With Plate Fixation|Active, not recruiting||N/A|56|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 00:10:36.511961|2018-06-01 00:10:36.511961
NCT01051856|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2015-05-29||2015-06-18|2010-01-19|2010-01-20|Estimate|2015-05-29|2015-06-12|Estimate||||2015-06-18|2015-07-15|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|PLATS||TissueLink Versus SEAMGUARD After Distal Pancreatectomy|A Multicenter Mayo-initiated Randomized Controlled Trial Comparing Pancreatic Leaks After TissueLink vs SEAMGUARD After Distal Pancreatectomy (PLATS)|Terminated||Phase 4|68|Actual|Mayo Clinic|The trial closed early due to poor accrual of subjects.|2||The trial closed early due to poor accrual.|f||||t||||||||||2018-06-01 00:10:36.600752|2018-06-01 00:10:36.600752
NCT01051843|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|AMAC||Orofacial Difficulties in Rooming-in|Orofacial Difficulties During the Maternal Breastfeeding in Rooming-in|Completed|||29|Actual|Fortaleza University|||||f||||t||||||||||2018-06-01 00:10:36.841853|2018-06-01 00:10:36.841853
NCT01051830|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-17|||2017-02-06|2010-01-19|2010-01-20|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2010||2010-01-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Care Model for Hip-fractured Elderly Persons With Diabetes Mellitus|A Care Model for Hip-fractured Elderly Persons With Diabetes Mellitus|Completed||N/A|176|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-06-01 00:10:36.885252|2018-06-01 00:10:36.885252
NCT01051635|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2018-05-26|2010-01-15|2010-01-18|Estimate|||||||2018-05-26|2018-05-30|Actual|January 13, 2010||2010-01-13|May 25, 2018|2018-05-25|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas|A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas|Completed||Phase 1|55|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:10:39.115742|2018-06-01 00:10:39.115742
NCT01051817|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2015-02-12||2015-02-12|2010-01-19|2010-01-20|Estimate|2015-02-12|2015-02-27|Estimate||||2015-02-12|2015-02-27|Estimate|December 2009||2009-12-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler|A Randomized, Multi-center, Double-blind, Proof-of-concept Study to Assess the Effect of Multiple Infusion of AIN457 (10 mg/kg) Versus Placebo on Disease Activity as Measured by MRI Scans Over a 24 Week Period in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|73|Actual|Novartis||2|||f||||f||||||||||2018-06-01 00:10:36.981679|2018-06-01 00:10:36.981679
NCT01051804|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2012-01-31|2010-01-19|2010-01-20|Estimate|||||||2012-01-31|2012-02-02|Estimate|November 2009||2009-11-30|January 2012|2012-01-31||||July 2010|Actual|2010-07-31||Interventional|||Evaluation of the Repeated Usage of Systane Ultra Eyedrop||Completed||Phase 4|57|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:10:37.462958|2018-06-01 00:10:37.462958
NCT01051791|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|2017-11-20||2017-11-20|2010-01-18|2010-01-20|Estimate|2017-11-20|2017-12-19|Actual||||2017-11-20|2017-12-19|Actual|January 2010||2010-01-31|November 2017|2017-11-30|August 5, 2016|Actual|2016-08-05|April 26, 2011|Actual|2011-04-26||Interventional|||Phase II Study of RAD001 Head and Neck Cancer|Phase II Study of RAD001 for Treatment of Refractory, Recurrent, Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|13|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 00:10:37.56717|2018-06-01 00:10:37.56717
NCT01051778|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|2010-05-10||2011-07-29|2010-01-19|2010-01-20|Estimate|2011-07-29|2011-08-29|Estimate||||2011-07-29|2011-08-29|Estimate|June 2006||2006-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome|Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial|Completed||Phase 2|60|Actual|Cairo University||2|||f||||t||||||||||2018-06-01 00:10:37.81331|2018-06-01 00:10:37.81331
NCT01051765|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-19|||2010-01-19|2010-01-19|2010-01-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2009||2009-08-31|May 2009|2009-05-31|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial|Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Peking University||1|||f||||t||||||||||2018-06-01 00:10:38.063272|2018-06-01 00:10:38.063272
NCT01051752|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-18|||2012-05-21|2010-01-19|2010-01-20|Estimate|||||||2012-05-21|2012-05-22|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Observational|NTM||PK and PD of Drugs for Nontuberculous Mycobacterial Diseases in Dutch Patients|Pharmacokinetics and Pharmacodynamics of Drugs for Nontuberculous Mycobacterial Diseases in Dutch Patients|Completed|||26|Actual|Radboud University|||1||f||||f||||||Samples Without DNA|"~     Blood samples for pharmacokinetic analysis will be retained. Sputum samples for~     pharmacodynamic analysis will be retained.~   "|||2018-06-01 00:10:38.12534|2018-06-01 00:10:38.12534
NCT01051739|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2016-10-25||2017-02-13|2010-01-15|2010-01-20|Estimate|2016-12-19|2017-02-10|Actual||||2017-02-13|2017-03-21|Actual|July 2010||2010-07-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|VIPII||Variability in Perimetry Study|Improved Assessment of Visual Field Change|Completed|||180|Actual|VA Office of Research and Development|not all subjects completed the study (dropouts).||2||f||||f||||||||Undecided||2018-06-01 00:10:38.190921|2018-06-01 00:10:38.190921
NCT01051726|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2013-01-15|2010-01-15|2010-01-18|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Effects of Aromatherapy on Childbirth|Effects of Aromatherapy on Childbirth|Unknown status|Recruiting|Phase 2|90|Anticipated|University of Nottingham||3|||f||||f||||||||||2018-06-01 00:10:38.408609|2018-06-01 00:10:38.408609
NCT01051713|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-11-10|2010-01-15|2010-01-18|Estimate|||||||2016-11-10|2016-11-11|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|ENGAGED||ENGAGED: E-Networks Guiding Adherence to Goals for Exercise and Diet|ENGAGED: E-Networks Guiding Adherence to Goals for Exercise and Diet|Completed||Phase 1/Phase 2|96|Actual|Northwestern University||3|||f||||t||||||||||2018-06-01 00:10:38.487132|2018-06-01 00:10:38.487132
NCT01051700|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2017-11-10|2010-01-14|2010-01-18|Estimate|||||||2017-11-10|2017-11-14|Actual|January 12, 2010|Actual|2010-01-12|November 2017|2017-11-30|May 27, 2010|Actual|2010-05-27|May 27, 2010|Actual|2010-05-27||Interventional|||A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans|A Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Oral Doses of Pazopanib in Healthy Adult Subjects|Completed||Phase 1|72|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 00:10:38.661686|2018-06-01 00:10:38.661686
NCT01051687|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-01-15|2010-01-15|2010-01-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|April 2009||2009-04-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Botulinum Toxin Treatment for Localized Vitiligo|Botulinum Toxin Treatment for Localized Vitiligo|Completed||Phase 4|10|Actual|King Saud University||2|||f||||t||||||||||2018-06-01 00:10:38.745955|2018-06-01 00:10:38.745955
NCT01051674|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2014-06-27|2010-01-15|2010-01-18|Estimate|||||||2014-06-27|2014-07-01|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss|A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss in Obese Individuals With or Without Type 2 Diabetes|Completed||Phase 4|173|Actual|Loma Linda University||2|||f||||f||||||||||2018-06-01 00:10:38.814984|2018-06-01 00:10:38.814984
NCT01051661|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14||2011-11-10|2017-01-16|2010-01-14|2010-01-18|Estimate||||2011-11-10|2011-11-16|Estimate|2017-01-16|2017-01-18|Estimate|February 2010||2010-02-28|January 2017|2017-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age|A Study to Evaluate the Safety and Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children Aged 6 Months to Less Than 10 Years of Age|Completed||Phase 3|6154|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:10:38.891547|2018-06-01 00:10:38.891547
NCT01051648|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-01-15|2010-01-15|2010-01-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|December 2007||2007-12-31|February 2008|2008-02-29|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Triamcinolone Assisted Anterior Vitrectomy|Triamcinolone Assisted Anterior Vitrectomy in Complicated Cataract Surgery and Anterior Segment Reconstruction|Completed||Phase 2|10|Actual|Cairo University||1|||f||||t||||||||||2018-06-01 00:10:39.028634|2018-06-01 00:10:39.028634
NCT01051622|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2014-05-29|2010-01-14|2010-01-18|Estimate|||||||2014-05-29|2014-06-02|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||PBMC (Peripheral Blood Mononuclear Cells) /Lymphocyte SPECT (Single Photon Emission Computerized Tomography) Imaging in Crohn's Disease|An Exploratory SPECT Imaging Study to Assess the Utility of High-specific Activity 99mTc-HMPAO Labeling as a Tool to Detect PBMC and Lymphocyte Trafficking in the Small Bowel or Ileo-caecal Region of Crohn's Disease Patients|Completed||Phase 1|13|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:10:39.202187|2018-06-01 00:10:39.202187
NCT01051609|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-09-07|2010-01-15|2010-01-18|Estimate|||||||2016-09-07|2016-09-09|Estimate|May 2010||2010-05-31|September 2016|2016-09-30||||July 2013|Actual|2013-07-31||Observational|||Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients|Prospective Study of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients|Completed|||27|Actual|Jonsson Comprehensive Cancer Center|||1||f||||t||||||||||2018-06-01 00:10:39.28304|2018-06-01 00:10:39.28304
NCT01051596|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2018-05-06|2010-01-15|2010-01-18|Estimate|||||||2018-05-06|2018-05-11|Actual|September 2009||2009-09-30|May 2018|2018-05-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer|A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer|Completed||Phase 2|75|Actual|Georgetown University||1|||f||||t||||||||||2018-06-01 00:10:39.351975|2018-06-01 00:10:39.351975
NCT01051583|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-15|2010-01-15|2010-01-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma|Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma|Completed||Phase 2|16|Actual|Cairo University||2|||f||||t||||||||||2018-06-01 00:10:39.467297|2018-06-01 00:10:39.467297
NCT01051570|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2014-08-09||2018-02-11|2010-01-15|2010-01-18|Estimate|2014-08-09|2014-08-25|Estimate||||2018-02-11|2018-03-12|Actual|February 2010||2010-02-28|February 2018|2018-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel|Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.|Completed||Phase 2|26|Actual|Barbara Ann Karmanos Cancer Institute|Small sample size; Correlates were conducted in <50% of the patients.|1|||f||||t||||||||||2018-06-01 00:10:39.555543|2018-06-01 00:10:39.555543
NCT01051557|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2016-03-17||2017-10-31|2010-01-15|2010-01-18|Estimate|2016-03-17|2016-04-18|Estimate||||2017-10-31|2017-12-06|Actual|January 27, 2010|Actual|2010-01-27|October 2017|2017-10-31|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Interventional|||Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma|Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas|Terminated||Phase 1/Phase 2|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:10:39.813435|2018-06-01 00:10:39.813435
NCT01051544|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2018-04-12|2010-01-15|2010-01-18|Estimate|||||||2018-04-12|2018-04-13|Actual|September 25, 2009|Actual|2009-09-25|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|RESIST NAIVE||Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive|Randomised Study of First TIME Immunotolerance Induction in Patients With Severe Type A Haemophilia With Inhibitor at High Risk of Failure: Comparison of Induction of Immune Tolerance With FVIII Concentrates With or Without Von Willebrand Factor Acronym: RES.I.S.T.- Naive|Active, not recruiting||N/A|148|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 00:10:40.560837|2018-06-01 00:10:40.560837
NCT01051531|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2014-03-27|2010-01-15|2010-01-18|Estimate|||||||2014-03-27|2014-03-28|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia|Safety, Tolerability, and Treatment Response of Paliperidone Palmitate in Subjects With Schizophrenia When Switching From Oral Antipsychotics|Completed||Phase 3|546|Actual|Johnson & Johnson Pte Ltd||1|||f||||f||||||||||2018-06-01 00:10:40.738942|2018-06-01 00:10:40.738942
NCT01051518|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-06-20|2010-01-15|2010-01-18|Estimate|||||||2017-06-20|2017-06-22|Actual|May 2006||2006-05-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|February 2009|Actual|2009-02-28||Interventional|||Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)|Clinical Evaluation of Percutaneous Implantation of the CoreValve Aortic Valve Prosthesis. Safety and Performance Study on Patients at High Risk for Surgical Valve Replacement (18Fr Safety and Efficacy Study)|Completed||N/A|126|Actual|Medtronic Cardiovascular||1|||f||||t||||||||||2018-06-01 00:10:40.884106|2018-06-01 00:10:40.884106
NCT01051505|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-06-24|2010-01-15|2010-01-18|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Administration of Multiple Ascending Doses for 8 Days in Healthy Male or Female Subjects|Completed||Phase 1|8|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:10:40.980139|2018-06-01 00:10:40.980139
NCT01051492|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2014-01-13|2010-01-15|2010-01-18|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2010||2010-01-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Observational|||Development of Predictive Biomarkers and Novel Approached to Therapy in Breast Cancer||Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 00:10:41.049985|2018-06-01 00:10:41.049985
NCT01051479|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-12-04|2010-01-15|2010-01-18|Estimate|||||||2017-12-04|2017-12-05|Actual|March 2010||2010-03-31|April 2017|2017-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer|A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer|Completed||Phase 1|22|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-06-01 00:10:41.109071|2018-06-01 00:10:41.109071
NCT01051297|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-09-29|2010-01-15|2010-01-18|Estimate|||||||2016-09-29|2016-09-30|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|OSAVTE||Obstructive Sleep Apnea and Venous Thromboembolism|Patients With Obstructive Sleep Apnea (OSA), Independent of Obesity, Are at Increased Risk of Venous Thromboembolic Events (VTE)|Terminated|||85|Actual|University of Missouri-Columbia|||5|Investigator left the institution|f||||f||||||||No||2018-06-01 00:10:43.732115|2018-06-01 00:10:43.732115
NCT01051466|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2014-02-17||2014-10-02|2010-01-15|2010-01-18|Estimate|2014-02-17|2014-04-02|Estimate||||2014-10-02|2014-10-10|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All enrolled participants.|A Study of the Neurobiology of Depression|Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects With Major Depressive Disorder|Completed||Phase 4|60|Actual|Eli Lilly and Company|Three healthy participants were identified as not meeting inclusion/exclusion criteria after enrollment. They were discontinued and excluded from secondary outcome analyses, but included in participant flow, primary outcome analyses, and safety.|2|||f||||f||||||||||2018-06-01 00:10:41.214002|2018-06-01 00:10:41.214002
NCT01051440|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2012-07-30||2012-12-19|2010-01-15|2010-01-18|Estimate|2012-12-19|2013-01-30|Estimate||||2012-12-19|2013-01-30|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression|A Magnetic Resonance Spectroscopy and fMRI Study of the Effects of Lisdexamfetamine on Bipolar Depression|Terminated||Phase 4|2|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.|The study was terminated before completion due to low enrollment. One subject was randomized to lisdexamfetamine and one was randomized to placebo. Therefore, it was not possible to obtain complete data.|2||Slow enrollment|f||||||||||||||2018-06-01 00:10:41.91007|2018-06-01 00:10:41.91007
NCT01051427|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2011-12-22|2010-01-15|2010-01-18|Estimate|||||||2011-12-22|2011-12-23|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|August 2012|Anticipated|2012-08-31|March 2012|Anticipated|2012-03-31||Interventional|||Control of Epistaxis With Surgiflo|Control of Epistaxis With Surgiflo|Terminated||N/A|3|Actual|Hospital Universitario Ramon y Cajal||2||"Now we use better procedures for the patient instead of nasal catheter for epistaxis. So it~   would be unethical to use the nasal catheter to complete the trial."|f||||t||||||||||2018-06-01 00:10:42.137819|2018-06-01 00:10:42.137819
NCT01051414|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15||2015-09-23|2015-09-23|2010-01-15|2010-01-18|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|May 2012|Actual|2012-05-31|September 2011|Actual|2011-09-30||Interventional|||An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject|A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection|Completed||Phase 2|43|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:10:42.211333|2018-06-01 00:10:42.211333
NCT01051401|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-05-25|2010-01-15|2010-01-18|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2010||2010-01-31|February 2017|2017-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer|Statin Therapy as a Protective Technique for Potential Cardiovascular Event Occurrences Among Breast Cancer Patients Undergoing Chemotherapy Treatment|Terminated||Phase 1|5|Actual|Wake Forest University Health Sciences||2||slow accrual|f||||t|t|f||||||||2018-06-01 00:10:42.283871|2018-06-01 00:10:42.283871
NCT01051388|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2011-04-01|2010-01-15|2010-01-18|Estimate|||||||2011-04-01|2011-04-04|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|CARE||Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation|Prophylactic Efficacy of Proton Pump Inhibitor on Recurrence of Peptic Ulcer in Patients Continuously Treated With Low-dose Aspirin－Randomized, Multi-center, Single-blinded, Parallel-group, Comparative Study|Completed||Phase 3|280|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||3|||f||||f||||||||||2018-06-01 00:10:42.352224|2018-06-01 00:10:42.352224
NCT01051375|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-05-10|2010-01-15|2010-01-18|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Examining the Effectiveness of a Wait List Intervention for the Management of Adolescent Eating Disorders|Examining the Effectiveness of a Wait List Intervention for the Management of Adolescent Eating Disorders|Completed||N/A|51|Actual|University of Ottawa||2|||f||||f||||||||||2018-06-01 00:10:42.421309|2018-06-01 00:10:42.421309
NCT01051362|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-01-15|2010-01-15|2010-01-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|February 2006||2006-02-28|January 2006|2006-01-31|November 2011|Anticipated|2011-11-30|February 2011|Anticipated|2011-02-28||Interventional|||Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer|Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|48|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||1|||f||||t||||||||||2018-06-01 00:10:42.484202|2018-06-01 00:10:42.484202
NCT01051349|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-10-13|2010-01-15|2010-01-18|Estimate|||||||2016-10-13|2016-10-17|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SELECTED||Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis|A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)|Completed||Phase 2|410|Actual|Biogen||1|||f||||t||||||||||2018-06-01 00:10:42.565648|2018-06-01 00:10:42.565648
NCT01051336|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-01-15|2010-01-15|2010-01-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety and Tolerability Study of the Taris Placebo System|Phase I Safety and Tolerability Study of the Taris Placebo System (A Novel Bladder Drug Delivery Platform)|Completed||Phase 1|10|Actual|TARIS Biomedical, Inc.||2|||f||||f||||||||||2018-06-01 00:10:42.842396|2018-06-01 00:10:42.842396
NCT01051323|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2015-11-17||2015-11-17|2010-01-15|2010-01-18|Estimate|2015-11-17|2015-12-18|Estimate||||2015-11-17|2015-12-18|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational||Full Analysis Set (FAS): all participants for whom at least one hemoglobin value after the first application of methoxy polyethylene glycol-epoetin beta during the study course was documented.|An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia|Non-interventional Study to Investigate Hemoglobin Levels and Dose Over Time in the Daily Use of Mircera for Renal Anemia in Larger Centers, and to Detect Differences Between Standard of Care in the Centers|Completed|||1580|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-06-01 00:10:42.950502|2018-06-01 00:10:42.950502
NCT01051310|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-06-20|2010-01-15|2010-01-18|Estimate|||||||2017-06-20|2017-06-22|Actual|June 2008||2008-06-30|June 2017|2017-06-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|REDO||Medtronic CoreValve REDO Study|Feasibility Study of Percutaneous Aortic Valve Implantation With the Medtronic CoreValve System for Percutaneous Aortic Valve Replacement (PAVR) in Patients With a Failing Previously Surgically Implanted Aortic Bioprosthesis and Presenting a High Risk for Repeat Surgical Valve Replacement|Completed||N/A|17|Actual|Medtronic Cardiovascular||1|||f||||t||||||||||2018-06-01 00:10:43.656586|2018-06-01 00:10:43.656586
NCT01051284|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2012-04-23|2010-01-15|2010-01-18|Estimate|||||||2012-04-23|2012-04-24|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional|||A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer|A Pilot Study of Full Dose Gemcitabine and Hypofractionated Stereotactic Radiosurgery in the Treatment of Unresectable Pancreatic Cancer|Completed||Phase 1|14|Actual|Georgetown University||1|||f||||t||||||||||2018-06-01 00:10:43.787758|2018-06-01 00:10:43.787758
NCT01051271|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-01-15|2010-01-15|2010-01-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Prophylaxis Against Metoclopramide-Induced Akathisia||Completed||N/A|225|Actual|Pamukkale University||2|||f||||||||||||||2018-06-01 00:10:43.865723|2018-06-01 00:10:43.865723
NCT01051258|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2013-06-25|2010-01-15|2010-01-18|Estimate|||||||2013-06-25|2013-06-26|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|August 2011|Actual|2011-08-31||Interventional|||AeriSeal System for Lung Volume Reduction|A Study of the AeriSeal System for Lung Volume Reduction in Patients With Advanced Emphysema|Completed||Phase 1/Phase 2|55|Actual|Aeris Therapeutics|||||f||||t||||||||||2018-06-01 00:10:43.933834|2018-06-01 00:10:43.933834
NCT01051245|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2013-04-26|2010-01-15|2010-01-18|Estimate|||||||2013-04-26|2013-04-29|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Effectiveness of a High-risk Diabetic Patients Program|Effectiveness of a High-risk Diabetic Patients Program|Completed||N/A|223|Actual|Hospital Italiano de Buenos Aires||2|||f||||f||||||||||2018-06-01 00:10:44.009818|2018-06-01 00:10:44.009818
NCT01051232|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-04-22|2010-01-14|2010-01-18|Estimate|||||||2010-04-22|2010-04-26|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers|A Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 (Filibuvir) Following Single Oral Administrations Of PF-00868554 (Filibuvir) Under Fasting Conditions In Japanese Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:10:44.087305|2018-06-01 00:10:44.087305
NCT01051219|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2015-10-06|2010-01-15|2010-01-18|Estimate|||||||2015-10-06|2015-10-07|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|FELINE||Anti-Fibrotic Effects of Losartan In Nash Evaluation Study|A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis|Completed||Phase 3|45|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 00:10:44.162083|2018-06-01 00:10:44.162083
NCT01051206|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-07-09|2010-01-15|2010-01-18|Estimate|||||||2010-07-09|2010-07-12|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery|The Effect of 6% Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients Medicated With Antiplatelet Agents Prior to Off-Pump Coronary Bypass Graft Surgery|Completed||Phase 4|106|Anticipated|Yonsei University|||||f||||t||||||||||2018-06-01 00:10:44.256298|2018-06-01 00:10:44.256298
NCT01051193|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-04-20|2010-01-15|2010-01-18|Estimate|||||||2017-04-20|2017-04-21|Actual|January 5, 2010|Actual|2010-01-05|April 2017|2017-04-30|December 20, 2017|Anticipated|2017-12-20|December 20, 2017|Anticipated|2017-12-20||Interventional|||Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures|A Multicentre, Open-label, Extension Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy|Active, not recruiting||Phase 2/Phase 3|88|Actual|Novartis||1|||f|||||f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 00:10:44.310481|2018-06-01 00:10:44.310481
NCT01051180|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-04-03|2010-01-15|2010-01-18|Estimate|||||||2017-04-03|2017-04-05|Actual|January 2010|Actual|2010-01-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|||Is Doppler Necessary in Haemorrhoidal Artery Ligation Operation?|Haemorrhoidal Artery Ligation Operation; is Doppler Necessary?|Terminated|||150|Actual|Poole Hospital NHS Foundation Trust|||2|Doppler device company wanted hospital to stop recruiting|f||||f||||||||||2018-06-01 00:10:44.401552|2018-06-01 00:10:44.401552
NCT01051167|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-05-03|2010-01-15|2010-01-18|Estimate|||||||2017-05-03|2017-05-08|Actual|February 2009||2009-02-28|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CEBIFOX||Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer|Bi-weekly Cetuximab Combined With FOLFOX-6 as First-line Treatment in Metastatic Colorectal Cancer Patients With Wild-type K-ras Status|Completed||Phase 2|59|Actual|Universität Duisburg-Essen||1|||f||||f||||||||No||2018-06-01 00:10:44.463255|2018-06-01 00:10:44.463255
NCT01051154|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-08-19|2010-01-15|2010-01-18|Estimate|||||||2016-08-19|2016-08-22|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DHA-ALL||Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia|The Effect of Enteral Administration of Polyunsaturated Omega-3 Fatty Acids on Nutritional Status; the Treatment Toxicity and Early Mortality in Children With Acute Lymphoblastic Leukemia - a Controlled Study|Completed||Phase 2|72|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||Undecided||2018-06-01 00:10:44.590367|2018-06-01 00:10:44.590367
NCT01051141|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2015-04-20|2010-01-15|2010-01-18|Estimate|||||||2015-04-20|2015-04-22|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Project U Connect - Optimizing Brief Alcohol Intervention for Underage Drinkers in the ER|Optimizing Brief Alcohol Intervention for Underage Drinkers in the ER|Completed||N/A|870|Actual|University of Michigan||6|||f||||f||||||||||2018-06-01 00:10:44.717939|2018-06-01 00:10:44.717939
NCT01051128|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2015-03-05|2010-01-15|2010-01-18|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|CIBI||Continuous Intrathecal Baclofen Infusion for Chronic Spasticity|Continuous Intrathecal Baclofen Infusion for the Management of Chronic Spasticity|Withdrawn||Phase 3|0|Actual|Flowonix Medical||1||Study was never started. Full IDE-approval not obtained. new IDE will be submitted|f||||f||||||||||2018-06-01 00:10:44.787123|2018-06-01 00:10:44.787123
NCT01051115|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2011-08-29|2010-01-15|2010-01-18|Estimate|||||||2011-08-29|2011-08-31|Estimate|October 2008||2008-10-31|August 2011|2011-08-31|January 2016|Anticipated|2016-01-31|January 2013|Anticipated|2013-01-31||Interventional|D'ACCORD||Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease|Dasatinib Combination for Chronic Lymphocytic Leukemia Patients With Chemo Refractory Disease|Unknown status|Recruiting|Phase 2|35|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-06-01 00:10:44.84284|2018-06-01 00:10:44.84284
NCT01051102|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-02-09|2010-01-15|2010-01-18|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2010||2010-01-31|February 2017|2017-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of NN5401 in Japanese Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN5401 in Japanese Subjects With Type 1 Diabetes|Completed||Phase 1|21|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:10:44.983456|2018-06-01 00:10:44.983456
NCT01051089|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-01-15|2010-01-15|2010-01-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Effects of Lifestyle Modification on Metabolic Parameters in Type 2 Diabetic Patients|Effects of Lifestyle Modification Focusing on Exercise Intervention on Risk of Atherosclerosis and Metabolic Parameters in Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|60|Anticipated|Inha University Hospital||2|||f||||||||||||||2018-06-01 00:10:45.162222|2018-06-01 00:10:45.162222
NCT01051076|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2018-04-12|2010-01-15|2010-01-18|Estimate|||||||2018-04-12|2018-04-13|Actual|September 23, 2009|Actual|2009-09-23|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|RESIST EXP||Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)|Immune Tolerance Induction Study in Patients With Severe Type A Haemophilia With Inhibitor After Failure of a Previous Induction of Immune Tolerance With FVII Concentrates Without Von Willebrand Factor Rescue|Active, not recruiting||N/A|3|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 00:10:45.253268|2018-06-01 00:10:45.253268
NCT01051063|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2017-03-09|2010-01-15|2010-01-18|Estimate|||||||2017-03-09|2017-03-10|Actual|December 2009||2009-12-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy|Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy|Completed||Phase 1|17|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 00:10:45.395231|2018-06-01 00:10:45.395231
NCT01051050|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2011-10-14|2010-01-15|2010-01-18|Estimate|||||||2011-10-14|2011-10-17|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Use of Wikis and Evidence-Based Medicine in Surgical Practice|Using Wikis to Improve the Dissemination, Evaluation, and Application of Evidence-Based Medicine in Surgical Practice|Completed||N/A|45|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 00:10:45.548543|2018-06-01 00:10:45.548543
NCT01051037|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2018-04-26|2010-01-15|2010-01-18|Estimate|||||||2018-04-26|2018-04-30|Actual|February 8, 2010|Actual|2010-02-08|April 2018|2018-04-30|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways|Phase II Study Evaluating Safety and Efficacy of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable and Recurrent Lung Tumors Near Central Airways|Completed||N/A|17|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:10:45.640343|2018-06-01 00:10:45.640343
NCT01051024|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2012-05-02|2010-01-15|2010-01-18|Estimate|||||||2012-05-02|2012-05-04|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Diamel in the Treatment of Polycystic Ovary Syndrome|Efficacy of Diamel in the Treatment of Polycystic Ovary Syndrome|Completed||Phase 3|110|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:10:45.722254|2018-06-01 00:10:45.722254
NCT01051011|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-11-01|2010-01-15|2010-01-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy|A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naive Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy.|Terminated||Phase 3|370|Actual|Hoffmann-La Roche||3||"high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation~   plan to address hypersensitivity reactions"|f||||||||||||||2018-06-01 00:10:45.81948|2018-06-01 00:10:45.81948
NCT01050998|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|2016-09-15||2016-12-22|2010-01-15|2010-01-18|Estimate|2016-12-22|2017-02-16|Actual||||2016-12-22|2017-02-16|Actual|January 2010||2010-01-31|December 2016|2016-12-31|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional||The intent-to-treat (ITT) population constituted all participants who were randomized into the study regardless of whether participants received any investigational product. Six participants were excluded from the ITT population for data integrity issues.|A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects With Rheumatoid Arthritis|Completed||Phase 2|516|Actual|MedImmune LLC||5|||f||||f||||||||||2018-06-01 00:10:46.226812|2018-06-01 00:10:46.226812
NCT01050985|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2014-02-12|2010-01-15|2010-01-18|Estimate|||||||2014-02-12|2014-02-13|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer|A Phase I Study of the mTOR Inhibitor Temsirolimus Plus Capecitabine in Patients With Advanced Malignancies|Completed||Phase 1|47|Actual|Georgetown University||1|||f||||t||||||||||2018-06-01 00:10:50.904596|2018-06-01 00:10:50.904596
NCT01050972|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2010-07-08|2010-01-15|2010-01-18|Estimate|||||||2010-07-08|2010-07-09|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|November 2011|Anticipated|2011-11-30|June 2011|Anticipated|2011-06-30||Interventional|||Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Large Population|Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Population of an Extensive Territory|Unknown status|Recruiting|Phase 3|15000|Anticipated|University of Turin, Italy||1|||f||||f||||||||||2018-06-01 00:10:50.985043|2018-06-01 00:10:50.985043
NCT01050959|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2013-11-06|2010-01-15|2010-01-18|Estimate|||||||2013-11-06|2013-11-07|Estimate|January 2010||2010-01-31|November 2013|2013-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Bion Occipital Nerve Stimulation (ONS) Compassionate Use Study|Compassionate Use Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches|Completed|||11|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 00:10:51.193956|2018-06-01 00:10:51.193956
NCT01050946|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2015-08-26||2015-10-21|2010-01-15|2010-01-18|Estimate|2015-08-26|2015-09-25|Estimate||||2015-10-21|2015-11-20|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Haplo/Cord||Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit|Phase II Study: HSCT Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit|Terminated||Phase 2|1|Actual|Medical College of Wisconsin||1||Only one patient was enrolled. Due to low accrual study was terminated|f||||t||||||||||2018-06-01 00:10:51.294268|2018-06-01 00:10:51.294268
NCT01050933|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-11-15|2010-01-15|2010-01-18|Estimate|||||||2015-11-15|2015-11-17|Estimate|September 2010||2010-09-30|November 2015|2015-11-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Safety Study of Inhaling Carbon Monoxide in Healthy Volunteers|Safety and Tolerability of Inhaled Carbon Monoxide in Healthy Volunteers|Terminated||Phase 1|10|Actual|Queen's University||1||resident left and no one to take over|f||||f||||||||||2018-06-01 00:10:51.485982|2018-06-01 00:10:51.485982
NCT01050920|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2014-01-21|2010-01-15|2010-01-18|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population||Unknown status|Recruiting||||National University Hospital, Singapore|||1||f||||||||||||||2018-06-01 00:10:51.545935|2018-06-01 00:10:51.545935
NCT01050907|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-03-24|2010-01-14|2010-01-18|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2010||2010-05-31|January 2011|2011-01-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Miltefosine to Treat Mucocutaneous Leishmaniasis|Treatment of Mucocutaneous Leishmaniasis With Miltefosine|Completed||Phase 2|4|Actual|Knight Therapeutics (USA) Inc||1|||f||||f||||||||||2018-06-01 00:10:51.61013|2018-06-01 00:10:51.61013
NCT01050894|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2017-03-17|2010-01-15|2010-01-18|Estimate|||||||2017-03-17|2017-03-21|Actual|May 2010||2010-05-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Feasibility Study of Anti-inflammatory Cytokines in Whole Blood in Osteoarthritis Patients|A Feasibility Study to Determine the Up-regulation of Anti-inflammatory Cytokines in Whole Blood From Patients With Osteoarthritis|Completed|||105|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 00:10:51.692281|2018-06-01 00:10:51.692281
NCT01050881|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-02-12|2010-01-15|2010-01-18|Estimate|||||||2010-02-12|2010-02-15|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|October 2010|Anticipated|2010-10-31|June 2010|Anticipated|2010-06-30||Observational|||Notification of Donors With Positive Microbiology Markers|Assessment of the Impact of Notification of Blood Donors Testing Positive for Microbiology Markers: What is the Psychological Impact of Notification and Does the Method of Notification Influence the Outcome?|Unknown status|Not yet recruiting||600|Anticipated|NHS Blood and Transplant|||1||f||||t||||||||||2018-06-01 00:10:51.766334|2018-06-01 00:10:51.766334
NCT01050868|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2016-03-01|2010-01-15|2010-01-18|Estimate|||||||2016-03-01|2016-03-03|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparison of the Management of Post-prandial Hyperglycemia by Multiple Bolus Calculators||Completed||N/A|24|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:10:51.848068|2018-06-01 00:10:51.848068
NCT01050855|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-15|||2017-12-21|2010-01-15|2010-01-18|Estimate|||||||2017-12-21|2017-12-26|Actual|January 2008||2008-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RIC||Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders|Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders|Recruiting||Phase 2|50|Anticipated|Children's Hospital of Philadelphia||3|||f||||f||||||||||2018-06-01 00:10:51.904042|2018-06-01 00:10:51.904042
NCT01050842|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2017-03-21|2010-01-14|2010-01-15|Estimate|||||||2017-03-21|2017-03-23|Actual|February 2010|Actual|2010-02-28|March 2016|2016-03-31|October 4, 2012|Actual|2012-10-04|May 2012|Actual|2012-05-31||Interventional|||Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer|Pilot Trial to Evaluate the Safety and Efficacy of the Administration of Bicalutamide (Casodex TM) Per Day in Combination With Raloxifene (Evista TM) Per Day in Patients With Hormone Refractory Prostate Cancer|Completed||Early Phase 1|18|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:10:52.174598|2018-06-01 00:10:52.174598
NCT01050829|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2014-12-26|2010-01-14|2010-01-15|Estimate|||||||2014-12-26|2014-12-30|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Gadobutrol Magnevist-controlled Body Study|A Multi-center/Multi-national, Randomized, Controlled, Single-blind, Group Comparison Phase 3 Study to Determine the Efficacy and Safety of Gadobutrol 1.0 Molar in Comparison to Magnevist Following Single Injection in Patients Referred for Contrast-enhanced MRI of the Body/Extremities Regions (Breast, Heart, Abdomen, Kidney, Pelvis, or Extremities)|Completed||Phase 3|370|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:10:52.258224|2018-06-01 00:10:52.258224
NCT01050816|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2010-01-21||2010-05-06|2010-01-14|2010-01-15|Estimate|2010-04-18|2010-05-07|Estimate||||2010-05-06|2010-05-11|Estimate|January 2006||2006-01-31|May 2010|2010-05-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Effects of CHONDRON (Autologous Chondrocytes) With Ankle Cartilage Defect|An Investigator Clinical Trial to Observe Effects of CHONDRON (Autologous Chondrocytes) for 12 Months in Patients With Ankle Cartilage Defect|Completed||Phase 3|30|Actual|Sewon Cellontech Co., Ltd.||1|||f||||t||||||||||2018-06-01 00:10:52.36096|2018-06-01 00:10:52.36096
NCT01050803|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2016-05-16|2010-01-14|2010-01-15|Estimate|||||||2016-05-16|2016-05-17|Estimate|August 2009||2009-08-31|May 2016|2016-05-31|April 2011|Actual|2011-04-30|March 2010|Actual|2010-03-31||Interventional|FDSME||Effectiveness of the Farsi Diabetes Self-management Education (FDSME) Program for People With Type 2 Diabetes|Effectiveness of the Farsi Diabetes Self-management Education Program for People With Type 2 Diabetes: Randomized Controlled Trial|Completed||N/A|280|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-06-01 00:10:52.563532|2018-06-01 00:10:52.563532
NCT01050790|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2015-07-16||2016-10-18|2010-01-14|2010-01-15|Estimate|2015-09-01|2015-10-05|Estimate||||2016-10-18|2016-11-29|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2014|Actual|2014-08-31||Interventional||Multiple Myeloma in either first or subsequent partial remission with measurable disease, eligible for autologous SCT.|Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma|Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy|Completed||N/A|17|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 00:10:52.657731|2018-06-01 00:10:52.657731
NCT01050608|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2011-06-22|2010-01-14|2010-01-15|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Observational|Sprixx-ICU||Evaluation of Body-worn Multimodal Hand Hygiene System. Impact on Health-Care Associated Infections|Real Time Deployment of Multimodal Personal Dispenser Hand Hygiene System in a Multidisciplinary Intensive Care Unit.|Completed|||2954|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||t||||||||||2018-06-01 00:10:55.677793|2018-06-01 00:10:55.677793
NCT01050777|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2012-06-19|2010-01-14|2010-01-15|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2011||2011-03-31|February 2011|2011-02-28|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis|Pilot Study of Efficacy of Topical Nano-liposomal Meglumine Antimoniate (Glucantime) or Paromomycin in Combination With Systemic Glucantime for the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL) Caused by Leishmania Tropica|Completed||Early Phase 1|30|Anticipated|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-06-01 00:10:53.015356|2018-06-01 00:10:53.015356
NCT01050764|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2017-02-14||2017-04-03|2010-01-14|2010-01-15|Estimate|2017-04-03|2017-05-11|Actual||||2017-04-03|2017-05-11|Actual|June 2009||2009-06-30|April 2017|2017-04-30|June 2014|Actual|2014-06-30|August 2012|Actual|2012-08-31||Interventional|||Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells|A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors|Terminated||Phase 1/Phase 2|10|Actual|Stanford University||1||Safety|f||||t|t|f||||||No||2018-06-01 00:10:53.123647|2018-06-01 00:10:53.123647
NCT01050751|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-03-08|2010-01-14|2010-01-15|Estimate|||||||2010-03-08|2010-03-09|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bioavailability Of Lersivirine Single 750 Mg Tablet Versus 3 X 250 Mg Tablets|Open-Label, Randomized, 2-Way Crossover Study To Estimate The Pharmacokinetics And Bioavailability Of Lersivirine (UK 453,061) Administered As A Single 750 Mg Tablet And 3 X 250 Mg Tablets In Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:10:53.41053|2018-06-01 00:10:53.41053
NCT01050738|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-08-17|2010-01-14|2010-01-15|Estimate|||||||2010-08-17|2010-08-18|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Local Analgesia in Knee- and Hipatroplastic Surgery in Patients With Rheumatic Disease: Extra- vs. Intracapsulare Position of Catheter|Local Analgesia in Knee- and Hipatroplastic Surgery in Patients With Rheumatic Disease: Extra- vs. Intracapsulare Position of Catheter|Unknown status|Recruiting|N/A|72|Anticipated|Spenshult Hospital||2|||f||||f||||||||||2018-06-01 00:10:53.491036|2018-06-01 00:10:53.491036
NCT01050725|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2011-06-29|2010-01-13|2010-01-15|Estimate|||||||2011-06-29|2011-06-30|Estimate|November 2009||2009-11-30|June 2011|2011-06-30||||June 2013|Anticipated|2013-06-30||Observational|||Pilot Study of Biomarkers for Radiation Therapy|Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study|Suspended|||100|Anticipated|Benaroya Research Institute|||1|On hold: pending grant funding for further enrollment|f||||t|||||||"~     whole blood samples.~   "|||2018-06-01 00:10:53.559132|2018-06-01 00:10:53.559132
NCT01050712|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2015-11-15|2010-01-14|2010-01-15|Estimate|||||||2015-11-15|2015-11-17|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study of Inhaling Carbon Monoxide to Treat Patients With Intestinal Paralysis After Colon Surgery.|Inhaled Carbon Monoxide in Patients With Post-Operative Ileus Following Colon Resection.|Terminated||Phase 2|3|Actual|Queen's University||2||According to retired PI, resident graduated and next resident never carried it to fruition.|f||||f||||||||||2018-06-01 00:10:53.619353|2018-06-01 00:10:53.619353
NCT01050699|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2016-10-24|2010-01-14|2010-01-15|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Sleep Intervention During Acute Lung Injury|Sleep Intervention During Acute Lung Injury|Active, not recruiting||Phase 4|90|Anticipated|University of Arizona||2|||f||||t||||||||||2018-06-01 00:10:53.676307|2018-06-01 00:10:53.676307
NCT01050686|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2015-02-11|2010-01-14|2010-01-15|Estimate|||||||2015-02-11|2015-02-12|Estimate|March 2010||2010-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|DRASTAR||Need for Subcutaneous Wound Drains in Ileostomy Reversal|Need for Subcutaneous Wound Drains in Ileostomy Reversal|Completed||N/A|102|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:10:53.751789|2018-06-01 00:10:53.751789
NCT01050673|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2012-06-12||2018-02-12|2010-01-14|2010-01-15|Estimate|2012-09-07|2012-10-08|Estimate||||2018-02-12|2018-03-12|Actual|November 2007||2007-11-30|February 2018|2018-02-28|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Trial of Versajet Compared With Conventional Treatment in Acute and Chronic Wounds|A Study to Investigate the Time to Closure of Delayed Healing Dehisced Incisions, Delayed Healing Traumatic Wounds or Chronic Cutaneous Defects Surgically Excised With VERSAJET Compared Conventional Operating Room Techniques|Completed||N/A|40|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-06-01 00:10:53.857871|2018-06-01 00:10:53.857871
NCT01050660|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2014-01-21||2014-10-27|2010-01-14|2010-01-15|Estimate|2014-10-27|2014-10-28|Estimate||||2014-10-27|2014-10-28|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates|Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates|Completed||N/A|136|Actual|Yale University||2|||f||||t||||||||||2018-06-01 00:10:54.464425|2018-06-01 00:10:54.464425
NCT01050647|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2018-02-13||2018-04-16|2010-01-14|2010-01-15|Estimate|2018-03-16|2018-04-17|Actual||||2018-04-16|2018-05-16|Actual|February 2010||2010-02-28|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|December 2015|Actual|2015-12-31||Interventional|||Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.|Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.|Active, not recruiting||Phase 1/Phase 2|21|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 00:10:54.840487|2018-06-01 00:10:54.840487
NCT01050634|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2010-04-26||2010-06-23|2010-01-14|2010-01-15|Estimate|2010-06-23|2010-07-23|Estimate||||2010-06-23|2010-07-23|Estimate|November 2005||2005-11-30|June 2010|2010-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|FAST||Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)|Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) a Non-interventional Trial With Aromasin®|Completed|||980|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:10:55.237731|2018-06-01 00:10:55.237731
NCT01050621|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-06-20|2010-01-14|2010-01-15|Estimate|||||||2013-06-20|2013-06-21|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective|Phase I - II Clinical Trial of Combination Conventional Cytotoxic Chemotherapy and Intravenous Vitamin C in Patients With Advanced Cancer or Hematologic Malignancy for Whom Cytotoxic Chemotherapy Alone is Only Marginally Effective|Completed||Phase 1/Phase 2|14|Actual|Jewish General Hospital|||||f||||f||||||||||2018-06-01 00:10:55.609435|2018-06-01 00:10:55.609435
NCT01050595|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-01-13|2010-01-13|2010-01-15|Estimate|||||||2010-01-13|2010-01-15|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|MOVE-IT||Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit|Methylnaltrexone for the Reversal of Opiate-Induced Constipation in the Intensive Care Unit|Unknown status|Recruiting|Phase 3|80|Anticipated|St. John Health System, Michigan||2|||f||||t||||||||||2018-06-01 00:10:55.762858|2018-06-01 00:10:55.762858
NCT01050582|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2012-07-26||2012-10-26|2010-01-14|2010-01-15|Estimate|2012-10-26|2012-11-27|Estimate||||2012-10-26|2012-11-27|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children|Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs|Completed||Phase 4|244|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|A total of 350 subjects in a 1:1 ratio between the two arms was planned. Recruitment difficulties led to an imbalance in the number of subjects per arm and to early termination of the study. The results should be interpreted within this context.|2|||f||||f||||||||||2018-06-01 00:10:55.880041|2018-06-01 00:10:55.880041
NCT01050569|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2013-10-29||2016-11-16|2010-01-14|2010-01-15|Estimate|2014-01-14|2014-02-28|Estimate||||2016-11-16|2017-01-04|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Innovative Interventions for Smoking Cessation|Innovative Interventions for Smoking Cessation: Comparison of Very Low Nicotine Content Cigarettes Plus Nicotine Patch; Very Low Nicotine Content Cigarettes Alone or Nicotine Patch Alone|Completed||Phase 2|235|Actual|University of Minnesota - Clinical and Translational Science Institute|Small sample size.|3|||f||||t||||||||||2018-06-01 00:10:56.340435|2018-06-01 00:10:56.340435
NCT01050556|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2012-07-31|2010-01-13|2010-01-15|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|FACTA||Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic|Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic|Completed||Phase 4|600|Actual|Columbia University||5|||f||||t||||||||||2018-06-01 00:10:56.689923|2018-06-01 00:10:56.689923
NCT01050543|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2012-02-13||2017-06-01|2010-01-14|2010-01-15|Estimate|2012-04-10|2012-05-07|Estimate||||2017-06-01|2017-07-02|Actual|February 1, 2010|Actual|2010-02-01|June 2017|2017-06-30|August 20, 2010|Actual|2010-08-20|August 20, 2010|Actual|2010-08-20||Interventional|DANCHEONG||Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)|A Randomized Safety-Assessor Blinded Trial Comparing Sugammadex With Neostigmine in Korean Subjects Scheduled for Surgeries Requiring Moderate Neuromuscular Blockade|Completed||Phase 3|128|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:10:56.766921|2018-06-01 00:10:56.766921
NCT01050530|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2013-12-15||2014-01-30|2010-01-13|2010-01-15|Estimate|2013-12-15|2014-01-31|Estimate||||2014-01-30|2014-03-04|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema|Completed||Phase 3|162|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:10:56.928494|2018-06-01 00:10:56.928494
NCT01050517|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy of Drug Combinations Against Triple Infections|Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections|Completed||N/A|250|Anticipated|DBL -Institute for Health Research and Development||2|||f||||f||||||||||2018-06-01 00:10:57.210607|2018-06-01 00:10:57.210607
NCT01050504|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-12-04|2010-01-14|2010-01-15|Estimate|||||||2017-12-04|2017-12-06|Actual|August 2009||2009-08-31|December 2017|2017-12-31||||September 1, 2018|Anticipated|2018-09-01||Observational|||Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer|Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy|Recruiting|||300|Anticipated|University of Washington|||1||f||||f||||||Samples With DNA|"~     Blood and tissue~   "|||2018-06-01 00:10:57.406075|2018-06-01 00:10:57.406075
NCT01050491|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2012-05-09|2010-01-14|2010-01-15|Estimate|||||||2012-05-09|2012-05-10|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Sitax||Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma|Effect of a Receptor Antagonist of Endothelin 1 (Sitaxsentan, Thelin) on Bronchial Remodeling in Severe Asthma With Fixed Bronchial Obstruction|Terminated||Phase 2|17|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2||sitaxentan is not commercialized anymore|f||||f||||||||||2018-06-01 00:10:57.486381|2018-06-01 00:10:57.486381
NCT01050478|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2016-02-08|2010-01-14|2010-01-15|Estimate|||||||2016-02-08|2016-02-09|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation|Open-label, Single Arm, Interventional Study to Explore the Efficacy and Safety of Paliperidone ER in the Management of Patients With Acute Agitation and/or Aggression|Completed||Phase 4|56|Actual|Janssen Cilag N.V./S.A.||1|||f||||f||||||||||2018-06-01 00:10:57.583535|2018-06-01 00:10:57.583535
NCT01050465|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2016-09-29|2010-01-14|2010-01-15|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use|MedlinePlus Health Prescriptions: Developing a Real World Approach for Clinic Use|Completed||N/A|907|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 00:10:57.687849|2018-06-01 00:10:57.687849
NCT01050452|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy of Drug Combinations Against Trichuris Trichiura|Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Study on Trichuris Trichiura.|Completed||N/A|750|Anticipated|DBL -Institute for Health Research and Development||5|||f||||f||||||||||2018-06-01 00:10:57.768948|2018-06-01 00:10:57.768948
NCT01042821|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-05|2010-01-05|2010-01-06|Estimate|||||||2010-01-05|2010-01-06|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|flap||Treatment of Anal Fistulas Advancement Flap|Treatment of Anal Fistulas by Partial Rectal Wall Advancement Flap or Mucosal Advancement Flap: a Prospective Randomized Study|Completed||N/A|40|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:13:00.320544|2018-06-01 00:13:00.320544
NCT01050426|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2016-10-13|2010-01-14|2010-01-15|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PERU||A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)|A Multicentre Randomised Phase II Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)|Terminated||Phase 2|17|Actual|Royal Marsden NHS Foundation Trust||2||Data from other trials failed to demonstrate meaningful survival advantage|f||||t||||||||||2018-06-01 00:10:57.977631|2018-06-01 00:10:57.977631
NCT01050413|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-06-02|2010-01-14|2010-01-15|Estimate|||||||2010-06-02|2010-06-03|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors|Evaluation of Serum Thymidine Kinase Activity in Diagnosis,Prognosis and Monitoring of Treatment in Patients With Solid Tumors|Unknown status|Recruiting||300|Anticipated|Hadassah Medical Organization|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 00:10:58.078258|2018-06-01 00:10:58.078258
NCT01050400|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2017-08-25|2010-01-13|2010-01-15|Estimate|||||||2017-08-25|2017-08-28|Actual|February 24, 2009|Actual|2009-02-24|August 2017|2017-08-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|||CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk|CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk|Completed|||330|Actual|Lawson Health Research Institute|||2||f||||t||||||Samples With DNA|"~     Saliva and breast milk samples.~   "|||2018-06-01 00:10:58.146404|2018-06-01 00:10:58.146404
NCT01050387|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2014-08-02|2010-01-14|2010-01-15|Estimate|||||||2014-08-02|2014-08-05|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|VitaD||Effects of Vitamin D Dose and Genotype of the Binding Protein in Infants and Children|A Randomized, Controlled Trial of Vitamin D Supplementation in Infants and Children: Effects of Vitamin D Dose and Genotype of the Binding Protein|Completed||N/A|193|Actual|Yale University|||||f||||f||||||||||2018-06-01 00:10:58.22109|2018-06-01 00:10:58.22109
NCT01050374|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy of Drug Combinations Against Schistosomiasis|Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Praziquantel Study|Completed||N/A|650|Anticipated|DBL -Institute for Health Research and Development||2|||f||||f||||||||||2018-06-01 00:10:58.316252|2018-06-01 00:10:58.316252
NCT01050361|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2016-05-16|2010-01-14|2010-01-15|Estimate|||||||2016-05-16|2016-05-17|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|EGHEM||Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery|Echocardiography-Guided Hemodynamic Management Strategy for Patients Requiring Perioperative Care for Non-Cardiac Surgery|Completed||Phase 3|35|Actual|University of Nebraska||2|||f||||t||||||||||2018-06-01 00:10:58.381445|2018-06-01 00:10:58.381445
NCT01050348|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2016-11-29|2010-01-14|2010-01-15|Estimate|||||||2016-11-29|2016-11-30|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|IMPRES||To Investigate the Role of Upstream High Dose Statin in STEMI|A Double Blinded Randomized Placebo Controlled Study: To Investigate the Role of Upstream High Dose Statin Treatment in Patients With ST Segment Elevation Myocardial Infarction|Completed||Phase 4|120|Actual|The Western Pennsylvania Hospital||2|||f||||t||||||||||2018-06-01 00:10:58.449463|2018-06-01 00:10:58.449463
NCT01050335|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|June 2007||2007-06-30|June 2009|2009-06-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Collaborative Surgical Proficiency Initiative|Collaborative Surgical Proficiency Initiative|Unknown status|Enrolling by invitation||90|Anticipated|Phoenix Integrated Surgical Residency|||1||f||||f||||||||||2018-06-01 00:10:58.522478|2018-06-01 00:10:58.522478
NCT01050322|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2013-06-04|2010-01-14|2010-01-15|Estimate|||||||2013-06-04|2013-06-05|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|GLICO-0801||Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.|A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment|Completed||Phase 2|142|Actual|Latin American Cooperative Oncology Group||3|||f||||t||||||||||2018-06-01 00:10:58.584503|2018-06-01 00:10:58.584503
NCT01050309|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|November 2009||2009-11-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers|An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers|Completed||Phase 1|8|Anticipated|Photocure||3|||f||||||||||||||2018-06-01 00:10:58.685958|2018-06-01 00:10:58.685958
NCT01050296|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2018-05-09|2010-01-14|2010-01-15|Estimate|||||||2018-05-09|2018-05-11|Actual|February 10, 2010|Actual|2010-02-10|May 2018|2018-05-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Observational|MAST||Molecular Analysis Of Solid Tumors|Molecular Analysis Of Solid Tumors|Recruiting|||400|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     Tumor tissue - Tumor tissue will be obtained from patients with a diagnosis of neuroblastoma,~     retinoblastoma, osteosarcoma, Ewing sarcoma or soft tissue sarcoma at some or all of the~     following time points: initial biopsy, primary tumor resection, time of disease recurrence.~     Whole blood - 5 ml of whole blood will be collected from each patient and be used as a~     matched control. Bone marrow aspiration - 5ml of bone marrow will be taken at the time a~     patient is having a bone marrow aspirate performed and processed to remove only tumor cells.~   "|||2018-06-01 00:10:58.750683|2018-06-01 00:10:58.750683
NCT01050283|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-07-24|2010-01-14|2010-01-15|Estimate|||||||2015-07-24|2015-07-27|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144)|A Multicenter Trial to Evaluate 18F-FDG Uptake by PET in Patients With Advanced Pancreatic Adenocarcinoma as an Early Indicator of Drug Activity|Terminated||Phase 1|15|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:10:58.820295|2018-06-01 00:10:58.820295
NCT01050270|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2013-07-30|2010-01-14|2010-01-15|Estimate|||||||2013-07-30|2013-07-31|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|SNAP||Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning Study (SNAP)|A Randomised Trial to Assess the Effectiveness of Pre-treatment With Ondansetron at Reducing Nausea and Vomiting in Patients Treated With Either the Conventional Regimen or a Modified Regimen of Acetylcysteine for Paracetamol Poisoning|Completed||Phase 4|222|Actual|University of Edinburgh||4|||f||||t||||||||||2018-06-01 00:10:58.894503|2018-06-01 00:10:58.894503
NCT01050257|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2013-08-28||2013-08-28|2010-01-14|2010-01-15|Estimate|2013-08-28|2013-11-01|Estimate||||2013-08-28|2013-11-01|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Demographics are based on the all enrolled patients population.|A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza|A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years|Completed||Phase 3|118|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:10:59.019643|2018-06-01 00:10:59.019643
NCT01050244|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2016-03-21|2010-01-14|2010-01-15|Estimate|||||||2016-03-21|2016-03-22|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effect of Soy Protein on Neuropathic Pain|The Effect of Soy Protein on Neuropathic Pain: Randomized N-of-1 Trials|Terminated||Phase 2|14|Actual|McGill University Health Center||2||Funding ran out_difficulties with study product (delays in authorization).|f||||f||||||||||2018-06-01 00:10:59.783004|2018-06-01 00:10:59.783004
NCT01050231|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2013-06-27|2010-01-13|2010-01-15|Estimate|||||||2013-06-27|2013-06-28|Estimate|October 2006||2006-10-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Robotics For Rehabilitation Therapy|Robotics For Rehabilitation Therapy|Completed||Phase 1/Phase 2|24|Actual|University of California, Irvine||2|||f||||f||||||||||2018-06-01 00:10:59.887502|2018-06-01 00:10:59.887502
NCT01050218|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2010-01-29||2010-07-15|2010-01-14|2010-01-15|Estimate|2010-04-20|2010-05-11|Estimate||||2010-07-15|2010-07-20|Estimate|July 2006||2006-07-31|July 2010|2010-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy|A 9-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Pain Associated With Diabetic Peripheral Neuropathy|Terminated||Phase 3|237|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1||Business reasons|f||||f||||||||||2018-06-01 00:10:59.956626|2018-06-01 00:10:59.956626
NCT01050205|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2017-05-03||2017-07-25|2010-01-14|2010-01-15|Estimate|2017-05-03|2017-07-25|Actual||||2017-07-25|2017-08-25|Actual|September 2010||2010-09-30|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Diabetes Prevention Translation: the Healthy Lifestyle Project|Diabetes Prevention Translation Project: the Healthy Lifestyle Project|Completed||N/A|223|Actual|University of Pittsburgh|Physical activity data was self-reported. Sample was predominantly white, female, which may not be representative of other groups.|2|||f||||f||||||||||2018-06-01 00:11:00.355077|2018-06-01 00:11:00.355077
NCT01050192|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2017-03-21|2010-01-14|2010-01-15|Estimate|||||||2017-03-21|2017-03-23|Actual|December 2009||2009-12-31|March 2017|2017-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Nutritional Content of Breast Milk From Mothers of Premies|The Nutritional Content of Breast Milk From Mothers of Premature Neonates During the First 28 Days of Life|Withdrawn|||0|Actual|Mednax Center for Research, Education, Quality and Safety||||Lack of enrollment|f||||f||||||||||2018-06-01 00:11:00.699175|2018-06-01 00:11:00.699175
NCT01050179|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-04-16|2010-01-14|2010-01-15|Estimate|||||||2010-04-16|2010-04-19|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Chemoreflex Gain on Exercise|Chemoreflex Gain on Exercise|Unknown status|Recruiting|Phase 1|20|Anticipated|Imperial College London|||||f||||f||||||||||2018-06-01 00:11:00.752215|2018-06-01 00:11:00.752215
NCT01050166|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|December 2015|Anticipated|2015-12-31|December 2012|Anticipated|2012-12-31||Observational|||MRI Imaging of Labeled Human Islets Transplanted Into the Liver|Phase 1 Study to Test Safety and Efficacy of Magnetic Resonance Imaging of Human Labeled Islets Transplanted Into the Liver in Type 1 Diabetic Recipients|Unknown status|Recruiting||10|Anticipated|Institute for Clinical and Experimental Medicine|||1||f||||f||||||||||2018-06-01 00:11:00.90549|2018-06-01 00:11:00.90549
NCT01050153|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2013-08-14||2015-10-16|2010-01-14|2010-01-15|Estimate|2014-03-25|2014-04-25|Estimate||||2015-10-16|2015-10-20|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|VTEPX||The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma|An Evaluation of the Clinical Utility of Thrombelastography (TEG) in Guiding Low Molecular Weight Heparin (LMWH) and Antiplatelet Prophylaxis of Venous Thromboembolism (VTE) Following Trauma|Completed||N/A|50|Actual|Denver Health and Hospital Authority|"lower than expected incidence of VTE events~Control group patients were followed for 5 days, while TEG-guided group was followed as long as in SICU~adherence to VTE prophylaxis with Daltaparin was significantly low in the TEG-guided group"|2|||f||||f||||||||||2018-06-01 00:11:01.03296|2018-06-01 00:11:01.03296
NCT01050140|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2012-07-03|2010-01-14|2010-01-15|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||The Metabolic Effects of a High Fructose Versus a High Glucose Diet in Overweight Men|The Metabolic Effects of a High Fructose Versus a High Glucose Diet in Overweight Men|Completed||N/A|32|Actual|University of Nottingham||2|||f||||f||||||||||2018-06-01 00:11:01.505928|2018-06-01 00:11:01.505928
NCT01050127|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2010-11-02|2010-01-13|2010-01-15|Estimate|||||||2010-11-02|2010-11-03|Estimate|December 2009||2009-12-31|September 2010|2010-09-30||||February 2010|Actual|2010-02-28||Interventional|||A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults||Completed||Phase 1|36|Actual|Abbott||3|||f||||||||||||||2018-06-01 00:11:01.620594|2018-06-01 00:11:01.620594
NCT01050114|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2016-08-29|2010-01-14|2010-01-15|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER|A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04)|Recruiting||Phase 3|36|Anticipated|Baylor College of Medicine||2|||f||||t||||||||No|Data will be published in aggregate.|2018-06-01 00:11:01.704448|2018-06-01 00:11:01.704448
NCT01050101|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-03-15|2010-01-14|2010-01-15|Estimate|||||||2018-03-15|2018-03-16|Actual|August 1, 2008|Actual|2008-08-01|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|FS||The Effects of Fiber on Appetite and Digestion Hormones|The Effect of Meal Viscosity on Postprandial Metabolic, Gut Hormone and Satiety Responses to Low and High Glycemic Index Preload Meals in Overweight Pre- and Post-menopausal Women.|Active, not recruiting||N/A|22|Actual|Institute for Food Safety and Health, United States||3|||f||||f||||||||Undecided||2018-06-01 00:11:01.819038|2018-06-01 00:11:01.819038
NCT01050088|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|March 2010||2010-03-31|January 2010|2010-01-31|March 2011|Anticipated|2011-03-31|September 2010|Anticipated|2010-09-30||Interventional|SCF||Sucrose Analgesia in Infants Undergoing Casting for Club Foot|Effectiveness of Sucrose Analgesia in Infants Undergoing Casting for Club Foot|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 00:11:01.892543|2018-06-01 00:11:01.892543
NCT01050075|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2017-11-02|2010-01-14|2010-01-15|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2010||2010-01-31|November 2017|2017-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel|A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy|Terminated||N/A|7|Actual|City of Hope Medical Center||2||Unable to recruit patients in the 6 month extension allowed.|f||||t||||||||||2018-06-01 00:11:01.996172|2018-06-01 00:11:01.996172
NCT01050062|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|2012-12-18||2014-04-04|2010-01-14|2010-01-15|Estimate|2012-12-18|2013-01-30|Estimate||||2014-04-04|2014-05-01|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational||The 18 patients which had no information including safety due to no visit after enrolled, were excluded from the safety analysis, 1,425 patients were included in the safety set.|Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use|Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension|Completed|||1452|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-06-01 00:11:02.150306|2018-06-01 00:11:02.150306
NCT01050049|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2010-01-14|2010-01-14|2010-01-15|Estimate|||||||2010-01-14|2010-01-15|Estimate||||October 2008|2008-10-31||||||||Observational|||The Effect of Implementing Hyper-acute Stroke Guidelines on Decision-Making for or Against Thrombolytic Therapy for Stroke in the Emergency Department|The Effect of Implementing Hyper-acute Stroke Guidelines on Decision-Making for or Against Thrombolytic Therapy for Stroke in the Emergency Department|Completed|||||Temple University|||2||f||||f||||||||||2018-06-01 00:11:02.993216|2018-06-01 00:11:02.993216
NCT01050036|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2018-04-16|2010-01-14|2010-01-15|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia|Phase 2 Study of Autologous Hematopoietic Cell Transplantation for Core-binding Factor Positive Acute Myeloid Leukemia in the First Complete Remission|Recruiting||N/A|39|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-06-01 00:11:03.064651|2018-06-01 00:11:03.064651
NCT01050023|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2011-07-19|2010-01-13|2010-01-15|Estimate|||||||2011-07-19|2011-07-20|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Provant Therapy of Venous Stasis Ulcer Trial|Provant Therapy of Venous Stasis Ulcer Trial|Unknown status|Active, not recruiting|N/A|25|Actual|Southern California Institute for Research and Education||2|||f||||f||||||||||2018-06-01 00:11:03.214008|2018-06-01 00:11:03.214008
NCT01050010|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2011-12-08|2010-01-14|2010-01-15|Estimate|||||||2011-12-08|2011-12-09|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|April 2010|Actual|2010-04-30||Interventional|||The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission. Preliminary Study|The Relation Between Dedicated Extremity MRI Synovitis and Structural Deterioration Radiographic in Patients With Rheumatoid Arthritis in Clinical Remission.Preliminary Study|Unknown status|Recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 00:11:03.284962|2018-06-01 00:11:03.284962
NCT01049997|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2015-03-30|2010-01-14|2010-01-15|Estimate|||||||2015-03-30|2015-03-31|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|June 2011|Actual|2011-06-30||Observational|FINE75+||Frailty as an INstrument for Evaluation of Elderly Patients With Non ST Elevation Myocardial Infarction (NSTEMI)|Frailty as an INstrument for Evaluation of Elderly Patients With Non ST Elevation Myocardial Infarction (NSTEMI)|Completed|||307|Actual|Linkoeping University|||1||f||||t||||||||||2018-06-01 00:11:03.355308|2018-06-01 00:11:03.355308
NCT01049984|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2014-10-09|2014-02-19|2016-04-20|2010-01-14|2010-01-15|Estimate|2014-10-09|2014-10-15|Estimate|2014-02-19|2014-03-19|Estimate|2016-04-20|2016-05-20|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ANDANTE|Safety population|Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease|A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease|Completed||Phase 4|328|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 00:11:03.426967|2018-06-01 00:11:03.426967
NCT01049971|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2011-07-06|2010-01-14|2010-01-15|Estimate|||||||2011-07-06|2011-07-07|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|REDWIL||REDWIL: Reduction of Wound Infections in Laparoscopic Colon Resections by Wound Protectors|Reduction of Wound Infections in Laparoscopic Colon Resections by Wound Protectors|Completed||N/A|109|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:11:05.014827|2018-06-01 00:11:05.014827
NCT01049958|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2013-01-13|2010-01-14|2010-01-15|Estimate|||||||2013-01-13|2013-01-15|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|April 2011|Actual|2011-04-30|May 2010|Actual|2010-05-31||Observational|Asynchrony||Study to Measure the Prevalence of Asynchrony In Mechanically Ventilated Patients|Prevalence of Patient Ventilator Asynchrony in Trauma and Surgical Patients|Completed|||36|Actual|University of Cincinnati|||||f||||f||||||||||2018-06-01 00:11:05.846209|2018-06-01 00:11:05.846209
NCT01049945|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|2015-03-23||2016-04-28|2010-01-14|2010-01-15|Estimate|2015-03-23|2015-03-30|Estimate||||2016-04-28|2016-05-27|Estimate|February 2010||2010-02-28|April 2016|2016-04-30||||November 2012|Actual|2012-11-30||Interventional|||Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma|A Phase I/II, Multicenter, Open-label, Dose-escalation Study of Bendamustine in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma|Unknown status|Active, not recruiting|Phase 1/Phase 2|70|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:11:05.965195|2018-06-01 00:11:05.965195
NCT01049932|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-08-13|2010-01-14|2010-01-15|Estimate|||||||2010-08-13|2010-08-16|Estimate|March 2010||2010-03-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Pre-Exposure Prophylaxis Using TMC278LA|PrEP TMC278LA: Safety, Tolerability and Pharmacokinetics of TMC278LA in HIV Negative Volunteers|Terminated||Phase 1/Phase 2|0|Actual|St Stephens Aids Trust||1||Trial closed due to additional safety information.|f||||t||||||||||2018-06-01 00:11:07.183853|2018-06-01 00:11:07.183853
NCT01049919|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14||2017-06-19|2017-06-19|2010-01-14|2010-01-15|Estimate||||2017-06-19|2017-06-23|Actual|2017-06-19|2017-06-23|Actual|June 2010||2010-06-30|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|June 2016|Actual|2016-06-30||Interventional|MOBILE||Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)|MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects With Severe Peripheral Arterial Disease (PAD)|Active, not recruiting||N/A|152|Anticipated|Zimmer Biomet||2|||f||||t|f|t|t|||||Undecided||2018-06-01 00:11:07.278946|2018-06-01 00:11:07.278946
NCT01049906|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2012-06-20|2010-01-14|2010-01-15|Estimate|||||||2012-06-20|2012-06-21|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Popliteal Sciatic Nerve Block Catheter Placement for Foot Surgery|A Study to Determine the Quality of Sensory and Motor Blockade of Popliteal Sciatic Nerve Block Catheters Placed Under Ultrasound Guidance With and Without Nerve Stimulation|Completed||N/A|21|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:11:07.408061|2018-06-01 00:11:07.408061
NCT01049893|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-11-11|2010-01-14|2010-01-15|Estimate|||||||2015-11-11|2015-11-13|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors|A Phase 1 Open-Label, Dose Finding, Safety and Tolerability Study of AC220 Administered Daily to Patients With Advanced Solid Tumors|Completed||Phase 1|45|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 00:11:07.472904|2018-06-01 00:11:07.472904
NCT01049880|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2017-04-19|2010-01-14|2010-01-15|Estimate|||||||2017-04-19|2017-04-21|Actual|December 2009||2009-12-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer|A Phase I Trial of Ascorbic Acid and Gemcitabine for the Treatment of Metastatic Pancreatic Cancer|Completed||Phase 1|15|Actual|University of Iowa||1|||f||||t||||||||||2018-06-01 00:11:07.534249|2018-06-01 00:11:07.534249
NCT01049867|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-01-13|2010-01-13|2010-01-15|Estimate|||||||2010-01-13|2010-01-15|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||CD133+ Cell Therapy for Refractory Coronary Heart Disease|Phase 1-2 Study of Intracoronary Infusion of CD133+ Endothelial Precursor Cells for Patients With Coronary Heart Disease in Selected Obstructed Artery|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Hospital y Clinica OCA, S.A. de C.V.|||||f||||f||||||||||2018-06-01 00:11:07.638078|2018-06-01 00:11:07.638078
NCT01049854|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2018-04-06|2010-01-14|2010-01-15|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2011||2011-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant|CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease|Active, not recruiting||Phase 2|20|Actual|New York Medical College||4|||f||||f||||||||||2018-06-01 00:11:07.841781|2018-06-01 00:11:07.841781
NCT01049841|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2017-03-09|2010-01-14|2010-01-15|Estimate|||||||2017-03-09|2017-03-10|Actual|January 2010|Actual|2010-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors|Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors|Completed||Phase 1|23|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:11:07.936569|2018-06-01 00:11:07.936569
NCT01049828|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-14|||2011-07-29|2010-01-14|2010-01-15|Estimate|||||||2011-07-29|2011-08-01|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|||Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother|Resting-State Neural Connectivity in Patients With Subjective Tinnitus Without Bother|Unknown status|Active, not recruiting||19|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-06-01 00:11:08.00871|2018-06-01 00:11:08.00871
NCT01049815|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-01-13|2010-01-13|2010-01-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|February 2005||2005-02-28|January 2010|2010-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|SUMMER||Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease|A Randomized-controlled Trial Comparing the Efficacy of Two Phosphorous Binders, Renagel and Caltrate in Reducing the Rate of Progression of Femoral and Carotid IMT Thickening as Measured by B-mode Ultrasound in Dialysis Patients.|Completed||N/A|175|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:11:08.094161|2018-06-01 00:11:08.094161
NCT01049802|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2015-07-31||2016-11-02|2010-01-13|2010-01-14|Estimate|2016-11-02|2016-12-29|Estimate||||2016-11-02|2016-12-29|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|November 2013|Actual|2013-11-30||Interventional|ContraStim||Contrastim Stroke Trial|Evaluation of Therapeutic Effects of Navigation-guided 1 Hz rTMS Administered to the Contralesional Hemisphere in Patients With Stroke|Completed||Phase 1/Phase 2|30|Actual|Shirley Ryan AbilityLab|Active group included combination of two types of active rTMS. Data was intended purely for pilot purposes to estimate sample size for a larger multicenter trial (the NICHE clinical trial).|2|||f||||f||||||||||2018-06-01 00:11:08.183911|2018-06-01 00:11:08.183911
NCT01049789|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2017-02-27|2010-01-13|2010-01-14|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2010||2010-06-30|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Treatment for Depression Among HIV-Infected Youth|Treatment for Depression Among HIV-Infected Youth|Completed||N/A|42|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:11:08.5029|2018-06-01 00:11:08.5029
NCT01049776|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2014-08-11||2014-09-16|2010-01-13|2010-01-14|Estimate|2014-09-16|2014-09-19|Estimate||||2014-09-16|2014-09-19|Estimate|January 2010||2010-01-31|September 2014|2014-09-30||||March 2014|Actual|2014-03-31||Interventional||Stratification was performed based on histology of disease. Enrollment was targeted to 21 patients with squamous histology and 21 patients with non- squamous histology. Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.|GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line|A Phase II Study of GW786034 in Patients With Non Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens. An Institutional Pilot Study|Terminated||Phase 2|32|Actual|Illinois CancerCare, P.C.|Due to the lack of patients with squamous histology, the study was closed prior to meeting the enrollment goal of 44 subjects.|1||"Study was terminated due to positive results seen in statistical analysis. Adequate patient~   enrollment was achieved."|f||||f||||||||||2018-06-01 00:11:08.770342|2018-06-01 00:11:08.770342
NCT01049763|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-10-07|2010-01-13|2010-01-14|Estimate|||||||2010-10-07|2010-10-08|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Open-Label Pharmacokinetic of Oseltamivir in Healthy Obese Thai Adult Subjects|Phase I, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Oseltamivir in Healthy Obese Thai Adult Subjects|Completed||Phase 1|24|Actual|South East Asia Infectious Disease Clinical Research Network||2|||f||||t||||||||||2018-06-01 00:11:09.090755|2018-06-01 00:11:09.090755
NCT01049750|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-03-15|2010-01-13|2010-01-14|Estimate|||||||2015-03-15|2015-03-17|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Prevalence and Risk Factors of Erectile Dysfunction in Type 2 Diabetic Patients||Completed|||220|Actual|University of Pavia|||1||f||||t||||||||||2018-06-01 00:11:09.186064|2018-06-01 00:11:09.186064
NCT01049737|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-03-07|2010-01-13|2010-01-14|Estimate|||||||2018-03-07|2018-03-08|Actual|May 2005||2005-05-31|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|CARDIPP||Cardiovascular Risk Factors in Patients With Diabetes -a Prospective Study in Primary Care|Cardiovascular Risk Factors in Patients With Diabetes -a Prospective Study in Primary Care|Completed|||761|Actual|Linkoeping University|||||f||||f||||||Samples With DNA|"~     Blood samples were drawn in the fasting state and analysed for levels of HbA1c, hs-CRP,~     cytokines, lipid and lipoprotein status etc. RNA is extracted from whole blood and the~     PPAR-gamma isoform was determined after RT-PCR and analysis of DNA sequence. Several small~     vials of plasma and serum are stored for later analysis of different hormones, cytokines and~     antibodies (when the economy of the project allows this, high priority is antibodies against~     GAD and islet beta-cells and levels of hormones such as resistin, adiponectin, leptin and~     markers of inflammation in terms of cytokines as IL-1, IL-6, IL-10). Other genetic~     polymorphisms of importance for risk assessment will also be analysed when the economy allows~     this.~   "|||2018-06-01 00:11:09.25735|2018-06-01 00:11:09.25735
NCT01049724|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-02-06|2010-01-13|2010-01-14|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2010||2010-01-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Lacritin and Heparanase Levels in Human Tears After Laser Refractive Surgery|Lacritin and Heparanase Levels in Human Tears After Laser Refractive Surgery|Completed|||196|Actual|Fort Belvoir Community Hospital|||2||f||||t||||||||||2018-06-01 00:11:09.381735|2018-06-01 00:11:09.381735
NCT01049711|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-09-28|2010-01-13|2010-01-14|Estimate|||||||2015-09-28|2015-09-29|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Observational|CUAEPO||Cost Utility Analysis of Erythropoietin for Anemia Treatment in Hemodialysis Patients|Cost-Utility Analysis of Erythropoietin for Anemia Treatmentin Thai End-Stage Renal Disease Patients With Hemodialysis|Completed|||152|Actual|Mahidol University|||1||f||||f||||||||||2018-06-01 00:11:09.447734|2018-06-01 00:11:09.447734
NCT01049698|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2017-03-10|2010-01-13|2010-01-14|Estimate|||||||2017-03-10|2017-03-14|Actual|February 2010||2010-02-28|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|I'MFIT||Improving Muscle for Functional Independence Trial|Improving Muscle for Functional Independence Trial|Completed||N/A|126|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||Yes|All data will be made available upon email request to the study PI and upon completion of a data-sharing agreement. This agreement will require that data be used only for research purposes, that no attempts be made to identify individual patients, that the data will be kept secure, that the user will not distribute the data to other researchers, that the user will return the files or destroy them once the project is completed, and that the user will acknowledge the data source. All data files will be de-identified. In addition, variables that could permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects will be removed or recoded. We will create a link on our website that describes our study and the data available for data sharing with descriptions.|2018-06-01 00:11:09.522435|2018-06-01 00:11:09.522435
NCT01049685|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-02-12|2010-01-13|2010-01-14|Estimate|||||||2010-02-12|2010-02-15|Estimate|August 2006||2006-08-31|January 2010|2010-01-31|March 2010|Anticipated|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy|"Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a Real Life Study"|Unknown status|Active, not recruiting|Phase 4|36|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||||2018-06-01 00:11:09.61024|2018-06-01 00:11:09.61024
NCT01049672|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-03-15|2010-01-13|2010-01-14|Estimate|||||||2015-03-15|2015-03-17|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DASH||Diamorphine or Alfentanil for Subcutaneous Use in Hospice In-patients?|An Open-label Pilot Comparison Between Alfentanil and Diamorphine for Palliative Care Patients Who Require Subcutaneous Opioids|Completed||N/A|18|Actual|Gloucestershire Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:11:09.698978|2018-06-01 00:11:09.698978
NCT01049659|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-12-08|2010-01-13|2010-01-14|Estimate|||||||2011-12-08|2011-12-09|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Iodine Supplementation During Pregnancy and Neuropsychological Development|Effect of Iodine Supplementation and During Pregnancy on Neuropsychological Development of Children Assessed at 2 Years Old|Completed||N/A|85|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 00:11:09.776711|2018-06-01 00:11:09.776711
NCT01049646|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-08-09|2010-01-13|2010-01-14|Estimate|||||||2010-08-09|2010-08-10|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Interaction of Apelin and Angiotensin in the Systemic Circulation||Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:11:09.839708|2018-06-01 00:11:09.839708
NCT01049633|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2014-06-09|2010-01-12|2010-01-14|Estimate|||||||2014-06-09|2014-06-11|Estimate||||June 2014|2014-06-30||||||||Expanded Access|||B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure|B-Lymphocyte Immunotherapy in Islet Transplantation: Single Subject Modification to Calcineurin-Inhibitor Based Immunosuppression for Initial Islet Graft (CIT-0501)|No longer available|||||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||t||||||||||2018-06-01 00:11:09.901402|2018-06-01 00:11:09.901402
NCT01049620|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-01-11|2010-01-13|2010-01-14|Estimate|||||||2015-01-11|2015-01-13|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|September 2013|Actual|2013-09-30|July 2011|Actual|2011-07-31||Interventional|||RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer|A Phase I Dose Finding Study of RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer|Completed||Phase 1|40|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 00:11:10.002632|2018-06-01 00:11:10.002632
NCT01049607|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2013-05-16|2010-01-13|2010-01-14|Estimate|||||||2013-05-16|2013-05-17|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|CRUNSH||Stapler Hepatectomy for Elective Liver Resection|Clamp-Crushing vs. Stapler Hepatectomy for Transection of the Parenchyma in Elective Hepatic Resection: CRUNSH - A Randomized Controlled Trial|Completed||Phase 3|130|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 00:11:10.068842|2018-06-01 00:11:10.068842
NCT01049594|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-06-02|2010-01-13|2010-01-14|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|ePrime||ePrime: Evaluation of Magnetic Resonance (MR) Imaging to Predict Neurodevelopmental Impairment in Preterm Infants|Evaluation of MR Imaging to Predict Neurodevelopmental Impairment in Preterm Infants|Unknown status|Active, not recruiting||625|Anticipated|Imperial College London|||1||f||||t||||||Samples With DNA|"~     Saliva samples containing DNA.~   "|||2018-06-01 00:11:10.134242|2018-06-01 00:11:10.134242
NCT01049581|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2013-06-03||2015-02-10|2010-01-12|2010-01-14|Estimate|2015-02-10|2015-02-11|Estimate||||2015-02-10|2015-02-11|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy|Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy|Completed||N/A|27|Actual|Chang Gung Memorial Hospital|no pain or falling down or other adverse effect were report|2|||f||||t||||||||||2018-06-01 00:11:10.210564|2018-06-01 00:11:10.210564
NCT01049568|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2017-02-27|2010-01-13|2010-01-14|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2009||2009-10-31|March 2016|2016-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Cell Phone Reminders Intervention|A Pilot Study Using Cell Phone Interactions to Improve Medication Adherence in Adolescents Who Have Previously Failed Antiretroviral Therapy Due to Non-Adherence|Completed||N/A|43|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:11:10.444627|2018-06-01 00:11:10.444627
NCT01049555|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-09-29|2010-01-13|2010-01-14|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|09-PP-06||Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research|Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research|Completed||N/A|42|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-06-01 00:11:10.519725|2018-06-01 00:11:10.519725
NCT01049542|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-11-15|2010-01-13|2010-01-14|Estimate|||||||2010-11-15|2010-11-16|Estimate|May 2010||2010-05-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers|Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers|Completed||N/A|6|Actual|University of Edinburgh||1|||f||||f||||||||||2018-06-01 00:11:10.733516|2018-06-01 00:11:10.733516
NCT01049529|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2017-01-12|2010-01-13|2010-01-14|Estimate|||||||2017-01-12|2017-01-13|Estimate|March 2007||2007-03-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|June 2011|Actual|2011-06-30||Interventional|DHA-IRCO||Effect of Docosahexaenoic Acid on the Inflammatory Response and Clinical Outcomes From Surgical Patients|Efecto Modulador de la Administracion Del Acido Docosahexaenoico Sobre la Respuesta Inflamatoria, la evolución Clinica y el Estado Nutricional de Neonatos Sometidos a cirugía|Completed||Phase 2|55|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||No||2018-06-01 00:11:10.807799|2018-06-01 00:11:10.807799
NCT01049516|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2017-10-13|2010-01-13|2010-01-14|Estimate|||||||2017-10-13|2017-10-17|Actual|November 2010||2010-11-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|STRONG STAR||Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) Among Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Personnel|Prolonged Exposure for PTSD Among OIF/OEF Personnel: Massed vs. Spaced Trials|Active, not recruiting||N/A|366|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 00:11:10.899816|2018-06-01 00:11:10.899816
NCT01049503|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2012-05-07||2012-08-20|2010-01-13|2010-01-14|Estimate|2012-07-12|2012-08-21|Estimate||||2012-08-20|2012-08-30|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|February 2012|Actual|2012-02-29|December 2010|Actual|2010-12-31||Interventional|EPHFCDCC||Effect of pH and Fluoride Concentration of Dentifrices on Caries Control|Effect of pH and Fluoride Concentration of Liquid Dentifrices on Caries Control in a Fluoridated Area: a Randomized Clinical Trial|Completed||Phase 3|315|Actual|University of Sao Paulo||6|||f||||t||||||||||2018-06-01 00:11:11.014868|2018-06-01 00:11:11.014868
NCT01049490|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2013-12-13|2010-01-13|2010-01-14|Estimate|||||||2013-12-13|2013-12-16|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device|Safety and Efficacy of Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination With the Novel Microneedle Delivery Device|Completed||N/A|262|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:11:11.44106|2018-06-01 00:11:11.44106
NCT01049477|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2017-11-06|2010-01-13|2010-01-14|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2008||2008-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery|The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery|Completed||N/A|50|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 00:11:11.575857|2018-06-01 00:11:11.575857
NCT01049464|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2016-03-28|2010-01-13|2010-01-14|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|EMSAF||Magnesium Sulphate for Treatment of New Onset Atrial Fibrillation in Medical Intensive Care Unit Patient|Efficacy of Magnesium Sulphate for Rate and Rhythm Control of New-onset Atrial Fibrillation in the Medical Critically Ill Patients: A Randomized, Controlled Trial|Unknown status|Recruiting|N/A|128|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 00:11:11.650227|2018-06-01 00:11:11.650227
NCT01049451|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2017-04-17|2010-01-13|2010-01-14|Estimate|||||||2017-04-17|2017-04-19|Actual|November 2009||2009-11-30|April 2017|2017-04-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Pulse ACTH vs. MP for MS|Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)|Completed||Phase 1|23|Actual|University of Southern California||2|||f||||t||||||||Undecided||2018-06-01 00:11:11.734171|2018-06-01 00:11:11.734171
NCT01049269|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-06-23|2010-01-13|2010-01-14|Estimate|||||||2015-06-23|2015-06-25|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Validation and Evaluation of a Portable Body Scanner for Determination of Obesity|Validation and Evaluation of a Portable Body Scanner for Determination of Obesity|Completed|||180|Actual|University of Texas at Austin|||1||f||||t||||||||||2018-06-01 00:11:15.320495|2018-06-01 00:11:15.320495
NCT01049438|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-01-13|2010-01-13|2010-01-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|August 2006||2006-08-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections|A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections|Completed||N/A|31|Actual|Natividad Medical Center||1|||f||||t||||||||||2018-06-01 00:11:11.808092|2018-06-01 00:11:11.808092
NCT01049425|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-06-18|2010-01-13|2010-01-14|Estimate|||||||2015-06-18|2015-06-19|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|July 2011|Actual|2011-07-31||Interventional|planB||Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer|Randomised Comparison of Adjuvant Docetaxel / Cyclophosphamide With Sequential Adjuvant EC / Docetaxel Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer|Unknown status|Active, not recruiting|Phase 3|2448|Anticipated|West German Study Group||2|||f||||t||||||||||2018-06-01 00:11:11.878234|2018-06-01 00:11:11.878234
NCT01049412|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2018-03-17|2011-04-05|2018-03-17|2010-01-12|2010-01-14|Estimate|2018-03-17|2018-04-17|Actual|2011-04-05|2011-04-13|Estimate|2018-03-17|2018-04-17|Actual|January 2010||2010-01-31|March 2018|2018-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Study for Patients With Type 1 Diabetes|A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus|Completed||Phase 2|138|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:11:11.998152|2018-06-01 00:11:11.998152
NCT01049399|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2012-01-02|2010-01-13|2010-01-14|Estimate|||||||2012-01-02|2012-01-05|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|Tauros||Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy|Completed||N/A|146|Actual|Noscira SA||3|||f||||t||||||||||2018-06-01 00:11:12.540366|2018-06-01 00:11:12.540366
NCT01049386|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-07-26|2010-01-13|2010-01-14|Estimate|||||||2010-07-26|2010-07-27|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Intestinal Permeability|Methods to Examine Intestinal Permeability Under Different Conditions|Completed||Phase 2|16|Actual|TNO||2|||f||||f||||||||||2018-06-01 00:11:12.652825|2018-06-01 00:11:12.652825
NCT01049373|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2012-05-10||2012-08-03|2010-01-13|2010-01-14|Estimate|2012-08-03|2012-09-06|Estimate||||2012-08-03|2012-09-06|Estimate|December 2003||2003-12-31|June 2012|2012-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|144||Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain|Efficacy and Safety of Lymphdiaral Basistropfen (a Fixed Homoeopathic Remedy [HDC]) in the Treatment of Chronic Low-back Pain Considering Constitution and Diathesism: a Double Blind, Randomised, Placebo Controlled, Single-centre Study|Completed||Phase 3|221|Actual|Pascoe Pharmazeutische Praeparate GmbH||2|||f||||f||||||||||2018-06-01 00:11:12.723859|2018-06-01 00:11:12.723859
NCT01049360|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2016-09-22|2011-09-30|2017-01-16|2010-01-13|2010-01-14|Estimate|2016-09-22|2016-11-09|Estimate|2011-09-30|2011-10-05|Estimate|2017-01-16|2017-02-28|Actual|December 2009||2009-12-31|January 2017|2017-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|LAC-MD-27||Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo|Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|128|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 00:11:13.055123|2018-06-01 00:11:13.055123
NCT01049347|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-13|2010-01-13|2010-01-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|October 1997||1997-10-31|December 2009|2009-12-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Amitriptyline and Paroxetine Treatment of Major Depression|Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients|Completed||Phase 3|127|Actual|Central Institute of Mental Health, Mannheim||2|||f||||t||||||||||2018-06-01 00:11:13.693191|2018-06-01 00:11:13.693191
NCT01049334|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2015-06-30||2017-08-23|2010-01-13|2010-01-14|Estimate|2017-08-23|2017-09-21|Actual||||2017-08-23|2017-09-21|Actual|November 2009||2009-11-30|August 2017|2017-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis|A Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study to Determine the Efficacy, Onset, and Duration of Action of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis|Completed||Phase 3|204|Actual|Reckitt Benckiser LLC||2|||f||||t||||||||||2018-06-01 00:11:13.817559|2018-06-01 00:11:13.817559
NCT01049321|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-01-13|2010-01-13|2010-01-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|December 2008||2008-12-31|March 2008|2008-03-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients||Completed||Phase 4|36|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:11:14.654436|2018-06-01 00:11:14.654436
NCT01049308|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2014-10-06||2015-04-06|2010-01-13|2010-01-14|Estimate|2014-11-20|2014-11-24|Estimate||||2015-04-06|2015-04-28|Estimate|February 2010||2010-02-28|August 2014|2014-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Cognitive Problems in Veterans With Heart Failure|Cognitive Impairment as a Risk for the Admission-Readmission Cycle Seen in Veterans With Heart Failure: Closing the Adherence Gap|Completed|||300|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 00:11:14.749504|2018-06-01 00:11:14.749504
NCT01049295|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2011-10-29|2010-01-13|2010-01-14|Estimate|||||||2011-10-29|2011-11-01|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|February 2012|Anticipated|2012-02-29|November 2011|Anticipated|2011-11-30||Interventional|||Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer|The Effects of Omega-3 Fatty Acids on Chemotherapy-induced Neuropathy and Inflammation in Patients With Breast Cancer|Unknown status|Recruiting|Phase 4|52|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:11:15.166939|2018-06-01 00:11:15.166939
NCT01049282|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-04-16|2010-01-13|2010-01-14|Estimate|||||||2015-04-16|2015-04-17|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|THYB-03||A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)|A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered in Different Antigen/Adjuvant Formulations in TST Negative and TST Positive Volunteers at 0 and 2 Months|Completed||Phase 1|39|Actual|Statens Serum Institut||4|||f||||t||||||||||2018-06-01 00:11:15.251055|2018-06-01 00:11:15.251055
NCT01049256|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-01-13|2010-01-13|2010-01-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|October 2010|Anticipated|2010-10-31|April 2010|Anticipated|2010-04-30||Interventional|||The Cyclocapnic Method for Measurement of Chemosensitivity|Developing an Improved Measure of Chemosensitivity for the Study of Periodic Breathing in Heart Failure: the Cyclocapnic Method|Unknown status|Recruiting|Phase 1|45|Anticipated|Imperial College London|||||f||||f||||||||||2018-06-01 00:11:15.386988|2018-06-01 00:11:15.386988
NCT01049243|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2012-12-21||2017-11-01|2010-01-13|2010-01-14|Estimate|2013-01-28|2013-03-05|Estimate||||2017-11-01|2017-12-07|Actual|March 2009||2009-03-31|November 2017|2017-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|Vanos||A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis|An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis|Completed||Phase 4|20|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-06-01 00:11:15.457152|2018-06-01 00:11:15.457152
NCT01049230|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-01-17|2010-01-13|2010-01-14|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2010||2010-06-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors|Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors: Evaluation of Acute and Late Side Effects|Active, not recruiting||N/A|45|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:11:15.596206|2018-06-01 00:11:15.596206
NCT01049217|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2013-05-06||2013-08-27|2010-01-13|2010-01-14|Estimate|2013-05-06|2013-07-17|Estimate||||2013-08-27|2013-09-09|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial Of Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy (Pregabalin A0081244)|Terminated||Phase 3|377|Actual|Pfizer|Based on Data Monitoring Committee (DMC) interim efficacy analysis results indicating a low probability for success, the study was terminated on April 2, 2012; the termination was unrelated to any safety findings that could impact participant health.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:11:15.763206|2018-06-01 00:11:15.763206
NCT01049204|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-10-31|2010-01-13|2010-01-14|Estimate|||||||2011-10-31|2011-11-01|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens|Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study on Maraviroc, an Oral ART CCR5 Inhibitor, on the Intensification of Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens|Terminated||Phase 4|48|Actual|St Stephens Aids Trust||4||"The data from the first 48 patients recruited has now been analysed, and it has been determined~   that it is sufficient to meet the study objectives."|f||||f||||||||||2018-06-01 00:11:17.801278|2018-06-01 00:11:17.801278
NCT01049191|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-10-01|2010-01-13|2010-01-14|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|mMRI||Bone Microarchitecture in Women With and Without Fracture|Bone Microarchitecture in Women With and Without Fracture|Completed|||78|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||Samples Without DNA|"~     Blood samples are being collected to obtain chemistry panel and test related to skeletal~     status. These samples will not be retained or stored after these analyses are completed.~   "|||2018-06-01 00:11:17.872626|2018-06-01 00:11:17.872626
NCT01049178|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2014-02-20|2010-01-13|2010-01-14|Estimate|||||||2014-02-20|2014-02-24|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Randomized Controlled Trial of Silymarin in Asthma|Antioxidant Enzyme Induction as a New Approach to Therapy in Patients With Asthma|Withdrawn||Phase 2/Phase 3|0|Actual|Vanderbilt University||2||Lack of funding|f||||t||||||||||2018-06-01 00:11:17.928509|2018-06-01 00:11:17.928509
NCT01049165|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-02-10|2010-01-12|2010-01-14|Estimate|||||||2011-02-10|2011-02-11|Estimate|February 2010||2010-02-28|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Single Ascending Dose (BMS-813160) Study|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-813160 in Healthy Subjects|Completed||Phase 1|70|Actual|Bristol-Myers Squibb||9|||f||||f||||||||||2018-06-01 00:11:18.137597|2018-06-01 00:11:18.137597
NCT01049152|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2013-08-18|2010-01-13|2010-01-14|Estimate|||||||2013-08-18|2013-08-20|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Continuous Glucose Monitoring and Inflammation in Nondiabetic and Diabetic Patients Undergone Hemodialysis||Unknown status|Recruiting||36|Anticipated|University of Pavia|||2||f||||f||||||||||2018-06-01 00:11:18.234479|2018-06-01 00:11:18.234479
NCT01049139|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2017-03-02|2010-01-13|2010-01-14|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2010||2010-01-31|March 2016|2016-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Preventative Misconception Intervention|Evaluation of an Intervention to Reduce Preventive Misconception in HIV Vaccine Clinical Trials|Completed||N/A|120|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-06-01 00:11:18.320032|2018-06-01 00:11:18.320032
NCT01049126|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2011-03-14|2010-01-13|2010-01-14|Estimate|||||||2011-03-14|2011-03-16|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Observational|||Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients|Retrospective Case Study to Determine the Correlation of Patient Outcome to the ChemoFx Assay in Cases With Late Stage Endometrial Cancer|Completed|||76|Actual|Precision Therapeutics|||1||f||||f||||||||||2018-06-01 00:11:18.402222|2018-06-01 00:11:18.402222
NCT01049113|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-12-07|2010-01-12|2010-01-14|Estimate|||||||2015-12-07|2015-12-08|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia|Phase 1, Dose Escalation Study To Assess the Safety, Pharmacokinetics and Activity of 2-Hour Continuous Intravenous Dosing of ON 013105 Administered Weekly in Patients With Relapsed/Refractory Lymphoma and Acute Lymphoid Leukemia|Terminated||Phase 1|7|Actual|Onconova Therapeutics, Inc.||1||Lack of available clinical drug supply|f||||f||||||||||2018-06-01 00:11:18.461965|2018-06-01 00:11:18.461965
NCT01049100|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-01-14|2010-01-13|2010-01-14|Estimate|||||||2010-01-14|2010-01-15|Estimate|April 2009||2009-04-30|August 2009|2009-08-31|April 2017|Anticipated|2017-04-30|April 2013|Anticipated|2013-04-30||Interventional|uterus11||Surgical Staging in Cervical Cancer Prior to Chemoradiation|Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation|Unknown status|Recruiting|N/A|250|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 00:11:18.529126|2018-06-01 00:11:18.529126
NCT01049087|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2013-03-19|2010-01-13|2010-01-14|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2012||2012-01-31|January 2010|2010-01-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Plasma Volume Determination by 99mTc-labeled Albumin and 125I-labeled Albumin|Comparison of Plasma Volume Determination by 99mTc-labeled Albumin and 125I-labeled Albumin|Completed||N/A|15|Actual|Zealand University Hospital|||||f||||t||||||||||2018-06-01 00:11:18.642532|2018-06-01 00:11:18.642532
NCT01049074|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2010-03-18|2010-01-13|2010-01-14|Estimate|||||||2010-03-18|2010-03-19|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|November 2011|Anticipated|2011-11-30|November 2010|Anticipated|2010-11-30||Interventional|ANLBP||A Random Controlled Test (RCT): Acupuncture Treatment on Nonspecific Low Back Pain (NLBP)|A Random Controlled Test (RCT): Acupuncture Treatment on Nonspecific Low Back Pain (NLBP) (ANLBP)|Unknown status|Recruiting|N/A|534|Anticipated|Beijing Hospital of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:11:18.702953|2018-06-01 00:11:18.702953
NCT01049061|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2014-02-20|2010-01-13|2010-01-14|Estimate|||||||2014-02-20|2014-02-21|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Study of MORAb-003 in Patients With Solid Tumor|A Phase 1 Study of MORAb-003 in Patients With Solid Tumor|Completed||Phase 1|16|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 00:11:18.770987|2018-06-01 00:11:18.770987
NCT01049048|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-10-01|2010-01-13|2010-01-14|Estimate|||||||2015-10-01|2015-10-05|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CVD Cookie||The Effect of Vitamin D Statues on Endothelial Function|The Effect of Vitamin D Statues on Endothelial Function|Completed||Early Phase 1|80|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:11:18.823362|2018-06-01 00:11:18.823362
NCT01049035|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13||2013-04-16|2017-04-24|2010-01-13|2010-01-14|Estimate||||2013-04-16|2013-04-25|Estimate|2017-04-24|2017-04-25|Actual|December 2009||2009-12-31|April 2017|2017-04-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine (TetraMen-T) in Infants and Toddlers|Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) Administered in Infants and Toddlers|Completed||Phase 2|580|Actual|Sanofi||7|||f||||f||||||||||2018-06-01 00:11:18.888475|2018-06-01 00:11:18.888475
NCT01049022|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-07-21|2010-01-13|2010-01-14|Estimate|||||||2015-07-21|2015-07-22|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients|Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients|Completed||Phase 1|31|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:11:18.999301|2018-06-01 00:11:18.999301
NCT01049009|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2014-12-12||2017-03-13|2010-01-13|2010-01-14|Estimate|2014-12-12|2014-12-19|Estimate||||2017-03-13|2017-04-11|Actual|December 2009||2009-12-31|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Baseline population characteristics only account for subjects that completed the entire study.|The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension|The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension|Completed||Phase 4|91|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:11:20.059902|2018-06-01 00:11:20.059902
NCT01048996|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-08-21|2010-01-13|2010-01-14|Estimate|||||||2015-08-21|2015-08-24|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|BALI||Genetic Variability and Biomarkers in Children With Acute Lung Injury|Genetic Variability and Biomarkers in Children With Acute Lung Injury|Withdrawn|||0|Actual|Medical College of Wisconsin|||2|PI has left institution|f||||f||||||Samples With DNA|"~     3 samples will be collected from each patient, one whole blood and three plasma samples will~     be retained.~   "|||2018-06-01 00:11:20.285137|2018-06-01 00:11:20.285137
NCT01048983|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-03-04|2010-01-13|2010-01-14|Estimate|||||||2015-03-04|2015-03-05|Estimate||||March 2015|2015-03-31||||||||Interventional|||Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)|A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||16||No accrual.|f||||t||||||||||2018-06-01 00:11:20.345934|2018-06-01 00:11:20.345934
NCT01048970|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-09|||2010-01-12|2010-01-12|2010-01-14|Estimate|||||||2010-01-12|2010-01-14|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|May 2010|Anticipated|2010-05-31||Interventional|||Effect on the Nutritional and Inflammatory Status of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement in Patients With Advanced Lung Cancer|A Prospective Randomized Trial: Effect of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)- Containing Supplement on the Nutritional and Inflammatory Status, Quality of Life, Toxicity and Response Rate to First-line Chemotherapy in Patients With Advanced Lung Cancer|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|National Institute of Cancerología||2|||f||||f||||||||||2018-06-01 00:11:20.459362|2018-06-01 00:11:20.459362
NCT01048957|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-05-16|2010-01-13|2010-01-14|Estimate|||||||2018-05-16|2018-05-17|Actual|January 9, 2007||2007-01-09|April 8, 2013|2013-04-08|April 8, 2013|Actual|2013-04-08|April 8, 2013|Actual|2013-04-08||Interventional|||The Neural Basis of Cue-Elicited Cigarette Craving and Its Control|The Neural Basis of Cue-Elicited Cigarette Craving and Its Control|Completed||N/A|79|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:11:20.537508|2018-06-01 00:11:20.537508
NCT01048944|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2014-05-19||2014-11-18|2010-01-13|2010-01-14|Estimate|2014-11-18|2014-11-25|Estimate||||2014-11-18|2014-11-25|Estimate|June 2005||2005-06-30|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Personality trait questionnaires, history of psychiatric disorders, SES, age, smoking and drug use history.|Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers|NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial|Completed||Phase 4|197|Actual|Southern Illinois University Carbondale|The modest sample size limited the ability to detect more subtle treatment effects. The exclusionary criteria limits generalization to excluded groups.|4|||f||||t||||||||||2018-06-01 00:11:20.737993|2018-06-01 00:11:20.737993
NCT01048931|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-13|2010-01-13|2010-01-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Single-port Access Laparoscopic-assisted Vaginal Hysterectomy|To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|100|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f||||t||||||||||2018-06-01 00:11:21.202959|2018-06-01 00:11:21.202959
NCT01048580|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-09|||2014-02-14|2010-01-12|2010-01-13|Estimate|||||||2014-02-14|2014-02-19|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Study of Perifosine + Capecitabine for Colon Cancer Patients|A Phase I Study of Perifosine + Capecitabine for Patients With Advanced Colon Cancer|Completed||Phase 1|10|Actual|AEterna Zentaris||1|||f||||f||||||||||2018-06-01 00:11:26.296809|2018-06-01 00:11:26.296809
NCT01048918|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2018-03-30|2010-01-13|2010-01-14|Estimate|||||||2018-03-30|2018-04-03|Actual|September 2008||2008-09-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer|Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer|Recruiting|||280|Anticipated|City of Hope Medical Center|||1||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 00:11:21.299914|2018-06-01 00:11:21.299914
NCT01048905|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2014-07-17|2010-01-13|2010-01-14|Estimate|||||||2014-07-17|2014-07-18|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension|Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension|Completed||Phase 2|32|Actual|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-06-01 00:11:21.377272|2018-06-01 00:11:21.377272
NCT01048892|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2014-01-29|2010-01-13|2010-01-14|Estimate|||||||2014-01-29|2014-01-30|Estimate|September 2009||2009-09-30|January 2014|2014-01-31||||June 2013|Actual|2013-06-30||Interventional|||Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features|A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients With Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features|Completed||Phase 1|22|Actual|Children's Oncology Group||1|||f||||||||||||||2018-06-01 00:11:21.448284|2018-06-01 00:11:21.448284
NCT01048879|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2012-06-13||2012-07-17|2010-01-13|2010-01-14|Estimate|2012-07-17|2012-08-21|Estimate||||2012-07-17|2012-08-21|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)|Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO|Completed||Phase 4|15|Actual|University of Michigan||3|||f||||f||||||||||2018-06-01 00:11:21.546364|2018-06-01 00:11:21.546364
NCT01048866|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2015-06-30||2017-08-23|2010-01-13|2010-01-14|Estimate|2017-08-23|2017-09-21|Actual||||2017-08-23|2017-09-21|Actual|November 2009||2009-11-30|August 2017|2017-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis|A Repeat-Dose, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Study to Determine the Safety and Efficacy of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis|Completed||Phase 3|198|Actual|Reckitt Benckiser LLC||2|||f||||f||||||||||2018-06-01 00:11:21.892571|2018-06-01 00:11:21.892571
NCT01048853|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2018-03-05|2010-01-12|2010-01-14|Estimate|||||||2018-03-05|2018-03-07|Actual|August 2009|Actual|2009-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Conservative Surgery for Women With Cervical Cancer|Conservative Surgery for Women With Low-risk, Early Stage Cervical Cancer|Recruiting||Phase 2|195|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:11:22.78349|2018-06-01 00:11:22.78349
NCT01048840|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2013-10-23|2010-01-13|2010-01-14|Estimate|||||||2013-10-23|2013-10-24|Estimate|September 2004||2004-09-30|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|June 2010|Actual|2010-06-30||Observational|||Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age|The Natural History of Children With Gastroesophageal Reflux Disease (Ages 15 Months to 11 Years)|Unknown status|Active, not recruiting||100|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 00:11:22.883267|2018-06-01 00:11:22.883267
NCT01048827|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2017-08-09|2010-01-13|2010-01-14|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2009||2009-11-30|August 2017|2017-08-31|February 25, 2015|Actual|2015-02-25|December 31, 2013|Actual|2013-12-31||Interventional|Busulfan||Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen|A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation|Completed||Phase 1|12|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:11:22.971512|2018-06-01 00:11:22.971512
NCT01048814|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2011-06-02|2010-01-13|2010-01-14|Estimate|||||||2011-06-02|2011-06-03|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases|Retrospective Study to Develop a Training Set for a Cross Validated Chemoresponse Marker Algorithm in Cases With Ovarian, Peritoneal or Fallopian Tube Cancer|Completed|||512|Anticipated|Precision Therapeutics|||1||f||||f||||||||||2018-06-01 00:11:23.06013|2018-06-01 00:11:23.06013
NCT01048801|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2012-10-11|2010-01-13|2010-01-14|Estimate|||||||2012-10-11|2012-10-12|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|ACTUGA2||Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria|Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria: Comparative Trials in Two Areas of High and Low Transmission in Uganda|Completed||N/A|2000|Actual|DBL -Institute for Health Research and Development||2|||f||||t||||||||||2018-06-01 00:11:23.125118|2018-06-01 00:11:23.125118
NCT01048788|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2013-12-15||2016-03-13|2010-01-12|2010-01-14|Estimate|2014-01-30|2014-03-04|Estimate||||2016-03-13|2016-04-11|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg|A Multicenter, Uncontrolled, Open-label Phase 3 Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg|Completed||Phase 3|51|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:11:23.214203|2018-06-01 00:11:23.214203
NCT01048775|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2012-04-15|2010-01-13|2010-01-14|Estimate|||||||2012-04-15|2012-04-17|Estimate|February 2010||2010-02-28|April 2012|2012-04-30||||||||Observational|||Bilateral Bispectral Index (BIS)-Monitoring in Cardiac Surgery Patients|Investigation on the Diagnostic and Predictive Value of Bilateral Bispectral Index (BIS)-Monitoring in Cardiac Surgery|Completed|||87|Actual|University Hospital, Bonn|||||f||||f||||||||||2018-06-01 00:11:23.565377|2018-06-01 00:11:23.565377
NCT01048762|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2015-10-21|2010-01-13|2010-01-14|Estimate|||||||2015-10-21|2015-10-22|Estimate|February 2006||2006-02-28|October 2015|2015-10-31|September 2010|Actual|2010-09-30|January 2010|Actual|2010-01-31||Interventional|||Multidisciplinary Rehabilitation After Cancer Pulmonis Operation|Multidisciplinary Rehabilitation After Cancer Pulmonis Operation - a Randomized Controlled Trial|Completed||Phase 2|78|Actual|Aalborg Universitetshospital||2|||f||||t||||||||||2018-06-01 00:11:23.648673|2018-06-01 00:11:23.648673
NCT00823056|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2012-04-22|2009-01-14|2009-01-15|Estimate|||||||2012-04-22|2012-04-24|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effect of Probiotics on Infections in Toddlers|The Effect of Probiotics on Infections in Toddlers|Completed||Phase 3|454|Actual|Zealand University Hospital||2|||f||||f||||||||||2018-06-01 01:24:39.209207|2018-06-01 01:24:39.209207
NCT01048749|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-13|2010-01-13|2010-01-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Interventional Study of Effects on Spine Height With Two Unloading Positions|Immediate Changes in Spinal Height and Pain Following Aquatic Vertical Suspension in Patients With Low Back Pain and Signs of Nerve Root Compression|Completed||N/A|60|Actual|Texas Tech University Health Sciences Center||2|||f||||t||||||||||2018-06-01 00:11:23.750866|2018-06-01 00:11:23.750866
NCT01048736|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-09-09|2010-01-13|2010-01-14|Estimate|||||||2014-09-09|2014-09-10|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|INFINITE||Investigating Fitness Interventions in the Elderly (INFINITE)|Investigating Fitness Interventions in the Elderly (INFINITE)|Completed||N/A|180|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||||2018-06-01 00:11:23.843058|2018-06-01 00:11:23.843058
NCT01048723|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|2012-07-13||2013-11-21|2010-01-13|2010-01-14|Estimate|2012-07-13|2012-08-17|Estimate||||2013-11-21|2013-12-16|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas|A Single-arm, Open Label Phase II Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|This study was terminated early due to sponsor budget cuts. We could not meet our accrual goal to perform planned analysis of 40 participants.|1||Novartis terminated funding|f||||t||||||||||2018-06-01 00:11:23.933565|2018-06-01 00:11:23.933565
NCT01048710|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2018-05-24|2010-01-13|2010-01-14|Estimate|||||||2018-05-24|2018-05-25|Actual|July 1, 2009|Actual|2009-07-01|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|March 31, 2015|Actual|2015-03-31||Observational|||Treatment of Medial Compartmental Osteoarthritis Grade 1-4 With TomoFix™ Small or Conservatively|Treatment of Medial Compartmental Osteoarthritis Grade 1-4 (Kellgren-Lawrence) or Osteonecrosis With TomoFix™ Small or Conservatively|Active, not recruiting|||148|Actual|Synthes GmbH|||2||f||||f||||||||||2018-06-01 00:11:24.179821|2018-06-01 00:11:24.179821
NCT01048697|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2012-12-13||2013-01-23|2010-01-13|2010-01-14|Estimate|2013-01-23|2013-01-24|Estimate||||2013-01-23|2013-01-24|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Weight and/or Obesity on Ethambutol Drug Concentrations|Population Pharmacokinetics Analysis of Ethambutol in Overweight and Obese Volunteers|Completed||Phase 4|18|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||||2018-06-01 00:11:24.2623|2018-06-01 00:11:24.2623
NCT01048684|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-13|||2011-05-04|2010-01-13|2010-01-14|Estimate|||||||2011-05-04|2011-05-05|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy|Comparison of Two Doses of Mannitol on Brain Relaxation During Supratentorial Craniotomy|Completed||N/A|80|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 00:11:24.408266|2018-06-01 00:11:24.408266
NCT01048671|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2013-12-23||2015-10-29|2010-01-13|2010-01-14|Estimate|2013-12-23|2014-02-14|Estimate||||2015-10-29|2015-10-30|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|RACING||Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)|Collection of Data on the Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including the HIV Integrase Inhibitor Raltegravir|Completed|||482|Actual|Merck Sharp & Dohme Corp.|||1||f||||t||||||||||2018-06-01 00:11:24.496121|2018-06-01 00:11:24.496121
NCT01048658|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2017-06-14||2017-08-07|2010-01-12|2010-01-13|Estimate|2017-08-07|2017-08-09|Actual||||2017-08-07|2017-08-09|Actual|September 2009||2009-09-30|August 2017|2017-08-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures|Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures: Does it Increase Blood Loss and Interventions for Blood Loss and Why Do Anesthesiologists Choose to Use It?|Completed||Phase 4|160|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 00:11:25.025417|2018-06-01 00:11:25.025417
NCT01048645|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Interventional|||Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer|Randomized Phase II Trial: Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|107|Actual|National Institute of Cancerología||2|||f||||t||||||||||2018-06-01 00:11:25.323702|2018-06-01 00:11:25.323702
NCT01048632|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-01-06|2010-01-11|2010-01-13|Estimate|||||||2017-01-06|2017-01-10|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants|A Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants After Cardiac Surgery|Active, not recruiting||Phase 1|20|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 00:11:25.392696|2018-06-01 00:11:25.392696
NCT01048619|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2017-06-22|2010-01-12|2010-01-13|Estimate|||||||2017-06-22|2017-06-23|Actual|December 2009||2009-12-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome|Phase 1 Study to Assess Tolerability, PK and PD Activity of ON 01910.Na Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Day Cycle in Patients With Myelodysplastic Syndrome|Completed||Phase 1|36|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-06-01 00:11:25.467735|2018-06-01 00:11:25.467735
NCT01048606|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2013-12-18||2013-12-18|2010-01-12|2010-01-13|Estimate|2013-12-18|2014-02-12|Estimate||||2013-12-18|2014-02-12|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Healthy overweight to obese postmenopausal women.|Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women|Exercise and Phytoestrogens: a Synergistic Effect on Factors Predisposing to CVD in Postmenopausal Women|Completed||Phase 4|45|Actual|Université de Sherbrooke||4|||f||||f||||||||||2018-06-01 00:11:25.556387|2018-06-01 00:11:25.556387
NCT01048593|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2012-05-24||2012-08-16|2010-01-12|2010-01-13|Estimate|2012-07-09|2012-08-16|Estimate||||2012-08-16|2012-08-20|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery|A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Cataract Surgery Patients|Terminated||Phase 2|6|Actual|ICON Bioscience Inc|Early termination leading to small numbers of subjects analyzed.|3||Study was terminated in order to examine study data.|f||||f||||||||||2018-06-01 00:11:26.025187|2018-06-01 00:11:26.025187
NCT01048567|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2013-12-17|2010-01-12|2010-01-13|Estimate|||||||2013-12-17|2013-12-19|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly|Use of Lactobacillus Acidophilus/Rhamnosus Complex for the Prevention of Antibiotic-associated Diarrhea in Elderly Hospitalized Patients|Terminated||Phase 2|7|Actual|Vancouver Island Health Authority||2||Insufficient resources to meet enrollment target|f||||f||||||||||2018-06-01 00:11:26.375363|2018-06-01 00:11:26.375363
NCT01048554|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2012-04-18|2010-01-12|2010-01-13|Estimate|||||||2012-04-18|2012-04-19|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|MEL0107||Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System|A Phase II Trial of Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System|Completed||Phase 2|34|Actual|Mt. Sinai Medical Center, Miami||1|||f||||f||||||||||2018-06-01 00:11:26.446324|2018-06-01 00:11:26.446324
NCT01048541|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2012-01-09||2012-08-02|2010-01-12|2010-01-13|Estimate|2012-08-02|2012-09-03|Estimate||||2012-08-02|2012-09-03|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bladder Scan of Residual Urine With New Catheter|A Non-Inferiority Bladder Scan Study to Investigate Residual Urine After Use of Intermittent Catheters in Male Subjects|Completed||Phase 2/Phase 3|37|Actual|Coloplast A/S||2|||f||||f||||||||||2018-06-01 00:11:26.534572|2018-06-01 00:11:26.534572
NCT01048528|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-03-26|2010-01-12|2010-01-13|Estimate|||||||2012-03-26|2012-03-27|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Health SMART (Stress Management and Relaxation Training)|Phase II Study of Stress Management and Vaccine Response Among Women at Risk for Breast Cancer|Completed||Phase 2|33|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 00:11:26.902018|2018-06-01 00:11:26.902018
NCT01048515|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2005||2005-02-28|January 2010|2010-01-31||||November 2005|Actual|2005-11-30||Interventional|||The Effect of Caffeine in Elderly Citizen Following Eight Hour Abstinence From Caffeine Containing Drinks & Foods|The Effect of Caffeine as Endurance Enhancing Drug in the Elderly Following Eight Hour Abstinence From Caffeine Containing Drinks and Foods|Completed||Phase 4|30|Actual|Herning Hospital||2|||f||||t||||||||||2018-06-01 00:11:26.986435|2018-06-01 00:11:26.986435
NCT01048502|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2015-07-29||2016-01-21|2010-01-11|2010-01-13|Estimate|2016-01-21|2016-02-19|Estimate||||2016-01-21|2016-02-19|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|FFAME||Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia|Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia: The FFAME Study|Completed||N/A|100|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 00:11:27.086051|2018-06-01 00:11:27.086051
NCT01048489|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|July 2010|Anticipated|2010-07-31|July 2008|Actual|2008-07-31||Interventional|TAB_es||Evaluation of a Program to Reduce Smoking in High School Students|Effectiveness of a Community Integrated Program to Reduce Smoking Incidence in High School Students|Unknown status|Active, not recruiting|N/A|2256|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-06-01 00:11:27.524132|2018-06-01 00:11:27.524132
NCT01048476|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2012-03-15|2010-01-12|2010-01-13|Estimate|||||||2012-03-15|2012-03-16|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|April 2012|Anticipated|2012-04-30||Interventional|||Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration|Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|Peking University||4|||f||||t||||||||||2018-06-01 00:11:27.667086|2018-06-01 00:11:27.667086
NCT01048463|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-10-04|2010-01-12|2010-01-13|Estimate|||||||2011-10-04|2011-10-06|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor|Phase 3 Study of Enteral Nutrition Rich in Eicosapentaenoic Acid in Patients Receiving Chemotherapy for Gastric Cancer or Colorectal Cancer|Unknown status|Recruiting|Phase 3|90|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-06-01 00:11:27.857321|2018-06-01 00:11:27.857321
NCT01048450|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2011-08-17|2010-01-12|2010-01-13|Estimate|||||||2011-08-17|2011-08-19|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Surgical Treatment for Hallux Rigidus|A Multi-Center Retrospective Review of Resectional Arthroplasty, Arthrodesis and, Hemi-Metallic Joint Implants in the Surgical Treatment of End Stage Hallux Rigidus|Completed||N/A|158|Actual|American College of Foot and Ankle Surgeons||1|||f||||f||||||||||2018-06-01 00:11:28.052205|2018-06-01 00:11:28.052205
NCT01048437|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2011-09-13|2010-01-11|2010-01-13|Estimate|||||||2011-09-13|2011-09-15|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Educating Missouri Patients About Preemptive Living Donor Transplantation|Educating Missouri Patients About Preemptive Living Donor Transplantation: A Randomized Controlled Trial|Completed||N/A|370|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 00:11:28.173986|2018-06-01 00:11:28.173986
NCT01048424|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2013-05-22||2013-10-29|2010-01-11|2010-01-13|Estimate|2013-10-29|2013-11-21|Estimate||||2013-10-29|2013-11-21|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|SPIRIT||Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)|Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)|Completed||N/A|20|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:11:28.302634|2018-06-01 00:11:28.302634
NCT01048411|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|naja-comp||Trial to Investigate the Influence of the Homeopathic Remedy Naja-comp on Stroke Therapy in Geriatric Rehabilitation|Multicenter Randomized Controlled Trial to Investigate the Influence of the Homeopathic Remedy 'Naja-comp' on Stroke Therapy in Geriatric Rehabilitation|Completed||N/A|344|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-06-01 00:11:29.02753|2018-06-01 00:11:29.02753
NCT01048398|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-04-13|2010-01-12|2010-01-13|Estimate|||||||2011-04-13|2011-04-14|Estimate|June 2010||2010-06-30|September 2010|2010-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Remifentanil Versus Paracetamol for Pain Treatment External Cephalic Versions.|Remifentanil Versus Placebo for Pain Treatment External Cephalic Versions. Randomized, Controlled and Masked|Completed||Phase 3|60|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-06-01 00:11:29.165641|2018-06-01 00:11:29.165641
NCT01048385|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-09-05|2010-01-12|2010-01-13|Estimate|||||||2014-09-05|2014-09-09|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CoQ10-IVF||The Effect of Co Enzyme Q10 Together With Fertility Drugs on Pregnancy Outcome of in Vitro Fertilization|The Effect of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome of IVF|Terminated||N/A|34|Actual|University of Toronto||2||"A new study had shown that polar body biopsies might negatively effect the implantation~   potential of the embryo."|f||||f||||||||||2018-06-01 00:11:29.307533|2018-06-01 00:11:29.307533
NCT01048372|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-05-17|2010-01-11|2010-01-13|Estimate|||||||2013-05-17|2013-05-21|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|January 2011|Actual|2011-01-31||Observational|||Observational Study of Blood Treated With Cytolin|An Observational Study to Determine the In-vitro Immunologic and Virology Activity of Cytolin|Completed|||20|Actual|CytoDyn, Inc.|||2||f||||f||||||||||2018-06-01 00:11:29.409264|2018-06-01 00:11:29.409264
NCT01048359|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-11-23|2010-01-11|2010-01-13|Estimate|||||||2015-11-23|2015-11-25|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Interventional|||Multidisciplinary Approach to Reduce Injury and Substance Abuse|Multidisciplinary Approach to Reduce Injury and Substance Abuse|Completed||Phase 3|417|Actual|University of Texas at Austin||3|||f||||t||||||||||2018-06-01 00:11:29.487286|2018-06-01 00:11:29.487286
NCT01048346|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|December 2004||2004-12-31|June 2005|2005-06-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Efficacy of the Individual Placement and Support (IPS) Model|Efficacy of the Individual Placement and Support (IPS) Model for Consumers With Disability and Substance Use Disorders|Unknown status|Active, not recruiting|Phase 1|192|Anticipated|Wright State University||1|||f||||t||||||||||2018-06-01 00:11:29.586476|2018-06-01 00:11:29.586476
NCT01048333|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2011-09-09||2012-09-25|2010-01-12|2010-01-13|Estimate|2012-09-25|2012-10-25|Estimate||||2012-09-25|2012-10-25|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®|A Randomised, Placebo-controlled, Double-blind (Double-dummy Technique),Crossover, Multi-centre Study, to Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler® 9 μg, Compared With Serevent® Diskus® 50 μg.|Completed||Phase 2|109|Actual|AstraZeneca||6|||f||||f||||||||||2018-06-01 00:11:29.720602|2018-06-01 00:11:29.720602
NCT01048320|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-09-21|2010-01-12|2010-01-13|Estimate|||||||2012-09-21|2012-09-25|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|RPGOG1||Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer|A Phase I Study of Gemcitabine Plus Oxaliplatin in Combination With Imatinib Mesylate (Glivec) in Patients With Gemcitabine-refractory Advanced Adenocarcinoma of the Pancreas|Completed||Phase 1|36|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-06-01 00:11:30.109839|2018-06-01 00:11:30.109839
NCT01048307|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-08-16|2010-01-12|2010-01-13|Estimate|||||||2010-08-16|2010-08-17|Estimate|June 2009||2009-06-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Prontosan Wound Irrigation Solution on Venous Ulcers|Randomised, Controlled, Clinical Trial on the Safety and Efficacy of Prontosan Wound Irrigation Solution Compared to Standard Therapy in the Treatment of Hard-to-Heal Venous Leg Ulcers|Completed||N/A|20|Anticipated|Calvary Hospital, Bronx, NY||2|||f||||f||||||||||2018-06-01 00:11:30.194434|2018-06-01 00:11:30.194434
NCT01048294|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Blue Enriched Versus Standard Light Treatment for Seasonal Affective Disorder(SAD)|Gerandomiseerde en Gecontroleerde Studie Naar de Effecten Van Lichttoediening Met Een Hogere Kleurtemperatuur in Vergelijking Met de Standaard Lichttherapie in de Behandeling Van Winterdepressie|Completed||N/A|52|Actual|University Medical Center Groningen||3|||f||||f||||||||||2018-06-01 00:11:30.283393|2018-06-01 00:11:30.283393
NCT01048281|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2016-07-12|2010-01-12|2010-01-13|Estimate|||||||2016-07-12|2016-07-14|Estimate|August 2002||2002-08-31|July 2016|2016-07-31|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Observational|||Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma|Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma|Recruiting|||100|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     blood, tumor~   "|||2018-06-01 00:11:30.353642|2018-06-01 00:11:30.353642
NCT01048268|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-07-10|2010-01-12|2010-01-13|Estimate|||||||2015-07-10|2015-07-14|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?|Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?|Completed||Phase 1/Phase 2|30|Actual|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-06-01 00:11:30.509098|2018-06-01 00:11:30.509098
NCT01048255|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08||2013-12-19|2013-12-19|2010-01-11|2010-01-13|Estimate||||2013-12-19|2014-01-27|Estimate|2013-12-19|2014-01-27|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy|A Phase 2, Randomized, Double-blind,Placebo-controlled Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy|Completed||Phase 2|60|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||f||||||||||2018-06-01 00:11:30.646381|2018-06-01 00:11:30.646381
NCT01048242|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2017-03-22||2017-05-03|2010-01-11|2010-01-13|Estimate|2017-03-22|2017-05-03|Actual||||2017-05-03|2017-06-01|Actual|July 2006||2006-07-31|May 2017|2017-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)|Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)|Completed||Phase 3|27|Actual|University of Pennsylvania|Auto-Continuous Positive Airway Pressure units used. Single-night of polysomnography Unequal sized arms despite randomization Low rate of completion of at-home sleep diaries Small sample size (pilot study)|2|||f||||t||||||||||2018-06-01 00:11:30.748811|2018-06-01 00:11:30.748811
NCT01048229|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2012-05-25|2010-01-12|2010-01-13|Estimate|||||||2012-05-25|2012-05-28|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|ACTOR||Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease|Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease|Terminated||Phase 4|112|Actual|Qualissima||2||recruitment|f||||f||||||||||2018-06-01 00:11:31.126067|2018-06-01 00:11:31.126067
NCT01048216|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|November 2006||2006-11-30|January 2010|2010-01-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Partial Liver Radiotherapy for Unresectable Liver Metastases|Partial Liver Radiotherapy for Patients With Unresectable Colorectal Liver Metastases|Unknown status|Recruiting|N/A|18|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 00:11:31.262202|2018-06-01 00:11:31.262202
NCT01048203|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2014-08-26|2010-01-12|2010-01-13|Estimate|||||||2014-08-26|2014-08-27|Estimate|January 2009||2009-01-31|August 2014|2014-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects|An Open Label, Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects|Completed||Phase 1|6|Actual|Active Biotech AB||1|||f||||f||||||||||2018-06-01 00:11:31.340765|2018-06-01 00:11:31.340765
NCT01048190|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-13|2010-01-12|2010-01-13|Estimate|||||||2010-01-13|2010-01-14|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|IPV||The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|The Phase I Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains|Completed||Phase 1|130|Actual|Chinese Academy of Medical Sciences||3|||f||||t||||||||||2018-06-01 00:11:31.471554|2018-06-01 00:11:31.471554
NCT01048177|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-05-12|2010-01-12|2010-01-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|VV/IC||A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia|A Trial of Intravesical Therapy for Interstitial Cystitis in Patients With Generalized Vulvodynia|Withdrawn||Phase 2|0|Actual|Scripps Health||1|||f||||f||||||||||2018-06-01 00:11:31.64466|2018-06-01 00:11:31.64466
NCT01048164|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2012-01-03|2010-01-12|2010-01-13|Estimate|||||||2012-01-03|2012-01-05|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Measuring the Effect of Therapeutic Massage on Pain and Discomfort in Cardiac Cath Lab Staff|Measuring the Effect of Therapeutic Massage on Pain and Discomfort in Cardiac Cath Lab Staff - A Pilot Study|Completed||N/A|60|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 00:11:31.755195|2018-06-01 00:11:31.755195
NCT01048151|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2012-03-08|2010-01-12|2010-01-13|Estimate|||||||2012-03-08|2012-03-12|Estimate||||March 2012|2012-03-31||||||||Interventional|||TNFerade Biologic to Treat Locally Advanced Prostate Cancer|A PHASE I SAFETY AND TOLERABILITY TRIAL OF RADIOTHERAPY, ANDROGEN DEPRIVATION, AND INTRATUMORAL INJECTIONS OF AdGVEGR.TNF.11D (TNFeradeTM) FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER|Unknown status|Recruiting|Phase 1|20|Anticipated|GenVec||1|||f||||f||||||||||2018-06-01 00:11:31.869476|2018-06-01 00:11:31.869476
NCT01048138|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2018-03-05|2010-01-12|2010-01-13|Estimate|||||||2018-03-05|2018-03-06|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Use of Biperiden for the Prevention of Post-traumatic Epilepsy|Use of Biperiden as a Disease Modifying Agent After Traumatic Brain Injury: a Placebo Controlled, Randomized, Double Blind Study|Recruiting||Phase 3|132|Anticipated|Federal University of São Paulo||2|||f||||t|f|f||||||||2018-06-01 00:11:32.091592|2018-06-01 00:11:32.091592
NCT01048125|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2016-09-23||2016-11-22|2010-01-11|2010-01-13|Estimate|2016-11-22|2016-11-23|Estimate||||2016-11-22|2016-11-23|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Due to difficulty in recruitment and resource restraints the study did not progress as expected and was closed.|Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy|Characterization of Sympathetic Nerve Activity in Stress Cardiomyopathy|Terminated||N/A|2|Actual|University of Missouri-Columbia|2 participants were consented, but due to difficulty in recruitment and resource restraints the study did not progress as expected and was closed.|2||Due to difficulty in recruitment and resource restraints|f||||f||||||||||2018-06-01 00:11:32.4095|2018-06-01 00:11:32.4095
NCT01048112|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|September 2011|Anticipated|2011-09-30|December 2010|Anticipated|2010-12-31||Interventional|||Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection|Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection|Unknown status|Recruiting|Phase 1|16|Anticipated|University of Vermont||2|||f||||t||||||||||2018-06-01 00:11:34.157636|2018-06-01 00:11:34.157636
NCT01048099|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2015-10-08||2015-12-22|2010-01-12|2010-01-13|Estimate|2015-12-22|2016-01-29|Estimate||||2015-12-22|2016-01-29|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Excludes patients with no circulating tumor cells for the PRO Onc Assay|Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer|Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing|Completed||N/A|283|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 00:11:34.943541|2018-06-01 00:11:34.943541
NCT01048086|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2016-06-17|2010-01-12|2010-01-13|Estimate|||||||2016-06-17|2016-06-21|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)|90Y-DOTA-tyr3-Octreotide With or Without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults. A Randomized, Placebo Controlled Phase II Trial With Dosimetry Guided Dosing|Withdrawn||Phase 2|0|Actual|University of Iowa||2||"No patients were enrolled because the company that pledged the drug does not yet have it~   available."|f||||t||||||||||2018-06-01 00:11:36.04275|2018-06-01 00:11:36.04275
NCT01048073|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-05-25|2010-01-12|2010-01-13|Estimate|||||||2011-05-25|2011-05-27|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Non-influenza Etiologies of Acute Respiratory Illness in Southeast Asia|Non-influenza Etiologies of Acute Respiratory Illness in Southeast Asia|Completed|||1200|Actual|South East Asia Infectious Disease Clinical Research Network|||||f||||t||||||Samples With DNA|"~     -  nose swab~        -  throat swab~        -  nasopharyngeal aspirate~        -  nasal wash~        -  tracheal aspirate~        -  bronchoalveolar lavage~   "|||2018-06-01 00:11:36.354391|2018-06-01 00:11:36.354391
NCT01048060|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2016-11-08|2010-01-12|2010-01-13|Estimate|||||||2016-11-08|2016-11-09|Estimate|February 2002||2002-02-28|November 2016|2016-11-30|February 2060|Anticipated|2060-02-29|February 2060|Anticipated|2060-02-29||Observational|||Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure|Consent for Obtaining Additional Bone Marrow Specimens at the Time of a Diagnostic Bone Marrow Procedure|Recruiting|||200|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     bone marow~   "|||2018-06-01 00:11:36.72175|2018-06-01 00:11:36.72175
NCT01048047|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients||Unknown status|Active, not recruiting|Phase 4|88|Anticipated|University of Pavia||2|||f||||f||||||||||2018-06-01 00:11:37.084797|2018-06-01 00:11:37.084797
NCT01048034|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2013-10-28|2010-01-12|2010-01-13|Estimate|||||||2013-10-28|2013-10-29|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)|Clinical and Biological Evaluation of Azacitidine in Transfusion-dependent Patients With Low and Intermediate-1 Risk MDS, and Low-risk CMML, Who Are Either Refractory to or Not Eligible for Treatment With Erythropoietin +/- G-CSF|Completed||Phase 2|30|Actual|Nordic MDS Group||1|||f||||t||||||||||2018-06-01 00:11:37.45495|2018-06-01 00:11:37.45495
NCT01048021|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-05-04|2010-01-12|2010-01-13|Estimate|||||||2017-05-04|2017-05-08|Actual|October 2009||2009-10-31|May 2017|2017-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Pulmonary Function Changes and Diaphragmatic Paralysis Following Ultrasound Guided Supraclavicular Brachial Plexus Blockade: The Effects of Decreased Local Anesthetic Volume|Pulmonary Function Changes and Diaphragmatic Paralysis Following Ultrasound Guided Supraclavicular Brachial Plexus Blockade: The Effects of Decreased Local Anesthetic Volume|Completed|||30|Actual|University of Manitoba|||1||f||||||||||||||2018-06-01 00:11:38.247651|2018-06-01 00:11:38.247651
NCT01048008|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-01-09|2010-01-12|2010-01-13|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|DM-CHOC-PEN||Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer|A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer|Completed||Phase 1|18|Anticipated|DEKK-TEC, Inc.||1|||f||||t||||||||||2018-06-01 00:11:38.565542|2018-06-01 00:11:38.565542
NCT01047995|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects|Plasma and Intracellular Pharmacokinetics of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects|Completed||Phase 1|26|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-06-01 00:11:38.966521|2018-06-01 00:11:38.966521
NCT01047982|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2014-02-27|2010-01-12|2010-01-13|Estimate|||||||2014-02-27|2014-02-28|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Myo-inositol in Obese Pregnant Women|Myo-inositol May Prevent Gestational Diabetes in Obese Women|Completed||N/A|220|Actual|University of Messina||2|||f||||||||||||||2018-06-01 00:11:39.277661|2018-06-01 00:11:39.277661
NCT01047969|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2016-05-27|2010-01-12|2010-01-13|Estimate|||||||2016-05-27|2016-05-30|Estimate|September 2006||2006-09-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy|Non-Operative Treatment for Rectal Cancer Following Complete Response to Neo-Adjuvant Therapy|Active, not recruiting||Phase 2|99|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:11:39.576777|2018-06-01 00:11:39.576777
NCT01047956|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-13|2010-01-12|2010-01-13|Estimate|||||||2010-01-13|2010-01-14|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|MNAC||Compare Methadone Combined With N-Acetyl-Cysteine (NAC) and Methadone Alone for Opioids Astaining|Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-06-01 00:11:39.72303|2018-06-01 00:11:39.72303
NCT01047943|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||STA-21 Topical Efficacy on Psoriasis|Intrapatient Comparison Study of Efficacy of STA-21 Ointment on Psoriatic Skin Lesions|Completed||Phase 1/Phase 2|8|Actual|Kochi University||1|||f||||f||||||||||2018-06-01 00:11:41.289152|2018-06-01 00:11:41.289152
NCT01047930|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2014-12-01|2010-01-12|2010-01-13|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|NicEx||The Effect of Exercise on Acute Nicotine Withdrawal|The Effect of Exercise on Acute Nicotine Withdrawal: Human Study|Completed||N/A|88|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 00:11:41.385141|2018-06-01 00:11:41.385141
NCT01047917|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-01-04|2010-01-12|2010-01-13|Estimate|||||||2012-01-04|2012-01-06|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Meditation to Reduce Stress and Improve Quality of Life|Meditation to Reduce Stress and Improve Quality of Life: A Feasibility Study|Completed||N/A|17|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:11:41.544275|2018-06-01 00:11:41.544275
NCT01047904|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-03-06|2010-01-12|2010-01-13|Estimate|||||||2014-03-06|2014-03-10|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Anesthetizing the Tympanic Membrane in Healthy Volunteers|Performance and Reliability of the Acclarent Iontophoresis System for Anesthetizing the Tympanic Membrane in Healthy Volunteers|Completed||Phase 1|21|Actual|Acclarent||1|||f||||f||||||||||2018-06-01 00:11:41.637706|2018-06-01 00:11:41.637706
NCT01047891|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-02-17|2010-01-12|2010-01-13|Estimate|||||||2015-02-17|2015-02-18|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TRIAS 2009||Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer|A Randomized, Double-blind, Placebo Controlled, Multicenter Phase II Study to Assess the Efficacy and Safety of Sorafenib Added to Standard Treatment With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer|Completed||Phase 2|174|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-06-01 00:11:41.746626|2018-06-01 00:11:41.746626
NCT01047878|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2016-04-22|2010-01-12|2010-01-13|Estimate|||||||2016-04-22|2016-04-26|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Genomic Analysis of Pediatric Bone Tumors|Genomic Analysis of Pediatric Bone Tumors (Other Title: Pediatric Bone Tumor Biology Study)|Unknown status|Recruiting||150|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     tumor samples and blood~   "|||2018-06-01 00:11:42.0597|2018-06-01 00:11:42.0597
NCT01047865|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2018-05-02|2010-01-12|2010-01-13|Estimate|||||||2018-05-02|2018-05-04|Actual|May 2005||2005-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Type 1 Diabetes Recurrence in Pancreas Transplants|Recurrence of T1D in Pancreas Transplantation|Recruiting|||400|Anticipated|University of Miami|||1||f||||f||||||Samples Without DNA|"~     peripheral blood~   "|No||2018-06-01 00:11:42.305754|2018-06-01 00:11:42.305754
NCT01047852|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2015-03-04|2010-01-12|2010-01-13|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|VHYPER||Noninvasive Ventilation After Extubation in Hypercapnic Patients|Sequential and Early Used of Noninvasive Ventilation After Extubation in Hypercapnic Patients or in Patients With Chronic Respiratory Disorders|Completed||N/A|144|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 00:11:42.634556|2018-06-01 00:11:42.634556
NCT01047839|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2014-09-25||2014-12-10|2010-01-12|2010-01-13|Estimate|2014-12-10|2014-12-19|Estimate||||2014-12-10|2014-12-19|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries|Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries. Uncontrolled, Open-label Phase 3 Study|Completed||Phase 3|100|Actual|Valneva Austria GmbH||3|||f||||t||||||||||2018-06-01 00:11:42.888945|2018-06-01 00:11:42.888945
NCT01047826|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-06-22|2010-01-12|2010-01-13|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2010||2010-12-31|October 2010|2010-10-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|MINT||M.I.P.O. vs Intramedullary Nailing in Tibia Fractures|Intramedullary Nailing vs. M.I.P.O. in Fractures of the Tibia a Randomized Controlled Trial|Unknown status|Recruiting|N/A|180|Anticipated|King Abdullah International Medical Research Center||2|||f||||t||||||||||2018-06-01 00:11:43.376362|2018-06-01 00:11:43.376362
NCT01047813|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|September 2010|Anticipated|2010-09-30|March 2010|Anticipated|2010-03-31||Observational|||The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes|The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes|Unknown status|Recruiting||50|Anticipated|University of Leeds|||2||f||||t||||||||||2018-06-01 00:11:43.462515|2018-06-01 00:11:43.462515
NCT01047800|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2017-04-25|2010-01-12|2010-01-13|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2010|Actual|2010-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Interventional|FGISP-RCT||Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial|Effectiveness of Counseling for Functional Gastrointestinal Disorder Patients: A Double-blind Randomized Controlled Trial|Completed||N/A|200|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-06-01 00:11:43.549306|2018-06-01 00:11:43.549306
NCT01047787|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|November 2001||2001-11-30|May 2007|2007-05-31|March 2004|Actual|2004-03-31|||||Observational|||Breathing Disorders in Patients With Congestive Heart Failure|Breathing Disorders in Patients With Congestive Heart Failure: Gender and Mortality Impact|Completed|||89|Actual|University of Sao Paulo|||1||f||||t||||||||||2018-06-01 00:11:43.642433|2018-06-01 00:11:43.642433
NCT01047774|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-10-05|2010-01-12|2010-01-13|Estimate|||||||2015-10-05|2015-10-07|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effect of Soy Protein on Post- Breast Cancer Surgery Pain|Soy-rich Diet for Preventing Chronic Pain After Breast Cancer Surgery|Terminated||Phase 2|6|Actual|McGill University Health Center||2||Difficulty with recruitment - few eligible for enrolment.|f||||t||||||||||2018-06-01 00:11:43.699159|2018-06-01 00:11:43.699159
NCT01047761|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2016-10-28|2010-01-12|2010-01-13|Estimate|||||||2016-10-28|2016-11-01|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Exercise for Stable Myasthenia Gravis|Multi-modal Exercise Program for Chronic Stable Myasthenia Gravis|Recruiting||Phase 1|30|Anticipated|Baltimore VA Medical Center||1|||f||||t||||||||Undecided||2018-06-01 00:11:43.77673|2018-06-01 00:11:43.77673
NCT01047748|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-04-29|2010-01-12|2010-01-13|Estimate|||||||2013-04-29|2013-05-01|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Trial of Digoxin Before Second-Trimester Abortion|A Randomized Clinical Trial of Intra-fetal Versus Intra-amniotic Digoxin Prior to Second-Trimester Pregnancy Termination|Completed||N/A|272|Actual|White, Katharine O'Connell, M.D., M.P.H.||2|||f||||f||||||||||2018-06-01 00:11:43.849861|2018-06-01 00:11:43.849861
NCT01047735|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2018-04-03|2010-01-12|2010-01-13|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2009||2009-09-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TRIABETES||The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes|Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes (Triabetes) - Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes ARMMST2D)|Active, not recruiting||N/A|60|Anticipated|University of Pittsburgh||3|||f||||t||||||||No||2018-06-01 00:11:44.03215|2018-06-01 00:11:44.03215
NCT01047722|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-07-18|2010-01-12|2010-01-13|Estimate|||||||2015-07-18|2015-07-21|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|Aspirin-BVT||In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction|Bleeding Volume Test: A Double-Blind Crossover Randomized Clinical Trial of an In-Vivo On-Line Test for Aspirin Effect and Resistance|Unknown status|Active, not recruiting|Phase 1|100|Anticipated|Klein, Jeffrey A., M.D.||2|||f||||f||||||||||2018-06-01 00:11:44.177434|2018-06-01 00:11:44.177434
NCT01047709|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2013-01-18||2013-06-06|2010-01-12|2010-01-13|Estimate|2013-06-06|2013-06-10|Estimate||||2013-06-06|2013-06-10|Estimate|December 2008||2008-12-31|June 2013|2013-06-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Positional Therapy After Stroke|Positional Therapy After Stroke|Completed||Phase 2|18|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:11:44.262369|2018-06-01 00:11:44.262369
NCT01047696|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|October 2002||2002-10-31|August 2009|2009-08-31|March 2005|Actual|2005-03-31|December 2004|Actual|2004-12-31||Interventional|RESPIRE||Randomised Exposure Study of Pollution Indoors and Respiratory Effects|Particulate Air Pollution Exposure and Childhood Acute Respiratory Infections in Guatemala: A Randomized Intervention|Completed||N/A|537|Actual|University of California, Berkeley||2|||f||||t||||||||||2018-06-01 00:11:44.424438|2018-06-01 00:11:44.424438
NCT01047683|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11||2013-10-10|2013-12-18|2010-01-12|2010-01-13|Estimate||||2013-12-18|2014-01-17|Estimate|2013-12-18|2014-01-17|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|MARINE||Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL|Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels ≥ 500 mg/dL and ≤ 2000 mg/dL|Completed||Phase 3|229|Actual|Amarin Pharma Inc.||3|||f||||f||||||||||2018-06-01 00:11:44.513207|2018-06-01 00:11:44.513207
NCT01047670|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|May 2008||2008-05-31|March 2008|2008-03-31||||||||Interventional|||Septic Shock em Steroids|Reposição de Esteróides em Crianças Com Choque Séptico|Unknown status|Recruiting|Phase 2/Phase 3|160|Anticipated|Unidade de Terapia Intensiva||2|||f||||t||||||||||2018-06-01 00:11:44.69716|2018-06-01 00:11:44.69716
NCT01047657|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-02-21|2010-01-12|2010-01-13|Estimate|||||||2011-02-21|2011-02-23|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Weight Loss in Obese Difficult-to-treat Asthmatics|Effects of Weight Loss in Obese Difficult-to-treat Asthmatics: a Pilot Study|Completed||Phase 3|33|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-06-01 00:11:44.775452|2018-06-01 00:11:44.775452
NCT01047644|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2018-03-01|2010-01-12|2010-01-13|Estimate|||||||2018-03-01|2018-03-05|Actual|March 2009||2009-03-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Port Will be Flushed Every 3 Months Instead of Every 4-6 Wks, as Recommended by Port Manufacturer.|Extended Interval Port Flushes: A Phase II Clinical Trial|Completed||Phase 2|87|Actual|University of Louisville||1|||f||||t||||||||||2018-06-01 00:11:44.866632|2018-06-01 00:11:44.866632
NCT01047631|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-05-27|2010-01-12|2010-01-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Role of Exercise in Diastolic Heart Failure|Relationship of Cardiovascular and Muscular Capacity to Daily Functioning in Frail Older Adults|Completed||N/A|50|Anticipated|University of Michigan||2|||f||||f||||||||||2018-06-01 00:11:44.944916|2018-06-01 00:11:44.944916
NCT01047618|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2015-06-24|2010-01-12|2010-01-13|Estimate|||||||2015-06-24|2015-06-26|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Venous Thromboembolism in Advanced Gastric Cancer Patients|The Incidence and Risk Factors of Venous Thromboembolism in Advanced Gastric Cancer Patients : Prospective Observational Study|Completed|||259|Actual|Asan Medical Center|||1||f||||f||||||||||2018-06-01 00:11:45.014532|2018-06-01 00:11:45.014532
NCT01047605|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-05-14|2010-01-12|2010-01-13|Estimate|||||||2010-05-14|2010-05-17|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|NCAG 5209||Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers|Evaluation of the Pharmacological Effects of NEURAPAS® Balance and PASCOFLAIR® 425 mg by Quantitative Measurement of Brain Activity in 16 Healthy Volunteers. A Single-blinded, Randomised, Placebo-controlled, 3-armed Phase-I-study With Cross-over Design|Completed||Phase 1|16|Anticipated|Pascoe Pharmazeutische Praeparate GmbH||3|||f||||f||||||||||2018-06-01 00:11:45.07606|2018-06-01 00:11:45.07606
NCT01047592|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2014-07-06|2010-01-12|2010-01-13|Estimate|||||||2014-07-06|2014-07-08|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia|N-methyl-D-aspartate (NMDA) Enhancers' Benefit to Schizophrenia Treatment|Completed||Phase 2|63|Actual|Chang-Hua Hospital||3|||f||||t||||||||||2018-06-01 00:11:45.139836|2018-06-01 00:11:45.139836
NCT01047579|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2017-02-22|2010-01-12|2010-01-13|Estimate|||||||2017-02-22|2017-02-24|Actual|April 2010||2010-04-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|BETTER||A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease|A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease|Completed||Phase 4|51|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:11:45.222104|2018-06-01 00:11:45.222104
NCT01047566|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2011-11-09|2010-01-12|2010-01-13|Estimate|||||||2011-11-09|2011-11-10|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|AFRODITE||Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)|The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Persistent Atrial Fibrillation|Completed||Phase 4|183|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:11:45.288012|2018-06-01 00:11:45.288012
NCT01047553|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|2012-07-18||2012-12-04|2010-01-12|2010-01-13|Estimate|2012-12-04|2013-01-04|Estimate||||2012-12-04|2013-01-04|Estimate|December 2009||2009-12-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients|An Open Phase III, Multi-centre 52-week, Parallel-group Study Evaluating the Safety and Efficacy of Formoterol 18 μg Daily Dose Compared With Standard COPD Treatment, in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|251|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 00:11:45.486714|2018-06-01 00:11:45.486714
NCT01047540|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12||2012-01-18|2012-07-20|2010-01-12|2010-01-13|Estimate||||2012-07-20|2012-07-27|Estimate|2012-07-20|2012-07-27|Estimate|March 2010||2010-03-31|October 2010|2010-10-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2|A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection|Completed||Phase 2|156|Actual|AiCuris Anti-infective Cures GmbH||5|||f||||f||||||||||2018-06-01 00:11:46.581439|2018-06-01 00:11:46.581439
NCT01047527|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2015-05-27||2015-06-10|2010-01-11|2010-01-13|Estimate|2015-06-10|2015-07-08|Estimate||||2015-06-10|2015-07-08|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence|An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence|Completed||Phase 4|525|Actual|University of Pennsylvania|Lack of placebo; low adherence to nicotine patches; nicotine patches are not the most effective treatment for nicotine dependence; participant attrition was high.|3|||f||||f||||||||||2018-06-01 00:11:46.721305|2018-06-01 00:11:46.721305
NCT01047514|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-09-15|2010-01-12|2010-01-13|Estimate|||||||2014-09-15|2014-09-17|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||Healthier Living Canada|Chronic Disease Self-Management Online Workshop for Canada|Completed||Phase 2|297|Actual|Stanford University||1|||f||||f||||||||||2018-06-01 00:11:47.159256|2018-06-01 00:11:47.159256
NCT01047501|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11||2013-10-10|2013-11-05|2010-01-12|2010-01-13|Estimate||||2013-10-10|2013-11-05|Estimate|2013-11-05|2013-11-27|Estimate|December 2009||2009-12-31|November 2013|2013-11-30||||February 2011|Actual|2011-02-28||Interventional|ANCHOR||Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)|Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (≥ 200 mg/dL and < 500 mg/dL) Despite Statin Therapy|Completed||Phase 3|702|Actual|Amarin Pharma Inc.||3|||f||||f||||||||||2018-06-01 00:11:47.303757|2018-06-01 00:11:47.303757
NCT01045746|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2014-12-19|2010-01-08|2010-01-11|Estimate|||||||2014-12-19|2014-12-23|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Whole-Body Vibration on Balance in the Elderly Population|Effects of Stochastic Resonance Therapy on Postural Control in the Elderly Population (Pilot Study)|Completed||N/A|20|Actual|Bern University of Applied Sciences||2|||f||||f||||||||||2018-06-01 00:12:11.123015|2018-06-01 00:12:11.123015
NCT01047488|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2010-01-12|2010-01-12|2010-01-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Imipramine and Pregabalin Combination in Painful Polyneuropathy|Randomised, Double-blind, Placebo-controlled Trial of the Effect of the Combination of Imipramine and Pregabalin for the Treatment of Painful Polyneuropathy|Unknown status|Not yet recruiting|Phase 4|75|Anticipated|Odense University Hospital||4|||f||||t||||||||||2018-06-01 00:11:47.508376|2018-06-01 00:11:47.508376
NCT01047475|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2015-04-28||2015-04-28|2010-01-12|2010-01-13|Estimate|2015-04-28|2015-05-13|Estimate||||2015-04-28|2015-05-13|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)|A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer|Completed||Phase 2|72|Actual|Microbio Co Ltd||2|||f||||t||||||||||2018-06-01 00:11:47.750671|2018-06-01 00:11:47.750671
NCT01047462|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2017-01-23|2010-01-12|2010-01-13|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2010|Actual|2010-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2014|Actual|2014-10-31||Interventional|SCANDIV||Scandinavian Diverticulitis Trial|Scandinavian Diverticulitis Trial. Laparoscopic Lavage vs Primary Resection as Treatment for Perforated Diverticulitis. A Randomized Prospective Multicenter Trial|Completed||N/A|150|Anticipated|University Hospital, Akershus||2|||f||||f||||||||||2018-06-01 00:11:48.11647|2018-06-01 00:11:48.11647
NCT01047449|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-12|||2017-10-04|2010-01-12|2010-01-13|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2011||2011-07-31|October 2017|2017-10-31|March 21, 2017|Actual|2017-03-21|August 2015|Actual|2015-08-31||Interventional|SUPERIORSVG||Improving the Results of Heart Bypass Surgery Using New Approaches to Surgery and Medication|Surgical and Pharmacological Novel Interventions to Improve Overall Results of Saphenous Vein Graft Patency in Coronary Artery Bypass Grafting Surgery: An International Multi-Center Randomized Controlled Clinical Trial|Completed||N/A|250|Actual|Sunnybrook Health Sciences Centre||4|||f||||t||||||||||2018-06-01 00:11:48.207143|2018-06-01 00:11:48.207143
NCT01047436|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2010-09-29||2011-01-26|2010-01-11|2010-01-12|Estimate|2010-12-13|2011-01-14|Estimate||||2011-01-26|2011-01-27|Estimate|December 2009||2009-12-31|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy of ArTiMist™ in Children|An Open Label Randomised Comparative Trial to Establish the Efficacy of 3 mg/kg ArTiMist™ When Compared to Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications|Completed||Phase 2|31|Actual|Proto Pharma Ltd||2|||f||||t||||||||||2018-06-01 00:11:48.318573|2018-06-01 00:11:48.318573
NCT01047423|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Targeting Microvascular Dysfunction in Young Hypertensive Patients|Targeting Microvascular Dysfunction in Young Hypertensive Patients|Unknown status|Recruiting|Phase 4|50|Anticipated|Queen's University, Belfast||2|||f||||t||||||||||2018-06-01 00:11:48.658206|2018-06-01 00:11:48.658206
NCT01047410|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-06-15|2010-01-11|2010-01-12|Estimate|||||||2015-06-15|2015-06-16|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|ACT||ACtive Care After Transplantation|ACtive Care After Transplantation|Unknown status|Recruiting|N/A|219|Anticipated|University Medical Center Groningen||3|||f||||f||||||||||2018-06-01 00:11:48.746768|2018-06-01 00:11:48.746768
NCT01047397|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-11-07|2010-01-11|2010-01-12|Estimate|||||||2013-11-07|2013-11-11|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia|A Phase IIa, Randomized, Single-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of 28-day Repeat Oral Doses of GSK1278863A in Anemic Pre-dialysis and Hemodialysis-dependent Patients|Completed||Phase 2|107|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:11:48.839334|2018-06-01 00:11:48.839334
NCT01047384|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2014-05-19|2010-01-08|2010-01-12|Estimate|||||||2014-05-19|2014-05-21|Estimate|January 2010||2010-01-31|January 2010|2010-01-31||||June 2011|Actual|2011-06-30||Interventional|||Management of Postoperative Pain Following Total Knee Arthroplasty by Using Acupuncture-moxibustion Therapy||Completed||Phase 2/Phase 3|100|Actual|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-06-01 00:11:48.976283|2018-06-01 00:11:48.976283
NCT01047371|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2011-09-28|2010-01-11|2010-01-12|Estimate|||||||2011-09-28|2011-09-29|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Why in Hospital - Factors Determining Time to Discharge Readiness After Arthroplasty Surgery|Why in Hospital - Factors Determining Time to Discharge Readiness After Arthroplasty Surgery: An Prospective Observational Study|Completed|||200|Anticipated|Hvidovre University Hospital|||1||f||||f||||||||||2018-06-01 00:11:49.049414|2018-06-01 00:11:49.049414
NCT01047358|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|2015-05-26||2015-10-06|2010-01-08|2010-01-12|Estimate|2015-05-26|2015-06-09|Estimate||||2015-10-06|2015-10-08|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer|Completed|||206|Actual|Pfizer|||2||f||||f||||||||||2018-06-01 00:11:49.119322|2018-06-01 00:11:49.119322
NCT01047345|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2014-12-12||2017-03-23|2010-01-11|2010-01-12|Estimate|2014-12-12|2014-12-22|Estimate||||2017-03-23|2017-04-21|Actual|February 24, 2010|Actual|2010-02-24|March 2017|2017-03-31|November 28, 2015|Actual|2015-11-28|June 10, 2011|Actual|2011-06-10||Interventional|||A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)|A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™|Completed||Phase 3|924|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:11:49.357488|2018-06-01 00:11:49.357488
NCT01047332|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2017-02-28||2017-02-28|2010-01-11|2010-01-12|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|October 2002|Actual|2002-10-31|February 2017|2017-02-28|November 2009|Actual|2009-11-30|May 2008|Actual|2008-05-31||Interventional|Wallstent||A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures|A Randomized Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures|Completed||N/A|129|Actual|Brigham and Women's Hospital||2|||f||||t||||||||No||2018-06-01 00:11:49.77142|2018-06-01 00:11:49.77142
NCT01047319|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-09-13|2010-01-11|2010-01-12|Estimate|||||||2017-09-13|2017-09-14|Actual|April 30, 2010|Actual|2010-04-30|September 2017|2017-09-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis|A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis|Terminated||Phase 3|634|Actual|Teva Pharmaceutical Industries||1||"Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the~   study drug in the relevant dose"|f||||t|t|f||||||||2018-06-01 00:11:50.18793|2018-06-01 00:11:50.18793
NCT01047306|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2015-02-09||2016-02-29|2010-01-11|2010-01-12|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational||A maximum of 25 patients with MPS IIIA will be enrolled in the study to provide at least 12 patients who complete the study. This number was not based on any statistical consideration, but is expected to be adequate to describe the natural progression of Sanfilippo A syndrome.|A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)|A Longitudinal, Prospective, Natural History Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)|Completed|||25|Actual|Shire|||1||f||||f||||||Samples With DNA|"~     CSF, urine and serum~   "|||2018-06-01 00:11:50.495127|2018-06-01 00:11:50.495127
NCT01047293|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2016-09-29||2017-03-06|2010-01-11|2010-01-12|Estimate|2017-01-16|2017-03-06|Actual||||2017-03-06|2017-04-04|Actual|May 2010||2010-05-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma|A Phase I/II Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma|Completed||Phase 1/Phase 2|47|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 00:11:51.4304|2018-06-01 00:11:51.4304
NCT01047280|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|November 2006||2006-11-30|December 2009|2009-12-31|May 2009|Actual|2009-05-31|March 2008|Actual|2008-03-31||Interventional|CLA||Use of Conjugated Linoleic Acid as a Nutraceutical for Weight Loss in Humans|Use of Conjugated Linoleic Acid as a Nutraceutical for Weight Loss in Humans|Completed||Phase 1|36|Actual|University of Manitoba||3|||f||||t||||||||||2018-06-01 00:11:51.730353|2018-06-01 00:11:51.730353
NCT01047267|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-04-05|2010-01-11|2010-01-12|Estimate|||||||2012-04-05|2012-04-06|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)|Pharmacokinetics of Anidulafungin in Critically Ill Patients With Invasive Candidiasis|Completed|||20|Actual|University Medical Center Groningen|||||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 00:11:51.795355|2018-06-01 00:11:51.795355
NCT01047254|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2017-05-08|2010-01-11|2010-01-12|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2010||2010-01-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|APA-AD||Bupropion for the Treatment of Apathy in Alzheimer's Dementia|A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)|Completed||Phase 3|110|Actual|University Hospital, Bonn||2|||f||||t||||||||||2018-06-01 00:11:51.861102|2018-06-01 00:11:51.861102
NCT01047241|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2014-01-06||2014-09-12|2010-01-11|2010-01-12|Estimate|2014-09-12|2014-09-17|Estimate||||2014-09-12|2014-09-17|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children|Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children|Completed||Phase 2|50|Actual|Danish University of Pharmaceutical Sciences||1|||f||||f||||||||||2018-06-01 00:11:51.92997|2018-06-01 00:11:51.92997
NCT01047215|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|August 2009||2009-08-31|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|August 2009|Actual|2009-08-31||Interventional|HeartAriQue||Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine|Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine|Unknown status|Recruiting|Phase 4|120|Anticipated|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-06-01 00:11:52.082175|2018-06-01 00:11:52.082175
NCT01047202|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-03-13|2010-01-11|2010-01-12|Estimate|||||||2013-03-13|2013-03-15|Estimate|December 2009||2009-12-31|March 2013|2013-03-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants|A Blinded, Randomized and Controlled Clinical Trial With Influenza A/H1N1 Split-virion Vaccine in 6 to 35 Months Infants|Completed||Phase 4|310|Actual|Sinovac Biotech Co., Ltd||3|||f||||||||||||||2018-06-01 00:11:52.141182|2018-06-01 00:11:52.141182
NCT01047189|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2011-07-01||2017-11-01|2010-01-11|2010-01-12|Estimate|2011-09-12|2011-10-17|Estimate||||2017-11-01|2017-11-06|Actual|March 2009||2009-03-31|November 2017|2017-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris|Adherence to ZIANA (Clindamycin Phosphate 1.2% With Tretinoin 0.025%)Gel Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris|Completed||Phase 4|26|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 00:11:52.197539|2018-06-01 00:11:52.197539
NCT01047176|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-02-29|2010-01-11|2010-01-12|Estimate|||||||2012-02-29|2012-03-01|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|OPTIMA||Observational Study to Estimate the Rates of Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI) With Drug Eluting Stent (DES) Implantation Who Take Statins|Observational Prospective Study to esTIMAte the Rates of Outcomes in Patients Undergoing PCI With Drug Eluting Stent (DES) Implantation Who Take Statins|Completed|||602|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:11:52.391584|2018-06-01 00:11:52.391584
NCT01047163|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2016-04-26|2010-01-11|2010-01-12|Estimate|||||||2016-04-26|2016-04-27|Estimate|June 2009||2009-06-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Observational|||Maintenance of Muscle Mass in Older People: the Negative Impact of Statin Therapy|Maintenance of Muscle Mass in Older People: the Negative Impact of Statin Therapy|Completed|||18|Actual|University of Nottingham|||2||f||||f||||||Samples With DNA|"~     Plasma, Muscle biopsy, Serum & Whole blood~   "|No||2018-06-01 00:11:52.521079|2018-06-01 00:11:52.521079
NCT01047150|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|||The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetro and Tc-99m Mibi|The Comparison of the Necessity of Repeat Myocardial Perfusion SPECT Studies Between Tc-99m Tetrofosmin and Tc-99m Sestamibi|Unknown status|Not yet recruiting||250|Anticipated|Cardiac Imaging of Augusta|||4||f||||t||||||||||2018-06-01 00:11:52.592547|2018-06-01 00:11:52.592547
NCT01047137|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2018-02-16|2010-01-11|2010-01-12|Estimate|||||||2018-02-16|2018-02-20|Estimate|July 2010||2010-07-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Response of Urticaria to Stress Intervention|Effect of Psychological Stress Intervention on Chronic Urticaria Activity and Immune Dysregulation|Withdrawn||N/A|0|Actual|University of Mississippi Medical Center||2||No patients enrolled. A pilot study variation of this study was done instead.|f||||f||||||||||2018-06-01 00:11:52.696551|2018-06-01 00:11:52.696551
NCT01047124|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-12-08|2010-01-11|2010-01-12|Estimate|||||||2015-12-08|2015-12-09|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder|Randomised Control Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory Unipolar Depressive Disorder|Unknown status|Recruiting|N/A|219|Anticipated|University of Nottingham||2|||f||||t||||||||||2018-06-01 00:11:52.798772|2018-06-01 00:11:52.798772
NCT01047111|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-02-26|2010-01-11|2010-01-12|Estimate|||||||2013-02-26|2013-02-27|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|July 2016|Anticipated|2016-07-31|July 2012|Actual|2012-07-31||Interventional|ESVIL||Esophagectomy: Sweet Versus Ivor-Lewis|A Phase Ⅲ Study of Left Side Thoracotomy Approach (Sweet Procedure) Versus Right Side Thoracotomy Plus Midline Laparotomy Approach (Ivor-Lewis Procedure) Esophagectomy in Middle or Lower Third Intrathoracic Esophageal Cancer|Unknown status|Active, not recruiting|Phase 3|280|Anticipated|Fudan University||2|||f||||f||||||||||2018-06-01 00:11:52.927258|2018-06-01 00:11:52.927258
NCT01047098|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-05-25|2010-01-11|2010-01-12|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2008||2008-10-31|May 2017|2017-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation|Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation|Completed||N/A|114|Actual|University of California, Davis||3|||f||||f||||||||||2018-06-01 00:11:53.027925|2018-06-01 00:11:53.027925
NCT01047085|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Does Cholecystectomy Increase the Esophageal Alkaline Reflux? Evaluation by Impedance-pH Technique|Does Cholecystectomy Increase the Esophageal Alkaline Reflux? Evaluation by Impedance-pH Technique|Completed||N/A|24|Actual|Istanbul University||2|||f||||f||||||||||2018-06-01 00:11:53.109812|2018-06-01 00:11:53.109812
NCT01047072|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-10-29|2010-01-11|2010-01-12|Estimate|||||||2012-10-29|2012-10-31|Estimate||||October 2012|2012-10-31||||September 2017|Anticipated|2017-09-30||Interventional|||Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis|Phase II Clinical Trial of Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis|Withdrawn||Phase 2|0|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 00:11:53.177178|2018-06-01 00:11:53.177178
NCT01047059|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-10|||2016-05-19|2010-01-11|2010-01-12|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|October 2012|Actual|2012-10-31||Interventional|MIMEB||Molecular Imaging With Erlotinib and Bevacizumab|Clinical Pilot to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients With Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) Treated With Erlotinib and Bevacizumab and to Associate Imaging Findings With Molecular Markers|Completed||Phase 2|40|Actual|University of Cologne||1|||f||||t||||||||||2018-06-01 00:11:53.299696|2018-06-01 00:11:53.299696
NCT01047046|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-07-13|2010-01-11|2010-01-12|Estimate|||||||2010-07-13|2010-07-15|Estimate|January 2008||2008-01-31|July 2010|2010-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder|Use of Combined Anticholinergic Medication and Sacral Neuromodulation in the Treatment of Refractory Overactive Bladder|Completed|||88|Actual|University of California, Irvine|||1||f||||t||||||||||2018-06-01 00:11:53.378841|2018-06-01 00:11:53.378841
NCT01047033|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2007||2007-01-31|January 2010|2010-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Impacts of Health Education for Children of Microcredit Clients in Peru||Completed||N/A|2453|Actual|Innovations for Poverty Action||2|||f||||f||||||||||2018-06-01 00:11:53.445771|2018-06-01 00:11:53.445771
NCT01047020|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-08-26|2010-01-11|2010-01-12|Estimate|||||||2015-08-26|2015-08-27|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Motor Proficiency And Physical Activity in Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)|Motor Proficiency And Physical Activity in Adult Survivors of Childhood ALL|Completed|||807|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||||||2018-06-01 00:11:53.523538|2018-06-01 00:11:53.523538
NCT01047007|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-02-03|2010-01-11|2010-01-12|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005)|A Phase I Dose Escalation Study of MK1775 in Monotherapy, in Combination With 5-Fluorouracil, and in Combination With 5-Fluorouracil and Cisplatin in Patients With Advanced Solid Tumor|Terminated||Phase 1|11|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 00:11:53.598266|2018-06-01 00:11:53.598266
NCT01046994|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|December 2016|Anticipated|2016-12-31|December 2011|Anticipated|2011-12-31||Interventional|DIA-BPD 25-30||Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion|Prospective Controlled Trial on Surgical Treatment of Type 2 Diabetes Patients With BMI 25-30 by Means of Biliopancreatic Diversion|Unknown status|Recruiting|Phase 3|40|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||t||||||||||2018-06-01 00:11:53.672099|2018-06-01 00:11:53.672099
NCT01046981|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2011-09-27|2010-01-11|2010-01-12|Estimate|||||||2011-09-27|2011-09-28|Estimate|March 2009||2009-03-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|||Tumescent Antibiotic Delivery Pharmacokinetics|Tumescent Antibiotic Delivery: Pharmacokinetic Evidence for Improved Surgical Site Infection Prevention|Completed||Phase 1|4|Anticipated|Klein, Jeffrey A., M.D.||2|||f||||f||||||||||2018-06-01 00:11:53.759991|2018-06-01 00:11:53.759991
NCT01046968|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Lepticore in Metabolic Syndrome and Weight Loss|The Use of LeptiCore® in Reducing Fat Gain and Managing Weight Loss in Patients With Metabolic Syndrome|Completed||Phase 1/Phase 2|92|Actual|University of Yaounde 1||1|||f||||t||||||||||2018-06-01 00:11:53.861628|2018-06-01 00:11:53.861628
NCT01046955|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|November 2005||2005-11-30|May 2008|2008-05-31|December 2008|Actual|2008-12-31|April 2007|Actual|2007-04-30||Interventional|||Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation|Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-term Nephrotoxic Calcineurin Inhibitor Therapy|Completed||Phase 4|38|Actual|University of Miami||3|||f||||f||||||||||2018-06-01 00:11:53.953254|2018-06-01 00:11:53.953254
NCT01046942|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-09-23|2010-01-11|2010-01-12|Estimate|||||||2013-09-23|2013-09-24|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Interventional|TEG-CABG||ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery|ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG Surgery|Unknown status|Recruiting|Phase 3|250|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 00:11:54.04796|2018-06-01 00:11:54.04796
NCT01046929|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-10-25|2010-01-08|2010-01-12|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2009||2009-08-31|October 2017|2017-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Limonene Study in Women With Breast Cancer|Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery|Completed||Phase 1|59|Actual|University of Arizona||1|||f||||t||||||||||2018-06-01 00:11:54.264825|2018-06-01 00:11:54.264825
NCT01046916|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11||2016-03-04|2016-03-04|2010-01-11|2010-01-12|Estimate||||2016-03-04|2016-04-04|Estimate|2016-03-04|2016-04-04|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen|A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA)|Completed||Phase 2|38|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:11:54.338479|2018-06-01 00:11:54.338479
NCT01046903|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2012-01-03||2012-02-24|2010-01-11|2010-01-12|Estimate|2012-01-03|2012-02-13|Estimate||||2012-02-24|2012-02-27|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®|An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® (Dalteparin Sodium) In Patients Undergoing Major Orthopedic Surgery|Completed|||503|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:11:54.425032|2018-06-01 00:11:54.425032
NCT01046890|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-05-04|2010-01-11|2010-01-12|Estimate|||||||2010-05-04|2010-05-05|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir|Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir|Completed||Phase 4|15|Actual|Germans Trias i Pujol Hospital||1|||f||||f||||||||||2018-06-01 00:11:54.732285|2018-06-01 00:11:54.732285
NCT01046877|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2014-11-12||2015-01-04|2010-01-11|2010-01-12|Estimate|2014-11-12|2014-11-18|Estimate||||2015-01-04|2015-01-15|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Interventional|||Singapore Tympanostomy Tube Delivery System Study|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System For The Treatment of Patients Requiring Tympanostomy Tube Insertion For Otitis Media|Completed||N/A|25|Actual|Acclarent|The protocol called for outcome measure assessing patency (openness/lack of obstruction) of unextruded tubes at 12 mos post procedure. Since all tubes had already been extruded by 12 mos, no ears with tubes remained for assessment and it was omitted.|1|||f||||f||||||||||2018-06-01 00:11:54.841203|2018-06-01 00:11:54.841203
NCT01046864|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2014-09-15|2010-01-11|2010-01-12|Estimate|||||||2014-09-15|2014-09-16|Estimate|February 2010||2010-02-28|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)|A Phase Ib Multiple Ascending Dose Study to Evaluate the Safety of Brivanib in Combination With 5-Fluorouracil/Leucovorin (5FU/LV) and Brivanib in Combination With 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) in Subjects With Advanced or Metastatic Gastrointestinal Malignancies|Completed||Phase 1|49|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:11:55.039881|2018-06-01 00:11:55.039881
NCT01046851|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2011-12-31|2010-01-11|2010-01-12|Estimate|||||||2011-12-31|2012-01-04|Estimate|September 2008||2008-09-30|December 2011|2011-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||A Study of Nopan Treatment of Acute Suicidality|Phase 3 Study of the Effects of Nopan as add-on Treatment to Antidepressants in Treating Depression and Suicidality|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Haifa||2|||f||||t||||||||||2018-06-01 00:11:55.140304|2018-06-01 00:11:55.140304
NCT01046838|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-05-23|2010-01-11|2010-01-12|Estimate|||||||2012-05-23|2012-05-24|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|SIDAMI||SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI)|SIDAMI - Sildenafil and Diastolic Dysfunction After AMI|Completed||Phase 4|70|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 00:11:55.206817|2018-06-01 00:11:55.206817
NCT01046825|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-05-19|2010-01-11|2010-01-12|Estimate|||||||2017-05-19|2017-05-23|Actual|September 9, 2010|Actual|2010-09-09|May 2017|2017-05-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2022|Anticipated|2022-10-31||Interventional|||Mature B-Cell Lymphoma And Leukemia Study III|Mature B-Cell Lymphoma And Leukemia Study III|Recruiting||Phase 2/Phase 3|122|Anticipated|St. Jude Children's Research Hospital||3|||f||||f|t|f||||||||2018-06-01 00:11:55.286257|2018-06-01 00:11:55.286257
NCT01046812|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2015-10-05|2010-01-11|2010-01-12|Estimate|||||||2015-10-05|2015-10-06|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Halitosis Devised Questionnaire Evaluating a New Treatment|Halitosis Devised Questionnaire Evaluating a New Treatment|Completed||N/A|30|Actual|New York Head & Neck Institute|||||f||||t||||||||||2018-06-01 00:11:56.435579|2018-06-01 00:11:56.435579
NCT01046799|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-09|||2014-11-04|2010-01-09|2010-01-12|Estimate|||||||2014-11-04|2014-11-05|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir|Prevention of HBV Reinfection After Liver Transplantation Using Entecavir Monotherapy After Short-term HBIg Administration: A Pilot Study|Completed||Phase 3|20|Anticipated|HepNet Study House, German Liverfoundation||1|||f||||f||||||||||2018-06-01 00:11:56.532093|2018-06-01 00:11:56.532093
NCT01046786|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-10|||2014-01-27|2010-01-11|2010-01-12|Estimate|||||||2014-01-27|2014-01-28|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord|Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord: an Open-Labeled, Dose-Escalating Clinical Tiral|Completed||Phase 1/Phase 2|8|Actual|China Spinal Cord Injury Network||5|||f||||t||||||||||2018-06-01 00:11:56.627901|2018-06-01 00:11:56.627901
NCT01046773|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2018-02-05|2010-01-11|2010-01-12|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2010||2010-01-31|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease|Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease|Terminated||Phase 1|3|Actual|University of California, Los Angeles||2||Low enrollment|f||||t||||||||||2018-06-01 00:11:56.791919|2018-06-01 00:11:56.791919
NCT01046760|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-10-19|2010-01-11|2010-01-12|Estimate|||||||2010-10-19|2010-10-20|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||Scholar Performance and Praxis Assessment in Children With Rolandic Epilepsy|Scholar Performance and Praxis Assessment in Children With Rolandic Epilepsy|Unknown status|Active, not recruiting||20|Anticipated|University of Campinas, Brazil|||1||f||||t||||||||||2018-06-01 00:11:56.877785|2018-06-01 00:11:56.877785
NCT01046747|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|July 2009||2009-07-31|August 2009|2009-08-31||||August 2011|Anticipated|2011-08-31||Interventional|||Pre-drilling or Self Drilling External Fixation Pins|Pre-drilling Pilot Holes for Self-drilling Schanz Pins: Does it Reduce the Incidence of Pin Tract Infection and Pin Loosening?|Unknown status|Recruiting|N/A|100|Anticipated|Temple University||2|||f||||t||||||||||2018-06-01 00:11:56.948405|2018-06-01 00:11:56.948405
NCT01046734|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-09-26|2010-01-11|2010-01-12|Estimate|||||||2012-09-26|2012-09-27|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Virus Shedding and Environmental Deposition of a Novel Influenza Virus|Virus Shedding and Environmental Deposition of Novel A(H1N1) Pandemic Influenza Virus|Completed|||105|Actual|University of Nottingham|||4||f||||f||||||||||2018-06-01 00:11:57.122257|2018-06-01 00:11:57.122257
NCT01046721|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2018-03-04|2010-01-11|2010-01-12|Estimate|||||||2018-03-04|2018-03-06|Actual|September 2009||2009-09-30|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms|Investigation of the Cardiovascular Effects of Exenatide in Healthy Male Subjects|Completed||N/A|8|Actual|University of Nottingham||2|||f||||f||||||||No||2018-06-01 00:11:57.197934|2018-06-01 00:11:57.197934
NCT01046708|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-07-01|2010-01-11|2010-01-12|Estimate|||||||2013-07-01|2013-07-03|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|August 2009|Actual|2009-08-31||Interventional|||Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate|Ovulation Induction With Clomiphene Citrate: to Support or Not to Support the Luteal Phase|Completed||N/A|300|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-06-01 00:11:57.319097|2018-06-01 00:11:57.319097
NCT01046695|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2012-11-14||2012-12-13|2010-01-11|2010-01-12|Estimate|2012-11-14|2012-12-11|Estimate||||2012-12-13|2012-12-19|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Evaluating Transcutaneous Electrical Nerve Stimulation for Postoperative Pain After Video-Assisted Thoracotomy Surgery|Evaluating Efficacy of Transcutaneous Electrical Nerve Stimulation (TENS) for Postoperative Pain After Video-Assisted Thoracotomy Surgery (VATS)|Completed||N/A|56|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:11:57.435714|2018-06-01 00:11:57.435714
NCT01046682|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2012-03-12||2014-12-18|2010-01-11|2010-01-12|Estimate|2012-03-12|2012-04-09|Estimate||||2014-12-18|2015-01-07|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|Salsalate||Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults|Assessment of the Use of Salsalate to Decrease Endothelial Cell Activation and Inflammation in HIV-infected Adults|Completed||Phase 2|40|Actual|University Hospitals Cleveland Medical Center|Lack of placebo in the control group precluded blinding of the study investigators. Adherence was measured utilizing pill counts which assumes that pills not returned were taken by the participant. Sample size too small to detect a small effect.|2|||f||||f||||||||||2018-06-01 00:11:57.903705|2018-06-01 00:11:57.903705
NCT01046669|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-12-01|2010-01-11|2010-01-12|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2010|Actual|2010-06-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|EUPHRATES||Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock|Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock|Completed||N/A|450|Actual|Spectral Diagnostics (US) Inc.||2|||t||||t||||||||||2018-06-01 00:11:58.651602|2018-06-01 00:11:58.651602
NCT01046656|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2012-01-27|2010-01-11|2010-01-12|Estimate|||||||2012-01-27|2012-01-31|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|PND||L Reuteri for the Prevention of Nosocomial Diarrhea|Efficacy of Lactobacillus Reuteri DSM 17938 in the Prevention of Nosocomial Diarrhea in Children. Randomized Double-blind Placebo Controlled Trial|Completed||Phase 3|106|Anticipated|Medical University of Warsaw|||||f||||t||||||||||2018-06-01 00:11:58.779455|2018-06-01 00:11:58.779455
NCT01046643|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|2013-02-02||2014-05-16|2010-01-11|2010-01-12|Estimate|2014-05-16|2014-05-19|Estimate||||2014-05-16|2014-05-19|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|R21||Early Menopause Hormone Treatment and Cognition|Hormones and Cognitive Processing in Early Postmenopausal Women|Completed||N/A|30|Actual|University of Michigan||4|||f||||t||||||||||2018-06-01 00:11:58.899609|2018-06-01 00:11:58.899609
NCT01046630|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2014-10-10|2010-01-11|2010-01-12|Estimate|||||||2014-10-10|2014-10-13|Estimate|December 2009||2009-12-31|October 2014|2014-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects|A Phase I, Multi-centre, Double-blind, Placebo-controlled Parallel Group Study to Assess the pharmacoMRI Effects of AZD6765 in Male and Female Subjects Fulfilling the Criteria for Major Depressive Disorder|Completed||Phase 1|128|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:11:59.536544|2018-06-01 00:11:59.536544
NCT01046617|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-06-04|2010-01-11|2010-01-12|Estimate|||||||2012-06-04|2012-06-05|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|LRTIC||Lactobacillus Reuteri for the Treatment of Infantile Colic:|Lactobacillus Reuteri (DSM 17938) for the Treatment of Infantile Colic: a Randomized Double-blind Placebo Controlled Trial|Completed||Phase 3|80|Anticipated|Medical University of Warsaw|||||f||||t||||||||||2018-06-01 00:11:59.660468|2018-06-01 00:11:59.660468
NCT01046604|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2013-09-06|2010-01-11|2010-01-12|Estimate|||||||2013-09-06|2013-09-10|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery|Mitigating Cardiac Inflammation and Oxidative Stress in Atrial Myocardium Via Short-term Lovaza Treatment Prior to Surgery|Unknown status|Active, not recruiting|Phase 4|24|Anticipated|East Carolina University||2|||f||||t||||||||||2018-06-01 00:11:59.750882|2018-06-01 00:11:59.750882
NCT01046591|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-03-06|2010-01-11|2010-01-12|Estimate|||||||2012-03-06|2012-03-07|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Sleep and Behavior in Children With Cleft Palate|Sleep and Neurobehavioral Performance After Cleft Palate Repair|Completed|||82|Actual|University of Michigan|||2||f||||t||||||||||2018-06-01 00:11:59.897184|2018-06-01 00:11:59.897184
NCT01046578|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2016-11-23|2010-01-11|2010-01-12|Estimate|||||||2016-11-23|2016-11-28|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women|Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women|Completed||Phase 4|41|Actual|University of Saskatchewan||7|||f||||f||||||||||2018-06-01 00:12:00.021573|2018-06-01 00:12:00.021573
NCT01046565|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2011-02-28||2011-11-15|2010-01-11|2010-01-12|Estimate|2011-04-05|2011-05-02|Estimate||||2011-11-15|2011-11-23|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin|Completed||Phase 1|75|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 00:12:00.139086|2018-06-01 00:12:00.139086
NCT01046552|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Comparison Between Pre and Intraoperative ERCP in Treatment of Common Bile Duct Stones|Preoperative Versus Intraoperative Endoscopic Sphincterotomy for Management of Choledocholithiasis and Cholecystolithiasis|Completed||N/A|210|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:12:00.520785|2018-06-01 00:12:00.520785
NCT01046539|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-01-10|2010-01-08|2010-01-12|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults|A Phase 1 Study to Evaluate the Pharmacodynamics of RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults|Completed||Phase 1|12|Anticipated|National Institute on Drug Abuse (NIDA)||2|||f||||||||||||||2018-06-01 00:12:00.599234|2018-06-01 00:12:00.599234
NCT01046526|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-09|||2017-06-30|2010-01-09|2010-01-12|Estimate|||||||2017-06-30|2017-07-02|Actual|February 8, 2005||2005-02-08|May 3, 2012|2012-05-03|May 3, 2012||2012-05-03|||||Observational|||fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia|fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia|Completed|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:12:00.675467|2018-06-01 00:12:00.675467
NCT01046513|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-09|||2017-06-30|2010-01-09|2010-01-12|Estimate|||||||2017-06-30|2017-07-02|Actual|August 31, 2007||2007-08-31|September 28, 2011|2011-09-28|September 28, 2011||2011-09-28|||||Observational|||PET Imaging of Nicotinic Acetylcholine Receptors|PET Imaging of Nicotinic Acetylcholine Receptors With 2-[18F]F-A-85380-Injection, Initial Evaluation of Radiotracer in Human Volunteers|Completed|||14|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:12:00.73202|2018-06-01 00:12:00.73202
NCT01046500|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2014-05-19|2010-01-11|2010-01-12|Estimate|||||||2014-05-19|2014-05-20|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome||Unknown status|Recruiting|Phase 2|100|Anticipated|University of Messina||2|||f||||f||||||||||2018-06-01 00:12:00.786482|2018-06-01 00:12:00.786482
NCT01046487|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-06-06|2010-01-11|2010-01-12|Estimate|||||||2012-06-06|2012-06-07|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|April 2011|Actual|2011-04-30||Interventional|PALANGI3||Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate|Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)|Completed||Phase 1|26|Actual|Centre Oscar Lambret|||||f||||f||||||||||2018-06-01 00:12:00.85767|2018-06-01 00:12:00.85767
NCT01046474|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2011-07-19|2010-01-11|2010-01-12|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|PAPAS||Reducing Beverages and Sugar and Increasing Physical Activity in Public School Adolescents From Brazil|Preventing Excessive Weight Gain by Reducing Carbonated Beverage and Sugar Consumption and Increasing Physical Activity Among Public School Adolescents From the Metropolitan Area of Rio de Janeiro|Completed||Phase 3|600|Anticipated|Rio de Janeiro State University||2|||f||||f||||||||||2018-06-01 00:12:00.940834|2018-06-01 00:12:00.940834
NCT01046461|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2012-02-16|2010-01-11|2010-01-12|Estimate|||||||2012-02-16|2012-02-17|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|RAD||Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer|A Phase II Study to Evaluate the Efficacy and Tolerability of Ramosetron, Aprepitant and Dexamethasone (RAD) in Preventing Cisplatin-induced Nausea and Vomiting in Chemotherapy-naïve Patients With Solid Cancer|Unknown status|Active, not recruiting|Phase 2|41|Actual|Hallym University Medical Center||1|||f||||f||||||||||2018-06-01 00:12:01.038339|2018-06-01 00:12:01.038339
NCT01046448|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2010-01-11|2010-01-11|2010-01-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|4C||The Cardiovascular Comorbidity in Children With Chronic Kidney Disease Study|The Cardiovascular Morbidity in Children With Chronic Renal Failure Study|Unknown status|Recruiting||650|Anticipated|Heidelberg University|||1||f||||t||||||Samples With DNA|"~     serum, whole blood, urine, DNA, vessel biopsies,~   "|||2018-06-01 00:12:01.236014|2018-06-01 00:12:01.236014
NCT01046435|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2010-03-24|2010-01-11|2010-01-12|Estimate|||||||2010-03-24|2010-03-25|Estimate|March 2007||2007-03-31|May 2006|2006-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Periodontal Therapy on Systemic Inflammation|Effects of Periodontal Therapy on Markers of Systemic Inflammation in Subjects at Cardiovascular Disease Risk|Completed||N/A|186|Actual|University of Chile||2|||f||||t||||||||||2018-06-01 00:12:01.557077|2018-06-01 00:12:01.557077
NCT01046422|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11||2012-03-24|2015-09-23|2010-01-11|2010-01-12|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|May 2010||2010-05-31|September 2015|2015-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety Study of BMS-770767 in Subjects With Type 2 Diabetes|A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin|Completed||Phase 2|76|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:12:01.720679|2018-06-01 00:12:01.720679
NCT01046409|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2011-08-18|2010-01-10|2010-01-12|Estimate|||||||2011-08-18|2011-08-22|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Comparison Between Main Branch and Side Branch Vessels|Comparison of Clinical, Electrical and Physiologic Significance Between Main Branch and Side Branch Vessels|Unknown status|Active, not recruiting||51|Anticipated|Seoul National University Hospital|||1||f||||f||||||||||2018-06-01 00:12:01.908097|2018-06-01 00:12:01.908097
NCT01046396|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2011-02-28||2012-09-21|2010-01-11|2010-01-12|Estimate|2011-05-05|2011-05-09|Estimate||||2012-09-21|2012-10-02|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin|Split-Face Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin|Completed||Phase 1|69|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 00:12:02.023208|2018-06-01 00:12:02.023208
NCT01046383|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-01-16|2010-01-08|2010-01-12|Estimate|||||||2015-01-16|2015-01-21|Estimate|June 2010||2010-06-30|June 2011|2011-06-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients|Effect of IMN1207 Versus Casein on, Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients During or Following Chemotherapy, Radiation or Surgery: A Multi-center Randomized, Double-blind Study - Phase III Trial|Terminated||Phase 3|16|Actual|Immunotec Inc.||2||Slower than anticipated recruitment|f||||f||||||||||2018-06-01 00:12:02.250335|2018-06-01 00:12:02.250335
NCT01046370|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-05-02|2010-01-11|2010-01-12|Estimate|||||||2012-05-02|2012-05-03|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia|A Pilot Study of Amygdala Retraining Program (ARP) Versus Control (C) in Patients With Chronic Fatigue Syndrome (CFS), Chronic Fatigue (CF) and Fibromyalgia (FM)|Completed||N/A|57|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:12:02.355927|2018-06-01 00:12:02.355927
NCT01046357|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-02-10|2010-01-11|2010-01-12|Estimate|||||||2012-02-10|2012-02-13|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687|A Randomized, Blind, Placebo-controlled, Single-centre Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD7687 After Single Ascending Oral Doses|Completed||Phase 1|64|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:12:02.481649|2018-06-01 00:12:02.481649
NCT01046331|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2016-04-13|2010-01-08|2010-01-12|Estimate|||||||2016-04-13|2016-04-14|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Observational|||Novel Influenza A (H1N1) Surveillance Registry|Novel Influenza A (H1N1) Surveillance Registry|Completed|||894|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||2||f||||f||||||||||2018-06-01 00:12:02.566493|2018-06-01 00:12:02.566493
NCT01046318|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2014-01-06|2010-01-07|2010-01-11|Estimate|||||||2014-01-06|2014-01-08|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of OPC-262 in Patients With Type 2 Diabetes|A Long-term Study of OPC-262 in Patients With Type 2 Diabetes|Completed||Phase 3|100|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 00:12:02.752678|2018-06-01 00:12:02.752678
NCT01046305|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-10-25|2010-01-08|2010-01-11|Estimate|||||||2017-10-25|2017-10-26|Actual|November 2009|Actual|2009-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Symptom Burden in Chronic Myeloid Leukemia (CML)|Symptom Burden of Patients With Chronic Myeloid Leukemia (CML)|Active, not recruiting|||210|Actual|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-06-01 00:12:02.845833|2018-06-01 00:12:02.845833
NCT01046292|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-10-12|2010-01-08|2010-01-11|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI|Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI: a Randomized, Double-blind, Placebo-controlled Exploratory Study|Completed||Phase 4|50|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 00:12:02.937308|2018-06-01 00:12:02.937308
NCT01046279|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2013-06-12|2010-01-08|2010-01-11|Estimate|||||||2013-06-12|2013-06-13|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Hypertension Monitoring in Glioma Patients Treated With Bevacizumab|Hypertension Monitoring in Glioma Patients Treated With Bevacizumab|Terminated|||40|Actual|University of Zurich|||1|Problems with enrollement of patients, less patients than expected|f||||t||||||Samples Without DNA|"~     Plasma and Urine Samples~   "|||2018-06-01 00:12:03.012074|2018-06-01 00:12:03.012074
NCT01046266|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2016-09-12|2010-01-08|2010-01-11|Estimate|||||||2016-09-12|2016-09-14|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma|An Exploratory, Open Label Multicenter Study to Investigate Pharmacodynamic of RO5083945, a Human Monoclonal Antibody Antagonist of Epidermal Growth Factor Receptor (EGFR), Compared to Cetuximab in Patients With Operable Head and Neck Squamous Cell Carcinoma|Completed||Phase 1|62|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:12:03.101206|2018-06-01 00:12:03.101206
NCT01046253|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2010-02-22||2010-11-22|2010-01-08|2010-01-11|Estimate|2010-02-22|2010-03-19|Estimate||||2010-11-22|2010-12-08|Estimate|January 2004||2004-01-31|November 2010|2010-11-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study|A Relative Bioavailability Replicate Sprinkle Study of Lansoprazole 30 mg Delayed-Release Capsules Under Fasting Conditions|Completed||Phase 1|50|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 00:12:03.189252|2018-06-01 00:12:03.189252
NCT01046084|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2010-02-22||2010-11-22|2010-01-08|2010-01-11|Estimate|2010-02-22|2010-03-19|Estimate||||2010-11-22|2010-12-08|Estimate|August 2003||2003-08-31|November 2010|2010-11-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Lansoprazole 30 mg DR Capsule Replicate Food Study|A Relative Bioavailability Replicated Crossover Study of Lansoprazole 30 mg Delayed-Release Capsules Under Non-Fasting Conditions.|Completed||Phase 1|50|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 00:12:05.314558|2018-06-01 00:12:05.314558
NCT01046240|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2015-01-26|2010-01-08|2010-01-11|Estimate|||||||2015-01-26|2015-01-27|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy|Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous (SC) Versus Intravenous Palonosetron in Cancer Patients Treated With Platinum Based Chemotherapy|Completed||Phase 1/Phase 2|29|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-06-01 00:12:03.623377|2018-06-01 00:12:03.623377
NCT01046227|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|June 2010|Anticipated|2010-06-30|February 2010|Anticipated|2010-02-28||Observational|||Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients|Antibody Titer Analysis Afer Monovalent Vaccination in Pediatric Haemato-oncology Patients|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     Serum for serology of H1N1 antibody Nasopharyngeal or oropharyngeal swab for Novel H1N1 PCR~   "|||2018-06-01 00:12:03.719611|2018-06-01 00:12:03.719611
NCT01046214|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-11-19|2010-01-08|2010-01-11|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2010||2010-01-31|November 2015|2015-11-30||||||||Interventional|||Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions|A Multiple-Dose, Double Blind, Double Dummy, Comparative Bioavailability Study of Two Formulations of Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions|Terminated||Phase 1|8|Actual|Teva Pharmaceuticals USA||2||Recruitment issues|f||||f||||||||||2018-06-01 00:12:03.826655|2018-06-01 00:12:03.826655
NCT01046201|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2015-10-19|2010-01-08|2010-01-11|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|PORR||Pediatric Obesity Research Registry|Pediatric Obesity Research Registry|Withdrawn|||0|Actual|Phoenix Children's Hospital|||1|To revise protocol for a more concise inclusion/exclusion criteria|f||||f||||||Samples Without DNA|"~     Whole Blood~   "|||2018-06-01 00:12:03.904108|2018-06-01 00:12:03.904108
NCT01046188|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-14|2010-01-08|2010-01-11|Estimate|||||||2010-01-14|2010-01-15|Estimate|January 2010||2010-01-31|January 2010|2010-01-31||||||||Interventional|WebIVF||Development of an Interactive Web-based Teaching Tool for in Vitro Fertilization (IVF) Patients|Development of an Interactive Web-based Teaching Tool for IVF Patients|Unknown status|Recruiting|N/A|40|Anticipated|Ottawa Fertility Centre||2|||f||||f||||||||||2018-06-01 00:12:03.970182|2018-06-01 00:12:03.970182
NCT01046175|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2010-11-11|2010-01-08|2010-01-11|Estimate|||||||2010-11-11|2010-11-15|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|June 2011|Anticipated|2011-06-30|February 2011|Anticipated|2011-02-28||Interventional|||Effect of Air-stacking on Peak Cough Flow in Patients With Acute Cervical or High Thoracic Spinal Cord Injury|Effect of Two Different Air-stacking Techniques, Combined With Manually Assisted Cough, on Peak Cough Flow (PCF) in Patients With Acute Cervical or High Thoracic Spinal Cord Injury|Withdrawn||Phase 2|10|Anticipated|Ullevaal University Hospital||2||Lack of patients. Investigator changed job.|f||||f||||||||||2018-06-01 00:12:04.093533|2018-06-01 00:12:04.093533
NCT01046162|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-08-05|2010-01-08|2010-01-11|Estimate|||||||2010-08-05|2010-08-06|Estimate|July 2010||2010-07-31|August 2010|2010-08-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions|An Open Label, Crossover, Randomized Study of Two Periods, Two Treatments, Two Sequences, and a Single Dose of Two Oral Drug Products of Alprazolam 2mg (Tafil ® 2 mg, Product of Pharmacia & Upjohn SA de CV vs Xanax ® 2 mg, Product of Pfizer Pharmaceuticals LLC) in Healthy Volunteers in Fasting Conditions|Withdrawn||Phase 1|26|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 00:12:04.188035|2018-06-01 00:12:04.188035
NCT01046149|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2014-09-25|2010-01-08|2010-01-11|Estimate|||||||2014-09-25|2014-09-26|Estimate|February 2010||2010-02-28|September 2014|2014-09-30||||||||Interventional|||Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms-2||Withdrawn||N/A|0|Actual|National Science Council, Taiwan||2||"No participants were recruited at this study site. Study has been conducted and monitored at~   ClinicalTrials.gov ID: NCT01044563."|f||||t||||||||||2018-06-01 00:12:04.278559|2018-06-01 00:12:04.278559
NCT01046136|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2011-03-03||2012-08-24|2010-01-08|2010-01-11|Estimate|2012-08-23|2012-08-24|Estimate||||2012-08-24|2012-08-27|Estimate|December 2009||2009-12-31|August 2012|2012-08-31||||March 2010|Actual|2010-03-31||Interventional|||Mucinex Exploratory Cold Study|Double Blind, Randomized, Placebo Controlled Study of Mucinex® for the Treatment of Symptoms of an Acute Respiratory Tract Infection When Two 600 mg Tablets Are Given Every 12 Hours for 7 Days|Completed||Phase 2|378|Actual|Reckitt Benckiser LLC||2|||f||||f||||||||||2018-06-01 00:12:04.370364|2018-06-01 00:12:04.370364
NCT01046123|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2016-10-18|2010-01-08|2010-01-11|Estimate|||||||2016-10-18|2016-10-20|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|June 2013|Actual|2013-06-30||Interventional|||Volumetric Modulated Arc Therapy (VMAT) for Brain Metastases|A Phase II Study of Whole Brain Radiotherapy With Simultaneous Integrated Boost Using Volumetric Modulated Arc Therapy for One to Ten Brain Metastases|Active, not recruiting||Phase 2|60|Actual|British Columbia Cancer Agency||1|||f||||t||||||||||2018-06-01 00:12:04.700585|2018-06-01 00:12:04.700585
NCT01046110|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2015-10-19|2011-02-24|2017-01-19|2010-01-08|2010-01-11|Estimate|2015-10-19|2015-11-18|Estimate|2011-02-24|2011-03-09|Estimate|2017-01-19|2017-03-03|Actual|January 2010||2010-01-31|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|BEGIN™|The full analysis set (FAS) included all randomised patients except for 11 subjects whose site was closed (4 subjects with IDeg; 7 subjects with DPP-IV group/arm). For 4 subjects each in IDeg OD and DPP-IV inhibitor arm, the fasting plasma glucose (FPG) values were missing at baseline.|Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin|A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN™ : EARLY)|Completed||Phase 3|458|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:12:04.798911|2018-06-01 00:12:04.798911
NCT01046097|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2016-05-12|2010-01-07|2010-01-11|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines|Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines|Terminated|||28|Actual|GlaxoSmithKline|||1|"Local authorities no longer require routine PMS studies;GSK does not believe the study would~   add meaningfully to the safety data already available for Synflorix"|f||||||||||||||2018-06-01 00:12:05.224129|2018-06-01 00:12:05.224129
NCT01046071|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2011-11-17|2010-01-08|2010-01-11|Estimate|||||||2011-11-17|2011-11-18|Estimate|March 2010||2010-03-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy|The Analgesic Efficacy of Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy: A Randomized Controlled Trial|Completed||Phase 4|80|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-06-01 00:12:05.632561|2018-06-01 00:12:05.632561
NCT01046058|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2013-10-11|2010-01-07|2010-01-11|Estimate|||||||2013-10-11|2013-10-14|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435|A Phase I, Open-label, Sequential Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of TMC435 in Subjects With Moderately or Severely Impaired Hepatic Function|Completed||Phase 1|23|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||t||||||||||2018-06-01 00:12:05.707454|2018-06-01 00:12:05.707454
NCT01046045|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2015-06-19|2010-01-08|2010-01-11|Estimate|||||||2015-06-19|2015-06-22|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|June 2013|Actual|2013-06-30|November 2011|Actual|2011-11-30||Interventional|||Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients|Impact and Efficacy of Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients|Completed||Phase 4|17|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:12:05.776931|2018-06-01 00:12:05.776931
NCT01046032|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-03|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Metformin Treatment Before in Vitro Fertilization (IVF) in Women With Ultrasound Evidence of Polycystic Ovaries|Metformin Treatment Before IVF in Women With Ultrasound Evidence of Polycystic Ovaries; a Prospective, Randomised, Double Blind, Placebo Study|Completed||N/A|134|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 00:12:05.83798|2018-06-01 00:12:05.83798
NCT01046019|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2011-07-03|2010-01-08|2010-01-11|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Observational|DXACorail||Measurement of Early Bone Loss Around a Total Hip Arthroplasty|Measurement of Early Bone Loss Around a Total Hip Arthroplasty. A Prospective Trial With Dual Energy X-ray Absorptiometry.|Completed|||23|Actual|Oslo University Hospital|||||f||||t||||||||||2018-06-01 00:12:06.011985|2018-06-01 00:12:06.011985
NCT01046006|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2014-01-30|2010-01-08|2010-01-11|Estimate|||||||2014-01-30|2014-01-31|Estimate|March 2007||2007-03-31|January 2014|2014-01-31||||February 2014|Anticipated|2014-02-28||Interventional|||Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network|Unknown status|Active, not recruiting|Phase 2|61|Anticipated|University of Athens||1|||f||||f||||||||||2018-06-01 00:12:06.096087|2018-06-01 00:12:06.096087
NCT01045993|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2011-12-05||2013-02-21|2010-01-08|2010-01-11|Estimate|2013-02-21|2013-04-01|Estimate||||2013-02-21|2013-04-01|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study To Evaluate Methods To Evaluate Back Pain|A Pilot Study To Evaluate Various Methodologies For Assessing The Treatment Of Low Back Pain|Completed||N/A|61|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|No primary endpoint was prespecified in this Pilot study; 1 key efficacy endpoint was selected for reporting purposes only.|4|||f||||f||||||||||2018-06-01 00:12:06.331875|2018-06-01 00:12:06.331875
NCT01045980|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2013-12-10|2010-01-08|2010-01-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|August 2015|Anticipated|2015-08-31|August 2014|Anticipated|2014-08-31||Interventional|FLUID||Effect of Bio-impedance Analysis and Vitamin D vs Usual Care on Left Ventricular Mass in Peritoneal Dialysis Patients: A Randomized Controlled Trial (FLUID Study)|The Effect of Bio-impedance Analysis and Vitamin D Versus Usual Care on Left Ventricular Mass in Peritoneal Dialysis Patients: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|70|Anticipated|St. Joseph's Healthcare Hamilton||4|||f||||t||||||||||2018-06-01 00:12:08.183789|2018-06-01 00:12:08.183789
NCT01045967|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2010-02-22||2010-11-22|2010-01-08|2010-01-11|Estimate|2010-02-22|2010-03-18|Estimate||||2010-11-22|2010-12-08|Estimate|May 2004||2004-05-31|November 2010|2010-11-30|July 2004|Actual|2004-07-31|June 2004|Actual|2004-06-30||Interventional|||Lansoprazole 30 mg DR Capsule Fasting Study|A Relative Bioavailability Study of Lansoprazole 30 mg DR Capsules Under Fasting Conditions.|Completed||Phase 1|56|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 00:12:08.291358|2018-06-01 00:12:08.291358
NCT01045954|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|||A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections|A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections|Unknown status|Recruiting|N/A|50|Anticipated|Diabetes Care Center|||||f||||f||||||||||2018-06-01 00:12:08.609699|2018-06-01 00:12:08.609699
NCT01045941|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2016-10-05|2010-01-07|2010-01-11|Estimate|||||||2016-10-05|2016-10-06|Estimate||||October 2016|2016-10-31||||||||Interventional|||Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma|Phase II Study of Adjuvant Gemcitabine Started One Week After Laparoscopic|Withdrawn||Phase 2|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||The study was never initiated|f||||t||||||||||2018-06-01 00:12:08.692088|2018-06-01 00:12:08.692088
NCT01045928|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-11-25|2010-01-08|2010-01-11|Estimate|||||||2015-11-25|2015-11-26|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma|Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma|Terminated||Phase 1|5|Actual|Case Comprehensive Cancer Center||1||Extreme toxicity in Phase I, study did not proceed to Phase II|f||||t||||||||||2018-06-01 00:12:08.769292|2018-06-01 00:12:08.769292
NCT01045915|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-09-10|2010-01-08|2010-01-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|July 2010||2010-07-31|May 2012|2012-05-31|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|AMEP||Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma|Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial|Terminated||Phase 1|5|Actual|Onxeo||1||The study has been halted due to the low enrolment rate.|f||||t||||||||||2018-06-01 00:12:08.867015|2018-06-01 00:12:08.867015
NCT01045902|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|February 2001||2001-02-28|January 2010|2010-01-31|January 2005|Actual|2005-01-31|||||Interventional|||BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia|Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia|Completed||Phase 3|139|Actual|Bayer||2|||f||||||||||||||2018-06-01 00:12:08.933059|2018-06-01 00:12:08.933059
NCT01045889|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2016-08-18|2010-01-08|2010-01-11|Estimate|||||||2016-08-18|2016-08-19|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HDT-HIV||High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk|"First Line Treatment in HIV-related Large Cell Non Hodgkin Lymphoma at High Risk, Including Early Consolidation With High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation"|Completed||Phase 2|27|Actual|Azienda Ospedaliera Spedali Civili di Brescia||1|||f||||t||||||||||2018-06-01 00:12:09.010295|2018-06-01 00:12:09.010295
NCT01045876|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2016-04-18|2010-01-08|2010-01-11|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|February 2016|Anticipated|2016-02-29|February 2014|Anticipated|2014-02-28||Interventional|||The Effect of Dexamethasone on Cortisol Levels in Patients Undergoing Thyroid Surgery|The Effect of Dexamethasone on Plasma Cortisol Levels, Pain and PONV in Female Patients Undergoing Thyroid Surgery|Withdrawn||Phase 4|0|Actual|St. Paul's Hospital, Canada||2||Lack of resources|f||||f||||||||||2018-06-01 00:12:09.086075|2018-06-01 00:12:09.086075
NCT01045863|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-08-03|2010-01-08|2010-01-11|Estimate|||||||2010-08-03|2010-08-04|Estimate|February 2010||2010-02-28|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers|A Phase 1, First-Into-Human, Escalating Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-03382792 After Administration Of Single Oral Doses To Healthy Adult Subjects|Terminated||Phase 1|10|Actual|Pfizer||3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:12:10.045305|2018-06-01 00:12:10.045305
NCT01045850|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-12|2010-01-08|2010-01-11|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2006||2006-02-28|January 2010|2010-01-31|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Observational|RECO||Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery|Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.|Completed|||1312|Actual|University Hospital, Grenoble|||||f||||f||||||||||2018-06-01 00:12:10.148075|2018-06-01 00:12:10.148075
NCT01045837|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2012-01-18|2010-01-08|2010-01-11|Estimate|||||||2012-01-18|2012-01-19|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|CD||Effect of Addition of Short Course of Prednisolone to Gluten Free Diet in Naive Celiac Disease Patients|Effect of Addition of Short Course of Prednisolone to Gluten Free Diet and Gluten Free Diet Alone in the Recovery of Clinical, Histological and Immunological Features in Naive Adult Patients With Celiac Disease|Completed||Phase 2/Phase 3|33|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 00:12:10.262198|2018-06-01 00:12:10.262198
NCT01045824|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-14|2010-01-08|2010-01-11|Estimate|||||||2010-01-14|2010-01-15|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|FamilySchizo||Family-based Genetic Long-term Study of Brain Function in Schizophrenia|The Genetic Study of Longitudinal Brain Function Among Schizophrenic Patients With Family History|Unknown status|Recruiting||600|Anticipated|Taichung Veterans General Hospital|||||f||||t||||||Samples With DNA|"~     10-20cc of blood will be drawn for DNA analysis~   "|||2018-06-01 00:12:10.346302|2018-06-01 00:12:10.346302
NCT01045811|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2014-09-25|2010-01-08|2010-01-11|Estimate|||||||2014-09-25|2014-09-26|Estimate|May 2010||2010-05-31|September 2014|2014-09-30||||||||Interventional|||Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms-3||Withdrawn||N/A|0|Actual|National Science Council, Taiwan||2||"No participants were recruited at this study site. Study has been conducted and monitored with~   ClinicalTrials.gov ID: NCT01044563."|f||||t||||||||||2018-06-01 00:12:10.416794|2018-06-01 00:12:10.416794
NCT01045798|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2013-03-26||2017-02-21|2010-01-08|2010-01-11|Estimate|2013-03-26|2013-05-10|Estimate||||2017-02-21|2017-03-24|Actual|December 2010||2010-12-31|February 2017|2017-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)|MSG-04 (Also Known as Merck Caspofungin Protocol 067): A Pilot, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Empirical Therapy for Invasive Candidiasis in High-Risk Patients in the Critical Care Setting|Terminated||Phase 2|15|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to low participant enrollment.|2||Low participant enrollment: 15 enrolled of 114 planned|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:12:10.607002|2018-06-01 00:12:10.607002
NCT01045785|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Observational|||Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient|Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient|Unknown status|Active, not recruiting||300|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 00:12:10.908104|2018-06-01 00:12:10.908104
NCT01045772|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2012-05-30|2010-01-08|2010-01-11|Estimate|||||||2012-05-30|2012-05-31|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|ACCILTRA1||Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)|A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)|Completed||Phase 2|10|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-06-01 00:12:10.993771|2018-06-01 00:12:10.993771
NCT01045759|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2016-09-29|2010-01-07|2010-01-11|Estimate|||||||2016-09-29|2016-09-30|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Point of Care Ultrasound (US) Versus Detailed Radiology US for Deep Vein Thrombosis (DVT)|Intensivist Performed Limited B Mode Compression Ultrasound for Diagnosis of Deep Vein Thrombosis in the Intensive Care Unit|Terminated|||150|Actual|University of Missouri-Columbia||||Investigator left the institution|f||||f||||||||No||2018-06-01 00:12:11.060371|2018-06-01 00:12:11.060371
NCT01045733|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2012-11-27|2010-01-08|2010-01-11|Estimate|||||||2012-11-27|2012-11-29|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Comparison of Corneal Aberrations in Subjects With Contralateral AcrySof IQ Toric Intraocular Lens (IOL) and AcrySof IQ IOL With Limbal Relaxing Incision (LRI)|A Prospective Contralateral Comparison of Corneal Aberrations in Subjects Undergoing Aspheric Lens Implantation With Concomitant LRI and Aspheric Toric IOL Implantation|Completed||N/A|70|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:12:11.186442|2018-06-01 00:12:11.186442
NCT01045720|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-13|2010-01-08|2010-01-11|Estimate|||||||2010-01-13|2010-01-14|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia|The Treatment Effect of 2 Traditional Chinese Medicines[Suo Quan Wan]and [Wu Lin San] in Clozapine-induced Hypersalivation in Schizophrenia Patient.|Unknown status|Recruiting|Phase 2|45|Anticipated|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-06-01 00:12:11.288105|2018-06-01 00:12:11.288105
NCT01045707|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2015-10-19|2011-02-24|2016-10-26|2010-01-08|2010-01-11|Estimate|2015-10-19|2015-11-20|Estimate|2011-02-24|2011-03-09|Estimate|2016-10-26|2016-12-08|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|BOOST™|Baseline characteristics for all the randomised subjects (the full analysis set [FAS]) were collected at the beginning of main trial. One subject was excluded from FAS because the subject was randomised in error and was not dosed.|Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes|NN5401-3590: A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1) / NN5401-3726: An Extension Trial Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes (BOOST™: START 1)|Completed||Phase 3|530|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:12:11.41209|2018-06-01 00:12:11.41209
NCT01045694|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2017-05-18||2017-09-07|2010-01-08|2010-01-11|Estimate|2017-06-14|2017-07-13|Actual||||2017-09-07|2017-10-06|Actual|March 2011||2011-03-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|August 2012|Actual|2012-08-31||Interventional||8 participants were randomized; 2 withdrew voluntarily. Study was terminated due to lack of funds, and unblinding did not occur - it is not known how many participants were placed in each group.|Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint|Botulinum Toxin Versus Steroid Injection for Basal Joint Arthritis of the Thumb: a Randomized, Double Blind, Placebo-controlled Clinical Trial|Terminated||Phase 4|8|Actual|University of Missouri-Columbia|The study was terminated early due to lack of funds and no data was analyzed.|3||Unable to acquire additional funding needed to continue this study.|f||||t||||||||No||2018-06-01 00:12:12.059392|2018-06-01 00:12:12.059392
NCT01045681|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2012-03-28|2010-01-08|2010-01-11|Estimate|||||||2012-03-28|2012-03-30|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|June 2013|Anticipated|2013-06-30|November 2011|Actual|2011-11-30||Interventional|BVD||Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma|A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|Intergroupe Francophone du Myelome||1|||f||||t||||||||||2018-06-01 00:12:12.250259|2018-06-01 00:12:12.250259
NCT01045668|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2014-08-21|2010-01-08|2010-01-11|Estimate|||||||2014-08-21|2014-08-25|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|VISTA||Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation|Comparison of the Effect of Ablation of the Clinically Presenting Ventricular Tachycardia (VT) Only Versus the Addition of Substrate Ablation Based on Scar Mapping; on the Long Term Success Rate of VT Ablation|Completed||Phase 3|120|Actual|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-06-01 00:12:12.397771|2018-06-01 00:12:12.397771
NCT01045655|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2016-01-13|2010-01-08|2010-01-11|Estimate|||||||2016-01-13|2016-01-15|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|MOMCare||MOMCare: Culturally Relevant Treatment Services for Perinatal Depression|For Moms: Culturally Relevant Treatment Services for Perinatal Depression|Completed||N/A|168|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 00:12:12.461955|2018-06-01 00:12:12.461955
NCT01045642|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-19|2010-01-08|2010-01-11|Estimate|||||||2010-01-19|2010-01-20|Estimate|December 2006||2006-12-31|January 2010|2010-01-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions|Open Label Balanced Randomized,Two-treatment,Two-period,Two-sequence,Single Dose,Crossover Oral Bioequivalence Study of Omeprazole Mg 20mg DR Capsules With Prilosec OTCTM 20mg in 38 Healthy,Adult,Human Subjects Under Fasting Conditions|Completed||Phase 1|38|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:12:12.535066|2018-06-01 00:12:12.535066
NCT01045629|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-13|2010-01-08|2010-01-11|Estimate|||||||2010-01-13|2010-01-14|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|CompSchizo||Competence Ability Study in People With Schizophrenia|Competence Ability Study in People With Schizophrenia|Unknown status|Recruiting||90|Anticipated|Taichung Veterans General Hospital|||2||f||||t||||||||||2018-06-01 00:12:12.60353|2018-06-01 00:12:12.60353
NCT01045616|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Evaluation of Refractive Status and Ophthalmological Problems of Prematurity|Evaluation of Refractive Status and Ophthalmological Problems of Prematurity|Completed|||100|Actual|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 00:12:12.665722|2018-06-01 00:12:12.665722
NCT01045603|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2012-10-26|2010-01-08|2010-01-11|Estimate|||||||2012-10-26|2012-10-29|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|INIS||Instanyl® Non-Interventional Study|A 3 Month Observational Prospective Patient Cohort Study of the Treatment of Breakthrough Pain in Cancer Patients With Instanyl®|Completed|||309|Actual|Takeda|||||f||||f||||||||||2018-06-01 00:12:12.730689|2018-06-01 00:12:12.730689
NCT01045434|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-19|2010-01-08|2010-01-11|Estimate|||||||2010-01-19|2010-01-20|Estimate|December 2006||2006-12-31|January 2010|2010-01-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions|Open Label, Balanced, Randomized, Two-treatment,Two-period,Single-dose, Cross-over Oral Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule With Prilosec® OTCTM 20 mg Tablets in Healthy Human Adult Subjects, Under Fed Conditions|Completed||Phase 1|62|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-06-01 00:12:14.34936|2018-06-01 00:12:14.34936
NCT01045590|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-06-14|2010-01-07|2010-01-11|Estimate|||||||2012-06-14|2012-06-18|Estimate|December 2003||2003-12-31|February 2011|2011-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus|Phase IV, Multicenter, Single-blind, Positive-controlled, Parallel Group Study of Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Adm|Completed||Phase 4|100|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:12:12.959161|2018-06-01 00:12:12.959161
NCT01045577|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|September 2005||2005-09-30|January 2010|2010-01-31|February 2008|Actual|2008-02-29|January 2006|Actual|2006-01-31||Interventional|||A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|25|Actual|AB Science||2|||f||||f||||||||||2018-06-01 00:12:13.05235|2018-06-01 00:12:13.05235
NCT01045564|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2015-03-19|2010-01-07|2010-01-11|Estimate|||||||2015-03-19|2015-03-23|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure|Safety and Immunogenicity of GSK 15574484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||5||Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|f||||||||||||||2018-06-01 00:12:13.12086|2018-06-01 00:12:13.12086
NCT01045551|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2015-07-30||2016-10-29|2010-01-08|2010-01-11|Estimate|2016-08-10|2016-10-04|Estimate||||2016-10-29|2016-12-13|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|April 2014|Actual|2014-04-30|January 2013|Actual|2013-01-31||Interventional|||Open Label Pilot Study of Apremilast in Treatment of Rosacea|An Open Label, Pilot Study to Determine the Efficacy of Apremilast in the Treatment of Rosacea in Patients With Both Erythematotelangiectatic Rosacea and Papulopustular Rosacea|Completed||Phase 2|10|Actual|Columbia University||1|||f||||f||||||||Undecided||2018-06-01 00:12:13.20778|2018-06-01 00:12:13.20778
NCT01045538|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2017-07-13|2010-01-08|2010-01-11|Estimate|||||||2017-07-13|2017-07-14|Actual|February 2010|Actual|2010-02-28|July 2017|2017-07-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|Zolinza+XP||Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer|A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer|Completed||Phase 1/Phase 2|45|Actual|Asan Medical Center||1|||f||||t||||||||||2018-06-01 00:12:13.41865|2018-06-01 00:12:13.41865
NCT01045525|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-07-21|2010-01-08|2010-01-11|Estimate|||||||2015-07-21|2015-07-22|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SAIGNEES||Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only in Patients With Dysmetabolic Liversiderosis|Prospective Randomized Study Comparing the Effect of Phlebotomy and Lifestyle and Diet Advices vs Lifestyle and Diet Advices Only on Glycemia in Patients With Dysmetabolic Liversiderosis|Unknown status|Active, not recruiting|Phase 3|270|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 00:12:13.497361|2018-06-01 00:12:13.497361
NCT01045512|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-01-27|2010-01-08|2010-01-11|Estimate|||||||2015-01-27|2015-01-28|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AntiCardAgeing||"The Role of the Inflammatory/ Pathogen Burden for Cardiac Ageing"|"The Role of the Inflammatory/ Pathogen Burden for Cardiac Ageing"|Terminated||Phase 2|96|Actual|Martin-Luther-Universität Halle-Wittenberg||2||unsufficient recruitment|f||||t||||||||||2018-06-01 00:12:13.592289|2018-06-01 00:12:13.592289
NCT01045499|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2017-02-10|2010-01-08|2010-01-11|Estimate|||||||2017-02-10|2017-02-13|Actual|September 13, 2005|Actual|2005-09-13|February 2017|2017-02-28|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||LAGB as a Treatment for Morbid Obesity in Adolescents|Laparoscopic Adjustable Gastric Banding (LAGB) as a Treatment for Morbid Obesity in Adolescents|Completed||N/A|137|Actual|Columbia University||1|||f||||f|f|t|f|f||||Undecided||2018-06-01 00:12:13.671823|2018-06-01 00:12:13.671823
NCT01045486|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2011-07-20|2010-01-08|2010-01-11|Estimate|||||||2011-07-20|2011-07-21|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Interventional|||the Effectiveness of Probiotics on Atopic Dermatitis With Cow Milk Allergy|A Double Blind, Randomized, Placebo-Controlled, Crossover Study to Compare the Effectiveness of Probiotics on Atopic Dermatitis With Cow Milk Allergy in Korean Infants|Withdrawn||N/A|36|Anticipated|Soonchunhyang University Hospital||2||failed to enroll patients|f||||t||||||||||2018-06-01 00:12:13.765669|2018-06-01 00:12:13.765669
NCT01045473|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-08|2010-01-08|2010-01-11|Estimate|||||||2010-01-08|2010-01-11|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Observational|||Prospective Study of Minimally Invasive Spine Surgery|Prospective Study of Minimally Invasive Spinal Fusion Surgery for the Treatment of Spondylolisthesis, Degenerative Disk Disease, Spinal Stenosis and Degenerative Scoliosis|Unknown status|Not yet recruiting||450|Anticipated|Society for Minimally Invasive Spine Surgery|||||f||||f||||||||||2018-06-01 00:12:13.841187|2018-06-01 00:12:13.841187
NCT01045460|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2016-10-14|2010-01-07|2010-01-11|Estimate|||||||2016-10-14|2016-10-17|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|December 2014|Actual|2014-12-31||Interventional|aMILs||Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma|Randomized Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic GM-CSF-based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma|Active, not recruiting||Phase 2|32|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-06-01 00:12:13.898328|2018-06-01 00:12:13.898328
NCT01045447|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2015-10-19|2011-02-24|2017-02-09|2010-01-08|2010-01-11|Estimate|2015-10-19|2015-11-18|Estimate|2011-02-24|2011-03-09|Estimate|2017-02-09|2017-03-20|Actual|January 2010||2010-01-31|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|BOOST™||Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes (BOOST™ : INTENSIFY BASAL)|Completed||Phase 3|465|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:12:13.995415|2018-06-01 00:12:13.995415
NCT01045421|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2015-07-22||2016-07-01|2010-01-08|2010-01-11|Estimate|2016-07-01|2016-08-15|Estimate||||2016-07-01|2016-08-15|Estimate|February 2010||2010-02-28|July 2016|2016-07-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|||Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies|A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies|Completed||Phase 1/Phase 2|273|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:12:14.476046|2018-06-01 00:12:14.476046
NCT01045408|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2010-01-13|2010-01-08|2010-01-11|Estimate|||||||2010-01-13|2010-01-14|Estimate|January 2009||2009-01-31|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||The Effect of Berry Extract on Helicobacter Pylori Eradication|The Adjuvant Effect of Berry Extract on Triple Therapy for Helicobacter Pylori Eradication|Unknown status|Recruiting|Phase 1|120|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:12:17.105138|2018-06-01 00:12:17.105138
NCT01045395|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2011-03-15|2010-01-08|2010-01-11|Estimate|||||||2011-03-15|2011-03-16|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|PCA||Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis|Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis|Completed||Phase 1|30|Anticipated|University of Manitoba||3|||f||||t||||||||||2018-06-01 00:12:17.197354|2018-06-01 00:12:17.197354
NCT01045382|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2018-05-02|2010-01-08|2010-01-11|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2010||2010-07-31|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2021|Anticipated|2021-07-31||Interventional|||MSC and HSC Coinfusion in Mismatched Minitransplants|Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study|Recruiting||Phase 2|120|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-06-01 00:12:17.273246|2018-06-01 00:12:17.273246
NCT01045369|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-04-27|2010-01-08|2010-01-11|Estimate|||||||2017-04-27|2017-05-01|Actual|January 2010||2010-01-31|January 2010|2010-01-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|KALYINTE||A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects|A Phase IV 48 Week, Open Label, Pilot Study of Kaletra and Intelence Tablets in Naive Subjects|Completed||Phase 4|30|Anticipated|Therapeutic Concepts||1|||f||||t||||||||||2018-06-01 00:12:17.480752|2018-06-01 00:12:17.480752
NCT01045356|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2015-07-29|2010-01-08|2010-01-11|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass|Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass|Completed|||55|Actual|Boston Children’s Hospital|||3||f||||t||||||||||2018-06-01 00:12:17.549531|2018-06-01 00:12:17.549531
NCT01045343|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2012-04-13|2010-01-08|2010-01-11|Estimate|||||||2012-04-13|2012-04-17|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|INDICATE HF||Feasibility Study of an Integrated Diagnostic System to Manage Heart Failure|Integrated Diagnostics Can Alter Heart Failure|Completed||N/A|136|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-06-01 00:12:17.663865|2018-06-01 00:12:17.663865
NCT01045330|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2017-10-04|2010-01-08|2010-01-11|Estimate|||||||2017-10-04|2017-10-06|Actual|August 2009||2009-08-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||a Modified NTU-HELP Program|Effect of the National Taiwan University Hospital Elder Life Program|Completed||N/A|377|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 00:12:17.880035|2018-06-01 00:12:17.880035
NCT01045317|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-04-01|2010-01-08|2010-01-11|Estimate|||||||2010-04-01|2010-04-02|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body|An Exploratory, Open Label, Randomized, Parallel Group Study To Investigate The Pharmacokinetics Of Single Intravenous And Oral Micro Doses Of [14-C]-PF-04776548 In Healthy Male Subjects|Completed||Phase 1|10|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:12:17.940359|2018-06-01 00:12:17.940359
NCT01045304|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2014-01-13|2010-01-08|2010-01-11|Estimate|||||||2014-01-13|2014-01-14|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|November 2012|Actual|2012-11-30|March 2011|Actual|2011-03-31||Interventional|||Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer|Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibitor, SAR240550 (BSI-201), Administered Twice Weekly or Weekly, in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (mTNBC)|Completed||Phase 2|163|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:12:18.127738|2018-06-01 00:12:18.127738
NCT01045291|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2013-05-29|2010-01-08|2010-01-11|Estimate|||||||2013-05-29|2013-05-30|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|HFpEF||Pacing for Heart Failure With Preserved Ejection Fraction|Pacing for Heart Failure With Preserved Ejection Fraction|Completed||N/A|22|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-06-01 00:12:19.117658|2018-06-01 00:12:19.117658
NCT01045278|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-10-01|2010-01-08|2010-01-11|Estimate|||||||2013-10-01|2013-10-07|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy|Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy|Completed||Phase 4|277|Actual|Region Skane|||||f||||f||||||||||2018-06-01 00:12:19.40848|2018-06-01 00:12:19.40848
NCT01045265|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|2014-06-16||2014-08-12|2010-01-08|2010-01-11|Estimate|2014-08-12|2014-08-13|Estimate||||2014-08-12|2014-08-13|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Observational||The median age and baseline CD4+ T-cell count of the study participants were 48 years (IQR 42–53) and 450 cells/mm3 (IQR 289–585).|Concentrations of Raltegravir in the Semen of HIV-Infected Men|Study to Determine the Concentrations of Raltegravir in Semen, the Seminal to Plasma Ratio of Raltegravir and the Variability in Seminal to Plasma Ratios Over the Raltegravir Dosing Period.|Completed|||16|Actual|Canadian Immunodeficiency Research Collaborative|||1||f||||f||||||||||2018-06-01 00:12:20.642009|2018-06-01 00:12:20.642009
NCT01045252|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-08|||2010-01-11|2010-01-08|2010-01-11|Estimate|||||||2010-01-11|2010-01-12|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|HNEU||Study of Hemodynamics of Neonates by Echocardiography and USCOM|Study of Hemodynamics of Healthy Neonates and Those With Congenital Heart Diseases and Sepsis by Echocardiography and USCOM|Unknown status|Active, not recruiting||60|Anticipated|Guangdong General Hospital|||3||f||||f||||||||||2018-06-01 00:12:20.946974|2018-06-01 00:12:20.946974
NCT01045239|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|January 2012|Anticipated|2012-01-31|October 2011|Anticipated|2011-10-31||Interventional|UMDMO||Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema|A Randomized, Controlled Trial Comparing Micropulse 577 nm Laser Photocoagulation And Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema|Unknown status|Recruiting|Phase 2|100|Anticipated|University of Malaya||2|||f||||t||||||||||2018-06-01 00:12:21.374325|2018-06-01 00:12:21.374325
NCT01045226|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2016-09-23|2010-01-07|2010-01-08|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2009||2009-08-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Proton Radiation Therapy in Treating Patients With Prostate Cancer|A Phase II Trial of Proton Radiation Therapy of Using Standard Fractionation for Low-and Low-Intermediate Risk Adenocarcinoma of the Prostate|Recruiting||N/A|262|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:12:21.550791|2018-06-01 00:12:21.550791
NCT01045213|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-10-03|2010-01-07|2010-01-08|Estimate|||||||2012-10-03|2012-10-05|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Integrated Care Program for Chronic Obstructive Pulmonary Disease|Phase 3 Study of the Efficacy of Proactive Integrated Care in Advanced COPD Patients Located in Areas With High COPD-related Mortality|Completed||Phase 3|100|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-06-01 00:12:21.63772|2018-06-01 00:12:21.63772
NCT01045200|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|January 2002||2002-01-31|January 2002|2002-01-31|September 2009|Actual|2009-09-30|October 2004|Actual|2004-10-31||Observational|||Nurse-or Surgeon-led Follow-up After Rectal Cancer|Nurse-or Surgeon-led Follow-up After Rectal Cancer: a Randomised Trial.|Completed|||110|Actual|Centrallasarettet Västerås|||1||f||||t||||||||||2018-06-01 00:12:21.730433|2018-06-01 00:12:21.730433
NCT01045187|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2011-01-24||2012-07-24|2010-01-07|2010-01-08|Estimate|2011-01-24|2011-02-21|Estimate||||2012-07-24|2012-08-01|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer|Feasibility Study Using the Xoft Axxent Electronic Brachytherapy System for the Treatment of Endometrial Cancer|Completed||N/A|15|Actual|Xoft, Inc.|Small sample size.|1|||f||||f||||||||||2018-06-01 00:12:21.797757|2018-06-01 00:12:21.797757
NCT01045174|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2012-06-13|2010-01-07|2010-01-08|Estimate|||||||2012-06-13|2012-06-14|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Breath-Actuated Nebulizer Versus Conventional Continuous-Output Nebulizer in Pediatric Asthma Patients|A Randomized Controlled Trial Comparing the Effectiveness of a Breath-Actuated Nebulizer Device Versus a Conventional Continuous-Output Nebulizer in Treating Pediatric Asthma Patients in the Emergency Department|Terminated||N/A|190|Actual|University Hospitals Cleveland Medical Center||2||change in availability of study investigators|f||||f||||||||||2018-06-01 00:12:22.047177|2018-06-01 00:12:22.047177
NCT01045161|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2012-08-14|2012-01-05|2016-11-30|2010-01-07|2010-01-08|Estimate|2015-11-04|2015-12-09|Estimate|2012-01-05|2012-01-09|Estimate|2016-11-30|2017-01-23|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|LAS-MD-38|A total of 544 patients were randomized, with 542 in the Part A Safety population. Of the 454 patients who completed Part A, 448 patients continued into Part B, receiving at least 1 dose of open-label treatment, were included in the Part B Safety Population. Baseline characteristics for Part B are based on participant totals of 147, 154 and 147|Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose|Completed||Phase 3|544|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:12:22.272107|2018-06-01 00:12:22.272107
NCT01045148|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2017-07-18|2010-01-07|2010-01-08|Estimate|||||||2017-07-18|2017-07-21|Actual|March 2006||2006-03-31|July 2017|2017-07-31||||December 2020|Anticipated|2020-12-31||Interventional|||CyberKnife Radiosurgery for Localized Prostatic Carcinoma|Virtual HDR CyberKnife Radiosurgery for Localized Prostatic Carcinoma: A Phase II Study|Recruiting||Phase 2|258|Anticipated|CyberKnife Centers of San Diego||1|||f||||f||||||||||2018-06-01 00:12:25.253329|2018-06-01 00:12:25.253329
NCT01045135|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||||||Observational|||The Effect of Pregnancy and Labour on the Pelvic Floor Diagnosed With 3D and 4D Ultrasound|The Effect of Pregnancy and Labour on the Pelvic Floor Diagnosed With 3D and 4D Ultrasound|Unknown status|Recruiting||300|Anticipated|University Hospital, Akershus|||1||f||||f||||||||||2018-06-01 00:12:25.529614|2018-06-01 00:12:25.529614
NCT01045122|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2014-04-07||2015-04-24|2010-01-07|2010-01-08|Estimate|2015-04-24|2015-04-27|Estimate||||2015-04-24|2015-04-27|Estimate|December 2006||2006-12-31|April 2015|2015-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Sedation in Patients at Risk for Upper Airway Collapse|Sedation in Patients at Risk for Sleep-induced Upper Airway Collapse|Completed||N/A|15|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 00:12:25.782653|2018-06-01 00:12:25.782653
NCT01045109|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2011-08-04|2010-01-07|2010-01-08|Estimate|||||||2011-08-04|2011-08-05|Estimate|October 2007||2007-10-31|August 2010|2010-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|D3/PCa||Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.|Vitamin D and Prostate Cancer|Completed||Phase 2|52|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-06-01 00:12:26.05826|2018-06-01 00:12:26.05826
NCT01045096|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2012-01-30||2012-03-08|2010-01-07|2010-01-08|Estimate|2012-03-08|2012-04-05|Estimate||||2012-03-08|2012-04-05|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease|A Phase 1, Randomized, Open-Label, Parallel Design, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Delayed Release Capsules in Pediatric Subjects Ages 1 to 11 Years Old With Symptomatic Gastroesophageal Reflux Disease|Completed||Phase 1|36|Actual|Takeda||3|||f||||f||||||||||2018-06-01 00:12:26.166706|2018-06-01 00:12:26.166706
NCT01045083|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2016-11-01|2010-01-07|2010-01-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers|Randomized, Observer-blind, Placebo-controlled, Four-way Cross-over Study to Study the Ability of Functional Magnetic Resonance Imaging (fMRI) of the Brain to Detect and Characterize the Effects of Single Doses of a Selective Serotonin Reuptake Inhibitor (Escitalopram [Lexapro&#61650;]), a Dopamine|Completed||Phase 1|25|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:12:27.422549|2018-06-01 00:12:27.422549
NCT01045070|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2012-05-01|2010-01-07|2010-01-08|Estimate|||||||2012-05-01|2012-05-02|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|December 2010|Actual|2010-12-31||Observational|||Periodontitis and Coronary Heart Disease|Periodontitis and Its Microbiological Agents as Prognostic Factors in Patients With Coronary Heart Disease|Completed|||960|Actual|Martin-Luther-Universität Halle-Wittenberg|||1||f||||f||||||Samples With DNA|"~     Blood-samples and samples from gingival pockets~   "|||2018-06-01 00:12:27.538671|2018-06-01 00:12:27.538671
NCT01045057|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2015-01-15||2015-02-10|2010-01-07|2010-01-08|Estimate|2015-01-15|2015-02-10|Estimate||||2015-02-10|2015-02-27|Estimate|December 2009||2009-12-31|February 2015|2015-02-28|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Clinical Feasibility of New Tracheoesophageal Puncture Set|Clinical Feasibility of a New Surgical Tool for Primary or Secondary Tracheoesophageal Puncture and Voice Prosthesis Insertion for Prosthetic Voice Rehabilitation After Total Laryngectomy|Completed||Phase 1/Phase 2|27|Actual|Atos Medical AB||1|||f||||f||||||||||2018-06-01 00:12:27.712724|2018-06-01 00:12:27.712724
NCT01045044|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-04-04|2010-01-07|2010-01-08|Estimate|||||||2012-04-04|2012-04-05|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy|Magnetic Resonance Imaging of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Anthracycline-based Systemic Chemotherapy|Withdrawn|||0|Actual|Kettering Health Network|||2|No participants enrolled|f||||f||||||||||2018-06-01 00:12:27.984507|2018-06-01 00:12:27.984507
NCT01045031|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2016-03-15||2016-05-31|2010-01-07|2010-01-08|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|February 2014|Actual|2014-02-28||Observational|APSOEM|Of 136 screened individuals (63 athletes, 73 controls), 56 athletes and 58 controls have been enrolled since they met the inclusion criteria.|Cognitive Function in Elderly Marathon Runners|Austrian Prospective Cohort Study in Cognitive Function of Elderly Marathon-runners|Active, not recruiting|||114|Actual|Medical University of Vienna|||2||f||||f||||||Samples With DNA|"~     Apolipoprotein E4 genotype, Insulin-like growth factor-1, Brain-derived neurotrophic factor,~     rs6265-Genotype~   "|No||2018-06-01 00:12:28.103628|2018-06-01 00:12:28.103628
NCT01045018|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis|BE Study With Clinical Endpoints Comparing Mesalamine Delayed Release Tablets 400 mg to the Reference Listed Drug ASACOL® Delayed Release Tablets 400 mg in Patients With Mild to Moderately Active Ulcerative Colitis|Completed||Phase 3|||EMET Pharmaceuticals, LLC||3|||f||||f||||||||||2018-06-01 00:12:28.527155|2018-06-01 00:12:28.527155
NCT01045005|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|May 2011|Anticipated|2011-05-31|May 2007|Actual|2007-05-31||Interventional|||Doppler Ultrasound Investigation of Microcirculations|Doppler Ultrasound Investigation of Ocular and Skeletal Microcirculations in Health and Disease|Unknown status|Recruiting|N/A|72|Anticipated|Queen's University, Belfast||2|||f||||t||||||||||2018-06-01 00:12:28.640394|2018-06-01 00:12:28.640394
NCT01044992|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-02-25|2010-01-07|2010-01-08|Estimate|||||||2010-02-25|2010-02-26|Estimate|May 2002||2002-05-31|February 2010|2010-02-28|May 2006|Actual|2006-05-31|May 2005|Actual|2005-05-31||Interventional|MSAJOY||Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study|Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge|Completed||N/A|38|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-06-01 00:12:28.889792|2018-06-01 00:12:28.889792
NCT01044979|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2014-07-03|2010-01-07|2010-01-08|Estimate|||||||2014-07-03|2014-07-04|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma|Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma, a Methodological Study|Completed|||50|Actual|Haukeland University Hospital|||||f||||f||||||Samples Without DNA|"~     Serum and interstitial fluid~   "|||2018-06-01 00:12:28.991233|2018-06-01 00:12:28.991233
NCT01044966|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2015-10-01|2010-01-07|2010-01-08|Estimate|||||||2015-10-01|2015-10-02|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|||A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma|Phase I/II Intraventricular DepoCyt (OD # 06-2348) in Glioblastoma (76,730, 11/06)|Terminated||Phase 1/Phase 2|29|Actual|Medical University of South Carolina||1||The study was terminated due to lack of adequate patient enrollment into trial.|f||||t||||||||||2018-06-01 00:12:29.060197|2018-06-01 00:12:29.060197
NCT01044953|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2011-01-04|2010-01-07|2010-01-08|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Injury Incidence in Professional Soccer|Repercussions of a Shortened Winter Break on Injury Incidence Within the German Professional Soccer Leagues|Completed|||240|Anticipated|Saarland University|||1||f||||f||||||||||2018-06-01 00:12:29.205285|2018-06-01 00:12:29.205285
NCT01044940|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2015-09-09|2010-01-07|2010-01-08|Estimate|||||||2015-09-09|2015-09-10|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma in Healthy and Sick Children|Measurements of Colloid Osmotic Pressure in Interstitial Fluid and Plasma in Healthy and Sick Children|Completed|||17|Actual|Haukeland University Hospital|||3||f||||f||||||Samples Without DNA|"~     Plasma and interstitial fluid~   "|||2018-06-01 00:12:29.428676|2018-06-01 00:12:29.428676
NCT01044927|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-10-03|2010-01-07|2010-01-08|Estimate|||||||2012-10-03|2012-10-05|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|June 2008|Actual|2008-06-30|August 2007|Actual|2007-08-31||Interventional|||Advanced eHealth for Chronic Obstructive Pulmonary Disease (COPD) in Colorado|Phase 3 Clinical Trial Studying the Efficacy of a Proactive Integrated Approach to Care in Patients With Advanced COPD|Completed||Phase 3|511|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 00:12:29.569666|2018-06-01 00:12:29.569666
NCT01044914|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2016-05-12|2010-01-07|2010-01-08|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Genes, Intermediate Phenotypes and Response to Quetiapine RX|Use of Clinical and Intermediate Phenotypes to Assess Response to Quetiapine: the Role of Putative Causative Genes|Completed|||100|Actual|University of Bari|||||f||||t||||||||||2018-06-01 00:12:29.665476|2018-06-01 00:12:29.665476
NCT01044901|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2016-08-23|2010-01-07|2010-01-08|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Cardiovascular Complications of Sickle Cell Disease|Cardiovascular Complications of Sickle Cell Disease|Recruiting|||220|Anticipated|University of Chicago|||2||f||||f||||||Samples With DNA|"~     We will study blood samples for chemicals related to sickle cell and heart and lung disease,~     and will be evaluating DNA for purposes of the study.~   "|||2018-06-01 00:12:29.860086|2018-06-01 00:12:29.860086
NCT01044888|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2012-01-31|2010-01-07|2010-01-08|Estimate|||||||2012-01-31|2012-02-02|Estimate|April 2007||2007-04-30|January 2012|2012-01-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||Heparin Resistance: Predictors and Outcomes|Heparin Resistance During Off-pump Coronary Artery Bypass Graft Surgery: Predictors and Clinical Implication|Completed||N/A|199|Actual|Yonsei University|||||f||||t||||||||||2018-06-01 00:12:29.988858|2018-06-01 00:12:29.988858
NCT01044875|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|UMPDR||Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy|A Randomised Control Trial Comparing the Effectiveness of Yellow 577 nm Laser to Conventional Green 532 nm Laser for Proliferative Diabetic Retinopathy|Unknown status|Recruiting|N/A|120|Anticipated|University of Malaya||2|||f||||t||||||||||2018-06-01 00:12:30.555064|2018-06-01 00:12:30.555064
NCT01044862|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2015-01-06||2015-01-22|2010-01-07|2010-01-08|Estimate|2015-01-22|2015-02-02|Estimate||||2015-01-22|2015-02-02|Estimate|June 2010||2010-06-30|January 2015|2015-01-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|AMIGOS||Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation|Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation|Completed||Phase 3|900|Actual|Yale University||3|||f||||t||||||||||2018-06-01 00:12:30.748144|2018-06-01 00:12:30.748144
NCT01044849|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Clinical Test Report for Blood Pressure Meter CH-609||Completed|||85|Actual|Citizen Systems Japan Co., Ltd.|||||f||||f||||||||||2018-06-01 00:12:31.311294|2018-06-01 00:12:31.311294
NCT01044836|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2014-07-13|2010-01-07|2010-01-08|Estimate|||||||2014-07-13|2014-07-15|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|SPH||Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers|A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers|Completed||Phase 1|42|Actual|Hanwha Chemical||1|||f||||f||||||||||2018-06-01 00:12:31.38709|2018-06-01 00:12:31.38709
NCT01044823|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2017-07-26|2010-01-07|2010-01-08|Estimate|||||||2017-07-26|2017-07-31|Actual|January 2010||2010-01-31|February 2011|2011-02-28|January 2014|Actual|2014-01-31|March 2011|Actual|2011-03-31||Observational|||Use of Thermal and 3D Imaging to Quantify Arthritis|Use of Thermal and 3D Imaging to Quantify Arthritis|Completed|||157|Actual|University of Pittsburgh|||2||f||||f||||||||||2018-06-01 00:12:31.56999|2018-06-01 00:12:31.56999
NCT01044810|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2011-03-14|2010-01-07|2010-01-08|Estimate|||||||2011-03-14|2011-03-15|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity|Comparison of Virological and Immunological Results of Efavirenz-based Regimen in HIV-infected Patients With or Without Allergic Reactions to Nevirapine|Completed|||559|Actual|Bamrasnaradura Infectious Diseases Institute|||3||f||||f||||||||||2018-06-01 00:12:31.643069|2018-06-01 00:12:31.643069
NCT01044797|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|Remote capsule||Remote Manipulation of a Capsule Endoscope|Remote Manipulation of a Capsule Endoscope in the Esophagus and Stomach of a Human Volunteer Using an External Hand-held Magnet|Completed|||1|Actual|Dartmouth-Hitchcock Medical Center|||||f||||f||||||||||2018-06-01 00:12:31.710788|2018-06-01 00:12:31.710788
NCT01044784|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-03-24|2010-01-07|2010-01-08|Estimate|||||||2012-03-24|2012-03-27|Estimate|February 2010||2010-02-28|March 2012|2012-03-31||||||||Observational|||Acute Evaluation of the Safety of Left Ventricular-left Ventricular (LV-LV) Delays and Its Effects on Mechanical Dyssynchrony|Acute Evaluation of the Safety of LV-LV Delays and Its Effects on Mechanical Dyssynchrony|Completed|||50|Anticipated|St. Jude Medical|||||f||||f||||||||||2018-06-01 00:12:31.751062|2018-06-01 00:12:31.751062
NCT01044771|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2014-01-20||2015-05-08|2010-01-07|2010-01-08|Estimate|2015-05-08|2015-05-12|Estimate||||2015-05-08|2015-05-12|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|RALPIR|HIV|Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria|A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads|Completed||N/A|20|Actual|Metropolis Medical||1|||f||||t||||||||||2018-06-01 00:12:31.867344|2018-06-01 00:12:31.867344
NCT01044758|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2014-09-08||2017-07-19|2010-01-07|2010-01-08|Estimate|2017-07-19|2017-08-21|Actual||||2017-07-19|2017-08-21|Actual|December 2009||2009-12-31|July 2017|2017-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)|Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI|Completed||Phase 2|96|Actual|Johns Hopkins University||7|||f||||t||||||||||2018-06-01 00:12:32.20568|2018-06-01 00:12:32.20568
NCT01044745|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2017-09-29|2010-01-07|2010-01-08|Estimate|||||||2017-09-29|2017-10-02|Actual|December 2009||2009-12-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)|Active, not recruiting||Phase 2|50|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-06-01 00:12:33.240631|2018-06-01 00:12:33.240631
NCT01044563|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2014-09-25|2010-01-07|2010-01-08|Estimate|||||||2014-09-25|2014-09-26|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|May 2012|Actual|2012-05-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Breathing Training on Psychosocial Functioning and Heart Rate Variability in Postmenopausal Women With Depressive Symptoms||Completed||N/A|81|Actual|National Science Council, Taiwan||2|||f||||t||||||||||2018-06-01 00:12:36.457286|2018-06-01 00:12:36.457286
NCT01044732|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2015-08-28||2017-06-26|2010-01-06|2010-01-08|Estimate|2015-08-28|2015-10-01|Estimate||||2017-06-26|2017-07-25|Actual|March 2009||2009-03-31|June 2017|2017-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|TERRACE|Intention-to-treat population, i.e., those who were actually examined during the study|Third Eye Retroscope Randomized Clinical Evaluation|"Third Eye Retroscope Randomized Clinical Evaluation (The TERRACE Study)"|Completed||N/A|448|Actual|Avantis Medical Systems|With mean subject age of 57.8 years, population was younger than in some studies, so polyp prevalence might be below average.|2|||f||||f||||||||No|Aggregated, de-identified data to be published in peer-reviewed medical journal|2018-06-01 00:12:33.428592|2018-06-01 00:12:33.428592
NCT01044719|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-04-12|2010-01-07|2010-01-08|Estimate|||||||2010-04-12|2010-04-13|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|April 2011|Anticipated|2011-04-30|October 2010|Anticipated|2010-10-31||Interventional|||Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis|What Duration of Intravenous Antibiotic Therapy Should be Used in the Treatment of Infective Exacerbations of Cystic Fibrosis Chronically Colonised With Pseudomonas Aeruginosa|Unknown status|Not yet recruiting|Phase 4|240|Anticipated|Imperial College London||3|||f||||f||||||||||2018-06-01 00:12:33.880077|2018-06-01 00:12:33.880077
NCT01044706|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2010-02-08||2010-02-28|2010-01-07|2010-01-08|Estimate|2010-02-08|2010-03-01|Estimate||||2010-02-28|2010-03-02|Estimate|May 2005||2005-05-31|February 2010|2010-02-28|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions|Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fed Conditions|Completed||Phase 1|60|Actual|Kremers Urban Development Company||2|||f||||t||||||||||2018-06-01 00:12:33.981135|2018-06-01 00:12:33.981135
NCT01044693|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2015-04-14||2015-04-14|2010-01-07|2010-01-08|Estimate|2015-04-14|2015-05-01|Estimate||||2015-04-14|2015-05-01|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional||Patients with primary forms of autonomic failure and supine hypertension|Nebivolol in the Supine Hypertension of Autonomic Failure|Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity|Completed||N/A|20|Actual|Vanderbilt University||4|||f||||f||||||||||2018-06-01 00:12:34.256781|2018-06-01 00:12:34.256781
NCT01044680|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-07|2010-01-07|2010-01-08|Estimate|||||||2010-01-07|2010-01-08|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effects of NUTRIOSE®FB Dietary Fiber Supplementation on Satiety, Body Fat, and Metabolic Syndrome in Overweight Adult Men|The Effects of NUTRIOSE®FB Dietary Fiber Supplementation on the Satiety, Body Fat Distribution, and Metabolic Syndrome Biomarkers of Overweight Adult Chinese Men 20-35 Years of Age.|Completed||Phase 2/Phase 3|120|Actual|Roquette Freres||2|||f||||f||||||||||2018-06-01 00:12:34.815304|2018-06-01 00:12:34.815304
NCT01044667|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2018-02-16|2010-01-07|2010-01-08|Estimate|||||||2018-02-16|2018-02-20|Estimate|January 2010||2010-01-31|February 2018|2018-02-28|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||A Gastrointestinal Quality of Life Study in Lung Transplant Recipients Converted From Mycophenolate Mofetil to Myfortic|Reduced Gastrointestinal Complaints and Improved Quality of Life in Lung Transplant Recipients Converted From Mycophenolate Mofetil (MMF) to Myfortic (Enteric-coated Mycophenolate Sodium, Ec-mps)|Terminated||N/A|3|Actual|Vanderbilt University Medical Center||1||poor enrollment and lack of study staff|f||||f||||||||||2018-06-01 00:12:34.934671|2018-06-01 00:12:34.934671
NCT01044654|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2015-03-11|2010-01-07|2010-01-08|Estimate|||||||2015-03-11|2015-03-13|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients|A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy|Completed||Phase 1|19|Actual|Sangamo Therapeutics||5|||f||||f||||||||||2018-06-01 00:12:35.184655|2018-06-01 00:12:35.184655
NCT01044641|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2014-07-03|2010-01-07|2010-01-08|Estimate|||||||2014-07-03|2014-07-08|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Measurement of Colloid Osmotic Pressure in Plasma and Interstitial Fluid in Children|Measurement of Colloid Osmotic Pressure in Plasma and Interstitial Fluid in Children|Completed|||99|Actual|Haukeland University Hospital|||||f||||f||||||Samples Without DNA|"~     Interstitial fluid and serum~   "|||2018-06-01 00:12:35.317126|2018-06-01 00:12:35.317126
NCT01044628|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2018-03-06|2010-01-07|2010-01-08|Estimate|||||||2018-03-06|2018-03-08|Actual|October 2010||2010-10-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|INOX||The International Nocturnal Oxygen (INOX) Trial|Multi-Center Randomized Placebo-controlled Trial of Nocturnal Oxygen Therapy in Chronic Obstructive Pulmonary Disease. The International Nocturnal Oxygen (INOX) Trial|Active, not recruiting||N/A|243|Actual|Laval University||2|||f||||t||||||||Undecided||2018-06-01 00:12:35.427134|2018-06-01 00:12:35.427134
NCT01044615|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2013-01-10|2010-01-07|2010-01-08|Estimate|||||||2013-01-10|2013-01-14|Estimate|December 2010||2010-12-31|January 2013|2013-01-31||||||||Observational|mTBI||Advanced Imaging Tools in the Study of Mild Traumatic Brain Injury|Advanced Imaging Tools in the Study of Mild Traumatic Brain Injury|Completed|||20|Anticipated|Kettering Health Network|||2||f||||f||||||||||2018-06-01 00:12:35.617439|2018-06-01 00:12:35.617439
NCT01044602|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2015-04-20|2010-01-07|2010-01-08|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes|Metabolic Surgery vs. Medical Management for Resolution of Type II Diabetes: A Prospective Group Match Study|Completed||N/A|120|Actual|Ohio State University||2|||f||||f||||||||||2018-06-01 00:12:35.714876|2018-06-01 00:12:35.714876
NCT01044589|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2017-04-18||2017-07-05|2010-01-07|2010-01-08|Estimate|2017-07-05|2017-08-01|Actual||||2017-07-05|2017-08-01|Actual|May 2010||2010-05-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone|Comparison of the Efficacy of a Biological Implant to Reinforce Overlapping Sphincter Repair Versus Overlapping Sphincter Repair Alone|Terminated||N/A|13|Actual|The Cleveland Clinic||2||The study was stopped due to low enrollment|f||||||||||||No||2018-06-01 00:12:35.867284|2018-06-01 00:12:35.867284
NCT01044576|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2015-08-04|2010-01-07|2010-01-08|Estimate|||||||2015-08-04|2015-08-05|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|PRC-REMS||Patient Research Cohort: Rapidly Evolving Multiple Sclerosis|Patient Research Cohort: Rapidly Evolving Multiple Sclerosis Opening the Window of Therapeutic Opportunity|Completed|||200|Actual|Imperial College London|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells~   "|||2018-06-01 00:12:36.39034|2018-06-01 00:12:36.39034
NCT01044550|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2015-01-21|2010-01-07|2010-01-08|Estimate|||||||2015-01-21|2015-01-22|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Laparoscopy Versus Clinical Follow up to Detect Diaphragm Injury|Laparoscopy (to Detect Occult Diaphragm Injury) Versus Clinical and Radiological Follow up to Detect Diaphragm Injury and Herniation, in Patients With Asymptomatic Left Thoracoabdominal Stab Wounds: A Prospective Randomized Controlled Study|Completed||N/A|66|Actual|University of Cape Town||2|||f||||t||||||||||2018-06-01 00:12:36.612816|2018-06-01 00:12:36.612816
NCT01044537|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2017-01-20||2017-01-20|2010-01-07|2010-01-08|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|February 2010||2010-02-28|January 2017|2017-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Safety analysis set included all participants who received at least 1 dose of study medication.|A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus|A Phase 1 Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Escalating Oral Doses Of Pf-04937319 In Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|50|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:12:36.799115|2018-06-01 00:12:36.799115
NCT01044524|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2010-09-16|2010-01-07|2010-01-08|Estimate|||||||2010-09-16|2010-09-17|Estimate|February 2010||2010-02-28|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Investigate ADME of 14C Labeled SLV334 After an i.v. Infusion|An Open Label Study to Determine ADME of 14C Labeled SLV334 and Its Metabolites After Single Intravenous Dose Infusion|Completed||Phase 1|6|Actual|Solvay Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:12:37.963395|2018-06-01 00:12:37.963395
NCT01044511|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2011-11-21|2010-01-07|2010-01-08|Estimate|||||||2011-11-21|2011-11-23|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|QUEST||Quality of Life With Esophageal Stent Trial|Prospective, Randomized Trial of the Effects on HRQoL, Cost-Utility and Reintervention Rate, of Nurse Home Visits, in Patients With SEMS Treated Malignant Disease in the Esophagus and Cardia.|Unknown status|Recruiting|N/A|80|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-06-01 00:12:38.046151|2018-06-01 00:12:38.046151
NCT01044498|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|2013-02-07||2013-03-22|2010-01-07|2010-01-08|Estimate|2013-02-07|2013-03-12|Estimate||||2013-03-22|2013-04-01|Estimate|December 2009||2009-12-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis|An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)|Completed||Phase 3|46|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:12:38.141183|2018-06-01 00:12:38.141183
NCT01044485|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2012-09-24|2010-01-07|2010-01-08|Estimate|||||||2012-09-24|2012-09-25|Estimate|November 2008||2008-11-30|September 2012|2012-09-30||||November 2011|Actual|2011-11-30||Interventional|LapDoc||Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer|A Multicenter Open-label, Phase I/II Dose Escalation Study of Oral Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|17|Actual|Centre Georges Francois Leclerc||1|||f||||t||||||||||2018-06-01 00:12:38.91833|2018-06-01 00:12:38.91833
NCT01044472|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-07|||2016-04-13|2010-01-07|2010-01-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|MSLV||Multi-site Left Ventricular (MSLV) Pacing With Quartet 1458Q Lead|Multi-site Left Ventricular (MSLV) Pacing With Quartet 1458Q Lead|Completed|||61|Actual|St. Jude Medical|||||f||||f||||||||No||2018-06-01 00:12:39.031384|2018-06-01 00:12:39.031384
NCT01044459|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2012-08-14|2011-07-26|2017-03-09|2010-01-06|2010-01-07|Estimate|2012-08-14|2012-09-13|Estimate|2011-07-26|2011-08-01|Estimate|2017-03-09|2017-04-20|Actual|November 2009||2009-11-30|February 2017|2017-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|LAS-MD-35|Of 605 patients randomized, 602 patients (99.5%) received at least 1 dose of double-blind treatment and were included in the Safety Population|Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)|A Long-Term, Randomized, Double-Blind Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide At Two Dosage Levels When Administered to Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease|Completed||Phase 3|605|Actual|AstraZeneca|Site 1420 randomized 31 patients who were discontinued by 21 Jan 2011 due to significant deviations documented in a letter to the FDA on 07 Jan 2011. No changes to the analyses were prospectively specified in the amended statistical analysis plan.|2|||f||||f||||||||||2018-06-01 00:12:39.169044|2018-06-01 00:12:39.169044
NCT01044446|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2016-08-09|2010-01-06|2010-01-07|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional|||Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis|Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients|Completed||Phase 4|56|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:12:39.904432|2018-06-01 00:12:39.904432
NCT01044433|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-01-24|2010-01-05|2010-01-07|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2009|Actual|2009-10-31|January 2017|2017-01-31||||March 2017|Anticipated|2017-03-31||Interventional|||Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck|A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 2|44|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:12:40.971546|2018-06-01 00:12:40.971546
NCT01044420|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-06|2010-01-06|2010-01-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Interventional|||mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial||Unknown status|Recruiting|Phase 2|50|Anticipated|Peking University||1|||f||||||||||||||2018-06-01 00:12:41.070244|2018-06-01 00:12:41.070244
NCT01044407|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-22|2010-01-06|2010-01-07|Estimate|||||||2010-01-22|2010-01-25|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|October 2010|Anticipated|2010-10-31|February 2010|Anticipated|2010-02-28||Interventional|||Developing a New, Dynamic, Therapeutic Pacemaker Algorithm for Stabilising Periodic Breathing in Chronic Heart Failure.|Developing a New, Dynamic, Therapeutic Pacemaker Algorithm for Stabilising Periodic Breathing in Chronic Heart Failure.|Unknown status|Recruiting|Phase 2|14|Anticipated|Imperial College London|||||f||||f||||||||||2018-06-01 00:12:41.148227|2018-06-01 00:12:41.148227
NCT01044394|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2012-08-30|2010-01-06|2010-01-07|Estimate|||||||2012-08-30|2012-08-31|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Same-day, Reduced Volume Bowel Preparation|Evaluating the Effectiveness of a Same-day, Reduced Volume Polyethylene Glycol + Electrolyte Solution (PEG-ELS) Bowel Preparation for Afternoon Colonoscopies|Withdrawn||Phase 2|0|Actual|Boston Medical Center||1||A phase III RCT was published showing this approach is effective|f||||t||||||||||2018-06-01 00:12:41.239343|2018-06-01 00:12:41.239343
NCT01044381|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04||2011-06-13|2014-11-13|2010-01-05|2010-01-07|Estimate||||2011-07-19|2011-07-22|Estimate|2014-11-13|2014-11-26|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Open-Label Pharmacokinetics (PK)/Safety Study of Luliconazole Solution, 10% in Distal Subungual Onychomycosis|A Phase 1/2a, Open-Label Study Evaluating the Pharmacokinetics, Safety and Tolerability of Luliconazole Solution, 10% in Subjects With Moderate to Severe Distal Subungual Onychomycosis|Completed||Phase 1/Phase 2|24|Actual|Topica Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:12:41.3717|2018-06-01 00:12:41.3717
NCT01044368|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2011-09-14|2010-01-06|2010-01-07|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2010||2010-01-31|January 2010|2010-01-31||||||||Interventional|||Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM) on Monotherapy|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus on Monotherapy|Suspended||N/A|50|Anticipated|Endocrine Research Society||2||To focus on a similar study NCT01175408 prior to recruiting participants.|f||||f||||||||||2018-06-01 00:12:41.459915|2018-06-01 00:12:41.459915
NCT01044355|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2018-03-20|2010-01-06|2010-01-07|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2009||2009-12-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Continuous Positive Airway Pressure (CPAP) Versus Auto-titrating Continuous Positive Airway Pressure (APAP) on Resistant Hypertension (HTN) and Arterial Stiffness|Effect of Fixed Versus Auto-titrating Continuous Positive Airway Pressure on Blood Pressure and Arterial Stiffness in Patients With Resistant Hypertension and Obstructive Sleep Apnea|Active, not recruiting||N/A|34|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-06-01 00:12:41.563263|2018-06-01 00:12:41.563263
NCT01044342|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-05-06|2010-01-06|2010-01-07|Estimate|||||||2010-05-06|2010-05-10|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition|A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-period Cross-over Study to Evaluate the Scopolamine Cognition Model in Healthy Male Subjects Using AZD1446 and Donepezil Versus Placebo|Completed||Phase 1|20|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:12:41.736942|2018-06-01 00:12:41.736942
NCT01044329|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-06|2010-01-06|2010-01-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Interventional|BRVO||Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion|Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion|Unknown status|Recruiting|Phase 2|90|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:12:41.820384|2018-06-01 00:12:41.820384
NCT01044316|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-03|||2011-12-27|2010-01-05|2010-01-07|Estimate|||||||2011-12-27|2011-12-30|Estimate|April 2010||2010-04-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China|A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Using a Local Dosing Regimen in Infants|Completed||Phase 3|670|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:12:41.906108|2018-06-01 00:12:41.906108
NCT01044303|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2014-08-27||2014-10-16|2010-01-06|2010-01-07|Estimate|2014-10-16|2014-10-20|Estimate||||2014-10-16|2014-10-20|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)|An Exploratory, Open-Label, Single Center Study to Assess the Efficacy and Dose Titration of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients|Completed||Phase 4|32|Actual|East Carolina University|Lost to follow-up was a limitation in this study.|1|||f||||f||||||||||2018-06-01 00:12:41.989709|2018-06-01 00:12:41.989709
NCT01044290|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2015-02-23||2015-10-19|2010-01-05|2010-01-07|Estimate|2015-09-18|2015-10-19|Estimate||||2015-10-19|2015-11-20|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional||A total of 261 Durham VAMC patients with serious life-limiting disease were consented, and 221 were randomized to the study. Seventy-five were randomized to the Life completion intervention, 74 to the active control intervention, and 72 to the usual care control group.|Outlook Quality of Life Intervention Study|Outlook: An Intervention to Improve Quality of Life in Serious Illness Study|Completed||N/A|221|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 00:12:42.206228|2018-06-01 00:12:42.206228
NCT01044277|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2017-06-23|2010-01-06|2010-01-07|Estimate|||||||2017-06-23|2017-06-27|Actual|February 2010||2010-02-28|June 2017|2017-06-30|October 2014|Actual|2014-10-31|September 2011|Actual|2011-09-30||Interventional|||Oral Glutathione Supplementation on the Levels of Blood Glutathione|Effect of Oral Glutathione Supplementation on the Levels of Blood Glutathione and Markers of Oxidative Stress in Healthy Adults (Glutathione Supplementation and Health (GSH) Study)|Terminated||N/A|61|Actual|Milton S. Hershey Medical Center||3||Drugs unavailable|f||||t|f|f||||||Undecided|At this time we have no plan for sharing, however, if the need should arise, then sharing may be a possibility.|2018-06-01 00:12:43.035486|2018-06-01 00:12:43.035486
NCT01044264|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2012-09-14|2012-03-15|2013-01-17|2010-01-05|2010-01-07|Estimate|2012-11-19|2012-12-17|Estimate|2012-03-15|2012-03-19|Estimate|2013-01-17|2013-01-24|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris|Completed||N/A|602|Actual|Perrigo Company||3|||f||||t||||||||||2018-06-01 00:12:43.120204|2018-06-01 00:12:43.120204
NCT01044251|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2016-08-16|2010-01-06|2010-01-07|Estimate|||||||2016-08-16|2016-08-18|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Frovatriptan as a Transitional Therapy in Medication Overuse Headache|Frovatriptan as a Transitional Therapy in Medication Overuse Headache|Recruiting||Phase 2|56|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 00:12:43.450069|2018-06-01 00:12:43.450069
NCT01044238|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2014-05-19|2010-01-06|2010-01-07|Estimate|||||||2014-05-19|2014-05-20|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|MPH||Methylphenidate to Treat Methamphetamine Dependence|Sustained-Release Methylphenidate for Management of Methamphetamine Dependence|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:12:43.552508|2018-06-01 00:12:43.552508
NCT01044225|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-03-21|2010-01-06|2010-01-07|Estimate|||||||2012-03-21|2012-03-22|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma|CeCil: A Randomized, Non-comparative Clinical Trial of the Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma|Terminated||Phase 2|12|Actual|Universitair Ziekenhuis Brussel||2||"Results of the phase III RTOG0525 trial made the manufacturer of cilengitide decide to end~   their support to the trial"|f||||t||||||||||2018-06-01 00:12:43.626933|2018-06-01 00:12:43.626933
NCT01044212|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2012-09-14||2015-09-21|2010-01-06|2010-01-07|Estimate|2015-09-21|2015-10-21|Estimate||||2015-09-21|2015-10-21|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Bowel Function After Minimally Invasive Urogynecologic Surgery|Bowel Function After Minimally Invasive Urogynecologic Surgery: A Prospective Randomized Controlled Trial|Completed||N/A|72|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 00:12:43.714232|2018-06-01 00:12:43.714232
NCT01044199|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2014-01-28|2010-01-06|2010-01-07|Estimate|||||||2014-01-28|2014-01-29|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|August 2013|Actual|2013-08-31|September 2009|Actual|2009-09-30||Interventional|Rabies-ID||Study of Intradermal Administration of PCEC Rabies Vaccine|A Single Center, Open-Label, Study of Intradermal Administration of an Inactivated PCEC Rabies Vaccine in Adult Subjects|Completed||N/A|130|Actual|Centers for Disease Control and Prevention||4|||f||||f||||||||||2018-06-01 00:12:44.005503|2018-06-01 00:12:44.005503
NCT01044186|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2017-02-21|2010-01-06|2010-01-07|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2003||2003-06-30|February 2017|2017-02-28||||December 2007|Actual|2007-12-31||Interventional|||A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity|A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity|Completed||Phase 2|30|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:12:44.089152|2018-06-01 00:12:44.089152
NCT01044173|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2017-01-29|2010-01-06|2010-01-07|Estimate|||||||2017-01-29|2017-01-31|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|October 2012|Actual|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Plain Magnetic Resonance (MR) in the Assessment of Patients With Acute Abdomen|Assessment of Patients With Nontraumatic Acute Abdominal Pain With Plain MR of the Abdomen - a Comparison With CT|Withdrawn||N/A|0|Actual|Zealand University Hospital|||||f||||f||||||||||2018-06-01 00:12:44.175689|2018-06-01 00:12:44.175689
NCT01044160|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2017-06-20|2010-01-06|2010-01-07|Estimate|||||||2017-06-20|2017-06-21|Actual|July 7, 2009|Actual|2009-07-07|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Stress, Adjustment And Growth In Children With Cancer And Their Parents|Stress, Adjustment And Growth In Children With Cancer And Their Parents|Active, not recruiting|||663|Actual|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-06-01 00:12:44.254071|2018-06-01 00:12:44.254071
NCT01044147|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2016-01-13|2010-01-05|2010-01-07|Estimate|||||||2016-01-13|2016-01-14|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|OCELOT-PC||Online Counseling to Enable Lifestyle-focused Obesity Treatment in Primary Care|Online Counseling to Enable Lifestyle-focused Obesity Treatment in Primary Care|Completed||Phase 2/Phase 3|360|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 00:12:44.393811|2018-06-01 00:12:44.393811
NCT01044134|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2015-07-27|2010-01-05|2010-01-07|Estimate|||||||2015-07-27|2015-07-29|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Think AHEAD (A Healthy Eating And Drinking) Study|A 6-Month Study on Diet and Weight Loss in Overweight Adolescents|Terminated||N/A|38|Actual|Boston Children’s Hospital||2||We achieved n=38, due to slow recruitment (=2/3 of target).|f||||f||||||||||2018-06-01 00:12:44.474621|2018-06-01 00:12:44.474621
NCT01044121|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2013-01-08|2010-01-06|2010-01-07|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Mattress Firmness on Pain in Patients With Chronic Low-Back Pain|A Latin-Square Crossover Study of the Effects of Mattress Firmness on Pain in Patients With Chronic Low-Back Pain|Terminated||N/A|40|Actual|Sleep To Live Institute||1|||f||||||||||||||2018-06-01 00:12:44.600283|2018-06-01 00:12:44.600283
NCT01044108|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2017-07-25|2010-01-06|2010-01-07|Estimate|||||||2017-07-25|2017-07-27|Actual|January 5, 2010|Actual|2010-01-05|July 2017|2017-07-31|September 20, 2011|Actual|2011-09-20|December 13, 2010|Actual|2010-12-13||Interventional|||A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Two Part Trial (Sequential Single Subcutaneous Dose Rising Trial and Semi-Sequential Multiple Subcutaneous Dose Response Trial) to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0453 in Overweight/Obese Male and Female Subjects|Terminated||Phase 1|117|Actual|Novo Nordisk A/S||2||See detailed description|f||||f||||||||||2018-06-01 00:12:44.676631|2018-06-01 00:12:44.676631
NCT01044095|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2013-07-22|2010-01-06|2010-01-07|Estimate|||||||2013-07-22|2013-07-23|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|July 2010|Actual|2010-07-31||Interventional|||Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus|Evaluation of In Vitro Cross-Reactivity With Avian Influenza H5N1 Virus in Healthy Volunteers Vaccinated With a Prime Boost Regimen of Seasonal Influenza Vaccine|Completed||N/A|26|Actual|Armed Forces Research Institute of Medical Sciences, Thailand||4|||f||||f||||||||||2018-06-01 00:12:44.841905|2018-06-01 00:12:44.841905
NCT01044082|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-07-25|2010-01-06|2010-01-07|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|January 2011|Actual|2011-01-31||Interventional|TRACOR||Prevention of Post-partum Haemorrhage|Impact of Controlled Cord Traction During the Third Stage of Labour on the Incidence of Post Partum Haemorrhage|Completed||N/A|4382|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:12:44.912284|2018-06-01 00:12:44.912284
NCT01044069|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2018-03-22|2010-01-06|2010-01-07|Estimate|||||||2018-03-22|2018-03-23|Actual|January 5, 2010|Actual|2010-01-05|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19|A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19|Active, not recruiting||Phase 1|93|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 00:12:44.990082|2018-06-01 00:12:44.990082
NCT01044056|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2010-02-11||2015-06-04|2010-01-06|2010-01-07|Estimate|2010-03-17|2010-03-31|Estimate||||2015-06-04|2015-07-01|Estimate|March 2004||2004-03-31|June 2015|2015-06-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)|An Open-label, Randomized, Parallel Group Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30)|Completed||Phase 4|24|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 00:12:45.161819|2018-06-01 00:12:45.161819
NCT01044043|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2011-01-10|2010-01-06|2010-01-07|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Observational|||Prevalence and Subjective Impairment of Quality of Life (QoL) Due to Dermatologic Diseases in Internal Medicine Patients||Completed|||200|Anticipated|University of Zurich|||||f||||t||||||||||2018-06-01 00:12:45.555646|2018-06-01 00:12:45.555646
NCT01044030|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2015-03-10||2015-04-08|2010-01-06|2010-01-07|Estimate|2015-03-10|2015-03-20|Estimate||||2015-04-08|2015-04-29|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children|Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children|Completed||Phase 3|326|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 00:12:45.636784|2018-06-01 00:12:45.636784
NCT01044017|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2016-11-01|2010-01-06|2010-01-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes|A Single-center, Double-blind, Randomized, Cross-over, Placebo-controlled, Single-dose Study to Investigate Glycemic Parameters of Efficacy During 24 Hours, Safety/ Tolerability and Pharmacokinetics of Two Dose Levels of RO4998452 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|22|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:12:45.964171|2018-06-01 00:12:45.964171
NCT01044004|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2013-07-22|2010-01-06|2010-01-07|Estimate|||||||2013-07-22|2013-07-23|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue|A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue Undergoing Standard R-CHOP Chemotherapy or in Remission Following Chemo and/or Radiation|Withdrawn||N/A|0|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 00:12:46.083162|2018-06-01 00:12:46.083162
NCT01043991|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2016-05-31|2010-01-06|2010-01-07|Estimate|||||||2016-05-31|2016-06-01|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|October 2011|Actual|2011-10-31|July 2010|Actual|2010-07-31||Interventional|||"Intracoronary Injection of Epo After Myocardial Infarct Intra-CO-EpoMI"|Intracoronary Injection of Epo During Reperfusion in Patients Hospitalized for First Acute Myocardial Infarct STEMI|Completed||Phase 3|54|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-06-01 00:12:46.183796|2018-06-01 00:12:46.183796
NCT01043978|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2012-08-23|2010-01-06|2010-01-07|Estimate|||||||2012-08-23|2012-08-24|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|September 2011|Actual|2011-09-30||Interventional|||Prevention of Overfeeding During Infancy|Prevention of Overfeeding During Infancy|Completed||Phase 2|231|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 00:12:46.259089|2018-06-01 00:12:46.259089
NCT01043965|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-06|2010-01-06|2010-01-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Myocardial Perfusion in Type 2 Diabetes|Evaluation of Myocardial Perfusion and Microvascular Reserve in Real-time Utilizing Myocardial Contrast Echocardiography in Type 2 Diabetes.|Completed||Phase 1/Phase 2|61|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-06-01 00:12:46.328925|2018-06-01 00:12:46.328925
NCT01043952|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2015-06-23|2010-01-06|2010-01-07|Estimate|||||||2015-06-23|2015-06-25|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Use of Bispectral Index (BIS) for Monitoring of Total Intravenous Anaesthesia in Pediatric Patients|Use of Bispectral Index (BIS) Monitoring of Anaesthesia With Propofol and Remifentanyl in Pediatric Patients in Ear Nose and Throat Surgery: Are There Clinical Advantages?|Terminated||N/A|157|Actual|Aalborg Universitetshospital||2||Poor enrollment.|f||||f||||||||||2018-06-01 00:12:46.433545|2018-06-01 00:12:46.433545
NCT01043939|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2011-12-04||2014-12-09|2010-01-06|2010-01-07|Estimate|2012-10-29|2012-11-29|Estimate||||2014-12-09|2014-12-31|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|JAVA||Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors|A Pilot Study to Evaluate the Effects of Purple Grape Juice on the Vascular Health of Childhood Cancer Survivors|Completed||Phase 1|24|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 00:12:46.587149|2018-06-01 00:12:46.587149
NCT01043926|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2014-08-19||2017-06-01|2010-01-06|2010-01-07|Estimate|2014-08-19|2014-08-29|Estimate||||2017-06-01|2017-07-02|Actual|February 22, 2010|Actual|2010-02-22|June 2017|2017-06-30|April 14, 2010|Actual|2010-04-14|April 14, 2010|Actual|2010-04-14||Interventional||Baseline characteristics were only presented for participants in Part I of the study (N=16). No participants were enrolled in Part II of the study.|Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)|A Single Dose Study to Investigate the Pharmacokinetics of MK-4305 in Patients With Hepatic Insufficiency|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 00:12:46.885109|2018-06-01 00:12:46.885109
NCT01043913|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2010-01-06|2010-01-06|2010-01-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|February 2008||2008-02-29|November 2009|2009-11-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue|"Guaraná (Paullinia Cupana) for Chemotherapy Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study"|Completed||Phase 2|60|Actual|Faculdade de Medicina do ABC||2|||f||||f||||||||||2018-06-01 00:12:47.146182|2018-06-01 00:12:47.146182
NCT01043900|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-06|2010-01-06|2010-01-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2003||2003-08-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant OCD|Right Prefrontal High Frequency rTMS in Treatment of Resistant OCD: a Double Blind, Randomized Controlled Trial|Completed||Phase 2|30|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-06-01 00:12:47.220378|2018-06-01 00:12:47.220378
NCT01043887|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2015-04-28|2010-01-06|2010-01-07|Estimate|||||||2015-04-28|2015-04-29|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)|A Single Dose Study to Investigate the Pharmacokinetics of Ridaforolimus in Patients With Hepatic Insufficiency|Completed||Phase 1|19|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:12:47.289209|2018-06-01 00:12:47.289209
NCT01043874|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2015-01-14||2016-03-10|2010-01-06|2010-01-07|Estimate|2015-01-22|2015-02-09|Estimate||||2016-03-10|2016-04-08|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|MACS0911||Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response|A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib|Completed||Phase 4|45|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:12:47.35833|2018-06-01 00:12:47.35833
NCT01043848|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2016-03-18|2010-01-06|2010-01-07|Estimate|||||||2016-03-18|2016-03-21|Estimate|December 2009||2009-12-31|March 2016|2016-03-31||||October 2012|Actual|2012-10-31||Interventional|||Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients|Therapeutic Effects of Early and Late Onset Peripheral Pudendal Neurostimulation on Bladder Function and Autonomic Neuroplasticity in SCI - a Controlled European Multicenter Study|Suspended||N/A|36|Anticipated|University of Zurich||3||"Poor patient recruitment, necessary number of patients could not be included within the~   required time frame"|f||||||||||||||2018-06-01 00:12:47.62013|2018-06-01 00:12:47.62013
NCT01043835|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-06-04|2010-01-06|2010-01-07|Estimate|||||||2012-06-04|2012-06-05|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Comparison of Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer:A Prospective Randomized Trial|Prospective Randomized Trial of Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer|Unknown status|Active, not recruiting|N/A|328|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-06-01 00:12:47.763843|2018-06-01 00:12:47.763843
NCT01043822|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-10-28|2010-01-06|2010-01-07|Estimate|||||||2010-10-28|2010-10-29|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Observational|||Pain and Emotional Expression in Children With Autism or Mental Retardation|Pain and Emotional Expression in Children With Autism or Mental Retardation|Unknown status|Recruiting||138|Anticipated|University Hospital, Montpellier|||||f||||t||||||||||2018-06-01 00:12:47.89015|2018-06-01 00:12:47.89015
NCT01043809|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2013-02-05|2010-01-06|2010-01-07|Estimate|||||||2013-02-05|2013-02-06|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of a Handwashing Promotion Program in Three Countries|Evaluation of a School-based Handwashing Promotion Program in Three Countries|Completed||N/A|15000|Anticipated|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-06-01 00:12:47.981058|2018-06-01 00:12:47.981058
NCT01043796|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2015-02-02|2010-01-06|2010-01-07|Estimate|||||||2015-02-02|2015-02-03|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|June 2011|Actual|2011-06-30||Interventional|MTC-ITWL||Evaluation of Insecticide Treated Nets and Wall Liners for the Prevention of Malaria|Malaria Transmission Consortium: The Added Effects of Insecticide Treated Materials, Artemisinin-containing Combination Treatments, and Larviciding on Malaria Transmission and Illness|Completed||Phase 3|1730|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 00:12:48.124172|2018-06-01 00:12:48.124172
NCT01043783|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2015-10-06|2010-01-06|2010-01-07|Estimate|||||||2015-10-06|2015-10-08|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|April 2011|Actual|2011-04-30|||||Interventional|||Preliminary Data for Breath Biofeedback of Dietary Compliance|Preliminary Data for Breath Biofeedback of Dietary Compliance|Completed||N/A|6|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 00:12:48.19436|2018-06-01 00:12:48.19436
NCT01043770|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2015-06-03|2010-01-06|2010-01-07|Estimate|||||||2015-06-03|2015-06-04|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TRIMS||The Reversal Intervention for Metabolic Syndrome Study|A Randomised Controlled Trial to Investigate the Effects of a Structured Self-management Education Programme for People With Metabolic Syndrome|Completed||N/A|82|Actual|University of Leicester||2|||f||||f||||||||||2018-06-01 00:12:48.248837|2018-06-01 00:12:48.248837
NCT01043757|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2015-06-23|2010-01-06|2010-01-07|Estimate|||||||2015-06-23|2015-06-24|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|October 2013|Anticipated|2013-10-31|April 2013|Anticipated|2013-04-30||Interventional|||Financial Incentives for Increasing Exercise|A Randomized Controlled Trial of Financial Incentives for Increasing Exercise|Withdrawn||N/A|0|Actual|Harvard University||4||"The study was stopped prior to recruitment due to logistical issues with the company in which~   it was going to be run."|f||||t||||||||||2018-06-01 00:12:48.323841|2018-06-01 00:12:48.323841
NCT01043744|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2013-03-08|2010-01-06|2010-01-07|Estimate|||||||2013-03-08|2013-03-11|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission|Treatment Outcomes for Non-malarial Febrile Illness in Children Aged 6-59 Months in Areas of Perennial Malaria Transmission|Completed||N/A|1000|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 00:12:48.398832|2018-06-01 00:12:48.398832
NCT01043731|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-12-09|2010-01-06|2010-01-07|Estimate|||||||2010-12-09|2010-12-10|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Laparoscopic Transvaginal Hybrid Anterior Resection: a Prospective Data Collection||Completed|||45|Anticipated|Cantonal Hospital of St. Gallen|||1||f||||f||||||||||2018-06-01 00:12:48.508644|2018-06-01 00:12:48.508644
NCT01043718|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2016-01-13|2010-01-05|2010-01-07|Estimate|||||||2016-01-13|2016-01-14|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Delivering an Evidence-Based Lifestyle Intervention Via the Internet: A Randomized Controlled Study|Delivering an Evidence-Based Lifestyle Intervention Via the Internet: A Randomized Controlled Study|Completed||Phase 2/Phase 3|120|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 00:12:48.578243|2018-06-01 00:12:48.578243
NCT01043705|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2015-10-13||2015-11-20|2010-01-06|2010-01-07|Estimate|2015-11-20|2015-12-24|Estimate||||2015-11-20|2015-12-24|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Observational|Centurion|Prospective Population: ICD and CRT replacement implant patients receiving a TYRX Envelope Retrospective Population: CRT Patients receiving a CRT and no TYRX envelope. Patients are site medical charts from just previous to use of TYRX Evelope|TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD|Centurion and Citadel Studies of TYRX™ Anti-Bacterial Envelope and Custom Mesh for Prevention of Infection Following CIED Replacement With a CRT or ICD|Completed|||1262|Actual|TYRX, Inc.|This was a non-randomized study and did not have an active comparator.||5||f||||t||||||||||2018-06-01 00:12:48.694226|2018-06-01 00:12:48.694226
NCT01043692|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2013-10-07|2010-01-06|2010-01-07|Estimate|||||||2013-10-07|2013-10-08|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|ACUPUNCTURE||Acceptability of an Acupuncture Intervention in Painful Elderly|Acceptability of a Strategy Including Acupuncture in the Treatment of MusculoSkeletal Pain in Hospitalised Elderly|Completed||N/A|60|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:12:49.385192|2018-06-01 00:12:49.385192
NCT01043679|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2010-01-14|2010-01-06|2010-01-07|Estimate|||||||2010-01-14|2010-01-15|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|UtapMani||Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania|A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania|Unknown status|Recruiting|Phase 4|40|Anticipated|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-06-01 00:12:49.449004|2018-06-01 00:12:49.449004
NCT01043666|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2017-02-14|2010-01-06|2010-01-07|Estimate|||||||2017-02-14|2017-02-16|Actual|December 2009||2009-12-31|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of YM178 in Subjects With Symptoms of Overactive Bladder|Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder|Completed||Phase 3|1126|Actual|Astellas Pharma Inc||3|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:12:49.519445|2018-06-01 00:12:49.519445
NCT01043653|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2016-11-10||2017-01-25|2010-01-06|2010-01-07|Estimate|2016-11-10|2017-01-10|Estimate||||2017-01-25|2017-03-08|Actual|January 2010||2010-01-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|MARS||Assessing Mental Illness Recovery|Assessing Recovery in Veterans With Serious Mental Illness|Completed|||250|Actual|VA Office of Research and Development|||1||f||||f||||||None Retained|"~     no specimens collected~   "|Undecided||2018-06-01 00:12:49.652833|2018-06-01 00:12:49.652833
NCT01043640|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2017-03-31||2018-01-09|2010-01-06|2010-01-07|Estimate|2017-03-31|2017-05-12|Actual||||2018-01-09|2018-02-05|Actual|December 2009||2009-12-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2015|Actual|2015-06-30||Interventional|||Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders|Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders|Completed||Phase 2|46|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 00:12:49.784785|2018-06-01 00:12:49.784785
NCT01043627|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-11-02|2010-01-06|2010-01-07|Estimate|||||||2012-11-02|2012-11-05|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|SITAR||Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)|Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)|Completed|||100|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 00:12:50.057417|2018-06-01 00:12:50.057417
NCT01043614|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2010-01-06|2010-01-06|2010-01-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|ProjectPEER||Peer Education, Exercising and Eating Right - Obesity Prevention in Freshmen Women|Project PEER: Peer Education, Exercising and Eating Right|Unknown status|Active, not recruiting|N/A|300|Anticipated|University of Illinois at Urbana-Champaign||1|||f||||f||||||||||2018-06-01 00:12:50.177931|2018-06-01 00:12:50.177931
NCT01043601|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2014-07-09|2010-01-05|2010-01-07|Estimate|||||||2014-07-09|2014-07-11|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control|A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled, Multi-dose, Four-period, Cross-over Study of Two Doses of Formoterol Fumarate MDI (PT005; 7.2 and 9.6 µg Ex-actuator), Administered Twice Daily for 1 Week in Patients With Moderate to Very Severe COPD, Compared to Open Label Marketed Formoterol Fumarate Inhalation Powder (Foradil® Aerolizer®, 12 µg) as an Active Control|Withdrawn||Phase 2|0|Actual|Pearl Therapeutics, Inc.||4||Similar data obtained in another study [see NCT01085045], therefore study not implemented.|f||||f||||||||||2018-06-01 00:12:50.268472|2018-06-01 00:12:50.268472
NCT01043588|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2013-04-30|2010-01-06|2010-01-07|Estimate|||||||2013-04-30|2013-05-01|Estimate|November 2007||2007-11-30|December 2012|2012-12-31|February 2011|Actual|2011-02-28|December 2009|Actual|2009-12-31||Interventional|REVAPRO||TRP Versus Photo Selective Vaporization for Obstructive Benign Prostatic Hyperplasia Management|Transurethral Resection of the Prostate With Photo Selective Vaporization of the Prostate Using the High Powered 532nm Laser Obstructive Benign Prostatic Hyperplasia Management: Focus on Efficiency and Cost-effectiveness|Completed||N/A|142|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:12:50.381947|2018-06-01 00:12:50.381947
NCT01043575|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|||2012-08-15|2010-01-06|2010-01-07|Estimate|||||||2012-08-15|2012-08-17|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TBTC-29PK||High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis|Pharmacokinetic and Pharmacodynamic Studies of Efficacy, Tolerability and Safety of Higher Dosage Rifapentine for Treatment of Tuberculosis|Completed||Phase 2|60|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 00:12:50.473999|2018-06-01 00:12:50.473999
NCT01043562|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-06|2017-04-04||2017-07-24|2010-01-06|2010-01-07|Estimate|2017-07-24|2018-02-05|Actual||||2017-07-24|2018-02-05|Actual|June 4, 2009|Actual|2009-06-04|July 2017|2017-07-31|May 10, 2012|Actual|2012-05-10|May 26, 2010|Actual|2010-05-26||Observational|||Precise Measurement of Pediatric Defibrillation Thresholds|Defibrillation Thresholds in a Pediatric Cohort Using Binary Search Protocol|Completed|||20|Actual|Boston Children’s Hospital|||1||f||||f|f|f||||||No||2018-06-01 00:12:50.598496|2018-06-01 00:12:50.598496
NCT01043367|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-03-06|2010-01-05|2010-01-06|Estimate|||||||2011-03-06|2011-03-08|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Deprexil in Subjects With Signs and Symptoms of Depression|Efficacy of Deprexil Administration in Subjects With Signs and Symptoms of Depression.|Completed||Phase 3|200|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:12:52.892241|2018-06-01 00:12:52.892241
NCT01043549|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2016-02-24|2010-01-05|2010-01-06|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|rTMSPPCGT||Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome|Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome|Terminated||Phase 2|5|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2||lake of efficacy|f||||f||||||||||2018-06-01 00:12:50.849953|2018-06-01 00:12:50.849953
NCT01043536|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2012-09-24|2010-01-05|2010-01-06|Estimate|||||||2012-09-24|2012-09-25|Estimate|September 2009||2009-09-30|September 2012|2012-09-30||||January 2012|Actual|2012-01-31||Interventional|SIB-IMRT||Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults|Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost in Association With a Temozolomide in the Treatment of Glioblastoma|Completed||Phase 1|10|Actual|Centre Georges Francois Leclerc||1|||f||||t||||||||||2018-06-01 00:12:50.925012|2018-06-01 00:12:50.925012
NCT01043523|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2014-02-24||2016-10-14|2010-01-05|2010-01-06|Estimate|2014-05-06|2014-06-03|Estimate||||2016-10-14|2016-11-28|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.|An Observational Study of the Administration of Eovist/Primovist in Pediatric Subjects (> 2 Months and Less Than 18 Years) Who Are Referred for a Routine Contrast Enhanced Liver MRI Because of Suspected or Known Focal Liver Lesions|Completed|||52|Actual|Bayer|||1||f||||f||||||None Retained|"~     Pediatric subjects who have had a Eovist/Primovist enhanced MRI for known or suspected focal~     liver disease~   "|||2018-06-01 00:12:51.046275|2018-06-01 00:12:51.046275
NCT01043510|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2017-01-20|2010-01-05|2010-01-06|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin|A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 at Steady State Conditions in Subjects With Type 2 Diabetes of Different Race and/or Ethnicity|Completed||Phase 1|63|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 00:12:51.519177|2018-06-01 00:12:51.519177
NCT01043497|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2016-01-12|2010-01-05|2010-01-06|Estimate|||||||2016-01-12|2016-01-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:12:51.588094|2018-06-01 00:12:51.588094
NCT01043484|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2016-10-18|2010-01-05|2010-01-06|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|January 2013|Actual|2013-01-31||Interventional|AVAXEL||Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer|Phase II Randomized Study to Compare Capecitabine + Bevacizumab Concomitantly With Radiotherapy Versus Capecitabine Concomitantly With Radiotherapy, as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer|Completed||Phase 2|90|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-06-01 00:12:51.631617|2018-06-01 00:12:51.631617
NCT01043471|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2015-10-06|2010-01-04|2010-01-06|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|January 2011|Actual|2011-01-31|||||Interventional|||The Effects of Gum Chewing on Energy Intake and Expenditure|The Effects of Gum Chewing on Energy Intake and Expenditure|Completed||N/A|31|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:12:51.700917|2018-06-01 00:12:51.700917
NCT01043458|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2010-11-01|2010-01-05|2010-01-06|Estimate|||||||2010-11-01|2010-11-02|Estimate|November 2009||2009-11-30|September 2010|2010-09-30||||January 2010|Actual|2010-01-31||Interventional|||Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia|A Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ABT-126 in Stable Subjects With Schizophrenia|Completed||Phase 1|16|Actual|Abbott||3|||f||||f||||||||||2018-06-01 00:12:51.764689|2018-06-01 00:12:51.764689
NCT01043445|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-10-08|2010-01-05|2010-01-06|Estimate|||||||2014-10-08|2014-10-09|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.|G Protein-coupled Receptor in the Intestine (GPR 119) Stimulated GLP-1 Secretion|Completed||N/A|8|Actual|Glostrup University Hospital, Copenhagen||3|||f||||f||||||||||2018-06-01 00:12:51.855044|2018-06-01 00:12:51.855044
NCT01043432|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2015-02-11||2015-04-21|2010-01-04|2010-01-06|Estimate|2015-04-21|2015-05-12|Estimate||||2015-04-21|2015-05-12|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Observational|||Executive Dysfunction and Suicide in Psychiatric Outpatients and Inpatients|Executive Dysfunction and Suicide in Psychiatric Outpatients and Inpatients|Completed|||133|Actual|VA Office of Research and Development|Majority of control group had lifetime history of psychiatric disorders Significant challenges with recruiting||4||f||||f||||||||||2018-06-01 00:12:51.935204|2018-06-01 00:12:51.935204
NCT01043419|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-06-29|2010-01-05|2010-01-06|Estimate|||||||2010-06-29|2010-06-30|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Sympathetic Neural Outflow During Xenon Anesthesia in Humans|Sympathetic Neural Outflow During Xenon Anesthesia in Humans|Completed||Phase 1|8|Anticipated|Air Liquide Santé International||1|||f||||f||||||||||2018-06-01 00:12:52.354138|2018-06-01 00:12:52.354138
NCT01043406|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2012-10-22|2010-01-04|2010-01-06|Estimate|||||||2012-10-22|2012-10-24|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Seizure Advisory System Feasibility Study|Safety and Effectiveness of a Seizure Advisory System in Epilepsy: A Feasibility Study (Victoria)|Terminated||Phase 1|15|Actual|NeuroVista Corporation||1||Sponsor restructuring.|f||||f||||||||||2018-06-01 00:12:52.431686|2018-06-01 00:12:52.431686
NCT01043393|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2014-01-22||2014-05-05|2010-01-04|2010-01-06|Estimate|2014-05-05|2014-06-02|Estimate||||2014-05-05|2014-06-02|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study|An Open Label, Safety/Efficacy Study to Assess the Potential for Adrenal Suppression Following Multiple Dosing With Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|24|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:12:52.504498|2018-06-01 00:12:52.504498
NCT01043380|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2015-03-30|2010-01-05|2010-01-06|Estimate|||||||2015-03-30|2015-04-01|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|PRECISE-IVUS||Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound|Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound|Completed||Phase 4|245|Actual|Kumamoto University||2|||f||||t||||||||||2018-06-01 00:12:52.827787|2018-06-01 00:12:52.827787
NCT01043354|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2014-04-01|2010-01-05|2010-01-06|Estimate|||||||2014-04-01|2014-04-02|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|TACTICS||TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)|TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)|Completed||N/A|247|Actual|Narrows Institute for Biomedical Research||3|||f||||f||||||||||2018-06-01 00:12:52.952876|2018-06-01 00:12:52.952876
NCT01043341|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-08|2010-01-05|2010-01-06|Estimate|||||||2010-01-08|2010-01-11|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Knowledge and Attitude About HPV Vaccines|Knowledge and Attitude About HPV Vaccines Among Women|Completed||Phase 4|200|Actual|Universidade Cidade de Sao Paulo||2|||f||||f||||||||||2018-06-01 00:12:53.041745|2018-06-01 00:12:53.041745
NCT01043328|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2013-03-23|2010-01-05|2010-01-06|Estimate|||||||2013-03-23|2013-03-26|Estimate|May 2009||2009-05-31|March 2013|2013-03-31|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Observational|CDHPOTSS||Human Papillomavirus on Oral Tissue, Saliva and Serum|Comparison of Detection of Human Papillomavirus on Tissue, Saliva and Serum|Completed|||80|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||f||||||Samples With DNA|"~     This biospecimens will be retained: whole blood, exfoliated cells, saliva and formalin-fixed~     paraffin-embedded tissues.~   "|||2018-06-01 00:12:54.14044|2018-06-01 00:12:54.14044
NCT01043315|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-05|2010-01-05|2010-01-06|Estimate|||||||2010-01-05|2010-01-06|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|TimePoints||Cognitive Function in Adults With Cardiac Disease|Cognitive Function in Adults With Cardiac Disease|Unknown status|Recruiting||60|Anticipated|University Hospitals Cleveland Medical Center|||1||f||||||||||||||2018-06-01 00:12:54.292106|2018-06-01 00:12:54.292106
NCT01043302|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-07-27|2010-01-05|2010-01-06|Estimate|||||||2010-07-27|2010-07-28|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Multicenter Cross Sectional Study of Primary Intestine Lymphoma|Multicenter Cross Sectional Study of Primary Intestine Lymphoma: Treatment Outcome and Quality of Life|Completed|||545|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-06-01 00:12:54.372158|2018-06-01 00:12:54.372158
NCT01043289|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-05|2010-01-05|2010-01-06|Estimate|||||||2010-01-05|2010-01-06|Estimate|October 2004||2004-10-31|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Light Therapy for Depression During Pregnancy|A Randomised, Double-blind, Placebo-controlled Study of Light Therapy for Antepartum Depression|Completed||N/A|46|Actual|Psychiatric Hospital of the University of Basel||2|||f||||f||||||||||2018-06-01 00:12:54.452057|2018-06-01 00:12:54.452057
NCT01043276|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-04-26|2010-01-05|2010-01-06|Estimate|||||||2010-04-26|2010-04-27|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355|A Single Dose, Open, Randomized, 5-Way Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of PF-00258210 Administered Alone Or PF-00258210 Administered Together With PF-00610355 Either As A Free Or A Fixed Dose Combination|Completed||Phase 1|20|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 00:12:54.525692|2018-06-01 00:12:54.525692
NCT01043263|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18||2012-08-15|2015-03-13|2010-01-04|2010-01-06|Estimate||||2012-09-02|2012-09-06|Estimate|2015-03-13|2015-04-02|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CLBP||Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain|A Phase IIB, Randomized, Double-blind, Two-arm, Multi-center, Placebo-controlled, Study to Assess the Efficacy and Safety of EN3324 (Axomadol) in Subjects With Moderate to Severe Chronic Low Back Pain|Completed||Phase 2|236|Actual|Grünenthal GmbH||2|||f||||f||||||||||2018-06-01 00:12:54.620342|2018-06-01 00:12:54.620342
NCT01043250|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2011-07-22|2010-01-05|2010-01-06|Estimate|||||||2011-07-22|2011-07-25|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Observational|||Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients|Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain|Completed|||81|Actual|Samsung Medical Center|||3||f||||t||||||||||2018-06-01 00:12:54.910243|2018-06-01 00:12:54.910243
NCT01043237|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2014-09-03|2010-01-04|2010-01-06|Estimate|||||||2014-09-03|2014-09-05|Estimate|March 2009||2009-03-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Frequency Analysis of Coronary Artery Disease|A Single-centered Investigation Into the Frequency Domain Patterns in Vessels of Patients With Coronary Artery Disease|Completed|||330|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 00:12:55.118278|2018-06-01 00:12:55.118278
NCT01043224|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2013-10-24|2010-01-05|2010-01-06|Estimate|||||||2013-10-24|2013-10-25|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris|A Psoriasis Plaque Study Comparing Clobetasol Propionate Plus Calcipotriol Ointment With Clobetasol Propionate Ointment Alone, Calcipotriol Ointment Alone and a Vehicle Control for the Treatment of Psoriasis Vulgaris|Completed||Phase 1|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 00:12:55.197591|2018-06-01 00:12:55.197591
NCT01043211|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2015-03-06|2010-01-04|2010-01-06|Estimate|||||||2015-03-06|2015-03-10|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery|Analgesic Efficacy of Intravenous Lidocaine for Postoperative Pain Following Adult Spine Surgery: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University of Alabama at Birmingham||||Did not have the research staff necessary to follow through with this study.|f||||t||||||||||2018-06-01 00:12:55.28483|2018-06-01 00:12:55.28483
NCT01043198|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2012-06-13|2010-01-05|2010-01-06|Estimate|||||||2012-06-13|2012-06-14|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|REMOB||Microarray Analysis in Syndromic Obesity|Phenotypic Characterization and Array CGH Analysis in Patients With Syndromic Obesity of Unknown Etiology|Completed||N/A|90|Actual|University Hospital, Bordeaux|||||f||||t||||||||||2018-06-01 00:12:55.372059|2018-06-01 00:12:55.372059
NCT01043185|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2011-04-08||2011-05-13|2010-01-05|2010-01-06|Estimate|2011-05-13|2011-06-14|Estimate||||2011-05-13|2011-06-14|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience|A Double-blind, Placebo Controlled, Randomised, Phase IIA Pharmacodynamic 4-way Cross-over Study to Estimate the Dose Response Relationship of AZD3355 on the Number of Reflux Episodes Assessed by Impedance/pH in Patients With GERD and a Partial Response to PPI Treatment|Completed||Phase 2|27|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 00:12:55.476241|2018-06-01 00:12:55.476241
NCT01043172|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2018-01-01|2010-01-05|2010-01-06|Estimate|||||||2018-01-01|2018-01-03|Actual|July 20, 2009|Actual|2009-07-20|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection|A Phase II Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection|Completed||Phase 2|72|Actual|National Cancer Center, Korea||1|||f||||f||||||||No||2018-06-01 00:12:55.867252|2018-06-01 00:12:55.867252
NCT01043146|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2012-10-26||2013-03-05|2010-01-05|2010-01-06|Estimate|2013-03-05|2013-04-08|Estimate||||2013-03-05|2013-04-08|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|COR-1-01||Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide|A Single-Blind Placebo-Controlled Dose Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of Cor-1, An Anti-ß1 Receptor Antibody Cyclopeptide, in Five Different Strengths in Healthy Male Volunteers|Completed||Phase 1|50|Actual|Corimmun GmbH||2|||f||||f||||||||||2018-06-01 00:12:55.952527|2018-06-01 00:12:55.952527
NCT01043133|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2010-12-03||2011-07-14|2010-01-05|2010-01-06|Estimate|2011-07-14|2011-08-12|Estimate||||2011-07-14|2011-08-12|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Medical Student Use of Templates to Document Outpatient Asthma Care in Electronic Medical Record|Social Marketing in Medical Education: Influencing Medical Student Use of Evidence-based Templates in Outpatient Documentation of Asthma Care Using an Electronic Medical Record|Completed||N/A|155|Actual|Uniformed Services University of the Health Sciences||2|||f||||f||||||||||2018-06-01 00:12:56.356797|2018-06-01 00:12:56.356797
NCT01043120|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2017-06-20|2010-01-05|2010-01-06|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2010||2010-02-28|June 2017|2017-06-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|EFFORT||Effect of Oxytocin Antagonist on Reduction of Uterine Contractions|A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Trial in Oocyte Donors Assessing the Effects of Barusiban, a Selective Oxytocin Antagonist, on Uterine Contractions on the Day of Embryo Transfer|Completed||Phase 2|99|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:12:56.684182|2018-06-01 00:12:56.684182
NCT01043107|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-02-04|2010-01-05|2010-01-06|Estimate|||||||2010-02-04|2010-02-05|Estimate|February 2010||2010-02-28|January 2010|2010-01-31||||||||Observational|||Relationship Between Computer and Cancer|Study on the Relationship Between The Computer Radiation and The Recrudesce Rate of Thyroid Cancer|Unknown status|Not yet recruiting||2000|Anticipated|Guangdong General Hospital|||2||f||||||||||||||2018-06-01 00:12:56.768559|2018-06-01 00:12:56.768559
NCT01043094|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2012-03-23||2012-07-05|2010-01-04|2010-01-06|Estimate|2012-07-05|2012-08-13|Estimate||||2012-07-05|2012-08-13|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers|A Study to Compare the Safety, Tolerability, and Pharmacokinetic Profile of a Single Oral Dose of Pitavastatin 4 mg in Adult Volunteers With Severe Renal Impairment Who Are Not Being Treated With Hemodialysis Versus Healthy Adult Volunteers|Completed||Phase 4|16|Actual|Kowa Research Institute, Inc.||2|||f||||f||||||||||2018-06-01 00:12:56.858563|2018-06-01 00:12:56.858563
NCT01043081|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2016-05-10|2010-01-04|2010-01-06|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Observational|WSW||Sexually Transmitted Infections Among African American Women Who Have Sex With Women|Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women|Completed|||300|Actual|University of Mississippi Medical Center|||||f||||f||||||Samples With DNA|"~     Endocervical and vaginal secretion specimens are being retained for future research studies~     in this field of sexually transmitted diseases.~   "|No|Data will only be shared with investigators|2018-06-01 00:12:57.136103|2018-06-01 00:12:57.136103
NCT01043068|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2012-04-25|2010-01-05|2010-01-06|Estimate|||||||2012-04-25|2012-04-27|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients: A Pilot Study|A Pilot Study: The Effect of Cancer Pain Management Protocol on Hospitalized Cancer Patients|Completed||Phase 4|25|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 00:12:57.225293|2018-06-01 00:12:57.225293
NCT01043055|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-05|2010-01-05|2010-01-06|Estimate|||||||2010-01-05|2010-01-06|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Observational|||Evaluation the Diagnostic Ability of the Cancer Detection Technology (CDT) to Detect Breast Cancer Among Women Population Over Age 40|Evaluation the Diagnostic Ability of the CDT to Detect Breast Cancer Among Women Population Over Age 40|Unknown status|Not yet recruiting||140|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 00:12:57.290966|2018-06-01 00:12:57.290966
NCT01043042|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2017-03-30|2010-01-05|2010-01-06|Estimate|||||||2017-03-30|2017-04-04|Actual|January 2010||2010-01-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Identification of Inpatients at Risk for Poor Glycemic Control|Identification of Inpatients at Risk for Poor Glycemic Control|Completed|||33011|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||||2018-06-01 00:12:57.37799|2018-06-01 00:12:57.37799
NCT01043029|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05||2016-07-08|2016-11-01|2010-01-05|2010-01-06|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment|Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®|Completed||Phase 2|302|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:12:57.468674|2018-06-01 00:12:57.468674
NCT01043016|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-05|2010-01-05|2010-01-06|Estimate|||||||2010-01-05|2010-01-06|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors|Safety Study of Photodynamic Therapy Using Photocyanine Injection in Treating Patients With Malignant Tumors|Unknown status|Recruiting|Phase 1|18|Anticipated|Fujian Longhua Pharmaceutical Co. Ltd||1|||f||||t||||||||||2018-06-01 00:12:57.666268|2018-06-01 00:12:57.666268
NCT01043003|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2015-06-03|2010-01-04|2010-01-06|Estimate|||||||2015-06-03|2015-06-08|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers|Support for Hispanic Breast Cancer Patients and Caregivers|Completed||N/A|49|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 00:12:57.742848|2018-06-01 00:12:57.742848
NCT01042977|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2013-01-21||2013-12-18|2010-01-05|2010-01-06|Estimate|2013-07-19|2013-08-23|Estimate||||2013-12-18|2014-02-17|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease|A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care|Completed||Phase 3|964|Actual|AstraZeneca|For participants who did not complete 8 and/or 24 weeks, respectively, LOCF was used. For HbA1c: excluding data after glycemic rescue, Weight: including data after rescue, SBP: excluding data after anti-hypertensive rescue.|2|||f||||||||||||||2018-06-01 00:12:58.006483|2018-06-01 00:12:58.006483
NCT01042964|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2012-10-18|2010-01-05|2010-01-06|Estimate|||||||2012-10-18|2012-10-19|Estimate|March 2006||2006-03-31|October 2012|2012-10-31|October 2007|Actual|2007-10-31|January 2007|Actual|2007-01-31||Interventional|PR-15/01||Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion|An Open-Label, Dose-Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of PR-15, an Inhibitor of Platelet Adhesion, in Six Different Strengths in Healthy Male Volunteers|Completed||Phase 1|30|Actual|AdvanceCor GmbH|||||f||||t||||||||||2018-06-01 00:12:59.016534|2018-06-01 00:12:59.016534
NCT01042951|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2014-10-29|2010-01-05|2010-01-06|Estimate|||||||2014-10-29|2014-10-30|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh|Randomized, Double-blind, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of Orally Administered, Killed, Bivalent Whole-cell, Cholera Vaccine, ShanChol in Bangladeshi Adults and Children|Completed||Phase 2|330|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 00:12:59.091636|2018-06-01 00:12:59.091636
NCT01042938|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2012-01-26||2012-06-19|2010-01-05|2010-01-06|Estimate|2012-05-17|2012-06-20|Estimate||||2012-06-19|2012-06-25|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients|Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients|Completed||Phase 2|35|Actual|University of Rochester|The primary limitation of this clinical study is the small sample size. This study was a pilot trial to generate an effect and sample size for a larger confirmatory trial. We accrued patients to this study until we had 30 fully evaluable patients.|2|||f||||t||||||||||2018-06-01 00:12:59.212018|2018-06-01 00:12:59.212018
NCT01042925|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04||2016-05-09|2016-05-09|2010-01-05|2010-01-06|Estimate||||2016-05-09|2016-06-03|Estimate|2016-05-09|2016-06-03|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen|A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen|Completed||Phase 1/Phase 2|42|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:12:59.571069|2018-06-01 00:12:59.571069
NCT01042912|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2014-09-18|2010-01-04|2010-01-06|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|||Frequency Analysis of Carotid Artery Disease|A Single-centered Investigation Into the Frequency Domain Patterns in the Carotid Vessel in Patients With Suspected Stenosis|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute||||PI left inistitution|f||||t||||||||||2018-06-01 00:12:59.653391|2018-06-01 00:12:59.653391
NCT01042899|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2016-03-07|2010-01-05|2010-01-06|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|RRTC--TOPS||Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions--Teen Online Problem Solving Study|Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions|Completed||N/A|153|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-06-01 00:12:59.70299|2018-06-01 00:12:59.70299
NCT01042886|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-04|2010-01-04|2010-01-06|Estimate|||||||2010-01-04|2010-01-06|Estimate|February 2007||2007-02-28|January 2010|2010-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PILI||PILI 'Ohana Project: Partnerships to Overcome Obesity Disparities in Hawaii (3-Year Pilot)|Partnerships to Overcome Obesity Disparities in Hawaii|Completed||N/A|277|Actual|University of Hawaii||2|||f||||t||||||||||2018-06-01 00:12:59.881334|2018-06-01 00:12:59.881334
NCT01042873|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-07-03|2010-01-05|2010-01-06|Estimate|||||||2011-07-03|2011-07-06|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|December 2019|Anticipated|2019-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Hemodynamic Response to Prolonged Dobutamine Infusion||Recruiting||Phase 4|100|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-06-01 00:12:59.94299|2018-06-01 00:12:59.94299
NCT01042860|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2010-01-07|2010-01-05|2010-01-06|Estimate|||||||2010-01-07|2010-01-08|Estimate|August 2007||2007-08-31|January 2010|2010-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Influence of Lutein Supplements on Age-related Macular Degeneration|The Influence of Lutein Supplements on Age-related Macular Degeneration|Completed||N/A|80|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-06-01 00:13:00.00731|2018-06-01 00:13:00.00731
NCT01042847|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2016-12-30|2010-01-05|2010-01-06|Estimate|||||||2016-12-30|2017-01-02|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||How Our Immune System Can Help Fight Cancer|The Effect of Genetic Polymorphisms in Indoleamine 2, 3-Dioxygenase in Epithelial Ovarian Cancer|Completed|||169|Actual|Winthrop University Hospital|||||f||||f||||||Samples With DNA|"~     surgical tissue ascites fluid~   "|||2018-06-01 00:13:00.107716|2018-06-01 00:13:00.107716
NCT01042834|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-01-12|2010-01-05|2010-01-06|Estimate|||||||2011-01-12|2011-01-13|Estimate|February 2008||2008-02-29|January 2011|2011-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|POLLAIR||Impact of Air Pollution on the Autonomic Nervous System Activity and the Presence of Sleep Apnea in Older Subjects|Impact of Air Pollution on the Autonomic Nervous System Activity and the Presence of Sleep Apnea in Older Subjects: Longitudinal Multicentric Study|Completed|||60|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-06-01 00:13:00.236374|2018-06-01 00:13:00.236374
NCT01042808|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2015-07-20|2010-01-05|2010-01-06|Estimate|||||||2015-07-20|2015-07-21|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Isentress Re-examination Study (MK-0518-115)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy of ISENTRESS in Usual Practice|Completed|||996|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:13:00.401501|2018-06-01 00:13:00.401501
NCT01042795|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|2017-04-11||2017-05-26|2010-01-05|2010-01-06|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|September 2009||2009-09-30|May 2017|2017-05-31|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy|Phase II Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy|Terminated||Phase 2|7|Actual|University of Michigan||1||Study closed due to poor accrual|f||||t|t|f||||||No||2018-06-01 00:13:00.470564|2018-06-01 00:13:00.470564
NCT01042782|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2012-08-02|2010-01-05|2010-01-06|Estimate|||||||2012-08-02|2012-08-03|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|S387||Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction|Phase I Study of Daily RAD001 Administered Orally in Combination With Mitomycin C, Administered Every Three Weeks to Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction|Completed||Phase 1|16|Actual|Krankenhaus Nordwest||1|||f||||t||||||||||2018-06-01 00:13:00.659149|2018-06-01 00:13:00.659149
NCT01042769|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05||2016-07-20|2016-11-01|2010-01-05|2010-01-06|Estimate||||2016-07-20|2016-07-22|Estimate|2016-11-01|2016-11-02|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus|A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)|Completed||Phase 3|7226|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:13:00.846719|2018-06-01 00:13:00.846719
NCT01042743|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-12-18|2010-01-05|2010-01-06|Estimate|||||||2011-12-18|2011-12-20|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Laparoscopic Surgery Versus Robot Surgery for Right-side Colon Cancer: Short-term Outcome of a Randomised Clinical Trial||Completed||Phase 2|80|Actual|Kyungpook National University||2|||f||||t||||||||||2018-06-01 00:13:02.111551|2018-06-01 00:13:02.111551
NCT01042730|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-10-17|2010-01-05|2010-01-06|Estimate|||||||2011-10-17|2011-10-18|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)|Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)|Unknown status|Recruiting|N/A|12600|Anticipated|Juntendo University Hospital||2|||f||||t||||||||||2018-06-01 00:13:02.174016|2018-06-01 00:13:02.174016
NCT01042717|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-05|||2011-09-26|2010-01-05|2010-01-06|Estimate|||||||2011-09-26|2011-09-27|Estimate|February 2010||2010-02-28|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection|Mobilization Kinetics of Plerixafor and G-CSF in Patients With NHL and MM Undergoing Autologous Peripheral Blood Progenitor Cell Collection|Unknown status|Recruiting|N/A|10|Anticipated|Shi, Patricia, M.D.||1|||f||||f||||||||||2018-06-01 00:13:02.287521|2018-06-01 00:13:02.287521
NCT01042704|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2017-07-26|2010-01-04|2010-01-05|Estimate|||||||2017-07-26|2017-07-31|Actual|February 2008||2008-02-29|July 2017|2017-07-31|March 2015|Actual|2015-03-31|January 2011|Actual|2011-01-31||Interventional|||Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma|Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma|Completed||Phase 1|29|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 00:13:02.380394|2018-06-01 00:13:02.380394
NCT01042691|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2017-12-19|2010-01-04|2010-01-05|Estimate|||||||2017-12-19|2017-12-20|Actual|May 2003||2003-05-31|December 2017|2017-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Isolated Liver Perfusion With Oxaliplatin|A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases|Completed||Phase 1|10|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 00:13:02.51692|2018-06-01 00:13:02.51692
NCT01042678|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-01|2014-04-14||2014-04-14|2010-01-04|2010-01-05|Estimate|2014-04-14|2014-05-13|Estimate||||2014-04-14|2014-05-13|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema|A Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (DME)|Terminated||Phase 1|18|Actual|Allergan||6||The study was terminated due to a company decision.|f||||t||||||||||2018-06-01 00:13:02.714309|2018-06-01 00:13:02.714309
NCT01042665|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2014-03-27|2010-01-04|2010-01-05|Estimate|||||||2014-03-27|2014-03-28|Estimate|February 2006||2006-02-28|March 2014|2014-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo|Relationship Between Intraocular Pressure Fluctuation and Retinal Ganglion Cell Function in Eyes Receiving Latanoprost 0.005% Versus Placebo|Completed|||82|Actual|University of Miami|||2||f||||t||||||||||2018-06-01 00:13:03.302415|2018-06-01 00:13:03.302415
NCT01042652|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2011-06-14|2010-01-04|2010-01-05|Estimate|||||||2011-06-14|2011-06-15|Estimate|February 2011||2011-02-28|June 2011|2011-06-30|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|||A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance|A Pilot Study With Randomized Controlled Open-label Design to Compare Drug-drug Interaction, Antiretroviral Efficacy and Tolerability of Raltegravir Versus Nevirapine as Anchor Drug in Combination Therapy for Treatment-naive HIV+ Chinese Injection Drug Users on Methadone Maintenance|Unknown status|Recruiting|N/A|60|Anticipated|Centers for Disease Control and Prevention, China||2|||f||||f||||||||||2018-06-01 00:13:03.390583|2018-06-01 00:13:03.390583
NCT01042639|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2012-03-15|2010-01-04|2010-01-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||The Effect of Physical Activity on Bone Mineralization and Immune System in Very Low Birth Weight Infants|The Effect of Physical Activity on Bone Strength and Immune System in Very Low Birth Weight Infants: is More Really Better??|Unknown status|Recruiting|N/A|45|Anticipated|Meir Medical Center||3|||f||||t||||||||||2018-06-01 00:13:03.469924|2018-06-01 00:13:03.469924
NCT01042626|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate|July 2004||2004-07-31|January 2010|2010-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects|Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects|Completed||N/A|60|Actual|University of Eastern Piedmont||3|||f||||||||||||||2018-06-01 00:13:03.555839|2018-06-01 00:13:03.555839
NCT01042613|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2011-09-09||2011-11-02|2010-01-04|2010-01-05|Estimate|2011-11-02|2011-12-07|Estimate||||2011-11-02|2011-12-07|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Comparison of the Success Rate Of Cannulation Between The Accuvein Apparatus And Standard Technique|A Comparison of the Success Rate Of Cannulation Between The Accuvein Apparatus And Standard Technique|Completed||N/A|146|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 00:13:03.627262|2018-06-01 00:13:03.627262
NCT01042600|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2014-06-16||2018-01-25|2010-01-04|2010-01-05|Estimate|2014-06-16|2014-07-16|Estimate||||2018-01-25|2018-02-22|Actual|December 2009||2009-12-31|January 2018|2018-01-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional||Single ineligible patient excluded in the endotracheal intubation group|Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation|Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation|Completed||Phase 4|61|Actual|Albany Medical College||2|||f||||t||||||||||2018-06-01 00:13:03.85855|2018-06-01 00:13:03.85855
NCT01042587|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-08-10|2010-01-04|2010-01-05|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|BrightLights||Effect of Bright Light Treatment On Elders In a Long Term Care Environment|Effect of Bright Light Treatment On Elders In A Long Term Care Environment|Completed||N/A|32|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 00:13:04.204688|2018-06-01 00:13:04.204688
NCT01042574|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2018-03-20|2010-01-04|2010-01-05|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2010||2010-05-31|March 2018|2018-03-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy|The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Investigator Initiated Trial|Withdrawn||Phase 4|0|Actual|Methodist Healthcare|||||f||||f||||||||||2018-06-01 00:13:04.276562|2018-06-01 00:13:04.276562
NCT01042561|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2011-11-07|2010-01-04|2010-01-05|Estimate|||||||2011-11-07|2011-11-09|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Vitamin D Status and Dose Response in Infants|Vitamin D Status and Dose Response in Infants|Completed||Early Phase 1|64|Anticipated|University of Nebraska||2|||f||||f||||||||||2018-06-01 00:13:04.345614|2018-06-01 00:13:04.345614
NCT01042548|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2018-04-09|2010-01-04|2010-01-05|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2009||2009-09-30|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Observational|||Proteomics Research of Breast Cancer Markers in Interstitial Fluid and Serum|Proteomics Research of Breast Cancer Markers in Interstitial Fluid and Serum|Recruiting|||300|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Subjects will be asked to allow us to collect an extra 2 tablespoons of blood at the time of~     pre-operative blood work. For those subjects with cancer who undergo surgery, a follow-up~     blood sample will be collected prior to chemotherapy, radiation, or hormonal therapy, and~     every six months afterwards at the time of their standard clinic/office visit for two years,~     then once a year for year 3-5. This will allow researchers to examine the samples to~     determine if blood changes over time after surgery, and what type of result may indicate a~     risk for recurrence.~      Any remaining blood samples not used for the study will remain in the laboratory for future~     research.~   "|||2018-06-01 00:13:04.427021|2018-06-01 00:13:04.427021
NCT01042535|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2015-02-19||2018-03-14|2010-01-04|2010-01-05|Estimate|2015-02-19|2015-03-05|Estimate||||2018-03-14|2018-04-11|Actual|December 28, 2009|Actual|2009-12-28|March 2018|2018-03-31|February 27, 2018|Actual|2018-02-27|December 1, 2014|Actual|2014-12-01||Interventional||All participants|Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer|A Phase 1/2 Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer|Completed||Phase 1/Phase 2|44|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 00:13:04.500946|2018-06-01 00:13:04.500946
NCT01042522|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-01|||2018-02-14|2010-01-01|2010-01-05|Estimate|||||||2018-02-14|2018-02-16|Estimate|February 8, 2010|Actual|2010-02-08|February 2018|2018-02-28||||January 2, 2024|Anticipated|2024-01-02||Interventional|||Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors|A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary|Recruiting||Phase 2|128|Anticipated|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 00:13:04.826414|2018-06-01 00:13:04.826414
NCT01042509|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2012-02-16||2016-12-07|2010-01-04|2010-01-05|Estimate|2016-12-07|2017-02-01|Estimate||||2016-12-07|2017-02-01|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|LowAR||Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease|Combination of Alemtuzumab (Anti-CD52) and Rituximab (Anti-CD20) at Low-doses in Chronic Graft Versus Host Disease Treatment After First-line Therapy Failure.|Completed||N/A|15|Actual|Hospital Universitario Dr. Jose E. Gonzalez|A limitation of this trial is the small number of subjects included|1|||f||||t||||||||No||2018-06-01 00:13:06.264696|2018-06-01 00:13:06.264696
NCT01042496|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2015-09-24||2016-01-12|2010-01-04|2010-01-05|Estimate|2015-12-08|2016-01-12|Estimate||||2016-01-12|2016-02-08|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|1HMRS-BP|Only participants who took part in the study were included in the baseline analysis population.|Bipolar Depression Before and After Lamotrigine Treatment|1H-MR Spectroscopy of Bipolar Depression Before and After Lamotrigine Treatment|Completed||Phase 3|72|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:13:06.573424|2018-06-01 00:13:06.573424
NCT01042483|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-03|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based+Continuous Vacuum Mode|Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based, Multiple Parameters+Continuous Vacuum Mode|Unknown status|Not yet recruiting|N/A|450|Anticipated|Trig Medical Inc|||||f||||f||||||||||2018-06-01 00:13:06.995982|2018-06-01 00:13:06.995982
NCT01042470|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2018-05-11|2010-01-04|2010-01-05|Estimate|||||||2018-05-11|2018-05-14|Actual|January 2010||2010-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2015|Actual|2015-06-30||Observational|||Pelvic Floor Study: Biomechanical Properties of the Female Pelvic Floor|Pelvic Floor Study: Biomechanical Properties of the Female Pelvic Floor - Evaluation of Clinical, Mechanical, Sonographic and Histological Parameters|Active, not recruiting|||40|Anticipated|University of Zurich|||2||f||||f||||||Samples With DNA|"~     tissue (vaginal wall, urogenital diaphragm), whole blood~   "|||2018-06-01 00:13:07.086197|2018-06-01 00:13:07.086197
NCT01042457|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2013-09-27|2010-01-04|2010-01-05|Estimate|||||||2013-09-27|2013-09-30|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis||Completed||Phase 3|24|Actual|Chulalongkorn University||1|||f||||f||||||||||2018-06-01 00:13:07.174594|2018-06-01 00:13:07.174594
NCT01042444|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2018-01-01|2010-01-04|2010-01-05|Estimate|||||||2018-01-01|2018-01-03|Actual|December 2009||2009-12-31|January 2018|2018-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft|Phase I Study to Demonstrate the Safety and Performance of the GARDEX™ Embolic Protection Device When Used During Percutaneous Coronary Intervention (PCI) of Saphenous Vein Graft|Terminated||N/A|6|Actual|Gardia Medical||1|||f||||t||||||||||2018-06-01 00:13:07.270628|2018-06-01 00:13:07.270628
NCT01042431|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2010|Anticipated|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Nutrition Day in Hospitals, Nursing Homes and Community. Israel January 2010||Unknown status|Not yet recruiting||30|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-06-01 00:13:07.341294|2018-06-01 00:13:07.341294
NCT01042418|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Appetite Profile After Intake of Rye Breakfast Meal|Appetite Profile After Intake of Rye Breakfast Meal|Completed||N/A|50|Actual|Swedish University of Agricultural Sciences||3|||f||||f||||||||||2018-06-01 00:13:07.409602|2018-06-01 00:13:07.409602
NCT01042405|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-01|||2010-03-03|2010-01-04|2010-01-05|Estimate|||||||2010-03-03|2010-03-04|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|HD- dialysis||Development of New Computerized Predictive Method for Morbidity and Mortality Risk in Hemodialysis (HD) Patients Based on Nutritional Evaluation and Scoring|Development of a Risk Computerized Predictive Method in HD Patients by Nutritional Scoring|Unknown status|Enrolling by invitation||130|Anticipated|Wolfson Medical Center|||||f||||f||||||||||2018-06-01 00:13:07.483758|2018-06-01 00:13:07.483758
NCT01042392|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-01|2012-01-12||2012-03-06|2010-01-04|2010-01-05|Estimate|2012-03-06|2012-04-03|Estimate||||2012-03-06|2012-04-03|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|ALIAS||Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients|Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients|Completed||Phase 4|506|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:13:07.570773|2018-06-01 00:13:07.570773
NCT01042379|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2018-01-23|2010-01-04|2010-01-05|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2010||2010-03-31|January 2018|2018-01-31||||December 2020|Anticipated|2020-12-31||Interventional|I-SPY 2||I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer|I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)|Recruiting||Phase 2|1920|Anticipated|QuantumLeap Healthcare Collaborative||15|||f||||t||||||||||2018-06-01 00:13:08.375262|2018-06-01 00:13:08.375262
NCT01042366|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2016-01-13||2017-07-16|2010-01-04|2010-01-05|Estimate|2017-07-16|2017-08-16|Actual||||2017-07-16|2017-08-16|Actual|October 2002||2002-10-31|July 2017|2017-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Dendritic Cells (DC) Vaccine for Metastatic Melanoma|Randomized Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Metastatic Melanoma Using Autologous Mature Dendritic Cells|Terminated||Phase 2|16|Actual|University of Pittsburgh||3||Closed to accrual in March 2009 for slow accrual.|f||||t||||||||||2018-06-01 00:13:08.597613|2018-06-01 00:13:08.597613
NCT01042353|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate||||January 2010|2010-01-31||||||||Interventional|||Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia|Rapid Bacterial Antibiograms Determined by Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia: a Prospective Comparison With Standard Culture Methods|Completed||Phase 4|20|Anticipated|Université Victor Segalen Bordeaux 2||2|||f||||f||||||||||2018-06-01 00:13:08.82355|2018-06-01 00:13:08.82355
NCT01042340|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2015-03-31|2010-01-04|2010-01-05|Estimate|||||||2015-03-31|2015-04-01|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Energy Dense Oleic Acid Formula to Geriatric Patients|Energy Dense Oleic Acid Rich Formula to Newly Admitted Geriatric Patients - Feasibility and Effects on Energy Intake|Completed||N/A|71|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-06-01 00:13:08.882676|2018-06-01 00:13:08.882676
NCT01042327|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2015-09-14|2010-01-04|2010-01-05|Estimate|||||||2015-09-14|2015-09-15|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study to Assess Clearances and Bio-compatibility of ELISIO Dialyzer|Study to Assess Clearances and Bio-compatibility of ELISIO Dialyzer|Completed||Phase 4|15|Actual|Royal Free Hampstead NHS Trust||1|||f||||f||||||||||2018-06-01 00:13:08.9475|2018-06-01 00:13:08.9475
NCT01042314|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2011-01-24|2010-01-04|2010-01-05|Estimate|||||||2011-01-24|2011-01-25|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Drug-Drug Interaction Study With Aricept® (Donepezil)|A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects|Completed||Phase 1|18|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:13:09.032083|2018-06-01 00:13:09.032083
NCT01042301|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2015-09-07|2010-01-04|2010-01-05|Estimate|||||||2015-09-07|2015-09-09|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Lymphoscreen||Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes|Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes|Completed||N/A|120|Actual|Nantes University Hospital||6|||f||||t||||||||||2018-06-01 00:13:09.121353|2018-06-01 00:13:09.121353
NCT01042288|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|2016-03-16||2016-04-14|2010-01-04|2010-01-05|Estimate|2016-03-16|2016-04-15|Estimate||||2016-04-14|2016-05-11|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC|A Phase II Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type Non-Small-Cell Lung Cancer|Completed||Phase 2|70|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 00:13:09.288323|2018-06-01 00:13:09.288323
NCT01042275|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-04-06|2010-01-04|2010-01-05|Estimate|||||||2010-04-06|2010-04-07|Estimate|March 2009||2009-03-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Patient-reported Outcome After Sling Insertion Using the Incontinence Outcome Questionnaire (IOQ)|Patient-reported Mid- and Long-term Outcome After Insertion of Retropubic and Transobturator Tapes Using the Incontinence Outcome Questionnaire (IOQ)|Completed|||628|Actual|University of Zurich|||5||f||||f||||||||||2018-06-01 00:13:09.655235|2018-06-01 00:13:09.655235
NCT01042262|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate|February 2007||2007-02-28|December 2009|2009-12-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Maternal Oxygen Use During Delivery and Cord Blood Superoxide Dismutase|Maternal Oxygen Use During Delivery and Cord Blood Superoxide Dismutase: A Randomized Controlled Trial|Completed||N/A|60|Actual|George Washington University||2|||f||||f||||||||||2018-06-01 00:13:09.718517|2018-06-01 00:13:09.718517
NCT01042249|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2015-03-09|2010-01-04|2010-01-05|Estimate|||||||2015-03-09|2015-03-11|Estimate|February 2010||2010-02-28|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Pelvic Floor Muscle Training(PFMT) on Lower Urinary Tract Symptoms (LUTS) in Men With Stroke|The Effect of Pelvic Floor Muscle Training on Lower Urinary Tract Symptoms (LUTS) in Men With Stroke|Unknown status|Active, not recruiting|N/A|120|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-06-01 00:13:09.801343|2018-06-01 00:13:09.801343
NCT01042236|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2011-06-08||2011-07-20|2010-01-04|2010-01-05|Estimate|2011-06-08|2011-07-01|Estimate||||2011-07-20|2011-07-22|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients|A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Crossover Study Of The Efficacy Of Fesoterodine In Increasing Urethral Pressure In Stress Urinary Incontinence Patients.|Completed||Phase 2|22|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:13:09.894155|2018-06-01 00:13:09.894155
NCT01042223|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-07-16|2010-01-04|2010-01-05|Estimate|||||||2010-07-16|2010-07-19|Estimate|January 2006||2006-01-31|December 2008|2008-12-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Observational|||Laryngomalacia Exposed|Laryngomalacia Exposed|Completed|||1500|Actual|Boushahri Clinic Medical Center|||||f||||t||||||||||2018-06-01 00:13:10.449021|2018-06-01 00:13:10.449021
NCT01042210|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate|January 2005||2005-01-31|November 2009|2009-11-30|December 2006|Actual|2006-12-31|March 2006|Actual|2006-03-31||Observational|||Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring|Genotype-phenotype Associations of Agouti-related Peptide (AgRP) in Postpartum Period in Preeclamptic and Non-preeclamptic Women and Their Offspring|Completed|||84|Actual|Masaryk University|||4||f||||f||||||Samples With DNA|"~     whole blood, umbilical blood~   "|||2018-06-01 00:13:10.504207|2018-06-01 00:13:10.504207
NCT01042197|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-11|2010-01-04|2010-01-05|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||The Relation Between Vitamin D Production and UVB Exposed Body Surface Area|Interdependence Between Body Surface Area and UVB Dose in Vitamin D Production: A Randomized Controlled Trial|Completed||N/A|92|Actual|Bispebjerg Hospital||9|||f||||t||||||||||2018-06-01 00:13:10.572558|2018-06-01 00:13:10.572558
NCT01042184|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-03|||2012-11-15|2010-01-04|2010-01-05|Estimate|||||||2012-11-15|2012-11-16|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori|Phase IV Study Comparing the Duration of Sequential Therapy|Completed||Phase 4|900|Actual|National Taiwan University Hospital||3|||f||||t||||||||||2018-06-01 00:13:10.66001|2018-06-01 00:13:10.66001
NCT01042171|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2012-07-17|2010-01-04|2010-01-05|Estimate|||||||2012-07-17|2012-07-18|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Evaluation of Image Quality Over Time After Injection of the ﬂuorescein Sodium for Confocal Laser Endomicroscopy|Evaluation of Image Quality Over Time After Injection of the ﬂuorescein Sodium for Confocal Laser Endomicroscopy|Completed|||20|Actual|Shandong University|||||f||||t||||||||||2018-06-01 00:13:10.736384|2018-06-01 00:13:10.736384
NCT01042158|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2017-07-13||2017-08-11|2010-01-04|2010-01-05|Estimate|2017-08-11|2017-09-12|Actual||||2017-08-11|2017-09-12|Actual|January 2010||2010-01-31|August 2017|2017-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ATPAHSS||A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis|A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis|Completed||Phase 4|25|Actual|Johns Hopkins University|"An open-label study with no placebo group~Relatively small number of patients and therefore vulnerable to confounding natural history with treatment effects~Measurements performed at four different institutions~Few missing data"|1|||f||||t||||||||||2018-06-01 00:13:10.797619|2018-06-01 00:13:10.797619
NCT01042145|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2012-12-24||2014-09-11|2010-01-04|2010-01-05|Estimate|2014-09-11|2014-09-15|Estimate||||2014-09-11|2014-09-15|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Community Care for Croup (RCT)|Community Care for Croup (RCT)|Completed||Phase 4|87|Actual|Washington University School of Medicine|Our failure to demonstrate any difference bewteen the two study groups may be due to the small sample size. We were unable to recruit the targeted sample size of 200.|2|||f||||t||||||||||2018-06-01 00:13:10.968915|2018-06-01 00:13:10.968915
NCT01042132|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2016-11-30|2010-01-04|2010-01-05|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2003||2003-05-31|April 2002|2002-04-30|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||Intramedullary Femoral Reaming, Human Study|Pathophysiological Effects of- and Inflammatory Response to Intramedullary Femoral Nailing in Patients With Femoral Shaft Fracture|Completed||N/A|17|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 00:13:11.328281|2018-06-01 00:13:11.328281
NCT01042119|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-06-23|2010-01-04|2010-01-05|Estimate|||||||2010-06-23|2010-06-24|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females|Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study|Completed|||200|Anticipated|University of Zurich|||1||f||||f||||||||||2018-06-01 00:13:11.415508|2018-06-01 00:13:11.415508
NCT01042106|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2013-09-12|2010-01-03|2010-01-05|Estimate|||||||2013-09-12|2013-09-16|Estimate|November 2009||2009-11-30|September 2013|2013-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Oral Dose Study to Evaulate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Type 2 Diabetic and Healthy Subjects|Completed||Phase 1|40|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 00:13:11.477649|2018-06-01 00:13:11.477649
NCT01042093|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|2013-06-20||2013-09-05|2010-01-04|2010-01-05|Estimate|2013-09-05|2013-11-08|Estimate||||2013-09-05|2013-11-08|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy of Multimodal Perioperative Analgesia With Periarticular Drug Injection in Total Knee Arthroplasty(TKA)|Efficacy of Multimodal Perioperative Analgesia Protocol With Periarticular Drug Injection in Total Knee Arthroplasty: A Randomized, Double Blind Study|Completed||N/A|160|Actual|Towson Orthopaedic Associates||4|||f||||f||||||||||2018-06-01 00:13:11.554254|2018-06-01 00:13:11.554254
NCT01042080|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2018-05-01|2010-01-04|2010-01-05|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2009||2009-12-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|April 2011|Actual|2011-04-30||Interventional|NAVASYNC||Neurally Adjusted Ventilatory Assist and Synchrony in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Mechanical Ventilation With NAVA and PSV on Inspiratory Muscle Workload and Synchrony in Patients With Chronic Obstructive Pulmonary Disease|Active, not recruiting||N/A|15|Anticipated|Hôpital Européen Marseille||3|||f||||f||||||||||2018-06-01 00:13:11.993553|2018-06-01 00:13:11.993553
NCT01042067|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2011-04-26|2010-01-04|2010-01-05|Estimate|||||||2011-04-26|2011-04-27|Estimate|January 2010||2010-01-31|April 2011|2011-04-30||||||||Observational|CYKOWAR||Safer Warfarin Treatment|Safer Warfarin Treatment - the Influence of CYP2C9 Genotyping, Genotyping of Vitamine K Dependent Proteins and Dietary Vitamine K Status on Dosing, Clinical Effect and Adverse Events With Emphasis on the Initial Phase of Treatment|Suspended|||200|Anticipated|Oslo University Hospital|||1|Enrolling participants has halted due to lack of investigator.|f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-06-01 00:13:12.077442|2018-06-01 00:13:12.077442
NCT01042054|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2015-03-12|2010-01-04|2010-01-05|Estimate|||||||2015-03-12|2015-03-13|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|LIVER||Comparison of Analgesic Methods, and Their Effects on Patient Recovery, Following Liver Surgery|The Effects of Local Infiltration Versus Epidural on Recovery|Completed||N/A|65|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:13:12.151003|2018-06-01 00:13:12.151003
NCT01042041|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2013-02-25|2010-01-04|2010-01-05|Estimate|||||||2013-02-25|2013-02-26|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer|A Phase 1 Study of Sorafenib Integrated With Chemoembolization for Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 1|18|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:13:12.224749|2018-06-01 00:13:12.224749
NCT01042028|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2015-10-18|2010-01-04|2010-01-05|Estimate|||||||2015-10-18|2015-10-20|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|November 2012|Actual|2012-11-30||Interventional|||A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer|A Randomised Fase I/II Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer|Terminated||Phase 1/Phase 2|39|Actual|Odense University Hospital||2||Emergence of FOLFIRINOX and slow recruitment|f||||t||||||||||2018-06-01 00:13:12.340222|2018-06-01 00:13:12.340222
NCT01042015|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2018-05-15|2010-01-04|2010-01-05|Estimate|||||||2018-05-15|2018-05-18|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|EPR-CAT||Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest From Trauma|Emergency Preservation and Resuscitation for Cardiac Arrest From Trauma|Recruiting||Phase 2|20|Anticipated|University of Maryland||2|||f||||t|t|t|f|f||||No||2018-06-01 00:13:12.427233|2018-06-01 00:13:12.427233
NCT01042002|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2017-02-21|2010-01-04|2010-01-05|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2006|Actual|2006-08-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Exercise Before Gastric Bypass|Effect of Exercise Before Gastric bypass-a Pilot Study|Completed||N/A|43|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-06-01 00:13:12.51157|2018-06-01 00:13:12.51157
NCT01041989|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2016-10-07|2010-01-04|2010-01-05|Estimate|||||||2016-10-07|2016-10-10|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Interventional|FINGER||Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability|Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability|Active, not recruiting||N/A|1200|Anticipated|National Institute for Health and Welfare, Finland||2|||f||||t||||||||||2018-06-01 00:13:12.570111|2018-06-01 00:13:12.570111
NCT01041976|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|2015-08-24||2016-02-08|2009-12-31|2010-01-05|Estimate|2015-09-28|2015-09-29|Estimate||||2016-02-08|2016-03-08|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|May 2014|Actual|2014-05-31||Interventional|||Supported Employment: Motivational Enhancement for Entry and Outcome|Supported Employment: Motivational Enhancement for Entry and Outcome|Completed||Phase 2|168|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:13:12.68226|2018-06-01 00:13:12.68226
NCT01041963|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-05-09|2010-01-04|2010-01-05|Estimate|||||||2010-05-09|2010-05-12|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients|The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients|Unknown status|Recruiting|Phase 4|90|Anticipated|Chulalongkorn University||3|||f||||t||||||||||2018-06-01 00:13:13.035846|2018-06-01 00:13:13.035846
NCT01041950|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2016-10-25|2010-01-04|2010-01-05|Estimate|||||||2016-10-25|2016-10-27|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|LUCAS-IVH||A Randomised Controlled Trial of Lumbar Drainage to Treat Communicating Hydrocephalus After Severe Intraventricular Hemorrhage|Lumbar Drainage for Communicating Hydrocephalus After Intraventricular Hemorrhage: a Randomised, Controlled Trial(LUCAS-IVH: LUmbar CAtheter for Severe IntraVentricular Hemorrhage)|Completed||Phase 2/Phase 3|30|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-06-01 00:13:13.284653|2018-06-01 00:13:13.284653
NCT01041937|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-05|2010-01-04|2010-01-05|Estimate|||||||2010-01-05|2010-01-06|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|TKA||Total Knee Arthroplasty (TKA) Cemented Versus Cementless Tibial Prosthesis Study|Total Knee Arthroplasty Randomized Clinical Trial- Cemented vs. Cementless Tibial Prosthesis Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|250|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:13:13.400587|2018-06-01 00:13:13.400587
NCT01041248|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-07-09|2009-12-30|2009-12-31|Estimate|||||||2012-07-09|2012-07-10|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab|Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis|Completed||N/A|1|Actual|Children's Hospital of Eastern Ontario||1|||f||||f||||||||||2018-06-01 00:13:26.812278|2018-06-01 00:13:26.812278
NCT01041924|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-04|||2010-01-04|2010-01-04|2010-01-05|Estimate|||||||2010-01-04|2010-01-05|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Dynamic Carbon Dioxide (CO2) Administration for Sleep Apnoea|Dynamic Carbon Dioxide Administration for Central Sleep Apnoea in Heart Failure|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|Imperial College London|||||f||||t||||||||||2018-06-01 00:13:13.463864|2018-06-01 00:13:13.463864
NCT01041911|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2012-12-04|2009-12-31|2010-01-01|Estimate|||||||2012-12-04|2012-12-06|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids|Double-blind, Randomized, Placebo-controlled, Dose Response Study to Evaluate the Safety and Efficacy of Three Doses of Euphorbia Prostrata Dry Extract Tablets in Patients of Hemorrhoids|Completed||Phase 2|102|Actual|Panacea Biotec Ltd||4|||f||||f||||||||||2018-06-01 00:13:13.524127|2018-06-01 00:13:13.524127
NCT01041898|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-02-24|2009-12-31|2010-01-01|Estimate|||||||2012-02-24|2012-02-27|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||The Bone-Fat-Pancreas Axis in Children|The Bone-Fat-Pancreas Axis in Children: Establishing a Role for Undercarboxylated Osteocalcin in Energy Homeostasis|Completed|||28|Actual|University of Alabama at Birmingham|||||f||||t||||||Samples With DNA|"~     Samples will be labeled with the study protocol number, a unique identifier, and the date of~     collection.~      Specimens will be obtained by the nursing staff at the PCIR. The PCIR processing lab will~     process the samples, which will then be stored in a locked freezer at -80oC in the restricted~     access CNRU Metabolism Core lab (WEBB 337).~   "|||2018-06-01 00:13:13.627407|2018-06-01 00:13:13.627407
NCT01041885|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2015-02-02|2009-12-31|2010-01-01|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|September 2012|Actual|2012-09-30||Interventional|||INSTRUCT for Repair of Knee Cartilage Defects|Prospective Feasibility, Non-randomized, Single Arm Multicentre, Multinational Interventional Clinical Investigation Using INSTRUCT Therapy for the Repair of Knee Cartilage Defects|Completed||N/A|40|Actual|CellCoTec B.V.||1|||f||||f||||||||||2018-06-01 00:13:13.709745|2018-06-01 00:13:13.709745
NCT01041872|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2016-09-23|2009-12-31|2010-01-01|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2009||2009-12-31|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Propofols||Comparison of Different Propofol Formulations|Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Lidocaine|Completed||Phase 4|212|Actual|Hopital Foch||6|||f||||f||||||||||2018-06-01 00:13:13.77517|2018-06-01 00:13:13.77517
NCT01041859|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|2012-03-08||2013-08-29|2009-12-30|2010-01-01|Estimate|2012-04-13|2012-05-14|Estimate||||2013-08-29|2013-09-11|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy|A Randomized-Withdrawal, Placebo-Controlled, Study Evaluating the Efficacy, Safety, and Tolerability of Tapentadol Extended-Release (ER) in Subjects With Chronic, Painful Diabetic Peripheral Neuropathy (DPN)|Completed||Phase 3|460|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 00:13:13.881192|2018-06-01 00:13:13.881192
NCT01041846|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-07-26|2009-12-30|2010-01-01|Estimate|||||||2013-07-26|2013-07-29|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome|A Prospective Multicenter Observational Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome|Completed|||103|Actual|Janssen Korea, Ltd., Korea|||1||f||||t||||||||||2018-06-01 00:13:14.642599|2018-06-01 00:13:14.642599
NCT01041833|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2009-12-31|2009-12-31|2010-01-01|Estimate|||||||2009-12-31|2010-01-01|Estimate|January 2010||2010-01-31|September 2009|2009-09-30|September 2013|Anticipated|2013-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker|Randomized Phase III Trial: Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarkers|Unknown status|Not yet recruiting|Phase 3|230|Anticipated|National Institute of Cancerología||2|||f||||t||||||||||2018-06-01 00:13:14.738289|2018-06-01 00:13:14.738289
NCT01041820|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-04-18|2009-12-31|2010-01-01|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Critical Periods of Exercise|Critical Periods of Exercise|Completed||N/A|20|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 00:13:14.862607|2018-06-01 00:13:14.862607
NCT01041807|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2015-04-09|2009-12-31|2010-01-01|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Cozaar XQ Re-examination Study (MK-0954-349)|Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of COZAAR XQ in Usual Practice|Completed|||669|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:13:14.927312|2018-06-01 00:13:14.927312
NCT01041794|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-04-18|2009-12-31|2010-01-01|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Tissue Partitioning in Early Childhood|Tissue Partitioning in Early Childhood: A Critical Period for Obesity Risk?|Completed|||24|Actual|University of Alabama at Birmingham|||1||f||||t||||||Samples With DNA|"~     Samples will be labeled with the study protocol number, a unique identifier, and the date of~     collection.~      Blood specimens will be obtained by the nursing staff at the PCIR. The PCIR processing lab~     will process the samples, which will then be stored in a locked freezer at -80oC in the~     restricted access CNRU Metabolism Core lab (WEBB 337).~   "|||2018-06-01 00:13:15.004054|2018-06-01 00:13:15.004054
NCT01041781|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2017-08-09|2009-12-31|2010-01-01|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2010|Actual|2010-02-28|August 2017|2017-08-31|December 2016|Actual|2016-12-31|November 2013|Actual|2013-11-30||Interventional|||Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer|Terminated||Phase 3|313|Actual|Alliance for Clinical Trials in Oncology||2||DSMB recommendation|f||||t||||||||||2018-06-01 00:13:15.139066|2018-06-01 00:13:15.139066
NCT01038206|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2015-06-02|2009-12-22|2009-12-23|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Familias Unidas: Preventing Substance Abuse in Hispanic Youth|Familias Unidas Stage III Study: Preventing Substance Abuse in Hispanic Youth|Completed||Phase 2/Phase 3|746|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 00:14:16.921514|2018-06-01 00:14:16.921514
NCT01041768|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2010-03-29|2009-12-31|2010-01-01|Estimate|||||||2010-03-29|2010-03-30|Estimate|March 2009||2009-03-31|December 2009|2009-12-31|December 2015|Anticipated|2015-12-31|December 2010|Anticipated|2010-12-31||Interventional|DIA-CHIR-MULT||Multicentric Prospective Randomized Trial on Surgery Versus Standard Medical Care in Type 2 Diabetic Patients BMI 30-35|Multicentric Prospective Randomized Controlled Trial on the Effect of Gastric Bypass and Bilopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI Between 30 and 35|Unknown status|Recruiting|N/A|300|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||t||||||||||2018-06-01 00:13:15.820483|2018-06-01 00:13:15.820483
NCT01041755|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2014-09-22|2009-12-31|2010-01-01|Estimate|||||||2014-09-22|2014-09-25|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.|The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy.|Completed||Phase 4|30|Actual|Centro Regional para el Estudio de las Enfermedades Digestivas||2|||f||||f||||||||||2018-06-01 00:13:15.941043|2018-06-01 00:13:15.941043
NCT01041742|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2010-07-25|2009-12-31|2010-01-01|Estimate|||||||2010-07-25|2010-07-27|Estimate|December 2009||2009-12-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Pulse Pressure Variation (PPV) to Predict Fluid Responsiveness During Cardiac Displacement in Patients Undergoing Off-pump Coronary Artery Bypass Surgery (OPCAB)|Pulse Pressure Variation to Predict Fluid Responsiveness During Cardiac Displacement in Patients Undergoing Off-pump Coronary Artery Bypass Surgery|Completed||N/A|35|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-06-01 00:13:16.020692|2018-06-01 00:13:16.020692
NCT01041729|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2010-01-04|2009-12-31|2010-01-01|Estimate|||||||2010-01-04|2010-01-05|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Long-term Pleiotropic Effect of Statins in Patients With Peripheral Arterial Disease|Phase IV Study of Statins for Assess the Long-term Pleiotropic Effect Upon Nitric Oxide and C-Reactive Protein Levels in Patients With Peripheral Arterial Disease|Completed||Phase 4|60|Actual|Hospital Universitario Getafe||2|||f||||f||||||||||2018-06-01 00:13:16.087912|2018-06-01 00:13:16.087912
NCT01041716|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2011-08-18|2009-12-31|2010-01-01|Estimate|||||||2011-08-18|2011-08-19|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria|Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria|Completed|||300|Anticipated|Maimonides Medical Center|||||f||||f||||||||||2018-06-01 00:13:16.165121|2018-06-01 00:13:16.165121
NCT01041690|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|||2009-12-31|2009-12-31|2010-01-01|Estimate|||||||2009-12-31|2010-01-01|Estimate|June 2007||2007-06-30|January 2007|2007-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease|Bevacizumab (Avastin) as an Adjunct to Vitrectomy in the Management of Severe Proliferative Diabetic Retinopathy: a Prospective Case Series|Completed||N/A|19|Actual|Cairo University||1|||f||||t||||||||||2018-06-01 00:13:16.259996|2018-06-01 00:13:16.259996
NCT01041677|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30||2010-01-19|2013-01-15|2009-12-30|2010-01-01|Estimate||||2010-01-19|2010-01-21|Estimate|2013-01-15|2013-01-24|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of the Safety of R256918 in Obese Patients|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-Center Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects|Completed||Phase 2|71|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||t||||||||||2018-06-01 00:13:16.348881|2018-06-01 00:13:16.348881
NCT01041664|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-04-18|2009-12-31|2010-01-01|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Bad Genes or Genes Behaving Badly|Bad Genes or Genes Behaving Badly|Completed|||30|Actual|University of Alabama at Birmingham|||||f||||t||||||Samples With DNA|"~     Samples will be labeled with the study protocol number, a unique identifier, and the date of~     collection.~      Specimens will be obtained by the nursing staff at the PCIR. The PCIR processing lab will~     process the samples, which will then be stored in a locked freezer at -80oC in the restricted~     access CNRU Metabolism Core lab (WEBB 337).~   "|||2018-06-01 00:13:16.454276|2018-06-01 00:13:16.454276
NCT01041638|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-31|2015-02-03||2016-03-14|2009-12-31|2010-01-01|Estimate|2015-02-03|2015-02-19|Estimate||||2016-03-14|2016-04-13|Estimate|December 2009||2009-12-31|March 2016|2016-03-31||||April 2014|Actual|2014-04-30||Interventional|||Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma|A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) With GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy|Completed||Phase 3|105|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:13:16.591706|2018-06-01 00:13:16.591706
NCT01041625|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2009-12-31|2009-12-31|2010-01-01|Estimate|||||||2009-12-31|2010-01-01|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus|An Open-Label Pilot Study to Evaluate the Safety and Efficacy of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Virginia Clinical Research, Inc.||1|||f||||t||||||||||2018-06-01 00:13:17.376132|2018-06-01 00:13:17.376132
NCT01041612|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2016-10-19|2009-12-30|2010-01-01|Estimate|||||||2016-10-19|2016-10-21|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi|Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study|Completed||Phase 4|120|Actual|Taewoong Medical Co., Ltd.||2|||f||||f||||||||No||2018-06-01 00:13:17.459022|2018-06-01 00:13:17.459022
NCT01041599|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2016-08-29|2009-12-31|2010-01-01|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Observational|||Correlation of Albuminuria With Arterial Stiffness|Assessment of the Association Between Albuminuria and Arterial Stiffness in Diabetic Patients, Hypertensive Patients and Healthy Controls|Completed|||152|Actual|Istanbul University|||3||f||||f||||||Samples Without DNA|"~     Serum and urine samples.~   "|Yes|yes|2018-06-01 00:13:17.580606|2018-06-01 00:13:17.580606
NCT01041014|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2015-09-29|2009-12-29|2009-12-30|Estimate|||||||2015-09-29|2015-10-01|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|January 2010|Actual|2010-01-31|April 2009|Actual|2009-04-30||Interventional|||Cost Effectiveness of Language Services in Hospital Emergency Departments (EDs)|Cost Effectiveness of Language Services in Hospital Emergency Departments|Completed||N/A|447|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-06-01 00:13:28.497045|2018-06-01 00:13:28.497045
NCT01041586|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-02-21|2009-12-30|2009-12-31|Estimate|||||||2012-02-21|2012-02-23|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|BTVA||Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction|US Pilot Safety and Feasibility Study of Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction in Patients With Heterogeneous Emphysema With Upper Lobe Predominance|Completed||Phase 1|10|Actual|Uptake Medical Corp||1|||f||||t||||||||||2018-06-01 00:13:17.652797|2018-06-01 00:13:17.652797
NCT01041573|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|2014-01-16||2016-03-29|2009-12-30|2009-12-31|Estimate|2014-01-16|2014-02-27|Estimate||||2016-03-29|2016-05-06|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population|Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study|Completed||Phase 3|1869|Actual|Valneva Austria GmbH||4|||f||||t||||||||||2018-06-01 00:13:17.733743|2018-06-01 00:13:17.733743
NCT01041560|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2009-12-30|2009-12-30|2009-12-31|Estimate|||||||2009-12-30|2009-12-31|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Muscle Tone Changes in Acute Stroke According to Brain Injury|Muscle Tone Changes in Acute Stroke According to Brain Injury in Relation to Changes in Functioning|Unknown status|Recruiting||100|Anticipated|Jyväskylä Central Hospital|||1||f||||f||||||||||2018-06-01 00:13:18.194363|2018-06-01 00:13:18.194363
NCT01041547|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2014-01-13|2009-12-30|2009-12-31|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|VIVID||Vascular Function, Insulin Sensitivity, and Vitamin D|Vitamin D, Vascular Function, and Insulin Sensitivity in Adults [The VIVID Study|Completed|||63|Actual|University of Alabama at Birmingham|||1||f||||t||||||Samples Without DNA|"~     Seum~   "|||2018-06-01 00:13:18.250828|2018-06-01 00:13:18.250828
NCT01041534|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2012-07-03|2009-12-29|2009-12-31|Estimate|||||||2012-07-03|2012-07-06|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|September 2012|Anticipated|2012-09-30|July 2011|Actual|2011-07-31||Observational|AGB||Adjustable Gastric Band Survey Study|Data Investigation of Bariatric Surgery and Economic Savings: Adjustable Gastric Band (AGB) Survey Study|Unknown status|Active, not recruiting||1000|Anticipated|University of Washington|||1||f||||t||||||||||2018-06-01 00:13:18.324708|2018-06-01 00:13:18.324708
NCT01041521|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2016-12-14|2009-12-30|2009-12-31|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|HOST||The Impact of Omega Three Fatty Acids on Vascular Function in HIV|The Impact of Omega Three Fatty Acids on Vascular Function in HIV|Completed||Phase 4|129|Actual|Tufts University||2|||f||||t||||||||||2018-06-01 00:13:18.376506|2018-06-01 00:13:18.376506
NCT01041508|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2015-05-14|2009-12-29|2009-12-31|Estimate|||||||2015-05-14|2015-05-18|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.|Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematologic Malignancies|Completed||Phase 1|36|Anticipated|Therapeutic Advances in Childhood Leukemia Consortium||2|||f||||t||||||||||2018-06-01 00:13:19.345009|2018-06-01 00:13:19.345009
NCT01041495|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2012-09-06|2009-12-29|2009-12-31|Estimate|||||||2012-09-06|2012-09-07|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Cyclobenzaprine Extended Release (ER) for Fibromyalgia|An Eight Week, Double-Blind Efficacy Study of Cyclobenzaprine ER (Amrix TM) Augmentation to Alleviate Fibromyalgia Fatigue and Muscle Pain|Unknown status|Recruiting|Phase 4|60|Anticipated|State University of New York - Upstate Medical University||2|||f||||f||||||||||2018-06-01 00:13:19.436977|2018-06-01 00:13:19.436977
NCT01041482|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2010-01-05|2009-12-30|2009-12-31|Estimate|||||||2010-01-05|2010-01-06|Estimate|November 2008||2008-11-30|August 2008|2008-08-31|November 2013|Anticipated|2013-11-30|November 2011|Anticipated|2011-11-30||Interventional|AGuo||A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma|A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Locally Advanced Renal-Cell Carcinoma After Radical Nephrectomy|Unknown status|Recruiting|Phase 2|140|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-06-01 00:13:19.52091|2018-06-01 00:13:19.52091
NCT01041469|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-03-21|2009-12-30|2009-12-31|Estimate|||||||2012-03-21|2012-03-22|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|December 2010|Actual|2010-12-31|||||Observational|IMMUTRI||Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome|Pilot Study of Auto-immune Abnormalities Associated With Down Syndrome|Completed|||72|Actual|Institut Jerome Lejeune|||2||f||||f||||||Samples With DNA|"~     whole blood and white cells~   "|||2018-06-01 00:13:19.598708|2018-06-01 00:13:19.598708
NCT01041456|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2009-12-31|2009-12-29|2009-12-31|Estimate|||||||2009-12-31|2010-01-01|Estimate|March 2009||2009-03-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Observational|BPD-to-RYGB||Laparoscopic Revision From Biliopancreatic Diversion to Gastric Bypass|Another Revisional Strategy to Address Severe Late Complications After Previous Biliopancreatic Diversion for Obesity: Major Revision From Standard Biliopancreatic Diversion to Proximal Roux-en-Y Gastric Bypass|Completed|||10|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:19.669427|2018-06-01 00:13:19.669427
NCT01041443|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2015-06-03|2009-12-29|2009-12-31|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|A Phase I Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) in Myeloid Leukemia and MDS|Completed||Phase 1|25|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 00:13:19.777202|2018-06-01 00:13:19.777202
NCT01041430|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2015-04-17|2009-12-30|2009-12-31|Estimate|||||||2015-04-17|2015-04-21|Estimate|February 2006||2006-02-28|April 2015|2015-04-30||||February 2008|Actual|2008-02-29||Interventional|||Day-case or Inpatient Care Following Inguinal Hernia Repair in Elderly Patients|Randomized Clinical Trial Comparing Day-case and Inpatient Care Following Inguinal Hernia Repair in Elderly Patients|Completed||N/A|89|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-06-01 00:13:19.954783|2018-06-01 00:13:19.954783
NCT01041235|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-09-04|2009-12-30|2009-12-31|Estimate|||||||2012-09-04|2012-09-06|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies|A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered ATI-1123, a Liposomal Docetaxel Formulation, on an Every 3 Week Schedule, in Patients With Advanced Solid Tumors|Completed||Phase 1|29|Actual|Azaya Therapeutics, Inc.||1|||f||||f||||||||||2018-06-01 00:13:26.897801|2018-06-01 00:13:26.897801
NCT01041417|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2014-05-15||2014-12-12|2009-12-30|2009-12-31|Estimate|2014-12-12|2014-12-23|Estimate||||2014-12-12|2014-12-23|Estimate|September 2009||2009-09-30|December 2014|2014-12-31||||March 2014|Actual|2014-03-31||Interventional|GPAD-2||Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease|Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study|Completed||Phase 2|159|Actual|Emory University|Study population were subjects with claudication who underwent angiography. Study design could not show therapeutic benefit of GM-CSF therapy with dose and duration changes. And study design encouraged all subjects to walk to claudication daily.|2|||f||||t||||||||||2018-06-01 00:13:20.090442|2018-06-01 00:13:20.090442
NCT01041404|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2014-07-22||2014-10-31|2009-12-29|2009-12-31|Estimate|2014-10-31|2014-11-05|Estimate||||2014-10-31|2014-11-05|Estimate|September 2005||2005-09-30|October 2014|2014-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Full analysis set (FAS) included all randomized participants who received at least 1 dose of study treatment.|ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer|A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer|Completed||Phase 3|584|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:13:21.036632|2018-06-01 00:13:21.036632
NCT01041391|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2013-09-06|2009-12-29|2009-12-31|Estimate|||||||2013-09-06|2013-09-09|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Lumbar Disc Herniation Outcome Measures|Lumbar Disc Herniation Outcome Measures-Surgical Versus Non-Operative Treatment|Terminated|||35|Actual|State University of New York - Upstate Medical University|||2|Slow/low enrollment|f||||f||||||||||2018-06-01 00:13:25.55163|2018-06-01 00:13:25.55163
NCT01041378|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2010-06-15|2009-12-30|2009-12-31|Estimate|||||||2010-06-15|2010-06-16|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy of Intravenous Dexamethasone on Postoperative Caudal Analgesia in Pediatric Orchiopexy||Completed||N/A|80|Actual|Yonsei University|||||f||||f||||||||||2018-06-01 00:13:25.74038|2018-06-01 00:13:25.74038
NCT01041365|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2014-01-13|2009-12-30|2009-12-31|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|DIVA||Vitamin D, Insulin Sensitivity, and Vascular Associations in Adolescents|Serum 25-hydroxyvitamin D, Vascular Functioning, and Insulin Sensitivity in Adolescent Girls [The DIVA Study (Vitamin D, Insulin, and Vascular Associations)] (Pediatric Physician Training in Translational Research)|Completed|||62|Actual|University of Alabama at Birmingham|||1||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 00:13:25.790177|2018-06-01 00:13:25.790177
NCT01041352|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-01-17|2009-12-30|2009-12-31|Estimate|||||||2012-01-17|2012-01-18|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Laryngeal Mask or Endotracheal Tube for Back Surgery in the Prone Position|Laryngeal Mask or Endotracheal Tube for Back Surgery in the Prone Position. Advantages, Adverse Effects and Time Consumation for the Two Methods.|Completed||N/A|136|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-06-01 00:13:25.853072|2018-06-01 00:13:25.853072
NCT01041339|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2015-12-13|2009-12-30|2009-12-31|Estimate|||||||2015-12-13|2015-12-15|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Observational|||ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?|ST Elevation (Acute Coronary Syndrome Versus Pericarditis;Could Measurement of Lp-associated PLA2 -a Vascular Specific Marker of Inflammation- be Helpful to the Clinician?|Completed|||40|Actual|Wolfson Medical Center|||2||f||||f||||||Samples Without DNA|"~     plasma kept in -80 celsius refrigerator~   "|||2018-06-01 00:13:25.921741|2018-06-01 00:13:25.921741
NCT01041326|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2013-07-16|2009-12-30|2009-12-31|Estimate|||||||2013-07-16|2013-07-17|Estimate|April 2005||2005-04-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Preoperative Radiation Therapy for High Risk Prostate Cancer|A Phase I Dose-Escalation Study of Preoperative Radiation Therapy Followed by Radical Prostatectomy in Patients With High Risk, Localized Carcinoma of the Prostate|Completed||Phase 1|15|Actual|Duke University||4|||f||||t||||||||||2018-06-01 00:13:25.990589|2018-06-01 00:13:25.990589
NCT01041313|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2010-06-25|2009-12-30|2009-12-31|Estimate|||||||2010-06-25|2010-06-29|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|||Memantine for Post-Operative Pain Control|Memantine for Post-Operative Pain Control|Unknown status|Recruiting|Phase 4|120|Anticipated|University of Washington||2|||f||||f||||||||||2018-06-01 00:13:26.08497|2018-06-01 00:13:26.08497
NCT01041300|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-01-04|2009-12-30|2009-12-31|Estimate|||||||2012-01-04|2012-01-05|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effects of Trancranial Magnetic Stimulation Multichannel Stimulator on Motor Excitation|The Effects of Trancranial Magnetic Stimulation Multichannel Stimulator on Motor Excitation|Completed||N/A|34|Actual|Shalvata Mental Health Center|||||f||||t||||||||||2018-06-01 00:13:26.17537|2018-06-01 00:13:26.17537
NCT01041287|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2014-12-12||2014-12-12|2009-12-30|2009-12-31|Estimate|2014-12-12|2014-12-19|Estimate||||2014-12-12|2014-12-19|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||The population analysis for baseline characteristics are from subjects that completed both treatment periods.|Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells|Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells in Subjects With Hypertension|Completed||Phase 4|96|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:13:26.25532|2018-06-01 00:13:26.25532
NCT01041274|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2018-04-04|2009-12-30|2009-12-31|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2009|Actual|2009-12-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|July 2018|Anticipated|2018-07-31||Interventional|DECIFER||DECIFER: Depression and Citalopram In First Episode Recovery|Citalopram in First Episode Schizophrenia|Active, not recruiting||Phase 4|150|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 00:13:26.485454|2018-06-01 00:13:26.485454
NCT01041261|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2012-01-11|2009-12-30|2009-12-31|Estimate|||||||2012-01-11|2012-01-13|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of a Novel Dietary Intervention on Body Composition After Laparoscopic Gastric Bypass Surgery|Randomized, Pilot Study to Compare the Effects of a Novel Dietary Intervention With the Post-operative Standard of Care on Body Composition After Laparoscopic Gastric Bypass Surgery|Terminated||N/A|7|Actual|MetaProteomics LLC||2|||f||||f||||||||||2018-06-01 00:13:26.595487|2018-06-01 00:13:26.595487
NCT01041222|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2012-04-12|2009-12-30|2009-12-31|Estimate|||||||2012-04-12|2012-04-13|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|SOD-1||Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations|A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients With Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations|Completed||Phase 1|33|Actual|Ionis Pharmaceuticals, Inc.||5|||f||||t||||||||||2018-06-01 00:13:26.987269|2018-06-01 00:13:26.987269
NCT01041209|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|2012-06-29||2016-11-07|2009-12-30|2009-12-31|Estimate|2012-08-27|2012-09-27|Estimate||||2016-11-07|2016-12-28|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia|Efficacy of BPS (Bacterial Pneumonia Score) Guided Antibiotic Use in Children With Community Acquired Pneumonia on Reducing Antibiotic Use as Compared to Standard Care Practice (Current Guidelines for CAP)|Completed||N/A|120|Actual|Hospital General de Niños Pedro de Elizalde||2|||f||||t||||||||||2018-06-01 00:13:27.125086|2018-06-01 00:13:27.125086
NCT01041196|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2009-12-31|2009-12-29|2009-12-31|Estimate|||||||2009-12-31|2010-01-01|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Observational|PerforatedMU||Perforated Marginal Ulcer After Gastric Bypass|Laparoscopic Revision Gastric Bypass Surgery for Perforated Marginal Ulcer: A 10 Year Experience|Completed|||30|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:27.344747|2018-06-01 00:13:27.344747
NCT01041183|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2009-12-30|2009-12-30|2009-12-31|Estimate|||||||2009-12-30|2009-12-31|Estimate|November 2009||2009-11-30|November 2009|2009-11-30||||December 2009|Actual|2009-12-31||Interventional|||The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy||Unknown status|Recruiting|N/A|120|Anticipated|Seoul National University Bundang Hospital||3|||f||||||||||||||2018-06-01 00:13:27.425519|2018-06-01 00:13:27.425519
NCT01041170|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2017-06-30|2009-12-30|2009-12-31|Estimate|||||||2017-06-30|2017-07-02|Actual|April 16, 2006||2006-04-16|January 11, 2010|2010-01-11|January 11, 2010|Actual|2010-01-11|January 11, 2010|Actual|2010-01-11||Interventional|||Antagonist-Elicited Cannabis Withdrawal|Antagonist-Elicited Cannabis Withdrawal|Completed||Phase 1|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:13:27.578798|2018-06-01 00:13:27.578798
NCT01041157|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-30|2009-12-30|2009-12-31|Estimate|||||||2009-12-30|2009-12-31|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|December 2011|Anticipated|2011-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Botulinum Toxin Injection Efficiency|Effectiveness of Botulinum Toxin Injection After Exercising Splenius Capitis Muscle in Patients With Cervical Dystonia|Unknown status|Active, not recruiting|Phase 1|22|Anticipated|Jyväskylä Central Hospital||1|||f||||f||||||||||2018-06-01 00:13:27.738112|2018-06-01 00:13:27.738112
NCT01041144|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2009-12-30|2009-12-30|2009-12-31|Estimate|||||||2009-12-30|2009-12-31|Estimate||||June 2005|2005-06-30||||||||Interventional|||Effects of Health Care Provider-mediated, Remote Coaching System Through the PDA-type Glucometer and the Internet on Diabetes Management||Completed||N/A|115||The Catholic University of Korea||1|||f||||t||||||||||2018-06-01 00:13:27.811211|2018-06-01 00:13:27.811211
NCT01041131|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2009-12-31|2009-12-29|2009-12-31|Estimate|||||||2009-12-31|2010-01-01|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|VBG||Laparoscopic Revision of Vertical Banded Gastroplasty to Gastric Bypass|Laparoscopic Revisional Gastric Bypass Surgery for Failed and/or Complicated Open Vertical Banded Gastroplasty: Our Experience With 70 Patients|Completed|||70|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:27.88518|2018-06-01 00:13:27.88518
NCT01041105|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2009-12-31|2009-12-29|2009-12-31|Estimate|||||||2009-12-31|2010-01-01|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|RYGBafterARS||Gastric Bypass After Previous Anti-reflux Surgery|Laparoscopic Revision Roux-en-Y Gastric Bypass Surgery After Previous Anti-rflux Surgery: Intermediate Results|Completed|||22|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:27.97343|2018-06-01 00:13:27.97343
NCT01041092|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2009-12-30|2009-12-30|2009-12-31|Estimate|||||||2009-12-30|2009-12-31|Estimate|June 2004||2004-06-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women|Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women|Completed||Phase 4|34|Actual|Fundació Sant Joan de Déu||2|||f||||t||||||||||2018-06-01 00:13:28.086169|2018-06-01 00:13:28.086169
NCT01041079|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-25|||2009-12-31|2009-12-29|2009-12-31|Estimate|||||||2009-12-31|2010-01-01|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|ChronicMU||Chronic Marginal Ulcers After Gastric Bypass|Laparoscopic Revision Gastric Bypass Surgery for Chronic Marginal Ulcers: a 10 Year Experience|Completed|||50|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:28.148809|2018-06-01 00:13:28.148809
NCT01041066|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-30|||2009-12-30|2009-12-30|2009-12-31|Estimate|||||||2009-12-30|2009-12-31|Estimate|September 2009||2009-09-30|September 2009|2009-09-30||||December 2009|Anticipated|2009-12-31||Interventional|||Nicardipine Versus Labetalol During Intubation||Unknown status|Recruiting|N/A|70|Anticipated|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-06-01 00:13:28.23999|2018-06-01 00:13:28.23999
NCT01041040|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2013-07-30|2009-12-29|2009-12-30|Estimate|||||||2013-07-30|2013-07-31|Estimate|October 2007||2007-10-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)|PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)|Completed||Phase 4|200|Actual|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 00:13:28.341683|2018-06-01 00:13:28.341683
NCT01041027|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2016-01-11|2009-12-29|2009-12-30|Estimate|||||||2016-01-11|2016-01-13|Estimate|September 2008||2008-09-30|January 2016|2016-01-31||||January 2017|Anticipated|2017-01-31||Interventional|||Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer|"A Pilot Phase II Trial of Radiation Therapy Sandwiched Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging"|Unknown status|Recruiting|Phase 2|25|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-06-01 00:13:28.406832|2018-06-01 00:13:28.406832
NCT01041001|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2017-04-18|2009-12-29|2009-12-30|Estimate|||||||2017-04-18|2017-04-20|Actual|February 2009||2009-02-28|April 2012|2012-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury|Randomized, Open-Label, Multi-Center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of Cartistem® and Microfracture in Patients With Knee Articular Cartilage Injury or Defect|Completed||Phase 3|104|Actual|Medipost Co Ltd.||2|||f||||t||||||||Undecided||2018-06-01 00:13:28.558471|2018-06-01 00:13:28.558471
NCT01040988|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2017-04-12|2009-12-29|2009-12-30|Estimate|||||||2017-04-12|2017-04-13|Actual|August 2009||2009-08-31|April 2017|2017-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|IDEAS||The Implantable Cardioverter-defibrillators (ICD)/Device Expectations, Adaptations, and Successes Study|The ICD/Device Expectations, Adaptations, and Successes (IDEAS) Study: the Relationship Between Implantable Cardioverter-defibrillators, Pacemakers and Psychiatric Symptoms in a Pediatric Population|Completed|||166|Actual|Boston Children’s Hospital|||2||f||||f||||||||||2018-06-01 00:13:28.628749|2018-06-01 00:13:28.628749
NCT01040975|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2016-09-22|2009-12-29|2009-12-30|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|TeenCHAT||Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight|Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight|Completed||N/A|684|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:13:28.697002|2018-06-01 00:13:28.697002
NCT01040962|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2012-06-15|2009-12-29|2009-12-30|Estimate|||||||2012-06-15|2012-06-19|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Fall Risk Assessment in People With Diabetic Neuropathy|Fall Risk Assessment in People With Diabetic Neuropathy|Completed|||37|Actual|University of Kansas Medical Center|||1||f||||t||||||||||2018-06-01 00:13:28.777756|2018-06-01 00:13:28.777756
NCT01040949|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2013-06-14|2009-12-29|2009-12-30|Estimate|||||||2013-06-14|2013-06-18|Estimate|September 2008||2008-09-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional|Parejas||En Pareja: A Latino Couples Intervention to Help Expectant Fathers Quit Smoking|En Pareja: A Latino Couples Intervention to Help Expectant Fathers Quit Smoking|Completed||N/A|705|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:13:28.83117|2018-06-01 00:13:28.83117
NCT01040936|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2011-06-14|2009-12-29|2009-12-30|Estimate|||||||2011-06-14|2011-06-15|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|November 2011|Anticipated|2011-11-30|October 2011|Anticipated|2011-10-31||Interventional|ILLEPE-ACS||Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients|Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 4|300|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 00:13:29.017389|2018-06-01 00:13:29.017389
NCT01040923|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2018-04-16|2009-12-29|2009-12-30|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2010||2010-01-31|April 2018|2018-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Comparison of Digital Electronic Stethoscope to Computed Tomography (CT) Angiography in Detection of Coronary Artery Disease|Validation of the Cardiosond Sonospectrographic Digital Electronic Stethoscope in Diagnosing Coronary Artery Disease Versus CT Angiography|Completed|||200|Actual|SonoMedica, Inc.|||1||f||||f||||||||||2018-06-01 00:13:29.108156|2018-06-01 00:13:29.108156
NCT01040910|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2011-12-15|2009-12-29|2009-12-30|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2010||2010-01-31|December 2011|2011-12-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Interventional|||Cannabis for Inflammatory Bowel Disease|A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-06-01 00:13:29.186568|2018-06-01 00:13:29.186568
NCT01040897|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2017-07-16|2009-12-28|2009-12-30|Estimate|||||||2017-07-16|2017-07-18|Actual|December 2009||2009-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|GreenLight||Addressing Health Literacy and Numeracy to Prevent Childhood Obesity|Addressing Health Literacy and Numeracy to Prevent Childhood Obesity|Active, not recruiting||N/A|865|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-06-01 00:13:29.275033|2018-06-01 00:13:29.275033
NCT01040884|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2012-07-10|2009-12-29|2009-12-30|Estimate|||||||2012-07-10|2012-07-12|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety And Accuracy Study Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Procedures|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Preliminary Safety and Accuracy of the ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Aspiration, Biopsy and RF Ablations|Completed||Phase 4|40|Actual|ActiViews Ltd.||1|||f||||f||||||||||2018-06-01 00:13:29.388835|2018-06-01 00:13:29.388835
NCT01040871|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2013-07-05||2013-12-11|2009-12-29|2009-12-30|Estimate|2013-09-24|2013-11-27|Estimate||||2013-12-11|2014-01-13|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional||Intent to Treat, Randomized|Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma|A Randomized, Open-Label, Multicenter Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma|Completed||Phase 2|164|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:13:29.486985|2018-06-01 00:13:29.486985
NCT01040858|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|2014-11-07||2015-01-14|2009-12-29|2009-12-30|Estimate|2015-01-14|2015-01-26|Estimate||||2015-01-14|2015-01-26|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|CROVCD|Of the 128 subjects who consented to participate in the study, 9 participants who were randomized to the Cognitive Strategies Training, did not complete the training due to schedule conflict, etc. Thus, their data was not included in the final analysis.|Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder|Cognitive Rehabilitation of OIF/OEF Veterans With Cognitive Disorder|Completed||N/A|128|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:13:30.350822|2018-06-01 00:13:30.350822
NCT01040845|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-12-30|2009-12-01|2009-12-30|Estimate|2009-12-01|2009-12-30|Estimate||||2009-12-30|2010-01-05|Estimate|August 2007||2007-08-31|December 2009|2009-12-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||A Pharmacokinetic Study of Colchicine With an Oral Contraceptive|A Pharmacokinetic Study to Evaluate the Effect of Colchicine on the Pharmacokinetic Profile of an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone in Healthy Women|Completed||Phase 1|30|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:13:30.881812|2018-06-01 00:13:30.881812
NCT01040832|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2014-06-24||2017-01-12|2009-12-29|2009-12-30|Estimate|2014-07-28|2014-07-29|Estimate||||2017-01-12|2017-01-30|Estimate|December 2009||2009-12-31|July 2014|2014-07-31||||January 2012|Actual|2012-01-31||Interventional||Intent-to-treat (ITT) population included all the randomized participants who had received study treatment.|EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)|Completed||Phase 2|107|Actual|EMD Serono|Few of the secondary outcome measures were planned and later removed due to Sponsor's decision to discontinue development of EMD 1201081. Overall survival data was analyzed only for participants who received EMD 1201081 plus cetuximab.|2|||f||||t||||||||||2018-06-01 00:13:31.31596|2018-06-01 00:13:31.31596
NCT01040819|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2015-12-22||2016-05-14|2009-12-29|2009-12-30|Estimate|2016-05-14|2016-06-22|Estimate||||2016-05-14|2016-06-22|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?|Does Pioglitazone Increase the Production of Prostacyclin (PGI2) and/or 15-EPI-Lipoxin A4 in Humans With Diabetes Mellitus Type 2?|Completed||Phase 4|25|Actual|Baylor College of Medicine||2|||f||||f||||||||No||2018-06-01 00:13:31.925531|2018-06-01 00:13:31.925531
NCT01040806|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2011-12-09|2009-12-29|2009-12-30|Estimate|||||||2011-12-09|2011-12-13|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Peer Coaching for Low-Income Patients With Diabetes in Primary Care|Peer Coaching for Low-Income Patients With Diabetes in Primary Care|Completed||N/A|300|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:13:32.155308|2018-06-01 00:13:32.155308
NCT01040793|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2014-03-28||2014-07-04|2009-12-29|2009-12-30|Estimate|2014-07-04|2014-07-08|Estimate||||2014-07-04|2014-07-08|Estimate|January 2010||2010-01-31|July 2014|2014-07-31||||April 2011|Actual|2011-04-30||Interventional|||Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II|Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease.|Completed||Phase 3|157|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 00:13:32.296129|2018-06-01 00:13:32.296129
NCT01040780|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-27|2012-02-21||2014-01-21|2009-12-29|2009-12-30|Estimate|2012-04-23|2012-05-24|Estimate||||2014-01-21|2014-02-14|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|December 2011|Actual|2011-12-31|March 2010|Actual|2010-03-31||Interventional|ICOGEN||Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients|A Randomized,Double-blind,Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated With Chemotherapy|Completed||Phase 3|399|Actual|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-06-01 00:13:33.262654|2018-06-01 00:13:33.262654
NCT01040767|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2009-12-29|2009-12-29|2009-12-30|Estimate|||||||2009-12-29|2009-12-30|Estimate|November 2008||2008-11-30|December 2009|2009-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Comparison of Web- Versus Classroom-based Basic Ultrasound and Extended Focused Assessment With Sonography for Trauma (EFAST) Training in Two European Hospitals|Comparison of Web- Versus Classroom-based Basic Ultrasound and EFAST Training in Two European Hospitals|Completed||N/A|55|Actual|Brigham and Women's Hospital||3|||f||||f||||||||||2018-06-01 00:13:33.634704|2018-06-01 00:13:33.634704
NCT01040754|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2016-03-10|2009-12-29|2009-12-30|Estimate|||||||2016-03-10|2016-03-14|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|KOA||fMRI Study of Expectancy on Acupuncture Treatment Outcomes in Knee OA|An fMRI Study of Expectancy on Acupuncture Treatment Outcomes in Knee OA|Completed||N/A|144|Actual|Massachusetts General Hospital||2|||f||||t||||||||Undecided||2018-06-01 00:13:33.698712|2018-06-01 00:13:33.698712
NCT01040741|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2011-10-04|2009-12-29|2009-12-30|Estimate|||||||2011-10-04|2011-10-05|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine|A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine Focetria|Completed|||7284|Actual|Novartis|||6||f||||||||||||||2018-06-01 00:13:33.763002|2018-06-01 00:13:33.763002
NCT01040728|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2014-03-28||2014-05-28|2009-12-29|2009-12-30|Estimate|2014-05-28|2014-06-30|Estimate||||2014-05-28|2014-06-30|Estimate|January 2010||2010-01-31|May 2014|2014-05-31||||January 2011|Actual|2011-01-31||Interventional|||A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease|Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour FEV1-time Profiles of BI 1744 CL 5μg and 10μg (Oral Inhalation, Delivered by the Respimat® Inhaler) and Tiotropium Bromide 18μg (Oral Inhalation, Delivered by the HandiHaler®) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|122|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 00:13:33.871022|2018-06-01 00:13:33.871022
NCT01040715|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2014-09-17|2009-12-29|2009-12-30|Estimate|||||||2014-09-17|2014-09-18|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|October 2012|Actual|2012-10-31||Interventional|||Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists|A Phase II, Randomized, Double-blind, Controlled Study to Evaluate the Immune Responses, Safety and Clinical Efficacy of Three Doses of Neovacs' TNF-Kinoid in Adult Patients With Rheumatoid Arthritis Who Have Relapsed Despite Anti-TNFα Biological Therapy|Completed||Phase 2|40|Actual|Neovacs||3|||f||||t||||||||||2018-06-01 00:13:34.870416|2018-06-01 00:13:34.870416
NCT01040702|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|||2009-12-29|2009-12-29|2009-12-30|Estimate|||||||2009-12-29|2009-12-30|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||The Effect of Methylphenidate on Decision-making Ability of Attention Deficit Hyperactivity Disorder (ADHD) Adults|The Effect of Methylphenidate on Decision-making Ability of ADHD Adults|Completed||Phase 1|58|Actual|Shalvata Mental Health Center||4|||f||||t||||||||||2018-06-01 00:13:34.980781|2018-06-01 00:13:34.980781
NCT01040520|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2015-05-28|2009-12-28|2009-12-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Value of CT-based Autopsy Compared With Conventional Autopsy in ICU Patients|Computertomography-based Autopsy (Virtopsy) Versus Conventional Autopsy in Patients Dying in Intensive Care Units|Completed|||284|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-06-01 00:13:37.279736|2018-06-01 00:13:37.279736
NCT01040689|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-29|2014-03-28||2014-05-28|2009-12-29|2009-12-30|Estimate|2014-05-28|2014-06-30|Estimate||||2014-05-28|2014-06-30|Estimate|January 2010||2010-01-31|May 2014|2014-05-31||||January 2011|Actual|2011-01-31||Interventional|||Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease|Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced, Expiratory Volume After 1 Second (FEV1) Time Profiles of BI 1744 CL 5µg and 10µg (Oral Inhalation, Delivered by the Respimat® Inhaler) and Tiotropium Bromide 18µg (Oral Inhalation, Delivered by the HandiHaler®) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|108|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 00:13:35.112218|2018-06-01 00:13:35.112218
NCT01040676|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-27|||2012-06-22|2009-12-28|2009-12-29|Estimate|||||||2012-06-22|2012-06-26|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ATNS||Automated Telephone Nutrition Support|The Use Of Automated Telephone Nutrition Support In Spanish-Speaking Latino Patients With Diabetes|Completed||N/A|75|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:13:36.097976|2018-06-01 00:13:36.097976
NCT01040663|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2013-04-09|2009-12-28|2009-12-29|Estimate|||||||2013-04-09|2013-04-10|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Isocaloric Dietary Interventions for Insulin Resistance and the Metabolic Syndrome|Isocaloric Dietary Interventions for Insulin Resistance and the Metabolic Syndrome|Completed||N/A|42|Actual|Rockefeller University||3|||f||||f||||||||||2018-06-01 00:13:36.196955|2018-06-01 00:13:36.196955
NCT01040650|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2013-08-29|2009-12-28|2009-12-29|Estimate|||||||2013-08-29|2013-08-30|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment|Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment|Terminated|||23|Actual|Rockefeller University|||2|Principal Investigator left institution|f||||f||||||Samples With DNA|"~     Blood and urine~   "|||2018-06-01 00:13:36.273551|2018-06-01 00:13:36.273551
NCT01040637|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22||2013-02-08|2014-09-03|2009-12-24|2009-12-29|Estimate||||2013-02-13|2013-02-18|Estimate|2014-09-03|2014-09-10|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation|A Phase 1/Phase 2, Randomized, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Effect on Opioid Analgesia of TD-1211 Administered Orally to Healthy Volunteers and to Assess the Safety, Pharmacokinetics, and Effect on Bowel Movements in Subjects With Opioid-Induced Constipation|Completed||Phase 1/Phase 2|102|Actual|Theravance Biopharma Antibiotics, Inc.||10|||f||||f||||||||||2018-06-01 00:13:36.32734|2018-06-01 00:13:36.32734
NCT01040624|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|2015-06-25||2017-08-10|2009-12-24|2009-12-29|Estimate|2015-06-25|2015-07-22|Estimate||||2017-08-10|2017-08-23|Actual|December 2009||2009-12-31|August 2017|2017-08-31|January 2035|Anticipated|2035-01-31|January 2015|Actual|2015-01-31||Interventional|PR05||Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer|A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma|Active, not recruiting||N/A|77|Actual|University of Florida||2|||f||||t|f|f||||||||2018-06-01 00:13:36.425785|2018-06-01 00:13:36.425785
NCT01040611|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2010-11-18|2009-12-28|2009-12-29|Estimate|||||||2010-11-18|2010-11-19|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|TMT||Effectiveness of Music Therapy|Effectiveness of Music Therapy on Anxiety, Depression and Physiological Responses for Inpatients of Tuberculosis|Unknown status|Active, not recruiting|N/A|66|Actual|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-06-01 00:13:36.688184|2018-06-01 00:13:36.688184
NCT01040598|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-27|||2012-03-13|2009-12-28|2009-12-29|Estimate|||||||2012-03-13|2012-03-14|Estimate|June 2009||2009-06-30|March 2012|2012-03-31||||December 2011|Actual|2011-12-31||Interventional|||Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model|Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model|Completed||Phase 1|19|Actual|O & O Alpan LLC|||||f||||||||||||||2018-06-01 00:13:36.749747|2018-06-01 00:13:36.749747
NCT01040585|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2012-03-01|2009-12-24|2009-12-29|Estimate|||||||2012-03-01|2012-03-02|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Cost Effectiveness Of Linezolid In Central America|Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America|Withdrawn|||0|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:13:36.817832|2018-06-01 00:13:36.817832
NCT01040572|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-26|2009-12-26|2009-12-29|Estimate|||||||2009-12-26|2009-12-29|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|WR||Laparoscopic Revision Gastric Bypass for Weight Recidivism|Laparoscopic Revision Gastric Bypass Surgery for Weight Recidivism: Our Experience in 170 Patients|Completed|||132|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:36.876049|2018-06-01 00:13:36.876049
NCT01040559|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2013-01-08|2009-12-28|2009-12-29|Estimate|||||||2013-01-08|2013-01-09|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas|Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas Combining DC Bead Microspheres Loaded With Idarubicin (Zavedos®): Phase I Trial|Completed||Phase 1|18|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||t||||||||||2018-06-01 00:13:36.950615|2018-06-01 00:13:36.950615
NCT01040546|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2009-12-28|2009-12-28|2009-12-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|March 2007||2007-03-31|December 2009|2009-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Effect of a Diet- and Exercise- Related Weight Control Intervention Program on Obesity in Adult Aged 40 and Over|The Association of Obesity With Food Intake and Metabolic Syndrome in Adult Aged 40 and Over and the Effect of a Diet- and Exercise- Related Weight Control Intervention Program on Obesity|Completed||N/A|240|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-06-01 00:13:37.113509|2018-06-01 00:13:37.113509
NCT01040533|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2009-12-28|2009-12-28|2009-12-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|JIB-to-RYGB||Laparoscopic Revision of Jejunoileal Bypass to Gastric Bypass|One-stage Laparoscopic Revision of Failed and/or Complicated Jejunoileal Bypass to Roux-en-Y Gastric Bypass|Completed|||4|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:37.192776|2018-06-01 00:13:37.192776
NCT01038011|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2017-05-03|2009-12-21|2009-12-23|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2004||2004-06-30|May 2017|2017-05-31|August 2006||2006-08-31|||||Interventional|||Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study||Completed||Phase 2|||University of Zurich|||||f||||f||||||||No||2018-06-01 00:14:18.34642|2018-06-01 00:14:18.34642
NCT01040507|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-28|2009-12-28|2009-12-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|>10yrsRYGB||Very Long Term Results After Laparoscopic Retrocolic Antegastric Gastric Bypass|Very Long Term Results After Laparoscopic Retrocolic Antegastric Gastric Bypass|Completed|||242|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:37.337293|2018-06-01 00:13:37.337293
NCT01040494|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-25|||2010-01-18|2009-12-28|2009-12-29|Estimate|||||||2010-01-18|2010-01-20|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|January 2011|Anticipated|2011-01-31|July 2010|Anticipated|2010-07-31||Interventional|||Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure|Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project)|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 00:13:37.416226|2018-06-01 00:13:37.416226
NCT01040481|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2009-12-26|2009-12-26|2009-12-29|Estimate|||||||2009-12-26|2009-12-29|Estimate|August 2009||2009-08-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Observational|||Adding Malabsorption for Failed Gastric Bypass|Laparoscopic Revisional Surgery: Adding Malabsorption for Failed Gastric Bypass|Completed|||19|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:37.489474|2018-06-01 00:13:37.489474
NCT01040468|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2016-08-17|2009-12-24|2009-12-29|Estimate|||||||2016-08-17|2016-08-19|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SOLID||Surgery Or Lifestyle Intervention for Type 2 Diabetes (SOLID)|Lifestyle Intervention Versus Bariatric Surgery for Type 2 Diabetes|Completed||Phase 3|7|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 00:13:37.559394|2018-06-01 00:13:37.559394
NCT01040455|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-25|||2014-04-13|2009-12-28|2009-12-29|Estimate|||||||2014-04-13|2014-04-15|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Lansoprazole for Subgroups of Functional Dyspepsia|Therapeutic Response to Lansoprazole Among Different Subgroups of Functional Dyspepsia: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial|Terminated||Phase 4|30|Actual|National Taiwan University Hospital||2||failure to recruit enough patients|f||||t||||||||||2018-06-01 00:13:37.63072|2018-06-01 00:13:37.63072
NCT01040442|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2009-12-28|2009-12-28|2009-12-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|||The Effect of Plantar Vibration Stimuli on the Balance of Older Women|The Effect of Plantar Vibration Stimuli on the Balance of Older Women|Completed||N/A|30|Actual|Universidade Federal de Sao Carlos||1|||t||||f||||||||||2018-06-01 00:13:37.716529|2018-06-01 00:13:37.716529
NCT01040429|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2012-11-19|2009-12-28|2009-12-29|Estimate|||||||2012-11-19|2012-11-20|Estimate|February 2010||2010-02-28|November 2012|2012-11-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|NorCAPITAL||The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial|The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial|Completed||Phase 2|120|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 00:13:37.768655|2018-06-01 00:13:37.768655
NCT01040416|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-28|2009-12-28|2009-12-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|BleedingMU||Endoscopic Therapy for Bleeding Marginal Ulcers After Gastric Bypass|Endoscopic Therapy for Actively Bleeding Marginal Ulcers: Our Experience After 7,020 Roux-en-Y Gastric Bypass Surgeries|Completed|||45|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:37.86363|2018-06-01 00:13:37.86363
NCT01040403|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|2015-06-19|2014-03-28|2015-06-19|2009-12-28|2009-12-29|Estimate|2015-06-19|2015-07-15|Estimate|2014-03-28|2014-04-25|Estimate|2015-06-19|2015-07-15|Estimate|January 2010||2010-01-31|June 2015|2015-06-30||||February 2011|Actual|2011-02-28||Interventional||Treated Set (TS) which comprised all patients who were dispensed study medication and were documented to have taken at least 1 dose of investigational treatment.|Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, 8 Treatments, 4 Periods, Incomplete Crossover Study to Determine the Optimal Free Dose Combination of BI 1744 CL and Tiotropium Bromide (Both Delivered by the Respimat® Inhaler) After 4 Weeks Once Daily Treatment in Patients With COPD|Completed||Phase 2|233|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-06-01 00:13:38.045763|2018-06-01 00:13:38.045763
NCT01040390|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2012-02-15|2009-12-26|2009-12-29|Estimate|||||||2012-02-15|2012-02-17|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy of Lappa Arctium (Homoeopathic Medicine) in Treatment of Acne Vulgaris|Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Lappa Arctium|Completed||Phase 1|34|Actual|Miglani, Anjali|||||f||||t||||||||||2018-06-01 00:13:41.673319|2018-06-01 00:13:41.673319
NCT01040377|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-28|2009-12-28|2009-12-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|IIWL||Laparoscopic Revision Gastric Bypass for Inadequate Initial Weight Loss|Laparoscopic Revision Gastric Bypass for Inadequate Initial Weight Loss After Gastric Bypass: Intermediate Results|Completed|||42|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:41.732643|2018-06-01 00:13:41.732643
NCT01040364|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-26|||2013-09-23|2009-12-26|2009-12-29|Estimate|||||||2013-09-23|2013-09-24|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|IHafterLRYGB||Internal Hernias After Laparoscopic Gastric Bypass|Incidence of Internal Hernias After Laparoscopic Roux-en-Y Gastric Bypass Over the Last Decade: 1997 to 2008|Completed|||220|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 00:13:41.892917|2018-06-01 00:13:41.892917
NCT01040351|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|2010-05-10||2011-07-29|2009-12-28|2009-12-29|Estimate|2011-07-29|2011-08-29|Estimate||||2011-07-29|2011-08-29|Estimate|October 2006||2006-10-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Ultrasound Guided Aspiration of Hydrosalpingeal Fluid and IVF-ET Outcomes|Effect of Ultrasound Guided Aspiration of Hydrosalpingeal Fluid at the Time of Oocyte Retrieval on the Outcomes of IVF-ET, a Randomized Controlled Trial|Completed||Phase 2|110|Actual|Cairo University|Several patients refused to participate in the study|2|||f||||t||||||||||2018-06-01 00:13:41.989506|2018-06-01 00:13:41.989506
NCT01040169|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-27|2008-09-27||2013-11-15|2009-11-19|2009-12-29|Estimate|2009-11-19|2009-12-29|Estimate||||2013-11-15|2013-12-10|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Yeaple||Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction|Clinical Efficacy of a Toothpaste on Hypersensitivity Reduction|Completed||N/A|79|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 00:13:43.861125|2018-06-01 00:13:43.861125
NCT01040338|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2013-07-18|2009-12-28|2009-12-29|Estimate|||||||2013-07-18|2013-07-19|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Effects of Nicotine on Brain Opioid Receptors|Functional Characterization of OPRM1 A118G in Nicotine Dependence: IV Nicotine Study|Terminated|||15|Actual|University of Pennsylvania|||2|Issues & unreliability with [11C]Carfentanil production|f||||t||||||Samples With DNA|"~     The samples that shall be collected for this study are as follows:~        1. A 2ml saliva sample will be collected for DNA extraction using the Oragene™ kit at the~          Medical screening session for genetic analyses.~        2. An additional saliva sample (~ 5ml) will be also be collected at Medical screening and~          will be used to analyze baseline nicotine metabolites (i.e., cotinine and~          3-hydroxycotinine).~        3. All participants will provide two tubes of blood (10 ml each) to measure plasma~          estradiol & cortisol levels before each PET scanning session. They will also provide two~          tubes of blood (10 ml each) at the end of the scan to measure plasma nicotine and~          cortisol levels.~   "|||2018-06-01 00:13:42.258583|2018-06-01 00:13:42.258583
NCT01040325|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-25|||2012-03-13|2009-12-28|2009-12-29|Estimate|||||||2012-03-13|2012-03-14|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study|A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia|Completed||Phase 2|723|Actual|Intercell USA, Inc.||2|||f||||t||||||||||2018-06-01 00:13:42.343015|2018-06-01 00:13:42.343015
NCT01040312|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2013-03-28|2009-12-28|2009-12-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Observational|||An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors|A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors|Unknown status|Active, not recruiting||1000|Anticipated|Daiichi Sankyo Co., Ltd.|||1||f||||t||||||Samples With DNA|"~     white cells~   "|||2018-06-01 00:13:42.436636|2018-06-01 00:13:42.436636
NCT01040299|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2012-03-23|2009-12-28|2009-12-29|Estimate|||||||2012-03-23|2012-03-26|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|GT-1-tDCS||Mechanized Gait Trainer Combine Transcranial Galvanic Stimulation (tDCS) in Chronic Stroke|Combine Mechanized Gait Trainer and Transcranial Direct Current Stimulation in Chronic Stroke Patients: Randomized Control Trial|Completed||N/A|30|Actual|Universita di Verona||3|||f||||t||||||||||2018-06-01 00:13:42.515341|2018-06-01 00:13:42.515341
NCT01040286|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-27|||2010-07-05|2009-12-28|2009-12-29|Estimate|||||||2010-07-05|2010-07-07|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|||||Interventional|||The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis|The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis|Completed||Phase 2|||Dexcel Pharma Technologies Ltd.||2|||f||||f||||||||||2018-06-01 00:13:42.652308|2018-06-01 00:13:42.652308
NCT01040273|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2009-12-27|2009-12-27|2009-12-29|Estimate|||||||2009-12-27|2009-12-29|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||December 2010|Anticipated|2010-12-31||Interventional|||Management of Postoperative Pain After Total Hip Arthroplasty||Unknown status|Not yet recruiting|Phase 2/Phase 3|||Chang Gung Memorial Hospital||2|||f||||||||||||||2018-06-01 00:13:42.725481|2018-06-01 00:13:42.725481
NCT01040260|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-27|2013-06-23||2013-06-23|2009-12-28|2009-12-29|Estimate|2013-06-23|2013-08-30|Estimate||||2013-06-23|2013-08-30|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Low-Cost Contingency Management for Smoking Cessation|Low-Cost Contingency Management for Smoking Cessation|Completed||N/A|103|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:13:42.799356|2018-06-01 00:13:42.799356
NCT01040247|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2015-06-21|2009-12-28|2009-12-29|Estimate|||||||2015-06-21|2015-06-23|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Optimal Timing For Embryo Transfer For Low Responder Patients||Terminated||N/A|20|Actual|HaEmek Medical Center, Israel||2||Difficulty in recruiting patients|f||||||||||||||2018-06-01 00:13:43.043077|2018-06-01 00:13:43.043077
NCT01040234|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2015-10-21|2009-12-28|2009-12-29|Estimate|||||||2015-10-21|2015-10-23|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Bilateral Dual TAP Block: Description of a Novel Four-point Approach|Ultrasound-guided Bilateral Dual Transversus Abdominis Plane (BD-TAP) Block: Description of a Novel Four-point Ultrasound-guided TAP Block Approach|Completed|||30|Actual|Bispebjerg Hospital|||1||f||||t||||||||||2018-06-01 00:13:43.126566|2018-06-01 00:13:43.126566
NCT01040221|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2018-03-30|2009-12-28|2009-12-29|Estimate|||||||2018-03-30|2018-04-03|Actual|November 2012||2012-11-30|March 2018|2018-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|TSO||Trichuris Suis Ova in Autism Spectrum Disorders|Trichuris Suis Ova in Autism Spectrum Disorders|Completed||Phase 1|10|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-06-01 00:13:43.209815|2018-06-01 00:13:43.209815
NCT01040208|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|2013-06-06||2016-07-14|2009-12-28|2009-12-29|Estimate|2016-07-14|2016-08-24|Estimate||||2016-07-14|2016-08-24|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress|Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire|Terminated||Phase 3|111|Actual|Sprout Pharmaceuticals, Inc||3||Study terminated by Sponsor for administrative reasons prior to completion|f||||t||||||||||2018-06-01 00:13:43.293818|2018-06-01 00:13:43.293818
NCT01040195|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-25|||2013-03-21|2009-12-28|2009-12-29|Estimate|||||||2013-03-21|2013-03-22|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain|A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs (DMARDs) vs Monotherapy (Sulfasalazine) in Patients With Inflammatory Low Backache in Early Seronegative Spondylarthropathy|Completed||Phase 3|33|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:13:43.714623|2018-06-01 00:13:43.714623
NCT01040182|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-27|||2010-12-01|2009-12-28|2009-12-29|Estimate|||||||2010-12-01|2010-12-03|Estimate|December 2009||2009-12-31|December 2010|2010-12-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|||Polymorphism of Estrogen Genes in Stroke|Polymorphism of Estrogen Genes in Stroke|Unknown status|Recruiting||300|Anticipated|Taipei Medical University WanFang Hospital|||2||f||||f||||||Samples With DNA|"~     Buffy coat and plasma will be retained.~   "|||2018-06-01 00:13:43.789835|2018-06-01 00:13:43.789835
NCT01040156|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2009-12-28|2009-12-28|2009-12-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|August 2008||2008-08-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation|Safety, Feasibility and Efficacy of Caspofungin Versus Liposomal Amphotericin B as Antifungal Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients - a Retrospective Phase I/II Study|Completed|||||University Children’s Hospital Tuebingen|||2||f||||t||||||||||2018-06-01 00:13:44.164073|2018-06-01 00:13:44.164073
NCT01040143|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2010-09-02|2009-12-28|2009-12-29|Estimate|||||||2010-09-02|2010-09-03|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|Pneucast||A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci|A Study to Assess the Impact of Pneumococcal Conjugate Vaccination Programme on the Carriage of Pneumococci|Completed|||450|Anticipated|Public Health England|||||f||||f||||||||||2018-06-01 00:13:44.234475|2018-06-01 00:13:44.234475
NCT01040130|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|2014-03-28||2014-07-04|2009-12-28|2009-12-29|Estimate|2014-07-04|2014-07-08|Estimate||||2014-07-04|2014-07-08|Estimate|January 2010||2010-01-31|July 2014|2014-07-31||||April 2011|Actual|2011-04-30||Interventional|||Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I|Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|151|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 00:13:44.347476|2018-06-01 00:13:44.347476
NCT01040117|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2012-03-14|2009-12-28|2009-12-29|Estimate|||||||2012-03-14|2012-03-15|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Sensori-motor Integration Training in Multiple Sclerosis|Effects of Sensori-motor Integration Balance Training on Balance Disturbances in Patients With Multiple Sclerosis|Completed||Early Phase 1|80|Actual|Universita di Verona||2|||f||||t||||||||||2018-06-01 00:13:45.184296|2018-06-01 00:13:45.184296
NCT01040104|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-28|||2013-11-10|2009-12-28|2009-12-29|Estimate|||||||2013-11-10|2013-11-13|Estimate|July 2009||2009-07-31|November 2013|2013-11-30||||July 2011|Actual|2011-07-31||Observational|RESOLVE||Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals|Pilot Study of Prospective Clinical Trials on Skin Wound Healing in Young and Aged Individuals|Completed|||51|Actual|Medical University of Vienna|||8||f||||t||||||Samples With DNA|"~     Skin biopsy Blood samples~   "|||2018-06-01 00:13:45.262185|2018-06-01 00:13:45.262185
NCT01040091|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2016-12-15|2009-12-23|2009-12-25|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status|Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep)|Completed||Phase 1|34|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-06-01 00:13:45.357172|2018-06-01 00:13:45.357172
NCT01040078|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2009-12-29|2009-12-24|2009-12-25|Estimate|||||||2009-12-29|2009-12-30|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|June 2010|Anticipated|2010-06-30|February 2010|Anticipated|2010-02-28||Interventional|||Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month||Unknown status|Recruiting|Phase 3|900|Anticipated|Centers for Disease Control and Prevention, China||3|||f||||t||||||||||2018-06-01 00:13:45.464814|2018-06-01 00:13:45.464814
NCT01040065|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2011-06-28|2009-12-24|2009-12-25|Estimate|||||||2011-06-28|2011-06-29|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|February 2010|Actual|2010-02-28||Observational|||Distal Clavicle Resection With Rotator Cuff Repair|Distal Clavicle Resection of Symptomatic Acromioclavicular Joint Arthritis Combined With Rotator Cuff Tear. Prospective Randomized Trial|Unknown status|Recruiting||60|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-06-01 00:13:45.528994|2018-06-01 00:13:45.528994
NCT01040052|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|2011-03-01||2016-04-12|2009-12-24|2009-12-25|Estimate|2011-03-01|2011-03-29|Estimate||||2016-04-12|2016-05-16|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||A Study to Assess the Safety of Adacel® Vaccine|A Bridging Study to Assess the Safety of the Vaccine Adacel® in a Clinical Trial|Completed||Phase 3|30|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:13:45.599261|2018-06-01 00:13:45.599261
NCT01040039|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2013-05-16|2009-12-23|2009-12-25|Estimate|||||||2013-05-16|2013-05-17|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV|Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV|Terminated|||20|Anticipated|Rockefeller University|||2|Investigator left Rockefeller University|f||||f||||||Samples With DNA|"~     whole blood, mucosal samples~   "|||2018-06-01 00:13:45.77597|2018-06-01 00:13:45.77597
NCT01040026|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-11-13|2009-12-24|2009-12-25|Estimate|||||||2017-11-13|2017-11-14|Actual|December 2010||2010-12-31|November 2017|2017-11-30|November 2021|Anticipated|2021-11-30|September 2016|Actual|2016-09-30||Interventional|||Expanded Natural Killer (NK) Cells for Multiple Myeloma Study|A Phase I/II Single Center Study to Assess Tolerability and Feasibility of Infusions of Allogeneic Expanded Haploidentical Natural Killer (NK) Cells in Patients Treated With High Dose Melphalan Chemotherapy and Autologous Stem Cell Transplantation for a Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 00:13:45.925682|2018-06-01 00:13:45.925682
NCT01040013|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2009-12-24|2009-12-24|2009-12-25|Estimate|||||||2009-12-24|2009-12-25|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Gut Oxygenation and Laparoscopy|GUT OXYGENATION DURING AND AFTER LAPAROSCOPIC AND OPEN COLON RESECTION. A RANDOMIZAD CLINICAL TRIAL|Completed||Phase 2|40|Actual|University of Milano Bicocca||2|||f||||f||||||||||2018-06-01 00:13:46.000677|2018-06-01 00:13:46.000677
NCT01040000|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-08-03|2009-12-23|2009-12-25|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2012||2012-01-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer|A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy|Completed||Phase 1/Phase 2|94|Actual|Precision Biologics, Inc||1|||f||||f||||||||||2018-06-01 00:13:46.093239|2018-06-01 00:13:46.093239
NCT01039987|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-08-14|2009-12-24|2009-12-25|Estimate|||||||2017-08-14|2017-08-17|Actual|September 1999||1999-09-30|August 2017|2017-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|CRISP II||Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease|Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) II|Completed|||211|Actual|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     blood, urine~   "|||2018-06-01 00:13:46.178995|2018-06-01 00:13:46.178995
NCT01039974|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-06-19|2009-12-23|2009-12-25|Estimate|||||||2017-06-19|2017-06-20|Actual|September 18, 2009|Actual|2009-09-18|June 2017|2017-06-30|November 30, 2009|Actual|2009-11-30|November 30, 2009|Actual|2009-11-30||Interventional|||GSK962040 Drug-drug Interaction Study With Ketoconazole|An Open-label, Randomized, Single Sequence, Two Period Study to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of GSK962040 in Healthy Volunteers|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:13:46.241639|2018-06-01 00:13:46.241639
NCT01039961|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-06-13|2009-12-23|2009-12-25|Estimate|||||||2017-06-13|2017-06-14|Actual|February 2, 2010|Actual|2010-02-02|June 2017|2017-06-30|April 15, 2010|Actual|2010-04-15|April 15, 2010|Actual|2010-04-15||Interventional|||PK Study of IV Formulation of GW856553|Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Dose(s) and a Single Oral Dose of GW856553 in Healthy Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:13:46.355076|2018-06-01 00:13:46.355076
NCT01039948|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2015-04-06|2009-12-24|2009-12-25|Estimate|||||||2015-04-06|2015-04-08|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer|A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162)|Completed||Phase 1/Phase 2|203|Actual|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:13:46.519777|2018-06-01 00:13:46.519777
NCT01039935|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-09-05|2009-12-24|2009-12-25|Estimate|||||||2012-09-05|2012-09-06|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Genetic Basis of Odor Discrimination|Genetic Basis of Odor Discrimination|Completed|||512|Actual|Rockefeller University|||||f||||f||||||Samples With DNA|"~     Blood sample taken~   "|||2018-06-01 00:13:46.653286|2018-06-01 00:13:46.653286
NCT01039922|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2017-04-18|2009-12-24|2009-12-25|Estimate|||||||2017-04-18|2017-04-19|Actual|January 2008||2008-01-31|April 2017|2017-04-30|January 2028|Anticipated|2028-01-31|January 2028|Anticipated|2028-01-31||Observational|SwissNET||SwissNET - a Registry for Neuroendocrine Tumours in Switzerland|SwissNET - a Prospective Registry of Patients With Neuroendocrine Tumours in Switzerland|Recruiting|||1245|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-06-01 00:13:46.714489|2018-06-01 00:13:46.714489
NCT01039909|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2015-04-15|2009-12-23|2009-12-25|Estimate|||||||2015-04-15|2015-04-17|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2||Subjects were never screened/enrolled|f||||f||||||||||2018-06-01 00:13:46.794061|2018-06-01 00:13:46.794061
NCT01039896|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2013-02-11|2009-12-23|2009-12-25|Estimate|||||||2013-02-11|2013-02-13|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||A Drug Interaction Study of SLM0807 and HKB0701 in Healthy Subjects|An Open-label, Randomized, Crossover Study to Evaluate the Safety and Pharmacokinetics After Multiple Administration of SLM0807 Alone and Multiple Co-administration of HKB0701/SLM0807 in Korean Healthy Subjects|Completed||Phase 1|24|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-06-01 00:13:46.85976|2018-06-01 00:13:46.85976
NCT01039883|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-06-21|2009-12-24|2009-12-25|Estimate|||||||2017-06-21|2017-06-22|Actual|November 23, 2009|Actual|2009-11-23|June 2017|2017-06-30|January 20, 2010|Actual|2010-01-20|January 20, 2010|Actual|2010-01-20||Interventional|||A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule|A Phase 1, Randomized, Open-Label, Crossover Safety and Pharmacokinetic Study of 400 mg Albaconazole as a Tablet Formulation Versus a Capsule Formulation in Healthy Subjects|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:13:46.924618|2018-06-01 00:13:46.924618
NCT01039870|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-02-16|2009-12-24|2009-12-25|Estimate|||||||2012-02-16|2012-02-20|Estimate|July 2010||2010-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Effect of Paravertebral Block Using a Multi-orifice Catheter on Preventing Acute and Chronic Post-thoracotomy Pain||Completed||N/A|90|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:13:47.010983|2018-06-01 00:13:47.010983
NCT01039857|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2015-07-08|2009-12-24|2009-12-25|Estimate|||||||2015-07-08|2015-07-10|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Interventional|||Does an Integrative Neuro-psychotherapy Program Foster the Adjustment in Depressed Stroke Patients? A Randomized Controlled Study.|Does an Integrative Neuro-psychotherapy Program Foster the Adjustment in Depressed Stroke Patients? A Randomized Controlled Study.|Terminated||Phase 1|25|Actual|University of Bern||2||Project end after 3 years; prolongation was rejected|f||||f||||||||||2018-06-01 00:13:47.085358|2018-06-01 00:13:47.085358
NCT01039844|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2016-10-26|2009-12-23|2009-12-25|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of Weekly LOC-paclitaxel Injection for Melanoma|Phase I Study of Weekly LOC-paclitaxel Injection|Terminated||Phase 1|37|Actual|M.D. Anderson Cancer Center||1||Poor Accrual|f||||f||||||||||2018-06-01 00:13:47.169343|2018-06-01 00:13:47.169343
NCT01039831|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-24|2009-12-24|2009-12-25|Estimate|||||||2009-12-24|2009-12-25|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|January 2012|Anticipated|2012-01-31|||||Observational|||White Matter Pathology in Parkinson's Disease (PD)|The Role of White Matter Pathology in the Development of the Postural Instability and Gait Disturbance (PIGD) Type of Parkinson's Disease (PD)|Unknown status|Not yet recruiting||120|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-06-01 00:13:47.256999|2018-06-01 00:13:47.256999
NCT01039818|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2012-09-04|2009-12-24|2009-12-25|Estimate|||||||2012-09-04|2012-09-06|Estimate|February 1997||1997-02-28|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism|Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism: A Clinical Trial With Historical Control|Completed||Phase 3|30|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:13:47.322493|2018-06-01 00:13:47.322493
NCT01039649|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2015-01-16|2009-12-24|2009-12-25|Estimate|||||||2015-01-16|2015-01-19|Estimate|June 2009||2009-06-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|PFS||A Study to Test Lung Function After Radiation Therapy|Quantifying Radiation Induced Changes in Pulmonary Function in Irradiated and Non-irradiated Lung Tissue|Completed|||50|Actual|University of Iowa|||1||f||||t||||||||||2018-06-01 00:13:57.956225|2018-06-01 00:13:57.956225
NCT01039805|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23||2012-03-01|2017-01-27|2009-12-24|2009-12-25|Estimate||||2012-03-01|2012-03-05|Estimate|2017-01-27|2017-01-30|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance|A Double-blind, Randomized, Placebo Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Critically Ill Male and Female Patients With Enteral Feed Intolerance|Completed||Phase 2|34|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:13:47.397433|2018-06-01 00:13:47.397433
NCT01039792|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2016-11-04||2017-01-04|2009-12-24|2009-12-25|Estimate|2017-01-04|2017-02-24|Actual||||2017-01-04|2017-02-24|Actual|January 2010||2010-01-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|B12|Greater number of subjects (N=50) and thus larger power (93%), than the pilot study (N=30) was necessary to determine efficacy of methyl B12.|Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism|Double Blind Placebo Controlled Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism|Completed||Phase 2/Phase 3|57|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:13:47.525106|2018-06-01 00:13:47.525106
NCT01039779|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2015-05-18|2009-12-24|2009-12-25|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Tai Chi Exercise in Older People|A Randomized Trial of Tai Chi Exercise on Reducing Falls in Older Taiwanese People|Completed||N/A|456|Actual|Taipei Medical University||2|||f||||t||||||||||2018-06-01 00:13:47.79269|2018-06-01 00:13:47.79269
NCT01039766|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2010-02-07|2009-12-23|2009-12-25|Estimate|||||||2010-02-07|2010-02-09|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Interventional|||The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)|The Efficacy of the Proximate Administration of Oxytocin After a Traumatic Event in Preventing the Development of Post Traumatic Stress Disorder|Unknown status|Recruiting|N/A|24|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 00:13:47.876799|2018-06-01 00:13:47.876799
NCT01039753|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2010-01-28|2009-12-24|2009-12-25|Estimate|||||||2010-01-28|2010-01-29|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Observational|||Analysis of Clinical Outcomes in Patients Undergoing Acute Dialysis Therapy at Intensive Care Units|Analysis of Clinical Outcomes in Patients Undergoing Acute Dialysis Therapy at Intensive Care Units|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     Collect serum and urine sample for biomarkers at the following timing: start date of renal~     replacement therapy, discontinuation date of renal replacement therapy, 7 days after~     discontinuation date of renal replacement therapy. 10ml blood and 10ml urine will be~     collected at each sampling~   "|||2018-06-01 00:13:47.990292|2018-06-01 00:13:47.990292
NCT01039740|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2015-12-30|2009-12-23|2009-12-25|Estimate|||||||2015-12-30|2015-12-31|Estimate|February 2003||2003-02-28|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pharmacogenetic Study of Mirtazapine Response in Depressed Patients|Pharmacogenetic Study of Mirtazapine Response in Depressed Patients|Recruiting||N/A|100|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:13:48.059674|2018-06-01 00:13:48.059674
NCT01039727|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2011-07-15|2009-12-24|2009-12-25|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2011||2011-09-30|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|September 2012|Anticipated|2012-09-30||Interventional|PALPI||Prerecorded Autosuggestion in Long-standing Pain Intervention|Prerecorded Autosuggestion in Long-standing Pain Intervention|Unknown status|Not yet recruiting|N/A|100|Anticipated|Free University Medical Center||3|||f||||f||||||||||2018-06-01 00:13:48.133139|2018-06-01 00:13:48.133139
NCT01039714|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-12-24|2009-12-24|2009-12-25|Estimate|||||||2009-12-24|2009-12-25|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Observational|||Vitamin D Levels and Postoperative Hypocalcemia After Total Thyroidectomy|Preoperative Vitamin D Levels as a Prognostic Factor for Postoperative Hypocalcemia and Hypoparathyroidism After Total Thyroidectomy|Unknown status|Recruiting||200|Anticipated|Aristotle University Of Thessaloniki|||1||f||||f||||||||||2018-06-01 00:13:48.208902|2018-06-01 00:13:48.208902
NCT01039701|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2010-08-10|2009-12-24|2009-12-25|Estimate|||||||2010-08-10|2010-08-11|Estimate|December 2009||2009-12-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ROBIN||4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease|Safety, Tolerability and Pharmacokinetics of 3 Dose Regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo Controlled, Parallel Group Phase IIa Study in Patients With Mild to Moderate Alzheimer's Disease During 4 Weeks of Treatment|Completed||Phase 2|99|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:13:48.281687|2018-06-01 00:13:48.281687
NCT01039688|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2014-03-10||2018-03-08|2009-12-23|2009-12-25|Estimate|2018-03-08|2018-04-06|Actual||||2018-03-08|2018-04-06|Actual|January 2010|Actual|2010-01-31|March 2018|2018-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ORAL1069|All participants randomized to the study who received at least 1 dose of study drug (CP-690,550) or MTX.|Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX|Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis|Completed||Phase 3|956|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 00:13:48.942768|2018-06-01 00:13:48.942768
NCT01039675|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2013-12-19|2012-03-15|2017-10-09|2009-12-23|2009-12-25|Estimate|2013-12-19|2014-02-10|Estimate|2012-03-15|2012-03-19|Estimate|2017-10-09|2017-11-08|Actual|January 1, 2010||2010-01-01|October 2017|2017-10-31|April 20, 2010|Actual|2010-04-20|April 1, 2010|Actual|2010-04-01||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD|Completed||Phase 2|51|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:13:57.626371|2018-06-01 00:13:57.626371
NCT01039662|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2011-06-22|2009-12-24|2009-12-25|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin|Effects of the Combination of L-Arabinose and Indigestible Dextrin on Glycemic Index: a Double-Blind, Crossover Trial|Completed||N/A|19|Actual|Hiroshima University||2|||f||||f||||||||||2018-06-01 00:13:57.902596|2018-06-01 00:13:57.902596
NCT01039636|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-02-08|2009-12-23|2009-12-25|Estimate|||||||2012-02-08|2012-02-10|Estimate|November 2009||2009-11-30|January 2011|2011-01-31||||December 2010|Actual|2010-12-31||Interventional|||Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload|A PHASE 1b OPEN LABEL, MULTI-CENTER, ESCALATING MULTIPLE DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF FBS0701 IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD|Completed||Phase 1|20|Actual|FerroKin BioSciences, Inc.||1|||f||||f||||||||||2018-06-01 00:13:58.023646|2018-06-01 00:13:58.023646
NCT01039623|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2009-12-24|2009-12-24|2009-12-25|Estimate|||||||2009-12-24|2009-12-25|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|April 2012|Anticipated|2012-04-30|December 2011|Anticipated|2011-12-31||Interventional|||Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference|Randomized Assessment of Safety and Immunogenicity of Intradermal Unadjuvanted Portion of Pandemrix® Via a Microneedle Device With Intramuscular Adjuvanted Pandemrix® as Reference|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 00:13:58.090016|2018-06-01 00:13:58.090016
NCT01039610|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2015-04-20|2009-12-23|2009-12-25|Estimate|||||||2015-04-20|2015-04-22|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|August 2010|Anticipated|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.|A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||9||Internal decision to progress alternate molecule with more preferable profile|f||||f||||||||||2018-06-01 00:13:58.154035|2018-06-01 00:13:58.154035
NCT01039597|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2011-06-07|2009-12-24|2009-12-25|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|June 2011|Anticipated|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Therapeutic Activity of ORE1001 in Subjects With Ulcerative Colitis|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Ore Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:13:58.355316|2018-06-01 00:13:58.355316
NCT01039584|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2012-09-10|2012-03-15|2012-12-12|2009-12-24|2009-12-25|Estimate|2012-12-12|2013-01-21|Estimate|2012-03-15|2012-03-19|Estimate|2012-12-12|2013-01-21|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations|A Randomized Study Evaluating the Therapeutic Equivalence and Safety of Butoconazole Nitrate Vaginal Cream, 2% and Gynazole 1 (Butoconazole Nitrate) Vaginal Cream, 2%, Against a Vehicle Control in the Treatment of Vulvovaginal Candidiasis|Completed||N/A|611|Actual|Perrigo Company||3|||f||||f||||||||||2018-06-01 00:13:58.478186|2018-06-01 00:13:58.478186
NCT01039571|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2011-04-21|2009-12-24|2009-12-25|Estimate|||||||2011-04-21|2011-04-22|Estimate|January 2005||2005-01-31|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears|Prospective Randomized Case-controlled Blinded Study of Single Versus Double Row Suture Anchor Repair in Medium to Large Rotator Cuff Tears|Completed|||71|Actual|Samsung Medical Center|||||f||||f||||||||||2018-06-01 00:13:58.805822|2018-06-01 00:13:58.805822
NCT01039558|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2011-07-27|2009-12-24|2009-12-25|Estimate|||||||2011-07-27|2011-07-28|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease|Randomized Controlled Trial to Evaluate the Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease|Completed||N/A|30|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:13:58.865431|2018-06-01 00:13:58.865431
NCT01039545|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2015-07-08|2009-12-24|2009-12-25|Estimate|||||||2015-07-08|2015-07-09|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.|Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting. A Randomized, Double Blind Trial|Terminated||Phase 4|253|Actual|University Hospital Inselspital, Berne||2||New power calculation (reduction of necessary patient number)|f||||f||||||||||2018-06-01 00:13:58.943094|2018-06-01 00:13:58.943094
NCT01039532|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2015-10-23|2009-12-24|2009-12-25|Estimate|||||||2015-10-23|2015-10-26|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Comparison of Thrice Daily Biphasic Human Insulin With Basal Bolus Regimen in Type 2 Diabetes Mellitus Patients|Comparison of Thrice Daily Biphasic Human Insulin Versus Basal Detemir and Bolus Aspart in Patients With Poorly Controlled Type 2 Diabetes Mellitus|Completed|||50|Actual|Postgraduate Institute of Medical Education and Research|||2||f||||t||||||||||2018-06-01 00:13:59.010143|2018-06-01 00:13:59.010143
NCT01039519|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2016-02-11|2014-01-31|2016-02-11|2009-12-24|2009-12-25|Estimate|2016-02-11|2016-03-10|Estimate|2014-01-31|2014-03-04|Estimate|2016-02-11|2016-03-10|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Full analysis set, which includes participants given at least one dose of study medication.|A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)|A Non-randomized, Open Label, Multi-center Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Patients With Metastatic and/or Unresectable GIST Resistant or Refractory to Prior Systemic Treatments Including Imatinib and Sunitinib|Completed||Phase 2|27|Actual|Synta Pharmaceuticals Corp.||1|||f||||t||||||||||2018-06-01 00:13:59.175941|2018-06-01 00:13:59.175941
NCT01039506|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2013-03-28|2009-12-23|2009-12-25|Estimate|||||||2013-03-28|2013-03-29|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Observational|||An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in mCRC|A Prospective Observational Study of the Efficacy and Safety of CPT-11 Based Regimens for UGT1A1 Genotype Guided Patients With Metastatic Colorectal Cancer|Unknown status|Active, not recruiting||2000|Anticipated|Daiichi Sankyo Co., Ltd.|||1||f||||t||||||Samples With DNA|"~     white cells~   "|||2018-06-01 00:13:59.58632|2018-06-01 00:13:59.58632
NCT01039493|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2015-09-30|2009-12-23|2009-12-25|Estimate|||||||2015-09-30|2015-10-02|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications|Living With Cervical Cancer: Assessing Utilities Associated With Common Treatment Complications|Completed|||40|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-06-01 00:13:59.659791|2018-06-01 00:13:59.659791
NCT01039480|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-02-08|2009-12-24|2009-12-25|Estimate|||||||2012-02-08|2012-02-09|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Observational|||Aspirin and Clopidogrel Resistance Study|Aspirin- and Clopidogrel-Resistance: Non-compliance and Other Contributing Factors|Completed|||82|Actual|University Hospital, Basel, Switzerland|||3||f||||f||||||Samples With DNA|"~     blood samples for routine laboratory testing and platelet aggregometry blood samples for~     pharmacogenetic analysis~   "|||2018-06-01 00:13:59.728542|2018-06-01 00:13:59.728542
NCT01039467|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-08-20|2009-12-23|2009-12-25|Estimate|||||||2012-08-20|2012-08-22|Estimate|June 2009||2009-06-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|COMPARE||An Comparison of the Pacemaker Automatic Features in Reduction of Ventricular Pacing|Study of an Comparison of the Pacemaker Automatic Features in Reduction of Ventricular Pacing|Completed||N/A|385|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-06-01 00:13:59.79813|2018-06-01 00:13:59.79813
NCT01039454|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-06-16|2009-12-23|2009-12-25|Estimate|||||||2017-06-16|2017-06-20|Actual|December 18, 2008|Actual|2008-12-18|June 2017|2017-06-30|April 26, 2010|Actual|2010-04-26|April 26, 2010|Actual|2010-04-26||Interventional|||Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement|A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects.|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:13:59.905791|2018-06-01 00:13:59.905791
NCT01039441|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-23|2009-12-23|2009-12-25|Estimate|||||||2009-12-23|2009-12-25|Estimate|December 2008||2008-12-31|October 2008|2008-10-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||The Effect of Local Anesthesia and Simple Maneuver on Shoulder Pain After Gynecologic Laparoscopy|The Effect of Local Anesthesia and Simple Maneuver on Shoulder Pain After Gynecologic Laparoscopy|Completed||Phase 2|291|Actual|Samsung Medical Center||4|||f||||f||||||||||2018-06-01 00:13:59.998945|2018-06-01 00:13:59.998945
NCT01039428|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|2012-02-29||2015-08-31|2009-12-24|2009-12-25|Estimate|2012-05-01|2012-06-01|Estimate||||2015-08-31|2015-09-14|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia||Completed||Phase 2|68|Actual|KDL Inc.||2|||f||||t||||||||||2018-06-01 00:14:00.082836|2018-06-01 00:14:00.082836
NCT01039415|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2016-10-27|2009-12-24|2009-12-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Attempts to Stop/Reduce Marijuana Among Dependent Users|Attempts to Stop/Reduce Marijuana Among Dependent Users|Completed|||234|Actual|University of Vermont|||||f||||f||||||||||2018-06-01 00:14:00.49729|2018-06-01 00:14:00.49729
NCT01039402|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2010-09-14|2009-12-24|2009-12-25|Estimate|||||||2010-09-14|2010-09-16|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Connection Between General Practitioner's (GP's) Estimation of Cardiovascular Risk and Theoretical Calculation in France|Connection Between GP's Estimation of Cardiovascular Risk and Theoretical Calculation in France|Completed|||13502|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:14:00.624698|2018-06-01 00:14:00.624698
NCT01039389|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-24|||2013-07-11|2009-12-24|2009-12-25|Estimate|||||||2013-07-11|2013-07-12|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease|Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease|Completed||N/A|43|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 00:14:01.087537|2018-06-01 00:14:01.087537
NCT01039376|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2015-02-12||2018-04-17|2009-12-24|2009-12-25|Estimate|2015-04-02|2015-04-21|Estimate||||2018-04-17|2018-05-16|Actual|May 6, 2010|Actual|2010-05-06|April 2018|2018-04-30|June 29, 2018|Anticipated|2018-06-29|June 19, 2014|Actual|2014-06-19||Interventional|PROLONG||Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy|A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy|Active, not recruiting||Phase 3|480|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:14:01.270724|2018-06-01 00:14:01.270724
NCT01039363|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-24|2009-12-24|2009-12-25|Estimate|||||||2009-12-24|2009-12-25|Estimate||||October 2009|2009-10-31||||||||Interventional|||Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia|Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older|Unknown status|Not yet recruiting|Phase 2|27|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-06-01 00:14:03.569816|2018-06-01 00:14:03.569816
NCT01039350|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2010-01-12|2009-12-23|2009-12-24|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2006||2006-02-28|January 2010|2010-01-31|July 2009|Anticipated|2009-07-31|July 2008|Anticipated|2008-07-31||Interventional|||Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.|Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.|Terminated||Phase 2|80|Actual|Fundacion para el Estudio de la Hematologia y Hemoterapia en Aragon||||It was stopped due to a lack of recruitment after 48 patients included|f||||f||||||||||2018-06-01 00:14:03.733643|2018-06-01 00:14:03.733643
NCT01039337|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2016-03-29|2009-12-23|2009-12-24|Estimate|||||||2016-03-29|2016-03-30|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|COHART||Conservative Treatment for Hip Osteoarthritis|Conservative Treatment for Hip Osteoarthritis: Effect of Manual Treatment and Hip School on Pain, Disability and Quality of Life - a Single-blinded Randomized Controlled Trial|Completed||N/A|118|Actual|Nordic Institute of Chiropractic and Clinical Biomechanics||3|||f||||f||||||||||2018-06-01 00:14:03.841633|2018-06-01 00:14:03.841633
NCT01039324|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2014-05-14|2009-12-23|2009-12-24|Estimate|||||||2014-05-14|2014-05-15|Estimate|December 2009||2009-12-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Care Transitions for Complex Patient - Cycle 1 and Cycle 2|Improving Care Transitions for Complex Patients Through Decision Support|Completed||N/A|8422|Actual|Duke University||3|||f||||f||||||||||2018-06-01 00:14:03.933649|2018-06-01 00:14:03.933649
NCT01039129|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2015-08-19|2009-12-23|2009-12-24|Estimate|||||||2015-08-19|2015-08-21|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Hybrid Transvaginal-Transabdominal Endoscopic Surgery|Hybrid Transvaginal-Transabdominal Endoscopic Surgery|Withdrawn||N/A|0|Actual|St. Luke's-Roosevelt Hospital Center||3||unable to recruit participants|f||||f||||||||||2018-06-01 00:14:06.467135|2018-06-01 00:14:06.467135
NCT01039311|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2013-01-31|2009-12-23|2009-12-24|Estimate|||||||2013-01-31|2013-02-01|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|OCT||Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer|Optical Coherence Tomography: An Adjunct to Flexible Bronchoscopy in the Diagnosis of Lung Cancer|Terminated|||16|Actual|University of Oklahoma|||1|Unable to enroll subjects|f||||t||||||||||2018-06-01 00:14:04.025512|2018-06-01 00:14:04.025512
NCT01039298|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2014-09-08|2009-12-23|2009-12-24|Estimate|||||||2014-09-08|2014-09-10|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL|Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS|Unknown status|Recruiting|Phase 3|200|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-06-01 00:14:04.097805|2018-06-01 00:14:04.097805
NCT01039285|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-08-28|2009-12-23|2009-12-24|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2009|Actual|2009-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2012|Actual|2012-12-31||Interventional|CURDYS||Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia|Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia|Active, not recruiting||Phase 4|100|Anticipated|Maternite Regionale Universitaire||2|||f||||t||||||||||2018-06-01 00:14:04.209396|2018-06-01 00:14:04.209396
NCT01039272|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2015-06-24|2009-12-22|2009-12-24|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2008|Actual|2008-04-30||Observational|||Epstein-Barr Detection in Oral Cancer|Epstein-Barr Detection in Squamous Cell Carcinoma and Healthy Oral Mucosa|Completed|||60|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||t||||||Samples With DNA|"~     paraffin-embedded tissue samples~   "|||2018-06-01 00:14:04.285786|2018-06-01 00:14:04.285786
NCT01039259|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|August 2008||2008-08-31|January 2009|2009-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||The Impact of Material on Microbiota in Association With Tongue and Lip Piercing||Completed|||170||Medical University Innsbruck|||2||f||||||||||||||2018-06-01 00:14:04.349187|2018-06-01 00:14:04.349187
NCT01039233|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|May 2005||2005-05-31|December 2009|2009-12-31|July 2005|Actual|2005-07-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting Conditions|Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|60|Actual|Kremers Urban Development Company||2|||f||||t||||||||||2018-06-01 00:14:04.414556|2018-06-01 00:14:04.414556
NCT01039220|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2017-04-27|2009-12-23|2009-12-24|Estimate|||||||2017-04-27|2017-04-28|Actual|December 2009||2009-12-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ANRS 2H||Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients|Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients|Completed||N/A|1266|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||||2018-06-01 00:14:04.502789|2018-06-01 00:14:04.502789
NCT01039207|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2017-08-08||2017-08-08|2009-12-22|2009-12-24|Estimate|2017-08-08|2017-09-07|Actual||||2017-08-08|2017-09-07|Actual|October 2010||2010-10-31|August 2017|2017-08-31|July 2014|Actual|2014-07-31|July 2012|Actual|2012-07-31||Interventional||Eligible and treated patients.|Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of AMG 102 (Rilotumumab) (NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|31|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 00:14:04.574445|2018-06-01 00:14:04.574445
NCT01039194|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2011-01-24|2009-12-23|2009-12-24|Estimate|||||||2011-01-24|2011-01-25|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)|A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects|Completed||Phase 1|18|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:14:05.95722|2018-06-01 00:14:05.95722
NCT01039181|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Calcitriol in Advanced Intrahepatic Cholangiocarcinoma|A Clinical Trial Phase II of Calcitriol in Combination With 5-fluorouracil, Mitomycin C and Leucovorin in an Open Label-non-randomized Study to Evaluate the Tumor Response in Patients With Advanced Intrahepatic Cholangiocarcinoma|Unknown status|Not yet recruiting|Phase 2|28|Anticipated|National Science and Technology Development Agency, Thailand|||||f||||t||||||||||2018-06-01 00:14:06.045541|2018-06-01 00:14:06.045541
NCT01039168|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-22|2009-12-22|2009-12-24|Estimate|||||||2009-12-22|2009-12-24|Estimate|November 2003||2003-11-30|December 2009|2009-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|ADA model||Return to Work After a Workplace-oriented Intervention for Patients on Sick Leave Due to Burnout|Reduction of Person-job Mismatch to Increase Work Capacity, by Education of, and Dialogue Between Involved Parties - Evaluation of an Intervention Program|Completed||N/A|76|Actual|Region Skane||2|||f||||f||||||||||2018-06-01 00:14:06.141525|2018-06-01 00:14:06.141525
NCT01039155|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2015-10-05|2009-12-23|2009-12-24|Estimate|||||||2015-10-05|2015-10-06|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|July 2015|Actual|2015-07-31|September 2012|Actual|2012-09-30||Interventional|||Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy|A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy|Completed||Phase 1|41|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:14:06.298879|2018-06-01 00:14:06.298879
NCT01039142|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|March 2008||2008-03-31|February 2008|2008-02-29|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis|EFFICACY AND SAFETY OF ACITRETIN IN DOSES OF 25mg,35mg or50mg IN PATIENTS WITH SEVERE PLAQUE TYPE PSORIASIS: A RANDOMISED,DOUBLE BLIND , PARALLEL GROUP DOSE- RANGING STUDY|Completed||Phase 4|61|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||||||||||||2018-06-01 00:14:06.392611|2018-06-01 00:14:06.392611
NCT01039116|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2011-05-03|2009-12-23|2009-12-24|Estimate|||||||2011-05-03|2011-05-04|Estimate|March 2005||2005-03-31|March 2007|2007-03-31|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional|TAT||Taking Action Together- A Diabetes Prevention Program|Taking Action Together: Development, Implementation and Evaluation of Community-Based Programs That Aims to Reduce Risk of Type 2 Diabetes in High BMI African American Children.|Completed||N/A|240|Actual|University of California, Berkeley||1|||f||||f||||||||||2018-06-01 00:14:06.558166|2018-06-01 00:14:06.558166
NCT01039103|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2016-10-05|2009-12-22|2009-12-24|Estimate|||||||2016-10-05|2016-10-06|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)|A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)|Terminated||Phase 2|15|Actual|Galapagos NV||2|||f||||f||||||||||2018-06-01 00:14:06.652119|2018-06-01 00:14:06.652119
NCT01039090|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-11-30|2009-12-23|2009-12-24|Estimate|||||||2012-11-30|2012-12-03|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|August 2014|Anticipated|2014-08-31|February 2014|Anticipated|2014-02-28||Interventional|APO-TEP||Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease|Prospective, Randomised, Comparative Study Comparing Efficacy of Continuous Apomorphine Infusion Versus Usual Dopaminergic Per os Treatment on Cognitive and Neuropsychological Functions in Parkinson's Disease: a Clinical and PET-scan Study|Unknown status|Recruiting|Phase 3|30|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 00:14:06.76273|2018-06-01 00:14:06.76273
NCT01039077|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2015-08-05|2009-12-23|2009-12-24|Estimate|||||||2015-08-05|2015-08-06|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Single Incision Laparoscopic Gastric Banding Versus Conventional Five Port Laparoscopic Gastric Banding|Single Incision Laparoscopic Gastric Banding Versus Conventional Five Port Laparoscopic Gastric Banding|Completed||N/A|32|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||||||||||||2018-06-01 00:14:06.88823|2018-06-01 00:14:06.88823
NCT01039064|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:14:06.991363|2018-06-01 00:14:06.991363
NCT01039051|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|June 2009||2009-06-30|December 2009|2009-12-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Diet and Lifestyle Intervention Study in Postpartum Women in China|Randomized Controlled Trials of Diet and Lifestyle Intervention to Promote Chinese Postpartum Women's Health|Unknown status|Recruiting|Phase 2/Phase 3|1600|Anticipated|Huazhong University of Science and Technology||1|||f||||t||||||||||2018-06-01 00:14:07.030978|2018-06-01 00:14:07.030978
NCT01039038|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2011-11-24|2009-12-23|2009-12-24|Estimate|||||||2011-11-24|2011-11-28|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|CURIEBOOST||Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer|A Phase II Study Evaluating the Feasibility of a Dose Increase by a Boost of Curietherapy in PDR Associated With the Extern Radiotherapy in Intermediate Risk in the Prostate Cancer|Terminated||Phase 2|50|Anticipated|Centre Francois Baclesse||||lack of recruitment|f||||t||||||||||2018-06-01 00:14:07.108705|2018-06-01 00:14:07.108705
NCT01039025|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-07-31|2009-12-23|2009-12-24|Estimate|||||||2012-07-31|2012-08-01|Estimate|February 2002||2002-02-28|July 2012|2012-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma|Phase II Study of High-Dose Topotecan, Cyclophosphamide and Melphalan for the Treatment of Multiple Myeloma|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:14:07.160401|2018-06-01 00:14:07.160401
NCT01039012|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|June 2010|Anticipated|2010-06-30|February 2010|Anticipated|2010-02-28||Interventional|||Tai Chi for Osteopenic Women|Tai Chi for Osteopenic Women: A Pilot Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 2|86|Actual|Harvard University Faculty of Medicine||2|||f||||f||||||||||2018-06-01 00:14:07.247628|2018-06-01 00:14:07.247628
NCT01038999|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-12-26|2009-12-23|2009-12-24|Estimate|||||||2012-12-26|2012-12-27|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|April 2010|Actual|2010-04-30||Observational|EP 45||Accelerated Aging, HIV Infection, Antiretroviral Therapies|Accelerated Aging, HIV Infection, Antiretroviral Therapies|Completed|||200|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||3||f||||f||||||||||2018-06-01 00:14:07.31403|2018-06-01 00:14:07.31403
NCT01038986|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2013-01-30|2009-12-23|2009-12-24|Estimate|||||||2013-01-30|2013-01-31|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Observational|||A Post-marketing Observational Study of Cell Therapy for Chronic Wounds|A Post-marketing Multi-center Observational Study to Provide Data Describing the Safety and Effectiveness of CUREXCELL™ as it is Applied in a Real-life Setting for Treatment in Patients With Chronic and/or Refractory Wounds|Completed|||70|Actual|Macrocure Ltd.|||1||f||||f||||||||||2018-06-01 00:14:07.398019|2018-06-01 00:14:07.398019
NCT01038960|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2016-08-24|2009-12-23|2009-12-24|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ETHIC||Exercise Training in ICD Recipients; Effect on Therapy Delivered, Depression and Anxiety|Exercise Training to Reduce Ventricular Arrhythmia in Heart Failure Patients With ICD - The Ethic Study|Completed||Phase 3|40|Actual|Helse Stavanger HF||2|||f||||t||||||||No||2018-06-01 00:14:07.550584|2018-06-01 00:14:07.550584
NCT01038947|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-22|2009-12-22|2009-12-24|Estimate|||||||2009-12-22|2009-12-24|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Interventional|||Safety and Efficacy Study of Intramuscular Uricase-PEG 20|A Cohort Dose-Escalation Phase 1 Study of Intramuscular Injection of Uricase-PEG 20|Unknown status|Recruiting|Phase 1|28|Anticipated|EnzymeRx||1|||f||||f||||||||||2018-06-01 00:14:07.640505|2018-06-01 00:14:07.640505
NCT01038934|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|March 2006||2006-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||DNA of Oral Cytobrush in Three Means Conservation|Evaluation of Genomic DNA of Oral Cytobrush in Three Means Conservation|Completed||Early Phase 1|18|Actual|UPECLIN HC FM Botucatu Unesp||1|||f||||t||||||||||2018-06-01 00:14:07.733145|2018-06-01 00:14:07.733145
NCT01038921|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2013-08-13||2015-02-11|2009-12-23|2009-12-24|Estimate|2014-04-01|2014-05-01|Estimate||||2015-02-11|2015-02-27|Estimate|July 2009||2009-07-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional|MetSyn|Expected to enroll 40 subjects but only randomized 39 subjects|Melatonin and the Metabolic Syndrome|Melatonin Supplementation and the Metabolic Syndrome: A Phase II Crossover Design Clinical Trial|Completed||Phase 2|39|Actual|Emory University|Study was designed as a pilot Phase II cross-over design to study the safety of melatonin and to estimate the effect sizes associated with average changes while subjects were on melatonin versus average changes while subjects were on placebo.|2|||f||||t||||||||||2018-06-01 00:14:07.80579|2018-06-01 00:14:07.80579
NCT01038908|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2013-02-12|2009-12-22|2009-12-24|Estimate|||||||2013-02-12|2013-02-15|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Breast Lymph Node Mapping|Axillary Reverse Mapping in Breast Cancer|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:14:08.165679|2018-06-01 00:14:08.165679
NCT01038895|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|June 2011|Anticipated|2011-06-30|March 2010|Anticipated|2010-03-31||Interventional|||Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria||Unknown status|Recruiting|Phase 4|120|Anticipated|University of Pavia||2|||f||||f||||||||||2018-06-01 00:14:08.263347|2018-06-01 00:14:08.263347
NCT01038882|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Randomized Study With Midazolam for Sedation in Flexible Bronchoscopy|MIDAZOLAM EFFECTIVENESS TO THE SEDATION IN FLEXIBLE BRONCHOSCOPY. A RANDOMIZED STUDY|Completed||N/A|238|Actual|Hospital Universitario La Fe||2|||f||||t||||||||||2018-06-01 00:14:08.358507|2018-06-01 00:14:08.358507
NCT01038869|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2012-03-26||2012-08-24|2009-12-23|2009-12-24|Estimate|2012-08-24|2012-09-25|Estimate||||2012-08-24|2012-09-25|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)|Efficacy and Safety of Finacea in the Treatment of Post-Inflammatory Hyperpigmentation and Acne Vulgaris|Completed||Phase 4|20|Actual|Derm Research, PLLC|This is an open-label study with a small number of subjects.|1|||f||||f||||||||||2018-06-01 00:14:08.452749|2018-06-01 00:14:08.452749
NCT01038856|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2015-05-28||2018-01-10|2009-12-22|2009-12-24|Estimate|2018-01-10|2018-02-07|Actual||||2018-01-10|2018-02-07|Actual|December 2009||2009-12-31|January 2018|2018-01-31|February 2014|Actual|2014-02-28|December 2012|Actual|2012-12-31||Interventional|OSI-TAR-766|patients diagnosed with JAK2V617F-positive PV|Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera|Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera|Terminated||Phase 2|5|Actual|University of Oklahoma||1||The study was terminated by the sponsor|f||||t||||||||||2018-06-01 00:14:08.652357|2018-06-01 00:14:08.652357
NCT01038843|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22||2014-06-18|2014-06-18|2009-12-22|2009-12-24|Estimate||||2014-06-18|2014-06-20|Estimate|2014-06-18|2014-06-20|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy Study of VA106483 in Males With Nocturia.|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-titration Study to Determine the Efficacy and Safety of VA106483 in Male Subjects With Nocturia|Completed||Phase 2|152|Actual|Vantia Ltd||4|||f||||f||||||||||2018-06-01 00:14:08.870829|2018-06-01 00:14:08.870829
NCT01038830|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2010-06-11|2009-12-23|2009-12-24|Estimate|||||||2010-06-11|2010-06-14|Estimate|May 2008||2008-05-31|December 2009|2009-12-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|||QuantiFERON Change During Anti-tuberculosis Medication|The Change in Level of Interferon-gamma Assay in Active Tuberculosis Patients During Treatment|Completed|||50|Anticipated|Armed Forces Capital Hospital, Republic of Korea|||||f||||f||||||||||2018-06-01 00:14:08.975454|2018-06-01 00:14:08.975454
NCT01038817|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2016-05-09|2009-12-22|2009-12-24|Estimate|||||||2016-05-09|2016-05-10|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2013|Actual|2013-05-31||Interventional|VERNIS||Impact of Fluoride Vanish Application in Dental Prevention for Elderly|Evaluation of the Impact of Fluoride Vanish Application in Dental Prevention Among Institutionalised Elderly People|Completed||Phase 4|179|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:14:09.02763|2018-06-01 00:14:09.02763
NCT01038804|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22||2013-07-11|2013-09-12|2009-12-22|2009-12-24|Estimate||||2013-07-11|2013-07-15|Estimate|2013-09-12|2013-09-18|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer|A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer|Completed||Phase 2|101|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:14:09.112315|2018-06-01 00:14:09.112315
NCT01038791|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2014-10-08|2009-12-23|2009-12-24|Estimate|||||||2014-10-08|2014-10-09|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Patients-ventilator Interaction During Sleep: Effect of Humidification System|Patients-ventilator Interaction During Sleep: the Role of Humidification. A Pilot Short Term Study|Completed||Phase 4|15|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||3|||f||||t||||||||||2018-06-01 00:14:09.384592|2018-06-01 00:14:09.384592
NCT01038778|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-03-22|2009-12-22|2009-12-24|Estimate|||||||2018-03-22|2018-03-23|Actual|October 29, 2009|Actual|2009-10-29|February 2018|2018-02-28||||February 23, 2019|Anticipated|2019-02-23||Interventional|||Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer|Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|45|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 00:14:09.497693|2018-06-01 00:14:09.497693
NCT01038765|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2009-12-23|2009-12-23|2009-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|January 2005||2005-01-31|December 2009|2009-12-31|January 2011|Anticipated|2011-01-31|March 2010|Anticipated|2010-03-31||Interventional|||Mindfulness Based Cognitive Therapy for Recurrent Depression|Mindfulness Based Cognitive Therapy for Patients With Recurrent Depression: a Clinical Trial|Unknown status|Active, not recruiting|N/A|338|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 00:14:09.611716|2018-06-01 00:14:09.611716
NCT01038596|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2017-04-13|2009-12-23|2009-12-24|Estimate|||||||2017-04-13|2017-04-14|Actual|January 2009||2009-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Mesenchymal Stromal Cells and Osteoarthritis|Proliferation and Osteogenic Differentiation of Bone Marrow-derived Mesenchymal Stromal Cells From Osteoarthritic Versus Healthy Donors|Completed|||30|Actual|Technische Universität Dresden|||2||f||||f||||||Samples With DNA|"~     bone marrow aspirates~   "|||2018-06-01 00:14:13.613913|2018-06-01 00:14:13.613913
NCT01038752|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2014-10-15||2015-05-04|2009-12-22|2009-12-24|Estimate|2014-10-15|2014-10-21|Estimate||||2015-05-04|2015-05-21|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer|Combination of Non-Cytotoxic Suramin With Docetaxel and Carboplatin in Chemo-Naive Non-small Cell Lung Cancer (NSCLC): A Randomized Single-Blind Placebo-Controlled Phase II Study|Terminated||Phase 2|14|Actual|Optimum Therapeutics, LLC|The study was terminated prematurely due to the loss of follow-up of 6 of 14 participants before progression and slow accrual. Due to the resulting small numbers, no analysis was attempted.|2|||f||||t||||||||||2018-06-01 00:14:09.710434|2018-06-01 00:14:09.710434
NCT01038739|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22||2017-06-21|2017-07-20|2009-12-23|2009-12-24|Estimate||||2017-06-21|2017-06-26|Actual|2017-07-20|2017-07-21|Actual|January 2010||2010-01-31|July 2017|2017-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis|Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis|Terminated||Phase 3|330|Actual|Dr. Falk Pharma GmbH||3||Stopped due to futility.|f||||t||||||||||2018-06-01 00:14:10.197429|2018-06-01 00:14:10.197429
NCT01038726|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2013-09-17|2009-12-22|2009-12-24|Estimate|||||||2013-09-17|2013-09-18|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults|Neural Effects of Exercise, Cognitive, or Combined Training in AD At-Risk Elders|Completed||N/A|108|Actual|The Cleveland Clinic||4|||f||||f||||||||||2018-06-01 00:14:10.281955|2018-06-01 00:14:10.281955
NCT01038713|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2016-06-09||2016-06-21|2009-12-23|2009-12-24|Estimate|2016-06-09|2016-06-22|Estimate||||2016-06-21|2016-06-23|Estimate|December 2009||2009-12-31|June 2016|2016-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction|A Prospective Randomized Trial of Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction|Completed||N/A|94|Actual|Dartmouth-Hitchcock Medical Center||5|||f||||t||||||||||2018-06-01 00:14:10.378551|2018-06-01 00:14:10.378551
NCT01038700|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2015-09-30|2009-12-23|2009-12-24|Estimate|||||||2015-09-30|2015-10-01|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|August 2009|Actual|2009-08-31||Observational|VIMOPEIL||Circulating Endothelial Compartment During Normal and Pathological Aging|Impact du Vieillissement (VI) Sur le Compartiment Circulant et Sur la Mobilisation (MO) Des progéniteurs endothéliaux (PE) Par ischémie Locale (IL) : étude Pilote|Completed|||84|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 00:14:10.71633|2018-06-01 00:14:10.71633
NCT01038687|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22||2012-07-31|2012-07-31|2009-12-23|2009-12-24|Estimate||||2012-07-31|2012-08-07|Estimate|2012-07-31|2012-08-07|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation|Effects of A3309, an Ileal Bile Acid Transport Inhibitor, on Gastrointestinal and Colonic Motor Functions in Female Patients With Functional Constipation|Completed||Phase 2|36|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 00:14:10.779233|2018-06-01 00:14:10.779233
NCT01038674|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2017-02-08|2009-12-22|2009-12-24|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2010||2010-02-28|February 2017|2017-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis|A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Dose-escalation, Phase 1 Trial of Anti-IL-20 in Subjects With Rheumatoid Arthritis|Completed||Phase 1|16|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:14:10.864871|2018-06-01 00:14:10.864871
NCT01038661|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2014-02-27|2009-12-22|2009-12-24|Estimate|||||||2014-02-27|2014-02-28|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|TFINE||Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy|Randomized, Controlled Study Comparing the Efficacy and Safety of Docetaxel （60mg/m2）Maintenance Treatment vs. Best Supportive Care Following First Line Chemotherapy With Different Doses of Docetaxel（75/60mg/m2）in Combination With Cisplatin in Patients With Local Advanced or Metastatic （Stage IIIB/IV）Non-Small Cell Lung Cancer|Completed||Phase 3|375|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 00:14:10.943538|2018-06-01 00:14:10.943538
NCT01038648|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2015-12-29|2009-12-23|2009-12-24|Estimate|||||||2015-12-29|2015-12-30|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|December 2014|Anticipated|2014-12-31|February 2014|Anticipated|2014-02-28||Interventional|SITAGLIPTIN||Sitagliptin in Prevention of Type 2 Diabetes Mellitus|Does the DPP4 Inhibitor Sitagliptin Have a Role in Preventing Type 2 Diabetes- A Randomised Controlled Study.|Withdrawn||Phase 3|0|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals||2|||f||||t||||||||||2018-06-01 00:14:11.02146|2018-06-01 00:14:11.02146
NCT01038635|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|2016-12-19||2016-12-19|2009-12-23|2009-12-24|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|December 2009||2009-12-31|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Baseline characteristics represented in study phase, Phase I and Phase II separately.|5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)|Phase I/II Study of the Combination of 5-azacitidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)|Completed||Phase 1/Phase 2|94|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:14:11.133341|2018-06-01 00:14:11.133341
NCT01038622|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2013-09-17|2009-12-23|2009-12-24|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|Immunolarg||Directed Immuno Nutrition by L-arginine for Critically Ill Patients|Randomized Directed Immuno Nutrition by L-arginine for Critically Ill Patients|Completed||Phase 4|30|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:14:12.929431|2018-06-01 00:14:12.929431
NCT01038609|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2013-11-01|2011-11-04|2014-03-10|2009-12-22|2009-12-24|Estimate|2014-01-22|2014-03-07|Estimate|2011-11-04|2011-11-10|Estimate|2014-03-10|2014-04-08|Estimate|December 2009||2009-12-31|March 2014|2014-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy|A Randomized, Multicenter, Single-Blind Study Comparing Hydrocodone/Acetaminophen Extended Release 10/650, Morphine Extended Release, and Acetaminophen to Placebo in Subjects With Acute Pain Following Bunionectomy|Completed||Phase 2|250|Actual|AbbVie||5|||f||||f||||||||||2018-06-01 00:14:13.041348|2018-06-01 00:14:13.041348
NCT01038583|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2017-07-20|2009-12-23|2009-12-24|Estimate|||||||2017-07-20|2017-07-21|Actual|January 2010||2010-01-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ASPREE||Aspirin in Reducing Events in the Elderly|Aspirin in Reducing Events in the Elderly|Active, not recruiting||Phase 4|19000|Anticipated|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-06-01 00:14:13.705593|2018-06-01 00:14:13.705593
NCT01038570|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2017-05-10|2009-12-22|2009-12-24|Estimate|||||||2017-05-10|2017-05-12|Actual|June 2009||2009-06-30|May 2017|2017-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus Placebo|Evaluation of the Effect of the Oxytocin Administered in Nasal Pulverizing on the Social Skills, the Stress, the Anxiety and the Eating Habits at Grown-up Patients Presenting a Syndrome of Prader-Willi: Pilot Study|Completed||Phase 2|24|Actual|University Hospital, Toulouse||2|||f||||t||||||||No||2018-06-01 00:14:13.839141|2018-06-01 00:14:13.839141
NCT01038557|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2010-03-11|2009-12-23|2009-12-24|Estimate|||||||2010-03-11|2010-03-12|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|February 2011|Anticipated|2011-02-28|August 2010|Anticipated|2010-08-31||Interventional|||Frozen Red Blood Cell Transfusions in Trauma Patients|Efficacy and Safety of Frozen Red Blood Cells for Transfusion in Trauma Patients|Unknown status|Not yet recruiting|N/A|350|Anticipated|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 00:14:13.915185|2018-06-01 00:14:13.915185
NCT01038544|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-06-20|2009-12-22|2009-12-24|Estimate|||||||2012-06-20|2012-06-22|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CT0003||Endobronchial Ultrasound (EBUS) for Nodal Staging in Esophageal Cancer|Endobronchial Ultrasound (EBUS) for Nodal Staging in Esophageal Cancer|Completed||N/A|50|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-06-01 00:14:13.986872|2018-06-01 00:14:13.986872
NCT01038531|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2016-12-16|2009-12-23|2009-12-24|Estimate|||||||2016-12-16|2016-12-19|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation|Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation|Terminated||N/A|3|Actual|Boston Medical Center||2||slow enrollment|f||||t||||||||||2018-06-01 00:14:14.045796|2018-06-01 00:14:14.045796
NCT01038518|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2015-01-21|2009-12-23|2009-12-24|Estimate|||||||2015-01-21|2015-01-22|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|Health2010-4||Health2010-14: Monitoring Biomarkers of Chronic Diseases in the General Population|Health2010-14: Monitoring Biomarkers of Chronic Diseases in the General Population|Completed|||1522|Actual|Glostrup University Hospital, Copenhagen|||1||f||||f||||||Samples With DNA|"~     Urine, serum, whole blood, extracted DNA~   "|||2018-06-01 00:14:14.203637|2018-06-01 00:14:14.203637
NCT01038505|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2012-03-09|2009-12-23|2009-12-24|Estimate|||||||2012-03-09|2012-03-12|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus|Head to Head Comparison of Tacrolimus and Myfortic vs Tacrolimus and Sirolimus Used in Combination in Non-HLA Identical Living Donor Kidney Transplants|Withdrawn||Phase 4|0|Actual|University of Miami||2||Lost funding source|t||||f||||||||||2018-06-01 00:14:14.302734|2018-06-01 00:14:14.302734
NCT01038492|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2013-06-26|2009-12-23|2009-12-24|Estimate|||||||2013-06-26|2013-06-28|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||p16 Methylation for Smoking Cessation|Testing the Feasibility of Using an Epigenetic Marker, p16, to Promote Smoking Cessation|Completed||N/A|35|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:14:14.379301|2018-06-01 00:14:14.379301
NCT01038479|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-23|||2011-06-14|2009-12-23|2009-12-24|Estimate|||||||2011-06-14|2011-06-15|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|May 2016|Anticipated|2016-05-31|March 2012|Anticipated|2012-03-31||Interventional|MaXED||Maternal Consumption of Xylitol to Reduce Early Childhood Decay (MaXED Study)|Maternal Consumption of Xylitol to Reduce Early Childhood Decay (MaXED Study)|Unknown status|Active, not recruiting|N/A|1064|Anticipated|NHS Fife||2|||f||||t||||||||||2018-06-01 00:14:14.452096|2018-06-01 00:14:14.452096
NCT01038466|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-12-22|2009-12-22|2009-12-24|Estimate|||||||2009-12-22|2009-12-24|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Observational|||Observation Only Study Involving Participants Enrolled in the CHAT Trial|Follow-Up Observational Study In CHAT Trial Participants With Advanced And/Or Metastatic Breast Cancers That Overexpress HER2, Who Were Randomised To Receive Trastuzumab And Docetaxel With Or Without Capecitabine|Unknown status|Enrolling by invitation||222|Actual|Contact Asia Pacific|||1||f||||t||||||||||2018-06-01 00:14:14.539463|2018-06-01 00:14:14.539463
NCT01038453|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2011-11-03|2009-12-22|2009-12-24|Estimate|||||||2011-11-03|2011-11-04|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|Gravita||Effects of Vitamin D Supplement Before and During Pregnancy on Birth Weight|Effects of Vitamin D Supplement Before and During Pregnancy on Complications, Birth Weight and Bone Mineral Density During Lactation|Unknown status|Recruiting|N/A|400|Anticipated|University of Aarhus||3|||f||||f||||||||||2018-06-01 00:14:14.597759|2018-06-01 00:14:14.597759
NCT01038440|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-06-15|2009-12-23|2009-12-24|Estimate|||||||2012-06-15|2012-06-18|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|NK||Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells|Evaluation of the Relationships of Time and Dose of Eicosapentaenoic Acid and Stearidonic Acid to the Changes in Eicosapentaenoic Acid Levels in Red Blood Cells|Completed||N/A|137|Actual|Solae, LLC||8|||f||||t||||||||||2018-06-01 00:14:14.693855|2018-06-01 00:14:14.693855
NCT01038427|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22||2012-08-10|2017-03-27|2009-12-23|2009-12-24|Estimate||||2012-12-14|2012-12-19|Estimate|2017-03-27|2017-03-28|Actual|December 2009||2009-12-31|March 2017|2017-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Lek Pharmaceuticals) With NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|Completed||Phase 3|1103|Actual|Sandoz||3|||f||||||||||||||2018-06-01 00:14:14.778817|2018-06-01 00:14:14.778817
NCT01038414|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2011-06-22|2009-12-23|2009-12-24|Estimate|||||||2011-06-22|2011-06-23|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|EDC||Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence|Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence|Unknown status|Recruiting|Phase 4|450|Anticipated|Harvard University Faculty of Medicine||3|||f||||f||||||||||2018-06-01 00:14:14.856583|2018-06-01 00:14:14.856583
NCT01038219|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2015-04-13|2009-12-22|2009-12-23|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Reliability of Subjective Assessment of Fever by Parents and Health Care Providers in Children and Adolescents|Reliability of Subjective Assessment of Fever by Parents and Health Care Providers in Children and Adolescents|Completed|||520|Actual|Meir Medical Center|||1||f||||f||||||||||2018-06-01 00:14:16.869633|2018-06-01 00:14:16.869633
NCT01038401|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2010-07-13|2009-12-23|2009-12-24|Estimate|||||||2010-07-13|2010-07-14|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|EP 44||Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study|Characterization of the Residual Replication of HIV-1 in the Gut-associated Lymphoid Tissue in Patients Receiving Effective Highly Active Antiretroviral Therapy: the ANRS EP 44 Study|Completed||N/A|30|Anticipated|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||f||||||||||2018-06-01 00:14:14.918811|2018-06-01 00:14:14.918811
NCT01038388|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2018-02-06|2009-12-22|2009-12-24|Estimate|||||||2018-02-06|2018-02-08|Actual|January 15, 2010|Actual|2010-01-15|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma|A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza ®) + RVD (Lenalidomide {Revlimid ®} + Bortezomib {Velcade ®} + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 1|30|Actual|Emory University||1|||f||||t|t|f||||||||2018-06-01 00:14:15.206303|2018-06-01 00:14:15.206303
NCT01038375|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-04-30|2009-12-22|2009-12-23|Estimate|||||||2012-04-30|2012-05-01|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|TIMSII||Tailored Interventions to Improve Hypertension Management After Stroke or Transient Ischemic Attack (TIA)|Tailored Interventions to Improve Hypertension Management After Stroke or TIA|Completed|||56|Actual|McMaster University|||2||f||||t||||||||||2018-06-01 00:14:15.298956|2018-06-01 00:14:15.298956
NCT01038362|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2009-12-21|2009-12-21|2009-12-23|Estimate|||||||2009-12-21|2009-12-23|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Almonds On Endothelial Function In Patients With Coronary Artery Disease|Effects Of Almonds On Vascular Reactivity And Biomarkers Of Inflammation, Oxidative Stress And Endothelial Function In Patients With Coronary Artery Disease|Completed||N/A|52|Actual|Boston University||2|||f||||f||||||||||2018-06-01 00:14:15.376502|2018-06-01 00:14:15.376502
NCT01038349|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-06-01|2009-12-18|2009-12-23|Estimate|||||||2011-06-01|2011-06-02|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|AMORA||Applications for Methotrexate Optimization in Rheumatoid Arthritis|Applications for Methotrexate Optimization in Rheumatoid Arthritis|Completed|||256|Actual|Cypress Bioscience, Inc.|||||f||||f||||||||||2018-06-01 00:14:15.445768|2018-06-01 00:14:15.445768
NCT01038336|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|2014-10-21||2014-11-19|2009-12-21|2009-12-23|Estimate|2014-11-19|2014-11-20|Estimate||||2014-11-19|2014-11-20|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|HLPP||Hearing Loss Prevention for Veterans|Hearing Loss Prevention for Veterans|Completed||N/A|129|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 00:14:15.52863|2018-06-01 00:14:15.52863
NCT01038323|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2016-04-14||2017-01-23|2009-12-21|2009-12-23|Estimate|2016-06-09|2016-07-21|Estimate||||2017-01-23|2017-03-06|Actual|December 2009||2009-12-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Drug and Talk Therapy for Fibromyalgia|A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran|Completed||Phase 4|58|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 00:14:16.077364|2018-06-01 00:14:16.077364
NCT01038310|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2010-07-22|2009-12-22|2009-12-23|Estimate|||||||2010-07-22|2010-07-23|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Prognostic Value of FP-CIT-SPECT in Parkinson´s Disease|Prognostic Value of FP-CIT-SPECT in Patients With Parkinson´s Disease|Completed|||25|Anticipated|Saarland University|||||f||||f||||||||||2018-06-01 00:14:16.418429|2018-06-01 00:14:16.418429
NCT01038297|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21||2012-07-17|2012-10-09|2009-12-22|2009-12-23|Estimate||||2012-07-17|2012-07-25|Estimate|2012-10-09|2012-10-11|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty|A Phase 2, Randomized, Double-Blind, Within-subject Controlled, Dose- Ranging Study to Evaluate Efficacy and Safety of EXC 001 for the Amelioration of Incision Scars in the Abdominal Pannus of Subjects Undergoing an Elective Abdominoplasty|Completed||Phase 2|30|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:14:16.484679|2018-06-01 00:14:16.484679
NCT01038284|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2014-03-14|2009-12-21|2009-12-23|Estimate|||||||2014-03-14|2014-03-17|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ETHAP||Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)|Evaluation of Multidisciplinary Collaboration Care Program in Pulmonary Arterial Hypertension|Completed||N/A|101|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 00:14:16.559807|2018-06-01 00:14:16.559807
NCT01038271|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2018-03-19|2009-12-22|2009-12-23|Estimate|||||||2018-03-19|2018-03-21|Actual|May 2006||2006-05-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|July 2009|Actual|2009-07-31||Interventional|||Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC|Completed||N/A|151|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:14:16.643516|2018-06-01 00:14:16.643516
NCT01038258|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-07-11|2009-12-22|2009-12-23|Estimate|||||||2012-07-11|2012-07-13|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|December 2011|Actual|2011-12-31||Interventional|PETBreast||Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy|Monitoring Response After The First Chemotherapy Cycle In Newly Diagnosed Breast Cancer As A Guide For Neoadjuvant Therapy|Unknown status|Active, not recruiting|N/A|80|Actual|Auxilio Mutuo Cancer Center||1|||f||||t||||||||||2018-06-01 00:14:16.71337|2018-06-01 00:14:16.71337
NCT01038245|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2017-06-30|2009-12-19|2009-12-23|Estimate|||||||2017-06-30|2017-07-02|Actual|July 8, 2003||2003-07-08|November 18, 2011|2011-11-18|November 18, 2011||2011-11-18|||||Observational|||Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers|Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers|Completed|||72|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:16.769072|2018-06-01 00:14:16.769072
NCT01038232|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2018-04-26|2009-12-19|2009-12-23|Estimate|||||||2018-04-26|2018-04-27|Actual|December 4, 2009||2009-12-04|March 24, 2015|2015-03-24|March 24, 2015||2015-03-24|||||Observational|||Measuring Distress Tolerance With Functional MRI|Measuring Distress Tolerance With Functional MRI|Completed|||99|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:16.815322|2018-06-01 00:14:16.815322
NCT01038193|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2017-11-13|2009-12-22|2009-12-23|Estimate|||||||2017-11-13|2017-11-14|Actual|March 2009||2009-03-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Observational|||Cognitive Dysfunction After Aneurysmal Subarachnoid Haemorrhage|Cognitive Dysfunction After Aneurysmal Subarachnoid Haemorrhage|Recruiting|||600|Anticipated|Chinese University of Hong Kong|||1||f||||t||||||||No||2018-06-01 00:14:16.996281|2018-06-01 00:14:16.996281
NCT01038180|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2009-12-22|2009-12-22|2009-12-23|Estimate|||||||2009-12-22|2009-12-23|Estimate|January 1997||1997-01-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|||||Observational|||Complications Following Pacemaker Implantation|Complications Following Pacemaker or ICD Implantation: Results From The Danish Pacemaker and ICD Register|Completed|||28000|Actual|University of Aarhus|||1||f||||f||||||||||2018-06-01 00:14:17.186401|2018-06-01 00:14:17.186401
NCT01038167|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2010-04-06|2009-12-18|2009-12-23|Estimate|||||||2010-04-06|2010-04-08|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults|An Open-Label Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus|Completed||Phase 1|20|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-06-01 00:14:17.241072|2018-06-01 00:14:17.241072
NCT01038154|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2011-06-24|2009-12-22|2009-12-23|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|November 2012|Anticipated|2012-11-30|November 2011|Anticipated|2011-11-30||Interventional|AGIM-1||Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer|Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer|Unknown status|Recruiting|Phase 4|146|Anticipated|Hospital Donostia||2|||f||||t||||||||||2018-06-01 00:14:17.322021|2018-06-01 00:14:17.322021
NCT01038141|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2014-07-29|2009-12-22|2009-12-23|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 2009||2009-11-30|June 2014|2014-06-30||||September 2013|Actual|2013-09-30||Interventional|||Recto Anal Repair or Milligan Morgans Operation of Grade 3 and 4 Symptomatic Haemorrhoidal Disease|Recto Anal Repair or Milligan Morgans Operation of Grade 3 and 4 Symptomatic Haemorrhoidal Disease. A Prospective Randomized Controlled Study|Terminated||N/A|80|Actual|University Hospital, Akershus||2||Due to lack of time.|f||||f||||||||||2018-06-01 00:14:17.39501|2018-06-01 00:14:17.39501
NCT01038128|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|2012-03-19||2015-04-13|2009-12-21|2009-12-23|Estimate|2012-05-09|2012-06-12|Estimate||||2015-04-13|2015-05-04|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder|Antiglutamatergic Treatment of Bulimia Nervosa and Body Dysmorphic Disorder: An Open-Label Trial of Memantine|Completed||N/A|5|Actual|Mclean Hospital||1|||f||||f||||||||||2018-06-01 00:14:17.472049|2018-06-01 00:14:17.472049
NCT01038115|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2014-02-17|2009-12-22|2009-12-23|Estimate|||||||2014-02-17|2014-02-19|Estimate|September 2008||2008-09-30|March 2011|2011-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Cryo Vs RFA||Study Comparing Pulmonary Vein Isolation With the Cryoballoon, Radiofrequency Energy, or Both in the Treatment of Atrial Fibrillation (AF)|A Randomised Study Comparing Pulmonary Vein Isolation Using the Occluding Cryoballoon, Conventional Radiofrequency Energy, or Both in the Treatment of Atrial Fibrillation (AF).|Completed||Phase 4|237|Actual|Barts & The London NHS Trust||3|||f||||||||||||||2018-06-01 00:14:17.680365|2018-06-01 00:14:17.680365
NCT01038102|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2010-07-12|2009-12-21|2009-12-23|Estimate|||||||2010-07-12|2010-07-13|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|HEPFAT||Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance|Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance: a Randomized Controlled Study|Completed||N/A|65|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 00:14:17.819611|2018-06-01 00:14:17.819611
NCT01038089|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2010-12-17|2009-12-21|2009-12-23|Estimate|||||||2010-12-17|2010-12-21|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus|Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus|Completed||N/A|20|Anticipated|Boston University||1|||f||||f||||||||||2018-06-01 00:14:17.899793|2018-06-01 00:14:17.899793
NCT01038076|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2018-02-17|2009-12-19|2009-12-23|Estimate|||||||2018-02-17|2018-02-20|Estimate|December 2009|Actual|2009-12-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 2013|Actual|2013-06-30||Interventional|MedCHEC||Medications for Chronic HIV: Education and Collaboration|Implementing Computerized Clinical Assessment of HIV Patient Adherence|Completed||N/A|371|Actual|Boston University||2|||f||||t|f|f||||||Undecided||2018-06-01 00:14:17.981266|2018-06-01 00:14:17.981266
NCT01038063|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2010-12-08|2009-12-22|2009-12-23|Estimate|||||||2010-12-08|2010-12-09|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period|Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period|Unknown status|Recruiting|Phase 4|1200|Anticipated|Liverpool School of Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:14:18.066137|2018-06-01 00:14:18.066137
NCT01038050|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2009-12-22|2009-12-22|2009-12-23|Estimate|||||||2009-12-22|2009-12-23|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease||Unknown status|Enrolling by invitation|Phase 4|60|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f||||||||||2018-06-01 00:14:18.146634|2018-06-01 00:14:18.146634
NCT01038037|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2014-12-03|2009-12-22|2009-12-23|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|Lung-TRIO||First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer|A Phase II Study of First-Line Chemotherapy and Panitumumab in Advanced NSCLC Selected by Mutational Status|Terminated||Phase 2|23|Actual|Vejle Hospital||||"1. Very low enrollment rate.~      2. Recent studies question the effect of adding panitumumab in this category of patients.~      3. Too high toxicity rate"|f||||t||||||||||2018-06-01 00:14:18.222361|2018-06-01 00:14:18.222361
NCT01038024|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2013-03-07|2009-12-22|2009-12-23|Estimate|||||||2013-03-07|2013-03-08|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|February 2011|Actual|2011-02-28||Interventional|||Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage|A Pilot Study for the LC-MS/MS Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage|Completed||N/A|38|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 00:14:18.284897|2018-06-01 00:14:18.284897
NCT01037998|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-12-22|2009-12-22|2009-12-23|Estimate|||||||2009-12-22|2009-12-23|Estimate|November 2005||2005-11-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer|Phase II Trial of Adding UFUR to Non-small-cell Lung Cancer Patients Treated With Iressa|Completed||Phase 2|115|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-06-01 00:14:18.400959|2018-06-01 00:14:18.400959
NCT01037985|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21||2012-07-17|2012-10-09|2009-12-22|2009-12-23|Estimate||||2012-07-17|2012-07-25|Estimate|2012-10-09|2012-10-11|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty|A Phase 2, Randomized, Double-Blind, Within-subject Controlled Study to Evaluate Efficacy and Safety of EXC 001 for the Amelioration of Scarring of the Surgical Incision in Subjects Undergoing an Elective Abdominoplasty|Completed||Phase 2|41|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:14:18.478043|2018-06-01 00:14:18.478043
NCT01037972|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2011-10-07|2009-12-22|2009-12-23|Estimate|||||||2011-10-07|2011-10-12|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Observational|||Influence of Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Gonarthrosis|Influence of Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Gonarthrosis|Completed|||40|Actual|University of Cologne|||2||f||||f||||||||||2018-06-01 00:14:18.550458|2018-06-01 00:14:18.550458
NCT01037959|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2015-12-08|2009-12-22|2009-12-23|Estimate|||||||2015-12-08|2015-12-09|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|NORFLOCIR||Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure|Randomized, Double-Blind, Placebo-Controlled Trial Assessing Norfloxacin in the Prevention of Complications in Patients With Cirrhosis and Severe Liver Failure|Terminated||Phase 3|291|Actual|Assistance Publique - Hôpitaux de Paris||2||lack of recruitement|f||||t||||||||||2018-06-01 00:14:18.626247|2018-06-01 00:14:18.626247
NCT01037946|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2012-02-22|2009-12-22|2009-12-23|Estimate|||||||2012-02-22|2012-02-24|Estimate|September 2005||2005-09-30|June 2009|2009-06-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Family to Family: Psychoeducation to Improve Children's Outcomes in HIV+ Families|Family to Family: Psychoeducation to Improve Children's Outcomes in HIV+ Families|Completed||N/A|1033|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:14:18.696061|2018-06-01 00:14:18.696061
NCT01037933|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2009-12-22|2009-12-22|2009-12-23|Estimate|||||||2009-12-22|2009-12-23|Estimate|February 2007||2007-02-28|December 2009|2009-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|COMIC||Comedy in Chemotherapy (COMIC) Study|Comedy in Chemotherapy (COMIC) Study|Completed||Phase 2|50|Actual|Queen's Medical Centre||2|||f||||f||||||||||2018-06-01 00:14:18.773638|2018-06-01 00:14:18.773638
NCT01037920|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2012-07-11|2009-12-18|2009-12-23|Estimate|||||||2012-07-11|2012-07-13|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension|An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension|Completed||N/A|179|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||||2018-06-01 00:14:18.839988|2018-06-01 00:14:18.839988
NCT01037907|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2013-07-25|2009-12-22|2009-12-23|Estimate|||||||2013-07-25|2013-07-29|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS|Terminated||Phase 2|173|Actual|BTG International Inc.||2||Lack of efficacy|f||||t||||||||||2018-06-01 00:14:18.918882|2018-06-01 00:14:18.918882
NCT01037894|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2013-01-10|2009-12-22|2009-12-23|Estimate|||||||2013-01-10|2013-01-14|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Can Acupuncture Benefit Surgical Patients With Haemorrhagic Stroke?|Can Acupuncture Benefit Surgical Patients With Haemorrhagic Stroke?|Completed||Phase 1/Phase 2|55|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 00:14:19.034224|2018-06-01 00:14:19.034224
NCT01037881|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2013-10-21|2009-12-22|2009-12-23|Estimate|||||||2013-10-21|2013-10-22|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||LEO 29102 Cream in the Treatment of Atopic Dermatitis|A Phase 2, Proof of Concept and Dose Finding Study, Investigating Treatment Efficacy of LEO 29102 Cream, LEO 29102 Cream Vehicle, and Elidel® Cream 10 mg/g, After Cutaneous Administration Twice Daily for 4 Weeks|Completed||Phase 2|183|Actual|LEO Pharma||7|||f||||t||||||||||2018-06-01 00:14:19.093914|2018-06-01 00:14:19.093914
NCT01037868|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2013-03-26|2009-12-22|2009-12-23|Estimate|||||||2013-03-26|2013-03-28|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Usefulness of Supportive Text Messages in the Treatment of Depressed Alcoholics|A Randomised Trial on the Usefulness of Supportive Text Messages in the Treatment of Depressed Patients With Co-morbid Alcohol Dependency Syndrome|Completed||N/A|56|Actual|University of Dublin, Trinity College||2|||f||||t||||||||||2018-06-01 00:14:19.154213|2018-06-01 00:14:19.154213
NCT01037855|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2017-03-13|2009-12-22|2009-12-23|Estimate|||||||2017-03-13|2017-03-14|Actual|December 2009||2009-12-31|March 2017|2017-03-31|January 2011|Actual|2011-01-31|June 2010|Actual|2010-06-30||Observational|||Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine|A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine Celtura|Completed|||4028|Actual|Novartis|||6||f||||||||||||||2018-06-01 00:14:19.239288|2018-06-01 00:14:19.239288
NCT01037842|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2009-12-19|2009-12-19|2009-12-23|Estimate|||||||2009-12-19|2009-12-23|Estimate|August 2006||2006-08-31|December 2009|2009-12-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus|Phase 3 Study of Combination of Mitiglinide and Metformin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|145|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:14:19.454457|2018-06-01 00:14:19.454457
NCT01037829|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2011-09-28|2009-12-22|2009-12-23|Estimate|||||||2011-09-28|2011-09-29|Estimate|January 2010||2010-01-31|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study|A Post-Marketing, Observational, Comparative Safety Study of the Novartis Pandemic Influenza A (H1N1) Vaccine(s) in Pregnant Women Versus Non-Vaccinated Pregnant Women|Completed|||4529|Actual|Novartis|||1||f||||||||||||||2018-06-01 00:14:19.555611|2018-06-01 00:14:19.555611
NCT01037816|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18||2015-03-17|2015-05-12|2009-12-22|2009-12-23|Estimate||||2015-05-12|2015-06-04|Estimate|2015-05-12|2015-06-04|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||FS-67 in the Treatment of Pediatric Patients With Ankle Sprain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of FS-67 Patches in Adolescent Subjects With Ankle Sprain|Completed||Phase 4|252|Actual|Hisamitsu Pharmaceutical Co., Inc.||2|||f||||f||||||||||2018-06-01 00:14:19.690099|2018-06-01 00:14:19.690099
NCT01037803|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2011-01-17|2009-12-22|2009-12-23|Estimate|||||||2011-01-17|2011-01-19|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|||||Observational|||Perioperative Observation of the Sublingual Microcirculation With SDF|Visualisation of Changes in the Sublingual Microcirculation During Major Surgery Using Sidestream Darkfield Imaging (SDF).|Completed|||50|Anticipated|Region Skane|||||f||||f||||||||||2018-06-01 00:14:19.785498|2018-06-01 00:14:19.785498
NCT01037790|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2016-08-24|2009-12-22|2009-12-23|Estimate|||||||2016-08-24|2016-08-25|Estimate|October 2009||2009-10-31|July 2016|2016-07-31||||October 2016|Anticipated|2016-10-31||Interventional|||PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER|Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer|Recruiting||Phase 2|205|Anticipated|Abramson Cancer Center of the University of Pennsylvania||5|||f||||t||||||||||2018-06-01 00:14:19.896753|2018-06-01 00:14:19.896753
NCT01037777|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2012-01-27|2009-12-22|2009-12-23|Estimate|||||||2012-01-27|2012-01-31|Estimate|May 2009||2009-05-31|January 2012|2012-01-31||||||||Observational|RISCA||RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7|Prospective Study of Individuals at Risk for Spinocerebellar Ataxia Type 1, Type 2, Type 3, Type 6 and Type 7 (SCA1, SCA2, SCA3, SCA6, SCA7)|Unknown status|Active, not recruiting||60|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||||||||||||2018-06-01 00:14:20.02803|2018-06-01 00:14:20.02803
NCT01037764|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2017-07-15|2009-12-22|2009-12-23|Estimate|||||||2017-07-15|2017-07-18|Actual|January 2010||2010-01-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional|AHCTALL||Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)|Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia in Remission Using HLA-matched Sibling Donors, HLA-matched Unrelated Donors, or HLA-mismatched Familial Donors-A Phase 2 Study|Terminated||Phase 2|100|Anticipated|Asan Medical Center||1||"The PI resigned the institute, and the rest investigators at the institute decided to terminate~   the study."|f||||f||||||||||2018-06-01 00:14:20.112519|2018-06-01 00:14:20.112519
NCT01037751|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2018-05-03|2009-12-22|2009-12-23|Estimate|||||||2018-05-03|2018-05-07|Actual|December 2009|Actual|2009-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||M. D. Anderson Symptom Inventory - Ovarian Cancer|M. D. Anderson Symptom Inventory - Ovarian Cancer: Development and Validation in Patients With Ovarian Cancer|Active, not recruiting|||158|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 00:14:20.23353|2018-06-01 00:14:20.23353
NCT01037738|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-22|2009-12-22|2009-12-23|Estimate|||||||2009-12-22|2009-12-23|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Study of Autologous Conditioned Serum After Anterior Cruciate Ligament Reconstructive Surgery|Intraarticular Application of Autologous Conditioned Serum (ACS/Orthokine) Reduces Bone Tunnel Widening After ACL Reconstructive Surgery A Prospective, Randomized, Saline-controlled, Patient- and Observer-blinded, Parallel-design Trial|Completed||Phase 1|62|Actual|University of Zagreb||2|||f||||t||||||||||2018-06-01 00:14:20.332741|2018-06-01 00:14:20.332741
NCT01037725|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2010-07-13|2009-12-22|2009-12-23|Estimate|||||||2010-07-13|2010-07-14|Estimate|December 2009||2009-12-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|||||Interventional|||Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers|A Phase-1, Single Center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics (Including Food Effect) of Ascending Oral Doses of AZD5847 in Healthy Male Subjects and Female Subjects of Non-childbearing Potential|Completed||Phase 1|64|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:14:20.422116|2018-06-01 00:14:20.422116
NCT01037712|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2012-10-12|2009-12-22|2009-12-23|Estimate|||||||2012-10-12|2012-10-15|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|CYMEVAL||In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir|In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo|Terminated||Phase 4|6|Actual|Assistance Publique - Hôpitaux de Paris||2||not enough inclusion|f||||t||||||||||2018-06-01 00:14:20.503523|2018-06-01 00:14:20.503523
NCT01037699|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2009-12-22|2009-12-22|2009-12-23|Estimate|||||||2009-12-22|2009-12-23|Estimate|January 2005||2005-01-31|December 2009|2009-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles||Completed||Phase 3|720|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||4|||f||||f||||||||||2018-06-01 00:14:20.591355|2018-06-01 00:14:20.591355
NCT01037686|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-12-22|2009-12-22|2009-12-23|Estimate|||||||2009-12-22|2009-12-23|Estimate|February 2006||2006-02-28|December 2009|2009-12-31|October 2010|Anticipated|2010-10-31|April 2010|Anticipated|2010-04-30||Interventional|||The Effect of Electrode Implantation for Deep Brain Stimulation (DBS) on Brain Function Using Single Photon Emission Computed Tomography (SPECT) With Technetium-99m-ethyl Cysteinatedimer (Tc-ECD)|Exploring the Effect of Electrode Implantation for DBS on Brain Function During Rest and During Semantic Verbal Fluency Task Using SPECT With Tc-ECD|Unknown status|Recruiting|N/A|120|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:14:20.674413|2018-06-01 00:14:20.674413
NCT01037673|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2011-06-16|2009-12-22|2009-12-23|Estimate|||||||2011-06-16|2011-06-17|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|||Subacromial Impingement - The Need of Arthroscopic Subacromial Decompression After Eccentric Physical Therapy Exercises|Does the Need of Arthroscopic Subacromial Decompression Change After Eccentric Physical Therapy Exercises in Patients With Subacromial Pain? - A Randomized Clinical Trial|Completed||N/A|102|Actual|Linkoeping University||2|||f||||f||||||||||2018-06-01 00:14:20.770156|2018-06-01 00:14:20.770156
NCT01037660|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2017-03-08|2009-12-21|2009-12-23|Estimate|||||||2017-03-08|2017-03-10|Actual|September 2005|Actual|2005-09-30|March 2017|2017-03-31|December 1, 2016|Actual|2016-12-01|December 1, 2015|Actual|2015-12-01||Interventional|||Effects of Lipemia and Metformin on Endothelial Function|Effects of Lipemia and Metformin on Endothelial Function|Completed||Early Phase 1|139|Actual|Boston University||1|||f||||f|t|f|||f|||No||2018-06-01 00:14:20.855519|2018-06-01 00:14:20.855519
NCT01037647|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2011-11-04|2009-12-22|2009-12-23|Estimate|||||||2011-11-04|2011-11-07|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||VLDL-triglyceride Kinetics in Type 2 Diabetes|VLDL-triglyceride Kinetics and -Metabolism in the Post Absorptive State and During Hyperinsulinemia in Type 2 Diabetes|Completed|||22|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Blood samples Subcutaneous adipose tissue biopsies Muscle biopsies~   "|||2018-06-01 00:14:20.924595|2018-06-01 00:14:20.924595
NCT01037634|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2014-08-05|2009-12-18|2009-12-23|Estimate|||||||2014-08-05|2014-08-06|Estimate|March 2010||2010-03-31|August 2014|2014-08-31||||March 2012|Anticipated|2012-03-31||Interventional|||Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age|Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-06-01 00:14:20.989312|2018-06-01 00:14:20.989312
NCT01037621|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2011-11-04|2009-12-22|2009-12-23|Estimate|||||||2011-11-04|2011-11-07|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C|The Interaction of HSV-2 Co-infection in Veterans With Chronic Hepatitis C: the Effect of Valacyclovir on HCV Viral Load|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|G.V. (Sonny) Montgomery VA Medical Center|||||f||||f||||||||||2018-06-01 00:14:21.062034|2018-06-01 00:14:21.062034
NCT01037608|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2017-06-30|2009-12-19|2009-12-23|Estimate|||||||2017-06-30|2017-07-02|Actual|May 8, 2007||2007-05-08|December 12, 2011|2011-12-12|December 12, 2011|Actual|2011-12-12|August 15, 2011|Actual|2011-08-15||Interventional|||Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation|Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation|Completed||Phase 1|108|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:21.12197|2018-06-01 00:14:21.12197
NCT01037595|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2013-05-12|2009-12-22|2009-12-23|Estimate|||||||2013-05-12|2013-05-14|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Turmeric on Pruritus in Hemodialysis Patients||Completed||Early Phase 1|60|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-06-01 00:14:21.195052|2018-06-01 00:14:21.195052
NCT01037582|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2017-02-23|2009-12-21|2009-12-23|Estimate|||||||2017-02-23|2017-02-27|Actual|December 17, 2009|Actual|2009-12-17|February 2017|2017-02-28|May 7, 2010|Actual|2010-05-07|May 7, 2010|Actual|2010-05-07||Interventional|||A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects|Investigation on Safety, Tolerability and Bioavailability of Oral NN9924 in Healthy Male Subjects|Completed||Phase 1|155|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:14:21.261319|2018-06-01 00:14:21.261319
NCT01037569|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2017-06-30|2009-12-19|2009-12-23|Estimate|||||||2017-06-30|2017-07-02|Actual|July 10, 2007||2007-07-10|March 22, 2011|2011-03-22|March 22, 2011||2011-03-22|||||Observational|||Optimizing Toxicological Screening in Drug Endangered Children|Optimizing Toxicological Screening in Drug Endangered Children|Completed|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:21.434255|2018-06-01 00:14:21.434255
NCT01037556|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2012-08-30|2009-12-21|2009-12-23|Estimate|||||||2012-08-30|2012-08-31|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia|Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Proacta, Incorporated||1|||f||||f||||||||||2018-06-01 00:14:21.482068|2018-06-01 00:14:21.482068
NCT01037543|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2014-02-05|2009-12-21|2009-12-23|Estimate|||||||2014-02-05|2014-02-07|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects|A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and PK of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Japanese and Caucasian Subjects.|Completed||Phase 1|84|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||||2018-06-01 00:14:21.545335|2018-06-01 00:14:21.545335
NCT01037530|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2014-12-18|2009-12-22|2009-12-23|Estimate|||||||2014-12-18|2014-12-19|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants|A Double Blind, Randomised, Placebo Controlled Trial to Study the Clinical and Cost Effectiveness of the Angiotensin Converting Enzyme Inhibitor, Ramipril, in Intermittent Claudicants|Completed||Phase 4|33|Actual|University of Hull||1|||f||||t||||||||||2018-06-01 00:14:21.617429|2018-06-01 00:14:21.617429
NCT01037517|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2013-10-30|2009-12-22|2009-12-23|Estimate|||||||2013-10-30|2013-10-31|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization|Open Label Phase II Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization|Completed||Phase 2|52|Actual|CancerCare Manitoba||2|||f||||f||||||||||2018-06-01 00:14:21.690286|2018-06-01 00:14:21.690286
NCT01037504|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2015-01-13|2009-12-22|2009-12-23|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||AZD5423 Multiple Ascending Dose Study|Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled AZD5423 After Administration of Multiple Ascending Doses for 14 Days in Healthy Male and Female Subjects|Completed||Phase 1|27|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:14:21.760973|2018-06-01 00:14:21.760973
NCT01037491|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2010-06-06|2009-12-22|2009-12-23|Estimate|||||||2010-06-06|2010-06-08|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets|Comparison of Ulcer Healing in Patients Taking Rabeprazole Plus Aspirin Versus Rabeprazole Plus Clopidogrel for Acute Peptic Ulcer|Unknown status|Recruiting|N/A|200|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||||||||||||2018-06-01 00:14:21.824546|2018-06-01 00:14:21.824546
NCT01037478|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2014-01-15|2009-12-22|2009-12-23|Estimate|||||||2014-01-15|2014-01-16|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|January 2012|Actual|2012-01-31||Interventional|SAPHIRE||Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma|A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma|Completed||Phase 2|37|Actual|4SC AG||1|||f||||||||||||||2018-06-01 00:14:21.897764|2018-06-01 00:14:21.897764
NCT01037452|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|2010-12-14||2011-03-01|2009-12-22|2009-12-23|Estimate|2011-03-01|2011-03-28|Estimate||||2011-03-01|2011-03-28|Estimate|December 2009||2009-12-31|March 2011|2011-03-31||||January 2010|Actual|2010-01-31||Interventional|||Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn|A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Proof-of-Concept Trial to Assess Relief of Meal Induced Heartburn by a Combination of Lansoprazole 15 mg and Antacid Versus Lansoprazole 15 mg and Antacid (Calcium Carbonate and Magnesium Hydroxide) Alone|Completed||Phase 2|120|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:14:22.076876|2018-06-01 00:14:22.076876
NCT01037439|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2009-12-21|2009-12-21|2009-12-23|Estimate|||||||2009-12-21|2009-12-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:14:22.380491|2018-06-01 00:14:22.380491
NCT01037426|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-09-04|2009-12-22|2009-12-23|Estimate|||||||2017-09-04|2017-09-07|Actual|August 2009||2009-08-31|September 2017|2017-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Falls and Cardiovascular Events in Pacemaker Patients|Falls and Cardiovascular Events in Elderly Patients With Sinus Node Disease Treated With a MVPTM Pacemaker According to the ESC 2007 Guidelines|Completed||Phase 4|87|Actual|Medtronic Bakken Research Center||1|||f||||f||||||||No|there is no plan|2018-06-01 00:14:22.410273|2018-06-01 00:14:22.410273
NCT01037413|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21||2012-07-17|2012-10-09|2009-12-22|2009-12-23|Estimate||||2012-07-17|2012-07-25|Estimate|2012-10-09|2012-10-11|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery|A Phase 2, Randomized, Double-Blind, Within-subject Controlled Study to Evaluate Efficacy and Safety of EXC 001 for the Amelioration of Scarring Following Revision of Scars Resulting From Prior Breast Surgery in Adult Female Subjects|Completed||Phase 2|25|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:14:22.482284|2018-06-01 00:14:22.482284
NCT01037400|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2014-09-16|2009-12-22|2009-12-23|Estimate|||||||2014-09-16|2014-09-17|Estimate|February 2010||2010-02-28|September 2014|2014-09-30||||February 2011|Anticipated|2011-02-28||Observational|||Biochemical Approach to Measuring Surgical Trauma|Further Development of a Biochemical Approach to Measuring Surgical Trauma to Musculoskeletal Tissues|Withdrawn|||0|Actual|McMaster University|||1|No patients recruited|f||||f||||||Samples With DNA|"~     Plasma and Serum~   "|||2018-06-01 00:14:23.509305|2018-06-01 00:14:23.509305
NCT01037387|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2016-06-24|2009-12-22|2009-12-23|Estimate|||||||2016-06-24|2016-06-27|Estimate|December 2009||2009-12-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients|Effect of the Noninvasive Mechanical Ventilation on the Daily Physical Activity and the Inflammatory Biomarkers in Stable Patients With COPD|Recruiting||Phase 4|50|Anticipated|Hospital Universitario La Paz||2|||f||||f||||||||||2018-06-01 00:14:23.572939|2018-06-01 00:14:23.572939
NCT01037374|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2014-09-23|2009-12-21|2009-12-23|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2008||2008-08-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Anticipation of the Difficult Airway: the Preoperative Airway Assessment Form|Anticipation of the Difficult Airway: the Preoperative Airway Assessment Form as an Educational and Quality Improvement Tool|Completed||N/A|89|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-06-01 00:14:23.669528|2018-06-01 00:14:23.669528
NCT01037361|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-19|||2018-05-19|2009-12-19|2009-12-23|Estimate|||||||2018-05-19|2018-05-22|Actual|December 2, 2009||2009-12-02|June 29, 2012|2012-06-29|June 29, 2012||2012-06-29|||||Observational|||Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study.|Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study|Completed|||17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:23.749039|2018-06-01 00:14:23.749039
NCT01037348|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2016-04-15|2009-12-22|2009-12-23|Estimate|||||||2016-04-15|2016-04-19|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|REPAIR||Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen|A Phase II, Open-label, Multicentre, 12 Month Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5mg) in Patients With Choroidal Neovascularisation Secondary to Pathological Myopia (PM)|Completed||Phase 2|65|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:14:23.823498|2018-06-01 00:14:23.823498
NCT01037335|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-22|||2017-04-11|2009-12-22|2009-12-23|Estimate|||||||2017-04-11|2017-04-13|Actual|April 2009|Actual|2009-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Local Administration of Morphine for Analgesia After Iliac Bone Graft Harvest|Local Administration of Morphine for Analgesia After Iliac Bone Graft Harvest|Withdrawn||Phase 4|0|Actual|The Cleveland Clinic||3||No participants enrolled|f||||t||||||||||2018-06-01 00:14:23.965446|2018-06-01 00:14:23.965446
NCT01037322|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-20|||2013-04-13|2009-12-22|2009-12-23|Estimate|||||||2013-04-13|2013-04-16|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Cannabidiol for Inflammatory Bowel Disease|Use of Cannabidiol for the Treatment of Inflammatory Bowel Disease|Completed||Phase 1/Phase 2|20|Actual|Meir Medical Center||2|||f||||f||||||||||2018-06-01 00:14:24.050489|2018-06-01 00:14:24.050489
NCT01037309|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|2014-09-01||2017-12-06|2009-12-21|2009-12-23|Estimate|2015-03-26|2015-04-09|Estimate||||2017-12-06|2018-01-02|Actual|December 2009||2009-12-31|December 2017|2017-12-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)|A Phase I/IIa, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous and Intravenous Doses of PRO044 in Patients With Duchenne Muscular Dystrophy|Completed||Phase 1/Phase 2|18|Actual|BioMarin Pharmaceutical||9|||f||||t|t|f||||||||2018-06-01 00:14:24.297112|2018-06-01 00:14:24.297112
NCT01037296|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-21|||2014-07-09|2009-12-22|2009-12-23|Estimate|||||||2014-07-09|2014-07-10|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|Hansen||Catheter Ablation of Atrial Fibrillation Using Hansen Medical Robotic Navigation|Catheter Ablation of Atrial Fibrillation Using Hansen Medical Robotic Navigation - A Randomised Controlled Trial|Terminated||Phase 4|166|Actual|Barts & The London NHS Trust||2||Based on interim analysis study felt unlikely to reach the primary aim|f||||f||||||||||2018-06-01 00:14:25.308289|2018-06-01 00:14:25.308289
NCT01037283|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2011-09-14|2009-12-18|2009-12-22|Estimate|||||||2011-09-14|2011-09-16|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|IPSRT||Interpersonal and Social Rhythm Therapy Enter the Brief Title for Protocol IRB 09-003781>|Feasibility of Interpersonal and Social Rhythm Therapy for Outpatients With Bipolar Disorder|Completed||N/A|9|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:14:25.396647|2018-06-01 00:14:25.396647
NCT01037270|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-02-08|2009-12-19|2009-12-22|Estimate|||||||2013-02-08|2013-02-11|Estimate|August 2009||2009-08-31|February 2013|2013-02-28|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|ECLIPSE-01||Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity||Completed|||271|Actual|Biosite|||||f||||f||||||Samples Without DNA|"~     Plasma specimens for reference testing.~   "|||2018-06-01 00:14:25.56151|2018-06-01 00:14:25.56151
NCT01037244|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2011-07-12||2011-12-21|2009-12-18|2009-12-22|Estimate|2011-12-21|2011-12-22|Estimate||||2011-12-21|2011-12-22|Estimate|September 2009||2009-09-30|December 2011|2011-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Treatment of Erectile Dysfunction I|Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction|Completed||Phase 3|618|Actual|Warner Chilcott||4|||f||||f||||||||||2018-06-01 00:14:25.68476|2018-06-01 00:14:25.68476
NCT01037231|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18||2013-05-07|2013-05-07|2009-12-18|2009-12-22|Estimate||||2013-05-07|2013-05-15|Estimate|2013-05-07|2013-05-15|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase 2/3 Oxabact Study|A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria.|Completed||Phase 2/Phase 3|36|Actual|OxThera||2|||f||||t||||||||||2018-06-01 00:14:26.789245|2018-06-01 00:14:26.789245
NCT01037218|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2011-07-12||2015-05-20|2009-12-18|2009-12-22|Estimate|2011-12-21|2011-12-22|Estimate||||2015-05-20|2015-06-19|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Subjects Randomized/Enrolled; Age, Ethnic, Race only available for Safety Population|Treatment of Erectile Dysfunction II|Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction|Completed||Phase 3|601|Actual|Warner Chilcott||4|||f||||f||||||||||2018-06-01 00:14:26.922619|2018-06-01 00:14:26.922619
NCT01037205|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2014-04-05|2009-12-18|2009-12-22|Estimate|||||||2014-04-05|2014-04-08|Estimate|December 2009||2009-12-31|July 2013|2013-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza||Completed||Phase 2|264|Actual|Ansun Biopharma, Inc.||3|||f||||t||||||||||2018-06-01 00:14:28.362304|2018-06-01 00:14:28.362304
NCT01037192|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2011-05-10||2015-08-18|2009-12-18|2009-12-22|Estimate|2011-06-11|2011-07-08|Estimate||||2015-08-18|2015-08-27|Estimate|March 2010||2010-03-31|August 2015|2015-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|VOD||Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections|Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections|Completed||N/A|4|Actual|Fraser Health|The main limitation was low enrollment, primarily caused by stringent inclusion criteria. The age limitation was required to ensure safe vancomycin administration. The weight limitation was required for medication preparation.|2|||f||||f||||||||||2018-06-01 00:14:28.494133|2018-06-01 00:14:28.494133
NCT01037179|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18||2014-07-28|2014-07-31|2009-12-18|2009-12-22|Estimate||||2014-07-28|2014-07-31|Estimate|2014-07-31|2014-08-04|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis|An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis|Completed||Phase 3|110|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:14:28.752706|2018-06-01 00:14:28.752706
NCT01037166|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17||2010-01-29|2011-01-24|2009-12-18|2009-12-21|Estimate||||2010-01-29|2010-02-02|Estimate|2011-01-24|2011-01-31|Estimate|December 2002||2002-12-31|June 2010|2010-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy|A Phase II Study in Japan of the Safety And Antiviral Activity of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B With Incomplete Response to Current Lamivudine Therapy|Completed||Phase 2|84|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 00:14:28.832908|2018-06-01 00:14:28.832908
NCT01037153|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2017-06-30|2009-12-18|2009-12-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 6, 2002||2002-08-06|July 25, 2011|2011-07-25|July 25, 2011||2011-07-25|||||Observational|||Effects of Nicotine on Brain Activity as Measured by fMRI|Effects of Nicotine on Brain Activity as Measured by fMRI|Completed|||128|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:28.947571|2018-06-01 00:14:28.947571
NCT01037140|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2012-08-01|2009-12-18|2009-12-21|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Vitamin D Supplementation in Obesity|Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Subject.|Completed||Phase 4|55|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:14:29.01046|2018-06-01 00:14:29.01046
NCT01037127|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2013-06-12|2012-03-15|2014-02-13|2009-12-18|2009-12-21|Estimate|2014-02-13|2014-03-31|Estimate|2012-03-15|2012-03-19|Estimate|2014-02-13|2014-03-31|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|July 2011|Actual|2011-07-31||Interventional|||Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor|An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated With or Without a BRAF Inhibitor|Completed||Phase 2|97|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:14:29.141018|2018-06-01 00:14:29.141018
NCT01037114|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2011-04-01||2015-11-19|2009-12-18|2009-12-21|Estimate|2011-04-01|2011-04-27|Estimate||||2015-11-19|2015-12-22|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Long-term Persistence Study in Healthy Adults Previously Vaccinated With TwinrixTM Adult|An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-032 (208127/022) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.|Completed||Phase 4|50|Actual|GlaxoSmithKline|A decrease in specificity of the anti-HB ELISA had been observed in some studies for low levels of antibody(10-100 mIU/mL).The tables show updated results following complete retesting/reanalysis for Y16-18.Y19 & 20 results were only analyzed by CLIA.|1|||f||||||||||||||2018-06-01 00:14:29.857041|2018-06-01 00:14:29.857041
NCT01037101|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2013-10-11|2009-12-18|2009-12-21|Estimate|||||||2013-10-11|2013-10-14|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights|D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults|Unknown status|Recruiting|N/A|80|Anticipated|CAMC Health System||5|||f||||f||||||||||2018-06-01 00:14:30.219238|2018-06-01 00:14:30.219238
NCT01037088|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2012-12-06||2018-01-11|2009-12-18|2009-12-21|Estimate|2013-04-05|2013-04-09|Estimate||||2018-01-11|2018-01-31|Actual|December 2009||2009-12-31|October 2017|2017-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Vaporized Marijuana on Neuropathic Pain|CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain|Completed||Phase 1/Phase 2|44|Actual|University of California, Davis|Inclusion of patients with complex regional pain syndrome type I. In the past, there was no doubt that this disorder should be classified as classical neuropathic pain condition; Unmasking of blinding secondary to the psychoactive effects of cannabis|3|||f||||f||||||||||2018-06-01 00:14:30.322416|2018-06-01 00:14:30.322416
NCT01037075|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-04-27|2009-12-18|2009-12-21|Estimate|||||||2018-04-27|2018-04-30|Actual|May 14, 2006||2006-05-14|January 22, 2013|2013-01-22|January 22, 2013||2013-01-22|||||Observational|||Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence|Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence|Completed|||82|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:30.710508|2018-06-01 00:14:30.710508
NCT01037062|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17||2010-01-29|2011-01-24|2009-12-17|2009-12-21|Estimate||||2010-01-29|2010-02-02|Estimate|2011-01-24|2011-01-31|Estimate|December 2003||2003-12-31|December 2009|2009-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection|An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Who Have Completed Previous Phase II Studies in Japan But Who Require Further Treatment|Completed||Phase 2|282|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 00:14:30.876228|2018-06-01 00:14:30.876228
NCT01037049|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2015-06-22|2009-12-18|2009-12-21|Estimate|||||||2015-06-22|2015-06-23|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|July 2019|Anticipated|2019-07-31|June 2015|Actual|2015-06-30||Interventional|||Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks|Is Greater Downstaging and Tumour Regression Observed When Surgery is Delayed to 12 Weeks After Completion of Chemoradiotherapy vs 6 Weeks?|Active, not recruiting||Phase 2|237|Actual|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:14:31.1078|2018-06-01 00:14:31.1078
NCT01037036|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17||2011-06-17|2013-12-10|2009-12-18|2009-12-21|Estimate||||2011-06-27|2011-06-29|Estimate|2013-12-10|2014-01-10|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG|An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Adjunctive Xalatan® Eye Drops in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)|Completed||Phase 2|15|Actual|Mati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 00:14:31.264383|2018-06-01 00:14:31.264383
NCT01037023|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2015-04-14|2009-12-18|2009-12-21|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|Hycamtin PMS||Regulatory Hycamtin(Oral) PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of HYCAMTIN Administered in Korean Patients According to the Prescribing Information|Completed|||92|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:14:31.352621|2018-06-01 00:14:31.352621
NCT01036971|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-05-08|2009-12-18|2009-12-21|Estimate|||||||2018-05-08|2018-05-09|Actual|May 16, 2006||2006-05-16|April 26, 2018|2018-04-26||||||||Observational|||Screening Protocol for the Evaluation of Potential Research Subjects|Screening Protocol for the Evaluation of Potential Research Subjects|Recruiting|||7500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:31.435327|2018-06-01 00:14:31.435327
NCT01036958|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-02-07|2009-12-18|2009-12-21|Estimate|||||||2018-02-07|2018-02-08|Actual|November 25, 2009||2009-11-25|February 6, 2018|2018-02-06|February 6, 2018||2018-02-06|||||Observational|||Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease|Development and Validation of a Symptom Scale for Children With Chronic Graft-Versus-Host Disease|Completed|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:31.514834|2018-06-01 00:14:31.514834
NCT01036932|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2009-12-18|2009-12-18|2009-12-21|Estimate|||||||2009-12-18|2009-12-21|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF|To Study the Safety and Efficacy of G-CSF Therapy on the CD 34 Cell Mobilization and Outcome of Patients With ACLF|Unknown status|Recruiting|N/A|50|Anticipated|Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-06-01 00:14:31.63942|2018-06-01 00:14:31.63942
NCT01036893|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2011-05-16|2009-12-18|2009-12-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||M0001 Effects on Oral Contraceptive Plasma Levels|The Effect of Prucalopride on the Plasma Levels of Oral Contraceptives (Ethinylestradiol and Norethisterone) in Healthy Subjects|Completed||Phase 1|16|Anticipated|Movetis||2|||f||||f||||||||||2018-06-01 00:14:31.774337|2018-06-01 00:14:31.774337
NCT01036854|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-02-08|2009-12-17|2009-12-21|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2009||2009-02-28|February 2017|2017-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)|Parallel, Group, Laboratory-Blinded, Single and Multiple-dose Pharmacokinetic Study of Ondansetron Administered as the Immediate-Release (Zofran) and Modified-Release (EUR1025) Formulations|Completed||Phase 1|128|Actual|Forest Laboratories||4|||f||||f||||||||||2018-06-01 00:14:31.913263|2018-06-01 00:14:31.913263
NCT01036841|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2011-05-25|2009-12-18|2009-12-21|Estimate|||||||2011-05-25|2011-05-26|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|TM||Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation|Influence of Food-intake on Pharmacokinetic and Pharmacodynamic Parameters of Desmopressin Oral Tablet Formulation, in Comparison With Desmopressin MELT Formulation|Completed||Phase 4|24|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 00:14:32.013178|2018-06-01 00:14:32.013178
NCT01036802|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2013-07-03||2016-04-05|2009-12-18|2009-12-21|Estimate|2014-01-06|2014-02-21|Estimate||||2016-04-05|2016-05-09|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease|An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease|Terminated||Phase 2|3|Actual|University of North Carolina, Chapel Hill|This study was terminated early due to difficulty in accruing subjects.|2||Difficulty in accruing subjects|f||||t||||||||||2018-06-01 00:14:32.158141|2018-06-01 00:14:32.158141
NCT01036763|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2012-02-15||2014-02-27|2009-12-18|2009-12-21|Estimate|2012-02-15|2012-03-22|Estimate||||2014-02-27|2014-03-27|Estimate|January 2010||2010-01-31|February 2014|2014-02-28||||August 2010|Actual|2010-08-31||Observational|||Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example|Assessment of COPD Therapy From the Physicians Perspective Using Tiotropium as an Example|Completed|||||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 00:14:32.833008|2018-06-01 00:14:32.833008
NCT01036724|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2014-06-18||2017-08-30|2009-12-18|2009-12-21|Estimate|2014-07-17|2014-07-21|Estimate||||2017-08-30|2017-09-27|Actual|November 1, 2009|Actual|2009-11-01|August 2017|2017-08-31|August 25, 2010|Actual|2010-08-25|August 1, 2010|Actual|2010-08-01||Observational|CO1||Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation|Comparative Study of Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation|Terminated|||107|Actual|Biosense Webster, Inc.|The study was terminated early, with 107 enrolled and 93 evaluable subjects, due to difficulty enrolling despite prolonged extension of the enrollment period. The original design called for 176 enrolled and 122 evaluable patients.||2|Enrollment challenges|f||||f||||||||||2018-06-01 00:14:34.165543|2018-06-01 00:14:34.165543
NCT01036711|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-04-04|2009-12-18|2009-12-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 17, 2002||2002-09-17|November 26, 2012|2012-11-26|November 26, 2012||2012-11-26|||||Observational|||Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI|Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI|Completed|||249|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:34.367034|2018-06-01 00:14:34.367034
NCT01036685|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-05-24|2009-12-18|2009-12-21|Estimate|||||||2018-05-24|2018-05-25|Actual|May 13, 2003||2003-05-13|January 4, 2018|2018-01-04||||||||Observational|||Cognitive Task Development and Implementation for Functional MRI Studies|Cognitive Task Development and Implementation for Functional MRI Studies|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:34.470165|2018-06-01 00:14:34.470165
NCT01036659|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2012-03-08|2009-12-18|2009-12-21|Estimate|||||||2012-03-08|2012-03-09|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|ACE||Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema|Evaluation of Ecallantide for Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema|Unknown status|Recruiting|Phase 2|50|Anticipated|Bernstein, Jonathan A., M.D.||3|||f||||t||||||||||2018-06-01 00:14:34.62973|2018-06-01 00:14:34.62973
NCT01036646|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-02-08|2009-12-18|2009-12-21|Estimate|||||||2013-02-08|2013-02-11|Estimate|August 2009||2009-08-31|February 2013|2013-02-28|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Observational|ECLIPSE-02||User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity||Completed|||183|Actual|Biosite|||2||f||||f||||||Samples Without DNA|"~     Plasma specimens retained for reference method comparison.~   "|||2018-06-01 00:14:35.315994|2018-06-01 00:14:35.315994
NCT01036633|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2012-03-21|2009-12-18|2009-12-21|Estimate|||||||2012-03-21|2012-03-22|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|Mucositis||Oral Mucositis in Patients Undergoing Antineoplastic Chemotherapy|Use of an Infrared Thermometer to Grade the Severity of Oral Mucositis in Patients Undergoing Antineoplastic Chemotherapy|Completed|||4|Actual|University of Arkansas|||2||f||||f||||||||||2018-06-01 00:14:35.584208|2018-06-01 00:14:35.584208
NCT01036594|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-09-15|2009-12-18|2009-12-21|Estimate|||||||2017-09-15|2017-09-18|Actual|December 11, 2009|Actual|2009-12-11|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|December 11, 2012|Actual|2012-12-11||Interventional|Keto/Dex||Ketoconazole and Dexamethasone in Prostate Cancer|An Endocrinologically and Pharmacologically Directed Trial of Ketoconazole and Corticosteroids in Castration Resistant Prostate Cancer|Active, not recruiting||Phase 2|32|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:14:36.149941|2018-06-01 00:14:36.149941
NCT01036581|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-04-03|2009-12-18|2009-12-21|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 30, 2003||2003-10-30|March 22, 2018|2018-03-22||||||||Observational|||Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging|Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:36.222993|2018-06-01 00:14:36.222993
NCT01036568|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-04-04|2009-12-18|2009-12-21|Estimate|||||||2018-04-04|2018-04-05|Actual|February 14, 2006||2006-02-14|March 7, 2013|2013-03-07|March 7, 2013||2013-03-07|||||Observational|||Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia|Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia|Completed|||121|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:36.286211|2018-06-01 00:14:36.286211
NCT01036529|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2013-06-04||2013-09-30|2009-12-17|2009-12-21|Estimate|2013-09-30|2013-10-28|Estimate||||2013-09-30|2013-10-28|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Evidence|This represents the number of subjects with demographic information provided at enrollment (collected before baseline visit).|Spinal Cord Stimulation With Precision® System Versus Reoperation for Failed Back Surgery Syndrome|Spinal Cord Stimulation With Precision® Spinal Cord Stimulation System Versus Reoperation for Failed Back Surgery Syndrome|Terminated||Phase 4|28|Actual|Boston Scientific Corporation|This study was terminated early due to slow enrollment. Only 28 of the 200 planned subjects were enrolled. Based on the small numbers and early termination, the primary outcome measures were not analyzed.|2||Closed due to continued slow enrollment.|f||||f||||||||||2018-06-01 00:14:36.381176|2018-06-01 00:14:36.381176
NCT01036516|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2017-06-30|2009-12-18|2009-12-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 23, 1998||1998-06-23|March 27, 2012|2012-03-27|March 27, 2012||2012-03-27|||||Observational|||PET Assays of Striatal Dopamine Marker in Cocaine Craving|PET Assays of Striatal Dopamine Markers in Cocaine Craving|Completed|||14|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:36.786157|2018-06-01 00:14:36.786157
NCT01036490|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2016-03-24||2017-12-06|2009-12-17|2009-12-21|Estimate|2016-03-24|2016-04-27|Estimate||||2017-12-06|2017-12-08|Actual|July 1, 2010|Actual|2010-07-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2014|Actual|2014-12-31||Interventional|EX-ODCKD||Exercise in Obese Diabetic Patients With Chronic Kidney Disease|Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease|Active, not recruiting||N/A|36|Actual|VA Office of Research and Development|Due to inability to reach our expected target randomization (30 per group), our study may be underpowered to detect differences between the groups.|2|||f||||f|f|f|||f|||No||2018-06-01 00:14:36.870082|2018-06-01 00:14:36.870082
NCT01036438|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2014-09-04||2014-09-11|2009-12-18|2009-12-21|Estimate|2014-09-11|2014-09-12|Estimate||||2014-09-11|2014-09-12|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers|A Double-blind, Comparative, Superiority, Multi-centre Investigation Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers|Completed||Phase 4|201|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-06-01 00:14:37.113338|2018-06-01 00:14:37.113338
NCT01036412|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2016-02-17|2009-12-17|2009-12-21|Estimate|||||||2016-02-17|2016-02-19|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Chlorhexidine Gel Therapy for Cariogenic Oral Microflora|Chlorhexidine Gel Therapy for Cariogenic Oral Microflora in Irradiated Head and Neck Cancer Patients|Completed||Phase 1|4|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:14:38.452782|2018-06-01 00:14:38.452782
NCT01036399|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2012-08-24|2009-12-18|2009-12-21|Estimate|||||||2012-08-24|2012-08-27|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients||Terminated||Phase 2|9|Actual|University of Bologna||1||"The EC withdrawn the approval becuase of possible conflicts of interests between our Institute~   and Supporter (Celgene)"|f||||t||||||||||2018-06-01 00:14:38.540618|2018-06-01 00:14:38.540618
NCT01036360|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2011-01-18|2009-12-18|2009-12-21|Estimate|||||||2011-01-18|2011-01-19|Estimate|December 2009||2009-12-31|January 2011|2011-01-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Acute Exercise and Energy Balance Regulation: Effect of Intensity|Regulation of the Energy Balance Following an Acute Exercise in Metabolic Chambers: Effect of the Exercise Intensity, Age and Weight Status|Unknown status|Recruiting||40|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||||||||"~     Defined population~   "|||2018-06-01 00:14:38.625019|2018-06-01 00:14:38.625019
NCT01036321|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2015-06-18||2018-02-26|2009-12-17|2009-12-21|Estimate|2015-08-06|2015-08-13|Estimate||||2018-02-26|2018-03-26|Estimate|December 11, 2009|Actual|2009-12-11|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 26, 2014|Actual|2014-06-26||Interventional||All participants who were randomized to a study arm.|Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness|Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness and Mechanism of Action Between African American and Caucasian Men|Active, not recruiting||Phase 2|71|Actual|H. Lee Moffitt Cancer Center and Research Institute|Since the accrual of African American Men (AAM) was far lower than expected, this study was ultimately underpowered to detect small changes in specific biomarkers of disease progression proposed in men with localized prostate cancer (PCa).|2|||f||||t||||||||||2018-06-01 00:14:38.792547|2018-06-01 00:14:38.792547
NCT01036308|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-11-05|2009-12-18|2009-12-21|Estimate|||||||2012-11-05|2012-11-06|Estimate|July 2007||2007-07-31|December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Intervention With Legume Kernel Fibre in Healthy Subjects|Comparison of the Effects of Three Native Legume Kernel Fibres on Cholesterol Metabolism in Healthy Subjects|Completed||N/A|76|Actual|University of Jena||3|||f||||t||||||||||2018-06-01 00:14:39.486046|2018-06-01 00:14:39.486046
NCT01036282|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2017-07-18|2009-12-18|2009-12-21|Estimate|||||||2017-07-18|2017-07-21|Actual|February 2003|Actual|2003-02-28|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cognitive Skills Training Using Computer for Patients With Severe Mental Illness|Computerized Cognitive Skills Training in Severe Mental Illness|Completed||Phase 4|448|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||t||||||||||2018-06-01 00:14:39.62749|2018-06-01 00:14:39.62749
NCT01036243|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-06-21|2009-12-18|2009-12-21|Estimate|||||||2012-06-21|2012-06-22|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Digestive Tolerance of Slightly Hydrolyzed Starter Infant Formula With Probiotics|Tolerance of a Slightly Hydrolyzed Starter Formula Containing Probiotics|Completed||N/A|480|Actual|Nestlé||4|||f||||f||||||||||2018-06-01 00:14:39.721597|2018-06-01 00:14:39.721597
NCT01036230|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-04-04|2009-12-18|2009-12-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 14, 2004||2004-09-14|July 5, 2017|2017-07-05||||||||Observational|||The Effects of Expectation on Natural and Drug -Induced Rewards|The Effects of Expectation on Natural and Drug -Induced Rewards|Completed|||48|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:39.804684|2018-06-01 00:14:39.804684
NCT01036217|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2017-06-30|2009-12-18|2009-12-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 17, 2006||2006-05-17|June 17, 2010|2010-06-17|June 17, 2010||2010-06-17|||||Observational|||Screening Protocol for the Evaluation of Research Participants|Evaluation of Potential Research Subjects - Screening Protocol for Clinical Studies|Completed|||55000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:39.903006|2018-06-01 00:14:39.903006
NCT01036165|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2010-11-30||2013-08-02|2009-12-18|2009-12-21|Estimate|2010-11-30|2010-12-22|Estimate||||2013-08-02|2013-08-08|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|Performs||A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study|A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of an Electronic Autoinjector (RebiSmart™) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc) Three Times a Week (Tiw)|Completed||Phase 3|103|Actual|EMD Serono|||||f||||f||||||||||2018-06-01 00:14:39.969997|2018-06-01 00:14:39.969997
NCT01036139|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2013-04-11|2009-12-18|2009-12-21|Estimate|||||||2013-04-11|2013-04-12|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HARPS1||Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease|A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase|Completed||Phase 3|268|Actual|Bioprojet||2|||f||||f||||||||||2018-06-01 00:14:40.185128|2018-06-01 00:14:40.185128
NCT01036126|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2017-06-30|2009-12-18|2009-12-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 12, 2003||2003-08-12|August 19, 2010|2010-08-19|August 19, 2010||2010-08-19|||||Observational|||Automatic Versus Evaluative Components of Cue Reactivity|Automatic Versus Evaluative Components of Cue Reactivity|Completed|||320|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:40.252012|2018-06-01 00:14:40.252012
NCT01036113|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-10-01|2009-12-17|2009-12-21|Estimate|||||||2012-10-01|2012-10-03|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|June 2013|Anticipated|2013-06-30|February 2012|Actual|2012-02-29||Interventional|PEG-SN38||A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer|A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|Enzon Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 00:14:40.308652|2018-06-01 00:14:40.308652
NCT01036087|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2018-05-24|2009-12-17|2009-12-21|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 2010|Actual|2010-11-30|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer|Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin for Patients With Primary Inflammatory Breast Cancer (IBC) Without HER2 Overexpression|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:14:40.522234|2018-06-01 00:14:40.522234
NCT01036061|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-06-21|2009-12-17|2009-12-21|Estimate|||||||2017-06-21|2017-06-22|Actual|September 28, 2009|Actual|2009-09-28|June 2017|2017-06-30|February 17, 2010|Actual|2010-02-17|February 17, 2010|Actual|2010-02-17||Interventional|||GSK618334 Repeat Dose Study|A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers.|Completed||Phase 1|46|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:14:40.69972|2018-06-01 00:14:40.69972
NCT01036048|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-18|2009-12-18|2009-12-21|Estimate|||||||2009-12-18|2009-12-21|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A Meta-analysis of Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease|Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease: Insights From a Meta-analysis|Completed|||5806|Actual|Catholic University of the Sacred Heart|||1||f||||f||||||||||2018-06-01 00:14:40.821038|2018-06-01 00:14:40.821038
NCT01036035|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2015-12-28|2009-12-17|2009-12-21|Estimate|||||||2015-12-28|2015-12-30|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects|Effects of THVD-201 on Pharmacokinetics and Pharmacodynamics of Tolterodine in Healthy Subjects|Completed||Phase 1|18|Actual|TheraVida, Inc.||5|||f||||t||||||||||2018-06-01 00:14:40.91065|2018-06-01 00:14:40.91065
NCT01036022|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2017-04-09||2017-11-08|2009-12-18|2009-12-21|Estimate|2017-04-09|2017-06-26|Actual||||2017-11-08|2017-12-18|Actual|September 15, 2009|Actual|2009-09-15|November 2017|2017-11-30|January 10, 2013|Actual|2013-01-10|January 10, 2013|Actual|2013-01-10||Interventional|||Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis|A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis|Completed||Phase 2|120|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:14:41.17533|2018-06-01 00:14:41.17533
NCT01036009|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2014-10-21||2016-05-18|2009-12-18|2009-12-21|Estimate|2014-10-26|2014-10-31|Estimate||||2016-05-18|2016-06-23|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies|A Phase II Study of Preemptive Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions for Achieving Complete Donor Chimerism Following Allogeneic Transplant for Pediatric Hematologic Malignancies|Completed||Phase 2|43|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:14:43.941832|2018-06-01 00:14:43.941832
NCT01035996|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-05-24|2009-12-18|2009-12-21|Estimate|||||||2018-05-24|2018-05-25|Actual|March 8, 2005||2005-03-08|February 13, 2017|2017-02-13|February 13, 2017||2017-02-13|||||Observational|||Dopamine Function and Reward Processing In Schizophrenia|Dopamine Function and Reward Processing In Schizophrenia|Completed|||159|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:44.277847|2018-06-01 00:14:44.277847
NCT01035983|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2010-02-12|2009-12-18|2009-12-21|Estimate|||||||2010-02-12|2010-02-15|Estimate|December 2003||2003-12-31|February 2010|2010-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|MAM||Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches|An Open Label Study to Assess the Safety, Tolerability and Efficacy of Frovatriptan in the Prevention of Menstrually Associated Migraine (MAM) Headaches.|Completed||Phase 3|550|Actual|Endo Pharmaceuticals||1|||f||||t||||||||||2018-06-01 00:14:44.357793|2018-06-01 00:14:44.357793
NCT01035944|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2014-05-12||2014-06-20|2009-12-17|2009-12-21|Estimate|2014-05-12|2014-06-09|Estimate||||2014-06-20|2014-07-01|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Chitosan Dressings to Facilitate Safe Effective Debridement of Chronic Wounds & Minimize Wound Bacterial Re-colonization|Evaluation of Use of Chitosan-Based Dressings to Facilitate Safe, Effective Debridement of Chronic Wounds in Operating Room and Inpatient Ward and Minimize Bacterial Re-Colonization of Wounds.|Terminated||N/A|37|Actual|HemCon Medical Technologies, Inc|Early termination of the study; unable to reach enrollment milestones. No outcome measure data was analyzed; zero participants were analyzed.|4||Unable to meet enrollment milestones|f||||f||||||||||2018-06-01 00:14:44.510619|2018-06-01 00:14:44.510619
NCT01035905|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|2010-09-27||2012-06-26|2009-12-18|2009-12-21|Estimate|2010-09-27|2010-10-19|Estimate||||2012-06-26|2012-07-10|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Comparative Clinical Evaluation of Daily Disposable Lenses in Symptomatic Daily Disposable Lens Wearers|Comparative Clinical Evaluation of Daily Disposable Lenses in Symptomatic Daily Disposable Lens Wearers|Completed||N/A|63|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:14:44.863275|2018-06-01 00:14:44.863275
NCT01035879|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17||2015-02-16|2015-03-30|2009-12-18|2009-12-21|Estimate||||2015-03-09|2015-03-30|Estimate|2015-03-30|2015-04-17|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes|Phase 2, Randomized, Double-Blind, Placebo and Active-Comparator Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes|Completed||Phase 2|100|Actual|CymaBay Therapeutics, Inc.||5|||f||||f||||||||||2018-06-01 00:14:45.044113|2018-06-01 00:14:45.044113
NCT01035853|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-03-20|2009-12-18|2009-12-21|Estimate|||||||2013-03-20|2013-03-21|Estimate|December 2009||2009-12-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization|Sino-nasal Inhalation of Colistin Via the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Colonization of the Upper Airways With Pseudomonas Aeruginosa|Completed||Phase 2|10|Actual|University of Jena|||||f||||f||||||||||2018-06-01 00:14:45.16932|2018-06-01 00:14:45.16932
NCT01035801|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-01-19|2009-12-18|2009-12-21|Estimate|||||||2018-01-19|2018-01-23|Actual|August 21, 2010|Actual|2010-08-21|January 2018|2018-01-31|March 12, 2011|Actual|2011-03-12|March 12, 2011|Actual|2011-03-12||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients|An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus|Terminated||Phase 1|20|Actual|Biocon Limited||2||This study was temporarily paused due to an unanticipated bioanalytical issue.|f||||f||||||||||2018-06-01 00:14:45.235559|2018-06-01 00:14:45.235559
NCT01035788|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2015-09-23||2018-03-21|2009-12-18|2009-12-21|Estimate|2015-11-10|2015-12-16|Estimate||||2018-03-21|2018-03-23|Actual|July 1, 2010|Actual|2010-07-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2014|Actual|2014-06-30||Interventional|RELIEVE|Data is included for Veterans only since this was the data needed for the primary outcome analysis of the Clinician Administered PTSD Scale for the Veteran participants who had PTSD.|Effects of Mindfulness-Based Cognitive-Behavioral Conjoint Therapy on PTSD and Relationship Function|Effects of Mindfulness-Based Cognitive-Behavioral Conjoint Therapy on PTSD and Relationship Function|Active, not recruiting||N/A|92|Actual|VA Office of Research and Development|Detecting significant differences between groups may be limited by loss to follow-up of 3x more CBCT-S subjects than MB-CBCT. Differences between CAPS and PCL ratings may suggest issues with CAPS assessors although inter-rater reliability was strong.|2|||f||||f|f|f|||f|||Undecided||2018-06-01 00:14:45.31996|2018-06-01 00:14:45.31996
NCT01035775|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2017-03-15|2009-12-18|2009-12-21|Estimate|||||||2017-03-15|2017-03-16|Actual|December 2009||2009-12-31|March 2017|2017-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?|Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?|Completed||N/A|340|Actual|Indiana University||2|||f||||f||||||||No||2018-06-01 00:14:45.635551|2018-06-01 00:14:45.635551
NCT01035749|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2016-11-28|2012-07-23|2016-11-28|2009-12-17|2009-12-21|Estimate|2016-11-28|2017-01-25|Estimate|2012-07-23|2012-07-31|Estimate|2016-11-28|2017-01-25|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|||Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Children Aged 10 to Less Than 18 Years|Completed||Phase 2|310|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:14:45.785773|2018-06-01 00:14:45.785773
NCT01035723|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2018-05-10|2009-12-18|2009-12-21|Estimate|||||||2018-05-10|2018-05-11|Actual|September 13, 2005||2005-09-13|February 25, 2013|2013-02-25|February 25, 2013||2013-02-25|||||Observational|||Effect of Functional Genetic Polymorphisms on Brain Morphology and Function|Effect of Functional Genetic Polymorphisms on Brain Morphology|Completed|||221|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:48.000553|2018-06-01 00:14:48.000553
NCT01035697|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-09-22|2009-12-17|2009-12-21|Estimate|||||||2017-09-22|2017-09-26|Actual|July 1999||1999-07-31|September 2017|2017-09-30|May 2004|Actual|2004-05-31|July 2002|Actual|2002-07-31||Observational|Cytokines||Inflammatory Cytokines Associated With Perinatal Brain Injury|A Study to Determine If Inflammatory Cytokines Are Associated With Perinatal Brain Injury and Long Term Neurodevelopmental Handicap or Death|Completed|||1067|Actual|NICHD Neonatal Research Network|||||f||||f||||||Samples With DNA|"~     Whole blood spots collected on filter paper.~   "|||2018-06-01 00:14:48.072304|2018-06-01 00:14:48.072304
NCT01035671|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2011-04-21|2009-12-18|2009-12-21|Estimate|||||||2011-04-21|2011-04-22|Estimate|December 2009||2009-12-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia|A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia|Completed||Phase 2|42|Anticipated|Penwest Pharmaceuticals Co.||3|||f||||f||||||||||2018-06-01 00:14:48.15838|2018-06-01 00:14:48.15838
NCT01035658|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2014-12-16||2016-03-11|2009-12-18|2009-12-21|Estimate|2015-05-18|2015-05-21|Estimate||||2016-03-11|2016-04-11|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|June 2012|Actual|2012-06-30||Interventional|||Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma|A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma|Terminated||Phase 1/Phase 2|22|Actual|SCRI Development Innovations, LLC|Per protocol, study did not proceed to phase II based on analyses from phase I. Therefore, Phase II outcomes (all outcomes other than determination of the MTD) were not evaluated and will not be posted.|4||Based on analyses in Phase I, the study did not advance to Phase II.|f||||f||||||||||2018-06-01 00:14:48.327572|2018-06-01 00:14:48.327572
NCT01035645|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-06-09|2009-12-18|2009-12-21|Estimate|||||||2017-06-09|2017-06-12|Actual|January 5, 2010|Actual|2010-01-05|June 2017|2017-06-30|July 11, 2012|Actual|2012-07-11|July 11, 2012|Actual|2012-07-11||Interventional|A18110040||First Time in Human Study of Intravenous Interleukin-18 Antibody|A Single-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Intravenously Infused GSK1070806 in Healthy and Obese Subjects.|Completed||Phase 1|78|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:14:48.724036|2018-06-01 00:14:48.724036
NCT01035632|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2017-06-30|2009-12-18|2009-12-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 7, 2006||2006-04-07|January 12, 2011|2011-01-12|January 12, 2011||2011-01-12|||||Observational|||Study of Smoking Abstinence|Study of Smoking Abstinence|Completed|||210|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:14:48.812243|2018-06-01 00:14:48.812243
NCT01035619|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-03-27|2009-12-18|2009-12-21|Estimate|||||||2012-03-27|2012-03-29|Estimate|April 2011||2011-04-30|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pediatric Pharmacokinetics And Safety Study Of Moxidectin|A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection|Withdrawn||Phase 2|0|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 00:14:48.861757|2018-06-01 00:14:48.861757
NCT01035606|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2017-02-27||2017-10-18|2009-12-16|2009-12-18|Estimate|2017-10-18|2017-10-20|Actual||||2017-10-18|2017-10-20|Actual|September 2009||2009-09-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|December 2015|Actual|2015-12-31||Interventional|||Training in Goal-directed Attention Regulation for Individuals With Brain Injury|Plasticity in Brain Network to Enhance Cognitive Rehabilitation|Completed||N/A|49|Actual|VA Office of Research and Development|Overall, recruitment challenges resulted in small numbers.|3|||f||||f||||||||||2018-06-01 00:14:48.987919|2018-06-01 00:14:48.987919
NCT01035593|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2012-02-15|2009-12-16|2009-12-18|Estimate|||||||2012-02-15|2012-02-17|Estimate|December 2010||2010-12-31|February 2012|2012-02-29|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation|Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation|Withdrawn||Phase 2|0|Actual|Pharming Technologies B.V.||2||"Recent improvements in clinical practice have reduced the apparent incidence of AMR in renal~   transplantation."|f||||t||||||||||2018-06-01 00:14:49.338282|2018-06-01 00:14:49.338282
NCT01035580|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-11-27|2009-12-17|2009-12-18|Estimate|||||||2013-11-27|2013-11-28|Estimate|January 2010||2010-01-31|November 2013|2013-11-30|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|||Trial on Safety and Pharmacokinetics of Intravaginal Curcumin|Phase I Trial on Safety and Pharmacokinetics of Intravaginal Curcumin in Normal Female Subjects|Completed||Phase 1|13|Actual|Emory University||1|||f||||t||||||||||2018-06-01 00:14:49.414552|2018-06-01 00:14:49.414552
NCT01035567|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2013-12-01|2009-12-17|2009-12-18|Estimate|||||||2013-12-01|2013-12-03|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|POL-MIDES||Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease|Prospective Randomised Pilot Study Evaluating the Safety and Efficacy of Hybrid Revascularization in Multivessel Coronary Artery Disease|Completed||Phase 2/Phase 3|200|Actual|Silesian Centre for Heart Diseases||2|||f||||t||||||||||2018-06-01 00:14:49.498075|2018-06-01 00:14:49.498075
NCT01035554|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-11-07|2009-12-17|2009-12-18|Estimate|||||||2013-11-07|2013-11-11|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Behavioral Study to Control Blood Pressure|Effect of a Novel Behavioral Intervention on Blood Pressure Control in Hypertension Patients|Completed||Phase 2/Phase 3|203|Actual|Milton S. Hershey Medical Center||4|||f||||f||||||||||2018-06-01 00:14:49.576501|2018-06-01 00:14:49.576501
NCT01035541|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-01-16|2009-12-17|2009-12-18|Estimate|||||||2013-01-16|2013-01-17|Estimate|December 2009||2009-12-31|January 2013|2013-01-31||||December 2012|Actual|2012-12-31||Observational|IROM||Goal Directed Hemodynamic Management and Renal Outcome After Major Non-cardiac Surgery|Can Goal Directed Hemodynamic Management Improve Renal Outcome After Major Non-cardiac Surgery?|Completed|||180|Actual|Technische Universität München|||2||f||||t||||||||||2018-06-01 00:14:49.653458|2018-06-01 00:14:49.653458
NCT01035528|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2009-12-17|2009-12-17|2009-12-18|Estimate|||||||2009-12-17|2009-12-18|Estimate|April 2005||2005-04-30|August 2004|2004-08-31|August 2010|Anticipated|2010-08-31|February 2010|Anticipated|2010-02-28||Interventional|||Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)|Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data|Unknown status|Active, not recruiting|Phase 4|32|Anticipated|Munich Municipal Hospital||2|||f||||t||||||||||2018-06-01 00:14:49.738039|2018-06-01 00:14:49.738039
NCT01035515|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2010-06-17|2009-12-17|2009-12-18|Estimate|||||||2010-06-17|2010-06-22|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||BIIB014 Cardiovascular Monitoring Study|A Single-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Cardiovascular Effects of Single Doses of Oral BIIB014 in Healthy Volunteers|Completed||Phase 1|24|Actual|Biogen||6|||f||||f||||||||||2018-06-01 00:14:49.816839|2018-06-01 00:14:49.816839
NCT01035502|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15||2013-09-12|2013-09-20|2009-12-17|2009-12-18|Estimate||||2013-09-12|2013-09-18|Estimate|2013-09-20|2013-09-27|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia|A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia|Completed||Phase 2|51|Actual|Clavis Pharma||1|||f||||f||||||||||2018-06-01 00:14:49.893869|2018-06-01 00:14:49.893869
NCT01035489|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2011-05-23|2009-12-17|2009-12-18|Estimate|||||||2011-05-23|2011-05-24|Estimate|January 2009||2009-01-31|May 2011|2011-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Trial in Cardiac Resynchronization Therapy (CRT): Right Ventricular Apex Versus High Posterior Septum|Echocardiographic Dyssynchrony in Heart Failure in CRT; Right Ventricular Apex v.s. High Posterior Septum|Unknown status|Active, not recruiting|Phase 2|85|Anticipated|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 00:14:49.966881|2018-06-01 00:14:49.966881
NCT01035476|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2016-01-05|2009-12-16|2009-12-18|Estimate|||||||2016-01-05|2016-01-07|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Optimizing NIPPV Use for Patients With ALS|Effectiveness Trial of Detailed NIPPV Feedback to Patients|Completed||N/A|31|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 00:14:50.042993|2018-06-01 00:14:50.042993
NCT01035463|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2018-01-13|2009-12-17|2009-12-18|Estimate|||||||2018-01-13|2018-01-17|Actual|November 2009||2009-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|July 27, 2017|Actual|2017-07-27||Interventional|||Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab|Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|66|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 00:14:50.12068|2018-06-01 00:14:50.12068
NCT01035450|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2015-12-09|2009-12-17|2009-12-18|Estimate|||||||2015-12-09|2015-12-10|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|RESET||Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial|Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial|Completed||Phase 4|3206|Actual|Kyoto University, Graduate School of Medicine||2|||f||||t||||||||||2018-06-01 00:14:50.396749|2018-06-01 00:14:50.396749
NCT01035437|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-06-28|2009-12-17|2009-12-18|Estimate|||||||2012-06-28|2012-07-02|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer|A Pilot Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||1||no accrual|f||||t||||||||||2018-06-01 00:14:50.483967|2018-06-01 00:14:50.483967
NCT01035424|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-12-12|2009-12-16|2009-12-18|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2010||2010-03-31|December 2017|2017-12-31|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30||Observational|||Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis|Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis|Active, not recruiting|||75|Anticipated|Weill Medical College of Cornell University|||||f||||t||||||Samples With DNA|"~     whole blood, serum~   "|No||2018-06-01 00:14:50.553259|2018-06-01 00:14:50.553259
NCT01035411|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2013-01-28|2009-12-17|2009-12-18|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||AZD9668 Relative Bioavailability|An Open-label, Single-centre, 3-way Single Dose Crossover Study to Assess the Relative Bioavailability After Oral Administration of a Tablet Variant of AZD9668 Compared to AZD9668 Tablets and to Further Investigate the Safety and Tolerability of AZD9668 in Healthy Subjects|Completed||Phase 1|15|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:14:50.614109|2018-06-01 00:14:50.614109
NCT01035398|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-08-31|2009-12-17|2009-12-18|Estimate|||||||2017-08-31|2017-09-05|Actual|April 2000||2000-04-30|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|June 2022|Anticipated|2022-06-30||Observational|||Genetic and Environmental Risk Factors Related to Esophageal Cancer|Molecular Epidemiology of Esophageal Cancer: Pilot Project|Recruiting|||1200|Anticipated|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     Blood and/or buccal cells may be collected~   "|No||2018-06-01 00:14:50.681815|2018-06-01 00:14:50.681815
NCT01035385|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-17|2009-12-17|2009-12-18|Estimate|||||||2009-12-17|2009-12-18|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2015|Anticipated|2015-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Compare FOFLOX4 in Preoperative and Postoperative and Postoperative in Resectable Liver Metastasis Colorectal Cancer (MCC)|Phase III Study to Compared Preoperative and Postoperative With FOFLOX4 Chemotherapy and Postoperative With FOFLOX4 Chemotherapy in Patients With Resectable Liver Metastasis From Colorectal Cancer|Unknown status|Recruiting|Phase 3|340|Anticipated|Guangdong General Hospital||1|||f||||f||||||||||2018-06-01 00:14:50.752868|2018-06-01 00:14:50.752868
NCT01035372|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2011-04-12|2009-12-16|2009-12-18|Estimate|||||||2011-04-12|2011-04-14|Estimate|December 2009||2009-12-31|April 2011|2011-04-30||||September 2010|Actual|2010-09-30||Interventional|||Pilot Study on the Tolerability of Dietary Dried Plum|Pilot Study on the Tolerability of Dietary Dried Plum|Completed||N/A|6|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 00:14:50.834623|2018-06-01 00:14:50.834623
NCT01035359|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2014-03-12|2009-12-17|2009-12-18|Estimate|||||||2014-03-12|2014-03-13|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Intraarticular Distal Radius Fractures, X-fix or Volar Fixation|Dorsally Displaced Intraarticular Distal Radius Fractures - Volar Plate or External Fixation. A Prospective Randomized Trial.|Completed||N/A|70|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 00:14:50.905311|2018-06-01 00:14:50.905311
NCT01035346|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2012-07-13||2012-07-13|2009-12-17|2009-12-18|Estimate|2012-07-13|2012-08-21|Estimate||||2012-07-13|2012-08-21|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection|Evaluation Of The Antipyretic Efficacy Of Ibuprofen Sodium Tablets In Subjects With An Uncomplicated Acute Infection|Terminated||Phase 3|16|Actual|Pfizer|Definitive conclusion could not be made due to early termination of study, due to low enrollment rate, and small number of enrolled participants.|2|||f||||f||||||||||2018-06-01 00:14:51.060385|2018-06-01 00:14:51.060385
NCT01035333|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2014-01-08||2014-02-25|2009-12-17|2009-12-18|Estimate|2014-02-25|2014-04-04|Estimate||||2014-02-25|2014-04-04|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.|A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.|Completed||Phase 4|19|Actual|Albany College of Pharmacy and Health Sciences|High drop out rate. Patients did not return to clinic and were lost to follow up.|1|||f||||f||||||||||2018-06-01 00:14:51.459011|2018-06-01 00:14:51.459011
NCT01035320|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2011-02-25|2009-12-17|2009-12-18|Estimate|||||||2011-02-25|2011-02-28|Estimate|January 2006||2006-01-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PLAUDIT||Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment|Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment|Completed||Phase 4|39|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-06-01 00:14:51.642393|2018-06-01 00:14:51.642393
NCT01035307|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2016-05-17|2009-12-17|2009-12-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|October 2009||2009-10-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421|Genomic and Proteomic Profiling of Childhood AML|Completed|||90|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples Without DNA|"~     Collected for laboratory studies, including phospho-protein signaling and gene expression~     profiling studies.~   "|||2018-06-01 00:14:51.725951|2018-06-01 00:14:51.725951
NCT01035294|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2012-01-25|2009-12-17|2009-12-18|Estimate|||||||2012-01-25|2012-01-30|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Mindfulness-based Intervention for Treatment of Anxiety in ICD (Implantable Cardioverter Defibrillator) Patients|A Mindfulness-based Intervention for Treatment of Anxiety in ICD Patients|Completed||Phase 2/Phase 3|46|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 00:14:51.802247|2018-06-01 00:14:51.802247
NCT01035281|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2009-12-17|2009-12-17|2009-12-18|Estimate|||||||2009-12-17|2009-12-18|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Interventional|||Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain|A Randomized, Double-Blind, Placebo Controlled, Parallel Assignment, Efficacy Study of Nabilone in the Treatment of Diabetic Peripheral Neuropathic Pain|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Calgary||2|||f||||t||||||||||2018-06-01 00:14:51.888224|2018-06-01 00:14:51.888224
NCT01035268|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2018-02-12|2009-12-17|2009-12-18|Estimate|||||||2018-02-12|2018-02-13|Actual|February 8, 2010|Actual|2010-02-08|February 2018|2018-02-28|February 21, 2017|Actual|2017-02-21|October 2015|Actual|2015-10-31||Interventional|GRATSEC||Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella|Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella. Adipocyte Transplant for Esthetical Relapse Treatment of Breast Conservative Treatment|Completed||Phase 3|196|Actual|Institut Claudius Regaud||2|||f||||f||||||||||2018-06-01 00:14:51.988179|2018-06-01 00:14:51.988179
NCT01035255|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2015-08-06||2016-07-13|2009-12-17|2009-12-18|Estimate|2015-08-06|2015-09-07|Estimate||||2016-07-13|2016-08-15|Estimate|December 2009||2009-12-31|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|PARADIGM-HF||This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction|Terminated||Phase 3|8442|Actual|Novartis||2||"Early termination was approved due to compelling efficacy of LCZ696 in patients with HF &~   reduced EF after final pre-specified interim analysis 28-Mar-2014."|f||||||||||||||2018-06-01 00:14:52.307875|2018-06-01 00:14:52.307875
NCT01035242|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2015-03-24|2009-12-17|2009-12-18|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||"Association Splitting in Obsessive-Compulsive Disorder (OCD)"|"Association Splitting Compared With Cognitive Remediation (CR) in Obsessive-compulsive Disorder (OCD): a Randomized Controlled Trial"|Completed||N/A|156|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-06-01 00:14:59.286849|2018-06-01 00:14:59.286849
NCT01035229|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2014-09-24||2016-08-16|2009-12-17|2009-12-18|Estimate|2014-10-23|2014-10-27|Estimate||||2016-08-16|2016-09-22|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EVOLVE-1||Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.|A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study|Completed||Phase 3|546|Actual|Novartis|Three patients (1 in the everolimus arm and 2 in the placebo arm were excluded from the Safety Set. These three patients were randomized but never received any study treatment.|2|||f||||t||||||||||2018-06-01 00:14:59.457865|2018-06-01 00:14:59.457865
NCT01035216|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2014-12-22|2009-12-17|2009-12-18|Estimate|||||||2014-12-22|2014-12-23|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|A Phase I Study of GNKG168 Administered by Intravenous Infusion in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Terminated||Phase 1|18|Actual|SBI Biotech Co., Ltd.||1||This study has been terminated.|f||||f||||||||||2018-06-01 00:15:00.739615|2018-06-01 00:15:00.739615
NCT01035203|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2010-03-29|2009-12-17|2009-12-18|Estimate|||||||2010-03-29|2010-03-30|Estimate|December 2009||2009-12-31|March 2010|2010-03-31|September 2010|Anticipated|2010-09-30|July 2010|Anticipated|2010-07-31||Interventional|||Exercise Versus Cognitive Behavioural Therapy on Cancer-related Fatigue|Effects of a Brief Endurance Exercise Program and of a Cognitive Behavioural Therapy on Patients With Cancer-related Fatigue|Unknown status|Recruiting|Phase 3|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:15:00.846681|2018-06-01 00:15:00.846681
NCT01035190|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2016-07-04|2009-12-17|2009-12-18|Estimate|||||||2016-07-04|2016-07-06|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|October 2013|Actual|2013-10-31||Interventional|NEuroSIS||Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia|Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia|Completed||Phase 3|863|Actual|University Children’s Hospital Tuebingen||1|||f||||t||||||||Undecided||2018-06-01 00:15:00.922451|2018-06-01 00:15:00.922451
NCT01035177|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2009-12-17|2009-12-17|2009-12-18|Estimate|||||||2009-12-17|2009-12-18|Estimate|February 2005||2005-02-28|March 2008|2008-03-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Observational|FEMFRACT||In Vivo Hip Fracture Discrimination With Quantitative Computed Tomography (QCT)|In Vivo Discrimination of Hip Fracture With Quantitative Computed Tomography|Terminated|||107|Actual|Assistance Publique - Hôpitaux de Paris|||2|Difficulties of recruitment, lack of elligible patients|f||||t||||||||||2018-06-01 00:15:01.169379|2018-06-01 00:15:01.169379
NCT01035164|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2015-01-07|2009-12-17|2009-12-18|Estimate|||||||2015-01-07|2015-01-08|Estimate|June 2007||2007-06-30|January 2015|2015-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers|Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq (6.75 mCi) ZK 6032924 (18F-FEDAA1106) for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimer's Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of 185 MBq (5 mCi) ZK 6032924 in Healthy Volunteers.|Completed||Phase 1|25|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:15:01.260318|2018-06-01 00:15:01.260318
NCT01035151|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2009-12-17|2009-12-17|2009-12-18|Estimate|||||||2009-12-17|2009-12-18|Estimate|July 2009||2009-07-31|December 2009|2009-12-31|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|||Smoking Cessation Intervention in Public Housing|Social Ecological Based Smoking Cessation Intervention in Public Housing Neighborhoods|Unknown status|Enrolling by invitation|N/A|420|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 00:15:01.361448|2018-06-01 00:15:01.361448
NCT01035138|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2013-11-06|2011-08-09|2014-09-22|2009-12-17|2009-12-18|Estimate|2014-09-22|2014-09-25|Estimate|2011-08-09|2011-08-15|Estimate|2014-09-22|2014-09-25|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|Identity XT||A Study of Semagacestat for Alzheimer's Patients|Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC)|Completed||Phase 3|180|Actual|Eli Lilly and Company|Very few participants from LFBC rolled over into LFBF (N = 9). Due to insufficient sample size, the data for LFBC participants who rolled into LFBF were not analyzed.|1|||f||||f||||||||||2018-06-01 00:15:01.610652|2018-06-01 00:15:01.610652
NCT01035125|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2011-07-27|2009-12-17|2009-12-18|Estimate|||||||2011-07-27|2011-07-28|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Effect of One Week Self-management Program in Patients With Fibromyalgia|A Study of Effect of One Week Self-management Program in Patients With Fibromyalgia|Completed||N/A|153|Actual|Revmatismesykehuset AS||2|||f||||t||||||||||2018-06-01 00:15:03.56537|2018-06-01 00:15:03.56537
NCT01035112|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-05-24|2009-12-17|2009-12-18|Estimate|||||||2017-05-24|2017-05-30|Actual|April 1995||1995-04-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Magnetic Resonance Imaging of Breast Cancer|Magnetic Resonance Imaging of Breast Cancer|Recruiting|||445|Anticipated|Stanford University|||1||f||||||||||||||2018-06-01 00:15:03.643359|2018-06-01 00:15:03.643359
NCT01035099|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2017-04-27|2009-12-17|2009-12-18|Estimate|||||||2017-04-27|2017-05-01|Actual|November 2009||2009-11-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF|A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients|Recruiting||N/A|50|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-06-01 00:15:03.727672|2018-06-01 00:15:03.727672
NCT01035086|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-12-04|2009-12-17|2009-12-18|Estimate|||||||2012-12-04|2012-12-05|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Intervention With Lupin Kernel Fibre in Hypercholesterolemic Subjects|The Preventive Effects of Lupin Kernel Fibre-enriched Food on Colon Cancer and Cardiovascular Diseases in Moderate Hypercholesterolemic Subjects|Completed||N/A|54|Actual|University of Jena||3|||f||||t||||||||||2018-06-01 00:15:03.824836|2018-06-01 00:15:03.824836
NCT01035073|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-07-27|2009-12-17|2009-12-18|Estimate|||||||2012-07-27|2012-07-31|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome|Functional Change and Efficacy of Duloxetine in Patients With Major Depression and Co-Morbid Soft Tissue Discomfort Symptoms|Completed||Phase 4|22|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:15:03.901508|2018-06-01 00:15:03.901508
NCT01035060|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2012-12-04||2012-12-04|2009-12-17|2009-12-18|Estimate|2012-12-04|2013-01-09|Estimate||||2012-12-04|2013-01-09|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Blood Flow, Muscle Regeneration and Sarcopenia|Role of Skeletal Muscle Blood in Muscle Regeneration and Sarcopenia|Completed|||68|Actual|University of Florida|||2||f||||t||||||Samples Without DNA|"~     Serum/Plasma; Skeletal Muscle; Adipose Tissue~   "|||2018-06-01 00:15:03.973261|2018-06-01 00:15:03.973261
NCT01035047|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|2012-10-31||2017-11-06|2009-12-17|2009-12-18|Estimate|2012-10-31|2012-11-29|Estimate||||2017-11-06|2017-12-08|Actual|January 2010||2010-01-31|February 2017|2017-02-28|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|||Randomized Investigation of Chest Pain Diagnostic Strategies|Randomized Investigation of Chest Pain Diagnostic Strategies|Completed||N/A|105|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-06-01 00:15:04.236392|2018-06-01 00:15:04.236392
NCT01035034|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2009-12-18|2009-12-17|2009-12-18|Estimate|||||||2009-12-18|2009-12-21|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||December 2012|Anticipated|2012-12-31||Interventional|||Comparison of One-stop Hybrid Revascularization Versus Percutaneous Coronary Intervention for the Treatment of Multi-vessel Disease|"Comparison of One-stop Hybrid Coronary Revascularization Versus Percutaneous Coronary Intervention for the Treatment of Multi-vessel Coronary Artery Disease"|Unknown status|Recruiting|N/A|480|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||||2018-06-01 00:15:04.959665|2018-06-01 00:15:04.959665
NCT01035021|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-11-14|2009-12-17|2009-12-18|Estimate|||||||2013-11-14|2013-11-15|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Neuromuscular Block in Laryngeal Mask Airway(LMA) Insertion|Effect of Neuromuscular Blockade on the Insertion of ProSeal™ Laryngeal Mask Airway and Postoperative Pharyngolaryngeal Discomfort|Completed||N/A|160|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:15:05.089285|2018-06-01 00:15:05.089285
NCT01035008|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2012-10-19|2009-12-17|2009-12-18|Estimate|||||||2012-10-19|2012-10-23|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Confocal Endomicroscopy of Pancreatic InVivo|Detection of Neoplastic Pancreatic Cysts Using Probe Based Confocal Laser Endomicroscopy: A Prospective in Vivo Study|Completed||N/A|20|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:15:05.173858|2018-06-01 00:15:05.173858
NCT01034995|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2011-04-13|2009-12-17|2009-12-18|Estimate|||||||2011-04-13|2011-04-14|Estimate|February 2010||2010-02-28|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|AGATE||A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder|An Eight-week, Multinational, Multicenter, Double-blind, Active- and Placebo-controlled Clinical Trial Evaluating the Efficacy and Tolerability of Three Fixed Doses of SSR125543 (20 mg Daily, 50 mg Daily and 100 mg Daily) in Outpatients With Major Depressive Disorder|Completed||Phase 2|580|Anticipated|Sanofi||5|||f||||t||||||||||2018-06-01 00:15:05.26343|2018-06-01 00:15:05.26343
NCT01034982|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-02-04|2009-12-17|2009-12-18|Estimate|||||||2010-02-04|2010-02-05|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||AZD9668 Relative Bioavailability|A Phase I Open-label, Single-centre, Two Cohort Crossover Study to Assess the Relative Bioavailability After Oral Administration of AZD9668 Free Base Dosed as a Suspension Compared to AZD9669 Tosylate Salt Dosed as a Tablet|Completed||Phase 1|28|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:15:05.504873|2018-06-01 00:15:05.504873
NCT01034969|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2017-01-26|2009-12-17|2009-12-18|Estimate|||||||2017-01-26|2017-01-27|Estimate|May 2009||2009-05-31|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS)|Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS)|Recruiting|||3000|Anticipated|Shire|||1||f||||f||||||||No||2018-06-01 00:15:05.671934|2018-06-01 00:15:05.671934
NCT01034956|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2012-04-29|2009-12-17|2009-12-18|Estimate|||||||2012-04-29|2012-05-01|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|||Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections|Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections|Completed|||20|Actual|The New York Eye & Ear Infirmary|||1||f||||f||||||||||2018-06-01 00:15:06.130469|2018-06-01 00:15:06.130469
NCT01034943|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2014-03-12|2009-12-17|2009-12-18|Estimate|||||||2014-03-12|2014-03-13|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Extraarticular Distal Radius Fractures, X-fix or Volar Fixation|Dorsally Displaced Extraarticular Distal Radius Fractures - Volar Plate or External Fixation. A Prospective Randomized Trial|Completed||N/A|70|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 00:15:06.261899|2018-06-01 00:15:06.261899
NCT01034930|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2015-02-02|2009-12-17|2009-12-18|Estimate|||||||2015-02-02|2015-02-04|Estimate|August 2004||2004-08-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|September 2009|Actual|2009-09-30||Interventional|||Clinical Study on the Efficiency of Three Different Attachment Systems for Implant-supported Mandibular Overdenture|A 5-year Prospective Randomised Clinical Study on the Efficiency of Three Different Attachment Systems as Retention for Implant-supported Mandibular Overdenture.|Completed||N/A|69|Actual|Concordia Dent Srl||3|||f||||t||||||||||2018-06-01 00:15:06.395766|2018-06-01 00:15:06.395766
NCT01034917|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-10-24|2009-12-17|2009-12-18|Estimate|||||||2012-10-24|2012-10-25|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression|Pilot Study to Assess the Efficacy and Safety of Switching Protease Inhibitor to Etravirine in HIV-1-infected Subjects With Viremia Suppression|Completed||Phase 3|43|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 00:15:06.662235|2018-06-01 00:15:06.662235
NCT01034904|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2013-12-08|2009-12-17|2009-12-18|Estimate|||||||2013-12-08|2013-12-10|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Observational|||Health Related Quality of Life of Youth and Young Adults With Hemophilia A|A Prospective Non-Interventional Study to Describe Health Related Quality of Life of Youth and Young Adults With Moderate or Severe Hemophilia A Using Recombinant Factor VIII (Helixate FS).|Completed|||48|Actual|CSL Behring|||1||f||||t||||||||||2018-06-01 00:15:06.791522|2018-06-01 00:15:06.791522
NCT01034891|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2009-12-17|2009-12-17|2009-12-18|Estimate|||||||2009-12-17|2009-12-18|Estimate|January 1991||1991-01-31|October 2009|2009-10-31||||||||Observational|WAR||Women At Risk: The High Risk Breast Cancer Program|Women At Risk: The High Risk Breast Cancer Program|Unknown status|Recruiting||2000|Anticipated|New York Presbyterian Hospital|||||f||||f||||||||||2018-06-01 00:15:06.912048|2018-06-01 00:15:06.912048
NCT01034878|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2014-12-22|2009-12-17|2009-12-18|Estimate|||||||2014-12-22|2014-12-23|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Sunitinib in Metastatic Renal Cancer|Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology|Completed||Phase 2|25|Actual|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-06-01 00:15:07.015789|2018-06-01 00:15:07.015789
NCT01034865|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-04-27|2009-12-16|2009-12-18|Estimate|||||||2017-04-27|2017-05-01|Actual|May 2001||2001-05-31|April 2017|2017-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer|Risk Factors and Molecular Genomics for Hepatocellular Carcinoma in U.S. Patients With Chronic Liver Disease: A Case Control Study|Completed|||750|Actual|Stanford University|||2||f||||||||||Samples With DNA|"~     blood~   "|||2018-06-01 00:15:07.106038|2018-06-01 00:15:07.106038
NCT01034852|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2012-02-17|2009-12-17|2009-12-18|Estimate|||||||2012-02-17|2012-02-22|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|SAVED||Efficacy Study for Surgery After Previous Failed Catheter Ablation|Surgery After Previous Failed Catheter Ablation|Completed|||45|Actual|Cardiopulmonary Research Science and Technology Institute|||1||f||||f||||||None Retained|"~     no biospecimens will be obtained.~   "|||2018-06-01 00:15:07.163834|2018-06-01 00:15:07.163834
NCT01034839|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-18|Estimate|||||||2009-12-16|2009-12-18|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|||High-dose Cytarabine and Survival in AML|Role of Consolidation With High-dose Cytarabine in Overall Survival of Adults With Acute Myeloid Leukemia|Completed|||499|Actual|University of Sao Paulo General Hospital|||1||f||||t||||||||||2018-06-01 00:15:07.570457|2018-06-01 00:15:07.570457
NCT01034826|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-17|||2010-06-08|2009-12-17|2009-12-18|Estimate|||||||2010-06-08|2010-06-09|Estimate|February 2007||2007-02-28|December 2009|2009-12-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Observational|||Progression to Impaired Glucose Tolerance and Type 2 Diabetes in the Korean People-based KNDP Study||Completed|||500|Anticipated|Korea University Guro Hospital|||1||f||||t||||||||||2018-06-01 00:15:07.677751|2018-06-01 00:15:07.677751
NCT01034813|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2015-02-02|2009-12-16|2009-12-18|Estimate|||||||2015-02-02|2015-02-04|Estimate|March 2010||2010-03-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Joint Range of Motion in Burn Scars|Assessment of Joint Range of Motion and Cutaneous Functional Unit Recruitment: Association With Burn Scar Characteristics|Terminated|||43|Actual|United States Army Institute of Surgical Research|||2|New PI discovered that some of previously collected data may not be accurate|f||||f||||||||||2018-06-01 00:15:07.764514|2018-06-01 00:15:07.764514
NCT01034800|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|September 2006||2006-09-30|January 2009|2009-01-31||||||||Observational|||The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215|The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:15:07.861271|2018-06-01 00:15:07.861271
NCT01034787|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2017-10-25|2009-12-16|2009-12-17|Estimate|||||||2017-10-25|2017-10-27|Actual|August 17, 2009|Actual|2009-08-17|October 2017|2017-10-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma|Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma|Completed||Phase 2|11|Actual|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-06-01 00:15:07.945519|2018-06-01 00:15:07.945519
NCT01034774|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2012-02-24|2009-12-16|2009-12-17|Estimate|||||||2012-02-24|2012-02-27|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Phase 1 Study to Determine Safety, Blood PK and Lung Penetration|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) ACHN-490 in Healthy Subjects|Completed||Phase 1|40|Actual|Achaogen, Inc.||2|||f||||f||||||||||2018-06-01 00:15:08.133601|2018-06-01 00:15:08.133601
NCT01034761|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2015-03-07|2009-12-16|2009-12-17|Estimate|||||||2015-03-07|2015-03-10|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Using Clinical Alerts to Decrease Inappropriate Medication Prescribing|Using Clinical Alerts in a Computerized Provider Order Entry System to Decrease Inappropriate Medication Prescribing Among Hospitalized Elders|Completed||N/A|719|Actual|Baystate Medical Center||2|||f||||f||||||||||2018-06-01 00:15:08.226646|2018-06-01 00:15:08.226646
NCT01034748|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2010-03-11|2009-12-15|2009-12-17|Estimate|||||||2010-03-11|2010-03-12|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-00299804 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:15:08.338994|2018-06-01 00:15:08.338994
NCT01034735|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2013-10-22|2009-12-16|2009-12-17|Estimate|||||||2013-10-22|2013-10-23|Estimate|July 2008||2008-07-31|October 2013|2013-10-31||||August 2008|Actual|2008-08-31||Interventional|||r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial|Phase I, Open Label, Randomised Three-way Cross Over, Single-centre Trial to Assess the Bioequivalence for Two Concentrations of the New r-hGH Liquid Multidose Formulation Versus the r-hGH Freeze-dried Multidose Formulation Administered in Healthy Volunteers|Completed||Phase 1|30|Actual|EMD Serono||3|||f||||f||||||||||2018-06-01 00:15:08.471162|2018-06-01 00:15:08.471162
NCT01034722|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Fat Globules in Breast Milk||Unknown status|Not yet recruiting||45|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||f||||||||||2018-06-01 00:15:08.69987|2018-06-01 00:15:08.69987
NCT01034709|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2014-07-08||2014-08-01|2009-12-16|2009-12-17|Estimate|2014-08-01|2014-08-20|Estimate||||2014-08-01|2014-08-20|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Observational|CMV|Age, gender, and race/ethnicity data was not collected for the Asymptomatic arm of this study.|Evaluation of the Artus® CMV PCR Test|Clinical Evaluation of the Artus® CMV RG PCR Test|Completed|||111|Actual|QIAGEN Gaithersburg, Inc|||2||f||||f||||||Samples With DNA|"~     Extracted DNA~   "|||2018-06-01 00:15:08.797898|2018-06-01 00:15:08.797898
NCT01034696|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2016-05-20|2009-12-16|2009-12-17|Estimate|||||||2016-05-20|2016-05-23|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting|Pain Prevalence and Risk Factors Amongst Sarcoma/Melanoma Oncology Outpatients. A Baseline, Cross Sectional Study Towards a Pain Free Hospital|Completed|||250|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:15:09.123561|2018-06-01 00:15:09.123561
NCT01034683|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2010-01-04|2009-12-16|2009-12-17|Estimate|||||||2010-01-04|2010-01-05|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma|Phase 3 Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Recurrent or Metastatic Esophageal Carcinoma|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|Taian Cancer Hospital||1|||f||||f||||||||||2018-06-01 00:15:09.204212|2018-06-01 00:15:09.204212
NCT01034657|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2016-08-25||2017-08-08|2009-12-16|2009-12-17|Estimate|2016-11-30|2017-01-25|Estimate||||2017-08-08|2017-08-11|Actual|November 2009||2009-11-30|August 2017|2017-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|GEPARD|Core Phase (all participants)|LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)|A One Year, Open Label, Multicenter Trial of LBH589 Alone or in Combination With ESA in Red Blood Cell Transfusion-dependent LOW and INT-1 MDS Patients Being Either Refractory to ESA or With a Low Probability of Response - the GErman PAnobinostat Low Risk MDS Trial - GEPARD Study|Terminated||Phase 2|34|Actual|Novartis||2||"The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open~   label core phase and due to enrollment difficulties."|f||||||||||||||2018-06-01 00:15:09.527343|2018-06-01 00:15:09.527343
NCT01034644|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2014-07-30|2009-12-16|2009-12-17|Estimate|||||||2014-07-30|2014-07-31|Estimate|March 2010||2010-03-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Observational|PRISMS-15||Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)|A Multinational, Multicenter, Single Visit, Exploratory Pharmacogenetic Trial and Long-term Follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Trial|Completed|||290|Actual|Merck KGaA|||1||f||||f||||||Samples With DNA|"~     Whole blood sampling for:~      Genetic markers BAbs/NAbs~   "|||2018-06-01 00:15:10.176656|2018-06-01 00:15:10.176656
NCT01034631|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2017-01-25||2017-04-17|2009-12-15|2009-12-17|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|January 2010||2010-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma|Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors|Completed||Phase 1/Phase 2|154|Actual|Hoosier Cancer Research Network||2|||f||||t||||||||||2018-06-01 00:15:10.313249|2018-06-01 00:15:10.313249
NCT01034618|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|December 2007||2007-12-31|December 2009|2009-12-31|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional|||Protein Hydrolyzation and Glycemic Control|The Additional Effects of Protein Hydrolysate Supplementation on Glucose Homeostasis in Type 2 Diabetes|Completed||N/A|||Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 00:15:13.02555|2018-06-01 00:15:13.02555
NCT01034605|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-08-29|2009-12-16|2009-12-17|Estimate|||||||2012-08-29|2012-08-30|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|PinnoThin||The Effect of PinnoThin on Satiety and Food Intake|The Effect of PinnoThin on Satiety and Food Intake|Completed||N/A|40|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-06-01 00:15:13.235416|2018-06-01 00:15:13.235416
NCT01034592|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2016-12-13||2017-06-27|2009-12-15|2009-12-17|Estimate|2016-12-13|2017-02-07|Estimate||||2017-06-27|2017-08-02|Actual|November 2009||2009-11-30|June 2017|2017-06-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia|A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia|Terminated||Phase 1|2|Actual|Stanford University|Only 2 subjects were enrolled on this protocol. Low accrual was related to various factors. Given the accrual status, no substantive conclusions about the efficacy or safety of lenalidomide in adults with Diamond-Blackfan Anemia could be reached.|1||Poor accrual related to rarity of Diamond-Blackfan anemia (DBA)|f||||t|t|f||||||No||2018-06-01 00:15:13.321437|2018-06-01 00:15:13.321437
NCT01034579|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2014-01-27||2014-01-27|2009-12-16|2009-12-17|Estimate|2014-01-27|2014-03-10|Estimate||||2014-01-27|2014-03-10|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|REGARD-PGx|Evaluable population included all randomized participants who had received at least 1 dose of Rebif® or Copaxone® in 24735 (NCT00078338) and not participated in the initial PGx sub-study and provided consent to take part in this EMR200136_023 study (NCT01034579).|The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial|A Multinational, Multicenter, Single Blood Sampling Exploratory Pharmacogenetic Study of the REGARD (the REbif® vs Glatiramer Acetate in Relapsing MS Disease) Trial|Completed||Phase 4|324|Actual|EMD Serono||2|||f||||f||||||||||2018-06-01 00:15:14.585626|2018-06-01 00:15:14.585626
NCT01034566|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2016-07-15|2009-12-15|2009-12-17|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2009||2009-11-30|July 2016|2016-07-31||||November 2012|Actual|2012-11-30||Interventional|||Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma|Proton Radiotherapy for Retroperitoneal Sarcoma|Active, not recruiting||Phase 1|54|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:15:15.228319|2018-06-01 00:15:15.228319
NCT01034553|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2015-10-16||2016-04-18|2009-12-16|2009-12-17|Estimate|2016-04-18|2016-05-25|Estimate||||2016-04-18|2016-05-25|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase I/II Study of Combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|26|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:15:15.3433|2018-06-01 00:15:15.3433
NCT01034540|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2013-05-28||2013-08-14|2009-12-16|2009-12-17|Estimate|2013-08-14|2013-10-22|Estimate||||2013-08-14|2013-10-22|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional||Baseline/adverse event analyses reported for safety population (all randomized subjects who consumed at least 1 dose of study product; n=23). Outcome measures reported for per protocol population (excluded subjects with poor compliance, protocol violations, or without at least 1 outcome data point during each treatment intervention n=19).|Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia|A Double-blind, Randomized, Placebo-controlled, Crossover Trial to Assess the Effects of 4 g/d Prescription Omega-3 Acid Ethyl Esters on Indices of Glucose Homeostasis and Lipoprotein Lipids in Subjects With Hypertriglyceridemia|Completed||N/A|23|Actual|Provident Clinical Research|Potential limitations: 1) relatively small sample size, and 2) relatively short length of wash-out period between treatments.|2|||f||||f||||||||||2018-06-01 00:15:16.091183|2018-06-01 00:15:16.091183
NCT01034527|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2014-03-25|2009-12-16|2009-12-17|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes|Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female|Completed||N/A|593|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 00:15:16.533152|2018-06-01 00:15:16.533152
NCT01034514|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-05-03|2009-12-16|2009-12-17|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2009|Actual|2009-12-31|May 2017|2017-05-31|June 24, 2014|Actual|2014-06-24|June 24, 2014|Actual|2014-06-24||Interventional|||4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy|4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy|Terminated||Early Phase 1|35|Actual|Stanford University||1||business decision|f||||t|t|f||||||||2018-06-01 00:15:16.669736|2018-06-01 00:15:16.669736
NCT01034501|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2013-10-09|2009-12-16|2009-12-17|Estimate|||||||2013-10-09|2013-10-10|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Adjunctive Photodynamic Therapy in Treatment of Chronic Periodontitis|Efficacy of Adjunctive Photodynamic Therapy in Non-surgical Treatment of Chronic Periodontitis: a Randomized , Controlled Clinical Trial|Completed||Phase 4|38|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:15:16.80731|2018-06-01 00:15:16.80731
NCT01034488|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2011-01-27|2009-12-16|2009-12-17|Estimate|||||||2011-01-27|2011-01-28|Estimate|August 2010||2010-08-31|January 2011|2011-01-31|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Pharmacodynamics Aspects Of Porcine Heparin Sodium, Produced by Eurofarma, Compared Heparin Sodium, Produced by APP Pharmaceuticasls, in Patients With Chronic Renal Failure||Unknown status|Not yet recruiting|Phase 2/Phase 3|128|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:15:16.907339|2018-06-01 00:15:16.907339
NCT01034475|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-05-25|2009-12-16|2009-12-17|Estimate|||||||2017-05-25|2017-05-30|Actual|March 2010||2010-03-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Interventional|||Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies|An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies|Completed||Phase 1|26|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-06-01 00:15:17.00638|2018-06-01 00:15:17.00638
NCT01034462|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2013-08-22|2011-12-30|2013-08-22|2009-12-16|2009-12-17|Estimate|2013-08-22|2013-10-25|Estimate|2011-12-30|2012-01-04|Estimate|2013-08-22|2013-10-25|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||While 442 patients were randomized to receive double-blind treatment, 8 of these patients discontined before receiving double-blind treatment. The Baseline Participant population is based on the 434 randomized patients who went on to receive double-blind treatment (Safety Population).|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder|Completed||Phase 3|442|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:15:17.100429|2018-06-01 00:15:17.100429
NCT01034449|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2015-01-12|2009-12-16|2009-12-17|Estimate|||||||2015-01-12|2015-01-13|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|September 2014|Actual|2014-09-30|October 2013|Actual|2013-10-31||Interventional|GRAPA||Transplantation of Ex-vivo Expanded Cord Blood Stems Cells|Transplantation of Ex-vivo Expanded Human Cord Blood Hematopoietic Stem Cells Expanded: Evaluation of Hematopoietic and Immunologic Reconstitution After a Reduced-intensity Conditioning Regimen|Completed||Phase 2|16|Actual|University Hospital, Bordeaux|||||f||||t||||||||||2018-06-01 00:15:17.71919|2018-06-01 00:15:17.71919
NCT01034436|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2015-06-17|2009-12-16|2009-12-17|Estimate|||||||2015-06-17|2015-06-18|Estimate|February 2009||2009-02-28|June 2015|2015-06-30||||June 2009|Actual|2009-06-30||Interventional|||Fatty Acid Quality and Overweight (FO-study)|Fatty Acid Quality and Overweight|Completed||N/A|41|Actual|Oslo and Akershus University College of Applied Sciences||3|||f||||f||||||||||2018-06-01 00:15:17.921737|2018-06-01 00:15:17.921737
NCT01034423|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2015-02-03|2009-12-16|2009-12-17|Estimate|||||||2015-02-03|2015-02-04|Estimate|September 2009||2009-09-30|February 2015|2015-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Omega-3 Fatty Acids and Health Effects|Omega-3 Fatty Acids and Health Effects|Completed||N/A|69|Actual|Oslo and Akershus University College of Applied Sciences||3|||f||||f||||||||||2018-06-01 00:15:18.02674|2018-06-01 00:15:18.02674
NCT01034410|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2011-02-01|2009-12-16|2009-12-17|Estimate|||||||2011-02-01|2011-02-02|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia|An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia|Terminated||Phase 2|90|Anticipated|Antisoma Research||3|||f||||f||||||||||2018-06-01 00:15:18.145305|2018-06-01 00:15:18.145305
NCT01034397|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2014-07-09||2018-02-28|2009-12-16|2009-12-17|Estimate|2015-01-22|2015-02-06|Estimate||||2018-02-28|2018-03-29|Actual|March 2010||2010-03-31|February 2018|2018-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Intent-to Treat (ITT) population: all participants randomized who had at least one efficacy measurement performed.|A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs|A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs|Completed||Phase 4|54|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:15:18.358952|2018-06-01 00:15:18.358952
NCT01034384|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2018-04-04|2009-12-16|2009-12-17|Estimate|||||||2018-04-04|2018-04-05|Actual|December 5, 2000||2000-12-05|November 6, 2012|2012-11-06|November 6, 2012||2012-11-06|||||Observational|||Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence|Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence|Completed|||119|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:15:19.950828|2018-06-01 00:15:19.950828
NCT01034371|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-18|2009-12-16|2009-12-17|Estimate|||||||2009-12-18|2009-12-21|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||December 2012|Anticipated|2012-12-31||Interventional|||Comparison of One-stop Hybrid Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Disease|"Comparison of One-stop Hybrid Coronary Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Coronary Artery Disease"|Unknown status|Recruiting|N/A|400|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||||2018-06-01 00:15:20.083633|2018-06-01 00:15:20.083633
NCT01034176|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2014-01-21||2017-03-24|2009-12-16|2009-12-17|Estimate|2017-01-15|2017-03-06|Actual||||2017-03-24|2017-04-24|Actual|February 2009||2009-02-28|March 2017|2017-03-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||BK Treatment Study|Effect of Fluoroquinolones on BK Viremia in the Renal Transplant Recipient, A Multi-Center Study|Completed||Phase 4|43|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 00:15:21.748227|2018-06-01 00:15:21.748227
NCT01034358|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2012-09-21||2012-09-21|2009-12-16|2009-12-17|Estimate|2012-09-21|2012-10-23|Estimate||||2012-09-21|2012-10-23|Estimate|February 2010||2010-02-28|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease|Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease|Completed||Phase 4|15|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:15:20.209772|2018-06-01 00:15:20.209772
NCT01034345|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients|Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients|Unknown status|Recruiting|Phase 2|52|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 00:15:20.436491|2018-06-01 00:15:20.436491
NCT01034332|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2009-12-17|2009-12-16|2009-12-17|Estimate|||||||2009-12-17|2009-12-18|Estimate|December 2007||2007-12-31|December 2009|2009-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Paclitaxel/Cisplatin/Fluorouracil Followed by Paclitaxel/Cisplatin/Radiotherapy and Esophagectomy for Esophageal Cancer|A Phase II Study With One-cycle Weekly TP-HDFL Followed by Twice Weekly TP-CCRT and Esophagectomy for Locally Advanced Esophageal Cancer|Unknown status|Recruiting|Phase 2|58|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:15:20.536322|2018-06-01 00:15:20.536322
NCT01034319|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2011-07-19|2009-12-16|2009-12-17|Estimate|||||||2011-07-19|2011-07-20|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|August 2011|Anticipated|2011-08-31||Interventional|GC/LC||Genetic Counseling and Lifestyle Change for Diabetes Prevention|Genetic Counseling and Lifestyle Change for Diabetes Prevention|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 00:15:20.614903|2018-06-01 00:15:20.614903
NCT01034306|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2015-02-24||2015-02-24|2009-12-16|2009-12-17|Estimate|2015-02-24|2015-03-09|Estimate||||2015-02-24|2015-03-09|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis|A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors|Completed||Phase 2|79|Actual|Can-Fite BioPharma||2|||f||||f||||||||||2018-06-01 00:15:20.70113|2018-06-01 00:15:20.70113
NCT01034293|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2010-07-22|2009-12-16|2009-12-17|Estimate|||||||2010-07-22|2010-07-23|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning|Effect of Feeding Frequency on Glucose and Insulin Metabolism and Substrate Partitioning|Completed||N/A|14|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:15:20.924253|2018-06-01 00:15:20.924253
NCT01034280|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2012-03-21|2009-12-16|2009-12-17|Estimate|||||||2012-03-21|2012-03-22|Estimate|March 2004||2004-03-31|December 2009|2009-12-31|May 2011|Actual|2011-05-31|||||Observational|INTREPID||Correlations Phenotype / Genotype in Down Syndrome|Epidemiological Study of Trisomy 21 With Research of Correlations Between Phenotype (Physical, Psychometrical) and Genotype (Genome, Transcriptome, Proteome)|Completed|||524|Actual|Institut Jerome Lejeune|||||f||||||||||||||2018-06-01 00:15:21.00595|2018-06-01 00:15:21.00595
NCT01034267|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2012-08-15|2009-12-16|2009-12-17|Estimate|||||||2012-08-15|2012-08-17|Estimate|December 2009||2009-12-31|August 2012|2012-08-31||||June 2012|Actual|2012-06-30||Interventional|LVM-MD-04||Safety Study of F2695 SR in Major Depressive Disorder|A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder|Completed||Phase 3|828|Actual|Forest Laboratories||1|||f||||f||||||||||2018-06-01 00:15:21.074963|2018-06-01 00:15:21.074963
NCT01034254|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2016-03-03|2009-12-16|2009-12-17|Estimate|||||||2016-03-03|2016-03-07|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|Mothers'Gift||Field Trial of Maternal Influenza Immunization in Asia|Field Trial of Maternal Influenza Immunization in Asia|Active, not recruiting||Phase 3|3000|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||Undecided|To be determined|2018-06-01 00:15:21.223272|2018-06-01 00:15:21.223272
NCT01034241|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2010-07-22|2009-12-16|2009-12-17|Estimate|||||||2010-07-22|2010-07-23|Estimate|April 2009||2009-04-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Different Protein Diets on Glucose and Insulin Metabolism and Substrate Partitioning|Effect of Different Protein Diets on Glucose and Insulin Metabolism and Substrate Partitioning|Completed||N/A|12|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-06-01 00:15:21.316598|2018-06-01 00:15:21.316598
NCT01034228|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|July 2007||2007-07-31|April 2006|2006-04-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Isoleucine Added ORS in Children With Diarrhoea|Exploratory Study to Evaluate the Effect of L-isoleucine Supplemented Oral Rehydration Solution in the Treatment of Acute Diarrhoea in Children and in Inducing Innate Immunity|Completed||Phase 2|50|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 00:15:21.405939|2018-06-01 00:15:21.405939
NCT01034215|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|August 2008||2008-08-31|December 2009|2009-12-31|October 2010|Anticipated|2010-10-31|September 2010|Anticipated|2010-09-30||Interventional|||Multi-Media Imagery Program for Breast Cancer Patients (Phase II)|Multi-Media Imagery Program for Breast Cancer Patients (Phase II)|Unknown status|Recruiting|Phase 2|135|Anticipated|Mind Matters Research LLC||3|||f||||f||||||||||2018-06-01 00:15:21.482917|2018-06-01 00:15:21.482917
NCT01034202|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-02-08|2009-12-16|2009-12-17|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2007||2007-08-31|February 2017|2017-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®|A Randomised, Double Blind, Placebo-controlled, Single Dose, Dose-escalating Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin® SimpleXx® in Healthy Male Subjects|Completed||Phase 1|56|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-06-01 00:15:21.571545|2018-06-01 00:15:21.571545
NCT01034189|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|June 2012|Anticipated|2012-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer|A Phase II Study of Combining Cetuximab Plus Twice Weekly Paclitaxel/Cisplatin Concurrent Chemoradiotherapy (TP-CCRT) Followed With or Without Esophagectomy for Loco-regional Esophageal Squamous Cell Carcinoma (ESCC)|Unknown status|Recruiting|Phase 2|62|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 00:15:21.657063|2018-06-01 00:15:21.657063
NCT01034163|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2016-03-01||2016-05-27|2009-12-16|2009-12-17|Estimate|2016-05-27|2016-07-07|Estimate||||2016-05-27|2016-07-07|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PATH||A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)|A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT)|Completed||Phase 3|41|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:15:21.97204|2018-06-01 00:15:21.97204
NCT01034150|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|December 2007||2007-12-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Effects of Home-based Neurostimulation Associated With Motor Training in Chronic Stroke Patients|Effects of Home-based Neurostimulation Associated With Motor Training in Chronic Stroke Patients|Completed||Phase 1/Phase 2|20|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-06-01 00:15:22.439425|2018-06-01 00:15:22.439425
NCT01034137|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2016-01-29||2016-06-01|2009-12-16|2009-12-17|Estimate|2016-06-01|2016-07-11|Estimate||||2016-06-01|2016-07-11|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis|U-ACT-EARLY: A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Evaluate Remission in DMARD and Biological naïve Early Rheumatoid Arthritis (RA) Subjects Treated With Tocilizumab (TCZ) Plus Tight Control Methotrexate (MTX) , TCZ Monotherapy or Tight Control MTX Monotherapy|Completed||Phase 3|317|Actual|Hoffmann-La Roche||3|||f||||t||||||||Yes||2018-06-01 00:15:22.612023|2018-06-01 00:15:22.612023
NCT01034124|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-17|Estimate|||||||2009-12-15|2009-12-17|Estimate|January 2007||2007-01-31|December 2009|2009-12-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Mechanisms Underlying Drug-Diet Interactions|Mechanisms Underlying Drug-Diet Interactions|Completed||N/A|19|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:15:24.633233|2018-06-01 00:15:24.633233
NCT01034111|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2011-10-03||2017-04-28|2009-12-16|2009-12-17|Estimate|2011-10-03|2011-11-07|Estimate||||2017-04-28|2017-05-30|Actual|March 1, 2010|Actual|2010-03-01|April 2017|2017-04-30|October 4, 2010|Actual|2010-10-04|October 4, 2010|Actual|2010-10-04||Interventional|||A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)|An Open-label Study to Assess the Safety and Tolerability of JANUVIA (Sitagliptin) in 30 Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|30|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:15:24.713479|2018-06-01 00:15:24.713479
NCT01034098|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Ventilatory Constraint, Breathing Pattern and Ventilatory Responses in Obese Postmenopausal Women|Ventilatory Constraint, Breathing Pattern and Ventilatory Responses in Obese Postmenopausal Women|Completed|||50|Actual|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 00:15:24.959842|2018-06-01 00:15:24.959842
NCT01034085|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2018-04-04|2009-12-16|2009-12-17|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2, 2009||2009-06-02|June 11, 2013|2013-06-11|June 11, 2013||2013-06-11|||||Observational|||Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia|Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia|Completed|||62|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:15:25.033267|2018-06-01 00:15:25.033267
NCT01034072|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2018-04-10|2009-12-16|2009-12-17|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2009|Actual|2009-12-31|April 2018|2018-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Iron Overload in Pediatric Oncology Patients|Evaluation of Iron Overload in Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients|Completed|||75|Actual|Northwell Health|||||f||||f||||||||||2018-06-01 00:15:25.184784|2018-06-01 00:15:25.184784
NCT01034059|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever|Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever|Completed|||75|Actual|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 00:15:25.253051|2018-06-01 00:15:25.253051
NCT01034046|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2010-04-29|2009-12-16|2009-12-17|Estimate|||||||2010-04-29|2010-04-30|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Weight Loss and Abdominal Fat Responses to Different Diet Compositions|Weight Loss and Visceral Fat Responses to Different Diet Compositions|Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Nevada, Las Vegas||2|||f||||t||||||||||2018-06-01 00:15:25.297404|2018-06-01 00:15:25.297404
NCT01034033|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2016-07-12|2009-12-16|2009-12-17|Estimate|||||||2016-07-12|2016-07-14|Estimate|August 2001||2001-08-31|July 2016|2016-07-31|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Observational|||Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples|Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples|Recruiting|||1500|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     blood~   "|||2018-06-01 00:15:25.369815|2018-06-01 00:15:25.369815
NCT01034020|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-06-30|2009-12-16|2009-12-17|Estimate|||||||2017-06-30|2017-07-02|Actual|February 14, 2006||2006-02-14|September 22, 2010|2010-09-22|November 3, 2009|Actual|2009-11-03|November 3, 2009|Actual|2009-11-03||Interventional|||Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers|Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers|Completed||Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:15:25.4702|2018-06-01 00:15:25.4702
NCT01034007|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2018-02-28|2009-12-15|2009-12-17|Estimate|||||||2018-02-28|2018-03-02|Actual|December 2009||2009-12-31|February 2018|2018-02-28|January 23, 2018|Actual|2018-01-23|December 26, 2017|Actual|2017-12-26||Interventional|||A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery|A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery|Completed||Phase 1|4|Actual|Nationwide Children's Hospital||1|||f||||t||||||||||2018-06-01 00:15:25.556027|2018-06-01 00:15:25.556027
NCT01033344|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2010-09-30|2009-12-15|2009-12-16|Estimate|||||||2010-09-30|2010-10-01|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Cat-PAD Exposure Chamber Study|A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber|Completed||Phase 2|210|Anticipated|Circassia Limited||3|||f||||f||||||||||2018-06-01 00:15:44.72346|2018-06-01 00:15:44.72346
NCT01033994|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2014-06-24|2009-12-16|2009-12-17|Estimate|||||||2014-06-24|2014-06-25|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery|A Randomized, Double Blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Primary Osteoarthritis of the Knee Who Are Not Expected to Require Knee Surgery Within One Year|Completed||Phase 1|192|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 00:15:25.660029|2018-06-01 00:15:25.660029
NCT01033981|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2012-04-17|2009-12-15|2009-12-17|Estimate|||||||2012-04-17|2012-04-19|Estimate|May 2010||2010-05-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Cost Effectiveness Of Sunitinib In Central America And Caribbean|Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean|Terminated|||4|Actual|Pfizer|||1|See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:15:25.796658|2018-06-01 00:15:25.796658
NCT01033968|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2010-05-19|2009-12-16|2009-12-17|Estimate|||||||2010-05-19|2010-05-20|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Pain Perception at Laser Treatment|Pain Perception at Laser Treatment of Peripheral Retinal Degenerations With Green and Infrared Wavelengths|Completed||Phase 4|30|Actual|University of Campinas, Brazil|||||f||||t||||||||||2018-06-01 00:15:25.922286|2018-06-01 00:15:25.922286
NCT01033955|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2013-02-20|2009-12-16|2009-12-17|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|CHAT||Collaborative H1N1 Adjuvant Treatment Pilot Trial|Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial|Terminated||Phase 2|8|Actual|Canadian Critical Care Trials Group||2||H1N1 pandemic concluded in early 2010|f||||t||||||||||2018-06-01 00:15:25.982602|2018-06-01 00:15:25.982602
NCT01033942|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2014-10-28||2017-04-14|2009-12-16|2009-12-17|Estimate|2017-02-08|2017-03-29|Actual||||2017-04-14|2017-04-17|Actual|August 2009||2009-08-31|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pre-Exposure Prophylaxis in YMSM|Acceptability and Feasibility of a Pre-Exposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men (YMSM)|Completed||Phase 2|68|Actual|University of North Carolina, Chapel Hill|After release of Pre-exposure Prophylaxis Initiative efficacy results, the Data and Safety Monitoring Board recommended that subjects be unblinded, enrollment stopped, all be offered option of PrEP, subjects on PrEP arm continued as scheduled.|3|||f||||t||||||||||2018-06-01 00:15:26.172752|2018-06-01 00:15:26.172752
NCT01033929|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2013-01-18|2009-12-16|2009-12-17|Estimate|||||||2013-01-18|2013-01-21|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TESEC-02||A Safety and Dose Finding Trial of C-Tb, When Given to Adult Patients Recently Diagnosed With Active Tuberculosis|A Safety and Dose Finding Trial of the Diagnostic Test C-Tb, When Given Intradermally by the Mantoux Technique to Adult Patients Recently Diagnosed With Active TB|Completed||Phase 1|38|Actual|Statens Serum Institut||2|||f||||t||||||||||2018-06-01 00:15:30.554809|2018-06-01 00:15:30.554809
NCT01033916|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2016-05-24|2009-12-16|2009-12-17|Estimate|||||||2016-05-24|2016-05-25|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|April 2011|Actual|2011-04-30||Interventional|SLIP||Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery|Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery|Unknown status|Active, not recruiting|N/A|200|Anticipated|Inova Health Care Services||2|||f||||f||||||||||2018-06-01 00:15:30.624589|2018-06-01 00:15:30.624589
NCT01033903|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2016-02-17|2009-12-16|2009-12-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|December 2015|Actual|2015-12-31||Interventional|||Optimal Treatment of Miscarriage|Which is the Optimal Treatment for Miscarriage With a Gestational ac in the Uterus and Which Factors Can Predict if the Treatment Will be Successful?|Unknown status|Active, not recruiting|N/A|190|Actual|Region Skane||2|||f||||f||||||||||2018-06-01 00:15:30.778511|2018-06-01 00:15:30.778511
NCT01033890|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|IC||Local Anesthesia With Sedation for Cochlear Implant Surgery|Local Anesthesia With Sedation for Cochlear Implant Surgery: 3 Case Report|Completed|||3|Actual|Instituto Paranaense de Otorrinolaringologia|||||f||||t||||||||||2018-06-01 00:15:30.948538|2018-06-01 00:15:30.948538
NCT01033877|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2013-01-18|2009-12-16|2009-12-17|Estimate|||||||2013-01-18|2013-01-21|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults|Immunogenicity and Safety of a Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to a Tetanus and Diphtheria (Td) Vaccine When Given as a Booster Vaccination to Adults|Completed||Phase 3|802|Actual|Statens Serum Institut||2|||f||||f||||||||||2018-06-01 00:15:31.02614|2018-06-01 00:15:31.02614
NCT01033864|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2014-05-08||2015-08-19|2009-12-16|2009-12-17|Estimate|2014-10-08|2014-10-10|Estimate||||2015-08-19|2015-08-27|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||The pharmacokinetic (PK) population included all randomized participants.|A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients|Comparison of Pharmocokinetics of Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium in Calcineurininhibitor-free Treated Patients After Renal Transplantation|Completed||Phase 4|23|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:15:31.242013|2018-06-01 00:15:31.242013
NCT01033851|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2013-02-21||2014-05-29|2009-12-15|2009-12-17|Estimate|2013-05-07|2013-06-11|Estimate||||2014-05-29|2014-06-04|Estimate|March 2008||2008-03-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Interventional|||Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects|Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects|Completed||Phase 4|89|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 00:15:31.79665|2018-06-01 00:15:31.79665
NCT01033838|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2009-12-16|2009-12-16|2009-12-17|Estimate|||||||2009-12-16|2009-12-17|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||December 2011|Anticipated|2011-12-31||Interventional|LATA||Randomized Trial Comparing Laparoscopic-assisted Rectosigmoid Resection Versus Laparoscopic Rectosigmoid Resection With Transrectal Specimen Retrieval|Conventional Laparoscopic-assisted Rectosigmoid Resection Versus Laparoscopic Rectosigmoid Resection With Intracorporeal Anastomosis and Transrectal Specimen Retrieval|Unknown status|Recruiting|Phase 2|1|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-06-01 00:15:32.062065|2018-06-01 00:15:32.062065
NCT01033825|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|2012-02-15|2010-09-17|2012-07-17|2009-12-16|2009-12-17|Estimate|2012-07-17|2012-07-19|Estimate|2010-09-17|2010-09-21|Estimate|2012-07-17|2012-07-19|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis|A 6-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety and Efficacy Study of the Potential Inhibitory Effects on the Hypothalamic-Pituitary-Adrenal Axis of Ciclesonide HFA Nasal Aerosol and Ciclesonide Aqueous Nasal Spray in Subjects 12 Years and Older With Perennial Allergic Rhinitis|Completed||Phase 3|310|Actual|Sunovion|Dose levels investigated were higher than the US FDA approved dose (74 mcg once daily) for allergic rhinitis subjects. Publication references to 148 and 282mcg are equivalent to 160 and 320mcg.|7|||f||||f||||||||||2018-06-01 00:15:32.192604|2018-06-01 00:15:32.192604
NCT01033812|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-02-27|2009-12-16|2009-12-17|Estimate|||||||2017-02-27|2017-02-28|Actual|May 2010||2010-05-31|March 2016|2016-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||ID & Testing in Male Partners|A Pilot Study to Identify and Describe the Male Sexual Partners of Adolescent and Young Adult Women Enrolled in ATN 067|Completed|||177|Actual|University of North Carolina, Chapel Hill|||2||f||||t||||||||||2018-06-01 00:15:36.191348|2018-06-01 00:15:36.191348
NCT01033799|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-16|||2017-01-18|2009-12-16|2009-12-17|Estimate|||||||2017-01-18|2017-01-20|Estimate|October 2006||2006-10-31|January 2017|2017-01-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers|Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers|Completed||N/A|1000|Actual|Danone Research||2|||f||||f||||||||||2018-06-01 00:15:36.27171|2018-06-01 00:15:36.27171
NCT01033786|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2011-04-08|2009-12-15|2009-12-16|Estimate|||||||2011-04-08|2011-04-11|Estimate|October 2009||2009-10-31|April 2011|2011-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Robotic Urogynecological Surgery: Hospital Stay and Perioperative Complications|Recovery After Robotic Urogynecological Surgery: Hospital Stay and Perioperative Complications of Patients Who Did Not Complete Questionnaires|Completed|||21|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 00:15:36.358305|2018-06-01 00:15:36.358305
NCT01033773|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2009-12-14|2009-12-14|2009-12-16|Estimate|||||||2009-12-14|2009-12-16|Estimate|September 2007||2007-09-30|December 2009|2009-12-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|STEP-DC||Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)|STEP-DC: Stop Emergency Room Visits for Uncontrolled Hyperglycemia Project in the District of Columbia|Completed||N/A|86|Actual|Medstar Health Research Institute|||||f||||f||||||||||2018-06-01 00:15:36.438054|2018-06-01 00:15:36.438054
NCT01033760|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2014-02-04|2009-12-15|2009-12-16|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2010||2010-04-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)|Optimisation of Primary HIV1 Infection Treatment (ANRS 147 OPTIPRIM)|Completed||Phase 3|90|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||f||||||||||2018-06-01 00:15:36.511702|2018-06-01 00:15:36.511702
NCT01033747|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2010-12-21||2011-07-18|2009-12-15|2009-12-16|Estimate|2011-07-18|2011-08-11|Estimate||||2011-07-18|2011-08-11|Estimate|February 2003||2003-02-28|July 2011|2011-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study|A 5-year Open Label, Non-comparative Extension to a Randomized, Open-label, Phase IIa Study to Evaluate Safety, Tolerability and the Effects on Liver Iron Concentration of Repeated Doses of 10 and 20 mg/kg/Day of Deferasirox in Comparison With 40 mg/kg/Day Deferoxamine in Patients With Transfusion-dependent Iron Overload|Completed||Phase 2/Phase 3|70|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:15:36.629803|2018-06-01 00:15:36.629803
NCT01033734|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2016-01-15||2016-07-13|2009-12-15|2009-12-16|Estimate|2016-07-13|2016-08-24|Estimate||||2016-07-13|2016-08-24|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All-participants population included all participants who were enrolled in the study.|A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza|An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection|Completed||Phase 1|8|Actual|Hoffmann-La Roche|Low number of participants enrolled in the study at the time that the study was terminated limits conclusions that can be derived from the study data.|1|||f||||||||||||||2018-06-01 00:15:37.320364|2018-06-01 00:15:37.320364
NCT01033721|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-09-20|2009-12-15|2009-12-16|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|P52901||Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration|A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients With Advanced Neovascular Age-Related Macular Degeneration (AMD)|Completed||Phase 1|13|Actual|Paloma Pharmaceuticals, Inc.|||||f||||t||||||||||2018-06-01 00:15:38.149694|2018-06-01 00:15:38.149694
NCT01033708|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2013|Anticipated|2013-10-31|October 2011|Anticipated|2011-10-31||Interventional|NET||A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder|A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder|Unknown status|Recruiting|N/A|80|Anticipated|Zentrum für Integrative Psychiatrie||2|||f||||f||||||||||2018-06-01 00:15:38.227509|2018-06-01 00:15:38.227509
NCT01033695|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Interobserver Agreement of Endoscopic Ultrasonography and Endoscopic Sonoelastography in the Evaluation of Lymph Nodes|Interobserver Agreement of Endoscopic Ultrasonography and Endoscopic Sonoelastography in the Evaluation of Lymph Nodes|Completed|||74||Odense University Hospital|||||f||||f||||||||||2018-06-01 00:15:38.324028|2018-06-01 00:15:38.324028
NCT01033682|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|FILL||Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging|Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging|Unknown status|Recruiting||10|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:15:38.394466|2018-06-01 00:15:38.394466
NCT01033669|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-03-15|2009-12-15|2009-12-16|Estimate|||||||2010-03-15|2010-03-17|Estimate|November 2009||2009-11-30|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction|A Randomized Cross-Over Study Investigating The Inhalation Profiles Of Four Dry Powder Inhalation Devices In Subjects With Asthma And Chronic Obstructive Pulmonary Disease.|Completed|||57|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:15:38.447731|2018-06-01 00:15:38.447731
NCT01033656|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2017-03-03|2009-12-15|2009-12-16|Estimate|||||||2017-03-03|2017-03-06|Actual|December 2005||2005-12-31|March 2017|2017-03-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|NordicAOSD05||Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study|An Open, Randomized Study Treating Refractory Adult-onset Still's Disease With Interleukin-1 Receptor Antagonist Anakinra (Kineret), Compared to an Established, Single Anti-rheumatic Drug Treatment|Completed||Phase 2|23|Actual|Helsinki University||2|||f||||f||||||||No||2018-06-01 00:15:38.565916|2018-06-01 00:15:38.565916
NCT01033643|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2015-06-23|2009-12-15|2009-12-16|Estimate|||||||2015-06-23|2015-06-24|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Multiple Dose Study of MK3614 (3614-002)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3614|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 00:15:38.642853|2018-06-01 00:15:38.642853
NCT01033630|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Cardiovascular-Protective Effects of Herbal Medicine Danshen-Gegen|A Novel Randomized Double-Blind Placebo-Control Clinical Trial in High-Risk Hypertensive Subjects|Completed||Phase 2|90|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 00:15:38.699538|2018-06-01 00:15:38.699538
NCT01033617|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2017-10-16|2009-12-15|2009-12-16|Estimate|||||||2017-10-16|2017-10-18|Actual|December 2009||2009-12-31|July 2015|2015-07-31|June 2016|Actual|2016-06-30|December 2014|Actual|2014-12-31||Interventional|IMPACT-CABG||IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG|The IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG With Left Ventricular Dysfunction: the IMPACT-CABG Study|Completed||N/A|20|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 00:15:38.857546|2018-06-01 00:15:38.857546
NCT01033604|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2014-12-04|2009-12-15|2009-12-16|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|||Glyaderm + Split Thickness Skin Graft Versus Split Thickness Skin Graft Alone in Full Thickness Skin Defects|Clinical Application of a Novel Dermal Substitute Based on Glycerol Preserved Allograft: GLYADERM|Completed||N/A|31|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 00:15:38.944957|2018-06-01 00:15:38.944957
NCT01033591|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2014-12-19|2009-12-15|2009-12-16|Estimate|||||||2014-12-19|2014-12-23|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|EFICAR||Exercise for Patients With Heart Failure in Primary Care: the EFICAR|Rationale and Design of a Randomised Controlled Trial Evaluating the Effectiveness of an Exercise Program to Improve the Quality of Life of Patients With Heart Failure in Primary Care: The EFICAR Study Protocol|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-06-01 00:15:39.012374|2018-06-01 00:15:39.012374
NCT01033578|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|October 1999||1999-10-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Efficacy of Postoperative Adjuvant Treatments After Hepatectomy and Thrombectomy for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Unknown status|Recruiting|N/A|260|Anticipated|Fudan University||4|||f||||t||||||||||2018-06-01 00:15:39.088978|2018-06-01 00:15:39.088978
NCT01033565|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2013-06-24||2013-09-04|2009-12-15|2009-12-16|Estimate|2013-09-04|2013-09-09|Estimate||||2013-09-04|2013-09-09|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders|Controlled-Release Melatonin (Melatonin CR)for the Treatment of Impaired Sleep Maintenance (ISM) in 4-8 Year Old Children With Autism Spectrum Disorders (ASD).|Terminated||Phase 4|1|Actual|University of Nebraska|Unable to recruit a sufficient number of subjects to complete the study as designed.|1||Unsuccessful in recruiting appropriate subjects.|f||||t||||||||||2018-06-01 00:15:39.196125|2018-06-01 00:15:39.196125
NCT01033552|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2017-11-27|2009-12-14|2009-12-16|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2010|Actual|2010-01-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||"Biochemical Correction of Severe EB by Allo HSCT and Off-the-shelf MSCs"|"MT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and Off-the-shelf Mesenchymal Stem Cells"|Recruiting||Phase 2|75|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|||||||||2018-06-01 00:15:39.408756|2018-06-01 00:15:39.408756
NCT01033539|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-03-28|2009-12-15|2009-12-16|Estimate|||||||2012-03-28|2012-03-29|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|August 2011|Actual|2011-08-31|April 2010|Actual|2010-04-30||Interventional|||To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans|To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans|Completed||N/A|30|Actual|Good Food Practice, Sweden||3|||f||||f||||||||||2018-06-01 00:15:39.623994|2018-06-01 00:15:39.623994
NCT01033526|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Symptomatic Treatment of Common Cold Symptoms|A Two-arm, Multicenter, Randomized, Double-blind, Single Dose Placebo-controlled Parallel Groups Study Evaluating Efficacy and Tolerability of 800 mg Acetylsalicylic Acid (Aspirina® C) in Adult Patients With a Common Cold During a Two Hour in Patient Phase; and a Follow-up Period of Five Days of Home Treatment as Required|Completed||Phase 4|388|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:15:39.985271|2018-06-01 00:15:39.985271
NCT01033513|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2017-10-30|2009-12-15|2009-12-16|Estimate|||||||2017-10-30|2017-10-31|Actual|May 2003||2003-05-31|October 2017|2017-10-31|September 22, 2006|Actual|2006-09-22|||||Observational|||SOS Nutrition Project|SOS Nutrition Project|Completed|||320|Actual|University of North Carolina, Charlotte|||4||f||||f||||||||||2018-06-01 00:15:40.210991|2018-06-01 00:15:40.210991
NCT01033149|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2014-03-04|2009-12-14|2009-12-16|Estimate|||||||2014-03-04|2014-03-05|Estimate|December 2009||2009-12-31|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||N-acetylcysteine in the Treatment of Bulimia Nervosa||Terminated||Phase 3|11|Actual|Lindner Center of HOPE||1|||f||||f||||||||||2018-06-01 00:15:46.449328|2018-06-01 00:15:46.449328
NCT01033500|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2013-05-06|2009-12-15|2009-12-16|Estimate|||||||2013-05-06|2013-05-08|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients|Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||1||Insufficient funding|f||||t||||||||||2018-06-01 00:15:40.271715|2018-06-01 00:15:40.271715
NCT01033487|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2012-08-09||2016-01-22|2009-12-15|2009-12-16|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease|A Phase 2A, Double Blind, Placebo-Controlled, Single Dose, 5-Way Crossover Study Assessing The Pharmacodynamic, Pharmacokinetic And Safety Profiles Of Oral Inhaled PF-03635659 In Patients With Moderate Chronic Obstructive Pulmonary Disease.|Completed||Phase 2|22|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:15:40.390728|2018-06-01 00:15:40.390728
NCT01033474|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2011-07-21|2009-12-15|2009-12-16|Estimate|||||||2011-07-21|2011-07-22|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|September 2010|Anticipated|2010-09-30||Observational|||Results Following the Vitrification of Human Oocytes Using 2 Methodologies|Embryonic Developmental Rates and Pregnancies Following the Vitrification of Human Oocytes Using Two Methodologies.|Withdrawn|||40|Anticipated|Northwest Center for Reproductive Sciences|||2|NW Center for Reproductive Sciences was sold and is no longer open|f||||t||||||||||2018-06-01 00:15:42.001143|2018-06-01 00:15:42.001143
NCT01033461|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-11-06|2009-12-15|2009-12-16|Estimate|||||||2012-11-06|2012-11-07|Estimate|March 2008||2008-03-31|November 2012|2012-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Combination of Probiotic and Calcium in Healthy Adults|The Effect of the Probiotic L. Paracasei LPC 37 Alone or in Combination With a Calcium Supplement in Healthy Subjects|Completed||N/A|32|Actual|University of Jena||3|||f||||t||||||||||2018-06-01 00:15:43.040143|2018-06-01 00:15:43.040143
NCT01033448|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2017-05-05||2017-05-05|2009-12-15|2009-12-16|Estimate|2017-05-05|2017-10-03|Actual||||2017-05-05|2017-10-03|Actual|December 2009||2009-12-31|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All enrolled participants were included in the baseline population.|A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response|An Open-Label, Multi-Center Study Evaluating the Effect on Viral Activity and the Safety and Tolerability of Extended Treatment of Pegasys® (Peginterferon Alfa 2a ) in Combination With Copegus® (Ribavirin) in Genotype 1, 2 and 3 Chronic Hepatitis C Patients Defined as Slow Responders/Non-RVR|Completed||Phase 4|59|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:15:43.160294|2018-06-01 00:15:43.160294
NCT01033435|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2011-08-16|2009-12-15|2009-12-16|Estimate|||||||2011-08-16|2011-08-17|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Observational|||The Influence of Cessation of Pomegranate Juice Intake on Inflammation and Oxidative Stress Markers and Glucose Control in Diabetic and Non Diabetic Chronic Hemodialysis Patients||Completed|||49|Actual|Western Galilee Hospital-Nahariya|||2||f||||f||||||||||2018-06-01 00:15:43.382665|2018-06-01 00:15:43.382665
NCT01033422|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2015-12-06|2009-12-15|2009-12-16|Estimate|||||||2015-12-06|2015-12-08|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure|A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure|Unknown status|Recruiting|Phase 2|88|Anticipated|Can-Fite BioPharma||2|||f||||f||||||||||2018-06-01 00:15:43.60835|2018-06-01 00:15:43.60835
NCT01033409|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-11-01|2009-12-15|2009-12-16|Estimate|||||||2011-11-01|2011-11-02|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA|Comparative Phase I Safety and Immunogenicity in Adult Volunteers of Three Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae Surface Protein Antigen PspA|Completed||Phase 1|60|Actual|Arizona State University||4|||f||||t||||||||||2018-06-01 00:15:43.739342|2018-06-01 00:15:43.739342
NCT01033396|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-08-16|2009-12-15|2009-12-16|Estimate|||||||2010-08-16|2010-08-17|Estimate|January 2010||2010-01-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis|A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.|Completed||Phase 2|64|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:15:43.856413|2018-06-01 00:15:43.856413
NCT01033383|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2013-03-19||2013-07-12|2009-12-15|2009-12-16|Estimate|2013-07-12|2013-08-15|Estimate||||2013-07-12|2013-08-15|Estimate|December 2009||2009-12-31|July 2013|2013-07-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents|Pilot Study: Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents|Completed||Phase 1|80|Actual|Yale University|Of 320 urine specimens that should have been collected by nursing staff, 302 (94%) urine cultures and 294 (92%) urinalyses were obtained.|4|||f||||f||||||||||2018-06-01 00:15:43.967275|2018-06-01 00:15:43.967275
NCT01033370|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2016-03-15|2009-12-15|2009-12-16|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PROMPT||A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)|A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT)|Terminated||Phase 4|5|Actual|The Methodist Hospital System||1||Project lacked funding.|f||||f||||||||No|Incomplete data set due to early trial closure.|2018-06-01 00:15:44.469403|2018-06-01 00:15:44.469403
NCT01033357|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15||2013-02-07|2013-02-07|2009-12-15|2009-12-16|Estimate||||2013-02-07|2013-02-11|Estimate|2013-02-07|2013-02-11|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|||Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access|A Long Term Safety Study of the Vascular Wrap(TM) Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® Graft in the Upper Extremity for Hemodialysis Vascular Access|Terminated||N/A|222|Actual|Angiotech Pharmaceuticals||2||Imbalance in the # graft infections between the tx's (graft vs. graft + wrap)|f||||f||||||||||2018-06-01 00:15:44.593947|2018-06-01 00:15:44.593947
NCT01033331|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|July 2006||2006-07-31|August 2008|2008-08-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Observational|||Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy(SMA) Treated With Valproic Acid|Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy Type II and III Treated With Valproic Acid|Completed|||22|Actual|University of Sao Paulo General Hospital|||||f||||t||||||||||2018-06-01 00:15:44.809667|2018-06-01 00:15:44.809667
NCT01033318|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2016-02-03|2009-12-15|2009-12-16|Estimate|||||||2016-02-03|2016-02-04|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)|A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||15|||f||||f||||||||||2018-06-01 00:15:44.87612|2018-06-01 00:15:44.87612
NCT01033305|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-04-18|2009-12-15|2009-12-16|Estimate|||||||2012-04-18|2012-04-19|Estimate|March 2010||2010-03-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)|A Phase II, Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapsule Formulation of Ciclosporin (CyCol™) in the Treatment of Mild to Moderate Ulcerative Colitis|Completed||Phase 2|118|Actual|Sigmoid Pharma||2|||f||||t||||||||||2018-06-01 00:15:44.979757|2018-06-01 00:15:44.979757
NCT01033292|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14||2016-02-17|2016-02-17|2009-12-15|2009-12-16|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer|A Phase 2, Multi-Center, Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer|Completed||Phase 2|43|Actual|Sanofi||1|||t||||f||||||||||2018-06-01 00:15:45.110417|2018-06-01 00:15:45.110417
NCT01033279|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-05-29|2009-12-15|2009-12-16|Estimate|||||||2012-05-29|2012-05-30|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|ESCAPE||Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy|Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts|Completed||N/A|120|Actual|Montreal Heart Institute||2|||f||||f||||||||||2018-06-01 00:15:45.187493|2018-06-01 00:15:45.187493
NCT01033266|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2014-05-19|2009-12-15|2009-12-16|Estimate|||||||2014-05-19|2014-05-20|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effect of Continuous Positive Airway Pressure (CPAP) and Cardiopulmonary Exercise Testing(CPET) in Patient With Obstructive Sleep Apnea (OSA) and Chronic Obstructive Pulmonary Disease (COPD)|Effect of Nasal CPAP on Cardiopulmonary Exercise Testing in Patients With Overlap Syndrome|Completed||N/A|12|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 00:15:45.27292|2018-06-01 00:15:45.27292
NCT01033253|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|July 2005||2005-07-31|December 2009|2009-12-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Multi-media Obesity Prevention Program for Adolescents|Multi-media Obesity Prevention Program for Adolescents|Completed||Phase 2|1800|Actual|Pro-Change Behavior Systems||2|||f||||t||||||||||2018-06-01 00:15:45.353836|2018-06-01 00:15:45.353836
NCT01033240|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15||2016-02-18|2016-02-18|2009-12-15|2009-12-16|Estimate||||2016-02-18|2016-03-17|Estimate|2016-02-18|2016-03-17|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer|Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma|Completed||Phase 2|172|Actual|Daiichi Sankyo, Inc.||6|||f||||f||||||||||2018-06-01 00:15:45.448639|2018-06-01 00:15:45.448639
NCT01033227|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2016-04-13||2017-09-15|2009-12-15|2009-12-16|Estimate|2016-12-15|2017-02-08|Estimate||||2017-09-15|2017-10-17|Actual|December 2009||2009-12-31|September 2017|2017-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease|A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease|Terminated||Phase 1/Phase 2|5|Actual|Children's Hospital Los Angeles||2||Low enrollment|f||||t||||||||No||2018-06-01 00:15:45.595501|2018-06-01 00:15:45.595501
NCT01033214|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2015-05-18|2009-12-15|2009-12-16|Estimate|||||||2015-05-18|2015-05-20|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|June 2011|Actual|2011-06-30||Interventional|||ENTRUST - TAArget® Thoracic Stent Graft Clinical Trial|A Phase I Feasibility Study of the TAArget Thoracic Stent Graft for the Treatment of Aneurysms in the Descending Thoracic Aorta|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Duke Vascular, Inc.||1|||f||||f||||||||||2018-06-01 00:15:46.065422|2018-06-01 00:15:46.065422
NCT01033201|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-01-25|2009-12-15|2009-12-16|Estimate|||||||2012-01-25|2012-01-26|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Alveoscopy, Endoscopic Confocal Microscopy and Lung Rejection, Parenchymal Lung Diseases in Vivo|The Role Of Endoscopic Alveoscopy by Confocal Endomicroscopy in Diagnosing Acute and Chronic Rejection in Lung Transplant Recipients, Diagnosis of End Stage Lung Disease, and Other Pulmonary Pathologies in Vivo|Completed|||71|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 00:15:46.151691|2018-06-01 00:15:46.151691
NCT01033188|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2017-09-23|2009-12-15|2009-12-16|Estimate|||||||2017-09-23|2017-09-26|Actual|January 2010||2010-01-31|September 2017|2017-09-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Double Bundle Anterior Cruciate Ligament Reconstruction|Single Bundle or Double Bundle Anterior Cruciate Ligament Reconstruction. A Randomized, Controlled Trial.|Completed||N/A|120|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 00:15:46.237092|2018-06-01 00:15:46.237092
NCT01033175|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2010-07-06|2009-12-15|2009-12-16|Estimate|||||||2010-07-06|2010-07-07|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||The Impact of Anemia of Chronic Disease on Chronic Obstructive Pulmonary Disease Patients|The Clinical Impact of Anemia of Chronic Disease on Chronic Obstructive Pulmonary Disease Patients|Completed||N/A|60|Anticipated|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 00:15:46.313676|2018-06-01 00:15:46.313676
NCT01033162|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2016-02-03|2009-12-15|2009-12-16|Estimate|||||||2016-02-03|2016-02-04|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effectiveness of the CHESS eHealth Cancer Support Intervention in Population-based Care|Using Technology to Enhance Cancer Communication and Improve Clinical Outcome: Effectiveness of the CHESS Ehealth Cancer Support Intervention in Population-Based Care Study|Completed||N/A|368|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:15:46.388103|2018-06-01 00:15:46.388103
NCT01033136|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2017-06-12|2009-12-14|2009-12-16|Estimate|||||||2017-06-12|2017-06-14|Actual|January 1, 2013|Actual|2013-01-01|June 2017|2017-06-30|January 1, 2017|Actual|2017-01-01|September 30, 2016|Actual|2016-09-30||Interventional|||Exposure Therapy For Veterans With PTSD And Panic Attacks|Exposure Therapy for Veterans With PTSD and Panic Attacks|Completed||N/A|96|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-06-01 00:15:46.530088|2018-06-01 00:15:46.530088
NCT01033123|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14||2016-02-17|2016-02-17|2009-12-15|2009-12-16|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer|A Phase 2, Multi-Center, Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer|Completed||Phase 2|41|Actual|Sanofi||1|||t||||f||||||||||2018-06-01 00:15:46.729827|2018-06-01 00:15:46.729827
NCT01033110|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2014-11-06|2009-12-15|2009-12-16|Estimate|||||||2014-11-06|2014-11-07|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Fit Over 45 - a Health Promotion Project for Inactive Female Hospital Staff Age 45+ From the University Hospital of Zürich||Completed||N/A|108|Actual|University of Zurich|||||f||||||||||||||2018-06-01 00:15:46.848328|2018-06-01 00:15:46.848328
NCT01033097|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2017-03-17|2009-12-15|2009-12-16|Estimate|||||||2017-03-17|2017-03-21|Actual|November 2009||2009-11-30|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Efficacy of DNK333 in Atopic Dermatitis Patients|A Multicenter, Randomized, Double-blinded, Placebo and Positive Controlled Study to Evaluate the Anti-pruritic Effect, Safety and Tolerability, Systemic and Skin Exposure, After 2 Weeks of Treatment With a Microemulsion Formulation of DNK333 in Atopic Dermatitis Patients|Completed||Phase 2|80|Actual|Novartis||9|||f||||||||||||||2018-06-01 00:15:46.944966|2018-06-01 00:15:46.944966
NCT01033084|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2011-12-02|2009-12-15|2009-12-16|Estimate|||||||2011-12-02|2011-12-06|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SELECT-TDCS||Efficacy Study of Transcranial Direct Current Stimulation to Treat Major Depressive Disorder|A Factorial, Double-blinded, Randomized Clinical Trial on Major Depressive Disorder Using Transcranial Direct Current Stimulation|Completed||Phase 2/Phase 3|120|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-06-01 00:15:47.057806|2018-06-01 00:15:47.057806
NCT01033071|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2012-01-04||2012-01-04|2009-12-14|2009-12-16|Estimate|2012-01-04|2012-02-07|Estimate||||2012-01-04|2012-02-07|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.|A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension|Completed||Phase 3|1071|Actual|Takeda||3|||f||||f||||||||||2018-06-01 00:15:47.236132|2018-06-01 00:15:47.236132
NCT01033058|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-23|2009-12-15|2009-12-16|Estimate|||||||2009-12-23|2009-12-24|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Interventional|||Intensive Statin Treatment for STEMI Patients Undergoing Primary PCI|Effect of Intensive Statin Treatment on 90-day Prognosis of STEMI Patients Undergoing Emergency Primary PCI Compared With Usual Care|Unknown status|Not yet recruiting|Phase 4|500|Anticipated|Beijing Chao Yang Hospital||2|||f||||f||||||||||2018-06-01 00:15:48.675949|2018-06-01 00:15:48.675949
NCT01033045|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2016-02-11|2009-12-15|2009-12-16|Estimate|||||||2016-02-11|2016-02-12|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure|Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure|Completed|||2178|Actual|Fundacion IMIM|||||f||||t||||||||||2018-06-01 00:15:48.770651|2018-06-01 00:15:48.770651
NCT01033032|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2014-11-21||2014-12-22|2009-12-15|2009-12-16|Estimate|2014-12-22|2015-01-06|Estimate||||2014-12-22|2015-01-06|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|July 2013|Actual|2013-07-31||Interventional||Includes Phase I and Phase II patients|Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer|Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer|Completed||Phase 1/Phase 2|78|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 00:15:48.954993|2018-06-01 00:15:48.954993
NCT01033019|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2015-08-18||2015-10-01|2009-12-15|2009-12-16|Estimate|2015-10-01|2015-10-30|Estimate||||2015-10-01|2015-10-30|Estimate|December 2009||2009-12-31|October 2015|2015-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)|Double-blind, Randomized, Vehicle-controlled Proof of Concept Study on the Efficacy, Safety, Local Tolerability, PK and Pharmacodynamics of Multiple Topical Administrations of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas|Terminated||Phase 2|25|Actual|Novartis||2||"The data from participants with sBCCs showed insufficient efficacy with current formulation and~   treatment conditions."|f||||f||||||||||2018-06-01 00:15:49.207635|2018-06-01 00:15:49.207635
NCT01033006|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2014-02-12|2009-12-15|2009-12-16|Estimate|||||||2014-02-12|2014-02-13|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|February 2011|Actual|2011-02-28||Interventional|||Axillary Plexus Block in a High Resolution MRI|Axillary Plexus Block in a High Resolution MRI|Completed||Phase 2|45|Actual|Diakonhjemmet Hospital||3|||f||||t||||||||||2018-06-01 00:15:49.43215|2018-06-01 00:15:49.43215
NCT01032993|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|2016-10-07||2016-11-29|2009-12-15|2009-12-16|Estimate|2016-11-29|2017-01-23|Estimate||||2016-11-29|2017-01-23|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms|Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms|Completed||Phase 2/Phase 3|68|Actual|Beth Israel Deaconess Medical Center|100 participants were planned to achieve >50 randomized. However, due to slow recruiting, the CoQ10 and placebo expired and we were unable to obtain more. Therefore only 68 participants were enrolled and ultimately 39 participants were randomized.|2|||f||||f||||||||No|No consent for sharing IPD from trial participants was obtained when this clinical trial began|2018-06-01 00:15:50.520723|2018-06-01 00:15:50.520723
NCT01032980|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2015-09-25|2009-12-15|2009-12-16|Estimate|||||||2015-09-25|2015-09-28|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Observational|||Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults|Post Authorization Safety Study of the Intramuscular Inactivated, Split Virion Pandemic A/H1N1 Influenza Vaccines in Children Aged Over 2 Months and in Adult Populations|Completed|||3934|Actual|Sanofi|||2||f||||f||||||||||2018-06-01 00:15:50.853405|2018-06-01 00:15:50.853405
NCT01032967|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2009-12-15|2009-12-15|2009-12-16|Estimate|||||||2009-12-15|2009-12-16|Estimate|July 2000||2000-07-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Surgery or Chemoradiation for Esophageal Cancer|Multicenter Prospective Randomized Trial Comparing Standard Esophagectomy With Chemoradiotherapy for Treatment of Squamous Esophageal Cancer: Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)|Completed||Phase 3|40|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 00:15:50.936515|2018-06-01 00:15:50.936515
NCT01032954|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2010-07-06|2009-12-15|2009-12-16|Estimate|||||||2010-07-06|2010-07-07|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)|Phase Iv Study On The Safety And Efficacy Of The Full Face Applications Of Variable Doses Of 125 To 250 Units Of A Commercial Botulinum Toxin Type A (Dysport®)|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|Brazilan Center for Studies in Dermatology||3|||f||||||||||||||2018-06-01 00:15:50.997287|2018-06-01 00:15:50.997287
NCT01032941|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-01-18|2009-12-15|2009-12-16|Estimate|||||||2012-01-18|2012-01-20|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effect of Probiotics (VSL) on Portal Hypertension|A Randomized Controlled Trial on the Beneficial Effects of Probiotics on Portal Hemodynamics in Decompensated Cirrhotic Patients|Completed||Phase 1/Phase 2|18|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 00:15:51.107967|2018-06-01 00:15:51.107967
NCT01032928|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2014-11-25||2014-12-09|2009-12-14|2009-12-16|Estimate|2014-11-25|2014-12-04|Estimate||||2014-12-09|2015-01-01|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|RSPT|Entire Enrolled Study Population|Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer|Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer|Completed||Phase 2|30|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 00:15:51.309406|2018-06-01 00:15:51.309406
NCT01032915|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2015-02-12|2013-02-14|2015-10-08|2009-12-15|2009-12-16|Estimate|2015-10-08|2015-11-05|Estimate|2013-02-14|2013-02-20|Estimate|2015-10-08|2015-11-05|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|ENDURE|Randomized Set: This set included all randomized patients|Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis|A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.|Terminated||Phase 3|125|Actual|Novartis||4||"Results of a planned interim analysis did not show significant effects for any of the 3 AIN~   dose regimens versus placebo on any primary or secondary endpoint"|f||||t||||||||||2018-06-01 00:15:51.708391|2018-06-01 00:15:51.708391
NCT01032902|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-04-27|2009-12-15|2009-12-16|Estimate|||||||2012-04-27|2012-04-30|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test|Study to Establish the Ability of the Chembio Diagnostics Systems, Inc. DPP HIV 1/2 Rapid Test to Qualitatively Detect the Presence of Antibodies Against HIV-1 in Oral Fluid, Whole Blood (Capillary and Venous), Serum and Plasma|Completed|||2808|Actual|Chembio Diagnostic Systems, Inc.|||3||f||||t||||||Samples Without DNA|"~     serum and plasma~   "|||2018-06-01 00:15:52.334092|2018-06-01 00:15:52.334092
NCT01032889|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2015-05-28|2014-05-30|2015-05-28|2009-12-14|2009-12-16|Estimate|2015-05-28|2015-06-15|Estimate|2014-05-30|2014-06-17|Estimate|2015-05-28|2015-06-15|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study|Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (SMF) Using Magnetic Resonance Imaging (MRI) and a Battery of Clinician- and Subject-reported Measurements.|Completed||Phase 2|129|Actual|Kythera Biopharmaceuticals||3|||f||||f||||||||||2018-06-01 00:15:52.436672|2018-06-01 00:15:52.436672
NCT01032876|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2012-06-28|2009-12-15|2009-12-16|Estimate|||||||2012-06-28|2012-06-29|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Cerebral Perfusion During Neonatal Cardiac Surgery|Randomized Controlled Trial on Deep Hypothermic Circulatory Arrest Versus Antegrade Cerebral Perfusion During Neonatal Cardiac Surgery|Completed||N/A|37|Actual|UMC Utrecht||2|||f||||f||||||||||2018-06-01 00:15:53.121938|2018-06-01 00:15:53.121938
NCT01032863|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-03-23|2009-12-15|2009-12-16|Estimate|||||||2010-03-23|2010-03-24|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|HAMS||Association Between Hypermobility and Chronic Musculoskeletal Pain|A Study of Association Between Hypermobility And Chronic MusculoSkeletal Pain:a Pilot Study|Completed|||112|Actual|Amrita Institute of Medical Sciences & Research Center|||1||f||||t||||||||||2018-06-01 00:15:53.213032|2018-06-01 00:15:53.213032
NCT01032850|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2015-06-06||2016-06-13|2009-12-14|2009-12-16|Estimate|2015-06-23|2015-07-17|Estimate||||2016-06-13|2016-07-26|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|February 2012|Actual|2012-02-29||Interventional|||Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma|Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma|Terminated||Phase 2|15|Actual|New Mexico Cancer Care Alliance||1||Low accrual rate|f||||t||||||||||2018-06-01 00:15:53.325622|2018-06-01 00:15:53.325622
NCT01032837|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2012-07-12||2012-09-18|2009-12-15|2009-12-16|Estimate|2012-07-12|2012-08-20|Estimate||||2012-09-18|2012-10-02|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain|A Randomized, Multicenter Trial of Oseltamivir [Tamiflu] Doses of 75 mg for 5 or 10 Days Versus 150 mg for 5 or 10 Days to Evaluate the Effect on the Duration of Viral Shedding in Influenza Patients With Pandemic (H1N1) 2009|Terminated||Phase 4|102|Actual|Hoffmann-La Roche||4||Study closed prematurely due to the end of the influenza (H1N1) 2009 pandemic|f||||||||||||||2018-06-01 00:15:53.734456|2018-06-01 00:15:53.734456
NCT01032824|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2017-10-11|2009-12-15|2009-12-16|Estimate|||||||2017-10-11|2017-10-13|Actual|October 2007||2007-10-31|October 2017|2017-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|PRIME||Self-Managing HIV and Chronic Disease|Community-based Self-management of HIV and Chronic Disease|Completed||N/A|452|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-06-01 00:15:55.52742|2018-06-01 00:15:55.52742
NCT01025934|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate||||December 2009|2009-12-31||||||||Interventional|||Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy|Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy|Completed||Phase 4|||"University of Campania Luigi Vanvitelli"||3|||f||||f||||||||||2018-06-01 00:18:10.879622|2018-06-01 00:18:10.879622
NCT01032811|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2013-09-05|2009-12-15|2009-12-16|Estimate|||||||2013-09-05|2013-09-06|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Pilot Study Of Primary And Secondary Attention-Deficit/Hyperactivity Disorder Among Survivors Of Childhood Cancer|Pilot Study Of Primary And Secondary Attention-Deficit/Hyperactivity Disorder Among Survivors Of Childhood Cancer|Completed|||100|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 00:15:55.732699|2018-06-01 00:15:55.732699
NCT01032798|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2010-01-19|2009-12-15|2009-12-16|Estimate|||||||2010-01-19|2010-01-20|Estimate|May 2007||2007-05-31|April 2007|2007-04-30|May 2008|Actual|2008-05-31|||||Interventional|||Local Anesthetics New Formulations: From Development to Clinical Tests|Efficacy and Pharmacokinetics of Liposomal Mepivacaine Formulations in Dentistry|Completed||Phase 1|30|Actual|University of Campinas, Brazil|||||f||||t||||||||||2018-06-01 00:15:55.948258|2018-06-01 00:15:55.948258
NCT01032785|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-15|||2010-09-12|2009-12-15|2009-12-16|Estimate|||||||2010-09-12|2010-09-14|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Observational|||Timing of Closure of Patent Foramen Ovale Following Birth|Timing of Closure of Patent Foramen Ovale and Patent Ductus Arteriosus Following Birth|Unknown status|Recruiting||100|Anticipated|Wolfson Medical Center|||1||f||||t||||||||||2018-06-01 00:15:56.029292|2018-06-01 00:15:56.029292
NCT01032772|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2015-11-23|2009-12-12|2009-12-15|Estimate|||||||2015-11-23|2015-11-25|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ChoicesPlus||ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy|ChoicesPlus: Preconception Approach to Reducing Alcohol- and Tobacco-Exposed Pregnancy|Completed||N/A|261|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-06-01 00:15:56.116648|2018-06-01 00:15:56.116648
NCT01032759|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2016-01-19||2016-02-15|2009-12-14|2009-12-15|Estimate|2016-02-15|2016-03-14|Estimate||||2016-02-15|2016-03-14|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Memantine and Postoperative Pain|Memantine for Postoperative Analgesia|Terminated||Phase 4|77|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:15:56.215011|2018-06-01 00:15:56.215011
NCT01032746|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2013-12-17|2009-12-13|2009-12-15|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2005||2005-03-31|June 2011|2011-06-30||||September 2010|Anticipated|2010-09-30||Interventional|||Personal Electronic Health Records in Improving Screening Rates for Colorectal Cancer|Use of a Personal Health Record to Improve Colorectal Cancer Screening|Unknown status|Recruiting|N/A|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:15:57.025957|2018-06-01 00:15:57.025957
NCT01032733|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2012-02-14||2012-05-11|2009-12-14|2009-12-15|Estimate|2012-05-11|2012-06-14|Estimate||||2012-05-11|2012-06-14|Estimate|September 2006||2006-09-30|May 2012|2012-05-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|WL+E||Biological Effects of Weight Loss In Older, Obese Women|Biological Effects of Weight Loss Plus Exercise in Obese Older African-American Women: An Investigation of Aging-related Changes in Black and White Women|Completed||Phase 2|34|Actual|University of Florida|Limitations include the following: (1) the sample size was relatively small,(2)the study was not adequately powered to detect differences between African American and Caucasian women in response to the intervention, (3) inclusion of only women.|2|||f||||f||||||||||2018-06-01 00:15:57.240633|2018-06-01 00:15:57.240633
NCT01032720|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2015-07-05|2009-12-14|2009-12-15|Estimate|||||||2015-07-05|2015-07-08|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Ultrasound (US)-Guided Versus Sham Ultrasound Corticosteroid (CS) Knee Injections|Ultrasound-guided Versus Sham Ultrasound Corticosteroid Knee Injections|Terminated||N/A|33|Actual|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-06-01 00:15:57.645318|2018-06-01 00:15:57.645318
NCT01032694|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2011-11-21||2011-11-21|2009-12-14|2009-12-15|Estimate|2011-11-21|2011-12-21|Estimate||||2011-11-21|2011-12-21|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|PROSTO||Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia|Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia|Terminated|||30|Actual|Pfizer|||2|"This study was terminated January 11, 2011 due to low enrollment. This study is not being~   terminated because of safety or efficacy concerns."|f||||f||||||||||2018-06-01 00:15:57.751049|2018-06-01 00:15:57.751049
NCT01032681|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2014-07-30|2009-12-14|2009-12-15|Estimate|||||||2014-07-30|2014-07-31|Estimate|December 2006||2006-12-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional|||EMD 521873 in Advanced Solid Tumors, MTD Finding|A Phase 1, Open-Label, Two-Group, Dose- Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of EMD 521873 Alone and in Combination With Fixed Low Doses of Cyclophosphamide in Patients With Metastatic or Locally Advanced Solid Tumors or B-Cell Non-Hodgkin Lymphoma|Completed||Phase 1|66|Actual|Merck KGaA||3|||f||||f||||||||||2018-06-01 00:15:58.030818|2018-06-01 00:15:58.030818
NCT01032668|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2009-12-14|2009-12-14|2009-12-15|Estimate|||||||2009-12-14|2009-12-15|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|EFFICIENT||The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance||Completed||Phase 3|192|Actual|Bursa Postgraduate Hospital||1|||f||||f||||||||||2018-06-01 00:15:58.15337|2018-06-01 00:15:58.15337
NCT01032655|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2012-06-23|2009-12-14|2009-12-15|Estimate|||||||2012-06-23|2012-06-26|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection|The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection|Completed||Phase 4|134|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:15:58.23014|2018-06-01 00:15:58.23014
NCT01032642|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2009-12-15|2009-12-14|2009-12-15|Estimate|||||||2009-12-15|2009-12-16|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|HSG||A Thin Catheter For Hystrosalpingography|A Simple Technique to Reduce the Pain in Hysterosalpingography Using A Thin Catheter|Completed||N/A|70|Actual|Kasr El Aini Hospital||1|||f||||f||||||||||2018-06-01 00:15:58.29742|2018-06-01 00:15:58.29742
NCT01032629|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10||2018-02-20|2018-02-20|2009-12-14|2009-12-15|Estimate||||2018-02-20|2018-02-22|Actual|2018-02-20|2018-02-22|Actual|December 9, 2009|Actual|2009-12-09|February 2018|2018-02-28|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|CANVAS||CANVAS - CANagliflozin cardioVascular Assessment Study|A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|4330|Actual|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-06-01 00:15:58.405015|2018-06-01 00:15:58.405015
NCT01032616|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2013-08-01|2009-12-14|2009-12-15|Estimate|||||||2013-08-01|2013-08-05|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Uptake and Utilization of Amino Acids by Splanchnic Bed|Determination of the Difference in Uptake and Utilization of Two Amino Acids by the Splanchnic Bed|Completed||Phase 1|6|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:15:58.947218|2018-06-01 00:15:58.947218
NCT01032603|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2018-05-24|2009-12-14|2009-12-15|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2010||2010-06-30|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 9, 2017|Actual|2017-02-09||Interventional|IXT1||Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia|A Randomized Trial of Bilateral Lateral Rectus Recession Versus Unilateral Lateral Rectus Recession With Medial Rectus Resection for Intermittent Exotropia|Active, not recruiting||N/A|336|Anticipated|Jaeb Center for Health Research||2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-06-01 00:15:59.037316|2018-06-01 00:15:59.037316
NCT01032590|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2017-03-02|2009-12-13|2009-12-15|Estimate|||||||2017-03-02|2017-03-06|Actual|July 2009||2009-07-31|March 2017|2017-03-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Interventional|||Internet-Based Weight-Loss Program for Colorectal Cancer Survivors|Internet Weight Loss Intervention for Individuals Diagnosed With Colorectal Cancer|Withdrawn||N/A|0|Actual|Rutgers, The State University of New Jersey||2||Trial was only opened at RCINJ for analysis of data, no patient enrollment took place here.|f||||t||||||||||2018-06-01 00:15:59.142633|2018-06-01 00:15:59.142633
NCT01032577|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2012-02-27|2009-12-14|2009-12-15|Estimate|||||||2012-02-27|2012-02-28|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|PropR||A Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations|Prospective Study Comparing the Sensed R Wave in Bipolar and Extended Bipolar Configurations|Completed|||50|Actual|Saint Francis Care|||1||f||||f||||||||||2018-06-01 00:15:59.226993|2018-06-01 00:15:59.226993
NCT01032564|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2014-08-28|2009-12-13|2009-12-15|Estimate|||||||2014-08-28|2014-08-29|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Interest of HI-RTE Elasticity in Obstetric||Completed||N/A|73|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 00:15:59.311793|2018-06-01 00:15:59.311793
NCT01032551|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-01-17|2009-12-12|2009-12-15|Estimate|||||||2011-01-17|2011-01-19|Estimate|June 2010||2010-06-30|December 2009|2009-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|VADAS||Vascular Access Decision Aid|Vascular Access Options in Coronary Angiogram Procedures: A Patient Decision Aid Randomized Controlled Trial|Completed||N/A|100|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 00:15:59.373849|2018-06-01 00:15:59.373849
NCT01032538|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2013-10-25||2016-09-12|2009-12-14|2009-12-15|Estimate|2015-01-03|2015-01-13|Estimate||||2016-09-12|2016-10-28|Estimate|November 2003||2003-11-30|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2009|Actual|2009-02-28||Observational||Number of patients were 96. 3 patients were operated bilaterally. Number of knees were therefore 99.|Time-dependent Improvement of Functional Outcome Following Oxford Medial Unicondylar Knee Replacement|Time-dependent Improvement of Functional Outcome Following Oxford Medial Unicondylar Knee Replacement - A Prospective Longitudinal Study With Repetitive Measures of KOOS in 100 Patients|Active, not recruiting|||99|Actual|Martina Hansen's Hospital|||1||f||||f||||||||||2018-06-01 00:15:59.488081|2018-06-01 00:15:59.488081
NCT01032525|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2015-10-12|2009-12-14|2009-12-15|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 1981||1981-01-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|May 2013|Actual|2013-05-31||Observational|||Monroe County Inflammatory Bowel Disease (IBD) Registry|Epidemiologic Study of Inflammatory Bowel Disease in Monroe County, New York|Completed|||720|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 00:15:59.653464|2018-06-01 00:15:59.653464
NCT01032512|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2018-02-15|2009-12-14|2009-12-15|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2009|Actual|2009-12-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology|Preoperative Nutrition Support in Major Oncologic Surgery|Withdrawn||Phase 3|0|Actual|University of Chile||2||impossibility to include patients in the study|f||||f||||||||||2018-06-01 00:15:59.704989|2018-06-01 00:15:59.704989
NCT01032499|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-03-18|2009-12-14|2009-12-15|Estimate|||||||2010-03-18|2010-03-19|Estimate|May 2010||2010-05-31|December 2009|2009-12-31|October 2010|Anticipated|2010-10-31|July 2010|Anticipated|2010-07-31||Interventional|E01GOU-INH0109||Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir|Multicenter Clinical Study,Phase III, Prospective, Randomized, Open and Comparative to Measure Tolerability and Efficacy of Taro Elixir on the Evolution Treatment of Acne Vulgaris II and III Degree or of Furunculosis Compared With Oxytetracycline|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Laboratorios Goulart S.A.||2|||f||||t||||||||||2018-06-01 00:15:59.804626|2018-06-01 00:15:59.804626
NCT01032486|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2013-08-27|2009-12-14|2009-12-15|Estimate|||||||2013-08-27|2013-08-28|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|PD||Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease|An Open-Label, Multi-Center, Single Arm Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease Subjects|Completed|||120|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-06-01 00:15:59.895947|2018-06-01 00:15:59.895947
NCT01032473|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2011-05-11|2009-12-14|2009-12-15|Estimate|||||||2011-05-11|2011-05-12|Estimate|August 2009||2009-08-31|May 2011|2011-05-31||||||||Observational|||Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)|Mechanisms of Sleep Disturbance in Children With Generalized Anxiety Disorder (GAD)|Unknown status|Recruiting||80|Anticipated|Children's Research Institute|||2||f||||f||||||Samples Without DNA|"~     Salivary cortisol~   "|||2018-06-01 00:15:59.966328|2018-06-01 00:15:59.966328
NCT01032460|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-11-08|2009-12-14|2009-12-15|Estimate|||||||2010-11-08|2010-11-09|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparison of Two Novel Indirect Laryngoscopes to the Macintosh Laryngoscope in Patients With Cervical Spine Immobilization.||Completed||N/A|90|Actual|University College Hospital Galway||3|||f||||f||||||||||2018-06-01 00:16:00.040138|2018-06-01 00:16:00.040138
NCT01032447|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2016-09-26|2009-12-11|2009-12-15|Estimate|||||||2016-09-26|2016-09-28|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|July 2013|Actual|2013-07-31|January 2011|Actual|2011-01-31||Observational|||Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program|Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program|Terminated|||45|Actual|Stanford University|||||f||||t||||||||||2018-06-01 00:16:00.116764|2018-06-01 00:16:00.116764
NCT01032434|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2015-04-30|2009-12-14|2009-12-15|Estimate|||||||2015-04-30|2015-05-04|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||An 8-week, Open-label Study to Evaluate the Effect of Sertraline on Polysomnogram in Depressive Patients With Insomnia|An 8-week, Open-label Study to Evaluate the Effect of Sertraline on Polysomnogram in Depressive Patients With Insomnia|Completed||N/A|31|Actual|Guang Dong Provincial Mental Health Institute||1|||f||||f||||||||||2018-06-01 00:16:00.200198|2018-06-01 00:16:00.200198
NCT01032421|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-12-13|2009-12-13|2009-12-15|Estimate|||||||2009-12-13|2009-12-15|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|IVF||Gonadal Steroid Manipulation and Personality Characteristics: Association With Mood Fluctuations and in Vitro Fertilization (IVF) Outcomes|Gonadal Steroid Manipulation and Personality Characteristics: Association With Mood Fluctuations & IVF Outcomes|Completed|||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-06-01 00:16:00.350917|2018-06-01 00:16:00.350917
NCT01032408|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2013-06-04|2009-12-14|2009-12-15|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Interventional|||Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection|A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Infection|Completed||Phase 3|154|Actual|Chiltern Pesquisa Clinica Ltda||4|||f||||||||||||||2018-06-01 00:16:00.403914|2018-06-01 00:16:00.403914
NCT01032395|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2013-06-13|2009-12-14|2009-12-15|Estimate|||||||2013-06-13|2013-06-14|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|||Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus|A Phase 3, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus|Completed||Phase 3|342|Actual|Chiltern Pesquisa Clinica Ltda||4|||f||||||||||||||2018-06-01 00:16:00.477601|2018-06-01 00:16:00.477601
NCT01032382|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2014-06-06||2015-06-23|2009-12-14|2009-12-15|Estimate|2014-08-06|2014-08-22|Estimate||||2015-06-23|2015-07-16|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)|Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Peru|Completed||Phase 2|30|Actual|U.S. Army Medical Research and Materiel Command|All randomized subjects were included in the mITT analysis. All subjects also met the criteria for the evaluable subset; therefore, no separate analysis of an evaluable subset of subjects was performed.|2|||f||||f||||||||||2018-06-01 00:16:00.633936|2018-06-01 00:16:00.633936
NCT01032369|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2009-12-14|2009-12-14|2009-12-15|Estimate|||||||2009-12-14|2009-12-15|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Additive Effect of Cognitive Behavioral Treatment (CBT) to Conventional Weight Loss Intervention Program for Young Adults With Intellectual Disabilities|The Additive Effect of Cognitive Behavioral Treatment - CBT to Conventional Weight Loss Intervention Program for Young Adults With Intellectual Disabilities|Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:16:01.45863|2018-06-01 00:16:01.45863
NCT01032356|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2013-07-10|2009-12-13|2009-12-15|Estimate|||||||2013-07-10|2013-07-11|Estimate|January 2016||2016-01-31|July 2013|2013-07-31||||June 2016|Anticipated|2016-06-30||Interventional|||Dynasplint for Distal Radius Fracture|Contracture Reduction Following Distal Radius Fracture Surgical Management|Unknown status|Not yet recruiting|N/A|50|Anticipated|Dynasplint Systems, Inc.||1|||f||||t||||||||||2018-06-01 00:16:01.587224|2018-06-01 00:16:01.587224
NCT01032343|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2013-08-21|2009-12-14|2009-12-15|Estimate|||||||2013-08-21|2013-08-22|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||An Immunonutritional Approach to the Prevention of Skin Cancer|The Effect of Omega-3 Polyunsaturated Fatty Acids on UV-induced Immunosuppression|Completed||N/A|90|Actual|University of Manchester||2|||f||||f||||||||||2018-06-01 00:16:02.071014|2018-06-01 00:16:02.071014
NCT01032330|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2016-06-24|2009-12-11|2009-12-15|Estimate|||||||2016-06-24|2016-06-27|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IXT2||Observation Versus Occlusion Therapy for Intermittent Exotropia|A Randomized Clinical Trial of Observation Versus Occlusion Therapy for Intermittent Exotropia|Completed||N/A|611|Actual|Jaeb Center for Health Research||2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-06-01 00:16:02.243921|2018-06-01 00:16:02.243921
NCT01032317|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2014-12-02|2009-12-13|2009-12-15|Estimate|||||||2014-12-02|2014-12-04|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|EZCF-125||Study of a New Catheter Using Force Sensing Capabilities for the Treatment of Atrial Fibrillation and Ventricular Tachycardia|EZ Steer™ THERMOCOOL® With CF Sensing Capability (THERMOCOOL SMARTTOUCH™) for the Treatment of Atrial Fibrillation and Ventricular Tachycardia|Completed||Phase 1/Phase 2|22|Actual|Biosense Webster, Inc.||1|||f||||f||||||||||2018-06-01 00:16:02.377785|2018-06-01 00:16:02.377785
NCT01032304|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2014-06-12|2009-12-13|2009-12-15|Estimate|||||||2014-06-12|2014-06-13|Estimate|August 2009||2009-08-31|June 2014|2014-06-30|September 2015|Anticipated|2015-09-30|March 2014|Actual|2014-03-31||Interventional|RESTORE||The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)|The Efficacy and Safety of Erdosteine in the Long-term Therapy of Chronic Obstructive Pulmonary Disease (COPD). A 12-month, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study|Unknown status|Active, not recruiting|Phase 3|492|Anticipated|Edmond Pharma||2|||f||||t||||||||||2018-06-01 00:16:02.547716|2018-06-01 00:16:02.547716
NCT01032122|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2013-04-24|2009-12-14|2009-12-15|Estimate|||||||2013-04-24|2013-04-25|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Rituximab in Metastatic Melanoma|Efficacy and Safety of Rituximab, an Anti-CD20 (Cluster of Differentiation Antigen 20) Therapeutic Agent, in Metastatic Melanoma: a Pilot Study|Terminated||Phase 1|9|Actual|Medical University of Vienna||1||"the only reason is that recruitment was not sufficient to meet the planned patient numbers,~   because complete remissions are still infrequent."|f||||t||||||||||2018-06-01 00:16:10.824761|2018-06-01 00:16:10.824761
NCT01032291|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2013-04-01||2013-04-01|2009-12-14|2009-12-15|Estimate|2013-04-01|2013-05-21|Estimate||||2013-04-01|2013-05-21|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer|A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer|Terminated||Phase 2|51|Actual|Celgene|Enrollment stopped prematurely due to lack of efficacy and failure to achieve the planned response objective.|2||"A business decision not to continue with Phase 2b based on non-safety observations during proof~   of concept phase."|f||||f||||||||||2018-06-01 00:16:02.815622|2018-06-01 00:16:02.815622
NCT01032278|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2018-01-29|2009-12-13|2009-12-15|Estimate|||||||2018-01-29|2018-01-31|Actual|January 25, 2011|Actual|2011-01-25|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)|A Multicenter Study in Patients Undergoing AnthRacycline-Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)|Active, not recruiting||N/A|597|Actual|M.D. Anderson Cancer Center||1|||f||||t|f|f||||||||2018-06-01 00:16:03.838111|2018-06-01 00:16:03.838111
NCT01032265|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|2012-12-17||2013-02-08|2009-12-12|2009-12-15|Estimate|2013-02-08|2013-03-13|Estimate||||2013-02-08|2013-03-13|Estimate|December 2009||2009-12-31|February 2013|2013-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Web-based Management of Female Stress Urinary Incontinence|Web-based Management of Female Stress Urinary Incontinence. Evaluation of a Treatment Programme With Pelvic Floor Muscle Training and Elements of Cognitive Behavioural Therapy|Completed||N/A|250|Actual|Umeå University||2|||f||||f||||||||||2018-06-01 00:16:03.96695|2018-06-01 00:16:03.96695
NCT01032252|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2012-06-15|2009-12-12|2009-12-15|Estimate|||||||2012-06-15|2012-06-18|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Prevention of Falls in General Practitioner for Community-dwelling Older Adults [PreFalls]|Prevention of Falls in Community-dwelling Older Adults by a Standardized Assessment of Fall Risks in the General Practitioner Setting and Through Implementation of a Network for Effective Individual Reduction on Fall Risks.|Completed||Phase 4|378|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-06-01 00:16:04.663263|2018-06-01 00:16:04.663263
NCT01032239|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2017-09-21||2018-01-18|2009-12-14|2009-12-15|Estimate|2018-01-18|2018-02-15|Actual||||2018-01-18|2018-02-15|Actual|November 2009||2009-11-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SISTERS||SISTERS: Spasticity In Stroke Study - Randomized Study|A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment|Completed||Phase 4|61|Actual|MedtronicNeuro||2|||f||||t||||||||||2018-06-01 00:16:04.880288|2018-06-01 00:16:04.880288
NCT01032226|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2016-09-22|2009-12-12|2009-12-15|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2009||2009-12-31|September 2016|2016-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|CnapEval||Evaluation of CNAP During Anesthesia|Evaluation of CNAP During Induction and Maintenance of General Anesthesia|Terminated|||45|Actual|Hopital Foch||||Difficulty to include more patients|f||||f||||||||||2018-06-01 00:16:06.400174|2018-06-01 00:16:06.400174
NCT01032213|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2013-08-22|2009-12-14|2009-12-15|Estimate|||||||2013-08-22|2013-08-26|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Magnesium Sulphate on Coagulation|Effect of Magnesium Sulphate on Postoperative Coagulation as Measured by Thromboelastography|Completed||N/A|40|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:16:06.44802|2018-06-01 00:16:06.44802
NCT01032200|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|2016-11-03||2017-10-16|2009-12-13|2009-12-15|Estimate|2016-12-20|2017-02-13|Actual||||2017-10-16|2017-11-17|Actual|August 2010||2010-08-31|October 2017|2017-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All randomized participants.|Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors|A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue|Completed||Phase 2|54|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||No||2018-06-01 00:16:07.640619|2018-06-01 00:16:07.640619
NCT01032187|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2017-08-31|2009-12-14|2009-12-15|Estimate|||||||2017-08-31|2017-09-05|Actual|October 2007||2007-10-31|August 2017|2017-08-31|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|LVTO||Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children|Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children|Completed||Phase 4|101|Actual|University of Brasilia||2|||f||||f||||||||||2018-06-01 00:16:08.196563|2018-06-01 00:16:08.196563
NCT01032174|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2012-02-21||2012-04-10|2009-12-14|2009-12-15|Estimate|2012-02-21|2012-03-22|Estimate||||2012-04-10|2012-04-16|Estimate|April 2010||2010-04-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|EASY||Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis|Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis|Completed|||123|Actual|Pfizer|||2||f||||f||||||||||2018-06-01 00:16:08.29752|2018-06-01 00:16:08.29752
NCT01032161|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2013-02-24|2009-12-14|2009-12-15|Estimate|||||||2013-02-24|2013-02-26|Estimate|December 2009||2009-12-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Perioperative Risk Factors for Postoperative Delirium in Children|Perioperative Risk Factors for Postoperative Delirium in Children Following General Anesthesia|Completed|||300|Anticipated|Huazhong University of Science and Technology|||2||f||||t||||||||||2018-06-01 00:16:08.660962|2018-06-01 00:16:08.660962
NCT01032148|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2017-01-11|2009-12-14|2009-12-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma|Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma|Terminated||Phase 1|8|Actual|Roswell Park Cancer Institute||1||lack of funding|f||||t||||||||||2018-06-01 00:16:08.80444|2018-06-01 00:16:08.80444
NCT01032135|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|2017-03-28||2017-08-01|2009-12-14|2009-12-15|Estimate|2017-03-28|2017-05-15|Actual||||2017-08-01|2017-09-05|Actual|October 2008||2008-10-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Adaptive Treatment for Alcohol and Cocaine Dependence|Adaptive Treatment for Alcohol and Cocaine Dependence|Completed||Phase 2/Phase 3|500|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 00:16:08.981763|2018-06-01 00:16:08.981763
NCT01032109|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2016-02-25|2009-12-14|2009-12-15|Estimate|||||||2016-02-25|2016-02-26|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration|Verteporfin Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration|Completed||N/A|45|Actual|Kumamoto University||1|||f||||f||||||||||2018-06-01 00:16:11.05988|2018-06-01 00:16:11.05988
NCT01032096|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2016-05-20|2009-12-14|2009-12-15|Estimate|||||||2016-05-20|2016-05-23|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||The Physiological Response to Routine Head and Neck Cancer Surgery|The Neuroendocrine, Metabolic, Inflammatory and Immune Responses to Routine Head and Neck Surgery. An Observational Pilot Study|Completed|||15|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:16:11.235863|2018-06-01 00:16:11.235863
NCT01032083|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2015-03-25|2009-12-14|2009-12-15|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|ACTIONS||Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia|Individually Randomised, Placebo-controlled, Parallel Arm RCT With 12-month Follow-up to Establish the Clinical and Cost Effectiveness of the Antidepressant Citalopram in the Management of Negative Symptoms of Schizophrenia|Completed||Phase 4|62|Actual|Imperial College London||2|||f||||t||||||||||2018-06-01 00:16:11.3191|2018-06-01 00:16:11.3191
NCT01032070|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2013-11-20||2015-06-12|2009-12-11|2009-12-15|Estimate|2013-11-20|2014-01-08|Estimate||||2015-06-12|2015-07-10|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PETEY||Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma|A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma|Terminated||Phase 2|25|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2||"In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety~   concerns. As a result, it has been stopped."|f||||t||||||||||2018-06-01 00:16:11.501608|2018-06-01 00:16:11.501608
NCT01032057|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2014-02-13|2009-12-13|2009-12-15|Estimate|||||||2014-02-13|2014-02-14|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|SCALOP||Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery|A Multi-Center Randomized Phase II Study of Induction Chemotherapy Followed by Gemcitabine or Capecitabine Based Chemoradiotherapy for Locally Advanced Non-Metastatic Pancreatic Cancer|Completed||Phase 2|114|Actual|Cardiff University||2|||f||||t||||||||||2018-06-01 00:16:12.505563|2018-06-01 00:16:12.505563
NCT01032044|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2015-11-03||2016-03-22|2009-12-14|2009-12-15|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|February 2010||2010-02-28|March 2016|2016-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|CLEAN-MARGIN|Exploratory analysis of the data according to the intent-to-treat principle resulted in no suggestion of systematic bias in the two groups regarding withdrawals. Only 1 patient was withdrawn because of intolerance to fluorescein.|CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia|Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia|Completed||N/A|164|Actual|Mauna Kea Technologies||2|||f||||f||||||||||2018-06-01 00:16:12.626484|2018-06-01 00:16:12.626484
NCT01032031|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2016-03-07|2009-12-14|2009-12-15|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect of Green Tea and Vitamin C on Skin Health|The Effect of Dietary Bioactive Compounds on Skin Health in Humans in Vivo|Completed||N/A|95|Actual|University of Manchester||2|||f||||f||||||||||2018-06-01 00:16:12.881224|2018-06-01 00:16:12.881224
NCT01032018|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2013-07-30||2017-08-15|2009-12-13|2009-12-15|Estimate|2014-07-21|2014-08-12|Estimate||||2017-08-15|2017-09-13|Actual|January 2010||2010-01-31|August 2017|2017-08-31|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|CODIACS||Comparison of Depression Interventions After Acute Coronary Syndrome|Comparison of Depression Interventions After Acute Coronary Syndrome (CODIACS)|Completed||Phase 1/Phase 2|150|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 00:16:12.979695|2018-06-01 00:16:12.979695
NCT01032005|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2011-04-29|2009-12-14|2009-12-15|Estimate|||||||2011-04-29|2011-05-02|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|DFS||Efficacy of Double Fortified Salt (DFS) to Improve Work Productivity in Women in India|Double Fortified Salt Intervention and Work Performance (Productivity) of Women Plantation Workers in West Bengal, India|Completed||N/A|248|Actual|Micronutrient Initiative||2|||f||||f||||||||||2018-06-01 00:16:13.542845|2018-06-01 00:16:13.542845
NCT01031992|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2009-12-12|2009-12-12|2009-12-15|Estimate|||||||2009-12-12|2009-12-15|Estimate|March 2002||2002-03-31|December 2009|2009-12-31|October 2002|Actual|2002-10-31|August 2002|Actual|2002-08-31||Interventional|TAHHT||Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic Telangiectasia|Completed||Phase 3|23|Actual|University Hospital, Saarland||2|||f||||t||||||||||2018-06-01 00:16:13.617416|2018-06-01 00:16:13.617416
NCT01031979|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2016-11-03||2018-01-10|2009-12-14|2009-12-15|Estimate|2017-01-03|2017-02-24|Actual||||2018-01-10|2018-02-07|Actual|December 1, 2010|Actual|2010-12-01|January 2018|2018-01-31|July 7, 2015|Actual|2015-07-07|April 1, 2015|Actual|2015-04-01||Interventional||14 participants were randomized to the yohimbine group; however only 12 completed the primary outcome assessment at session 4 and were able to be analyzed.|Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine|Psychophysiology of Prolonged Exposure for PTSD With/Without Yohimbine|Completed||Phase 2|26|Actual|VA Office of Research and Development||2|||f||||f|t|f|||t|||No||2018-06-01 00:16:13.714461|2018-06-01 00:16:13.714461
NCT01031966|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2012-03-28|2009-12-14|2009-12-15|Estimate|||||||2012-03-28|2012-03-29|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine|A Pilot, Randomized, Open-label Study in Patients on Chronic Dialysis With End Stage Renal Disease (Esrd), to Evaluate the Enhancing Effect of Two Doses of Thymosin Alpha 1 on the Immunogenicity of h1n1sw Monovalent Vaccine|Completed||Phase 2|120|Actual|sigma-tau i.f.r. S.p.A.||3|||f||||t||||||||||2018-06-01 00:16:14.03094|2018-06-01 00:16:14.03094
NCT01031277|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2011-05-24|2009-12-11|2009-12-14|Estimate|||||||2011-05-24|2011-05-25|Estimate|November 2009||2009-11-30|May 2011|2011-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|CEPHEUS||Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States|Centralized Gulf States Survey on the Undertreatment of Hypercholesterolemia|Completed|||1000|Anticipated|AstraZeneca|||||f||||f||||||None Retained|"~     Whole blood~   "|||2018-06-01 00:16:23.247948|2018-06-01 00:16:23.247948
NCT01031953|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|2013-10-10||2017-05-07|2009-12-13|2009-12-15|Estimate|2013-12-12|2014-01-30|Estimate||||2017-05-07|2017-05-09|Actual|August 2008||2008-08-31|May 2017|2017-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy|Pilot Study of Fosaprepitant (MK-0517) for Breakthrough Chemotherapy Induced Nausea and Vomiting|Terminated||Phase 1/Phase 2|34|Actual|OHSU Knight Cancer Institute|"Missing data did affect results for the 24 hour mark~Lack of control group to measure possible neurokinin-1 antagonist (NK1a) inhibition"|1||Drug contract timelines and inadequate enrollment|f||||t||||||||||2018-06-01 00:16:14.124801|2018-06-01 00:16:14.124801
NCT01031940|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2012-06-17|2009-12-14|2009-12-15|Estimate|||||||2012-06-17|2012-06-19|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||CMAC® Versus Airtraq® and Macintosh Laryngoscope in Difficult Tracheal Intubation.|Comparison of the CMAC® Device to the Airtraq® and the Macintosh Laryngoscope in Patients With Anatomical Characteristics Predictive of Difficult Tracheal Intubation.|Terminated||N/A|15|Actual|University College Hospital Galway||3||"Insufficient Recruitment. Findings of concurrent study in low risk population not supportive of~   hypotheses in this study."|f||||f||||||||||2018-06-01 00:16:14.39179|2018-06-01 00:16:14.39179
NCT01031927|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2009-12-24|2009-12-14|2009-12-15|Estimate|||||||2009-12-24|2009-12-29|Estimate|June 2007||2007-06-30|December 2009|2009-12-31||||February 2009|Actual|2009-02-28||Interventional|||N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)|Sarcosine as Primary or Adjunctive Therapy in Obsessive Compulsive Disorder: A Prospective, Open-label Study|Completed||Phase 2|30|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-06-01 00:16:14.45531|2018-06-01 00:16:14.45531
NCT01031914|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2012-12-03||2013-04-01|2009-12-14|2009-12-15|Estimate|2013-04-01|2013-05-14|Estimate||||2013-04-01|2013-05-14|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PBSW||Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure (CPAP)|Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure Users Using Paced Breathing|Completed||N/A|36|Actual|Philips Respironics||1|||f||||f||||||||||2018-06-01 00:16:14.529539|2018-06-01 00:16:14.529539
NCT01031901|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-02-24|2009-12-14|2009-12-15|Estimate|||||||2012-02-24|2012-02-27|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)|Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex and Neurofibromatosis 1|Completed||Phase 1|52|Actual|The University of Texas Health Science Center, Houston||6|||f||||f||||||||||2018-06-01 00:16:14.696988|2018-06-01 00:16:14.696988
NCT01031888|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2009-12-14|2009-12-14|2009-12-15|Estimate|||||||2009-12-14|2009-12-15|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries|Phase 1 Study of Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries|Completed||Phase 1|18|Actual|National Taiwan University Hospital||4|||f||||f||||||||||2018-06-01 00:16:14.791193|2018-06-01 00:16:14.791193
NCT01031875|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2013-08-09|2009-12-13|2009-12-15|Estimate|||||||2013-08-09|2013-08-12|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment|Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer|Completed||Phase 2|41|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:16:14.864566|2018-06-01 00:16:14.864566
NCT01031862|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-06-24|2009-12-14|2009-12-15|Estimate|||||||2010-06-24|2010-06-28|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||BMS Reverse Cholesterol Transport (RCT) Study|A Pilot Study to Evaluate the Use of 3H Particulate Cholesterol as a Method to Study Reverse Cholesterol Transport in Humans|Completed||N/A|12|Anticipated|University of Pennsylvania||1|||f||||f||||||||||2018-06-01 00:16:14.935458|2018-06-01 00:16:14.935458
NCT01031849|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2013-04-05|2009-12-14|2009-12-15|Estimate|||||||2013-04-05|2013-04-08|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|BIOKAL||Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir|Análisis de Los Cambios en el Tejido Adiposo de Pacientes Con infección VIH y Lipoatrofia en Tratamiento Con análogos de nucleósidos timidínicos, Tras el Cambio a Monoterapia Con Lopinavir/Ritonavir|Terminated||Phase 4|7|Actual|Hospital San Carlos, Madrid||1||patient sample not reached|f||||f||||||||||2018-06-01 00:16:15.065086|2018-06-01 00:16:15.065086
NCT01031836|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2016-07-19|2009-12-13|2009-12-15|Estimate|||||||2016-07-19|2016-07-20|Estimate|November 2009||2009-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|November 2012|Actual|2012-11-30||Interventional|||A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.|A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|42|Actual|AstraZeneca||6|||f||||t||||||||||2018-06-01 00:16:15.158424|2018-06-01 00:16:15.158424
NCT01031823|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2011-01-25|2009-12-12|2009-12-15|Estimate|||||||2011-01-25|2011-01-26|Estimate|November 2009||2009-11-30|December 2010|2010-12-31|April 2011|Anticipated|2011-04-30|December 2010|Anticipated|2010-12-31||Interventional|ASST||Adolescent Social Skills Training Program|The Multi-media Social Skills Project: Validation of an Intervention for Adolescents With Autism Spectrum Disorders|Unknown status|Active, not recruiting|N/A|24|Anticipated|Penn State University||1|||f||||||||||||||2018-06-01 00:16:15.256278|2018-06-01 00:16:15.256278
NCT01031810|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|2013-10-08||2014-09-15|2009-12-12|2009-12-15|Estimate|2014-09-15|2014-09-18|Estimate||||2014-09-15|2014-09-18|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||PET Biomarkers in Treatment Resistant Depression|Developing a Biomarker to Predict Response in Treatment Resistant Depression|Terminated||Phase 4|13|Actual|New York State Psychiatric Institute|Early termination leading to small numbers of subjects analyzed|1||Needed PET facility closed|f||||f||||||||||2018-06-01 00:16:15.337718|2018-06-01 00:16:15.337718
NCT01031797|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2009-12-12|2009-12-12|2009-12-15|Estimate|||||||2009-12-12|2009-12-15|Estimate|January 2008||2008-01-31|July 2007|2007-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||QT Dispersion in Patients With Systemic Lupus Erythematosus (SLE)|QT Dispersion in Patients With Systemic Lupus Erythematosus: the Impact of Disease Activity|Completed|||124|Actual|Shiraz University of Medical Sciences|||2||f||||t||||||||||2018-06-01 00:16:15.568544|2018-06-01 00:16:15.568544
NCT01031784|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2012-01-30|2009-12-14|2009-12-15|Estimate|||||||2012-01-30|2012-01-31|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|HEPAR||Radioactive Holmium Microspheres for the Treatment of Liver Metastases|Radioactive Holmium Microspheres for the Treatment of Patients With Non-resectable Liver Metastases of Mixed Origin; a Single Center, Interventional, Non-randomized, Open Label, Safety Study.|Completed||Phase 1|15|Actual|UMC Utrecht||1|||f||||t||||||||||2018-06-01 00:16:15.625626|2018-06-01 00:16:15.625626
NCT01031771|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2009-12-14|2009-12-14|2009-12-15|Estimate|||||||2009-12-14|2009-12-15|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|November 2009|Actual|2009-11-30|||||Observational|CP||Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy|Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy|Completed|||50|Actual|Fortaleza University|||||f||||t||||||||||2018-06-01 00:16:15.693355|2018-06-01 00:16:15.693355
NCT01031758|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2010-06-25|2009-12-14|2009-12-15|Estimate|||||||2010-06-25|2010-06-29|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MeMo||Reverse Cholesterol Transport (RCT) Study|A Pilot Study To Evaluate The Use Of 3H Particulate Cholesterol As A Method To Study Reverse Cholesterol Transport In Humans Followed By A Study On The Effect Of HDL-C On RCT Measured By This Method|Completed||N/A|18|Anticipated|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 00:16:15.77483|2018-06-01 00:16:15.77483
NCT01031745|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-12|||2016-11-01|2009-12-12|2009-12-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Contingency Management in the Delivery of HAART to Drug Users in Chennai, India||Completed||Phase 2|120|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 00:16:15.920804|2018-06-01 00:16:15.920804
NCT01031732|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-13|||2010-05-27|2009-12-14|2009-12-15|Estimate|||||||2010-05-27|2010-05-31|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of Four Surgical Techniques in Primary Total Hip Arthroplasty|A Prospective Randomized Controlled 4-arm Study for the Evaluation of 4 Surgical Techniques in Primary Total Hip Arthroplasty|Unknown status|Recruiting|N/A|120|Anticipated|Chang Gung Memorial Hospital||4|||f||||t||||||||||2018-06-01 00:16:15.981974|2018-06-01 00:16:15.981974
NCT01031719|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-14|||2012-09-12|2009-12-14|2009-12-15|Estimate|||||||2012-09-12|2012-09-13|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Interventional|||Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors|A Phase III, Randomized, Controlled, Open Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Vaccine Versus Non-Adjuvanted Vaccines Against Novel H1N1 Virus in Patients With Invasive Solid Tumors|Completed||Phase 3|59|Actual|Chiltern Pesquisa Clinica Ltda||4|||f||||||||||||||2018-06-01 00:16:16.068352|2018-06-01 00:16:16.068352
NCT01031706|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2014-03-05||2017-01-18|2009-12-14|2009-12-15|Estimate|2014-05-29|2014-06-30|Estimate||||2017-01-18|2017-03-03|Actual|September 2009||2009-09-30|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Number of subjects passing screening|Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis|Sustained Impact of Hypertonic Saline on Mucociliary Clearance in Young Children With Cystic Fibrosis|Completed||N/A|23|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-06-01 00:16:16.163956|2018-06-01 00:16:16.163956
NCT01031693|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2018-04-04|2009-12-11|2009-12-14|Estimate|||||||2018-04-04|2018-04-05|Actual|July 13, 2009||2009-07-13|August 28, 2013|2013-08-28|August 28, 2013|Actual|2013-08-28|August 28, 2013|Actual|2013-08-28||Interventional|||Pilot Study of Transcranial Magnetic Stimulation (TMS) in Nicotine Addiction|Pilot Study of Transcranial Magnetic Stimulation (TMS) in Nicotine Addiction|Completed||Phase 1|75|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:16:16.454313|2018-06-01 00:16:16.454313
NCT01031680|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2013-01-21||2013-09-24|2009-12-11|2009-12-14|Estimate|2013-07-19|2013-08-23|Estimate||||2013-09-24|2013-10-29|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension|A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care|Completed||Phase 3|922|Actual|AstraZeneca|For participants who did not complete 8 and/or 24 weeks, respectively, LOCF was used. For HbA1c: excluding data after glycemic rescue, Weight: including data after rescue, SBP: excluding data after anti-hypertensive rescue.|2|||f||||||||||||||2018-06-01 00:16:16.611185|2018-06-01 00:16:16.611185
NCT01031667|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2011-06-16|2009-12-11|2009-12-14|Estimate|||||||2011-06-16|2011-06-17|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)||Completed||Phase 4|118|Actual|Yonsei University|||||f||||t||||||||||2018-06-01 00:16:17.360688|2018-06-01 00:16:17.360688
NCT01031654|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2009-12-10|2009-12-10|2009-12-14|Estimate|||||||2009-12-10|2009-12-14|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Observational|||Marital Functioning Among Combat Veterans|Marital Functioning Among Combat Veterans|Unknown status|Recruiting||20|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 00:16:17.414202|2018-06-01 00:16:17.414202
NCT01031641|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2018-04-04|2009-12-11|2009-12-14|Estimate|||||||2018-04-04|2018-04-05|Actual|December 1, 2009||2009-12-01|July 25, 2017|2017-07-25||||||||Observational|||Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing|Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing|Completed|||1448|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:17.484176|2018-06-01 00:16:17.484176
NCT01031459|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2012-01-03|2009-12-10|2009-12-14|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.|An Observational 20-year, Cross-sectional, Long-term Follow up of the Patient Cohort Enrolled in the Pivotal Study of Betaseron® (Interferon Beta-1b) in Relapsing-remitting Multiple Sclerosis|Completed|||176|Actual|Bayer|||1||f||||t||||||None Retained|"~     n.a~   "|||2018-06-01 00:16:21.018481|2018-06-01 00:16:21.018481
NCT01031628|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2013-06-12||2013-08-22|2009-12-11|2009-12-14|Estimate|2013-06-12|2013-08-16|Estimate||||2013-08-22|2013-09-09|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients|A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL|Terminated||Phase 3|5|Actual|Sarcoma Alliance for Research through Collaboration|A decision was made to discontinue the SARC019 trial effective March 3, 2011, due to lack of feasibility secondary to slow accrual. Due to early termination of the study, no patients were analyzed.|4||Lack of feasibility secondary to slow accrual|f||||t||||||||||2018-06-01 00:16:17.56229|2018-06-01 00:16:17.56229
NCT01031615|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2011-06-14|2009-12-11|2009-12-14|Estimate|||||||2011-06-14|2011-06-16|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|CFTSI||Evaluation of the Child and Family Traumatic Stress Intervention|Evaluation of the Child and Family Traumatic Stress Intervention|Completed||Phase 1/Phase 2|112|Actual|Yale University||2|||f||||f||||||||||2018-06-01 00:16:18.091415|2018-06-01 00:16:18.091415
NCT01031602|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2013-05-24|2009-12-11|2009-12-14|Estimate|||||||2013-05-24|2013-05-29|Estimate|October 2007||2007-10-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients|Assessment of the Prevalence of Sexual Dysfunction, Depression, and Anxiety in Underserved and Minority Patients With Gynecologic Cancers|Completed|||160|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 00:16:18.177755|2018-06-01 00:16:18.177755
NCT01031589|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-11-19|2009-12-10|2009-12-14|Estimate|||||||2012-11-19|2012-11-20|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278|Study in Healthy Volunteers to Examine the Safety, Tolerability and Plasma Pharmacokinetics of One Intramuscular (IM) Injection of a Novel TMC278 LA Formulation at 2 Different Doses (Open Label), Followed by a Placebo-controlled Part of Multiple IM Injections at a Selected Dose (Double Blind)|Completed||Phase 1|19|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 00:16:18.273657|2018-06-01 00:16:18.273657
NCT01031576|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-12-11|2009-12-11|2009-12-14|Estimate|||||||2009-12-11|2009-12-14|Estimate|February 2006||2006-02-28|April 2008|2008-04-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Observational|||Postural Analysis in Patients With Knee Osteoarthritis|Postural Analysis and Eletromiographic Activity in Patients With Knee Osteoarthritis|Completed|||30|Actual|University of Sao Paulo|||||f||||t||||||||||2018-06-01 00:16:18.403147|2018-06-01 00:16:18.403147
NCT01031563|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2017-06-30|2009-12-11|2009-12-14|Estimate|||||||2017-06-30|2017-07-02|Actual|August 18, 2009||2009-08-18|May 3, 2012|2012-05-03|May 3, 2012||2012-05-03|||||Observational|||Risk Perception in Drug-Dependent Adults With and Without Schizophrenia|Risk Perception in Drug-Dependent Adults With and Without Schizophrenia|Completed|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:18.686181|2018-06-01 00:16:18.686181
NCT01031550|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2013-09-16||2017-02-13|2009-12-11|2009-12-14|Estimate|2013-12-11|2013-12-12|Estimate||||2017-02-13|2017-03-20|Actual|January 2010||2010-01-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Isoflurane Preconditioning for Liver Resections|Isoflurane Induced Anesthetic Preconditioning in Elective Liver Resection|Terminated||N/A|8|Actual|Rutgers, The State University of New Jersey|Due to termination of the study no data analysis was performed.|2||We no longer had an appropriate patient population.Study closed|f||||f||||||||No||2018-06-01 00:16:18.762731|2018-06-01 00:16:18.762731
NCT01031537|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2017-10-05|2009-12-11|2009-12-14|Estimate|||||||2017-10-05|2017-10-06|Actual|September 25, 2009||2009-09-25|December 23, 2016|2016-12-23|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|||A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory|A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory|Terminated||Phase 2|26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:19.65836|2018-06-01 00:16:19.65836
NCT01031524|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-11|2009-12-11|2009-12-14|Estimate|||||||2009-12-11|2009-12-14|Estimate|March 2004||2004-03-31|December 2009|2009-12-31|November 2004|Actual|2004-11-30|July 2004|Actual|2004-07-31||Interventional|DG002||Trial to Assess the Efficacy of Malaria Vaccine PfCS 102|Randomized Double-blind Controlled Phase I/IIa Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 (282-383) to Protect Against Artificial Challenge With P. Falciparum|Completed||Phase 1/Phase 2|16|Actual|Swiss Tropical & Public Health Institute||2|||f||||f||||||||||2018-06-01 00:16:19.838051|2018-06-01 00:16:19.838051
NCT01031511|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2009-12-11|2009-12-11|2009-12-14|Estimate|||||||2009-12-11|2009-12-14|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|February 2011|Anticipated|2011-02-28|January 2010|Anticipated|2010-01-31||Interventional|||Effect of Cognitive Behavioural Therapy (CBT) for Children With Autistic Spectrum Disorders|A Randomised Controlled Trial on the Effect of Cognitive-behavioural Therapy for High-functioning Children With Autistic Spectrum Disorder|Unknown status|Active, not recruiting|Early Phase 1|73|Actual|National Healthcare Group, Singapore||2|||f||||t||||||||||2018-06-01 00:16:19.98518|2018-06-01 00:16:19.98518
NCT01031498|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2011-01-14||2012-08-01|2009-12-11|2009-12-14|Estimate|2011-01-14|2011-02-03|Estimate||||2012-08-01|2012-08-07|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting|Phase II, Open, Randomized Comparative Trial of Two Different Schedules of Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting in Patients With Hematologic Malignancies Receiving Regimens Containing High-dose Cytarabine|Completed||Phase 2|150|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 00:16:20.139697|2018-06-01 00:16:20.139697
NCT01031485|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2014-12-19|2009-12-11|2009-12-14|Estimate|||||||2014-12-19|2014-12-23|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Bioactive Milk Peptides and Blood Pressure||Completed||Phase 3|||Valio Ltd||2|||f||||||||||||||2018-06-01 00:16:20.790881|2018-06-01 00:16:20.790881
NCT01031472|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2010-11-02|2009-12-10|2009-12-14|Estimate|||||||2010-11-02|2010-11-03|Estimate|December 2009||2009-12-31|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761|A Single-center, Randomized, Two Part, Open-label, Crossover Study to Assess the Relative Bioavailability and Food Effect of New Formulations of GSK2248761 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:16:20.902669|2018-06-01 00:16:20.902669
NCT01031446|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2012-12-06||2017-07-24|2009-12-11|2009-12-14|Estimate|2013-02-05|2013-03-11|Estimate||||2017-07-24|2017-08-24|Actual|October 2009||2009-10-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|December 2011|Actual|2011-12-31||Interventional|||Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer|A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|55|Actual|Vanderbilt-Ingram Cancer Center|All patients began at the same dose level of the study drugs with no de-escalation of dose, thus results were combined for outcomes measures 3, 4, 5, and 6 for Phase II.|1|||f||||t||||||||||2018-06-01 00:16:21.189839|2018-06-01 00:16:21.189839
NCT01031433|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2018-05-17|2009-12-11|2009-12-14|Estimate|||||||2018-05-17|2018-05-18|Actual|July 28, 2009||2009-07-28|July 18, 2012|2012-07-18|July 18, 2012||2012-07-18|||||Observational|||Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality|Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality|Completed|||17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:21.613667|2018-06-01 00:16:21.613667
NCT01031420|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2015-11-03|2009-12-11|2009-12-14|Estimate|||||||2015-11-03|2015-11-04|Estimate|December 2009||2009-12-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Dose Dense MVAC for Muscle Invasive Bladder Cancer|Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract|Completed||Phase 2|54|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-06-01 00:16:21.686536|2018-06-01 00:16:21.686536
NCT01031407|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2018-03-27|2009-12-11|2009-12-14|Estimate|||||||2018-03-27|2018-03-29|Actual|November 19, 2009||2009-11-19|March 14, 2018|2018-03-14||||||||Observational|||Cognitive Neuroscience of Autism Spectrum Disorders|Cognitive Neuroscience of Autism Spectrum Disorders|Recruiting|||1600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:21.800384|2018-06-01 00:16:21.800384
NCT01031394|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2015-10-26|2009-12-11|2009-12-14|Estimate|||||||2015-10-26|2015-10-27|Estimate|January 2004||2004-01-31|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SWEET||Frequency of Aerobic/Resistance Training in Older Women|Frequency of Aerobic/Resistance Training in Older Women|Completed||N/A|105|Actual|University of Alabama at Birmingham||3|||f||||f||||||||||2018-06-01 00:16:21.919557|2018-06-01 00:16:21.919557
NCT01031381|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2016-01-31||2016-07-19|2009-12-11|2009-12-14|Estimate|2016-07-19|2016-08-30|Estimate||||2016-07-19|2016-08-30|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|RADBEV||Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer|Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital|Completed||Phase 2|50|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 00:16:22.05331|2018-06-01 00:16:22.05331
NCT01031368|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2014-08-13|2009-12-11|2009-12-14|Estimate|||||||2014-08-13|2014-08-15|Estimate|December 2009||2009-12-31|August 2014|2014-08-31||||September 2012|Actual|2012-09-30||Interventional|||Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia|Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients With AML|Completed||Phase 1|29|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 00:16:22.422622|2018-06-01 00:16:22.422622
NCT01031355|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2014-02-18|2009-12-11|2009-12-14|Estimate|||||||2014-02-18|2014-02-20|Estimate|December 2009||2009-12-31|February 2014|2014-02-28|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium|Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 3 mg EV Without and With 0.451 mg Levomefolate Calcium and a Tablet Formulation Containing 0.451 mg Levomefolate Calcium in 42 Healthy Postmenopausal Women|Completed||Phase 1|42|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:16:22.499042|2018-06-01 00:16:22.499042
NCT01031342|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2011-01-24|2009-12-11|2009-12-14|Estimate|||||||2011-01-24|2011-01-25|Estimate|August 2002||2002-08-31|January 2011|2011-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Early Colonoscopy for Lower Gastrointestinal (GI) Bleeding|Early Versus Elective Colonoscopy in the Management of Lower Gastrointestinal Bleeding|Terminated||N/A|72|Actual|University of Southern California||2||"Change in ER rules (no longer allowed endoscopies in ER) prevented ability to perform study~   according to protocol"|f||||f||||||||||2018-06-01 00:16:22.599716|2018-06-01 00:16:22.599716
NCT01031329|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2015-04-09|2009-12-10|2009-12-14|Estimate|||||||2015-04-09|2015-04-13|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Turkey|Withdrawn|||0|Actual|GlaxoSmithKline|||1|"Key aspects linked to sample management and analysis were not met during feasibility assessment~   limiting the ability of the study to reach its objectives."|f||||||||||Samples Without DNA|"~     Middle ear fluid and urine.~   "|||2018-06-01 00:16:22.688294|2018-06-01 00:16:22.688294
NCT01031316|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-12-31|2009-12-10|2009-12-14|Estimate|||||||2013-12-31|2014-01-03|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|||Patent Ductus Arteriosus (PDA) Screening Trial|The Role of Serial Echocardiography to Detect an Asymptomatic Patent Ductus Arteriosus (PDA) in Very Low Birth Weight (VLBW) Infants: A Pilot Randomized Controlled Trial|Completed||N/A|88|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:16:22.751422|2018-06-01 00:16:22.751422
NCT01031303|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2011-10-04|2009-12-10|2009-12-14|Estimate|||||||2011-10-04|2011-10-05|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age|Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34|Completed||Phase 4|123|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:16:22.942488|2018-06-01 00:16:22.942488
NCT01031290|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2017-06-30|2009-12-11|2009-12-14|Estimate|||||||2017-06-30|2017-07-02|Actual|August 19, 2009||2009-08-19|February 27, 2012|2012-02-27|February 27, 2012|Actual|2012-02-27|January 31, 2012|Actual|2012-01-31||Interventional|||Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving|Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:16:23.147469|2018-06-01 00:16:23.147469
NCT01031238|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2015-11-19|2009-12-11|2009-12-14|Estimate|||||||2015-11-19|2015-11-20|Estimate|December 2009||2009-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Comparison of PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast|Pilot Study to Compare the PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast|Completed|||5|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 00:16:23.463522|2018-06-01 00:16:23.463522
NCT01031225|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2014-09-18|2009-12-10|2009-12-14|Estimate|||||||2014-09-18|2014-09-19|Estimate|November 2009||2009-11-30|September 2014|2014-09-30|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|||A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)|A Non-Randomized, Open-label, Multi-Center, Multi-Cohort Phase 2 Study Evaluating the Efficacy and Safety of STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer|Completed||Phase 2|113|Actual|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-06-01 00:16:24.771181|2018-06-01 00:16:24.771181
NCT01031212|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-05-09|2009-12-10|2009-12-14|Estimate|||||||2013-05-09|2013-05-13|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors|A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors|Withdrawn||Phase 1|0|Actual|University of California, San Francisco||||The investigator has left the institution (UCSF) prior to study start-up|f||||t||||||||||2018-06-01 00:16:25.234005|2018-06-01 00:16:25.234005
NCT01031199|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2014-04-01|2009-12-11|2009-12-14|Estimate|||||||2014-04-01|2014-04-02|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers|Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers|Completed||Phase 1|16|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:16:25.65175|2018-06-01 00:16:25.65175
NCT01031186|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-07-25|2009-12-10|2009-12-14|Estimate|||||||2017-07-25|2017-07-27|Actual|November 23, 2009|Actual|2009-11-23|July 2017|2017-07-31|April 7, 2010|Actual|2010-04-07|April 7, 2010|Actual|2010-04-07||Interventional|FTIM||First Time in Human Study|A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers|Completed||Phase 1|20|Actual|GlaxoSmithKline||10|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:16:25.974162|2018-06-01 00:16:25.974162
NCT01031173|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2014-02-19|2009-12-11|2009-12-14|Estimate|||||||2014-02-19|2014-02-21|Estimate||||February 2014|2014-02-28||||||||Expanded Access|||Treatment Protocol of Replagal for Patients With Fabry Disease|An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients With Fabry Disease.|No longer available|||||Shire|||||||||||||||||||2018-06-01 00:16:26.147976|2018-06-01 00:16:26.147976
NCT01031160|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2018-04-24|2009-12-11|2009-12-14|Estimate|||||||2018-04-24|2018-04-25|Actual|October 1, 2009||2009-10-01|April 17, 2018|2018-04-17||||||||Observational|||Health Behavior in School-Age Children: NEXT Longitudinal Study 2009-2016|Health Behavior in School-Age Children: NEXT Longitudinal Study 2009-2016|Active, not recruiting|||4902|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:26.391009|2018-06-01 00:16:26.391009
NCT01031147|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2010-02-25|2009-12-11|2009-12-14|Estimate|||||||2010-02-25|2010-02-26|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2008|Actual|2008-12-31||Observational|||Contrast-free Magnetic Resonance Angiography (MRA) at 3.0 T for Intracranial Aneurysm Detection|Detection of Intracranial Aneurysm With Non-enhanced, Three-dimensional Time-of-flight Magnetic Resonance Angiography(3D−TOF−MRA): a Prospective Comparison With Three-dimensional Reconstructed Digital Subtraction Angiography (3D RDSA)|Unknown status|Recruiting||350|Anticipated|Shanghai Jiao Tong University School of Medicine|||1||f||||t||||||||||2018-06-01 00:16:26.487502|2018-06-01 00:16:26.487502
NCT01031134|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2017-01-27||2017-03-31|2009-12-11|2009-12-14|Estimate|2017-03-31|2017-06-16|Actual||||2017-03-31|2017-06-16|Actual|April 2010|Actual|2010-04-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Shared Decision-Making for Elderly Depressed Primary Care Patients|Shared Decision-Making for Elderly Depressed Primary Care Patients|Completed||N/A|202|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-06-01 00:16:26.622631|2018-06-01 00:16:26.622631
NCT01031121|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2017-06-30|2009-12-11|2009-12-14|Estimate|||||||2017-06-30|2017-07-02|Actual|June 8, 2009||2009-06-08|October 22, 2010|2010-10-22|October 22, 2010||2010-10-22|||||Observational|||Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers|Breath Carbon Monoxide and Cotinine as Biomarkers to Distinguish Smokers From Nonsmokers|Completed|||240|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:27.111197|2018-06-01 00:16:27.111197
NCT01031108|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-06-19|2009-12-10|2009-12-14|Estimate|||||||2017-06-19|2017-06-20|Actual|May 28, 2010|Actual|2010-05-28|June 2017|2017-06-30|October 12, 2011|Actual|2011-10-12|October 12, 2011|Actual|2011-10-12||Interventional|||A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus|A Phase I, Randomized, Placebo-Controlled, Crossover Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|38|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:16:27.206413|2018-06-01 00:16:27.206413
NCT01031095|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2012-01-21||2013-12-24|2009-12-11|2009-12-14|Estimate|2013-07-24|2013-10-10|Estimate||||2013-12-24|2014-01-30|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|REDUCED||(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)|A RandomisED StUdy Comparing Standard Systemic Anticoagulation ThErapy to Low Dose Intracoronary Anticoagulation Therapy for Elective Percutaneous Coronary Intervention|Completed||Phase 3|200|Actual|Bursa Postgraduate Hospital|The intraprocedural use of a heparinised flush was not controlled; however, given the maximum amount that was allowed to be used, this is not likely to have significantly affected the activated clotting times. .|2|||f||||f||||||||||2018-06-01 00:16:27.33633|2018-06-01 00:16:27.33633
NCT01031082|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2010-05-20|2009-12-10|2009-12-14|Estimate|||||||2010-05-20|2010-05-24|Estimate|May 2009||2009-05-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Study to Identify and Characterize Bacteria Causing Acute Otitis Media in South African Children|Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in HIV-positive and HIV-negative Children in South Africa|Completed|||265|Actual|GlaxoSmithKline|||2||f||||||||||Samples Without DNA|"~     Middle ear fluid, nasopharyngeal aspirate and urine.~   "|||2018-06-01 00:16:27.551765|2018-06-01 00:16:27.551765
NCT01031069|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2016-12-15|2009-12-10|2009-12-14|Estimate|||||||2016-12-15|2016-12-16|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females|Safety and Immunogenicity of Cervarix™ in Human Immunodeficiency Virus Infected Females|Active, not recruiting||Phase 4|649|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:16:27.632509|2018-06-01 00:16:27.632509
NCT01031056|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-05-24|2009-12-11|2009-12-14|Estimate|||||||2012-05-24|2012-05-28|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Observational|||Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers|Collection of Biospecimen and Clinical Information in Patients With Gastrointestinal Cancers|Withdrawn|||0|Actual|Stanford University||||Change in research focus|f||||||||||Samples Without DNA|"~     This study requires that we obtain archived tumor and normal tissue and blood.~   "|||2018-06-01 00:16:27.968814|2018-06-01 00:16:27.968814
NCT01031043|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2015-01-12||2015-01-27|2009-12-11|2009-12-14|Estimate|2015-01-27|2015-01-29|Estimate||||2015-01-27|2015-01-29|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Topical Bethanechol for Improvement of Esophageal Dysmotility|Topical Bethanechol for Improvement of Esophageal Dysmotility: A Pilot Study|Completed||Phase 1|5|Actual|Augusta University||1|||f||||t||||||||||2018-06-01 00:16:28.077081|2018-06-01 00:16:28.077081
NCT01031030|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2013-08-01|2009-12-11|2009-12-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 1997||1997-11-30|December 2009|2009-12-31||||December 2010|Anticipated|2010-12-31||Interventional|||Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)|Adjuvant Treatment of Biologically Aggressive Breast Cancer (N-,N+1,3): Controlled Clinical Study|Unknown status|Active, not recruiting|Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:16:28.227425|2018-06-01 00:16:28.227425
NCT01031017|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2014-12-03|2009-12-11|2009-12-14|Estimate|||||||2014-12-03|2014-12-04|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies|Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 4|390|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:16:28.2851|2018-06-01 00:16:28.2851
NCT01031004|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2011-02-22||2017-08-31|2009-12-10|2009-12-14|Estimate|2011-02-22|2011-03-17|Estimate||||2017-08-31|2017-09-29|Actual|October 1, 2009|Actual|2009-10-01|August 2017|2017-08-31|December 1, 2009|Actual|2009-12-01|December 1, 2009|Actual|2009-12-01||Interventional|||Vistakon Investigational Lens Worn as a Single Use Daily Wear||Completed||N/A|50|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 00:16:28.390232|2018-06-01 00:16:28.390232
NCT01030991|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2018-04-10|2009-12-10|2009-12-14|Estimate|||||||2018-04-10|2018-04-11|Actual|July 2008||2008-07-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Classification of Heart Failure With Preserved Ejection Fraction|Etiologic, Pathophysiologic, and Genetic Classification of Heart Failure With Preserved Ejection Fraction|Active, not recruiting|||1000|Anticipated|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Whole blood, saliva~   "|No||2018-06-01 00:16:28.990924|2018-06-01 00:16:28.990924
NCT01030978|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2014-06-16|2009-12-11|2009-12-14|Estimate|||||||2014-06-16|2014-06-17|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program|Prevention of Type 2 Diabetes in Children With a Family-based Healthy Lifestyle Program|Completed||N/A|72|Actual|Yale University||2|||f||||f||||||||||2018-06-01 00:16:29.090822|2018-06-01 00:16:29.090822
NCT01030965|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2014-01-09|2012-03-08|2018-02-08|2009-12-10|2009-12-14|Estimate|2014-01-09|2014-02-24|Estimate|2012-03-15|2012-03-19|Estimate|2018-02-08|2018-03-09|Actual|December 15, 2009|Actual|2009-12-15|February 2018|2018-02-28|July 4, 2010|Actual|2010-07-04|July 4, 2010|Actual|2010-07-04||Interventional|||28-day Repeat Dose Study of GSK573719|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-daily Over 28 Days in Subjects With COPD|Completed||Phase 2|285|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:16:29.200028|2018-06-01 00:16:29.200028
NCT01030952|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|2012-02-20||2012-09-18|2009-12-11|2009-12-14|Estimate|2012-09-18|2012-10-19|Estimate||||2012-09-18|2012-10-19|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion|A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus|Completed||Phase 4|103|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:16:29.709165|2018-06-01 00:16:29.709165
NCT01030939|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2017-06-19|2009-12-10|2009-12-14|Estimate|||||||2017-06-19|2017-06-20|Actual|August 27, 2009|Actual|2009-08-27|June 2017|2017-06-30|January 6, 2010|Actual|2010-01-06|January 6, 2010|Actual|2010-01-06||Interventional|||Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers|A Single-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate Safety, Tolerability, Pharmacokinetics and the Effects on Cardiac Function of Repeat Oral Doses of SB-649868 in Adult and Elderly Healthy Volunteers|Completed||Phase 1|72|Actual|GlaxoSmithKline||4|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:16:30.221421|2018-06-01 00:16:30.221421
NCT01030926|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2017-01-19|2009-12-11|2009-12-14|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes|Completed||Phase 1|39|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 00:16:30.334791|2018-06-01 00:16:30.334791
NCT01030913|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-12-13|2009-12-11|2009-12-14|Estimate|||||||2017-12-13|2017-12-15|Actual|December 1999||1999-12-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression|B-CLL Subgroups: Maturation Stage and Gene Expression|Recruiting|||1248|Anticipated|Northwell Health|||1||f||||f||||||Samples With DNA|"~     Blood Cells, Bone Marrow~   "|||2018-06-01 00:16:30.424041|2018-06-01 00:16:30.424041
NCT01030900|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2018-05-17|2009-12-11|2009-12-14|Estimate|||||||2018-05-17|2018-05-18|Actual|October 22, 2009||2009-10-22|December 12, 2017|2017-12-12|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas|Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas|Active, not recruiting||Phase 2|50|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 00:16:30.489631|2018-06-01 00:16:30.489631
NCT01030887|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2011-08-12|2009-12-11|2009-12-14|Estimate|||||||2011-08-12|2011-08-15|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|PEACH||PEACH Trial: Prescribed Exercise After Chemotherapy|Individually Prescribed Exercise Versus Usual Care in a Heterogeneous Cancer Survivor Population: A Pragmatic Randomized Controlled Trial|Completed||Phase 3|43|Actual|University of Dublin, Trinity College||2|||f||||t||||||||||2018-06-01 00:16:30.575698|2018-06-01 00:16:30.575698
NCT01030874|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2016-08-05|2009-12-11|2009-12-14|Estimate|||||||2016-08-05|2016-08-09|Estimate|October 2011||2011-10-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Orthostatic Hypotension Treatment on Rehab Unit|Effect of Treatment of Orthostatic Hypotension on a Rehabilitation Unit|Completed||N/A|356|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-06-01 00:16:30.666497|2018-06-01 00:16:30.666497
NCT01030861|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2017-08-04|2009-12-11|2009-12-14|Estimate|||||||2017-08-04|2017-08-07|Actual|August 2010||2010-08-31|August 2017|2017-08-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||"Teplizumab for Prevention of Type 1 Diabetes In Relatives At-Risk"|AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus|Active, not recruiting||Phase 2|71|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 00:16:30.750488|2018-06-01 00:16:30.750488
NCT01030848|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2009-12-14|2009-12-11|2009-12-14|Estimate|||||||2009-12-14|2009-12-15|Estimate|February 2003||2003-02-28|December 2009|2009-12-31|September 2013|Anticipated|2013-09-30|September 2007|Actual|2007-09-30||Observational|||Time-dependent Improvement of Functional Outcome Following LCS Rotating Platform TKR|Time-dependent Improvement of Functional Outcome Following LCS Rotating Platform TKR - A Prospective Longitudinal Study With Repetitive Measures of KOOS|Unknown status|Active, not recruiting||50|Actual|Martina Hansen's Hospital|||1||f||||f||||||||||2018-06-01 00:16:30.858309|2018-06-01 00:16:30.858309
NCT01030835|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-11|||2017-06-30|2009-12-11|2009-12-14|Estimate|||||||2017-06-30|2017-07-02|Actual|May 28, 2009||2009-05-28|April 10, 2012|2012-04-10|April 10, 2012||2012-04-10|||||Observational|||Screening Protocol for the Evaluation of Research Participants at the Maryland Psychiatric Research Center (MPRC)|Screening Protocol for the Evaluation of Research Participants at MPRC|Completed|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:16:30.928523|2018-06-01 00:16:30.928523
NCT01030822|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2017-01-09|2012-07-24|2017-01-09|2009-12-10|2009-12-14|Estimate|2017-01-09|2017-02-28|Actual|2012-07-24|2012-08-01|Estimate|2017-01-09|2017-02-28|Actual|April 2010||2010-04-30|August 2016|2016-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Booster and Catch-up Vaccination With Vaccine GSK1024850A|Booster Vaccination With Pneumococcal Vaccine GSK1024850A in Primed Children and Catch-up Vaccination in Unprimed Children|Completed||Phase 3|282|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:16:31.066015|2018-06-01 00:16:31.066015
NCT01030809|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2014-03-19|2009-12-10|2009-12-11|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|REACT||Trial of a Treatment Algorithm for the Management of Crohn's Disease|A Cluster Randomized Controlled Trial of a Treatment Algorithm for the Management of Crohn's Disease|Completed||Phase 4|1999|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-06-01 00:16:32.086923|2018-06-01 00:16:32.086923
NCT01030796|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2011-02-03|2009-12-10|2009-12-11|Estimate|||||||2011-02-03|2011-02-07|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Quitting Caffeine for Better Glucose Metabolism|Quitting Caffeine for Better Glucose Metabolism|Completed||Phase 1|25|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||||2018-06-01 00:16:32.167998|2018-06-01 00:16:32.167998
NCT01030783|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09||2013-01-22|2014-02-19|2009-12-10|2009-12-11|Estimate||||2013-01-22|2013-01-29|Estimate|2014-02-19|2014-03-18|Estimate|December 2009||2009-12-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|July 2012|Actual|2012-07-31||Interventional|TIVO-1||A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma|A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)|Completed||Phase 3|517|Actual|AVEO Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 00:16:32.250225|2018-06-01 00:16:32.250225
NCT01030770|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2015-08-14|2009-12-10|2009-12-11|Estimate|||||||2015-08-14|2015-08-17|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:|Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: A Randomized, Double-masked, Controlled Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|24|Anticipated|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-06-01 00:16:32.427871|2018-06-01 00:16:32.427871
NCT01030757|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2015-06-13||2015-06-13|2009-12-09|2009-12-11|Estimate|2015-06-13|2015-07-07|Estimate||||2015-06-13|2015-07-07|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver|Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver|Terminated||Phase 2|2|Actual|New Mexico Cancer Care Alliance||1||Low accrual rate|f||||t||||||||||2018-06-01 00:16:32.535532|2018-06-01 00:16:32.535532
NCT01030380|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-10|2009-12-10|2009-12-11|Estimate|||||||2009-12-10|2009-12-11|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|Face||Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging|Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging|Completed||Phase 3|108|Actual|Bio-Medical Research, Ltd.||2|||f||||f||||||||||2018-06-01 00:16:38.963845|2018-06-01 00:16:38.963845
NCT01030744|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-12-06|2009-12-09|2009-12-11|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|GDM Elasy||Evaluation of the Gestational Diabetes Self-Management Education Program and Quality Improvement Plan|Evaluation of the Gestational Diabetes Self-Management Education Program and Quality Improvement Plan|Withdrawn|||0|Actual|Vanderbilt University Medical Center|||1|"This is quality improvement review and should not have been registered. No participants were~   enrolled"|f||||f|f|f||||||||2018-06-01 00:16:32.695261|2018-06-01 00:16:32.695261
NCT01030731|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-08-27|2009-12-10|2009-12-11|Estimate|||||||2012-08-27|2012-08-28|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease|An Open-Label Pharmacokinetic Study of Ceftobiprole in Healthy Volunteers and Patients With End Stage Renal Disease Receiving Hemodialysis|Completed||Phase 1|12|Actual|Basilea Pharmaceutica||2|||f||||f||||||||||2018-06-01 00:16:32.761106|2018-06-01 00:16:32.761106
NCT01030718|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2010-07-26||2010-11-15|2009-12-10|2009-12-11|Estimate|2010-11-15|2010-12-14|Estimate||||2010-11-15|2010-12-14|Estimate|January 2006||2006-01-31|November 2010|2010-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Rollover Study of BMS-354825 in Patients With CML and Ph+ALL|A Study to Document the Long-Term Safety and Efficacy of BMS-354825 in Subjects With Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Previous Treatment and Have Completed the Previous Phase I/II Protocol (CA180-031/NCT00337454)|Completed||Phase 1/Phase 2|54|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 00:16:32.878973|2018-06-01 00:16:32.878973
NCT01030705|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-09-28|2009-12-10|2009-12-11|Estimate|||||||2011-09-28|2011-09-29|Estimate|November 2009||2009-11-30|September 2011|2011-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|COGNATE||Common Sensing and Right Ventricular Automatic Capture (COGNATE)|Common Sensing and Right Ventricular Automatic Capture|Completed|||80|Anticipated|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 00:16:33.86369|2018-06-01 00:16:33.86369
NCT01030692|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2015-01-26|2009-12-10|2009-12-11|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2009||2009-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Rivastigmine and Huperzine A as Treatments for Cocaine Dependence|Rivastigmine and Huperzine A as Treatments for Cocaine Dependence|Completed||Phase 1|72|Actual|Baylor College of Medicine||5|||f||||t||||||||||2018-06-01 00:16:33.929656|2018-06-01 00:16:33.929656
NCT01030679|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-14|2009-12-10|2009-12-11|Estimate|||||||2009-12-14|2009-12-16|Estimate|July 2007||2007-07-31|December 2009|2009-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus|To Investigate the Glycemic Control and Lipid Profile of CKD-501 Monotherapy in Patients With Type 2 Diabetes Mellitus:a Eight-week, Multicenter, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-ranging Study.|Completed||Phase 2|214|Actual|Chong Kun Dang Pharmaceutical||4|||f||||t||||||||||2018-06-01 00:16:34.027115|2018-06-01 00:16:34.027115
NCT01030666|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2012-09-22||2016-09-28|2009-12-10|2009-12-11|Estimate|2012-10-26|2012-11-27|Estimate||||2016-09-28|2016-11-03|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|GTRDOXY||Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy|Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy. A Randomized Placebo-controlled Clinical Trial|Terminated||Phase 4|61|Actual|Goethe University|The study had to be terminated due to shelf life of test drug running out prior to including 90 patients resulting in the low test power of 50%.|2||shelf life of investigational drug ran out before 90 patients could be included|f||||f||||||||No||2018-06-01 00:16:34.112391|2018-06-01 00:16:34.112391
NCT01030653|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|2011-06-23||2016-12-16|2009-12-10|2009-12-11|Estimate|2016-12-16|2017-02-09|Estimate||||2016-12-16|2017-02-09|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Pharmacokinetics of Voriconazole in Obese Subjects|Pharmacokinetics of Voriconazole in Obese Subjects|Completed||Phase 4|10|Actual|University of Michigan|The study sample size was small.|2|||f||||f||||||||||2018-06-01 00:16:34.373034|2018-06-01 00:16:34.373034
NCT01030640|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-04-22|2009-12-10|2009-12-11|Estimate|||||||2011-04-22|2011-04-26|Estimate|December 2009||2009-12-31|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected|A Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density Of Intraepidermal Nerve Fibers After A Single Subcutaneous Administration Of Tanezumab In Healthy Volunteers|Completed||Phase 1|28|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:16:34.57208|2018-06-01 00:16:34.57208
NCT01030627|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2011-08-10|2009-12-10|2009-12-11|Estimate|||||||2011-08-10|2011-08-11|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Treatment Approaches to Preeclampsia|Treatment Approaches to Preeclampsia|Completed||Phase 4|85|Actual|Gynuity Health Projects|||||f||||f||||||||||2018-06-01 00:16:34.732503|2018-06-01 00:16:34.732503
NCT01030614|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2009-12-10|2009-12-10|2009-12-11|Estimate|||||||2009-12-10|2009-12-11|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|dxt||Dexamethasone Improves Postoperative Symptoms After Laparoscopic Cholecystectomy|Dexamethasone Improves Postoperative Symptoms in Patients Undergoing Elective Laparoscopic Cholecystectomy: A Randomised Clinical Trial.|Completed||Phase 3|210|Actual|Instituto Mexicano del Seguro Social||2|||f||||f||||||||||2018-06-01 00:16:34.823575|2018-06-01 00:16:34.823575
NCT01030601|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-01-10|2009-12-10|2009-12-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2010||2010-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|IDDMECS||Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS)|Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS)|Completed||Phase 2|48|Anticipated|University Health Network, Toronto||2|||f||||||||||||||2018-06-01 00:16:34.925318|2018-06-01 00:16:34.925318
NCT01030588|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-10|2009-12-10|2009-12-11|Estimate|||||||2009-12-10|2009-12-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:16:35.023832|2018-06-01 00:16:35.023832
NCT01030575|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-06-20|2009-12-10|2009-12-11|Estimate|||||||2017-06-20|2017-06-21|Actual|January 2010||2010-01-31|June 2017|2017-06-30|September 2013|Actual|2013-09-30|May 2011|Actual|2011-05-31||Interventional|INS-2||Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)|Phase II Randomized, Double-Masked, Placebo-Controlled, Safety, Pharmacokinetic, and Dose-Ranging Study of Multiple Doses of Inositol in Premature Infants|Completed||Phase 2|125|Actual|NICHD Neonatal Research Network||4|||f||||t|t|f||||||Yes|NDASG|2018-06-01 00:16:35.094239|2018-06-01 00:16:35.094239
NCT01030562|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2013-12-26|2009-12-10|2009-12-11|Estimate|||||||2013-12-26|2013-12-30|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Immunogenicity of Off-Schedule Dosing of HPV Vaccine|Immunogenicity of the HPV-6, 11, 16, 18 Vaccine Among Adolescent Girls Who Receive Vaccine Doses at Non-recommended Intervals and Factors Related to Non-adherence|Unknown status|Recruiting||1400|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||5||f||||||||||Samples With DNA|"~     Serum samples.~   "|||2018-06-01 00:16:35.288173|2018-06-01 00:16:35.288173
NCT01030549|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-01-02|2009-12-10|2009-12-11|Estimate|||||||2015-01-02|2015-01-05|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Latin American Multicenter Cardiovascular Magnetic Resonance Reference Study|Latin American Multicenter Cardiovascular Magnetic Resonance Reference Study|Completed|||300|Actual|University of Campinas, Brazil|||||f||||f||||||||||2018-06-01 00:16:35.376318|2018-06-01 00:16:35.376318
NCT01030536|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2017-02-27|2016-05-23|2018-03-12|2009-12-10|2009-12-11|Estimate|2018-03-12|2018-04-09|Actual|2016-06-03|2016-06-07|Estimate|2018-03-12|2018-04-09|Actual|February 15, 2010|Actual|2010-02-15|March 2018|2018-03-31|March 4, 2013|Actual|2013-03-04|March 4, 2013|Actual|2013-03-04||Interventional|||Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)|A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|23|Actual|MedImmune LLC||5|||f||||f||||||||||2018-06-01 00:16:35.504989|2018-06-01 00:16:35.504989
NCT01030523|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-08-22|2009-12-10|2009-12-11|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2009||2009-11-30|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|November 2016|Actual|2016-11-30||Interventional|||Study on ASTRA TECH Implant System, Short Implants (OsseoSpeed™) Compared to Standard Length Implants (OsseoSpeed™) With Bone Substitution|Short Implants - An Alternative to Bone Grafting?|Active, not recruiting||N/A|100|Anticipated|Dentsply Sirona Implants||2|||f||||f||||||||||2018-06-01 00:16:36.823527|2018-06-01 00:16:36.823527
NCT01030510|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2011-12-14|2009-12-10|2009-12-11|Estimate|||||||2011-12-14|2011-12-16|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study of Rocuronium Onset Time According to Remifentanil Infusion|The Effect of Remifentanil on the Onset Time of Rocuronium in Total Intravenous Anesthesia|Completed||N/A|126|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:16:36.888513|2018-06-01 00:16:36.888513
NCT01030497|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2014-05-13|2009-12-10|2009-12-11|Estimate|||||||2014-05-13|2014-05-14|Estimate|December 2009||2009-12-31|May 2014|2014-05-31||||May 2014|Actual|2014-05-31||Observational|||Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System|Feasibility Study for Detection of Cervical Lymph Node Metastases With a High-Resolution PET Imaging System in Patients With Known or Suspected Cancers of the Upper Aerodigestive Tract|Completed|||1|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 00:16:36.969378|2018-06-01 00:16:36.969378
NCT01030484|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2018-03-12|2009-12-10|2009-12-11|Estimate|||||||2018-03-12|2018-03-14|Actual|October 2009||2009-10-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2|Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2|Recruiting|||2500|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||1||f||||t||||||Samples With DNA|"~     plasma, serum, liver tissue~   "|||2018-06-01 00:16:37.032099|2018-06-01 00:16:37.032099
NCT01030471|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2011-06-21|2009-12-10|2009-12-11|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|STAND||Supporting Treatment Adherence Needs in Diabetes|Supporting Treatment Adherence Needs in Diabetes: The STAND Study|Unknown status|Recruiting|N/A|52|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 00:16:37.157035|2018-06-01 00:16:37.157035
NCT01030458|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2013-07-09||2013-11-14|2009-12-10|2009-12-11|Estimate|2013-09-13|2013-11-15|Estimate||||2013-11-14|2013-12-09|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|NOAAH||Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) Trial|Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial|Completed||Phase 4|183|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-06-01 00:16:37.243092|2018-06-01 00:16:37.243092
NCT01030445|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-01-04|2009-12-10|2009-12-11|Estimate|||||||2017-01-04|2017-01-05|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children|A Pilot Study: Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children From Acute Illness (Disease) to Recovery (Health).|Completed|||83|Actual|Boston Children’s Hospital|||3||f||||f||||||||||2018-06-01 00:16:37.532568|2018-06-01 00:16:37.532568
NCT01030432|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10||2015-09-23|2015-09-23|2009-12-10|2009-12-11|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin|A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection|Completed||Phase 2|285|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 00:16:37.602197|2018-06-01 00:16:37.602197
NCT01030419|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2017-02-21|2009-12-10|2009-12-11|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2010||2010-02-28|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AGE II||Activity, Gait, and Efficacy (AGE II): Functional Limitations and Quality of Life|Activity, Gait, and Efficacy (AGE II): Functional Limitations and Quality of Life|Completed||N/A|410|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||No||2018-06-01 00:16:38.738378|2018-06-01 00:16:38.738378
NCT01030406|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2010-03-08|2009-12-10|2009-12-11|Estimate|||||||2010-03-08|2010-03-10|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users|A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users|Completed||Phase 2|47|Actual|Acura Pharmaceuticals Inc.||5|||f||||f||||||||||2018-06-01 00:16:38.81638|2018-06-01 00:16:38.81638
NCT01030393|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-08-18|2009-12-10|2009-12-11|Estimate|||||||2012-08-18|2012-08-21|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Intra-uterine Injection of Human Chorionic Gonadotrophin (hCG) Before Embryo Transfer|Intra-uterine Injection of Human Chorionic Gonadotrophin Before Embryo Transfer in ICSI|Completed||Phase 4|472|Actual|The Egyptian IVF-ET Center||1|||f||||t||||||||||2018-06-01 00:16:38.885107|2018-06-01 00:16:38.885107
NCT01030367|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2009-12-10|2009-12-10|2009-12-11|Estimate|||||||2009-12-10|2009-12-11|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2010|Anticipated|2010-01-31|November 2008|Anticipated|2008-11-30||Interventional|ONEEF||Pilot Study of Organic Nitrates on Endothelial Function in CAD Patients|Pilot Study of Organic Nitrates on Endothelial Progenitor Cells and Endothelial Function in Patients With Coronary Artery Disease|Unknown status|Active, not recruiting|N/A|50|Anticipated|Julius-Maximilians University||3|||f||||f||||||||||2018-06-01 00:16:39.069108|2018-06-01 00:16:39.069108
NCT01030354|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2009-12-10|2009-12-10|2009-12-11|Estimate|||||||2009-12-10|2009-12-11|Estimate|July 2004||2004-07-31|November 2009|2009-11-30|December 2005|Actual|2005-12-31|July 2005|Actual|2005-07-31||Interventional|||Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial||Completed||Phase 2/Phase 3|100|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:16:39.163452|2018-06-01 00:16:39.163452
NCT01030341|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2016-03-18|2009-12-10|2009-12-11|Estimate|||||||2016-03-18|2016-03-21|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|GLUMIT-DG||Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis|Pilot Study of the Safety, Feasibility, and Potential Efficacy of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG)|Completed||N/A|45|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t||||||||||2018-06-01 00:16:39.335276|2018-06-01 00:16:39.335276
NCT01030328|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2014-04-14|2009-12-10|2009-12-11|Estimate|||||||2014-04-14|2014-04-15|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|AFRICA||AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis|Atorvastatin Plus Fenofibric Acid in the Reduction of Intermediate|Terminated||Phase 3|18|Actual|Piedmont Healthcare||2||Lack of patient population|f||||f||||||||||2018-06-01 00:16:39.443556|2018-06-01 00:16:39.443556
NCT01030315|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2014-02-24|2009-12-10|2009-12-11|Estimate|||||||2014-02-24|2014-02-26|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|EPO||A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects|A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics and Pharmacokinetics of Single Intravenous Doses of HM10760A in Healthy Adult Caucasian and Japanese Subjects|Completed||Phase 1|65|Actual|Hanmi Pharmaceutical Company Limited||5|||f||||t||||||||||2018-06-01 00:16:39.525475|2018-06-01 00:16:39.525475
NCT01030302|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-03-07|2009-12-10|2009-12-11|Estimate|||||||2013-03-07|2013-03-08|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Retreatment Study With Bortezomib for Multiple Myeloma|An Observational, Prospective Analysis of Retreatment With Bortezomib for Multiple Myeloma|Completed|||56|Actual|Janssen Korea, Ltd., Korea|||1||f||||t||||||||||2018-06-01 00:16:39.616088|2018-06-01 00:16:39.616088
NCT01030289|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2010-12-22|2009-12-10|2009-12-11|Estimate|||||||2010-12-22|2010-12-23|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effectiveness of Transcranial Direct Current Stimulation (tDCS) in Decreasing Food Cravings|The Effectiveness of tDCS in Decreasing Food Cravings|Completed||N/A|100|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 00:16:39.73108|2018-06-01 00:16:39.73108
NCT01030276|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2009-12-10|2009-12-10|2009-12-11|Estimate|||||||2009-12-10|2009-12-11|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|April 2011|Anticipated|2011-04-30|March 2011|Anticipated|2011-03-31||Interventional|VAHAVA||Bright Light Therapy in Seasonal Affective Disorder (SAD)|Placebo-controlled, Double Blind RCT on the Efficacy of Bright Light Therapy in SAD|Unknown status|Recruiting|N/A|60|Anticipated|University of Oulu||2|||f||||f||||||||||2018-06-01 00:16:39.863985|2018-06-01 00:16:39.863985
NCT01030263|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-03-24|2009-12-09|2009-12-11|Estimate|||||||2010-03-24|2010-03-25|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies|A Prospective Randomized Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies With Random Biopsies in the Detection of Specialized Columnar Epithelium in Barrett's Esophagus|Terminated||Phase 4|18|Actual|Mayo Clinic||2||The investigators left the institution.|f||||f||||||||||2018-06-01 00:16:39.956627|2018-06-01 00:16:39.956627
NCT01030250|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2017-11-08|2009-12-10|2009-12-11|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2009||2009-07-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life|Adjuvant Therapy in Older Versus Younger Women With Breast Cancer: Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life|Recruiting|||200|Anticipated|City of Hope Medical Center|||2||f||||t||||||Samples With DNA|"~     Blood and Urine to be collected prior to commencement of chemotherapy~   "|||2018-06-01 00:16:40.029845|2018-06-01 00:16:40.029845
NCT01030237|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-02-01|2009-12-10|2009-12-11|Estimate|||||||2012-02-01|2012-02-02|Estimate|November 2009||2009-11-30|February 2012|2012-02-29||||January 2010|Actual|2010-01-31||Interventional|||An Evaluation of the Safety and Efficacy of FID 114657||Completed||N/A|153|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:16:40.107306|2018-06-01 00:16:40.107306
NCT01030224|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2012-07-26|2009-12-10|2009-12-11|Estimate|||||||2012-07-26|2012-07-27|Estimate|November 2009||2009-11-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects|A Phase-1, Single Center, Double Blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous AZD9742 After Single Ascending Doses in Healthy Male and Female Subjects|Completed||Phase 1|48|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 00:16:40.170434|2018-06-01 00:16:40.170434
NCT01030211|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2015-08-23|2009-12-09|2009-12-11|Estimate|||||||2015-08-23|2015-08-25|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ADEPT||Adult Dengue Platelet Study|Adult Dengue Platelet Study|Completed||N/A|372|Actual|Tan Tock Seng Hospital||2|||f||||t||||||||||2018-06-01 00:16:40.237747|2018-06-01 00:16:40.237747
NCT01030198|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2012-11-27|2009-12-10|2009-12-11|Estimate|||||||2012-11-27|2012-11-28|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Laser Treatment for Fresh Surgical Scars and Mature Scars|Post-Market, Two-Arm, Single Blind, Controlled Study of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminum Garnet (EO QS Nd:YAG) Laser System for the Treatment of Scars|Terminated||N/A|28|Actual|Cynosure, Inc.||2||Poor enrollment|f||||f||||||||||2018-06-01 00:16:40.315122|2018-06-01 00:16:40.315122
NCT01030185|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2013-09-05|2009-12-10|2009-12-11|Estimate|||||||2013-09-05|2013-09-06|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|June 2013|Actual|2013-06-30|November 2011|Actual|2011-11-30||Interventional|PIONEER||Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance|A Prospective, Multi-center, Open Label, Non-randomized Study to Investigate the Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance|Completed||Phase 2/Phase 3|40|Actual|NovaShunt AG||1|||f||||t||||||||||2018-06-01 00:16:40.382669|2018-06-01 00:16:40.382669
NCT01030159|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2014-04-08|2009-12-10|2009-12-11|Estimate|||||||2014-04-08|2014-04-09|Estimate|June 2006||2006-06-30|April 2014|2014-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||National Cancer Institute Thai Cancer Anemia Survey|Anemia Survey in Cancer Patients Study|Completed|||300|Actual|Janssen-Cilag Ltd.,Thailand|||1||f||||f||||||||||2018-06-01 00:16:40.459323|2018-06-01 00:16:40.459323
NCT01030146|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2014-08-14|2009-12-10|2009-12-11|Estimate|||||||2014-08-14|2014-08-18|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Management of Allergic Rhinitis Patients With Nasal Steroids and NeilMed® Sinus Rinse™ System With Isotonic Saline|Management of Allergic Rhinitis Patients With Nasal Steroids and NeilMed® Sinus Rinse™ System With Isotonic Saline: A Prospective Pilot Study|Completed||N/A|40|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-06-01 00:16:40.660288|2018-06-01 00:16:40.660288
NCT01030133|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2010-12-22|2009-12-10|2009-12-11|Estimate|||||||2010-12-22|2010-12-23|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|February 2010|Anticipated|2010-02-28|January 2010|Anticipated|2010-01-31||Interventional|||Effects of Transcranial Magnetic Stimulation (TMS) and Stimulus Controllability on Pain Perception|Effects of TMS and Stimulus Controllability on Pain Perception|Unknown status|Active, not recruiting|N/A|100|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 00:16:40.769075|2018-06-01 00:16:40.769075
NCT01030120|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-05-29|2009-12-10|2009-12-11|Estimate|||||||2015-05-29|2015-06-02|Estimate|December 2010||2010-12-31|May 2015|2015-05-31|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|EtanerceptCIU||Etanercept for the Treatment of Chronic Urticaria|A 6 Week Randomized, Double Blind, Placebo-controlled Study With a 6 Week Open Label Extension to Assess the Efficacy of Etanercept in the Treatment of Chronic Idiopathic Urticaria|Withdrawn||Phase 2/Phase 3|0|Actual|University of Utah||2||Unable to complete agreement with sponsor|f||||t||||||||||2018-06-01 00:16:40.870218|2018-06-01 00:16:40.870218
NCT01030107|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2012-10-04|2009-12-10|2009-12-11|Estimate|||||||2012-10-04|2012-10-05|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Effects of Sleep Duration on Eating and Activity Behaviors|Sleep Duration and Pediatric Overweight: the Role of Eating Behaviors|Completed|||37|Actual|The Miriam Hospital|||1||f||||f||||||Samples Without DNA|"~     2 ml of whole blood drawn at each of 3 assessments~   "|||2018-06-01 00:16:40.956013|2018-06-01 00:16:40.956013
NCT01030094|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2013-06-25|2009-12-10|2009-12-11|Estimate|||||||2013-06-25|2013-06-26|Estimate|February 2007||2007-02-28|June 2013|2013-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy|A Cross-sectional, Comparative, Multi-center Study to Investigate the Effect of Topiramate Monotherapy on Markers of Bone Mineral Metabolism and Bone Mineral Density in Premenopausal Women With Epilepsy|Completed|||140|Actual|Janssen Korea, Ltd., Korea|||4||f||||f||||||||||2018-06-01 00:16:41.079357|2018-06-01 00:16:41.079357
NCT01030081|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-10|||2014-05-21|2009-12-10|2009-12-11|Estimate|||||||2014-05-21|2014-05-22|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ARMORS||Amlodipine Prevents Morning Blood Pressure Surge Study|A Randomized Controlled Phase Ⅳ Trial With Two Equally Sized Treatment Groups: Amlodipine And Nifedipine GITS|Completed||Phase 4|510|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 00:16:41.186622|2018-06-01 00:16:41.186622
NCT01030068|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-10-06|2009-12-10|2009-12-11|Estimate|||||||2011-10-06|2011-10-07|Estimate|July 2007||2007-07-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Yoga for Smoking Cessation Feasibility Study|Yoga for Women Attempting Smoking Cessation: An Initial Investigation|Completed||N/A|30|Anticipated|The Miriam Hospital||2|||f||||f||||||||||2018-06-01 00:16:41.332811|2018-06-01 00:16:41.332811
NCT01030055|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-12-12|2009-12-09|2009-12-11|Estimate|||||||2013-12-12|2013-12-13|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors|A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors|Completed||Phase 1|60|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:16:41.522506|2018-06-01 00:16:41.522506
NCT01030042|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-07-14|2009-12-09|2009-12-10|Estimate|||||||2015-07-14|2015-07-15|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|COMETS||Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients|Randomized, Phase III, Multicenter Trial Comparing Two Different Sequences of therapyFOLFOX-4 vs FOLFOX-4 Followed by Irinotecan/Cetuximab in Metastatic Colorectal Patients Treated With FOLFIRI /Bevacizumab as First Line Chemotherapy|Completed||Phase 3|110|Actual|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||2|||f||||f||||||||||2018-06-01 00:16:41.638043|2018-06-01 00:16:41.638043
NCT01030029|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-04-07|2009-12-09|2009-12-10|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Auricular Acupuncture in Postoperative Pain|Auricular Acupuncture in Postoperative Pain: a Randomized Controlled Trail|Completed||Phase 4|40|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:16:42.006181|2018-06-01 00:16:42.006181
NCT01030016|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-14|2009-12-09|2009-12-10|Estimate|||||||2009-12-14|2009-12-15|Estimate|May 2007||2007-05-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of Atenolol Influence on Blood Pressure During Resistance Exercise|Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers|Completed||Phase 4|10|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 00:16:42.288822|2018-06-01 00:16:42.288822
NCT01030003|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2012-03-06|2009-12-09|2009-12-10|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Snoring in Pregnancy and Adverse Maternal and Fetal Outcomes|The Impact of Sleep-Disordered Breathing on Adverse Pregnancy Outcomes|Completed|||1685|Actual|University of Michigan|||||f||||f||||||||||2018-06-01 00:16:42.410346|2018-06-01 00:16:42.410346
NCT01029990|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2012-08-29|2009-12-09|2009-12-10|Estimate|||||||2012-08-29|2012-08-30|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|||Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program|Randomized Controlled Trial to Study Interventions to Increase Participation in Cervical Cancer Screening Program|Completed||Early Phase 1|8800|Actual|Göteborg University||3|||f||||f||||||||||2018-06-01 00:16:42.547821|2018-06-01 00:16:42.547821
NCT01029977|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2017-04-25|2009-12-09|2009-12-10|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2015|Anticipated|2015-05-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Observational|||Imaging Modality Effects on the Multi-dimensional InfraRed Analysis (MIRA) Technology||Withdrawn|||0|Actual|Real Imaging Ltd.||||Re-definition of MIRA technology goals.|f||||f||||||||||2018-06-01 00:16:42.8145|2018-06-01 00:16:42.8145
NCT01029964|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-09|2009-12-09|2009-12-10|Estimate|||||||2009-12-09|2009-12-10|Estimate|January 1997||1997-01-31|January 1997|1997-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Three-year Behavioral Treatment of Obese Children|A Three-year Behavioral Treatment of Obese Children: the Effect of Age on Change in BMI SDS and Dropout Rate|Completed||N/A|1000|Actual|Karolinska University Hospital||4|||f||||f||||||||||2018-06-01 00:16:42.881867|2018-06-01 00:16:42.881867
NCT01029951|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-09|2009-12-09|2009-12-10|Estimate|||||||2009-12-09|2009-12-10|Estimate|January 2007||2007-01-31|July 2006|2006-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Relative Effectiveness and Adverse Effects of Cervical Manipulation, Mobilisation and the Activator Instrument in Patients With Sub-acute Non-specific Neck Pain: a Pragmatic Randomised Trial|Neck Pain Comparative Study|Completed||N/A|47|Actual|Anglo-European College of Chiropractic|||||f||||f||||||||||2018-06-01 00:16:42.98459|2018-06-01 00:16:42.98459
NCT01029938|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2010-07-22|2009-12-09|2009-12-10|Estimate|||||||2010-07-22|2010-07-23|Estimate|April 2005||2005-04-30|December 2009|2009-12-31|June 2010|Anticipated|2010-06-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization|Comparative Study of Covered Stent With Coil Embolization in the Treatment of Cranial Internal Carotid Artery Aneurysm: A Nonrandomized Prospective Trial|Unknown status|Recruiting|Phase 4|85|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 00:16:43.142425|2018-06-01 00:16:43.142425
NCT01029925|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2013-04-02||2016-01-14|2009-12-09|2009-12-10|Estimate|2016-01-14|2016-02-12|Estimate||||2016-01-14|2016-02-12|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional||Stage 1 has best prognosis and stage IV has worst.Grade 1 is associated with best prognosis and grade 3 with poor prognosis.ECOG performance status grades a person's overall well-being and scaled from 0-5.ECOG of 0 is associated with best prognosis.Patients with ECOG 0-2 are considered well enough to receive additional treatments for their cancer.|Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)|A Multicenter, Phase II Open-Labeled, Single-Arm Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer|Terminated||Phase 2|7|Actual|Jonsson Comprehensive Cancer Center|The greatest limitation in our study was early termination due to perceived lack of drug efficacy leading to small number of subjects analyzed.|1||DSMB determined, due to higher than expected risk/safety concerns, study should be closed.|f||||t||||||||||2018-06-01 00:16:43.292861|2018-06-01 00:16:43.292861
NCT01029912|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2017-09-08||2017-11-02|2009-12-09|2009-12-10|Estimate|2017-10-04|2017-11-06|Actual||||2017-11-02|2017-12-07|Actual|November 2009||2009-11-30|November 2017|2017-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Only participants who completed treatment were analyzed.|Electrical Stimulation for Recovery of Ankle Dorsiflexion in Chronic Stroke Survivors|Contralaterally Controlled NMES in Chronic Ankle Dorsiflexor Paresis After Stroke|Completed||N/A|26|Actual|MetroHealth Medical Center||2|||f||||f|f|||||||No||2018-06-01 00:16:43.657059|2018-06-01 00:16:43.657059
NCT01029899|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2016-07-11|2009-12-09|2009-12-10|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2009||2009-12-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Characterize Differences in Force Patterns Used by Different Endoscopists and Trainee Endoscopists|Phase II Study of Evaluation of Handheld Colonoscopy Force Monitor by Expert and Trainee Endoscopists in the Performance of Colonoscopy|Completed|||153|Actual|Artann Laboratories|||||f||||t||||||||||2018-06-01 00:16:44.405996|2018-06-01 00:16:44.405996
NCT01029886|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2012-02-14|2011-06-17|2015-03-20|2009-12-08|2009-12-10|Estimate|2012-02-14|2012-03-21|Estimate|2011-06-17|2011-06-27|Estimate|2015-03-20|2015-04-09|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes|Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications|Completed||Phase 3|912|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:16:44.555333|2018-06-01 00:16:44.555333
NCT01029873|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09||2013-07-23|2016-10-26|2009-12-09|2009-12-10|Estimate||||2013-07-23|2013-07-30|Estimate|2016-10-26|2016-10-27|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|September 2013|Actual|2013-09-30|November 2011|Actual|2011-11-30||Interventional|||QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma|Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|25|Actual|Altor BioScience||1|||f||||t||||||||||2018-06-01 00:16:46.36507|2018-06-01 00:16:46.36507
NCT01029860|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-16|2009-12-09|2009-12-10|Estimate|||||||2009-12-16|2009-12-17|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Observational|||The Impact of Hospitalization on Ambulatory Blood Pressure and Intraocular Pressure|A Study Investigating the Impact of Hospitalization on Ambulatory Blood Pressure and Intraocular Pressure in Subjects With Mild to Moderate Arterial Hypertension and Untreated Ocular Hypertension|Completed|||40|Actual|Aristotle University Of Thessaloniki|||||f||||f||||||||||2018-06-01 00:16:46.617622|2018-06-01 00:16:46.617622
NCT01029847|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-08-18|2009-12-09|2009-12-10|Estimate|||||||2015-08-18|2015-08-19|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ASIM||Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis|Adalimumab in Axial Spondyloarthritis. An Investigation of Whole-body MRI, MRI of Sacroiliac Joints and Spine and Soluble Biomarkers of Joint Inflammation and Damage.|Completed||Phase 4|50|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-06-01 00:16:46.668633|2018-06-01 00:16:46.668633
NCT01029834|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2014-12-04|2009-12-09|2009-12-10|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Treating Pre-School Children at Risk for Overweight in the Primary Care Setting|Treating Overweight Youth: A Family Based Approach in Primary Care|Completed||N/A|105|Actual|University at Buffalo||2|||f||||t||||||||||2018-06-01 00:16:46.746763|2018-06-01 00:16:46.746763
NCT01029821|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-06-15|2009-12-09|2009-12-10|Estimate|||||||2011-06-15|2011-06-16|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis|Low-Molecular-Weight Heparin for DVT Prophylaxis After Open Reduction and Internal Fixation of Ankle Fractures: A Randomized, Prospective Trial|Unknown status|Recruiting|N/A|100|Anticipated|University of Tennessee||1|||f||||t||||||||||2018-06-01 00:16:46.942077|2018-06-01 00:16:46.942077
NCT01029808|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2016-10-18|2009-12-09|2009-12-10|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Bleeding Symptoms of Carriers of Hemophilia A and B|Bleeding Symptoms of Carriers of Hemophilia A and B|Completed|||126|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||||2018-06-01 00:16:47.18742|2018-06-01 00:16:47.18742
NCT01029795|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2011-09-15|2011-02-25|2011-11-29|2009-12-09|2009-12-10|Estimate|2011-09-15|2011-10-26|Estimate|2011-02-25|2011-03-11|Estimate|2011-11-29|2011-12-02|Estimate|February 2010||2010-02-28|November 2011|2011-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus|A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 2|38|Actual|Eli Lilly and Company|Since Study GMAJ was terminated after enrolling only 38 participants with just 1 participant completing 12 weeks of treatment, only disposition, demographics, and safety data are reported.|2||Terminated due to nonclinical safety findings|f||||f||||||||||2018-06-01 00:16:47.320976|2018-06-01 00:16:47.320976
NCT01029782|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-01-13|2009-12-09|2009-12-10|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis|Intravenous Cefazolin Plus Oral Probenecid vs. Oral Cephalexin for the Treatment of Cellulitis: a Randomized Controlled Trial|Completed||Phase 2|201|Actual|Kelowna General Hospital||2|||f||||f||||||||||2018-06-01 00:16:49.330318|2018-06-01 00:16:49.330318
NCT01029769|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-05-22|2009-12-09|2009-12-10|Estimate|||||||2015-05-22|2015-05-27|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia|The Switch Study - Efficacy of Early Antipsychotic Switch Versus Maintenance in Patients With Schizophrenia Poorly Responding to Two Weeks of Antipsychotic Treatment|Completed||N/A|351|Actual|Technische Universität München||5|||f||||t||||||||||2018-06-01 00:16:49.463496|2018-06-01 00:16:49.463496
NCT01029756|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2011-12-15|2009-12-09|2009-12-10|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|PAWS||Randomised Controlled Trial of Intubation, Comparing Pentax AWS Against Macintosh Laryngoscope.|A Randomised Controlled Trial of Intubation by Inexperienced Anaesthetists, Comparing the The Pentax Airway Scope AWS-S100 Rigid Video Laryngoscope(Pentax AWS) and the Macintosh Laryngoscope.|Unknown status|Not yet recruiting|N/A|120|Anticipated|NHS Grampian||2|||f||||f||||||||||2018-06-01 00:16:49.560628|2018-06-01 00:16:49.560628
NCT01029743|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2017-01-19|2009-12-09|2009-12-10|Estimate|||||||2017-01-19|2017-01-23|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Observational|||Xarelto Regulatory Post-Marketing Surveillance|Xarelto® Regulatory Post-Marketing Surveillance|Completed|||3388|Actual|Bayer|||2||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 00:16:49.645427|2018-06-01 00:16:49.645427
NCT01029730|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2015-11-19||2016-07-20|2009-12-09|2009-12-10|Estimate|2015-11-19|2015-12-28|Estimate||||2016-07-20|2016-08-19|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|October 2014|Actual|2014-10-31||Interventional||All enrolled patients|Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma|Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma|Completed||Phase 2|55|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 00:16:49.748859|2018-06-01 00:16:49.748859
NCT01029717|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-09|2009-12-09|2009-12-10|Estimate|||||||2009-12-09|2009-12-10|Estimate|January 2010||2010-01-31|December 2009|2009-12-31||||December 2012|Anticipated|2012-12-31||Interventional|||CATCH - Catheter Infections in Children|A Randomised Controlled Trial Comparing the Effectiveness of Heparin Bonded or Antibiotic Impregnated Central Venous Catheters (CVCs) With Standard CVCs for the Prevention of Hospital Acquired Blood Stream Infection in Children|Unknown status|Not yet recruiting|Phase 3|1200|Anticipated|Institute of Child Health||3|||f||||f||||||||||2018-06-01 00:16:50.558865|2018-06-01 00:16:50.558865
NCT01029704|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2011-06-21||2013-07-27|2009-12-09|2009-12-10|Estimate|2011-06-21|2011-07-20|Estimate||||2013-07-27|2013-08-07|Estimate|December 2009||2009-12-31|July 2013|2013-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus|A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Type 2 Diabetic Subjects|Completed||Phase 2|129|Actual|Theracos||2|||f||||t||||||||||2018-06-01 00:16:51.003604|2018-06-01 00:16:51.003604
NCT01029691|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2017-08-09||2017-09-14|2009-12-09|2009-12-10|Estimate|2017-09-14|2017-10-16|Actual||||2017-09-14|2017-10-16|Actual|May 2009||2009-05-31|September 2017|2017-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||These data are for those who initiated APAP only and do not include the standard of care arm as they did not have nocturnal blood pressure|Study of Positive Airway Pressure in Preeclampsia to Reduce Blood Pressure|Use of PAP in Women With Pre-eclampsia|Completed||N/A|125|Actual|University of Michigan|These tables represent full basic analysis of all the participants enrolled without adjustment for confounding variables. Future publications will present more complex subsequent analyses.|3|||f||||t||t|f|||||||2018-06-01 00:16:52.533743|2018-06-01 00:16:52.533743
NCT01029678|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2018-05-01|2009-12-09|2009-12-10|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2010||2010-01-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Interventional|RACCOSA||Concomitant Radio-chemotherapy in the Elderly|Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC|Completed||Phase 2|48|Actual|University Hospital, Limoges||1|||f||||t||||||||||2018-06-01 00:16:53.552911|2018-06-01 00:16:53.552911
NCT01029665|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2013-03-07|2009-12-09|2009-12-10|Estimate|||||||2013-03-07|2013-03-11|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Observational|CDH||Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors|Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors|Completed|||16|Actual|Duke University|||1||f||||f||||||||||2018-06-01 00:16:53.72129|2018-06-01 00:16:53.72129
NCT01029652|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2011-07-26||2013-12-24|2009-12-09|2009-12-10|Estimate|2011-10-12|2011-11-18|Estimate||||2013-12-24|2014-01-30|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|β-RELIEVED||Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study|A 12 Weeks Randomized, Controlled Core Study of ACZ885 (Canakinumab) on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective, Including a 12-week Double-blind Extension Study and an Open-label 48 Week Extension Study|Completed||Phase 3|230|Actual|Novartis|Bioanalytical results: With analytical method used, anti-canakinumab antibodies were detected in 10 patients. However, no patients showed any unexpected PK/ PD profile nor had adverse events suggestive of immunogenicity.|2|||f||||||||||||||2018-06-01 00:16:53.882283|2018-06-01 00:16:53.882283
NCT01029639|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-08-08|2009-12-09|2009-12-10|Estimate|||||||2016-08-08|2016-08-10|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness|Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness|Withdrawn||Phase 2/Phase 3|0|Actual|Florida Atlantic University||2||Administrative|f||||t||||||||||2018-06-01 00:16:56.108612|2018-06-01 00:16:56.108612
NCT01029626|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-09|2009-12-09|2009-12-10|Estimate|||||||2009-12-09|2009-12-10|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|March 2011|Anticipated|2011-03-31|June 2010|Anticipated|2010-06-30||Interventional|||Glasgow-Blatschford Score Validation in Digestive Hemorrhage|Glasgow-Blatschford Score Validation for Stratification of Patients With Digestive Hemorrhage|Unknown status|Recruiting|N/A|64|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-06-01 00:16:56.306647|2018-06-01 00:16:56.306647
NCT01029613|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-08-18|2009-12-09|2009-12-10|Estimate|||||||2015-08-18|2015-08-19|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers|Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers|Completed|||40|Actual|Glostrup University Hospital, Copenhagen|||1||f||||t||||||||||2018-06-01 00:16:56.47745|2018-06-01 00:16:56.47745
NCT01029600|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-15|2009-12-09|2009-12-10|Estimate|||||||2009-12-15|2009-12-16|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Interventional|||Surgery or Capsular Distention With Steroid in the Treatment of Primary Frozen Shoulder?|Arthroscopic Capsulotomy vs Arthrographic Distention With Steroid in the Treatment of Primary Frozen Shoulder. A Randomized Study|Unknown status|Recruiting|N/A|100|Anticipated|Bergen Surgical Hospital||2|||f||||f||||||||||2018-06-01 00:16:56.567078|2018-06-01 00:16:56.567078
NCT01029587|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2017-03-30|2009-12-09|2009-12-10|Estimate|||||||2017-03-30|2017-03-31|Actual|November 2009|Actual|2009-11-30|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome|Phase 2 Study of the Use of Eculizumab to Prevent Thrombosis After Renal Transplantation in Patients With a History of Catastrophic Antiphospholipid Antibody Syndrome (CAPS)|Active, not recruiting||Phase 2|3|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 00:16:56.992633|2018-06-01 00:16:56.992633
NCT01029574|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2014-12-02|2009-12-09|2009-12-10|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PRP||Platelet Rich Plasma on Rotator Cuff Repair|Platelet Rich Plasma on Arthroscopic Repair of the Complete Rotator Cuff Lesions: a Prospective and Randomized Study|Completed||Phase 3|54|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:16:57.392946|2018-06-01 00:16:57.392946
NCT01029561|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-09|2009-12-09|2009-12-10|Estimate|||||||2009-12-09|2009-12-10|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|January 2012|Anticipated|2012-01-31|June 2011|Anticipated|2011-06-30||Interventional|SYBILA||Impact of Obstructive Sleep Apnea Syndrome on Metabolic Syndrome in Severe Obesity|Impact of Obstructive Sleep Apnea Syndrome on Metabolic Syndrome in Severe Obesity|Unknown status|Active, not recruiting|N/A|126|Anticipated|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-06-01 00:16:57.734733|2018-06-01 00:16:57.734733
NCT01029548|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2016-03-03|2009-12-09|2009-12-10|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|May 2012|Actual|2012-05-31|||||Observational|ISS OBS T-003||Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects|Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects|Completed|||73|Actual|Istituto Superiore di Sanità|||||f||||f||||||Samples With DNA|"~     Whole Blood, serum, PBMCs~   "|||2018-06-01 00:16:58.372004|2018-06-01 00:16:58.372004
NCT01029535|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2012-05-01||2016-02-08|2009-12-09|2009-12-10|Estimate|2013-01-17|2013-02-20|Estimate||||2016-02-08|2016-03-09|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency||Completed||N/A|103|Actual|Allergan||1|||f||||||||||||||2018-06-01 00:16:58.589677|2018-06-01 00:16:58.589677
NCT01029522|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2012-08-08|2009-12-09|2009-12-10|Estimate|||||||2012-08-08|2012-08-09|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|November 2009|Actual|2009-11-30|October 2008|Actual|2008-10-31||Interventional|KoLipilou||Dyslipidemia in Cardiovascular Disease|A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea|Completed||Phase 4|244|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-06-01 00:16:59.678235|2018-06-01 00:16:59.678235
NCT01029509|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2012-07-19|2009-12-09|2009-12-10|Estimate|||||||2012-07-19|2012-07-23|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes|An Open-label, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Leukemias or Myelodysplastic Syndromes|Terminated||Phase 1|6|Actual|M.D. Anderson Cancer Center||1||Colloborator-Sponsor decision to terminate.|f||||f||||||||||2018-06-01 00:16:59.852712|2018-06-01 00:16:59.852712
NCT01029496|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2010-03-01|2009-12-09|2009-12-10|Estimate|||||||2010-03-01|2010-03-02|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|June 2011|Anticipated|2011-06-30|September 2010|Anticipated|2010-09-30||Interventional|||Immediate VS Delayed Cord Clamping on Newborns|Effect of Umbilical Cord Clamping Time on Newborns|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|Hainan Medical College|||||f||||t||||||||||2018-06-01 00:16:59.924998|2018-06-01 00:16:59.924998
NCT01029470|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2009-12-09|2009-12-09|2009-12-10|Estimate|||||||2009-12-09|2009-12-10|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|March 2011|Anticipated|2011-03-31|October 2010|Anticipated|2010-10-31||Interventional|||To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation|A Multicentre, Prospective, Open Study to Describe the Effects of rhLH Supplement in Women With Hyporesponse to rFSH After Pituitary Downregulation.|Unknown status|Not yet recruiting|Phase 2|150|Anticipated|Peking University Third Hospital||1|||f||||f||||||||||2018-06-01 00:17:00.188144|2018-06-01 00:17:00.188144
NCT01029444|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-02-02|2009-12-09|2009-12-10|Estimate|||||||2016-02-02|2016-02-03|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes|Effects of Pulsatile Intravenous Insulin on Brittle Diabetes and Glucose Control|Terminated||Phase 3|300|Actual|Florida Atlantic University||1||Administrative|f||||t||||||||||2018-06-01 00:17:00.53881|2018-06-01 00:17:00.53881
NCT01029431|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2017-06-22|2009-12-09|2009-12-10|Estimate|||||||2017-06-22|2017-06-26|Actual|December 2009||2009-12-31|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of the Intubating Laryngeal Airway in Children|Evaluation of the Intubating Laryngeal Airway in Children - Phase 2|Completed||Phase 3|90|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 00:17:00.720866|2018-06-01 00:17:00.720866
NCT01029418|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2015-04-14|2009-12-09|2009-12-10|Estimate|||||||2015-04-14|2015-04-16|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|||AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma|A Phase 1/2 Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|30|Actual|National Cancer Centre, Singapore||1||The phase II portion was not conducted due to funding issue.|f||||f||||||||||2018-06-01 00:17:00.942592|2018-06-01 00:17:00.942592
NCT01029405|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2017-01-12|2011-02-09|2017-01-12|2009-12-08|2009-12-10|Estimate|2017-01-12|2017-03-07|Actual|2011-02-09|2011-02-14|Estimate|2017-01-12|2017-03-07|Actual|November 2009||2009-11-30|January 2017|2017-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|AN2728PSR203|Intent-to-treat population included all randomized participants who received the study medication.|Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis|A Double-Blind,Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment B, 2% and 0.5%, Versus Ointment B Vehicle in the Treatment of Patients With Plaque Type Psoriasis|Completed||Phase 2|145|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 00:17:01.285881|2018-06-01 00:17:01.285881
NCT01029392|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2016-12-13||2017-03-03|2009-12-09|2009-12-10|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|November 2009||2009-11-30|December 2016|2016-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect of Supplementation on Insulin Requirements|Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D-A Pilot Study|Completed||Phase 3|75|Actual|William Beaumont Hospitals||2|||f||||f||||||||No|No data sharing.|2018-06-01 00:17:02.468512|2018-06-01 00:17:02.468512
NCT01029379|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2013-03-01|2009-12-09|2009-12-10|Estimate|||||||2013-03-01|2013-03-04|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Pharmacogenetics of Propofol and Depth of Anesthesia|The Effect of Pharamocogenetices on Anesthesia Induction With Propofol|Completed|||100|Actual|University Hospital, Linkoeping|||1||f||||t||||||||||2018-06-01 00:17:03.297322|2018-06-01 00:17:03.297322
NCT01029366|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|2016-06-28||2017-11-07|2009-12-09|2009-12-10|Estimate|2017-01-09|2017-02-28|Actual||||2017-11-07|2017-11-09|Actual|July 2009||2009-07-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|July 2015|Actual|2015-07-31||Interventional|||CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy|Pilot Study of Redirected Autologous T-cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma|Completed||Phase 1|26|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 00:17:03.376601|2018-06-01 00:17:03.376601
NCT01029353|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-09|||2017-11-07|2009-12-09|2009-12-10|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2010|Actual|2010-01-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|NEST||Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis|A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants With Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 Months Adjusted Age|Active, not recruiting||N/A|310|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 00:17:03.945835|2018-06-01 00:17:03.945835
NCT01029340|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2013-05-27||2016-10-14|2009-12-08|2009-12-09|Estimate|2013-09-12|2013-11-18|Estimate||||2016-10-14|2016-11-28|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|Leopold I||Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A|A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy|Completed||Phase 3|74|Actual|Bayer||5|||f||||t||||||||||2018-06-01 00:17:04.192061|2018-06-01 00:17:04.192061
NCT01029327|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|September 2009|Actual|2009-09-30|||||Observational|||Effects of Curcumin on Postprandial Blood Glucose, and Insulin in Healthy Subjects||Completed|||||Skane University Hospital|||1||f||||t||||||||||2018-06-01 00:17:05.760016|2018-06-01 00:17:05.760016
NCT01029314|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-07|2009-12-07|2009-12-09|Estimate|||||||2009-12-07|2009-12-09|Estimate|May 2008||2008-05-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass|Pilot Study of the Genius(TM)2 Tympanic Thermometer in Cardiac Patients Requiring Cardiopulmonary Bypass|Completed|||33|Actual|Tyco Healthcare Group|||1||f||||f||||||||||2018-06-01 00:17:05.804441|2018-06-01 00:17:05.804441
NCT01029301|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|November 2008||2008-11-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System for Skin Wrinkle Treatment on Body Areas|Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System|Completed||N/A|30|Actual|Endymion Medical Ltd||1|||f||||f||||||||||2018-06-01 00:17:05.880923|2018-06-01 00:17:05.880923
NCT01029288|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2016-02-01|2009-12-07|2009-12-09|Estimate|||||||2016-02-01|2016-02-02|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|DAD||Impact of Decision Aids to Enhance Shared Decision Making for Diabetes|Impact of Decision Aids to Enhance Shared Decision Making for Diabetes|Completed||N/A|110|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:17:05.947586|2018-06-01 00:17:05.947586
NCT01029275|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2014-07-30|2009-12-08|2009-12-09|Estimate|||||||2014-07-30|2014-07-31|Estimate|January 2005||2005-01-31|July 2014|2014-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SAPORO||Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone|Multicenter, Randomised Open Trial Comparing the Efficacy of a Medical Treatment With Sandostatin LP 30 mg Performed Before Surgery to a Prime Line transsphenoïdal Surgery in Previously Untreated Acromegalic Patients With Either a Micro or a Macro Pituitary Adenoma|Completed||N/A|89|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-06-01 00:17:06.04849|2018-06-01 00:17:06.04849
NCT01029262|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2015-05-08||2017-07-25|2009-12-08|2009-12-09|Estimate|2015-06-02|2015-06-18|Estimate||||2017-07-25|2017-07-27|Actual|January 26, 2010|Actual|2010-01-26|July 2017|2017-07-31|June 4, 2018|Anticipated|2018-06-04|March 17, 2013|Actual|2013-03-17||Interventional|MDS-005|The Intent-to-Treat (ITT) population includes all participants who were randomized.|A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Compare The Efficacy And Safety of Lenalidomide (Revlimid®) Versus Placebo In Subjects With Transufsion-Dependent Anemia Due to IPSS Low Or Imtermidate-1 Risk Myelodysplastic Syndromes Without Deletion 5Q(31) And Unresponsive Or Refractory To Erthropoiesis-Stimulating Agents|Active, not recruiting||Phase 3|239|Actual|Celgene||2|||f||||t||||||||||2018-06-01 00:17:06.290181|2018-06-01 00:17:06.290181
NCT01029249|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-12-05|2009-12-07|2009-12-09|Estimate|||||||2013-12-05|2013-12-06|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults|Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy|Completed|||500|Actual|AIDS Clinical Trials Group|||1||f||||t||||||Samples With DNA|"~     Saliva and blood will be collected from participants.~   "|||2018-06-01 00:17:08.293056|2018-06-01 00:17:08.293056
NCT01029236|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of Metabolism-Boosting Beverages|The Effect of Metabolism-Boosting Beverages on 24 Hr Energy Expenditure|Completed||N/A|30|Actual|Medifast, Inc.|||||f||||f||||||||||2018-06-01 00:17:08.406759|2018-06-01 00:17:08.406759
NCT01029223|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2011-11-07|2009-12-08|2009-12-09|Estimate|||||||2011-11-07|2011-11-09|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals|The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals|Withdrawn||Phase 4|42|Anticipated|Bayside Health||3|||f||||f||||||||||2018-06-01 00:17:08.486362|2018-06-01 00:17:08.486362
NCT01029210|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2011-12-19|2009-12-08|2009-12-09|Estimate|||||||2011-12-19|2011-12-20|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|December 2009|Actual|2009-12-31||Observational|TMDOST||Temporomandibular Disorders and Osteoporosis|Temporomandibular Disorders in Climacteric Women: Pain Sensibility, Risk Posed by Systemic Bone Mass and Diagnostic Made by RDC/TMD Compared to MRI (3.0 Tesla)|Completed|||100|Actual|University of Sao Paulo|||||f||||f||||||||||2018-06-01 00:17:08.559401|2018-06-01 00:17:08.559401
NCT01029197|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-07-06|2009-12-08|2009-12-09|Estimate|||||||2010-07-06|2010-07-07|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PTSD/SUD||Multicomponent Cognitive Behavioral Therapy(CBT) for Posttraumatic Stress Disorder (PTSD) and Substance Abuse|Multicomponent Cognitive Behavioral Therapy for Posttraumatic Stress Disorder and Substance Abuse: A Pilot Study|Completed||Phase 1|45|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:17:08.618679|2018-06-01 00:17:08.618679
NCT01029184|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2012-06-26|2009-12-08|2009-12-09|Estimate|||||||2012-06-26|2012-06-27|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Tolerance of Cereals for Atopic Children|Assessment of Tolerance of Cereals in Infants With Atopic Symptoms|Terminated||N/A|45|Actual|Nestlé||2||difficult to enrol and as a pilot study sample size was not powered anyway|f||||f||||||||||2018-06-01 00:17:08.710145|2018-06-01 00:17:08.710145
NCT01029171|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2017-10-02|2009-12-07|2009-12-09|Estimate|||||||2017-10-02|2017-10-04|Actual|November 2009||2009-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Action Seniors! Exercise to Prevent Falls|"Action Seniors!: A 12 Month Randomized Controlled Trial of a Home Based Strength and Balance Retraining Program in Reducing Falls."|Active, not recruiting||N/A|344|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-06-01 00:17:08.778279|2018-06-01 00:17:08.778279
NCT01029158|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2010-12-07|2009-12-07|2009-12-09|Estimate|||||||2010-12-07|2010-12-09|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|RN1006||A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo|A Double-blind, Placebo Controlled, Randomised Trial to Compare the Efficacy of 250ng and 500ng RN1006 (a New Formulation of Avotermin) and 250ng and 500ng Juvista (Standard Avotermin Formulation), in the Improvement of Scar Appearance in Healthy Volunteer Subjects|Completed||Phase 1|84|Anticipated|Renovo||8|||f||||f||||||||||2018-06-01 00:17:08.861879|2018-06-01 00:17:08.861879
NCT01029145|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2010-09-16|2009-12-08|2009-12-09|Estimate|||||||2010-09-16|2010-09-20|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Management of Index Episode in Patients With Bipolar Disorder Treated by Seroquel XR|Non-interventional Study to obSERve currENt Management of Index Episode in Patients With Bipolar Disorder Treated bY Seroquel XR|Completed|||537|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:17:08.972956|2018-06-01 00:17:08.972956
NCT01029132|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-06|||2016-01-04|2009-12-08|2009-12-09|Estimate|||||||2016-01-04|2016-01-06|Estimate|April 2007||2007-04-30|January 2016|2016-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Characteristics of Treatment Responders to Galantamine|Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease|Completed||N/A|66|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:17:09.096143|2018-06-01 00:17:09.096143
NCT01029119|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|August 2006||2006-08-31|December 2009|2009-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Clinical Test for Blood Pressure Meter of CH-101|Clinical Test of Blood Pressure Meter of CH-101|Completed|||85|Actual|Citizen Systems Japan Co., Ltd.|||||f||||f||||||||||2018-06-01 00:17:09.163772|2018-06-01 00:17:09.163772
NCT01028599|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2015-10-26|2009-12-08|2009-12-09|Estimate|||||||2015-10-26|2015-10-28|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients|Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients|Completed||N/A|30|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-06-01 00:17:15.792231|2018-06-01 00:17:15.792231
NCT01029106|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2011-07-27|2009-12-08|2009-12-09|Estimate|||||||2011-07-27|2011-07-28|Estimate|September 2009||2009-09-30|July 2011|2011-07-31||||September 2012|Anticipated|2012-09-30||Observational|||Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)|Prospective, Non-Randomized, Observational, Multicentre, Study of the TVT Secur in the Surgical Management of Women With Stress Urinary Incontinence|Terminated|||125|Anticipated|Sunnybrook Health Sciences Centre||||Study design required a change in device|f||||f||||||||||2018-06-01 00:17:10.194204|2018-06-01 00:17:10.194204
NCT01029093|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-12-07|2009-12-07|2009-12-09|Estimate|||||||2009-12-07|2009-12-09|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|||||Observational|||Effects of Sensory and Motor Deprivation on Brain Plasticity|Effects of Sensory and Motor Deprivation on Brain Plasticity After Injury and Immobilisation of Right Upper Extremity|Unknown status|Not yet recruiting||40|Anticipated|University of Zurich|||||f||||t||||||||||2018-06-01 00:17:10.259347|2018-06-01 00:17:10.259347
NCT01029080|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-04-12|2009-12-08|2009-12-09|Estimate|||||||2013-04-12|2013-04-15|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|||Cerebrovascular Autoregulation During Sepsis|Dynamic Cerebrovascular Autoregulation During Sepsis and Sepsis-associated Delirium|Completed|||30|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-06-01 00:17:10.317195|2018-06-01 00:17:10.317195
NCT01029067|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-05|||2015-03-02|2009-12-08|2009-12-09|Estimate|||||||2015-03-02|2015-03-03|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MCT||Metacognitive Training in Schizophrenia|Metacognitive Training (MCT) Compared With Cognitive Remediation (CR) in Schizophrenia: a Randomized Controlled Study Over 4 Weeks|Completed||N/A|60|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-06-01 00:17:10.398072|2018-06-01 00:17:10.398072
NCT01029054|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2014-11-13||2016-12-01|2009-12-08|2009-12-09|Estimate|2014-11-13|2014-11-20|Estimate||||2016-12-01|2017-01-30|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|December 2011|Actual|2011-12-31||Interventional|||Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma|Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in Subjects w/ Newly Diagnosed, Previously Untreated Multiple Myeloma Requiring Systemic Chemotherapy|Completed||Phase 1/Phase 2|53|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 00:17:10.52244|2018-06-01 00:17:10.52244
NCT01029041|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|August 2007||2007-08-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Stretching and Strengthening Exercise in Fibromyalgia Patients|Stretching and Strengthening Exercise in Treatment of Fibromyalgia Patients: a Randomized Clinical Trial|Completed||N/A|63|Actual|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-06-01 00:17:10.853448|2018-06-01 00:17:10.853448
NCT01029028|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-09|2009-12-08|2009-12-09|Estimate|||||||2009-12-09|2009-12-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:17:10.941035|2018-06-01 00:17:10.941035
NCT01029015|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2011-03-03|2009-12-08|2009-12-09|Estimate|||||||2011-03-03|2011-03-07|Estimate|November 2006||2006-11-30|November 2009|2009-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|Nocturia Plt 1||Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects|A Pilot, Phase 4, Sleep Laboratory Study Comparing the Physiology of Nocturnal Bladder Function in Subjects With Overactive Bladder - Associated Nocturia to Subjects With Primary Insomnia and Healthy Normal Subjects|Completed|||26|Actual|Astellas Pharma Inc|||3||f||||f||||||||||2018-06-01 00:17:10.991015|2018-06-01 00:17:10.991015
NCT01029002|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2018-04-19|2009-12-08|2009-12-09|Estimate|||||||2018-04-19|2018-04-23|Actual|October 2009||2009-10-31|April 2018|2018-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease|The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease|Completed||Phase 3|75|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-06-01 00:17:11.07294|2018-06-01 00:17:11.07294
NCT01028989|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-03-13|2009-12-08|2009-12-09|Estimate|||||||2013-03-13|2013-03-15|Estimate|December 2009||2009-12-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Reduced Carbohydrate Diet Intervention for Polycystic Ovary Syndrome (PCOS)|A Reduced Carbohydrate Diet Intervention for PCOS|Completed||N/A|23|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 00:17:11.157119|2018-06-01 00:17:11.157119
NCT01028976|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2015-11-30|2009-12-08|2009-12-09|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Obesity, Inflammation and Oxidative Stress|Obesity, Inflammation and Oxidative Stress|Completed||Phase 3|512|Actual|University of California, Berkeley||2|||f||||t||||||||||2018-06-01 00:17:11.244712|2018-06-01 00:17:11.244712
NCT01028963|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2012-02-08|2009-12-08|2009-12-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|159|Actual|ChemoCentryx||4|||f||||t||||||||||2018-06-01 00:17:11.353845|2018-06-01 00:17:11.353845
NCT01028950|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-06-14|2009-12-08|2009-12-09|Estimate|||||||2010-06-14|2010-06-16|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness|A Multi-center, Open Label Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness|Completed||Phase 3|52|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:17:11.50351|2018-06-01 00:17:11.50351
NCT01028937|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2017-01-23|2009-12-08|2009-12-09|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System|Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System|Active, not recruiting||N/A|200|Anticipated|NTK Enterprises, Inc.||1|||f||||t||||||||||2018-06-01 00:17:11.569823|2018-06-01 00:17:11.569823
NCT01027533|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-07-01|2009-12-07|2009-12-08|Estimate|||||||2010-07-01|2010-07-02|Estimate|December 2009||2009-12-31|March 2009|2009-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Visual Performance of New Apodized Diffractive Multifocal IOL With Addition of Plus Three||Completed|||32|Anticipated|University of Sao Paulo|||2||f||||f||||||||||2018-06-01 00:17:31.567164|2018-06-01 00:17:31.567164
NCT01028924|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2012-05-04|2009-12-08|2009-12-09|Estimate|||||||2012-05-04|2012-05-07|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers|A Randomised, 4-period, Placebo and Active-controlled, Single-dose, Change-over Trial to Evaluate the Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers|Completed||Phase 1|72|Actual|Nycomed||4|||f||||f||||||||||2018-06-01 00:17:11.635965|2018-06-01 00:17:11.635965
NCT01028911|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2014-04-09||2014-05-16|2009-12-08|2009-12-09|Estimate|2014-05-16|2014-06-04|Estimate||||2014-05-16|2014-06-04|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Safety population included all participants who took at least 1 dose of study drug.|A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease|A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy|Terminated||Phase 1|9|Actual|Pfizer|The study was terminated early due to slow recruitment and the need to use the existing information to determine dosing for another study.|2||"This study terminated 27Apr2010 due to slow recruitment and the need to use the existing~   information to determine dosing for another study."|f||||f||||||||||2018-06-01 00:17:11.769668|2018-06-01 00:17:11.769668
NCT01028898|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2011-02-10|2009-12-08|2009-12-09|Estimate|||||||2011-02-10|2011-02-11|Estimate|January 2006||2006-01-31|December 2006|2006-12-31|December 2012|Anticipated|2012-12-31|August 2011|Anticipated|2011-08-31||Observational|IBS||Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome|Screening and Identification of Abnormal Expression Proteins and miRNA From Colonic Mucosa of Patients With Irritable Bowel Syndrome.|Unknown status|Active, not recruiting||180|Anticipated|Chinese PLA General Hospital|||||f||||t||||||Samples With DNA|"~     The investigators enrolled IBS-D and IBS-C patients on the Rome III criteria and healthy~     volunteers as normal control group. Biopsies were taken from the cecum and sigmoid colon~     under direct vision. Five pieces were taken separately at each site. Four pieces were~     processed by cold saline water and frozen in liquid nitrogen immediately while the other one~     was fixed in formalin and then embedded in paraffin three days later.~   "|||2018-06-01 00:17:12.823555|2018-06-01 00:17:12.823555
NCT01028885|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2016-01-25|2009-12-07|2009-12-09|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2009||2009-06-30|May 2012|2012-05-31||||February 2012|Actual|2012-02-29||Interventional|||MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate|A Prospective Study Implementing MRI Based Treatment Planning for Clinical Target Volume Definition and Immobilization in Post-Prostatectomy Radiation Treatment|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:17:12.907538|2018-06-01 00:17:12.907538
NCT01028872|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate||||September 2006|2006-09-30||||||||Interventional|||Spherical Aberration and Contrast Sensitivity Function in Eyes Implanted With Spherical and Aspheric Intraocular Lenses: A Clinical Trial||Completed||Phase 4|||Shahid Beheshti University of Medical Sciences||3|||f||||||||||||||2018-06-01 00:17:12.998358|2018-06-01 00:17:12.998358
NCT01028859|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2011-12-20|2009-12-08|2009-12-09|Estimate|||||||2011-12-20|2011-12-22|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers|Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-516 in Patients With Advanced Solid Cancers Failed to Standard Therapy|Completed||Phase 1|30|Anticipated|Chong Kun Dang Pharmaceutical||1|||f||||t||||||||||2018-06-01 00:17:13.0637|2018-06-01 00:17:13.0637
NCT01028846|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2018-01-12|2009-12-08|2009-12-09|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2011||2011-05-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|September 2022|Anticipated|2022-09-30||Interventional|||Central Mechanisms That Regulate Glucose Metabolism in Humans|Central Mechanisms That Regulate Glucose Metabolism in Humans|Recruiting||Phase 2|40|Anticipated|Albert Einstein College of Medicine, Inc.||3|||||||t|t|f|||f|||Undecided||2018-06-01 00:17:13.13254|2018-06-01 00:17:13.13254
NCT01028833|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2016-01-13|2009-12-08|2009-12-09|Estimate|||||||2016-01-13|2016-01-14|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Power Mobility on Young Children With Severe Motor Impairments|Effects of Power Mobility on the Development and Function of Young Children With Severe Motor Impairments|Completed||Phase 2|41|Actual|University of Oklahoma||2|||f||||f||||||||||2018-06-01 00:17:13.215058|2018-06-01 00:17:13.215058
NCT01028820|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2012-11-07||2014-02-07|2009-12-08|2009-12-09|Estimate|2014-02-07|2014-03-11|Estimate||||2014-02-07|2014-03-11|Estimate|August 2009||2009-08-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|AripfMRI||FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders|Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms|Completed||Phase 4|13|Actual|University of North Carolina, Chapel Hill|The present study had 13 subjects. Due to sample size, analysis reflected an exploratory approach. If a mechanism for predicting RRB improvement is found in a study with a larger N, we could better understand therapies targeting core symptoms of ASD.|1|||f||||f||||||||||2018-06-01 00:17:13.293896|2018-06-01 00:17:13.293896
NCT01028807|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-09|2009-12-08|2009-12-09|Estimate|||||||2009-12-09|2009-12-10|Estimate|June 2003||2003-06-30|December 2009|2009-12-31|November 2004|Actual|2004-11-30|May 2004|Actual|2004-05-31||Interventional|||Early Feeding vs 5-day Fasting After Distal Elective Bowel Anastomoses in Children. A Randomized Controlled Trial|Early Feeding vs 5-day Fasting After Distal Elective Bowel Anastomoses in Children. A Randomized Controlled Trial|Completed||N/A|60|Actual|Hospital Infantil de Mexico Federico Gomez||2|||f||||t||||||||||2018-06-01 00:17:13.496793|2018-06-01 00:17:13.496793
NCT01028794|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-07-04|2009-12-08|2009-12-09|Estimate|||||||2013-07-04|2013-07-08|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients|Phase 1/2A Study of Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Patients After Cerebral Embolism|Completed||Phase 1/Phase 2|12|Actual|National Cerebral and Cardiovascular Center||2|||f||||t||||||||||2018-06-01 00:17:13.669525|2018-06-01 00:17:13.669525
NCT01028781|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2011-12-19|2009-12-08|2009-12-09|Estimate|||||||2011-12-19|2011-12-20|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis|Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis|Terminated||Phase 1|9|Actual|University of North Carolina, Chapel Hill||1||Difficulty finding eligible participants and lack of funding.|f||||t||||||||||2018-06-01 00:17:13.743482|2018-06-01 00:17:13.743482
NCT01028768|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-05-04|2009-12-07|2009-12-09|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function|Open Label Pharmacokinetic (PK) Study, Conducted at One Investigational Site in Germany, to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Teduglutide Following Subcutaneous Administration of 10 mg Teduglutide and to Evaluate Safety and Tolerability of 10 mg Teduglutide|Completed||Phase 1|36|Actual|Nycomed||1|||f||||f||||||||||2018-06-01 00:17:13.833818|2018-06-01 00:17:13.833818
NCT01028755|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2015-01-19|2009-12-06|2009-12-09|Estimate|||||||2015-01-19|2015-01-21|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors|An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:17:13.962254|2018-06-01 00:17:13.962254
NCT01028742|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2014-12-02|2009-12-08|2009-12-09|Estimate|||||||2014-12-02|2014-12-04|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity|Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity|Completed|||463|Actual|Rigshospitalet, Denmark|||||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-06-01 00:17:14.037642|2018-06-01 00:17:14.037642
NCT01028729|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|NSCLC||A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)|A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 4|120|Anticipated|Simcere Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-06-01 00:17:14.10167|2018-06-01 00:17:14.10167
NCT01028716|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2017-12-11|2009-12-08|2009-12-09|Estimate|||||||2017-12-11|2017-12-13|Actual|February 8, 2010|Actual|2010-02-08|December 2017|2017-12-31||||August 1, 2018|Anticipated|2018-08-01||Interventional|||Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source|Recruiting||Phase 2|50|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 00:17:14.194723|2018-06-01 00:17:14.194723
NCT01028703|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2015-12-02|2009-12-08|2009-12-09|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Effects of a Reduction in Kidney Function on Cardiovascular Structure and Function: A Prospective Study of Kidney Donors|Does a Reduction in Renal Function Increase Arterial Stiffness and Left Ventricular Mass? - A Prospective Study of Kidney Donors|Completed|||124|Actual|University Hospital Birmingham NHS Foundation Trust|||2||f||||t||||||||||2018-06-01 00:17:14.362122|2018-06-01 00:17:14.362122
NCT01028690|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2011-06-21|2009-12-08|2009-12-09|Estimate|||||||2011-06-21|2011-06-22|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|January 2012|Anticipated|2012-01-31|September 2011|Anticipated|2011-09-30||Interventional|||Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri|Control of Helicobacter Pylori Infection by Dietary Supplementation With Lactobacillus Reuteri|Unknown status|Active, not recruiting|N/A|100|Anticipated|Centro Regional para el Estudio de las Enfermedades Digestivas||2|||f||||f||||||||||2018-06-01 00:17:14.426326|2018-06-01 00:17:14.426326
NCT01028677|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2014-06-28||2017-03-06|2009-12-08|2009-12-09|Estimate|2017-03-06|2017-04-18|Actual||||2017-03-06|2017-04-18|Actual|November 2009||2009-11-30|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|OTS||Oxytocin Treatment of Schizophrenia|Oxytocin Treatment of Social Deficits and Paranoia in Schizophrenia|Completed||N/A|17|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:17:14.528559|2018-06-01 00:17:14.528559
NCT01028664|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-12-02|2009-12-08|2009-12-09|Estimate|||||||2010-12-02|2010-12-03|Estimate|December 2009||2009-12-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Use of an Ocular Telemetry Sensor in Diamox Treated Patients|Detection of IOP Fluctuation With SENSIMED Triggerfish in Patients With Glaucoma or Ocular Hypertension Treated With Diamox|Completed||N/A|20|Anticipated|Sensimed AG||1|||f||||f||||||||||2018-06-01 00:17:14.919508|2018-06-01 00:17:14.919508
NCT01028651|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2016-09-14||2017-01-05|2009-12-08|2009-12-09|Estimate|2017-01-05|2017-02-24|Actual||||2017-01-05|2017-02-24|Actual|January 2011||2011-01-31|January 2017|2017-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension|An Open-Label Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension|Completed|||13|Actual|United Therapeutics|||1||f||||f||||||||||2018-06-01 00:17:15.031598|2018-06-01 00:17:15.031598
NCT01028638|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2015-01-27|2009-12-08|2009-12-09|Estimate|||||||2015-01-27|2015-01-28|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|Everolimage||Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma|89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Everolimus; a Pilot Study|Completed|||13|Actual|University Medical Center Groningen|||1||f||||f||||||Samples With DNA|"~     whole blood, white blood cells, plasma, serum, urine~   "|||2018-06-01 00:17:15.468265|2018-06-01 00:17:15.468265
NCT01028625|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2014-05-27|2009-12-04|2009-12-09|Estimate|||||||2014-05-27|2014-05-29|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|DASH||Depression and Self-care in Heart Failure|Treatment of Functional Impairment in Patients With Heart Failure and Comorbid Depression|Completed||N/A|158|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:17:15.533319|2018-06-01 00:17:15.533319
NCT01028612|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2017-08-14|2009-12-08|2009-12-09|Estimate|||||||2017-08-14|2017-08-17|Actual|February 2010||2010-02-28|August 2017|2017-08-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|NSCLC||Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size|A Pilot Study of Interventional Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer > 3.5 cm in Size|Terminated||N/A|1|Actual|Wake Forest University Health Sciences||1||Slow accrual|f||||t|f|f||||||||2018-06-01 00:17:15.725679|2018-06-01 00:17:15.725679
NCT01028586|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-03-27|2009-12-08|2009-12-09|Estimate|||||||2013-03-27|2013-03-29|Estimate|October 2009||2009-10-31|August 2012|2012-08-31||||May 2012|Actual|2012-05-31||Interventional|MOTION||MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)|A Phase III, Double-blind, Placebo-controlled Extension Trial to Investigate the Long-term Efficacy and Safety of Low (50 mg/Day) and High (100 mg/Day) Dose Safinamide, as add-on Therapy in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|Terminated||Phase 3|507|Actual|Newron Pharmaceuticals SPA||3||"Trial is terminated due to a company decision to return all rights for Safinamide back to~   Newron Pharmaceuticals"|f||||t||||||||||2018-06-01 00:17:15.857362|2018-06-01 00:17:15.857362
NCT01028573|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2012-03-12|2009-12-08|2009-12-09|Estimate|||||||2012-03-12|2012-03-14|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy|A Randomized, Controlled, Single-Blind Study Comparing the Efficacy, Tolerability and Safety of PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy|Unknown status|Recruiting|N/A|400|Anticipated|Southern California Institute for Research and Education||4|||f||||f||||||||||2018-06-01 00:17:15.950738|2018-06-01 00:17:15.950738
NCT01028560|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2015-06-29|2009-12-08|2009-12-09|Estimate|||||||2015-06-29|2015-07-01|Estimate|October 2008||2008-10-31|June 2015|2015-06-30||||April 2015|Actual|2015-04-30||Interventional|AIR||Allergy Immunotherapy for the Reduction of Asthma|Efficacy of Allergy Immunotherapy in Preventing Asthma Morbidity in Atopic, Wheezing Children (Age 18 Months - 3 Years)|Suspended||Phase 1/Phase 2|60|Anticipated|Albert Einstein College of Medicine, Inc.||2||"No evidence of clinically meaningful benefits for asthma (reduction of asthma medication scores~   and symptoms) in preliminary analysis"|f||||t||||||||||2018-06-01 00:17:16.047596|2018-06-01 00:17:16.047596
NCT01028547|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-03-25|2009-12-08|2009-12-09|Estimate|||||||2010-03-25|2010-03-26|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Antiemetic Efficacy and Safety of Dexamethasone in Obstetric Surgical Patients|Antiemetic Efficacy and Safety of Dexamethasone in Patients Undergoing Caesarean Sections at Mulago Hospital|Completed||N/A|250|Actual|Makerere University||2|||f||||t||||||||||2018-06-01 00:17:16.150109|2018-06-01 00:17:16.150109
NCT01028534|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2015-04-01|2009-12-08|2009-12-09|Estimate|||||||2015-04-01|2015-04-03|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea (OSA)|Comparison of the Effects of Different Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea|Completed||N/A|150|Anticipated|Kyoto University, Graduate School of Medicine||3|||f||||t||||||||||2018-06-01 00:17:16.233981|2018-06-01 00:17:16.233981
NCT01028521|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-07-14|2009-12-08|2009-12-09|Estimate|||||||2010-07-14|2010-07-15|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100|Single-centre, Randomised, Double-blind, Placebo-controlled Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers|Completed||Phase 1|56|Anticipated|CellMed AG, a subsidiary of BTG plc.||2|||f||||f||||||||||2018-06-01 00:17:16.330053|2018-06-01 00:17:16.330053
NCT01028508|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2017-04-07|2009-12-08|2009-12-09|Estimate|||||||2017-04-07|2017-04-11|Actual|January 2010||2010-01-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|PRIDE||Prolonging Remission in Depressed Elderly (PRIDE)|Prolonging Remission in Depressed Elderly (PRIDE)|Completed||Phase 4|247|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||||2018-06-01 00:17:16.419719|2018-06-01 00:17:16.419719
NCT01028495|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2012-08-28|2009-12-08|2009-12-09|Estimate|||||||2012-08-28|2012-08-29|Estimate|May 2009||2009-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer|A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer|Completed||Phase 2|31|Actual|Rexahn Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 00:17:16.573231|2018-06-01 00:17:16.573231
NCT01028482|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2011-05-09|2009-12-08|2009-12-09|Estimate|||||||2011-05-09|2011-05-10|Estimate|March 2008||2008-03-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline|Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline|Completed||N/A|42|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-06-01 00:17:16.667681|2018-06-01 00:17:16.667681
NCT01028469|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-14|2009-12-08|2009-12-09|Estimate|||||||2009-12-14|2009-12-15|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||December 2011|Anticipated|2011-12-31||Interventional|||Artelon Metatarsophalangeal (MTP) Spacer|Artelon MTP Spacer - Surgical Treatment of Mild to Moderate Hallux Rigidus|Unknown status|Recruiting|Phase 4|15|Anticipated|Artimplant AB||1|||f||||f||||||||||2018-06-01 00:17:16.749244|2018-06-01 00:17:16.749244
NCT01028456|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|September 2010||2010-09-30|December 2009|2009-12-31|September 2011|Anticipated|2011-09-30|April 2011|Anticipated|2011-04-30||Interventional|||Clinical Trial of Light Therapy for Epilepsy|A Randomised Placebo Controlled Clinical Trial of Light Therapy for Medically Intractable Epilepsy.|Unknown status|Enrolling by invitation|N/A|100|Anticipated|University College, London||2|||f||||f||||||||||2018-06-01 00:17:16.835852|2018-06-01 00:17:16.835852
NCT01028443|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate||||April 2006|2006-04-30||||||||Interventional|||Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes||Completed||Phase 4|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 00:17:16.920162|2018-06-01 00:17:16.920162
NCT01028430|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2017-12-13|2009-12-08|2009-12-09|Estimate|||||||2017-12-13|2017-12-15|Actual|July 1998||1998-07-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging|B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging|Recruiting|||1000|Anticipated|Northwell Health|||1||f||||f|||||||"~     Blood cells, tissue~   "|||2018-06-01 00:17:16.99017|2018-06-01 00:17:16.99017
NCT01028417|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2014-02-28|2009-12-08|2009-12-09|Estimate|||||||2014-02-28|2014-03-03|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|October 2013|Actual|2013-10-31|June 2012|Actual|2012-06-30||Interventional|||Study to See if Microcoil Insertion Reduces the Rate of Open Thoracotomy for Removal of Lung Nodules|A Randomized Controlled Trial To Determine If Thoracoscopic Resection Of Subcentimetre Lung Nodules After Localization Using Percutaneously Inserted Platinum Microcoils Under CT Guidance Reduces Rate Of Conversion To Open Thoracotomy From 50% To 10%|Completed||Phase 3|60|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:17:17.071018|2018-06-01 00:17:17.071018
NCT01028404|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2017-07-24|2009-12-07|2009-12-09|Estimate|||||||2017-07-24|2017-07-25|Actual|November 2009||2009-11-30|July 2017|2017-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 0148-0000-0106 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes|Completed||Phase 1|84|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:17:17.151511|2018-06-01 00:17:17.151511
NCT01028391|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2010-01-11||2017-04-07|2009-12-08|2009-12-09|Estimate|2010-01-11|2010-02-10|Estimate||||2017-04-07|2017-05-12|Actual|September 1, 2007|Actual|2007-09-01|April 2017|2017-04-30|January 1, 2009|Actual|2009-01-01|January 1, 2009|Actual|2009-01-01||Interventional|||30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)|A 30-Week Extension to: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|317|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:17:17.244267|2018-06-01 00:17:17.244267
NCT01028378|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2014-01-28||2016-03-18|2009-12-08|2009-12-09|Estimate|2016-03-18|2016-04-11|Estimate||||2016-03-18|2016-04-11|Estimate|October 2009||2009-10-31|March 2016|2016-03-31||||April 2012|Actual|2012-04-30||Interventional||212 participants (249 eyes)|Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia|Topography-Guided LASIK Using the ALLEGRETTO WAVE Eye-Q 400 Hz Excimer Laser System For the Treatment of Manifest and Cornea Based Myopic and Hyperopic Optical Errors|Completed||Phase 3|212|Actual|Clinical Research Consultants, Inc.||1|||f||||f||||||||||2018-06-01 00:17:17.606767|2018-06-01 00:17:17.606767
NCT01028365|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2017-05-03|2009-12-08|2009-12-09|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2008||2008-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Time to Conceive: A Study of Fertility|Time to Conceive: A Study of Fertility: Biomarkers of Fertility|Completed|||843|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     Serum, Urine~   "|||2018-06-01 00:17:17.825792|2018-06-01 00:17:17.825792
NCT01028352|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2012-01-30||2013-07-26|2009-12-08|2009-12-09|Estimate|2012-07-09|2012-08-17|Estimate||||2013-07-26|2013-08-08|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Interventional|||Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain|UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients|Completed||N/A|35|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 00:17:17.890854|2018-06-01 00:17:17.890854
NCT01028339|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-08-07|2009-12-08|2009-12-09|Estimate|||||||2012-08-07|2012-08-08|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values|Mannitol Versus Hypertonic Saline to Treat Intracranial Hypertension After Severe Traumatic Brain Injury : a Comparative Study on the Effects on PtiO2 and Microdialysis Values|Terminated||Phase 3|30|Actual|Direction Centrale du Service de Santé des Armées||2||No patients enrolled during 2 years|f||||f||||||||||2018-06-01 00:17:18.099987|2018-06-01 00:17:18.099987
NCT01028326|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2018-02-22|2009-12-07|2009-12-09|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2010||2010-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2010|Actual|2010-09-30||Interventional|PRISM||PCV10 Reactogenicity and Immunogenicity Study - Malindi|Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months|Active, not recruiting||Phase 4|600|Anticipated|KEMRI-Wellcome Trust Collaborative Research Program||3|||f||||f||||||||||2018-06-01 00:17:18.173564|2018-06-01 00:17:18.173564
NCT01028313|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-02-11|2009-12-08|2009-12-09|Estimate|||||||2013-02-11|2013-02-13|Estimate||||February 2013|2013-02-28||||||||Interventional|||A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease|A Phase II Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease|Withdrawn||Phase 2|0|Actual|SCRI Development Innovations, LLC||1||"A decision was made to not move forward with the study. No participants were enrolled or~   treated."|f||||f||||||||||2018-06-01 00:17:18.333804|2018-06-01 00:17:18.333804
NCT01028300|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2015-12-22||2016-02-02|2009-12-08|2009-12-09|Estimate|2015-12-22|2016-02-02|Estimate||||2016-02-02|2016-03-02|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel|Clinical Outcomes of Lumbar Degenerative Disc Disease Treated Operatively in Active-Duty U.S. Service Personnel With Lumbar Total Disc Replacement|Terminated||N/A|4|Actual|Synthes USA HQ, Inc.|Study was terminated early due to slow enrollment. Only Two subjects were seen for follow-up visits, and only at 3 months post surgery.|1||Terminated due to enrollment failure|f||||t||||||||||2018-06-01 00:17:18.439628|2018-06-01 00:17:18.439628
NCT01028287|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-05-30|2009-12-08|2009-12-09|Estimate|||||||2013-05-30|2013-05-31|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|ACTH-NRDN||Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)|"Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study"|Completed||Phase 4|15|Actual|Southeast Renal Research Institute||2|||f||||f||||||||||2018-06-01 00:17:18.63926|2018-06-01 00:17:18.63926
NCT01028274|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2015-12-10|2009-12-08|2009-12-09|Estimate|||||||2015-12-10|2015-12-14|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of a Natural Health Product in Reducing Cholesterol and Triglyceride Levels.|Clinical Trial to Assess the Safety and Efficacy of a Combination Red Yeast Rice and Omega-3 (EPA+DHA) to Reduce LDL Cholesterol and Triglyceride Levels in Hypercholesterolemic and Hypertriglyceridemic Subjects.|Completed||Phase 1/Phase 2|148|Actual|Nordic Pharma, USA||3|||f||||||||||||||2018-06-01 00:17:18.776055|2018-06-01 00:17:18.776055
NCT01028261|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2012-01-09|2009-12-07|2009-12-09|Estimate|||||||2012-01-09|2012-01-11|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Doses of ZGN-433 in Obese Female Volunteers|A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZGN-433 in Obese Volunteers|Completed||Phase 1|31|Actual|Zafgen, Inc.||2|||f||||f||||||||||2018-06-01 00:17:18.867941|2018-06-01 00:17:18.867941
NCT01028248|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-12-10|2009-12-08|2009-12-09|Estimate|||||||2013-12-10|2013-12-12|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion|Phase I, Open-Label, Single-Center, Randomized, Study of the Safety and Efficacy of 0.5 mg and 2.0 mg Ranibizumab in Patients With Macular Edema Secondary to Perfused Central Retinal Vein Occlusion|Completed||Phase 1|20|Actual|California Retina Consultants||2|||f||||t||||||||||2018-06-01 00:17:18.976539|2018-06-01 00:17:18.976539
NCT01028235|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|January 2006||2006-01-31|November 2009|2009-11-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|||Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia|Routine Screening for Eosinophilic Esophagitis in Patients Presenting With Dysphagia|Unknown status|Recruiting||150|Anticipated|San Antonio Uniformed Services Health Education Consortium|||2||f||||t||||||Samples Without DNA|"~     4 endoscopic biopsies from 5 locations: duodenum, stomach, distal esophagus, mid esophagus~     and proximal esophagus~   "|||2018-06-01 00:17:19.085601|2018-06-01 00:17:19.085601
NCT01028222|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2015-10-23||2015-11-30|2009-12-08|2009-12-09|Estimate|2015-10-23|2015-11-26|Estimate||||2015-11-30|2015-12-30|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TEAM||A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation|The TEAM Trial (Tasigna Efficacy in Advanced Melanoma): A Phase II, Open Label, Multi-center, Single-arm Study to Assess the Efficacy of Tasigna ® in the Treatment of Patients With Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation|Completed||Phase 2|55|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:17:19.216068|2018-06-01 00:17:19.216068
NCT01028209|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2010-10-08|2009-12-08|2009-12-09|Estimate|||||||2010-10-08|2010-10-11|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|April 2010|Anticipated|2010-04-30||Interventional|PBR06||Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions||Terminated||Phase 1|12|Anticipated|Institute for Neurodegenerative Disorders||1|||f||||||||||||||2018-06-01 00:17:20.076321|2018-06-01 00:17:20.076321
NCT01028196|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2011-10-31|2009-12-08|2009-12-09|Estimate|||||||2011-10-31|2011-11-01|Estimate|November 2009||2009-11-30|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression|Epidemiological Observational Non-interventional Study to Research the Prevalence of Bipolar Criteria of Hospital In-patients With Schizophrenia and Patients With Recurrent Depression|Completed|||750|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 00:17:20.223556|2018-06-01 00:17:20.223556
NCT01028183|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-05|||2013-01-15|2009-12-08|2009-12-09|Estimate|||||||2013-01-15|2013-01-16|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|July 2011|Anticipated|2011-07-31||Observational|||Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability|Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability|Withdrawn|||0|Actual|Duke University|||4||f||||t||||||||||2018-06-01 00:17:20.303611|2018-06-01 00:17:20.303611
NCT01028170|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2012-02-08|2009-12-08|2009-12-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|REaCH||Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure|Assessing the Renal Consequences and Functional Efficacy of Low Dose Hypertonic Saline Solution and Furosemide for the Treatment of Congestive Heart Failure in a Randomized, Double Blind, Prospective Study|Completed||Phase 3|50|Actual|Aspirus Heart and Vascular Institute-Research and Education||2|||f||||f||||||||||2018-06-01 00:17:20.366386|2018-06-01 00:17:20.366386
NCT01028157|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2013-12-16|2009-12-04|2009-12-09|Estimate|||||||2013-12-16|2013-12-17|Estimate|October 2002||2002-10-31|December 2013|2013-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|STARS||S.T.A.R.S.: Sistas Talking About Real Solutions|STARS: Sistas Talking About Real Solutions|Completed||Phase 1|855|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:17:20.49188|2018-06-01 00:17:20.49188
NCT01028144|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-09|2009-12-08|2009-12-09|Estimate|||||||2009-12-09|2009-12-10|Estimate|July 2004||2004-07-31|December 2009|2009-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|ACT||The Active by Choice Today (ACT) Trial to Increase Physical Activity|Self-Determination for Increasing Physical Activity|Completed||Phase 1/Phase 2|1422|Actual|University of South Carolina||2|||f||||t||||||||||2018-06-01 00:17:20.644022|2018-06-01 00:17:20.644022
NCT01028131|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2011-10-12||2013-06-06|2009-12-08|2009-12-09|Estimate|2013-06-06|2013-06-10|Estimate||||2013-06-06|2013-06-10|Estimate|June 2007||2007-06-30|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|HPP||Computer-Assisted Intervention for Smoking During Pregnancy|A Computer-Assisted Brief Motivational Intervention for Smoking During Pregnancy: The Healthy Pregnancy Project (HPP)|Completed||Phase 2|110|Actual|Wayne State University|Although all effects favored brief computer session, the small sample size limited our ability to detect small effects. The sample was almost exclusively low-income African-American women. Follow-up period was also, of necessity, relatively brief.|4|||f||||f||||||||||2018-06-01 00:17:20.833352|2018-06-01 00:17:20.833352
NCT01028118|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-04-07|2009-12-08|2009-12-09|Estimate|||||||2010-04-07|2010-04-08|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|DV||Violence Against Women and Consequences During Climacteric´s Phase|Domestic and Sexual Violence Against Women: Consequences for Climacteric´s Phase|Completed||Phase 3|300|Actual|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-06-01 00:17:21.38226|2018-06-01 00:17:21.38226
NCT01028105|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|May 2011|Anticipated|2011-05-31|January 2011|Anticipated|2011-01-31||Interventional|MRSA||Incidence and Relationship of Positive Preoperative Methicillin Resistant Staphylococcus Aureus (MRSA) Screens and Post-operative Infections|Evaluation of the Prevalence of Methicillin Resistant Staphylococcus Aureus Colonization in Pre-Surgical Patients and Post-Operative Infection|Unknown status|Recruiting|N/A|975|Anticipated|Inova Health Care Services||2|||f||||f||||||||||2018-06-01 00:17:21.449417|2018-06-01 00:17:21.449417
NCT01028092|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2014-07-07|2009-12-08|2009-12-09|Estimate|||||||2014-07-07|2014-07-08|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|EVEROLD||mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation|mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation|Completed||Phase 3|327|Actual|University Hospital, Brest||3|||f||||t||||||||||2018-06-01 00:17:21.550704|2018-06-01 00:17:21.550704
NCT01028079|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|November 2005||2005-11-30|December 2009|2009-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Placebo and Active Controlled, Double Dummy Study to Prove Efficacy of Aspirin in Treatment of Acute Low Back Pain|Placebo and Active Controlled, Double Dummy Phase III Study to Prove Efficacy of Aspirin (1000 mg Solid Dose) in Treatment of Acute Low Back Pain.|Completed||Phase 3|338|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:17:22.689096|2018-06-01 00:17:22.689096
NCT01028066|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2009-12-10|2009-12-08|2009-12-09|Estimate|||||||2009-12-10|2009-12-11|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|January 2012|Anticipated|2012-01-31|August 2009|Actual|2009-08-31||Interventional|PTCA-Nutri||Feeding Education in Patients Submitted to Coronary Angioplasty|Feeding Education in Patients Submitted to Percutaneous Transluminal Coronary Angioplasty: Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 3|200|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-06-01 00:17:22.798217|2018-06-01 00:17:22.798217
NCT01028053|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2014-07-30||2014-09-03|2009-12-08|2009-12-09|Estimate|2014-09-03|2014-09-11|Estimate||||2014-09-03|2014-09-11|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease|A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease|Completed||Phase 3|365|Actual|GE Healthcare||1|||f||||t||||||||||2018-06-01 00:17:22.897371|2018-06-01 00:17:22.897371
NCT01028040|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2010-12-08|2009-12-08|2009-12-09|Estimate|||||||2010-12-08|2010-12-10|Estimate|December 2009||2009-12-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|JSAD||AZD Single Ascending Dose Study In Healthy Japanese Subjects|Phase I, Single Centre, Open Label Study to Access The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After A) a Single Ascending Bolus Dose and B) a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Japanese Volunteers (Age Range 20-45 Years)|Completed||Phase 1|72|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:17:23.17526|2018-06-01 00:17:23.17526
NCT01028027|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2011-07-14||2012-02-27|2009-12-08|2009-12-09|Estimate|2011-08-11|2011-09-15|Estimate||||2012-02-27|2012-02-28|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis|A Clinical Safety and Efficacy Evaluation of Zylet® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis|Completed||Phase 3|357|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:17:23.260462|2018-06-01 00:17:23.260462
NCT01028014|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2011-06-29||2012-06-01|2009-12-08|2009-12-09|Estimate|2011-08-03|2011-09-05|Estimate||||2012-06-01|2012-06-08|Estimate|April 2010||2010-04-30|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters|Medication Effects on Periurethral Sensation, Urethral Sphincter Activity and Pressure Flow Parameters|Completed||N/A|56|Actual|University of Alabama at Birmingham||6|||f||||t||||||||||2018-06-01 00:17:23.700216|2018-06-01 00:17:23.700216
NCT01027988|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-10-29|2009-12-08|2009-12-09|Estimate|||||||2013-10-29|2013-10-30|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2011|Actual|2011-09-30||Observational|||Retina Microvascularisation and Cardiovascular Heart Disease Prediction|Retina Microvascularisation and Cardiovascular Heart Disease Prediction|Completed|||40|Actual|Montreal Heart Institute|||||f||||t||||||||||2018-06-01 00:17:24.319922|2018-06-01 00:17:24.319922
NCT01027975|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-10|2009-12-08|2009-12-09|Estimate|||||||2009-12-10|2009-12-11|Estimate|July 1998||1998-07-31|February 2007|2007-02-28||||||||Interventional|||Comparison of Laparoscopic Nissen Versus Thal Fundoplication in Children|Long-term Outcome of Laparoscopic Nissen Fundoplication Compared With Laparoscopic Thal Fundoplication in Children|Completed||N/A|||Oxford University Hospitals NHS Trust|||||f||||||||||||||2018-06-01 00:17:24.375795|2018-06-01 00:17:24.375795
NCT01027962|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-01-14|2009-12-08|2009-12-09|Estimate|||||||2013-01-14|2013-01-15|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Psychosis (EOP)|Intensive Computerized Brain Training in Early Onset Psychosis-Pilot Phase|Completed||N/A|35|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-06-01 00:17:24.440732|2018-06-01 00:17:24.440732
NCT01027949|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2017-11-28|2009-12-08|2009-12-09|Estimate|||||||2017-11-28|2017-11-30|Actual|May 2006||2006-05-31|November 2017|2017-11-30||||December 2020|Anticipated|2020-12-31||Interventional|FREEDOM-EXT||An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension|An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension|Active, not recruiting||Phase 3|900|Anticipated|United Therapeutics||1|||f||||||||||||||2018-06-01 00:17:24.54514|2018-06-01 00:17:24.54514
NCT01027936|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2010-11-08|2009-12-08|2009-12-09|Estimate|||||||2010-11-08|2010-11-10|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|November 2010|Anticipated|2010-11-30|March 2010|Anticipated|2010-03-31||Observational|||An Age-Stratified Data Collection Study in Adult Males and Females, Ages 18 and Above to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II|An Age-Stratified Data Collection Study in Adult Males and Females, Ages 18 and Above to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II|Unknown status|Active, not recruiting||180|Anticipated|Topcon Corporation|||1||f||||f||||||||||2018-06-01 00:17:24.877362|2018-06-01 00:17:24.877362
NCT01027923|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2015-01-21|2009-12-08|2009-12-09|Estimate|||||||2015-01-21|2015-01-26|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|AML||IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)|A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia|Terminated||Phase 1|6|Actual|Washington University School of Medicine||3||Withdrawal of support from sponsor|f||||f||||||||||2018-06-01 00:17:24.960489|2018-06-01 00:17:24.960489
NCT01027910|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2016-03-09||2016-12-21|2009-12-08|2009-12-09|Estimate|2016-12-21|2017-02-14|Actual||||2016-12-21|2017-02-14|Actual|February 2009||2009-02-28|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||PCI-24781 in Combination With Doxorubicin to Treat Sarcoma|Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy|Completed||Phase 1/Phase 2|20|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-06-01 00:17:25.088608|2018-06-01 00:17:25.088608
NCT01026675|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2018-05-02|2009-12-03|2009-12-04|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2009|Actual|2009-04-30|May 2018|2018-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|DG2||Early Screening for Gestational Diabetes Mellitus|Early Screening for Gestational Diabetes Mellitus|Completed|||1442|Actual|Université de Sherbrooke|||1||f||||f||||||||||2018-06-01 00:17:48.89661|2018-06-01 00:17:48.89661
NCT01027897|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2012-04-05||2013-12-19|2009-12-08|2009-12-09|Estimate|2012-08-25|2012-09-25|Estimate||||2013-12-19|2014-01-27|Estimate|April 2010||2010-04-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients|Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients With Sepsis at Grady Health System|Completed||Phase 4|30|Actual|Emory University||1|||f||||f||||||||||2018-06-01 00:17:25.383341|2018-06-01 00:17:25.383341
NCT01027884|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|2015-06-15||2015-09-23|2009-12-08|2009-12-09|Estimate|2015-09-23|2015-10-19|Estimate||||2015-09-23|2015-10-19|Estimate|July 2009||2009-07-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|DELOS||Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)|A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients With Duchenne Muscular Dystrophy|Completed||Phase 3|65|Actual|Santhera Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:17:25.608395|2018-06-01 00:17:25.608395
NCT01027871|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08||2011-04-05|2011-04-05|2009-12-08|2009-12-09|Estimate||||2011-04-05|2011-04-13|Estimate|2011-04-05|2011-04-13|Estimate|January 2010||2010-01-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Study for Patients With Type 2 Diabetes|A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus|Completed||Phase 2|131|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 00:17:26.009844|2018-06-01 00:17:26.009844
NCT01027858|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2017-10-02|2009-12-08|2009-12-09|Estimate|||||||2017-10-02|2017-10-04|Actual|December 2009||2009-12-31|October 2017|2017-10-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||PROMOTE: Promotion of the Mind Through Exercise|Role of Exercise on Cognition and Function in Seniors With Vascular Cognitive Impairment: A Randomized Controlled Trial|Completed||N/A|71|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 00:17:26.120854|2018-06-01 00:17:26.120854
NCT01027845|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07||2012-07-24|2016-08-04|2009-12-07|2009-12-09|Estimate||||2012-07-24|2012-08-01|Estimate|2016-08-04|2016-08-05|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|September 2011|Actual|2011-09-30|August 2010|Actual|2010-08-31||Interventional|||Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children|Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline Biologicals' Pneumococcal Vaccine GSK1024850A Following Primary and Booster Vaccination of Healthy Japanese Children|Completed||Phase 3|360|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:17:26.193036|2018-06-01 00:17:26.193036
NCT01027832|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2009-12-08|2009-12-08|2009-12-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT)|Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT): A Randomized, Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 00:17:26.441191|2018-06-01 00:17:26.441191
NCT01027819|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2011-03-06||2012-12-13|2009-12-07|2009-12-09|Estimate|2011-03-06|2011-04-05|Estimate||||2012-12-13|2012-12-20|Estimate|November 2009||2009-11-30|December 2012|2012-12-31||||December 2013|Anticipated|2013-12-31||Interventional|||Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty|Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty|Unknown status|Active, not recruiting|Phase 4|80|Actual|Seoul National University Hospital|"First, our study population is composed of elderly patients with large female dominance~Second concern was inherent errors in making the measurements in this kind of study"|2|||f||||f||||||||||2018-06-01 00:17:26.536946|2018-06-01 00:17:26.536946
NCT01027806|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2016-04-07|2009-12-08|2009-12-09|Estimate|||||||2016-04-07|2016-04-08|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|32543||Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children|A Randomized Double Blind Controlled Trial on the Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome|Terminated||Phase 4|19|Actual|University of Chicago||2||Poor accrual|f||||f||||||||||2018-06-01 00:17:26.944018|2018-06-01 00:17:26.944018
NCT01027793|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2012-02-28|2009-12-08|2009-12-09|Estimate|||||||2012-02-28|2012-02-29|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Stretch Marks|Randomized Clinical Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Recent Stretch Marks|Completed||Phase 4|30|Actual|Brazilan Center for Studies in Dermatology||2|||f||||f||||||||||2018-06-01 00:17:27.024319|2018-06-01 00:17:27.024319
NCT01027780|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-06|2012-06-14||2014-08-12|2009-12-08|2009-12-09|Estimate|2014-08-12|2014-08-27|Estimate||||2014-08-12|2014-08-27|Estimate|March 2006||2006-03-31|January 2014|2014-01-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Mindfulness to Improve Elders' Immune and Health Status|Mindfulness to Improve Elders' Immune and Health Status|Completed||N/A|208|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 00:17:27.127524|2018-06-01 00:17:27.127524
NCT01027767|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-02-13|2009-12-08|2009-12-09|Estimate|||||||2013-02-13|2013-02-15|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging|Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging|Completed|||23|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 00:17:27.493123|2018-06-01 00:17:27.493123
NCT01027754|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2014-06-16|2009-12-07|2009-12-09|Estimate|||||||2014-06-16|2014-06-17|Estimate|August 2009||2009-08-31|June 2014|2014-06-30||||August 2014|Anticipated|2014-08-31||Interventional|||Smoking Cessation Treatment for Methadone Maintenance Patients|Smoking Cessation Treatment for Methadone Maintenance Patients|Unknown status|Active, not recruiting|Phase 4|134|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-06-01 00:17:27.569081|2018-06-01 00:17:27.569081
NCT01027741|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2018-05-03|2009-12-08|2009-12-09|Estimate|||||||2018-05-03|2018-05-10|Estimate|December 2009|Actual|2009-12-31|May 2018|2018-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Integrating Cancer Control Referrals and Navigators Into United Way 211 Missouri|Integrating Cancer Control Referrals and Navigators Into United Way 211 Missouri|Completed||N/A|4762|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 00:17:27.720207|2018-06-01 00:17:27.720207
NCT01027728|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2012-02-08|2009-12-08|2009-12-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CARAT-1||Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis|Completed||Phase 1/Phase 2|24|Actual|ChemoCentryx||1|||f||||t||||||||||2018-06-01 00:17:27.804063|2018-06-01 00:17:27.804063
NCT01027715|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2015-12-08|2009-12-08|2009-12-09|Estimate|||||||2015-12-08|2015-12-10|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy|The Impact of Electroencephalographic (EEG) Seizure Treatment in Near Term ≥ 36 Weeks Gestation and Term Infants With Neonatal Encephalopathy|Completed||N/A|69|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:17:27.892712|2018-06-01 00:17:27.892712
NCT01027702|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2017-09-09||2017-10-08|2009-12-08|2009-12-09|Estimate|2017-10-08|2017-11-08|Actual||||2017-10-08|2017-11-08|Actual|August 2009||2009-08-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Donor Lymphocyte Infusion After Alternative Donor Transplantation|Phase I/II Study of Donor Lymphocyte Infusion With Methotrexate GVHD Prophylaxis to Hasten Immune Reconstitution After CD34+ Cell-Selected Transplant|Terminated||Phase 1/Phase 2|38|Actual|Carolinas Healthcare System||1||Sponsor/ PI leaving institution, no plans to continue this research at this time|f||||t||||||||No||2018-06-01 00:17:28.015526|2018-06-01 00:17:28.015526
NCT01027689|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2012-05-29|2009-12-07|2009-12-09|Estimate|||||||2012-05-29|2012-05-30|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation|Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet|Withdrawn||Phase 1|0|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:17:28.52485|2018-06-01 00:17:28.52485
NCT01027676|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-08|||2013-11-13|2009-12-08|2009-12-09|Estimate|||||||2013-11-13|2013-11-14|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)|Phase I/II Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 00:17:28.588354|2018-06-01 00:17:28.588354
NCT01027663|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2016-08-05|2009-12-08|2009-12-09|Estimate|||||||2016-08-05|2016-08-08|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Impact of Host Iron Status and Iron Supplement Use on Erythrocytic Stage of Plasmodium Falciparum|Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum|Completed||N/A|45|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||No||2018-06-01 00:17:28.669349|2018-06-01 00:17:28.669349
NCT01027650|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2014-03-27|2013-04-19|2014-03-27|2009-12-04|2009-12-08|Estimate|2014-03-27|2014-04-29|Estimate|2013-04-19|2013-04-29|Estimate|2014-03-27|2014-04-29|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)||Completed||Phase 1/Phase 2|121|Actual|Allergan||8|||f||||f||||||||||2018-06-01 00:17:28.777493|2018-06-01 00:17:28.777493
NCT01027637|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-09-05|2009-12-07|2009-12-08|Estimate|||||||2013-09-05|2013-09-06|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Regenerative Tissue Matrix for Breast Reconstruction|In Situ Elasticity of Alloderm® in Breast Reconstruction|Completed||N/A|33|Actual|Henry Ford Health System||1|||f||||t||||||||||2018-06-01 00:17:30.41202|2018-06-01 00:17:30.41202
NCT01027624|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2011-04-14|2009-12-04|2009-12-08|Estimate|||||||2011-04-14|2011-04-15|Estimate|November 2009||2009-11-30|April 2011|2011-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|CEPHEUS||Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia|Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia.|Completed|||3000|Anticipated|AstraZeneca|||1||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 00:17:30.489777|2018-06-01 00:17:30.489777
NCT01027611|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2010-05-03|2009-12-07|2009-12-08|Estimate|||||||2010-05-03|2010-05-04|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections|Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections|Completed||Phase 3|120|Actual|Illinois Retina Associates||3|||f||||f||||||||||2018-06-01 00:17:30.554107|2018-06-01 00:17:30.554107
NCT01027598|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2015-10-08||2015-12-22|2009-12-07|2009-12-08|Estimate|2015-12-22|2016-01-29|Estimate||||2015-12-22|2016-01-29|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional||All treated patients|Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer|A Randomized Phase II Double-Blind Trial of Erlotinib and Pazopanib, or Erlotinib and Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 2|202|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 00:17:30.658076|2018-06-01 00:17:30.658076
NCT01027585|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-07|2009-12-07|2009-12-08|Estimate|||||||2009-12-07|2009-12-08|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|September 2009|Actual|2009-09-30|||||Observational|||The Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Impaired Glucose Tolerance|Effects of Cinnamon on Postprandial Blood Glucose, and Insulin in Subjects With Type 2 Diabetes or Impaired Glucose Tolerance|Completed|||10|Actual|Skane University Hospital|||||f||||t||||||||||2018-06-01 00:17:31.035403|2018-06-01 00:17:31.035403
NCT01027572|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-06-24|2009-12-07|2009-12-08|Estimate|||||||2011-06-24|2011-06-27|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Interventional|CATS\||Thalamic Stimulation of Patients in Vegetative or Minimally Conscious State|Efficacy of Thalamic Stimulation in the Treatment of Patients in Vegetative State and Minimally Conscious State From at Least Six Months. A Pilot Study|Unknown status|Recruiting|Phase 2|5|Anticipated|IRCCS Policlinico S. Matteo||1|||f||||t||||||||||2018-06-01 00:17:31.124863|2018-06-01 00:17:31.124863
NCT01027559|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2014-12-17|2009-12-04|2009-12-08|Estimate|||||||2014-12-17|2014-12-19|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||fMRI Study of Treatment Changes in Major Depression|fMRI Studies of Emotional Circuitry in Major Depression: Treatment Changes|Completed||N/A|97|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 00:17:31.246931|2018-06-01 00:17:31.246931
NCT01027546|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-07|2009-12-07|2009-12-08|Estimate|||||||2009-12-07|2009-12-08|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Tranexamic Acid on Reducing Postoperative Blood Loss in Cervical Laminoplasty||Completed||N/A|40|Actual|Yodakubo Hospital||1|||f||||f||||||||||2018-06-01 00:17:31.491228|2018-06-01 00:17:31.491228
NCT01027520|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2017-09-06|2009-12-07|2009-12-08|Estimate|||||||2017-09-06|2017-09-11|Actual|January 2010||2010-01-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Range of Motion Following Intraoperative Coban Dressing Application in Hand Burns|Day One Post Operative Range of Motion Following Skin Graft to Hand With Intraoperative Coban Dressing|Terminated||N/A|6|Actual|University of Missouri-Columbia||1||Insufficient enrollment numbers|f||||t||||||||No||2018-06-01 00:17:31.78379|2018-06-01 00:17:31.78379
NCT01027507|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-07|2009-12-07|2009-12-08|Estimate|||||||2009-12-07|2009-12-08|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|||||Observational|||Postprandial Hemodynamics|Relationship Between Postprandial Alterations in Hemodynamics, Blood Pressure, Blood Glucose, Insulin Concentrations, Gastric Emptying, and Satiety|Completed|||23|Actual|Skane University Hospital|||||f||||t||||||||||2018-06-01 00:17:31.891918|2018-06-01 00:17:31.891918
NCT01027494|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2013-03-14|2009-12-04|2009-12-08|Estimate|||||||2013-03-14|2013-03-18|Estimate|December 2009||2009-12-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora|Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora Distal to the Site of Infection|Completed|||318|Actual|Alcon Research|||2||f||||f||||||||||2018-06-01 00:17:31.951473|2018-06-01 00:17:31.951473
NCT01027481|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2009-12-07|2009-12-07|2009-12-08|Estimate|||||||2009-12-07|2009-12-08|Estimate|December 2007||2007-12-31|November 2007|2007-11-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Ranibizumab in Patients With Branch Retinal Vein Occlusion|Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor (VEGF) Treatment in Patients With Branch Retinal Vein Occlusion (BRVO)|Completed||Phase 4|30|Actual|Medical University of Vienna|||||f||||f||||||||||2018-06-01 00:17:32.03942|2018-06-01 00:17:32.03942
NCT01027468|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|2014-01-07||2014-01-07|2009-12-07|2009-12-08|Estimate|2014-01-07|2014-02-20|Estimate||||2014-01-07|2014-02-20|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration|Functional, Morphological And Safety Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration - 3 Years Of Follow-up|Completed||N/A|160|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-06-01 00:17:32.316083|2018-06-01 00:17:32.316083
NCT01027455|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2010-06-24|2009-12-07|2009-12-08|Estimate|||||||2010-06-24|2010-06-25|Estimate|March 2010||2010-03-31|October 2009|2009-10-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|WARMIST||Warm Humid Gas Insufflation for Appendix Removal by Minimally Invasive Surgery Warm Humid Insufflation for Appendix Removal by Minimally Invasive Surgery Trial (WARMIST)|Warm Humidified Insufflation for Laparoscopic Appendicectomy in Children: a Randomised Controlled Trial|Unknown status|Recruiting|N/A|190|Anticipated|University of Auckland, New Zealand||2|||f||||t||||||||||2018-06-01 00:17:32.568107|2018-06-01 00:17:32.568107
NCT01027442|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2013-11-26|2009-12-07|2009-12-08|Estimate|||||||2013-11-26|2013-11-27|Estimate|July 2008||2008-07-31|June 2007|2007-06-30|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|stereolitho||The Use of Bone-, Tooth- and Mucosa- Supported Stereolithographic Guides for Dental Implant Placement|Conventional Versus Computer Aided Implantology|Completed||N/A|61|Actual|Istanbul University||2|||f||||f||||||||||2018-06-01 00:17:32.695492|2018-06-01 00:17:32.695492
NCT01027429|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2015-06-26|2009-12-07|2009-12-08|Estimate|||||||2015-06-26|2015-06-29|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SATT||Simplified Antibiotic Therapy for Sepsis in Young Infants|Simplified Antibiotic Regimens for the Management of Sepsis in Young Infants in First-level Facilities: Randomized Controlled Trial|Completed||Phase 3|2543|Actual|Aga Khan University||3|||f||||t||||||||||2018-06-01 00:17:32.847848|2018-06-01 00:17:32.847848
NCT01027416|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2017-10-10||2017-11-15|2009-12-04|2009-12-08|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|December 14, 2009|Actual|2009-12-14|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All treated and eligible patients.|Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients|Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients|Completed||N/A|59|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 00:17:33.227618|2018-06-01 00:17:33.227618
NCT01027403|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2015-06-02|2009-12-07|2009-12-08|Estimate|||||||2015-06-02|2015-06-04|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31||Observational|CIRCSTEM-HF||Evaluation of Circulating Levels of Adult Stem Cells in the Peripheral Blood of Patients With Acute Decompensated Heart Failure and Following Stabilization, in Comparison With Healthy Volunteers|Evaluation of Circulating Levels of Adult Stem Cells in the Peripheral Blood of Patients With Acute Decompensated Heart Failure and Following Stabilization, in Comparison With Healthy Volunteers|Completed|||30|Actual|Monash University|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 00:17:33.768926|2018-06-01 00:17:33.768926
NCT01027390|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-07|||2012-12-08|2009-12-07|2009-12-08|Estimate|||||||2012-12-08|2012-12-11|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|VIMS||Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck (VIMS, Danish Acronym)|Completed||Early Phase 1|573|Actual|University of Southern Denmark||5|||f||||f||||||||||2018-06-01 00:17:33.843384|2018-06-01 00:17:33.843384
NCT01027377|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2017-02-27|2009-12-04|2009-12-07|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2009||2009-12-31|February 2017|2017-02-28|May 2011|Actual|2011-05-31|July 2010|Actual|2010-07-31||Interventional|||Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A|An Open-Label, Crossover, Dose-Escalation, and Multi-Center Study to Determine the Safety, Tolerability, and Pharmacokinetic of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients With Severe Hemophilia A|Completed||Phase 1|16|Actual|Bioverativ Therapeutics Inc.||2|||f||||t||||||||||2018-06-01 00:17:33.945585|2018-06-01 00:17:33.945585
NCT01027364|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2014-04-14||2017-02-27|2009-12-04|2009-12-07|Estimate|2014-08-29|2014-09-04|Estimate||||2017-02-27|2017-03-28|Actual|December 2009||2009-12-31|February 2017|2017-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B|B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B|Completed||Phase 3|123|Actual|Bioverativ Therapeutics Inc.||4|||f||||t||||||||||2018-06-01 00:17:34.364171|2018-06-01 00:17:34.364171
NCT01027351|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2013-12-18||2015-02-06|2009-12-04|2009-12-07|Estimate|2014-04-04|2014-05-06|Estimate||||2015-02-06|2015-02-26|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|May 2012|Actual|2012-05-31|September 2010|Actual|2010-09-30||Interventional||The analysis was done on the all enrolled set.|Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine|A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Novartis Vaccine as Infants in Study V72P6|Completed||Phase 2|163|Actual|Novartis||6|||f||||||||||||||2018-06-01 00:17:36.159309|2018-06-01 00:17:36.159309
NCT01027338|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate||||December 2009|2009-12-31||||||||Interventional|||Tai Chi Exercise in Patients With COPD|Tai Chi Exercise in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 1|||National Center for Complementary and Integrative Health (NCCIH)||2|||f||||f||||||||||2018-06-01 00:17:37.754218|2018-06-01 00:17:37.754218
NCT01027325|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-01-10|2009-12-04|2009-12-07|Estimate|||||||2013-01-10|2013-01-14|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|August 2011|Actual|2011-08-31||Interventional|RESIST||Resistant Starch Insulin Sensitivity Trial|Effects of Resistant Starch on Lipid and Glucose Metabolism in Insulin Resistance|Completed||N/A|52|Actual|Children's Hospital & Research Center Oakland||5|||f||||t||||||||||2018-06-01 00:17:37.827301|2018-06-01 00:17:37.827301
NCT01027312|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2016-11-19|2009-12-04|2009-12-07|Estimate|||||||2016-11-19|2016-11-22|Estimate|February 2008||2008-02-29|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|AARV||Assessment of Ability Related to Vision|Reproducibility and Clinical Usefulness of AARV (Assessment of Ability Related to Vision)|Completed|||121|Actual|Wills Eye|||2||f||||f||||||||Yes|A manuscript has been written and published|2018-06-01 00:17:37.91765|2018-06-01 00:17:37.91765
NCT01027299|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2011-06-22|2009-12-04|2009-12-07|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Temporary Epicardial Cardiac Resynchronisation.|A Randomised Study of Temporary Epicardial Cardiac Resynchronisation Versus Conventional Right Ventricular Pacing in Cardiac Surgical Patients.|Unknown status|Recruiting|N/A|100|Anticipated|Cardiff and Vale University Health Board||2|||f||||f||||||||||2018-06-01 00:17:37.97726|2018-06-01 00:17:37.97726
NCT01027286|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2012-08-30||2012-10-30|2009-12-04|2009-12-07|Estimate|2012-10-30|2012-11-29|Estimate||||2012-10-30|2012-11-29|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty|Prospective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty|Completed||Phase 4|108|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 00:17:38.079288|2018-06-01 00:17:38.079288
NCT01027273|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2014-06-19||2014-07-24|2009-12-04|2009-12-07|Estimate|2014-06-19|2014-07-21|Estimate||||2014-07-24|2014-07-31|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Prevent Return of Stroke Study|Preventing Recurrence of All Inner-city Strokes Through Education|Completed||N/A|600|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 00:17:38.437197|2018-06-01 00:17:38.437197
NCT01027260|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2013-06-17|2009-12-04|2009-12-07|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation|A Randomized, Placebo Controlled Study on the Efficacy of Itopride HCI on Irritable Bowel in Patients of Irritable Bowel Syndrome With Constipation (IBS-C)|Completed||Phase 2|268|Actual|Abbott||3|||f||||f||||||||||2018-06-01 00:17:38.687544|2018-06-01 00:17:38.687544
NCT01027247|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate||||December 2009|2009-12-31||||||||Interventional|||OculusGen™ Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: a Case-Control Study||Completed||Phase 3|||Singapore National Eye Centre|||||f||||t||||||||||2018-06-01 00:17:38.879298|2018-06-01 00:17:38.879298
NCT01027234|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2010-05-25|2009-12-04|2009-12-07|Estimate|||||||2010-05-25|2010-05-26|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses|A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single-ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and Pharmacokinetics (Part A) and an Open-label Assessment of the Effect of Food on the Pharmacokinetics (Part B) of Orally Administered AZD8418|Terminated||Phase 1|40|Actual|AstraZeneca||2||Pre-Clinical Safety Tox Findings|f||||f||||||||||2018-06-01 00:17:38.924634|2018-06-01 00:17:38.924634
NCT01027221|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2017-11-16|2009-12-04|2009-12-07|Estimate|||||||2017-11-16|2017-11-17|Actual|November 2009|Actual|2009-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|IMPACT2010||Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer|Randomised Phase I/II Trial in Order to Evaluate the Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Neoadjuvant Low-Dose-Radiation Therapy in Primarily Resectable Pancreatic Cancer|Recruiting||N/A|40|Anticipated|German Cancer Research Center||4|||f||||t||||||||||2018-06-01 00:17:38.991414|2018-06-01 00:17:38.991414
NCT01027208|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2017-01-27|2009-12-04|2009-12-07|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2006||2006-12-31|January 2017|2017-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline|A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline And Who Are Taxane Resistant Who Have Completed Study CA163107 And Who Are Benefiting From Continuation On Therapy With Ixabepilone|Completed||Phase 2|20|Actual|R-Pharm||1|||f||||t||||||||||2018-06-01 00:17:39.076837|2018-06-01 00:17:39.076837
NCT01027195|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2012-08-29||2012-10-30|2009-12-04|2009-12-07|Estimate|2012-10-30|2012-11-29|Estimate||||2012-10-30|2012-11-29|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|Hip||Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty|Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty|Completed||Phase 4|140|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 00:17:39.176325|2018-06-01 00:17:39.176325
NCT01027182|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2010-03-18|2009-12-04|2009-12-07|Estimate|||||||2010-03-18|2010-03-19|Estimate|December 2009||2009-12-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers|Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers.|Completed||Phase 1|6|Actual|Changi General Hospital||1|||f||||f||||||||||2018-06-01 00:17:39.517665|2018-06-01 00:17:39.517665
NCT01027169|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-03-27|2009-12-04|2009-12-07|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2009||2009-04-30|August 2011|2011-08-31||||October 2009|Actual|2009-10-31||Interventional|||A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics|An Open-label, Parallel-group, Single Centre, Single Oral Dose Study to Investigate the Pharmacokinetics of 50 mg Safinamide in Subjects With Mild and Moderate Hepatic Impairment as Compared to Matched Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Newron Pharmaceuticals SPA||3|||f||||||||||||||2018-06-01 00:17:39.595744|2018-06-01 00:17:39.595744
NCT01027156|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Influence of a High Intensity Physical Activity Intervention on a Selection of Health Related Outcomes: An Ecological Approach||Completed||N/A|||University of the West of Scotland||1|||f||||f||||||||||2018-06-01 00:17:39.665999|2018-06-01 00:17:39.665999
NCT01027143|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2017-02-10|2009-12-04|2009-12-07|Estimate|||||||2017-02-10|2017-02-13|Actual|July 2010||2010-07-31|March 2016|2016-03-31|October 22, 2016|Actual|2016-10-22|October 22, 2016|Actual|2016-10-22||Interventional|NOOA||Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids|Obesity & Asthma: Nutrigenetic Response to Omega-3 Fatty Acids|Completed||Phase 2/Phase 3|144|Actual|Nemours Children's Clinic||2|||f||||t||||||||||2018-06-01 00:17:39.73127|2018-06-01 00:17:39.73127
NCT01027130|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate||||December 2009|2009-12-31||||||||Observational|||Haptoglobin and Preeclampsia||Completed|||||Bnai Zion Medical Center|||2||f||||f||||||||||2018-06-01 00:17:39.803764|2018-06-01 00:17:39.803764
NCT01027117|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-03-07|2009-12-04|2009-12-07|Estimate|||||||2017-03-07|2017-03-10|Actual|September 2009||2009-09-30|March 2017|2017-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Relative Bioavailability Study of Revatio for the Crushed Tablets, Extemporaneously Prepared Formulation, and the Intact Tablets at 20 mg Dose in Healthy Volunteers|A Randomised, Open-Label 3-Way Crossover Study To Investigate The Relative Bioavailability Of The Crushed Revatio 20 Mg Tablet Mixed With Apple Sauce, The Extemporaneously Prepared Suspension (EP), And The Intact Revatio 20 Mg Tablet In Healthy Volunteers Under Fasting Conditions|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:17:39.851152|2018-06-01 00:17:39.851152
NCT01027104|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate|December 2007||2007-12-31|December 2009|2009-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of a Resident Curriculum in Firearm Injury Prevention|Evaluation of a Firearm Injury Prevention Web-based Curriculum|Completed||N/A|92|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 00:17:39.912339|2018-06-01 00:17:39.912339
NCT01027091|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate|November 2008||2008-11-30|November 2009|2009-11-30|January 2011|Anticipated|2011-01-31|June 2010|Anticipated|2010-06-30||Observational|||The Study of a Safe and Cost-effective Method to Identify Patients at Low Risk of Significant Hypocalcemia After Total Thyroidectomy.|The Study of a Safe and Cost-effective Method to Identify Patients at Low Risk for the Development of Significant Hypocalcemia After Total Thyroidectomy.|Unknown status|Recruiting||120|Anticipated|G. Hatzikosta General Hospital|||2||f||||||||||||||2018-06-01 00:17:39.96419|2018-06-01 00:17:39.96419
NCT01027078|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2018-04-03|2009-12-04|2009-12-07|Estimate|||||||2018-04-03|2018-04-04|Actual|November 2009||2009-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Mechanism of Endothelial Dysfunction in Obstructive Sleep Apnea (OSA)|Mechanism of Endothelial Dysfunction in Obstructive Sleep Apnea|Recruiting|||72|Anticipated|Ohio State University|||2||f||||t||||||Samples With DNA|"~     skin biopsies~   "|||2018-06-01 00:17:40.029668|2018-06-01 00:17:40.029668
NCT01027065|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2012-10-17|2009-12-04|2009-12-07|Estimate|||||||2012-10-17|2012-10-18|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|November 2012|Anticipated|2012-11-30||Interventional|CONVERT||Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients|"A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of CYT107 (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients"|Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Anticipated|Cytheris SA||2|||f||||t||||||||||2018-06-01 00:17:40.35323|2018-06-01 00:17:40.35323
NCT01027052|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2015-03-13|2009-12-04|2009-12-07|Estimate|||||||2015-03-13|2015-03-17|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|May 2009|Actual|2009-05-31|October 2008|Actual|2008-10-31||Interventional|||Spices Inhibit the Formation and Absorption of Malondialdehyde From Hamburger Meat|Absorption, Metabolism and Antioxidant Effects of Common Herbs|Completed||N/A|10|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:17:40.44557|2018-06-01 00:17:40.44557
NCT01027039|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2016-11-08|2009-12-04|2009-12-07|Estimate|||||||2016-11-08|2016-11-10|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Will Listening to Music Make it Easier to Take a Visual Field Test?|The Effect of Mozart Music on Visual Field Testing in Glaucoma Patients: Will Music Tame the Savage Perimeter?|Completed|||160|Actual|Wills Eye|||3||f||||f||||||||Yes|A manuscript has been published.|2018-06-01 00:17:40.515453|2018-06-01 00:17:40.515453
NCT01027026|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|May 2013|Anticipated|2013-05-31|June 2010|Anticipated|2010-06-30||Interventional|ACS||The Acute Coronary Syndrome Study|The Acute Coronary Syndrome Study. Organization and Treatment of Patients With Acute Coronary Syndrome, With a Focus on Costs, Organization and Security|Unknown status|Recruiting|N/A|400|Anticipated|Ullevaal University Hospital||2|||f||||f||||||||||2018-06-01 00:17:40.578585|2018-06-01 00:17:40.578585
NCT01027013|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04||2012-01-09|2012-01-09|2009-12-04|2009-12-07|Estimate||||2012-01-09|2012-01-11|Estimate|2012-01-09|2012-01-11|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye|A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo for the Treatment of Keratoconjunctivitis Sicca (Dry Eye)|Completed||Phase 2|220|Actual|Acucela Inc.||2|||f||||f||||||||||2018-06-01 00:17:40.656907|2018-06-01 00:17:40.656907
NCT01027000|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2017-03-23||2017-05-08|2009-12-04|2009-12-07|Estimate|2017-03-23|2017-05-03|Actual||||2017-05-08|2017-06-12|Actual|February 2010||2010-02-28|May 2017|2017-05-31||||January 2016|Actual|2016-01-31||Interventional|||Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 2|68|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 00:17:40.777723|2018-06-01 00:17:40.777723
NCT01026987|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2017-01-24|2009-12-04|2009-12-07|Estimate|||||||2017-01-24|2017-01-25|Estimate|April 29, 2010|Actual|2010-04-29|January 2017|2017-01-31|June 8, 2016|Actual|2016-06-08|April 2014|Actual|2014-04-30||Interventional|||Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant|A Pilot Study of G-CSF +/- Plerixafor (AMD3100) Mobilized Donor CD34+ Enriched Peripheral Blood Mononuclear Cells for the Treatment of Allogeneic Stem Cell Transplant Recipients With Limited Donor Engraftment|Completed||Phase 1|29|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-06-01 00:17:41.400145|2018-06-01 00:17:41.400145
NCT01026974|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|2013-05-13||2014-09-18|2009-12-04|2009-12-07|Estimate|2014-02-07|2014-03-11|Estimate||||2014-09-18|2014-10-01|Estimate|February 2010||2010-02-28|September 2014|2014-09-30|May 2012|Actual|2012-05-31|September 2010|Actual|2010-09-30||Interventional|||Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine|A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9|Completed||Phase 2|120|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:17:41.527542|2018-06-01 00:17:41.527542
NCT01026961|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2016-03-02|2009-12-04|2009-12-07|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2010||2010-09-30|March 2016|2016-03-31||||November 2010|Anticipated|2010-11-30||Interventional|||Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers|A Randomized, Crossover, Double-Blind Study To Evaluate The Safety Of An Association Of Phenylephrine Hydrochloride 10mg + Acetaminophen 500mg + Dimethindene Maleate 1 Mg Compared To Phenylephrine Hydrochloride 10mg In Healthy Volunteers|Withdrawn||Phase 1/Phase 2|0|Actual|Novartis||2||Study is no longer required by Brazil health authority.|f||||f||||||||||2018-06-01 00:17:42.786105|2018-06-01 00:17:42.786105
NCT01026948|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2011-06-22||2012-01-04|2009-12-04|2009-12-07|Estimate|2012-01-04|2012-01-06|Estimate||||2012-01-04|2012-01-06|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|PRAM||Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM)|Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM)|Completed|||70|Actual|Liverpool Women's NHS Foundation Trust|||1||f||||f||||||||||2018-06-01 00:17:42.863301|2018-06-01 00:17:42.863301
NCT01026935|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2011-07-19|2009-12-04|2009-12-07|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||The Outcome After Lichtenstein Operation vs. ProGrip Patch Repair of Inguinal Hernia|The Effect of Mesh Type on Pain After Surgery for Inguinal Hernia. Randomized Clinical Trial of Lichtenstein Operation With Sutured Polypropylene Patch or Self-adhesive ProGrip Patch.|Completed||N/A|398|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-06-01 00:17:43.036092|2018-06-01 00:17:43.036092
NCT01026922|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2017-07-24|2009-12-04|2009-12-07|Estimate|||||||2017-07-24|2017-07-26|Actual|December 2009||2009-12-31|July 2017|2017-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Use of an Ambulatory Capsule to Characterize Gastrointestinal Pressure Patterns in Children|Use of an Ambulatory Capsule to Characterize Gastrointestinal Pressure Patterns in Children|Completed|||22|Actual|Nationwide Children's Hospital|||1||f||||f||||||||No||2018-06-01 00:17:43.114929|2018-06-01 00:17:43.114929
NCT01026909|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2014-11-22||2015-12-22|2009-12-03|2009-12-07|Estimate|2015-12-22|2016-01-29|Estimate||||2015-12-22|2016-01-29|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Intraarticular Corticosteroid Therapy in Perthes Disease.|Intraarticular Corticosteroid Therapy in Legg-Calve Perthes Disease: a Randomized Controlled Clinical Trial.|Terminated||N/A|3|Actual|Seattle Children's Hospital||2||low recruitment|f||||t||||||||||2018-06-01 00:17:43.186574|2018-06-01 00:17:43.186574
NCT01026896|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2009-12-04|2009-12-04|2009-12-07|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Mental Practice Efficacy in Stroke-Induced Hemiparesis|Mental Practice in Chronic Stroke-Induced Hemiparesis|Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||||||||||||2018-06-01 00:17:43.512623|2018-06-01 00:17:43.512623
NCT01026883|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2014-11-13|2009-12-04|2009-12-07|Estimate|||||||2014-11-13|2014-11-14|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|November 2012|Actual|2012-11-30|August 2011|Actual|2011-08-31||Interventional|||Evaluation of a Novel Method for Hematocrit Level Determination|Evaluation of a Novel Method for Hematocrit Level Determination|Terminated||N/A|51|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 00:17:43.589481|2018-06-01 00:17:43.589481
NCT01026870|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2015-05-28|2009-12-04|2009-12-07|Estimate|||||||2015-05-28|2015-05-29|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)|A 12-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:17:43.64921|2018-06-01 00:17:43.64921
NCT01026857|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-04|||2017-06-13|2009-12-04|2009-12-07|Estimate|||||||2017-06-13|2017-06-15|Actual|May 2006||2006-05-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||Propionyl-L-Carnitine in Ulcerative Colitis|Phase II, Parallel-group, Placebo Controlled, Double-blind, Randomised, Multicenter Study to Investigate the Efficacy of Two Dosages of Propionyl-L-Carnitine Colon Release Tablets in Patients Affected by Ulcerative Colitis Under Oral Stable Treatment|Completed||Phase 2|121|Actual|sigma-tau i.f.r. S.p.A.||3|||f||||f||||||||||2018-06-01 00:17:43.722895|2018-06-01 00:17:43.722895
NCT01026844|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2012-11-25||2017-01-27|2009-12-03|2009-12-04|Estimate|2013-06-25|2013-07-31|Estimate||||2017-01-27|2017-01-30|Estimate|July 2007||2007-07-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced NSCLC|Terminated||Phase 1|27|Actual|Massachusetts General Hospital|Early termination of study leading to small numbers of subjects analyzed|2||slow enrollment|f||||t||||||||||2018-06-01 00:17:43.831494|2018-06-01 00:17:43.831494
NCT01026480|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2017-03-16|2009-12-03|2009-12-04|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2009||2009-11-30|March 2017|2017-03-31|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Observational|IPAA||Ileal Pouch-Anal Anastomosis Registry|Ileal Pouch-Anal Anastomosis (IPAA) Registry|Terminated|||936|Actual|Boston Medical Center|||1|Researchers leading this study have left BMC|f||||f||||||||||2018-06-01 00:17:52.656735|2018-06-01 00:17:52.656735
NCT01026831|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2011-08-09||2017-05-29|2009-12-02|2009-12-04|Estimate|2011-08-09|2011-09-13|Estimate||||2017-05-29|2017-06-21|Actual|January 6, 2010|Actual|2010-01-06|May 2017|2017-05-31|September 17, 2010|Actual|2010-09-17|September 17, 2010|Actual|2010-09-17||Interventional|||Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)|A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients With Open-Angle Glaucoma and Ocular Hypertension|Completed||Phase 3|643|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:17:44.12027|2018-06-01 00:17:44.12027
NCT01026818|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2013-09-10||2013-12-12|2009-12-03|2009-12-04|Estimate|2013-09-10|2013-11-14|Estimate||||2013-12-12|2014-01-14|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|REACTT|All randomized participants who received at least 1 dose of study drug.|A Study of Tadalafil After Radical Prostatectomy|A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy|Completed||Phase 4|583|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-06-01 00:17:44.497493|2018-06-01 00:17:44.497493
NCT01026805|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2009-04-30||2012-11-20|2009-11-03|2009-12-04|Estimate|2009-11-03|2009-12-04|Estimate||||2012-11-20|2012-11-22|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator|Retrospective Case Review - Clinical Evaluation of the Interlace Medical 1st Generation Hysteroscopic Morcellator|Completed|||11|Actual|Hologic, Inc.|Small number of cases; retrospective study design||1||f||||f||||||||||2018-06-01 00:17:47.680948|2018-06-01 00:17:47.680948
NCT01026792|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2015-07-06||2015-08-10|2009-12-03|2009-12-04|Estimate|2015-08-10|2015-09-10|Estimate||||2015-08-10|2015-09-10|Estimate|December 2009||2009-12-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional||All eligible patients|Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery|A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix|Completed||Phase 2|38|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:17:48.008867|2018-06-01 00:17:48.008867
NCT01026779|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2017-08-22|2009-12-03|2009-12-04|Estimate|||||||2017-08-22|2017-08-24|Actual|July 2009||2009-07-31|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island|Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island: Active Hospital-Based Surveillance, Serotype Surveillance and a Case-Control Study|Active, not recruiting|||560|Anticipated|Lifespan|||2||f||||f|f|f||||Samples Without DNA|"~     Stools~   "|No|There is no plan to share IPD since the study uses a deidentified dataset and deidentified stool specimens for serotype analysis|2018-06-01 00:17:48.301652|2018-06-01 00:17:48.301652
NCT01026766|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Effects of Heat and Moisture Exchanger in Combination With Air Forced Warming Blankets or Warming Intravenous Solutions on Intraoperative Hypothermia Prevention in Obese and Non Obese Patients During Intravenous Anesthesia||Completed|||40|Actual|UPECLIN HC FM Botucatu Unesp|||4||f||||t||||||||||2018-06-01 00:17:48.374806|2018-06-01 00:17:48.374806
NCT01026753|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-06-07|2009-12-03|2009-12-04|Estimate|||||||2013-06-07|2013-06-11|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba|Innovative Tools to Improve Colorectal Cancer Screening Rates in Manitoba|Completed||N/A|2395|Actual|University of Manitoba||2|||f||||t||||||||||2018-06-01 00:17:48.440732|2018-06-01 00:17:48.440732
NCT01026740|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-07-27|2009-12-03|2009-12-04|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers|An Exploratory Study to Evaluate the Penetration of Ceftobiprole Into Soft Tissue Determined by In Vivo Microdialysis in Healthy Volunteers|Completed||Phase 1|15|Actual|Basilea Pharmaceutica||1|||f||||f||||||||||2018-06-01 00:17:48.518118|2018-06-01 00:17:48.518118
NCT01026727|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-06-10|2009-12-03|2009-12-04|Estimate|||||||2010-06-10|2010-06-14|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy|A Phase 2b Multicenter, Randomized, Open Label, Comparative Trial of MPC-4326 in Combination With a Two to Three Drug Optimized Background Regimen Versus an Optimized, Three to Four Drug Antiretroviral Regimen for the Treatment of Triple Class Antiretroviral Experienced, HIV-1 Infected Subjects Failing Current Therapy|Terminated||Phase 2|2|Actual|Myrexis Inc.||2||For strategic buisness reasons.|f||||t||||||||||2018-06-01 00:17:48.585151|2018-06-01 00:17:48.585151
NCT01026714|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-01-10|2009-12-03|2009-12-04|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||CYP2C9 Activity Evaluated With a Simple Finger Prick|Evaluation of the CYP2C9 Activity With Dried Blood Spots on Filter Paper Obtained With a Simple Finger Prick|Completed||Phase 1/Phase 2|10|Anticipated|University Hospital, Geneva||3|||f||||||||||||||2018-06-01 00:17:48.68815|2018-06-01 00:17:48.68815
NCT01026701|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2014-04-24|2009-12-03|2009-12-04|Estimate|||||||2014-04-24|2014-04-28|Estimate|March 2008||2008-03-31|April 2014|2014-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.|Observational Study of Osteoblast Activity in Velcade�(Bortezomib) IV Treated Multiple Myeloma Patients.|Completed|||104|Actual|Janssen Korea, Ltd., Korea|||1||f||||t||||||||||2018-06-01 00:17:48.749642|2018-06-01 00:17:48.749642
NCT01026688|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-11-21|2009-12-03|2009-12-04|Estimate|||||||2014-11-21|2014-11-24|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Type 2 Diabetes|Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Type 2 Diabetes|Completed||N/A|1592|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 00:17:48.81638|2018-06-01 00:17:48.81638
NCT01026662|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2014-11-28|2009-12-03|2009-12-04|Estimate|||||||2014-11-28|2014-12-02|Estimate|November 2009||2009-11-30|November 2014|2014-11-30||||April 2010|Actual|2010-04-30||Observational|eMatrixCO2||In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue|In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue|Unknown status|Active, not recruiting||5|Anticipated|Syneron Medical|||1||f||||||||||Samples Without DNA|"~     Abdominal Skin tissue~   "|||2018-06-01 00:17:50.016646|2018-06-01 00:17:50.016646
NCT01026649|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2016-04-19|2009-12-03|2009-12-04|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The 2-stage Approach for Reducing Posterior Wall Puncture During the Internal Jugular Vein Catheterization||Completed||N/A|334|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:17:50.143557|2018-06-01 00:17:50.143557
NCT01026636|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-07-26|2009-12-03|2009-12-04|Estimate|||||||2012-07-26|2012-07-27|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age|An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients =3 Months to 17<18 Years of Age, Undergoing Treatment With Systemic Antibiotics|Completed||Phase 1|64|Actual|Basilea Pharmaceutica||1|||f||||f||||||||||2018-06-01 00:17:50.212063|2018-06-01 00:17:50.212063
NCT01026623|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2016-01-21|2009-12-03|2009-12-04|Estimate|||||||2016-01-21|2016-01-22|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer|Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration-Resistant Prostate Cancer (CRPC)|Completed||Phase 1/Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:17:50.286956|2018-06-01 00:17:50.286956
NCT01026610|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-10-04|2009-12-03|2009-12-04|Estimate|||||||2012-10-04|2012-10-05|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B|A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy and Safety at Week 24 of the Treatment for Selecting Optimal Dose|Completed||Phase 2|115|Actual|LG Life Sciences||3|||f||||f||||||||||2018-06-01 00:17:50.415072|2018-06-01 00:17:50.415072
NCT01026597|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2015-01-24|2009-12-02|2009-12-04|Estimate|||||||2015-01-24|2015-01-27|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers|A Randomized,Double-Blind,Placebo-Controlled,Ascending,Single-Dose Study of the Safety,Tolerability and Bioeffect of Intravenously Administered REGN727 in Healthy Volunteers|Completed||Phase 1|40|Actual|Regeneron Pharmaceuticals||5|||f||||f||||||||||2018-06-01 00:17:50.520061|2018-06-01 00:17:50.520061
NCT01026584|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-02-09|2009-12-03|2009-12-04|Estimate|||||||2012-02-09|2012-02-13|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Aripiprazole in First Episode Psychosis|Efficacy and Safety of Aripiprazole in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study|Completed||Phase 4|55|Actual|Chonbuk National University Hospital||1|||f||||f||||||||||2018-06-01 00:17:50.616216|2018-06-01 00:17:50.616216
NCT01026571|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2018-01-16|2009-12-03|2009-12-04|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2009||2009-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|BAV Genetics||Identification of Genetic Mechanisms of Bicuspid Aortic Valve Disease|Identification of Genetic Mechanisms of Bicuspid Aortic Valve Disease|Recruiting|||4000|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||Samples With DNA|"~     Collection of salivary DNA~   "|||2018-06-01 00:17:50.799182|2018-06-01 00:17:50.799182
NCT01026558|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2012-08-27|2009-12-03|2009-12-04|Estimate|||||||2012-08-27|2012-08-28|Estimate|August 2007||2007-08-31|August 2012|2012-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients|Open-Label, Single Dose, Parallel Group Pharmacokinetic Study of Ceftobiprole in Morbidly Obese and Non-Obese Patients|Completed||Phase 1|25|Actual|Basilea Pharmaceutica||2|||f||||f||||||||||2018-06-01 00:17:50.88246|2018-06-01 00:17:50.88246
NCT01026545|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2011-05-03|2009-12-03|2009-12-04|Estimate|||||||2011-05-03|2011-05-04|Estimate|December 2009||2009-12-31|May 2011|2011-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects|A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects|Completed||Phase 1|39|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 00:17:50.973275|2018-06-01 00:17:50.973275
NCT01026532|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2017-10-13|2009-12-03|2009-12-04|Estimate|||||||2017-10-13|2017-10-17|Actual|August 24, 2011|Actual|2011-08-24|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Functional Activity of Airway Eosinophils in Allergic Disease|Functional Activity of Airway Eosinophils in Allergic Disease|Recruiting||N/A|38|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||Yes||2018-06-01 00:17:51.091316|2018-06-01 00:17:51.091316
NCT01026519|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-09-27|2009-12-02|2009-12-04|Estimate|||||||2013-09-27|2013-09-30|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis|A Single-dose, Double-Blind, Placebo-Controlled, Parallel Group Safety, Tolerability and Pharmacodynamic Study of Subcutaneous REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate|Completed||Phase 1|32|Actual|Regeneron Pharmaceuticals||4|||f||||||||||||||2018-06-01 00:17:51.172413|2018-06-01 00:17:51.172413
NCT01026506|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||c9,t11-CLA in Children and Adolescents With Allergic Asthma|Pilot Study on the Effects of Oral Intervention With c9,t11-conjugated Linoleic Acid in Children and Adolescents With Allergic Asthma|Completed||N/A|29|Actual|University of Jena|||||f||||t||||||||||2018-06-01 00:17:51.256384|2018-06-01 00:17:51.256384
NCT01026493|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2017-01-17||2017-06-02|2009-12-03|2009-12-04|Estimate|2017-06-02|2017-07-02|Actual||||2017-06-02|2017-07-02|Actual|July 2010||2010-07-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|May 2014|Actual|2014-05-31||Interventional||Eligible patients|Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma|A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma|Completed||Phase 1/Phase 2|257|Actual|Radiation Therapy Oncology Group||8|||f||||t|t|f||||||No||2018-06-01 00:17:51.397437|2018-06-01 00:17:51.397437
NCT01026467|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2017-05-25|2009-12-03|2009-12-04|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2010|Actual|2010-01-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer|Completed|||45|Actual|Wake Forest University Health Sciences|||1||f||||t|f|f||||||||2018-06-01 00:17:52.735307|2018-06-01 00:17:52.735307
NCT01026454|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2013-11-15||2014-03-10|2009-12-03|2009-12-04|Estimate|2014-01-14|2014-03-05|Estimate||||2014-03-10|2014-04-08|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|ACV-VAL||Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons|A Randomized, Open-label, Crossover Trial of the Effect of High-dose Daily HSV-2 Suppressive Therapy on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons|Completed||Phase 4|32|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 00:17:52.839959|2018-06-01 00:17:52.839959
NCT01026441|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2011-05-04|2009-12-03|2009-12-04|Estimate|||||||2011-05-04|2011-05-05|Estimate|October 2008||2008-10-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Clinical Study to Evaluate the Safety and Efficacy of the Vela100|Clinical Study to Evaluate the Safety and Efficacy of the Vela100/eShape Uno Device for Cellulite and Circumference Reduction|Terminated||Phase 4|60|Anticipated|Syneron Medical||1||Product was not developed and study was cancelled|f||||||||||||||2018-06-01 00:17:53.100509|2018-06-01 00:17:53.100509
NCT01026428|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-03-27|2009-12-03|2009-12-04|Estimate|||||||2013-03-27|2013-03-29|Estimate|September 2009||2009-09-30|January 2012|2012-01-31||||July 2010|Actual|2010-07-31||Interventional|||A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics|A Randomised, Double-blind, Placebo-controlled, Two-period, Two-sequence-crossover Interaction Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease|Completed||Phase 1/Phase 2|24|Actual|Newron Pharmaceuticals SPA||2|||f||||f||||||||||2018-06-01 00:17:53.187167|2018-06-01 00:17:53.187167
NCT01026415|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-12-17|2009-12-02|2009-12-04|Estimate|||||||2014-12-17|2014-12-18|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)|An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations|Completed||Phase 1|73|Actual|Seattle Genetics, Inc.||4|||t||||f||||||||||2018-06-01 00:17:53.279941|2018-06-01 00:17:53.279941
NCT01026402|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2015-10-30||2016-01-13|2009-12-03|2009-12-04|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Safety Analysis Set - All patients that received at least 1 dose of AZD2014. This includes dosed patients who are not evaluable for dose escalation decision purposes.|Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014|A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTor Kinase Inhibitor AZD2014 Administered Orally to Patients With Advanced Solid Malignancies|Completed||Phase 1|172|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:17:53.587695|2018-06-01 00:17:53.587695
NCT01026389|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2012-11-14||2012-11-14|2009-12-03|2009-12-04|Estimate|2012-11-14|2012-12-11|Estimate||||2012-11-14|2012-12-11|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|DALIA||Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease|Efficacy Evaluation of Dotarem®-Enhanced MRA Compared to Gadovist®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Limb Arterial Diseases|Completed||Phase 4|189|Actual|Guerbet||2|||f||||f||||||||||2018-06-01 00:18:00.612578|2018-06-01 00:18:00.612578
NCT01026376|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-04-17|2009-12-03|2009-12-04|Estimate|||||||2013-04-17|2013-04-18|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Expanded Access|||An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)|An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)|No longer available|||||Janssen-Cilag Farmaceutica Ltda.|||||f||||||||||||||2018-06-01 00:18:00.997055|2018-06-01 00:18:00.997055
NCT01026363|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2015-09-21|2009-12-02|2009-12-04|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease|hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||Inadequate enrollment|f||||f||||||||||2018-06-01 00:18:01.080442|2018-06-01 00:18:01.080442
NCT01026350|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|January 2010||2010-01-31|November 2009|2009-11-30||||January 2011|Anticipated|2011-01-31||Interventional|||Safety and Efficacy of Oral Colostrum Derived Anti Influenza Antibodies in Healthy Volunteers||Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-06-01 00:18:01.17094|2018-06-01 00:18:01.17094
NCT01026337|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2015-12-14|2009-12-02|2009-12-04|Estimate|||||||2015-12-14|2015-12-15|Estimate|April 2009||2009-04-30|December 2015|2015-12-31||||April 2013|Actual|2013-04-30||Interventional|||Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer|An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic or Locally Advanced Renal Cell Carcinoma|Unknown status|Active, not recruiting|N/A|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:18:01.256489|2018-06-01 00:18:01.256489
NCT01026324|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2016-02-09||2017-03-03|2009-12-03|2009-12-04|Estimate|2016-06-22|2016-08-03|Estimate||||2017-03-03|2017-04-04|Actual|September 2009|Actual|2009-09-30|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Dinaciclib in Treating Patients With Stage III-IV Melanoma|A Phase 1/2 Study of SCH727965 in Patients With Malignant Melanoma|Terminated||Phase 1/Phase 2|12|Actual|National Cancer Institute (NCI)||1||Slow accrual|f||||||||||||||2018-06-01 00:18:01.384936|2018-06-01 00:18:01.384936
NCT01026311|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2012-05-01|2009-12-03|2009-12-04|Estimate|||||||2012-05-01|2012-05-03|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Coenzyme Q10 in Older Athletes Treated With Statin Medications|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Coenzyme Q10 in Improving Mitochondrial Function in Older Athletes Treated With Statin Medications|Completed||Phase 4|20|Actual|Ochsner Health System||2|||f||||t||||||||||2018-06-01 00:18:01.803144|2018-06-01 00:18:01.803144
NCT01026298|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2018-01-02|2009-12-03|2009-12-04|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2007|Actual|2007-03-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|||Asthma and Obstructive Sleep Apnea (OSA)|The Relationship Between Asthma and Obstructive Sleep Apnea (OSA) - A Pilot Study of the Effects of OSA and Its Treatment on Asthma|Active, not recruiting||N/A|12|Actual|University of Wisconsin, Madison||2|||f||||t||||||||No||2018-06-01 00:18:01.885425|2018-06-01 00:18:01.885425
NCT01026285|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-06-21|2009-12-03|2009-12-04|Estimate|||||||2013-06-21|2013-06-24|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics|Observational, Non-interventional Registry to Assess Medication Usage Patterns in Clinical Routine Practice, in Subjects Receiving Antipsychotic Treatment With Risperidone Long Acting Injectable (Gluteal or Deltoid) or Oral Antipsychotics|Completed|||1085|Actual|Janssen-Cilag International NV|||1||f||||f||||||||||2018-06-01 00:18:01.984502|2018-06-01 00:18:01.984502
NCT01026272|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-07-09|2009-12-03|2009-12-04|Estimate|||||||2010-07-09|2010-07-13|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|May 2011|Anticipated|2011-05-31|January 2011|Anticipated|2011-01-31||Observational|NIMMS||Novel Immune Markers in Patients With Multiple Sclerosis|Quantification of Novel Immune Markers in Human Serum of Patients With MS|Unknown status|Recruiting||120|Anticipated|University of Washington|||2||f||||f||||||||||2018-06-01 00:18:02.44299|2018-06-01 00:18:02.44299
NCT01026259|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Local Warming of Surgical Incisions|Local Warming: Effects on Wound Infection and Healing|Completed||Phase 3|146|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 00:18:02.512387|2018-06-01 00:18:02.512387
NCT01026246|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-03-28|2009-12-03|2009-12-04|Estimate|||||||2013-03-28|2013-03-29|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults|Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 00:18:02.578631|2018-06-01 00:18:02.578631
NCT01026233|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-12-11|2009-12-03|2009-12-04|Estimate|||||||2014-12-11|2014-12-12|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Cardiac Safety Study of Brentuximab Vedotin (SGN-35)|An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies|Completed||Phase 1|52|Actual|Seattle Genetics, Inc.||1|||t||||f||||||||||2018-06-01 00:18:02.728464|2018-06-01 00:18:02.728464
NCT01026220|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2017-02-08||2017-04-18|2009-12-03|2009-12-04|Estimate|2017-04-18|2017-05-30|Actual||||2017-04-18|2017-05-30|Actual|December 2009||2009-12-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|March 2012|Actual|2012-03-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma|A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma|Completed||Phase 3|166|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 00:18:02.90666|2018-06-01 00:18:02.90666
NCT01026207|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-10-22|2009-12-03|2009-12-04|Estimate|||||||2013-10-22|2013-10-23|Estimate|August 2009||2009-08-31|February 2011|2011-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Portable Monitoring Device for the Diagnosis of Sleep Apnea in Patients With Chronic Obstructive Pulmonary Disease|Validation of a Portable Monitoring Device for the Diagnosis of Obstructive Sleep Apnea Syndrome in Patients With Chronic Obstructive Pulmonary Disease|Terminated|||72|Actual|Associação Fundo de Incentivo à Pesquisa|||1|the data was completed.|f||||t||||||||||2018-06-01 00:18:03.7919|2018-06-01 00:18:03.7919
NCT01026194|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2013-08-21||2014-01-14|2009-12-02|2009-12-04|Estimate|2013-08-21|2013-10-28|Estimate||||2014-01-14|2014-01-16|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes|A Phase III Study of MP-513 in Combination With Thiazolidinedione in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|204|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 00:18:03.89319|2018-06-01 00:18:03.89319
NCT01026181|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2016-12-08||2017-05-03|2009-12-03|2009-12-04|Estimate|2017-05-03|2017-10-03|Actual||||2017-05-03|2017-10-03|Actual|September 2008||2008-09-30|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Gastric Procedures for Obesity|Phase II Study of Comparing Outcomes of Laparoscopic Sleeve Gastrectomy, Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Gastric Banding to Treat Morbid Obesity|Completed|||150|Actual|University of Alberta|||3||f||||f||||||||||2018-06-01 00:18:04.854444|2018-06-01 00:18:04.854444
NCT01026155|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate||||December 2009|2009-12-31||||||||Interventional|||Respiratory Muscle Endurance Training in Obese Patients|Respiratory Muscle Endurance Training in Obese Patients|Completed||N/A|20|Actual|Fondation Edith Seltzer||2|||f||||f||||||||||2018-06-01 00:18:05.199054|2018-06-01 00:18:05.199054
NCT01026142|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|2016-08-17||2017-08-14|2009-12-03|2009-12-04|Estimate|2016-08-17|2016-10-13|Estimate||||2017-08-14|2017-09-13|Actual|January 26, 2010|Actual|2010-01-26|August 2017|2017-08-31|August 7, 2017|Actual|2017-08-07|May 29, 2015|Actual|2015-05-29||Interventional|||A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)|A Multicenter Randomized Phase III Study to Compare the Combination Trastuzumab and Capecitabine, With or Without Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer That Have Progressed After One Line of Trastuzumab-Based Therapy in the Metastatic Setting (PHEREXA)|Completed||Phase 3|452|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:18:05.35663|2018-06-01 00:18:05.35663
NCT01026129|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2010-07-13|2009-12-03|2009-12-04|Estimate|||||||2010-07-13|2010-07-14|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy of Remifentanil Compared to Lidocaine on the Incidence of Coughing During Emergence of Anesthesia|Efficacy of a Bolus Dose of Remifentanil Compared to a Bolus Dose of Intravenous lidocaïne on the Incidence of Coughing During Emergence of Anesthesia.|Completed||N/A|93|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||f||||||||||2018-06-01 00:18:06.405667|2018-06-01 00:18:06.405667
NCT01026116|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||December 2017|Anticipated|2017-12-31||Interventional|PAY||A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old||Unknown status|Recruiting|Phase 3|1664|Anticipated|Fudan University|||||f||||f||||||||||2018-06-01 00:18:06.471373|2018-06-01 00:18:06.471373
NCT01026103|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|2014-01-29||2014-01-29|2009-12-03|2009-12-04|Estimate|2014-01-29|2014-03-14|Estimate||||2014-01-29|2014-03-14|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||30 patients consented; 1 patient was withdrawn by physician for elevated liver function test. Twenty-nine (29) patients had baseline characteristics but 1 did not receive study device in error leaving 28 patients enrolled.|Tri Staple Technology Stapler Used in Gastric Bypass|A Prospective, Single-center Investigation of the Safety and Performance of the Endo GIA™ Stapler With Endo GIA™ Sulu With Tri-Staple™ Technology in a Gastric Bypass Procedure|Completed||N/A|28|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-06-01 00:18:06.690081|2018-06-01 00:18:06.690081
NCT01026090|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-08-05|2009-12-03|2009-12-04|Estimate|||||||2014-08-05|2014-08-06|Estimate|November 2009||2009-11-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)|A Phase IV, Double-blind, Placebo-controlled, Canadian Multicentre Study Comparing Two Treatment Strategies of Dronedarone Administration Following ELECTive caRdioversion for Prevention of Symptomatic Atrial Fibrillation (AF) Recurrence|Terminated||Phase 4|292|Actual|Sanofi||2||'Sponsor decision following recruitment issues, not related to any safety concerns in the study|f||||t||||||||||2018-06-01 00:18:06.882712|2018-06-01 00:18:06.882712
NCT01026077|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2018-04-01|2009-12-03|2009-12-04|Estimate|||||||2018-04-01|2018-04-03|Actual|November 2009||2009-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|SPR||The Savella Pregnancy Registry|The Savella Pregnancy Registry|Recruiting|||350|Anticipated|INC Research|||1||f||||t||||||||No||2018-06-01 00:18:07.020573|2018-06-01 00:18:07.020573
NCT01026064|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2017-07-24|2009-12-03|2009-12-04|Estimate|||||||2017-07-24|2017-07-25|Actual|June 4, 2009|Actual|2009-06-04|July 2017|2017-07-31|November 27, 2009|Actual|2009-11-27|November 27, 2009|Actual|2009-11-27||Interventional|||Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides|Utility of the Cantharidin-induced Skin Blister Assay for Evaluation of Anti-inflammatory Effects of Macrolides in Healthy Volunteers|Completed||Phase 1|44|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:18:07.090755|2018-06-01 00:18:07.090755
NCT01026051|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03||2012-05-08|2012-05-10|2009-12-03|2009-12-04|Estimate||||2012-05-08|2012-05-10|Estimate|2012-05-10|2012-05-15|Estimate|October 2010||2010-10-31|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|September 2011|Actual|2011-09-30||Interventional|||Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma|A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma|Terminated||Phase 2|5|Actual|Mannkind Corporation||||Financial/Business Reasons|f||||f||||||||||2018-06-01 00:18:07.2479|2018-06-01 00:18:07.2479
NCT01026038|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2011-10-25||2012-01-05|2009-12-02|2009-12-04|Estimate|2012-01-05|2012-02-08|Estimate||||2012-01-05|2012-02-08|Estimate|April 2010||2010-04-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.|A Phase 3, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Pneumococcal Conjugate Vaccine in Healthy Children Who Have Been Previously Immunized With a 4-Dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 6096A1-008-EU and the Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Administered at Least 24 Months After the Last Toddler Dose of Pneumococcal Conjugate Vaccine|Completed||Phase 3|263|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:18:07.400782|2018-06-01 00:18:07.400782
NCT01026025|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-08-05|2009-12-03|2009-12-04|Estimate|||||||2013-08-05|2013-08-07|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Interventional|||Duet TRS Used in Pulmonary Resections|A Prospective, Multi-Center Evaluation of Endo GIA Staplers With Endo GIA Single Use Loading Units (SULUs) With Duet TRS TM in a Pulmonary Resection|Withdrawn||N/A|0|Actual|Medtronic - MITG||1||Sponsor is no longer pursuing this study|f||||f||||||||||2018-06-01 00:18:09.307817|2018-06-01 00:18:09.307817
NCT01026012|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2012-12-06||2014-12-18|2009-12-03|2009-12-04|Estimate|2014-12-18|2014-12-19|Estimate||||2014-12-18|2014-12-19|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Rega Stress||Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing|Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing|Completed||N/A|40|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 00:18:09.362677|2018-06-01 00:18:09.362677
NCT01025999|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2016-03-29|2009-12-03|2009-12-04|Estimate|||||||2016-03-29|2016-03-31|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Mechanisms of Glycemic Improvement After Gastrointestinal Surgery|Mechanisms of Glycemic Improvement After Gastrointestinal Surgery|Completed|||7|Actual|University of Washington|||1||f||||t||||||Samples Without DNA|"~     Plasma collected to measure markers of metabolic activity.~   "|||2018-06-01 00:18:09.482037|2018-06-01 00:18:09.482037
NCT01025986|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|July 2009||2009-07-31|December 2009|2009-12-31||||||||Observational|||Uveitis in Relation to Perceived Stress: A Prospective Study|Uveitis in Relation to Perceived Stress: A Prospective Study|Unknown status|Recruiting||200|Anticipated|The New York Eye & Ear Infirmary|||1||f||||f||||||||||2018-06-01 00:18:10.572166|2018-06-01 00:18:10.572166
NCT01025973|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2018-05-02|2009-12-03|2009-12-04|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2009||2009-10-31|May 2018|2018-05-31|February 2013|Actual|2013-02-28|May 2011|Actual|2011-05-31||Observational|DG7||Evaluation and Validation of New Biomarkers by Mass Spectrometry|A New Approach by Mass Spectrometry for Evaluation and Validation of New Biomarkers of Fetus and Mother|Completed|||99|Actual|Université de Sherbrooke|||2||f||||f|f|f||||Samples Without DNA|"~     Urine, whole blood, cord blood, plasma~   "|No||2018-06-01 00:18:10.655021|2018-06-01 00:18:10.655021
NCT01025960|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-03-26|2009-12-02|2009-12-04|Estimate|||||||2012-03-26|2012-03-27|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Comparison of Methods to Detect Polyps During Colonoscopy|Comparison of Detection of Polyps During Both Insertion and Withdrawal Phases of Colonoscopy Versus the Standard Practice of Detection of Polyps During the Withdrawal Phase of Colonoscopy: A Prospective Quality Improvement Study|Completed||N/A|768|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 00:18:10.721968|2018-06-01 00:18:10.721968
NCT01025947|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2010-06-25|2009-12-03|2009-12-04|Estimate|||||||2010-06-25|2010-06-28|Estimate|March 2009||2009-03-31|June 2010|2010-06-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|CRYPTONITE||"Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder (ILR)"|Observational Study on Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder|Unknown status|Recruiting||100|Anticipated|University of Valencia|||1||f||||f||||||||||2018-06-01 00:18:10.788675|2018-06-01 00:18:10.788675
NCT01025921|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2013-05-31|2009-12-03|2009-12-04|Estimate|||||||2013-05-31|2013-06-03|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TRAMA||Tracheobronchitis Prevention Trial|Study of Inhaled Antibiotics for Prevention of Tracheobronchitis and Ventilator Associated Pneumonia|Completed||N/A|84|Actual|University of Thessaly||2|||f||||t||||||||||2018-06-01 00:18:10.937201|2018-06-01 00:18:10.937201
NCT01025908|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2010-01-29|2009-12-03|2009-12-04|Estimate|||||||2010-01-29|2010-02-01|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|April 2007|Actual|2007-04-30|August 2006|Actual|2006-08-31||Interventional|||Cognitive Behavior Psychotherapy in Panic Disorder|Cognitive-behavioural Therapyin Panic Disorder: the Preparation of Patients With Panic Disorder for Interoceptive and in Vivo Agoraphobic Exposure|Completed||N/A|50|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-06-01 00:18:11.012532|2018-06-01 00:18:11.012532
NCT01025895|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|January 2010||2010-01-31|July 2009|2009-07-31|January 2013|Anticipated|2013-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Anterior Cruciate Ligament (ACL) Reconstruction: Single Bundle Versus Double Bundle||Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-06-01 00:18:11.989859|2018-06-01 00:18:11.989859
NCT01025882|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2009-12-03|2009-12-03|2009-12-04|Estimate|||||||2009-12-03|2009-12-04|Estimate|October 2009||2009-10-31|October 2009|2009-10-31||||October 2014|Anticipated|2014-10-31||Interventional|||Stereotactic Body Radiation Therapy With or Without Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|Phase I Study of Margin-Intense Combination Therapy for Patients With Potentially Resectable Pancreatic Adenocarcinoma|Unknown status|Recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:18:12.071638|2018-06-01 00:18:12.071638
NCT01025869|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2016-01-08|2009-12-03|2009-12-04|Estimate|||||||2016-01-08|2016-01-12|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|November 2010|Actual|2010-11-30||Interventional|VANTAGE-1||The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries|The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries|Terminated||N/A|31|Actual|Atrium Medical Corporation||1||Terminated following completion of 2 year time point: Sponsor decision|f||||t||||||||||2018-06-01 00:18:12.155086|2018-06-01 00:18:12.155086
NCT01025856|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-12-03|2009-12-03|2009-12-04|Estimate|||||||2012-12-03|2012-12-05|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes|Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes|Completed||N/A|45|Actual|Federico II University||4|||f||||f||||||||||2018-06-01 00:18:12.230818|2018-06-01 00:18:12.230818
NCT01025843|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2016-01-28||2017-05-10|2009-12-02|2009-12-04|Estimate|2016-01-28|2016-02-26|Estimate||||2017-05-10|2017-06-12|Actual|December 1, 2009|Actual|2009-12-01|May 2017|2017-05-31|May 1, 2010|Actual|2010-05-01|May 1, 2010|Actual|2010-05-01||Interventional||All randomized participants|Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)|A Single Dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of MK5478 in Subjects and in Patients With Hypertension|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-06-01 00:18:12.353412|2018-06-01 00:18:12.353412
NCT01025830|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2009-04-21||2009-12-31|2009-11-03|2009-12-04|Estimate|2009-11-03|2009-12-04|Estimate||||2009-12-31|2010-01-05|Estimate|February 2006||2006-02-28|December 2009|2009-12-31|March 2008|Actual|2008-03-31|June 2006|Actual|2006-06-30||Interventional|||Triomune Bioequivalence With Innovators|Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults|Completed||Phase 4|20|Actual|Makerere University|Stavudine (40mg) was used whereas currently it is Stavudine(30mg) that is recommended for usage. So our results may not be applicable to patients on Stavudine 30mg.|2|||f||||f||||||||||2018-06-01 00:18:13.611628|2018-06-01 00:18:13.611628
NCT01025817|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-03-03||2015-10-13|2009-12-03|2009-12-04|Estimate|2014-06-05|2014-06-06|Estimate||||2015-10-13|2015-11-11|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||"Full Analysis Set (FAS) consisted of all participants randomized after transplantation.~*The discrepancy with the Ns is that there are 613 participants overall and 610 in the safety population."|Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients|A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients|Completed||Phase 3|613|Actual|Novartis|HLA mismatches ≥3, everolimus group 261 vs MMF group 240|2|||f||||t||||||||||2018-06-01 00:18:13.947628|2018-06-01 00:18:13.947628
NCT01025804|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2016-03-03|2009-12-03|2009-12-04|Estimate|||||||2016-03-03|2016-03-04|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06|Post-marketing Surveillance Study of the Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06|Completed|||15|Actual|Aarhus University Hospital|||1||f||||f||||||Samples Without DNA|"~     Serum is retained for measurement of enzyme activities and antibodies~   "|||2018-06-01 00:18:15.393478|2018-06-01 00:18:15.393478
NCT01025791|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2015-06-23|2009-12-03|2009-12-04|Estimate|||||||2015-06-23|2015-06-24|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Single Dose Study of MK8266 (8266-001)|A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:18:15.462609|2018-06-01 00:18:15.462609
NCT01025778|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2015-03-30|2009-12-03|2009-12-04|Estimate|||||||2015-03-30|2015-03-31|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia|Clofarabine Based Remission Induction Followed by Haploidentical Stem Cell Transplantation in Children With Refractory Hematological Malignancies|Completed||Phase 2|7|Actual|Lund University Hospital||1|||f||||f||||||||||2018-06-01 00:18:15.523786|2018-06-01 00:18:15.523786
NCT01025765|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-11-23|2009-12-03|2009-12-04|Estimate|||||||2012-11-23|2012-11-27|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin|An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|National Taiwan University Hospital||4|||f||||f||||||||||2018-06-01 00:18:15.604232|2018-06-01 00:18:15.604232
NCT01025752|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-03|||2016-07-13|2009-12-03|2009-12-04|Estimate|||||||2016-07-13|2016-07-15|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Interactive Voice Response (IVR)-Based Treatment for Chronic Low Back Pain|IVR-based Cognitive Behavior Therapy for Chronic Low Back|Completed||N/A|134|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-06-01 00:18:15.66947|2018-06-01 00:18:15.66947
NCT01025739|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2015-04-27|2009-12-02|2009-12-03|Estimate|||||||2015-04-27|2015-04-29|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD|Phase II Study of Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD|Withdrawn||Phase 2|0|Actual|University of Alberta||||No funding source for device purchasing|f||||t||||||||||2018-06-01 00:18:15.751556|2018-06-01 00:18:15.751556
NCT01025726|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2012-09-21|2009-12-02|2009-12-03|Estimate|||||||2012-09-21|2012-09-25|Estimate|July 2007||2007-07-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|PATH||Positive Action for Today's Health|Improving Safety and Access for Physical Activity|Completed||N/A|439|Actual|University of South Carolina||3|||f||||t||||||||||2018-06-01 00:18:15.905681|2018-06-01 00:18:15.905681
NCT01025713|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2015-07-07|2009-12-02|2009-12-03|Estimate|||||||2015-07-07|2015-07-09|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|April 2010|Anticipated|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)|Withdrawn||Phase 1|0|Actual|Gilead Sciences||3||Development program terminated.|f||||f||||||||||2018-06-01 00:18:15.969683|2018-06-01 00:18:15.969683
NCT01025700|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2011-02-16|2009-12-02|2009-12-03|Estimate|||||||2011-02-16|2011-02-17|Estimate|June 2009||2009-06-30|February 2011|2011-02-28|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Nabilone & Marijuana Addiction|A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal|Completed||Phase 2/Phase 3|35|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:18:16.046149|2018-06-01 00:18:16.046149
NCT01025687|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-02|2009-12-02|2009-12-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Television Viewing (TVV) & Puberty on Lunchtime Food Intake|Effect of Television Viewing (TVV) & Puberty on Lunchtime Food Intake & Subjective Appetite in Girls|Completed||N/A|25|Actual|University of Toronto||4|||f||||f||||||||||2018-06-01 00:18:16.145667|2018-06-01 00:18:16.145667
NCT01025674|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2015-04-20|2009-12-01|2009-12-03|Estimate|||||||2015-04-20|2015-04-22|Estimate|September 2004||2004-09-30|September 2014|2014-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Randomized Trial of the Positive Action Program in Chicago Schools and Extension to Grade 8|Positive Action for Social and Character Development|Completed||N/A|4230|Actual|Oregon State University||2|||f||||f||||||||||2018-06-01 00:18:16.223977|2018-06-01 00:18:16.223977
NCT01025661|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-07|2009-12-02|2009-12-03|Estimate|||||||2009-12-07|2009-12-08|Estimate||||December 2009|2009-12-31||||||||Interventional|||Effects of Chiropractic Care in Patients With Hip Osteoarthritis|Effects of Chiropractic Care on Pain and Function in Patients With Hip Osteoarthritis Waiting for Arthroplasty - a Controlled Clinical Pilot Trial|Completed||N/A|14|Actual|Scandinavian College of Chiropractic||1|||f||||t||||||||||2018-06-01 00:18:16.311765|2018-06-01 00:18:16.311765
NCT01025648|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01||2013-07-10|2018-05-14|2009-12-01|2009-12-03|Estimate||||2013-07-11|2013-07-15|Estimate|2018-05-14|2018-05-16|Actual|December 2009||2009-12-31|May 2018|2018-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.|A Randomized, Double-blinded or Evaluator-blinded, Placebo and Active Controlled, Six-arm, Crossover, Single Dose, Dose-ranging Study, for Initial Evaluation of Safety and Efficacy in Asthma Patients|Terminated||Phase 1/Phase 2|9|Actual|Amphastar Pharmaceuticals, Inc.||6||Optimization of protocol|f||||f||||||||||2018-06-01 00:18:16.378321|2018-06-01 00:18:16.378321
NCT01025635|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|2013-05-07||2014-04-18|2009-12-02|2009-12-03|Estimate|2013-05-07|2013-07-01|Estimate||||2014-04-18|2014-05-05|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea|Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Study to Investigate Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily in Subjects With Papulopustular Rosacea|Completed||Phase 2|401|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:18:16.488462|2018-06-01 00:18:16.488462
NCT01025622|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-10-28|2009-12-02|2009-12-03|Estimate|||||||2010-10-28|2010-10-29|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Interventional|Cirrhosis133||Intrahepatic Reinfusion of CD133+ Stem Cells in Cirrhotic Patients|Phase 1 Study of Intrahepatic Reinfusion of Highly Purified CD133+ Stem Cells in Patients With End-Stage Liver Disease|Unknown status|Recruiting|Phase 1|12|Anticipated|University of Bologna|||||f||||t||||||||||2018-06-01 00:18:16.947792|2018-06-01 00:18:16.947792
NCT01025609|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2015-07-27|2009-12-02|2009-12-03|Estimate|||||||2015-07-27|2015-07-29|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|SCIDS||Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury|Dietary Patterns & There Relationship to Cardiovascular Disease Risk Factors In Individuals With Chronic Spinal Cord Injury|Completed|||100|Actual|Carolinas Healthcare System|||||f||||t||||||||||2018-06-01 00:18:17.042277|2018-06-01 00:18:17.042277
NCT01025596|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2012-10-17|2009-12-02|2009-12-03|Estimate|||||||2012-10-17|2012-10-18|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional|ECLIPSE 1||Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)|"A PHASE I/IIa DOSE ESCALATION STUDY IN ASIA OF REPEATED ADMINISTRATION OF CYT107 (Glyco-r-hIL-7) ADDED ON TREATMENT IN GENOTYPE 1 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED INTERFERON-ALPHA AND RIBAVIRIN"|Completed||Phase 1/Phase 2|10|Actual|Cytheris SA||1|||f||||t||||||||||2018-06-01 00:18:17.119692|2018-06-01 00:18:17.119692
NCT01025583|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-01-12|2009-12-02|2009-12-03|Estimate|||||||2010-01-12|2010-01-13|Estimate|November 2007||2007-11-30|December 2009|2009-12-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Oral Rehydration Solution With Zinc and Prebiotics in Acute Diarrhea|Efficacy of a New Hypotonic Oral Rehydration Solution Containing Zinc and Prebiotics in the Treatment of Children With Acute Diarrhea|Completed||Phase 2/Phase 3|130|Actual|Federico II University||2|||f||||t||||||||||2018-06-01 00:18:17.211046|2018-06-01 00:18:17.211046
NCT01025570|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2014-05-07|2009-12-02|2009-12-03|Estimate|||||||2014-05-07|2014-05-09|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|May 2012|Actual|2012-05-31||Interventional|||A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer|A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma|Terminated||Phase 1|3|Actual|University of California, San Francisco||1||Terminated due to slow accrual|f||||t||||||||||2018-06-01 00:18:17.363287|2018-06-01 00:18:17.363287
NCT01025557|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-06-13|2009-12-02|2009-12-03|Estimate|||||||2012-06-13|2012-06-14|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|June 2011|Actual|2011-06-30||Interventional|||Isovolumetric and Isocaloric Preloads of Various Types of Milk on Food Intake, Subjective Appetite and Glycemic Response|The Effects of Isovolumetric and Isocaloric Preloads of Various Types of Milk on Food Intake, Subjective Appetite and Glycemic Response in Healthy Young Men and Women|Completed||Phase 1/Phase 2|52|Actual|University of Toronto||5|||f||||f||||||||||2018-06-01 00:18:17.430498|2018-06-01 00:18:17.430498
NCT01025544|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2011-12-07|2009-12-02|2009-12-03|Estimate|||||||2011-12-07|2011-12-08|Estimate|September 2009||2009-09-30|December 2011|2011-12-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China|A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection|Completed||Phase 3|846|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:18:17.496638|2018-06-01 00:18:17.496638
NCT01025531|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-12-05|2009-12-02|2009-12-03|Estimate|||||||2014-12-05|2014-12-08|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Cell Bound Complement Activation Proteins as Markers of Liver Injury|Cell Bound Complement Activation Proteins as Markers of Liver Injury|Withdrawn|||0|Actual|University of Pittsburgh|||1||f||||t||||||Samples Without DNA|"~     All biologic samples will be under the control of the principal investigator . To protect~     confidentiality, all personal identifiers will be removed and replaced with a specific code~     number. The information linking these code numbers to the corresponding subjects' identities~     will be kept in a separate, secure location.~   "|||2018-06-01 00:18:17.565054|2018-06-01 00:18:17.565054
NCT01025518|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2016-11-28|2009-12-02|2009-12-03|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients|A Randomized Trial Evaluating Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients|Completed||N/A|30|Actual|Danish Head and Neck Cancer Group||2|||f||||t||||||||||2018-06-01 00:18:17.649504|2018-06-01 00:18:17.649504
NCT01025505|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2018-03-21|2009-12-02|2009-12-03|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2012|Actual|2012-06-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|December 2015|Actual|2015-12-31||Interventional|LAL1408||Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study|Front-line Treatment of Ph Positive (Ph+)/Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) With Two Tyrosine Kinase Inhibitors (TKI) (Imatinib and Nilotinib). A Phase II Exploratory Multicentric Study in Elderly Patients and in Patients Unfit for Program of Intensive Therapy and Allogeneic Stem Cell Transplantation. GIMEMA Protocol LAL1408. EudraCT 2009-01327122|Active, not recruiting||Phase 2|40|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||t||||||||No||2018-06-01 00:18:17.731049|2018-06-01 00:18:17.731049
NCT01025492|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2016-07-19||2016-07-19|2009-12-02|2009-12-03|Estimate|2016-07-19|2016-09-01|Estimate||||2016-07-19|2016-09-01|Estimate|November 2009||2009-11-30|July 2016|2016-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||The clinical trial collaborator/corporate sponsor prematurely terminated the study and did not provide unblinding information to the investigator or study team. It is not known to which arm/group each of the participants enrolled, therefore all enrolled subjects were included in a single arm/group.|Study of Trilipix Effects on Lipids and Arteries|Mechanisms of Atheroprotection by Fenofibric Acid (ABT 335) Added to a Statin in Subjects With Insulin Resistance (Hypertriglyceridemia and Low HDL-C)|Terminated||Phase 4|24|Actual|University of Utah||2||Collaborator/corporate sponsor withdrew funding and permission to continue.|f||||f||||||||No||2018-06-01 00:18:17.893881|2018-06-01 00:18:17.893881
NCT01025479|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-06-28|2009-12-02|2009-12-03|Estimate|||||||2010-06-28|2010-06-30|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent|Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent|Completed|||829|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:18:18.043232|2018-06-01 00:18:18.043232
NCT01025466|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-05-18|2009-12-02|2009-12-03|Estimate|||||||2010-05-18|2010-05-19|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|EXPECT||Exelon Patch and Combination With Memantine Comparative Trial|A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease|Completed||Phase 4|206|Actual|Inha University Hospital||2|||f||||t||||||||||2018-06-01 00:18:18.129796|2018-06-01 00:18:18.129796
NCT01025453|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2018-01-02|2009-12-02|2009-12-03|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2009||2009-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer|Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer|Active, not recruiting||Phase 2|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:18:18.238071|2018-06-01 00:18:18.238071
NCT01025440|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2017-06-16|2009-12-02|2009-12-03|Estimate|||||||2017-06-16|2017-06-19|Actual|November 2009||2009-11-30|June 2017|2017-06-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||An Investigation to Test the Efficacy of the High Flow (HF) Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea (OSA)|An Investigation to Test the Efficacy of a Novel CPAP Concept to Reduce the Apnea Hypopnea Index of Patients With Obstructive Sleep Apnea|Completed||N/A|25|Actual|Fisher and Paykel Healthcare||2|||f||||f|f|f|||f|||Undecided||2018-06-01 00:18:18.331712|2018-06-01 00:18:18.331712
NCT01025427|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2012-04-02|2009-12-02|2009-12-03|Estimate|||||||2012-04-02|2012-04-03|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|June 2011|Actual|2011-06-30||Interventional|||HIV Persistence and Viral Reservoirs|Treating HIV-infected Elite Controllers as a Model of HIV Remission|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:18:18.423436|2018-06-01 00:18:18.423436
NCT01025414|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-02|2009-12-02|2009-12-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|July 2006||2006-07-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|FIS-1||Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective Study|The Use of Enteral Nutrition in the Treatment of Pancreatic Fistulas - A Prospective, Randomized Clinical Trial|Completed||Phase 4|78|Actual|Jagiellonian University|||||f||||f||||||||||2018-06-01 00:18:18.544123|2018-06-01 00:18:18.544123
NCT01025401|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2010-11-22|2009-12-01|2009-12-03|Estimate|||||||2010-11-22|2010-11-23|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CAPAMETRIM2||Characterization of Epileptic Motor Patterns by Tridimensional Analysis of Movement 2|Caractérisation et détection Des Mouvements Durant Les Crises d'épilepsie à Des Fins d'Alarme, Pour un Usage en Institution et en Famille.|Terminated||N/A|50|Actual|University Hospital, Grenoble||1||departure of a collaborator in charge of the data collection|f||||f||||||||||2018-06-01 00:18:18.636141|2018-06-01 00:18:18.636141
NCT01025388|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-02-07|2009-12-02|2009-12-03|Estimate|||||||2013-02-07|2013-02-08|Estimate|November 2009||2009-11-30|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|CEPHEUS||Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia|Completed|||4053|Actual|AstraZeneca|||||f||||f||||||None Retained|"~     Whole blood~   "|||2018-06-01 00:18:18.709761|2018-06-01 00:18:18.709761
NCT01025375|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-08-29|2009-12-02|2009-12-03|Estimate|||||||2012-08-29|2012-08-30|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|Inulin||Effects of Inulin on Satiety and Food Intake|Effects of Inulin on Satiety and Food Intake|Completed||N/A|30|Actual|Maastricht University Medical Center|||||f||||t||||||||||2018-06-01 00:18:18.780275|2018-06-01 00:18:18.780275
NCT01025362|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2014-10-30|2009-12-02|2009-12-03|Estimate|||||||2014-10-30|2014-10-31|Estimate|August 2009||2009-08-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||Baby-Friendly Community Health Services Evaluation|Baby-Friendly Community Health Services Evaluation: A Cluster Randomised Controlled Study|Completed||N/A|2032|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 00:18:18.845258|2018-06-01 00:18:18.845258
NCT01025349|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-02|2009-12-02|2009-12-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|January 2005||2005-01-31|December 2009|2009-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer|Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer|Completed||Phase 2|20|Actual|Taipei Medical University Hospital||1|||f||||f||||||||||2018-06-01 00:18:18.923847|2018-06-01 00:18:18.923847
NCT01025336|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|2012-05-16|2011-09-26|2012-05-16|2009-12-02|2009-12-03|Estimate|2012-05-16|2012-06-20|Estimate|2011-09-26|2011-10-05|Estimate|2012-05-16|2012-06-20|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|AB PERSISTENCE||Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated|A Study To Evaluate The Persistence Of The Antibody Response Elicited By 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Adults Who Have Previously Been Vaccinated With Either 2 Doses Of 13vPnC Or 13vPnC And 23-Valent Pneumococcal Polysaccharide Vaccine In Different Sequential Order In Study 6115A1-3010 Or 6115A1 3005|Completed||Phase 3|962|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:18:19.128772|2018-06-01 00:18:19.128772
NCT01025323|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-03-12|2009-12-02|2009-12-03|Estimate|||||||2013-03-12|2013-03-13|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SHARPP||Study of Hispanics to Assess Risk Prevention in Prehypertension|Lifestyle Intervention in Multinational Hispanics With Prehypertension|Terminated||N/A|58|Actual|Florida Heart Research Institute||2||"The study was terminated due to difficult recruitment and retention of subjects, these were~   attributed by subjects to conflict with their job schedule."|f||||f||||||||||2018-06-01 00:18:23.267147|2018-06-01 00:18:23.267147
NCT01025310|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2015-10-12|2009-12-02|2009-12-03|Estimate|||||||2015-10-12|2015-10-14|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Visual Stress of the Open Urban Environment|Visual Stress of the Open Urban Environment|Withdrawn|||0|Actual|Meir Medical Center||||Administartive and technical problems|f||||t||||||||||2018-06-01 00:18:23.33634|2018-06-01 00:18:23.33634
NCT01025297|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-10-17|2009-12-02|2009-12-03|Estimate|||||||2012-10-17|2012-10-18|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|Eclipse 2||Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone|"A Phase I/IIa Dose Escalation Study of Repeated Administration of CYT107 (Glyco-r-hIL-7) Add-On Treatment in Genotype 1 or 4 Hcv Infected Patients Resistant to Pegylated Interferon-Alpha and Ribavirin"|Unknown status|Active, not recruiting|Phase 1/Phase 2|18|Anticipated|Cytheris SA||1|||f||||t||||||||||2018-06-01 00:18:23.395193|2018-06-01 00:18:23.395193
NCT01025284|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2017-09-27|2013-01-11|2017-10-28|2009-12-02|2009-12-03|Estimate|2017-10-28|2017-12-04|Actual|2013-01-11|2013-01-21|Estimate|2017-10-28|2017-12-04|Actual|December 2009||2009-12-31|October 2017|2017-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All participants who received at least 1 dose of study drug.|A Study for Participants With Small-Cell Lung Cancer|A Phase 2 Study of LY2523355 in Patients With Extensive-Stage Small-Cell Lung Cancer|Completed||Phase 2|64|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 00:18:23.534649|2018-06-01 00:18:23.534649
NCT01025271|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2012-08-23||2013-08-08|2009-12-02|2009-12-03|Estimate|2013-08-08|2013-08-12|Estimate||||2013-08-08|2013-08-12|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Cerebrospinal Fluid Pharmacokinetics of Daptomycin|Cerebrospinal Fluid Pharmacokinetics of Daptomycin|Terminated||N/A|2|Actual|University of Pittsburgh|unable to meet enrollment no data available.|1||unable to enroll subjects study stopped due to lack of enrollment|f||||t||||||||||2018-06-01 00:18:24.50468|2018-06-01 00:18:24.50468
NCT01025258|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-09-02|2009-12-02|2009-12-03|Estimate|||||||2013-09-02|2013-09-04|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Improving Adherence and Clinical Outcome in Cystic Fibrosis (CF) Patients|Improving Adherence and Clinical Outcomes of Cystic Fibrosis Patients Through a Collaborative Active Intervention Program of a Multidisciplinary Team|Completed||N/A|70|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:18:24.68767|2018-06-01 00:18:24.68767
NCT01025232|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2016-02-08||2016-11-03|2009-12-02|2009-12-03|Estimate|2016-11-03|2017-01-02|Estimate||||2016-11-03|2017-01-02|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|SAVE||A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)|A Phase I/II Open Label, Multicenter Study of the Safety, Tolerability and Efficacy of Multiple Intravitreal Injections of (Super-dose Anti-VEgf SAVE Trial) 2.0mg Ranibizumab in Subjects With Chronic Fluid on OCT Post Multiple Injections With Ranibizumab|Terminated||Phase 1/Phase 2|88|Actual|Greater Houston Retina Research||2||"The last remaining subject withdrew consent because the collaborator Genentech stopped~   supplying study drug."|f||||f||||||||||2018-06-01 00:18:24.885357|2018-06-01 00:18:24.885357
NCT01025219|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-03-21|2009-12-02|2009-12-03|Estimate|||||||2011-03-21|2011-03-22|Estimate|December 2009||2009-12-31|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|CRACK-ANT||A Contribution to the Analysis of the Phenotypic Heterogeneity in Crack/Cocaine Addiction : a Case Control Study|A Case Control Study on Contribution to the Analysis of the Phenotypic Heterogeneity in Crack/Cocaine Addiction|Unknown status|Recruiting|N/A|600|Anticipated|University Hospital Center of Martinique|||||f||||t||||||||||2018-06-01 00:18:25.440638|2018-06-01 00:18:25.440638
NCT01025206|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-03-14|2009-12-02|2009-12-03|Estimate|||||||2013-03-14|2013-03-15|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma|A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI 505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, in Patients With Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|35|Actual|BioInvent International AB||1|||f||||t||||||||||2018-06-01 00:18:25.530186|2018-06-01 00:18:25.530186
NCT01025193|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2013-07-18||2017-05-09|2009-12-02|2009-12-03|Estimate|2017-01-09|2017-02-28|Actual||||2017-05-09|2017-06-12|Actual|February 2010||2010-02-28|May 2017|2017-05-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant|One Year Exploratory Study to Evaluate the Efficacy and Safety of Belimumab for Normalization of Alloantibody Levels in Sensitized Patients Awaiting Kidney Transplantation|Terminated||Phase 2|8|Actual|University of Pennsylvania|Few patients enrolled, and limited follow-up due to trial being halted due to lack of efficacy after review by investigators and the data safety monitoring board. Only one patient was transplanted during the trial (unrelated to study treatment).|1||has not demonstrated efficacy in primary goal|f||||t|t|f||||||No||2018-06-01 00:18:25.685849|2018-06-01 00:18:25.685849
NCT01025180|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-12-03|2009-12-02|2009-12-03|Estimate|||||||2010-12-03|2010-12-06|Estimate|December 2007||2007-12-31|December 2009|2009-12-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|Pro-SEPS||Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection|Randomized Multicentre Prospective Study of Procalcitonin-guided Treatment on Antibiotic Use and Outcome in Severe Sepsis ICU Patients Without Obvious Infection|Terminated||Phase 4|62|Actual|Brahms France||2||65 patients were included after 2 years instead of 140|f||||t||||||||||2018-06-01 00:18:26.150743|2018-06-01 00:18:26.150743
NCT01025167|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-08-19|2009-12-02|2009-12-03|Estimate|||||||2010-08-19|2010-08-20|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients||Completed||N/A|111|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 00:18:26.300232|2018-06-01 00:18:26.300232
NCT01025154|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2013-08-19||2013-08-19|2009-12-01|2009-12-03|Estimate|2013-08-19|2013-10-30|Estimate||||2013-08-19|2013-10-30|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction|Clofarabine, Idarubicin, and Cytarabine Combination as Induction Therapy for Younger Patients With Acute Myeloid Leukemia (AML)|Completed||Phase 2|63|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:18:26.428265|2018-06-01 00:18:26.428265
NCT01025141|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-12-20|2009-12-02|2009-12-03|Estimate|||||||2017-12-20|2017-12-21|Actual|February 25, 2009|Actual|2009-02-25|December 2017|2017-12-31|February 20, 2014|Actual|2014-02-20|February 20, 2014|Actual|2014-02-20||Interventional|Minivis||Efficacy of Skeletal Anchorage (MINISCREW)|Study of the Efficacy of Skeletal Anchorage (MINISCREW) Compared to Dental Anchorage During Orthodontic Treatment|Completed||N/A|99|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:18:26.813015|2018-06-01 00:18:26.813015
NCT01025128|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2014-07-18|2009-12-02|2009-12-03|Estimate|||||||2014-07-18|2014-07-21|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density||Completed||Phase 4|210|Actual|Clalit Health Services||4|||f||||f||||||||||2018-06-01 00:18:26.94091|2018-06-01 00:18:26.94091
NCT01025115|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-03-30|2009-12-02|2009-12-03|Estimate|||||||2010-03-30|2010-03-31|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Diamel in the Treatment of Metabolic Syndrome|Efficacy of Diamel in the Treatment of Metabolic Syndrome|Completed||Phase 3|100|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:18:27.129251|2018-06-01 00:18:27.129251
NCT01025102|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-03-30|2009-12-02|2009-12-03|Estimate|||||||2013-03-30|2013-04-02|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||The Addition of Sufentanil Interscalene Block in Shoulder Surgery|Phase III Study of the Addition of Sufentanil to Interscalene Block in Shoulder Surgery|Completed||Phase 3|26|Actual|Frederiksberg University Hospital||1|||f||||t||||||||||2018-06-01 00:18:27.407057|2018-06-01 00:18:27.407057
NCT01025089|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2018-04-05|2009-12-02|2009-12-03|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2009||2009-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma|A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)|Active, not recruiting||Phase 2|18|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:18:27.517276|2018-06-01 00:18:27.517276
NCT01024907|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2015-12-14|2009-12-02|2009-12-03|Estimate|||||||2015-12-14|2015-12-15|Estimate|July 2009||2009-07-31|December 2015|2015-12-31||||February 2014|Actual|2014-02-28||Interventional|||Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas|Proton Radiation for Low Grade Gliomas|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:18:30.424091|2018-06-01 00:18:30.424091
NCT01025076|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2016-12-06||2017-01-30|2009-12-02|2009-12-03|Estimate|2016-12-06|2017-01-31|Estimate||||2017-01-30|2017-03-10|Actual|February 2009||2009-02-28|January 2017|2017-01-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma|Phase II Study of Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma|Completed||Phase 2|14|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 00:18:27.625775|2018-06-01 00:18:27.625775
NCT01025063|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2017-10-26|2009-12-02|2009-12-03|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2008||2008-01-31|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|Spectral OCT||Use of Spectral OCT in Combination Therapy|Use of Spectral OCT in Combination Therapy|Completed|||15|Actual|Barnes Retina Institute|||3||f||||f||||||||||2018-06-01 00:18:27.99221|2018-06-01 00:18:27.99221
NCT01025050|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2011-06-08|2009-12-02|2009-12-03|Estimate|||||||2011-06-08|2011-06-09|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Intrastromal Presbyopia Correction by Means of a Femtosecond Laser|Intrastromal Presbyopia Correction by Means of a Femtosecond Laser|Completed||Phase 3|58|Actual|Technolas Perfect Vision GmbH||3|||f||||t||||||||||2018-06-01 00:18:28.170451|2018-06-01 00:18:28.170451
NCT01025037|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2015-01-13||2015-01-21|2009-12-01|2009-12-03|Estimate|2015-01-21|2015-01-26|Estimate||||2015-01-21|2015-01-26|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Outcomes in Rotator Cuff Repair Using Graft Reinforcement|A Prospective, Multi-Center, Single-Arm Study to Assess Clinical Outcomes In Primary Open or Mini-Open Rotator Cuff Repair Using Conexa Graft Reinforcement|Completed||N/A|61|Actual|Tornier, Inc.||1|||f||||f||||||||||2018-06-01 00:18:28.452208|2018-06-01 00:18:28.452208
NCT01025024|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-02|2009-12-02|2009-12-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|January 2007||2007-01-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|||Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients|Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients Patients, A Single-nucleotide Polymorphism(SNP)Analysis for Primary Open Angle Glaucoma|Completed|||1224|Actual|Chungnam National University|||2||f||||t||||||Samples With DNA|"~     Peripheral blood sample~   "|||2018-06-01 00:18:28.810278|2018-06-01 00:18:28.810278
NCT01025011|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-02|2009-12-02|2009-12-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|||Non-invasive Measurement of Hemoglobin in Retinal Arteries|Non- Invasive Measurement of the Absolute Hemoglobin Value in the Retinal Arteries of Anemic and Healthy Subjects Using a New Approach|Unknown status|Recruiting||100|Anticipated|Triemli Hospital|||1||f||||f||||||||||2018-06-01 00:18:29.050564|2018-06-01 00:18:29.050564
NCT01024998|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2016-10-20|2009-12-02|2009-12-03|Estimate|||||||2016-10-20|2016-10-21|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)|A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration|Active, not recruiting||Phase 1|19|Anticipated|Sanofi||4|||f||||t||||||||||2018-06-01 00:18:29.200702|2018-06-01 00:18:29.200702
NCT01024985|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-06-24|2009-12-02|2009-12-03|Estimate|||||||2010-06-24|2010-06-28|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct|Evaluation of Macular and Retinal Nerve Fiber Layer Thickness Measurements for Detection of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Optical Coherence Tomography.|Unknown status|Recruiting||40|Anticipated|University of Sao Paulo|||3||f||||f||||||||||2018-06-01 00:18:29.305941|2018-06-01 00:18:29.305941
NCT01024972|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2015-01-02||2015-02-18|2009-12-01|2009-12-03|Estimate|2015-02-18|2015-03-05|Estimate||||2015-02-18|2015-03-05|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Safety Study of Dantrolene in Subarachnoid Hemorrhage|Dantrolene in the Prevention and Treatment of Cerebral Vasospasm in Subarachnoid Hemorrhage|Completed||Phase 1/Phase 2|31|Actual|University of Massachusetts, Worcester|Placebo group consisted of free water with 5% mannitol to achieve the same equiosmolar solution as IV-D which requires reconstitution in free water. Unable to differentiate whether hyponatremia or brain oedema was due to IV-D or its solution.|2|||f||||t||||||||||2018-06-01 00:18:29.418925|2018-06-01 00:18:29.418925
NCT01024959|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2012-10-08||2012-11-06|2009-12-02|2009-12-03|Estimate|2012-10-08|2012-11-07|Estimate||||2012-11-06|2012-11-12|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|PCA3||Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result|Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result|Completed||N/A|507|Actual|Gen-Probe, Incorporated||1|||f||||f||||||||||2018-06-01 00:18:29.804513|2018-06-01 00:18:29.804513
NCT01024946|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2015-04-07||2015-04-21|2009-12-02|2009-12-03|Estimate|2015-04-07|2015-04-20|Estimate||||2015-04-21|2015-05-12|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity|Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity|Completed||Phase 2|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:18:30.032438|2018-06-01 00:18:30.032438
NCT01024933|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2017-02-17|2009-12-02|2009-12-03|Estimate|||||||2017-02-17|2017-02-23|Actual|January 2010||2010-01-31|February 2017|2017-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Triumph||Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH)|Trial Using Motivational Interviewing Positive Affect and Self-Affirmation in Hypertension (TRIUMPH)|Completed||N/A|238|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No|there is no plan to share|2018-06-01 00:18:30.245524|2018-06-01 00:18:30.245524
NCT01024920|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2018-04-12|2009-12-02|2009-12-03|Estimate|||||||2018-04-12|2018-04-17|Actual|December 16, 2009||2009-12-16|April 2018|2018-04-30|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.|A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer|Active, not recruiting||Phase 2|99|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:18:30.326556|2018-06-01 00:18:30.326556
NCT01024894|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-10-17|2009-12-02|2009-12-03|Estimate|||||||2012-10-17|2012-10-18|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|ECLIPSE 3||Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy|"A Phase I/IIa Dose Escalation Study in Asia of Repeated Administration of CYT107 (Glyco-r-hIL-7) Added on Treatment in Genotype 1 HCV Infected Patients Resistant to Pegylated Interferon-alpha and Ribavirin"|Unknown status|Active, not recruiting|Phase 1/Phase 2|15|Anticipated|Cytheris SA||1|||f||||t||||||||||2018-06-01 00:18:30.528097|2018-06-01 00:18:30.528097
NCT01024881|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-02|2009-12-02|2009-12-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Influence of the Shoulder Position on the Catheter Tip Location During Infraclavicular Subclavian Approach||Completed||N/A|344|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:18:30.596257|2018-06-01 00:18:30.596257
NCT01024868|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2010-05-03|2009-12-02|2009-12-03|Estimate|||||||2010-05-03|2010-05-04|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||March 2010|Actual|2010-03-31||Observational|||Assessment of Spread of Transversus Abdominis Plane Block|Assessment of Spread of Transversus Abdominis Plane Block After Administration of 20 ml Ropivacaine 0,5% Bilaterally|Completed|||20|Anticipated|Herlev Hospital|||1||f||||f||||||||||2018-06-01 00:18:30.6757|2018-06-01 00:18:30.6757
NCT01024855|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2011-04-13||2015-09-30|2009-12-02|2009-12-03|Estimate|2012-03-01|2012-03-29|Estimate||||2015-09-30|2015-10-20|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions||Completed||Phase 1/Phase 2|30|Actual|Abbott Medical Optics||2|||f||||||||||||||2018-06-01 00:18:30.82327|2018-06-01 00:18:30.82327
NCT01024842|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2016-06-07|2009-12-01|2009-12-03|Estimate|||||||2016-06-07|2016-06-08|Estimate|December 2009||2009-12-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART|HIV-CORE 001 - A Randomised Placebo-controlled Study to Evaluate the Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVconsv, Delivered by Intramuscular Needle Injection to HIV-1 Seropositive Adult Subjects Receiving Antiretroviral Therapy (ART).|Terminated||Phase 1|19|Actual|University of Oxford||4||Slow recruitment therefore study was stopped after 95% volunteers were enrolled.|f||||t||||||||Yes|Data are presented in a manuscript submitted to a peer-reviewed journal.|2018-06-01 00:18:30.989076|2018-06-01 00:18:30.989076
NCT01024829|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2017-01-19|2009-12-02|2009-12-03|Estimate|||||||2017-01-19|2017-01-20|Estimate|May 2010||2010-05-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|PET Boost||Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC|Dose Escalation by Boosting Radiation Dose Within the Primary Tumor on the Basis of a Pre-treatment FDG-PET-CT Scan in Stage IB, II and III NSCLC: a Randomized Phase II Trial|Recruiting||N/A|168|Anticipated|The Netherlands Cancer Institute||2|||f||||t||||||||No||2018-06-01 00:18:31.073507|2018-06-01 00:18:31.073507
NCT01024816|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2014-06-24|2009-12-01|2009-12-03|Estimate|||||||2014-06-24|2014-06-26|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Interventional|PRYSMS||Practicing Restorative Yoga or Stretching for the Metabolic Syndrome|Practicing Restorative Yoga or Stretching for the Metabolic Syndrome|Completed||N/A|180|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:18:31.218274|2018-06-01 00:18:31.218274
NCT01024803|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2017-09-26|2009-12-02|2009-12-03|Estimate|||||||2017-09-26|2017-09-28|Actual|December 2009||2009-12-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2017|Actual|2017-04-30||Interventional|||Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients|Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients: A Prospective Multicenter Clinical Study Based on Randomized Intra-individual Implant Activation in Patients With Degenerative Retinal Diseases|Active, not recruiting||N/A|39|Actual|Retina Implant AG|||||f||||t||||||||||2018-06-01 00:18:31.312207|2018-06-01 00:18:31.312207
NCT01024790|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-10-07|2009-12-01|2009-12-03|Estimate|||||||2013-10-07|2013-10-09|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Exercise Study to Help Patients Who Have Type 2 Diabetes and Depression.|Behavioral Activation Enhanced Exercise Intervention:Pre-Pilot|Completed||Phase 1|29|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 00:18:31.424755|2018-06-01 00:18:31.424755
NCT01024777|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-02-05|2009-12-02|2009-12-03|Estimate|||||||2013-02-05|2013-02-06|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis|A Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple Sclerosis|Completed||Phase 1|40|Actual|Johns Hopkins University||2|||f||||||||||||||2018-06-01 00:18:31.539786|2018-06-01 00:18:31.539786
NCT01024764|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2011-02-28|2009-12-02|2009-12-03|Estimate|||||||2011-02-28|2011-03-01|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|December 2010|Actual|2010-12-31|||||Observational|ISS OBS P-001||Observational Study of the Preventive Trial With HIV-1 Tat Protein|Observational Study of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in HIV-1 Uninfected Adult Volunteers|Completed|||5|Actual|Istituto Superiore di Sanità|||||f||||f||||||Samples Without DNA|"~     Whole blood, serum, PBMCs~   "|||2018-06-01 00:18:31.659049|2018-06-01 00:18:31.659049
NCT01024751|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2011-06-16||2011-08-11|2009-12-01|2009-12-03|Estimate|2011-07-15|2011-08-11|Estimate||||2011-08-11|2011-08-15|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution|A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution|Completed||N/A|312|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:18:31.74405|2018-06-01 00:18:31.74405
NCT01024738|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2009-11-27|2009-11-27|2009-12-03|Estimate|2009-11-27|2009-12-03|Estimate||||2009-11-27|2009-12-03|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse|Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse|Completed||Phase 3|22|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 00:18:32.109159|2018-06-01 00:18:32.109159
NCT01024725|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2014-09-24|2009-12-02|2009-12-03|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2009||2009-11-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|April 2010|Actual|2010-04-30||Observational|||Evaluation of Pandemic Vaccination Campaign|Evaluation of a Vaccination Campaign With A(H1N1)v Pandemic Vaccines: a Prospective Cohort Study|Completed|||3518|Actual|National Institute for Health and Welfare, Finland|||2||f||||f||||||Samples With DNA|"~     nasal/oral swabs, serum samples and peripheral blood mononuclear cells~   "|||2018-06-01 00:18:32.424354|2018-06-01 00:18:32.424354
NCT01024712|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2013-08-09|2009-12-02|2009-12-03|Estimate|||||||2013-08-09|2013-08-12|Estimate|May 2009||2009-05-31|December 2009|2009-12-31||||||||Interventional|||Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer|Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase Ⅱa Trial|Unknown status|Recruiting|Phase 2|26|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:18:32.505267|2018-06-01 00:18:32.505267
NCT01024699|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2015-04-29|2009-12-01|2009-12-03|Estimate|||||||2015-04-29|2015-04-30|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.|A Prospective Multi-Center Randomized Evaluation of the Clinical and Radiographic Outcomes of XLIF® Compared With MAS® TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis|Completed|||55|Actual|NuVasive|||2||f||||f||||||||||2018-06-01 00:18:32.605843|2018-06-01 00:18:32.605843
NCT01024686|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-05-28|2009-12-01|2009-12-03|Estimate|||||||2013-05-28|2013-05-30|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine|Phase 1/2a Trial to Assess the Safety, Immunogenicity and Efficacy of Genetically-attenuated Plasmodium Falciparum Parasites p52-/p36- (GAP) Vaccine, Administered by Bite of Infected Anopheles Mosquito to Malaria-naïve Adults Living in the United States.|Terminated||Phase 1/Phase 2|6|Actual|Seattle Biomedical Research Institute||3|||f||||t||||||||||2018-06-01 00:18:32.675954|2018-06-01 00:18:32.675954
NCT01024673|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2017-06-08|2009-12-02|2009-12-03|Estimate|||||||2017-06-08|2017-06-09|Actual|October 2009||2009-10-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)|Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)|Recruiting|||600|Anticipated|University of Pittsburgh|||1||f||||t||||||Samples Without DNA|"~     All the biologic samples and data will be under the control of the principal investigator .~     To protect confidentiality, all personal identifiers will be removed and replaced with a~     specific code number. The information linking these code numbers to the corresponding~     subjects' identities will be kept in a separate, secure location. The investigators will keep~     the samples and data indefinitely. All samples will be stored in the principal investigators~     laboratory in Scaife Hall, Room 835.~   "|||2018-06-01 00:18:32.750245|2018-06-01 00:18:32.750245
NCT01024660|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2011-02-06|2009-12-02|2009-12-03|Estimate|||||||2011-02-06|2011-02-08|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil|A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer's Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 Weeks|Completed||Early Phase 1|155|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:18:32.82921|2018-06-01 00:18:32.82921
NCT01024647|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-11-01|2009-12-02|2009-12-03|Estimate|||||||2012-11-01|2012-11-05|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Optimizing Cimzia in Crohn's Patients|Optimizing Response in Crohn's Disease Patients Who Have Insufficient Initial Response or Who Have Loss of Successful Response to Certolizumab Pegol (Cimzia) Induction Therapy|Unknown status|Recruiting|Phase 4|50|Anticipated|Atlanta Gastroenterology Associates||4|||f||||f||||||||||2018-06-01 00:18:32.940367|2018-06-01 00:18:32.940367
NCT01024634|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-12-14|2009-12-02|2009-12-03|Estimate|||||||2012-12-14|2012-12-17|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|VINE||Vascular and Neuro-inflammatory Effects of Endurance Exercise Training in African Americans|Vascular and Neuro-inflammatory Effects of Endurance Exercise Training in African Americans|Completed||N/A|91|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||||2018-06-01 00:18:33.039904|2018-06-01 00:18:33.039904
NCT01024621|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2012-07-16|2009-12-02|2009-12-03|Estimate|||||||2012-07-16|2012-07-17|Estimate|November 2009||2009-11-30|July 2012|2012-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Confocal Laser Endomicroscopy for the Detection of Gastric Intestinal Metaplasia: a Randomized Controlled Trial|Comparison of Confocal Laser Endomicroscopy With Standard Endoscopy for the Detection and Evaluation of Gastric Intestinal Metaplasia in a High Risk Population: A Randomized Controlled Trial|Completed||N/A|168|Actual|Shandong University||2|||f||||t||||||||||2018-06-01 00:18:33.108042|2018-06-01 00:18:33.108042
NCT01024608|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|2012-04-23|2011-08-25|2012-04-23|2009-12-02|2009-12-03|Estimate|2012-04-23|2012-05-23|Estimate|2011-08-25|2011-08-29|Estimate|2012-04-23|2012-05-23|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR|Completed||Phase 3|340|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 00:18:33.197338|2018-06-01 00:18:33.197338
NCT01024595|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2011-02-28|2009-12-02|2009-12-03|Estimate|||||||2011-02-28|2011-03-01|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|December 2010|Actual|2010-12-31|||||Observational|ISS OBS T-001||Observational Study of the Therapeutic Study of Recombinant HIV-1 TAT|Observational Study of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in Hiv-1 Infected Adult Volunteers|Completed|||24|Actual|Istituto Superiore di Sanità|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, PBMCs~   "|||2018-06-01 00:18:33.557654|2018-06-01 00:18:33.557654
NCT01024582|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2017-09-26|2009-12-02|2009-12-03|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2009||2009-10-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|PAPBI||Radiation Therapy Followed by Surgery in Treating Patients With Early-Stage Breast Cancer|Image Guided Preoperative Accelerated Partial Breast Irradiation (PAPBI): Defining Radiotherapy Sensitivity|Completed||N/A|139|Actual|The Netherlands Cancer Institute||1|||f||||f||||||||No||2018-06-01 00:18:33.622718|2018-06-01 00:18:33.622718
NCT01024569|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-02|||2009-12-02|2009-12-02|2009-12-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|December 2007||2007-12-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|WRAP RCT||Randomized Controlled Trial of Wellness Recovery Action Planning|Mental Illness Self-Management Through Wellness Recovery Action Planning In Ohio|Completed||Phase 1/Phase 2|550|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-06-01 00:18:33.798739|2018-06-01 00:18:33.798739
NCT01024556|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2016-03-03|2009-12-01|2009-12-02|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|February 2012|Actual|2012-02-29|||||Observational|ISS OBS T-002||Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects|Observational Study With Additional Diagnostic Procedures on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects|Completed|||142|Actual|Istituto Superiore di Sanità|||||f||||f||||||Samples With DNA|"~     whole blood, serum, PBMCs~   "|||2018-06-01 00:18:33.913739|2018-06-01 00:18:33.913739
NCT01024543|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|October 2006||2006-10-31|December 2009|2009-12-31|November 2009||2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Role of Angiotensin II in Insulin-induced Microvascular Activity|Role of Angiotensin II in Insulin-induced Microvascular Activity|Completed||N/A|18|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 00:18:34.051458|2018-06-01 00:18:34.051458
NCT01024530|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-11|2009-12-01|2009-12-02|Estimate|||||||2009-12-11|2009-12-14|Estimate|May 2009||2009-05-31|December 2009|2009-12-31||||May 2012|Anticipated|2012-05-31||Interventional|||Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||||||||||||2018-06-01 00:18:34.151492|2018-06-01 00:18:34.151492
NCT01024517|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-04-26|2009-12-01|2009-12-02|Estimate|||||||2010-04-26|2010-04-27|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||GLPG0259 Solid Formulation Bioavailability and Food Effect|An Open Label Study to Compare the Oral Bioavailability of a Solid Dose Formulation of GLPG0259 Relative to an Oral Solution After Single-dose Intake in Healthy Subjects and to Evaluate the Effect of Food on the Solid Dose Formulation.|Completed||Phase 1|12|Actual|Galapagos NV||3|||f||||f||||||||||2018-06-01 00:18:34.259974|2018-06-01 00:18:34.259974
NCT01024504|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2010-04-08|2009-12-01|2009-12-02|Estimate|||||||2010-04-08|2010-04-09|Estimate|March 2006||2006-03-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer|A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer|Completed||Phase 2|46|Anticipated|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 00:18:34.356708|2018-06-01 00:18:34.356708
NCT01024491|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|August 2008||2008-08-31|December 2009|2009-12-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation|A Parallel Randomized Double Blind Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation|Completed||Phase 3|174|Actual|MorePharma Corporation||3|||f||||f||||||||||2018-06-01 00:18:34.492074|2018-06-01 00:18:34.492074
NCT01024478|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-07-06|2009-12-01|2009-12-02|Estimate|||||||2011-07-06|2011-07-07|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Contrast-Enhanced Whole-Heart Coronary Magnetic Resonance Angiography at 3.0-T: A Multicenter Trial|Contrast-Enhanced Whole-Heart Coronary Magnetic Resonance Angiography at 3.0-T: A Multicenter Trial|Completed|||272|Actual|Capital Medical University|||||f||||f||||||||||2018-06-01 00:18:34.61145|2018-06-01 00:18:34.61145
NCT01024465|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2015-08-13||2015-09-10|2009-12-01|2009-12-02|Estimate|2015-08-13|2015-09-11|Estimate||||2015-09-10|2015-09-29|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|ITALYIII|Participants were enrolled who met the study's inclusion/exclusion criteria.|ReShape Intragastric Balloon for the Treatment of Obesity|ReShape Intragastric Balloon for the Treatment of Obesity|Completed||N/A|26|Actual|ReShape Lifesciences|No limitations nor caveats apply.|1|||f||||f||||||||||2018-06-01 00:18:34.711696|2018-06-01 00:18:34.711696
NCT01024452|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-07-19|2009-12-01|2009-12-02|Estimate|||||||2011-07-19|2011-07-20|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Randomized Comparison of Warfarin Dosing Quality Between the Hamilton Nomogram and a Commercial Computer System|Randomized Comparison of Warfarin Dosing Quality Between the Hamilton Nomogram and a Commercial Computer System|Completed||Phase 3|1298|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-06-01 00:18:34.889077|2018-06-01 00:18:34.889077
NCT01024439|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-02-11|2009-12-01|2009-12-02|Estimate|||||||2014-02-11|2014-02-12|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|September 2010|Actual|2010-09-30||Interventional|||Transumbilical Single Incision Versus Conventional Three Incisions Laparoscopic Appendicectomy|Double Blinded Randomized Controlled Study of Conventional Laparoscopic Appendicectomy Versus Transumbilical Single Incision Laparoscopic Appendicectomy|Completed||N/A|80|Actual|Pamela Youde Nethersole Eastern Hospital||2|||f||||f||||||||||2018-06-01 00:18:34.991616|2018-06-01 00:18:34.991616
NCT01024426|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-10-31|2009-12-01|2009-12-02|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Impact of Enhanced Health Facility Care in Uganda|Evaluating the Impact of Enhanced Health Facility-based Care for Malaria and Febrile Illnesses in Children in Tororo, Uganda|Completed||Phase 4|25000|Actual|Uganda Malaria Surveillance Project||2|||f||||t||||||||||2018-06-01 00:18:35.092586|2018-06-01 00:18:35.092586
NCT01024413|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2017-02-28|2009-12-01|2009-12-02|Estimate|||||||2017-02-28|2017-03-01|Actual|July 2009||2009-07-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations|A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations|Completed||Phase 3|256|Actual|Chinese Society of Lung Cancer||2|||f||||f|f|f||||||Undecided||2018-06-01 00:18:35.18967|2018-06-01 00:18:35.18967
NCT01024400|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2011-12-29|2009-11-30|2009-12-02|Estimate|||||||2011-12-29|2012-01-02|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|PREFLUVAC||Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women|Etude de Phase II évaluant l'immunogénicité et la tolérance d'un Vaccin inactivé Non adjuvanté Contre la Grippe A(H1N1)v Chez la Femme Enceinte|Completed||Phase 2|110|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-06-01 00:18:35.28773|2018-06-01 00:18:35.28773
NCT01024387|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2017-11-30||2018-02-07|2009-12-01|2009-12-02|Estimate|2017-11-30|2017-12-27|Actual||||2018-02-07|2018-03-08|Actual|March 2010|Actual|2010-03-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional||The analysis dataset is comprised of all enrolled patients.|AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors|A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors|Completed||Phase 2|60|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:18:35.401789|2018-06-01 00:18:35.401789
NCT01024374|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|April 2010||2010-04-30|December 2009|2009-12-31||||||||Observational|13244/2009||Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face|Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face.|Unknown status|Not yet recruiting||60|Anticipated|Allergisa Pesquisa Dermato-Cosmetica LTDA|||||f||||f||||||||||2018-06-01 00:18:35.743463|2018-06-01 00:18:35.743463
NCT01024361|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-12-21|2009-12-01|2009-12-02|Estimate|||||||2009-12-21|2009-12-23|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|CPAP-DR||Cpap at Delivery Room for Preterm Infants|CPAP Application at Delivery Room at Very Low Birth Weight Infants|Unknown status|Active, not recruiting|Phase 4|200|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 00:18:35.78964|2018-06-01 00:18:35.78964
NCT01024348|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2010-02-01|2009-12-01|2009-12-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|December 2009||2009-12-31|February 2010|2010-02-28|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Safety and Effectiveness of Tramadex-OD After Knee Arthroscopy|Open-label Study of the Safety and Effectiveness of Short-term Therapy With Extended-release Tramadol (TRAMADEX-OD) in the Management of Pain After Knee Arthroscopy.|Unknown status|Not yet recruiting|N/A|100|Anticipated|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-06-01 00:18:35.895863|2018-06-01 00:18:35.895863
NCT01024335|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2014-04-28||2014-09-03|2009-11-30|2009-12-02|Estimate|2014-09-03|2014-09-05|Estimate||||2014-09-03|2014-09-05|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Domino||Dronabinol Naltrexone Treatment for Opioid Dependence|Dronabinol Naltrexone Treatment for Opioid Dependence|Completed||Phase 2/Phase 3|60|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 00:18:36.006231|2018-06-01 00:18:36.006231
NCT01024322|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2017-02-01|2009-12-01|2009-12-02|Estimate|||||||2017-02-01|2017-02-03|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Recruiting|||1500|Anticipated|Cxlusa|||3||f||||||||||||||2018-06-01 00:18:36.255043|2018-06-01 00:18:36.255043
NCT01024309|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2013-12-31||2014-10-28|2009-12-01|2009-12-02|Estimate|2014-10-28|2014-10-30|Estimate||||2014-10-28|2014-10-30|Estimate|November 2009||2009-11-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Trial Comparing Mini-posterior Approach and Direct Anterior Approach|A Prospective, Randomized, Clinical Trial Comparing the Clinical Outcomes Following Total Hip Arthroplasty by a Single Surgeon Using Either a Mini-posterior Approach or a Direct Anterior Approach|Completed||N/A|66|Actual|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-06-01 00:18:36.346751|2018-06-01 00:18:36.346751
NCT01024296|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2017-09-15||2017-09-15|2009-11-30|2009-12-02|Estimate|2017-09-15|2017-10-12|Actual||||2017-09-15|2017-10-12|Actual|July 2009|Actual|2009-07-31|September 2017|2017-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy Study to Evaluate Laparoscopic Fascial Closure Device|Pivotal Study to Evaluate the Efficacy of a Laparoscopic Port Closure Device|Completed||N/A|4|Actual|Stanford University||1|||f||||||||||||||2018-06-01 00:18:37.756189|2018-06-01 00:18:37.756189
NCT01024283|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor|Analysis of Pharmacodynamic Changes Associated With the Administration of the Heat Shock Protein 90 Inhibitor AUY922A in Patients With Advanced Solid Malignancies|Unknown status|Recruiting||25|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:18:38.057298|2018-06-01 00:18:38.057298
NCT01024270|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-30|2009-11-30|2009-12-02|Estimate|||||||2009-11-30|2009-12-02|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Cervical Priming With Misoprostol Prior to Operative Hysteroscopy|Cervical Priming With Misoprostol Prior to Operative Hysteroscopy|Completed||Phase 3|141|Actual|Samsung Medical Center||1|||f||||||||||||||2018-06-01 00:18:38.170166|2018-06-01 00:18:38.170166
NCT01024257|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate||||December 2009|2009-12-31||||||||Interventional|||Pterygium Treatment Using Single Beta-therapy as Adjuvant Treatment Compared to Conjunctival Autograft||Completed||Phase 3|||Marilia Medicine School||2|||f||||f||||||||||2018-06-01 00:18:38.252279|2018-06-01 00:18:38.252279
NCT01024244|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2011-09-15|2011-02-25|2011-11-29|2009-12-01|2009-12-02|Estimate|2011-09-15|2011-10-26|Estimate|2011-02-25|2011-03-11|Estimate|2011-11-29|2011-12-02|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of LY2599506 in Patients With Type 2 Diabetes|A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients With Type 2 Diabetes Mellitus Treated With Diet and Exercise, With or Without Metformin|Terminated||Phase 2|78|Actual|Eli Lilly and Company|Since Study GMAH was terminated after enrolling only 78 participants with just 10 participants completing 12 weeks of treatment with LY2599506, only disposition, demographics, and safety data are reported.|5||Terminated due to nonclinical safety findings|f||||f||||||||||2018-06-01 00:18:38.415398|2018-06-01 00:18:38.415398
NCT01024231|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2017-12-11|2009-12-01|2009-12-02|Estimate|||||||2017-12-11|2017-12-13|Actual|December 14, 2009|Actual|2009-12-14|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|April 7, 2019|Anticipated|2019-04-07||Interventional|||Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma|A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma|Active, not recruiting||Phase 1|136|Anticipated|Bristol-Myers Squibb||8|||f||||t|t|f||||||||2018-06-01 00:18:39.789029|2018-06-01 00:18:39.789029
NCT01024218|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-02-22|2009-11-30|2009-12-02|Estimate|||||||2017-02-22|2017-02-24|Actual|December 1, 2004|Actual|2004-12-01|February 2017|2017-02-28|April 26, 2005|Actual|2005-04-26|April 26, 2005|Actual|2005-04-26||Interventional|||Preference Study Between NovoFine® Autocover™ and a NovoFine® 8 mm Needle|An Open-label, Multicenter, Handling Test and Prospective Cross-over Study on Nurse/Health Assistants Preference Between NovoFine® Autocover™ and 8 mm NovoFine® Needle|Completed||Phase 4|78|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 00:18:39.89024|2018-06-01 00:18:39.89024
NCT01024205|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-08-09|2009-12-01|2009-12-02|Estimate|||||||2013-08-09|2013-08-12|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|May 2012|Actual|2012-05-31|August 2010|Actual|2010-08-31||Interventional|||Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer|Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients With Metastatic Renal Cancer: A Pilot Phase II Study [SuMR]|Completed||Phase 2|43|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:18:39.959948|2018-06-01 00:18:39.959948
NCT01024192|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2010-10-04|2009-11-30|2009-12-02|Estimate|||||||2010-10-04|2010-10-05|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA|Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) Administered on as Needed Basis in Patients With Chronic insomNIA|Completed||Phase 4|135|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:18:40.024999|2018-06-01 00:18:40.024999
NCT01024179|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-04|2009-12-01|2009-12-02|Estimate|||||||2009-12-04|2009-12-07|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns|Relationship Between Initial Plaque Characteristics and Stent Surface Coverage Patterns After Sirolimus-eluting Stent Implantation Assessment by Optical Coherence Tomography|Unknown status|Recruiting|Phase 4|90|Anticipated|Harbin Medical University||2|||f||||f||||||||||2018-06-01 00:18:40.112546|2018-06-01 00:18:40.112546
NCT01024166|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2013-06-06|2009-12-01|2009-12-02|Estimate|||||||2013-06-06|2013-06-07|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study|A Usability Study of Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: Integrating PROs and Decision Support Into an Electronic Record|Completed|||18|Actual|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-06-01 00:18:40.223085|2018-06-01 00:18:40.223085
NCT01024153|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2012-02-01|2009-12-01|2009-12-02|Estimate|||||||2012-02-01|2012-02-03|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Exergames||Active Video Games and Sustainable Physical Activity|Active Video Games and Sustainable Physical Activity|Completed||N/A|84|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 00:18:40.399996|2018-06-01 00:18:40.399996
NCT01024140|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|February 2003||2003-02-28|December 2009|2009-12-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder|Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder|Completed||N/A|16|Actual|Northern California Institute of Research and Education||1|||f||||f||||||||||2018-06-01 00:18:40.498309|2018-06-01 00:18:40.498309
NCT01024127|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2016-05-17|2009-12-01|2009-12-02|Estimate|||||||2016-05-17|2016-05-18|Estimate|December 2009||2009-12-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia|Genetic Predictors of AML Treatment Response|Completed|||2500|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     blood and bone marrow~   "|||2018-06-01 00:18:40.589136|2018-06-01 00:18:40.589136
NCT01024114|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-04-16|2009-12-01|2009-12-02|Estimate|||||||2012-04-16|2012-04-18|Estimate|July 2009||2009-07-31|April 2012|2012-04-30||||December 2012|Anticipated|2012-12-31||Observational|||Study to Evaluate the Diagnostic Value of a Combined Molecular Breast Imaging/ Breast Tomosynthesis Modality|Pilot Study to Evaluate the Incremental Diagnostic Value of a Combined Molecular Breast Imaging / Breast Tomosynthesis Modality|Withdrawn|||0|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 00:18:40.677071|2018-06-01 00:18:40.677071
NCT01024101|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30||2010-02-02|2011-04-08|2009-11-30|2009-12-02|Estimate||||2010-02-02|2010-02-04|Estimate|2011-04-08|2011-04-25|Estimate|January 2004||2004-01-31|April 2011|2011-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer|Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer|Completed||Phase 2|36|Anticipated|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 00:18:40.750506|2018-06-01 00:18:40.750506
NCT01024088|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-09-15|2009-11-30|2009-12-02|Estimate|||||||2014-09-15|2014-09-16|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|DGVSB||Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.|Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.|Completed|||60|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-06-01 00:18:40.890393|2018-06-01 00:18:40.890393
NCT01024075|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|May 2011|Anticipated|2011-05-31|November 2010|Anticipated|2010-11-30||Interventional|||Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes|The Adjunctive Use of a Dexamethasone-Sinufoam Mixture on Endoscopic Sinus Surgery Outcomes: A Randomized, Double-Blind, Placebo-controlled Trial|Unknown status|Recruiting|Phase 4|40|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 00:18:40.976028|2018-06-01 00:18:40.976028
NCT01024062|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30||2010-02-02|2011-04-08|2009-11-30|2009-12-02|Estimate||||2010-02-02|2010-02-04|Estimate|2011-04-08|2011-04-25|Estimate|December 2002||2002-12-31|April 2011|2011-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)|Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|60|Anticipated|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 00:18:41.080538|2018-06-01 00:18:41.080538
NCT01024049|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-01-27|2009-12-01|2009-12-02|Estimate|||||||2012-01-27|2012-01-31|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|IBLOMAVED||Identification Of Blood Markers For Asymptomatic Ventricular Dysfunction|Identification Of Blood Markers For Asymptomatic Ventricular Dysfunction|Unknown status|Recruiting||1000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||5||f||||f||||||Samples Without DNA|"~     plasma sample blood RNA sample~   "|||2018-06-01 00:18:41.161587|2018-06-01 00:18:41.161587
NCT01024036|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2014-05-16|2014-01-20|2018-02-22|2009-12-01|2009-12-02|Estimate|2014-08-01|2014-08-20|Estimate|2014-01-20|2014-02-14|Estimate|2018-02-22|2018-03-21|Actual|March 18, 2010|Actual|2010-03-18|February 2018|2018-02-28|February 24, 2017|Actual|2017-02-24|March 25, 2013|Actual|2013-03-25||Interventional|||A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease|A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease|Completed||Phase 2|79|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-06-01 00:18:41.341273|2018-06-01 00:18:41.341273
NCT01024023|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|December 2004||2004-12-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|HEART||Hull Early Walking Aids for Transtibial Amputees - Randomised Control Trial (HEART)|Hull - Early Walking Aids for Transtibial Amputees - Does an Articulated Knee Have Benefits? A Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|26|Actual|University of Hull||2|||f||||t||||||||||2018-06-01 00:18:43.135459|2018-06-01 00:18:43.135459
NCT01024010|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2014-10-30|2009-12-01|2009-12-02|Estimate|||||||2014-10-30|2014-10-31|Estimate|August 2010||2010-08-31|October 2014|2014-10-31||||May 2014|Actual|2014-05-31||Interventional|||Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab For Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)|Unknown status|Active, not recruiting|Phase 2|82|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:18:43.257391|2018-06-01 00:18:43.257391
NCT01023997|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2014-05-09|2009-12-01|2009-12-02|Estimate|||||||2014-05-09|2014-05-12|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Central Corneal Thickness in Glaucoma|Central Corneal Thickness in Patients With Exfoliation Syndrome, Exfoliative Glaucoma, Exfoliative Glaucoma, Primary Open-angle Glaucoma and Ocular Hypertension|Completed|||700|Actual|Aristotle University Of Thessaloniki|||4||f||||f||||||||||2018-06-01 00:18:43.465026|2018-06-01 00:18:43.465026
NCT01023984|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2016-08-04|2009-12-01|2009-12-02|Estimate|||||||2016-08-04|2016-08-08|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TEMENDO||Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas||Recruiting||Phase 4|120|Anticipated|European Association for Endoscopic Surgery||2|||f||||t||||||||||2018-06-01 00:18:43.562075|2018-06-01 00:18:43.562075
NCT01023971|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|January 2009||2009-01-31|December 2009|2009-12-31||||||||Observational|MAFAT||Macular Function During Anti-VEGF Treatment|Study of Macular Function During Anti-VEGF Treatment|Unknown status|Recruiting||40|Anticipated|Royal Liverpool University Hospital|||2||f||||f||||||||||2018-06-01 00:18:43.690744|2018-06-01 00:18:43.690744
NCT01023958|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2017-10-23|2014-04-30|2017-10-23|2009-12-01|2009-12-02|Estimate|2017-10-23|2017-11-22|Actual|2014-04-30|2014-05-16|Estimate|2017-10-23|2017-11-22|Actual|November 19, 2009|Actual|2009-11-19|October 2017|2017-10-31|September 19, 2011|Actual|2011-09-19|September 19, 2011|Actual|2011-09-19||Interventional||Treated set (TS) which included all patients who received at least one dose of trial medication.|Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer|An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy|Completed||Phase 2|50|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:18:43.844592|2018-06-01 00:18:43.844592
NCT01023945|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2016-01-18|2009-11-30|2009-12-02|Estimate|||||||2016-01-18|2016-01-20|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Double-blind, Placebo Controlled, Monotherapy Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|30|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-06-01 00:18:44.461098|2018-06-01 00:18:44.461098
NCT01023932|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|September 2006||2006-09-30|December 2009|2009-12-31|September 2009||2009-09-30|||||Observational|||Auditory Neuropathy and Cochlear Implants|Cochlear Implants in Children With Auditory Neuropathy/ Auditory Dys-Synchrony|Completed|||||University of Sao Paulo|||1||f||||||||||||||2018-06-01 00:18:44.545447|2018-06-01 00:18:44.545447
NCT01023919|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-03-29|2009-12-01|2009-12-02|Estimate|||||||2010-03-29|2010-03-30|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus|Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography|Unknown status|Recruiting|Phase 4|120|Anticipated|Harbin Medical University||2|||f||||||||||||||2018-06-01 00:18:44.611355|2018-06-01 00:18:44.611355
NCT01023906|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-05-21|2009-12-01|2009-12-02|Estimate|||||||2014-05-21|2014-05-23|Estimate|July 2008||2008-07-31|May 2014|2014-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Taste Perception and Chronic Disease Risk|Relationship Between Variations in Taste Perception and Chronic Disease Risk Factors as a Function of Age|Completed|||90|Actual|Tufts University|||2||f||||f||||||Samples With DNA|"~     Blood, and DNA~   "|||2018-06-01 00:18:44.706275|2018-06-01 00:18:44.706275
NCT01023893|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|November 2009||2009-11-30|December 2009|2009-12-31||||November 2010|Anticipated|2010-11-30||Observational|BEAM-1||Blood Viscosity, End-Stage Renal Disease, And Mortality (BEAM-1)|Clinical Diagnostic Evaluation Study of Blood Viscosity, End-Stage Renal Disease, And Mortality|Unknown status|Enrolling by invitation||400|Anticipated|ProMetrics, Inc.|||1||f||||f||||||||||2018-06-01 00:18:44.800498|2018-06-01 00:18:44.800498
NCT01023880|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01||2013-08-30|2016-03-10|2009-12-01|2009-12-02|Estimate||||2013-08-30|2013-09-13|Estimate|2016-03-10|2016-04-11|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy|An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy|Terminated||Phase 1/Phase 2|62|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 00:18:44.855002|2018-06-01 00:18:44.855002
NCT01023867|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2016-01-04|2009-12-01|2009-12-02|Estimate|||||||2016-01-04|2016-01-06|Estimate|March 2007||2007-03-31|January 2016|2016-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia|Comparative Assessment of Clinical Efficacy of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia|Completed||N/A|88|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:18:44.958596|2018-06-01 00:18:44.958596
NCT01023854|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2014-07-29|2009-12-01|2009-12-02|Estimate|||||||2014-07-29|2014-07-30|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|BPV||Merits of Continuous Paravertebral Block in the Management of Renal/Adrenal Surgery by Laparotomy|Consideration of the Merits of Continuous Paravertebral Block in the Management of Renal and/or Adrenal Surgery by Laparotomy in Adults|Terminated||N/A|41|Actual|University Hospital, Brest||2||No more potentiel patients for study|f||||f||||||||||2018-06-01 00:18:45.03771|2018-06-01 00:18:45.03771
NCT01023841|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2013-07-09||2013-07-09|2009-11-30|2009-12-02|Estimate|2013-07-09|2013-09-13|Estimate||||2013-07-09|2013-09-13|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children||Completed||Phase 4|71|Actual|Allergan||2|||f||||f||||||||||2018-06-01 00:18:45.114708|2018-06-01 00:18:45.114708
NCT01023828|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-06-27|2009-12-01|2009-12-02|Estimate|||||||2012-06-27|2012-06-29|Estimate|April 2005||2005-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|January 2010|Actual|2010-01-31||Observational|007/055/OMI||K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications|K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications|Completed|||150|Actual|National Institute of Cancerología|||4||f||||f||||||Samples With DNA|"~     The tumor samples, both formalin-fixed or paraffin-embedded, used for the histological~     diagnosis of patients will be obtained from the Pathology Departments of the National Cancer~     Institute and the National Institute of Respiratory Diseases; these samples will be used to~     gather DNA for the analysis of K-RAS mutations. The clinical data of the patients will be~     obtained from their medical files.~   "|||2018-06-01 00:18:45.632744|2018-06-01 00:18:45.632744
NCT01023815|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2013-07-04||2016-06-17|2009-12-01|2009-12-02|Estimate|2013-10-11|2013-11-14|Estimate||||2016-06-17|2016-07-19|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|EVIDENCE|Safety Population: The Safety Population (SAF population) includes all patients who signed an informed consent, performed renal transplantation and received at least one dose of study drug (everolimus).|Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.|Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).|Completed||Phase 3|330|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:18:45.763229|2018-06-01 00:18:45.763229
NCT01023802|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2013-05-08|2009-12-01|2009-12-02|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer|The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer - A Pilot Study|Completed|||20|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 00:18:47.977844|2018-06-01 00:18:47.977844
NCT01023789|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2017-05-18||2018-01-18|2009-11-30|2009-12-02|Estimate|2017-05-18|2017-12-18|Actual||||2018-01-18|2018-02-14|Actual|January 2010||2010-01-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ABSORB EXTEND||ABSORB EXTEND Clinical Investigation|ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions|Completed||N/A|812|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 00:18:48.473408|2018-06-01 00:18:48.473408
NCT01023776|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2011-08-02||2015-11-17|2009-12-01|2009-12-02|Estimate|2015-11-17|2015-12-23|Estimate||||2015-11-17|2015-12-23|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine|Evaluation of the Infectivity, Replication, and Immunogenicity of Live, Attenuated A/California/07/09 (nH1N1) Influenza Vaccine in Serosusceptible Adults|Completed||Phase 4|20|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 00:18:51.080838|2018-06-01 00:18:51.080838
NCT01023763|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2016-05-12|2009-12-01|2009-12-02|Estimate|||||||2016-05-12|2016-05-13|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|3IV||Intravenous Treatment in Nursing Homes|Can a Structured Training Program in Intravenous Treatment of Infections in Nursing Homes Lead to a Better Patient Trajectory and Reduced Hospital Admittance?|Completed||Phase 2|330|Actual|University of Oslo||2|||f||||f||||||||No||2018-06-01 00:18:51.260245|2018-06-01 00:18:51.260245
NCT01023750|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2015-10-11|2009-12-01|2009-12-02|Estimate|||||||2015-10-11|2015-10-14|Estimate|January 2010||2010-01-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|PreFar||Predictors of Response to Fenofibrate|Pretreatment Genotyping at APOA5 and GCKR Loci and Response to Fenofibrate Therapy|Completed|||39|Actual|University of Alabama at Birmingham|||1||f||||f||||||||||2018-06-01 00:18:51.529049|2018-06-01 00:18:51.529049
NCT01023737|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-08-16|2009-11-30|2009-12-02|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2009||2009-11-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Hydroxychloroquine + Vorinostat in Advanced Solid Tumors|Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer|Recruiting||Phase 1|48|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-06-01 00:18:51.631016|2018-06-01 00:18:51.631016
NCT01023724|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2011-05-25||2011-07-28|2009-12-01|2009-12-02|Estimate|2011-07-28|2011-08-26|Estimate||||2011-07-28|2011-08-26|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)|A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% BID and Bromfenac 0.09% BID|Completed||Phase 4|50|Actual|Bucci Laser Vision Institute||2|||f||||f||||||||||2018-06-01 00:18:51.74716|2018-06-01 00:18:51.74716
NCT01023711|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2015-04-24||2015-04-24|2009-12-01|2009-12-02|Estimate|2015-04-24|2015-05-12|Estimate||||2015-04-24|2015-05-12|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|July 2011|Actual|2011-07-31|November 2010|Actual|2010-11-30||Interventional|||Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus|Assessment of the Effect of Age and Priming on the Immunological Response to an Inactivated Vaccine for Novel H1N1 Virus.|Completed||N/A|107|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 00:18:52.007315|2018-06-01 00:18:52.007315
NCT01023698|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|PFC||Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters|Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters|Unknown status|Enrolling by invitation|Phase 4|30|Actual|Asociación para Evitar la Ceguera en México||1|||f||||f||||||||||2018-06-01 00:18:52.194714|2018-06-01 00:18:52.194714
NCT01023685|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-06-25|2009-12-01|2009-12-02|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients|An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106.|Completed||Phase 2|24|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:18:52.276682|2018-06-01 00:18:52.276682
NCT01023672|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2013-06-24||2013-06-24|2009-12-01|2009-12-02|Estimate|2013-06-24|2013-09-05|Estimate||||2013-06-24|2013-09-05|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"|An Open Label, Single-Center Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies|Completed||Phase 4|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:18:52.454537|2018-06-01 00:18:52.454537
NCT01023659|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2013-02-14||2018-01-23|2009-12-01|2009-12-02|Estimate|2013-02-14|2013-03-15|Estimate||||2018-01-23|2018-01-24|Actual|April 2010||2010-04-30|January 2018|2018-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts|An Innovative Approach to Maximizing the Impact of Efficacious Pharmacotherapies on Smoking Cessation Attempts.|Completed||Phase 4|893|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||No||2018-06-01 00:18:52.666059|2018-06-01 00:18:52.666059
NCT01023646|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-04-24|2009-12-01|2009-12-02|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2007||2007-12-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|||Glycemic Index - Variability Among Individuals|Evaluation of Glycemic Index to Assess Diet Associated Chronic Disease Risk|Completed||N/A|124|Anticipated|Tufts University||4|||f||||f||||||||||2018-06-01 00:18:53.198984|2018-06-01 00:18:53.198984
NCT01023633|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|July 2015|Anticipated|2015-07-31|January 2014|Anticipated|2014-01-31||Interventional|||OPTIMOX1 in Chinese mCRC Patients|A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer|Unknown status|Recruiting|Phase 4|300|Anticipated|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 00:18:53.294015|2018-06-01 00:18:53.294015
NCT01023620|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|HAL||HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)|Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations|Unknown status|Recruiting|N/A|24|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:18:53.385332|2018-06-01 00:18:53.385332
NCT01023607|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2013-09-10|2009-12-01|2009-12-02|Estimate|||||||2013-09-10|2013-09-11|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT) Combined With Intravascular Ultrasound (IVUS)|Evaluation of Statin-induced Lipid-rich Plaque Progression by Optical Coherence Tomography (OCT)Combined With Intravascular Ultrasound (IVUS)|Completed||Phase 4|120|Actual|Harbin Medical University||3|||f||||f||||||||||2018-06-01 00:18:53.464625|2018-06-01 00:18:53.464625
NCT01023594|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2015-09-14|2009-12-01|2009-12-02|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparison of Feasibility Between Internal and External Pancreatic Drainage in Pancreaticoduodenectomy|Comparison of Feasibility Between Internal and External Pancreatic Drainage in Pancreaticoduodenectomy: Prospective Randomized Study|Unknown status|Active, not recruiting|N/A|328|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:18:53.555906|2018-06-01 00:18:53.555906
NCT01023581|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2013-02-17||2013-02-17|2009-12-01|2009-12-02|Estimate|2013-02-17|2013-03-26|Estimate||||2013-02-17|2013-03-26|Estimate|November 2009||2009-11-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|AM7D||Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes|Completed||Phase 3|784|Actual|Takeda||7|||f||||t||||||||||2018-06-01 00:18:53.697976|2018-06-01 00:18:53.697976
NCT01023568|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2016-06-21||2016-12-08|2009-12-01|2009-12-02|Estimate|2016-12-08|2017-02-02|Estimate||||2016-12-08|2017-02-02|Estimate|December 2009||2009-12-31|December 2016|2016-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparison of Direct Laryngoscopy, Truview EVO2 and Glidescope in Pediatric Patients|Comparison of Direct Laryngoscopy, Truview EVO2 and Glidescope in Pediatric Patients|Terminated||N/A|134|Actual|The Cleveland Clinic||3||The study was stopped for futility at the first interim analysis|f||||f||||||||||2018-06-01 00:18:55.599724|2018-06-01 00:18:55.599724
NCT01023555|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-07-24|2009-12-01|2009-12-02|Estimate|||||||2011-07-24|2011-07-26|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Increasing the Yield of Blood Cultures in Neonates|Increasing the Yield of Blood Cultures in the Neonatal Intensive Care Unit- A Prospective Controlled Trial|Completed||N/A|1500|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 00:18:56.105952|2018-06-01 00:18:56.105952
NCT01023542|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-06-30|2009-12-01|2009-12-02|Estimate|||||||2011-06-30|2011-07-01|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|BUILT_01||"CNI-free Bottom-up Immunosuppression in Patients Undergoing Liver Transplantation"|A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores≥25|Unknown status|Recruiting|Phase 2/Phase 3|45|Anticipated|University of Regensburg||3|||f||||t||||||||||2018-06-01 00:18:56.308198|2018-06-01 00:18:56.308198
NCT01023529|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2015-11-17|2009-12-01|2009-12-02|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|PallRad1||Symptoms and Quality of Life (QoL) After Palliative Pelvic Radiation of Prostate and Rectal Cancers|A Prospective Multicenter Study of Symptoms and QOL in Patients With Prostate and Rectal Cancers Receiving Palliative Pelvic Radiation|Completed|||98|Actual|Sorlandet Hospital HF|||2||f||||f||||||||||2018-06-01 00:18:56.419022|2018-06-01 00:18:56.419022
NCT01023516|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2012-01-24||2012-06-19|2009-12-01|2009-12-02|Estimate|2012-06-19|2012-08-03|Estimate||||2012-06-19|2012-08-03|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol|A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol|Completed||Phase 2|615|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 00:18:56.574993|2018-06-01 00:18:56.574993
NCT01023503|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-31|||2013-07-23|2009-12-01|2009-12-02|Estimate|||||||2013-07-23|2013-07-24|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Observational|||Observational Study To Evaluate Statins Patterns Of Use In Spain|Statins Use Patterns in Spain|Withdrawn|||0|Actual|AstraZeneca|||1|"Changes affecting Post Authorization Study Regulatory effective from Dec09, impacted the~   requirements for Spanish studies at National and Regional level."|f||||f||||||||||2018-06-01 00:18:57.951136|2018-06-01 00:18:57.951136
NCT01023490|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-10-14|2009-12-01|2009-12-02|Estimate|||||||2012-10-14|2012-10-16|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Vitamin D Treatment to Patients Suffering From Chronic Pain and Vitamin D Hypovitaminosis|A Randomised, Double-blind, Placebo-controlled Study to Check Whether Vitamin D Will Lead to a Decrease in Pain Intensity in Patients Suffering From Chronic Pain and Hypovitaminosis D|Completed||N/A|12|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-06-01 00:18:58.112186|2018-06-01 00:18:58.112186
NCT01023477|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2017-03-07|2009-12-01|2009-12-02|Estimate|||||||2017-03-07|2017-03-08|Actual|December 2009||2009-12-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)|Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial|Completed||Phase 1/Phase 2|12|Actual|Inova Health Care Services||2|||f||||t||||||||||2018-06-01 00:18:58.287895|2018-06-01 00:18:58.287895
NCT01023464|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2016-11-17|2009-11-30|2009-12-02|Estimate|||||||2016-11-17|2016-11-18|Estimate|October 2009||2009-10-31|February 2012|2012-02-29||||January 2010|Actual|2010-01-31||Interventional|||Tear Film Break-Up Time Evaluation of FID 114657||Completed||N/A|38|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:18:58.410555|2018-06-01 00:18:58.410555
NCT01023451|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2014-06-24|2009-12-01|2009-12-02|Estimate|||||||2014-06-24|2014-06-26|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients|Serum Brain Natriuretic Peptide Levels and Its Correlation With Echocardiographic Measurements Suggestive of Pulmonary Hypertension in Pediatric Patients With Sickle Cell Disease|Completed|||21|Actual|Akron Children's Hospital|||||f||||f||||||||||2018-06-01 00:18:58.504558|2018-06-01 00:18:58.504558
NCT01023438|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-04-07|2009-12-01|2009-12-02|Estimate|||||||2017-04-07|2017-04-10|Actual|January 2010|Actual|2010-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|April 2010|Actual|2010-04-30||Interventional|||Strategies to Improve Prescribing in Heart Failure Patients|Strategies To Improve Appropriate Prescribing In Heart Failure Patients. Assessment of the Effectiveness of an Integrated Clinical Pathway Between Cardiology and Primary Care Physicians to Implement Pharmacological Treatment|Suspended||N/A|122|Anticipated|Niguarda Hospital||2||Up to sponsor decision|f||||f||||||||||2018-06-01 00:18:58.743999|2018-06-01 00:18:58.743999
NCT01023425|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2016-01-04|2009-12-01|2009-12-02|Estimate|||||||2016-01-04|2016-01-06|Estimate|February 2008||2008-02-29|January 2016|2016-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Clinical Trial of Donepezil Between the Naive Group and the Switching Group|Comparative Assessment of Clinical Efficacy of Donepezil Between the Naive Group and the Switching Group|Completed||N/A|72|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:18:59.073618|2018-06-01 00:18:59.073618
NCT01023412|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2012-04-24|2009-12-01|2009-12-02|Estimate|||||||2012-04-24|2012-04-25|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|IPOD-3||Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery|Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial|Terminated||Phase 3|107|Actual|Nestlé||2||"interim review of the data indicated that the hypothesis put forth on the efficacy of a 3 day~   regimen was not met."|f||||f||||||||||2018-06-01 00:18:59.6608|2018-06-01 00:18:59.6608
NCT01023399|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2015-02-20|2009-12-01|2009-12-02|Estimate|||||||2015-02-20|2015-02-23|Estimate|November 2009||2009-11-30|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire|A Nested Open Labeled Study to Compare the Effectiveness and Safety of a Fixed-dose Combination of Artesunate Plus Amodiaquine (ASAQ Winthrop®) in the Unsupervised Treatment of Uncomplicated Plasmodium Falciparum Malaria Attacks in Two Patient Groups Enrolled at Two Year-intervals in a Pilot District of Côte d'Ivoire|Completed||Phase 4|580|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:18:59.799849|2018-06-01 00:18:59.799849
NCT01023386|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2010-04-12|2009-11-30|2009-12-02|Estimate|||||||2010-04-12|2010-04-13|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer|A Clinical Pharmacological Study to Assess the Distribution, Metabolism, and Elimination of YM155 After i.v. Infusion in Patients With Advanced Cancer|Completed||Phase 1|6|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-06-01 00:18:59.912832|2018-06-01 00:18:59.912832
NCT01023373|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|October 2003||2003-10-31|December 2009|2009-12-31|May 2009|Anticipated|2009-05-31|September 2008|Anticipated|2008-09-30||Interventional|NITER||Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy|Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|Azienda Unità Sanitaria Locale di Piacenza||2|||f||||t||||||||||2018-06-01 00:19:00.007522|2018-06-01 00:19:00.007522
NCT01023360|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|May 2008||2008-05-31|June 2008|2008-06-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay|Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping™ Assay|Unknown status|Recruiting|Phase 4|30|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:19:00.131395|2018-06-01 00:19:00.131395
NCT01023347|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-05-08|2009-12-01|2009-12-02|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2008|Actual|2008-06-30|May 2017|2017-05-31|June 2012|Actual|2012-06-30|December 2009|Actual|2009-12-31||Interventional|||A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer||Completed||Phase 2|276|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||||||||||||2018-06-01 00:19:00.321193|2018-06-01 00:19:00.321193
NCT01023334|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-07-30|2009-12-01|2009-12-02|Estimate|||||||2010-07-30|2010-08-02|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Combined Intracameral Lidocaine for Manual Small Incision Cataract Surgery Under Topical Anesthesia|Combined Intracameral Lidocaine for Manual Small Incision Cataract Surgery Under Topical Anesthesia|Completed||N/A|200|Anticipated|Wenzhou Medical University||2|||f||||t||||||||||2018-06-01 00:19:00.410215|2018-06-01 00:19:00.410215
NCT01023321|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2010-08-11|2009-12-01|2009-12-02|Estimate|||||||2010-08-11|2010-08-12|Estimate|December 2009||2009-12-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||First-in-Human Single Ascending and Multiple Dose of GLPG0555|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0555 in Healthy Subjects.|Completed||Phase 1|35|Actual|Galapagos NV||4|||f||||f||||||||||2018-06-01 00:19:00.510996|2018-06-01 00:19:00.510996
NCT01023308|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2015-03-23||2016-11-02|2009-12-01|2009-12-02|Estimate|2015-09-21|2015-10-23|Estimate||||2016-11-02|2016-12-29|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|March 2013|Actual|2013-03-31||Interventional|PANORAMA-1||Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma|A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma|Completed||Phase 3|768|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:19:00.72097|2018-06-01 00:19:00.72097
NCT01023295|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30||2011-10-28|2011-10-28|2009-12-01|2009-12-02|Estimate||||2011-10-28|2011-11-01|Estimate|2011-10-28|2011-11-01|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)|OXiGENE OXC402-201: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Biological Effects of Intravenous Fosbretabulin in Asian Subjects With Polypoidal Choroidal Vasculopathy (PCV)|Completed||Phase 2|20|Actual|Mateon Therapeutics||5|||f||||t||||||||||2018-06-01 00:19:03.79686|2018-06-01 00:19:03.79686
NCT01023282|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-11-01|2009-12-01|2009-12-02|Estimate|||||||2011-11-01|2011-11-02|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients|Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure|Completed||Phase 1|22|Actual|NeuroSearch A/S||2|||f||||f||||||||||2018-06-01 00:19:03.904189|2018-06-01 00:19:03.904189
NCT01023269|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-01-13|2009-12-01|2009-12-02|Estimate|||||||2012-01-13|2012-01-16|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|ACCEPTANCE||Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder|Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder|Terminated||Phase 4|17|Actual|Medtronic International Trading Sarl||2||difficulty in the enrolment|f||||t||||||||||2018-06-01 00:19:03.98384|2018-06-01 00:19:03.98384
NCT01023256|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-04-07||2014-10-15|2009-12-01|2009-12-02|Estimate|2014-04-07|2014-05-08|Estimate||||2014-10-15|2014-10-24|Estimate|December 2009||2009-12-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||All baseline participants were included in baseline analyses.|Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of MOR103 Administered Intravenously to Patients With Active Rheumatoid Arthritis|Completed||Phase 1/Phase 2|96|Actual|MorphoSys AG|Key limitations of this trial include its small sample size, limited duration, and exclusion of patients with severe rheumatoid arthritis. Larger clinical trials are needed to confirm these data and define the optimal MOR103 dosage.|3|||f||||t||||||||||2018-06-01 00:19:04.134352|2018-06-01 00:19:04.134352
NCT01023243|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2016-01-05|2009-12-01|2009-12-02|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Natural Language Processing and Quality Assessment in Primary Care|Novel Use of Natural Language Processing and Targeted Patient Education Information Regarding the Process for Completion of the Foot Examination in Primary Care|Completed||N/A|389|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 00:19:05.086908|2018-06-01 00:19:05.086908
NCT01023230|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2018-02-27|2009-11-30|2009-12-02|Estimate|||||||2018-02-27|2018-03-01|Actual|September 2009||2009-09-30|February 2018|2018-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Assess DV-601 in Subjects With Chronic Hepatitis B|A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue|Completed||Phase 1|14|Actual|Dynavax Technologies Corporation||1|||f||||f||||||||Undecided|a/o August 2016, decision is still pending.|2018-06-01 00:19:05.17011|2018-06-01 00:19:05.17011
NCT01023217|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|2013-11-23||2014-01-15|2009-12-01|2009-12-02|Estimate|2013-11-23|2014-01-13|Estimate||||2014-01-15|2014-02-10|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|CAESAR|Lamivudine-resistant CHB patients who had failed to respond to lamivudine plus adefovir combination therapy|Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir|Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir|Completed||Phase 4|90|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 00:19:05.263521|2018-06-01 00:19:05.263521
NCT01023204|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30||2010-02-02|2010-02-02|2009-11-30|2009-12-02|Estimate||||2010-02-02|2010-02-04|Estimate|2010-02-02|2010-02-04|Estimate|October 2002||2002-10-31|December 2009|2009-12-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer|Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer|Completed||Phase 2|68|Anticipated|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 00:19:05.57205|2018-06-01 00:19:05.57205
NCT01023191|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-07-14|2009-12-01|2009-12-02|Estimate|||||||2011-07-14|2011-07-15|Estimate|December 2011||2011-12-31|May 2010|2010-05-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|||Open Versus Percutaneous Insertion of CAPD Catheters|A Prospective Randomized Controlled Trial of Local Anaesthetic Percutaneous Insertion Versus General Anaesthetic Open Surgical Placement of Continuous Peritoneal Dialysis Catheters in a University Teaching Hospital|Unknown status|Not yet recruiting|N/A|124|Anticipated|University of Hull||2|||f||||f||||||||||2018-06-01 00:19:05.643685|2018-06-01 00:19:05.643685
NCT01023178|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2014-07-16||2016-11-28|2009-11-30|2009-12-02|Estimate|2016-11-28|2017-01-20|Estimate||||2016-11-28|2017-01-20|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure|Comparison of Transdermal and Oral Estrogens in Adolescents With Ovarian Failure|Completed||N/A|20|Actual|Stanford University||3|||f||||f||||||||||2018-06-01 00:19:05.733593|2018-06-01 00:19:05.733593
NCT01023165|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-06-21|2009-12-01|2009-12-02|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes|Multicenter Trial to Evaluate the Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetics Who Despite Tight Control and Proper Diet Still Suffer From Metabolic Problems|Unknown status|Recruiting|Phase 3|2000|Anticipated|Global Infusion and Aspiration Systems, LLC||1|||f||||t||||||||||2018-06-01 00:19:06.116212|2018-06-01 00:19:06.116212
NCT01023152|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate||||December 2009|2009-12-31||||||||Interventional|||Effect of Remote Ischemic Preconditioning on Acute Kidney Injury in Patients Undergoing Heart Valve Replacement Surgery With Cardiopulmonary Bypass||Completed||N/A|74|Actual|Yonsei University||1|||f||||f||||||||||2018-06-01 00:19:06.209026|2018-06-01 00:19:06.209026
NCT01023139|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|March 2011|Anticipated|2011-03-31|November 2010|Anticipated|2010-11-30||Interventional|AOS||"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"|"Efficacy in Adolescents of Continued Behavior Modification Following a Six Month Sibutramine-based Weight Management Intervention"|Unknown status|Recruiting|N/A|100|Anticipated|Brooke Army Medical Center||2|||f||||f||||||||||2018-06-01 00:19:06.290185|2018-06-01 00:19:06.290185
NCT01023126|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|May 2007||2007-05-31|December 2009|2009-12-31|September 2009|Actual|2009-09-30|August 2007|Actual|2007-08-31||Interventional|||Obesity and Psychotherapy as an Alternative to Treatment|Poor Patients Adherence to Exercise and Group Therapy as an Approach to Obesity Treatment|Completed||N/A|40|Actual|Feevale||2|||f||||t||||||||||2018-06-01 00:19:06.38815|2018-06-01 00:19:06.38815
NCT01023113|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2009-12-01|2009-12-01|2009-12-02|Estimate|||||||2009-12-01|2009-12-02|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|||To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation|To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation|Unknown status|Recruiting|N/A|60|Anticipated|L.V. Prasad Eye Institute||2|||f||||f||||||||||2018-06-01 00:19:06.472876|2018-06-01 00:19:06.472876
NCT01023100|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2010-06-14|2009-11-30|2009-12-02|Estimate|||||||2010-06-14|2010-06-16|Estimate|March 2010||2010-03-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers|A Study In Trained Taste Panel Healthy Adult Volunteers To Investigate The Palatability Of Select Formulations Of CP-690,550 Oral Solution|Completed||Phase 1|5|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:19:06.541544|2018-06-01 00:19:06.541544
NCT01023087|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-01|||2011-07-24|2009-12-01|2009-12-02|Estimate|||||||2011-07-24|2011-07-26|Estimate|December 2009||2009-12-31|July 2010|2010-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Renal Impairment Associated With Colistin Levels|The Incidence of Renal Impairment Associated With Polymyxin E Treatment and the Impact of Measuring Colistin Levels|Completed|||70|Actual|Shaare Zedek Medical Center|||2||f||||f||||||Samples Without DNA|"~     Separated blood samples for Colistin levels assesment are kept in the immunology department~     refrigirator for analysis when the immunological method of the blood Colistin levels will be~     ready for use.~   "|||2018-06-01 00:19:06.61473|2018-06-01 00:19:06.61473
NCT01023074|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2015-01-29||2015-03-13|2009-12-01|2009-12-02|Estimate|2015-03-13|2015-03-17|Estimate||||2015-03-13|2015-03-17|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Training on Central Auditory Function in Multiple Sclerosis|Effects of Training on Central Auditory Function in Multiple Sclerosis|Completed||N/A|52|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 00:19:06.717292|2018-06-01 00:19:06.717292
NCT01023061|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2017-03-23||2017-05-03|2009-11-30|2009-12-02|Estimate|2017-05-03|2017-06-06|Actual||||2017-05-03|2017-06-06|Actual|March 2010||2010-03-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|RAD1|Men with intermediate or high risk localized prostate cancer|Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer|Phase II Trial of Radiation With Androgen Deprivation: Abiraterone Acetate, Prednisone and Luteinizing Hormone Releasing Hormone Agonist Prior to Radiation Therapy|Completed||Phase 2|24|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 00:19:06.98256|2018-06-01 00:19:06.98256
NCT01023048|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-04-01|2009-11-30|2009-12-02|Estimate|||||||2014-04-01|2014-04-02|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|IVF008||Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)|First Use of Parental Support Technology(R) for Single Gene Analysis Plus Aneuploidy Screening in Preimplantation Genetic Diagnosis|Completed||N/A|56|Actual|Natera, Inc.||1|||f||||f||||||||||2018-06-01 00:19:07.212013|2018-06-01 00:19:07.212013
NCT01023035|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2012-10-16||2017-03-09|2009-11-25|2009-12-01|Estimate|2012-10-16|2012-11-15|Estimate||||2017-03-09|2017-04-07|Actual|December 2009||2009-12-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)|Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia|Completed||Phase 3|687|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:19:07.304841|2018-06-01 00:19:07.304841
NCT01023022|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|2014-08-22||2016-11-24|2009-11-30|2009-12-01|Estimate|2015-04-21|2015-04-23|Estimate||||2016-11-24|2016-11-28|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Observational|||CareLink® Network Evaluation|Medtronic CareLink® Network Evaluation Protocol|Completed|||176|Actual|Medtronic Bakken Research Center|||1||f||||f||||||||||2018-06-01 00:19:08.13372|2018-06-01 00:19:08.13372
NCT01023009|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-29|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Observational|Vitrectomy||Postoperative Evolution After Small Gauge Vitrectomy Without Eye Occlusion||Unknown status|Recruiting||50|Anticipated|Asociación para Evitar la Ceguera en México|||1||f||||f||||||||||2018-06-01 00:19:08.52023|2018-06-01 00:19:08.52023
NCT01022996|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2015-11-23||2016-04-18|2009-11-30|2009-12-01|Estimate|2016-03-08|2016-04-06|Estimate||||2016-04-18|2016-05-18|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug.|Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.|An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma|Completed||Phase 2|57|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:19:08.611639|2018-06-01 00:19:08.611639
NCT01022983|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2012-12-12|2009-11-30|2009-12-01|Estimate|||||||2012-12-12|2012-12-17|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PELS||Preoperative Levosimendan and Heart Failure|Preoperative Levosimendan in Patients With Heart Failure Undergoing Elective Noncardiac Surgery: A Randomized, Placebocontrolled Trial. SIMPLE Study|Withdrawn||Phase 4|0|Actual|Sykehuset i Vestfold HF||2||Not finding patients for including|f||||t||||||||||2018-06-01 00:19:08.983869|2018-06-01 00:19:08.983869
NCT01022970|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25||2013-10-29|2013-11-21|2009-11-30|2009-12-01|Estimate||||2013-10-29|2013-11-21|Estimate|2013-11-21|2013-12-16|Estimate|November 2009||2009-11-30|November 2013|2013-11-30||||February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis|A Double Blinded Randomized Placebo-controlled Trial of Intravenous QAX576 in the Treatment of Eosinophilic Esophagitis (EoE)|Completed||Phase 2|25|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:19:09.070459|2018-06-01 00:19:09.070459
NCT01022957|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-11-17|2009-11-30|2009-12-01|Estimate|||||||2017-11-17|2017-11-20|Actual|November 2006||2006-11-30|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|NEPHAER||Nephronophthisis : Clinical and Genetic Study|Characterization and Analysis of Long-term Evolution of Renal and Extra-renal Damages in the Course of Nephronophthisis|Completed||N/A|150|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:19:09.144999|2018-06-01 00:19:09.144999
NCT01022944|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2013-02-20|2009-11-30|2009-12-01|Estimate|||||||2013-02-20|2013-02-21|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|BOLERO||Prevalence of Mucosal Biofilm Formations in Adenoidectomy Specimens|Prevalence of Mucosal Biofilm Formations in Adenoidectomy Specimens. A Case Control Study|Completed||Early Phase 1|113|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:19:09.220403|2018-06-01 00:19:09.220403
NCT01022931|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2012-12-10|2009-11-30|2009-12-01|Estimate|||||||2012-12-10|2012-12-11|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|February 2010|Actual|2010-02-28||Observational|||Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva|Evaluation of a New Virus(Influenza A H1N1/09) in Children: Epidemiology, Clinical Presentation and Outcome, and Response to Treatment|Completed|||200|Actual|University Hospital, Geneva|||||f||||t||||||Samples With DNA|"~     Nasal swab; DNA for genetic polymorphisms (Response to oseltamivir)~   "|||2018-06-01 00:19:09.310294|2018-06-01 00:19:09.310294
NCT01022918|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2012-09-24|2009-11-30|2009-12-01|Estimate|||||||2012-09-24|2012-09-25|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|TemAvIr||Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma|Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide|Completed||Phase 2|134|Actual|Centre Georges Francois Leclerc||2|||f||||t||||||||||2018-06-01 00:19:09.371678|2018-06-01 00:19:09.371678
NCT01022905|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2010-02-26|2009-11-30|2009-12-01|Estimate|||||||2010-02-26|2010-03-01|Estimate|November 2009||2009-11-30|February 2009|2009-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients|Prospective Cohort Study of the Influence of Age, Underlying Disease and Immunosuppression on Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients.|Completed||Phase 4|1141|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 00:19:09.455754|2018-06-01 00:19:09.455754
NCT01022892|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2012-03-05|2009-11-30|2009-12-01|Estimate|||||||2012-03-05|2012-03-07|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Contrast Ultrasound in the Surveillance of Endovascular Abdominal Aortic Aneurysm Repair|Contrast Ultrasound in the Surveillance of Endovascular Abdominal Aortic Aneurysm Repair|Completed|||140|Actual|Ottawa Hospital Research Institute|||2||f||||t||||||||||2018-06-01 00:19:09.533966|2018-06-01 00:19:09.533966
NCT01022879|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-29|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Interventional|Anesthesia||Topical Anesthesia in Small Gauge Vitrectomy|Pain Scale in the Use of Topical Anesthesia in Small Gauge Vitrectomy|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||f||||||||||2018-06-01 00:19:09.615432|2018-06-01 00:19:09.615432
NCT01022866|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2018-05-01|2009-11-27|2009-12-01|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2010||2010-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Falls Prevention Clinic|Vancouver Falls Prevention Clinic Database|Recruiting|||440|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 00:19:09.660904|2018-06-01 00:19:09.660904
NCT01022853|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2013-11-01|2009-11-26|2009-12-01|Estimate|||||||2013-11-01|2013-11-04|Estimate|December 2009||2009-12-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors|An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBF 1120 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|30|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:19:09.75064|2018-06-01 00:19:09.75064
NCT01022840|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-21|||2012-10-01|2009-11-30|2009-12-01|Estimate|||||||2012-10-01|2012-10-02|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|Miniket||The Preemptive Analgetic Potency of Low Dose S-Ketamine|The Opioid Sparing Effect of Minimal Dose S-Ketamine Applied as a Coanalgesic During the Perioperative Period - An Active Placebo-Controlled, Double Blinded, Randomized Clinical Trial (МiniKet)|Completed||Phase 3|60|Actual|Medical University of Graz||3|||f||||t||||||||||2018-06-01 00:19:09.823793|2018-06-01 00:19:09.823793
NCT01022827|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2012-01-03|2009-11-30|2009-12-01|Estimate|||||||2012-01-03|2012-01-05|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Shoulder Muscle Massage Shoulder Stiffness|Effects and Predictors of Effectiveness of Shoulder Muscle Massage for Patients With Posterior Shoulder Stiffness|Completed||Phase 1|52|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 00:19:09.897503|2018-06-01 00:19:09.897503
NCT01022801|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30||2010-01-29|2010-01-29|2009-11-30|2009-12-01|Estimate||||2010-01-29|2010-02-02|Estimate|2010-01-29|2010-02-02|Estimate|August 2003||2003-08-31|November 2009|2009-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Phase II Dose Response Study in Japan in Chronic Hepatitis B|A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) vs Lamivudine in Adults With Chronic Hepatitis B Infection|Completed||Phase 2|120|Anticipated|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 00:19:10.13065|2018-06-01 00:19:10.13065
NCT01022788|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2015-04-27|2009-11-27|2009-12-01|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|INSIST||Improving Newborn Survival In Southern Tanzania|Improving Newborn Survival in Rural Southern Tanzania: a Study to Evaluate the Impact and Cost of a Scaleable Package of Interventions at Community Level With Health System Strengthening|Completed||N/A|47688|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:19:10.205171|2018-06-01 00:19:10.205171
NCT01022775|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|April 2001||2001-04-30|November 2009|2009-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|ADHCIS||Dynamic Humeral Centering in Impingement Syndrome|Assessment of Dynamic Humeral Centering in Impingement Syndrome: a Randomized Clinical Trial|Completed||Phase 3|70|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:19:10.300251|2018-06-01 00:19:10.300251
NCT01022762|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|2011-11-24||2014-06-25|2009-11-26|2009-12-01|Estimate|2011-11-24|2011-12-29|Estimate||||2014-06-25|2014-07-09|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment|A 16-week, Multicentre, Randomised, Open-label, Parallel Group Study to Investigate the Efficacy and Safety Profiles of Repaglinide Monotherapy Compared to Gliclazide Monotherapy in Chinese Antidiabetic-naïve Subjects With Type 2 Diabetes|Completed||Phase 4|440|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:19:10.448877|2018-06-01 00:19:10.448877
NCT01022749|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2013-08-02|2009-11-30|2009-12-01|Estimate|||||||2013-08-02|2013-08-05|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2011|Actual|2011-07-31||Interventional|MICIVAX||Efficacy Safety Study of Flu Vaccine in Immunodepression Patients|Prospective, Multicentre, Open-label Study Evaluating the Immunogenicity and Safety of Influenza Vaccine in Patients With Inflammatory Bowel Disease (IBD) Receiving or Not Immunosuppressive Therapy|Completed||Phase 3|228|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-06-01 00:19:11.098566|2018-06-01 00:19:11.098566
NCT01022736|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-12-07|2009-11-27|2009-12-01|Estimate|||||||2009-12-07|2009-12-08|Estimate|May 2007||2007-05-31|December 2009|2009-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Plasma Gabapentin Concentration During and Following Cardiac Bypass|Preemptive Gabapentin Administration and Perioperative Plasma Concentrations With Cardiac Bypass|Completed||Phase 4|16|Actual|Queen's University||1|||f||||f||||||||||2018-06-01 00:19:11.208639|2018-06-01 00:19:11.208639
NCT01022723|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2017-12-17|2009-11-30|2009-12-01|Estimate|||||||2017-12-17|2017-12-19|Actual|October 2009||2009-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CTC||Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells|Clinical Validation of a Microfluidic Device for Isolation and Molecular Characterization of Circulating Tumor Cells|Recruiting|||366|Anticipated|National Cancer Centre, Singapore|||6||f||||t||||||Samples With DNA|"~     Circulating Tumor Cells~   "|||2018-06-01 00:19:11.276731|2018-06-01 00:19:11.276731
NCT01022710|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-12-22|2009-11-30|2009-12-01|Estimate|||||||2015-12-22|2015-12-24|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Early Detection of Noise-Induced Hearing Loss|Early Detection of Noise-Induced Hearing Loss|Withdrawn|||0|Actual|VA Office of Research and Development|||1|"We did not enroll any subjects because we realized we needed to establish the technique more~   definitively before proceeding to human testing."|f||||f||||||None Retained|"~     No biospecimens will be collected for this study~   "|||2018-06-01 00:19:11.427774|2018-06-01 00:19:11.427774
NCT01022697|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2012-08-31|2009-11-30|2009-12-01|Estimate|||||||2012-08-31|2012-09-03|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SOLISO||Evaluation of the Benefits of Glucose Drinks During Childbirth|Randomized Control Study : Evaluation of the Benefits of Glucose Drinks During Childbirth|Completed||N/A|4142|Actual|University Hospital, Caen||2|||f||||||||||||||2018-06-01 00:19:11.55098|2018-06-01 00:19:11.55098
NCT01022684|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2010-02-19|2009-11-30|2009-12-01|Estimate|||||||2010-02-19|2010-02-22|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Correlation Between Various Inflammatory Markers and Vascular Inflammation Measured by 18FDG-PET|Correlation of Inflammatory Markers Such as LpPLA2,MCP-1 and hsCRP for Predicting Vascular Inflammation; Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography|Completed|||150|Actual|Korea University|||1||f||||t||||||Samples Without DNA|"~     Whole blood, serum~   "|||2018-06-01 00:19:11.647251|2018-06-01 00:19:11.647251
NCT01022671|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2016-01-27|2009-11-30|2009-12-01|Estimate|||||||2016-01-27|2016-01-28|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy|Single-Arm, Open-label, Multicenter, Phase 2 Clinical Trial to Assess the Efficacy and Safety of Single-Agent Camtobell Inj.(Belotecan) Administered on A Weekly Schedule in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Previously Treated With Chemotherapy|Completed||Phase 2|52|Actual|Chong Kun Dang Pharmaceutical||1|||f||||t||||||||No||2018-06-01 00:19:11.741961|2018-06-01 00:19:11.741961
NCT01022658|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2013-02-20|2009-11-30|2009-12-01|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|INSUVASC||INSUlin Regimens and VASCular Functions|Effects of Different Insulin Regimens on Artery Compliance, Endothelium Function and Autonomic Cardiac Function in Patients With Poorly Controlled Type 2 Diabetes: a Pilot Study|Completed||N/A|42|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-06-01 00:19:11.825017|2018-06-01 00:19:11.825017
NCT01022645|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2014-11-19|2009-11-30|2009-12-01|Estimate|||||||2014-11-19|2014-11-20|Estimate|November 2009||2009-11-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes|Postpartum Glucose Tolerance in Women With Recent Gestational Diabetes Using the Levonorgestrel IUD and Non-Hormonal Contraception: A Prospective Cohort Study|Completed|||42|Actual|Northwestern University|||2||f||||f||||||||||2018-06-01 00:19:11.935916|2018-06-01 00:19:11.935916
NCT01022632|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2010-01-27|2009-11-30|2009-12-01|Estimate|||||||2010-01-27|2010-01-28|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Curcumin as Nutraceutical in Patients of Depression|A Randomized, Active Controlled, Open Label, Parallel Group Study to Compare the Efficacy of Extract of Curcuma Longa (Turmeric) With Fluoxetine and to Study Its Effect as an Add on Therapy to Fluoxetine in Patients of Depression|Completed||N/A|60|Actual|Government Medical College, Bhavnagar||3|||f||||||||||||||2018-06-01 00:19:12.053214|2018-06-01 00:19:12.053214
NCT01022619|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|January 2010||2010-01-31|November 2009|2009-11-30||||January 2012|Anticipated|2012-01-31||Observational|||The Association Between High Risk Pregnancy and Sleep-disordered Breathing|The Association Between High Risk Pregnancy and Sleep-disordered Breathing|Unknown status|Not yet recruiting||150|Anticipated|Assaf-Harofeh Medical Center|||4||f||||f||||||Samples With DNA|"~     Cord blood will be obtained in EDTA tubes and serum-seperating tubes~   "|||2018-06-01 00:19:12.164415|2018-06-01 00:19:12.164415
NCT01022606|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2013-03-15|2009-11-25|2009-12-01|Estimate|||||||2013-03-15|2013-03-18|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Initial-VHS||Intra-arterial Measurement of pO2 in Walking Induced Transient Hack Profiles|"Intra-arterial Measurement of pO2 in Walking Induced Transient Hack (WITH) Profiles"|Terminated||Phase 1|10|Actual|University Hospital, Angers||1||Stopped for one complication event (arterial occlusion)|f||||t||||||||||2018-06-01 00:19:12.260037|2018-06-01 00:19:12.260037
NCT01022580|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2013-09-20|2009-11-30|2009-12-01|Estimate|||||||2013-09-20|2013-09-24|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|July 2015|Anticipated|2015-07-31|December 2013|Anticipated|2013-12-31||Interventional|TOLSURF||Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia|Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide|Unknown status|Active, not recruiting|Phase 3|524|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:19:12.347177|2018-06-01 00:19:12.347177
NCT01022567|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|2016-08-21||2017-07-26|2009-11-30|2009-12-01|Estimate|2017-01-02|2017-02-23|Actual||||2017-07-26|2017-08-25|Actual|November 2009||2009-11-30|July 2017|2017-07-31|December 2025|Anticipated|2025-12-31|June 2012|Actual|2012-06-30||Interventional|APPAC||Appendicectomy Versus Antibiotics in the Treatment of Acute Uncomplicated Appendicitis|Study of Surgical Treatment (Open Appendicectomy) Versus Antibiotic Treatment (Ertapenem) in the Treatment of Acute Uncomplicated Appendicitis|Active, not recruiting||N/A|530|Actual|Turku University Hospital||2|||f||||f||||||||No||2018-06-01 00:19:12.520446|2018-06-01 00:19:12.520446
NCT01022554|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-11-25|2009-11-25|2009-12-01|Estimate|||||||2009-11-25|2009-12-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:19:12.938234|2018-06-01 00:19:12.938234
NCT01022541|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2015-11-23|2009-11-30|2009-12-01|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2006||2006-06-30|May 2013|2013-05-31|February 2015|Actual|2015-02-28|December 2010|Actual|2010-12-31||Interventional|||Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer|Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer|Completed||Phase 2|47|Actual|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-06-01 00:19:12.979778|2018-06-01 00:19:12.979778
NCT01022528|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2013-10-15|2009-11-30|2009-12-01|Estimate|||||||2013-10-15|2013-10-17|Estimate|March 2009||2009-03-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Analgesic Effect of Preoperative Dexamethasone in Gynecological Laparotomies - a Dose-ranging Study||Completed||N/A|138|Actual|Women's College Hospital||2|||f||||||||||||||2018-06-01 00:19:13.164413|2018-06-01 00:19:13.164413
NCT01022515|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2014-06-18|2009-11-30|2009-12-01|Estimate|||||||2014-06-18|2014-06-19|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PHEO||Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma|Clinical Application of New Pheochromocytoma Markers: INSERM Pilot Study of the Specificity of Elevated Plasma EM66 Concentrations in Patients With Pheochromocytoma or Paraganglioma Compared to Patients With Essential Hypertension|Completed|||60|Actual|University Hospital, Rouen|||2||f||||f||||||Samples Without DNA|"~     5 ml blood sample on EDTA to collect 2,5 ml plasma, kept at -80°C, once a year.~   "|||2018-06-01 00:19:13.294583|2018-06-01 00:19:13.294583
NCT01022502|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2011-10-01||2012-09-14|2009-11-25|2009-12-01|Estimate|2012-09-14|2012-10-16|Estimate||||2012-09-14|2012-10-16|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Refined and Crude Indigo Naturalis Ointment in Treating Psoriasis|Efficacy and Safety Comparison Between Refined and Crude Indigo Naturalis Ointment in the Treatment of Psoriatic Vulgaris|Completed||Phase 2|38|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:19:13.469496|2018-06-01 00:19:13.469496
NCT01022489|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2015-07-28|2009-11-30|2009-12-01|Estimate|||||||2015-07-28|2015-07-29|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|TMS-Hz||High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled Study|Evaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) at High Frequency With Neuronavigation in the Treatment of Auditory Hallucinations : A Randomized Multicentric Controlled Study|Completed||Phase 2/Phase 3|72|Actual|University Hospital, Caen||2|||f||||t||||||||||2018-06-01 00:19:13.82628|2018-06-01 00:19:13.82628
NCT01022476|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2013-07-17|2009-11-30|2009-12-01|Estimate|||||||2013-07-17|2013-07-18|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|LIVERAL||Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients|A Pilot Study of Pharmacokinetics, Tolerance and Efficacy of Raltegravir Combined to Two Fully Active Molecules Among Nucleosi(ti)de Analogs and Enfuvirtide Before and After Liver Transplant in HIV Infected Patients With End Stage Liver Disease (ANRS 148 LIVERAL)|Completed||Phase 1/Phase 2|14|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-06-01 00:19:14.115001|2018-06-01 00:19:14.115001
NCT01022463|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2011-07-06|2009-11-30|2009-12-01|Estimate|||||||2011-07-06|2011-07-07|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|IVA-MS||Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm|Effect of Ivabradine vs Atenolol on Heart Rate and Effort Tolerance in Patients With Mild to Moderate Mitral Stenosis and Normal Sinus Rhythm|Completed||Phase 3|50|Actual|Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-06-01 00:19:14.272276|2018-06-01 00:19:14.272276
NCT01022450|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2009||2009-11-30|November 2009|2009-11-30||||November 2010|Anticipated|2010-11-30||Observational|||Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients|Rhabdomyolysis - A Retrospective Study in Hospitalized Patients|Unknown status|Recruiting||2500|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 00:19:14.530531|2018-06-01 00:19:14.530531
NCT01022437|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-12-17|2009-11-30|2009-12-01|Estimate|||||||2015-12-17|2015-12-18|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Geranium Oil and Its Components for the Relief of Numbness-OB 100|Geranium Oil and Its Components for the Relief of Numbness-OB 100|Completed||N/A|13|Actual|Pennington Biomedical Research Center||1|||f||||f||||||||||2018-06-01 00:19:16.087861|2018-06-01 00:19:16.087861
NCT01022424|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2015-10-16|2009-11-30|2009-12-01|Estimate|||||||2015-10-16|2015-10-19|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]|A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]|Completed||Phase 3|13|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:19:16.974111|2018-06-01 00:19:16.974111
NCT01022411|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2010-10-20|2009-11-30|2009-12-01|Estimate|||||||2010-10-20|2010-10-21|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|BRIMS||Brown Rice Intervention on Metabolic Syndrome (BRIMS)|A Randomized Prevention Trial Substituting Brown Rice for White Rice to Lower Markers for Diabetes Risk|Completed||Phase 2/Phase 3|202|Actual|Chinese Academy of Sciences||2|||f||||f||||||||||2018-06-01 00:19:18.018403|2018-06-01 00:19:18.018403
NCT01022398|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|2013-03-28||2013-03-28|2009-11-27|2009-12-01|Estimate|2013-03-28|2013-05-20|Estimate||||2013-03-28|2013-05-20|Estimate|February 2010||2010-02-28|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Vitamin D Replacement: The Effect on Statin-Related Myalgias|Vitamin D Replacement: The Effect on Statin-Related Myalgias|Terminated||N/A|4|Actual|Creighton University||2||Recruitment slow, funding ended.|f||||f||||||||||2018-06-01 00:19:19.102547|2018-06-01 00:19:19.102547
NCT01022385|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Effect of a Very Low-residual Diet on the Preparation Before Capsule Endoscopy||Unknown status|Not yet recruiting|N/A|||Hillel Yaffe Medical Center||2|||f||||||||||||||2018-06-01 00:19:21.484595|2018-06-01 00:19:21.484595
NCT01022372|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2011-05-09|2009-11-30|2009-12-01|Estimate|||||||2011-05-09|2011-05-10|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Endometrial Biopsy as Diagnostic Method for Endometriosis and Endometrioma|The Evaluation of Endometrial Biopsy in the Diagnosis of Endometriosis and Endometrioma: a Double Blind Study|Unknown status|Active, not recruiting||60|Anticipated|Selcuk University|||3||f||||||||||||||2018-06-01 00:19:22.228662|2018-06-01 00:19:22.228662
NCT01022359|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2016-05-12|2009-11-30|2009-12-01|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|VyTes||Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters|Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters|Completed||N/A|80|Actual|Imperial College Healthcare NHS Trust||2|||f||||f||||||||||2018-06-01 00:19:22.766505|2018-06-01 00:19:22.766505
NCT01022346|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20||2016-07-07|2016-08-11|2009-11-27|2009-12-01|Estimate||||2016-07-07|2016-07-11|Estimate|2016-08-11|2016-08-15|Estimate|August 2009||2009-08-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study of the Safety and Response Rate of 3 Subcutaneously Administered Doses of 5 X 10^7 PFU RO5217790 in Patients With High Grade Cervical Intraepithelial Neoplasia Grade 2 or 3 Associated With High Risk HPV Infection|Completed||Phase 2|206|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:19:23.480191|2018-06-01 00:19:23.480191
NCT01022333|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers|The Potential for Oral DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers|Unknown status|Recruiting|Phase 1|300|Anticipated|Women's College Hospital||3|||f||||t||||||||||2018-06-01 00:19:24.870186|2018-06-01 00:19:24.870186
NCT01022320|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Effect of Lateral Pharyngoplasty on Blood Pressure in Obstructive Sleep Apnea (OSA) Patients|Effect of Lateral Pharyngoplasty on Blood Pressure in Obstructive Sleep Apnea Patients|Unknown status|Recruiting|N/A|20|Anticipated|Hospital do Servidor Publico Estadual||1|||f||||f||||||||||2018-06-01 00:19:25.031041|2018-06-01 00:19:25.031041
NCT01022307|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2015-12-08||2015-12-08|2009-11-25|2009-12-01|Estimate|2015-12-08|2016-01-14|Estimate||||2015-12-08|2016-01-14|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|QALD||Quantitative Automated Lesion Detection of Traumatic Brain Injury|Quantitative Automated Lesion Detection of TBI|Completed|||212|Actual|VA Office of Research and Development|||2||f||||f||||||None Retained|"~     No biospecimen, only digital data.~   "|||2018-06-01 00:19:25.167428|2018-06-01 00:19:25.167428
NCT01022294|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2012-01-30|2009-11-27|2009-12-01|Estimate|||||||2012-01-30|2012-01-31|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Analgetic Effect of Nitrousoxide-oxygen Inhalation for Dental Treatment of Children|Analgetic Effect of Nitrousoxide-oxygen Inhalation for Dental Treatment of Children|Completed||N/A|56|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 00:19:25.743267|2018-06-01 00:19:25.743267
NCT01022281|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-05-09|2009-11-30|2009-12-01|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2007||2007-09-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Observational|||Early Diagnosis in Glaucoma With GDxVcc|Evaluation of Scanning Laser Polarimetry Findings in Individuals With Exfoliation Syndrome Compared With Normal Controls|Completed|||82|Actual|Aristotle University Of Thessaloniki|||2||f||||f||||||||||2018-06-01 00:19:26.070342|2018-06-01 00:19:26.070342
NCT01021800|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2010-01-12|2009-11-27|2009-11-30|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2009||2009-04-30|November 2009|2009-11-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|SYSTHER||Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma||Unknown status|Recruiting|Phase 2|30|Anticipated|Blood Transfusion Centre of Slovenia||1|||f||||t||||||||||2018-06-01 00:19:37.375545|2018-06-01 00:19:37.375545
NCT01022268|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2011-11-04|2009-11-30|2009-12-01|Estimate|||||||2011-11-04|2011-11-07|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|September 2014|Anticipated|2014-09-30|July 2012|Anticipated|2012-07-31||Observational|||Understanding Childhood Infection, Inflammation and Allergy|A Comprehensive, Long-term Integrated Programme to Study the Aetiology and Immunopathology of Childhood Infectious, Inflammatory and Allergic Disease, Using the Large Patient Base of Children Attending St Mary's Hospital, London|Unknown status|Recruiting||300|Anticipated|Imperial College London|||2||f||||f||||||Samples With DNA|"~     Serum Plasma DNA RNA~   "|||2018-06-01 00:19:26.212134|2018-06-01 00:19:26.212134
NCT01022255|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-01-29|2009-11-30|2009-12-01|Estimate|||||||2014-01-29|2014-01-30|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Autologous Vaccine for Follicular Lymphoma|Phase I Study of an Autologous Recombinant Idiotypic Vaccine Manufactured by magnICON® Technology for the Treatment of Patients With Relapsed or Transformed Follicular Lymphoma|Completed||Phase 1|28|Actual|Icon Genetics GmbH||1|||f||||f||||||||||2018-06-01 00:19:26.742803|2018-06-01 00:19:26.742803
NCT01022242|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2014-02-04||2014-04-30|2009-11-30|2009-12-01|Estimate|2014-04-30|2014-05-29|Estimate||||2014-04-30|2014-05-29|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional|PHSU02|3 patients were treated with an incorrect mixture of IMP and were analyzed separately.|Study of PXL01 Versus Placebo to Inhibit Adhesion Formation After Flexor Tendon Surgery|A Prospective Double-blind, Randomised Concept Study of PXL01 Versus Placebo in Flexor Tendon Surgery|Completed||Phase 2|138|Actual|Pergamum AB|High drop out rate leading to a low number of subjects analyzed.|2|||f||||f||||||||||2018-06-01 00:19:26.992875|2018-06-01 00:19:26.992875
NCT01022229|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2016-01-27|2009-11-30|2009-12-01|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Phase 3 Study of a Compound Natural Health Product in Children With ADHD|Completed||Phase 3|16|Actual|The Canadian College of Naturopathic Medicine||2|||f||||t||||||||||2018-06-01 00:19:28.065026|2018-06-01 00:19:28.065026
NCT01022216|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2012-02-20|2009-11-25|2009-12-01|Estimate|||||||2012-02-20|2012-02-22|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Efficacy Study of a Bioelectric Dressing Used With Negative Pressure Wound Therapy to Treat Diabetic and Pressure Ulcers|A Randomized, Controlled Trial of the Procellera™ Wound Dressing Used With Negative Pressure Wound Therapy (NPWT) in the Healing of Diabetic and Pressure Ulcers of the Foot|Completed||Phase 2|30|Anticipated|Vomaris Innovations||2|||f||||t||||||||||2018-06-01 00:19:28.312077|2018-06-01 00:19:28.312077
NCT01022203|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2014-12-12||2016-10-05|2009-11-30|2009-12-01|Estimate|2015-02-23|2015-03-09|Estimate||||2016-10-05|2016-11-16|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|December 2013|Actual|2013-12-31||Interventional||These variables were entered into initial GLMM outcome models with no variable predicting outcome.|Comparison of Couple-Based PTSD Treatment and Couple-Based PTSD Education|Couples Treatment of PTSD in OEF/OIF Veterans|Completed||N/A|138|Actual|VA Office of Research and Development|The study's small sample size makes results preliminary and precludes formal hypothesis testing of mediating variables. Our report of decreased PTSD may reflect regression toward the mean.|2|||f||||f||||||||No||2018-06-01 00:19:28.427649|2018-06-01 00:19:28.427649
NCT01022190|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|2013-02-08||2013-08-31|2009-11-30|2009-12-01|Estimate|2013-08-30|2013-09-02|Estimate||||2013-08-31|2013-09-09|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Arcoxia||Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement|Effect of Etoricoxib (Arcoxia) in Preventing Heterotopic Ossification After Total Hip Arthroplasty|Completed||Phase 4|42|Actual|Radboud University|Small sample size. However, due to ethical considerations, a two phase model is necessary to indicate effectivity of Etoricoxib in prevention HO in this phase.|1|||f||||f||||||||||2018-06-01 00:19:28.851813|2018-06-01 00:19:28.851813
NCT01022177|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2011-12-01|2009-11-30|2009-12-01|Estimate|||||||2011-12-01|2011-12-02|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|October 2010|Actual|2010-10-31||Interventional|||Influence of Acupuncture to Ocular Microcirculation in Patients With Diabetes Mellitus|Influence of Acupuncture to Ocular Microcirculation in Patients With Diabetes Mellitus|Unknown status|Recruiting|Phase 2|40|Anticipated|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 00:19:29.139258|2018-06-01 00:19:29.139258
NCT01022164|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-29|||2009-11-30|2009-11-30|2009-12-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|April 2010|Anticipated|2010-04-30|November 2009|Anticipated|2009-11-30||Interventional|fibringlue||Use of Fibrin Glue in Vitreoretinalsurgery|Safety and Efficacy in the Use of Fibrin Glue in Vitreoretinal Surgery|Unknown status|Recruiting|Phase 4|50|Anticipated|Asociación para Evitar la Ceguera en México||1|||f||||f||||||||||2018-06-01 00:19:29.261816|2018-06-01 00:19:29.261816
NCT01022151|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2010-11-18|2009-11-30|2009-12-01|Estimate|||||||2010-11-18|2010-11-19|Estimate|November 2007||2007-11-30|November 2010|2010-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Aminophylline and Cognitive Function After Sevoflurane Anaesthesia|Aminophylline Improves Early Postoperative Cognitive Recovery After Sevoflurane Anaesthesia: A Dose-Dependent Study|Completed||Phase 2|180|Actual|King Faisal University||6|||f||||f||||||||||2018-06-01 00:19:29.362938|2018-06-01 00:19:29.362938
NCT01022138|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-26|||2017-05-19|2009-11-26|2009-12-01|Estimate|||||||2017-05-19|2017-05-22|Actual|February 2011||2011-02-28|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer|A Phase II Study of Anti-CD3 x Anti-HER2/Neu Armed Activated T Cells After Second Line Chemotherapy in Women With HER2/Neu (0, 1+ or 2+) Metastatic Breast Cancers|Active, not recruiting||Phase 2|63|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 00:19:29.475997|2018-06-01 00:19:29.475997
NCT01022125|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2010-05-13|2009-11-25|2009-12-01|Estimate|||||||2010-05-13|2010-05-17|Estimate|January 2010||2010-01-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435|A Phase I Study in Healthy Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of Potential Phase III Formulations Compared to the Phase IIb Capsule and to Assess the Effect of Food on the Bioavailability of TMC435 Following Intake of the Phase IIb Capsule|Completed||Phase 1|28|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 00:19:29.590383|2018-06-01 00:19:29.590383
NCT01021605|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2012-08-02|2009-11-25|2009-11-30|Estimate|||||||2012-08-02|2012-08-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:19:40.633074|2018-06-01 00:19:40.633074
NCT01022112|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-29|2014-03-26||2014-05-27|2009-11-29|2009-12-01|Estimate|2014-05-27|2014-06-05|Estimate||||2014-05-27|2014-06-05|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally-Administered SGLT2 Inhibitor TA-7284|Completed||Phase 2|383|Actual|Mitsubishi Tanabe Pharma Corporation||5|||f||||f||||||||||2018-06-01 00:19:29.706404|2018-06-01 00:19:29.706404
NCT01022099|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2009-12-17|2009-11-30|2009-12-01|Estimate|||||||2009-12-17|2009-12-18|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|April 2007|Actual|2007-04-30||Interventional|||Prospective Randomized Trial of Navigated and Conventional TKA|Prospective Randomized Trial of Navigated and Conventional TKA With Radiographic and CT Evaluations|Completed||N/A|80|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 00:19:30.955563|2018-06-01 00:19:30.955563
NCT01022086|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2017-07-11|2009-11-30|2009-12-01|Estimate|||||||2017-07-11|2017-07-12|Actual|November 2009||2009-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab|Assessment of Cardiotoxicity by Cardiac MRI Versus MUGA Scans in Breast Cancer Patients Receiving Trastuzumab: A Double-Blinded Prospective Observational Pilot Study|Recruiting|||50|Anticipated|St. Michael's Hospital, Toronto|||5||f||||f||||||Samples Without DNA|"~     Mandatory: Troponin I/T and BNP will be assessed at each CMR time-point (and measured as per~     the institution's standard biochemistry laboratory commercial assay techniques.~      Optional: For consenting patients only, peripheral venous blood samples will be drawn at each~     CMR time-point. Each sample will be obtained with a tourniquet free technique, then undergo~     centrifugation to prevent platelet degranulation and enable platelet free serum to be~     obtained. Serum will then be separated and stored at -800C for subsequent analysis. TGF β1,~     amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the~     carboxyterminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay~     with commercially available kits. The intra-assay variations for determining PINP, PIINP, and~     CITP are 7%, 5%, and 8% respectively. CITP will be measured by ELISA according to the~     manufacturer's instructions.~   "|||2018-06-01 00:19:31.075511|2018-06-01 00:19:31.075511
NCT01022073|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2016-03-31||2016-05-04|2009-11-30|2009-12-01|Estimate|2016-05-04|2016-06-10|Estimate||||2016-05-04|2016-06-10|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|CSP#468F|All enrolled participants.|Follow Up Study for Treatment of Parkinson's Disease With Deep Brain Stimulation|CSP #468F - Long Term Study of Deep Brain Stimulation for Parkinson's Disease: A Longitudinal Follow-Up Study of the VA/NINDS CSP #468 Cohort|Completed|||156|Actual|VA Office of Research and Development|||2||f||||t||||||||Undecided|We can share the data based on the VA approved Data Use Agreement(DUA)|2018-06-01 00:19:31.213743|2018-06-01 00:19:31.213743
NCT01022060|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2010-02-03|2009-11-27|2009-12-01|Estimate|||||||2010-02-03|2010-02-04|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis|Efficacy of Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis|Completed||Phase 3|110|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:19:31.783383|2018-06-01 00:19:31.783383
NCT01022047|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2015-07-24|2009-11-30|2009-12-01|Estimate|||||||2015-07-24|2015-07-27|Estimate|February 2010||2010-02-28|December 2010|2010-12-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|NOEX||Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis|A Phase III, Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis in a Test Group Treated With Noex 32 mcg and a Reference Group Treated With Budecort Aqua® 32 mcg|Completed||Phase 3|280|Actual|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-06-01 00:19:31.961018|2018-06-01 00:19:31.961018
NCT01022034|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-12-01|2009-11-30|2009-12-01|Estimate|||||||2009-12-01|2009-12-02|Estimate|January 2003||2003-01-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Interventional|Bergamaschi||Pexy Versus Non-pexy for Full Thickness Rectal Prolapse|Pexy vs. No Pexy in Abdominal Surgery for Full Thickness Rectal Prolapse in Adults: A Randomized Controlled Trial|Completed||Phase 3|180|Anticipated|Societa Italiana di Chirurgia ColoRettale||2|||f||||||||||||||2018-06-01 00:19:32.056919|2018-06-01 00:19:32.056919
NCT01022021|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2017-01-06|2009-11-30|2009-12-01|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|April 2014|Actual|2014-04-30||Interventional|||Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine|Adequacy of Peripheral Blood Stem Cell Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine: A Pilot Project and a Proof of Concept Study|Completed||Early Phase 1|17|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 00:19:32.142588|2018-06-01 00:19:32.142588
NCT01022008|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2015-04-09|2009-11-30|2009-12-01|Estimate|||||||2015-04-09|2015-04-10|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|September 2014|Actual|2014-09-30||Interventional|CRANIORESP||Assessment Study of Faciocraniosynostosis by Craniofacial Osteodistraction|Respiratory Improvement of Faciocraniosynostosis by Craniofacial Osteodistraction|Unknown status|Active, not recruiting|N/A|25|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:19:32.235472|2018-06-01 00:19:32.235472
NCT01021995|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-07-22|2009-11-30|2009-12-01|Estimate|||||||2014-07-22|2014-07-23|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|August 2010|Actual|2010-08-31||Interventional|||Echinacea Safety Study|Safety and Efficacy of Long-term Treatment With Echinaforce® Over 4 Months|Completed||Phase 4|757|Actual|Bioforce AG||2|||f||||f||||||||||2018-06-01 00:19:32.321762|2018-06-01 00:19:32.321762
NCT01021982|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-29|||2014-11-18|2009-11-29|2009-12-01|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2009||2009-11-30|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Evaluation of Objective Perimetry Using Pupillometer|Objective Perimetry in Normal Subjects,Glaucoma Patients and Retinitis Pigmentosa Patients .|Completed|||60|Actual|Sheba Medical Center|||2||f||||f||||||||||2018-06-01 00:19:32.400157|2018-06-01 00:19:32.400157
NCT01021969|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2011-07-18|2009-11-30|2009-12-01|Estimate|||||||2011-07-18|2011-07-19|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Dietary Fructose on Glucose and Lipid Metabolism in Healthy Human Subjects|Effects of Dietary Fructose on Glucose and Lipid Metabolism in Healthy Human Subjects|Completed||N/A|36|Anticipated|University of Zurich|||||f||||||||||||||2018-06-01 00:19:32.686839|2018-06-01 00:19:32.686839
NCT01021956|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-29|||2015-04-27|2009-11-29|2009-12-01|Estimate|||||||2015-04-27|2015-04-29|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD|A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)|Terminated||Phase 2|11|Actual|Steba Biotech S.A.||1||As two cases of retinal vascular occlusion in patients who received anti-VEGF|f||||f||||||||||2018-06-01 00:19:32.907545|2018-06-01 00:19:32.907545
NCT01021943|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2014-07-23|2009-11-30|2009-12-01|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 2009||2009-11-30|July 2014|2014-07-31||||||||Interventional|||Spironolactone and Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients|The Role of Spironolactone in Prevention of Calcineurin Inhibitor Toxicity in Kidney Transplant Recipients|Suspended||Phase 2|40|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||t||||||||||2018-06-01 00:19:33.329538|2018-06-01 00:19:33.329538
NCT01021930|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-30|||2010-05-25|2009-11-30|2009-12-01|Estimate|||||||2010-05-25|2010-05-26|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|DM-COVER||Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT|Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study)|Unknown status|Recruiting|Phase 4|70|Anticipated|Harbin Medical University||2|||f||||||||||||||2018-06-01 00:19:33.550286|2018-06-01 00:19:33.550286
NCT01021917|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2017-08-28|2009-11-25|2009-11-30|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2008||2008-03-31|August 2017|2017-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||SUCCESS Tracking Study|Weight Loss & Maintenance of Weight Loss Tracking Study (SUCCESS Tracking Study)|Terminated|||332|Anticipated|Medifast, Inc.|||3|"Given the length of time data was collected (i.e. 5 1/3 years), we do not anticipate a change~   any potential conclusions by completing the final survey."|f||||f||||||||||2018-06-01 00:19:33.676244|2018-06-01 00:19:33.676244
NCT01021904|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|June 2010||2010-06-30|November 2009|2009-11-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China||Unknown status|Not yet recruiting|Phase 4|6200|Anticipated|Chinese Academy of Medical Sciences|||||f||||t||||||||||2018-06-01 00:19:33.761725|2018-06-01 00:19:33.761725
NCT01021891|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2013-12-13|2009-11-27|2009-11-30|Estimate|||||||2013-12-13|2013-12-17|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)|A Phase 1b, Single-Dose, Open-Label, Parallel, Controlled Pharmacology Trial of Inhaled Technosphere®/Insulin in Non-Diabetic Subjects With COPD Versus Matched Non-Diabetic Subjects Without COPD.|Completed||Phase 1|39|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-06-01 00:19:33.871813|2018-06-01 00:19:33.871813
NCT01021878|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|2014-06-24||2014-09-30|2009-11-27|2009-11-30|Estimate|2014-09-30|2014-10-01|Estimate||||2014-09-30|2014-10-01|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|STARCH|From October 2009 to February 2012 60 patients were randomly assigned to the intervention (n=33) or the control (n=27) group. Completed follow-up was achieved for 34 patients, of which 17 of the control and 17 of the study group.|Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients|A Study to Evaluate the Effects of Icodextrin vs 2.5% Dianeal Used for the Long Dwell in Apd: a Randomized, Open-label Clinical Trial to Analyse the Insulin Resistance Using the Homa Index in Prevalent, Non-diabetic Patients|Completed||Phase 4|60|Actual|Pontifícia Universidade Católica do Paraná||2|||f||||t||||||||||2018-06-01 00:19:33.976195|2018-06-01 00:19:33.976195
NCT01021865|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2015-07-03|2009-11-25|2009-11-30|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|GLP-1||Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes|Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes: Modulation by Glucagon-Like-Peptide-1|Completed|||33|Actual|Mayo Clinic|||2||f||||t||||||||||2018-06-01 00:19:34.621583|2018-06-01 00:19:34.621583
NCT01021852|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2016-05-06||2017-06-02|2009-11-25|2009-11-30|Estimate|2016-05-06|2016-06-15|Estimate||||2017-06-02|2017-07-02|Actual|November 30, 2009|Actual|2009-11-30|June 2017|2017-06-30|February 1, 2011|Actual|2011-02-01|February 1, 2011|Actual|2011-02-01||Interventional||All Randomized Participants|Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period Adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK-6096 in Patients With Primary Insomnia|Completed||Phase 2|326|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-06-01 00:19:34.981975|2018-06-01 00:19:34.981975
NCT01021839|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-25|2009-11-25|2009-11-30|Estimate|||||||2009-11-25|2009-11-30|Estimate|April 2006||2006-04-30|November 2009|2009-11-30|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Comparison of Bovine Carotid Artery and Expanded Polytetrafluoroethylene (ePTFE) for Permanent Hemodialysis Access|Bovine Carotid Artery Graft Revisited: A Prospective, Randomized Comparison of Bovine Carotid Artery and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access|Completed||N/A|57|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:19:35.833971|2018-06-01 00:19:35.833971
NCT01021826|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2015-08-09|2009-11-27|2009-11-30|Estimate|||||||2015-08-09|2015-08-11|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Observational|HyTe-1||Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement|Determinants of Perioperative Hyperglycaemia in Primary Hip and Knee Replacement|Completed|||193|Actual|Coxa, Hospital for Joint Replacement|||1||f||||f||||||Samples Without DNA|"~     plasma sample (one per patient, collected before surgery)~   "|||2018-06-01 00:19:35.987817|2018-06-01 00:19:35.987817
NCT01021813|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2014-08-19||2017-06-01|2009-11-25|2009-11-30|Estimate|2014-08-19|2014-08-29|Estimate||||2017-06-01|2017-07-02|Actual|December 10, 2009|Actual|2009-12-10|June 2017|2017-06-30|August 1, 2011|Actual|2011-08-01|May 17, 2011|Actual|2011-05-17||Interventional||781 participants were randomized on study (suvorexant=522, placebo=259). 2 participants were randomized but not treated, thus the total number of participants evaluated for baseline age and gender was 779 (suvorexant=521, placebo=258). 771 participants had data available for evaluation of baseline sleep parameters (suvorexant=517, placebo=254)|A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients With Primary Insomnia|Completed||Phase 3|781|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 00:19:36.121335|2018-06-01 00:19:36.121335
NCT01021787|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2011-06-13|2009-11-27|2009-11-30|Estimate|||||||2011-06-13|2011-06-14|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream|Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF 40 Sunscreen Cream With Micronized TiO2 and Anthelios SX SPF 40 Cream (With Pigmentary TiO2) Into the Stratum Corneum of Compromised (Induced Sunburn) Human Skin|Completed||Phase 4|26|Actual|Loreal USA|||||f||||f||||||||||2018-06-01 00:19:37.446342|2018-06-01 00:19:37.446342
NCT01021774|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2016-11-28|2009-11-27|2009-11-30|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|||Anal Fistula Treatment Outcome - Collagen Plug Versus Advancement Flap Surgery|Comparison of Anal Fistula Treatment Outcome - Collagen Plug vs Advancement Flap Surgery. A Randomised Prospective Blinded Multi-centre Study|Completed||N/A|94|Actual|University Hospital, Akershus||2|||f||||f||||||||||2018-06-01 00:19:37.501961|2018-06-01 00:19:37.501961
NCT01021761|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2011-05-25||2011-08-26|2009-11-27|2009-11-30|Estimate|2011-07-28|2011-08-26|Estimate||||2011-08-26|2011-08-31|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification|A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification|Completed||Phase 4|126|Actual|Bucci Laser Vision Institute||3|||f||||f||||||||||2018-06-01 00:19:37.626572|2018-06-01 00:19:37.626572
NCT01021748|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-03-20|2009-11-25|2009-11-30|Estimate|||||||2015-03-20|2015-03-23|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|November 2012|Actual|2012-11-30||Interventional|||A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)|A Phase I Study of Oral MK-2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|63|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:19:37.934376|2018-06-01 00:19:37.934376
NCT01021735|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2015-05-28|2009-11-27|2009-11-30|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|ORBIT||Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy|Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy|Completed||Phase 4|302|Actual|University of Glasgow||2|||f||||t||||||||||2018-06-01 00:19:38.063123|2018-06-01 00:19:38.063123
NCT01021722|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|November 2002||2002-11-30|November 2009|2009-11-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Modified Surgical Approach to Women With Obstetric Anal Sphincter Tears|A Modified Surgical Approach to Women With Obstetric Anal Sphincter Tears|Completed||Phase 4|239|Actual|Karolinska University Hospital||3|||f||||f||||||||||2018-06-01 00:19:38.256092|2018-06-01 00:19:38.256092
NCT01021709|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2016-05-22|2009-11-27|2009-11-30|Estimate|||||||2016-05-22|2016-05-24|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Trial of Transcranial Direct Current Stimulation (tDCS) Using Alternative Electrode Montages||Completed||Phase 2|29|Actual|The University of New South Wales||1|||f||||t||||||||||2018-06-01 00:19:38.347365|2018-06-01 00:19:38.347365
NCT01021696|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2011-08-09|2009-11-27|2009-11-30|Estimate|||||||2011-08-09|2011-08-10|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Pain in Patients With Dementia and Behavioural Disturbances|The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial|Completed||Phase 2/Phase 3|352|Actual|University of Bergen||5|||f||||t||||||||||2018-06-01 00:19:38.459067|2018-06-01 00:19:38.459067
NCT01021683|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2013-04-15||2013-07-24|2009-11-27|2009-11-30|Estimate|2013-04-15|2013-07-03|Estimate||||2013-07-24|2013-08-12|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational||Baseline characteristics were reported only for intent-to-treat (ITT) population which included 150 participants.|The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants|The Relationship of Defeverscence and Itraconazole Plasma Level Using Sporanox IV as an Empiric Therapy in Immunocompromised Patients Who Have Been Treated With Sporanox Oral Solution as Prophylaxis|Completed|||203|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||Samples Without DNA|"~     Blood cultures~   "|||2018-06-01 00:19:38.629252|2018-06-01 00:19:38.629252
NCT01021670|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2013-11-25|2009-11-25|2009-11-30|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|September 2012|Actual|2012-09-30|||||Observational|||An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride|A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY or Alternate Care|Completed|||10027|Actual|Janssen Research & Development, LLC|||2||f||||f||||||||||2018-06-01 00:19:39.015578|2018-06-01 00:19:39.015578
NCT01021657|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Lipid Profile of Tenon's Capsule|Lipid Profile of Tenon's Capsule in Glaucoma Patients|Completed|||27|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||f||||||Samples Without DNA|"~     Eye Tenon's Capsule~   "|||2018-06-01 00:19:39.369124|2018-06-01 00:19:39.369124
NCT01021644|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2014-02-13|2009-11-25|2009-11-30|Estimate|||||||2014-02-13|2014-02-14|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Genes, Exercise, Memory and Neurodegeneration|Effects of Standardized Aerobic Exercise-Training on Neurocognitive and Neurodegeneration|Completed||N/A|73|Actual|Howard University||2|||f||||t||||||||||2018-06-01 00:19:39.437966|2018-06-01 00:19:39.437966
NCT01021631|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|February 2009||2009-02-28|November 2009|2009-11-30|April 2010|Anticipated|2010-04-30|February 2010|Anticipated|2010-02-28||Interventional|TRACS||TRACS STUDY: Transfusion Requirements After Cardiac Surgery|Transfusion Requirements After Cardiac Surgery: a Randomized Controlled Clinical Trial (TRACS STUDY)|Unknown status|Recruiting|Phase 3|500|Anticipated|Instituto do Coracao||2|||f||||t||||||||||2018-06-01 00:19:39.933701|2018-06-01 00:19:39.933701
NCT01021618|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2012-10-23||2013-03-18|2009-11-27|2009-11-30|Estimate|2012-11-27|2012-12-28|Estimate||||2013-03-18|2013-03-21|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging|The Ex-Lex Trial: A Randomized Trial Combining Regadenoson With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging|Completed||N/A|140|Actual|Hartford Hospital||2|||f||||f||||||||||2018-06-01 00:19:40.075098|2018-06-01 00:19:40.075098
NCT01021592|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2014-12-22|2009-11-25|2009-11-30|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Quality of Life in Multiple Myeloma Patients Treated With Bortezomib|Evaluation of Improvement of Quality of Life in Multiple Myeloma Patients Treated With Velcade (Bortezomib) IV: Prospective, Multicenter, Observational Study|Completed|||140|Actual|Janssen Korea, Ltd., Korea|||1||f||||t||||||||||2018-06-01 00:19:40.68267|2018-06-01 00:19:40.68267
NCT01021579|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study||Completed||Phase 4|84|Anticipated|Fasa University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:19:40.780916|2018-06-01 00:19:40.780916
NCT01021566|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|HPDMT||Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis|Advances in Opiate Detoxification Using the Combined Hemoperfusion-hemodialysis: A Comparison Study With Conventional Methadone Treatment (HPDMT)|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|First People's Hospital of Foshan||2|||t||||||||||||||2018-06-01 00:19:40.899367|2018-06-01 00:19:40.899367
NCT01021553|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2017-06-20|2012-02-16|2017-08-11|2009-11-27|2009-11-30|Estimate|2017-08-11|2017-09-12|Actual|2012-02-16|2012-02-20|Estimate|2017-08-11|2017-09-12|Actual|December 23, 2009|Actual|2009-12-23|August 2017|2017-08-31|May 5, 2011|Actual|2011-05-05|May 5, 2011|Actual|2011-05-05||Interventional|||A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation|A Phase II Study to Evaluate: Delay in Intravaginal Ejaculatory Latency Time (IELT), Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Randomized, Double Blind, Placebo-Controlled, Parallel Group Study in Men With Premature Ejaculation|Completed||Phase 2|77|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:19:41.131156|2018-06-01 00:19:41.131156
NCT01021540|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2011-07-13|2009-11-27|2009-11-30|Estimate|||||||2011-07-13|2011-07-14|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|ACTH||Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes|Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes|Completed||Phase 4|18|Anticipated|Arizona Kidney Disease and Hypertension Center|||||f||||f||||||||||2018-06-01 00:19:42.569858|2018-06-01 00:19:42.569858
NCT01021527|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-04-27|2009-11-25|2009-11-30|Estimate|||||||2015-04-27|2015-04-28|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)|A Randomized, 4-Period Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:19:42.65972|2018-06-01 00:19:42.65972
NCT01021514|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2011-04-05|2009-11-27|2009-11-30|Estimate|||||||2011-04-05|2011-04-06|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Observational|||Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE|Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE|Completed|||82|Actual|Korea University|||2||f||||f||||||||||2018-06-01 00:19:42.757779|2018-06-01 00:19:42.757779
NCT01021501|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|April 2011|Anticipated|2011-04-30|December 2010|Anticipated|2010-12-31||Interventional|PICASSO||The Pharmacokinetics of Nifedipine Controlled Release Tablets in Hypertensive Patients on Hemodialysis|the Effect of Nifedipine Controlled Release Tablets in Hypertensive Patients on Chronic Maintenance Hemodialysis and the Influence of Hemodialysis on the Plasma Concentration of Nifedipine|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Guangzhou First People's Hospital||1|||f||||t||||||||||2018-06-01 00:19:42.838586|2018-06-01 00:19:42.838586
NCT01021488|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2011-10-04|2009-11-27|2009-11-30|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|STOP-DVT||Rosuvastatin for Preventing Deep Vein Thrombosis|Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|180|Anticipated|Hallym University Medical Center||2|||f||||t||||||||||2018-06-01 00:19:42.926353|2018-06-01 00:19:42.926353
NCT01021475|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2009-11-27|2009-11-27|2009-11-30|Estimate|||||||2009-11-27|2009-11-30|Estimate|November 2009||2009-11-30|November 2009|2009-11-30||||November 2010|Anticipated|2010-11-30||Interventional|||Does Visceral Manipulation Works in Treating Functional Dyspepsia?|Does Visceral Manipulation Works in Treating Functional Dyspepsia? A Randomized Study|Unknown status|Recruiting|Phase 1|50|Anticipated|International College of Osteopathic Medicine||2|||f||||f||||||||||2018-06-01 00:19:43.032928|2018-06-01 00:19:43.032928
NCT01021462|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-07-29|2009-11-25|2009-11-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates (MK-0000-078)|An Open-Label, 2-Period, Pilot Study in Healthy Male Subjects to Evaluate the Use of a Graded Infusion of Intravenous Glucose in the Assessment of Insulin Secretion Rates|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:19:43.189009|2018-06-01 00:19:43.189009
NCT01021449|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2013-09-11|2009-11-27|2009-11-30|Estimate|||||||2013-09-11|2013-09-12|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Epigenetic Regulation of BDNF in Schizophrenia|Epigenetic Regulation of BDNF and TrK B in Schizophrenic Patients|Completed|||129|Actual|Chang Gung Memorial Hospital|||2||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:19:43.272666|2018-06-01 00:19:43.272666
NCT01021436|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2016-02-17|2009-11-25|2009-11-30|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia|An Open-Label, Multicenter, Multinational Study to Assess the Safety,Tolerability and Pharmacokinetics of Aerosolized Amikacin Delivered Via the Pulmonary Drug Delivery System (NKTR-061) in Intubated and Mechanically- Ventilated Patients With Nosocomial Pneumonia|Completed||Phase 2|30|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:19:43.404558|2018-06-01 00:19:43.404558
NCT01021423|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2011-10-31||2012-02-10|2009-11-25|2009-11-30|Estimate|2011-10-31|2011-12-02|Estimate||||2012-02-10|2012-02-14|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|RENEW||A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma|Terminated||Phase 3|9|Actual|Celgene|Study terminated early. Most analyses were not performed.|2||"Terminated by sponsor due to new unpublished data that rendered the current design of the study~   no longer clinically relevant. There were no safety concerns."|f||||t||||||||||2018-06-01 00:19:43.567182|2018-06-01 00:19:43.567182
NCT01021410|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2012-08-07|2009-11-27|2009-11-30|Estimate|||||||2012-08-07|2012-08-08|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|AR||Acetaminophen-Protein Adduct Resolution|Serum Acetaminophen-Cysteine (APAP-cys) Adduct Concentrations After 16 Days of Acetaminophen Dosing|Completed|||100|Actual|Denver Health and Hospital Authority|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:19:45.03728|2018-06-01 00:19:45.03728
NCT01021397|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2012-12-31|2009-11-25|2009-11-30|Estimate|||||||2012-12-31|2013-01-03|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children|Phase I Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-Passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval|Completed||Phase 1|12|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 00:19:45.430605|2018-06-01 00:19:45.430605
NCT01021384|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2013-04-26|2009-11-27|2009-11-30|Estimate|||||||2013-04-26|2013-04-29|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Supporting the Well Being of Families of Young Children With Autism Spectrum Disorders|Supporting the Well Being of Families of Young Children With Autism Spectrum|Completed||Phase 3|122|Actual|Boston Medical Center||1|||f||||||||||||||2018-06-01 00:19:45.806149|2018-06-01 00:19:45.806149
NCT01021371|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-27|||2016-10-26|2009-11-27|2009-11-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The GP's Role in Cancer Rehabilitation: a Randomised, Controlled Study.|The GP's Role in Cancer Rehabilitation: a Randomised, Controlled Study.|Completed||Early Phase 1|959|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-06-01 00:19:45.962807|2018-06-01 00:19:45.962807
NCT01021358|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2010-12-16|2009-11-25|2009-11-30|Estimate|||||||2010-12-16|2010-12-20|Estimate|January 2010||2010-01-31|December 2010|2010-12-31||||October 2010|Actual|2010-10-31||Interventional|||A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).|A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-263 (Navitoclax)|Completed||Phase 1|12|Anticipated|Abbott||1|||f||||f||||||||||2018-06-01 00:19:46.324579|2018-06-01 00:19:46.324579
NCT01021332|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2015-10-14||2017-11-20|2009-11-25|2009-11-26|Estimate|2015-12-16|2016-01-22|Estimate||||2017-11-20|2017-12-18|Actual|April 26, 2010|Actual|2010-04-26|November 2017|2017-11-30|December 14, 2011|Actual|2011-12-14|December 14, 2011|Actual|2011-12-14||Interventional|Neptune II|SAF and FAS (study-specific)|Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms|An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component|Completed||Phase 3|1067|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|1|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:19:46.745531|2018-06-01 00:19:46.745531
NCT01021319|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2012-01-31|2009-11-25|2009-11-26|Estimate|||||||2012-01-31|2012-02-02|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|PRE-FLAIR||Identification of Stroke Patients ≤ 3 and ≤ 4.5 Hours of Symptom Onset by Fluid Attenuated Inversion Recovery (FLAIR) Imaging and Diffusion Weighted Imaging (DWI)|PREdictive Value of FLAIR and DWI for the Identification of Acute Ischemic Stroke Patients ≤ 3 and ≤ 4.5 h of Symptom Onset - a Multicenter Observational Study|Completed|||643|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||t||||||||||2018-06-01 00:19:49.18845|2018-06-01 00:19:49.18845
NCT01021306|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2014-10-31||2017-04-17|2009-11-25|2009-11-26|Estimate|2014-11-14|2014-11-17|Estimate||||2017-04-17|2017-05-22|Actual|January 2010||2010-01-31|April 2017|2017-04-30|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|D1P2-TMD||Conservative Treatment of Patients With Temporomandibular Disorders|Conservative Treatment of Patients With Temporomandibular Disorders|Completed||N/A|80|Actual|Palmer College of Chiropractic||4|||f||||t||||||||Yes|Once the resulting manuscripts have been published, data sets will be provided for public access. Potential investigators can contact one of the Co-PIs to present their hypothesis, study design, instruments and/or data on which to focus, and resources required. Depending upon the needs and desires of the requesting party, the data that are shared may include analytic tables or de-identified or limited data sets that are transmitted to the requesting parties for additional analyses.|2018-06-01 00:19:50.228753|2018-06-01 00:19:50.228753
NCT01021293|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2017-03-06|2010-12-24|2017-04-19|2009-11-25|2009-11-26|Estimate|2017-04-19|2017-04-25|Actual|2010-12-24|2010-12-30|Estimate|2017-04-19|2017-04-25|Actual|November 1, 2009||2009-11-01|March 2017|2017-03-31|July 5, 2010|Actual|2010-07-05|July 5, 2010|Actual|2010-07-05||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine|Immunogenicity and Safety of GSK Biologicals' IPV (Poliorix™) in Infants|Completed||Phase 3|1101|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:19:51.472993|2018-06-01 00:19:51.472993
NCT01021280|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2012-06-13|2009-11-25|2009-11-26|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2013||2013-01-31|June 2012|2012-06-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Observational|||Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome|Case-control Study of the PTH Homeostasis in Adolescents and Young Adults With Bartter Syndrome|Unknown status|Not yet recruiting||15|Anticipated|Soroka University Medical Center|||3||f||||f||||||Samples Without DNA|"~     Serum and urine will be later analyzed for FGF-23 and other key molecules in PTH homeostasis.~   "|||2018-06-01 00:19:52.579152|2018-06-01 00:19:52.579152
NCT01021267|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-11-25|2009-11-25|2009-11-26|Estimate|||||||2009-11-25|2009-11-26|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions|Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Bioforce AG||1|||f||||f||||||||||2018-06-01 00:19:52.782067|2018-06-01 00:19:52.782067
NCT01021241|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2010-02-22|2009-11-24|2009-11-26|Estimate|||||||2010-02-22|2010-02-23|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Safety and Efficacy Study of Intravenous Uricase-PEG 20|A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|EnzymeRx||1|||f||||f||||||||||2018-06-01 00:19:53.210299|2018-06-01 00:19:53.210299
NCT01021228|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-11-25|2009-11-25|2009-11-26|Estimate|||||||2009-11-25|2009-11-26|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Preconditioning Volatile Anesthesia in Liver Surgery|Preconditioning is Indeed Protective|Completed|||257|Actual|University of Zurich|||3||f||||f||||||||||2018-06-01 00:19:55.0001|2018-06-01 00:19:55.0001
NCT01021215|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2014-12-17||2015-04-01|2009-11-25|2009-11-26|Estimate|2015-04-01|2015-04-02|Estimate||||2015-04-01|2015-04-02|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional||Of the 80 participants treated three (3) were lost to follow up leaving 77 who completed treatment, and of those reflected as a subset are the 70 compliant participants who completed treatment.|Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers|Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers|Completed||Phase 1/Phase 2|84|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 00:19:55.562353|2018-06-01 00:19:55.562353
NCT01021202|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2015-07-15|2009-11-25|2009-11-26|Estimate|||||||2015-07-15|2015-07-16|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Timing of Dilation Tracheostomy in Mechanically Ventilated Chronic Obstructive Pulmonary Disease (COPD) Patients|Early vs. Late Percutaneous Dilation Tracheostomy in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease|Suspended||N/A|40|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2||unexpectedly slow recruitment|f||||f||||||||||2018-06-01 00:19:56.713636|2018-06-01 00:19:56.713636
NCT01021189|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2010-06-09|2009-11-25|2009-11-26|Estimate|||||||2010-06-09|2010-06-10|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study to Assess Safety, Tolerability and Pharmacokinetics After Single and Multiple Doses of AZD1446 to Japanese Subject|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Young and Elderly Japanese Volunteers After Oral Single and Multiple Ascending Doses|Completed||Phase 1|97|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:19:56.956379|2018-06-01 00:19:56.956379
NCT01021176|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2015-12-17|2009-11-25|2009-11-26|Estimate|||||||2015-12-17|2015-12-18|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Evaluate a Medication on How Hunger and Appetite Are Influenced by Smell|A Single Dose Pilot Study to Evaluate the Safety and Dose-Response of Smell to Intranasal Diltiazem|Terminated||Phase 1|12|Actual|Pennington Biomedical Research Center||4|||f||||f||||||||||2018-06-01 00:19:57.124568|2018-06-01 00:19:57.124568
NCT01021163|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2009-11-25|2009-11-25|2009-11-26|Estimate|||||||2009-11-25|2009-11-26|Estimate||||November 2009|2009-11-30||||||||Interventional|||Effects of N-acetylcysteine on Pulmonary Function in High-risk Patients Undergoing Off-pump Coronary Bypass Surgery||Completed||Phase 4|48|Actual|Yonsei University||1|||f||||t||||||||||2018-06-01 00:19:57.674476|2018-06-01 00:19:57.674476
NCT01021150|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-06-10|2009-11-25|2009-11-26|Estimate|||||||2011-06-10|2011-06-13|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors|An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With Ombrabulin Administered as a 30-minute Intravenous Infusion in Combination With Cisplatin Administered as an Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|12|Anticipated|Sanofi||1|||f||||f||||||||||2018-06-01 00:19:58.1616|2018-06-01 00:19:58.1616
NCT01021137|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-04-25|2009-11-24|2009-11-26|Estimate|||||||2017-04-25|2017-04-27|Actual|May 1, 2011|Actual|2011-05-01|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 30, 2016|Actual|2016-12-30||Observational|||Vestibular Consequences of Blast-related Mild Traumatic Brain Injury (TBI)|Vestibular Consequences of Blast-related Mild Traumatic Brain Injury|Active, not recruiting|||192|Anticipated|VA Office of Research and Development|||4||f||||f||||||||No||2018-06-01 00:19:58.417092|2018-06-01 00:19:58.417092
NCT01021124|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2013-07-17|2009-11-25|2009-11-26|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Latent Tuberculosis Infection in Bone Marrow Transplant Recipients|A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Hematopoietic Stem Cell Transplant Recipients|Completed|||409|Actual|Asan Medical Center|||1||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 00:19:58.63939|2018-06-01 00:19:58.63939
NCT01021111|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2016-10-26||2017-03-15|2009-11-24|2009-11-26|Estimate|2017-03-15|2017-04-21|Actual||||2017-03-15|2017-04-21|Actual|November 2009||2009-11-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|April 2011|Actual|2011-04-30||Interventional|||The Design and Evaluation of an Active Intervention for the Prevention of Non-contact ACL Injury|The Design and Evaluation of an Active Intervention for the Prevention of Non-contact ACL Injury|Completed||N/A|17|Actual|Stanford University||1|||f||||f||||||||No||2018-06-01 00:19:58.805924|2018-06-01 00:19:58.805924
NCT01020929|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-06-05|2009-11-24|2009-11-26|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||Incidence of Simultaneous Epidural and Intravascular Injection|Incidence of Simultaneous Epidural and Intravascular Injection During Cervical and Lumbosacral Transforaminal Epidural Injections|Completed|||200|Actual|Stanford University|||||f||||f||||||||||2018-06-01 00:20:03.831586|2018-06-01 00:20:03.831586
NCT01020916|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2013-07-08|2009-11-25|2009-11-26|Estimate|||||||2013-07-08|2013-07-10|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TTM||Target Temperature Management After Cardiac Arrest|Target Temperature Management 33°C Versus 36°C After Out-of-hospital Cardiac Arrest, a Randomised, Parallel Groups, Assessor Blinded Clinical Trial|Completed||N/A|950|Anticipated|Helsingborgs Hospital||2|||f||||t||||||||||2018-06-01 00:20:04.022253|2018-06-01 00:20:04.022253
NCT01021098|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2016-12-22|2009-11-25|2009-11-26|Estimate|||||||2016-12-22|2016-12-23|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|ARIC||Acute Respiratory Infection Consortium|A Multi-center Military Consortium for Clinical Research Into the Natural History, Host Response, and Potential Therapy of Acute Respiratory Infection in Military Members and Their Families|Recruiting|||2000|Anticipated|Uniformed Services University of the Health Sciences|||2||f||||f||||||Samples With DNA|"~     nasal swabs with storage of multiple harvested (expanded) first generation viral isolates~     (all must opt in); buccal swab storage (may opt out) rectal swab storage (may opt out) serum~     storage (may opt out)~   "|Yes|We plan to directly share de-identified data with the third party Menssana Research Inc. for a substudy of an investigational device for the diagnosis of influenza. This data will include basic demographic information, flu diagnostic results, smoking status, and symptom history. This data will be de-identified and shared directly with the third party via secure file transfer. This applies only to participants recruited into the substudy at the site San Antonio Military Medical Center.|2018-06-01 00:19:59.423861|2018-06-01 00:19:59.423861
NCT01021085|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2011-09-01|2009-11-25|2009-11-26|Estimate|||||||2011-09-01|2011-09-05|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|PREVIEW||Evaluation of Fetal Sex in Assisted Reproductive Technology (ART) Achieved Pregnancies|Evaluation Of A Fetal Sex Determination Test At 36-56 Days Gestation In Assisted Reproductive Technology (ART) Achieved Pregnancies|Completed|||500|Anticipated|Sequenom, Inc.|||1||f||||f||||||Samples With DNA|"~     Maternal whole blood and urine will be collected. Whole blood will be processed to plasma and~     buffy coat.~   "|||2018-06-01 00:19:59.70495|2018-06-01 00:19:59.70495
NCT01021072|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2013-10-15|2009-11-24|2009-11-26|Estimate|||||||2013-10-15|2013-10-17|Estimate|March 2010||2010-03-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|||A First in Man Study of MABp1 in Patients With Advanced Cancers|A Phase 1 Study of MABp1 in Patients With Advanced Cancers|Completed||Phase 1|52|Actual|XBiotech, Inc.||1|||f||||f||||||||||2018-06-01 00:19:59.788906|2018-06-01 00:19:59.788906
NCT01021059|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2018-04-14|2009-11-25|2009-11-26|Estimate|||||||2018-04-14|2018-04-17|Actual|November 10, 2009||2009-11-10|October 25, 2016|2016-10-25|October 25, 2016|Actual|2016-10-25|May 31, 2013|Actual|2013-05-31||Interventional|||A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer|A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults With Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer|Completed||Phase 1|18|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 00:19:59.920355|2018-06-01 00:19:59.920355
NCT01021046|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2010-08-02|2009-11-25|2009-11-26|Estimate|||||||2010-08-02|2010-08-03|Estimate|December 2006||2006-12-31|November 2006|2006-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Deep Anterior Lamellar Keratoplasty (DALK) Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients|Deep Anterior Lamellar Keratoplasty Using Acellular Corneal Tissue Promotes Corneal Allograft Survival in High Risk Patients|Completed||N/A|78|Anticipated|Wenzhou Medical University||2|||f||||t||||||||||2018-06-01 00:20:00.355919|2018-06-01 00:20:00.355919
NCT01021033|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2018-03-27|2009-11-25|2009-11-26|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2, 2009||2009-11-02|February 6, 2018|2018-02-06||||||||Observational|||Screening Protocol for Patients With Stroke|Screening Protocol for Patients With Stroke|Recruiting|||1200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:20:00.503126|2018-06-01 00:20:00.503126
NCT01021020|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2009-08-12||2009-12-01|2009-10-16|2009-11-26|Estimate|2009-10-16|2009-11-26|Estimate||||2009-12-01|2009-12-09|Estimate|September 2007||2007-09-30|December 2009|2009-12-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Bioequivalence Study of Colchicine Tablets|Randomized, 3-Way Crossover Bioequivalence Study of Single Dose Colchicine Tablets and Effect of Food|Completed||Phase 1|28|Actual|Mutual Pharmaceutical Company, Inc.||3|||f||||f||||||||||2018-06-01 00:20:00.635698|2018-06-01 00:20:00.635698
NCT01021007|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2009-11-27|2009-10-15|2009-11-26|Estimate|2009-10-15|2009-11-26|Estimate||||2009-11-27|2009-12-01|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|Quigley||Clinical Research Study Efficacy of a Prototype Oral Rinse|Clinical Research Study Efficacy of a Prototype Oral Rinse|Completed||Phase 3|67|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 00:20:01.334242|2018-06-01 00:20:01.334242
NCT01020994|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2010-07-08|2009-11-25|2009-11-26|Estimate|||||||2010-07-08|2010-07-09|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema|Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema|Completed||Phase 2|150|Anticipated|Almirall, S.A.||3|||f||||f||||||||||2018-06-01 00:20:02.189934|2018-06-01 00:20:02.189934
NCT01020981|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2014-11-05||2015-04-06|2009-11-25|2009-11-26|Estimate|2015-01-26|2015-02-11|Estimate||||2015-04-06|2015-04-28|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|||National Guard Outreach and Linkage to Treatment|National Guard Outreach and Linkage to Treatment|Completed|||141|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-06-01 00:20:02.416009|2018-06-01 00:20:02.416009
NCT01020968|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25||2016-06-27|2017-06-01|2009-11-25|2009-11-26|Estimate||||2016-06-28|2016-06-30|Estimate|2017-06-01|2017-06-06|Actual|December 2009||2009-12-31|June 2017|2017-06-30|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy|Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy|Completed||Phase 2|22|Actual|Vericel Corporation||2|||f||||t||||||||||2018-06-01 00:20:03.260085|2018-06-01 00:20:03.260085
NCT01020955|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-04-06|2009-11-25|2009-11-26|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)|Effects on Insulin Sensitivity and Body Composition of GH and IGF-I in Adult-GHD With Impaired Glucose Tolerance or Diabetes|Completed||Phase 3|14|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-06-01 00:20:03.411559|2018-06-01 00:20:03.411559
NCT01020942|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-12-15|2009-11-25|2009-11-26|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2010||2010-01-31|November 2011|2011-11-30|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Cardioprotective Effects of Electroacupuncture Pretreatment Against Coronary Stenting|Cardioprotective of Electroacupuncture Pretreatment in Patients Underwent Coronary Stenting: A Prospective, Multicenter, Randomized Control Trial|Unknown status|Enrolling by invitation|N/A|500|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-06-01 00:20:03.540278|2018-06-01 00:20:03.540278
NCT01020903|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2014-05-08||2015-06-03|2009-11-25|2009-11-26|Estimate|2015-06-03|2015-06-04|Estimate||||2015-06-03|2015-06-04|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Records for this study are no longer available to the sponsor to update this study record as they were destroyed in Hurricane Sandy in 10/2012. thus, we do not have any information to use to update the records. PI for this study is no longer with the institution and no contact information is available.|Aprepitant for Post-operative Nausea|Aprepitant vs. Placebo for the Prevention of Postoperative Nausea and Vomiting: a Randomized, Double-blind Study in Patients Undergoing Laparoscopic Cholecystectomy|Completed||N/A|200|Actual|Northwell Health||2|||f||||f||||||||||2018-06-01 00:20:04.303855|2018-06-01 00:20:04.303855
NCT01020890|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2010-07-09|2009-11-25|2009-11-26|Estimate|||||||2010-07-09|2010-07-12|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms|A Cross-sectional Study on the Prevalence of GERD in Primary Care Patients With Upper GI Symptoms Using the GERD-Q. The Bulgarian GERD-Q Study|Completed|||2210|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:20:04.692042|2018-06-01 00:20:04.692042
NCT01020877|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2010-02-22||2010-06-21|2009-11-25|2009-11-26|Estimate|2010-02-22|2010-03-23|Estimate||||2010-06-21|2010-06-29|Estimate|November 2001||2001-11-30|June 2010|2010-06-30|January 2002|Actual|2002-01-31|November 2001|Actual|2001-11-30||Interventional|||Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects|A Study to Evaluate the Relative Bioavailability of Two Metronidazole Vaginal Gel Formulations|Completed||Phase 1|38|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:20:04.812493|2018-06-01 00:20:04.812493
NCT01020864|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-01-20|2009-11-25|2009-11-26|Estimate|||||||2015-01-20|2015-01-21|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|January 2018|Anticipated|2018-01-31|September 2012|Actual|2012-09-30||Interventional|CECAVI||Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer|Phase II Trial of Cetuximab in Combination With Chemotherapy (Carboplatin and Navelbine) for Patients With Platinum-resistant Head and Neck Cancer|Unknown status|Recruiting|Phase 2|55|Anticipated|Odense University Hospital||1|||f||||t||||||||||2018-06-01 00:20:05.631377|2018-06-01 00:20:05.631377
NCT01020851|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2015-04-14|2009-11-25|2009-11-26|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PREVENTS||The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke Trial|The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating TIA or Stroke Trial|Completed||N/A|202|Anticipated|Narrows Institute for Biomedical Research||2|||f||||f||||||||||2018-06-01 00:20:05.901218|2018-06-01 00:20:05.901218
NCT01020838|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2015-02-02|2013-05-09|2016-04-27|2009-11-25|2009-11-26|Estimate|2015-03-13|2015-03-25|Estimate|2013-05-09|2013-05-16|Estimate|2016-04-27|2016-05-27|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|December 2013|Actual|2013-12-31|September 2011|Actual|2011-09-30||Interventional||Participants in the safety analysis set were treated with study drug.|Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology|An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) Imaging for Detection/Exclusion of Cerebral Beta-amyloid When Compared to Postmortem Histopathology|Completed||Phase 3|218|Actual|Piramal Imaging SA||1|||f||||f||||||||||2018-06-01 00:20:06.005401|2018-06-01 00:20:06.005401
NCT01020825|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2011-06-13|2009-11-25|2009-11-26|Estimate|||||||2011-06-13|2011-06-14|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|LTE||Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled Trial|A Prospective Study for the Assessment of the Long-term Safety and Efficacy of Cx401 in Patients Taking Part in the FATT-1 Trial|Completed|||148|Actual|Cellerix|||3||f||||f||||||||||2018-06-01 00:20:06.874153|2018-06-01 00:20:06.874153
NCT01020812|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2014-12-05||2016-06-27|2009-11-24|2009-11-26|Estimate|2015-05-20|2015-05-22|Estimate||||2016-06-27|2016-07-27|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma|Phase II Study of Combination Stereotactic Body Radiotherapy (SBRT) With Transarterial Chemo-Embolization (TACE) for Unresectable Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|11|Actual|Stanford University|The low enrollment of patients led to the study being terminated before the full sample size could be reached. This resulted in a smaller than anticipated pool of patients to be analyzed and conclusions that are more difficult to generalize.|1||enrollment was too low|f||||t||||||||||2018-06-01 00:20:07.165267|2018-06-01 00:20:07.165267
NCT01020799|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|2012-01-11||2012-04-11|2009-11-25|2009-11-26|Estimate|2012-03-15|2012-04-10|Estimate||||2012-04-11|2012-04-17|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||AZD7268 Safety and Tolerability Study|A Phase II, Multi-center, Randomized, Double-bind, Double-dummy, Active and Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of AZD7268 in Patients With Major Depressive Disorder|Completed||Phase 2|247|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:20:07.537315|2018-06-01 00:20:07.537315
NCT01020786|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2012-01-12||2013-06-19|2009-11-24|2009-11-26|Estimate|2012-02-17|2012-03-16|Estimate||||2013-06-19|2013-08-27|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional|||A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients|Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer|Completed||Phase 4|109|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:20:08.25504|2018-06-01 00:20:08.25504
NCT01020773|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-21|2009-03-21||2009-10-14|2009-10-14|2009-11-26|Estimate|2009-10-14|2009-11-26|Estimate||||2009-10-14|2009-11-26|Estimate|June 2006||2006-06-30|October 2009|2009-10-31|October 2007|Actual|2007-10-31|July 2007|Actual|2007-07-31||Interventional|SBT||Extubation With or Without Spontaneous Breathing Trial||Completed||N/A|67|Actual|Beijing Shijitan Hospital||2|||f||||t||||||||||2018-06-01 00:20:08.83732|2018-06-01 00:20:08.83732
NCT01020760|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-25|||2012-04-25|2009-11-25|2009-11-26|Estimate|||||||2012-04-25|2012-04-26|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Protocol for RCT of Posturing in Phacovitrectomy for Full Thickness Macular Hole (FTMH)|Pilot Study of Prone Posturing Following Phacovitrectomy for Thickness Macular Hole|Completed||N/A|30|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-06-01 00:20:09.440188|2018-06-01 00:20:09.440188
NCT01019811|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|May 2001||2001-05-31|November 2009|2009-11-30|May 2008|Actual|2008-05-31|May 2006|Actual|2006-05-31||Interventional|ISCF||Innervated Sensory Cross-Finger Flap|The Innervated Sensory Cross-finger Flap Based on the Dorsal Branch Artery for Reconstruction of Fingertip Degloving Injury|Completed||N/A|16|Actual|The Second Hospital of Tangshan|||||f||||t||||||||||2018-06-01 00:20:25.694734|2018-06-01 00:20:25.694734
NCT01020747|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2012-04-23||2012-12-18|2009-11-20|2009-11-25|Estimate|2012-11-04|2012-12-04|Estimate||||2012-12-18|2012-12-20|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)|A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold|Completed||Phase 1|20|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 00:20:09.636828|2018-06-01 00:20:09.636828
NCT01020734|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2015-12-29|2009-11-24|2009-11-25|Estimate|||||||2015-12-29|2015-12-31|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission|Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study|Completed||Phase 2|263|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 00:20:10.113134|2018-06-01 00:20:10.113134
NCT01020721|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|September 2010|Anticipated|2010-09-30|March 2010|Anticipated|2010-03-31||Observational|||The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma|Study of Gene, Inheritance Pattern and Genotype - Phenotype Correlations in South Korean Patients With Primary Congenital Glaucoma|Unknown status|Recruiting||100|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     peripheral blood~      - Genomic DNA was extracted from the peripheral leukocyte of all subjects through peripheral~     blood sampling~   "|||2018-06-01 00:20:10.303009|2018-06-01 00:20:10.303009
NCT01020695|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2012-11-06|2009-11-23|2009-11-25|Estimate|||||||2012-11-06|2012-11-07|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Quantitative Electroencephalography (QEEG) and Low-resolution Electromagnetic Tomography (LORETA) Analysis in Post Traumatic Stress Disorder (PTSD) Patients|QEEG and LORETA Analysis in PTSD Patients|Completed|||10|Actual|Beersheva Mental Health Center|||2||f||||t||||||||||2018-06-01 00:20:10.414778|2018-06-01 00:20:10.414778
NCT01020682|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|January 2005||2005-01-31|November 2009|2009-11-30|June 2011|Anticipated|2011-06-30|February 2006|Actual|2006-02-28||Observational|||Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study|Apathy in Parkinson Disease: Clinical, Physiopathological and Pharmacological Study|Unknown status|Recruiting||120|Anticipated|University Hospital, Grenoble|||||f||||f||||||||||2018-06-01 00:20:10.536129|2018-06-01 00:20:10.536129
NCT01020669|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-06-30|2009-11-24|2009-11-25|Estimate|||||||2017-06-30|2017-07-02|Actual|October 16, 2009||2009-10-16|July 13, 2011|2011-07-13|July 13, 2011||2011-07-13|||||Observational|||Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development|Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development: Supplementary Control Subjects Recruitment|Completed|||24|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:20:10.630707|2018-06-01 00:20:10.630707
NCT01020656|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Anticoagulant and Antiplatelet Agents in Patients Undergoing Vitreoretinal Surgery|Maintenance of Anticoagulant and Antiplatelet Agents for Patients Undergoing Vitreoretinal Surgery|Completed|||206|Actual|Centre Hospitalier Universitaire Dijon|||7||f||||f||||||||||2018-06-01 00:20:10.770379|2018-06-01 00:20:10.770379
NCT01020643|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2013-10-24|2009-11-24|2009-11-25|Estimate|||||||2013-10-24|2013-10-25|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Closed-loop Sedation of Propofol for Patients Undergoing Spinal Anesthesia|Comparison of Closed-loop Control System of Propofol Versus Manual Control Using Bispectral Index for Controlled Sedation - a Pilot Study|Completed||Phase 4|203|Actual|McGill University Health Center||1|||f||||f||||||||||2018-06-01 00:20:10.932318|2018-06-01 00:20:10.932318
NCT01020630|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2014-05-13|2009-11-23|2009-11-25|Estimate|||||||2014-05-13|2014-05-14|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|July 2013|Actual|2013-07-31|November 2012|Actual|2012-11-30||Interventional|SUN-CASE||Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI|A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI|Completed||Phase 2|91|Actual|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-06-01 00:20:11.059827|2018-06-01 00:20:11.059827
NCT01020617|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-01-18|2009-11-24|2009-11-25|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2009||2009-04-30|November 2009|2009-11-30|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||The Effect of Probiotics on Low-grade Inflammation, Microbiota and Risk Factors for Metabolic Syndrome in Obese Children|Association Between the Diet, the Composition of Microbiota of the Intestinal Tract, Human Health and Well-being|Completed||N/A|51|Actual|University of Copenhagen|||||f||||f||||||||||2018-06-01 00:20:11.217259|2018-06-01 00:20:11.217259
NCT01020604|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2013-04-29|2009-11-24|2009-11-25|Estimate|||||||2013-04-29|2013-04-30|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|PROTECT-Z||PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients|PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients Assessment of the Correlation Between Body Mass Index and Recurrence Among Zoladex Treated Prostate Cancer Patients|Completed|||1376|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:20:11.368555|2018-06-01 00:20:11.368555
NCT01020591|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2012-02-12||2017-03-24|2009-11-24|2009-11-25|Estimate|2017-03-24|2017-05-04|Actual||||2017-03-24|2017-05-04|Actual|December 2009||2009-12-31|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect of Osteopathic Manual Therapy on Vascular Supply|The Effect of Osteopathic Manual Therapy on the Vascular Supply to the Lower Extremity in Individuals With Knee Osteoarthritis, a Randomized Trial|Completed||N/A|30|Actual|Nova Scotia Health Authority||2|||f|||||f|f||||||No||2018-06-01 00:20:11.536128|2018-06-01 00:20:11.536128
NCT01020578|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|June 2008||2008-06-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Observational|||Low Density Lipoprotein (LDL) Cholesterol Metabolism in Impaired Glucose Tolerance|Plasma Kinetics Study the of Free Cholesterol and Cholesterol Ester in Subjects With Impaired Glucose Tolerance|Completed|||29|Actual|University of Sao Paulo General Hospital|||2||f||||f||||||Samples Without DNA|"~     whole blood samples~   "|||2018-06-01 00:20:12.285419|2018-06-01 00:20:12.285419
NCT01010191|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-06-21|2009-11-06|2009-11-09|Estimate|||||||2011-06-21|2011-06-22|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Harnessing Placebo Effects: Non-Deceptive Use of Placebo in Irritable Bowel Syndrome (IBS)|Pilot Randomized Controlled Trial|Completed||N/A|70|Anticipated|Harvard University Faculty of Medicine||2|||f||||f||||||||||2018-06-01 00:23:51.308247|2018-06-01 00:23:51.308247
NCT01020565|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24||2010-01-29|2010-08-04|2009-11-24|2009-11-25|Estimate||||2010-01-29|2010-02-02|Estimate|2010-08-04|2010-08-06|Estimate|February 2003||2003-02-28|June 2010|2010-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection|A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection|Completed||Phase 2|60|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 00:20:12.411437|2018-06-01 00:20:12.411437
NCT01020552|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2010-04-28|2009-11-24|2009-11-25|Estimate|||||||2010-04-28|2010-04-29|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Integrating Family Planning Into Postabortion Care|ESD: Integrated Services for Women Seeking Postabortion Care in Kenya|Completed|||300|Anticipated|FHI 360|||||f||||f||||||||||2018-06-01 00:20:12.519542|2018-06-01 00:20:12.519542
NCT01020539|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2017-07-25|2009-11-23|2009-11-25|Estimate|||||||2017-07-25|2017-07-27|Actual|September 11, 2002|Actual|2002-09-11|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2012|Actual|2012-03-31||Interventional|AML/MDS/JMML||Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia|Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML)|Active, not recruiting||Phase 1|18|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 00:20:12.684746|2018-06-01 00:20:12.684746
NCT01020526|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|2016-05-24||2016-05-24|2009-11-23|2009-11-25|Estimate|2016-05-24|2016-07-01|Estimate||||2016-05-24|2016-07-01|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pregabalin In Adolescent Patients With Fibromyalgia|A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia|Completed||Phase 4|63|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 00:20:12.846078|2018-06-01 00:20:12.846078
NCT01020513|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2013-12-10|2009-11-24|2009-11-25|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|Hylenex-ED||Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design|Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design|Withdrawn|||0|Actual|University of California, San Diego||||This study was closed before accrual due to FDA recall of Medication|f||||f||||||||||2018-06-01 00:20:13.156189|2018-06-01 00:20:13.156189
NCT01020500|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-06-20|2009-11-24|2009-11-25|Estimate|||||||2011-06-20|2011-06-21|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|ULIS2||To Document the Effectiveness of BoNT-A Injection in Adult Subjects With Upper Limb Spasticity Following Stroke|An International, Prospective Cohort to Document the Effectiveness of One BoNT-A Injection Cycle Based on Attainment of Individual Person-centred Goals in Adult Subjects Suffering From Upper Limb Spasticity Following Stroke|Completed|||469|Actual|Ipsen|||||f||||f||||||||||2018-06-01 00:20:13.262154|2018-06-01 00:20:13.262154
NCT01020474|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|2015-05-26||2015-06-22|2009-11-23|2009-11-25|Estimate|2015-06-22|2015-06-25|Estimate||||2015-06-22|2015-06-25|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Adolescent Fibromyalgia Study|A 15 Week, Randomized, Double Blind, Parallel-group, Placebo-controlled, Flexible-dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia|Completed||Phase 4|107|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:20:13.680479|2018-06-01 00:20:13.680479
NCT01020461|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2016-09-22|2009-11-23|2009-11-25|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of Accuvein in Adult Patients|Evaluation of Accuvein for Blood Sampling and for Intravenous Catheter Placement in Adult Patients|Terminated||Phase 4|522|Actual|Hopital Foch||2||"Arm placement periph iv cath COMPLETED - Arm blood sampling : study will not be performed~   because of the results of the arm placement periph. iv cath"|f||||f||||||||||2018-06-01 00:20:14.769613|2018-06-01 00:20:14.769613
NCT01020448|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2015-04-30||2015-08-06|2009-11-24|2009-11-25|Estimate|2015-06-17|2015-07-15|Estimate||||2015-08-06|2015-08-24|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|November 2011|Actual|2011-11-30||Interventional|Triptocare||Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer|Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study|Completed||Phase 3|339|Actual|Ipsen||1|||f||||f||||||||||2018-06-01 00:20:14.895382|2018-06-01 00:20:14.895382
NCT01020435|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2017-04-18||2018-01-30|2009-11-24|2009-11-25|Estimate|2018-01-30|2018-02-07|Actual||||2018-01-30|2018-02-07|Actual|October 2010||2010-10-31|January 2018|2018-01-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|CHiP||Chiropractic for Hypertension in Patients|Upper Cervical Manipulation for Patients With Stage 1 Hypertension|Completed||N/A|51|Actual|Palmer College of Chiropractic||2|||f||||t||||||||No|Feasibility/pilot study|2018-06-01 00:20:15.549777|2018-06-01 00:20:15.549777
NCT01020422|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2014-03-05|2009-11-20|2009-11-25|Estimate|||||||2014-03-05|2014-03-07|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|September 2011|Actual|2011-09-30|November 2009|Actual|2009-11-30||Interventional|||Sexuality After Reduction Mammaplasty|Sexuality and Depression Predictors Among Breast Hypertrophy Women Undergoing Reduction Mammaplasty|Completed||N/A|60|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 00:20:15.964562|2018-06-01 00:20:15.964562
NCT01020409|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2016-11-14|2009-11-24|2009-11-25|Estimate|||||||2016-11-14|2016-11-15|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|April 2011|Actual|2011-04-30||Observational|INFLACOR||INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery|INFLACOR (INFLA-mmation A-fter C-ardiac O-pe-R-ation) - Use of Selected Genetic Variants, Cytokines, and Physiologic Parameters in the Prognosis of Postoperative Complications in Patients Undergoing Cardiopulmonary Bypass Cardiac Surgery|Completed|||525|Actual|Medical University of Gdansk|||1||f||||t||||||Samples With DNA|"~     plasma, serum, and blood morphologic elements after centrifugation frozen to -75C.~   "|Yes|IPD can be made available to other researcher upon reasonable request.|2018-06-01 00:20:16.062502|2018-06-01 00:20:16.062502
NCT01020396|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|January 2002||2002-01-31|November 2009|2009-11-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis|A Multi-Center, Double-Blind, Parallel Group Study Comparing the Bioequivalence of Teva Pharmaceuticals, USA's Generic Formulation of Metronidazole Vaginal Gel, 0.75% and MetroGel-Vaginal® Metronidazole Vaginal Gel, 0.75% in the Treatment of Bacterial Vaginosis|Completed||Phase 1/Phase 2|579|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 00:20:16.15052|2018-06-01 00:20:16.15052
NCT01020370|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate||||November 2009|2009-11-30||||||||Observational|||Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies|An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies|Completed|||||Wayne State University|||2||f||||||||||||||2018-06-01 00:20:17.383027|2018-06-01 00:20:17.383027
NCT01020357|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2014-12-03|2009-11-24|2009-11-25|Estimate|||||||2014-12-03|2014-12-05|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|CAP-S||Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study|Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity|Completed||Phase 3|201|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 00:20:17.536372|2018-06-01 00:20:17.536372
NCT01020344|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2014-10-15|2009-11-24|2009-11-25|Estimate|||||||2014-10-15|2014-10-16|Estimate|November 2009||2009-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Mechanisms of Vascular Damage in Patients With Chronic Obstructive Pulmonary Disease|Randomized Controlled Trial on the Cardiovascular Effects of Lung Volume Reduction Surgery in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|30|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 00:20:17.723697|2018-06-01 00:20:17.723697
NCT01020331|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|June 2005||2005-06-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|TAME||Memantine Therapy in Amyotrophic Lateral Sclerosis|Phase IIA Open Label Trial of Memantine in Combination With Riluzole (Customary Care) for the Treatment of ALS|Completed||Phase 2|20|Actual|Phoenix Neurological Associates, LTD||1|||t||||t||||||||||2018-06-01 00:20:17.8014|2018-06-01 00:20:17.8014
NCT01020318|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-10-05|2009-11-24|2009-11-25|Estimate|||||||2017-10-05|2017-10-06|Actual|October 16, 2009||2009-10-16|May 16, 2014|2014-05-16|May 16, 2014||2014-05-16|||||Observational|||Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury|Evaluation of Outcome Measures for Patients Diagnosed With Traumatic Brain Injury|Completed|||9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:20:17.880903|2018-06-01 00:20:17.880903
NCT01020305|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2014-10-03||2014-10-03|2009-11-20|2009-11-25|Estimate|2014-10-03|2014-10-13|Estimate||||2014-10-03|2014-10-13|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer|Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer|Terminated||Phase 1/Phase 2|5|Actual|Stanford University||1||Decision by funding sponsor due to poor accrual|f||||t||||||||||2018-06-01 00:20:17.962059|2018-06-01 00:20:17.962059
NCT01020279|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2010-06-24|2009-11-23|2009-11-25|Estimate|||||||2010-06-24|2010-06-28|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|January 2010|Actual|2010-01-31|||||Interventional|||Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise|Multiple-dose, Randomized, Subject and Observer Blinded, Placebo-controlled, Double-dummy Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise|Completed||Phase 1|82|Actual|X-pert Med GmbH||2|||f||||||||||||||2018-06-01 00:20:18.40054|2018-06-01 00:20:18.40054
NCT01020266|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2015-06-23|2009-11-23|2009-11-25|Estimate|||||||2015-06-23|2015-06-25|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|June 2013|Actual|2013-06-30|September 2010|Actual|2010-09-30||Interventional|||Neuroprotective Study of Electroacupuncture Pretreatment in Patients Undergoing Cardiac Surgery|Clinical Trial of Cerebral Protective Effects of Repeated Electroacupuncture Pretreatment in Heart Valve Replacement Surgery|Completed||N/A|300|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-06-01 00:20:18.503535|2018-06-01 00:20:18.503535
NCT01020253|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-12-02|2009-11-24|2009-11-25|Estimate|||||||2009-12-02|2009-12-03|Estimate|January 2006||2006-01-31|December 2009|2009-12-31||||April 2008|Actual|2008-04-30||Interventional|ETOD||The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)|A Comparison of Alendronate vs. Alfacalcidol Medication for the Preservation of Bone Mineral Density Around the Femoral Implant and in the Lumbar Spine After a Total Hip Arthroplasty|Unknown status|Active, not recruiting|N/A|60|Actual|Yokohama City University Medical Center||3|||f||||f||||||||||2018-06-01 00:20:18.596635|2018-06-01 00:20:18.596635
NCT01020240|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-25|2009-11-24|2009-11-25|Estimate|||||||2009-11-25|2009-11-26|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Physiotherapy in Postpartum After a Cesarean|Effectiveness of an Orientation Guide for Puerperal Women After Cesarean.|Completed||N/A|45|Actual|Sao Marcos University||3|||f||||t||||||||||2018-06-01 00:20:18.682949|2018-06-01 00:20:18.682949
NCT01020227|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2014-01-27|2009-11-24|2009-11-25|Estimate|||||||2014-01-27|2014-01-29|Estimate|February 2004||2004-02-29|January 2014|2014-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Usefulness of Integrative Medicine Tools As Adjunctive Care for Women After Coronary Artery Bypass Grafting|A Randomized Controlled Trial to Assess the Usefulness of Integrative Medicine Tools As Adjunctive Care for Women After Coronary Artery Bypass Grafting|Completed||Phase 1|100|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 00:20:18.803767|2018-06-01 00:20:18.803767
NCT01020214|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2006||2006-11-30|November 2009|2009-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg|Single-Dose Fasting Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:20:18.970901|2018-06-01 00:20:18.970901
NCT01020201|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2012-07-30|2009-11-24|2009-11-25|Estimate|||||||2012-07-30|2012-07-31|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Risk Factors for Post Operative Nausea and Vomiting(PONV) in Patients Underwent Gynecological Operation Under General Anesthesia|A Observational Cohort Study to Identify Risk Factors for Post Operative Nausea and Vomiting Following General Anesthesia in Female Patient Underwent Gynecological Operation|Completed|||774|Actual|Huazhong University of Science and Technology|||2||f||||t||||||||||2018-06-01 00:20:19.070052|2018-06-01 00:20:19.070052
NCT01019213|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2012-05-14|2009-11-23|2009-11-25|Estimate|||||||2012-05-14|2012-05-15|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block|Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block|Completed||Phase 4|40|Anticipated|Aarhus University Hospital Skejby||2|||f||||f||||||||||2018-06-01 00:20:33.554353|2018-06-01 00:20:33.554353
NCT01020188|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2010-05-25|2009-11-23|2009-11-25|Estimate|||||||2010-05-25|2010-05-26|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria|A Pilot Study Investigating the Role of Thrombin Generation and Rotational Thromboelastometry in Assessing the Prothrombotic Phenotype of Paroxysmal Nocturnal Haemaglobinuria|Unknown status|Recruiting||60|Anticipated|King's College Hospital NHS Trust|||||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 00:20:19.159583|2018-06-01 00:20:19.159583
NCT01020175|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|January 1995||1995-01-31|November 2009|2009-11-30|December 2002|Actual|2002-12-31|December 1999|Actual|1999-12-31||Interventional|||Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation|A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome|Completed||Phase 3|350|Actual|European Group for Blood and Marrow Transplantation||2|||f||||t||||||||||2018-06-01 00:20:19.243382|2018-06-01 00:20:19.243382
NCT01020162|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|September 1995||1995-09-30|November 2009|2009-11-30|November 2007|Actual|2007-11-30|December 2006|Actual|2006-12-31||Interventional|||Treatment of Ilioinguinal Entrapment Syndrome - an Often Overlooked Cause of Chronic Pelvic Pain|Treatment of Ilioinguinal Entrapment Syndrome - a Randomised Controlled Trial|Completed||N/A|19|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 00:20:19.351079|2018-06-01 00:20:19.351079
NCT01020149|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2016-03-29|2009-11-23|2009-11-25|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Evaluation of Nerve Regeneration After Nerve Transsection Using (Diffusion-tensor Magnetic Resonance Imaging) DTI MR Imaging||Completed|||25|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 00:20:19.476147|2018-06-01 00:20:19.476147
NCT01020136|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2010-04-21|2009-11-23|2009-11-25|Estimate|||||||2010-04-21|2010-04-22|Estimate|January 2010||2010-01-31|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers|A Phase 1 Bioequivalence Study To Compare The Plasma Pharmacokinetics Of AG-013736 Polymorph Form IV Versus Market-Image Polymorph Form XLI Tablets In Healthy Volunteers Under Fed Conditions|Completed||Phase 1|42|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:20:19.58203|2018-06-01 00:20:19.58203
NCT01020123|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2012-07-24||2012-11-22|2009-11-24|2009-11-25|Estimate|2012-11-22|2012-11-26|Estimate||||2012-11-22|2012-11-26|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients|A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, With an Optional 2-month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients|Completed||Phase 2|530|Actual|AstraZeneca||7|||f||||f||||||||||2018-06-01 00:20:19.792249|2018-06-01 00:20:19.792249
NCT01020110|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2012-04-22|2009-11-23|2009-11-25|Estimate|||||||2012-04-22|2012-04-24|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|April 2012|Anticipated|2012-04-30|September 2011|Actual|2011-09-30||Observational|HUVEC||Study in an Ex-vivo Thrombosis Model With Human Umbilical Vein Endothelial Cells (HUVEC)-Perfusion|Human Umbilical Vein Endothelial Cells (HUVEC)-Perfusion|Unknown status|Active, not recruiting||30|Anticipated|Medical University of Vienna|||||f||||f||||||Samples Without DNA|"~     supernatant of plasmin degraded thrombus including fibrin monomers~   "|||2018-06-01 00:20:21.723931|2018-06-01 00:20:21.723931
NCT01020084|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|August 2006||2006-08-31|November 2009|2009-11-30|November 2007|Actual|2007-11-30|August 2006|Actual|2006-08-31||Observational|SOF||Salivary Flow Rate and Oral Function|Effect of Hyposalivation on Mastication and Speech|Completed|||40|Actual|University of Campinas, Brazil|||2||f||||f||||||||||2018-06-01 00:20:21.819984|2018-06-01 00:20:21.819984
NCT01020071|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2014-04-24|2009-11-22|2009-11-25|Estimate|||||||2014-04-24|2014-04-28|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot Study|Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot Study|Completed||N/A|22|Actual|National University Hospital, Singapore||1|||f||||f||||||||||2018-06-01 00:20:21.874736|2018-06-01 00:20:21.874736
NCT01020058|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2016-01-05|2009-11-24|2009-11-25|Estimate|||||||2016-01-05|2016-01-06|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Randomized Study of Open Mesh Repair in Local Anesthesia Versus Cost-optimized Laparoscopic Repair for Inguinal Hernia|Randomized Controlled Trial Comparing Open Mesh Repair in Local Anesthesia to Cost-Optimized Laparoscopic Repair for Primary Inguinal Hernia|Completed||N/A|384|Actual|Uppsala University Hospital||2|||f||||f||||||||||2018-06-01 00:20:21.983284|2018-06-01 00:20:21.983284
NCT01020045|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2015-10-15|2009-11-24|2009-11-25|Estimate|||||||2015-10-15|2015-10-19|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|May 2013|Actual|2013-05-31||Observational|OPG-2||Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis|Effect of HIV Infection and HAART on Bone Homeostasis|Completed|||120|Actual|Emory University|||2||f||||f||||||||||2018-06-01 00:20:22.166815|2018-06-01 00:20:22.166815
NCT01020032|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|September 2006||2006-09-30|November 2009|2009-11-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Effect of Music Therapy on Pain|Effect of Music Therapy on Chronic Pain in Hospitalized Patients in a Pain Center|Completed||N/A|87|Actual|Association de Musicothérapie Applications et Recherches Cliniques||1|||f||||f||||||||||2018-06-01 00:20:22.310341|2018-06-01 00:20:22.310341
NCT01020019|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2016-04-06||2018-05-10|2009-11-24|2009-11-25|Estimate|2016-04-06|2016-05-11|Estimate||||2018-05-10|2018-05-15|Actual|January 2010||2010-01-31|May 2018|2018-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|D-LUCS||Combined Pharmacotherapy for Cannabis Dependency|A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence|Completed||Phase 2/Phase 3|156|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-06-01 00:20:22.426724|2018-06-01 00:20:22.426724
NCT01020006|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|2014-02-18||2014-04-04|2009-11-23|2009-11-25|Estimate|2014-02-18|2014-04-02|Estimate||||2014-04-04|2014-04-24|Estimate|November 2009||2009-11-30|April 2014|2014-04-30||||August 2012|Actual|2012-08-31||Interventional|||Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine|Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine|Completed||Phase 2|42|Actual|Pharmacyclics LLC.||2|||f||||t||||||||||2018-06-01 00:20:22.882141|2018-06-01 00:20:22.882141
NCT01019993|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2010-05-26|2009-11-24|2009-11-25|Estimate|||||||2010-05-26|2010-05-28|Estimate|February 2004||2004-02-29|May 2010|2010-05-31|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|||Non-dependent Lung High Frequency Positive Pressure Ventilation (HFPPV) and Right Ventricular Function|Prospective Study of the Effects of Non-dependent Lung High Frequency Positive Pressure Ventilation on the Right Ventricular Function for Thoracotomy|Completed||Phase 1|33|Actual|King Faisal University||2|||f||||f||||||||||2018-06-01 00:20:23.954124|2018-06-01 00:20:23.954124
NCT01019980|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|2012-03-15||2012-10-18|2009-11-24|2009-11-25|Estimate|2012-10-18|2012-11-19|Estimate||||2012-10-18|2012-11-19|Estimate|March 2010||2010-03-31|October 2012|2012-10-31||||March 2010|Actual|2010-03-31||Interventional|||Efficacy of Diclofenac Potassium Versus Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections|A Comparative Double Blind, Double Dummy, Randomized Study on the Effectiveness of Diclofenac Potassium vs. Acetaminophen in Febrile Children With Acute Upper Respiratory Tract Infections|Terminated||Phase 4|2|Actual|Novartis|This study was cancelled. Two patients were enrolled, but neither received drug as it was not available in the region.|2||"Placebo - Active Drug Not Available. No patients received drug. There are no study results to~   disclose."|f||||||||||||||2018-06-01 00:20:24.042151|2018-06-01 00:20:24.042151
NCT01019967|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-10-05|2009-11-24|2009-11-25|Estimate|||||||2017-10-05|2017-10-06|Actual|November 17, 2009||2009-11-17|September 20, 2012|2012-09-20|September 20, 2012||2012-09-20|||||Observational|||A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder|A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder|Terminated|||17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:20:24.229492|2018-06-01 00:20:24.229492
NCT01019941|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2010-12-15|2009-11-24|2009-11-25|Estimate|||||||2010-12-15|2010-12-16|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|126ASC08Q||Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics of Docetaxel Between Two Docetaxel Products, CKD-810 and Taxotere Inj., in Patients With Advanced Solid Cancer|Completed||Phase 1|44|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-06-01 00:20:24.288424|2018-06-01 00:20:24.288424
NCT01019928|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|2012-01-27||2012-10-10|2009-11-24|2009-11-25|Estimate|2012-10-10|2012-11-09|Estimate||||2012-10-10|2012-11-09|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)|A Phase IIa, Double-blind, Randomized, 2-way Cross-over Study to Evaluate the Effect of a Single Dose of AZD1386 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity in GERD Patients With a Partial Response to PPI Treatment|Completed||Phase 2|14|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:20:24.391563|2018-06-01 00:20:24.391563
NCT01019915|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2015-07-27|2009-11-23|2009-11-25|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2004||2004-01-31|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Cardiac Resynchronization Therapy (CRT) on Skeletal Muscle Histology, Neuroendocrine Activation and Inflammatory Response|Effect of Cardiac Resynchronization Therapy on Skeletal Muscle Histology, Neuroendocrine Activation and Inflammatory Response|Completed||Phase 4|21|Actual|Helse Stavanger HF||1|||f||||f||||||||||2018-06-01 00:20:24.942896|2018-06-01 00:20:24.942896
NCT01019902|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2014-03-19|2009-11-24|2009-11-25|Estimate|||||||2014-03-19|2014-03-20|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Observational|||Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn|Impact of Maternal Iron Status on Neonatal Iron Status and Auditory Brainstem Response in the Newborn|Completed|||144|Actual|Cornell University|||||f||||t||||||Samples With DNA|"~     At delivery a 15 mL maternal blood sample, 20 ml cord blood sample and the placenta are~     collected.~   "|||2018-06-01 00:20:25.017324|2018-06-01 00:20:25.017324
NCT01019889|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2012-04-04|2009-11-23|2009-11-25|Estimate|||||||2012-04-04|2012-04-06|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|ESYUI||Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection|Effect of Socheongryong-tang and Yeongyopaedok-san in Upper Respiratory Tract Infection|Completed||Phase 3|480|Actual|Korea Health Industry Development Institute||3|||f||||f||||||||||2018-06-01 00:20:25.085422|2018-06-01 00:20:25.085422
NCT01019876|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2011-10-18|2009-11-23|2009-11-25|Estimate|||||||2011-10-18|2011-10-19|Estimate|June 2002||2002-06-30|October 2011|2011-10-31|May 2013|Anticipated|2013-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases|Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Columbia University||4|||f||||t||||||||||2018-06-01 00:20:25.181175|2018-06-01 00:20:25.181175
NCT01019863|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-01-11|2009-11-24|2009-11-25|Estimate|||||||2011-01-11|2011-01-12|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Interventional|LNH-RGDOX||Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.|Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.|Unknown status|Recruiting|Phase 2|50|Anticipated|Centre de recherche du Centre hospitalier universitaire de Sherbrooke||1|||f||||t||||||||||2018-06-01 00:20:25.30449|2018-06-01 00:20:25.30449
NCT01019850|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2015-12-11|2009-11-24|2009-11-25|Estimate|||||||2015-12-11|2015-12-14|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma|Vorinostat With 131-I MIBG Therapy for Resistant/Relapsed Neuroblastoma: A Phase I Study IND# 105,744|Completed||Phase 1|27|Actual|New Approaches to Neuroblastoma Therapy Consortium||1|||f||||t||||||||||2018-06-01 00:20:25.398965|2018-06-01 00:20:25.398965
NCT01019837|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|April 2010|Anticipated|2010-04-30|November 2009|Anticipated|2009-11-30||Interventional|||Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases (IBD) Treated Immunomodulators and Biologics|Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Inflammatory Bowel Diseases Treated With Immunomodulators and Biologics|Unknown status|Active, not recruiting|N/A|200|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||||2018-06-01 00:20:25.552297|2018-06-01 00:20:25.552297
NCT01019824|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2017-09-14|2009-11-23|2009-11-25|Estimate|||||||2017-09-14|2017-09-15|Actual|March 20, 2009|Actual|2009-03-20|September 2017|2017-09-30|August 9, 2011|Actual|2011-08-09|May 11, 2010|Actual|2010-05-11||Interventional|||Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain|A Phase III Study to Assess the Efficacy and Safety of Ralfinamide.|Completed||Phase 3|411|Actual|Newron Pharmaceuticals SPA||3|||f||||t||||||||||2018-06-01 00:20:25.615815|2018-06-01 00:20:25.615815
NCT01019798|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer|Phase II Study of Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|16|Anticipated|Taipei Medical University Hospital||1|||f||||t||||||||||2018-06-01 00:20:25.756066|2018-06-01 00:20:25.756066
NCT01019785|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2009||2009-11-30|November 2009|2009-11-30||||November 2011|Anticipated|2011-11-30||Interventional|Delivery||Vitamin D During In Vitro Fertilisation (IVF) - A Prospective Randomized Trial||Unknown status|Enrolling by invitation|Phase 3|1000|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-06-01 00:20:25.85529|2018-06-01 00:20:25.85529
NCT01019772|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|August 2008|Actual|2008-08-31|||||Interventional|||Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age|A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberix™ Vaccine in Healthy Infants at Two, Four and Six Months of Age|Completed||Phase 3|217|Actual|LG Life Sciences||2|||f||||f||||||||||2018-06-01 00:20:25.992244|2018-06-01 00:20:25.992244
NCT01019759|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|September 2002||2002-09-30|November 2009|2009-11-30|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||The Value of add-on Arrhythmia Surgery in Patients With Atrial Fibrillation Undergoing Cardiac Surgery|The Value of add-on Arrhythmia Surgery in Patients With Paroxysmal or Persistent Atrial Fibrillation Undergoing Valvular or Coronary Bypass Surgery. A Randomised Comparison on Quality of Life, Cost-effectiveness, Morbidity and Rhythm Outcome.|Completed||N/A|150|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:20:26.093137|2018-06-01 00:20:26.093137
NCT01019746|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|August 2007||2007-08-31|November 2009|2009-11-30||||May 2008|Actual|2008-05-31||Interventional|||Controlled Propofol Administration|Comparison of Closed-oop of Propofol Versus Manual Control Using Bispectral Index (BIS)|Completed||Phase 4|40|Anticipated|McGill University Health Center||1|||f||||||||||||||2018-06-01 00:20:26.20361|2018-06-01 00:20:26.20361
NCT01019733|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-01-25|2009-11-24|2009-11-25|Estimate|||||||2011-01-25|2011-01-26|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|April 2010|Actual|2010-04-30||Interventional|ISC||Intrathecal Stem Cells in Brain Injury|Intrathecal Autologous Stem Cells for Children With Hipoxic/Ischemic Brain Injury|Completed||N/A|18|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t||||||||||2018-06-01 00:20:26.278566|2018-06-01 00:20:26.278566
NCT01019707|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2013-04-02||2017-05-01|2009-11-24|2009-11-25|Estimate|2013-06-25|2013-07-31|Estimate||||2017-05-01|2017-06-02|Actual|October 2009||2009-10-31|May 2017|2017-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Four (4) subjects completed both components (atomoxetine and placebo) in this double-blind, placebo-controlled crossover trial design.|Safety Assessment of Atomoxetine With MA IV Administration|A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine|Terminated||Phase 1|6|Actual|University of California, Los Angeles|Early termination leading to small number of subject analyzed|2||End in funding|f||||t||||||||||2018-06-01 00:20:26.380055|2018-06-01 00:20:26.380055
NCT01019694|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2012-04-05||2014-10-14|2009-11-24|2009-11-25|Estimate|2012-04-05|2012-05-01|Estimate||||2014-10-14|2014-10-23|Estimate|November 2009||2009-11-30|October 2014|2014-10-31||||April 2011|Actual|2011-04-30||Interventional|||Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease|Patient Acceptability of Ipratropium Bromide/Albuteroll Delivered by the Respimat® Inhaler in Adults With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|470|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 00:20:26.86105|2018-06-01 00:20:26.86105
NCT01019681|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2014-01-31|2009-11-24|2009-11-25|Estimate|||||||2014-01-31|2014-02-03|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia|Umbilical Cord Blood Stem Cell Injection for Critical Limb Ischemia|Terminated||Phase 1|1|Actual|Northwestern University||1||Only patient enrolled on study died -the cause of death not study related|f||||f||||||||||2018-06-01 00:20:28.961653|2018-06-01 00:20:28.961653
NCT01019668|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2011-07-22|2009-11-23|2009-11-25|Estimate|||||||2011-07-22|2011-07-25|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|||Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy|Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy|Completed||N/A|24|Actual|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||f||||||||||2018-06-01 00:20:29.058737|2018-06-01 00:20:29.058737
NCT01019655|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|December 2012|Anticipated|2012-12-31|January 2012|Anticipated|2012-01-31||Interventional|||Heparin for Pregnant Women With Thrombophilia|Low Molecular Weight Heparin for Pregnant Women With Thrombophilia: a Prospective, Randomized, Open Trial|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:20:29.141263|2018-06-01 00:20:29.141263
NCT01019642|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Vitamin D, C-reactive Protein and Insulin Resistance|Effect of Vitamin D Supplementation on C-reactive Protein and Insulin Resistance in Postmenopausal Women With Type 2 Diabetes Mellitus|Completed||Phase 3|104|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||t||||||||||2018-06-01 00:20:29.216046|2018-06-01 00:20:29.216046
NCT01019629|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2018-02-12|2009-11-23|2009-11-25|Estimate|||||||2018-02-12|2018-02-13|Actual|January 29, 2009|Actual|2009-01-29|February 2018|2018-02-28|December 7, 2017|Actual|2017-12-07|April 17, 2013|Actual|2013-04-17||Observational|||Fabry Screening Study|Expanded Screening for Fabry Trait|Completed|||2724|Actual|Baylor Research Institute|||||f||||f||||||Samples With DNA|"~     Blood and Urine~   "|||2018-06-01 00:20:29.299322|2018-06-01 00:20:29.299322
NCT01019616|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-12-17|2009-11-24|2009-11-25|Estimate|||||||2017-12-17|2017-12-19|Actual|December 2010|Actual|2010-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy|A Phase Ⅲ Study of Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy|Recruiting||Phase 3|400|Anticipated|Peking University||2|||f||||t||||||||||2018-06-01 00:20:29.380574|2018-06-01 00:20:29.380574
NCT01019603|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2017-06-22|2009-11-23|2009-11-25|Estimate|||||||2017-06-22|2017-06-23|Actual|October 12, 2009|Actual|2009-10-12|June 2017|2017-06-30|December 20, 2009|Actual|2009-12-20|December 20, 2009|Actual|2009-12-20||Interventional|||A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris|A Single-Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:20:29.551106|2018-06-01 00:20:29.551106
NCT01019590|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2006||2006-11-30|November 2009|2009-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg|Single-Dose Fed Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:20:29.662341|2018-06-01 00:20:29.662341
NCT01019577|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-01-27|2009-11-24|2009-11-25|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant|Phase II Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant|Completed||Phase 2|54|Anticipated|R-Pharm||1|||f||||t||||||||||2018-06-01 00:20:29.736531|2018-06-01 00:20:29.736531
NCT01019564|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2017-06-26|2009-11-24|2009-11-25|Estimate|||||||2017-06-26|2017-06-28|Actual|December 2009||2009-12-31|June 2017|2017-06-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Complete Easy Rub Comparative Efficacy Study||Withdrawn||N/A|0|Actual|Abbott Medical Optics||2||Business decision|f||||||||||||||2018-06-01 00:20:29.81292|2018-06-01 00:20:29.81292
NCT01019551|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2013-06-12|2009-11-24|2009-11-25|Estimate|||||||2013-06-12|2013-06-13|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Interventional|ERAMUNE-01||Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients|International, Multicenter, Randomized, Non-comparative Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression|Completed||Phase 2|29|Actual|Objectif Recherche Vaccins SIDA||2|||f||||t||||||||||2018-06-01 00:20:29.874598|2018-06-01 00:20:29.874598
NCT01019538|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2011-07-03|2009-11-23|2009-11-25|Estimate|||||||2011-07-03|2011-07-06|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Pre-flight Titration of Supplemental Oxygen|COPD and Air Travel: Oxygen Equipment and Pre-flight Titration of Supplemental Oxygen|Completed|||20|Anticipated|Oslo University Hospital|||||f||||t||||||Samples Without DNA|"~     Arterial blood gases~   "|||2018-06-01 00:20:30.011198|2018-06-01 00:20:30.011198
NCT01019525|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-25|2009-11-24|2009-11-25|Estimate|||||||2009-11-25|2009-11-26|Estimate|June 2004||2004-06-30|November 2009|2009-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Posture and Pulmonary Function of Mouth-breathing Children|Posture and Pulmonary Function of Mouth-breathing Children|Completed|||34|Actual|Universidade Federal do Rio de Janeiro|||2||f||||f||||||||||2018-06-01 00:20:30.139805|2018-06-01 00:20:30.139805
NCT01019499|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2010-06-18|2009-11-24|2009-11-25|Estimate|||||||2010-06-18|2010-06-22|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effect of Berry Consumption on Indicators of Cardiovascular Disease Risk|The Effect of Berry Consumption on Indicators of Cardiovascular Disease Risk|Completed||N/A|37|Anticipated|National Institute for Health and Welfare, Finland||2|||f||||f||||||||||2018-06-01 00:20:30.280337|2018-06-01 00:20:30.280337
NCT01019486|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|2013-01-02||2015-11-09|2009-11-23|2009-11-25|Estimate|2015-11-09|2015-12-14|Estimate||||2015-11-09|2015-12-14|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|RABIT1D|mean age value with standard deviation.|Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)|Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)|Completed||Phase 4|26|Actual|University of Colorado, Denver|3 subject had visual perfusion defects, leading to a small % of individuals being referred for invasive CFR measurements. MBF values were less than reported, either from microvascular disease in T1D subjects or the order of rest first then stress.|2|||f||||f||||||||||2018-06-01 00:20:30.409635|2018-06-01 00:20:30.409635
NCT01019473|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2011-09-22|2009-11-24|2009-11-25|Estimate|||||||2011-09-22|2011-09-23|Estimate|November 2009||2009-11-30|September 2011|2011-09-30||||August 2011|Actual|2011-08-31||Interventional|||Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing Chorea|Terminated||Phase 2|44|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:20:30.935084|2018-06-01 00:20:30.935084
NCT01019460|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-09-20|2009-11-24|2009-11-25|Estimate|||||||2011-09-20|2011-09-21|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|October 2010|Actual|2010-10-31||Interventional|||A Comparative Study of Capsule Endoscopy, Magnetic Resonance Imaging and Computer Tomography Scanning of the Small Bowel in Crohn's Disease|A Comparative Study of Capsule Endoscopy, Magnetic Resonance Imaging and Computer Tomography Scanning of the Small Bowel in Crohn's Disease|Completed||N/A|150|Actual|University of Southern Denmark|||||f||||t||||||||||2018-06-01 00:20:31.069824|2018-06-01 00:20:31.069824
NCT01019447|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2011-06-21|2009-11-23|2009-11-25|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection|"The Impact of Using Triclosan-antibacterial Sutures on the Incidence of Surgical Site Infection Prospective, Randomized, Controlled, Double Blind, Multi-centre Study."|Completed||Phase 4|701|Actual|Cairo University||2|||f||||t||||||||||2018-06-01 00:20:31.149718|2018-06-01 00:20:31.149718
NCT01019434|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2016-10-11|2009-11-24|2009-11-25|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|Radiation Therapy and Concurrent Plus Adjuvant Temsirolimus (CCI-779) Versus Chemo-Irradiation With Temozolomide in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Gene Promoter - A Randomized Multicenter, Open-Label, Phase II Study.|Completed||Phase 2|111|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-06-01 00:20:31.263923|2018-06-01 00:20:31.263923
NCT01019421|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2012-01-05|2009-11-24|2009-11-25|Estimate|||||||2012-01-05|2012-01-06|Estimate|December 2009||2009-12-31|January 2012|2012-01-31||||December 2011|Actual|2011-12-31||Interventional|||Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil|Completed||Phase 2|278|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 00:20:31.441587|2018-06-01 00:20:31.441587
NCT01019408|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 1993||1993-11-30|November 2009|2009-11-30|January 1995|Actual|1995-01-31|January 1995|Actual|1995-01-31||Interventional|ECQNWFP||Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan|Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan|Completed||Phase 4|163|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:20:31.694011|2018-06-01 00:20:31.694011
NCT01019395|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2017-10-04|2009-11-24|2009-11-25|Estimate|||||||2017-10-04|2017-10-06|Actual|January 5, 2010|Actual|2010-01-05|October 2017|2017-10-31|March 20, 2012|Actual|2012-03-20|March 20, 2012|Actual|2012-03-20||Interventional|||Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics|An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged 3 Months to Twenty-Four Months Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Bacterial Infection Including Peri-Operative Prophylactic Use of Antibiotics|Completed||Phase 1|23|Actual|Cubist Pharmaceuticals LLC||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:20:31.835658|2018-06-01 00:20:31.835658
NCT01019382|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2014-12-03|2009-11-23|2009-11-25|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer|Phase II Trial of the Effect of Gemcitabine With Intravenous Omega-3 Fish Oil Infusion in Patients With Unresectable Pancreatic Adenocarcinoma|Completed||Phase 2|50|Actual|University Hospitals, Leicester||1|||f||||f||||||||||2018-06-01 00:20:32.156607|2018-06-01 00:20:32.156607
NCT01019369|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2014-12-04||2018-01-23|2009-11-24|2009-11-25|Estimate|2015-04-14|2015-04-15|Estimate||||2018-01-23|2018-02-23|Actual|March 2010||2010-03-31|January 2018|2018-01-31|November 2012|Actual|2012-11-30|January 2011|Actual|2011-01-31||Interventional|||Study of Self or Clinic Administration of DepoProvera|Randomized Clinical Trial of Self Versus Clinical Administration of Depot Medroxyprogesterone Acetate|Completed||N/A|132|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 00:20:32.322398|2018-06-01 00:20:32.322398
NCT01019356|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2016-10-25|2009-11-24|2009-11-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|October 2021|Anticipated|2021-10-31|July 2021|Anticipated|2021-07-31||Interventional|||Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome|Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome|Active, not recruiting||N/A|78|Anticipated|Université de Sherbrooke||3|||f||||f||||||||||2018-06-01 00:20:32.566242|2018-06-01 00:20:32.566242
NCT01019343|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2018-03-27|2009-11-24|2009-11-25|Estimate|||||||2018-03-27|2018-03-29|Actual|October 20, 2009||2009-10-20|February 5, 2018|2018-02-05||||||||Observational|||Physiological Investigations of Movement Disorders|Physiological Investigations of Movement Disorders|Completed|||1273|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:20:32.644112|2018-06-01 00:20:32.644112
NCT01019330|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2015-11-27|2009-11-23|2009-11-25|Estimate|||||||2015-11-27|2015-11-30|Estimate|June 2010||2010-06-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Radial Versus Femoral Arterial Access for Cardiac Catheterization: Comparison of Complications at 30 Days|Radial Versus Femoral Arterial Access for Cardiac Catheterization: Comparison of Complications at 30 Days|Completed|||243|Actual|Creighton University|||2||f||||f||||||||||2018-06-01 00:20:32.716296|2018-06-01 00:20:32.716296
NCT01019317|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|2013-10-04||2016-02-17|2009-11-23|2009-11-25|Estimate|2013-10-04|2013-12-03|Estimate||||2016-02-17|2016-03-15|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|A Phase II Study of Twice Daily Cytarabine and Fludarabine in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome|Completed||Phase 2|151|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:20:32.842356|2018-06-01 00:20:32.842356
NCT01019291|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2015-03-26|2009-11-23|2009-11-25|Estimate|||||||2015-03-26|2015-03-27|Estimate||||March 2015|2015-03-31||||||||Interventional|||Role of Indoor Pollutants on House Dust Mite Allergic Asthma|Aldehyde and Nitrogen Dioxide at Homes: Measurement of the Exposure and Their Role on Allergic Asthma|Withdrawn||N/A|0|Actual|University Hospital, Strasbourg, France||4|||f||||f||||||||||2018-06-01 00:20:33.057081|2018-06-01 00:20:33.057081
NCT01019265|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2015-07-07|2009-11-24|2009-11-25|Estimate|||||||2015-07-07|2015-07-08|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||A Study Comparing Norspan Patch and Oral Tramadol|A Randomised Open Label Parallel Group Study Comparing Norspan Patch and Oral Tramadol|Completed||Phase 4|170|Actual|Mundipharma Korea Ltd||2|||f||||f||||||||||2018-06-01 00:20:33.177859|2018-06-01 00:20:33.177859
NCT01019252|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2012-05-24|2009-11-20|2009-11-25|Estimate|||||||2012-05-24|2012-05-25|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Skills Training for Adolescents With ADHD|Compensatory Executive Functioning Skills Training in Adolescents With ADHD|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 00:20:33.281459|2018-06-01 00:20:33.281459
NCT01019239|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-30|2009-11-23|2009-11-25|Estimate|||||||2009-11-30|2009-12-01|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|LapLAND||LapLAND Laparoscopic Lavage for Acute Non-Faeculant Diverticulitis|Laparoscopic Lavage for Acute Non-Faeculant Diverticulitis|Unknown status|Enrolling by invitation|N/A|300|Anticipated|St Vincent's University Hospital, Ireland||2|||f||||t||||||||||2018-06-01 00:20:33.362603|2018-06-01 00:20:33.362603
NCT01019226|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2010-05-09|2009-11-23|2009-11-25|Estimate|||||||2010-05-09|2010-05-11|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Implementation of Work in Progress (WIP) Sequences in Magnetic Resonance Imaging (MRI)|Implementation of Work in Progress (WIP) Sequences in MRI|Unknown status|Recruiting||500|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 00:20:33.449132|2018-06-01 00:20:33.449132
NCT01019200|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2016-06-15|2009-11-23|2009-11-25|Estimate|||||||2016-06-15|2016-06-16|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|||Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis|A Case Control Study to Evaluate Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis.|Completed|||210|Actual|George Washington University|||2||f||||f||||||||Yes||2018-06-01 00:20:33.704024|2018-06-01 00:20:33.704024
NCT01019174|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-02-17|2009-11-24|2009-11-25|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2009||2009-11-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MM_LEN_DEX_CY||Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma|An Open, Randomized Clinical Phase I/II Trial to Investigate Maximum Tolerated Dose, Efficacy, and Safety of Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|40|Actual|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||2|||f||||t||||||||||2018-06-01 00:20:33.793626|2018-06-01 00:20:33.793626
NCT01019161|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2010-10-19|2009-11-23|2009-11-25|Estimate|||||||2010-10-19|2010-10-20|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)|A Phase I Open, Non-randomised, Single-centre Study to Assess the Metabolism, Excretion and Pharmacokinetics of AZD1152 and AZD1152 hQPA Following Intravenous Administration of [14C]-AZD1152 in Patients With Acute Myeloid Leukaemia (AML)|Completed||Phase 1|5|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:20:33.917403|2018-06-01 00:20:33.917403
NCT01019148|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2016-03-17|2009-11-20|2009-11-25|Estimate|||||||2016-03-17|2016-03-18|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa|Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa|Unknown status|Recruiting||30|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     Skin biopsies, serum~   "|||2018-06-01 00:20:34.050658|2018-06-01 00:20:34.050658
NCT01019135|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|2015-06-23||2015-10-28|2009-11-23|2009-11-25|Estimate|2015-10-28|2015-11-30|Estimate||||2015-10-28|2015-11-30|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CR4HER||Cardiac Rehabilitation for Heart Event Recovery (HER)|A Randomized Controlled Trial of Women's Adherence to Women-only, Home-based and Traditional Cardiac Rehabilitation (Cardiac Rehabilitation for Her Heart Event Recovery [CR4HER])|Completed||N/A|169|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-06-01 00:20:34.208429|2018-06-01 00:20:34.208429
NCT01019109|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2018-03-20|2009-11-20|2009-11-25|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2010||2010-05-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Scoliosis Surgery Using the PASS® LP System|Idiopathic Scoliosis Treated by Posterior Spinal Instrumentation. Evaluation of the 3D Correction, Aesthetic Outcomes and Quality of Life.|Completed|||79|Actual|Medicrea, USA Corp.|||2||f||||f||||||||||2018-06-01 00:20:34.649642|2018-06-01 00:20:34.649642
NCT01019096|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2012-03-21|2009-11-24|2009-11-25|Estimate|||||||2012-03-21|2012-03-22|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer|Absorption of Heme and Non-Heme Iron in Pregnant and Non-pregnant Women and Mechanisms of Fetal Iron Transfer|Completed|||55|Actual|Cornell University|||||f||||t||||||Samples With DNA|"~     For non-pregnant subjects 15 mL of blood are collected. For pregnant subjects two 15 mL blood~     samples are collected. The placenta and up to 30 mL of cord blood are also collected at~     delivery.~   "|||2018-06-01 00:20:34.735954|2018-06-01 00:20:34.735954
NCT01019083|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2011-07-11|2009-11-24|2009-11-25|Estimate|||||||2011-07-11|2011-07-12|Estimate|February 2008||2008-02-29|November 2009|2009-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Studies of Immune Responses to Orally Administered Vaccines in Developing Country|Studies of Acute and Memory Immune Responses to Orally Administered Vaccines in Developing Country Children and Factors That May Augment Such Responses|Completed||Phase 1/Phase 2|1016|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||6|||f||||t||||||||||2018-06-01 00:20:34.805926|2018-06-01 00:20:34.805926
NCT01019070|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-10-25|2009-11-24|2009-11-25|Estimate|||||||2011-10-25|2011-10-26|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032|Multiple-Dose Pharmacokinetics of BMS-650032 in Subjects With Hepatic Impairment Compared to Healthy Subjects|Completed||Phase 1|28|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 00:20:34.932739|2018-06-01 00:20:34.932739
NCT01019057|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2014-07-14|2009-11-24|2009-11-25|Estimate|||||||2014-07-14|2014-07-15|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|ILIF||An Evaluation of Interlaminar Lumbar Instrumented (ILIF™)|A Prospective, Non-randomized, Multi-Center Evaluation of Interlaminar Lumbar Instrumented (ILIF™)|Completed|||77|Actual|NuVasive|||||f||||f||||||||||2018-06-01 00:20:35.001645|2018-06-01 00:20:35.001645
NCT01019044|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2013-02-12|2009-11-24|2009-11-25|Estimate|||||||2013-02-12|2013-02-13|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|MUCOVIR||Exploration of HIV Reservoirs|Virologic and Immunologic Evaluation of the Deep Viral Reservoirs in HIV-1 Infected Patients With Long Term Viral Suppression|Completed|||11|Actual|Objectif Recherche Vaccins SIDA|||1||f||||f||||||None Retained|"~     Plasma and total blood samples A maximum of 15 rectal mucosa biopsy samples~   "|||2018-06-01 00:20:35.068184|2018-06-01 00:20:35.068184
NCT01019018|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|October 2011|Anticipated|2011-10-31|April 2011|Anticipated|2011-04-30||Interventional|||Efficacy of Subtenon's Block With Olive Tipped Cannula|Efficacy of Subtenon Anesthesia With Olive Tipped Cannula: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|120|Anticipated|King Khaled Eye Specialist Hospital||2|||f||||t||||||||||2018-06-01 00:20:35.154429|2018-06-01 00:20:35.154429
NCT01019005|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|February 2010||2010-02-28|November 2009|2009-11-30|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Interventional|||Pain Relief After Forefoot Surgery|Pain Relief After Forefoot Surgery: Tibial Perineural Catheter vs. Wound Catheter Infusion|Unknown status|Not yet recruiting|N/A|75|Anticipated|Nottingham University Hospitals NHS Trust||3|||f||||t||||||||||2018-06-01 00:20:35.35196|2018-06-01 00:20:35.35196
NCT01018992|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2015-07-02||2017-01-24|2009-11-24|2009-11-25|Estimate|2015-07-02|2015-07-30|Estimate||||2017-01-24|2017-03-07|Actual|December 2009||2009-12-31|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||All participants randomized to receive the double-blind study medication|Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder|Evaluation of the Efficacy of the CRF1 Antagonist GSK561679 in Women With Post-traumatic Stress Disorder|Completed||Phase 2|267|Actual|Emory University|Limitations of this trial include short duration of treatment (6 weeks) and generalizability due to study population composed of only females.|2|||f||||t||||||||||2018-06-01 00:20:35.437749|2018-06-01 00:20:35.437749
NCT01018979|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2014-12-18||2015-01-13|2009-11-24|2009-11-25|Estimate|2015-01-13|2015-01-15|Estimate||||2015-01-13|2015-01-15|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||19 subjects met all eligibility criteria and received at least one dose of TG-0054.|Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients|A Phase II, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease|Completed||Phase 2|19|Actual|TaiGen Biotechnology Co., Ltd.||2|||f||||t||||||||||2018-06-01 00:20:35.889115|2018-06-01 00:20:35.889115
NCT01018966|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-01-27|2009-11-24|2009-11-25|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2004||2004-04-30|January 2017|2017-01-31|April 2005|Actual|2005-04-30|March 2005|Actual|2005-03-31||Interventional|||Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors|Phase I Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors|Completed||Phase 1|25|Anticipated|R-Pharm||1|||f||||t||||||||||2018-06-01 00:20:36.580404|2018-06-01 00:20:36.580404
NCT01018953|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2015-06-15||2015-08-06|2009-11-24|2009-11-25|Estimate|2015-08-06|2015-09-07|Estimate||||2015-08-06|2015-09-07|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|CAMPANULA||Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome|Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome|Terminated||Phase 2|8|Actual|Ipsen|Due to premature termination of the study, no data was collected/analyzed and no patient participated in Part B.|1||Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1|f||||f||||||||||2018-06-01 00:20:36.7083|2018-06-01 00:20:36.7083
NCT01018940|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2014-12-02|2009-11-23|2009-11-25|Estimate|||||||2014-12-02|2014-12-04|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease|Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease|Completed|||30|Actual|University of Oklahoma|||2||f||||t||||||Samples With DNA|"~     Blood specimens for platelet activity and genotyping~   "|||2018-06-01 00:20:37.166846|2018-06-01 00:20:37.166846
NCT01018927|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2017-05-30|2009-11-24|2009-11-25|Estimate|||||||2017-05-30|2017-05-31|Actual|June 2009||2009-06-30|May 2017|2017-05-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Observational|||Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects|Role of Cardiac MR (CMR) In Detecting Features of Early Myocardial Infiltration With Amyloid and Light Chain Deposition Disease in Subjects With Multiple Myeloma|Terminated|||44|Actual|University of Arkansas|||1|PI does not have time to continue study|f||||f||||||||||2018-06-01 00:20:37.24569|2018-06-01 00:20:37.24569
NCT01018914|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2016-01-28|2009-11-23|2009-11-25|Estimate|||||||2016-01-28|2016-01-29|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients|A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus)/ Myfortic® and Advagraf® (Extended Release Tacrolimus) / Myfortic® in de Novo Liver Transplant Recipients|Completed||Phase 4|44|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 00:20:37.323581|2018-06-01 00:20:37.323581
NCT01018888|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2013-01-07|2009-11-24|2009-11-25|Estimate|||||||2013-01-07|2013-01-08|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|AuroKPro||Safety and Efficacy Study of Artificial Cornea|Clinical Assessment of Auro KPro|Unknown status|Recruiting|Phase 4|20|Anticipated|Aurolab||1|||f||||t||||||||||2018-06-01 00:20:37.40437|2018-06-01 00:20:37.40437
NCT01018862|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2012-03-22||2012-05-10|2009-11-24|2009-11-25|Estimate|2012-05-10|2012-06-11|Estimate||||2012-05-10|2012-06-11|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 (0.15% Solution) and MP03-33 (0.10% Solution) in Children Ages >6 to <12 With Perennial Allergic Rhinitis|Completed||Phase 3|489|Actual|Meda Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:20:37.528615|2018-06-01 00:20:37.528615
NCT01018849|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2016-01-14|2009-11-23|2009-11-25|Estimate|||||||2016-01-14|2016-01-15|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|July 2013|Actual|2013-07-31||Interventional|||Role of Vitamin D in Secondary Prevention of Cardiovascular Events|Role of Vitamin D in Secondary Prevention of Cardiovascular Events|Completed||N/A|24|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 00:20:38.097724|2018-06-01 00:20:38.097724
NCT01018836|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2014-04-30|2009-11-24|2009-11-25|Estimate|||||||2014-04-30|2014-05-02|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase I Trial of Riluzole in Combination With Radiation Therapy in Patients Undergoing Whole Brain Radiation Therapy for Brain Metastasis|Terminated||Phase 1|9|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||f||||||||||2018-06-01 00:20:38.175236|2018-06-01 00:20:38.175236
NCT01018823|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2017-10-30|2009-11-23|2009-11-25|Estimate|||||||2017-10-30|2017-10-31|Actual|December 14, 2009|Actual|2009-12-14|October 2017|2017-10-31|March 18, 2010|Actual|2010-03-18|March 18, 2010|Actual|2010-03-18||Interventional|||A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)|A Phase 1, Randomized, Placebo-Controlled, Parallel Group, 14 Day Repeated Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729 In Otherwise Healthy Overweight And Obese Adult Subjects|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 00:20:38.273223|2018-06-01 00:20:38.273223
NCT01018810|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|2011-06-01|2011-02-25|2011-07-27|2009-11-24|2009-11-25|Estimate|2011-06-01|2011-06-30|Estimate|2011-02-25|2011-03-11|Estimate|2011-07-27|2011-07-29|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||A Study for Adults With Plaque Psoriasis|LY2525623 (IL-23 Antibody) Multiple-Dose Study in Adults With Plaque Psoriasis|Terminated||Phase 2|8|Actual|Eli Lilly and Company|Study BDAD was terminated early due to non-safety related complexities in LY2525623 development. Numerical summaries and statistical comparisons for the 8 patients enrolled are not appropriate and may be scientifically/clinically misleading.|7||"The trial was terminated for several reasons, including complexities in development of~   LY2525623, but not because of safety concerns"|f||||t||||||||||2018-06-01 00:20:38.398168|2018-06-01 00:20:38.398168
NCT01018797|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-21|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|Anel||Intrastromal Corneal Ring for High Astigmatism on Postkeratoplasty|Intrastromal Corneal Ring Segment Implantation for High Astigmatism on Postkeratoplasty Eyes|Completed||Phase 4|18|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-06-01 00:20:39.142005|2018-06-01 00:20:39.142005
NCT01018784|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2016-01-19|2009-11-23|2009-11-25|Estimate|||||||2016-01-19|2016-01-21|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional|||A Study of MORAb-009 in Patients With Solid Tumor|A Phase 1 Study of MORAb-009 in Patients With Solid Tumor|Completed||Phase 1|17|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 00:20:39.20624|2018-06-01 00:20:39.20624
NCT01018771|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-04-04|2009-11-24|2009-11-25|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2009||2009-07-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|APPRAISET2||Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion|A Prospective, Randomised Study Comparing the Use of Actifuse (Trademark) Advanced Bone Matrix (ABX) Synthetic Bone Substitute With INFUSE (Trademark) on Fusion in Patients Requiring Posterolateral Instrumented Lumbar Fusion|Completed||N/A|100|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-06-01 00:20:39.260227|2018-06-01 00:20:39.260227
NCT01018758|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2009-11-24|2009-11-24|2009-11-25|Estimate|||||||2009-11-24|2009-11-25|Estimate|July 2006||2006-07-31|November 2009|2009-11-30|July 2008|Actual|2008-07-31|||||Interventional|NHLPal||Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy|Phase II Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy|Completed||Phase 2|86|Actual|Gruppo Italiano Studio Linfomi||1|||f||||f||||||||||2018-06-01 00:20:39.332963|2018-06-01 00:20:39.332963
NCT01018745|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2011-01-06|2009-11-24|2009-11-25|Estimate|||||||2011-01-06|2011-01-07|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan|Phase 1 Multiple Ascending Dose Study of BMS-907351 (XL184) Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|3|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:20:39.401496|2018-06-01 00:20:39.401496
NCT01018732|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2011-08-09||2015-07-14|2009-11-24|2009-11-25|Estimate|2011-08-09|2011-09-13|Estimate||||2015-07-14|2015-07-15|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY|A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vaccinated as Adolescents With Either MenACWY Conjugate Vaccine or Menomune®.|Completed||Phase 2|155|Actual|Novartis||3|||f||||f||||||||||2018-06-01 00:20:40.530941|2018-06-01 00:20:40.530941
NCT01018719|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-23|2009-11-23|2009-11-25|Estimate|||||||2009-11-23|2009-11-25|Estimate|January 2010||2010-01-31|November 2009|2009-11-30||||December 2011|Anticipated|2011-12-31||Observational|||Evaluation of Radiation Induced Toxicity to the Heart by Multi-detector Computed Tomography (MDCT)|Evaluation of Radiation Induced Cardiotoxicity by Multi-detector Computed Tomography (MDCT)|Unknown status|Not yet recruiting||100|Anticipated|Western Galilee Hospital-Nahariya|||2||f||||f||||||||||2018-06-01 00:20:41.416086|2018-06-01 00:20:41.416086
NCT01018706|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2013-12-16|2009-11-24|2009-11-25|Estimate|||||||2013-12-16|2013-12-17|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|GHOST||Goodness of Clinical History During Stemi PCI|Goodness of Clinical History During Stemi PCI (GHOST)|Completed|||400|Actual|Umberto I Hospital, Frosinone Italy|||1||f||||f||||||||||2018-06-01 00:20:41.528433|2018-06-01 00:20:41.528433
NCT01018693|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-24|||2017-03-17|2009-11-24|2009-11-25|Estimate|||||||2017-03-17|2017-03-21|Actual|November 2009|Actual|2009-11-30|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Determine the Capacity of VAK694 When Combined With Allergen Immunotherapy to Bring About Specific Immune Tolerance|Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 2|37|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:20:41.603042|2018-06-01 00:20:41.603042
NCT01018680|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|2012-03-29||2012-09-04|2009-11-24|2009-11-25|Estimate|2012-09-04|2012-10-05|Estimate||||2012-09-04|2012-10-05|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis|A Randomized, Placebo-Controlled Trial of Duloxetine Added to Nonsteroidal Anti-inflammatory Drugs in Patients With Knee Pain Due to Osteoarthritis Who Have Had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment.|Completed||Phase 3|524|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:20:41.893511|2018-06-01 00:20:41.893511
NCT01018667|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-22|||2010-07-21|2009-11-23|2009-11-25|Estimate|||||||2010-07-21|2010-07-23|Estimate|October 2008||2008-10-31|June 2010|2010-06-30||||December 2011|Anticipated|2011-12-31||Observational|ADOPT||Assessment of Efficacies of Cardiac Resynchronization Therapies (CRT-P/D) for Heart Failure Patients in China|The ADOPT Trial (Assessment of Efficacies of Cardiac Resynchronization Therapies (CRT-P/D) for Heart Failure Patients in China): Rationale, Design and End-points|Unknown status|Recruiting||400|Anticipated|Xijing Hospital|||2||f||||t||||||||||2018-06-01 00:20:43.498036|2018-06-01 00:20:43.498036
NCT01018654|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2013-04-19|2009-11-23|2009-11-25|Estimate|||||||2013-04-19|2013-04-22|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|VIDA||Validating Interventions for Diverse Adolescents|Efficacy of Group Treatment for Hispanic Adolescents - RCT|Completed||Phase 2|70|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 00:20:43.647759|2018-06-01 00:20:43.647759
NCT01020708|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2011-03-28|2009-11-23|2009-11-24|Estimate|||||||2011-03-28|2011-03-29|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis|A Phase I Double-blind, Randomized, Comparator-controlled Study of the Safety and Tolerability of N-acetylcysteine Plus Mesalamine Enema in Subjects With Left-sided Ulcerative Colitis|Completed||Phase 1|9|Anticipated|Altheus Therapeutics, Inc.||3|||f||||t||||||||||2018-06-01 00:20:43.81196|2018-06-01 00:20:43.81196
NCT01020487|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2017-02-13|2015-05-22|2017-02-13|2009-11-20|2009-11-24|Estimate|2017-02-13|2017-03-29|Actual|2015-05-22|2015-06-19|Estimate|2017-02-13|2017-03-29|Actual|February 2010||2010-02-28|February 2017|2017-02-28|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional||All enrolled participants. Note: Two participants enrolled in Part 2 after completing Part 1 of the study, hence the actual total number of enrolled participants was 47. These 2 participants are counted in both arms they enrolled in for Baseline Measure data and are hence double-counted in the Total column for gender, race and CKD stage.|Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)|A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Parathyroid Hormone Levels in Pediatric Subjects Ages 10 to 16 Years With Moderate to Severe Chronic Kidney Disease|Completed||Phase 3|47|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 00:20:43.960814|2018-06-01 00:20:43.960814
NCT01020383|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2012-07-11|2009-11-23|2009-11-24|Estimate|||||||2012-07-11|2012-07-12|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients|A Phase 2 Randomized, Open Label Clinical Trial in High Risk Percutaneous Coronary Intervention (PCI) Patients Receiving Standard Antithrombotic Treatment Plus Either ALX-0081 or GPIIb/IIIa Inhibitor (ReoPro®) Over a Period of 24 Hours|Completed||Phase 2|364|Actual|Ablynx||2|||f||||t||||||||||2018-06-01 00:20:44.995626|2018-06-01 00:20:44.995626
NCT01020292|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2017-07-31|2009-11-23|2009-11-24|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2009||2009-04-30|July 2017|2017-07-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma|Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma|Active, not recruiting||Phase 1|31|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 00:20:45.265347|2018-06-01 00:20:45.265347
NCT01020097|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-12-14|2009-11-23|2009-11-24|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2009||2009-03-31|December 2015|2015-12-31||||December 2013|Actual|2013-12-31||Interventional|||Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx|Is 18F-EF5 PET Imaging Useful in Determining the Prognosis of Newly Diagnosed Head and Neck Squamous Cell Carcinoma?|Unknown status|Active, not recruiting|N/A|48|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:20:45.343826|2018-06-01 00:20:45.343826
NCT01019954|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2014-11-06|2009-11-23|2009-11-24|Estimate|||||||2014-11-06|2014-11-10|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Photodynamic Therapy for Early Head and Neck Tumors|Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors|Completed||Phase 1|48|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 00:20:45.413556|2018-06-01 00:20:45.413556
NCT01019512|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2015-03-24|2009-11-23|2009-11-24|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 2009||2009-07-31|March 2015|2015-03-31||||January 2011|Actual|2011-01-31||Interventional|||Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer|A Pilot, Randomized, Single-Blind Study to Assess the Efficacy of the FlexitouchÂ® Lymphedema System in Reducing Lymphedema in Patients Treated for Breast Cancer|Terminated||N/A|60|Anticipated|Abramson Cancer Center of the University of Pennsylvania||3|||f||||t||||||||||2018-06-01 00:20:45.510418|2018-06-01 00:20:45.510418
NCT01019278|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2016-09-23|2009-11-23|2009-11-24|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 2009||2009-07-31|September 2016|2016-09-30||||August 2011|Actual|2011-08-31||Interventional|||Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes|A Feasibility and Phase II Study of Proton Beam Radiotherapy for Patients With Cervical Cancer and FDG-PET Positive Para-aortic Lymph Nodes|Withdrawn||Phase 2|0|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:20:45.602828|2018-06-01 00:20:45.602828
NCT01019187|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2017-01-24|2009-11-23|2009-11-24|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 2009||2009-06-30|January 2017|2017-01-31||||August 2013|Actual|2013-08-31||Interventional|||Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy|Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy|Active, not recruiting||Phase 2|226|Anticipated|Abramson Cancer Center of the University of Pennsylvania||4|||f||||||||||||||2018-06-01 00:20:45.711085|2018-06-01 00:20:45.711085
NCT01019122|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2011-03-08|2009-11-23|2009-11-24|Estimate|||||||2011-03-08|2011-03-10|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Observational|||Longitudinal Assessment of Bone Growth in Children With Cerebral Palsy|Longitudinal Assessment of Bone Growth and Development in a Facility-Based Population of Children With Cerebral Palsy|Completed|||56|Anticipated|Akron Children's Hospital|||1||f||||f||||||||||2018-06-01 00:20:45.843909|2018-06-01 00:20:45.843909
NCT01018901|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-23|||2016-01-25|2009-11-23|2009-11-24|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2009||2009-01-31|January 2016|2016-01-31||||January 2013|Actual|2013-01-31||Interventional|||Goals of Sexual Function in Prostate Cancer Survivors and Their Partners After Cancer Treatment|Goals for Sexual Functioning of Prostate Cancer Survivors and Their Partners Following Cancer Treatment|Unknown status|Active, not recruiting|N/A|80|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||f||||||||||2018-06-01 00:20:45.910519|2018-06-01 00:20:45.910519
NCT01018875|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20||2012-02-01|2013-01-22|2009-11-23|2009-11-24|Estimate||||2012-02-01|2012-02-03|Estimate|2013-01-22|2013-01-29|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease|A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease|Completed||Phase 2|242|Actual|AbbVie||4|||f||||t||||||||||2018-06-01 00:20:45.99686|2018-06-01 00:20:45.99686
NCT01018641|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2014-04-23|2009-11-20|2009-11-23|Estimate|||||||2014-04-23|2014-04-24|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults|A Phase 1 Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Ascending Dose Levels Of A 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults|Completed||Phase 1|449|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 00:20:46.137041|2018-06-01 00:20:46.137041
NCT01018628|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2017-06-07|2009-11-19|2009-11-23|Estimate|||||||2017-06-07|2017-06-09|Actual|December 7, 2009|Actual|2009-12-07|June 2017|2017-06-30|August 6, 2010|Actual|2010-08-06|August 6, 2010|Actual|2010-08-06||Interventional|||A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers|A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers|Completed||Phase 1|64|Actual|GlaxoSmithKline||8|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:20:46.274128|2018-06-01 00:20:46.274128
NCT01018615|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2017-04-15|2009-11-20|2009-11-23|Estimate|||||||2017-04-15|2017-04-18|Actual|November 2009||2009-11-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C|Steady-State Pharmacokinetic Interactions of Green Tea Catechins and Silymarin Flavonolignans in Treatment Naïve Patients With Chronic Hepatitis C Infection|Completed||Phase 1|28|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:20:46.407024|2018-06-01 00:20:46.407024
NCT01018602|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2011-06-24|2009-11-20|2009-11-23|Estimate|||||||2011-06-24|2011-06-27|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|June 2015|Anticipated|2015-06-30|June 2012|Anticipated|2012-06-30||Interventional|||PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)|A Phase II, Randomized, Double-blind, 2-arm Controlled Study to Evaluate Efficacy of the DPPIV-inhibitor Vildagliptin for Prevention of Type 2 Diabetes in Women With a Recent History of Insulin-requiring Gestational Diabetes|Unknown status|Recruiting|Phase 2|140|Anticipated|Institut fur Diabetesforschung, Munich, Germany||2|||f||||t||||||||||2018-06-01 00:20:46.548682|2018-06-01 00:20:46.548682
NCT01018589|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2010-12-07|2009-11-20|2009-11-23|Estimate|||||||2010-12-07|2010-12-08|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cicatrix Cream in Post Surgical Scars and Epidermic Burn|Effect the Cicatrix Cream in in Treatment of Post Surgical Scars and and Epidermic Burn.|Completed||Phase 2|100|Anticipated|Catalysis SL||1|||f||||t||||||||||2018-06-01 00:20:46.625476|2018-06-01 00:20:46.625476
NCT01018576|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2014-12-01|2009-11-19|2009-11-23|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Delayed Cord Clamping in Premature Infants|Delayed Cord Clamping: Prevention of Anemia and Hypothermia in Premature Infants|Terminated||N/A|6|Actual|University of California, Davis||1||Inadequate numbers of babies enrolled and departure of co-investigator|f||||t||||||||||2018-06-01 00:20:46.737489|2018-06-01 00:20:46.737489
NCT01018563|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18||2015-06-25|2015-11-13|2009-11-19|2009-11-23|Estimate||||2015-06-25|2015-07-20|Estimate|2015-11-13|2015-12-11|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|||An Open Label Extension Study of the Efficacy of MORAb-003|An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse|Completed||Phase 2|3|Actual|Morphotek||1|||f||||f||||||||||2018-06-01 00:20:46.933693|2018-06-01 00:20:46.933693
NCT01018550|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19||2016-02-23|2016-02-23|2009-11-19|2009-11-23|Estimate||||2016-02-23|2016-03-23|Estimate|2016-02-23|2016-03-23|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma|A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects With Inadequately Controlled Asthma|Completed||Phase 2|397|Actual|Amgen||2|||f||||||||||||||2018-06-01 00:20:47.004728|2018-06-01 00:20:47.004728
NCT01018537|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2018-04-30|2009-11-20|2009-11-23|Estimate|||||||2018-04-30|2018-05-03|Actual|January 1996||1996-01-31|April 2018|2018-04-30|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31|10 Years|Observational [Patient Registry]|NARCOMS||NARCOMS Registry: A Multiple Sclerosis Registry|NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis|Recruiting|||50000|Anticipated|Washington University School of Medicine|||||f||||t||||||||||2018-06-01 00:20:47.113425|2018-06-01 00:20:47.113425
NCT01018524|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2010-03-07|2009-11-20|2009-11-23|Estimate|||||||2010-03-07|2010-03-09|Estimate|March 2002||2002-03-31|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|HSS-AHS||Open Mesh Versus Suture Repair in Treatment of Abdominal Wall Hernias|Results of Open Mesh Versus Suture Repair in Treatment of Abdominal Wall (Multicentric, Prospective, Randomised, Internet-based, Clinical Trial)|Completed||Phase 4|2|Actual|Hungarian Surgical Society||4|||f||||t||||||||||2018-06-01 00:20:47.310426|2018-06-01 00:20:47.310426
NCT01018511|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2015-10-14|2012-04-04|2017-02-15|2009-11-19|2009-11-23|Estimate|2015-12-16|2015-12-17|Estimate|2012-04-04|2012-04-06|Estimate|2017-02-15|2017-03-21|Actual|January 2010||2010-01-31|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|Neptune|Safety Analysis Set (SAF): participants who received at least 1 dose of double-blind study drug and had any data reported after the first dose; For study-specific: Full Analysis Set (FAS): participants who received at least 1 dose of double-blind study drug and had either a total IPSS or TUS at baseline and at least 1 postbaseline total IPSS or TUS|Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms|A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study of Fixed Dose Combinations of Solifenacin Succinate (6 mg and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg and Tamsulosin Hydrochloride OCAS 0.4 mg Monotherapy, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component|Completed||Phase 3|1334|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|4|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:20:47.518472|2018-06-01 00:20:47.518472
NCT01018498|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2018-01-16|2009-11-19|2009-11-23|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2009||2009-10-31|January 2018|2018-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome|Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome|Completed||N/A|12|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 00:20:50.812823|2018-06-01 00:20:50.812823
NCT01018485|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2015-05-08|2009-11-20|2009-11-23|Estimate|||||||2015-05-08|2015-05-12|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor|Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis|Completed||Phase 3|30|Anticipated|Melbourne Health||2|||f||||f||||||||||2018-06-01 00:20:50.951556|2018-06-01 00:20:50.951556
NCT01018472|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2014-12-01|2009-11-19|2009-11-23|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|||Probiotics in Infants With Cyanotic Congenital Heart Disease|Probiotics in Infants With Cyanotic Congenital Heart Disease|Completed||N/A|12|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 00:20:51.023664|2018-06-01 00:20:51.023664
NCT01018459|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2014-06-05|2009-11-19|2009-11-23|Estimate|||||||2014-06-05|2014-06-06|Estimate|April 2010||2010-04-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso|A Phase I Randomized, Controlled, Double-Blinded, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabè, Semi-Immune, Healthy Adults 18 to 45 Years of Age|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 00:20:51.11153|2018-06-01 00:20:51.11153
NCT01018446|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2013-11-17|2009-11-20|2009-11-23|Estimate|||||||2013-11-17|2013-11-19|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Hematopoietic Stem Cell Transplantation Based on Pharmacokinetic and Pharmacodynamic Modeling|Determination of Optimal Busulfan Dose Using Pharmacokinetic Modeling in Hematopoietic Stem Cell Transplantation|Completed||Phase 1|30|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-06-01 00:20:51.195389|2018-06-01 00:20:51.195389
NCT01018433|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2015-03-09|2009-11-20|2009-11-23|Estimate|||||||2015-03-09|2015-03-10|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|T-SIB||Treatment for Non-Suicidal Self-Injury in Young Adults|Development of an Intervention for Non-Suicidal Self-Injury in Young Adults|Completed||Phase 1/Phase 2|45|Actual|Fordham University||2|||f||||t||||||||||2018-06-01 00:20:51.266676|2018-06-01 00:20:51.266676
NCT01018420|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2009-08-12||2009-11-24|2009-10-05|2009-11-23|Estimate|2009-10-05|2009-11-23|Estimate||||2009-11-24|2009-12-01|Estimate|November 2007||2007-11-30|November 2009|2009-11-30|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study|A Randomized, Double-Blind, Double-Dummy Pharmacokinetic and Exploratory Electrocardiogram (ECG) Safety Study of a Standard Acute Gout Regimen|Completed||Phase 1|18|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:20:51.386324|2018-06-01 00:20:51.386324
NCT01018407|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2015-06-04|2009-11-20|2009-11-23|Estimate|||||||2015-06-04|2015-06-08|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ICAN||Interventions for Communication in Autism Network|Multisite Randomized Control Treatment of Early Intervention for Spoken Communication in Autism|Completed||N/A|192|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:20:51.926943|2018-06-01 00:20:51.926943
NCT01018394|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2013-06-20||2013-09-11|2009-11-19|2009-11-23|Estimate|2013-09-11|2013-09-13|Estimate||||2013-09-11|2013-09-13|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction|A Pilot Study to Compare the Nicotine Lozenge and Tobacco-Free Snuff for Smokeless Tobacco Reduction|Completed||Phase 2/Phase 3|81|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:20:52.077223|2018-06-01 00:20:52.077223
NCT01018381|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2009-11-20|2009-11-20|2009-11-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|June 2006||2006-06-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|July 2008|Actual|2008-07-31||Interventional|||Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection|Randomized Clinical Study of Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection|Completed||N/A|130|Actual|The 108 Military Central Hospital||2|||f||||f||||||||||2018-06-01 00:20:52.342443|2018-06-01 00:20:52.342443
NCT01018368|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2010-05-06|2009-11-19|2009-11-23|Estimate|||||||2010-05-06|2010-05-10|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of VX-770 and Rifampin in Healthy Male Subjects|An Open-Label Phase 1 Study to Examine the Effect of Multiple Doses of Rifampin on the Single-Dose Pharmacokinetics of VX 770 in Healthy Subjects|Completed||Phase 1|24|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-06-01 00:20:52.427734|2018-06-01 00:20:52.427734
NCT01018355|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2010-05-05|2009-11-20|2009-11-23|Estimate|||||||2010-05-05|2010-05-06|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|June 2015|Anticipated|2015-06-30|September 2011|Anticipated|2011-09-30||Interventional|CryptoCard||The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI|The Effect of Device Closure of Patent Foramen Ovale in Elderly Patients With Crytogenic Stoke/TCI|Terminated||N/A|3000|Anticipated|Hillerod Hospital, Denmark||2||Dissatisfactory enrollment rate|f||||t||||||||||2018-06-01 00:20:52.508518|2018-06-01 00:20:52.508518
NCT01018342|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-19|2009-11-19|2009-11-23|Estimate|||||||2009-11-19|2009-11-23|Estimate|July 2002||2002-07-31|November 2009|2009-11-30||||August 2002|Actual|2002-08-31||Interventional|||Fed Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Mylan Nitrofurantoin Monohydrate/Macrocrystals Capsules (100 mg; Mylan) and Macrobid® Capsules (100 mg; Procter & Gamble) in Healthy Volunteers.|Completed||Phase 1|80|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:20:52.676449|2018-06-01 00:20:52.676449
NCT01018329|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2012-12-10|2009-11-20|2009-11-23|Estimate|||||||2012-12-10|2012-12-11|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma|Multimodality Statistical Model of Early Response of High Grade Glioma to Radiation Therapy|Completed||N/A|10|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:20:52.762593|2018-06-01 00:20:52.762593
NCT01018316|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2009-11-20|2009-11-20|2009-11-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|September 2009||2009-09-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||UMOX - New Device for Oropharyngeal Preoxygenation||Completed|||60|Actual|Maisonneuve-Rosemont Hospital|||||f||||f||||||||||2018-06-01 00:20:52.837328|2018-06-01 00:20:52.837328
NCT01018303|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2012-10-11|2009-11-20|2009-11-23|Estimate|||||||2012-10-11|2012-10-15|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy of an Antioxidant-rich Multivitamin Supplement in Cystic Fibrosis|Safety and Efficacy of a Novel Antioxidant-rich Multivitamin Supplement for Persons With Cystic Fibrosis|Completed||Phase 1/Phase 2|17|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-06-01 00:20:52.879147|2018-06-01 00:20:52.879147
NCT01018290|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2011-06-07|2009-11-20|2009-11-23|Estimate|||||||2011-06-07|2011-06-08|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Navigated Transcranial Magnetic Stimulation in Tumor Surgery|Preoperative Non-Invasive Motor Mapping in Tumor Surgery by Navigated Transcranial Magnetic Stimulation|Terminated|||20|Anticipated|Nexstim Ltd|||1|Recruitment goals not met|f||||f||||||||||2018-06-01 00:20:52.946217|2018-06-01 00:20:52.946217
NCT01018277|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2012-04-19|2009-11-20|2009-11-23|Estimate|||||||2012-04-19|2012-04-20|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Effect of Mobilization on Acute Postoperative Pain and Nociceptive Function|Effect of Mobilization on Acute Postoperative Pain and Nociceptive Function After Total Knee Arthroplasty: A Prospective, Consecutive, Trial|Completed|||26|Actual|Hvidovre University Hospital|||||f||||f||||||||||2018-06-01 00:20:53.006259|2018-06-01 00:20:53.006259
NCT01018264|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2015-04-15||2015-09-23|2009-11-20|2009-11-23|Estimate|2015-05-07|2015-05-27|Estimate||||2015-09-23|2015-10-15|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|URGE-PD||Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease|URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease|Completed||Phase 4|23|Actual|University of South Florida||2|||f||||f||||||||||2018-06-01 00:20:53.170973|2018-06-01 00:20:53.170973
NCT01018251|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-12-14|2009-11-19|2009-11-23|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer|Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT|Withdrawn||N/A|0|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:20:53.713404|2018-06-01 00:20:53.713404
NCT01018238|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2014-08-14|2009-11-20|2009-11-23|Estimate|||||||2014-08-14|2014-08-15|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)|A Multiple Dose, Randomised, Double-blind, Placebo-controlled, Multiple Site Study of Anti-C5a Receptor Antibody (NNC 0151-0000-0000) in Subjects With Systemic Lupus Erythematosus (SLE)|Withdrawn||Phase 1|0|Actual|Novo Nordisk A/S||5||See detailed description|f||||f||||||||||2018-06-01 00:20:53.77665|2018-06-01 00:20:53.77665
NCT01018225|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2016-04-12|2009-11-20|2009-11-23|Estimate|||||||2016-04-12|2016-04-13|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|July 2010|Anticipated|2010-07-31|||||Interventional|||Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness||Withdrawn||Phase 4|0|Actual|Cognitive Research Corporation||2||Study was cancelled due to lack of enrollment|f||||f||||||||||2018-06-01 00:20:53.889197|2018-06-01 00:20:53.889197
NCT01018212|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2010-12-07|2009-11-20|2009-11-23|Estimate|||||||2010-12-07|2010-12-08|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cicatrix Cream in Cutaneous Groves|Effect the Cicatrix Cream in Cutaneous Groves Treatment|Completed||Phase 2|50|Anticipated|Catalysis SL||1|||f||||t||||||||||2018-06-01 00:20:53.996417|2018-06-01 00:20:53.996417
NCT01018199|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2016-02-01|2009-11-20|2009-11-23|Estimate|||||||2016-02-01|2016-02-03|Estimate|January 2016||2016-01-31|March 2012|2012-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CAP-Marker||Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia|Use of Procalcitonin (PCT) and C-reactive Protein (CRP) to Guide Antibiotic Therapy in Community Acquired Pneumonia: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Federal University of Minas Gerais||2||Changes in the profile of patients assisted by the hospital|f||||t||||||||Undecided||2018-06-01 00:20:54.081309|2018-06-01 00:20:54.081309
NCT01018186|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-06-06|2012-03-01|2018-01-18|2009-11-19|2009-11-23|Estimate|2013-08-22|2013-10-29|Estimate|2012-03-01|2012-03-05|Estimate|2018-01-18|2018-02-15|Actual|October 19, 2009||2009-10-19|January 2018|2018-01-31|May 12, 2011|Actual|2011-05-12|May 1, 2011|Actual|2011-05-01||Interventional|||Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study|A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma|Completed||Phase 3|503|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:20:54.353255|2018-06-01 00:20:54.353255
NCT01018173|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20||2016-07-08|2016-11-01|2009-11-20|2009-11-23|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease|A Randomized Double Blind, Placebo-controlled Clinical Trial to Assess the Effects of Taspoglutide (RO5073031) on Cardiovascular Outcomes in Subjects With Inadequately Controlled Type 2 Diabetes and Established Cardiovascular Disease|Completed||Phase 3|2118|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:20:56.089651|2018-06-01 00:20:56.089651
NCT01018160|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2014-04-24|2009-11-19|2009-11-23|Estimate|||||||2014-04-24|2014-04-28|Estimate|June 2008||2008-06-30|April 2014|2014-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea|Practice and Patient Compliance on the PPI(Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea: A Prospective Observational Study|Completed|||1197|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-06-01 00:20:56.686744|2018-06-01 00:20:56.686744
NCT01018147|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2016-02-04|2009-11-20|2009-11-23|Estimate|||||||2016-02-04|2016-02-08|Estimate|September 2006||2006-09-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|April 2012|Actual|2012-04-30||Interventional|||4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition|4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition|Completed||N/A|22|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 00:20:56.76062|2018-06-01 00:20:56.76062
NCT01010178|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-06|2009-11-06|2009-11-09|Estimate|||||||2009-11-06|2009-11-09|Estimate|February 2008||2008-02-29|November 2009|2009-11-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?|Combination of Approved Drug in COPD|Completed||Phase 4|64|Actual|Baqiyatallah Medical Sciences University||1|||f||||t||||||||||2018-06-01 00:23:51.381375|2018-06-01 00:23:51.381375
NCT01018134|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-01-31||2014-07-09|2009-11-19|2009-11-23|Estimate|2014-07-09|2014-08-05|Estimate||||2014-07-09|2014-08-05|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study|A Double-Blind, Vehicle-Controlled, Randomized, Dose Ranging, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone Topical Sprays (0.05%, 0.25%) in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|151|Actual|Taro Pharmaceuticals USA||6|||f||||f||||||||||2018-06-01 00:20:56.887851|2018-06-01 00:20:56.887851
NCT01018121|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-20|2009-11-20|2009-11-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|November 2007||2007-11-30|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|LAUNCH||Behavioral Rx & Nutrition in Pediatric Chronic Disease|LAUNCH II: Learning About Activity and Understanding Nutrition for Better Child Health|Completed||Phase 1/Phase 2|18|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 00:20:57.667413|2018-06-01 00:20:57.667413
NCT01018108|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2016-01-25|2009-11-19|2009-11-23|Estimate|||||||2016-01-25|2016-01-26|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Visualization of the Effect of Acupuncture on Brain Serotonin in Breast Cancer Survivors|Effect of Acupuncture on Brain Serotonin Among Breast Cancer Survivors|Completed||Phase 1|7|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||f||||||||||2018-06-01 00:20:57.747864|2018-06-01 00:20:57.747864
NCT01018095|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|2013-04-11||2016-12-16|2009-11-20|2009-11-23|Estimate|2013-06-06|2013-07-15|Estimate||||2016-12-16|2016-12-20|Estimate|May 2005||2005-05-31|December 2016|2016-12-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Trichomonas Vaginalis Recurrence Among HIV+ Women|Randomized Phase IV Trial of Metronidazole Single Dose Versus 7 Day Dose for Treatment of Trichomonas Vaginalis Among HIV-infected Women|Completed||Phase 4|270|Actual|Tulane University|Generalizability is always a concern in clinical trials, however our findings are likely generalizable to the majority of HIV-infected women in the U.S. though studies in Caucasian and Hispanic women are needed.|2|||f||||f||||||||No||2018-06-01 00:20:57.839528|2018-06-01 00:20:57.839528
NCT01018082|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2017-03-21|2009-11-20|2009-11-23|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2009||2009-09-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|PHACE||Longitudinal Study of Neurologic, Cognitive, and Radiologic Outcomes of PHACE Syndrome|Longitudinal Study of Neurologic, Cognitive, and Radiologic Outcomes in PHACE Syndrome|Completed|||30|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 00:20:58.07954|2018-06-01 00:20:58.07954
NCT01018069|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2011-07-12|2009-11-20|2009-11-23|Estimate|||||||2011-07-12|2011-07-13|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen|An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen|Terminated||Phase 2|60|Anticipated|Aegera Therapeutics||2||Failed to reach endpoints|f||||f||||||||||2018-06-01 00:20:58.14563|2018-06-01 00:20:58.14563
NCT01018056|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|2014-03-24||2018-01-05|2009-11-20|2009-11-23|Estimate|2014-05-29|2014-07-01|Estimate||||2018-01-05|2018-01-30|Actual|November 2009||2009-11-30|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission|Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission|Completed||Phase 4|39|Actual|Johns Hopkins University|Study was limited by its small sample size as well as a small placebo group.|3|||f||||t||||||||||2018-06-01 00:20:58.23701|2018-06-01 00:20:58.23701
NCT01018043|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2014-05-22|2009-11-20|2009-11-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Thai Cancer Anemia Survey in Chulalongkorn Hospital|Thai Cancer Anemia Survey in Chulalongkorn Hospital|Completed|||264|Actual|Janssen-Cilag Ltd.,Thailand|||1||f||||f||||||||||2018-06-01 00:20:58.782342|2018-06-01 00:20:58.782342
NCT01018030|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2011-03-17||2017-04-20|2009-11-19|2009-11-23|Estimate|2011-03-17|2011-04-12|Estimate||||2017-04-20|2017-05-17|Actual|January 6, 2010||2010-01-06|April 2017|2017-04-30|July 16, 2010|Actual|2010-07-16|July 1, 2010|Actual|2010-07-01||Interventional|||Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 2-week Treatment Study to Evaluate the Safety and Efficacy of Fluticasone Furoate Nasal Spray 110 mcg in the Treatment in the Treatment of Uncomplicated Acute Rhinosinusitis in Adults and Adolescents >= 12 Years of Age|Completed||Phase 2|741|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 00:20:58.871334|2018-06-01 00:20:58.871334
NCT01018017|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2017-04-22|2009-11-19|2009-11-23|Estimate|||||||2017-04-22|2017-04-25|Actual|March 3, 2010|Actual|2010-03-03|April 2017|2017-04-30|December 25, 2010|Actual|2010-12-25|December 25, 2010|Actual|2010-12-25||Interventional|||A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus|A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|86|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:21:00.597935|2018-06-01 00:21:00.597935
NCT01018004|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2013-08-23|2009-11-20|2009-11-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2006||2006-03-31|July 2010|2010-07-31||||December 2011|Anticipated|2011-12-31||Observational|||Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma|Prospective Randomized Trial for the Evaluation of a Theoretical Follow-Up Schedule in Cutaneous Melanoma Patients, the MELFO-Study.|Unknown status|Recruiting||178|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:21:00.778756|2018-06-01 00:21:00.778756
NCT01017991|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2017-11-13|2009-11-20|2009-11-23|Estimate|||||||2017-11-13|2017-11-17|Actual|December 2009||2009-12-31|November 2017|2017-11-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Feeding Intervention for Infants With Crying|"Effects of an Infant Formula With Probiotics on Signs and Symptoms of Colic."|Terminated||N/A|65|Actual|Nestlé||2||The study has been terminated as a result of low enrollment.|f||||f||||||||||2018-06-01 00:21:00.859433|2018-06-01 00:21:00.859433
NCT01017978|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2015-12-02|2009-11-20|2009-11-23|Estimate|||||||2015-12-02|2015-12-04|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Quantitative MR Biomarkers for Sarcoma Treatment|Quantitative MR Biomarkers for Sarcoma Treatment|Completed||N/A|11|Actual|University of Michigan||1|||f||||t||||||||||2018-06-01 00:21:00.931725|2018-06-01 00:21:00.931725
NCT01017965|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2012-10-04|2009-11-20|2009-11-23|Estimate|||||||2012-10-04|2012-10-05|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|DIAPASOM2||Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients|Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients|Terminated|||79|Actual|University Hospital, Grenoble||||intermediary analysis was performed and significant results were found for the main objective|f||||f||||||Samples Without DNA|"~     A sample of serum will be retained in order to compare indicators of inflammation with sleep~     duration and diabetes complications~   "|||2018-06-01 00:21:00.999504|2018-06-01 00:21:00.999504
NCT01017952|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2013-05-30|2012-04-03|2017-06-12|2009-11-19|2009-11-23|Estimate|2013-08-15|2013-08-19|Estimate|2012-04-03|2012-04-05|Estimate|2017-06-12|2017-07-07|Actual|September 25, 2009||2009-09-25|June 2017|2017-06-30|October 17, 2011|Actual|2011-10-17|October 1, 2011|Actual|2011-10-01||Interventional|||A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|HZC102970: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1635|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:21:01.963105|2018-06-01 00:21:01.963105
NCT01017939|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2013-04-11|2009-11-19|2009-11-23|Estimate|||||||2013-04-11|2013-04-12|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|June 2010|Actual|2010-06-30||Interventional|||A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer|An Abiraterone Acetate Plus Prednisone Drug-Drug Interaction Study With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 1|34|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-06-01 00:21:03.802658|2018-06-01 00:21:03.802658
NCT01017926|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2016-04-04|2009-11-20|2009-11-23|Estimate|||||||2016-04-04|2016-04-06|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption|An Open, Two Period, Two Treatment, Two Sequence, Crossed, Randomized, Single-Dose Study Of Two Oral Preparations Containing 0.25 Mg Of Triazolam (Halcion, Pharmacia & Upjohn S.A. De C.V. Vs. Product Made By Pfizer Pharmaceuticals LLC) In Healthy Volunteers Under Fasting Conditions|Withdrawn||Phase 1|0|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:21:03.999632|2018-06-01 00:21:03.999632
NCT01017913|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-11-20|2009-11-20|2009-11-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|March 2006||2006-03-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Transcutaneous Electrical Nerve Stimulation and Interferential Currents in Chronic Low Back Pain|Effects of Transcutaneous Electrical Nerve Stimulation (TENS) and Interferential Currents (IFC) in Patients With Non Specific Chronic Low Back Pain: Randomized Clinical Trial|Completed||N/A|150|Actual|Federal University of São Paulo||3|||f||||f||||||||||2018-06-01 00:21:04.151559|2018-06-01 00:21:04.151559
NCT01017900|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-05-12|2009-11-20|2009-11-23|Estimate|||||||2012-05-12|2012-05-15|Estimate|August 2008||2008-08-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Surgery Versus Manual Rupture for Dorsal Carpal Ganglion|Comparison Between Surgical Excision and Manual Rupture for Dorsal Carpal Ganglion|Completed||Phase 3|100|Anticipated|Prince of Songkla University|||||f||||f||||||||||2018-06-01 00:21:04.31434|2018-06-01 00:21:04.31434
NCT01017887|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2013-09-03|2009-11-20|2009-11-23|Estimate|||||||2013-09-03|2013-09-04|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||Intraperitoneal Carbon Dioxide Concentration Measurement During Standard Laparoscopy With a New Airseal Access Port|SurgiQuest AirSeal CO2 Gas Quality|Withdrawn|||0|Actual|Baystate Medical Center|||2|Unable to recruit any subjects|f||||f||||||||||2018-06-01 00:21:04.39331|2018-06-01 00:21:04.39331
NCT01017874|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-02-21||2015-06-09|2009-11-19|2009-11-23|Estimate|2014-02-21|2014-04-03|Estimate||||2015-06-09|2015-07-08|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|April 2013|Actual|2013-04-30||Interventional||All randomized participants.|A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer|A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC|Completed||Phase 3|236|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:21:04.511736|2018-06-01 00:21:04.511736
NCT01017861|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2010-09-27|2009-11-20|2009-11-23|Estimate|||||||2010-09-27|2010-09-28|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||The Effect of Pregnancy on Temporal Summation and Venipuncture Pain Perception|The Effect of Pregnancy on Temporal Summation and Venipuncture Pain Perception|Completed|||80|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||4||f||||f||||||||||2018-06-01 00:21:05.214697|2018-06-01 00:21:05.214697
NCT01017848|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2013-06-10|2009-11-20|2009-11-23|Estimate|||||||2013-06-10|2013-06-11|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Urine pH as a Predictor of Diabetes|Urine pH as a Predictor of Diabetes|Completed|||92|Actual|Northwell Health|||1||f||||t||||||||||2018-06-01 00:21:05.276625|2018-06-01 00:21:05.276625
NCT01017835|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2009-11-20|2009-11-20|2009-11-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|January 2012|Anticipated|2012-01-31|June 2011|Anticipated|2011-06-30||Observational|STIPPARE||Simvastatin in Patients With Isolated Arterial Hypertension|Simvastatin in the Treatment of Isolated Arterial hyPertension and Prevention of cARdiovascular Events|Unknown status|Recruiting||50|Anticipated|Medical Universtity of Lodz|||2||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 00:21:05.342624|2018-06-01 00:21:05.342624
NCT01017822|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2013-06-21|2009-11-20|2009-11-23|Estimate|||||||2013-06-21|2013-06-24|Estimate||||June 2013|2013-06-30||||||||Interventional|||Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase I/II Study of Induction Conatumumab and Gemcitabine, Followed by Conatumumab, Capecitabine and 3-D Conformal Radiation Therapy (3D-CRT) With Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Radiation Therapy Oncology Group||||This study was withdrawn due to study agent availability.|f||||t||||||||||2018-06-01 00:21:05.414247|2018-06-01 00:21:05.414247
NCT01017809|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2015-03-16|2009-11-20|2009-11-23|Estimate|||||||2015-03-16|2015-03-18|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer|Pilot Study Exploring the Efficacy of Prolonged Emend to Reduce Nausea and Vomiting During Treatment in a Phase II Study (NYU 03-67) of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer|Withdrawn||N/A|0|Actual|New York University School of Medicine||1||NYU 03-67 reached accrual prior to this study opening.|f||||t||||||||||2018-06-01 00:21:05.47911|2018-06-01 00:21:05.47911
NCT01017796|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2009-11-20|2009-11-20|2009-11-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|June 2010|Anticipated|2010-06-30|January 2010|Anticipated|2010-01-31||Interventional|ICU||Contrast Agent-associated Nephrotoxicity in Intensive Care Unit Patients|The Effect of Acetylcysteine and Ascorbic Acid on the Prevention of Radiographic-contrast-agent Induced Reduction in Renal Function in ICU Patients.|Unknown status|Active, not recruiting|Early Phase 1|100|Anticipated|University of Thessaly||2|||f||||f||||||||||2018-06-01 00:21:05.566486|2018-06-01 00:21:05.566486
NCT01017783|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2011-08-01|2009-11-20|2009-11-23|Estimate|||||||2011-08-01|2011-08-03|Estimate|March 2008||2008-03-31|August 2011|2011-08-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults|Randomized Controlled Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults|Completed||N/A|318|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-06-01 00:21:05.695818|2018-06-01 00:21:05.695818
NCT01017770|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2015-07-29|2009-11-20|2009-11-23|Estimate|||||||2015-07-29|2015-07-31|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|ACTE||Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso|Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy|Completed||Phase 4|340|Anticipated|Centre Muraz||2|||f||||f||||||||||2018-06-01 00:21:05.771454|2018-06-01 00:21:05.771454
NCT01017757|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-20|2009-11-20|2009-11-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|June 2007||2007-06-30|November 2009|2009-11-30|November 2009|Anticipated|2009-11-30|October 2007|Actual|2007-10-31||Observational|LCRT||Interstitial Lung Abnormalities in Renal Transplant Recipients|Cross-sectional Analysis of Subclinical Interstitial Lung Abnormalities in Stable Renal Transplant Recipients by High-resolution CT Scan|Unknown status|Active, not recruiting||63|Actual|University of Parma|||1||f||||f||||||||||2018-06-01 00:21:05.923063|2018-06-01 00:21:05.923063
NCT01017744|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2013-09-02|2009-11-20|2009-11-23|Estimate|||||||2013-09-02|2013-09-04|Estimate|November 2009||2009-11-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Pressure Support Ventilation With the Anesthetic Conserving Device|Respiratory Mechanical Effects of Sevoflurane Administered With the Anesthetic Conserving Device in Pressure Support Ventilation|Completed||Phase 3|15|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:21:06.043881|2018-06-01 00:21:06.043881
NCT01017731|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-05-16|2010-07-29|2015-05-15|2009-11-20|2009-11-23|Estimate|2014-05-16|2014-06-18|Estimate|2010-09-01|2010-09-06|Estimate|2015-05-15|2015-06-10|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|April 2010|Actual|2010-04-30||Interventional||Safety population: Participants who received any quantity of ramucirumab, regardless of their eligibility for the study.|Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes|A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer|Completed||Phase 2|68|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:21:06.173147|2018-06-01 00:21:06.173147
NCT01017718|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2011-09-24|2009-11-20|2009-11-23|Estimate|||||||2011-09-24|2011-09-27|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Observational|||Nerve Conduction Velocity in Diabetic Children|Prevalence of Pathological Nerve Conduction Velocity in Children and Adolescents Suffering From Diabetes Mellitus Type I|Completed|||40|Actual|Landeskrankenhaus Feldkirch|||||f||||t||||||||||2018-06-01 00:21:06.640319|2018-06-01 00:21:06.640319
NCT01017692|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-05-22|2009-11-19|2009-11-20|Estimate|||||||2015-05-22|2015-05-25|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Magnetic Resonance Imaging (MRI) Interpretations for Lumbar Spinal Stenosis (LSS)|Variability of Magnetic Resonancy Imaging Interpretation for Lumbar Spinal Stenosis|Completed|||36|Actual|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 00:21:06.726994|2018-06-01 00:21:06.726994
NCT01017679|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2013-12-08|2009-11-19|2009-11-20|Estimate|||||||2013-12-08|2013-12-10|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|December 2013|Actual|2013-12-31|January 2012|Actual|2012-01-31||Interventional|||Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg|Phase II Multi-centre Randomized Controlled Study of Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg|Completed||Phase 2|96|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-06-01 00:21:06.821021|2018-06-01 00:21:06.821021
NCT01017666|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2010-09-16|2009-11-19|2009-11-20|Estimate|||||||2010-09-16|2010-09-17|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers|Completed||Phase 1|28|Actual|Biogen||2|||f||||f||||||||||2018-06-01 00:21:06.896215|2018-06-01 00:21:06.896215
NCT01017653|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2013-04-30||2013-07-29|2009-11-19|2009-11-20|Estimate|2013-07-29|2013-09-04|Estimate||||2013-07-29|2013-09-04|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Panitumumab and Irinotecan for Malignant Gliomas|Phase II Study of Panitumumab in Combination With Irinotecan for Malignant Gliomas|Terminated||Phase 2|16|Actual|Duke University||1||study did not reach benchmark efficacy rule at 16 subjects|f||||f||||||||||2018-06-01 00:21:07.009693|2018-06-01 00:21:07.009693
NCT01017640|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2016-07-07|2009-11-19|2009-11-20|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2009||2009-10-31|July 2016|2016-07-31||||May 2016|Actual|2016-05-31||Interventional|||Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors|ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 00:21:07.298043|2018-06-01 00:21:07.298043
NCT01017627|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2010-04-01|2009-11-19|2009-11-20|Estimate|||||||2010-04-01|2010-04-02|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)|A Case Controlled Study to Determine the Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in ESRD|Unknown status|Enrolling by invitation|N/A|1500|Anticipated|Fresenius Medical Care North America||2|||f||||f||||||||||2018-06-01 00:21:07.406376|2018-06-01 00:21:07.406376
NCT01017614|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2012-11-22|2009-11-19|2009-11-20|Estimate|||||||2012-11-22|2012-11-27|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia|A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Oligosaccharide (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia|Completed||Phase 3|350|Anticipated|Pharmacosmos A/S||2|||f||||f||||||||||2018-06-01 00:21:07.544169|2018-06-01 00:21:07.544169
NCT01017601|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2016-11-29||2017-03-28|2009-11-19|2009-11-20|Estimate|2017-03-28|2017-05-08|Actual||||2017-03-28|2017-05-08|Actual|January 2010||2010-01-31|March 2017|2017-03-31|November 15, 2014|Actual|2014-11-15|January 2013|Actual|2013-01-31||Interventional||All registered participants who have met eligibility criteria and started the treatment.|Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer|Terminated||Phase 2|59|Actual|Alliance for Clinical Trials in Oncology||2||Interim analysis declared futility.|f||||t||||||||||2018-06-01 00:21:07.68614|2018-06-01 00:21:07.68614
NCT01017588|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-05-12|2009-11-19|2009-11-20|Estimate|||||||2012-05-12|2012-05-15|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||PSU Lumbar Support for Prevention of Low Back Pain in Rubber Tapper|Lumbar Support for Low Back Pain Prevention in Rubber Tapper|Completed||Phase 3|200|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:08.681829|2018-06-01 00:21:08.681829
NCT01017575|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2015-08-13||2015-08-13|2009-11-19|2009-11-20|Estimate|2015-08-13|2015-09-11|Estimate||||2015-08-13|2015-09-11|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||All treated participants who received at least 1 dose of study therapy.|Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)|A Phase 2a Study of Daclatasvir in Combination With Peginterferon Alfa-2a(Pegasys®) and Ribavirin (Copegus®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|55|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:21:08.805328|2018-06-01 00:21:08.805328
NCT01017562|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|April 2007||2007-04-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Observational|||Differentiation of Aseptic From Septic Loosening by 18F-fluoride PET|Differentiation of Aseptic From Septic Loosening in Patients With Total Hip Arthroplasty Using 18F-fluoride PET|Completed|||61|Actual|Yokohama City University Medical Center|||1||f||||f||||||||||2018-06-01 00:21:09.841786|2018-06-01 00:21:09.841786
NCT01017549|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2010-09-07||2016-05-16|2009-11-19|2009-11-20|Estimate|2011-04-08|2011-04-11|Estimate||||2016-05-16|2016-06-17|Estimate|March 2007||2007-03-31|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Post Market Study Using the Xoft Axxent System|Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer|Completed||Phase 4|44|Actual|Xoft, Inc.||1|||f||||t||||||||No||2018-06-01 00:21:09.929905|2018-06-01 00:21:09.929905
NCT01017536|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2014-10-08||2016-07-25|2009-11-18|2009-11-20|Estimate|2014-10-08|2014-10-13|Estimate||||2016-07-25|2016-09-09|Estimate|December 2009||2009-12-31|July 2016|2016-07-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults|Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of AERAS-402 in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3|Completed||Phase 2|26|Actual|Aeras||2|||f||||t||||||||Undecided||2018-06-01 00:21:10.094031|2018-06-01 00:21:10.094031
NCT01017523|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-05-21|2009-11-19|2009-11-20|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|DSP||Diabetes Support Project: Couples Intervention|Improving Diabetes Outcome: The Diabetes Support Project|Completed||Phase 3|268|Actual|State University of New York - Upstate Medical University||3|||f||||f||||||||||2018-06-01 00:21:10.493591|2018-06-01 00:21:10.493591
NCT01017510|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2010-07-18|2009-11-19|2009-11-20|Estimate|||||||2010-07-18|2010-07-20|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata|Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata|Unknown status|Recruiting|N/A|20|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 00:21:10.562653|2018-06-01 00:21:10.562653
NCT01017497|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-09-30||2015-01-27|2009-11-19|2009-11-20|Estimate|2014-10-23|2014-10-27|Estimate||||2015-01-27|2015-02-13|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Optimal Planning Target Volume With Stereotactic Radiosurgery|Determination of the Optimal Planning Target Volume for Brain Metastases Treated With Stereotactic Radiosurgery|Completed||N/A|49|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:21:10.733419|2018-06-01 00:21:10.733419
NCT01017484|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2013-04-09|2009-11-19|2009-11-20|Estimate|||||||2013-04-09|2013-04-11|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Mechanism of the Blood Pressure Lowering Effect of the DASH Dietary Pattern|Mechanism of the Blood Pressure Lowering Effect of the DASH Dietary Pattern|Completed||N/A|20|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:21:10.985801|2018-06-01 00:21:10.985801
NCT01017471|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-05-12|2009-11-19|2009-11-20|Estimate|||||||2012-05-12|2012-05-15|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Carpal Tunnel Syndrome Release Using PSU Retractor|Comparison Results of Carpal Tunnel Release Between Standard Incision and Limited Incision Using PSU Retractor: A Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 3|60|Anticipated|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:11.05081|2018-06-01 00:21:11.05081
NCT01017458|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2016-07-11|2009-11-19|2009-11-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2007||2007-06-30|July 2016|2016-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)|A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Endpoints of MK0773 in Healthy Older Men|Completed||Phase 1|68|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 00:21:11.128496|2018-06-01 00:21:11.128496
NCT01017445|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-05-12|2009-11-19|2009-11-20|Estimate|||||||2012-05-12|2012-05-15|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Stick Versus Quadricep Exercise for Knee Osteoarthritis|Boonme Stick Exercise vs. Quadriceps Strengthening Exercise in Knee Osteoarthritis : A Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 3|100|Anticipated|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:11.21648|2018-06-01 00:21:11.21648
NCT01017432|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-04-02|2009-11-18|2009-11-20|Estimate|||||||2011-04-02|2011-04-05|Estimate|December 2008||2008-12-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Observational|COMADE||Compliance Of Medication After Discharge From the Hospital in the Elderly|Compliance Of Medication After Discharge From the Hospital in the Elderly|Completed|||200|Anticipated|William Beaumont Hospitals|||||f||||t||||||||||2018-06-01 00:21:11.317593|2018-06-01 00:21:11.317593
NCT01017419|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|March 2004||2004-03-31|November 2009|2009-11-30|January 2008|Actual|2008-01-31|January 2006|Actual|2006-01-31||Observational|||Orientation for Hearing Aid Users: Information Retention|Orientation for Hearing Aid Users: Information Retention|Completed|||30|Actual|University of Sao Paulo|||1||f||||t||||||||||2018-06-01 00:21:11.369835|2018-06-01 00:21:11.369835
NCT01017406|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-07-26|2009-11-19|2009-11-20|Estimate|||||||2011-07-26|2011-07-27|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|April 2012|Anticipated|2012-04-30|January 2012|Anticipated|2012-01-31||Interventional|||Heel Cushion for Plantar Fasciitis|PSU Heel Cushion for Treatment of Plantar Fasciitis:A Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 3|160|Anticipated|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:11.430098|2018-06-01 00:21:11.430098
NCT01017393|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|April 2004||2004-04-30|November 2009|2009-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Preemptive Low-dose Epidural Ketamine for Preventing Chronic Post-thoracotomy Pain||Completed||N/A|209|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-06-01 00:21:11.512627|2018-06-01 00:21:11.512627
NCT01017380|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||Preemptive Analgesia in Cruciate Reconstruction|Comparing Etoricoxib and Celecoxib for Preemptive Analgesia for Acute Postoperative Pain in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial|Completed||Phase 3|30|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:11.572613|2018-06-01 00:21:11.572613
NCT01017367|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2010-04-22|2009-11-19|2009-11-20|Estimate|||||||2010-04-22|2010-04-23|Estimate|February 2008||2008-02-29|April 2010|2010-04-30|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|MDX1100-04||Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)|Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)|Completed||Phase 2|70|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 00:21:11.636733|2018-06-01 00:21:11.636733
NCT01017354|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2015-08-21|2009-11-19|2009-11-20|Estimate|||||||2015-08-21|2015-08-24|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|ZDPT||Zurich Disability Prevention Trial|Monthly Vitamin D to Improve Vitamin D Status and Maintain Function in Pre-frail Older Individuals Living at Home|Completed||Phase 2|200|Actual|University of Zurich||3|||f||||t||||||||||2018-06-01 00:21:11.741522|2018-06-01 00:21:11.741522
NCT01017341|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-05-12|2009-11-19|2009-11-20|Estimate|||||||2012-05-12|2012-05-15|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|||Hip Protector for Prevention of Hip Fracture|PSU Hip Protector for Prevention of Hip Fracture From Falling|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:11.818134|2018-06-01 00:21:11.818134
NCT01017328|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-20|2009-11-19|2009-11-20|Estimate|||||||2009-11-20|2009-11-25|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Effect of Head Rotation on Overlap and Relative Position of Internal Jugular Vein to Carotid Artery in Infants and Children: A Study of the Anatomy Using Ultrasonography|Effect of Head Rotation on Overlap and Relative Position of Internal Jugular Vein to Carotid Artery in Infants and Children: A Study of the Anatomy Using Ultrasonography|Completed|||120|Actual|Yonsei University|||1||f||||f||||||||||2018-06-01 00:21:11.889853|2018-06-01 00:21:11.889853
NCT01017315|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-05-12|2009-11-19|2009-11-20|Estimate|||||||2012-05-12|2012-05-15|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|||Efficacy of Baby Talcum in Prevention of Pruritus Assosiated With Cast|Efficacy of Baby Talcum in Prevention of Pruritus Assosiated With Cast; a Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 3|50|Anticipated|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:11.944678|2018-06-01 00:21:11.944678
NCT01017302|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2016-11-01|2009-11-19|2009-11-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.|A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 in Patients With Type 2 Diabetes Mellitus on Stable Background Therapy|Completed||Phase 1|32|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 00:21:12.151299|2018-06-01 00:21:12.151299
NCT01017289|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Intramedullary Fixation of Humerus Fractures|A Study Evaluating the Quantum - Composite Nailing System for Intramedullary Fixation of Humerus Fractures|Unknown status|Not yet recruiting|N/A|20|Anticipated|N.M.B. Medical Applications Ltd||1|||f||||f||||||||||2018-06-01 00:21:12.227372|2018-06-01 00:21:12.227372
NCT00821977|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13||2013-01-02|2013-01-02|2009-01-13|2009-01-14|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-02|2013-01-04|Estimate|November 2008||2008-11-30|May 2012|2012-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes||Completed||Phase 2/Phase 3|338|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:24:55.662465|2018-06-01 01:24:55.662465
NCT01017276|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2015-04-30|2009-11-19|2009-11-20|Estimate|||||||2015-04-30|2015-05-04|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis|A Phase 3 Study in Patients With Chronic Kidney Disease (CKD) With Hyperphosphatemia on Peritoneal Dialysis|Completed||Phase 3|35|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:21:12.287981|2018-06-01 00:21:12.287981
NCT01017263|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2013-09-13||2014-02-18|2009-11-19|2009-11-20|Estimate|2014-02-18|2014-02-20|Estimate||||2014-02-18|2014-02-20|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity|Vyvanse and Glucose Intolerance in Children With ADHD and Obesity|Terminated||Phase 4|14|Actual|Duke University|Study was terminated due to the high number of failures of lab criteria for glucose intolerance which is one of the entry criterion. No data were analyzed.|1||Due very high screen fail rate, pre study feasibility not consistent with screened population.|f||||f||||||||||2018-06-01 00:21:12.361492|2018-06-01 00:21:12.361492
NCT01017250|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2012-04-11||2014-01-28|2009-11-19|2009-11-20|Estimate|2012-04-11|2012-05-09|Estimate||||2014-01-28|2014-02-28|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|||Radiosurgery and Avastin for Recurrent Malignant Gliomas|Radiosurgery and Avastin for Recurrent Malignant Gliomas|Completed||N/A|15|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:21:12.519734|2018-06-01 00:21:12.519734
NCT01017237|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2013-01-31||2013-05-07|2009-11-19|2009-11-20|Estimate|2013-05-07|2013-06-17|Estimate||||2013-05-07|2013-06-17|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Total of 5 Dex plus midazolam subjects and 2 of 8 Dex plus midazolam plus ketamine sujects were disqualified and the protocol aborted due to lack of effect and uncooperative behavior requiring use of additional sedative agents|Dexmedetomidine Sedation With Third Molar Surgery|Comparison of the Effectiveness of Sedation With i.v. Dexmedetomidine in Combination With Midazolam Alone or Midazolam and Low Dose Ketamine for Extraction of Third Molars.|Terminated||Phase 4|18|Actual|University of North Carolina, Chapel Hill|Early termination due to ineffective sedation. We had to abandon the protocol in 5 of 10 patients in the dexmedetomidine plus midazolam group and 2 of 8 patients in the dexmedetomidine plus midazolam and ketamine group because of combative behavior.|2||Protocol proved to be ineffective for adequate sedation for third molar surgery.|f||||f||||||||||2018-06-01 00:21:13.162813|2018-06-01 00:21:13.162813
NCT01017224|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2012-05-11|2009-11-19|2009-11-20|Estimate|||||||2012-05-11|2012-05-14|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC)|DAHANCA 24: Prognostic Value of 18F-FAZA Positron Emission Tomography After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck|Completed|||40|Actual|University of Aarhus|||||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-06-01 00:21:13.663994|2018-06-01 00:21:13.663994
NCT01017211|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-05-16|2009-11-19|2009-11-20|Estimate|||||||2011-05-16|2011-05-17|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Does Auricular Acupuncture Improve Tolerance to Electromyography (EMG) Testing?|Does Auricular Acupuncture Improve Tolerance to Electromyography (EMG) Testing?|Completed||Phase 1|21|Actual|Kessler Foundation||2|||f||||f||||||||||2018-06-01 00:21:13.733568|2018-06-01 00:21:13.733568
NCT01017198|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2013-09-12|2009-11-18|2009-11-20|Estimate|||||||2013-09-12|2013-09-16|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors|An Assessment of the Effect of Food and Antacid on BIIB021 Pharmacokinetics in Subjects With Advanced Solid Tumors.|Completed||Phase 1|20|Actual|Biogen||2|||f||||t||||||||||2018-06-01 00:21:13.813227|2018-06-01 00:21:13.813227
NCT01017185|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-05-11|2009-11-19|2009-11-20|Estimate|||||||2015-05-11|2015-05-13|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions|Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions|Completed||Phase 1|28|Actual|Takara Bio Inc.||1|||f||||f||||||||||2018-06-01 00:21:13.894744|2018-06-01 00:21:13.894744
NCT01017172|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients|Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adults|Unknown status|Recruiting|Phase 4|500|Anticipated|Goethe University|||||f||||f||||||||||2018-06-01 00:21:13.968343|2018-06-01 00:21:13.968343
NCT01017159|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2011-11-09|2009-11-19|2009-11-20|Estimate|||||||2011-11-09|2011-11-10|Estimate|April 2010||2010-04-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|Randomised, Double-blinded, Placebo-controlled Trial of Subcutaneous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|Completed||Phase 2|30|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:21:14.049341|2018-06-01 00:21:14.049341
NCT01017146|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2012-05-31|2012-02-16|2016-11-30|2009-11-19|2009-11-20|Estimate|2012-05-31|2012-07-06|Estimate|2012-02-16|2012-02-20|Estimate|2016-11-30|2017-01-18|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris|Completed||Phase 3|744|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:21:14.173282|2018-06-01 00:21:14.173282
NCT01017133|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2012-09-25|2009-11-19|2009-11-20|Estimate|||||||2012-09-25|2012-09-26|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer|Completed||Phase 1|56|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:21:15.030621|2018-06-01 00:21:15.030621
NCT01017120|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2012-05-31|2012-02-16|2017-04-17|2009-11-19|2009-11-20|Estimate|2012-05-31|2012-07-06|Estimate|2012-02-16|2012-02-20|Estimate|2017-04-17|2017-05-18|Actual|October 1, 2009||2009-10-01|March 2017|2017-03-31|November 9, 2010|Actual|2010-11-09|November 1, 2010|Actual|2010-11-01||Interventional|||A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Acne Vulgaris|Completed||Phase 3|742|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:21:15.147609|2018-06-01 00:21:15.147609
NCT01017107|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2010-10-13|2009-11-19|2009-11-20|Estimate|||||||2010-10-13|2010-10-14|Estimate|June 2003||2003-06-30|November 2009|2009-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Activated Protein C in Severe Acute Pancreatitis|APCAP - Activated Protein C in Severe Acute Pancreatitis: A Double-blind Randomized Human Pilot Trial|Completed||Phase 4|32|Actual|Helsinki University Central Hospital||1|||f||||f||||||||||2018-06-01 00:21:16.429807|2018-06-01 00:21:16.429807
NCT01017094|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Interventional|||Pin Site Infection Prevention for Open Tibial Fracture|Can Silversulfadiazine Prevent Pin-site Infection in Open Tibial Fracture?: A Randomized Controlled Trial|Completed||Phase 3|30|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-06-01 00:21:16.514154|2018-06-01 00:21:16.514154
NCT01017081|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-19|2009-11-19|2009-11-20|Estimate|||||||2009-11-19|2009-11-20|Estimate|September 2001||2001-09-30|November 2009|2009-11-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Chest Physiotherapy in Pediatrics Patients With Pneumonia|Chest Physiotherapy in Pediatric Patients Hospitalised With Community-acquired Pneumonia: a Randomized Clinical Trial|Completed||N/A|72|Actual|Santa Casa de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:21:16.591442|2018-06-01 00:21:16.591442
NCT01017068|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2009-11-23|2009-11-19|2009-11-20|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|AME||Aqueous Mushroom Extract and Intraocular Pressure|Aqueous Mushroom Extract as a Glaucoma Agent|Unknown status|Not yet recruiting|Phase 1/Phase 2|42|Anticipated|University of Benin||6|||f||||f||||||||||2018-06-01 00:21:16.649381|2018-06-01 00:21:16.649381
NCT01017055|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2017-09-01|2009-11-19|2009-11-20|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2009||2009-10-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery|Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery|Recruiting|||50|Anticipated|University of Alabama at Birmingham|||1||f||||f||||||||||2018-06-01 00:21:16.76454|2018-06-01 00:21:16.76454
NCT01017042|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2009-08-12||2009-10-05|2009-10-05|2009-11-20|Estimate|2009-10-05|2009-11-20|Estimate||||2009-10-05|2009-11-20|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Pharmacokinetic Study of an Acute Gout Regimen|Open-Label Pharmacokinetic Study of a Low-Dose Acute Gout Regimen|Completed||Phase 1|13|Actual|Mutual Pharmaceutical Company, Inc.||1|||f||||f||||||||||2018-06-01 00:21:16.875803|2018-06-01 00:21:16.875803
NCT01017029|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-12-10||2014-12-23|2009-11-19|2009-11-20|Estimate|2014-12-10|2014-12-18|Estimate||||2014-12-23|2015-01-12|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EVERHEART|safety population|Everolimus in de Novo Heart Transplant Recipients|Early vs. Delayed EVERolimus in de Novo HEART Transplant Recipients: Optimization of the Safety/Efficacy Profile (EVERHEART Study)|Completed||Phase 4|182|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:21:17.159177|2018-06-01 00:21:17.159177
NCT01017003|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-05|2009-10-05|2009-11-20|Estimate|2009-10-05|2009-11-20|Estimate||||2009-10-05|2009-11-20|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Pharmacokinetic Study With Colchicine in Healthy Volunteers|An Open Label, Two Period, Sequential, Single Dose and Multiple Dose Pharmacokinetic Study With 0.6mg Colchicine Tablets in Healthy Volunteers|Completed||Phase 1|14|Actual|Mutual Pharmaceutical Company, Inc.|14 subjects were sought, 13 enrolled due difficult recruitment. It was impossible to determine the kinetics of metabolites because none reached the level of detectability.|2|||f||||f||||||||||2018-06-01 00:21:18.130969|2018-06-01 00:21:18.130969
NCT01016990|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2014-01-09|2009-11-19|2009-11-20|Estimate|||||||2014-01-09|2014-01-10|Estimate|August 2009||2009-08-31|November 2009|2009-11-30||||September 2011|Anticipated|2011-09-30||Interventional|||Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia|Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL|Unknown status|Recruiting|Phase 2|52|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:21:18.322039|2018-06-01 00:21:18.322039
NCT01016977|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2012-01-19||2016-12-01|2009-11-19|2009-11-20|Estimate|2012-01-19|2012-02-23|Estimate||||2016-12-01|2017-01-30|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|C0000-411||A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris|A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris|Completed||Phase 4|40|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:21:18.417811|2018-06-01 00:21:18.417811
NCT01016964|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2012-06-25||2012-08-07|2009-11-19|2009-11-20|Estimate|2012-08-07|2012-09-07|Estimate||||2012-08-07|2012-09-07|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Treatment of Androgenetic Alopecia in Females, 12 Beam|A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 12 Beam Model For The Treatment of Androgenetic Alopecia in Females|Completed||N/A|63|Actual|Lexington International, LLC||2|||f||||t||||||||||2018-06-01 00:21:20.068363|2018-06-01 00:21:20.068363
NCT01016795|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-06-24|2009-11-19|2009-11-20|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 1999||1999-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2000|Actual|2000-11-30||Interventional|SCF980266||Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma|A Randomized Study of Peripheral Blood Progenitor Cell Priming Comparing a Combination of r-metHuSCF and Filgrastim or Chemotherapy and Filgrastim on Mobilization and Engraftment in Patients With Relapsed or Refractory Lymphomas|Terminated||Phase 2|32|Actual|Aalborg Universitetshospital||2||Study closed Nov 2000 by Amgen, who stopped drug delivery|f||||f||||||||||2018-06-01 00:21:23.736667|2018-06-01 00:21:23.736667
NCT01016951|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2010-11-18|2009-11-19|2009-11-20|Estimate|||||||2010-11-18|2010-11-19|Estimate|December 2009||2009-12-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease|A Phase I, Multi Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD9164 Given Once Daily as Inhaled Formulation Via Turbuhaler for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Terminated||Phase 1|36|Anticipated|AstraZeneca||2||Study stopped since it was considered that one of the pre-defined stopping criterion was met.|f||||f||||||||||2018-06-01 00:21:20.267018|2018-06-01 00:21:20.267018
NCT01016938|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2015-12-02||2016-04-11|2009-11-19|2009-11-20|Estimate|2016-04-11|2016-05-18|Estimate||||2016-04-11|2016-05-18|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)|Dynamic MRI for Lung Tumor Motion and Lung Function|Completed|||16|Actual|University of Maryland|||1||f||||t||||||||||2018-06-01 00:21:20.443967|2018-06-01 00:21:20.443967
NCT01016925|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2012-06-22|2009-11-19|2009-11-20|Estimate|||||||2012-06-22|2012-06-25|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Tunnelized KT||Bacterial Colonization After Tunneling in Femoral Perineural Catheters|Bacterial Colonization After Tunneling in Femoral Perineural Catheters|Completed||N/A|338|Actual|University Hospital, Rouen||2|||f||||||||||||||2018-06-01 00:21:20.612223|2018-06-01 00:21:20.612223
NCT01016912|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2015-08-17||2015-09-23|2009-11-19|2009-11-20|Estimate|2015-09-23|2015-10-12|Estimate||||2015-09-23|2015-10-12|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||All treated participants who received at least 1 dose of study therapy.|Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients|A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron®) and Ribavirin (Rebetol®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|51|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:21:20.764724|2018-06-01 00:21:20.764724
NCT01016899|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2017-09-08|2009-11-19|2009-11-20|Estimate|||||||2017-09-08|2017-09-11|Actual|July 2009||2009-07-31|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Observational|||Electronic Brachytherapy for the Treatment of NMSC|Xoft Electronic Brachytherapy Clinical Protocol For The Primary Treatment Of Non-Melanoma Skin Cancer|Active, not recruiting|||100|Anticipated|Xoft, Inc.|||1||f||||t||||||||||2018-06-01 00:21:21.740719|2018-06-01 00:21:21.740719
NCT01016886|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2016-02-08|2009-11-19|2009-11-20|Estimate|||||||2016-02-08|2016-02-09|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|September 2015|Actual|2015-09-30||Interventional|MANTICORE||Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research|A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications|Unknown status|Active, not recruiting|Phase 1/Phase 2|99|Actual|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-06-01 00:21:22.018077|2018-06-01 00:21:22.018077
NCT01016873|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|2014-11-13||2014-12-01|2009-11-19|2009-11-20|Estimate|2014-12-01|2014-12-05|Estimate||||2014-12-01|2014-12-05|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|May 2012|Actual|2012-05-31||Interventional|INTREPID||INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD|A Double-masked, Sham Controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of Low Voltage Stereotactic Radiosurgery in Patients With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|Completed||Phase 2|230|Actual|Oraya Therapeutics, Inc.||4|||f||||t||||||||||2018-06-01 00:21:22.124739|2018-06-01 00:21:22.124739
NCT01016860|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2013-10-18|2009-11-19|2009-11-20|Estimate|||||||2013-10-18|2013-10-21|Estimate|December 2009||2009-12-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||OSI-906 and Irinotecan in Patients With Advanced Cancer|A Phase I/IB Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With Colorectal Cancer Stratified by the OSI-906 Integrated Classifier|Terminated||Phase 1|16|Actual|University of Colorado, Denver||1||This study was discontinued due to a shown lack of efficacy in the investigational agent|f||||t||||||||||2018-06-01 00:21:22.86678|2018-06-01 00:21:22.86678
NCT01016847|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2014-11-07||2014-11-07|2009-11-19|2009-11-20|Estimate|2014-11-07|2014-11-17|Estimate||||2014-11-07|2014-11-17|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Moderate to Persistent Asthma in the Obese Subject|A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study to Evaluate the Effect of the Leukotriene Antagonist (Singulair©) Plus Moderate Dose Beclomethasone Compared to High Dose Beclomethasone in Obese Subjects With Moderate Persistent Asthma|Terminated||Phase 4|38|Actual|Duke University|Early terminiation due to poor enrollment.|2||Unable to enroll enough study subjects. Study has been terminated|f||||t||||||||||2018-06-01 00:21:22.956566|2018-06-01 00:21:22.956566
NCT01016834|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2011-11-28||2011-11-28|2009-11-19|2009-11-20|Estimate|2011-11-28|2011-12-29|Estimate||||2011-11-28|2011-12-29|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine|A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans|Completed||Phase 4|246|Actual|Zogenix, Inc.||1|||f||||f||||||||||2018-06-01 00:21:23.308393|2018-06-01 00:21:23.308393
NCT01016821|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19|||2011-01-10|2009-11-19|2009-11-20|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Oksiobs||Oxycodone for Labor Pain - Pharmacokinetics (PK), Safety and Efficacy|The Efficacy and Safety of Intravenous Oxycodone and Plasma Oxycodone Concentrations in Labour Pain|Completed||N/A|15|Anticipated|Kuopio University Hospital||1|||f||||t||||||||||2018-06-01 00:21:23.539207|2018-06-01 00:21:23.539207
NCT01016808|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-19||2010-12-06|2012-05-15|2009-11-19|2009-11-20|Estimate||||2010-12-06|2010-12-10|Estimate|2012-05-15|2012-05-17|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients|A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of Q8003 With Oxycodone and Morphine for the Management of Acute Moderate to Severe Postoperative Pain Following Bunionectomy Surgery|Completed||Phase 3|522|Actual|QRxPharma Inc.||3|||f||||f||||||||||2018-06-01 00:21:23.605014|2018-06-01 00:21:23.605014
NCT01016782|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17||2014-06-30|2014-07-02|2009-11-18|2009-11-19|Estimate||||2014-07-02|2014-07-04|Estimate|2014-07-02|2014-07-04|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea|Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel Group Study of 0444 Gel|Completed||Phase 3|867|Actual|Fougera Pharmaceuticals Inc.||3|||f||||||||||||||2018-06-01 00:21:23.828025|2018-06-01 00:21:23.828025
NCT01016769|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2018-04-17|2009-11-18|2009-11-19|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2009|Actual|2009-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)|A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)|Active, not recruiting||Phase 1/Phase 2|48|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:21:23.980497|2018-06-01 00:21:23.980497
NCT01016756|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2018-02-01|2009-11-18|2009-11-19|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2007||2007-02-28|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|PHACE||Genetic Analysis of PHACE Syndrome (Hemangioma With Other Congenital Anomalies)|Genetic Analysis of PHACE Syndrome.(PHACE Syndrome is Defined as a Hemangioma Plus One or More of the Following: Brain, Heart, Eye, Sternal or Cerebral Artery Anomalies).|Recruiting|||600|Anticipated|Medical College of Wisconsin|||||f||||f||||||Samples With DNA|"~     Blood (4 ml) for lymphocyte cell lines and DNA and tissue collection from tissue that would~     otherwise be discarded after surgery.~   "|||2018-06-01 00:21:24.066547|2018-06-01 00:21:24.066547
NCT01016743|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|November 2009||2009-11-30|November 2009|2009-11-30||||July 2010|Anticipated|2010-07-31||Interventional|||The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease||Unknown status|Not yet recruiting|N/A|20|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:21:24.134352|2018-06-01 00:21:24.134352
NCT01016730|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2018-02-19|2009-11-18|2009-11-19|Estimate|||||||2018-02-19|2018-02-20|Actual|January 22, 2010|Actual|2010-01-22|February 2018|2018-02-28|January 7, 2015|Actual|2015-01-07|January 7, 2015|Actual|2015-01-07||Interventional|||Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma|Single-Arm, Dose-Finding Pilot Trial of Single-Agent Bortezomib in Patients With Relapsed/Refractory AIDS-Associated Kaposi Sarcoma With Correlative Assessments of KSHV and HIV|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:21:24.201189|2018-06-01 00:21:24.201189
NCT01016717|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2016-10-19|2009-11-18|2009-11-19|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clopidogrel Proton-Pump Inhibitors Study|Clopidogrel Proton-Pump Inhibitors Study|Withdrawn||Phase 4|0|Actual|Sheba Medical Center||2||Since the published data resolved the study goals we decided not to start it|f||||f||||||||No||2018-06-01 00:21:24.288713|2018-06-01 00:21:24.288713
NCT01016704|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-07-26|2009-11-18|2009-11-19|Estimate|||||||2011-07-26|2011-07-27|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|RTP||Reinforcing Therapist Performance|Reinforcing Therapist Performance|Completed||N/A|105|Actual|Chestnut Health Systems||2|||f||||f||||||||||2018-06-01 00:21:24.424366|2018-06-01 00:21:24.424366
NCT01016691|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2011-09-26||2015-02-18|2009-11-18|2009-11-19|Estimate|2011-12-20|2012-01-27|Estimate||||2015-02-18|2015-03-06|Estimate|October 2009||2009-10-31|February 2015|2015-02-28||||February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy of a Drug Delivery System in Glaucoma||Completed||Phase 2|47|Actual|Vistakon Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:21:24.501505|2018-06-01 00:21:24.501505
NCT01016678|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2015-10-19||2016-03-31|2009-11-18|2009-11-19|Estimate|2016-03-31|2016-05-04|Estimate||||2016-03-31|2016-05-04|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|TEAM|104 subjects were randomized in the study but only 94 subjects actually dosed with study drug and completed at least one diary assessment post dose.|Treximet Early Intervention Adolescent Migraine|Early Intervention, Randomized, Mulitcenter, Placebo-Controlled, 4-Period Crossover, Multi-Attack Study to Evaluate Efficacy & Safety of ComboProduct Containing Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine in Adolescents|Completed||Phase 2/Phase 3|104|Actual|Premiere Research Institute||5|||f||||t||||||||No|There is no plan in place to enter every single patient in separtely|2018-06-01 00:21:24.825121|2018-06-01 00:21:24.825121
NCT01016665|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|April 2005||2005-04-30|November 2009|2009-11-30|June 2008|Actual|2008-06-30|July 2007|Actual|2007-07-31||Interventional|||Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy|Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study|Completed||N/A|71|Actual|Federal University of São Paulo||3|||f||||f||||||||||2018-06-01 00:21:25.251864|2018-06-01 00:21:25.251864
NCT01016652|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2013-09-19||2017-08-31|2009-11-18|2009-11-19|Estimate|2013-12-06|2014-01-23|Estimate||||2017-08-31|2017-09-29|Actual|October 1, 2009|Actual|2009-10-01|August 2017|2017-08-31|December 1, 2009|Actual|2009-12-01|December 1, 2009|Actual|2009-12-01||Interventional|||Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients||Completed||N/A|49|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 00:21:25.366585|2018-06-01 00:21:25.366585
NCT01016639|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-10-14|2009-11-18|2009-11-19|Estimate|||||||2011-10-14|2011-10-17|Estimate|June 2003||2003-06-30|October 2011|2011-10-31|July 2009|Actual|2009-07-31|July 2007|Actual|2007-07-31||Interventional|CORGI||Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer|Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer|Completed||Phase 1/Phase 2|106|Actual|Lund University Hospital||1|||f||||f||||||||||2018-06-01 00:21:26.195857|2018-06-01 00:21:26.195857
NCT01016626|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 (Mycophenolate Mofetil) Tablet|Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 Tablet, in Healthy Volunteers|Completed||Phase 1|28|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-06-01 00:21:26.483942|2018-06-01 00:21:26.483942
NCT01016613|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2017-06-02|2009-11-18|2009-11-19|Estimate|||||||2017-06-02|2017-06-05|Actual|January 2009||2009-01-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|C-PROBE||Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center|Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center|Recruiting|||1620|Anticipated|University of Michigan|||3||f||||t|f|f||||Samples With DNA|"~     Urine, blood and renal tissue, if available~   "|No||2018-06-01 00:21:26.82682|2018-06-01 00:21:26.82682
NCT01016600|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2015-06-08||2015-08-10|2009-11-18|2009-11-19|Estimate|2015-08-10|2015-09-07|Estimate||||2015-08-10|2015-09-07|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|November 2013|Actual|2013-11-30||Interventional|||Azacitidine and Lenalidomide for Acute Myeloid Leukemia|Phase I/II Trial of Azacitidine Plus Lenalidomide in the Treatment of Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|31|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 00:21:27.27516|2018-06-01 00:21:27.27516
NCT01016587|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2014-02-10|2009-11-18|2009-11-19|Estimate|||||||2014-02-10|2014-02-11|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Observational|SGIS||Symptom Clusters and Immune Markers in Patients With Chronic Obstructive Pulmonary Disease (COPD) - a Longitudinal Study|Symptom Clusters and Immune Markers in Patients With COPD|Completed|||275|Actual|Oslo University Hospital|||1||f||||t||||||Samples With DNA|"~     One foci is to perform a genome wide association study in patient with COPD to identify novel~     genetic markers for the patient subgroups who report different experiences with the symptom~     cluster of pain, fatigue, breathlessness, sleep disturbance, and depression. It is likely~     that genetic and immunologic factors may be involved in symptom severity and morbidity.~     Specifically, low levels of circulating immunoglobulins have been observed in a subset of~     COPD patients. Although hypogammaglobulinemia (HGG) is known to lead to frequent airway~     infections in other patients groups, the relationship between HGG and clinical symptoms in~     COPD has not been studied. The resulting knowledge can help clinicians to better identify~     COPD patients at particular risk for severe single and multiple symptoms.~   "|||2018-06-01 00:21:31.698059|2018-06-01 00:21:31.698059
NCT01016574|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-08-02|2009-11-18|2009-11-19|Estimate|||||||2011-08-02|2011-08-03|Estimate|December 2011||2011-12-31|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|IN902||Evaluating the Adequacy of Giro-Couch to Support Prone Breast Boost Irradiation Using IMRT Technique With IGRT.|Evaluating the Adequacy of Giro-Couch to Support Prone Breast Boost Irradiation Using Intensity Modulated Radiation Therapy(IMRT)Technique With Image-guided Radiation Therapy(IGRT).|Unknown status|Not yet recruiting|Phase 1|15|Anticipated|Azimuth Therapy Ltd.||1|||f||||f||||||||||2018-06-01 00:21:31.957694|2018-06-01 00:21:31.957694
NCT01016561|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-12-14|2009-11-18|2009-11-19|Estimate|||||||2015-12-14|2015-12-15|Estimate|July 2009||2009-07-31|December 2015|2015-12-31||||July 2012|Actual|2012-07-31||Interventional|||Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer|A Pilot Study of MR Imaging Based Intracavitary Brachytherapy for Cervical Cancer|Unknown status|Active, not recruiting|N/A|20|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:21:32.356562|2018-06-01 00:21:32.356562
NCT01016548|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2010-06-03|2009-11-18|2009-11-19|Estimate|||||||2010-06-03|2010-06-04|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy|Evaluation of Pandemic H1N1(2009) Influenza Vaccine in Adults With Lymphoid Malignancies on Active Systemic Treatment or Post Stem Cell Transplantation|Completed||Phase 3|42|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:21:32.518384|2018-06-01 00:21:32.518384
NCT01016535|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|CCH||Care of Child's Hygiene From Zero to Two Years Old|Care of Child's Hygiene From Zero to Two Years Old: Health Professionals' Perceptions of the Strategy and the Family Caregivers|Completed|||19|Actual|Faculdade Santa Marcelina|||1||f||||t||||||||||2018-06-01 00:21:32.631581|2018-06-01 00:21:32.631581
NCT01016522|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-03-30|2009-11-18|2009-11-19|Estimate|||||||2015-03-30|2015-04-01|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional|||Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)|Safety and Tolerability of the Ketogenic Diet in ALS|Terminated||Phase 3|1|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 00:21:32.786049|2018-06-01 00:21:32.786049
NCT01016509|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-12-20|2009-11-18|2009-11-19|Estimate|||||||2011-12-20|2011-12-21|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis|Tight Glycemic Control During Angioplasty Revascularization for Acute Coronary Syndrome Reduces Circulating Inflammatory Cytokines and Coronary Stent Restenosis|Completed||N/A|200|Actual|"University of Campania Luigi Vanvitelli"||3|||f||||t||||||||||2018-06-01 00:21:32.860048|2018-06-01 00:21:32.860048
NCT01016496|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2014-06-23|2009-11-18|2009-11-19|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||New Perspectives in the Rehabilitation of Children With Motor Disorders : the Role of the Mirror Neuron System|Rehabilitation Strategies in Children With Neuro-motor Disorders Due to the Impairment of the Central Nervous System or the Peripheral Nervous System|Completed||N/A|20|Actual|University of Modena and Reggio Emilia||2|||f||||||||||||||2018-06-01 00:21:33.054561|2018-06-01 00:21:33.054561
NCT01016483|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2017-05-02||2017-07-12|2009-11-18|2009-11-19|Estimate|2017-06-21|2017-06-23|Actual||||2017-07-12|2017-07-13|Actual|November 30, 2009|Actual|2009-11-30|July 2017|2017-07-31|April 30, 2015|Actual|2015-04-30|December 31, 2013|Actual|2013-12-31||Interventional||The safety analysis set (SAF) analysis set for the safety run-in part included subjects who received at least 1 (non-zero) administration of trial medication (pimasertib or gemcitabine). For Phase II: Intention-to-treat (ITT) set included subjects who were randomized, as per Interactive Voice Response System (IVRS).|Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer|Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects|Completed||Phase 1/Phase 2|141|Actual|EMD Serono||4|||f||||f||||||||||2018-06-01 00:21:33.350228|2018-06-01 00:21:33.350228
NCT01016470|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2012-05-02|2009-11-18|2009-11-19|Estimate|||||||2012-05-02|2012-05-04|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease|Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease|Completed||Phase 3|100|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:21:37.755377|2018-06-01 00:21:37.755377
NCT01016457|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus|Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus|Unknown status|Recruiting|Phase 4|15|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 00:21:38.010207|2018-06-01 00:21:38.010207
NCT01016444|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-05-24|2009-11-18|2009-11-19|Estimate|||||||2011-05-24|2011-05-25|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms|β2AR Polymorphisms and Albuterol Responsiveness in Acute Asthma|Unknown status|Recruiting||1250|Anticipated|MetroHealth Medical Center|||2||f||||f||||||Samples With DNA|"~     DNA for analysis of B2AR polymorphysims, DNA for genes for inflamation,steroid and~     leukotriene responsiveness.~   "|||2018-06-01 00:21:38.11827|2018-06-01 00:21:38.11827
NCT01016431|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2011-06-24|2009-11-18|2009-11-19|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence|Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence|Unknown status|Recruiting|Phase 4|20|Anticipated|Federico II University||2|||f||||f||||||||||2018-06-01 00:21:38.24461|2018-06-01 00:21:38.24461
NCT01016418|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2010-09-16|2009-11-18|2009-11-19|Estimate|||||||2010-09-16|2010-09-17|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease||Completed||Phase 1/Phase 2|30|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-06-01 00:21:38.331213|2018-06-01 00:21:38.331213
NCT01016405|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2011-01-31|2009-11-18|2009-11-19|Estimate|||||||2011-01-31|2011-02-01|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Prospective Health Assessment of Cataract Patients' Ocular Surface|Cataract and Dry Eye The PHACO Study (Prospective Health Assessment of Cataract Patients' Ocular Surface)|Completed|||200|Anticipated|Innovative Medical|||1||f||||||||||||||2018-06-01 00:21:38.419039|2018-06-01 00:21:38.419039
NCT01016392|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2018-01-23|2009-11-18|2009-11-19|Estimate|||||||2018-01-23|2018-01-24|Actual|December 2009||2009-12-31|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31|5 Years|Observational [Patient Registry]|KAMPER||Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency|Kuvan® Adult Maternal Pediatric European Registry|Active, not recruiting|||627|Actual|BioMarin Pharmaceutical|||||f||||f||||||||||2018-06-01 00:21:38.516038|2018-06-01 00:21:38.516038
NCT01016379|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2016-05-16|2009-11-18|2009-11-19|Estimate|||||||2016-05-16|2016-05-17|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia|Genome-Wide Interrogations in Childhood Acute Lymphoblastic Leukemia (ALL)|Completed|||1000|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Blood and Bone Marrow~   "|||2018-06-01 00:21:38.690111|2018-06-01 00:21:38.690111
NCT01016366|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2016-11-07|2009-11-18|2009-11-19|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia|Randomised, Double Blind, Placebo Controlled Study of Lu AA24493 in Patients With Friedreich's Ataxia to Evaluate Safety and Tolerability and to Explore Efficacy|Completed||Phase 2|36|Actual|H. Lundbeck A/S||2|||f||||t||||||||||2018-06-01 00:21:38.898314|2018-06-01 00:21:38.898314
NCT01016353|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|2017-07-05||2017-12-29|2009-11-18|2009-11-19|Estimate|2017-12-29|2018-01-03|Actual||||2017-12-29|2018-01-03|Actual|December 2009||2009-12-31|December 2017|2017-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Open Abdomen Study Comparing ABThera™ Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique|A Prospective Study Examining Clinical Outcomes Associated With the Management of the Open Abdomen With the ABThera™ Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique|Completed|||283|Actual|KCI USA, Inc.|||||f||||t||||||||||2018-06-01 00:21:39.003227|2018-06-01 00:21:39.003227
NCT01016340|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-12-13|2009-11-18|2009-11-19|Estimate|||||||2011-12-13|2011-12-14|Estimate|December 2009||2009-12-31|December 2011|2011-12-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|MCS_MOS||Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia (MCS_MOS)|Unknown status|Recruiting|Phase 2|116|Anticipated|Health Ever Bio-Tech Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:21:39.305949|2018-06-01 00:21:39.305949
NCT01016327|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-09-06|2009-11-18|2009-11-19|Estimate|||||||2012-09-06|2012-09-07|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Study of NMS-1116354 in Solid Tumors|A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors|Terminated||Phase 1|15|Actual|Nerviano Medical Sciences||1||Discontinuation of clinical investigation with NMS-1116354|f||||f||||||||||2018-06-01 00:21:39.368773|2018-06-01 00:21:39.368773
NCT01016314|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2018-03-23|2009-11-18|2009-11-19|Estimate|||||||2018-03-23|2018-03-27|Actual|November 2009|Actual|2009-11-30|March 2018|2018-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy of the Aspen Spinous Process System in Anterior Lumbar Interbody Fusion (ALIF)|A Multi-Center Prospective Randomized Study to Evaluate the Efficacy of the Aspen Spinous Process System for Use in Anterior Lumbar Interbody Fusion (ALIF)|Terminated||N/A|39|Actual|Zimmer Biomet||2||Low enrollment; protocol and patients amended to NCT01549366|f||||f||||||||Undecided||2018-06-01 00:21:39.428456|2018-06-01 00:21:39.428456
NCT01016301|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2015-11-17|2009-11-18|2009-11-19|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2007||2007-09-30|November 2015|2015-11-30|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|||Effects of a Clinical Pharmacist Service on Health-related Quality of Life|Effects of a Clinical Pharmacist Service on Health-related Quality of Life|Completed||N/A|400|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-06-01 00:21:39.494978|2018-06-01 00:21:39.494978
NCT01016288|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2014-04-07|2009-11-18|2009-11-19|Estimate|||||||2014-04-07|2014-04-08|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|April 2010|Actual|2010-04-30||Observational|||Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles (FNA-22G-25G)|Multicenter Randomized Controlled Trial Comparing the Performance of 22 Gauge Versus 25 Gauge EUS-FNA Needles|Completed|||135|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||f||||||Samples With DNA|"~     Pathology samples obtained through EUS-FNA biopsy processed by paraffin embedding.~   "|||2018-06-01 00:21:39.6396|2018-06-01 00:21:39.6396
NCT01016275|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2014-08-05|2009-11-18|2009-11-19|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Observational|MISAGO ILIAC||Misago Iliac Study|Physician Initiated Multi-center Belgian-German Trial Investigating the Terumo Misago Stent in the Treatment of TASC A & B Iliac Lesions|Completed|||100|Anticipated|Flanders Medical Research Program|||1||f||||t||||||||||2018-06-01 00:21:39.745173|2018-06-01 00:21:39.745173
NCT01016262|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-07-06|2009-11-18|2009-11-19|Estimate|||||||2011-07-06|2011-07-07|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|July 2011|Anticipated|2011-07-31||Interventional|||Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis|A Multicenter, Double-blind, Controlled, Randomized, Parallel Group Comparison Phase IIIa Treatment Investigation on the Efficacy and Safety of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis|Terminated||Phase 3|549|Anticipated|Axcan Pharma||3||"The decision was taken solely for business/administrative reasons, no safety considerations~   entered into this. Ongoing randomized patients to complete."|f||||f||||||||||2018-06-01 00:21:39.848188|2018-06-01 00:21:39.848188
NCT01016249|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|April 2007||2007-04-30|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis|Nebulized 5% Hypertonic Saline for Infirmary Treatment of Acute Infant Bronchiolitis: A Randomized Trial|Completed||Phase 4|187|Actual|Hamad Medical Corporation||3|||f||||f||||||||||2018-06-01 00:21:39.985872|2018-06-01 00:21:39.985872
NCT01016236|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2010-12-22|2009-11-18|2009-11-19|Estimate|||||||2010-12-22|2010-12-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:21:40.055513|2018-06-01 00:21:40.055513
NCT01016223|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2012-11-29|2009-11-18|2009-11-19|Estimate|||||||2012-11-29|2012-11-30|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||A Randomized Double Blind Placebo Controlled Study of the Effect of Swallowed Beclomethasone Dipropionate on Inflammatory Markers in Adult Patients With Eosinophilic Esophagitis||Completed||Phase 1|20|Anticipated|Penn State University||2|||f||||t||||||||||2018-06-01 00:21:40.094283|2018-06-01 00:21:40.094283
NCT01016210|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2014-01-16|2009-11-18|2009-11-19|Estimate|||||||2014-01-16|2014-01-17|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|April 2013|Actual|2013-04-30|March 2012|Actual|2012-03-31||Interventional|||The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)||Completed||Phase 4|60|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||f||||||||||2018-06-01 00:21:40.17179|2018-06-01 00:21:40.17179
NCT01016197|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2016-09-26|2009-11-18|2009-11-19|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Surgical Versus Conservative Treatment of Acute Mallet Fingers; a Randomised Controlled Trial|Surgical Versus Conservative Treatment of Acute Mallet Fingers; a Randomised Controlled Trial|Withdrawn||N/A|0|Actual|Mid Cheshire Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:21:40.544817|2018-06-01 00:21:40.544817
NCT01016184|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2013-01-30|2009-11-18|2009-11-19|Estimate|||||||2013-01-30|2013-02-01|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Influence of Vitamin D Treatment on Multi-systemic Functions in Young Men With Vitamin D Deficiency Due to Work Conditions|Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Multi- Systemic Effect of Vitamin D Supplementation on Young Men With Vitamin D Deficiency|Completed||Phase 4|358|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-06-01 00:21:40.624712|2018-06-01 00:21:40.624712
NCT01016158|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|April 2006||2006-04-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Umbilical Cord Serum Eye Drops||Completed||N/A|||Chonnam National University Hospital||1|||f||||t||||||||||2018-06-01 00:21:40.687353|2018-06-01 00:21:40.687353
NCT01016145|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-18|||2009-11-18|2009-11-18|2009-11-19|Estimate|||||||2009-11-18|2009-11-19|Estimate|April 2009||2009-04-30|November 2009|2009-11-30|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm|Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia|Unknown status|Recruiting|Phase 4|126|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:21:40.747363|2018-06-01 00:21:40.747363
NCT01016132|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2010-12-17||2012-06-26|2009-11-17|2009-11-18|Estimate|2010-12-17|2011-01-12|Estimate||||2012-06-26|2012-06-29|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Clinical Evaluation of a Silicone Hydrogel Lens||Completed||N/A|152|Actual|Alcon Research|||||f||||||||||||||2018-06-01 00:21:40.855055|2018-06-01 00:21:40.855055
NCT01016119|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2010-03-04|2009-11-17|2009-11-18|Estimate|||||||2010-03-04|2010-03-08|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke|Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke|Completed||Phase 3|40|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:21:40.97902|2018-06-01 00:21:40.97902
NCT01016106|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2013-04-30||2015-04-10|2009-11-17|2009-11-18|Estimate|2013-04-30|2013-06-20|Estimate||||2015-04-10|2015-05-01|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|October 2010|Actual|2010-10-31||Interventional|||Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population|Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population|Completed||N/A|35|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 00:21:41.050309|2018-06-01 00:21:41.050309
NCT01016093|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-07-25|2009-11-17|2009-11-18|Estimate|||||||2011-07-25|2011-07-26|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients|Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients: A Prospective Pilot Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|50|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:21:41.334848|2018-06-01 00:21:41.334848
NCT01016080|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-17|2009-11-17|2009-11-18|Estimate|||||||2009-11-17|2009-11-18|Estimate|February 2009||2009-02-28|November 2009|2009-11-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Role of Oral Glutathione in Skin Whitening|Glutathione as an Oral Whitening Agent: a Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 1|60|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-06-01 00:21:41.415165|2018-06-01 00:21:41.415165
NCT01015911|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2014-12-17|2009-11-16|2009-11-18|Estimate|||||||2014-12-17|2014-12-18|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma|A Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients With CD70-positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma|Completed||Phase 1|58|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 00:21:43.588268|2018-06-01 00:21:43.588268
NCT01016067|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2014-10-29||2015-01-07|2009-11-17|2009-11-18|Estimate|2014-10-29|2014-11-04|Estimate||||2015-01-07|2015-01-21|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Tibial Delayed Healing Pivotal Clinical Trial|A Prospective, Randomized, Multicenter Pivotal Clinical Trial of the INFUSE/MASTERGRAFT™ Delayed Healing Device With Rigid Internal Fixation in the Treatment of Tibial Delayed Healing|Terminated||Phase 3|23|Actual|Medtronic Spinal and Biologics|This trial was terminated due to difficulty in patient recruitment. Early termination led to a small number of subjects analyzed. Results should be interpreted with caution.|2||Difficulty in patient recruitment|f||||t||||||||||2018-06-01 00:21:41.505531|2018-06-01 00:21:41.505531
NCT01016054|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2013-02-26|2009-11-17|2009-11-18|Estimate|||||||2013-02-26|2013-02-27|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer|A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer|Terminated||Phase 1|4|Actual|Astellas Pharma Inc||2||Trial was terminated to allow sponsors to evaluate the future development of the drug program|f||||f||||||||||2018-06-01 00:21:41.939115|2018-06-01 00:21:41.939115
NCT01016041|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2015-12-24|2009-11-17|2009-11-18|Estimate|||||||2015-12-24|2015-12-28|Estimate|February 2007||2007-02-28|December 2015|2015-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|COMPARE 1||A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial|A Randomized Controlled Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial|Completed||Phase 3|1800|Actual|Maasstad Hospital||2|||f||||t||||||||||2018-06-01 00:21:42.021583|2018-06-01 00:21:42.021583
NCT01016028|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2016-04-29|2009-11-17|2009-11-18|Estimate|||||||2016-04-29|2016-05-03|Estimate|November 2009||2009-11-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Chemotherapy-Induced Peripheral Neuropathy Survey|Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1|Study assessment tool development delayed.|f||||f||||||||||2018-06-01 00:21:42.161534|2018-06-01 00:21:42.161534
NCT01016015|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2015-07-02||2015-07-02|2009-11-17|2009-11-18|Estimate|2015-07-02|2015-07-30|Estimate||||2015-07-02|2015-07-30|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma|A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas|Completed||Phase 2|178|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:21:42.267037|2018-06-01 00:21:42.267037
NCT01016002|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2009-11-16|2009-11-16|2009-11-18|Estimate|||||||2009-11-16|2009-11-18|Estimate|January 2006||2006-01-31|November 2009|2009-11-30||||December 2011|Anticipated|2011-12-31||Interventional|||Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma|A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma|Unknown status|Recruiting|Phase 2|35|Anticipated|University of Salzburg||1|||f||||f||||||||||2018-06-01 00:21:42.75929|2018-06-01 00:21:42.75929
NCT01015989|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-02-20|2009-11-17|2009-11-18|Estimate|||||||2012-02-20|2012-02-22|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|June 2013|Anticipated|2013-06-30|February 2012|Anticipated|2012-02-29||Interventional|CARE+ Kenya||Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya|Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya|Unknown status|Recruiting|Phase 4|250|Anticipated|New York University||2|||f||||t||||||||||2018-06-01 00:21:42.854139|2018-06-01 00:21:42.854139
NCT01015976|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2013-10-28||2014-02-13|2009-11-17|2009-11-18|Estimate|2014-02-13|2014-03-31|Estimate||||2014-02-13|2014-03-31|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects|A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects|Completed||Phase 3|10|Actual|Neuropsychiatric Research Institute, Fargo, North Dakota|small sample size absence of men in either group. short data collection period, characterization of the linear elimination phase of the AUC was not possible.|2|||f||||f||||||||||2018-06-01 00:21:42.959412|2018-06-01 00:21:42.959412
NCT01015963|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2017-07-11|2009-11-17|2009-11-18|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2008||2008-10-31|July 2017|2017-07-31|January 1, 2013|Actual|2013-01-01|January 2013|Actual|2013-01-31||Observational|||Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871|A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3 in Caucasian and African-American Cancer Patients|Completed|||69|Actual|Alliance for Clinical Trials in Oncology|||1||f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:21:43.130386|2018-06-01 00:21:43.130386
NCT01015950|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-09-09|2009-11-17|2009-11-18|Estimate|||||||2011-09-09|2011-09-12|Estimate|May 2010||2010-05-31|September 2011|2011-09-30|June 2012|Anticipated|2012-06-30|November 2011|Anticipated|2011-11-30||Interventional|Mali-MMAM||Management of Children With Moderate Acute Malnutrition in Mali|Randomized, Community-Based Effectiveness Trial of Selected Dietary Strategies for the Management of Young Malian Children With Moderate Acute Malnutrition (MAM) in the Context of the National Community Management of Acute Malnutrition|Unknown status|Active, not recruiting|N/A|1260|Anticipated|Helen Keller International||4|||f||||f||||||||||2018-06-01 00:21:43.23555|2018-06-01 00:21:43.23555
NCT01015937|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2009-11-17|2009-11-17|2009-11-18|Estimate|||||||2009-11-17|2009-11-18|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Effect of Turmeric on Diabetic Nephropathy||Completed||N/A|50|Actual|Shaheed Faghihi Hospital||2|||f||||t||||||||||2018-06-01 00:21:43.391215|2018-06-01 00:21:43.391215
NCT01015924|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2014-01-30|2009-11-17|2009-11-18|Estimate|||||||2014-01-30|2014-01-31|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Plate Osteosynthesis Versus ESIN of Displaced Midclavicular Fractures|Intramedullary Nailing Compared With Plate Fixation of Displaced Mid-clavicular Fractures. A Prospective Randomized Controlled Trial|Completed||Phase 2/Phase 3|125|Actual|University Hospital, Akershus||2|||f||||f||||||||||2018-06-01 00:21:43.492476|2018-06-01 00:21:43.492476
NCT01015378|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2010-06-24|2009-11-17|2009-11-18|Estimate|||||||2010-06-24|2010-06-25|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|January 2017|Anticipated|2017-01-31|January 2012|Anticipated|2012-01-31||Observational|||Natural History of Sigmoid Diverticulitis: The Geneva Cohort Study||Unknown status|Recruiting||500|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-06-01 00:21:56.707352|2018-06-01 00:21:56.707352
NCT01015898|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-17|2009-11-17|2009-11-18|Estimate|||||||2009-11-17|2009-11-18|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Short Term Effects of Photodynamic Therapy in Basal Cell Carcinoma|Short Term Effects of Photodynamic Therapy in Basal Cell Carcinoma|Completed||Phase 1|28|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-06-01 00:21:43.68707|2018-06-01 00:21:43.68707
NCT01015872|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2013-03-25|2009-11-17|2009-11-18|Estimate|||||||2013-03-25|2013-03-27|Estimate|December 2009||2009-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Roles of Prostanoids in Patients With Sleep Apnea Syndrome|The Investigation of the Roles of Prostanoids in Patients With Sleep Apnea Syndrome|Completed||N/A|46|Actual|Kyoto University, Graduate School of Medicine||1|||f||||f||||||||||2018-06-01 00:21:43.748698|2018-06-01 00:21:43.748698
NCT01015859|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2013-10-29|2009-11-17|2009-11-18|Estimate|||||||2013-10-29|2013-10-30|Estimate|June 2006||2006-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|CAN-SAVER||Spontaneous Atrioventricular Conduction Preservation|A Prospective Canadian Multi-center Randomized Study of the Benefits of Spontaneous Atrioventricular Conduction (Can Save R)|Completed||Phase 4|370|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-06-01 00:21:43.8245|2018-06-01 00:21:43.8245
NCT01015846|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2009-11-16|2009-11-16|2009-11-18|Estimate|||||||2009-11-16|2009-11-18|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Redcord RUSI||Ultrasound Assessment During Exercise|Assessment of Transverse Abdominis Muscle Function Associated With Stabilization Exercises in Low Back Pain Patients|Completed||N/A|80|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 00:21:43.9154|2018-06-01 00:21:43.9154
NCT01015833|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2017-12-01||2018-04-03|2009-11-17|2009-11-18|Estimate|2018-04-03|2018-05-02|Actual||||2018-04-03|2018-05-02|Actual|February 15, 2010||2010-02-15|April 2018|2018-04-30||||May 21, 2015|Actual|2015-05-21||Interventional|||Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer|Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|Active, not recruiting||Phase 3|356|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 00:21:44.089313|2018-06-01 00:21:44.089313
NCT01015820|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2014-05-29||2014-07-03|2009-11-17|2009-11-18|Estimate|2014-05-29|2014-07-02|Estimate||||2014-07-03|2014-07-16|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Among the 15 participants in the cancer group, 1 participant was excluded from the final analysis due to suboptimal measurements. Therefore 14 participants in the cancer group and 15 participants in the control group were included in the baseline analysis population.|Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer|Detectable Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer|Completed||N/A|37|Actual|Mayo Clinic|Small sample size, unmatched cohorts|2|||f||||t||||||||||2018-06-01 00:21:46.947428|2018-06-01 00:21:46.947428
NCT01015807|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2014-12-02||2017-09-21|2009-11-16|2009-11-18|Estimate|2017-05-04|2017-05-30|Actual||||2017-09-21|2017-10-23|Actual|November 2009||2009-11-30|September 2017|2017-09-30|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Interventional|CLOTAP||Transversus Abdominis Plane (TAP) Block for Cesarean Section|Transversus Abdominis Plane (TAP) Block for Cesarean Section|Completed||N/A|90|Actual|University of Washington||3|||f||||t||||||||No||2018-06-01 00:21:47.22283|2018-06-01 00:21:47.22283
NCT01015794|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-02-12|2009-11-17|2009-11-18|Estimate|||||||2013-02-12|2013-02-15|Estimate|December 2009||2009-12-31|November 2009|2009-11-30||||December 2012|Actual|2012-12-31||Interventional|||Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation|Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation|Completed||N/A|25|Actual|Bayside Health||1|||f||||f||||||||||2018-06-01 00:21:47.487215|2018-06-01 00:21:47.487215
NCT01015781|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2014-11-19||2014-12-11|2009-11-16|2009-11-18|Estimate|2014-12-11|2014-12-19|Estimate||||2014-12-11|2014-12-19|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Multi-Site Evaluation of Progressive Tinnitus Management|Multi-Site Evaluation of Progressive Tinnitus Management|Completed||N/A|300|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:21:47.552993|2018-06-01 00:21:47.552993
NCT01015768|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2010-09-08|2009-11-16|2009-11-18|Estimate|||||||2010-09-08|2010-09-09|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Corneal Staining and Physiological Compromise After Eight Hours of Soft Contact Lens Wear|Corneal Staining and Physiological Compromise After Eight Hours of Soft Contact Lens Wear|Completed||Phase 4|30|Anticipated|Southern California College of Optometry||2|||f||||f||||||||||2018-06-01 00:21:47.821201|2018-06-01 00:21:47.821201
NCT01015755|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2013-03-07|2009-11-17|2009-11-18|Estimate|||||||2013-03-07|2013-03-08|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Palliation of Thirst in ICU Patients|Palliation of Thirst in ICU Patients|Completed||Early Phase 1|353|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 00:21:47.95106|2018-06-01 00:21:47.95106
NCT01015742|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-05-31|2009-11-17|2009-11-18|Estimate|||||||2012-05-31|2012-06-04|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Unrelated Double Umbilical Cord Blood Units Transplantation|Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 00:21:48.065093|2018-06-01 00:21:48.065093
NCT01015729|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-01-13|2009-11-17|2009-11-18|Estimate|||||||2012-01-13|2012-01-16|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|March 2010|Actual|2010-03-31|||||Interventional|||Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately|An Open-Label, Randomized, Single-Center, 3-Way Crossover Study Comparing The Therapeutic Efficacy of a Fixed Dose Combination Capsule of Esomeprazole 20 mg And Acetylsalicylic Acid (ASA) 81 mg With Free Combinations of ASA Tablet 81 mg And Esomeprazole 20 mg as a Capsule or Tablet in Patients At Risk of Gastrointestinal Events Using Low Dose ASA for Cardiovascular Protection|Terminated||Phase 1|30|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:21:48.17516|2018-06-01 00:21:48.17516
NCT01015716|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-10-16|2009-11-17|2009-11-18|Estimate|||||||2012-10-16|2012-10-17|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|May 2012|Actual|2012-05-31|June 2011|Actual|2011-06-30||Interventional|FINALE-Health||Physical Exercise, Dietary Counseling and Cognitive Behavioral Training as a Combined Intervention to Reduce Weight and Increase Workability in Health Care Workers|Physical Exercise, Dietary Counseling and Cognitive Behavioral Training as a Combined Life-style Intervention to Reduce Weight and Increase Workability in Health Care Workers|Completed||Phase 1|146|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:21:48.266055|2018-06-01 00:21:48.266055
NCT01015703|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2014-06-04||2014-09-09|2009-11-17|2009-11-18|Estimate|2014-09-09|2014-09-15|Estimate||||2014-09-09|2014-09-15|Estimate|November 2009||2009-11-30|September 2014|2014-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Safety population, subjects who received at least one dose of test article|Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers|A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of CoVaccine HT™ in Healthy Adult Volunteers|Completed||Phase 1|50|Actual|BTG International Inc.||1|||f||||t||||||||||2018-06-01 00:21:48.357014|2018-06-01 00:21:48.357014
NCT01015690|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-17|2009-11-17|2009-11-18|Estimate|||||||2009-11-17|2009-11-18|Estimate|June 2006||2006-06-30|November 2009|2009-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|UNEXPLAINED||Incidence of Early Pregnancy Loss in Patients With Unexplained Infertility|Incidence of Early Pregnancy Loss in Patients With Unexplained Infertility Measured by hCG Rise in Urine|Completed|||134|Actual|UMC Utrecht|||3||f||||f||||||Samples Without DNA|"~     urine~   "|||2018-06-01 00:21:48.833966|2018-06-01 00:21:48.833966
NCT01015677|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2016-02-26||2017-06-05|2009-11-17|2009-11-18|Estimate|2016-04-01|2016-05-04|Estimate||||2017-06-05|2017-07-02|Actual|December 17, 2009|Actual|2009-12-17|June 2017|2017-06-30|July 30, 2010|Actual|2010-07-30|July 30, 2010|Actual|2010-07-30||Interventional|||A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)|A Phase IIa, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Examine MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Women|Terminated||Phase 2|99|Actual|Merck Sharp & Dohme Corp.|The study was terminated at the end of Stage 1 so no participants entered Stage 2 and no participants received MK-6913 25 mg.|4|||f||||f||||||||||2018-06-01 00:21:48.921283|2018-06-01 00:21:48.921283
NCT01015664|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-12-13|2009-11-17|2009-11-18|Estimate|||||||2012-12-13|2012-12-17|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1/Phase 2|11|Actual|University of Tennessee Cancer Institute|||||f||||t||||||||||2018-06-01 00:21:49.515082|2018-06-01 00:21:49.515082
NCT01015651|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2010-04-06|2009-11-17|2009-11-18|Estimate|||||||2010-04-06|2010-04-07|Estimate|April 2009||2009-04-30|April 2010|2010-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|CARDEAN-2||Assessment of the Nociception During Lumbar Surgery|Assessment of the Nociception During Lumbar Surgery|Completed||N/A|16|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-06-01 00:21:49.590967|2018-06-01 00:21:49.590967
NCT01015638|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2010-07-12||2017-03-21|2009-11-17|2009-11-18|Estimate|2012-01-11|2012-02-13|Estimate||||2017-03-21|2017-03-31|Actual|August 2009||2009-08-31|March 2017|2017-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications|Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac® Topical Gel (Clindamycin 1% and Benzoyl Peroxide 5%) to ACANYA™ Gel (Clindamycin Phosphate 1.2% and Benzoyl Peroxide 2.5%) Topical Acne Medications|Completed||Phase 4|36|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:21:49.709618|2018-06-01 00:21:49.709618
NCT01015625|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2015-11-17|2009-11-17|2009-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|POSYTIVE||Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer|Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer, a Multicenter Prospective Randomized Study to Evaluate the Use of Local Therapy|Active, not recruiting||N/A|254|Anticipated|Austrian Breast & Colorectal Cancer Study Group||2|||f||||f||||||||||2018-06-01 00:21:50.583694|2018-06-01 00:21:50.583694
NCT01015612|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2016-11-02|2009-11-17|2009-11-18|Estimate|||||||2016-11-02|2016-11-03|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|October 2014|Actual|2014-10-31||Interventional|||CoreValve® System Australia/New Zealand Clinical Study|CoreValve® System Australia/New Zealand Clinical Study|Completed||N/A|635|Actual|Medtronic Cardiovascular||1|||f||||t||||||||No||2018-06-01 00:21:50.724766|2018-06-01 00:21:50.724766
NCT01015599|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2010-04-29|2009-11-17|2009-11-18|Estimate|||||||2010-04-29|2010-04-30|Estimate|August 2005||2005-08-31|November 2009|2009-11-30|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|HOP'N||Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project|Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project|Unknown status|Active, not recruiting|Phase 4|273|Actual|Kansas State University||1|||f||||f||||||||||2018-06-01 00:21:50.820151|2018-06-01 00:21:50.820151
NCT01015586|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2010-07-08|2009-11-17|2009-11-18|Estimate|||||||2010-07-08|2010-07-09|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Treatment of Alcohol Dependence and Comorbid Bipolar Disorder|A Double-Blind, Placebo-Controlled Trial of Lamotrigine In Individuals With Bipolar Disorder and Comorbid Alcohol Dependence|Unknown status|Recruiting|Phase 4|60|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 00:21:50.894331|2018-06-01 00:21:50.894331
NCT01015573|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2010-04-23|2009-11-17|2009-11-18|Estimate|||||||2010-04-23|2010-04-26|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Database Creation and Evaluation of Motor Function of Finger Tapping Measured by Magnetic Sensor System in Healthy Subjects||Completed||N/A|375|Actual|Hiroshima University||1|||f||||f||||||||||2018-06-01 00:21:50.990316|2018-06-01 00:21:50.990316
NCT01015560|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2014-04-24||2015-03-05|2009-11-17|2009-11-18|Estimate|2014-04-24|2014-05-28|Estimate||||2015-03-05|2015-03-25|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Eligible and analyzable patients included.|S0916, MLN1202 in Treating Patients With Bone Metastases|S0916, A Phase II, Window Trial of the Anti-CCR2 Antibody MLN1202 in Patients With Bone Metastases|Completed||Phase 2|44|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 00:21:51.049791|2018-06-01 00:21:51.049791
NCT01015547|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2015-10-13|2009-11-17|2009-11-18|Estimate|||||||2015-10-13|2015-10-15|Estimate|May 2003||2003-05-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|November 2007|Actual|2007-11-30||Interventional|ACUTE-JIA||Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis|Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial.|Completed||Phase 3|60|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-06-01 00:21:53.907847|2018-06-01 00:21:53.907847
NCT01015534|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2012-08-23||2013-03-25|2009-11-17|2009-11-18|Estimate|2013-03-25|2013-05-08|Estimate||||2013-03-25|2013-05-08|Estimate|January 2006||2006-01-31|March 2013|2013-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment|Phase II Randomized Study: Whole Brain Radiotherapy and Concomitant Temozolomide, Compared With Whole Brain Radiotherapy for Brain Metastases Treatment|Completed||Phase 2|55|Actual|Instituto Nacional de Cancerologia de Mexico|Our study had methodological limitations, such as the two temozolomide dose levels, which in future clinical trials may be adjusted to a single level.|2|||f||||t||||||||||2018-06-01 00:21:54.295751|2018-06-01 00:21:54.295751
NCT01015521|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2010-11-01|2009-11-17|2009-11-18|Estimate|||||||2010-11-01|2010-11-03|Estimate|April 2010||2010-04-30|November 2010|2010-11-30||||December 2012|Anticipated|2012-12-31||Interventional|||Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer|A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients|Withdrawn||Phase 2|50|Anticipated|Tigris Pharmaceuticals||2||Study was not initiated as planned|f||||f||||||||||2018-06-01 00:21:54.932507|2018-06-01 00:21:54.932507
NCT01015508|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-10-24|2009-11-17|2009-11-18|Estimate|||||||2012-10-24|2012-10-25|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Adipogenic Capacity as a Mediator of Weight Gain|The Role of the Genetic Background Involved in Weight Regain Through Mechanisms Including Energy Expenditure, Physical Activity and Adipogenic Capacity|Unknown status|Active, not recruiting|N/A|200|Anticipated|Maastricht University Medical Center||3|||f||||t||||||||||2018-06-01 00:21:55.025023|2018-06-01 00:21:55.025023
NCT01015495|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2012-06-28|2009-11-17|2009-11-18|Estimate|||||||2012-06-28|2012-07-02|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|||Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks|Ranibizumab Therapy for Choroidal Neovascularization Associated With Angioid Streaks|Withdrawn||Phase 1/Phase 2|0|Actual|University of Illinois at Chicago||1||Not enough patients within the time frame to allow for a meaningful study.|f||||f||||||||||2018-06-01 00:21:55.094739|2018-06-01 00:21:55.094739
NCT01015482|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-17|2009-11-17|2009-11-18|Estimate|||||||2009-11-17|2009-11-18|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)|The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)|Unknown status|Recruiting|Phase 4|24|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:21:55.256007|2018-06-01 00:21:55.256007
NCT01015469|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-02-16|2009-11-17|2009-11-18|Estimate|||||||2011-02-16|2011-02-17|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Interventional|GABY||Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)|International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)|Unknown status|Recruiting|Phase 4|384|Anticipated|ClinTrio Ltd.||2|||f||||f||||||||||2018-06-01 00:21:55.357936|2018-06-01 00:21:55.357936
NCT01015456|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2014-10-09|2009-11-17|2009-11-18|Estimate|||||||2014-10-09|2014-10-10|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|CONTROL||The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis|The Clinical Efficacy and Economic Evaluation of EC-MPS (Myfortic) in the Treatment of Relapse or Resistant Proliferative Lupus Nephritis|Terminated||Phase 3|59|Actual|Chulalongkorn University||2||Data Safety Monitoring Board concerning of the participants' safety|f||||f||||||||||2018-06-01 00:21:55.473056|2018-06-01 00:21:55.473056
NCT01015443|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2016-06-17||2016-09-16|2009-11-17|2009-11-18|Estimate|2016-06-17|2016-08-02|Estimate||||2016-09-16|2016-10-26|Estimate|December 2009||2009-12-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|INSPIRE|Intention to treat (ITT) subjects included all the subjects randomized into the study.|Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population|A Multi-national, Double-blind, Placebo-controlled, Randomized, Phase III Clinical Trial of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Asian Subjects With Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) Who Have Demonstrated Either Stable Disease or Objective Response Following Primary Chemo-radiotherapy|Terminated||Phase 3|285|Actual|Merck KGaA|The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.|2||"The study is terminated prematurely as the sponsor decided to discontinue program with~   Tecemotide in NSCLC."|f||||t||||||||||2018-06-01 00:21:55.600474|2018-06-01 00:21:55.600474
NCT01015430|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17||2016-07-06|2016-11-01|2009-11-17|2009-11-18|Estimate||||2016-07-06|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study With RO4917523 in Patients With Fragile X Syndrome|A Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Safety and Tolerability, and Exploratory Efficacy and Pharmacodynamic Effects Study of RO4917523 in Adult Patients With Fragile X Syndrome.|Completed||Phase 2|40|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 00:21:56.15164|2018-06-01 00:21:56.15164
NCT01015417|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2016-04-27|2009-11-17|2009-11-18|Estimate|||||||2016-04-27|2016-04-28|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ABCAL||Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis|Antibiotic Treatment Versus no Antibiotics in the Postoperative Acute Cholecystitis Low and Moderately Severe|Completed||Phase 3|414|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-06-01 00:21:56.264894|2018-06-01 00:21:56.264894
NCT01015404|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2013-10-17|2009-11-16|2009-11-18|Estimate|||||||2013-10-17|2013-10-21|Estimate|November 2009||2009-11-30|October 2013|2013-10-31||||March 2010|Actual|2010-03-31||Interventional|||A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)|A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)|Completed||Phase 3|25|Actual|Kaken Pharmaceutical||2|||f||||f||||||||||2018-06-01 00:21:56.505049|2018-06-01 00:21:56.505049
NCT01015391|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2013-06-01|2009-11-17|2009-11-18|Estimate|||||||2013-06-01|2013-06-04|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|T2||Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease|A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection|Unknown status|Recruiting|N/A|100|Anticipated|Jinling Hospital, China||2|||f||||f||||||||||2018-06-01 00:21:56.602349|2018-06-01 00:21:56.602349
NCT01015365|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-11-17|2009-11-17|2009-11-18|Estimate|||||||2017-11-17|2017-11-20|Actual|November 2009||2009-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 2016|Actual|2016-10-31||Interventional|CORIHA||Cementless One-stage Revision of the Chronic Infected Hip Arthroplasty|Cementless One-stage Revision in Fast-track Setting of the Chronic Infected Hip Arthroplasty|Completed||N/A|56|Actual|University of Aarhus||1|||f||||t||||||||||2018-06-01 00:21:56.799397|2018-06-01 00:21:56.799397
NCT01015352|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2014-03-18|2009-11-17|2009-11-18|Estimate|||||||2014-03-18|2014-03-19|Estimate|February 2009||2009-02-28|November 2009|2009-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)|A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA|Completed||Phase 2|98|Actual|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||||2018-06-01 00:21:56.925628|2018-06-01 00:21:56.925628
NCT01015339|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2015-05-17|2009-11-17|2009-11-18|Estimate|||||||2015-05-17|2015-05-19|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|A Randomized Multicenter Phase III Study Comparing Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment or Cisplatin Plus Capecitabine in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|Unknown status|Recruiting|Phase 3|320|Anticipated|Peking University||2|||f||||t||||||||||2018-06-01 00:21:57.065586|2018-06-01 00:21:57.065586
NCT01015326|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2013-02-26||2014-12-11|2009-11-16|2009-11-18|Estimate|2013-02-26|2013-04-08|Estimate||||2014-12-11|2015-01-05|Estimate|July 2006||2006-07-31|December 2014|2014-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|FAST||Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors|Development of a Functional Assessment of Side-effects to Therapy (FAST) Questionnaire to Assess Dermatology-Related Quality of Life in Patients Treated With EGFR Inhibitors: The FAST-EGFR Inhibitors: The FAST-EGFRI and Development of an Investigator Grading System: The Skin and Eye Reactions to Inhibitors of EGFR (SERIES) Score|Completed|||32|Actual|Northwestern University|||2||f||||t||||||||||2018-06-01 00:21:57.177608|2018-06-01 00:21:57.177608
NCT01015313|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2015-09-30|2009-11-17|2009-11-18|Estimate|||||||2015-09-30|2015-10-01|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effects of Intensified Sodium Management in Hemodialysis Patients|A Multi-center, Randomized, Controlled and Prospective Pilot Study on the Effects of Intensified Sodium Management on Hospitalization in Chronic Hemodialysis Patients.|Withdrawn||N/A|0|Actual|Renal Research Institute||2|||f||||f||||||||||2018-06-01 00:21:57.482595|2018-06-01 00:21:57.482595
NCT01015300|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2012-05-09|2009-11-17|2009-11-18|Estimate|||||||2012-05-09|2012-05-11|Estimate|December 2009||2009-12-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease|D0904 - A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von Hippel-Lindau Disease.|Terminated||Early Phase 1|1|Actual|Dartmouth-Hitchcock Medical Center||||Study terminated due to low accrual.|f||||t||||||||||2018-06-01 00:21:57.557198|2018-06-01 00:21:57.557198
NCT01015287|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2014-01-17||2014-01-17|2009-11-17|2009-11-18|Estimate|2014-01-17|2014-02-28|Estimate||||2014-01-17|2014-02-28|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|ACCOAST|All randomized participants who received at least 1 dose of study drug.|A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction|A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI): The ACCOAST Study|Completed||Phase 3|4033|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 00:21:57.74862|2018-06-01 00:21:57.74862
NCT01015274|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-07-13|2009-11-17|2009-11-18|Estimate|||||||2011-07-13|2011-07-14|Estimate|October 2009||2009-10-31|July 2011|2011-07-31||||||||Observational|||Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients|Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients|Completed|||10|Anticipated|The University of Texas Medical Branch, Galveston|||1||f||||f||||||||||2018-06-01 00:21:59.734693|2018-06-01 00:21:59.734693
NCT01015261|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2010-11-19|2009-11-17|2009-11-18|Estimate|||||||2010-11-19|2010-11-22|Estimate|October 2008||2008-10-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients|Comparison of Efficacy of Allogenic Bone Marrow Transplantation With Cytoreduction and Chemotherapy in ALL Patients|Completed||Phase 2/Phase 3|30|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:21:59.875382|2018-06-01 00:21:59.875382
NCT01015248|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2016-09-06|2009-11-17|2009-11-18|Estimate|||||||2016-09-06|2016-09-07|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma|Multicentric, Non-Randomized Phase 2 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma|Completed||Phase 2|60|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||||2018-06-01 00:21:59.947804|2018-06-01 00:21:59.947804
NCT01015235|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-08-31|2009-11-17|2009-11-18|Estimate|||||||2011-08-31|2011-09-02|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain|A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion for the Treatment of Postoperative Pain|Completed||Phase 2|90|Actual|KAI Pharmaceuticals||3|||f||||t||||||||||2018-06-01 00:22:00.049847|2018-06-01 00:22:00.049847
NCT01015222|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2018-01-09|2009-11-17|2009-11-18|Estimate|||||||2018-01-09|2018-01-11|Actual|November 2009|Actual|2009-11-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies|A Phase I Trial of Dasatinib (Src Inhibitor), Bevacizumab (Anti-VEGF Monoclonal Antibody) and Metronomic Paclitaxel + or - Methylnaltrexone in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|218|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:22:00.131918|2018-06-01 00:22:00.131918
NCT01015196|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-17|2009-11-17|2009-11-18|Estimate|||||||2009-11-17|2009-11-18|Estimate|January 2001||2001-01-31|November 2009|2009-11-30||||||||Interventional|AML2001||Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation|AML 2001: a Phase III Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation (ASCT) as Consolidation Strategy for Adults Aged 15 to 60 With Acute Myeloid Leukemia (AML) in First Complete Remission (CR).rémission complète d'Une Leucémie Aiguë Myéloblastique|Completed||Phase 2/Phase 3|832|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 00:22:00.289603|2018-06-01 00:22:00.289603
NCT01015183|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2011-07-25|2009-11-17|2009-11-18|Estimate|||||||2011-07-25|2011-07-26|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||Prevention Chemotherapy Induced Mucositis by Zinc Sulfate|Prevention High Dose Chemotherapy Induced Mucositis by Using Zinc Sulfate|Completed||Phase 2/Phase 3|60|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:22:00.34884|2018-06-01 00:22:00.34884
NCT01015170|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2016-06-29||2017-02-07|2009-11-17|2009-11-18|Estimate|2017-02-07|2017-03-27|Actual||||2017-02-07|2017-03-27|Actual|October 2009||2009-10-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Ontario smokers who are interested in quitting smoking.|STOP Study: Effectiveness of Zyban in a Clinical Population|The STOP Study: Real World Effectiveness of Zyban Treatment in a Clinical Population|Completed||Phase 4|454|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||No|No plan to share data|2018-06-01 00:22:00.431057|2018-06-01 00:22:00.431057
NCT01015157|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-01-04|2009-11-17|2009-11-18|Estimate|||||||2010-01-04|2010-01-05|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Prospective Trial Using Gastric Stapling Line Reinforcement With Seamguard in Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass Outcomes With Systematic Gastric Stapling Line Reinforcement With Seamguard Biomaterial|Completed||N/A|80|Anticipated|Clinique de l'Anjou||2|||f||||f||||||||||2018-06-01 00:22:00.72136|2018-06-01 00:22:00.72136
NCT01015144|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2009-11-17|2009-11-17|2009-11-18|Estimate|||||||2009-11-17|2009-11-18|Estimate|February 2007||2007-02-28|November 2009|2009-11-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Observational|||The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle|The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle in Patients With Dilated Cardiomyopathy|Completed|||||Medical Universtity of Lodz|||2||f||||t||||||Samples Without DNA|"~     blood68~   "|||2018-06-01 00:22:00.802189|2018-06-01 00:22:00.802189
NCT01015131|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|2012-11-06||2015-02-09|2009-11-17|2009-11-18|Estimate|2012-12-17|2012-12-20|Estimate||||2015-02-09|2015-02-26|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||18F-FLT-PET in Breast Cancer (MK-0000-139)|A Pilot Study to Evaluate the Correlation Between 18F-FLT-PET Uptake, Ki-67 Immunohistochemistry, and Proliferation Signature in Response to Neo-Adjuvant Chemotherapy in Breast Cancer|Completed||Phase 2|46|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:22:00.873399|2018-06-01 00:22:00.873399
NCT01015118|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2014-11-14|2014-03-27|2017-11-03|2009-11-17|2009-11-18|Estimate|2015-01-13|2015-01-15|Estimate|2014-03-27|2014-04-24|Estimate|2017-11-03|2017-12-07|Actual|November 17, 2009|Actual|2009-11-17|November 2017|2017-11-30|September 15, 2016|Actual|2016-09-15|April 1, 2013|Actual|2013-04-01||Interventional||Randomised Set (RS): included all randomised patients, regardless of whether or not they had received treatment. Patients were assigned to nintedanib or placebo as randomised.|LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer|Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer|Completed||Phase 3|1366|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:22:01.38297|2018-06-01 00:22:01.38297
NCT01015105|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-17|||2016-11-04|2009-11-17|2009-11-18|Estimate|||||||2016-11-04|2016-11-08|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|January 2016|Actual|2016-01-31|May 2010|Actual|2010-05-31||Observational|||Troponin Elevation in Consecutive Patients With Hip Fracture|Troponin Elevation in Consecutive Patients With Hip Fracture|Completed|||200|Actual|Turku University Hospital|||1||f||||f||||||||||2018-06-01 00:22:03.28344|2018-06-01 00:22:03.28344
NCT01015092|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2009-11-16|2009-11-16|2009-11-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|June 2005||2005-06-30|November 2009|2009-11-30|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Observational|CREATE1||Cardiovascular Risk Evaluation and Antiretrovirals in HIV|Predicted 10-year Coronary Heart Disease Risk in HIV and Implications for Clinical Management: the CREATE Study|Completed|||1024|Actual|King's College London|||1||f||||f||||||||||2018-06-01 00:22:03.363051|2018-06-01 00:22:03.363051
NCT01015079|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2009-11-16|2009-11-16|2009-11-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|November 2009||2009-11-30|November 2009|2009-11-30||||||||Observational|||The Association Between Cervical Cancer Screening and Cancer Occurrence|The Association Between Cervical Cancer Screening Participation and Corresponding Results and Subsequent Cancer Occurrence and Death|Unknown status|Recruiting||6000000|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-06-01 00:22:03.418113|2018-06-01 00:22:03.418113
NCT01015066|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2014-06-06|2009-11-16|2009-11-17|Estimate|||||||2014-06-06|2014-06-10|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents|A Randomized Controlled Trial Comparing Buprenorphine/Naloxone With Naltrexone for Treatment in Opioid Dependent Adolescents and Young Adults|Withdrawn||Phase 4|0|Actual|State University of New York at Buffalo||2||Study personnel left institution, anticipated funding did not occur|f||||t||||||||||2018-06-01 00:22:03.471467|2018-06-01 00:22:03.471467
NCT01015053|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2017-09-14|2009-11-16|2009-11-17|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2009||2009-11-30|September 2017|2017-09-30|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|||Postoperative Pain After Pediatric Umbilical Hernia Repair|Postoperative Pain After Pediatric Umbilical Hernia Repair: a Randomized Clinical Trial of Ultrasound-guided Bilateral Rectus Sheath Blocks Versus Local Anesthetic Infiltration|Completed||N/A|53|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 00:22:03.538165|2018-06-01 00:22:03.538165
NCT01015040|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2009-12-04|2009-11-16|2009-11-17|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers|A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Address the Relative Bioavailability of Solifenacin Liquid Suspension 10mg (Fed and Fasting) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet (Fasting) in Healthy Volunteers|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 00:22:03.624701|2018-06-01 00:22:03.624701
NCT01015027|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2013-06-13|2009-11-16|2009-11-17|Estimate|||||||2013-06-13|2013-06-17|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study of the Safety and Tolerability of Intravenously Administered REGN668 in Healthy Volunteers|Completed||Phase 1|48|Actual|Regeneron Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:22:03.771501|2018-06-01 00:22:03.771501
NCT01015014|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2018-03-17|2009-11-16|2009-11-17|Estimate|||||||2018-03-17|2018-03-20|Actual|November 30, 2009|Actual|2009-11-30|March 2018|2018-03-31|August 31, 2010|Actual|2010-08-31|July 31, 2010|Actual|2010-07-31||Interventional|||Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections|First-in-human, Two-stage, Randomized, Placebo-controlled, Double-blind, Dose Escalation Study To Determine The Safety, Tolerability, And Pharmacokinetic Profile Of An3365 In Single And Multiple Doses In Young Healthy Subjects|Completed||Phase 1|64|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:22:03.862308|2018-06-01 00:22:03.862308
NCT01015001|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2010-08-11|2009-11-16|2009-11-17|Estimate|||||||2010-08-11|2010-08-12|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine|A Pilot Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation for Patients With Refractory Schizophrenia Treated With Clozapine|Completed||Phase 3|20|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:22:03.979271|2018-06-01 00:22:03.979271
NCT01014988|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2017-02-08|2012-07-26|2017-02-08|2009-11-16|2009-11-17|Estimate|2017-02-08|2017-03-28|Actual|2012-07-26|2012-08-03|Estimate|2017-02-08|2017-03-28|Actual|November 2009||2009-11-30|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital|An Open-label, Multi-center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects With Confirmed Influenza Infection|Completed||Phase 2|202|Actual|GlaxoSmithKline|Two participants who withdrew consent prior to receiving intravenous zanamivir have not been captured in any of the tables.|1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:22:04.194445|2018-06-01 00:22:04.194445
NCT01014975|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2015-08-20||2015-09-22|2009-11-16|2009-11-17|Estimate|2015-09-22|2015-10-21|Estimate||||2015-09-22|2015-10-21|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional||Safety population includes all subject who received any amount of Plasmin.|A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients|A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke|Completed||Phase 1/Phase 2|40|Actual|Grifols Therapeutics LLC||3|||f||||t||||||||||2018-06-01 00:22:08.455105|2018-06-01 00:22:08.455105
NCT01014962|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2017-06-19|2009-11-16|2009-11-17|Estimate|||||||2017-06-19|2017-06-20|Actual|August 24, 2009|Actual|2009-08-24|June 2017|2017-06-30|December 4, 2009|Actual|2009-12-04|December 4, 2009|Actual|2009-12-04||Interventional|||A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus|A Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Tolerability And Pharmacokinetic Study Of Escalating Doses Of Albaconazole In Healthy Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 00:22:08.979909|2018-06-01 00:22:08.979909
NCT01014949|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2010-07-21|2009-11-16|2009-11-17|Estimate|||||||2010-07-21|2010-07-22|Estimate|July 2008||2008-07-31|November 2009|2009-11-30|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|MADAME||Microcirculation Assessment in Diabetes and Metabolic Syndrome|Invasive Coronary Microcirculation Assessment in Diabetes and Metabolic Syndrome|Completed||N/A|50|Anticipated|S.M. Misericordia Hospital||1|||f||||||||||||||2018-06-01 00:22:09.071309|2018-06-01 00:22:09.071309
NCT01014936|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2016-10-14||2017-07-19|2009-11-16|2009-11-17|Estimate|2017-03-03|2017-04-17|Actual||||2017-07-19|2017-08-23|Actual|November 30, 2009|Actual|2009-11-30|July 2017|2017-07-31|October 31, 2015|Actual|2015-10-31|October 31, 2015|Actual|2015-10-31||Interventional||Safety set included all subjects who had received at least 1 dose of MSC2156119J treatment.|First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors|A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors|Completed||Phase 1|149|Actual|EMD Serono|It was not possible to calculate data for PK parameters such as t1/2, AUC0-inf, CL/f, Vz/f, λz because dosing interval was too small compared to the long half-life to characterize terminal phase rate constant, which is needed for the calculation.|3|||f||||f||||||||||2018-06-01 00:22:09.536771|2018-06-01 00:22:09.536771
NCT01014923|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-02-18|2009-11-16|2009-11-17|Estimate|||||||2011-02-18|2011-02-21|Estimate|July 2007||2007-07-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Parent-based Intervention to Increase Safe Teen Driving|Parent-based Intervention to Increase Safe Teen Driving|Completed||N/A|163|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 00:22:12.945654|2018-06-01 00:22:12.945654
NCT01014910|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2016-01-26||2016-02-22|2009-11-16|2009-11-17|Estimate|2016-02-22|2016-03-21|Estimate||||2016-02-22|2016-03-21|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis|Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis|Completed||N/A|161|Actual|Children's Mercy Hospital Kansas City|Our study was not designed or powered to detect differences in ICU transfers.|2|||f||||t||||||||No|IRB approval at participating institutions does not provide an avenue for sharing study data after study completion.|2018-06-01 00:22:13.04264|2018-06-01 00:22:13.04264
NCT01014897|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2016-02-03|2009-11-13|2009-11-17|Estimate|||||||2016-02-03|2016-02-04|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) in Chronic Stroke Recovery|tDCS in Chronic Stroke Recovery-pilot|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-06-01 00:22:13.348743|2018-06-01 00:22:13.348743
NCT01014715|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2018-02-19|2009-11-16|2009-11-17|Estimate|||||||2018-02-19|2018-02-20|Estimate|September 2009|Actual|2009-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|GCC 0919||Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer|Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer|Active, not recruiting||N/A|40|Anticipated|University of Maryland||1|||f||||t|f|f||||||||2018-06-01 00:22:15.451722|2018-06-01 00:22:15.451722
NCT01014884|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2010-01-20|2009-11-16|2009-11-17|Estimate|||||||2010-01-20|2010-01-21|Estimate|November 2009||2009-11-30|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|COSS||Coventry Outcomes Study of Seniors (COSS): A Comparative Effectiveness Study to Evaluate the Effect of a Multidisciplinary Team's Intervention on the Incidence of Nonelective Hospitalizations in a Medicare Population|Coventry Outcomes Study of Seniors: A Dual-arm, Controlled, Randomized, Comparative Effectiveness Study to Evaluate the Effect of a Multidisciplinary Team's Intervention Versus Usual Care on the Incidence of Nonelective Hospitalizations in a Medicare Population|Terminated||N/A|2150|Anticipated|Medco Health Solutions, Inc.||2||Terminated by Sponsor|f||||f||||||||||2018-06-01 00:22:13.420836|2018-06-01 00:22:13.420836
NCT01014871|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2011-08-12||2012-04-17|2009-11-16|2009-11-17|Estimate|2012-03-09|2012-04-05|Estimate||||2012-04-17|2012-04-20|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles|Intra-individual Comparison of the Efficacy of Two Botulinum Toxins Type A on Moderate to Severe Forehead Wrinkles After One Injection|Completed||Phase 2|30|Actual|Galderma||1|||f||||f||||||||||2018-06-01 00:22:13.563187|2018-06-01 00:22:13.563187
NCT01014858|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2017-09-21|2009-11-16|2009-11-17|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2013||2013-01-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MUSTARDD-PD||Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease|Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease|Terminated||Phase 3|64|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2||Due to low recruitment|f||||t||||||||||2018-06-01 00:22:13.881317|2018-06-01 00:22:13.881317
NCT01014845|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2016-01-03|2009-11-16|2009-11-17|Estimate|||||||2016-01-03|2016-01-05|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Clinical Trial of Recombinant Hepatitis E Vaccine|A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine|Unknown status|Active, not recruiting|Phase 3|112604|Actual|Xiamen University||2|||f||||t||||||||||2018-06-01 00:22:13.998333|2018-06-01 00:22:13.998333
NCT01014832|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2009-11-16|2009-11-16|2009-11-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of Frequently Modified Intensive Insulin|An Efficacy and Safety Evaluation of Frequently Modified Intensive Insulin Therapy in Subjects With Uncontrolled Type-I or Type-2 Diabetes|Completed||N/A|14|Actual|Hygieia, Inc||1|||f||||f||||||||||2018-06-01 00:22:14.097055|2018-06-01 00:22:14.097055
NCT01014819|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-08-02|2009-11-16|2009-11-17|Estimate|||||||2011-08-02|2011-08-03|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|Dermacorder||A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions|A Phase I Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions|Completed|||30|Anticipated|Children's Hospital & Research Center Oakland|||||f||||f||||||||||2018-06-01 00:22:14.160913|2018-06-01 00:22:14.160913
NCT01014806|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-14||2013-07-16|2013-07-16|2009-11-16|2009-11-17|Estimate||||2013-07-16|2013-07-18|Estimate|2013-07-16|2013-07-18|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults|A Phase 2a Randomized, Double-Blind, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Older Adults|Completed||Phase 2|467|Actual|Novavax||3|||f||||t||||||||||2018-06-01 00:22:14.210502|2018-06-01 00:22:14.210502
NCT01014793|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2009-11-16|2009-11-16|2009-11-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|May 2005||2005-05-31|November 2009|2009-11-30|December 2008|Actual|2008-12-31|May 2007|Actual|2007-05-31||Observational|||Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients|Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly|Completed|||19|Actual|Federal University of São Paulo|||1||f||||t||||||Samples Without DNA|"~     serum for IGI-I, GH and prolactin measures~   "|||2018-06-01 00:22:14.278191|2018-06-01 00:22:14.278191
NCT01014780|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2010-10-08|2009-11-16|2009-11-17|Estimate|||||||2010-10-08|2010-10-11|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Observational|||Tear Film Thickness Measured Using a Novel Technique|Tear Film Thickness Measured Using a Novel Technique|Completed|||40|Anticipated|Southern California College of Optometry|||2||f||||f||||||||||2018-06-01 00:22:14.344162|2018-06-01 00:22:14.344162
NCT01014767|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2016-07-21|2009-11-16|2009-11-17|Estimate|||||||2016-07-21|2016-07-25|Estimate|November 2009||2009-11-30|July 2016|2016-07-31||||October 2013|Actual|2013-10-31||Interventional|||Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors|CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors|Suspended||Phase 3|190|Anticipated|Tufts Medical Center||4||PI departure from coordinating institution|f||||t||||||||||2018-06-01 00:22:14.403259|2018-06-01 00:22:14.403259
NCT01014754|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2014-12-02|2009-11-16|2009-11-17|Estimate|||||||2014-12-02|2014-12-04|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Observational|NSF||Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels|Nephrogenic Systemic Fibrosis and Gadolinium—A Medical Record Review With Analysis of Existing Skin and Other Tissue Specimens to Assess Potential Causative or Associated Factors|Completed|||24|Actual|Northwestern University|||6||f||||t||||||Samples With DNA|"~     Existing skin tissue from standard of care biopsies~   "|||2018-06-01 00:22:14.520381|2018-06-01 00:22:14.520381
NCT01014741|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2017-04-17||2018-01-17|2009-11-16|2009-11-17|Estimate|2017-04-17|2017-05-24|Actual||||2018-01-17|2018-02-14|Actual|October 2009||2009-10-31|January 2018|2018-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|MAGIC-AF||Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation|Modified Stepwise Ablation Guided by Low Dose Ibutilide in Chronic Atrial Fibrillation|Completed||N/A|200|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-06-01 00:22:14.593714|2018-06-01 00:22:14.593714
NCT01014728|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2013-11-20||2014-01-21|2009-11-16|2009-11-17|Estimate|2013-11-20|2014-01-09|Estimate||||2014-01-21|2014-02-14|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Intraoperative Bleeding During Endoscopic Sinus Surgery|Comparison of Intraoperative Bleeding During Endoscopic Sinus Surgery Between Patients Receiving Total Intravenous Anesthesia With Propofol and Patients Receiving an Inhalational Anesthetic With Sevoflurane|Completed||N/A|33|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 00:22:15.244198|2018-06-01 00:22:15.244198
NCT01014702|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2011-04-14|2009-11-16|2009-11-17|Estimate|||||||2011-04-14|2011-04-15|Estimate|November 2009||2009-11-30|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Prospective Clinical Trial of the LensAR Laser System|Prospective Clinical Trial of the LensAR Laser System in the Treatment of Cataracts of Different Grades of Maturity|Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Anticipated|LensAR Incorporated||2|||f||||f||||||||||2018-06-01 00:22:15.52218|2018-06-01 00:22:15.52218
NCT01014689|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2011-08-12||2012-04-17|2009-11-16|2009-11-17|Estimate|2012-03-09|2012-04-05|Estimate||||2012-04-17|2012-04-20|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|TEAM||Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris|Efficacy and Safety Comparison of Epiduo Gel Associated With Lymecycline 300 mg Capsules Versus Epiduo Vehicle Gel Associated With Lymecycline 300 mg Capsules in the Treatment of Moderate to Severe Acne Vulgaris|Completed||Phase 3|378|Actual|Galderma||2|||f||||f||||||||||2018-06-01 00:22:15.600546|2018-06-01 00:22:15.600546
NCT01014676|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-07-06|2009-11-16|2009-11-17|Estimate|||||||2011-07-06|2011-07-07|Estimate||||July 2011|2011-07-31||||||||Interventional|||Probiotics and Infections in Children Attending Day Care Centres||Completed||Phase 3|||Valio Ltd||2|||f||||||||||||||2018-06-01 00:22:16.00208|2018-06-01 00:22:16.00208
NCT01014663|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2014-11-20|2009-11-16|2009-11-17|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Non-contact Boxing Training and Traditional Therapeutic Exercise for Persons With Parkinson's Disease|Comparison of Non-contact Boxing Training and Traditional Therapeutic Exercise on Functional Outcomes in Persons With Parkinson's Disease|Completed||Phase 1/Phase 2|31|Actual|University of Indianapolis||2|||f||||f||||||||||2018-06-01 00:22:16.063954|2018-06-01 00:22:16.063954
NCT01014650|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2016-02-18|2009-11-14|2009-11-17|Estimate|||||||2016-02-18|2016-02-22|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers|A Randomized, Double-Blind, Placebo-Controlled Single Intravenous Dose, Ascending Dose Level Study of the Safety, Tolerability and Pharmacokinetics of GLYX-13 in Normal Healthy Volunteers|Completed||Phase 1|53|Actual|Naurex, Inc||3|||f||||f||||||||||2018-06-01 00:22:16.141633|2018-06-01 00:22:16.141633
NCT01014637|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2009-11-16|2009-11-16|2009-11-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|ONICO||Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis|A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement|Unknown status|Recruiting|Phase 4|260|Anticipated|Pierre Fabre Dermo Cosmetique||2|||f||||f||||||||||2018-06-01 00:22:16.221258|2018-06-01 00:22:16.221258
NCT01014624|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2011-05-31||2012-02-08|2009-11-16|2009-11-17|Estimate|2011-08-05|2011-09-09|Estimate||||2012-02-08|2012-02-13|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Prasugrel/Clopidogrel Maintenance Dose Washout Study|Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease|Completed||Phase 4|56|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 00:22:16.339353|2018-06-01 00:22:16.339353
NCT01014611|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2012-09-26|2009-11-16|2009-11-17|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|November 2011|Actual|2011-11-30|||||Observational|Calcicard||Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle|Evaluation of Calcium Homeostasis and Mitochondrial Function in Skeletal Muscle in Subjects With Heart Failure, Before and After Exercise Training|Terminated|||3|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||3|Difficulties of recruitement|f||||f||||||||||2018-06-01 00:22:16.923519|2018-06-01 00:22:16.923519
NCT01014598|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2018-03-28|2009-11-16|2009-11-17|Estimate|||||||2018-03-28|2018-03-29|Actual|December 4, 2007|Actual|2007-12-04|March 2018|2018-03-31|May 21, 2018|Anticipated|2018-05-21|May 21, 2015|Actual|2015-05-21||Interventional|||Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis|Phase I Study of Targeted Lung Chemotherapy in the Treatment of Metastatic Tumors|Active, not recruiting||Phase 1|11|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-06-01 00:22:17.004626|2018-06-01 00:22:17.004626
NCT01014585|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2011-06-07||2011-09-02|2009-11-16|2009-11-17|Estimate|2011-09-02|2011-09-07|Estimate||||2011-09-02|2011-09-07|Estimate|November 2009||2009-11-30|September 2011|2011-09-30||||May 2010|Actual|2010-05-31||Interventional|||Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia|A Multicenter, Randomized, Double-blind, Placebo-Controlled Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia in Patients Receiving Long-term Milnacipran Treatment|Completed||Phase 4|340|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:22:17.113711|2018-06-01 00:22:17.113711
NCT01014572|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13||2014-05-19|2017-11-17|2009-11-16|2009-11-17|Estimate||||2014-05-19|2014-05-29|Estimate|2017-11-17|2017-11-21|Actual|July 2008||2008-07-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|AGE||The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart|The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart|Completed||Phase 2|62|Actual|University of Texas Southwestern Medical Center||4|||f||||t||||||||||2018-06-01 00:22:17.551546|2018-06-01 00:22:17.551546
NCT01014559|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2015-09-25|2009-11-16|2009-11-17|Estimate|||||||2015-09-25|2015-09-28|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|February 2013|Actual|2013-02-28|June 2011|Actual|2011-06-30||Interventional|OXN3505||Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients|Study of Efficacy of OXN PR, Compared to Oxy PR, for Reduction of Intensity of Opioid-induced Constipation Symptoms in Pts Treated for Cancer or Non-cancer Pain: A Randomised, Double-blind, Controlled, Multicentre Study|Terminated||Phase 3|225|Actual|Mundipharma SAS||2||Lack of recruitment|f||||f||||||||||2018-06-01 00:22:17.72383|2018-06-01 00:22:17.72383
NCT01014546|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2016-07-25|2009-11-16|2009-11-17|Estimate|||||||2016-07-25|2016-07-26|Estimate|April 2010||2010-04-30|July 2016|2016-07-31||||February 2015|Actual|2015-02-28||Interventional|||Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis|A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis|Terminated||Phase 1|5|Actual|Roswell Park Cancer Institute||1||low accrual|f||||t||||||||||2018-06-01 00:22:17.797711|2018-06-01 00:22:17.797711
NCT01014533|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2017-09-30||2017-10-31|2009-11-16|2009-11-17|Estimate|2017-09-30|2017-11-01|Actual||||2017-10-31|2017-12-06|Actual|May 2007|Actual|2007-05-31|October 2017|2017-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|MA||Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence|This is a Study Exploring the Reasons Why People With Alcohol Dependence Have Sleep Disturbances, and Whether or Not a Study Medication, Gabapentin, vs. Placebo, Affects Those Sleep Patterns.|Completed||N/A|59|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 00:22:17.897844|2018-06-01 00:22:17.897844
NCT01014520|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-14|||2009-11-16|2009-11-16|2009-11-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|||Efficacy of Gabapentin or Amitriptyline to Reduce Postoperative Pain After Lumbar Laminectomy and Diskectomy|Comparative Effects of Single Dose Preemptive Gabapentin or Amitriptyline on Postoperative Pain and Opioid Consumption in Single Level Lumbar Laminectomy and Diskectomy: A Double Blind RCT With Placebo Control|Unknown status|Recruiting|Phase 2|120|Anticipated|Tabriz University||2|||f||||t||||||||||2018-06-01 00:22:18.211336|2018-06-01 00:22:18.211336
NCT01014507|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2012-06-22|2009-11-16|2009-11-17|Estimate|||||||2012-06-22|2012-06-25|Estimate|January 2004||2004-01-31|October 2011|2011-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|PROFE||Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma|Randomisierte Phase II Studie Zum Einsatz Von Goserelin Und Oralen Kontrazeptiva Zur Reduktion Ovarieller Toxizitäten während Zytostatischer Primärtherapie Bei Fertilen Patientinnen Mit Hodgkin Lymphom in Fortgeschrittenen Stadien|Completed||Phase 2|60|Actual|University of Cologne||2|||f||||||||||||||2018-06-01 00:22:18.2969|2018-06-01 00:22:18.2969
NCT01014494|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2010-12-07|2009-11-16|2009-11-17|Estimate|||||||2010-12-07|2010-12-09|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Adaprev in Digital Flexor Tendon Repair|A Randomized, Double Blind Clinical Investigation to Evaluate the Safety, Tolerability, and Preliminary Performance of Adaprev™ in Improving Recovery of Tendon Function in Subjects Undergoing Surgical Repair of Flexor Tendons in Zone II of the Hand|Unknown status|Recruiting|N/A|44|Anticipated|Renovo||2|||f||||f||||||||||2018-06-01 00:22:18.423604|2018-06-01 00:22:18.423604
NCT01014481|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-11-16|2009-11-16|2009-11-17|Estimate|||||||2011-11-16|2011-11-17|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|TIME||Appropriate Timing of HAART in Co-infected HIV/TB Patients|Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study)|Terminated||Phase 4|156|Actual|Bamrasnaradura Infectious Diseases Institute||1||"this study was ended prematurely by ethical committees with a reason of the final outcome was~   achieved with no longer recruitment was needed."|f||||f||||||||||2018-06-01 00:22:18.528148|2018-06-01 00:22:18.528148
NCT01014468|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2011-11-19|2009-11-16|2009-11-17|Estimate|||||||2011-11-19|2011-11-22|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|February 2012|Anticipated|2012-02-29|November 2009|Actual|2009-11-30||Interventional|AxL-2009||Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration|Comparative Study - Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration|Unknown status|Active, not recruiting|Phase 3|500|Actual|Instituto de Olhos de Goiania||2|||f||||t||||||||||2018-06-01 00:22:18.606938|2018-06-01 00:22:18.606938
NCT01014455|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2011-07-25||2011-07-25|2009-11-16|2009-11-17|Estimate|2011-07-25|2011-08-22|Estimate||||2011-07-25|2011-08-22|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation|Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation|Completed||N/A|169|Actual|Mayo Clinic|Study subjects received the additional questionnaire on smoking behavior, which itself could heighten awareness of perioperative tobacco use issues and could be viewed as an additional intervention.|2|||f||||t||||||||||2018-06-01 00:22:18.681668|2018-06-01 00:22:18.681668
NCT01014442|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2016-12-19||2016-12-19|2009-11-16|2009-11-17|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|January 2010||2010-01-31|July 2015|2015-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||The safety population included all participants who received at least one dose of study drug and a safety follow-up, whether withdrawn prematurely or not.|A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients|Pharmacokinetics of Mycophenolate Mofetil in de Novo Lung Allograft Recipients|Completed||Phase 3|68|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:22:18.991818|2018-06-01 00:22:18.991818
NCT01014429|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2012-09-06|2009-11-16|2009-11-17|Estimate|||||||2012-09-06|2012-09-07|Estimate|November 2009||2009-11-30|September 2012|2012-09-30||||October 2011|Actual|2011-10-31||Interventional|||Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors|A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors|Completed||Phase 1|21|Actual|Nerviano Medical Sciences||1|||f||||f||||||||||2018-06-01 00:22:21.015467|2018-06-01 00:22:21.015467
NCT01014416|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2010-03-10|2009-11-15|2009-11-17|Estimate|||||||2010-03-10|2010-03-11|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male|A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Tolvaptan in Healthy Korean Male Subjects Bipolar Disorder|Completed||Phase 1|46|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-06-01 00:22:21.119908|2018-06-01 00:22:21.119908
NCT01014403|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2009-11-16|2009-11-16|2009-11-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|DEEP||Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)|The Delayed vs Early Enoxaparin Prophylaxis (DEEP) Study After Traumatic Brain Injury: A Randomized, Double-Blinded, Placebo Controlled Pilot Trial|Unknown status|Recruiting|Phase 1|80|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 00:22:21.268132|2018-06-01 00:22:21.268132
NCT01014390|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2016-06-13|2009-11-16|2009-11-17|Estimate|||||||2016-06-13|2016-06-14|Estimate|December 2009||2009-12-31|June 2016|2016-06-30|November 2017|Anticipated|2017-11-30|November 2012|Actual|2012-11-30||Interventional|||WallFlex Biliary Fully Covered (FC) Benign Stricture Study|A Multi-Center, Prospective Study of the WallFlex Biliary RX Fully Covered Stent for the Treatment of Benign Biliary Strictures|Active, not recruiting||Phase 3|187|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 00:22:21.717044|2018-06-01 00:22:21.717044
NCT01013896|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2015-03-30|2009-11-13|2009-11-16|Estimate|||||||2015-03-30|2015-03-31|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|BALANCE||Building Adherence to Live With And Navigate my Cystic Fibrosis (CF) Experience|Building Adherence to Live With And Navigate my CF Experience|Completed||N/A|128|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:22:43.710407|2018-06-01 00:22:43.710407
NCT01014377|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2010-05-20|2009-11-16|2009-11-17|Estimate|||||||2010-05-20|2010-05-21|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia|Assessment of the Safety of the VascuActive™ Device and Its Preliminary Efficacy on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With Peripheral Vascular Disease and Limb Ischemia|Completed||N/A|15|Anticipated|VascuActive LTD|||||f||||||||||||||2018-06-01 00:22:21.840409|2018-06-01 00:22:21.840409
NCT01014364|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2014-12-17|2009-11-16|2009-11-17|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|CORTIFLU||Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu|Phase III Study of Hydrocortisone in Patients With Severe H1N1 Related Pneumonia|Terminated||Phase 3|40|Actual|University of Versailles||2||the H1N1 pandemic is now over, and fewer cases than expected were observed|f||||t||||||||||2018-06-01 00:22:21.966142|2018-06-01 00:22:21.966142
NCT01014351|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|2014-02-10||2014-02-10|2009-11-16|2009-11-17|Estimate|2014-02-10|2014-03-26|Estimate||||2014-02-10|2014-03-26|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|August 2013|Actual|2013-08-31|February 2012|Actual|2012-02-29||Interventional|||Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma|A Phase II Study of Everolimus in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma|Completed||Phase 2|70|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 00:22:22.143207|2018-06-01 00:22:22.143207
NCT01014338|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-16|||2015-03-24|2009-11-16|2009-11-17|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)|ACE-inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease|Completed||Phase 4|80|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 00:22:22.637955|2018-06-01 00:22:22.637955
NCT01014325|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2015-11-02|2009-11-13|2009-11-16|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2016||2016-09-30|November 2015|2015-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy|Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy|Unknown status|Not yet recruiting|Phase 3|130|Anticipated|Roxall Medizin||2|||f||||||||||||||2018-06-01 00:22:22.911778|2018-06-01 00:22:22.911778
NCT01014312|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2017-02-17|2009-11-13|2009-11-16|Estimate|||||||2017-02-17|2017-02-23|Actual|September 1, 2009|Actual|2009-09-01|February 2017|2017-02-28|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional|||Treatment for Depressed Primary Care Patients|Community-Based Depression Care Management for Elderly Primary Care Patients|Completed||N/A|11|Actual|Weill Medical College of Cornell University||2|||f||||t|f|f||||||No||2018-06-01 00:22:23.307643|2018-06-01 00:22:23.307643
NCT01014299|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2009-11-23|2009-11-13|2009-11-16|Estimate|||||||2009-11-23|2009-11-25|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Recruitment Maneuver After Intubation|Recruitment Maneuver Increases Oxygenation After Intubation in Hypoxemic ICU Patients: a Randomized Controlled Study|Completed||Phase 4|40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:22:23.505983|2018-06-01 00:22:23.505983
NCT01014286|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2017-08-29|2009-11-13|2009-11-16|Estimate|||||||2017-08-29|2017-08-30|Actual|September 2009||2009-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Lung Cancer Mutation Consortium Protocol|Lung Cancer Mutation Consortium Protocol|Active, not recruiting|||1100|Actual|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     Biopsy remnant tissue~   "|||2018-06-01 00:22:23.667978|2018-06-01 00:22:23.667978
NCT01014273|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2011-04-06|2009-11-13|2009-11-16|Estimate|||||||2011-04-06|2011-04-07|Estimate|June 2006||2006-06-30|February 2011|2011-02-28|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|RIVAL||A Trial of Trans-radial Versus Trans-femoral Percutaneous Coronary Intervention (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy|An International Randomized Trial of Trans-radial Versus Trans-femoral PCI Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy. An Extension to the CURRENT (OASIS 7) Substudy (EFC5695): Effect of Type of Access for PCI (Radial or Femoral) on Bleeding Rate-Substudy.|Completed||Phase 3|7021|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-06-01 00:22:24.298536|2018-06-01 00:22:24.298536
NCT01014260|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-03-29|2009-11-13|2009-11-16|Estimate|||||||2012-03-29|2012-03-30|Estimate|September 2010||2010-09-30|May 2010|2010-05-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Doxycycline Outcomes in Lupus Erythematosus|Doxycycline Outcomes in Lupus Erythematosus: (DOLE)|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||2||We could not get funding for study.|f||||t||||||||||2018-06-01 00:22:24.530433|2018-06-01 00:22:24.530433
NCT01014247|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2013-05-31|2009-11-13|2009-11-16|Estimate|||||||2013-05-31|2013-06-03|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation|A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 Trial|Completed||Phase 1|56|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:22:24.622124|2018-06-01 00:22:24.622124
NCT01014234|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2015-03-24|2009-11-13|2009-11-16|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Rapamycin and Regulatory T Cells in Kidney Transplantation|Rapamycin and Regulatory T Cells in Renal Transplant Patients: a Two-year Randomized Prospective Study|Completed||Phase 2|56|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-06-01 00:22:24.981745|2018-06-01 00:22:24.981745
NCT01014221|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2009-11-16|2009-11-13|2009-11-16|Estimate|||||||2009-11-16|2009-11-17|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|||Acupuncture in Patients With Carpal Tunnel Syndrome ~ A Randomized Controlled Trial|Acupuncture in Patients With Carpal Tunnel Syndrome ~ A Randomized Controlled Trial|Completed||N/A|77|Actual|Kuang Tien General Hospital||2|||f||||f||||||||||2018-06-01 00:22:25.883252|2018-06-01 00:22:25.883252
NCT01013883|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2013-08-23||2014-01-28|2009-11-13|2009-11-16|Estimate|2014-01-28|2014-03-14|Estimate||||2014-01-28|2014-03-14|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|DROPSY||The Darlington Retrospective Outpatient Study|Long Term Outcomes in Patients With Heart Failure|Completed|||509|Actual|County Durham and Darlington NHS Foundation Trust|||2||f||||f||||||||||2018-06-01 00:22:43.817583|2018-06-01 00:22:43.817583
NCT01014208|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|2014-10-09||2015-07-09|2009-11-12|2009-11-16|Estimate|2014-10-09|2014-10-16|Estimate||||2015-07-09|2015-08-07|Estimate|March 2010||2010-03-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|ORCHARRD||Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma|Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Completed||Phase 3|447|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 00:22:26.533738|2018-06-01 00:22:26.533738
NCT01014195|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2016-06-06|2009-11-13|2009-11-16|Estimate|||||||2016-06-06|2016-06-07|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors|Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors|Completed|||237|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 00:22:31.473119|2018-06-01 00:22:31.473119
NCT01014182|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2009-11-13|2009-11-13|2009-11-16|Estimate|||||||2009-11-13|2009-11-16|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Early Percutaneous Coronary Intervention (PCI) After Fibrinolysis Versus Standard Therapy in ST Segment Elevation Myocardial Infarction (STEMI) Patients|Early Invasive Strategy After Fibrinolysis vs Standard Management in STEMI Patients: Results From an Individual Patient Data Meta-analysis (OTTER Meta-analysis) OTTER: Optimal Timing for Post-Thrombolysis Elective Revascularization|Unknown status|Recruiting||3000|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||2||f||||||||||||||2018-06-01 00:22:31.55552|2018-06-01 00:22:31.55552
NCT01014169|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2012-08-20||2012-09-20|2009-11-13|2009-11-16|Estimate|2012-09-20|2012-10-19|Estimate||||2012-09-20|2012-10-19|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of the Impact of Parental Note Taking on the Effectiveness of Anticipatory Guidance|A Randomized Controlled Trial of The Impact of Parental Note Taking on the Effectiveness of Anticipatory Guidance: the Suzuki Music Model Applied to Urban Pediatrics|Completed||N/A|126|Actual|Boston Medical Center|Conducted as a pilot study and not powered to demonstrate a significant difference between the two groups; subjects and NPs were aware of the group assignment; outcomes were determined using maternal self report.|2|||f||||f||||||||||2018-06-01 00:22:31.949592|2018-06-01 00:22:31.949592
NCT01014156|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2009-11-13|2009-11-13|2009-11-16|Estimate|||||||2009-11-13|2009-11-16|Estimate|January 2004||2004-01-31|November 2009|2009-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Epoprostenol in Pulmonary Embolism|Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism|Completed||Phase 4|14|Actual|Free University Medical Center||1|||f||||f||||||||||2018-06-01 00:22:33.67484|2018-06-01 00:22:33.67484
NCT01014143|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2011-06-10|2009-10-05|2009-11-16|Estimate|2009-10-05|2009-11-16|Estimate||||2011-06-10|2011-06-14|Estimate|August 2007||2007-08-31|June 2011|2011-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Evaluating Commercial Anti-Plaque Products and Oral Rinse|Evaluating Commercial Anti-Plaque Products and Oral Rinse|Completed||Phase 2|26|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 00:22:33.875077|2018-06-01 00:22:33.875077
NCT01014130|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-07-10|2009-11-12|2009-11-16|Estimate|||||||2017-07-10|2017-07-12|Actual|December 2009|Actual|2009-12-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CHISEL||Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)|"A Randomised Phase III Trial of Highly Conformal Hypofractionated Image Guided (Stereotactic) Radiotherapy (HypoRT) Versus Conventionally Fractionated Radiotherapy (ConRT) for Inoperable Early Stage I Non-small Cell Lung Cancer (CHISEL)"|Active, not recruiting||Phase 3|101|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||t||||||||||2018-06-01 00:22:34.673264|2018-06-01 00:22:34.673264
NCT01014117|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2017-06-21|2009-11-12|2009-11-16|Estimate|||||||2017-06-21|2017-06-22|Actual|December 9, 2009|Actual|2009-12-09|June 2017|2017-06-30|May 10, 2010|Actual|2010-05-10|May 10, 2010|Actual|2010-05-10||Interventional|||Effect of SRT2104 on Endotoxin-induced Inflammation|A Phase I Study to Evaluate Single and Multiple (Seven) Oral Doses of SRT2104 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects|Completed||Phase 1|41|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:22:34.952593|2018-06-01 00:22:34.952593
NCT01014104|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2011-07-14|2009-11-13|2009-11-16|Estimate|||||||2011-07-14|2011-07-15|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome|Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome in In-vitro Fertilization Cycles: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|218|Actual|Royan Institute||2|||f||||t||||||||||2018-06-01 00:22:35.187941|2018-06-01 00:22:35.187941
NCT01014091|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2017-03-07|2011-02-04|2017-03-21|2009-11-12|2009-11-16|Estimate|2017-03-21|2017-05-04|Actual|2011-02-04|2011-02-10|Estimate|2017-03-21|2017-05-04|Actual|December 2009||2009-12-31|March 2017|2017-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 9 Years|Terminated||Phase 3|60|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:22:35.525557|2018-06-01 00:22:35.525557
NCT01014078|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12||2011-01-13|2011-09-20|2009-11-13|2009-11-16|Estimate||||2011-01-13|2011-01-28|Estimate|2011-09-20|2011-09-26|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease||Completed||Phase 4|112|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:22:38.692678|2018-06-01 00:22:38.692678
NCT01014065|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2016-02-24|2009-11-13|2009-11-16|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2011||2011-07-31|March 2012|2012-03-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|SUPER||A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)|A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients|Completed|||42|Actual|AHS Cancer Control Alberta|||1||f||||f||||||Samples With DNA|"~     Blood and urine banked~   "|||2018-06-01 00:22:39.152501|2018-06-01 00:22:39.152501
NCT01014052|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2013-05-13|2009-11-13|2009-11-16|Estimate|||||||2013-05-13|2013-05-14|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations|Phase 1b Study to Evaluate QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)|Completed||Phase 1|32|Actual|QLT Inc.|||||f||||f||||||||||2018-06-01 00:22:39.559226|2018-06-01 00:22:39.559226
NCT01014039|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2017-09-13|2009-11-13|2009-11-16|Estimate|||||||2017-09-13|2017-09-14|Actual|March 1983||1983-03-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|TPS||Telemark Polyp Study, a Trial on Colonoscopy Screening|Telemark Polyp Study, a Randomized Trial on Colonoscopy Screening|Completed||N/A|1433|Actual|Norwegian Department of Health and Social Affairs||2|||f||||f||||||||||2018-06-01 00:22:39.875959|2018-06-01 00:22:39.875959
NCT01014026|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2011-05-12|2009-11-13|2009-11-16|Estimate|||||||2011-05-12|2011-05-13|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|APACHE-1||Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention|Human Papillomavirus DNA Testing Using Self-collected Samples for Cervical Cancer Screening: an Alternative Strategy for Unscreened Women?|Completed||Phase 3|734|Actual|University Hospital, Tours|||||f||||f||||||||||2018-06-01 00:22:40.053305|2018-06-01 00:22:40.053305
NCT01014013|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2010-01-19||2017-02-16|2009-11-12|2009-11-16|Estimate|2010-02-12|2010-03-01|Estimate||||2017-02-16|2017-03-22|Actual|April 2008||2008-04-30|February 2017|2017-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)|A Prospective, Multicenter, Partially-Blinded, Randomized, Comparative Study to Evaluate the Safety, Tolerability and Efficacy of INVANZ Versus Ceftriaxone Sodium in the Treatment of Complicated Urinary Tract Infections in Adults|Completed||Phase 3|271|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:22:40.229442|2018-06-01 00:22:40.229442
NCT01014000|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2015-09-03|2009-11-13|2009-11-16|Estimate|||||||2015-09-03|2015-09-04|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|E-OPT||Comparative Study to Examine Whether Echocardiography Performed During Cardiac Resynchronization Therapy Device Implantation Can Improve the Response Rate|OPTimization of Left-Ventricular Lead Implantation by Echocardiography- E-OPT Study|Withdrawn||N/A|0|Actual|Princess Margaret Hospital, Hong Kong||2||On reviewing of new data|f||||f||||||||||2018-06-01 00:22:41.206386|2018-06-01 00:22:41.206386
NCT01013987|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2010-02-09|2009-11-13|2009-11-16|Estimate|||||||2010-02-09|2010-02-10|Estimate|February 2010||2010-02-28|November 2009|2009-11-30||||||||Interventional|TERCETO||Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients|A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients.|Unknown status|Recruiting|Phase 4|60|Anticipated|The Huesped Foundation|||||f||||f||||||||||2018-06-01 00:22:41.455557|2018-06-01 00:22:41.455557
NCT01013974|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2017-08-01|2009-11-12|2009-11-16|Estimate|||||||2017-08-01|2017-08-03|Actual|October 5, 2009|Actual|2009-10-05|August 2017|2017-08-31|December 18, 2009|Actual|2009-12-18|December 18, 2009|Actual|2009-12-18||Interventional|||A Study of GSK573719 in Healthy Japanese Male Subjects|Phase I Study of GSK573719 -A Randomized, Double Blind, Placebo Controlled, Dose Ascending, Single and Repeat Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled Dose of GSK573719 From a Novel Dry Powder Device in Healthy Japanese Male Subjects|Completed||Phase 1|48|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:22:41.698632|2018-06-01 00:22:41.698632
NCT01013961|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2015-12-22||2016-02-01|2009-11-13|2009-11-16|Estimate|2015-12-22|2016-01-28|Estimate||||2016-02-01|2016-02-03|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|July 2015|Actual|2015-07-31||Interventional||All randomized patients|Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia|A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab and Rituximab|Terminated||Phase 2|31|Actual|Eastern Cooperative Oncology Group||2||Slow accrual|f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 00:22:42.010578|2018-06-01 00:22:42.010578
NCT01013948|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-10-17|2009-11-12|2009-11-16|Estimate|||||||2012-10-17|2012-10-18|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting|Prevalence of Chronic Airway Onstruction in a Subject Population With a History of Cigarette Smoking in a Primary Care Setting|Completed|||1574|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:22:43.053452|2018-06-01 00:22:43.053452
NCT01013935|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2014-11-21|2009-11-13|2009-11-16|Estimate|||||||2014-11-21|2014-11-24|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|CARE+ Spanish||A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]|A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]|Completed||Phase 4|556|Actual|New York University||2|||f||||t||||||||||2018-06-01 00:22:43.208255|2018-06-01 00:22:43.208255
NCT01013922|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2010-11-18|2009-11-13|2009-11-16|Estimate|||||||2010-11-18|2010-11-19|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||A Descriptive Study to Explore Certain Characteristics of Patients at Risk for Chronic Obstructive Pulmonary Disease (COPD) in a Primary Care Setting|A Descriptive Study to Explore Certain Characteristics of Patients at Risk for COPD in a Primary Care Setting|Completed|||309|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:22:43.427195|2018-06-01 00:22:43.427195
NCT01013909|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2015-01-26|2009-11-13|2009-11-16|Estimate|||||||2015-01-26|2015-01-27|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|Porsche||Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo|An Investigator-blind, Randomized, Multicenter, 5-arm, Placebo- and Active Controlled Parallel Group Pilot Trial to Explore the Efficacy and Tolerability of Topical Bifonazole Liquid Spray in Patients With Athlete's Foot.|Completed||Phase 2|220|Actual|Bayer||5|||f||||f||||||||||2018-06-01 00:22:43.587787|2018-06-01 00:22:43.587787
NCT01013870|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2016-08-03||2016-11-17|2009-11-13|2009-11-16|Estimate|2016-09-27|2016-11-17|Estimate||||2016-11-17|2017-01-09|Estimate|February 2010||2010-02-28|November 2016|2016-11-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol|The Mission Connect Mild TBI Translational Research Consortium's Integrated Clinical Protocol|Terminated||Phase 2|52|Actual|Baylor College of Medicine||2||inability to recruit adequate numbers of subjects|f||||f||||||||Yes|Data has been shared through the TED metadataset (https://tbiendpoints.ucsf.edu/ted-metadataset) and plans are to contribute the data to FITBIR as a legacy database.|2018-06-01 00:22:44.107695|2018-06-01 00:22:44.107695
NCT01013857|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-11-09|2009-11-13|2009-11-16|Estimate|||||||2012-11-09|2012-11-14|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|February 2010|Actual|2010-02-28||Interventional|||Treating to Target for Patients With Hypertension|Treating to Target for Patients With Hypertension|Completed||N/A|240|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:22:44.787978|2018-06-01 00:22:44.787978
NCT01013844|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2010-12-03||2014-09-24|2009-11-13|2009-11-16|Estimate|2011-02-11|2011-03-10|Estimate||||2014-09-24|2014-10-02|Estimate|December 2003||2003-12-31|September 2014|2014-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Partner Assistance in Learning and Performing Skin Self-Examination|Partner Assistance in Learning and Performing Skin Self-Examination|Completed||N/A|130|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 00:22:44.871489|2018-06-01 00:22:44.871489
NCT01013831|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2015-02-17|2009-11-13|2009-11-16|Estimate|||||||2015-02-17|2015-02-18|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|February 2012|Actual|2012-02-29||Interventional|||Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung|A Phase I Study of Erlotinib in Patients With Premalignant Lesions of the Lung|Terminated||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:22:45.165014|2018-06-01 00:22:45.165014
NCT01013818|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2013-08-01|2009-11-13|2009-11-16|Estimate|||||||2013-08-01|2013-08-02|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies|A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies|Terminated||Phase 1|11|Actual|Human Genome Sciences Inc.||1||Terminated due to slow accrual|f||||f||||||||||2018-06-01 00:22:45.236124|2018-06-01 00:22:45.236124
NCT01013805|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-07-10|2009-11-13|2009-11-16|Estimate|||||||2017-07-10|2017-07-12|Actual|November 2009||2009-11-30|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PROArCT||Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer|A Phase II Trial of Integrated Preoperative Radiotherapy and Chemotherapy With Oxaliplatin 5-FU and Folinic Acid in Patients With Locally Advanced Rectal Cancer|Completed||Phase 2|41|Actual|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||f||||||||||2018-06-01 00:22:45.296416|2018-06-01 00:22:45.296416
NCT01013792|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2015-03-02||2015-03-16|2009-11-13|2009-11-16|Estimate|2015-03-16|2015-03-23|Estimate||||2015-03-16|2015-03-23|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All subjects had diabetic foot ulcers between 1.0cm2 and 25.0cm2 at randomization|A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers|A Multi-centered, Prospective, Randomized, Double-blinded, Comparison of an Investigational Non-adherent Dressing to 3M Tegaderm Matrix Dressing With PHI Technology in the Management of Non-healing Diabetic Foot Ulcers|Terminated||N/A|30|Actual|3M|Early termination leading to small numbers of subjects analyzed|2||Expired study materials; low subject recruitment|f||||f||||||||||2018-06-01 00:22:45.508542|2018-06-01 00:22:45.508542
NCT01013779|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2017-07-10|2009-11-13|2009-11-16|Estimate|||||||2017-07-10|2017-07-12|Actual|December 2009||2009-12-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|MP3||Merkel Positron Emission Tomography (PET) Protocol|A Phase II Efficacy Study of Chemo-Radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin|Active, not recruiting||Phase 2|43|Actual|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||t||||||||||2018-06-01 00:22:45.844249|2018-06-01 00:22:45.844249
NCT01013766|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-06-19|2009-11-12|2009-11-16|Estimate|||||||2017-06-19|2017-06-20|Actual|August 13, 2009|Actual|2009-08-13|June 2017|2017-06-30|November 20, 2009|Actual|2009-11-20|November 20, 2009|Actual|2009-11-20||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics|A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|23|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:22:45.961095|2018-06-01 00:22:45.961095
NCT01013753|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2014-03-28||2014-06-17|2009-11-13|2009-11-16|Estimate|2014-05-29|2014-06-05|Estimate||||2014-06-17|2014-06-27|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.|A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation Solution Delivered by the Respimat® in Patients With Asthma|Completed||Phase 2|198|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-06-01 00:22:46.196482|2018-06-01 00:22:46.196482
NCT01013740|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2013-02-28||2017-03-30|2009-11-12|2009-11-16|Estimate|2013-05-09|2013-07-18|Estimate||||2017-03-30|2017-05-31|Actual|November 25, 2009|Actual|2009-11-25|March 2017|2017-03-31|March 1, 2016|Actual|2016-03-01|August 21, 2012|Actual|2012-08-21||Interventional|VITAL||Lapatinib in Combination With Vinorelbine|A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination With Vinorelbine or Capecitabine in Women With ErbB2 Overexpressing Metastatic Breast Cancer|Completed||Phase 2|112|Actual|Novartis||2|||f||||f||||||||||2018-06-01 00:22:47.987405|2018-06-01 00:22:47.987405
NCT01013727|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2010-04-28|2009-11-13|2009-11-16|Estimate|||||||2010-04-28|2010-04-29|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Functional Neuroimaging of Postural Reconstruction|Functional Neuroimaging of Postural Reconstruction: Preliminary Study on a Dorsiflexion Motion of the Ankle and Comparison Between an Arm Following Postural Reconstruction Program and a Comparator Arm Following a Muscular Stretching Program|Completed||N/A|16|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 00:22:48.817122|2018-06-01 00:22:48.817122
NCT01013545|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2013-07-10|2009-11-12|2009-11-13|Estimate|||||||2013-07-10|2013-07-11|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|CCNIA||Developmental and Augmented Intervention for Facilitating Expressive Language|Developmental and Augmented Intervention for Facilitating Expressive Language|Completed||N/A|96|Anticipated|Autism Speaks||2|||f||||f||||||||||2018-06-01 00:22:54.438235|2018-06-01 00:22:54.438235
NCT01013714|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2017-10-26|2009-11-13|2009-11-16|Estimate|||||||2017-10-26|2017-10-30|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|PREVENT VT||Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias|Prophylactic Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias (PREVENT VT)|Not yet recruiting||Phase 3|100|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||||2018-06-01 00:22:48.900358|2018-06-01 00:22:48.900358
NCT01013701|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|2017-07-17||2017-08-15|2009-11-13|2009-11-16|Estimate|2017-08-15|2017-09-13|Actual||||2017-08-15|2017-09-13|Actual|November 2009|Actual|2009-11-30|August 2017|2017-08-31|July 29, 2010|Actual|2010-07-29|July 29, 2010|Actual|2010-07-29||Interventional||The PI has left the institution and neither he, nor the data if any, is available. All information provided has been obtained from the Johns Hopkins University School of Medicine Institutional Review Board and was only available as one arm.|Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Center Study to Compare the Effects of Fluticasone Furoate Nasal Spray vs Placebo in Patients With Nasal Polypoid Disease|Terminated||Phase 4|7|Actual|Johns Hopkins University||2||Terminated based on mutual agreement between PI and sponsor (Glaxo Smith Kline)|f||||t||||||||||2018-06-01 00:22:49.068858|2018-06-01 00:22:49.068858
NCT01013688|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2009-11-16|2009-11-13|2009-11-16|Estimate|||||||2009-11-16|2009-11-18|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|May 2010|Anticipated|2010-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease|Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease|Unknown status|Recruiting|Phase 3|150|Anticipated|China National Center for Cardiovascular Diseases||3|||f||||t||||||||||2018-06-01 00:22:49.250449|2018-06-01 00:22:49.250449
NCT01013675|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2011-10-26|2009-11-13|2009-11-16|Estimate|||||||2011-10-26|2011-10-27|Estimate|November 2009||2009-11-30|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly|Randomized, Double-blind, Active -Controlled Trial to Assess Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine, Including Revaccination, in Elderly Subjects|Completed||Phase 2|622|Actual|Abbott||2|||f||||f||||||||||2018-06-01 00:22:49.350954|2018-06-01 00:22:49.350954
NCT01013662|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2011-08-02|2009-11-13|2009-11-16|Estimate|||||||2011-08-02|2011-08-04|Estimate|January 2005||2005-01-31|November 2009|2009-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Lipid Profile in Patients With Severe Sepsis or Septic Shock Under Strict or Liberal Glycemic Control|Tight Glycemic Control and Sepsis Related Dyslipidemia|Completed||N/A|69|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:22:49.475153|2018-06-01 00:22:49.475153
NCT01013649|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-13|||2018-05-25|2009-11-13|2009-11-16|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 17, 2009|Actual|2009-11-17|May 2018|2018-05-31||||August 31, 2020|Anticipated|2020-08-31||Interventional|||Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery|A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma|Recruiting||Phase 3|545|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-06-01 00:22:49.726174|2018-06-01 00:22:49.726174
NCT01013636|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2011-08-29|2009-11-13|2009-11-16|Estimate|||||||2011-08-29|2011-08-30|Estimate|November 2009||2009-11-30|August 2011|2011-08-31||||April 2012|Anticipated|2012-04-30||Observational|||Human Anaplasmosis in Eastern France|Epidemiology and Clinical Presentation of Human Anaplasmosis in Eastern France|Unknown status|Recruiting||300|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 00:22:52.415093|2018-06-01 00:22:52.415093
NCT01013623|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-09-24|2009-11-13|2009-11-16|Estimate|||||||2012-09-24|2012-09-26|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|STG4SURG||Stage IV Surgery Versus Best Medical Therapy|A Phase III, Randomized Trial of Surgical Resection With or Without BCG Versus Best Medical Therapy as Initial Treatment in Stage IV Melanoma|Terminated||Phase 3|12|Actual|John Wayne Cancer Institute||3||Lack of accrual, lack of continued funding.|f||||t||||||||||2018-06-01 00:22:53.379316|2018-06-01 00:22:53.379316
NCT01013610|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2011-03-14|2009-11-13|2009-11-16|Estimate|||||||2011-03-14|2011-03-15|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease|A Double-Blind, Randomized, Placebo-Controlled, Multiple, Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease|Completed||Phase 1|110|Anticipated|Link Medicine Corporation||2|||f||||t||||||||||2018-06-01 00:22:53.478196|2018-06-01 00:22:53.478196
NCT01013597|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2016-04-28||2017-03-06|2009-11-12|2009-11-13|Estimate|2016-05-31|2016-07-11|Estimate||||2017-03-06|2017-04-04|Actual|January 2010||2010-01-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|August 2013|Actual|2013-08-31||Interventional|||Trial of LBH589 in Metastatic Thyroid Cancer|A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer|Completed||Phase 2|13|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 00:22:53.572518|2018-06-01 00:22:53.572518
NCT01013584|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-06-25|2009-11-12|2009-11-13|Estimate|||||||2012-06-25|2012-06-26|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|Weight||The Effect of Weight on Vitamin D Dose Response|The Effect of Weight on Vitamin D Dose Response|Completed||N/A|67|Actual|Creighton University||3|||f||||f||||||||||2018-06-01 00:22:54.040694|2018-06-01 00:22:54.040694
NCT01013571|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-03-20|2009-11-12|2009-11-13|Estimate|||||||2012-03-20|2012-03-21|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Self Titration With Apidra to Reach Target Study (START)|A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insulin Glulisine at Breakfast Following Optimization of Insulin Glargine|Completed||Phase 4|493|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:22:54.232688|2018-06-01 00:22:54.232688
NCT01013558|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-12-07|2009-11-12|2009-11-13|Estimate|||||||2009-12-07|2009-12-08|Estimate|September 2004||2004-09-30|November 2009|2009-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|NO PAIN||New Options for Preoperative Anesthesia in Intrauterine Needling|NO PAIN: New Options for Preoperative Anesthesia in Intrauterine Needling|Completed||Phase 1|50|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-06-01 00:22:54.330793|2018-06-01 00:22:54.330793
NCT01013532|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2015-12-23|2009-11-12|2009-11-13|Estimate|||||||2015-12-23|2015-12-24|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|PICASSO||PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage|A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events|Unknown status|Active, not recruiting|Phase 4|1600|Anticipated|Asan Medical Center||4|||f||||t||||||||||2018-06-01 00:22:54.550015|2018-06-01 00:22:54.550015
NCT01013506|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2013-05-22|2009-11-12|2009-11-13|Estimate|||||||2013-05-22|2013-05-23|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer|A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) With or Without Erlotinib (Tarceva, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer.|Withdrawn||Phase 2|0|Actual|Vanderbilt-Ingram Cancer Center||2||Study was abandoned before opening to accrual. Replaced by another study.|f||||t||||||||||2018-06-01 00:22:54.821126|2018-06-01 00:22:54.821126
NCT01013493|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-12-01|2009-11-12|2009-11-13|Estimate|||||||2009-12-01|2009-12-02|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Observational|||Association Between Breastfeeding and Likelihood of Myopia in 6-7 Years Old Children|Association Between Breastfeeding and Likelihood of Myopia in 6-7 Years Old Children|Completed|||245|Actual|National Nutrition and Food Technology Institute|||2||f||||t||||||||||2018-06-01 00:22:54.963542|2018-06-01 00:22:54.963542
NCT01013480|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-12-19|2009-11-12|2009-11-13|Estimate|||||||2012-12-19|2012-12-20|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome|An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Fragile X Syndrome|Terminated||Phase 2|45|Actual|Seaside Therapeutics, Inc.||1||all active subjects rolled into 209FX303/NCT01013480|f||||f||||||||||2018-06-01 00:22:55.061881|2018-06-01 00:22:55.061881
NCT01013467|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2013-12-10|2009-11-12|2009-11-13|Estimate|||||||2013-12-10|2013-12-11|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|CoCo||CoCo: Colour Coded Blood Pressure Control|Does a Colour-coded Blood Pressure Diary Improve Blood Pressure Control for Patients in General Practice? A Randomised Controlled Study|Completed||N/A|121|Actual|University of Zurich||1|||f||||||||||||||2018-06-01 00:22:55.174326|2018-06-01 00:22:55.174326
NCT01013454|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2009-12-18|2009-11-11|2009-11-13|Estimate|||||||2009-12-18|2009-12-21|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Patch Applied To The Skin|A Phase 1, Open-Label, Single Dose Study To Characterize The Pharmacokinetics Of A Varenicline (CP-526,555) Transdermal Delivery System Applied To The Skin Of Adult Smokers|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:22:55.252794|2018-06-01 00:22:55.252794
NCT01013441|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2016-09-06|2009-11-11|2009-11-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia|Trial of Immune Reconstitution With CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|University of Pennsylvania|||||f||||f||||||||||2018-06-01 00:22:55.341174|2018-06-01 00:22:55.341174
NCT01013428|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2016-03-29|2009-11-12|2009-11-13|Estimate|||||||2016-03-29|2016-03-30|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||FLEX-Trial: Prospective Sonographic Assessment Of Healing Process Following Suture of Profound Flexor Tendon Due to Traumatic Rupture of FDP-Tendon in Zone II.||Completed|||50|Actual|University of Zurich|||||f||||||||||||||2018-06-01 00:22:55.457583|2018-06-01 00:22:55.457583
NCT01013415|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-07-05|2009-11-12|2009-11-13|Estimate|||||||2017-07-05|2017-07-11|Actual|September 2001||2001-09-30|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|CD4-ZETA||CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients|A Phase I/II Study Of the Safety, Survival, and Trafficking of Autologous CD4-ZETA Gene-Modified T Cells With and Without Extension Interleukin-2 in HIV Infected Patients|Active, not recruiting||Phase 1|17|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 00:22:55.523978|2018-06-01 00:22:55.523978
NCT01013402|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia|Phase IV Study to Compare the Accuracy and Precission of Five Different Home Glucose Monitors;Optium Xceed, Contour Ts, Accu-chek Go, One Touch Select and Ez Smart|Completed||Phase 4|51|Actual|Gulhane School of Medicine||1|||f||||f||||||||||2018-06-01 00:22:55.674504|2018-06-01 00:22:55.674504
NCT01013389|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2017-04-04|2009-11-12|2009-11-13|Estimate|||||||2017-04-04|2017-04-05|Actual|June 2007||2007-06-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|APPRAISET1||Actifuse ABX Versus INFUSE in Posterolateral Instrumented Lumbar Fusion (PLIF) With Interbody Fusion|A Prospective, Randomised Study Comparing the Use of Actifuse (Trademark)ABX Synthetic Bone Substitute With INFUSE (Registrered Trademark) in Patients Requiring Posterolateral Instrumented Lumbar Fusion With Interbody Fusion|Completed||N/A|20|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-06-01 00:22:55.754972|2018-06-01 00:22:55.754972
NCT01013376|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD|A Pilot, Single-Center, Open-Label Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Non-exudative Age-Related Macular Degeneration|Completed||Phase 1|31|Actual|MacuCLEAR, Inc.||2|||f||||f||||||||||2018-06-01 00:22:55.842228|2018-06-01 00:22:55.842228
NCT01013363|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2012-11-16|2009-11-11|2009-11-13|Estimate|||||||2012-11-16|2012-11-19|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Use of Music for Pain and Anxiety Control During Abortion|Music as an Auxiliary Analgesic and Anxiolytic During First Trimester Abortion|Completed||N/A|106|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 00:22:55.924717|2018-06-01 00:22:55.924717
NCT01013350|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2018-04-11|2009-11-12|2009-11-13|Estimate|||||||2018-04-11|2018-04-12|Actual|November 30, 2009|Actual|2009-11-30|March 2018|2018-03-31|October 26, 2018|Anticipated|2018-10-26|July 10, 2017|Actual|2017-07-10||Observational|PREMIERE||Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials|Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials|Active, not recruiting|||1183|Actual|EMD Serono|||1||f||||f||||||||||2018-06-01 00:22:56.010114|2018-06-01 00:22:56.010114
NCT01013337|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2017-07-31|2009-11-12|2009-11-13|Estimate|||||||2017-07-31|2017-08-02|Actual|May 2009||2009-05-31|July 2017|2017-07-31||||October 2012|Actual|2012-10-31||Interventional|||Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain|Acupuncture and Aromatase Inhibitor Related Arthralgia|Active, not recruiting||Phase 2|75|Anticipated|Abramson Cancer Center of the University of Pennsylvania||3|||f||||t||||||||||2018-06-01 00:22:56.088003|2018-06-01 00:22:56.088003
NCT01013324|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10||2016-05-09|2016-05-09|2009-11-10|2009-11-13|Estimate||||2016-05-09|2016-06-03|Estimate|2016-05-09|2016-06-03|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma|A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma|Completed||Phase 2|67|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 00:22:56.190503|2018-06-01 00:22:56.190503
NCT01013311|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2017-08-23|2009-11-12|2009-11-13|Estimate|||||||2017-08-23|2017-08-24|Actual|November 2009||2009-11-30|August 2017|2017-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Implantable Cardiac Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis|Efficacy if Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis|Completed|||10|Actual|Virginia Commonwealth University|||1||f||||f||||||||||2018-06-01 00:22:56.283311|2018-06-01 00:22:56.283311
NCT01013298|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|August 2010|Anticipated|2010-08-31|June 2010|Anticipated|2010-06-30||Interventional|||Video-guided Percutaneous Tracheostomy (PCT): A Feasibility Study|Video-guided Percutaneous Tracheostomy (PCT): Evaluating the Safety, Efficacy and Simplicity of a Novel Technique|Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-06-01 00:22:56.368637|2018-06-01 00:22:56.368637
NCT01013285|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2016-01-19|2009-11-11|2009-11-13|Estimate|||||||2016-01-19|2016-01-21|Estimate|June 2006||2006-06-30|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|October 2013|Actual|2013-10-31||Interventional|||Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:22:56.471385|2018-06-01 00:22:56.471385
NCT01013272|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2015-11-30|2009-11-12|2009-11-13|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2007||2007-06-30|November 2015|2015-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load|Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load|Completed||N/A|50|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:22:56.581062|2018-06-01 00:22:56.581062
NCT01013259|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|February 2009||2009-02-28|November 2009|2009-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|Ecorhino||Immunomodulation of E.Coli Nissle 1917 in Patients With Grass Pollen Rhinoconjunctivitis|Explorative Analysis of the Immunomodulatory Capacities of Apathogenic Escherichia Coli Nissle 1917 in Patients With Rhinoconjunctivitis Due to Grass Pollen Allergy|Completed||Phase 2|34|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:22:56.674612|2018-06-01 00:22:56.674612
NCT01013246|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2011-08-09|2009-11-12|2009-11-13|Estimate|||||||2011-08-09|2011-08-10|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Effects of Playing Video Games on Energy Balance|Effects of Playing Video Games on Energy Balance: a Randomized, 2-condition, Crossover Study in Adolescents|Completed||N/A|22|Actual|University of Copenhagen||1|||f||||f||||||||||2018-06-01 00:22:56.748065|2018-06-01 00:22:56.748065
NCT01013233|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|KT||Cognitive Training to Improve Cognitive Function Following Chemotherapy|Training of Cognitive Function of Patients After Chemotherapy|Unknown status|Not yet recruiting|N/A|20|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:22:56.806957|2018-06-01 00:22:56.806957
NCT01013220|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2014-12-15|2009-11-12|2009-11-13|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|DMW||Depression Management at the Workplace|Influencing Employer Purchasing Behavior|Completed||N/A|293|Actual|Florida State University||2|||f||||f||||||||||2018-06-01 00:22:56.891647|2018-06-01 00:22:56.891647
NCT01013207|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2010-07-12||2010-09-01|2009-11-11|2009-11-13|Estimate|2010-08-12|2010-09-01|Estimate||||2010-09-01|2010-09-08|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Nexus Compliance Study|Assessment of the Compliance and Usability of the Nexus (S9) CPAP System in Sleep Disordered Breathing|Completed||N/A|50|Actual|ResMed||1|||f||||f||||||||||2018-06-01 00:22:56.968946|2018-06-01 00:22:56.968946
NCT01013194|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2014-10-29||2015-10-02|2009-11-12|2009-11-13|Estimate|2015-10-02|2015-11-03|Estimate||||2015-10-02|2015-11-03|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|hFLCTx||Human Fetal Liver Cell Transplantation in Chronic Liver Failure|Human Fetal Liver Cell Transplantation for Treatment of Chronic Liver Failure|Completed||Phase 1/Phase 2|25|Actual|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|Using a single gynecology unit we had only a 22% rate of fetal donation, necessarily limiting the availability of hFLCs. Our strict inclusion criteria limited the pool of potential patients to enroll.|2|||f||||t||||||||||2018-06-01 00:22:57.130244|2018-06-01 00:22:57.130244
NCT01013181|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-16|2009-11-12|2009-11-13|Estimate|||||||2009-11-16|2009-11-17|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|July 2008|Actual|2008-07-31||Observational|ATU-r||"Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the  Real-life  : Result of the French Experience in 72 Adults"||Completed|||100|Actual|Henri Mondor University Hospital|||||f||||t||||||||||2018-06-01 00:22:57.441501|2018-06-01 00:22:57.441501
NCT01013168|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2011-07-21|2009-11-11|2009-11-13|Estimate|||||||2011-07-21|2011-07-22|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|April 2010|Actual|2010-04-30||Interventional|BP-005||Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities|Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities|Terminated||Phase 1/Phase 2|4|Actual|BioPheresis GmbH||1||Achievement of feasibility and safety without achievement of clinical response.|f||||t||||||||||2018-06-01 00:22:57.573973|2018-06-01 00:22:57.573973
NCT01013155|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2018-01-19|2009-11-12|2009-11-13|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2007||2007-05-31|January 2018|2018-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fed Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:22:57.660801|2018-06-01 00:22:57.660801
NCT01013142|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2015-05-12|2009-11-12|2009-11-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase I Randomized, Double-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously to Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|48|Actual|MediciNova||2|||f||||f||||||||||2018-06-01 00:22:57.725998|2018-06-01 00:22:57.725998
NCT01013129|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2013-02-21|2009-11-11|2009-11-13|Estimate|||||||2013-02-21|2013-02-22|Estimate|July 2008||2008-07-31|February 2013|2013-02-28||||December 2012|Actual|2012-12-31||Observational|||Studying Genes, Environment, and Prostate Cancer Risk in Patients With or Without Prostate Cancer and Their First-Degree Relatives|Genetic Susceptibility, Environment & Prostate Cancer Risk|Unknown status|Active, not recruiting||2250|Anticipated|Portland VA Medical Center|||||f||||f||||||Samples With DNA|"~     10ml blood specimen drawn from probands consented in person at the Portland VA; saliva~     samples from all consented probands; saliva samples from first degree relatives~   "|||2018-06-01 00:22:57.812744|2018-06-01 00:22:57.812744
NCT01013116|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2015-11-02|2009-11-12|2009-11-13|Estimate|||||||2015-11-02|2015-11-03|Estimate|April 2016||2016-04-30|November 2015|2015-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites|A Double-blind Placebo-controlled Trial to Evaluate Efficacy and Safety of Specific Subcutaneous Immunotherapy in Patients With Perennial Allergic Rhinitis Due to House Dust Mites|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Roxall Medizin||2|||f||||||||||||||2018-06-01 00:22:57.899075|2018-06-01 00:22:57.899075
NCT01013103|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2012-03-16|2009-11-12|2009-11-13|Estimate|||||||2012-03-16|2012-03-19|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients|Effects of Atorvastatin on Endothelial Function, Vascular and Myocardial Redox State in High Cardiovascular Risk Patients|Completed||Phase 4|72|Actual|Hippocration General Hospital||2|||f||||f||||||||||2018-06-01 00:22:58.008461|2018-06-01 00:22:58.008461
NCT01013090|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-12-22|2009-11-12|2009-11-13|Estimate|||||||2009-12-22|2009-12-23|Estimate|July 2009||2009-07-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|VOHOCUNA||Fluid Volume-hypotension Association in Cesarean Under Neuraxial Anesthesia|Fluid Volume-hypotension Association in Elective Cesarean Section Under Neuraxial Anesthesia|Completed||N/A|1000|Actual|Nanjing Medical University||6|||f||||t||||||||||2018-06-01 00:22:58.105061|2018-06-01 00:22:58.105061
NCT01013077|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2012-06-29|2009-11-12|2009-11-13|Estimate|||||||2012-06-29|2012-07-03|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability|The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability.|Completed||N/A|20|Actual|Southern California College of Optometry||3|||f||||f||||||||||2018-06-01 00:22:58.201375|2018-06-01 00:22:58.201375
NCT01013064|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2014-02-06|2009-11-12|2009-11-13|Estimate|||||||2014-02-06|2014-02-07|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects|A Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics and Pharmacokinetics of Single Intravenous Doses of HM10760A in Healthy Adult Korean Subjects|Completed||Phase 1|48|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||t||||||||||2018-06-01 00:22:58.293637|2018-06-01 00:22:58.293637
NCT01013051|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2011-03-02|2009-11-12|2009-11-13|Estimate|||||||2011-03-02|2011-03-03|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|December 2010|Actual|2010-12-31|||||Observational|ABSORB-Met||Effect of Gastric Bypass on the Absorption of Metformin|Effect of Gastric Bypass on the Absorption of Metformin|Completed|||34|Anticipated|University of Alberta|||2||f||||f||||||||||2018-06-01 00:22:58.37715|2018-06-01 00:22:58.37715
NCT01013038|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|December 2007||2007-12-31|November 2009|2009-11-30|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Interventional|TAPAS II||Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study|Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II)|Unknown status|Recruiting|Phase 4|540|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 00:22:58.441071|2018-06-01 00:22:58.441071
NCT01013025|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2011-07-13|2009-11-12|2009-11-13|Estimate|||||||2011-07-13|2011-07-14|Estimate|July 2006||2006-07-31|July 2011|2011-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Vantas Implant Retrieval Study|Phave IV, Multicenter, Open-label Study to Collect VANTAS® Implant Retrieval Data From Patients With Advanced Prostate Cancer and Difficult to Remove Implants|Completed|||12|Actual|Endo Pharmaceuticals|||1||f||||f||||||||||2018-06-01 00:22:58.521164|2018-06-01 00:22:58.521164
NCT01013012|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-02-02|2009-11-12|2009-11-13|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy of Dexamethasone Added to Ramosetron for Preventing Postoperative Nausea and Vomiting in Highly Susceptible Patients Following Spine Surgery||Completed||Phase 4|94|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 00:22:58.579482|2018-06-01 00:22:58.579482
NCT01012830|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|December 2009||2009-12-31|November 2009|2009-11-30|April 2011|Anticipated|2011-04-30|December 2010|Anticipated|2010-12-31||Interventional|||Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia|Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia|Unknown status|Not yet recruiting|Phase 4|15|Anticipated|VA Nebraska Western Iowa Health Care System||1|||f||||f||||||||||2018-06-01 00:23:01.223435|2018-06-01 00:23:01.223435
NCT01012999|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2013-07-04||2017-06-21|2009-11-12|2009-11-13|Estimate|2017-06-21|2017-06-22|Actual||||2017-06-21|2017-06-22|Actual|November 2009||2009-11-30|June 2017|2017-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||"Patients with a suspected acute bony injury to an extremity and in moderate to severe pain.~Intranasal administration, 0.5-0.9 mcg/kg, maximum dosage of 100 mcg"|A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain|Pain Control and Patient Satisfaction: a Dosing Study to Determine a Safe and Effective Dose of Intra-nasal Sufentanil to Treat Emergency Department Patients With Moderate to Severe Pain Due to Extremity Trauma|Terminated||Phase 1/Phase 2|16|Actual|University of Utah|A single episode of transient, mild hypoxia that resolved with 2 L nasal canula oxygen and that completely resolved after 20 minutes and no longer required oxygen|1||Difficulty enrolling patients|f||||f||||||||No||2018-06-01 00:22:58.645632|2018-06-01 00:22:58.645632
NCT01012986|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate||||November 2009|2009-11-30||||||||Observational|||"Reading Subtitles Skills in the Elementary School"|"Reading Subtitles Skills in the Elementary School"|Completed|||60|Actual|University of Sao Paulo|||2||f||||t||||||||||2018-06-01 00:22:58.786752|2018-06-01 00:22:58.786752
NCT01012973|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2012-10-23|2012-01-26|2014-10-27|2009-11-12|2009-11-13|Estimate|2012-10-23|2012-11-22|Estimate|2012-01-26|2012-01-30|Estimate|2014-10-27|2014-11-03|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|GALILEO||Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)|A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)|Completed||Phase 3|177|Actual|Bayer||2|||f||||t||||||||||2018-06-01 00:22:58.884914|2018-06-01 00:22:58.884914
NCT01012960|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2011-12-08|2009-11-12|2009-11-13|Estimate|||||||2011-12-08|2011-12-09|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Opioids and Esophageal Function|Is the Opioid-induced Pharyngeal and Esophageal Dysfunction Peripherally or Central Mediated?|Completed||Phase 4|13|Actual|Region Örebro County||2|||f||||t||||||||||2018-06-01 00:22:59.695797|2018-06-01 00:22:59.695797
NCT01012947|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2011-08-18||2012-01-19|2009-11-12|2009-11-13|Estimate|2012-01-19|2012-02-24|Estimate||||2012-01-19|2012-02-24|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Cognitive Health Promotion Project in the Community|Cognitive Health Promotion Project in the Community|Completed||Phase 1|1115|Actual|Ajou University School of Medicine||5|||f||||t||||||||||2018-06-01 00:22:59.814153|2018-06-01 00:22:59.814153
NCT01012934|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|July 2002||2002-07-31|November 2009|2009-11-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)|Single-Dose Fasting In Vivo Bioequivalence Study of Alendronate Sodium Tablets (70 mg; Mylan) and Fosamax Tablets (70 mg; Merck) in Healthy Volunteers|Completed||Phase 1|110|Actual|Mylan Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:23:00.223522|2018-06-01 00:23:00.223522
NCT01012921|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2016-12-21||2017-05-29|2009-11-11|2009-11-13|Estimate|2017-05-29|2018-01-02|Actual||||2017-05-29|2018-01-02|Actual|September 2009||2009-09-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|October 2011|Actual|2011-10-31||Interventional||Analysis population is PP|Comparison of a PEG Membrane and a Collagen Membrane for the Treatment of Bone Dehiscence Defects at Bone Level Implants|Straumann® MembraGel Comparison of a PEG Membrane and a Collagen Membrane for the Treatment of Bone Dehiscence Defects at Bone Level Implants|Completed||N/A|117|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:23:00.309204|2018-06-01 00:23:00.309204
NCT01012908|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2010-10-26|2009-11-12|2009-11-13|Estimate|||||||2010-10-26|2010-10-28|Estimate|March 2010||2010-03-31|November 2009|2009-11-30|June 2011|Anticipated|2011-06-30|April 2010|Anticipated|2010-04-30||Interventional|||Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency||Unknown status|Active, not recruiting|Phase 2/Phase 3|25|Anticipated|Azidus Brasil||2|||f||||t||||||||||2018-06-01 00:23:00.65556|2018-06-01 00:23:00.65556
NCT01012895|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12||2015-09-23|2015-09-23|2009-11-12|2009-11-13|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|October 2012|Actual|2012-10-31||Interventional|||Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care|Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected With Chronic Hepatitis C Virus Genotype 1|Completed||Phase 2|215|Actual|Bristol-Myers Squibb||7|||f||||f||||||||||2018-06-01 00:23:00.741806|2018-06-01 00:23:00.741806
NCT01012882|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2015-11-02|2009-11-12|2009-11-13|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2016||2016-11-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Efficacy and Safety of Sublingual Immunotherapy (SLIT)|A Multicenter Randomized DBPC Trial to Evaluate Efficacy and Safety of Sublingual Immunotherapy (SLIT) With Allergen Extracts From Pollen in Patients With Seasonal Allergic Rhinitis|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Roxall Medizin||2|||f||||||||||||||2018-06-01 00:23:00.875835|2018-06-01 00:23:00.875835
NCT01012869|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2013-10-28|2009-11-12|2009-11-13|Estimate|||||||2013-10-28|2013-10-29|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ACE-CTO||AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study|AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study|Completed||Phase 4|100|Anticipated|North Texas Veterans Healthcare System||1|||f||||t||||||||||2018-06-01 00:23:00.96024|2018-06-01 00:23:00.96024
NCT01012856|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2012-10-30|2009-11-11|2009-11-13|Estimate|||||||2012-10-30|2012-10-31|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Randomized Clinical Trial of an Exposure-based Cognitive Therapy for Depression|Explicit and Implicit Change of Depression in Exposure-based Cognitive Therapy|Unknown status|Active, not recruiting|Phase 2|142|Anticipated|University of Zurich||2|||f||||f||||||||||2018-06-01 00:23:01.035429|2018-06-01 00:23:01.035429
NCT01012843|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-13|2009-11-12|2009-11-13|Estimate|||||||2009-11-13|2009-11-16|Estimate|September 2005||2005-09-30|November 2009|2009-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Do Antibiotics Prevent Anal Fistulae Formation?|Does Adjuvant Antibiotic Treatment After Drainage of Anorectal Abscess Prevent the Development of Anal Fistulae? A Prospective Randomized, Placebo Controlled, Double Blind, Multi-Center Clinical Study|Completed||N/A|151|Actual|Ankara University||2|||f||||f||||||||||2018-06-01 00:23:01.133489|2018-06-01 00:23:01.133489
NCT01012817|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2018-05-04|2009-11-11|2009-11-13|Estimate|||||||2018-05-04|2018-05-07|Actual|October 29, 2009|Actual|2009-10-29|April 2018|2018-04-30||||August 31, 2020|Anticipated|2020-08-31||Interventional|||Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer|A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy|Recruiting||Phase 1/Phase 2|102|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 00:23:01.323256|2018-06-01 00:23:01.323256
NCT01012804|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2011-03-23|2009-11-12|2009-11-13|Estimate|||||||2011-03-23|2011-03-24|Estimate|January 2000||2000-01-31|March 2011|2011-03-31||||||||Observational|||Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer|Assessment of Variation of PKA and Other Molecular Markers in Patients Undergoing Resection of Colon Cancer Metastases|Withdrawn|||0|Actual|Georgetown University|||||f||||f||||||||||2018-06-01 00:23:01.461588|2018-06-01 00:23:01.461588
NCT01012791|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2012-05-02|2009-11-12|2009-11-13|Estimate|||||||2012-05-02|2012-05-03|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Does Zumba Improve Cognition in Healthy APOE e4 Carriers and Noncarriers|Does Zumba Improve Cognition in Healthy APOE e4 Carriers and Noncarriers|Completed||N/A|65|Actual|Mayo Clinic||2|||f||||||||||||||2018-06-01 00:23:01.5265|2018-06-01 00:23:01.5265
NCT01012778|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2015-08-03|2009-11-12|2009-11-13|Estimate|||||||2015-08-03|2015-08-04|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ClimbUp||Implementation of Climb Up Program for Children With Attention Deficit Hyperactivity Disorder (ADHD) and Dyslexia in a School in India|Implementation of a Multimodal Program Including Yoga and Meditation as Well as Play Therapy for ADHD and Dyslexia in a Public School in Najibabad, India|Completed||Phase 1/Phase 2|76|Actual|Climb Up Kids||1|||f||||||||||||||2018-06-01 00:23:01.587032|2018-06-01 00:23:01.587032
NCT01012765|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2012-01-17||2016-02-16|2009-11-12|2009-11-13|Estimate|2012-01-17|2012-02-17|Estimate||||2016-02-16|2016-02-17|Estimate|November 2009||2009-11-30|February 2016|2016-02-29||||January 2011|Actual|2011-01-31||Interventional|||Effect of Indacaterol on Inspiratory Capacity (IC)|A Randomized, Double-blind, Placebo Controlled, Multicenter, 3-period Crossover Study to Compare the Effect of Indacaterol (150μg o.d.) on Inspiratory Capacity to Placebo in Patients With Moderate COPD, Using Open Label Tiotropium (18μg o.d.) as Active Control|Completed||Phase 3|173|Actual|Novartis||6|||f||||||||||||||2018-06-01 00:23:01.66964|2018-06-01 00:23:01.66964
NCT01012752|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2015-11-02|2009-11-12|2009-11-13|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2016||2016-10-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts|A Multicenter, Double-Blind, Placebo-Controlled Study With a Modified Allergen Extract for Specific Immunotherapy in Patients With Seasonal Allergic Rhinitis/Rhinoconjunctivitis|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|Roxall Medizin||2|||f||||||||||||||2018-06-01 00:23:02.053483|2018-06-01 00:23:02.053483
NCT01012739|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2011-07-22||2011-08-25|2009-11-12|2009-11-13|Estimate|2011-07-22|2011-08-17|Estimate||||2011-08-25|2011-08-29|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices|A Randomized, Partially-blinded, Single-dose, 4-way Cross-over Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Indacaterol Maleate Administered Via the Concept1 Device or Via the Simoon Device|Completed||Phase 2|35|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:23:02.128116|2018-06-01 00:23:02.128116
NCT01012726|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2014-12-03|2009-11-12|2009-11-13|Estimate|||||||2014-12-03|2014-12-04|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Study About the Effect of Doxycycline and Acetylcystein in the Treatment of CD-associated Fistulae|FIST-MC-09 Study About the Effect of Doxycycline and Acetylcystein in the Treatment of CD-associated Fistulae|Terminated||N/A|20|Anticipated|University of Zurich||||not enough patients enrolled|f||||||||||||||2018-06-01 00:23:02.452762|2018-06-01 00:23:02.452762
NCT01012713|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2015-05-28||2015-06-16|2009-11-12|2009-11-13|Estimate|2015-06-16|2015-06-18|Estimate||||2015-06-16|2015-06-18|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis|Pilot Open-Label Clinical Trial to Test Efficacy and Safety of Combination of Clobex® Spray With Excimer Laser Therapy [Photomedex XTRAC ® Velocity] in the Treatment of Generalized Plaque Psoriasis Followed by Maintenance With Topical Vectical® Ointment|Completed||Phase 4|30|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 00:23:02.511157|2018-06-01 00:23:02.511157
NCT01012700|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2014-03-27|2009-11-12|2009-11-13|Estimate|||||||2014-03-27|2014-03-28|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers|A Randomized, Placebo-controlled, Phase I Study to Evaluate the Safety and Immunogenicity of Poly ICLC (Hiltonol) in Healthy Volunteers|Completed||Phase 1|24|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 00:23:02.726799|2018-06-01 00:23:02.726799
NCT01012687|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2018-01-19|2009-11-12|2009-11-13|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2007||2007-04-30|January 2018|2018-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fasting Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:23:02.856083|2018-06-01 00:23:02.856083
NCT01012674|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2015-07-29|2012-11-09|2016-05-11|2009-11-12|2009-11-13|Estimate|2015-07-29|2015-08-25|Estimate|2012-11-09|2012-11-15|Estimate|2016-05-11|2016-06-16|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)|Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease|Completed||Phase 3|211|Actual|Guerbet||1|||f||||f||||||||||2018-06-01 00:23:02.918527|2018-06-01 00:23:02.918527
NCT01012661|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2009-12-03||2013-04-19|2009-11-12|2009-11-13|Estimate|2010-01-14|2010-01-15|Estimate||||2013-04-19|2013-04-26|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler|Evaluation of Pain With the Use of Lidocaine-Mixed Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds|Completed||Phase 4|50|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-06-01 00:23:03.228236|2018-06-01 00:23:03.228236
NCT01012622|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-04-30||2014-02-17|2009-11-12|2009-11-13|Estimate|2013-12-18|2014-02-06|Estimate||||2014-02-17|2014-03-14|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Safety Population included all participants who took at least one dose of study drug.|An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children With ADHD (FOSCO)|Completed||Phase 4|142|Actual|Janssen Korea, Ltd., Korea||1|||f||||f||||||||||2018-06-01 00:23:03.632178|2018-06-01 00:23:03.632178
NCT01012609|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2017-10-03|2009-11-12|2009-11-13|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2009||2009-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas|A Phase II Trial of External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas (POE08-01)|Active, not recruiting||Phase 2|51|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 00:23:04.121243|2018-06-01 00:23:04.121243
NCT01012596|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2013-05-13|2009-11-10|2009-11-13|Estimate|||||||2013-05-13|2013-05-15|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Observational|CEIBA||Creighton Model Effectiveness, Intentions and Behaviors Assessment (CEIBA)|Effectiveness, Intention, and Behavior in Creighton Model NFP Use|Completed|||624|Actual|University of Utah|||1||f||||f||||||||||2018-06-01 00:23:04.236076|2018-06-01 00:23:04.236076
NCT01012583|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|OCTOBER||Optical Coherence TomOgraphy Assessment of the Drug-Eluting Stent|Optical Coherence TomOgraphy Assessment of the Excel Drug-Eluting Stent With BiodegradablE polymeR vs. the Cypher Drug-Eluting Stent With Permanent Polymer|Unknown status|Not yet recruiting||1|Anticipated|Chinese PLA General Hospital|||||f||||||||||||||2018-06-01 00:23:04.339014|2018-06-01 00:23:04.339014
NCT01012570|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2014-12-03|2009-11-12|2009-11-13|Estimate|||||||2014-12-03|2014-12-04|Estimate|August 2009||2009-08-31|December 2014|2014-12-31||||August 2011|Actual|2011-08-31||Observational|||The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients||Terminated|||34|Actual|University of Zurich||||not enough patients enrolled|f||||||||||||||2018-06-01 00:23:04.393658|2018-06-01 00:23:04.393658
NCT01012557|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2015-02-04|2009-11-12|2009-11-13|Estimate|||||||2015-02-04|2015-02-05|Estimate|November 2009||2009-11-30|February 2015|2015-02-28|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women|H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza AH1N1v Vaccination in Pregnant Women|Completed||N/A|296|Actual|Copenhagen Studies on Asthma in Childhood||4|||f||||t||||||||||2018-06-01 00:23:04.451482|2018-06-01 00:23:04.451482
NCT01012544|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2011-08-22|2009-11-12|2009-11-13|Estimate|||||||2011-08-22|2011-08-23|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MAPCAT||Platelet Reactivity in Stent Thrombosis Patients|The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).|Completed||Phase 4|187|Actual|St. Antonius Hospital||2|||f||||f||||||||||2018-06-01 00:23:04.534704|2018-06-01 00:23:04.534704
NCT01012531|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2011-07-13|2009-11-12|2009-11-13|Estimate|||||||2011-07-13|2011-07-14|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen|Efficacy and Safety of Subcutaneous Cluster Immunotherapy With Cluster-allergoid CLUSTOID Grasses/Rye (Glutaraldehyde-polymerized Allergen Extract of Mixtures of Grass and Rye Allergens) in Patients With Allergic Rhinoconjunctivitis Sensitized to Grass and With or Without Rye Pollen Sensitization|Completed||Phase 3|121|Actual|Roxall Medizin||2|||f||||||||||||||2018-06-01 00:23:04.626526|2018-06-01 00:23:04.626526
NCT01012518|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|||Video-guided Percutaneous Tracheostomy (PCT) Versus Conventional PCT: Comparing Safety and Efficacy|Video-guided Percutaneous Tracheostomy (PCT): Evaluating the Safety, Efficacy and Simplicity of a Novel Technique, Compared to Conventional PCT|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:23:04.703632|2018-06-01 00:23:04.703632
NCT01012505|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|December 2009||2009-12-31|November 2009|2009-11-30||||||||Observational|||The Effect of Exposure to Maternal Human Milk Odor on Physiological State of Preterms.|The Effect of Exposure to Maternal Human Milk Odor on Physiological State of Preterms.|Unknown status|Not yet recruiting||20|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 00:23:04.791472|2018-06-01 00:23:04.791472
NCT01012492|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2015-11-25||2017-10-30|2009-11-12|2009-11-13|Estimate|2017-08-16|2017-09-15|Actual||||2017-10-30|2017-12-05|Actual|November 2009||2009-11-30|October 2017|2017-10-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant|Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant|Completed||Phase 2|11|Actual|Seattle Children's Hospital||1|||f||||t||||||||||2018-06-01 00:23:04.859559|2018-06-01 00:23:04.859559
NCT01012479|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2010-07-12|2009-11-12|2009-11-13|Estimate|||||||2010-07-12|2010-07-14|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension|Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension|Completed||Phase 4|107|Actual|Takeda||1|||f||||f||||||||||2018-06-01 00:23:05.041116|2018-06-01 00:23:05.041116
NCT01012466|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|June 2009||2009-06-30|November 2009|2009-11-30|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Observational|||The Physical Effects of Pain Catastrophizing in Labor|The Physical Effects of Pain Catastrophizing on Normal Labor|Unknown status|Recruiting||140|Anticipated|Oregon Health and Science University|||||f||||f||||||||||2018-06-01 00:23:05.139247|2018-06-01 00:23:05.139247
NCT01012453|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2009-11-12|2009-11-12|2009-11-13|Estimate|||||||2009-11-12|2009-11-13|Estimate|October 2009||2009-10-31|November 2009|2009-11-30||||October 2009|Actual|2009-10-31||Interventional|HET||A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema|Hand Eczema Trial: A Randomised Clinical Trial of the Effect of Classification and Individual Counselling Among Health Care Workers With Hand Eczema|Unknown status|Recruiting|N/A|300|Anticipated|Zealand University Hospital||1|||f||||f||||||||||2018-06-01 00:23:05.208097|2018-06-01 00:23:05.208097
NCT01012440|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2015-05-27||2015-06-29|2009-11-11|2009-11-13|Estimate|2015-06-29|2015-07-27|Estimate||||2015-06-29|2015-07-27|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|||Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer|Role of PEM Flex Solo II PET Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer|Terminated||N/A|5|Actual|University of Chicago||1||Poor accrual|f||||t||||||||||2018-06-01 00:23:05.287185|2018-06-01 00:23:05.287185
NCT01012427|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2016-01-04|2009-11-12|2009-11-13|Estimate|||||||2016-01-04|2016-01-05|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Percutaneous Renal Tumor Cryoablation Followed by Biopsy|Percutaneous Renal Tumor Cryoablation Followed by Biopsy|Completed||Phase 1|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:23:05.421203|2018-06-01 00:23:05.421203
NCT01012414|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2013-05-30||2014-05-13|2009-11-11|2009-11-13|Estimate|2013-09-05|2013-11-11|Estimate||||2014-05-13|2014-05-20|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|VINCA-CKD||Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease|The Effect of Vitamin D Supplementation on Markers of Inflammation in High-Risk Cardiovascular Patients With Low Levels of Serum 25-Hydroxyvitamin D|Terminated||Phase 3|10|Actual|Thomas Jefferson University|Early termination secondary to enrollment futility.|2||Futility in enrollment as of May 31, 2011|f||||f||||||||||2018-06-01 00:23:05.493415|2018-06-01 00:23:05.493415
NCT01012401|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2018-05-01|2009-11-12|2009-11-13|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2009||2009-11-30|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|May 2014|Actual|2014-05-31||Interventional|||Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer|Interactive Cancer Communication System (ICCS) in Lung Cancer: Evaluating Survival Benefits. Center of Excellence in Cancer Communication Research: Using Technology to Enhance Cancer Communication and Improve Clinical Outcomes|Active, not recruiting||N/A|284|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:23:05.686367|2018-06-01 00:23:05.686367
NCT01012388|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2009-11-19||2013-04-19|2009-11-12|2009-11-13|Estimate|2009-11-19|2009-12-23|Estimate||||2013-04-19|2013-04-26|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color|Post-Marketing Study of Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color|Completed||Phase 4|100|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-06-01 00:23:05.76625|2018-06-01 00:23:05.76625
NCT01012375|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2011-08-31|2009-11-12|2009-11-13|Estimate|||||||2011-08-31|2011-09-02|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.|A Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-Over Study to Assess the Efficacy, Safety ,Tolerability and Pharmacokinetics of Three Oral AZD1446 Dose Regimens and Placebo During 2 Weeks of Treatment in Adult Non-Users and Users of Nicotine Containing Products|Completed||Phase 2|135|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:23:06.019179|2018-06-01 00:23:06.019179
NCT01012362|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2017-04-11||2017-12-03|2009-11-12|2009-11-13|Estimate|2017-04-11|2017-06-26|Actual||||2017-12-03|2017-12-28|Actual|December 2009||2009-12-31|December 2017|2017-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of Pazopanib and Ixabepilone in Patients With Solid Tumors|Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors|Terminated||Phase 1|31|Actual|Masonic Cancer Center, University of Minnesota||2||PI left institution.|f||||t||||||||||2018-06-01 00:23:06.132367|2018-06-01 00:23:06.132367
NCT01012349|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2011-01-27|2009-11-12|2009-11-13|Estimate|||||||2011-01-27|2011-01-28|Estimate|February 2011||2011-02-28|October 2010|2010-10-31|August 2011|Anticipated|2011-08-31|May 2011|Anticipated|2011-05-31||Interventional|||Efficacy and Safety Clinical Trial of the Combination of Acetylsalicylic Acid, Sodium Bicarbonate and Citric Acid, Produced by Geolab Pharmaceutical Industries Ltd., Compared to Acetylsalicylic Acid (Aspirin ® - Bayer) in Patients With Episodic Tension-type Headache.||Unknown status|Not yet recruiting|Phase 2/Phase 3|152|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:23:07.003533|2018-06-01 00:23:07.003533
NCT01012336|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2012-08-29||2012-10-08|2009-11-12|2009-11-13|Estimate|2012-10-08|2012-10-10|Estimate||||2012-10-08|2012-10-10|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin|Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin|Completed||Phase 2|89|Actual|Samsung Medical Center||1|||f||||||||||||||2018-06-01 00:23:07.098743|2018-06-01 00:23:07.098743
NCT01012323|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2016-11-09||2017-02-08|2009-11-12|2009-11-13|Estimate|2017-02-08|2017-03-16|Actual||||2017-02-08|2017-03-16|Actual|January 2010||2010-01-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Total set: All enrolled participants.|A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases|Clinical Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases|Completed||Phase 3|51|Actual|Octapharma||1|||f||||t||||||||||2018-06-01 00:23:07.298533|2018-06-01 00:23:07.298533
NCT01012310|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2010-04-15|2009-11-12|2009-11-13|Estimate|||||||2010-04-15|2010-04-16|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects|A Double Blind, 3rd Party Open, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects|Completed||Phase 1|40|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:23:07.645545|2018-06-01 00:23:07.645545
NCT01011946|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2015-06-01||2015-06-16|2009-11-10|2009-11-11|Estimate|2015-06-16|2015-07-09|Estimate||||2015-06-16|2015-07-09|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|May 2012|Actual|2012-05-31|March 2011|Actual|2011-03-31||Interventional|||Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer|Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer|Completed||N/A|36|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 00:23:18.408077|2018-06-01 00:23:18.408077
NCT01012297|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|2017-01-26||2017-07-13|2009-11-12|2009-11-13|Estimate|2017-07-13|2017-07-14|Actual||||2017-07-13|2017-07-14|Actual|November 2009||2009-11-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma|A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus|Terminated||Phase 3|107|Actual|National Cancer Institute (NCI)|The study was targeted to accrue 130 patients, but closed early for futility. Early termination leading to small numbers of subjects analyzed.|2||The study was targeted to accrue 130 patients, but closed early for futility.|f||||||||||||||2018-06-01 00:23:07.827016|2018-06-01 00:23:07.827016
NCT01012284|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-12|||2012-12-19|2009-11-12|2009-11-13|Estimate|||||||2012-12-19|2012-12-20|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of TMC207 in Patients With Moderately Impaired Hepatic Function|Pharmacokinetics, Safety, and Tolerability of TMC207 in Subjects With Moderately Impaired Hepatic Function|Completed||Phase 1|16|Actual|Tibotec BVBA||2|||f||||f||||||||||2018-06-01 00:23:10.075428|2018-06-01 00:23:10.075428
NCT01012271|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|||2016-03-29|2009-11-12|2009-11-13|Estimate|||||||2016-03-29|2016-03-30|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Diagnostic Accuracy of Direct MR Arthrography Of The Wrist At 1.5, 3.0 And 7.0T||Completed|||70|Actual|University of Zurich|||||f||||||||||||||2018-06-01 00:23:10.160232|2018-06-01 00:23:10.160232
NCT01012258|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2012-07-05||2015-06-11|2009-11-12|2009-11-13|Estimate|2012-07-05|2012-08-14|Estimate||||2015-06-11|2015-07-09|Estimate|February 2009||2009-02-28|June 2015|2015-06-30|May 2014|Actual|2014-05-31|September 2010|Actual|2010-09-30||Interventional|CHANCE||Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects|Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects|Completed||Phase 3|70|Actual|Merck KGaA||1|||f||||f||||||||||2018-06-01 00:23:10.242972|2018-06-01 00:23:10.242972
NCT01012245|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-11|2009-12-11||2010-02-18|2009-11-11|2009-11-13|Estimate|2009-12-11|2010-01-21|Estimate||||2010-02-18|2010-02-23|Estimate|January 2000||2000-01-31|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|XCHANGE||Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom|"Project XCHANGE Non-Interventional Study"|Completed|||28812|Actual|Pfizer|Except at baseline, number of subjects analyzed in treatment groups do not necessarily summarize to “All subjects” total; subjects drop out of treatment group when therapy changes. “All subjects” shows all subjects irrespective of any therapy change.||1||f||||f||||||||||2018-06-01 00:23:10.700391|2018-06-01 00:23:10.700391
NCT01012232|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|June 2009||2009-06-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Local Anesthetic in Total Knee Arthroplasty (TKA): Volume Versus Concentration|The Volume-concentration Relationship of Analgesic Efficacy With Intra-capsular Local Anesthetic in Total Knee Arthroplasty: a Randomized, Double-blind, Cross-over Trial.|Completed||Phase 4|48|Actual|Lundbeck Foundation||2|||f||||f||||||||||2018-06-01 00:23:13.308089|2018-06-01 00:23:13.308089
NCT01012219|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2011-03-24||2015-10-30|2009-11-10|2009-11-11|Estimate|2011-03-24|2011-04-18|Estimate||||2015-10-30|2015-11-02|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)|A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 00:23:13.397315|2018-06-01 00:23:13.397315
NCT01012206|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2016-09-02|2009-11-10|2009-11-11|Estimate|||||||2016-09-02|2016-09-05|Estimate|August 2006||2006-08-31|September 2016|2016-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SELFH||Overweighed Children´s Health - Studies of the Effect of Lifestyle and Food Habits|Overweighed Children´s Health - Studies of the Effect of Lifestyle and Food Habits|Completed||N/A|105|Actual|Umeå University||2|||f||||f||||||||||2018-06-01 00:23:13.643831|2018-06-01 00:23:13.643831
NCT01012193|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2011-05-15|2009-11-10|2009-11-11|Estimate|||||||2011-05-15|2011-05-17|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|ACCEL-2C19||Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism|CYP 2C19 Polymorphism and Response to Adjunctive Cilostazol and High Maintenance-dose Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention|Completed||Phase 4|134|Actual|Gyeongsang National University Hospital||2|||f||||t||||||||||2018-06-01 00:23:13.73838|2018-06-01 00:23:13.73838
NCT01012180|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2018-04-04|2009-11-10|2009-11-11|Estimate|||||||2018-04-04|2018-04-05|Actual|October 23, 2009||2009-10-23|June 7, 2013|2013-06-07|June 7, 2013||2013-06-07|||||Observational|||Parents With Bipolar Disorder: Relationship of Adaptation to Own Illness With Risk Perception and Coping With Perceived Risk to a Child|Parents With Bipolar Disorder: Relationship of Adaptation to Own Illness With Risk Perception and Coping With Perceived Risk to a Child|Completed|||266|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:23:13.816868|2018-06-01 00:23:13.816868
NCT01012167|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2016-05-25||2017-05-02|2009-11-05|2009-11-11|Estimate|2017-05-02|2017-06-02|Actual||||2017-05-02|2017-06-02|Actual|February 2010||2010-02-28|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CIDAR-3|"Number of participants randomized N=58~Withdrawn prior to exposure to study drug (N=2) Oxytocin N=1 withdrawn due to abnormal EKG Placebo N=1 Participant withdrew consent~Exposed to study drug N=56"|Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia|Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia|Completed||Phase 2|86|Actual|University of Maryland||3|||f||||t||||||||||2018-06-01 00:23:14.030457|2018-06-01 00:23:14.030457
NCT01012154|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||In Vivo Confocal Microscopy Tumor Atlas Study|In Vivo Confocal Microscopy Tumor Atlas Study|Unknown status|Recruiting|Phase 1|150|Anticipated|Carl Zeiss Surgical GmbH||1|||f||||f||||||||||2018-06-01 00:23:16.477252|2018-06-01 00:23:16.477252
NCT01012141|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2013-04-09|2009-11-10|2009-11-11|Estimate|||||||2013-04-09|2013-04-10|Estimate|September 2009||2009-09-30|November 2009|2009-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PROTAXY||Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate Cancer|Pilot Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First Line Treatment of Hormone Independent Metastatic Prostate Cancer|Completed||Phase 2|30|Actual|Centre Jean Perrin|||||f||||f||||||||||2018-06-01 00:23:16.562314|2018-06-01 00:23:16.562314
NCT01012128|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2015-04-03|2009-11-10|2009-11-11|Estimate|||||||2015-04-03|2015-04-06|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2011|Anticipated|2011-12-31|January 2011|Anticipated|2011-01-31||Observational|||Comparison of Three Methods of Taking Temperatures in the Newborn Intensive Care Unit|Comparison of Temporal Artery, Axillary, and Rectal Temperatures in Preterm Infants in the NICU|Withdrawn|||0|Actual|Christiana Care Health Services||||Closed: logistical problems that could not be resolved.|f||||f||||||||||2018-06-01 00:23:16.629235|2018-06-01 00:23:16.629235
NCT01012115|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2012-04-05|2009-11-10|2009-11-11|Estimate|||||||2012-04-05|2012-04-09|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|Histone||Coagulation Factors, Cytokines and Tissue Injury Markers in Sepsis|Temporal Behavior of Coagulation Factors,Cytokines and Tissue Injury Markers in Sepsis: Validation of Extracellular Histones|Completed|||500|Actual|University of Oklahoma|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 00:23:16.685493|2018-06-01 00:23:16.685493
NCT01012102|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2014-02-19|2009-11-10|2009-11-11|Estimate|||||||2014-02-19|2014-02-20|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|October 2009|Actual|2009-10-31||Interventional|||EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors|An Open Label, Parallel Group, Randomized Phase I Study of Biological Activity, Safety, Tolerability, and Clinical Activity of Different Dose Levels of EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors|Completed||Phase 1|104|Actual|Merck KGaA||3|||f||||f||||||||||2018-06-01 00:23:16.773746|2018-06-01 00:23:16.773746
NCT01012089|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2014-12-02|2009-11-10|2009-11-11|Estimate|||||||2014-12-02|2014-12-04|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease|Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease|Completed||N/A|6|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 00:23:16.843076|2018-06-01 00:23:16.843076
NCT01012076|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2012-06-13|2009-11-10|2009-11-11|Estimate|||||||2012-06-13|2012-06-14|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Promoting Development in Toddlers With Communication Delays|Promoting Development in Toddlers With Communication Delays|Completed||N/A|60|Actual|Autism Speaks||2|||f||||f||||||||||2018-06-01 00:23:16.986983|2018-06-01 00:23:16.986983
NCT01012063|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2013-08-16|2009-11-10|2009-11-11|Estimate|||||||2013-08-16|2013-08-19|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|SNUBH||Perioperative Iron With Erythropoietin in Bilateral Total Knee Replacement Arthroplasty (TKRA)|Perioperative Intravenous Iron With Erythropoietin for the Prevention of Postoperative Severe Anemia and Reduction of Transfusion in Bilateral Total Knee Replacement Arthroplasty|Completed||N/A|54|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:23:17.074491|2018-06-01 00:23:17.074491
NCT01012050|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|June 2007||2007-06-30|November 2009|2009-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|NV||Radioaerosol Pulmonary Deposition During Asthma Exacerbation Through Noninvasive Ventilation|Analysing the Effects of Coupling Nebulization to Noninvasive Ventilation Through Pulmonary Scintigraphy on the Radioaerosol Deposition During Asthma Exacerbation|Completed||N/A|39|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-06-01 00:23:17.143806|2018-06-01 00:23:17.143806
NCT01012037|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2011-09-21||2014-06-17|2009-11-10|2009-11-11|Estimate|2011-09-21|2011-10-31|Estimate||||2014-06-17|2014-06-27|Estimate|November 2009||2009-11-30|December 2013|2013-12-31||||September 2010|Actual|2010-09-30||Interventional|||Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes|12 Week Randomised Double-blind BI 1356 2.5 mg Bid vs 5 mg qd add-on to Metformin|Completed||Phase 2|491|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 00:23:17.332807|2018-06-01 00:23:17.332807
NCT01012011|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2015-09-18|2009-11-10|2009-11-11|Estimate|||||||2015-09-18|2015-09-21|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Observational|||Regulatory Post Marketing Surveillance Study on Nexavar®|Regulatory Post Marketing Surveillance Study on Nexavar®|Completed|||2845|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 00:23:17.983078|2018-06-01 00:23:17.983078
NCT01011998|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-09-23|2009-11-10|2009-11-11|Estimate|||||||2011-09-23|2011-09-27|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)|A Phase II Study of Imatinib and Valproic Acid in Patients With CML|Withdrawn||Phase 2|0|Actual|New Mexico Cancer Care Alliance||||Withdrawn due to lack of accrual per Center DSMP, with PI concurrence|f||||f||||||||||2018-06-01 00:23:18.070752|2018-06-01 00:23:18.070752
NCT01011985|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2009-12-02|2009-11-10|2009-11-11|Estimate|||||||2009-12-02|2009-12-03|Estimate|August 2006||2006-08-31|December 2009|2009-12-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Observational|||A Study Evaluating the Association of Inflammation With Hemodialysis Access Type|A Study of the Effect of Hemodialysis Access Type on Markers of Inflammation|Completed|||64|Actual|Montefiore Medical Center|||3||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:23:18.140451|2018-06-01 00:23:18.140451
NCT01011972|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2018-01-29|2009-11-10|2009-11-11|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2010|Actual|2010-03-31|September 2016|2016-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|XMT-1107||A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors|A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors|Completed||Phase 1|52|Actual|Mersana Therapeutics||1|||f||||f||||||||No||2018-06-01 00:23:18.203268|2018-06-01 00:23:18.203268
NCT01011959|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2013-09-27|2009-11-10|2009-11-11|Estimate|||||||2013-09-27|2013-09-30|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Parallel-group Study of the Safety and Tolerability of REGN88 in Subjects With Rheumatoid Arthritis Receiving Concomitant Methotrexate|Completed||Phase 1|60|Actual|Regeneron Pharmaceuticals||6|||f||||f||||||||||2018-06-01 00:23:18.306735|2018-06-01 00:23:18.306735
NCT01011933|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2013-08-21||2018-01-10|2009-11-10|2009-11-11|Estimate|2013-12-05|2014-01-20|Estimate||||2018-01-10|2018-02-06|Actual|September 2009||2009-09-30|January 2018|2018-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||total number of eligible and evaluable participants|Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|54|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:23:18.720691|2018-06-01 00:23:18.720691
NCT01011920|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2017-08-22|2009-11-10|2009-11-11|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2009||2009-11-30|July 2016|2016-07-31|March 2017|Actual|2017-03-31|March 2015|Actual|2015-03-31||Interventional|||Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma|Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma|Completed||Phase 2|126|Actual|International Extranodal Lymphoma Study Group (IELSG)||5|||f||||t||||||||||2018-06-01 00:23:19.348495|2018-06-01 00:23:19.348495
NCT01011907|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2013-01-14||2013-02-22|2009-11-10|2009-11-11|Estimate|2013-02-22|2013-02-25|Estimate||||2013-02-22|2013-02-25|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|July 2011|Actual|2011-07-31||Interventional|||A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence|Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence|Completed||N/A|99|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:23:19.471099|2018-06-01 00:23:19.471099
NCT01011894|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2017-02-23||2017-04-07|2009-11-09|2009-11-11|Estimate|2017-04-07|2017-05-18|Actual||||2017-04-07|2017-05-18|Actual|November 6, 2009||2009-11-06|April 2017|2017-04-30|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Interventional|||Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age|A Phase II Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age|Completed||Phase 2|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:23:19.717721|2018-06-01 00:23:19.717721
NCT01011881|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2016-06-08|2009-11-10|2009-11-11|Estimate|||||||2016-06-08|2016-06-09|Estimate|October 2009||2009-10-31|June 2016|2016-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Procalcitonin in Pleural Pleuritis|Evaluation de la Mesure du Taux de la Procalcitonine Dans Les Liquides Pleuraux|Completed|||34|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-06-01 00:23:19.90813|2018-06-01 00:23:19.90813
NCT01011868|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2014-05-16||2014-09-24|2009-11-10|2009-11-11|Estimate|2014-09-24|2014-09-30|Estimate||||2014-09-24|2014-09-30|Estimate|November 2009||2009-11-30|September 2014|2014-09-30||||May 2012|Actual|2012-05-31||Interventional||Full analysis set (FAS) – including all randomized and treated patients who had a baseline HbA1c value. Treatment assignment as randomized.|Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes|A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, Detemir, or NPH Insulin Only) With or Without Concomitant Metformin and/or Sulfonylurea Therapy and Insufficient Glycemic Control|Completed||Phase 2|494|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 00:23:20.015408|2018-06-01 00:23:20.015408
NCT01011855|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2015-09-10|2009-11-10|2009-11-11|Estimate|||||||2015-09-10|2015-09-14|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Radiant Warmer Trial|A Comparison of Thermal Responses Among Newborns to Proportional Versus Adaptive Heating Algorithms in Radiant Warmer Devices|Withdrawn||N/A|0|Actual|GE Healthcare||6||Study never developed due to a change in business priority.|f||||f||||||||||2018-06-01 00:23:21.229963|2018-06-01 00:23:21.229963
NCT01011842|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2015-05-26|2009-11-10|2009-11-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|November 2011|Actual|2011-11-30|March 2010|Actual|2010-03-31||Interventional|||Real-Time kV Imaging vs. Real-Time 3D Patient Surface Tracking for Head & Neck Cancer|Comparison of Intrafraction Motion in Patients With Head and Neck Cancer Using Real-Time kV Imaging vs. Real-Time 3D Patient Surface Tracking|Terminated||N/A|11|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 00:23:21.319405|2018-06-01 00:23:21.319405
NCT01011829|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2012-11-21||2013-02-11|2009-11-09|2009-11-11|Estimate|2013-02-11|2013-03-14|Estimate||||2013-02-11|2013-03-14|Estimate|November 2009||2009-11-30|February 2013|2013-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|RAVEN||Varenicline vs Placebo for the Treatment of Methamphetamine Dependence|A Randomized, Double-blind Trial of Varenicline Versus Placebo, in Conjunction With Cognitive Behavioral Therapy, for Methamphetamine Dependence|Completed||Phase 2|20|Actual|University of California, Los Angeles|Limitations in funding resulted in a small number of subjects enrolled.|2|||f||||t||||||||||2018-06-01 00:23:21.409574|2018-06-01 00:23:21.409574
NCT01011816|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2014-04-02||2014-05-05|2009-11-10|2009-11-11|Estimate|2014-04-02|2014-05-05|Estimate||||2014-05-05|2014-05-16|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System|A Multicenter, Randomized, Blinded, Saline-Controlled Trial of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System|Terminated||Phase 3|220|Actual|Spinal Restoration, Inc.||2||"Stopped prior to last subject's last extended follow-up visit (78 weeks) due to lack of~   efficacy at the primary study endpoint (26 weeks)"|f||||t||||||||||2018-06-01 00:23:21.737219|2018-06-01 00:23:21.737219
NCT01011803|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-07-09|2009-11-09|2009-11-11|Estimate|||||||2013-07-09|2013-07-11|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Correlation of Phonation With Deglutition and Aspiration Risk in the ICU Patients - an Exploratory Study|Correlation of Phonation With Deglutition and Aspiration Risk in the ICU Patients - an Exploratory Study|Completed||N/A|60|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:23:22.834068|2018-06-01 00:23:22.834068
NCT01011790|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2012-02-03|2009-11-10|2009-11-11|Estimate|||||||2012-02-03|2012-02-07|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of a Biofeedback-assisted Meditation Program as a Stress Management Tool for Hospital Nurses|Evaluation of a Biofeedback-assisted Meditation Program as a Stress Management Tool for Hospital Nurses: A Pilot Study|Completed||N/A|11|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:23:22.921057|2018-06-01 00:23:22.921057
NCT01011439|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2017-07-17|2009-11-10|2009-11-11|Estimate|||||||2017-07-17|2017-07-18|Actual|March 2009||2009-03-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|October 2017|Anticipated|2017-10-31||Interventional|||Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma|Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy|Active, not recruiting||Phase 2|60|Actual|Tiziana Life Sciences, PLC||1|||f||||f||||||||||2018-06-01 00:23:31.306881|2018-06-01 00:23:31.306881
NCT01011777|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2017-10-03|2009-11-10|2009-11-11|Estimate|||||||2017-10-03|2017-10-04|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|MDC||Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence|A Phase I Clinical Protocol to Study the Safety and Tolerability of Endoscopic Injection of Autologous Muscle Derived Cells (MDC) in Children With Exstrophy-epispadias Complex Related Urinary Incontinence|Recruiting||Phase 1|20|Anticipated|Johns Hopkins University||1|||f||||t|t|f||||||||2018-06-01 00:23:23.017641|2018-06-01 00:23:23.017641
NCT01011764|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2012-08-14|2009-11-10|2009-11-11|Estimate|||||||2012-08-14|2012-08-16|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|HRSAII||Study of Peer Relationships at School|Autism Intervention Research Network on Behavior Health (AIR-B): Study of Peer Relationships at School|Completed||N/A|200|Actual|Health Resources and Services Administration (HRSA)||2|||f||||f||||||||||2018-06-01 00:23:23.131654|2018-06-01 00:23:23.131654
NCT01011751|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2015-07-29|2009-11-10|2009-11-11|Estimate|||||||2015-07-29|2015-07-30|Estimate|April 2004||2004-04-30|July 2015|2015-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma|Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma|Completed||Phase 3|311|Actual|Takeda||3|||f||||f||||||||||2018-06-01 00:23:23.24539|2018-06-01 00:23:23.24539
NCT01011738|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2016-01-28||2017-03-10|2009-11-10|2009-11-11|Estimate|2016-03-10|2016-04-08|Estimate||||2017-03-10|2017-04-10|Actual|April 11, 2009|Actual|2009-04-11|March 2017|2017-03-31|November 18, 2014|Actual|2014-11-18|November 18, 2014|Actual|2014-11-18||Observational||Safety population was defined to include participants with informed consent who received at least one dose of peginterferon alfa-2a and had at least one post-baseline safety assessment (any assessment after baseline).|An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys|A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)|Completed|||1842|Actual|Hoffmann-La Roche|The study treatment was not harmonized as per local standard of care and possibly lead to country effects. Generalization of results was hampered by missing values. However, efficacy analyses endeavored to allow it by ITT and “as observed” approach.||1||f||||||||||||||2018-06-01 00:23:23.430858|2018-06-01 00:23:23.430858
NCT01011725|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2016-08-09|2009-11-10|2009-11-11|Estimate|||||||2016-08-09|2016-08-10|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|March 2009|Actual|2009-03-31|April 2006|Actual|2006-04-30||Interventional|||Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Efficacy of MK0773 in Healthy Postmenopausal Women|Completed||Phase 1|67|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:23:25.933538|2018-06-01 00:23:25.933538
NCT01011712|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2018-05-08|2009-11-10|2009-11-11|Estimate|||||||2018-05-08|2018-05-09|Actual|November 9, 2009||2009-11-09|April 24, 2018|2018-04-24||||||||Observational|||The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise|The Natural History of Severe Viral Infections and Characterization of Immune Defects|Recruiting|||325|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:23:25.991949|2018-06-01 00:23:25.991949
NCT01011699|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2016-05-13|2009-11-10|2009-11-11|Estimate|||||||2016-05-13|2016-05-16|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NICOREN||Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients|Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients|Terminated||Phase 3|176|Actual|Centre Hospitalier Universitaire, Amiens||2||Financial problem|f||||f||||||||||2018-06-01 00:23:26.077761|2018-06-01 00:23:26.077761
NCT01011686|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2011-03-08|2009-11-10|2009-11-11|Estimate|||||||2011-03-08|2011-03-10|Estimate||||March 2011|2011-03-31||||||||Interventional|||Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence|A Phase I Clinical Study of ANT-SM (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Fecal Incontinence to Evaluate Safety|Terminated||Phase 1|||Anterogen Co., Ltd.||1||Few subject enrolled|f||||||||||||||2018-06-01 00:23:26.315678|2018-06-01 00:23:26.315678
NCT01011673|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2012-11-03||2018-04-15|2009-11-10|2009-11-11|Estimate|2012-11-03|2012-12-03|Estimate||||2018-04-15|2018-05-15|Actual|November 2009||2009-11-30|April 2018|2018-04-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Metoclopramide Versus Ketorolac for Tension-type Headache|An RCT of Metoclopramide/Diphenhydramine vs. Ketorolac Alone for Tension-type Headache|Completed||Phase 4|123|Actual|Montefiore Medical Center||2|||f||||f|t|f|||f|||||2018-06-01 00:23:26.395074|2018-06-01 00:23:26.395074
NCT01011660|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2012-08-09|2009-11-10|2009-11-11|Estimate|||||||2012-08-09|2012-08-13|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|CHIEF||Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients|Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks|Unknown status|Recruiting|Phase 4|13542|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||4|||f||||t||||||||||2018-06-01 00:23:26.63988|2018-06-01 00:23:26.63988
NCT01011647|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2012-01-04|2009-11-10|2009-11-11|Estimate|||||||2012-01-04|2012-01-05|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Prevalence of Sleep Disordered Breathing|Prevalence of Sleep Disordered Breathing|Terminated|||53|Actual|GE Healthcare|||1|Inadequate recruitment|f||||f||||||||||2018-06-01 00:23:26.727812|2018-06-01 00:23:26.727812
NCT01011634|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2013-02-24||2013-05-14|2009-11-10|2009-11-11|Estimate|2013-05-14|2013-05-16|Estimate||||2013-05-14|2013-05-16|Estimate|May 2007||2007-05-31|May 2013|2013-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions|A Double Blinded, Placebo-controlled Randomized Control Trial Comparing Intravenous Moderate Sedation and Oral/Sublingual Analgesia/Anxiolysis for First Trimester Surgical Abortions|Terminated||Phase 4|18|Actual|University of California, San Francisco||2||7% enrollment. Study terminated after a small number of recruited patients|f||||t||||||||||2018-06-01 00:23:26.799315|2018-06-01 00:23:26.799315
NCT01011426|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-07|||2014-01-16|2009-11-10|2009-11-11|Estimate|||||||2014-01-16|2014-01-20|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients|Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients|Completed||Phase 2|285|Anticipated|The Cooper Health System||2|||f||||f||||||||||2018-06-01 00:23:31.516419|2018-06-01 00:23:31.516419
NCT01011621|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|February 2010||2010-02-28|November 2009|2009-11-30||||February 2012|Anticipated|2012-02-29||Interventional|||Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis|Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis|Unknown status|Not yet recruiting|Phase 3|170|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||t||||||||||2018-06-01 00:23:27.004846|2018-06-01 00:23:27.004846
NCT01011608|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2011-04-01|2009-11-10|2009-11-11|Estimate|||||||2011-04-01|2011-04-04|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Effect of a Medical Food Supplement in Hospitalized Patients Recovering From Surgery|Effect of a Medical Food Supplement in Hospitalized Patients Recovering From Hip Fracture Surgery|Completed||Phase 3|127|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-06-01 00:23:27.090337|2018-06-01 00:23:27.090337
NCT01011595|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2012-06-20|2009-11-09|2009-11-11|Estimate|||||||2012-06-20|2012-06-21|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Minimally Invasive, Diagnosis and Staging of Lung Cancer|Minimally Invasive, Trans-Luminal Diagnosis and Staging of Lung Cancer: A Prospective Head-to-Head Comparison With Traditional Gold Standard Diagnostic Techniques|Completed||N/A|166|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-06-01 00:23:27.193423|2018-06-01 00:23:27.193423
NCT01011582|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-01-07|2009-11-10|2009-11-11|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza|Human Subjects Registry of Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza|Completed|||4|Actual|Virginia Commonwealth University|||2||f||||f||||||Samples Without DNA|"~     Blood specimens and sputum specimens will be collected.~   "|||2018-06-01 00:23:27.280146|2018-06-01 00:23:27.280146
NCT01011569|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2018-04-13|2009-11-10|2009-11-11|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2004||2004-04-30|April 2018|2018-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|||Comparison of Cage Versus Plate in One Level Cervical Disc Disease|Randomized Controlled Trial of Cage Versus Plate in One Level Cervical Disc Disease|Completed|||80|Anticipated|Seoul National University Hospital|||2||f||||t||||||||||2018-06-01 00:23:27.357326|2018-06-01 00:23:27.357326
NCT01011556|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2012-09-21|2012-07-13|2012-09-21|2009-11-09|2009-11-11|Estimate|2012-09-21|2012-10-23|Estimate|2012-07-13|2012-07-23|Estimate|2012-09-21|2012-10-23|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study for the Transdermal Application of Teriparatide|A Phase 2 Study for Transdermal Application of Teriparatide|Completed||Phase 2|233|Actual|Eli Lilly and Company||4|||f||||t||||||||||2018-06-01 00:23:27.498306|2018-06-01 00:23:27.498306
NCT01011543|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2015-08-07|2009-11-10|2009-11-11|Estimate|||||||2015-08-07|2015-08-10|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis|Comparison of Induced Sputum and Bronchoscopic Approach (BAL, Fluoroscopy-guided Transbronchial Biopsies) in Patients Suspected of Pulmonary Tuberculosis With Negative Direct Exam on Three Consecutive Non-induced Sputum Samples|Unknown status|Recruiting|N/A|154|Anticipated|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f||||||||||2018-06-01 00:23:29.152853|2018-06-01 00:23:29.152853
NCT01011530|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-07-15|2009-11-10|2009-11-11|Estimate|||||||2013-07-15|2013-07-16|Estimate|December 2009||2009-12-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Interventional|||Dose Escalation Study of MLN4924 in Adults With Melanoma|A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma|Completed||Phase 1|37|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:23:29.236199|2018-06-01 00:23:29.236199
NCT01011517|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2017-11-06|2009-11-10|2009-11-11|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2007||2007-06-30|March 2017|2017-03-31|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Interventional|||Muscadine Grape Seed Supplementation and Vascular Function|Effect of Muscadine Grape Seed Supplementation on Vascular Function in Subjects With or at Risk for Cardiovascular Disease: A Randomized Crossover Trial|Completed||N/A|50|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 00:23:29.299975|2018-06-01 00:23:29.299975
NCT01011504|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2012-01-18|2009-11-10|2009-11-11|Estimate|||||||2012-01-18|2012-01-19|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|EURO-vision||Utilisation of Angiox® in European Practice|A Registry Study to Determine Utilisation Patterns in Patients Receiving Angiox®, and Collect Descriptive Safety and Outcome Data to Inform the Risk Management Strategy for Europe.|Completed|||2019|Actual|The Medicines Company|||||f||||f||||||||||2018-06-01 00:23:29.364874|2018-06-01 00:23:29.364874
NCT01011491|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparison of Medifast's 5 & 1 Plan to a Food-based Plan of Equal Calories|Efficacy of Medifast's 5 & 1 Program Compared to a Food-based Diet After a Period of Weight Loss and Weight Maintenance|Completed||N/A|90|Actual|Medifast, Inc.||2|||f||||f||||||||||2018-06-01 00:23:29.425477|2018-06-01 00:23:29.425477
NCT01011478|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2016-04-08|2009-11-10|2009-11-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery|Statin Polyp Prevention Trial in Patients With Resected Colon Cancer|Terminated||Phase 3|406|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 00:23:29.698613|2018-06-01 00:23:29.698613
NCT01011465|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2012-09-13||2012-10-24|2009-11-10|2009-11-11|Estimate|2012-10-24|2012-11-26|Estimate||||2012-10-24|2012-11-26|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Biology of Resilience|The Biology of Resilience: Oxytocin, Social Relationships and Health|Completed||N/A|270|Actual|Harvard School of Public Health|Data collected earlier in the study is missing blood pressure data due to technical problems.|6|||f||||f||||||||||2018-06-01 00:23:30.749249|2018-06-01 00:23:30.749249
NCT01011452|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|May 2001||2001-05-31|November 2009|2009-11-30|October 2004|Actual|2004-10-31|August 2004|Actual|2004-08-31||Interventional|AcMk||Acute Montelukast in Asthma|Assessment of the Effect of Oral Montelukast as Additional Treatment in the Management of Patients With Acute Severe Asthma.|Completed||Phase 4|87|Actual|University of East Anglia||2|||f||||f||||||||||2018-06-01 00:23:31.238883|2018-06-01 00:23:31.238883
NCT01011413|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2014-12-18|2009-11-10|2009-11-11|Estimate|||||||2014-12-18|2014-12-19|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Interventional|encore1||Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals.|A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals Over 96 Weeks|Completed||Phase 3|630|Actual|Kirby Institute||2|||f||||t||||||||||2018-06-01 00:23:31.597413|2018-06-01 00:23:31.597413
NCT01011400|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2013-08-27|2009-11-10|2009-11-11|Estimate|||||||2013-08-27|2013-08-28|Estimate|November 2009||2009-11-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Ultrasonic Measurements of the Clitoris in Fetuses|Measurements of the Fetal Clitoris by 2D Ultrasound|Withdrawn|||0|Actual|Meir Medical Center|||||f||||t||||||||||2018-06-01 00:23:31.688968|2018-06-01 00:23:31.688968
NCT01011387|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|2010-12-22||2012-03-20|2009-11-10|2009-11-11|Estimate|2012-03-20|2012-03-21|Estimate||||2012-03-20|2012-03-21|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a NPWT (Negative Pressure Wound Therapy) System to be Used in the Treatment of Diabetic Foot Ulcers (DFUs) Including Post Amputation Wounds Associated With Diabetes.|Completed||N/A|16|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-06-01 00:23:31.753524|2018-06-01 00:23:31.753524
NCT01011374|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2011-03-16|2009-11-10|2009-11-11|Estimate|||||||2011-03-16|2011-03-18|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion|Impact of Lucentis on Psychological Morbidity in Patients With Macular Edema and Neovascularization Secondary to Retinal Vein Occlusion|Unknown status|Active, not recruiting|Phase 1|45|Anticipated|Retina Associates of Cleveland, Inc|||||f||||f||||||||||2018-06-01 00:23:31.899721|2018-06-01 00:23:31.899721
NCT01011361|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2016-03-23|2009-11-09|2009-11-11|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Red Cell Mass and Plasma Volume Measurements in Elderly Men and Women With Anemia|Red Cell Mass and Plasma Volume Measurements in Elderly Men and Women With Anemia|Completed|||5|Actual|Stanford University|||||f||||f||||||||No||2018-06-01 00:23:31.972853|2018-06-01 00:23:31.972853
NCT01011348|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2016-10-26|2009-11-10|2009-11-11|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2008||2008-07-31|October 2016|2016-10-31||||September 2010|Actual|2010-09-30||Interventional|GULF||Q10 for Gulf War Veterans|Q10 for Gulf War Veterans|Active, not recruiting||N/A|46|Anticipated|University of California, San Diego||4|||f||||f||||||||||2018-06-01 00:23:32.028716|2018-06-01 00:23:32.028716
NCT01011335|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2013-06-21||2017-12-11|2009-11-10|2009-11-11|Estimate|2017-12-11|2017-12-12|Actual||||2017-12-11|2017-12-12|Actual|November 2009||2009-11-30|December 2017|2017-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial|A Randomized, Multi-Center Trial to Evaluate the Safety & Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers|Completed||Phase 1/Phase 2|176|Actual|Uniformed Services University of the Health Sciences|Numbers in each of the dose arms were small|3|||f||||t||||||||||2018-06-01 00:23:32.209477|2018-06-01 00:23:32.209477
NCT01011322|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2011-11-15|2009-11-10|2009-11-11|Estimate|||||||2011-11-15|2011-11-16|Estimate|December 2009||2009-12-31|August 2010|2010-08-31|February 2012|Anticipated|2012-02-29|July 2011|Actual|2011-07-31||Interventional|||A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis||Unknown status|Active, not recruiting|Phase 2|156|Actual|Lipid Therapeutics GmbH||4|||f||||f||||||||||2018-06-01 00:23:33.20114|2018-06-01 00:23:33.20114
NCT01011309|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2013-09-16||2013-11-15|2009-11-10|2009-11-11|Estimate|2013-09-16|2013-11-18|Estimate||||2013-11-15|2013-12-11|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis|A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in the Treatment of Patients With Cutaneous Leishmaniasis|Completed||Phase 2|45|Actual|IDRI|A total of 150 patients was planned, including age de-escalation to adolescents after the first 60 adults enrolled. Owing to slow recruitment and insufficient evidence of efficacy in the immunotherapy group, enrollment was closed early.|2|||f||||t||||||||||2018-06-01 00:23:33.331897|2018-06-01 00:23:33.331897
NCT01011296|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2010-05-14|2009-11-10|2009-11-11|Estimate|||||||2010-05-14|2010-05-17|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers|A Randomized, Placebo Controlled, Double-Blind, Third Party Open, Parallel Group, First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers|Completed||Phase 1|24|Anticipated|Pfizer||3|||f||||f||||||||||2018-06-01 00:23:33.762445|2018-06-01 00:23:33.762445
NCT01011283|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-07-14||2014-10-21|2009-11-10|2009-11-11|Estimate|2013-07-14|2013-09-18|Estimate||||2014-10-21|2014-10-29|Estimate|November 2009||2009-11-30|October 2014|2014-10-31||||January 2011|Actual|2011-01-31||Interventional|||To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.|A Randomized, Open-label, Parallel-Group Study Comparing the Efficacy and Safety of DACOGEN (Decitabine) for Injection and VIDAZA (Azacitidine) for Injection In Subjects With Intermediate or High Risk Myelodysplastic Syndromes (MDS)|Terminated||Phase 4|26|Actual|Eisai Inc.||2||The study was stopped due to insufficient enrollment.|f||||||||||||||2018-06-01 00:23:33.83861|2018-06-01 00:23:33.83861
NCT01011270|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|November 2009|Anticipated|2009-11-30|September 2009|Actual|2009-09-30||Observational|RDM||Rehabilitation of Dynamic Muscle, Back Pain and Postural Balance|Rehabilitation of Dynamic Muscle, Back Pain and Postural Balance of Industrial Operators|Unknown status|Enrolling by invitation||82|Actual|Universidade Camilo Castelo Branco|||2||f||||f||||||||||2018-06-01 00:23:34.437633|2018-06-01 00:23:34.437633
NCT01011257|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2018-01-29|2009-11-10|2009-11-11|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2009||2009-09-30|January 2018|2018-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|Dual-Dosing||Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.|Methods to Augment the Efficacy of Aspirin and Clopidogrel in Healthy Subjects (ASA Only) and Patients With Stable Coronary Artery Disease (Taking Clopidogrel Only) or (Taking Clopidogrel & ASA) With an Elevated Platelet Turnover (Reticulated Platelets).|Withdrawn||Phase 4|0|Actual|The Methodist Hospital System||2||No funding secured.|f||||f||||||||No||2018-06-01 00:23:34.510882|2018-06-01 00:23:34.510882
NCT01011244|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2012-03-14|2009-11-10|2009-11-11|Estimate|||||||2012-03-14|2012-03-15|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula|A Phase II Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate Safety and Efficacy|Completed||Phase 2|40|Anticipated|Anterogen Co., Ltd.||1|||f||||t||||||||||2018-06-01 00:23:34.587006|2018-06-01 00:23:34.587006
NCT01011231|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2013-05-03|2009-11-09|2009-11-11|Estimate|||||||2013-05-03|2013-05-06|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|GKS||Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma|Phase II Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Spectroscopy for Target Definition in Patients With Recurrent Glioma|Terminated||Phase 2|1|Actual|University of California, San Francisco||||low accrual|f||||t||||||||||2018-06-01 00:23:34.646668|2018-06-01 00:23:34.646668
NCT01011218|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2016-06-23|2009-11-10|2009-11-11|Estimate|||||||2016-06-23|2016-06-24|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Management of Insomnia in Breast Cancer Patients|Management of Insomnia in Breast Cancer Patients: A Preliminary Pilot Study|Active, not recruiting||Phase 2/Phase 3|64|Anticipated|Stanford University||4|||f||||t||||||||||2018-06-01 00:23:34.706615|2018-06-01 00:23:34.706615
NCT01011205|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2017-11-20|2009-11-10|2009-11-11|Estimate|||||||2017-11-20|2017-11-22|Actual|September 30, 2009|Actual|2009-09-30|November 2017|2017-11-30|January 4, 2013|Actual|2013-01-04|January 4, 2013|Actual|2013-01-04||Interventional|DIAMOND||Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation|A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive Regimen of Advagraf (Immediately or Delayed Post-transplant) and MMF With or Without a Monoclonal Anti-IL2R Antibody (Basiliximab)|Completed||Phase 3|893|Actual|Astellas Pharma Inc||3|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:23:34.861932|2018-06-01 00:23:34.861932
NCT01011192|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-12|2009-11-10|2009-11-11|Estimate|||||||2009-11-12|2009-11-13|Estimate|September 2009||2009-09-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|||Performance of Two Different ke0s in the Same Pharmacokinetic Propofol Model|Performance of Two Different Ke0s in the Same Pharmacokinetic Propofol Model. Study on Loss and Recovery of Consciousness|Completed|||20|Actual|Centro Medico Campinas|||2||f||||t||||||||||2018-06-01 00:23:35.061407|2018-06-01 00:23:35.061407
NCT01011179|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|2013-12-04||2017-12-29|2009-11-09|2009-11-11|Estimate|2014-01-22|2014-03-07|Estimate||||2017-12-29|2018-01-24|Actual|November 2008||2008-11-30|December 2017|2017-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Internet Self-Management Program With Telephone Support for Adolescents With Arthritis|An Internet-based Self-management Program With Telephone Support for Adolescents With Arthritis: A Pilot Randomized Controlled Trial|Completed||N/A|46|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:23:35.148123|2018-06-01 00:23:35.148123
NCT01011166|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-04-22|2009-11-10|2009-11-11|Estimate|||||||2015-04-22|2015-04-23|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)|A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin in Subjects With Genotype 1 Chronic Hepatitis C Infection|Completed||Phase 2|81|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:23:35.393809|2018-06-01 00:23:35.393809
NCT01011153|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|2010-05-26||2012-02-10|2009-11-10|2009-11-11|Estimate|2011-01-19|2011-01-24|Estimate||||2012-02-10|2012-02-14|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Survey Study - Sensitivity Comparison Between MelaFind and Physician Group|Comparison of Diagnostic and Biopsy/Referral Sensitivity to Melanoma Between Three Groups of Physicians and MelaFind|Completed|||241|Actual|MELA Sciences, Inc.|The only limitation to having complete data sets was the time a physician was willing to spend on completing the survey.||1||f||||f||||||||||2018-06-01 00:23:35.491501|2018-06-01 00:23:35.491501
NCT01011140|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2018-01-09|2009-11-10|2009-11-11|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2010|Actual|2010-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Physician Perceptions About Parenteral Hydration in Latin America and Spain|Physician Perceptions About Parenteral Hydration in Latin America and Spain: A Survey of Physicians Affiliated With the Latin American Association for Palliative Care (ALCP) and the Spanish Society for Palliative Care (SECPAL)|Recruiting|||516|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 00:23:36.070993|2018-06-01 00:23:36.070993
NCT01011127|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2010-10-04|2009-11-10|2009-11-11|Estimate|||||||2010-10-04|2010-10-05|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Different Metabolic Effects of Statins||Completed|||||Gachon University Gil Medical Center|||2||f||||t||||||||||2018-06-01 00:23:36.153908|2018-06-01 00:23:36.153908
NCT01011114|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2012-10-22|2009-11-10|2009-11-11|Estimate|||||||2012-10-22|2012-10-23|Estimate|November 2009||2009-11-30|October 2012|2012-10-31||||November 2013|Anticipated|2013-11-30||Interventional|||Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant|Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant|Unknown status|Recruiting|N/A|40|Anticipated|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 00:23:36.233295|2018-06-01 00:23:36.233295
NCT01011101|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2017-10-05|2009-11-10|2009-11-11|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2, 2009||2009-11-02|August 16, 2016|2016-08-16|August 16, 2016||2016-08-16|||||Observational|||Internal Monitoring of Eye Movement in Schizophrenia|Internal Monitoring of Eye Movement in Schizophrenia|Terminated|||2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:23:36.313488|2018-06-01 00:23:36.313488
NCT01011088|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2010-06-03|2009-11-10|2009-11-11|Estimate|||||||2010-06-03|2010-06-04|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|PAPABAB||Paternal Psychosis After Baby Born|Paternal Psychosis Evaluation After First Baby Born|Completed|||387|Actual|Nanjing Medical University|||2||f||||t||||||||||2018-06-01 00:23:36.382322|2018-06-01 00:23:36.382322
NCT01011075|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2013-02-01||2015-06-06|2009-11-10|2009-11-11|Estimate|2015-06-06|2015-07-03|Estimate||||2015-06-06|2015-07-03|Estimate|August 2009||2009-08-31|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|6137p||Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer|A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|34|Actual|New Mexico Cancer Care Alliance||1|||f||||t||||||||||2018-06-01 00:23:36.46957|2018-06-01 00:23:36.46957
NCT01011062|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2013-10-17|2009-11-10|2009-11-11|Estimate|||||||2013-10-17|2013-10-18|Estimate|January 2004||2004-01-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Angiotensin Receptor Blockade on Insulin Resistance and Adipose Tissue Cytokines in Type 2 Diabetes|Effect of Acute Angiotensin Receptor Blockade on Insulin Resistance and Selected Cytokines in Adipose Tissue in Type 2 Diabetes|Completed||N/A|23|Actual|Institute for Clinical and Experimental Medicine||3|||f||||t||||||||||2018-06-01 00:23:36.749588|2018-06-01 00:23:36.749588
NCT01011049|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2011-07-14|2010-03-31|2016-04-12|2009-11-10|2009-11-11|Estimate|2011-07-14|2011-08-11|Estimate|2010-03-31|2010-04-02|Estimate|2016-04-12|2016-04-14|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM|Safety and Immunogenicity of Revaccination With Influenza Vaccine in Healthy Adult Subjects Aged 18 to 64 Years Who Were Previously Vaccinated With Fluzone ID or Fluzone IM|Completed||Phase 2|1250|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 00:23:36.876281|2018-06-01 00:23:36.876281
NCT01011036|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2010-08-10|2009-11-10|2009-11-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|December 2009||2009-12-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers|Effects of Gaba-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers|Completed||Phase 3|17|Actual|University Hospital Inselspital, Berne||3|||f||||t||||||||||2018-06-01 00:23:37.724639|2018-06-01 00:23:37.724639
NCT01011023|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2009-11-10|2009-11-10|2009-11-11|Estimate|||||||2009-11-10|2009-11-11|Estimate|September 2000||2000-09-30|November 2009|2009-11-30|November 2001|Actual|2001-11-30|April 2001|Actual|2001-04-30||Interventional|||Unnecessary Gastric Decompression in Distal Elective Bowel Anastomoses in Children. A Randomized Study|Unnecessary Gastric Decompression in Distal Elective Bowel Anastomoses in Children. A Randomized Study|Completed||N/A|60|Actual|Hospital Infantil de Mexico Federico Gomez||2|||f||||t||||||||||2018-06-01 00:23:37.808196|2018-06-01 00:23:37.808196
NCT01011010|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-10|||2018-01-03|2009-11-10|2009-11-11|Estimate|||||||2018-01-03|2018-01-05|Actual|July 22, 2009|Actual|2009-07-22|January 2018|2018-01-31|September 29, 2017|Actual|2017-09-29|December 2012|Actual|2012-12-31||Interventional|||Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC)|Completed||Phase 1|11|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:23:37.895447|2018-06-01 00:23:37.895447
NCT01010997|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-08|||2012-07-30|2009-11-09|2009-11-10|Estimate|||||||2012-07-30|2012-07-31|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|Foresee Home||Foresee Home for Monitoring Age Related Macular Degeneration (AMD)|Foresee Home for Monitoring Age Related Macular Degeneration (AMD)|Completed|||10|Actual|Notal Vision Ltd|||2||f||||t||||||||||2018-06-01 00:23:37.9724|2018-06-01 00:23:37.9724
NCT01010984|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2013-12-20|2009-11-06|2009-11-10|Estimate|||||||2013-12-20|2013-12-23|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DEBDOX||LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma|Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma|Completed||Phase 1|20|Actual|University of Louisville||1|||f||||f||||||||||2018-06-01 00:23:38.05504|2018-06-01 00:23:38.05504
NCT01010971|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2012-02-15|2010-09-17|2012-06-08|2009-11-09|2009-11-10|Estimate|2012-05-07|2012-06-08|Estimate|2010-09-17|2010-09-21|Estimate|2012-06-08|2012-06-13|Estimate|December 2009||2009-12-31|June 2012|2012-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older|Completed||Phase 3|671|Actual|Sunovion|This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg|3|||f||||f||||||||||2018-06-01 00:23:38.213148|2018-06-01 00:23:38.213148
NCT01010958|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2015-05-20|2009-11-09|2009-11-10|Estimate|||||||2015-05-20|2015-05-21|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Adjuvant Valproate for High Grade Sarcomas|A Pilot Study of Adjuvant Valproate for Patients With High Grade Sarcomas|Terminated||Phase 1|7|Actual|Columbia University||1||Slow accrual|f||||t||||||||||2018-06-01 00:23:40.153735|2018-06-01 00:23:40.153735
NCT01010945|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2014-06-17|2009-11-06|2009-11-10|Estimate|||||||2014-06-17|2014-06-18|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer|A Phase IB Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer|Completed||Phase 1|19|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:23:40.230768|2018-06-01 00:23:40.230768
NCT01010932|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2015-07-29|2012-11-09|2016-05-11|2009-11-09|2009-11-10|Estimate|2015-07-29|2015-08-25|Estimate|2012-11-09|2012-11-15|Estimate|2016-05-11|2016-06-16|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)|Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease|Completed||Phase 3|222|Actual|Guerbet||1|||f||||f||||||||||2018-06-01 00:23:40.335873|2018-06-01 00:23:40.335873
NCT01010919|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-09|2009-11-09|2009-11-10|Estimate|||||||2009-11-09|2009-11-10|Estimate||||November 2009|2009-11-30||||||||Interventional|||A Study of Chicory for Treatment of Osteoarthritis of the Hip or Knee|A Phase I Study of Chicory for Treatment of Osteoarthritis of the Hip or Knee|Completed||Phase 1|||Phytomedics Inc.|||||f||||||||||||||2018-06-01 00:23:40.623014|2018-06-01 00:23:40.623014
NCT01010906|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2014-09-26||2017-03-03|2009-11-06|2009-11-10|Estimate|2014-09-26|2014-09-29|Estimate||||2017-03-03|2017-03-31|Actual|July 2009||2009-07-31|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)|An Open-label, 3-Part, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-7009|Completed||Phase 1|60|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:23:40.694749|2018-06-01 00:23:40.694749
NCT01010893|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-07|||2012-05-18|2009-11-07|2009-11-10|Estimate|||||||2012-05-18|2012-05-21|Estimate|August 2009||2009-08-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|||Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine|Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons|Completed||N/A|355|Actual|Fluart Innovative Vaccine Ltd, Hungary||2|||f||||t||||||||||2018-06-01 00:23:41.071805|2018-06-01 00:23:41.071805
NCT01010880|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2011-06-09|2009-11-09|2009-11-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients|A Phase I/IIA, Non-Randomized, Open Label, Single Dose, Dose-Escalation, Safety Study of BKT140, a CXCR4 Antagonist in Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|16|Anticipated|Biokine Therapeutics Ltd|||||f||||t||||||||||2018-06-01 00:23:41.150874|2018-06-01 00:23:41.150874
NCT01010867|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2015-11-09||2017-07-11|2009-11-09|2009-11-10|Estimate|2017-07-11|2017-07-13|Actual||||2017-07-11|2017-07-13|Actual|February 2010||2010-02-28|July 2017|2017-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|A Limited Institution Pilot Trial Evaluating the Safety of Administering the Probiotic, Lactobacillus Plantarum, to Children and Adolescents Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT) - A Pilot Study|Completed||Phase 1|31|Actual|Columbia University||1|||f||||t|t|f||||||Undecided||2018-06-01 00:23:41.222897|2018-06-01 00:23:41.222897
NCT01010854|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2017-11-02||2018-02-08|2009-11-09|2009-11-10|Estimate|2018-02-08|2018-03-09|Actual||||2018-02-08|2018-03-09|Actual|December 10, 2008|Actual|2008-12-10|February 2018|2018-02-28|July 29, 2011|Actual|2011-07-29|December 12, 2010|Actual|2010-12-12||Interventional|VPA-FEC100||Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer|A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer|Terminated||Phase 2|6|Actual|University of California, San Francisco||1||Premature closure for lack of efficacy.|f||||t|t|f|||t|||||2018-06-01 00:23:41.404577|2018-06-01 00:23:41.404577
NCT01010841|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2012-01-11|2009-11-09|2009-11-10|Estimate|||||||2012-01-11|2012-01-12|Estimate|August 2008||2008-08-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|HMS4||Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome|Multi-center, Randomized Intervention to Compare the Effects of 2 Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome|Completed||N/A|89|Actual|MetaProteomics LLC||2|||f||||f||||||||||2018-06-01 00:23:41.560044|2018-06-01 00:23:41.560044
NCT01010828|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2012-10-15|2009-11-09|2009-11-10|Estimate|||||||2012-10-15|2012-10-16|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Review on Minimally Invasive Skin Incision in Vanguard PS Artificial Knee Joint System||Completed||N/A|72|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 00:23:41.638163|2018-06-01 00:23:41.638163
NCT01010815|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-08|||2009-11-09|2009-11-09|2009-11-10|Estimate|||||||2009-11-09|2009-11-10|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|November 2011|Anticipated|2011-11-30|November 2010|Anticipated|2010-11-30||Observational|||Metagenomic Analysis of Gut Microbiome in Korean Patients With Ulcerative Colitis|Metagenomic Analysis of Gut Microbiome in Korean Patients With Ulcerative Colitis|Unknown status|Recruiting||15|Anticipated|Seoul National University Hospital|||2||f||||f||||||Samples With DNA|"~     Participants will need to give stool samples and colorectal biopsy specimens on 1 or 2~     separate occasions~   "|||2018-06-01 00:23:41.84664|2018-06-01 00:23:41.84664
NCT01010802|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-08|||2009-11-09|2009-11-09|2009-11-10|Estimate|||||||2009-11-09|2009-11-10|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety Study of Erythropoietin (EPO) in Parkinson's Disease|Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)|Completed||Phase 1|10|Actual|International Center for Neurological Restoration, Cuba||1|||f||||f||||||||||2018-06-01 00:23:41.923766|2018-06-01 00:23:41.923766
NCT01010789|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2015-05-13|2009-11-09|2009-11-10|Estimate|||||||2015-05-13|2015-05-14|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Armodafinil in Binge Eating Disorder (BED)||Completed||Phase 3|60|Actual|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 00:23:41.996761|2018-06-01 00:23:41.996761
NCT01010776|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-04-15||2013-09-17|2009-11-09|2009-11-10|Estimate|2013-09-17|2013-11-20|Estimate||||2013-09-17|2013-11-20|Estimate|February 2008||2008-02-29|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone|A Study to Evaluate Switching From Risperidone to Paliperidone ER (Extended Release) in the Treatment of Stable But Symptomatic Schizophrenia Outpatients: Patients Satisfaction and Quality of Life|Completed||Phase 4|223|Actual|Janssen-Cilag Farmaceutica Ltda.||1|||f||||f||||||||||2018-06-01 00:23:42.152791|2018-06-01 00:23:42.152791
NCT01010763|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2016-09-26|2009-11-09|2009-11-10|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||A Study on M2a Magnum Total Hip Arthroplasty|A Prospective Controlled Multi-Center Study on M2a Magnum Total Hip Arthroplasty|Active, not recruiting||N/A|184|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 00:23:43.060399|2018-06-01 00:23:43.060399
NCT01010750|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2011-01-07||2014-02-06|2009-11-09|2009-11-10|Estimate|2011-01-28|2011-02-25|Estimate||||2014-02-06|2014-03-10|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase I, Randomized, Double Blind, Three-Period Crossover, Estimation Study Using Lisdexamfetamine Dimesylate, Immediate Release Mixed Amphetamine Salts and Placebo to Evaluate the Utility of a Standardized Computer Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 1|18|Actual|Shire||3|||f||||||||||||||2018-06-01 00:23:43.183473|2018-06-01 00:23:43.183473
NCT01010737|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2012-07-30|2009-11-09|2009-11-10|Estimate|||||||2012-07-30|2012-07-31|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers|A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose, Safety and Priming Potential Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers|Completed||Phase 1/Phase 2|60|Actual|BiondVax Pharmaceuticals ltd.||6|||f||||t||||||||||2018-06-01 00:23:43.749216|2018-06-01 00:23:43.749216
NCT01010724|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2009-11-09|2009-11-09|2009-11-10|Estimate|||||||2009-11-09|2009-11-10|Estimate||||November 2009|2009-11-30||||||||Interventional|APPIRED||Efficacy and Safety Study on bIAP|A Randomized, Double-Blind, Placebo Controlled Study of Biap, an Endotoxin Detoxificating Moiety, in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass|Completed||Phase 3|||Catharina Ziekenhuis Eindhoven||2|||f||||t||||||||||2018-06-01 00:23:43.845013|2018-06-01 00:23:43.845013
NCT01010711|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2010-02-01|2009-11-09|2009-11-10|Estimate|||||||2010-02-01|2010-02-02|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|April 2011|Anticipated|2011-04-30|December 2010|Anticipated|2010-12-31||Interventional|||Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents|Study for Documentation of the Influence of a Specific Dietary Supplement Treatment of Migraine in Children and Adolescents|Unknown status|Recruiting|N/A|76|Anticipated|Complen Health GmbH||1|||f||||t||||||||||2018-06-01 00:23:43.907286|2018-06-01 00:23:43.907286
NCT01010698|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-11-21|2009-11-09|2009-11-10|Estimate|||||||2013-11-21|2013-11-25|Estimate|June 2009||2009-06-30|December 2010|2010-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Class 3 Biowaivers|Evaluation of Biopharmaceutics Classification System Class 3 Drugs for Possible Biowaivers|Completed||Phase 1|48|Actual|University of Maryland||4|||f||||t||||||||||2018-06-01 00:23:43.990477|2018-06-01 00:23:43.990477
NCT01010685|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-07|||2014-02-04|2009-11-09|2009-11-10|Estimate|||||||2014-02-04|2014-02-05|Estimate|December 2009||2009-12-31|February 2014|2014-02-28|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Safety Study of Keyhole Gallbladder Surgery With Removal of Gallbladder Via the Stomach Rather Than Through the Skin|Safety and Feasibility Trial of Laparoscopic Small Port Cholecystectomy With Transgastric Gallbladder Recovery|Withdrawn||N/A|0|Actual|Colchester Hospital University NHS Foundation Trust||||Specialised equipment required withdrawn from market|f||||t||||||||||2018-06-01 00:23:44.064011|2018-06-01 00:23:44.064011
NCT01010672|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2015-04-29|2009-11-09|2009-11-10|Estimate|||||||2015-04-29|2015-04-30|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|January 2013|Actual|2013-01-31|September 2011|Actual|2011-09-30||Interventional|||Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)|A Phase II Study of MK-8669 When Administered as Maintenance Therapy to Japanese Patients With Metastatic Bone or Soft-tissue Sarcomas|Completed||Phase 2|50|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-06-01 00:23:44.138265|2018-06-01 00:23:44.138265
NCT01010659|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-07-14|2009-11-09|2009-11-10|Estimate|||||||2011-07-14|2011-07-15|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||The Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora|Prospective Clinical Evaluation of Dacryocystorhinostomy (DCR) With Lacrimal Intubation|Completed||Phase 4|30|Actual|Aurolab||1|||f||||t||||||||||2018-06-01 00:23:44.210616|2018-06-01 00:23:44.210616
NCT01010646|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-09-19|2009-11-09|2009-11-10|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|September 2012|Actual|2012-09-30||Interventional|COAT IFN||Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4|Multicentre, Randomised, Open-label Study Comparing the Tolerability and Viral Reduction of the Combination of IFN Alpha-2b XL + Ribavirin Versus Peg IFN Alpha-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4.|Unknown status|Active, not recruiting|Phase 2|84|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3|||f||||t||||||||||2018-06-01 00:23:44.294172|2018-06-01 00:23:44.294172
NCT01010633|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2011-08-30||2011-12-08|2009-11-09|2009-11-10|Estimate|2011-12-08|2012-01-09|Estimate||||2011-12-08|2012-01-09|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery||Completed||Phase 3|406|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:23:44.387565|2018-06-01 00:23:44.387565
NCT01010620|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2018-05-15|2009-11-09|2009-11-10|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2009||2009-12-31|May 2018|2018-05-31|March 2025|Anticipated|2025-03-31|March 2020|Anticipated|2020-03-31||Observational|ScreenProt||Screening Protocol for Research Participants|Screening Protocol for the Evaluation of Research Participants|Recruiting|||5000|Anticipated|University of Maryland|||1||f||||f||||||||||2018-06-01 00:23:44.699003|2018-06-01 00:23:44.699003
NCT01010607|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-08|||2010-06-02|2009-11-09|2009-11-10|Estimate|||||||2010-06-02|2010-06-03|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|November 2011|Anticipated|2011-11-30|December 2010|Anticipated|2010-12-31||Interventional|VibMirror||Use of Tendon Vibration and Mirror for the Improvement of Upper Limb Function and Pain Reduction|Use of Tendon Vibration and Mirror for the Improvement of Upper Limb Function and Pain Reduction After Stroke|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Hadassah Medical Organization||3|||f||||||||||||||2018-06-01 00:23:44.788626|2018-06-01 00:23:44.788626
NCT01010594|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2013-03-20|2009-11-09|2009-11-10|Estimate|||||||2013-03-20|2013-03-21|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Two Pieces of Fruit to Type 2 Diabetics?|Two Pieces of Fruit to Type 2 Diabetics?|Terminated||N/A|64|Actual|Hospitalsenheden Vest||2||PI changed job and project was not economically viable and therefor terminated|f||||t||||||||||2018-06-01 00:23:44.984267|2018-06-01 00:23:44.984267
NCT01010581|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2012-02-29|2009-11-09|2009-11-10|Estimate|||||||2012-02-29|2012-03-01|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|COMPONENT||SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis|Completed||Phase 2|266|Actual|4SC AG||2|||f||||||||||||||2018-06-01 00:23:45.05982|2018-06-01 00:23:45.05982
NCT01010568|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2015-07-22||2015-11-10|2009-11-09|2009-11-10|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)|Ofatumumab and Bendamustine in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia|Terminated||Phase 2|10|Actual|Georgetown University||1||Unable to accrue patients due to change in standard CLL therapy|f||||t||||||||||2018-06-01 00:23:45.174053|2018-06-01 00:23:45.174053
NCT01010555|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2011-05-03||2012-06-26|2009-11-09|2009-11-10|Estimate|2011-05-03|2011-05-30|Estimate||||2012-06-26|2012-07-10|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|CIAN||In-vivo Wettability Grading and Assessment Study||Completed||N/A|25|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 00:23:45.352029|2018-06-01 00:23:45.352029
NCT01010542|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-01-05|2009-11-09|2009-11-10|Estimate|||||||2017-01-05|2017-01-06|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects|A Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Clinical Activity Of ILV-095 Administered Subcutaneously To Subjects With Psoriasis|Terminated||Phase 1|39|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:23:45.600346|2018-06-01 00:23:45.600346
NCT01010529|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2011-03-17|2009-11-09|2009-11-10|Estimate|||||||2011-03-17|2011-03-18|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|OTiP pilot||Feasibility of a Trial Evaluating the Effectiveness of Occupational Therapy in Parkinson's Disease||Completed||N/A|43|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 00:23:45.686349|2018-06-01 00:23:45.686349
NCT01010516|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2011-08-09|2009-11-09|2009-11-10|Estimate|||||||2011-08-09|2011-08-10|Estimate|October 2009||2009-10-31|November 2009|2009-11-30||||December 2011|Anticipated|2011-12-31||Interventional|||Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia|Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia|Unknown status|Recruiting|Phase 4|120|Anticipated|University of Ioannina||3|||f||||f||||||||||2018-06-01 00:23:45.785658|2018-06-01 00:23:45.785658
NCT01010503|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2014-04-08||2014-07-23|2009-11-09|2009-11-10|Estimate|2014-07-23|2014-08-13|Estimate||||2014-07-23|2014-08-13|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||All participants who received at least one dose of study drug.|A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.|Evaluation of Adherence and Persistence to Tocilizumab in Combination With Methotrexate or Tocilizumab Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis in Local Environment.|Completed||Phase 4|32|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:23:45.937712|2018-06-01 00:23:45.937712
NCT01010490|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2009-11-11|2009-11-09|2009-11-10|Estimate|||||||2009-11-11|2009-11-13|Estimate|May 2007||2007-05-31|November 2009|2009-11-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Outcomes of Phacoemulsification With Torsional Ultrasound|A Randomised Trial of Torsional Ultrasound Versus Longitudinal Ultrasound During Phacoemulsification of Age-related Cataracts: Comparison of Intra-operative Performance and Impact on Post-operative Endothelium Integrity|Completed||Phase 4|360|Actual|Iladevi Cataract and IOL Research Center||3|||f||||t||||||||||2018-06-01 00:23:46.44878|2018-06-01 00:23:46.44878
NCT01010477|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2014-03-06||2014-09-05|2009-11-09|2009-11-10|Estimate|2014-09-05|2014-09-08|Estimate||||2014-09-05|2014-09-08|Estimate|August 2009||2009-08-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia|Double-Blind, Placebo-Controlled Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia|Completed||Phase 4|66|Actual|Rutgers, The State University of New Jersey|small sample size|2|||f||||t||||||||||2018-06-01 00:23:46.548822|2018-06-01 00:23:46.548822
NCT01010464|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2016-08-19|2009-11-09|2009-11-10|Estimate|||||||2016-08-19|2016-08-23|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||An Adhesion Reduction Plan in the Management of the Surgical Open Abdomen|Effect of an Adhesion Reduction Plan on Enteric Adhesions, Obstruction, and Fistulae in the Management of the Surgical Open Abdomen: A Prospective, Randomized Clinical Trial in Trauma and Emergency General Surgery|Withdrawn||N/A|0|Actual|University of Maryland||2||No participants enrolled|f||||t||||||||||2018-06-01 00:23:46.813639|2018-06-01 00:23:46.813639
NCT01010451|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-09|2009-11-09|2009-11-10|Estimate|||||||2009-11-09|2009-11-10|Estimate|August 2000||2000-08-31|November 2009|2009-11-30|August 2006|Actual|2006-08-31|||||Interventional|||Antimicrobial Pulpotomy of Primary Molars|Survival of Primary Molars Treated With Antimicrobial Pulpotomy or Calcium Hydroxide Pulpectomy|Completed||Phase 4|||Universidade Federal de Goias||2|||f||||t||||||||||2018-06-01 00:23:46.888905|2018-06-01 00:23:46.888905
NCT01010438|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-08|||2016-11-01|2009-11-09|2009-11-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Observational|||Clinical Evaluation of an Apnea Index for Diagnosis and Screening of Obstructive Sleep Apnea (OSA)|Clinical Evaluation of an Apnea Index Provided by a Capnograph/Pulse Oximeter to Assist in the Diagnosis and Screening of Obstructive Sleep Apnea|Completed|||59|Actual|Medtronic - MITG|||2||f||||t||||||||||2018-06-01 00:23:46.968211|2018-06-01 00:23:46.968211
NCT01010425|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2010-06-07|2009-11-09|2009-11-10|Estimate|||||||2010-06-07|2010-06-08|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)|Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)|Completed||Phase 1|44|Actual|Ascendis Pharma A/S||4|||f||||t||||||||||2018-06-01 00:23:47.037612|2018-06-01 00:23:47.037612
NCT01010412|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2012-08-29|2009-11-09|2009-11-10|Estimate|||||||2012-08-29|2012-08-30|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|October 2011|Actual|2011-10-31|March 2010|Actual|2010-03-31||Interventional|||Ultrasound Visualization Versus Electrical Nerve Stimulation|Ultrasound Visualization v. Electrical Nerve Stimulation for the Safety and Effectiveness of Interscalene/Axillary Nerve Block in Upper Extremity Surgery: A Randomized Trial|Completed||Phase 4|158|Actual|Allentown Anesthesia Associates||2|||f||||f||||||||||2018-06-01 00:23:47.105025|2018-06-01 00:23:47.105025
NCT01010399|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|2012-03-26||2012-03-26|2009-11-09|2009-11-10|Estimate|2012-03-26|2012-04-18|Estimate||||2012-03-26|2012-04-18|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|BuLLET||Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects|A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza® in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva® 1400mg Plus Norvir® 100mg Plus Optimized Background|Completed||Phase 4|36|Actual|Felizarta, Franco, M.D.||1|||f||||f||||||||||2018-06-01 00:23:47.174591|2018-06-01 00:23:47.174591
NCT01010386|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-05-05|2009-11-09|2009-11-10|Estimate|||||||2017-05-05|2017-05-08|Actual|March 2010||2010-03-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PhOx||The Effects of Physiologic Oxygen Tension on Clinical In Vitro Fertilization Outcomes|A Prospective, Randomized, Double-Blind, Controlled Clinical Trial of the Effects of Oxygen Tension on Clinical In Vitro Fertilization Outcomes|Completed||Phase 3|851|Actual|Yale University||2|||f||||t||||||||||2018-06-01 00:23:47.326429|2018-06-01 00:23:47.326429
NCT01010204|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2015-02-27||2017-10-27|2009-11-06|2009-11-09|Estimate|2015-02-27|2015-03-12|Estimate||||2017-10-27|2017-12-04|Actual|January 2010||2010-01-31|April 2015|2015-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|BEST||Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder|Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder|Completed||Phase 4|60|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 00:23:50.188364|2018-06-01 00:23:50.188364
NCT01010373|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2015-02-09|2009-11-09|2009-11-10|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients|Application of AS101 in Combination With Chemotherapy for Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Suspended||Phase 2|12|Anticipated|BioMAS Ltd||1||The sponsor is currently focusing on different indications|f||||f||||||||||2018-06-01 00:23:47.399588|2018-06-01 00:23:47.399588
NCT01010360|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2016-02-29|2009-11-09|2009-11-10|Estimate|||||||2016-02-29|2016-03-01|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Identification of Celiac Ganglia|Identification of Celiac Ganglia for Endoscopic Ultrasound|Completed|||50|Actual|Indiana University|||||f||||f||||||||||2018-06-01 00:23:47.610606|2018-06-01 00:23:47.610606
NCT01010347|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2011-09-22|2009-11-09|2009-11-10|Estimate|||||||2011-09-22|2011-09-26|Estimate|December 2005||2005-12-31|September 2011|2011-09-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||A Comparison of Casting and Splinting in Pediatric Radial Buckle Fractures|A Comparison of Casting and Splinting in Pediatric Radial Buckle Fractures|Completed||Phase 2|100|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:23:47.678045|2018-06-01 00:23:47.678045
NCT01010334|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2013-08-13|2009-11-06|2009-11-10|Estimate|||||||2013-08-13|2013-08-14|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparison of Standard of Care or Treatment on Protocol|Randomized Study of Patients (Patient Choice) Who Are Not Eligible for Variations of Standard of Care Protocols When Treated Either on Best Standard of Care Pathways or Per a Protocol Arm That They Failed to Enroll to|Terminated||N/A|13|Actual|New Mexico Cancer Care Alliance||2||PI deparature and very low (<2%) accrual rate.(No results required)|f||||f||||||||||2018-06-01 00:23:47.749712|2018-06-01 00:23:47.749712
NCT01010321|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2010-06-27|2009-11-08|2009-11-10|Estimate|||||||2010-06-27|2010-06-29|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|||Confocal Microscopy of Benign and Malignant Skin Tumors|Confocal Microscopy of Benign and Malignant Skin Tumors|Suspended|||60|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 00:23:47.8207|2018-06-01 00:23:47.8207
NCT01010308|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-08|||2013-08-01|2009-11-09|2009-11-10|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 2009||2009-11-30|August 2013|2013-08-31|February 2012|Actual|2012-02-29|May 2011|Actual|2011-05-31||Interventional|||Nadolol for Proliferating Infantile Hemangiomas|Nadolol for Proliferating Infantile Hemangiomas: A Prospective Open Label Study With a Historical Control|Completed||Phase 2|20|Actual|The Hospital for Sick Children||3|||f||||t||||||||||2018-06-01 00:23:47.882489|2018-06-01 00:23:47.882489
NCT01010295|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2013-11-22|2009-11-09|2009-11-10|Estimate|||||||2013-11-22|2013-11-25|Estimate|September 2006||2006-09-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|IELSG27||A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae|A Clinico-pathological Phase II Study With Translational Elements to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae With Particular Reference to Chlamydia Species and the Effects of MALT Lymphoma Treatment With Tetracycline|Completed||Phase 2|54|Actual|International Extranodal Lymphoma Study Group (IELSG)||1|||f||||f||||||||||2018-06-01 00:23:47.948778|2018-06-01 00:23:47.948778
NCT01010282|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2011-11-09||2015-07-22|2009-11-09|2009-11-10|Estimate|2011-11-09|2011-12-13|Estimate||||2015-07-22|2015-08-17|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects||Completed||N/A|288|Actual|Allergan||3|||f||||||||||||||2018-06-01 00:23:48.050524|2018-06-01 00:23:48.050524
NCT01010269|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-03-20|2009-11-06|2009-11-10|Estimate|||||||2017-03-20|2017-03-22|Actual|October 2009||2009-10-31|July 2016|2016-07-31|October 2021|Anticipated|2021-10-31|October 2012|Actual|2012-10-31||Interventional|||Vanguard Complete Knee Versus Vanguard High Flex Rotating Platform (RP) Knee Study|A Prospective Controlled Multi-center Study on Vanguard Complete Knee and Vanguard High Flex RP Knee|Active, not recruiting||N/A|300|Anticipated|Zimmer Biomet||2|||f||||f||||||||Yes||2018-06-01 00:23:48.413165|2018-06-01 00:23:48.413165
NCT01010256|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2018-02-13|2009-11-06|2009-11-09|Estimate|||||||2018-02-13|2018-02-14|Actual|November 1, 2009|Actual|2009-11-01|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia|The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia|Recruiting|||22|Anticipated|University of Arkansas|||2||f||||f||||||||||2018-06-01 00:23:48.4766|2018-06-01 00:23:48.4766
NCT01010243|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2012-05-29|2009-11-06|2009-11-09|Estimate|||||||2012-05-29|2012-05-30|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|October 2016|Anticipated|2016-10-31|October 2013|Anticipated|2013-10-31||Interventional|MM03||Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial|Third-line Therapy of Multiple Myeloma With Lenalidomide in Combination With Pioglitazone, Dexamethasone and Metronomic Low-dose Chemotherapy With Treosulfan|Unknown status|Recruiting|Phase 1/Phase 2|54|Anticipated|University of Regensburg|||||f||||t||||||||||2018-06-01 00:23:48.535013|2018-06-01 00:23:48.535013
NCT01010230|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2014-04-25||2014-05-27|2009-11-06|2009-11-09|Estimate|2014-04-25|2014-05-26|Estimate||||2014-05-27|2014-06-04|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The power estimates were based on two-sided two-sample t-tests. With 30 subjects in each of the two arms and assuming no change in the control arm (0% change) and assuming the common standard deviation (SD) of 6.8%3 we will have roughly 87% power to detect an improvement of 5.5% change in the intervention arm, with type I error control α=0.05.|Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors|Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors|Completed||N/A|81|Actual|St. Jude Children's Research Hospital|Dropout was higher than expected leading to small numbers for analysis. It was estimated that 30 persons were needed in each arm to detect a 5.5% difference in change in bone outcomes between the active device and placebo device arms of the study.|2|||f||||f||||||||||2018-06-01 00:23:48.627498|2018-06-01 00:23:48.627498
NCT01010217|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-10-06|2009-11-06|2009-11-09|Estimate|||||||2017-10-06|2017-10-09|Actual|November 5, 2009|Actual|2009-11-05|October 2017|2017-10-31|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide|Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide|Completed||Phase 2|177|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-06-01 00:23:50.037078|2018-06-01 00:23:50.037078
NCT01010165|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2012-10-25|2009-11-06|2009-11-09|Estimate|||||||2012-10-25|2012-10-26|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|NOUBASST||Determination of New Biomarkers of Septic Arthritis by Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight (SELDI-TOF)|Caractérisation de Nouveaux Biomarqueurs de l'Arthrite Septique Par Technique SELDI-TOF|Completed|||89|Actual|University Hospital, Grenoble|||3||f||||f||||||Samples Without DNA|"~     joint fluid proteom~   "|||2018-06-01 00:23:51.447839|2018-06-01 00:23:51.447839
NCT01010152|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2018-01-19|2009-11-06|2009-11-09|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2008||2008-01-31|January 2018|2018-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Comparative Bioavailability Study of Codeine Sulfate|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Comparative Bioavailability Study fo Codeine 30 mg Tablets and Tylenol #3 Tablets Under Fasting Conditions|Completed||Phase 1|34|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-06-01 00:23:51.503527|2018-06-01 00:23:51.503527
NCT01010139|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2018-01-19|2009-11-06|2009-11-09|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2006||2006-08-31|January 2018|2018-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions|A Single Dose, 3-Period, 3-Treatment, 6-Sequence Crossover Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Tablet Formulations Under Fasting Conditions|Completed||N/A|18|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:23:51.568679|2018-06-01 00:23:51.568679
NCT01010126|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-07-10|2009-11-06|2009-11-09|Estimate|||||||2017-07-10|2017-07-11|Actual|September 8, 2009|Actual|2009-09-08|July 2017|2017-07-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer|A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer|Completed||Phase 2|252|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 00:23:51.663766|2018-06-01 00:23:51.663766
NCT01010113|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-04-20|2009-11-06|2009-11-09|Estimate|||||||2012-04-20|2012-04-23|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Effects of a Synbiotics-containing Starter Formula on Infant Growth|Growth of Infants Consuming Starter Formula Containing Synbiotics|Completed||N/A|140|Actual|Nestlé||2|||f||||f||||||||||2018-06-01 00:23:51.965181|2018-06-01 00:23:51.965181
NCT01010100|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2010-12-23|2009-11-06|2009-11-09|Estimate|||||||2010-12-23|2010-12-28|Estimate|August 2000||2000-08-31|December 2010|2010-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care|A Multi-centre, Parallel, Double-blind, Randomised and Placebo Controlled Spanish Study, to Prevent or Delay the Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care (PREDIAP)|Completed||Phase 3|204|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:23:52.052871|2018-06-01 00:23:52.052871
NCT01010087|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-06-09|2009-11-06|2009-11-09|Estimate|||||||2011-06-09|2011-06-10|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ROSII||Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU|"A Randomized, Double-Blinded Controlled Trial Comparing High vs Standard Dose Oseltamivir in Severe, Influenza Infection in ICU. ROSII Study"|Terminated||Phase 2|59|Actual|University of Manitoba||2||Patient population no longer available.|f||||t||||||||||2018-06-01 00:23:52.170332|2018-06-01 00:23:52.170332
NCT01010074|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-06|2009-11-06|2009-11-09|Estimate|||||||2009-11-06|2009-11-09|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Retinal Function in Parkinson's Disease|Intrinsically Photosensitive Retinal Ganglion Cells in Parkinson's Disease|Unknown status|Recruiting||50|Anticipated|Edward Hines Jr. VA Hospital|||||f||||f||||||||||2018-06-01 00:23:52.258705|2018-06-01 00:23:52.258705
NCT01010061|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2013-12-02||2017-11-10|2009-11-06|2009-11-09|Estimate|2014-02-14|2014-04-01|Estimate||||2017-11-10|2017-12-11|Actual|December 21, 2009|Actual|2009-12-21|November 2017|2017-11-30|August 23, 2017|Actual|2017-08-23|July 1, 2012|Actual|2012-07-01||Interventional||Baseline measures are based on the participants who were included in the Stage 1a analysis.|CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)|An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.|Completed||Phase 3|787|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:23:52.458589|2018-06-01 00:23:52.458589
NCT01010048|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-12|2009-11-06|2009-11-09|Estimate|||||||2009-11-12|2009-11-13|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|December 2010|Anticipated|2010-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus|the Therapeutic Effect Treated With Tamsulosin After ESWL in Urinary Calculus|Unknown status|Recruiting|Phase 4|120|Anticipated|Chongqing Medical University||1|||f||||t||||||||||2018-06-01 00:23:53.927216|2018-06-01 00:23:53.927216
NCT01010035|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-06|2009-11-06|2009-11-09|Estimate|||||||2009-11-06|2009-11-09|Estimate|September 2006||2006-09-30|November 2009|2009-11-30|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Observational|||Cholesterol Metabolism and Lipid Transfer in Diabetes|Plasma Kinetics Study of Free Cholesterol and Cholesteryl Ester in Type 2 Diabetes Mellitus Patients|Completed|||26|Actual|University of Sao Paulo General Hospital|||2||f||||f||||||Samples Without DNA|"~     whole blood samples~   "|||2018-06-01 00:23:54.000227|2018-06-01 00:23:54.000227
NCT01010022|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2011-03-09|2009-11-06|2009-11-09|Estimate|||||||2011-03-09|2011-03-10|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Trial of 6% HES130/0.4|Examination of Safety and Efficacy of 6% Hydroxyethyl Starch 130/0.4 vs. 6% Hydroxyethyl Starch 70/0.5 in Patients Undergoing Orthopedic Surgery - a Double-blind, Parallel Group, Comparative, Multi-centre Phase III Study|Completed||Phase 3|64|Actual|Fresenius Kabi||2|||f||||f||||||||||2018-06-01 00:23:54.173881|2018-06-01 00:23:54.173881
NCT01010009|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2010-06-26||2012-05-17|2009-11-06|2009-11-09|Estimate|2011-03-16|2011-04-18|Estimate||||2012-05-17|2012-05-23|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||The Cognitive and Cerebral Blood Flow Effects of Resveratrol|Effects of Resveratrol on Cerebral Blood Flow Parameters and Cognitive Performance in Humans: a Double-blind, Placebo-controlled, Crossover Investigation|Completed||N/A|24|Actual|Northumbria University||3|||f||||f||||||||||2018-06-01 00:23:54.418223|2018-06-01 00:23:54.418223
NCT01009996|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-10|2009-11-06|2009-11-09|Estimate|||||||2009-11-10|2009-11-11|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Observational|KISSING DEBBIE||Efficacy Study of Kissing Drug‐Eluting Balloons in Coronary Bifurcation Lesions|Kissing Drug‐Eluting Balloons After Bare Metal Stenting of Coronary Bifurcation Lesions.|Unknown status|Recruiting||25|Anticipated|Ospedale Santa Maria Goretti|||1||f||||||||||||||2018-06-01 00:23:54.78294|2018-06-01 00:23:54.78294
NCT01009983|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2014-05-19||2018-01-19|2009-11-06|2009-11-09|Estimate|2014-05-19|2014-06-18|Estimate||||2018-01-19|2018-02-15|Actual|March 2010||2010-03-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer|A Phase II Clinical Trial of Weekly Paclitaxel and Carboplatin in Combination With Panitumumab in Metastatic Breast Cancer Patients With Triple Negative Disease|Terminated||Phase 2|14|Actual|Wake Forest University Health Sciences|the worst adverse event of each type was recorded for the course of treatment|1||Slow accrual|f||||f|t|f||||||||2018-06-01 00:23:54.897263|2018-06-01 00:23:54.897263
NCT01009970|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2011-10-12|2009-11-06|2009-11-09|Estimate|||||||2011-10-12|2011-10-13|Estimate|May 2010||2010-05-31|October 2011|2011-10-31|May 2012|Anticipated|2012-05-31|May 2011|Actual|2011-05-31||Interventional|||Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma|Multicenter Study of Phase II With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet ®), Vincristine, Prednisone, (R-COMP) in Non-Hodgkin's Lymphoma Diffuse Large B Cell in Cardiopathic Patients|Unknown status|Recruiting|Phase 2|50|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-06-01 00:23:55.358843|2018-06-01 00:23:55.358843
NCT01009957|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2015-06-22|2009-11-06|2009-11-09|Estimate|||||||2015-06-22|2015-06-23|Estimate|June 2008||2008-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|January 2014|Actual|2014-01-31||Interventional|||Everolimus on CKD Progression in ADPKD Patients|Everolimus on CKD (Chronic Kidney Disease) Progression in ADPKD Patients|Terminated||Phase 2/Phase 3|71|Actual|A. Manzoni Hospital||2||After primary completition date, experimental drug was no longer available|f||||t||||||||||2018-06-01 00:23:55.520231|2018-06-01 00:23:55.520231
NCT01009944|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-05-17|2009-11-06|2009-11-09|Estimate|||||||2017-05-17|2017-05-18|Actual|January 2007|Actual|2007-01-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study|Genetic Mechanisms in Human Hypertension RAAS Inhibition Study|Active, not recruiting||N/A|100|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-06-01 00:23:55.601599|2018-06-01 00:23:55.601599
NCT01009931|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2015-06-16||2015-11-02|2009-11-06|2009-11-09|Estimate|2015-06-19|2015-06-22|Estimate||||2015-11-02|2015-11-04|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|October 2011|Actual|2011-10-31||Interventional|||Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies|A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia|Terminated||Phase 2|1|Actual|Rutgers, The State University of New Jersey||1||Study was terminated early due to lack of experimental medication (supply issues)|f||||f||||||||||2018-06-01 00:23:55.678005|2018-06-01 00:23:55.678005
NCT01009918|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2016-09-16|2009-11-06|2009-11-09|Estimate|||||||2016-09-16|2016-09-19|Estimate|March 2010||2010-03-31|September 2016|2016-09-30||||July 2017|Anticipated|2017-07-31||Interventional|||Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab|Phase II Placebo-controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin®)|Active, not recruiting||Phase 2|468|Anticipated|University of South Florida||3|||f||||t||||||||||2018-06-01 00:23:55.887636|2018-06-01 00:23:55.887636
NCT01009905|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-04-11|2009-11-06|2009-11-09|Estimate|||||||2017-04-11|2017-04-12|Actual|June 24, 2002|Actual|2002-06-24|April 2017|2017-04-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|ANSWER||An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)|Registry of Patients Being Treated With Norditropin®, Recombinant Human Growth Hormone|Completed|||22960|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 00:23:56.258786|2018-06-01 00:23:56.258786
NCT01009892|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2018-01-19|2009-11-06|2009-11-09|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2008||2008-01-31|January 2018|2018-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Food Effect Study of Codeine Sulfate|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Codeine Sulfate Tablets Under Fasting and Fed Conditions|Completed||Phase 1|36|Actual|West-Ward Pharmaceutical||3|||f||||f||||||||||2018-06-01 00:23:56.33357|2018-06-01 00:23:56.33357
NCT01009879|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2013-06-30|2009-11-06|2009-11-09|Estimate|||||||2013-06-30|2013-07-02|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants|Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants|Withdrawn||Phase 4|0|Actual|University of Pittsburgh||1||No subjects were enrolled|f||||f||||||||||2018-06-01 00:23:56.409468|2018-06-01 00:23:56.409468
NCT01009866|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2015-03-18|2009-11-06|2009-11-09|Estimate|||||||2015-03-18|2015-03-20|Estimate|November 2006||2006-11-30|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MR1-1||Study of Immunotoxin, MR1-1|Phase I Study of Immunotoxin, MR1-1|Terminated||Phase 1|9|Actual|Duke University||1||low accrual|f||||f||||||||||2018-06-01 00:23:56.496691|2018-06-01 00:23:56.496691
NCT01009853|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2018-01-19|2009-11-06|2009-11-09|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2008||2008-01-31|January 2018|2018-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Steady State Study of Codeine Sulfate|A Single Dose, 1-Period, 1-Treatment Study of Codeine Sulfate 15 mg Tablets Under Steady State Conditions|Completed||Phase 1|34|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:23:56.566058|2018-06-01 00:23:56.566058
NCT01009840|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2014-07-14|2013-04-30|2014-09-23|2009-11-06|2009-11-09|Estimate|2014-07-14|2014-08-07|Estimate|2013-04-30|2013-05-08|Estimate|2014-09-23|2014-09-25|Estimate|May 2010||2010-05-31|September 2014|2014-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients|A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT|Completed||Phase 2|30|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-06-01 00:23:56.670832|2018-06-01 00:23:56.670832
NCT01009827|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-02-27|2009-11-06|2009-11-09|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2009||2009-10-31|March 2016|2016-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Managerial Database II|Network-Wide Assessment of Current Health Status and Behavioral Risk Factors|Completed|||1712|Actual|University of North Carolina, Chapel Hill|||1||f||||t||||||||||2018-06-01 00:23:57.075633|2018-06-01 00:23:57.075633
NCT01009814|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-07-25|2009-11-06|2009-11-09|Estimate|||||||2017-07-25|2017-07-27|Actual|November 23, 2009|Actual|2009-11-23|July 2017|2017-07-31|June 25, 2010|Actual|2010-06-25|June 25, 2010|Actual|2010-06-25||Interventional|||Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1|Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects|Completed||Phase 2|50|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-06-01 00:23:57.168533|2018-06-01 00:23:57.168533
NCT01009801|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2015-07-03|2009-11-06|2009-11-09|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|November 2011|Actual|2011-11-30||Interventional|||Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer|A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolization (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|27|Actual|Swiss Group for Clinical Cancer Research||2||due to slow patient recruitement.|f||||f||||||||||2018-06-01 00:23:57.237972|2018-06-01 00:23:57.237972
NCT01009788|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2018-04-05|2009-11-06|2009-11-09|Estimate|||||||2018-04-05|2018-04-09|Actual|November 2009||2009-11-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer|A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers|Active, not recruiting||Phase 2|64|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 00:23:57.343436|2018-06-01 00:23:57.343436
NCT01009775|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06||2015-08-20|2015-08-20|2009-11-06|2009-11-09|Estimate||||2015-08-20|2015-09-04|Estimate|2015-08-20|2015-09-04|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|August 2012|Actual|2012-08-31|March 2011|Actual|2011-03-31||Interventional|||A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma|A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma|Completed||Phase 2|64|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:23:57.442727|2018-06-01 00:23:57.442727
NCT01009762|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2013-07-29||2014-02-27|2009-11-06|2009-11-09|Estimate|2014-01-08|2014-02-27|Estimate||||2014-02-27|2014-03-27|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|HIV-VAC||Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection|Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With|Completed||Phase 1|11|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-06-01 00:23:57.531115|2018-06-01 00:23:57.531115
NCT01009749|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-07-28|2009-11-06|2009-11-09|Estimate|||||||2017-07-28|2017-08-01|Actual|August 2009||2009-08-31|July 2017|2017-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Motivational Enhancement System for Adherence|Computer-Delivered Motivational Intervention to Prevent Adherence Problems Among Youth Newly Recommended for HIV Medications: Project MESA (Motivational Enhancement System for Adherence)|Completed||N/A|76|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:23:57.772063|2018-06-01 00:23:57.772063
NCT01009736|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2014-10-15|2009-11-06|2009-11-09|Estimate|||||||2014-10-15|2014-10-16|Estimate|January 2008||2008-01-31|October 2014|2014-10-31||||July 2009|Actual|2009-07-31||Interventional|||Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy|Biomarkers of Prostate and Cardiovascular Health of Men Undergoing Prostatectomy Consuming Different Amounts of Soy-Tomato Juice|Completed||Phase 1/Phase 2|60|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 00:23:57.884182|2018-06-01 00:23:57.884182
NCT01009723|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-06-07|2009-11-06|2009-11-09|Estimate|||||||2012-06-07|2012-06-08|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers|Early Prediction Of Preterm Delivery By Measurement Of Maternal Serum Markers|Unknown status|Active, not recruiting||2000|Anticipated|Esoterix Genetic Laboratories, LLC|||||f||||f||||||Samples Without DNA|"~     Serum and plasma samples from the study subjects~   "|||2018-06-01 00:23:57.954488|2018-06-01 00:23:57.954488
NCT01009710|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-01-14|2009-11-06|2009-11-09|Estimate|||||||2017-01-14|2017-01-18|Estimate|July 2009||2009-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Observational|||Measured Hypocretin Levels and Recovery After Hip Surgery|Preoperative Cerebrospinal Fluid (CSF) Levels of Hypocretin and Recovery After Hip Surgery With Combined Spinal and General Anesthesia|Active, not recruiting|||50|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 00:23:58.024635|2018-06-01 00:23:58.024635
NCT01009697|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2018-01-19|2009-11-06|2009-11-09|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2008||2008-03-31|January 2018|2018-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Dose Linearity Study of Codeine Sulfate Under Fasted Conditions|A Single Dose, 3-Period, 3-Treatment, 6-Sequence, 3-Way Crossover Study of the Dose Linearity of Codeine Sulfate Tablets Under Fasting Conditions|Completed||Phase 1|34|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:23:58.143144|2018-06-01 00:23:58.143144
NCT01009684|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2017-05-19|2009-11-06|2009-11-09|Estimate|||||||2017-05-19|2017-05-22|Actual|August 2009||2009-08-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|February 2017|Actual|2017-02-28||Observational|INAS-SCORE||International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens|INAS-SCORE International Active Surveillance Study - Safety of Contraceptives: Role of Estrogens|Active, not recruiting|||50203|Actual|Center for Epidemiology and Health Research, Germany|||2||f||||t||||||||||2018-06-01 00:23:58.207933|2018-06-01 00:23:58.207933
NCT01009671|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2009-11-06|2009-11-06|2009-11-09|Estimate|||||||2009-11-06|2009-11-09|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|||Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee|Randomised, Comparative, Double-blind, Parallel-group Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee|Unknown status|Active, not recruiting|Phase 3|210|Actual|Laboratoires NEGMA||2|||f||||f||||||||||2018-06-01 00:23:58.292178|2018-06-01 00:23:58.292178
NCT01009658|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2015-03-25|2009-11-06|2009-11-09|Estimate|||||||2015-03-25|2015-03-26|Estimate|December 2009||2009-12-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Interventional|||MSG and Gastrointestinal Motility|Effect of Monosodium Glutamate on Upper Gastrointestinal Tract Motility|Completed||N/A|40|Anticipated|Gunma University||2|||f||||||||||||||2018-06-01 00:23:58.389494|2018-06-01 00:23:58.389494
NCT01009294|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-05-30|2009-11-05|2009-11-06|Estimate|||||||2017-05-30|2017-06-01|Actual|November 2009||2009-11-30|May 2017|2017-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Study of Ataluren (PTC124®) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)|A Phase 2a Study of Ataluren (PTC124) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy|Terminated||Phase 2|6|Actual|PTC Therapeutics||1|||f||||t||||||||No||2018-06-01 00:24:06.689657|2018-06-01 00:24:06.689657
NCT01009645|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2012-04-25||2012-08-20|2009-11-06|2009-11-09|Estimate|2012-08-20|2012-09-18|Estimate||||2012-08-20|2012-09-18|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination|The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination|Completed||N/A|125|Actual|Northwestern University|Low participation in the trial due to the emergence of H1N1; many individuals >50 years of age opted to receive seasonal flu vaccine as they were initially unable to receive the H1N1 vaccine. Hence, the available study population shrank markedly.|4|||f||||f||||||||||2018-06-01 00:23:58.468399|2018-06-01 00:23:58.468399
NCT01009632|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-11-06|2009-11-06|2009-11-09|Estimate|||||||2009-11-06|2009-11-09|Estimate|February 2004||2004-02-29|November 2009|2009-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Role of Exercise for Wound Healing in the Larynx|Role of Exercise for Wound Healing in the Larynx|Completed||N/A|9|Actual|University of Pittsburgh||3|||f||||f||||||||||2018-06-01 00:23:58.845315|2018-06-01 00:23:58.845315
NCT01009619|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|2011-04-21||2011-08-29|2009-11-06|2009-11-09|Estimate|2011-07-27|2011-08-25|Estimate||||2011-08-29|2011-10-03|Estimate|September 2005||2005-09-30|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|AZI001||Azithromycin in Bronchiolitis Obliterans Syndrome|Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation.|Completed||Phase 4|83|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 00:23:58.947031|2018-06-01 00:23:58.947031
NCT01009606|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-06|||2013-01-17|2009-11-06|2009-11-09|Estimate|||||||2013-01-17|2013-01-18|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PRESENCE||Cardiopulmonary Resuscitation Witnessing by a Relative|Interest for a Relative of Seeing Himself Proposing to Witness Resuscitation of a Family Member Victim of a Cardiac Arrest|Completed||Phase 4|570|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:23:59.289816|2018-06-01 00:23:59.289816
NCT01009593|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-09-07|2009-11-05|2009-11-06|Estimate|||||||2012-09-07|2012-09-10|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)|An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)|Terminated||Phase 3|1035|Actual|Abbott||2||See termination reason in detailed description|f||||||||||||||2018-06-01 00:23:59.400956|2018-06-01 00:23:59.400956
NCT01009580|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2015-10-19|2010-11-09|2017-02-09|2009-11-05|2009-11-06|Estimate|2015-10-19|2015-11-20|Estimate|2011-01-07|2011-01-20|Estimate|2017-02-09|2017-03-20|Actual|November 2009||2009-11-30|February 2017|2017-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|BOOST™||Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes|A 26-week, Randomised, Open-labelled, Two-arm, Parallel-group, Treat-to-target Trial Comparing Efficacy and Safety of Soluble Insulin Analogue Combination (SIAC) Twice Daily (BID) With Biphasic Insulin Aspart (BIAsp) 30 BID, With or Without Metformin, With or Without DPP-4 Inhibitor, With or Without Pioglitazone in Subjects With Type 2 Diabetes in Inadequate Glycaemic Control on Once or Twice Daily Premixed or Self-mixed Insulin Regimen With or Without OADs (BOOST™: Intensify Premix 1)|Completed||Phase 3|447|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:23:59.692486|2018-06-01 00:23:59.692486
NCT01009567|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2015-05-05|2009-11-05|2009-11-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|June 2009||2009-06-30|November 2009|2009-11-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program|Compare the Efficacy of Human Albumin With Cabergoline to Prevent of Ovarian Hyper Stimulation in ART Program|Completed||Phase 1/Phase 2|10|Anticipated|Royan Institute||2|||f||||t||||||||||2018-06-01 00:24:00.086803|2018-06-01 00:24:00.086803
NCT01009554|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2015-06-04||2015-06-04|2009-11-05|2009-11-06|Estimate|2015-06-04|2015-07-03|Estimate||||2015-06-04|2015-07-03|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Oral Tissue Tolerance of a Mouthrinse|Assessment of the Oral Tissue Tolerance of a Potassium Oxalate Containing Mouthrinse|Completed||N/A|96|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 00:24:00.209624|2018-06-01 00:24:00.209624
NCT01009541|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-12-28|2009-11-05|2009-11-06|Estimate|||||||2009-12-28|2009-12-29|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||An Investigation of the Absorption and Pharmacokinetics of Multiple Doses of Three Controlled Release Pregabalin Tablets as Compared to Multiple Doses of the Immediate Release Pregabalin Capsule|An Open-Label, Multiple-Dose, Randomized, Crossover Study In Healthy Volunteers To Investigate The Pharmacokinetics Of Three Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal As Compared To The Immediate Release Formulation|Completed||Phase 1|20|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:24:01.797783|2018-06-01 00:24:01.797783
NCT01009528|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-11-06|2009-11-05|2009-11-06|Estimate|||||||2009-11-06|2009-11-09|Estimate|March 2007||2007-03-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Interventional|||Electronic Feedback on Diabetic Care to General Practitioners|Development and Evaluation of Electronic Feedback, a Tool for Quality Assurance of the Diabetic Care in General Practice|Completed||N/A|2458|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:24:01.87002|2018-06-01 00:24:01.87002
NCT01009515|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2015-08-14||2017-09-15|2009-11-05|2009-11-06|Estimate|2015-10-05|2015-11-03|Estimate||||2017-09-15|2017-10-18|Actual|August 2009||2009-08-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|September 2013|Actual|2013-09-30||Interventional|||Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma|Phase II Trial of Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma|Terminated||Phase 2|19|Actual|New Mexico Cancer Care Alliance||1||Low accrual; target accrual not met|f||||t||||||||||2018-06-01 00:24:01.991198|2018-06-01 00:24:01.991198
NCT01009502|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2013-11-06|2009-11-05|2009-11-06|Estimate|||||||2013-11-06|2013-11-08|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|March 2012|Actual|2012-03-31||Interventional|||Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome|SHP2 as a Therapeutic Target For Myelodysplastic Syndrome: Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome|Terminated||Phase 1|1|Actual|Northwestern University||1||Lack of funding, never moved into the phase II portion that was originally planned.|f||||t||||||||||2018-06-01 00:24:02.429479|2018-06-01 00:24:02.429479
NCT01009476|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2014-06-17|2009-11-05|2009-11-06|Estimate|||||||2014-06-17|2014-06-18|Estimate|March 2006||2006-03-31|June 2014|2014-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine|Non-interventional Study on Long-term Application of Galantamine and Nootropics in Patients With Alzheimer's Disease|Completed|||1134|Actual|Janssen-Cilag G.m.b.H|||2||f||||f||||||||||2018-06-01 00:24:02.499435|2018-06-01 00:24:02.499435
NCT01009463|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-05-30|2012-05-10|2017-10-09|2009-11-05|2009-11-06|Estimate|2013-08-15|2013-08-19|Estimate|2012-05-10|2012-05-15|Estimate|2017-10-09|2017-11-09|Actual|September 25, 2009||2009-09-25|October 2017|2017-10-31|October 31, 2011|Actual|2011-10-31|October 1, 2011|Actual|2011-10-01||Interventional|||A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1626|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:24:02.630097|2018-06-01 00:24:02.630097
NCT01009450|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-11-05|2009-11-05|2009-11-06|Estimate|||||||2009-11-05|2009-11-06|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|CLC||Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel in Cirrhotic Patients a Prospective Randomized Study|Clipless Laparoscopic Cholecystectomy Using Harmonic Scalpel in Cirrhotic Patients a Prospective Randomized Study|Completed||N/A|120|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:24:05.272117|2018-06-01 00:24:05.272117
NCT01009437|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-12-03|2009-11-05|2009-11-06|Estimate|||||||2017-12-03|2017-12-05|Actual|May 26, 2010|Actual|2010-05-26|December 2017|2017-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer|A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer|Completed||Phase 1|28|Actual|Masonic Cancer Center, University of Minnesota||3|||f||||t||||||||||2018-06-01 00:24:05.367778|2018-06-01 00:24:05.367778
NCT01009424|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2016-10-26|2009-11-05|2009-11-06|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease|A Multi-center, Placebo-controlled, Double Blind Multiple-ascending Dose Study in a Leapfrog Design to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of RO5024118 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease|Withdrawn||Phase 1|0|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 00:24:05.456682|2018-06-01 00:24:05.456682
NCT01009411|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2014-06-19|2009-11-05|2009-11-06|Estimate|||||||2014-06-19|2014-06-20|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Labor Progress Indices and the Dynamics of the Individual Contraction During the Active Stage of Labor|Physiological Study of the Active Stage of Labor|Completed|||40|Actual|Western Galilee Hospital-Nahariya|||3||f||||f||||||||||2018-06-01 00:24:05.521506|2018-06-01 00:24:05.521506
NCT01009398|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-02-02|2009-11-05|2009-11-06|Estimate|||||||2011-02-02|2011-02-03|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Thoracic Paravertebral Catheters|Radiological Evaluation of Thoracic Paravertebral Catheters: A Prospective Clinical Trial|Completed|||30|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 00:24:05.580793|2018-06-01 00:24:05.580793
NCT01009385|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2009-11-05|2009-11-05|2009-11-06|Estimate|||||||2009-11-05|2009-11-06|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Cervical Epidural Pressure Measurement|Cervical Epidural Pressure Measurement: Comparison in the Prone and Sitting Positions|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:24:05.652557|2018-06-01 00:24:05.652557
NCT01009372|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-11-05|2009-11-05|2009-11-06|Estimate|||||||2009-11-05|2009-11-06|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|February 2008|Actual|2008-02-29||Interventional|IPP||The Intermittent Pneumoperitoneum Scheme of Work Breaks in Complex Laparoscopic Surgery|Prospective Study on the Effects of the Intermittent Pneumoperitoneum (IPP) Work Break Scheme on Surgeons and Patients.|Completed||N/A|56|Actual|Hannover Medical School||1|||f||||t||||||||||2018-06-01 00:24:05.734255|2018-06-01 00:24:05.734255
NCT01009359|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2013-07-30|2009-11-05|2009-11-06|Estimate|||||||2013-07-30|2013-07-31|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers|Open-label, Non-randomized, Multicenter Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq BAY85-8102 F-18, DPA-714 for Its Diagnostic Potential in Discriminating Patients With Probable Alzheimers Disease From Healthy Volunteers and to Evaluate the Radiation Dosimetry of a Single Dose of 150 MBq BAY858102 F-18, DPA-714 in Healthy Volunteers.|Completed||Phase 1|22|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:24:05.912482|2018-06-01 00:24:05.912482
NCT01009346|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2014-03-23||2017-01-04|2009-11-05|2009-11-06|Estimate|2014-05-21|2014-06-09|Estimate||||2017-01-04|2017-02-20|Actual|October 2009||2009-10-31|January 2017|2017-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic Squamous Cell Cancer of the Head and Neck|A Phase 1/2 Study of RAD001 in Combination w/ Cetuximab and Cisplatin as First-line Therapy in Recurrent & Metastatic Squamous Cell Cancer of the Head & Neck|Terminated||Phase 1/Phase 2|9|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Early termination leading to small numbers of subjects analyzed|1||Toxicity|f||||t||||||||||2018-06-01 00:24:06.013709|2018-06-01 00:24:06.013709
NCT01009333|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2011-11-28||2013-05-17|2009-11-05|2009-11-06|Estimate|2012-04-05|2012-05-02|Estimate||||2013-05-17|2013-05-27|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||InterStim Therapy Programming Study|InterStim Therapy Programming Study|Completed||N/A|13|Actual|MedtronicNeuro||3|||f||||f||||||||||2018-06-01 00:24:06.211687|2018-06-01 00:24:06.211687
NCT01009320|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2013-03-05|2009-11-05|2009-11-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||The Potential Interference of Magnets From a Surgical Magnetic Drape With Cardiac Pacemakers|The Potential Interference of Magnets From a Surgical Magnetic Drape With Cardiac Pacemakers|Completed|||50|Actual|Maisonneuve-Rosemont Hospital|||1||f||||f||||||||||2018-06-01 00:24:06.553951|2018-06-01 00:24:06.553951
NCT01009307|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2015-05-14|2009-11-05|2009-11-06|Estimate|||||||2015-05-14|2015-05-15|Estimate|October 2001||2001-10-31|May 2015|2015-05-31||||July 2006|Actual|2006-07-31||Observational|||Study of Blood and Cheek Cell Samples From Patients With Glioma|San Francisco Bay Area Adult Glioma Prognosis Study Protocol|Completed|||1709|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 00:24:06.619736|2018-06-01 00:24:06.619736
NCT01009281|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-05-31|2009-11-05|2009-11-06|Estimate|||||||2012-05-31|2012-06-01|Estimate|October 2009||2009-10-31|May 2012|2012-05-31||||August 2010|Actual|2010-08-31||Interventional|||An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease|A 52 Week Open Label Extension Study to Evaluate the Safety and Tolerability of AIN457 (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Crohn's Disease|Terminated||Phase 2|7|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:24:06.810742|2018-06-01 00:24:06.810742
NCT01009268|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2013-05-15|2009-11-05|2009-11-06|Estimate|||||||2013-05-15|2013-05-16|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||The Effect of a Pre- and Postoperative Orthogeriatric Service|The Effect of a Pre- and Postoperative Orthogeriatric Service. A Randomised, Controlled Trial|Completed||N/A|332|Actual|Oslo University Hospital|||||f||||f||||||||||2018-06-01 00:24:06.922299|2018-06-01 00:24:06.922299
NCT01009255|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-04-11|2009-11-05|2009-11-06|Estimate|||||||2017-04-11|2017-04-13|Actual|November 2, 2009|Actual|2009-11-02|April 2017|2017-04-30|November 10, 2010|Actual|2010-11-10|November 10, 2010|Actual|2010-11-10||Interventional|||Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease.|Completed||Phase 2|196|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:24:07.134969|2018-06-01 00:24:07.134969
NCT01009242|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04||2011-10-03|2014-08-26|2009-11-04|2009-11-06|Estimate||||2011-10-03|2011-10-05|Estimate|2014-08-26|2014-08-27|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single Dose Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis on a Stable Dose of Methotrexate|Completed||Phase 1/Phase 2|40|Actual|UCB Pharma||3|||f||||t||||||||||2018-06-01 00:24:07.371588|2018-06-01 00:24:07.371588
NCT01009229|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-05-24|2009-11-05|2009-11-06|Estimate|||||||2011-05-24|2011-05-25|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Reduced 11-b-HSD Activity, a Novel Mechanism of Salt Sensitivity and Hypertension After Renal Allograft Donation?|A Reduced 11 Beta Hydroxysteroid Dehydrogenase 2 (11 Beta HSD2) Activity, a Novel Mechanism of Salt Sensitivity and Hypertension After Renal Allograft Donation?|Completed||N/A|100|Anticipated|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 00:24:07.465017|2018-06-01 00:24:07.465017
NCT01009216|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2010-12-13|2009-11-05|2009-11-06|Estimate|||||||2010-12-13|2010-12-14|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid|A Study to Evaluate the Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-384 in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Abbott||1|||f||||||||||||||2018-06-01 00:24:07.571713|2018-06-01 00:24:07.571713
NCT01009203|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2015-06-15||2015-07-14|2009-11-05|2009-11-06|Estimate|2015-07-14|2015-08-10|Estimate||||2015-07-14|2015-08-10|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma|A Phase II Study of Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|13|Actual|New Mexico Cancer Care Alliance||1||High patient withdrawal rate|f||||t||||||||||2018-06-01 00:24:07.67074|2018-06-01 00:24:07.67074
NCT01009190|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2017-08-07|2009-11-05|2009-11-06|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2010||2010-02-28|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens|A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor|Completed||Phase 1|85|Actual|Clovis Oncology, Inc.||2|||f||||f||||||||||2018-06-01 00:24:08.192677|2018-06-01 00:24:08.192677
NCT01009177|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2015-04-28|2009-11-05|2009-11-06|Estimate|||||||2015-04-28|2015-04-30|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of Bosentan in Patients With Stage IV Metastatic Melanoma Treated With Dacarbazine|Completed||Phase 2|80|Actual|Actelion||2|||f||||t||||||||||2018-06-01 00:24:08.349633|2018-06-01 00:24:08.349633
NCT01009151|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2015-05-26|2009-11-05|2009-11-06|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Heart Failure Patient Self-Management Web Portal Pilot Study|University of Michigan Heart Failure Patient Self-Management Web Portal Pilot Study|Completed||N/A|43|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 00:24:08.49362|2018-06-01 00:24:08.49362
NCT01009138|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2015-08-14||2015-10-26|2009-11-05|2009-11-06|Estimate|2015-10-26|2015-11-26|Estimate||||2015-10-26|2015-11-26|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Evaluation of a Diabetes-specific Cognitive Behavioural Treatment for Subthreshold Depression|Development and Evaluation of a Diabetes-specific Cognitive Behavioural Treatment (DS-CBT) for Diabetic Patients With Subthreshold Depression|Completed||N/A|214|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||t||||||||||2018-06-01 00:24:08.644236|2018-06-01 00:24:08.644236
NCT01009125|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2010-06-08|2009-11-05|2009-11-06|Estimate|||||||2010-06-08|2010-06-09|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Healthcare Access and Utilization Among Living Kidney Donors|Randomized Trial of Financial Incentives to Increase Response Rates to a Mailed Survey of Healthcare Access and Utilization Among Living Kidney Donors|Completed||N/A|600|Anticipated|St. Barnabas Medical Center||2|||f||||f||||||||||2018-06-01 00:24:09.286883|2018-06-01 00:24:09.286883
NCT01009112|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2015-05-26|2009-11-05|2009-11-06|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Treating Insomnia & Nightmares After Trauma: Impact on Symptoms & Quality of Life|Treating Insomnia & Nightmares After Trauma: Impact on Symptoms & Quality of Life|Completed||N/A|45|Actual|University of California, San Diego||4|||f||||f||||||||||2018-06-01 00:24:09.359132|2018-06-01 00:24:09.359132
NCT01009099|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2015-02-02||2015-02-02|2009-11-05|2009-11-06|Estimate|2015-02-02|2015-02-18|Estimate||||2015-02-02|2015-02-18|Estimate|July 2009||2009-07-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Reducing Dynamic Hyperinflation Through Breathing Retraining|Reducing Dynamic Hyperinflation Through Breathing Retraining|Completed||Phase 2/Phase 3|119|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:24:09.462451|2018-06-01 00:24:09.462451
NCT01009086|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-10-11|2012-10-16|2015-02-11|2009-11-05|2009-11-06|Estimate|2014-01-28|2014-03-13|Estimate|2012-10-16|2012-10-18|Estimate|2015-02-11|2015-03-03|Estimate|December 2009||2009-12-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|October 2011|Actual|2011-10-31||Interventional|||A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis|Completed||Phase 3|615|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-06-01 00:24:09.84733|2018-06-01 00:24:09.84733
NCT01009073|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-11-16|2009-11-05|2009-11-06|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2009||2009-10-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-263 in Combination With Erlotinib and ABT-263 in Combination With Irinotecan, and Evaluating the Safety of ABT-263 Monotherapy in Subjects With Cancer|Completed||Phase 1|51|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 00:24:11.58476|2018-06-01 00:24:11.58476
NCT01009060|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2017-07-05|2012-03-15|2017-10-09|2009-11-05|2009-11-06|Estimate|2017-08-29|2017-09-27|Actual|2012-03-15|2012-03-19|Estimate|2017-10-09|2017-11-08|Actual|December 1, 2009|Actual|2009-12-01|August 2017|2017-08-31|August 10, 2011|Actual|2011-08-10|August 10, 2011|Actual|2011-08-10||Interventional||Baseline characteristic data is presented for ITT population which consisted of all participants randomized to treatment, who had taken at least one dose of investigational product and who had at least one post-Baseline CogState Schizophrenia Battery (CSSB) assessment during the on-treatment phase.|Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia|A Randomised Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients With Schizophrenia|Completed||Phase 2|50|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:24:11.879975|2018-06-01 00:24:11.879975
NCT01009047|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-03-29||2013-06-20|2009-11-05|2009-11-06|Estimate|2013-06-20|2013-06-21|Estimate||||2013-06-20|2013-06-21|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia|A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age|Completed||Phase 3|228|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-06-01 00:24:12.584976|2018-06-01 00:24:12.584976
NCT01009034|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2014-06-16||2014-09-08|2009-11-05|2009-11-06|Estimate|2014-09-08|2014-09-09|Estimate||||2014-09-08|2014-09-09|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|NCT01009034|10 HIV+ men on maraviroc with VL <50 copies per M|Concentrations of Maraviroc in the Semen of HIV-Infected Men|Study to Determine the Concentrations of Maraviroc in Semen, the Seminal to Plasma Ratio of Maraviroc and the Variability in Seminal to Plasma Ratios Over the Maraviroc Dosing Period.|Completed|||14|Actual|Canadian Immunodeficiency Research Collaborative|||1||f||||f||||||||||2018-06-01 00:24:13.250146|2018-06-01 00:24:13.250146
NCT01009021|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-11-05|2009-11-05|2009-11-06|Estimate|||||||2009-11-05|2009-11-06|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy|Analgesic Effectiveness of Potassium Diclofenac for Retinal Photocoagulation in Patients With High-risk Proliferative Diabetic Retinopathy|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:24:13.414232|2018-06-01 00:24:13.414232
NCT01009008|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2013-06-13|2009-11-05|2009-11-06|Estimate|||||||2013-06-13|2013-06-17|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|PACE||Patient Activated Controlled Expansion (PACE) Trial|Patient Activated Controlled Expansion (PACE) for Breast Reconstruction Utilizing Controlled CO2 Inflation|Completed||N/A|40|Actual|AirXpanders, Inc.||1|||f||||t||||||||||2018-06-01 00:24:13.483403|2018-06-01 00:24:13.483403
NCT01008995|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2012-08-15||2013-10-17|2009-11-05|2009-11-06|Estimate|2012-08-15|2012-09-14|Estimate||||2013-10-17|2013-11-11|Estimate|October 2009||2009-10-31|October 2013|2013-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis|Completed||Phase 3|322|Actual|Centocor, Inc.||2|||f||||t||||||||||2018-06-01 00:24:13.624844|2018-06-01 00:24:13.624844
NCT01008982|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-09-03|2009-11-05|2009-11-06|Estimate|||||||2012-09-03|2012-09-05|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome|A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Primary Sjögren's Syndrome.|Completed||Phase 2|15|Actual|University of Udine||1|||f||||t||||||||||2018-06-01 00:24:14.050297|2018-06-01 00:24:14.050297
NCT01008969|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2011-07-19||2011-12-29|2009-11-05|2009-11-06|Estimate|2011-12-29|2012-02-02|Estimate||||2011-12-29|2012-02-02|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients|Practice Procedure for 99mTc-Sulfur Nanocolloid Lymphatic Drainage Mapping in Prostate Cancer Using SPECT-CT (Single Photon Emission Computed Tomography / Computed Tomography)|Completed||N/A|10|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 00:24:14.145285|2018-06-01 00:24:14.145285
NCT01008956|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2015-03-19|2009-11-05|2009-11-06|Estimate|||||||2015-03-19|2015-03-23|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults|Immunogenicity and Safety Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine GSK2340274A in Adults 18 to 64 Years of Age|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||1||Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|f||||||||||||||2018-06-01 00:24:14.348442|2018-06-01 00:24:14.348442
NCT01008943|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2015-10-01||2015-11-02|2009-11-05|2009-11-06|Estimate|2015-10-01|2015-11-03|Estimate||||2015-11-02|2015-11-30|Estimate|July 2010||2010-07-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Autologous Cell Therapy for Female Stress Urinary Incontinence|A Canadian Prospective Nonrandomized Study of Autologous Cell Therapy for Female Stress Urinary Incontinence|Completed||Phase 2|16|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-06-01 00:24:14.428127|2018-06-01 00:24:14.428127
NCT01008930|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2014-08-19|2009-11-05|2009-11-06|Estimate|||||||2014-08-19|2014-08-20|Estimate|December 2009||2009-12-31|August 2014|2014-08-31||||August 2014|Actual|2014-08-31||Interventional|||Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System|Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System|Completed||N/A|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:24:14.622981|2018-06-01 00:24:14.622981
NCT01008917|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-06-15|2009-11-05|2009-11-06|Estimate|||||||2017-06-15|2017-06-16|Actual|November 17, 2009|Actual|2009-11-17|June 2017|2017-06-30|September 12, 2012|Actual|2012-09-12|September 12, 2012|Actual|2012-09-12||Interventional|||Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma|Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma|Completed||Phase 1|25|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:24:14.702402|2018-06-01 00:24:14.702402
NCT01008904|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-08-12||2016-06-17|2009-11-05|2009-11-06|Estimate|2013-12-17|2014-02-05|Estimate||||2016-06-17|2016-06-21|Estimate|July 2009||2009-07-31|June 2016|2016-06-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional||patient who started study treatment|Magnesium Oxide in Treating Hot Flashes in Menopausal Women With Cancer|A Pilot Phase II Trial of Magnesium Supplements to Reduce Menopausal Hot Flashes in Cancer Patients|Completed||Phase 2|31|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 00:24:14.807703|2018-06-01 00:24:14.807703
NCT01008891|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-10-18|2009-11-05|2009-11-06|Estimate|||||||2012-10-18|2012-10-19|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Augment™ Injectable Bone Graft Compared to Autologous Bone Graft in Foot and Ankle Fusions|Prospective, Randomized, Controlled, Multi-Center, Pivotal Clinical Trial to Evaluate the Safety and Effectiveness of Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions|Completed||N/A|180|Anticipated|BioMimetic Therapeutics||2|||f||||t||||||||||2018-06-01 00:24:15.25465|2018-06-01 00:24:15.25465
NCT01008878|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-11-05|2009-11-05|2009-11-06|Estimate|||||||2009-11-05|2009-11-06|Estimate|March 2004||2004-03-31|November 2009|2009-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Treatment of the Metabolic Syndrome in an Interdisciplinary Obesity Clinic: a Randomized Controlled Study|Treatment of the Metabolic Syndrome in an Interdisciplinary Obesity Clinic: a Randomized Controlled Study|Completed||N/A|60||Université de Sherbrooke|||||f||||f||||||||||2018-06-01 00:24:15.356051|2018-06-01 00:24:15.356051
NCT01008865|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2018-03-28|2009-11-05|2009-11-06|Estimate|||||||2018-03-28|2018-03-30|Actual|January 4, 2002|Actual|2002-01-04|March 2018|2018-03-31|June 4, 2019|Anticipated|2019-06-04|December 8, 2018|Anticipated|2018-12-08||Interventional|||A Comparison of the Studer Pouch Versus the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients|A Randomized Comparison of the Studer Pouch vs. the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients|Active, not recruiting||N/A|529|Actual|University of Southern California||2|||f||||t|f|f||||||||2018-06-01 00:24:15.435853|2018-06-01 00:24:15.435853
NCT01008852|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05||2012-11-12|2013-11-07|2009-11-05|2009-11-06|Estimate||||2013-02-07|2013-02-11|Estimate|2013-11-07|2013-12-03|Estimate|December 2009||2009-12-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|September 2011|Actual|2011-09-30||Interventional|||Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis|Randomized, Parallel, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate|Completed||Phase 2|210|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 00:24:15.81356|2018-06-01 00:24:15.81356
NCT01008839|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-05-13|2009-11-05|2009-11-06|Estimate|||||||2011-05-13|2011-05-16|Estimate|March 2010||2010-03-31|May 2011|2011-05-31||||||||Observational|||Protein Synthesis in Midthigh Muscles PET/CT||Completed|||10|Anticipated|University of California, San Francisco|||2||f||||||||||||||2018-06-01 00:24:16.088944|2018-06-01 00:24:16.088944
NCT01008826|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-09-15|2009-11-05|2009-11-06|Estimate|||||||2011-09-15|2011-09-16|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Cross-Over Broccoli Sprouts Trial|Cross-Over Broccoli Sprouts Trial - Qidong|Completed||Phase 1|50|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 00:24:16.156029|2018-06-01 00:24:16.156029
NCT01008813|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-12-21|2009-11-05|2009-11-06|Estimate|||||||2011-12-21|2011-12-22|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)|A Randomized Phase II Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)|Completed||Phase 2|306|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||t||||||||||2018-06-01 00:24:16.349904|2018-06-01 00:24:16.349904
NCT01008800|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2018-05-21|2009-11-05|2009-11-06|Estimate|||||||2018-05-21|2018-05-22|Actual|September 2009||2009-09-30|May 2018|2018-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Randomized Clinical Trial for Toddlers With ASD|Parent-mediated vs Center-based Intervention for Toddlers With ASD: An RCT|Completed||N/A|196|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||t||||||||||2018-06-01 00:24:16.493946|2018-06-01 00:24:16.493946
NCT01008787|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2018-01-08|2009-11-05|2009-11-06|Estimate|||||||2018-01-08|2018-01-10|Actual|July 2009|Actual|2009-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Motivational Interviewing for Physical Activity|Peer-support Motivational Interviewing Physical Activity Intervention for African American Women|Active, not recruiting||N/A|80|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|f|||||||||2018-06-01 00:24:16.585717|2018-06-01 00:24:16.585717
NCT01008774|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-01-20|2009-11-05|2009-11-06|Estimate|||||||2012-01-20|2012-01-23|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||START: Swiss Taxotere Alopecia Prevention Trial|A Comparison of Different Scalp Cooling Systems for the Prevention of Chemotherapy Induced Alopecia|Completed||N/A|239|Actual|Sanofi||3|||f||||||||||||||2018-06-01 00:24:16.78588|2018-06-01 00:24:16.78588
NCT01007708|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-06-20|2009-11-03|2009-11-04|Estimate|||||||2012-06-20|2012-06-22|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis||Completed||Phase 3|780|Actual|Dow Pharmaceutical Sciences||2|||f||||f||||||||||2018-06-01 00:24:37.604808|2018-06-01 00:24:37.604808
NCT01008761|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2012-07-11|2009-11-05|2009-11-06|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Trial for the Treatment of Acute Asthma in Wheezy Pre-school Aged Children|A Double Blind Randomized Control Trail of Azithromycin for the Acute Management of Wheezy Pre-school Children|Unknown status|Recruiting|N/A|440|Anticipated|Alberta Children's Hospital||2|||f||||f||||||||||2018-06-01 00:24:16.882856|2018-06-01 00:24:16.882856
NCT01008748|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2016-09-21|2009-11-05|2009-11-06|Estimate|||||||2016-09-21|2016-09-23|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Determinants of Smoking Cessation Among Latinos|Determinants of Smoking Cessation Among Latinos|Completed||N/A|200|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:24:17.006274|2018-06-01 00:24:17.006274
NCT01008735|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2009-11-11|2009-11-05|2009-11-06|Estimate|||||||2009-11-11|2009-11-13|Estimate|July 2009||2009-07-31|November 2009|2009-11-30||||||||Observational|FertHD||Gonadal Toxicity in Women With Hodgkin Lymphoma|Observational Retrospective Study to Evaluate the Incidence of the Gonadal Toxicity in Women of Reproductive Age With Hodgkin Lymphoma|Unknown status|Recruiting||150|Anticipated|Gruppo Italiano Studio Linfomi|||1||f||||f||||||||||2018-06-01 00:24:17.156773|2018-06-01 00:24:17.156773
NCT01008722|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2016-12-12||2016-12-12|2009-11-05|2009-11-06|Estimate|2016-12-12|2017-02-08|Estimate||||2016-12-12|2017-02-08|Estimate|June 2009||2009-06-30|December 2016|2016-12-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational||From Medical Record|The Dynamics of Human Atrial Fibrillation|The Dynamics of Human Atrial Fibrillation|Completed|||98|Actual|University of California, San Diego|||||f||||f||||||||||2018-06-01 00:24:17.330117|2018-06-01 00:24:17.330117
NCT01008709|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-04-17|2009-11-05|2009-11-06|Estimate|||||||2017-04-17|2017-04-19|Actual|October 2009||2009-10-31|April 2017|2017-04-30|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional|||Comparison Study of Two Different Surgical Clips During Laparoscopic Urologic Surgery|Minimally Invasive Urologic Surgery Clip Evaluation: Can We Improve Our Surgical Technique, Reduce Costs and Waste With the Aesculap U-clip Versus the Tele-Flex Hemolock Clip?|Terminated||N/A|11|Actual|Vanderbilt University Medical Center||2||poor enrollment|f||||f|f|t|f|||||||2018-06-01 00:24:17.579912|2018-06-01 00:24:17.579912
NCT01008696|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-04-26||2013-07-11|2009-11-05|2009-11-06|Estimate|2013-07-11|2013-08-13|Estimate||||2013-07-11|2013-08-13|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||Baseline characteristics were measured for full analysis set (FAS) population. It included participants who received study medication at least once and had follow-up data that could be used after Baseline among participants who met eligibility criteria. Last observation carried forward (LOCF) was used.|An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis|Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study|Completed||Phase 4|217|Actual|Janssen Korea, Ltd., Korea||2|||f||||f||||||||||2018-06-01 00:24:17.696322|2018-06-01 00:24:17.696322
NCT01008683|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2009-11-05|2009-11-05|2009-11-06|Estimate|||||||2009-11-05|2009-11-06|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|July 2010|Anticipated|2010-07-31|April 2010|Anticipated|2010-04-30||Observational|||Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation|Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation|Unknown status|Recruiting||300|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 00:24:18.107064|2018-06-01 00:24:18.107064
NCT01008670|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2010-11-22|2009-11-04|2009-11-06|Estimate|||||||2010-11-22|2010-11-24|Estimate|December 2007||2007-12-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|IDPV-003||Identification of the Pericardiophrenic Vein During Cardiac Device Implant Procedures to Prevent Extracardiac Stimulation|Identification of the Pericardiophrenic Vein During Cardiac Device Implant Procedures to Prevent Extracardiac Stimulation|Completed|||120|Anticipated|Respicardia, Inc.|||1||f||||f||||||||||2018-06-01 00:24:18.175|2018-06-01 00:24:18.175
NCT01008657|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-08-28|2009-11-05|2009-11-06|Estimate|||||||2017-08-28|2017-08-29|Actual|February 9, 2010|Actual|2010-02-09|August 2017|2017-08-31|October 6, 2016|Actual|2016-10-06|October 6, 2016|Actual|2016-10-06||Interventional|ARMCENVIN||Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique|"Multipolar Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma Using Classical Intranodular Technique Versus Extra Nodular Technique So-called No Touch Technique: A Prospective Randomized Trial"|Completed||N/A|216|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:24:18.246596|2018-06-01 00:24:18.246596
NCT01008644|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2012-10-15|2009-11-05|2009-11-06|Estimate|||||||2012-10-15|2012-10-17|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|OSM||Do Changes in Plasma Osmolality Influence Ventilation?|Do Plasma Osmolality Changes Influence Ventilation, and Are There Gender Differences?|Completed||Early Phase 1|26|Actual|Kalmar County Hospital||2|||f||||f||||||||||2018-06-01 00:24:18.326012|2018-06-01 00:24:18.326012
NCT01008631|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2011-10-12|2009-11-05|2009-11-06|Estimate|||||||2011-10-12|2011-10-13|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers|The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy|Completed||N/A|19|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 00:24:18.520821|2018-06-01 00:24:18.520821
NCT01008618|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-03-20||2013-11-29|2009-11-05|2009-11-06|Estimate|2013-06-03|2013-07-10|Estimate||||2013-11-29|2013-12-25|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain|A Verification Study of JNS020QD in Patients With Osteoarthritis or Low Back Pain|Completed||Phase 3|218|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 00:24:18.695116|2018-06-01 00:24:18.695116
NCT01008605|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2012-02-28||2012-04-04|2009-11-05|2009-11-06|Estimate|2012-02-28|2012-03-28|Estimate||||2012-04-04|2012-04-06|Estimate|February 2011||2011-02-28|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Caverject User Study|Representative Users Study Of Operating Characteristics Of The Caverject Delivery System.|Completed||Phase 3|48|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:24:19.932122|2018-06-01 00:24:19.932122
NCT01008592|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2017-02-24|2009-11-05|2009-11-06|Estimate|||||||2017-02-24|2017-02-28|Actual|April 2009||2009-04-30|November 2009|2009-11-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism|The Effect of Levocetirizine (Xyzal®) on the Skin Levels of Inflammatory Mediators Histamine, Serine Proteases, Prostaglandin E2, Leukotriene B4 and Cathepsins in Patients With Symptomatic Dermatographism and Chronic Idiopathic Urticaria|Terminated|||11|Actual|Wake Forest University Health Sciences|||1|Mediators of interest were not consistently detectable with the analytical methods employed.|f||||f||||||||||2018-06-01 00:24:20.357478|2018-06-01 00:24:20.357478
NCT01008579|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2017-11-02|2009-11-05|2009-11-06|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2009||2009-12-31|November 2017|2017-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Assessing Patient Care Through Routine Use of Patient-Reported Outcomes|Routine Use of Patient Reported Outcomes Among Older Adults at High Risk of Falls: A 12-Month Cohort Study|Withdrawn|||0|Actual|University of British Columbia||||Redundant with another study|f||||f||||||||||2018-06-01 00:24:20.441407|2018-06-01 00:24:20.441407
NCT01008566|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2016-05-11|2009-11-05|2009-11-06|Estimate|||||||2016-05-11|2016-05-12|Estimate|August 2009||2009-08-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Interventional|||Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer|A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma|Completed||Phase 1|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:24:20.505625|2018-06-01 00:24:20.505625
NCT01008553|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|2013-03-21||2013-06-19|2009-11-05|2009-11-06|Estimate|2013-06-19|2013-07-25|Estimate||||2013-06-19|2013-07-25|Estimate|December 2008||2008-12-31|June 2013|2013-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome|A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome|Completed||Phase 3|258|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 00:24:20.651488|2018-06-01 00:24:20.651488
NCT01008540|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-05|||2016-09-02|2009-11-05|2009-11-06|Estimate|||||||2016-09-02|2016-09-05|Estimate|August 2006||2006-08-31|September 2016|2016-09-30|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|PHRC CMV||Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients|Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients in the Prophylaxis Era, a French Multicentric Cohort Study|Completed||N/A|800|Anticipated|University Hospital, Limoges|||||f||||t||||||||||2018-06-01 00:24:21.654357|2018-06-01 00:24:21.654357
NCT01008527|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2015-09-23|2009-11-02|2009-11-05|Estimate|||||||2015-09-23|2015-09-24|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100|A Phase I Study of Poly IC:LC and NY-ESO-1/gp100 Peptides Either Emulsified With Montanide ISA 51 or in Aqueous Solution With Escalating Doses of CP 870,893 in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma|Completed||Phase 1|22|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 00:24:21.811752|2018-06-01 00:24:21.811752
NCT01008514|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2015-03-25|2009-11-04|2009-11-05|Estimate|||||||2015-03-25|2015-03-26|Estimate||||March 2015|2015-03-31||||||||Interventional|||Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer|A Single Institution, Prospective, Non-randomized Study of Partial Breast Irradiation Using the MammoSite Radiation Therapy System (Breast Brachytherapy Applicator)|Withdrawn||Phase 2|0|Actual|Ohio State University Comprehensive Cancer Center||||funding issues and Principal Investigator leaving the institution|f||||t||||||||||2018-06-01 00:24:21.907397|2018-06-01 00:24:21.907397
NCT01008501|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2018-01-07|2009-11-04|2009-11-05|Estimate|||||||2018-01-07|2018-01-09|Actual|December 1998|Actual|1998-12-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles|Genetic Studies in Gestational Trophoblastic Disease|Recruiting|||100|Anticipated|Baylor College of Medicine|||1||f||||f||||||Samples With DNA|"~     lymphoblast DNA; tissue~   "|Yes|Patient data with no identification information will be published following peer review in journals and/or presented at scientific meetings.|2018-06-01 00:24:21.9924|2018-06-01 00:24:21.9924
NCT01008488|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2011-12-22|2009-11-04|2009-11-05|Estimate|||||||2011-12-22|2011-12-23|Estimate|November 2002||2002-11-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Antibiotic Therapy of Acute Uncomplicated Colonic Diverticulitis|Is Antibiotic Therapy Mandatory for Treatment of Uncomplicated Acute Colonic Diverticulitis: a Randomized Clinical Trial|Completed||N/A|600|Actual|Uppsala University||2|||f||||t||||||||||2018-06-01 00:24:22.072131|2018-06-01 00:24:22.072131
NCT01008475|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2016-02-26||2016-02-26|2009-11-04|2009-11-05|Estimate|2016-02-26|2016-03-30|Estimate||||2016-02-26|2016-03-30|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|POSEIDON|All the subjects who were enrolled in to the study (safety and randomized part).|EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer|An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line Treatment for Subjects With K-ras Wild Type Metastatic Colorectal Cancer (mCRC)|Completed||Phase 1/Phase 2|232|Actual|Merck KGaA||7|||f||||f||||||||||2018-06-01 00:24:22.224256|2018-06-01 00:24:22.224256
NCT01008462|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2017-12-26|2009-11-04|2009-11-05|Estimate|||||||2017-12-26|2017-12-28|Actual|March 18, 2010|Actual|2010-03-18|December 2017|2017-12-31||||January 31, 2020|Anticipated|2020-01-31||Interventional|||Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia|Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia|Recruiting||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 00:24:26.368835|2018-06-01 00:24:26.368835
NCT01008449|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|2014-07-15||2014-09-02|2009-11-04|2009-11-05|Estimate|2014-09-02|2014-09-03|Estimate||||2014-09-02|2014-09-03|Estimate|August 2009||2009-08-31|September 2014|2014-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SVS|subjects that that were lost to follow up were not included in the results|Staples Versus Suture for Cesarean Wound Closure|Surgical Staples vs. Absorbable Subcuticular Suture for Wound Closure of Cesarean Deliveries|Terminated||N/A|398|Actual|University of Alabama at Birmingham||2||"New studies were reporting that sutures are beneficial, hindering the possibility of~   enrollment."|f||||t||||||||||2018-06-01 00:24:26.580416|2018-06-01 00:24:26.580416
NCT01008436|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-02-19|2009-11-04|2009-11-05|Estimate|||||||2012-02-19|2012-02-22|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.||Terminated||N/A|400|Actual|Cardiochirurgia E.H.||2||"Lack of product due to industrial changes in the manufacturing process altering the final~   product."|f||||t||||||||||2018-06-01 00:24:26.889372|2018-06-01 00:24:26.889372
NCT01005784|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2009-10-30|2009-10-30|2009-11-02|Estimate|||||||2009-10-30|2009-11-02|Estimate|June 2005||2005-06-30|October 2009|2009-10-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Fixed Versus Flexible Gonadotropin-releasing Hormone (GnRH) Antagonist Initiation|Fixed Versus Flexible GnRH Antagonist Initiation|Completed||Phase 4|146|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 00:25:25.238934|2018-06-01 00:25:25.238934
NCT01008423|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2013-05-17|2009-11-04|2009-11-05|Estimate|||||||2013-05-17|2013-05-20|Estimate|November 2009||2009-11-30|November 2012|2012-11-30||||March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis|Completed||Phase 3|281|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 00:24:26.977935|2018-06-01 00:24:26.977935
NCT01008410|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2013-05-17|2009-11-04|2009-11-05|Estimate|||||||2013-05-17|2013-05-20|Estimate|November 2009||2009-11-30|November 2012|2012-11-30||||April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis|Completed||Phase 3|265|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 00:24:27.325457|2018-06-01 00:24:27.325457
NCT01008397|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2014-03-04|2009-11-04|2009-11-05|Estimate|||||||2014-03-04|2014-03-06|Estimate|April 2011||2011-04-30|February 2011|2011-02-28|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|||Study of AHIST in Seasonal Allergic Rhinitis Patients|Phase 1 Study of AHIST in Seasonal Allergic Rhinitis Patients|Withdrawn||Phase 1|0|Actual|Magna Pharmaceuticals, Inc.||1||Manufacturer unable to produce|f||||t||||||||||2018-06-01 00:24:27.474623|2018-06-01 00:24:27.474623
NCT01008384|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2012-05-31|2009-11-04|2009-11-05|Estimate|||||||2012-05-31|2012-06-01|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk|The Effect of Vitamin D Repletion on Small LDL Particle Number in Subjects at Elevated Cardiovascular Risk|Completed||N/A|150|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 00:24:27.616917|2018-06-01 00:24:27.616917
NCT01008371|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2013-05-21|2009-11-03|2009-11-05|Estimate|||||||2013-05-21|2013-05-22|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Investigation of Neuro-hormonal Mechanisms of Hunger, Fullness and Obesity.|CCK-dysregulation: Mechanisms of Abnormal Food Regulation and Obesity|Withdrawn|||0|Actual|Medical University of South Carolina|||2|No recruitment|f||||f||||||||||2018-06-01 00:24:27.692706|2018-06-01 00:24:27.692706
NCT01008345|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2009-11-05|2009-11-04|2009-11-05|Estimate|||||||2009-11-05|2009-11-06|Estimate|September 2008||2008-09-30|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol|Effect of Ezetimibe on Oxidized LDL Cholesterol|Completed||Phase 4|100|Actual|Hotel Dieu de France Hospital||2|||f||||t||||||||||2018-06-01 00:24:27.766833|2018-06-01 00:24:27.766833
NCT01008332|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2010-11-09|2009-11-04|2009-11-05|Estimate|||||||2010-11-09|2010-11-10|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With Rhinoconjunctivitis|An Escalating, Multiple-dose Study in House Dust Mite Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune HDM|Completed||Phase 2|50|Anticipated|Circassia Limited||5|||f||||f||||||||||2018-06-01 00:24:27.842521|2018-06-01 00:24:27.842521
NCT01008319|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|2017-03-29||2018-01-05|2009-11-03|2009-11-05|Estimate|2018-01-05|2018-01-08|Actual||||2018-01-05|2018-01-08|Actual|October 2009||2009-10-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Clomid|A total of 120 patients (60 stair-step, 60 traditional) were randomized.|Traditional Clomiphene Citrate Administration vs. Stair-step Approach|Traditional Clomiphene Citrate Administration Versus a Stair-Step Approach: A Randomized Controlled Trial|Completed||Phase 3|120|Actual|University of Oklahoma||2|||f||||t||||||||||2018-06-01 00:24:27.947086|2018-06-01 00:24:27.947086
NCT01008306|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2009-11-04|2009-11-04|2009-11-05|Estimate|||||||2009-11-04|2009-11-05|Estimate|June 2007||2007-06-30|November 2009|2009-11-30||||June 2010|Anticipated|2010-06-30||Observational|HENT||Cardiovascular Risk Factors After Renal Transplantation in Children and Adults|Outcome After Pediatric Renal Transplantation: Cardiorespiratory Fitness, Cardiovascular Risk Factors and Quality of Life|Unknown status|Active, not recruiting||60|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples Without DNA|"~     Freezing of serum and plasma from study participants~   "|||2018-06-01 00:24:28.302742|2018-06-01 00:24:28.302742
NCT01008293|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2013-06-03|2009-11-04|2009-11-05|Estimate|||||||2013-06-03|2013-06-04|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|MHE||Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life|Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life|Completed||Phase 2/Phase 3|120|Actual|CD Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-06-01 00:24:28.371156|2018-06-01 00:24:28.371156
NCT01008280|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|2015-04-22||2016-01-11|2009-11-03|2009-11-05|Estimate|2015-05-21|2015-06-09|Estimate||||2016-01-11|2016-02-08|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional|BRAC||Baclofen to Reduce Alcohol Use in Veterans With HCV|Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV|Completed||Phase 4|180|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:24:28.463948|2018-06-01 00:24:28.463948
NCT01008267|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2009-11-04|2009-11-04|2009-11-05|Estimate|||||||2009-11-04|2009-11-05|Estimate|November 2009||2009-11-30|March 2009|2009-03-31||||October 2010|Anticipated|2010-10-31||Observational|||Shockwave Lithotripsy (SWL) Under Selective, General Anesthesia.|Shockwave Lithotripsy (SWL) Under Regular General Anesthesia and Under General Anesthesia Using Bronchial Blocker.|Unknown status|Not yet recruiting||60|Anticipated|Assaf-Harofeh Medical Center|||2||f||||||||||||||2018-06-01 00:24:28.86375|2018-06-01 00:24:28.86375
NCT01008254|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2011-10-18|2009-11-04|2009-11-05|Estimate|||||||2011-10-18|2011-10-19|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|TEAM||Interdisciplinary Mobility Approach To Reduction Of Facility-Acquired Pressure Ulcers|Interdisciplinary Mobility Approach To Reduction Of Facility-Acquired Pressure Ulcers|Completed||Phase 2/Phase 3|2000|Anticipated|University of Cincinnati||3|||f||||t||||||||||2018-06-01 00:24:29.031074|2018-06-01 00:24:29.031074
NCT01008241|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2009-11-03|2009-11-03|2009-11-05|Estimate|||||||2009-11-03|2009-11-05|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|Project HOPE||South Florida Residents Knowledge and Opinions on End-of-Life Issues|Project HOPE: Survey of South Florida Residents Knowledge and Opinions on End-of-Life Issues|Unknown status|Recruiting||250|Anticipated|Nova Southeastern University|||1||f||||f||||||||||2018-06-01 00:24:29.093275|2018-06-01 00:24:29.093275
NCT01008228|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-02-23|2009-11-04|2009-11-05|Estimate|||||||2015-02-23|2015-02-24|Estimate|June 2009||2009-06-30|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|March 2014|Actual|2014-03-31||Interventional|EXPRED||Comparison of Exsufflation Versus Drainage in Primary Spontaneous Pneumothorax|Comparison of Efficacity of Simple Aspiration Versus Standard Drainage in the Management of Large Size Primary Spontaneous Pneumothorax|Unknown status|Active, not recruiting|N/A|400|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-06-01 00:24:29.172681|2018-06-01 00:24:29.172681
NCT01008215|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2011-07-20|2009-11-04|2009-11-05|Estimate|||||||2011-07-20|2011-07-22|Estimate|October 2009||2009-10-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|KT-INR||Simple Warfarin Dosing Algorithm Study|Cluster Randomized Trial to Assess the Effect of Using a Simple Warfarin Maintenance Dosing Algorithm on the Quality of INR Control Among Canadian Family Practices|Completed||N/A|553|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-06-01 00:24:29.289697|2018-06-01 00:24:29.289697
NCT01008202|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2011-01-25|2009-11-04|2009-11-05|Estimate|||||||2011-01-25|2011-01-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:24:29.353407|2018-06-01 00:24:29.353407
NCT01008176|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2017-03-10|2009-11-04|2009-11-05|Estimate|||||||2017-03-10|2017-03-14|Actual|September 2005||2005-09-30|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Restoring Sleep Homeostasis to Lower Blood Pressure|Restoring Sleep Homeostasis to Lower Blood Pressure: A Behavioral Prevention and Treatment Approach|Completed||N/A|23|Actual|Beth Israel Deaconess Medical Center|||||f||||f||||||||||2018-06-01 00:24:29.386978|2018-06-01 00:24:29.386978
NCT01008150|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2015-10-05|2009-11-04|2009-11-05|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|September 2015|Actual|2015-09-30||Interventional|||Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer|A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel Plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2-Positive Breast Cancer|Unknown status|Active, not recruiting|Phase 2|141|Actual|NSABP Foundation Inc||3|||f||||f||||||||||2018-06-01 00:24:29.453813|2018-06-01 00:24:29.453813
NCT01008137|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2012-11-26|2009-11-03|2009-11-05|Estimate|||||||2012-11-26|2012-11-27|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults|Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults|Completed||Phase 4|150|Actual|Sinovac Biotech Co., Ltd||3|||f||||||||||||||2018-06-01 00:24:29.7173|2018-06-01 00:24:29.7173
NCT01008124|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2009-11-04|2009-11-04|2009-11-05|Estimate|||||||2009-11-04|2009-11-05|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|LM_BPPV||The Liberatory Maneuver for the Treatment of Benign Paroxysmal Positional Vertigo (BPPV)|The Liberatory Maneuver for the Treatment of Benign Paroxysmal Positional Vertigo: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|40|Anticipated|Midwestern University||2|||f||||f||||||||||2018-06-01 00:24:29.803164|2018-06-01 00:24:29.803164
NCT01008111|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2017-11-02|2009-11-04|2009-11-05|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2009||2009-10-31|January 2017|2017-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Wound Healing of Incisional Wounds for Bilateral Hernia Repair|The Effect of a Sodium Bicarbonate and Hydrogen Peroxide Gel on Wound Healing of Incisional Wounds for Bilateral Hernia Repair|Withdrawn||Phase 1|0|Actual|Wake Forest University Health Sciences||2||study never initiated|f||||f||||||||Undecided||2018-06-01 00:24:29.902524|2018-06-01 00:24:29.902524
NCT01008098|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-06-06|2009-11-04|2009-11-05|Estimate|||||||2012-06-06|2012-06-07|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Neuroprotective/Neurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder|Neuroprotective/Neurotrophic Effect of Lexapro® in Patients With Posttraumatic Stress Disorder|Unknown status|Recruiting|Phase 2|26|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-06-01 00:24:29.997034|2018-06-01 00:24:29.997034
NCT01008085|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2011-01-21|2009-11-04|2009-11-05|Estimate|||||||2011-01-21|2011-01-24|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|APPOSITION ll||STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)|Randomized Comparison Between the STENTYS Self-expanding Coronary Stent and a Balloon-expandable Stent in Acute Myocardial Infarction - APPOSITION II|Completed||Phase 3|80|Anticipated|Stentys||2|||f||||t||||||||||2018-06-01 00:24:30.126774|2018-06-01 00:24:30.126774
NCT01008072|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2009-11-04|2009-11-04|2009-11-05|Estimate|||||||2009-11-04|2009-11-05|Estimate|December 2009||2009-12-31|November 2009|2009-11-30||||December 2009|Anticipated|2009-12-31||Observational|||Ultra-rapid Opiate Detoxification Using Deep Sedation and Prior Oral Buprenorphine Preparation.||Unknown status|Not yet recruiting||40|Anticipated|Assaf-Harofeh Medical Center|||2||f||||||||||||||2018-06-01 00:24:30.210577|2018-06-01 00:24:30.210577
NCT01008059|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2017-12-11|2009-11-03|2009-11-05|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2009|Actual|2009-10-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Alfentanil: Simultaneous Testing Pilot|Novel Noninvasive Assessment of Cytochrome P4450 Activity: Simultaneous Testing Pilot|Completed||N/A|9|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 00:24:30.27335|2018-06-01 00:24:30.27335
NCT01008046|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2009-11-04|2009-11-04|2009-11-05|Estimate|||||||2009-11-04|2009-11-05|Estimate|April 2007||2007-04-30|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||N-acetyl Cysteine and Clomiphene Citrate or Metformin and Clomiphene Citrate for Women With CC Resistant Polycystic Ovary Syndrome (PCOS).|N-acetyl Cysteine Plus Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Treatment of Clomiphene-resistant Polycystic Ovary Syndrome|Completed||N/A|192|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:24:30.357341|2018-06-01 00:24:30.357341
NCT01008033|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-06-20|2009-11-03|2009-11-05|Estimate|||||||2012-06-20|2012-06-22|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis||Completed||Phase 3|870|Actual|Dow Pharmaceutical Sciences||2|||f||||||||||||||2018-06-01 00:24:30.557046|2018-06-01 00:24:30.557046
NCT01005589|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-04-05|2009-10-30|2009-11-02|Estimate|||||||2017-04-05|2017-04-07|Actual|October 2009||2009-10-31|April 2017|2017-04-30|June 2, 2010|Actual|2010-06-02|June 2, 2010|Actual|2010-06-02||Observational|||CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis|Measurement of Neutrophil Membrane CD64 as an Early Indication of Neonatal Infection and Necrotising Enterocolitis (NEC).|Completed|||59|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||||f||||f||||||||||2018-06-01 00:25:28.769576|2018-06-01 00:25:28.769576
NCT01008020|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-07-14|2009-11-03|2009-11-05|Estimate|||||||2013-07-14|2013-07-16|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection|A Randomized Controlled Study on the Effects of Tea Catechin Consumption on the Prevention of Influenza Infection in Healthy Adults|Completed||N/A|200|Anticipated|University of Shizuoka||2|||f||||f||||||||||2018-06-01 00:24:30.767082|2018-06-01 00:24:30.767082
NCT01008007|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2010-05-17|2009-11-03|2009-11-05|Estimate|||||||2010-05-17|2010-05-18|Estimate|September 2009||2009-09-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Viusid in Adults With Acute Fever of Viral Etiology|Effect of VIUSID Administration on Adults With Acute Fever of Viral Etiology|Completed||Phase 2|200|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:24:30.886402|2018-06-01 00:24:30.886402
NCT01007994|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2018-05-25|2009-11-04|2009-11-05|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2009||2009-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients|Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients|Active, not recruiting||Phase 2/Phase 3|33|Actual|Northwell Health||2|||f||||f||||||||||2018-06-01 00:24:31.013992|2018-06-01 00:24:31.013992
NCT01007981|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-04|||2016-10-03|2009-11-04|2009-11-05|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||A Novel Echocardiography Modality to Assess Left Ventricular Dyssynchrony|A Novel Echocardiography Modality to Assess Left Ventricular Dyssynchrony: Hemodynamic Assessment by 4D Segmental Ejection Fraction|Withdrawn|||0|Actual|University of Missouri-Columbia|||1|investigator left the institution|f||||f||||||||No||2018-06-01 00:24:31.234946|2018-06-01 00:24:31.234946
NCT01007968|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2016-08-17|2009-11-04|2009-11-05|Estimate|||||||2016-08-17|2016-08-18|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function|A Phase I, Open-label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function|Completed||Phase 1|25|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:24:31.392639|2018-06-01 00:24:31.392639
NCT01007955|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-08-23|2009-11-03|2009-11-05|Estimate|||||||2012-08-23|2012-08-24|Estimate|November 2006||2006-11-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery|"Assessment of Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Predictors of Cardiovascular Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass: Development of a New Paradigm in Defining Morbid Obesity and in the Application of Bariatric Surgery"|Completed|||61|Actual|University of Massachusetts, Worcester|||1||f||||f||||||Samples With DNA|"~     Subcutaneous and visceral adipose tissue.~   "|||2018-06-01 00:24:31.534753|2018-06-01 00:24:31.534753
NCT01007929|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-11-19|2009-11-04|2009-11-05|Estimate|||||||2009-11-19|2009-11-20|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|November 2009|Anticipated|2009-11-30|||||Interventional|||Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects|An Open-Label. Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of 60 mg of [14C] AZD1236 in Healthy Male Subjects|Terminated||Phase 1|4|Anticipated|AstraZeneca||1||"Future development of AZD1236 is currently under review by the project team and no new studies~   will be started until this review is completed."|f||||t||||||||||2018-06-01 00:24:31.60837|2018-06-01 00:24:31.60837
NCT01007916|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2011-01-31||2012-06-26|2009-11-03|2009-11-05|Estimate|2011-01-31|2011-02-25|Estimate||||2012-06-26|2012-07-10|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Subjective Evaluation of a Commercially Marketed Contact Lens Amongst a Subset of the Contact Lens Wearing Population||Completed||N/A|50|Actual|Alcon Research|Participants were masked to lotrafilcon B lenses only.|2|||f||||f||||||||||2018-06-01 00:24:31.684593|2018-06-01 00:24:31.684593
NCT01007903|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2017-02-23|2009-11-03|2009-11-05|Estimate|||||||2017-02-23|2017-02-27|Actual||||February 2017|2017-02-28||||||||Interventional|||Mind-Body Exercise for COPD: A Pilot Study|Tai Chi Exercise in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 1|10||Beth Israel Deaconess Medical Center||2|||f||||||||||||||2018-06-01 00:24:31.957936|2018-06-01 00:24:31.957936
NCT01007890|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-10-04|2009-11-03|2009-11-05|Estimate|||||||2012-10-04|2012-10-05|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|PT-304||Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer|Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer|Terminated|||134|Actual|Precision Therapeutics|||||f||||t||||||Samples With DNA|"~     Core needle biopsy specimens will be collected and stored in RNAlater® until the time of RNA~     extraction, using standard procedures. Isolated total RNA will be assayed for gene expression~     using methods such as TaqMan® RT-PCR technology or Affymetrix or Agilent gene array~     platforms.~   "|||2018-06-01 00:24:32.029617|2018-06-01 00:24:32.029617
NCT01008358|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-06-07|2009-11-03|2009-11-04|Estimate|||||||2012-06-07|2012-06-08|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma|Phase II Trial of Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 2|20|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||||f||||f||||||||||2018-06-01 00:24:32.166264|2018-06-01 00:24:32.166264
NCT01008189|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-11-03|2009-11-03|2009-11-04|Estimate|||||||2009-11-03|2009-11-04|Estimate|January 1996||1996-01-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|July 2005|Actual|2005-07-31||Interventional|||6-Year Follow-up of a Prevention Program for Bereaved Families|6-Year Follow-up of a Prevention Program for Bereaved Families|Completed||Phase 3|244|Actual|Arizona State University||2|||f||||t||||||||||2018-06-01 00:24:32.25852|2018-06-01 00:24:32.25852
NCT01008163|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2009-11-03|2009-11-03|2009-11-04|Estimate|||||||2009-11-03|2009-11-04|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Dose-Finding, Efficacy and Safety Study of YY-351 in Patients With Type 2 Diabetes|A Phase Ⅱ, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Efficacy and Safety of YY-351 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|72|Anticipated|Yuyu Pharma, Inc.||4|||f||||t||||||||||2018-06-01 00:24:32.351398|2018-06-01 00:24:32.351398
NCT01007942|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2016-06-10||2017-02-20|2009-11-03|2009-11-04|Estimate|2017-02-20|2017-04-05|Actual||||2017-02-20|2017-04-05|Actual|October 2009||2009-10-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BOLERO-3|The Full Analysis Set (FAS) consisted of all randomized patients.|Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer|A Randomized Phase III, Double-blind, Placebo-controlled Multicenter Trial of Daily Everolimus in Combination With Trastuzumab and Vinorelbine, in Pretreated Women With HER2/Neu Over-expressing Locally Advanced or Metastatic Breast Cancer.|Completed||Phase 3|569|Actual|Novartis|All randomized patients were included in the FAS. Seven patients (4 in the everolimus arm & 3 in the placebo arm) were randomized but never received treatment & were therefore excluded from the Safety Set.|2|||f||||t||||||||||2018-06-01 00:24:32.471481|2018-06-01 00:24:32.471481
NCT01007877|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-04-08|2009-11-03|2009-11-04|Estimate|||||||2011-04-08|2011-04-11|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Energy Drinks & Driving Ability|'Study to Investigate the Effects of an Energy Drink During a 15-minute Break Versus Continued Driving on Driving Performance in the STISIM Driving Simulator'|Completed||N/A|24|Anticipated|Utrecht Institute for Pharmaceutical Sciences||3|||f||||f||||||||||2018-06-01 00:24:35.531275|2018-06-01 00:24:35.531275
NCT01007864|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-05-23|2009-11-03|2009-11-04|Estimate|||||||2012-05-23|2012-05-24|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PIVICOG-PD||Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists|Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists|Completed||Phase 3|80|Actual|Desitin Arzneimittel GmbH||2|||f||||f||||||||||2018-06-01 00:24:35.700487|2018-06-01 00:24:35.700487
NCT01007851|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2009-11-03|2009-11-03|2009-11-04|Estimate|||||||2009-11-03|2009-11-04|Estimate|September 2006||2006-09-30|November 2009|2009-11-30|December 2007|Actual|2007-12-31|||||Interventional|||Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles||Terminated||Phase 3|||V.K.V. American Hospital, Istanbul||2||Lower than anticipated recruitment|f||||||||||||||2018-06-01 00:24:35.841956|2018-06-01 00:24:35.841956
NCT01007838|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2011-11-24||2012-01-03|2009-11-03|2009-11-04|Estimate|2011-11-24|2011-12-23|Estimate||||2012-01-03|2012-01-05|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|PRT||Intradialytic Progressive Resistance Training for Maintenance Haemodialysis Patients|Effects of Progressive Resistance Training During Haemodialysis on Muscle Quantity and Function in Patients With Chronic Kidney Disease|Completed||N/A|32|Actual|Bangor University|Small sample size in healthy control group. Variable gender mix in all groups.|4|||f||||f||||||||||2018-06-01 00:24:35.96838|2018-06-01 00:24:35.96838
NCT01007812|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2010-09-29||2012-06-26|2009-11-03|2009-11-04|Estimate|2010-10-21|2010-11-17|Estimate||||2012-06-26|2012-06-29|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Clinical Comparison of Two Silicone Hydrogel Toric Lenses in the US|Clinical Comparison of Two Silicone Hydrogel Toric Lenses in the US|Completed||N/A|50|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 00:24:36.37405|2018-06-01 00:24:36.37405
NCT01007799|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2016-08-25|2009-11-03|2009-11-04|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vitamin D for Chronic Sinusitis|A Randomized, Clinical Trial of a Novel Immunotherapy for Chronic Sinusitis: Vitamin D|Completed||N/A|30|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 00:24:36.552274|2018-06-01 00:24:36.552274
NCT01007786|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2012-06-12|2009-11-02|2009-11-04|Estimate|||||||2012-06-12|2012-06-14|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|February 2010|Actual|2010-02-28||Observational|||The Ventricular Catheter Placement Study: Assessment of Efficacy and Safety of an Ultrasound Guided Shunt Insertion Technique|The Ventricular Catheter Placement Study: Assessment of Efficacy and Safety of an Ultrasound Guided Shunt Insertion Technique|Completed|||67|Actual|University of Utah|||||f||||f||||||||||2018-06-01 00:24:36.630167|2018-06-01 00:24:36.630167
NCT01007773|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2015-05-26|2009-11-02|2009-11-04|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Safety of Dexmedetomidine in Severe Traumatic Brain Injury|Safety of Dexmedetomidine in Severe Traumatic Brain Injury|Withdrawn||Phase 2|0|Actual|University of Maryland||2||Study will not be intiated|f||||t||||||||||2018-06-01 00:24:36.737456|2018-06-01 00:24:36.737456
NCT01007760|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2011-07-18|2009-11-03|2009-11-04|Estimate|||||||2011-07-18|2011-07-19|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|June 2010|Actual|2010-06-30||Interventional|||Dose-dependent Effects of Second-hand Smoke on Vascular Function|Dose-dependent Biological Mechanisms of Second-hand Smoke on Endothelial Function and Oxidative Stress|Completed||N/A|33|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-06-01 00:24:36.858233|2018-06-01 00:24:36.858233
NCT01007747|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2015-12-17|2009-11-03|2009-11-04|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|Geranium Oil||EPT 100: Geranium Oil for the Relief of Neuropathic Pain|EPT 100: Geranium Oil for the Relief of Neuropathic Pain|Completed||N/A|166|Actual|Pennington Biomedical Research Center||1|||f||||f||||||||||2018-06-01 00:24:36.940663|2018-06-01 00:24:36.940663
NCT01007734|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-31|||2010-07-26|2009-11-03|2009-11-04|Estimate|||||||2010-07-26|2010-07-27|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|VITALITE||Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients|Factors Determining Quality of Life Related to Respiratory Status According to Gender of COPD Patients Followed by a Pneumologist|Completed|||449|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:24:37.050116|2018-06-01 00:24:37.050116
NCT01007721|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03||2014-04-30|2014-04-30|2009-11-03|2009-11-04|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|October 2009||2009-10-31|April 2014|2014-04-30||||April 2010|Actual|2010-04-30||Interventional|||Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season|Randomised, Double-blind, Triple Dummy, Partial Cross-over (Each Active Treatment With Placebo) Study Using an Environmental Challenge Chamber (ECC) to Assess the Safety and Efficacy of 2 Weeks of Oral BI 671800 ED 50, 200 or 400 mg Bid, Compared to Montelukast 10 mg qd, Fluticasone Propionate Nasal Spray 200 µg qd (2 Nasal Actuations Each Nostril of 50 µg) Versus Placebo in Seasonal Allergic Rhinitis Patients Out of Season, Sensitive to Dactylis Glomerata.|Completed||Phase 2|146|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-06-01 00:24:37.443764|2018-06-01 00:24:37.443764
NCT01007695|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2016-07-19|2009-11-03|2009-11-04|Estimate|||||||2016-07-19|2016-07-20|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|VAST||Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot|Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot|Terminated||Phase 1|31|Actual|University of Utah||1||Enrollment was going slowly and needed to be closed.|f||||t||||||||||2018-06-01 00:24:37.749094|2018-06-01 00:24:37.749094
NCT01007682|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-03-07|2009-11-03|2009-11-04|Estimate|||||||2012-03-07|2012-03-08|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Intrusive Reexperiencing: The Role of Working Memory Capacity and Thought Suppression|Intrusive Reexperiencing: The Role of Working Memory Capacity and Thought Suppression|Completed||N/A|200|Actual|University Hospital, Basel, Switzerland||2|||f||||||||||||||2018-06-01 00:24:37.833786|2018-06-01 00:24:37.833786
NCT01007669|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2013-02-08|2009-11-03|2009-11-04|Estimate|||||||2013-02-08|2013-02-11|Estimate|August 2009||2009-08-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|||Effects of Specified Work Site Physical Activity Intervention Among Employees With Physical Heavy Work|Effects of Specified Work Site Physical Activity Intervention on Musculoskeletal Disorders Among Employees With Physical Heavy Work|Completed||Phase 1|67|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-06-01 00:24:37.900833|2018-06-01 00:24:37.900833
NCT01007656|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2013-05-26||2016-05-17|2009-11-03|2009-11-04|Estimate|2013-10-01|2013-12-02|Estimate||||2016-05-17|2016-06-21|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional||Laboratory measurements, including serum glutamic oxaloacetate transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT), albumin, glucose, creatinine, uric acid, cholesterol, Triglycerides (TG), r-glutamyl transpeptidase(r-GT), alkaline phosphatase, total bilirubin, Direct- bilirubin (D-Bil), BUN, Total protein (TP), Globulin (GLO).|A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects|A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects|Completed||N/A|31|Actual|Golden Biotechnology Corporation||1|||f||||f||||||||Yes||2018-06-01 00:24:38.003999|2018-06-01 00:24:38.003999
NCT01007643|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|2012-07-23||2012-08-27|2009-11-03|2009-11-04|Estimate|2012-08-27|2012-09-27|Estimate||||2012-08-27|2012-09-27|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Use of Wii Fit (TM) to Increase Compliance With Home Exercises in Treating Patellofemoral Syndrome|The Use of Wii Fit ™ to Increase Compliance With Home Exercises for Treatment of Patellofemoral Syndrome in Adolescent Females|Terminated||N/A|22|Actual|University of Manitoba|Early termination of the study lead to less than the required number of study subjects enrolled. Thus secondary outcome measures could not be calculated with certainty.|2||Difficulty in recruitment of study participants in alloted time and funding|f||||f||||||||||2018-06-01 00:24:38.418613|2018-06-01 00:24:38.418613
NCT01007630|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2013-11-27|2009-11-03|2009-11-04|Estimate|||||||2013-11-27|2013-12-02|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|PD-SOAR||A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients|A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease|Unknown status|Active, not recruiting|Phase 4|36|Anticipated|The Parkinson's Institute||2|||f||||f||||||||||2018-06-01 00:24:38.643712|2018-06-01 00:24:38.643712
NCT01007617|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2011-01-18|2009-11-03|2009-11-04|Estimate|||||||2011-01-18|2011-01-19|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Low-energy Laser Therapy for Prevention of Oral Mucositis in Children|"Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children Mucositis Laser 1"|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:24:38.729412|2018-06-01 00:24:38.729412
NCT01007604|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2009-11-03|2009-11-03|2009-11-04|Estimate|||||||2009-11-03|2009-11-04|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Treatment of Claudication With a Peristaltic Pulse Pneumatic Device|Efficacy Study of a Peristaltic Pulse Pneumatic Device in the Treatment of Claudication|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|White River Junction Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 00:24:38.901586|2018-06-01 00:24:38.901586
NCT01007591|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2013-10-25|2009-11-03|2009-11-04|Estimate|||||||2013-10-25|2013-10-28|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas|Calcipotriol Plus Hydrocortisone in Paediatric Patients (Aged 6 to 17 Years) With Psoriasis Vulgaris on the Face and on the Intertriginous Areas|Completed||Phase 3|40|Actual|LEO Pharma||2|||f||||t||||||||||2018-06-01 00:24:39.014452|2018-06-01 00:24:39.014452
NCT01007578|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2015-03-24|2009-11-03|2009-11-04|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Drug-Eluting Balloon Catheters and the Treatment of Peripheral Arterial Occlusive Disease|An Open-Labeled Multicenter Study to Investigate Plasma Levels and Catheter Tolerability Following Application of Paclitaxel Coated Balloon Catheter in Patients With Stenotic, or Occluded Femoro-Popliteal Arteries Due to Atherosclerosis|Completed||Phase 1|14|Actual|Bayer||1|||f||||t||||||||||2018-06-01 00:24:39.100336|2018-06-01 00:24:39.100336
NCT01007565|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2009-11-03|2009-11-03|2009-11-04|Estimate|||||||2009-11-03|2009-11-04|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Postoperative Pain After Volar Plating for Distal Radius Fractures|Postoperative Pain After Volar Plating for Distal Radius Fractures|Completed||Phase 2|44|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-06-01 00:24:39.220584|2018-06-01 00:24:39.220584
NCT01007552|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2016-10-24||2017-02-09|2009-11-03|2009-11-04|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|December 2009||2009-12-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||All treated and eligible patients|A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts|A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts.|Completed||Phase 2|50|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 00:24:39.344461|2018-06-01 00:24:39.344461
NCT01007539|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-08-29|2009-11-03|2009-11-04|Estimate|||||||2012-08-29|2012-08-31|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence||Completed||Phase 3|31|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:24:39.854517|2018-06-01 00:24:39.854517
NCT01007526|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2012-05-22|2009-11-03|2009-11-04|Estimate|||||||2012-05-22|2012-05-24|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|CCRT-VIDL||Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma|Open-labeled, Multicenter Phase II Study of Concomitant Chemo-radiotherapy Followed by VIDL Chemotherapy With Risk-based Application of Autologous Stem Cell Transplantation in Stage I/II Extranodal NK/T-cell Lymphoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 00:24:39.93238|2018-06-01 00:24:39.93238
NCT01007513|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2012-03-28|2009-11-03|2009-11-04|Estimate|||||||2012-03-28|2012-03-29|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|COLIBRI||Study of Cervix and Inflammation in Preterm Birth Prediction|Cervical Assessment by Supracervical, Cervical and Vaginal Markers: Simultaneous Transvaginal Ultrasound and Inflammatory Proteins Detection|Completed|||100|Actual|Université de Sherbrooke|||1||f||||f||||||Samples Without DNA|"~     Vaginal secretion~   "|||2018-06-01 00:24:40.043858|2018-06-01 00:24:40.043858
NCT01007500|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2016-12-29|2009-11-03|2009-11-04|Estimate|||||||2016-12-29|2016-12-30|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery||Completed||Phase 4|123|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 00:24:40.129088|2018-06-01 00:24:40.129088
NCT01007487|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2011-07-19|2009-11-03|2009-11-04|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Plastic Wound Retractors and Bacterial Translocation in Abdominal Surgery|Wound Retractor or Protector? Efficacy of a Plastic Wound Retractor (Alexis®) in Impeding Translocation of Enteric Bacteria to the Surgical Incision Site in Abdominal Surgery.|Completed|||250|Actual|St Vincent's University Hospital, Ireland|||||f||||f||||||||||2018-06-01 00:24:40.199491|2018-06-01 00:24:40.199491
NCT01007474|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2018-04-05|2009-11-03|2009-11-04|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2004||2004-01-31|April 2018|2018-04-30|January 2030|Anticipated|2030-01-31|January 2028|Anticipated|2028-01-31||Observational|OHCS||One Hospital ClinicalService Project|One Hospital ClinicalService Project on Patients Implanted With Medtronic Implantable Devices or Treated by Medtronic Therapies|Recruiting|||10000|Anticipated|Medtronic Italia|||||f||||f||||||||||2018-06-01 00:24:40.280705|2018-06-01 00:24:40.280705
NCT01007461|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-05-18|2009-11-03|2009-11-04|Estimate|||||||2017-05-18|2017-05-19|Actual|December 2009||2009-12-31|May 2017|2017-05-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction|A Phase 2, Randomized. Double-Blind, Dose-Escalation, Dose-Expansion, Placebo-Controlled, Multi-Center Study of IK-1001 to Evaluate Safety, Pharmacokinetics , and Proof-of-Concept Efficacy in Subjects With Acute ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention|Withdrawn||Phase 2|0|Actual|Mallinckrodt||2||Company decision. Non-safety related|f||||t||||||||||2018-06-01 00:24:40.412538|2018-06-01 00:24:40.412538
NCT01007448|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2015-06-01|2009-11-03|2009-11-04|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)|Phase IV Randomized Study Of Two Dose Levels Of Targretin~ Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma|Completed||Phase 4|59|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 00:24:40.486836|2018-06-01 00:24:40.486836
NCT01007435|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|2013-05-23||2017-06-28|2009-11-03|2009-11-04|Estimate|2013-05-23|2013-07-12|Estimate||||2017-06-28|2017-07-26|Actual|October 31, 2009|Actual|2009-10-31|June 2017|2017-06-30|January 28, 2014|Actual|2014-01-28|May 31, 2012|Actual|2012-05-31||Interventional||Baseline Characteristics were based on the intent-to-treat (ITT) population. Five of 1162 randomized patients (2 placebo + methotrexate, 2 tocilizumab 4 mg/kg + methotrexate, 1 tocilizumab 8 mg/kg + methotrexate) did not receive any study treatment and were excluded from all analysis populations. The ITT population therefore included 1157 patients.|A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis|A Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission and Prevention of Structural Joint Damage During Treatment With Tocilizumab (TCZ), as a Monotherapy and in Combination With Methotrexate (MTX), Versus Methotrexate in Patients With Early, Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|1162|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 00:24:40.649936|2018-06-01 00:24:40.649936
NCT01007422|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2013-03-29|2009-11-03|2009-11-04|Estimate|||||||2013-03-29|2013-04-02|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Opioids Titration in Hospice Patients|Opioid Titration In the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol Stage 2, Part B|Withdrawn|||0|Actual|Vanderbilt-Ingram Cancer Center|||1|Issues with Hospice|f||||t||||||||||2018-06-01 00:24:42.14056|2018-06-01 00:24:42.14056
NCT01007409|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-12-23|2009-11-03|2009-11-04|Estimate|||||||2009-12-23|2009-12-24|Estimate|October 2009||2009-10-31|December 2009|2009-12-31||||November 2009|Actual|2009-11-30||Interventional|||A Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|Randomized, Open-labeled, Single Dosing Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||||||||||||2018-06-01 00:24:42.217077|2018-06-01 00:24:42.217077
NCT01007396|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2010-05-17||2011-12-06|2009-11-03|2009-11-04|Estimate|2011-12-06|2012-01-11|Estimate||||2011-12-06|2012-01-11|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay|Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay|Completed||N/A|322|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 00:24:42.279984|2018-06-01 00:24:42.279984
NCT01007383|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2013-11-04|2009-11-03|2009-11-04|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||LEO 27847 - A Study in Healthy Male Subjects|LEO 27847 - A Phase 1, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects|Completed||Phase 1|48|Actual|LEO Pharma||3|||f||||f||||||||||2018-06-01 00:24:42.45044|2018-06-01 00:24:42.45044
NCT01007370|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2017-08-02|2009-11-03|2009-11-04|Estimate|||||||2017-08-02|2017-08-03|Actual|March 2010|Actual|2010-03-31|August 2017|2017-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of LMA-Fastrach and I-gel for Blind Tracheal Intubation.|Comparison of LMA-Fastrach and I-gel for Blind Tracheal Intubation.|Completed||N/A|160|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 00:24:42.510771|2018-06-01 00:24:42.510771
NCT01007357|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2015-11-12|2009-11-03|2009-11-04|Estimate|||||||2015-11-12|2015-11-13|Estimate|December 2009||2009-12-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation|Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation|Terminated||N/A|25|Actual|University of Nebraska||1||Principal Investigator left institution; did not complete the study|f||||f||||||||||2018-06-01 00:24:42.587404|2018-06-01 00:24:42.587404
NCT01007344|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2013-08-25|2009-11-03|2009-11-04|Estimate|||||||2013-08-25|2013-08-27|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Flaxseed Compared With Placebo in Patients With Hypercholesterolemia|A 4-week Study in Children and Adolescents With Familial or Severe Hypercholesterolemia Comparing Flaxseed Therapy to Placebo|Completed||Phase 3|30|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:24:42.704318|2018-06-01 00:24:42.704318
NCT01007331|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2010-02-16|2009-11-03|2009-11-04|Estimate|||||||2010-02-16|2010-02-17|Estimate|November 2006||2006-11-30|November 2009|2009-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Probiotic Bacteria to Infants With Atopic Dermatitis|Probiotic Bacteria to Infants With Atopic Dermatitis; an Investigation of the Effect on Eczema, Immunologic Status and the Intestinal Microflora, Inflammation and Permeability|Completed||N/A|62|Actual|University of Copenhagen|||||f||||f||||||||||2018-06-01 00:24:42.897447|2018-06-01 00:24:42.897447
NCT01007318|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2018-04-24|2009-11-03|2009-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2009||2009-12-31|April 2018|2018-04-30|February 2016|Actual|2016-02-29|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy Study of Single Port Laparoscopic Appendectomy in Acute Appendicitis|Prospective, Randomized Study of Single Port and Conventional Laparoscopic Appendectomy in Acute Appendicitis|Completed||N/A|194|Actual|Kyunghee University Medical Center||2|||f||||t||||||||||2018-06-01 00:24:42.996434|2018-06-01 00:24:42.996434
NCT01007305|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2011-08-04|2009-11-03|2009-11-04|Estimate|||||||2011-08-04|2011-08-05|Estimate|May 2009||2009-05-31|November 2009|2009-11-30||||April 2011|Actual|2011-04-30||Interventional|||Bilateral Oophorectomy Versus Ovarian Conservation|Elective Bilateral Salpingo-oophorectomy Versus Ovarian Conservation: A Pilot Randomized, Controlled Trial|Completed||N/A|20|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:24:43.087689|2018-06-01 00:24:43.087689
NCT01007292|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24||2015-08-20|2015-09-29|2009-11-02|2009-11-04|Estimate||||2015-08-20|2015-09-04|Estimate|2015-09-29|2015-10-19|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|March 2013|Actual|2013-03-31||Interventional|||A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment|A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant|Completed||Phase 2|43|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:24:43.172483|2018-06-01 00:24:43.172483
NCT01007279|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2010-10-25|2009-11-03|2009-11-04|Estimate|||||||2010-10-25|2010-10-26|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|ROMA||Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)|ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis|Completed||Phase 3|160|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-06-01 00:24:43.29036|2018-06-01 00:24:43.29036
NCT01007266|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|||2018-05-22|2009-11-03|2009-11-04|Estimate|||||||2018-05-22|2018-05-23|Actual|October 9, 2009||2009-10-09|April 14, 2016|2016-04-14|January 24, 2013|Actual|2013-01-24|||||Interventional|||Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study|Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:24:43.357001|2018-06-01 00:24:43.357001
NCT01007253|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-03|2013-03-26||2013-06-12|2009-11-03|2009-11-04|Estimate|2013-06-12|2013-07-17|Estimate||||2013-06-12|2013-07-17|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|August 2011|Actual|2011-08-31|April 2010|Actual|2010-04-30||Interventional|||Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms|Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution Alone and In Combination on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen.|Completed||Phase 4|21|Actual|University of Chicago||4|||f||||f||||||||||2018-06-01 00:24:43.439921|2018-06-01 00:24:43.439921
NCT01007240|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-11-03|2009-11-03|2009-11-04|Estimate|||||||2009-11-03|2009-11-04|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|December 2010|Anticipated|2010-12-31|May 2010|Anticipated|2010-05-31||Interventional|||Antibacterial Properties of Silicon Incorporated With Quaternary Ammonium Polyethylenimine Nanoparticles|Clinical Study of the Antibacterial Properties of the Nano Particles Which Incorporated With the Soft Liner Silicone - in Obturators|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-06-01 00:24:43.855846|2018-06-01 00:24:43.855846
NCT01007227|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2013-09-25|2009-11-02|2009-11-03|Estimate|||||||2013-09-25|2013-09-26|Estimate|August 2006||2006-08-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Metabolic Syndrome and Fingertip Endothelial Dysfunction|Achievement of Dietetic and Exercise Therapy Evaluated by Self-assessment Score Significantly Improved Endothelial Dysfunction in Patients With Metabolic Syndrome|Completed||N/A|70|Actual|Kumamoto University||1|||f||||f||||||||||2018-06-01 00:24:43.928944|2018-06-01 00:24:43.928944
NCT01007214|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2014-02-26|2009-11-02|2009-11-03|Estimate|||||||2014-02-26|2014-02-27|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HIT||Guided Biopsy for Mapping Prostate Cancer|Hybrid Imaging Technique (HIT) Guided Biopsy to Map Prostatic Adenocarcinoma in Patients Undergoing Prostatectomy|Terminated||N/A|7|Actual|Roswell Park Cancer Institute||1||Not able to meet accrual|f||||t||||||||||2018-06-01 00:24:43.992166|2018-06-01 00:24:43.992166
NCT01007201|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2012-01-19|2009-11-01|2009-11-03|Estimate|||||||2012-01-19|2012-01-20|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population|A Clinical Study to Assess the Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Subjects Aged Over 1 Year Old to 18 Years Old|Completed||N/A|183|Actual|Adimmune Corporation||2|||f||||||||||||||2018-06-01 00:24:44.062699|2018-06-01 00:24:44.062699
NCT01007188|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2011-02-08|2009-11-02|2009-11-03|Estimate|||||||2011-02-08|2011-02-09|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Energy Value of Macronutrients From Almonds and Mechanisms of Nutrient Action|Energy Value of Macronutrients From Almonds and Mechanisms of Nutrient Action|Completed||N/A|18|Anticipated|USDA Beltsville Human Nutrition Research Center||3|||f||||t||||||||||2018-06-01 00:24:44.142666|2018-06-01 00:24:44.142666
NCT01007175|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2013-09-03|2009-11-02|2009-11-03|Estimate|||||||2013-09-03|2013-09-04|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ATN-103 Administered To Japanese Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate|Completed||Phase 1/Phase 2|60|Actual|Ablynx||5|||f||||f||||||||||2018-06-01 00:24:44.212329|2018-06-01 00:24:44.212329
NCT01007162|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-11-02|2009-11-02|2009-11-03|Estimate|||||||2009-11-02|2009-11-03|Estimate|February 2009||2009-02-28|November 2009|2009-11-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Observational|||Patient Satisfaction in the Critical Care Unit: A Qualitative Phenomenological Study|Patient Satisfaction in the Critical Care Unit: A Qualitative Phenomenological Study|Unknown status|Recruiting||8|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:24:44.34988|2018-06-01 00:24:44.34988
NCT01007149|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2012-02-20||2012-07-18|2009-11-02|2009-11-03|Estimate|2012-05-07|2012-06-08|Estimate||||2012-07-18|2012-07-20|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|NATAIR||Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma|A 16-week Treatment, Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study to Assess the Effect of Omalizumab on the Expression of FcεRI Receptors of Blood Basophils and Dendritic Cells in Patients With Severe Persistent Non-atopic Asthma, Uncontrolled Despite Optimal Therapy|Completed||Phase 3|79|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:24:44.549836|2018-06-01 00:24:44.549836
NCT01007136|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2015-05-29|2009-11-02|2009-11-03|Estimate|||||||2015-05-29|2015-06-01|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Transcranial Direct Current Stimulation (tDCS)-Enhanced Stroke Recovery|TDCS-enhanced Stroke Recovery and Cortical Reorganization|Completed||Phase 2|62|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:24:44.986135|2018-06-01 00:24:44.986135
NCT01007123|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2016-11-01||2017-02-01|2009-11-02|2009-11-03|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|November 2009||2009-11-30|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|ACCESS||Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation|A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of Elobixibat in Patients With Chronic Idiopathic Constipation|Completed||Phase 2|190|Actual|Albireo||4|||f||||f||||||||||2018-06-01 00:24:45.108279|2018-06-01 00:24:45.108279
NCT01007110|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2014-02-27||2014-06-02|2009-11-02|2009-11-03|Estimate|2014-04-14|2014-05-14|Estimate||||2014-06-02|2014-06-09|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes|The Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes|Completed||Phase 3|67|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 00:24:45.793063|2018-06-01 00:24:45.793063
NCT01007097|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02||2016-03-13|2016-03-13|2009-11-02|2009-11-03|Estimate||||2016-03-13|2016-04-13|Estimate|2016-03-13|2016-04-13|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-Blind, Double-Dummy Placebo-and Active-Controlled, Multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|426|Actual|Takeda||7|||f||||f||||||||||2018-06-01 00:24:46.212922|2018-06-01 00:24:46.212922
NCT01007084|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2011-12-07|2009-11-02|2009-11-03|Estimate|||||||2011-12-07|2011-12-08|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|TRAUMA_HELP||TRAUMA HELP: Healing and Analgesia With Propranolol|Phase IIB Study: TRAUMA HELP: Healing and Analgesia With Propranolol|Withdrawn||Phase 2|0|Actual|University of North Carolina, Chapel Hill||2||Lack of eligible patient recruits/feasibility considerations.|f||||t||||||||||2018-06-01 00:24:46.433474|2018-06-01 00:24:46.433474
NCT01007071|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2017-05-25||2017-10-13|2009-11-02|2009-11-03|Estimate|2017-10-13|2017-11-17|Actual||||2017-10-13|2017-11-17|Actual|November 1, 2009|Actual|2009-11-01|October 2017|2017-10-31|December 12, 2012|Actual|2012-12-12|December 12, 2012|Actual|2012-12-12||Interventional|GHD|all subjects were adults with growth hormone deficiency based on standard definitions.|Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency|Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults|Completed||Phase 3|11|Actual|Stanford University||2|||f||||t||||||||Undecided||2018-06-01 00:24:46.557402|2018-06-01 00:24:46.557402
NCT01007058|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2016-12-05|2009-11-02|2009-11-03|Estimate|||||||2016-12-05|2016-12-07|Estimate|June 2005||2005-06-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Markers of Response to Intravesical Bladder Cancer Therapy|Markers of Response to Intravesical Bladder Cancer Therapy|Completed|||150|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     4 tablespoons of urine and a bladder wash sample during catheterization (for planned~     treatment) or during routine cystoscopic exam, both samples at 4 different time points~     before, during and after therapy courses.~   "|||2018-06-01 00:24:46.914726|2018-06-01 00:24:46.914726
NCT01007045|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2011-06-08|2009-11-02|2009-11-03|Estimate|||||||2011-06-08|2011-06-09|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Limited Compression Ultrasound by Emergency Physicians to Exclude Deep Vein Thrombosis|Can Emergency Physicians Safely Exclude Proximal Deep Vein Thrombosis Using Limited Compression Emergency Department Ultrasound?|Completed|||227|Actual|Queen's University|||2||f||||f||||||||||2018-06-01 00:24:46.995552|2018-06-01 00:24:46.995552
NCT01007032|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2015-05-08|2009-11-02|2009-11-03|Estimate|||||||2015-05-08|2015-05-12|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|December 2012|Actual|2012-12-31||Interventional|||A Study of IMC-A12 in Advanced Solid Tumors|A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-A12 Administered Every 2 Weeks or Every 3 Weeks to Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|21|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 00:24:47.069713|2018-06-01 00:24:47.069713
NCT01007019|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2014-07-08|2009-11-02|2009-11-03|Estimate|||||||2014-07-08|2014-07-10|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects|A Dose-block Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and PKs/PDs of YH4808 After Oral Administration in Healthy Male Subjects|Completed||Phase 1|134|Actual|Yuhan Corporation||12|||f||||t||||||||||2018-06-01 00:24:47.150466|2018-06-01 00:24:47.150466
NCT01007006|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-11-03|2009-11-02|2009-11-03|Estimate|||||||2009-11-03|2009-11-04|Estimate|March 2010||2010-03-31|November 2009|2009-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||"Telepharmacy Robotic Medicine Delivery Unit TRMDU Assessment"|Evaluation of a Telepharmacy Robotic Medicine Delivery Unit in Warrior Transition Unit Patients With Traumatic Brain Injury, Post-Traumatic Stress Disorder, or Polytrauma|Unknown status|Not yet recruiting|N/A|165|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 00:24:47.240844|2018-06-01 00:24:47.240844
NCT01006993|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2010-03-10|2009-11-02|2009-11-03|Estimate|||||||2010-03-10|2010-03-11|Estimate|May 2007||2007-05-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|FASTFlo tPA||Feasibility and Safety of NeuroFlo in Stroke Patients Receiving Tissue Plasminogen Activator|Feasibility and Safety of NeuroFlo in Stroke Patients Receiving tPA|Completed||Phase 1|22|Actual|CoAxia||1|||f||||t||||||||||2018-06-01 00:24:47.334995|2018-06-01 00:24:47.334995
NCT01006980|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2011-07-29||2016-08-19|2009-11-02|2009-11-03|Estimate|2011-10-10|2011-11-16|Estimate||||2016-08-19|2016-09-28|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)|BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine|Completed||Phase 3|675|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:24:47.541737|2018-06-01 00:24:47.541737
NCT01006967|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2016-01-20|2009-11-02|2009-11-03|Estimate|||||||2016-01-20|2016-01-22|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|July 2015|Actual|2015-07-31||Interventional|RACE||ActiveStep Comparative Effectiveness Trial|Randomized ActiveStep Comparative Effectiveness Trial|Unknown status|Active, not recruiting|N/A|507|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-06-01 00:24:49.133083|2018-06-01 00:24:49.133083
NCT01006954|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2014-05-07|2009-11-02|2009-11-03|Estimate|||||||2014-05-07|2014-05-08|Estimate|September 2008||2008-09-30|November 2009|2009-11-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Outcome of Two Protocols in Poor Responders in Assisted Reproductive Technology (ART) Cycle|Comparison of Micro Dose Gonadotropin-Releasing Hormone (GnRH) Agonist Flare up & Flare Protocol in Poor Responders in Assisted Reproductive Technology (ART) Cycle|Completed||Phase 3|200|Actual|Royan Institute||2|||f||||t||||||||||2018-06-01 00:24:49.284835|2018-06-01 00:24:49.284835
NCT01006941|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2011-11-09|2009-11-02|2009-11-03|Estimate|||||||2011-11-09|2011-11-10|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|TRIMS A||Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study|Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study|Completed||Phase 2|10|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-06-01 00:24:49.403634|2018-06-01 00:24:49.403634
NCT01006928|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2011-06-05|2009-11-02|2009-11-03|Estimate|||||||2011-06-05|2011-06-08|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Association Between the Support of NICU Team and Subjective Health of Parents|Association Between the Support of Neonatal Intensive Care Unit (NICU) Team and Subjective Health of Parents to a Premature Infant|Completed|||150|Actual|Hillel Yaffe Medical Center|||1||f||||f||||||||||2018-06-01 00:24:49.479614|2018-06-01 00:24:49.479614
NCT01006915|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2016-05-04|2009-11-02|2009-11-03|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||Surgical Decompression for Diabetic Neuropathy in the Foot|Surgical Peripheral Nerve Decompression for the Treatment of Diabetic Neuropathy in the Foot|Completed||N/A|21|Actual|Timothy J. Best Medicine Professional Corporation||2|||f||||f||||||||||2018-06-01 00:24:49.711424|2018-06-01 00:24:49.711424
NCT01006902|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2011-11-28|2009-11-02|2009-11-03|Estimate|||||||2011-11-28|2011-11-29|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|May 2011|Actual|2011-05-31|||||Observational|||Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change|Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and Correlates of Change|Terminated|||3|Actual|University of Vermont|||1|Insufficient recruitment|f||||t||||||Samples Without DNA|"~     Serum samples will be obtained and stored at -80 degrees celsius~   "|||2018-06-01 00:24:49.849526|2018-06-01 00:24:49.849526
NCT01006889|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2015-03-02||2016-08-22|2009-11-02|2009-11-03|Estimate|2016-06-16|2016-07-29|Estimate||||2016-08-22|2016-09-28|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease|A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)|Completed||Phase 4|24|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 00:24:50.094115|2018-06-01 00:24:50.094115
NCT01006876|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2015-05-19|2009-11-02|2009-11-03|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|March 2013|Actual|2013-03-31||Interventional|COMPARE||Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation|Role of Coumadin in Preventing Periprocedural Thrombo-Embolism as a Complication of Radio Frequency Catheter Ablation in High-risk Atrial Fibrillation Patients|Completed||Phase 3|1584|Actual|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-06-01 00:24:50.652603|2018-06-01 00:24:50.652603
NCT01006863|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2010-05-26|2009-11-02|2009-11-03|Estimate|||||||2010-05-26|2010-05-28|Estimate|March 2004||2004-03-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study|Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study|Completed||Phase 2|150|Actual|King Faisal University||5|||f||||f||||||||||2018-06-01 00:24:50.919683|2018-06-01 00:24:50.919683
NCT01006837|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2017-02-12|2009-11-02|2009-11-03|Estimate|||||||2017-02-12|2017-02-14|Actual|October 2009||2009-10-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Observational|||Hypothermia in the Trauma Patient - When do Trauma Patients Get Cold?|Hypothermia in the Trauma Patient - Temperature Changes During Transport and Initial Treatment in Hospital|Completed|||60|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 00:24:51.119308|2018-06-01 00:24:51.119308
NCT01006824|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2011-01-24|2009-11-02|2009-11-03|Estimate|||||||2011-01-24|2011-01-25|Estimate|March 2003||2003-03-31|January 2011|2011-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding|Randomized Controlled Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding|Completed||Phase 4|136|Actual|University of Southern California||2|||f||||f||||||||||2018-06-01 00:24:51.443469|2018-06-01 00:24:51.443469
NCT01006811|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2010-11-19|2009-11-02|2009-11-03|Estimate|||||||2010-11-19|2010-11-22|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|ADIS||Use of the Modified Atkins Diet in Infantile Spasms|Efficacy and Tolerability of the Modified Atkins Diet in Patients With Infantile Spasms: a Pilot Study.|Completed||Phase 2/Phase 3|15|Anticipated|All India Institute of Medical Sciences, New Delhi||1|||f||||t||||||||||2018-06-01 00:24:51.693566|2018-06-01 00:24:51.693566
NCT01006798|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2013-06-27|2009-11-02|2009-11-03|Estimate|||||||2013-06-27|2013-07-01|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1|Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn|Completed||Phase 1|166|Actual|PaxVax, Inc.||5|||f||||t||||||||||2018-06-01 00:24:51.932156|2018-06-01 00:24:51.932156
NCT01006785|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2012-10-17|2009-11-02|2009-11-03|Estimate|||||||2012-10-17|2012-10-18|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer|Phase II Clinical Study: A Randomized, Open, and Dose Ranging Study to Evaluate the Efficacy and Safety of DLBS1425 in Subjects With Metastatic / Advanced Breast Cancer|Terminated||Phase 2|15|Actual|Dexa Medica Group||2||The study was terminated due to difficulty of find eligible subjects|f||||||||||||||2018-06-01 00:24:52.183342|2018-06-01 00:24:52.183342
NCT01006772|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2010-01-11|2009-11-02|2009-11-03|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2010||2010-01-31|November 2009|2009-11-30|September 2011|Anticipated|2011-09-30|April 2011|Anticipated|2011-04-30||Interventional|||Rehabilitation of Early Stroke Patients Using an AFO: an RCT|Rehabilitation of Early Stroke Patients Using a Custom-made Solid Ankle-foot Orthosis: a Randomised Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|University of Strathclyde||2|||f||||f||||||||||2018-06-01 00:24:52.373245|2018-06-01 00:24:52.373245
NCT01006759|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-11-02|2009-11-02|2009-11-03|Estimate|||||||2009-11-02|2009-11-03|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients|Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients|Completed||Phase 1|55|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 00:24:52.543737|2018-06-01 00:24:52.543737
NCT01006746|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2014-03-03|2009-11-02|2009-11-03|Estimate|||||||2014-03-03|2014-03-04|Estimate|February 2009||2009-02-28|March 2014|2014-03-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Observational|Educ@t||Observational Study of Patient Comprehension, Perception, Fears and Appreciation Following Home-Monitoring Implementation|Evaluation and Description of Mutual Influences Between Patient Training, Perception and Adoption of Home-Monitoring Technology|Completed|||571|Actual|Biotronik France|||1||f||||f||||||||||2018-06-01 00:24:52.937552|2018-06-01 00:24:52.937552
NCT01006733|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2016-12-28|2009-11-02|2009-11-03|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2011||2011-03-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|GIFT||Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT|Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis (DVT)|Completed||Phase 3|1598|Actual|Washington University School of Medicine||4|||f||||t||||||||Yes|GIFT plans to share anonymous IPD with other researchers via BioLINCC in March 2018.|2018-06-01 00:24:53.115119|2018-06-01 00:24:53.115119
NCT01006720|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2012-12-12|2009-11-02|2009-11-03|Estimate|||||||2012-12-12|2012-12-13|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Observational|SUNDRO20||Sugammadex and Neostigmine at Residual Neuromuscular Blockade|Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.2)|Completed|||99|Actual|Technische Universität München|||11||f||||t||||||||||2018-06-01 00:24:54.915316|2018-06-01 00:24:54.915316
NCT01006707|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2016-02-08||2017-10-18|2009-10-30|2009-11-03|Estimate|2017-10-18|2017-11-17|Actual||||2017-10-18|2017-11-17|Actual|November 2010||2010-11-30|October 2017|2017-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers|fMRI Imaging of Opioid Withdrawal in Healthy Human Volunteers|Completed||N/A|15|Actual|Stanford University|Opioid withdrawal model not necessarily generalizable to individuals with chronic pain and chronic opioid usage; short duration of scan; potential physiological noise in data; unable to obtain strong assessments of OOWS and SOWS during the scan.|2|||f||||f||||||||No||2018-06-01 00:24:55.122266|2018-06-01 00:24:55.122266
NCT01006694|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2015-03-04|2009-11-02|2009-11-03|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Paraprofessional Treatment of Depression in Vietnam|Paraprofessional Treatment of Depression in Vietnam|Completed||N/A|473|Actual|Vietnam Veterans of America Foundation||2|||f||||f||||||||||2018-06-01 00:24:55.723353|2018-06-01 00:24:55.723353
NCT01006681|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-31|||2009-11-02|2009-11-02|2009-11-03|Estimate|||||||2009-11-02|2009-11-03|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Vaccination Against Influenza H1N1 in Rheumatic Diseases|Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Immunomodulatory Drugs|Unknown status|Not yet recruiting|Phase 2|400|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-06-01 00:24:55.830292|2018-06-01 00:24:55.830292
NCT01006668|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2014-08-28|2009-11-02|2009-11-03|Estimate|||||||2014-08-28|2014-08-29|Estimate|November 2009||2009-11-30|August 2014|2014-08-31||||November 2014|Anticipated|2014-11-30||Interventional|||Sevoflurane Versus Propofol for Intubation in Neonatal Intensive Care|Sevoflurane Versus Propofol for Intubation in Neonatal Intensive Care|Unknown status|Recruiting|Phase 3|44|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 00:24:56.510945|2018-06-01 00:24:56.510945
NCT01006655|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2010-07-10||2015-10-28|2009-11-02|2009-11-03|Estimate|2010-08-11|2010-08-31|Estimate||||2015-10-28|2015-11-24|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children|The Effect of HFA - Beclomethasone Dipropionate - Qvar - on Bronchial Hyperreactivity in Preschool Children|Completed||Phase 2|21|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-06-01 00:24:57.587011|2018-06-01 00:24:57.587011
NCT01006642|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-11-02|2009-11-02|2009-11-03|Estimate|||||||2009-11-02|2009-11-03|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|July 2010|Anticipated|2010-07-31|March 2010|Anticipated|2010-03-31||Observational|||Mucosal Barrier Defects in Functional Dyspepsia by Confocal Laser Endomicroscopy|Minimal Changes of Gastric Mucosal Barrier in the Pathophysiologic Mechanisms of Functional Dyspepsia|Unknown status|Recruiting||80|Anticipated|Shandong University|||3||f||||t||||||Samples With DNA|"~     Biopsies during endoscopy~   "|||2018-06-01 00:24:58.450012|2018-06-01 00:24:58.450012
NCT01006629|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|2011-04-29||2011-06-21|2009-11-02|2009-11-03|Estimate|2011-06-21|2011-07-19|Estimate||||2011-06-21|2011-07-19|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children|A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation|Completed||Phase 2/Phase 3|100|Actual|Abbott|This study had no control group; relative comparisons are only possible with current product information for palivizumab. No RSV hospitalizations occurred during the study; therefore, secondary outcome measures could not be evaluated.|1|||f||||||||||||||2018-06-01 00:24:58.896469|2018-06-01 00:24:58.896469
NCT01006616|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2014-10-02||2017-03-10|2009-11-02|2009-11-03|Estimate|2014-11-14|2014-11-17|Estimate||||2017-03-10|2017-04-10|Actual|October 2009||2009-10-31|March 2017|2017-03-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional||Baseline Analysis Population consists of all treated participants (1 participant in the Navarixin 50 mg group and 1 participant in the Placebo group did not receive study drug).|Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)|A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD|Terminated||Phase 2|616|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-06-01 00:24:59.500579|2018-06-01 00:24:59.500579
NCT01006603|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-31|2013-06-12||2013-09-27|2009-11-02|2009-11-03|Estimate|2013-09-27|2013-11-28|Estimate||||2013-09-27|2013-11-28|Estimate|October 2009||2009-10-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|GENERATION||Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin|A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Monotherapy|Completed||Phase 4|957|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:25:03.078617|2018-06-01 00:25:03.078617
NCT01006590|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-31|2011-11-30||2012-01-16|2009-11-02|2009-11-03|Estimate|2011-11-30|2012-01-05|Estimate||||2012-01-16|2012-01-19|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|||||Interventional|PROMPT||Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 Diabetes|A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Sub-Maximal Doses of Metformin|Completed||Phase 4|286|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:25:05.494618|2018-06-01 00:25:05.494618
NCT01006577|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2009-11-02|2009-11-02|2009-11-03|Estimate|||||||2009-11-02|2009-11-03|Estimate|June 2010||2010-06-30|November 2009|2009-11-30|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|SAVE||Side-to-end Anastomosis Versus Colon J Pouch for Reconstruction After Low Anterior Resection for Rectal Cancer (SAVE)|Side-to-end Anastomosis Versus Colon J Pouch for Reconstruction After Low Anterior Resection for Rectal Cancer (SAVE)|Unknown status|Not yet recruiting|N/A|306|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 00:25:06.60801|2018-06-01 00:25:06.60801
NCT01006564|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-11-02|2009-11-02|2009-11-03|Estimate|||||||2009-11-02|2009-11-03|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer|Multifunctional MR for Radiotherapy Planning in Prostate Cancer|Unknown status|Recruiting|N/A|30|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:25:06.808455|2018-06-01 00:25:06.808455
NCT01006551|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2009-11-02|2009-11-02|2009-11-03|Estimate|||||||2009-11-02|2009-11-03|Estimate|December 2002||2002-12-31|November 2009|2009-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|ZEOSS||Ziprasidone in Early Onset Schizophrenia Spectrum Disorders|Ziprasidone in Early Onset Schizophrenia Spectrum Disorders|Completed||Phase 2|40|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-06-01 00:25:07.175639|2018-06-01 00:25:07.175639
NCT01006538|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2016-12-21|2009-11-02|2009-11-03|Estimate|||||||2016-12-21|2016-12-22|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2015|Actual|2015-03-31||Interventional|MERLOT||Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)|A Randomised Controlled Trial of Epimacular Brachytherapy Versus Ranibizumab Monotherapy for the Treatment of Subfoveal Choroidal Neovascularisation Associated With Wet Age-related Macular Degeneration in Patients Who Have Commenced Anti-VEGF Therapy|Completed||Phase 4|363|Actual|King's College Hospital NHS Trust||2|||f||||t||||||||No||2018-06-01 00:25:07.561621|2018-06-01 00:25:07.561621
NCT01006525|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-02|||2011-11-04|2009-11-02|2009-11-03|Estimate|||||||2011-11-04|2011-11-07|Estimate|December 2005||2005-12-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Safety and Efficacy of Chronic Hypnotic Use|Abuse Liability Associated With Chronic Hypnotic Use|Completed|||116|Actual|Henry Ford Health System|||1||f||||t||||||Samples Without DNA|"~     urine and saliva~   "|||2018-06-01 00:25:07.967985|2018-06-01 00:25:07.967985
NCT01006499|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2011-03-10|2009-11-01|2009-11-02|Estimate|||||||2011-03-10|2011-03-11|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'|Phase 4 Study of Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'|Unknown status|Active, not recruiting|Phase 4|204|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||4|||f||||t||||||||||2018-06-01 00:25:08.441703|2018-06-01 00:25:08.441703
NCT01006486|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2011-10-24|2009-11-01|2009-11-02|Estimate|||||||2011-10-24|2011-10-25|Estimate|November 2009||2009-11-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Outcomes of an Anticoagulation Clinic in an University Hospital|Evaluation of Impact of the Implantation of an Anticoagulation Clinic in an University Hospital in Brazil|Completed||Phase 4|280|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-06-01 00:25:08.801491|2018-06-01 00:25:08.801491
NCT01006473|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2015-08-10|2009-11-01|2009-11-02|Estimate|||||||2015-08-10|2015-08-13|Estimate|March 2007||2007-03-31|August 2015|2015-08-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Exercise Training in Chagas Cardiomyopathy|A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy|Completed||Phase 4|37|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-06-01 00:25:09.225667|2018-06-01 00:25:09.225667
NCT01004367|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2015-06-03|2009-10-28|2009-10-29|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ACTIVITAL||Health Promotion in Adolescents in Ecuador|ACTIVITAL: Health Promotion Intervention in Ecuadorian Adolescents to Promote Healthy Dietary and Physical Activity Patterns.|Unknown status|Recruiting|N/A|1400|Anticipated|University Ghent||1|||f||||f||||||||||2018-06-01 00:25:49.934738|2018-06-01 00:25:49.934738
NCT01006460|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2010-08-26|2009-11-01|2009-11-02|Estimate|||||||2010-08-26|2010-08-27|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||A Study With Arctic Root Compared With the Extract When Combined With Schizandra and Russian Root (Adapt 232), Standardized Ginseng Extract and Placebo Regarding Impact on the Level of Energy, Ability to Work Under Stress, Quality of Life and Wellbeing, in Middleaged Women Who Are Still Employed|A Randomized, Placebo Controlled, Parallel, Double Blinded Trial With Rhodiola Rosea Extract SHR-5 (Arctic Root) Compared With the Extract When Combined With Schizandra and Russian Root (Adapt 232), Standardized Ginseng Extract and Placebo Regarding Impact on the Level of Energy, Ability to Work Under Stress, Quality of Life and Wellbeing, in Middleaged Women Who Are Still Employed|Completed||N/A|200|Anticipated|Frederiksberg University Hospital||4|||f||||f||||||||||2018-06-01 00:25:09.590511|2018-06-01 00:25:09.590511
NCT01006447|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2009-11-01|2009-11-01|2009-11-02|Estimate|||||||2009-11-01|2009-11-02|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Tai Chi/Qigong Exercise Persistence Among Residents of Senior Housing|Tai Chi/Qigong Exercise Persistence Among Residents of Senior Housing: a Randomized Field Trial|Completed||Phase 1|77|Actual|D'Youville College||2|||f||||f||||||||||2018-06-01 00:25:09.730575|2018-06-01 00:25:09.730575
NCT01006434|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2013-05-13|2009-11-01|2009-11-02|Estimate|||||||2013-05-13|2013-05-14|Estimate|April 2008||2008-04-30|May 2013|2013-05-31||||December 2013|Anticipated|2013-12-31||Observational|WAIST||Weight Approximation in Stroke Before Thrombolysis||Unknown status|Recruiting||800|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-06-01 00:25:09.82949|2018-06-01 00:25:09.82949
NCT01006421|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2009-11-04|2009-11-01|2009-11-02|Estimate|||||||2009-11-04|2009-11-05|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|January 2011|Anticipated|2011-01-31|||||Observational|GB||Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo|Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial|Unknown status|Recruiting||160|Anticipated|King Saud University|||||f||||f||||||||||2018-06-01 00:25:09.96815|2018-06-01 00:25:09.96815
NCT01006408|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2012-10-17|2009-11-01|2009-11-02|Estimate|||||||2012-10-17|2012-10-19|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|LLL||Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy|Pilot, Single Center, Randomized, Double Blind, Placebo Controlled, Single Crossover Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy|Completed||N/A|20|Actual|Legacy Health System||2|||f||||f||||||||||2018-06-01 00:25:10.08166|2018-06-01 00:25:10.08166
NCT01006395|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-01|||2016-07-11|2009-11-01|2009-11-02|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)|Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT)|Recruiting||Phase 2/Phase 3|100|Anticipated|Austin Health||2|||f||||t||||||||||2018-06-01 00:25:10.193979|2018-06-01 00:25:10.193979
NCT01006382|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2011-06-21|2009-10-30|2009-11-02|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Adherence to Self-care Regimens for Young People With Food Allergy|To What Extent do Social Cognition Models Explain Adherence to Self-care Regimens in Adolescents and Young Adults With Food Allergy|Completed|||275|Anticipated|Brighton & Sussex Medical School|||1||f||||t||||||||||2018-06-01 00:25:10.367194|2018-06-01 00:25:10.367194
NCT01006369|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-02-14|2009-10-30|2009-11-02|Estimate|||||||2017-02-14|2017-02-15|Actual|May 2009|Actual|2009-05-31|February 2017|2017-02-28|April 27, 2016|Actual|2016-04-27|August 6, 2015|Actual|2015-08-06||Interventional|||Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Autophagy and Anti-Angiogenesis in Metastatic Colorectal Carcinoma: A Phase II Trial of Hydroxychloroquine to Augment Effectiveness of XELOX-Bevacizumab. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)|Completed||Phase 2|39|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 00:25:10.525844|2018-06-01 00:25:10.525844
NCT01006356|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2013-03-26||2013-07-09|2009-10-29|2009-11-02|Estimate|2013-07-09|2013-08-08|Estimate||||2013-07-09|2013-08-08|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Baseline characteristics was measured for intent-to-treat (ITT) analysis population which was defined as participants who received at least 1 dose of study drug and had available data in the dosing frequency of short-acting narcotic analgesics for treating breakthrough pain at Visit 3 (Day 8).|An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer|Cancer Pain Management With Hydromorphone HCl ORal Osmotic System in Korean Cancer Patient: Evaluation of Its Clinical Usefulness in Reduction of Breakthrough Pain Medication Frequency|Completed||Phase 4|141|Actual|Janssen Korea, Ltd., Korea||1|||f||||f||||||||||2018-06-01 00:25:10.804293|2018-06-01 00:25:10.804293
NCT01006343|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2013-09-23|2009-10-30|2009-11-02|Estimate|||||||2013-09-23|2013-09-24|Estimate||||October 2009|2009-10-31||||||||Interventional|||Dietary Pork, Appetite and Weight Loss in Human||Completed||N/A|||Purdue University||2|||f||||||||||||||2018-06-01 00:25:11.27545|2018-06-01 00:25:11.27545
NCT01006330|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2011-06-15|2009-10-30|2009-11-02|Estimate|||||||2011-06-15|2011-06-16|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|DEM||Dysphagia in Elderly Medical Patients|Dysphagia in Elderly Medical Patients: Occupational Therapy Evaluation and Prevalence|Completed|||110|Actual|Herlev Hospital|||1||f||||t||||||||||2018-06-01 00:25:11.365528|2018-06-01 00:25:11.365528
NCT01006317|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2015-08-20|2009-10-30|2009-11-02|Estimate|||||||2015-08-20|2015-08-21|Estimate|March 2008||2008-03-31|August 2015|2015-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|CHIMACA||Intervention on Maternal Health Care in Rural China|Structural Hinders to and Promoters of Good Maternal Care in Rural China|Completed||N/A|108|Actual|National Institute for Health and Welfare, Finland||4|||f||||t||||||||||2018-06-01 00:25:11.44422|2018-06-01 00:25:11.44422
NCT01006304|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2010-07-01|2009-10-29|2009-11-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|||||Interventional|||An Exploratory Study to Assess the Effects of JNJ-39439335 on the Relief of Pain Using a Thermal-Grill Experimental Model|A Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Effects of JNJ-39439335 (a TRPV1 Antagonist) in Healthy Male Adult Subjects on the Paradoxical Pain Induced by a Thermal Grill|Completed||Phase 1|12|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 00:25:11.58212|2018-06-01 00:25:11.58212
NCT01006291|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2015-10-12|2010-11-05|2016-12-16|2009-10-30|2009-11-02|Estimate|2015-10-12|2015-11-13|Estimate|2011-01-07|2011-01-20|Estimate|2016-12-16|2017-02-09|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|BEGIN™||Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes|A 26 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Three-arm, Treat to Target Trial Comparing Efficacy and Safety of Three Different Dosing Regimens of Either Soluble Insulin Basal Analogue (SIBA) or Insulin Glargine With or Without Combination With OAD Treatment, in Subjects With Type 2 Diabetes Mellitus (BEGIN™ : FLEX)|Completed||Phase 3|687|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 00:25:11.689954|2018-06-01 00:25:11.689954
NCT01006278|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2009-10-30|2009-10-30|2009-11-02|Estimate|||||||2009-10-30|2009-11-02|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|January 2008|Actual|2008-01-31||Observational|||Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee|Molecular Biomarkers Associated With Degenerative Joint Disease|Completed|||40|Actual|Scuderi, Gaetano J., M.D.|||2||f||||t||||||Samples Without DNA|"~     synovial fluid ananysis~   "|||2018-06-01 00:25:12.389552|2018-06-01 00:25:12.389552
NCT01006265|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30||2012-09-27|2017-03-31|2009-10-30|2009-11-02|Estimate||||2012-09-27|2012-10-01|Estimate|2017-03-31|2017-04-04|Actual|October 1, 2009||2009-10-01|March 2017|2017-03-31|July 1, 2011|Actual|2011-07-01|June 1, 2011|Actual|2011-06-01||Interventional|||Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis|Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|464|Actual|Actelion||4|||f||||t|t|f||||||||2018-06-01 00:25:12.460845|2018-06-01 00:25:12.460845
NCT01006252|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30||2011-08-09|2011-08-09|2009-10-30|2009-11-02|Estimate||||2011-08-09|2011-08-15|Estimate|2011-08-09|2011-08-15|Estimate|December 2009||2009-12-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SUMMIT-1||A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma|A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients With Metastatic Melanoma|Terminated||Phase 3|323|Actual|Eli Lilly and Company||2||More possibly-related deaths on tasisulam arm; failed to pass futility hurdle|f||||t||||||||||2018-06-01 00:25:12.873299|2018-06-01 00:25:12.873299
NCT01006239|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2018-04-16|2009-10-30|2009-11-02|Estimate|||||||2018-04-16|2018-04-17|Actual|November 2009||2009-11-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|BIF||The Biorepository for Scripps Health|The Biorepository for Scripps Health|Active, not recruiting|||10000|Anticipated|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     We will be collecting solid tumor and adjacent non-diseased tissue from patients undergoing~     surgical resection of a solid tumor.~   "|||2018-06-01 00:25:13.671269|2018-06-01 00:25:13.671269
NCT01006226|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-07-22|2009-10-30|2009-11-02|Estimate|||||||2013-07-22|2013-07-23|Estimate||||July 2013|2013-07-31||||||||Interventional|||64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab|A Pilot Study of 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer Patients Treated With Carboplatin, Paclitaxel, and Bevacizumab|Withdrawn||N/A|0|Actual|Washington University School of Medicine||1||Withdrawn due to funding issues|f||||f||||||||||2018-06-01 00:25:13.994975|2018-06-01 00:25:13.994975
NCT01006213|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2009-10-30|2009-10-30|2009-11-02|Estimate|||||||2009-10-30|2009-11-02|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|January 2008|Anticipated|2008-01-31||Interventional|IMOAP||Group Motivational Intervention in Overweight/Obese Patients|Group Motivational Intervention in Overweight/Obese Patients in Primary Prevention of Cardiovascular Disease in the Primary Healthcare Area (IMOAP)|Unknown status|Recruiting|N/A|1200|Anticipated|Jordi Gol i Gurina Foundation||1|||f||||f||||||||||2018-06-01 00:25:14.288178|2018-06-01 00:25:14.288178
NCT01006200|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-10-30|2009-10-30|2009-11-02|Estimate|||||||2009-10-30|2009-11-02|Estimate|August 2001||2001-08-31|October 2009|2009-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Factors to Obstructive Granulation Tissue Formation After Ultraflex Stenting in Benign Tracheal Narrowing|Factors to Obstructive Granulation Tissue Formation After Ultraflex Stenting in Benign Tracheal Narrowing|Completed|||67|Actual|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-06-01 00:25:14.6349|2018-06-01 00:25:14.6349
NCT01006187|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2011-07-18|2009-10-29|2009-11-02|Estimate|||||||2011-07-18|2011-07-19|Estimate|October 2009||2009-10-31|July 2011|2011-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Comparison of Different Methods for Reducing Pain From Influenza Vaccine Injections|Comparison of Different Analgesic Methods for Reducing Pain From Adult Intramuscular Influenza Virus Vaccine Injection|Completed||Phase 3|352|Actual|The Hospital for Sick Children||4|||f||||f||||||||||2018-06-01 00:25:14.895632|2018-06-01 00:25:14.895632
NCT01006174|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2013-01-16|2009-10-30|2009-11-02|Estimate|||||||2013-01-16|2013-01-17|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Dietary Lipids as Primary Modulators of Carotenoid Absorption in Vegetables|Dietary Lipids as Primary Modulators of Carotenoid Absorption in Vegetables|Completed||N/A|55|Actual|Purdue University||3|||f||||||||||||||2018-06-01 00:25:15.023849|2018-06-01 00:25:15.023849
NCT01006161|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2015-10-12|2009-10-30|2009-11-02|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)|Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects With Severe Asthma|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-06-01 00:25:15.157569|2018-06-01 00:25:15.157569
NCT01006148|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2016-09-29|2009-10-30|2009-11-02|Estimate|||||||2016-09-29|2016-09-30|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|DBM||Comparison of a Bone Product to Bone Dust in Ossification of Small Calvarial Defects.|Comparison of Allogenix Plus Demineralized Bone Matrix and Autogenous Bone Dust Versus Autogenous Bone Dust Alone in Ossification of Small Calvarial Defects, a Pilot Study.|Withdrawn||Phase 4|0|Actual|University of Missouri-Columbia||1||problems obtaining the investigational agent, Allogenix(TM) Plus|f||||f||||||||No||2018-06-01 00:25:15.254014|2018-06-01 00:25:15.254014
NCT01006135|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2012-06-02||2014-03-12|2009-10-30|2009-11-02|Estimate|2012-06-02|2012-07-09|Estimate||||2014-03-12|2014-04-10|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region|Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European Region|Completed|||4852|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 00:25:15.508048|2018-06-01 00:25:15.508048
NCT01006122|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2014-04-08|2013-04-09|2014-04-08|2009-10-29|2009-11-02|Estimate|2014-04-08|2014-05-09|Estimate|2013-04-09|2013-04-16|Estimate|2014-04-08|2014-05-09|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Full analysis set (FAS) consisted of all participants who were randomized to a treatment sequence and received at least 1 dose of study drug.|A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy|A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy|Completed||Phase 2|95|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:25:17.256436|2018-06-01 00:25:17.256436
NCT01006109|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2018-05-23|2009-10-30|2009-11-02|Estimate|||||||2018-05-23|2018-05-24|Actual|October 22, 2009||2009-10-22|September 7, 2017|2017-09-07|September 7, 2017||2017-09-07|||||Observational|||Recording and Modulation of Neuronal Mechanisms During Operant Conditioning: a MEG Study|Recording and Modulation of Neuronal Mechanisms During Operant Conditioning: A MEG Study|Terminated|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:25:19.613967|2018-06-01 00:25:19.613967
NCT01006096|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2014-11-07|2009-10-29|2009-11-02|Estimate|||||||2014-11-07|2014-11-10|Estimate||||November 2014|2014-11-30||||||||Interventional|||Erlotinib for Treatment of Psoriasis|Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis|Withdrawn||Phase 2|0|Actual|Northwestern University||2||IND not obtained|f||||f||||||||||2018-06-01 00:25:19.701189|2018-06-01 00:25:19.701189
NCT01006083|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2009-10-30|2009-10-30|2009-11-02|Estimate|||||||2009-10-30|2009-11-02|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|February 2012|Anticipated|2012-02-29|January 2012|Anticipated|2012-01-31||Observational|||Antiplatelet Therapy Continuation in Spine Surgery - Its Effect on Postoperative Morbidity and Mortality|Impact of Continued Use of Clopidogrel and / or Aspirin on Outcomes in Patients Undergoing Lumbar Spine Surgery. A Prospective Observational Study|Unknown status|Not yet recruiting||200|Anticipated|Tel-Aviv Sourasky Medical Center|||4||f||||f||||||||||2018-06-01 00:25:19.804571|2018-06-01 00:25:19.804571
NCT01006070|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2012-03-19|2009-10-30|2009-11-02|Estimate|||||||2012-03-19|2012-03-21|Estimate|February 2010||2010-02-28|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Health-Related Quality of Life (QOL), Physical and Respiratory Function in Patients With Myeloma Affecting the Spine|Prospective Observation Study of Health-related QOL, Physical Function & Respiratory Function in Patients w/ Myeloma Affecting Spine: The Impact of Disease,Fractures & Effect of Vertebral Augmentation w/ Kyphoplasty|Completed|||50|Actual|University of California, San Francisco|||2||f||||f||||||||||2018-06-01 00:25:19.89276|2018-06-01 00:25:19.89276
NCT01006057|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-01-19|2009-10-30|2009-11-02|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2009||2009-11-30|January 2017|2017-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function|A Trial Investigating the Pharmacokinetic and Safety of NN1250 in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-06-01 00:25:20.833936|2018-06-01 00:25:20.833936
NCT01006044|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2014-09-02|2009-10-30|2009-11-02|Estimate|||||||2014-09-02|2014-09-03|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection|Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope|Completed||Phase 2|26|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-06-01 00:25:20.926544|2018-06-01 00:25:20.926544
NCT01006031|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2011-12-28|2009-10-29|2009-11-02|Estimate|||||||2011-12-28|2011-12-30|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4|Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy.|Completed||Phase 2/Phase 3|25|Actual|Sociedad Andaluza de Enfermedades Infecciosas||1|||f||||t||||||||||2018-06-01 00:25:20.998641|2018-06-01 00:25:20.998641
NCT01006018|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2013-03-14||2013-11-12|2009-10-30|2009-11-02|Estimate|2013-05-01|2013-06-07|Estimate||||2013-11-12|2013-12-05|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|DInT DM||DPP-4 Inhibition and TZD for DM Prevention|DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)|Terminated||N/A|3|Actual|Emory University||3||Unanticipated delays due to sterilization/stabilization testing of GLP-1.|f||||f||||||||||2018-06-01 00:25:21.083115|2018-06-01 00:25:21.083115
NCT01006005|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2012-11-20|2009-10-30|2009-11-02|Estimate|||||||2012-11-20|2012-11-22|Estimate|July 2007||2007-07-31|November 2012|2012-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens|Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens|Completed|||51|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 00:25:21.244386|2018-06-01 00:25:21.244386
NCT01005992|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2009-10-30|2009-10-30|2009-11-02|Estimate|||||||2009-10-30|2009-11-02|Estimate|November 2009||2009-11-30|October 2009|2009-10-31||||April 2010|Anticipated|2010-04-30||Interventional|||Fractional Photothermolysis for the Treatment of Burn Scars|Fractional Photothermolysis for the Treatment of Burn Scars|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Clinica las Condes, Chile||2|||f||||f||||||||||2018-06-01 00:25:21.292016|2018-06-01 00:25:21.292016
NCT01005979|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2014-08-12|2009-10-30|2009-11-02|Estimate|||||||2014-08-12|2014-08-13|Estimate|July 2010||2010-07-31|August 2014|2014-08-31||||October 2012|Actual|2012-10-31||Interventional|||A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)|A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and SLL|Terminated||Phase 1|6|Actual|Emory University||1||Slow Accrual|f||||t||||||||||2018-06-01 00:25:21.585992|2018-06-01 00:25:21.585992
NCT01005966|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2012-11-28|2012-11-28|2013-06-20|2009-10-29|2009-11-02|Estimate|2013-06-20|2013-07-29|Estimate|2013-06-20|2013-07-29|Estimate|2013-06-20|2013-07-29|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||In Situ Caries Model of Fluoride Toothpastes|Clinical Efficacy of Fluoride Toothpastes Using an in Situ Caries Model|Completed||Phase 3|65|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 00:25:21.702518|2018-06-01 00:25:21.702518
NCT01005953|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2011-06-06|2009-10-30|2009-11-02|Estimate|||||||2011-06-06|2011-06-07|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|CCCCSys||Comprehensive Collection, Charting, and Communication System|Phase 1 Study of a Digital/Internet/Mobile System for Collecting, Charting and Communicating About the Behaviors of Children on the Autism Spectrum|Unknown status|Active, not recruiting||70|Anticipated|SymTrend Inc.|||2||f||||f||||||||||2018-06-01 00:25:22.195671|2018-06-01 00:25:22.195671
NCT01005940|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2014-03-24|2009-10-30|2009-11-02|Estimate|||||||2014-03-24|2014-03-26|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|OSA-MAD||Dental Device for Treatment of Sleep Apnea|Health Outcomes of Treatment of Obstructive Sleep Apnea With Dental Devices|Unknown status|Active, not recruiting|N/A|40|Anticipated|Ohio State University||2|||f||||t||||||||||2018-06-01 00:25:22.301163|2018-06-01 00:25:22.301163
NCT01005927|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2018-05-02|2009-10-30|2009-11-02|Estimate|||||||2018-05-02|2018-05-07|Actual|January 2009||2009-01-31|May 2018|2018-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Fructooligosaccharide and Calcium Absorption in Adolescent Girls|Fructooligosaccharide and Calcium Absorption in Adolescent Girls|Completed||Phase 1/Phase 2|26|Actual|Purdue University||2|||f||||f||||||||||2018-06-01 00:25:22.380269|2018-06-01 00:25:22.380269
NCT01005914|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2014-10-28||2015-02-12|2009-10-30|2009-11-02|Estimate|2015-02-09|2015-02-11|Estimate||||2015-02-12|2015-03-04|Estimate|June 2009||2009-06-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|March 2013|Actual|2013-03-31||Interventional||Analysis was not performed due to early termination of the study due to safety concerns.|Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Phase II Trial of the Addition of PEG-Asparaginase to the Hyper-CVAD Regimen in Adult Newly-Diagnosed Acute Lymphoblastic Leukemia|Terminated||Phase 2|11|Actual|OHSU Knight Cancer Institute|Early termination of the study due to adverse events.|1||Increased rate of bacterial infections|f||||t||||||||||2018-06-01 00:25:22.4712|2018-06-01 00:25:22.4712
NCT01005901|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2011-12-15||2012-03-15|2009-10-30|2009-11-02|Estimate|2012-03-15|2012-04-12|Estimate||||2012-03-15|2012-04-12|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|GLOW 1||A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo|A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1324|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:25:22.783354|2018-06-01 00:25:22.783354
NCT01005888|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2010-03-17||2014-03-19|2009-10-30|2009-11-02|Estimate|2010-05-03|2010-06-03|Estimate||||2014-03-19|2014-04-15|Estimate|September 2005||2005-09-30|March 2014|2014-03-31|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks|LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks|Completed||Phase 3|26|Actual|Shire||2|||f||||t||||||||||2018-06-01 00:25:23.922999|2018-06-01 00:25:23.922999
NCT01005875|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2014-04-09||2017-04-03|2009-10-30|2009-11-02|Estimate|2014-05-12|2014-06-11|Estimate||||2017-04-03|2017-05-10|Actual|November 2009||2009-11-30|April 2017|2017-04-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|RAD 0901||Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma|RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma|Terminated||N/A|5|Actual|University of Alabama at Birmingham|The study was closed due to slow accural and enrolled 5 of the 10 planned patients.|1||"Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is~   insufficient data and will not be any study results/outcomes."|f||||t||||||||||2018-06-01 00:25:24.381258|2018-06-01 00:25:24.381258
NCT01005862|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2012-09-25|2009-10-30|2009-11-02|Estimate|||||||2012-09-25|2012-09-26|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers|A Randomized, Investigator And Subject-Blind, Sponsor-Open, Placebo-Controlled Study To Examine The Effects Of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers|Completed||Phase 1|17|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:25:24.678016|2018-06-01 00:25:24.678016
NCT01005849|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2012-01-18|2009-10-30|2009-11-02|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|TD||Probiotics and the Prevention of Traveler's Diarrhea|A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea|Terminated||Phase 4|420|Actual|Lallemand SAS||2||because of low rate recruitment and the inability to reach the target expected|f||||t||||||||||2018-06-01 00:25:24.764671|2018-06-01 00:25:24.764671
NCT01005836|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-03-28|2009-10-30|2009-11-02|Estimate|||||||2017-03-28|2017-03-30|Actual|February 1998||1998-02-28|March 2017|2017-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|YADS||Community Clinic Test of Youth Anxiety Treatment|Community Clinic Test of Youth Anxiety and Depression Study|Completed||N/A|105|Actual|Harvard University||4|||f||||t||||||||||2018-06-01 00:25:24.845438|2018-06-01 00:25:24.845438
NCT01005823|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2013-10-21|2009-10-30|2009-11-02|Estimate|||||||2013-10-21|2013-10-22|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis|A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis|Completed||Phase 1|36|Actual|LEO Pharma||4|||f||||f||||||||||2018-06-01 00:25:24.92247|2018-06-01 00:25:24.92247
NCT01005810|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-10-30|2009-10-30|2009-11-02|Estimate|||||||2009-10-30|2009-11-02|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana|A Controlled Trial of N-Acetylcysteine (NAC) in Cannabis Dependent Adolescents|Unknown status|Recruiting|Phase 2|72|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 00:25:25.019161|2018-06-01 00:25:25.019161
NCT01005797|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-02-28|2009-10-30|2009-11-02|Estimate|||||||2017-02-28|2017-03-03|Actual|November 2009||2009-11-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|March 2014|Actual|2014-03-31||Interventional|||Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers|A Phase I Safety and Tolerability Study of LBH589 in Combination With Sorafenib in Patients With Advanced Renal Cell Carcinoma, Soft Tissue Sarcoma, and Non-small Cell Lung Carcinoma (NSCLC) of Non-squamous Histologies.|Completed||Phase 1|38|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-06-01 00:25:25.136353|2018-06-01 00:25:25.136353
NCT01005771|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2010-06-08|2009-10-30|2009-11-02|Estimate|||||||2010-06-08|2010-06-09|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions|GF-001001-00 Cream.A Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of 3 Different Doses of GF-001001-00 Cream Versus Placebo Cream Applied 2 Times Daily for 7 Days in the Treatment of Adult Patients With Secondarily-infected Traumatic Lesions|Completed||Phase 2|200|Actual|Ferrer Internacional S.A.||4|||f||||f||||||||||2018-06-01 00:25:25.331678|2018-06-01 00:25:25.331678
NCT01005758|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2014-01-09|2009-10-30|2009-11-02|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2009||2009-01-31|October 2009|2009-10-31||||January 2013|Anticipated|2013-01-31||Interventional|||Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|DFCI ALL Adult Consortium Protocol: Adult ALL Trial|Unknown status|Not yet recruiting|Phase 2|180|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:25:25.40851|2018-06-01 00:25:25.40851
NCT01005745|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2014-05-01||2018-01-09|2009-10-29|2009-11-02|Estimate|2014-05-01|2014-06-02|Estimate||||2018-01-09|2018-02-05|Actual|October 20, 2009|Actual|2009-10-20|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|January 31, 2014|Actual|2014-01-31||Interventional||All 19 participants accrued are listed for baseline, Primary Outcome Measure and Adverse Events. All 13 participants who completed treatment are listed for analysis of Secondary Outcome Measure.|Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma|Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma|Active, not recruiting||N/A|19|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 00:25:25.513548|2018-06-01 00:25:25.513548
NCT01005732|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2011-01-11||2011-04-01|2009-10-30|2009-11-02|Estimate|2011-04-01|2011-04-04|Estimate||||2011-04-01|2011-04-04|Estimate|November 1995||1995-11-30|April 2011|2011-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effectiveness of Pressure Garment Therapy After Burns|Effectiveness of Pressure Garment Therapy After Burns|Completed||N/A|67|Actual|University of Washington|||||f||||f||||||||||2018-06-01 00:25:25.849568|2018-06-01 00:25:25.849568
NCT01005719|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2011-01-04||2015-02-20|2009-10-30|2009-11-02|Estimate|2011-01-04|2011-01-28|Estimate||||2015-02-20|2015-03-11|Estimate|September 2009||2009-09-30|February 2015|2015-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)|Randomized, Crossover, Pharmacodynamic Study Comparing the Effects of Two Proton Pump Inhibitors|Completed||Phase 3|63|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:25:26.151692|2018-06-01 00:25:26.151692
NCT01005706|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2015-05-14||2016-02-12|2009-10-30|2009-11-02|Estimate|2016-02-12|2016-03-11|Estimate||||2016-02-12|2016-03-11|Estimate|August 2009||2009-08-31|February 2014|2014-02-28|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Sirolimus Conversions in African-American Renal Transplant Recipients|A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients|Completed||N/A|40|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 00:25:26.75122|2018-06-01 00:25:26.75122
NCT01005693|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2013-05-14|2009-10-30|2009-11-02|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 2009||2009-10-31|May 2010|2010-05-31||||October 2011|Anticipated|2011-10-31||Interventional|||Screening Tools to Predict Treatment Outcome in Older Cancer Patients Who Are Undergoing Treatment|Impact of Frailty in Senior Cancer Patients: Feasibility and Value of Screening Tools and Geriatric Intervention and Predictive Value of a Screening Tool in Relation to Treatment Outcome|Unknown status|Recruiting|N/A|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:25:27.019627|2018-06-01 00:25:27.019627
NCT01005680|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2013-10-18||2013-10-18|2009-10-29|2009-11-02|Estimate|2013-10-18|2013-12-13|Estimate||||2013-10-18|2013-12-13|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||All randomized participants.|A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer|A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.|Completed||Phase 3|256|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:25:27.140836|2018-06-01 00:25:27.140836
NCT01005667|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2011-06-22|2009-10-30|2009-11-02|Estimate|||||||2011-06-22|2011-06-23|Estimate||||October 2009|2009-10-31||||||||Interventional|BirthTrack||Study to Determine if Monitoring of Labor Shortens the Time to Delivery|Management of Labor Using the BirthTrack Computerized Labor Monitoring System|Withdrawn||N/A|600|Anticipated|Barnev, Inc.||2||Lack of funding for the company has resulted in termination of the study.|f||||f||||||||||2018-06-01 00:25:27.760276|2018-06-01 00:25:27.760276
NCT01005654|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2018-05-12|2009-10-30|2009-11-02|Estimate|||||||2018-05-12|2018-05-15|Actual|September 23, 2009||2009-09-23|May 11, 2018|2018-05-11||||||||Observational|||Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms|Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms|Recruiting|||1350|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:25:27.842986|2018-06-01 00:25:27.842986
NCT01005641|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2012-07-12|2009-10-30|2009-11-02|Estimate|||||||2012-07-12|2012-07-13|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|March 2012|Anticipated|2012-03-31|October 2011|Anticipated|2011-10-31||Interventional|ELBA||ELBA: Exemestane and Lapatinib in Advanced Breast Cancer|Phase II Multicentered Study of Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer|Withdrawn||Phase 2|0|Actual|National Cancer Institute, Naples||1||Study not started for administrative reasons|f||||f||||||||||2018-06-01 00:25:27.924426|2018-06-01 00:25:27.924426
NCT01005628|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-02-18|2009-10-29|2009-11-02|Estimate|||||||2013-02-18|2013-02-20|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)|Velcade - Regulatory Post Marketing Surveillance (PMS)|Completed|||1121|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-06-01 00:25:28.0366|2018-06-01 00:25:28.0366
NCT01005615|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2018-04-04|2009-10-30|2009-11-02|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2009||2009-09-30|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury|Advanced Restoration Therapies in Spinal Cord Injury. AIM1: Patterned FES Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury|Active, not recruiting||Phase 1/Phase 2|18|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||t||||||||||2018-06-01 00:25:28.125249|2018-06-01 00:25:28.125249
NCT01005602|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2014-04-16||2014-05-19|2009-10-30|2009-11-02|Estimate|2014-04-16|2014-05-19|Estimate||||2014-05-19|2014-05-22|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care|Use of a Simplified Nomogram and Pharmacogenetics to Individualize Digoxin Dosing in Heart Failure Patients vs. Standard Care|Completed||Phase 4|131|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 00:25:28.21269|2018-06-01 00:25:28.21269
NCT01005576|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2017-09-13||2017-11-17|2009-10-29|2009-11-02|Estimate|2017-10-19|2017-10-20|Actual||||2017-11-17|2017-12-13|Actual|January 2010||2010-01-31|November 2017|2017-11-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|URTH||Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia|A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)|Completed||Phase 2|21|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 00:25:28.892279|2018-06-01 00:25:28.892279
NCT01005563|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2014-03-19|2009-10-30|2009-11-02|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Dietary Protein Intake From Beef/Pork and Soy/Legumes on Appetite, Mood, and Weight Loss|Effects of Dietary Protein Intake From Beef/Pork and Soy/Legumes on Appetite, Mood, and Weight Loss|Completed||N/A|37|Actual|Purdue University||2|||f||||||||||||||2018-06-01 00:25:29.145239|2018-06-01 00:25:29.145239
NCT01005550|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-03-08|2009-10-30|2009-11-02|Estimate|||||||2012-03-08|2012-03-09|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Ropivacaine Hypobaric Spinal Anaesthesia in Traumatic Hip Surgery|Determining the Minimum Effective Ropivacaine Dose for Unilateral Hypobaric Spinal Anaesthesia During Traumatic Femoral Neck Surgery in the Aged Person: Prospective Comparative Randomized Study|Completed||Phase 4|64|Actual|Hospices Civils de Lyon||4|||f||||t||||||||||2018-06-01 00:25:29.208512|2018-06-01 00:25:29.208512
NCT01005537|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2010-08-04|2009-10-30|2009-11-02|Estimate|||||||2010-08-04|2010-08-06|Estimate|June 2009||2009-06-30|August 2010|2010-08-31||||October 2010|Anticipated|2010-10-31||Expanded Access|||Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma|Single Patient Study to Evaluate Cellular Adoptive Immunotherapy Using Autologous Lymphocytes Following Cyclophosphamide Conditioning for a Single Patient With Metastatic Melanoma|No longer available|||||Fred Hutchinson Cancer Research Center|||||||||||||||||||2018-06-01 00:25:29.279108|2018-06-01 00:25:29.279108
NCT01005524|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2012-05-21|2009-10-30|2009-11-02|Estimate|||||||2012-05-21|2012-05-23|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|RoBIK-1||Brain Computer Interface for Communication in ICU: a Feasibility Study|A Feasibility Study for Daily Use of a Brain Computer Interface for Communication in an ICU|Completed|||12|Actual|University of Versailles|||||f||||f||||||||||2018-06-01 00:25:29.332346|2018-06-01 00:25:29.332346
NCT01005511|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2011-06-07|2009-10-30|2009-11-02|Estimate|||||||2011-06-07|2011-06-08|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism|A Single Centre, Randomised, Clinical Placebo Controlled Study of the Optimal Treatment and Long-term Effect of FES on Sleep Bruxism|Terminated||N/A|48|Anticipated|Medotech A/S||2||The population described via ex- and inclusion criteria did not excisit|f||||f||||||||||2018-06-01 00:25:29.395417|2018-06-01 00:25:29.395417
NCT01005498|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2011-12-04|2009-10-30|2009-11-02|Estimate|||||||2011-12-04|2011-12-06|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|VÄSTKOST||Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.|Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.|Completed||Phase 1/Phase 2|61|Actual|Vårdcentralen Lyckorna||2|||f||||f||||||||||2018-06-01 00:25:29.461633|2018-06-01 00:25:29.461633
NCT01005485|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2018-04-16|2009-10-30|2009-11-02|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|April 2017|Actual|2017-04-30||Observational|CEC||Molecular and Morphologic Characterization of Circulating Endothelial Cells|Comprehensive Molecular and Morphologic Characterization of Circulating Endothelial Cells|Active, not recruiting|||664|Actual|Scripps Translational Science Institute|||3||f||||f||||||Samples With DNA|"~     Blood for each patient will be collected from arterial access established as part of standard~     of care or via venipuncture. Blood must be collected in the order listed below. By drawing~     the PAX gene tube first, the likelihood of contamination of the sample with vessel wall~     endothelial cells is decreased.~      Enrollment:~        1. x 8.5 ml PAX gene (blue top) tube~        2. x 10 ml EDTA purple top tubes~      Follow-up visits: (healthy controls only)~        1. x 5 ml red top (discard)~        2. x 10 ml EDTA purple top tube~   "|||2018-06-01 00:25:29.526395|2018-06-01 00:25:29.526395
NCT01005472|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2018-04-26|2009-10-30|2009-11-02|Estimate|||||||2018-04-26|2018-04-30|Actual|December 1, 2008|Actual|2008-12-01|April 2018|2018-04-30|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|||Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma|A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma|Completed||Phase 1|16|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:25:29.589577|2018-06-01 00:25:29.589577
NCT01005459|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|2017-06-16||2017-11-06|2009-10-30|2009-11-02|Estimate|2017-06-16|2017-07-13|Actual||||2017-11-06|2017-11-08|Actual|August 2009||2009-08-31|June 2017|2017-06-30|December 12, 2011|Actual|2011-12-12|December 12, 2011|Actual|2011-12-12||Interventional|||Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE|Comparison of Spinal Tetracaine With Fentanyl and Epinephrine Versus Bupivacaine With Fentanyl and Epinephrine for Combined Spinal Epidural Labor Analgesia|Terminated||Phase 4|46|Actual|Wake Forest University Health Sciences||2||feasibility /drug availability issues - No study drug sources available|f||||t|t|f||||||||2018-06-01 00:25:29.700017|2018-06-01 00:25:29.700017
NCT01005446|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2017-02-06|2009-10-30|2009-11-02|Estimate|||||||2017-02-06|2017-02-07|Estimate|December 2009||2009-12-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2015|Actual|2015-01-31||Observational|RSP||RSP® Prospective Multi-Center Study|PS-901: Prospective Multicenter Open Label Study of the Encore Reverse® Shoulder Prosthesis|Active, not recruiting|||224|Anticipated|Encore Medical, L.P.|||1||f||||f||||||||||2018-06-01 00:25:30.096799|2018-06-01 00:25:30.096799
NCT01005433|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2012-03-22|2009-10-30|2009-11-02|Estimate|||||||2012-03-22|2012-03-26|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Dexmedetomidine for Cesarean Delivery|A Dose - Dependent Study of Dexmedetomidine in Suppressing Cardiovascular and Hormonal Responses for Cesarean Delivery|Completed||Phase 1|68|Actual|King Faisal University||4|||f||||f||||||||||2018-06-01 00:25:30.18326|2018-06-01 00:25:30.18326
NCT01005420|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2016-04-07|2009-10-30|2009-11-02|Estimate|||||||2016-04-07|2016-04-08|Estimate|February 2007||2007-02-28|April 2016|2016-04-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|BLUEBERRY||The Effect of Blueberries on Enhancing Insulin Sensitivity in Humans: A Pilot Study|The Effect of Anthocyanins in the Form of Blueberry Powder on Enhancing Insulin Sensitivity in Insulin Resistant and Obese Humans|Completed||N/A|37|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 00:25:30.271272|2018-06-01 00:25:30.271272
NCT01005407|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2017-12-08|2014-06-16|2018-01-15|2009-10-30|2009-11-02|Estimate|2017-12-08|2018-01-11|Actual|2014-06-16|2014-06-19|Estimate|2018-01-15|2018-02-08|Actual|February 2010||2010-02-28|January 2018|2018-01-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional||Safety Population: All participants who received at least 1 study injection and who had any post-baseline safety data|Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine|An Observer-Blinded, Randomized, Parallel-Group, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Healthy Subjects 40 to 70 Years of Age|Completed||Phase 3|2452|Actual|Dynavax Technologies Corporation||2|||f||||t|t|f||||||No||2018-06-01 00:25:30.369355|2018-06-01 00:25:30.369355
NCT01005394|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2015-04-15|2009-10-30|2009-11-02|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Navigated Transcranial Magnetic Stimulation in Monitoring Stroke Recovery|Acute Longitudinal Transcranial Magnetic Stimulation (TMS) After Stroke|Terminated|||5|Actual|Nexstim Ltd|||1|Insufficient recruitment|f||||t||||||||||2018-06-01 00:25:30.908053|2018-06-01 00:25:30.908053
NCT01005381|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-30|||2018-05-03|2009-10-30|2009-11-02|Estimate|||||||2018-05-03|2018-05-09|Actual|June 2007||2007-06-30|May 2018|2018-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effect of Calcium Supplement Particle Size and Vitamin D Supplement on Calcium Retention in Adolescent Girls|The Effect of Particle Size of Calcium Carbonate and Vitamin D on Calcium and Bone Parameters in Adolescent Girls|Completed||N/A|55|Actual|Purdue University||5|||f||||f||||||||||2018-06-01 00:25:30.998173|2018-06-01 00:25:30.998173
NCT01005368|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-08-07|2009-10-29|2009-10-30|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2009||2009-10-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia|Molecular Markers Of Chronic Lymphocytic Leukemia|Active, not recruiting|||600|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     blood and bone marrow samples~   "|||2018-06-01 00:25:31.10654|2018-06-01 00:25:31.10654
NCT01005355|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2014-05-16||2014-05-16|2009-10-29|2009-10-30|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||All participants who received at least 1 dose of study drug.|Study of IMC-1121B in Patients With Advanced Solid Tumors|Phase 1 Study of IMC-1121B in Patients With Advanced Solid Tumors|Completed||Phase 1|15|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 00:25:31.275725|2018-06-01 00:25:31.275725
NCT01005342|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-10-29|2009-10-29|2009-10-30|Estimate|||||||2009-10-29|2009-10-30|Estimate|May 2007||2007-05-31|October 2009|2009-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Influence of Dietary Fiber-rich Meals on Gene Expression and Postprandial Glucose and Lipid Response|The Influence of Dietary Fibre-rich Meals on Gene Expression in Leukocytes and Postprandial Glucose and Lipid Response in Healthy Subjects|Completed||N/A|18|Actual|Lund University||6|||f||||f||||||||||2018-06-01 00:25:31.975029|2018-06-01 00:25:31.975029
NCT01005329|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2014-01-08||2018-02-15|2009-10-29|2009-10-30|Estimate|2014-01-08|2014-02-24|Estimate||||2018-02-15|2018-03-15|Actual|November 6, 2009|Actual|2009-11-06|February 2018|2018-02-28|September 22, 2013|Actual|2013-09-22|June 30, 2012|Actual|2012-06-30||Interventional||All eligible patients.|Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer|A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer|Completed||Phase 2|34|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:25:32.107632|2018-06-01 00:25:32.107632
NCT01005316|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2017-01-06||2017-03-09|2009-10-28|2009-10-30|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|January 2010||2010-01-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||Transplanted Participants|Alloantibodies in Pediatric Heart Transplantation|Alloantibodies in Pediatric Heart Transplantation|Terminated|||290|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Study enrollment closed December 2013:target enrollment was not met (78% of target).Not all participants recv'd the planned 3 year follow-up. Participants were followed for a year after enrollment closure then enrolled into CTOTC-09 (NCT02752789).||2|Inability to meet accrual goals within the funding period.|f||||t||||||Samples With DNA|"~     Blood collection and biopsy tissue samples~   "|||2018-06-01 00:25:32.613552|2018-06-01 00:25:32.613552
NCT01005303|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-01-27|2009-10-29|2009-10-30|Estimate|||||||2015-01-27|2015-01-28|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|August 2013|Actual|2013-08-31||Interventional|MINT-HF||Micronutrient Supplementation in Patients With Heart Failure|A Trial of Micronutrient Supplementation in Patients With Heart Failure|Unknown status|Active, not recruiting|Phase 2/Phase 3|79|Actual|Belfast Health and Social Care Trust||2|||f||||t||||||||||2018-06-01 00:25:33.863526|2018-06-01 00:25:33.863526
NCT01005290|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2012-03-30||2012-06-20|2009-10-29|2009-10-30|Estimate|2012-06-20|2012-07-26|Estimate||||2012-06-20|2012-07-26|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure|Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Interaction Study to Evaluate the Effect of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin and Ramipril (Cardiovascular Fixed Dose Combination Pill) on Blood Pressure|Terminated||Phase 2|38|Actual|Ferrer Internacional S.A.|Early termination leading to small numbers of subjects analyzed|2|||f||||f||||||||||2018-06-01 00:25:33.969928|2018-06-01 00:25:33.969928
NCT01005277|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-10-05|2009-10-29|2009-10-30|Estimate|||||||2017-10-05|2017-10-09|Actual|April 2002||2002-04-30|October 2017|2017-10-31||||January 2100|Anticipated|2100-01-31||Observational|||Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|Genetic Polymorphisms in ALL Samples Submitted to Gene Array Analysis|Active, not recruiting|||100|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-06-01 00:25:34.263105|2018-06-01 00:25:34.263105
NCT01005264|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2009-10-29|2009-10-29|2009-10-30|Estimate|||||||2009-10-29|2009-10-30|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Removable Walker for Neuropathic Ulcers|Effectiveness of Removable Walker Cast Versus Non-removable Fiberglass Off-bearing Cast in the Healing of Diabetic Plantar Foot Ulcer- a Randomized Controlled Trial|Completed||Phase 3|48|Actual|IRCCS Multimedica||2|||f||||f||||||||||2018-06-01 00:25:34.32763|2018-06-01 00:25:34.32763
NCT01005251|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2011-02-23||2011-03-29|2009-10-29|2009-10-30|Estimate|2011-03-29|2011-04-25|Estimate||||2011-03-29|2011-04-25|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI||Completed||Phase 2|661|Actual|AstraZeneca||5|||f||||||||||||||2018-06-01 00:25:34.43892|2018-06-01 00:25:34.43892
NCT01005238|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-03-09|2009-10-29|2009-10-30|Estimate|||||||2015-03-09|2015-03-10|Estimate|September 2009||2009-09-30|March 2015|2015-03-31||||December 2014|Actual|2014-12-31||Interventional|SASL28||Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine|A Randomized Open Label Study Evaluating the Efficacy of Continuous Telbivudine Versus Lamivudine in Patients With HBeAg-negative Chronic Hepatitis B Who Had Previously Achieved an Undetectable Viral Load During 24 Weeks of Telbivudine Therapy|Terminated||Phase 4|27|Actual|University Hospital, Basel, Switzerland||2||unsufficient patient recruitment|f||||t||||||||||2018-06-01 00:25:34.798472|2018-06-01 00:25:34.798472
NCT01005225|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2014-06-10|2009-10-28|2009-10-30|Estimate|||||||2014-06-10|2014-06-12|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Genetic Investigation of Solid Tumors Cohort|Genetic Investigation of Solid Tumors Cohort|Completed|||25|Actual|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Approximately 19.5 milliliters (mls) of blood will be collected in (2 x 8.5 ml) PAXgene DNA~     tubes and (1 x 2.5 ml) PAXgene RNA tube.~      Solid tumor and/or benign hyperplasia samples will be collected from the participants during~     surgery scheduled for standard medical care.~   "|||2018-06-01 00:25:34.889679|2018-06-01 00:25:34.889679
NCT01005212|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2017-09-29|2009-10-29|2009-10-30|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2008||2008-01-31|September 2017|2017-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|AAA CEUS||Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair|Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair|Completed|||40|Actual|The Methodist Hospital System|||||f||||f||||||||No||2018-06-01 00:25:34.948271|2018-06-01 00:25:34.948271
NCT01005199|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2016-04-14|2009-10-29|2009-10-30|Estimate|||||||2016-04-14|2016-04-15|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|June 2013|Actual|2013-06-30||Interventional|||Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer|Sorafenib Alone or in Combination With Everolimus in Patients With Unresectable Hepatocellular Carcinoma. A Randomized Multicenter Phase II Trial.|Completed||Phase 2|106|Actual|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-06-01 00:25:35.033801|2018-06-01 00:25:35.033801
NCT01005186|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2016-01-07|2009-10-29|2009-10-30|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2006||2006-07-31|January 2016|2016-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|ALLChange||Changing Lifestyle in Children|Changing Lifestyle in Children: All Change: Can This Reduce Cardiovascular Risk?|Completed||Phase 4|92|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 00:25:35.16497|2018-06-01 00:25:35.16497
NCT01005173|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2017-11-21|2009-10-29|2009-10-30|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2009||2009-08-31|November 2017|2017-11-30||||June 2018|Anticipated|2018-06-30||Observational|||Acetaminophen Biomarkers|Identification of New Mechanistic Biomarkers of Adverse Response to Acetaminophen|Enrolling by invitation|||253|Anticipated|Arkansas Children's Hospital Research Institute|||3||f||||f||||||||||2018-06-01 00:25:35.213294|2018-06-01 00:25:35.213294
NCT01005160|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2011-01-10|2009-10-29|2009-10-30|Estimate|||||||2011-01-10|2011-01-12|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|CKD-19HPS09H||Drug Interaction Between CKD-501 and Metformin|A Sequence-randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Metformin After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|24|Anticipated|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||||2018-06-01 00:25:35.286012|2018-06-01 00:25:35.286012
NCT01005147|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-04-05|2009-10-29|2009-10-30|Estimate|||||||2012-04-05|2012-04-09|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|October 2011|Actual|2011-10-31|||||Interventional|||Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding|Effect of Tranexamic Acid on Blood Transfusion in Upper Gastrointestinal Bleeding|Withdrawn||N/A|0|Actual|University of Oklahoma||2||No participants enrolled|f||||t||||||||||2018-06-01 00:25:35.349726|2018-06-01 00:25:35.349726
NCT01005121|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-01-03|2009-10-29|2009-10-30|Estimate|||||||2013-01-03|2013-01-04|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Colchicine for Diabetic Nephropathy|Colchicine for Diabetic Nephropathy|Unknown status|Recruiting|Phase 2|12|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:25:35.453402|2018-06-01 00:25:35.453402
NCT01005108|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-07-31|2009-10-29|2009-10-30|Estimate|||||||2017-07-31|2017-08-02|Actual|January 2009||2009-01-31|July 2017|2017-07-31||||February 2018|Anticipated|2018-02-28||Interventional|||Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors|Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors|Active, not recruiting||Phase 2|124|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 00:25:35.539335|2018-06-01 00:25:35.539335
NCT01005095|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2012-09-02|2009-10-29|2009-10-30|Estimate|||||||2012-09-02|2012-09-05|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients|A One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple Sclerosis|Terminated||Phase 4|45|Actual|Carmel Medical Center||2||Interim analysis showed that the odds for proving primary hypothesis are low.|f||||f||||||||||2018-06-01 00:25:35.612657|2018-06-01 00:25:35.612657
NCT01005082|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-10-29|2009-10-29|2009-10-30|Estimate|||||||2009-10-29|2009-10-30|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|LOSALT01||Low Salt Diet in Idiopathic Hypercalciuria|Calcium Nephrolithiasis: Clinical Characteristics and Nutritional Determinants|Completed||Phase 2/Phase 3|210|Actual|University of Parma||2|||f||||||||||||||2018-06-01 00:25:36.8506|2018-06-01 00:25:36.8506
NCT01005069|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2010-09-26|2009-10-29|2009-10-30|Estimate|||||||2010-09-26|2010-09-28|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus|Phase-II Clinical Study: A Randomized, Double Blind, Dose Ranging, and Controlled Study to Evaluate the Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus|Completed||Phase 2|72|Actual|Dexa Medica Group||5|||f||||||||||||||2018-06-01 00:25:36.964442|2018-06-01 00:25:36.964442
NCT01005056|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2015-04-28|2009-10-29|2009-10-30|Estimate|||||||2015-04-28|2015-04-29|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083)|Drug Use Investigation of MARVELON|Completed|||3838|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:25:37.045167|2018-06-01 00:25:37.045167
NCT01005043|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2010-06-24|2009-10-29|2009-10-30|Estimate|||||||2010-06-24|2010-06-25|Estimate|December 2010||2010-12-31|October 2009|2009-10-31|January 2020|Anticipated|2020-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma|Phase I/II Therapy Trial to Determine the Safety and Efficacy of Heavy Ion Radiotherapy in Patients With Osteosarcoma|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Heidelberg University||1|||f||||f||||||||||2018-06-01 00:25:37.109056|2018-06-01 00:25:37.109056
NCT01005030|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-11-09|2009-10-29|2009-10-30|Estimate|||||||2009-11-09|2009-11-10|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Observational|SPIN-PD||Spectroscopy in Parkinson Disease|Evaluation of Blood Biospectroscopy as a Novel Diagnostic Test for Idiopathic Parkinson Disease|Unknown status|Enrolling by invitation||500|Anticipated|Molecular Biometrics, Inc.|||2||f||||f||||||Samples Without DNA|"~     Blood plasma, cell free~   "|||2018-06-01 00:25:37.233616|2018-06-01 00:25:37.233616
NCT01005017|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2011-07-25|2009-10-29|2009-10-30|Estimate|||||||2011-07-25|2011-07-26|Estimate|February 2011||2011-02-28|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|February 2013|Anticipated|2013-02-28||Interventional|PRFLSN||Percutaneous Lesioning Splanchnic Nerves in Patients With Chronic Pancreatitis|Percutaneous Radiofrequent Lesioning of the Splanchnic Nerves in Patients With Chronic Pancreatitis|Unknown status|Recruiting|N/A|30|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:25:37.322045|2018-06-01 00:25:37.322045
NCT01005004|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2015-01-13|2009-10-28|2009-10-30|Estimate|||||||2015-01-13|2015-01-15|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects|Phase I Study of the Safety and Preliminary Efficacy of Intracerebral Transplantation of HuCNS-SC® Cells for Connatal Pelizaeus-Merzbacher Disease (PMD)|Completed||Phase 1|4|Actual|StemCells, Inc.||1|||f||||t||||||||||2018-06-01 00:25:37.400744|2018-06-01 00:25:37.400744
NCT01004991|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2017-02-23||2017-02-23|2009-10-29|2009-10-30|Estimate|2017-02-23|2017-04-10|Actual||||2017-02-23|2017-04-10|Actual|January 2010|Actual|2010-01-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|September 2013|Actual|2013-09-30||Interventional|||Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma|Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma|Completed||Phase 1/Phase 2|14|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 00:25:37.565893|2018-06-01 00:25:37.565893
NCT01004978|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2018-05-15|2009-10-29|2009-10-30|Estimate|||||||2018-05-15|2018-05-16|Actual|October 28, 2009|Actual|2009-10-28|May 2018|2018-05-31||||July 1, 2018|Anticipated|2018-07-01||Interventional|||Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion|Active, not recruiting||Phase 3|400|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 00:25:37.876466|2018-06-01 00:25:37.876466
NCT01004965|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-08-07|2009-10-29|2009-10-30|Estimate|||||||2017-08-07|2017-08-08|Actual|March 1997||1997-03-31|August 2017|2017-08-31||||January 2011|Actual|2011-01-31||Observational|||Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720|Multidrug Resistance Studies in Acute Myeloid Leukemia|Active, not recruiting|||2034|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Bone marrow, blood~   "|||2018-06-01 00:25:38.5846|2018-06-01 00:25:38.5846
NCT01004952|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-12-20|2009-10-29|2009-10-30|Estimate|||||||2017-12-20|2017-12-22|Actual|October 2009||2009-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection|Measuring Real Time Decision-Making About UVR Protection|Active, not recruiting|||85|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 00:25:38.747406|2018-06-01 00:25:38.747406
NCT01004939|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2011-06-30||2011-07-28|2009-10-29|2009-10-30|Estimate|2011-07-28|2011-08-26|Estimate||||2011-07-28|2011-08-26|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|FondaPPP||Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism|Retrospektive Studie zu Patientinnen, Die pränatal, Perinatal Oder Postnatal Prophylaktisch Oder Therapeutisch Mit Fondaparinux Behandelt Wurden|Completed|||120|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:25:38.915739|2018-06-01 00:25:38.915739
NCT01004926|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2016-04-14|2009-10-29|2009-10-30|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2009||2009-10-31|April 2016|2016-04-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of the Efficiency of the Echelon Foot in Traumatic Trans Tibial Amputees|Evaluation of the Efficiency of the Echelon Foot in Traumatic Trans Tibial|Completed||Phase 1/Phase 2|10|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:25:40.293714|2018-06-01 00:25:40.293714
NCT01004913|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-02-11|2009-10-29|2009-10-30|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2009||2009-11-30|August 2011|2011-08-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|||Vestibular Evoked Myogenic Potentials in Benign Paroxysmal Positional Vertigo (VEMP in BPPV)|Evaluation of the Otolithic Organs Function in Patients Suffering From Benign Paroxysmal Positional Vertigo (BPPV) by Vestibular Evoked Myogenic Potentials (VEMP).|Completed|||30|Actual|Meir Medical Center|||||f||||f||||||||||2018-06-01 00:25:40.367679|2018-06-01 00:25:40.367679
NCT01004900|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2010-05-10|2009-10-29|2009-10-30|Estimate|||||||2010-05-10|2010-05-12|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma|Comparison of Selective Laser Trabeculoplasty With Prostaglandin Analogues for Lowering Intraocular Pressure in Eyes With Primary Angle Closure Glaucoma|Unknown status|Recruiting|Phase 3|90|Anticipated|Singapore Eye Research Institute||2|||f||||f||||||||||2018-06-01 00:25:40.4508|2018-06-01 00:25:40.4508
NCT01004887|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-08-07|2009-10-29|2009-10-30|Estimate|||||||2017-08-07|2017-08-08|Actual|November 1995||1995-11-30|August 2017|2017-08-31||||December 2014|Actual|2014-12-31||Observational|||Study of Tissue and Blood Samples From Patients With High-Grade Glioma|Diagnostic And Prognostic Markers In High-Grade Glioma|Active, not recruiting|||200|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Blood and tissue~   "|||2018-06-01 00:25:40.581143|2018-06-01 00:25:40.581143
NCT01004354|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2011-10-17||2017-11-01|2009-10-28|2009-10-29|Estimate|2012-01-10|2012-02-10|Estimate||||2017-11-01|2017-11-06|Actual|June 2009||2009-06-30|November 2017|2017-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|VDSS||Vitamin D Supplementation in Psychiatric Illnesses|Effect of Vitamin D Supplementation on the Metabolic Abnormalities of Second Generation Antipsychotics in Children and Adolescents|Completed||N/A|12|Actual|University of Massachusetts, Worcester||1|||f||||f||||||||||2018-06-01 00:25:50.020642|2018-06-01 00:25:50.020642
NCT01004874|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2012-12-12||2018-03-05|2009-10-29|2009-10-30|Estimate|2012-12-12|2013-01-18|Estimate||||2018-03-05|2018-04-02|Actual|December 30, 2009|Actual|2009-12-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2012|Actual|2012-07-31||Interventional|||Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma|Avastin in Combination With Radiation and Temozolomide Followed by Avastin, Temozolomide, and Topotecan for Glioblastoma Multiformes and Gliosarcomas|Active, not recruiting||Phase 2|80|Actual|Duke University||1|||f||||f||||||||No||2018-06-01 00:25:40.848161|2018-06-01 00:25:40.848161
NCT01004861|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2018-01-31|2009-10-28|2009-10-30|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2011||2011-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety Study of PLX108-01 in Patients With Solid Tumors|A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology|Active, not recruiting||Phase 1|150|Anticipated|Plexxikon||1|||f||||f||||||||||2018-06-01 00:25:41.108755|2018-06-01 00:25:41.108755
NCT01004848|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2013-09-04||2014-10-22|2009-10-29|2009-10-30|Estimate|2014-10-22|2014-10-23|Estimate||||2014-10-22|2014-10-23|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|HEED||Effectiveness Study of Community-Based, Peer-Led Education on Weight Loss and Diabetes|Collaborations for Health Improvement in East Harlem—Project HEED|Completed||N/A|402|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 00:25:41.216563|2018-06-01 00:25:41.216563
NCT01004835|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-10-14|2009-10-29|2009-10-30|Estimate|||||||2015-10-14|2015-10-16|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|MAPS||The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)|The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)|Completed|||61|Actual|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Approximately 20 milliliters of blood will be dispensed as follows: 2 X 8.5 ml PAX DNA Tubes~     OR 2 mLs of Saliva may be collected from each patient in a provided container. Saliva will~     only be collected on those individuals who do not wish to undergo phlebotomy for blood~     collection.~   "|||2018-06-01 00:25:41.711738|2018-06-01 00:25:41.711738
NCT01004822|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2015-05-11||2015-10-16|2009-10-28|2009-10-30|Estimate|2015-06-04|2015-07-02|Estimate||||2015-10-16|2015-11-20|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Safety analysis population included all randomized subjects who received at least one dose of study medication.|A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Cvx-241, A Selective Angiopoietin-2 And Vascular Endothelial Growth Factor Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors|Terminated||Phase 1|31|Actual|Pfizer|The study was terminated early by the sponsor due to lack of significant pharmacological effects (safety/Pharmacodynamics/efficacy) through 25 mg/kg cohort. Hence, no participant could reach out to Stage 2.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:25:41.837001|2018-06-01 00:25:41.837001
NCT01004809|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2018-05-17|2009-10-29|2009-10-30|Estimate|||||||2018-05-17|2018-05-21|Actual|April 29, 2010||2010-04-29|May 2018|2018-05-31|December 21, 2012|Actual|2012-12-21|December 1, 2012|Actual|2012-12-01||Observational|AVODART®PMS||AVODART® Alopecia Post-marketing Surveillance (PMS)|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and Effectiveness of AVODART® Administered in Korean Androgenetic Alopecia Patients According to the Prescribing Information|Completed|||712|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:25:43.893551|2018-06-01 00:25:43.893551
NCT01004796|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2016-02-26|2009-10-29|2009-10-30|Estimate|||||||2016-02-26|2016-02-29|Estimate||||February 2016|2016-02-29||||||||Observational|||Study of Biomarkers in Tissue Samples From Patients With Breast Cancer|Estrogen-Related Receptor Alpha As A Novel Biomarker For Breast Cancer|Unknown status|Not yet recruiting||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:25:43.966323|2018-06-01 00:25:43.966323
NCT01004783|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-05-06|2009-10-29|2009-10-30|Estimate|||||||2015-05-06|2015-05-07|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors|Validation of Prognostic Markers for Very Low Risk Wilms Tumors|Completed|||165|Actual|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Tumor Tissue~   "|||2018-06-01 00:25:44.025014|2018-06-01 00:25:44.025014
NCT01004770|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2011-09-14||2012-04-04|2009-10-29|2009-10-30|Estimate|2012-03-07|2012-04-04|Estimate||||2012-04-04|2012-04-05|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)|An Intravenous, Single Dose Safety, Tolerance and Pharmacokinetic Study of GE-145 in Healthy Volunteers Undergoing a Contrast-enhanced Abdominal Computed Tomography (CT) Scan|Completed||Phase 1/Phase 2|50|Actual|GE Healthcare||2|||f||||t||||||||||2018-06-01 00:25:44.104982|2018-06-01 00:25:44.104982
NCT01004757|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-10-29|2009-10-29|2009-10-30|Estimate|||||||2009-10-29|2009-10-30|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Interventional|||Effects of Low Versus High Carbohydrate Diet During Rehabilitation on Cardiovascular Function and Metabolism in Type 2 Diabetes|Improvement of Myocardial Function and Metabolic Syndrome in Type 2 Diabetes Patients by a Low Glycemic and Insulinemic Diet (LOGI®) Compared to the Traditional Low Fat Diet - a Prospective Parallel Group/Cross Over Study|Unknown status|Active, not recruiting|N/A|41|Anticipated|Munich Municipal Hospital||2|||f||||t||||||||||2018-06-01 00:25:44.900673|2018-06-01 00:25:44.900673
NCT01004744|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2013-02-11|2009-10-29|2009-10-30|Estimate|||||||2013-02-11|2013-02-13|Estimate|February 2007||2007-02-28|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer|Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer|Completed||N/A|10|Actual|Columbia University||1|||f||||t||||||||||2018-06-01 00:25:45.056913|2018-06-01 00:25:45.056913
NCT01004731|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2010-06-25|2009-10-29|2009-10-30|Estimate|||||||2010-06-25|2010-06-28|Estimate|June 2001||2001-06-30|June 2010|2010-06-30|January 2006|Actual|2006-01-31|January 2002|Actual|2002-01-31||Interventional|||Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer|Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|7|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 00:25:45.192156|2018-06-01 00:25:45.192156
NCT01004718|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2016-09-18|2009-10-29|2009-10-30|Estimate|||||||2016-09-18|2016-09-20|Estimate|May 2009||2009-05-31|September 2016|2016-09-30||||July 2013|Actual|2013-07-31||Interventional|||Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)|A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging|Active, not recruiting||N/A|10|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:25:45.271359|2018-06-01 00:25:45.271359
NCT01004705|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2012-06-01||2012-07-31|2009-10-29|2009-10-30|Estimate|2012-07-31|2012-08-31|Estimate||||2012-07-31|2012-08-31|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol|Cardiovascular Fixed Dose Combination Pill: A Pharmacodynamic Study of a Fixed Dose Combination of Acetylsalicylic Acid, Simvastatin, and Ramipril in Subjects With Elevated LDL Cholesterol|Terminated||Phase 2|36|Actual|Ferrer Internacional S.A.|Early termination leading to small numbers of subjects analyzed.|2|||f||||||||||||||2018-06-01 00:25:45.366035|2018-06-01 00:25:45.366035
NCT01004692|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-10-29|2009-10-29|2009-10-30|Estimate|||||||2009-10-29|2009-10-30|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|June 2010|Anticipated|2010-06-30|January 2010|Anticipated|2010-01-31||Interventional|||The Effect of Occlusal Splints on Respiratory Variables in Obstructive Sleep Apnea (OSA) Patients|The Effect of Occlusal Splints on Sleep and Respiratory Variables of OSA Patients|Unknown status|Enrolling by invitation|Phase 1|10|Actual|Academic Centre for Dentistry in Amsterdam|||||f||||f||||||||||2018-06-01 00:25:45.60519|2018-06-01 00:25:45.60519
NCT01004666|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-01-03|2009-10-29|2009-10-30|Estimate|||||||2013-01-03|2013-01-04|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Observational|||Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions|Molecular Breast Imaging: A Novel Technology for Detection of Malignant Breast Lesions.|Unknown status|Recruiting||500|Anticipated|Tel-Aviv Sourasky Medical Center|||4||f||||t||||||||||2018-06-01 00:25:45.694657|2018-06-01 00:25:45.694657
NCT01004653|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2013-03-13|2009-10-29|2009-10-30|Estimate|||||||2013-03-13|2013-03-15|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines|An Open-Label Clinical Trial With Split-virion Influenza A/H1N1 Vaccines in Healthy Elders|Completed||Phase 4|100|Actual|Sinovac Biotech Co., Ltd||1|||f||||||||||||||2018-06-01 00:25:45.76523|2018-06-01 00:25:45.76523
NCT01004640|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2017-08-07|2009-10-29|2009-10-30|Estimate|||||||2017-08-07|2017-08-08|Actual|December 1998||1998-12-31|August 2017|2017-08-31||||February 2001|Actual|2001-02-28||Observational|||Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial|Molecular and Cytogenetic Monitoring of CML - A Mandatory Companion to CALGB 19804|Active, not recruiting|||60|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 00:25:45.850676|2018-06-01 00:25:45.850676
NCT01004627|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2014-05-30|2009-10-29|2009-10-30|Estimate|||||||2014-05-30|2014-06-02|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||A Study of Routine Versus Selective Use of Ultrasound Scanning Prior to Haemodialysis Fistula Surgery|A Prospective Randomized Controlled Trial of the Clinical Effectiveness of Obligatory Versus Elective Duplex Ultrasound Scanning Prior to Arteriovenous Fistula Formation for Haemodialysis Vascular Access in a University Teaching Hospital.|Completed||Phase 4|98|Actual|University of Hull||2|||f||||f||||||||||2018-06-01 00:25:46.288556|2018-06-01 00:25:46.288556
NCT01004614|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2010-12-03||2011-11-29|2009-10-29|2009-10-30|Estimate|2011-11-29|2012-01-04|Estimate||||2011-11-29|2012-01-04|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet|An Open, Randomized, Parallel-Cohort, 2-Periods, Crossover, Single Dose Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet In Healthy Male Subjects|Completed||Phase 1|48|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:25:46.479756|2018-06-01 00:25:46.479756
NCT01004601|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-28|2009-10-28|2009-10-30|Estimate|||||||2009-10-28|2009-10-30|Estimate|March 2005||2005-03-31|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer|Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taipei, Taiwan|Completed||N/A|179|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:25:46.9751|2018-06-01 00:25:46.9751
NCT01004588|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2015-04-09|2009-10-29|2009-10-30|Estimate|||||||2015-04-09|2015-04-10|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Effects of Resistance Training and Protein Supplementation in Healthy Elderly Men and Women.|The Effects of Resistance Type Exercise Training and Protein Supplementation on Skeletal Muscle Mass, Strength, and Muscle Characteristics in Healthy Elderly Men and Women|Completed||N/A|60|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:25:47.072119|2018-06-01 00:25:47.072119
NCT01004575|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-09-10|2009-10-29|2009-10-30|Estimate|||||||2015-09-10|2015-09-14|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|July 2011|Actual|2011-07-31||Interventional|KARE||Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease|Clinical Evaluation of Kaname Cobalt-Chromium Coronary Stent System in the Treatment of Patients With Coronary Artery Disease|Unknown status|Active, not recruiting|Phase 2/Phase 3|280|Anticipated|Terumo Europe N.V.||1|||f||||t||||||||||2018-06-01 00:25:47.150769|2018-06-01 00:25:47.150769
NCT01004562|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-10-11|2009-10-29|2009-10-30|Estimate|||||||2015-10-11|2015-10-14|Estimate|August 2007||2007-08-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Collecting Information From Patients Enrolled in the Breast Specialized Program of Research Excellence|The Breast Cancer Specialized Program of Research Excellence (SPORE): Core A-Administrative/Biostatistics Core|Completed|||1025|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 00:25:47.275947|2018-06-01 00:25:47.275947
NCT01004549|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2011-06-24|2009-10-29|2009-10-30|Estimate|||||||2011-06-24|2011-06-28|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||An Open-Label Evaluation of Degree of Accommodation in Pseudophakic Patients Bilaterally Implanted With Monofocal Intraocular Lenses||Completed|||30|Anticipated|Innovative Medical|||1||f||||||||||||||2018-06-01 00:25:47.3443|2018-06-01 00:25:47.3443
NCT01004341|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2013-06-18|2009-10-28|2009-10-29|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Role of Parenting Skills and Parenting Style in Pediatric Weight Loss Programs|Role of Parenting Skills, Style and Family Functioning in Pediatric Weight Loss|Completed||N/A|44|Actual|University of California, San Diego||1|||f||||f||||||||||2018-06-01 00:25:50.273556|2018-06-01 00:25:50.273556
NCT01004536|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2010-12-09|2009-10-29|2009-10-30|Estimate|||||||2010-12-09|2010-12-13|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||An Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix)|A Randomized Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix) in the Prevention of Hypertrophic Scar in Subjects Undergoing Caesarean Section|Unknown status|Active, not recruiting|Phase 4|47|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 00:25:47.407459|2018-06-01 00:25:47.407459
NCT01004523|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2016-07-15|2009-10-29|2009-10-30|Estimate|||||||2016-07-15|2016-07-18|Estimate|December 1995||1995-12-31|July 2016|2016-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Study of Tissue and Blood Samples From Patients With Low-Grade Glioma|Diagnostic and Prognostic Markers in Low-Grade Gliomas|Completed|||135|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     tissue and blood samples~   "|||2018-06-01 00:25:47.495391|2018-06-01 00:25:47.495391
NCT01004510|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2012-08-14||2012-11-05|2009-10-29|2009-10-30|Estimate|2012-11-05|2012-12-04|Estimate||||2012-11-05|2012-12-04|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|ZAP||Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer|An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer|Terminated||Phase 2|3|Actual|Rochester General Hospital||1||failure to accrue projected number of patients|f||||f||||||||||2018-06-01 00:25:47.635484|2018-06-01 00:25:47.635484
NCT01004497|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-05-28|2009-10-29|2009-10-30|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|ALL||First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL|A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|Completed||Phase 2|51|Actual|The Catholic University of Korea||1|||f||||t||||||||||2018-06-01 00:25:47.825476|2018-06-01 00:25:47.825476
NCT01004484|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2010-12-17|2009-10-29|2009-10-30|Estimate|||||||2010-12-17|2010-12-21|Estimate|June 2009||2009-06-30|December 2010|2010-12-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|GM-WGTT||Physiological Effects of Yogurt With Bb12 in Subjects With GI Symptoms Strointestinal Symptoms|Physiological Effects of Yogurt Containing Bifidobacterium Lactis (Bb12) in Subjects With Non-Diarrhea Functional Gastrointestinal Symptoms|Completed||N/A|40|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:25:47.939429|2018-06-01 00:25:47.939429
NCT01004471|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-10-11|2009-10-29|2009-10-30|Estimate|||||||2012-10-11|2012-10-15|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||An Exploratory Study of a Nasal Dilator Strip|An Exploratory Study of a Nasal Dilator Strip|Completed||Phase 2|48|Anticipated|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 00:25:48.028905|2018-06-01 00:25:48.028905
NCT01004458|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2009-10-29|2009-10-29|2009-10-30|Estimate|||||||2009-10-29|2009-10-30|Estimate|January 2001||2001-01-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2003|Actual|2003-12-31||Interventional|(FIBCOG)||Cognitive Behavioral Therapy Trial in Fibromyalgia|Randomized Clinical Trial of Cognitive Behavioral Therapy in Women With the Fibromyalgia Disorder|Completed||N/A|48|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 00:25:48.085981|2018-06-01 00:25:48.085981
NCT01004445|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2011-04-07|2009-10-29|2009-10-30|Estimate|||||||2011-04-07|2011-04-08|Estimate|May 2005||2005-05-31|April 2011|2011-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)|A Double-Blind, Placebo-controlled Parallel Group, Phase II Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Ventilated Patients With Nosocomial Pneumonia Due to Gram Negative Organisms|Completed||Phase 2|69|Actual|Bayer||3|||f||||t||||||||||2018-06-01 00:25:48.153819|2018-06-01 00:25:48.153819
NCT01004432|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|2014-03-13||2015-04-09|2009-10-29|2009-10-30|Estimate|2014-04-14|2014-05-13|Estimate||||2015-04-09|2015-04-30|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)|A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)|Completed||Phase 3|433|Actual|Janssen Biotech, Inc.|Since participants assigned to the double blind groups were non-responders to at least 2 anti-Tumor Necrosis Factors (TNF), thus comprising a very difficult group to treat.|5|||f||||t||||||||||2018-06-01 00:25:48.436542|2018-06-01 00:25:48.436542
NCT01004419|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2015-09-30|2009-10-29|2009-10-30|Estimate|||||||2015-09-30|2015-10-02|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|May 2011|Anticipated|2011-05-31|November 2010|Anticipated|2010-11-30||Interventional|||Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer|Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|University of Wisconsin, Madison||1||Support for investigational products has been withdrawn.|f||||t||||||||||2018-06-01 00:25:49.359571|2018-06-01 00:25:49.359571
NCT01004406|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-29|||2015-01-14|2009-10-29|2009-10-30|Estimate|||||||2015-01-14|2015-01-15|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|March 2014|Actual|2014-03-31|January 2013|Actual|2013-01-31||Interventional|PREMIER||Intensive Lipid-Lowering Therapy for Patients With Acute Coronary Syndrome|Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER)|Completed||Phase 3|31|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:25:49.48018|2018-06-01 00:25:49.48018
NCT01004393|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2015-06-14||2015-12-29|2009-10-28|2009-10-29|Estimate|2015-12-29|2016-02-02|Estimate||||2015-12-29|2016-02-02|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Methylnaltrexone for Opioid-induced Constipation in Cancer Patients|Phase II Trial of Subcutaneous Methylnaltrexone in the Treatment of Severe Opioid-induced Constipation in Cancer Patients|Completed||Phase 2|12|Actual|University of Vermont||1|||f||||t||||||||||2018-06-01 00:25:49.590604|2018-06-01 00:25:49.590604
NCT01004380|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2014-07-15|2009-10-28|2009-10-29|Estimate|||||||2014-07-15|2014-07-17|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer|A Phase I Safety Study of Farletuzumab (MORAb-003), Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Subjects With Platinum-sensitive Ovarian Cancer|Completed||Phase 1|15|Actual|Morphotek||1|||f||||f||||||||||2018-06-01 00:25:49.829816|2018-06-01 00:25:49.829816
NCT01004328|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-04-23|2009-10-28|2009-10-29|Estimate|||||||2014-04-23|2014-04-24|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|RAMPAGEII||Using Health Information Technology (HIT) to Improve Transitions of Complex Elderly Patients From Skilled Nursing Facility (SNF) to Home|Using HIT to Improve Transitions of Complex Elderly Patients From SNF to Home|Completed||N/A|626|Actual|University of Massachusetts, Worcester||1|||f||||t||||||||||2018-06-01 00:25:50.343195|2018-06-01 00:25:50.343195
NCT01004315|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2010-07-25|2009-10-27|2009-10-29|Estimate|||||||2010-07-25|2010-07-27|Estimate||||July 2010|2010-07-31||||||||Interventional|||A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder|A Randomized, Double Blind, Placebo Controlled, Phase III Study of KUC-7483 in Patients With Overactive Bladder|Completed||Phase 3|750|Anticipated|Kissei Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-06-01 00:25:50.403703|2018-06-01 00:25:50.403703
NCT01004302|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-10-11|2009-10-28|2009-10-29|Estimate|||||||2012-10-11|2012-10-12|Estimate|July 2003||2003-07-31|October 2012|2012-10-31|January 2015|Anticipated|2015-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Radiosurgical Treatment for Obsessive-compulsive Disorder|Ventral Capsular/Ventral Striatal Gamma Capsulotomy for Obsessive-compulsive Disorder: a Randomized Controlled Trial|Terminated||Phase 2|16|Actual|University of Sao Paulo General Hospital||2||"Our Co sources were in a state of advanced decay. That prolonged our surgical procedures,~   making them inconveniently and perhaps dangerously long (> 12 hours)"|f||||f||||||||||2018-06-01 00:25:50.475061|2018-06-01 00:25:50.475061
NCT01004289|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2010-10-14|2009-10-28|2009-10-29|Estimate|||||||2010-10-14|2010-10-15|Estimate|April 2007||2007-04-30|October 2010|2010-10-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|POST-AMI||POSTconditioning During Coronary Angioplasty in Acute Myocardial Infarction Study|POSTconditioning During Coronary Angioplasty in Acute Myocardial Infarction Study (POST-AMI)|Completed||Phase 2|78|Actual|University of Padua||2|||f||||f||||||||||2018-06-01 00:25:50.555029|2018-06-01 00:25:50.555029
NCT01004276|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2009-10-28|2009-10-28|2009-10-29|Estimate|||||||2009-10-28|2009-10-29|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Increasing Smoking Cessation Counselling in Primary Care Using a Chronic Disease Management System|A Cluster Randomized Controlled Pilot Trial of the Effect of a New, Improved Smoking Cessation Management Module, Compared With Use of the Standard Version of Such a Management Module, on Smoking Counselling Initiation and Continuation Rates in Primary Care Practices Currently Using P-PROMPT Chronic Disease Management System in Ontario|Unknown status|Enrolling by invitation|N/A|10|Anticipated|McMaster University||2|||f||||t||||||||||2018-06-01 00:25:50.775415|2018-06-01 00:25:50.775415
NCT01004263|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2012-04-06||2017-05-25|2009-10-28|2009-10-29|Estimate|2012-04-06|2012-05-04|Estimate||||2017-05-25|2017-06-19|Actual|December 1, 2009|Actual|2009-12-01|May 2017|2017-05-31|April 18, 2011|Actual|2011-04-18|April 18, 2011|Actual|2011-04-18||Interventional|||A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)|A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura|Completed||Phase 3|674|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:25:50.871264|2018-06-01 00:25:50.871264
NCT01004250|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2013-11-07||2014-04-23|2009-10-28|2009-10-29|Estimate|2013-11-07|2013-12-25|Estimate||||2014-04-23|2014-05-21|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Interventional||Intent To Treat population who receive at least 1 dose of study drug.|A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer|A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC|Completed||Phase 2|109|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:25:51.130837|2018-06-01 00:25:51.130837
NCT01004237|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-08-08|2009-10-28|2009-10-29|Estimate|||||||2012-08-08|2012-08-09|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Additive Effects of Pravastatin and Valsartan||Completed||Phase 4|52|Actual|Gachon University Gil Medical Center||3|||f||||||||||||||2018-06-01 00:25:52.079571|2018-06-01 00:25:52.079571
NCT01004224|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2018-05-29|2009-10-28|2009-10-29|Estimate|||||||2018-05-29|2018-05-30|Actual|December 11, 2009|Actual|2009-12-11|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|June 28, 2012|Actual|2012-06-28||Interventional|||A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies|A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies|Active, not recruiting||Phase 1|208|Actual|Novartis||1|||f||||t|t|f||||||No||2018-06-01 00:25:52.170872|2018-06-01 00:25:52.170872
NCT01004211|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2018-01-13|2009-10-28|2009-10-29|Estimate|||||||2018-01-13|2018-01-17|Actual|August 2009||2009-08-31|January 2018|2018-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging|A Phase III Prospective Multicenter Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging.|Completed||N/A|188|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||f||||||||||2018-06-01 00:25:52.315915|2018-06-01 00:25:52.315915
NCT01004198|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2013-08-15|2009-10-28|2009-10-29|Estimate|||||||2013-08-15|2013-08-19|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients|A Multi-center, Randomized, Double-blind, Controlled Dose-finding Study to Evaluate the Safety and Efficacy of MP4OX Treatment Plus Standard of Care in Severely Injured Trauma Patients With Lactic Acidosis Due to Hemorrhagic Shock|Completed||Phase 2|51|Actual|Sangart||3|||f||||t||||||||||2018-06-01 00:25:52.404003|2018-06-01 00:25:52.404003
NCT01004185|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2012-03-27||2012-04-24|2009-10-28|2009-10-29|Estimate|2012-04-24|2012-05-25|Estimate||||2012-04-24|2012-05-25|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|CAMPIII||Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis|A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8g/Day) 400 mg Delayed-release Tablets Given Twice Daily for 26 Weeks to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis|Terminated||Phase 3|39|Actual|Warner Chilcott||2||Pediatric enrollment very slow.|f||||f||||||||||2018-06-01 00:25:52.582571|2018-06-01 00:25:52.582571
NCT01003847|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2011-05-09|2009-10-28|2009-10-29|Estimate|||||||2011-05-09|2011-05-10|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Differential Metabolic Effects of Fenofibrate and Fatty Acid||Completed||Phase 4|150|Actual|Gachon University Gil Medical Center||3|||f||||t||||||||||2018-06-01 00:26:01.715359|2018-06-01 00:26:01.715359
NCT01004172|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2017-01-18||2017-10-02|2009-10-28|2009-10-29|Estimate|2017-04-10|2017-05-22|Actual||||2017-10-02|2017-11-06|Actual|November 2009|Actual|2009-11-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|January 2014|Actual|2014-01-31||Interventional|||Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases|Phase II Trial of Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases|Completed||Phase 2|38|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 00:25:53.108553|2018-06-01 00:25:53.108553
NCT01004159|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2013-12-26||2015-09-29|2009-10-28|2009-10-29|Estimate|2014-04-15|2014-05-16|Estimate||||2015-09-29|2015-10-19|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||All treated and eligible patients|Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan|A Phase II Study of High Dose Cetuximab Plus Irinotecan in Colorectal Cancer Patients With KRS-Wild Type Tumors Who Progressed After Failure of Prior Standard Dose ofCetuximab Plus Irinotecan|Terminated||Phase 2|20|Actual|Roswell Park Cancer Institute|Early termination leading to small numbers of subjects analyzed|1||former PI left institute|f||||t||||||||||2018-06-01 00:25:53.404245|2018-06-01 00:25:53.404245
NCT01004146|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2013-06-17||2013-12-13|2009-10-28|2009-10-29|Estimate|2013-12-13|2014-02-03|Estimate||||2013-12-13|2014-02-03|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|IS||Pre-op Use of Incentive Spirometry in Obese Patients|A Study on the Preoperative Use of Incentive Spirometry in Morbidly Obese Patients Undergoing General Anesthesia|Completed||N/A|50|Actual|The University of Texas Health Science Center, Houston|Our analysis was limited to measuring lung volumes up until postoperative day 1.Extending this study a few days postoperatively likely would allow us to achieve a better understanding of the course of respiratory function recovery.|2|||f||||t||||||||||2018-06-01 00:25:53.648941|2018-06-01 00:25:53.648941
NCT01004133|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2018-03-08|2009-10-28|2009-10-29|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2007||2007-08-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|Wellderly||The Healthy Elderly Longevity Cohort|The Healthy Elderly Longevity Cohort|Recruiting|||5000|Anticipated|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     A single blood specimen or saliva specimen is collected from each subject. If blood is~     collected, approximately thirty eight milliliters of blood will be dispensed as follows:~      3 x 8.5 mls DNA Tubes~      1 x 2.5 mls RNA tube~      1 x 10 mls EBV tube (EDTA) for immortalized cell lines~   "|||2018-06-01 00:25:53.935018|2018-06-01 00:25:53.935018
NCT01004120|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2016-03-24|2009-10-28|2009-10-29|Estimate|||||||2016-03-24|2016-03-25|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults|Double-blind, Placebo Controlled, Randomised, Cross-over Study to Determine the Effect of a Prebiotic Galactooligosaccharide on Microbiota and Metabolic Syndrome Risk Factors in Overweight Adults|Completed||Phase 1/Phase 2|48|Actual|Clasado||2|||f||||t||||||||||2018-06-01 00:25:54.010362|2018-06-01 00:25:54.010362
NCT01004107|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27||2012-04-20|2014-06-17|2009-10-28|2009-10-29|Estimate||||2012-04-23|2012-04-25|Estimate|2014-06-17|2014-06-20|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Evaluation of Radiesse® Dermal Filler for Hand Rejuvenation||Completed||Phase 4|101|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-06-01 00:25:54.211791|2018-06-01 00:25:54.211791
NCT01004094|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2016-01-18|2009-10-28|2009-10-29|Estimate|||||||2016-01-18|2016-01-20|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SQ!II||Squire's Quest! II: Implementation Intentions and Children's Fruit, Juice, and Vegetable (FJV) Consumption|Squire's Quest! II: Implementation Intentions and Children's FJV Consumption|Completed||Phase 2|800|Actual|Baylor College of Medicine||4|||f||||t||||||||||2018-06-01 00:25:54.349844|2018-06-01 00:25:54.349844
NCT01004081|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18||2015-09-17|2015-09-17|2009-10-28|2009-10-29|Estimate||||2015-09-17|2015-10-02|Estimate|2015-09-17|2015-10-02|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding|Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in Combination With Exemestane in Women With Hormone Receptor-Positive, Advanced Metastatic Breast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor|Completed||Phase 2|54|Actual|Biogen||2|||f||||f||||||||||2018-06-01 00:25:54.595588|2018-06-01 00:25:54.595588
NCT01004068|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-11-02|2009-10-28|2009-10-29|Estimate|||||||2010-11-02|2010-11-03|Estimate|February 2008||2008-02-29|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS)|Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study|Completed||Phase 4|96|Actual|University Magna Graecia||3|||f||||t||||||||||2018-06-01 00:25:54.771702|2018-06-01 00:25:54.771702
NCT01004055|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-28|2009-10-28|2009-10-29|Estimate|||||||2009-10-28|2009-10-29|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation|Efficacy of the PROCELLERA Wound Dressing in the Healing of Wounds After Curettage and Electrodesiccation of Skin Lesions|Completed||Phase 2|15|Actual|Vomaris Innovations||3|||f||||t||||||||||2018-06-01 00:25:54.847679|2018-06-01 00:25:54.847679
NCT01004042|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-02-28|2009-10-28|2009-10-29|Estimate|||||||2012-02-28|2012-02-29|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Evaluation of Quality of Life and Self-steem After Botox® in Depressed and Non-depressed Patients|Evaluation of Quality of Life and Self-steem After Botulinum Toxin type-a (Botox®) Injections in Depressed and Non-depressed Patients|Completed||Phase 4|50|Actual|Brazilan Center for Studies in Dermatology||2|||f||||f||||||||||2018-06-01 00:25:55.022622|2018-06-01 00:25:55.022622
NCT01004029|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2018-04-05|2009-10-28|2009-10-29|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2009||2009-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PROLONG||Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery|A Phase 3B, Multi-Center, Randomized, Double-Blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery|Active, not recruiting||Phase 3|1710|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 00:25:55.165639|2018-06-01 00:25:55.165639
NCT01004016|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2010-09-27|2009-10-28|2009-10-29|Estimate|||||||2010-09-27|2010-09-28|Estimate||||September 2010|2010-09-30||||||||Interventional|||A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCD|Completed||Phase 2|20|Anticipated|Kissei Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:25:55.43229|2018-06-01 00:25:55.43229
NCT01004003|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2015-07-09|2014-08-18|2017-09-25|2009-10-28|2009-10-29|Estimate|2015-07-09|2015-08-07|Estimate|2014-08-18|2014-08-20|Estimate|2017-09-25|2017-10-26|Actual|October 22, 2009|Actual|2009-10-22|September 2017|2017-09-30|October 12, 2016|Actual|2016-10-12|July 14, 2014|Actual|2014-07-14||Interventional||Treated set which included all patients who received at least one single dose of trial medication.|Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.|Completed||Phase 2|125|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:25:55.602227|2018-06-01 00:25:55.602227
NCT01003990|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2017-02-02||2017-04-04|2009-10-28|2009-10-29|Estimate|2017-04-04|2017-05-11|Actual||||2017-04-04|2017-05-11|Actual|October 2002||2002-10-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||All Treated Participants|Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access|Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study|Completed||Phase 3|710|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:25:58.002988|2018-06-01 00:25:58.002988
NCT01003977|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2013-03-28|2009-10-28|2009-10-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|September 2013|Anticipated|2013-09-30|September 2011|Actual|2011-09-30||Observational|REWARDS XV||Registry Experience at the Washington Hospital Center, DES - Xience V|REWARDS (Registry Experience at the Washington Hospital Center, DES - Xience V)|Unknown status|Active, not recruiting||1000|Anticipated|Medstar Health Research Institute|||1||f||||f||||||||||2018-06-01 00:25:59.902701|2018-06-01 00:25:59.902701
NCT01003964|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2013-11-13|2009-10-28|2009-10-29|Estimate|||||||2013-11-13|2013-11-14|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV|Randomized phase2 Study of IP vs. GP as the First-line Therapy Followed by Two Different Sequences as the 2nd or 3rd-line Therapy for Patients With Advanced NSCLC;|Unknown status|Active, not recruiting|Phase 2|284|Anticipated|National Cancer Center, Korea||4|||f||||f||||||||||2018-06-01 00:25:59.966053|2018-06-01 00:25:59.966053
NCT01003951|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-08-15|2009-10-28|2009-10-29|Estimate|||||||2012-08-15|2012-08-16|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Acupuncture for the Treatment of Chronic Lymphedema|Acupuncture for the Treatment of Chronic Lymphedema: A Feasibility Study|Completed||Phase 2|37|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:26:00.061666|2018-06-01 00:26:00.061666
NCT01003938|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2013-09-06||2016-05-31|2009-10-28|2009-10-29|Estimate|2013-12-02|2014-01-16|Estimate||||2016-05-31|2016-06-30|Estimate|August 2009||2009-08-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer|Continuous Infusion Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer: Tumor Features and Phase II/Pharmacokinetic Evaluation|Terminated||Phase 2|6|Actual|New York University School of Medicine||1||due to administrative issue and financial sponsor decision to suspend ovarian cancer studies|f||||t||||||||||2018-06-01 00:26:00.214103|2018-06-01 00:26:00.214103
NCT01003925|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2015-08-20|2009-10-28|2009-10-29|Estimate|||||||2015-08-20|2015-08-24|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Observational|||Conjoint Analysis of Treatment Preferences for Osteoarthritis|Conjoint Analysis of Patient Preferences in Medical Management of Osteoarthritis of the Knee|Completed|||182|Actual|Baylor College of Medicine|||2||f||||f||||||||||2018-06-01 00:26:00.602542|2018-06-01 00:26:00.602542
NCT01003912|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2017-06-27|2009-10-28|2009-10-29|Estimate|||||||2017-06-27|2017-06-29|Actual|October 2009||2009-10-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|IUHST-001||Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases|Treatment of Early Infantile-Onset Lysosomal Storage Diseases With Fetal Umbilical Cord Blood (UCB) Transplantation|Withdrawn||Phase 1|0|Actual|Duke University||||Patients were consented to screening but none were enrolled and proceeded with transplant.|f||||t||||||||No||2018-06-01 00:26:00.735341|2018-06-01 00:26:00.735341
NCT01003899|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2013-08-08||2013-12-05|2009-10-28|2009-10-29|Estimate|2013-08-08|2013-10-17|Estimate||||2013-12-05|2013-12-31|Estimate|October 2009||2009-10-31|August 2013|2013-08-31||||November 2011|Actual|2011-11-30||Interventional||Treated Set (TS) consists of all patients treated with at least one dose of study drug.|A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]|A Phase II Trial of BIBW 2992 as a Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type EGFR|Completed||Phase 2|43|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:26:00.825284|2018-06-01 00:26:00.825284
NCT01003886|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|2011-09-19||2011-09-19|2009-10-28|2009-10-29|Estimate|2011-09-19|2011-10-28|Estimate||||2011-09-19|2011-10-28|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)|A Post Marketing Surveillance Study To Determine The Safety, Tolerability And Effectiveness Of Doxazosin Mesylate GITS Among Filipino Adult Males With Benign Prostatic Hyperplasia (BPH)|Completed|||989|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:26:01.112945|2018-06-01 00:26:01.112945
NCT01003873|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2015-01-13|2009-10-28|2009-10-29|Estimate|||||||2015-01-13|2015-01-14|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|CC ENDO||Gastric Bypass and Peripheral Activity of the Endocannabinoid System|Effect of Weight Loss Induced Either by Gastric Bypass or Lifestyle Intervention on the Peripheral Activity of the Endocannabinoid System|Completed|||44|Actual|University Hospital, Bordeaux|||3||f||||f||||||Samples Without DNA|"~     Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral~     adipose tissue will be done 6 months after surgery~   "|||2018-06-01 00:26:01.455869|2018-06-01 00:26:01.455869
NCT01003860|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2009-10-28|2009-10-28|2009-10-29|Estimate|||||||2009-10-28|2009-10-29|Estimate|June 2006||2006-06-30|October 2009|2009-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Postoperative Analgesia After Shoulder Replacement|Comparison Of 0.5% Vs. 0.75% Ropivacaine Interscalene Brachial Plexus Block (ISB) Prior To Elective Total Shoulder Replacement Surgery On Use of Analgesic Medication During Post-Discharge Week|Completed|||39|Actual|Thomas Jefferson University|||2||f||||f||||||||||2018-06-01 00:26:01.555093|2018-06-01 00:26:01.555093
NCT01003834|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2015-12-07|2009-10-28|2009-10-29|Estimate|||||||2015-12-07|2015-12-08|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|SBIRT||Computerized Screening, Brief Intervention, and Referral to Treatment in Primary Care|Computer vs Therapist-Delivered Brief Interventions for Substance Use in Primary Care|Completed||N/A|713|Actual|Virginia Commonwealth University||4|||f||||t||||||||||2018-06-01 00:26:01.800852|2018-06-01 00:26:01.800852
NCT01003808|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2013-04-16|2009-10-28|2009-10-29|Estimate|||||||2013-04-16|2013-04-17|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer|IMF-001 Phase 1 Study With Refractory Esophageal Tumor|Completed||Phase 1|25|Actual|ImmunoFrontier, Inc.||1|||f||||t||||||||||2018-06-01 00:26:01.896115|2018-06-01 00:26:01.896115
NCT01003795|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2013-03-28|2009-10-28|2009-10-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|October 2013|Anticipated|2013-10-31|July 2012|Actual|2012-07-31||Observational|P-REWARDS||Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES)|P-REWARDS (Promus - Registry Experience at the Washington Hospital Center, DES)|Unknown status|Active, not recruiting||800|Anticipated|Medstar Health Research Institute|||1||f||||f||||||||||2018-06-01 00:26:02.013938|2018-06-01 00:26:02.013938
NCT01003782|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2009-10-28|2009-10-28|2009-10-29|Estimate|||||||2009-10-28|2009-10-29|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|ERCP||Routine Bile Collection for Microbiological Analysis During Cholangiography|Routine Bile Collection for Microbiological Analysis During Cholangiography and Its Impact on Management of Cholangitis: Results of a Prospective Study|Completed|||||Hannover Medical School|||||f||||f||||||Samples Without DNA|"~     Bile samples for microbiological analysis~   "|||2018-06-01 00:26:02.078042|2018-06-01 00:26:02.078042
NCT01003769|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2017-08-08|2009-10-28|2009-10-29|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2013||2013-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia|A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Recruiting||Phase 1/Phase 2|60|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:26:02.14256|2018-06-01 00:26:02.14256
NCT01003756|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-02-06|2009-10-28|2009-10-29|Estimate|||||||2012-02-06|2012-02-07|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Preoperative Exercise in Patients Undergoing Total Hip or Knee Replacement||Completed||N/A|165|Actual|University of Southern Denmark||4|||f||||||||||||||2018-06-01 00:26:02.26105|2018-06-01 00:26:02.26105
NCT01003743|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-29|Estimate|||||||2009-10-27|2009-10-29|Estimate||||October 2009|2009-10-31||||||||Interventional|||Endolumenal Gastric Pouch and Gastrojejunal Anastomosis Reduction|Endolumenal Gastric Pouch and Gastrojejunal Anastomosis Reduction|Completed||N/A|||USGI Medical|||||f||||f||||||||||2018-06-01 00:26:02.380139|2018-06-01 00:26:02.380139
NCT01003730|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2015-05-01|2009-10-28|2009-10-29|Estimate|||||||2015-05-01|2015-05-05|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs|The Effects of Different Ventilator Strategies on Inflammation and Injury in Normal Lungs|Terminated||N/A|1|Actual|Rutgers, The State University of New Jersey||3||PI has left the UMDNJ but may resume the study in her new place of employment.|f||||f||||||||||2018-06-01 00:26:02.43886|2018-06-01 00:26:02.43886
NCT01003717|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2013-03-28|2009-10-28|2009-10-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|October 2013|Anticipated|2013-10-31|October 2011|Actual|2011-10-31||Observational|REWARDS-EMI||Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction|REWARDS-EMI (Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction)|Unknown status|Active, not recruiting||120|Anticipated|Medstar Health Research Institute|||1||f||||f||||||||||2018-06-01 00:26:02.544031|2018-06-01 00:26:02.544031
NCT01003704|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2009-10-28|2009-10-28|2009-10-29|Estimate|||||||2009-10-28|2009-10-29|Estimate||||October 2009|2009-10-31||||||||Observational|||Incidence of Phantom Limb Pain and Method of Anesthesia After Lower Extremity Amputation|Incidence of Phantom Limb Pain and Method of Anesthesia After Lower Extremity Amputation|Completed|||||North Texas Veterans Healthcare System|||3||f||||||||||||||2018-06-01 00:26:02.627978|2018-06-01 00:26:02.627978
NCT01003691|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2013-03-27|2009-10-28|2009-10-29|Estimate|||||||2013-03-27|2013-03-29|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy|A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy|Completed||Phase 1|24|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:26:02.69659|2018-06-01 00:26:02.69659
NCT01003678|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2016-06-01|2009-10-28|2009-10-29|Estimate|||||||2016-06-01|2016-06-03|Estimate|October 2009||2009-10-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients|A Phase I Study Evaluating the Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients|Terminated||Phase 1|4|Actual|Roswell Park Cancer Institute||1||Drug provider withdrew support|f||||t||||||||||2018-06-01 00:26:02.848851|2018-06-01 00:26:02.848851
NCT01003665|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-04-13|2009-10-28|2009-10-29|Estimate|||||||2012-04-13|2012-04-16|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|January 2012|Actual|2012-01-31|May 2010|Actual|2010-05-31||Observational|||Comparison of Continuous Non-invasive Arterial Pressure (CNAP) With Invasive Arterial Pressure Monitoring|Accuracy of the CNAP™ Monitor (Continuous Non-invasive Arterial Pressure) Versus Invasive Radial Arterial Monitoring in Surgical Patients|Completed|||195|Actual|University of Schleswig-Holstein|||1||f||||f||||||||||2018-06-01 00:26:02.959721|2018-06-01 00:26:02.959721
NCT01003652|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-28|2009-10-28|2009-10-29|Estimate|||||||2009-10-28|2009-10-29|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Clinical Trial on Harmonic Focus Shears|Randomized Clinical Trial on Harmonic Focus Shears Versus Clamp-and-technique for Total Thyroidectomy|Completed|||68|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||4||f||||t||||||||||2018-06-01 00:26:03.05019|2018-06-01 00:26:03.05019
NCT01003444|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2010-11-23|2009-10-27|2009-10-28|Estimate|||||||2010-11-23|2010-11-24|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Muscle Malonyl Coa Biomarker Assay Development|Muscle Biopsy Study In Healthy Subjects For Malonyl Coa Biomarker Assay Development|Terminated||Phase 1|4|Actual|Pfizer||1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:26:04.718881|2018-06-01 00:26:04.718881
NCT01003639|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2015-03-03|2009-10-28|2009-10-29|Estimate|||||||2015-03-03|2015-03-04|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|IIHTT||Idiopathic Intracranial Hypertension Treatment Trial|A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss|Completed||Phase 2/Phase 3|166|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-06-01 00:26:03.167348|2018-06-01 00:26:03.167348
NCT01003626|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-02-20|2009-10-28|2009-10-29|Estimate|||||||2012-02-20|2012-02-22|Estimate|March 2010||2010-03-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma Patients|A Pilot Study Assessing the Feasibility and Safety of Measuring Interstitial Fluid Pressure (IFP) in Patients With Advanced Malignant Melanoma Before Starting Systemic Treatment|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 00:26:03.35166|2018-06-01 00:26:03.35166
NCT01003613|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2012-04-16|2009-10-28|2009-10-29|Estimate|||||||2012-04-16|2012-04-18|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Interventional|TPS||Evaluation of Tranilast to Treat Pterygium Before Excision|Evaluation of Tranilast as Adjunctive Therapy Before Primary Pterygium Excision Compared With Conjunctival Autograft|Completed||Phase 3|32|Actual|Sao Jose do Rio Preto Medical School||2|||f||||t||||||||||2018-06-01 00:26:03.443404|2018-06-01 00:26:03.443404
NCT01003600|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2014-11-26|2009-10-28|2009-10-29|Estimate|||||||2014-11-26|2014-12-02|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information|Colorectal Cancer Survivors' Needs and Preferences for Survivorship Information|Completed|||177|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 00:26:03.531271|2018-06-01 00:26:03.531271
NCT01003587|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-28|||2015-06-03|2009-10-28|2009-10-29|Estimate|||||||2015-06-03|2015-06-04|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|DESH||Promoting Evidence-Based Decision-Making in India: District Evaluation Study on Health|Improving Use of Evidence in Policy: District Evaluation Study on Health|Unknown status|Active, not recruiting|N/A|594|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 00:26:03.725253|2018-06-01 00:26:03.725253
NCT01003574|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2013-11-25|2009-10-28|2009-10-29|Estimate|||||||2013-11-25|2013-11-26|Estimate|March 2010||2010-03-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ECHOS||Evaluation of Cardiovascular Health Outcomes Among Survivors|Evaluation of Cardiovascular Health Outcomes Among Survivors|Completed||N/A|509|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 00:26:03.824079|2018-06-01 00:26:03.824079
NCT01003561|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate||||October 2009|2009-10-31||||||||Interventional|||Hemodynamic Changes of Upper and Lower Extremities After Spinal Anesthesia||Unknown status|Not yet recruiting|N/A|40|Anticipated|Yonsei University||1|||f||||||||||||||2018-06-01 00:26:03.926553|2018-06-01 00:26:03.926553
NCT01003548|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Embryo Development in Microfluidics System of Culture|Comparison of the in Vitro Development of Human Embryos in Static and and Microfluidics Systems of Culture|Unknown status|Recruiting|Phase 2|400|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 00:26:04.010149|2018-06-01 00:26:04.010149
NCT01003535|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2012-07-03|2009-10-27|2009-10-28|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Quantification of Cerebral Cholinergic Function in Parkinson´s Disease by Means of Nuclear Medicine Methods|Quantification of Cerebral Cholinergic Function in Patients With Parkinson´s Disease by Means of Nuclear Medicine Methods|Completed|||25|Actual|Saarland University|||1||f||||f||||||||||2018-06-01 00:26:04.131239|2018-06-01 00:26:04.131239
NCT01003522|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|RESTORE-AIR||Evaluation of Stents to Open Restricted Airways in Patients With Centrally Placed Non-small Cell Lung Cancer|Randomised Evaluation of Stents to Open Restricted Airways in Patients With Centrally Placed Non-small Cell Lung Cancer (RESTORE-AIR)|Unknown status|Recruiting|Phase 3|60|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:26:04.218438|2018-06-01 00:26:04.218438
NCT01003509|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2011-05-03|2009-10-27|2009-10-28|Estimate|||||||2011-05-03|2011-05-04|Estimate|January 2001||2001-01-31|October 2009|2009-10-31|January 2012|Anticipated|2012-01-31|January 2006|Actual|2006-01-31||Interventional|herni||A New Approach in Inguinal Hernia Repair: Double Repair. A Prospective, Randomized, Controlled Clinical Trial|A New Approach in Inguinal Hernia Repair: Double Repair. A Prospective, Randomized, Controlled Clinical Trial|Unknown status|Recruiting|N/A|50|Anticipated|SB Istanbul Education and Research Hospital||2|||f||||f||||||||||2018-06-01 00:26:04.316463|2018-06-01 00:26:04.316463
NCT01003496|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2010-10-06|2009-10-27|2009-10-28|Estimate|||||||2010-10-06|2010-10-07|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial|Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 3|204|Actual|Wright State University||2|||f||||f||||||||||2018-06-01 00:26:04.408619|2018-06-01 00:26:04.408619
NCT01003483|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients|Orlistat Administration Facilitates the Obesity Treatment Among Obese PCOS Women|Completed||Phase 2|80|Actual|Yazd Research & Clinical Center for Infertility||1|||f||||t||||||||||2018-06-01 00:26:04.492194|2018-06-01 00:26:04.492194
NCT01003470|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|October 2006||2006-10-31|October 2009|2009-10-31|October 2010|Anticipated|2010-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study|Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study|Unknown status|Recruiting|Phase 2|288|Anticipated|Tianjin University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-06-01 00:26:04.573799|2018-06-01 00:26:04.573799
NCT01003457|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity|Ultrasonographic Bladder Wall Thickness and Different Forms of Detrusor Overactivity|Completed|||||Università degli Studi dell'Insubria|||1||f||||||||||||||2018-06-01 00:26:04.663371|2018-06-01 00:26:04.663371
NCT01003431|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2015-10-08|2009-10-27|2009-10-28|Estimate|||||||2015-10-08|2015-10-09|Estimate|December 2009||2009-12-31|October 2015|2015-10-31|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Interventional|||A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)|A Randomized, Open-Label Clinical Study to Assess the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine When Administered Concomitantly With RotaTeq™ or Rotarix™ in Healthy Infants in South Africa|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 00:26:04.793157|2018-06-01 00:26:04.793157
NCT01003418|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27||2010-12-23|2016-09-22|2009-10-27|2009-10-28|Estimate||||2010-12-23|2010-12-30|Estimate|2016-09-22|2016-09-23|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 8 to 12 Weeks|Completed||Phase 2|8|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:26:04.871762|2018-06-01 00:26:04.871762
NCT01003405|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2010-07-25|2009-10-27|2009-10-28|Estimate|||||||2010-07-25|2010-07-27|Estimate||||July 2010|2010-07-31||||||||Interventional|||Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder|A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder|Withdrawn||Phase 3|100|Anticipated|Kissei Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:26:04.977097|2018-06-01 00:26:04.977097
NCT01003392|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2014-01-06|2009-10-27|2009-10-28|Estimate|||||||2014-01-06|2014-01-07|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|Coffee&Heart||Influence of Coffee on the Health and on the Heart of Normal, Diabetics e Coronary Artery Disease Patients|Study of Coffee and Its Influence on the Heart in Normal People, Those With Coronary Artery Disease and Diabetics.|Unknown status|Recruiting||300|Anticipated|University of Sao Paulo|||3||f||||t||||||Samples With DNA|"~     Blood samples.~   "|||2018-06-01 00:26:05.04054|2018-06-01 00:26:05.04054
NCT01003379|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27||2011-12-09|2013-09-03|2009-10-27|2009-10-28|Estimate||||2011-12-09|2011-12-22|Estimate|2013-09-03|2013-09-13|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia|Completed||Phase 2|184|Actual|Targacept Inc.||2|||f||||f||||||||||2018-06-01 00:26:05.114202|2018-06-01 00:26:05.114202
NCT01003366|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2011-03-18|2009-10-27|2009-10-28|Estimate|||||||2011-03-18|2011-03-22|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Effect of the Bevel Direction of Puncture Needle on Success Rate and Complications During Central Venous Catheterization||Completed||N/A|338|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:26:05.197347|2018-06-01 00:26:05.197347
NCT01003353|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2012-06-22|2009-10-27|2009-10-28|Estimate|||||||2012-06-22|2012-06-25|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Strength Training for Chronic Stroke Patients|Maximal Strength Training for Chronic Phase Stroke Patients|Completed||N/A|10|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 00:26:05.266905|2018-06-01 00:26:05.266905
NCT01003340|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2018-02-13|2009-10-27|2009-10-28|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2009||2009-07-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Community Health Worker Home Intervention to Improve Pediatric Asthma Outcomes|A Randomized Controlled Trial of a Community Health Worker Home-Based Asthma Intervention|Completed||N/A|188|Actual|Montefiore Medical Center||1|||f||||f||||||||No||2018-06-01 00:26:05.360846|2018-06-01 00:26:05.360846
NCT01003327|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2010-07-22|2009-10-27|2009-10-28|Estimate|||||||2010-07-22|2010-07-23|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Comparison of the I-gel Laryngeal Mask and the Classic Laryngeal Mask in Patients With a BMI>25|Comparison of the I-gel Laryngeal Mask and the Classic Laryngeal Mask in Patients With a BMI>25 During Elective Surgery|Completed||Phase 4|50|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:26:05.434709|2018-06-01 00:26:05.434709
NCT01003314|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2011-03-25|2009-10-27|2009-10-28|Estimate|||||||2011-03-25|2011-03-28|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of the Safety and Effectiveness of Two New Malaria Vaccines|A Phase I/IIa Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 MSP1 Alone and With MVA MSP1|Completed||Phase 1/Phase 2|16|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 00:26:05.497314|2018-06-01 00:26:05.497314
NCT01003301|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2014-01-07||2014-02-24|2009-10-27|2009-10-28|Estimate|2014-02-24|2014-04-07|Estimate||||2014-02-24|2014-04-07|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|||The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge|The Effects of Omalizumab on the Late-phase Response to Nasal Allergen Challenge|Completed||Phase 2|19|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:26:05.573516|2018-06-01 00:26:05.573516
NCT01003288|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2015-06-06||2016-09-19|2009-10-27|2009-10-28|Estimate|2016-07-14|2016-08-24|Estimate||||2016-09-19|2016-11-07|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|January 2010|Actual|2010-01-31||Interventional|H1N1VAC||Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen|Safety and Immunogenicity Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen|Completed||N/A|255|Actual|University of Bergen||1|||f||||f||||||||||2018-06-01 00:26:05.75178|2018-06-01 00:26:05.75178
NCT01003275|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2013-06-18||2014-04-09|2009-10-27|2009-10-28|Estimate|2013-09-26|2013-09-27|Estimate||||2014-04-09|2014-04-28|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Metabolic Effects of Paricalcitol|Effects of Oral Paricalcitol on Glucose Tolerance, Immune Cell Function, and Oxidative Stress in Stage 3-4 Chronic Kidney Disease|Completed||Phase 2|22|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 00:26:06.141446|2018-06-01 00:26:06.141446
NCT01003262|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2016-11-23|2009-10-27|2009-10-28|Estimate|||||||2016-11-23|2016-11-28|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluating an Emergency Department Observation Syncope Protocol for Older Adults||Completed||N/A|123|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:26:06.386153|2018-06-01 00:26:06.386153
NCT01003249|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2017-11-30||2018-02-01|2009-10-26|2009-10-28|Estimate|2018-02-01|2018-03-01|Actual||||2018-02-01|2018-03-01|Actual|September 2009||2009-09-30|November 2017|2017-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen|Treatment of Patients With Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen: a Randomized Double-blind Placebo-controlled Cross-over Trial|Terminated||Phase 4|12|Actual|Wake Forest University Health Sciences||2||recruitment was going too slowly|f|||||t|f|||f|||||2018-06-01 00:26:06.49109|2018-06-01 00:26:06.49109
NCT01003236|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2012-06-21|2009-10-27|2009-10-28|Estimate|||||||2012-06-21|2012-06-25|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy|Evaluating the Preventive Effect of Milk Thistle Extract (Silymarin) on Progression of Diabetic Nephropathy, a Randomized, Double-blind, Placebo-controlled Clinical Trial.|Completed||Phase 2|60|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:26:06.807031|2018-06-01 00:26:06.807031
NCT01003223|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2014-08-14|2009-10-27|2009-10-28|Estimate|||||||2014-08-14|2014-08-18|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|PKM||Phosphate Kinetic Modeling|Phosphate Kinetic Modeling|Completed||N/A|190|Actual|Fresenius Medical Care North America||1|||f||||f||||||||||2018-06-01 00:26:06.906484|2018-06-01 00:26:06.906484
NCT01003210|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2014-05-19||2014-07-23|2009-10-27|2009-10-28|Estimate|2014-06-24|2014-07-22|Estimate||||2014-07-23|2014-07-30|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional||Children 6 months - 11 years old diagnosed with acute otitis media and managed with a delayed antibiotic treatment approach|Homeopathic Ear Drops for Otitis Media Study|Homeopathic Ear Drops for Children With Otitis Media Study|Completed||N/A|210|Actual|University of Washington|Initially planned sample size --150. Study size was increased after analysis of initial data found a non-significant trend between antibiotic fill rates in the homeopathic ear drop and standard therapy treatment groups.|2|||f||||f||||||||||2018-06-01 00:26:06.992726|2018-06-01 00:26:06.992726
NCT01003197|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Novel Preoperative Score Predicting Outcome Following Liver Resection|Novel Preoperative Score Predicting Outcome Following Liver Resection|Completed|||||University of Zurich|||2||f||||t||||||||||2018-06-01 00:26:07.325295|2018-06-01 00:26:07.325295
NCT01003184|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2012-11-20||2015-03-19|2009-10-27|2009-10-28|Estimate|2012-11-20|2012-12-18|Estimate||||2015-03-19|2015-04-07|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes|Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulphonylurea|Completed||Phase 3|222|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:26:07.43824|2018-06-01 00:26:07.43824
NCT01003171|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-06-28|2009-10-27|2009-10-28|Estimate|||||||2011-06-28|2011-06-30|Estimate|August 2011||2011-08-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|MCS-2-US-pk||Pharmacokinetics of MCS in Healthy Volunteers|An Open-Label, Multiple-Dose Study of MCS-2 to Examine the Pharmacokinetics of MCS and Other Components After Once-daily Oral Dosing in Healthy Adult Volunteers|Unknown status|Not yet recruiting|Phase 1|12|Anticipated|Health Ever Bio-Tech Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:26:08.036741|2018-06-01 00:26:08.036741
NCT01003158|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2014-07-09|2009-10-27|2009-10-28|Estimate|||||||2014-07-09|2014-07-10|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.|A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer|Completed||Phase 1|17|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:26:08.095718|2018-06-01 00:26:08.095718
NCT01003145|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2012-01-19|2009-10-27|2009-10-28|Estimate|||||||2012-01-19|2012-01-20|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders|A Clinical Study to Assess the Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Healthy Volunteers|Completed||N/A|292|Actual|Adimmune Corporation||3|||f||||f||||||||||2018-06-01 00:26:08.162326|2018-06-01 00:26:08.162326
NCT01003132|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2010-11-08|2009-10-27|2009-10-28|Estimate|||||||2010-11-08|2010-11-09|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|PACT||Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following Psychosis|A Pilot Randomised Controlled Trial of Acceptance and Commitment Therapy for Distress Following Psychosis|Completed||N/A|27|Actual|University of Glasgow||2|||f||||t||||||||||2018-06-01 00:26:08.226849|2018-06-01 00:26:08.226849
NCT01003119|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2016-02-03|2009-10-27|2009-10-28|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Computer-Based Alcohol Use Disorder Recovery System|Developing and Testing a Computer-Based Alcohol Use Disorder Recovery System|Completed||N/A|350|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:26:08.335092|2018-06-01 00:26:08.335092
NCT01003106|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2015-08-25||2016-02-16|2009-10-27|2009-10-28|Estimate|2016-02-16|2016-03-15|Estimate||||2016-02-16|2016-03-15|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|RELATE||Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions|RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach(RELATE)|Completed||Phase 1/Phase 2|81|Actual|Johns Hopkins University||8|||f||||f||||||||||2018-06-01 00:26:08.412472|2018-06-01 00:26:08.412472
NCT01003093|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2013-01-18|2009-10-27|2009-10-28|Estimate|||||||2013-01-18|2013-01-21|Estimate|November 2005||2005-11-30|January 2013|2013-01-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|THYB-01||A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine|A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) Administered at 0 and 2 Months|Completed||Phase 1|36|Actual|Statens Serum Institut||3|||f||||t||||||||||2018-06-01 00:26:08.916876|2018-06-01 00:26:08.916876
NCT01002404|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-10-10|2009-10-26|2009-10-27|Estimate|||||||2011-10-10|2011-10-12|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Use of Guide Wire in Biliary Cannulation: Angled or Straight Tipped Guide Wire?|The Use of Guide Wire in Biliary Cannulation: Angled or Straight Tipped Guide Wire?|Completed||N/A|164|Actual|Turku University Hospital||2|||f||||f||||||||||2018-06-01 00:26:16.399734|2018-06-01 00:26:16.399734
NCT01003080|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2010-11-19||2011-03-04|2009-10-27|2009-10-28|Estimate|2011-03-04|2011-04-07|Estimate||||2011-03-04|2011-04-07|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial|Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial|Completed||Phase 4|111|Actual|Montefiore Medical Center|Operator dependent modifications may affect the standardization of the procedure; Surgeon is not blinded to the treatment used on each patient.|2|||f||||||||||||||2018-06-01 00:26:08.994541|2018-06-01 00:26:08.994541
NCT01003067|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2017-03-06||2017-05-29|2009-10-27|2009-10-28|Estimate|2017-03-06|2017-04-17|Actual||||2017-05-29|2017-06-21|Actual|March 2008||2008-03-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 2013|Actual|2013-05-31||Interventional|||Intraperitoneal Mesh-Implementation After Laparotomy|Intraperitoneal Mesh-Implementation After Laparotomy to Reduce Risk of Incisional Hernia: a Prospective Randomized Controlled Trial|Active, not recruiting||N/A|267|Actual|Kantonsspital Liestal||2|||f||||f||||||||||2018-06-01 00:26:09.276865|2018-06-01 00:26:09.276865
NCT01003054|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-10-31|2009-10-27|2009-10-28|Estimate|||||||2011-10-31|2011-11-02|Estimate|March 2005||2005-03-31|October 2011|2011-10-31|October 2009|Actual|2009-10-31|December 2007|Actual|2007-12-31||Interventional|||Autologous Transplantation for Chronic Myelogenous Leukemia|Busulfan, Cyclophosphamide, Imatinib Mesylate and Autologous Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia|Completed||Phase 2|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:26:09.476702|2018-06-01 00:26:09.476702
NCT01003041|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|October 2009||2009-10-31|October 2009|2009-10-31||||||||Observational|||The Influence of Hearing Discrete Phonemes in Mother's Voice in the Infant's Natural Environment and With Natural Melody on Developing Phonetic Categories Between 4-10 Months Old||Unknown status|Not yet recruiting||50|Anticipated|Maaynei Hayesha Medical Center|||1||f||||||||||||||2018-06-01 00:26:09.572638|2018-06-01 00:26:09.572638
NCT01003028|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2015-05-27|2009-10-27|2009-10-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2015||2015-11-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion||Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:26:09.632243|2018-06-01 00:26:09.632243
NCT01003015|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-04-02|2009-10-27|2009-10-28|Estimate|||||||2015-04-02|2015-04-03|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|March 2013|Actual|2013-03-31|November 2010|Actual|2010-11-30||Interventional|||Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma|An Uncontrolled Open Label Multicenter Phase II Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (HCC)|Completed||Phase 2|36|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:26:09.740007|2018-06-01 00:26:09.740007
NCT01003002|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2016-04-04|2009-10-27|2009-10-28|Estimate|||||||2016-04-04|2016-04-06|Estimate|December 2010||2010-12-31|October 2009|2009-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Natural History of Levodopa-Induced Dyskinesia (LID)|Determining the Natural History of Levodopa-Induced Dyskinesia (LID)|Withdrawn|||0|Actual|Oregon Health and Science University|||1|Funding not secured.|f||||f||||||||||2018-06-01 00:26:09.85113|2018-06-01 00:26:09.85113
NCT01002989|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|2010-08-23||2012-01-20|2009-10-27|2009-10-28|Estimate|2011-12-08|2012-01-13|Estimate||||2012-01-20|2012-01-23|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|ABI||Validation of WatchBP Office Ankle-brachial Index (ABI) Function|Assessment of the Oscillometric Measurement of the Ankle-brachial Index (ABI) With WatchBP Office ABI Device.|Completed|||98|Actual|University of Athens|||1||f||||f||||||||||2018-06-01 00:26:09.954633|2018-06-01 00:26:09.954633
NCT01002976|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-25|||2012-01-23|2009-10-27|2009-10-28|Estimate|||||||2012-01-23|2012-01-24|Estimate|December 2009||2009-12-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|OM-2009-XO||Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma|Correlation Between Level of Free IgE, Total IgE, Specific IgE and FceRI Expression on Effectors Cells and the Respond to Omalizumab in Subjects With Severe Asthma. Single Arm Open Label Study|Withdrawn|||0|Actual|Carmel Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood Sputum~   "|||2018-06-01 00:26:10.141265|2018-06-01 00:26:10.141265
NCT01002963|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2010-10-22|2009-10-27|2009-10-28|Estimate|||||||2010-10-22|2010-10-25|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers|A Double-Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Doses Of PF-04418948 In Healthy Male Subjects|Completed||Phase 1|56|Anticipated|Pfizer||7|||f||||f||||||||||2018-06-01 00:26:10.202923|2018-06-01 00:26:10.202923
NCT01002950|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26||2014-02-07|2014-02-07|2009-10-26|2009-10-28|Estimate||||2014-02-07|2014-03-11|Estimate|2014-02-07|2014-03-11|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy|Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)|Completed||Phase 2|72|Actual|Acucela Inc.||2|||f||||t||||||||||2018-06-01 00:26:10.326024|2018-06-01 00:26:10.326024
NCT01002937|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2009-10-27|2009-10-27|2009-10-28|Estimate|||||||2009-10-27|2009-10-28|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Novel Prognostic Markers in Renal Cancer|Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples|Unknown status|Recruiting||500|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-06-01 00:26:10.401114|2018-06-01 00:26:10.401114
NCT01002924|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-08-23|2009-10-26|2009-10-28|Estimate|||||||2017-08-23|2017-08-24|Actual|December 2009||2009-12-31|August 2017|2017-08-31|December 11, 2013|Actual|2013-12-11|December 11, 2013|Actual|2013-12-11||Interventional|||Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)|Protocol EC-FV-05: An Open-label, Multi-center, Extension Study of EC145 Administered Weeks 1 and 3 of a 4-Week Cycle in Subjects Enrolled in a Previous Study With EC145|Completed||Phase 2|1|Actual|Endocyte||1|||f||||f||||||||||2018-06-01 00:26:10.466211|2018-06-01 00:26:10.466211
NCT01002911|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2013-05-14|2009-10-27|2009-10-28|Estimate|||||||2013-05-14|2013-05-16|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PADIT||Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)|Phase III Pilot Study - A Simple Randomized Trial of Conventional Versus Multimodal Prevention of Arrhythmia Device Infection|Completed||Phase 3|500|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-06-01 00:26:10.535324|2018-06-01 00:26:10.535324
NCT01002898|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2011-11-10|2009-10-27|2009-10-28|Estimate|||||||2011-11-10|2011-11-11|Estimate|April 2007||2007-04-30|October 2009|2009-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Ritonavir-boosted Lopinavir Monotherapy|Treatment Outcomes and Plasma Level of Ritonavir-boosted Lopinavir Monotherapy Among HIV-infected Patients Who Had Non-nucleoside Reverse Transcriptase Inhibitor (NRTI) and NNRTI Failure: A Pilot Study|Completed||Phase 3|40|Actual|Bamrasnaradura Infectious Diseases Institute||1|||f||||t||||||||||2018-06-01 00:26:10.601695|2018-06-01 00:26:10.601695
NCT01002885|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2013-12-09|2009-10-26|2009-10-28|Estimate|||||||2013-12-09|2013-12-10|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|||Follicle Stimulating Hormone (FSH) Receptor Polymorphisms in In-Vitro Fertilization Cycles.|The Use of FSH Receptor Polymorphisms To Improve Pregnancy Rates In In-Vitro Fertilization|Completed|||75|Actual|University Reproductive Associates|||||f||||f||||||Samples With DNA|"~     2 EDTA containing lavender topped tubes will be collected before, during or within 3 months~     after an IVF cycle. Genomic DNA will be extracted and saved for genotyping.~   "|||2018-06-01 00:26:10.673486|2018-06-01 00:26:10.673486
NCT01002872|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-27|||2012-03-07|2009-10-27|2009-10-28|Estimate|||||||2012-03-07|2012-03-08|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|May 2012|Anticipated|2012-05-31||Interventional|||The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease|The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 (FGF23 ) in Chronic Kidney Disease|Unknown status|Active, not recruiting|N/A|20|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-06-01 00:26:10.740911|2018-06-01 00:26:10.740911
NCT01002859|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2014-09-04|2009-10-26|2009-10-27|Estimate|||||||2014-09-04|2014-09-05|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|Ciclo et CEC||Effect of Preliminary Administration of Cyclosporine (Sandimmun ®) on Different Markers of Cardiac Ischaemia Induced by Cardiopulmonary Bypass|Double-Blind Phase II Pilot Monocentric Randomized Clinical Trial Evaluating the Effect of a Preliminary Administration of Cyclosporine on Different Markers of Cardiac Ischemia Led by the Aortic Cross-clamp During Coronary Artery Bypass Surgery With Cardiopulmonary Bypass.|Terminated||Phase 2|50|Actual|University Hospital, Grenoble||2||difficulties to include patients|f||||t||||||||||2018-06-01 00:26:10.838758|2018-06-01 00:26:10.838758
NCT01002846|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Effects of Acupuncture at ST36 and PC6 on Blood Pressure and Endothelial Dysfunction in Hypertensive Patients|Effects of Acupuncture at ST36 and PC6 on Blood Pressure and Endothelial|Unknown status|Recruiting|Phase 3|32|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-06-01 00:26:10.9287|2018-06-01 00:26:10.9287
NCT01002833|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2010-11-08|2009-10-26|2009-10-27|Estimate|||||||2010-11-08|2010-11-09|Estimate|April 2010||2010-04-30|February 2010|2010-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TIP1||Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection|Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection|Completed||N/A|15|Anticipated|Radboud University||3|||f||||f||||||||||2018-06-01 00:26:10.993627|2018-06-01 00:26:10.993627
NCT01002820|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16||2012-04-18|2015-10-01|2009-10-23|2009-10-27|Estimate||||2012-04-18|2012-04-20|Estimate|2015-10-01|2015-10-22|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|August 2013|Actual|2013-08-31|October 2010|Actual|2010-10-31||Interventional|0602||A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601|A Treatment Protocol for Ganaxolone as add-on Therapy in Adult Patients With Uncontrolled Partial-onset Seizures Deriving Benefit From Protocol 1042-0601|Completed||Phase 2|11|Actual|Marinus Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:26:11.062179|2018-06-01 00:26:11.062179
NCT01002807|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2016-10-14|2009-10-26|2009-10-27|Estimate|||||||2016-10-14|2016-10-17|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State|Bioavailability Study of Two Prototype Fixed Dose Combination (FDC) Formulations of 10 mg Dapagliflozin and 1000 mg Metformin Extended Release (XR) Tablet Relative to Dapagliflozin 10 mg Tablet and Glucophage® XR 2 X 500 mg Tablets Coadministered to Healthy Subjects in a Fasted State|Completed||Phase 1|15|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:26:11.145746|2018-06-01 00:26:11.145746
NCT01002794|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-25|||2014-05-30|2009-10-26|2009-10-27|Estimate|||||||2014-05-30|2014-06-02|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|||Surgical or Exercise Therapy on Patients With Degenerative Meniscus Tears|The Effect of Arthroscopic Partial Meniscectomy or Exercise Therapy as Treatment of Degenerative Meniscus Tears in Middle-aged Patients. A Randomized, Controlled Trial|Unknown status|Active, not recruiting|N/A|140|Actual|Oslo University Hospital||2|||f||||||||||||||2018-06-01 00:26:11.230322|2018-06-01 00:26:11.230322
NCT01002781|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Efficacy and Safety of Tocilizumab in Adult's Still Disease|Efficacy and Safety of Tocilizumab (a Monoclonal Antibody to Receptor of IL-6) in the Treatment of Adult's Still Disease|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 00:26:11.381969|2018-06-01 00:26:11.381969
NCT01002768|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-01-19|2009-10-26|2009-10-27|Estimate|||||||2017-01-19|2017-01-20|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics|A Trial Investigating the Hypoglycaemic Response to NN1250 in Subjects With Type 1 Diabetes|Completed||Phase 1|28|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:26:11.510422|2018-06-01 00:26:11.510422
NCT01002755|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2018-02-01|2009-10-26|2009-10-27|Estimate|||||||2018-02-01|2018-02-05|Actual|January 19, 2010|Actual|2010-01-19|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)|Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)|Completed||Phase 2|37|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:26:11.612469|2018-06-01 00:26:11.612469
NCT01002391|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2012-03-12|2009-10-26|2009-10-27|Estimate|||||||2012-03-12|2012-03-13|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|September 2010|Actual|2010-09-30|November 2009|Actual|2009-11-30||Interventional|||Dressing Wear Time After Reduction Mammaplasty|Twenty-four Hours or 6 Days? A Prospective Randomized Trial Comparing Dressing Wear Time After Reduction Mammaplasty|Completed||N/A|70|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 00:26:16.47645|2018-06-01 00:26:16.47645
NCT01002742|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2016-01-06||2017-09-27|2009-10-23|2009-10-27|Estimate|2016-04-21|2016-05-27|Estimate||||2017-09-27|2017-10-27|Actual|January 2010|Actual|2010-01-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|January 2012|Actual|2012-01-31||Interventional||All randomized patients were included in primary, intention-to-treat analysis.|Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)|A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802)|Completed||Phase 3|236|Actual|Medical College of Wisconsin||2|||f||||t||||||||Yes|Findings will be published in a manuscript.|2018-06-01 00:26:11.712123|2018-06-01 00:26:11.712123
NCT01002729|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-25|||2011-08-02|2009-10-26|2009-10-27|Estimate|||||||2011-08-02|2011-08-03|Estimate|November 2009||2009-11-30|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|OPTIMO||Oseltamivir Pharmacokinetics in Morbid Obesity|Oseltamivir Pharmacokinetics in Morbid Obesity|Completed||N/A|20|Actual|IWK Health Centre|||||f||||f||||||||||2018-06-01 00:26:12.641481|2018-06-01 00:26:12.641481
NCT01002716|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis|Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis|Unknown status|Recruiting|Phase 4|90|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 00:26:12.726561|2018-06-01 00:26:12.726561
NCT01002703|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2011-08-11|2009-10-26|2009-10-27|Estimate|||||||2011-08-11|2011-08-12|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|October 2014|Anticipated|2014-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma|Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma After Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|University of Leipzig||1|||f||||t||||||||||2018-06-01 00:26:12.829693|2018-06-01 00:26:12.829693
NCT01002690|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2013-04-23|2009-10-26|2009-10-27|Estimate|||||||2013-04-23|2013-04-24|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||COX-2 Inhibition in Allergic Asthma|Effect of COX-2 Inhibition on Allergen-induced Airway Obstruction in Subjects With Asthma|Completed||N/A|16|Actual|Karolinska University Hospital||1|||f||||t||||||||||2018-06-01 00:26:12.926189|2018-06-01 00:26:12.926189
NCT01002677|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2013-01-16|2009-10-26|2009-10-27|Estimate|||||||2013-01-16|2013-01-17|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|MAP||Behavioral Trial Studying Programmed Training to Improve Advocacy Skills for Individuals With Traumatic Brain Injury|Midwest Advocacy Project: A Community-based Randomized Practical Behavioral Trial of Programmed Advocacy Training for Individuals With Traumatic Brain Injury and Their Significant Others|Completed||Phase 2/Phase 3|234|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:26:13.002541|2018-06-01 00:26:13.002541
NCT01002664|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2016-07-31|2009-10-25|2009-10-27|Estimate|||||||2016-07-31|2016-08-02|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MCS_LUTS||Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms|A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects|Completed||Phase 3|272|Actual|Health Ever Bio-Tech Co., Ltd.||2|||f||||f||||||||No||2018-06-01 00:26:13.097663|2018-06-01 00:26:13.097663
NCT01002651|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Adults)|In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects: a Randomized, Placebo-controlled, Double-blind, Cross-over Study|Completed||N/A|66|Actual|Fugeia NV||3|||f||||t||||||||||2018-06-01 00:26:13.179801|2018-06-01 00:26:13.179801
NCT01002638|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-09-07|2009-10-26|2009-10-27|Estimate|||||||2017-09-07|2017-09-08|Actual|December 2009||2009-12-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Occlusive Dressing|The Occlusive Dressing: a Comparative Randomized Trial on 2 Procedures of Treatment of Fingertips Traumatic Amputations|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 00:26:13.259004|2018-06-01 00:26:13.259004
NCT01002625|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2010-07-06|2009-10-26|2009-10-27|Estimate|||||||2010-07-06|2010-07-08|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers|Double-Blind, Randomized, Multiple-Dose, Placebo-Controlled, 2-Way Crossover Study To Study Effects Of PF-04457845 On Polysomnographic Endpoints In Healthy Volunteers|Terminated||Phase 1|18|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:26:13.34256|2018-06-01 00:26:13.34256
NCT01002612|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2009-11-06|2009-10-24|2009-10-27|Estimate|||||||2009-11-06|2009-11-09|Estimate|December 2007||2007-12-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|TACHIN003-1||Reassessment of the Nutritional Status in Thai Orphans Living With HIV in a Family Style Community|Reassessment of the Nutritional Status in Thai Orphans Living With HIV in a Family Style Community: 6 Months After Nutrition Care Support by the Thai-Australian Collaboration HIV-Nutrition (TACHIN) Project|Completed|||73|Actual|Thai Red Cross AIDS Research Centre|||||f||||f||||||||||2018-06-01 00:26:13.423588|2018-06-01 00:26:13.423588
NCT01002599|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2010-01-22|2009-10-26|2009-10-27|Estimate|||||||2010-01-22|2010-01-26|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Oxygenation and Pulmonary Function in Morbidly Obese Patients Undergoing Bariatric Surgery|Does BoussignacTM CPAP Compared to Venturi Mask Improve Oxygenation and Pulmonary Function in Morbidly Obese Patients Undergoing Bariatric Surgery?|Unknown status|Recruiting|N/A|54|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:26:13.49581|2018-06-01 00:26:13.49581
NCT01002586|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2017-09-01|2009-10-26|2009-10-27|Estimate|||||||2017-09-01|2017-09-06|Actual|November 2009|Actual|2009-11-30|September 2017|2017-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia|Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia|Completed||N/A|22|Actual|University of Nebraska||2|||f||||f||||||||||2018-06-01 00:26:13.5723|2018-06-01 00:26:13.5723
NCT00815620|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2017-03-20|2008-12-29|2008-12-30|Estimate|||||||2017-03-20|2017-03-21|Actual|November 2008||2008-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|August 2016|Actual|2016-08-31||Observational|BESTTHERAPYNET||Best Therapy for Patients With Neuroendocrine Tumors|Best Therapy for Patients With Neuroendocrine Tumors|Completed|||150|Actual|Zentralklinik Bad Berka|||3||f||||f||||||||||2018-06-01 01:26:27.7168|2018-06-01 01:26:27.7168
NCT01002573|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2016-07-29|2014-07-07|2016-09-22|2009-10-26|2009-10-27|Estimate|2016-09-22|2016-11-07|Estimate|2014-07-07|2014-07-09|Estimate|2016-09-22|2016-11-07|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All Treated Subjects|Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients|A Multicenter, Randomized, Open-Label, Parallel, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Pediatric Patients|Completed||Phase 3|118|Actual|Cumberland Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:26:13.670622|2018-06-01 00:26:13.670622
NCT01002560|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||The Identification of Novel Prognostic Markers in Melanoma|Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples|Unknown status|Recruiting||500|Anticipated|Royal Marsden NHS Foundation Trust|||2||f||||f||||||||||2018-06-01 00:26:14.084791|2018-06-01 00:26:14.084791
NCT01002547|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2017-04-10|2009-10-26|2009-10-27|Estimate|||||||2017-04-10|2017-04-12|Actual|June 24, 2010|Actual|2010-06-24|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|September 30, 2016|Actual|2016-09-30||Interventional|VA NASH||Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment|NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment|Completed||Phase 4|105|Actual|VA Office of Research and Development||3|||f||||t||||||||No||2018-06-01 00:26:14.148294|2018-06-01 00:26:14.148294
NCT01002534|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2012-06-06|2009-10-26|2009-10-27|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|June 2012|Anticipated|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?|Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind, Placebo-controlled Study.|Suspended||Phase 2|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3||not yet started|f||||f||||||||||2018-06-01 00:26:14.228404|2018-06-01 00:26:14.228404
NCT01002521|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|December 2009||2009-12-31|October 2009|2009-10-31|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Observational|WHy||Wound Healing In Diabetes (WHy) Study|Molecular and Genetic Analysis of Disturbed Wound Healing in Barbadians With Diabetic Foot Ulcers|Unknown status|Not yet recruiting||605|Anticipated|The University of The West Indies|||2||f||||t||||||Samples With DNA|"~     Whole blood,Serum,DNA,Urine~   "|||2018-06-01 00:26:14.295311|2018-06-01 00:26:14.295311
NCT01002508|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|November 2009||2009-11-30|August 2009|2009-08-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Influenza Vaccination in Patients With Scleroderma|Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 00:26:14.387722|2018-06-01 00:26:14.387722
NCT01002495|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-24|||2015-02-06|2009-10-24|2009-10-27|Estimate|||||||2015-02-06|2015-02-09|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|July 2015|Anticipated|2015-07-31||Interventional|||Gene Therapy for the Treatment of Chronic Stable Angina|A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia|Withdrawn||Phase 1/Phase 2|0|Actual|ViroMed Co., Ltd.||3||The study was never initiated at any sites.|f||||t||||||||||2018-06-01 00:26:14.457107|2018-06-01 00:26:14.457107
NCT01002482|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2013-04-24||2013-11-08|2009-10-26|2009-10-27|Estimate|2013-11-08|2013-12-03|Estimate||||2013-11-08|2013-12-03|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|CGAO-REA|Among the 2684 randomized patients, 1351 were assigned to tight computerized glucose control and 1333 to conventional glucose control. Thirty six patients were discarded from any analysis, 35 because they withdrew consent and 1 because he/she was included twice. Baseline analysis was performed only for the 2648 included and not discarded patients.|Computerized Glucose Control in Critically Ill Patients|Impact of the Use of a Computerized Protocol for Glucose Control Named CGAOtm on the Outcome of Critically Ill Patients|Completed||Phase 3|2684|Actual|Centre Hospitalier of Chartres||2|||f||||t||||||||||2018-06-01 00:26:14.542789|2018-06-01 00:26:14.542789
NCT01002469|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2010-01-14|2009-10-26|2009-10-27|Estimate|||||||2010-01-14|2010-01-15|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Study to Evaluate 13 C Isotope Ratio Measurement for Urea Cycle Capacity Assessment|Pilot Feasibility Study in Healthy Subjects and Healthy Asymptomatic Subjects Genetically Disposed to Urea Cycle Disorders to Evaluate the Use of 13 C Isotope Ratio Measurement|Completed||N/A|10|Actual|Cytonet GmbH & Co. KG||1|||f||||f||||||||||2018-06-01 00:26:14.878178|2018-06-01 00:26:14.878178
NCT01002456|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2014-09-26||2015-04-06|2009-10-26|2009-10-27|Estimate|2014-10-08|2014-10-15|Estimate||||2015-04-06|2015-04-28|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|October 2012|Actual|2012-10-31|June 2011|Actual|2011-06-30||Interventional|||Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison|Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison|Completed||N/A|220|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:26:15.932203|2018-06-01 00:26:15.932203
NCT01002443|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|July 2003||2003-07-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|March 2006|Actual|2006-03-31||Interventional|||Efficacy Study of Helicobacter Pylori Eradication in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer|Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Intestinal Metaplasia in Patients Undergoing Subtotal Gastrectomy for Gastric Cancer|Completed||Phase 2|190|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-06-01 00:26:16.160933|2018-06-01 00:26:16.160933
NCT01002430|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2018-03-07|2009-10-26|2009-10-27|Estimate|||||||2018-03-07|2018-03-08|Actual|January 10, 2010|Actual|2010-01-10|March 2018|2018-03-31|June 15, 2015|Actual|2015-06-15|June 15, 2015|Actual|2015-06-15||Interventional|KAT301||EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease|Endocardial VEGF-D Gene Therapy for the Treatment of Severe Coronary Heart Disease - A Phase 1 Single-blinded Placebo-controlled Phase 1 Clinical Trial|Completed||Phase 1|30|Anticipated|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 00:26:16.240516|2018-06-01 00:26:16.240516
NCT01002417|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-25|||2015-03-01|2009-10-26|2009-10-27|Estimate|||||||2015-03-01|2015-03-03|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|MCS_LUTS||MCS in the Treatment of Lower Urinary Tract Symptoms|An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects|Completed||Phase 2/Phase 3|274|Actual|Health Ever Bio-Tech Co., Ltd.||3|||f||||f||||||||||2018-06-01 00:26:16.319039|2018-06-01 00:26:16.319039
NCT01002378|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2013-05-21|2009-10-26|2009-10-27|Estimate|||||||2013-05-21|2013-05-23|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib|A Phase I, Randomized, Open Label, 3-Way Cross-Over Study to Determine the Effect of a High-Fat Breakfast, a Low-Fat Breakfast and Fasting State on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers|Completed||Phase 1|24|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:26:16.555493|2018-06-01 00:26:16.555493
NCT01002365|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-25|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate||||October 2009|2009-10-31||||||||Interventional|||Perioperative Hyperoxygenation and Wound Site Infection Following Surgery for Acute Appendicitis||Completed||N/A|||Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-06-01 00:26:16.722278|2018-06-01 00:26:16.722278
NCT01002352|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-11-21|2009-10-26|2009-10-27|Estimate|||||||2011-11-21|2011-11-22|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|BOLD||Bariatric Outcomes Longitudinal Database (BOLD)|Bariatric Outcomes Longitudinal Database (BOLD)|Unknown status|Active, not recruiting||600000|Anticipated|Surgical Review Corporation|||||f||||f||||||||||2018-06-01 00:26:16.779067|2018-06-01 00:26:16.779067
NCT01002339|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2016-02-05||2017-03-23|2009-10-26|2009-10-27|Estimate|2016-06-21|2016-08-03|Estimate||||2017-03-23|2017-05-03|Actual|February 2010||2010-02-28|March 2017|2017-03-31|June 2015|Actual|2015-06-30|February 2014|Actual|2014-02-28||Interventional|01-DMPT||Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation|Optimum Immunosuppression in Renal Transplant Recipients at High Risk of Developing New Onset Diabetes After Transplantation: A Multicenter, Prospective, Controlled and Randomized Trial.|Terminated||Phase 4|134|Actual|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||3||Terminated: higher rate of acute rejection in the Cyclosporin A group|f||||f||||||||Undecided||2018-06-01 00:26:16.90016|2018-06-01 00:26:16.90016
NCT01002326|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2016-03-15|2009-10-26|2009-10-27|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Cognitive-Behavioral Therapy for Pediatric Body Dysmorphic Disorder|An Open Trial of Cognitive-Behavioral Therapy (CBT) for Pediatric Body Dysmorphic Disorder (BDD)|Completed||N/A|13|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 00:26:18.000074|2018-06-01 00:26:18.000074
NCT01002313|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2014-03-26|2009-10-26|2009-10-27|Estimate|||||||2014-03-26|2014-03-27|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Observational|||Effect of Prednisone onTregs and TH17|Effect of Prednisone on Peripheral Blood T-cell Function (Tregs and Th17) in Patients With Chronic Rhinosinusitis (CRS)|Completed|||40|Actual|University of Chicago|||2||f||||f||||||||||2018-06-01 00:26:18.070969|2018-06-01 00:26:18.070969
NCT01002300|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2014-03-17|2009-10-26|2009-10-27|Estimate|||||||2014-03-17|2014-03-18|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Oxytocin and Social Cognition in Frontotemporal Dementia|Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia|Completed||N/A|24|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 00:26:18.222187|2018-06-01 00:26:18.222187
NCT01002287|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2012-06-21||2014-11-07|2009-10-26|2009-10-27|Estimate|2013-12-23|2014-01-29|Estimate||||2014-11-07|2014-11-20|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|||An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery|An Evaluation of the SprayShield Adhesion Barrier System in Reducing Post-Operative Adhesion in Abdominal Surgery|Terminated||N/A|11|Actual|Integra LifeSciences Corporation|Early termination leading to small numbers of subjects analyzed|2||Study was terminated for business purposes, not for safety or efficacy reasons.|f||||f||||||||||2018-06-01 00:26:18.310564|2018-06-01 00:26:18.310564
NCT01002274|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2016-11-10|2009-10-25|2009-10-27|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MCS-2-TWN-c||Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms|Open-Label, 40-weeks Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects|Completed||Phase 3|180|Actual|Health Ever Bio-Tech Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:26:18.611304|2018-06-01 00:26:18.611304
NCT01002261|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2015-01-22|2009-10-26|2009-10-27|Estimate|||||||2015-01-22|2015-01-26|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Hepatic Metabolism of Galactose and the Galactose Analog FDGal in Patients With Liver Disease and Healthy Subjects|Determination of Hepatic Metabolism of Galactose and the Galactose Analog FDGal in Patients With Liver Disease and Healthy Subjects|Completed|||16|Actual|Aarhus University Hospital|||2||f||||f||||||||||2018-06-01 00:26:18.684194|2018-06-01 00:26:18.684194
NCT01002248|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23||2018-02-06|2018-02-06|2009-10-26|2009-10-27|Estimate||||2018-02-06|2018-02-09|Actual|2018-02-06|2018-02-09|Actual|December 2009||2009-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients|A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients|Terminated||Phase 3|135|Actual|AEterna Zentaris||2|||f||||t||||||||||2018-06-01 00:26:18.766076|2018-06-01 00:26:18.766076
NCT01002235|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-24||2015-01-30|2015-01-30|2009-10-24|2009-10-27|Estimate||||2015-01-30|2015-02-09|Estimate|2015-01-30|2015-02-09|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Gene Therapy for Painful Diabetic Neuropathy|A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Patients With Painful Diabetic Peripheral Neuropathy|Completed||Phase 1/Phase 2|12|Actual|ViroMed Co., Ltd.||3|||f||||t||||||||||2018-06-01 00:26:18.960437|2018-06-01 00:26:18.960437
NCT01002222|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-25|||2015-03-01|2009-10-26|2009-10-27|Estimate|||||||2015-03-01|2015-03-03|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|MCS-2-US-c||Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)|Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects|Completed||Phase 3|200|Anticipated|Health Ever Bio-Tech Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:26:19.058569|2018-06-01 00:26:19.058569
NCT01002027|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|November 2004||2004-11-30|October 2009|2009-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Three Model Care Pathways for Postnatal Depression|Models of Care: Evaluating a Best Practice Model of Treating Postnatal Depression (PND)|Completed||N/A|68|Actual|University of Melbourne||3|||f||||f||||||||||2018-06-01 00:26:22.376071|2018-06-01 00:26:22.376071
NCT01002209|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2015-05-06|2009-10-26|2009-10-27|Estimate|||||||2015-05-06|2015-05-08|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|HODiVA||Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery|Postoperative Hyperbaric Oxygen Treatments to Reduce Complications in Diabetic Patients Undergoing Vascular Surgery (HODiVA) - A Double Blind, Randomized Controlled Study|Unknown status|Recruiting|Phase 2/Phase 3|112|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 00:26:19.142746|2018-06-01 00:26:19.142746
NCT01002196|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2014-06-19|2009-10-26|2009-10-27|Estimate|||||||2014-06-19|2014-06-20|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Randomised Controlled Treatment Study of Selective Mutism|How to Help When Silence is Not Golden A RCT Study of Selective Mutism|Completed||Phase 2|24|Actual|Regionsenter for barn og unges psykiske helse||2|||f||||f||||||||||2018-06-01 00:26:19.225588|2018-06-01 00:26:19.225588
NCT01002183|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-09-26|2009-10-26|2009-10-27|Estimate|||||||2011-09-26|2011-09-27|Estimate||||August 2010|2010-08-31||||||||Interventional|JP015||Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate|Evaluation of Fosmidomycin and Clindamycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria|Withdrawn||Phase 2|40|Anticipated|Jomaa Pharma GmbH||1||Drug combination is no longer pursued|f||||f||||||||||2018-06-01 00:26:19.291834|2018-06-01 00:26:19.291834
NCT01002170|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2010-11-01|2009-10-25|2009-10-27|Estimate|||||||2010-11-01|2010-11-03|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|May 2010|Actual|2010-05-31|June 2009|Actual|2009-06-30||Observational|CSPK||Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament|The Impact Factor Analysis of the Therapeutic Drug Monitoring of Oral 2nd Line Antituberculosis Agent, Cycloserine|Completed|||30|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-06-01 00:26:19.398903|2018-06-01 00:26:19.398903
NCT01002157|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-03-21|2009-10-26|2009-10-27|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2011||2011-10-31|March 2016|2016-03-31||||September 2019|Anticipated|2019-09-30||Interventional|VitaK-CAC||The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification|The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification|Recruiting||N/A|180|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:26:19.454977|2018-06-01 00:26:19.454977
NCT01002144|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|March 2007||2007-03-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Observational|||C-Reactive Protein as a Predictor for Airway Hyper-Responsiveness|C-Reactive Protein as a Predictor for Airway Hyper-responsiveness|Completed|||88|Actual|Rambam Health Care Campus|||||f||||f||||||||||2018-06-01 00:26:19.534738|2018-06-01 00:26:19.534738
NCT01002131|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-02-24|2009-10-26|2009-10-27|Estimate|||||||2017-02-24|2017-02-28|Actual|May 2007|Actual|2007-05-31|February 2017|2017-02-28|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Observational|||Exact Localisation of Impacted and Supernumerary Teeth by Cone Beam Computer Tomography|Exact Three-dimensional Localisation of Impacted and Supernumerary Teeth by Cone Beam Computer Tomography|Completed|||61|Actual|Norwegian University of Science and Technology|||1||f||||t|f|f||||||||2018-06-01 00:26:19.649788|2018-06-01 00:26:19.649788
NCT01002118|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2017-05-02||2017-08-07|2009-10-26|2009-10-27|Estimate|2017-08-07|2017-08-09|Actual||||2017-08-07|2017-08-09|Actual|January 25, 2008|Actual|2008-01-25|August 2017|2017-08-31|February 23, 2011|Actual|2011-02-23|February 23, 2011|Actual|2011-02-23||Interventional|||Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients|Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients|Terminated||N/A|1|Actual|University of Iowa||2||Unable to recruit eligible subjects; no data analyzed|f||||f||||||||||2018-06-01 00:26:19.74373|2018-06-01 00:26:19.74373
NCT01002105|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2015-02-23||2016-11-30|2009-10-26|2009-10-27|Estimate|2016-11-30|2017-01-27|Estimate||||2016-11-30|2017-01-27|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients|Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients and Its Effect on Quality of Life, Clinical and Psychosocial Features: A 12-Week Double-Blind Randomized Controlled Trial|Completed||Phase 4|75|Actual|Sha’ar Menashe Mental Health Center||2|||f||||t||||||||No||2018-06-01 00:26:19.924545|2018-06-01 00:26:19.924545
NCT01002092|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-25|||2014-08-31|2009-10-25|2009-10-27|Estimate|||||||2014-08-31|2014-09-03|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma|A Randomized, Controlled Multicenter Trial of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-06-01 00:26:20.787925|2018-06-01 00:26:20.787925
NCT01002079|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-01-24|2009-10-26|2009-10-27|Estimate|||||||2011-01-24|2011-01-25|Estimate|August 2010||2010-08-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Drug-Drug Interaction Study With Rifampin|A Study of the Effect of Concomitant Administration of Rifampin on the Pharmacokinetics of BMS-708163 in Healthy Subjects|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:26:21.090331|2018-06-01 00:26:21.090331
NCT01002066|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-11-14|2009-10-26|2009-10-27|Estimate|||||||2011-11-14|2011-11-15|Estimate|May 2010||2010-05-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Observational|RDTACT||Effectiveness Of Rapid Diagnostic Tests in the New Context of Low Malaria Endemicity in Zanzibar|Rapid Malaria Diagnostic Tests in Fever Patients Attending Primary Health Care Facilities in Zanzibar - Effectiveness as Diagnostic and Surveillance Tool in the New Context of Low Malaria Endemicity|Completed|||3890|Actual|Karolinska University Hospital|||||f||||t||||||Samples With DNA|"~     Whole blood collected on Rapid diagnostic tests (RDT)s and Filter paper (FP)~   "|||2018-06-01 00:26:21.394016|2018-06-01 00:26:21.394016
NCT01002053|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-11-21|2009-10-26|2009-10-27|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2012||2012-02-29|November 2011|2011-11-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Can Ultrasound Predict Nerve Injury Following Posterior Tibial Nerve Block in Patients With Peripheral Neuropathy?|Can Ultrasound Predict Nerve Injury Following Posterior Tibial Nerve Block in Patients With Peripheral Neuropathy?|Completed|||40|Actual|University Health Network, Toronto|||1||f||||f||||||||||2018-06-01 00:26:21.714849|2018-06-01 00:26:21.714849
NCT01002040|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2015-04-14|2009-10-26|2009-10-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Adults With Human Immunodeficiency Virus Infection|Completed||Phase 4|150|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:26:22.03387|2018-06-01 00:26:22.03387
NCT01002014|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2017-02-06|2009-10-26|2009-10-27|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2009||2009-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Nipple Sparing Mastectomy - Cosmetic Outcomes|Preservation of the Nipple Areolar Complex With Skin Sparing Mastectomy|Active, not recruiting||N/A|75|Actual|Carolinas Healthcare System||1|||f||||t||||||||||2018-06-01 00:26:22.722622|2018-06-01 00:26:22.722622
NCT01002001|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Sleep Disorders Pre and Post Liver Transplantation|Prospective Study to Evaluate Sleep Disturbance in Patients With Liver Disease Pre and Post Liver Transplantation|Unknown status|Enrolling by invitation||200|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 00:26:23.021506|2018-06-01 00:26:23.021506
NCT01001988|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2017-09-18||2017-10-23|2009-10-23|2009-10-27|Estimate|2017-10-23|2017-11-29|Actual||||2017-10-23|2017-11-29|Actual|August 7, 2009|Actual|2009-08-07|October 2017|2017-10-31|October 16, 2013|Actual|2013-10-16|October 16, 2013|Actual|2013-10-16||Interventional||The baseline analysis population includes all participants in the Per Protocol Analysis Set at Year 1 of JEC05|Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers|Long-term Follow-up of Immunogenicity of a Single Dose of JE-CV in Toddlers in Thailand and the Philippines|Completed||Phase 3|596|Actual|Sanofi||1|||f||||f|t|f|||t|||||2018-06-01 00:26:23.263755|2018-06-01 00:26:23.263755
NCT01001975|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2010-11-04|2010-07-30|2015-02-20|2009-10-26|2009-10-27|Estimate|2010-11-04|2010-12-07|Estimate|2010-07-30|2010-08-03|Estimate|2015-02-20|2015-03-11|Estimate|July 2009||2009-07-31|February 2015|2015-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PFA and SPF||Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED)|Determination of Sun Protection Factors (PFA and SPF) in Sunscreen Formulas Containing Combinations of Zinc Oxide and Avobenzone|Completed||Phase 3|10|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:26:23.959657|2018-06-01 00:26:23.959657
NCT01001962|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2015-04-06|2009-10-26|2009-10-27|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2016||2016-01-31|April 2015|2015-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|PREHYPD||Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics|Double Blind Comparison Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics With Metformin|Not yet recruiting||Phase 4|1054|Anticipated|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-06-01 00:26:24.731535|2018-06-01 00:26:24.731535
NCT01001949|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Juniors)|In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects: a Randomized, Placebo-controlled, Double-blind, Cross-over Study|Completed||N/A|29|Actual|Fugeia NV||2|||f||||t||||||||||2018-06-01 00:26:25.103882|2018-06-01 00:26:25.103882
NCT01001936|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|February 2006||2006-02-28|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating SKI-606 in Subject With Solid Tumors|Phase 1 Does-escalation Study of Oral SKI-606 in Subjects With Advanced Malignant Solid Tumors|Completed||Phase 1|28|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||t||||||||||2018-06-01 00:26:25.268062|2018-06-01 00:26:25.268062
NCT01001923|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26||2012-10-23|2013-05-20|2009-10-26|2009-10-27|Estimate||||2012-10-23|2012-10-30|Estimate|2013-05-20|2013-05-27|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain|Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Chronic Pancreatitis|Terminated||Phase 2|15|Actual|Regeneron Pharmaceuticals||2||Business decision due to low subject recruitment and enrollment|f||||t||||||||||2018-06-01 00:26:25.386218|2018-06-01 00:26:25.386218
NCT01001910|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2015-12-10|2009-10-26|2009-10-27|Estimate|||||||2015-12-10|2015-12-14|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Pemetrexed Disodium and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma|Completed||Phase 2|12|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-06-01 00:26:25.484348|2018-06-01 00:26:25.484348
NCT01001897|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2012-06-13|2009-10-26|2009-10-27|Estimate|||||||2012-06-13|2012-06-14|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Use of Misoprostol for Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol vs. Placebo for Cervical Preparation in IUD Insertion for Nulliparous Women|Completed||N/A|61|Actual|University of Arizona||2|||f||||t||||||||||2018-06-01 00:26:25.571702|2018-06-01 00:26:25.571702
NCT01001884|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2010-08-12|2009-10-26|2009-10-27|Estimate|||||||2010-08-12|2010-08-16|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Efficacy of the Caregiver Psychoeducational Consultation Program|The Efficacy of the Caregiver Psychoeducational Consultation Program in Spouse Caregivers of Resectable Colorectal Cancer|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 00:26:25.646599|2018-06-01 00:26:25.646599
NCT01001871|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-10-26|2009-10-26|2009-10-27|Estimate|||||||2009-10-26|2009-10-27|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|May 2011|Anticipated|2011-05-31|October 2010|Anticipated|2010-10-31||Interventional|||Treatment of Iron Deficiency Anemia in Malaria Endemic Ghana|Seasonal Impact of Iron Fortification on Malaria Incidence in Ghanaian Children|Unknown status|Not yet recruiting|N/A|3880|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 00:26:25.73801|2018-06-01 00:26:25.73801
NCT01001858|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-07-26|2009-10-26|2009-10-27|Estimate|||||||2010-07-26|2010-07-27|Estimate|June 2003||2003-06-30|October 2009|2009-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Domiciliary Diagnosis and Follow up in Obstructive Apnoea Syndrome|Domiciliary Diagnosis and Follow up in Obstructive Apnoea Syndrome|Completed||N/A|66|Actual|Hospital Universitario San Juan de Alicante||3|||f||||f||||||||||2018-06-01 00:26:25.810167|2018-06-01 00:26:25.810167
NCT01001845|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2011-01-21|2009-10-26|2009-10-27|Estimate|||||||2011-01-21|2011-01-24|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Comparative Effects of Milk Thistle Extract With Vitamin-E in Hemodialysis Patients|Comparative Effects of Milk Thistle Extract With Vitamin-E on Oxidative Stress Biomarkers in Hemodialysis Patients|Completed||Phase 2|80|Anticipated|Shiraz University of Medical Sciences||4|||f||||t||||||||||2018-06-01 00:26:25.885048|2018-06-01 00:26:25.885048
NCT01001832|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|2012-10-22||2014-01-02|2009-10-26|2009-10-27|Estimate|2013-01-08|2013-02-07|Estimate||||2014-01-02|2014-02-06|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|February 2011|Actual|2011-02-28||Interventional|||Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients|A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate|Completed||Phase 2/Phase 3|118|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 00:26:25.990912|2018-06-01 00:26:25.990912
NCT01001819|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2018-04-03|2009-10-26|2009-10-27|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2005||2005-03-31|April 2018|2018-04-30|November 18, 2008|Actual|2008-11-18|November 18, 2008|Actual|2008-11-18||Observational|||DNA Microarray Analysis of Gene Expression in Chronic Rhinosinusitis|DNA Microarray Analysis of Gene Expression in Chronic Rhinosinusitis|Completed|||30|Actual|Montefiore Medical Center|||2||f||||f||||||||||2018-06-01 00:26:26.995362|2018-06-01 00:26:26.995362
NCT01001806|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2011-05-25||2011-08-26|2009-10-26|2009-10-27|Estimate|2011-07-28|2011-08-26|Estimate||||2011-08-26|2011-10-03|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification|A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification|Completed||Phase 4|126|Actual|Bucci Laser Vision Institute||3|||f||||f||||||||||2018-06-01 00:26:27.047913|2018-06-01 00:26:27.047913
NCT01001793|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-24|||2011-12-22|2009-10-26|2009-10-27|Estimate|||||||2011-12-22|2011-12-23|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Levacor™ Ventricular Assist Device (VAD) Bridge to Transplant Study|Evaluation of the Levacor™ Ventricular Assist Device as a Bridge to Cardiac Transplantation|Terminated||N/A|15|Actual|World Heart Corporation||||Commercial considerations relating to required device modifications.|f||||t||||||||||2018-06-01 00:26:27.27337|2018-06-01 00:26:27.27337
NCT01001780|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2013-10-14|2009-10-26|2009-10-27|Estimate|||||||2013-10-14|2013-10-16|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease|Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease|Withdrawn||Phase 2|0|Actual|University of Rochester||1||Study stopped early due to poor accrual.|f||||t||||||||||2018-06-01 00:26:27.341867|2018-06-01 00:26:27.341867
NCT01001767|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2012-03-12||2014-12-18|2009-10-26|2009-10-27|Estimate|2012-03-12|2012-04-09|Estimate||||2014-12-18|2015-01-07|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease|Prospective Randomized Placebo Controlled Trial of Omega-3 Fatty Acids in HIV Infected Subjects to Modulate Cardiovascular Risk|Completed||Phase 2|35|Actual|University Hospitals Cleveland Medical Center|Small sample size may have precluded our ability to detect a small effect. Pill counts were used to monitor adherence. All participants were male.|2|||f||||f||||||||||2018-06-01 00:26:27.410741|2018-06-01 00:26:27.410741
NCT01001754|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2011-12-02|2009-10-26|2009-10-27|Estimate|||||||2011-12-02|2011-12-05|Estimate|May 2010||2010-05-31|December 2011|2011-12-31|May 2012|Anticipated|2012-05-31|November 2010|Actual|2010-11-30||Interventional|EMERGE||Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection|Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection|Unknown status|Active, not recruiting|Phase 2|600|Anticipated|ZymoGenetics||3|||f||||t||||||||||2018-06-01 00:26:27.702876|2018-06-01 00:26:27.702876
NCT01001741|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2015-09-16|2009-10-26|2009-10-27|Estimate|||||||2015-09-16|2015-09-17|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pilot Study of Text Message Reminders to Improve HIV Medication Adherence in Botswana|A Pilot Study of Cellular Phone Text Message Reminders to Improve HIV Medication Adherence at Independence Surgery Clinic Gaborone, Botswana|Completed||N/A|128|Actual|University of Pennsylvania|||||f||||f||||||||||2018-06-01 00:26:28.062751|2018-06-01 00:26:28.062751
NCT01001728|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2016-05-20|2009-10-26|2009-10-27|Estimate|||||||2016-05-20|2016-05-23|Estimate|November 2008||2008-11-30|May 2016|2016-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|SuPr||SuPr Study (Supine Versus Prone Treatment Position in Breast Radiotherapy)|A Randomised Trial Investigating the Prone Treatment Position as a Method of Sparing Healthy Tissues in Women Prescribed Breast Radiotherapy (SuPr Study)|Completed||Phase 3|25|Actual|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:26:28.12899|2018-06-01 00:26:28.12899
NCT01001715|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26||2012-10-23|2013-05-20|2009-10-26|2009-10-27|Estimate||||2012-10-23|2012-10-30|Estimate|2013-05-20|2013-05-27|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain|Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of SAR164877 (REGN475) on Reduction of Pain From Vertebral Fracture Associated With Osteoporosis|Terminated||Phase 2|41|Actual|Regeneron Pharmaceuticals||2||Business decision due to low subject recruitment and enrollment|f||||t||||||||||2018-06-01 00:26:28.201082|2018-06-01 00:26:28.201082
NCT01001702|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2013-07-29||2013-07-29|2009-10-23|2009-10-27|Estimate|2013-07-29|2013-09-27|Estimate||||2013-07-29|2013-09-27|Estimate|April 2006||2006-04-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Oral Aripiprazole Open-Label Rollover Study|An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241|Completed||Phase 3|85|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-06-01 00:26:28.318579|2018-06-01 00:26:28.318579
NCT01001689|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2018-01-17|2009-10-26|2009-10-27|Estimate|||||||2018-01-17|2018-01-18|Actual|September 2009||2009-09-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|FFF||Fit For Delivery: A Study of the Effect of Exercise Sessions and Nutritional Counselling on Pregnancy Outcome|Fit For Delivery: A Study of the Effect of Exercise Intervention and Nutritional Counselling on Pregnancy Outcome.|Completed||N/A|606|Actual|Sorlandet Hospital HF||2|||f||||t||||||||||2018-06-01 00:26:28.615929|2018-06-01 00:26:28.615929
NCT01001676|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-26|||2014-11-14|2009-10-26|2009-10-27|Estimate|||||||2014-11-14|2014-11-17|Estimate|February 2012||2012-02-29|January 2012|2012-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Restenosis Following Paclitaxel Eluting Balloon Angioplasty of Hemodialysis Access Stenosis|Local Delivery of Paclitaxel for Prevention of Restenosis in Hemodialysis Access|Completed||Phase 2|32|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:26:28.698366|2018-06-01 00:26:28.698366
NCT01001663|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2013-09-05|2009-10-23|2009-10-26|Estimate|||||||2013-09-05|2013-09-06|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|CLOSE-UP I||Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography|Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography: the CLOSE-UP I Randomized Trial|Completed||Phase 4|1005|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-06-01 00:26:28.777507|2018-06-01 00:26:28.777507
NCT01001650|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2014-09-09|2009-10-23|2009-10-26|Estimate|||||||2014-09-09|2014-09-10|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Clinical Trial of the PfSPZ Vaccine|A Phase 1/2a Trial of the PfSPZ Vaccine Administered Subcutaneously or Intradermally to Malaria-Naïve Adult Volunteers|Completed||Phase 1|80|Actual|Sanaria Inc.||4|||f||||t||||||||||2018-06-01 00:26:28.908768|2018-06-01 00:26:28.908768
NCT01001637|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2009-10-23|2009-10-23|2009-10-26|Estimate|||||||2009-10-23|2009-10-26|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|November 2010|Anticipated|2010-11-30|June 2010|Anticipated|2010-06-30||Interventional|||Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease|Phase II Study of Curcumin Formulation (Longvida) or Placebo on Plasma Biomarkers and Mental State in Moderate to Severe Alzheimer's Disease or Normal Cognition|Unknown status|Recruiting|Phase 2|26|Anticipated|Jaslok Hospital and Research Centre||2|||f||||f||||||||||2018-06-01 00:26:29.033654|2018-06-01 00:26:29.033654
NCT01001624|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2012-05-02|2009-10-23|2009-10-26|Estimate|||||||2012-05-02|2012-05-04|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Melanil in the Treatment of Melasma|Efficacy of Melanil in the Treatment of Melasma|Completed||Phase 3|150|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:26:29.128594|2018-06-01 00:26:29.128594
NCT01001611|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2013-07-17|2009-10-23|2009-10-26|Estimate|||||||2013-07-17|2013-07-19|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus|An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus: A 24-week, Multi Center, Randomized, Double-blind, Parallel-group, Placebo Control, Therapeutic Confirmatory Study|Completed||Phase 3|173|Actual|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-06-01 00:26:29.203075|2018-06-01 00:26:29.203075
NCT01001598|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2014-09-12|2009-10-23|2009-10-26|Estimate|||||||2014-09-12|2014-09-15|Estimate|November 2009||2009-11-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita|Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita|Terminated||Phase 1/Phase 2|5|Actual|Boston Children’s Hospital||1||Study was terminated due to under enrollment|f||||t||||||||||2018-06-01 00:26:29.30118|2018-06-01 00:26:29.30118
NCT01001585|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2015-03-05|2009-10-23|2009-10-26|Estimate|||||||2015-03-05|2015-03-09|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Anesthetic Effects in Mitochondrial Disease|Anesthetic Effects in Mitochondrial Disease|Terminated||N/A|55|Actual|The Cleveland Clinic||1||However, no intervention reduced the risk of major morbidity or 1 yr mortality|f||||f||||||||||2018-06-01 00:26:29.368625|2018-06-01 00:26:29.368625
NCT01001572|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2011-04-22||2011-05-18|2009-10-23|2009-10-26|Estimate|2011-05-18|2011-05-24|Estimate||||2011-05-18|2011-05-24|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension|A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy|Completed||Phase 3|932|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:26:29.460255|2018-06-01 00:26:29.460255
NCT01001559|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2013-04-19||2013-11-25|2009-10-23|2009-10-26|Estimate|2013-11-25|2013-12-19|Estimate||||2013-11-25|2013-12-19|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis|Combination Deplin® and Antidepressant Therapy Compared to Antidepressant Therapy Alone for an Episode of Major Depression- a Retrospective Analysis|Completed|||242|Actual|Pamlab, Inc.|||2||f||||f||||||||||2018-06-01 00:26:29.716213|2018-06-01 00:26:29.716213
NCT01001546|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2015-01-13||2015-04-06|2009-10-23|2009-10-26|Estimate|2015-02-17|2015-03-09|Estimate||||2015-04-06|2015-04-27|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Internet-Based Smoking Cessation for Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans|Internet-Based Smoking Cessation for OEF/OIF Veterans|Completed||N/A|413|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:26:29.949433|2018-06-01 00:26:29.949433
NCT01001533|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2017-01-04|2009-10-23|2009-10-26|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|DEX-CO||Assess the Ability of Electrical Cardiometry to Trend Hemodynamic Variables During Dexmedetomidine Sedation|A Pilot Study to Assess the Ability of Non-invasive Bio-impedance Cardiac Monitoring to Detect and Trend Hemodynamic Variables During Dexmedetomidine (DEX) Sedation in Children for Radiology Procedures|Completed|||17|Actual|Boston Children’s Hospital|||1||f||||f||||||||||2018-06-01 00:26:30.253034|2018-06-01 00:26:30.253034
NCT01001520|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2014-01-07||2014-05-29|2009-10-23|2009-10-26|Estimate|2014-05-29|2014-07-02|Estimate||||2014-05-29|2014-07-02|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Measurements were taken during their first study visit, the medical screening visit.|Neural Substrates in Nicotine Withdrawal|Neural Substrates of Cognitive Deficits in Nicotine Withdrawal|Completed||Phase 2|218|Actual|University of Pennsylvania|Genetic studies, particularly imaging studies, have drawbacks such as small sample size and focus on single candidate genes; both can be said of this study.|2|||f||||t||||||||||2018-06-01 00:26:30.31651|2018-06-01 00:26:30.31651
NCT01001507|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2013-12-06|2009-10-23|2009-10-26|Estimate|||||||2013-12-06|2013-12-09|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Integrating Family Planning Services Into HIV Care and Treatment in Nyanza Province, Kenya|Cluster Randomized Trial of Integration of Family Planning Services Into HIV Care and Treatment in Suba, Kisumu East, Rongo and Migori Districts of Nyanza Province|Completed||N/A|5040|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:26:30.680987|2018-06-01 00:26:30.680987
NCT00811694|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2014-11-20|2008-12-18|2008-12-19|Estimate|||||||2014-11-20|2014-11-21|Estimate|October 2006||2006-10-31|November 2014|2014-11-30|May 2012|Actual|2012-05-31|April 2007|Actual|2007-04-30||Observational|||Neurovascular Coupling in Patients With Open Angle Glaucoma|Neurovascular Coupling in Patients With Open Angle Glaucoma|Terminated|||15|Anticipated|Medical University of Vienna|||2||f||||t||||||||||2018-06-01 01:27:49.413934|2018-06-01 01:27:49.413934
NCT01001494|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2012-08-14||2016-11-16|2009-10-23|2009-10-26|Estimate|2012-08-14|2012-09-17|Estimate||||2016-11-16|2017-01-04|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients|Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|828|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:26:30.829174|2018-06-01 00:26:30.829174
NCT01001481|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2014-04-08|2009-10-23|2009-10-26|Estimate|||||||2014-04-08|2014-04-09|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Schizophrenia Treatment Adherence Investigation (STAI)|Clinical Audit and Feedback Program to Determine Risk for Medication Adherence in Outpatients Diagnosed With Schizophrenia in Australia|Completed|||550|Actual|Janssen-Cilag Pty Ltd|||1||f||||f||||||||||2018-06-01 00:26:31.74146|2018-06-01 00:26:31.74146
NCT01001468|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-11-15|2009-10-23|2009-10-26|Estimate|||||||2011-11-15|2011-11-16|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Assess VB-201 in Patients With Psoriasis|A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|185|Actual|Vascular Biogenics Ltd. operating as VBL Therapeutics||3|||f||||t||||||||||2018-06-01 00:26:31.812835|2018-06-01 00:26:31.812835
NCT01001455|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2009-10-23|2009-10-23|2009-10-26|Estimate|||||||2009-10-23|2009-10-26|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Clinical Test for Armed-used Blood Pressure Monitor With Preformed Cuff||Completed|||90|Actual|Andon Health Co., Ltd|||2||f||||f||||||||||2018-06-01 00:26:31.928116|2018-06-01 00:26:31.928116
NCT01001442|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2018-01-03||2018-04-06|2009-10-23|2009-10-26|Estimate|2018-04-06|2018-05-08|Actual||||2018-04-06|2018-05-08|Actual|August 2010||2010-08-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|July 2014|Actual|2014-07-31||Interventional||ITT: The Intention-to-treat (ITT) population included all subjects who were enrolled in the study and received at least 1 dose of BT062 and who had any post-Baseline evaluations or data. One subject did not have at least one post-injection assessment of the treatment response and was excluded from both the ITT and PP populations (n = 34).|Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/IIa Multi-Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), Safety and Efficacy of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|35|Actual|Biotest Pharmaceuticals Corporation||1|||f||||t||||||||||2018-06-01 00:26:32.047006|2018-06-01 00:26:32.047006
NCT01001429|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2016-02-11||2017-07-18|2009-10-23|2009-10-26|Estimate|2017-07-18|2017-08-21|Actual||||2017-07-18|2017-08-21|Actual|October 2009||2009-10-31|April 2017|2017-04-30|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Interventional|||Dexmedetomidine Versus Propofol in Vitreoretinal Surgery|Comparison of Dexmedetomidine vs. Propofol in Vitreoretinal Surgery Under Sub-Tenon's Block|Completed||Phase 4|78|Actual|Rutgers, The State University of New Jersey|Termination of study due to difficulty recruiting subjects who fit the study criteria.|2|||f||||f||||||||No||2018-06-01 00:26:33.455293|2018-06-01 00:26:33.455293
NCT01001403|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2010-03-21||2010-05-04|2009-10-23|2009-10-26|Estimate|2010-04-08|2010-05-03|Estimate||||2010-05-04|2010-05-11|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Effect of Nafamostat on Postreperfusion Syndrome (PRS)|Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft|Completed||Phase 4|62|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:26:33.74325|2018-06-01 00:26:33.74325
NCT01001390|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2014-01-15||2014-02-27|2009-10-23|2009-10-26|Estimate|2014-01-15|2014-02-28|Estimate||||2014-02-27|2014-03-27|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Two participants were enrolled, however, neither participant continued to wear their ankle foot orthoses after the initial visit.|The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop|The Effects of Ankle Foot Orthoses on Gait Efficiency in Children With Acute Lymphoblastic Leukemia and Foot Drop|Terminated||N/A|2|Actual|St. Jude Children's Research Hospital|The study was terminated due to poor accrual and poor participant compliance.|2||The study closed due to poor accrual and difficulty with participant compliance.|f||||f||||||||||2018-06-01 00:26:33.92268|2018-06-01 00:26:33.92268
NCT01001377|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2014-02-03||2017-03-17|2009-10-22|2009-10-26|Estimate|2014-02-03|2014-03-24|Estimate||||2017-03-17|2017-04-14|Actual|February 2, 2010|Actual|2010-02-02|March 2017|2017-03-31|March 7, 2017|Actual|2017-03-07|February 5, 2013|Actual|2013-02-05||Interventional|||ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer|A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer|Completed||Phase 3|1010|Actual|Amgen||2|||f||||t||||||||||2018-06-01 00:26:34.083672|2018-06-01 00:26:34.083672
NCT01001364|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2011-06-27|2009-10-23|2009-10-26|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2010||2010-02-28|June 2010|2010-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|CAINAS||A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma|A Phase III, Randomized, Open-Label, Non-Inferiority Comparative Study Between Foraseq Inhalation Capsules 12/200 µg And Formoterol/ Budesonide Inhalation Capsules 12/200 µg Eurofarma In Patients With Asthma|Completed||Phase 3|88|Actual|Eurofarma Laboratorios S.A.||2|||f||||t||||||||||2018-06-01 00:26:36.488146|2018-06-01 00:26:36.488146
NCT01001351|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22||2014-04-02|2015-04-08|2009-10-23|2009-10-26|Estimate||||2014-04-02|2014-04-30|Estimate|2015-04-08|2015-04-30|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PRT-201-102||A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease|Completed||Phase 1/Phase 2|89|Actual|Proteon Therapeutics||2|||f||||t||||||||||2018-06-01 00:26:36.555404|2018-06-01 00:26:36.555404
NCT01001338|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22||2014-01-07|2017-01-23|2009-10-23|2009-10-26|Estimate||||2014-02-05|2014-03-07|Estimate|2017-01-23|2017-01-24|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|January 2011|Actual|2011-01-31||Interventional|RDEA594-203||Allopurinol Combination Study|Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients With an Inadequate Hypouricemic Response With Standard Doses of Allopurinol|Completed||Phase 2|227|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-06-01 00:26:36.74548|2018-06-01 00:26:36.74548
NCT01001325|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2011-05-13||2012-04-18|2009-10-23|2009-10-26|Estimate|2011-05-13|2011-06-15|Estimate||||2012-04-18|2012-04-20|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?|A Randomized Controlled Trial of the Effect of Seasonal Influenza Vaccination on the Incidence of Infection Due to the 2009 H1N1 Influenza|Completed||Phase 3|468|Actual|Mount Sinai Hospital, Canada|A major limitation to this study was the date of enrolment for the subjects: only 249 (53%) of the subjects were enrolled by the end of second wave of the pandemic (and a third wave did not occur before the end of the study).|2|||f||||t||||||||||2018-06-01 00:26:36.929934|2018-06-01 00:26:36.929934
NCT01001312|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2015-10-08|2009-10-22|2009-10-26|Estimate|||||||2015-10-08|2015-10-09|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|TEAM-HF||Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure|Treating to Euvolemia by Clinical Assessment and Measured Blood Volume in Heart Failure|Terminated||Phase 4|22|Actual|New York University School of Medicine||2||Poor enrollment|f||||t||||||||||2018-06-01 00:26:37.176429|2018-06-01 00:26:37.176429
NCT01001299|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2015-07-27||2017-07-06|2009-10-23|2009-10-26|Estimate|2015-09-01|2015-10-05|Estimate||||2017-07-06|2017-08-15|Actual|November 30, 2009|Actual|2009-11-30|June 2017|2017-06-30|February 29, 2012|Actual|2012-02-29|February 29, 2012|Actual|2012-02-29||Interventional||Baseline analysis population included all enrolled participants.|A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma|"A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a Cocktail of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma"|Completed||Phase 1|25|Actual|Hoffmann-La Roche|The data for ‘Duration of Response’, ‘Time to Response’, and ‘PFS’ was not collected as the outcomes were removed as per changes in planned analysis (protocol amendment).|1|||f||||||||||||||2018-06-01 00:26:37.311627|2018-06-01 00:26:37.311627
NCT01001286|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2011-08-03|2009-10-23|2009-10-26|Estimate|||||||2011-08-03|2011-08-04|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|May 2010|Actual|2010-05-31||Interventional|QSNFEIS||Questscope Non-Formal Education Impact Study||Completed||Phase 2|200|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 00:26:37.919993|2018-06-01 00:26:37.919993
NCT01001273|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2011-03-25|2009-10-23|2009-10-26|Estimate|||||||2011-03-25|2011-03-28|Estimate|April 2010||2010-04-30|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|April 2012|Anticipated|2012-04-30||Interventional|||Hyperinsulinemic Normoglycemic Clamp for Pancreas and Simultaneous Pancreas/Kidney Transplant Recipients|Hyperinsulinemic Normoglycemic Clamp for Pancreas and Simultaneous Pancreas/Kidney Transplant Recipients|Unknown status|Recruiting|N/A|80|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-06-01 00:26:38.011952|2018-06-01 00:26:38.011952
NCT01001260|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2018-03-16|2009-10-22|2009-10-26|Estimate|||||||2018-03-16|2018-03-20|Actual|August 2007||2007-08-31|March 2018|2018-03-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Observational|PGD2||PGD2 Formation in Vascular Injury|Biosynthesis of PGD2 in Vascular Injury|Terminated|||51|Actual|University of Pennsylvania|||3|Unable to find subjects that met inclusion/exclusion criteria.|f||||f||||||Samples With DNA|"~     -  Specimens:~           3 urine collections will be obtained (Prior to PTCA, During PTCA and Post PTCA)~        -  Genetic Testing:~      analysis of the association of SNPs in Cox genes with variability in selectively or in the~     PGEs genes in quantitative biosynthesis of PGD2 and related compounds.~   "|||2018-06-01 00:26:38.163455|2018-06-01 00:26:38.163455
NCT01001247|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2010-07-08|2009-10-23|2009-10-26|Estimate|||||||2010-07-08|2010-07-09|Estimate|January 2010||2010-01-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers|A Phase I, Open Label, Randomized, 4-way Crossover Trial to Evaluate the Pharmacokinetics of TMC278 25mg and 50mg in the Presence of Omeprazole 20mg q.d., in Healthy Subjects|Completed||Phase 1|18|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 00:26:38.248921|2018-06-01 00:26:38.248921
NCT01001234|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2012-04-10||2017-05-11|2009-10-23|2009-10-26|Estimate|2012-04-10|2012-05-08|Estimate||||2017-05-11|2017-06-09|Actual|November 30, 2009|Actual|2009-11-30|May 2017|2017-05-31|April 21, 2011|Actual|2011-04-21|April 21, 2011|Actual|2011-04-21||Interventional|||A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)|A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents|Completed||Phase 3|1382|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:26:38.329163|2018-06-01 00:26:38.329163
NCT01001221|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|2013-05-20||2013-09-09|2009-10-23|2009-10-26|Estimate|2013-09-09|2013-09-11|Estimate||||2013-09-09|2013-09-11|Estimate|November 2009||2009-11-30|September 2013|2013-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor|A Dose-Escalation, Single Arm, Combination Study of Cabazitaxel With Gemcitabine to Determine The Safety, And Pharmacokinetics In Subjects With Advanced Solid Malignancies|Terminated||Phase 1/Phase 2|19|Actual|Sanofi|Pharmacokinetic results need to be confirmed due to the limited data available.|1||Maximum tolerated dose not able to be determined|f||||f||||||||||2018-06-01 00:26:38.810525|2018-06-01 00:26:38.810525
NCT01001208|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2011-12-21||2013-07-10|2009-10-22|2009-10-26|Estimate|2013-07-10|2013-08-12|Estimate||||2013-07-10|2013-08-12|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|478|Actual|Amgen||2|||f||||||||||||||2018-06-01 00:26:40.861467|2018-06-01 00:26:40.861467
NCT01001195|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2013-08-13|2011-05-03|2013-08-13|2009-10-23|2009-10-26|Estimate|2013-08-13|2013-10-18|Estimate|2011-05-03|2011-05-05|Estimate|2013-08-13|2013-10-18|Estimate|November 2009||2009-11-30|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution||Completed||Phase 2|165|Actual|Allergan||4|||f||||f||||||||||2018-06-01 00:26:41.39554|2018-06-01 00:26:41.39554
NCT01001182|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-23|||2014-07-25|2009-10-23|2009-10-26|Estimate|||||||2014-07-25|2014-07-28|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|HORA||Health Outcomes in Rheumatoid Arthritis in Greece|Rheumatoid Arthritis in Greece: The Economic Burden of the Disease and the Impact on Quality of Life|Completed|||210|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:26:41.682837|2018-06-01 00:26:41.682837
NCT01001169|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2017-03-14|2010-07-02|2017-03-22|2009-10-22|2009-10-23|Estimate|2017-03-22|2017-05-02|Actual|2010-07-02|2010-07-07|Estimate|2017-03-22|2017-05-02|Actual|October 2009||2009-10-31|March 2017|2017-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years|Completed||Phase 2|60|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:26:41.852867|2018-06-01 00:26:41.852867
NCT01001156|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-10-22|2009-10-22|2009-10-23|Estimate|||||||2009-10-22|2009-10-23|Estimate|October 2008||2008-10-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Effects of the Breathing Muscular Training of Institutionalized Elderly|Effects of the Breathing Muscular Training to Volume and the Pressure in MIP and MEP of Institutionalized Elderly|Completed||Phase 2/Phase 3|37|Actual|Universidade Camilo Castelo Branco|||||f||||t||||||||||2018-06-01 00:26:44.197975|2018-06-01 00:26:44.197975
NCT01001143|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2014-07-28|2009-10-22|2009-10-23|Estimate|||||||2014-07-28|2014-07-29|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|AML||Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)|A Phase I Dose Escalation Study of Intravenous Decitabine in Combination With Oral Bexarotene in Patients With Acute Myeloid Leukemia (AML)|Completed||Phase 1|19|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 00:26:44.270269|2018-06-01 00:26:44.270269
NCT01001130|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2014-06-26|2009-10-22|2009-10-23|Estimate|||||||2014-06-26|2014-06-30|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Regulatory AVAMYS Nasal Spray PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamys® Administered in Korean Patients According to the Prescribing Information|Completed|||3244|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:26:44.345429|2018-06-01 00:26:44.345429
NCT01001117|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2011-04-14|2009-10-22|2009-10-23|Estimate|||||||2011-04-14|2011-04-15|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|April 2011|Anticipated|2011-04-30|October 2009|Actual|2009-10-31||Interventional|||Laser Treatment of the Crystalline Lens|A Prospective Single-Center Clinical Trial to Evaluate the Feasibility of Laser Treatment of the Crystalline Lens in Subjects Having Elected to Undergo Lens Extraction and Intraocular Lens Implantation|Unknown status|Active, not recruiting|Phase 2/Phase 3|75|Actual|LensAR Incorporated||2|||f||||f||||||||||2018-06-01 00:26:44.413544|2018-06-01 00:26:44.413544
NCT01001104|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2014-10-03|2011-04-05|2015-08-28|2009-10-22|2009-10-23|Estimate|2015-08-28|2015-09-28|Estimate|2011-04-05|2011-04-13|Estimate|2015-08-28|2015-09-28|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of LY2189265 in Japanese Patients With Type 2 Diabetes|Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Japanese Patients With Type 2 Diabetes|Completed||Phase 2|145|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 00:26:44.512253|2018-06-01 00:26:44.512253
NCT01001091|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22||2014-07-15|2014-07-15|2009-10-22|2009-10-23|Estimate||||2014-07-15|2014-07-17|Estimate|2014-07-15|2014-07-17|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation||Completed||Phase 2|312|Actual|Alcon Research||5|||f||||f||||||||||2018-06-01 00:26:45.420406|2018-06-01 00:26:45.420406
NCT01001078|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2014-01-26||2015-01-13|2009-10-22|2009-10-23|Estimate|2015-01-13|2015-01-22|Estimate||||2015-01-13|2015-01-22|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||Since previous studies on SAD had found SD values for leak pressure around seven cmH2O, it was estimated that fifty patients per group would allow us to find a difference just under four cmH2O between groups with an alpha error = 0.05 and a power of 80%.|Comparison Study of Two Supraglottic Airway Devices Used for Patients Under General Anesthesia|Prospective Randomized Trial Comparing the Performance of Two Supraglottic Airway Management Devices: I-Gel and Supreme LMA|Completed||N/A|100|Actual|Maisonneuve-Rosemont Hospital||3|||f||||f||||||||||2018-06-01 00:26:45.535875|2018-06-01 00:26:45.535875
NCT01001065|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-06-28|2009-10-22|2009-10-23|Estimate|||||||2010-06-28|2010-06-29|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|October 2010||2010-10-31|||||Observational|||Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis||Unknown status|Recruiting||160|Anticipated|University of Zurich|||||f||||||||||||||2018-06-01 00:26:45.894285|2018-06-01 00:26:45.894285
NCT01001052|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2010-08-11||2010-09-24|2009-10-22|2009-10-23|Estimate|2010-08-11|2010-09-14|Estimate||||2010-09-24|2010-09-28|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Relative Bioavailability of Colcrys™ 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions|Relative Bioavailability of Colcrys™ (Colchicine, USP) 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions|Completed||Phase 1|38|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:26:45.957858|2018-06-01 00:26:45.957858
NCT01001039|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2012-06-27|2009-10-22|2009-10-23|Estimate|||||||2012-06-27|2012-06-29|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|July 2011|Actual|2011-07-31||Observational|FACE PAIN||Validation of the Facial and Cephalic Pain Inventory|Validation of the FAcial and CEphalic PAin INventory (FACE PAIN)|Completed|||68|Actual|University of Washington|||2||f||||f||||||||||2018-06-01 00:26:46.182365|2018-06-01 00:26:46.182365
NCT01001026|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2015-04-08|2009-10-22|2009-10-23|Estimate|||||||2015-04-08|2015-04-10|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Aboriginal Children and Adults|Completed||Phase 4|156|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:26:46.237499|2018-06-01 00:26:46.237499
NCT01001013|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2010-11-30|2009-10-22|2009-10-23|Estimate|||||||2010-11-30|2010-12-02|Estimate|February 2009||2009-02-28|November 2010|2010-11-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction of LC15-0444 and Pioglitazone After Oral Administration in Healthy Male Subjects|Completed||Phase 1|24|Anticipated|LG Life Sciences||3|||f||||f||||||||||2018-06-01 00:26:46.3068|2018-06-01 00:26:46.3068
NCT01001000|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-06-28|2009-10-22|2009-10-23|Estimate|||||||2010-06-28|2010-06-29|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|October 2010||2010-10-31|||||Observational|||Colour Coded Duplex Ultrasound of Native Arterio-venous Fistula for Haemodialysis With Venous Pressure Measurement Using Controlled Compression Ultrasound as a Predictor for Shunt Maturation in the Early Postoperative Phase||Unknown status|Recruiting||40|Anticipated|University of Zurich|||||f||||t||||||||||2018-06-01 00:26:46.557205|2018-06-01 00:26:46.557205
NCT01000987|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2017-11-20||2018-01-22|2009-10-22|2009-10-23|Estimate|2018-01-22|2018-02-16|Estimate||||2018-01-22|2018-02-16|Estimate|October 2009||2009-10-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders|Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders|Completed||Phase 2|44|Actual|Yale University||2|||f||||t||||||||||2018-06-01 00:26:46.627936|2018-06-01 00:26:46.627936
NCT01000974|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2013-04-11||2017-08-29|2009-10-22|2009-10-23|Estimate|2013-08-15|2013-08-19|Estimate||||2017-08-29|2017-09-26|Actual|June 18, 2010||2010-06-18|August 2017|2017-08-31|July 17, 2013|Actual|2013-07-17|November 18, 2011|Actual|2011-11-18||Interventional|||Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants|Phase III, Partially Double-blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals' Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants|Completed||Phase 3|4003|Actual|GlaxoSmithKline|Anti-HBs antibody concentration cut off defining seropositivity was based on 6.2 mIU/mL instead of 3.3 mIU/mL for the pre-booster vaccination phase as tested by the commercial assay Centaur|3|||f||||||||||||||2018-06-01 00:26:47.012397|2018-06-01 00:26:47.012397
NCT01000961|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2012-11-02||2017-04-11|2009-10-22|2009-10-23|Estimate|2014-11-18|2014-11-19|Estimate||||2017-04-11|2017-05-19|Actual|June 2010||2010-06-30|April 2017|2017-04-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional||There were 39 participants analyzed for Cystagon®; and there were 37 participants analyzed for RP103.|Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis|A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis|Completed||Phase 3|43|Actual|Horizon Pharma USA, Inc.||2|||f||||f||||||||||2018-06-01 00:26:48.828693|2018-06-01 00:26:48.828693
NCT01000948|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2014-01-07|2009-10-22|2009-10-23|Estimate|||||||2014-01-07|2014-01-08|Estimate|October 2009||2009-10-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DAPROCA-1||A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer|An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer|Terminated||Phase 2|24|Actual|Aarhus University Hospital||1||A consequence of the results of the ENTHUSE phase III study program|f||||t||||||||||2018-06-01 00:26:49.174645|2018-06-01 00:26:49.174645
NCT01000935|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2015-05-04|2009-10-22|2009-10-23|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Impact of Autologous Platelet Rich Plasma on Healing of Rotator Cuff Repairs|Impact of Autologous Platelet Rich Plasma on Enhancing Repair of Rotator Cuff Tendons: A Multicentre Randomized Controlled Trial|Completed||Phase 2/Phase 3|92|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 00:26:49.248385|2018-06-01 00:26:49.248385
NCT01000922|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21||2015-07-28|2015-07-28|2009-10-22|2009-10-23|Estimate||||2015-07-28|2015-07-29|Estimate|2015-07-28|2015-07-29|Estimate|June 2006||2006-06-30|July 2015|2015-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro|A Single Center, Randomized, Open-Label, Crossover Study, Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro Either in Combination With a Basal Insulin Infusion or With Insulin Glargine Relative to a Standardized Meal in Patients With Type 1 Diabetes|Completed||Phase 2|24|Actual|Biodel||6|||f||||f||||||||||2018-06-01 00:26:49.331963|2018-06-01 00:26:49.331963
NCT01000909|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-06-28|2009-10-22|2009-10-23|Estimate|||||||2010-06-28|2010-06-29|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|July 2010||2010-07-31|||||Observational|||Venous Pressure Measurement of the Great Saphenous Vein Using Controlled Compression Ultrasound in Healthy Persons and Patients With Chronic Venous Disease as a New Non Invasive Method for Investigation of the Pathophysiology in Primary Varicose Veins||Unknown status|Recruiting||60|Anticipated|University of Zurich|||||f||||||||||||||2018-06-01 00:26:49.408716|2018-06-01 00:26:49.408716
NCT01000896|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2010-02-03|2009-10-22|2009-10-23|Estimate|||||||2010-02-03|2010-02-04|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|September 2010|Anticipated|2010-09-30||Interventional|||Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel|A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies|Withdrawn||Phase 1|27|Anticipated|AstraZeneca||1||"AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical~   studies will be initiated.."|f||||t||||||||||2018-06-01 00:26:49.464206|2018-06-01 00:26:49.464206
NCT01000883|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2017-10-24|2009-10-22|2009-10-23|Estimate|||||||2017-10-24|2017-10-26|Actual|December 1, 1998|Actual|1998-12-01|September 2017|2017-09-30|November 2022|Anticipated|2022-11-30|November 2020|Anticipated|2020-11-30||Observational|||Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior|Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior|Recruiting|||1000|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||Samples With DNA|"~     Primary tumor and metastatic site tumor tissue; whole blood~   "|||2018-06-01 00:26:49.546554|2018-06-01 00:26:49.546554
NCT01000870|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-10-05|2009-10-22|2009-10-23|Estimate|||||||2010-10-05|2010-10-06|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513|An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate Efficacy & Safety of MNI-513 Positron Emission Tomography for Detection/Exclusion of Cerebral Amyloid Beta in Patients w/ Alzheimer Disease Compared to Healthy Volunteers|Terminated||Early Phase 1|6|Actual|Institute for Neurodegenerative Disorders||1||Results did not show reason to continue with study|f||||f||||||||||2018-06-01 00:26:49.61433|2018-06-01 00:26:49.61433
NCT01000857|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2018-05-17|2009-10-22|2009-10-23|Estimate|||||||2018-05-17|2018-05-21|Actual|November 5, 2009|Actual|2009-11-05|May 2018|2018-05-31|February 25, 2010|Actual|2010-02-25|February 25, 2010|Actual|2010-02-25||Interventional|||Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects|A Steady-state, Two-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Repeated Daily Dosing of the Controlled-release Paroxetine Tablet (25 mg) With That of the Standard Immediate-release Paroxetine Tablet (20 mg) in Healthy Japanese Male Subjects|Completed||Phase 1|26|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:26:49.748417|2018-06-01 00:26:49.748417
NCT01000844|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2017-06-22|2009-10-22|2009-10-23|Estimate|||||||2017-06-22|2017-06-26|Actual|November 2009||2009-11-30|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|JOSC||Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency|Continuation of Children Enrolled in Protocol #95-011, 'A Randomized Prospective Study for the Prevention of Joint Disease in Children With Severe Factor VIII Deficiency'|Enrolling by invitation|||50|Anticipated|University of Colorado, Denver|||||f||||t||||||Samples With DNA|"~     Whole Blood - EDTA, Citrate Plasma, and DNA~   "|||2018-06-01 00:26:49.82792|2018-06-01 00:26:49.82792
NCT01000831|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2015-04-14|2009-10-22|2009-10-23|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine After One andTtwo Doses in Young Children|Completed||Phase 4|167|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 00:26:49.895603|2018-06-01 00:26:49.895603
NCT01000818|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2010-03-10||2017-02-14|2009-10-22|2009-10-23|Estimate|2010-05-03|2010-05-28|Estimate||||2017-02-14|2017-03-21|Actual|June 2008||2008-06-30|February 2017|2017-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)|An Open-Label, 3-Period, Fixed-Sequence Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 Pharmacokinetics in HIV-Infected Patients on a Stable MK0518-Containing Regimen|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:26:49.991641|2018-06-01 00:26:49.991641
NCT01000805|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2011-10-05||2011-12-08|2009-10-22|2009-10-23|Estimate|2011-12-08|2012-01-13|Estimate||||2011-12-08|2012-01-13|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms|A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients With Major Depressive Disorder and Associated Painful Physical Symptoms|Completed||Phase 4|528|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:26:50.235088|2018-06-01 00:26:50.235088
NCT01000792|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2011-06-21|2009-10-22|2009-10-23|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2009||2009-11-30|June 2011|2011-06-30|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|LevoNasalFlo||3-D Visualization of the Anti-Obstructive Effect of Levocetirizine|3-D Visualization of the Anti-Obstructive Effect of Levocetirizine - A Monocentric Clinical Trail With One Patient (Phase-IV-Study)|Completed||Phase 3|1|Actual|Clinical Research International Limited||1|||f||||f||||||||||2018-06-01 00:26:51.168389|2018-06-01 00:26:51.168389
NCT01000779|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-12-21|2009-10-22|2009-10-23|Estimate|||||||2010-12-21|2010-12-22|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)|Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial|Completed||Phase 3|100|Anticipated|Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-06-01 00:26:51.232345|2018-06-01 00:26:51.232345
NCT01000766|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2017-04-15|2009-10-22|2009-10-23|Estimate|||||||2017-04-15|2017-04-18|Actual|September 2009|Actual|2009-09-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury|Identification of New Biomarkers of Drug Induced Liver Injury|Completed|||25|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-06-01 00:26:51.301965|2018-06-01 00:26:51.301965
NCT01000753|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2017-12-11|2009-10-22|2009-10-23|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2005||2005-05-31|December 2017|2017-12-31|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma|Rare And Cutaneous Non-Hodgkin Lymphoma Registry|Active, not recruiting|||250|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tumor tissue, bone marrow, blood~   "|||2018-06-01 00:26:51.37601|2018-06-01 00:26:51.37601
NCT01000740|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2010-05-20|2009-10-22|2009-10-23|Estimate|||||||2010-05-20|2010-05-21|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa|An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa|Completed||Phase 4|59|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:26:51.724217|2018-06-01 00:26:51.724217
NCT01000727|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2017-06-09|2014-09-11|2017-07-12|2009-10-22|2009-10-23|Estimate|2017-07-12|2017-08-10|Actual|2014-09-11|2014-09-22|Estimate|2017-07-12|2017-08-10|Actual|December 1, 2009||2009-12-01|June 2017|2017-06-30|April 24, 2014|Actual|2014-04-24|April 1, 2014|Actual|2014-04-01||Interventional|SOLID-TIMI 52||The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial|A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).|Completed||Phase 3|13026|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:26:52.056173|2018-06-01 00:26:52.056173
NCT01000714|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2009-10-22|2009-10-22|2009-10-23|Estimate|||||||2009-10-22|2009-10-23|Estimate||||October 2009|2009-10-31||||||||Interventional|||Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis||Completed||Phase 2|||Etwal Ltd.|||||f||||||||||||||2018-06-01 00:26:59.385698|2018-06-01 00:26:59.385698
NCT01000701|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2016-09-08|2009-10-22|2009-10-23|Estimate|||||||2016-09-08|2016-09-09|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|SPUM-ACS||Inflammation and Acute Coronary Syndromes|Inflammation and Acute Coronary Syndromes (ACS) - Novel Strategies for Prevention and Clinical Management|Recruiting|||4000|Anticipated|University of Zurich|||||f||||t||||||Samples With DNA|"~     Blood, Thrombus, blood cells, urine~   "|||2018-06-01 00:26:59.449252|2018-06-01 00:26:59.449252
NCT01000688|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2010-11-04|2009-10-22|2009-10-23|Estimate|||||||2010-11-04|2010-11-05|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Vildagliptin and Endothelium-dependent Vasodilatation|The Effect of Vildagliptin on Endothelium-dependent Vasodilatation. A Double Blind Cross-over Study in Type 2 Diabetes Mellitus.|Completed||Phase 3|16|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 00:26:59.619471|2018-06-01 00:26:59.619471
NCT01000675|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2016-03-17|2009-10-22|2009-10-23|Estimate|||||||2016-03-17|2016-03-18|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|Gel-the-nec||Registry for Study of Coils in Intracranial Aneurysms|Gaining Efficacy Long Term: Hydrosoft, an Emerging, New, Embolic Coil (Gel-the-nec)|Unknown status|Active, not recruiting||114|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 00:26:59.691656|2018-06-01 00:26:59.691656
NCT01000662|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2015-05-12||2017-08-24|2009-10-22|2009-10-23|Estimate|2015-05-13|2015-05-29|Estimate||||2017-08-24|2017-09-25|Actual|March 2009||2009-03-31|August 2017|2017-08-31|June 14, 2017|Actual|2017-06-14|July 2012|Actual|2012-07-31||Interventional|||Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor|Phase III Study Comparing Whole Breast Radiotherapy With a Daily Tumor Red Boost|Completed||Phase 3|412|Actual|New York University School of Medicine||2|||f||||t|f|t|f|f|f|||||2018-06-01 00:26:59.770318|2018-06-01 00:26:59.770318
NCT01000649|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2016-12-13|2012-09-11|2017-08-24|2009-10-22|2009-10-23|Estimate|2017-04-28|2017-06-02|Actual|2012-09-11|2012-09-12|Estimate|2017-08-24|2017-09-25|Actual|November 2009||2009-11-30|August 2017|2017-08-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional||Analysis population consist of FAS.|Effects of the V1a Agonist FE 202158 in Patients With Septic Shock|Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock|Completed||Phase 2|53|Actual|Ferring Pharmaceuticals||4|||f||||t||||||||||2018-06-01 00:27:00.147123|2018-06-01 00:27:00.147123
NCT01000636|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2012-02-23|2009-10-22|2009-10-23|Estimate|||||||2012-02-23|2012-02-24|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)|Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT|Completed||Phase 4|9|Actual|Galderma||1|||f||||f||||||||||2018-06-01 00:27:02.216171|2018-06-01 00:27:02.216171
NCT01000623|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2016-12-15|2009-10-22|2009-10-23|Estimate|||||||2016-12-15|2016-12-16|Estimate|November 2009||2009-11-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|November 2012|Actual|2012-11-30||Interventional|||Venlafaxine and Hypnosis or Focused Attention In Treating Patients With Hot Flashes|Evaluation of a Biobehavioral Intervention for Hot Flashes|Withdrawn||N/A|0|Actual|Mayo Clinic||4|||f||||t||||||||||2018-06-01 00:27:02.296177|2018-06-01 00:27:02.296177
NCT01000610|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2015-02-27||2017-07-07|2009-10-22|2009-10-23|Estimate|2015-03-17|2015-03-19|Estimate||||2017-07-07|2017-08-16|Actual|March 17, 2008|Actual|2008-03-17|June 2017|2017-06-30|May 16, 2012|Actual|2012-05-16|May 16, 2012|Actual|2012-05-16||Interventional||Intent-to-Treat (ITT) population: All participants who received any part of an infusion have been included in the ITT analysis. Participants who prematurely withdrew from the study for any reason and for whom an assessment was not performed for whatever reason, were still included in the ITT analyses.|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate|Completed||Phase 4|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:27:02.454749|2018-06-01 00:27:02.454749
NCT01000597|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2017-06-21|2009-10-22|2009-10-23|Estimate|||||||2017-06-21|2017-06-22|Actual|September 17, 2009|Actual|2009-09-17|June 2017|2017-06-30|December 23, 2009|Actual|2009-12-23|December 23, 2009|Actual|2009-12-23||Interventional|||Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects|An Open-label, Randomised, Two-way Crossover Study, to Evaluate and Compare the Pharmacokinetics of Fluticasone Furoate, Administered From a Novel Dry Powder Device (Repeat Dose) and Intravenously (Single Dose), in Healthy Caucasian, Japanese, Korean and Chinese Subjects|Completed||Phase 1|80|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:27:02.63913|2018-06-01 00:27:02.63913
NCT01000584|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2015-04-08|2009-10-22|2009-10-23|Estimate|||||||2015-04-08|2015-04-10|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine|PCIRN Evaluation of Pandemic H1N12009 Influenza Vaccine in Adults, Including Randomized Comparison of Concurrent or Delayed Seasonal Influenza Vaccination|Completed||Phase 4|309|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:27:02.801263|2018-06-01 00:27:02.801263
NCT01000571|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2011-10-05|2009-10-22|2009-10-23|Estimate|||||||2011-10-05|2011-10-07|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults|Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults|Completed|||104|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples With DNA|"~     Blood sample collection will be done according to the description provided in the~     institutional policy manual. When possible, blood draws will be made through existing~     implanted catheters. If the research participant does not have a catheter, a peripheral~     venipuncture will be performed. Serum and whole blood for immune assays will be frozen at~     -20ºC or in liquid nitrogen until processed in batched assays.~   "|||2018-06-01 00:27:02.883125|2018-06-01 00:27:02.883125
NCT01000558|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2013-05-17|2009-10-22|2009-10-23|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 2005||2005-03-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma|Central Lymphoma Serum Repository Protocol|Completed|||939|Actual|Southwest Oncology Group|||||f||||f||||||Samples With DNA|"~     blood and serum for patients consenting to banking on lymphoma treatment studies~   "|||2018-06-01 00:27:02.978059|2018-06-01 00:27:02.978059
NCT01000545|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2009-10-29|2009-10-22|2009-10-23|Estimate|||||||2009-10-29|2009-10-30|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|December 2012|Anticipated|2012-12-31|January 2011|Anticipated|2011-01-31||Interventional|DEFINE||The Efficacy and Safety Study of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease|The Efficacy and Safety of Sulodexide in Filipino Diabetic Patients With Chronic Kidney Disease: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|1508|Anticipated|Corbridge Group Philippines, Inc.||4|||f||||t||||||||||2018-06-01 00:27:03.280978|2018-06-01 00:27:03.280978
NCT01000532|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2011-11-15|2009-10-22|2009-10-23|Estimate|||||||2011-11-15|2011-11-16|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Observational|||SIELLO Pilot Study for Comparison of Steroid Versus Non-Steroid Pacing Leads|Pilot Study to Compare Steroid (SIELLO T/JT) Versus Non-Steroid Pacing Leads (BPPU T/JT)|Completed|||88|Actual|Biotronik SE & Co. KG|||1||f||||f||||||||||2018-06-01 00:27:03.380468|2018-06-01 00:27:03.380468
NCT01000519|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2017-02-08|2009-10-21|2009-10-23|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2002||2002-12-31|February 2017|2017-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Effects of Different Mode of Exercise Training on Type 2 Diabetes|Differential Effects of Aerobic Versus Progressive Resistance Training on Metabolic Profile and Fitness in Older Adults With Diabetes Mellitus - a Randomized Controlled Trial|Completed||N/A|60|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-06-01 00:27:03.444819|2018-06-01 00:27:03.444819
NCT01000506|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2015-11-09|2012-11-15|2018-01-18|2009-10-22|2009-10-23|Estimate|2016-01-07|2016-02-05|Estimate|2012-11-15|2012-11-20|Estimate|2018-01-18|2018-01-24|Actual|November 1, 2009||2009-11-01|January 2018|2018-01-31|March 23, 2012|Actual|2012-03-23|March 23, 2012|Actual|2012-03-23||Interventional|DREAM||Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma|Completed||Phase 2|621|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:27:03.794621|2018-06-01 00:27:03.794621
NCT01000493|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2017-03-31|2012-02-23|2017-08-31|2009-10-22|2009-10-23|Estimate|2017-08-31|2017-09-01|Actual|2012-02-23|2012-02-27|Estimate|2017-08-31|2017-09-01|Actual|November 2, 2009|Actual|2009-11-02|July 2017|2017-07-31|June 28, 2010|Actual|2010-06-28|June 28, 2010|Actual|2010-06-28||Interventional|||Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study Evaluating the Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Orvepitant (GW823296) in Post Traumatic Stress Disorder (PTSD)|Completed||Phase 2|132|Actual|GlaxoSmithKline|The study was prematurely terminated on 11 May 2010 upon the recommendation of the Data Safety Monitoring Board.|2|||f||||t|t|f||||||||2018-06-01 00:27:05.344552|2018-06-01 00:27:05.344552
NCT01000480|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2013-11-12||2014-03-05|2009-10-22|2009-10-23|Estimate|2013-11-12|2014-01-01|Estimate||||2014-03-05|2014-04-02|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional||Intent-to-treat population: participants who received at least 1 dose of study drug (pemetrexed or cisplatin).|A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer|Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin With Concurrent Thoracic Radiotherapy, in Patients With Unresectable, Locally Advanced, Stage III, Nonsquamous Non-Small Cell Lung Cancer|Completed||Phase 2|90|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:27:06.632623|2018-06-01 00:27:06.632623
NCT01000467|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-21|2009-10-21|2009-10-23|Estimate|||||||2009-10-21|2009-10-23|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetics Study for Probucol|A Randomized, Open-label, Single-center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Probucol by Multiple Administration in Healthy Male Subjects|Completed||Phase 4|30|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-06-01 00:27:06.957405|2018-06-01 00:27:06.957405
NCT01000454|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-10-22|2009-10-22|2009-10-23|Estimate|||||||2009-10-22|2009-10-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:27:07.030875|2018-06-01 00:27:07.030875
NCT01000441|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-06-25|2009-10-22|2009-10-23|Estimate|||||||2010-06-25|2010-06-28|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|ROC||Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis|Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis|Unknown status|Recruiting|Phase 4|300|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 00:27:07.070286|2018-06-01 00:27:07.070286
NCT01000428|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2009-10-23|2009-10-22|2009-10-23|Estimate|||||||2009-10-23|2009-10-27|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|December 2011|Anticipated|2011-12-31|May 2010|Anticipated|2010-05-31||Observational|||The Role of Positron Emission Tomography (PET) During Erlotinib Treatment for Non-small Cell Lung Cancer|The Role of PET During Erlotinib Treatment to See the Responsiveness of Tumor Early in Patients With Non-small Cell Lung Cancer|Unknown status|Recruiting||34|Anticipated|Asan Medical Center|||||f||||||||||||||2018-06-01 00:27:07.449836|2018-06-01 00:27:07.449836
NCT01000415|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2010-06-23|2009-10-22|2009-10-23|Estimate|||||||2010-06-23|2010-06-24|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|June 2018|Anticipated|2018-06-30|September 2013|Anticipated|2013-09-30||Interventional|TGOCphaseIII||Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients|Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma|Recruiting||Phase 3|824|Anticipated|Thai Gynecologic Oncology Collaborative Group||1|||f||||t||||||||||2018-06-01 00:27:07.515056|2018-06-01 00:27:07.515056
NCT01000402|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2009-10-22|2009-10-22|2009-10-23|Estimate|||||||2009-10-22|2009-10-23|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|November 2014|Anticipated|2014-11-30|October 2012|Anticipated|2012-10-31||Interventional|ProCAB||Juvenile Bipolar Disorder Outpatient Program|Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder|Unknown status|Recruiting|Phase 4|150|Anticipated|Federal University of Rio Grande do Sul||1|||f||||t||||||||||2018-06-01 00:27:07.606555|2018-06-01 00:27:07.606555
NCT01000389|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2011-06-07|2009-10-22|2009-10-23|Estimate|||||||2011-06-07|2011-06-08|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Clinical Trial of the Optimal Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism||Completed||N/A|23|Actual|Medotech A/S|||||f||||f||||||||||2018-06-01 00:27:07.71836|2018-06-01 00:27:07.71836
NCT01000376|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2011-12-22||2013-09-19|2009-10-22|2009-10-23|Estimate|2013-09-19|2013-09-23|Estimate||||2013-09-19|2013-09-23|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors|An Open-Label, Phase I Study to Evaluate the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 00:27:07.788802|2018-06-01 00:27:07.788802
NCT01000363|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2014-07-07|2009-10-22|2009-10-23|Estimate|||||||2014-07-07|2014-07-09|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Diabetes Group Visits|Diabetes Medical Group Visits Pilot Study|Completed|||92|Actual|Emory University|||2||f||||f||||||||||2018-06-01 00:27:08.188566|2018-06-01 00:27:08.188566
NCT01000350|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2017-07-12|2009-10-22|2009-10-23|Estimate|||||||2017-07-12|2017-07-17|Actual|October 2009||2009-10-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)|Intravenous Saline on Exercise Tolerance in Orthostatic Intolerance|Active, not recruiting||N/A|40|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 00:27:08.252005|2018-06-01 00:27:08.252005
NCT01000337|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2012-05-07||2017-04-18|2009-10-22|2009-10-23|Estimate|2012-08-12|2012-09-11|Estimate||||2017-04-18|2017-05-19|Actual|October 2009||2009-10-31|April 2017|2017-04-30|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|||Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol|The Impact of Sevoflurane and Propofol Anesthesia on Hepatic Apoptosis Markers|Completed||N/A|67|Actual|University of Athens|The study was accomplished with no problems leading to data questioning.|2|||f||||f||||||||No||2018-06-01 00:27:08.322809|2018-06-01 00:27:08.322809
NCT01000324|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2010-12-14||2015-10-19|2009-10-22|2009-10-23|Estimate|2010-12-14|2011-01-13|Estimate||||2015-10-19|2015-11-20|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix™ Adult|An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-028 (208127/021) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.|Completed||Phase 4|44|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/ml). The table shows updated results following partial or complete retesting/reanalysis.|1|||f||||||||||||||2018-06-01 00:27:08.564155|2018-06-01 00:27:08.564155
NCT01000311|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|2013-08-22|2011-12-13|2014-04-03|2009-10-22|2009-10-23|Estimate|2014-02-06|2014-03-26|Estimate|2011-12-13|2011-12-22|Estimate|2014-04-03|2014-04-21|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Analysis was performed on all enrolled subjects.|A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months|A Phase 3, Randomized, Open Label, Controlled Multicenter Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months|Completed||Phase 3|529|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:27:08.875763|2018-06-01 00:27:08.875763
NCT01000298|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2011-07-01|2009-10-22|2009-10-23|Estimate|||||||2011-07-01|2011-07-06|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition|Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Oral Antibiotics in the Community-based Treatment of Severe Acute Malnutrition in Malawian Children|Completed||N/A|2700|Anticipated|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 00:27:09.871926|2018-06-01 00:27:09.871926
NCT01000285|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2016-10-19||2017-02-08|2009-10-22|2009-10-23|Estimate|2016-10-19|2016-12-13|Estimate||||2017-02-08|2017-03-28|Actual|September 2010||2010-09-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|May 2014|Actual|2014-05-31||Interventional|ATLL||EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma|Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma|Completed||Phase 1/Phase 2|18|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 00:27:09.997587|2018-06-01 00:27:09.997587
NCT01000272|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2014-06-25|2009-10-22|2009-10-23|Estimate|||||||2014-06-25|2014-06-26|Estimate|December 2009||2009-12-31|October 2009|2009-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Respiratory Tract Inflammation in Children With Inflammatory Bowel Disease (IBD)|Pulmonary Inflammation in Children With Inflammatory Bowel Disease as Expressed by the Fraction of Exhaled Nitric Oxide Levels and Spirometry|Completed|||45|Actual|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 00:27:10.539664|2018-06-01 00:27:10.539664
NCT01000259|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2017-05-02|2009-10-22|2009-10-23|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2004||2004-09-30|May 2017|2017-05-31||||January 2100|Anticipated|2100-01-31||Observational|||Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer|Validation of Tumor-Infiltrating T-Cells as a Biomarker for Advanced Epithelial Ovarian Cancer|Recruiting|||174|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-06-01 00:27:10.607404|2018-06-01 00:27:10.607404
NCT01000246|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2009-12-17|2009-10-22|2009-10-23|Estimate|||||||2009-12-17|2009-12-18|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|RIFLUVAC||Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy|Response to Influenza Virus Vaccination in Patients Immunocompromised Due to Chemotherapy|Completed||N/A|50|Anticipated|St. Antonius Hospital||3|||f||||f||||||||||2018-06-01 00:27:10.67876|2018-06-01 00:27:10.67876
NCT01000233|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-22|||2010-05-25|2009-10-22|2009-10-23|Estimate|||||||2010-05-25|2010-05-26|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|October 2012|Anticipated|2012-10-31|March 2012|Anticipated|2012-03-31||Interventional|CALCIFICA||Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications|Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications|Unknown status|Recruiting|Phase 2/Phase 3|250|Anticipated|Hospital Universitari Son Dureta||2|||f||||f||||||||||2018-06-01 00:27:10.768515|2018-06-01 00:27:10.768515
NCT01000220|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-05-03|2009-10-21|2009-10-22|Estimate|||||||2010-05-03|2010-05-04|Estimate||||October 2009|2009-10-31||||||||Interventional|||Evaluation of Omeprazole Effect on Glaucoma|Evaluation of Omeprazole Effect on Glaucoma|Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-06-01 00:27:10.876571|2018-06-01 00:27:10.876571
NCT01000207|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2016-11-30|2009-10-21|2009-10-22|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects|A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric Subjects|Completed||Phase 2/Phase 3|123|Actual|Novartis||2|||f||||f||||||||||2018-06-01 00:27:10.943782|2018-06-01 00:27:10.943782
NCT01000194|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-10-21|2009-10-21|2009-10-22|Estimate|||||||2009-10-21|2009-10-22|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|AFAST||Acute Fatty Acid Intervention Study (AFAST)|Acute Fatty Acid Intervention Study|Completed||N/A|21|Actual|Wageningen University||3|||f||||f||||||||||2018-06-01 00:27:11.024673|2018-06-01 00:27:11.024673
NCT01000181|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2012-04-05|2009-10-21|2009-10-22|Estimate|||||||2012-04-05|2012-04-06|Estimate|October 2012||2012-10-31|April 2012|2012-04-30||||||||Observational|||Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT|A Mechanistic, Non-randomised Study to Examine the Uptake of a Specific Radionuclide (61CuATSM) in Carotid Artery Plaque|Suspended|||10|Anticipated|King's College London|||1|Difficulty producing tracer|f||||f||||||||||2018-06-01 00:27:11.095128|2018-06-01 00:27:11.095128
NCT01000168|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-10-22|2009-10-21|2009-10-22|Estimate|||||||2009-10-22|2009-10-23|Estimate|November 2004||2004-11-30|October 2009|2009-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Treadmill Therapy and Brain Injuries|The Effect of Treadmill Therapy With Body Weight Support on Walking and Transfer in Patients With Moderate to Severe Ambulatory Deficits After Stroke|Completed||N/A|60|Actual|Sunnaas Rehabilitation Hospital||2|||f||||f||||||||||2018-06-01 00:27:11.16906|2018-06-01 00:27:11.16906
NCT01000155|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2015-09-09||2017-06-21|2009-10-21|2009-10-22|Estimate|2015-09-09|2015-10-08|Estimate||||2017-06-21|2017-07-21|Actual|October 2009||2009-10-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The analysis dataset is comprised of all treated patients.|Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease|A Phase II Pharmacodynamic Investigation of the Efficacy of Vorinostat to Induce Fetal Hemoglobin in Adults With Severe Sickle Cell Disease Who Have Not Benefitted From Prior Therapy|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|The trial did not meet it's accrual goal due to slow accrual.|1||The study terminated early due to slow accrual.|f||||t||||||||||2018-06-01 00:27:11.247048|2018-06-01 00:27:11.247048
NCT01000142|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-07-22|2009-10-21|2009-10-22|Estimate|||||||2011-07-22|2011-07-25|Estimate|October 2009||2009-10-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Preventative Osteopathic Manipulative Treatment (OMT) and the Nursing Home Patient|Preventative OMT and the Nursing Home Patient|Completed||Phase 3|22|Actual|A.T. Still University of Health Sciences||3|||f||||f||||||||||2018-06-01 00:27:11.434936|2018-06-01 00:27:11.434936
NCT01000129|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-21|2009-10-21|2009-10-22|Estimate|||||||2009-10-21|2009-10-22|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|APPLY||Adaptive Planning in Bladder Cancer|Adaptive - Predictive Planning for Hypofractionated Bladder Radiotherapy|Unknown status|Recruiting|Phase 2|32|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:27:11.509188|2018-06-01 00:27:11.509188
NCT01000116|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2012-04-12|2009-10-21|2009-10-22|Estimate|||||||2012-04-12|2012-04-13|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|||Fibrin Glue Versus Tacked Fixation in Groin Hernia Repair (TAPP)|Fibrin Glue Versus Tacked Fixation in Laparoscopic Groin Hernia Repair. A Randomized Double-blind Placebo-controlled Trial.|Completed||N/A|112|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-06-01 00:27:11.573439|2018-06-01 00:27:11.573439
NCT01000103|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2011-10-28|2009-10-21|2009-10-22|Estimate|||||||2011-10-28|2011-10-31|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|February 2014|Anticipated|2014-02-28|February 2013|Anticipated|2013-02-28||Interventional|NEGLECT||Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke|Using Repetitive Transcranial Magnetic Stimulation (rTMS) in the Rehabilitation of Chronic Spatial Neglect After Stroke: A Double Blind Study|Unknown status|Recruiting|Phase 3|148|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:27:11.651072|2018-06-01 00:27:11.651072
NCT01000090|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2015-12-02|2009-10-21|2009-10-22|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|February 2010|Actual|2010-02-28||Observational|||Surgical Versus Medical Treatment of Acromegaly|Surgical Versus Medical Treatment of Acromegaly: Effects on Biochemical Markers|Completed|||63|Actual|University of Aarhus|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 00:27:11.752577|2018-06-01 00:27:11.752577
NCT01000077|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2017-08-09|2009-10-21|2009-10-22|Estimate|||||||2017-08-09|2017-08-11|Actual|February 2009|Actual|2009-02-28|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Establishment of Cell Culture Systems From Discarded Operating Room Tissue|Establishment of Cell Culture Systems From Discarded Operating Room Tissue|Recruiting|||1000|Anticipated|Wake Forest University Health Sciences|||2||f|||||f|f||||Samples Without DNA|"~     Healthy and diseased tissue will be harvested from tissue routinely discarded in the NCBH~     operating rooms, or from delivery rooms at Forsyth Medical Center during routine operative or~     childbirth procedures~   "|||2018-06-01 00:27:11.805569|2018-06-01 00:27:11.805569
NCT01000064|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2015-12-22||2017-04-10|2009-10-21|2009-10-22|Estimate|2017-04-10|2017-05-19|Actual||||2017-04-10|2017-05-19|Actual|October 2009||2009-10-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|December 2013|Actual|2013-12-31||Interventional|||Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits|Psychostimulant Treatment of TBI-Related Attention Deficits: fMRI Analysis of Neural Mechanisms of Response|Terminated||Phase 3|22|Actual|Vanderbilt University Medical Center|Participant withdrawal during study leading to small numbers of participants analyzed.|2||unable to meet recruitment goals|f||||f||||||||||2018-06-01 00:27:11.874789|2018-06-01 00:27:11.874789
NCT01000051|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2018-04-23|2009-10-20|2009-10-22|Estimate|||||||2018-04-23|2018-04-25|Actual|February 17, 2010|Actual|2010-02-17|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|||Eltrombopag for Post Transplant Thrombocytopenia|Eltrombopag for Post Transplant Thrombocytopenia|Completed||Phase 2|64|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 00:27:12.142784|2018-06-01 00:27:12.142784
NCT01000038|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-10-23|2009-10-21|2009-10-22|Estimate|||||||2009-10-23|2009-10-27|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Wii-fit for Activity, Balance and Gait in Assisted Living|Wii-fit for Activity, Balance and Gait in Assisted Living|Unknown status|Recruiting|N/A|22|Anticipated|University of Nebraska||2|||f||||f||||||||||2018-06-01 00:27:12.207231|2018-06-01 00:27:12.207231
NCT01000025|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2014-09-19||2016-07-12|2009-10-21|2009-10-22|Estimate|2014-10-23|2014-10-27|Estimate||||2016-07-12|2016-08-12|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2013|Actual|2013-10-31||Interventional|||PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer|A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease|Completed||Phase 3|720|Actual|Canadian Cancer Trials Group|Despite the eligibility requirement for tumor samples, samples were not available or inadequate for translational studies in 30 - 40% of patients. This does limits the power of the secondary analyses examining biomarker driven outcomes.|2|||f||||t||||||||||2018-06-01 00:27:12.298307|2018-06-01 00:27:12.298307
NCT01000012|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2013-10-28|2009-10-21|2009-10-22|Estimate|||||||2013-10-28|2013-10-29|Estimate||||October 2013|2013-10-31||||||||Expanded Access|||Compassionate Use of the Becker Expander/Breast Implant|Compassionate Use of the Becker Expander/Breast Implant|No longer available|||||Mentor Worldwide, LLC|||||||||||||||||||2018-06-01 00:27:13.386556|2018-06-01 00:27:13.386556
NCT00999999|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2015-09-14|2009-10-21|2009-10-22|Estimate|||||||2015-09-14|2015-09-15|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy of Tachosil as Dural Sealant Compared to Standard Treatment|Fleece Bound Tissue Sealing With TachoSil® to Assist in Closing of the Dura Mater After Elective Craniotomy to Reduce Postoperative Cerebrospinal Fluid (CSF) Leakage.|Completed||Phase 4|241|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 00:27:13.447199|2018-06-01 00:27:13.447199
NCT00999986|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-11-24|2009-10-21|2009-10-22|Estimate|||||||2009-11-24|2009-11-25|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Low Dose Cyclophosphamide Treats Genital Warts|Phase III Study of the Treatment of Genital Warts by Low Dose Cyclophosphamide|Completed||Phase 3|104|Actual|Huazhong University of Science and Technology||2|||f||||f||||||||||2018-06-01 00:27:13.528311|2018-06-01 00:27:13.528311
NCT00999973|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-21|2009-10-21|2009-10-22|Estimate|||||||2009-10-21|2009-10-22|Estimate|September 2009||2009-09-30|October 2009|2009-10-31||||||||Interventional|||Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia|Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia|Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:27:13.614268|2018-06-01 00:27:13.614268
NCT00999960|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2017-04-13|2009-10-21|2009-10-22|Estimate|||||||2017-04-13|2017-04-14|Actual|February 2010|Actual|2010-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PERLE||Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator|A Prospective Randomized Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Online Simulator|Suspended||N/A|20|Anticipated|Assistance Publique - Hôpitaux de Paris||2||Decision of sponsor|f||||f||||||||||2018-06-01 00:27:13.684202|2018-06-01 00:27:13.684202
NCT00999947|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-11-21|2009-10-21|2009-10-22|Estimate|||||||2013-11-21|2013-11-25|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|DVDA||Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy|Genetic Study of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy|Completed|||351|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-06-01 00:27:13.76623|2018-06-01 00:27:13.76623
NCT00999934|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2017-01-10|2009-10-21|2009-10-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|June 2017|Anticipated|2017-06-30||Observational|||Neural Mechanisms Engaged in Control of Eye Movements||Unknown status|Recruiting||250|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-06-01 00:27:13.833341|2018-06-01 00:27:13.833341
NCT00999921|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2010-11-15||2015-04-28|2009-10-21|2009-10-22|Estimate|2015-04-10|2015-04-29|Estimate||||2015-04-28|2015-05-18|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer|A Single Blinded Randomized Controlled Trial of the Comparative Effects of Tamoxifen and Evening Primrose Oil in Premenopausal Non-high Risk Patients With Benign Breast Disease With Respect to the Estrogen Receptor Status.|Completed||Phase 4|256|Actual|Medical College and Hospital Kolkata||2|||f||||t||||||||||2018-06-01 00:27:13.913046|2018-06-01 00:27:13.913046
NCT00999908|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2011-07-22||2016-02-16|2009-10-21|2009-10-22|Estimate|2011-07-22|2011-08-19|Estimate||||2016-02-16|2016-02-17|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity|Multicenter, Randomized, Blinded, Placebo-controlled, Crossover, Single-dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||Phase 3|54|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:27:14.243101|2018-06-01 00:27:14.243101
NCT00999895|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-01-31|2009-10-21|2009-10-22|Estimate|||||||2011-01-31|2011-02-01|Estimate|October 2009||2009-10-31|January 2011|2011-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|ETOS||A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients|A Non-interventional, Prospective, Open-label Study for the Evaluation of the Selection and Outcome of the Antipsychotic Treatment Switch in Outpatients With Schizophrenia - ETOS Study|Completed|||574|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:27:14.450917|2018-06-01 00:27:14.450917
NCT00999882|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2012-07-09|2009-10-21|2009-10-22|Estimate|||||||2012-07-09|2012-07-10|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients|A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Tor Kinase Inhibitor (AZD8055) in Asian Patients With Advanced Stage Hepatocellular Carcinoma (HCC) and With Mild or Moderate Hepatic Impairment|Completed||Phase 1|26|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 00:27:14.570676|2018-06-01 00:27:14.570676
NCT00999869|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2012-08-06|2009-10-21|2009-10-22|Estimate|||||||2012-08-06|2012-08-07|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata|The Comparison Study of Intralesional Botulinum Toxin A and Corticosteroid Injection for Alopecia Areata|Unknown status|Recruiting|N/A|20|Anticipated|Siriraj Hospital||2|||f||||t||||||||||2018-06-01 00:27:14.762718|2018-06-01 00:27:14.762718
NCT00999856|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2015-02-24|2009-10-21|2009-10-22|Estimate|||||||2015-02-24|2015-02-25|Estimate|August 2008||2008-08-31|October 2011|2011-10-31|May 2013|Actual|2013-05-31|March 2012|Actual|2012-03-31||Interventional|||Investigation of a Sub-Conjunctival Insert|Investigation of a Sub-Conjunctival Insert|Terminated||Phase 2|28|Actual|EyeSense GmbH||5||Two cohorts successfully completed; further cohorts not needed; no safety issue!|f||||f||||||||||2018-06-01 00:27:14.875446|2018-06-01 00:27:14.875446
NCT00999843|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-10-21|2009-10-21|2009-10-22|Estimate|||||||2009-10-21|2009-10-22|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2012|Anticipated|2012-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer|Maintenance of Sorafenib Following Combined Therapy of Three-dimensional Conformal Radiation Therapy/Intensity-modulated Radiation Therapy and Transcatheter Arterial Chemoembolization in Patients With Locally Advanced Hepatocellular Carcinoma: a Phase I/II Study.|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Fudan University|||||f||||t||||||||||2018-06-01 00:27:14.960982|2018-06-01 00:27:14.960982
NCT00998621|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2015-10-14|2009-10-19|2009-10-20|Estimate|||||||2015-10-14|2015-10-16|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|January 2013|Actual|2013-01-31|September 2010|Actual|2010-09-30||Observational|ADHEPTA||ADHEPTA Study: Adherence Questionnaire in Hepatitis C|Development and Validation of a Questionnaire Measuring Treatment Adherence in Patients With Hepatitis C|Completed|||1120|Actual|Fundacion IMIM|||2||f||||f||||||||||2018-06-01 00:27:32.588169|2018-06-01 00:27:32.588169
NCT00999830|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2013-10-15||2016-02-23|2009-10-21|2009-10-22|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|REMYKIR||Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma|Randomised Phase II Study Evaluating the Anti-tumour Activity, Safety and Pharmacology of Two Dose Regimens of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy|Completed||Phase 2|27|Actual|Innate Pharma||2|||f||||t||||||||||2018-06-01 00:27:15.057919|2018-06-01 00:27:15.057919
NCT00999817|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-01-05|2009-10-21|2009-10-22|Estimate|||||||2010-01-05|2010-01-07|Estimate|November 2009||2009-11-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Pharmacokinetic (PK) Study Of PF-00299804 And Dextromethorphan In Healthy Volunteers|An Open Label Phase 1, Randomized Cross Over Trial To Estimate The Effect Of PF- 00299804 On The Pharmacokinetics Of Dextromethorphan In Healthy Volunteers|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:27:15.34087|2018-06-01 00:27:15.34087
NCT00999804|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2015-12-29||2017-02-02|2009-10-21|2009-10-22|Estimate|2016-10-19|2016-12-12|Estimate||||2017-02-02|2017-03-14|Actual|October 2011||2011-10-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|November 2014|Actual|2014-11-30||Interventional|HELEX||Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy|TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer|Active, not recruiting||Phase 2|128|Actual|Baylor Breast Care Center||2|||f||||t||||||||No||2018-06-01 00:27:15.430745|2018-06-01 00:27:15.430745
NCT00999791|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-05-03|2009-10-21|2009-10-22|Estimate|||||||2010-05-03|2010-05-04|Estimate|July 2009||2009-07-31|October 2009|2009-10-31||||||||Interventional|||Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema||Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:27:15.809815|2018-06-01 00:27:15.809815
NCT00999778|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2012-08-14|2009-10-21|2009-10-22|Estimate|||||||2012-08-14|2012-08-16|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Optimizing Social and Communication Outcomes for Toddlers With Autism|Optimizing Social and Communication Outcomes for Toddlers With Autism|Completed||N/A|86|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 00:27:15.884293|2018-06-01 00:27:15.884293
NCT00999765|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2012-01-30|2009-10-21|2009-10-22|Estimate|||||||2012-01-30|2012-01-31|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|March 2010|Actual|2010-03-31||Observational|||Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder|Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder|Unknown status|Active, not recruiting||36|Anticipated|Douglas Mental Health University Institute|||1||f||||f||||||||||2018-06-01 00:27:17.03647|2018-06-01 00:27:17.03647
NCT00999752|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2011-05-04|2009-10-21|2009-10-22|Estimate|||||||2011-05-04|2011-05-05|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|NASAA||Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension|A 25 Week, Open Label Study to Determine the Effects of Nebivolol When Added to Hydrochlorothiazide on Diastolic Function and Arterial Stiffness in African Americans With Hypertension|Completed||N/A|40|Actual|InVasc Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 00:27:17.102896|2018-06-01 00:27:17.102896
NCT00999739|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-11-06|2009-10-21|2009-10-22|Estimate|||||||2009-11-06|2009-11-09|Estimate|December 2007||2007-12-31|October 2009|2009-10-31|April 2010|Anticipated|2010-04-30|April 2008|Anticipated|2008-04-30||Interventional|||Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults|A Sequential Vaccination Strategy With Conjugated and Polysaccharide Pneumococcal Vaccines Compared With Polysaccharide Vaccine in HIV- Infected Adults.|Unknown status|Recruiting|Phase 3|220|Anticipated|Hospital Universitari Son Dureta||2|||f||||f||||||||||2018-06-01 00:27:17.189766|2018-06-01 00:27:17.189766
NCT00999713|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|2018-01-19||2018-02-15|2009-10-21|2009-10-22|Estimate|2018-02-15|2018-03-16|Actual||||2018-02-15|2018-03-16|Actual|June 2010||2010-06-30|February 2018|2018-02-28|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|CALIPSO||CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients|A Phase 3 Trial of Calfactant for ALI in Pediatric Leukemia and HSCT Patients|Completed||Phase 2/Phase 3|43|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-06-01 00:27:17.314486|2018-06-01 00:27:17.314486
NCT00999700|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2017-09-01|2009-10-21|2009-10-22|Estimate|||||||2017-09-01|2017-09-05|Actual|September 2009||2009-09-30|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 31, 2016|Actual|2016-12-31||Interventional|INTERCEPTOR||Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin|Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin|Active, not recruiting||Phase 3|282|Anticipated|Gruppo Oncologico del Nord-Ovest||2|||f||||f||||||||||2018-06-01 00:27:17.743759|2018-06-01 00:27:17.743759
NCT00999687|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2012-06-06||2013-01-03|2009-10-21|2009-10-22|Estimate|2012-08-13|2012-09-12|Estimate||||2013-01-03|2013-01-08|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails|Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails|Completed||Phase 2/Phase 3|31|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 00:27:17.932042|2018-06-01 00:27:17.932042
NCT00999674|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-21|2009-10-21|2009-10-22|Estimate|||||||2009-10-21|2009-10-22|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|HQL||The Effect of an Exercise Program on the Health-quality of Life (HQL) in Older Adults|The Effect of an Exercise Program on the Health-quality of Life (HQL) in Older|Completed||N/A|60|Actual|Shahrekord University|||||f||||f||||||||||2018-06-01 00:27:18.106629|2018-06-01 00:27:18.106629
NCT00999661|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2013-08-14||2014-01-08|2009-10-20|2009-10-22|Estimate|2014-01-08|2014-02-07|Estimate||||2014-01-08|2014-02-07|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational||Intent-to-Treat population defined as all subjects implanted with the Realize Gastric Band-C who signed informed consent.|A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C|A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C at 2 Years in a US Patient Population of Morbidly Obese Patients|Completed|||231|Actual|Ethicon Endo-Surgery|||||f||||f||||||||||2018-06-01 00:27:18.175184|2018-06-01 00:27:18.175184
NCT00998257|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2015-01-19|2009-10-19|2009-10-20|Estimate|||||||2015-01-19|2015-01-21|Estimate|July 2009||2009-07-31|January 2015|2015-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Regulatory Post Marketing Surveillance Study on YAZ|Regulatory Post Marketing Surveillance Study on YAZ|Completed|||770|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 00:27:40.586538|2018-06-01 00:27:40.586538
NCT00999648|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-10-21|2009-10-21|2009-10-22|Estimate|||||||2009-10-21|2009-10-22|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MTP||Efficacy of Myofascial Trigger Point Pressure Release on Tinnitus Patients|Efficacy of Myofascial Trigger Point Pressure Release on Tinnitus Patients With Both Tinnitus and Myofascial Pain: a Double-blind Placebo Controlled Randomized Clinical Trial.|Completed||N/A|57|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-06-01 00:27:18.365125|2018-06-01 00:27:18.365125
NCT00999635|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2009-10-23|2009-10-21|2009-10-22|Estimate|||||||2009-10-23|2009-10-27|Estimate|March 2006||2006-03-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Interventional|||A Comparison of Insoles Used to Prevent Neuropathic Diabetic Foot Ulceration|A Comparison of Functional and Prefabricated Insoles Used for the Preventative Management of Neuropathic Diabetic Foot Ulceration: a Single Blind Randomised Control Trial|Completed||Phase 2/Phase 3|119|Actual|University of Plymouth||2|||f||||f||||||||||2018-06-01 00:27:18.456252|2018-06-01 00:27:18.456252
NCT00999622|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2012-05-24|2009-10-21|2009-10-22|Estimate|||||||2012-05-24|2012-05-28|Estimate|July 2004||2004-07-31|May 2012|2012-05-31||||August 2009|Actual|2009-08-31||Observational|||Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma|CD4 Count And Risk Of Infection In Patients With Brain Tumors|Completed|||104|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 00:27:18.538313|2018-06-01 00:27:18.538313
NCT00999609|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2018-01-12|2016-02-16|2018-02-23|2009-10-21|2009-10-22|Estimate|2018-02-23|2018-03-26|Estimate|2016-02-16|2016-03-16|Estimate|2018-02-23|2018-03-26|Estimate|October 2012|Actual|2012-10-31|February 2018|2018-02-28|July 2029|Anticipated|2029-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis|A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]|Active, not recruiting||Phase 3|31|Actual|Spark Therapeutics||2|||f||||t|t|f||||||||2018-06-01 00:27:18.621284|2018-06-01 00:27:18.621284
NCT00999596|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|2011-06-14||2012-11-30|2009-10-21|2009-10-22|Estimate|2012-04-03|2012-05-02|Estimate||||2012-11-30|2012-12-04|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Observational|||Image Evaluation of Philips Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM)|Clinical Image Evaluation Study for Philips MammoDiagnost DR Full Field Digital Mammography System (FFDM)|Completed|||107|Actual|Philips Healthcare|Change in requirements from FDA modified the reading study per the Nov 5, 2010 FDA Guideline for FFDM.||1||f||||t||||||||||2018-06-01 00:27:18.983616|2018-06-01 00:27:18.983616
NCT00999583|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2014-06-25|2009-10-21|2009-10-22|Estimate|||||||2014-06-25|2014-06-26|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|Epo-ACR-02||High Dose of Erythropoietin Analogue After Cardiac Arrest|High Dose of Erythropoietin Analogue After Cardiac Arrest: a Multicentre, Randomised, Controlled Trial (Epo-ACR-02 Trial)|Completed||Phase 3|500|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:27:19.20099|2018-06-01 00:27:19.20099
NCT00999570|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-10-21|2009-10-21|2009-10-22|Estimate|||||||2009-10-21|2009-10-22|Estimate|January 2004||2004-01-31|October 2009|2009-10-31|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Observational|||High Volume Specialty Knee Replacement Surgeons Achieve Better Clinical and Quality-of-Life Scores|High Volume Specialty Knee Replacement Surgeons Achieve Better Clinical and Quality-of-Life Scores|Completed|||3458|Actual|Singapore General Hospital|||2||f||||t||||||||||2018-06-01 00:27:19.283357|2018-06-01 00:27:19.283357
NCT00999557|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2016-04-06|2009-10-21|2009-10-22|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2016||2016-01-31|April 2016|2016-04-30||||August 2017|Anticipated|2017-08-31||Interventional|||Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants|Efficacy of Topical Bimatoprost in Promoting Hair Growth in the Region of the Eyebrow and Eyelashes for Post-chemotherapy Patients Versus Normal Patients|Withdrawn||N/A|0|Actual|Jonsson Comprehensive Cancer Center||2||Study was never opened|f||||t||||||||||2018-06-01 00:27:19.359785|2018-06-01 00:27:19.359785
NCT00999544|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2012-11-13||2017-08-03|2009-10-20|2009-10-21|Estimate|2013-07-19|2013-08-23|Estimate||||2017-08-03|2017-09-01|Actual|October 2009||2009-10-31|August 2017|2017-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Aprepitant Effects on Oxycodone Response|New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone|Completed||N/A|9|Actual|University of Kentucky|No significant adverse effects occurred. No adverse events led to study drop-out.|15|||f||||f||||||||||2018-06-01 00:27:19.458614|2018-06-01 00:27:19.458614
NCT00999531|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2010-03-08|2009-10-20|2009-10-21|Estimate|||||||2010-03-08|2010-03-10|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Volunteers|Completed||Phase 1|24|Anticipated|Gilead Sciences||4|||f||||f||||||||||2018-06-01 00:27:19.833153|2018-06-01 00:27:19.833153
NCT00999518|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20||2012-01-27|2012-08-23|2009-10-20|2009-10-21|Estimate||||2012-08-23|2012-08-30|Estimate|2012-08-23|2012-08-30|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome|A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS)|Terminated||Phase 2|222|Actual|Pfizer||5||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:27:19.957815|2018-06-01 00:27:19.957815
NCT00999505|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-02-15|2009-10-20|2009-10-21|Estimate|||||||2011-02-15|2011-02-16|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia|A Double-blind, Randomized, Placebo-controlled Trial With Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia|Unknown status|Recruiting|Phase 3|40|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:27:20.225333|2018-06-01 00:27:20.225333
NCT00999492|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2014-02-26|2009-10-20|2009-10-21|Estimate|||||||2014-02-26|2014-02-28|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront|Selection of Aspheric Diffractive Multifocal IOLS Based on Corneal Wavefront|Completed||Phase 4|8|Actual|Drs. Fine, Hoffman and Packer, LLC|||||f||||f||||||||||2018-06-01 00:27:20.303927|2018-06-01 00:27:20.303927
NCT00999479|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2013-12-09|2009-10-20|2009-10-21|Estimate|||||||2013-12-09|2013-12-10|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation|Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation|Withdrawn||N/A|0|Actual|University of Oklahoma||2||Poor enrollment|f||||t||||||||||2018-06-01 00:27:20.368128|2018-06-01 00:27:20.368128
NCT00999466|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2015-08-31||2016-01-28|2009-10-20|2009-10-21|Estimate|2015-12-17|2016-01-26|Estimate||||2016-01-28|2016-02-26|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional||AZD8848 30 μg nasal spray was only done in Pilot part. 3 of the 28 placebo subjects were from the PILOT part and 25 placebo subjects were from the MAIN part.|The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen|A Double-blind, Placebo-controlled, Randomised, Parallel Group, Phase IIa Study to Investigate the Efficacy, Tolerability and Safety of 8 Doses of AZD8848 Administered Intranasally Once Weekly in Mild to Moderate Allergic Asthma Subjects Challenged With an Inhaled Allergen.|Completed||Phase 2|60|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:27:20.613335|2018-06-01 00:27:20.613335
NCT00999453|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2017-03-15|2009-10-20|2009-10-21|Estimate|||||||2017-03-15|2017-03-17|Actual|October 2009||2009-10-31|October 2009|2009-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effects of Lowering Low-density Lipoprotein Cholesterol Levels to New Targets on Cardiovascular Complications in Peritoneal Dialysis Patients||Completed||N/A|43|Actual|Clinical Research Center for End Stage Renal Disease, Korea||2|||f||||t||||||||||2018-06-01 00:27:22.402869|2018-06-01 00:27:22.402869
NCT00999440|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2010-01-20|2009-10-20|2009-10-21|Estimate|||||||2010-01-20|2010-01-21|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||QTc and Perceived Sleep Follow up Among Chronic Pain Patients With Opiate Medication|QTc and Perceived Sleep Follow up Among Chronic Pain Patients With Opiate Medication|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-06-01 00:27:22.457066|2018-06-01 00:27:22.457066
NCT00999427|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2012-05-04|2009-10-20|2009-10-21|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Prostate Biopsy Antisepsis|Antiseptic Preparation of the Rectum Prior to Transrectal Prostate Biopsy|Completed||N/A|865|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 00:27:22.525186|2018-06-01 00:27:22.525186
NCT00999414|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2015-10-23|2009-10-20|2009-10-21|Estimate|||||||2015-10-23|2015-10-26|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Expanded Access|2009-32||UARK 2009-32 Compassionate Use Study of Carfilzomib|Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma|No longer available|||||University of Arkansas|||||||||f||||||||||2018-06-01 00:27:22.598169|2018-06-01 00:27:22.598169
NCT00999401|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2016-05-02|2009-10-20|2009-10-21|Estimate|||||||2016-05-02|2016-05-03|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors|A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors|Recruiting||Phase 1|90|Anticipated|Cyclacel Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:27:22.751421|2018-06-01 00:27:22.751421
NCT00999388|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2018-04-04|2009-10-20|2009-10-21|Estimate|||||||2018-04-04|2018-04-05|Actual|October 14, 2009||2009-10-14|January 25, 2018|2018-01-25|January 25, 2018||2018-01-25|||||Observational|||Shanghai Parkinson's Study|Shanghai Parkinson's Study|Completed|||149|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:27:22.840733|2018-06-01 00:27:22.840733
NCT00999375|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2018-05-17|2009-10-20|2009-10-21|Estimate|||||||2018-05-17|2018-05-18|Actual|September 18, 2009||2009-09-18|September 29, 2017|2017-09-29|November 27, 2013|Actual|2013-11-27|November 27, 2013|Actual|2013-11-27||Interventional|||Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)|Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)|Completed||Phase 2|293|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:27:22.901496|2018-06-01 00:27:22.901496
NCT00999362|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-10-20|2009-10-20|2009-10-21|Estimate|||||||2009-10-20|2009-10-21|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Observational|||Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?|Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?|Completed|||40|Actual|University of Aarhus|||2||f||||t||||||||||2018-06-01 00:27:22.994833|2018-06-01 00:27:22.994833
NCT00999349|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-10-20|2009-10-20|2009-10-21|Estimate|||||||2009-10-20|2009-10-21|Estimate|March 2009||2009-03-31|October 2009|2009-10-31||||December 2009|Anticipated|2009-12-31||Interventional|||Therapeutic Effects of Silymarin in Patients With B-thalassemia Major|Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|140|Anticipated|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-06-01 00:27:23.087367|2018-06-01 00:27:23.087367
NCT00999336|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2010-09-23|2009-10-20|2009-10-21|Estimate|||||||2010-09-23|2010-09-27|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment|Pharmacokinetics, Pharmacodynamics, and Tolerability of Betrixaban Administered Orally in Subjects With Normal and Reduced Renal Function.|Completed||Phase 1|32|Anticipated|Portola Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:27:23.179009|2018-06-01 00:27:23.179009
NCT00999323|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2015-07-27|2009-10-20|2009-10-21|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2007||2007-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Observational|FUNKIS||Endothelial Function and Heart Rate Variability After Stenting|Endothelial Function and Heart Rate Variability After Stenting in Coronary Arteries|Completed|||100|Actual|Helse Stavanger HF|||1||f||||f||||||Samples With DNA|"~     serum, plasma and full blood~   "|||2018-06-01 00:27:23.272716|2018-06-01 00:27:23.272716
NCT00999310|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2015-05-31|2009-10-20|2009-10-21|Estimate|||||||2015-05-31|2015-06-02|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|June 2013|Actual|2013-06-30|April 2012|Actual|2012-04-30||Observational|||Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome|Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome|Completed|||146|Actual|University of Aarhus|||4||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-06-01 00:27:23.335494|2018-06-01 00:27:23.335494
NCT00997893|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2015-07-23|2009-10-18|2009-10-19|Estimate|||||||2015-07-23|2015-07-27|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RISE||Research Investigation of Soy and Estrogen|Effects of Estradiol and Soy on Menopausal Symptoms|Completed||Phase 2|96|Actual|University of Illinois at Chicago||3|||f||||t||||||||||2018-06-01 00:27:45.487533|2018-06-01 00:27:45.487533
NCT00999297|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2015-11-18|2009-10-20|2009-10-21|Estimate|||||||2015-11-18|2015-11-20|Estimate|July 2008||2008-07-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|November 2009|Actual|2009-11-30||Interventional|CAPSPAL||Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate|Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate: A Double-blind Randomized Parallel Arm Study|Completed||N/A|79|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-06-01 00:27:23.406497|2018-06-01 00:27:23.406497
NCT00999284|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-10-20|2009-10-20|2009-10-21|Estimate|||||||2009-10-20|2009-10-21|Estimate|December 1996||1996-12-31|October 2009|2009-10-31|April 1998|Actual|1998-04-30|April 1998|Actual|1998-04-30||Interventional|||Ophthalmologic Examinations After Infusion of ZK200775|Ophthalmologic Examinations After 4-hour Infusion of ZK200775 in Healthy Elder Male Volunteers|Completed||Phase 1|18|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-06-01 00:27:23.491959|2018-06-01 00:27:23.491959
NCT00999271|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-10-20|2009-10-20|2009-10-21|Estimate|||||||2009-10-20|2009-10-21|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism|On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans|Completed|||30||Hvidovre University Hospital|||1||f||||f||||||||||2018-06-01 00:27:23.563437|2018-06-01 00:27:23.563437
NCT00999258|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-10-20|2009-10-20|2009-10-21|Estimate|||||||2009-10-20|2009-10-21|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients|Prospective Trial of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients With Chronic Allograft Nephropathy|Unknown status|Recruiting|Phase 4|50|Anticipated|Temple University||2|||f||||f||||||||||2018-06-01 00:27:23.634573|2018-06-01 00:27:23.634573
NCT00999245|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2013-04-16|2009-10-20|2009-10-21|Estimate|||||||2013-04-16|2013-04-18|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|IMPROVE||THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)|Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)|Terminated||Phase 3|38|Actual|New England Research Institutes||2||Inability to meet target enrollment prior to ending of network in March 2011.|f||||t||||||||||2018-06-01 00:27:23.735342|2018-06-01 00:27:23.735342
NCT00999232|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2010-01-21|2009-10-20|2009-10-21|Estimate|||||||2010-01-21|2010-01-22|Estimate|October 2004||2004-10-31|October 2009|2009-10-31||||July 2007|Actual|2007-07-31||Interventional|||Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube||Completed||Phase 4|||Canisius-Wilhelmina Hospital||2|||f||||||||||||||2018-06-01 00:27:23.844947|2018-06-01 00:27:23.844947
NCT00999219|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2014-08-19|2009-10-20|2009-10-21|Estimate|||||||2014-08-19|2014-08-20|Estimate|March 2006||2006-03-31|August 2014|2014-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia|FK199B (Zolpidem MR Tablet) Phase III Clinical Study - A Double-Blind, Crossover, Comparative Polysomnographic Study Using Zolpidem (Myslee®) as a Positive Control in Patients With Insomnia, Excluding Patients With Schizophrenia or Manic-Depressive Psychosis|Completed||Phase 3|55|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:27:23.917294|2018-06-01 00:27:23.917294
NCT00999206|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-08-25|2009-10-20|2009-10-21|Estimate|||||||2011-08-25|2011-08-26|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine|Randomized, Double-Blind Study to Assess Safety, Immunogenicity, and Lot Consistency of Solvay's Cell-Derived Influenza Vaccine and Its Non-Inferiority Compared to Influvac®.|Completed||Phase 3|3138|Actual|Abbott||4|||f||||f||||||||||2018-06-01 00:27:24.030878|2018-06-01 00:27:24.030878
NCT00999193|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2017-01-03|2009-10-20|2009-10-21|Estimate|||||||2017-01-03|2017-01-04|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Proximal Humeral Comminuted Fractures in the Elderly - PERCELE Trial|Effectiveness and Cost-effectiveness of Conservative and Operative Treatment of Three- and Four-part Fractures of the Proximal Humerus. A Nested Randomised Controlled Trial and Cohort Study|Recruiting||N/A|90|Anticipated|Helsinki University||3|||f||||f||||||||||2018-06-01 00:27:24.130194|2018-06-01 00:27:24.130194
NCT00999180|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-12-14|2009-10-20|2009-10-21|Estimate|||||||2011-12-14|2011-12-15|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Interventional|||Botulinum Toxin Type A and Kinesitherapy of Post-stroke Patients|Botulinum Toxin Type A and Kinesitherapy Use in the Functional Performance of Post-stroke Patients|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Federal University of Bahia||2|||f||||t||||||||||2018-06-01 00:27:24.217378|2018-06-01 00:27:24.217378
NCT00999167|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2015-07-01||2017-01-13|2009-10-20|2009-10-21|Estimate|2015-08-27|2015-09-30|Estimate||||2017-01-13|2017-01-16|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|HALT-HE|Only the baseline characteristics of the subjects enrolled in Part B are presented.|A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy|Completed||Phase 2|189|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||t||||||||||2018-06-01 00:27:24.423717|2018-06-01 00:27:24.423717
NCT00999154|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2018-05-02|2009-10-20|2009-10-21|Estimate|||||||2018-05-02|2018-05-03|Actual|September 19, 2009||2009-09-19|October 22, 2012|2012-10-22|October 22, 2012||2012-10-22|||||Observational|||Diet-Induced-Obesity Resistant Phenotypes in Humans|Diet-Induced-Obesity Resistant Phenotypes in Humans|Terminated|||9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:27:24.918154|2018-06-01 00:27:24.918154
NCT00999141|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2011-10-06|2010-12-17|2012-10-04|2009-10-20|2009-10-21|Estimate|2012-08-14|2012-08-27|Estimate|2010-12-17|2010-12-23|Estimate|2012-10-04|2012-10-08|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy|A Randomized, Controlled Phase 3 Study to Evaluate Safety and Efficacy of Fibrin Sealant (FS) VH S/D 4 S-apr (ARTISS) to Adhere Tissues and Improve Wound Healing in Subjects Undergoing Rhytidectomy (Facelift)|Completed||Phase 3|75|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 00:27:25.062867|2018-06-01 00:27:25.062867
NCT00998959|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2012-04-27|2009-10-20|2009-10-21|Estimate|||||||2012-04-27|2012-04-30|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients|Feasibility and Efficacy of a Stress Reduction Intervention for Enhancing Treatment Outcome for Depressed Minority Patients|Completed||N/A|40|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:27:28.372021|2018-06-01 00:27:28.372021
NCT00999128|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-02-07|2009-10-20|2009-10-21|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 26, 2009|Actual|2009-10-26|February 2010|2010-02-28|February 26, 2010|Actual|2010-02-26|February 26, 2010|Actual|2010-02-26||Interventional|||A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers|An Open-Label, Two-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers|Completed||Phase 1|50|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 00:27:26.146464|2018-06-01 00:27:26.146464
NCT00999115|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2012-01-25|2009-10-20|2009-10-21|Estimate|||||||2012-01-25|2012-01-26|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|ALOREVA||Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA)|Clinical Trial in Phase I-IIa to Study the Feasibility and Security of the Allogenic Use of Adipose-derived Stem Cells for the Local Treatment of Recto-vaginal Fistula in Crohn´s Disease|Completed||Phase 1/Phase 2|10|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||1|||f||||f||||||||||2018-06-01 00:27:26.235018|2018-06-01 00:27:26.235018
NCT00999102|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2012-03-16|2009-10-20|2009-10-21|Estimate|||||||2012-03-16|2012-03-19|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life|Nebivolol Vs. Metoprolol: Comparative Effects on Fatigue and Quality of Life|Completed||Phase 4|37|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 00:27:26.305318|2018-06-01 00:27:26.305318
NCT00999089|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2009-10-20|2009-10-20|2009-10-21|Estimate|||||||2009-10-20|2009-10-21|Estimate|January 2003||2003-01-31|October 2009|2009-10-31|September 2010|Anticipated|2010-09-30|September 2006|Actual|2006-09-30||Interventional|||Arrested Versus Beating Heart Techniques in Coronary Revascularisation|Arrested Versus Beating Heart Techniques in Coronary Revascularisation: Randomized Clinical Trial in Unselected Patients|Unknown status|Active, not recruiting|Phase 3|616|Actual|Martin-Luther-Universität Halle-Wittenberg||3|||f||||f||||||||||2018-06-01 00:27:26.388518|2018-06-01 00:27:26.388518
NCT00999076|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2012-12-17|2009-10-20|2009-10-21|Estimate|||||||2012-12-17|2012-12-18|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens|Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens|Terminated|||200|Actual|Samsung Medical Center|||1||f||||f||||||Samples With DNA|"~     Sputum with positive AFB smear~   "|||2018-06-01 00:27:26.458637|2018-06-01 00:27:26.458637
NCT00999063|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-03-30|2009-10-20|2009-10-21|Estimate|||||||2011-03-30|2011-03-31|Estimate|December 2009||2009-12-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|GerdQ||Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand|Prevalence of GERD in Patients With upperGITsymptoms in Thailand|Completed|||4108|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:27:26.514981|2018-06-01 00:27:26.514981
NCT00999050|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2011-01-03|2009-10-20|2009-10-21|Estimate|||||||2011-01-03|2011-01-04|Estimate|October 2009||2009-10-31|January 2011|2011-01-31|November 2013|Anticipated|2013-11-30|October 2011|Anticipated|2011-10-31||Interventional|||Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus With Body Mass Index (BMI) < 35|Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus: a Pilot Prospective Study in Overweight and Mildly Obese Subjects|Unknown status|Recruiting|N/A|50|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-06-01 00:27:26.684907|2018-06-01 00:27:26.684907
NCT00999037|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2016-12-22||2017-02-14|2009-10-20|2009-10-21|Estimate|2017-02-14|2017-03-31|Actual||||2017-02-14|2017-03-31|Actual|October 2009||2009-10-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease|FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease|Completed||N/A|18|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:27:26.768247|2018-06-01 00:27:26.768247
NCT00999024|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2013-02-01|2009-10-20|2009-10-21|Estimate|||||||2013-02-01|2013-02-04|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Reflectometric Measurement of Retinal Oxygen Saturation in Patients With Chronic Obstructive Pulmonary Disease (COPD) Grade IV and Healthy Subjects|Reflectometric Measurement of Retinal Oxygen Saturation in Patients With COPD Grade IV and Healthy Subjects|Completed|||40|Actual|Medical University of Vienna|||2||f||||t||||||||||2018-06-01 00:27:27.008935|2018-06-01 00:27:27.008935
NCT00999011|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2014-07-11|2009-10-20|2009-10-21|Estimate|||||||2014-07-11|2014-07-15|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|June 2011|Actual|2011-06-30||Interventional|ETM||Dose of Early Therapeutic Mobility: Does Type or Frequency Matter?|Dose of Early Therapeutic Mobility: Does Type or Frequency Matter?|Completed||N/A|54|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-06-01 00:27:27.063097|2018-06-01 00:27:27.063097
NCT00998998|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2010-07-19|2009-10-20|2009-10-21|Estimate|||||||2010-07-19|2010-07-21|Estimate|April 1992||1992-04-30|June 2010|2010-06-30|July 1996|Actual|1996-07-31|July 1996|Actual|1996-07-31||Interventional|||The Anemia Control Program: Early Intervention|Iron Deficiency Anemia and Infant Behavior: Early Intervention Study II|Completed||N/A|277|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||4|||f||||||||||||||2018-06-01 00:27:27.157599|2018-06-01 00:27:27.157599
NCT00998985|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2016-02-03||2017-03-01|2009-10-20|2009-10-21|Estimate|2016-02-03|2016-03-02|Estimate||||2017-03-01|2017-03-30|Actual|February 2010||2010-02-28|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||All randomized participants|A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Grazoprevir (MK-5172) in Hepatitis C Infected Male Patients|Completed||Phase 1|91|Actual|Merck Sharp & Dohme Corp.||14|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:27:27.254738|2018-06-01 00:27:27.254738
NCT00998972|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-17|||2011-07-09|2009-10-20|2009-10-21|Estimate|||||||2011-07-09|2011-07-12|Estimate|September 2006||2006-09-30|June 2009|2009-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||N-acetyl-cysteine (NAC) and Kidney Graft Function|Preventive Administration of N-acetyl-cysteine (NAC) in Organ Donor: Effects on Kidney Graft Function|Completed||Phase 3|236|Actual|Institut d'Anesthesiologie des Alpes Maritimes||2|||f||||f||||||||||2018-06-01 00:27:28.291432|2018-06-01 00:27:28.291432
NCT00998946|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2015-03-18|2009-10-19|2009-10-21|Estimate|||||||2015-03-18|2015-03-20|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|Completed||Phase 2|27|Actual|Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 00:27:28.446415|2018-06-01 00:27:28.446415
NCT00998933|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-11-24|2009-10-20|2009-10-21|Estimate|||||||2009-11-24|2009-11-25|Estimate|October 2009||2009-10-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure|An Open-label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62%|Completed||Phase 1|24|Actual|Solvay Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:27:28.533413|2018-06-01 00:27:28.533413
NCT00998920|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2012-07-11|2009-10-20|2009-10-21|Estimate|||||||2012-07-11|2012-07-12|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers|Randomized, Double-Blind, Rising Multiple Dose Study of S-Equol in Normal Volunteers|Completed||Phase 1|41|Actual|Ausio Pharmaceuticals, LLC||6|||f||||f||||||||||2018-06-01 00:27:28.603479|2018-06-01 00:27:28.603479
NCT00998907|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2012-01-17|2009-10-20|2009-10-21|Estimate|||||||2012-01-17|2012-01-18|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|PDS*plus||PDS*Plus and Wound Infections After Laparotomy|Pathway Driven Study to Evaluate the Incidence of Wound Infections and Incisional Hernias After Laparotomy and Fascial Closure With PDS*Plus Sutures|Completed||N/A|1042|Actual|University Hospital, Saarland||2|||f||||f||||||||||2018-06-01 00:27:28.705778|2018-06-01 00:27:28.705778
NCT00998894|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-03-20|2009-10-20|2009-10-21|Estimate|||||||2017-03-20|2017-03-21|Actual|October 2009||2009-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|||"Randomized Trial of Alerts in Patients Demonstrating a Triple Low"|"A Randomized Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Triple Low of Mean-arterial Pressure, End-tidal Anesthetic Concentration, and Bispectral Index"|Completed|||9846|Actual|The Cleveland Clinic|||2||f||||t||||||||No||2018-06-01 00:27:28.787076|2018-06-01 00:27:28.787076
NCT00998881|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2014-01-08||2014-01-08|2009-10-20|2009-10-21|Estimate|2014-01-08|2014-02-21|Estimate||||2014-01-08|2014-02-21|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Monotherapy Study of MP-513 in Patients With Type 2 Diabetes|A Phase III, Double-blind, Placebo Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus - Confirmative Study|Completed||Phase 3|203|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 00:27:28.869141|2018-06-01 00:27:28.869141
NCT00998868|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|2010-08-15||2011-09-23|2009-10-20|2009-10-21|Estimate|2011-08-17|2011-09-22|Estimate||||2011-09-23|2011-09-30|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Observational|||Rotator Cuff Tears in Hemiplegic Shoulder|Observational Study to Evaluate the Prevalence of Rotator Cuff Tears in Hemiplegic Shoulders|Completed|||51|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-06-01 00:27:29.230594|2018-06-01 00:27:29.230594
NCT00998855|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2011-06-06|2009-10-20|2009-10-21|Estimate|||||||2011-06-06|2011-06-07|Estimate|February 2004||2004-02-29|October 2009|2009-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Glucose and Lipid Metabolism in Adolescents|Glucose and Lipid Metabolism in Adolescents|Unknown status|Recruiting||42|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||1||f||||f||||||||||2018-06-01 00:27:29.380048|2018-06-01 00:27:29.380048
NCT00998842|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2009-11-03|2009-10-20|2009-10-21|Estimate|||||||2009-11-03|2009-11-04|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Comparison of a Novel 12-Lead Wireless Electrocardiogram (ECG) and a Standard Wired ECG|Comparison of a Novel 12-Lead Wireless ECG and a Standard Wired ECG|Completed|||10|Actual|University of Oklahoma|||1||f||||||||||||||2018-06-01 00:27:29.461361|2018-06-01 00:27:29.461361
NCT00998829|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2012-11-28|2009-10-20|2009-10-21|Estimate|||||||2012-11-28|2012-11-29|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis|An Australian Cross-Sectional Epidemiological Study To Evaluate The Prevalence Of Undiagnosed Psoriatic Arthritis In Psoriasis Patients In Dermatology Practice Focusing On Disease Severity, Disease Burden And Quality Of Life|Completed|||458|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:27:29.642009|2018-06-01 00:27:29.642009
NCT00998816|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-20|||2012-04-10|2009-10-20|2009-10-21|Estimate|||||||2012-04-10|2012-04-11|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||The Effect of Perioperative Pregabalin on the Incidence of Chronic Post-thoracotomy Pain Syndrome|A Multicenter Prospective Randomized Double-blind Placebo Controlled Trial Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome|Withdrawn||Phase 3|0|Actual|Queen's University||2||No funding|f||||f||||||||||2018-06-01 00:27:29.736314|2018-06-01 00:27:29.736314
NCT00998803|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2012-10-30|2009-10-20|2009-10-21|Estimate|||||||2012-10-30|2012-11-01|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults|Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults|Completed|||9|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples With DNA|"~     -  Nasopharyngeal swab collection is as follows: after tilting the tip of the patient's~          nose upward, a swab is inserted through the nostril along the floor of the nose into the~          nasopharynx. Then, the swab is gently rotated, removed and placed in its receptacle for~          delivery to the laboratory.~        -  Respiratory specimens will be stored at 2-8ºC and processed within 24-48 hours of~          collection. Serum and whole blood for immune assays will be frozen at -20ºC or in liquid~          nitrogen until processed in batched assays.~        -  All blood specimens will be sent to the laboratory for immunologic assays.~   "|||2018-06-01 00:27:29.812954|2018-06-01 00:27:29.812954
NCT00998790|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2011-03-31|2009-10-19|2009-10-20|Estimate|||||||2011-03-31|2011-04-01|Estimate|January 2007||2007-01-31|March 2011|2011-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence|A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence|Unknown status|Active, not recruiting|Phase 4|113|Actual|American Medical Systems|||||f||||f||||||||||2018-06-01 00:27:29.884013|2018-06-01 00:27:29.884013
NCT00998777|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2012-01-09|2009-10-19|2009-10-20|Estimate|||||||2012-01-09|2012-01-11|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Shoulder Injury Prevention Program in Swimmers|The Effect of a 6-week Shoulder Strengthening Program on Scapular Kinematics and Shoulder Strength in Division I Collegiate Swimmers|Completed||Phase 2|48|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 00:27:29.968559|2018-06-01 00:27:29.968559
NCT00998764|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2013-10-15||2015-11-30|2009-10-19|2009-10-20|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|December 2009||2009-12-31|November 2015|2015-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional||The safety population included all participants who consented to participate in the extension and received at least one dose of the investigational product (in the extension study).|A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.|Terminated||Phase 3|494|Actual|Pfizer||1||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical~   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2018-06-01 00:27:30.096943|2018-06-01 00:27:30.096943
NCT00998751|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2012-09-19|2009-10-19|2009-10-20|Estimate|||||||2012-09-19|2012-09-20|Estimate|June 2005||2005-06-30|September 2012|2012-09-30|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)|Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|AB Science||1|||f||||f||||||||||2018-06-01 00:27:31.376502|2018-06-01 00:27:31.376502
NCT00998738|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2013-05-16||2016-01-07|2009-10-19|2009-10-20|Estimate|2013-07-26|2013-08-29|Estimate||||2016-01-07|2016-02-04|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|January 2013|Actual|2013-01-31|July 2010|Actual|2010-07-31||Interventional||Since only one patient was accrued, patient confidentiality prevents the reporting of this patient.|Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer|The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study|Terminated||Phase 3|1|Actual|Mayo Clinic||2||lack of accrual|f||||t||||||||||2018-06-01 00:27:31.455691|2018-06-01 00:27:31.455691
NCT00998725|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2017-02-15|2009-10-19|2009-10-20|Estimate|||||||2017-02-15|2017-02-17|Actual|November 2009||2009-11-30|February 2017|2017-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|COCARVPK||Combined Oral Contraceptive (COC) Antiretroviral (ARV) Pharmacokinetics (PK) and Pharmacodynamics (PD) in Malawi|A Pilot Study of Pharmacokinetic and Pharmacodynamic Activity of LoFemenal|Withdrawn|||0|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-06-01 00:27:31.762762|2018-06-01 00:27:31.762762
NCT00998712|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2013-08-28|2009-10-19|2009-10-20|Estimate|||||||2013-08-28|2013-08-29|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Observational|||Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction|Gestational Diabetes Mellitus and Cardiovascular Disease: The Role of Vascular Dysfunction|Unknown status|Recruiting||88|Anticipated|Brigham and Women's Hospital|||4||f||||f||||||Samples With DNA|"~     blood and urine samples~   "|||2018-06-01 00:27:31.830695|2018-06-01 00:27:31.830695
NCT00998699|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2014-03-03|2009-10-19|2009-10-20|Estimate|||||||2014-03-03|2014-03-04|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well-controlled Type 1 Diabetes|Completed||Phase 2|22|Actual|XOMA (US) LLC||2|||f||||t||||||||||2018-06-01 00:27:31.904039|2018-06-01 00:27:31.904039
NCT00998686|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2010-08-10|2009-10-19|2009-10-20|Estimate|||||||2010-08-10|2010-08-11|Estimate|November 2009||2009-11-30|August 2010|2010-08-31|November 2011|Anticipated|2011-11-30|October 2011|Anticipated|2011-10-31||Interventional|||Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin|A Phase 3, Randomized, Double-Blind, Active-Controlled, Multi-Center Extension Study to Evaluate Safety and Efficacy of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin|Terminated||Phase 3|650|Anticipated|Phenomix||2|||f||||f||||||||||2018-06-01 00:27:31.997387|2018-06-01 00:27:31.997387
NCT00998673|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-07-13|2009-10-19|2009-10-20|Estimate|||||||2015-07-13|2015-07-14|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Silica Gel Fiber Wound Dressing for Chronic Venous Leg Ulcers|Randomized Standard-of-Care-Controlled Trial of a Silica Gel Fiber (SGF) Wound Dressing in the Treatment of Chronic Venous Leg Ulcers|Terminated||Phase 2|121|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:27:32.115279|2018-06-01 00:27:32.115279
NCT00998660|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2015-02-19||2015-02-19|2009-10-19|2009-10-20|Estimate|2015-02-19|2015-03-06|Estimate||||2015-02-19|2015-03-06|Estimate|July 2009||2009-07-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|RECHARGE||RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)|RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)|Completed||Phase 4|100|Actual|MedtronicNeuro|Potential limitations of the study include the limited sample size to fully characterize recharge use by indication. In addition, inferences to a broader population should also be limited given the relatively short duration of the study.|1|||f||||f||||||||||2018-06-01 00:27:32.220039|2018-06-01 00:27:32.220039
NCT00998647|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2010-04-22|2009-10-19|2009-10-20|Estimate|||||||2010-04-22|2010-04-23|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Modified Ultrafiltration in Cardiac Surgery|Assessment of the Influence of Modified Ultrafiltration on Primary and Secondary Hemostasis in Cardiac Surgery Patients|Completed|||60|Actual|Goethe University|||2||f||||f||||||||||2018-06-01 00:27:32.453449|2018-06-01 00:27:32.453449
NCT00998634|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2013-01-07|2009-10-19|2009-10-20|Estimate|||||||2013-01-07|2013-01-08|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|LISCA2||Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)|Randomized, Placebo-controlled Trial to Test Safety, Tolerability and Efficacy of Lithium Carbonate in Spinocerebellar Ataxia 2|Completed||Phase 2|20|Actual|Federico II University||2|||f||||f||||||||||2018-06-01 00:27:32.519388|2018-06-01 00:27:32.519388
NCT00811499|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17||2009-12-08|2012-03-01|2008-12-17|2008-12-19|Estimate||||2009-12-08|2009-12-10|Estimate|2012-03-01|2012-03-05|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis||Terminated||Phase 2|25|Actual|Array BioPharma||3|||f||||f||||||||||2018-06-01 01:27:51.997523|2018-06-01 01:27:51.997523
NCT00998608|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2009-10-18|2009-10-18|2009-10-20|Estimate|||||||2009-10-18|2009-10-20|Estimate|August 2007||2007-08-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Plus Low Dose of Haloperidol in the Treatment of Schizophrenia|A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder|Terminated||Phase 4|88|Actual|Kaohsiung Kai-Suan Psychiatric Hospital||1||terminated|f||||t||||||||||2018-06-01 00:27:32.797491|2018-06-01 00:27:32.797491
NCT00998595|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-03-29|2009-10-19|2009-10-20|Estimate|||||||2017-03-29|2017-03-31|Actual|June 2009||2009-06-30|September 2011|2011-09-30|October 2011|Actual|2011-10-31|February 2011|Actual|2011-02-28||Interventional|||Gestational Diabetes Follow Up Study|Es Mejor Saber: A Proactive Approach to Gestational Diabetes Follow Up|Completed||N/A|216|Actual|University of Southern California||2|||f||||f||||||||||2018-06-01 00:27:32.872924|2018-06-01 00:27:32.872924
NCT00998582|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2012-01-16||2012-10-03|2009-10-19|2009-10-20|Estimate|2012-02-17|2012-03-23|Estimate||||2012-10-03|2012-10-08|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Artery Elasticity After Switch From Epzicom to Truvada|Artery Elasticity After Switch From Epzicom to Truvada|Terminated||Phase 4|27|Actual|Minneapolis Medical Research Foundation|Study stopped early due to low/inadequate enrollment and findings are subsequently limited by low power to detect differences.|2||Low enrollment|f||||f||||||||||2018-06-01 00:27:32.961985|2018-06-01 00:27:32.961985
NCT00998569|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2015-08-27|2009-10-19|2009-10-20|Estimate|||||||2015-08-27|2015-08-31|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|MDDNET||Neurocognitive Enhancement in Major Depressive Disorder|Neurocognitive Enhancement in Major Depressive Disorder|Completed||N/A|33|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 00:27:33.194372|2018-06-01 00:27:33.194372
NCT00998556|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2016-11-17|2009-10-19|2009-10-20|Estimate|||||||2016-11-17|2016-11-18|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|PPCM||Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy|Effect of Bromocriptine on LV Function in Women With Peripartum Cardiomyopathy A Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Bromocriptine for Improvement of Left Ventricular Function of Women With PPCM|Completed||Phase 2|64|Actual|Hannover Medical School||2|||f||||f||||||||||2018-06-01 00:27:33.258967|2018-06-01 00:27:33.258967
NCT00998543|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2012-08-02|2009-10-19|2009-10-20|Estimate|||||||2012-08-02|2012-08-06|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Observational|||A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)|A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)|Completed|||147|Actual|Sanofi|||1||f||||f||||||||||2018-06-01 00:27:33.342833|2018-06-01 00:27:33.342833
NCT00998530|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2018-05-01|2009-10-19|2009-10-20|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2009|Actual|2009-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Trichomoniasis: Genotype and Phenotype Correlations in African American Women|Trichomoniasis: Genotype and Phenotype Correlations in African American Women|Active, not recruiting|||320|Anticipated|University of Mississippi Medical Center|||3||f||||f||||||Samples With DNA|"~     Trichomonas vaginalis clinical isolates~   "|Yes|Data will be shared with other investigators upon completion of the study and journal acceptance of manuscripts detailing study results. Data may be accessed by contacting Dr. Meade|2018-06-01 00:27:33.416257|2018-06-01 00:27:33.416257
NCT00998517|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2012-08-15||2014-04-14|2009-10-19|2009-10-20|Estimate|2014-04-14|2014-05-12|Estimate||||2014-04-14|2014-05-12|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effectiveness Comparison of Three Supplementary Foods in the Treatment of Moderate Acute Malnutrition|Comparison of a Novel Fortified Blended Flour to Ready-to-use Supplemental Foods for the Treatment of Moderate Acute Malnutrition in Rural Malawian Children: a Randomized, Investigator-blinded, Clinical Effectiveness Trial|Completed||N/A|2712|Actual|Washington University School of Medicine||3|||f||||||||||||||2018-06-01 00:27:33.577984|2018-06-01 00:27:33.577984
NCT00998504|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2011-03-17|2009-10-19|2009-10-20|Estimate|||||||2011-03-17|2011-03-18|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||resVida and Fat Oxidation|Effect of resVida on Fat Oxidation and Mitochondrial Biogenesis in Healthy Obese Subjects|Completed||N/A|18|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:27:33.988217|2018-06-01 00:27:33.988217
NCT00998478|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2009-10-19|2009-10-19|2009-10-20|Estimate|||||||2009-10-19|2009-10-20|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Cardiovascular Disease and the Effects of a Cross-curricular Physical Activity Intervention|Cardiovascular Disease Risk Factors and the Effects of a Cross-curricular Physical Activity Intervention in 11-14 Year Olds. Activity Knowledge Circuit|Completed||N/A|192|Actual|University of Glamorgan||2|||f||||||||||||||2018-06-01 00:27:34.083848|2018-06-01 00:27:34.083848
NCT00998465|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2013-03-19|2009-10-19|2009-10-20|Estimate|||||||2013-03-19|2013-03-20|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Hemodynamics, Salt Sensitivity and Body Composition in Patients With Morbid Obesity|Hemodynamics, Salt Sensitivity and Body Composition in Patients With Morbid Obesity - Effect of Weight Loss Following Laparoscopic Gastric Bypass|Completed|||36|Actual|Zealand University Hospital|||3||f||||||||||Samples With DNA|"~     Blood samples: p-glucose, p-insulin, MR-proANP, hemoglobine, sodium, potassium, creatinine,~     albumine.~      Urine collections: u-sodium, u-potassium, u-creatinine~   "|||2018-06-01 00:27:34.183774|2018-06-01 00:27:34.183774
NCT00998452|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-04-21|2009-10-19|2009-10-20|Estimate|||||||2017-04-21|2017-04-25|Actual|December 2009||2009-12-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Dissemination of a Weight Management Program Among US Veterans|Dissemination of a Weight Management Program Among US Veterans|Completed||N/A|732|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:27:34.28688|2018-06-01 00:27:34.28688
NCT00998439|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2011-05-19|2009-10-19|2009-10-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter|PEPCAD DES - Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA Catheter|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|Klinikum Coburg||2|||f||||f||||||||||2018-06-01 00:27:34.387225|2018-06-01 00:27:34.387225
NCT00998426|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2015-02-09||2015-08-26|2009-10-19|2009-10-20|Estimate|2015-08-26|2015-09-28|Estimate||||2015-08-26|2015-09-28|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients|Evaluation of Blood Glucose Levels for Hepatitis B Immune Globulin (HepaGam B) Administration|Completed||Phase 4|5|Actual|Georgetown University||1|||f||||f||||||||||2018-06-01 00:27:34.48651|2018-06-01 00:27:34.48651
NCT00998413|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2013-09-30|2009-10-19|2009-10-20|Estimate|||||||2013-09-30|2013-10-01|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Weight-reduction Intervention in Asthmatic Children With Overweight/Obesity|Secondary Prevention of Asthma in Overweight/Obese Children by a Combined Dietary-behavioural-physical Activity Intervention|Completed||N/A|87|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:27:34.701959|2018-06-01 00:27:34.701959
NCT00998400|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-10-24|2009-10-19|2009-10-20|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2010||2010-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TREATED-ACS||Treatment of Depression in Acute Coronary Syndrome (ACS) Patients|Cognitive-behavioral Treatment of Depression in Patients With Acute Coronary Syndrome|Active, not recruiting||N/A|100|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 00:27:34.780115|2018-06-01 00:27:34.780115
NCT00998387|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-17|2009-10-17|2009-10-20|Estimate|||||||2009-10-17|2009-10-20|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Validation of the Korean Confusion Assessment Method for the Intensive Care Unit (CAM-ICU)|Translation and Validation of the Korean Version of Confusion Assessment Method for the Intensive Care Unit|Completed|||63|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-06-01 00:27:34.84954|2018-06-01 00:27:34.84954
NCT00998374|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2014-01-27||2014-03-19|2009-10-19|2009-10-20|Estimate|2014-03-19|2014-04-21|Estimate||||2014-03-19|2014-04-21|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Observational|||Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge|Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge|Completed|||62|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-06-01 00:27:34.914866|2018-06-01 00:27:34.914866
NCT00998361|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-19|2009-10-19|2009-10-20|Estimate|||||||2009-10-19|2009-10-20|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas|Hematopoietic Stem Cell Transplantation From HLA Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas|Unknown status|Active, not recruiting|Phase 2|140|Actual|St. Orsola Hospital||1|||f||||t||||||||||2018-06-01 00:27:35.377233|2018-06-01 00:27:35.377233
NCT00998348|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2013-06-13|2009-10-19|2009-10-20|Estimate|||||||2013-06-13|2013-06-17|Estimate|July 2009||2009-07-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Study of Parenting Intervention to Prevent Child Obesity|Healthy Child Weight Through Improved Parent Practices and Environmental Change|Completed||N/A|324|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:27:35.449597|2018-06-01 00:27:35.449597
NCT00998335|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2012-08-22||2016-08-22|2009-10-19|2009-10-20|Estimate|2016-06-16|2016-07-29|Estimate||||2016-08-22|2016-09-28|Estimate|June 2007||2007-06-30|June 2016|2016-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||"All participants were started in the Insulin detemir only arm. At week 12 the participants were randomized in a 2:1 ratio between the two arms."|Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes|Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes|Completed||Phase 4|30|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 00:27:35.560906|2018-06-01 00:27:35.560906
NCT00998322|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2015-04-08|2009-10-19|2009-10-20|Estimate|||||||2015-04-08|2015-04-10|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|December 2013|Actual|2013-12-31||Interventional|||A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma|A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma|Completed||Phase 2|34|Actual|Oncolytics Biotech|||||f||||f||||||||||2018-06-01 00:27:36.073271|2018-06-01 00:27:36.073271
NCT00998309|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2012-01-12||2012-04-02|2009-10-19|2009-10-20|Estimate|2012-04-02|2012-05-01|Estimate||||2012-04-02|2012-05-01|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)|Zithromax-SR 2g, Special Investigation For Skin And Soft Tissue Infection, Sexually-Transmitted Infection, And Infection Of The Oral (Regulatory Post Marketing Commitment Plan)|Completed|||502|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:27:36.207445|2018-06-01 00:27:36.207445
NCT00998296|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2014-11-14||2015-07-23|2009-10-19|2009-10-20|Estimate|2015-02-06|2015-02-09|Estimate||||2015-07-23|2015-08-19|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|December 2012|Actual|2012-12-31||Interventional||Treated Set (TS): A treated set (TS) was defined consisting of all patients who received at least one dose of nintedanib or afatinib during the study period.|Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.|Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.|Completed||Phase 1|70|Actual|Boehringer Ingelheim|Statistics of PK parameters are only estimated when at least 2/3 of the data are evaluable.|1|||f||||||||||||||2018-06-01 00:27:37.389782|2018-06-01 00:27:37.389782
NCT00998283|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2014-02-05|2009-10-19|2009-10-20|Estimate|||||||2014-02-05|2014-02-07|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects|A Randomized, Double-Blind, Placebo-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HM10460A (HNK460) When Administered Subcutaneously to Healthy Adult Korean Subjects|Completed||Phase 1|40|Actual|Hanmi Pharmaceutical Company Limited||5|||f||||t||||||||||2018-06-01 00:27:40.380881|2018-06-01 00:27:40.380881
NCT00998270|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-17|||2012-05-31|2009-10-19|2009-10-20|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|October 2017|Anticipated|2017-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma|A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation Compare With Allogeneic Bone Marrow Transplantation in Multiple Myeloma|Unknown status|Recruiting|Phase 2/Phase 3|185|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:27:40.448609|2018-06-01 00:27:40.448609
NCT00998244|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-01-06|2009-10-19|2009-10-20|Estimate|||||||2012-01-06|2012-01-09|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease|A Randomized, Double-Blind Crossover Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease|Completed||N/A|40|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:27:40.686171|2018-06-01 00:27:40.686171
NCT00998231|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-02-24|2009-10-19|2009-10-20|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2009||2009-07-31|February 2014|2014-02-28||||September 2012|Actual|2012-09-30||Interventional|||Major Depression and Messenger RNAs|Major Depression and Messenger RNAs|Completed||N/A|30|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 00:27:40.78135|2018-06-01 00:27:40.78135
NCT00998218|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2012-02-08|2009-10-19|2009-10-20|Estimate|||||||2012-02-08|2012-02-09|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction|The Effect of Ranolazine on Cardiac Arrhythmias and Microvolt T- Wave Alternans in Patients With Significant Left Ventricular Dysfunction|Completed||Phase 3|7|Actual|Aspirus Heart and Vascular Institute-Research and Education||2|||f||||f||||||||||2018-06-01 00:27:40.91686|2018-06-01 00:27:40.91686
NCT00998205|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2016-11-21||2017-04-03|2009-10-19|2009-10-20|Estimate|2017-04-03|2017-04-06|Actual||||2017-04-03|2017-04-06|Actual|June 2008||2008-06-30|April 2017|2017-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction|Early Diagnosis of Diastolic Dysfunction and Reliability of Dobutamine Stress Echo (DSE) in Detecting Stress Diastolic Dysfunction|Completed||N/A|16|Actual|University of Missouri-Columbia||1|||f||||f||||||||Undecided||2018-06-01 00:27:41.015685|2018-06-01 00:27:41.015685
NCT00998192|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2016-03-29|2009-10-19|2009-10-20|Estimate|||||||2016-03-29|2016-03-31|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|September 2013|Actual|2013-09-30||Interventional|||A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung|A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung|Completed||Phase 2|32|Actual|Oncolytics Biotech|||||f||||f||||||||||2018-06-01 00:27:41.195804|2018-06-01 00:27:41.195804
NCT00998179|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-19|2009-10-19|2009-10-20|Estimate|||||||2009-10-19|2009-10-20|Estimate||||October 2009|2009-10-31||||||||Interventional|||Effect of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Expiratory Flow Volume in Healthy Subjects|Effect of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Post-exercise Expiratory Flow Volume in Healthy Subjects|Completed||N/A|11|Actual|The Hong Kong Polytechnic University||2|||f||||||||||||||2018-06-01 00:27:41.318782|2018-06-01 00:27:41.318782
NCT00998166|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2013-09-10|2009-10-16|2009-10-20|Estimate|||||||2013-09-10|2013-09-11|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)|A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma|Terminated||Phase 2|4|Actual|Columbia University||1||Poor enrollment|f||||t||||||||||2018-06-01 00:27:41.410329|2018-06-01 00:27:41.410329
NCT00998153|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2016-03-15|2009-10-19|2009-10-20|Estimate|||||||2016-03-15|2016-03-17|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|RRFT||Risk Reduction for Drug Use and Sexual Revictimization|Risk Reduction for Drug Use and Sexual Revictimization|Unknown status|Recruiting|Phase 1|30|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 00:27:41.510087|2018-06-01 00:27:41.510087
NCT00998140|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2017-04-27|2009-10-19|2009-10-20|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2009||2009-03-31|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Observational|||Optimizing Resuscitation After Cardiac Arrest in the Community|Optimizing Resuscitation After Cardiac Arrest in the Community: Increasing the Probability of Survival While Reducing Costs|Active, not recruiting|||1600|Anticipated|Shaare Zedek Medical Center|||||f||||f||||||||Yes||2018-06-01 00:27:41.578399|2018-06-01 00:27:41.578399
NCT00998127|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2016-02-10|2009-10-19|2009-10-20|Estimate|||||||2016-02-10|2016-02-11|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|PARIS||Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients|Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)|Completed|||5031|Actual|Icahn School of Medicine at Mount Sinai|||||f||||t||||||||||2018-06-01 00:27:41.660509|2018-06-01 00:27:41.660509
NCT00998114|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2016-10-03|2009-10-19|2009-10-20|Estimate|||||||2016-10-03|2016-10-05|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Early Detection of Diastolic Dysfunction and the Role of Lifestyle Measures in Its Treatment|Early Detection of Diastolic Dysfunction and the Role of Lifestyle Measures in Its Treatment|Completed||N/A|9|Actual|University of Missouri-Columbia||1|||f||||f||||||||No||2018-06-01 00:27:41.769461|2018-06-01 00:27:41.769461
NCT00998101|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-17|||2012-03-05|2009-10-17|2009-10-20|Estimate|||||||2012-03-05|2012-03-06|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy|A Phase II Trial of Carboplatin, Ixabepilone and Cetuximab in Chemotherapy Naive Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|UNC Lineberger Comprehensive Cancer Center||||Study was withdrawn due issuses related to the science|f||||t||||||||||2018-06-01 00:27:41.849882|2018-06-01 00:27:41.849882
NCT00998088|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2009-10-19|2009-10-19|2009-10-20|Estimate|||||||2009-10-19|2009-10-20|Estimate|May 2004||2004-05-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|TOMaat||Blood Management in Orthopedic Surgery|"Optimal Blood Management in Elective Orthopaedic Surgery: The Transfusion Op Maat (TOMaat) Study"|Completed||Phase 4|2598|Actual|Sanquin Research & Blood Bank Divisions||6|||f||||t||||||||||2018-06-01 00:27:41.965335|2018-06-01 00:27:41.965335
NCT00998075|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2010-12-06|2009-10-19|2009-10-20|Estimate|||||||2010-12-06|2010-12-07|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately|A Phase I, Open-Label, Randomized, Single-Centre, 3-Way Crossover Bioequivalence Study Comparing a Fixed Dose Combination Capsule of Esomeprazole 40 mg and Acetylsalicylic Acid 325 mg With Free Combinations of Esomeprazole Capsule 40 mg and Acetylsalicylic Acid Tablet 325 mg and Esomeprazole Tablet|Completed||Phase 1|138|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 00:27:42.117965|2018-06-01 00:27:42.117965
NCT00998062|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2011-10-19|2009-10-19|2009-10-20|Estimate|||||||2011-10-19|2011-10-20|Estimate|November 2009||2009-11-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|DARIOS||Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain|Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population|Completed|||30181|Anticipated|AstraZeneca|||1||f||||f||||||None Retained|"~     No samples will be obtained, but biomarkers will be analysed from frozen serum samples~     retained by the pervious studies performed.~   "|||2018-06-01 00:27:42.210759|2018-06-01 00:27:42.210759
NCT00998049|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2012-06-26||2015-04-24|2009-10-19|2009-10-20|Estimate|2012-06-26|2012-07-30|Estimate||||2015-04-24|2015-05-14|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|November 2011|Actual|2011-11-30||Interventional|||Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant|Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy|Completed||Phase 2|40|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:27:42.285969|2018-06-01 00:27:42.285969
NCT00998036|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-12-11|2009-10-19|2009-10-20|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2009||2009-09-30|December 2017|2017-12-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors|Phase I Study of Combined Temsirolimus, Erlotinib and Cisplatin in Advanced Solid Tumors|Completed||Phase 1|9|Actual|Columbia University||1|||f||||t|t|f|||f|||||2018-06-01 00:27:42.483843|2018-06-01 00:27:42.483843
NCT00998023|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2011-09-21||2011-12-05|2009-10-19|2009-10-20|Estimate|2011-12-05|2011-12-06|Estimate||||2011-12-05|2011-12-06|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Patient Comfort With Vascular Closure|Patient Comfort Study With Vascular Closure: Mynx vs. Angio-Seal Evolution|Completed||N/A|64|Actual|University of Florida|The Angio-Seal Evolution is only one of a variety of potential vascular closure devices available on the market that would be suitable for comparison with the Mynx; however, this study was limited to just one of such alternative devices.|2|||f||||f||||||||||2018-06-01 00:27:42.566416|2018-06-01 00:27:42.566416
NCT00998010|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-17|||2017-11-09|2009-10-17|2009-10-20|Estimate|||||||2017-11-09|2017-11-14|Actual|June 7, 2011||2011-06-07|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme|Active, not recruiting||Phase 2|25|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:27:42.961174|2018-06-01 00:27:42.961174
NCT00997997|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-11-14|2009-10-19|2009-10-20|Estimate|||||||2012-11-14|2012-11-16|Estimate|October 2005||2005-10-31|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|ARTOS||Avelox in Complicated Skin and Skin Structure Infections|ARTOS - Avelox® in Routine Treatment of Complicated Skin and Skin Structure Infections|Completed|||6127|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:27:43.051461|2018-06-01 00:27:43.051461
NCT00997984|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|2011-09-16||2014-01-07|2009-10-19|2009-10-20|Estimate|2011-09-16|2011-10-26|Estimate||||2014-01-07|2014-02-06|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)|A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|340|Actual|Shire||3|||f||||||||||||||2018-06-01 00:27:43.193733|2018-06-01 00:27:43.193733
NCT00997971|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2009-10-19|2009-10-19|2009-10-20|Estimate|||||||2009-10-19|2009-10-20|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|Rose||Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein|Phase 3 Safety Study of a Partially Hydrolyzed Rice Protein Formula in Healthy Infants|Completed||Phase 3|86|Actual|Sodilac||1|||f||||f||||||||||2018-06-01 00:27:44.002061|2018-06-01 00:27:44.002061
NCT00997958|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2014-04-24|2009-10-16|2009-10-20|Estimate|||||||2014-04-24|2014-04-25|Estimate|June 2004||2004-06-30|April 2014|2014-04-30|January 2009|Actual|2009-01-31|October 2007|Actual|2007-10-31||Interventional|||Study of CellCept for Advanced Pancreatic Cancer|Phase I Study of CellCept for Advanced Pancreatic Cancer|Completed||Phase 1|12|Actual|Columbia University||1|||f||||t||||||||||2018-06-01 00:27:44.06837|2018-06-01 00:27:44.06837
NCT00997945|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2011-05-18|2009-10-19|2009-10-20|Estimate|||||||2011-05-18|2011-05-19|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies|A Phase I, Open-label, Single-arm Study to Determine the Single and Multiple Dose Pharmacokinetics of 10mg ZD4054 (Zibotentan) Administered Once Daily in Male, Elderly Chinese Patients With Advanced Solid Malignancies|Completed||Phase 1|15|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:27:45.09322|2018-06-01 00:27:45.09322
NCT00997932|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|2017-01-11||2017-03-28|2009-10-16|2009-10-20|Estimate|2017-03-28|2017-03-29|Actual||||2017-03-28|2017-03-29|Actual|June 2009||2009-06-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|October 2010|Actual|2010-10-31||Interventional|ImmPPIUD||A Pilot Study of Early Postpartum Intrauterine Contraception|A Pilot Study of Early Postpartum Intrauterine Contraception|Completed||Phase 4|40|Actual|University of North Carolina, Chapel Hill||1|||f||||f|t|f||||||No||2018-06-01 00:27:45.195047|2018-06-01 00:27:45.195047
NCT00997919|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-19|||2017-05-25|2009-10-19|2009-10-20|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2009|Actual|2009-10-31|May 2017|2017-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers|A Phase I, Single-Dose, Randomized, Parallel-Group, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers|Completed||Phase 1|22|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 00:27:45.355849|2018-06-01 00:27:45.355849
NCT00997906|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-17|||2018-03-28|2009-10-17|2009-10-20|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2009||2009-09-30|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC|A Randomised Phase II/III Study of Concurrent Cisplatin-Radiotherapy With or Without Induction Chemotherapy Using Gemcitabine, Carboplatin and Paclitaxel in Locally Advanced Nasopharyngeal Cancer|Active, not recruiting||Phase 2/Phase 3|172|Anticipated|National Cancer Centre, Singapore||2|||f||||t||||||||No||2018-06-01 00:27:45.412056|2018-06-01 00:27:45.412056
NCT00997880|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2014-12-23|2009-10-18|2009-10-19|Estimate|||||||2014-12-23|2014-12-25|Estimate|April 2010||2010-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|STABLE||Statin and Atheroma Vulnerability Evaluation|Effect of High-Dose and Low-Dose Statin for Coronary Plaque Modification|Completed||Phase 4|312|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 00:27:45.565362|2018-06-01 00:27:45.565362
NCT00997867|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2010-10-27|2009-10-18|2009-10-19|Estimate|||||||2010-10-27|2010-10-28|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Perineural Catheter Insertion Distance for Continuous Peripheral Nerve Blocks|Perineural Catheter Insertion Distance for Continuous Peripheral Nerve Blocks|Completed||Phase 4|350|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 00:27:45.642418|2018-06-01 00:27:45.642418
NCT00997854|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2010-07-21|2009-10-18|2009-10-19|Estimate|||||||2010-07-21|2010-07-22|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Preterm Neonatal Feeding Protocol Comparing Feed Administration Time|Preterm Neonatal Feeding Protocol Comparing Feed Administration Time|Unknown status|Recruiting|N/A|136|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 00:27:46.537778|2018-06-01 00:27:46.537778
NCT00997841|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2010-05-03|2009-10-18|2009-10-19|Estimate|||||||2010-05-03|2010-05-04|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Conventional Versus Point-of-care Based Coagulation Management|Conventional Versus Point-of-care Based Coagulation Management in Cardiac Surgery Patients Suffering From Increased Bleeding Tendency - a Prospective and Randomized Study|Completed||Phase 4|200|Anticipated|Goethe University||2|||f||||f||||||||||2018-06-01 00:27:46.616356|2018-06-01 00:27:46.616356
NCT00997828|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2018-05-21|2009-10-18|2009-10-19|Estimate|||||||2018-05-21|2018-05-22|Actual|July 28, 2008|Actual|2008-07-28|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|April 2016|Actual|2016-04-30||Interventional|BEST||Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST)|Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease (BEST)|Active, not recruiting||N/A|888|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 00:27:46.698235|2018-06-01 00:27:46.698235
NCT00997815|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2012-08-01|2009-10-18|2009-10-19|Estimate|||||||2012-08-01|2012-08-02|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis|The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis|Completed||Phase 2/Phase 3|20|Actual|Siriraj Hospital||2|||f||||f||||||||||2018-06-01 00:27:46.825347|2018-06-01 00:27:46.825347
NCT00997802|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2017-03-16|2009-10-18|2009-10-19|Estimate|||||||2017-03-16|2017-03-17|Actual|October 2009||2009-10-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 11, 2015|Actual|2015-12-11||Interventional|JANCT||Japanese National Computed Tomographic (CT) Colonography Trial|Evaluation of Accuracy of Computed Tomographic Colonography (CTC) in the Diagnosis of Colorectal Tumors by Gastroenterologists and Radiologists With Computer-aided Detection (CAD): A Multicenter Study|Completed||N/A|1257|Actual|Japanese CT Colonography Society||1|||f||||||||||||||2018-06-01 00:27:46.903195|2018-06-01 00:27:46.903195
NCT00997789|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-18|2009-10-18|2009-10-19|Estimate|||||||2009-10-18|2009-10-19|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Bioequivalence of Rebamipide in Korean|Bioequivalence Evaluation of Two Rebamipide Preparations After a Single Oral Dose to Healthy Korean Volunteers|Completed||N/A|30|Actual|Chonnam National University Hospital||1|||f||||t||||||||||2018-06-01 00:27:47.084552|2018-06-01 00:27:47.084552
NCT00997776|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-18|2009-10-18|2009-10-19|Estimate|||||||2009-10-18|2009-10-19|Estimate|August 2002||2002-08-31|October 2009|2009-10-31|June 2006|Actual|2006-06-30|January 2006|Actual|2006-01-31||Interventional|||Effect of Leg Strengthening Exercise After Hip Fracture|Effect of Leg Strengthening Exercise After Hip Fracture|Completed||Phase 1/Phase 2|26|Actual|Arcadia University||2|||f||||f||||||||||2018-06-01 00:27:47.161681|2018-06-01 00:27:47.161681
NCT00997763|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2016-12-12|2009-10-18|2009-10-19|Estimate|||||||2016-12-12|2016-12-13|Estimate|July 2008||2008-07-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ESSENCE-DM||Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus|Randomized Comparison of Everolimus- Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus|Completed||Phase 4|300|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-06-01 00:27:47.305122|2018-06-01 00:27:47.305122
NCT00997750|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-18|2009-10-18|2009-10-19|Estimate|||||||2009-10-18|2009-10-19|Estimate|March 2007||2007-03-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|PLEA||Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome|Prospective Randomized Double-center Study of Nonsteroidal Antinflammatory Drug Lornoxicam in Patients With Acute Coronary Syndrome Without Persistent ST- Segment Elevation|Completed||Phase 4|85|Actual|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||t||||||||||2018-06-01 00:27:47.424087|2018-06-01 00:27:47.424087
NCT00997737|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2010-05-27|2009-10-18|2009-10-19|Estimate|||||||2010-05-27|2010-05-28|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Diaphragm Activity During Incentive Spirometry and Diaphragmatic Breathing|Diaphragm Mobility During Respiratory Exercises With Incentive Spirometry in Healthy Individuals|Completed||Phase 1|17|Actual|Hospital Sirio-Libanes||1|||f||||t||||||||||2018-06-01 00:27:47.512444|2018-06-01 00:27:47.512444
NCT00997724|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2010-01-04|2009-10-18|2009-10-19|Estimate|||||||2010-01-04|2010-01-05|Estimate|February 1996||1996-02-29|October 2009|2009-10-31|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|VATS||Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung Cancer|Feasibility of Assisted-VATS(Video-Assisted Thoracoscopic Surgery) Sleeve Lobectomy for Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||1|||f||||t||||||||||2018-06-01 00:27:47.594405|2018-06-01 00:27:47.594405
NCT00997711|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2015-11-16|2009-10-18|2009-10-19|Estimate|||||||2015-11-16|2015-11-17|Estimate|April 2009||2009-04-30|November 2015|2015-11-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|DESSIAN||Evaluation of Diabetic Effects on Clinical Outcomes After Sirolimus-Eluting Stents in the AsIAN Population|Evaluation of Diabetic Effects on Clinical Outcomes After Sirolimus-Eluting Stents in the AsIAN Population|Completed||Phase 4|953|Actual|CardioVascular Research Foundation, Korea||1|||f||||t||||||||||2018-06-01 00:27:47.670145|2018-06-01 00:27:47.670145
NCT00997698|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-26|2009-10-18|2009-10-19|Estimate|||||||2009-10-26|2009-10-27|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Observational|EIIA||Contrast-enhanced Magnetic Resonance Angiography Investigation of Intracranial Aneurysms and Prospective Study of Risk Factors|Imaging Epidemiological Investigation of Intracranial Aneurysms and the Prospective Study of Risk Factors：Assessment of MR Imaging Trail|Unknown status|Enrolling by invitation||4000|Anticipated|Second Military Medical University|||||f||||t||||||||||2018-06-01 00:27:47.780626|2018-06-01 00:27:47.780626
NCT00997685|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-18|||2009-10-18|2009-10-18|2009-10-19|Estimate|||||||2009-10-18|2009-10-19|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)|A Single Arm, Open-label Phase II Study to Evaluate the Efficacy and Safety of Capecitabine Plus Oxaliplatin (XELOX) in the Peri-operative Treatment of Patients With Potentially Resectable Liver Metastasis From Colorectal Cancer|Unknown status|Not yet recruiting|Phase 2|110|Anticipated|Guangdong General Hospital||1|||f||||f||||||||||2018-06-01 00:27:47.839578|2018-06-01 00:27:47.839578
NCT00997672|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2013-03-06||2013-12-17|2009-10-18|2009-10-19|Estimate|2013-12-17|2014-02-03|Estimate||||2013-12-17|2014-02-03|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|LAMU||Lithium in Multiple System Atrophy|A Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy.|Terminated||Phase 2|10|Actual|Federico II University|Limitation of the study is small sample size of nine randomized patients. This may have determined uneven distribution of AEs due to random variation. Taking into account these limitations, we do not encourage future studies with lithium in MSA.|2||Data Monitoring Committee decision on 22nd August 2011 for safety issues|f||||t||||||||||2018-06-01 00:27:47.932313|2018-06-01 00:27:47.932313
NCT00997659|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2011-08-11|2009-10-16|2009-10-19|Estimate|||||||2011-08-11|2011-08-12|Estimate|April 2007||2007-04-30|August 2011|2011-08-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Chromium's Effect on Insulin Resistance in Obesity|Efficacy and Safety of Chromium as a Therapeutic Intervention for Insulin Resistance Associated With Obesity|Completed||N/A|40|Anticipated|Stony Brook University||1|||f||||t||||||||||2018-06-01 00:27:48.199866|2018-06-01 00:27:48.199866
NCT00997646|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2009-10-16|2009-10-16|2009-10-19|Estimate|||||||2009-10-16|2009-10-19|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Observational|||Performance of a Hospitalist-run Ward: a Prospective Observational Study||Unknown status|Recruiting||500|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 00:27:48.355159|2018-06-01 00:27:48.355159
NCT00997633|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-16|2009-10-16|2009-10-19|Estimate|||||||2009-10-16|2009-10-19|Estimate|May 1991||1991-05-31|October 2009|2009-10-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Observational|||Single-photon Emission Computed Tomography (SPECT) to Predict Peritoneal Chemotherapy|Single-photon Emission Computed Tomography for Prediction of Treatment Results in Sequential Intraperitoneal Chemotherapy at Peritoneal Carcinomatosis|Completed|||51|Actual|Uppsala University|||1||f||||f||||||||||2018-06-01 00:27:48.427638|2018-06-01 00:27:48.427638
NCT00997620|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2017-03-15||2018-05-14|2009-10-16|2009-10-19|Estimate|2018-05-14|2018-05-18|Actual||||2018-05-14|2018-05-18|Actual|March 2010||2010-03-31|May 2018|2018-05-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Fluticasone Furoate Treatment of Daytime Somnolence and Cognitive Performance in Seasonal Allergic Rhinitis|A Double Blind, Placebo Controlled Randomized Trial Evaluating the Effects of Fluticasone Nasal Spray in Subjects With Seasonal Allergic Rhinitis and a History of Sleep Disturbance on Cognitive Performance and Daytime Sleepiness|Completed||Phase 4|40|Actual|Western Sky Medical Research||2|||f||||f||||||||Undecided|This a single study site and at end IPD will be used in analyis by PI|2018-06-01 00:27:48.508441|2018-06-01 00:27:48.508441
NCT00997607|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2013-01-25|2009-10-16|2009-10-19|Estimate|||||||2013-01-25|2013-01-28|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluating an Ebola and a Marburg Vaccine in Uganda|A Phase IB Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults in Kampala, Uganda|Completed||Phase 1|108|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 00:27:48.879858|2018-06-01 00:27:48.879858
NCT00997594|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2010-10-27||2015-04-06|2009-10-16|2009-10-19|Estimate|2011-01-27|2011-02-23|Estimate||||2015-04-06|2015-04-28|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation|Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation|Completed||Phase 2/Phase 3|18|Actual|Mie University|Small patient series is one of limitations of this study|2|||f||||t||||||||||2018-06-01 00:27:48.979305|2018-06-01 00:27:48.979305
NCT00997581|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2018-03-29|2009-10-16|2009-10-19|Estimate|||||||2018-03-29|2018-04-02|Actual|April 2010|Anticipated|2010-04-30|March 2018|2018-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Apremilast Therapy for Acute Gouty Arthritis|Apremilast Therapy for Acute Gouty Arthritis|Withdrawn||Phase 2|0|Actual|Dartmouth-Hitchcock Medical Center||2||Colaborator withdrew support.|f||||t||||||||||2018-06-01 00:27:49.223501|2018-06-01 00:27:49.223501
NCT00997568|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2010-08-19|2009-10-16|2009-10-19|Estimate|||||||2010-08-19|2010-08-20|Estimate|October 2009||2009-10-31|August 2010|2010-08-31||||||||Observational|TEE||Safety of the PET-511BTM Transesophageal Transducer|Safety of the PET-511BTM Transesophageal Transducer (TEE)|Completed|||50|Anticipated|Toshiba America Medical Systems, Inc.|||1||f||||t||||||||||2018-06-01 00:27:49.290471|2018-06-01 00:27:49.290471
NCT00997555|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2012-09-04||2012-12-22|2009-10-16|2009-10-19|Estimate|2012-12-22|2013-01-31|Estimate||||2012-12-22|2013-01-31|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients|Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients|Completed||N/A|28|Actual|Hurley Medical Center||2|||f||||f||||||||||2018-06-01 00:27:49.376122|2018-06-01 00:27:49.376122
NCT00997542|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-16|2009-10-16|2009-10-19|Estimate|||||||2009-10-16|2009-10-19|Estimate||||October 2009|2009-10-31||||||||Interventional|||Allopurinol in Chronic Heart Failure|A Double-blind, Placebo-controlled, Cross-over Study of the Effects of Allopurinol on Oxidative Metabolism, Peripheral Blood Flow and Immune Function in Patients With Advanced Chronic Heart Failure (CHF).|Completed||Phase 4|16|Actual|National Heart and Lung Institute||2|||f||||||||||||||2018-06-01 00:27:49.748656|2018-06-01 00:27:49.748656
NCT00997529|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2016-07-14|2009-10-16|2009-10-19|Estimate|||||||2016-07-14|2016-07-18|Estimate|November 2000||2000-11-30|July 2016|2016-07-31|June 2010|Actual|2010-06-30|November 2007|Actual|2007-11-30||Interventional|MiniSolid||Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors|Nonmyeloablative Allogeneic Stem Cell Transplantation for the Treatment of Solid|Completed||N/A|14|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-06-01 00:27:49.81358|2018-06-01 00:27:49.81358
NCT00997516|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2014-08-06||2014-08-06|2009-10-16|2009-10-19|Estimate|2014-08-06|2014-08-22|Estimate||||2014-08-06|2014-08-22|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|December 2012|Actual|2012-12-31||Interventional|||Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis|A Randomized, Controlled Trial of Single-incision Laparoscopic (SILS) Versus Conventional Laparoscopic Appendectomy for the Treatment of Acute Appendicitis|Terminated||N/A|75|Actual|University of California, San Francisco||2||Planned interim analysis showed worse outcomes in experimental group|f||||f||||||||||2018-06-01 00:27:49.897103|2018-06-01 00:27:49.897103
NCT00997503|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2014-03-13||2015-07-20|2009-10-16|2009-10-19|Estimate|2015-03-25|2015-04-13|Estimate||||2015-07-20|2015-08-07|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|July 2015|Actual|2015-07-31|March 2013|Actual|2013-03-31||Observational|||TAXUS Libertē Post Approval Study|TAXUS Libertē Post Approval Study: A U.S. Post-Approval Study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System|Completed|||4199|Actual|Boston Scientific Corporation|||||f||||t||||||||||2018-06-01 00:27:50.555507|2018-06-01 00:27:50.555507
NCT00997490|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2010-05-14|2009-10-16|2009-10-19|Estimate|||||||2010-05-14|2010-05-17|Estimate|January 2001||2001-01-31|May 2010|2010-05-31|February 2003|Actual|2003-02-28|July 2002|Actual|2002-07-31||Interventional|||Study of the Antidepressant Efficacy of a Combination Herbal Drug Preparation (NEURAPAS Balance)|Phase III Placebo-controlled, Randomised, Single-centre, Double-blind Study of the Antidepressant Efficacy of a Combination Herbal Drug Preparation|Terminated||Phase 3|67|Actual|Pascoe Pharmazeutische Praeparate GmbH||2||Clearly identifiable benefits 50% of patients included|f||||t||||||||||2018-06-01 00:27:52.350188|2018-06-01 00:27:52.350188
NCT00997477|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2017-04-19|2009-10-16|2009-10-19|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2010||2010-06-30|March 2016|2016-03-31||||July 2010|Anticipated|2010-07-31||Interventional|||Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics|A Single Arm, 12 Week, Multicentre, Open Label, Phase IV Study to Evaluate Correct Use of and Patient Satisfaction From Sequential Use of Formoterol and Budesonide Inhaler Capsules Via Aerolizer™ Device in Patients With Asthma.|Withdrawn||Phase 4|0|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:27:52.436105|2018-06-01 00:27:52.436105
NCT00997464|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-16|2009-10-16|2009-10-19|Estimate|||||||2009-10-16|2009-10-19|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|||An Exploration of Genetic Testing for Prostate Cancer Susceptibility|An Exploration of Factors Affecting Interest and Uptake of Genetic Testing for Prostate Cancer Susceptibility: The Clinical Application of Genetic Testing for Lower Risk Cancer Predisposition Genes|Unknown status|Recruiting||200|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:27:52.515914|2018-06-01 00:27:52.515914
NCT00997451|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-28|||2012-09-28|2009-10-16|2009-10-19|Estimate|||||||2012-09-28|2012-10-01|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Fatigue Self-Management in Primary Care|Fatigue Self- Management in Primary Care: Efficacy, Credibility, and Economics|Completed||N/A|107|Actual|Stony Brook University||3|||f||||f||||||||||2018-06-01 00:27:52.605453|2018-06-01 00:27:52.605453
NCT00997438|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2016-09-30||2016-11-30|2009-10-16|2009-10-19|Estimate|2016-11-30|2017-01-26|Estimate||||2016-11-30|2017-01-26|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis|Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis|Completed||Phase 1|69|Actual|Portland VA Medical Center||3|||f||||f||||||||||2018-06-01 00:27:52.711726|2018-06-01 00:27:52.711726
NCT00997425|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2013-10-09||2014-11-19|2009-10-15|2009-10-19|Estimate|2014-11-19|2014-11-21|Estimate||||2014-11-19|2014-11-21|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|October 2010|Actual|2010-10-31||Interventional|HEEBW||Home Evaluation of Exit Barriers in Wandering|Home Evaluation of Visual Exit Barriers in Dementia-related Wandering|Completed||N/A|19|Actual|VA Office of Research and Development|Radio Frequency Identification Device measurement method cumbersome and obtrusive; small sample size (n=19). Further investigation is necessary in order to draw conclusions about visual barriers deterring wandering defined as exit door approaching.|1|||f||||f||||||||||2018-06-01 00:27:53.184813|2018-06-01 00:27:53.184813
NCT00997412|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-16|2009-10-16|2009-10-19|Estimate|||||||2009-10-16|2009-10-19|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|Myfortic||Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis|Randomized, Double-blind, Double-dummy Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis|Unknown status|Active, not recruiting|N/A|40|Anticipated|Qualitix Clinical Research Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:27:53.411766|2018-06-01 00:27:53.411766
NCT00997399|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2014-11-05|2009-10-16|2009-10-19|Estimate|||||||2014-11-05|2014-11-06|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function|A Phase I, Open-label, Multi-center Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Varying Degrees of Renal Function|Completed||Phase 1|37|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:27:53.489959|2018-06-01 00:27:53.489959
NCT00997386|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2016-03-30|2009-10-16|2009-10-19|Estimate|||||||2016-03-30|2016-04-01|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|January 2016|Actual|2016-01-31|April 2014|Actual|2014-04-30||Interventional|ALBUM||Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States|A Phase II Study of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Treatment of Hematologic Malignancies and Hematopoietic Failure States|Completed||Phase 2|16|Actual|University of Arizona||1|||f||||t||||||||||2018-06-01 00:27:53.575057|2018-06-01 00:27:53.575057
NCT00997373|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2015-01-26||2017-05-25|2009-10-16|2009-10-19|Estimate|2015-04-03|2015-04-06|Estimate||||2017-05-25|2017-05-30|Actual|October 2009||2009-10-31|May 2017|2017-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Subjects and controls selected to give groups similar in age and tumor grade. Four subjects excluded - wrong tumor type. One treatment arm completed but was excluded from analysis because of late completion.|Letrozole as a Treatment of Endometrial Cancer|Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma|Completed||N/A|43|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 00:27:53.672882|2018-06-01 00:27:53.672882
NCT00997360|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-12-01|2009-10-16|2009-10-19|Estimate|||||||2009-12-01|2009-12-02|Estimate|February 2010||2010-02-28|December 2009|2009-12-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Study of PKI-179 Administered Orally to Subjects With Solid Tumors|A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors|Terminated||Phase 1|80|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 00:27:54.161973|2018-06-01 00:27:54.161973
NCT00997347|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-06-28|2009-10-16|2009-10-19|Estimate|||||||2012-06-28|2012-07-02|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Extended Gestational Age Medical Abortion Study|The Extended Gestational Age Medical Abortion Study: The Effectiveness of Medical Abortion With Mifepristone and Misoprostol at 57-63 Days Versus 64-70 Days Gestation|Completed||Phase 4|1400|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-06-01 00:27:54.245834|2018-06-01 00:27:54.245834
NCT00997334|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2017-01-05||2018-01-29|2009-10-16|2009-10-19|Estimate|2017-02-28|2017-04-11|Actual||||2018-01-29|2018-02-23|Actual|February 2010|Actual|2010-02-28|January 2018|2018-01-31|January 2017|Actual|2017-01-31|May 2015|Actual|2015-05-31||Interventional||The analysis data is comprised of all treated patients|Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC|First-Line Erlotinib Therapy and the Subsequent Development of Mechanisms of Secondary Resistance in Patients With Non-Small Cell Lung Cancer and Known Sensitizing EGFR Mutations|Completed||Phase 2|60|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 00:27:54.418397|2018-06-01 00:27:54.418397
NCT00997321|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2011-07-20||2012-03-28|2009-10-16|2009-10-19|Estimate|2012-02-22|2012-03-26|Estimate||||2012-03-28|2012-04-02|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Propofol Versus Ketamine for Moderate Procedural Sedation in the Emergency Department (ED)|Propofol Versus Ketamine for Procedural Sedation During Painful Procedures in the Emergency Department|Completed||Phase 4|100|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-06-01 00:27:54.772909|2018-06-01 00:27:54.772909
NCT00997308|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2010-01-21|2009-10-16|2009-10-19|Estimate|||||||2010-01-21|2010-01-22|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Healthy Elderly Male and Female Volunteers During 4 Weeks of Treatment|Completed||Phase 1|97|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:27:55.232301|2018-06-01 00:27:55.232301
NCT00997295|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-16|2009-10-16|2009-10-19|Estimate|||||||2009-10-16|2009-10-19|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|June 2008|Actual|2008-06-30||Observational|||Heat and Moisture Exchanger and Low-flow Gas|The Effects of a Heat and Moisture Exchanger on Temperature and Humidity in Low -Flow Anesthesia Workstation|Completed|||30|Actual|UPECLIN HC FM Botucatu Unesp|||4||f||||t||||||||||2018-06-01 00:27:55.310771|2018-06-01 00:27:55.310771
NCT00997282|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2014-01-06|2009-10-16|2009-10-19|Estimate|||||||2014-01-06|2014-01-08|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of OPC-262 in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arms Parallel Group Comparative Study of OPC-262 in Patients With Type 2 Diabetes (Phase 2/3 Study)|Completed||Phase 2/Phase 3|255|Anticipated|Kyowa Hakko Kirin Co., Ltd||3|||f||||f||||||||||2018-06-01 00:27:55.36556|2018-06-01 00:27:55.36556
NCT00997269|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2016-04-28|2009-10-16|2009-10-19|Estimate|||||||2016-04-28|2016-05-02|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CoQ-10||Benefit of CoQ-10 in Patients on Statins|Benefit of CoQ-10 in Patients on Statins|Completed||N/A|37|Actual|Stony Brook University||2|||f||||t||||||||||2018-06-01 00:27:55.437959|2018-06-01 00:27:55.437959
NCT00997256|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2010-05-14|2009-10-16|2009-10-19|Estimate|||||||2010-05-14|2010-05-17|Estimate|December 2004||2004-12-31|May 2010|2010-05-31|February 2005|Actual|2005-02-28|January 2005|Actual|2005-01-31||Interventional|sleep-EEG||Study to Investigate Effects of a Herbal Drug Compared to Placebo on Sleep|Phase I, Placebo-controlled, Double-blind, Randomised, Single-centre Study of Single Cross-over Design to Investigate the Effects of the Herbal Preparation Neurapas® Balance Compared With Placebo on Sleep EEG, Mental Performance and Well-being|Completed||Phase 1|20|Actual|Pascoe Pharmazeutische Praeparate GmbH||2|||f||||t||||||||||2018-06-01 00:27:55.501274|2018-06-01 00:27:55.501274
NCT00997243|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2013-05-07||2017-04-03|2009-10-16|2009-10-19|Estimate|2013-10-31|2013-11-26|Estimate||||2017-04-03|2017-05-10|Actual|November 2009|Actual|2009-11-30|April 2017|2017-04-30|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|||Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes|Phase II Study of 5-azacytidine and Lintuzumab in Myelodysplastic Syndromes (MDS)|Terminated||Phase 2|7|Actual|Ohio State University Comprehensive Cancer Center|The study was terminated early by the sponsor due to the removal of lintuzumab from the market.|1||Drug no longer being supplied by sponsor|f||||t||||||||||2018-06-01 00:27:55.581031|2018-06-01 00:27:55.581031
NCT00997230|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2013-10-25|2009-10-16|2009-10-19|Estimate|||||||2013-10-25|2013-10-28|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|REASON||Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m|An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer (Stage IIIB/IV Non-small Cell Lung Cancer)|Completed|||4243|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:27:56.056003|2018-06-01 00:27:56.056003
NCT00997217|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2011-02-22|2009-10-16|2009-10-19|Estimate|||||||2011-02-22|2011-02-24|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|RIPC||The Effect of Remote Ischemic Preconditioning in the Cardiac Surgery|The Effect of Remote Ischemic Preconditioning on Mortality and Morbidity in Cardiac Surgery: a Randomized Controlled Trial|Completed||Phase 1|1200|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 00:27:56.278994|2018-06-01 00:27:56.278994
NCT00997204|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|2013-11-04||2014-06-30|2009-10-16|2009-10-19|Estimate|2014-06-30|2014-07-28|Estimate||||2014-06-30|2014-07-28|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|EASSI||EASSI - Evaluation of the Safety of Self-Administration With Icatibant|Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema|Completed||Phase 3|151|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:27:56.382001|2018-06-01 00:27:56.382001
NCT00997191|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-02-28|2009-10-16|2009-10-19|Estimate|||||||2013-02-28|2013-03-04|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|IBeTA||Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)|Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)|Completed||Phase 3|12|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-06-01 00:27:56.799163|2018-06-01 00:27:56.799163
NCT00997178|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2014-01-17|2009-10-16|2009-10-19|Estimate|||||||2014-01-17|2014-01-20|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|DPTT||Diabetes and Periodontal Therapy Trial|A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis|Completed||Phase 3|514|Actual|Stony Brook University||2|||f||||t||||||||||2018-06-01 00:27:56.97024|2018-06-01 00:27:56.97024
NCT00997165|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2009-10-16|2009-10-16|2009-10-19|Estimate|||||||2009-10-16|2009-10-19|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|March 2017|Anticipated|2017-03-31|March 2014|Anticipated|2014-03-31||Observational|NUMEVOX||Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort|Impact of Adipose Tissue Repartition on the Time Course of Vascular Dysfunction - the NUMEVOX Cohort|Unknown status|Recruiting||500|Anticipated|University Hospital, Angers|||3||f||||f||||||Samples With DNA|"~     serum and DNA~   "|||2018-06-01 00:27:57.060408|2018-06-01 00:27:57.060408
NCT00997152|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14||2013-01-31|2013-01-31|2009-10-16|2009-10-19|Estimate||||2013-01-31|2013-02-04|Estimate|2013-01-31|2013-02-04|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients|A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-Center, Parallel Group Study Evaluating the Efficacy, Safety and Pharmacokinetics of JTT-654 Administered for 12 Weeks in Untreated or Metformin-treated Type 2 Diabetic Patients|Terminated||Phase 2|152|Actual|Akros Pharma Inc.||3|||f||||f||||||||||2018-06-01 00:27:57.130568|2018-06-01 00:27:57.130568
NCT00997139|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2012-04-10||2014-12-11|2009-10-16|2009-10-19|Estimate|2012-04-10|2012-05-08|Estimate||||2014-12-11|2015-01-05|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment|Clearance of Nasal Staphylococcus Aureus Colonization With Triple Antibiotic Ointment|Completed||N/A|216|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 00:27:57.239569|2018-06-01 00:27:57.239569
NCT00997126|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2016-09-12||2016-12-01|2009-10-16|2009-10-19|Estimate|2016-12-01|2017-01-27|Estimate||||2016-12-01|2017-01-27|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation|Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation in the Emergency Department|Completed||Phase 4|126|Actual|Minneapolis Medical Research Foundation|our capability of administering nitrous oxide was diminished as the trial was started, and the trial was conducted using on the propofol and alfentanil arms.|2|||f||||t||||||||||2018-06-01 00:27:57.41928|2018-06-01 00:27:57.41928
NCT00997113|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2014-03-28||2014-09-21|2009-10-16|2009-10-19|Estimate|2014-09-21|2014-09-25|Estimate||||2014-09-21|2014-09-25|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Stress During Deep Sedation With Propofol With and Without Alfentanil|Physiologic Stress During Procedural Sedation With and Without Alfentanil|Completed||Phase 4|20|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-06-01 00:27:57.822305|2018-06-01 00:27:57.822305
NCT00997100|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-16|||2015-06-24|2009-10-16|2009-10-19|Estimate|||||||2015-06-24|2015-06-25|Estimate|August 2009||2009-08-31|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)|An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|13|Actual|Active Biotech AB||1|||f||||f||||||||||2018-06-01 00:27:58.236629|2018-06-01 00:27:58.236629
NCT00997087|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2014-04-18|2009-10-15|2009-10-16|Estimate|||||||2014-04-18|2014-04-22|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|OCD||A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder|Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.|Terminated||Phase 2|11|Actual|Parkway Medical Center||2||Study completed and data was inconclusive.|f||||f||||||||||2018-06-01 00:27:58.357068|2018-06-01 00:27:58.357068
NCT00997074|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2012-02-15|2009-10-15|2009-10-16|Estimate|||||||2012-02-15|2012-02-17|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy Study of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion|The Effect of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion: A Double-blind Randomized Placebo Controlled Study|Completed||Phase 3|61|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 00:27:58.452701|2018-06-01 00:27:58.452701
NCT00997061|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2014-01-30|2009-10-15|2009-10-16|Estimate|||||||2014-01-30|2014-02-03|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|SCOT||SCOT Registry: Small Cell Lung Cancer Treatment and Outcome|SCOT Registry: Small Cell Lung Cancer Treatment and Outcome|Completed|||500|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:27:58.551227|2018-06-01 00:27:58.551227
NCT00997048|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2009-10-15|2009-10-15|2009-10-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|October 2002||2002-10-31|October 2009|2009-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Comparison Between Laying Open and Sinus Excision of Pilonidal Sinus - a Randomized Study|Comparison Between Laying Open and Sinus Excision of Pilonidal Sinus - a Randomized Study|Completed||N/A|80|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 00:27:58.718104|2018-06-01 00:27:58.718104
NCT00997035|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2016-06-09||2017-05-17|2009-10-15|2009-10-16|Estimate|2017-05-17|2017-06-14|Actual||||2017-05-17|2017-06-14|Actual|May 2010||2010-05-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|MUTTII||The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo|The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo|Completed||Phase 3|240|Actual|University of California, San Francisco||2|||f||||t||||||||Undecided||2018-06-01 00:27:58.813217|2018-06-01 00:27:58.813217
NCT00997022|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2015-08-07|2009-10-15|2009-10-16|Estimate|||||||2015-08-07|2015-08-10|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients|Phase I Open-Label, Dose-Finding Study of BAY 43-9006 (Sorafenib) in High-risk Hepatocellular Cancer Patients After Liver Transplantation|Completed||Phase 1|14|Actual|Columbia University||1|||f||||t||||||||||2018-06-01 00:27:59.236794|2018-06-01 00:27:59.236794
NCT00995579|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Assessment of Energy Expenditure by Indirect Calorimetry for a Daily 10,000 Steps Goal|Assessment of Energy Expenditure by Indirect Calorimetry for a Daily 10,000 Steps Goal|Completed|||20|Actual|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 00:28:55.999325|2018-06-01 00:28:55.999325
NCT00997009|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-07-14|2009-10-15|2009-10-16|Estimate|||||||2017-07-14|2017-07-17|Actual|October 2009||2009-10-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|March 2015|Actual|2015-03-31||Interventional|MITO CERV 2||Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer|Randomized Phase II Study of Carboplatin and Paclitaxel +/- Cetuximab, in Advanced and/or Recurrent Cervical Cancer|Active, not recruiting||Phase 2|108|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||||2018-06-01 00:27:59.330655|2018-06-01 00:27:59.330655
NCT00996996|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2012-05-31||2016-11-23|2009-10-15|2009-10-16|Estimate|2012-05-31|2012-07-04|Estimate||||2016-11-23|2017-01-11|Estimate|June 1996||1996-06-30|November 2016|2016-11-30|October 2011|Actual|2011-10-31|March 1999|Actual|1999-03-31||Interventional|||Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma|Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin's Lymphoma|Completed||Phase 2|77|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:27:59.521214|2018-06-01 00:27:59.521214
NCT00996983|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-03-28|2009-10-15|2009-10-16|Estimate|||||||2017-03-28|2017-03-29|Actual|September 2009||2009-09-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|September 2017|Anticipated|2017-09-30||Interventional|ZIDON||Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer|Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer|Active, not recruiting||Phase 2|16|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-06-01 00:28:00.160984|2018-06-01 00:28:00.160984
NCT00996970|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-12-11|2009-10-15|2009-10-16|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2009||2009-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2009|Actual|2009-12-31||Observational|||Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons|Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons|Active, not recruiting|||132|Actual|Uniformed Services University of the Health Sciences|||||f||||f||||||Samples Without DNA|"~     Blood samples will be collected for immunologic studies including antibody titers and~     cellular responses. Viral isolates will be obtained and characterized among ILI cases during~     study participation. Blood for CD4/HIV RNA levels will also be obtained among HIV patients to~     determine the impact of the vaccine on these counts.~   "|||2018-06-01 00:28:00.219681|2018-06-01 00:28:00.219681
NCT00996957|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2013-03-14|2009-10-14|2009-10-16|Estimate|||||||2013-03-14|2013-03-18|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma|A Phase 1 Open-Label, Multiple Dose, Dose Escalation Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|37|Actual|Acceleron Pharma, Inc.||1|||f||||t||||||||||2018-06-01 00:28:00.281922|2018-06-01 00:28:00.281922
NCT00996944|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2011-02-10||2016-11-30|2009-10-15|2009-10-16|Estimate|2011-05-12|2011-06-13|Estimate||||2016-11-30|2017-01-18|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)|Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)|Terminated||Phase 2|34|Actual|GlaxoSmithKline||2||"Because GSK concluded that it was impossible to recruit sufficient participants within a~   reasonable timeframe."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:28:00.358474|2018-06-01 00:28:00.358474
NCT00996931|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2011-08-30||2013-04-24|2009-10-15|2009-10-16|Estimate|2013-04-24|2013-05-29|Estimate||||2013-04-24|2013-05-29|Estimate|February 2009||2009-02-28|April 2013|2013-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders|A Phase II Pilot Study to Determine Efficacy and Safety of Lenalidomide (Revlimid) for Treatment of Autistic Spectrum Disorders(ASD) With Regression and Markers of Cerebrospinal Fluid Cytokine Elevation and Elevated TNF-alpha Levels|Completed||Phase 2|6|Actual|Sutter Medical Foundation||1|||f||||t||||||||||2018-06-01 00:28:02.102305|2018-06-01 00:28:02.102305
NCT00996918|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2013-11-12||2013-11-12|2009-10-15|2009-10-16|Estimate|2013-11-12|2014-01-01|Estimate||||2013-11-12|2014-01-01|Estimate|December 2009||2009-12-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000|Terminated||Phase 3|198|Actual|Pfizer|Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.|2||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical~   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2018-06-01 00:28:02.4555|2018-06-01 00:28:02.4555
NCT00996905|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2011-02-22|2009-10-15|2009-10-16|Estimate|||||||2011-02-22|2011-02-23|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Does Ultrasound Scanning of the Lumbar Spine Improve Patient Satisfaction and the Ease of Insertion Epidurals?|Does Ultrasound Scanning of the Lumbar Spine Improve Patient Satisfaction and the Ease of Insertion of Labour Epidural Catheters|Completed||N/A|128|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||4|||f||||f||||||||||2018-06-01 00:28:03.934552|2018-06-01 00:28:03.934552
NCT00996892|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2016-03-03||2016-11-04|2009-10-15|2009-10-16|Estimate|2016-11-04|2016-12-30|Estimate||||2016-11-04|2016-12-30|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||All enrolled participants.|Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors|Terminated||Phase 1|178|Actual|Genentech, Inc.|The study was terminated prior to the initiation of Stage 2B and as per changes in planned analysis the data for duration of objective response and PFS were not analyzed.|6||"A recommended Phase 2 dose and schedule was not identified and the study was terminated before~   initiation of Stage 2B."|f||||||||||||||2018-06-01 00:28:04.41102|2018-06-01 00:28:04.41102
NCT00996879|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2014-05-05|2009-10-15|2009-10-16|Estimate|||||||2014-05-05|2014-05-06|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects|Study to Evaluate the Effect of BMS-791325 on the Pharmacokinetics of the CYP3A4 Probe Midazolam Administered Orally in Healthy Subjects|Completed||Phase 1|48|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:28:13.031203|2018-06-01 00:28:13.031203
NCT00996866|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2014-12-12|2009-10-15|2009-10-16|Estimate|||||||2014-12-12|2014-12-15|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Vitamin D Supplementation Requirement in Obese Subjects|Vitamin D Supplementation Requirement in Obese Subjects|Completed||N/A|23|Actual|Winthrop University Hospital||2|||f||||f||||||||||2018-06-01 00:28:13.205848|2018-06-01 00:28:13.205848
NCT00996853|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2018-01-12|2009-10-15|2009-10-16|Estimate|||||||2018-01-12|2018-01-16|Actual|October 31, 2009|Actual|2009-10-31|January 2018|2018-01-31|April 6, 2011|Actual|2011-04-06|October 20, 2010|Actual|2010-10-20||Observational|H1N1 PASS UK||Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom|Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)|Completed|||9206|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 00:28:13.291616|2018-06-01 00:28:13.291616
NCT00996840|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2017-08-04|2015-04-27|2017-10-17|2009-10-15|2009-10-16|Estimate|2017-10-17|2017-10-18|Actual|2015-04-27|2015-05-13|Estimate|2017-10-17|2017-10-18|Actual|October 16, 2009|Actual|2009-10-16|September 2017|2017-09-30|February 9, 2013|Actual|2013-02-09|February 9, 2013|Actual|2013-02-09||Interventional|||SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS|Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).|Completed||Phase 2|77|Actual|GlaxoSmithKline||5|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:28:13.902506|2018-06-01 00:28:13.902506
NCT00996827|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2015-06-17|2009-10-15|2009-10-16|Estimate|||||||2015-06-17|2015-06-18|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Observational|||Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma|Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma|Terminated|||100|Actual|New Mexico Cancer Care Alliance||||Sufficient samples collected when 73% of target enrollment was reached.|f||||f||||||Samples With DNA|"~     -  Serum samples will be collected to evaluate the immune status of these patients.~        -  Serum cytokine profiles~        -  Whole blood samples - lymphocyte sub-populations from fresh, refrigerated whole blood~          samples. Whole blood samples will be used to extract DNA and RNA material. The remaining~          DNA for future research related to cytokine gene and vitamin D receptor single~          nucleotide polymorphisms studies of the Molecular Epidemiology Laboratory~        -  H & E slides will be evaluated by our collaborating pathologist to validate diagnoses~          and Breslow thickness~        -  Formalin-fixed paraffin embedded blocks will be sectioned and stained for~          immunohistochemistry~        -  One slide will be prepared from the skin block to evaluate the presence of solar~          elastosis in relation to UV exposure~   "|||2018-06-01 00:28:16.818982|2018-06-01 00:28:16.818982
NCT00996814|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2012-01-10|2009-10-15|2009-10-16|Estimate|||||||2012-01-10|2012-01-11|Estimate|October 2007||2007-10-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|PEI||Proactive Ethics Intervention to Improve Intensive Care Unit (ICU) Care|Proactive Ethics Intervention to Improve ICU Care|Completed||N/A|386|Actual|California Pacific Medical Center Research Institute||2|||f||||f||||||||||2018-06-01 00:28:16.893632|2018-06-01 00:28:16.893632
NCT00996801|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2012-08-31||2016-01-21|2009-10-15|2009-10-16|Estimate|2012-10-16|2012-11-16|Estimate||||2016-01-21|2016-01-22|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)|A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate|Completed||Phase 2|526|Actual|Merck Sharp & Dohme Corp.||6|||f||||t||||||||||2018-06-01 00:28:16.993716|2018-06-01 00:28:16.993716
NCT00996788|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-05-14|2009-10-15|2009-10-16|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 2007||2007-10-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis|Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis|Completed||Phase 3|55|Actual|PT Otsuka Indonesia||1|||f||||f||||||||||2018-06-01 00:28:18.203184|2018-06-01 00:28:18.203184
NCT00996775|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2014-07-22||2016-11-14|2009-10-14|2009-10-16|Estimate|2014-08-28|2014-09-01|Estimate||||2016-11-14|2017-01-02|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|December 2012|Actual|2012-12-31||Interventional|||Implementing Evidence-Based Mental Health Practices in Primary Care|Implementing Evidence-Based Mental Health Practices in Primary Care|Completed||Phase 3|167|Actual|VA Office of Research and Development||2|||f||||f||||||||Yes|This project will include data from 167 Veterans screening positive for alcohol misuse (without and without posttraumatic stress disorder [PTSD] or depression). Data was collected at three time points including baseline, 3- and 6-month follow-up. The final dataset includes quantitative data including on alcohol consumption, and symptoms of PTSD, and depression. The final dataset will be stripped of identifiers prior to sharing. Release of data for data sharing will occur after publication of the main findings from the dataset. The investigators will make the data and associated documentation available to users under our own auspices by mailing an encrypted hard-drive to users. A data-sharing agreement must be signed that accounts for (1) commitment to using the data only for research; (2) IRB approval at the host institution, (3) a plan for securing the data using appropriate technology, and (4) an agreed upon plan to destroy or return the data upon completion.|2018-06-01 00:28:18.272281|2018-06-01 00:28:18.272281
NCT00996762|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-11-08|2009-10-15|2009-10-16|Estimate|||||||2017-11-08|2017-11-13|Actual|November 12, 2009|Actual|2009-11-12|November 2017|2017-11-30|September 18, 2012|Actual|2012-09-18|September 18, 2012|Actual|2012-09-18||Interventional|||A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib|An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet|Completed||Phase 1|158|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 00:28:18.583155|2018-06-01 00:28:18.583155
NCT00996749|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-05-25|2009-10-15|2009-10-16|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2011||2011-05-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer|Pilot Study to Determine the Optimal Dosage of Omega-3 Polyunsaturated Fatty Acid (PUFA) in Men With Advanced Prostate Cancer|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||1||No Participants enrolled; slow accrual|f||||t|f|f||||||||2018-06-01 00:28:18.674417|2018-06-01 00:28:18.674417
NCT00996736|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2013-07-26||2015-03-24|2009-10-15|2009-10-16|Estimate|2013-10-18|2013-12-11|Estimate||||2015-03-24|2015-04-14|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|MUTT I||Mycotic Ulcer Treatment Trial I|Mycotic Ulcer Treatment Trial|Completed||Phase 3|323|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:28:18.771318|2018-06-01 00:28:18.771318
NCT00996723|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2015-04-03|2009-10-15|2009-10-16|Estimate|||||||2015-04-03|2015-04-06|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|April 2012|Actual|2012-04-30||Interventional|||Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)|Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma|Completed||Phase 1|25|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 00:28:19.091733|2018-06-01 00:28:19.091733
NCT00996710|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2018-05-01|2009-10-15|2009-10-16|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2009||2009-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Genomic Structural Variation in Cancer Susceptibility|Genomic Structural Variation in Cancer Susceptibility|Enrolling by invitation|||1850|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     blood or saliva sample~   "|||2018-06-01 00:28:19.167716|2018-06-01 00:28:19.167716
NCT00996697|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2016-10-24|2009-10-15|2009-10-16|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|FARD12||Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)|A Proof Of Concept Study To Evaluate Tiotropium as Add-on Therapy to Inhaled Budesonide/Formoterol Combination in COPD|Completed||Phase 4|23|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 00:28:19.312391|2018-06-01 00:28:19.312391
NCT00996684|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2011-09-26|2009-10-15|2009-10-16|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|AMD||Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration|Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin|Unknown status|Recruiting|Phase 2|30|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:28:19.409285|2018-06-01 00:28:19.409285
NCT00996671|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-06-13|2009-10-15|2009-10-16|Estimate|||||||2017-06-13|2017-06-14|Actual|November 6, 2009|Actual|2009-11-06|June 2017|2017-06-30|March 17, 2010|Actual|2010-03-17|March 17, 2010|Actual|2010-03-17||Interventional|FTIH||Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers|A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects|Completed||Phase 1|38|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:28:19.512208|2018-06-01 00:28:19.512208
NCT00996658|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2013-02-13||2014-02-24|2009-10-15|2009-10-16|Estimate|2013-02-13|2013-03-26|Estimate||||2014-02-24|2014-03-26|Estimate|October 2009||2009-10-31|February 2014|2014-02-28||||March 2012|Actual|2012-03-31||Interventional||Six participants (three participants per treatment) were excluded from all analyses due to serious site non-compliance. Thus, the total participants in Baseline Measures (272) is six less than total in Participant Flow (278).|Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone|A Phase III, Randomised, Double Blind, Placebo Controlled Parallel Group Efficacy and Safety Study of Linagliptin 5 mg Administered Orally Once Daily Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With Pioglitazone|Completed||Phase 3|278|Actual|Boehringer Ingelheim|During the conduct of this trial, pioglitazone was removed from the market in France due to safety issues, and this resulted in premature termination of a number of French patients.|2|||f||||||||||||||2018-06-01 00:28:19.665837|2018-06-01 00:28:19.665837
NCT00996645|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-06-04|2009-10-15|2009-10-16|Estimate|||||||2013-06-04|2013-06-05|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Optimizing Audit and Feedback for Primary Care|Cluster Randomized Trial of a Goal-Setting Intervention With Performance Feedback Reports Regarding Diabetes and Coronary Artery Disease for Family Physicians in Ontario|Completed||N/A|55|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 00:28:20.40652|2018-06-01 00:28:20.40652
NCT00996632|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2009-04-24||2009-11-04|2009-09-30|2009-10-16|Estimate|2009-09-30|2009-10-16|Estimate||||2009-11-04|2009-11-11|Estimate|September 2000||2000-09-30|November 2009|2009-11-30|November 2004|Actual|2004-11-30|September 2004|Actual|2004-09-30||Interventional|UKBC||The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery|Randomized Controlled Study of Benefits of Ultrasonic Knife in Breast Cancer Surgery|Completed||N/A|94|Actual|University of Trieste||2|||f||||f||||||||||2018-06-01 00:28:20.484489|2018-06-01 00:28:20.484489
NCT00996619|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-10-15|2009-10-15|2009-10-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||Measuring the Spectrum of Tissues During Endoscopy|Measuring the Spectrum of Tissues During Endoscopy|Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 00:28:20.745334|2018-06-01 00:28:20.745334
NCT00996606|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2016-09-20||2017-05-25|2009-10-15|2009-10-16|Estimate|2016-09-20|2016-11-09|Estimate||||2017-05-25|2017-06-19|Actual|October 2009||2009-10-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Intent-to-Treat (ITT) Population: All participants who received at least one dose of study medication.|A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs|Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA)|Completed||Phase 3|58|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:28:20.914179|2018-06-01 00:28:20.914179
NCT00996593|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2011-12-21|2010-08-12|2016-10-11|2009-10-15|2009-10-16|Estimate|2011-12-21|2012-01-26|Estimate|2010-08-12|2010-08-17|Estimate|2016-10-11|2016-11-23|Estimate|July 1998||1998-07-31|October 2016|2016-10-31|August 2009|Actual|2009-08-31|April 2001|Actual|2001-04-30||Interventional|||Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab|Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma Patients Who Have Previously Received Rituximab|Completed||Phase 2|43|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:28:23.545366|2018-06-01 00:28:23.545366
NCT00996580|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2013-04-26||2013-06-13|2009-10-15|2009-10-16|Estimate|2013-04-26|2013-06-14|Estimate||||2013-06-13|2013-06-24|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Safety population: participants who took at least one dose of intervention.|A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy|A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-103) for the Prevention of Pregnancy in Women|Completed||Phase 3|3597|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 00:28:25.274912|2018-06-01 00:28:25.274912
NCT00996567|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-02-07|2009-10-15|2009-10-16|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2009||2009-10-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|MesoMab||A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.|Phase II Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.|Completed||Phase 2|22|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 00:28:25.952965|2018-06-01 00:28:25.952965
NCT00996554|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2015-12-07|2009-10-15|2009-10-16|Estimate|||||||2015-12-07|2015-12-08|Estimate|January 2004||2004-01-31|December 2015|2015-12-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|ANATECH||Randomized Study Comparing Two Established Gastrointestinal Suture Techniques - One-layer-continuous Versus Double-layer-continuous Suture|Randomized Trial to Compare Two Gastrointestinal Anastomosis Techniques - Single Layer Continuous Versus Double Layer Continuous|Terminated||Phase 3|252|Actual|Universitätsmedizin Mannheim||2||Feasibility reasons; recruitment was too slow.|f||||t||||||||||2018-06-01 00:28:26.028866|2018-06-01 00:28:26.028866
NCT00996541|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2009-11-06|2009-10-15|2009-10-16|Estimate|||||||2009-11-06|2009-11-09|Estimate|September 2004||2004-09-30|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|STRIVE||Support To Reunite Involve and Value Each Other|Diverting Homeless Youth From Chronic Homelessness and Risk for HIV|Completed||N/A|302|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:28:26.102689|2018-06-01 00:28:26.102689
NCT00996528|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-05-12|2009-10-15|2009-10-16|Estimate|||||||2017-05-12|2017-05-16|Actual|September 2007||2007-09-30|May 2017|2017-05-31|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Interventional|||Neighborhood Alcohol & HIV Prevention in South African Townships (Philani)|Neighborhood Alcohol & HIV Prevention in South African Townships (Philani)|Active, not recruiting||Phase 2|1239|Actual|University of California, Los Angeles||2|||f||||f||||||||Yes|Data up to the fifth year is being shared with researcher from other institutions.|2018-06-01 00:28:26.184221|2018-06-01 00:28:26.184221
NCT00996515|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2013-04-30|2009-10-15|2009-10-16|Estimate|||||||2013-04-30|2013-05-01|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies|A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies|Completed||Phase 1|30|Actual|New Mexico Cancer Care Alliance||5|||f||||t||||||||||2018-06-01 00:28:26.286074|2018-06-01 00:28:26.286074
NCT00996502|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2016-03-23||2016-03-23|2009-10-15|2009-10-16|Estimate|2016-03-23|2016-03-25|Estimate||||2016-03-23|2016-03-25|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer|A Phase I/II Study of Bevacizumab and Erlotinib in Combination With Docetaxel and Prednisone for Patients With Hormone Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|4|Actual|Columbia University||1||Poor enrollment; PI left the institution|f||||t||||||||||2018-06-01 00:28:26.450655|2018-06-01 00:28:26.450655
NCT00996489|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2016-09-13|2009-10-15|2009-10-16|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2007||2007-11-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|||Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence||Completed||Phase 4|459|Actual|Merz North America, Inc.||1|||f||||||||||||||2018-06-01 00:28:26.616289|2018-06-01 00:28:26.616289
NCT00996476|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2013-10-17|2013-05-13|2014-03-21|2009-10-15|2009-10-16|Estimate|2014-03-21|2014-04-17|Estimate|2013-05-13|2013-05-21|Estimate|2014-03-21|2014-04-17|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|DRAGON||A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients|A Phase II, Randomized, Open-label Study in Japan to Investigate the Efficacy, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment naïve, Genotype 1, Chronic Hepatitis C Subjects|Completed||Phase 2|92|Actual|Janssen Pharmaceutical K.K.|"All outcome measures reported in this study are Exploratory; not Primary as indicated. Primary was chosen for each outcome measure because Exploratory is not available as an outcome measure type."|5|||f||||f||||||||||2018-06-01 00:28:26.789597|2018-06-01 00:28:26.789597
NCT00996463|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2011-03-25|2009-10-15|2009-10-16|Estimate|||||||2011-03-25|2011-03-28|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|LEICO||Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients|Phase II Open Randomized Clinical & Health Economic Trial Comparing Intralesional Antimony Therapy Versus Wound Care Management in Old World Cutaneous Leishmaniasis Patients in Northern Afghanistan|Completed||Phase 2|63|Anticipated|Waisenmedizin e. V. Promoting Access to Essential Medicine||3|||f||||t||||||||||2018-06-01 00:28:28.336323|2018-06-01 00:28:28.336323
NCT00996450|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2016-05-20|2009-10-15|2009-10-16|Estimate|||||||2016-05-20|2016-05-23|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Educational Follow-up in a Cohort of Children at the Royal Marsden Hospital (RMH)|Educational Follow-up in a Cohort of Children at the Royal Marsden Hospital, Following the Treatment of a Brain Tumour|Completed|||110|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:28:28.429912|2018-06-01 00:28:28.429912
NCT00995254|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2011-06-23|2009-10-14|2009-10-15|Estimate|||||||2011-06-23|2011-06-27|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|China SHARE||Secondhand Smoke Exposure Reduction Among Young Children in China|Reducing Secondhand Smoke Exposure Among Young Children|Completed||N/A|400|Anticipated|Boston University||2|||f||||f||||||||||2018-06-01 00:29:01.025974|2018-06-01 00:29:01.025974
NCT00996437|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2013-02-19||2016-08-25|2009-10-14|2009-10-16|Estimate|2013-04-02|2013-05-16|Estimate||||2016-08-25|2016-08-26|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|N||Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)|An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy|Completed||Phase 2/Phase 3|261|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 00:28:28.601171|2018-06-01 00:28:28.601171
NCT00996424|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2011-08-12|2009-10-15|2009-10-16|Estimate|||||||2011-08-12|2011-08-15|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function|The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function.|Terminated||Phase 4|19|Actual|University Hospital, Ghent||2||Insufficient recruitment.|f||||f||||||||||2018-06-01 00:28:29.943193|2018-06-01 00:28:29.943193
NCT00996411|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2014-03-21|2009-10-15|2009-10-16|Estimate|||||||2014-03-21|2014-03-24|Estimate|November 2008||2008-11-30|March 2014|2014-03-31||||November 2013|Actual|2013-11-30||Interventional|||Human Psychopharmacology of Salvinorin A||Completed||Phase 1|14|Anticipated|Johns Hopkins University||1|||f||||||||||||||2018-06-01 00:28:30.025725|2018-06-01 00:28:30.025725
NCT00996398|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-15|2009-10-15|2009-10-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Cold Water Immersion Does Not Reduce Knee Joint Position Sense in Healthy Participants: a Randomised Cross-over Trial|Cold Water Immersion Does Not Reduce Knee Joint Position Sense in Healthy Participants: a Randomised Cross-over Trial'|Completed||N/A|14|Actual|University of Limerick||1|||f||||f||||||||||2018-06-01 00:28:30.183677|2018-06-01 00:28:30.183677
NCT00996385|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2011-10-28|2009-10-15|2009-10-16|Estimate|||||||2011-10-28|2011-10-31|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma|A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma|Unknown status|Recruiting|Phase 2|29|Anticipated|Columbia University||1|||f||||t||||||||||2018-06-01 00:28:30.357204|2018-06-01 00:28:30.357204
NCT00996372|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2014-02-26||2014-05-14|2009-10-15|2009-10-16|Estimate|2014-05-14|2014-06-12|Estimate||||2014-05-14|2014-06-12|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women|24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States|Completed||Phase 3|949|Actual|Sprout Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 00:28:30.500043|2018-06-01 00:28:30.500043
NCT00996359|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-09-13|2009-10-15|2009-10-16|Estimate|||||||2013-09-13|2013-09-17|Estimate|October 2009||2009-10-31|September 2013|2013-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation|Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation|Terminated||Phase 1|4|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||f||||||||||2018-06-01 00:28:31.244431|2018-06-01 00:28:31.244431
NCT00996346|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2015-06-06||2015-08-02|2009-10-14|2009-10-16|Estimate|2015-08-02|2015-09-01|Estimate||||2015-08-02|2015-09-01|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2011|Actual|2011-11-30||Interventional|||Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas|Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas|Terminated||Phase 1|17|Actual|New Mexico Cancer Care Alliance||3||Original PI left institution and sponsor decided to end support.|f||||f||||||||||2018-06-01 00:28:31.363301|2018-06-01 00:28:31.363301
NCT00996333|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2016-04-27||2016-06-22|2009-10-15|2009-10-16|Estimate|2016-05-16|2016-06-22|Estimate||||2016-06-22|2016-07-25|Estimate|June 2003||2003-06-30|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)|Phase II Study of a Biochemically Synergistic Regimen for Metastatic Pancreatic Cancer (Stage IVB) With Gemzar, Taxotere and Xeloda (GTX)|Completed||Phase 2|46|Actual|Columbia University||1|||f||||t||||||||Undecided||2018-06-01 00:28:32.012656|2018-06-01 00:28:32.012656
NCT00996320|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2009-10-15|2009-10-15|2009-10-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit|Effect of Reducing ICU Interns' Work Hours on Sleep, Intern Well-Being, and Medical Errors|Completed||N/A|22|Actual|Providence Health & Services||2|||f||||f||||||||||2018-06-01 00:28:32.328484|2018-06-01 00:28:32.328484
NCT00996307|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2011-04-28|2010-10-08|2017-04-19|2009-10-15|2009-10-16|Estimate|2011-04-28|2011-05-25|Estimate|2010-12-10|2010-12-15|Estimate|2017-04-19|2017-05-30|Actual|October 2009||2009-10-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months|Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1) 2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months|Completed||Phase 2/Phase 3|654|Actual|Novartis||4|||f||||t||||||||||2018-06-01 00:28:32.487388|2018-06-01 00:28:32.487388
NCT00996294|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2010-01-11|2009-10-15|2009-10-16|Estimate|||||||2010-01-11|2010-01-12|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|October 2013|Anticipated|2013-10-31|October 2009|Actual|2009-10-31||Interventional|||Surgical Treatment of Type 2 Diabetes Mellitus in <35 Body Mass Index (BMI)|"Surgical Treatment of Type 2 Diabetes Mellitus in Patients With BMI <35 kg/m2 (Italian Title: La Terapia Chirurgica Del Diabete Mellito di Tipo 2 Nel Paziente Con BMI Inferiore a 35 kg/m2)"|Unknown status|Active, not recruiting|N/A|50|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||1|||f||||f||||||||||2018-06-01 00:28:33.768946|2018-06-01 00:28:33.768946
NCT00996281|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2012-10-15|2012-01-09|2012-10-15|2009-10-15|2009-10-16|Estimate|2012-10-15|2012-11-12|Estimate|2012-01-17|2012-01-19|Estimate|2012-10-15|2012-11-12|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension|A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension|Completed||Phase 3|837|Actual|Takeda||2|||f||||f||||||||||2018-06-01 00:28:33.930066|2018-06-01 00:28:33.930066
NCT00996268|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-06-21|2009-10-15|2009-10-16|Estimate|||||||2017-06-21|2017-06-22|Actual|October 15, 2009|Actual|2009-10-15|June 2017|2017-06-30|January 4, 2010|Actual|2010-01-04|January 4, 2010|Actual|2010-01-04||Interventional|||An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.|An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836|Completed||Phase 1|46|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:28:36.120424|2018-06-01 00:28:36.120424
NCT00996255|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-15|2009-10-15|2009-10-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|November 2006||2006-11-30|October 2009|2009-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors|A Phase I Dose-Escalation Study of PHA-793887 Administered as a 1-hour IV Infusion on Days 1, 8 and 15 in a 4-Week Cycle in Patients With Advanced/Metastatic Solid Tumors|Terminated||Phase 1|19|Actual|Nerviano Medical Sciences||1|||f||||f||||||||||2018-06-01 00:28:36.744402|2018-06-01 00:28:36.744402
NCT00996242|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2009-10-15|2009-10-15|2009-10-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia|An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia|Completed||N/A|10|Actual|Göteborg University||1|||f||||f||||||||||2018-06-01 00:28:36.965689|2018-06-01 00:28:36.965689
NCT00996229|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2013-04-18|2009-10-15|2009-10-16|Estimate|||||||2013-04-18|2013-04-19|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Dietary Interventions on the Aging Brain|Phase IV Interventional Study: Effects of Dietary Interventions on Brain Functions in Healthy Elderly People|Unknown status|Recruiting|Phase 3|300|Anticipated|University Hospital Muenster||4|||f||||t||||||||||2018-06-01 00:28:37.232537|2018-06-01 00:28:37.232537
NCT00996216|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2013-10-10||2013-10-10|2009-10-15|2009-10-16|Estimate|2013-10-10|2013-12-06|Estimate||||2013-10-10|2013-12-06|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ENABLE-ALL||Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390|An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)|Completed||Phase 3|27|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 00:28:37.999586|2018-06-01 00:28:37.999586
NCT00996203|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2014-04-07||2018-02-28|2009-10-15|2009-10-16|Estimate|2014-06-30|2014-07-02|Estimate||||2018-02-28|2018-03-29|Actual|October 31, 2009|Actual|2009-10-31|February 2018|2018-02-28|February 14, 2011|Actual|2011-02-14|February 14, 2011|Actual|2011-02-14||Interventional||Safety population: All patients who received at least one dose and had at least one safety assessment after the drug administration.|A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.|Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ)|Completed||Phase 4|201|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:28:40.008131|2018-06-01 00:28:40.008131
NCT00996190|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2011-02-22|2009-10-15|2009-10-16|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Best Regimen for Phenylephrine Administration During Cesarean Section|Study to Determine the Best Regimen for Administration of Phenylephrine During Spinal Anesthesia for Cesarean Delivery, as Determined by Maternal Blood Pressure and Cardiac Output|Completed||Phase 4|60|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 00:28:41.182063|2018-06-01 00:28:41.182063
NCT00996177|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2014-01-28|2009-10-15|2009-10-16|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2004||2004-06-30|January 2014|2014-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|EuroTrans||A Study to Compare Patient-controlled Pain Medications Delivered Either Through the Skin or Intravenously|Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control|Completed||Phase 4|657|Actual|Janssen-Cilag International NV||2|||f||||f||||||||||2018-06-01 00:28:41.409918|2018-06-01 00:28:41.409918
NCT00996164|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2014-03-11||2014-04-16|2009-10-15|2009-10-16|Estimate|2014-04-16|2014-05-19|Estimate||||2014-04-16|2014-05-19|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder|A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin (100 Milligrams) Administered Orally Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder in the United States|Completed||Phase 3|1090|Actual|Sprout Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 00:28:41.971321|2018-06-01 00:28:41.971321
NCT00996151|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2010-02-28|2009-10-15|2009-10-16|Estimate|||||||2010-02-28|2010-03-02|Estimate|December 2009||2009-12-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|MTE11||Testosterone MD-Lotion Residual Washing Study|A Healthy Volunteer, Single Dose Phase I Trial to Determine the Amount of Testerone MD-Lotion 2% Remaining on the Axilla After Washing.|Completed||Phase 1|10|Actual|Acrux DDS Pty Ltd|||||f||||f||||||||||2018-06-01 00:28:43.307814|2018-06-01 00:28:43.307814
NCT00996138|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2016-11-30|2009-10-15|2009-10-16|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects|A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Adult Subjects|Completed||Phase 2/Phase 3|200|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:28:43.477779|2018-06-01 00:28:43.477779
NCT00996125|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2012-05-24||2016-09-22|2009-10-15|2009-10-16|Estimate|2012-05-24|2012-06-27|Estimate||||2016-09-22|2016-10-20|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects|Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects|Completed||Phase 3|750|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:28:43.628366|2018-06-01 00:28:43.628366
NCT00996112|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2013-01-23|2009-10-15|2009-10-16|Estimate|||||||2013-01-23|2013-01-25|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Observational|||Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections|Management by Primary Care Clinicians of Patients Suspected of Having Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections|Completed|||4518|Actual|University of Colorado, Denver|||2||f||||f||||||||||2018-06-01 00:28:44.21727|2018-06-01 00:28:44.21727
NCT00996099|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2009-10-15|2009-10-15|2009-10-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|September 2008||2008-09-30|October 2009|2009-10-31||||August 2009|Actual|2009-08-31||Interventional|||Continuous Glucose Monitoring Combined With Computer Algorithm for Intensive Insulin Therapy in Cardiosurgical Patients|Feasibility Study of the Use of Continuous Glucose Monitoring Combined With Computer-based eMPC Algorithm for Tight Glucose Control in Cardiosurgical ICU|Completed||N/A|24|Actual|Charles University, Czech Republic||2|||f||||f||||||||||2018-06-01 00:28:44.336025|2018-06-01 00:28:44.336025
NCT00996086|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2013-07-17|2009-10-15|2009-10-16|Estimate|||||||2013-07-17|2013-07-19|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|BENEFIT||Risk Stratification and Benefits With Cardiac Resynchronization Therapy (CRT)|Risk Stratification and Benefits With Cardiac Resynchronization Therapy|Completed|||154|Actual|St. Jude Medical|||1||f||||t||||||Samples With DNA|"~     There is a genetic substudy that will evaluate the presence of certain protein markers.~   "|||2018-06-01 00:28:44.441455|2018-06-01 00:28:44.441455
NCT00996073|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2016-12-15|2009-10-15|2009-10-16|Estimate|||||||2016-12-15|2016-12-19|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion|A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Lumbar Interbody Fusion With Instrumentation|Completed||Phase 2|24|Actual|Mesoblast, Ltd.||3|||f||||t||||||||||2018-06-01 00:28:44.5827|2018-06-01 00:28:44.5827
NCT00996060|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2016-01-15|2009-10-14|2009-10-16|Estimate|||||||2016-01-15|2016-01-18|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies|A Phase 1 Protocol of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies|Completed||Phase 1|29|Actual|New Mexico Cancer Care Alliance||1|||f||||t||||||||||2018-06-01 00:28:44.678497|2018-06-01 00:28:44.678497
NCT00996047|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2015-03-05|2009-10-15|2009-10-16|Estimate|||||||2015-03-05|2015-03-06|Estimate|July 1991||1991-07-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers|S9007, Cytogenetic Studies in Leukemia Patients|Completed|||3341|Actual|Southwest Oncology Group|||||f||||f||||||None Retained|"~     Blood and bone marrow~   "|||2018-06-01 00:28:44.872443|2018-06-01 00:28:44.872443
NCT00996034|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2012-09-12||2015-11-19|2009-10-15|2009-10-16|Estimate|2015-11-19|2015-12-24|Estimate||||2015-11-19|2015-12-24|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Nicotine Vaccination and Nicotinic Receptor Occupancy|123I-5-IA SPECT Imaging of Nicotinic Receptors and Effects of Nicotine Vaccine|Completed||Phase 2|14|Actual|Yale University||1|||f||||t||||||||||2018-06-01 00:28:45.519125|2018-06-01 00:28:45.519125
NCT00996021|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-01-21|2009-10-15|2009-10-16|Estimate|||||||2010-01-21|2010-01-25|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Study to Assess Cardiac Conduction of GSK1349572|A Study to Evaluate the Effect of a Single 250 mg Oral Dose of GSK1349572 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin (ING111856).|Completed||Phase 1|42|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 00:28:45.765372|2018-06-01 00:28:45.765372
NCT00996008|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2010-10-25|2009-10-15|2009-10-16|Estimate|||||||2010-10-25|2010-10-26|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||CT 327 in the Treatment of Atopic Dermatitis|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of the Safety and Efficacy of CT 327, Pegylated K-252, Formulated as a Cream, When Administered Twice Daily for 14 Days to Subjects With Mild-to-Moderate Atopic Dermatitis|Terminated||Phase 2|15|Actual|Creabilis SA||2||Due to slow recruitment, study was stopped before target enrollment was achieved|f||||f||||||||||2018-06-01 00:28:45.853011|2018-06-01 00:28:45.853011
NCT00995995|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-05-25|2009-10-15|2009-10-16|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2008||2008-10-31|May 2017|2017-05-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Observational|||Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK|Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK|Completed|||7641|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:28:46.023976|2018-06-01 00:28:46.023976
NCT00995982|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2017-06-30|2009-10-15|2009-10-16|Estimate|||||||2017-06-30|2017-07-02|Actual|October 8, 2009||2009-10-08|September 3, 2010|2010-09-03|September 3, 2010|Actual|2010-09-03|September 3, 2010|Actual|2010-09-03||Interventional|||VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years|VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years|Completed||Phase 1|60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:28:46.484671|2018-06-01 00:28:46.484671
NCT00995969|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2011-02-09|2009-10-15|2009-10-16|Estimate|||||||2011-02-09|2011-02-10|Estimate|March 2010||2010-03-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||CT 327 in the Treatment of Psoriasis Vulgaris|A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a Topical Cream Formulation of Pegylated K252a, When Administered Twice Daily for Eight Weeks to Patients With Mild to Moderate Psoriasis Vulgaris|Completed||Phase 2|58|Actual|Creabilis SA||2|||f||||f||||||||||2018-06-01 00:28:48.014417|2018-06-01 00:28:48.014417
NCT00995956|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|||2012-09-13|2009-10-15|2009-10-16|Estimate|||||||2012-09-13|2012-09-14|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|Albumix||Albumin, Total and Free Fraction of Mycophenolic Acid, and Measurement of IMPDH Activity in Liver Transplants.|Quantitative Measurements of Albumin, Total and Free Fraction of Mycophenolic Acid, and Measurement of IMPDH Activity in Liver Transplants.|Completed|||20|Actual|Oslo University Hospital|||||f||||f||||||Samples Without DNA|"~     Blood for drug analyzes~   "|||2018-06-01 00:28:48.394203|2018-06-01 00:28:48.394203
NCT00995930|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-15|2015-01-29||2015-06-01|2009-10-15|2009-10-16|Estimate|2015-02-19|2015-03-06|Estimate||||2015-06-01|2015-06-29|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients|A Multi-center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT|Completed||Phase 2|189|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:28:48.524768|2018-06-01 00:28:48.524768
NCT00995917|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-04-18|2009-10-15|2009-10-16|Estimate|||||||2012-04-18|2012-04-20|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|DAT||A Pilot Study of Acupoint Injection for Primary Dysmenorrhea|A Randomized, Crossover, Pilot Trial of the Feasibility and Safety of Acupoint Injection of Vitamin K for Treatment of Primary Dysmenorrhea|Completed||N/A|18|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:28:49.507343|2018-06-01 00:28:49.507343
NCT00995904|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2013-04-17||2013-12-09|2009-10-14|2009-10-15|Estimate|2013-10-28|2013-11-20|Estimate||||2013-12-09|2014-01-09|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma|A Randomized, Open-Label, 3-Dose, 3-Period, Crossover Phase 2 Study Investigating the Tolerability and Pharmacokinetics of MAP0010 in Children 4 Through 11 Years Old With a History of Mild-To-Moderate Stable Asthma|Completed||Phase 2|25|Actual|Allergan||6|||f||||f||||||||||2018-06-01 00:28:49.664133|2018-06-01 00:28:49.664133
NCT00995891|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2018-04-03|2009-10-14|2009-10-15|Estimate|||||||2018-04-03|2018-04-04|Actual|September 9, 2009||2009-09-09|March 16, 2018|2018-03-16||||||||Observational|||Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies|Collection of Blood, Bone Marrow, Skin Biopsies and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols Laboratory Research Studies|Completed|||88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:28:50.009164|2018-06-01 00:28:50.009164
NCT00995878|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2018-01-10|2009-10-14|2009-10-15|Estimate|||||||2018-01-10|2018-01-12|Actual|April 29, 2010|Actual|2010-04-29|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.|The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids|Completed||Phase 4|56|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:28:50.18073|2018-06-01 00:28:50.18073
NCT00995865|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2015-10-12||2016-04-01|2009-10-14|2009-10-15|Estimate|2016-04-01|2016-05-05|Estimate||||2016-04-01|2016-05-05|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Trial of Yellow Fever Inactivated Vaccine|Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability,and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults.|Completed||Phase 1|60|Actual|GE Healthcare||3|||f||||t||||||||||2018-06-01 00:28:50.291678|2018-06-01 00:28:50.291678
NCT00995852|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2011-04-26|2009-10-14|2009-10-15|Estimate|||||||2011-04-26|2011-04-27|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study|Unilateral vs. Bilateral IBV Placement|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-06-01 00:28:50.843276|2018-06-01 00:28:50.843276
NCT00995839|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2010-02-03|2009-10-14|2009-10-15|Estimate|||||||2010-02-03|2010-02-04|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Terlipressin in Septic Shock: Effects on Microcirculation|Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation|Completed||Phase 2/Phase 3|60|Actual|University of Roma La Sapienza||3|||f||||f||||||||||2018-06-01 00:28:51.04342|2018-06-01 00:28:51.04342
NCT00995826|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-11|||2018-05-29|2009-10-14|2009-10-15|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2009||2009-04-30|May 2018|2018-05-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958|CS-8958 - A Phase I, Double-blind, Placebo-controlled, Ascending, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects.|Completed||Phase 1|16|Actual|Vaxart||2|||f||||t||||||||||2018-06-01 00:28:51.192365|2018-06-01 00:28:51.192365
NCT00995813|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2015-11-17|2009-10-14|2009-10-15|Estimate|||||||2015-11-17|2015-11-18|Estimate|December 2009||2009-12-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|May 2012|Actual|2012-05-31||Interventional|||Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure|Pilot Study of the Safety and Immunogenicity of the Rotavirus Vaccine in Infants With Intestinal Failure|Completed||Phase 4|15|Actual|Seattle Children's Hospital|||||f||||f||||||||||2018-06-01 00:28:51.261734|2018-06-01 00:28:51.261734
NCT00995800|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-08-08|2009-10-14|2009-10-15|Estimate|||||||2012-08-08|2012-08-09|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|FLT2503||Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma|A Double-blind, Randomised, Incomplete Block, Crossover, Placebo-controlled, Dose-response Study to Assess Bronchial Hyperresponsiveness and Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adult Subjects With Mild to Moderate Asthma|Completed||Phase 2|46|Actual|Mundipharma Research Limited||2|||f||||||||||||||2018-06-01 00:28:51.348204|2018-06-01 00:28:51.348204
NCT00995787|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2010-02-25|2009-10-14|2009-10-15|Estimate|||||||2010-02-25|2010-02-26|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea|A Randomized, Single-blind, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 Compared to Placebo in T2DM Patients Treated With Metformin and Sulfonylurea|Completed||Phase 1|75|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:28:51.604151|2018-06-01 00:28:51.604151
NCT00995774|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2013-10-31||2014-02-14|2009-10-13|2009-10-15|Estimate|2013-12-20|2014-02-14|Estimate||||2014-02-14|2014-03-14|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Extension of the MIME Robotic System for Stroke Rehabilitation|Extension of the MIME Robotic System for Stroke Rehabilitation|Completed||Phase 2|12|Actual|VA Office of Research and Development|The limited therapy hours could mask potential gains that would have been made with additional therapy. Due to the small sample size, these results need to be confirmed in a larger scale study using a parallel study design.|2|||f||||f||||||||||2018-06-01 00:28:51.809317|2018-06-01 00:28:51.809317
NCT00995761|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2011-06-21||2014-02-09|2009-10-14|2009-10-15|Estimate|2014-02-09|2014-03-03|Estimate||||2014-02-09|2014-03-03|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)|Phase II Study of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer|Completed||Phase 2|48|Actual|Gyeongsang National University Hospital|completed without a major limitation|1|||f||||t||||||||||2018-06-01 00:28:52.250036|2018-06-01 00:28:52.250036
NCT00995748|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-02-16|2009-10-14|2009-10-15|Estimate|||||||2012-02-16|2012-02-20|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|RECORDAF-AP||The RECORD Asia-Pacific Atrial Fibrillation Registry|REgistry on Cardiac Rhythm disORDers in Asia-Pacific|Completed|||2674|Actual|Sanofi|||||f||||f||||||||||2018-06-01 00:28:52.569834|2018-06-01 00:28:52.569834
NCT00995735|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|June 2007||2007-06-30|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|August 2009|Actual|2009-08-31||Observational|IMTN||IMTN Study- International Prospective Multicenter Trial on Clinical NOTES|IMTN Study- International Prospective Multicenter Trial on Clinical NOTES|Unknown status|Recruiting||1000|Anticipated|IMTN NOTES Research Group|||2||f||||t||||||||||2018-06-01 00:28:52.683257|2018-06-01 00:28:52.683257
NCT00995722|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2015-09-28|2014-12-02|2017-05-01|2009-10-14|2009-10-15|Estimate|2015-10-01|2015-11-02|Estimate|2014-12-02|2014-12-17|Estimate|2017-05-01|2017-06-02|Actual|December 2011||2011-12-31|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EPITOME'||Efficacy of Prednisone In the Treatment of Ocular Myasthenia|Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study|Terminated||Phase 3|11|Actual|University of Miami|Early termination leading to small numbers of subjects analyzed|2||Slow recruitment rate|f||||t||||||||||2018-06-01 00:28:52.821373|2018-06-01 00:28:52.821373
NCT00995709|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2015-02-12|2012-05-02|2015-08-13|2009-10-14|2009-10-15|Estimate|2015-08-13|2015-08-31|Estimate|2012-05-02|2012-05-04|Estimate|2015-08-13|2015-08-31|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SHIELD|a. One patient who screen-failed was inadvertently randomized to the AIN457 300 mg monthly group. This patient did not receive any study medication.|Phase III Study in Refractory Behcet's Disease|A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy|Completed||Phase 3|118|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:28:53.53485|2018-06-01 00:28:53.53485
NCT00995696|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2011-06-21|2009-10-14|2009-10-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|PhaST||Treatment Follow-up Study|Pharmaceutical Safety Tracking (PhaST): Managing Medications for Patient Safety|Completed||Phase 2|800|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||||2018-06-01 00:28:55.131539|2018-06-01 00:28:55.131539
NCT00995683|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-10|||2011-07-09|2009-10-14|2009-10-15|Estimate|||||||2011-07-09|2011-07-12|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Preventive Sodium Lactate and Traumatic Brain Injury|Effect of Preventive Sodium Lactate Infusion on Intracranial Hypertension in Severe Trauma Tic Brain Injury|Completed||Phase 2/Phase 3|60|Actual|Institut d'Anesthesiologie des Alpes Maritimes||2|||f||||t||||||||||2018-06-01 00:28:55.21565|2018-06-01 00:28:55.21565
NCT00995670|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2015-01-22||2015-03-12|2009-10-14|2009-10-15|Estimate|2015-03-12|2015-03-17|Estimate||||2015-03-12|2015-03-17|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||All volunteers served as their own controls (placebo) and participated in one or more interventions, after each of which the study was repeated.|Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins|Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins|Completed||N/A|59|Actual|VA Office of Research and Development|Some substudies were not completed because we had difficulty creating ischemia/reperfusion (I/R) injury or a consistent FBF response, which was critical to the purpose of the study to investigate the role of glucose and statins in I/R injury.|3|||f||||f||||||||||2018-06-01 00:28:55.31372|2018-06-01 00:28:55.31372
NCT00995657|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-06-11|2009-10-14|2009-10-15|Estimate|||||||2012-06-11|2012-06-12|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma|Dose Response of FENO to Inhaled Steroids in Mild-to-moderate Asthma|Completed||Phase 4|21|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 00:28:55.610163|2018-06-01 00:28:55.610163
NCT00995644|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2016-10-27|2009-10-14|2009-10-15|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Natural History of Attempts to Stop Smoking|Natural History of Attempts to Stop Smoking|Completed|||238|Actual|University of Vermont|||||f||||f||||||||No||2018-06-01 00:28:55.67717|2018-06-01 00:28:55.67717
NCT00995631|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2017-01-10|2009-10-13|2009-10-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional|FLARE||Following Lipectomy to Understand Adipose Tissue Re-accumulation|Regional Fat Re-accumulation Following Lipectomy in Pre- and Post-menopausal Women|Completed||N/A|53|Actual|University of Colorado, Denver||4|||f||||f||||||||||2018-06-01 00:28:55.734923|2018-06-01 00:28:55.734923
NCT00995618|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2011-01-05|2009-10-13|2009-10-15|Estimate|||||||2011-01-05|2011-01-06|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia|A Randomized, Double-Blind, Crossover, Pharmacodynamic and Pharmacokinetic Drug Interaction Study of Tranilast in Combination With Febuxostat Compared With Tranilast Alone and Febuxostat Alone in Healthy Subjects With Hyperuricemia|Completed||Phase 2|24|Actual|Nuon Therapeutics, Inc.||3|||f||||f||||||||||2018-06-01 00:28:55.802873|2018-06-01 00:28:55.802873
NCT00995605|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects|AMAP102 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Subjects|Terminated||Phase 1|40|Actual|AnaMar AB||2||Reached sufficient pharmacokinetic exposures|f||||f||||||||||2018-06-01 00:28:55.87367|2018-06-01 00:28:55.87367
NCT00995592|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|November 2002||2002-11-30|October 2009|2009-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Philani Home-based Nutrition Intervention Program|Philani Home-based Nutrition Intervention Program|Completed||Phase 2|684|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:28:55.932974|2018-06-01 00:28:55.932974
NCT00995566|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2011-12-27||2012-02-06|2009-10-14|2009-10-15|Estimate|2011-12-27|2012-02-01|Estimate||||2012-02-06|2012-02-07|Estimate|April 2010||2010-04-30|May 2011|2011-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|PROSE||A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin|Thelin (Sitaxentan Sodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin|Terminated|||54|Actual|Pfizer|The protocol did not identify the priority of endpoints. Therefore, all endpoints arbitrarily assigned as primary.||1|"The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new~   emerging evidence of hepatic injury."|f||||f||||||||||2018-06-01 00:28:56.111545|2018-06-01 00:28:56.111545
NCT00995553|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2016-02-25||2016-04-12|2009-10-14|2009-10-15|Estimate|2016-04-12|2016-04-25|Estimate||||2016-04-12|2016-04-25|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||Remediation of Working Memory in Schizophrenia|Remediation of Working Memory in Schizophrenia|Completed||N/A|86|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:28:56.379289|2018-06-01 00:28:56.379289
NCT00995540|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2014-02-11|2009-10-14|2009-10-15|Estimate|||||||2014-02-11|2014-02-12|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults|A Multiple-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Tolerability, Safety, and Efficacy of INGAP Peptide Given Subcutaneously as Injections t.i.d. for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus|Terminated||Phase 2|23|Actual|Exsulin Corporation||3||Preserve clinical supplies|f||||t||||||||||2018-06-01 00:28:56.576693|2018-06-01 00:28:56.576693
NCT00995527|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2017-10-05|2009-10-14|2009-10-15|Estimate|||||||2017-10-05|2017-10-06|Actual|September 30, 2009||2009-09-30|June 25, 2014|2014-06-25|June 25, 2014||2014-06-25|||||Observational|||Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine|Characterization of the Innate Immune Response in Healthy NIH Employees at Baseline and After Immunization With the H1N1 Vaccine|Completed|||26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:28:56.679145|2018-06-01 00:28:56.679145
NCT00995514|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-05-29|2009-10-14|2009-10-15|Estimate|||||||2012-05-29|2012-05-30|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|GeCCO||Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study|Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study|Terminated|||4471|Actual|Medco Health Solutions, Inc.|||2|Administrative reasons|f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-06-01 00:28:56.767654|2018-06-01 00:28:56.767654
NCT00995501|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2017-03-15||2017-03-15|2009-10-14|2009-10-15|Estimate|2017-03-15|2017-04-25|Actual||||2017-03-15|2017-04-25|Actual|January 2007||2007-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))|The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))|Terminated||N/A|381|Actual|The Cleveland Clinic||8||Per interim analysis, for futility.|f||||t||||||||||2018-06-01 00:28:56.923583|2018-06-01 00:28:56.923583
NCT00995488|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2014-09-10||2015-08-28|2009-10-14|2009-10-15|Estimate|2014-09-10|2014-09-19|Estimate||||2015-08-28|2015-09-11|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer|ABX209: Phase II Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer.|Terminated||Phase 2|16|Actual|University of Michigan Cancer Center||1||Terminated prematurely due to low accrual.|f||||t||||||||||2018-06-01 00:28:57.510972|2018-06-01 00:28:57.510972
NCT00995475|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|October 2006||2006-10-31|October 2009|2009-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease|A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease|Completed||Phase 4|18|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 00:28:57.83675|2018-06-01 00:28:57.83675
NCT00995462|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2013-12-10|2009-10-14|2009-10-15|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2006||2006-09-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|PGP2||Prevention of Weight Gain in University Students|Prevention of Weight Gain in University Students|Completed||N/A|319|Actual|Université de Sherbrooke||3|||f||||f||||||||||2018-06-01 00:28:57.928497|2018-06-01 00:28:57.928497
NCT00995449|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2012-05-07||2014-06-04|2009-10-14|2009-10-15|Estimate|2012-09-21|2012-09-25|Estimate||||2014-06-04|2014-06-09|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|||Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis|A Phase 2, Randomized, Placebo‑Controlled, Dose‑Ranging Study to Evaluate the Safety and Efficacy of the Anti-GM-CSF Monoclonal Antibody KB003 in Subjects With Active Rheumatoid Arthritis and Inadequate Prior Treatment Outcome From Biologic Therapy|Terminated||Phase 2|9|Actual|Humanigen, Inc.|The study was terminated upon completion of safety run-in due to program refocus.|4||Program refocus|f||||t||||||||||2018-06-01 00:28:58.054902|2018-06-01 00:28:58.054902
NCT00995436|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2014-02-03||2016-08-03|2009-10-14|2009-10-15|Estimate|2016-08-03|2016-08-05|Estimate||||2016-08-03|2016-08-05|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|PJSPhD||Chesterfield Micro-implant Study Involving Three Types of Anchorage Methods in Orthodontics|Efficiency and Effectiveness of Three Methods of Anchorage Reinforcement in Orthodontics|Completed||N/A|78|Actual|Chesterfield and North Derbyshire Royal Hospital||3|||f||||t||||||||||2018-06-01 00:28:58.369386|2018-06-01 00:28:58.369386
NCT00995423|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2010-08-17|2009-10-14|2009-10-15|Estimate|||||||2010-08-17|2010-08-18|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|PIPA||Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent|Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease|Completed||Phase 4|500|Anticipated|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 00:28:58.636212|2018-06-01 00:28:58.636212
NCT00995410|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2015-10-22|2012-10-29|2016-01-20|2009-10-13|2009-10-15|Estimate|2016-01-20|2016-02-17|Estimate|2012-10-29|2012-10-31|Estimate|2016-01-20|2016-02-17|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Overall safety population: the overall safety population consisted of all enrolled subjects who received at least one dose of study drug.|Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers|A 12-Month, Phase 3, Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers|Completed||Phase 3|380|Actual|POZEN||1|||f||||t||||||||||2018-06-01 00:28:58.760876|2018-06-01 00:28:58.760876
NCT00995397|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-20|2009-10-14|2009-10-15|Estimate|||||||2009-10-20|2009-10-22|Estimate||||October 2009|2009-10-31||||||||Interventional|||Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Insect Bite Related Symptoms|Non-inferiority, Monocentric Comparative Open Study of Two Topical Pharmaceutical Preparations (Cream and Lotion) of Dexchlorpheniramine Maleate in the Evaluation of Safety and Efficacy for the Relief of Insect Bite Related-symptoms|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||t||||||||||2018-06-01 00:28:58.997736|2018-06-01 00:28:58.997736
NCT00995384|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-03-21|2009-10-14|2009-10-15|Estimate|||||||2012-03-21|2012-03-22|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Cardiac Computed Tomography (CT) Scan Compared to Transesophageal Echocardiogram (TEE) in Endocarditis|A Novel Modality of Cardiac CT in Characterization of Acute Infective Endocarditis|Terminated||N/A|2|Actual|William Beaumont Hospitals||1||Difficult recruitment|f||||t||||||||||2018-06-01 00:28:59.066086|2018-06-01 00:28:59.066086
NCT00995371|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|2013-07-02||2013-09-13|2009-10-14|2009-10-15|Estimate|2013-09-13|2013-11-15|Estimate||||2013-09-13|2013-11-15|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|June 2012|Actual|2012-06-30||Interventional||ITT analysis includes all patients at weeks 6 post-treatment. Week 26 cohort analysis includes 16 mild patients who reported outcomes at Week 26 and the 12 ESI patients who reported outcomes at Week 26 after cross-over to mild.|Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis|Comparative Study of Epidural Steroid Injection Versus Mild® (Minimally Invasive Lumbar Decompression) Procedure in Patients Diagnosed With Symptomatic Moderate to Severe Lumbar Central Canal Stenosis|Completed||Phase 4|38|Actual|Coastal Orthopedics & Sports Medicine||2|||f||||f||||||||||2018-06-01 00:28:59.127765|2018-06-01 00:28:59.127765
NCT00995358|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Interventional|||A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer|Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 2|60|Anticipated|University of Yamanashi||1|||f||||t||||||||||2018-06-01 00:28:59.36864|2018-06-01 00:28:59.36864
NCT00995345|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2013-08-14||2014-06-23|2009-10-14|2009-10-15|Estimate|2014-06-23|2014-06-26|Estimate||||2014-06-23|2014-06-26|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Synergy104||Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone|A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Safety and Efficacy of Once-Daily KRP-104 in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Alone.|Completed||Phase 2|403|Actual|ActivX Biosciences, Inc.||5|||f||||f||||||||||2018-06-01 00:28:59.450331|2018-06-01 00:28:59.450331
NCT00995332|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2015-06-23|2009-10-14|2009-10-15|Estimate|||||||2015-06-23|2015-06-24|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine|Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine|Completed||Phase 1/Phase 2|36|Actual|University of Bergen||1|||f||||f||||||||||2018-06-01 00:29:00.615902|2018-06-01 00:29:00.615902
NCT00995319|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2017-03-31|2009-10-14|2009-10-15|Estimate|||||||2017-03-31|2017-04-04|Actual|January 2008|Actual|2008-01-31|March 2017|2017-03-31|July 2014|Actual|2014-07-31|January 2013|Actual|2013-01-31||Observational|||Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area|Acute and Longlasting Side Effects Caused by Radiotherapy in the Head and Neck Area|Completed|||58|Actual|Norwegian University of Science and Technology|||1||f||||t|f|f||||||||2018-06-01 00:29:00.704416|2018-06-01 00:29:00.704416
NCT00995306|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2011-06-08|2009-10-14|2009-10-15|Estimate|||||||2011-06-08|2011-06-10|Estimate|June 2003||2003-06-30|June 2011|2011-06-30|June 2004|Actual|2004-06-30|April 2004|Actual|2004-04-30||Interventional|||Evaluating the Safety and Efficacy Civamide in Osteoarthritis (OA) of the Knee(s)|A Double-Blind, Randomized, Controlled, Parallel-Group, Multicenter Study Evaluating the Safety and Efficacy of Civamide Cream 0.075% as a Treatment in Subjects With Osteoarthritis of the Knee|Completed||Phase 3|695|Actual|Winston Laboratories||2|||f||||f||||||||||2018-06-01 00:29:00.764551|2018-06-01 00:29:00.764551
NCT00995293|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2018-03-01|2009-10-14|2009-10-15|Estimate|||||||2018-03-01|2018-03-02|Actual|August 27, 2009|Actual|2009-08-27|March 2018|2018-03-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial|An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere®) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|240|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:29:00.834153|2018-06-01 00:29:00.834153
NCT00995280|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Single Lumen Needle Without Flushing or Double Lumen Needle With Follicle Flushing in Oocyte Retrieval|Single Lumen Needle Without Flushing or Double Lumen Needle With Follicle Flushing in Oocyte Retrieval|Completed||N/A|400|Actual|Baskent University||2|||f||||t||||||||||2018-06-01 00:29:00.903228|2018-06-01 00:29:00.903228
NCT00995267|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2017-11-29|2009-10-14|2009-10-15|Estimate|||||||2017-11-29|2017-11-30|Actual|March 2008||2008-03-31|October 2009|2009-10-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Eating Habits and Obesity in First and Second Grade School Children|The Influence of the Family as Agents of Change on Eating Habits and Obesity in First and Second Grade School Children in Israel.|Completed||N/A|508|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 00:29:00.96514|2018-06-01 00:29:00.96514
NCT00995241|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-09-09|2009-10-14|2009-10-15|Estimate|||||||2010-09-09|2010-09-10|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV|Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV|Completed||Phase 4|5|Anticipated|Germans Trias i Pujol Hospital||1|||f||||f||||||||||2018-06-01 00:29:01.083184|2018-06-01 00:29:01.083184
NCT00995228|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2009-10-14|2009-10-14|2009-10-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Observational|||Fluid Management in the Post-Anesthetic Care Unit (PACU) at Sourasky Medical Center|The Practice of Fluid Management in the Post-anesthetic Care Unit (PACU) in Patients Undergoing Elective Surgery: an Observational Study|Unknown status|Active, not recruiting||1000|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 00:29:01.227792|2018-06-01 00:29:01.227792
NCT00995215|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2018-01-30|2009-10-14|2009-10-15|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2009||2009-10-31|January 2018|2018-01-31|October 31, 2017|Actual|2017-10-31|October 15, 2017|Actual|2017-10-15||Interventional|||Sub-study to Spinal Cord Stimulation to Restore Cough|Evaluation of Wire Electrodes to Activate the Expiratory Muscles to Restore Cough|Completed||N/A|7|Actual|Case Western Reserve University||1|||f||||t||||||||||2018-06-01 00:29:01.290779|2018-06-01 00:29:01.290779
NCT00995202|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2016-12-27|2009-10-14|2009-10-15|Estimate|||||||2016-12-27|2016-12-28|Estimate|September 2009||2009-09-30|December 2016|2016-12-31||||April 2018|Anticipated|2018-04-30||Interventional|SURVEILLANCE||Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer|Follow-Up of Fully Resected Stage II or III Colorectal Cancer. Phase III Multicentric Prospective Randomised Study|Active, not recruiting||Phase 3|1997|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||f||||||||||2018-06-01 00:29:01.408074|2018-06-01 00:29:01.408074
NCT00995189|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2016-11-15|2009-10-14|2009-10-15|Estimate|||||||2016-11-15|2016-11-17|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Clinical Evaluation of the Causes of Contact Lens Related Dry Eye|A Clinical Evaluation of the Causes of Soft Contact Lens Related Dry Eye|Completed||N/A|159|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:29:01.642557|2018-06-01 00:29:01.642557
NCT00995176|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2016-01-20|2009-10-14|2009-10-15|Estimate|||||||2016-01-20|2016-01-21|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||The Women's HIV SeroIncidence Study (ISIS)|The Women's HIV SeroIncidence Study (ISIS)|Completed|||2099|Actual|HIV Prevention Trials Network|||2||f||||f||||||||No|Data was collated into manuscripts by the statistical and data management center for the HPTN.|2018-06-01 00:29:01.927856|2018-06-01 00:29:01.927856
NCT00995163|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2012-08-22|2009-10-14|2009-10-15|Estimate|||||||2012-08-22|2012-08-23|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|MBD-5D||Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease|Mineral and Bone Disorders Outcomes Study for Japanese Chronic Kidney Disease Stage 5D Patients (MBD-5D)|Completed|||8020|Actual|Kyowa Hakko Kirin Co., Ltd|||||f||||f||||||||||2018-06-01 00:29:02.176246|2018-06-01 00:29:02.176246
NCT00995150|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2017-12-20|2009-10-14|2009-10-15|Estimate|||||||2017-12-20|2017-12-22|Actual|November 2009||2009-11-30|December 2017|2017-12-31|May 2024|Anticipated|2024-05-31|May 2023|Anticipated|2023-05-31||Interventional|||A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception|A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception|Active, not recruiting||Phase 3|1910|Actual|Medicines360||2|||f||||t||||||||Yes||2018-06-01 00:29:02.265615|2018-06-01 00:29:02.265615
NCT00995137|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-14|||2017-04-24|2009-10-14|2009-10-15|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2009||2009-10-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia|Pilot Study of Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia|Completed||Phase 1|14|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 00:29:02.404674|2018-06-01 00:29:02.404674
NCT00995124|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2010-07-26|2009-10-14|2009-10-15|Estimate|||||||2010-07-26|2010-07-28|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application|A Randomised, Assessor Blind, Parallel Group, Comparative Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application|Completed||Phase 4|90|Anticipated|Altman Biomedical Consulting Pty. Ltd.||3|||f||||f||||||||||2018-06-01 00:29:02.490042|2018-06-01 00:29:02.490042
NCT00995098|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-11|||2010-11-29|2009-10-14|2009-10-15|Estimate|||||||2010-11-29|2010-11-30|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Early Enteral Nutrition for Severe Acute Pancreatitis|The Impact of Early Enteral Nutrition on the Clinical Outcomes of Severe Acute Pancreatitis Patients: A Randomized Control Trial|Completed||Phase 4|42|Actual|Sichuan Academy of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:29:02.594727|2018-06-01 00:29:02.594727
NCT00995085|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2010-12-27||2017-01-31|2009-10-13|2009-10-14|Estimate|2011-06-09|2011-07-06|Estimate||||2017-01-31|2017-03-13|Actual|October 2009||2009-10-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects|Efficacy Study of Metadoxine SR Formulation in ADHD Subjects|Completed||Phase 1|43|Actual|Alcobra Ltd.||1|||f||||f||||||||||2018-06-01 00:29:02.679356|2018-06-01 00:29:02.679356
NCT00995072|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2012-08-13|2009-10-13|2009-10-14|Estimate|||||||2012-08-13|2012-08-15|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function|Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function|Unknown status|Recruiting|N/A|80|Anticipated|East Coast Institute for Research||2|||f||||t||||||||||2018-06-01 00:29:02.88287|2018-06-01 00:29:02.88287
NCT00995059|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2016-04-18|2009-10-13|2009-10-14|Estimate|||||||2016-04-18|2016-04-19|Estimate||||February 2011|2011-02-28||||||||Interventional|||Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase I/II Study of a Novel Reduced Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients With Multiple Myeloma|Withdrawn||Phase 1/Phase 2|0|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:29:02.990871|2018-06-01 00:29:02.990871
NCT00995046|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2013-05-13|2009-10-13|2009-10-14|Estimate|||||||2013-05-13|2013-05-14|Estimate|September 2009||2009-09-30|October 2009|2009-10-31||||September 2012|Actual|2012-09-30||Interventional|OPTIPHASE||Individually Tailored Prophylaxis in Patients With Severe Hemophilia A|Optimizing Prophylaxis in Patients With Severe Haemophilia A by Tailoring the Infusions to Individual Patients' Needs Using the Calibrated Automated Thrombin Generation Test|Terminated||N/A|5|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 00:29:03.169859|2018-06-01 00:29:03.169859
NCT00995033|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2013-02-18|2009-10-12|2009-10-14|Estimate|||||||2013-02-18|2013-02-20|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)|A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm , Study to Assess Efficacy and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or Placebo Co-Administered With Varenicline (Champix®) as an Aid in Smoking Cessation|Completed||Phase 2|558|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:29:03.265791|2018-06-01 00:29:03.265791
NCT00995020|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2012-10-15||2015-06-14|2009-10-13|2009-10-14|Estimate|2012-10-15|2012-11-15|Estimate||||2015-06-14|2015-07-10|Estimate|November 1999||1999-11-30|June 2015|2015-06-30|December 2010|Actual|2010-12-31|December 2004|Actual|2004-12-31||Interventional|||Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion|A Study of Two Cone Biopsy Techniques For Women With Cervical Pre-Invasive Disease. LLETZ Cone and SWETZ.|Completed||Phase 3|103|Actual|Oswaldo Cruz Foundation||2|||f||||f||||||||||2018-06-01 00:29:03.392377|2018-06-01 00:29:03.392377
NCT00995007|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-10|2015-12-09||2016-02-25|2009-10-10|2009-10-14|Estimate|2016-02-25|2016-03-29|Estimate||||2016-02-25|2016-03-29|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas|A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas|Completed||Phase 2|112|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 00:29:03.7038|2018-06-01 00:29:03.7038
NCT00994994|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|April 2008|Actual|2008-04-30|August 2007|Actual|2007-08-31||Interventional|TXA||Tranexamic Acid in Pediatric Cardiac Surgery|Tranexamic Acid Reduces Blood Loss in Pediatric Cardiac Surgery|Completed||N/A|160|Actual|Okayama University||2|||f||||t||||||||||2018-06-01 00:29:04.642342|2018-06-01 00:29:04.642342
NCT00994981|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-11-27|2009-10-13|2009-10-14|Estimate|||||||2011-11-27|2011-11-29|Estimate|September 2007||2007-09-30|November 2011|2011-11-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Magnesium Administration in Liver Transplantation and Reperfusion Injury|Does Pretreated Magnesium Protect Against Reperfusion Injury in Liver Transplanted Patients?|Completed||Phase 4|61|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-06-01 00:29:04.718103|2018-06-01 00:29:04.718103
NCT00994968|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2010-10-28|2009-10-13|2009-10-14|Estimate|||||||2010-10-28|2010-10-29|Estimate|July 2009||2009-07-31|October 2009|2009-10-31||||||||Interventional|||Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer|Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel and S-1 in Breast Cancer|Unknown status|Recruiting|Phase 2|49|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:29:04.810026|2018-06-01 00:29:04.810026
NCT00994955|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2013-01-15|2009-10-13|2009-10-14|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||Selective Retina Therapy (SRT) for Clinically Significant Diabetic Macular Edema|Selective Retina Therapy (SRT) for Clinically Significant Diabetic Macular|Completed||Phase 1/Phase 2|39|Actual|University of Schleswig-Holstein||1|||f||||f||||||||||2018-06-01 00:29:04.880868|2018-06-01 00:29:04.880868
NCT00994942|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2018-01-19|2009-10-13|2009-10-14|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2006||2006-04-30|January 2018|2018-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Bioequivalency Study of Morphine Sulfate Injection, Solution and Tablet Under Fasted Conditions|A Single Dose, Three-Period, Three-Treatment, Six-Sequence, Three-Way Crossover Pharmacokinetic and Comparative Bioavailability Study of Morphine Sulfate Injection, Solution, and Tablet Formulations Under Fasting Conditions.|Completed||N/A|18|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:29:04.946957|2018-06-01 00:29:04.946957
NCT00994929|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2014-12-19||2016-02-03|2009-10-13|2009-10-14|Estimate|2016-02-03|2016-03-02|Estimate||||2016-02-03|2016-03-02|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|IL-11DDAVP|5 subjects were mild or moderate hemophilia A; 4 were mild or moderate VWD; all unresponsive or allergic to DDAVP The VWD subjects - 2, type 1 and 2, type 2 VWD, including one with type 2B, and one with type 2M. All subjects had positive past bleeding histories.|Efficacy and Safety of IL-11 in DDAVP Unresponsive|Phase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVP|Completed||Phase 2|9|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-06-01 00:29:05.021167|2018-06-01 00:29:05.021167
NCT00994916|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-11-03|2009-10-09|2009-10-14|Estimate|||||||2017-11-03|2017-11-07|Actual||||November 2017|2017-11-30||||||||Expanded Access|||Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine|Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine|Available|||||University of Pittsburgh|||||||||||||||||||2018-06-01 00:29:05.266153|2018-06-01 00:29:05.266153
NCT00994903|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2013-11-27|2009-10-13|2009-10-14|Estimate|||||||2013-11-27|2013-12-02|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|StatCol||Simvastatin in Colorectal Surgery|Prospective, Double-Blinded, Multi-Centred, Randomised Controlled Trial of Perioperative Simvastatin Use in Elective Colorectal Surgery|Completed||Phase 3|132|Actual|University of Auckland, New Zealand||2|||f||||f||||||||||2018-06-01 00:29:05.331752|2018-06-01 00:29:05.331752
NCT00994890|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12||2012-10-01|2012-10-01|2009-10-13|2009-10-14|Estimate||||2012-10-01|2012-10-05|Estimate|2012-10-01|2012-10-05|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections|A Multicenter, Randomized, Double-Blind, Long Term Study Of The Safety Of Subcutaneous Administration Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip|Terminated||Phase 2|679|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:29:05.417051|2018-06-01 00:29:05.417051
NCT00994877|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||Thromboelastography in in Patients With Sepsis|Thromboelastography in Patients Admitted to the ICU for Severe Sepsis|Unknown status|Recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||||2018-06-01 00:29:05.53859|2018-06-01 00:29:05.53859
NCT00994864|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2017-03-07|2009-10-13|2009-10-14|Estimate|||||||2017-03-07|2017-03-08|Actual|November 2009||2009-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PePiTA||Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer|Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial|Recruiting||N/A|235|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-06-01 00:29:05.665138|2018-06-01 00:29:05.665138
NCT00994851|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2013-03-28|2009-10-13|2009-10-14|Estimate|||||||2013-03-28|2013-03-29|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.|National Study, Phase III, Parallel, Double Blind, Placebo Comparative and Randomized to Evaluate the Therapeutic Efficacy and Tolerability of the Combination Naturetti® (Cassia Fistula + Senna Alexandrina Miller) in the Chronic Functional Constipation.|Completed||Phase 3|96|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:29:05.855182|2018-06-01 00:29:05.855182
NCT00994838|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2015-07-16|2009-10-12|2009-10-14|Estimate|||||||2015-07-16|2015-07-17|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Reduced Calorie Diet Intervention in Kidney Transplant Recipients|Reduced Calorie Diet Intervention in Kidney Transplant Recipients|Completed||Phase 2|27|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 00:29:05.932633|2018-06-01 00:29:05.932633
NCT00994825|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2016-07-21|2009-10-13|2009-10-14|Estimate|||||||2016-07-21|2016-07-22|Estimate|November 2009||2009-11-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CHEETAH||Levosimendan in High Risk Patients Undergoing Cardiac Surgery|Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial|Completed||Phase 4|1000|Anticipated|Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-06-01 00:29:06.005916|2018-06-01 00:29:06.005916
NCT00994812|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2010-02-22|2009-10-13|2009-10-14|Estimate|||||||2010-02-22|2010-02-23|Estimate|August 2002||2002-08-31|October 2009|2009-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effects of Metformin on Pregnancy and Miscarriage Rates in Polycystic Ovary Syndrome (PCOS)|Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study|Completed||Phase 3|326|Actual|University of Oulu||1|||f||||f||||||||||2018-06-01 00:29:06.123714|2018-06-01 00:29:06.123714
NCT00994799|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-15|2009-10-13|2009-10-14|Estimate|||||||2009-10-15|2009-10-16|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|February 2011|Anticipated|2011-02-28|||||Observational|||Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema|Comparison of the Effect of Intravitreal Ranibizumab Injections Compared to Macular Grid-pattern Laser Therapy for the Symptomatic Treatment of Diabetic Macular Edema (a Randomized, Controlled, Phase III Trial)|Unknown status|Recruiting||50|Anticipated|Szeged University|||2||f||||f||||||||||2018-06-01 00:29:06.213921|2018-06-01 00:29:06.213921
NCT00994786|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2018-04-09|2009-10-13|2009-10-14|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2009||2009-01-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder|A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder|Recruiting||Phase 4|66|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 00:29:06.322418|2018-06-01 00:29:06.322418
NCT00994773|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-10|||2012-08-15|2009-10-13|2009-10-14|Estimate|||||||2012-08-15|2012-08-16|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Simvastatin for the Treatment of Chronic Hepatitis B|A Pilot Trial of Simvastatin Alone and Added to Tenofovir or Entecavir for the Treatment of Chronic Hepatitis B|Completed||Phase 1|32|Actual|Bader, Ted, M.D.||3|||f||||f||||||||||2018-06-01 00:29:06.426417|2018-06-01 00:29:06.426417
NCT00994760|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2012-03-13||2012-08-27|2009-10-13|2009-10-14|Estimate|2012-08-27|2012-09-27|Estimate||||2012-08-27|2012-09-27|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|GENISIS||Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years|A Prospective Non-interventional/Observational Patient Cohort Study on the Efficacy of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients.|Completed|||131|Actual|Takeda|||1||f||||f||||||||||2018-06-01 00:29:06.544498|2018-06-01 00:29:06.544498
NCT00994747|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2012-10-02|2009-10-13|2009-10-14|Estimate|||||||2012-10-02|2012-10-03|Estimate|November 2006||2006-11-30|October 2012|2012-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Sensitive Periods in Early Flavor Learning|Sensitive Periods in Early Flavor Learning|Completed||N/A|79|Actual|Monell Chemical Senses Center||6|||f||||f||||||||||2018-06-01 00:29:07.68059|2018-06-01 00:29:07.68059
NCT00994734|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2012-04-16|2009-10-13|2009-10-14|Estimate|||||||2012-04-16|2012-04-17|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion|Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion|Completed||N/A|615|Actual|Gynuity Health Projects||2|||f||||||||||||||2018-06-01 00:29:07.772382|2018-06-01 00:29:07.772382
NCT00994721|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2016-05-03|2009-10-11|2009-10-14|Estimate|||||||2016-05-03|2016-05-04|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||A Phase III Study of Pancreatic Cancer|A Randomized Phase III Study of Adjuvant Gemcitabine Versus Gemcitabine Plus Concurrent Chemoradiation in Pancreatic Cancer Underwent Curative Intent (R0 / R1) Resection|Completed|||147|Actual|National Health Research Institutes, Taiwan|||1||f||||t||||||||No||2018-06-01 00:29:07.855707|2018-06-01 00:29:07.855707
NCT00994708|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|December 2004||2004-12-31|October 2009|2009-10-31||||||||Interventional|||The Effect of Esomeprazole and Fundoplication on Airways|The Effect of Esomeprazole and Nissen Fundoplication on Bronchial Responsiveness, Quality of Life, Exhaled Nitric Oxide and Pulmonary Function in Patients With Gastroesophageal Reflux Disease|Completed||Phase 3|||Tampere University Hospital|||||f||||||||||||||2018-06-01 00:29:07.929146|2018-06-01 00:29:07.929146
NCT00994695|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-15|2009-10-13|2009-10-14|Estimate|||||||2009-10-15|2009-10-16|Estimate|November 2005||2005-11-30|October 2009|2009-10-31|November 2007|Actual|2007-11-30|January 2006|Actual|2006-01-31||Interventional|ETH-TVT||Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine|A Phase II Open and Parallel Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Polysaccharide Vaccine Comparing Three Groups: 2 - 4 Year, 5 - 14 Year and 15 - 29 Year Old Ethiopians|Completed||Phase 2|412|Actual|Armauer Hansen Research Institute, Ethiopia|||||f||||t||||||||||2018-06-01 00:29:07.976656|2018-06-01 00:29:07.976656
NCT00994682|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2016-09-06||2017-02-20|2009-10-13|2009-10-14|Estimate|2017-02-20|2017-04-05|Actual||||2017-02-20|2017-04-05|Actual|December 2008||2008-12-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)|Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).|Completed||Phase 4|176|Actual|University of Florida|The single-center nature of this study is a limitation that calls for additional work from a larger, longer-term (>3 years), multicenter trial.|2|||f||||f|f|f||||||||2018-06-01 00:29:08.113824|2018-06-01 00:29:08.113824
NCT00994669|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2015-12-03|2009-10-13|2009-10-14|Estimate|||||||2015-12-03|2015-12-04|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients|Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients|Completed|||17|Actual|The University of Texas Medical Branch, Galveston|||2||f||||f||||||||||2018-06-01 00:29:09.035026|2018-06-01 00:29:09.035026
NCT00994656|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2011-02-09|2009-10-13|2009-10-14|Estimate|||||||2011-02-09|2011-02-11|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Is Pleth Variability Index (PVI) a Surrogate for Pulse Pressure Variations (PPV) in Pediatric Spine Fusion (SF) Surgery?|Is the Pleth Variability Index (PVI) a Useful Surrogate for Pulse Pressure Variations (PPV) in a Pediatric Population Undergoing Spine Fusion?|Completed|||24|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-06-01 00:29:09.100472|2018-06-01 00:29:09.100472
NCT00994643|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2017-05-10||2018-04-03|2009-10-13|2009-10-14|Estimate|2017-09-05|2017-10-06|Actual||||2018-04-03|2018-05-04|Actual|February 5, 2009|Actual|2009-02-05|April 2018|2018-04-30|June 25, 2015|Actual|2015-06-25|June 25, 2014|Actual|2014-06-25||Interventional|||Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma|Phase II Study of IL-2 and Rituximab Maintenance in High Risk B Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|11|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 00:29:09.185004|2018-06-01 00:29:09.185004
NCT00994630|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-08-15|2009-10-13|2009-10-14|Estimate|||||||2011-08-15|2011-08-16|Estimate|January 2010||2010-01-31|May 2011|2011-05-31||||August 2011|Anticipated|2011-08-31||Observational|CHAPS||Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study|Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study|Suspended|||20|Anticipated|University of Sao Paulo|||1|fail to get funding|f||||t||||||Samples With DNA|"~     Dna and Rna analysis~   "|||2018-06-01 00:29:09.47765|2018-06-01 00:29:09.47765
NCT00994617|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2013-06-11|2009-10-13|2009-10-14|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|Pathway 1||Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension|Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension|Unknown status|Recruiting|Phase 4|600|Anticipated|University of Cambridge||2|||f||||f||||||||||2018-06-01 00:29:09.526579|2018-06-01 00:29:09.526579
NCT00994604|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2016-08-09||2016-12-05|2009-10-13|2009-10-14|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effects of Broccoli Sprout Extract on Obstructive Lung Disease|The Effects of Broccoli Sprout Extract on Obstructive Lung Disease|Completed||N/A|51|Actual|Johns Hopkins University||1|||f||||f||||||||No|This was a pilot study.|2018-06-01 00:29:09.62201|2018-06-01 00:29:09.62201
NCT00994591|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2013-05-23|2009-10-09|2009-10-14|Estimate|||||||2013-05-23|2013-05-24|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|1058||Cotinine Metabolism in Infants and Children|Cotinine Metabolism in Infants and Children|Completed||Phase 1|56|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 00:29:09.825231|2018-06-01 00:29:09.825231
NCT00994578|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2014-09-11|2009-10-13|2009-10-14|Estimate|||||||2014-09-11|2014-09-12|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|COPE||Intervention Study of Communication in Oncologist-Patient Encounters|The COPE Trial: Communication in Oncologist-Patient Encounters|Completed||N/A|659|Actual|Duke University||4|||f||||f||||||||||2018-06-01 00:29:09.9033|2018-06-01 00:29:09.9033
NCT00994565|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-06-21|2009-10-13|2009-10-14|Estimate|||||||2011-06-21|2011-06-23|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|CoAct||The Effectiveness of Physical Activity Monitoring and Distance Counseling in an Occupational Health Setting|The Effectiveness of Physical Activity Monitoring and Distance Counselling in an Occupational Health Setting - a Randomised Controlled Trial (CoAct)|Completed||N/A|544|Actual|Helsinki University of Technology||2|||f||||f||||||||||2018-06-01 00:29:09.974262|2018-06-01 00:29:09.974262
NCT00994552|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|August 2009||2009-08-31|October 2009|2009-10-31||||April 2010|Anticipated|2010-04-30||Interventional|||Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure|A Pilot Study: Comparing Physiological Parameters and Outcome Variables Using Pressure Support Ventilation Versus Pressure Controlled Ventilation in Patients With Chronic Respiratory Failure|Unknown status|Recruiting|Phase 4|20|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:29:10.033186|2018-06-01 00:29:10.033186
NCT00994539|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2018-01-19|2009-10-13|2009-10-14|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2007||2007-01-31|January 2018|2018-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Dose Proportionality and Food Effect of Morphine Sulfate|A Single Dose, Three-Period, Three-Treatment, Six-Sequence, Three-Way Crossover Study of the Dose Proportionality of and Effect of Food on Morphine Sulfate Tablets.|Completed||N/A|36|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:29:11.107187|2018-06-01 00:29:11.107187
NCT00994526|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2012-12-13|2009-10-13|2009-10-14|Estimate|||||||2012-12-13|2012-12-17|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|Hemcancer||Processed Meat and Colon Carcinogenesis|Effect of Processed Meat on Colorectal Carcinogenesis. Study of Mechanisms. Choice of Preventive Strategies|Completed||N/A|18|Actual|Institut National de la Recherche Agronomique||3|||f||||f||||||||||2018-06-01 00:29:11.161241|2018-06-01 00:29:11.161241
NCT00994513|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2010-09-23|2009-10-13|2009-10-14|Estimate|||||||2010-09-23|2010-09-24|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Alpha Lipoic Acid on Obesity Related Comorbidities|Effect of Alpha Lipoic Acid on Obesity Related Comorbidities|Completed||Phase 2/Phase 3|70|Anticipated|Augusta University||2|||f||||t||||||||||2018-06-01 00:29:11.234097|2018-06-01 00:29:11.234097
NCT00994500|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-10|||2013-07-01|2009-10-10|2009-10-14|Estimate|||||||2013-07-01|2013-07-02|Estimate|August 2009||2009-08-31|July 2013|2013-07-31||||July 2011|Actual|2011-07-31||Interventional|||Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma|A Phase I Study of Vorinostat and Bortezomib in Children With Refractory or Recurrent Solid Tumors, Including CNS Tumors and Lymphomas|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:29:11.310232|2018-06-01 00:29:11.310232
NCT00994487|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2018-04-03|2009-10-13|2009-10-14|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2010||2010-06-30|April 2018|2018-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Breastfeeding in Infancy and Food Intake in Preschool-Aged Children|Breastfeeding, Parental Feeding Style, and Self-regulation Capabilities in Female Preschool-age Children|Completed||N/A|7|Actual|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-06-01 00:29:11.419467|2018-06-01 00:29:11.419467
NCT00994474|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Comparison of Outcome Parameters in Laser Rhytide Treatment|Comparison of Clinical Outcome Parameters, the Patient Benefit Index (PBI) and Patient Satisfaction After Ablative Fractional Laser Treatment of Peri-orbital Rhytides|Completed||Phase 4|28|Actual|Laserklinik Karlsruhe||2|||f||||f||||||||||2018-06-01 00:29:11.494624|2018-06-01 00:29:11.494624
NCT00994461|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2011-04-22||2011-05-19|2009-10-13|2009-10-14|Estimate|2011-04-22|2011-05-17|Estimate||||2011-05-19|2011-05-25|Estimate|November 2009||2009-11-30|May 2011|2011-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study Of Celecoxib In Healthy Subjects|A Randomized, Placebo-Controlled, Double-Blind, Phase 4 Study To Compare The Effect Of Celecoxib 100 Mg BID, Loxoprofen 60 Mg TID And Placebo On The Gastroduodenal Mucosa In Healthy Subjects|Completed||Phase 4|190|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:29:11.680395|2018-06-01 00:29:11.680395
NCT00994448|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2013-01-14||2013-02-25|2009-10-13|2009-10-14|Estimate|2013-02-25|2013-04-04|Estimate||||2013-02-25|2013-04-04|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents|Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents|Completed||Phase 2|19|Actual|University of California, Los Angeles|Study was not powered or designed to determine if bupropion is more effective than placebo for treating methamphetamine dependence. Only for pilot testing procedures for a clinical trial in methamphetamine abusing adolescents.|2|||f||||t||||||||||2018-06-01 00:29:12.250386|2018-06-01 00:29:12.250386
NCT00994435|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2011-03-23|2009-10-13|2009-10-14|Estimate|||||||2011-03-23|2011-03-24|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Observational|||The Incretin Secretion in the Gut System Related to the Physiological Stimulus|The Incretin Secretion in the Gut System Related to the Physiological Stimulus|Completed|||20|Actual|Catholic University of the Sacred Heart|||||f||||f||||||||||2018-06-01 00:29:12.567424|2018-06-01 00:29:12.567424
NCT00994422|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2012-03-07|2011-03-15|2012-04-04|2009-10-13|2009-10-14|Estimate|2012-03-07|2012-04-04|Estimate|2011-03-15|2011-03-25|Estimate|2012-04-04|2012-04-06|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects|A Double-Blind Randomized Study to Compare the Safety, Local Tolerability and Efficacy of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation|Completed||Phase 2|264|Actual|Topaz Pharmaceuticals Inc||2|||f||||f||||||||||2018-06-01 00:29:12.654825|2018-06-01 00:29:12.654825
NCT00994409|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2010-11-30|2009-10-13|2009-10-14|Estimate|||||||2010-11-30|2010-12-01|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Observational|PatZuFrie||Patient Satisfaction in Stroke Patients|Berliner Schlaganfallregister - Nachbefragung Von Patienten Mit Schlaganfall|Completed|||1200|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 00:29:13.129869|2018-06-01 00:29:13.129869
NCT00994396|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2016-10-05|2009-10-13|2009-10-14|Estimate|||||||2016-10-05|2016-10-06|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|April 2013|Actual|2013-04-30|January 2011|Actual|2011-01-31||Interventional|||Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents|Use of Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents on a Standard Weight Loss Program|Completed||N/A|44|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 00:29:13.196792|2018-06-01 00:29:13.196792
NCT00994383|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2018-01-19|2009-10-13|2009-10-14|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2007||2007-01-31|January 2018|2018-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Comparative Bioavailability Study of Morphine Sulfate Immediate Release and Controlled Release|A Single Dose, Three-Period, Three-Treatment, Six-Sequence, Three-Way Crossover Comparative Bioavailability Study of Morphine Sulfate Immediate Release Tablets and Solution and Controlled Release Capsules Under Steady-State Conditions.|Completed||N/A|36|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:29:13.296743|2018-06-01 00:29:13.296743
NCT00994370|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2014-03-18|2009-10-13|2009-10-14|Estimate|||||||2014-03-18|2014-03-20|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT|Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)|Completed|||36|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||Samples Without DNA|"~     Whole blood will be obtained at intervals based on standard of care blood draws. Each sample~     will be analysed for circulating indicators of angiogenesis.~   "|||2018-06-01 00:29:13.353721|2018-06-01 00:29:13.353721
NCT00994357|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2012-05-08|2009-10-13|2009-10-14|Estimate|||||||2012-05-08|2012-05-09|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes|The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes: a Randomised Controlled Study|Completed||N/A|154|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 00:29:13.418671|2018-06-01 00:29:13.418671
NCT00994344|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2014-02-12|2009-10-13|2009-10-14|Estimate|||||||2014-02-12|2014-02-13|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens|Randomised and Prospective Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens|Completed||Phase 4|73|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 00:29:13.48667|2018-06-01 00:29:13.48667
NCT00994331|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2011-03-08|2009-10-13|2009-10-14|Estimate|||||||2011-03-08|2011-03-10|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Stereotaxis Computed Tomography (CT) Co-Registration Study|Randomized Feasibility Study Comparing the Clinical Utility of the Stereotaxis Navigant™ Computed Tomography Angiography Importation and Co- Registration Feature, the NaviView™ Assisted Navigation Feature, and Standard Angiography|Terminated||N/A|4|Actual|Stereotaxis||3||Study terminated due to lack of enrollment.|f||||f||||||||||2018-06-01 00:29:13.566266|2018-06-01 00:29:13.566266
NCT00994318|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2014-04-04||2014-05-09|2009-10-13|2009-10-14|Estimate|2014-04-04|2014-05-07|Estimate||||2014-05-09|2014-05-20|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|FIND-CKD|Baseline analysis population is the Full Analysis Set (FAS); all subjects randomised to treatment, received at least 1 dose study drug or, per protocol, not treated due to ferritin <100 mcg/L, and attended at least 1 post-baseline visit with at least 1 non-missing assessment. Overall 626 subjects were randomised, the FAS consists of 613 subjects.|Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)|An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High and Low Dosage Regimens) Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease|Completed||Phase 3|626|Actual|Vifor Inc.|Initially 1,016 subjects were planned, but due to slow enrollment only 626 were randomised which was sufficient to make the primary comparison between FCM targeting high ferritin level and oral iron.|3|||f||||t||||||||||2018-06-01 00:29:13.69186|2018-06-01 00:29:13.69186
NCT00994305|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|April 2005||2005-04-30|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|June 2008|Actual|2008-06-30||Interventional|NACTX||Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant|Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant|Unknown status|Active, not recruiting|N/A|74|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-06-01 00:29:14.843582|2018-06-01 00:29:14.843582
NCT00994292|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13||2015-07-28|2015-09-29|2009-10-13|2009-10-14|Estimate||||2015-07-28|2015-08-18|Estimate|2015-09-29|2015-10-19|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|RUBY-1||Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes|A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes|Completed||Phase 2|1276|Actual|Astellas Pharma Inc||7|||f||||t||||||||||2018-06-01 00:29:15.021165|2018-06-01 00:29:15.021165
NCT00994279|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2015-07-15||2017-11-27|2009-10-13|2009-10-14|Estimate|2017-01-18|2017-03-09|Actual||||2017-11-27|2017-12-21|Actual|October 2009||2009-10-31|November 2017|2017-11-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional||All randomized participants|Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy|Yoga or Wellness Education During Breast Cancer Treatment: Establishing Community-Based Partnerships|Completed||N/A|40|Actual|Wake Forest University Health Sciences|There were no limitations.|2|||f||||t|f|f||||||No||2018-06-01 00:29:15.289764|2018-06-01 00:29:15.289764
NCT00994266|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-04-27|2009-10-13|2009-10-14|Estimate|||||||2011-04-27|2011-04-29|Estimate|October 2009||2009-10-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy|Efficacy of Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin Therapy|Completed||Phase 3|116|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:29:15.722409|2018-06-01 00:29:15.722409
NCT00994253|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|||2017-09-27|2009-10-13|2009-10-14|Estimate|||||||2017-09-27|2017-10-02|Actual|August 2009|Anticipated|2009-08-31|September 2017|2017-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics|A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tekturna (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension|Withdrawn||Phase 4|0|Actual|William Beaumont Hospitals||2||Due to safety concerns re: the concomitant use of aliskiren with an ACEi or ARB.|f||||t||||||||No||2018-06-01 00:29:15.798778|2018-06-01 00:29:15.798778
NCT00994240|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2014-12-05||2015-02-25|2009-10-13|2009-10-14|Estimate|2015-02-25|2015-02-27|Estimate||||2015-02-25|2015-02-27|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC|Cure Rates of Superficial Basal Cell Carcinoma Following 1 Versus 3 Cycles of Electrodessication & Curettage: A Randomized Prospective Study|Terminated||N/A|85|Actual|University of Wisconsin, Madison||2||slow enrollment, lack of funding|f||||t||||||||||2018-06-01 00:29:15.883664|2018-06-01 00:29:15.883664
NCT00994227|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-04-20|2009-10-13|2009-10-14|Estimate|||||||2011-04-20|2011-04-21|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Interventional|||Clinicopathologic Findings for Macular Disease|Clinicopathologic Findings for Macular Disease|Completed||N/A|60|Anticipated|Hallym University Medical Center||1|||f||||t||||||||||2018-06-01 00:29:16.116505|2018-06-01 00:29:16.116505
NCT00994214|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2015-10-14||2016-01-07|2009-10-13|2009-10-14|Estimate|2016-01-07|2016-02-10|Estimate||||2016-01-07|2016-02-10|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|TULIPIA||Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly|Phase II, Open, Randomised, Parallel Group, Noncomparative Multicentre Study to Assess the Efficacy and Safety of Repeated Subcutaneous (S.C.) Administration of Different Doses of BIM 23A760 in Acromegalic Patients|Terminated||Phase 2|109|Actual|Ipsen|The study was terminated prematurely due to lack of efficacy.|4||Preliminary data from this study does not support expected inhibition of GH and IGF-1|f||||f||||||||||2018-06-01 00:29:16.24517|2018-06-01 00:29:16.24517
NCT00994201|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2016-03-24|2009-10-13|2009-10-14|Estimate|||||||2016-03-24|2016-03-25|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Magnetic Resonance Imaging (MRI) in the Assessment of Head and Neck Squamous Cell Carcinoma (HNSCC) Response|Pilot Study of DCE-MRI, DW-MRI, and MRS in the Assessment of Head and Neck Cancer Response to Chemo-radiation|Terminated|||10|Actual|OHSU Knight Cancer Institute||||Study never accrued sufficient subjects|f||||t||||||||||2018-06-01 00:29:17.788593|2018-06-01 00:29:17.788593
NCT00810290|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2010-02-04|2008-12-17|2008-12-18|Estimate|||||||2010-02-04|2010-02-08|Estimate|July 2004||2004-07-31|February 2010|2010-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|LLDPP||Lawrence Latino Diabetes Prevention Project|Lawrence Latino Diabetes Prevention Project|Completed||N/A|312|Actual|University of Massachusetts, Worcester|||||f||||f||||||||||2018-06-01 01:28:19.280019|2018-06-01 01:28:19.280019
NCT00994188|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members|A Clinical Study of the Living-related Renal Transplantation With Restored Kidneys (Interventional Trial)|Unknown status|Recruiting|N/A|5|Anticipated|Tokushukai Medical Group|||||f||||t||||||||||2018-06-01 00:29:17.850578|2018-06-01 00:29:17.850578
NCT00994175|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-10|2017-06-16||2017-08-01|2009-10-10|2009-10-14|Estimate|2017-08-01|2017-09-05|Actual||||2017-08-01|2017-09-05|Actual|September 23, 2009||2009-09-23|August 2017|2017-08-31|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Interventional|||A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma|A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma|Completed||Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f||||||Yes|The NIH Biomedical Translational Research Information System|2018-06-01 00:29:17.935293|2018-06-01 00:29:17.935293
NCT00994162|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2012-09-07|2009-10-13|2009-10-14|Estimate|||||||2012-09-07|2012-09-10|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|EZCARE-CIME||Evaluation of the Use of EZCare◊ in the Management of Acute and Chronic Wounds|A Prospective, Open Labelled, Multicentre Evaluation of the Use of EZCare◊ in the Management of Acute and Chronic Wounds|Completed||Phase 4|131|Actual|Smith & Nephew Wound Management Inc||1|||f||||f||||||||||2018-06-01 00:29:18.251995|2018-06-01 00:29:18.251995
NCT00994149|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-10|2009-10-10|2009-10-14|Estimate|||||||2009-10-10|2009-10-14|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|DIMOHN||Diazoxide In the Management Of Hypoglycemic Neonates|Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|University of Saskatchewan||2|||f||||t||||||||||2018-06-01 00:29:18.328825|2018-06-01 00:29:18.328825
NCT00994136|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2011-06-08|2009-10-13|2009-10-14|Estimate|||||||2011-06-08|2011-06-09|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters|Locking of Totally Implanted Venous Access Devices and Tunneled Catheters With or Without Heparin: a Randomised Open-labeled Controlled Trial|Completed||Phase 4|1100|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-06-01 00:29:18.422017|2018-06-01 00:29:18.422017
NCT00994123|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2016-02-14||2016-07-12|2009-10-13|2009-10-14|Estimate|2016-07-12|2016-08-22|Estimate||||2016-07-12|2016-08-22|Estimate|February 2010||2010-02-28|July 2016|2016-07-31|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional||Ph 1: Patients with NSCLC Ph 2:Patients whose tumors are wild-type for EGFR and who have not received prior EGFR TKI targeted therapy.|A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer|A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|162|Actual|Merrimack Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:29:18.528239|2018-06-01 00:29:18.528239
NCT00994110|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2015-12-22||2015-12-22|2009-10-13|2009-10-14|Estimate|2015-12-22|2016-02-01|Estimate||||2015-12-22|2016-02-01|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess|Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess|Completed||Phase 3|439|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 00:29:19.5278|2018-06-01 00:29:19.5278
NCT00994097|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2015-10-08|2009-10-13|2009-10-14|Estimate|||||||2015-10-08|2015-10-09|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer|NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Unknown status|Active, not recruiting|Phase 2|102|Anticipated|MolMed S.p.A.||2|||f||||f||||||||||2018-06-01 00:29:20.048079|2018-06-01 00:29:20.048079
NCT00994084|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2015-01-27|2009-10-13|2009-10-14|Estimate|||||||2015-01-27|2015-01-28|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|HKH||Healthy Kids-Houston: A Community Childhood Obesity Intervention Program|Healthy Kids-Houston: An Integrated Community Program for the Prevention of Obesity Among Minority Children|Completed||N/A|1094|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 00:29:20.154751|2018-06-01 00:29:20.154751
NCT00994071|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-10|||2018-05-19|2009-10-10|2009-10-14|Estimate|||||||2018-05-19|2018-05-22|Actual|September 22, 2009||2009-09-22|July 16, 2014|2014-07-16|March 19, 2013|Actual|2013-03-19|||||Interventional|||A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors|A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:29:20.221792|2018-06-01 00:29:20.221792
NCT00994058|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2015-12-22|2009-10-13|2009-10-14|Estimate|||||||2015-12-22|2015-12-24|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|PSEUCI||Pilot Study of Electronic Uterine Contraction Inhibitor|Pilot Study to Evaluate A Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions|Withdrawn||Phase 1|0|Actual|Winthrop University Hospital||1||The Investigator has changed institutions.|f||||f||||||||||2018-06-01 00:29:20.298791|2018-06-01 00:29:20.298791
NCT00994045|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2017-01-28|2009-10-13|2009-10-14|Estimate|||||||2017-01-28|2017-01-31|Estimate|June 2010|Actual|2010-06-30|January 2017|2017-01-31||||August 2013|Actual|2013-08-31||Interventional|||Fibrinogen as an Alternative to FFP in Aortic Surgery.|Coagulopathy During Surgery for the Repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - Feasibility Study of the Use of Fibrinogen Concentrate by Infusion in Place of Fresh Frozen Plasma.|Completed||Phase 4|20|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:29:20.358978|2018-06-01 00:29:20.358978
NCT00994032|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2017-02-22|2009-10-13|2009-10-14|Estimate|||||||2017-02-22|2017-02-23|Actual|March 2006||2006-03-31|February 2017|2017-02-28|June 1, 2011|Actual|2011-06-01|June 1, 2011|Actual|2011-06-01||Interventional|||Quality of Life After Vertebroplasty Versus Conservative Treatment in Patients With Painful Osteoporotic Vertebral Fractures|Analysis of the Impact in the Quality of Life of Patients With Pain Secondary to Osteoporotic Vertebral Fractures Receiving Conservative Treatment Versus Percutaneous Vertebroplasty|Completed||N/A|120|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 00:29:20.514937|2018-06-01 00:29:20.514937
NCT00994019|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2015-03-30|2009-10-13|2009-10-14|Estimate|||||||2015-03-30|2015-03-31|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|SPITT||Study of Oral Papillomavirus In Teens and Twenties|Short-term Natural History of Oral HPV Infection Among Young Adults|Completed|||550|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||||||2018-06-01 00:29:20.612613|2018-06-01 00:29:20.612613
NCT00994006|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-11|||2011-05-03|2009-10-13|2009-10-14|Estimate|||||||2011-05-03|2011-05-04|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects|The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease|Completed||Phase 4|41|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 00:29:20.674748|2018-06-01 00:29:20.674748
NCT00993993|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2015-09-29|2009-10-13|2009-10-14|Estimate|||||||2015-09-29|2015-09-30|Estimate|January 2010||2010-01-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|January 2013|Actual|2013-01-31||Observational|||Relational Development in Children With Cleft Lips and Palates: Influence of the Waiting Period Prior to the First Surgical Intervention and the Parents' Psychological Perception of the Abnormality||Completed|||150|Actual|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-06-01 00:29:20.761229|2018-06-01 00:29:20.761229
NCT00993980|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2012-07-09|2009-10-13|2009-10-14|Estimate|||||||2012-07-09|2012-07-10|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Interventional|QEBA||Qigong and Exercise Therapy for Low Back Pain in Adults|Randomized Multicenter Trial on the Effectiveness of Qigong and a Stabilizing Exercise Therapy in Patients With Low Back Pain|Completed||N/A|127|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:29:20.836597|2018-06-01 00:29:20.836597
NCT00993967|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2016-10-14||2017-08-21|2009-10-13|2009-10-14|Estimate|2017-08-21|2018-03-05|Actual||||2017-08-21|2018-03-05|Actual|June 2007||2007-06-30|August 2017|2017-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)|A Phase III Open-Label, Single-Group, Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients.|Completed||Phase 3|200|Actual|Santhera Pharmaceuticals||1|||f||||t||||||||||2018-06-01 00:29:20.943734|2018-06-01 00:29:20.943734
NCT00993954|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2014-11-25||2014-12-28|2009-10-13|2009-10-14|Estimate|2014-12-28|2014-12-30|Estimate||||2014-12-28|2014-12-30|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Nurse Reduction of Pulled Elbow|Reduction of Radial Head Subluxation in Children Via a Nurse Initiated Pathway: A Randomized Control Trial|Completed||N/A|245|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||||2018-06-01 00:29:21.290574|2018-06-01 00:29:21.290574
NCT00993941|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2010-12-03|2009-10-13|2009-10-14|Estimate|||||||2010-12-03|2010-12-06|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|April 2011|Anticipated|2011-04-30|October 2010|Anticipated|2010-10-31||Interventional|||Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein|Evaluation the Efficacy and Safety of Autologous Bone Marrow Mesenchymal Stem Cells (MSCs) Transplantation in Patients With Early and Middle Stage of Liver Cirrhosis|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 00:29:21.565526|2018-06-01 00:29:21.565526
NCT00993928|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2017-01-11||2017-07-25|2009-10-13|2009-10-14|Estimate|2017-01-11|2017-03-03|Actual||||2017-07-25|2017-09-25|Actual|April 2010||2010-04-30|July 2017|2017-07-31|April 2015|Actual|2015-04-30|March 2014|Actual|2014-03-31||Interventional||All eligible patients that started protocol treatment were included in baseline analysis.|Home-Based Programs for Improving Sleep in Cancer Survivors|A Randomized Phase II Trial Evaluating Two Non-pharmacologic Interventions in Cancer Survivors for the Treatment of Sleep-wake Disturbances|Terminated||Phase 2|93|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 00:29:21.700476|2018-06-01 00:29:21.700476
NCT00993915|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|2012-11-21||2013-01-07|2009-10-13|2009-10-14|Estimate|2012-11-21|2012-12-20|Estimate||||2013-01-07|2013-01-10|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|LIGHT||Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications|Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications|Completed|||687|Actual|Pfizer|The end of study final status of 3 participants was not completed and therefore defaulted to ongoing.||1||f||||t||||||||||2018-06-01 00:29:22.200517|2018-06-01 00:29:22.200517
NCT00993902|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Double and Single Intrauterine Insemination In Controlled Ovarian Stimulation (COH) Cycles With Multifollicular Development||Completed||Phase 4|228|Actual|Baskent University||2|||f||||f||||||||||2018-06-01 00:29:22.357131|2018-06-01 00:29:22.357131
NCT00993889|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2017-08-30|2009-10-13|2009-10-14|Estimate|||||||2017-08-30|2017-09-01|Actual|May 2009||2009-05-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|VRD/Peds||Virtual Reality Analgesia During Pediatric Physical Therapy|Virtual Reality Analgesia During Pediatric Physical Therapy|Completed||N/A|18|Anticipated|National Institute of General Medical Sciences (NIGMS)||3|||f||||f||||||||||2018-06-01 00:29:22.411375|2018-06-01 00:29:22.411375
NCT00993876|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|August 2005||2005-08-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Decoflex||Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment|Cognitive Flexibility and Its Correlation to Sleep and Neuroplasticity In The Course Of Depression During Different Treatments|Completed||N/A|45|Actual|Zentrum für Integrative Psychiatrie||3|||f||||f||||||||||2018-06-01 00:29:22.495639|2018-06-01 00:29:22.495639
NCT00993863|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2015-07-16|2009-10-13|2009-10-14|Estimate|||||||2015-07-16|2015-07-17|Estimate|June 2007||2007-06-30|October 2009|2009-10-31||||September 2007|Actual|2007-09-30||Interventional|||Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction|A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled Study of ADL5859 for the Treatment of Pain After Surgical Removal of Impacted Third Molars|Completed||Phase 2|201|Actual|Cubist Pharmaceuticals LLC||5|||f||||f||||||||||2018-06-01 00:29:22.567611|2018-06-01 00:29:22.567611
NCT00993850|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-13|||2013-04-12|2009-10-13|2009-10-14|Estimate|||||||2013-04-12|2013-04-16|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Sleep Disturbance and Bipolar Disorder|A Psychological Intervention for Individuals Who Suffer From Sleep Disturbance and Bipolar Disorder|Completed||Phase 3|52|Actual|University of California, Berkeley||2|||f||||t||||||||||2018-06-01 00:29:22.633112|2018-06-01 00:29:22.633112
NCT00993837|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-10-13|2009-10-13|2009-10-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma|Comparison of Effectiveness and Safety of Thyroidectomy for Thyroid Carcinoma in Patients Undergo Endoscopic Surgery and Those Receive Conversion|Unknown status|Not yet recruiting|N/A|60|Anticipated|Second Military Medical University||1|||f||||f||||||||||2018-06-01 00:29:22.693661|2018-06-01 00:29:22.693661
NCT00993824|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-12|2013-09-05||2015-11-25|2009-10-13|2009-10-14|Estimate|2014-06-16|2014-06-17|Estimate||||2015-11-25|2015-11-30|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes|Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes|Completed||Phase 2/Phase 3|21|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-06-01 00:29:22.760879|2018-06-01 00:29:22.760879
NCT00993811|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2010-12-03|2009-10-13|2009-10-14|Estimate|||||||2010-12-03|2010-12-06|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|ShangRing||The Shang Ring: A Novel Male Circumcision Device for HIV Prevention|The Shang Ring: A Novel Male Circumcision Device for HIV Prevention|Completed||Phase 1|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 00:29:23.029708|2018-06-01 00:29:23.029708
NCT00993798|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09||2013-01-23|2013-01-30|2009-10-09|2009-10-12|Estimate||||2013-01-23|2013-01-29|Estimate|2013-01-30|2013-02-04|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||An International Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery|An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery|Completed||Phase 2|107|Actual|Durect||6|||f||||f||||||||||2018-06-01 00:29:24.103806|2018-06-01 00:29:24.103806
NCT00993785|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-27|2009-10-09|2009-10-12|Estimate|||||||2009-10-27|2009-10-29|Estimate|February 2007||2007-02-28|October 2009|2009-10-31|April 2008|Actual|2008-04-30|||||Interventional|CONCISE||CoStar Catheter System Evaluation||Terminated||Phase 3|58|Actual|Conor Medsystems||1||CoStar Stent IDE failed to meet primary endpoint|f||||||||||||||2018-06-01 00:29:24.219204|2018-06-01 00:29:24.219204
NCT00993772|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2011-05-10|2009-10-09|2009-10-12|Estimate|||||||2011-05-10|2011-05-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:29:24.275025|2018-06-01 00:29:24.275025
NCT00993759|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2009-10-09|2009-10-09|2009-10-12|Estimate|||||||2009-10-09|2009-10-12|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Efficacy Study of A Lotion to Prevent Common Colds|Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects|Unknown status|Active, not recruiting|Phase 2|212|Actual|The Dial Corporation||2|||f||||f||||||||||2018-06-01 00:29:24.312728|2018-06-01 00:29:24.312728
NCT00993746|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-27|||2010-05-14|2009-10-09|2009-10-12|Estimate|||||||2010-05-14|2010-05-17|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|||2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula|Comparison of Onset of Action Between 2% Lidocaine Plus 0.5% Bupivacaine and 0.5% Bupivacaine in Brachial Plexus Anesthesia for Creation of Arteriovenous Fistula in ESRD Patient|Unknown status|Recruiting|Phase 4|90|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 00:29:24.392962|2018-06-01 00:29:24.392962
NCT00993733|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2016-03-22|2009-10-09|2009-10-12|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care|Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||This study has never been started|f||||f||||||||No||2018-06-01 00:29:24.48033|2018-06-01 00:29:24.48033
NCT00993720|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2011-01-20|2009-10-09|2009-10-12|Estimate|||||||2011-01-20|2011-01-21|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes|Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes|Completed||Phase 2/Phase 3|30|Actual|Hvidovre University Hospital||3|||f||||t||||||||||2018-06-01 00:29:24.557495|2018-06-01 00:29:24.557495
NCT00993707|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2011-06-16|2009-10-09|2009-10-12|Estimate|||||||2011-06-16|2011-06-20|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|||Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)|A Phase 2a, Ascending Dose, Placebo-Controlled Study to Evaluate the Safety of CTX-100 (Formerly ETX-100) Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|Phase 2|48|Anticipated|Turino, Gerard, M.D.||3|||f||||t||||||||||2018-06-01 00:29:25.439872|2018-06-01 00:29:25.439872
NCT00993694|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2017-04-13|2009-10-09|2009-10-12|Estimate|||||||2017-04-13|2017-04-17|Actual|January 2009|Actual|2009-01-31|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone|Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia|Completed|||41|Actual|Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 00:29:25.56354|2018-06-01 00:29:25.56354
NCT00993681|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2012-03-13|2009-10-09|2009-10-12|Estimate|||||||2012-03-13|2012-03-14|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|||Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study|A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System|Completed||Phase 3|2036|Actual|Intercell USA, Inc.||2|||f||||t||||||||||2018-06-01 00:29:25.671272|2018-06-01 00:29:25.671272
NCT00993668|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2011-05-23||2012-01-16|2009-10-09|2009-10-12|Estimate|2011-05-23|2011-06-20|Estimate||||2012-01-16|2012-01-19|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines|A Phase 4, Randomized, Single-blind, Placebo-controlled, Multicenter Study to Evaluate the Immunogenicity of Pneumococcal and Influenza Vaccines in Adult Subjects With Rheumatoid Arthritis Receiving Certolizumab Pegol or Placebo|Completed||Phase 4|224|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 00:29:25.817786|2018-06-01 00:29:25.817786
NCT00993655|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2017-06-08||2017-07-11|2009-10-09|2009-10-12|Estimate|2017-07-11|2017-08-10|Actual||||2017-07-11|2017-08-10|Actual|September 2009||2009-09-30|July 2017|2017-07-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional||All randomized patients|Randomized Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer|A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy|Completed||Phase 2|275|Actual|Canadian Cancer Trials Group||3|||f||||t||||||||Undecided||2018-06-01 00:29:26.613301|2018-06-01 00:29:26.613301
NCT00993642|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2017-03-09|2009-10-09|2009-10-12|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2009||2009-09-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer|Pilot Study Evaluating the Expression of ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer|Withdrawn||Early Phase 1|0|Actual|Tulane University||1||Lack of accrual|f||||f||||||||||2018-06-01 00:29:27.306519|2018-06-01 00:29:27.306519
NCT00993629|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2014-10-23|2009-10-09|2009-10-12|Estimate|||||||2014-10-23|2014-10-27|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans|Adjunctive Pregnenolone in PTSD and Depression in OEF/OIF Veterans|Withdrawn||Phase 2|0|Actual|VA Office of Research and Development||2||PI turned down funding.|f||||t||||||||||2018-06-01 00:29:27.373849|2018-06-01 00:29:27.373849
NCT00993616|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2013-12-05||2017-10-18|2009-10-09|2009-10-12|Estimate|2013-12-06|2014-01-21|Estimate||||2017-10-18|2017-11-21|Actual|December 2009||2009-12-31|October 2017|2017-10-31|July 29, 2012|Actual|2012-07-29|July 2012|Actual|2012-07-31||Interventional||Number of eligible and evaluable participants|Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin|A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed||Phase 2|29|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:29:27.484247|2018-06-01 00:29:27.484247
NCT00993603|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2012-12-04|2009-10-09|2009-10-12|Estimate|||||||2012-12-04|2012-12-05|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Lifestyle Intervention in Obese Non-diabetic Adults With a Family History of Diabetes.|The Effect of an 8-month Intensive Lifestyle Intervention on Hormonal Factors Regulating Food Intake in Obese, Non-diabetic Adults With a Family History of Diabetes.|Completed||N/A|66|Actual|The Royal Bournemouth Hospital||1|||f||||f||||||||||2018-06-01 00:29:28.068772|2018-06-01 00:29:28.068772
NCT00993590|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2016-02-03|2009-10-09|2009-10-12|Estimate|||||||2016-02-03|2016-02-04|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Mobile CHESS Research on Emergency Medical Services for Children|Mobile CHESS Research on Emergency Medical Services for Children|Completed||N/A|219|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:29:28.138987|2018-06-01 00:29:28.138987
NCT00993577|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-29|2009-10-09|2009-10-12|Estimate|||||||2009-10-29|2009-10-30|Estimate|February 2004||2004-02-29|October 2009|2009-10-31|March 2007|Actual|2007-03-31|July 2006|Actual|2006-07-31||Interventional|Stretching||Stretching Exercises and Temporomandibular Disorders|Global Postural Reeducation and Static Stretching Exercises in the Treatment of Myogenic Temporomandibular Disorders. A Randomized Study|Completed||Phase 1|24|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-06-01 00:29:28.208967|2018-06-01 00:29:28.208967
NCT00993564|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2013-07-05|2009-10-08|2009-10-12|Estimate|||||||2013-07-05|2013-07-09|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|December 2012|Anticipated|2012-12-31||Observational|||Magnetic Resonance Imaging (MRI) Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy (HIE)|MRI Thermal Imaging of Infants Undergoing Cooling for HIE|Withdrawn|||0|Actual|Vanderbilt University|||2|this is an accidentical duplication of 090575Walsh NCT01128673 and I would like to remove|f||||f||||||||||2018-06-01 00:29:28.280384|2018-06-01 00:29:28.280384
NCT00993551|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2017-11-16|2009-10-09|2009-10-12|Estimate|||||||2017-11-16|2017-11-20|Actual|July 2010||2010-07-31|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|August 2020|Anticipated|2020-08-31||Interventional|TOPS||Timing of Primary Surgery for Cleft Palate|Timing of Primary Surgery for Cleft Palate|Active, not recruiting||N/A|558|Actual|University of Manchester||2|||f||||t||||||||||2018-06-01 00:29:28.356365|2018-06-01 00:29:28.356365
NCT00993538|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2011-08-29|2009-10-09|2009-10-12|Estimate|||||||2011-08-29|2011-08-30|Estimate|July 2009||2009-07-31|August 2011|2011-08-31||||||||Interventional|||Leukemia Cell Cultures for Research of New Anti-Cancer Therapies|Leukemia Cell Cultures for Research of New Anti-cancer Therapies|Unknown status|Recruiting|N/A|180|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-06-01 00:29:28.469792|2018-06-01 00:29:28.469792
NCT00993525|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-09|2009-10-09|2009-10-12|Estimate|||||||2009-10-09|2009-10-12|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|INIPE||Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)|INTRAVITREAL RANIBIZUMAB FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (INIPE STUDY)|Unknown status|Active, not recruiting|Phase 1/Phase 2|22|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 00:29:28.634001|2018-06-01 00:29:28.634001
NCT00993512|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2011-06-17|2009-10-09|2009-10-12|Estimate|||||||2011-06-17|2011-06-20|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer|Phase I, Dose-escalating Study to Evaluate Safety and Tolerance of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Local Recurrence or Advanced/Metastatic, Cutaneous or Sub-cutaneous Malignancies|Completed||Phase 1|19|Actual|PCI Biotech AS||1|||f||||t||||||||||2018-06-01 00:29:28.782587|2018-06-01 00:29:28.782587
NCT00993499|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2015-09-04||2015-09-04|2009-10-09|2009-10-12|Estimate|2015-09-04|2015-10-07|Estimate||||2015-09-04|2015-10-07|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Treated set which included all patients who recieved at least one dose of the trial drug during the first and second treatment counrses.|Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib|A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib|Completed||Phase 1|44|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:29:28.980303|2018-06-01 00:29:28.980303
NCT00993486|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2013-06-19|2009-10-09|2009-10-12|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 2005||2005-01-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|October 2008|Actual|2008-10-31||Interventional|||Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor|Phase I, Dose-ranging, Open-label, Study of a Single Administration of T-cells Add-back Depleted of Host Alloreactive Cells Using Theralux™ Therapy, Following Haploidentical Peripheral Blood Stem Cell Transplantation Submitted to CD34+ Cell Selection, in Patients With Severe Hematologic Malignancies|Completed||Phase 1/Phase 2|19|Actual|Kiadis Pharma||7|||f||||f||||||||||2018-06-01 00:29:30.551434|2018-06-01 00:29:30.551434
NCT00993473|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2012-03-28||2012-06-25|2009-10-09|2009-10-12|Estimate|2012-05-16|2012-06-22|Estimate||||2012-06-25|2012-06-27|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|PRESCHOOL||6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes|A 24-week, Randomized, Open-label, Parallel Group Multinational Comparison of Lantus® (Insulin Glargine) Given in the Morning as Once-a-day Basal Insulin Versus Neutral Protamine Hagedorn (NPH) Insulin, in Children With Type 1 Diabetes Mellitus Aged at Least 1 Year to Less Than 6 Years|Completed||Phase 3|125|Actual|Sanofi|There are numerous potential biases that could affect the timing and frequency of performance of sporadic FSBG, such as mealtime dosing and choice of bolus insulin dose, stability and familiarity with insulin regimens, and parental anxiety levels.|2|||f||||f||||||||||2018-06-01 00:29:30.661302|2018-06-01 00:29:30.661302
NCT00993460|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2018-04-03|2009-10-08|2009-10-12|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2011||2011-03-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2013|Actual|2013-11-30||Observational|||Study of Changes in Skeletal Muscle After Caloric Restriction|Diacylglycerols and Insulin Action in Skeletal Muscle Upon Caloric Restriction|Active, not recruiting|||24|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||Samples With DNA|"~     Whole blood, plasma, muscle tissue~   "|||2018-06-01 00:29:31.523591|2018-06-01 00:29:31.523591
NCT00993447|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2016-10-04|2012-04-16|2016-10-04|2009-10-09|2009-10-12|Estimate|2016-10-04|2016-11-29|Estimate|2012-04-16|2012-04-18|Estimate|2016-10-04|2016-11-29|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America|Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America|Completed||Phase 2|600|Actual|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-06-01 00:29:31.661907|2018-06-01 00:29:31.661907
NCT00993434|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2015-09-30|2009-10-09|2009-10-12|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Impact of Educational Materials on Family Behavior|The Impact of Educational Materials on Family Behavior|Completed||N/A|95|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:29:33.024963|2018-06-01 00:29:33.024963
NCT00993421|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2011-05-11|2011-02-25|2011-06-02|2009-10-09|2009-10-12|Estimate|2011-05-11|2011-06-02|Estimate|2011-02-25|2011-03-07|Estimate|2011-06-02|2011-06-03|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Weight Loss Study in Overweight Men and Women|LY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women|Terminated||Phase 2|343|Actual|Eli Lilly and Company||7||Clinical trial terminated due to results from recent nonclinical studies|f||||t||||||||||2018-06-01 00:29:33.189505|2018-06-01 00:29:33.189505
NCT00993408|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-09|2009-10-09|2009-10-12|Estimate|||||||2009-10-09|2009-10-12|Estimate|April 2008||2008-04-30|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)|A Multi-centre, Multinational, Open-label, Single-dose Acute Hemodynamic Study Followed by Multi-centre, Multinational, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy (Proof-of-concept) of ACT-293987 (NS-304) in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over|Completed||Phase 2|43|Actual|Actelion||1|||f||||t||||||||||2018-06-01 00:29:34.91759|2018-06-01 00:29:34.91759
NCT00993395|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-09|2009-10-09|2009-10-12|Estimate|||||||2009-10-09|2009-10-12|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Comprehensive Peer Mentor-based Disease Management Program for Medically Complex Substance Users|A Comprehensive Peer Mentor-based Disease Management Program for Medically Complex Substance Users|Unknown status|Not yet recruiting|N/A|160|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 00:29:34.996064|2018-06-01 00:29:34.996064
NCT00993382|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09||2016-03-30|2016-05-02|2009-10-09|2009-10-12|Estimate||||2016-03-30|2016-05-02|Estimate|2016-05-02|2016-05-30|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ALPHEE||Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death|Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone at 50, 100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or Death|Completed||Phase 2|486|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 00:29:35.082014|2018-06-01 00:29:35.082014
NCT00993369|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2016-11-08|2009-10-09|2009-10-12|Estimate|||||||2016-11-08|2016-11-10|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|HRV ART||Heart Rate Variability in Children Conceived Via Assisted Reproductive Technologies|Heart Rate Variability in Children Conceived Via Assisted Reproductive Technologies|Completed|||60|Actual|University of Utah|||2||f||||f||||||||||2018-06-01 00:29:35.442288|2018-06-01 00:29:35.442288
NCT00993356|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2009-10-09|2009-10-09|2009-10-12|Estimate|||||||2009-10-09|2009-10-12|Estimate|January 2004||2004-01-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas|A Prospective, Randomized Trial of Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas|Unknown status|Recruiting|Phase 2|96|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 00:29:35.505486|2018-06-01 00:29:35.505486
NCT00791427|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2015-05-07|2008-11-13|2008-11-14|Estimate|||||||2015-05-07|2015-05-08|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|FVF4154s||ERG/EOG Study in AMD Patients Treated With Ranibizumab|ERG/EOG Study in AMD Patients Treated With Ranibizumab|Completed|||10|Actual|Retina Center, Minnesota|||1||f||||||||||||||2018-06-01 01:34:26.229126|2018-06-01 01:34:26.229126
NCT00993343|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2015-04-13|2009-10-09|2009-10-12|Estimate|||||||2015-04-13|2015-04-14|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation|A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study.|Completed||Phase 3|215|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 00:29:35.658554|2018-06-01 00:29:35.658554
NCT00993330|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2014-11-13|2009-10-09|2009-10-12|Estimate|||||||2014-11-13|2014-11-14|Estimate|May 2009||2009-05-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Macular Pigment Optical Density in Healthy Subjects|Macular Pigment Optical Density in Healthy Subjects|Terminated|||96|Actual|Medical University of Vienna|||6||f||||t||||||||||2018-06-01 00:29:35.754031|2018-06-01 00:29:35.754031
NCT00993317|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2012-05-22||2012-09-25|2009-10-09|2009-10-12|Estimate|2012-09-25|2012-09-27|Estimate||||2012-09-25|2012-09-27|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis|A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate|Completed||Phase 3|127|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:29:35.832764|2018-06-01 00:29:35.832764
NCT00993304|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2017-01-25|2009-10-09|2009-10-12|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics|A Trial to Assess the Effect of Liraglutide on Postprandial Triglyceride Levels in Subjects With Type 2 Diabetes|Completed||Phase 1|20|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:29:36.307015|2018-06-01 00:29:36.307015
NCT00993291|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2011-08-22||2011-12-21|2009-10-09|2009-10-12|Estimate|2011-12-21|2012-01-27|Estimate||||2011-12-21|2012-01-27|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)|Effect of Frequency Change in Bilateral Subthalamic Nucleus (STN)-DBS on Gait Function in PD|Completed||Phase 1/Phase 2|20|Actual|Vanderbilt University||1|||f||||t||||||||||2018-06-01 00:29:36.390328|2018-06-01 00:29:36.390328
NCT00993278|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2015-05-13|2009-10-09|2009-10-12|Estimate|||||||2015-05-13|2015-05-14|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effects of the Atkins Diet Versus a Low Fat Diet on Inflammation|Effects of the Atkins Diet Versus a Low Fat Diet on Endothelial Function, Lipid Profiles, and Systemic Markers of Inflammation|Completed||Phase 3|60|Actual|Boston Medical Center||2|||f||||f||||||||||2018-06-01 00:29:36.562657|2018-06-01 00:29:36.562657
NCT00993265|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2014-03-07||2014-06-26|2009-10-09|2009-10-12|Estimate|2014-06-26|2014-07-25|Estimate||||2014-06-26|2014-07-25|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|April 2012|Actual|2012-04-30||Interventional|||N-Acetylcysteine for Pediatric Trichotillomania|Double-Blind, Placebo-Controlled Trial of N-acetylcysteine for the Treatment of Pediatric Trichotillomania|Completed||Phase 2|39|Actual|Yale University||2|||f||||f||||||||||2018-06-01 00:29:36.647408|2018-06-01 00:29:36.647408
NCT00993252|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2010-10-13|2009-10-09|2009-10-12|Estimate|||||||2010-10-13|2010-10-15|Estimate|September 2003||2003-09-30|October 2010|2010-10-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Canadian Computed Tomography (CT) Head Rule Study|Evaluation of an Active Strategy to Implement the Canadian CT Head Rule: Phase III|Completed||Phase 3|4531|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 00:29:37.039203|2018-06-01 00:29:37.039203
NCT00993239|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2016-03-01|2009-10-09|2009-10-12|Estimate|||||||2016-03-01|2016-03-03|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma|A Phase 1, Open-Label, Non-randomized, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TL32711 in Adults With Refractory Solid Tumors or Lymphoma|Completed||Phase 1|50|Actual|TetraLogic Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:29:37.313792|2018-06-01 00:29:37.313792
NCT00993226|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09||2013-01-23|2013-01-30|2009-10-09|2009-10-12|Estimate||||2013-01-23|2013-01-29|Estimate|2013-01-30|2013-02-04|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||An International Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy|An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Primary, Elective, Open, Abdominal Hysterectomy|Completed||Phase 2|115|Actual|Durect||6|||f||||f||||||||||2018-06-01 00:29:37.399928|2018-06-01 00:29:37.399928
NCT00993213|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2016-12-02|2009-10-08|2009-10-12|Estimate|||||||2016-12-02|2016-12-06|Estimate|April 2004||2004-04-30|December 2016|2016-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Mechanisms Defending Fat Mass in Humans After Lipectomy|Mechanisms Defending Fat Mass in Humans After Lipectomy|Completed||N/A|32|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 00:29:37.503598|2018-06-01 00:29:37.503598
NCT00993200|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2012-08-13||2015-05-28|2009-10-09|2009-10-12|Estimate|2013-04-08|2013-05-16|Estimate||||2015-05-28|2015-06-24|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|PerMIT||Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy|PerMIT: Warfarin : A Prospective Randomized Controlled Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy|Completed||Phase 4|26|Actual|University of Utah|Small sample size in this pilot trial|2|||f||||t||||||||||2018-06-01 00:29:37.592053|2018-06-01 00:29:37.592053
NCT00993187|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|2014-09-08||2017-08-31|2009-10-09|2009-10-12|Estimate|2014-09-08|2014-09-15|Estimate||||2017-08-31|2017-09-29|Actual|May 4, 2010|Actual|2010-05-04|August 2017|2017-08-31|October 29, 2013|Actual|2013-10-29|October 29, 2013|Actual|2013-10-29||Interventional|||Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)|A Multicenter, Randomized, Double Blind Study to Compare the Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (Janumet®) Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|292|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:29:37.825735|2018-06-01 00:29:37.825735
NCT00993174|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2011-06-24|2009-10-09|2009-10-12|Estimate|||||||2011-06-24|2011-06-27|Estimate|May 2004||2004-05-31|May 2010|2010-05-31|June 2013|Anticipated|2013-06-30|June 2009|Actual|2009-06-30||Interventional|SETTA||Surgery for Esotropia Under Topical Anesthesia|Amount of Surgery for Esotropia Under Topical Anesthesia|Unknown status|Active, not recruiting|N/A|60|Anticipated|Hospital Universitario Ramon y Cajal||2|||f||||f||||||||||2018-06-01 00:29:38.259852|2018-06-01 00:29:38.259852
NCT00993161|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2017-10-10|2009-10-09|2009-10-12|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2010|Actual|2010-01-31|October 2017|2017-10-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|ULENAP||Upper Limb Evaluation in Non Ambulatory Patients With Neuromuscular Disorder|Development and Evaluation of a Clinical Test in Order Quantify Muscular Function in Upper Limb of Non Ambulatory Patients With Neuromuscular Disorder|Completed||N/A|174|Actual|Institut de Myologie, France||2|||f||||f||||||||||2018-06-01 00:29:38.332406|2018-06-01 00:29:38.332406
NCT00993148|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2014-07-28||2014-08-26|2009-10-09|2009-10-12|Estimate|2014-07-28|2014-08-19|Estimate||||2014-08-26|2014-09-05|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MIDAS|HIV-infected treatment naïve participants with R5 virus|Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1|Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile|Completed||Phase 2|25|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 00:29:38.414831|2018-06-01 00:29:38.414831
NCT00993135|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2017-04-06|2009-10-09|2009-10-12|Estimate|||||||2017-04-06|2017-04-10|Actual|December 2008||2008-12-31|April 2017|2017-04-30||||December 2009|Actual|2009-12-31||Observational|||Kidney Dysfunction in Children and Young Adults Who Have Received Methotrexate for Acute Lymphoblastic Leukemia|Renal Dysfunction With Low to Intermediate Dose Methotrexate in Acute Lymphoblastic Leukemia Treatment|Completed|||10|Actual|Vanderbilt University Medical Center|||||f|||||f|f||||||||2018-06-01 00:29:38.681624|2018-06-01 00:29:38.681624
NCT00993122|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2015-06-19|2009-10-09|2009-10-12|Estimate|||||||2015-06-19|2015-06-22|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|February 2012|Actual|2012-02-29|April 2010|Actual|2010-04-30||Interventional|RBV||Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients|Phase 2 Randomized Multicenter Controlled Study of Ribavirin Pre-treatment (8 Weeks) Followed by Standard Therapy With Ribavirin and Pegylated Interferon (48 Weeks) in Transplanted Patients With Recurrence of Chronic Hepatitis C|Completed||Phase 4|100|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-06-01 00:29:38.763396|2018-06-01 00:29:38.763396
NCT00993109|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-09|||2014-06-04|2009-10-09|2009-10-12|Estimate|||||||2014-06-04|2014-06-05|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension|Randomized,Open-label,Parallel Design Comparator Study of Effect of Nifedipine GITS/OROS (Adalat) 30 mg in Combination With Valsartan (Diovan) 80 mg Compared to Valsartan (Diovan) 160 mg Monotherapy in Patients Whose Blood Pressure is Not Well Controlled by Valsartan 80 mg Alone|Completed||Phase 4|360|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:29:38.860643|2018-06-01 00:29:38.860643
NCT00993096|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-02-09|2009-10-08|2009-10-09|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2009||2009-09-30|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Investigation of the Response Relationship of NN5401 in Type 1 Diabetics|A Trial Investigating the Pharmacodynamic Response of NN5401 in Subjects With Type 1 Diabetes|Completed||Phase 1|33|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-06-01 00:29:38.959172|2018-06-01 00:29:38.959172
NCT00993083|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2011-08-10|2009-10-08|2009-10-09|Estimate|||||||2011-08-10|2011-08-11|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults|A Phase IIA Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults|Completed||Phase 2|27|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 00:29:39.035068|2018-06-01 00:29:39.035068
NCT00993070|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2012-05-08|2009-10-08|2009-10-09|Estimate|||||||2012-05-08|2012-05-09|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy|A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy|Completed||Phase 2/Phase 3|33|Actual|Thammasat University||2|||f||||f||||||||||2018-06-01 00:29:39.118515|2018-06-01 00:29:39.118515
NCT00993057|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2016-06-14|2009-10-08|2009-10-09|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2009||2009-10-31|June 2016|2016-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia|Comparing Two Glucose Sampling Frequencies for an Intensive Insulin Protocol During Craniotomy in Non-Diabetic Patients—How Efficiently and Safely Can We Maintain Target Glucose Levels|Completed||Early Phase 1|120|Actual|Northwestern University||2|||f||||f||||||||No||2018-06-01 00:29:39.255348|2018-06-01 00:29:39.255348
NCT00993044|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2014-01-03||2014-07-22|2009-10-08|2009-10-09|Estimate|2014-07-21|2014-07-23|Estimate||||2014-07-22|2014-07-29|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|VIT-B||A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin|A Phase I Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin|Completed||Phase 1|13|Actual|Children's Hospital Los Angeles||1|||f||||t||||||||||2018-06-01 00:29:39.382627|2018-06-01 00:29:39.382627
NCT00993031|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2015-01-05||2017-10-25|2009-10-08|2009-10-09|Estimate|2017-10-25|2017-12-02|Actual||||2017-10-25|2017-12-02|Actual|December 15, 2009|Actual|2009-12-15|October 2017|2017-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PROMOTE-PIs||Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women|Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women|Completed||Phase 3|389|Actual|University of California, San Francisco|A semi-immune population of adults at relatively low risk for malaria; a high rate of TMP-SMX prophylaxis ; A lower than expected incidence of malaria, resulting in the possibility that the study was underpowered|2|||f||||t||||||||||2018-06-01 00:29:39.907506|2018-06-01 00:29:39.907506
NCT00992836|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2011-08-23||2014-12-02|2009-10-08|2009-10-09|Estimate|2012-01-05|2012-02-09|Estimate||||2014-12-02|2014-12-17|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth|A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Perinatally Infected Children and Youth|Completed||Phase 2|155|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 00:29:42.410969|2018-06-01 00:29:42.410969
NCT00993018|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08||2012-04-26|2016-05-09|2009-10-08|2009-10-09|Estimate||||2012-04-26|2012-04-30|Estimate|2016-05-09|2016-06-03|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Diabetic Painful Neuropathy, Followed by a Double-Blind Safety Extension and an Open-Label Safety Extension|Terminated||Phase 2|77|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4||Logistic reasons associated with the FDA-imposed clinical hold.|f||||t||||||||||2018-06-01 00:29:40.60413|2018-06-01 00:29:40.60413
NCT00993005|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-12-07|2009-10-08|2009-10-09|Estimate|||||||2010-12-07|2010-12-08|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||CICATRIX in the Treatment of Hypertrophic Scars and Keloids Scars|Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Hypertrophic Scars and Keloids Scars.|Completed||Phase 3|90|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:29:40.756205|2018-06-01 00:29:40.756205
NCT00992992|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2014-02-27||2014-02-27|2009-10-08|2009-10-09|Estimate|2014-02-27|2014-04-08|Estimate||||2014-02-27|2014-04-08|Estimate|June 2001||2001-06-30|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma|Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma|Completed||Phase 2|25|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 00:29:40.867158|2018-06-01 00:29:40.867158
NCT00992979|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-08|2009-10-08|2009-10-09|Estimate|||||||2009-10-08|2009-10-09|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Therapeutic Massage to Manage Withdrawal Related Anxiety|Use of Massage Therapy to Reduce Anxiety and Improve Sleep in Patients Participating in an Inpatient Withdrawal Management (Detox) Program: A Randomized Controlled Pilot Study|Completed||Phase 2|80|Actual|Dalhousie University||2|||f||||t||||||||||2018-06-01 00:29:41.390199|2018-06-01 00:29:41.390199
NCT00992966|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-08-19|2009-10-08|2009-10-09|Estimate|||||||2010-08-19|2010-08-20|Estimate||||August 2010|2010-08-31||||||||Observational|||Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms|Vibration Response Imaging (VRI) in Children With Acute Respiratory Symptoms.|Suspended|||80|Anticipated|Deep Breeze||||Study initiation has been delayed due to Sponsor decision|f||||t||||||||||2018-06-01 00:29:41.460563|2018-06-01 00:29:41.460563
NCT00992953|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2009-10-08|2009-10-08|2009-10-09|Estimate|||||||2009-10-08|2009-10-09|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)|The Efficacy of Virtual Reality (VR) as an Adjunct Therapy for Acute Combat-related Post-Traumatic Stress Disorder (PTSD) in Non-Combatants|Completed||Phase 1/Phase 2|136|Anticipated|United States Naval Medical Center, San Diego||2|||f||||t||||||||||2018-06-01 00:29:41.538877|2018-06-01 00:29:41.538877
NCT00992940|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2013-01-07|2009-10-08|2009-10-09|Estimate|||||||2013-01-07|2013-01-09|Estimate||||January 2013|2013-01-31||||||||Interventional|||Patient-controlled Versus Anesthesiologist-controlled Propofol-remifentanil in Awake Craniotomy|A Comparison of Patient-controlled Versus Anesthesiologist-controlled Propofol-remifentanil in Awake Craniotomy for Tumor Surgery|Withdrawn||N/A|0|Actual|University Health Network, Toronto||2||Funds needed to carry on the project were not secured.|f||||t||||||||||2018-06-01 00:29:41.625293|2018-06-01 00:29:41.625293
NCT00992927|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2010-08-15||2011-07-21|2009-10-08|2009-10-09|Estimate|2011-07-21|2011-08-17|Estimate||||2011-07-21|2011-08-17|Estimate|March 2008||2008-03-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Should the Joint Capsule of the Painful Stiff Shoulder be Ruptured During Intra-articular Hydraulic Distension?|Comparative Study for the Efficacy of Capsule-Preserving Versus Capsule-Rupturing Intra-articular Hydraulic Distension in Patients With Painful Stiff Shoulders|Completed||N/A|54|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:29:41.711301|2018-06-01 00:29:41.711301
NCT00992914|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-03-28|2009-10-08|2009-10-09|Estimate|||||||2017-03-28|2017-03-30|Actual|February 2009||2009-02-28|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of Stellate Ganglion Injection to Provide Relief From Hot Flushes|Pilot Study of Stellate Ganglion Injection With Anesthetic as a Method to Provide Relief From Hot Flushes|Active, not recruiting||N/A|40|Anticipated|Northwestern University||2|||f||||f||||||||||2018-06-01 00:29:41.952226|2018-06-01 00:29:41.952226
NCT00992901|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2018-05-17|2009-10-08|2009-10-09|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2009||2009-10-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery|Hormonal and Neural Control of Insulin Secretion Following Gastric Bypass Surgery|Recruiting||Early Phase 1|160|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||No||2018-06-01 00:29:42.042862|2018-06-01 00:29:42.042862
NCT00992888|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2011-09-14|2009-10-08|2009-10-09|Estimate|||||||2011-09-14|2011-09-15|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Heliac||Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis|Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis. A Pato-etiological Study With Focus on the Endotoxin Pathway.|Completed||N/A|60|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:29:42.126089|2018-06-01 00:29:42.126089
NCT00992875|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2012-05-04|2009-10-07|2009-10-09|Estimate|||||||2012-05-04|2012-05-07|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Does Mindfulness Training Change the Processing of Social Threat?|Does Mindfulness Training Change the Processing of Social Threat?|Completed||N/A|28|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 00:29:42.203084|2018-06-01 00:29:42.203084
NCT00992862|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2013-09-24|2009-10-08|2009-10-09|Estimate|||||||2013-09-24|2013-09-26|Estimate||||October 2009|2009-10-31||||||||Interventional|||A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Moexipril HCl 15mg Tablets Under Fasting Conditions|Completed||Phase 1|60||Paddock Laboratories, Inc.||2|||f||||||||||||||2018-06-01 00:29:42.26721|2018-06-01 00:29:42.26721
NCT00992849|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2009-10-13|2009-10-08|2009-10-09|Estimate|||||||2009-10-13|2009-10-15|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|April 2012|Anticipated|2012-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Bevacizumab for the Treatment of Corneal Neovascularization|Topical/Subconjunctival Injection of Bevacizumab(Avastin) for the Treatment of Corneal Neovascularization|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 00:29:42.323606|2018-06-01 00:29:42.323606
NCT00992823|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2009-10-14|2009-10-08|2009-10-09|Estimate|||||||2009-10-14|2009-10-15|Estimate|March 2006||2006-03-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|February 2007|Actual|2007-02-28||Interventional|||Iron Supplementation to Reduce Preschoolers Anemia: Comparison Between Intermittent and Cyclic Procedure|Iron Supplementation to Reduce Preschoolers Anemia: Comparison Between Intermittent and Cyclic Procedure|Completed||N/A|99|Actual|Sao Jose do Rio Preto Medical School||2|||f||||f||||||||||2018-06-01 00:29:42.740924|2018-06-01 00:29:42.740924
NCT00992810|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-11-30|2009-10-08|2009-10-09|Estimate|||||||2017-11-30|2017-12-04|Actual|August 2009||2009-08-31|January 2010|2010-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Medial Versus Lateral Approach in Ultrasound (US)-Guided Supraclavicular Block|Medial vs. Lateral Approach to Ultrasound-Guided Supraclavicular Block: A Prospective Randomized Controlled Trial|Completed||N/A|78|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:29:42.799768|2018-06-01 00:29:42.799768
NCT00992797|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-11-02|2009-10-08|2009-10-09|Estimate|||||||2009-11-02|2009-11-03|Estimate|September 2009||2009-09-30|November 2009|2009-11-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|DIVINE||Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity|A Randomized Controlled Trial of the Effect of Vitamin D Supplementation on Insulin Sensitivity and Secretion in Subjects With Type 2 Diabetes of Nordic and Sub-Indian Ethnicity .|Unknown status|Recruiting|Phase 2|60|Anticipated|University Hospital, Aker||2|||f||||f||||||||||2018-06-01 00:29:42.850674|2018-06-01 00:29:42.850674
NCT00992784|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2012-03-08|2010-07-02|2016-09-27|2009-10-08|2009-10-09|Estimate|2012-03-08|2012-04-05|Estimate|2010-07-02|2010-07-07|Estimate|2016-09-27|2016-11-02|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People|Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects|Completed||Phase 3|370|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:29:43.110249|2018-06-01 00:29:43.110249
NCT00992771|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2012-06-15|2009-10-08|2009-10-09|Estimate|||||||2012-06-15|2012-06-18|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3|A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3|Completed||Phase 2|20|Actual|University of South Florida||2|||f||||||||||||||2018-06-01 00:29:44.495518|2018-06-01 00:29:44.495518
NCT00992758|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-07-24|2009-10-08|2009-10-09|Estimate|||||||2017-07-24|2017-07-25|Actual|May 28, 1999|Actual|1999-05-28|July 2017|2017-07-31|June 7, 2012|Actual|2012-06-07|June 7, 2012|Actual|2012-06-07||Interventional|||Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement|Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement|Completed||Phase 1|11|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:29:44.633657|2018-06-01 00:29:44.633657
NCT00992745|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2011-10-07|2009-10-08|2009-10-09|Estimate|||||||2011-10-07|2011-10-12|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer|A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer|Completed||Phase 1|24|Anticipated|Molecular Insight Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:29:44.735879|2018-06-01 00:29:44.735879
NCT00992732|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07||2011-07-28|2011-07-28|2009-10-08|2009-10-09|Estimate||||2011-07-28|2011-08-01|Estimate|2011-07-28|2011-08-01|Estimate|May 2010||2010-05-31|July 2011|2011-07-31||||November 2010|Actual|2010-11-30||Interventional|||Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders|A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders|Terminated||Phase 2|1|Actual|HemaQuest Pharmaceuticals Inc.||1|||f||||t||||||||||2018-06-01 00:29:44.829758|2018-06-01 00:29:44.829758
NCT00992719|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2012-01-19||2013-08-01|2009-10-08|2009-10-09|Estimate|2012-02-02|2012-03-05|Estimate||||2013-08-01|2013-08-07|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Novartis H1N1 Vaccine in Pregnant Women|A Phase II Study In Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels|Completed||Phase 2|84|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Although 200 pregnant and 100 non-pregnant subjects were targeted for enrollment, enrollment closed in May 2010 prior to reaching the target due to slow accrual.|3|||f||||||||||||||2018-06-01 00:29:44.945767|2018-06-01 00:29:44.945767
NCT00992706|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2012-06-20|2009-10-08|2009-10-09|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|August 2011|Actual|2011-08-31||Interventional|||F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer|Local Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (PPE) in Patients Treated With Pegylated Liposomal Doxorubicin: A Randomized, Multicenter, Double Blinded, Phase III Trial|Completed||Phase 3|91|Actual|Swiss Group for Clinical Cancer Research|||||f||||f||||||||||2018-06-01 00:29:45.71821|2018-06-01 00:29:45.71821
NCT00992693|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2018-05-02|2009-10-08|2009-10-09|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2009|Actual|2009-09-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|July 19, 2016|Actual|2016-07-19||Interventional|||Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities|Treatment of Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) With Intravenous Ribavirin in Department of Defense (DOD) Associated Medical Treatment Facilities: A Phase 2 Study|Enrolling by invitation||Phase 2|50|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 00:29:45.796309|2018-06-01 00:29:45.796309
NCT00992680|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2014-04-17|2009-10-08|2009-10-09|Estimate|||||||2014-04-17|2014-04-21|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|||A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease|A Prospective, Randomized, Multicenter, Open Label, Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|49|Actual|ROX Medical, Inc.||2|||f||||t||||||||||2018-06-01 00:29:45.913254|2018-06-01 00:29:45.913254
NCT00992667|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-08|2009-10-08|2009-10-09|Estimate|||||||2009-10-08|2009-10-09|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Inhaled Apocynin Decreases Reactive Oxygen Species Concentrations in Exhaled Breath Condensate in Mild Asthmatics|Inhaled Apocynin Decreases Reactive Oxygen Species Concentrations in Exhaled Breath Condensate in Mild Asthmatics|Completed||Phase 1|10|Actual|Medical Universtity of Lodz||1|||f||||f||||||||||2018-06-01 00:29:45.986418|2018-06-01 00:29:45.986418
NCT00992654|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-11-15|2009-10-08|2009-10-09|Estimate|||||||2010-11-15|2010-11-16|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Expanded Access|||A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India|A Local, Multicentre, Open Label Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India|No longer available|||||ViiV Healthcare|||||f||||f||||||||||2018-06-01 00:29:46.061473|2018-06-01 00:29:46.061473
NCT00992641|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2012-04-16|2009-10-08|2009-10-09|Estimate|||||||2012-04-16|2012-04-17|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|SYSDIET||The Effect of Nordic Recommended Diet on the Features of Metabolic Syndrome - Multicentre Study|The Effect of Nordic Diet Rich in Whole Grain, Berries, Fruits, Vegetables and Fish on Features of Metabolic Syndrome - a Systems Biology Approach|Completed||N/A|167|Actual|University of Eastern Finland||2|||f||||f||||||||||2018-06-01 00:29:46.114387|2018-06-01 00:29:46.114387
NCT00992628|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2011-04-14|2009-10-08|2009-10-09|Estimate|||||||2011-04-14|2011-04-15|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope|Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope|Completed||N/A|70|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 00:29:46.197766|2018-06-01 00:29:46.197766
NCT00992615|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2012-08-28|2009-10-08|2009-10-09|Estimate|||||||2012-08-28|2012-08-29|Estimate||||November 2009|2009-11-30||||||||Interventional|||Comparison of 20-core Versus 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer|Comparison of 20-core vs 12-core Prostate Biopsy Diagnostic Performance in the Detection of Prostate Cancer|Completed||N/A|||Poitiers University Hospital||2|||f||||||||||||||2018-06-01 00:29:46.25331|2018-06-01 00:29:46.25331
NCT00992602|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2017-04-07||2017-06-07|2009-10-08|2009-10-09|Estimate|2017-06-07|2017-07-07|Actual||||2017-06-07|2017-07-07|Actual|April 2011||2011-04-30|June 2017|2017-06-30|October 2014|Actual|2014-10-31|June 2013|Actual|2013-06-30||Interventional|||Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer|Phase II Study of the Combination of High-Dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients With Leptomeningeal Metastases With or Without Parenchymal Brain Involvement|Completed||Phase 2|3|Actual|University of Washington|Our accrual limitations highlight the challenges of conducting studies in “orphan diseases” such as LC and underscore the importance of multi-center collaboration.|1|||f||||t||||||||||2018-06-01 00:29:46.304776|2018-06-01 00:29:46.304776
NCT00992589|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|2012-11-15||2013-04-16|2009-10-08|2009-10-09|Estimate|2013-04-16|2013-05-22|Estimate||||2013-04-16|2013-05-22|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Disease (GERD)|Completed||Phase 3|344|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||t||||||||||2018-06-01 00:29:47.498805|2018-06-01 00:29:47.498805
NCT00992576|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-02-14|2009-10-08|2009-10-09|Estimate|||||||2012-02-14|2012-02-15|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|HMX3501||Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain|A Confirmatory, Placebo-controlled, Randomised, Double-blind, Single-dummy, Parallel Group, Ratio-finding Study in Constipated Pain Patients to Establish an Optimal Hydromorphone - Naloxone Ratio With an Improved Bowel Function and a Comparable Analgesic Efficacy Compared to Hydromorphone Alone|Completed||Phase 2/Phase 3|600|Anticipated|Mundipharma Research GmbH & Co KG|||||f||||||||||||||2018-06-01 00:29:48.317391|2018-06-01 00:29:48.317391
NCT00992563|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07||2014-07-16|2014-07-16|2009-10-08|2009-10-09|Estimate||||2014-07-16|2014-07-18|Estimate|2014-07-16|2014-07-18|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination|A Dose-Escalation Study of AL-39324 Suspension Versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration|Completed||Phase 2|35|Actual|Alcon Research||6|||f||||f||||||||||2018-06-01 00:29:48.402417|2018-06-01 00:29:48.402417
NCT00992550|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2013-05-23|2009-10-07|2009-10-09|Estimate|||||||2013-05-23|2013-05-24|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|6114||Comparison of Hookah and Cigarette Smoking|Comparison of Hookah and Cigarette Smoking|Completed||Phase 1|13|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:29:48.472612|2018-06-01 00:29:48.472612
NCT00992537|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2013-11-26|2009-10-08|2009-10-09|Estimate|||||||2013-11-26|2013-11-27|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics|A Trial Comparing the Pharmacokinetic and Pharmacodynamic Properties Between NN5401 and NN1250 and Between NN5401 and Insulin Aspart in Subjects With Type 1 Diabetes|Completed||Phase 1|27|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 00:29:48.540341|2018-06-01 00:29:48.540341
NCT00992524|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2011-06-22|2009-10-08|2009-10-09|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|OTISMISO||Oral Titrated Misoprostol for Induction of Labour|Oral Misoprostol Titrated Solution Versus Vaginal Misoprostol for Induction of Labour: Randomized Controlled Trial|Completed||N/A|400|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-06-01 00:29:48.613305|2018-06-01 00:29:48.613305
NCT00992511|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08||2010-12-10|2016-09-23|2009-10-08|2009-10-09|Estimate||||2010-12-10|2010-12-16|Estimate|2016-09-23|2016-09-26|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes|Immunological Non-inferiority Between Two Process-manufactured Influenza Vaccines in Adults Aged 18 to 60 Years|Completed||Phase 3|300|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:29:48.693509|2018-06-01 00:29:48.693509
NCT00992498|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2012-12-20|2009-10-08|2009-10-09|Estimate|||||||2012-12-20|2012-12-21|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|||Rehabilitation in Chronic Obstructive Pulmonary Disease Outpatients|Effectiveness of Rehabilitation in COPD Outpatients With Comorbidities|Completed|||316|Actual|Villa Pineta Hospital|||||f||||f||||||||||2018-06-01 00:29:48.878535|2018-06-01 00:29:48.878535
NCT00992485|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2010-05-07|2009-10-08|2009-10-09|Estimate|||||||2010-05-07|2010-05-10|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula|A Phase I Dose Escalation Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate Safety and Efficacy|Completed||Phase 1|9|Actual|Anterogen Co., Ltd.||1|||f||||||||||||||2018-06-01 00:29:48.94677|2018-06-01 00:29:48.94677
NCT00992472|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2013-09-24|2009-10-08|2009-10-09|Estimate|||||||2013-09-24|2013-09-26|Estimate||||October 2009|2009-10-31||||||||Interventional|||Bioavailability of Prochlorperazine Suppositories, 25 mg|Bioavailability of Prochlorperazine Suppositories, 25 mg|Completed||Phase 1|42||Paddock Laboratories, Inc.||2|||f||||||||||||||2018-06-01 00:29:49.0058|2018-06-01 00:29:49.0058
NCT00992459|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2013-04-04||2017-01-13|2009-10-08|2009-10-09|Estimate|2013-07-10|2013-08-12|Estimate||||2017-01-13|2017-01-16|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders|A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)|Completed||Phase 3|46|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||t||||||||||2018-06-01 00:29:49.091588|2018-06-01 00:29:49.091588
NCT00992446|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2017-03-31||2017-05-10|2009-10-08|2009-10-09|Estimate|2017-03-31|2017-05-10|Actual||||2017-05-10|2017-06-12|Actual|September 2, 2010|Actual|2010-09-02|May 2017|2017-05-31||||June 17, 2015|Actual|2015-06-17||Interventional|||Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen|Completed||Phase 2|27|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||No||2018-06-01 00:29:49.543951|2018-06-01 00:29:49.543951
NCT00992433|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2011-10-13||2012-05-10|2009-10-08|2009-10-09|Estimate|2011-10-13|2011-11-17|Estimate||||2012-05-10|2012-05-16|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||H1N1 Vaccine at Two Dose Levels in HIV Positive Adults|A Phase II Study in HIV-seropositive Adults to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels|Completed||Phase 2|192|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 00:29:49.919035|2018-06-01 00:29:49.919035
NCT00992420|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-01-13|2009-10-08|2009-10-09|Estimate|||||||2011-01-13|2011-01-14|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|GIFT||Genotype Information and Functional Testing Study|GIFT: Genotype Information and Functional Testing Study|Completed|||2000|Anticipated|Scripps Health|||3||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:29:50.688232|2018-06-01 00:29:50.688232
NCT00992407|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2013-03-12||2014-02-06|2009-10-08|2009-10-09|Estimate|2014-02-06|2014-03-11|Estimate||||2014-02-06|2014-03-11|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||"N (number of participants analyzed) signifies the participants evaluable for this measure."|An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder|A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|75|Actual|Janssen Korea, Ltd., Korea||2|||f||||f||||||||||2018-06-01 00:29:50.789678|2018-06-01 00:29:50.789678
NCT00992394|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2014-04-03||2015-12-04|2009-10-08|2009-10-09|Estimate|2015-12-04|2016-01-08|Estimate||||2015-12-04|2016-01-08|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ReSPONSE|A total of 174 subjects were randomized.Three subjects were randomized but did not take at least 1 dose of investigational product, and were therefore excluded from the safety population. One subject was excluded from the mITT population. The reason for exclusion was lack of at least one post-baseline PGA.|Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept|Randomized Open-label Study Comparing 2 Different Strategies For Management Of Subjects With Plaque Psoriasis Who Have Responded To Etanercept Treatment|Completed||Phase 4|174|Actual|Pfizer|Enrollment in this study was slower than expected. Thus, recruitment was terminated early and only 58 percent of planned participants were randomized. As a result, no hypothesis testing was conducted and only descriptive statistics are reported.|2|||f||||f||||||||||2018-06-01 00:29:51.588587|2018-06-01 00:29:51.588587
NCT00992381|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-01-15|2009-10-08|2009-10-09|Estimate|||||||2010-01-15|2010-01-18|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|October 2009|Actual|2009-10-31|||||Interventional|||Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone|A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500 mg of Naproxen Plus 20 mg of Esomeprazole Versus Naprosyn® Containing Naproxen 500 mg)|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:29:52.241033|2018-06-01 00:29:52.241033
NCT00992368|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2014-03-03|2009-10-08|2009-10-09|Estimate|||||||2014-03-03|2014-03-04|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|December 2009|Actual|2009-12-31||Interventional|||Cost-effectiveness of Reduction Mammaplasty|Cost-effectiveness of Reduction Mammaplasty|Completed||N/A|50|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 00:29:52.303978|2018-06-01 00:29:52.303978
NCT00992355|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2009-10-08|2009-10-08|2009-10-09|Estimate|||||||2009-10-08|2009-10-09|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery|Tobramycin 0.3% - Dexamethasone 0.1% Versus Tobramycin 0.3% - Dexamethasone 0.1% Plus Ketorolac Tromethamine 0.5% After Phacoemulsification Surgery. A Randomized Trial|Completed||N/A|97|Actual|Veroia General Hospital||2|||f||||t||||||||||2018-06-01 00:29:52.374243|2018-06-01 00:29:52.374243
NCT00988390|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2016-11-23|2009-10-01|2009-10-02|Estimate|||||||2016-11-23|2016-11-28|Estimate|February 2005||2005-02-28|November 2016|2016-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|TALK LA||Mothers Living With HIV and Their Adolescent Children|Mothers Living With HIV and Their Adolescent Children|Completed||N/A|543|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-06-01 00:30:55.57552|2018-06-01 00:30:55.57552
NCT00992342|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-03-17|2009-10-08|2009-10-09|Estimate|||||||2010-03-17|2010-03-18|Estimate|November 2009||2009-11-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers|A Double Blind (3rd Party Open), Randomised, Placebo-Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03893787 In Healthy Subjects|Completed||Phase 1|36|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:29:52.424957|2018-06-01 00:29:52.424957
NCT00992329|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2013-11-21|2009-10-08|2009-10-09|Estimate|||||||2013-11-21|2013-11-25|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Impact of Formulation on Ciprofloxacin Oral Absorption|Impact of Formulation on Ciprofloxacin Oral Absorption|Completed||Phase 1|16|Actual|University of Maryland||4|||f||||t||||||||||2018-06-01 00:29:52.481256|2018-06-01 00:29:52.481256
NCT00992316|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2009-12-16|2009-10-07|2009-10-09|Estimate|||||||2009-12-16|2009-12-17|Estimate|August 2009||2009-08-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Parallel Group, Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects|Completed|||80|Actual|Pfizer|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:29:52.623146|2018-06-01 00:29:52.623146
NCT00992303|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2018-04-20|2009-10-08|2009-10-09|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2009||2009-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy|Tissue Procurement and Outcome Collection for Radiotherapy Treated Patients|Recruiting|||10000|Anticipated|University of Texas Southwestern Medical Center|||||f||||t||||||||||2018-06-01 00:29:52.698407|2018-06-01 00:29:52.698407
NCT00992290|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2014-01-06|2009-10-07|2009-10-09|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy|Probiotic LGG in Patients With Minimal Hepatic Encephalopathy|Completed||Phase 1|37|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 00:29:52.777687|2018-06-01 00:29:52.777687
NCT00992277|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2014-11-30|2009-10-08|2009-10-09|Estimate|||||||2014-11-30|2014-12-02|Estimate|October 2009||2009-10-31|November 2014|2014-11-30||||April 2010|Actual|2010-04-30||Interventional|eMatrixCO2||In-vivo Analysis and Clinical Evaluation of the Performance of a Fractional CO2 Laser System (eMatrixCO2)|In-vivo Analysis and Clinical Evaluation of the Performance of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue|Completed||Phase 2/Phase 3|25|Actual|Syneron Medical||1|||f||||||||||||||2018-06-01 00:29:52.851452|2018-06-01 00:29:52.851452
NCT00992264|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2014-04-04||2017-10-11|2009-10-08|2009-10-09|Estimate|2014-08-13|2014-08-15|Estimate||||2017-10-11|2017-10-13|Actual|May 2010||2010-05-31|October 2017|2017-10-31|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|Q2|1865 participants were enrolled and randomized. For the analyses, participants assigned to each contrasting level of each of the 4 experimental factors were compared against one another. Thus, 1865 people were in each analytic arm in this factorial screening experiment.|'Questions About Quitting' Smoking Cessation Trial|Optimizing an Online Motivational Tobacco Cessation Program|Completed||N/A|1865|Actual|Kaiser Permanente|The study was powered to detect differences between each factor level of 5% or more.|4|||f||||f||||||||||2018-06-01 00:29:52.940608|2018-06-01 00:29:52.940608
NCT00992251|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2016-12-21|2009-10-08|2009-10-09|Estimate|||||||2016-12-21|2016-12-22|Estimate|August 2009||2009-08-31|December 2016|2016-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Eligard Observational Registry for Patients With Prostate Cancer|A Prospective, Single Product, Observational Registry Involving Patients Presenting With Locally Advanced or Metastatic Prostate Cancer Receiving Eligard as Androgen Deprivation Treatment.|Completed|||354|Actual|CMX Research|||||f||||t||||||||Undecided||2018-06-01 00:29:53.714494|2018-06-01 00:29:53.714494
NCT00992238|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2013-09-24|2009-10-08|2009-10-09|Estimate|||||||2013-09-24|2013-09-26|Estimate||||October 2009|2009-10-31||||||||Interventional|||A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions|A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions|Completed||Phase 1|48||Paddock Laboratories, Inc.||2|||f||||||||||||||2018-06-01 00:29:53.848729|2018-06-01 00:29:53.848729
NCT00992225|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07||2011-08-09|2011-08-09|2009-10-07|2009-10-09|Estimate||||2011-08-09|2011-08-15|Estimate|2011-08-09|2011-08-15|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of LY573636 in Patients With Metastatic Breast Cancer|Phase 2 Evaluation of a Once Every 28 Days Dosing Regimen for LY573636-sodium in Patients With Metastatic Breast Cancer|Completed||Phase 2|33|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:29:53.982186|2018-06-01 00:29:53.982186
NCT00992212|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2016-11-30|2009-10-08|2009-10-09|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10|A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of an Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above|Completed||Phase 2|418|Actual|Novartis||5|||f||||f||||||||||2018-06-01 00:29:54.146227|2018-06-01 00:29:54.146227
NCT00992199|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2010-09-07|2009-10-08|2009-10-09|Estimate|||||||2010-09-07|2010-09-08|Estimate|August 2009||2009-08-31|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|IPchemo-AGC||Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer|Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Local Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|79|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 00:29:54.258971|2018-06-01 00:29:54.258971
NCT00992186|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2013-03-29||2013-06-18|2009-10-08|2009-10-09|Estimate|2013-03-29|2013-05-20|Estimate||||2013-06-18|2013-06-24|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer|An Open-Label, Multicenter, Phase 2 Study of Single-Agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects With Metastatic Castrate-Resistant Prostate Cancer|Completed||Phase 2|46|Actual|Centocor Research & Development, Inc.||1|||f||||t||||||||||2018-06-01 00:29:54.397679|2018-06-01 00:29:54.397679
NCT00992173|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2015-11-24|2009-10-08|2009-10-09|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2010||2010-01-31|November 2015|2015-11-30||||October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma|A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma|Withdrawn||Phase 2|0|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 00:29:54.739473|2018-06-01 00:29:54.739473
NCT00992160|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2016-10-26|2009-10-08|2009-10-09|Estimate|||||||2016-10-26|2016-10-28|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Vestipitant 28-day Tolerance Study|A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/Day) for the Treatment of Primary Insomnia in Adult Outpatients|Completed||Phase 2|161|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:29:54.845779|2018-06-01 00:29:54.845779
NCT00992147|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2009-10-08|2009-10-08|2009-10-09|Estimate|||||||2009-10-08|2009-10-09|Estimate|May 2004||2004-05-31|October 2009|2009-10-31|March 2007|Actual|2007-03-31|||||Interventional|||Safety and Efficacy of Autologous Cultured Adipocytes in Patient With Depressed Scar|A Phase II/III Clinical Study of ANTG-adip for the Treatment of Depressed Scar to Evaluate Safety and Efficacy|Completed||Phase 2/Phase 3|36|Actual|Anterogen Co., Ltd.||1|||f||||||||||||||2018-06-01 00:29:54.961542|2018-06-01 00:29:54.961542
NCT00992134|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2012-09-25|2009-10-08|2009-10-09|Estimate|||||||2012-09-25|2012-09-26|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma|Immunochemotherapy With Rituximab-Bendamustine-Cytarabine for Patients With Mantle Cell Lymphoma Not Eligible for Intensive Regimens or Autologous Transplantation.|Completed||Phase 2|41|Actual|St. Bortolo Hospital|||||f||||t||||||||||2018-06-01 00:29:55.021986|2018-06-01 00:29:55.021986
NCT00992121|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2017-11-08|2009-10-08|2009-10-09|Estimate|||||||2017-11-08|2017-11-13|Actual|November 18, 2009|Actual|2009-11-18|November 2017|2017-11-30|November 1, 2013|Actual|2013-11-01|November 1, 2013|Actual|2013-11-01||Interventional|||An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma|An Open-Label Study to Investigate the Pharmacodynamics of a Repeat Dose Regimen of Bevacizumab (10 mg/kg q2w) and Escalating Repeat Doses of Pazopanib in Renal Cell Carcinoma|Completed||Phase 1|11|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:29:55.086265|2018-06-01 00:29:55.086265
NCT00992108|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|2016-08-29||2016-11-02|2009-10-08|2009-10-09|Estimate|2016-11-02|2016-12-29|Estimate||||2016-11-02|2016-12-29|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques|Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques|Terminated||Phase 4|17|Actual|University of California, Los Angeles||2||Lack of eligible patients willing and able to participate|f||||t||||||||||2018-06-01 00:29:55.161314|2018-06-01 00:29:55.161314
NCT00992095|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2018-01-19|2009-10-08|2009-10-09|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2006||2006-08-31|January 2018|2018-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Buprenorphine HCl (Sublingual) 8 mg Tablets With a Naltrexone Block Under Fasting Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 00:29:55.482833|2018-06-01 00:29:55.482833
NCT00992082|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-08|2009-10-07|2009-10-08|Estimate|||||||2009-10-08|2009-10-09|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|August 2011|Anticipated|2011-08-31|May 2011|Anticipated|2011-05-31||Interventional|||Local Infiltration Analgesia or Intrathecal Morphine in Total Knee Arthroplasty|Local Infiltration Analgesia or Intrathecal Morphine in Total Knee Arthroplasty|Unknown status|Recruiting|N/A|50|Anticipated|Region Örebro County||2|||f||||t||||||||||2018-06-01 00:29:55.545125|2018-06-01 00:29:55.545125
NCT00992069|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2013-04-01|2009-10-06|2009-10-08|Estimate|||||||2013-04-01|2013-04-04|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers|A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Healthy Volunteers|Completed||Phase 1|37|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 00:29:55.631783|2018-06-01 00:29:55.631783
NCT00992056|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2014-04-15||2017-05-12|2009-10-07|2009-10-08|Estimate|2014-05-20|2014-06-23|Estimate||||2017-05-12|2017-06-08|Actual|December 2010||2010-12-31|May 2017|2017-05-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Nebivolol Versus Metoprolol: Sodium Sensitivity|Comparative Effects of Nebivolol Versus Metoprolol on Sodium Sensitivity and Renal Sodium Handling in Hypertensive Hispanic Postmenopausal Women|Completed||Phase 4|24|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 00:29:55.724415|2018-06-01 00:29:55.724415
NCT00992043|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-03-22|2009-10-07|2009-10-08|Estimate|||||||2010-03-22|2010-03-23|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|January 2010|Actual|2010-01-31|||||Interventional|||Creatine Supplementation and Diabetes|Efficacy and Safety of Creatine Supplementation Combined With Exercise Training in Type 2 Diabetic Patients|Completed||N/A|28|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:29:55.977874|2018-06-01 00:29:55.977874
NCT00992030|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2018-02-06|2009-10-07|2009-10-08|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2009||2009-09-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma|Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) With ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in Limited Stage (Stage I-IIA With no Areas of Bulk) Hodgkin's Lymphoma|Active, not recruiting||Phase 3|336|Anticipated|Fondazione Michelangelo||2|||f||||f||||||||||2018-06-01 00:29:56.06797|2018-06-01 00:29:56.06797
NCT00992017|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2011-11-07||2014-12-08|2009-10-07|2009-10-08|Estimate|2012-02-09|2012-03-13|Estimate||||2014-12-08|2014-12-30|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women|A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Monovalent Influenza A (H1N1) Vaccine in HIV-1 Infected Pregnant Women|Completed||Phase 2|130|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 00:29:56.172242|2018-06-01 00:29:56.172242
NCT00991003|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2009-10-06|2009-10-06|2009-10-07|Estimate|||||||2009-10-06|2009-10-07|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A New Method for Colorectal Cancer Screening: Colon Capsule Endoscopy Compared to Conventional Endoscopy|A New Method for Colorectal Cancer Screening: Colon Capsule Endoscopy Compared to Conventional Endoscopy|Completed||N/A|59|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-06-01 00:30:13.578082|2018-06-01 00:30:13.578082
NCT00992004|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-05-06|2009-10-07|2009-10-08|Estimate|||||||2010-05-06|2010-05-07|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of the Efficacy of a Turmeric Extract (Arantal®) in Patients With Osteoarthritis of the Knee (Gonarthrosis).|Comparative, Randomized, Double-blind, Placebo-controlled, Parallel Group Study, to Evaluate the Efficacy of a Turmeric Extract (Arantal®) Versus Placebo in Patients With Osteoarthritis of the Knee (Gonarthrosis).|Completed||Phase 2|280|Anticipated|Bioxtract SA||2|||f||||t||||||||||2018-06-01 00:29:56.649286|2018-06-01 00:29:56.649286
NCT00991991|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2016-05-16|2009-10-07|2009-10-08|Estimate|||||||2016-05-16|2016-05-17|Estimate|July 2009||2009-07-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma|Identification of Genomic Lesions Promoting Nodal Metastasis in Malignant Melanoma|Terminated|||5|Actual|Case Comprehensive Cancer Center||||Not enough tissue for analysis|f||||f||||||Samples With DNA|"~     tumor tissue samples from patients with stage I, stage II, or stage III malignant melanoma~   "|||2018-06-01 00:29:56.785641|2018-06-01 00:29:56.785641
NCT00991978|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2012-03-29|2009-10-07|2009-10-08|Estimate|||||||2012-03-29|2012-03-30|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||VEGF Early Imaging for Breast Cancer|Vascular Endothelial Growth Factor (VEGF) Imaging for Early Breast Cancer Detection A Feasibility Study|Completed||Early Phase 1|23|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-06-01 00:29:56.888214|2018-06-01 00:29:56.888214
NCT00991965|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-02-15|2009-10-07|2009-10-08|Estimate|||||||2012-02-15|2012-02-17|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|RidgeDI||Localized Alveolar Ridge Augmentation With Dental Implant|An Open Label, Non-randomized, Single-arm, Multi-center Study to Assess Localized Alveolar Ridge Augmentation Utilizing INFUSE® Bone Graft Concurrent With Dental Implant Placement|Terminated|||8|Actual|Medtronic Spinal and Biologics|||1||f||||f||||||||||2018-06-01 00:29:56.963472|2018-06-01 00:29:56.963472
NCT00991952|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2013-11-07||2014-05-09|2009-10-07|2009-10-08|Estimate|2013-12-06|2014-01-21|Estimate||||2014-05-09|2014-05-26|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|April 2014|Actual|2014-04-30|February 2012|Actual|2012-02-29||Interventional|||Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery|A Multicenter Random Assignment Phase II Study of Irinotecan and Alvocidib (Flavopiridol) Versus Irinotecan Alone for Patients With p53 Wild Type Gastric Adenocarcinoma|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:29:57.055742|2018-06-01 00:29:57.055742
NCT00991939|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2014-01-02||2014-01-02|2009-10-07|2009-10-08|Estimate|2014-01-02|2014-02-14|Estimate||||2014-01-02|2014-02-14|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ITP^2||Initial Treatment of Patients With Immune Thrombocytopenic Purpura|Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study|Terminated||Phase 3|8|Actual|New England Research Institutes||2||The study was closed due to accrual futility there were only a total of 8 subjects enrolled.|f||||t||||||||||2018-06-01 00:29:57.501192|2018-06-01 00:29:57.501192
NCT00991926|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-13|2009-10-07|2009-10-08|Estimate|||||||2009-10-13|2009-10-14|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|December 2006|Actual|2006-12-31||Observational|||Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat|Evaluation of Baseline and Stimulated GH/IGF-1 AXIS in Obese Subjects in Treatment With Orlistat|Completed|||20|Actual|Federico II University|||2||f||||f||||||||||2018-06-01 00:29:58.056004|2018-06-01 00:29:58.056004
NCT00991913|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2013-05-28|2009-10-07|2009-10-08|Estimate|||||||2013-05-28|2013-05-29|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Risk Factors of Recovery Room Delirium After Elective Non-cardiovascular Surgery|Risk Factors of Recovery Room Delirium After Elective Non-cardiovascular Surgery in Post-anaesthesia Care Unit|Completed|||715|Actual|Huazhong University of Science and Technology|||2||f||||t||||||||||2018-06-01 00:29:58.118919|2018-06-01 00:29:58.118919
NCT00991900|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Observational|||Short Term and Day to Day Reproducibility of Reflectometric Measurement of Retinal Oxygen Saturation in Healthy Subjects|Short Term and Day to Day Reproducibility of Reflectometric Measurement of Retinal Oxygen Saturation in Healthy Subjects|Withdrawn|||20|Anticipated|Medical University of Vienna|||1||f||||t||||||||||2018-06-01 00:29:58.17397|2018-06-01 00:29:58.17397
NCT00991887|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2011-04-18||2017-09-20|2009-10-07|2009-10-08|Estimate|2017-09-20|2017-09-21|Actual||||2017-09-20|2017-09-21|Actual|September 2005||2005-09-30|September 2017|2017-09-30|July 2010|Actual|2010-07-31|August 2009|Actual|2009-08-31||Interventional|ElbowHO||Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma|Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma|Terminated||N/A|48|Actual|Carolinas Healthcare System||2||there was an unacceptably high adverse event rate in the treatment group.|f||||t||||||||No||2018-06-01 00:29:58.235665|2018-06-01 00:29:58.235665
NCT00991874|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2016-02-26|2009-10-07|2009-10-08|Estimate|||||||2016-02-26|2016-02-29|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|LENOS||A Longitudinal Study of Exhaled Nitric Oxide in Children|A Longitudinal Study of Exhaled Nitric Oxide in Children|Completed|||200|Actual|University of Aberdeen|||||f||||f||||||||||2018-06-01 00:29:58.472657|2018-06-01 00:29:58.472657
NCT00991861|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2015-05-28|2009-10-07|2009-10-08|Estimate|||||||2015-05-28|2015-05-29|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis|Double-blind, Randomized, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41007 Once Daily and LAS41007 Twice Daily Versus LAS106521 Gel Twice Daily in the Treatment of Actinic Keratosis Grade I to II|Completed||Phase 2|100|Anticipated|Almirall, S.A.||3|||f||||f||||||||||2018-06-01 00:29:58.602858|2018-06-01 00:29:58.602858
NCT00991848|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2009-10-08|2009-10-07|2009-10-08|Estimate|||||||2009-10-08|2009-10-09|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|July 2007|Actual|2007-07-31||Interventional|LIMAFIBRO||Lidocaine on Manifestations of Fibromyalgia|Effect of Intravenous Lidocaine on Manifestations of Fibromyalgia|Completed||Phase 1|30|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 00:29:58.697459|2018-06-01 00:29:58.697459
NCT00990639|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2009-10-06|2009-10-06|2009-10-07|Estimate|||||||2009-10-06|2009-10-07|Estimate|September 2005||2005-09-30|October 2009|2009-10-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Candesartan in Alcoholic Liver Fibrosis|Beneficial Effect of Angiotensin-blocking Agent Candesartan on Alcoholic Liver Fibrosis: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|85|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 00:30:17.849922|2018-06-01 00:30:17.849922
NCT00991835|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2013-03-18|2009-10-07|2009-10-08|Estimate|||||||2013-03-18|2013-03-20|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|December 2012|Actual|2012-12-31||Observational|PREDICT||Plaque Registration and Event Detection In Computed Tomography|Prospective Multicenter Study to Investigate the Relationship Between the Characteristics of Coronary Artery Plaques and Cardiovascular Events Using Multidetector Computed Tomography Coronary Angiography|Unknown status|Active, not recruiting||3015|Actual|Hiroshima University|||||f||||f||||||||||2018-06-01 00:29:58.78171|2018-06-01 00:29:58.78171
NCT00991822|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|May 1999||1999-05-31|October 2009|2009-10-31|December 2003|Actual|2003-12-31|December 2001|Actual|2001-12-31||Interventional|||A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma|A Double-masked Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma|Completed||Phase 2/Phase 3|160|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:29:58.863019|2018-06-01 00:29:58.863019
NCT00991809|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2013-08-09||2017-09-07|2009-10-07|2009-10-08|Estimate|2013-08-09|2013-10-14|Estimate||||2017-09-07|2017-10-06|Actual|February 2009||2009-02-28|September 2017|2017-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|0813||Study on the Development of Opioid Induced Hyperalgesia (OIH) After Exposure to Alfentanil|A Pilot Study of Prolonged, Intermittent Exposure to Alfentanil on Opioid-Induced Hyperalgesia in Healthy Volunteers|Completed||N/A|22|Actual|Johns Hopkins University|The sample size was intentionally small as this was to be a preliminary proof-of-concept step in the development of a human OIH model.|2|||f||||f||||||||||2018-06-01 00:29:58.956421|2018-06-01 00:29:58.956421
NCT00991796|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2012-09-07|2009-10-07|2009-10-08|Estimate|||||||2012-09-07|2012-09-10|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)|Randomised, Double-Blinded, Placebo Controlled, Phase 2 Study of CS-1008 in Combination With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer|Completed||Phase 2|109|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 00:29:59.271601|2018-06-01 00:29:59.271601
NCT00991783|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-11-02|2009-10-07|2009-10-08|Estimate|||||||2009-11-02|2009-11-04|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers|A Clinical Trial to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers|Completed||Phase 1|14|Anticipated|Boryung Pharmaceutical Co., Ltd|||||f||||t||||||||||2018-06-01 00:29:59.358771|2018-06-01 00:29:59.358771
NCT00991770|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2011-12-06|2009-10-07|2009-10-08|Estimate|||||||2011-12-06|2011-12-07|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Massage Therapy and Port-a-Catheter Insertion|Effect of Massage Therapy on Preoperative Anxiety and Postoperative Pain in Cancer Patients Undergoing Port Implantation|Completed||Phase 1|60|Actual|Boston Medical Center||2|||f||||t||||||||||2018-06-01 00:29:59.439334|2018-06-01 00:29:59.439334
NCT00991757|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06||2013-01-15|2013-06-10|2009-10-07|2009-10-08|Estimate||||2013-01-15|2013-01-24|Estimate|2013-06-10|2013-06-18|Estimate|February 2007||2007-02-28|June 2013|2013-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period|Completed||Phase 3|991|Actual|SK Life Science||1|||f||||||||||||||2018-06-01 00:29:59.528412|2018-06-01 00:29:59.528412
NCT00991744|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2012-10-06|2009-10-07|2009-10-08|Estimate|||||||2012-10-06|2012-10-10|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)|Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol|Suspended||Phase 3|100|Anticipated|Nordic Society for Pediatric Hematology and Oncology||2||Sterility problems in DepoCyte production|f||||t||||||||||2018-06-01 00:29:59.593675|2018-06-01 00:29:59.593675
NCT00991731|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2015-08-10|2009-10-07|2009-10-08|Estimate|||||||2015-08-10|2015-08-13|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Program to Increase Physical Activity Among Blacks|A Faith-Based Intervention to Increase Physical Activity Among Blacks|Completed||N/A|496|Actual|Gramercy Research Group||3|||f||||f||||||||||2018-06-01 00:29:59.717874|2018-06-01 00:29:59.717874
NCT00991718|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2017-06-23|2009-10-07|2009-10-08|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2009|Actual|2009-09-30|June 2017|2017-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential|A Phase I, Open-Label Absorption, Distribution, Metabolism, and Excretion (ADME) Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential|Completed||Phase 1|24|Actual|Genentech, Inc.||4|||f||||||||||||||2018-06-01 00:29:59.793803|2018-06-01 00:29:59.793803
NCT00991705|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|An Open-label, Two-treatment, Two-period, Two-sequence, Crossover Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|Completed||Phase 1|28|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-06-01 00:29:59.856429|2018-06-01 00:29:59.856429
NCT00991692|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||A Multisite Trial of ACQUIREc Therapy|A Multisite Trial of ACQUIREc Therapy|Completed||N/A|18|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 00:29:59.920837|2018-06-01 00:29:59.920837
NCT00991679|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|||CXCL9, CXCL10, CXCL11, and CXCR3 in Dry Eye Syndrome|Expression of CXCL9, CXCL10, CXCL11, and CXCR3 in the Tear Film and Ocular Surface of Patients With Dry Eye Syndrome|Completed|||48|Actual|Chonnam National University Hospital|||2||f||||t||||||Samples Without DNA|"~     tears, conjunctiva~   "|||2018-06-01 00:29:59.988745|2018-06-01 00:29:59.988745
NCT00991666|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2014-11-13|2009-10-07|2009-10-08|Estimate|||||||2014-11-13|2014-11-14|Estimate|July 2001||2001-07-31|November 2014|2014-11-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Association Between Laser Interferometric Measurement of Fundus Pulsation and Pneumotonometric Measurement of Pulsatile Ocular Blood Flow in Patients With Age-related Macular Degeneration|Association Between Laser Interferometric Measurement of Fundus Pulsation and Pneumotonometric Measurement of Pulsatile Ocular Blood Flow in Patients With Age-related Macular Degeneration|Completed||N/A|100|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:30:00.049723|2018-06-01 00:30:00.049723
NCT00991653|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-12-03|2009-10-07|2009-10-08|Estimate|||||||2012-12-03|2012-12-04|Estimate|August 2008||2008-08-31|December 2012|2012-12-31||||January 2013|Anticipated|2013-01-31||Observational|||Weight Fluctuation After Breast Cancer Treatment|Weight Fluctuation After Breast Cancer Treatment|Unknown status|Active, not recruiting||250|Anticipated|The Royal Bournemouth Hospital|||1||f||||t||||||Samples With DNA|"~     Fasting blood sample to determine participants genotype, insulin and glucose levels.~   "|||2018-06-01 00:30:00.128143|2018-06-01 00:30:00.128143
NCT00991640|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2017-10-24|2009-10-07|2009-10-08|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2009||2009-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2013|Actual|2013-12-31||Interventional|ROGMF-2||Impact of an Integrated Obesity Management System on Patient's Care|Impact of an Integrated Obesity Management System on Patient's Care|Active, not recruiting||N/A|460|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-06-01 00:30:00.190483|2018-06-01 00:30:00.190483
NCT00991627|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-08-26|2009-10-07|2009-10-08|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Different Approaches to Maternal Hypotension During Cesarean Section|Pharmacological or Non-Pharmacological Management of Maternal Hypotension During Elective Cesarean Section Under Subarachnoid Anesthesia: a Randomized, Controlled Trial|Completed||Phase 4|36|Anticipated|University of Parma||2|||f||||f||||||||||2018-06-01 00:30:00.255913|2018-06-01 00:30:00.255913
NCT00991614|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2012-03-28|2009-10-07|2009-10-08|Estimate|||||||2012-03-28|2012-03-29|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|June 2011|Actual|2011-06-30||Observational|||EVOLUTION® Duodenal Stent for Duodenal or Gastric Outlet Obstruction Caused by Malignant Neoplasms|Treatment of Duodenal or Gastric Outlet Obstruction and Duodenal Strictures Caused by Malignant Neoplasms With the EVOLUTION® Duodenal Stent|Completed|||110|Actual|Cook Group Incorporated|||1||f||||f||||||||||2018-06-01 00:30:00.350718|2018-06-01 00:30:00.350718
NCT00991601|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-10-12|2009-10-07|2009-10-08|Estimate|||||||2010-10-12|2010-10-13|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Ultra Sound Guided Fine Needle Aspiration Cytology (FNAC) of Liver and Pancreas Tumours||Suspended||N/A|150|Anticipated|Herlev Hospital||1||"New ultra sound technology have made this present study design less relevant and force us to~   change the design of the study."|f||||f||||||||||2018-06-01 00:30:00.433722|2018-06-01 00:30:00.433722
NCT00991588|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2017-01-30|2009-10-07|2009-10-08|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|10 Years|Observational [Patient Registry]|||Clinical Outcome of Posterior Cruciate Ligament (PCL) Posterolateral Reconstruction|Reconstruction of the Posterior Cruciate Ligament and Posterolateral Structures of the Knee|Enrolling by invitation|||20|Anticipated|Cincinnati Sportsmedicine Research and Education Foundation|||1||f||||t||||||||Yes||2018-06-01 00:30:00.492736|2018-06-01 00:30:00.492736
NCT00991575|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Observational|DM09||Long Term Vascular Changes in Type 1 Diabetes|Long Term Vascular Changes in Type 1 Diabetes, Clinical Aspects and Biological Markers|Unknown status|Enrolling by invitation||45|Anticipated|Oslo University Hospital|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells, urine, tissue~   "|||2018-06-01 00:30:00.555277|2018-06-01 00:30:00.555277
NCT00991562|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2014-11-20|2009-10-07|2009-10-08|Estimate|||||||2014-11-20|2014-11-21|Estimate|December 2009||2009-12-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|August 2013|Actual|2013-08-31||Interventional|||IMGN901 in Combination With Lenalidomide and Dexamethasone|An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|50|Anticipated|ImmunoGen, Inc.|||||f||||f||||||||||2018-06-01 00:30:00.610621|2018-06-01 00:30:00.610621
NCT00991549|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|December 2004||2004-12-31|October 2009|2009-10-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||Diabetes Prevention In Estrie|Comparative Evaluation of the Effectiveness of 2 Available Resources in Estrie, for the Prevention of Type 2 Diabetes in High-risk Subjects|Completed||N/A|53|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-06-01 00:30:00.682226|2018-06-01 00:30:00.682226
NCT00991536|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|January 1987||1987-01-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Impact of Non Invasive Ventilation on Quality of Sleep|Impact of Non Invasive Ventilation on Quality of Sleep|Completed|||95|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||||2018-06-01 00:30:00.757486|2018-06-01 00:30:00.757486
NCT00991523|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2011-04-19|2009-10-07|2009-10-08|Estimate|||||||2011-04-19|2011-04-20|Estimate|October 2009||2009-10-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Overnight Post-Exercise Recovery After Protein Ingestion Prior to Sleep|Protein Ingestion Prior to Sleep as a Dietary Strategy to Improve Post-exercise, Overnight Recovery.|Completed||N/A|24|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:30:00.807034|2018-06-01 00:30:00.807034
NCT00991510|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|2013-05-13||2013-10-29|2009-10-07|2009-10-08|Estimate|2013-07-25|2013-07-30|Estimate||||2013-10-29|2013-11-21|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients|Comparative Bioavailability of Myfenax® (Teva) and CellCept® (Roche) in Stable Patients After Renal Transplantation|Terminated||Phase 4|43|Actual|Teva Pharmaceutical Industries|The study was designed to have a power of at least 80 % to show bioequivalence with 80 subjects. Only 43 subjects were included.|2||Slow recruitment and lack of time to product launch|f||||f||||||||||2018-06-01 00:30:00.914872|2018-06-01 00:30:00.914872
NCT00990626|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2010-11-16|2009-10-06|2009-10-07|Estimate|||||||2010-11-16|2010-11-17|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Seroquel XR in Schizophrenia Relapse Prevention|Seroquel XR in Schizophrenia Relapse Prevention|Completed|||1600|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:30:17.920045|2018-06-01 00:30:17.920045
NCT00991497|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Trial to Compare the Outcome of Localised Varicosity Compression for 24 Hours and 5 Days After Foam Sclerotherapy to Truncal Varices|A Randomised Controlled Trial to Compare the Outcome of Localised Varicosity Compression for 24 Hours and 5 Days After Foam Sclerotherapy to Truncal Varices|Completed||N/A|124|Actual|Gloucestershire Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:30:01.392544|2018-06-01 00:30:01.392544
NCT00991484|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-10-12|2009-10-07|2009-10-08|Estimate|||||||2010-10-12|2010-10-13|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Observational|||Collagen Analysis and Genetic Analysis of Families With Tendency to Hernias|Collagen-subtype Analysis in Subcutaneous Tissue and Genetic Analysis on Patients From Families With a Tendency to Hernias|Unknown status|Recruiting||60|Anticipated|Herlev Hospital|||2||f||||f||||||Samples With DNA|"~     blood samples and subcutaneous tissue~   "|||2018-06-01 00:30:01.526741|2018-06-01 00:30:01.526741
NCT00991471|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2017-10-27|2009-10-07|2009-10-08|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2009||2009-09-30|October 2017|2017-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|MDRNSTAT||The Effect of an Physician-Nurse Supplementary Triage Assistance Team on Emergency Department Patient Wait Times|A Cluster Randomized Trial of the Effect of an Physician-Nurse Supplementary Triage Assistance Team (MDRN STAT) on Emergency Department Patient Wait Times|Completed||N/A|6300|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 00:30:01.7329|2018-06-01 00:30:01.7329
NCT00991458|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2013-05-02|2012-04-02|2013-07-09|2009-10-07|2009-10-08|Estimate|2013-07-09|2013-07-11|Estimate|2012-04-02|2012-04-05|Estimate|2013-07-09|2013-07-11|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study of Cyclosporine in Post-LASIK Patients|Study of Cyclosporine in Post-LASIK Patients|Completed||Phase 2|621|Actual|Allergan||3|||f||||f||||||||||2018-06-01 00:30:03.171961|2018-06-01 00:30:03.171961
NCT00991445|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2009-10-07|2009-10-07|2009-10-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|September 2011|Anticipated|2011-09-30|May 2011|Anticipated|2011-05-31||Interventional|||Minimal Versus Conventional Exposure in Unicompartmental Knee Arthroplasty|Minimal vs. Conventional Exposure in Unicompartmental Knee Arthroplasty|Unknown status|Recruiting|N/A|40|Anticipated|Region Örebro County||2|||f||||t||||||||||2018-06-01 00:30:03.587309|2018-06-01 00:30:03.587309
NCT00991432|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-02-15|2009-10-07|2009-10-08|Estimate|||||||2012-02-15|2012-02-17|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|Ridge Mesh||Localized Alveolar Ridge Augmentation With Space Maintenance Devices|An Open Label, Non-randomized, Single-arm, Multi-center Study to Assess Localized Alveolar Ridge Augmentation Utilizing INFUSE® Bone Graft Concurrent With Space Maintenance Devices for Soft Tissue Management|Terminated|||10|Actual|Medtronic Spinal and Biologics|||1||f||||f||||||||||2018-06-01 00:30:03.689998|2018-06-01 00:30:03.689998
NCT00991419|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2013-01-29|2009-10-07|2009-10-08|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden|A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients With AD & HV|Completed||Phase 2|25|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:30:03.778596|2018-06-01 00:30:03.778596
NCT00991406|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2016-12-14|2009-10-06|2009-10-08|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2009||2009-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Neural Prostheses and Gait Performance: Model-Based Strategies|Neural Prostheses and Gait Performance: Model-Based Strategies|Completed||N/A|9|Actual|VA Office of Research and Development||1|||f||||t||||||||Undecided||2018-06-01 00:30:03.84545|2018-06-01 00:30:03.84545
NCT00991393|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-02-15|2009-10-07|2009-10-08|Estimate|||||||2012-02-15|2012-02-17|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|SinusDI||Sinus Augmentation With Dental Implant|An Open Label, Non Randomized, Single Arm, Multi Center Study to Assess Sinus Augmentation (Sinus Lift) Utilizing INFUSE® Bone Graft Concurrent With Dental Implant Placement|Terminated|||23|Actual|Medtronic Spinal and Biologics|||1||f||||f||||||||||2018-06-01 00:30:04.028492|2018-06-01 00:30:04.028492
NCT00991380|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2013-07-09|2009-10-07|2009-10-08|Estimate|||||||2013-07-09|2013-07-11|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|HEALD-PCN||Healthy Eating & Active Living for Diabetes in Primary Care Networks|Healthy Eating & Active Living for Diabetes in Primary Care Networks|Completed||N/A|200|Actual|The Alliance for Canadian Health Outcomes Research in Diabetes||2|||f||||f||||||||||2018-06-01 00:30:04.130451|2018-06-01 00:30:04.130451
NCT00991367|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2010-12-07|2009-10-07|2009-10-08|Estimate|||||||2010-12-07|2010-12-08|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||CICATRIX in the Treatment of Recent Post-surgical Scars|Efficacy of CICATRIX (Asian Gotu Kola or Pennywort) in the Treatment of Recent Post-surgical Scars|Completed||Phase 3|90|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:30:04.223455|2018-06-01 00:30:04.223455
NCT00991354|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2016-07-26|2009-10-06|2009-10-08|Estimate|||||||2016-07-26|2016-07-27|Estimate|November 2009||2009-11-30|July 2016|2016-07-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX™-B (Gag, Pol, Env) Vaccine, With or Without IL-12 DNA Plasmid, Delivered Via Electroporation in Healthy, HIV-1-Uninfected Adult Participants|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 00:30:04.311757|2018-06-01 00:30:04.311757
NCT00991341|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2015-02-17||2015-05-22|2009-10-07|2009-10-08|Estimate|2015-05-22|2015-06-09|Estimate||||2015-05-22|2015-06-09|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|RECESS|Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).|Red Cell Storage Duration Study|Red Cell Storage Duration Study|Completed||Phase 3|1481|Actual|New England Research Institutes|Only 4 pediatric subjects were enrolled. One treatment arm had only one subject with available data for analyzing the change in ALT outcome. Therefore, to protect patient confidentiality, results were not entered for this outcome.|2|||f||||t||||||||||2018-06-01 00:30:04.535451|2018-06-01 00:30:04.535451
NCT00791414|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2009-03-02|2008-11-12|2008-11-14|Estimate|||||||2009-03-02|2009-03-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:34:26.356395|2018-06-01 01:34:26.356395
NCT00991328|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2016-09-14|2009-10-07|2009-10-08|Estimate|||||||2016-09-14|2016-09-16|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Role of Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery|Tailored Patient Management Guided With Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery.|Terminated||Phase 3|15|Actual|Icahn School of Medicine at Mount Sinai||2||low enrollment|f||||t||||||||||2018-06-01 00:30:06.940449|2018-06-01 00:30:06.940449
NCT00991315|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|||2017-11-15|2009-10-07|2009-10-08|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2008||2008-12-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate|Assessment of Tumor Resistance and Stem Cells in Prostate Cancer|Active, not recruiting|||126|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||Samples With DNA|"~     Samples will be collected at time of TURP and will be deidentified and processed by standard~     procedures.~   "|||2018-06-01 00:30:07.028762|2018-06-01 00:30:07.028762
NCT00991302|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2015-07-29||2018-02-21|2009-10-07|2009-10-08|Estimate|2015-07-30|2015-08-26|Estimate||||2018-02-21|2018-03-20|Actual|January 2010||2010-01-31|February 2018|2018-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|DASH|Intention to treat: All eligible participants were included in the baseline characteristics.|Durability of Adherence in Self-Management of HIV|Durability of Adherence in Self-Management of HIV|Completed||N/A|172|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-06-01 00:30:07.122434|2018-06-01 00:30:07.122434
NCT00991289|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-07|2011-08-29||2016-07-06|2009-10-07|2009-10-08|Estimate|2011-08-29|2011-09-27|Estimate||||2016-07-06|2016-07-07|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|January 2012|Actual|2012-01-31|November 2010|Actual|2010-11-30||Interventional|||Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects|The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection|Completed||Phase 2|68|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 00:30:07.74071|2018-06-01 00:30:07.74071
NCT00991276|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2012-05-18||2012-09-06|2009-10-06|2009-10-07|Estimate|2012-09-06|2012-10-08|Estimate||||2012-09-06|2012-10-08|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study Of Pregabalin And Pramipexole In Adults With Restless Legs Syndrome|Completed||Phase 3|85|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:30:08.377437|2018-06-01 00:30:08.377437
NCT00991263|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2017-08-07|2009-10-06|2009-10-07|Estimate|||||||2017-08-07|2017-08-08|Actual|April 2009||2009-04-30|August 2017|2017-08-31|February 2012|Actual|2012-02-29|May 2010|Actual|2010-05-31||Observational|||Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741|Intrinsic Breast Cancer Subtypes and Benefit of Paclitaxel in CALGB 9344 and Dose Dense Therapy in CALGB 9741|Completed|||3677|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tumor tissue samples~   "|||2018-06-01 00:30:10.679133|2018-06-01 00:30:10.679133
NCT00991250|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2010-02-04|2009-10-06|2009-10-07|Estimate|||||||2010-02-04|2010-02-05|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma|A Multi-centre, Two-arm, Randomized, Open, Phase II Study Investigating SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma|Unknown status|Recruiting|Phase 2|140|Anticipated|SentoClone AB||2|||f||||t||||||||||2018-06-01 00:30:10.766317|2018-06-01 00:30:10.766317
NCT00991237|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2013-10-23|2009-10-06|2009-10-07|Estimate|||||||2013-10-23|2013-10-24|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||PRF Treatment for Patients With Chronic Lumbosacral Radicular Pain Compared to Conventional Medical Management|Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for Patients With Chronic Lumbosacral Radicular Pain|Completed||N/A|45|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-06-01 00:30:10.869328|2018-06-01 00:30:10.869328
NCT00991224|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2017-12-11|2009-10-06|2009-10-07|Estimate|||||||2017-12-11|2017-12-13|Actual|November 2009||2009-11-30|December 2017|2017-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy|A Pilot, Open Label, Multi Arm, Single Ctr Study to Evaluate Safety & Tolerability of Escalating Doses of Autologous T Cells Modified With Lentiviral Vectors Expressing High Affinity Gag-specific TCRS in HLA-A02 Patients With HIV|Completed||Phase 1|2|Actual|University of Pennsylvania||4|||f||||t|t|f||||||||2018-06-01 00:30:10.937478|2018-06-01 00:30:10.937478
NCT00991211|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-03-13|2009-10-06|2009-10-07|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2004||2004-01-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Bendamustine Plus Rituximab Versus CHOP Plus Rituximab|Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas|Completed||Phase 3|549|Actual|University of Giessen||2|||f||||t||||||||||2018-06-01 00:30:11.01016|2018-06-01 00:30:11.01016
NCT00991198|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2011-06-06|2009-10-06|2009-10-07|Estimate|||||||2011-06-06|2011-06-08|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage|The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial|Completed||Phase 2|49|Actual|Aria Aesthetics Inc.||3|||f||||f||||||||||2018-06-01 00:30:11.083208|2018-06-01 00:30:11.083208
NCT00991185|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2014-06-13||2014-07-23|2009-10-06|2009-10-07|Estimate|2014-06-13|2014-07-16|Estimate||||2014-07-23|2014-07-29|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children|CSF Pharmacokinetics of Antimicrobials in Children|Completed|||8|Actual|Duke University|||||f||||t||||||Samples With DNA|"~     CSF, Blood, urine, bronchial, salivary, peritoneal, wound/abscess~   "|||2018-06-01 00:30:11.257836|2018-06-01 00:30:11.257836
NCT00991172|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04||2011-03-17|2011-12-01|2009-10-05|2009-10-07|Estimate||||2011-03-17|2011-03-28|Estimate|2011-12-01|2011-12-08|Estimate|November 2009||2009-11-30|December 2011|2011-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Sciatic Pain|Completed||Phase 2|159|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-06-01 00:30:11.398931|2018-06-01 00:30:11.398931
NCT00991159|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2012-07-02|2009-10-06|2009-10-07|Estimate|||||||2012-07-02|2012-07-04|Estimate|November 2009||2009-11-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating, Intravenous Doses Of RN316 (PF-04950615) In Healthy Adult Subjects|Completed||Phase 1|48|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:30:11.514823|2018-06-01 00:30:11.514823
NCT00991146|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2017-02-21|2009-10-06|2009-10-07|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2009||2009-10-31|February 2017|2017-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase|An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan|Completed||Phase 3|19|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:30:11.59305|2018-06-01 00:30:11.59305
NCT00991133|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2015-04-29|2009-10-06|2009-10-07|Estimate|||||||2015-04-29|2015-04-30|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)|A Phase 1, Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) in First Relapse|Completed||Phase 1|8|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 00:30:11.687879|2018-06-01 00:30:11.687879
NCT00991120|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2017-11-28|2009-10-06|2009-10-07|Estimate|||||||2017-11-28|2017-11-30|Actual|October 2009||2009-10-31|November 2017|2017-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study|Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study|Completed|||165|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-06-01 00:30:11.840673|2018-06-01 00:30:11.840673
NCT00991107|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-03-08|2009-10-06|2009-10-07|Estimate|||||||2011-03-08|2011-03-09|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production|A Phase I, Open Label Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production When Administered Orally to Obese Insulin-Resistant Adult Subjects for 28 Days|Completed||Phase 1|5|Actual|Harbor Therapeutics||1|||f||||f||||||||||2018-06-01 00:30:11.921312|2018-06-01 00:30:11.921312
NCT00991094|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2018-02-20|2009-10-06|2009-10-07|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2005|Actual|2005-05-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Data Collection of Normal Tissue Toxicity for Proton Therapy|Data Collection to Assess Acute and Late Normal Tissue Sequelae in Proton Therapy for Adults|Recruiting|||5000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 00:30:12.005528|2018-06-01 00:30:12.005528
NCT00991081|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2012-06-25||2012-08-21|2009-10-06|2009-10-07|Estimate|2012-08-21|2012-09-19|Estimate||||2012-08-21|2012-09-19|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.|Exploratory/Developmental Study of Pharmacogenetic Smoking Cessation Therapy.|Completed||Phase 4|36|Actual|Stanford University|Possible selection bias as 32 of 36 participants had taken part in previous research|2|||f||||t||||||||||2018-06-01 00:30:12.08224|2018-06-01 00:30:12.08224
NCT00991068|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06||2012-03-14|2012-03-14|2009-10-06|2009-10-07|Estimate||||2012-03-14|2012-03-16|Estimate|2012-03-14|2012-03-16|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome|An Open-Label Pilot Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome|Completed||Phase 2|24|Actual|ZARS Pharma Inc.||1|||f||||f||||||||||2018-06-01 00:30:12.499552|2018-06-01 00:30:12.499552
NCT00991055|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-06|2009-10-06|2009-10-07|Estimate|||||||2009-10-06|2009-10-07|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|October 2010|Anticipated|2010-10-31|June 2010|Anticipated|2010-06-30||Interventional|||Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes|To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes|Unknown status|Recruiting|Phase 4|40|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-06-01 00:30:12.569444|2018-06-01 00:30:12.569444
NCT00991042|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2009-10-06|2009-10-06|2009-10-07|Estimate|||||||2009-10-06|2009-10-07|Estimate|August 2003||2003-08-31|October 2009|2009-10-31|March 2005|Actual|2005-03-31|September 2004|Actual|2004-09-30||Interventional|cytokine||Study of Cytokines Serum Levels in Chronic Low Back Pain|Analytical Transversal Study of Cytokines Serum Levels in Chronic Low Back Pain Due to Herniated Disk|Completed||Phase 1|23|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 00:30:12.640456|2018-06-01 00:30:12.640456
NCT00991029|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2018-05-01|2009-10-06|2009-10-07|Estimate|||||||2018-05-01|2018-05-07|Actual|May 28, 2010|Actual|2010-05-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|POINT||Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial|Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial|Active, not recruiting||Phase 3|5840|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||||2018-06-01 00:30:12.76559|2018-06-01 00:30:12.76559
NCT00991016|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2010-11-23|2009-10-05|2009-10-07|Estimate|||||||2010-11-23|2010-11-24|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Single and Multiple Dose Safety, Tolerability, and Pharmacokinetics Study of PF-04805712 in Healthy Volunteers|A Phase 1 Randomized, Double Blind (3rd Party Open), Placebo Controlled Combined Single And Multiple Dose Safety, Tolerability And Pharmacokinetics Study Of Orally Administered PF-04805712 In Healthy Volunteers|Terminated||Phase 1|61|Actual|Pfizer||1||"B1411001 was terminated after completion of 4 cohorts of the multiple ascending dose phase, as~   additional data were deemed unnecessary. No safety concerns."|f||||f||||||||||2018-06-01 00:30:13.508852|2018-06-01 00:30:13.508852
NCT00990990|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2013-08-27|2009-10-06|2009-10-07|Estimate|||||||2013-08-27|2013-08-28|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers|A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PNU-100480 (PF-02341272) After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects|Completed||Phase 1|59|Actual|Sequella, Inc.||7|||f||||f||||||||||2018-06-01 00:30:13.668583|2018-06-01 00:30:13.668583
NCT00990977|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-06-29|2009-10-06|2009-10-07|Estimate|||||||2015-06-29|2015-06-30|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Interventional|MICA||Mindfulness and Cancer Mamma - Clinical Trial MBSR Among Women Operated for Breast Cancer|A Prospective, Randomized Controlled Trial of Mindfulness-based Stress Reduction (MBSR) Among Women Operated for Breast Cancer|Completed||Phase 2/Phase 3|336|Actual|Danish Cancer Society||2|||f||||f||||||||||2018-06-01 00:30:13.771584|2018-06-01 00:30:13.771584
NCT00990964|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2012-08-13||2012-08-13|2009-10-06|2009-10-07|Estimate|2012-08-13|2012-09-12|Estimate||||2012-08-13|2012-09-12|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Attain Success Clinical Trial|Attain Success Clinical Trial|Completed|||2014|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-06-01 00:30:13.885651|2018-06-01 00:30:13.885651
NCT00990951|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2014-07-07|2009-10-05|2009-10-07|Estimate|||||||2014-07-07|2014-07-08|Estimate|June 2010||2010-06-30|July 2014|2014-07-31|July 2014|Anticipated|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study of Efficacy of Association of Senna Alexandrina Mill and Associations on Functional Intestinal Constipation|Double-blind, Randomized, Placebo-controlled Study of Efficacy of Association of Senna Alexandrina, Cassia Fistula, Tamarindus Indica, Coriandrum Sativum, Periandra Mediterranea in Patients With Functional Intestinal Constipation|Suspended||Phase 3|80|Anticipated|Marjan Industria e Comercio ltda||1||The study was interrupted by recruitment failure.|f||||t||||||||||2018-06-01 00:30:14.237741|2018-06-01 00:30:14.237741
NCT00990938|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-05-15|2009-10-06|2009-10-07|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|January 2011|Actual|2011-01-31|May 2010|Actual|2010-05-31||Interventional|||Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients|A Phase 1, Multi-center, Randomized, Double-Blind, Placebo-controlled, Dose-escalation Safety Assessment Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients|Completed||Phase 1|50|Actual|Idera Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 00:30:14.310455|2018-06-01 00:30:14.310455
NCT00990925|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2015-11-04|2009-10-06|2009-10-07|Estimate|||||||2015-11-04|2015-11-05|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Lifestyle Modification for Weight Loss in Schizophrenia|Lifestyle Modification for Weight Loss in Schizophrenia|Completed||N/A|149|Actual|Yale University||2|||f||||f||||||||||2018-06-01 00:30:14.502387|2018-06-01 00:30:14.502387
NCT00990912|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05||2010-02-03|2010-02-03|2009-10-06|2009-10-07|Estimate||||2010-02-03|2010-02-05|Estimate|2010-02-03|2010-02-05|Estimate|January 2004||2004-01-31|October 2009|2009-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)|A Study to Document Long-term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects 1 - 21 Years of Age With Refractory Solid Tumors Who Have Experienced Clinical Benefit Following a Minimum of 6 Cycles of Therapy on BMS Protocol CA124-001 or BMS Protocol CA124-002|Completed||Phase 1/Phase 2|20|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:30:14.572244|2018-06-01 00:30:14.572244
NCT00990899|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2016-10-31|2009-10-06|2009-10-07|Estimate|||||||2016-10-31|2016-11-02|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Hypertension and Sleep Disordered Breathing in Pediatrics|Hypertension and Sleep Disordered Breathing in Pediatrics|Completed|||24|Actual|Winthrop University Hospital|||||f||||t||||||||||2018-06-01 00:30:14.651388|2018-06-01 00:30:14.651388
NCT00990886|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2012-12-11|2009-10-05|2009-10-07|Estimate|||||||2012-12-11|2012-12-12|Estimate|April 2004||2004-04-30|December 2012|2012-12-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women|The Effect of Ditropan XL on Vasomotor Symptoms in Healthy Postmenopausal Women: a Double-blind Placebo Controlled Pilot Study|Completed||Phase 2|148|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC||2|||f||||||||||||||2018-06-01 00:30:14.714651|2018-06-01 00:30:14.714651
NCT00990873|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2016-06-27|2009-10-06|2009-10-07|Estimate|||||||2016-06-27|2016-06-28|Estimate|July 2009||2009-07-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Study of Tissue Samples From Patients With Stage I Non-Small Cell Lung Cancer Enrolled on Research Study CALGB-140202|A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202)|Completed|||100|Actual|Alliance for Clinical Trials in Oncology|||||f||||f||||||Samples With DNA|"~     Tissues and blood samples~   "|||2018-06-01 00:30:14.785531|2018-06-01 00:30:14.785531
NCT00990860|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-01-03|2009-10-06|2009-10-07|Estimate|||||||2011-01-03|2011-01-05|Estimate|February 2009||2009-02-28|June 2010|2010-06-30||||February 2011|Anticipated|2011-02-28||Interventional|START||Study in Asia of the Combination of TACE With Sorafenib in HCC Patients|START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f||||f||||||||||2018-06-01 00:30:14.843397|2018-06-01 00:30:14.843397
NCT00990847|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-06|2009-10-06|2009-10-07|Estimate|||||||2009-10-06|2009-10-07|Estimate|June 2007||2007-06-30|October 2009|2009-10-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Nebulized Procaterol Versus Nebule Salbutamol for the Treatment of Moderate Acute Asthma|The Efficacy of Nebulized Procaterol Versus Nebulized Salbutamol for the Treatment of Moderate Acute Asthma: a Randomized, Double-blind, Parallel Group Study|Completed||Phase 3|140|Actual|PT Otsuka Indonesia||2|||f||||f||||||||||2018-06-01 00:30:14.918435|2018-06-01 00:30:14.918435
NCT00990834|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2015-05-21|2009-10-06|2009-10-07|Estimate|||||||2015-05-21|2015-05-22|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Muscle Characteristics Associated With Statin Therapy|Muscle Characteristics Associated With Statin Therapy|Withdrawn||N/A|0|Actual|Scripps Health||1||Unable to recruit subjects.|f||||t||||||||||2018-06-01 00:30:15.04568|2018-06-01 00:30:15.04568
NCT00990821|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2010-04-09||2015-08-18|2009-10-06|2009-10-07|Estimate|2013-10-21|2013-12-12|Estimate||||2015-08-18|2015-08-19|Estimate|January 2005||2005-01-31|August 2015|2015-08-31|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)|A Randomized, 5-Part, Intravenous Study of the Safety, Tolerability, Bioequivalence, and Drug Interaction Potential of Final Market Image Formulation of MK0517 in Young Healthy Subjects|Completed||Phase 1|188|Actual|Merck Sharp & Dohme Corp.||14|||f||||||||||||||2018-06-01 00:30:15.162703|2018-06-01 00:30:15.162703
NCT00990808|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2015-06-03|2009-10-06|2009-10-07|Estimate|||||||2015-06-03|2015-06-04|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)|A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients|Completed||Phase 1|46|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:30:15.861229|2018-06-01 00:30:15.861229
NCT00990795|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2010-11-01|2009-10-06|2009-10-07|Estimate|||||||2010-11-01|2010-11-02|Estimate|April 2010||2010-04-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CYCLO1||Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery|A Randomized Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery|Terminated||Phase 1|72|Anticipated|The University of Texas Health Science Center, Houston||2||PI left institution.|f||||f||||||||||2018-06-01 00:30:15.947135|2018-06-01 00:30:15.947135
NCT00990782|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2017-04-20||2017-05-30|2009-10-06|2009-10-07|Estimate|2017-05-30|2017-07-02|Actual||||2017-05-30|2017-07-02|Actual|September 2009||2009-09-30|May 2017|2017-05-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|CEPELA||Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment|CEPELA I Trial: Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment|Completed||N/A|93|Actual|The Cleveland Clinic||1|||f||||f||||||||No||2018-06-01 00:30:16.041097|2018-06-01 00:30:16.041097
NCT00990769|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2013-04-10||2013-05-30|2009-10-05|2009-10-07|Estimate|2013-05-30|2013-05-31|Estimate||||2013-05-30|2013-05-31|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children|The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children|Completed||N/A|40|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:30:16.190541|2018-06-01 00:30:16.190541
NCT00990756|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2010-01-21|2009-10-05|2009-10-07|Estimate|||||||2010-01-21|2010-01-22|Estimate|November 2009||2009-11-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers|A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Inhaled Doses Of PF-03526299 In Healthy Male Subjects|Completed||Phase 1|24|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 00:30:16.414748|2018-06-01 00:30:16.414748
NCT00990743|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2010-10-21|2009-10-06|2009-10-07|Estimate|||||||2010-10-21|2010-10-22|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Tolerance and Effect on Intraocular Pressure After Administration of SYL040012|Phase I Study With SYL040012. Tolerance and Effect on Intraocular Pressure|Completed||Phase 1|30|Actual|Sylentis, S.A.||1|||f||||f||||||||||2018-06-01 00:30:16.473483|2018-06-01 00:30:16.473483
NCT00990730|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-01-23|2009-10-05|2009-10-07|Estimate|||||||2012-01-23|2012-01-25|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Atherosclerosis in Rheumatoid Arthritis|Atherosclerosis in Rheumatoid Arthritis: Role of Inflammation, Lipoproteins, and Endothelial Dysfunction|Completed|||80|Actual|University of California, San Francisco|||2||f||||t||||||Samples Without DNA|"~     serum, plasma~   "|||2018-06-01 00:30:16.531161|2018-06-01 00:30:16.531161
NCT00990717|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2016-06-21|2009-10-06|2009-10-07|Estimate|||||||2016-06-21|2016-06-23|Estimate|March 2005||2005-03-31|June 2016|2016-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies|A Dose Escalation Study of NK-92 Cell Infusions in Patients With Hematological Malignancies in Relapse After Autologous Stem Cell Transplantation.|Completed||Phase 1|8|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 00:30:16.597935|2018-06-01 00:30:16.597935
NCT00990704|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2011-05-20||2011-06-30|2009-10-06|2009-10-07|Estimate|2011-05-20|2011-06-17|Estimate||||2011-06-30|2011-07-11|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism|Phase II, Open Study, Exploratory Examination of Efficacy and Safety of Paricalcitol Injection and Maxacalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism|Completed||Phase 2|47|Actual|Abbott||2|||f||||f||||||||||2018-06-01 00:30:16.691873|2018-06-01 00:30:16.691873
NCT00990691|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2015-08-06|2009-10-06|2009-10-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|October 2008||2008-10-31|August 2015|2015-08-31||||December 2014|Actual|2014-12-31||Interventional|||Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome|Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome|Completed||Phase 2|36|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 00:30:17.245085|2018-06-01 00:30:17.245085
NCT00990678|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2012-09-13|2009-10-06|2009-10-07|Estimate|||||||2012-09-13|2012-09-17|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|||Study of Vitamin D Supplementation to Male HIV Sero-positive Patients|Study of Vitamin D Supplementation to Male HIV Sero-positive Patients|Completed||N/A|60|Actual|Hvidovre University Hospital||3|||f||||t||||||||||2018-06-01 00:30:17.325011|2018-06-01 00:30:17.325011
NCT00990665|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2013-02-14|2009-10-06|2009-10-07|Estimate|||||||2013-02-14|2013-02-18|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|September 2010|Actual|2010-09-30||Interventional|Promote Q||Promote Q Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Quartet Left Ventricular Heart Lead Study|Promote Q CRT-D and Quartet Left Ventricular Heart Lead Study|Completed||N/A|178|Actual|St. Jude Medical||1|||f||||t||||||||||2018-06-01 00:30:17.406229|2018-06-01 00:30:17.406229
NCT00990652|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|2013-12-11||2013-12-11|2009-10-06|2009-10-07|Estimate|2013-12-11|2014-01-13|Estimate||||2013-12-11|2014-01-13|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional|||Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide|A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-operatively|Completed||Phase 2|10|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 00:30:17.573986|2018-06-01 00:30:17.573986
NCT00990613|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2010-02-02|2009-10-06|2009-10-07|Estimate|||||||2010-02-02|2010-02-03|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin|A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults|Completed||Phase 1|19|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:30:18.041325|2018-06-01 00:30:18.041325
NCT00990600|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2009-10-28|2009-10-06|2009-10-07|Estimate|||||||2009-10-28|2009-10-29|Estimate|April 2008||2008-04-30|October 2009|2009-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|ADONE||QoL and Adherence to One-pill Once-a-day HAART|Adherence to a One Pill, Once-a-day Antiretroviral Regimen|Completed||Phase 3|212|Actual|A.O. Ospedale Papa Giovanni XXIII||1|||f||||f||||||||||2018-06-01 00:30:18.120912|2018-06-01 00:30:18.120912
NCT00990587|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2015-06-19|2009-10-06|2009-10-07|Estimate|||||||2015-06-19|2015-06-22|Estimate|October 2009||2009-10-31|June 2015|2015-06-30||||May 2013|Actual|2013-05-31||Interventional|||Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy|Phase 1 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy|Completed||Phase 1|20|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:30:18.184516|2018-06-01 00:30:18.184516
NCT00990574|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2015-10-07|2009-10-06|2009-10-07|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study Comparing Two Spinal Techniques for for Cesarean Delivery Anesthesia|Spinal Anesthesia for Cesarean Delivery: The Wiley Spinal Catheter Intermittent Bolus Technique Versus Single Shot Spinal Anesthesia|Withdrawn||N/A|0|Actual|Stanford University||2||device not found to be adequate|f||||f||||||||||2018-06-01 00:30:18.253349|2018-06-01 00:30:18.253349
NCT00990561|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2012-01-19||2012-12-04|2009-10-06|2009-10-07|Estimate|2012-11-08|2012-12-05|Estimate||||2012-12-04|2012-12-06|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis|A Clinical Study Comparing the Efficacy of Ultravate Ointment Once Daily vs. Twice Daily in Combination With Lac-Hydrin Lotion in the Treatment of Stable Plaque Psoriasis|Completed||Phase 4|40|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:30:18.568531|2018-06-01 00:30:18.568531
NCT00990548|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2013-05-14|2009-10-06|2009-10-07|Estimate|||||||2013-05-14|2013-05-15|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|July 2012|Actual|2012-07-31|September 2010|Actual|2010-09-30||Observational|FIT-O||Family Cardiac Caregiver Investigation to Evaluate Outcomes|Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)|Completed|||4500|Actual|Columbia University|||1||f||||f||||||||||2018-06-01 00:30:18.770641|2018-06-01 00:30:18.770641
NCT00990535|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-06|2009-10-06|2009-10-07|Estimate|||||||2009-10-06|2009-10-07|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|HIDONET||High Dose Somatostatin Analogues in Neuroendocrine Tumors|Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study|Completed||Phase 2|28|Actual|Federico II University||1|||f||||t||||||||||2018-06-01 00:30:18.846387|2018-06-01 00:30:18.846387
NCT00990522|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-06|||2015-12-10|2009-10-06|2009-10-07|Estimate|||||||2015-12-10|2015-12-14|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study of the Efficacy of Sharp Debridement for the Management of Chronic Wounds|A Prospective, Randomized, Controlled Study of the Efficacy of Sharp Debridement for the Management of Chronic Wounds|Withdrawn||N/A|0|Actual|Southwest Regional Wound Care Center||1||No participants enrolled, per PI discretion|f||||f||||||||||2018-06-01 00:30:18.926142|2018-06-01 00:30:18.926142
NCT00990509|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2014-07-22||2014-08-19|2009-10-06|2009-10-07|Estimate|2014-08-19|2014-08-29|Estimate||||2014-08-19|2014-08-29|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ACHIEVE||Albumin for Intracerebral Hemorrhage Intervention|Albumin for Intracerebral Hemorrhage Intervention|Terminated||Phase 2|14|Actual|Georgetown University|There was an insufficient number of subjects in each treatment arm to allow for a meaningful analysis of the effects of albumin on HARM status (blood brain barrier disruption).|2||Enrollment was stopped due to low recruitment and the PI's move to a different institution.|f||||f||||||||||2018-06-01 00:30:19.004471|2018-06-01 00:30:19.004471
NCT00990496|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2018-04-30|2009-10-05|2009-10-06|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2009||2009-09-30|April 2018|2018-04-30|October 28, 2010|Actual|2010-10-28|October 28, 2010|Actual|2010-10-28||Interventional|||A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)|A Phase I-II Study of Allogeneic CMV Specific Cytotoxic T Lymphocytes (CTL) for Patients With Refractory Glioblastoma Multiforme (GBM)|Terminated||Phase 1|25|Actual|Milton S. Hershey Medical Center||1||Accrual goals not met|f||||t||||||||||2018-06-01 00:30:19.373977|2018-06-01 00:30:19.373977
NCT00990483|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-05|2009-10-05|2009-10-06|Estimate|||||||2009-10-05|2009-10-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:30:19.449529|2018-06-01 00:30:19.449529
NCT00990470|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-10-07|2009-10-05|2009-10-06|Estimate|||||||2011-10-07|2011-10-10|Estimate|February 2006||2006-02-28|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Endoscopic Evaluation in Transplantation Candidates|Endoscopic Evaluation in Transplantation Candidates - Frequency and Prognostic Relevance of Upper and Lower Gastrointestinal Tract Findings|Completed|||300|Anticipated|Hannover Medical School|||||f||||f||||||||||2018-06-01 00:30:19.485629|2018-06-01 00:30:19.485629
NCT00990457|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2013-04-01|2009-10-05|2009-10-06|Estimate|||||||2013-04-01|2013-04-04|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SHAPE5||Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study)|Two Diets With Exercise in Abdominal Obesity: Cardiovascular Effects|Completed||Phase 3|77|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:30:19.540962|2018-06-01 00:30:19.540962
NCT00990444|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2010-10-03|2009-10-05|2009-10-06|Estimate|||||||2010-10-03|2010-10-05|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|ORA2||A Two Part Study of Peroral Insulin in Type 2 Diabetes|A Double-Blind Two Part Placebo-Controlled Study Consisting of a Single Ascending and Multiple-Dose Tolerance Study of Peroral Insulin in Patients With Type 2 Diabetes|Suspended||Phase 1/Phase 2|32|Anticipated|Bows Pharmaceuticals AG||2|||f||||t||||||||||2018-06-01 00:30:19.618458|2018-06-01 00:30:19.618458
NCT00990431|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-13|2009-10-05|2009-10-06|Estimate|||||||2009-10-13|2009-10-14|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Ablative Fractional Lasers to Treat Peri-orbital Rhytides|Ablative Fractional Lasers (CO2 and Er:YAG): A Randomized Controlled Blinded Split-face Trial of the Treatment of Peri-orbital Rhytides|Completed||Phase 4|28|Actual|Laserklinik Karlsruhe||2|||f||||f||||||||||2018-06-01 00:30:19.703907|2018-06-01 00:30:19.703907
NCT00990418|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2010-04-26|2009-10-05|2009-10-06|Estimate|||||||2010-04-26|2010-04-27|Estimate|March 2008||2008-03-31|April 2010|2010-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System|Bioequivalence Between Integrated E-TRANS (Fentanyl) System and Separated (Two-Part) E-TRANS (Fentanyl) System|Completed||Phase 1|60|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 00:30:19.767165|2018-06-01 00:30:19.767165
NCT00990405|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-05|2009-10-05|2009-10-06|Estimate|||||||2009-10-05|2009-10-06|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia|Phase 4 Study of Helicobacter Pylori Eradication Therapy|Unknown status|Active, not recruiting|Phase 4|400|Anticipated|Korean College of Helicobacter and Upper Gastrointestinal Research||1|||f||||t||||||||||2018-06-01 00:30:19.829342|2018-06-01 00:30:19.829342
NCT00990392|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2015-05-28|2009-10-05|2009-10-06|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|ToPICL||Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections|Pilot Study: Topical Antibiotics for Prevention of ICU Central Line Infections|Withdrawn||N/A|0|Actual|Fraser Health||2||"Change of practice to antibiotic impregnated catheters and large study published showing their~   efficacy. Made topical antibiotics obselete."|f||||t||||||||||2018-06-01 00:30:19.913941|2018-06-01 00:30:19.913941
NCT00990379|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-03-30|2009-10-05|2009-10-06|Estimate|||||||2015-03-30|2015-03-31|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|||Using Heavy Water to Study Cell Dynamics in Parkinson's Disease|Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases|Unknown status|Active, not recruiting||45|Anticipated|KineMed|||3||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 00:30:20.000527|2018-06-01 00:30:20.000527
NCT00990366|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-10-10|2009-10-05|2009-10-06|Estimate|||||||2011-10-10|2011-10-12|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve|Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve|Terminated||N/A|15|Actual|Turku University Hospital||2||Interim analysis results, study terminated 5/2010|f||||f||||||||||2018-06-01 00:30:20.065428|2018-06-01 00:30:20.065428
NCT00990353|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2015-03-31|2009-10-02|2009-10-06|Estimate|||||||2015-03-31|2015-04-01|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|October 2020|Anticipated|2020-10-31|January 2016|Anticipated|2016-01-31||Observational|||A Model to Identify Specific Predictors of Spatial Neglect Recovery|Comparing Prism Adaptation Therapy and Bromocriptine Medication for Spatial Neglect: Theoretical and Practical Outcomes|Recruiting|||80|Anticipated|Kessler Foundation|||2||f||||t||||||||||2018-06-01 00:30:20.137859|2018-06-01 00:30:20.137859
NCT00990340|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2011-03-14||2011-06-23|2009-10-05|2009-10-06|Estimate|2011-06-23|2011-07-25|Estimate||||2011-06-23|2011-07-25|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|T-jet®||Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method|Study to Compare Injection Anxiety Immediately Before the Administration of Each Dose of Tev-Tropin® Between a Needle-syringe Injection Method and a Needle-free Injection Method in Pediatric Subjects With Human Growth Hormone Deficiency|Completed||Phase 4|52|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 00:30:20.241482|2018-06-01 00:30:20.241482
NCT00990327|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02||2012-04-26|2012-04-27|2009-10-05|2009-10-06|Estimate||||2012-04-27|2012-05-01|Estimate|2012-04-27|2012-05-01|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|ASPECT||Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI|The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)|Terminated||Phase 3|863|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:30:20.482873|2018-06-01 00:30:20.482873
NCT00990314|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05||2014-02-11|2014-05-19|2009-10-05|2009-10-06|Estimate||||2014-02-11|2014-03-13|Estimate|2014-05-19|2014-05-29|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients|An Open-label Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients|Completed||Phase 2|31|Actual|Lung Biotechnology PBC||2|||f||||f||||||||||2018-06-01 00:30:20.834958|2018-06-01 00:30:20.834958
NCT00990301|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-04|||2013-11-21|2009-10-05|2009-10-06|Estimate|||||||2013-11-21|2013-11-25|Estimate||||November 2013|2013-11-30||||||||Interventional|||A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide 15mg/25mg Tablets (Paddock Laboratories, Inc) and Uniretic® 15mg/25mg Tablets (Schwarz Pharma)(Moexipril HCl/Hydrochlorothiazide) in Healthy Adult Volunteers Under Fasting Conditions.|Completed||Phase 1|48|Actual|Paddock Laboratories, Inc.||2|||f||||||||||||||2018-06-01 00:30:20.92103|2018-06-01 00:30:20.92103
NCT00990288|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2013-02-04||2017-11-10|2009-10-05|2009-10-06|Estimate|2017-11-10|2017-12-12|Actual||||2017-11-10|2017-12-12|Actual|October 2007||2007-10-31|November 2017|2017-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery|The Role of a Topical Hemostatic Agent in Reducing Blood Loss in Unilateral Total Knee Arthroplasty|Completed||Phase 4|196|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||No||2018-06-01 00:30:21.006672|2018-06-01 00:30:21.006672
NCT00990275|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-11-30|2009-10-05|2009-10-06|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Alcohol Exposure and Airway Hyperresponsiveness|Alcohol Exposure and Airway Hyperresponsiveness|Completed||N/A|4|Actual|University of Nebraska||1|||f||||f||||||||||2018-06-01 00:30:21.447254|2018-06-01 00:30:21.447254
NCT00988572|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2015-03-30|2009-10-01|2009-10-02|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|February 2013|Actual|2013-02-28||Interventional|||Vestibular Rehabilitation for Patients With Fall-related Wrist Fractures|Vestibular Rehabilitation for Patients With Fall-related Wrist Fractures - a Randomized Controlled Trial|Completed||N/A|82|Actual|Lund University||2|||f||||f||||||||||2018-06-01 00:30:52.349278|2018-06-01 00:30:52.349278
NCT00990262|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-02|2009-10-02|2009-10-06|Estimate|||||||2009-10-02|2009-10-06|Estimate|May 2005||2005-05-31|October 2009|2009-10-31|April 2009|Actual|2009-04-30|May 2007|Actual|2007-05-31||Observational|ROMICAT||Rule Out Myocardial Infarction by Computer Assisted Tomography|Accuracy of Contrast Enhanced Multidetector Computed Tomography to Identify Cardiac Cause of Symptoms in Patients With Intermediate Likelihood of Acute Coronary Syndrome (ACS) - A Comparison to Standard Care|Completed|||368|Actual|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Plasma~   "|||2018-06-01 00:30:21.535034|2018-06-01 00:30:21.535034
NCT00990249|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2016-05-10|2009-10-02|2009-10-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation|Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Lymphoblastic Leukemia or Lymphoma, or Biphenotypic Leukemia|Completed||Phase 2|120|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:30:21.624753|2018-06-01 00:30:21.624753
NCT00990236|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-10-05|2009-10-05|2009-10-06|Estimate|||||||2009-10-05|2009-10-06|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|||Thrombelastography Based Dosing of Enoxaparin|Thrombelastography Based Dosing of Enoxaparin for Thromboprophylaxis: a Prospective Randomized Trial|Unknown status|Recruiting|N/A|200|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 00:30:21.73053|2018-06-01 00:30:21.73053
NCT00990223|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-02-16|2009-10-05|2009-10-06|Estimate|||||||2011-02-16|2011-02-17|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effects Of Eplerenone On Serum Aldesterone And Plasma Renin Activity|A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo-Controlled Trial To Evaluate The Effects Of 100 MG Once Daily Of Eplerenone On Serum Aldesterone And Plasma Renin Activity During 10 Days Of Dosing In Healthy Volunteers|Completed||Phase 1|20|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:30:21.816646|2018-06-01 00:30:21.816646
NCT00990210|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2016-09-13|2009-10-02|2009-10-06|Estimate|||||||2016-09-13|2016-09-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:30:21.88498|2018-06-01 00:30:21.88498
NCT00990197|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-05|2009-10-05|2009-10-06|Estimate|||||||2009-10-05|2009-10-06|Estimate|June 2005||2005-06-30|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Interventional|STADIA||The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome|The Safety of Transdermal Nicotine Immediately Following an Acute Coronary Syndrome: The STADIA Pilot Study|Suspended||N/A|30|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2||Difficulties with enrollment.|f||||t||||||||||2018-06-01 00:30:21.925404|2018-06-01 00:30:21.925404
NCT00990184|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|2012-02-01||2012-10-22|2009-10-05|2009-10-06|Estimate|2012-10-22|2012-11-21|Estimate||||2012-10-22|2012-11-21|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)|A Single-Blind Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)|Completed||Phase 3|21|Actual|Seattle Institute for Biomedical and Clinical Research||1|||f||||t||||||||||2018-06-01 00:30:22.048434|2018-06-01 00:30:22.048434
NCT00990171|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2014-04-11|2009-10-05|2009-10-06|Estimate|||||||2014-04-11|2014-04-14|Estimate|December 2011||2011-12-31|April 2014|2014-04-30||||December 2016|Anticipated|2016-12-31||Observational|||The Effects Nutrition Status and Body Composition On Peritoneal Dialysis Outcome|The Effects Nutrition Status and Body Composition On Peritoneal Dialysis Outcome|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma dianeal~   "|||2018-06-01 00:30:22.228881|2018-06-01 00:30:22.228881
NCT00990158|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2015-05-19|2009-10-05|2009-10-06|Estimate|||||||2015-05-19|2015-05-21|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|OVWAC VII||Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?|A Multicentre Study of Low Dose Oral Vitamin K for INR Control in Patients Receiving Warfarin|Completed||Phase 3|235|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-06-01 00:30:22.335658|2018-06-01 00:30:22.335658
NCT00990145|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-07|2009-10-05|2009-10-06|Estimate|||||||2009-10-07|2009-10-08|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers|Completed||Phase 1|52|Actual|Enanta Pharmaceuticals||1|||||||f||||||||||2018-06-01 00:30:22.426445|2018-06-01 00:30:22.426445
NCT00990132|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2016-05-11|2009-10-05|2009-10-06|Estimate|||||||2016-05-11|2016-05-13|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Home Mechanical Ventilation vs Home Oxygen Therapy in COPD|Randomised Controlled Trial of Home Mechanical Ventilation in Hypercapnic Chronic Obstructive Pulmonary Disease Patients Post Acute Hypercapnic Exacerbation|Completed||Phase 2/Phase 3|116|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:30:22.488341|2018-06-01 00:30:22.488341
NCT00990119|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2014-02-26|2009-10-02|2009-10-06|Estimate|||||||2014-02-26|2014-02-27|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||High Flow Therapy (HFT) to Treat Respiratory Insufficiency in Chronic Obstructive Pulmonary Disease (COPD)|Vapotherm High Flow Therapy Via Nasal Cannula to Treat Respiratory Insufficiency in Patients With Chronic Obstructive Pulmonary Disease|Suspended||N/A|30|Anticipated|Vapotherm, Inc.||1|||f||||f||||||||||2018-06-01 00:30:22.575427|2018-06-01 00:30:22.575427
NCT00990106|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|2014-04-16||2018-04-25|2009-10-05|2009-10-06|Estimate|2014-08-28|2014-09-01|Estimate||||2018-04-25|2018-05-23|Actual|September 2009||2009-09-30|April 2018|2018-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)|A Placebo-Controlled Augmentation Trial of Prazosin for PTSD|Completed||N/A|67|Actual|Seattle Institute for Biomedical and Clinical Research|The sample was restricted to soldiers with frequent recalled combat trauma nightmares. More studies in civilian trauma PTSD are needed. Results cannot be extrapolated to persons with PTSD who do not recall trauma nightmares.|2|||f||||t||||||||||2018-06-01 00:30:22.665592|2018-06-01 00:30:22.665592
NCT00990093|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2012-01-09||2012-08-02|2009-10-05|2009-10-06|Estimate|2012-08-02|2012-09-05|Estimate||||2012-08-02|2012-09-05|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Randomised, Cross-over, Open-labelled Test Catheter Acceptance Study|A Randomised, Cross-over, Open-labelled Study Evaluating the Acceptance of Test Catheters Compared to SpeediCath Catheters|Completed||N/A|36|Actual|Coloplast A/S||2|||f||||f||||||||||2018-06-01 00:30:22.894097|2018-06-01 00:30:22.894097
NCT00990080|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-06-14|2009-10-05|2009-10-06|Estimate|||||||2011-06-14|2011-06-15|Estimate|May 2010||2010-05-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Interchangeability of Infanrix™ IPV/Hib and Pediacel® at 2,4 & 6 Months of Age|Safety and Immunogenicity of Two Mixed Primary Immunization Schedules: Pediacel® at 2 and 4 Months of Age Followed by One Dose of Infanrix™ IPV/Hib at 6 Months of Age; and, Infanrix™ IPV/Hib at 2 Months of Age, Followed by Pediacel® at 4 and 6 Months of Age|Completed||Phase 3|253|Actual|Dalhousie University||2|||f||||f||||||||||2018-06-01 00:30:23.084038|2018-06-01 00:30:23.084038
NCT00990067|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2013-01-24|2009-10-05|2009-10-06|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)|Pharmacological Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacodynamics (PD) and Pharmacokinetics (PK)|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-06-01 00:30:23.169848|2018-06-01 00:30:23.169848
NCT00990054|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-03-19|2009-10-05|2009-10-06|Estimate|||||||2015-03-19|2015-03-24|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 1|36|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 00:30:23.240992|2018-06-01 00:30:23.240992
NCT00990041|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-05|2009-10-05|2009-10-06|Estimate|||||||2009-10-05|2009-10-06|Estimate||||October 2009|2009-10-31||||||||Observational|||Release of Cytokines by Stimulated Peripheral Blood Mononuclear Cells (PBMC) From Chronic Periodontitis Subjects||Completed|||||Escola Bahiana de Medicina e Saude Publica|||2||f||||||||||||||2018-06-01 00:30:23.472775|2018-06-01 00:30:23.472775
NCT00990028|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-10-05|2009-10-05|2009-10-06|Estimate|||||||2011-10-05|2011-10-06|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury|Effect of Rosuvastatin on Immunological Markers After Traumatic Brain Injury: Clinical Randomized Double Blind Study Phase 2|Completed||Phase 1/Phase 2|40|Actual|Universidad Autonoma de San Luis Potosí||2|||f||||t||||||||||2018-06-01 00:30:23.52922|2018-06-01 00:30:23.52922
NCT00990015|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2010-01-29|2009-10-05|2009-10-06|Estimate|||||||2010-01-29|2010-02-01|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single-Dose Escalation Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04308515 in Healthy Volunteers|Completed||Phase 1|27|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:30:23.613378|2018-06-01 00:30:23.613378
NCT00990002|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2011-05-09|2009-10-05|2009-10-06|Estimate|||||||2011-05-09|2011-05-10|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Investigation of A Children's Beverage Containing Different Probiotics|INVESTIGATION OF CHANGES IN LEUKOCYTE POPULATIONS AMONG CHILDREN RECEIVING A FOLLOW-ON COW'S MILK-BASED FORMULA CONTAINING DIFFERENT BIOACTIVE INGREDIENTS.|Completed|||30|Anticipated|Mead Johnson Nutrition|||3||f||||f||||||||||2018-06-01 00:30:23.685366|2018-06-01 00:30:23.685366
NCT00989989|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|2012-07-26||2012-09-18|2009-10-05|2009-10-06|Estimate|2012-09-18|2012-10-18|Estimate||||2012-09-18|2012-10-18|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|REVEAL||Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema|A Randomized, Double-masked, Multicenter, Laser Controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema|Completed||Phase 3|396|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:30:23.778209|2018-06-01 00:30:23.778209
NCT00989976|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2014-12-05|2009-10-02|2009-10-06|Estimate|||||||2014-12-05|2014-12-08|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Individual Differences in Diabetes Risk: Role of Sleep Disturbances|Individual Differences in Diabetes Risk: Role of Sleep Disturbances|Completed||N/A|16|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 00:30:24.72206|2018-06-01 00:30:24.72206
NCT00989963|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05||2013-04-16|2013-04-16|2009-10-05|2009-10-06|Estimate||||2013-04-16|2013-04-24|Estimate|2013-04-16|2013-04-24|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)|A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 2|36|Actual|Lung Biotechnology PBC||3|||f||||f||||||||||2018-06-01 00:30:24.798526|2018-06-01 00:30:24.798526
NCT00989950|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2012-03-12||2012-07-16|2009-10-05|2009-10-06|Estimate|2012-05-15|2012-06-14|Estimate||||2012-07-16|2012-07-19|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|Daytsleep||Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD|Open Label Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children 6-12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|26|Actual|Cox Health Systems|Small sample size, did not permit an examination of more specific differences among patch wear time conditions. Small sample size resulted in weaker randomization to patch wear time sequences that was not completely balanced in baseline covariates.|4|||f||||t||||||||||2018-06-01 00:30:24.921246|2018-06-01 00:30:24.921246
NCT00989937|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2016-12-20|2009-10-05|2009-10-06|Estimate|||||||2016-12-20|2016-12-22|Estimate|February 2009||2009-02-28|December 2016|2016-12-31||||April 2011|Actual|2011-04-30||Interventional|||Oxytocin Add-on Study for Stable Anxiety Patients|Double-Blind, Randomized, Placebo-Controlled, Cross-Over Pilot Study of Intranasal Oxytocin in Patients With Anxiety Disorder|Suspended||N/A|40|Anticipated|University of California, San Diego||2||Break in funding|f||||f||||||||||2018-06-01 00:30:25.31478|2018-06-01 00:30:25.31478
NCT00989924|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2010-08-12|2009-10-05|2009-10-06|Estimate|||||||2010-08-12|2010-08-16|Estimate|October 2009||2009-10-31|July 2010|2010-07-31||||||||Observational|||Research on the Correlation Among Magnetocardiography Patterns and Known Cardiovascular Risk Factors in Diabetic Patients|Research on the Correlation Among Magnetocardiography Patterns and Known Cardiovascular Risk Factors in Diabetic Patients|Unknown status|Recruiting||1100|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 00:30:25.391616|2018-06-01 00:30:25.391616
NCT00989911|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2014-12-03||2015-02-09|2009-10-05|2009-10-06|Estimate|2015-01-08|2015-01-13|Estimate||||2015-02-09|2015-02-27|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Fontan, single ventricle patients all treated with Bosentan.|Endothelin Blockade in Patients With Single Ventricle Physiology|Endothelin Blockade in Patients With Single Ventricle Physiology|Completed||N/A|10|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-06-01 00:30:25.468129|2018-06-01 00:30:25.468129
NCT00989898|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2012-06-22|2009-10-05|2009-10-06|Estimate|||||||2012-06-22|2012-06-25|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|APCam05||Automated Overnight Closed-loop Glucose Control in Young People With Type 1 Diabetes|Open Randomised, Two Period Cross-over Study to Assess the Feasibility, Efficacy and Safety of Automated Closed-loop Glucose Control Initiated at the Time of Dinner or Before Sleep in Children and Adolescents With Type 1 Diabetes|Completed||N/A|16|Actual|University of Cambridge||2|||f||||||||||||||2018-06-01 00:30:25.616305|2018-06-01 00:30:25.616305
NCT00989885|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-05|2009-10-05|2009-10-06|Estimate|||||||2009-10-05|2009-10-06|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|July 2007|Actual|2007-07-31|March 2007|Actual|2007-03-31||Observational|||ESS as a Diagnosis Resource Aid of the Syndrome of Obstructive Sleep Apnea|The Effectiveness of the Epworth´s Sleepiness Scale as a Resource Aid in the Diagnosis of the Syndrome of Obstructive Sleep Apnea|Completed|||475|Actual|Fortaleza University|||1||f||||t||||||||||2018-06-01 00:30:25.699217|2018-06-01 00:30:25.699217
NCT00989872|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-05|2009-10-05|2009-10-06|Estimate|||||||2009-10-05|2009-10-06|Estimate||||October 2009|2009-10-31||||||||Interventional|||Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers|A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers|Completed||Phase 1|67|Actual|Enanta Pharmaceuticals|||||||||||||||||||2018-06-01 00:30:25.906151|2018-06-01 00:30:25.906151
NCT00989859|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2017-02-08|2009-10-05|2009-10-06|Estimate|||||||2017-02-08|2017-02-10|Actual|September 2009||2009-09-30|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Photo-Plethysmographic Camera to Monitor Heart Rate, Respiration Rate and Oxygen Saturation in Infants|A Pilot Study Using Photo-plethysmographic (PPG) Camera to Monitor Heart Rate, Respiration Rate and Oxygen Saturation in Infants.|Completed|||20|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 00:30:25.968235|2018-06-01 00:30:25.968235
NCT00989846|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2009-10-13|2009-10-05|2009-10-06|Estimate|||||||2009-10-13|2009-10-14|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|June 2010|Anticipated|2010-06-30|March 2010|Anticipated|2010-03-31||Observational|||Biomarker in Lung Diseases|Feasibility Study on Establishing Biomarkers in Lung Diseases|Unknown status|Recruiting||120|Anticipated|Heidelberg University|||1||f||||f||||||Samples Without DNA|"~     Serum (blood)~   "|||2018-06-01 00:30:26.02875|2018-06-01 00:30:26.02875
NCT00989833|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2011-08-22||2012-07-06|2009-10-05|2009-10-06|Estimate|2012-07-06|2012-08-14|Estimate||||2012-07-06|2012-08-14|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MIA||Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients|"A Randomised, Double Blind, Placebo Controlled, Parallel-group Study With Use of Budesonide/Formoterol As-needed, or Terbutaline As-needed or Regular Use of Budesonide + Terbutaline As-needed, in Patients With Mild Intermittent Asthma"|Completed||Phase 2|66|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:30:26.127152|2018-06-01 00:30:26.127152
NCT00989820|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|||2017-05-29|2009-10-05|2009-10-06|Estimate|||||||2017-05-29|2017-05-31|Actual|October 2009|Actual|2009-10-31|April 2016|2016-04-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Efficacy of Hyperbaric Oxygen Therapy in the Treatment of Osteoradionecrosis|Efficacy of Adding Hyperbaric Oxygen Therapy to the Treatment of Late Radiation Damage of the Lower Jaw (Osteoradionecrosis).|Terminated||Phase 2/Phase 3|20|Actual|Radboud University||2||Recruitment problems, patients refused to participate|f||||t||||||||||2018-06-01 00:30:26.541572|2018-06-01 00:30:26.541572
NCT00989807|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-12-12|2009-10-05|2009-10-06|Estimate|||||||2012-12-12|2012-12-13|Estimate||||October 2012|2012-10-31||||||||Expanded Access|EAP||Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis|Expanded Access for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression|Approved for marketing|||||Gilead Sciences|||||f||||||||||||||2018-06-01 00:30:26.6232|2018-06-01 00:30:26.6232
NCT00989794|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-04|||2017-10-06|2009-10-05|2009-10-06|Estimate|||||||2017-10-06|2017-10-09|Actual|September 2009||2009-09-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2015|Actual|2015-12-31||Interventional|||Study to Evaluate the Safety and Performance of Treatment of Articular Cartilage Lesions Located on the Femoral Condyle With gelrinC|Phase I/II Study for the Safety and Performance of GELRIN C|Active, not recruiting||Phase 1/Phase 2|56|Actual|Regentis Biomaterials||1|||f||||t||||||||||2018-06-01 00:30:26.679065|2018-06-01 00:30:26.679065
NCT00989781|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2015-06-18||2017-09-14|2009-10-05|2009-10-06|Estimate|2017-09-14|2017-10-17|Actual||||2017-09-14|2017-10-17|Actual|September 2009||2009-09-30|September 2017|2017-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome|Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome|Completed||N/A|41|Actual|University of California, San Diego||2|||f||||t||||||||No||2018-06-01 00:30:26.736373|2018-06-01 00:30:26.736373
NCT00989768|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-05|2009-10-28||2010-05-24|2009-10-05|2009-10-06|Estimate|2010-04-13|2010-04-27|Estimate||||2010-05-24|2010-06-02|Estimate|May 2005||2005-05-31|October 2009|2009-10-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A|Field Effects of Two Commercial Preparations of Botulinum Toxin Type a Administered to the Frontalis Muscles|Completed||Phase 4|29|Actual|Brazilan Center for Studies in Dermatology|The field of muscular effects of the studied toxins was objectively measured by EMG and it is not very precise. However, there is no more precise objective measurement to currently evaluate the field effects in muscles than EMG.|1|||f||||f||||||||||2018-06-01 00:30:26.996429|2018-06-01 00:30:26.996429
NCT00989755|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2015-12-07|2009-10-02|2009-10-05|Estimate|||||||2015-12-07|2015-12-09|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|F2Q/EAD||Center for Disease Control (CDC) Fax to Quit/Academic Detailing Grant|An Evaluation of the Fax to Quit Program and Wisconsin Tobacco Quitline Utilization by Southeastern Wisconsin Clinics|Completed||N/A|49|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-06-01 00:30:28.247912|2018-06-01 00:30:28.247912
NCT00989742|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-12-01|2009-10-02|2009-10-05|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Doxycycline In Lymphangioleiomyomatosis (LAM)|A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.|Completed||Phase 4|24|Actual|University of Nottingham||2|||f||||f||||||||||2018-06-01 00:30:28.314015|2018-06-01 00:30:28.314015
NCT00989729|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2014-11-12|2009-10-02|2009-10-05|Estimate|||||||2014-11-12|2014-11-14|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|POMEVAR||Preoperative Methylprednisolone in Endovascular Aortic Repair|Preoperative Methylprednisolone in Endovascular Aortic Repair - a Randomized Double Blind Placebo Controlled Clinical Trial|Completed||N/A|150|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 00:30:28.401191|2018-06-01 00:30:28.401191
NCT00989716|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-07-23|2009-10-02|2009-10-05|Estimate|||||||2012-07-23|2012-07-24|Estimate|July 2001||2001-07-31|July 2012|2012-07-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|ENOS||The Efficacy of Nitric Oxide in Stroke (ENOS) Trial|A Prospective, Collaborative, International, Multicentre, Randomised, Parallel-group, Single and Outcome Blinded, Controlled, Factorial Trial to Investigate the Safety and Efficacy of Treatment With Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, and of Continuing or Stopping Temporarily Pre-stroke Antihypertensive Therapy, in Patients With Acute Stroke|Unknown status|Recruiting|Phase 3|3500|Anticipated|University of Nottingham||2|||f||||t||||||||||2018-06-01 00:30:28.506704|2018-06-01 00:30:28.506704
NCT00989703|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-02-17|2009-10-02|2009-10-05|Estimate|||||||2012-02-17|2012-02-20|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects|Double Blind, Placebo Controlled, Dose Ranging and Methotrexate Interaction Study for the Assessment of Safety, Tolerability and Pharmacokinetics (PK) of Multiple Oral Doses of GLPG0259 in Healthy Subjects|Completed||Phase 1|24|Actual|Galapagos NV||2|||f||||f||||||||||2018-06-01 00:30:28.59049|2018-06-01 00:30:28.59049
NCT00989690|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2013-08-09|2009-10-02|2009-10-05|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2008||2008-02-29|October 2009|2009-10-31||||||||Interventional|||Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer|Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer|Unknown status|Recruiting|Phase 3|275|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:30:28.684817|2018-06-01 00:30:28.684817
NCT00989677|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2009-10-02|2009-10-02|2009-10-05|Estimate|||||||2009-10-02|2009-10-05|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|RADAM||Rheumatoid Arthritis Disease Activity Monitor|Rheumatoid Arthritis Disease Activity Monitor|Completed|||75|Actual|Maxima Medical Center|||1||f||||f||||||||||2018-06-01 00:30:28.758058|2018-06-01 00:30:28.758058
NCT00989664|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2012-03-15||2016-10-28|2009-10-01|2009-10-05|Estimate|2012-03-15|2012-04-10|Estimate||||2016-10-28|2016-12-13|Estimate|November 1996||1996-11-30|October 2016|2016-10-31|September 2008|Actual|2008-09-30|January 2004|Actual|2004-01-31||Interventional|||Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma|Multicenter, Pivotal Phase III Study of Iodine-131 Anti-B1 Antibody (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies|Completed||Phase 2|60|Actual|GlaxoSmithKline||1|||t||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:30:29.000819|2018-06-01 00:30:29.000819
NCT00989651|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2018-03-22|2009-10-02|2009-10-05|Estimate|||||||2018-03-22|2018-03-23|Actual|October 28, 2009|Actual|2009-10-28|December 2017|2017-12-31||||September 1, 2020|Anticipated|2020-09-01||Interventional|||Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 1|474|Anticipated|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-06-01 00:30:29.786468|2018-06-01 00:30:29.786468
NCT00989638|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2018-04-30|2009-10-02|2009-10-05|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2004||2004-06-30|April 2018|2018-04-30|February 2027|Anticipated|2027-02-28|February 2022|Anticipated|2022-02-28||Observational|||A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer|A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer|Active, not recruiting|||305|Actual|University of Chicago|||1||f||||f|f|f||||||||2018-06-01 00:30:29.930222|2018-06-01 00:30:29.930222
NCT00989625|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2017-06-16|2009-10-01|2009-10-05|Estimate|||||||2017-06-16|2017-06-19|Actual|November 4, 2008|Actual|2008-11-04|June 2017|2017-06-30|September 10, 2009|Actual|2009-09-10|September 10, 2009|Actual|2009-09-10||Interventional|||A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.|An Open Label, Single Dose, Randomised, Parallel Group Pharmacokinetic Study to Evaluate a Combination Product Containing Naproxen Sodium and Sumatriptan in Adolescent Subjects With Migraine and Healthy Adult Subjects Administered at Three Doses.|Completed||Phase 1|50|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:30:30.136376|2018-06-01 00:30:30.136376
NCT00989612|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01||2010-07-02|2017-03-22|2009-10-01|2009-10-05|Estimate||||2010-07-02|2010-07-07|Estimate|2017-03-22|2017-03-23|Actual|October 2009||2009-10-31|March 2017|2017-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)|Immunogenicity and Safety Study of GSK Biologicals' Influenza Candidate Vaccine GSK2340274A|Completed||Phase 2|100|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:30:30.316158|2018-06-01 00:30:30.316158
NCT00989599|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2009-10-02|2009-10-02|2009-10-05|Estimate|||||||2009-10-02|2009-10-05|Estimate|September 2004||2004-09-30|October 2009|2009-10-31|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Interventional|||Use of Chamomilla Recutita in Phlebitis|Therapeutic Topic Use of Chamomilla Recutita in Phlebitis Due to Peripheral Intravenous Therapy|Completed||Phase 3|123|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 00:30:30.514916|2018-06-01 00:30:30.514916
NCT00989248|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2011-04-27|2009-10-02|2009-10-05|Estimate|||||||2011-04-27|2011-04-28|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|CHF||Comparative Study of Cardiopulmonary Exercise Test Land Versus Water|Comparative Study of Cardiopulmonary Exercise Test on Land and Underwater in Patients With Congestive Heart Failure|Unknown status|Recruiting|Phase 2/Phase 3|90|Anticipated|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-06-01 00:30:36.590264|2018-06-01 00:30:36.590264
NCT00989586|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|2016-04-28||2016-12-08|2009-10-02|2009-10-05|Estimate|2016-12-08|2017-02-06|Estimate||||2016-12-08|2017-02-06|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional||Patients with histologically confirmed B-cell NHL including marginal zone lymphoma, Waldenstrom's macroglobulinemia or lymphoplasmacytic lymphoma, follicular lymphoma, or mantle cell lymphoma by WHO criteria.|Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined With Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody, in Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|35|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-06-01 00:30:30.656526|2018-06-01 00:30:30.656526
NCT00989573|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2013-02-19|2009-10-02|2009-10-05|Estimate|||||||2013-02-19|2013-02-21|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease|A Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease|Completed||Phase 2/Phase 3|191|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-06-01 00:30:31.030317|2018-06-01 00:30:31.030317
NCT00989560|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2014-01-10|2009-10-02|2009-10-05|Estimate|||||||2014-01-10|2014-01-13|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|POCER||Post-operative Crohn's Endoscopic Recurrence Study|"Post-Operative Crohn's Disease Endoscopic Recurrence POCER Study: Endoscopic Guided Therapeutic Intervention & Determination of Cause"|Completed||Phase 3|175|Actual|University of Melbourne||2|||f||||t||||||||||2018-06-01 00:30:31.129752|2018-06-01 00:30:31.129752
NCT00989547|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2013-07-22|2009-10-02|2009-10-05|Estimate|||||||2013-07-22|2013-07-23|Estimate|September 2008||2008-09-30|July 2013|2013-07-31||||September 2014|Anticipated|2014-09-30||Interventional|||Cord Blood Infusion for Type 1 Diabetes Mellitus (T1DM)|Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study.|Unknown status|Active, not recruiting|Phase 1|18|Actual|Technische Universität München||2|||f||||t||||||||||2018-06-01 00:30:31.199816|2018-06-01 00:30:31.199816
NCT00989534|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2016-09-29|2009-10-02|2009-10-05|Estimate|||||||2016-09-29|2016-10-03|Estimate|January 2003||2003-01-31|September 2016|2016-09-30|September 2009|Actual|2009-09-30|December 2007|Actual|2007-12-31||Interventional|EW and EWD||Extended Work Schedules, Sleep Loss and Health|Extended Work Schedules and Health: Role of Sleep Loss|Completed||N/A|49|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 00:30:31.267602|2018-06-01 00:30:31.267602
NCT00989521|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2011-11-21|2009-10-02|2009-10-05|Estimate|||||||2011-11-21|2011-11-22|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of PUR003 on Asthma|Double-blind, Placebo-controlled Crossover Evaluation of the Effect of PUR003 on Subjects With Asthma|Completed||Phase 1|7|Actual|Pulmatrix Inc.||2|||f||||f||||||||||2018-06-01 00:30:31.333416|2018-06-01 00:30:31.333416
NCT00989508|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2011-08-10|2009-10-02|2009-10-05|Estimate|||||||2011-08-10|2011-08-11|Estimate|October 2009||2009-10-31|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|HYPER||Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy|Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy|Unknown status|Recruiting|Phase 2/Phase 3|220|Anticipated|University Hospital Birmingham||2|||f||||t||||||||||2018-06-01 00:30:31.406499|2018-06-01 00:30:31.406499
NCT00989495|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2014-12-01|2009-10-02|2009-10-05|Estimate|||||||2014-12-01|2014-12-03|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||Comprehensive Cohort Study of Bracing for Adolescent Idiopathic Scoliosis (AIS): A Feasibility Study|Single-blind Comprehensive Cohort Study Incorporating a Randomized Controlled Design on Bracing in AIS: A Feasibility Study|Completed||N/A|68|Actual|The University of Hong Kong||4|||f||||f||||||||||2018-06-01 00:30:31.512629|2018-06-01 00:30:31.512629
NCT00989482|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2011-05-12|2009-10-02|2009-10-05|Estimate|||||||2011-05-12|2011-05-16|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Improving Antibiotic Prescribing Practices in Mexican Primary Care Clinics|Improving Antibiotic Prescribing Practices in Mexican Primary Care Clinics|Completed||N/A|847|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 00:30:31.590311|2018-06-01 00:30:31.590311
NCT00989469|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-02-09|2009-10-02|2009-10-05|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|NEXIRI||Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation|SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.|Completed||Phase 1/Phase 2|64|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||t||||||||||2018-06-01 00:30:31.653482|2018-06-01 00:30:31.653482
NCT00989456|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-02-28|2009-10-02|2009-10-05|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2009|Actual|2009-09-30|February 2017|2017-02-28|April 2013|Actual|2013-04-30|November 2011|Actual|2011-11-30||Interventional|||Well Being and Rehabilitation in Chronically Ill Patients: Structured Patient Education and Physical Exercise|Structured Patient Education in Combination With Physical Exercise as Part of the Integrated Care to Chronically Ill Patients With Chronic Obstructive Pulmonary Disease, Heart Failure and Stroke. A Randomized Controlled Intervention Trial.|Completed||N/A|54|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 00:30:31.727459|2018-06-01 00:30:31.727459
NCT00989443|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2010-10-20|2009-10-02|2009-10-05|Estimate|||||||2010-10-20|2010-10-21|Estimate|May 2010||2010-05-31|October 2010|2010-10-31||||September 2010|Actual|2010-09-30||Interventional|||Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions|A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3)|Completed||Phase 1|6|Anticipated|Mithra Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:30:31.825798|2018-06-01 00:30:31.825798
NCT00989430|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2016-02-22|2009-10-02|2009-10-05|Estimate|||||||2016-02-22|2016-02-24|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Prism Adaptation Therapy for Spatial Neglect|Prism Adaptation Therapy for Spatial Neglect: Theoretical and Practical Outcomes|Active, not recruiting||N/A|160|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-06-01 00:30:31.89029|2018-06-01 00:30:31.89029
NCT00989417|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2011-05-24|2009-10-02|2009-10-05|Estimate|||||||2011-05-24|2011-05-25|Estimate|January 2007||2007-01-31|May 2011|2011-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|ECOST||Benefits of Implantable Cardioverter Defibrillator Follow-up Using Remote Monitoring|Effectiveness and Cost Of ICD Follow-up Schedule With Telecardiology|Completed||N/A|473|Actual|Biotronik SE & Co. KG||2|||f||||t||||||||||2018-06-01 00:30:31.960355|2018-06-01 00:30:31.960355
NCT00989404|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2017-06-13|2009-10-01|2009-10-05|Estimate|||||||2017-06-13|2017-06-14|Actual|October 12, 2009|Actual|2009-10-12|June 2017|2017-06-30|December 7, 2009|Actual|2009-12-07|December 7, 2009|Actual|2009-12-07||Interventional|NAI113625||Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days|A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:30:32.179021|2018-06-01 00:30:32.179021
NCT00989391|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2009-12-15|2009-10-02|2009-10-05|Estimate|||||||2009-12-15|2009-12-16|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects|Completed||Phase 1|36|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:30:32.292392|2018-06-01 00:30:32.292392
NCT00989378|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2013-09-04|2009-10-02|2009-10-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Individual Differences in Diabetes Risk: Role of Slow WaveSleep|Ancillary Studies to Major Ongoing NIDDK Clinical Research Studies|Completed|||5|Actual|University of Chicago|||1||f||||||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:30:32.385063|2018-06-01 00:30:32.385063
NCT00989365|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2009-10-02|2009-10-02|2009-10-05|Estimate|||||||2009-10-02|2009-10-05|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effect of Aerobic Training on Asthmatic Patients|Effect of Aerobic Training on Psychosocial Morbidity, Symptoms, Airway Inflammation and Autonomic Modulation in Asthmatic Patients|Completed||N/A|100|Actual|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-06-01 00:30:32.463326|2018-06-01 00:30:32.463326
NCT00989352|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2009-10-02|2009-10-02|2009-10-05|Estimate|||||||2009-10-02|2009-10-05|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|PRIMAIN||Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma|Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy|Unknown status|Recruiting|Phase 2|56|Anticipated|University Hospital Freiburg|||||f||||f||||||||||2018-06-01 00:30:32.568259|2018-06-01 00:30:32.568259
NCT00989339|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2014-07-02|2009-10-02|2009-10-05|Estimate|||||||2014-07-02|2014-07-04|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Intralipid Versus Olive Oil Infusions on Endothelial Function, Immune Function, Inflammatory Markers|Effects of Intralipid and Olive Oil Infusion on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function, Autonomic Nervous System, Insulin Sensitivity and Carbohydrate Metabolism|Withdrawn||Phase 2/Phase 3|0|Actual|Emory University||1||Sub-investigator left facility prior to study initiation|f||||t||||||||||2018-06-01 00:30:32.678871|2018-06-01 00:30:32.678871
NCT00989326|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2010-06-23|2009-10-02|2009-10-05|Estimate|||||||2010-06-23|2010-06-24|Estimate|December 2005||2005-12-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|COMPAS||Evaluate the Benefits of Pacemaker Follow-Up With Home-Monitoring|Comparative Follow-up Schedule With Home Monitoring|Completed||N/A|543|Actual|Biotronik France||2|||f||||t||||||||||2018-06-01 00:30:32.758412|2018-06-01 00:30:32.758412
NCT00989313|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2015-03-25|2009-10-02|2009-10-05|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study|A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Locations (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-028 (REGION Ib)|Completed|||43|Actual|Peplin|||1||f||||f||||||||||2018-06-01 00:30:32.851173|2018-06-01 00:30:32.851173
NCT00989300|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-09-19|2009-10-02|2009-10-05|Estimate|||||||2012-09-19|2012-09-21|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|CLARA||Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel|Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel. A Prospective, placebo-and Active Treatment-controlled, Open Label, Randomized 3-way Cross Over Study in Healthy Subjects|Completed||Phase 1|39|Actual|Janssen Cilag S.A.S.||2|||f||||f||||||||||2018-06-01 00:30:32.947659|2018-06-01 00:30:32.947659
NCT00989287|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2017-08-08|2010-12-10|2017-08-08|2009-10-01|2009-10-05|Estimate|2017-08-08|2018-03-05|Actual|2010-12-10|2010-12-16|Estimate|2017-08-08|2018-03-05|Actual|October 1, 2009|Actual|2009-10-01|August 2017|2017-08-31|October 26, 2010|Actual|2010-10-26|October 9, 2009|Actual|2009-10-09||Interventional|||Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years|Completed||Phase 3|131|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:30:33.11273|2018-06-01 00:30:33.11273
NCT00989274|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2012-03-28|2009-10-02|2009-10-05|Estimate|||||||2012-03-28|2012-04-02|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1|Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Pandemic Influenza A/H1N1 Produced by Sanofi|Withdrawn||Phase 2|0|Actual|Instituto Nacional de Salud Publica, Mexico||3||Late approval by the Secretariat of Health, and expiration of vaccine|f||||t||||||||||2018-06-01 00:30:34.995136|2018-06-01 00:30:34.995136
NCT00989261|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01||2016-09-30|2018-01-03|2009-10-01|2009-10-05|Estimate||||2016-09-30|2016-10-03|Estimate|2018-01-03|2018-01-05|Actual|November 2009||2009-11-30|January 2018|2018-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ACE||Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)|Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations|Completed||Phase 2|333|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||||2018-06-01 00:30:35.725631|2018-06-01 00:30:35.725631
NCT00989235|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|2011-05-12||2011-06-18|2009-10-02|2009-10-05|Estimate|2011-05-12|2011-06-03|Estimate||||2011-06-18|2011-06-21|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis|A Phase 3B, Multi-Center, Randomized, Double-blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate-naïve Early Erosive Rheumatoid Arthritis Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate - Low Dose Sub-Study|Completed||Phase 3|108|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 00:30:36.897328|2018-06-01 00:30:36.897328
NCT00989222|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2009-10-02|2009-10-02|2009-10-05|Estimate|||||||2009-10-02|2009-10-05|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Volar Plating or External Fixation of Dorsally Displaced Fractures of the Distal Radius?|Volar Plating or External Fixation of Dorsally Displaced Fractures of the Distal Radius? A Prospective Randomized Study|Completed||N/A|63|Actual|Danderyd Hospital||2|||f||||f||||||||||2018-06-01 00:30:41.058225|2018-06-01 00:30:41.058225
NCT00989209|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2009-10-02|2009-10-02|2009-10-05|Estimate|||||||2009-10-02|2009-10-05|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|December 2006|Actual|2006-12-31|December 2005|Actual|2005-12-31||Interventional|||Myofunctional Therapy in Facial Palsy|Improvement of Facial Symmetry With Myofunctional Therapy Combined to Botulinum Toxin Injections in Long Standing Facial Paralysis|Completed||N/A|25|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-06-01 00:30:42.17522|2018-06-01 00:30:42.17522
NCT00989196|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2013-03-01||2013-12-16|2009-10-01|2009-10-02|Estimate|2013-12-16|2014-01-17|Estimate||||2013-12-16|2014-01-17|Estimate|May 2010||2010-05-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A|Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A|Completed||Phase 2|22|Actual|Octapharma||2|||f||||t||||||||||2018-06-01 00:30:42.782234|2018-06-01 00:30:42.782234
NCT00989183|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2017-11-21|2009-10-01|2009-10-02|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2009||2009-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Lifestyle Factors Study|Lifestyle Factors and Their Impact on Ovarian Reserve|Active, not recruiting|||41|Actual|University of Oklahoma|||||f||||f||||||Samples With DNA|"~     Telomere length assay~   "|||2018-06-01 00:30:43.809913|2018-06-01 00:30:43.809913
NCT00989170|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2016-02-09|2009-10-01|2009-10-02|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Family Program for Weight Gain Prevention|Family Program for Weight Gain Prevention|Completed||N/A|418|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 00:30:43.883031|2018-06-01 00:30:43.883031
NCT00989157|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2014-04-08||2014-07-17|2009-10-01|2009-10-02|Estimate|2014-07-17|2014-08-11|Estimate||||2014-07-17|2014-08-11|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional||Available Bariatric surgery candidates and pilot study results.|Effects of Gastric Bypass on Blood Levels of Duloxetine|A Preliminary Comparison of the Effect of Roux-en-Y Bariatric Surgery on Blood Levels of Duloxetine|Completed||Phase 3|20|Actual|Neuropsychiatric Research Institute, Fargo, North Dakota||1|||f||||f||||||||||2018-06-01 00:30:44.007929|2018-06-01 00:30:44.007929
NCT00989144|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-28|2009-10-01|2009-10-02|Estimate|||||||2009-10-28|2009-10-29|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|SEARCH004||Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort|Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort.|Completed|||1000|Actual|Thai Red Cross AIDS Research Centre|||||f||||f||||||Samples With DNA|"~     Pools will be made by aliquoting 40ul per subject into each pool, with a maximum of 20~     subjects per pool, yielding a maximum pool volume of 800 ul. Samples will be run with the~     Roche Amplicor ver 1.5 test in ultrasensitive mode with appropriate controls as per~     manufacturer's instructions. Quality assurance will be per SOP. Pools testing positive will~     be re-analyzed at the individual sample level. Positive samples will be confirmed by Bayer~     bDNA NAT. Frequency of infection will be tabulated.~   "|||2018-06-01 00:30:44.330456|2018-06-01 00:30:44.330456
NCT00989131|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2014-02-03|2009-10-01|2009-10-02|Estimate|||||||2014-02-03|2014-02-04|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of Paclitaxel in Patients With Ovarian Cancer|An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL)|Completed||Phase 3|789|Actual|Oasmia Pharmaceutical AB||2|||f||||t||||||||||2018-06-01 00:30:44.458504|2018-06-01 00:30:44.458504
NCT00989118|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|May 2000||2000-05-31|October 2009|2009-10-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Randomized Study on Endometrioma Treatment||Completed||Phase 3|||Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 00:30:44.78165|2018-06-01 00:30:44.78165
NCT00989105|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-02-27|2009-10-01|2009-10-02|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer|A Cancer Research UK Phase I Trial of 99mTc Demobesin-4 (a Diagnostic Radiopharmaceutical) Given Once Via Bolus Intravenous Injection for Imaging of Prostate Cancer|Terminated||Phase 1|8|Actual|Cancer Research UK|||||f||||||||||||||2018-06-01 00:30:44.854367|2018-06-01 00:30:44.854367
NCT00989092|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2010-09-03||2013-12-11|2009-10-01|2009-10-02|Estimate|2013-12-11|2014-01-29|Estimate||||2013-12-11|2014-01-29|Estimate|May 2002||2002-05-31|December 2013|2013-12-31|June 2004|Actual|2004-06-30|January 2004|Actual|2004-01-31||Interventional|||Darbepoetin Alfa and Anemia of Cancer|A Randomized, Open-label, Comparative Study to Estimate the Effect of Darbepoetin Alfa on Hospital Days, Economic Outcomes, and Health-related Quality of Life in Subjects With Nonmyeloid Malignancies and Anemia of Cancer|Terminated||Phase 2|287|Actual|Amgen||2||slow enrollment and change in product development strategy|f||||||||||||||2018-06-01 00:30:44.99618|2018-06-01 00:30:44.99618
NCT00989079|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2016-03-17|2009-10-01|2009-10-02|Estimate|||||||2016-03-17|2016-03-18|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)|A Phase 1 Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of PF-04971729 After Administration of Single Escalating Oral Doses Under Fed and Fasted Conditions in Healthy Volunteers|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:30:45.9026|2018-06-01 00:30:45.9026
NCT00989066|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-11-26|2009-10-01|2009-10-02|Estimate|||||||2012-11-26|2012-11-27|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Observational|BRAVO||"Brazil Xience V Everolimus-Eluting Coronary Stent System Real-World Outcomes Registry"|"Brazil Xience V Everolimus-Eluting Coronary Stent System Real-World Outcomes Registry"|Completed|||535|Actual|Cardiovascular Research Center, Brazil|||||f||||t||||||||||2018-06-01 00:30:45.998131|2018-06-01 00:30:45.998131
NCT00989053|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF)|The Effect of SSRI Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing In Vitro Fertilization for Unexplained Infertility - a Prospective Placebo-Controlled Study.|Unknown status|Not yet recruiting|N/A|120|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-06-01 00:30:46.110386|2018-06-01 00:30:46.110386
NCT00989040|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2012-01-26|2009-10-01|2009-10-02|Estimate|||||||2012-01-26|2012-01-30|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Observational|||Impact of Neuropathic Post-Zosterian Pain on the Cognition|Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)|Completed|||100|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:30:46.17899|2018-06-01 00:30:46.17899
NCT00989027|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-02-19|2009-10-01|2009-10-02|Estimate|||||||2014-02-19|2014-02-20|Estimate|June 2007||2007-06-30|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Impact of Uterotonic Agents on Isolated Human Myometrium|Impact of Uterotonic Agents on Isolated Human Myometrium|Completed||N/A|56|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 00:30:46.232215|2018-06-01 00:30:46.232215
NCT00989014|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2013-09-19|2010-10-16|2013-09-19|2009-10-01|2009-10-02|Estimate|2013-09-19|2013-11-21|Estimate|2010-12-02|2010-12-06|Estimate|2013-09-19|2013-11-21|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea|Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea|Completed||Phase 2|122|Actual|Galderma||4|||f||||f||||||||||2018-06-01 00:30:46.32124|2018-06-01 00:30:46.32124
NCT00989001|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01||2014-02-06|2014-02-06|2009-10-01|2009-10-02|Estimate||||2014-02-06|2014-03-10|Estimate|2014-02-06|2014-03-10|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ACT V||A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)|A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation|Terminated||Phase 3|217|Actual|Cardiome Pharma||2|||f||||t||||||||||2018-06-01 00:30:46.626528|2018-06-01 00:30:46.626528
NCT00988988|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-08-02|2009-10-01|2009-10-02|Estimate|||||||2011-08-02|2011-08-03|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections|The Effects of Ethyl-alpha-Guanido-methyl Ethanoate on Skin Reactions Form Glatiramer Acetate|Withdrawn||Phase 4|0|Actual|University of Nebraska||3||Not approved by IRB|f||||f||||||||||2018-06-01 00:30:46.70728|2018-06-01 00:30:46.70728
NCT00988975|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Trial to Determine Which of Two Surgical Techniques Works Better to Correct Vaginal Bulging|Does Pelvicol Graft in the Posterior Compartment Offer Any Benefit to Surgical Outcomes During Laparoscopic Sacral Colpoperineopexy?|Unknown status|Recruiting|N/A|120|Anticipated|Urogynecology Associates, Indiana||2|||f||||f||||||||||2018-06-01 00:30:46.776318|2018-06-01 00:30:46.776318
NCT00988962|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-06-22|2009-10-01|2009-10-02|Estimate|||||||2011-06-22|2011-06-27|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy|Substance Abuse Treatment for High Risk Chronic Pain Patients on Opioid Therapy|Completed||N/A|84|Anticipated|Brigham and Women's Hospital||3|||f||||f||||||||||2018-06-01 00:30:46.857941|2018-06-01 00:30:46.857941
NCT00988949|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2010-01-05|2009-10-01|2009-10-02|Estimate|||||||2010-01-05|2010-01-07|Estimate|November 2009||2009-11-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release|Phase I, Randomized, Placebo Controlled Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release In Healthy Male Adult Subjects|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:30:46.935695|2018-06-01 00:30:46.935695
NCT00988936|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-08-21|2009-10-01|2009-10-02|Estimate|||||||2012-08-21|2012-08-22|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|K5-101||Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug|A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug|Completed||Phase 2|35|Actual|Siemens Molecular Imaging||1|||f||||f||||||||||2018-06-01 00:30:47.017547|2018-06-01 00:30:47.017547
NCT00988923|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||"Hyperthermia As A Conservative Treatment For Carpal Tunnel Syndrome. A Randomized Sham Controlled Trial"|"Hyperthermia As A Conservative Treatment For Carpal Tunnel Syndrome. A Randomized Sham Controlled Trial"|Completed||N/A|34|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 00:30:48.132281|2018-06-01 00:30:48.132281
NCT00988910|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2014-06-25|2009-10-01|2009-10-02|Estimate|||||||2014-06-25|2014-06-26|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|COSME||Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being|Observational Study on the Effects of DRSP-Containing Combined Oral Contraceptives (Yasmin,Yasminelle) and Other Combined Oral Contraceptives on the General and Sexual Well-Being in COC Users|Completed|||632|Actual|Bayer|||2||f||||f||||||||||2018-06-01 00:30:48.201743|2018-06-01 00:30:48.201743
NCT00988897|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2009-12-21|2009-10-01|2009-10-02|Estimate|||||||2009-12-21|2009-12-23|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Colorectal Cancer RECHALLENGE|A Phase II Study of Modified FOLFOX-6 Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer in Patients Who Have Received Oxaliplatin-based Adjuvant Chemotherapy|Withdrawn||Phase 2|0|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:30:48.275027|2018-06-01 00:30:48.275027
NCT00988884|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2014-12-12||2017-03-20|2009-10-01|2009-10-02|Estimate|2015-01-12|2015-01-13|Estimate||||2017-03-20|2017-04-17|Actual|October 1, 2009|Actual|2009-10-01|March 2017|2017-03-31|February 22, 2011|Actual|2011-02-22|February 22, 2011|Actual|2011-02-22||Interventional|||A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)|A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) Given Concomitantly With Menactra™ and Adacel™ in Preadolescents and Adolescents (11 to 15 Year Olds)|Completed||Phase 3|1241|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:30:48.385464|2018-06-01 00:30:48.385464
NCT00988871|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|PICC||Comparison of Central Venous Pressures (CVPs) Measured From Peripherally Inserted Central Catheters (PICC) and CICC in Liver Transplantation Recipients|Comparison of the Central Venous Pressures Measured From the Peripherally Inserted Antecubital Central Catheters and the Internal Jugular Vein Central Catheters in Liver Transplantation Recipients|Completed|||35|Actual|National Cancer Center, Korea|||1||f||||f||||||||||2018-06-01 00:30:49.008007|2018-06-01 00:30:49.008007
NCT00988858|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2017-07-14|2012-05-24|2017-07-14|2009-09-30|2009-10-02|Estimate|2017-07-14|2017-08-15|Actual|2012-05-24|2012-06-01|Estimate|2017-07-14|2017-08-15|Actual|November 2009||2009-11-30|July 2017|2017-07-31|November 2014|Actual|2014-11-30|July 2012|Actual|2012-07-31||Interventional|||A Study of Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|Completed||Phase 2|55|Actual|Eli Lilly and Company||1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 00:30:49.12312|2018-06-01 00:30:49.12312
NCT00988845|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2015-04-07|2009-10-01|2009-10-02|Estimate|||||||2015-04-07|2015-04-09|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|July 2010|Actual|2010-07-31||Interventional|||Indole-3-Carbinol Effects on Estrogen Metabolism|Effects of Dietary Indole-3-Carbinol on Estrogen Metabolites Across a Wide Range of Body Mass Index: Implications for the Prevention of Endometrial Cancer in Obese Women|Terminated||Phase 2|38|Actual|University of Wisconsin, Madison||1||Slow accrual in the high BMI group|f||||t||||||||||2018-06-01 00:30:49.492287|2018-06-01 00:30:49.492287
NCT00988832|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2011-12-06||2015-09-01|2009-10-01|2009-10-02|Estimate|2012-06-19|2012-07-26|Estimate||||2015-09-01|2015-09-02|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)|A UK Retrospective Audit of Patients With Crohn's Disease Treated With Infliximab|Completed|||380|Actual|Merck Sharp & Dohme Corp.|||1||f||||t||||||||||2018-06-01 00:30:49.588852|2018-06-01 00:30:49.588852
NCT00988819|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2010-02-28|2009-10-01|2009-10-02|Estimate|||||||2010-02-28|2010-03-02|Estimate|July 2009||2009-07-31|February 2010|2010-02-28||||||||Observational|SAMS-1||To Investigate the Influence of Ethnicity in Metabolic Disease in Healthy, Overweight and Obese Subjects|Developmental Pathways to Metabolic Diseases: Metabolic Physiology, Epigenetics and Body Composition in Healthy Overweight and Obese Subjects With a Fixed Range of Body Mass Index in Singapore - To Investigate the Influence of Ethnicity|Unknown status|Recruiting||200|Anticipated|National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     plasma, serum, packed cells, blood clot, urine, buccal cells, muscle tissue~   "|||2018-06-01 00:30:50.080609|2018-06-01 00:30:50.080609
NCT00988806|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-09-17|2009-09-30|2009-10-02|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2009||2009-11-30|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|LAICA||Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure|Double-blind Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of Intermittent, Long-term Administration of Levosimendan in Patients With Advanced Heart Failure|Unknown status|Enrolling by invitation|Phase 4|213|Anticipated|Hospital Universitario de Canarias||2|||f||||f||||||||||2018-06-01 00:30:50.177173|2018-06-01 00:30:50.177173
NCT00988793|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-03-27|2009-10-01|2009-10-02|Estimate|||||||2012-03-27|2012-03-28|Estimate||||March 2012|2012-03-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Laparoscopic Versus Open Pancreatectomy|Randomized Trial of Laparoscopic Versus Open Distal Pancreatectomy in Patients With Pancreatic Disease|Terminated||N/A|128|Anticipated|Indiana University||2||Protocol needed major revisions; lack of money to institute changes|f||||t||||||||||2018-06-01 00:30:50.252273|2018-06-01 00:30:50.252273
NCT00988780|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-11-22|2009-10-01|2009-10-02|Estimate|||||||2012-11-22|2012-11-27|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|CADIRIS||Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients|CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients|Unknown status|Active, not recruiting|N/A|276|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-06-01 00:30:50.335726|2018-06-01 00:30:50.335726
NCT00988767|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-02|2009-10-01|2009-10-02|Estimate|||||||2009-10-02|2009-10-05|Estimate|February 2001||2001-02-28|October 2009|2009-10-31|October 2004|Actual|2004-10-31|November 2003|Actual|2003-11-30||Interventional|RBM99026||Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B|Specific Vaccine Therapy in Chronic Hepatitis B Using a Naked DNA: Phase I Study Using a GMO|Completed||Phase 1|10|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-06-01 00:30:50.495368|2018-06-01 00:30:50.495368
NCT00988754|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2017-10-12|2009-10-01|2009-10-02|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2008||2008-07-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|JuvenTUM 3||School Based Health Promotion Program in Secondary Schools|School Children and Adolescents as Health Experts - Step 3|Completed||N/A|595|Actual|Technische Universität München||2|||f||||f||||||||||2018-06-01 00:30:50.602454|2018-06-01 00:30:50.602454
NCT00988741|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30||2013-02-21|2013-02-22|2009-10-01|2009-10-02|Estimate||||2013-02-21|2013-02-25|Estimate|2013-02-22|2013-02-28|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy|A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy|Completed||Phase 2|107|Actual|ArQule||2|||f||||f||||||||||2018-06-01 00:30:50.717506|2018-06-01 00:30:50.717506
NCT00988728|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2015-12-16|2009-10-01|2009-10-02|Estimate|||||||2015-12-16|2015-12-17|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|GUEST||Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)|A Multicenter, Randomized, Parallel-Group, Double-blind, Fixed-Dose, 28-Day Trial to Assess the Efficacy and Safety of SCH 900435 Compared With Placebo, Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia (GUEST - Glycine Uptake Inhibitor Efficacy and Safety Trial, Phase 2, Protocol No. P06079)|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 00:30:50.825764|2018-06-01 00:30:50.825764
NCT00988715|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2017-08-28|2009-10-01|2009-10-02|Estimate|||||||2017-08-28|2017-08-30|Actual|April 21, 2010|Actual|2010-04-21|August 2017|2017-08-31||||January 2015|Actual|2015-01-31||Interventional|||Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome|Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate|Completed||Phase 1|17|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 00:30:50.897324|2018-06-01 00:30:50.897324
NCT00988702|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|October 2008||2008-10-31|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Shaolin Dan Tian Breathing Fosters Relaxed and Attentive Mind|Shaolin Dan Tian Breathing Fosters Relaxed and Attentive Mind: A Randomized Controlled Neuroelectrophysiological Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|100|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-06-01 00:30:51.013396|2018-06-01 00:30:51.013396
NCT00988689|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-09-30|2009-09-30|2009-10-02|Estimate|||||||2009-09-30|2009-10-02|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake|The Effect of Different Types of Starch on Glycemic Response, Subjective Appetite and Short-term Food Intake in Young Men|Completed||N/A|16|Actual|University of Toronto||5|||f||||t||||||||||2018-06-01 00:30:51.081116|2018-06-01 00:30:51.081116
NCT00988676|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2010-04-19|2009-10-01|2009-10-02|Estimate|||||||2010-04-19|2010-04-20|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Observational|||The Effect of Bowel Preparation Status on the Polyp Missing Rate|The Effect of Bowel Preparation Status on the Polyp Missing Rate During Colonoscopy: Prospective Study Using Tandem Colonoscopic Evaluation|Completed|||200|Actual|Konkuk University Hospital|||1||f||||t||||||||||2018-06-01 00:30:51.162509|2018-06-01 00:30:51.162509
NCT00988663|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2017-03-21|2009-10-01|2009-10-02|Estimate|||||||2017-03-21|2017-03-24|Actual|November 2009|Actual|2009-11-30|March 2017|2017-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|ECTAug||The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?|Memantine Augmentation of Electroconvulsive Therapy in Patients With Major Depression|Withdrawn||N/A|0|Actual|University of Iowa||2||PI deceased; study did not start.|f||||t||||||||||2018-06-01 00:30:51.219609|2018-06-01 00:30:51.219609
NCT00988650|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2013-03-04|2009-10-01|2009-10-02|Estimate|||||||2013-03-04|2013-03-05|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MedDiet||Mediterranean Diet and the Metabolic Syndrome|Mechanistic Investigation of the Mediterranean Diet and Its Impact on the Metabolic Syndrome in Men|Completed||N/A|26|Actual|Laval University||4|||f||||f||||||||||2018-06-01 00:30:51.29851|2018-06-01 00:30:51.29851
NCT00988637|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2011-03-30||2012-09-21|2009-10-01|2009-10-02|Estimate|2011-05-05|2011-06-03|Estimate||||2012-09-21|2012-10-02|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluate Safety/Efficacy of Two Treatment Regimens for Vectical™ Ointment & Clobex® Spray for Moderate Plaque Psoriasis|An Open-label, Multi-center, Randomized, Evaluator-Blinded Study to Evaluate the Safety and Efficacy of Two Treatment Regimens Involving Vectical™ (Calcitriol) Ointment 3 µg/g and Clobex® (Clobetasol Propionate) Spray, 0.05% in the Treatment of Moderate Plaque Psoriasis|Completed||Phase 4|138|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 00:30:51.402777|2018-06-01 00:30:51.402777
NCT00988624|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2010-01-11|2009-10-01|2009-10-02|Estimate|||||||2010-01-11|2010-01-12|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)|A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)|Completed||Phase 1|20|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 00:30:51.986786|2018-06-01 00:30:51.986786
NCT00988611|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2017-03-16|2009-10-01|2009-10-02|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2009|Actual|2009-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ART||Assisted Reproductive Technology (ART) Predictors Study|Novel Predictors of ART Outcomes|Completed|||138|Actual|University of Oklahoma|||||f||||f||||||Samples With DNA|"~     Telomere length assay~   "|||2018-06-01 00:30:52.082361|2018-06-01 00:30:52.082361
NCT00988598|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2010-08-05|2009-10-01|2009-10-02|Estimate|||||||2010-08-05|2010-08-09|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease|A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Mild To Moderate Alzheimer's Disease Subjects On Stable Donepezil Therapy|Completed||Phase 1|15|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:30:52.157509|2018-06-01 00:30:52.157509
NCT00988585|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-06-22|2009-10-01|2009-10-02|Estimate|||||||2011-06-22|2011-06-23|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|EPA||Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil|Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil|Completed||Phase 1|120|Anticipated|Cardiovascular Research Associates||4|||f||||f||||||||||2018-06-01 00:30:52.252381|2018-06-01 00:30:52.252381
NCT00988559|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2016-03-08|2009-10-01|2009-10-02|Estimate|||||||2016-03-08|2016-03-10|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|||Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)|A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)|Unknown status|Recruiting|N/A|39|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4|||f||||t||||||||No||2018-06-01 00:30:52.436585|2018-06-01 00:30:52.436585
NCT00988546|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|May 2005||2005-05-31|October 2009|2009-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Evaluation of Computerized Template Entry for Compensation and Pension (C&P) Examinations|Evaluation of Computerized Template Entry for C&P Examinations|Completed||N/A|37|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:30:52.562273|2018-06-01 00:30:52.562273
NCT00988533|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2012-03-01||2012-03-30|2009-10-01|2009-10-02|Estimate|2012-03-30|2012-04-25|Estimate||||2012-03-30|2012-04-25|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age|An Open-label Study to Assess the Bioavailability, Safety, Local Tolerance, and Efficacy of 0.5% Ivermectin Cream in Subjects 6 Months to 3 Years of Age With Pediculus Humanus Capitis (Head Lice) Infestation|Completed||Phase 1|30|Actual|Topaz Pharmaceuticals Inc||1|||f||||f||||||||||2018-06-01 00:30:52.667746|2018-06-01 00:30:52.667746
NCT00988520|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2015-05-11|2009-10-01|2009-10-02|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2003||2003-05-31|May 2015|2015-05-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)|Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 Following a Single Intubating Dose in Adult Patients Undergoing Operation Under Sevoflurane or Propofol Anesthesia.|Completed||Phase 3|38|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-06-01 00:30:52.99297|2018-06-01 00:30:52.99297
NCT00988507|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2011-06-27|2009-10-01|2009-10-02|Estimate|||||||2011-06-27|2011-06-28|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|FARM||Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|Parallel Group, Double-blind, Randomized Study Assessing the Efficacy, Safety and Pharmacokinetic Profiles of Ferroquine Associated With Artesunate and a Single-blind Dose Level of Ferroquine Alone in a 3-day Treatment of Uncomplicated Malaria Due to Plasmodium Falciparum in an Immune Symptomatic African Adult and Pediatric Population.|Terminated||Phase 2|440|Anticipated|Sanofi||4||"Company decision to modify the ferroquine development strategy; discontinuation not due to~   safety or activity unexpected findings"|f||||t||||||||||2018-06-01 00:30:53.081358|2018-06-01 00:30:53.081358
NCT00988494|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2012-11-21|2009-10-01|2009-10-02|Estimate|||||||2012-11-21|2012-11-22|Estimate|September 2009||2009-09-30|November 2012|2012-11-30||||||||Interventional|||Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect|Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect|Completed||Phase 2|45|Anticipated|Santen Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-06-01 00:30:53.164375|2018-06-01 00:30:53.164375
NCT00988481|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2015-07-13|2009-10-01|2009-10-02|Estimate|||||||2015-07-13|2015-07-15|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Interventional|||Topiramate Augmentation in Bulimia Nervosa Partial Responders|Topiramate Augmentation in Bulimia Nervosa Partial Responders|Withdrawn||Phase 4|0|Actual|Neuropsychiatric Research Institute, Fargo, North Dakota||||Difficulty with enrollment.|f||||f||||||||||2018-06-01 00:30:53.232184|2018-06-01 00:30:53.232184
NCT00988468|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2010-11-15|2009-10-01|2009-10-02|Estimate|||||||2010-11-15|2010-11-16|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Manual Therapy Versus Exercise on Knee Osteoarthritis|Effects of Manual Therapy Versus Therapeutic Exercise on Knee Osteoarthritis: A Randomized Control Trial|Terminated||Phase 2|1|Actual|Texas Tech University Health Sciences Center||3||Study failed to recruit a sufficient number of subjects in the time anticipated.|f||||f||||||||||2018-06-01 00:30:53.304605|2018-06-01 00:30:53.304605
NCT00988455|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up||Completed||Phase 1/Phase 2|28|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-06-01 00:30:53.374501|2018-06-01 00:30:53.374501
NCT00988442|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2017-02-13||2017-04-17|2009-10-01|2009-10-02|Estimate|2017-04-17|2017-07-17|Actual||||2017-04-17|2017-07-17|Actual|October 2010|Actual|2010-10-31|April 2017|2017-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All participants enrolled in the study.|Telephone Support to Improve Adherence to Anti-HIV Medications|A Randomized Trial of Enhanced Nursing Telephone Support to Improve Medication Self-Management and Viral Outcomes of Antiretroviral Therapy-Experienced Patients|Terminated||Phase 2|59|Actual|AIDS Clinical Trials Group|This study was closed to recruitment and follow-up early due to slow enrollment.|2||This study was closed to recruitment and follow-up early due to low recruitment.|f||||t||||||||||2018-06-01 00:30:53.459564|2018-06-01 00:30:53.459564
NCT00988429|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2013-12-03||2016-12-20|2009-10-01|2009-10-02|Estimate|2014-03-10|2014-04-15|Estimate||||2016-12-20|2017-02-09|Estimate|December 2008||2008-12-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|January 2012|Actual|2012-01-31||Interventional||Data Sets Analyzed: Safety Population (all randomized subjects who received at least one dose of study drug after randomization)|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial|Active, not recruiting||Phase 3|653|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-06-01 00:30:54.581062|2018-06-01 00:30:54.581062
NCT00988416|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2016-07-11|2009-10-01|2009-10-02|Estimate|||||||2016-07-11|2016-07-13|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Positron Emission Tomography-computed Tomography (PET-CT) for Main & Branch Intraductal Papillary Mucinous Neoplasm|PET-CT for Intraductal Papillary Mucinous Neoplasm (IPMN)|Completed|||69|Actual|Indiana University|||||f||||t||||||||||2018-06-01 00:30:55.447646|2018-06-01 00:30:55.447646
NCT00988403|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-07-11|2009-10-01|2009-10-02|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2009||2009-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Investigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Dose Response Study|Investigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Randomized, Double-Blind Dose Response Study|Active, not recruiting||N/A|19|Actual|Augusta University||4|||f||||f||||||||||2018-06-01 00:30:55.499373|2018-06-01 00:30:55.499373
NCT00988377|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|May 2007||2007-05-31|October 2009|2009-10-31|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||The Effect of Whey Protein on Short-Term Food Intake and Post-Meal Blood Glucose Response in Young Men|The Effect of Whey Protein on Short-term Food Intake and Post-meal Blood Glucose Response in Young Men|Completed||N/A|16|Actual|University of Toronto||5|||f||||t||||||||||2018-06-01 00:30:55.634006|2018-06-01 00:30:55.634006
NCT00988364|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-05|2009-10-01|2009-10-02|Estimate|||||||2009-10-05|2009-10-06|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|July 2010|Anticipated|2010-07-31|April 2010|Anticipated|2010-04-30||Interventional|||Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.|Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome|Unknown status|Not yet recruiting|Phase 4|24|Anticipated|Baylor College of Medicine||4|||f||||t||||||||||2018-06-01 00:30:55.69579|2018-06-01 00:30:55.69579
NCT00988351|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2014-03-23||2014-10-30|2009-10-01|2009-10-02|Estimate|2014-10-30|2014-11-03|Estimate||||2014-10-30|2014-11-03|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Apnea+hypopnea index >= 10/hour|Continuous Positive Airway Pressure (PAP) Titration and Treatment Versus Auto-adjusting PAP Treatment for Sleep Apnea|Portable Monitoring and APAP Treatment for Diagnosis and Treatment of OSA|Completed||N/A|156|Actual|North Florida Foundation for Research and Education|Carefully selected group with male predominance|2|||f||||f||||||||||2018-06-01 00:30:55.785006|2018-06-01 00:30:55.785006
NCT00988338|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2014-04-07|2009-10-01|2009-10-02|Estimate|||||||2014-04-07|2014-04-08|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|TAF||Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion|A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells (Trinity Evolution Matrix) in Subjects Undergoing Foot and Ankle Fusion|Completed||N/A|106|Actual|Orthofix Inc.||1|||f||||f||||||||||2018-06-01 00:30:56.211327|2018-06-01 00:30:56.211327
NCT00988325|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2016-02-18||2017-01-30|2009-09-30|2009-10-02|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|January 2011||2011-01-31|January 2017|2017-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Safety population included all treated participants with at least one post-baseline safety assessment (vital sings like temperature, respiratory rate, blood pressure, pulse rate).|A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection|An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to <12 Months of Age With Confirmed Influenza Infection|Completed||Phase 1|65|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:30:56.315894|2018-06-01 00:30:56.315894
NCT00988312|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate|March 2002||2002-03-31|October 2009|2009-10-31|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|||Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma|Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma|Completed||Phase 1|9|Actual|University Hospital Carl Gustav Carus||2|||f||||f||||||||||2018-06-01 00:30:56.972281|2018-06-01 00:30:56.972281
NCT00988299|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2011-12-02|2009-10-01|2009-10-02|Estimate|||||||2011-12-02|2011-12-06|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CEE||Energy Expenditure Responses to Acute Exercise in Older Women (Calorie Expenditure and Exercise)|Energy Expenditure Responses to Acute Exercise in Older Women|Completed||N/A|26|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 00:30:57.047667|2018-06-01 00:30:57.047667
NCT00988286|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-07-11|2009-10-01|2009-10-02|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2005|Actual|2005-08-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Mechanism of Action of Biofeedback Therapy|Mechanism of Action of Biofeedback Therapy|Completed||N/A|50|Actual|Augusta University||1|||f||||f||||||||||2018-06-01 00:30:57.109556|2018-06-01 00:30:57.109556
NCT00988273|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2012-04-27|2009-10-01|2009-10-02|Estimate|||||||2012-04-27|2012-05-01|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||Confocal Endomicroscopy During Endoscopy|Confocal Endomicroscopy in Patients Undergoing Endoscopy|Unknown status|Recruiting||400|Anticipated|University of Alberta|||2||f||||f||||||Samples Without DNA|"~     Biopsy samples~   "|||2018-06-01 00:30:57.172989|2018-06-01 00:30:57.172989
NCT00988260|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2017-06-02|2009-10-01|2009-10-02|Estimate|||||||2017-06-02|2017-06-05|Actual|February 3, 2003|Actual|2003-02-03|June 2017|2017-06-30|April 12, 2004|Actual|2004-04-12|April 12, 2004|Actual|2004-04-12||Interventional|||Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)|A Phase II Bridging Trial of Org 37462|Completed||Phase 2|266|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 00:30:57.24432|2018-06-01 00:30:57.24432
NCT00988247|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2012-04-23|2011-08-25|2012-04-23|2009-10-01|2009-10-02|Estimate|2012-04-23|2012-05-23|Estimate|2011-08-25|2011-08-29|Estimate|2012-04-23|2012-05-23|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 Mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|529|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 00:30:57.344377|2018-06-01 00:30:57.344377
NCT00988234|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|||2011-02-16|2009-10-01|2009-10-02|Estimate|||||||2011-02-16|2011-02-17|Estimate|April 2009||2009-04-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Two Position for Ultrasound Guided Lumbar Plexus and Sciatic Nerve Block|Comparison of Lateral Decubitus Position Versus Prone Position for Ultrasound Guided Posterior Lumbar Plexus Block and Sciatic Nerve Block|Completed||N/A|200|Anticipated|Huazhong University of Science and Technology||4|||f||||t||||||||||2018-06-01 00:30:57.786989|2018-06-01 00:30:57.786989
NCT00988221|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2012-08-29||2017-06-27|2009-10-01|2009-10-02|Estimate|2012-10-03|2012-11-01|Estimate||||2017-06-27|2017-07-26|Actual|November 30, 2009|Actual|2009-11-30|June 2017|2017-06-30|January 28, 2013|Actual|2013-01-28|November 30, 2011|Actual|2011-11-30||Interventional|||A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis|A 24 Week Randomized, Double-blind, Placebo-controlled Withdrawal Trial With a 16 Week Open-label lead-in Phase, and 64 Week Open-label Follow-up, to Evaluate the Effect on Clinical Response and the Safety of Tocilizumab in Patients With Active Polyarticular-course Juvenile Idiopathic Arthritis|Completed||Phase 3|188|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 00:30:57.928942|2018-06-01 00:30:57.928942
NCT00988208|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2013-06-27||2018-03-09|2009-10-01|2009-10-02|Estimate|2013-06-27|2013-09-05|Estimate||||2018-03-09|2018-04-04|Estimate|November 11, 2009|Actual|2009-11-11|March 2018|2018-03-31|November 28, 2016|Actual|2016-11-28|January 13, 2012|Actual|2012-01-13||Interventional|Mainsail|Includes those from the Intent to Treat population (ITT). The ITT population is defined as all participants who were randomized, independent of whether they received study treatment or not.|Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer|A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)|Completed||Phase 3|1059|Actual|Celgene|The independent DMC concluded that it was unlikely the trial would achieve its primary endpoint of improved overall survival. The sponsor agreed and the experimental lenalidomide/placebo treatment arm of the study was discontinued.|2|||f||||t||||||||||2018-06-01 00:31:00.370024|2018-06-01 00:31:00.370024
NCT00988195|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2012-03-13|2009-09-30|2009-10-02|Estimate|||||||2012-03-13|2012-03-14|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Pegylated Human Recombinant Arginase for Liver Cancer|Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC): An Adaptive Design Dose Escalation Trial With Addition of Standard Doxorubicin Treatment|Completed||Phase 1|15|Actual|Bio-Cancer Treatment International Limited||1|||f||||t||||||||||2018-06-01 00:31:03.362817|2018-06-01 00:31:03.362817
NCT00988182|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-10-01|2009-10-01|2009-10-02|Estimate|||||||2009-10-01|2009-10-02|Estimate||||October 2009|2009-10-31||||||||Interventional|||The Effect of Whey Protein and Its Hydrolysate on Pre- and Post-Fixed Meal Glycemia and Insulin in Young Adults|The Effect of Whey Protein and Its Hydrolysate on Pre- and Post-Fixed Meal Glycemia and Insulin in Young Adults|Completed||N/A|22|Actual|University of Toronto||5|||f||||t||||||||||2018-06-01 00:31:03.459251|2018-06-01 00:31:03.459251
NCT00988169|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2015-10-19||2015-10-19|2009-10-01|2009-10-02|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations|A Phase II Trial of Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Activating Mutations|Terminated||Phase 2|6|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:31:03.548386|2018-06-01 00:31:03.548386
NCT00988156|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2014-05-09||2017-08-23|2009-10-01|2009-10-02|Estimate|2014-07-16|2014-07-17|Estimate||||2017-08-23|2017-09-20|Actual|December 2007|Actual|2007-12-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 20, 2012|Actual|2012-08-20||Interventional|||Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children|Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children|Active, not recruiting||Phase 3|304|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-06-01 00:31:03.738138|2018-06-01 00:31:03.738138
NCT00988143|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-01|2013-07-03|2011-01-03|2013-11-18|2009-10-01|2009-10-02|Estimate|2013-11-18|2013-12-12|Estimate|2011-01-03|2011-01-05|Estimate|2013-11-18|2013-12-12|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Influenza Virus Vaccines in Children and Adults|Immunogenicity and Safety Among Children and Adults of the 2009-2010 Trivalent Influenza Vaccine, 2008-2009 Trivalent Influenza Vaccine, and Quadrivalent Influenza Vaccine (Intramuscular Route)|Completed||Phase 2|600|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 00:31:04.393077|2018-06-01 00:31:04.393077
NCT00988130|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2013-08-23|2009-09-30|2009-10-01|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2009||2009-07-31|May 2011|2011-05-31||||||||Interventional|||High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate Cancer|HIFU Lesion Control in Patients With Non-metastatic Progressive Prostate Cancer|Unknown status|Recruiting|Phase 2|26|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:31:05.154653|2018-06-01 00:31:05.154653
NCT00988117|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2013-07-28||2014-01-24|2009-09-30|2009-10-01|Estimate|2014-01-24|2014-02-26|Estimate||||2014-01-24|2014-02-26|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems|The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD)|Completed||Phase 4|15|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:31:05.255866|2018-06-01 00:31:05.255866
NCT00988104|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-01-19|2009-09-30|2009-10-01|Estimate|||||||2017-01-19|2017-01-23|Estimate|October 16, 2007|Actual|2007-10-16|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|October 15, 2018|Anticipated|2018-10-15||Interventional|SMART||Preventing Long Term Psychiatric Disability Among Those With Major Burn Injuries|Preventing Long Term Psychiatric Disability Among Those With Major Burn Injuries: the Safety, Meaning, Activation and Resilience Trial (SMART)|Active, not recruiting||N/A|130|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 00:31:05.503427|2018-06-01 00:31:05.503427
NCT00988091|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2012-05-02||2012-06-13|2009-09-30|2009-10-01|Estimate|2012-05-02|2012-06-04|Estimate||||2012-06-13|2012-06-15|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee|A 26 Week, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Single Intra-Articular Injection 1.2% Sodium Hyaluronate for Treatment of Painful Osteoarthritis of the Knee, With Optional 26-Week Open-Label Safety Extension|Completed||Phase 3|596|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:31:05.629778|2018-06-01 00:31:05.629778
NCT00988078|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2012-06-24|2009-09-30|2009-10-01|Estimate|||||||2012-06-24|2012-06-26|Estimate|July 2011||2011-07-31|October 2009|2009-10-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Effects of Metformin and Oral Hormonal Contraceptive in Adolescents With Polycystic Ovary Syndrome|Effect of Metformin Therapy on Insulin Resistance and Melatonin in Adolescents With Polycystic Ovary Syndrome.|Unknown status|Recruiting|N/A|90|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 00:31:06.252779|2018-06-01 00:31:06.252779
NCT00988065|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2011-04-13||2015-04-07|2009-09-30|2009-10-01|Estimate|2011-06-10|2011-07-11|Estimate||||2015-04-07|2015-04-29|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Sugammadex Hypersensitivity Study (Study P06042)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administrations of Sugammadex (SCH 900616) in Healthy Subjects|Completed||Phase 1|448|Actual|Merck Sharp & Dohme Corp.|Results from this study in healthy/conscious subjects may not be fully applicable to anesthetized patient settings.|3|||f||||t||||||||||2018-06-01 00:31:06.368935|2018-06-01 00:31:06.368935
NCT00988052|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2017-09-13|2009-09-30|2009-10-01|Estimate|||||||2017-09-13|2017-09-14|Actual|November 30, 2009|Actual|2009-11-30|September 2017|2017-09-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course|A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis|Terminated||Phase 3|472|Actual|Teva Pharmaceutical Industries||1||"Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the~   study drug in the relevant dose."|f||||t|t|f||||||||2018-06-01 00:31:06.814631|2018-06-01 00:31:06.814631
NCT00988039|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2014-04-03|2009-09-30|2009-10-01|Estimate|||||||2014-04-03|2014-04-04|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|EARNEST||Europe-Africa Research Network for Evaluation of Second-line Therapy|A Randomised Controlled Trial to Evaluate Options for Second-line Therapy in Patients Failing a First-line 2NRTI + NNRTI Regimen in Africa|Completed||Phase 3|1277|Actual|Medical Research Council||3|||f||||t||||||||||2018-06-01 00:31:07.044859|2018-06-01 00:31:07.044859
NCT00988026|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-09-30|2009-09-30|2009-10-01|Estimate|||||||2009-09-30|2009-10-01|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|April 2010|Anticipated|2010-04-30|February 2010|Anticipated|2010-02-28||Interventional|MXMIN-001||Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne|Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks|Unknown status|Recruiting|Phase 4|168|Anticipated|Darier||2|||f||||t||||||||||2018-06-01 00:31:07.15057|2018-06-01 00:31:07.15057
NCT00988013|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2016-10-24|2009-09-30|2009-10-01|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|IM-TMI||Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies|A Phase I Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies|Active, not recruiting||Phase 1|24|Anticipated|University of Illinois at Chicago||4|||f||||t||||||||||2018-06-01 00:31:07.231625|2018-06-01 00:31:07.231625
NCT00988000|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2015-06-03|2009-09-30|2009-10-01|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Initial Specialist Telephone Consultation With New Patients in Secondary Care|Telephone Consultations for New Patients Being Referred to a Specialist Respiratory Outpatient Clinic|Completed||N/A|100|Actual|Imperial College London||1|||f||||f||||||||||2018-06-01 00:31:07.328268|2018-06-01 00:31:07.328268
NCT00987987|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-01-21|2009-09-30|2009-10-01|Estimate|||||||2011-01-21|2011-01-24|Estimate|December 2005||2005-12-31|September 2009|2009-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ILD-Treg||Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion|Amplifying Graft-versus-tumor Effect by Donor Regulatory T-cell Depletion Before Donor Lymphocytes Infusion: a Phase I/II Clinical Study|Completed||Phase 1/Phase 2|21|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:31:07.405199|2018-06-01 00:31:07.405199
NCT00987974|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2010-04-27|2009-09-30|2009-10-01|Estimate|||||||2010-04-27|2010-04-28|Estimate|September 2009||2009-09-30|April 2001|2001-04-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury|Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury|Completed||Phase 4|48|Anticipated|Radboud University||6|||f||||f||||||||||2018-06-01 00:31:07.494176|2018-06-01 00:31:07.494176
NCT00987961|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2015-11-10|2009-09-30|2009-10-01|Estimate|||||||2015-11-10|2015-11-11|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional|||Linking Hospitalized Injection Drug Users to Buprenorphine|Linking Hospitalized Injection Drug Users to Buprenorphine|Completed||Phase 3|147|Actual|Butler Hospital||2|||f||||f||||||||||2018-06-01 00:31:07.581673|2018-06-01 00:31:07.581673
NCT00987948|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2015-01-20||2017-02-01|2009-09-30|2009-10-01|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|January 2010||2010-01-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|November 2012|Actual|2012-11-30||Interventional|||Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels|Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA|Completed||Phase 2|15|Actual|University of Hawaii||1|||f||||f||||||||||2018-06-01 00:31:07.670178|2018-06-01 00:31:07.670178
NCT00987935|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2015-06-03||2016-02-09|2009-09-30|2009-10-01|Estimate|2015-07-31|2015-08-27|Estimate||||2016-02-09|2016-03-10|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|July 2014|Actual|2014-07-31||Interventional||Treated set (TS): Treated set included all patients who received at least one dose of trial medication|A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients|A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.|Completed||Phase 2|134|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:31:07.960973|2018-06-01 00:31:07.960973
NCT00987922|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-09-17|2009-09-30|2009-10-01|Estimate|||||||2011-09-17|2011-09-20|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Mild Hypothermia in Acute Ischemic Stroke|Mild Hypothermia in Acute Ischemic Stroke After Thrombolytic Therapy: a Prospective,Open,Randomized,Single-center,Safety and Feasibility Study|Completed||Phase 2|36|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 00:31:10.284924|2018-06-01 00:31:10.284924
NCT00987909|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2010-08-17|2009-09-30|2009-10-01|Estimate|||||||2010-08-17|2010-08-18|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Exposure Chamber Trial With Cat Immunotherapy|A Phase II Trial Assessing the Tolerability and Pharmacodynamic Effect of US SLIT Cat Hair in Subject With Cat Allergy and Investigating Efficacy Variables in an Environmental Exposure Chamber Model|Completed||Phase 2|60|Anticipated|ALK-Abelló A/S||4|||f||||t||||||||||2018-06-01 00:31:10.344224|2018-06-01 00:31:10.344224
NCT00987896|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-09-30|2009-09-30|2009-10-01|Estimate|||||||2009-09-30|2009-10-01|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Megachannel Device for Advanced Colonoscopy|A Novel Endoscopic Device (Megachannel™) For Repeated Right Colonic Access During Colonoscopy|Completed||Phase 2|41|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-06-01 00:31:10.415097|2018-06-01 00:31:10.415097
NCT00987883|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-09-30|2009-09-30|2009-10-01|Estimate|||||||2009-09-30|2009-10-01|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||The Impact of Perioperational Malnutrition on the Cost on Gastroenterological Cancer Patients|Malnutrition and Its Impact on the Perioperational Hospitalization Cost: A Prospective, Cohort Study on Gastroenterological Cancer Patients|Unknown status|Recruiting||200|Anticipated|Peking Union Medical College Hospital|||2||f||||t||||||||||2018-06-01 00:31:10.528683|2018-06-01 00:31:10.528683
NCT00987870|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-03-25|2009-09-30|2009-10-01|Estimate|||||||2011-03-25|2011-03-28|Estimate|September 2009||2009-09-30|March 2011|2011-03-31||||February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy of BFH772 in Psoriasis Patients|A Proof of Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Topical Administrations of BFH772 in Patients With Psoriasis.|Completed||Phase 1/Phase 2|15|Actual|Novartis||5|||f||||||||||||||2018-06-01 00:31:10.59657|2018-06-01 00:31:10.59657
NCT00987857|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-08-17|2009-09-30|2009-10-01|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2009||2009-03-31|August 2017|2017-08-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus|Barrett's Oesophagus Two Yearly Surveillance Versus Endoscopy at Need: a Randomised Controlled Trial to Estimate Effectiveness and Cost-effectiveness Study (BOSS)|Active, not recruiting||N/A|3400|Actual|Gloucestershire Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:31:10.674053|2018-06-01 00:31:10.674053
NCT00987844|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-30|2009-09-30|2009-10-01|Estimate|||||||2009-09-30|2009-10-01|Estimate|July 1998||1998-07-31|September 2009|2009-09-30||||November 2000|Actual|2000-11-30||Interventional|||Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation|A Study to Evaluate the Long-Term Tolerability, Safety, Patient Satisfaction, Pharmacokinetics, and Use Patterns of Oral Prucalopride Tablets in Patients With Chronic Constipation|Completed||Phase 3|1775|Actual|Movetis|||||f||||f||||||||||2018-06-01 00:31:10.822433|2018-06-01 00:31:10.822433
NCT00987831|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2013-08-28||2014-10-17|2009-09-30|2009-10-01|Estimate|2014-10-17|2014-10-20|Estimate||||2014-10-17|2014-10-20|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BOLD||Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)|Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity|Completed||Phase 1/Phase 2|158|Actual|Oklahoma Medical Research Foundation||3|||f||||t||||||||||2018-06-01 00:31:10.884527|2018-06-01 00:31:10.884527
NCT00987818|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2015-08-31|2009-09-30|2009-10-01|Estimate|||||||2015-08-31|2015-09-02|Estimate||||December 2012|2012-12-31||||||||Interventional|||Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU|Reduction of Antibiotic Use in the ICU: Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU|Withdrawn||N/A|0|Actual|Rijnstate Hospital||2||No MEC approval|f||||f||||||||||2018-06-01 00:31:11.200482|2018-06-01 00:31:11.200482
NCT00987805|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2012-06-20|2009-09-30|2009-10-01|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Banhasasim-tang on Functional Dyspepsia|Efficacy of Banhasasim-tang on Functional Dyspepsia : a Randomized, Double Blind, Placebo Controlled, Two-center Trial|Completed||Phase 4|84|Actual|Korea Health Industry Development Institute||2|||f||||t||||||||||2018-06-01 00:31:11.27363|2018-06-01 00:31:11.27363
NCT00987792|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2015-08-06|2009-09-30|2009-10-01|Estimate|||||||2015-08-06|2015-08-07|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|October 2012|Actual|2012-10-31|June 2011|Actual|2011-06-30||Observational|||CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients|CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients|Completed|||2595|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:31:11.34974|2018-06-01 00:31:11.34974
NCT00987779|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2010-09-15|2009-09-30|2009-10-01|Estimate|||||||2010-09-15|2010-09-16|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Bioequivalence Study Of Gabapentin Between Tablet And Liquid Formulation And The Food Effect Study Of Liquid Formulation|An Open, Randomized, Crossover Study In Healthy Subjects To Assess The Bioequivalence Of Gabapentin Between Japanese Commercial Tablet And Japanese Commercial Image Liquid Formulation And The Effect Of Food On The Pharmacokinetics Of Japanese Commercial Image Liquid Formulation|Completed||Phase 1|26|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:31:11.47393|2018-06-01 00:31:11.47393
NCT00987766|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-06-29|2009-09-30|2009-10-01|Estimate|||||||2017-06-29|2017-07-02|Actual|November 2009||2009-11-30|June 2017|2017-06-30|October 2016|Actual|2016-10-31|July 2013|Actual|2013-07-31||Interventional|||Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer|Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer.|Completed||Phase 1|28|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 00:31:11.554547|2018-06-01 00:31:11.554547
NCT00987753|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2010-06-25|2009-09-30|2009-10-01|Estimate|||||||2010-06-25|2010-06-28|Estimate|March 1999||1999-03-31|June 2010|2010-06-30|November 2001|Actual|2001-11-30|September 2000|Actual|2000-09-30||Interventional|||Study Evaluating the Safety and Tolerability of L-377202|A PhaseI/II Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of L-377202 Administered Once Every 3 Weeks|Completed||Phase 1/Phase 2|13|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 00:31:11.659557|2018-06-01 00:31:11.659557
NCT00987740|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-08-09|2009-09-30|2009-10-01|Estimate|||||||2017-08-09|2017-08-10|Actual|October 2009||2009-10-31|August 2017|2017-08-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Feasibility Study of the Hemolung Respiratory Assist System|A Prospective, Non-Randomized Feasibility Study of the Hemolung Respiratory Assist System in COPD Patients With Acute Respiratory Failure That Are at a 50% Risk of Failing Non Invasive Ventilation (NIV)|Completed||N/A|2|Actual|Alung Technologies||1|||f||||t|f|t|t|f|t|||||2018-06-01 00:31:11.721654|2018-06-01 00:31:11.721654
NCT00987727|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2011-08-17||2011-08-17|2009-09-30|2009-10-01|Estimate|2011-08-17|2011-09-21|Estimate||||2011-08-17|2011-09-21|Estimate|November 2009||2009-11-30|August 2011|2011-08-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye|Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye|Completed||Phase 4|82|Actual|Allergan||2|||f||||f||||||||||2018-06-01 00:31:11.787752|2018-06-01 00:31:11.787752
NCT00987714|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2018-04-03|2009-09-30|2009-10-01|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2009||2009-08-31|April 2018|2018-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|MOnIToR||Monitoring Organ Donors to Increase Transplantation Results (MOnIToR)|Monitoring Organ Donors to Increase Transplantation Results|Completed||N/A|556|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:31:12.291789|2018-06-01 00:31:12.291789
NCT00987701|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-07-26|2009-09-30|2009-10-01|Estimate|||||||2011-07-26|2011-07-27|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PAFUMIN||Perineuraxial Anesthesia Fluid Management and Infant Neurobehaviors|Correlation Between Perineuraxial Anesthesia Fluid Resuscitation in Cesarean Section and Infant Neurobehaviors|Completed||N/A|5000|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 00:31:12.392809|2018-06-01 00:31:12.392809
NCT00987688|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-09-19|2009-09-30|2009-10-01|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2010|Actual|2010-04-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|POLAR-RCT||The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury|Multi-centre Randomised Trial to Evaluate the Effect of Early Hypothermia on Neurological Function in Patients With Severe Traumatic Brain Injury. Including Renal Sub Study|Recruiting||N/A|510|Anticipated|Australian and New Zealand Intensive Care Research Centre||2|||f||||t||||||||Undecided||2018-06-01 00:31:12.48358|2018-06-01 00:31:12.48358
NCT00987675|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2013-08-23|2009-09-30|2009-10-01|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2009||2009-07-31|March 2011|2011-03-31||||July 2011|Anticipated|2011-07-31||Interventional|||High-Intensity Focused Ultrasound Ablation in Treating Patients With Progressive Prostate Cancer|An Evaluation of Lesion Control Using Focal Ablation With High Intensity Focused Ultrasound in the Treatment of Non-Metastatic Progressive Prostate Cancer|Unknown status|Recruiting|Phase 2|26|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:31:12.631432|2018-06-01 00:31:12.631432
NCT00987662|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2014-02-10|2009-09-30|2009-10-01|Estimate|||||||2014-02-10|2014-02-11|Estimate|January 2012||2012-01-31|September 2009|2009-09-30|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|OBI||Irbesartan Versus Amlodipine: The OBI Study|Double Blind Study of Irbesartan vs. Amlodipine in Obese Hypertensive Subjects- The OBI Study|Withdrawn||Phase 4|0|Actual|Aristotle University Of Thessaloniki||2||no funding|f||||t||||||||||2018-06-01 00:31:12.703614|2018-06-01 00:31:12.703614
NCT00987649|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-02-07|2009-09-30|2009-10-01|Estimate|||||||2011-02-07|2011-02-09|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||Ovarian Cancer Risk Estimation in Patients With Pelvic Mass|Evaluation of CA125 and HE4 Assays to Estimate the Risk of Ovarian Cancer in Patients Presenting to a General Surgeon or Obstetrician/Gynecologist With an Adnexal Mass|Completed|||512|Actual|Fujirebio Diagnostics, Inc.|||||f||||f||||||Samples Without DNA|"~     Serum, Plasma, Urine~   "|||2018-06-01 00:31:12.85698|2018-06-01 00:31:12.85698
NCT00987636|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2016-05-19|2009-09-30|2009-10-01|Estimate|||||||2016-05-19|2016-05-20|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|EWING2008||Study in Localized and Disseminated Ewing Sarcoma|Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma|Recruiting||Phase 3|1163|Anticipated|University Hospital Muenster||3|||f||||t||||||||||2018-06-01 00:31:12.943947|2018-06-01 00:31:12.943947
NCT00987623|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2010-12-17||2012-06-26|2009-09-30|2009-10-01|Estimate|2010-12-17|2011-01-13|Estimate||||2012-06-26|2012-07-10|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Clinical Evaluation of Two Daily Disposable Lenses in Neophytes|Clinical Evaluation of Two Daily Disposable Lenses in Neophytes|Completed||N/A|326|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:31:13.055855|2018-06-01 00:31:13.055855
NCT00987610|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-05-01|2009-09-30|2009-10-01|Estimate|||||||2015-05-01|2015-05-04|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|G-FORCE||Guidewire for Chronic Total Occlusion|Multicenter Prospective Randomized Study of First-choice Guidewires in Percutaneous Coronary Intervention for Chronic Total Occlusion|Completed||Phase 4|260|Actual|Tokai University||2|||f||||t||||||||||2018-06-01 00:31:13.228013|2018-06-01 00:31:13.228013
NCT00987597|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2016-12-23|2009-09-30|2009-10-01|Estimate|||||||2016-12-23|2016-12-26|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|PATPAC||Smoking Cessation for Patients With Acute Coronary Syndrome (ACS)|Effectiveness of a Managed Care Smoking Cessation Program in Patients With Acute Coronary Syndrome Based on Nicotine Replacement as a Treatment and a Cognitive-behavioral Approach|Completed||N/A|144|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:31:13.342428|2018-06-01 00:31:13.342428
NCT00987584|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2012-02-02|2009-09-30|2009-10-01|Estimate|||||||2012-02-02|2012-02-06|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|||Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk|"A Biologic Correlates Study for A Phase 2 Single-Arm Study To Assess The Efficacy and Safety Of 48-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Once a Week for 3 Weeks of a 4-Week Cycle in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-2 or High Ris"|Completed|||14|Actual|Stanford University|||||f||||t||||||Samples Without DNA|"~     marrow and peripheral blood~   "|||2018-06-01 00:31:13.422633|2018-06-01 00:31:13.422633
NCT00987571|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-09-30|2009-09-30|2009-10-01|Estimate|||||||2009-09-30|2009-10-01|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Carpal Tunnel Syndrome: Case Reports and Analysis - Ultrasound Imaging and Pathomechanics of Median Nerve Compression|Carpal Tunnel Syndrome: Case Reports and Analysis - Ultrasound Imaging and Pathomechanics of Median Nerve Compression|Completed|||4|Actual|EMG Labs of Arizona Arthritis & Rheumatology Associates|||2||f||||f||||||||||2018-06-01 00:31:13.476408|2018-06-01 00:31:13.476408
NCT00987558|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2014-12-03||2015-01-12|2009-09-30|2009-10-01|Estimate|2015-01-12|2015-01-13|Estimate||||2015-01-12|2015-01-13|Estimate|June 2009||2009-06-30|January 2015|2015-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects|Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects|Completed||Phase 1|30|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-06-01 00:31:13.546641|2018-06-01 00:31:13.546641
NCT00987545|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30||2012-05-02|2012-05-02|2009-09-30|2009-10-01|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence|A Post-shave Keloid Recurrence Study in Two Parts: A Biomarker Assessment Followed by a Randomized, Double-blind, Placebo Controlled Evaluation of Safety, Tolerability, and Efficacy of QAX576|Terminated||Phase 2|3|Actual|Novartis||2||"Negative pharmacodynamics due to lack of Interleukin-13 signature in biomarker data from Part I~   of the study."|f||||f||||||||||2018-06-01 00:31:13.817959|2018-06-01 00:31:13.817959
NCT00987532|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2009-09-30|2009-09-30|2009-10-01|Estimate|||||||2009-09-30|2009-10-01|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||A Participatory Parental Intervention Promoting Physical Activity in Preschools||Unknown status|Active, not recruiting|N/A|1047|Actual|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-06-01 00:31:13.88652|2018-06-01 00:31:13.88652
NCT00987519|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2010-07-06|2009-09-30|2009-10-01|Estimate|||||||2010-07-06|2010-07-07|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|||Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age|Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age - the Clinical Relevance of Newly Discovered Viruses|Unknown status|Recruiting||1260|Anticipated|University Medical Centre Ljubljana|||4||f||||f||||||Samples With DNA|"~     Whole blood, stool and nasopharyngeal swab samples.~   "|||2018-06-01 00:31:13.950514|2018-06-01 00:31:13.950514
NCT00987506|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2012-04-17|2009-09-30|2009-10-01|Estimate|||||||2012-04-17|2012-04-19|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|Far XIENCE V®||Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France|Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France|Completed|||1165|Actual|Abbott Vascular|||1||f||||t||||||||||2018-06-01 00:31:14.036591|2018-06-01 00:31:14.036591
NCT00987493|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2016-08-11|2009-09-30|2009-10-01|Estimate|||||||2016-08-11|2016-08-12|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2014|Actual|2014-04-30||Interventional|||Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma|Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.|Completed||Phase 1/Phase 2|49|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-06-01 00:31:14.161162|2018-06-01 00:31:14.161162
NCT00987480|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2017-08-15|2009-09-30|2009-10-01|Estimate|||||||2017-08-15|2017-08-18|Actual|September 25, 2009|Actual|2009-09-25|August 2016|2016-08-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|Completed||Phase 2|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:31:14.394518|2018-06-01 00:31:14.394518
NCT00987467|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2013-04-15||2018-03-06|2009-09-30|2009-10-01|Estimate|2013-10-04|2013-10-08|Estimate||||2018-03-06|2018-04-02|Actual|August 2007||2007-08-31|March 2018|2018-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis|Long-term Results of Topical Cyclosporine 0.05% in the Treatment of Atopic Keratoconjunctivitis|Completed||N/A|12|Actual|Johns Hopkins University|We were not able to have a control group and the treatment was not masked.|1|||f||||f||||||||||2018-06-01 00:31:14.507108|2018-06-01 00:31:14.507108
NCT00987454|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2016-07-24|2009-09-30|2009-10-01|Estimate|||||||2016-07-24|2016-07-26|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|EPO-TBI||Erythropoietin in Traumatic Brain Injury (EPO-TBI)|A Randomised, Placebo-controlled Trial of Erythropoietin in ICU Patients With Traumatic Brain Injury|Completed||Phase 3|606|Actual|Australian and New Zealand Intensive Care Research Centre||2|||f||||t||||||||||2018-06-01 00:31:14.798462|2018-06-01 00:31:14.798462
NCT00987441|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|||2011-07-26|2009-09-30|2009-10-01|Estimate|||||||2011-07-26|2011-07-27|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ELAIN||Epidural Labor Analgesia and Infant Neurobehavior|Epidural Analgesia for Labor Pain and Infant Neurobehavior|Completed||N/A|1200|Actual|Nanjing Medical University||6|||f||||t||||||||||2018-06-01 00:31:14.924712|2018-06-01 00:31:14.924712
NCT00987428|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-04-29|2009-09-30|2009-10-01|Estimate|||||||2015-04-29|2015-04-30|Estimate|August 2009||2009-08-31|April 2015|2015-04-30|March 2012|Actual|2012-03-31|June 2011|Actual|2011-06-30||Interventional|EEPAB2||Early Endoscopic Ultrasound - Based Sphincterotomy or Conservative Treatment in Severe Biliary Pancreatitis|Randomised Multicenter Trial of Early EUS Followed by Endoscopic Sphincterotomy in Case of Bile Duct Stone vs Conservative Treatment in Severe Biliary Pancreatitis|Terminated||N/A|27|Actual|Assistance Publique - Hôpitaux de Paris||2||Insufficient number of participants|f||||f||||||||||2018-06-01 00:31:15.08946|2018-06-01 00:31:15.08946
NCT00987415|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2014-10-14||2014-10-28|2009-09-30|2009-10-01|Estimate|2014-10-14|2014-10-20|Estimate||||2014-10-28|2014-11-04|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|EXACT-HF||Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels|Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients|Completed||Phase 2|253|Actual|Duke University||2|||f||||t||||||||||2018-06-01 00:31:15.211787|2018-06-01 00:31:15.211787
NCT00987402|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-30|2009-10-07||2012-08-20|2009-09-30|2009-10-01|Estimate|2012-08-20|2012-08-21|Estimate||||2012-08-20|2012-08-21|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of the Efficacy of Plain Soap and Water Versus Alcohol-based Rubs for Surgical Hand Preparation|Surgical Site Infections: a Cluster-randomized, Cross-over Study of the Efficacy of Plain Soap and Water Versus Alcohol-based Rubs for Surgical Hand Preparation|Completed||Phase 1/Phase 2|3317|Actual|University Hospital, Geneva|Most cases, post-discharge monitoring was not conducted by outpatient clinic visits following a standard protocol, some data was not collected, and routine microbiologic cultures were not obtained.|2|||f||||t||||||||||2018-06-01 00:31:15.863769|2018-06-01 00:31:15.863769
NCT00987389|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2018-03-14|2009-09-28|2009-09-30|Estimate|||||||2018-03-14|2018-03-16|Actual|May 2010|Actual|2010-05-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|PEXIVAS||Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis|Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial|Completed||Phase 3|704|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 00:31:16.103152|2018-06-01 00:31:16.103152
NCT00987376|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2016-01-12|2009-09-29|2009-09-30|Estimate|||||||2016-01-12|2016-01-13|Estimate|November 2003||2003-11-30|January 2016|2016-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Novel PET/CT Agents and MRS/MRI in Prostate CA and High Risk Prostate Cancer: An Inter-SPORE Collaboration|Comparison of Novel PET/CT Imaging Agents and MRS/MRI in Metastatic and High Risk Prostate Cancer: An Inter-SPORE Collaboration|Completed||Phase 1|8|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:31:16.323613|2018-06-01 00:31:16.323613
NCT00987181|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2015-02-20|2009-09-29|2009-09-30|Estimate|||||||2015-02-20|2015-02-23|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Observational|||Non-Contact Measurement of Aortic Compliance|Non Contact Measurement of Aortic Pulse Wave Velocity|Completed|||80|Actual|Barts & The London NHS Trust|||2||f||||f||||||||||2018-06-01 00:31:18.422908|2018-06-01 00:31:18.422908
NCT00987363|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2016-03-15|2009-09-29|2009-09-30|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2009||2009-07-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization|Phase II Clinical Trial of Therapeutic Angiogenesis With Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Ischemia Diabetics Critical Limb (CLI) no Revascularization.|Completed||Phase 1/Phase 2|60|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||4|||f||||t||||||||||2018-06-01 00:31:16.388515|2018-06-01 00:31:16.388515
NCT00987350|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-04-20|2009-09-29|2009-09-30|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2010||2010-01-31|April 2017|2017-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety Study of Seasonal Influenza Vaccine by Jet Injection|A Clinical Study to Assess the Safety, Tolerability, and Immunogenicity of Licensed Seasonal Trivalent Influenza Vaccine Administered by Needle-free Jet Injection in One Intramuscular Dose to Healthy Young Adults|Completed||Phase 4|60|Actual|University of Maryland||2|||f||||f||||||||||2018-06-01 00:31:16.469302|2018-06-01 00:31:16.469302
NCT00987337|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2013-12-10|2012-02-13|2013-12-10|2009-09-29|2009-09-30|Estimate|2013-12-10|2014-01-27|Estimate|2012-02-13|2012-02-16|Estimate|2013-12-10|2014-01-27|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|FITNESS|Intent-to-Treat (ITT) population included all randomized participants who took at least 1 dose of study drug.|Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Filibuvir Plus Pegylated Interferon Alfa-2a And Ribavirin In Treatment-Naive, HCV Genotype 1 Infected Subjects|Completed||Phase 2|288|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 00:31:16.571531|2018-06-01 00:31:16.571531
NCT00987324|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2016-11-18|2009-09-29|2009-09-30|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|July 2012|Actual|2012-07-31||Interventional|ISAR-DESIRE-3||Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent Restenosis|"Randomized Trial of Paclitaxel-Eluting Balloon, Paclitaxel-Eluting Stent and Plain Balloon Angioplasty for Restenosis in -Limus-Eluting Coronary Stents"|Completed||Phase 4|402|Actual|Deutsches Herzzentrum Muenchen||3|||f||||f||||||||||2018-06-01 00:31:17.446811|2018-06-01 00:31:17.446811
NCT00987311|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2017-01-18|2009-09-29|2009-09-30|Estimate|||||||2017-01-18|2017-01-20|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Probiotic Fermented Dairy Drinks on Intestinal Immune Response|Pilot Study on the Effects of Probiotic Fermented Dairy Drinks on the Intestinal Immune Response in Healthy Adults|Completed||N/A|33|Actual|Danone Research||3|||f||||f||||||||||2018-06-01 00:31:17.521431|2018-06-01 00:31:17.521431
NCT00987298|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2010-12-06|2009-09-29|2009-09-30|Estimate|||||||2010-12-06|2010-12-08|Estimate|December 2009||2009-12-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool|Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool|Completed|||124|Actual|GE Healthcare|||1||f||||f||||||||||2018-06-01 00:31:17.575491|2018-06-01 00:31:17.575491
NCT00987285|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-05-21|2009-09-29|2009-09-30|Estimate|||||||2015-05-21|2015-05-25|Estimate|January 2007||2007-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31||Interventional|LB2||Linking Self-Management and Primary Care for Diabetes 2|Linking Self-Management and Primary Care for Diabetes|Completed||N/A|463|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-06-01 00:31:17.639803|2018-06-01 00:31:17.639803
NCT00987272|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28||2014-07-28|2014-07-28|2009-09-29|2009-09-30|Estimate||||2014-07-28|2014-07-31|Estimate|2014-07-28|2014-07-31|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects|A Phase III Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the CAC Model of Acute Allergic Conjunctivitis in Japanese Subjects|Completed||Phase 3|267|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:31:17.785463|2018-06-01 00:31:17.785463
NCT00987259|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-01-31|2009-09-29|2009-09-30|Estimate|||||||2013-01-31|2013-02-01|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Observational|||Myocardial Oedema in Acute Myocardial Infarction (AMI)|Determination of the Time Course of Myocardial Oedema Post Myocardial Infarction Treated With Primary Angioplasty Using Cardiac Magnetic Resonance Imaging|Completed|||20|Actual|Barts & The London NHS Trust|||1||f||||f||||||||||2018-06-01 00:31:17.874318|2018-06-01 00:31:17.874318
NCT00987246|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-07-27|2009-09-29|2009-09-30|Estimate|||||||2015-07-27|2015-07-28|Estimate|June 2008||2008-06-30|July 2015|2015-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis|Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II|Completed||Phase 3|470|Actual|Almirall, S.A.||3|||f||||f||||||||||2018-06-01 00:31:17.952409|2018-06-01 00:31:17.952409
NCT00987233|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-09-29|2009-09-29|2009-09-30|Estimate|||||||2009-09-29|2009-09-30|Estimate||||September 2009|2009-09-30||||||||Interventional|||A Study Comparing the Bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (Apotex, Inc.) to That of Nasacort® AQ Nasal Spray (Sanofi-Aventis Pharmaceutical Products, Inc.) In the Treatment of Seasonal Allergic Rhinitis||Completed||Phase 3|||Apotex Inc.||3|||f||||||||||||||2018-06-01 00:31:18.118281|2018-06-01 00:31:18.118281
NCT00987220|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2011-02-10|2009-09-28|2009-09-30|Estimate|||||||2011-02-10|2011-02-14|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid|A Methodology Study To Evaluate Cerebrospinal Fluid Acetylcholine Following A Single Dose Administration Of Donepezil In Healthy Subjects|Completed|||12|Actual|Pfizer|||2||f||||f||||||Samples With DNA|"~     DNA, plasma, CSF~   "|||2018-06-01 00:31:18.189515|2018-06-01 00:31:18.189515
NCT00987207|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2011-11-08|2009-09-29|2009-09-30|Estimate|||||||2011-11-08|2011-11-09|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PC Pharma CVA||Pharmacological Postconditioning During the Aortic Valvular Surgery|Pharmacological Postconditioning During the Aortic Valvular Surgery|Completed||Phase 3|56|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 00:31:18.279641|2018-06-01 00:31:18.279641
NCT00987194|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2010-07-13|2009-09-29|2009-09-30|Estimate|||||||2010-07-13|2010-07-14|Estimate|March 2009||2009-03-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||HIV Testing in the Emergency Department at Baystate Medical Center: A Pilot Program|HIV Testing in the Emergency Department at Baystate Medical Center: A Pilot Program Version 1.5, May 2009|Completed|||1087|Actual|Baystate Medical Center|||||f||||f||||||||||2018-06-01 00:31:18.35633|2018-06-01 00:31:18.35633
NCT00987168|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-12-18|2009-09-29|2009-09-30|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2009||2009-05-31|October 2010|2010-10-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Sandostatine® LP and Hyperinsulinism|Replace Sandostatine® in Three Daily Subcutaneous Injections by a Single Intramuscular Injection of Sandostatine® LP Per Month in Patients With a Diffuse Form of Hyperinsulinism|Completed||Phase 2|10|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 00:31:18.488076|2018-06-01 00:31:18.488076
NCT00987155|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2017-01-16|2009-09-29|2009-09-30|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Spinal Cord Injury: Endurance, Strength and Cardiac Function Induced by Efficient Training Protocols|Spinal Cord Injury: Endurance, Strength and Cardiac Function Induced by Efficient Training Protocols|Completed||N/A|12|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-06-01 00:31:18.561631|2018-06-01 00:31:18.561631
NCT00987142|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2011-06-13|2009-09-29|2009-09-30|Estimate|||||||2011-06-13|2011-06-14|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TCEB||Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa|A Comparative Open-Label Multicentre Clinical Trial To Assess The Efficacy And Safety Of A New Therapy With Cultured Chimeric Skin For The Treatment Of Skin Lesions In Patients With Epidermolysis Bullosa|Completed||Phase 2|12|Actual|Cellerix||2|||f||||f||||||||||2018-06-01 00:31:18.645049|2018-06-01 00:31:18.645049
NCT00987129|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-01-04|2009-09-29|2009-09-30|Estimate|||||||2015-01-04|2015-01-06|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Observational|||Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).|Effect of Omega-6:Omega-3 Fatty Acid Ratio on Delaying Progression of Age-related Macular Degeneration (AMD) in Moderate to High Risk Individuals.|Terminated|||200|Actual|University of Alberta||||Insufficient recruitment|f||||t||||||Samples With DNA|"~     Whole blood for genotyping and measuring omega-3 FA status. Serum for Cytokine level~     analysis.~   "|||2018-06-01 00:31:18.708568|2018-06-01 00:31:18.708568
NCT00987116|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-10-12|2009-09-29|2009-09-30|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2009|Actual|2009-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|MYACOR||Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis|Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study|Completed||Phase 4|118|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:31:18.769361|2018-06-01 00:31:18.769361
NCT00987103|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2010-10-21|2009-09-29|2009-09-30|Estimate|||||||2010-10-21|2010-10-22|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients|Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients|Unknown status|Recruiting|Phase 1|18|Anticipated|Maastricht University Medical Center||6|||f||||t||||||||||2018-06-01 00:31:18.835543|2018-06-01 00:31:18.835543
NCT00987090|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-10-22|2009-09-29|2009-09-30|Estimate|||||||2015-10-22|2015-10-23|Estimate|October 2009||2009-10-31|October 2015|2015-10-31||||September 2016|Anticipated|2016-09-30||Interventional|||Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)|Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) : Variations of the Clinical Profile and Paraclinical Features Depending on the Age at the Onset of Clinical Signs|Unknown status|Recruiting|N/A|240|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 00:31:18.908476|2018-06-01 00:31:18.908476
NCT00987077|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-09-29|2009-09-29|2009-09-30|Estimate|||||||2009-09-29|2009-09-30|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy|Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial|Completed||Phase 2|30|Actual|University of Kiel||3|||f||||t||||||||||2018-06-01 00:31:18.979776|2018-06-01 00:31:18.979776
NCT00987064|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2015-01-13|2009-09-29|2009-09-30|Estimate|||||||2015-01-13|2015-01-14|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Clinical Effects of Temperature Controlled Laminar Airflow (TLA)|Clinical Effects of Purified Air Administered to the Breathing Zone in Allergic Asthma|Completed||Phase 2|28|Actual|Airsonett AB||2|||f||||f||||||||||2018-06-01 00:31:19.048426|2018-06-01 00:31:19.048426
NCT00987051|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2012-12-10|2009-09-29|2009-09-30|Estimate|||||||2012-12-10|2012-12-11|Estimate|April 2007||2007-04-30|December 2012|2012-12-31|October 2011|Actual|2011-10-31|December 2009|Actual|2009-12-31||Interventional|Senti-Endo||Sentinel Node and Endometrial Cancer|Validation of the Sentinel Node in Endometrial Cancer|Completed||N/A|133|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:31:19.123688|2018-06-01 00:31:19.123688
NCT00987038|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-12-07|2009-09-29|2009-09-30|Estimate|||||||2009-12-07|2009-12-08|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Midazolam Drug Interaction Study With PF-04171327|A Phase 1, Open Label, Multiple Dose Study Of The Effect Of PF-04171327 On Midazolam Pharmacokinetics In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:31:19.187822|2018-06-01 00:31:19.187822
NCT00987025|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2010-05-27|2009-09-29|2009-09-30|Estimate|||||||2010-05-27|2010-05-28|Estimate|October 2009||2009-10-31|May 2010|2010-05-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|TEAhM||Initial Evaluation of Telehealth Blood Pressure Stations in Nutrition Centers|Technologies for Enhancing Access and Health Management|Unknown status|Active, not recruiting|N/A|144|Anticipated|American Association of Homes and Services for the Aging||2|||f||||f||||||||||2018-06-01 00:31:19.386286|2018-06-01 00:31:19.386286
NCT00987012|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-09-29|2009-09-29|2009-09-30|Estimate|||||||2009-09-29|2009-09-30|Estimate|October 2009||2009-10-31|September 2009|2009-09-30||||April 2010|Anticipated|2010-04-30||Interventional|||The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients|The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients - A Prospective Randomized Trial|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hillel Yaffe Medical Center||2|||f||||||||||||||2018-06-01 00:31:19.467574|2018-06-01 00:31:19.467574
NCT00986999|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2015-01-20||2015-01-20|2009-09-29|2009-09-30|Estimate|2015-01-20|2015-01-29|Estimate||||2015-01-20|2015-01-29|Estimate|September 2009||2009-09-30|January 2015|2015-01-31||||January 2015|Actual|2015-01-31||Interventional|||Effect of Rosuvastatin on Endothelial Function|Pilot Study of the Effect of Low-Dose Rosuvastatin on Endothelial Function, Oxidative Stress and Inflammatory Parameters in HIV-Infected Individuals With Low HDL Cholesterol Levels and Low to Normal LDL Cholesterol Levels|Terminated||Phase 2/Phase 3|7|Actual|University of Hawaii||1||poor enrollment|f||||f||||||||||2018-06-01 00:31:19.548481|2018-06-01 00:31:19.548481
NCT00986986|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2011-08-14||2012-11-19|2009-09-29|2009-09-30|Estimate|2012-11-19|2012-12-18|Estimate||||2012-11-19|2012-12-18|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels|Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels|Completed||N/A|20|Actual|University of Hawaii|"Small sample size~Un-blinded pilot study~Increase in HDL was less than predicted in a non-HIV infected population"|2|||f||||t||||||||||2018-06-01 00:31:19.816529|2018-06-01 00:31:19.816529
NCT00986973|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|2013-02-22||2015-05-12|2009-09-29|2009-09-30|Estimate|2015-04-24|2015-05-12|Estimate||||2015-05-12|2015-06-08|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|PKU||Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy|A Pilot Study of FDG PET Findings in Patients With Phenylketonuria Before and After BH4 Supplementation|Completed||N/A|6|Actual|Children's Hospital of Philadelphia|Due to small sample size, the statistical power of this study is low. While it is useful in exploring potential trends, the results of this pilot study should be cautiously interpreted. Further studies with a larger sample of subjects are needed.|1|||f||||t||||||||||2018-06-01 00:31:20.087598|2018-06-01 00:31:20.087598
NCT00986960|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2013-12-09||2013-12-09|2009-09-29|2009-09-30|Estimate|2013-12-09|2014-01-23|Estimate||||2013-12-09|2014-01-23|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|ACTH||Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)|Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study|Terminated||Phase 2|3|Actual|University at Buffalo|"Patients did not want to be in the placebo group.~Too difficult to mask placebo vs. drug. Testing regimen too intensive - patients did not want to participate."|2||Difficult to recruit due to protocol requirements - participant burden.|f||||t||||||||||2018-06-01 00:31:20.319062|2018-06-01 00:31:20.319062
NCT00986947|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2017-03-21||2017-05-01|2009-09-29|2009-09-30|Estimate|2017-05-01|2017-06-01|Actual||||2017-05-01|2017-06-01|Actual|September 2009||2009-09-30|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates|Phase 2 Study of IVIg and Rituximab for Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates|Terminated||Phase 2|20|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 00:31:20.445148|2018-06-01 00:31:20.445148
NCT00986921|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2012-09-07||2013-12-28|2009-09-28|2009-09-30|Estimate|2013-09-29|2013-12-02|Estimate||||2013-12-28|2014-01-31|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SAMi||Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks|Mifepristone vs. Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks|Completed||N/A|50|Actual|Boston University|This study was completed as planned.|2|||f||||f||||||||||2018-06-01 00:31:20.577231|2018-06-01 00:31:20.577231
NCT00986908|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|||2018-03-12|2009-09-29|2009-09-30|Estimate|||||||2018-03-12|2018-03-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:31:21.870118|2018-06-01 00:31:21.870118
NCT00986895|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2017-01-13|2009-09-28|2009-09-30|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|June 2007|Actual|2007-06-30|||||Interventional|||A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group||Completed||Phase 1|32|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|||||||||||||||||||2018-06-01 00:31:21.936565|2018-06-01 00:31:21.936565
NCT00986882|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-05-02|2009-09-29|2009-09-30|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2009||2009-09-30|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||To Evaluate the Safety, Tolerability and Analgesic Efficacy of SAF312 in Postoperative Dental Pain Patients|A Double-blind, Randomized, Single Dose, Placebo Controlled, Three Part Study to Evaluate the Safety and Tolerability, Efficacy and Dose Response of SAF312 in Postoperative Dental Pain Patients|Completed||Phase 2|183|Actual|Novartis||3|||f||||f|t|f||||||No||2018-06-01 00:31:22.009016|2018-06-01 00:31:22.009016
NCT00986869|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2012-03-15|2009-09-29|2009-09-30|Estimate|||||||2012-03-15|2012-03-16|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Observational|||The Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension|Study of the Safety of Flexible Bronchoscopy in Patients With Pulmonary Hypertension|Unknown status|Recruiting||100|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-06-01 00:31:22.102316|2018-06-01 00:31:22.102316
NCT00986856|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2010-03-19||2015-03-25|2009-09-29|2009-09-30|Estimate|2010-09-07|2010-09-29|Estimate||||2015-03-25|2015-04-14|Estimate|May 2004||2004-05-31|March 2015|2015-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Fucidin® Cream in the Treatment of Impetigo|A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients|Terminated||Phase 4|58|Actual|LEO Pharma|It was planned to Incl. 360 Pts(Proport.3:1 Fucidin® cream:Fucidin® cream vehicle), but due to very slow recruitment in SE and N and inability to Incl. UK, only 59 Pts were enrolled. 58 Pts were randomised: 42Fucidin® cream:16 Fucidin® cream vehicle.|2||Enrollment failed|f||||f||||||||||2018-06-01 00:31:22.204968|2018-06-01 00:31:22.204968
NCT00986843|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-04-04|2009-09-29|2009-09-30|Estimate|||||||2013-04-04|2013-04-05|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|February 2010|Actual|2010-02-28||Interventional|||Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)|A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer((Q1DX5/W)X2 for 3W)|Completed||Phase 1|14|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-06-01 00:31:23.403868|2018-06-01 00:31:23.403868
NCT00986830|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2014-05-20|2009-09-29|2009-09-30|Estimate|||||||2014-05-20|2014-05-22|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|RELIEF||RELIEF: Healthcase Utilization and Outcomes of FinESS Treatment in the Office|Healthcare Utilization and Outcomes of FinESS Treatment in the Office|Completed||N/A|75|Anticipated|Entellus Medical, Inc.|||||f||||f||||||||||2018-06-01 00:31:23.468629|2018-06-01 00:31:23.468629
NCT00768976|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2012-05-22|2008-10-07|2008-10-08|Estimate|||||||2012-05-22|2012-05-23|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Study of Patient Satisfaction With the Cancer Clinical Trial Experience|Study of Patient Satisfaction With the Cancer Clinical Trial Experience|Completed|||100|Actual|Summa Health System|||||f||||f||||||||||2018-06-01 01:41:25.084213|2018-06-01 01:41:25.084213
NCT00986817|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-06-12|2009-09-29|2009-09-30|Estimate|||||||2015-06-12|2015-06-15|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|TERAS||Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin|Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study|Completed||Phase 3|82|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:31:23.546318|2018-06-01 00:31:23.546318
NCT00986804|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2016-02-11|2009-09-29|2009-09-30|Estimate|||||||2016-02-11|2016-02-15|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|May 2014|Actual|2014-05-31||Interventional|AML MDS||Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant|Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome|Completed||Phase 1|24|Actual|Washington University School of Medicine||4|||f||||f||||||||||2018-06-01 00:31:23.63661|2018-06-01 00:31:23.63661
NCT00986791|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2018-03-29|2009-09-29|2009-09-30|Estimate|||||||2018-03-29|2018-03-30|Actual|May 2010|Actual|2010-05-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|January 1, 2016|Actual|2016-01-01||Interventional|||Alcohol Cessation Intervention in an Acute Surgical Setting|Scand-Ankle: A Gold Standard Programme for Alcohol Cessation Intervention in Patients Undergoing Acute Fracture Surgery - A Randomised Clinical Multi-centre Study|Completed||N/A|70|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-06-01 00:31:23.726391|2018-06-01 00:31:23.726391
NCT00986778|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-08-31|2009-09-29|2009-09-30|Estimate|||||||2015-08-31|2015-09-01|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|June 2014|Anticipated|2014-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Entecavir Plus Adefovir in Lamivudine-Resistant Patients|A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects|Withdrawn||Phase 4|0|Actual|Bristol-Myers Squibb||3||Business Objectives Changed|f||||f||||||||||2018-06-01 00:31:23.801032|2018-06-01 00:31:23.801032
NCT00986765|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2016-01-16|2009-09-29|2009-09-30|Estimate|||||||2016-01-16|2016-01-20|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|HEPEPE||Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia|Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial|Completed||Phase 3|257|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:31:23.996822|2018-06-01 00:31:23.996822
NCT00986752|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2014-03-06|2009-09-29|2009-09-30|Estimate|||||||2014-03-06|2014-03-07|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|ISAR-STATH||Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease|Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease|Unknown status|Recruiting|Phase 4|150|Anticipated|Deutsches Herzzentrum Muenchen||3|||f||||f||||||||||2018-06-01 00:31:24.093442|2018-06-01 00:31:24.093442
NCT00986739|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-09-11|2009-09-29|2009-09-30|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2009|Actual|2009-07-31|October 2016|2016-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|RIEHO||Individual and Environmental Risk Factors of Unplanned Admissions of Elderly|Individual and Environmental Risk Factors of Unplanned Admissions of Elderly : RIEHO Inception Cohort|Completed|||973|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 00:31:24.211417|2018-06-01 00:31:24.211417
NCT00986713|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2009-09-29|2009-09-29|2009-09-30|Estimate|||||||2009-09-29|2009-09-30|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|October 2010|Anticipated|2010-10-31|September 2010|Anticipated|2010-09-30||Interventional|||Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation||Unknown status|Recruiting|Phase 4|400|Anticipated|Capital Medical University|||||f||||t||||||||||2018-06-01 00:31:24.278868|2018-06-01 00:31:24.278868
NCT00986700|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-06-18|2009-09-29|2009-09-30|Estimate|||||||2017-06-18|2017-06-20|Actual|October 2009||2009-10-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effect of Late Night Meals on Fasting Glucose in Type 2 Diabetes Patients|The Effect of Late Night Meals on Fasting Glucose in Type 2 Diabetes Patients|Completed||N/A|19|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:31:24.346397|2018-06-01 00:31:24.346397
NCT00986687|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-12-02|2009-09-29|2009-09-30|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Oocyte Cryopreservation Comparing Fresh and Vitrified Sibling Oocytes|Oocyte Cryopreservation: A Pilot Study Comparing Fertilization and Embryo Development Between Fresh and Vitrified Sibling Oocytes|Completed|||17|Actual|UConn Health|||2||f||||f||||||Samples With DNA|"~     Embryos~   "|||2018-06-01 00:31:24.409623|2018-06-01 00:31:24.409623
NCT00986674|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2014-09-19||2014-09-19|2009-09-29|2009-09-30|Estimate|2014-09-19|2014-09-26|Estimate||||2014-09-19|2014-09-26|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional||The primary population is eligible and treated patients in the study. Both baseline analysis and efficacy outcomes are based on this primary population.|Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer|Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination With Cetuximab, IMC-A12 or Both in Patients With Advanced Non-Small Cell Lung Cancer Who Will Not Receive Bevacizumab-Based Therapy|Completed||Phase 2|140|Actual|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-06-01 00:31:24.581202|2018-06-01 00:31:24.581202
NCT00986661|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2018-04-24|2009-09-29|2009-09-30|Estimate|||||||2018-04-24|2018-04-26|Actual|October 2009||2009-10-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Assess PV-10 Chemoablation of Cancer of the Liver|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant|Recruiting||Phase 1|66|Anticipated|Provectus Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:31:25.730195|2018-06-01 00:31:25.730195
NCT00986648|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2016-01-11|2009-09-29|2009-09-30|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2000||2000-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Multi-Center Group to Study Acute Liver Failure in Children|A Multi-Center Group to Study Acute Liver Failure in Children|Completed|||158|Actual|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     whole blood, serum, tissue~   "|||2018-06-01 00:31:25.824844|2018-06-01 00:31:25.824844
NCT00986635|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2011-04-07|2009-09-29|2009-09-30|Estimate|||||||2011-04-07|2011-04-08|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Observational|||Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study||Completed|||100|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-06-01 00:31:25.9012|2018-06-01 00:31:25.9012
NCT00986609|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-06-19|2009-09-29|2009-09-30|Estimate|||||||2015-06-19|2015-06-22|Estimate|August 2009||2009-08-31|June 2015|2015-06-30||||August 2015|Anticipated|2015-08-31||Interventional|||MUC1 Vaccine for Triple-negative Breast Cancer|Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer|Unknown status|Active, not recruiting|Early Phase 1|29|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:31:25.950759|2018-06-01 00:31:25.950759
NCT00986596|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2012-01-06|2009-09-29|2009-09-30|Estimate|||||||2012-01-06|2012-01-10|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women|A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women|Completed||N/A|24|Actual|Tufts University||2|||f||||f||||||||||2018-06-01 00:31:26.119986|2018-06-01 00:31:26.119986
NCT00986583|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2015-12-24||2016-08-24|2009-09-29|2009-09-30|Estimate|2016-06-20|2016-08-02|Estimate||||2016-08-24|2016-10-03|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Succinylcholine on Patients Using Statins|Effect of Succinylcholine on Patients Using Statins|Completed||N/A|70|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 00:31:26.231283|2018-06-01 00:31:26.231283
NCT00986570|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2010-11-17||2015-11-16|2009-09-29|2009-09-30|Estimate|2010-11-17|2010-12-06|Estimate||||2015-11-16|2015-12-11|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|XEO-001/07||Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face|Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face|Completed||Phase 3|121|Actual|Biolab Sanus Farmaceutica||1|||f||||f||||||||||2018-06-01 00:31:26.579712|2018-06-01 00:31:26.579712
NCT00986557|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-08-23|2009-09-29|2009-09-30|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2009||2009-09-30|April 2010|2010-04-30||||August 2013|Anticipated|2013-08-31||Interventional|||T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant|A Randomised Controlled Phase II Trial of the Adoptive Transfer of Selected Cytomegalovirus-Specific Cytotoxic T Lymphocytes (CMV-CTL) After Allogeneic Stem Cell Transplantation (SCT) in Patients at Risk of CMV Disease|Unknown status|Recruiting|Phase 2|78|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:31:26.750868|2018-06-01 00:31:26.750868
NCT00986544|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2012-01-16||2012-02-18|2009-09-29|2009-09-30|Estimate|2012-02-18|2012-03-23|Estimate||||2012-02-18|2012-03-23|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Drain After Elective Laparoscopic Cholecystectomy|Drain After Elective Laparoscopic Cholecystectomy. A Randomized Controlled Trial|Completed||N/A|106|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-06-01 00:31:26.837038|2018-06-01 00:31:26.837038
NCT00986531|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2011-10-31|2009-09-29|2009-09-30|Estimate|||||||2011-10-31|2011-11-01|Estimate|November 2009||2009-11-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics|A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms With AZD8529 in Patients With Schizophrenia|Completed||Phase 1|59|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 00:31:27.058049|2018-06-01 00:31:27.058049
NCT00986518|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-11-21|2009-09-29|2009-09-30|Estimate|||||||2013-11-21|2013-11-25|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|STARTREK||T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study|Controlled and Selective Depletion of Regulatory T-cell for Cancer Treatment, Efficacy and Safety Study|Completed||Phase 1/Phase 2|5|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 00:31:27.129927|2018-06-01 00:31:27.129927
NCT00986505|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-09-29|2009-09-29|2009-09-30|Estimate|||||||2009-09-29|2009-09-30|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Intravenous Lidocaine for Fibromyalgia|Effect of Intravenous Lidocaine on Manifestations of Fibromyalgia|Completed||N/A|30|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-06-01 00:31:27.199695|2018-06-01 00:31:27.199695
NCT00986492|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-29|2009-09-29|2009-09-30|Estimate|||||||2009-09-29|2009-09-30|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Effects of Sleep Deprivation on Food Intake and Motor Activity in Man|Influence de la Privation Aigue de Sommeil Sur la Prise Alimentaire et l'activité Physique Chez l'Homme|Completed|||12|Actual|University Hospital, Caen|||||f||||f||||||||||2018-06-01 00:31:27.260619|2018-06-01 00:31:27.260619
NCT00986479|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2014-10-15||2014-10-15|2009-09-29|2009-09-30|Estimate|2014-10-15|2014-10-21|Estimate||||2014-10-15|2014-10-21|Estimate|December 2009||2009-12-31|October 2014|2014-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||This is a Study to Determine the Antidepressant Effects of AZD6765|An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression|Completed||Phase 2|22|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:31:27.341943|2018-06-01 00:31:27.341943
NCT00986466|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2013-05-24|2009-09-29|2009-09-30|Estimate|||||||2013-05-24|2013-05-27|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|DEX||Vitamin D and Exercise in Falls Prevention|Effects of Vitamin D and Exercise in Preventing Falls of Elderly Women|Completed||N/A|409|Actual|UKK Institute||4|||f||||f||||||||||2018-06-01 00:31:28.111702|2018-06-01 00:31:28.111702
NCT00986453|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|2012-11-29||2012-11-29|2009-09-29|2009-09-30|Estimate|2012-11-29|2013-01-01|Estimate||||2012-11-29|2013-01-01|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PRECISE||PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction|A Prospective, Randomized, Controlled Study to Evaluate Use of the PEAK PlasmaBlade 4.0 in Bilateral Breast Reduction|Completed||N/A|45|Actual|Medtronic Surgical Technologies||2|||f||||f||||||||||2018-06-01 00:31:28.242115|2018-06-01 00:31:28.242115
NCT00986440|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2015-04-13|2009-09-29|2009-09-30|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy|A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy|Completed||Phase 2|86|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 00:31:28.513144|2018-06-01 00:31:28.513144
NCT00986427|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|2013-05-10||2013-07-17|2009-09-29|2009-09-30|Estimate|2013-07-17|2013-08-20|Estimate||||2013-07-17|2013-08-20|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|July 2010|Actual|2010-07-31||Interventional|||Restasis for Treatment of Brittle Nails|Restasis® Ophthalmic Emulsion for the Treatment of Brittle Nails|Completed||Phase 2|24|Actual|Columbia University|Small Sample Size|2|||f||||f||||||||||2018-06-01 00:31:28.663107|2018-06-01 00:31:28.663107
NCT00986414|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2017-02-20|2009-09-29|2009-09-30|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2009||2009-09-30|February 2017|2017-02-28||||December 2010|Actual|2010-12-31||Interventional|||Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease|13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease|Completed||Phase 2|260|Anticipated|Novartis||6|||f||||||||||||||2018-06-01 00:31:28.952957|2018-06-01 00:31:28.952957
NCT00986401|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2011-11-16||2011-11-16|2009-09-29|2009-09-30|Estimate|2011-11-16|2011-12-19|Estimate||||2011-11-16|2011-12-19|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects|Safety and Tolerability of Trospium Chloride Metformin Hydrochloride in Healthy Subjects|Completed||Phase 1|44|Actual|Allergan||2|||f||||||||||||||2018-06-01 00:31:29.105832|2018-06-01 00:31:29.105832
NCT00986375|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-29|||2012-11-12|2009-09-29|2009-09-30|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|OPAL||Online Program Assisting Lifestyle Changes (Asterix 1.0 & Obelix 2.0)|Online Program Assisting Lifestyle Changes: Adopting and Maintaining Physical Activity and Fruit & Vegetable Consumption (Asterix 1.0 & Obelix 2.0)|Completed||N/A|1000|Actual|Freie Universität Berlin||2|||f||||t||||||||||2018-06-01 00:31:29.316787|2018-06-01 00:31:29.316787
NCT00986362|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|2013-07-04||2014-12-02|2009-09-28|2009-09-29|Estimate|2014-02-18|2014-02-20|Estimate||||2014-12-02|2014-12-17|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|MIC|16 eyes randomized and treated (in 15 subjects) with ocriplasmin & 8 eyes randomized and treated (in 8 subjects) with placebo. Randomisation was at the eye not the subject level; in 1 subject, both eyes were randomised to ocriplasmin; in 1 subject, 1 eye was randomised to ocriplasmin & 1 eye randomised to placebo. 22 subjects participated, 24 eyes.|Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy|The MIC (Microplasmin In Children) Trial: A Randomized, Placebo-controlled, Double-masked, Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy|Completed||Phase 2|24|Actual|ThromboGenics||2|||f||||t||||||||||2018-06-01 00:31:29.401528|2018-06-01 00:31:29.401528
NCT00986349|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-27|2016-02-13||2017-01-03|2009-09-28|2009-09-29|Estimate|2016-11-01|2017-01-02|Estimate||||2017-01-03|2017-02-17|Actual|June 2010||2010-06-30|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional||Subjects with successful implants|Study of EndoBarrier Liner for Treatment of Type 2 Diabetes Study|A Phase II Single-Center, Prospective, Open Label Efficacy Study, of the GI EndoBarrier™ Liner for the Treatment of Type 2 Diabetes|Completed||N/A|23|Actual|GI Dynamics||1|||f||||f||||||||Yes|De-identified individual patient data is on file at the Sponsor|2018-06-01 00:31:29.729313|2018-06-01 00:31:29.729313
NCT00986336|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-06-08|2009-09-28|2009-09-29|Estimate|||||||2011-06-08|2011-06-10|Estimate|February 2001||2001-02-28|April 2010|2010-04-30|November 2002|Actual|2002-11-30|||||Interventional|||A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders|A Comparative Study of the Steady-state Pharmacokinetics of Risperidone and Topiramate on Monotherapy and During Combination Therapy in Patients With Bipolar or Schizoaffective Disorder|Completed||Phase 1|56|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||||||||||||||||2018-06-01 00:31:29.939843|2018-06-01 00:31:29.939843
NCT00986323|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-27|||2010-11-08|2009-09-28|2009-09-29|Estimate|||||||2010-11-08|2010-11-09|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|4A||Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma|Airsonett Airshower in Allergic Asthma a Double-blind Randomized Multi-centre Trial|Completed||Phase 3|312|Actual|Airsonett AB||2|||f||||t||||||||||2018-06-01 00:31:30.003945|2018-06-01 00:31:30.003945
NCT00986310|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2012-11-02|2009-09-28|2009-09-29|Estimate|||||||2012-11-02|2012-11-05|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy|Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy|Completed||N/A|60|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-06-01 00:31:30.177309|2018-06-01 00:31:30.177309
NCT00986297|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|||2014-05-19|2009-09-26|2009-09-29|Estimate|||||||2014-05-19|2014-05-20|Estimate|October 2009||2009-10-31|May 2014|2014-05-31||||October 2012|Actual|2012-10-31||Interventional|||Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status|Phase 1 Study of Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-IV Non-Small Cell Lung Cancer and Poor Performance Status|Completed||Phase 1|60|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 00:31:30.244306|2018-06-01 00:31:30.244306
NCT00986284|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-27|||2015-12-21|2009-09-28|2009-09-29|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)|Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients|Suspended||Phase 2|102|Actual|Tianjin Medical University Cancer Institute and Hospital||1||Lack of patients and some progressed disease soon after surgery|f||||t||||||||||2018-06-01 00:31:30.319625|2018-06-01 00:31:30.319625
NCT00986271|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-27|||2009-09-28|2009-09-28|2009-09-29|Estimate|||||||2009-09-28|2009-09-29|Estimate||||April 2008|2008-04-30||||||||Interventional|EVLI in sepsis||Extravascular Lung Water Index in Severe Sepsis||Completed||N/A|67|Actual|Chang Gung Memorial Hospital||1|||f||||||||||||||2018-06-01 00:31:30.398385|2018-06-01 00:31:30.398385
NCT00986115|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2017-05-24|2009-09-28|2009-09-29|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2010||2010-07-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|Forest||Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy|Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy|Withdrawn||N/A|0|Actual|University of California, Davis||2||our site was unable to enroll any qualified subjects|f||||t||||||||||2018-06-01 00:31:40.370956|2018-06-01 00:31:40.370956
NCT00986258|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|2012-05-31||2014-05-09|2009-09-28|2009-09-29|Estimate|2013-02-06|2013-03-18|Estimate||||2014-05-09|2014-05-19|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability|Terminated||Phase 3|136|Actual|Grünenthal GmbH|The results of this trial have to be interpreted under the consideration that it was an open-label trial which was prematurely terminated.|1||This clinical trial was terminated early, due to slow recruitment and study drug shortages.|f||||f||||||||||2018-06-01 00:31:30.500126|2018-06-01 00:31:30.500126
NCT00986245|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2012-07-07||2013-09-04|2009-09-27|2009-09-29|Estimate|2013-09-04|2013-09-09|Estimate||||2013-09-04|2013-09-09|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily|An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease|Completed||Phase 4|82|Actual|Seoul National University Hospital|This study was designed to open-label study. We cannot exclude the psychological effect of each regimen.|2|||f||||f||||||||||2018-06-01 00:31:31.048601|2018-06-01 00:31:31.048601
NCT00986232|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2010-01-25||2015-03-23|2009-09-25|2009-09-29|Estimate|2010-01-25|2010-02-15|Estimate||||2015-03-23|2015-04-10|Estimate|April 1999||1999-04-30|March 2015|2015-03-31|September 2000|Actual|2000-09-30|April 2000|Actual|2000-04-30||Interventional|||ProQuad Dose Selection Study (V221-011)(COMPLETED)|A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections|Completed||Phase 2|1551|Actual|Merck Sharp & Dohme Corp.|Seven (7) participants received unknown clinical material and 1 participant received diluent only; they were considered to be protocol violators and weren't included in the efficacy/safety analyses.|4|||f||||f||||||||||2018-06-01 00:31:31.53668|2018-06-01 00:31:31.53668
NCT00986219|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-12-16|2009-09-28|2009-09-29|Estimate|||||||2009-12-16|2009-12-17|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Observational|||A Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms|"A Cross Sectional Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms and the Limitations of Daily Activities in Primary Care. The  Asthma Language  Survey"|Completed|||696|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:31:32.570519|2018-06-01 00:31:32.570519
NCT00986206|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|||2018-01-03|2009-09-26|2009-09-29|Estimate|||||||2018-01-03|2018-01-05|Actual|June 2009||2009-06-30|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer|Development of an Assay for the Early Detection of Ovarian Cancer.|Completed|||525|Actual|Women and Infants Hospital of Rhode Island|||1||f||||f||||||Samples Without DNA|"~     Serum, Plasma, Urine~   "|||2018-06-01 00:31:32.665197|2018-06-01 00:31:32.665197
NCT00986193|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2017-05-31|2009-09-28|2009-09-29|Estimate|||||||2017-05-31|2017-06-01|Actual|December 2008||2008-12-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2011|Actual|2011-04-30||Interventional|||Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis|Randomized Comparison of Transapical Transcatheter Treatment Versus Conventional Surgery in Patients With Native Aortic Valve Stenosis|Terminated||N/A|72|Actual|Aarhus University Hospital Skejby||2||By recommendation from the Data and safety monitoring board|f||||f||||||||Undecided||2018-06-01 00:31:32.735604|2018-06-01 00:31:32.735604
NCT00986180|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2011-11-23||2012-12-17|2009-09-25|2009-09-29|Estimate|2012-01-27|2012-02-29|Estimate||||2012-12-17|2012-12-19|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain|A Randomized, Double-Blind, Parallel-Group Study of NUCYNTA (Tapentadol) Immediate Release vs. Oxycodone Immediate Release for the Treatment of Acute Low Back Pain|Completed||Phase 3|667|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|There were 19 subjects either did not take medication or did not have verifiable drug exposure. 2 subjects were randomized in two different sites, only one site information were included. 1 subject were randomized in error.|2|||f||||f||||||||||2018-06-01 00:31:32.839085|2018-06-01 00:31:32.839085
NCT00986167|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-28|2009-09-28|2009-09-29|Estimate|||||||2009-09-28|2009-09-29|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry|Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry|Unknown status|Not yet recruiting|Phase 4|72|Anticipated|Bayside Health||1|||f||||t||||||||||2018-06-01 00:31:34.52799|2018-06-01 00:31:34.52799
NCT00986154|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2015-02-05||2015-03-13|2009-09-28|2009-09-29|Estimate|2015-02-05|2015-02-25|Estimate||||2015-03-13|2015-04-02|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).|A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).|Completed||Phase 3|8292|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||||2018-06-01 00:31:35.104052|2018-06-01 00:31:35.104052
NCT00986141|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2013-04-23|2009-09-28|2009-09-29|Estimate|||||||2013-04-23|2013-04-24|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|SLT||Effects of Selective Laser Trabeculoplasty|Effect of Selective Laser Trabeculoplasty (SLT) on Diurnal Intraocular Pressure in Open-Angle Glaucoma Patients on Medical Treatment|Terminated|||30|Actual|University of Kentucky|||2|PI left the University|f||||f||||||||||2018-06-01 00:31:40.146537|2018-06-01 00:31:40.146537
NCT00986128|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-06-08|2009-09-25|2009-09-29|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2001||2001-03-31|April 2010|2010-04-30|October 2002|Actual|2002-10-31|||||Interventional|||A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients|A Comparative Study of the Steady State Pharmacokinetics of Lithium Before and During Multiple Oral Daily Topiramate (RWJ-17021) Dosing in Patients With Bipolar Disorders|Completed||Phase 1|32|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||||||||||||||||2018-06-01 00:31:40.210213|2018-06-01 00:31:40.210213
NCT00986102|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2013-01-04||2013-01-04|2009-09-28|2009-09-29|Estimate|2013-01-04|2013-02-07|Estimate||||2013-01-04|2013-02-07|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region|A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region|Completed||Phase 4|216|Actual|Johnson & Johnson Pte Ltd||1|||f||||||||||||||2018-06-01 00:31:40.486093|2018-06-01 00:31:40.486093
NCT00986089|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2016-12-20|2009-09-28|2009-09-29|Estimate|||||||2016-12-20|2016-12-22|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Intrauterine Device (IUD) Placement at the Time of Cesarean Section|Pilot Study of Copper IUD Placement at the Time of Cesarean Section|Withdrawn|||0|Actual|University of Kentucky|||1|Principal Investigator left the University of Kentucky before enrollment could begin.|f||||f||||||||||2018-06-01 00:31:41.884331|2018-06-01 00:31:41.884331
NCT00986076|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|||2009-09-28|2009-09-28|2009-09-29|Estimate|||||||2009-09-28|2009-09-29|Estimate|March 2008||2008-03-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery|Randomized Clinical Trial Evaluating Anti-inflammatory Effect of Low Molecular-Weight Heparin in Pediatric Cataract and Intraocular Lens Surgery|Completed||Phase 4|23|Actual|Iladevi Cataract and IOL Research Center||2|||f||||t||||||||||2018-06-01 00:31:41.946186|2018-06-01 00:31:41.946186
NCT00986063|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-27|||2013-04-19|2009-09-28|2009-09-29|Estimate|||||||2013-04-19|2013-04-22|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|GENPART||Genotype Based Personalized Prescription of Nevirapine|A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine|Completed||Phase 4|1200|Actual|Mahidol University||2|||f||||t||||||||||2018-06-01 00:31:42.023564|2018-06-01 00:31:42.023564
NCT00986050|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2011-07-25|2009-09-28|2009-09-29|Estimate|||||||2011-07-25|2011-07-26|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|May 2008|Actual|2008-05-31||Interventional|DEBATER||Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction|A Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Segment Elevation Myocardial Infarction The Eindhoven Reperfusion Study|Completed||Phase 4|907|Actual|Catharina Ziekenhuis Eindhoven||4|||f||||t||||||||||2018-06-01 00:31:42.097136|2018-06-01 00:31:42.097136
NCT00986037|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2017-11-17|2009-09-28|2009-09-29|Estimate|||||||2017-11-17|2017-11-21|Actual|October 2009||2009-10-31|March 2011|2011-03-31||||July 2010|Actual|2010-07-31||Interventional|||Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma||Completed||Phase 1|47|Anticipated|AbbVie||3|||f||||f||||||||||2018-06-01 00:31:42.173079|2018-06-01 00:31:42.173079
NCT00986024|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2012-12-12|2009-09-28|2009-09-29|Estimate|||||||2012-12-12|2012-12-13|Estimate|August 2006||2006-08-31|December 2012|2012-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Resistance and/or Endurance Training, What is Most Effective in Prevention of Cardiovascular Diseases?|Strength Training Versus Aerobic Interval Training to Modify Risk Factors of the Metabolic Syndrome|Completed||N/A|31|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-06-01 00:31:42.243709|2018-06-01 00:31:42.243709
NCT00986011|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|||2013-07-09|2009-09-26|2009-09-29|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Study of a Smart Growth Community's Effect on Prevention of Obesity in Middle-, Moderately Low- and Low-Income Families|Effects of A Smart Growth Community on Prevention of Family Obesity Risks|Completed|||780|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:31:42.33559|2018-06-01 00:31:42.33559
NCT00985998|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-27|||2015-08-18|2009-09-28|2009-09-29|Estimate|||||||2015-08-18|2015-08-19|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer|Phase 1 Study of Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|Biotech Pharmaceutical Co., Ltd.||1||no paticipants enrolled|f||||f||||||||||2018-06-01 00:31:42.440598|2018-06-01 00:31:42.440598
NCT00985985|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2013-07-25||2014-06-19|2009-09-26|2009-09-29|Estimate|2014-06-12|2014-06-16|Estimate||||2014-06-19|2014-06-27|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation|A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Evaluate Efficacy and Safety of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation|Completed||Phase 3|723|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 00:31:42.524578|2018-06-01 00:31:42.524578
NCT00985972|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2014-03-14|2009-09-28|2009-09-29|Estimate|||||||2014-03-14|2014-03-17|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|December 2010|Actual|2010-12-31||Observational|PANE||Physical Activity and Nutritional Education as School-based Interventions to Control Obesity in Children and Adolescents|Physical Activity and Nutritional Education as School-based Interventions to Control Overweight in Children and Adolescents: a Systematic Review (Project PANE)|Completed|||41634|Actual|University of Sao Paulo General Hospital|||2||f||||t||||||||||2018-06-01 00:31:43.167684|2018-06-01 00:31:43.167684
NCT00985959|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2013-05-30||2013-10-31|2009-09-25|2009-09-29|Estimate|2013-10-31|2013-12-02|Estimate||||2013-10-31|2013-12-02|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)|A Phase I/II Clinical Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)|Completed||Phase 1|101|Actual|Janssen Pharmaceutical K.K.||4|||f||||t||||||||||2018-06-01 00:31:43.290924|2018-06-01 00:31:43.290924
NCT00985946|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2017-03-17||2017-06-19|2009-09-28|2009-09-29|Estimate|2017-06-19|2017-07-17|Actual||||2017-06-19|2017-07-17|Actual|May 2010||2010-05-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study of Panobinostat in Patients With Neuroendocrine Tumors|A Phase II Trial of Panobinostat in Patients With Neuroendocrine Tumors|Terminated||Phase 2|15|Actual|University of Wisconsin, Madison|This study was terminated early because of the use of objective response rate as the primary outcome measure, which is a shortcoming of this study.|1||Study did not meet statistical requirements to continue.|f||||t||||||||||2018-06-01 00:31:44.231503|2018-06-01 00:31:44.231503
NCT00985764|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2010-11-03|2009-09-25|2009-09-28|Estimate|||||||2010-11-03|2010-11-04|Estimate|May 2007||2007-05-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Venous Air Embolism in Cesarean Delivery, Especially Placental Previa||Completed|||80|Actual|Yonsei University|||1||f||||||||||||||2018-06-01 00:31:46.537557|2018-06-01 00:31:46.537557
NCT00985933|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-05-03|2009-09-28|2009-09-29|Estimate|||||||2011-05-03|2011-05-04|Estimate|February 2010||2010-02-28|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers|A Single Center, Double-Blind, Randomized, Double Dummy, Placebo-Controlled, Three-Period Crossover Study to Assess the Effects of a mGluR2/3 Positive Allosteric Modulator [AZD8529] Upon Ketamine-Induced Cortical Stimulation and Impairment of Working-Memory Related Activation of the Prefrontal Cortex|Completed||Early Phase 1|20|Anticipated|AstraZeneca||3|||f||||||||||||||2018-06-01 00:31:44.585234|2018-06-01 00:31:44.585234
NCT00985920|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-28|||2011-04-08|2009-09-28|2009-09-29|Estimate|||||||2011-04-08|2011-04-11|Estimate|September 2007||2007-09-30|April 2011|2011-04-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Topical Tranexamic Acid for Total Knee Arthroplasty|Efficacy of Intraoperative Topical Application of Tranexamic Acid in Reducing Perioperative Bleeding in Total Knee Arthroplasty|Completed||Phase 4|125|Anticipated|University Health Network, Toronto||3|||f||||t||||||||||2018-06-01 00:31:44.695345|2018-06-01 00:31:44.695345
NCT00985907|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2017-09-15|2009-09-28|2009-09-29|Estimate|||||||2017-09-15|2017-09-18|Actual|June 2004||2004-06-30|September 2017|2017-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|DMV||Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|13|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:31:44.793989|2018-06-01 00:31:44.793989
NCT00985894|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2017-05-24|2009-09-28|2009-09-29|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2009||2009-09-30|May 2017|2017-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis|Comparison Between Asynchronous Online Care Model for the Management of Atopic Dermatitis With That of Face-to-Face, Office Visits|Completed||N/A|183|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 00:31:44.877978|2018-06-01 00:31:44.877978
NCT00985881|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2018-05-30|2009-09-28|2009-09-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 1, 2007|Actual|2007-04-01|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|February 28, 2020|Anticipated|2020-02-28||Interventional|||Use of Subtle Vibration to Improve Walking Ability by Lower Limb Amputees|Mechanically-induced Stochastic Resonance to Improve Amputee Gait|Recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-06-01 00:31:44.948663|2018-06-01 00:31:44.948663
NCT00985868|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|||2013-04-17|2009-09-26|2009-09-29|Estimate|||||||2013-04-17|2013-04-18|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors|A CCLG/Cancer Research UK Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) Given for 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents With Relapsed and Refractory Solid Tumors|Completed||Phase 1|24|Actual|Cancer Research UK|||||f||||||||||||||2018-06-01 00:31:45.02315|2018-06-01 00:31:45.02315
NCT00985855|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-09-13|2009-09-28|2009-09-29|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2009||2009-09-30|January 2011|2011-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer|Feasibility of Cetuximab (ERBITUX®) Associated With Concomitant Radio-chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer: a Phase II, Randomised Study|Completed||Phase 2|91|Actual|Institut de Cancérologie de la Loire||2|||f||||t||||||||||2018-06-01 00:31:45.088679|2018-06-01 00:31:45.088679
NCT00985842|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2018-05-30|2009-09-25|2009-09-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 1, 2009|Actual|2009-11-01|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|October 26, 2012|Actual|2012-10-26||Interventional|||Study to Determine if Different Prosthetic Sockets Effect How Much Oxygen is in the Tissue of Lower Limb Amputees While They Are Walking|Socket System Effect on Tissue Oxygenation During Amputee Gait|Active, not recruiting||N/A|40|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-06-01 00:31:45.155009|2018-06-01 00:31:45.155009
NCT00985829|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|2009-09-30||2009-11-18|2009-09-26|2009-09-28|Estimate|2009-11-18|2009-12-22|Estimate||||2009-11-18|2009-12-22|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|March 2009|Actual|2009-03-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma|Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma|Completed||Phase 1|28|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-06-01 00:31:45.239492|2018-06-01 00:31:45.239492
NCT00985816|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-11-07|2009-09-26|2009-09-28|Estimate|||||||2011-11-07|2011-11-08|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effects of Lactobacillus Reuteri DSM 17938 on Immunomodulation and Gastric Motility in Preterm Newborns|The Effects of Lactobacillus Reuteri DSM 17938 on Immunomodulation and Gastric Motility in Preterm Newborns|Completed||Early Phase 1|80|Anticipated|University of Bari||2|||f||||f||||||||||2018-06-01 00:31:45.442862|2018-06-01 00:31:45.442862
NCT00985803|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-26|||2009-10-07|2009-09-26|2009-09-28|Estimate|||||||2009-10-07|2009-10-08|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|March 2010||2010-03-31|November 2009||2009-11-30||Interventional|LESPA||Physical Activity in Patients With Systemic Lupus Erythematosus|Comparison of Cardiovascular Training Versus Resistance Training In Patients With Systemic Lupus Erythematosus: Controlled Randomized Clinical Trial|Unknown status|Enrolling by invitation|Phase 1|60|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-06-01 00:31:45.592141|2018-06-01 00:31:45.592141
NCT00985790|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2012-11-28|2010-07-02|2016-09-27|2009-09-24|2009-09-28|Estimate|2013-02-07|2013-03-12|Estimate|2010-07-02|2010-07-07|Estimate|2016-09-27|2016-11-02|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children|Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine GSK2321138A in Healthy Children|Completed||Phase 2|599|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:31:45.693702|2018-06-01 00:31:45.693702
NCT00985777|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2016-02-29|2009-09-25|2009-09-28|Estimate|||||||2016-02-29|2016-03-01|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Interventional|||Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia|A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia|Completed||Phase 1|26|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 00:31:46.424854|2018-06-01 00:31:46.424854
NCT00985751|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2017-05-11|2011-04-01|2017-05-11|2009-09-24|2009-09-28|Estimate|2017-05-11|2017-10-06|Actual|2011-04-01|2011-04-11|Estimate|2017-05-11|2017-10-06|Actual|November 24, 2009||2009-11-24|March 2017|2017-03-31|March 2, 2011|Actual|2011-03-02|October 12, 2010|Actual|2010-10-12||Interventional|||Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination|Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Children Aged 12-23 Months at the Time of First Vaccination.|Completed||Phase 2|257|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:31:46.669746|2018-06-01 00:31:46.669746
NCT00985738|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2016-03-16||2016-04-15|2009-09-25|2009-09-28|Estimate|2016-03-16|2016-04-18|Estimate||||2016-04-15|2016-05-17|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||A one sided test of proportions with an alpha level of 0.025 was performed for a conservative Fisher’s exact method. It was estimated that an 80% power in a test of proportions with 100 men in each arm would detect a 17% difference in proportion of men with increased tumor volume (upstaging) between the treatment arm and the control arm.|Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer|A Randomized Placebo-Controlled Double-Blind Clinical Trial to Assess the Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer|Terminated||Phase 2|16|Actual|University of Colorado, Denver|This study was terminated due to low accrual.|2||Low recruitment|f||||t||||||||No||2018-06-01 00:31:49.318093|2018-06-01 00:31:49.318093
NCT00985725|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2012-02-07||2015-03-03|2009-09-25|2009-09-28|Estimate|2012-03-09|2012-04-06|Estimate||||2015-03-03|2015-03-23|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder|Phase 2, Multicenter, Randomized, Double-blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Clinically Significant, Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder|Completed||Phase 2|143|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:31:49.728128|2018-06-01 00:31:49.728128
NCT00985712|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2012-05-02||2012-05-02|2009-09-25|2009-09-28|Estimate|2012-05-02|2012-06-04|Estimate||||2012-05-02|2012-06-04|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study on the Effect of 2 Pen Devices on HbA1c|A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults With Type 1 Diabetes: Novel Pen With Memory Function (HumaPen Memoir) vs. Conventional Pen Without Memory Function (HumaPen Luxura)|Completed||Phase 4|263|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:31:50.876202|2018-06-01 00:31:50.876202
NCT00985699|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2014-07-23|2009-09-25|2009-09-28|Estimate|||||||2014-07-23|2014-07-24|Estimate|April 2009||2009-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma|Pharmacogenomics of Oxidative Stress-Related Genes in Lymphoma|Completed|||337|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:31:51.692857|2018-06-01 00:31:51.692857
NCT00985686|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2015-01-14||2015-07-07|2009-09-24|2009-09-28|Estimate|2015-02-19|2015-03-06|Estimate||||2015-07-07|2015-07-29|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|LEAP|For study arm, older subgroup - the sample size indicated is 15 instead of 16 as the one participant dropped out after baseline. As no other data was collected for this participant, the decision of the team was to exclude them from the analysis.|E-Mental Health Adolescent Depression Program (LEAP)|Evaluation of a Spirituality Informed E-mental Health Intervention (LEAP Project) for Major Depressive Disorder in Adolescents and Young Adults - A Randomized Controlled Pilot Trial|Completed||N/A|63|Actual|Canadian Institute of Natural and Integrative Medicine|Limitations Inconsistent followup by all study participants Overall generalizability is limited due to a predominantly female sample Self-selection of participants with an open attitude to spirituality No comparison to placebo or active treatment|2|||f||||f||||||||||2018-06-01 00:31:51.954292|2018-06-01 00:31:51.954292
NCT00985673|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2011-12-21||2016-09-20|2009-09-24|2009-09-28|Estimate|2011-12-21|2012-01-30|Estimate||||2016-09-20|2016-10-20|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults|A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age|Completed||Phase 2|611|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:31:52.828753|2018-06-01 00:31:52.828753
NCT00985660|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-25|2009-09-25|2009-09-28|Estimate|||||||2009-09-25|2009-09-28|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg|Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets (30 mg; Mylan) and Sular® Extended Release Tablets (30 mg; First Horizon) in Healthy Volunteers|Completed||Phase 1|78|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:32:00.259456|2018-06-01 00:32:00.259456
NCT00985647|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-02-09|2009-09-25|2009-09-28|Estimate|||||||2011-02-09|2011-02-11|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|ENCORE2||Pharmacokinetics of Lamivudine at Two Different Doses|Pharmacokinetics of Plasma Lamivudine (3TC), and Its Active Intracellular Anabolite 3TC−Triphosphate Over a 24 Hour Dosing Interval Following Administration of 3TC 300 mg and 150 mg Once Daily to HIV−Negative Healthy Volunteers|Completed||Phase 1/Phase 2|24|Actual|Kirby Institute||2|||f||||t||||||||||2018-06-01 00:32:00.342932|2018-06-01 00:32:00.342932
NCT00985634|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-25|2009-09-25|2009-09-28|Estimate|||||||2009-09-25|2009-09-28|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|LeGoo||Clinical Evaluation of LeGoo™ Internal Vessel Occluder Versus Traditional Vessel Loops|Randomized Clinical Evaluation of LeGoo™ Internal Vessel Occluder Vs Traditional Vessel Loops|Unknown status|Recruiting|N/A|110|Anticipated|Pluromed, Inc.||2|||f||||t||||||||||2018-06-01 00:32:00.458309|2018-06-01 00:32:00.458309
NCT00985452|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2012-10-09|2009-09-25|2009-09-28|Estimate|||||||2012-10-09|2012-10-10|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Impact of GlowCaps Connect™ and Its Services on Hypertension Medication Adherence|The Impact of GlowCaps Connect™ and Its Services on Hypertension Medication Adherence: A Randomized Controlled Trial|Completed||N/A|139|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-06-01 00:32:04.284211|2018-06-01 00:32:04.284211
NCT00985621|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25||2012-01-27|2012-08-23|2009-09-25|2009-09-28|Estimate||||2012-08-23|2012-08-30|Estimate|2012-08-23|2012-08-30|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Tanezumab In Osteoarthritis Of The Hip Or Knee|A Phase 3 Randomized, Double-Blind, Placebo- And Oxycodone-Controlled, Multicenter Study Of The Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip|Terminated||Phase 3|600|Actual|Pfizer||4||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:32:00.602413|2018-06-01 00:32:00.602413
NCT00985608|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2010-01-25|2009-09-25|2009-09-28|Estimate|||||||2010-01-25|2010-01-26|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|September 2009|Anticipated|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study|Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 00:32:01.271835|2018-06-01 00:32:01.271835
NCT00985595|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2015-08-03|2009-09-25|2009-09-28|Estimate|||||||2015-08-03|2015-08-05|Estimate|January 2006||2006-01-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|CASALEAP||Learning Effective Approaches to Prevention|Quality Community Services for Adolescent Drug Abuse|Completed|||200|Actual|The National Center on Addiction and Substance Abuse at Columbia University|||||f||||t||||||||||2018-06-01 00:32:01.413369|2018-06-01 00:32:01.413369
NCT00985582|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-05-25|2009-09-25|2009-09-28|Estimate|||||||2011-05-25|2011-05-27|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|SEA032||Antiviral Therapy for Influenza A H1N1|Antiviral Treatment in Adults and Children With Novel Influenza A (H1N1) Respiratory Tract Infection - a Clinical, Virological and Pharmacokinetic Study.|Completed|||181|Actual|South East Asia Infectious Disease Clinical Research Network|||||f||||t||||||Samples With DNA|"~     Nasal swabs, throat swabs, nasopharyngeal aspirates, rectal swabs, urine, blood, will be~     obtained for virological analyses, according to the age group specific study schedules~   "|||2018-06-01 00:32:01.665694|2018-06-01 00:32:01.665694
NCT00985569|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-11-22|2009-09-25|2009-09-28|Estimate|||||||2010-11-22|2010-11-23|Estimate|November 2009||2009-11-30|November 2010|2010-11-30|November 2010|Anticipated|2010-11-30|April 2010|Anticipated|2010-04-30||Observational|STOOL||Surveying The Outcomes Of Lubiprostone (The STOOL Study) in Nursing Home Residents|Surveying The Outcomes Of Lubiprostone (The STOOL Study): The Effect of Lubiprostone on Reducing the Number of Medications Prescribed to Nursing Home Residents and Its Impact on Selected Quality Indicators|Withdrawn|||105|Anticipated|Synergy Health Solutions|||1|Enrollment was never begun.|f||||t||||||||||2018-06-01 00:32:01.781484|2018-06-01 00:32:01.781484
NCT00985556|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-10-19|2009-09-25|2009-09-28|Estimate|||||||2011-10-19|2011-10-20|Estimate|January 2009||2009-01-31|September 2009|2009-09-30||||||||Interventional|||Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer|Randomized Phase II Study of S-1 (SOX) or Capecitabine (XELOX) in Combination With Oxaliplatin in Patients With Recurrent or Metastatic Gastric Cancer|Unknown status|Recruiting|Phase 2|130|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:32:01.856394|2018-06-01 00:32:01.856394
NCT00985543|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2011-02-04||2011-03-02|2009-09-25|2009-09-28|Estimate|2011-03-02|2011-03-29|Estimate||||2011-03-02|2011-03-29|Estimate|October 2009||2009-10-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|ENCORE3||Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.|Pharmacokinetics of Plasma Lopinavir/Ritonavir Over a 12 Hour Dosing Interval Following Administration of 400/100, 200/150, and 200/50 mg Twice Daily to HIV-negative Healthy Volunteers|Completed||Phase 1|22|Actual|Kirby Institute||3|||f||||f||||||||||2018-06-01 00:32:02.070759|2018-06-01 00:32:02.070759
NCT00985530|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2013-10-28|2009-09-25|2009-09-28|Estimate|||||||2013-10-28|2013-10-30|Estimate|October 2009||2009-10-31|October 2013|2013-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia|A Phase I Trial of Tamibarotene and Arsenic Trioxide for the Treatment of Relapsed Acute Promyelocytic Leukemia|Terminated||Phase 1|4|Actual|Northwestern University||1||Supporting agency withdrew funding for study.|f||||||||||||||2018-06-01 00:32:02.320965|2018-06-01 00:32:02.320965
NCT00985517|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2017-01-06|2009-09-25|2009-09-28|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease|A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Sangamo Therapeutics||2|||f||||t||||||||||2018-06-01 00:32:02.424104|2018-06-01 00:32:02.424104
NCT00985504|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2011-08-29||2011-12-07|2009-09-25|2009-09-28|Estimate|2011-08-29|2011-10-03|Estimate||||2011-12-07|2011-12-13|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Patients With Major Depressive Disorder and Residual Apathy|A Phase 4, 8-week, Double-blind, Randomized Study Comparing Switching to Duloxetine or Escitalopram in Patients With Major Depressive Disorder and Residual Apathy in the Absence of Depressed Mood|Completed||Phase 4|483|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:32:02.595983|2018-06-01 00:32:02.595983
NCT00985491|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2016-02-13||2016-08-03|2009-09-25|2009-09-28|Estimate|2016-06-22|2016-08-03|Estimate||||2016-08-03|2016-09-15|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study for Short Term Weight Loss in Candidates for Bariatric Surgery|A Pilot Trial of the GI EndoBarrier Liner for Short Term Weight Loss in Subjects Who Are Candidates for Bariatric Surgery|Completed||Phase 2|46|Actual|GI Dynamics||1|||f||||f||||||||Yes||2018-06-01 00:32:03.791103|2018-06-01 00:32:03.791103
NCT00985478|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-08-24|2009-09-25|2009-09-28|Estimate|||||||2011-08-24|2011-08-25|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||First in Man Study With SLV342|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV342 in Young Healthy Male Subjects|Terminated||Phase 1|48|Actual|Abbott||2||Terminated on 14 Sep 2010 due to strategic considerations|f||||f||||||||||2018-06-01 00:32:03.966255|2018-06-01 00:32:03.966255
NCT00985465|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24||2012-11-16|2016-09-26|2009-09-24|2009-09-28|Estimate||||2012-11-16|2012-11-21|Estimate|2016-09-26|2016-09-28|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali|Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Malian Children|Completed||Phase 3|210|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:32:04.030543|2018-06-01 00:32:04.030543
NCT00985439|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2011-11-22||2012-05-15|2009-09-25|2009-09-28|Estimate|2012-03-01|2012-03-29|Estimate||||2012-05-15|2012-05-22|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of Diclofenac Capsules to Treat Dental Pain|A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars|Completed||Phase 2|202|Actual|Iroko Pharmaceuticals, LLC||4|||f||||f||||||||||2018-06-01 00:32:04.362708|2018-06-01 00:32:04.362708
NCT00985426|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24||2014-06-16|2018-02-20|2009-09-25|2009-09-28|Estimate||||2014-06-16|2014-06-19|Estimate|2018-02-20|2018-02-22|Actual|September 2009||2009-09-30|February 2018|2018-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients|An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)|Completed||Phase 3|521|Actual|Dynavax Technologies Corporation||2|||f||||t||||||||No||2018-06-01 00:32:04.666574|2018-06-01 00:32:04.666574
NCT00985413|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-06-22|2009-09-25|2009-09-28|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Observational Study to Assess Natural History in Cockayne Syndrome Patients|An Observational Study to Assess the Natural History Including Growth and Hearing in Patients With Cockayne Syndrome|Terminated|||40|Anticipated|DNage B.V.||||The company DNage is in receivership and no longer functional|f||||t||||||Samples With DNA|"~     whole blood, plasma, serum, white blood cells, urine, tissue~   "|||2018-06-01 00:32:04.742416|2018-06-01 00:32:04.742416
NCT00985400|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2018-03-13|2009-09-25|2009-09-28|Estimate|||||||2018-03-13|2018-03-14|Actual|November 2010|Actual|2010-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery|Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients|Active, not recruiting||N/A|154|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:32:04.80146|2018-06-01 00:32:04.80146
NCT00985387|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-10-11|2009-09-25|2009-09-28|Estimate|||||||2011-10-11|2011-10-12|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients|Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study|Completed|||1215|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-06-01 00:32:04.889375|2018-06-01 00:32:04.889375
NCT00985374|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2016-11-01|2009-09-25|2009-09-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors|Multiple Ascending Dose (MAD) Phase Ib/II Study of the mTOR Inhibitor (RAD001) in Combination With the IGF-1R Antagonist (R1507) for the Treatment of Patients With Advanced Solid Tumors|Terminated||Phase 1|11|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:32:05.082666|2018-06-01 00:32:05.082666
NCT00985361|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2010-05-05|2009-09-25|2009-09-28|Estimate|||||||2010-05-05|2010-05-06|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus|Effect of Vitamin D Supplementation on Hemoglobin A1c in Patients With Uncontrolled Type 2 Diabetes Mellitus|Completed||N/A|37|Actual|ProMedica Health System||2|||f||||f||||||||||2018-06-01 00:32:05.159634|2018-06-01 00:32:05.159634
NCT00985348|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2012-05-15|2009-09-25|2009-09-28|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)|Randomized, Monocenter, Open Label, Two-way Cross-over, Single Dose Bioequivalence Study of Two Oral Formulations of Levetiracetam in Healthy Male & Female Japanese Subjects|Completed||Phase 1|26|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 00:32:05.249627|2018-06-01 00:32:05.249627
NCT00985335|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2011-11-16|2009-09-25|2009-09-28|Estimate|||||||2011-11-16|2011-11-18|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|Neem||Effectiveness of TheraNeem Lip Therapy for Herpes Simplex Labialis|Effectiveness of TheraNeem Lip Therapy of Common Symptoms of Herpes Simplex Labialis A Prospective Experimental Case Series (n=5)|Completed||Phase 1|5|Actual|Southern California University of Health Sciences||1|||f||||f||||||||||2018-06-01 00:32:05.347564|2018-06-01 00:32:05.347564
NCT00985322|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2016-05-30|2009-09-25|2009-09-28|Estimate|||||||2016-05-30|2016-06-01|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ARCADIA||Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis|A Prospective, Randomized, Open Label, Blinded End-point (Probe) Trial to Evaluate Whether, at Comparable Blood Pressure Control, ACE Inhibitor Therapy More Effectively Than Non RAS Inhibitor Therapy Reduces CArdiovascular Morbidity and Mortality in Chronic DIAlysis Patients With Left Ventricular Hypertrophy and/or Arterial Hypertension (ARCADIA Study)|Completed||Phase 3|269|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-06-01 00:32:05.424509|2018-06-01 00:32:05.424509
NCT00985309|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-25|2009-09-25|2009-09-28|Estimate|||||||2009-09-25|2009-09-28|Estimate||||September 2009|2009-09-30||||||||Observational|||Clinical Parameters Predicting Unsatisfactory Cervicovaginal Cytology in Conventional Smears||Completed|||||Taichung Veterans General Hospital|||||f||||f||||||||||2018-06-01 00:32:05.534681|2018-06-01 00:32:05.534681
NCT00985296|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2010-09-20|2009-09-25|2009-09-28|Estimate|||||||2010-09-20|2010-09-21|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|ABC CAC||Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)|A Pilot Study Evaluating the Effect of Conjunctival Allergen Challenge (CAC) on Nasal and Ocular Allergic Symptoms Following Allergen Exposure in the Allergen BioCube (ABC) in Subjects With Seasonal Allergic Rhinoconjunctivitis|Completed|||120|Anticipated|ORA, Inc.|||3||f||||f||||||||||2018-06-01 00:32:05.581464|2018-06-01 00:32:05.581464
NCT00985283|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-09-15|2009-09-25|2009-09-28|Estimate|||||||2011-09-15|2011-09-16|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Feasibility and Effects of Preventive Home Visits for Older Adults|Feasibility and Effects of Preventive Home Visits for Older Adults|Completed||N/A|110|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:32:05.641305|2018-06-01 00:32:05.641305
NCT00985270|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2011-02-09|2009-09-25|2009-09-28|Estimate|||||||2011-02-09|2011-02-10|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis|PXR-agonisti Rifampisiinin Vaikutukset Glukoosi-, Lipidi- ja Hormonihomeostaasiin|Completed||Phase 4|12|Anticipated|University of Oulu||2|||f||||f||||||||||2018-06-01 00:32:05.733253|2018-06-01 00:32:05.733253
NCT00985257|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2010-04-06||2016-01-29|2009-09-25|2009-09-28|Estimate|2010-10-07|2010-11-02|Estimate||||2016-01-29|2016-02-29|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Performance of a New Glucose Meter System in Children and Young Adults|Performance of the DIDGET Blood Glucose Monitoring System in Children and Young Adults|Completed||N/A|123|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-06-01 00:32:05.813476|2018-06-01 00:32:05.813476
NCT00985244|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2013-06-25|2009-09-25|2009-09-28|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|COLUMBUS||Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease|Influence of Macrolide Maintenance Therapy and Bacterial Colonisation on Exacerbation Frequency and Progression of COPD, a Randomized Double-blind Placebo-controlled Trial|Completed||N/A|92|Actual|Amphia Hospital||2|||f||||t||||||||||2018-06-01 00:32:05.985812|2018-06-01 00:32:05.985812
NCT00985231|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2011-02-17||2015-03-04|2009-09-25|2009-09-28|Estimate|2011-02-17|2011-03-14|Estimate||||2015-03-04|2015-03-24|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers|Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers|Completed||N/A|272|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:32:06.1043|2018-06-01 00:32:06.1043
NCT00985218|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2010-09-08|2009-09-25|2009-09-28|Estimate|||||||2010-09-08|2010-09-09|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||In Vitro Human Embryo Culture System|In Vitro Human Embryo Culture System|Completed||Phase 1|40|Anticipated|Incept BioSystems, Inc.||2|||f||||f||||||||||2018-06-01 00:32:06.445004|2018-06-01 00:32:06.445004
NCT00985205|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2018-03-28|2009-09-25|2009-09-28|Estimate|||||||2018-03-28|2018-03-30|Actual|December 2010||2010-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|RE-ENERGIZE||The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury|Effects of Enteral Glutamine Supplementation on Mortality and Infectious Morbidity in Severely Burned Patients: a Multi-center Pilot Trial|Recruiting||Phase 3|2700|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||t||||||||No||2018-06-01 00:32:06.558339|2018-06-01 00:32:06.558339
NCT00985192|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2016-01-29||2016-02-26|2009-09-25|2009-09-28|Estimate|2016-02-26|2016-03-29|Estimate||||2016-02-26|2016-03-29|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Of the 49 subjects enrolled, only 45 were determined to be evaluable due to subject withdrawal, an adverse event, and 2 subjects later determined to be ineligible. 45 is the analysis population|Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer|A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach|Completed||Phase 2|49|Actual|Translational Oncology Research International|This study had several limitations with the major weakness being that it was a single- rm, non-comparative study. At the time this study was launched, a Japanese report indicating a DCR was 50 % was not yet reported.|1|||f||||t||||||||||2018-06-01 00:32:06.847919|2018-06-01 00:32:06.847919
NCT00985179|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2012-11-12|2009-09-25|2009-09-28|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|BIV-BIA||Increasing Vitamin Intake and Physical Activity|"Promoting the Adoption and Maintenance of a Physically Active Lifestyle and a Nutrition Rich in Vitamins With the Help of Two Theory-based Computerized Interventions BI Vit (Boehringer Ingelheim for a Nutrition Rich in Vitamines) and BI Active (Boehringer Ingelheim for Physical Activity) for Employees"|Completed||N/A|1000|Anticipated|Freie Universität Berlin||2|||f||||t||||||||||2018-06-01 00:32:07.287493|2018-06-01 00:32:07.287493
NCT00985166|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2009-12-23||2015-07-16|2009-09-25|2009-09-28|Estimate|2009-12-23|2010-01-29|Estimate||||2015-07-16|2015-07-28|Estimate|August 2000||2000-08-31|July 2015|2015-07-31|May 2003|Actual|2003-05-31|May 2002|Actual|2002-05-31||Interventional|||A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)|Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age|Completed||Phase 3|801|Actual|Merck Sharp & Dohme Corp.|GMTs (adjusted for prevaccination titer, study center, and primary vaccination history status) have been reported in the literature. One subject received diluent only at visit 1 and was excluded from all immunogenicity/safety summaries.|3|||f||||f||||||||||2018-06-01 00:32:07.386177|2018-06-01 00:32:07.386177
NCT00985153|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2010-01-13||2015-11-20|2009-09-25|2009-09-28|Estimate|2010-01-13|2010-02-09|Estimate||||2015-11-20|2015-11-23|Estimate|March 2000||2000-03-31|November 2015|2015-11-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)|Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children|Completed||Phase 3|3927|Actual|Merck Sharp & Dohme Corp.|One additional subject received M-M-R™ II and ProQuad™ vaccines at the same visit in error; this child was excluded from all immunogenicity and safety summaries.|4|||f||||f||||||||||2018-06-01 00:32:07.982455|2018-06-01 00:32:07.982455
NCT00985140|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2016-12-09||2017-05-04|2009-09-25|2009-09-28|Estimate|2017-02-15|2017-04-04|Actual||||2017-05-04|2017-06-02|Actual|June 2009||2009-06-30|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides|A Phase II Study of Total Skin Electron Beam Therapy (TSEBT) to Dose of 12 Gy in Stage IB-IIIA Mycosis Fungoides|Terminated|||13|Actual|Stanford University|||1|Competing studies|f||||t||||||Samples With DNA|"~     2 x 5mm punch biopsies taken at enrollment and during follow up.~   "|Yes||2018-06-01 00:32:08.964822|2018-06-01 00:32:08.964822
NCT00985127|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25||2012-01-18|2012-01-18|2009-09-25|2009-09-28|Estimate||||2012-01-18|2012-01-23|Estimate|2012-01-18|2012-01-23|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout|A Phase 2, Randomized, Double-Blind, Dose-Ranging, Two-Part, Multi-Center Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout|Completed||Phase 2|99|Actual|BioCryst Pharmaceuticals||7|||f||||f||||||||||2018-06-01 00:32:09.129129|2018-06-01 00:32:09.129129
NCT00985114|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|2016-03-20||2016-08-09|2009-09-25|2009-09-28|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity|An Open Label, Randomized, Controlled Study of a Second Generation EndoBarrier™ Liner vs. Diet Control for the Treatment of Type 2 Diabetes|Completed||N/A|77|Actual|GI Dynamics||2|||f||||t||||||||Undecided|"Yes~De-identified individual subject data is on file at the Sponsor"|2018-06-01 00:32:09.275691|2018-06-01 00:32:09.275691
NCT00985101|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-07-26|2009-09-25|2009-09-28|Estimate|||||||2010-07-26|2010-07-27|Estimate|April 2010||2010-04-30|September 2009|2009-09-30||||||||Observational|diabmito I||Study of Cellular Impairments Involved in Diabetic Complications|Study of the Significance of Mitochondrial Dysfunction for Development of Diabetic Complications|Unknown status|Active, not recruiting||80|Anticipated|Naestved Hospital|||2||f||||f||||||||||2018-06-01 00:32:09.720762|2018-06-01 00:32:09.720762
NCT00985088|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2017-09-15|2011-11-17|2017-11-13|2009-09-24|2009-09-28|Estimate|2017-11-13|2017-12-12|Actual|2011-11-17|2011-11-21|Estimate|2017-11-13|2017-12-12|Actual|October 11, 2009|Actual|2009-10-11|November 2017|2017-11-30|December 16, 2010|Actual|2010-12-16|November 9, 2009|Actual|2009-11-09||Interventional|||Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older|A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340273A and GSK2340274A in Adults Aged 18 Years and Older|Completed||Phase 2|1343|Actual|GlaxoSmithKline||8|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:32:10.886297|2018-06-01 00:32:10.886297
NCT00985075|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2009-09-25|2009-09-25|2009-09-28|Estimate|||||||2009-09-25|2009-09-28|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube|A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinitis and Conjunctivitis Following Allergen Exposure in the Allergen BioCube|Completed|||100|Anticipated|ORA, Inc.|||||f||||f||||||||||2018-06-01 00:32:26.256183|2018-06-01 00:32:26.256183
NCT00985062|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-25|2009-09-25|2009-09-28|Estimate|||||||2009-09-25|2009-09-28|Estimate|October 2004||2004-10-31|September 2009|2009-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|FOLFO||Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization|Food Lifestyle and Fertility Outcome|Completed||N/A|54|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-06-01 00:32:26.324486|2018-06-01 00:32:26.324486
NCT00985049|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2018-05-08|2009-09-25|2009-09-28|Estimate|||||||2018-05-08|2018-05-10|Estimate|March 2009||2009-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)|Whole Genome Expression of Left Ventricular Myocardium During Cardiac Surgery|Recruiting|||350|Anticipated|Brigham and Women's Hospital|||||f||||f||||||Samples With DNA|"~     DNA, EDTA , peripheral blood leucocytes, and left ventricle myocardium are all stored in -80C~     frreezer at BWH.~   "|||2018-06-01 00:32:26.403398|2018-06-01 00:32:26.403398
NCT00985036|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-25|||2012-04-20|2009-09-25|2009-09-28|Estimate|||||||2012-04-20|2012-04-24|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|January 2012|Anticipated|2012-01-31|September 2011|Anticipated|2011-09-30||Observational|||Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients|Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?|Withdrawn|||0|Actual|Marquette General Health System|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:32:26.466779|2018-06-01 00:32:26.466779
NCT00985023|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2017-01-13|2009-09-24|2009-09-25|Estimate|||||||2017-01-13|2017-01-18|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Lisfranc||A Comparison of Stainless Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|A Randomized, Prospective Comparison of Stainless Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|Completed||Phase 4|50|Actual|Rothman Institute Orthopaedics||2|||f||||t||||||||||2018-06-01 00:32:26.53639|2018-06-01 00:32:26.53639
NCT00985010|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2009-01-05||2016-10-04|2009-08-17|2009-09-25|Estimate|2009-08-17|2009-09-25|Estimate||||2016-10-04|2016-11-08|Estimate|January 2003||2003-01-31|August 2009|2009-08-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Observational|||Manganese in Women With Encephalopathy|Manganese, Possible Factor of Higher Mortality in Women With Encephalopathy|Terminated|||9|Actual|Materno-Perinatal Hospital of the State of Mexico|Small numbers of subjects analyzed|||The authors finished their jobs in the hospitals where the study was begun.|f||||f||||||||||2018-06-01 00:32:26.626789|2018-06-01 00:32:26.626789
NCT00984997|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2016-06-29|2009-09-24|2009-09-25|Estimate|||||||2016-06-29|2016-06-30|Estimate|October 1993||1993-10-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2007|Actual|2007-06-30||Interventional|||Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors|Phase II Study of Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors|Completed||Phase 2|38|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:32:26.870256|2018-06-01 00:32:26.870256
NCT00984984|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2012-12-04|2009-09-24|2009-09-25|Estimate|||||||2012-12-04|2012-12-05|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|COPOUSEP||Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses|Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses|Unknown status|Recruiting|Phase 3|200|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 00:32:27.009537|2018-06-01 00:32:27.009537
NCT00984971|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2015-08-27|2009-09-24|2009-09-25|Estimate|||||||2015-08-27|2015-08-28|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|RMP02-MTN006||Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet|A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults|Completed||Phase 1|18|Actual|CONRAD||3|||f||||t||||||||||2018-06-01 00:32:27.107917|2018-06-01 00:32:27.107917
NCT00984958|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2014-11-20|2009-09-24|2009-09-25|Estimate|||||||2014-11-20|2014-11-21|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure|Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure Because of Suspected ISD: A Prospective Randomized Study|Unknown status|Recruiting|Phase 3|100|Anticipated|Skaraborg Hospital||2|||f||||t||||||||||2018-06-01 00:32:27.172016|2018-06-01 00:32:27.172016
NCT00984945|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-11-02|2009-09-24|2009-09-25|Estimate|||||||2010-11-02|2010-11-04|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults|Phase 1 Single Centre, Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of Plant-based H5 VLP (Virus-like Particles), (H5N1) Pandemic Influenza Vaccine Adjuvanted With Aluminium Hydroxide and Administered to Healthy Adults 18-60 Years of Age|Completed||Phase 1|48|Anticipated|Medicago||4|||f||||t||||||||||2018-06-01 00:32:27.363725|2018-06-01 00:32:27.363725
NCT00984932|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension|The Effect of Rosuvastatin on Vascular Dysfunction and Inflammatory Markers in Systemic Sclerosis-related Pulmonary Hypertension: Randomized, Double-Blind Placebo-Controlled Trial|Completed||Phase 3|40|Actual|Faculty of Medicine, University of Alexandria||1|||f||||t||||||||||2018-06-01 00:32:27.441617|2018-06-01 00:32:27.441617
NCT00984919|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2016-02-12|2009-09-24|2009-09-25|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|||Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers|Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis|Completed|||10|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 00:32:27.510788|2018-06-01 00:32:27.510788
NCT00984906|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2010-06-07|2009-09-24|2009-09-25|Estimate|||||||2010-06-07|2010-06-08|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|PIFECO||Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler Inhalers|Inspiratory Flow Parameters and Device Handling With Empty Device-metered Dry Powder Inhalers, Easyhaler and Turbuhaler; an Open, Randomised, Multi Centre Study in Patients With Asthma or COPD|Completed||N/A|200|Anticipated|Orion Corporation, Orion Pharma||3|||f||||f||||||||||2018-06-01 00:32:27.578554|2018-06-01 00:32:27.578554
NCT00984893|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2016-03-03|2009-09-24|2009-09-25|Estimate|||||||2016-03-03|2016-03-04|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|IVORY||Intra-venous Zoledronic Acid Once Yearly|A Real-world Study Cohort of Postmenopausal Women With Osteoporosis Taking Zoledronic Acid or Oral Bisphosphonates|Completed|||1551|Actual|Novartis|||2||f||||||||||||||2018-06-01 00:32:27.664468|2018-06-01 00:32:27.664468
NCT00984880|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-12-17|2009-09-24|2009-09-25|Estimate|||||||2009-12-17|2009-12-18|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Interventional|||Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043|Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After a Single Ascending Bolus Dose, and a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Volunteers|Completed||Phase 1|72|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:32:27.749347|2018-06-01 00:32:27.749347
NCT00984867|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2013-01-21||2014-06-09|2009-09-24|2009-09-25|Estimate|2013-08-09|2013-10-14|Estimate||||2014-06-09|2014-06-13|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Dapagliflozin DPPIV Inhibitor add-on Study|A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin|Completed||Phase 3|833|Actual|AstraZeneca|For participants who did not complete 8 and/or 24 weeks, respectively, LOCF was used. All endpoints were evaluated by excluding data after rescue with the exception of systolic blood pressure which was evaluated regardless of rescue medication.|2|||f||||||||||||||2018-06-01 00:32:27.854221|2018-06-01 00:32:27.854221
NCT00984854|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|January 2004||2004-01-31|September 2009|2009-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Investigation Into the Safety of Intradermal Juvidex (M6P) Administered to Wounds of Healthy Subjects|A Trial to Investigate the Clinical Safety, Local Toleration, and Systemic Pharmacokinetics of Repeated, Escalating Concentrations of Intradermal RN1004 to Wounds of Healthy Subjects.|Completed||Phase 1|70|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:32:28.553153|2018-06-01 00:32:28.553153
NCT00984841|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?|"Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?"|Completed||N/A|467|Actual|Scranton-Temple Residency Program||2|||f||||f||||||||||2018-06-01 00:32:28.65387|2018-06-01 00:32:28.65387
NCT00984828|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2016-09-06|2009-09-24|2009-09-25|Estimate|||||||2016-09-06|2016-09-08|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients|A Randomized Study of 4 vs. 8 Cycles of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients|Terminated||Phase 2/Phase 3|23|Actual|Shanghai Jiao Tong University School of Medicine||2||Very slow recruitment|f||||t||||||||No||2018-06-01 00:32:28.726641|2018-06-01 00:32:28.726641
NCT00984815|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2013-03-18||2013-06-19|2009-09-24|2009-09-25|Estimate|2013-06-19|2013-07-25|Estimate||||2013-06-19|2013-07-25|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment|Open-Label Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-Steroidal Anti-Inflammatory Drug Treatment|Completed||Phase 3|86|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||f||||||||||2018-06-01 00:32:28.817969|2018-06-01 00:32:28.817969
NCT00984802|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2011-06-17|2009-09-24|2009-09-25|Estimate|||||||2011-06-17|2011-06-20|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|SUPPORT-1||Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy|A Prospective, Randomized, Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)|Completed||Phase 2|142|Actual|Ischemix, LLC||4|||f||||f||||||||||2018-06-01 00:32:29.054457|2018-06-01 00:32:29.054457
NCT00984776|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|March 2007||2007-03-31|September 2009|2009-09-30||||February 2009|Actual|2009-02-28||Interventional|T9M||Detection of Coronary Vulnerable Plaque With Contrast-enhanced Magnetic Resonance Imaging|Detection of Vulnerable Plaque With Coronary Vessel Wall MRI: Contrast Enhanced MRI With Gadofosveset MS-325.|Completed||N/A|20|Actual|Maastricht University Medical Center|||||f||||||||||||||2018-06-01 00:32:29.227877|2018-06-01 00:32:29.227877
NCT00984763|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2015-05-27|2009-09-24|2009-09-25|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria|A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria|Completed||Phase 1/Phase 2|8|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 00:32:29.286468|2018-06-01 00:32:29.286468
NCT00984750|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2013-02-22|2009-09-24|2009-09-25|Estimate|||||||2013-02-22|2013-02-25|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|DIABASI||Acetyl-L-Carnitine in Type 2 Diabetes|A Prospective, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effect of 6-month Acetylcarnitine Therapy on Arterial Blood Pressure, Lipid and Metabolic Profile, and Kidney Function in Hypertensive Patients With Type 2 Diabetes on Background Simvastatin Therapy|Completed||Phase 3|229|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-06-01 00:32:29.349548|2018-06-01 00:32:29.349548
NCT00984737|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Hyperglycemia in a Coronary Intensive Care Unit|Newly Diagnosed Hyperglycemia and Stress Hyperglycemia in a Coronary Intensive Care Unit|Completed||N/A|||Baskent University|||||f||||t||||||||||2018-06-01 00:32:29.415468|2018-06-01 00:32:29.415468
NCT00984724|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2016-10-06|2009-09-24|2009-09-25|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Reducing Tobacco Related Health Disparities|Reducing Tobacco Related Health Disparities|Completed||N/A|639|Actual|M.D. Anderson Cancer Center||6|||f||||f||||||||||2018-06-01 00:32:29.474688|2018-06-01 00:32:29.474688
NCT00984711|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2010-09-23|2009-09-24|2009-09-25|Estimate|||||||2010-09-23|2010-09-24|Estimate|May 2007||2007-05-31|September 2010|2010-09-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Observational|||Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice|A Phase IV, Post-marketing, Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice|Unknown status|Recruiting||150|Anticipated|PerCuro Clinical Research Ltd|||||f||||f||||||||||2018-06-01 00:32:30.843839|2018-06-01 00:32:30.843839
NCT00984698|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2014-01-06||2014-02-14|2009-09-24|2009-09-25|Estimate|2014-02-14|2014-03-31|Estimate||||2014-02-14|2014-03-31|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||A Trial of Group Psychotherapy for Veterans and Military Personnel With Post Traumatic Stress Disorder (PTSD)|A Trial of Group Psychotherapy for Veterans and Military Personnel With Post Traumatic Stress Disorder (PTSD)|Completed||N/A|115|Actual|University of Arizona||2|||f||||t||||||||||2018-06-01 00:32:30.940931|2018-06-01 00:32:30.940931
NCT00984685|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|October 2009|Anticipated|2009-10-31|September 2009|Anticipated|2009-09-30||Observational|||"Assessment of Risk Factors for Depression Treatment at a Safety Net Clinic"|"Assessment of Risk Factors for Depression Treatment at a Safety Net Clinic"|Unknown status|Recruiting||100|Anticipated|Scranton-Temple Residency Program|||1||f||||f||||||||||2018-06-01 00:32:31.223589|2018-06-01 00:32:31.223589
NCT00984672|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2016-02-17|2009-09-24|2009-09-25|Estimate|||||||2016-02-17|2016-02-19|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Observational|||Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery|Prospective Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery|Unknown status|Enrolling by invitation||240|Anticipated|Mayo Clinic|||2||f||||f||||||||||2018-06-01 00:32:31.319024|2018-06-01 00:32:31.319024
NCT00984659|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2011-12-21|2011-02-24|2017-10-09|2009-09-24|2009-09-25|Estimate|2012-02-09|2012-03-15|Estimate|2011-03-10|2011-03-24|Estimate|2017-10-09|2017-11-08|Actual|October 29, 2009||2009-10-29|October 2017|2017-10-31|July 1, 2010|Actual|2010-07-01|July 1, 2010|Actual|2010-07-01||Interventional|||Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease|Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|366|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:32:31.462049|2018-06-01 00:32:31.462049
NCT00984646|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|April 2005||2005-04-30|September 2009|2009-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10)|A Single-centre, Placebo- and Standard-care-controlled, Double-blind, Randomised Trial to Investigate the Efficacy of Eight Doses of RN1003 in the Reduction of Scarring From the Approximated Wound Margins of Incisional Wounds|Completed||Phase 2|175|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:32:32.730913|2018-06-01 00:32:32.730913
NCT00984633|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2015-05-11|2009-09-24|2009-09-25|Estimate|||||||2015-05-11|2015-05-12|Estimate|June 2003||2003-06-30|May 2015|2015-05-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED)|Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 Following a Single Intubating Dose in Adult Subjects Undergoing Operation Under Sevoflurane or Propofol Anesthesia|Completed||Phase 3|40|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-06-01 00:32:32.84439|2018-06-01 00:32:32.84439
NCT00984620|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2015-07-03|2014-03-27|2015-08-07|2009-09-24|2009-09-25|Estimate|2015-08-07|2015-09-07|Estimate|2014-03-27|2014-04-24|Estimate|2015-08-07|2015-09-07|Estimate|September 2009||2009-09-30|August 2015|2015-08-31||||April 2011|Actual|2011-04-30||Interventional||Full Analysis Set (FAS): contained all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.|Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)|Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II)|Completed||Phase 2|160|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:32:33.005651|2018-06-01 00:32:33.005651
NCT00984607|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-07-26|2009-09-24|2009-09-25|Estimate|||||||2010-07-26|2010-07-28|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Measurement of Gastric Band Stoma Diameter|Accurate Fluoroscopic Measurement of Adjustable Laparoscopic Gastric Band Stoma Diameter|Completed||N/A|30|Anticipated|Saint Raphael Healthcare System||1|||f||||t||||||||||2018-06-01 00:32:34.276444|2018-06-01 00:32:34.276444
NCT00984594|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2013-07-10||2014-05-22|2009-09-24|2009-09-25|Estimate|2014-05-22|2014-06-04|Estimate||||2014-05-22|2014-06-04|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||There are only 3 patients in the baseline analysis due to one patient withdrawing from the study before data collection.|Evaluation of a Composite Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Knee Osteochondral Defects|Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Osteochondral Defects in High-Load-Bearing Region and Low-Load-Bearing Region of the Femoral Condyle|Terminated||Phase 3|4|Actual|RTI Surgical|Enrollment was closed early due to slow enrollment & a potential change in the regulatory pathway for the allograft used in cartilage repair.|2||Slow enrolment & potential regulatory changes for allograft in cartilage repair|f||||f||||||||||2018-06-01 00:32:34.354903|2018-06-01 00:32:34.354903
NCT00984581|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|April 2003||2003-04-30|September 2009|2009-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects|A Single-site, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and Anti-scarring Potential of Intradermal Juvista in Female Subjects Aged 18-45 Years|Completed||Phase 1/Phase 2|35|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:32:34.59879|2018-06-01 00:32:34.59879
NCT00984568|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2013-02-19||2017-03-16|2009-09-24|2009-09-25|Estimate|2013-02-19|2013-04-02|Estimate||||2017-03-16|2017-04-13|Actual|November 2009||2009-11-30|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|MUNIX||Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)|Conventional Step-Up Versus Infliximab Monotherapy in Patients With Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study|Terminated||Phase 3|28|Actual|Merck Sharp & Dohme Corp.|Due to slow recruitment the study was stopped prematurely; participants on study at that time continued to receive treatment per protocol.|2||Due to slow recruitment the study was stopped prematurely.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:32:34.680636|2018-06-01 00:32:34.680636
NCT00984555|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-07-21|2009-09-24|2009-09-25|Estimate|||||||2010-07-21|2010-07-22|Estimate|December 2008||2008-12-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Observational|||Residence Time of Biomarkers of Semen Exposure|Assessment of the Vaginal Residence Time of Biomarkers of Semen Exposure|Completed|||64|Anticipated|CONRAD|||4||f||||f||||||Samples With DNA|"~     Vaginal swabs, semen~   "|||2018-06-01 00:32:35.042416|2018-06-01 00:32:35.042416
NCT00984542|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2013-08-16||2014-01-23|2009-09-24|2009-09-25|Estimate|2014-01-23|2014-03-12|Estimate||||2014-01-23|2014-03-12|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC)who received study drug|Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).|Completed||Phase 2|50|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 00:32:35.123525|2018-06-01 00:32:35.123525
NCT00984529|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2011-01-06|2009-09-24|2009-09-25|Estimate|||||||2011-01-06|2011-01-07|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia|Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia|Completed|||500|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:32:35.441771|2018-06-01 00:32:35.441771
NCT00984516|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times|A Single-site, Placebo-controlled, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and the Scar-improvement Efficacy of Intradermal Applications of Three Doses of Juvidex (5.64mg/100μl, 2.82mg/100μl and 11.28mg/100μl) Given Once Only or Three Times Within and Between Male and Female Subjects Aged 18-45.|Completed||Phase 2|102|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:32:35.525949|2018-06-01 00:32:35.525949
NCT00984503|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|October 2003||2003-10-31|September 2009|2009-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites|A Single-site, Randomised, Double-blind, Phase II Trial to Investigate the Safety, Toleration, Systemic Exposure, Accelerated Healing and Anti-scarring Potential of Juvista in Split Skin Graft Donor Sites in Male Subjects Aged 18-85 Years|Completed||Phase 2|102|Actual|Renovo||4|||f||||f||||||||||2018-06-01 00:32:35.620746|2018-06-01 00:32:35.620746
NCT00984490|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2012-03-12||2012-06-07|2009-09-24|2009-09-25|Estimate|2012-06-07|2012-07-13|Estimate||||2012-06-07|2012-07-13|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery|Pre-Surgical Trial of Metformin in Patients With Operable Breast Cancer|Terminated||N/A|5|Actual|Vanderbilt-Ingram Cancer Center|Because this study was closed prematurely, no assay level markers or pathways were performed consequently no data are available to provide results.|1||slow accrual|f||||t||||||||||2018-06-01 00:32:35.71184|2018-06-01 00:32:35.71184
NCT00984477|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-12-03|2009-09-24|2009-09-25|Estimate|||||||2009-12-03|2009-12-04|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|||||Interventional|||Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects|A Phase I, Exploratory Study to Assess the Pharmacokinetics of Single Oral Doses and a Single Intravenous Radiolabelled Microtracer Dose of AZD5122 in Healthy Male Subjects|Completed||Phase 1|100|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:32:35.864427|2018-06-01 00:32:35.864427
NCT00983996|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-09-22|2009-09-22|2009-09-24|Estimate|||||||2009-09-22|2009-09-24|Estimate|June 2002||2002-06-30|September 2009|2009-09-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)|Single-Dose Fasting In Vivo Bioequivalence Study of Alendronate Sodium Tablets (10 mg; Mylan) and Fosamax Tablets (10 mg; Merck) in Healthy Volunteers|Completed||Phase 1|112|Actual|Mylan Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:32:45.251388|2018-06-01 00:32:45.251388
NCT00984464|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2015-04-08|2009-09-24|2009-09-25|Estimate|||||||2015-04-08|2015-04-10|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma|A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma|Completed||Phase 2|14|Actual|Oncolytics Biotech|||||f||||f||||||||||2018-06-01 00:32:35.930277|2018-06-01 00:32:35.930277
NCT00984451|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2017-12-14|2009-09-24|2009-09-25|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2009||2009-09-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||A Pilot Study for Collection of Anti-Influenza A Immune Plasma|A Pilot Study for Collection of Anti-Influenza A Immune Plasma|Active, not recruiting|||1500|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||f||||||||||2018-06-01 00:32:35.995165|2018-06-01 00:32:35.995165
NCT00984438|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2013-06-26|2009-09-24|2009-09-25|Estimate|||||||2013-06-26|2013-06-27|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme|Phase I/II Trial for Patients With Recurrent Resectable Glioblastoma Multiforme Using Surgery With Implantable BCNU Polymer Followed by Post-operative Irinotecan and Bevacizumab|Withdrawn||Phase 1/Phase 2|0|Actual|University of Cincinnati||1||No accrual|f||||f||||||||||2018-06-01 00:32:36.065327|2018-06-01 00:32:36.065327
NCT00984425|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2014-11-26|2009-09-24|2009-09-25|Estimate|||||||2014-11-26|2014-12-02|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|August 2013|Actual|2013-08-31|July 2012|Actual|2012-07-31||Interventional|||The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors|Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors|Completed||Phase 1|30|Actual|Istituto Clinico Humanitas||4|||f||||f||||||||||2018-06-01 00:32:36.270554|2018-06-01 00:32:36.270554
NCT00984412|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-06|||2016-02-18|2009-09-24|2009-09-25|Estimate|||||||2016-02-18|2016-02-19|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|November 2020|Anticipated|2020-11-30|April 2020|Anticipated|2020-04-30||Interventional|AATT||Allo-Allo Tandem Bone Marrow Transplant (BMT)|Allo-allo Tandem Matched Stem Cell Transplantation (AATT) for the Treatment of Patients With Refractory Acute Leukemia; a Feasibility Phase I/II Study|Recruiting||Phase 1/Phase 2|15|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 00:32:36.347547|2018-06-01 00:32:36.347547
NCT00984399|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2017-05-31|2009-09-24|2009-09-25|Estimate|||||||2017-05-31|2017-06-01|Actual|September 2009|Actual|2009-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen|Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen|Active, not recruiting||N/A|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:32:36.429787|2018-06-01 00:32:36.429787
NCT00984386|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|March 2005||2005-03-31|September 2009|2009-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Investigation of the Efficacy of Zesteem in Accelerating Early Wound Healing|A Single Site, Placebo and Standard Care Controlled, Double Blind, Randomised Trial to Investigate the Efficacy of Four Doses of Zesteem in Accelerating Early Wound Healing of Punch Biopsy Skin Wounds.|Completed||Phase 2|44|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:32:36.518586|2018-06-01 00:32:36.518586
NCT00984373|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-02-02|2009-09-24|2009-09-25|Estimate|||||||2010-02-02|2010-02-04|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Epidemiology of Schizophrenia in Bulgaria|Epidemiological Study to Describe Approaches in Diagnosis, Treatment and Social Functioning of Schizophrenic Patients in Bulgaria|Completed|||440|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:32:36.616406|2018-06-01 00:32:36.616406
NCT00984360|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-05-29|2009-09-24|2009-09-25|Estimate|||||||2013-05-29|2013-05-31|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|||Study of Naltrexone for Methamphetamine Addiction|A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP|Completed||Phase 2|22|Actual|California Pacific Medical Center Research Institute||2|||f||||t||||||||||2018-06-01 00:32:36.686386|2018-06-01 00:32:36.686386
NCT00984347|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2009-09-24|2009-09-24|2009-09-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Breast Stimulation Versus Pitocin for Induction of Labor|Breast Pump Nipple Stimulation Versus Pitocin for Induction of Labor: Efficacy, Safety and Satisfaction|Unknown status|Not yet recruiting|N/A|150|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 00:32:36.764997|2018-06-01 00:32:36.764997
NCT00984334|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2013-11-07||2013-11-07|2009-09-24|2009-09-25|Estimate|2013-11-07|2013-12-27|Estimate||||2013-11-07|2013-12-27|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Naloxone SR Capsules in Patients With Opioid Induced Constipation|A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability and Efficacy of Naloxone SR Capsules in Subjects With Constipation Due to Opioids, Taken for Persistent Non-Cancer Pain|Completed||Phase 2|40|Actual|S.L.A. Pharma AG|Small number of subjects per group.|5|||f||||f||||||||||2018-06-01 00:32:36.908348|2018-06-01 00:32:36.908348
NCT00984321|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2018-01-05|2009-09-24|2009-09-25|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2009||2009-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer|A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer|Recruiting||N/A|126|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 00:32:37.357661|2018-06-01 00:32:37.357661
NCT00984308|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2015-03-31||2017-05-15|2009-09-24|2009-09-25|Estimate|2015-08-10|2015-09-01|Estimate||||2017-05-15|2017-06-14|Actual|December 23, 2008|Actual|2008-12-23|May 2017|2017-05-31|September 30, 2011|Actual|2011-09-30|September 30, 2011|Actual|2011-09-30||Interventional|Go To Sleep||Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease|Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease|Completed||Phase 2/Phase 3|225|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-06-01 00:32:37.45476|2018-06-01 00:32:37.45476
NCT00983983|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2014-09-16||2015-02-11|2009-09-23|2009-09-24|Estimate|2015-02-11|2015-02-27|Estimate||||2015-02-11|2015-02-27|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis|Phase II Safety and Tolerability Study of High Fat/High Calorie Versus High Calorie Versus Optimal Nutrition in Subjects With Amyotrophic Lateral Sclerosis|Completed||Phase 2|28|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 00:32:45.317545|2018-06-01 00:32:45.317545
NCT00984295|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2010-02-03||2015-07-16|2009-09-24|2009-09-25|Estimate|2010-02-03|2010-02-25|Estimate||||2015-07-16|2015-08-07|Estimate|June 2000||2000-06-30|July 2015|2015-07-31|December 2001|Actual|2001-12-31|October 2001|Actual|2001-10-31||Interventional|||Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines|An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Frozen MMRV Given Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines in Healthy Children 12 to 15 Months of Age|Completed||Phase 3|1913|Actual|Merck Sharp & Dohme Corp.|Two participants were incorrectly vaccinated and are not included in the efficacy/safety analyses. One received M-M-R™II+TRIPEDIA™+COMVAX™ and 1 received VARIVAX™+TRIPEDIA™+COMVAX™ instead of ProQuad™+TRIPEDIA™+COMVAX™|3|||f||||f||||||||||2018-06-01 00:32:37.754273|2018-06-01 00:32:37.754273
NCT00984282|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2013-08-19||2017-10-30|2009-09-24|2009-09-25|Estimate|2013-11-07|2013-12-10|Estimate||||2017-10-30|2017-12-04|Actual|October 15, 2009|Actual|2009-10-15|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 31, 2012|Actual|2012-08-31||Interventional|||Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer|A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer|Completed||Phase 3|417|Actual|Bayer||2|||f||||t|t|f||||||||2018-06-01 00:32:38.654509|2018-06-01 00:32:38.654509
NCT00984269|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2017-09-13|2009-09-24|2009-09-25|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2009||2009-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection|Lymphedema Following Elective Hand and Wrist Surgery in Women Who Are Post Axillary Lymph Node Dissection: A Prospective, Randomized, Clinical Trial|Recruiting||N/A|206|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-06-01 00:32:40.377556|2018-06-01 00:32:40.377556
NCT00984256|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2012-09-04||2013-10-29|2009-09-24|2009-09-25|Estimate|2013-10-29|2013-11-25|Estimate||||2013-10-29|2013-11-25|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|MALWEEK|one subject withdrew consent|Weekly Dosing of Malarone ® for Prevention of Malaria|Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone ®) for Malaria Chemoprophylaxis|Completed||Phase 2|35|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-06-01 00:32:40.468319|2018-06-01 00:32:40.468319
NCT00984243|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2012-11-13|2009-09-23|2009-09-25|Estimate|||||||2012-11-13|2012-11-15|Estimate|February 1994||1994-02-28|November 2012|2012-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|PDT||Photodynamic Therapy (PDT) in Lung Cancer|An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.|Completed||N/A|35|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:32:40.793071|2018-06-01 00:32:40.793071
NCT00984230|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2013-06-04|2009-09-24|2009-09-25|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||A New Adaptive Feeding Plan for Newborns|A New Adaptive Feeding Plan for Newborns: Effects on Gut Maturity and Gut Microbiota|Completed||N/A|186|Anticipated|Nestlé||4|||f||||f||||||||||2018-06-01 00:32:40.874666|2018-06-01 00:32:40.874666
NCT00984217|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2016-01-06|2009-09-24|2009-09-25|Estimate|||||||2016-01-06|2016-01-08|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies|Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||1||Decided not to pursue at UPCI|f||||t||||||||||2018-06-01 00:32:40.961924|2018-06-01 00:32:40.961924
NCT00984204|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2013-11-01||2013-11-01|2009-09-23|2009-09-25|Estimate|2013-11-01|2013-12-20|Estimate||||2013-11-01|2013-12-20|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|January 2012|Actual|2012-01-31|August 2010|Actual|2010-08-31||Interventional|||Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)|Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)|Completed||Phase 3|188|Actual|St. Jude Medical||1|||f||||t||||||||||2018-06-01 00:32:41.092619|2018-06-01 00:32:41.092619
NCT00984191|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2011-06-23|2009-09-24|2009-09-25|Estimate|||||||2011-06-23|2011-06-27|Estimate|March 2010||2010-03-31|June 2011|2011-06-30|November 2011|Anticipated|2011-11-30|October 2011|Anticipated|2011-10-31||Interventional|||Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid|99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study|Unknown status|Active, not recruiting|N/A|15|Anticipated|Chulalongkorn University||3|||f||||f||||||||||2018-06-01 00:32:41.301106|2018-06-01 00:32:41.301106
NCT00984178|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2010-02-01|2009-09-24|2009-09-25|Estimate|||||||2010-02-01|2010-02-02|Estimate|November 2005||2005-11-30|September 2009|2009-09-30||||November 2009|Anticipated|2009-11-30||Interventional|TECAM2||Trial of Hematopoietic Stem Cells in Acute Myocardial Infarction|Randomized Trial Comparing Intracoronary Delivery of Bone Marrow-derived Stem Cells Versus Stem Cell Mobilisation With GCSF, a Combination of Both Therapies and Conventional Treatment in Patients With Reperfused Acute Myocardial Infarction|Unknown status|Recruiting|Phase 2|120|Anticipated|TECAM Group||4|||f||||t||||||||||2018-06-01 00:32:41.372247|2018-06-01 00:32:41.372247
NCT00984165|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2015-06-25||2018-03-30|2009-09-24|2009-09-25|Estimate|2015-08-06|2015-09-07|Estimate||||2018-03-30|2018-05-02|Actual|January 19, 2010|Actual|2010-01-19|March 2018|2018-03-31|January 31, 2013|Actual|2013-01-31|January 18, 2013|Actual|2013-01-18||Interventional|||Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation|Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation|Terminated||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||4||Terminated due to slow accrual, PI left NIH and primary endpoint not met.|f||||f|t|f|||f|||No||2018-06-01 00:32:41.471792|2018-06-01 00:32:41.471792
NCT00984152|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2015-05-04|2009-09-24|2009-09-25|Estimate|||||||2015-05-04|2015-05-06|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|ICE-002||Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women|Open Label, Randomized Trial of TDF/FTC+Raltegravir Vs. TDF/FTC+Efavirenz in HIV-1-Infected Women: Differential Effects on Viral Suppression/Reservoir, & Immune Parameters in Different Compartments, Including Gut & Genital Tract|Withdrawn||Phase 3|0|Actual|Rush University Medical Center||2||Decision not to go forth with study.|f||||f||||||||||2018-06-01 00:32:42.454816|2018-06-01 00:32:42.454816
NCT00983970|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2009-09-23|2009-09-23|2009-09-24|Estimate|||||||2009-09-23|2009-09-24|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Interactive Video Game Cycling on Obese Adolescent Health|Effects of Interactive Video Game Cycling on Obese Adolescent Health|Completed||Phase 4|30|Actual|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-06-01 00:32:45.89647|2018-06-01 00:32:45.89647
NCT00984139|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|2011-02-03||2016-09-29|2009-09-24|2009-09-25|Estimate|2011-02-03|2011-03-01|Estimate||||2016-09-29|2016-11-03|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination|Long-term Persistence of Hepatitis B Antibodies and Immune Response to a Hepatitis B Vaccine Challenge in 12-13 Year Old Adolescents, Vaccinated in Infancy With GlaxoSmithKline (GSK) Biologicals' HBV Vaccine (Engerix™-B)|Completed||Phase 4|306|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following complete retesting and reanalysis.|1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:32:42.563927|2018-06-01 00:32:42.563927
NCT00984126|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2017-06-27||2017-06-27|2009-09-24|2009-09-25|Estimate|2017-06-27|2017-07-27|Actual||||2017-06-27|2017-07-27|Actual|October 26, 2009|Actual|2009-10-26|June 2017|2017-06-30|June 29, 2016|Actual|2016-06-29|June 28, 2016|Actual|2016-06-28||Interventional||Full analysis set includes all dosed patients with data after dosing.|Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015|Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A|Completed||Phase 3|214|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 00:32:42.900642|2018-06-01 00:32:42.900642
NCT00984113|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2010-11-22|2009-09-24|2009-09-25|Estimate|||||||2010-11-22|2010-11-24|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment|An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects|Terminated||Phase 1|44|Actual|Portola Pharmaceuticals||6||"For administrative reasons. Enrollment was sufficient to have statistical power without~   compromising the integrity of the study data"|f||||f||||||||||2018-06-01 00:32:43.885642|2018-06-01 00:32:43.885642
NCT00984100|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2015-11-17|2009-09-24|2009-09-25|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy|Completed||N/A|8|Actual|Baystate Medical Center||1|||f||||f||||||||||2018-06-01 00:32:43.982185|2018-06-01 00:32:43.982185
NCT00984087|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2013-04-01|2009-09-23|2009-09-24|Estimate|||||||2013-04-01|2013-04-04|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|JHU||rTMS for Adolescents and Young Adults|rTMS for Adolescent and Young Adult Depression|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||1||Difficulty with recruitment and therefore funding has been pulled.|f||||f||||||||||2018-06-01 00:32:44.073928|2018-06-01 00:32:44.073928
NCT00984074|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2011-02-24|2009-09-23|2009-09-24|Estimate|||||||2011-02-24|2011-02-25|Estimate|October 2008||2008-10-31|September 2009|2009-09-30||||September 2010|Anticipated|2010-09-30||Observational|||MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer|A Pilot Study of Functional Mapping and Brain Perfusion Imaging in Patients Receiving Base of Skull and Brain Radiotherapy: Developing Neurocognitive Functional Organs At Risk for Individualized Conformal Radiotherapy|Unknown status|Recruiting||6|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:32:44.181056|2018-06-01 00:32:44.181056
NCT00984061|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-05|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2009-10-05|2009-10-15|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Drug-Drug Interaction Study of Colchicine and Clarithromycin|A Pharmacokinetic Study to Evaluate the Effect of Clarithromycin on the Pharmacokinetic Profile of Colchicine in Healthy Adults|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:32:44.319504|2018-06-01 00:32:44.319504
NCT00984048|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2018-05-14|2009-09-23|2009-09-24|Estimate|||||||2018-05-14|2018-05-17|Actual|August 2009||2009-08-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|December 2017|Actual|2017-12-31||Observational|||Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer|Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Standard First-line Therapy in Patients With Metastatic Colorectal Cancer|Active, not recruiting|||160|Actual|Jewish General Hospital|||1||f||||f||||||Samples With DNA|"~     Tumor tissue from a hepatic metastasis will be removed by needle core biopsy (NCB) obtained~     under radiologic guidance and will be flash-frozen. To obtain sufficient material for tissue~     banking, three needle core biopsies (NCB) will be removed from the same metastasis.~     Additionally, monthly whole blood samples will be collected, as well as plasma.~   "|Undecided||2018-06-01 00:32:44.595142|2018-06-01 00:32:44.595142
NCT00984035|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-08-07|2009-09-23|2009-09-24|Estimate|||||||2017-08-07|2017-08-08|Actual|September 22, 2009|Actual|2009-09-22|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Investigation of Cisplatin-Related Kidney Toxicity|Investigation of Germline Genetic Determinants and Early Biomarkers of Cisplatin-Related Nephrotoxicity|Active, not recruiting|||341|Anticipated|University of Chicago|||2||f||||f||||||Samples With DNA|"~     Urine Blood Serum/Plasma Whole Blood~   "|||2018-06-01 00:32:44.69991|2018-06-01 00:32:44.69991
NCT00984022|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2010-08-11||2017-09-05|2009-09-23|2009-09-24|Estimate|2010-10-26|2010-10-27|Estimate||||2017-09-05|2017-10-04|Actual|March 2008||2008-03-31|September 2017|2017-09-30|February 23, 2010|Actual|2010-02-23|September 2009|Actual|2009-09-30||Interventional|||Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage|Aquacel vs. Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage: A Randomized Control Study|Completed||Phase 2|92|Actual|Maricopa Integrated Health System||2|||f||||t||||||||||2018-06-01 00:32:44.770775|2018-06-01 00:32:44.770775
NCT00984009|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2011-11-11|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2011-11-11|2011-11-21|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice|A One-Directional, Open-Label Drug-Food Interaction Study to Investigate the Effects of Multiple-Daily Consumptions of Grapefruit Juice on the Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:32:45.015042|2018-06-01 00:32:45.015042
NCT00983957|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2015-08-18||2015-09-16|2009-09-23|2009-09-24|Estimate|2015-08-18|2015-09-16|Estimate||||2015-09-16|2015-10-16|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||All participants who received at least one dose of study drug.|Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects|The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen®) in Healthy Female Subjects|Completed||Phase 1|47|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:32:46.031355|2018-06-01 00:32:46.031355
NCT00983944|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2017-11-28|2009-09-23|2009-09-24|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2009|Actual|2009-09-30|November 2017|2017-11-30|April 25, 2011|Actual|2011-04-25|April 25, 2011|Actual|2011-04-25||Interventional|||Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma|A Randomized Phase II Study of Dose-Adjusted EPOCH-R and R-VACOP-B in Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Withdrawn||Phase 2|0|Actual|Ohio State University Comprehensive Cancer Center||2||Inadequate Accrual|f||||t||||||||||2018-06-01 00:32:46.786827|2018-06-01 00:32:46.786827
NCT00983931|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-13|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2009-10-13|2009-10-15|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Drug-Drug Interaction Study Between Colchicine and Cyclosporine|A One-Directional, Open-label Drug Interaction Study to Investigate the Effects of Single-Dose Cyclosporine on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:32:46.978066|2018-06-01 00:32:46.978066
NCT00983918|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2012-02-14||2018-01-18|2009-09-23|2009-09-24|Estimate|2014-01-25|2014-03-11|Estimate||||2018-01-18|2018-02-14|Actual|September 2009||2009-09-30|January 2018|2018-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pain After Laparoscopic Cholecystectomy|Postoperative Pain After Laparoscopic Cholecystectomy After Anesthesia With Isoflurane, Desflurane, Sevoflurane or Propofol|Completed||N/A|80|Actual|Baylor College of Medicine||4|||f||||t||||||||||2018-06-01 00:32:47.301931|2018-06-01 00:32:47.301931
NCT00983905|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2010-02-23|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2010-02-23|2010-03-02|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Drug-Drug Interaction Study of Colchicine and Theophylline|A One-Directional, Open-Label, Drug Interaction Study to Investigate the Effects of Multiple-Dose Colchicine on Single-Dose Pharmacokinetics of Theophylline in Healthy Volunteers|Completed||Phase 1|30|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:32:48.577601|2018-06-01 00:32:48.577601
NCT00983892|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2016-02-02||2016-02-29|2009-09-23|2009-09-24|Estimate|2016-02-29|2016-03-22|Estimate||||2016-02-29|2016-03-22|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|||Care Partners: Web-based Support for Caregivers of Veterans Undergoing Chemotherapy|Web-based Support for Caregivers of Veterans Undergoing Chemotherapy|Completed||N/A|134|Actual|VA Office of Research and Development|Recruitment rates were lower than expected.|2|||f||||f||||||||No||2018-06-01 00:32:49.564762|2018-06-01 00:32:49.564762
NCT00983879|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2018-03-07|2009-09-23|2009-09-24|Estimate|||||||2018-03-07|2018-03-08|Actual|September 2009||2009-09-30|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||The Natural History of Infantile Globoid Cell Leukodystrophy|A Longitudinal Observational Study That Will Evaluate Prospectively Clinical and Surrogate Parameters That Are Affected in Infant Patients With Globoid Cell Leukodystrophy|Completed|||6|Actual|Chiesi Farmaceutici S.p.A.|||||f||||f||||||||||2018-06-01 00:32:51.050605|2018-06-01 00:32:51.050605
NCT00983866|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2018-02-09|2009-09-23|2009-09-24|Estimate|||||||2018-02-09|2018-02-13|Actual|September 2009||2009-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2012|Actual|2012-12-31||Interventional|CHOICES||CHOICES: Understanding Clinical Trials as a Treatment Option|Increasing Participation in Cancer Clinical Trials|Active, not recruiting||N/A|2110|Anticipated|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 00:32:51.246959|2018-06-01 00:32:51.246959
NCT00983853|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2013-08-02||2013-08-02|2009-09-23|2009-09-24|Estimate|2013-08-02|2013-10-10|Estimate||||2013-08-02|2013-10-10|Estimate|October 2009||2009-10-31|August 2013|2013-08-31||||March 2012|Actual|2012-03-31||Interventional||All randomized subjects who received at least 1 dose of study drug|Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV|A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C|Completed||Phase 2|62|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-06-01 00:32:51.416026|2018-06-01 00:32:51.416026
NCT00983840|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2015-03-18|2009-09-22|2009-09-24|Estimate|||||||2015-03-18|2015-03-20|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Family Eats||Family Eats:Cancer Prevention for Families|Family Eats:Cancer Prevention for Families|Completed||N/A|151|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 00:32:55.341499|2018-06-01 00:32:55.341499
NCT00983827|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2012-07-02||2012-12-10|2009-09-22|2009-09-24|Estimate|2012-12-10|2013-01-15|Estimate||||2012-12-10|2013-01-15|Estimate|May 2008||2008-05-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ATT||Aquatic Treadmill Therapy for Improving Gait, Balance, Fitness and Quality of Life in Stroke Patients|Safety and Efficacy of Aquatic Treadmill Therapy for Improving Economy of Gait, Gait Speed, Balance, Cardiovascular Fitness, and Quality of Life in Ambulatory Adult Stroke Patients: A Pilot Study|Completed||N/A|9|Actual|University of Utah||1|||f||||f||||||||||2018-06-01 00:32:55.546134|2018-06-01 00:32:55.546134
NCT00983814|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23||2013-03-27|2013-03-27|2009-09-23|2009-09-24|Estimate||||2013-03-27|2013-04-04|Estimate|2013-03-27|2013-04-04|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|ADD201||Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa|A Two-Period Trial (Open-Label and Randomized Placebo-Controlled Substitution) of Droxidopa Treatment in Adults With ADHD With Co-administration of Carbidopa|Completed||Phase 2|20|Actual|Chelsea Therapeutics||2|||f||||f||||||||||2018-06-01 00:32:56.097078|2018-06-01 00:32:56.097078
NCT00983801|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2012-06-20||2016-02-09|2009-09-23|2009-09-24|Estimate|2012-09-06|2012-09-19|Estimate||||2016-02-09|2016-03-10|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer|A Phase II Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer Previously Treated With Fluoropyrimidine-based Chemotherapy|Completed||Phase 2|58|Actual|R-Pharm||1|||f||||f||||||||||2018-06-01 00:32:56.46096|2018-06-01 00:32:56.46096
NCT00983788|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2012-05-29|2009-09-23|2009-09-24|Estimate|||||||2012-05-29|2012-05-30|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Bezafibrate||Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects|Evaluation of the Effect of Bezafibrate on Muscle Metabolism During Exercise in Patients With CPTII and VLCAD Deficiency|Completed||Phase 2|12|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 00:32:57.811604|2018-06-01 00:32:57.811604
NCT00983775|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2011-08-10|2009-09-23|2009-09-24|Estimate|||||||2011-08-10|2011-08-11|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pharmacology of Insulin Injected With Jet-Injection|Pharmacokinetic and Pharmacodynamic Profile of Rapid Acting Insulin Injected by Needle-free Jet-injection|Completed||N/A|48|Anticipated|Radboud University||3|||f||||||||||||||2018-06-01 00:32:58.317063|2018-06-01 00:32:58.317063
NCT00983762|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2009-11-04|2009-09-23|2009-09-24|Estimate|||||||2009-11-04|2009-11-05|Estimate|June 2009||2009-06-30|November 2009|2009-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Comparison of Functional Outcomes of Three Surgical Approaches in Knee Arthroplasty|Comparison of Functional Outcomes of Three Surgical Approaches in Knee Arthroplasty: The Minimally Invasive Surgery Mini-Incision (MIS) TKA, Standard Para-Patellar Surgery TKA and the Unicompartmental Knee Arthroplasty|Terminated|||12|Actual|Massachusetts General Hospital|||4|No continued funding.|f||||f||||||||||2018-06-01 00:32:58.622982|2018-06-01 00:32:58.622982
NCT00983749|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2016-01-07||2016-05-19|2009-09-23|2009-09-24|Estimate|2016-05-19|2016-06-28|Estimate||||2016-05-19|2016-06-28|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|CUFFS||Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke|A Randomized, Controlled Phase 1 Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke|Completed||Phase 1|23|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-06-01 00:32:59.915278|2018-06-01 00:32:59.915278
NCT00983736|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-08-24|2009-09-23|2009-09-24|Estimate|||||||2012-08-24|2012-08-27|Estimate|October 2009||2009-10-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation|Terminated||Phase 3|1050|Anticipated|Valeant Pharmaceuticals International, Inc.||2||This study was terminated because of recruitment difficulties.|f||||f||||||||||2018-06-01 00:33:00.604238|2018-06-01 00:33:00.604238
NCT00983723|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2013-05-22|2009-09-23|2009-09-24|Estimate|||||||2013-05-22|2013-05-23|Estimate|July 2005||2005-07-31|May 2013|2013-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|"CPR Brain"||Clinical Proteomic Research for the Brain|Clinical Proteomic Research on the Brain|Unknown status|Recruiting||750|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 00:33:00.90973|2018-06-01 00:33:00.90973
NCT00983710|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2018-01-18|2009-09-23|2009-09-24|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2009||2009-05-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|October 2011|Actual|2011-10-31||Interventional|||Prostate Cancer Symptom Management for Low Literacy Men|Prostate Cancer Symptom Management for Low Literacy Men|Completed||Phase 2|108|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 00:33:01.190156|2018-06-01 00:33:01.190156
NCT00983697|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2017-03-16|2009-09-23|2009-09-24|Estimate|||||||2017-03-16|2017-03-20|Actual|April 2010||2010-04-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ACRIN6685||FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer|A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients|Active, not recruiting||N/A|292|Anticipated|American College of Radiology Imaging Network||1|||f||||t||||||||Yes|"See ACRIN data sharing policy:~https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx"|2018-06-01 00:33:01.709837|2018-06-01 00:33:01.709837
NCT00983684|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2014-12-04|2009-09-23|2009-09-24|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2000||2000-03-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|TARGIT||Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer|TARGIT: A Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy With Conventional Post-operative Radiotherapy After Conservative Breast Surgery for Women With Early Stage Breast Cancer|Completed||Phase 3|3451|Actual|University College, London||2|||f||||t||||||||||2018-06-01 00:33:01.831349|2018-06-01 00:33:01.831349
NCT00983671|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-07-21|2009-09-23|2009-09-24|Estimate|||||||2011-07-21|2011-07-22|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Standardisation of Measurements in Exhaled Breath and Exhaled Breath Condensate.|Optimising and Standardising Measurements of Inflammatory Markers in Exhaled Breath (EB) and Exhaled Breath Condensate (EBC)|Unknown status|Recruiting||255|Anticipated|Maastricht University Medical Center|||4||f||||f||||||Samples Without DNA|"~     Exhaled breath condensate. Exhaled breath.~   "|||2018-06-01 00:33:01.967632|2018-06-01 00:33:01.967632
NCT00983658|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2016-08-01|2009-09-22|2009-09-24|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|Completed||Phase 2|29|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 00:33:02.060017|2018-06-01 00:33:02.060017
NCT00983645|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2015-09-17||2016-04-28|2009-09-23|2009-09-24|Estimate|2015-09-17|2015-10-20|Estimate||||2016-04-28|2016-06-03|Estimate|October 2004||2004-10-31|April 2016|2016-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity|A Prospective, Open-label, Randomized Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity|Terminated||Phase 4|15|Actual|Loma Linda University|A limitation to this study is early termination leading to a small number of subjects.|2||Insufficient funding|f||||f||||||||No||2018-06-01 00:33:02.167147|2018-06-01 00:33:02.167147
NCT00983632|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2016-01-06|2009-09-23|2009-09-24|Estimate|||||||2016-01-06|2016-01-07|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VNS||Selective Vagus Nerve Stimulation in Human|Selective Vagus Nerve Stimulation in Human|Completed||N/A|4|Actual|University Medical Centre Ljubljana||1|||f||||t||||||||||2018-06-01 00:33:02.531171|2018-06-01 00:33:02.531171
NCT00983619|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2018-05-18|2009-09-23|2009-09-24|Estimate|||||||2018-05-18|2018-05-21|Actual|April 16, 2010|Actual|2010-04-16|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies|A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies|Active, not recruiting||Phase 1|136|Actual|MedImmune LLC||18|||f||||f|t|f||||||||2018-06-01 00:33:02.737347|2018-06-01 00:33:02.737347
NCT00983606|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2012-11-13|2009-09-23|2009-09-24|Estimate|||||||2012-11-13|2012-11-14|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|||An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants|An Observational Prospective Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants (32 to 35 Week Gestational Age) - Outcomes and Risk Tracking Study (The Report Study)|Completed|||3000|Anticipated|MedImmune LLC|||1||f||||f||||||Samples Without DNA|"~     Serum (frozen)~   "|||2018-06-01 00:33:02.924077|2018-06-01 00:33:02.924077
NCT00983593|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-06-19|2009-09-22|2009-09-24|Estimate|||||||2017-06-19|2017-06-21|Actual|September 2009||2009-09-30|June 2017|2017-06-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||A Randomized Clinical Study of a Mind-Body Approach to Domestic Violence Offender Treatment|A Randomized Clinical Study of a Mind-Body Approach to Domestic Violence Offender Treatment|Completed||N/A|100|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 00:33:03.647775|2018-06-01 00:33:03.647775
NCT00983580|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2018-02-20||2018-04-27|2009-09-23|2009-09-24|Estimate|2018-04-27|2018-04-30|Actual||||2018-04-27|2018-04-30|Actual|August 2009||2009-08-31|April 2018|2018-04-30||||October 2016|Actual|2016-10-31||Interventional||All eligible patients that began protocol treatment were included in this analysis. Patients who cancelled prior to treatment, violations and ineligible patients were excluded.|Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer|Randomized Phase II Trial of Aspirin and Difluoromethylornithine (DFMO) in Patients at High Risk of Colorectal Cancer|Active, not recruiting||Phase 2|107|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:33:03.908976|2018-06-01 00:33:03.908976
NCT00983567|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2015-03-18|2009-09-23|2009-09-24|Estimate|||||||2015-03-18|2015-03-20|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Teen Web||An Interactive Web-Based Program to Improve Food and Activity Choices of Teens|An Interactive Web-Based Program to Improve Food and Activity Choices of Teens|Completed||N/A|400|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 00:33:04.519849|2018-06-01 00:33:04.519849
NCT00983554|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2011-03-15|2009-09-22|2009-09-24|Estimate|||||||2011-03-15|2011-03-16|Estimate|June 2005||2005-06-30|March 2011|2011-03-31|October 2009|Anticipated|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||Metabolic Effects of Steroids in Obese Men|Metabolic Effects of Testosterone Alone or in Combination With Dutasteride or Anastrazole in Obese Men|Unknown status|Active, not recruiting|N/A|57|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||t||||||||||2018-06-01 00:33:04.765873|2018-06-01 00:33:04.765873
NCT00983541|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2013-06-21||2015-07-23|2009-09-23|2009-09-24|Estimate|2015-07-23|2015-08-19|Estimate||||2015-07-23|2015-08-19|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma|Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma|Terminated||Phase 2|1|Actual|University of Utah||1||Low enrollment|f||||t||||||||||2018-06-01 00:33:05.004041|2018-06-01 00:33:05.004041
NCT00983528|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2011-05-03|2009-09-23|2009-09-24|Estimate|||||||2011-05-03|2011-05-04|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia|Unknown status|Active, not recruiting|Phase 1/Phase 2|28|Anticipated|University of California, San Diego|||||f||||t||||||||||2018-06-01 00:33:05.633754|2018-06-01 00:33:05.633754
NCT00983515|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-12|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2009-10-12|2009-10-15|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Drug-Drug Interaction Between Colchicine and Ritonavir|A One-Directional, Open-label Drug Interaction Study to Investigate the Effects of Multiple-Dose Ritonavir on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:33:06.058619|2018-06-01 00:33:06.058619
NCT00983502|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2011-12-13|2009-09-23|2009-09-24|Estimate|||||||2011-12-13|2011-12-15|Estimate|August 2008||2008-08-31|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Pilot Study of Alternative Treatments of Unexplained Chronic Fatigue|Pilot Study of Alternative Treatments of Unexplained Chronic Fatigue|Terminated|||154|Actual|University of Utah|||4|IRB ended and NIH study ended|f||||f||||||||||2018-06-01 00:33:06.684618|2018-06-01 00:33:06.684618
NCT00983489|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2013-04-05||2013-04-05|2009-09-23|2009-09-24|Estimate|2013-04-05|2013-05-24|Estimate||||2013-04-05|2013-05-24|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparison of Breast Feeding Counseling and Video Demonstration on Exclusive Breast Feeding Rates at 6 Weeks|Comparison of Impact of Breast Feeding Counseling of Mothers and Use of Audio-video Aids on Breast Feeding Rates at Six Weeks Postnatal Age|Completed||N/A|1411|Actual|Deen Dayal Upadhyay Hospital||3|||f||||f||||||||||2018-06-01 00:33:07.043808|2018-06-01 00:33:07.043808
NCT00983476|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2016-12-20||2017-03-14|2009-09-23|2009-09-24|Estimate|2016-12-20|2017-02-13|Actual||||2017-03-14|2017-04-13|Actual|March 2012||2012-03-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Web-MOVE!||Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness (SMI)|Web-Based Delivery of MOVE! to Veterans With Serious Mental Illness|Completed||N/A|276|Actual|VA Office of Research and Development|This study was conducted at one VA medical center in an urban, metropolitan area. Sites can vary markedly in contextual factors; There was a large proportion of overweight patients with SMI who declined to participate.|3|||f||||f||||||||No||2018-06-01 00:33:07.521356|2018-06-01 00:33:07.521356
NCT00983463|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2018-01-23|2009-09-23|2009-09-24|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2009||2009-10-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)|Relative Abundance and Spatial Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)|Enrolling by invitation|||45|Anticipated|Vanderbilt University Medical Center|||3||f||||f||||||Samples With DNA|"~     liver biopsy, blood, plasma~   "|||2018-06-01 00:33:09.027653|2018-06-01 00:33:09.027653
NCT00983450|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-06|||2010-06-02|2009-09-23|2009-09-24|Estimate|||||||2010-06-02|2010-06-03|Estimate|October 2009||2009-10-31|September 2009|2009-09-30||||December 2010|Anticipated|2010-12-31||Interventional|||The Influences of Watching a Movie Clip of Normal Walking on Measurable Walking Parameters Among Post-Brain-Stroke Patients as Opposed to the Influences of a Control Movie Clip Showing Backwards Walking|The Influences of Watching a Movie Clip of Normal Walking on Measurable Walking Parameters Among Post-brain-stroke Patients as Opposed to the Influences of a Control Movie Clip Showing Backwards Walking|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 00:33:09.221789|2018-06-01 00:33:09.221789
NCT00983437|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2013-05-09||2013-08-14|2009-09-23|2009-09-24|Estimate|2013-08-14|2013-10-18|Estimate||||2013-08-14|2013-10-18|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||Baseline Analysis Population includes 2 participants who were enrolled but not treated.|Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury|A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/Day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury|Terminated||Phase 3|49|Actual|Teva Pharmaceutical Industries|The sponsor’s decision to terminate the study early resulted in the small number of study participants, and related limitations to the interpretation of the study results.|1||Study has been stopped by sponsor decision|f||||||||||||||2018-06-01 00:33:09.833662|2018-06-01 00:33:09.833662
NCT00983424|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2013-09-13|2009-09-23|2009-09-24|Estimate|||||||2013-09-13|2013-09-16|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer|A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer|Completed||Phase 1|14|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 00:33:11.330302|2018-06-01 00:33:11.330302
NCT00983411|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2017-01-31|2009-09-23|2009-09-24|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Observational|NIV-Leaks||Impact of Non-intentional Leaks on Noninvasive Ventilation|Impact of Non-intentional Leaks on Breathing Pattern and Work of Breathing During Non-invasive Ventilation: Study in Awakened Healthy Subjects and Awakened Obesity Hypoventilation Syndrome(OHS)Patients and During the Sleep in OHS Patients.|Completed|||20|Actual|AGIR à Dom|||1||f||||f||||||||||2018-06-01 00:33:11.438679|2018-06-01 00:33:11.438679
NCT00983398|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2018-05-02|2009-09-23|2009-09-24|Estimate|||||||2018-05-02|2018-05-07|Actual|September 17, 2009|Actual|2009-09-17|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors|Phase I/II Study of Intra-arterial Melphalan Given With Intra-arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors|Suspended||Phase 1/Phase 2|55|Anticipated|OHSU Knight Cancer Institute||1||Staff training IRB modification deferred to July 2018|f||||t||||||||||2018-06-01 00:33:11.543505|2018-06-01 00:33:11.543505
NCT00983385|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2011-08-02||2016-02-25|2009-09-23|2009-09-24|Estimate|2012-03-23|2012-04-17|Estimate||||2016-02-25|2016-03-24|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Nociceptive, Mixed or Neuropathic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.|Completed||Phase 3|208|Actual|Grünenthal GmbH||1|||f||||f||||||||||2018-06-01 00:33:11.826149|2018-06-01 00:33:11.826149
NCT00983372|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-12|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2009-10-12|2009-10-15|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Drug-Drug Interaction Study Between Colchicine and Diltiazem ER|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Diltiazem ER on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:33:12.707521|2018-06-01 00:33:12.707521
NCT00983359|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2016-03-24||2017-05-15|2009-09-23|2009-09-24|Estimate|2016-04-28|2016-06-06|Estimate||||2017-05-15|2017-06-06|Actual|April 2007||2007-04-30|May 2017|2017-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Stereotactic Radiation Therapy in Treating Patients With Brain Metastases|A Phase II Trial of Focal Therapy in the Treatment of Patients With 1-3 Brain Metastases|Completed||N/A|40|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:33:13.06717|2018-06-01 00:33:13.06717
NCT00983346|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2015-09-28||2016-07-07|2009-09-23|2009-09-24|Estimate|2015-10-28|2015-11-30|Estimate||||2016-07-07|2016-07-11|Estimate|October 2009||2009-10-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients|Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients|Terminated||Phase 2|17|Actual|University of Utah||1||Lab Staff that was required left the institution, therefore accrual closed prematurely|f||||t||||||||||2018-06-01 00:33:13.340688|2018-06-01 00:33:13.340688
NCT00983333|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2015-10-14|2009-09-23|2009-09-24|Estimate|||||||2015-10-14|2015-10-16|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Initial Test of the Time to Talk CARDIO (Creating a Real Dialogue In the Office) Program|Beta Test of the Time to Talk CARDIO (Creating a Real Dialogue In the Office) Web-based Tool for Improving Communication Between Patients and Health Care Professionals|Completed||N/A|105|Actual|Oregon Health and Science University||3|||f||||f||||||||||2018-06-01 00:33:13.570314|2018-06-01 00:33:13.570314
NCT00983320|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2011-10-04|2009-09-23|2009-09-24|Estimate|||||||2011-10-04|2011-10-05|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study|Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study|Completed||Phase 4|52|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-06-01 00:33:13.654473|2018-06-01 00:33:13.654473
NCT00982306|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2010-07-28|2009-09-22|2009-09-23|Estimate|||||||2010-07-28|2010-07-29|Estimate|February 2010||2010-02-28|July 2010|2010-07-31|April 2012|Anticipated|2012-04-30|February 2012|Anticipated|2012-02-29||Interventional|BIG||Brief Interventions in General Hospital (BIG)|Brief Interventions for Heavy Alcohol Users Admitted to General Hospital|Unknown status|Recruiting|Phase 1|294|Anticipated|Partnerships in Care|||||f||||t||||||||||2018-06-01 00:33:29.957276|2018-06-01 00:33:29.957276
NCT00983307|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2017-11-20||2018-01-03|2009-09-22|2009-09-24|Estimate|2018-01-03|2018-01-30|Actual||||2018-01-03|2018-01-30|Actual|August 27, 2009|Actual|2009-08-27|January 2018|2018-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer|A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer|Completed||Phase 2|17|Actual|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-06-01 00:33:13.758353|2018-06-01 00:33:13.758353
NCT00983294|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-20|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2009-10-20|2009-10-28|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Drug-Drug Interaction Study of Colchicine and Azithromycin|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Azithromycin on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:33:14.024824|2018-06-01 00:33:14.024824
NCT00983281|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|2013-01-15||2017-05-15|2009-09-23|2009-09-24|Estimate|2013-01-15|2013-02-18|Estimate||||2017-05-15|2017-06-14|Actual|August 2008||2008-08-31|February 2013|2013-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Use of Hextend in Trauma|Use of Hextend in Trauma|Completed|||1714|Actual|University of Miami|||2||f||||f||||||||||2018-06-01 00:33:14.278796|2018-06-01 00:33:14.278796
NCT00983268|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2015-06-11|2009-09-23|2009-09-24|Estimate|||||||2015-06-11|2015-06-15|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer|Phase I Trial of Chemoradiation With Capecitabine and Vorinostat in Pancreatic Cancer.|Completed||Phase 1|21|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 00:33:14.468246|2018-06-01 00:33:14.468246
NCT00983255|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2016-05-18|2009-09-23|2009-09-24|Estimate|||||||2016-05-18|2016-05-19|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|IV/SAD/MAD||Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)|A Double-Blind, Placebo-Controlled, Single & Multiple Ascending Dose, Safety, Tolerability, & PK Study of an IV Form of TR-701 Free Acid & an Open-Label, Crossover Absolute BA Determination of a TR-701 FA Tablet in Normal Healthy Adults|Completed||Phase 1|90|Actual|Trius Therapeutics LLC||4|||f||||f||||||||||2018-06-01 00:33:14.632279|2018-06-01 00:33:14.632279
NCT00983242|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-12|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2009-10-12|2009-10-15|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Drug-Drug Interaction Between Colchicine and Verapamil ER|A One-Directional, Open Label Drug Interaction Study to Investigate the Effects of Multiple Dose Verapamil HCl ER on Single Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:33:14.712546|2018-06-01 00:33:14.712546
NCT00983229|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2010-11-12|2009-09-23|2009-09-24|Estimate|||||||2010-11-12|2010-11-15|Estimate|August 2009||2009-08-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Comparison of CTrach, Intubating Laryngeal Mask Airway (ILMA) and I-gel for Tracheal Intubation|Position of Supraglottic Airway as a Conduit for Tracheal Intubation - A Comparison of CTrach, Intubating LMA and I-gel Supraglottic Airway|Completed||N/A|120|Actual|Northern Health and Social Care Trust||3|||f||||f||||||||||2018-06-01 00:33:15.104439|2018-06-01 00:33:15.104439
NCT00983216|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2009-08-13||2009-10-12|2009-08-13|2009-09-24|Estimate|2009-08-13|2009-09-24|Estimate||||2009-10-12|2009-10-15|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Drug-Drug Interaction Study Between Colchicine and Ketoconazole|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Ketoconazole on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:33:15.210598|2018-06-01 00:33:15.210598
NCT00983203|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-23|||2012-01-31|2009-09-23|2009-09-24|Estimate|||||||2012-01-31|2012-02-02|Estimate|July 2009||2009-07-31|January 2012|2012-01-31||||August 2009|Actual|2009-08-31||Interventional|||Acute Comfort and Haze Profile of FID 114657||Completed||N/A|20|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:33:15.509053|2018-06-01 00:33:15.509053
NCT00983190|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2016-04-18|2009-09-23|2009-09-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|BeneMACs||BeneMACS Study:HeartMate 2 (HM2)Left Ventricular Assist Device (LVAD) Survival in Non Transplant Patients is Equal/Better Than Results in Medical Literature|HeartMate II BeneMACS Long Term LVAD Study|Completed||N/A|10|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 00:33:15.608109|2018-06-01 00:33:15.608109
NCT00983177|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2010-07-18|2009-09-22|2009-09-23|Estimate|||||||2010-07-18|2010-07-20|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis|Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis: Double Blind Placebo-controlled Study|Unknown status|Recruiting|N/A|80|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||||2018-06-01 00:33:15.73201|2018-06-01 00:33:15.73201
NCT00983164|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|December 2007|Actual|2007-12-31||Interventional|HepCAntSup||Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial|Blood Antioxidant Status in Chronic Hepatitis C Patients Before and After Antioxidant Supplementation: a Randomized Clinical Trial|Completed||N/A|32|Actual|Universidade do Sul de Santa Catarina||3|||f||||f||||||||||2018-06-01 00:33:15.828323|2018-06-01 00:33:15.828323
NCT00983151|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-08-24|2009-09-22|2009-09-23|Estimate|||||||2012-08-24|2012-08-27|Estimate|August 2009||2009-08-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation|Terminated||Phase 3|1050|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 00:33:15.923435|2018-06-01 00:33:15.923435
NCT00983138|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2011-02-28|2009-09-22|2009-09-23|Estimate|||||||2011-02-28|2011-03-01|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)|Efficacy and Safety of Recombinant Asparaginase in Infants (<1 Year) With Previously Untreated Acute Lymphoblastic Leukaemia - Phase II Clinical Trial|Completed||Phase 2|12|Anticipated|medac GmbH||1|||f||||f||||||||||2018-06-01 00:33:16.065274|2018-06-01 00:33:16.065274
NCT00983125|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2013-04-02|2009-09-22|2009-09-23|Estimate|||||||2013-04-02|2013-04-04|Estimate|August 2009||2009-08-31|April 2013|2013-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Systematic Clonidine for Epidural Analgesia in Labour|Effects of a Systematic Addition of Clonidine in the Local Anaesthetic and Opiate Solution for Epidural Patient Controlled Analgesia in Labour (Levobupivacaine 0.568 mg.mLl-1 + Sufentanil 0.45 µg.mL-1)|Completed||Phase 4|124|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-06-01 00:33:16.157047|2018-06-01 00:33:16.157047
NCT00983112|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2012-04-24|2009-09-22|2009-09-23|Estimate|||||||2012-04-24|2012-04-25|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery|Impact of a Biological Glue (Evicel®) on the Peri Operative Bleeding in Total Knee Prothesis Surgery|Unknown status|Recruiting|Phase 4|116|Anticipated|Clinique Mutualiste Chirurgicale de la Loire||2|||f||||f||||||||||2018-06-01 00:33:16.241565|2018-06-01 00:33:16.241565
NCT00983099|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2011-04-14|2009-09-22|2009-09-23|Estimate|||||||2011-04-14|2011-04-15|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects|Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects|Completed||Phase 1|56|Actual|Merz Pharmaceuticals GmbH|||||f||||||||||||||2018-06-01 00:33:16.357378|2018-06-01 00:33:16.357378
NCT00983086|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|FLORIDE||Effects of Consumption of Orange Juice on Vascular Protection and Immune Function: Clinical Study on the Specific Contribution of Citrus Flavanones|Effects of Consumption of Orange Juice on Vascular Protection and Immune Function: Clinical Study on the Specific Contribution of Citrus Flavanones|Completed||Phase 1|24|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:33:16.423334|2018-06-01 00:33:16.423334
NCT00983073|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2011-12-06||2013-02-04|2009-09-22|2009-09-23|Estimate|2012-03-01|2012-03-29|Estimate||||2013-02-04|2013-02-11|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Pain Due to Osteoarthritis of the Knee Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.|Completed||Phase 3|224|Actual|Grünenthal GmbH||1|||f||||f||||||||||2018-06-01 00:33:16.509668|2018-06-01 00:33:16.509668
NCT00983060|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-02-20|2009-09-22|2009-09-23|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2009||2009-09-30|February 2017|2017-02-28||||April 2011|Actual|2011-04-30||Interventional|||Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients|A Randomized, Adaptive-design, Dose-finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With the Standard of Care (SOC) in Relapsed Patients Infected With HCV Genotype-1|Completed||Phase 2|59|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:33:16.918062|2018-06-01 00:33:16.918062
NCT00983047|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2015-08-25|2009-09-22|2009-09-23|Estimate|||||||2015-08-25|2015-08-27|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer|Phase II Study of Nimotuzumab Plus Docetaxel in Chemotherapy-refractory/Resistant Patients With Advanced Non-small-cell Lung Cancer|Terminated||Phase 2|30|Actual|Biotech Pharmaceutical Co., Ltd.||2||The sponsor decide to terminate|f||||t||||||||||2018-06-01 00:33:17.016643|2018-06-01 00:33:17.016643
NCT00983034|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy|Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy|Completed||N/A|70|Actual|Istanbul University||3|||f||||f||||||||||2018-06-01 00:33:17.094758|2018-06-01 00:33:17.094758
NCT00983021|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-02-06|2009-09-22|2009-09-23|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2009||2009-09-30|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Tolerability of NN9068 in Healthy Male Volunteers|A Trial to Test for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9068 and Compared With NN1250 and NN2211 in Healthy Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 00:33:17.166155|2018-06-01 00:33:17.166155
NCT00983008|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts|A Prospective Cohort Study on the Effect and Utilization of Protected Time Among Interns on Extended Duty-Hour Call Shifts|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Providence Health & Services||1|||f||||f||||||||||2018-06-01 00:33:17.25314|2018-06-01 00:33:17.25314
NCT00982995|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2014-09-05||2015-11-05|2009-09-22|2009-09-23|Estimate|2014-09-05|2014-09-15|Estimate||||2015-11-05|2015-12-04|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|HUM21469||Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients|UMCC 2008.048 Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients|Terminated||Phase 2|3|Actual|University of Michigan Cancer Center|Accrual for the study was low. Due to issues with funding, we were unable to add a second site in order to accrue additional patients and the study was closed.|1||site terminated due to lack of enrollment|f||||t||||||||||2018-06-01 00:33:17.347426|2018-06-01 00:33:17.347426
NCT00982982|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2017-11-29|2009-09-22|2009-09-23|Estimate|||||||2017-11-29|2017-12-02|Actual|February 2009||2009-02-28|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Delta-9-THC and Iomazenil in Healthy Humans|Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis|Active, not recruiting||Phase 1|60|Anticipated|Yale University||2|||f||||t||||||||||2018-06-01 00:33:18.451521|2018-06-01 00:33:18.451521
NCT00980694|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2016-05-25|2009-09-18|2009-09-21|Estimate|||||||2016-05-25|2016-05-27|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Bioavailability of Ubiquinol in Huntington Disease|Bioavailability of Ubiquinol in Huntington Disease|Completed||Phase 1|6|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 00:33:59.809843|2018-06-01 00:33:59.809843
NCT00982969|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2010-07-19|2009-09-22|2009-09-23|Estimate|||||||2010-07-19|2010-07-20|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Observational|||The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis|The Clinical Utility of QuantiFERON in the Diagnosis of Active Tuberculosis Among Young Adults|Completed|||200|Anticipated|Armed Forces Capital Hospital, Republic of Korea|||1||f||||f||||||||||2018-06-01 00:33:18.565022|2018-06-01 00:33:18.565022
NCT00982956|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate||||September 2009|2009-09-30||||||||Observational|||Application of Computer-assisted Navigation in Total Knee Arthroplasty: A Randomized Pair-matched Double-blind Trial||Completed|||||Chinese PLA General Hospital|||||f||||||||||||||2018-06-01 00:33:18.634978|2018-06-01 00:33:18.634978
NCT00982943|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||The Epidemiological Study on Psychiatric Disorders and Psychotropic Drugs|The Epidemiological Study on Psychiatric Disorders and Psychotropic Drugs|Unknown status|Active, not recruiting||1000000|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 00:33:18.677792|2018-06-01 00:33:18.677792
NCT00982930|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2016-11-15|2009-09-22|2009-09-23|Estimate|||||||2016-11-15|2016-11-16|Estimate|August 2009||2009-08-31|April 2016|2016-04-30||||October 2011|Actual|2011-10-31||Interventional|||Open Label Extension to Bridging Study CTBM100C2303|A Phase III Open-label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.|Completed||Phase 3|57|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:33:18.735301|2018-06-01 00:33:18.735301
NCT00982917|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Stamp-in-Safety Playground Safety Project|Stamp-in-Safety Playground Safety Project|Completed||N/A|71|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-06-01 00:33:18.809732|2018-06-01 00:33:18.809732
NCT00982904|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-04-05|2009-09-22|2009-09-23|Estimate|||||||2017-04-05|2017-04-06|Actual|September 2009||2009-09-30|April 2017|2017-04-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole|Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers|Completed||Phase 1|108|Actual|Drugs for Neglected Diseases||2|||f||||f||||||||||2018-06-01 00:33:18.884445|2018-06-01 00:33:18.884445
NCT00982891|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2013-01-22|2009-09-22|2009-09-23|Estimate|||||||2013-01-22|2013-01-23|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ROS-003||Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)|Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease: Understanding Patients' and Caregivers' Experiences of Opioid Therapy|Completed||Phase 2/Phase 3|45|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-06-01 00:33:18.964737|2018-06-01 00:33:18.964737
NCT00982878|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2015-03-23|2009-09-22|2009-09-23|Estimate|||||||2015-03-23|2015-03-24|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|February 2011|Actual|2011-02-28|July 2010|Actual|2010-07-31||Interventional|||The Maraviroc Central Nervous System (CNS) Study|The Penetration of Maraviroc Into the Central Nervous System in HIV-1 Infected Subjects on Stable Antiretroviral Therapy; a Phase I Pharmacokinetic Study|Completed||Phase 1|12|Actual|Imperial College London||1|||f||||f||||||||||2018-06-01 00:33:19.158734|2018-06-01 00:33:19.158734
NCT00982865|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-02-12|2009-09-22|2009-09-23|Estimate|||||||2017-02-12|2017-02-14|Actual|December 2007|Actual|2007-12-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|March 2013|Actual|2013-03-31||Interventional|||Trial of MSC1936369B in Subjects With Solid Tumors|A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours|Completed||Phase 1|180|Actual|Merck KGaA||4|||f||||f||||||||||2018-06-01 00:33:19.260266|2018-06-01 00:33:19.260266
NCT00982852|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2013-07-11|2009-09-22|2009-09-23|Estimate|||||||2013-07-11|2013-07-12|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Observational|||Intravascular Ultrasound Derived Virtual Histology and Intracoronary Serum Markers of Inflammation|Intravascular Ultrasound Derived Virtual Histology and Intracoronary Serum Markers of Inflammation in Patients Referred for Percutaneous Coronary Intervention.|Terminated|||9|Actual|Ohio State University|||2|Lack of funding|f||||f||||||Samples With DNA|"~     The blood that is collected will be analyzed for markers of inflammation or irritation in the~     blood (c-reactive protein, myeloperoxidase, Monocyte chemotactic protein-1), as well and a~     gene called Matrix Metallopeptidase 3, which is believe to influence the progression of~     plaque on the walls of arteries and the progression of coronary artery disease.~   "|||2018-06-01 00:33:19.390727|2018-06-01 00:33:19.390727
NCT00982839|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2014-09-16|2009-09-22|2009-09-23|Estimate|||||||2014-09-16|2014-09-17|Estimate|March 2004||2004-03-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Rectal Sensory Training - A Study of Two Techniques|Rectal Sensory Training - A Randomized Controlled Study of Two Techniques|Completed||Phase 2|70|Anticipated|Augusta University||2|||f||||f||||||||||2018-06-01 00:33:19.472789|2018-06-01 00:33:19.472789
NCT00982826|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2010-10-19|2009-09-22|2009-09-23|Estimate|||||||2010-10-19|2010-10-21|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072|A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single and Multiple Doses (7 Days) of ABT-072 and an Open-label Study to Evaluate the Effect of Food on the Pharmacokinetic|Completed||Phase 1|52|Actual|Abbott||5|||f||||f||||||||||2018-06-01 00:33:19.556126|2018-06-01 00:33:19.556126
NCT00982813|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2013-10-04|2009-09-22|2009-09-23|Estimate|||||||2013-10-04|2013-10-07|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|||Prospective Study of the Influence of Periodontal Diseases on Pre-term Birth: Observation in the Maternity Hospital of Nantes|Prospective Study of the Influence of Periodontal Diseases on Pre-term Birth: Observation in the Maternity Hospital of Nantes|Terminated||N/A|52|Actual|Nantes University Hospital||||Difficulties of internal organization|f||||f||||||||||2018-06-01 00:33:19.655715|2018-06-01 00:33:19.655715
NCT00980278|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2015-07-10||2015-11-18|2009-09-18|2009-09-21|Estimate|2015-11-18|2015-12-23|Estimate||||2015-11-18|2015-12-23|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Bone Tissue Engineering Using Autologous Bone Repair Cell (BRC) Therapy for Sinus Floor Bone Augmentation|Cell Therapy Using Autologous Bone Marrow Cells Expanded Ex Vivo and Delivered Using Tricalcium Phosphate|Completed||Phase 1/Phase 2|26|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 00:34:11.136723|2018-06-01 00:34:11.136723
NCT00982800|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2010-08-04|2009-09-22|2009-09-23|Estimate|||||||2010-08-04|2010-08-06|Estimate|June 2007||2007-06-30|August 2010|2010-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?|Does Postoperative Gabapentin Reduce Pain, Opioid Consumption & Anxiety & Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?|Completed||Phase 4|60|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 00:33:19.746336|2018-06-01 00:33:19.746336
NCT00982787|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2011-02-22|2009-09-22|2009-09-23|Estimate|||||||2011-02-22|2011-02-23|Estimate|September 2009||2009-09-30|November 2009|2009-11-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy|A Phase II Randomized, Placebo Controlled, Double-blind, Cross-over Clinical Trial to Test the Safety and Potential Anticonvulsant Efficacy of a Botanical Extract From Passiflora Incarnata, in Patients With Partial Onset Epilepsy.|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 00:33:19.821749|2018-06-01 00:33:19.821749
NCT00982774|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2011-06-23|2009-09-22|2009-09-23|Estimate|||||||2011-06-23|2011-06-27|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL|Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL|Completed||Phase 1|42|Actual|IDRI|||||f||||t||||||||||2018-06-01 00:33:19.891454|2018-06-01 00:33:19.891454
NCT00982761|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2010-07-21|2009-09-22|2009-09-23|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Observational|||Metabolic Syndrome of Occupational Drivers|Analysis of Health Status of Occupational Driver|Completed|||50|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 00:33:19.94594|2018-06-01 00:33:19.94594
NCT00982748|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2011-08-23|2009-09-22|2009-09-23|Estimate|||||||2011-08-23|2011-08-25|Estimate|October 2008||2008-10-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Yoga Breathing for Fatigue in Patients Undergoing Chemotherapy|Effects of Pranayama on Fatigue Among Patients Undergoing Chemotherapy|Completed||N/A|25|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:33:19.995373|2018-06-01 00:33:19.995373
NCT00982735|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2010-02-09||2014-03-26|2009-09-22|2009-09-23|Estimate|2010-03-11|2010-03-24|Estimate||||2014-03-26|2014-04-16|Estimate|September 2007||2007-09-30|March 2014|2014-03-31||||August 2008|Actual|2008-08-31||Observational|||An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice|An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice.|Completed|||987|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 00:33:20.069657|2018-06-01 00:33:20.069657
NCT00982722|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-05-26|2009-09-22|2009-09-23|Estimate|||||||2017-05-26|2017-05-30|Actual|April 2008||2008-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vitamin D Supplementation After Parathyroid Surgery|Vitamin D Supplementation After Successful Parathyroid Surgery for Primary Hyperparathyroidism|Active, not recruiting||N/A|150|Anticipated|Karolinska University Hospital||2|||f||||t||||||||No||2018-06-01 00:33:20.319767|2018-06-01 00:33:20.319767
NCT00982709|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2014-10-31|2009-09-22|2009-09-23|Estimate|||||||2014-10-31|2014-11-03|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effects of Treadmill Versus Agility Training in Parkinson's Disease|The Effects of Treadmill Versus Agility Training in Parkinson's Disease|Completed||N/A|40|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 00:33:20.432118|2018-06-01 00:33:20.432118
NCT00982696|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22||2014-09-18|2014-09-18|2009-09-22|2009-09-23|Estimate||||2014-09-18|2014-09-30|Estimate|2014-09-18|2014-09-30|Estimate|February 2008||2008-02-29|September 2014|2014-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Treatment of Advanced Head and Neck Cancer|Treatment of Advanced Head and Neck Cancer With Opioid Growth Factors: Phase II|Terminated||Phase 2|5|Actual|Milton S. Hershey Medical Center||1||Deemed ineffective|f||||t||||||||||2018-06-01 00:33:20.520464|2018-06-01 00:33:20.520464
NCT00982683|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|January 1998||1998-01-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Observational|||Association of Lunar Phases With Post-surgical Morbidity|Association of Lunar Phases With Post-surgical Hemorrhagic Rate|Completed|||26244|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||||f||||f||||||||||2018-06-01 00:33:20.628332|2018-06-01 00:33:20.628332
NCT00982670|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Observational|||A Study of the Metabolic Syndrome in Patients With Systemic Lupus Erythematosus|Association of the Metabolic Syndrome and Systemic Lupus Erythematosus in Taiwan|Completed|||100|Actual|Far Eastern Memorial Hospital|||2||f||||t||||||Samples Without DNA|"~     Stored serum~   "|||2018-06-01 00:33:20.702758|2018-06-01 00:33:20.702758
NCT00982657|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2015-03-13||2015-10-16|2009-09-22|2009-09-23|Estimate|2015-07-24|2015-08-24|Estimate||||2015-10-16|2015-11-20|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Safety Analysis set consisted of all participants who received at least 1 dose of study medication.|A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma|A Phase Ib/ii, Multicenter, Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma|Terminated||Phase 2|34|Actual|Pfizer|On 25 Oct 2012, due to data safety signals in separate clinical trial with CVX-060, all CVX-060 studies were discontinued. Ongoing participants in B1131001 were permitted to remain on study at a reduced dose if determined to derive clinical benefit.|6||Refer to statement in Summary Section/Detailed Description|f||||f||||||||||2018-06-01 00:33:20.844207|2018-06-01 00:33:20.844207
NCT00982319|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22||2016-10-05|2016-10-05|2009-09-22|2009-09-23|Estimate||||2016-10-05|2016-11-03|Estimate|2016-10-05|2016-11-03|Estimate|April 2009||2009-04-30|October 2016|2016-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study to Evaluate the Effect of Sulforaphane in Broccoli Sprout Extract on Breast Tissue|Evaluating the Effect of Broccoli Sprouts (Sulforaphane) on Cellular Proliferation, an Intermediate Marker of Breast Cancer Risk|Completed||Phase 2|34|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-06-01 00:33:29.879695|2018-06-01 00:33:29.879695
NCT00982644|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2015-10-14|2011-02-23|2016-12-16|2009-09-22|2009-09-23|Estimate|2015-10-14|2015-11-13|Estimate|2011-02-23|2011-03-01|Estimate|2016-12-16|2017-02-09|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|BEGIN™||Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes|NN1250-3579: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing the Efficacy and Safety of SIBA and Insulin Glargine, Both Injected Once Daily in Combination With Oral Anti-diabetic Drugs (OAD), in Subjects With Type 2 Diabetes Mellitus Currently Treated With OAD(s) and Qualifying for More Intensified Treatment / NN1250-3643: An Extension Trial to NN1250-3579 Comparing Safety and Efficacy of NN1250 Plus OAD(s) With Insulin Glargine Plus OAD(s) in Type 2 Diabetes (BEGIN™: Once Long)|Completed||Phase 3|1030|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:33:22.085963|2018-06-01 00:33:22.085963
NCT00982631|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2012-04-10|2009-09-22|2009-09-23|Estimate|||||||2012-04-10|2012-04-11|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|August 2012|Anticipated|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer|A Phase Ib Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/ Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer|Unknown status|Recruiting|Phase 1|30|Anticipated|Radboud University||1|||f||||t||||||||||2018-06-01 00:33:23.191706|2018-06-01 00:33:23.191706
NCT00982618|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2011-11-24|2009-09-22|2009-09-23|Estimate|||||||2011-11-24|2011-11-28|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Functional Restoration After Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine|Post Operative Functional Restoration in Patients Undergoing Major Abdominal and Pelvic Laparoscopic Surgery: Effect of Perioperative Intravenous Lidocaine|Completed||N/A|60|Actual|McGill University Health Center||3|||f||||t||||||||||2018-06-01 00:33:23.274836|2018-06-01 00:33:23.274836
NCT00982605|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-10-05|2009-09-22|2009-09-23|Estimate|||||||2009-10-05|2009-10-06|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|January 2011|Anticipated|2011-01-31|October 2010|Anticipated|2010-10-31||Observational|||EBUS-guided TBNA for Molecular Diagnostic of Mediastinal Lymph Nodes (LN)|EBUS-guided TBNA for Molecular Diagnostic of Mediastinal Lymph Nodes|Unknown status|Recruiting||50|Anticipated|Heidelberg University|||1||f||||f||||||Samples With DNA|"~     lymph nodes~   "|||2018-06-01 00:33:23.402394|2018-06-01 00:33:23.402394
NCT00982592|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2015-12-16||2015-12-16|2009-09-22|2009-09-23|Estimate|2015-12-16|2016-01-25|Estimate||||2015-12-16|2016-01-25|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|April 2012|Actual|2012-04-30||Interventional||all the patients enrolled to the study|Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer|A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma|Completed||Phase 2|124|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 00:33:23.534653|2018-06-01 00:33:23.534653
NCT00982579|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-02-02|2009-09-22|2009-09-23|Estimate|||||||2012-02-02|2012-02-03|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|PedVacc001||Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers|An Open Randomized Phase I Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1/2-uninfected Mothers|Completed||Phase 1|48|Actual|Medical Research Council||2|||f||||t||||||||||2018-06-01 00:33:24.522234|2018-06-01 00:33:24.522234
NCT00982566|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2017-11-17|2009-09-22|2009-09-23|Estimate|||||||2017-11-17|2017-11-21|Actual|October 2009||2009-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer|A Phase 1 Study Evaluating the Relative Oral Bioavailability of New Formulations of ABT-263 in Subjects With Cancer|Completed||Phase 1|37|Actual|AbbVie||16|||f||||||||||||||2018-06-01 00:33:24.596648|2018-06-01 00:33:24.596648
NCT00982553|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2011-02-28||2011-11-04|2009-09-22|2009-09-23|Estimate|2011-05-10|2011-06-13|Estimate||||2011-11-04|2011-11-07|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||The Raltegravir and Ribavirin Pharmacokinetics (PK) Study|A Prospective, Open-label, Three Phase Pharmacokinetic Study, to Assess the Pharmacokinetic Profile and Safety of Raltegravir 400 mg Twice Daily and Ribavirin 800 mg Once Daily, When Dosed Separately and Together in Healthy Volunteers|Completed||Phase 1|14|Actual|Imperial College London||1|||f||||f||||||||||2018-06-01 00:33:24.695404|2018-06-01 00:33:24.695404
NCT00982540|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2014-01-28|2009-09-22|2009-09-23|Estimate|||||||2014-01-28|2014-01-29|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|Dindexval||Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients|Empirical Antifungal Treatment in Neutropenic Patients Stratified by Risk: Prospective Validation of an Algorithm Based on the D-index|Terminated||N/A|28|Actual|Universidade Federal do Rio de Janeiro||1||Low accrual|f||||f||||||||||2018-06-01 00:33:24.905761|2018-06-01 00:33:24.905761
NCT00982527|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-06-26|2009-09-22|2009-09-23|Estimate|||||||2012-06-26|2012-06-28|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Fenoldopam in Pediatric Cardiac Surgery|Intraoperative Fenoldopam Infusion in Children Requiring Cardiopulmonary Bypass During Cardiac Surgery|Completed||Phase 3|80|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||||2018-06-01 00:33:24.980467|2018-06-01 00:33:24.980467
NCT00982514|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-09-11|2009-09-22|2009-09-23|Estimate|||||||2012-09-11|2012-09-12|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008|Thromboembolic Complications Related to Asparaginase in Children With ALL Treated According to NOPHO ALL 2008|Unknown status|Recruiting||60|Anticipated|Oslo University Hospital|||2||f||||t||||||||||2018-06-01 00:33:25.061808|2018-06-01 00:33:25.061808
NCT00982501|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2014-05-13|2009-09-22|2009-09-23|Estimate|||||||2014-05-13|2014-05-14|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||WS®1442 in Slightly Overweight Subjects|Investigation of Safety of WS®1442 in Slightly Overweight Subjects With Pilot Assessment of Pharmacodynamic Effects of WS®1442 on Endothelial Function|Completed||Phase 1|60|Anticipated|Dr. Willmar Schwabe GmbH & Co. KG||4|||f||||f||||||||||2018-06-01 00:33:25.162648|2018-06-01 00:33:25.162648
NCT00982488|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2015-12-16||2015-12-16|2009-09-22|2009-09-23|Estimate|2015-12-16|2016-01-22|Estimate||||2015-12-16|2016-01-22|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|START rollover|All participants who received at least 1 dose of study drug|Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis|Completed||Phase 2|238|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:33:25.290018|2018-06-01 00:33:25.290018
NCT00982475|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2018-03-06|2009-09-22|2009-09-23|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2009||2009-09-30|March 2018|2018-03-31|February 27, 2018|Actual|2018-02-27|February 27, 2018|Actual|2018-02-27||Interventional|||Alster Man and Machine: Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation|Ablation at St. George Hospital - Prospective Randomized Comparison of Manual and Mechanical Remote Robotic Catheter Ablation for Drug-Refractory Atrial Fibrillation|Completed||N/A|130|Actual|Asklepios proresearch||2|||f||||f||||||||||2018-06-01 00:33:26.532587|2018-06-01 00:33:26.532587
NCT00982462|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2017-04-24|2009-09-22|2009-09-23|Estimate|||||||2017-04-24|2017-04-25|Actual|January 20, 2011|Actual|2011-01-20|April 2017|2017-04-30|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|||Effect of Long-Chain Polyunsaturated Fatty Acid Supplementation on Toddler Cognition|The Effects of Extended Duration of Long-Chain Polyunsaturated Fatty Acid (LCP)-Supplementation on Neurological and Immunological Development in Toddlers|Completed||N/A|116|Actual|Retina Foundation of the Southwest||2|||f||||f||||||||||2018-06-01 00:33:26.617451|2018-06-01 00:33:26.617451
NCT00982449|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2016-05-17|2009-09-22|2009-09-23|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||124I-FIAU Imaging in EBV and KSHV Associated Cancers|Study of Imaging of Viral Thymidine Kinase Activity in EBV-Associated and KSHV-Associated Malignancies|Recruiting||Early Phase 1|15|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-06-01 00:33:26.759577|2018-06-01 00:33:26.759577
NCT00982436|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-03-21|2009-09-22|2009-09-23|Estimate|||||||2012-03-21|2012-03-22|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer|A Pilot Study to Evaluate Response to Neoadjuvant Chemotherapy With Cisplatin and Docetaxel Followed by Chemoradiation Therapy With Carboplatin in Stage IV Non-metastatic Head and Neck Cancer|Unknown status|Recruiting|Phase 1/Phase 2|37|Anticipated|University of Vermont||1|||f||||t||||||||||2018-06-01 00:33:26.849329|2018-06-01 00:33:26.849329
NCT00982423|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2015-06-22||2015-06-22|2009-09-22|2009-09-23|Estimate|2015-06-22|2015-07-20|Estimate||||2015-06-22|2015-07-20|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Aim1||The Effects of Decreasing the Lasix Dose on the Cardiorenal System|To Define the Effects of Decreasing the Furosemide Dose on Cardiorenal and Humoral Function in Humans With Compensated Chronic Heart Failure (CHF) With and Without Renal Dysfunction|Completed||Phase 1/Phase 2|41|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:33:27.020228|2018-06-01 00:33:27.020228
NCT00982410|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2014-11-21||2015-06-15|2009-09-22|2009-09-23|Estimate|2014-12-10|2014-12-24|Estimate||||2015-06-15|2015-07-13|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Managing Chronic Pain in Veterans With Substance Use Disorders|Managing Chronic Pain in Veterans With Substance Use Disorders|Completed||Early Phase 1|131|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:33:27.314596|2018-06-01 00:33:27.314596
NCT00982397|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2016-05-25||2017-10-05|2009-09-22|2009-09-23|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|September 2009||2009-09-30|October 2017|2017-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Clinical Performance of the Protecta ICD and CRT-D|The PainFree SST Clinical Study: Clinical Study to Evaluate System Safety and Clinical Performance of the Protecta ICD + CRT-D and to Assess the Capacity of the Protecta Features to Reduce Inappropriate Shocks.|Completed||N/A|2770|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||No||2018-06-01 00:33:27.883413|2018-06-01 00:33:27.883413
NCT00982384|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2015-05-19|2009-09-22|2009-09-23|Estimate|||||||2015-05-19|2015-05-20|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|COPD_CDM||Comprehensive Disease Management Program in Chronic Obstructive Pulmonary Disease (COPD) Patients in the Community|Comprehensive Disease Management Program in COPD Patients in the Community: Randomized Controlled Trial|Completed||N/A|1202|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 00:33:29.35176|2018-06-01 00:33:29.35176
NCT00982371|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2012-06-17|2009-09-22|2009-09-23|Estimate|||||||2012-06-17|2012-06-19|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||An Investigation Into Bone Micro-architecture in Women With Type 2 Diabetes|A Cross-sectional Comparison of Bone Micro-architecture in Postmenopausal Women With Type 2 Diabetes and Age-matched Controls|Completed|||60|Actual|McMaster University|||2||f||||t||||||||||2018-06-01 00:33:29.416058|2018-06-01 00:33:29.416058
NCT00982358|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|July 2004||2004-07-31|September 2009|2009-09-30|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|||Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus|A 16-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Anti-inflammatory Actions of 320 mg Diovan in Patients With Type 2 Diabetes With and Without Coronary Artery Disease|Completed||Phase 4|121||Charite University, Berlin, Germany||2|||f||||||||||||||2018-06-01 00:33:29.464862|2018-06-01 00:33:29.464862
NCT00982345|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2013-10-07||2016-08-08|2009-09-22|2009-09-23|Estimate|2016-08-08|2016-09-30|Estimate||||2016-08-08|2016-09-30|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Brain Imaging of Quetiapine Response in Anxious Depression|Brain Imaging of Quetiapine Response in Anxious Depression|Completed||Phase 4|20|Actual|Indiana University|Open label study. Small sample|1|||f||||f||||||||No||2018-06-01 00:33:29.579532|2018-06-01 00:33:29.579532
NCT00982332|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-07-18|2009-09-22|2009-09-23|Estimate|||||||2010-07-18|2010-07-20|Estimate|March 2010||2010-03-31|July 2010|2010-07-31|March 2012|Anticipated|2012-03-31|September 2011|Anticipated|2011-09-30||Interventional|||Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica|Efficacy of Micro-pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica|Unknown status|Recruiting|N/A|20|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||||2018-06-01 00:33:29.737734|2018-06-01 00:33:29.737734
NCT00982293|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2011-05-04|2009-09-22|2009-09-23|Estimate|||||||2011-05-04|2011-05-05|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes|A Randomized, Double Blind, Placebo Controlled Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes Mellitus, Pilot Study II|Terminated||Phase 2|165|Anticipated|pico-tesla Magnetic Therapies, LLC||2||Difficulty in Recruitment|f||||t||||||||||2018-06-01 00:33:30.029911|2018-06-01 00:33:30.029911
NCT00982280|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2011-08-02||2011-11-09|2009-09-22|2009-09-23|Estimate|2011-11-09|2011-12-14|Estimate||||2011-11-09|2011-12-14|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking WHO Step III Analgesics But Showing a Lack of Tolerability.|An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.|Terminated||Phase 3|82|Actual|Grünenthal GmbH||1||Slow Recruitment and supply of Investigational Medicinal Product Issues|f||||f||||||||||2018-06-01 00:33:30.135486|2018-06-01 00:33:30.135486
NCT00982267|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2011-08-04|2009-09-22|2009-09-23|Estimate|||||||2011-08-04|2011-08-08|Estimate|December 2003||2003-12-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|November 2008|Actual|2008-11-30||Interventional|||A Trial Of SU14813 In Patients With Advanced Solid Malignancies|A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy|Completed||Phase 1|77|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:33:30.823624|2018-06-01 00:33:30.823624
NCT00982254|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|October 2001||2001-10-31|September 2009|2009-09-30||||November 2001|Actual|2001-11-30||Interventional|||Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes|A Comparison of the Pharmacodynamic and Pharmacokinetic Properties of Oral Insulin vs. s.c. Regular Insulin in Type 2 Diabetic Patients|Completed||Phase 1|10|Actual|Profil Institut für Stoffwechselforschung GmbH||2|||f||||f||||||||||2018-06-01 00:33:30.896349|2018-06-01 00:33:30.896349
NCT00982241|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-07-23|2009-09-22|2009-09-23|Estimate|||||||2012-07-23|2012-07-24|Estimate|July 2009||2009-07-31|September 2009|2009-09-30||||December 2010|Actual|2010-12-31||Interventional|||Overactive Bladder (OAB) Drink Advice Study|Prospective Intervention Study of Drink Advice in Overactive Bladder Syndrome (OAB)|Withdrawn||N/A|0|Actual|Radboud University||3||Difficulty in enrolling participants|f||||t||||||||||2018-06-01 00:33:30.975418|2018-06-01 00:33:30.975418
NCT00982228|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2015-10-14|2011-02-24|2017-03-08|2009-09-22|2009-09-23|Estimate|2015-11-24|2015-12-29|Estimate|2011-02-24|2011-03-09|Estimate|2017-03-08|2017-04-06|Actual|September 1, 2009|Actual|2009-09-01|March 2017|2017-03-31|November 8, 2010|Actual|2010-11-08|November 8, 2010|Actual|2010-11-08||Interventional|BEGIN™||Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes|NN1250-3583: A 52 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Parallel, Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: BB T1 LONG) / NN1250-3644: An Extension Trial to Trial NN1250-3583 Comparing Safety and Efficacy of NN1250 With Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin, in Type 1 Diabetes (BEGIN™: T1)|Completed||Phase 3|629|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:33:31.11702|2018-06-01 00:33:31.11702
NCT00982215|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2012-01-26|2009-09-22|2009-09-23|Estimate|||||||2012-01-26|2012-01-30|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|PMB||Pilot Study of Pharmacology of Paracetamol Administered Per-oral Mucosa|Pilot Study of Pharmacology of Paracetamol Administered Per-oral Mucosa|Completed||Phase 1|20|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:33:31.874707|2018-06-01 00:33:31.874707
NCT00982202|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Pioglitazone in Alzheimer Disease|Pioglitazone in Alzheimer Disease Progression|Completed||Phase 2|25|Actual|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 00:33:31.931962|2018-06-01 00:33:31.931962
NCT00982189|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|2012-01-16||2017-10-19|2009-09-22|2009-09-23|Estimate|2012-03-23|2012-04-18|Estimate||||2017-10-19|2017-11-22|Actual|September 2009||2009-09-30|October 2017|2017-10-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Cardiovascular Prevention for Persons With HIV|Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study|Completed||N/A|37|Actual|Minneapolis Medical Research Foundation|Study was small with limited power to detect differences.|4|||f||||f||||||||||2018-06-01 00:33:32.034099|2018-06-01 00:33:32.034099
NCT00982176|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2014-04-01|2009-09-22|2009-09-23|Estimate|||||||2014-04-01|2014-04-02|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|COSCA||Determinants of Cognitive Impairment After Acute Coronary Syndrome|Anatomo-functional Determinants of Cognitive Impairment After Acute Coronary Syndrome: A Brain MRI and Cerebral Perfusion Scintigraphy Study|Completed|||49|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-06-01 00:33:32.401705|2018-06-01 00:33:32.401705
NCT00982163|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22|||2009-09-22|2009-09-22|2009-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Observational|||A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season||Completed|||34|Actual|ORA, Inc.|||||f||||f||||||||||2018-06-01 00:33:32.47643|2018-06-01 00:33:32.47643
NCT00982150|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-22||2013-08-16|2013-08-16|2009-09-22|2009-09-23|Estimate||||2013-08-16|2013-08-26|Estimate|2013-08-16|2013-08-26|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ALSTAR OL||Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)|A Multinational, Multicenter, Open Label Phase to Assess Tolerability and Safety of Talampanel 50mg Tid in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Terminated||Phase 2|446|Actual|Teva Pharmaceutical Industries||1||Core study unsuccessful|f||||t||||||||||2018-06-01 00:33:32.526628|2018-06-01 00:33:32.526628
NCT00982137|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2012-07-11||2012-09-18|2009-09-21|2009-09-22|Estimate|2012-09-18|2012-09-20|Estimate||||2012-09-18|2012-09-20|Estimate|July 2004||2004-07-31|September 2012|2012-09-30|March 2007|Actual|2007-03-31|April 2005|Actual|2005-04-30||Interventional|||Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)|Randomised, Double-blind, Phase II Evaluation of the Safety and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)|Completed||Phase 2|108|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 00:33:32.603776|2018-06-01 00:33:32.603776
NCT00982124|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2016-04-18|2009-09-21|2009-09-22|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Interventional|INFOI||An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta|An International, Multicenter, Open-label, Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta|Completed||Phase 3|14|Actual|Shriners Hospitals for Children||1|||f||||||||||||||2018-06-01 00:33:34.21771|2018-06-01 00:33:34.21771
NCT00982111|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2015-12-21|2010-09-14|2017-11-21|2009-09-21|2009-09-22|Estimate|2016-05-20|2016-06-27|Estimate|2010-09-14|2010-09-16|Estimate|2017-11-21|2017-12-19|Actual|November 2009||2009-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|November 2012|Actual|2012-11-30||Interventional|INSPIRE||First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin|A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|633|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 00:33:34.392276|2018-06-01 00:33:34.392276
NCT00982098|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-09-21|2009-09-21|2009-09-22|Estimate|||||||2009-09-21|2009-09-22|Estimate|February 2007||2007-02-28|September 2009|2009-09-30|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Prevention of Urinary Incontinence After Prostatectomy||Unknown status|Active, not recruiting|N/A|110|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||||||||||||2018-06-01 00:33:36.921097|2018-06-01 00:33:36.921097
NCT00982085|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-09-21|2009-09-21|2009-09-22|Estimate|||||||2009-09-21|2009-09-22|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Observational|||The Status of Asthma in the Korean Military Personnel|The Status of Asthma in the Korean Military Personnel|Unknown status|Recruiting||4000|Anticipated|Armed Forces Capital Hospital, Republic of Korea|||1||f||||f||||||||||2018-06-01 00:33:36.993602|2018-06-01 00:33:36.993602
NCT00982072|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2017-03-03|2009-09-21|2009-09-22|Estimate|||||||2017-03-03|2017-03-06|Actual|December 2009||2009-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MinTAC||Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease|Tacrolimus vs Prednisolone for the Treatment Minimal Change Disease|Recruiting||Phase 4|52|Anticipated|Imperial College Healthcare NHS Trust||2|||f||||f||||||||||2018-06-01 00:33:37.053117|2018-06-01 00:33:37.053117
NCT00982059|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2018-01-30|2009-09-21|2009-09-22|Estimate|||||||2018-01-30|2018-01-31|Actual|May 2008||2008-05-31|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|December 2014|Actual|2014-12-31||Observational|||Colorectal Cancer Screening for Cancer Survivors|Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy|Completed|||140|Anticipated|University Health Network, Toronto|||1||f||||t||||||||||2018-06-01 00:33:37.154703|2018-06-01 00:33:37.154703
NCT00982046|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2016-11-15|2009-09-21|2009-09-22|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Clinical Comparison of Three Contact Lens Care Systems and Their Effect on Contact Lenses|A Clinical Comparison of Three Contact Lens Care Systems and Their Effect on Contact Lenses|Completed||N/A|75|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 00:33:37.274995|2018-06-01 00:33:37.274995
NCT00982033|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2016-10-31||2017-11-06|2009-09-21|2009-09-22|Estimate|2017-01-31|2017-03-22|Actual||||2017-11-06|2017-11-08|Actual|July 2009||2009-07-31|January 2017|2017-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|Aliskiren||Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction|A Randomized, Blinded, Placebo-Controlled Six Month Treatment Trial of Aliskiren to Improve Exercise Tolerance in Older Patients With Heart Failure and Normal Ejection Fraction|Completed||Phase 4|52|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-06-01 00:33:37.393211|2018-06-01 00:33:37.393211
NCT00982020|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2014-04-18||2014-12-08|2009-09-21|2009-09-22|Estimate|2014-12-08|2014-12-17|Estimate||||2014-12-08|2014-12-17|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All randomized participants who received at least one dose of study drug|Study in Adolescents With Schizophrenia or Bipolar Disorder|A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia|Completed||Phase 4|203|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:33:37.766458|2018-06-01 00:33:37.766458
NCT00982007|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2013-08-14||2018-01-22|2009-09-21|2009-09-22|Estimate|2013-08-14|2013-10-18|Estimate||||2018-01-22|2018-02-20|Actual|September 2009||2009-09-30|January 2018|2018-01-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)|A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)|Completed||Phase 3|997|Actual|Luitpold Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:33:38.749525|2018-06-01 00:33:38.749525
NCT00981994|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2016-11-23|2009-09-18|2009-09-22|Estimate|||||||2016-11-23|2016-11-28|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|May 2011|Actual|2011-05-31||Interventional|||Evaluation of an Algorithm to Reduce Antibiotic Prescribing for Acute Bronchitis|Development, Implementation, and Evaluation of Novel Strategies to Reduce Inappropriate Antimicrobial Use in Community and Healthcare Settings|Completed||N/A|3300|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 00:33:39.680425|2018-06-01 00:33:39.680425
NCT00981981|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2011-06-20|2009-09-21|2009-09-22|Estimate|||||||2011-06-20|2011-06-21|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|Bluebird||Effect of the Molecular Weight of Oat β-glucan on Its Ability to Lower Serum Cholesterol|Effect of Varying Dose and Molecular Weight on the Serum LDL-cholesterol-lowering Properties of Oat β-glucan|Completed||Phase 2|367|Actual|Glycemic Index Laboratories, Inc||5|||f||||f||||||||||2018-06-01 00:33:39.7934|2018-06-01 00:33:39.7934
NCT00981968|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2010-10-14|2009-09-21|2009-09-22|Estimate|||||||2010-10-14|2010-10-15|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects|An Investigator- And Subjects- Blind Phase 1 Study To Investigate Pharmacokinetics, Safety And Tolerability Of Sitaxentan In Japanese Healthy Subjects Following Single And Multiple Doses And Western Healthy Subjects Following Single Dose|Completed||Phase 1|22|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:33:39.895526|2018-06-01 00:33:39.895526
NCT00980252|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2014-06-13|2009-09-18|2009-09-21|Estimate|||||||2014-06-13|2014-06-16|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention|Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention|Completed||N/A|34|Actual|University of Illinois at Chicago||1|||f||||f||||||||||2018-06-01 00:34:11.417609|2018-06-01 00:34:11.417609
NCT00981955|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2010-07-22|2009-09-21|2009-09-22|Estimate|||||||2010-07-22|2010-07-23|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood|A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood.|Completed||Phase 4|24|Actual|Northumbria University||4|||f||||f||||||||||2018-06-01 00:33:39.963626|2018-06-01 00:33:39.963626
NCT00981942|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2012-06-04|2009-09-21|2009-09-22|Estimate|||||||2012-06-04|2012-06-05|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|NSF||Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec|An Open Label Clinical Trial of Imatinib Mesylate(Glivec)in Patients With Moderate to Severe Nephrogenic Systemic Fibrosis|Completed||Phase 3|10|Actual|University of Aarhus|||||f||||t||||||||||2018-06-01 00:33:40.16015|2018-06-01 00:33:40.16015
NCT00981929|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2010-06-24|2009-09-21|2009-09-22|Estimate|||||||2010-06-24|2010-06-28|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|January 2011|Anticipated|2011-01-31|December 2009|Anticipated|2009-12-31||Interventional|||Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes|Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes|Terminated||N/A|412|Anticipated|University of Southern Denmark||3||Unexpected non-serious adverse events|f||||t||||||||||2018-06-01 00:33:40.264341|2018-06-01 00:33:40.264341
NCT00981916|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2013-09-04|2009-09-21|2009-09-22|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Ultrasound Determination of Needle Depth in Epidurals in Adult Patients|Ultrasound Determination of Needle Depth in Lumbar and Thoracic Epidurals in Adult Non-Parturient Patients|Completed|||42|Actual|University of Chicago|||||f||||t||||||||||2018-06-01 00:33:40.366028|2018-06-01 00:33:40.366028
NCT00981903|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2017-07-05|2009-09-21|2009-09-22|Estimate|||||||2017-07-05|2017-07-06|Actual|July 2005||2005-07-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2012|Actual|2012-10-31||Interventional|||Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer|Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer|Terminated||Phase 2|131|Actual|University of Southern California||2||Tinzaparin will no longer be available in the United States|f||||f||||||||||2018-06-01 00:33:40.449587|2018-06-01 00:33:40.449587
NCT00981890|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2017-09-20|2009-09-21|2009-09-22|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2009||2009-07-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|July 2014|Actual|2014-07-31||Interventional|||Stereotactic Radiosurgery With Sunitinib for Brain Metastases|A Phase I Study of Stereotactic Radiosurgery Concurrent With Sunitinib in Patients With Brain Metastases|Active, not recruiting||Phase 1|22|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:33:40.570441|2018-06-01 00:33:40.570441
NCT00981877|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-21|2009-09-21|2009-09-22|Estimate|||||||2009-09-21|2009-09-22|Estimate|July 2007||2007-07-31|September 2009|2009-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian Children|Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian Children: Randomized Double-blind, Controlled Trial Using Two Different Preparations|Completed||N/A|76|Actual|Centro Pediatrico Albina de Patino||3|||f||||f||||||||||2018-06-01 00:33:40.803603|2018-06-01 00:33:40.803603
NCT00981864|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2012-12-19|2009-09-21|2009-09-22|Estimate|||||||2012-12-19|2012-12-21|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Concurrent Boost Radiotherapy|A Feasibility Study to Evaluate Intensity Modulated Radiation Therapy (IMRT) for Concomitant Boost Breast Radiotherapy (CBRT)|Completed||Phase 2|17|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:33:41.023822|2018-06-01 00:33:41.023822
NCT00981851|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2011-07-04|2009-09-21|2009-09-22|Estimate|||||||2011-07-04|2011-07-06|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ICE||Interaction in Chronic Obstructive Pulmonary Disease Experiment|A Hazardous Combination of Cigarette Smoking and Bronchodilation in Chronic Obstructive Pulmonary Disease|Completed||N/A|40|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 00:33:41.110805|2018-06-01 00:33:41.110805
NCT00981838|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2013-02-22|2009-09-21|2009-09-22|Estimate|||||||2013-02-22|2013-02-25|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|NEMO||Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)|A Prospective, Sequential Study to Assess the Efficacy of Rituximab Therapy in Maintaining Remission of Nephrotic Syndrome After Steroid and Immunosuppressive Therapy Withdrawal in Patients With Steroid-dependant or Multirelapsing Minimal Change Disease or Focal Segmental Glomerulosclerosis (NEMO Study)|Completed||Phase 3|24|Actual|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||||2018-06-01 00:33:41.191552|2018-06-01 00:33:41.191552
NCT00981825|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2011-06-10|2009-08-14|2009-09-22|Estimate|2009-08-14|2009-09-22|Estimate||||2011-06-10|2011-06-14|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Salivary Bacteria and Post Brushing|Efficacy of Salivary Bacteria and Post Brushing|Completed||Phase 3|22|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 00:33:41.27242|2018-06-01 00:33:41.27242
NCT00981812|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2014-12-23||2016-03-03|2009-09-21|2009-09-22|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional||Women 25 or older|Positron Emission Mammography (PEM) Biopsy Accessory for the Diagnosis of Breast Cancer|Clinical Utility and Initial Experience With PEM Flex Solo II PET Scanner and Stereo Navigator Biopsy Accessory for the Diagnosis of Breast Cancer|Completed||N/A|20|Actual|University of Cincinnati||1|||f||||f||||||||||2018-06-01 00:33:41.562211|2018-06-01 00:33:41.562211
NCT00981799|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-11-20|2009-09-18|2009-09-22|Estimate|||||||2015-11-20|2015-11-24|Estimate|June 2010||2010-06-30|November 2015|2015-11-30||||November 2015|Actual|2015-11-30||Interventional|||Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL|A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC|Terminated||Phase 1/Phase 2|23|Actual|Therapeutic Advances in Childhood Leukemia Consortium||||Slow accrual rate|f||||t||||||||||2018-06-01 00:33:41.734603|2018-06-01 00:33:41.734603
NCT00981786|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-05-09|2009-09-21|2009-09-22|Estimate|||||||2014-05-09|2014-05-12|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol|Quality of 24-hour Intraocular Pressure Control Obtained With the Brinzolamide/Timolol Fixed Combination Compared With the Brimonidine/Timolol Fixed Combination When Added to Travoprost Monotherapy in Subjects With Open-angle Glaucoma|Completed||Phase 4|51|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 00:33:41.892638|2018-06-01 00:33:41.892638
NCT00981773|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2014-05-20|2009-09-21|2009-09-22|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SMASH||The St. Marys and The Mater Switch Study|A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy|Completed||Phase 4|18|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 00:33:41.957325|2018-06-01 00:33:41.957325
NCT00981747|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2017-03-29|2009-09-19|2009-09-22|Estimate|||||||2017-03-29|2017-03-30|Actual|September 2009|Actual|2009-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis|A Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis|Completed||Phase 2/Phase 3|16|Actual|University of Iowa||4|||f||||t||||||||||2018-06-01 00:33:42.040655|2018-06-01 00:33:42.040655
NCT00981734|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2009-09-21|2009-09-21|2009-09-22|Estimate|||||||2009-09-21|2009-09-22|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Hiking Improves the Functional Autonomy|Effects of a Hiking Study About the Functional Autonomy Levels in Old Women Analyzed by the Family Health Program|Completed||N/A|98|Actual|Universidade Camilo Castelo Branco|||||f||||t||||||||||2018-06-01 00:33:42.119427|2018-06-01 00:33:42.119427
NCT00981721|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2011-06-17|2009-09-21|2009-09-22|Estimate|||||||2011-06-17|2011-06-20|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|May 2010|Actual|2010-05-31||Interventional|||A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies|A Phase I, Randomised, Multi-centre, Open-label Study to Determine the Pharmacokinetics and Tolerability of Cediranib (RECENTIN™, AZD2171) Following a Single and Multiple Oral 20mg or 30 mg Doses in Chinese Patients With Advanced Solid Malignancies|Completed||Phase 1|20|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:33:42.188412|2018-06-01 00:33:42.188412
NCT00981708|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2014-01-30|2009-09-21|2009-09-22|Estimate|||||||2014-01-30|2014-01-31|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|December 2011|Actual|2011-12-31||Interventional|||Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)|A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis|Unknown status|Active, not recruiting|Phase 1/Phase 2|37|Actual|University of Athens||1|||f||||f||||||||||2018-06-01 00:33:42.27018|2018-06-01 00:33:42.27018
NCT00981695|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2011-06-15|2009-09-21|2009-09-22|Estimate|||||||2011-06-15|2011-06-16|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Interventional|PedVacc002||Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers|An Open Randomized Phase I/II Study Evaluating Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Infants Born to HIV-1-infected Mothers|Unknown status|Recruiting|Phase 1/Phase 2|72|Anticipated|Medical Research Council||2|||f||||t||||||||||2018-06-01 00:33:42.48086|2018-06-01 00:33:42.48086
NCT00981682|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18||2013-12-19|2014-01-27|2009-09-21|2009-09-22|Estimate||||2014-01-27|2014-02-28|Estimate|2014-01-27|2014-02-28|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Long Term Safety Assessment of SER120 in Patients With Nocturia|A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902|Completed||Phase 3|376|Actual|Serenity Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 00:33:42.556847|2018-06-01 00:33:42.556847
NCT00981669|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2013-02-04||2013-03-15|2009-09-21|2009-09-22|Estimate|2013-03-15|2013-04-25|Estimate||||2013-03-15|2013-04-25|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional||In the vaccine gorup one volunteer was not considered for the final analysis because He received the second dose of the vaccine in an anapropriate interval.|Rotavirus Vaccine Produced by Butantan Institute|Evaluation of Rotavirus Vaccine Produced by Butantan Institute. Phase I - Safety, Tolerability and Immunogenicity Evaluation|Completed||Phase 1|80|Actual|Butantan Institute|The vaccine candidate needs to be evaluated further in larger trials, among the target population.|2|||f||||t||||||||||2018-06-01 00:33:42.628592|2018-06-01 00:33:42.628592
NCT00981656|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2017-12-21|2009-09-19|2009-09-22|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2009|Actual|2009-11-30|December 2017|2017-12-31|October 2023|Anticipated|2023-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer|A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging|Active, not recruiting||Phase 2|37|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 00:33:42.89498|2018-06-01 00:33:42.89498
NCT00981643|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2017-02-28|2009-09-21|2009-09-22|Estimate|||||||2017-02-28|2017-03-03|Actual|February 2009||2009-02-28|September 2011|2011-09-30|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Effects of Meditation on Multiple Sclerosis and Peripheral Neuropathy|The Effects of Meditation on Pain, Fatigue and Physical Functioning in Patients With Multiple Sclerosis and Peripheral Neuropathy|Completed||N/A|40|Actual|The Cleveland Clinic||4|||f||||f|f|f||||||No||2018-06-01 00:33:42.998556|2018-06-01 00:33:42.998556
NCT00981630|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2012-11-06||2012-11-06|2009-09-21|2009-09-22|Estimate|2012-11-06|2012-12-05|Estimate||||2012-11-06|2012-12-05|Estimate|November 2004||2004-11-30|November 2012|2012-11-30|November 2007|Actual|2007-11-30|February 2006|Actual|2006-02-28||Interventional|||Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine|Randomised, Double-blind, Placebo Controlled Phase II, Dose-ranging Study of the Safety, Tolerability and Immunogenicity of Live Attenuated ChimeriVax™-JE Vaccine (Lyophilised)|Completed||Phase 2|128|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 00:33:43.101852|2018-06-01 00:33:43.101852
NCT00981617|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21||2011-08-19|2011-08-19|2009-09-21|2009-09-22|Estimate||||2011-08-19|2011-08-23|Estimate|2011-08-19|2011-08-23|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Adaptive Study of the Safety and Efficacy of RDC-0313 in Adults With Alcohol Dependence|Completed||Phase 2|406|Actual|Alkermes, Inc.||4|||f||||f||||||||||2018-06-01 00:33:43.961897|2018-06-01 00:33:43.961897
NCT00981604|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2011-12-12|2009-09-21|2009-09-22|Estimate|||||||2011-12-12|2011-12-13|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SILS||Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy|Single Incision Versus Laparoscopic Cholecystectomy|Completed||N/A|60|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 00:33:44.090489|2018-06-01 00:33:44.090489
NCT00981591|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2015-01-15|2009-09-21|2009-09-22|Estimate|||||||2015-01-15|2015-01-19|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients|A Randomized, Double Blind, Placebo-controlled Pilot Study of the Safety and Effective Dosing of Inhaled Iloprost in Pediatric Patients With Pulmonary Hypertension Treated With Inhaled Nitric Oxide|Withdrawn||Phase 1/Phase 2|0|Actual|Seattle Children's Hospital||2||No patients recruited|f||||t||||||||||2018-06-01 00:33:44.174908|2018-06-01 00:33:44.174908
NCT00981578|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2016-09-12|2009-09-21|2009-09-22|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Feasibility Study to Evaluate the Safety and Initial Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System|Recruiting||Phase 1|50|Anticipated|InSightec||1|||f||||||||||||||2018-06-01 00:33:44.257788|2018-06-01 00:33:44.257788
NCT00981565|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2012-10-17|2009-09-21|2009-09-22|Estimate|||||||2012-10-17|2012-10-18|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Interventional|||Mild Carpal Tunnel Syndrome|Operative Versus Conservative Treatment in Mild Carpal Tunnel Syndrome, Randomized Prospective Multicenter Study|Completed||N/A|88|Actual|North Karelia Central Hospital||2|||f||||||||||||||2018-06-01 00:33:44.361526|2018-06-01 00:33:44.361526
NCT00981552|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-09-21|2009-09-21|2009-09-22|Estimate|||||||2009-09-21|2009-09-22|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Dosimetric Planning Study Comparing Intensity Modulated Radiotherapy (IMRT) and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix|Dosimetric Planning Study Comparing IMRT and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix|Completed||Early Phase 1|55|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-06-01 00:33:44.420127|2018-06-01 00:33:44.420127
NCT00981539|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-09-21|2009-09-21|2009-09-22|Estimate|||||||2009-09-21|2009-09-22|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Will Cleaning the Bowel With an Enema Before Vaginal Prolapse Surgery Prevent Complications?|Do Preoperative Enemas Prevent Complications in Vaginal Pelvic Reconstructive Surgery?|Unknown status|Recruiting|N/A|310|Anticipated|Illinois Urogynecology, Ltd.||2|||f||||f||||||||||2018-06-01 00:33:44.490176|2018-06-01 00:33:44.490176
NCT00981526|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18||2013-06-19|2013-08-12|2009-09-21|2009-09-22|Estimate||||2013-07-24|2013-07-31|Estimate|2013-08-12|2013-08-21|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia|Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia|Completed||Phase 4|57|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 00:33:44.570283|2018-06-01 00:33:44.570283
NCT00981513|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-20|||2011-08-18|2009-09-21|2009-09-22|Estimate|||||||2011-08-18|2011-08-19|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Direct and Indirect Benefits of Influenza Vaccination in Schools and Households|Direct and Indirect Benefits of Influenza Vaccination in Schools and Households|Completed||Phase 4|6300|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-06-01 00:33:44.66007|2018-06-01 00:33:44.66007
NCT00981500|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2017-12-04|2009-09-21|2009-09-22|Estimate|||||||2017-12-04|2017-12-06|Actual|December 2009||2009-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|RB||Glucose Homeostasis Pre and Post Bariatric Surgery|Effect of Bariatric Surgery-induced Weight Loss on Glucose Homeostasis|Active, not recruiting|||60|Actual|Washington University School of Medicine|||3||f||||t||||||Samples With DNA|"~     plasma, tongue tissue, muscle tissue, fat tissue,liver tissue, colon tissue, stool~   "|No||2018-06-01 00:33:44.724643|2018-06-01 00:33:44.724643
NCT00981487|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2017-02-08|2009-09-21|2009-09-22|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2009||2009-02-28|February 2017|2017-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|ODO-P8-689||Bioavailability Study of Anti Nausea Medication With and Without Food (EUR-1025)|Single-Dose Crossover Comparative Bioavailability Study to Assess the Effect of Food on the Pharmacokinetics of Ondansetron Modified-Release Capsules (EUR-1025) in Healthy Male and Female Volunteers|Completed||Phase 1|22|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:33:44.911457|2018-06-01 00:33:44.911457
NCT00981474|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2018-03-28|2009-09-21|2009-09-22|Estimate|||||||2018-03-28|2018-03-30|Actual|September 1, 2009|Actual|2009-09-01|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Cerebral Autoregulation Monitoring During Cardiac Surgery|Continuous Cerebral Autoregulation Monitoring to Reduce Brain Injury From Cardiac Surgery|Recruiting||N/A|490|Anticipated|Northwestern University||2|||f||||t|f|f|||f|||No||2018-06-01 00:33:44.998539|2018-06-01 00:33:44.998539
NCT00981461|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2012-04-12||2012-08-07|2009-09-21|2009-09-22|Estimate|2012-06-21|2012-07-30|Estimate||||2012-08-07|2012-08-10|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Treatment of Androgenetic Alopecia in Females, 9 Beam|A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 9 Beam Model: For the Treatment of Androgenetic Alopecia in Females|Completed||N/A|72|Actual|Lexington International, LLC||2|||f||||t||||||||||2018-06-01 00:33:45.090667|2018-06-01 00:33:45.090667
NCT00981448|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2012-09-28|2009-09-18|2009-09-22|Estimate|||||||2012-09-28|2012-10-02|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes|Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes|Completed||N/A|57|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 00:33:45.281563|2018-06-01 00:33:45.281563
NCT00981435|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2016-12-28||2018-04-25|2009-09-21|2009-09-22|Estimate|2017-02-28|2017-04-14|Actual||||2018-04-25|2018-05-23|Actual|September 2009||2009-09-30|April 2018|2018-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SALT||Steroids After Laser Trabeculoplasty for Glaucoma|Steroids And Laser Trabeculoplasty (SALT) Trial: Effect of Anti-Inflammatory Treatment on the Efficacy of SLT|Completed||Phase 4|97|Actual|Stanford University||3|||f||||f||||||||Yes|IPD is anticipated to be shared upon publication of results.|2018-06-01 00:33:45.362984|2018-06-01 00:33:45.362984
NCT00981422|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2009-09-21|2009-09-21|2009-09-22|Estimate|||||||2009-09-21|2009-09-22|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Observational|||Search for Biomarkers in Human Glaucoma: Lymphocytes Alterations and Rate of Progression|Search for Biomarkers in Human Glaucoma: Possible Correlations Between Alterations in Peripheral Lymphocytes and Disease Severity|Completed|||40|Actual|University of Parma|||2||f||||f||||||||||2018-06-01 00:33:45.794478|2018-06-01 00:33:45.794478
NCT00981409|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2009-10-14||2016-11-04|2009-09-21|2009-09-22|Estimate|2009-11-06|2009-12-10|Estimate||||2016-11-04|2016-12-16|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)|Completed||Phase 3|41|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:33:45.867583|2018-06-01 00:33:45.867583
NCT00981396|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2018-04-23|2009-09-21|2009-09-22|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2009||2009-09-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|||The Effect of Emotional Freedom Techniques (EFT) in Smokers Failing a Smoking Cessation Program|The Effect of EFT (Emotional Freedom Techniques) in Smokers Failing a Smoking Cessation Program|Recruiting||Early Phase 1|40|Anticipated|Soul Medicine Institute||2|||f||||f||||||||||2018-06-01 00:33:46.367164|2018-06-01 00:33:46.367164
NCT00981383|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2017-04-26|2009-09-21|2009-09-22|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2010||2010-06-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2014|Actual|2014-05-31||Interventional|CAROTID||Treating Depression in Coronary Artery Disease With Omega-3 Fatty Acids|CAROTID: CAD Randomized Omega-3 Trial In Depression|Completed||Phase 3|92|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 00:33:46.680164|2018-06-01 00:33:46.680164
NCT00981370|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2010-10-27||2016-12-15|2009-09-21|2009-09-22|Estimate|2016-12-15|2017-02-08|Estimate||||2016-12-15|2017-02-08|Estimate|April 2009||2009-04-30|December 2016|2016-12-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Clinical Importance of Treating Iron Overload in Sickle Cell Disease|Clinical Importance of Treating Iron Overload in Sickle Cell Disease|Terminated||Phase 3|1|Actual|Children's Hospital Los Angeles|1 consent patient, never treated, lost to follow up|1||1 consented patient never started on study drug, lost to follow up|f||||f||||||||No|no data entered, no subjects enrolled|2018-06-01 00:33:46.890263|2018-06-01 00:33:46.890263
NCT00981357|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21||2011-06-02|2017-09-13|2009-09-21|2009-09-22|Estimate||||2011-06-02|2011-06-07|Estimate|2017-09-13|2017-09-19|Actual|November 2009|Actual|2009-11-30|September 2017|2017-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee|A Phase 2a Randomized, Double-blinded, Double Dummy, Placebo And Active Controlled, Two-way Cross-over, Flare-enriched Multi-centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A Fatty Acid Amide Hydrolase (Faah) Inhibitor Pf-04457845 In Patients With Osteoarthritis Of The Knee.|Completed||Phase 2|76|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:33:47.048531|2018-06-01 00:33:47.048531
NCT00981344|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2012-11-07|2009-09-21|2009-09-22|Estimate|||||||2012-11-07|2012-11-09|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|RERC-4a||Wheeled Mobility in Everyday Life|Wheeled Mobility in Everyday Life: Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|Completed||N/A|59|Actual|Duke University|||||f||||f||||||||||2018-06-01 00:33:47.14246|2018-06-01 00:33:47.14246
NCT00981331|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2017-01-30|2009-09-21|2009-09-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2010||2010-05-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Changes in the Ankle Range of Motion Following Subtalar Joint Manipulation|Changes in the Ankle Range of Motion Following Subtalar Joint Manipulation in Patients With Sub-acute, Grade II, Ankle Inversion Sprains Quantified Using Quaternion Eigen Analysis.|Recruiting||N/A|20|Anticipated|Canadian Memorial Chiropractic College||2|||f||||f||||||||Undecided||2018-06-01 00:33:47.21614|2018-06-01 00:33:47.21614
NCT00981318|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2015-06-20|2009-09-21|2009-09-22|Estimate|||||||2015-06-20|2015-06-23|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PALM||Pilot Assessment of Lopinavir/Ritonavir and Maraviroc|Pilot Assessment of Lopinavir/Ritonavir and Maraviroc in Experienced Patients|Terminated||Phase 4|3|Actual|Rodwick, Barry M., M.D.||1||unable to enroll expected number of subjects|f||||f||||||||||2018-06-01 00:33:47.328628|2018-06-01 00:33:47.328628
NCT00981305|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-20|2016-10-09||2017-06-28|2009-09-21|2009-09-22|Estimate|2016-12-01|2017-01-26|Estimate||||2017-06-28|2017-08-07|Actual|September 2009||2009-09-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors|Impact of Lactate-containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors: Prospective Randomized Controlled Trial|Completed||Phase 3|136|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-06-01 00:33:47.425899|2018-06-01 00:33:47.425899
NCT00981292|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2010-06-25||2012-03-20|2009-09-21|2009-09-22|Estimate|2012-03-20|2012-04-13|Estimate||||2012-03-20|2012-04-13|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Epigallocatechin Gallate (EGCG) in Healthy, Young Adults|Cerebral Blood Flow, Cerebro-electrical Activity and Behavioural Effects of Epigallocatechin Gallate (EGCG) Administration in Healthy, Young Adults|Completed||Phase 4|32|Actual|Northumbria University||3|||f||||f||||||||||2018-06-01 00:33:47.790215|2018-06-01 00:33:47.790215
NCT00981279|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2009-10-28|2009-09-21|2009-09-22|Estimate|||||||2009-10-28|2009-10-29|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|PHSP||Profile of HIV Seropositive Patients|Profile of HIV Seropositive Patients on Antiretroviral Therapy at the Clinical Hospital of the Federal University of Goiás|Completed|||222|Actual|Universidade Federal de Goias|||1||f||||t||||||||||2018-06-01 00:33:48.251847|2018-06-01 00:33:48.251847
NCT00981266|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2013-02-27|2009-09-18|2009-09-22|Estimate|||||||2013-02-27|2013-03-01|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|October 2026|Anticipated|2026-10-31|January 2024|Anticipated|2024-01-31||Interventional|||Spectra Breast Implant Study|Study of the Safety and Effectiveness of the Mentor Spectra/Becker 80 Adjustable Breast Implant in Subjects Who Are Undergoing Primary Augmentation or Augmentation Revision|Withdrawn||Phase 3|0|Actual|Mentor Worldwide, LLC||2||Business decision. Study never started|f||||f||||||||||2018-06-01 00:33:48.343493|2018-06-01 00:33:48.343493
NCT00981253|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2017-07-25||2018-01-08|2009-09-21|2009-09-22|Estimate|2017-12-01|2018-01-05|Actual||||2018-01-08|2018-02-01|Actual|September 2009||2009-09-30|January 2018|2018-01-31|February 2016|Actual|2016-02-29|July 2014|Actual|2014-07-31||Interventional|ENHANCED||Stress Management and Biomarkers of Risk in Cardiac Rehabilitation|Enhancing Standard Cardiac Rehabilitation With Stress Management Training in Patients With Heart Disease|Completed||N/A|164|Actual|Duke University|Comparison group was not randomized to non-CR; relatively small sample and few 'hard' end points over the follow-up period.|2|||f||||t||||||||||2018-06-01 00:33:48.445976|2018-06-01 00:33:48.445976
NCT00979030|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2010-03-09|2009-09-16|2009-09-17|Estimate|||||||2010-03-09|2010-03-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:34:32.827002|2018-06-01 00:34:32.827002
NCT00981240|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2012-03-26|2009-09-21|2009-09-22|Estimate|||||||2012-03-26|2012-03-27|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes|A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.|Completed||Phase 1|30|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:33:48.927861|2018-06-01 00:33:48.927861
NCT00981227|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2013-02-07||2014-10-21|2009-09-21|2009-09-22|Estimate|2013-03-25|2013-05-03|Estimate||||2014-10-21|2014-10-29|Estimate|November 2007||2007-11-30|October 2014|2014-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2093) as Therapy for Patients With Post-herpetic Neuralgia: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial|Completed||Phase 2|567|Actual|Bial - Portela C S.A.||6|||f||||f||||||||||2018-06-01 00:33:49.027724|2018-06-01 00:33:49.027724
NCT00981214|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2014-02-24||2017-02-08|2009-09-21|2009-09-22|Estimate|2014-02-24|2014-04-04|Estimate||||2017-02-08|2017-03-16|Actual|May 2006||2006-05-31|February 2017|2017-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|An Open-Label Study to Evaluate the Efficacy and Safety of Pancreatic Enzyme Product (PEP) Microtabs in Pediatric Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|Completed||Phase 3|19|Actual|Forest Laboratories|Protocol amendment 4 extended screening period to 14 days, but this period not included in result as all participants started treatment prior to site Institutional Review Board approval of protocol amendment 4, this did not affect study procedures.|1|||f||||t||||||||||2018-06-01 00:33:49.689878|2018-06-01 00:33:49.689878
NCT00981201|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2012-07-31|2009-09-21|2009-09-22|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2001||2001-11-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|July 2007|Actual|2007-07-31||Interventional|||Celecoxib as a Chemopreventive Agent in Current and Former Smokers|A Randomized, Double-Blind Study of the Biological Effects and Tolerability of Celecoxib as a Chemopreventive Agent in Current and Former Smokers|Completed||Phase 3|219|Actual|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-06-01 00:33:50.15538|2018-06-01 00:33:50.15538
NCT00981188|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2009-09-23|2009-09-21|2009-09-22|Estimate|||||||2009-09-23|2009-09-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:33:50.250438|2018-06-01 00:33:50.250438
NCT00981175|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2011-04-05||2012-07-11|2009-09-21|2009-09-22|Estimate|2011-04-05|2011-04-29|Estimate||||2012-07-11|2012-07-16|Estimate|April 2003||2003-04-30|July 2012|2012-07-31|February 2008|Actual|2008-02-29|June 2004|Actual|2004-06-30||Interventional|||A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults|Randomised, Double-blind, Phase 2 Study of the Safety, Immunogenicity and Duration of Immunity of ChimeriVax™-JE, Live Attenuated Vaccine in Healthy Adults|Completed||Phase 2|202|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:33:50.338741|2018-06-01 00:33:50.338741
NCT00981162|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2017-03-31|2009-09-21|2009-09-22|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2009||2009-08-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|August 2011|Actual|2011-08-31||Interventional|||Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride|A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer|Completed||Phase 1|12|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 00:33:50.946781|2018-06-01 00:33:50.946781
NCT00981149|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2017-10-06||2018-03-14|2009-09-21|2009-09-22|Estimate|2017-10-06|2017-11-01|Actual||||2018-03-14|2018-04-13|Actual|May 2009||2009-05-31|March 2018|2018-03-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Duloxetine for Treatment of Painful Temporomandibular Joint Disorder|Duloxetine for Treatment of Painful Temporomandibular Joint Disorder|Completed||N/A|24|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 00:33:51.094915|2018-06-01 00:33:51.094915
NCT00981136|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2013-02-13|2009-09-21|2009-09-22|Estimate|||||||2013-02-13|2013-02-15|Estimate|August 2009||2009-08-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|||Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Appendectomy|Single Incision Versus Standard Laparoscopic Appendectomy for Non-Perforated Appendicitis|Completed||N/A|360|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 00:33:51.351944|2018-06-01 00:33:51.351944
NCT00981123|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2011-01-07|2009-09-21|2009-09-22|Estimate|||||||2011-01-07|2011-01-10|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia|Non-interventional Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia|Completed|||500|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:33:51.428176|2018-06-01 00:33:51.428176
NCT00981110|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-09-10|2009-09-21|2009-09-22|Estimate|||||||2012-09-10|2012-09-11|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|AM||Standard Versus Advanced Antimicrobial Dressing Containing Ionic Silver Following Colorectal Cancer Surgery|Surgical Sites Infections Following Colorectal Cancer Surgery. A Randomized Prospective Trial Comparing Standard and Advanced Antimicrobial Dressing Containing Ionic Silver.|Completed||Phase 3|120|Actual|European Institute of Oncology||2|||f||||f||||||||||2018-06-01 00:33:51.502125|2018-06-01 00:33:51.502125
NCT00981097|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2014-08-27|2009-09-19|2009-09-22|Estimate|||||||2014-08-27|2014-08-29|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma|Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma From Patients With Aggressive B-Cell Lymphomas|Completed|||52|Actual|AIDS Malignancy Consortium|||1||f||||f||||||Samples With DNA|"~     5 tubes of peripheral blood collected along with available tissue blocks or fresh frozen~     tissue collected at baseline.~   "|||2018-06-01 00:33:51.574971|2018-06-01 00:33:51.574971
NCT00980681|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2015-07-24||2016-04-19|2009-09-18|2009-09-21|Estimate|2016-04-19|2016-05-26|Estimate||||2016-04-19|2016-05-26|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)|Evaluation of Dotarem-enhanced Magnetic Resonance Angiography (MRA) Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Renal Arterial Disease|Terminated||Phase 3|13|Actual|Guerbet|The study was not completed due to poor enrolment. The statistical analysis was not perfomed.|2||Lack of recruitment.|f||||f||||||||||2018-06-01 00:33:59.871022|2018-06-01 00:33:59.871022
NCT00981084|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2013-04-22||2013-08-06|2009-09-21|2009-09-22|Estimate|2013-08-06|2013-10-14|Estimate||||2013-08-06|2013-10-14|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)|The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study|Completed||Phase 2/Phase 3|33|Actual|University of Missouri, Kansas City|A small pilot trial with only one dose of drug administered. Limitations include the very small sample and the use of a single-dose cross-over design.|1|||f||||t||||||||||2018-06-01 00:33:51.84479|2018-06-01 00:33:51.84479
NCT00981071|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|||2010-04-07|2009-09-21|2009-09-22|Estimate|||||||2010-04-07|2010-04-08|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure|The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure|Completed|||32|Actual|Armed Forces Capital Hospital, Republic of Korea|||1||f||||f||||||||||2018-06-01 00:33:52.205357|2018-06-01 00:33:52.205357
NCT00981058|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2015-12-21|2010-09-07|2017-11-21|2009-09-21|2009-09-22|Estimate|2016-05-20|2016-06-27|Estimate|2010-09-07|2010-09-09|Estimate|2017-11-21|2017-12-19|Actual|January 2010||2010-01-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2013|Actual|2013-06-30||Interventional|SQUIRE||First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin|A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|1093|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 00:33:52.332324|2018-06-01 00:33:52.332324
NCT00981045|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-21|2013-08-14||2018-01-22|2009-09-21|2009-09-22|Estimate|2013-08-14|2013-10-18|Estimate||||2018-01-22|2018-02-20|Estimate|August 2009||2009-08-31|January 2018|2018-01-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|REPAIR-IDA|14 subjects randomized to receive FCM and 9 subjects randomized to receive Venefor were randomized but discontinued prior to dosing due to subject request or selection criteria/study compliance reasons.|Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function|Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function|Completed||Phase 3|2561|Actual|Luitpold Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:33:55.547426|2018-06-01 00:33:55.547426
NCT00981032|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2011-02-16|2009-09-21|2009-09-22|Estimate|||||||2011-02-16|2011-02-17|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Improving Aspirin Use Among Adults at Risk for Cardiovascular Disease (CVD)|Improving Implementation of the US Preventive Service Task Force Recommendation for Prophylactic Aspirin Use Among Adults at Risk for Cardiovascular Disease|Completed||N/A|884|Actual|Geisinger Clinic||2|||f||||f||||||||||2018-06-01 00:33:56.344731|2018-06-01 00:33:56.344731
NCT00981019|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2011-05-20||2011-07-20|2009-09-21|2009-09-22|Estimate|2011-07-20|2011-08-15|Estimate||||2011-07-20|2011-08-15|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|MPIB||Doctors' Understanding of Survival Statistics|Study of Primary Care Physicians' Understanding and Use of Different Survival Measures|Completed|||778|Actual|Max Planck Institute for Human Development|"Mistaken exclusion of exclusively outpatient physicians due to a programming mistake of the online survey screener"||1||f||||t||||||||||2018-06-01 00:33:56.433134|2018-06-01 00:33:56.433134
NCT00981006|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2015-03-31|2009-09-19|2009-09-21|Estimate|||||||2015-03-31|2015-04-01|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ALCADIA||AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA)|Hybrid Biotherapy Involving Autologous Human Cardiac Stem Cell Transplantation Combined With the Controlled Release of bFGF Using a Gelatin Hydrogel Sheet to Treat Severe Refractory Heart Failure With Chronic Ischemic Cardiomyopathy|Completed||Phase 1|6|Actual|Kyoto Prefectural University of Medicine||1|||f||||t||||||||||2018-06-01 00:33:56.583795|2018-06-01 00:33:56.583795
NCT00980993|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|||2009-09-21|2009-09-19|2009-09-21|Estimate|||||||2009-09-21|2009-09-22|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|||Quantification of Respiratory-induced Prostate Motion|Pilot Study on the Quantification of Respiratory-induced Prostate Motion During Radiation Therapy Using Continuous Real-time Tracking|Unknown status|Active, not recruiting||5|Actual|Oregon Health and Science University|||||f||||f||||||||||2018-06-01 00:33:56.696259|2018-06-01 00:33:56.696259
NCT00980980|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-19|2014-05-14||2017-03-22|2009-09-19|2009-09-21|Estimate|2014-06-30|2014-07-30|Estimate||||2017-03-22|2017-05-02|Actual|September 2009||2009-09-30|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|REDUCE-MRSA|'Number of Participant' totals reflect total Baseline and Intervention participants combined. 45 hospitals were randomized to a study group, 2 dropped due to exclusion criteria, 43 began the assigned intervention. 1 hospital withdrew during the intervention and was included in as-assigned analyses.|Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)|Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal|Completed||N/A|74256|Actual|Harvard Pilgrim Health Care||3|||f||||f||||||||||2018-06-01 00:33:56.782156|2018-06-01 00:33:56.782156
NCT00980967|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2015-05-11|2009-09-18|2009-09-21|Estimate|||||||2015-05-11|2015-05-12|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|COLT||Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study|Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study|Unknown status|Active, not recruiting|N/A|700|Actual|Nantes University Hospital|||||f||||t||||||||||2018-06-01 00:33:57.391928|2018-06-01 00:33:57.391928
NCT00980954|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2017-12-21|2009-09-18|2009-09-21|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2009||2009-09-30|December 2017|2017-12-31|August 2026|Anticipated|2026-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy|Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy|Recruiting||Phase 3|400|Anticipated|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 00:33:57.513296|2018-06-01 00:33:57.513296
NCT00980941|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|April 2008|Actual|2008-04-30||Interventional|||Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake|The Effect of Different Types of Starch on Glycemic Response, Subjective Appetite and Short-term Food Intake in Young Men|Completed||N/A|17|Actual|University of Toronto||5|||f||||t||||||||||2018-06-01 00:33:57.947405|2018-06-01 00:33:57.947405
NCT00980915|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2018-01-07|2009-09-18|2009-09-21|Estimate|||||||2018-01-07|2018-01-09|Actual|December 2008||2008-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|LIPS||Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury|Identifying Patients at Risk of Developing Acute Lung Injury at the Time of Hospital Admission:Toward the Prevention of Acute Lung Injury (ALI)|Active, not recruiting|||6600|Anticipated|Mayo Clinic|||1||f||||t||||||Samples With DNA|"~     We will collect time sensitive peripheral blood samples for collaborative genome-wide~     association, gene expression, cytokines and proteonomic studies. Blood samples of the~     enrolled patients will be collected as baseline, after 24, 48 hours and at the time of~     development of ARDS.~   "|||2018-06-01 00:33:58.048012|2018-06-01 00:33:58.048012
NCT00980889|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2014-04-05|2009-09-18|2009-09-21|Estimate|||||||2014-04-05|2014-04-08|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|June 2012|Actual|2012-06-30||Interventional|||RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction|RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction|Completed||Phase 4|400|Actual|Stockholm South General Hospital||2|||f||||t||||||||||2018-06-01 00:33:58.122345|2018-06-01 00:33:58.122345
NCT00980876|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2015-04-16|2009-09-18|2009-09-21|Estimate|||||||2015-04-16|2015-04-17|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension|Multicentric, Double Blind, Randomized, Parallel Comparative Study Between Ciprofloxacin HCl 2 mg/mL + Hydrocortisone 10 mg/mL Ear Suspension and Cipro HC®, for the Assessment of Efficacy and Safety in Patients With Otitis Externa.|Completed||Phase 3|224|Actual|Farmoquimica S.A.||2|||f||||f||||||||||2018-06-01 00:33:58.239712|2018-06-01 00:33:58.239712
NCT00980863|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|March 2005||2005-03-31|September 2009|2009-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effects of a Lifestyle Intervention on Body Mass Index in Patients With Bipolar Disorder|Effects of a Lifestyle Intervention on Body Mass Index in Patients With Bipolar Disorder|Completed||N/A|50|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 00:33:58.33477|2018-06-01 00:33:58.33477
NCT00980850|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2013-05-07|2009-09-18|2009-09-21|Estimate|||||||2013-05-07|2013-05-09|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Swine Flu (Novel Influenza A H1N1) Vaccine Study|Open Label, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 Vaccine and GlaxoSmithKline H1N1 Vaccine in Children 6 Months to 12 Years of Age|Completed||Phase 2|1000|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 00:33:58.400803|2018-06-01 00:33:58.400803
NCT00980824|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2010-06-25|2009-09-18|2009-09-21|Estimate|||||||2010-06-25|2010-06-28|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|November 2010|Anticipated|2010-11-30|September 2010|Anticipated|2010-09-30||Interventional|ENGAGE||ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients|ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Attending A&E Following a Suicide Attempt. A Pilot Study.|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|University of Glasgow||2|||f||||f||||||||||2018-06-01 00:33:58.502323|2018-06-01 00:33:58.502323
NCT00980798|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2010-08-12||2014-04-08|2009-09-18|2009-09-21|Estimate|2010-08-12|2010-09-06|Estimate||||2014-04-08|2014-04-25|Estimate|October 2007||2007-10-31|April 2014|2014-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Placebo-controlled Trial With OROS Hydromorphone Hydrochloride to Treat Patients With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee|Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Investigate the Analgesic Effect of OROS Hydromorphone Hydrochloride in Comparison With Placebo in Subjects With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee|Completed||Phase 3|288|Actual|Janssen-Cilag International NV|Concomitant and rescue medication were permitted in the study. This may be why the results in the placebo arm so closely resemble those in the treatment arm. Patients were also less severely impacted by the underlying disease than in other studies.|2|||f||||f||||||||||2018-06-01 00:33:58.609272|2018-06-01 00:33:58.609272
NCT00980785|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2017-03-28|2009-09-18|2009-09-21|Estimate|||||||2017-03-28|2017-03-29|Actual|April 2009||2009-04-30|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SEAIRA||Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's|Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's|Completed||Phase 4|14|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:33:58.958691|2018-06-01 00:33:58.958691
NCT00980759|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2017-09-17|2009-09-18|2009-09-21|Estimate|||||||2017-09-17|2017-09-19|Actual|July 2006||2006-07-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Prophylactic Irradiation of the Para-Aortic Lymph Nodes in Locally Advanced Uterine Cervical Cancer|A Phase II Randomized Study of Prophylactic Irradiation of the Para-Aortic Lymph Nodes by 3-D Conformal Radiotherapy Technique With Concurrent Chemotherapy Based on the Hypoxic Status of Locally Advanced Uterine Cervical Cancer|Active, not recruiting||Phase 2|312|Anticipated|National Cancer Center, Korea||2|||f||||f|f|f||||||Undecided|undecided|2018-06-01 00:33:59.04604|2018-06-01 00:33:59.04604
NCT00980746|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2013-03-26||2016-05-18|2009-09-18|2009-09-21|Estimate|2013-03-26|2013-05-22|Estimate||||2016-05-18|2016-06-22|Estimate|November 2007||2007-11-30|May 2016|2016-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) as Therapy for Patients With Painful Diabetic Neuropathy: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial|Completed||Phase 2|557|Actual|Bial - Portela C S.A.||6|||f||||f||||||||||2018-06-01 00:33:59.147989|2018-06-01 00:33:59.147989
NCT00980733|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|August 2010|Anticipated|2010-08-31|April 2010|Anticipated|2010-04-30||Interventional|||Efficacy of Micronutrient Fortified Yoghurt in School Children for Health Benefits|Efficacy of Consumption of Micronutrient Fortified Yoghurt on Biochemical Markers, Cognitive Development, Morbidity and Physical Growth Among 6-9 Years School Going Children in Bangladesh - A Double Masked, Randomized Trial With a Concurrent Matched Control|Unknown status|Recruiting|Phase 3|1325|Anticipated|Annamalai University||3|||f||||t||||||||||2018-06-01 00:33:59.653565|2018-06-01 00:33:59.653565
NCT00980707|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2012-01-18|2009-09-18|2009-09-21|Estimate|||||||2012-01-18|2012-01-19|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma|Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma|Completed||Phase 4|10|Actual|Associated Scientists to Help Minimize Allergies||1|||f||||t||||||||||2018-06-01 00:33:59.73269|2018-06-01 00:33:59.73269
NCT00980655|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2014-03-17||2014-03-17|2009-09-18|2009-09-21|Estimate|2014-03-17|2014-04-21|Estimate||||2014-03-17|2014-04-21|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Safety population included all participants who received at least 1 dose of investigational product and had safety data available.|Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients|A Phase 3, Open-label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13vPnC Followed by 23vPS in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged 2 Years and Older.|Completed||Phase 3|251|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 00:34:00.349022|2018-06-01 00:34:00.349022
NCT00980642|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2017-04-06||2017-05-15|2009-09-18|2009-09-21|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|March 2010||2010-03-31|May 2017|2017-05-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Accuracy of the Drager Dual-sensor Temperature Measurement System|Accuracy of the Draeger Dual-sensor Temperature Measurement System in The Perioperative Period|Completed||N/A|56|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 00:34:04.849599|2018-06-01 00:34:04.849599
NCT00980629|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2010-11-02|2009-09-18|2009-09-21|Estimate|||||||2010-11-02|2010-11-03|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|September 2010||2010-09-30|||||Interventional|||Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis|A Randomized, Placebo-Controlled, Double-blind, Parallel Group, Multi-centre Phase II Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis|Completed||Phase 2|||Maruho Co., Ltd.|||||f||||||||||||||2018-06-01 00:34:05.085042|2018-06-01 00:34:05.085042
NCT00980616|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2012-03-26|2009-09-18|2009-09-21|Estimate|||||||2012-03-26|2012-03-27|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|||Use of Local Analgesia With Epinephrine During Total Hip Arthroplasty (THA)|Effect of the Injection of Local Analgesia With Epinephrine During Total Hip Arthroplasty on the Blood Losses Per and Operatively.|Completed||Phase 2|150|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-06-01 00:34:05.151|2018-06-01 00:34:05.151
NCT00980603|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|May 2011|Anticipated|2011-05-31|November 2010|Anticipated|2010-11-30||Interventional|||Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer|A Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-line Chemotherapy After Cisplatin Plus S-1 or Capecitabine in Metastatic Gastric Cancer|Unknown status|Recruiting|Phase 2|144|Anticipated|National Cancer Center, Korea||3|||f||||t||||||||||2018-06-01 00:34:05.224785|2018-06-01 00:34:05.224785
NCT00980590|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2016-12-12||2016-12-12|2009-09-18|2009-09-21|Estimate|2016-12-12|2017-02-06|Estimate||||2016-12-12|2017-02-06|Estimate|September 2008||2008-09-30|December 2016|2016-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Airway Scope and Macintosh Laryngoscope for Tracheal Intubation in Patients Lying on the Ground|Airway Scope and Macintosh Laryngoscope for Tracheal Intubation in Patients Lying on the Ground|Completed||N/A|100|Actual|The Cleveland Clinic|Patients with anticipated airway difficulties were excluded. All intubations were performed by a single investigator.|2|||f||||f||||||||||2018-06-01 00:34:05.32908|2018-06-01 00:34:05.32908
NCT00980577|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2010-11-09|2009-09-18|2009-09-21|Estimate|||||||2010-11-09|2010-11-10|Estimate|January 2008||2008-01-31|September 2009|2009-09-30||||November 2009|Anticipated|2009-11-30||Interventional|||Stimulating Catheter With or Without Ultrasound Guidance|Phase 2 Study of Stimulating Catheter for Continuous Femoral Nerve Block in Total Knee Replacement|Unknown status|Recruiting|Phase 4|100|Anticipated|Peking University Third Hospital||1|||f||||t||||||||||2018-06-01 00:34:05.732803|2018-06-01 00:34:05.732803
NCT00980551|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2017-02-28|2009-09-18|2009-09-21|Estimate|||||||2017-02-28|2017-03-03|Actual|May 2010|Actual|2010-05-31|February 2017|2017-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|RELRB1||Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma|A Pilot Study of Intravenous Topotecan and Vincristine in Combination With Subconjunctival Carboplatin for Patients With a History of Bilateral Retinoblastoma and Refractory/Recurrent Intraocular Disease (IND# 104,942)|Withdrawn||N/A|0|Actual|Children's Hospital Medical Center, Cincinnati||1||No enrollment and competing studies|f||||t||||||||||2018-06-01 00:34:05.799059|2018-06-01 00:34:05.799059
NCT00980538|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2018-02-27|2009-09-18|2009-09-21|Estimate|||||||2018-02-27|2018-02-28|Actual|December 9, 2009|Actual|2009-12-09|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents|Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents|Active, not recruiting||Phase 3|172|Actual|Janssen R&D Ireland||1|||f||||f||f||||||||2018-06-01 00:34:05.887042|2018-06-01 00:34:05.887042
NCT00980525|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2015-12-01|2009-09-18|2009-09-21|Estimate|||||||2015-12-01|2015-12-03|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Development of Inflammatory Disease Model Protein, Genetic and Microbial Biomarkers|Development of Inflammatory Disease Model Protein, Genetic and Microbial Biomarkers|Completed|||32|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     plaque, saliva, and intraoral specimens~   "|||2018-06-01 00:34:06.002157|2018-06-01 00:34:06.002157
NCT00980512|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2014-11-17|2009-09-18|2009-09-21|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|KEEP||Community Implementation of KEEP: Fidelity and Generalization of Parenting|Community Implementation of KEEP: Fidelity and Generalization of Parenting|Completed||N/A|354|Actual|San Diego State University||2|||f||||f||||||||||2018-06-01 00:34:06.071026|2018-06-01 00:34:06.071026
NCT00980486|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2010-10-07|2009-09-18|2009-09-21|Estimate|||||||2010-10-07|2010-10-08|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Obesity and Antibiotic Tissue Concentration|Effects of Maternal Obesity on Tissue Concentrations of Prophylactic Antibiotics During Cesarean Delivery|Completed|||31|Actual|MemorialCare|||3||f||||f||||||Samples Without DNA|"~     Adipose, myometrial and blood serum samples~   "|||2018-06-01 00:34:06.146958|2018-06-01 00:34:06.146958
NCT00980473|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2011-06-16|2009-09-18|2009-09-21|Estimate|||||||2011-06-16|2011-06-17|Estimate|September 2007||2007-09-30|November 2009|2009-11-30||||September 2011|Anticipated|2011-09-30||Interventional|ALPI||Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma|Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma: A Randomised Controlled Trial|Unknown status|Recruiting|Phase 3|80|Anticipated|Singapore National Eye Centre||2|||f||||f||||||||||2018-06-01 00:34:06.211825|2018-06-01 00:34:06.211825
NCT00980460|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2018-05-24|2009-09-18|2009-09-21|Estimate|||||||2018-05-24|2018-05-25|Actual|September 14, 2009|Actual|2009-09-14|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer|Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment|Suspended||Phase 3|253|Anticipated|National Cancer Institute (NCI)||4||Other - pending eval of currently enrolled patients|f||||||||||||||2018-06-01 00:34:06.338284|2018-06-01 00:34:06.338284
NCT00980447|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2010-02-05|2009-09-18|2009-09-21|Estimate|||||||2010-02-05|2010-02-08|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults|A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults.|Completed||Phase 2|90|Actual|UMN Pharma Inc.||3|||f||||t||||||||||2018-06-01 00:34:07.091494|2018-06-01 00:34:07.091494
NCT00980434|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2012-04-03|2009-09-18|2009-09-21|Estimate|||||||2012-04-03|2012-04-04|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Observational|WBS||S-100B and Neuron-specific Enolase (NSE) in Spinal Trauma|The Clinical Use of S-100B and NSE in Spinal Cord Injuries|Completed|||60|Actual|Medical University of Vienna|||2||f||||f||||||Samples Without DNA|"~     Serum probe~   "|||2018-06-01 00:34:07.226857|2018-06-01 00:34:07.226857
NCT00980421|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children|Effect of Mode of Delivery of Iron and/or Iron and Zinc Supplement on Iron Status Markers and Potential Markers of Iron Toxicity in Children Aged 24-36 Months|Unknown status|Not yet recruiting|Phase 3|240|Anticipated|Annamalai University||4|||f||||f||||||||||2018-06-01 00:34:07.338119|2018-06-01 00:34:07.338119
NCT00980408|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2014-12-02|2009-09-18|2009-09-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Influence of Glutamate on Memory in Humans|The NMDA Receptor Co-agonist D-cycloserine Accelerates Associative Learning in the Human Hippocampal CA Region|Completed||N/A|120|Actual|University Hospital, Bonn||8|||f||||||||||||||2018-06-01 00:34:07.459579|2018-06-01 00:34:07.459579
NCT00980395|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2018-04-24|2009-09-18|2009-09-21|Estimate|||||||2018-04-24|2018-04-25|Actual|July 7, 2009|Actual|2009-07-07|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|VCR||Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma|A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas|Active, not recruiting||Phase 2|25|Actual|University of Arizona||1|||f||||t|t|f||||||Undecided||2018-06-01 00:34:07.552349|2018-06-01 00:34:07.552349
NCT00980382|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma|A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma|Completed||Phase 1/Phase 2|85|Actual|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 00:34:07.684906|2018-06-01 00:34:07.684906
NCT00980369|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|January 2010|Anticipated|2010-01-31|March 2008|Anticipated|2008-03-31||Observational|||The Importance of Lateral Internal Sphincterotomy Incision: Parallel or Vertical|Incision Type for Lateral Internal Sphincterotomy|Unknown status|Enrolling by invitation||52|Actual|SB Istanbul Education and Research Hospital|||2||f||||t||||||||||2018-06-01 00:34:07.760059|2018-06-01 00:34:07.760059
NCT00980356|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2013-04-04|2009-09-18|2009-09-21|Estimate|||||||2013-04-04|2013-04-05|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|VINODAT||Vildagliptin in New Onset Diabetes After Transplantation|Vildagliptin in New Onset Diabetes After Transplantation - A Double-blind, Randomized, Placebo-controlled Trial|Completed||Phase 2|32|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:34:07.842104|2018-06-01 00:34:07.842104
NCT00980343|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|2016-10-27||2017-08-15|2009-09-18|2009-09-21|Estimate|2017-08-15|2017-08-16|Actual||||2017-08-15|2017-08-16|Actual|February 2010||2010-02-28|August 2017|2017-08-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional||40 patients were evaluable for toxicities, demographics but only 39 for tissue evaluation|GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery|A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||No||2018-06-01 00:34:07.96801|2018-06-01 00:34:07.96801
NCT00980330|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2013-12-18|2011-06-20|2014-05-30|2009-09-18|2009-09-21|Estimate|2013-12-18|2014-02-06|Estimate|2011-06-20|2011-06-28|Estimate|2014-05-30|2014-06-09|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ASPIRE||A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including PegIFNa-2a and Ribavirin in HCV Genotype 1 Infected Subjects Who Failed Previous Standard Therapy|Completed||Phase 2|463|Actual|Tibotec Pharmaceuticals, Ireland||7|||f||||t||||||||||2018-06-01 00:34:08.554623|2018-06-01 00:34:08.554623
NCT00980317|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2009-10-09|2009-09-18|2009-09-21|Estimate|||||||2009-10-09|2009-10-14|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Third Parties|A Clinical Study of the Living-unrelated Renal Transplantation With Restored Kidneys (Interventional Trial)|Unknown status|Recruiting|N/A|5|Anticipated|Tokushukai Medical Group|||||f||||t||||||||||2018-06-01 00:34:10.999877|2018-06-01 00:34:10.999877
NCT00980304|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2009-09-18|2009-09-18|2009-09-21|Estimate|||||||2009-09-18|2009-09-21|Estimate||||September 2009|2009-09-30||||||||Interventional|||R Retreatment in 1st Relapsed DLBCL|A Multicenter, Open Label, Phase II Trial of Rituximab in Combination With ICE as Salvage Therapy in the Relapsed DLBCL Patients After 1st Line Induction Treatment of 6-8 Cycles of RCHOP-LIKE Chemo|Unknown status|Not yet recruiting|Phase 2|||Shanghai Jiao Tong University School of Medicine||1|||f||||||||||||||2018-06-01 00:34:11.06886|2018-06-01 00:34:11.06886
NCT00978835|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2014-07-14|2009-09-16|2009-09-17|Estimate|||||||2014-07-14|2014-07-15|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TEACH-DM||Tailored Case Management for Diabetes and Hypertension|Tailored Case Management for Diabetes and Hypertension|Completed||N/A|377|Actual|Duke University||2|||f||||t||||||||||2018-06-01 00:34:34.015602|2018-06-01 00:34:34.015602
NCT00980239|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2015-11-09|2009-09-18|2009-09-21|Estimate|||||||2015-11-09|2015-11-11|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver|A Multi-arm Phase I Trial of Hepatic Arterial Infusion of Irinotecan With 1) Systemic Bevacizumab 2) Systemic Bevacizumab and Oxaliplatin 3) Systemic Bevacizumab and Cetuximab in Patients With Advanced Cancers Metastatic to the Liver|Completed||Phase 1|115|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 00:34:11.49065|2018-06-01 00:34:11.49065
NCT00980213|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-18|||2014-02-05|2009-09-18|2009-09-21|Estimate|||||||2014-02-05|2014-02-06|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|||Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland|Evaluation of the Cost and Effectiveness in the First-line Treatment of Advanced Renal Cell Cancer With Sunitinib Compared to Interferon-alfa in Finland.|Completed|||80|Actual|Tampere University Hospital|||1||f||||f||||||||||2018-06-01 00:34:11.705175|2018-06-01 00:34:11.705175
NCT00980200|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2013-06-06|2011-03-17|2016-12-01|2009-09-17|2009-09-18|Estimate|2013-06-06|2013-08-07|Estimate|2011-03-17|2011-03-28|Estimate|2016-12-01|2017-01-30|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy and Safety Study in Subjects With Asthma|A Multi-center, Randomized, Double-blind, Placebo-controlled, Five Period Cross-over Study to Evaluate the Efficacy and Safety of Selected Doses and Dose Intervals of GW642444 Administered Via a Novel Dry Powder Inhaler (NDPI) in Subjects ≥18 Years of Age With Persistent Asthma|Completed||Phase 2|75|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:34:11.811495|2018-06-01 00:34:11.811495
NCT00980187|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-06-14|2009-09-17|2009-09-18|Estimate|||||||2011-06-14|2011-06-15|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|AISHA||A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM|A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate Hypertension and Type 2 Diabetes Mellitus|Completed||Phase 4|56|Actual|LaborMed Pharma S.A.||2|||f||||f||||||||||2018-06-01 00:34:12.154563|2018-06-01 00:34:12.154563
NCT00980174|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2012-10-31||2013-01-22|2009-09-17|2009-09-18|Estimate|2012-10-31|2012-11-29|Estimate||||2013-01-22|2013-01-24|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab Versus Placebo in Males With Low Bone Mineral Density|Completed||Phase 3|242|Actual|Amgen||2|||f||||f||||||||||2018-06-01 00:34:12.240158|2018-06-01 00:34:12.240158
NCT00980161|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2010-03-25|2009-09-17|2009-09-18|Estimate|||||||2010-03-25|2010-03-26|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Observational|||Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C|The Predictive Role of Serum Micro RNA-122 to the Clinical Course of Chronic Hepatitis C Patients|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     Serum and hepatic micro RNA-122~   "|||2018-06-01 00:34:12.731932|2018-06-01 00:34:12.731932
NCT00980148|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2015-03-05||2015-03-05|2009-09-17|2009-09-18|Estimate|2015-03-05|2015-03-18|Estimate||||2015-03-05|2015-03-18|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||The per protocol population is comprised of participants who completed therapy and whose failure status could be established at the day 28 visit. Participants were considered to have completed therapy if they took a single dose of azithromycin or at least 10 of the 14 doses of doxycycline.|Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities|Randomized Clinical Trial Evaluating Treatment Failure Following Recommended Therapy (Azithromycin Versus Doxycycline) for Genital Chlamydial Infection in Males and Females in Youth Correctional Facilities|Completed||Phase 3|567|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The analysis of the secondary endpoint Demographical Characteristics and Clinical Parameters to Predict Treatment Outcome was limited by the small number of events and is not presented.|2|||f||||||||||||||2018-06-01 00:34:12.836507|2018-06-01 00:34:12.836507
NCT00980135|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-03-31|2009-09-17|2009-09-18|Estimate|||||||2014-03-31|2014-04-02|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|Sinecort Pilot||Sinecort Pilot Efficacy Study|An Investigator-blind, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a New Topical Medical Device in Patients With Mild Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin.|Completed||Phase 2|40|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:34:13.078365|2018-06-01 00:34:13.078365
NCT00980122|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2010-04-07|2009-09-17|2009-09-18|Estimate|||||||2010-04-07|2010-04-08|Estimate|March 2008||2008-03-31|April 2010|2010-04-30||||||||Observational|||Aggressiveness of Care at the End of Life in Cancer Patients|Aggressiveness of Care at the End of Life in Cancer Patients|Completed|||250|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 00:34:13.158609|2018-06-01 00:34:13.158609
NCT00980109|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2010-09-21|2009-09-17|2009-09-18|Estimate|||||||2010-09-21|2010-09-22|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|SEA 004||Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir|A Phase IV, Multi-center, Randomized, Partially Double Blinded, Placebo Controlled Study, to Evaluate the Safety of Daily Inhaled Zanamivir 10 mg Versus Placebo and Daily Oral Oseltamivir 75 mg Versus Placebo for Influenza Prophylaxis in Healthy Volunteers for 16 Weeks|Completed||Phase 4|390|Actual|University of Oxford||4|||f||||t||||||||||2018-06-01 00:34:13.215715|2018-06-01 00:34:13.215715
NCT00980083|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2009-09-17|2009-09-17|2009-09-18|Estimate|||||||2009-09-17|2009-09-18|Estimate|October 2004||2004-10-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|July 2005|Actual|2005-07-31||Interventional|||GLP-1 - Regulatory Mechanism of Postprandial Glycemia|Endogenous GLP-1 Regulates Postprandial Glycaemia in Human: Relative Contributions of Insulin, Glucagon, and Gastric Emptying|Completed||Phase 1|12|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-06-01 00:34:13.308125|2018-06-01 00:34:13.308125
NCT00980070|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2012-06-19|2009-09-17|2009-09-18|Estimate|||||||2012-06-19|2012-06-21|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|SNOWBOARD||The Effectiveness of a Pediatric Lumbar Puncture Restraint Device|The Effectiveness of a Pediatric Lumbar Puncture Restraint Device|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|University of Nebraska||2|||f||||f||||||||||2018-06-01 00:34:13.38712|2018-06-01 00:34:13.38712
NCT00980057|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16||2012-07-11|2012-09-05|2009-09-17|2009-09-18|Estimate||||2012-08-06|2012-08-15|Estimate|2012-09-05|2012-09-11|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|September 2012|Anticipated|2012-09-30|July 2011|Actual|2011-07-31||Interventional|aCRT||Adaptive Cardiac Resynchronization Therapy Study|Adaptive Cardiac Resynchronization Therapy Study|Unknown status|Active, not recruiting|N/A|522|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-06-01 00:34:13.749645|2018-06-01 00:34:13.749645
NCT00980044|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2013-06-10||2017-03-07|2009-09-17|2009-09-18|Estimate|2014-12-02|2014-12-03|Estimate||||2017-03-07|2017-04-05|Actual|October 2009||2009-10-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional||The study was a priori defined to evaluate only completers. There were 12 completers in each of the three study arms. We retained the description of the completers because it corresponds to the primary outcomes results that are reported (and this is what was proposed a priori and approved by NIDA review).|Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal|Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal|Completed||Phase 2/Phase 3|53|Actual|University of Kentucky|The study was designed to analyze only completers (12 subjects per group so the description of study participant characteristics and outcomes are from these a prior defined n=36 (12 per group) completers.|3|||f||||f||||||||||2018-06-01 00:34:13.99093|2018-06-01 00:34:13.99093
NCT00980031|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2014-03-27|2009-09-17|2009-09-18|Estimate|||||||2014-03-27|2014-03-28|Estimate|April 2007||2007-04-30|March 2014|2014-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Aldosterone||Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension|Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension|Terminated||N/A|20|Actual|Creighton University||2||Funding ended prior to study completion|f||||f||||||||||2018-06-01 00:34:14.432385|2018-06-01 00:34:14.432385
NCT00980018|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2015-04-14|2009-09-17|2009-09-18|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MACS0999||An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment|An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment|Completed||Phase 4|52|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:34:14.533246|2018-06-01 00:34:14.533246
NCT00980005|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2012-01-20||2016-09-26|2009-09-17|2009-09-18|Estimate|2012-01-26|2012-02-15|Estimate||||2016-09-26|2016-10-27|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children|Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children|Completed||Phase 3|2116|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:34:14.74087|2018-06-01 00:34:14.74087
NCT00979992|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2016-12-29||2017-06-22|2009-09-17|2009-09-18|Estimate|2017-06-22|2017-07-21|Actual||||2017-06-22|2017-07-21|Actual|April 2010||2010-04-30|June 2017|2017-06-30||||May 2014|Actual|2014-05-31||Interventional||Eligible and treated patients.|Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer|A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma|Active, not recruiting||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:34:15.576992|2018-06-01 00:34:15.576992
NCT00979979|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-10-19|2009-09-17|2009-09-18|Estimate|||||||2014-10-19|2014-10-21|Estimate|July 2009||2009-07-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test|Clinical Performance of Abbott RealTime HCV Genotype II Test|Completed|||255|Actual|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     Patient stored serum with detectable HCV RNA levels~   "|||2018-06-01 00:34:16.170923|2018-06-01 00:34:16.170923
NCT00979966|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-07-06|2009-09-17|2009-09-18|Estimate|||||||2012-07-06|2012-07-10|Estimate|July 2009||2009-07-31|July 2012|2012-07-31||||July 2012|Actual|2012-07-31||Interventional|||Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib|Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma|Completed||Phase 2|22|Actual|Central European Society for Anticancer Drug Research||2|||f||||t||||||||||2018-06-01 00:34:16.250743|2018-06-01 00:34:16.250743
NCT00979953|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2015-04-21||2015-07-27|2009-09-17|2009-09-18|Estimate|2015-04-21|2015-05-07|Estimate||||2015-07-27|2015-08-14|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional||All participants received at least 1 dose of study drug.|Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee|A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee|Completed||Phase 2|408|Actual|Cubist Pharmaceuticals LLC||4|||f||||f||||||||||2018-06-01 00:34:16.458397|2018-06-01 00:34:16.458397
NCT00979940|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2015-08-24||2015-08-24|2009-09-17|2009-09-18|Estimate|2015-08-24|2015-09-22|Estimate||||2015-08-24|2015-09-22|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|ESTATE||Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)|Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After PCI|Terminated||N/A|60|Actual|Indiana University||2||Slower than anticipated enrollment for pilot study.|f||||t||||||||||2018-06-01 00:34:16.789003|2018-06-01 00:34:16.789003
NCT00979927|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-10-04|2009-09-17|2009-09-18|Estimate|||||||2011-10-04|2011-10-05|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||SPC3649 Multiple Dose Study in Healthy Volunteers|A Placebo-controlled Double-blind, Randomised, Multiple Dose, Dose Escalating Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649|Completed||Phase 1|30|Anticipated|Santaris Pharma A/S||2|||f||||f||||||||||2018-06-01 00:34:16.996336|2018-06-01 00:34:16.996336
NCT00979914|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2015-03-30|2009-09-17|2009-09-18|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of an Education Programme for Patients With Osteoarthritis in Primary Care - a Randomized Controlled Trial||Completed||N/A|100|Actual|Lund University||2|||f||||f||||||||||2018-06-01 00:34:17.143859|2018-06-01 00:34:17.143859
NCT00979901|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2009-09-23||2015-05-04|2009-09-17|2009-09-18|Estimate|2010-05-13|2010-06-08|Estimate||||2015-05-04|2015-05-20|Estimate|March 2000||2000-03-31|May 2015|2015-05-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis--Spring Study|Completed||Phase 3|1577|Actual|Merck Sharp & Dohme Corp.|Montelukast/loratadine arm was discontinued due to business decision by sponsor to focus development on montelukast monotherapy. There was no efficacy data reported for this treatment arm.|4|||f||||f||||||||||2018-06-01 00:34:17.281266|2018-06-01 00:34:17.281266
NCT00979888|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2013-08-23|2009-09-17|2009-09-18|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2009||2009-07-31|September 2009|2009-09-30||||July 2010|Anticipated|2010-07-31||Interventional|||Study of How Caregivers Help Patients Cope With Respiratory and Other Symptoms Caused by Lung Cancer|A Non-pharmacological Supportive Care Intervention for Patients With Lung Cancer and Their Caregivers in the Management of the Respiratory Distress Symptom Cluster.|Unknown status|Recruiting|N/A|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:34:17.681876|2018-06-01 00:34:17.681876
NCT00979875|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2014-06-12||2014-06-12|2009-09-17|2009-09-18|Estimate|2014-06-12|2014-07-14|Estimate||||2014-06-12|2014-07-14|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional||All randomized participants.|A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone|Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic, 6-Way Crossover Study of Subcutaneously Administered Insulin Analogs With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Analogs Alone in Healthy Volunteers|Completed||Phase 1|14|Actual|Halozyme Therapeutics||1|||f||||f||||||||||2018-06-01 00:34:17.777275|2018-06-01 00:34:17.777275
NCT00979862|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2015-04-14|2009-09-17|2009-09-18|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|February 2014|Actual|2014-02-28|May 2012|Actual|2012-05-31||Interventional|||Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma|A Phase Ib Study of Cediranib in Combination With Cilengitide in Patients With Recurrent Glioblastoma|Completed||Phase 1|47|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:34:18.329612|2018-06-01 00:34:18.329612
NCT00979849|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2010-03-01|2009-09-17|2009-09-18|Estimate|||||||2010-03-01|2010-03-02|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||AZD8683 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD8683 After Single Ascending Doses in Healthy Male Subjects|Completed||Phase 1|130|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 00:34:18.455078|2018-06-01 00:34:18.455078
NCT00979836|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-02-16|2009-09-17|2009-09-18|Estimate|||||||2011-02-16|2011-02-17|Estimate|April 2008||2008-04-30|February 2011|2011-02-28||||July 2010|Actual|2010-07-31||Interventional|||Calcium Dobesilate for Chronic Venous Wounds|Randomized, Double-blind Multicenter Clinical Trial Comparing the Efficacy of Calcium Dobesilate With Placebo in the Treatment of Ulcer Secondaries to Chronic Venous Disease|Suspended||Phase 3|230|Anticipated|Fundacion Iberoamericana Itaca||2||The financial support was withdrawn.|f||||f||||||||||2018-06-01 00:34:18.541711|2018-06-01 00:34:18.541711
NCT00979823|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-12-01|2009-09-17|2009-09-18|Estimate|||||||2014-12-01|2014-12-03|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|SDT||Simulated Diabetes Training for Resident Physicians|Simulated Diabetes Training for Resident Physicians|Completed||N/A|341|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-06-01 00:34:18.645174|2018-06-01 00:34:18.645174
NCT00979810|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2017-09-05|2009-09-17|2009-09-18|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2009||2009-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Image-Guided Stereotactic Biopsy of High Grade Gliomas|Image-Guided Stereotactic Biopsy of High Grade Gliomas|Active, not recruiting||N/A|15|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:34:18.847228|2018-06-01 00:34:18.847228
NCT00979797|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2014-09-28|2009-09-17|2009-09-18|Estimate|||||||2014-09-28|2014-09-30|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Community-Integrated Management of Childhood Illness (IMCI) Programme Evaluation|An Assessment of Public Health Effectiveness of Approaches to Promote Key Family & Community Behaviors for Child Survival|Completed||N/A|140000|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||1|||f||||t||||||||||2018-06-01 00:34:18.934244|2018-06-01 00:34:18.934244
NCT00979784|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2013-06-11|2009-09-17|2009-09-18|Estimate|||||||2013-06-11|2013-06-12|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|BWBS||Better Weight-Better Sleep (BWBS) Trial|The Better Weight-Better Sleep Study: A Pilot Intervention in Primary Care|Completed||N/A|49|Actual|Summa Health System||2|||f||||f||||||||||2018-06-01 00:34:19.004749|2018-06-01 00:34:19.004749
NCT00979771|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2017-05-25|2009-09-17|2009-09-18|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2010||2010-02-28|May 2017|2017-05-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Patients With Rheumatoid Arthritis|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||internal decision|f||||f||||||||||2018-06-01 00:34:19.075121|2018-06-01 00:34:19.075121
NCT00979758|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2018-01-23|2009-09-17|2009-09-18|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2009|Actual|2009-01-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|STEM-AMI||Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction|Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction|Completed||Phase 2|100|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||4|||f||||f||||||||||2018-06-01 00:34:19.152775|2018-06-01 00:34:19.152775
NCT00979745|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-08-03|2009-09-17|2009-09-18|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)|A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)|Completed||Phase 3|70|Anticipated|Clinuvel Pharmaceuticals Limited||2|||f||||f||||||||||2018-06-01 00:34:19.231204|2018-06-01 00:34:19.231204
NCT00979732|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2018-03-15|2009-09-17|2009-09-18|Estimate|||||||2018-03-15|2018-03-16|Actual|November 15, 2009|Actual|2009-11-15|March 2018|2018-03-31|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|GSE||The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension|Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effect of Grape Seed Extract Delivered in a Beverage on Blood Pressure in Individuals With Pre-hypertension.|Active, not recruiting||N/A|72|Actual|Institute for Food Safety and Health, United States||4|||f||||f||||||||Undecided||2018-06-01 00:34:19.316372|2018-06-01 00:34:19.316372
NCT00979719|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2012-11-13|2009-09-17|2009-09-18|Estimate|||||||2012-11-13|2012-11-15|Estimate|October 2009||2009-10-31|January 2011|2011-01-31|September 2012|Actual|2012-09-30|November 2011|Actual|2011-11-30||Interventional|FaBA||Improvement of a Physically Active Lifestyle|Improvement of a Physically Active Lifestyle in Orthopedic and Cardiologic Rehabilitation Patients With an Expert System|Completed||N/A|1377|Actual|Freie Universität Berlin||3|||f||||t||||||||||2018-06-01 00:34:19.503752|2018-06-01 00:34:19.503752
NCT00979706|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-11-18|2009-09-17|2009-09-18|Estimate|||||||2014-11-18|2014-11-19|Estimate|March 2005||2005-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PHI-IMD||Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).|Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection With the Objective to Induce a Strong Specific HIV Immune Response Able to Control Viral Replication Without Highly Active Anti-Retroviral Therapy (HAART)|Completed||Phase 4|22|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 00:34:19.592822|2018-06-01 00:34:19.592822
NCT00979693|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-09-16|2009-09-17|2009-09-18|Estimate|||||||2014-09-16|2014-09-17|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|||Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma|Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.|Withdrawn||Phase 2|0|Actual|Multidisciplinary Association for Psychedelic Studies||2||"The study was suspended because the PI was unable to get permission from his department to~   submit the protocol to the local IRB?"|f||||f||||||||||2018-06-01 00:34:19.697964|2018-06-01 00:34:19.697964
NCT00979680|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2009-09-18|2009-09-17|2009-09-18|Estimate|||||||2009-09-18|2009-09-21|Estimate|April 2001||2001-04-30|September 2009|2009-09-30|September 2007|Actual|2007-09-30|||||Interventional|GRECCAR1||Sphincter-preserving Surgery After Preoperative Treatment of Ultra-low Rectal Carcinoma|Phase II Trial Comparing Two Neoadjuvant Treatments in Patients With Ultra-low Rectal Cancer: High-dose Radiotherapy Versus Radio-chemotherapy|Completed||Phase 3|207|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f||||||||||2018-06-01 00:34:19.817581|2018-06-01 00:34:19.817581
NCT00979667|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-04-08|2009-09-17|2009-09-18|Estimate|||||||2011-04-08|2011-04-11|Estimate|October 2009||2009-10-31|May 2010|2010-05-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection|Multicentre, Randomized, Controlled Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As The First Line Treatment For Human Swine Influenza (H1N1) Infection In Designated Flu Clinics During The Pandemic Influenza in Hong Kong|Terminated||Phase 3|4|Actual|Chinese University of Hong Kong||3||Decreased Influenza activity; thus decrease/no eligible patient to recruit|f||||f||||||||||2018-06-01 00:34:19.934273|2018-06-01 00:34:19.934273
NCT00979654|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2016-07-12||2016-08-29|2009-09-17|2009-09-18|Estimate|2016-07-12|2016-08-23|Estimate||||2016-08-29|2016-10-27|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis|A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis|Completed||Phase 2|118|Actual|MedImmune LLC|A business decision was made to discontinue the development of sifalimumab in favor of another type 1 interferon (IFN) inhibitor.|1|||f||||f||||||||||2018-06-01 00:34:20.096574|2018-06-01 00:34:20.096574
NCT00979641|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2014-02-05|2009-09-17|2009-09-18|Estimate|||||||2014-02-05|2014-02-06|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|AINO||Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer|Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|65|Anticipated|Tampere University Hospital||1|||f||||t||||||||||2018-06-01 00:34:20.527767|2018-06-01 00:34:20.527767
NCT00979628|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2014-03-24||2014-03-24|2009-09-17|2009-09-18|Estimate|2014-03-24|2014-04-24|Estimate||||2014-03-24|2014-04-24|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|Basal Plus||Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (DM)|Basal Bolus Versus Basal Insulin Regimen for the Treatment of Hospitalized Patients With Type 2 Diabetes Mellitus: a Randomized, Open Labeled, Non-inferiority Controlled Study|Completed||Phase 4|375|Actual|Emory University||3|||f||||t||||||||||2018-06-01 00:34:20.627714|2018-06-01 00:34:20.627714
NCT00979615|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2011-04-14||2011-04-14|2009-09-17|2009-09-18|Estimate|2011-04-14|2011-05-10|Estimate||||2011-04-14|2011-05-10|Estimate|September 2009||2009-09-30|April 2011|2011-04-30||||November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis||Completed||Phase 4|129|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 00:34:20.900386|2018-06-01 00:34:20.900386
NCT00979602|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2017-08-25|2011-02-04|2018-03-19|2009-09-17|2009-09-18|Estimate|2017-08-25|2017-09-21|Actual|2011-02-04|2011-02-09|Estimate|2018-03-19|2018-03-21|Actual|November 9, 2009|Actual|2009-11-09|March 2018|2018-03-31|February 1, 2011|Actual|2011-02-01|January 10, 2011|Actual|2011-01-10||Interventional|||Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older|A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older|Completed||Phase 3|4048|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:34:21.179589|2018-06-01 00:34:21.179589
NCT00979589|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2012-03-11|2009-09-17|2009-09-18|Estimate|||||||2012-03-11|2012-03-13|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|CHANCE||Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events|Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke|Completed||Phase 3|5100|Actual|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-06-01 00:34:24.655418|2018-06-01 00:34:24.655418
NCT00979576|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2014-11-14||2016-04-11|2009-09-17|2009-09-18|Estimate|2014-11-14|2014-11-20|Estimate||||2016-04-11|2016-05-13|Estimate|October 2009||2009-10-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|May 2012|Actual|2012-05-31||Interventional||Treated set: all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment|BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Pemetrexed - a Phase I, Open-label, Dose-escalation Study & a Phase II, 2 Arm, Randomized, Double-blind, Placebo-controlled Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy|Terminated||Phase 1|19|Actual|Boehringer Ingelheim|The trial was planned to comprise of two parts, with the phase II being based on the results of another study. The other study was stopped early due to futility analysis therefore only phase I of the study was completed.|3|||f||||||||||||||2018-06-01 00:34:24.789108|2018-06-01 00:34:24.789108
NCT00979563|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2011-12-05|2009-09-17|2009-09-18|Estimate|||||||2011-12-05|2011-12-07|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Interventional|Oratecan-101||Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies|A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer(Q1DX5/W for 3W)|Completed||Phase 1|15|Actual|Hanmi Pharmaceutical Company Limited|||||f||||f||||||||||2018-06-01 00:34:26.200901|2018-06-01 00:34:26.200901
NCT00979550|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2015-12-23||2018-03-19|2009-09-17|2009-09-18|Estimate|2018-03-19|2018-03-22|Actual||||2018-03-19|2018-03-22|Actual|October 2008||2008-10-31|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effects of Aldara as an Adjunct to Laser Treatment|The Effects of Aldara as an Adjunct to Laser Treatment of Port Wine Stains|Terminated||Phase 2|7|Actual|University of Kentucky||2||Failure to enroll enough participants|f||||f||||||||||2018-06-01 00:34:26.305645|2018-06-01 00:34:26.305645
NCT00979537|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2009-09-17|2009-09-17|2009-09-18|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2007||2007-03-31|September 2009|2009-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers|Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers|Completed||Phase 1|83|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:34:26.503364|2018-06-01 00:34:26.503364
NCT00979524|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2016-04-05|2009-09-17|2009-09-18|Estimate|||||||2016-04-05|2016-04-07|Estimate|November 2008||2008-11-30|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Addressing Mental Health in African American Job Training Adolescents and Young Adults|Addressing Mental Health in African American Job Training Adolescents and Young Adults|Completed||Phase 1|782|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:34:26.56319|2018-06-01 00:34:26.56319
NCT00979511|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2012-03-14|2009-09-17|2009-09-18|Estimate|||||||2012-03-14|2012-03-15|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|Bone Health||Effect of High-Calcium Milk and Weight-Bearing Exercise on Bone Mineral Status of Pre-Pubertal Girls|The Effect of a 10-month School-based Provision of High-calcium Milk and Weight-bearing Exercise Program on the Bone Mineral Status of 7 to 9 Year Old Pre-pubertal Girls|Completed||N/A|120|Actual|Nutrition Center of the Philippines||4|||f||||f||||||||||2018-06-01 00:34:26.622762|2018-06-01 00:34:26.622762
NCT00979498|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2009-09-17|2009-09-17|2009-09-18|Estimate|||||||2009-09-17|2009-09-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:34:26.786755|2018-06-01 00:34:26.786755
NCT00979485|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-06-22|2009-09-17|2009-09-18|Estimate|||||||2011-06-22|2011-06-23|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Microparticles in Pediatric Inflammatory Disease|Microparticles in Pediatric Inflammatory Bowel Disease|Terminated|||40|Anticipated|Indiana University||||initial results suggest no significant trends will be observed with completion of study|f||||t||||||||||2018-06-01 00:34:26.823192|2018-06-01 00:34:26.823192
NCT00979472|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2016-02-01|2009-09-17|2009-09-18|Estimate|||||||2016-02-01|2016-02-02|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency|Comparison of the Effect of Flexible Dosage of Solifenacin Succinate Between Patients Who Have Frequent Micturition With and Without Urgency|Completed||Phase 4|291|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 00:34:26.881343|2018-06-01 00:34:26.881343
NCT00979459|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2012-07-12||2016-02-04|2009-09-17|2009-09-18|Estimate|2012-07-12|2012-08-20|Estimate||||2016-02-04|2016-02-05|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)|A Single Dose Study to Compare the Pharmacokinetics of Two Probe Formulations of MK-1006|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:34:26.983063|2018-06-01 00:34:26.983063
NCT00979446|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-09-17|2009-09-17|2009-09-18|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Passport to Brain Wellness in Sedentary Adults|Developing a Multi-Domain Intervention to Maintain Cognitive Health in Sedentary Adults Ages 60 - 80|Completed||N/A|63|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-06-01 00:34:27.202438|2018-06-01 00:34:27.202438
NCT00979433|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2013-02-23|2009-09-17|2009-09-18|Estimate|||||||2013-02-23|2013-02-26|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Bubble Continuous Positive Airway Pressure (CPAP) With Conventional CPAP for Extubation in Preterm Infants|Bubble CPAP vs. Conventional CPAP Following Extubation in Preterm Very Low Birth Weight (VLBW) Infants: A Randomized Controlled Trial|Completed||N/A|32|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 00:34:27.289989|2018-06-01 00:34:27.289989
NCT00979420|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2012-05-30||2014-06-27|2009-09-17|2009-09-18|Estimate|2012-07-10|2012-08-16|Estimate||||2014-06-27|2014-06-30|Estimate|August 2009||2009-08-31|June 2014|2014-06-30||||November 2010|Actual|2010-11-30||Observational||Treated set - all patients receiving at least one dose of study medication|Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune|Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune|Completed|||||Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 00:34:27.426684|2018-06-01 00:34:27.426684
NCT00979407|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17||2010-12-10|2017-01-16|2009-09-17|2009-09-18|Estimate||||2010-12-10|2010-12-16|Estimate|2017-01-16|2017-01-18|Estimate|October 2009||2009-10-31|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|||Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)|Immunological Equivalence Between GSK2340272A and GSK2340274A Influenza Vaccines in Adults Aged 18 to 60 Years|Completed||Phase 3|336|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:34:28.422371|2018-06-01 00:34:28.422371
NCT00979394|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2010-08-16|2009-09-17|2009-09-18|Estimate|||||||2010-08-16|2010-08-17|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|DCA09||Evaluation of Diabetes Care at Austrian GPs|Diabetes Care Austria 2009|Terminated|||1513|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:34:28.549849|2018-06-01 00:34:28.549849
NCT00979381|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2010-03-17|2009-09-17|2009-09-18|Estimate|||||||2010-03-17|2010-03-18|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Observational|||Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor|Study to the Humoral and Cellular Immunoresponse After Influenza Vaccination in Patients With Metastasized RCC or GIST Treated With a Tyrosine Kinase Inhibitor(Sunitinib or Sorafenib)|Completed|||75|Actual|Radboud University|||3||f||||f||||||||||2018-06-01 00:34:28.607043|2018-06-01 00:34:28.607043
NCT00979368|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-02-22|2009-09-17|2009-09-18|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2009||2009-11-30|October 2009|2009-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety Study of BMS-816336 in Healthy Male Subjects|Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:34:28.689669|2018-06-01 00:34:28.689669
NCT00979355|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2010-06-24|2009-09-17|2009-09-18|Estimate|||||||2010-06-24|2010-06-28|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|GP_D-Spect||Study to Compare a Fast Gama Camera for Nuclear Imaging to Conventional Camera|Evaluation of Multi Purpose D-spect Camera for General Nuclear Scans|Withdrawn||N/A|40|Anticipated|Spectrum Dynamics|||||f||||||||||||||2018-06-01 00:34:28.785948|2018-06-01 00:34:28.785948
NCT00979342|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2010-07-22|2009-09-17|2009-09-18|Estimate|||||||2010-07-22|2010-07-23|Estimate|November 2009||2009-11-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparative Sedation Study of the MyoSure Hysteroscopic Tissue Removal System|Interlace Medical Comparative Sedation Study|Completed||N/A|40|Actual|Hologic, Inc.||4|||f||||f||||||||||2018-06-01 00:34:28.849242|2018-06-01 00:34:28.849242
NCT00979329|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2017-11-24|2009-09-17|2009-09-18|Estimate|||||||2017-11-24|2017-11-28|Actual|May 2008||2008-05-31|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2011|Actual|2011-12-31||Observational|||Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST|Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or GIST|Completed|||100|Actual|Radboud University|||1||f||||f||||||||||2018-06-01 00:34:28.940843|2018-06-01 00:34:28.940843
NCT00979316|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|||2011-01-06|2009-09-17|2009-09-18|Estimate|||||||2011-01-06|2011-01-07|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects|Randomized, Double-Blinded, Placebo-Controlled, Open Label Positive- Controlled, Four-Way Crossover Study of the Electrocardiographic Effects of BMS-708163 in Healthy Subjects|Completed||Phase 1|62|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 00:34:29.009054|2018-06-01 00:34:29.009054
NCT00979303|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-17|2017-11-10||2018-02-08|2009-09-17|2009-09-18|Estimate|2018-02-08|2018-03-08|Actual||||2018-02-08|2018-03-08|Actual|January 9, 2009|Actual|2009-01-09|February 2018|2018-02-28|May 28, 2010|Actual|2010-05-28|September 28, 2009|Actual|2009-09-28||Interventional|||Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia|The Adjunct Use of Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia|Completed||N/A|74|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 00:34:29.100252|2018-06-01 00:34:29.100252
NCT00979290|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2015-04-14|2009-09-16|2009-09-17|Estimate|||||||2015-04-14|2015-04-16|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|November 2011|Actual|2011-11-30|November 2009|Actual|2009-11-30||Observational|||Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs|Comparison of Adverse Reactions and Efficiency of Fixed-dose Combination Chemotherapy and Separate Formulations for Pulmonary Tuberculosis|Completed|||161|Actual|E-DA Hospital|||2||f||||||||||||||2018-06-01 00:34:29.391264|2018-06-01 00:34:29.391264
NCT00979277|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2014-01-08|2009-09-16|2009-09-17|Estimate|||||||2014-01-08|2014-01-10|Estimate||||January 2014|2014-01-31||||||||Observational|||Transcriptomal and Molecular Characterization of Tumor Associated Monocytes/Macrophages in Human Cancers|Transcriptomal and Molecular Characterization of Tumor Associated Monocytes / Macrophages in Human Cancers|Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 00:34:29.44803|2018-06-01 00:34:29.44803
NCT00979264|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2012-06-22|2009-09-16|2009-09-17|Estimate|||||||2012-06-22|2012-06-26|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CERTs-HF||Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study|Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study|Completed||N/A|147|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:34:29.506061|2018-06-01 00:34:29.506061
NCT00979251|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16||2014-02-14|2014-03-17|2009-09-16|2009-09-17|Estimate||||2014-03-17|2014-04-14|Estimate|2014-03-17|2014-04-14|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|August 2011|Actual|2011-08-31|May 2010|Actual|2010-05-31||Interventional|PO206||Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects|A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects|Completed||Phase 2|2|Actual|Adamas Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 00:34:29.577966|2018-06-01 00:34:29.577966
NCT00979238|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2017-07-10|2009-09-16|2009-09-17|Estimate|||||||2017-07-10|2017-07-12|Actual|February 22, 2010|Actual|2010-02-22|July 2017|2017-07-31|December 31, 2032|Anticipated|2032-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B|An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B|Active, not recruiting||Phase 1|14|Actual|St. Jude Children's Research Hospital||1|||f||||t|t|f||||||||2018-06-01 00:34:29.774614|2018-06-01 00:34:29.774614
NCT00979225|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2012-12-10|2009-09-16|2009-09-17|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Clinical Decision Support for Medication Management and Adherence|Improving Quality Through Decision Support for Evidence-Based Pharmacotherapy|Completed||N/A|5000|Actual|Duke University||3|||f||||f||||||||||2018-06-01 00:34:29.8717|2018-06-01 00:34:29.8717
NCT00979212|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2016-06-30||2018-03-23|2009-09-16|2009-09-17|Estimate|2016-06-30|2016-08-16|Estimate||||2018-03-23|2018-04-24|Actual|February 2011||2011-02-28|March 2018|2018-03-31||||December 2015|Actual|2015-12-31||Interventional||All eligible patients receiving protocol treatment|Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer|Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|71|Actual|Radiation Therapy Oncology Group|Following a recommendation on July 13, 2015 by the NRG Data Monitoring Committee accrual was halted early after accruing only 71 of 97 patients due to unexpectedly high rates of grade 5 toxicity on the panitumumab arm.|2|||f||||t||||||||||2018-06-01 00:34:29.982711|2018-06-01 00:34:29.982711
NCT00979199|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2014-04-23||2014-06-19|2009-09-16|2009-09-17|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|June 2012|Actual|2012-06-30|July 2010|Actual|2010-07-31||Interventional|EVINCI||Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease|Evaluation of Integrated Cardiac Imaging for the Detection and Characterization of Ischemic Heart Disease|Completed||Phase 4|697|Actual|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||1|||f||||||||||||||2018-06-01 00:34:30.601648|2018-06-01 00:34:30.601648
NCT00979186|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2011-11-28|2009-09-16|2009-09-17|Estimate|||||||2011-11-28|2011-11-29|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Trial to Evaluate Natural Orifice Transgastric Endoscopic Cholecystectomy With Laparoscopic Assistance|A Trial to Evaluate Natural Orifice Transgastric Endoscopic Cholecystectomy With Laparoscopic Assistance|Withdrawn||N/A|0|Actual|Ethicon Endo-Surgery||||Study Terminated - No enrollment, business decision.|f||||f||||||||||2018-06-01 00:34:30.800113|2018-06-01 00:34:30.800113
NCT00979173|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2014-01-28|2009-09-15|2009-09-17|Estimate|||||||2014-01-28|2014-01-29|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|June 2012|Actual|2012-06-30|October 2010|Actual|2010-10-31||Interventional|||Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma|A Pharmacokinetic Study of AC480 Administered Twice Daily in Surgically Resectable Malignant Glioma Patients Not on Enzyme-Inducing Anticonvulsants|Completed||Phase 1|5|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:34:30.857309|2018-06-01 00:34:30.857309
NCT00979160|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-09-17|2009-09-16|2009-09-17|Estimate|||||||2009-09-17|2009-09-18|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Evaluation of Response of Dasatinib to Treat Mastocytosis|Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Federico II University||1|||f||||t||||||||||2018-06-01 00:34:30.938468|2018-06-01 00:34:30.938468
NCT00979147|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2013-06-24|2009-09-16|2009-09-17|Estimate|||||||2013-06-24|2013-06-25|Estimate|November 2007||2007-11-30|June 2013|2013-06-30||||May 2013|Actual|2013-05-31||Interventional|||Comparison of a Metal Backed Fixed-Bearing Tibial Baseplate and an All-Polyethylene Tibia in Total Knee Arthroplasty|A Randomized Prospective Level 1 Comparison of a Modular Polished Fixed-Bearing Tibial Baseplate and an All-Polyethylene Tibia in Total Knee Arthroplasty|Completed||Phase 4|400|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||||||||||||2018-06-01 00:34:31.059992|2018-06-01 00:34:31.059992
NCT00979134|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2015-06-25|2009-09-16|2009-09-17|Estimate|||||||2015-06-25|2015-06-26|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|||Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients With Advanced Solid Malignancies|Completed||Phase 1|979|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:34:31.143541|2018-06-01 00:34:31.143541
NCT00979121|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2014-08-22||2016-04-12|2009-09-16|2009-09-17|Estimate|2014-10-02|2014-10-03|Estimate||||2016-04-12|2016-05-16|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|SAILS||Statins for Acutely Injured Lungs From Sepsis|Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis|Terminated||Phase 3|745|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2||stopped for futility|f||||t||||||||||2018-06-01 00:34:31.284186|2018-06-01 00:34:31.284186
NCT00979108|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-11-14|2009-09-16|2009-09-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|July 2009||2009-07-31|November 2014|2014-11-30|January 2013|Actual|2013-01-31|March 2012|Actual|2012-03-31||Interventional|||The Value of Traction in the Treatment of Cervical Radiculopathy|The Value of Mechanical Traction in the Treatment of Cervical Radiculopathy|Completed||Phase 3|86|Actual|Intermountain Health Care, Inc.||3|||f||||f||||||||||2018-06-01 00:34:32.147732|2018-06-01 00:34:32.147732
NCT00979095|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-10-12|2009-09-16|2009-09-17|Estimate|||||||2010-10-12|2010-10-13|Estimate|June 2009||2009-06-30|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Genetic Examination of Patients With Primary Multiple Hernia|Genetic Differences Between Patients With Multiple Hernia and a Healthy Control Group|Unknown status|Recruiting||60|Anticipated|Herlev Hospital|||2||f||||f||||||||||2018-06-01 00:34:32.247915|2018-06-01 00:34:32.247915
NCT00979069|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2014-09-18||2014-11-13|2009-09-16|2009-09-17|Estimate|2014-10-29|2014-11-06|Estimate||||2014-11-13|2014-11-26|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Aerobic Exercise to Improve Executive Language Function In Older Adults|Aerobic Exercise to Improve Executive Language Function in Older Adults|Completed||N/A|20|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:34:32.33349|2018-06-01 00:34:32.33349
NCT00979056|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2013-11-07|2009-09-16|2009-09-17|Estimate|||||||2013-11-07|2013-11-08|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Prophylactic Treatment of Travellers' Diarrhoea With Rifaximin|Prospective, Randomised, Placebo Controlled, Double Blind Monocenter Trial for the Prophylactic Treatment of Diarrhoea With Rifaximin for Travellers to South- and Southeast-Asia|Completed||Phase 3|258|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 00:34:32.658183|2018-06-01 00:34:32.658183
NCT00979043|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2017-01-23|2009-09-16|2009-09-17|Estimate|||||||2017-01-23|2017-01-25|Estimate|November 1997||1997-11-30|January 2017|2017-01-31|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|ADAPT||The Arthritis, Diet, and Activity Promotion Trial|The Arthritis, Diet, and Activity Promotion Trial|Completed||N/A|318|Actual|Wake Forest University Health Sciences||4|||f||||f||||||||||2018-06-01 00:34:32.750901|2018-06-01 00:34:32.750901
NCT00979017|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2013-06-05||2014-02-05|2009-09-16|2009-09-17|Estimate|2013-08-09|2013-08-12|Estimate||||2014-02-05|2014-03-19|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|February 2011|Actual|2011-02-28||Interventional|||Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme|Avastin in Combination With Temozolomide and Irinotecan for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas|Completed||Phase 2|41|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:34:32.867794|2018-06-01 00:34:32.867794
NCT00979004|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16||2011-07-07|2012-09-27|2009-09-16|2009-09-17|Estimate||||2011-07-07|2011-07-14|Estimate|2012-09-27|2012-10-04|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients|A Phase 2, Multi-Center, Single-Blind, Placebo-Controlled Pharmacodynamic Evaluation of ICA-105665 in Epilepsy Patients With a Photo-Induced Paroxysmal EEG Response|Terminated||Phase 2|13|Actual|Pfizer||1||"The study was terminated on September 12, 2010 per protocol following a serious adverse event~   that occurred with the first subject dosed at 600 mg."|f||||f||||||||||2018-06-01 00:34:33.10619|2018-06-01 00:34:33.10619
NCT00978991|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2013-02-06|2009-09-16|2009-09-17|Estimate|||||||2013-02-06|2013-02-08|Estimate|January 1988||1988-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Duke Urology Database and Specimen Bank|Duke Longitudinal Urologic Surgery Patient Outcome Database|Completed|||87820|Actual|Duke University|||||f||||t||||||||||2018-06-01 00:34:33.186786|2018-06-01 00:34:33.186786
NCT00978978|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-10-11|2009-09-16|2009-09-17|Estimate|||||||2009-10-11|2009-10-14|Estimate|October 2009||2009-10-31|September 2009|2009-09-30||||August 2010|Anticipated|2010-08-31||Interventional|||Propofol Versus Midazolam and Fentanyl for Diagnostic and Screening Colonoscopy in Patients With Advanced Liver Disease|Propofol Versus Midazolam and Fentanyl for Diagnostic and Screening Colonoscopy in Patients With Advanced Liver Disease|Unknown status|Not yet recruiting|N/A|60|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-06-01 00:34:33.242708|2018-06-01 00:34:33.242708
NCT00978965|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2017-12-25|2009-09-16|2009-09-17|Estimate|||||||2017-12-25|2017-12-27|Actual|October 2009||2009-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs|Identification of Patients With High Probability of Not or Poorly Responding to Mycophenolate-mofetil (Cellcept®) or Mycophenolate-natrium (Myfortic®) Therapy|Active, not recruiting|||250|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-06-01 00:34:33.315598|2018-06-01 00:34:33.315598
NCT00978952|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2017-06-29|2009-09-16|2009-09-17|Estimate|||||||2017-06-29|2017-07-02|Actual|September 2009||2009-09-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|May 2013|Actual|2013-05-31||Interventional|||Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta|Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta|Completed||N/A|70|Actual|Atrium Medical Corporation||1|||f||||t||||||||Undecided||2018-06-01 00:34:33.389741|2018-06-01 00:34:33.389741
NCT00978939|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2013-12-27|2009-09-16|2009-09-17|Estimate|||||||2013-12-27|2013-12-30|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Interventional|ASAP||Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter|Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter on the Incidence of Auto-Pleurodesis in Patients With Malignant Pleural Effusions|Completed||Phase 4|150|Actual|Duke University||2|||f||||t||||||||||2018-06-01 00:34:33.473285|2018-06-01 00:34:33.473285
NCT00978926|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2010-04-08|2009-09-16|2009-09-17|Estimate|||||||2010-04-08|2010-04-09|Estimate|September 2009||2009-09-30|April 2010|2010-04-30||||||||Observational|||A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies|A Study of the Pharmacodynamic Effects of Anti-vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies|Completed|||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 00:34:33.554846|2018-06-01 00:34:33.554846
NCT00978913|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2015-08-18|2009-09-16|2009-09-17|Estimate|||||||2015-08-18|2015-08-19|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|||Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma|Evaluation of Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA as a Treatment for Patients With Metastatic Breast Cancer or Malignant Melanoma|Completed||Phase 1|31|Actual|Herlev Hospital||1|||f||||t||||||||||2018-06-01 00:34:33.612201|2018-06-01 00:34:33.612201
NCT00978900|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-09-16|2009-09-16|2009-09-17|Estimate|||||||2009-09-16|2009-09-17|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion|Carbohydrates and Non Caloric Sweeteners: Differential Effects on Appetite and Secretion of Gastrointestinal Satiety Peptide|Completed||Phase 1|12|Actual|University Hospital, Basel, Switzerland||6|||f||||f||||||||||2018-06-01 00:34:33.687015|2018-06-01 00:34:33.687015
NCT00978887|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2010-05-17|2009-09-16|2009-09-17|Estimate|||||||2010-05-17|2010-05-18|Estimate|October 2009||2009-10-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Retorna Facial Cream in the Treatment of Facial Wrinkles|Efficacy of Retorna Facial Cream Usage in the Treatment of Facial Wrinkles|Completed||Phase 3|148|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:34:33.746776|2018-06-01 00:34:33.746776
NCT00978874|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-10-17|2009-09-16|2009-09-17|Estimate|||||||2009-10-17|2009-10-20|Estimate|May 2008||2008-05-31|September 2009|2009-09-30||||May 2010|Anticipated|2010-05-31||Interventional|||Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer|[F18]EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Carcinoma of the Cervix|Unknown status|Recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 00:34:33.809765|2018-06-01 00:34:33.809765
NCT00978861|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-09-16|2009-09-16|2009-09-17|Estimate|||||||2009-09-16|2009-09-17|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|REMEWHITE||Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE|A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate of The Whitening Efficacy and Safety of REMEWHITE|Completed||Phase 3|70|Actual|JDC Tech||1|||f||||t||||||||||2018-06-01 00:34:33.868988|2018-06-01 00:34:33.868988
NCT00978848|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2016-05-17|2009-09-16|2009-09-17|Estimate|||||||2016-05-17|2016-05-18|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing|Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing: Meeting the Needs of an At-Risk Population|Completed|||305|Actual|University of Pittsburgh|||2||f||||f||||||Samples Without DNA|"~     Any left over urine may be frozen for future use on infections in women~   "|No||2018-06-01 00:34:33.932605|2018-06-01 00:34:33.932605
NCT00978822|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-09-17|2009-09-16|2009-09-17|Estimate|||||||2009-09-17|2009-09-18|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|April 2010|Anticipated|2010-04-30||Interventional|CLASH||Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage|Clevidipine in Aneurysmal Subarachnoid Hemorrhage, A Pilot Study|Unknown status|Recruiting|Phase 2|20|Anticipated|Henry Ford Health System||1|||f||||t||||||||||2018-06-01 00:34:34.077545|2018-06-01 00:34:34.077545
NCT00978809|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2015-04-16|2009-09-16|2009-09-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Effects of Physical Treatment on Postural Stability in Benign Paroxysmal Positional Vertigo (BPPV) Patients|Epley Maneuver vs. Semont Maneuver for Benign Paroxysmal Positional Vertigo (BPPV): Evaluating Treatment Effectiveness by Postural Stability - a Double Blinded Randomized Controlled Trial.|Withdrawn||N/A|0|Actual|Assuta Hospital Systems||3||major difficulties recruiting patients|f||||f||||||||||2018-06-01 00:34:34.146537|2018-06-01 00:34:34.146537
NCT00978796|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2010-03-29|2009-09-16|2009-09-17|Estimate|||||||2010-03-29|2010-03-30|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes|Pilot Study Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes|Completed||Phase 4|20|Anticipated|University of Colorado Denver School of Medicine Barbara Davis Center||2|||f||||f||||||||||2018-06-01 00:34:34.313472|2018-06-01 00:34:34.313472
NCT00978783|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-16|2009-09-16|2009-09-17|Estimate|||||||2009-09-16|2009-09-17|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Speech Effects of a Speaking Valve Versus External Positive End-expiratory Pressure (PEEP) in Tracheostomized Ventilator-Dependent Neuromuscular Patients|Speech Effects of a Speaking Valve Versus External PEEP in Tracheostomized Ventilator-Dependent Neuromuscular Patients|Completed||Phase 2/Phase 3|10|Actual|University of Versailles||2|||f||||t||||||||||2018-06-01 00:34:34.406705|2018-06-01 00:34:34.406705
NCT00978770|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2013-08-06|2009-09-16|2009-09-17|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|January 2010|Actual|2010-01-31|||||Interventional|||MRI in Predicting Early Response to Chemotherapy in Patients With Locally Advanced Breast Cancer|Neo Comice Pilot; Efficacy of Advanced Semi-automated Functional Magnetic Resonance (MR) Imaging in the Early Prediction of Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:34:34.487418|2018-06-01 00:34:34.487418
NCT00978757|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2009-09-23||2009-12-11|2009-09-16|2009-09-17|Estimate|2009-12-11|2010-01-18|Estimate||||2009-12-11|2010-01-18|Estimate|June 2001||2001-06-30|October 2009|2009-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion|Phase 4: Study of Ketamine Inhibition of Interleukin 6 in Hepatic Resections Requiring Temporary Porto-arterial Occlusion|Completed||Phase 4|42|Actual|Hospital Italiano de Buenos Aires||2|||f||||f||||||||||2018-06-01 00:34:34.578836|2018-06-01 00:34:34.578836
NCT00978744|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2014-01-23|2009-09-15|2009-09-17|Estimate|||||||2014-01-23|2014-01-24|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|January 2012|Actual|2012-01-31||Observational|||Evaluation of a Regional Electronic Health Information Exchange's Clinical Health Record|Evaluation of a Regional Electronic Health Information Exchange's Clinical Health Record|Unknown status|Active, not recruiting||113|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 00:34:34.82776|2018-06-01 00:34:34.82776
NCT00978731|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2010-11-23||2011-04-25|2009-09-16|2009-09-17|Estimate|2011-03-14|2011-04-19|Estimate||||2011-04-25|2011-04-28|Estimate|December 2005||2005-12-31|April 2011|2011-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study|Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Subjects Who Experienced Clinical Benefit on Protocol CA180-002|Completed||Phase 1|46|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:34:34.962755|2018-06-01 00:34:34.962755
NCT00978718|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2012-08-13|2009-09-16|2009-09-17|Estimate|||||||2012-08-13|2012-08-15|Estimate|August 2001||2001-08-31|August 2012|2012-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Selenium in Preventing Prostate Cancer|Phase III Trial of Selenium for Prostate Cancer Prevention|Completed||Phase 3|700|Anticipated|University of Arizona||3|||f||||||||||||||2018-06-01 00:34:36.25243|2018-06-01 00:34:36.25243
NCT00978705|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-09-15|2009-09-15|2009-09-17|Estimate|||||||2009-09-15|2009-09-17|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|January 2010|Anticipated|2010-01-31|May 2008|Anticipated|2008-05-31||Interventional|keratinocyte||Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood|Clinical Study for Evaluation of Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood|Unknown status|Enrolling by invitation|Phase 3|19|Anticipated|Biosolution Co., Ltd.|||||f||||t||||||||||2018-06-01 00:34:36.317839|2018-06-01 00:34:36.317839
NCT00978692|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2016-02-18|2009-09-16|2009-09-17|Estimate|||||||2016-02-18|2016-02-22|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|TO-SEE||Toric Orthokeratology - Slowing Eye Elongation|Toric Orthokeratology for Slowing Eye Elongation in Astigmatic Children|Completed||N/A|80|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-06-01 00:34:36.378672|2018-06-01 00:34:36.378672
NCT00978679|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2016-02-22|2009-09-16|2009-09-17|Estimate|||||||2016-02-22|2016-02-23|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Peripheral Optics in Myopia and Orthokeratology|Peripheral Refraction and Aberration in Myopic Progression and Myopic Control|Completed||N/A|90|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-06-01 00:34:36.480141|2018-06-01 00:34:36.480141
NCT00978666|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-09-16|2009-09-16|2009-09-17|Estimate|||||||2009-09-16|2009-09-17|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Observational|ADOL_AN||Functional Magnetic Resonance Imaging (fMRI) Imaging Study in Adolescents With Anorexia Nervosa|Neural Dysfunction of Interoception in Adolescents Diagnosed With Anorexia Nervosa|Unknown status|Recruiting||22|Anticipated|University of California, San Diego|||||f||||t||||||||||2018-06-01 00:34:36.557575|2018-06-01 00:34:36.557575
NCT00978653|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2009-09-21|2009-09-16|2009-09-17|Estimate|||||||2009-09-21|2009-09-22|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure|Prospective Study of Allopurinol Treatment That Improves Endothelial Function by Decreasing Uric Acid Levels of Patients With Chronic Kidney Disease|Completed||N/A|20|Actual|Istanbul University||1|||f||||f||||||||||2018-06-01 00:34:36.611329|2018-06-01 00:34:36.611329
NCT00978640|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2012-06-19|2009-09-16|2009-09-17|Estimate|||||||2012-06-19|2012-06-20|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Sirtuin Mediated Effects of 36 Hour Fast and 1 Hour Exercise|Sirtuin Mediated Effects of 36 h Fast and 1 h Exercise|Unknown status|Active, not recruiting|N/A|8|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-06-01 00:34:36.680017|2018-06-01 00:34:36.680017
NCT00978627|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2015-10-19|2010-11-09|2017-02-09|2009-09-16|2009-09-17|Estimate|2015-10-19|2015-11-20|Estimate|2011-01-07|2011-01-20|Estimate|2017-02-09|2017-03-20|Actual|August 2009||2009-08-31|February 2017|2017-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|BOOST™||Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes|NN5401-3594: A 26-week, Open-labelled, Two-arm, Parallel, Randomised Trial Comparing Efficacy and Safety of NN5401 Once Daily Plus Insulin Aspart vs. Basal-bolus Treatment With Insulin Detemir Plus Insulin Aspart in Subjects With Type 1 Diabetes / NN5401-3645: An Extension Trial Comparing Safety and Efficacy of NN5401 Plus Meal-time Insulin Aspart for the Remaining Meals With Insulin Detemir Plus Meal-time Insulin Aspart in Type 1 Diabetes (BOOST™: T1)|Completed||Phase 3|548|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:34:36.753686|2018-06-01 00:34:36.753686
NCT00978614|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2011-02-14|2009-09-16|2009-09-17|Estimate|||||||2011-02-14|2011-02-15|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects|Valuation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration) Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled, Ascending Repeated-Dose, Three-Arm Parallel Design ECG Study in Healthy Adult Subjects|Completed||Phase 1|126|Anticipated|Merz Pharmaceuticals GmbH||1|||f||||||||||||||2018-06-01 00:34:38.343683|2018-06-01 00:34:38.343683
NCT00978601|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2009-09-16|2009-09-16|2009-09-17|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|||Improved Recovery Using Multimodal Peri-operative Analgesia in Minimally Invasive Myomectomy|Improved Recovery Using Multimodal Peri-operative Analgesia in Minimally Invasive Myomectomy.A Randomized Study.|Completed||N/A|95|Actual|Iakentro Fertility Centre||2|||f||||t||||||||||2018-06-01 00:34:38.405021|2018-06-01 00:34:38.405021
NCT00978588|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2012-02-02|2009-09-16|2009-09-17|Estimate|||||||2012-02-02|2012-02-03|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of 6% Hydroxyethyl Starch 130/0.4 With 5% Albumin as Priming Solution for Cardiopulmonary Bypass||Completed||N/A|36|Actual|Yonsei University||2|||f||||||||||||||2018-06-01 00:34:38.562709|2018-06-01 00:34:38.562709
NCT00978575|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2013-04-04|2009-09-16|2009-09-17|Estimate|||||||2013-04-04|2013-04-05|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Iron Substitution After Upper Gastro-Intestinal Bleeding|Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial|Completed||Phase 4|97|Actual|University of Aarhus||3|||f||||t||||||||||2018-06-01 00:34:38.706138|2018-06-01 00:34:38.706138
NCT00978562|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|2016-12-29||2018-01-30|2009-09-16|2009-09-17|Estimate|2017-04-19|2017-05-23|Actual||||2018-01-30|2018-02-01|Actual|August 2009||2009-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors|Imaging Vascular Properties of Pediatric Brain Tumors Using DSC-MRI With Ferumoxytol (Code 7228) and DCE-MRI With Gadolinium in a Single Imaging Session: An NCI Sponsored Exploratory Trial|Active, not recruiting||N/A|7|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 00:34:38.83783|2018-06-01 00:34:38.83783
NCT00978549|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2013-08-06|2009-09-16|2009-09-17|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer|Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma|Completed||Phase 3|320|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:34:39.089749|2018-06-01 00:34:39.089749
NCT00978536|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2013-09-27|2009-09-16|2009-09-17|Estimate|||||||2013-09-27|2013-09-30|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|BioCogS||A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).|A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).|Terminated||N/A|29|Actual|Nantes University Hospital||3||Difficulties of recruitment in a randomization arm|f||||||||||||||2018-06-01 00:34:39.186238|2018-06-01 00:34:39.186238
NCT00978523|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2014-01-28|2009-09-16|2009-09-17|Estimate|||||||2014-01-28|2014-01-29|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma|A Phase 1 Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma, for Which No Standard Therapy Is Available|Completed||Phase 1|35|Actual|Arno Therapeutics||1|||f||||f||||||||||2018-06-01 00:34:39.273496|2018-06-01 00:34:39.273496
NCT00978510|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2009-09-16|2009-09-16|2009-09-17|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 2004||2004-01-31|September 2009|2009-09-30|December 2006|Actual|2006-12-31|||||Observational|||Study of Health Personnel and the Assistance to Patients With Tuberculosis in Hospital Environment|Health Personnel and the Control of Tuberculosis in a Hospital Environment|Completed|||159|Actual|Sociedade Cearense de Infectologia|||||f||||f||||||||||2018-06-01 00:34:39.397678|2018-06-01 00:34:39.397678
NCT00978497|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16||2017-03-27|2017-03-29|2009-09-16|2009-09-17|Estimate||||2017-03-29|2017-03-31|Actual|2017-03-29|2017-03-31|Actual|September 2009||2009-09-30|March 2017|2017-03-31|August 2011|Actual|2011-08-31|April 2010|Actual|2010-04-30||Interventional|||Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients With Chronic Hepatitis C Infection|Completed||Phase 2|97|Actual|Hoffmann-La Roche||3|||f||||t||||||||||2018-06-01 00:34:39.474622|2018-06-01 00:34:39.474622
NCT00978484|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2014-06-27|2009-09-16|2009-09-17|Estimate|||||||2014-06-27|2014-06-30|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder|A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder|Unknown status|Active, not recruiting|Phase 3|150|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||||2018-06-01 00:34:39.629936|2018-06-01 00:34:39.629936
NCT00978471|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2016-12-01|2009-09-16|2009-09-17|Estimate|||||||2016-12-01|2016-12-02|Estimate|July 2009||2009-07-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|OSII-TTP||Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma|Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma|Active, not recruiting||Phase 2|45|Actual|Centre Leon Berard||2|||f||||t||||||||||2018-06-01 00:34:39.735101|2018-06-01 00:34:39.735101
NCT00978458|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-16|||2017-12-12|2009-09-16|2009-09-17|Estimate|||||||2017-12-12|2017-12-14|Actual|September 2009||2009-09-30|December 2017|2017-12-31|December 31, 2026|Anticipated|2026-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma|Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas|Active, not recruiting||Phase 3|540|Actual|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-06-01 00:34:40.000189|2018-06-01 00:34:40.000189
NCT00978445|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2012-07-18||2013-03-20|2009-09-16|2009-09-17|Estimate|2013-03-20|2013-03-21|Estimate||||2013-03-20|2013-03-21|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|vMetrics-AMS||Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System|Use of a Novel Remote Home PT/INR-monitoring Device for Long-Term Anticoagulation Management|Completed||N/A|25|Actual|ZIN Technologies, Inc.||2|||f||||t||||||||||2018-06-01 00:34:40.34334|2018-06-01 00:34:40.34334
NCT00978432|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2016-03-17||2016-10-12|2009-09-16|2009-09-17|Estimate|2016-04-27|2016-06-07|Estimate||||2016-10-12|2016-11-25|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Interventional|||Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Terminated||Phase 2|50|Actual|Duke University||3||The toxicity seemed to outweigh the benefit.|f||||f||||||||No||2018-06-01 00:34:40.613815|2018-06-01 00:34:40.613815
NCT00978419|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2011-07-12|2009-09-15|2009-09-16|Estimate|||||||2011-07-12|2011-07-13|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|BURNSTAT||Pilot Trial of Statin Use in Burn Patients|Randomized, Placebo Controlled, Pilot Trial of Statin Use in Burn Patients|Completed||Phase 2|40|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 00:34:41.337686|2018-06-01 00:34:41.337686
NCT00978406|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2018-04-04|2009-09-15|2009-09-16|Estimate|||||||2018-04-04|2018-04-05|Actual|August 26, 2009||2009-08-26|January 23, 2018|2018-01-23||||||||Observational|||National Cancer Institute Food Study|National Cancer Institute (NCI) Food Study|Completed|||83|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:34:41.429535|2018-06-01 00:34:41.429535
NCT00978393|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2017-07-25|2009-09-15|2009-09-16|Estimate|||||||2017-07-25|2017-07-27|Actual|September 16, 2009|Actual|2009-09-16|July 2017|2017-07-31|June 8, 2011|Actual|2011-06-08|June 8, 2011|Actual|2011-06-08||Interventional|||A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers|A Randomised, Placebo-controlled, Double-blind, Incomplete Cross-over Design Trial to Evaluate the Effects of Liraglutide on Gastric Emptying, Energy Expenditure and Appetite, and to Evaluate Liraglutide Pharmacokinetics in Non-diabetic Obese Subjects|Completed||Phase 1|49|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-06-01 00:34:41.481748|2018-06-01 00:34:41.481748
NCT00978380|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2016-10-19||2018-01-18|2009-09-15|2009-09-16|Estimate|2016-10-19|2016-12-13|Estimate||||2018-01-18|2018-01-24|Actual|September 21, 2009|Actual|2009-09-21|January 2018|2018-01-31|October 20, 2015|Actual|2015-10-20|October 20, 2015|Actual|2015-10-20||Interventional|mentor™2|All subjects who received trial product were considered for baseline characteristics including 3 subjects who were re-enrolled with new subject IDs.|Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725|A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency|Completed||Phase 3|63|Actual|Novo Nordisk A/S|Limitations of the trial include small number of children and adolescents (16 subjects), and the sensitivity of the Berichrome® FXIII activity assay. However, mean FXIII activity levels were consistent with few bleeds requiring haemostatic treatment.|1|||f||||f||||||||||2018-06-01 00:34:41.58343|2018-06-01 00:34:41.58343
NCT00978367|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2009-09-15|2009-09-15|2009-09-16|Estimate|||||||2009-09-15|2009-09-16|Estimate|February 2002||2002-02-28|September 2009|2009-09-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)|A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised Study to Investigate the Clinical Safety and Toleration (Including Systemic Pharmacokinetics), Wound Healing and Anti-scarring Potential of Two Applications of Intradermal RN1001 in Healthy Male Subjects.|Completed||Phase 1/Phase 2|43|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:34:42.149499|2018-06-01 00:34:42.149499
NCT00978354|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2015-09-28|2009-09-15|2009-09-16|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|SPARK||Furosemide in Early Acute Kidney Injury|A Phase II Randomized Blinded Controlled Trial of the Effect of furoSemide in Critically Ill Patients With eARly Acute Kidney Injury (The SPARK Study)|Terminated||Phase 2/Phase 3|72|Actual|University of Alberta||2||Feasibility of target enrollment within the context of available funding resources.|f||||t||||||||||2018-06-01 00:34:42.272418|2018-06-01 00:34:42.272418
NCT00978341|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2009-09-28||2010-01-06|2009-09-15|2009-09-16|Estimate|2009-09-28|2009-11-09|Estimate||||2010-01-06|2010-01-12|Estimate|February 2007||2007-02-28|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design|A Methodology Study to Assess the Ability of a Randomised, Double Blind, Placebo Controlled, Crossover Trial Design in Spinal Cord Injury Patients With Pain of Neuropathic Origin to Detect Improvement in Pain Endpoints Using Pregabalin as a Benchmark Compound|Terminated||N/A|15|Actual|Pfizer|This study was terminated prematurely.|2||See Detailed Description|f||||t||||||||||2018-06-01 00:34:42.449169|2018-06-01 00:34:42.449169
NCT00978328|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-04-01|2009-09-15|2009-09-16|Estimate|||||||2010-04-01|2010-04-02|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|January 2010|Actual|2010-01-31|||||Observational|||Oxycodone User Registry (OUR)|A Prospective, Multi-center, Observational Registry of Patients Using Prescription Medications Containing Oxycodone Immediate Release for the Treatment of Pain|Completed|||827|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|||1||f||||||||||||||2018-06-01 00:34:43.233949|2018-06-01 00:34:43.233949
NCT00978315|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2014-02-03|2009-09-15|2009-09-16|Estimate|||||||2014-02-03|2014-02-04|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ViDiAs||Trial of Vitamin D Supplementation in Asthma|Randomised, Multi-centre, Double-blind, Placebo-controlled Trial of Vitamin D Supplementation in Adult and Adolescent Patients With Asthma|Completed||Phase 2/Phase 3|250|Actual|Barts & The London NHS Trust||2|||f||||t||||||||||2018-06-01 00:34:43.322222|2018-06-01 00:34:43.322222
NCT00978302|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2009-09-15|2009-09-15|2009-09-16|Estimate|||||||2009-09-15|2009-09-16|Estimate|May 2001||2001-05-31|September 2009|2009-09-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)|A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised, Parallel Group Study to Investigate the Clinical Safety, Toleration, Systemic Pharmacokinetics and Local Pharmacodynamics of Repeated, Escalating Concentrations of Intradermal RN1001 in Healthy Male Subjects.|Completed||Phase 1|55|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:34:43.434457|2018-06-01 00:34:43.434457
NCT00978289|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2013-06-17|2009-09-15|2009-09-16|Estimate|||||||2013-06-17|2013-06-19|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Microenvironment of Adipose Tissue in Endocannabinoid System|Microenvironment of Adipose Tissue in Endocannabinoid System Before and After Roux-en-y Gastric Bypass Surgery|Completed|||20|Anticipated|Vanderbilt University|||||f||||f||||||Samples With DNA|"~     Whole blood, adipose tissue, adipose tissue microdialysate~   "|||2018-06-01 00:34:43.522683|2018-06-01 00:34:43.522683
NCT00978276|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2016-01-04|2009-09-15|2009-09-16|Estimate|||||||2016-01-04|2016-01-05|Estimate|May 2006||2006-05-31|January 2016|2016-01-31||||||||Observational|||Immunohistochemical (IHC) Scoring for Receptors Expression in Breast Tissues|Concordance Study for Over Expression Level of Antibodies Within Breast Tissues|Withdrawn|||0|Actual|Applied Spectral Imaging Ltd.||||Personal changes in the company|f||||f||||||Samples Without DNA|"~     Paraffin embedded tissue sections of the breast~   "|||2018-06-01 00:34:43.56423|2018-06-01 00:34:43.56423
NCT00978263|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-02-04|2009-09-15|2009-09-16|Estimate|||||||2013-02-04|2013-02-05|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes|An Efficacy and Safety Comparison of Basal Insulin and OADs in Newly Diagnosed Type 2 Diabetes After Short-term Intensive Insulin Therapy|Completed||N/A|47|Actual|Chongqing Medical University||2|||f||||t||||||||||2018-06-01 00:34:43.607706|2018-06-01 00:34:43.607706
NCT00978250|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2018-05-30|2009-09-15|2009-09-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 20, 2009||2009-08-20|May 3, 2018|2018-05-03|May 27, 2019|Anticipated|2019-05-27|June 2, 2018|Anticipated|2018-06-02||Interventional|||A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)|A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)|Active, not recruiting||Phase 2|90|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 00:34:43.798755|2018-06-01 00:34:43.798755
NCT00978237|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2014-09-17|2009-09-15|2009-09-16|Estimate|||||||2014-09-17|2014-09-18|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|LIPOKAL||Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients|CT to Assess the Effect on the Subcutaneous Fat of Change of EFV for LPV/r in HIV-infected Patients Who Developed Lipoatrophy and Remains Despite Treatment With Efavirenz and Fixed-dose Combination of no Thymidine Nucleoside Analogues.|Completed||Phase 4|20|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 00:34:43.896524|2018-06-01 00:34:43.896524
NCT00978224|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-07-06|2009-09-15|2009-09-16|Estimate|||||||2010-07-06|2010-07-07|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment|Efficacy of Viusid Administration in Subjects With Chronic Inflammatory Syndrome Under Hemodialysis Treatment|Suspended||Phase 3|152|Anticipated|Catalysis SL||2||Decision of the investigator|f||||t||||||||||2018-06-01 00:34:43.993029|2018-06-01 00:34:43.993029
NCT00978211|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2015-08-05|2009-09-15|2009-09-16|Estimate|||||||2015-08-05|2015-08-07|Estimate|September 1997||1997-09-30|August 2015|2015-08-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||DOTA-TOC in Metastasized Neuroendocrine Tumors|Phase II Study of [90Y-DOTA]-TOC and [177Lu-DOTA]-TOC in Metastasized Neuroendocrine Tumors|Completed||Phase 2|1499|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 00:34:44.128878|2018-06-01 00:34:44.128878
NCT00978198|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-06-16|2009-09-15|2009-09-16|Estimate|||||||2010-06-16|2010-06-22|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers|ASP1517 Phase 1 Clinical Study - Single and Multiple Oral Dosing of ASP1517 in Healthy Non-elderly Male Volunteers|Completed||Phase 1|100|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:34:44.215774|2018-06-01 00:34:44.215774
NCT00978185|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2013-08-23|2009-09-15|2009-09-16|Estimate|||||||2013-08-23|2013-08-26|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy|The Effectiveness and Cost Effectiveness of Acupressure for the Control and Management of Chemotherapy-related Nausea.|Completed||Phase 3|699|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:34:44.285709|2018-06-01 00:34:44.285709
NCT00978172|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-15|2009-09-15|2009-09-16|Estimate|||||||2009-09-15|2009-09-16|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|March 2009|Actual|2009-03-31|||||Interventional|||Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria|A Phase IV Study on the Safety and Effectiveness of a Fixed-dose Combination of Artesunate and Mefloquine (Artequin[TM] Paediatric) Administered for 3 Days in Children With Uncomplicated Plasmodium Falciparum Malaria in Africa|Completed||Phase 4|220|Actual|Mepha Ltd.|||||f||||f||||||||||2018-06-01 00:34:44.354199|2018-06-01 00:34:44.354199
NCT00978159|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2012-06-05|2009-09-15|2009-09-16|Estimate|||||||2012-06-05|2012-06-06|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia|Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study|Unknown status|Recruiting|Phase 4|128|Anticipated|Ruttonjee Hospital||2|||f||||t||||||||||2018-06-01 00:34:44.435802|2018-06-01 00:34:44.435802
NCT00978146|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2017-04-19|2009-09-15|2009-09-16|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2009||2009-10-31|April 2017|2017-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors|Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors in Adults and Children (CHP-914)|Withdrawn||Phase 2|0|Actual|Children's Hospital of Philadelphia||1||Study was administratively withdrawn by the IRB; no subjects were enrolled|f||||t||||||||||2018-06-01 00:34:44.541133|2018-06-01 00:34:44.541133
NCT00978133|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2018-04-16|2009-09-14|2009-09-16|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2006||2006-05-31|April 2018|2018-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study of DERMABOND ProPen in Closure of Colectomy Wounds|Prospective Randomized Study to Evaluate the Use of DERMABOND ProPen (2-octylcyanoacrylate) in the Closure of Abdominal Wounds Versus Closure With Skin Staples in Patients Undergoing Elective Colectomy.|Terminated||Phase 2|74|Actual|Singapore General Hospital||2||Difficulty in accrual of study subjects, small numbers of potential subjects|f||||t||||||||||2018-06-01 00:34:44.636166|2018-06-01 00:34:44.636166
NCT00978120|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2012-06-27||2012-08-08|2009-09-15|2009-09-16|Estimate|2012-06-27|2012-08-06|Estimate||||2012-08-08|2012-08-10|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma|A Phase II Study in Patients With Asthma to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Influenza Vaccine Administered at Two Dose Levels|Completed||Phase 2|390|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 00:34:44.816354|2018-06-01 00:34:44.816354
NCT00978107|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2014-07-15|2009-09-15|2009-09-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Trial of TG4023 Combined With Flucytosine in Liver Tumors|A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.|Completed||Phase 1|16|Actual|Transgene|||||f||||t||||||||||2018-06-01 00:34:45.734494|2018-06-01 00:34:45.734494
NCT00978094|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-11-16|2009-09-15|2009-09-16|Estimate|||||||2010-11-16|2010-11-17|Estimate|February 2009||2009-02-28|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Validation of a Novel Sham Cervical Spinal Manipulation Procedure|Validation of a Novel Sham Cervical Spinal Manipulation Procedure.|Completed|||80|Anticipated|Canadian Memorial Chiropractic College|||||f||||t||||||||||2018-06-01 00:34:45.803944|2018-06-01 00:34:45.803944
NCT00978081|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2016-02-09|2009-09-15|2009-09-16|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2009||2009-01-31|February 2016|2016-02-29||||October 2014|Actual|2014-10-31||Interventional|||Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors|Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors|Unknown status|Active, not recruiting|Phase 1|35|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||||||||||||||||2018-06-01 00:34:45.859424|2018-06-01 00:34:45.859424
NCT00978068|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-10-09|2009-09-15|2009-09-16|Estimate|||||||2013-10-09|2013-10-11|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PROMOTE-PEDS||HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children|A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children|Completed||Phase 3|186|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:34:45.933052|2018-06-01 00:34:45.933052
NCT00978055|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2009-09-15|2009-09-15|2009-09-16|Estimate|||||||2009-09-15|2009-09-16|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)|Single-Dose Fasting Bioequivalence Study of Liothyronine Sodium Tablets (50 Mcg; Mylan) to Cytomel® Tablets (50 Mcg; King) in Healthy Euthyroid Adult Volunteers|Completed||Phase 1|31|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:34:46.022874|2018-06-01 00:34:46.022874
NCT00978042|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2013-11-22||2015-09-25|2009-09-15|2009-09-16|Estimate|2014-01-06|2014-02-13|Estimate||||2015-09-25|2015-11-03|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation||Completed||N/A|345|Actual|Allergan||2|||f||||||||||||||2018-06-01 00:34:46.11347|2018-06-01 00:34:46.11347
NCT00978029|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2014-04-25|2010-04-13|2017-01-18|2009-09-15|2009-09-16|Estimate|2014-04-25|2014-05-23|Estimate|2010-04-13|2010-04-15|Estimate|2017-01-18|2017-03-03|Actual|November 2009||2009-11-30|January 2017|2017-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)|A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)|Completed||Phase 2|203|Actual|ALK-Abelló A/S||3|||f||||f||||||||||2018-06-01 00:34:46.37752|2018-06-01 00:34:46.37752
NCT00978016|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11||2012-01-25|2015-12-30|2009-09-15|2009-09-16|Estimate||||2012-01-27|2012-01-31|Estimate|2015-12-30|2016-02-02|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)|A Dose-Response Efficacy and Safety Study of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) Who Are Incomplete Responders to a Proton Pump Inhibitor (PPI)|Completed||Phase 2|460|Actual|Indivior Inc.||5|||f||||f||||||||||2018-06-01 00:34:46.675843|2018-06-01 00:34:46.675843
NCT00978003|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2018-05-10|2009-09-15|2009-09-16|Estimate|||||||2018-05-10|2018-05-11|Actual|August 26, 2009||2009-08-26|October 10, 2017|2017-10-10||||||||Observational|||Vasti Control of Patellofemoral Kinematics in Asymptomatic Volunteer|Vasti Control of Patellofemoral Kinematics in Asymptomatic Volunteers|Completed|||28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:34:46.956158|2018-06-01 00:34:46.956158
NCT00977990|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2017-06-30|2009-09-15|2009-09-16|Estimate|||||||2017-06-30|2017-07-02|Actual|August 25, 2009||2009-08-25|May 19, 2010|2010-05-19|May 19, 2010||2010-05-19|||||Observational|||Amplification of Merkel Cell Polyomavirus From Skin Swabs|Amplification of Merkel Cell Polyomavirus From Skin Swab Specimens|Completed|||30|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:34:47.031617|2018-06-01 00:34:47.031617
NCT00977977|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2018-03-27|2009-09-15|2009-09-16|Estimate|||||||2018-03-27|2018-03-29|Actual|September 1, 2009||2009-09-01|February 22, 2018|2018-02-22|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy|Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy|Recruiting||Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:34:47.105688|2018-06-01 00:34:47.105688
NCT00977951|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2009-09-15|2009-09-15|2009-09-16|Estimate|||||||2009-09-15|2009-09-16|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects|A Single Centre, Double-blind, Methodology Trial to Investigate the Genomic Changes Associated With Accelerated Healing and Reduced Scarring of Small Wounds Using RN1001 in Healthy Male Subjects|Completed||Phase 1/Phase 2|20|Actual|Renovo||2|||f||||f||||||||||2018-06-01 00:34:47.361665|2018-06-01 00:34:47.361665
NCT00977938|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2015-09-18||2017-05-10|2009-09-15|2009-09-16|Estimate|2015-09-18|2015-10-22|Estimate||||2017-05-10|2017-06-09|Actual|October 2009||2009-10-31|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Dual Antiplatelet Therapy Study (DAPT Study)|A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions|Completed||Phase 4|25682|Actual|Baim Institute for Clinical Research||2|||f||||t||||||||||2018-06-01 00:34:47.625364|2018-06-01 00:34:47.625364
NCT00977925|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2015-09-30|2009-09-15|2009-09-16|Estimate|||||||2015-09-30|2015-10-01|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||The Severe Soft Tissue Bleeding Study|A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Severe Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery|Completed||Phase 3|91|Actual|Ethicon, Inc.||2|||f||||t||||||||||2018-06-01 00:34:53.14763|2018-06-01 00:34:53.14763
NCT00977912|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2013-11-22|2009-09-15|2009-09-16|Estimate|||||||2013-11-22|2013-11-25|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Necrotizing Enterocolitis (Nec) and B. Lactis in Premature Babies|Prevention of NEC in Preterm Infants With B. Lactis|Terminated||N/A|318|Actual|Nestlé||2|||f||||f||||||||||2018-06-01 00:34:53.241634|2018-06-01 00:34:53.241634
NCT00977899|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2017-10-05|2009-09-15|2009-09-16|Estimate|||||||2017-10-05|2017-10-06|Actual|August 20, 2009||2009-08-20|March 5, 2013|2013-03-05|March 5, 2013|Actual|2013-03-05|March 5, 2013|Actual|2013-03-05||Interventional|||Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:34:53.316481|2018-06-01 00:34:53.316481
NCT00977886|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-11-15|2009-09-15|2009-09-16|Estimate|||||||2010-11-15|2010-11-16|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Pharmacokinetics of ELB353 in Healthy Men|A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Oral ELB353 in Healthy Male Volunteers - A Double-Blind, Randomized, Placebo-controlled, Sequential Group Study|Completed||Phase 1|48|Actual|Biotie Therapies Corp.||2|||f||||f||||||||||2018-06-01 00:34:53.375854|2018-06-01 00:34:53.375854
NCT00977873|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2014-02-03|2009-09-15|2009-09-16|Estimate|||||||2014-02-03|2014-02-04|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ViDiCO||Trial of Vitamin D Supplementation in Chronic Obstructive Pulmonary Disease|Randomised, Multi-Centre, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2/Phase 3|240|Actual|Barts & The London NHS Trust||2|||f||||t||||||||||2018-06-01 00:34:53.431681|2018-06-01 00:34:53.431681
NCT00977860|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2018-01-25|2009-09-15|2009-09-16|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2010||2010-10-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Hypofractionated SBRT For Prostate Cancer|Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer|Recruiting||Phase 2|111|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 00:34:53.637845|2018-06-01 00:34:53.637845
NCT00977847|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2012-03-17|2009-09-15|2009-09-16|Estimate|||||||2012-03-17|2012-03-20|Estimate|November 2010||2010-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Integrating Patient Generated Family Health History From Varied Electronic Health Record (EHR) Entry Portals|Integrating Patient Generated Family Health History From Varied Electronic Health Record Entry Portals|Completed||N/A|5000|Anticipated|Brigham and Women's Hospital||4|||f||||f||||||||||2018-06-01 00:34:53.770071|2018-06-01 00:34:53.770071
NCT00977834|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2011-09-19|2009-09-15|2009-09-16|Estimate|||||||2011-09-19|2011-09-21|Estimate|July 2009||2009-07-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Assessment of Older Adults With Cancer: Feasibility of Computer Survey Methodology|Assessment of Older Adults With Cancer: Feasibility of Computer Survey Methodology|Completed|||200|Anticipated|City of Hope Medical Center|||2||f||||t||||||||||2018-06-01 00:34:53.852812|2018-06-01 00:34:53.852812
NCT00977821|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2015-04-21|2009-09-15|2009-09-16|Estimate|||||||2015-04-21|2015-04-22|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Embryo Developmental Capacity After Egg Banking in an Ovum Donation Program||Completed||Phase 4|625|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 00:34:54.025438|2018-06-01 00:34:54.025438
NCT00977808|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2011-09-12||2014-08-25|2009-09-15|2009-09-16|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-25|2014-09-04|Estimate|May 2008||2008-05-31|August 2014|2014-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004)|Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes(BPK004)|Completed||N/A|12|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 00:34:54.135071|2018-06-01 00:34:54.135071
NCT00977795|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2013-08-16|2009-09-15|2009-09-16|Estimate|||||||2013-08-16|2013-08-19|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors|A Phase 1 and 2 Study of 5-aminolevulinic Acid (5-ALA) to Enhance Visualisation and Resection of Malignant Glial Tumors of the Brain|Withdrawn||Phase 1/Phase 2|0|Actual|NorthShore University HealthSystem Research Institute||1||PI moving to Southern Illinois University to start new protocol|f||||t||||||||||2018-06-01 00:34:54.364602|2018-06-01 00:34:54.364602
NCT00977769|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2013-04-24||2014-04-04|2009-09-15|2009-09-16|Estimate|2014-04-04|2014-05-06|Estimate||||2014-04-04|2014-05-06|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Carbetocin Versus Oxytocin and Hemodynamic Effects|Hemodynamic Effects of Carbetocin 100 µg, Oxytocin 5 U or Placebo After Cesarean Delivery Under Spinal Anesthesia in Healthy Pregnant Women.|Completed||Phase 4|76|Actual|Oslo University Hospital||3|||f||||f||||||||||2018-06-01 00:34:54.438374|2018-06-01 00:34:54.438374
NCT00977756|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2015-08-05|2009-09-15|2009-09-16|Estimate|||||||2015-08-05|2015-08-07|Estimate|August 2002||2002-08-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults|IMPAACT P1058A: Intensive Pharmacokinetic Studies of New Classes of Antiretroviral Drug Combinations in Children, Adolescents and Young Adults|Completed|||168|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||11||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 00:34:54.784421|2018-06-01 00:34:54.784421
NCT00977730|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-02-01|2009-09-15|2009-09-16|Estimate|||||||2013-02-01|2013-02-05|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|NASH||The Effect of Protandim on Non-alcoholic Steatohepatitis|The Effect of the Dietary Supplement Protandim on Non-Alcoholic Steatohepatitis: A Randomized, Double Blind, Placebo-Controlled Study|Completed||N/A|70|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 00:34:55.051669|2018-06-01 00:34:55.051669
NCT00977717|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2010-04-15|2009-09-14|2009-09-16|Estimate|||||||2010-04-15|2010-04-19|Estimate|September 2008||2008-09-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Observational|||Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin|Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy|Completed|||100|Anticipated|Samsung Medical Center|||1||f||||f||||||Samples With DNA|"~     DNA will be extracted from peripheral blood samples using DNA isolation kit.~   "|||2018-06-01 00:34:55.1373|2018-06-01 00:34:55.1373
NCT00977704|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2011-12-22||2013-05-07|2009-09-15|2009-09-16|Estimate|2013-05-07|2013-06-10|Estimate||||2013-05-07|2013-06-10|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Study of Restylane and Perlane in the Correction of Peri-Oral Wrinkles|An Open-label Study of the Safety of Restylane and Perlane in the Correction of Peri-oral Wrinkles.|Completed||Phase 4|20|Actual|Medicis Global Service Corporation||1|||f||||f||||||||||2018-06-01 00:34:55.201925|2018-06-01 00:34:55.201925
NCT00977691|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2018-05-22|2009-09-15|2009-09-16|Estimate|||||||2018-05-22|2018-05-23|Actual|September 9, 2009||2009-09-09|May 7, 2018|2018-05-07|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia|Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia|Active, not recruiting||Phase 1/Phase 2|56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:34:55.348473|2018-06-01 00:34:55.348473
NCT00977678|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-12-29|2009-09-15|2009-09-16|Estimate|||||||2009-12-29|2009-12-30|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Drop in Gastroscopy - Experience After 9 Months|Drop in Gastroscopy - Experience After 9 Months|Completed|||213|Actual|Norwegian Department of Health and Social Affairs|||2||f||||t||||||||||2018-06-01 00:34:55.423808|2018-06-01 00:34:55.423808
NCT00977665|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2015-02-10|2013-03-20|2015-02-10|2009-09-15|2009-09-16|Estimate|2015-02-10|2015-02-26|Estimate|2013-03-20|2013-03-28|Estimate|2015-02-10|2015-02-26|Estimate|December 2009||2009-12-31|February 2015|2015-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)|A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)|Completed||Phase 2|174|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 00:34:55.521613|2018-06-01 00:34:55.521613
NCT00977652|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2011-08-22|2009-09-15|2009-09-16|Estimate|||||||2011-08-22|2011-08-23|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|TENSIA||Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence|Short Term Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence:Randomized Controlled Study|Completed||Phase 2|144|Anticipated|University Hospital, Rouen||2|||f||||t||||||||||2018-06-01 00:34:56.711601|2018-06-01 00:34:56.711601
NCT00977639|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2010-03-26|2009-09-15|2009-09-16|Estimate|||||||2010-03-26|2010-03-29|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies|Evaluation of Pathwork Tissue of Origin (TOO) Test for Human Malignancies|Completed|||2|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     a tissue biopsy specimen~   "|||2018-06-01 00:34:56.941076|2018-06-01 00:34:56.941076
NCT00977626|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2012-01-20|2009-09-15|2009-09-16|Estimate|||||||2012-01-20|2012-01-23|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Multiple Ascending Doses in Young and Elderly Healthy Volunteers|Completed||Phase 1|74|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:34:57.030976|2018-06-01 00:34:57.030976
NCT00977613|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|2010-11-30||2011-03-01|2009-09-15|2009-09-16|Estimate|2011-02-24|2011-02-28|Estimate||||2011-03-01|2011-03-03|Estimate|April 2007||2007-04-30|March 2011|2011-03-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Adherence to a Recommended Exercise Regimen in Colorectal Cancer Patients|Prospective Evaluation of Adherence to Recommended Activity Regimen in Patients Following Treatment of Stages II and III Colorectal Cancer.|Completed||N/A|50|Actual|Beth Israel Medical Center|Many participants were lost to follow-up. Some participants had not been followed for at least 6 months at study termination.|1|||f||||f||||||||||2018-06-01 00:34:57.109276|2018-06-01 00:34:57.109276
NCT00977600|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2017-01-13|2009-09-15|2009-09-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2005||2005-03-31|June 2015|2015-06-30|July 2005|Actual|2005-07-31|||||Interventional|||A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)|A Randomized, Crossover, Open-label Phase 1 Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)|Completed||Phase 1|24|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||4|||||||f||||||||||2018-06-01 00:34:57.324464|2018-06-01 00:34:57.324464
NCT00977587|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-15|||2017-06-16|2009-09-15|2009-09-16|Estimate|||||||2017-06-16|2017-06-20|Actual|January 2011||2011-01-31|January 2012|2012-01-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Interventional|||Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction|Effect of Saccharomyces Cerevisiae CNCM I-3856 on Faecal Proteases and Symptoms Associated With IBS-D and Postinfective Bowel Dysfunction|Withdrawn||N/A|0|Actual|University of Nottingham||2||unable to get MHRA approval for formulation in present form|f||||f||||||||||2018-06-01 00:34:57.38991|2018-06-01 00:34:57.38991
NCT00977574|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-12|2017-10-20||2018-01-29|2009-09-12|2009-09-15|Estimate|2018-01-29|2018-02-27|Actual||||2018-01-29|2018-02-27|Actual|September 2009||2009-09-30|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|January 2017|Actual|2017-01-31||Interventional||All enrolled patients|Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer|Active, not recruiting||Phase 2|349|Actual|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-06-01 00:34:57.653279|2018-06-01 00:34:57.653279
NCT00977561|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2013-01-18|2012-05-08|2013-01-18|2009-09-14|2009-09-15|Estimate|2013-01-18|2013-02-25|Estimate|2012-05-08|2012-05-10|Estimate|2013-01-18|2013-02-25|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer|A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer|Terminated||Phase 2|9|Actual|Pfizer|The study was terminated prematurely due to low participants enrollment and the halting of the figitumumab development program. The only endpoint analyzed was safety and tolerability of figitumumab ± cisplatin (or carboplatin) and etoposide.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:35:01.894766|2018-06-01 00:35:01.894766
NCT00977548|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2013-06-26||2013-09-13|2009-09-14|2009-09-15|Estimate|2013-09-13|2013-09-16|Estimate||||2013-09-13|2013-09-16|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||4 of the initial 39 patients were found to be ineligible after signing informed consent.|Erlotinib Study for Myelodysplastic Syndrome (MDS)|Phase II Study Evaluating the Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome|Completed||Phase 2|39|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 00:35:02.525717|2018-06-01 00:35:02.525717
NCT00977522|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14||2012-01-26|2012-02-02|2009-09-14|2009-09-15|Estimate||||2012-02-02|2012-02-07|Estimate|2012-02-02|2012-02-07|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia|A Randomized Phase 2, Double-Blind, Placebo-Controlled, Multi-Center Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia Treated With A Stable Dose Of A Second Generation Antipsychotic|Terminated||Phase 2|207|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:35:02.913487|2018-06-01 00:35:02.913487
NCT00977509|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2013-11-29|2009-09-14|2009-09-15|Estimate|||||||2013-11-29|2013-12-02|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Gene Mutations in Non-Small Cell Lung Cancer Cells|Detection of Gene Mutations in Non-small Cell Lung Cancer Cells in Blood Samples or Fine-needle Aspiration|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     blood, pleural fluid, and biopsy.~   "|||2018-06-01 00:35:03.059129|2018-06-01 00:35:03.059129
NCT00977496|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2015-03-17|2009-09-14|2009-09-15|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2011||2011-05-31|March 2015|2015-03-31||||||||Observational|||Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S. Aureus|Development of a Probiotic Strategy to Prevent or Eliminate Nasal Colonization With S Aureus|Withdrawn|||0|Actual|Tufts Medical Center|||1||f||||f||||||||||2018-06-01 00:35:03.132256|2018-06-01 00:35:03.132256
NCT00977483|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2016-11-29|2009-09-14|2009-09-15|Estimate|||||||2016-11-29|2016-11-30|Estimate|May 1998||1998-05-31|November 2016|2016-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|NATHAN1||Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)|Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups|Completed||Phase 3|460|Actual|MEDA Pharma GmbH & Co. KG||2|||||||t||||||||||2018-06-01 00:35:03.208234|2018-06-01 00:35:03.208234
NCT00977470|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2017-03-22||2017-05-09|2009-09-14|2009-09-15|Estimate|2017-05-09|2017-06-06|Actual||||2017-05-09|2017-06-06|Actual|October 2009||2009-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|May 2015|Actual|2015-05-31||Interventional|||Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations|Phase II Study of Erlotinib With or Without Hydroxychloroquine in Patients With Previously Untreated Advanced NSCLC and EGFR Mutations|Active, not recruiting||Phase 2|76|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-06-01 00:35:03.36355|2018-06-01 00:35:03.36355
NCT00977457|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-12|||2018-04-13|2009-09-12|2009-09-15|Estimate|||||||2018-04-13|2018-04-17|Actual|November 26, 2007||2007-11-26|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery|Pre-Surgical EPS Biomarkers as Predictors of Biochemical Recurrence|Active, not recruiting||Phase 1|1200|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 00:35:04.092398|2018-06-01 00:35:04.092398
NCT00977444|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2010-01-19|2009-09-14|2009-09-15|Estimate|||||||2010-01-19|2010-01-20|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|October 2009|Anticipated|2009-10-31|February 2009|Anticipated|2009-02-28||Interventional|EFO||Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment|Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment|Unknown status|Active, not recruiting|Phase 2/Phase 3|114|Actual|Nucitec||3|||f||||t||||||||||2018-06-01 00:35:04.190368|2018-06-01 00:35:04.190368
NCT00977431|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2017-09-15|2009-09-14|2009-09-15|Estimate|||||||2017-09-15|2017-09-18|Actual|September 17, 2009|Actual|2009-09-17|September 2017|2017-09-30|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform|Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:35:04.278617|2018-06-01 00:35:04.278617
NCT00977418|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2016-07-06|2009-09-14|2009-09-15|Estimate|||||||2016-07-06|2016-07-11|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Brain and Cognitive Changes After Reasoning or Physical Training in Cognitively Normal Seniors|Brain & Cognitive Changes After Reasoning or Physical Training in Cognitively Normal Seniors|Completed||N/A|60|Actual|The University of Texas at Dallas||2|||f||||t||||||||||2018-06-01 00:35:04.368807|2018-06-01 00:35:04.368807
NCT00977405|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2018-04-19|2009-09-14|2009-09-15|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2009||2009-09-30|April 2018|2018-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Collagen-Gentamicin Implant in the Treatment of Contaminated Surgical Abdominal Wounds|Collagen-Gentamicin Implant in the Treatment of Contaminated Surgical Abdominal Wounds - A Randomized Controlled Trial|Terminated||Phase 2|70|Anticipated|Singapore General Hospital||2|||f||||t||||||||||2018-06-01 00:35:04.577874|2018-06-01 00:35:04.577874
NCT00977392|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-12|||2013-08-06|2009-09-12|2009-09-15|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|March 2011|Actual|2011-03-31|February 2010|Actual|2010-02-28||Observational|||Self-Sampling in Women Who Do Not Undergo Routine Cervical Screening|The Potential Role of Self-sampling in Women Who do Not Attend for Cervical Screening - a Randomised Controlled Trial|Completed|||3000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:35:04.656802|2018-06-01 00:35:04.656802
NCT00977379|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2016-09-26||2016-09-26|2009-09-14|2009-09-15|Estimate|2016-09-26|2016-11-15|Estimate||||2016-09-26|2016-11-15|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|XERAD|Intent to treat (ITT) population included all randomized participants except one participant from “WBRT+Capecitabine Followed by Capecitabine Maintenance” arm who was randomized by error.|A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis|XERAD: Open-Label, Phase II, Randomized, Comparative, Multicentre Trial of Concurrent Whole Brain Radiation Therapy (WBRT) and Capecitabine (Xeloda®) Followed by Maintenance Capecitabine Compared With Standard WBRT in Breast Cancer Patients With Newly Diagnosed Brain Metastasis|Terminated||Phase 2|24|Actual|Hoffmann-La Roche|Study was prematurely terminated due to an insufficient number of participants enrolled and therefore results are only based on a small sample of breast cancer participants with newly diagnosed brain metastasis and should be considered with caution.|2||Due to an insufficient number of participants enrolled.|f||||||||||||||2018-06-01 00:35:04.771462|2018-06-01 00:35:04.771462
NCT00977366|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-06-17|2009-09-14|2009-09-15|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|NOTCH||Neurophysiology of Cough Reflex Hypersensitivity|Pilot Study Investigating Central Sensitisation of the Cough Reflex in Subjects With Chronic Cough and Healthy Volunteers|Completed||N/A|27|Actual|University of Manchester||2|||f||||f||||||||||2018-06-01 00:35:05.409662|2018-06-01 00:35:05.409662
NCT00977353|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2011-07-10|2009-09-14|2009-09-15|Estimate|||||||2011-07-10|2011-07-12|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||N-methylglycine (Sarcosine) Treatment for Depression|N-methylglycine (Sarcosine) for Treatment of Major Depressive Disorder|Completed||Phase 2|40|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-06-01 00:35:05.499537|2018-06-01 00:35:05.499537
NCT00977340|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2016-04-27|2009-09-14|2009-09-15|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2009||2009-10-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study on the Psychotherapeutic Treatment of Chronic Nightmares|Psychotherapeutic Treatment of Chronic Nightmares: Differential Efficacy of Imagery Rehearsal Therapy Compared to Confrontation and Psychotherapeutic Placebo|Recruiting||N/A|90|Anticipated|Goethe University||3|||f||||f||||||||No||2018-06-01 00:35:05.597642|2018-06-01 00:35:05.597642
NCT00977327|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-30|||2009-09-14|2009-09-14|2009-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|September 2009||2009-09-30|September 2009|2009-09-30||||May 2011|Anticipated|2011-05-31||Interventional|||Comparison of Neuro-navigational Systems for Resection-Control of Brain Tumors|Comparison of Two Neuro-navigational Systems for Resection-control of Intra-axial Brain Tumors. The PoleStarN-20 Intra-operative Magnet Resonance Imager and the Mison SonoWand Intra-operative Ultrasound System|Unknown status|Not yet recruiting|N/A|120|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:35:05.723194|2018-06-01 00:35:05.723194
NCT00977314|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2013-06-04||2014-10-10|2009-09-14|2009-09-15|Estimate|2014-10-10|2014-10-17|Estimate||||2014-10-10|2014-10-17|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||35 subjects were enrolled in this study.Per protocol,the first 5 subjects enrolled were the pilot phase of the study. Data obtained from the first 5 subjects were excluded from analyses.An approximated 20% subject dropout rate anticipated, 30 subjects were enrolled with 24 subjects expected complete.|Bone Conduction Auditory Performance Via the Tooth for Single-Sided Deafness|Bone Conduction Auditory Performance Via the Tooth for Single-Sided Deafness|Completed||N/A|35|Actual|Sonitus Medical Inc||1|||f||||t||||||||||2018-06-01 00:35:05.876589|2018-06-01 00:35:05.876589
NCT00977301|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2011-01-07|2009-09-14|2009-09-15|Estimate|||||||2011-01-07|2011-01-10|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|FORZA||Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)|The Effect of FOsamprenavir/Ritonavir on the Pharmacokinetics of a Single-dose of the Antipsychotic Agent olanZApine (FORZA)|Completed||Phase 1|24|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 00:35:06.191631|2018-06-01 00:35:06.191631
NCT00977288|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2015-05-05|2009-09-14|2009-09-15|Estimate|||||||2015-05-05|2015-05-06|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|March 2010|Actual|2010-03-31||Interventional|||A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)|A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia|Completed||Phase 2|408|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-06-01 00:35:06.290914|2018-06-01 00:35:06.290914
NCT00977275|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-04-07|2009-09-11|2009-09-15|Estimate|||||||2017-04-07|2017-04-11|Actual|June 1997||1997-06-30|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2006|Actual|2006-05-31||Interventional|||Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant|The Treatment of T1N0 Invasive Breast Carcinoma by Local Excision and Interstitial Implant|Completed||Phase 1/Phase 2|45|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 00:35:06.399452|2018-06-01 00:35:06.399452
NCT00977262|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2010-04-20|2009-09-14|2009-09-15|Estimate|||||||2010-04-20|2010-04-21|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|PIFA||Postprandial Inflammation and Fatty Acids|Effects of Fatty Acids on Postprandial Inflammatory Response of Healthy Obese and Type 2 Diabetic Obese Subjects|Completed||N/A|42|Actual|Wageningen University||9|||f||||f||||||||||2018-06-01 00:35:06.466278|2018-06-01 00:35:06.466278
NCT00977249|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2009-09-14|2009-09-14|2009-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users|Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-06-01 00:35:06.547704|2018-06-01 00:35:06.547704
NCT00977236|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2013-07-11|2009-09-14|2009-09-15|Estimate|||||||2013-07-11|2013-07-12|Estimate|July 2008||2008-07-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|HM-PRO||Myopic Control for High Myopes Using Orthokeratology|High Myopia - Partial Reduction Orthokeratology Study|Completed||N/A|52|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-06-01 00:35:06.633894|2018-06-01 00:35:06.633894
NCT00977223|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2012-02-14|2009-09-14|2009-09-15|Estimate|||||||2012-02-14|2012-02-16|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|APHOS||Effects of Substance P Antagonists on Adrenal Secretion|Pilot Study of the Action of the Substance P Antagonist Aprepitant on Aldosterone and Cortisol Secretion in Healthy Volunteers.|Completed||Phase 4|20|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-06-01 00:35:06.713636|2018-06-01 00:35:06.713636
NCT00977210|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2011-10-28|2009-09-14|2009-09-15|Estimate|||||||2011-10-28|2011-10-31|Estimate|July 2005||2005-07-31|October 2011|2011-10-31||||September 2010|Actual|2010-09-30||Interventional|||Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors|A Phase I Trial of OXi4503 (a Vascular Disrupting Agent) Given by 3 Weekly Intravenous Infusions to Patients With Advanced Solid Tumors.|Completed||Phase 1|40|Anticipated|Mateon Therapeutics||1|||f||||f||||||||||2018-06-01 00:35:06.7889|2018-06-01 00:35:06.7889
NCT00977197|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2016-06-06||2016-09-26|2009-09-14|2009-09-15|Estimate|2016-06-06|2016-07-14|Estimate||||2016-09-26|2016-10-28|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome|A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome|Completed||Phase 2|85|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-06-01 00:35:06.868952|2018-06-01 00:35:06.868952
NCT00977184|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-12|2012-08-31||2012-11-22|2009-09-12|2009-09-15|Estimate|2012-11-22|2012-12-27|Estimate||||2012-11-22|2012-12-27|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease|Controlled Study of 50 Hz Repetitive Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease|Completed||Phase 1/Phase 2|26|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 00:35:07.523745|2018-06-01 00:35:07.523745
NCT00977171|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2014-04-24||2014-05-21|2009-09-14|2009-09-15|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CFS201|3 patients enrolled in the study before it was stopped for difficulty recruiting subjects|Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome|An Open-Label Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome|Terminated||Phase 2|3|Actual|Chelsea Therapeutics||1||Enrollment issues.|f||||f||||||||||2018-06-01 00:35:07.979881|2018-06-01 00:35:07.979881
NCT00977158|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2015-03-17|2009-09-14|2009-09-15|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2011||2011-05-31|March 2015|2015-03-31||||||||Observational|||Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life|Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life|Withdrawn|||0|Actual|Tufts Medical Center|||1|No problems with planned study- insufficient funding for this study to proceed.|f||||f||||||||||2018-06-01 00:35:08.167994|2018-06-01 00:35:08.167994
NCT00977145|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2016-12-15|2009-09-14|2009-09-15|Estimate|||||||2016-12-15|2016-12-16|Estimate|November 2009||2009-11-30|December 2016|2016-12-31||||October 2012|Actual|2012-10-31||Interventional|Mel 51||Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma|Evaluation of the Safety and Immunogenicity of Intratumoral Injection of Interferon Gamma During Vaccination in Patients With Subcutaneous or Cutaneous Metastases of Melanoma|Terminated||Phase 1|11|Actual|University of Virginia||1||"Closed short of the enrollment goal, due to slow enrollment and adequate data to address~   endpoints"|f||||t||||||||||2018-06-01 00:35:08.232967|2018-06-01 00:35:08.232967
NCT00977132|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2015-03-17|2009-09-14|2009-09-15|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|VALENA||Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome|Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile|Terminated||Phase 2|23|Actual|Heinrich-Heine University, Duesseldorf||1||delayed recruitment|f||||t||||||||||2018-06-01 00:35:08.30318|2018-06-01 00:35:08.30318
NCT00977119|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2018-03-07|2009-09-14|2009-09-15|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2009||2009-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 31, 2015|Actual|2015-05-31||Observational|||Investigation of Genetic Determinants of Capecitabine Toxicity|Investigation of Genetic Determinants of Capecitabine Toxicity|Active, not recruiting|||240|Actual|University of Chicago|||1||f||||f||||||Samples With DNA|"~     Blood (including DNA)~   "|||2018-06-01 00:35:08.386946|2018-06-01 00:35:08.386946
NCT00977106|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2014-06-26||2014-09-15|2009-09-14|2009-09-15|Estimate|2014-09-15|2014-09-22|Estimate||||2014-09-15|2014-09-22|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Intent-to-treat (ITT) population: all randomized participants who received at least 1 treatment infusion (completed or not). Three participants were randomized to the Placebo treatment group but received tocilizumab.|TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF|Comparative Double Blind Placebo Controlled Clinical Study on Tocilizumab Rapid Efficacy on Patients Relief in rheumatoïd Arthritis With an Inadequate Response to DMARDs or Anti TNF :TORPEDO|Completed||Phase 3|103|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:35:09.744823|2018-06-01 00:35:09.744823
NCT00977093|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2009-09-14|2009-09-14|2009-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|July 2003||2003-07-31|September 2009|2009-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|MR-IMPACT-II||A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging|A Multicenter, Phase III, Open-label Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging|Completed||Phase 3|533|Actual|Amersham Buchler, GmbH & Co KG||1|||f||||f||||||||||2018-06-01 00:35:11.517331|2018-06-01 00:35:11.517331
NCT00976768|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2014-01-13|2009-09-11|2009-09-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|October 2004||2004-10-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin|A Phase II Study of Biweekly Oxaliplatin and 5-Fluorouracil/Leucovorin Combination Chemotherapy (FOLFIRI) in Patients With Advanced Gastric Cancer (AGC) With Failure of Prior Chemotherapy Including Taxane, Fluoropyrimidine and Cisplatinum|Completed||Phase 2|44|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 00:35:29.637371|2018-06-01 00:35:29.637371
NCT00977080|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2012-05-18||2012-05-18|2009-09-14|2009-09-15|Estimate|2012-05-18|2012-06-20|Estimate||||2012-05-18|2012-06-20|Estimate|November 2009||2009-11-30|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|IMPACT SHPT||Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D|The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism|Completed||Phase 4|272|Actual|Abbott|Using a fixed dosing algorithm based on biochemical criteria may affect interpretation of the results. In the future, the risk/benefit profile of these interventions should be assessed by longer-term clinical outcomes.|4|||f||||f||||||||||2018-06-01 00:35:11.722171|2018-06-01 00:35:11.722171
NCT00977067|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-12|||2017-06-20|2009-09-14|2009-09-15|Estimate|||||||2017-06-20|2017-06-21|Actual|June 2007|Actual|2007-06-30|June 2017|2017-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies|A Phase Ia, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0152, an IAP Protein Antagonist, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies|Terminated||Phase 1|40|Actual|Genentech, Inc.||1||"The study was terminated early by the Sponsor for reasons unrelated to patient safety or~   anti-tumor activity."|f||||||||||||||2018-06-01 00:35:13.742172|2018-06-01 00:35:13.742172
NCT00977054|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-13|||2012-12-19|2009-09-14|2009-09-15|Estimate|||||||2012-12-19|2012-12-20|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load|Double Filtration Plasmapheresis (DFPP) in Combination With Pegylated Interferon Alfa-2a and Ribavirin for Patients With Chronic Hepatitis C With Genotype 1 and High Viral Load: a Randomized Controlled Trial|Terminated||Phase 4|59|Actual|National Taiwan University Hospital||2||Novel HCV DAA approved by FDA|f||||f||||||||||2018-06-01 00:35:13.856659|2018-06-01 00:35:13.856659
NCT00977041|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2013-06-04|2009-09-11|2009-09-15|Estimate|||||||2013-06-04|2013-06-06|Estimate|August 2010||2010-08-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Neurofeedback Treatment of Pain in Persons With Spinal Cord Injury (SCI)|Neurofeedback Treatment of Pain in Persons With SCI: Phase 2|Completed||Phase 2|13|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 00:35:14.242061|2018-06-01 00:35:14.242061
NCT00977028|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-12|||2011-06-14|2009-09-14|2009-09-15|Estimate|||||||2011-06-14|2011-06-16|Estimate|January 2005||2005-01-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|TLA||Tumescent Lidocaine Maximum Safe mg/kg Dosage|Tumescent Lidocaine Bioavailability and Absorption Kinetics:Maximum Safe mg/kg Lidocaine Dosage|Unknown status|Enrolling by invitation|Phase 1/Phase 2|14|Actual|Klein, Jeffrey A., M.D.||2|||f||||f||||||||||2018-06-01 00:35:14.326954|2018-06-01 00:35:14.326954
NCT00977015|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2010-02-09|2009-09-14|2009-09-15|Estimate|||||||2010-02-09|2010-02-11|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers.|Completed||Phase 1|36|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:35:14.508051|2018-06-01 00:35:14.508051
NCT00977002|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2011-02-01|2009-09-14|2009-09-15|Estimate|||||||2011-02-01|2011-02-02|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation|Prevention of Reintubation by Using Noninvasive Positive Pressure Ventilation: Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|100|Anticipated|UPECLIN HC FM Botucatu Unesp||2|||f||||f||||||||||2018-06-01 00:35:14.73814|2018-06-01 00:35:14.73814
NCT00976989|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2016-03-28||2016-12-12|2009-09-14|2009-09-15|Estimate|2016-05-11|2016-06-20|Estimate||||2016-12-12|2017-02-06|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|June 2011|Actual|2011-06-30||Interventional||Safety population included all participants who were randomized and received study drug.|A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer|A Randomised, Multicentre, Multinational Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab, Given Either Concomitantly or Sequentially With Standard Anthracycline-based Chemotherapy or Concomitantly With a Non-anthracycline-based Chemotherapy Regimen, as Neoadjuvant Therapy for Patients With Locally Advanced, Inflammatory or Early Stage HER2-positive Breast Cancer|Completed||Phase 2|225|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:35:14.96888|2018-06-01 00:35:14.96888
NCT00976976|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2014-01-13|2009-09-14|2009-09-15|Estimate|||||||2014-01-13|2014-01-14|Estimate|May 2007||2007-05-31|January 2014|2014-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Adjuvant DXP||Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer|Phase 2 Study of Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer|Completed||Phase 2|46|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 00:35:16.138071|2018-06-01 00:35:16.138071
NCT00976963|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-11-15|2009-09-14|2009-09-15|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2009||2009-09-30|November 2017|2017-11-30|May 30, 2018|Anticipated|2018-05-30|June 2017|Actual|2017-06-30||Interventional|||Single Dose Monurol for Treatment of Acute Cystitis|Single Dose Monurol for Treatment of Acute Cystitis|Active, not recruiting||N/A|300|Actual|University of Washington||2|||f||||f||||||||Undecided||2018-06-01 00:35:16.217109|2018-06-01 00:35:16.217109
NCT00976950|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2012-05-30||2014-02-24|2009-09-14|2009-09-15|Estimate|2012-07-09|2012-08-16|Estimate||||2014-02-24|2014-03-20|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.|A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.|Completed|||42|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 00:35:16.314112|2018-06-01 00:35:16.314112
NCT00976755|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2018-02-09|2009-09-11|2009-09-14|Estimate|||||||2018-02-09|2018-02-12|Actual|September 14, 2009|Actual|2009-09-14|February 2018|2018-02-28|December 31, 2031|Anticipated|2031-12-31|November 29, 2012|Actual|2012-11-29||Interventional|||Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer|Everolimus First-line Therapy in Non-rapidly Progressive Castration Resistant Prostate Cancer (CRPC). A Multicenter Phase II Trial.|Active, not recruiting||Phase 2|37|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-06-01 00:35:29.728792|2018-06-01 00:35:29.728792
NCT00976937|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2016-08-18|2012-05-07|2016-08-18|2009-09-14|2009-09-15|Estimate|2016-08-18|2016-10-11|Estimate|2012-05-07|2012-05-08|Estimate|2016-08-18|2016-10-11|Estimate|August 2009||2009-08-31|August 2016|2016-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years|A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin|Completed||Phase 3|319|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:35:16.630926|2018-06-01 00:35:16.630926
NCT00976924|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-14|2009-09-14|2009-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Clinical Test of Blood Glucose Test Strips|Clinical Test of Blood Glucose Test Strips|Completed||N/A|200|Actual|Andon Medical Co.,Ltd||2|||f||||f||||||||||2018-06-01 00:35:17.608947|2018-06-01 00:35:17.608947
NCT00976911|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|2014-12-03||2015-02-24|2009-09-14|2009-09-15|Estimate|2015-02-24|2015-02-25|Estimate||||2015-02-24|2015-02-25|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All randomized participants|AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer|AURELIA: A Multi-center, Open-label, Randomised, Two-arm Phase III Trial of the Effect on Progression Free Survival of Bevacizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 3|361|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:35:17.728352|2018-06-01 00:35:17.728352
NCT00976898|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2017-12-07||2018-01-05|2009-09-14|2009-09-15|Estimate|2018-01-05|2018-01-31|Actual||||2018-01-05|2018-01-31|Actual|August 2009||2009-08-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2017|Actual|2017-03-31||Interventional|||Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma|Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma|Active, not recruiting||N/A|83|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:35:18.512455|2018-06-01 00:35:18.512455
NCT00976885|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2009-09-14|2009-09-14|2009-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate||||September 2009|2009-09-30||||||||Observational|||Oxygen Consumption Required by Stroke Patients During Completion of the Modified Rivermead Mobility Index (MRMI)||Completed|||||The Hong Kong Polytechnic University|||2||f||||||||||||||2018-06-01 00:35:18.940753|2018-06-01 00:35:18.940753
NCT00976872|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-13|||2010-06-07|2009-09-14|2009-09-15|Estimate|||||||2010-06-07|2010-06-08|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins|Supplementation of Omega-3 Fatty Acid Complex to Routine Statin Treatment Decreases Patients' Day-time Blood Pressure, Improves Inflammatory Status and Prohibits Platelet Aggregation|Completed||N/A|52|Actual|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 00:35:18.999895|2018-06-01 00:35:18.999895
NCT00976859|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-14|||2012-05-15|2009-09-14|2009-09-15|Estimate|||||||2012-05-15|2012-05-16|Estimate|June 2010||2010-06-30|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Cognitive Restructuring and Imagery Modification to Reduce the Feeling of Being Contaminated After Childhood Sexual Abuse|Efficacy of a Two-session Treatment of Cognitive Restructuring and Imagery Modification (CRIM) to Reduce the Feeling of Being Contaminated (FBC) in Adult Survivors of Childhood Sexual Abuse|Completed||N/A|28|Actual|Goethe University||2|||f||||f||||||||||2018-06-01 00:35:19.085766|2018-06-01 00:35:19.085766
NCT00976846|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-14|2009-09-14|2009-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Investigation of Performance and Compatibility of the Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration|Clinical Study Investigating the Performance and Compatibility Characteristics of the Baxter Hollow Fiber Dialyzer Xenium XPH 210 During On-line Hemodiafiltration|Completed||N/A|8|Actual|Praxisverbund Dialyse und Apherese||1|||f||||f||||||||||2018-06-01 00:35:19.155525|2018-06-01 00:35:19.155525
NCT00976833|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-11-02|2009-09-11|2009-09-14|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2009||2009-10-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|||Standardized Rehabilitation for Intensive Care Unit (ICU) Patients With Acute Respiratory Failure|Standardized Rehabilitation for ICU Patients With Acute Respiratory Failure|Completed||N/A|300|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-06-01 00:35:19.229989|2018-06-01 00:35:19.229989
NCT00976820|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2017-07-31|2010-12-23|2017-11-10|2009-09-11|2009-09-14|Estimate|2017-11-10|2017-12-12|Actual|2010-12-23|2010-12-30|Estimate|2017-11-10|2017-12-12|Actual|October 20, 2009|Actual|2009-10-20|July 2017|2017-07-31|March 21, 2011|Actual|2011-03-21|March 21, 2011|Actual|2011-03-21||Interventional|||Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age|A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age|Completed||Phase 2|323|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:35:19.95359|2018-06-01 00:35:19.95359
NCT00976807|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2015-01-05|2009-09-11|2009-09-14|Estimate|||||||2015-01-05|2015-01-06|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Rehabilitation Following Critical Illness|A Randomised Controlled Trial of Rehabilitation Following Critical Illness: A Short Term Feasibility and Follow-Up Pilot Study|Completed||N/A|20|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:35:29.231304|2018-06-01 00:35:29.231304
NCT00976794|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-07-10|2009-09-11|2009-09-14|Estimate|||||||2013-07-10|2013-07-12|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|LICAVAL||Efficacy of Combined Treatment for Young Bipolar I Disorder|Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients|Completed||Phase 4|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:35:29.414603|2018-06-01 00:35:29.414603
NCT00976781|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-11|2009-09-11|2009-09-14|Estimate|||||||2009-09-11|2009-09-14|Estimate|August 2008||2008-08-31|September 2009|2009-09-30||||||||Observational|||Identifying the Gaps in the Diagnosis and Management of Hepatitis C|Identifying the Gaps in the Diagnosis and Management of Hepatitis C|Unknown status|Active, not recruiting||200|Anticipated|Henry Ford Health System|||||f||||f||||||||||2018-06-01 00:35:29.566712|2018-06-01 00:35:29.566712
NCT00976729|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-02-12|2009-09-11|2009-09-14|Estimate|||||||2013-02-12|2013-02-13|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||NOX-E36 First-in-Human (FIH) Study|NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects|Completed||Phase 1|72|Actual|NOXXON Pharma AG||10|||f||||f||||||||||2018-06-01 00:35:29.976953|2018-06-01 00:35:29.976953
NCT00976716|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2010-10-25||2011-04-25|2009-09-11|2009-09-14|Estimate|2011-04-25|2011-05-19|Estimate||||2011-04-25|2011-05-19|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||An Open-Label Study Of Celecoxib In Patients With Posttraumatic Pain|An Open-Label, Multicenter Study To Evaluate The Efficacy, Safety And Tolerability Of Celecoxib (YM177) In Patients With Posttraumatic Pain|Completed||Phase 3|80|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:35:30.097278|2018-06-01 00:35:30.097278
NCT00976703|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2013-02-26||2013-05-31|2009-09-11|2009-09-14|Estimate|2013-04-25|2013-06-03|Estimate||||2013-05-31|2013-06-07|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Foley Bulb Traction for Cervical Ripening|Weighted Bag Versus Inner Thigh Taping for Cervical Ripening With a Foley Catheter Prior to an Induction of Labor|Completed||N/A|197|Actual|MetroHealth Medical Center|Nine patients had minor protocol violations yet were included in the intention to treat analysis. Patients and providers were not be blinded. Our inner city, minority population at a single site may also limit the generalizability of the results.|2|||f||||f||||||||||2018-06-01 00:35:30.77377|2018-06-01 00:35:30.77377
NCT00976690|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2011-08-30|2009-09-11|2009-09-14|Estimate|||||||2011-08-30|2011-08-31|Estimate|October 2002||2002-10-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|IMURELPOST||Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease|A Multicentre Randomized Open Study Comparing Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease|Completed||Phase 3|83|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||2|||f||||f||||||||||2018-06-01 00:35:31.090843|2018-06-01 00:35:31.090843
NCT00976677|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2013-04-24||2014-05-23|2009-09-11|2009-09-14|Estimate|2013-05-28|2013-07-22|Estimate||||2014-05-23|2014-05-30|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Interventional|||Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer|Randomized Double-Blind Placebo Controlled Phase II Trial Evaluating Erlotinib in Non-Smoking Patients With (Bevacizumab-Eligible and Ineligible) Advanced Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:35:31.308707|2018-06-01 00:35:31.308707
NCT00976664|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2012-04-30||2017-03-30|2009-09-11|2009-09-14|Estimate|2014-11-13|2014-11-17|Estimate||||2017-03-30|2017-05-03|Actual|June 2009||2009-06-30|March 2017|2017-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Orthotic Use for Chronic Low Back Pain|Orthotic Use for Chronic Low Back Pain|Completed||N/A|50|Actual|National University of Health Sciences|Subjects and clinicians were not blind to group. Subjects came from 1 region of the US, majority were white and ~50 years old. One type of orthotic was used as the only form of care. Several subjects felt discomfort/stiffness rather than pain.|2|||f||||f||||||||||2018-06-01 00:35:31.861165|2018-06-01 00:35:31.861165
NCT00976651|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2010-03-24|2009-09-11|2009-09-14|Estimate|||||||2010-03-24|2010-03-25|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Low Dose Human Chorionic Gonadotropin: Influence on the Endometrium|Influence of Ovarian Stimulation With 200 IU of hCG, (Administered in the Late Follicular Phase Among ICSI Patients Undergoing a GnRH-antagonist Protocol), on the Endometrium on the Day of Oocyte Pick-up|Completed||Phase 4|30|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-06-01 00:35:32.177083|2018-06-01 00:35:32.177083
NCT00976638|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2012-08-03|2009-09-11|2009-09-14|Estimate|||||||2012-08-03|2012-08-06|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|MOSAR-ICU||Clinical Trial to Reduce Antibiotic Resistance in European Intensive Cares|Mastering Hospital Antibiotic Resistance, a Cluster Randomized Intervention Study in Intensive Care Units Throughout Europe (Work Package 3)|Completed||N/A|14318|Actual|UMC Utrecht||2|||f||||f||||||||||2018-06-01 00:35:32.313555|2018-06-01 00:35:32.313555
NCT00976625|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-11|2009-09-11|2009-09-14|Estimate|||||||2009-09-11|2009-09-14|Estimate|January 1996||1996-01-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Diastolic Dysfunction in Aortic Regurgitation|Persistent Diastolic Dysfunction Late After Valve Replacement in Severe Aortic Regurgitation|Completed||N/A|26|Actual|University of Bern||2|||f||||f||||||||||2018-06-01 00:35:32.48894|2018-06-01 00:35:32.48894
NCT00976612|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-07-03|2009-09-11|2009-09-14|Estimate|||||||2013-07-03|2013-07-04|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Observational|||Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST)|Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib|Completed|||17|Actual|Asan Medical Center|||1||f||||f||||||Samples Without DNA|"~     blood about 4ml~   "|||2018-06-01 00:35:32.581658|2018-06-01 00:35:32.581658
NCT00976599|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2012-12-04|2012-11-05|2012-12-04|2009-09-11|2009-09-14|Estimate|2012-12-04|2013-01-09|Estimate|2012-11-05|2012-11-07|Estimate|2012-12-04|2013-01-09|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis|An Exploratory Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess The Pharmacodynamics Of CP-690,550, Administered Orally Twice Daily (BID) For 4 Weeks, In Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|29|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:35:32.941907|2018-06-01 00:35:32.941907
NCT00976586|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2013-12-03|2009-09-11|2009-09-14|Estimate|||||||2013-12-03|2013-12-04|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Role of Pseudogene in Incontinentia Pigmenti, and Its Potential Treatment|In Vitro Observation of Chromosome Recombination and Treatment in Vitro|Completed|||50|Actual|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     blood for DNA and plasma. Skin for cultured fibroblast~   "|||2018-06-01 00:35:36.400675|2018-06-01 00:35:36.400675
NCT00976573|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2017-01-17||2017-03-07|2009-09-11|2009-09-14|Estimate|2017-01-17|2017-03-07|Actual||||2017-03-07|2017-04-04|Actual|April 2010||2010-04-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Interventional|||Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma|A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, With or Without Everolimus for Therapy of Metastatic Malignant Melanoma|Completed||Phase 2|149|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 00:35:36.535116|2018-06-01 00:35:36.535116
NCT00976560|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2017-08-14|2012-03-15|2017-10-11|2009-09-11|2009-09-14|Estimate|2017-10-11|2017-11-14|Actual|2012-03-15|2012-03-19|Estimate|2017-10-11|2017-11-14|Actual|September 25, 2009|Actual|2009-09-25|October 2017|2017-10-31|July 7, 2010|Actual|2010-07-07|July 7, 2010|Actual|2010-07-07||Interventional|PKI113009||Clinical Study to Test a New Drug to Treat Major Depression|A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder|Completed||Phase 2|128|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:35:37.947993|2018-06-01 00:35:37.947993
NCT00976547|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-11|2009-09-11|2009-09-14|Estimate|||||||2009-09-11|2009-09-14|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Observational|||Correlation Analysis of Hearing Thresholds, Validated Questionnaires and Psychoacoustic Measurements in Tinnitus Patients|Correlation Analysis of Hearing Thresholds, Validated Questionnaires and Psychoacoustic Measurements in Tinnitus Patients|Completed|||48|Actual|Faculdade de Medicina de Valenca|||1||f||||f||||||||||2018-06-01 00:35:38.901823|2018-06-01 00:35:38.901823
NCT00976534|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2009-12-21|2009-09-11|2009-09-14|Estimate|||||||2009-12-21|2009-12-23|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|February 2010|Anticipated|2010-02-28|||||Interventional|AVANT||Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain|A Phase IIa Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 After 3 Weeks of Treatment in Patients With Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)|Terminated||Phase 2|90|Anticipated|AstraZeneca||2||The study was terminated due to results in another study (NCT00878501).|f||||f||||||||||2018-06-01 00:35:38.951494|2018-06-01 00:35:38.951494
NCT00976521|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2013-04-12||2013-05-31|2009-09-11|2009-09-14|Estimate|2013-05-31|2013-07-08|Estimate||||2013-05-31|2013-07-08|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|February 2012|Actual|2012-02-29||Interventional|||The INFUSE - Anterior Myocardial Infarction (AMI) Study|A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction|Completed||N/A|452|Actual|Atrium Medical Corporation||4|||f||||t||||||||||2018-06-01 00:35:39.033527|2018-06-01 00:35:39.033527
NCT00976508|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2013-10-23||2013-10-23|2009-09-11|2009-09-14|Estimate|2013-10-23|2013-12-13|Estimate||||2013-10-23|2013-12-13|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|September 2011|Actual|2011-09-30||Interventional|||Figitumumab Combined With Pegvisomant For Advanced Solid Tumors|Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors|Terminated||Phase 1|24|Actual|Pfizer|The study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:35:40.053722|2018-06-01 00:35:40.053722
NCT00976495|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2016-09-30|2012-03-24|2017-01-18|2009-09-11|2009-09-14|Estimate|2017-01-18|2017-03-08|Actual|2014-06-06|2014-06-18|Estimate|2017-01-18|2017-03-08|Actual|October 2009||2009-10-31|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||All randomized participants who received at least 1 dose of study medication|Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes|An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic and Blood Pressure (BP) Control|Completed||Phase 2|154|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:35:40.854558|2018-06-01 00:35:40.854558
NCT00976482|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2015-03-15||2016-12-05|2009-09-11|2009-09-14|Estimate|2016-10-10|2016-12-02|Estimate||||2016-12-05|2017-02-01|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|OPTI-MIND|among the 1745 initial patients 5 were excluded for inclusion criteria violations (deviations from correct signature of informed consent)|Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications|Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications|Completed|||1745|Actual|Boston Scientific Corporation|||1||f||||t||||||||||2018-06-01 00:35:41.31918|2018-06-01 00:35:41.31918
NCT00976469|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2015-10-07|2009-09-11|2009-09-14|Estimate|||||||2015-10-07|2015-10-09|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents|An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of Two Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years|Completed||Phase 1/Phase 2|400|Anticipated|Ology Bioservices||2|||f||||t||||||||||2018-06-01 00:35:41.538088|2018-06-01 00:35:41.538088
NCT00976456|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2016-01-12||2016-02-11|2009-09-11|2009-09-14|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|65plus|271 patients were enrolled and randomized, due to Screening failure and subject withdrawn consent the intent-to-treat (ITT) population comprised 253 evaluable patients (BP n=119; BPC n=134).|Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer|Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer|Completed||Phase 3|271|Actual|Martha-Maria Krankenhaus Halle-Dölau gGmbH||2|||f||||t||||||||||2018-06-01 00:35:41.608961|2018-06-01 00:35:41.608961
NCT00976443|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-01-02|2009-09-11|2009-09-14|Estimate|||||||2013-01-02|2013-01-03|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Gastric Antral Botulinum Toxin Injections in Obese Subjects|Physiologic Effects of High-Dose Gastric Antral Botulinum Toxin Injections|Completed||Phase 1|60|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 00:35:41.901037|2018-06-01 00:35:41.901037
NCT00976430|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-03-07|2009-09-11|2009-09-14|Estimate|||||||2017-03-07|2017-03-09|Actual|July 2009||2009-07-31|March 2017|2017-03-31||||November 30, 2011|Actual|2011-11-30||Interventional|||Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease|To Study the Safety and Efficacy of Bone Marrow Derived Mesenchymal Stem Cells Transplant in Parkinson's Disease|Suspended||N/A|5|Anticipated|Jaslok Hospital and Research Centre||1||Adequate no. of patients could not be recruited in the set time frame.|f||||f||||||||No||2018-06-01 00:35:42.028238|2018-06-01 00:35:42.028238
NCT00975949|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-01-14|2009-09-11|2009-09-14|Estimate|||||||2013-01-14|2013-01-15|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|June 2010|Actual|2010-06-30|October 2008|Actual|2008-10-31||Observational|NDFP||Neurodevelopmental Outcomes and Fluconazole Prophylaxis|Neurodevelopmental Outcomes and Quality of Life and Fluconazole Prophylaxis|Completed|||39|Actual|University of Virginia|||2||f||||t||||||||||2018-06-01 00:35:53.605336|2018-06-01 00:35:53.605336
NCT00976417|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2011-12-05|2009-09-11|2009-09-14|Estimate|||||||2011-12-05|2011-12-07|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Mechanisms of Action of Adaptive Servoventilation|Mechanisms of Action of Adaptive Servoventilation: Ventilatory Control in Heart Failure Patients With Central Sleep Apnoea|Completed|||50|Anticipated|ResMed|||2||f||||f||||||Samples Without DNA|"~     Venous blood will be collected.~   "|||2018-06-01 00:35:42.17711|2018-06-01 00:35:42.17711
NCT00976404|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2014-09-04||2014-09-10|2009-09-11|2009-09-14|Estimate|2014-09-10|2014-09-12|Estimate||||2014-09-10|2014-09-12|Estimate|November 2009||2009-11-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|July 2013|Actual|2013-07-31||Interventional|EraMune02||Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir|Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression|Completed||Phase 2|28|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 00:35:42.263207|2018-06-01 00:35:42.263207
NCT00976391|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2014-05-01|2012-04-05|2016-11-21|2009-09-11|2009-09-14|Estimate|2014-06-12|2014-07-16|Estimate|2012-04-05|2012-04-09|Estimate|2016-11-21|2017-01-11|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine|A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared With the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|586|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:35:42.950038|2018-06-01 00:35:42.950038
NCT00976378|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2014-06-25|2009-09-11|2009-09-14|Estimate|||||||2014-06-25|2014-06-26|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||NOX-A12 First-in-human (FIH) Study|NOX-A12 to Mobilize Stem Cells in Healthy Volunteers - A Single-center, Single Dose, Open Label, Dose Escalation Study of Intravenous NOX-A12 in up to 48 Healthy Subjects|Completed||Phase 1|48|Actual|NOXXON Pharma AG||8|||f||||f||||||||||2018-06-01 00:35:44.093773|2018-06-01 00:35:44.093773
NCT00976365|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2011-06-08|2009-09-11|2009-09-14|Estimate|||||||2011-06-08|2011-06-09|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer|Phase IIa Study of Metastatic Breast Cancer|Completed||Phase 2|60|Anticipated|Taiwan THL Co.LTd.||2|||f||||t||||||||||2018-06-01 00:35:44.180414|2018-06-01 00:35:44.180414
NCT00976352|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2017-06-01||2018-04-04|2009-09-11|2009-09-14|Estimate|2017-10-17|2017-11-17|Actual||||2018-04-04|2018-04-06|Actual|September 2010|Actual|2010-09-30|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease|Phase I/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV-GAA) Gene Vector in Patients With Pompe Disease|Completed||Phase 1/Phase 2|9|Actual|University of Florida||2|||f||||t|t|f||||||No||2018-06-01 00:35:44.265526|2018-06-01 00:35:44.265526
NCT00976339|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2015-07-27||2017-08-30|2009-09-11|2009-09-14|Estimate|2016-05-05|2016-06-15|Estimate||||2017-08-30|2017-09-29|Actual|September 2007||2007-09-30|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer|Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer|Completed||Phase 1|20|Actual|Columbia University|Data for this study (NCT00976339) is combined with the data for another study (NCT00859651); see NCT00859651 for combined results. Data for this study alone was not analyzed.|2|||f||||t|t|f||||||Undecided||2018-06-01 00:35:44.654925|2018-06-01 00:35:44.654925
NCT00976326|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-01-19|2009-09-11|2009-09-14|Estimate|||||||2017-01-19|2017-01-20|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function|A Trial Investigating the Pharmacokinetic and Safety Profiles of NN1250 in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment and in Subjects With Normal Hepatic Function|Completed||Phase 1|12|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 00:35:44.842806|2018-06-01 00:35:44.842806
NCT00976313|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2010-06-08|2009-09-11|2009-09-14|Estimate|||||||2010-06-08|2010-06-09|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Does Thoracic Epidural Analgesia Influence Urinary Micturition by Patients Undergoing Thoracic Surgery?|Does Thoracic Epidural Analgesia Influence Urinary Micturition by Patients Undergoing Thoracic Surgery? An Observational, Prospective Study|Completed|||26|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 00:35:44.922219|2018-06-01 00:35:44.922219
NCT00976300|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2010-06-22|2009-09-11|2009-09-14|Estimate|||||||2010-06-22|2010-06-23|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|May 2008|Actual|2008-05-31||Interventional|CYCLOFA-LUNE||Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study|Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study|Completed||Phase 2|40|Actual|Institute of Rheumatology, Prague||2|||f||||t||||||||||2018-06-01 00:35:44.988229|2018-06-01 00:35:44.988229
NCT00976287|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-09-14|2009-09-11|2009-09-14|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis|Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis|Unknown status|Active, not recruiting|Phase 2|50|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 00:35:45.069029|2018-06-01 00:35:45.069029
NCT00976274|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2012-01-19||2012-02-23|2009-09-11|2009-09-14|Estimate|2012-01-19|2012-02-24|Estimate||||2012-02-23|2012-02-27|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Korean Red Ginseng and Metabolic Syndrome|Effects of Korean Red Ginseng on Cardiovascular Risks in Subjects With Metabolic Syndrome|Completed||N/A|60|Actual|The Korean Society of Ginseng|First, we could not fully control participants’ lifestyle such as exercise and diet.Second, the relationship between Korean red ginseng dosage and its effect on cardiovascular disease risks was not evaluated.|2|||f||||t||||||||||2018-06-01 00:35:45.145851|2018-06-01 00:35:45.145851
NCT00974038|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-10-25|2009-09-09|2009-09-10|Estimate|||||||2012-10-25|2012-10-26|Estimate|November 2006||2006-11-30|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Cognitive Behavior Therapy for Adolescents With Bulimia|Cognitive Behavior Therapy for Adolescents With Bulimia Nervosa|Completed||N/A|8|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 00:36:54.848451|2018-06-01 00:36:54.848451
NCT00976261|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-06-07|2009-09-11|2009-09-14|Estimate|||||||2017-06-07|2017-06-08|Actual|October 17, 2009|Actual|2009-10-17|June 2017|2017-06-30|September 5, 2010|Actual|2010-09-05|September 5, 2010|Actual|2010-09-05||Interventional|SGA112534||A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes|A 2-Part Trial: a Randomized 6-day Repeat-dose, Parallel-group Study in Subjects With T2DM to Assess the Safety and Tolerability of GSK1614235 Compared to Placebo and Sitagliptin; and a Randomized Single-dose, Food Effect Study in Healthy Volunteers to Assess Safety and Tolerability of GSK1614235|Completed||Phase 1|72|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 00:35:45.553329|2018-06-01 00:35:45.553329
NCT00976248|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2013-06-13||2017-10-10|2009-09-11|2009-09-14|Estimate|2014-06-11|2014-06-16|Estimate||||2017-10-10|2017-10-12|Actual|November 2009||2009-11-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Interventional|||Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia|Phase II Study of Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia|Active, not recruiting||Phase 2|33|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:35:45.689514|2018-06-01 00:35:45.689514
NCT00976235|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2017-11-01|2009-09-11|2009-09-14|Estimate|||||||2017-11-01|2017-11-06|Actual|June 2006||2006-06-30|November 2017|2017-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Long-Term Monitoring Study of the IMT-002 Patients|Five Year Follow up of IMT-002 Patients; A Long-Term Monitoring Study of IMT-002 Patients|Completed||N/A|129|Actual|VisionCare, Inc.||1|||f||||f||||||||||2018-06-01 00:35:45.8917|2018-06-01 00:35:45.8917
NCT00976222|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-09-27|2009-09-11|2009-09-14|Estimate|||||||2017-09-27|2017-09-29|Actual|December 2008||2008-12-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments|Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration|Completed||Phase 4|40|Actual|University Hospital Muenster||1|||f||||||||||||||2018-06-01 00:35:46.077441|2018-06-01 00:35:46.077441
NCT00976209|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2010-10-29||2015-02-20|2009-09-11|2009-09-14|Estimate|2011-02-25|2011-03-25|Estimate||||2015-02-20|2015-03-11|Estimate|August 2009||2009-08-31|February 2015|2015-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)|A Randomized, Two-Way Crossover, Multicenter, Consumer Preference Study of Two Oral Formulations of Phenylephrine Hydrochloride.|Completed||Phase 3|331|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:35:46.209457|2018-06-01 00:35:46.209457
NCT00976196|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2015-12-01|2009-09-11|2009-09-14|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|PHP||Platelet Hyperreactivity Project|Platelet Hyperreactivity Project: A System Biology Approach of High On-treatment Platelet Reactivity in Aspirin-treated Cardiovascular Patients|Completed|||110|Actual|University Hospital, Geneva|||||f||||f||||||Samples With DNA|"~     Plasma Serum Platelets~   "|||2018-06-01 00:35:46.45011|2018-06-01 00:35:46.45011
NCT00976183|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2016-08-09||2017-02-24|2009-09-11|2009-09-14|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|October 2009||2009-10-31|August 2016|2016-08-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma|A Phase I/II, Open-Label, Non-Randomized, Pilot Study of Weekly Paclitaxel, Every Four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed With Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer|Terminated||Phase 1/Phase 2|18|Actual|Gynecologic Oncology Associates||1||toxicities|f||||f||||||||||2018-06-01 00:35:46.531673|2018-06-01 00:35:46.531673
NCT00976170|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2014-10-01|2009-09-11|2009-09-14|Estimate|||||||2014-10-01|2014-10-03|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Interventional|||Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)|A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).|Completed||Phase 1|42|Actual|Chugai Pharmaceutical||1|||f||||||||||||||2018-06-01 00:35:46.843594|2018-06-01 00:35:46.843594
NCT00976157|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-14|2009-09-11|2009-09-14|Estimate|||||||2009-09-14|2009-09-15|Estimate|August 2006||2006-08-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Observational|||Serial Changes in sTREM-1 During Ventilator-associated Pneumonia (VAP)|Serial Changes of Soluble TREM-1 Level in Bronchoalveolar Lavage Fluid During Ventilator-associated Pneumonia|Completed|||35|Actual|Mackay Memorial Hospital|||1||f||||t||||||||||2018-06-01 00:35:46.946179|2018-06-01 00:35:46.946179
NCT00976144|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2017-06-26|2009-09-11|2009-09-14|Estimate|||||||2017-06-26|2017-06-27|Actual|July 29, 2009|Actual|2009-07-29|June 2017|2017-06-30|September 22, 2009|Actual|2009-09-22|September 22, 2009|Actual|2009-09-22||Interventional|DB2113208||Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects|A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 and GW642444 as Monotherapies and Concurrently in Healthy Japanese Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:35:47.021393|2018-06-01 00:35:47.021393
NCT00976131|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2016-05-19|2009-09-11|2009-09-14|Estimate|||||||2016-05-19|2016-05-20|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer|Phase I Randomized, Placebo-Controlled, Cross-Over, Dose-Finding Pharmacokinetic Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer|Unknown status|Active, not recruiting|Phase 1|7|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-06-01 00:35:47.122288|2018-06-01 00:35:47.122288
NCT00976118|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-05-21|2009-09-11|2009-09-14|Estimate|||||||2013-05-21|2013-05-22|Estimate|February 2006||2006-02-28|September 2009|2009-09-30|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease|A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.|Completed||Phase 2|34|Actual|AB Science||2|||f||||f||||||||||2018-06-01 00:35:47.225505|2018-06-01 00:35:47.225505
NCT00975936|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-06-26|2009-09-11|2009-09-14|Estimate|||||||2017-06-26|2017-06-27|Actual|September 21, 2009|Actual|2009-09-21|June 2017|2017-06-30|November 12, 2009|Actual|2009-11-12|November 12, 2009|Actual|2009-11-12||Interventional|||Phase 0 Microdose Study|A Human Phase 0, Microdose Drug-Drug Interaction Study With [14C]-GSK706769 and Ketoconazole in Healthy Male Volunteers|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:35:53.68131|2018-06-01 00:35:53.68131
NCT00976105|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-06-19|2009-09-11|2009-09-14|Estimate|||||||2017-06-19|2017-06-20|Actual|September 22, 2009|Actual|2009-09-22|June 2017|2017-06-30|March 9, 2010|Actual|2010-03-09|March 9, 2010|Actual|2010-03-09||Interventional|||Effects of Repeat Dosing of GSK1521498|A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of 10 Days of Repeat Dosing of GSK1521498 in Overweight or Obese But Otherwise Healthy Subjects.|Completed||Phase 1|49|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:35:47.296147|2018-06-01 00:35:47.296147
NCT00976092|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2014-01-06|2009-09-11|2009-09-14|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|February 2014|Anticipated|2014-02-28||Interventional|BRAVE-4||Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction|Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI|Unknown status|Active, not recruiting|Phase 4|548|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 00:35:47.402023|2018-06-01 00:35:47.402023
NCT00976079|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-11|2009-09-11|2009-09-14|Estimate|||||||2009-09-11|2009-09-14|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||The Effect of Transcutaneous Electrical Nerve Stimulation on Quadriceps Central Activation and Gait|The Effect of Transcutaneous Electrical Nerve Stimulation on Quadriceps Central Activation and Gait|Completed||N/A|49|Actual|University of Virginia||3|||f||||f||||||||||2018-06-01 00:35:47.479876|2018-06-01 00:35:47.479876
NCT00976066|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2017-06-19|2009-09-11|2009-09-14|Estimate|||||||2017-06-19|2017-06-20|Actual|June 15, 2009|Actual|2009-06-15|June 2017|2017-06-30|December 7, 2009|Actual|2009-12-07|December 7, 2009|Actual|2009-12-07||Interventional|||[11C]Carfentanil PET Study of GSK1521498|An Open-label, Non-randomized [11C]Carfentanil PET Study in Healthy Male Subjects to Investigate Brain Mu-opioid Receptor Occupancy, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1521498 and Naltrexone.|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:35:47.543323|2018-06-01 00:35:47.543323
NCT00976053|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2014-10-30|2009-09-11|2009-09-14|Estimate|||||||2014-10-30|2014-10-31|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Interventional|||Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging|Clinical Effectiveness of Pharmacologic Stress Radionuclide Myocardial Perfusion Imaging as a Guide to Management of Patients With Known CAD: Comparison of Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)|Completed||Phase 4|330|Actual|Aspire Foundation||2|||f||||t||||||||||2018-06-01 00:35:47.64696|2018-06-01 00:35:47.64696
NCT00976040|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2012-02-03|2009-09-11|2009-09-14|Estimate|||||||2012-02-03|2012-02-07|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|Crypto||Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis|A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis|Completed||Phase 4|28|Actual|Botswana-UPenn Partnership||2|||f||||t||||||||||2018-06-01 00:35:47.72135|2018-06-01 00:35:47.72135
NCT00976027|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2012-06-19||2012-07-24|2009-09-11|2009-09-14|Estimate|2012-06-19|2012-07-25|Estimate||||2012-07-24|2012-08-01|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|May 2011|Actual|2011-05-31||Interventional|||Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older|Multi-Year Efficacy Study of Fluzone High-Dose Trivalent Vaccine Compared With Fluzone® Vaccine In Adults ≥ 65 Years of Age|Terminated||Phase 3|9172|Actual|Sanofi|The study was terminated due to lack of primary endpoint cases in 2009-2010 influenza season (coincided with the H1N1 Pandemic). There were no safety concerns; enrolled subjects were followed per-protocol.|2||"No safety concerns, study terminated due to lack of primary endpoint cases in 2009-2010 Flu~   season (coincided with H1N1 Pandemic) Subjects followed per-protocol"|f||||t||||||||||2018-06-01 00:35:47.835659|2018-06-01 00:35:47.835659
NCT00976014|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-18|2009-09-11|2009-09-14|Estimate|||||||2009-09-18|2009-09-22|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|FATS||Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study|Effects of Long-term Therapy With LDL-lowering Plus HDL Raising on Carotid Intima-media Thickness (CIMT) - Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study|Unknown status|Enrolling by invitation||55|Anticipated|University of Washington|||2||f||||t||||||||||2018-06-01 00:35:51.138457|2018-06-01 00:35:51.138457
NCT00976001|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-11|2009-09-11|2009-09-14|Estimate|||||||2009-09-11|2009-09-14|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Follow-up Pilot Study After a First Stroke|Open, Randomized Follow-up Pilot Study After a First Stroke|Completed||N/A|163|Actual|Skaraborg Hospital||2|||f||||f||||||||||2018-06-01 00:35:51.360034|2018-06-01 00:35:51.360034
NCT00975988|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2014-10-23|2009-09-11|2009-09-14|Estimate|||||||2014-10-23|2014-10-27|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Regulatory TYKERB® Tablets PMS|An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of TYKERB® Tablets Administered in Korean Patients According to the Prescribing Information|Completed|||750|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 00:35:51.645071|2018-06-01 00:35:51.645071
NCT00975975|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|2016-01-28||2016-01-28|2009-09-11|2009-09-14|Estimate|2016-01-28|2016-02-26|Estimate||||2016-01-28|2016-02-26|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|November 2013|Actual|2013-11-30|October 2012|Actual|2012-10-31||Interventional|||Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer|Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer|Completed||Phase 2|17|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 00:35:51.998391|2018-06-01 00:35:51.998391
NCT00975962|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2011-06-22|2009-09-11|2009-09-14|Estimate|||||||2011-06-22|2011-06-23|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||New Acute Treatment for Stroke - The Effect of Remote PERconditioning|New Acute Treatment for Stroke - The Effect of Remote PERconditioning|Completed||Phase 3|120|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-06-01 00:35:53.518631|2018-06-01 00:35:53.518631
NCT00975923|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2013-06-16||2015-12-08|2009-09-11|2009-09-14|Estimate|2015-12-08|2016-01-12|Estimate||||2015-12-08|2016-01-12|Estimate|February 2006||2006-02-28|December 2015|2015-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||Unit of analysis is Hospital and ICU|Safe Critical Care: Testing Improvement Strategies|Safe Critical Care: Testing Improvement Strategies|Completed||N/A|59|Actual|Vanderbilt University|Each participant tailored their interventions; we were not able to test the components of CQI. Data were dependent on self-reports. Our collaborative was virtual and does not address benefits from face-to-face networking of large scale projects.|2|||f||||f||||||||||2018-06-01 00:35:53.800458|2018-06-01 00:35:53.800458
NCT00975910|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-05-21|2009-09-11|2009-09-14|Estimate|||||||2013-05-21|2013-05-22|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Lidocaine in Antiarrhythmic Dosage on Postoperative Cognitive Dysfunction in Supratentorial Craniotomy Dysfunction in Supratentorial Craniotomy||Completed||Phase 2|100|Actual|Capital Medical University||2|||f||||t||||||||||2018-06-01 00:35:54.161444|2018-06-01 00:35:54.161444
NCT00975897|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2013-12-18|2009-09-11|2009-09-14|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|December 2012|Actual|2012-12-31|August 2010|Actual|2010-08-31||Interventional|||Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer|FOCUS 3 - A Study to Determine the Feasibility of Molecular Selection of Therapy Using KRAS, BRAF and Topo-1 in Patients With Metastatic or Locally Advanced Colorectal Cancer|Completed||Phase 2/Phase 3|3240|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:35:54.497352|2018-06-01 00:35:54.497352
NCT00975884|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11||2010-07-02|2016-09-29|2009-09-11|2009-09-14|Estimate||||2010-07-02|2010-07-07|Estimate|2016-09-29|2016-09-30|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above|Completed||Phase 3|312|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:35:54.648363|2018-06-01 00:35:54.648363
NCT00975871|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-10-21|2009-09-11|2009-09-14|Estimate|||||||2009-10-21|2009-10-23|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Correlation of Genetic Polymorphism and Livedo Vasculitis|Correlation of Genetic Polymorphism and Livedo Vasculitis|Completed|||50|Actual|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     Buccal mucosa cotton tip swab~   "|||2018-06-01 00:35:54.787135|2018-06-01 00:35:54.787135
NCT00975858|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-11|||2009-09-14|2009-09-11|2009-09-14|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 1998||1998-01-31|September 2009|2009-09-30|February 2001|Actual|2001-02-28|January 2001|Actual|2001-01-31||Interventional|OCTOSTENT||Long-term Comparison of Stenting Versus Off-pump Coronary Bypass Surgery|A Randomized Comparison of Long-term Clinical , Neurocognitive, Angiographical and Health-costs, After Stenting Versus Off-pump Coronary Bypass Surgery in Patients With Symptomatic Coronary Artery Disease|Completed||N/A|280|Actual|UMC Utrecht||2|||f||||f||||||||||2018-06-01 00:35:54.872172|2018-06-01 00:35:54.872172
NCT00975845|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2018-02-05|2009-09-10|2009-09-11|Estimate|||||||2018-02-05|2018-02-06|Actual|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Observational|||BioCleanse Tibialis Tendon Anterior Cruciate Ligament (ACL) Study|A Prospective, Double-Blind Evaluation of the Effects of BioCleanse Tibialis Tendon Allograft and Donor Age on Clinical Outcomes of ACL Reconstruction|Completed|||50|Anticipated|RTI Surgical|||1||f||||f||||||||No||2018-06-01 00:35:55.009107|2018-06-01 00:35:55.009107
NCT00975832|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-10|2009-09-10|2009-09-11|Estimate|||||||2009-09-10|2009-09-11|Estimate||||September 2009|2009-09-30||||||||Observational|||Adipocytokines and Polycystic Ovary Syndrome (PCOS)|Adipose Expression of Leptin, Adiponectin and IL-6, and Plasma Levels of Adipocytokines in Lean and Obese Women With PCOS|Completed|||60|Actual|Hvidovre University Hospital|||3||f||||t||||||||||2018-06-01 00:35:55.100454|2018-06-01 00:35:55.100454
NCT00975819|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-02-03|2009-09-10|2009-09-11|Estimate|||||||2015-02-03|2015-02-05|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|October 2019|Anticipated|2019-10-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies|A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies|Active, not recruiting||Phase 2|60|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 00:35:55.221015|2018-06-01 00:35:55.221015
NCT00975806|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2014-12-17||2017-05-02|2009-09-10|2009-09-11|Estimate|2014-12-17|2014-12-29|Estimate||||2017-05-02|2017-05-31|Actual|September 2009||2009-09-30|May 2017|2017-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Safety Population includes all participants who received at least one dose of study drug.|Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma|A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Lenalidomide in Combination With Sunitinib in Subjects With Advanced or Metastatic Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|16|Actual|Celgene||2||MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.|f||||f||||||||||2018-06-01 00:35:55.374701|2018-06-01 00:35:55.374701
NCT00975793|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2014-04-23|2009-09-10|2009-09-11|Estimate|||||||2014-04-23|2014-04-24|Estimate|October 2008||2008-10-31|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|July 2014|Anticipated|2014-07-31||Interventional|ARISE||Australasian Resuscitation In Sepsis Evaluation Randomised Controlled Trial|A Multi-centre, Randomised Controlled Trial of Early Goal-directed Therapy in Patients Presenting to the Emergency Department With Severe Sepsis in Australasia|Unknown status|Active, not recruiting|Phase 3|1600|Anticipated|Monash University||2|||f||||t||||||||||2018-06-01 00:35:57.14732|2018-06-01 00:35:57.14732
NCT00975780|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2013-12-06||2014-11-07|2009-09-10|2009-09-11|Estimate|2013-12-06|2014-01-21|Estimate||||2014-11-07|2014-11-20|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PRIDE||A Trial to Reduce Pneumonia in Nursing Home Residents|A Randomized Controlled Trial to Reduce Pneumonia in Nursing Home Residents|Completed||Phase 3|834|Actual|Yale University|"Participant flow and outcome information pertains to data collected through 10/25/2012- the official trial termination date.~Serious and Other Adverse Event information pertains to requested surveillance of subjects through 12/10/2012 per the NIA."|2|||f||||t||||||||||2018-06-01 00:35:57.319165|2018-06-01 00:35:57.319165
NCT00975585|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2011-02-18||2017-08-31|2009-09-10|2009-09-11|Estimate|2011-02-18|2011-03-22|Estimate||||2017-08-31|2017-09-28|Actual|August 1, 2009|Actual|2009-08-01|August 2017|2017-08-31|October 1, 2009|Actual|2009-10-01|October 1, 2009|Actual|2009-10-01||Interventional|||Clinical Performance Comparison of Two Contact Lenses|Clinical Evaluation of Two Silicone Hydrogel Frequent Replacement Contact Lenses|Completed||N/A|379|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 00:36:00.70006|2018-06-01 00:36:00.70006
NCT00975767|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-01-06|2009-09-10|2009-09-11|Estimate|||||||2015-01-06|2015-01-08|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer|A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|126|Actual|Mirati Therapeutics Inc.||2||"The study was terminated due to a need for a reformulation of the study drug. Phase 1~   completed, no patients enrolled in Phase 2."|f||||f||||||||||2018-06-01 00:35:57.653217|2018-06-01 00:35:57.653217
NCT00975754|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-12-10|2009-09-10|2009-09-11|Estimate|||||||2009-12-10|2009-12-11|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|||||Interventional|||Lung Deposition Via Different Inhalation Devices|A Phase I, Randomized, Open-label, 5-way Crossover, Single Centre Study in Healthy Subjects to Assess the Lung Deposition of Inhaled Budesonide Delivered Via Different Inhalation Devices|Completed||Phase 1|16|Anticipated|AstraZeneca||5|||f||||f||||||||||2018-06-01 00:35:57.769772|2018-06-01 00:35:57.769772
NCT00975741|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2009-09-09|2009-09-09|2009-09-11|Estimate|||||||2009-09-09|2009-09-11|Estimate|October 2002||2002-10-31|September 2009|2009-09-30|August 2003|Actual|2003-08-31|||||Interventional|||Efficacy and Safety of Two Dry Power Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma|An Open-label, Comparative, Randomized, Parallel, Multicenter Study to Determine the Efficacy and Safety of Two Dry Powder Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma|Completed||Phase 3|97|Actual|Mantecorp Industria Quimica e Farmaceutica Ltd.||2|||f||||f||||||||||2018-06-01 00:35:57.879642|2018-06-01 00:35:57.879642
NCT00975728|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2011-06-22|2009-09-10|2009-09-11|Estimate|||||||2011-06-22|2011-06-23|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||High Total Antioxidant Capacity Products Added to Diet|High Total Antioxidant Capacity (TAC) Products Added to Diet: Clinical and Instrumental Evaluation of Their Effect on Skin Surface Parameters and on Photo-induced Acute Damage of the Skin (Double Blind Clinical Study vs Placebo)|Completed||Phase 3|120|Actual|Derming SRL||4|||f||||t||||||||||2018-06-01 00:35:57.999717|2018-06-01 00:35:57.999717
NCT00975715|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2013-10-08||2014-07-09|2009-09-10|2009-09-11|Estimate|2013-12-06|2014-01-24|Estimate||||2014-07-09|2014-07-16|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures|A Multicentre, Randomized, Double-blind, Placebo Controlled, Parallel-group Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy|Completed||Phase 2/Phase 3|99|Actual|Novartis||2|||f||||f||||||||||2018-06-01 00:35:58.176455|2018-06-01 00:35:58.176455
NCT00975702|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-01-13|2009-09-10|2009-09-11|Estimate|||||||2015-01-13|2015-01-14|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|December 2010|Actual|2010-12-31||Interventional|RIPCOT||Remote Ischemic Preconditioning In Abdominal Organ Transplantation|Phase III Study of Efficacy of Remote Ischemic Preconditioning in Improving Outcomes in Organ Transplantation|Completed||Phase 3|85|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 00:35:58.734612|2018-06-01 00:35:58.734612
NCT00975689|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2012-05-23||2013-04-30|2009-09-10|2009-09-11|Estimate|2012-06-07|2012-07-12|Estimate||||2013-04-30|2013-05-06|Estimate|August 2009||2009-08-31|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine|Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine|Completed||Phase 1/Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||t||||||||||2018-06-01 00:35:58.889491|2018-06-01 00:35:58.889491
NCT00975676|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2017-08-08|2009-09-10|2009-09-11|Estimate|||||||2017-08-08|2017-08-09|Actual|November 2008||2008-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SOFT-EST||Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02|A Substudy of the IBCSG 24-02/ SOFT Trial to Investigate Estrogen Suppression for Patients Participating in Arms B and C of the IBCSG 24-02/ SOFT Trial|Active, not recruiting||N/A|123|Actual|International Breast Cancer Study Group||2|||f||||t||||||||No||2018-06-01 00:35:59.213464|2018-06-01 00:35:59.213464
NCT00975663|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2011-04-23|2009-09-10|2009-09-11|Estimate|||||||2011-04-23|2011-04-26|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|BASALT||Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation|Evaluation of the Interest of Therapeutic Drug Monitoring of Immunosuppressants (Tacrolimus, Mycophenolate Mofetil) Based on Bayesian Estimation During the Three First Years Following Lung Transplantation, in Patients With or Without Cystic Fibrosis|Terminated||Phase 4|180|Anticipated|University Hospital, Limoges||2|||f||||t||||||||||2018-06-01 00:35:59.425118|2018-06-01 00:35:59.425118
NCT00975650|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2010-08-05|2009-09-10|2009-09-11|Estimate|||||||2010-08-05|2010-08-09|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Tolerability of an Intra-Nasal Testosterone Product|Efficacy and Tolerability of Nasobol®, an Intra-Nasal Testosterone Product, for Testosterone Replacement in Hypogonadal Men|Completed||Phase 2|40|Anticipated|Acerus Pharmaceuticals Corporation||4|||f||||f||||||||||2018-06-01 00:35:59.54686|2018-06-01 00:35:59.54686
NCT00975637|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2016-11-02|2015-06-22|2017-02-08|2009-09-10|2009-09-11|Estimate|2016-11-02|2016-12-30|Estimate|2015-06-22|2015-07-15|Estimate|2017-02-08|2017-03-17|Actual|December 2009||2009-12-31|February 2017|2017-02-28|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis|Completed||Phase 2|198|Actual|Valeant Pharmaceuticals International, Inc.||5|||f||||||||||||Yes||2018-06-01 00:35:59.702794|2018-06-01 00:35:59.702794
NCT00975611|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2013-01-28||2013-05-03|2009-09-10|2009-09-11|Estimate|2013-05-03|2013-06-10|Estimate||||2013-05-03|2013-06-10|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation|Amantadine Addition to Paliperidone ER or Risperidone Consta Therapy for Prolactin Elevation|Terminated||Phase 4|6|Actual|North Suffolk Mental Health Association|Too few subjects met study's eligibility criteria to run statistical analyses on primary outcomes. The baseline demographic data are reported here. Future research is needed to understand the prevalence of elevated prolactin in schizophrenia.|3||The sponsor withdrew support due to slow accrual of eligible subjects.|f||||f||||||||||2018-06-01 00:36:00.474222|2018-06-01 00:36:00.474222
NCT00975572|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2012-09-11|2009-09-09|2009-09-11|Estimate|||||||2012-09-11|2012-09-12|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|||Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older|A Double-blind, Randomized, Stratified and Controlled Clinical Trial With Split-virion, Adjuvanted and Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders, Adolescents and Children|Completed||Phase 2|2200|Actual|Jiangsu Province Centers for Disease Control and Prevention||6|||f||||t||||||||||2018-06-01 00:36:01.083077|2018-06-01 00:36:01.083077
NCT00975559|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-04-25|2009-09-10|2009-09-11|Estimate|||||||2012-04-25|2012-04-26|Estimate|September 2003||2003-09-30|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||The Relationship Between the Response to Mental Stress and Vascular Endothelial Function|The Relationship Between the Response to Mental Stress and Vascular Endothelial Function|Completed|||190|Actual|Mayo Clinic|||4||f||||f||||||Samples Without DNA|"~     Catecholomines~   "|||2018-06-01 00:36:01.178354|2018-06-01 00:36:01.178354
NCT00975546|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-11-30|2009-09-10|2009-09-11|Estimate|||||||2015-11-30|2015-12-02|Estimate||||November 2015|2015-11-30||||||||Expanded Access|||HIV-discordant Couple Intrauterine Insemination|Intrauterine Insemination for HIV-discordant Couples|No longer available|||||University of Missouri-Columbia|||||f||||||||||||||2018-06-01 00:36:01.243305|2018-06-01 00:36:01.243305
NCT00975533|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-10|2009-09-10|2009-09-11|Estimate|||||||2009-09-10|2009-09-11|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|October 2011|Anticipated|2011-10-31|July 2011|Anticipated|2011-07-31||Interventional|||Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial|A Randomized Study to Evaluate the Efficacy and Acceptability of Laparoscopic Placement of Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients Sub-optimally Controlled With Oral Anti-diabetic Agents.|Unknown status|Not yet recruiting|Phase 3|24|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:36:01.32191|2018-06-01 00:36:01.32191
NCT00975520|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2018-03-07|2009-09-10|2009-09-11|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2009||2009-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|RTN2||Neurotropic Melanoma of the Head and Neck|A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck|Recruiting||N/A|100|Anticipated|Australia and New Zealand Melanoma Trials Group||2|||f||||t|f|f||||||No|Not sharing IPD|2018-06-01 00:36:01.43511|2018-06-01 00:36:01.43511
NCT00975507|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2009-09-23||2015-10-05|2009-09-10|2009-09-11|Estimate|2010-01-25|2010-02-10|Estimate||||2015-10-05|2015-10-06|Estimate|March 1998||1998-03-31|October 2015|2015-10-31|June 1999|Actual|1999-06-30|January 1999|Actual|1999-01-31||Interventional|||ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)|A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children|Completed||Phase 3|480|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:36:01.579839|2018-06-01 00:36:01.579839
NCT00975494|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-09-10|2009-09-10|2009-09-11|Estimate|||||||2009-09-10|2009-09-11|Estimate|April 2005||2005-04-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|||||Interventional|||Chronic Sildenafil Treatment in Heart Failure|Chronic PDE5-Inhibition With Sildenafil Improves Diastolic Function, Cardiac Geometry and Clinical Status in Patients With Stable HF: A 1-Year Prospective Randomized, Placebo-Controlled Study|Completed||Phase 3|50|Actual|University of Milan||2|||f||||t||||||||||2018-06-01 00:36:02.054255|2018-06-01 00:36:02.054255
NCT00975481|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2012-12-03||2013-02-20|2009-09-10|2009-09-11|Estimate|2013-02-20|2013-04-02|Estimate||||2013-02-20|2013-04-02|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users|A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users|Completed||Phase 1|36|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 00:36:02.333669|2018-06-01 00:36:02.333669
NCT00975468|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2011-06-21|2009-09-10|2009-09-11|Estimate|||||||2011-06-21|2011-06-23|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Interventional|||Pressure-Controlled vs Volume-Controlled Ventilation During One Lung Ventilation|Prospective, Randomized Study of the Effects of Pressure-controlled vs. Volume-controlled Ventilation During One Lung Ventilation on Lung Injury After Thoracotomy|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|King Faisal University||2|||f||||t||||||||||2018-06-01 00:36:04.493781|2018-06-01 00:36:04.493781
NCT00975455|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2011-06-07|2009-09-10|2009-09-11|Estimate|||||||2011-06-07|2011-06-08|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Observational|||Hematuria Evaluation Trial for Subjects With Microscopic or Gross Hematuria to Determine the Absence or Presence of Bladder Cancer|Phase 3 Study of Hematuria Evaluation|Completed|||1400|Anticipated|Predictive Biosciences|||1||f||||f|||||||"~     urine sample~   "|||2018-06-01 00:36:04.574701|2018-06-01 00:36:04.574701
NCT00975442|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-10|2009-09-10|2009-09-11|Estimate|||||||2009-09-10|2009-09-11|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Effects of Eccentric Training for Patients With Lateral Epicondylalgia|Effects of Eccentric Training for Patients With Lateral Epicondylalgia - a Randomized Controlled Trial|Completed||N/A|42|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 00:36:04.652628|2018-06-01 00:36:04.652628
NCT00975429|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-04-27|2009-09-10|2009-09-11|Estimate|||||||2015-04-27|2015-04-28|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||Study Using WST11 in Patients With Localized Prostate Cancer|Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer|Completed||Phase 2|86|Actual|Steba Biotech S.A.||2|||f||||f||||||||||2018-06-01 00:36:04.737412|2018-06-01 00:36:04.737412
NCT00975416|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2014-03-26||2015-10-19|2009-09-10|2009-09-11|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Oxytocin and Cognitive Behavioral Therapy in Drug Dependence|Oxytocin and Cognitive Behavioral Therapy in Drug Dependence|Terminated||Phase 4|63|Actual|National Institutes of Health Clinical Center (CC)|"1 participant committed suicide outside of that occurred outside of adverse event time frame.~There were 12 occurrences of computer malfunction during the study. This did not effect data collection for primary outcome measures."|3|||f||||||||||||||2018-06-01 00:36:04.842942|2018-06-01 00:36:04.842942
NCT00973323|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2014-12-26|2009-09-08|2009-09-09|Estimate|||||||2014-12-26|2014-12-30|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|March 2006|Actual|2006-03-31|||||Interventional|||BAY59-7939 Japanese in Atrial Fibrillation (2nd)|BAY 59-7939 (Factor Xa Inhibitor) Phase II Low Dose Study in Patients With Atrial Fibrillation|Completed||Phase 2|100|Actual|Bayer||4|||f||||f||||||||||2018-06-01 00:37:10.874672|2018-06-01 00:37:10.874672
NCT00975403|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2012-12-14|2009-09-10|2009-09-11|Estimate|||||||2012-12-14|2012-12-17|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pathophysiological Mechanisms of Dyspnea and Activity-limitation in Mild Chronic Obstructive Pulmonary Disease (COPD)|Pathophysiological Mechanisms of Dyspnea and Activity-Limitation in Mild COPD|Completed||N/A|20|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 00:36:05.089204|2018-06-01 00:36:05.089204
NCT00975390|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-04-13|2009-09-10|2009-09-11|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Muscle Glycogen Synthesis When Caffeine and Protein is Co-Ingested With Carbohydrates|The Effect of Caffeine or Protein Co-ingestion With Carbohydrate on Post-exercise Muscle Glycogen Synthesis Rate.|Completed||N/A|14|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 00:36:05.149253|2018-06-01 00:36:05.149253
NCT00975377|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-09-04|2009-09-10|2009-09-11|Estimate|||||||2015-09-04|2015-09-07|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Clipping Versus No Hair Removal and the Risk of Surgical Site Infections|Clipping vs. No Hair Removal and the Risk of Surgical Site Infection: A Randomized, Assessor Blinded Non-inferiority Clinical Trial Among Patients Undergoing General Surgical Procedures at a Community Hospital|Completed||N/A|1678|Actual|Gundersen Lutheran Medical Foundation||2|||f||||f||||||||||2018-06-01 00:36:05.208809|2018-06-01 00:36:05.208809
NCT00975364|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2013-02-15|2009-09-10|2009-09-11|Estimate|||||||2013-02-15|2013-02-18|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Observational|FolGene||Folate Gene Polymorphisms and Cellular Folate Speciation Pilot Study|Pilot Study to Investigate Relationship Between Common Folate Gene Polymorphisms, Folate Status and Cellular Folate Speciation|Completed|||100|Actual|Quadram Institute|||1||f||||t||||||Samples With DNA|"~     One-off blood sample collected. DNA extracted for genotyping of folate metabolism-related~     gene single nucleotide polymorphisms~   "|||2018-06-01 00:36:05.270629|2018-06-01 00:36:05.270629
NCT00975351|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2013-02-15|2009-09-10|2009-09-11|Estimate|||||||2013-02-15|2013-02-18|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|FOLCAN||Estimation of Plasma Folate Apparent Volume of Distribution in Adults|Estimation of Plasma Folate Apparent Volume of Distribution in Adults|Completed||N/A|20|Actual|Quadram Institute||1|||f||||f||||||||||2018-06-01 00:36:05.324845|2018-06-01 00:36:05.324845
NCT00975338|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2016-07-19|2009-09-10|2009-09-11|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|June 2014|Actual|2014-06-30||Observational|LETS||The LETS Study: A Longitudinal Evaluation of Transition Services|The LETS Study: A Longitudinal Evaluation of Transition Services|Active, not recruiting|||331|Anticipated|Holland Bloorview Kids Rehabilitation Hospital|||5||f||||f||||||||||2018-06-01 00:36:05.39098|2018-06-01 00:36:05.39098
NCT00975325|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2015-06-25|2009-09-10|2009-09-11|Estimate|||||||2015-06-25|2015-06-26|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine|Characterisation of Relative Bioavailability and Assessment of Bioequivalence of Two Generic Yohimbine Formulations in Comparison With a Marketed Reference Product - an Open, Randomised, Single Dose, 3-period Change-over Study|Completed||Phase 4|42|Actual|Walter Ritter GmbH & Co||2|||f||||f||||||||||2018-06-01 00:36:05.468099|2018-06-01 00:36:05.468099
NCT00975312|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-10|2009-09-10|2009-09-11|Estimate|||||||2009-09-10|2009-09-11|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Solar Lentigines Treatment With the Triple Combination Cream|Solar Lentigines Treatment With the Triple Combination Cream (Hydroquinone 4%, Tretinoin 0.05%, and Fluocinolone Acetonide 0.01%). Randomized, Double Blind, Controlled Trial.|Completed||Phase 2|22|Actual|Pontificia Universidad Catolica de Chile||1|||f||||f||||||||||2018-06-01 00:36:05.648255|2018-06-01 00:36:05.648255
NCT00975299|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2014-06-25|2009-09-10|2009-09-11|Estimate|||||||2014-06-25|2014-06-26|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers|Open-label, Multicenter PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 18F Labeled PET Tracer BAY86-4367 Following a Single Intravenous Administration of 300 MBq (Corresponding to </= 40 µg Mass Dose) in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability of the Tracer in PET/CT in Healthy Volunteers|Terminated||Phase 1|16|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:36:05.729419|2018-06-01 00:36:05.729419
NCT00975286|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2016-08-18|2012-05-07|2016-08-18|2009-09-10|2009-09-11|Estimate|2016-08-18|2016-10-11|Estimate|2012-05-07|2012-05-10|Estimate|2016-08-18|2016-10-11|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|GetGoal-Duo1|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine|A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin|Completed||Phase 3|446|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:36:05.876209|2018-06-01 00:36:05.876209
NCT00975273|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2012-06-11|2009-09-10|2009-09-11|Estimate|||||||2012-06-11|2012-06-13|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Breathing Training for Asthma|Targeting CO2 Levels in Breathing Training for Asthma|Unknown status|Active, not recruiting|N/A|120|Anticipated|Southern Methodist University||2|||f||||t||||||||||2018-06-01 00:36:07.031247|2018-06-01 00:36:07.031247
NCT00975247|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2014-12-09|2009-09-10|2009-09-11|Estimate|||||||2014-12-09|2014-12-10|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Impact of a Novel Patient Educational Booklet on Colonoscopy Quality|Impact of a Novel Patient Educational Booklet on Colonoscopy Quality|Completed||N/A|500|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||||2018-06-01 00:36:07.199785|2018-06-01 00:36:07.199785
NCT00974402|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2014-09-16|2009-09-09|2009-09-10|Estimate|||||||2014-09-16|2014-09-18|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings|Psychotherapy Treatment of Deployment-related PTSD in Primary Care Settings|Completed||N/A|35|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-06-01 00:36:43.431711|2018-06-01 00:36:43.431711
NCT00975234|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2012-06-07|2009-09-10|2009-09-11|Estimate|||||||2012-06-07|2012-06-08|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Treatment With Autologous Skeletal Myoblasts|Phase II, Randomised, Controlled Study of Treatment With Revascularisation Surgery With or Without Injection of Autologous Skeletal Myoblasts in Patients With Old Myocardial Infarction|Terminated||Phase 2|3|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2||Lack of recruitment|f||||f||||||||||2018-06-01 00:36:07.286055|2018-06-01 00:36:07.286055
NCT00975221|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2015-12-17|2013-12-19|2016-02-02|2009-09-10|2009-09-11|Estimate|2015-12-17|2016-01-25|Estimate|2013-12-19|2014-01-27|Estimate|2016-02-02|2016-03-01|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy|A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy|Completed||Phase 3|67|Actual|Amgen||2|||f||||f||||||||||2018-06-01 00:36:07.423516|2018-06-01 00:36:07.423516
NCT00975208|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-10|2009-09-10|2009-09-11|Estimate|||||||2009-09-10|2009-09-11|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|August 2010|Anticipated|2010-08-31|November 2007|Anticipated|2007-11-30||Observational|||Osteogenesis and Dental Eruption Through Electrical Stimuli|Osteogenesis and Dental Eruption Through Electrical Stimuli Following Periosteoplasty for Alveolar Clefts in Patients With Cleft Lip and Palate Deformities. A Preliminary Report.|Unknown status|Active, not recruiting||9|Actual|University of Guadalajara|||||f||||t||||||||||2018-06-01 00:36:08.142725|2018-06-01 00:36:08.142725
NCT00975195|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2014-12-23|2014-04-30|2015-02-09|2009-09-10|2009-09-11|Estimate|2015-02-09|2015-02-10|Estimate|2014-04-30|2014-05-16|Estimate|2015-02-09|2015-02-10|Estimate|February 2009||2009-02-28|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Treated Set (TS) which included all patients who were dispensed study medication and were documented to have taken ≥1 dose of randomised treatment.|Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy|Completed||Phase 4|2488|Actual|Boehringer Ingelheim|"Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information."|2|||f||||||||||||||2018-06-01 00:36:08.255223|2018-06-01 00:36:08.255223
NCT00975182|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2016-11-01|2009-09-09|2009-09-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors|Completed||Phase 1|58|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 00:36:10.410283|2018-06-01 00:36:10.410283
NCT00975169|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2010-03-16|2009-09-10|2009-09-11|Estimate|||||||2010-03-16|2010-03-18|Estimate|February 2009||2009-02-28|March 2010|2010-03-31||||December 2011|Anticipated|2011-12-31||Observational|||Association Study of Genetic Polymorphisms of Candidate Genes With Thiazolidinedione-Related Peripheral Edema and Drug Responsiveness|Association Study of Genetic Polymorphisms of Candidate Genes With Thiazolidinedione-Related Peripheral Edema and Drug Responsiveness|Unknown status|Recruiting||400|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 00:36:10.487879|2018-06-01 00:36:10.487879
NCT00975156|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2012-08-14||2013-02-20|2009-09-10|2009-09-11|Estimate|2012-08-14|2012-09-13|Estimate||||2013-02-20|2013-02-25|Estimate|May 2008||2008-05-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Improving Ambulation Post Stroke With Robotic Training|Improving Ambulation Post Stroke With Robotic Training|Completed||N/A|21|Actual|The University of Texas Health Science Center, Houston|Limitations include: small sample (n=21 enrolled, n=20 completed) and significant (p=0.025) difference between groups in time since stroke (Lokomat group, time since stroke mean=1353.60 days; Conventional group, time since stroke mean=525.00 days).|2|||f||||f||||||||||2018-06-01 00:36:10.672388|2018-06-01 00:36:10.672388
NCT00975143|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2012-07-04|2012-05-30|2014-06-05|2009-09-10|2009-09-11|Estimate|2014-06-05|2014-07-04|Estimate|2012-06-04|2012-06-07|Estimate|2014-06-05|2014-07-04|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne|A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne|Completed||Phase 3|925|Actual|Cipher Pharmaceuticals Inc.|Generic isotretinoin control because Accutane® was discontinued in the US. 201 PPP exclusions (CIP-Isotretinoin 101, Isotretinoin 100) due to discontinuation < Week 20 (61+51), non-compliance with treatment (76+75) or other requirements (≥1 reason).|2|||f||||t||||||||||2018-06-01 00:36:10.965936|2018-06-01 00:36:10.965936
NCT00975130|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2012-07-18||2017-03-16|2009-09-10|2009-09-11|Estimate|2012-11-08|2012-12-07|Estimate||||2017-03-16|2017-04-13|Actual|September 2009||2009-09-30|March 2017|2017-03-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|GO-MORE||Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)|An Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Biologic-Naïve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2)|Completed||Phase 3|3366|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:36:11.679377|2018-06-01 00:36:11.679377
NCT00975117|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2011-03-06|2009-09-10|2009-09-11|Estimate|||||||2011-03-06|2011-03-08|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Spermotrend in the Treatment of Male Infertility|Assessment of the Efficacy of Dietary Supplement Spermotrend in the Treatment of Male Infertility|Completed||Phase 3|86|Anticipated|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:36:18.248317|2018-06-01 00:36:18.248317
NCT00975104|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2010-07-22|2009-09-10|2009-09-11|Estimate|||||||2010-07-22|2010-07-23|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|May 2011|Anticipated|2011-05-31||Interventional|||AMG 745 in Subjects With Age-associated Muscle Loss|A Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss|Withdrawn||Phase 2|200|Anticipated|Amgen||4||Amgen has chosen at this time not to continue with AMG 745 study 20080733|f||||||||||||||2018-06-01 00:36:18.394681|2018-06-01 00:36:18.394681
NCT00975091|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08||2010-01-29|2010-01-29|2009-09-10|2009-09-11|Estimate||||2010-01-29|2010-02-02|Estimate|2010-01-29|2010-02-02|Estimate|May 2004||2004-05-31|November 2009|2009-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Continue Entecavir Rollover From China|A Study of the Safety and Antiviral Activity of Open-Label Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Who Have Completed Dosing in a Previous Phase II/III Study in China|Completed||Phase 3|600|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 00:36:18.513417|2018-06-01 00:36:18.513417
NCT00975078|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2011-08-08|2009-09-10|2009-09-11|Estimate|||||||2011-08-08|2011-08-09|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment|Dexamethasone-suppression-test Predicts Later Development of Adrenal Insufficiency After a 14 Days' Course of Prednisone in Healthy Volunteers|Completed||Phase 4|39|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 00:36:18.611103|2018-06-01 00:36:18.611103
NCT00975065|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-08-21|2009-09-10|2009-09-11|Estimate|||||||2012-08-21|2012-08-23|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus|A 24-week, Open-label, Randomized, Multi-center, Parallel-group Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Prior Metformin Monotherapy in Comparison to up Titrating Metformin Dose.|Completed||Phase 4|266|Actual|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:36:18.745791|2018-06-01 00:36:18.745791
NCT00975052|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-08-18|2009-09-10|2009-09-11|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2006||2006-01-31|August 2015|2015-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)|A Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Four-Period Crossover Study to Assess the Effects of Concomitant Administration of MK0431 and Metformin Alone and in Combination on Post-Meal Incretin Hormone Concentrations in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 00:36:19.094549|2018-06-01 00:36:19.094549
NCT00975039|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2016-04-14|2009-09-10|2009-09-11|Estimate|||||||2016-04-14|2016-04-18|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|September 2012|Actual|2012-09-30|June 2011|Actual|2011-06-30||Interventional|||Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma|Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy in Non-resectable or Inoperable Cholangiocarcinoma|Terminated||Phase 2|8|Actual|Steba Biotech S.A.||1||Early end of enrolment with regards to difficulty met to enrol patients .|f||||f||||||||No||2018-06-01 00:36:19.173968|2018-06-01 00:36:19.173968
NCT00975026|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2012-01-04|2009-09-10|2009-09-11|Estimate|||||||2012-01-04|2012-01-05|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Measuring the Feasibility and the Effects of Chair Massage on Pain and Discomfort in the Cardiac Sonographer|Measuring the Feasibility and the Effects of Chair Massage on Pain and Discomfort in the Cardiac Sonographer - A Pilot Study|Completed||N/A|45|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 00:36:19.267762|2018-06-01 00:36:19.267762
NCT00975013|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-09-04|2009-09-10|2009-09-11|Estimate|||||||2015-09-04|2015-09-07|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass|Losing More Than Just Weight: Bone Loss After Laparoscopic Roux-en-Y Gastric Bypass|Completed|||40|Actual|Gundersen Lutheran Medical Foundation|||1||f||||||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 00:36:19.366492|2018-06-01 00:36:19.366492
NCT00975000|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2015-12-23|2014-01-09|2017-02-07|2009-09-10|2009-09-11|Estimate|2015-12-23|2016-01-29|Estimate|2014-01-09|2014-02-07|Estimate|2017-02-07|2017-03-15|Actual|December 2009||2009-12-31|February 2017|2017-02-28||||April 2013|Actual|2013-04-30||Interventional|||Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism|Completed||Phase 3|114|Actual|Amgen||2|||f||||f||||||||||2018-06-01 00:36:19.651794|2018-06-01 00:36:19.651794
NCT00974987|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2018-04-24|2009-09-10|2009-09-11|Estimate|||||||2018-04-24|2018-04-25|Actual|September 1, 2009|Actual|2009-09-01|June 2017|2017-06-30|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|||Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II, Multicenter, Study for Newly Diagnosed Glioblastomas Using Boron Neutron Capture Therapy, Additional X-ray Treatment and Chemotherapy|Completed||Phase 2|32|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||||2018-06-01 00:36:21.650353|2018-06-01 00:36:21.650353
NCT00974974|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2015-12-08|2013-09-27|2017-01-20|2009-09-10|2009-09-11|Estimate|2015-12-08|2016-01-14|Estimate|2013-09-27|2013-10-28|Estimate|2017-01-20|2017-03-06|Actual|September 2009||2009-09-30|January 2017|2017-01-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional||All treated|A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).|A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease|Completed||Phase 3|471|Actual|IMPAX Laboratories, Inc.||2|||f||||f||||||||No||2018-06-01 00:36:22.670731|2018-06-01 00:36:22.670731
NCT00974961|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2010-03-16|2009-09-10|2009-09-11|Estimate|||||||2010-03-16|2010-03-18|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|December 2009|Anticipated|2009-12-31||Interventional|HRV||Levobupivacaine on Heart Rate Variability (HRV) in Spinal Anesthesia|Comparison of the Effects of Levobupivacaine and Bupivacaine on Heart Rate Variability in Spinal Anesthesia|Unknown status|Recruiting|Phase 4|70|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 00:36:25.491143|2018-06-01 00:36:25.491143
NCT00974948|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2009-09-10|2009-09-10|2009-09-11|Estimate|||||||2009-09-10|2009-09-11|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Trial of Endoscopic Ultrasound (EUS) - Guided Celiac Plexus Neurolysis|A Randomized, Double Blind, Sham-Controlled Trial of EUS-Guided Celiac Plexus Neurolysis (EUS-CPN) for Pain Due to Newly Diagnosed, Inoperable Pancreatic Cancer|Completed||Phase 3|100|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 00:36:26.212376|2018-06-01 00:36:26.212376
NCT00974935|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2015-06-18|2009-09-10|2009-09-11|Estimate|||||||2015-06-18|2015-06-19|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase I STEBVax in Healthy Adults|Phase I Study of the Safety and Immunogenicity of Recombinant Staphylococcal Enterotoxin B Vaccine (STEBVax) in Healthy Adults|Completed||Phase 1|29|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 00:36:27.353289|2018-06-01 00:36:27.353289
NCT00974922|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|2016-12-14||2018-02-09|2009-09-10|2009-09-11|Estimate|2018-02-09|2018-03-09|Actual||||2018-02-09|2018-03-09|Actual|August 2009||2009-08-31|February 2018|2018-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Group assignment was blinded to the PI and was never unblinded due to the discontinuation of the study by the sponsor. Therefore we are unable to determine the number of participants in each group. No data analyses occurred due to lack of any scientific utility of the information.|Vitamin D Deficiency in Patients With Hypertension|Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension|Terminated||Phase 4|40|Actual|UConn Health|Study was never completed due to early termination of the trial by sponsor. Data were never analyzed because group assignment was never un-blinded and data lacked any scientific utility.|3||Administrative/Sponsor Business Decision - terminated - study was not completed|f||||f||||||||||2018-06-01 00:36:28.320573|2018-06-01 00:36:28.320573
NCT00974909|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2015-08-25|2009-09-10|2009-09-11|Estimate|||||||2015-08-25|2015-08-26|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|August 2015|Actual|2015-08-31|October 2011|Actual|2011-10-31||Interventional|||Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence|Percutaneous Tibial Nerve Stimulation in the Treatment of Fecal Incontinence: a Multi-center, Randomized, Placebo Controlled Study|Completed||Phase 3|59|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:36:29.368731|2018-06-01 00:36:29.368731
NCT00974896|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-10|||2016-10-26|2009-09-10|2009-09-11|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors|A Phase 1b Study of AMG 479 With Biologics or Chemotherapy in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|46|Actual|NantCell, Inc.||2|||f||||||||||||||2018-06-01 00:36:29.94947|2018-06-01 00:36:29.94947
NCT00974883|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-07-16|2009-09-09|2009-09-10|Estimate|||||||2015-07-16|2015-07-17|Estimate|June 2010||2010-06-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|TABUL||Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)|The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (GCA).|Completed|||880|Actual|University of Oxford|||2||f||||t||||||Samples With DNA|"~     Temporal artery biopsy samples Serum Plasma White cells Video images of temporal and axillary~     arteries~   "|||2018-06-01 00:36:30.155597|2018-06-01 00:36:30.155597
NCT00974870|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-09-14|2009-09-09|2009-09-10|Estimate|||||||2012-09-14|2012-09-17|Estimate|November 2009||2009-11-30|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Pilot Study Testing the Efficacy of a Needling Device for the Treatment of Acne Scars|A Split-face Randomized Controlled Trial to Assess the Efficacy of a Needling Device for the Treatment of Acne Scars|Completed||N/A|20|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 00:36:30.540343|2018-06-01 00:36:30.540343
NCT00974857|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2013-09-06|2009-09-09|2009-09-10|Estimate|||||||2013-09-06|2013-09-09|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Effects Of Volume Control Guided by Body Composition Monitor (BCM) on Blood Pressure and Cardiac Condition in Hemodialysis Patients|Effects Of Volume Control Guided By Bioimpedance Spectroscopy On Blood Pressure And Cardiac Condition In Hemodialysis Patients|Completed||Phase 4|126|Actual|Ege University||2|||f||||t||||||||||2018-06-01 00:36:30.753082|2018-06-01 00:36:30.753082
NCT00974844|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-08-23|2009-09-09|2009-09-10|Estimate|||||||2011-08-23|2011-08-24|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|PAL||Posterior Assisted Levitation of Dropped Nucleus|Posterior Assisted Levitation by Pars-Plana Levitator|Completed|||14|Anticipated|Dow University of Health Sciences|||||f||||t||||||||||2018-06-01 00:36:31.518072|2018-06-01 00:36:31.518072
NCT00974831|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2010-11-24|2009-09-09|2009-09-10|Estimate|||||||2010-11-24|2010-11-25|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Glucose Tolerance in Healthy Overweight Adults|Glucose Tolerance in Healthy Overweight Adults|Completed||Phase 2|24|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-06-01 00:36:31.926389|2018-06-01 00:36:31.926389
NCT00974818|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2015-10-20||2015-10-20|2009-09-09|2009-09-10|Estimate|2015-10-20|2015-11-20|Estimate||||2015-10-20|2015-11-20|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients|Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients: A Randomized Phase III Non-inferiority Trial|Terminated||Phase 3|50|Actual|Memorial Sloan Kettering Cancer Center||2||Lack of accrual|f||||t||||||||||2018-06-01 00:36:32.128725|2018-06-01 00:36:32.128725
NCT00974805|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2014-12-05|2009-09-09|2009-09-10|Estimate|||||||2014-12-05|2014-12-08|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|IMAS||An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease|An Investigation Into the Mechanisms of Action of a Combined Long Acting Beta Agonist/Inhaled Corticosteroid (Seretide 500 Accuhaler) on the Bacterial Colonisation, Immunology and Inflammation of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|48|Anticipated|University of Southampton||1|||f||||t||||||||||2018-06-01 00:36:32.497109|2018-06-01 00:36:32.497109
NCT00974792|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2013-08-23|2009-09-09|2009-09-10|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2006||2006-01-31|September 2009|2009-09-30||||May 2011|Anticipated|2011-05-31||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma|A Phase II Single Arm Study of the Use of CODOX-M/IVAC With Rituximab (R-CODOX-M/IVAC) in the Treatment of Patients With Diffuse Large B-Cell Lymphoma (International Prognostic Index High or High-Intermediate Risk)|Unknown status|Recruiting|Phase 2|150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:36:32.591987|2018-06-01 00:36:32.591987
NCT00974779|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-01-13|2009-09-09|2009-09-10|Estimate|||||||2012-01-13|2012-01-18|Estimate|November 2009||2009-11-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|HCO1100||High-cutoff Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients|"Application of the High-cutoff (HCO1100) Hemodialyzer to Reduce Chronic Inflammation in Hemodialysis Patients With Elevated CRP Levels"|Completed||Phase 2/Phase 3|19|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-06-01 00:36:32.674054|2018-06-01 00:36:32.674054
NCT00974766|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-02-22|2009-09-09|2009-09-10|Estimate|||||||2015-02-22|2015-02-24|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis|Randomized Controlled Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis|Completed||Phase 2/Phase 3|92|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-06-01 00:36:32.902143|2018-06-01 00:36:32.902143
NCT00974753|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2016-01-12|2009-09-09|2009-09-10|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Prophylactic Ketorolac Post Epiretinal Membrane Surgery|A Placebo-controlled, Randomized, Clinical Trial of Prophylactic Ketorolac 0.5% in Patients Undergoing Pars Plana Vitrectomy and Phacovitrectomy Epiretinal Membrane Peel Surgery: Assessing Macular Volume With Spectral-domain OCT|Completed||N/A|18|Actual|Queen's University||4|||f||||f||||||||||2018-06-01 00:36:33.149948|2018-06-01 00:36:33.149948
NCT00974740|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2017-06-16|2009-09-09|2009-09-10|Estimate|||||||2017-06-16|2017-06-19|Actual|March 2004||2004-03-31|June 2017|2017-06-30|March 2009|Actual|2009-03-31|January 2008|Actual|2008-01-31||Interventional|||DIATOR-Diabetes Intervention With Atorvastatin|DIATOR - Diabetes Intervention With Atorvastatin. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of Atorvastatin on Residual Beta-cell Function and Glycemic Control in Patients With Newly Diagnosed Type 1 Diabetes Mellitus|Terminated||Phase 1|63|Actual|Profil Institut für Stoffwechselforschung GmbH||2||for lack of recruitment|f||||f||||||||||2018-06-01 00:36:33.417004|2018-06-01 00:36:33.417004
NCT00974727|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-10-01|2009-09-09|2009-09-10|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2009||2009-05-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Gardening Program to Assess Unhealthy Lifestyle Contributions to Summer Weight Gain in Children|Use of Biomarkers to Assess Unhealthy Lifestyle Contributions to Summer Weight Gain in Children|Completed||N/A|12|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:36:33.687113|2018-06-01 00:36:33.687113
NCT00974714|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2010-01-19|2009-09-09|2009-09-10|Estimate|||||||2010-01-19|2010-01-20|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||L-arginine Effects on Chronic Hypertension in Pregnancy|Effects of Oral L-arginine on Chronic Hypertension in Pregnancy|Completed||Phase 3|80|Anticipated|University of Modena and Reggio Emilia||2|||f||||t||||||||||2018-06-01 00:36:33.914182|2018-06-01 00:36:33.914182
NCT00974701|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2011-06-09|2009-09-09|2009-09-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|MA-79||A Pilot and Feasibility Study to Evaluate Capsule Endoscopy|A Pilot and Feasibility Study to Evaluate Capsule Endoscopy in Subjects Presenting With Acute, Overt Upper Gastrointestinal Hemorrhage|Completed||N/A|50|Anticipated|Given Imaging Ltd.||1|||f||||f||||||||||2018-06-01 00:36:34.184|2018-06-01 00:36:34.184
NCT00974688|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2013-08-25|2009-09-09|2009-09-10|Estimate|||||||2013-08-25|2013-08-27|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Optimizing Health Among Children With Congenital Heart Defects|Optimizing Health Among Children With Congenital Heart Defects Through Rehabilitation Focused on Physical Activity Determinants|Completed||N/A|172|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:36:34.370559|2018-06-01 00:36:34.370559
NCT00974675|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|2017-03-22||2017-03-22|2009-09-09|2009-09-10|Estimate|2017-03-22|2017-05-02|Actual||||2017-03-22|2017-05-02|Actual|September 29, 2006|Actual|2006-09-29|March 2017|2017-03-31|August 3, 2007|Actual|2007-08-03|August 3, 2007|Actual|2007-08-03||Interventional||Safety population included all participants who received at least 1 dose of investigational medicinal product (IMP: CAT-354 or placebo) including those who did not complete the study.|A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma|A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma|Terminated||Phase 1|23|Actual|MedImmune LLC|Recruitment to the study was terminated before the planned number of participants was enrolled in CAT-354 10 mg/kg group due to the slow recruitment rate.|4||"Study recruitment was terminated before the planned number of subjects was enrolled in CAT-354~   10 mg/kg group due to the slow recruitment rate."|f||||f||||||||||2018-06-01 00:36:34.601447|2018-06-01 00:36:34.601447
NCT00974662|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-04-27|2009-09-09|2009-09-10|Estimate|||||||2015-04-27|2015-04-28|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|||Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer|Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy on Obstructing Endobronchial Non-Small Cell Lung Cancer|Terminated||Phase 2|3|Actual|Steba Biotech S.A.||1||Early end of enrolment with regards to difficulty met to enrol patients.|f||||f||||||||||2018-06-01 00:36:37.029781|2018-06-01 00:36:37.029781
NCT00974649|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2013-03-28|2009-09-09|2009-09-10|Estimate|||||||2013-03-28|2013-03-29|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Psychosocial Determinants of Continuing or Discontinuing Infertility Treatment: A Psychological Analysis|Psychosocial Determinants of Continuing or Discontinuing Infertility Treatment: A Psychological Analysis|Completed||N/A|315|Actual|University Hospital, Gasthuisberg||1|||f||||f||||||||||2018-06-01 00:36:37.251093|2018-06-01 00:36:37.251093
NCT00974636|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-08-04|2009-09-09|2009-09-10|Estimate|||||||2015-08-04|2015-08-05|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|BIA||Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial|Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial|Completed||N/A|35|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:36:37.483255|2018-06-01 00:36:37.483255
NCT00974623|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2017-04-04|2009-09-09|2009-09-10|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2009||2009-09-30|April 2017|2017-04-30|November 2013|Actual|2013-11-30|January 2013|Actual|2013-01-31||Observational|APPROACH-001||Bone Graft Materials Observational Registry|A Prospective Patient Registry for Bone Graft Substitutes in Spinal Fusion: Patient Outcomes and Use in Clinical Practice|Terminated|||329|Actual|Baxter Healthcare Corporation|||1|Parent sponsor company (Baxter Healthcare) company cut funding|f||||f||||||||||2018-06-01 00:36:37.553216|2018-06-01 00:36:37.553216
NCT00974610|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2017-05-23|2009-09-09|2009-09-10|Estimate|||||||2017-05-23|2017-05-24|Actual|August 2008||2008-08-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Observational|||Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.|Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer|Completed|||803|Actual|Cancer Trials Ireland|||5||f||||||||||||||2018-06-01 00:36:37.754272|2018-06-01 00:36:37.754272
NCT00974597|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2010-06-21|2009-09-09|2009-09-10|Estimate|||||||2010-06-21|2010-06-22|Estimate|September 2009||2009-09-30|December 2009|2009-12-31||||September 2010|Anticipated|2010-09-30||Interventional|||Comparison of AWBAT™-D and MEPILEX® AG for Treatment of Donor Sites in Burn Surgery|A Randomized, Prospective Comparison of AWBAT™-D and MEPILEX® AG for Treatment of Donor Sites in Burn Surgery|Terminated||N/A|30|Anticipated|Aubrey Inc.||||Management Decision|f||||f||||||||||2018-06-01 00:36:37.937419|2018-06-01 00:36:37.937419
NCT00974584|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2016-11-01|2009-09-08|2009-09-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|65|Actual|Genentech, Inc.||4|||f||||||||||||||2018-06-01 00:36:38.020223|2018-06-01 00:36:38.020223
NCT00974571|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2009-09-17||2015-06-23|2009-09-09|2009-09-10|Estimate|2010-05-07|2010-06-07|Estimate||||2015-06-23|2015-07-16|Estimate|November 2001||2001-11-30|June 2015|2015-06-30|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis|Completed||Phase 3|1365|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 00:36:38.354935|2018-06-01 00:36:38.354935
NCT00974558|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-01-30|2009-09-09|2009-09-10|Estimate|||||||2015-01-30|2015-02-02|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Use of a Handheld Fan to Manage Breathlessness - A Feasibility Study|The Use of a Handheld Fan to Improve Breathlessness - a Feasibility Study to Assess Relief From Breathlessness After Five Minutes Use of a Handheld Fan Directed at the Cheeks|Completed||N/A|31|Actual|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-06-01 00:36:39.269345|2018-06-01 00:36:39.269345
NCT00974532|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2012-12-03|2009-09-09|2009-09-10|Estimate|||||||2012-12-03|2012-12-05|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Analysis of Calcium Balance in Chronic Kidney Disease|Analysis of Calcium Balance in Chronic Kidney Disease|Completed||N/A|16|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 00:36:39.583318|2018-06-01 00:36:39.583318
NCT00974519|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2009-10-28|2009-09-09|2009-09-10|Estimate|||||||2009-10-28|2009-10-29|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||The Effect of Combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on Immune Reconstitution of HIV/AIDS Patients|Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trials on the Effect of Combination of TCM and HAART on Immune Reconstitution of HIV/AIDS Patients|Unknown status|Recruiting|N/A|180|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||3|||f||||f||||||||||2018-06-01 00:36:39.880348|2018-06-01 00:36:39.880348
NCT00974506|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-07-10|2009-09-09|2009-09-10|Estimate|||||||2012-07-10|2012-07-11|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Pilot Study: Complementary Therapies in Geriatric Patients|Pilot Study Complementary Therapies in Geriatric Patients|Completed||N/A|50|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:36:40.11481|2018-06-01 00:36:40.11481
NCT00974493|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2017-11-02|2009-09-09|2009-09-10|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2010||2010-06-30|October 2014|2014-10-31|February 28, 2017|Actual|2017-02-28|March 2013|Actual|2013-03-31||Interventional|OVIVA||Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)|Randomized Open Label Study of Oral Versus Intravenous Antibiotic Treatment for Bone and Joint Infections Requiring Prolonged Antibiotic Treatment: Multi-centre Study|Completed||Phase 4|1050|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 00:36:40.324904|2018-06-01 00:36:40.324904
NCT00974480|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2010-11-16||2011-09-18|2009-09-09|2009-09-10|Estimate|2010-11-16|2010-12-15|Estimate||||2011-09-18|2011-09-20|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging|Single Blind Study to Evaluate the Tolerance and Effectiveness of Redermic Versus Rejuva-A™ (0.025% Tretinoin) and Redermic in Combination With Rejuva-A™ (0.025% Tretinoin) Under Normal Conditions in Subjects With Signs of Aging|Completed||N/A|120|Actual|Cosmetique Active International||3|||f||||f||||||||||2018-06-01 00:36:41.150825|2018-06-01 00:36:41.150825
NCT00974467|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-03-11|2009-09-09|2009-09-10|Estimate|||||||2015-03-11|2015-03-12|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluating a Website for Parents of Injured Children|Evaluating a Website for Parents of Injured Children|Completed||Phase 2|100|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 00:36:42.847733|2018-06-01 00:36:42.847733
NCT00974454|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2009-10-28|2009-09-09|2009-09-10|Estimate|||||||2009-10-28|2009-10-29|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|April 2010|Anticipated|2010-04-30||Interventional|||Research on Effect of Traditional Chinese Medicine (TCM) on Immune Reconstitution of HIV/AIDS Patients After Highly Active Antiretroviral Therapy (HAART)|Research on Effect of TCM on Immune Reconstitution of HIV/AIDS Patients After HAART|Unknown status|Recruiting|N/A|180|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-06-01 00:36:43.064369|2018-06-01 00:36:43.064369
NCT00974441|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2009-09-09|2009-09-09|2009-09-10|Estimate|||||||2009-09-09|2009-09-10|Estimate|August 2006||2006-08-31|September 2009|2009-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Divalproex Sodium 500 mg Extended Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|48|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:36:43.150744|2018-06-01 00:36:43.150744
NCT00974428|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2016-07-11|2009-09-09|2009-09-10|Estimate|||||||2016-07-11|2016-07-12|Estimate|October 2009||2009-10-31|July 2016|2016-07-31||||March 2010|Anticipated|2010-03-31||Interventional|||Multi-Center Study Evaluating the Efficacy of Wobenzym(R)N in Treating Knee Osteoarthritis|A 6 Week, Double Blind, Placebo-controlled, Multi-center Pilot Study Evaluating the Efficacy of Wobenzym(R)N at Reducing Pain Severity as Measured by the WOMAC Pain Score in Subjects With Knee Osteoarthritis|Withdrawn||Phase 2/Phase 3|0|Actual|Atrium Innovations||3|||f||||t||||||||||2018-06-01 00:36:43.228168|2018-06-01 00:36:43.228168
NCT00974415|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2018-02-20|2009-09-09|2009-09-10|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2010||2010-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of the Carbon Dioxide Treatment for Fat Reduction|A Pilot Study of the Carbon Dioxide Treatment for Fat Reduction|Active, not recruiting||N/A|25|Anticipated|Northwestern University||2|||f||||f||||||||||2018-06-01 00:36:43.345083|2018-06-01 00:36:43.345083
NCT00974389|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2013-08-09|2009-09-09|2009-09-10|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2009||2009-07-31|September 2009|2009-09-30||||June 2010|Anticipated|2010-06-30||Interventional|||S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery|Phase II Study of Combination Chemotherapy With S-1 Plus Avastin in Unresectable or Recurrent Colorectal Cancer After Failure of Prior Chemotherapy, Including Irinotecan and Oxaliplatin Regimens.|Unknown status|Recruiting|Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:36:43.5158|2018-06-01 00:36:43.5158
NCT00974376|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2017-05-08||2017-05-08|2009-09-09|2009-09-10|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|November 4, 2009|Actual|2009-11-04|May 2017|2017-05-31|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|||Gabapentin Treatment of Cannabis Dependence|Gabapentin Treatment of Cannabis Dependence|Completed||Phase 2|150|Actual|The Scripps Research Institute||2|||f||||f||||||||No||2018-06-01 00:36:43.575811|2018-06-01 00:36:43.575811
NCT00974363|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|2016-12-12||2017-03-01|2009-09-09|2009-09-10|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|September 2009||2009-09-30|December 2016|2016-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612|Persistence of Antibodies After Vaccination With GSK Biologicals' Meningococcal Vaccine GSK134612 in Adolescents and Young Adults|Completed||Phase 3|697|Actual|GlaxoSmithKline|None reported.|2|||f||||||||||||||2018-06-01 00:36:43.774952|2018-06-01 00:36:43.774952
NCT00974350|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08||2009-12-21|2012-04-25|2009-09-09|2009-09-10|Estimate||||2009-12-21|2009-12-23|Estimate|2012-04-25|2012-04-27|Estimate|January 2007||2007-01-31|December 2009|2009-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Safety and Efficacy Study of SABER™-Bupivacaine for Pain Following Hernia Repair|A Double-Blind, Placebo-Controlled, Pharmacodynamic and Pharmacokinetic Dose Response Study of SABER™-Bupivacaine Instilled Into the Wound in Patients Undergoing Open Inguinal Hernia Repair|Completed||Phase 2|124|Actual|Durect||3|||f||||f||||||||||2018-06-01 00:36:45.237842|2018-06-01 00:36:45.237842
NCT00974337|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-01-13|2009-09-09|2009-09-10|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Relative Adrenal Insufficiency in Preterm Very Low Birth Weight Infants With Shock|Basal and Stimulated Cortisol Levels in Preterm Very Low Birth Weight Infants With and Without Shock: A Cross-sectional Study|Completed|||39|Actual|All India Institute of Medical Sciences, New Delhi|||2||f||||f||||||||||2018-06-01 00:36:45.350735|2018-06-01 00:36:45.350735
NCT00974324|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2010-09-14|2009-09-09|2009-09-10|Estimate|||||||2010-09-14|2010-09-15|Estimate|August 2009||2009-08-31|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|PTCL||Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma|Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma|Unknown status|Recruiting|Phase 2|15|Anticipated|Fudan University||1|||f||||t||||||||||2018-06-01 00:36:45.414875|2018-06-01 00:36:45.414875
NCT00974311|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2012-09-28||2018-04-19|2009-09-09|2009-09-10|Estimate|2012-09-28|2012-10-30|Estimate||||2018-04-19|2018-04-23|Actual|September 30, 2009|Actual|2009-09-30|April 2018|2018-04-30|November 2, 2017|Actual|2017-11-02|September 15, 2011|Actual|2011-09-15||Interventional|AFFIRM|Intent-to-treat population (ITT) included all participants who were randomized into the study.|Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy|Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy|Completed||Phase 3|1199|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:36:45.612257|2018-06-01 00:36:45.612257
NCT00974298|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2014-08-05|2009-09-09|2009-09-10|Estimate|||||||2014-08-05|2014-08-06|Estimate|March 2009||2009-03-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Uncemented Total Elbow Arthroplasty Data Collection|Uncemented Total Elbow Arthroplasty Data Collection|Terminated|||2|Actual|Vanderbilt University|||1||f||||f||||||||||2018-06-01 00:36:47.464197|2018-06-01 00:36:47.464197
NCT00974285|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2009-10-28|2009-09-09|2009-09-10|Estimate|||||||2009-10-28|2009-10-29|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Clinical Trials on the Effect of Immunity 1 (Fuzheng 1) on Immune Reconstitution of HIV Patients|Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trials on the Effect of Immunity 1 (Fuzheng 1) on Immune Reconstitution of HIV Patients|Unknown status|Recruiting|N/A|60|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-06-01 00:36:47.532262|2018-06-01 00:36:47.532262
NCT00974272|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2009-09-09|2009-09-09|2009-09-10|Estimate|||||||2009-09-09|2009-09-10|Estimate|August 2006||2006-08-31|September 2009|2009-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation|Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation|Completed||Phase 4|39|Actual|Carl T. Hayden VA Medical Center||2|||f||||f||||||||||2018-06-01 00:36:47.610528|2018-06-01 00:36:47.610528
NCT00974259|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2015-12-31|2009-09-09|2009-09-10|Estimate|||||||2015-12-31|2016-01-01|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|BOOST 2||Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)|Phase 2, Randomized Clinical Trial of the Safety and Efficacy of Brain Tissue Oxygen Monitoring in the Management of Severe Traumatic Brain Injury.|Completed||Phase 2|122|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 00:36:47.681036|2018-06-01 00:36:47.681036
NCT00974246|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|2015-06-15||2016-11-04|2009-09-09|2009-09-10|Estimate|2015-06-30|2015-07-02|Estimate||||2016-11-04|2016-12-28|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DISK-02||The Effect on Depressive Symptoms in ECF Residents With COPD|The Effect of Advair Diskus Treatment on Depression in Nursing Home Residents With COPD|Completed||Phase 4|30|Actual|Valley Medical Research||1|||f||||f||||||||No||2018-06-01 00:36:47.817817|2018-06-01 00:36:47.817817
NCT00974233|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2016-05-17||2017-07-12|2009-09-09|2009-09-10|Estimate|2017-07-12|2017-07-13|Actual||||2017-07-12|2017-07-13|Actual|October 2009||2009-10-31|July 2017|2017-07-31|April 2015|Actual|2015-04-30|July 2013|Actual|2013-07-31||Interventional||Subjects with progressive chronic lymphocytic leukemia/small lymphocytic lymphoma receiving 1-5 prior unique treatment regimens.|Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL|Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL|Completed||Phase 2|34|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 00:36:48.151017|2018-06-01 00:36:48.151017
NCT00974220|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2013-09-25||2015-11-19|2009-09-09|2009-09-10|Estimate|2015-11-19|2015-12-30|Estimate||||2015-11-19|2015-12-30|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)|Effect of Inhaled Nebulized Fentanyl on Exertional Dyspnea and Exercise Tolerance in Patients With Moderate-to-severe COPD|Completed||N/A|16|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 00:36:49.385675|2018-06-01 00:36:49.385675
NCT00974194|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2017-11-14|2009-09-09|2009-09-10|Estimate|||||||2017-11-14|2017-11-17|Actual|September 2009|Actual|2009-09-30|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2017|Actual|2017-09-01||Interventional|SPoCOT||Safety and Cost-effectiveness Study of Single Port Laparoscopic Cholecystectomies|Single Port vs Tree Trocars Laparoscopic Cholecystectomy: a Randomized Controlled Trial|Active, not recruiting||N/A|268|Actual|University of Lausanne Hospitals||2|||f||||t||||||||||2018-06-01 00:36:50.258131|2018-06-01 00:36:50.258131
NCT00974181|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2010-05-14|2009-09-09|2009-09-10|Estimate|||||||2010-05-14|2010-05-17|Estimate|January 2004||2004-01-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|May 2005|Actual|2005-05-31||Interventional|||The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)|The European Cobalt STent With Antiproliferative for Restenosis Trial (EuroSTAR Trial)|Completed||Phase 3|282|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 00:36:50.56675|2018-06-01 00:36:50.56675
NCT00974168|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2016-12-20|2009-09-09|2009-09-10|Estimate|||||||2016-12-20|2016-12-21|Estimate|October 2007||2007-10-31|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|||Radiation Therapy in Treating Patients With Malignant Spinal Cord Compression Who Were Previously Treated With Radiation Therapy. ICORG 07-11|A Phase II Trial Evaluating the Efficacy of a Radio-Biological Based Re-Irradiation Strategy for Patients With Malignant Spinal Cord Compression|Active, not recruiting||Phase 2|22|Actual|Cancer Trials Ireland||2|||f||||f||||||||||2018-06-01 00:36:50.888756|2018-06-01 00:36:50.888756
NCT00974155|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2015-03-31|2009-09-09|2009-09-10|Estimate|||||||2015-03-31|2015-04-01|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|EMC||The Early Medication Change (EMC) Trial|Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial|Completed||Phase 4|889|Actual|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-06-01 00:36:51.176104|2018-06-01 00:36:51.176104
NCT00974142|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2018-01-03||2018-04-04|2009-09-09|2009-09-10|Estimate|2018-04-04|2018-05-09|Actual||||2018-04-04|2018-05-09|Actual|September 2009||2009-09-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Oral Cyclosporine in Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blinded, Placebo-Controlled Protocol of Oral Cyclosporine in Patients With Advanced Stage Chronic Obstructive Pulmonary Disease|Completed||Phase 1/Phase 2|43|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 00:36:51.528123|2018-06-01 00:36:51.528123
NCT00974129|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2014-06-23|2009-09-09|2009-09-10|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas|Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six|Withdrawn|||0|Actual|Yale University|||1|no subjects were enrolled, study was halted due to study staff departure|f||||t||||||Samples With DNA|"~     Over the course of the study, one blood draw will be performed on each patient. This blood~     will be used for genetic analysis.~   "|||2018-06-01 00:36:52.809809|2018-06-01 00:36:52.809809
NCT00974116|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2009-09-09|2009-09-09|2009-09-10|Estimate|||||||2009-09-09|2009-09-10|Estimate|January 2010||2010-01-31|September 2009|2009-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|MEND||Trial of the MEND Childhood Obesity Treatment Program|MEND Childhood Obesity Treatment Programme: An RCT to Improve Body Composition and Cardiovascular Health in Overweight and Obese Children.|Unknown status|Not yet recruiting|N/A|300|Anticipated|Institute of Child Health|||||f||||f||||||||||2018-06-01 00:36:52.865014|2018-06-01 00:36:52.865014
NCT00974103|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-08-31|2009-09-09|2009-09-10|Estimate|||||||2012-08-31|2012-09-03|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Persistent Low Back and Pelvic Pain 3-6 Months Post Partum|Persistent Low Back Pain and Pelvic Pain 3-6 Months Post Partum|Completed||N/A|13|Actual|Helse Stavanger HF||2|||f||||f||||||||||2018-06-01 00:36:52.984976|2018-06-01 00:36:52.984976
NCT00974090|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|2014-04-07||2014-04-07|2009-09-09|2009-09-10|Estimate|2014-04-07|2014-05-08|Estimate||||2014-04-07|2014-05-08|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes|A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|194|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 00:36:53.126279|2018-06-01 00:36:53.126279
NCT00974077|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2014-12-19|2009-09-09|2009-09-10|Estimate|||||||2014-12-19|2014-12-23|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|MBCT & EEG||Psychophysiological Correlates of Mindfulness Based Cognitive Therapy (MBCT) in Recurrent Depression|Psychophysiological Correlates of Mindfulness and Attention in Recurrent Depression and Healthy Volunteers|Completed||N/A|120|Actual|University Hospital Tuebingen||2|||f||||t||||||||||2018-06-01 00:36:54.318543|2018-06-01 00:36:54.318543
NCT00974064|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2018-04-30|2009-09-09|2009-09-10|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2009||2009-12-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease|The Natural History of Gene Expression in Lung Cells of Non-Smokers, Smokers, and Ex-Smokers in Health and Disease|Active, not recruiting|||210|Anticipated|Weill Medical College of Cornell University|||5||f||||f||||||Samples With DNA|"~     Subjects will not have more than 550 mL of blood drawn over a period of 8 weeks. Airway~     epithelium from airway brushing samples and alveolar macrophages from bronchoalveolar lavage~     is processed to yield high quality RNA. Complimentary DNA (cDNA) is transcribed from the RNA~     in vitro and the product is hybridized onto gene microarray chips.~   "|Undecided||2018-06-01 00:36:54.48455|2018-06-01 00:36:54.48455
NCT00974051|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|2012-09-17||2013-08-02|2009-09-09|2009-09-10|Estimate|2013-08-02|2013-10-11|Estimate||||2013-08-02|2013-10-11|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia|The Effect of Using Terbutaline or a Reduction in Basal Insulin Infusion as a Therapeutic Agent to Prevent Delayed Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes|Completed||N/A|16|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-06-01 00:36:54.595138|2018-06-01 00:36:54.595138
NCT00974025|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2017-05-31|2009-09-09|2009-09-10|Estimate|||||||2017-05-31|2017-06-01|Actual|June 2009||2009-06-30|May 2017|2017-05-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients|Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation|Completed||N/A|53|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:36:54.916824|2018-06-01 00:36:54.916824
NCT00974012|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2009-09-09|2009-09-09|2009-09-10|Estimate|||||||2009-09-09|2009-09-10|Estimate|October 2006||2006-10-31|September 2009|2009-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Extended Release Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:36:54.98808|2018-06-01 00:36:54.98808
NCT00973999|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2012-09-05|2009-09-08|2009-09-09|Estimate|||||||2012-09-05|2012-09-06|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Botulinum Toxin and Saliva Management in Tracheotomised Patients|A Randomised Placebo Controlled Trial to Explore the Effectiveness of Botulinum Toxin Injection at Reducing Oral Secretions and Frequency of Tracheal Suctioning in Tracheotomised Patients.|Withdrawn||Phase 2|0|Actual|HCA International Limited||1|||f||||t||||||||||2018-06-01 00:36:55.071421|2018-06-01 00:36:55.071421
NCT00973986|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2011-11-28|2009-09-08|2009-09-09|Estimate|||||||2011-11-28|2011-11-29|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|ECGPPA||Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin|Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease|Completed||Phase 1|20|Actual|Liuhuaqiao Hospital||3|||f||||t||||||||||2018-06-01 00:36:55.150084|2018-06-01 00:36:55.150084
NCT00973973|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07||2012-02-06|2013-01-02|2009-09-07|2009-09-09|Estimate||||2012-02-06|2012-02-08|Estimate|2013-01-02|2013-01-08|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety Study of NBI-56418 Sodium in Subjects With Endometriosis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis|Completed||Phase 2|137|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 00:36:55.218365|2018-06-01 00:36:55.218365
NCT00973960|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-06|||2011-08-05|2009-09-08|2009-09-09|Estimate|||||||2011-08-05|2011-08-08|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics|A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics|Completed|||50|Anticipated|GI Dynamics|||||f||||f||||||||||2018-06-01 00:36:55.328146|2018-06-01 00:36:55.328146
NCT00973947|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-05|||2014-12-30|2009-09-05|2009-09-09|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer|A Prospective Randomised Controlled Clinical Trial Investigating the Benefits of Patient-customised Headrests Versus Standard (Non-patient Specific) Headrests in the Immobilisation of Patients Receiving Radiotherapy for Head and Neck Cancer|Completed||N/A|40|Actual|Cancer Trials Ireland||2|||f||||||||||||||2018-06-01 00:36:55.472714|2018-06-01 00:36:55.472714
NCT00973934|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2014-06-09|2009-09-08|2009-09-09|Estimate|||||||2014-06-09|2014-06-10|Estimate|April 2002||2002-04-30|June 2014|2014-06-30|December 2009|Actual|2009-12-31|January 2006|Actual|2006-01-31||Interventional|MST-2||Magnetic Seizure Therapy (MST) for the Treatment of Major Depression|Magnetic Seizure Therapy (MST) for the Treatment of Major Depression|Completed||Phase 2|20|Actual|Duke University||2|||f||||t||||||||||2018-06-01 00:36:55.554283|2018-06-01 00:36:55.554283
NCT00973921|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-06|2012-06-05||2014-03-06|2009-09-08|2009-09-09|Estimate|2014-03-06|2014-04-11|Estimate||||2014-03-06|2014-04-11|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Comparison of StentOptimizer With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography|Comparison of StentOptimizer - an Angiography-based Post Deployment Stent Analysis Application With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography for Post Deployment Stent Analysis|Completed|||40|Actual|Paieon Inc.|This is a relatively small study designed to evaluate the procedural decision about post-deployment dilatation not powered to evaluate the outcome of patients. The operator decision of his post-dilatation strategy was qualitative.||1||f||||f||||||||||2018-06-01 00:36:55.62728|2018-06-01 00:36:55.62728
NCT00973908|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2013-04-25|2009-09-08|2009-09-09|Estimate|||||||2013-04-25|2013-04-26|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea|Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea|Completed||Phase 2/Phase 3|231|Actual|National Health Service, United Kingdom||2|||f||||t||||||||||2018-06-01 00:36:55.797204|2018-06-01 00:36:55.797204
NCT00973895|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-05|||2017-06-30|2009-09-05|2009-09-09|Estimate|||||||2017-06-30|2017-07-02|Actual|August 6, 2009||2009-08-06|September 3, 2010|2010-09-03|September 3, 2010|Actual|2010-09-03|September 3, 2010|Actual|2010-09-03||Interventional|||VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old|VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old|Completed||Phase 1|20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:36:55.881449|2018-06-01 00:36:55.881449
NCT00973882|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2011-11-02|2009-09-08|2009-09-09|Estimate|||||||2011-11-02|2011-11-03|Estimate|April 2005||2005-04-30|November 2011|2011-11-30|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|||Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers|Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.|Completed||Phase 2|60|Actual|Centre Leon Berard||1|||f||||f||||||||||2018-06-01 00:36:55.947345|2018-06-01 00:36:55.947345
NCT00973869|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-05|||2014-06-23|2009-09-05|2009-09-09|Estimate|||||||2014-06-23|2014-06-24|Estimate|July 2009||2009-07-31|September 2009|2009-09-30||||January 2010|Anticipated|2010-01-31||Interventional|||Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery|A Pilot Study of Administration of Curcumin to Determine Colonic Curcumin Tissue Levels in Patients Awaiting Colorectal Endoscopy or Patients With Colorectal Cancer Awaiting Resection|Unknown status|Recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:36:56.068082|2018-06-01 00:36:56.068082
NCT00973856|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2015-06-22|2009-09-08|2009-09-09|Estimate|||||||2015-06-22|2015-06-23|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands|Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands|Completed||N/A|5|Actual|Akron General Medical Center||2|||f||||||||||||||2018-06-01 00:36:56.162941|2018-06-01 00:36:56.162941
NCT00973830|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|July 2010|Anticipated|2010-07-31|April 2010|Anticipated|2010-04-30||Interventional|||The Missouri Health Literacy and Diabetes Communication Initiative|The Missouri Health Literacy and Diabetes Communication Initiative|Unknown status|Recruiting|N/A|1080|Anticipated|Northwestern University||3|||f||||||||||||||2018-06-01 00:36:56.243705|2018-06-01 00:36:56.243705
NCT00973817|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02||2012-07-24|2013-04-01|2009-09-07|2009-09-09|Estimate||||2012-07-24|2012-08-01|Estimate|2013-04-01|2013-04-08|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|SILVER||Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis|Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Subjects With Acute On Chronic Hepatitis (AOCH)|Completed||Phase 2/Phase 3|62|Actual|Vital Therapies, Inc.||2|||f||||t||||||||||2018-06-01 00:36:56.477027|2018-06-01 00:36:56.477027
NCT00973804|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-05|||2018-05-19|2009-09-05|2009-09-09|Estimate|||||||2018-05-19|2018-05-22|Actual|August 25, 2009||2009-08-25|May 20, 2013|2013-05-20|May 20, 2013|Actual|2013-05-20|May 20, 2013|Actual|2013-05-20||Interventional|||Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders|Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders|Terminated||Phase 1|4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:36:56.587186|2018-06-01 00:36:56.587186
NCT00973791|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|FMCS-II||Fluid Management for Cesarean Section II|Fluid Management for Cesarean Section Undergoing Spinal Anesthesia|Completed||N/A|860|Actual|Nanjing Medical University||4|||f||||t||||||||||2018-06-01 00:36:56.659163|2018-06-01 00:36:56.659163
NCT00973778|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2011-06-14|2009-09-08|2009-09-09|Estimate|||||||2011-06-14|2011-06-15|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Interventional|IMRT||A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma|A Phase II Study for Short Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination With Capecitabine in Patients With Resectable Rectal Carcinoma|Unknown status|Recruiting|Phase 2|62|Anticipated|Shanghai Jiao Tong University School of Medicine|||||f||||t||||||||||2018-06-01 00:36:56.737335|2018-06-01 00:36:56.737335
NCT00973765|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|2010-01-19||2010-03-01|2009-09-08|2009-09-09|Estimate|2010-02-12|2010-03-02|Estimate||||2010-03-01|2010-03-09|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses|Randomized Placebo-Controlled Trial of Bactrim on 7 Day Outcome in Emergency Department Patients With Uncomplicated Abscesses at Risk for Community Acquired Methicillin Resistant Staph Aureus|Completed||Phase 3|212|Actual|Wilford Hall Medical Center||2|||f||||t||||||||||2018-06-01 00:36:56.897589|2018-06-01 00:36:56.897589
NCT00973752|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|2016-12-16||2017-02-10|2009-09-08|2009-09-09|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|August 2009||2009-08-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|||Treatment of Older Adults With Acute Lymphoblastic Leukemia|Treatment of Older Adults With Acute Lymphoblastic Leukemia|Completed||Phase 2|30|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:36:57.207812|2018-06-01 00:36:57.207812
NCT00973739|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2013-06-27||2016-02-19|2009-09-08|2009-09-09|Estimate|2016-02-19|2016-03-22|Estimate||||2016-02-19|2016-03-22|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors|Phase II Study of Lapatinib in Children and Adults With Neurofibromatosis Type 2(NF2) and NF2-related Tumors|Completed||Phase 2|21|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 00:36:57.630355|2018-06-01 00:36:57.630355
NCT00973726|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-23|2009-09-08|2009-09-09|Estimate|||||||2009-09-23|2009-09-24|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||The Retinal Function in Relation to Glucose Changes|The Retinal Function in Relation to Glucose Changes|Unknown status|Recruiting|N/A|80|Anticipated|Glostrup University Hospital, Copenhagen||1|||f||||t||||||||||2018-06-01 00:36:57.891594|2018-06-01 00:36:57.891594
NCT00973713|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|March 2012|Anticipated|2012-03-31|September 2011|Anticipated|2011-09-30||Interventional|RADiChol||Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol|Phase II Study of RAD001 in Advanced Cholangiocarcinoma|Unknown status|Recruiting|Phase 2|27|Anticipated|Austin Health||1|||f||||t||||||||||2018-06-01 00:36:58.031276|2018-06-01 00:36:58.031276
NCT00973700|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2010-10-20||2015-10-29|2009-09-07|2009-09-09|Estimate|2011-04-22|2011-05-23|Estimate||||2015-10-29|2015-12-02|Estimate|August 2009||2009-08-31|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)|A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Children and Adults Ages 3 to 64 Years|Completed||Phase 3|784|Actual|Novartis||5|||f||||||||||||||2018-06-01 00:36:58.186915|2018-06-01 00:36:58.186915
NCT00973687|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2015-08-25|2009-09-08|2009-09-09|Estimate|||||||2015-08-25|2015-08-26|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|May 2006|Actual|2006-05-31|April 2006|Actual|2006-04-30||Interventional|||Dexamethasone Tolerability in the Treatment of Acute Asthma in Children|Dexamethasone Tolerability in the Treatment of Acute Asthma in Children|Completed||N/A|430|Actual|IWK Health Centre||4|||f||||f||||||||||2018-06-01 00:36:59.910644|2018-06-01 00:36:59.910644
NCT00973674|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14||2013-02-26|2014-04-04|2009-09-04|2009-09-09|Estimate||||2013-03-11|2013-03-18|Estimate|2014-04-04|2014-05-01|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|RESCUE - TBI||Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Brain Injury|A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Severe Traumatic Brain Injury|Completed||Phase 2|50|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:36:59.990045|2018-06-01 00:36:59.990045
NCT00973661|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2011-07-26|2009-09-08|2009-09-09|Estimate|||||||2011-07-26|2011-07-27|Estimate|March 2010||2010-03-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Electronic Tools to Assist With Identification of and Counseling for Overweight Patients|Electronic Tools to Assist With Identification of and Counseling for Overweight Patients|Completed||N/A|2600|Anticipated|Northwestern University||2|||f||||f||||||||||2018-06-01 00:37:00.109345|2018-06-01 00:37:00.109345
NCT00973648|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2013-06-10|2009-09-08|2009-09-09|Estimate|||||||2013-06-10|2013-06-11|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|August 2010|Actual|2010-08-31||Observational|||Exploring Voluntary Control of Tinnitus|Exploring Voluntary Control of Tinnitus: A Pilot Study|Completed|||17|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 00:37:00.30067|2018-06-01 00:37:00.30067
NCT00973635|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2013-04-12|2009-09-08|2009-09-09|Estimate|||||||2013-04-12|2013-04-15|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||The Web-Based Education of Beginning Interns on Handoffs|The Web-Based Education of Beginning Interns on Handoffs|Withdrawn||N/A|0|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 00:37:00.371837|2018-06-01 00:37:00.371837
NCT00973622|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2013-01-23||2013-07-31|2009-09-04|2009-09-09|Estimate|2013-07-31|2013-09-24|Estimate||||2013-07-31|2013-09-24|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|rTMS||Changing Thought and Action in Tobacco Dependence With Transcranial Magnetic Stimulation|Changing Thought and Action in Tobacco Dependence With Transcranial Magnetic Stimulation|Completed||N/A|66|Actual|University of Arkansas|We experienced significant subject attrition among smokers. We did not experience such attrition among nonsmokers. Also, six smokers were withdrawn because the MRI screen revealed brain abnormalities. No nonsmokers were withdrawn for this reason.|2|||f||||f||||||||||2018-06-01 00:37:00.489615|2018-06-01 00:37:00.489615
NCT00973609|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2015-08-31|2009-09-08|2009-09-09|Estimate|||||||2015-08-31|2015-09-01|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)|Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maintenance Treatment and Reinduction in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer|Completed||Phase 3|853|Actual|AIO-Studien-gGmbH||3|||f||||t||||||||||2018-06-01 00:37:00.838623|2018-06-01 00:37:00.838623
NCT00973596|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2014-12-01|2009-09-08|2009-09-09|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|March 2012|Actual|2012-03-31||Observational|SWITCO65+||The Swiss Venous Thromboembolism Cohort 65+|Swiss Venous Thromboembolism Cohort Study of Elderly Patients With Acute Venous Thromboembolism|Completed|||1003|Actual|University of Lausanne Hospitals|||||f||||f||||||||||2018-06-01 00:37:01.065218|2018-06-01 00:37:01.065218
NCT00973583|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2014-12-02|2009-09-08|2009-09-09|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2005||2005-05-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infections|Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infections; a Randomized Double-blinded Trial in Young Finnish Men|Completed||N/A|164|Actual|University of Tampere||2|||f||||f||||||||||2018-06-01 00:37:01.151003|2018-06-01 00:37:01.151003
NCT00973570|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|TABADO||Smoking Cessation Program Among Adolescents in Vocational Training Centers|Evaluation of a Smoking Cessation Program Among ADOlescents in Vocational Training Centers|Unknown status|Recruiting|N/A|2000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-06-01 00:37:01.245662|2018-06-01 00:37:01.245662
NCT00973557|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2012-02-06|2009-09-08|2009-09-09|Estimate|||||||2012-02-06|2012-02-07|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Observational|||The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function|The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function|Completed|||6|Actual|Cedars-Sinai Medical Center|||1||f||||f||||||Samples Without DNA|"~     10 ml of whole blood will be collected to measure prolactin, growth hormone, IGF-I, TSH,~     thyroxine, ACTH, and cortisol levels~   "|||2018-06-01 00:37:01.390833|2018-06-01 00:37:01.390833
NCT00973544|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|September 2009||2009-09-30|September 2009|2009-09-30||||||||Observational|||Do Closed Suction Drains Affect the Complications Rate of Breast Reconstruction With Silicone Prosthesis?|Complications of Breast Reconstruction With Silicone Prosthesis in Relation to Closed Suction Drains|Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||2||f||||f||||||Samples Without DNA|"~     cultures of fluids from drain~   "|||2018-06-01 00:37:01.511203|2018-06-01 00:37:01.511203
NCT00973531|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-01-25|2009-09-08|2009-09-09|Estimate|||||||2012-01-25|2012-01-26|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension|Effect of Treating Sleep Disorder Breathing Therapy in Patients With Resistant Hypertension|Withdrawn||N/A|0|Actual|Albert Einstein Healthcare Network||2|||f||||f||||||||||2018-06-01 00:37:01.587515|2018-06-01 00:37:01.587515
NCT00973518|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2010-08-12|2009-09-08|2009-09-09|Estimate|||||||2010-08-12|2010-08-13|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG)|Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction Test: A One-month Study|Completed|||160|Anticipated|Orasi Medical, Inc.|||2||f||||f||||||||||2018-06-01 00:37:01.667042|2018-06-01 00:37:01.667042
NCT00973505|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|AI-CYP19||CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)|Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)|Unknown status|Recruiting||100|Anticipated|Korea University Anam Hospital|||1||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 00:37:01.778966|2018-06-01 00:37:01.778966
NCT00972829|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-09|2009-09-08|2009-09-09|Estimate|||||||2009-09-09|2009-09-10|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia||Unknown status|Recruiting|Phase 4|30|Anticipated|Bronx VA Medical Center||2|||f||||f||||||||||2018-06-01 00:37:15.262148|2018-06-01 00:37:15.262148
NCT00973492|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|VARIAFIT||Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes|Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes|Unknown status|Active, not recruiting||30|Actual|Association Grenobloise pour le Developpement D'etudes et de Recherches en Physiopathologie Endocrinienne, Diabetologie et Maladies de la Nutrition|||1||f||||f||||||||||2018-06-01 00:37:01.932042|2018-06-01 00:37:01.932042
NCT00973479|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|2013-08-08|2012-03-12|2013-11-29|2009-09-04|2009-09-09|Estimate|2013-08-08|2013-10-14|Estimate|2012-03-12|2012-03-14|Estimate|2013-11-29|2013-12-25|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|February 2013|Actual|2013-02-28|March 2011|Actual|2011-03-31||Interventional|||An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 3|592|Actual|Centocor, Inc.||2|||f||||t||||||||||2018-06-01 00:37:02.040813|2018-06-01 00:37:02.040813
NCT00973466|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2011-01-12|2009-09-07|2009-09-09|Estimate|||||||2011-01-12|2011-01-13|Estimate|May 2009||2009-05-31|January 2011|2011-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|CTNG||Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients|Prevalence of Asymptomatic and Symptomatic Infection of N. Gonorrheae and C. Trachomatis and Seroprevalence of HSV Typ 2 and Sexual Health Seeking Behaviour in People With HIV Infection in Bern|Completed|||300|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-06-01 00:37:03.431874|2018-06-01 00:37:03.431874
NCT00973453|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2011-09-09|2009-09-08|2009-09-09|Estimate|||||||2011-09-09|2011-09-12|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients|Dose Tolerability Study With High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients|Completed||Phase 2|48|Actual|HAL Allergy||3|||f||||t||||||||||2018-06-01 00:37:03.527339|2018-06-01 00:37:03.527339
NCT00973440|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2013-10-21|2009-09-08|2009-09-09|Estimate|||||||2013-10-21|2013-10-22|Estimate|March 2009||2009-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2011|Actual|2011-07-31||Observational|||Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Gastrointestinal Malignancies|Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Colorectal, Breast or Lung Cancer|Completed|||59|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 00:37:03.643552|2018-06-01 00:37:03.643552
NCT00973427|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2015-09-22|2009-09-08|2009-09-09|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2008||2008-06-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||DNA Chip Based Prognosis of Lung Cancer|DNA Chip Based Prognosis of Lung Cancer|Completed|||144|Actual|Medical Prognosis Institute A/S|||||f||||f||||||Samples Without DNA|"~     post resection specimen~   "|||2018-06-01 00:37:03.706037|2018-06-01 00:37:03.706037
NCT00973414|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|FMCS-III||Fluid Management for Cesarean Section III|Fluid Management for Cesarean Section Undergoing Combined Spinal Epidural Anesthesia (CSEA)|Completed||N/A|850|Actual|Nanjing Medical University||4|||f||||t||||||||||2018-06-01 00:37:03.885754|2018-06-01 00:37:03.885754
NCT00973401|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-23|2009-09-08|2009-09-09|Estimate|||||||2009-09-23|2009-09-24|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|||Retinal Function in Relation to Long Term Changes in the Glucose Level||Unknown status|Recruiting||30|Anticipated|Glostrup University Hospital, Copenhagen|||1||f||||f||||||||||2018-06-01 00:37:03.998326|2018-06-01 00:37:03.998326
NCT00973388|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2010-12-16|2009-09-04|2009-09-09|Estimate|||||||2010-12-16|2010-12-17|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers|A Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled, Four-period Crossover Trial to Evaluate the Effect of Telaprevir (TVR) on the QT/QTc Interval in Healthy Subjects|Completed||Phase 1|44|Actual|Tibotec BVBA|||||f||||||||||||||2018-06-01 00:37:04.105559|2018-06-01 00:37:04.105559
NCT00973375|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|May 2009||2009-05-31|September 2009|2009-09-30||||||||Observational|AIFSIDDES||Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals||Unknown status|Recruiting||30|Anticipated|Liuhuaqiao Hospital|||1||f||||f||||||||||2018-06-01 00:37:04.20059|2018-06-01 00:37:04.20059
NCT00973362|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|2016-07-28||2016-11-09|2009-09-08|2009-09-09|Estimate|2016-11-09|2017-01-06|Estimate||||2016-11-09|2017-01-06|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional||Baseline Evaluable Analysis Population|Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System|Clinical Evaluation of the APTIMA® HPV Assay on the TIGRIS® DTS® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens|Completed||Phase 3|12896|Actual|Gen-Probe, Incorporated||2|||f||||f||||||||No||2018-06-01 00:37:04.327257|2018-06-01 00:37:04.327257
NCT00973349|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2010-12-07||2015-10-29|2009-09-07|2009-09-09|Estimate|2011-04-21|2011-05-25|Estimate||||2015-10-29|2015-12-07|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional||ITT population for immunology assessments. Participants from one center excluded for GCP issues.|Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults|A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Adult Subjects 18 or More Years of Age|Completed||Phase 2/Phase 3|2719|Actual|Novartis||8|||f||||f||||||||||2018-06-01 00:37:05.131768|2018-06-01 00:37:05.131768
NCT00973336|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2016-03-14|2009-09-08|2009-09-09|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?|Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Successful Surgery in Patients Without Osteoporosis?|Unknown status|Recruiting|Phase 2|80|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:37:10.795098|2018-06-01 00:37:10.795098
NCT00973310|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2015-12-21|2009-09-08|2009-09-09|Estimate|||||||2015-12-21|2015-12-22|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer|A Phase II Study on the Safety and Efficacy of Radiation Therapy and Concurrent Erlotinib in Locally Advanced Non-small-cell Lung Cancer|Unknown status|Recruiting|Phase 2|50|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||f||||||||||2018-06-01 00:37:11.048639|2018-06-01 00:37:11.048639
NCT00973297|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||A Targeted Falls Prevention Program in Rehabilitation In-Patients|A Targeted Falls Prevention Program in Rehabilitation In-Patients|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 00:37:11.147609|2018-06-01 00:37:11.147609
NCT00973284|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08||2016-03-29|2017-08-04|2009-09-08|2009-09-09|Estimate||||2016-03-29|2016-05-02|Estimate|2017-08-04|2017-08-08|Actual|August 4, 2009|Actual|2009-08-04|August 2017|2017-08-31|August 18, 2010|Actual|2010-08-18|April 7, 2010|Actual|2010-04-07||Interventional|||Norwalk Vaccine Study|Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety and Efficacy Study in Healthy Adults of Intranasal Norwalk Virus-like Particle Vaccine in Experimental Human Norwalk Virus Infection|Completed||Phase 1/Phase 2|98|Actual|Takeda||2|||f||||t||||||||||2018-06-01 00:37:11.234995|2018-06-01 00:37:11.234995
NCT00973271|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-05|||2016-08-30|2009-09-08|2009-09-09|Estimate|||||||2016-08-30|2016-09-01|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides|A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind Active-Controlled Extension Assessing Safety and Tolerability|Withdrawn||Phase 3|0|Actual|Essentialis, Inc.||4||Did not continue with development of DCCR in Very High Triglycerides|f||||t||||||||||2018-06-01 00:37:11.332326|2018-06-01 00:37:11.332326
NCT00973258|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2014-09-15|2009-09-08|2009-09-09|Estimate|||||||2014-09-15|2014-09-17|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|FIT||Randomized Controlled Trial of Community-based Nutritional, Physical and Cognitive Training Intervention Programmes for At Risk Frail Elderly|Randomized Controlled Trial of Community-based Nutritional, Physical and Cognitive Training Intervention Programmes for At Risk Frail Elderly|Completed||Phase 3|246|Actual|National Medical Research Council (NMRC), Singapore||5|||f||||t||||||||||2018-06-01 00:37:11.417126|2018-06-01 00:37:11.417126
NCT00973245|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2014-12-26|2009-09-08|2009-09-09|Estimate|||||||2014-12-26|2014-12-30|Estimate|July 2006||2006-07-31|December 2014|2014-12-31|January 2007|Actual|2007-01-31|||||Interventional|||BAY59-7939 in Atrial Fibrillation Once Daily (OD)|BAY 59-7939 (Factor Xa Inhibitor) Phase II Once Daily Dose Study in Patients With Atrial Fibrillation|Completed||Phase 2|102|Actual|Bayer||4|||f||||f||||||||||2018-06-01 00:37:11.516495|2018-06-01 00:37:11.516495
NCT00973232|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2012-04-24|2009-09-08|2009-09-09|Estimate|||||||2012-04-24|2012-04-25|Estimate|May 2008||2008-05-31|April 2012|2012-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Comparative Bioavailability/Food Effect Study of Immediate-Release and Extended-Release Tramadol HCl/Acetaminophen Combination Products Following Single-Dose and Multiple-Dose Administration in Healthy Adult Volunteers|A Single-Centre, Open-Label, Randomised Study to Compare the Single Dose (Including the Effect of Food) and Multiple Dose Pharmacokinetic Profiles of Acetram Contramid® BID Tablets vs the Immediate-Release Tablet Reference Products Zaldiar® and Ultracet®|Completed||Phase 1|58|Actual|Labopharm Inc.||7|||f||||f||||||||||2018-06-01 00:37:11.610448|2018-06-01 00:37:11.610448
NCT00973219|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2016-08-02|2009-09-08|2009-09-09|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|LVL||Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load|A Randomized Prospective Open-label Trial for Comparing Combination Therapy Peg-Interferon Alfa-2a/Adefovir Dipivoxil and Peg-Interferon Alfa-2a/Tenofovir Disoproxil Fumarate Versus no Treatment in HBeAg Negative Chronic Hepatitis B Patients With Low Viral Load.|Active, not recruiting||N/A|150|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||t||||||||||2018-06-01 00:37:11.696437|2018-06-01 00:37:11.696437
NCT00973206|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2014-06-24|2009-09-08|2009-09-09|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2017||2017-01-31|June 2014|2014-06-30|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Observational|Pythia-GR||Factors Influencing Cardiovascular Prognosis|Factors Influencing Cardiovascular Prognosis in Hypertensive Patients (Pythia Study)|Not yet recruiting|||5000|Anticipated|Aristotle University Of Thessaloniki|||||f||||t||||||||||2018-06-01 00:37:11.921141|2018-06-01 00:37:11.921141
NCT00973193|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2016-04-19|2009-09-08|2009-09-09|Estimate|||||||2016-04-19|2016-04-20|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|September 2011|Actual|2011-09-30||Interventional|PrePaRad||Preoperative Panitumumab and Radiotherapy in Rectal Cancer|Phase II Study of Preoperative Panitumumab and External Beam Radiotherapy in Patients With Locally Advanced Rectal Cancer|Terminated||Phase 2|20|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1||The intermediate analyses did not allowed to continue the clinical study.|f||||f||||||||||2018-06-01 00:37:11.976848|2018-06-01 00:37:11.976848
NCT00973180|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2014-09-25|2009-09-08|2009-09-09|Estimate|||||||2014-09-25|2014-09-29|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Enhanced Prescription Drug Label to Improve Patient Understanding and Use|Enhanced Prescription Drug Label to Improve Patient Understanding and Use|Completed||N/A|850|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 00:37:12.066463|2018-06-01 00:37:12.066463
NCT00973167|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-04-23|2009-09-08|2009-09-09|Estimate|||||||2012-04-23|2012-04-24|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Low-magnitude High-frequency Vibration Study on Fracture Rate in Community Elderly|The Efficacy of Low-magnitude, High-frequency Vibration Treatment on Reducing Fracture Risks and Fracture Incidences in the Community Elderly - a Prospective Randomized Trial|Completed||Phase 2/Phase 3|704|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:37:12.144044|2018-06-01 00:37:12.144044
NCT00973154|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2015-04-20|2009-09-08|2009-09-09|Estimate|||||||2015-04-20|2015-04-21|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|STEP||Corticosteroid Treatment for Community-Acquired Pneumonia - The STEP Trial|Corticosteroid Treatment for Community-Acquired Pneumonia A Randomized, Double-blind Study- The STEP Trial|Completed||Phase 3|800|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 00:37:12.212859|2018-06-01 00:37:12.212859
NCT00973141|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04||2011-07-08|2016-03-29|2009-09-04|2009-09-09|Estimate||||2011-07-08|2011-07-14|Estimate|2016-03-29|2016-05-02|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee or Hip Pain From Osteoarthritis|Terminated||Phase 2|467|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||6||Logistic reasons associated with the FDA-imposed clinical hold.|f||||t||||||||||2018-06-01 00:37:12.325902|2018-06-01 00:37:12.325902
NCT00973128|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|May 2007|Actual|2007-05-31|October 2006|Actual|2006-10-31||Interventional|GMCSFSbv||Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis|Reduced Doses of Antimony Plus Recombinant Human GM-CSF Compared With Antimony in Standard Doses for Cutaneous Leishmaniasis: a Randomized, Single-blind, Placebo-controlled, Pilot Study|Completed||Phase 2|40|Actual|Hospital Universitário Professor Edgard Santos||2|||f||||f||||||||||2018-06-01 00:37:12.582625|2018-06-01 00:37:12.582625
NCT00973115|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-06|||2016-10-10|2009-09-08|2009-09-09|Estimate|||||||2016-10-10|2016-10-12|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia|Efficacy and Safety of Morning Versus Evening Intake of Simvast CR Tablet in Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 3 Trial|Completed||Phase 3|132|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-06-01 00:37:12.690462|2018-06-01 00:37:12.690462
NCT00973102|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19||2013-02-26|2014-04-04|2009-09-04|2009-09-09|Estimate||||2013-03-04|2013-03-12|Estimate|2014-04-04|2014-05-01|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|RESCUE - Shock||Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Hemorrhagic Shock (RESCUE - Shock)|Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen - Traumatic Hemorrhagic Shock (RESCUE - Shock): A Phase II Trial to Evaluate the Effects of A Single Dose of Intravenous Premarin for the Treatment of Patients With Hemorrhagic Shock|Completed||Phase 2|50|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:37:12.771769|2018-06-01 00:37:12.771769
NCT00973089|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-06|||2015-08-18|2009-09-06|2009-09-09|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Alternative Treatment of Deep Carious Lesions Based on Biological Evidences|Alternative Treatment of Deep Carious Lesions Based on Biological Evidences|Withdrawn||N/A|0|Actual|Hadassah Medical Organization||2||recruiting or enrolling participants has halted prematurely and will not resume|f||||t||||||||||2018-06-01 00:37:12.855325|2018-06-01 00:37:12.855325
NCT00973076|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2011-06-14|2009-09-08|2009-09-09|Estimate|||||||2011-06-14|2011-06-15|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055|A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours|Completed||Phase 1|19|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 00:37:12.934942|2018-06-01 00:37:12.934942
NCT00973063|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2013-12-03|2009-09-08|2009-09-09|Estimate|||||||2013-12-03|2013-12-04|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effectiveness of Routine Sterile Gloving in Blood Culture|Influence of Routine Sterile Gloving on Contamination Rates in Blood Culture|Completed||N/A|1854|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:37:13.004859|2018-06-01 00:37:13.004859
NCT00973050|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions|Randomized, 1-Way Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablets and Casodex® Administered as 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:37:13.087231|2018-06-01 00:37:13.087231
NCT00973037|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|ASTRRA-CYP2D6||CYP2D6 Genotype on the Clinical Effect of Tamoxifen|Impact of CYP2D6 Genotype on the Clinical Effects of Tamoxifen Using With Samples From Prospective Randomized Multicenter Study|Unknown status|Recruiting||922|Anticipated|Korea University Anam Hospital|||1||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 00:37:13.159157|2018-06-01 00:37:13.159157
NCT00973024|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04||2012-04-26|2016-05-23|2009-09-04|2009-09-09|Estimate||||2012-04-26|2012-04-30|Estimate|2016-05-23|2016-06-06|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately Controlled, Moderate to Severe, Chronic Low Back Pain|Terminated||Phase 2|389|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4||Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial.|f||||t||||||||||2018-06-01 00:37:13.250915|2018-06-01 00:37:13.250915
NCT00973011|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2012-02-02|2009-09-08|2009-09-09|Estimate|||||||2012-02-02|2012-02-06|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy|A Phase Ia, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy|Completed||Phase 1|18|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 00:37:13.421946|2018-06-01 00:37:13.421946
NCT00972998|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-12-28|2009-09-07|2009-09-09|Estimate|||||||2009-12-28|2009-12-29|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects|An Open Label Study to Examine the Effect of Coated Phenylephrine Suppositories on Anal Pressure in Healthy Subjects|Completed||Phase 1/Phase 2|8|Actual|RDD Pharma Ltd||1|||f||||f||||||||||2018-06-01 00:37:13.513346|2018-06-01 00:37:13.513346
NCT00972985|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2010-01-12|2009-09-04|2009-09-09|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test|Acute Effect of Three Neuroactive Drugs on Brain Activity Measured by MEG, EEG and the Synchronous Neural Interaction Test|Completed||N/A|15|Anticipated|Orasi Medical, Inc.||4|||f||||f||||||||||2018-06-01 00:37:13.753899|2018-06-01 00:37:13.753899
NCT00972972|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-09-11|2009-09-08|2009-09-09|Estimate|||||||2009-09-11|2009-09-15|Estimate|December 2006||2006-12-31|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|July 2007|Anticipated|2007-07-31||Interventional|BLUEBERRY||Effect of Bilberry (European Blueberries) and Grape Polyphenols on Cognition and Blood Parameters|Effect of Bilberry (European Blueberries) and Grape Polyphenols on Cognition and Blood Parameters in Normal, Aged Men With Subjective Memory Decline|Unknown status|Active, not recruiting|Early Phase 1|61|Actual|Ullevaal University Hospital||2|||f||||f||||||||||2018-06-01 00:37:13.866448|2018-06-01 00:37:13.866448
NCT00972959|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|2014-01-15||2014-07-08|2009-09-08|2009-09-09|Estimate|2014-07-08|2014-08-05|Estimate||||2014-07-08|2014-08-05|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy|A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of the Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Mineral Density, Bone Metabolism, Radiographically-detected Osteolytic Bone Lesions, Skeletal-related Events and Bone Pain in Patients With Multiple Myeloma Who Have Relapsed After 1-3 Prior Lines of Therapy|Completed||Phase 2|17|Actual|University of Athens||1|||f||||f||||||||||2018-06-01 00:37:14.005048|2018-06-01 00:37:14.005048
NCT00972946|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Cell Tracking Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI) - A Pilot Study|The Use of Magnetic Resonance Imaging and Superparamagnetic Particles of Iron Oxide in Cardiovascular Disease - a Pilot Study in Healthy Volunteers|Unknown status|Recruiting|N/A|20|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:37:14.366466|2018-06-01 00:37:14.366466
NCT00972933|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2017-12-05|2009-09-08|2009-09-09|Estimate|||||||2017-12-05|2017-12-07|Actual|December 2009||2009-12-31|December 2017|2017-12-31|September 26, 2017|Actual|2017-09-26|July 17, 2013|Actual|2013-07-17||Interventional|||Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma|Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis|Completed||Early Phase 1|59|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 00:37:14.527339|2018-06-01 00:37:14.527339
NCT00972920|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2015-10-20|2009-09-08|2009-09-09|Estimate|||||||2015-10-20|2015-10-21|Estimate|August 2009||2009-08-31|October 2015|2015-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||TAP Block for Gynaecological Laparotomies - a Comparison of Ultrasound-guided Block and Blind Technique|Transversus Abdominis Plane (TAP) Block for Gynaecological Laparotomies - a Comparison of Ultrasound-guided Block and Blind Technique|Completed||N/A|120|Anticipated|Northern Health and Social Care Trust||2|||f||||f||||||||||2018-06-01 00:37:14.670672|2018-06-01 00:37:14.670672
NCT00972907|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2011-02-15|2009-09-08|2009-09-09|Estimate|||||||2011-02-15|2011-02-16|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects|An Open Label Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing in Human Subjects|Completed||Phase 1/Phase 2|20|Anticipated|RDD Pharma Ltd||1|||f||||f||||||||||2018-06-01 00:37:14.750683|2018-06-01 00:37:14.750683
NCT00972894|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2010-06-22|2009-09-08|2009-09-09|Estimate|||||||2010-06-22|2010-06-23|Estimate|January 2010||2010-01-31|September 2009|2009-09-30|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Observational|||Group B Streptococcus (GBS) Polymerase Chain Reaction (PCR) Concordance Study|Prospective Evaluation of a Polymerase Chain Reaction (PCR) Assay (GenExpert DX™) for the Rapid Detection of Recto-vaginal Group B Streptococcus (GBS) Colonisation During Intrapartum Screening|Unknown status|Active, not recruiting||500|Anticipated|HCA International Limited|||||f||||f||||||None Retained|"~     Vaginal culture swabs~   "|||2018-06-01 00:37:14.827333|2018-06-01 00:37:14.827333
NCT00972881|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-05|||2017-10-24|2009-09-05|2009-09-09|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2009||2009-04-30|December 2014|2014-12-31|December 31, 2016|Actual|2016-12-31|December 2011|Actual|2011-12-31||Interventional|EXCITE||Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer|EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for Locally Advanced Rectal Cancer (North West Clinical Oncology Group-04 on Behalf of the NCRI Rectal Cancer Subgroup)|Completed||Phase 1/Phase 2|82|Actual|University College, London|||||f||||t||||||||||2018-06-01 00:37:14.911737|2018-06-01 00:37:14.911737
NCT00972868|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2017-01-13|2009-09-08|2009-09-09|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||A Novel Unidirectional Face Mask During NPPV in COPD Patients|Use of a Novel Unidirectional Face Mask During Noninvasive Positive Pressure Ventilation (NPPV) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||Inability to enrole subjucts.|f||||f||||||||||2018-06-01 00:37:15.023328|2018-06-01 00:37:15.023328
NCT00972855|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions|Randomized, 1-Way, Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablets and Casodex® Administered as 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:37:15.094795|2018-06-01 00:37:15.094795
NCT00972842|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-07|||2013-12-23|2009-09-08|2009-09-09|Estimate|||||||2013-12-23|2013-12-24|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|LenVoDex||Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)|Phase I/II Trial of Lenalidomide in Combination With Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)|Terminated||Phase 1/Phase 2|20|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||||slow recruitment|f||||f||||||||||2018-06-01 00:37:15.179804|2018-06-01 00:37:15.179804
NCT00972816|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2010-12-06||2016-03-14|2009-09-07|2009-09-09|Estimate|2011-01-24|2011-01-27|Estimate||||2016-03-14|2016-04-14|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|October 2010|Actual|2010-10-31|November 2009|Actual|2009-11-30||Interventional|||Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)|A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Pediatric Subjects 3 to < 9 Years of Age|Completed||Phase 2/Phase 3|1357|Actual|Novartis||8|||f||||f||||||||||2018-06-01 00:37:15.434273|2018-06-01 00:37:15.434273
NCT00972803|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-08|||2009-09-08|2009-09-08|2009-09-09|Estimate|||||||2009-09-08|2009-09-09|Estimate|May 2008||2008-05-31|February 2007|2007-02-28|May 2009|Actual|2009-05-31|||||Interventional|||The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms|The Effects of Pistacia Mutica on De Novo Dental Plaque Formation, Gingival Inflammation and Oral Microorganisms|Completed||Phase 2|25|Actual|Tabriz University||3|||f||||f||||||||||2018-06-01 00:37:18.095408|2018-06-01 00:37:18.095408
NCT00972790|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2012-02-29|2009-09-08|2009-09-09|Estimate|||||||2012-02-29|2012-03-01|Estimate|March 2010||2010-03-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Scalp Nerve Blocks for Post-Craniotomy Pain|Effect of Bilateral Scalp Nerve Blocks on Post-operative Pain and Discharge Times in Patients Undergoing Supra-tentorial Craniotomy and General Anaesthesia|Completed||N/A|89|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 00:37:18.174679|2018-06-01 00:37:18.174679
NCT00972777|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|2012-01-12||2012-02-14|2009-09-08|2009-09-09|Estimate|2012-02-14|2012-03-29|Estimate||||2012-02-14|2012-03-29|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|||Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.|Completed||Phase 2/Phase 3|474|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:37:18.293615|2018-06-01 00:37:18.293615
NCT00972764|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2009-09-04|2009-09-04|2009-09-07|Estimate|||||||2009-09-04|2009-09-07|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Observational|||Laryngomalacia No Longer An Ambiguity|Laryngomalacia No Longer An Ambiguity|Completed|||1500|Actual|Boushahri Clinic Medical Center|||2||f||||t||||||||||2018-06-01 00:37:18.655581|2018-06-01 00:37:18.655581
NCT00972751|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2015-09-28|2009-09-04|2009-09-07|Estimate|||||||2015-09-28|2015-09-30|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||S9304A Study of Protein Expression in Tumor Tissue Samples From Patients With Stage II or Stage III Rectal Cancer Enrolled in Clinical Trial SWOG-9304|Investigation of Thioredoxin-1 Family Protein Expression in Rectal Cancer|Completed|||220|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:37:18.711872|2018-06-01 00:37:18.711872
NCT00972738|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|2009-09-15||2015-07-01|2009-09-04|2009-09-07|Estimate|2010-05-14|2010-06-16|Estimate||||2015-07-01|2015-07-23|Estimate|April 2001||2001-04-30|July 2015|2015-07-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)|A Multi-Center, Double-blind, Randomized, Parallel-Group Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring 2001 Study|Completed||Phase 3|1214|Actual|Merck Sharp & Dohme Corp.|In the paper patients who withdrew for worsening allergic rhinitis/conjunctivitis were included under category of discontinued due to lack of efficacy rather than discontinued due to clinical Adverse Events|3|||f||||f||||||||||2018-06-01 00:37:18.881895|2018-06-01 00:37:18.881895
NCT00972725|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2016-11-28|2010-12-23|2017-03-02|2009-09-03|2009-09-07|Estimate|2017-03-02|2017-04-13|Actual|2010-12-23|2010-12-30|Estimate|2017-03-02|2017-04-13|Actual|December 2009||2009-12-31|March 2017|2017-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose|A Study to Evaluate the Safety and Immunogenicity of a Booster Dose of GSK Biologicals' HIV Candidate Vaccine (732461) After Administration of Chloroquine in Healthy Adults.|Completed||Phase 2|28|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:37:19.374752|2018-06-01 00:37:19.374752
NCT00972712|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2015-03-09|2009-09-04|2009-09-07|Estimate|||||||2015-03-09|2015-03-10|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2009|Actual|2009-12-31||Interventional|||Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma|A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|12|Actual|Emory University||1|||f||||t||||||||||2018-06-01 00:37:23.401366|2018-06-01 00:37:23.401366
NCT00972699|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2013-05-01|2009-09-04|2009-09-07|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Mentor Mothers: A Sustainable Family Intervention in South African Townships|Mentor Mothers: A Sustainable Family Intervention in South African Townships|Completed||Phase 2|1200|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:37:23.492846|2018-06-01 00:37:23.492846
NCT00972686|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2017-05-05|2009-09-04|2009-09-07|Estimate|||||||2017-05-05|2017-05-09|Actual|August 31, 2009|Actual|2009-08-31|May 2017|2017-05-31|March 31, 2015|Actual|2015-03-31|December 12, 2012|Actual|2012-12-12||Interventional|FTIH||Dose-Escalation Study of GSK2126458|A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects With Solid Tumors or Lymphoma|Completed||Phase 1|79|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:37:23.582269|2018-06-01 00:37:23.582269
NCT00972673|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2017-08-01|2009-09-03|2009-09-07|Estimate|||||||2017-08-01|2017-08-03|Actual|September 24, 2008|Actual|2008-09-24|August 2017|2017-08-31|December 19, 2008|Actual|2008-12-19|December 19, 2008|Actual|2008-12-19||Interventional|||A Study of GW685698X in Healthy Japanese Male Subjects|Phase I Study of GW685698X-A Randomized, Double Blind, Placebo Controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose From a Novel Dry Powder Device in Healthy Japanese Male Subjects.|Completed||Phase 1|48|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:37:23.725823|2018-06-01 00:37:23.725823
NCT00972192|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-09-03|2009-09-03|2009-09-04|Estimate|||||||2009-09-03|2009-09-04|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effectiveness of Inpatient Voluntary Counseling and Testing (VCT) in Uganda|Effectiveness of Inpatient HIV Voluntary Counseling and Testing in Uganda|Completed||N/A|500|Actual|Makerere University||2|||f||||f||||||||||2018-06-01 00:37:34.06292|2018-06-01 00:37:34.06292
NCT00972660|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2014-08-25|2009-09-04|2009-09-07|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2009||2009-09-30|May 2010|2010-05-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease|A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Ex-Vivo Cultured Allogenic Mesenchymal Stem Cells For the Treatment of Extensive Chronic Graft Versus Host Disease|Unknown status|Enrolling by invitation|Phase 2|52|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-06-01 00:37:23.81716|2018-06-01 00:37:23.81716
NCT00972647|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-09-29|2009-09-04|2009-09-07|Estimate|||||||2013-09-29|2013-10-01|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Radiation Exposure Using Laser Guided Fluoroscopy in Various Orthopaedic Procedures|Radiation Exposure Using Laser Guided Fluoroscopy in Various Orthopaedic Procedures|Withdrawn||N/A|0|Actual|Loma Linda University||2||Lack of personnel|f||||t||||||||||2018-06-01 00:37:23.946255|2018-06-01 00:37:23.946255
NCT00972634|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2017-01-16|2009-09-04|2009-09-07|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2008||2008-10-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer|The European Palliative Care Research Collaborative - Computerised Symptom Assessment and Classification of Pain, Depression and Physical Function (Cachexia) (EPCRC - CSA)|Completed|||1051|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 00:37:24.031142|2018-06-01 00:37:24.031142
NCT00972621|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2012-01-18||2018-02-21|2009-09-04|2009-09-07|Estimate|2012-01-18|2012-02-22|Estimate||||2018-02-21|2018-02-23|Actual|September 2009||2009-09-30|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Results based on safety population (i.e., the population based on the viscoelastic used). If the randomization scheme had been followed correctly, there would have been 199 Vitrax II subjects and 201 Viscoat subjects, but one subject that should have received Viscoat (control treatment) was treated with Vitrax II, which resulted in 200 per group.|Clinical Evaluation of a New Viscoelastic for Cataract Surgery|Clinical Evaluation of a New Viscoelastic for Cataract Surgery|Completed||N/A|400|Actual|Abbott Medical Optics||2|||f||||f||||||||||2018-06-01 00:37:24.117875|2018-06-01 00:37:24.117875
NCT00972608|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2017-08-05|2009-09-04|2009-09-07|Estimate|||||||2017-08-05|2017-08-08|Actual|August 2009||2009-08-31|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Observational|||Surgical Planning for Reconstruction of Complex Heart Defects|Surgical Planning for Reconstruction of Complex Heart Defects|Recruiting|||80|Anticipated|Emory University|||||f||||f||||||||||2018-06-01 00:37:24.377209|2018-06-01 00:37:24.377209
NCT00972595|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2010-05-19||2015-08-18|2009-09-04|2009-09-07|Estimate|2010-05-19|2010-06-22|Estimate||||2015-08-18|2015-08-19|Estimate|June 2004||2004-06-30|August 2015|2015-08-31|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)|An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Determine the Bioequivalence of 2 Formulations of Ondansetron in Healthy Young Adult Male and Female Subjects|Completed||Phase 1|45|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:37:24.452224|2018-06-01 00:37:24.452224
NCT00972582|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2013-07-26|2009-09-04|2009-09-07|Estimate|||||||2013-07-26|2013-07-29|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Upper Limit of Leucine Intake in Adults|Determination of the Tolerable Upper Limit of Leucine Intake in Adult Humans|Completed||Phase 1|5|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 00:37:24.64469|2018-06-01 00:37:24.64469
NCT00972569|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2018-05-22|2009-09-04|2009-09-07|Estimate|||||||2018-05-22|2018-05-24|Actual|October 2009||2009-10-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|Aim 3 BNP/PDEV||Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction|Specific Aims 3: Define in Hospitalized Decompensated CHF Patients With Renal Dysfunction, the Renal Actions of Low Dose Intravenous Infusion of BNP in the Presence and Absence of Acute PDE V Inhibition in Improving Renal Function|Enrolling by invitation||Phase 1/Phase 2|69|Anticipated|Mayo Clinic||3|||f||||t||||||||||2018-06-01 00:37:24.708307|2018-06-01 00:37:24.708307
NCT00972556|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2012-08-22|2009-09-04|2009-09-07|Estimate|||||||2012-08-22|2012-08-23|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Comparison of Mineral Trioxide Aggregate (MTA) and 20% Formocresol (FC) in Pulpotomized Human Primary Molars|Comparison of Mineral Trioxide Aggregate and 20% Formocresol in Pulpotomized Human Primary Molars :A Long-Term Follow-Up Study|Unknown status|Recruiting|N/A|200|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 00:37:24.801485|2018-06-01 00:37:24.801485
NCT00972543|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|2010-06-28||2014-01-20|2009-09-04|2009-09-07|Estimate|2010-08-04|2010-09-02|Estimate||||2014-01-20|2014-02-13|Estimate|September 2008||2008-09-30|January 2014|2014-01-31||||May 2009|Actual|2009-05-31||Interventional|||Raptiva in Palm and Sole Psoriasis|A Phase IV Multicentre, Randomized Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Raptiva in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis Involving Palms and/or Soles, With or Without Pustules.|Terminated||Phase 4|6|Actual|Merck KGaA||2||"The study was terminated after the European Medicines Evaluation Agency recommended to suspend~   the marketing authorisation of Raptiva in the European Union"|f||||f||||||||||2018-06-01 00:37:24.919046|2018-06-01 00:37:24.919046
NCT00972530|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2009-09-10||2009-10-09|2009-09-04|2009-09-07|Estimate|2009-10-09|2009-11-11|Estimate||||2009-10-09|2009-11-11|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Intra-articular Glucocorticoid Treatment of the Elbow|The Importance of Immobilisation After Intra-articular Glucocorticoid Treatment for Elbow Synovitis - a Randomised and Controlled Study|Completed||N/A|90|Actual|Department of Research and Development, County Council of Gavleborg and Uppsala University||2|||f||||f||||||||||2018-06-01 00:37:25.764878|2018-06-01 00:37:25.764878
NCT00972517|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03||2011-11-17|2016-10-31|2009-09-04|2009-09-07|Estimate||||2011-11-17|2011-11-21|Estimate|2016-10-31|2016-11-01|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years|Completed||Phase 3|245|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:37:25.994314|2018-06-01 00:37:25.994314
NCT00972504|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2017-03-03||2017-04-19|2009-09-03|2009-09-07|Estimate|2017-04-19|2017-08-02|Actual||||2017-04-19|2017-08-02|Actual|June 1, 2009||2009-06-01|March 2017|2017-03-31|August 14, 2009|Actual|2009-08-14|August 1, 2009|Actual|2009-08-01||Interventional|||723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover|A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000µg), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 2|54|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:37:26.136227|2018-06-01 00:37:26.136227
NCT00972491|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2013-12-03|2009-09-04|2009-09-07|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LMA||The Optimal Time to Put Laryngeal Mask Airway in the Mouth Under General Anesthesia|The Optimal Time of Insertion of Laryngeal Mask Airway With Propofol Induction|Completed||N/A|198|Actual|Tufts Medical Center||1|||f||||f||||||||||2018-06-01 00:37:26.876532|2018-06-01 00:37:26.876532
NCT00972478|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|2016-09-08||2017-09-12|2009-09-04|2009-09-07|Estimate|2016-09-08|2016-10-31|Estimate||||2017-09-12|2017-10-13|Actual|November 2010||2010-11-30|September 2017|2017-09-30||||December 2015|Actual|2015-12-31||Interventional||Eligible patients who began protocol therapy|Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)|Active, not recruiting||Phase 1/Phase 2|83|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 00:37:27.038759|2018-06-01 00:37:27.038759
NCT00972465|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2009-09-04|2009-09-04|2009-09-07|Estimate|||||||2009-09-04|2009-09-07|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Interventional|||Study of Nimotuzumab to Treat Colorectal Cancer|Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras|Unknown status|Recruiting|Phase 2|48|Anticipated|Peking University|||||f||||t||||||||||2018-06-01 00:37:28.277872|2018-06-01 00:37:28.277872
NCT00972452|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-04|||2015-09-23|2009-09-04|2009-09-07|Estimate|||||||2015-09-23|2015-09-24|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|OGTT||Blood Flow Responses to an Oral Glucose Tolerance Test in Type 2 Diabetes|Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals|Completed||N/A|30|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 00:37:28.406968|2018-06-01 00:37:28.406968
NCT00972439|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2013-02-14||2018-01-24|2009-09-04|2009-09-07|Estimate|2018-01-24|2018-02-23|Actual||||2018-01-24|2018-02-23|Actual|August 2007||2007-08-31|December 2017|2017-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Oral Contraceptive (OC) Progestin Dose and Breast Proliferation|Evaluating the Effect of Oral Contraceptive Progestin Dose on Breast Epithelial Cell Proliferation|Completed||N/A|33|Actual|University of Southern California||2|||f||||f||||||||||2018-06-01 00:37:28.469369|2018-06-01 00:37:28.469369
NCT00972426|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2011-09-01|2009-09-04|2009-09-07|Estimate|||||||2011-09-01|2011-09-05|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients|A Randomized, Parallel, Open-label Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients|Completed||Phase 4|32|Anticipated|Taiwan Otsuka Pharm. Co., Ltd||2|||f||||||||||||||2018-06-01 00:37:28.650353|2018-06-01 00:37:28.650353
NCT00972413|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2012-12-13|2009-09-04|2009-09-07|Estimate|||||||2012-12-13|2012-12-17|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|May 2012|Actual|2012-05-31|January 2010|Actual|2010-01-31||Interventional|CBCTBI||Cone Beam Computed Tomography for Breast Imaging|Cone Beam Computed Tomography for Breast Imaging and IV Contrast Enhanced Cone Beam Computed Tomography Breast Imaging|Completed||Phase 1|104|Actual|Koning Corporation||3|||f||||t||||||||||2018-06-01 00:37:28.712068|2018-06-01 00:37:28.712068
NCT00972400|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2013-08-23|2009-09-03|2009-09-04|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2009||2009-01-31|September 2009|2009-09-30||||January 2011|Anticipated|2011-01-31||Observational|||Fatigue in Breast Cancer Survivors|Biological Mechanisms of Fatigue in Breast Cancer Survivors|Unknown status|Recruiting||96|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:37:28.779414|2018-06-01 00:37:28.779414
NCT00972387|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2018-04-03|2009-09-03|2009-09-04|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2009||2009-08-31|April 2018|2018-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Carbohydrate-Protein Supplementation During Endurance Running|"Nutritional Ergogenic Aids: The Effects of Carbohydrate-Protein Supplementation During Endurance Exercise"|Completed||N/A|12|Actual|The University of Tennessee, Knoxville||4|||f||||f||||||||||2018-06-01 00:37:28.835607|2018-06-01 00:37:28.835607
NCT00972374|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2013-03-13|2011-10-20|2013-03-13|2009-09-03|2009-09-04|Estimate|2013-03-13|2013-04-24|Estimate|2011-10-20|2011-10-26|Estimate|2013-03-13|2013-04-24|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function||Completed||Phase 2|44|Actual|Allergan||3|||f||||t||||||||||2018-06-01 00:37:30.007959|2018-06-01 00:37:30.007959
NCT00972361|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-08-25|2009-09-03|2009-09-04|Estimate|||||||2011-08-25|2011-08-26|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Routine Preoperative Hemostatic Laboratory Evaluation Prior to Tonsillectomy or Adenoidectomy in Children|Routine Preoperative Hemostatic Laboratory Evaluation Prior to Tonsillectomy or Adenoidectomy in Children - a Necessity or Habitude?|Completed|||200|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 00:37:30.429361|2018-06-01 00:37:30.429361
NCT00972348|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2013-11-18|2009-09-03|2009-09-04|Estimate|||||||2013-11-18|2013-11-20|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Trial Embedded in an Electronic Personal Medical Health Records|A Randomized Controlled Trial Embedded in an Electronic Medical Record (myHERO).|Completed||N/A|338|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:37:30.495638|2018-06-01 00:37:30.495638
NCT00972179|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-08-25|2009-09-03|2009-09-04|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety Study of AMG 157 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 157 in Healthy Subjects|Completed||Phase 1|49|Actual|Amgen||2|||f||||||||||||||2018-06-01 00:37:34.150107|2018-06-01 00:37:34.150107
NCT00972335|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2015-01-05||2015-05-18|2009-09-03|2009-09-04|Estimate|2015-05-18|2015-06-04|Estimate||||2015-05-18|2015-06-04|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All treated patients (one enrolled patient was not treated)|Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma|A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma|Terminated||Phase 2|18|Actual|SCRI Development Innovations, LLC|Enrollment closed early due to slow accrual, leading to small number of subjects analyzed - biomarker analysis outcome measure not analyzed or reported|1||Study terminated early due to slow accrual|f||||f||||||||||2018-06-01 00:37:30.599541|2018-06-01 00:37:30.599541
NCT00972322|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2014-05-14||2017-06-02|2009-09-03|2009-09-04|Estimate|2014-05-14|2014-06-12|Estimate||||2017-06-02|2017-07-02|Actual|August 24, 2009|Actual|2009-08-24|June 2017|2017-06-30|January 26, 2010|Actual|2010-01-26|January 12, 2010|Actual|2010-01-12||Interventional|||Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)|A Placebo-Controlled Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacokinetics of MK-8245 in Subjects With Type 2 Diabetes|Completed||Phase 1|56|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:37:31.027383|2018-06-01 00:37:31.027383
NCT00972309|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2018-02-13|2009-09-03|2009-09-04|Estimate|||||||2018-02-13|2018-02-14|Actual|May 25, 2009||2009-05-25|September 7, 2017|2017-09-07|February 4, 2015|Actual|2015-02-04|February 4, 2015|Actual|2015-02-04||Interventional|||A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer|A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer|Completed||Phase 1|41|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:37:31.292184|2018-06-01 00:37:31.292184
NCT00972296|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2017-04-03|2009-09-03|2009-09-04|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2009||2009-09-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|May 2011|Actual|2011-05-31||Observational|||Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia|Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in Hemophilia|Completed|||27|Actual|Oregon Health and Science University|||1||f||||t||||||||||2018-06-01 00:37:31.398646|2018-06-01 00:37:31.398646
NCT00972283|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2015-10-14|2011-12-01|2017-03-08|2009-09-03|2009-09-04|Estimate|2015-10-14|2015-11-13|Estimate|2011-12-01|2011-12-02|Estimate|2017-03-08|2017-04-06|Actual|September 1, 2009|Actual|2009-09-01|March 2017|2017-03-31|October 28, 2010|Actual|2010-10-28|October 28, 2010|Actual|2010-10-28||Interventional|BEGIN™||Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes|NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)|Completed||Phase 3|1006|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:37:31.563626|2018-06-01 00:37:31.563626
NCT00972270|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-03-18|2009-09-03|2009-09-04|Estimate|||||||2011-03-18|2011-03-21|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|RECOVER II||Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability|RECOVER II Trial: A Prospective Randomized Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability|Terminated||Phase 3|1|Actual|Abiomed Inc.||2||Study closed due to insufficient enrollment|f||||t||||||||||2018-06-01 00:37:32.776034|2018-06-01 00:37:32.776034
NCT00972257|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2014-05-09|2009-09-03|2009-09-04|Estimate|||||||2014-05-09|2014-05-12|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination|Quality of 24-hour Intraocular Pressure Control Obtained With Dorzolamide/Timolol Fixed Combination (DTFC) Compared With the Brimonidine/Timolol Fixed Combination (BTFC) in Subjects With Primary Open-angle Glaucoma|Completed||Phase 4|64|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 00:37:32.85977|2018-06-01 00:37:32.85977
NCT00972244|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2013-01-21||2013-08-09|2009-09-03|2009-09-04|Estimate|2013-08-09|2013-10-14|Estimate||||2013-08-09|2013-10-14|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Full Analysis Set defined as all randomised participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind period.|Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Japanese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 2|417|Actual|AstraZeneca|If an efficacy measurement was unavailable at the time point for analysis, last observation was carried forward (LOCF).|5|||f||||f||||||||||2018-06-01 00:37:32.957343|2018-06-01 00:37:32.957343
NCT00972231|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2015-08-30|2009-09-03|2009-09-04|Estimate|||||||2015-08-30|2015-09-01|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia|Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia|Completed|||93|Actual|HaEmek Medical Center, Israel|||2||f||||f||||||||||2018-06-01 00:37:33.554777|2018-06-01 00:37:33.554777
NCT00972218|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2016-09-14|2009-09-03|2009-09-04|Estimate|||||||2016-09-14|2016-09-16|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease|Efficacy of Adalimumab (Humira®) in Spondyloarthritis Related to Crohn's Disease|Withdrawn||Phase 4|0|Actual|University of Alberta||1||Difficulty with enrollment|f||||f||||||||||2018-06-01 00:37:33.633816|2018-06-01 00:37:33.633816
NCT00972205|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2011-09-20||2012-07-13|2009-09-03|2009-09-04|Estimate|2012-01-03|2012-02-06|Estimate||||2012-07-13|2012-07-19|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors|A Pharmacodynamic Study of the P-glycoprotein (Pgp) Antagonist, CBT-1(Registered Trademark), Evaluating Pgp Inhibition in Tumors and Normal Tissues|Completed||N/A|12|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 00:37:33.731102|2018-06-01 00:37:33.731102
NCT00972153|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2010-04-22||2012-03-14|2009-09-03|2009-09-04|Estimate|2010-04-22|2010-05-18|Estimate||||2012-03-14|2012-03-16|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Device to Reduce Surgery Site Contamination|Reduction of Airborne Particulate in the Surgical Field Using Directed Local Airflow|Completed||N/A|29|Actual|Nimbic Systems, LLC||3|||f||||||||||||||2018-06-01 00:37:34.220364|2018-06-01 00:37:34.220364
NCT00972140|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-12-12|2009-09-03|2009-09-04|Estimate|||||||2011-12-12|2011-12-13|Estimate|August 2005||2005-08-31|December 2011|2011-12-31|October 2006|Actual|2006-10-31|April 2006|Actual|2006-04-30||Interventional|||Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 3-month, Double-blind, Double-dummy, Randomised, Multinational, Multicenter, 2-arm Parallel-group Study Comparing the Efficacy and Safety of Formoterol-HFA pMDI 12µg Twice Daily and Formoterol-DPI 12µg Twice Daily, in Patients With Stable Chronic Obstructive Pulmonary Disease|Completed||Phase 3|457|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 00:37:34.471236|2018-06-01 00:37:34.471236
NCT00972127|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-02-04|2009-09-03|2009-09-04|Estimate|||||||2011-02-04|2011-02-07|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen|Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Open-Label, Randomized, Single Center, Multiple Dose, 2-Period, 2-Sequence, Crossover Study With and Without Application of a Urinary pH Acidification Regimen|Completed||Phase 1|||Merz Pharmaceuticals GmbH|||||f||||||||||||||2018-06-01 00:37:34.53761|2018-06-01 00:37:34.53761
NCT00972114|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-12-09|2009-09-03|2009-09-04|Estimate|||||||2009-12-09|2009-12-10|Estimate|October 2009||2009-10-31|December 2009|2009-12-31|December 2011|Anticipated|2011-12-31|June 2010|Anticipated|2010-06-30||Interventional|||CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy|Coronary Artery Bypass Graft Surgery Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Patients With Ischemic Cardiomyopathy: a Prospective Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|70|Anticipated|China National Center for Cardiovascular Diseases||3|||f||||t||||||||||2018-06-01 00:37:34.588935|2018-06-01 00:37:34.588935
NCT00972101|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2012-10-10|2009-09-03|2009-09-04|Estimate|||||||2012-10-10|2012-10-11|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Infusion of Expanded Cord Blood T Cells|Infusion of Expanded Cord Blood T Cells Following Cord Blood Transplantation|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||2||Development of other studies led to termination without recruitment.|f||||f||||||||||2018-06-01 00:37:34.694161|2018-06-01 00:37:34.694161
NCT00972088|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2012-02-04||2013-05-15|2009-09-03|2009-09-04|Estimate|2013-05-15|2013-06-24|Estimate||||2013-05-15|2013-06-24|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease|Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease|Completed||N/A|26|Actual|Bikkur Holim Hospital||1|||f||||t||||||||||2018-06-01 00:37:34.830508|2018-06-01 00:37:34.830508
NCT00972075|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-09-06|2009-09-03|2009-09-04|Estimate|||||||2009-09-06|2009-09-09|Estimate|February 2006||2006-02-28|September 2009|2009-09-30|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects|A Double-Blind, Placebo-Controlled Study of Circadin™ for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects|Completed||Phase 2|13|Actual|Neurim Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 00:37:34.966244|2018-06-01 00:37:34.966244
NCT00972062|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-03-06|2009-09-03|2009-09-04|Estimate|||||||2012-03-06|2012-03-07|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|MSSkin||Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis|Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis|Completed||N/A|60|Actual|University of North Carolina, Charlotte||2|||f||||t||||||||||2018-06-01 00:37:35.039492|2018-06-01 00:37:35.039492
NCT00972049|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2010-03-02|2009-09-03|2009-09-04|Estimate|||||||2010-03-02|2010-03-04|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects|A Phase I, Single-centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics After Oral Single Ascending Doses of AZD2516 in Young and Elderly Japanese Healthy Subjects|Completed||Phase 1|40|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:37:35.111927|2018-06-01 00:37:35.111927
NCT00972036|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2014-12-10|2009-09-03|2009-09-04|Estimate|||||||2014-12-10|2014-12-11|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy|Phase I Study of Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy|Completed||Phase 1|32|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 00:37:35.173206|2018-06-01 00:37:35.173206
NCT00972023|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2013-04-23||2017-02-15|2009-09-03|2009-09-04|Estimate|2013-07-08|2013-07-10|Estimate||||2017-02-15|2017-03-21|Actual|February 2010||2010-02-28|February 2017|2017-02-28|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|||DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer|A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer|Terminated||Phase 1|1|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||||||||||||2018-06-01 00:37:35.273572|2018-06-01 00:37:35.273572
NCT00972010|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2010-11-09|2009-09-03|2009-09-04|Estimate|||||||2010-11-09|2010-11-10|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Observational|||Study to Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade|A Prospective, Controlled Study To Evaluate Surgical Excision Margins in Malignant Breast Lumpectomies With the PEAK PlasmaBlade Compared to Traditional Electrosurgery|Completed|||21|Actual|University of California, San Diego|||||f||||f||||||Samples With DNA|"~     Breast tissue~   "|||2018-06-01 00:37:35.504518|2018-06-01 00:37:35.504518
NCT00971997|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2012-03-15||2012-03-15|2009-09-02|2009-09-04|Estimate|2012-03-15|2012-04-11|Estimate||||2012-03-15|2012-04-11|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|SIMPLE||A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients|The Study of Stepwise Introduction of Insulin Analog Mixture as a Post-marketing Clinical Trial of Lispro Mix 50/50 to Evaluate Efficacy and Safety in Type 2 Diabetic Patients With Inadequate Glycemic Control on Oral Therapy. (SIMPLE Study)|Completed||Phase 4|135|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:37:35.587856|2018-06-01 00:37:35.587856
NCT00971984|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2015-08-30|2009-09-03|2009-09-04|Estimate|||||||2015-08-30|2015-09-01|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel|Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel|Completed|||50|Actual|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-06-01 00:37:35.987925|2018-06-01 00:37:35.987925
NCT00971971|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-09-04|2009-09-03|2009-09-04|Estimate|||||||2009-09-04|2009-09-07|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|July 2007|Actual|2007-07-31||Interventional|||Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients|Assessment of a Protocol Aiming to Prevent Intradialytic Hypotension in Critically Ill Acute Kidney Injury Patients|Completed||N/A|40|Actual|Sao Jose do Rio Preto Medical School||2|||f||||f||||||||||2018-06-01 00:37:36.065206|2018-06-01 00:37:36.065206
NCT00971958|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2013-08-19|2009-09-03|2009-09-04|Estimate|||||||2013-08-19|2013-08-21|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Infant Male Circumcision in Gaborone, Botswana, and Surrounding Areas: Feasibility, Safety and Acceptability|Infant Male Circumcision in Gaborone, Botswana, and Surrounding Areas: Feasibility, Safety and Acceptability|Completed||N/A|1235|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-06-01 00:37:36.151198|2018-06-01 00:37:36.151198
NCT00971945|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03||2010-09-10|2010-09-10|2009-09-03|2009-09-04|Estimate||||2010-09-10|2010-09-13|Estimate|2010-09-10|2010-09-13|Estimate|June 2005||2005-06-30|November 2009|2009-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer|Completed||Phase 2|10|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 00:37:36.229412|2018-06-01 00:37:36.229412
NCT00971932|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2012-07-04||2014-03-10|2009-09-03|2009-09-04|Estimate|2012-07-04|2012-08-10|Estimate||||2014-03-10|2014-04-08|Estimate|July 2009||2009-07-31|March 2014|2014-03-31||||March 2011|Actual|2011-03-31||Interventional|||Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Open-label, Single-arm, Multicenter, Phase II Study Investigating Cetuximab in Combination With Chemotherapy in the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) in Japanese Subjects|Completed||Phase 2|33|Actual|Merck KGaA||1|||f||||t||||||||||2018-06-01 00:37:36.310531|2018-06-01 00:37:36.310531
NCT00971919|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2013-08-06|2009-09-03|2009-09-04|Estimate|||||||2013-08-06|2013-08-07|Estimate|March 2007||2007-03-31|September 2009|2009-09-30||||May 2010|Anticipated|2010-05-31||Observational|||Chronic Pain in Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer|Prospective Cohort Study to Investigate Chronic Pain After Breast Cancer Surgery|Unknown status|Recruiting||284|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:37:36.6596|2018-06-01 00:37:36.6596
NCT00971906|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-10-10|2009-09-03|2009-09-04|Estimate|||||||2011-10-10|2011-10-12|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|October 2009|Actual|2009-10-31||Interventional|||Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age|A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of Age|Completed||Phase 3|660|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:37:36.741668|2018-06-01 00:37:36.741668
NCT00971893|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-10-29|2009-09-03|2009-09-04|Estimate|||||||2009-10-29|2009-10-30|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Observational|||A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients|A Prospective Study to Assess the Safety and Effectiveness of Medrol® in Acute Asthma in Indian Patients|Withdrawn|||100|Anticipated|Pfizer|||1||f||||f||||||||||2018-06-01 00:37:36.814311|2018-06-01 00:37:36.814311
NCT00971880|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-08-25|2009-09-03|2009-09-04|Estimate|||||||2011-08-25|2011-08-26|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects|Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects.|Completed|||100|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-06-01 00:37:36.88366|2018-06-01 00:37:36.88366
NCT00971867|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03||2010-09-10|2010-09-10|2009-09-03|2009-09-04|Estimate||||2010-09-10|2010-09-13|Estimate|2010-09-10|2010-09-13|Estimate|August 2006||2006-08-31|September 2010|2010-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer|Completed||Phase 2|10|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 00:37:36.948196|2018-06-01 00:37:36.948196
NCT00971854|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-10-12|2009-09-03|2009-09-04|Estimate|||||||2009-10-12|2009-10-14|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|February 2010|Anticipated|2010-02-28|January 2010|Anticipated|2010-01-31||Interventional|||Alteration of Deep Brain Stimulation Parameters for Dystonia|Alteration of Deep Brain Stimulation Parameters for Dystonia- A Double Blinded Randomised Controlled Trial|Unknown status|Recruiting|N/A|20|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 00:37:37.018922|2018-06-01 00:37:37.018922
NCT00971841|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2013-05-24||2013-07-18|2009-09-03|2009-09-04|Estimate|2013-05-24|2013-07-19|Estimate||||2013-07-18|2013-07-26|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer|Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer|Completed||Phase 2|1|Actual|Bristol-Myers Squibb|Upon completion of Study CA139-540 (NCT 00344552), one subject (who had received 7 courses paclitaxel) rolled over into Study CA139-557. During four years in Study CA139-557, subject received an additional 30 courses of paclitaxel.|1|||f||||t||||||||||2018-06-01 00:37:37.121986|2018-06-01 00:37:37.121986
NCT00971828|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-08-12|2009-09-03|2009-09-04|Estimate|||||||2011-08-12|2011-08-15|Estimate|July 2011||2011-07-31|October 2009|2009-10-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy|A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy|Unknown status|Recruiting||30|Anticipated|Salford Royal NHS Foundation Trust|||1||f||||t||||||Samples Without DNA|"~     Bloods, including fasting blood sugar, lipid profile and C-reactive protein, serum creatine~     kinase, erythrocyte sedimentation rate, serology including antiphospholipid status.~   "|||2018-06-01 00:37:37.287059|2018-06-01 00:37:37.287059
NCT00971815|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-06-02|2009-09-03|2009-09-04|Estimate|||||||2017-06-02|2017-06-05|Actual|May 2009||2009-05-31|May 2013|2013-05-31|April 2014|Actual|2014-04-30|September 2011|Actual|2011-09-30||Interventional|LBW-SSRI||Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight|Effects of 3 Months of SSRI-Treatment on Metabolism and HPA-axis in Young Men Born With Low Birth Weight - a Randomized, Double Blinded and Placebo-controlled Trial|Completed||N/A|60|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:37:37.34777|2018-06-01 00:37:37.34777
NCT00971802|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2010-02-22|2009-09-03|2009-09-04|Estimate|||||||2010-02-22|2010-02-23|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers|A Phase 1, Double-Blind (Sponsor Open), Randomized, Placebo- Controlled, Parallel Group, Oral Multiple-Dose Trial to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-03882845 in Healthy Volunteers|Completed||Phase 1|50|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:37:37.428317|2018-06-01 00:37:37.428317
NCT00971789|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2013-05-03||2015-09-29|2009-09-03|2009-09-04|Estimate|2013-07-18|2013-07-19|Estimate||||2015-09-29|2015-09-30|Estimate|July 2008||2008-07-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes|A Pilot Study of Sirolimus (Rapamycin, Rapamune[Registered Trademark]) in Subjects With Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN|Completed||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 00:37:37.50782|2018-06-01 00:37:37.50782
NCT00971776|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2013-05-01|2009-09-03|2009-09-04|Estimate|||||||2013-05-01|2013-05-03|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|September 2013|Anticipated|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Voyager I: Patient Discharge Using the AB5000 Portable Driver System|Voyager I: Patient Discharge Using the AB5000 Portable Driver System|Terminated||Phase 3|9|Actual|Abiomed Inc.||||Terminated due to slow enrollment and change in business priority|f||||t||||||||||2018-06-01 00:37:37.890995|2018-06-01 00:37:37.890995
NCT00971763|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2014-12-03|2009-09-03|2009-09-04|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma|A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy|Completed||Phase 2|62|Actual|University College, London||1|||f||||t||||||||||2018-06-01 00:37:37.956982|2018-06-01 00:37:37.956982
NCT00971750|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2012-03-23||2012-06-29|2009-09-03|2009-09-04|Estimate|2012-05-29|2012-07-02|Estimate||||2012-06-29|2012-07-11|Estimate|October 2003||2003-10-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Observational|||Laparoscopic Versus Transabdominal Ultrasound in Morbidly Obese Patients|Comparison of Laparoscopic Ultrasound to Transabdominal Ultrasound for the Detection of Gallbladder Pathology in the Bariatric Surgical Population.|Completed|||253|Actual|Gundersen Lutheran Medical Foundation|||1||f||||||||||||||2018-06-01 00:37:38.162289|2018-06-01 00:37:38.162289
NCT00971737|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2015-09-23|2009-09-03|2009-09-04|Estimate|||||||2015-09-23|2015-09-25|Estimate|July 2009||2009-07-31|September 2015|2015-09-30||||March 2016|Anticipated|2016-03-31||Interventional|||Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer|A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-06-01 00:37:38.383231|2018-06-01 00:37:38.383231
NCT00971724|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2015-05-21|2009-09-03|2009-09-04|Estimate|||||||2015-05-21|2015-05-22|Estimate|May 2006||2006-05-31|May 2015|2015-05-31|March 2008|Actual|2008-03-31|October 2006|Actual|2006-10-31||Interventional|||Biomarkers of Prednisolone Treatment (P05888)|A Randomized, Placebo-controlled, Double-blind, Single-center Study Using Multiple Doses of Prednisolone to Quantify Effects on Selected Biomarkers and Assess Pharmacokinetics in Healthy Males|Completed||N/A|72|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:37:38.484426|2018-06-01 00:37:38.484426
NCT00971711|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2016-03-04|2009-09-03|2009-09-04|Estimate|||||||2016-03-04|2016-03-08|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety Study of Probiotics in Adults With Irritable Bowel Syndrome|Phase I, Open Label Safety Study of VSL#3 in Adults With Irritable Bowel Syndrome|Completed||Phase 1|21|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 00:37:38.567013|2018-06-01 00:37:38.567013
NCT00971698|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-08-25|2009-09-03|2009-09-04|Estimate|||||||2011-08-25|2011-08-26|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia|The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.|Completed|||50|Anticipated|HaEmek Medical Center, Israel|||2||f||||f||||||||||2018-06-01 00:37:38.754615|2018-06-01 00:37:38.754615
NCT00971685|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2010-09-01|2009-09-03|2009-09-04|Estimate|||||||2010-09-01|2010-09-02|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|July 2011|Anticipated|2011-07-31|December 2009|Actual|2009-12-31||Interventional|||The Treatment of Lenalidomide in Patients With POEMS Syndrome|Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome|Unknown status|Recruiting|Phase 2|16|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-06-01 00:37:38.832288|2018-06-01 00:37:38.832288
NCT00971672|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2015-08-30|2009-09-03|2009-09-04|Estimate|||||||2015-08-30|2015-09-01|Estimate|February 2010||2010-02-28|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Incidence of Iron Deficiency Anemia in Toddlers|Incidence of Iron Deficiency Anemia in Toddlers|Completed|||260|Actual|HaEmek Medical Center, Israel|||2||f||||f||||||||||2018-06-01 00:37:38.913978|2018-06-01 00:37:38.913978
NCT00971659|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2009-09-03|2009-09-03|2009-09-04|Estimate|||||||2009-09-03|2009-09-04|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 Diabetes|Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily|Completed||Phase 1|48|Actual|Profil Institut für Stoffwechselforschung GmbH||3|||f||||f||||||||||2018-06-01 00:37:38.98257|2018-06-01 00:37:38.98257
NCT00971646|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|||2011-07-14|2009-09-03|2009-09-04|Estimate|||||||2011-07-14|2011-07-15|Estimate|June 2010||2010-06-30|July 2011|2011-07-31||||December 2011|Anticipated|2011-12-31||Observational|||Cohort Study: Perceptual Urge Sensation|Cohort Study: Perceptual Urge Sensation|Unknown status|Recruiting||160|Anticipated|Maastricht University Medical Center|||2||f||||f||||||||||2018-06-01 00:37:39.086225|2018-06-01 00:37:39.086225
NCT00971633|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2010-07-30||2016-09-13|2009-09-03|2009-09-04|Estimate|2010-07-30|2010-08-26|Estimate||||2016-09-13|2016-09-14|Estimate|November 2003||2003-11-30|September 2016|2016-09-30|January 2004|Actual|2004-01-31|December 2003|Actual|2003-12-31||Interventional|||A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)|An Open-Label, Randomized, Single Dose, 3-period Crossover Study to Determine the Bioequivalence of 3 Formulations of Ondansetron in Healthy Young Adult Male and Female Subjects|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:37:39.184304|2018-06-01 00:37:39.184304
NCT00971620|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-03|2014-12-11||2017-02-23|2009-09-03|2009-09-04|Estimate|2014-12-22|2015-01-06|Estimate||||2017-02-23|2017-04-07|Actual|November 17, 2008|Actual|2008-11-17|February 2017|2017-02-28|October 12, 2016|Actual|2016-10-12|January 9, 2014|Actual|2014-01-09||Interventional|||Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin|Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin|Completed||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|f|f|||t|||No||2018-06-01 00:37:39.493488|2018-06-01 00:37:39.493488
NCT00971607|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2014-09-08|2009-09-02|2009-09-03|Estimate|||||||2014-09-08|2014-09-09|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SIAMI||Sevoflurane In Acute Myocardial Infarction|Sevoflurane Sedation During Primary Percutaneous Coronary Intervention.|Completed||Phase 2|50|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 00:37:40.203609|2018-06-01 00:37:40.203609
NCT00971594|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2009-09-02|2009-09-02|2009-09-03|Estimate|||||||2009-09-02|2009-09-03|Estimate|June 2004||2004-06-30|September 2009|2009-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Age, Lifestyle, Muscle Mechanisms in Insulin Resistance|Age, Lifestyle, Muscle Mechanisms in Insulin Resistance|Completed||N/A|15|Actual|National Institute on Aging (NIA)||1|||f||||t||||||||||2018-06-01 00:37:40.327182|2018-06-01 00:37:40.327182
NCT00971581|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2010-06-28|2009-09-02|2009-09-03|Estimate|||||||2010-06-28|2010-06-29|Estimate|August 2009||2009-08-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole|Safety, Tolerability and Efficacy of FDC Ketoprofen + Omeprazole in Patients With Rheumatological Conditions With History or Who Are at Risk of Developing NSAID Associated Benign Gastric Ulcers, Duodenal Ulcers and Gastroduodenal Erosions|Completed||Phase 3|52|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:37:40.410665|2018-06-01 00:37:40.410665
NCT00971568|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-03-15|2009-09-02|2009-09-03|Estimate|||||||2012-03-15|2012-03-19|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Urinary Biomarkers Characteristic to Interstitial Cystitis|Urinary Biomarkers Characteristic to Interstitial Cystitis- Proteomic Analysis of Urine|Completed|||15|Actual|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 00:37:40.470301|2018-06-01 00:37:40.470301
NCT00971555|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-03-22|2009-09-02|2009-09-03|Estimate|||||||2011-03-22|2011-03-23|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Thyroid Function in Late Preterm Infants|Thyroid Function in Late Preterm Infants in Relation to Severity of Illness|Completed|||150|Anticipated|Christiana Care Health Services|||1||f||||f||||||Samples With DNA|"~     Blood for total T4 and TSH testing will be done utilizing standardized filter paper used for~     the State of Delaware Newborn Screening Program.~   "|||2018-06-01 00:37:40.52662|2018-06-01 00:37:40.52662
NCT00971542|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-10-10|2009-09-02|2009-09-03|Estimate|||||||2011-10-10|2011-10-12|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|July 2011|Actual|2011-07-31|February 2010|Actual|2010-02-28||Interventional|||Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age|A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Egg-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age|Completed||Phase 3|778|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:37:40.581501|2018-06-01 00:37:40.581501
NCT00971529|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-09-03|2009-09-02|2009-09-03|Estimate|||||||2009-09-03|2009-09-04|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Observational|||Smoking Cessation Effect of Tea Filter Through Inhibition of Nicotine Receptor|Phase 1 Study on Smoking Cessation Effect of Tea Filter|Completed|||159|Actual|General Hospital of Beijing PLA Military Region|||2||f||||t||||||Samples Without DNA|"~     CO~   "|||2018-06-01 00:37:40.650468|2018-06-01 00:37:40.650468
NCT00971516|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-05-05|2009-09-02|2009-09-03|Estimate|||||||2012-05-05|2012-05-08|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|October 2010|Actual|2010-10-31||Interventional|||Healing Profile of Titanium Dental Implants Placed in Patients With Diabetes|Healing Profile of Titanium Dental Implants Placed in Patients With Type 2 Diabetes: a Prospective Osteoimmunological and Clinical Pilot Study|Completed||N/A|20|Anticipated|Escola Bahiana de Medicina e Saude Publica||2|||f||||t||||||||||2018-06-01 00:37:40.717339|2018-06-01 00:37:40.717339
NCT00971503|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-07-26|2009-09-02|2009-09-03|Estimate|||||||2011-07-26|2011-07-27|Estimate|February 2011||2011-02-28|July 2011|2011-07-31|February 2012|Anticipated|2012-02-29|February 2011|Anticipated|2011-02-28||Interventional|||Safety and Efficacy of Arterial Delivery of Autologous Bone Marrow Cells in the Treatment of Insulin-Dependent Diabetes|Método Para Regenerar el páncreas Con localización in Vivo de médula ósea Total Autologa en Pacientes diabéticos Tipo 1. Estudio Fase IIB.|Withdrawn||Phase 2|34|Anticipated|University of Moron||2||Principal Investigator moved to Chile from Argentina|f||||t||||||||||2018-06-01 00:37:40.869138|2018-06-01 00:37:40.869138
NCT00971490|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-09-02|2009-09-02|2009-09-03|Estimate|||||||2009-09-02|2009-09-03|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of a 4-week Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) Program on Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD)|Effects of a 4-week Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) Program on Subjects With Stable Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|30|Actual|The Hong Kong Polytechnic University||3|||f||||||||||||||2018-06-01 00:37:40.946589|2018-06-01 00:37:40.946589
NCT00971477|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2010-12-09|2009-09-02|2009-09-03|Estimate|||||||2010-12-09|2010-12-13|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis|Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis|Completed||Phase 2|64|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 00:37:41.045052|2018-06-01 00:37:41.045052
NCT00768963|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2017-07-07|2008-10-07|2008-10-08|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2008||2008-10-31|July 2017|2017-07-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Ranibizumab for the Inhibition of Neovascularization in Pterygia|Ranibizumab for the Inhibition of Neovascularization in Pterygia|Completed||Phase 1|10|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 01:41:25.239248|2018-06-01 01:41:25.239248
NCT00971464|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-09-07|2009-09-02|2009-09-03|Estimate|||||||2012-09-07|2012-09-10|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|AMD||Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation|A Randomized Controlled Trial of Eccentric Viewing Training vs. Closed Circuit Television Use for Visual Rehabilitation From Age-Related Macular Degeneration|Completed||Phase 2|10|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 00:37:41.134863|2018-06-01 00:37:41.134863
NCT00971451|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-03-04|2009-09-02|2009-09-03|Estimate|||||||2011-03-04|2011-03-08|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Quadriceps Function Prior to Anterior Cruciate Ligament Reconstruction|Quadriceps Function Prior to Anterior Cruciate Ligament Reconstruction|Unknown status|Recruiting|N/A|50|Anticipated|University of Virginia||3|||f||||f||||||||||2018-06-01 00:37:41.231128|2018-06-01 00:37:41.231128
NCT00971438|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2015-05-04|2009-09-02|2009-09-03|Estimate|||||||2015-05-04|2015-05-05|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|STRAPPSCORE||Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging|Structured Management of Patients With Suspicion of Appendicitis Using a Clinical Score and Selective Imaging|Terminated||N/A|1312|Actual|Ryhov County Hospital||2||Failing recruitement and more exclusions than anticipated.|f||||f||||||||||2018-06-01 00:37:41.338932|2018-06-01 00:37:41.338932
NCT00971425|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2011-02-10||2017-01-16|2009-09-02|2009-09-03|Estimate|2011-02-10|2011-03-04|Estimate||||2017-01-16|2017-02-28|Actual|September 2009||2009-09-30|January 2017|2017-01-31|October 2010|Actual|2010-10-31|November 2009|Actual|2009-11-30||Interventional|||Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)|Immunogenicity and Safety of GSK Biologicals' Pandemic Influenza Candidate Vaccine GSK2340272A|Completed||Phase 3|145|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:37:41.465428|2018-06-01 00:37:41.465428
NCT00971399|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-02-24|2009-09-02|2009-09-03|Estimate|||||||2011-02-24|2011-02-28|Estimate|September 2009||2009-09-30|February 2011|2011-02-28||||February 2011|Actual|2011-02-28||Interventional|||Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting|Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer|Completed||Phase 3|172|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:37:42.242435|2018-06-01 00:37:42.242435
NCT00971386|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-05-09|2009-09-02|2009-09-03|Estimate|||||||2011-05-09|2011-05-10|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Short Term Hemodynamic Effects of Controlled Slow Breathing With Biofeedback in Patients With Heart Failure|Short Term Hemodynamic Effects of Controlled Slow Breathing With Biofeedback in Patients With Heart Failure: Normal Healthy Subjects vs. Chronic Ambulatory Heart Failure Patients vs Acute Heart Failure|Completed||N/A|11|Actual|Albert Einstein Healthcare Network||3|||f||||f||||||||||2018-06-01 00:37:42.303667|2018-06-01 00:37:42.303667
NCT00971373|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2016-06-06|2009-09-02|2009-09-03|Estimate|||||||2016-06-06|2016-06-08|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Pilot Study to Determine the Effectiveness of Antimicrobial Healthcare Worker's (HCW) Hands and Clothing|Pilot Study to Determine the Effectiveness of Antimicrobial Scrubs on Bacterial Burden of HCW's Hands and Clothing in a Clinical Setting|Completed||N/A|30|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 00:37:42.366329|2018-06-01 00:37:42.366329
NCT00971360|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2010-10-19|2009-09-02|2009-09-03|Estimate|||||||2010-10-19|2010-10-20|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Cytokine Levels in Conversion Disorder|Proinflammatory Cytokine Levels in Patients With Conversion Disorder|Completed|||30|Anticipated|Trakya University|||2||f||||f||||||||||2018-06-01 00:37:42.430317|2018-06-01 00:37:42.430317
NCT00971347|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2010-11-22|2009-09-02|2009-09-03|Estimate|||||||2010-11-22|2010-11-23|Estimate|August 2009||2009-08-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Chewing Gum for Weight Loss|Randomized Controlled Trial of Chewing Gum for Weight Loss|Completed||N/A|200|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 00:37:42.497616|2018-06-01 00:37:42.497616
NCT00971334|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2012-02-15|2009-09-02|2009-09-03|Estimate|||||||2012-02-15|2012-02-17|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|Completed|||2502|Actual|Sequenom, Inc.|||||f||||f||||||Samples With DNA|"~     Plasma and PBMCs~   "|||2018-06-01 00:37:42.578163|2018-06-01 00:37:42.578163
NCT00971321|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27||2010-12-10|2016-09-22|2009-09-02|2009-09-03|Estimate||||2010-12-10|2010-12-16|Estimate|2016-09-22|2016-09-23|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 6 to 35 Months|Completed||Phase 2|157|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:37:42.69285|2018-06-01 00:37:42.69285
NCT00971308|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-01-24|2009-09-02|2009-09-03|Estimate|||||||2011-01-24|2011-01-25|Estimate|October 2009||2009-10-31|January 2011|2011-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus|Open Label, Multiple-Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of BMS-824393 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1|Completed||Phase 1|37|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:37:42.793344|2018-06-01 00:37:42.793344
NCT00971295|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2014-12-04||2014-12-15|2009-09-02|2009-09-03|Estimate|2014-12-15|2014-12-16|Estimate||||2014-12-15|2014-12-16|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Interventional|||Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers|Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers|Completed||Phase 1|20|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-06-01 00:37:42.871824|2018-06-01 00:37:42.871824
NCT00971113|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2009-09-02|2009-09-02|2009-09-03|Estimate|||||||2009-09-02|2009-09-03|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Prebiotic Effect of a Jelly Containing Short Chain Fructo-Oligosaccharides and Sideritis Euboea Extract|Impact of a Jelly Containing Short Chain Fructo-oligosaccharides and Sideritis Euboea Extract on Human Gut Microflora|Completed||N/A|64|Actual|Harokopio University||2|||f||||f||||||||||2018-06-01 00:37:46.771532|2018-06-01 00:37:46.771532
NCT00971282|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2011-08-31||2012-04-16|2009-09-02|2009-09-03|Estimate|2012-04-16|2012-05-15|Estimate||||2012-04-16|2012-05-15|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-Up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins|Adjunctive Usage of a Moisturizing Lotion (Cetaphil® Moisturizing Lotion) to Limit the Skin Irritation Linked to the Set-up of a Treatment by Topical Retinoid (Differin® Gel 0,1%) in Healthy Subjects of Chinese Origins|Completed||Phase 4|30|Actual|Galderma||1|||f||||f||||||||||2018-06-01 00:37:43.05852|2018-06-01 00:37:43.05852
NCT00971269|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2009-09-02|2009-09-02|2009-09-03|Estimate|||||||2009-09-02|2009-09-03|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Pilot Study of NASHA/Dx Gel for Fecal Incontinence|A Pilot Study of Intersphincteric Injection of NASHA/Dx Gel for Fecal Incontinence|Unknown status|Recruiting|Phase 1/Phase 2|16|Anticipated|Uppsala University Hospital|||||f||||f||||||||||2018-06-01 00:37:44.258618|2018-06-01 00:37:44.258618
NCT00971256|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-11-22|2009-09-02|2009-09-03|Estimate|||||||2011-11-22|2011-11-23|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Urine Cytology and Utility in Bladder Recurrence|Urine Cytology and Utility in Bladder Recurrence|Completed|||10|Actual|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 00:37:44.326387|2018-06-01 00:37:44.326387
NCT00971243|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2014-08-21||2014-08-21|2009-09-02|2009-09-03|Estimate|2014-08-21|2014-09-01|Estimate||||2014-08-21|2014-09-01|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes|A Phase IIb, Double-blind, Parallel Group, Multi-center, Dose-finding Study to Investigate the Efficacy and Safety of 4 Doses of MP-513 When Added to Ongoing Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus, With an Open Label Extension|Completed||Phase 2|448|Actual|Mitsubishi Tanabe Pharma Corporation||5|||f||||t||||||||||2018-06-01 00:37:44.458332|2018-06-01 00:37:44.458332
NCT00971230|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2010-08-05|2009-09-02|2009-09-03|Estimate|||||||2010-08-05|2010-08-09|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa|A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Kenya, Africa|Completed||Phase 1/Phase 2|72|Anticipated|International AIDS Vaccine Initiative||4|||f||||||||||||||2018-06-01 00:37:45.798974|2018-06-01 00:37:45.798974
NCT00971217|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-07-29|2009-09-02|2009-09-03|Estimate|||||||2011-07-29|2011-08-01|Estimate|August 2010||2010-08-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|BTN||Exploring the Effectiveness of the 'Back of the Net' Intervention on Indices of Physical and Psychological Measures|Exploring the Effectiveness of the 'Back of the Net' Intervention on Indices of Physical and Psychological Measures|Completed||N/A|140|Actual|Dublin City University||4|||f||||f||||||||||2018-06-01 00:37:45.900932|2018-06-01 00:37:45.900932
NCT00971204|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2016-04-18||2016-07-27|2009-09-02|2009-09-03|Estimate|2016-06-16|2016-07-27|Estimate||||2016-07-27|2016-08-01|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional||100 participants were enrolled in the study. 86 participants that met all inclusion/exclusion criteria received treatment with the HeartLight System and are included in the reported results.|Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation|Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation|Completed||Phase 2|100|Actual|CardioFocus||1|||f||||t||||||||||2018-06-01 00:37:46.005737|2018-06-01 00:37:46.005737
NCT00971191|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-06-21|2009-09-02|2009-09-03|Estimate|||||||2012-06-21|2012-06-22|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804|A Presurgical Study To Evaluate Molecular Changes That Occur In Human Non-Small Cell Lung Cancer Tissue After Short Term Exposure To PF-00299804|Terminated||Phase 1|22|Actual|Pfizer||1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:37:46.215423|2018-06-01 00:37:46.215423
NCT00971178|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2010-06-07|2009-09-02|2009-09-03|Estimate|||||||2010-06-07|2010-06-08|Estimate|February 2006||2006-02-28|June 2010|2010-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Analgesic Effect of Peripheral Dexmedetomidine|Effectiveness of Peripheral Dexmedetomidine for Bilateral Third Molar Surgery Under General Anaesthesia|Completed||Phase 3|105|Actual|The University of Hong Kong||3|||f||||t||||||||||2018-06-01 00:37:46.37907|2018-06-01 00:37:46.37907
NCT00971165|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2015-02-11|2009-09-02|2009-09-03|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PREVER||Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension|A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study|Completed||Phase 3|655|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 00:37:46.451643|2018-06-01 00:37:46.451643
NCT00971152|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2014-03-12|2009-09-02|2009-09-03|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|||Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle|Effect of a Higher Than Maximum 450IU Gonadotropin Dose on Patient Outcomes in an In-Vitro Fertilization Setting: a Randomized Controlled Non-infertility Trial|Completed||Phase 3|366|Actual|OVO R & D||2|||f||||f||||||||||2018-06-01 00:37:46.535398|2018-06-01 00:37:46.535398
NCT00971139|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2015-11-02|2009-09-02|2009-09-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|OPPC||Implementing Online Patient-Provider Communication Into Clinical Practice|Implementing Online Patient-Provider Communication Into Clinical Practice: Implementation Research|Completed||N/A|199|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 00:37:46.613348|2018-06-01 00:37:46.613348
NCT00971126|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2016-05-03|2009-09-02|2009-09-03|Estimate|||||||2016-05-03|2016-05-04|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)|A Phase I/II Study of Sorafenib With Combination of Thalidomide in Advanced or Metastatic Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|3|Actual|National Health Research Institutes, Taiwan||1||"Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated~   early this trial."|f||||t||||||||||2018-06-01 00:37:46.690928|2018-06-01 00:37:46.690928
NCT00971100|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2016-11-30|2009-09-02|2009-09-03|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|March 2010|Actual|2010-03-31||Interventional|||Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age|A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Cell-derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects From 6 Months to 17 Years of Age|Completed||Phase 3|752|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:37:46.838185|2018-06-01 00:37:46.838185
NCT00971087|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-12-05|2009-09-02|2009-09-03|Estimate|||||||2012-12-05|2012-12-06|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Multicenter Hologic Tomosynthesis Study|A Multicenter, Controlled Clinical Trial to Evaluate the Hologic Tomosynthesis Mammography|Unknown status|Active, not recruiting|N/A|3800|Anticipated|Hologic, Inc.||2|||f||||f||||||||||2018-06-01 00:37:46.915412|2018-06-01 00:37:46.915412
NCT00971074|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-03-27|2009-09-02|2009-09-03|Estimate|||||||2012-03-27|2012-03-28|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy|The Use of Viscosupplementation for the Treatment of Patients With Persistent Non-mechanical Pain Status-post Partial Menisectomy|Withdrawn||N/A|0|Actual|Ohio State University||2||Patients did not meet inclusion criteria.|f||||t||||||||||2018-06-01 00:37:47.014093|2018-06-01 00:37:47.014093
NCT00971061|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2009-09-03|2009-09-02|2009-09-03|Estimate|||||||2009-09-03|2009-09-04|Estimate|January 2003||2003-01-31|September 2009|2009-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Ahmed Glaucoma Valve and Single-Plate Molteno Implants in Treatment of Refractory Glaucoma||Completed||Phase 3|72|Actual|Vanak Eye Surgery Center||2|||f||||t||||||||||2018-06-01 00:37:47.092823|2018-06-01 00:37:47.092823
NCT00971048|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2013-10-09||2013-12-11|2009-09-02|2009-09-03|Estimate|2013-12-11|2014-01-27|Estimate||||2013-12-11|2014-01-27|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds|Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds|Completed||N/A|88|Actual|Healthpoint||2|||f||||f||||||||||2018-06-01 00:37:47.311389|2018-06-01 00:37:47.311389
NCT00971035|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01||2011-06-30|2016-11-25|2009-09-02|2009-09-03|Estimate||||2011-06-30|2011-07-13|Estimate|2016-11-25|2016-11-29|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|MOLLY||A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids|A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)|Completed||Phase 2|210|Actual|Genentech, Inc.||4|||f||||||||||||||2018-06-01 00:37:47.718539|2018-06-01 00:37:47.718539
NCT00971022|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-04-16|2009-09-02|2009-09-03|Estimate|||||||2012-04-16|2012-04-18|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Discount Generic Prescription Study|Discount Generic Prescription Utilization in Low-income Populations|Completed|||574|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 00:37:47.802643|2018-06-01 00:37:47.802643
NCT00971009|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2015-10-19|2009-09-02|2009-09-03|Estimate|||||||2015-10-19|2015-10-20|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|March 2014|Actual|2014-03-31||Interventional|WebChoice 2||Effects of Internet Support for Cancer Patients|Effects of Internet Support for Cancer Patients on Health Outcomes, Health Care Utilization and Costs: A Randomized Clinical Trial|Completed||N/A|200|Actual|Oslo University Hospital||3|||f||||f||||||||||2018-06-01 00:37:47.872873|2018-06-01 00:37:47.872873
NCT00970996|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-12-31|2009-09-02|2009-09-03|Estimate|||||||2012-12-31|2013-01-03|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BCAA||Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma|Phase I Biochemotherapy With Cisplatin, Temozolomide, With Increasing Doses of Abraxane, Combined With Interleukin-2 and Interferon in Patients With Metastatic Melanoma|Completed||Phase 1|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:37:48.012561|2018-06-01 00:37:48.012561
NCT00970983|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2011-11-28|2009-09-02|2009-09-03|Estimate|||||||2011-11-28|2011-11-29|Estimate|March 1998||1998-03-31|November 2011|2011-11-30|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||Axillary Dissection Based on the Histological Result of the Sentinel Node, in Patients With Breast Carcinoma|"Randomized Clinical Trial Comparing Axillary Dissection by Principle and Axillary Dissection Based on the Histological Result of the Sentinel Node, in Patients With Breast Carcinoma of Small Size"|Completed||N/A|532|Actual|European Institute of Oncology||2|||f||||f||||||||||2018-06-01 00:37:48.109593|2018-06-01 00:37:48.109593
NCT00970970|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2012-11-05|2009-09-02|2009-09-03|Estimate|||||||2012-11-05|2012-11-06|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|VHLimage||Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease|Visualizing VEGF Producing Lesions in Von Hippel-Lindau Disease|Completed|||22|Actual|University Medical Center Groningen|||1||f||||f||||||Samples With DNA|"~     Blood samples will be taken at day 1 and at the day of the MRI scan for analysis of VEGF~     pathway related biomarkers (such as plasma VEGF, PDGF, placental growth factor (PlGF),~     soluble VEGF receptors) and endothelial activation markers (such as Von Willebrand Factor~     (VWF), plasminogen activator inhibitor type 1 antigen (PAI-1), tissue-type plasminogen~     activator antigen (t-PA) and circulating endothelial cells (CECs)). DNA analysis for~     evaluation of polymorphisms in genes involved in angiogenesis is optional. In available~     biopsy or resection specimens, additional molecular staining of VEGF pathway related proteins~     will be performed (such as VEGF, VEGF receptors, HIF).~   "|||2018-06-01 00:37:48.174279|2018-06-01 00:37:48.174279
NCT00970957|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2014-03-18|2009-09-02|2009-09-03|Estimate|||||||2014-03-18|2014-03-19|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|EBOVER||Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion|Study of the Safety and Efficacy of Bevacizumab Intravitreal Injections for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions|Completed||Phase 3|107|Actual|Instituto Universitario de Oftalmobiología Aplicada||4|||f||||||||||||||2018-06-01 00:37:48.245183|2018-06-01 00:37:48.245183
NCT00970944|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2011-12-12||2012-09-11|2009-09-02|2009-09-03|Estimate|2012-09-11|2012-09-24|Estimate||||2012-09-11|2012-09-24|Estimate|February 2003||2003-02-28|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)|A Multicenter Prospective Randomized Controlled Trial of the Effectiveness of Amantadine Hydrochloride in Promoting Recovery of Function Following Severe Traumatic Brain Injury|Completed||Phase 2/Phase 3|184|Actual|JFK Medical Center||2|||f||||t||||||||||2018-06-01 00:37:48.372699|2018-06-01 00:37:48.372699
NCT00970931|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2015-02-11|2009-09-02|2009-09-03|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2010||2010-07-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PREVER||Hypertension Prevention in Pre-Hypertensive Individuals|Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study|Completed||Phase 3|730|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 00:37:48.833212|2018-06-01 00:37:48.833212
NCT00970918|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-09-22|2009-09-02|2009-09-03|Estimate|||||||2010-09-22|2010-09-24|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|CIMT||Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs|Prevalence of Atherosclerotic Disease in Asian Subjects Not on Lipid-lowering Agents, But With at Least Two CVD Risk Factors|Completed||N/A|2609|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:37:48.924074|2018-06-01 00:37:48.924074
NCT00970905|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-12-02|2009-09-02|2009-09-03|Estimate|||||||2017-12-02|2017-12-05|Actual|October 2009||2009-10-31|December 2017|2017-12-31|August 1, 2016|Actual|2016-08-01|July 1, 2016|Actual|2016-07-01||Interventional|AVERT||Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy|Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Fractionated Radiotherapy to the Upper Abdomen|Completed||Phase 2|52|Actual|University of Vermont||1|||f||||t||||||||||2018-06-01 00:37:49.015397|2018-06-01 00:37:49.015397
NCT00970892|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2009-09-02|2009-09-02|2009-09-03|Estimate|||||||2009-09-02|2009-09-03|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Observational|||VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management|Evaluation of VKORC1 and Cytochrome P450 CYP2C9 Gene Polymorphisms and Management of Warfarin Dose Using Pharmacogenetic Data|Unknown status|Recruiting||500|Anticipated|Ankara University|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:37:49.093235|2018-06-01 00:37:49.093235
NCT00970879|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|||2013-01-21|2009-09-02|2009-09-03|Estimate|||||||2013-01-21|2013-01-23|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|PACOME||Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine|Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomised Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine|Completed||Phase 3|430|Actual|Institut de Recherche pour le Developpement||4|||f||||t||||||||||2018-06-01 00:37:49.177279|2018-06-01 00:37:49.177279
NCT00970866|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2018-03-01|2009-09-02|2009-09-03|Estimate|||||||2018-03-01|2018-03-05|Actual|November 2009||2009-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy of Lipid-Based Nutrient Supplements (LNS) for Pregnant and Lactating Women and Their Infants|Efficacy of Lipid-based Nutrient Supplements (LNS) for Pregnant and Lactating Women and Their Infants|Active, not recruiting||N/A|864|Anticipated|University of California, Davis||3|||f||||t||||||||||2018-06-01 00:37:49.270184|2018-06-01 00:37:49.270184
NCT00970853|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-02|2011-12-07||2014-03-20|2009-09-02|2009-09-03|Estimate|2014-02-04|2014-03-21|Estimate||||2014-03-20|2014-04-15|Estimate|March 2009||2009-03-31|March 2014|2014-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||MOM Program 8-Year Follow-up|The MOM Program Continuation - 8 Year Follow-up|Completed||Phase 3|187|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 00:37:49.523435|2018-06-01 00:37:49.523435
NCT00970840|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2017-03-22|2009-09-02|2009-09-03|Estimate|||||||2017-03-22|2017-03-27|Actual|June 2009||2009-06-30|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Acceptability of Lipid-Based Nutrient Supplements (LNS) for Women and Infants|Acceptability of Lipid-based Nutrient Supplements (LNS) for Women and Infants|Completed||N/A|46|Actual|University of California, Davis||1|||f||||f||||||||||2018-06-01 00:37:49.89041|2018-06-01 00:37:49.89041
NCT00970827|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2014-09-08|2009-09-02|2009-09-03|Estimate|||||||2014-09-08|2014-09-09|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|RIP-PCI||Remote Ischemic Postconditioning During Percutaneous Coronary Interventions|Remote Ischemic Postconditioning During Percutaneous Coronary Interventions.|Completed||Phase 2|360|Actual|Lawson Health Research Institute||3|||f||||f||||||||||2018-06-01 00:37:49.960682|2018-06-01 00:37:49.960682
NCT00970814|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2012-04-26||2014-08-20|2009-09-01|2009-09-02|Estimate|2012-05-30|2012-07-06|Estimate||||2014-08-20|2014-08-28|Estimate|October 2009||2009-10-31|August 2014|2014-08-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|NCIG 002||Levetiracetam XR in Very Heavy Drinkers|A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers|Completed||Phase 2|130|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||t||||||||||2018-06-01 00:37:50.063768|2018-06-01 00:37:50.063768
NCT00970801|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2016-10-16|2009-09-01|2009-09-02|Estimate|||||||2016-10-16|2016-10-18|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|||Study of Nontuberculous Mycobacterial Lung Disease|Identification of Host Susceptibility Factors and Development of Biomarkers for Diagnosis, Prognosis and Treatment of Nontuberculous Mycobacterial Lung Disease|Recruiting|||300|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-06-01 00:37:50.491712|2018-06-01 00:37:50.491712
NCT00970788|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2012-04-28|2009-09-01|2009-09-02|Estimate|||||||2012-04-28|2012-05-01|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Pilot Study of Using Video Images in Advance Care Planning in Malignant Glioma Patients|A Pilot Study of Using Video Images in Advance Care Planning in Malignant Glioma Patients|Completed||N/A|50|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:37:50.560774|2018-06-01 00:37:50.560774
NCT00970775|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2010-03-17|2009-09-01|2009-09-02|Estimate|||||||2010-03-17|2010-03-18|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|JSAD||AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers|Completed||Phase 1|32|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:37:50.63757|2018-06-01 00:37:50.63757
NCT00970762|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2015-04-16|2009-09-01|2009-09-02|Estimate|||||||2015-04-16|2015-04-17|Estimate|February 2003||2003-02-28|April 2015|2015-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)|Comparative Study of Org 9426 With Vecuronium Bromide (Phase III)|Completed||Phase 3|90|Actual|Merck Sharp & Dohme Corp.||7|||f||||t||||||||||2018-06-01 00:37:50.711423|2018-06-01 00:37:50.711423
NCT00970749|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|||2017-04-05|2009-09-01|2009-09-02|Estimate|||||||2017-04-05|2017-04-07|Actual|December 2009||2009-12-31|April 2017|2017-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis|Antigen-specific Cell Mediated Immune Response to Chlamydia Trachomatis|Completed|||55|Actual|University of Pittsburgh|||2||f||||f||||||||No||2018-06-01 00:37:50.793761|2018-06-01 00:37:50.793761
NCT00970736|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2014-12-03||2015-03-05|2009-09-01|2009-09-02|Estimate|2015-03-05|2015-04-08|Estimate||||2015-03-05|2015-04-08|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational||Healthy adults between the ages of 60 and 80 years|Stability of Motor Output in Aging Adults|Corticobulbar Motor Output in Aging Adults|Completed|||20|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 00:37:50.855169|2018-06-01 00:37:50.855169
NCT00970723|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2014-04-11|2009-09-01|2009-09-02|Estimate|||||||2014-04-11|2014-04-14|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|OMHADIA||High Blood Pressure and Sleep Apnea in Diabetic Macular Edema|Role of High Blood Pressure and Sleep Apnea in Type 2 Diabetic Macular Edema|Completed||N/A|86|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:37:51.014414|2018-06-01 00:37:51.014414
NCT00970710|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2017-02-12|2009-09-01|2009-09-02|Estimate|||||||2017-02-12|2017-02-14|Actual|January 1, 2009|Actual|2009-01-01|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|VACOPP||Vaasa Childhood Obesity Primary Prevention Study|Vaasa Childhood Obesity Primary Prevention Study|Completed||N/A|185|Actual|University of Tampere||1|||f||||t|f|f||||||Undecided||2018-06-01 00:37:51.105878|2018-06-01 00:37:51.105878
NCT00970697|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-10-03|2009-09-01|2009-09-02|Estimate|||||||2011-10-03|2011-10-04|Estimate|January 2004||2004-01-31|September 2011|2011-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|ERAN||Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers|Double Blind Randomized Controlled Trial of Recombinant Human Platelet Derived Growth Factor-BB Gel (Regranex Gel®) Versus Hydrogel (Duoderm Hydrogel®) for Healing of MARTORELL's Hypertensive Leg Ulcers. ERAN Trial.|Completed||Phase 3|64|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:37:51.191578|2018-06-01 00:37:51.191578
NCT00970684|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2013-12-18||2013-12-18|2009-09-01|2009-09-02|Estimate|2013-12-18|2014-02-04|Estimate||||2013-12-18|2014-02-04|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase II Study of Bevacizumab Plus Docetaxel and Gemcitabine in Subjects With Advanced, Previously Untreated, Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 2|13|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:37:51.273984|2018-06-01 00:37:51.273984
NCT00970671|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2012-10-20|2009-09-01|2009-09-02|Estimate|||||||2012-10-20|2012-10-23|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Surgical Scars Using the Pulsed Dye Laser|Treatment of Surgical Scars With the 595nm Pulsed Dye Laser Using Purpuric and Nonpurpuric Parameters: A Comparative Study|Completed||N/A|28|Actual|University of California, San Diego|||||f||||t||||||||||2018-06-01 00:37:51.562978|2018-06-01 00:37:51.562978
NCT00970658|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2009-09-03|2009-09-01|2009-09-02|Estimate|||||||2009-09-03|2009-09-04|Estimate|December 2009||2009-12-31|September 2009|2009-09-30|February 2010|Anticipated|2010-02-28|January 2010|Anticipated|2010-01-31||Interventional|SAL-SIP-03/09||Efficacy and Safety of Salonsip Compared to Sabiá Plaster|Clinical Multicenter Study, Randomized, Open, to Evaluate the Efficacy and Safety of Salonsip Compared to Sabiá Plaster Relief of the Signs and Symptoms in Patients With Contusions, Sprains, Injuries and Muscular Injuries With Less Than 24 Hours Early or Holders of Myalgia, Pain and Tendonitis in Regions Miofasciais Articulated.|Unknown status|Not yet recruiting|Phase 3|70|Anticipated|Hisamitsu Farmaceutica do Brasil Ltda||2|||f||||t||||||||||2018-06-01 00:37:51.619934|2018-06-01 00:37:51.619934
NCT00970645|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-07-15|2009-09-01|2009-09-02|Estimate|||||||2011-07-15|2011-07-18|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer|A Prospective Multicenter Study Comparing Endobronchial and Endoscopic Ultrasound-Guided FNA to Mediastinoscopy/Thoracoscopy in the Staging and Early Detection of Metastases in Lung Cancer|Terminated||N/A|2|Actual|Mayo Clinic||2||Similar study published results|f||||f||||||||||2018-06-01 00:37:51.675428|2018-06-01 00:37:51.675428
NCT00970632|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2011-11-21||2012-03-08|2009-09-01|2009-09-02|Estimate|2011-11-21|2011-12-23|Estimate||||2012-03-08|2012-03-12|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of Tadalafil in Men With Benign Prostatic Hyperplasia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|511|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 00:37:51.797269|2018-06-01 00:37:51.797269
NCT00970619|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2018-01-10|2009-09-01|2009-09-02|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2010||2010-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NL28394||DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT.|Ultrasound Accelerated Catheter-directed Thrombolysis for Primary Iliofemoral Deep Vein Thrombosis (IFDVT) Compared to Non-invasive Conventional Anticoagulant Therapy Alone: a Dutch Randomized Controlled Multicenter Clinical Trial.|Recruiting||Phase 3|180|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:37:53.455133|2018-06-01 00:37:53.455133
NCT00970606|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2013-03-12||2017-02-16|2009-09-01|2009-09-02|Estimate|2013-03-12|2013-04-24|Estimate||||2017-02-16|2017-03-22|Actual|October 2009||2009-10-31|June 2013|2013-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|STIP||STIP: Statin Trial for Influenza Patients|Randomized, Placebo Controlled Trial of the Effectiveness of Statins for Preventing Mortality Following ICU Admission for Influenza Complications|Terminated||N/A|7|Actual|Vanderbilt University Medical Center|Only able to enroll only 7 participants of >2000 planned/anticipated, leading to early termination of the study and therefore unable to perform statistical analysis with such a small sample size.|2||Inability to recruit participants since H1N1 epidemic resolved.|f||||t||||||||||2018-06-01 00:37:53.575922|2018-06-01 00:37:53.575922
NCT00970593|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-08-11|2009-09-01|2009-09-02|Estimate|||||||2011-08-11|2011-08-12|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|3283K1-1008-US||Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin|A Randomized, Double-Blind, Placebo-Controlled Study Of Multiple Doses Of OAP-189 To Determine The Safety, Tolerability, Pharmacodynamics, And Pharmacokinetics When Coadministered With Metformin In Type 2 Diabetic Subject|Completed||Phase 1|88|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 00:37:53.901545|2018-06-01 00:37:53.901545
NCT00970580|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2013-09-12|2009-09-01|2009-09-02|Estimate|||||||2013-09-12|2013-09-16|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer|A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 1|18|Actual|Biogen||1|||f||||t||||||||||2018-06-01 00:37:53.973398|2018-06-01 00:37:53.973398
NCT00970567|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-09-01|2009-09-01|2009-09-02|Estimate|||||||2009-09-01|2009-09-02|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Ketoacidosis in Individuals With Type I Diabetes Mellitus (T1DM)|Ketoacidosis in Individuals With T1DM|Completed||N/A|19|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-06-01 00:37:54.111147|2018-06-01 00:37:54.111147
NCT00970554|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2013-08-26|2009-09-01|2009-09-02|Estimate|||||||2013-08-26|2013-08-27|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effectiveness of Telescopic Magnification in the Treatment of Amblyopia|Effectiveness of Telescopic Magnification in the Treatment of Amblyopia|Completed||Phase 1/Phase 2|15|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:37:54.208572|2018-06-01 00:37:54.208572
NCT00970541|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2018-05-23|2009-09-01|2009-09-02|Estimate|||||||2018-05-23|2018-05-24|Actual|August 2009||2009-08-31|May 2018|2018-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Eccentric||Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome|Phase 1 Study That Will Compare 12 Weeks of Supplementation With Cinnamon Extract on the Action of Insulin and Blood Sugar (Glucose) With 12 Weeks of Supplementation With a Placebo.|Terminated||Phase 1|8|Actual|Pennington Biomedical Research Center||2||Recruitment|f||||f||||||||||2018-06-01 00:37:54.340147|2018-06-01 00:37:54.340147
NCT00970528|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2014-02-18|2009-09-01|2009-09-02|Estimate|||||||2014-02-18|2014-02-20|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|GREAN||Glucose Reduction by Early Acarbose Treatment in Basal Insulin|A Randomized, Parallel Group, Open-Label, Active-Controlled Study Comparing Acarbose With Voglibose in Patients Who Are Inadequately Controlled With Insulin Glargine Alone or in Combination With Metformin Based on Glycemic Control|Completed||Phase 4|124|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:37:54.474216|2018-06-01 00:37:54.474216
NCT00970515|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-10-27|2009-09-01|2009-09-02|Estimate|||||||2011-10-27|2011-10-28|Estimate|November 2009||2009-11-30|May 2011|2011-05-31|March 2014|Anticipated|2014-03-31|March 2012|Anticipated|2012-03-31||Interventional|EVENTRALAP||Laparoscopic or Conventional Mesh Repair of Incisional and Umbilical Hernia|A Prospective, Multicenter, Randomized Trial Comparing Laparoscopy VS Conventional Mesh Repair of Incisional and Umbilical Hernia|Unknown status|Recruiting|N/A|500|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:37:54.577145|2018-06-01 00:37:54.577145
NCT00970502|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2016-12-23||2017-02-24|2009-09-01|2009-09-02|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|February 2007||2007-02-28|February 2017|2017-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||15 subjects consented, one withdrew before receiving study treatment and was excluded from analysis|Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer|Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation|Completed||Phase 1/Phase 2|15|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-06-01 00:37:54.702232|2018-06-01 00:37:54.702232
NCT00970489|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2013-07-26||2017-02-24|2009-09-01|2009-09-02|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|August 2010||2010-08-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|OPERA|Patients scheduled for cardiac surgery across 28 centers in the US, Italy, and Argentina, enrolled between Aug 2010 and Jun 2012. Inclusion criteria were broad; the main exclusions were regular use of fish oil or absence of sinus rhythm at enrollment. Forty-eight percent of screened patients and 94% of eligible patients were enrolled.|Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation|(OPERA)Randomized Clinical Trial to Examine Whether Peri-operative Intake of n-3 Polyunsaturated Fatty Acids Will Reduce the Occurrence of Post-operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery|Completed||Phase 3|1516|Actual|Brigham and Women's Hospital|Best-practice guidelines for preventing post-op atrial fibrillation were recommended to Centers. The duration prior to surgery may have been too short to be effective; or the dose of n-3 PUFA too low to produce benefit|2|||f||||t||||||||||2018-06-01 00:37:55.058383|2018-06-01 00:37:55.058383
NCT00970476|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2012-08-28|2009-09-01|2009-09-02|Estimate|||||||2012-08-28|2012-08-30|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Response To Cardiac Resynchronization Therapy In Heart Failure: Role Of Arterial Stiffness|Response To Cardiac Resynchronization Therapy In Heart Failure: Role Of Arterial Stiffness|Withdrawn|||0|Actual|Creighton University||||limited enrollment|f||||f||||||||||2018-06-01 00:37:55.591854|2018-06-01 00:37:55.591854
NCT00970463|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2009-09-01|2009-09-01|2009-09-02|Estimate|||||||2009-09-01|2009-09-02|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly|Impact of Growth Hormone on Serum N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and on Cardiac Function and Morphology Evaluated by Magnetic Resonance Imaging in Growth Hormone Deficiency and Acromegaly|Completed|||22|Actual|Herlev Hospital|||2||f||||t||||||||||2018-06-01 00:37:55.691637|2018-06-01 00:37:55.691637
NCT00970450|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-01-28|2009-09-01|2009-09-02|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||The Central Analgesic Effects of Paracetamol on Serotonergic Pathways|The Central Analgesic Effects of Paracetamol on Serotonergic Pathways|Completed||N/A|16|Actual|University Hospital, Basel, Switzerland||4|||f||||t||||||||||2018-06-01 00:37:55.745222|2018-06-01 00:37:55.745222
NCT00970099|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2014-01-22|2009-09-01|2009-09-02|Estimate|||||||2014-01-22|2014-01-23|Estimate|February 2004||2004-02-29|January 2014|2014-01-31|December 2009|Actual|2009-12-31|March 2007|Actual|2007-03-31||Interventional|||Mechanism of Insulin-Resistant in Lean Non-Diabetics|Mechanism of Exercise Training in Lean Insulin-Resistant Non-Diabetics|Completed||Phase 1|149|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:38:05.224837|2018-06-01 00:38:05.224837
NCT00970437|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2017-07-03|2009-09-01|2009-09-02|Estimate|||||||2017-07-03|2017-07-05|Actual|April 2010||2010-04-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|October 2013|Actual|2013-10-31||Interventional|||A Comparison of Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and System of Supportive Psychotherapy (SYSP) for Early Onset Chronic Depression|A Comparison of Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and System of Supportive Psychotherapy (SYSP) for Early Onset Chronic Depression|Completed||N/A|268|Actual|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 00:37:55.809635|2018-06-01 00:37:55.809635
NCT00970424|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01||2011-09-09|2011-09-09|2009-09-01|2009-09-02|Estimate||||2011-09-09|2011-09-21|Estimate|2011-09-09|2011-09-21|Estimate|August 2009||2009-08-31|September 2011|2011-09-30||||August 2010|Actual|2010-08-31||Interventional|||Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Pioglitazone|Terminated||Phase 3|252|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:37:56.003608|2018-06-01 00:37:56.003608
NCT00970411|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2017-01-03|2009-09-01|2009-09-02|Estimate|||||||2017-01-03|2017-01-05|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of KRN951 in Patients With Solid Tumors|An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients With Solid Tumors|Completed||Phase 1|12|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||t||||||||||2018-06-01 00:37:56.289194|2018-06-01 00:37:56.289194
NCT00970398|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2013-04-18|2009-09-01|2009-09-02|Estimate|||||||2013-04-18|2013-04-22|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|September 2012|Actual|2012-09-30||Interventional|||Effect of an Infant Formula on Infant Growth, Health and Immune Functions|Effect of Infant Formula With Bovine Milk Osteopontin on Infant Growth, Health and Immune functions-a Double-blind Randomized Trial|Unknown status|Active, not recruiting|N/A|320|Anticipated|Biostime, Inc.||4|||f||||t||||||||||2018-06-01 00:37:56.355583|2018-06-01 00:37:56.355583
NCT00970385|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-09-08|2009-09-01|2009-09-02|Estimate|||||||2009-09-08|2009-09-09|Estimate|January 1995||1995-01-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|December 2002|Actual|2002-12-31||Interventional|LTP||Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma|Multicentric Study About Treatment of High Grade Peripheral T Cell Lymphoma in Adults. LTP Study Comparison Between VIP ABVD Versus CHOP|Completed||Phase 3|95|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 00:37:56.460025|2018-06-01 00:37:56.460025
NCT00970372|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2014-04-15|2009-09-01|2009-09-02|Estimate|||||||2014-04-15|2014-04-16|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Dual-Diagnosis and Compulsory Treatment|Compulsory Treatment of Alcohol and Drug Dependent Patients and Dual Diagnosis in 5 Counties of Health Region South-East, Norway|Completed|||202|Actual|Sorlandet Hospital HF|||2||f||||t||||||||||2018-06-01 00:37:56.545271|2018-06-01 00:37:56.545271
NCT00970359|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2015-10-20||2017-03-01|2009-09-01|2009-09-02|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|September 2009||2009-09-30|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244|Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study|Completed||N/A|24|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 00:37:56.623951|2018-06-01 00:37:56.623951
NCT00970346|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2016-03-22|2009-09-01|2009-09-02|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis|A Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy Volunteers|Completed||Phase 1|26|Actual|AlgiPharma AS||1|||f||||f||||||||||2018-06-01 00:37:56.818174|2018-06-01 00:37:56.818174
NCT00970333|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-02-07|2009-09-01|2009-09-02|Estimate|||||||2012-02-07|2012-02-08|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions|Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions|Completed||Phase 1|3|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 00:37:56.882798|2018-06-01 00:37:56.882798
NCT00970320|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2016-06-09||2016-08-24|2009-09-01|2009-09-02|Estimate|2016-08-24|2016-10-18|Estimate||||2016-08-24|2016-10-18|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Prevalence and Treatment of Anal Incontinence (AI) in Primiparous Women|Prevalence and Treatment of Anal Incontinence in Primiparous Women|Completed||N/A|1718|Actual|Ostfold Hospital Trust|Due to financial restrictions and Ostfold Hospital moving to a new hospital, the number of included participants were not as high as expected in RCT 2.|5|||f||||f||||||||No||2018-06-01 00:37:56.975156|2018-06-01 00:37:56.975156
NCT00970307|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2017-03-03|2010-12-10|2017-04-20|2009-09-01|2009-09-02|Estimate|2017-03-03|2017-04-14|Actual|2010-12-10|2010-12-16|Estimate|2017-04-20|2017-05-30|Actual|August 1, 2009||2009-08-01|March 2017|2017-03-31|January 27, 2010|Actual|2010-01-27|January 27, 2010|Actual|2010-01-27||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age|Completed||Phase 2|421|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:37:57.358823|2018-06-01 00:37:57.358823
NCT00970294|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2012-05-29||2012-07-18|2009-09-01|2009-09-02|Estimate|2012-07-18|2012-08-21|Estimate||||2012-07-18|2012-08-21|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pilot Project of Health Promotion for People With Diabetes|Feasibility and Effectiveness of a Health Promotion Program on Aerobic Fitness and Glycemic Control for Adults With Type 2 Diabetes|Completed||N/A|11|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 00:37:58.95523|2018-06-01 00:37:58.95523
NCT00970281|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2012-01-18||2012-03-06|2009-09-01|2009-09-02|Estimate|2012-01-18|2012-02-22|Estimate||||2012-03-06|2012-03-07|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Olanzapine in Patients With Schizophrenia|A Double-Blind Confirmatory Study Comparing Rapid-Acting Intramuscular Olanzapine and Rapid-Acting Intramuscular Placebo in Patients With an Exacerbation of Schizophrenia With Acute Psychotic Agitation|Completed||Phase 3|91|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:37:59.658307|2018-06-01 00:37:59.658307
NCT00970268|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2012-08-14|2011-10-04|2016-11-16|2009-09-01|2009-09-02|Estimate|2012-08-14|2012-09-14|Estimate|2011-10-04|2011-10-06|Estimate|2016-11-16|2017-01-06|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)|A Long-term, Randomized, Double-blind Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|291|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:38:01.414501|2018-06-01 00:38:01.414501
NCT00970255|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2012-08-01|2009-09-01|2009-09-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|October 2009||2009-10-31|August 2012|2012-08-31||||October 2015|Anticipated|2015-10-31||Interventional|||Frenotomy of the Labial Frenulum in Infants With Breastfeeding Difficulties|Effect of Labial Frenulum Clipping on Nipple Pain and Latch Problems in Breastfeeding Infants|Suspended||N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2||Difficulty in recruiting participants|f||||f||||||||||2018-06-01 00:38:03.407309|2018-06-01 00:38:03.407309
NCT00970242|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2009-09-03|2009-09-01|2009-09-02|Estimate|||||||2009-09-03|2009-09-04|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Ambulatory Urodynamic Evaluation of Sacral Neuromodulation for Non-Obstructive Urinary Retention|Ambulatory Urodynamic Evaluation of Sacral Neuromodulation for Non-obstructive Urinary Retention|Unknown status|Enrolling by invitation||25|Anticipated|Maastricht University Medical Center|||||f||||f||||||||||2018-06-01 00:38:03.470461|2018-06-01 00:38:03.470461
NCT00970229|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2017-01-05|2009-09-01|2009-09-02|Estimate|||||||2017-01-05|2017-01-06|Estimate|July 2009||2009-07-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|MNI-420||Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.|Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy Controls|Completed||Phase 1|19|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 00:38:03.520373|2018-06-01 00:38:03.520373
NCT00970216|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|2016-01-31||2016-01-31|2009-09-01|2009-09-02|Estimate|2016-01-31|2016-02-29|Estimate||||2016-01-31|2016-02-29|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Study of Telbivudine in Chronic Hepatitis B|A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.|Completed|||160|Actual|Chang Gung Memorial Hospital|||||f||||t||||||Samples With DNA|"~     Serum will be stored at screening/baseline and complete study after corresponding with~     inclusion/exclusion criteria.~   "|No||2018-06-01 00:38:04.405377|2018-06-01 00:38:04.405377
NCT00970203|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2018-04-05|2009-09-01|2009-09-02|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2009||2009-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer|Feasibility, Safety and Efficacy Evaluation of Alpha-Type 1 Dendritic Cell(DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With PSA Progression After Local Therapy for Prostate Cancer|Recruiting||Phase 2|12|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 00:38:04.5987|2018-06-01 00:38:04.5987
NCT00970190|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2014-12-10|2009-09-01|2009-09-02|Estimate|||||||2014-12-10|2014-12-11|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|cAMP||Olfactory Dysfunction of Rhinosinusitis - Cyclic Adenosine Monophosphate (cAMP)/Calcium Signaling Study|Olfactory Dysfunction of Rhinosinusitis - cAMP/Calcium Signaling Study|Completed|||99|Actual|University of Washington|||||f||||f||||||Samples Without DNA|"~     Samples consist of discarded tissue resulting from the following clinical procedures:~     endoscopic sinus surgery for chronic sinusitis, endoscopic transnasal approach to the~     pituitary for pituitary tumor removal, endoscopic inferior turbinectomy or septoplasty for~     nasal congestion and endoscopic repair of CSF leaks. Samples will only be retained for 1 year~     post-surgery and then destroyed.~   "|||2018-06-01 00:38:04.730753|2018-06-01 00:38:04.730753
NCT00970177|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2016-11-30|2009-09-01|2009-09-02|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|March 2011|Actual|2011-03-31|October 2009|Actual|2009-10-31||Interventional|||Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age|A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and Non Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of Age|Completed||Phase 3|812|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:38:04.787576|2018-06-01 00:38:04.787576
NCT00970151|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2009-10-09|2009-09-01|2009-09-02|Estimate|||||||2009-10-09|2009-10-12|Estimate|June 2005||2005-06-30|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Determinants of Fetal Inflammatory Exposure at Term|Determinants of Fetal Inflammatory Exposure at Term|Completed|||618|Actual|Medical University of South Carolina|||||f||||f||||||Samples With DNA|"~     Whole blood, blood serum, placenta, spinal fluid (for some subjects)~   "|||2018-06-01 00:38:04.861314|2018-06-01 00:38:04.861314
NCT00970138|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-07-11|2009-09-01|2009-09-02|Estimate|||||||2011-07-11|2011-07-12|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer|A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma|Completed||Phase 2/Phase 3|141|Actual|Fudan University||3|||f||||f||||||||||2018-06-01 00:38:04.919195|2018-06-01 00:38:04.919195
NCT00970125|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2012-04-28|2009-09-01|2009-09-02|Estimate|||||||2012-04-28|2012-05-01|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Using Video Images to Improve Advance Care Planning in Patients With Cancer|Using Video Images to Improve Advance Care Planning in Patients With Cancer|Completed||N/A|80|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 00:38:04.99157|2018-06-01 00:38:04.99157
NCT00970112|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2010-05-17|2009-09-01|2009-09-02|Estimate|||||||2010-05-17|2010-05-18|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||Dexamethasone and Etoricoxib for Pain Prevention Following Periodontal Surgery|O Uso de Dexametasona e Etoricoxibe Para a prevenção e Controle da Dor pós-operatória após Cirurgia Periodontal|Completed||Phase 2/Phase 3|20|Actual|Universidade Estadual de Ponta Grossa||3|||f||||t||||||||||2018-06-01 00:38:05.154191|2018-06-01 00:38:05.154191
NCT00970086|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2015-12-02|2009-09-01|2009-09-02|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TAP||Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Groin Surgery|"Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Inguinal Surgical Procedures: How Does it Compare With the Gold Standard Caudal Blockade"|Terminated||Phase 4|22|Actual|University Hospital, Basel, Switzerland||1||Groin surgery was changed to a laparoscopic technique; recruitable patients ceased.|f||||f||||||||||2018-06-01 00:38:05.294248|2018-06-01 00:38:05.294248
NCT00970073|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2017-03-25|2009-09-01|2009-09-02|Estimate|||||||2017-03-25|2017-03-28|Actual|August 2009||2009-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant|A Randomized Controlled Clinical Trial of Low Dose Thymoglobulin and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection After Liver Transplantation|Active, not recruiting||N/A|30|Anticipated|The Cleveland Clinic||3|||f||||f||||||||No||2018-06-01 00:38:05.369957|2018-06-01 00:38:05.369957
NCT00970060|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2013-07-03|2009-09-01|2009-09-02|Estimate|||||||2013-07-03|2013-07-04|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Exercise and Nerve Function in Diabetes|Effectiveness of an Exercise Program on Nerve Function and Cutaneous Nerve Fibers in Adults With Type 2 Diabetes|Completed||N/A|26|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 00:38:05.465218|2018-06-01 00:38:05.465218
NCT00970047|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2011-01-31|2009-09-01|2009-09-02|Estimate|||||||2011-01-31|2011-02-02|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Development of a Fetal Sex Assay From Maternal Whole Blood|Development of a Noninvasive Fetal Sex Determination Test Between 6 and 16 Weeks of Gestation|Completed|||500|Anticipated|Sequenom, Inc.|||1||f||||f||||||Samples With DNA|"~     Plasma and PBMCs~   "|||2018-06-01 00:38:05.540231|2018-06-01 00:38:05.540231
NCT00970034|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2009-09-02|2009-09-01|2009-09-02|Estimate|||||||2009-09-02|2009-09-03|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|December 2011|Anticipated|2011-12-31|||||Observational|||Gene Expression Profiles in Patients With Permanent Atrial Fibrillation (AF) Versus Sinus Rhythm (SR)|Comparative Gene Expression Profiles in Patients With Permanent Atrial Fibrillation and Normal Sinus Rhythm|Unknown status|Recruiting||60|Anticipated|Ankara University|||2||f||||f||||||Samples With DNA|"~     Human atrial tissue~   "|||2018-06-01 00:38:05.612772|2018-06-01 00:38:05.612772
NCT00970021|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2014-02-22|2009-09-01|2009-09-02|Estimate|||||||2014-02-22|2014-02-25|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|May 2011|Actual|2011-05-31||Interventional|||Agaricus Blazei Murill in Patients With Multiple Myeloma|Use of the Medicinal Mushroom Agaricus Blazei Murill in Addition to High Dose Chemotherapy in Patients With Multiple Myeloma.|Completed||Phase 2|39|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 00:38:05.711804|2018-06-01 00:38:05.711804
NCT00970008|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2015-05-01|2009-08-31|2009-09-02|Estimate|||||||2015-05-01|2015-05-05|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|EMBARK||Exploring Massage Benefits for Arthritis of the Knee|Exploring Massage Benefits for Arthritis of the Knee|Completed||Phase 2|125|Actual|Rutgers, The State University of New Jersey||5|||f||||t||||||||||2018-06-01 00:38:05.787133|2018-06-01 00:38:05.787133
NCT00969995|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2009-09-01|2009-09-01|2009-09-02|Estimate|||||||2009-09-01|2009-09-02|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Identification of Inflammatory Markers in Migraine Patients|Identification of Inflammatory Markers in Migraine Patients|Unknown status|Not yet recruiting||250|Anticipated|Tel-Aviv Sourasky Medical Center|||5||f||||f||||||||||2018-06-01 00:38:05.861757|2018-06-01 00:38:05.861757
NCT00969982|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2014-02-18|2009-09-01|2009-09-02|Estimate|||||||2014-02-18|2014-02-20|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial|Completed||N/A|238|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 00:38:05.938857|2018-06-01 00:38:05.938857
NCT00969969|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2016-11-10|2009-09-01|2009-09-02|Estimate|||||||2016-11-10|2016-11-15|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment of Osteoarthritis of the Great Toe|A Study to Evaluate the Effectiveness and Safety of an Implant in the Treatment of Osteoarthritis of the Great Toe|Completed||Phase 3|236|Actual|Cartiva, Inc.||2|||f||||f||||||||No||2018-06-01 00:38:06.006068|2018-06-01 00:38:06.006068
NCT00969956|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2015-04-08|2009-09-01|2009-09-02|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 2012||2012-04-30|May 2012|2012-05-31|May 2027|Anticipated|2027-05-31|May 2027|Anticipated|2027-05-31||Observational|||Time To Complications Occurs in Diabetes|Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur|Enrolling by invitation|||950|Anticipated|Karolinska Institutet|||4||f||||f||||||||||2018-06-01 00:38:06.090817|2018-06-01 00:38:06.090817
NCT00969943|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2018-05-02|2009-09-01|2009-09-02|Estimate|||||||2018-05-02|2018-05-07|Actual|March 2003|Actual|2003-03-31|May 2018|2018-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Gender Differences in Response to Cues in Cocaine Dependence|Gender Differences in Response to Cues in Cocaine Dependence|Completed|||||Medical University of South Carolina|||4||f||||f||||||||||2018-06-01 00:38:06.187415|2018-06-01 00:38:06.187415
NCT00969930|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2011-08-15|2009-09-01|2009-09-02|Estimate|||||||2011-08-15|2011-08-16|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|March 2012|Anticipated|2012-03-31|March 2011|Actual|2011-03-31||Observational|Licavalgene||Genetic Association Study Between Single Nucleotide Polymorphisms (SNPs) and Cognitive Performance in Young Bipolar Type I Patients: LICAVALGENE|Genetic Association Study Between Single Nucleotide Polymorphisms (SNPs) and Cognitive Performance in Young Bipolar Type I Patients: LICAVALGENE|Unknown status|Enrolling by invitation||80|Anticipated|University of Sao Paulo|||2||f||||f||||||||||2018-06-01 00:38:06.338|2018-06-01 00:38:06.338
NCT00969917|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-01|||2015-04-13|2009-09-01|2009-09-02|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2010||2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma|A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma|Withdrawn||Phase 2|0|Actual|Infinity Pharmaceuticals, Inc.||1||Company decision not to start the study|f||||f||||||||||2018-06-01 00:38:06.398601|2018-06-01 00:38:06.398601
NCT00969904|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-06-29|2009-08-31|2009-09-01|Estimate|||||||2012-06-29|2012-07-03|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pilot Study to Assess the Effect of High Dose N-acetylcysteine (NAC) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Double Blind, Randomized, Placebo-controlled, Two-way Crossover, Pilot Study to Assess the Effect of High Dose N-acetylcysteine on Small Airways and on Inflammation and Oxidative Stress in COPD Patients.|Completed||Phase 4|12|Actual|University Hospital, Antwerp||2|||f||||f||||||||||2018-06-01 00:38:06.48505|2018-06-01 00:38:06.48505
NCT00969891|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2011-08-24|2009-08-31|2009-09-01|Estimate|||||||2011-08-24|2011-08-25|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Observational|||Study of Dosage Individualisation for the Treatment of Acute Myeloid Leukemia|Population Based Pharmacokinetic and Pharmacodynamic Dosage Model for Cytarabine, Daunorubicin and Etoposide for Acute Myeloid Leukemia|Completed|||23|Actual|University of Copenhagen|||1||f||||||||||Samples Without DNA|"~     plasma samples~   "|||2018-06-01 00:38:06.557064|2018-06-01 00:38:06.557064
NCT00969878|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2014-07-17||2017-02-04|2009-08-31|2009-09-01|Estimate|2014-12-11|2014-12-12|Estimate||||2017-02-04|2017-03-15|Actual|August 2010||2010-08-31|February 2017|2017-02-28|July 2014|Actual|2014-07-31|August 2012|Actual|2012-08-31||Interventional|TA-CD||Multisite Controlled Trial of Cocaine Vaccine|A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence|Completed||Phase 2|300|Actual|Baylor College of Medicine||2|||f||||t||||||||No||2018-06-01 00:38:06.641312|2018-06-01 00:38:06.641312
NCT00969865|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2017-11-16|2009-08-31|2009-09-01|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2011|Actual|2011-10-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|iCARE||Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program|Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program|Completed|||170|Actual|Piedmont Healthcare|||2||f||||f||||||||||2018-06-01 00:38:06.954685|2018-06-01 00:38:06.954685
NCT00969852|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|||2011-01-09|2009-08-31|2009-09-01|Estimate|||||||2011-01-09|2011-01-11|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration|[11C] Sertraline PET Imaging Study That Investigates Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration|Completed||Phase 4|10|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-06-01 00:38:07.027225|2018-06-01 00:38:07.027225
NCT00969839|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-30|||2009-09-16|2009-08-31|2009-09-01|Estimate|||||||2009-09-16|2009-09-18|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||NovaLign Intramedullary Fixation System (IFS) for the Treatment of Humeral Fractures|A Study to Evaluate the Safety and Effectiveness of the NovaLign Intramedullary Fixation System for the Treatment of Humeral Diaphysis Fractures|Unknown status|Recruiting|Phase 4|20|Anticipated|NovaLign Orthopaedics, Inc||1|||f||||f||||||||||2018-06-01 00:38:07.129814|2018-06-01 00:38:07.129814
NCT00969826|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|||2011-01-09|2009-08-31|2009-09-01|Estimate|||||||2011-01-09|2011-01-11|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|September 2009|Actual|2009-09-30|January 2009|Actual|2009-01-31||Interventional|GCPGC||Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor|A Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of GCPGC After Single Subcutaneous Administration in Healthy Male Volunteers|Completed||Phase 1|38|Anticipated|Seoul National University Hospital||4|||f||||f||||||||||2018-06-01 00:38:07.218326|2018-06-01 00:38:07.218326
NCT00969813|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2010-02-10|2009-08-31|2009-09-01|Estimate|||||||2010-02-10|2010-02-11|Estimate|November 2009||2009-11-30|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function|A Phase 1, Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:38:07.312304|2018-06-01 00:38:07.312304
NCT00969800|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-30|||2010-02-02|2009-08-30|2009-09-01|Estimate|||||||2010-02-02|2010-02-04|Estimate|October 2009||2009-10-31|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|Cleverin||Test of a Preventive Effect of a Deodorant Device Against Respiratory Infections|Double-blind Sham Device-controlled Multi-center Crossover Trial of Chlorine Dioxide Gas on the Protective Effect Against Respiratory Infections|Unknown status|Active, not recruiting|N/A|1469|Actual|Taiko Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:38:07.399812|2018-06-01 00:38:07.399812
NCT00969787|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2010-03-31|2009-08-31|2009-09-01|Estimate|||||||2010-03-31|2010-04-01|Estimate|April 2009||2009-04-30|August 2009|2009-08-31||||November 2009|Actual|2009-11-30||Interventional|||DWP05195 in Healthy Adult Male Volunteers|DWP05195 in Healthy Adult Male Volunteers|Completed||Phase 1|80|Anticipated|Daewoong Pharmaceutical Co. LTD.||1|||f||||t||||||||||2018-06-01 00:38:07.484177|2018-06-01 00:38:07.484177
NCT00969774|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-09-01|2009-08-31|2009-09-01|Estimate|||||||2009-09-01|2009-09-02|Estimate|February 2006||2006-02-28|September 2009|2009-09-30||||November 2006|Actual|2006-11-30||Observational|||Facial Type Determination Through Cephalometry, Anthropometry and Facial Analysis|Facial Type Determination Through Ricketts Cephalometric Analysis, Anthropometric Measurements, Indices and Proportions and Facial Analysis Performed by Means of Photographs|Completed|||105|Actual|Pontificia Universidade Catolica de Sao Paulo|||||f||||t||||||||||2018-06-01 00:38:07.550838|2018-06-01 00:38:07.550838
NCT00969761|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-07-25|2009-08-31|2009-09-01|Estimate|||||||2012-07-25|2012-07-26|Estimate|August 2009||2009-08-31|July 2012|2012-07-31||||February 2012|Actual|2012-02-29||Interventional|||BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour|A Phase I Dose Escalation Trial of BI 6727 in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|61|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:38:07.604493|2018-06-01 00:38:07.604493
NCT00969748|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-08-31|2009-08-31|2009-09-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:38:07.681224|2018-06-01 00:38:07.681224
NCT00969735|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2013-04-01|2009-08-31|2009-09-01|Estimate|||||||2013-04-01|2013-04-04|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|COR||Cryoenergy Or Radiofrequency for Pulmonary Vein Isolation|Cryoenergy Or Radiofrequency for Pulmonary Vein Isolation (COR Trial)|Completed||Phase 4|50|Actual|Hospital San Carlos, Madrid||2|||f||||f||||||||||2018-06-01 00:38:07.717784|2018-06-01 00:38:07.717784
NCT00969722|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31||2013-02-28|2013-02-28|2009-08-31|2009-09-01|Estimate||||2013-02-28|2013-03-08|Estimate|2013-02-28|2013-03-08|Estimate|August 2009||2009-08-31|February 2013|2013-02-28||||August 2010|Actual|2010-08-31||Interventional|||A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients|A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients|Terminated||Phase 2|1|Actual|United Therapeutics||2||Lack of enrollment.|f||||t||||||||||2018-06-01 00:38:07.806745|2018-06-01 00:38:07.806745
NCT00969709|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2013-08-22|2011-07-08|2013-08-22|2009-08-31|2009-09-01|Estimate|2013-08-22|2013-10-25|Estimate|2011-07-08|2011-07-14|Estimate|2013-08-22|2013-10-25|Estimate|September 2009||2009-09-30|August 2013|2013-08-31||||May 2011|Actual|2011-05-31||Interventional||A total of 724 patients were randomized to receive double-blind treatment (Randomized Population); 713 patients received at least 1 dose of treatment (Safety Population). The demographic analyses of the baseline participants is based on the Safety Population|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Fixed-Dose Study of F2695 SR in Patients With Major Depressive Disorder|Completed||Phase 3|724|Actual|Forest Laboratories||4|||f||||f||||||||||2018-06-01 00:38:07.933812|2018-06-01 00:38:07.933812
NCT00969696|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-07-24|2009-08-31|2009-09-01|Estimate|||||||2012-07-24|2012-07-25|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Galantamine Effects on Cognitive Function in Marijuana Users|Galantamine Effects on Cognitive Function in Marijuana Users|Completed||Phase 1|29|Actual|Yale University||2|||f||||t||||||||||2018-06-01 00:38:08.841101|2018-06-01 00:38:08.841101
NCT00969683|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2016-09-22|2009-08-31|2009-09-01|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Double-Lumen Tube With or Without a Carinal Hook|Comparison Between Left Double-lumen Tube With or Without a Carinal Hook During Lung Surgery|Completed||N/A|184|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 00:38:08.94258|2018-06-01 00:38:08.94258
NCT00969670|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|||2009-11-21|2009-08-31|2009-09-01|Estimate|||||||2009-11-21|2009-11-25|Estimate|October 2009||2009-10-31|November 2009|2009-11-30||||||||Observational|||Correlation of Particulate Matter and Heme Oxygenase-1 Protein Activity in Asthmatic Children by Induced Sputum Analysis.|Correlation of Particulate Matter and Heme Oxygenase-1 Protein Activity in Asthmatic Children by Induced Sputum Analysis.|Unknown status|Recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||Samples Without DNA|"~     Samples of indused sputum~   "|||2018-06-01 00:38:09.021589|2018-06-01 00:38:09.021589
NCT00969657|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2015-01-12|2009-08-31|2009-09-01|Estimate|||||||2015-01-12|2015-01-13|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2011|Actual|2011-10-31||Observational|Thunder||Validation of a Predictive Model After Complete Response in Rectal Cancer|Prospective Validation of a Predictive Model for Pathologic Complete Response After Chemoradiotherapy in Rectal Cancer: A Prognostic Study|Completed|||80|Anticipated|Maastricht Radiation Oncology|||||f||||t||||||Samples With DNA|"~     serum,plasma~   "|||2018-06-01 00:38:09.0848|2018-06-01 00:38:09.0848
NCT00969644|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-08-31|2009-08-31|2009-09-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons|The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons|Unknown status|Enrolling by invitation|N/A|12|Anticipated|Herlev Hospital||2|||f||||t||||||||||2018-06-01 00:38:09.154526|2018-06-01 00:38:09.154526
NCT00969631|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-08-31|2009-08-31|2009-09-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Combined Metformin and Clomiphene Citrate (CC) or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome (PCOS)|Combined Metformin and Clomiphene Citrate Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome|Completed||N/A|282|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:38:09.242738|2018-06-01 00:38:09.242738
NCT00969618|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2012-11-15||2012-11-15|2009-08-31|2009-09-01|Estimate|2012-11-15|2012-12-12|Estimate||||2012-11-15|2012-12-12|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder|Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|211|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 00:38:09.361636|2018-06-01 00:38:09.361636
NCT00969605|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2010-05-26|2009-08-31|2009-09-01|Estimate|||||||2010-05-26|2010-05-27|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Adaptive Support Ventilation in the Weaning of COPD|Adaptive Support Ventilation for Faster Weaning in COPD: A Randomized Controlled Trial|Completed||Phase 4|97|Actual|Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital||2|||f||||f||||||||||2018-06-01 00:38:09.692498|2018-06-01 00:38:09.692498
NCT00969592|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-09-01|2009-08-31|2009-09-01|Estimate|||||||2009-09-01|2009-09-02|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers|Comparison of Pharmacodynamics and Pharmacokinetics of the Two Fast-acting Insulin Analogs Insulin Glulisine and Insulin Aspart in Healthy Volunteers|Completed||Phase 1|12|Actual|Profil Institut für Stoffwechselforschung GmbH||2|||f||||f||||||||||2018-06-01 00:38:09.793166|2018-06-01 00:38:09.793166
NCT00969579|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|||2018-05-24|2009-08-29|2009-09-01|Estimate|||||||2018-05-24|2018-05-25|Actual|August 6, 2009||2009-08-06|March 8, 2018|2018-03-08|March 8, 2018||2018-03-08|||||Observational|||Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer|Characterizing Lone Parenting: A Multi-Institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With Cancer|Completed|||275|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:38:09.870677|2018-06-01 00:38:09.870677
NCT00969566|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-01-05|2009-08-31|2009-09-01|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|June 2010|Actual|2010-06-30||Interventional|COSMETIC||Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination|Predictive Parameters for Therapeutic Efficacy of Initial Combination Therapy With Sitagliptin and Metformin in Type 2 Diabetic Patients|Completed||Phase 4|150|Actual|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-06-01 00:38:09.938207|2018-06-01 00:38:09.938207
NCT00969553|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-03-06|2009-08-31|2009-09-01|Estimate|||||||2012-03-06|2012-03-07|Estimate|August 2009||2009-08-31|March 2012|2012-03-31||||September 2011|Actual|2011-09-30||Interventional|||Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers|A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|59|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:38:10.002072|2018-06-01 00:38:10.002072
NCT00969540|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2012-06-29||2014-12-02|2009-08-31|2009-09-01|Estimate|2014-12-02|2014-12-03|Estimate||||2014-12-02|2014-12-03|Estimate|June 2009||2009-06-30|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Trial on the Effect of Optically Modified Fiber Mattress Covers on Sleep Disturbances in Patients With Chronic Back Pain|Double Blind, Placebo Controlled, Crossover Pilot Trial on the Effect of Optically Modified Polyethylene Terephthalate Fiber Mattress Covers on Sleep Disturbances in Patients With Chronic Back Pain|Completed||N/A|8|Actual|University of California, Irvine|This is a pilot study to determine the framework to study sleep, pain and mattress covers. The number of subjects is small. The observed data is evaluated in a descriptive (bar graph) presentation.|2|||f||||f||||||||||2018-06-01 00:38:10.077834|2018-06-01 00:38:10.077834
NCT00969527|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2011-05-06|2009-08-31|2009-09-01|Estimate|||||||2011-05-06|2011-05-09|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis|Assessment of the Efficacy of Oncoxin+Viusid Administration in the Treatment of Rheumatoid Arthritis|Completed||Phase 3|86|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:38:10.409247|2018-06-01 00:38:10.409247
NCT00969514|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2011-09-30|2009-08-31|2009-09-01|Estimate|||||||2011-09-30|2011-10-03|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Robotic-Assisted Laparoscopic Cystectomy|Robotic-assisted Laparoscopic Cystectomy: Our Center's Clinical Experience|Completed|||31|Anticipated|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 00:38:10.561869|2018-06-01 00:38:10.561869
NCT00969501|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2012-09-05||2013-03-27|2009-08-31|2009-09-01|Estimate|2013-03-27|2013-05-07|Estimate||||2013-03-27|2013-05-07|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)|Investigator Initiated, Exploratory Case Study Three Injections of EUFLEXXA (Sodium Hyaluronate)Treatment of Chronic Shoulder Pain Associated With Osteoarthritis|Completed||N/A|32|Actual|Georgia Institute for Clinical Research, LLC||1|||f||||t||||||||||2018-06-01 00:38:10.620831|2018-06-01 00:38:10.620831
NCT00969488|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2011-07-19|2009-08-31|2009-09-01|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of a High Protein Diet on Body Weight Change During Post-partum|The Effect of a High Protein Diet on Body Weight Change and Body Composition During Post-partum: Randomized Clinical Trial Study|Completed||N/A|180|Anticipated|Rio de Janeiro State University||2|||f||||t||||||||||2018-06-01 00:38:10.78116|2018-06-01 00:38:10.78116
NCT00969475|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|||2009-09-13|2009-08-31|2009-09-01|Estimate|||||||2009-09-13|2009-09-15|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||The Effects of Fractional Carbon Dioxide (CO2) Laser Treatment Prior to Wound Closure|The Effects of Fractional CO2 Resurfacing Prior to Complex Wound Closure|Unknown status|Not yet recruiting|N/A|10|Anticipated|Moy-Fincher Medical Group||2|||f||||f||||||||||2018-06-01 00:38:10.856926|2018-06-01 00:38:10.856926
NCT00969462|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2013-06-27|2009-08-31|2009-09-01|Estimate|||||||2013-06-27|2013-07-01|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma|Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients|Completed||Phase 4|18|Actual|Meir Medical Center||1|||f||||f||||||||||2018-06-01 00:38:10.948552|2018-06-01 00:38:10.948552
NCT00969449|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2014-05-19|2009-08-31|2009-09-01|Estimate|||||||2014-05-19|2014-05-20|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan|An Open Label, Randomized, Two-Way Crossover Trial to Compare the Pharmacokinetic Parameters of an Extended- Release Naproxen Sodium Tablet Relative to Naprelan® Tablets Following Single Dose Administration Under Fasted Conditions|Completed||Phase 1|28|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:38:11.017054|2018-06-01 00:38:11.017054
NCT00969436|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2017-05-04|2011-04-01|2017-05-04|2009-08-31|2009-09-01|Estimate|2017-05-04|2017-09-25|Actual|2011-04-01|2011-04-11|Estimate|2017-05-04|2017-09-25|Actual|November 9, 2009|Actual|2009-11-09|May 2017|2017-05-31|February 21, 2011|Actual|2011-02-21|February 21, 2011|Actual|2011-02-21||Interventional|||Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM|A Phase IIIb, Open, Randomised, Multicentre, Primary Study in Healthy Children, to Establish the Non-inferiority of GlaxoSmithKline (GSK) Biologicals' MeMuRu-OKA Vaccine (Administered at 9 and 15 Months of Age) Versus Priorix™ (9 Months of Age) and Priorix™ Co-administered With Varilrix™ at 15 Months of Age (Comparator) and Also to Evaluate the Non-inferiority of Priorix™ (9 Months of Age) and MeMuRu-OKA Vaccine (15 Months of Age) Versus the Comparator, All Administered Subcutaneously as Two-dose Primary Vaccination Course|Completed||Phase 3|450|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:38:11.123322|2018-06-01 00:38:11.123322
NCT00969423|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2011-08-17|2009-08-31|2009-09-01|Estimate|||||||2011-08-17|2011-08-18|Estimate|October 2009||2009-10-31|August 2011|2011-08-31||||December 2011|Anticipated|2011-12-31||Interventional|||Chronic Pain After Video-assisted Thoracoscopic Surgery (VATS) Surgery for Pneumothorax|Chronic Pain After VATS Surgery for Pneumothorax|Terminated||N/A|10|Actual|Rigshospitalet, Denmark||2||unable to recruit|f||||f||||||||||2018-06-01 00:38:11.896268|2018-06-01 00:38:11.896268
NCT00969410|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-04-11|2009-08-31|2009-09-01|Estimate|||||||2012-04-11|2012-04-12|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases|A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670)|Completed||Phase 1|19|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:38:11.967377|2018-06-01 00:38:11.967377
NCT00969215|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-29|||2011-07-24|2009-08-31|2009-09-01|Estimate|||||||2011-07-24|2011-07-26|Estimate|December 2009||2009-12-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Burn Scar Appearance After Treatment With Fractional Carbon Dioxide (CO2) Laser|Burn Scar Characteristics After Treatment With Fractional CO2 Laser: A Clinical and Histological Study|Completed||N/A|20|Anticipated|Moy-Fincher Medical Group||2|||f||||f||||||||||2018-06-01 00:38:13.553145|2018-06-01 00:38:13.553145
NCT00969397|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2017-02-08|2009-08-31|2009-09-01|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2009||2009-11-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks|Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, Irvine||2||We have decided not to pursue the study|f||||t||||||||||2018-06-01 00:38:12.038831|2018-06-01 00:38:12.038831
NCT00969384|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-08-31|2009-08-31|2009-09-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|February 2009||2009-02-28|August 2009|2009-08-31||||August 2009|Actual|2009-08-31||Interventional|||Physical Health of Residents in Psychiatric Institutions|Physical Health of Residents in Psychiatric Institutions|Unknown status|Active, not recruiting|N/A|350|Actual|Aarhus University Hospital||2|||f||||||||||||||2018-06-01 00:38:12.107991|2018-06-01 00:38:12.107991
NCT00969371|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-08-31|2009-08-31|2009-09-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Lenstec Tetraflex Accommodating Posterior Chamber Intraocular Lens (IOL) Clinical Investigation|Lenstec TetraFlex Accommodating Posterior Chamber Intraocular Lens (IOL)Clinical Investigation|Completed||N/A|470|Actual|Lenstec Incorporated||2|||f||||f||||||||||2018-06-01 00:38:12.17902|2018-06-01 00:38:12.17902
NCT00969358|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2016-09-22|2009-08-31|2009-09-01|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Evaluation of a Rehabilitation Program After Lung Surgery|Evaluation of a Rehabilitation Program After Lung Surgery (Prospective Observational Study)|Completed|||100|Actual|Hopital Foch|||||f||||f||||||||||2018-06-01 00:38:12.23695|2018-06-01 00:38:12.23695
NCT00969345|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-08-31|2009-08-31|2009-09-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Respiratory Yoga Training on Heart Rate Variability and Baroreflex of Healthy Elderly Subjects|Effects of Respiratory Yoga Training (Bhastrika) on Heart Rate Variability and Baroreflex, and Quality of Life of Healthy Elderly Subjects|Completed||Phase 3|30|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:38:12.289552|2018-06-01 00:38:12.289552
NCT00969332|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2018-03-02|2009-08-31|2009-09-01|Estimate|||||||2018-03-02|2018-03-06|Actual|August 2009||2009-08-31|March 2018|2018-03-31|August 2024|Anticipated|2024-08-31|August 2019|Anticipated|2019-08-31||Interventional|FO||A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease|Omegaven and Parenteral Nutrition Associated Cholestasis|Recruiting||Phase 2|40|Anticipated|University of California, Los Angeles||1|||f||||t||||||||No||2018-06-01 00:38:12.358678|2018-06-01 00:38:12.358678
NCT00969319|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2015-01-16|2009-08-31|2009-09-01|Estimate|||||||2015-01-16|2015-01-19|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Observational|||Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America|Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America|Completed|||105|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 00:38:12.433479|2018-06-01 00:38:12.433479
NCT00969306|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2017-04-13|2009-08-31|2009-09-01|Estimate|||||||2017-04-13|2017-04-14|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Chloroquine IV||Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients|Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial|Completed||Phase 1|5|Actual|Maastricht Radiation Oncology||1|||f||||||||||||||2018-06-01 00:38:12.499219|2018-06-01 00:38:12.499219
NCT00969293|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2012-01-09|2009-08-31|2009-09-01|Estimate|||||||2012-01-09|2012-01-10|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|March 2012|Anticipated|2012-03-31|July 2011|Actual|2011-07-31||Interventional|FOV2302||Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion|An Open-label, Dose Escalating Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion|Terminated||Phase 1|11|Actual|Fovea Pharmaceuticals SA|||||f||||t||||||||||2018-06-01 00:38:12.565437|2018-06-01 00:38:12.565437
NCT00969280|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2010-09-17||2010-12-17|2009-08-31|2009-09-01|Estimate|2010-09-17|2010-09-20|Estimate||||2010-12-17|2010-12-21|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Acupuncture for Dry Eye Syndrome|Acupuncture for Dry Eye Syndrome : A Randomized, Patient-Assessor Blinded, Non-acupuncture Point Shallow Penetration-Controlled Study|Completed||Phase 3|42|Actual|Korea Institute of Oriental Medicine||2|||f||||t||||||||||2018-06-01 00:38:12.635747|2018-06-01 00:38:12.635747
NCT00969267|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2014-05-28|2009-08-31|2009-09-01|Estimate|||||||2014-05-28|2014-05-29|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||The Effect of Auricular Point Stimulation on Obese Women|The Effect of Auricular Point Stimulation on Obese Women: a Randomized Controlled Trial|Completed||Phase 3|90|Actual|Taipei City Hospital||3|||f||||t||||||||||2018-06-01 00:38:12.831202|2018-06-01 00:38:12.831202
NCT00969254|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2009-08-31|2009-08-31|2009-09-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|December 2009||2009-12-31|August 2009|2009-08-31|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|E01OSMPLS0108||"Study to Assess the Efficacy and Safety of Pílulas de Lussen® Compared to the Pyridium® in the Symptomatic Control of Dysuria"|"Phase III Clinical Study, Prospective, Multicenter, Double-blind, Randomized, Double-dummy to Assess the Efficacy and Safety of Pílulas de Lussen® Compared to the Pyridium® in the Symptomatic Control of Dysuria"|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Laboratorios Osorio de Moraes Ltda.||2|||f||||f||||||||||2018-06-01 00:38:12.903571|2018-06-01 00:38:12.903571
NCT00969241|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-30|||2010-12-22|2009-08-31|2009-09-01|Estimate|||||||2010-12-22|2010-12-23|Estimate|July 2009||2009-07-31|August 2009|2009-08-31||||December 2010|Anticipated|2010-12-31||Observational|||The Effect of Periodontal Treatment on the Level of Free Radicals in the Saliva|The Effect of Periodontal Treatment on the Level of Free Radicals in the Saliva|Unknown status|Recruiting||30|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||f||||||||||2018-06-01 00:38:13.063474|2018-06-01 00:38:13.063474
NCT00969228|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2011-06-16||2016-09-26|2009-08-31|2009-09-01|Estimate|2011-10-20|2011-11-28|Estimate||||2016-09-26|2016-10-27|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants|Immunogenicity, Reactogenicity and Safety Study to Evaluate Two Doses of the Lyophilised Formulation of the Human Rotavirus (HRV) Vaccine When Administered to Healthy Korean Infants Previously Uninfected With HRV|Completed||Phase 4|684|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:38:13.146639|2018-06-01 00:38:13.146639
NCT00969202|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2015-11-17|2009-08-31|2009-09-01|Estimate|||||||2015-11-17|2015-11-18|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer|Phase 1 Study of Stereotactic Hypofractionated Radiosurgery of Low Grade Prostate Cancer/Early Stage|Unknown status|Recruiting|Phase 1|50|Anticipated|San Diego Radiosurgery||1|||f||||f||||||||||2018-06-01 00:38:13.614023|2018-06-01 00:38:13.614023
NCT00969189|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2011-12-14|2009-08-31|2009-09-01|Estimate|||||||2011-12-14|2011-12-15|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Evaluation of the Pediatric Igel Airway in 250 Children|A Cohort Evaluation of the Pediatric Igel Airway in 200 Children and in 50 Infants|Terminated|||120|Actual|University Hospitals Bristol NHS Foundation Trust|||2|"Initial number of 250 was not based on sample size. Most airway studies use n=100 therefore~   trial stopped when 120 children recruited"|f||||f||||||||||2018-06-01 00:38:13.688712|2018-06-01 00:38:13.688712
NCT00969176|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2010-12-21|2009-08-31|2009-09-01|Estimate|||||||2010-12-21|2010-12-22|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|PARANEO||Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in Neonates|Single and Multiple Dose Trial to Evaluate Pharmacokinetics, -Dynamics and Safety of iv Paracetamol in Preterm and Term Neonates|Completed||Phase 2/Phase 3|60|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||||2018-06-01 00:38:13.745219|2018-06-01 00:38:13.745219
NCT00969163|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2014-09-03|2009-08-31|2009-09-01|Estimate|||||||2014-09-03|2014-09-04|Estimate|October 2004||2004-10-31|September 2014|2014-09-30|June 2005|Actual|2005-06-30|April 2005|Actual|2005-04-30||Interventional|||A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).|A Pilot Study to Investigate Biomarkers of Skin Androgenization Following Short-Term Testosterone Administration in Healthy Postmenopausal Women|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 00:38:13.812268|2018-06-01 00:38:13.812268
NCT00969150|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|2013-08-22|2012-03-01|2013-08-22|2009-08-31|2009-09-01|Estimate|2013-08-22|2013-10-25|Estimate|2012-03-01|2012-03-05|Estimate|2013-08-22|2013-10-25|Estimate|September 2009||2009-09-30|August 2013|2013-08-31||||November 2010|Actual|2010-11-30||Interventional||While a total of 362 patients were randomized to receive double-blind treatment, 5 of these patients were either lost to follow up or withdrew consent before receiving double-blind treatment. The Baseline Participant population is based on the 357 randomized patients who went on to receive double-blind treatment (Safety Population).|Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder|A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder|Completed||Phase 3|362|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:38:13.903172|2018-06-01 00:38:13.903172
NCT00969137|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-31|||2017-04-17|2009-08-31|2009-09-01|Estimate|||||||2017-04-17|2017-04-19|Actual|June 2, 2009|Actual|2009-06-02|April 2017|2017-04-30|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Sensitivity to Intravenous Nicotine: Genetic Moderators|Sensitivity to Intravenous Nicotine: Genetic Moderators|Completed||Phase 1|213|Actual|Yale University||2|||f||||t||||||||No||2018-06-01 00:38:14.306326|2018-06-01 00:38:14.306326
NCT00969124|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2016-07-18||2017-06-26|2009-08-31|2009-09-01|Estimate|2017-06-26|2017-07-26|Actual||||2017-06-26|2017-07-26|Actual|January 2009||2009-01-31|June 2017|2017-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Per-protocol population of patients for whom the colonoscopy procedure was completed using the Third Eye Retroscope, not including the 30 who were withdrawn due to reasons stated above.|Impact of Experience on Results With the Third Eye Retroscope|Impact of Experience With the Third Eye Retroscope on Detection Rates and Withdrawal Times During Colonoscopy|Completed||N/A|328|Actual|Avantis Medical Systems|No randomization or blinding and no separate control group. Determinations regarding adequacy of bowel cleansing and whether each polyp could have been detected with the colonoscope alone involved a judgement by the endoscopist.|1|||f||||f||||||||No||2018-06-01 00:38:14.376482|2018-06-01 00:38:14.376482
NCT00969111|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2018-03-01|2009-08-28|2009-08-31|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2009||2009-08-31|March 2018|2018-03-31|August 2050|Anticipated|2050-08-31|August 2031|Anticipated|2031-08-31||Interventional|PR06||Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy|Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy|Recruiting||N/A|70|Anticipated|University of Florida||4|||f||||t|f|f||||||||2018-06-01 00:38:14.569878|2018-06-01 00:38:14.569878
NCT00969098|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2015-08-05|2009-08-28|2009-08-31|Estimate|||||||2015-08-05|2015-08-06|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Response Evaluation in Malignant Pleural Mesothelioma|Early Response Evaluation in Malignant Pleural Mesothelioma By Total Glycolytic Volume (TGV) Analysis of Serial FDG-PET Scans (Positron Emission Tomography Scans)|Unknown status|Active, not recruiting||150|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||||||2018-06-01 00:38:14.675316|2018-06-01 00:38:14.675316
NCT00969085|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2012-09-05|2009-08-28|2009-08-31|Estimate|||||||2012-09-05|2012-09-07|Estimate|November 2012||2012-11-30|September 2012|2012-09-30||||November 2014|Anticipated|2014-11-30||Interventional|||Trial of Curcumin in Cutaneous T-cell Lymphoma Patients|Phase II Trial of Curcumin in Cutaneous T-cell Lymphoma Patients|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:38:14.736975|2018-06-01 00:38:14.736975
NCT00969072|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2010-09-09|2009-08-27|2009-08-31|Estimate|||||||2010-09-09|2010-09-13|Estimate|August 2003||2003-08-31|September 2010|2010-09-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia|A Long-term Extension Study of GI198745 in Subjects With Benign Prostatic Hyperplasia|Completed||Phase 2|121|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 00:38:14.810686|2018-06-01 00:38:14.810686
NCT00969059|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2017-02-15|2009-08-27|2009-08-31|Estimate|||||||2017-02-15|2017-02-17|Actual|August 2009||2009-08-31|February 2017|2017-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PNI||Study in Neuropathic Pain Patients With Peripheral Nerve Injury|A Randomised, Double Blind Study to Evaluate the Safety and Efficacy of the p38 Kinase Inhibitor, GW856553, in Subjects With Neuropathic Pain From Peripheral Nerve Injury|Completed||Phase 2|168|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:38:14.884588|2018-06-01 00:38:14.884588
NCT00969046|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2016-04-20|2009-08-27|2009-08-31|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2003||2003-11-30|April 2016|2016-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Dose-Escalation Study in Advanced Colon Cancer Patients|EPO906 Phase I 6-arm Trial to Optimize Administration Exploring Single Dose Bolus and Continuous Infusion Over 1 or 5 Days Every 3 or 4 Weeks in Patients With Pretreated Advanced Colon Cancer With Nutritional Support Treatment and Intensive Management of Diarrhea|Completed||Phase 1|60|Actual|Novartis||3|||f||||f||||||||||2018-06-01 00:38:15.021421|2018-06-01 00:38:15.021421
NCT00969033|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2012-01-30|2009-08-28|2009-08-31|Estimate|||||||2012-01-30|2012-01-31|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin|A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen|Terminated||Phase 2|8|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 00:38:15.09522|2018-06-01 00:38:15.09522
NCT00969020|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2012-10-22|2009-08-28|2009-08-31|Estimate|||||||2012-10-22|2012-10-24|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|RRS||A Telemedicine Solution for Remote Support of Rehabilitation, for Patients Undergoing, Total Hip Arthroplasty Surgery|The Effect of Remote Rehabilitation Support Via a Telemedicine Solution for Patients Undergoing an Optimized Fast-track Orthopedic Surgery Procedure With the Implementation of a Total Hip Arthroplasty.|Completed||N/A|72|Actual|Regionshospitalet Silkeborg||2|||f||||f||||||||||2018-06-01 00:38:15.172795|2018-06-01 00:38:15.172795
NCT00969007|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2013-12-11|2009-08-28|2009-08-31|Estimate|||||||2013-12-11|2013-12-13|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Identification of Predictors of Success for Lifestyle Modifications in Overweight Pre-diabetic Subjects|Identification of Predictors of Success for Lifestyle Modifications in Overweight Pre-diabetic Subjects|Completed||N/A|81|Actual|Université de Sherbrooke||1|||f||||f||||||||||2018-06-01 00:38:15.237435|2018-06-01 00:38:15.237435
NCT00968994|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2009-12-22|2009-08-28|2009-08-31|Estimate|||||||2009-12-22|2009-12-24|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|||Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites|A Randomized, Site-Matched, Controlled Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites|Unknown status|Recruiting|N/A|25|Anticipated|Exciton Technologies Inc.||2|||f||||f||||||||||2018-06-01 00:38:15.297589|2018-06-01 00:38:15.297589
NCT00968981|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|2015-07-09||2017-06-08|2009-08-28|2009-08-31|Estimate|2015-11-03|2015-12-09|Estimate||||2017-06-08|2017-07-11|Actual|September 2009|Actual|2009-09-30|June 2017|2017-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||All enrolled participants were included for baseline parameters.|A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists|A Phase Ib, Open-Label, Dose-Scheduling Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists|Completed||Phase 1|67|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 00:38:15.411696|2018-06-01 00:38:15.411696
NCT00968968|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2018-05-18|2009-08-27|2009-08-31|Estimate|||||||2018-05-18|2018-05-22|Actual|January 20, 2010|Actual|2010-01-20|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone|A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer|Completed||Phase 3|280|Actual|Novartis||2|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 00:38:16.507573|2018-06-01 00:38:16.507573
NCT00968955|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2011-09-28|2009-08-28|2009-08-31|Estimate|||||||2011-09-28|2011-09-29|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Local Infiltration Analgesia in Total Hip Arthroplasty|Effect of Local Infiltration Analgesia With Ropivacaine in Total Hip Arthroplasty: a Prospective, Randomized, Double-blind, Placebo-controlled Trail|Completed||Phase 4|120|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 00:38:16.773379|2018-06-01 00:38:16.773379
NCT00968942|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28||2011-06-13|2013-10-25|2009-08-28|2009-08-31|Estimate||||2011-06-13|2011-06-27|Estimate|2013-10-25|2013-11-19|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Repeat Dose, Single Center Study to Evaluate the Efficacy and Safety of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|Completed||Phase 2|36|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 00:38:16.851528|2018-06-01 00:38:16.851528
NCT00968929|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2009-08-31|2009-08-28|2009-08-31|Estimate|||||||2009-08-31|2009-09-01|Estimate|June 2006||2006-06-30|August 2009|2009-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|RESUPEC||Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)|Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China|Completed||Phase 4|83|Actual|Beijing Chao Yang Hospital||2|||f||||f||||||||||2018-06-01 00:38:16.932807|2018-06-01 00:38:16.932807
NCT00968916|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2014-09-18|2009-08-28|2009-08-31|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors|An Open-label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With AVE8062 Administered as a 30-minute Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.|Completed||Phase 1|15|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:38:17.181985|2018-06-01 00:38:17.181985
NCT00968903|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2011-09-28|2009-08-28|2009-08-31|Estimate|||||||2011-09-28|2011-09-29|Estimate|April 2010||2010-04-30|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effects of Methylprednisolone After Total Hip Arthroplasty|Effects of Pre-operative Methylprednisolone (125mg iv) After Total Hip Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail|Completed||Phase 4|48|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 00:38:17.245768|2018-06-01 00:38:17.245768
NCT00968721|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2016-04-28|2009-08-28|2009-08-31|Estimate|||||||2016-04-28|2016-05-02|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use|Decisional Influences and IBD Patients' Medication Use|Terminated|||55|Actual|Vanderbilt University|||1|lack of support|f||||f||||||||||2018-06-01 00:38:22.704767|2018-06-01 00:38:22.704767
NCT00968890|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2011-02-17|2010-07-02|2016-09-23|2009-08-27|2009-08-31|Estimate|2011-02-17|2011-03-16|Estimate|2010-07-02|2010-07-07|Estimate|2016-09-23|2016-10-20|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza GSK2340272A and Fluarix™ 2009-2010 Vaccines When Co-administered in Elderly Subjects Aged 61 Years and Older|Completed||Phase 2|168|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:38:17.352647|2018-06-01 00:38:17.352647
NCT00968877|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2011-01-25|2009-08-28|2009-08-31|Estimate|||||||2011-01-25|2011-01-26|Estimate|September 2009||2009-09-30|December 2009|2009-12-31|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Interventional|||Vitamin D and Chronic Renal Insufficiency|Vitamin D and Chronic Renal Insufficiency|Completed||Phase 3|56|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 00:38:18.85801|2018-06-01 00:38:18.85801
NCT00968864|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|2017-09-09||2017-10-08|2009-08-28|2009-08-31|Estimate|2017-10-08|2017-11-08|Actual||||2017-10-08|2017-11-08|Actual|August 2009||2009-08-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||T-cell Depleted Alternative Donor Transplantation|A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients|Terminated||Phase 2|53|Actual|Carolinas Healthcare System||1||Sponsor/ PI leaving institution, no plans to continue this research at this time|f||||t||||||||No||2018-06-01 00:38:18.965929|2018-06-01 00:38:18.965929
NCT00968851|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28||2012-02-23|2014-03-28|2009-08-28|2009-08-31|Estimate||||2012-03-02|2012-03-06|Estimate|2014-03-28|2014-04-25|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia|A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy|Completed||Phase 2|317|Actual|FORUM Pharmaceuticals Inc||3|||f||||f||||||||||2018-06-01 00:38:19.473409|2018-06-01 00:38:19.473409
NCT00968838|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2013-06-06||2013-11-01|2009-08-28|2009-08-31|Estimate|2013-11-01|2013-11-26|Estimate||||2013-11-01|2013-11-26|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study for Leukemia Patients With Life-Threatening Infections|Comparative Study of Radiated and Unradiated Leukocyte Transfusions for Patients With Life-threatening Infections: A Collaborative Study by the Leukemia Department and Laboratory Medicine|Completed||Phase 3|178|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:38:19.612555|2018-06-01 00:38:19.612555
NCT00968825|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27||2011-06-13|2013-10-25|2009-08-28|2009-08-31|Estimate||||2011-06-13|2011-06-27|Estimate|2013-10-25|2013-11-19|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Administration of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults|Completed||Phase 2|73|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 00:38:19.820643|2018-06-01 00:38:19.820643
NCT00968812|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|2013-04-17|2012-06-27|2016-12-01|2009-08-28|2009-08-31|Estimate|2013-04-17|2013-06-04|Estimate|2012-04-24|2012-04-25|Estimate|2016-12-01|2017-01-30|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional|||CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride|A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy|Completed||Phase 3|1452|Actual|Janssen Research & Development, LLC|No notable study limitations were identified by the Sponsor.|3|||f||||t||||||||||2018-06-01 00:38:19.989549|2018-06-01 00:38:19.989549
NCT00968799|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2013-03-26||2013-05-13|2009-08-28|2009-08-31|Estimate|2013-03-26|2013-05-10|Estimate||||2013-05-13|2013-05-15|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study|Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study|Terminated||N/A|6|Actual|Cantonal Hospital of St. Gallen||1||poor patient accrual|f||||t||||||||||2018-06-01 00:38:22.019845|2018-06-01 00:38:22.019845
NCT00968786|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2009-08-28|2009-08-28|2009-08-31|Estimate|||||||2009-08-28|2009-08-31|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|September 2009|Anticipated|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Home Monitoring in the Management of Hypertension and Diabetes Mellitus|A Trial of the Use of Multiple Automated Measuring Devices in the Management of Patients With Hypertension and Type 2 Diabetes Mellitus|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||||2018-06-01 00:38:22.212033|2018-06-01 00:38:22.212033
NCT00968773|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2016-03-14|2009-08-28|2009-08-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2013|Anticipated|2013-09-30|March 2012|Anticipated|2012-03-31||Interventional|||Rebound Hernia Repair Device Mesh Trial|Rebound Hernia Repair Device Trial|Unknown status|Active, not recruiting|Phase 4|70|Anticipated|Minnesota Medical Development, Inc.||2|||f||||t||||||||||2018-06-01 00:38:22.347086|2018-06-01 00:38:22.347086
NCT00968760|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2018-01-08|2009-08-28|2009-08-31|Estimate|||||||2018-01-08|2018-01-10|Actual|June 2011|Actual|2011-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies|CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies|Active, not recruiting||Phase 1|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-06-01 00:38:22.424864|2018-06-01 00:38:22.424864
NCT00968747|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2018-04-08|2009-08-28|2009-08-31|Estimate|||||||2018-04-08|2018-04-10|Actual|July 2009||2009-07-31|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Regulation of FGF21 by Nutritional Challenges|The Effect of Acute Nutritional Challenges on FGF21 Levels in Humans|Active, not recruiting||N/A|40|Anticipated|Beth Israel Deaconess Medical Center||4|||f||||f||||||||||2018-06-01 00:38:22.531317|2018-06-01 00:38:22.531317
NCT00968734|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2010-03-04|2009-08-28|2009-08-31|Estimate|||||||2010-03-04|2010-03-05|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|VITDAB_08606||Vitamin D Status After Single Oral Dose of Cholecalciferol in Low Fat Meal Compared to High-fat Meal|Vitamin D Status After Single Oral Dose of Cholecalciferol in Low Fat Meal Compared to High-fat Meal|Completed||N/A|30|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-06-01 00:38:22.628391|2018-06-01 00:38:22.628391
NCT00968708|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|2014-03-08||2014-04-15|2009-08-28|2009-08-31|Estimate|2014-03-08|2014-04-15|Estimate||||2014-04-15|2014-05-02|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|EXAMINE|Full Analysis Set (FAS) - all randomized participants who signed informed consent.|Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome|Completed||Phase 3|5380|Actual|Takeda||2|||f||||t||||||||||2018-06-01 00:38:22.937249|2018-06-01 00:38:22.937249
NCT00968695|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2015-04-14|2009-08-28|2009-08-31|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.|Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.|Completed||Phase 4|33|Actual|Instituto Grifols, S.A.||1|||f||||f||||||||||2018-06-01 00:38:27.577607|2018-06-01 00:38:27.577607
NCT00968682|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2014-12-30|2009-08-28|2009-08-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|April 2008||2008-04-30|August 2014|2014-08-31||||April 2014|Actual|2014-04-30||Observational|||CADY Study ICORG 08-01|Detection of Cardiac Dysfunction in Patients Treated With Trastuzumab for HER-2 Positive Breast Cancer. The CADY Study|Completed|||480|Anticipated|Cancer Trials Ireland|||||f||||||||||||||2018-06-01 00:38:27.66812|2018-06-01 00:38:27.66812
NCT00968669|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|2014-02-25|2013-08-05|2014-05-06|2009-08-28|2009-08-31|Estimate|2014-05-06|2014-06-04|Estimate|2013-08-05|2013-08-09|Estimate|2014-05-06|2014-06-04|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults|A Phase 2b, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous MEDI-528 in Adults With Uncontrolled Asthma|Completed||Phase 2|329|Actual|MedImmune LLC||4|||f||||t||||||||||2018-06-01 00:38:27.858667|2018-06-01 00:38:27.858667
NCT00968656|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2014-12-08|2009-08-28|2009-08-31|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|FISO PET/CT||Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1|Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1|Completed||Phase 1|31|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 00:38:29.084551|2018-06-01 00:38:29.084551
NCT00968643|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2014-12-30|2009-08-28|2009-08-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2006||2006-01-31|August 2014|2014-08-31||||May 2014|Actual|2014-05-31||Interventional|||Spinal Cord Compression. ICORG 05-03, V6|A Randomised Phase III Trial of Two Fractionation Schemes in the Treatment of Malignant Spinal Cord Compression|Completed||Phase 3|126|Anticipated|Cancer Trials Ireland||2|||f||||f||||||||||2018-06-01 00:38:29.163838|2018-06-01 00:38:29.163838
NCT00968630|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2017-05-22|2009-08-28|2009-08-31|Estimate|||||||2017-05-22|2017-05-24|Actual|December 17, 2009|Actual|2009-12-17|May 2017|2017-05-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer|Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected With HIV|Completed||Phase 2|9|Actual|Fred Hutchinson Cancer Research Center||1|||f||||||||||||||2018-06-01 00:38:29.291205|2018-06-01 00:38:29.291205
NCT00968617|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2011-10-07||2015-10-30|2009-08-28|2009-08-31|Estimate|2011-10-07|2011-11-11|Estimate||||2015-10-30|2015-11-02|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)|A Phase IIb Randomized, Active Comparator-Controlled, Open-Label Clinical Trial to Study the Efficacy and Safety of MK2578 for the Treatment of Anemia in ESA (Erythropoiesis-Stimulating Agent)-Naive Patients With Chronic Kidney Disease Who Are Not on Dialysis.|Terminated||Phase 2|7|Actual|Merck Sharp & Dohme Corp.|Cohort 1 (MK2578 1.0 mcg/kg) was the only cohort initiated because the study was prematurely terminated by the sponsor. 7 participants received at least 1 dose of MK2578 & 2 participants received all 3 doses. Data presented are for Cohort 1.|4|||f||||f||||||||||2018-06-01 00:38:29.369925|2018-06-01 00:38:29.369925
NCT00968604|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2018-01-17|2009-08-28|2009-08-31|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2015||2015-03-31|January 2018|2018-01-31||||March 2017|Anticipated|2017-03-31||Interventional|||C-VISA BikDD: Liposome in Advanced Pancreatic Cancer|A Phase I Open-Label Dose Escalation Study to Assess the Safety and Tolerability of the BikDD Nanoparticle in Patients With Advanced Pancreatic Cancer|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Stability of the DNA when admixed with the liposome failed|f||||f||||||||||2018-06-01 00:38:29.601682|2018-06-01 00:38:29.601682
NCT00968591|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2016-04-20|2009-08-28|2009-08-31|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2009||2009-11-30|April 2016|2016-04-30||||November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency|An Open-label, Single-dose Study to Assess the Pharmacokinetics of Oral Everolimus (Afinitor®) in Subjects With Impaired Hepatic Function|Completed||Phase 1|34|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:38:29.687147|2018-06-01 00:38:29.687147
NCT00968578|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2012-09-25|2009-08-28|2009-08-31|Estimate|||||||2012-09-25|2012-09-26|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Methylprednisolone After Total Knee Arthroplasty|Effects of Pre-operative Methylprednisolone (125mg iv) After Total Knee Arthroplasty: A Prospective, Randomized, Double-blind, Placebo-controlled Trail|Completed||Phase 4|48|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 00:38:29.749282|2018-06-01 00:38:29.749282
NCT00968565|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2015-06-01|2009-08-28|2009-08-31|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)|Regional Citrate Anticoagulation in ECMO|Completed||Early Phase 1|2|Actual|Vanderbilt University||1|||f||||t||||||||||2018-06-01 00:38:29.819125|2018-06-01 00:38:29.819125
NCT00968552|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2016-10-25|2009-08-28|2009-08-31|Estimate|||||||2016-10-25|2016-10-27|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents|Prospective Evaluation of the Clinical Utility of Endoscopically Placed Self-expandable Stents|Completed|||23|Actual|University of Florida|||1||f||||f||||||||||2018-06-01 00:38:29.883104|2018-06-01 00:38:29.883104
NCT00968539|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2017-03-13|2010-12-10|2017-05-18|2009-08-27|2009-08-31|Estimate|2017-05-18|2017-12-18|Actual|2010-12-10|2010-12-16|Estimate|2017-05-18|2017-12-18|Actual|September 1, 2009||2009-09-01|March 2017|2017-03-31|September 28, 2010|Actual|2010-09-28|September 28, 2010|Actual|2010-09-28||Interventional|||Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years|Completed||Phase 3|130|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:38:29.975203|2018-06-01 00:38:29.975203
NCT00968526|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27||2010-12-10|2017-01-16|2009-08-27|2009-08-31|Estimate||||2010-12-10|2010-12-16|Estimate|2017-01-16|2017-01-18|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above|Completed||Phase 3|240|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:38:31.23422|2018-06-01 00:38:31.23422
NCT00968513|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2015-11-19|2009-08-28|2009-08-31|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|November 2015|Anticipated|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry|Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry|Unknown status|Active, not recruiting|Phase 3|956|Actual|Stanford University||3|||f||||t||||||||||2018-06-01 00:38:31.344935|2018-06-01 00:38:31.344935
NCT00968500|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2017-07-05|2009-08-28|2009-08-31|Estimate|||||||2017-07-05|2017-07-06|Actual|August 2009||2009-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer|Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer|Active, not recruiting|||160|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 00:38:31.43358|2018-06-01 00:38:31.43358
NCT00968487|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2012-02-23|2009-08-28|2009-08-31|Estimate|||||||2012-02-23|2012-02-24|Estimate|June 2010||2010-06-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Safety of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Healthy Volunteers|A Clinical Study of the Safety of Ascending Doses of Autologous Lyophilized Plasma Versus Fresh Frozen Plasma in Normal Healthy Volunteers|Completed||Phase 1|16|Actual|HemCon Medical Technologies, Inc||2|||f||||f||||||||||2018-06-01 00:38:31.507044|2018-06-01 00:38:31.507044
NCT00968474|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2009-08-28|2009-08-28|2009-08-31|Estimate|||||||2009-08-28|2009-08-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:38:31.578416|2018-06-01 00:38:31.578416
NCT00968461|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2013-04-12|2009-08-28|2009-08-31|Estimate|||||||2013-04-12|2013-04-15|Estimate|May 2013||2013-05-31|April 2013|2013-04-30||||May 2015|Anticipated|2015-05-31||Interventional|||Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders|A Phase I Study of Phenethyl Isothiocyanate (PEITC) in Patients With Lymphoproliferative Disorders Previously Treated With Fludarabine|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:38:31.622811|2018-06-01 00:38:31.622811
NCT00968448|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2011-01-04|2009-08-28|2009-08-31|Estimate|||||||2011-01-04|2011-01-05|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Inspiratory Muscle Training (IMT) in Athletes|Inspiratory Muscle Training (IMT) in Athletes|Completed||N/A|40|Anticipated|Saarland University||2|||f||||f||||||||||2018-06-01 00:38:31.737594|2018-06-01 00:38:31.737594
NCT00968435|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2016-08-09|2009-08-28|2009-08-31|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2009||2009-08-31|August 2016|2016-08-31||||August 2016|Actual|2016-08-31||Interventional|||Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma|Phase II Trial of Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma|Completed||Phase 2|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 00:38:31.801322|2018-06-01 00:38:31.801322
NCT00968422|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2010-11-01|2009-08-28|2009-08-31|Estimate|||||||2010-11-01|2010-11-03|Estimate|August 2009||2009-08-31|September 2010|2010-09-30||||January 2010|Actual|2010-01-31||Interventional|||A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects||Completed||Phase 1|28|Actual|Abbott||4|||f||||||||||||||2018-06-01 00:38:31.871407|2018-06-01 00:38:31.871407
NCT00968409|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2015-12-07|2009-08-28|2009-08-31|Estimate|||||||2015-12-07|2015-12-09|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|FFNP||Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)|Labeling of Receptor Ligands and Other Compounds With Halogen Radionuclides: Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using FFNP|Completed||Phase 1|20|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 00:38:31.939258|2018-06-01 00:38:31.939258
NCT00968396|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2013-04-04|2009-08-28|2009-08-31|Estimate|||||||2013-04-04|2013-04-05|Estimate|February 2013||2013-02-28|April 2013|2013-04-30||||February 2015|Anticipated|2015-02-28||Interventional|||Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts|Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:38:32.011374|2018-06-01 00:38:32.011374
NCT00968383|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2015-05-13|2009-08-28|2009-08-31|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|COAT||Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment|Late Percutaneous Coronary Intervention of the Occluded Infarct-Related Artery in Patients With Preserved Infarct Zone Viability Determined With Magnetic Resonance Imaging|Terminated||N/A|11|Actual|Institute of Cardiology, Warsaw, Poland||2||The study was prematurely terminated due to low enrollment.|f||||f||||||||||2018-06-01 00:38:32.075711|2018-06-01 00:38:32.075711
NCT00968370|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2013-07-14|2009-08-28|2009-08-31|Estimate|||||||2013-07-14|2013-07-16|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Trial in Childhood Pneumonia With Malnutrition|Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children|Completed||Phase 4|440|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 00:38:32.163419|2018-06-01 00:38:32.163419
NCT00968357|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2012-06-06|2009-08-28|2009-08-31|Estimate|||||||2012-06-06|2012-06-08|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed|A Phase 2, Multicenter, Multidose, Open-Label Study to Evaluate the Safety and Immunomodulatory Effects of SCV-07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Genotype 1 Chronic Hepatitis C Who Have Relapsed After a Response to a Course of at Least 44 Weeks Treatment With Pegylated Interferon and Ribavirin|Completed||Phase 2|40|Actual|SciClone Pharmaceuticals||1|||f||||t||||||||||2018-06-01 00:38:32.380089|2018-06-01 00:38:32.380089
NCT00968344|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2015-05-27|2009-08-28|2009-08-31|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Muscle Mass During Space Exploration|An Integrated Low-Volume Nutritional Countermeasure to Maintain Muscle Mass and Function During Space Exploration|Completed||Phase 3|40|Actual|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-06-01 00:38:32.468684|2018-06-01 00:38:32.468684
NCT00968331|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-28|||2012-08-24|2009-08-28|2009-08-31|Estimate|||||||2012-08-24|2012-08-27|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)||Terminated||Phase 2|25|Actual|University of Bologna||1||"The EC withdrawn the approval becuase of possible conflicts of interests between our Institute~   and Supporter (Celgene)"|f||||||||||||||2018-06-01 00:38:32.533953|2018-06-01 00:38:32.533953
NCT00968318|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2009-08-27|2009-08-27|2009-08-28|Estimate|||||||2009-08-27|2009-08-28|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders|Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders|Completed||N/A|56|Actual|Cairo University||1|||f||||f||||||||||2018-06-01 00:38:32.595115|2018-06-01 00:38:32.595115
NCT00968305|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2009-08-26|2009-08-26|2009-08-28|Estimate|||||||2009-08-26|2009-08-28|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Interleukin (IL)-13 as a Marker in Pediatrics Asthma|Cytokine Production in Children With Asthma.|Completed|||19|Actual|Rush University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Venous blood was obtained to measure total serum immunoglobulin E, radioallergosorbent test~     for environmental aeroallergens, and for peripheral blood mononuclear cells isolation~   "|||2018-06-01 00:38:32.694092|2018-06-01 00:38:32.694092
NCT00968292|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-27|2009-08-27|2009-08-28|Estimate|||||||2009-08-27|2009-08-28|Estimate|May 2010||2010-05-31|August 2009|2009-08-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Stability and 3D Motion Study of an Experimental Prosthetic Foot|Stability & 3D Motion Study of an Experimental Prosthetic Foot|Unknown status|Not yet recruiting|Phase 3|50|Anticipated|Tensegrity Prosthetics||2|||f||||||||||||||2018-06-01 00:38:32.755664|2018-06-01 00:38:32.755664
NCT00968279|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2013-05-02|2009-08-27|2009-08-28|Estimate|||||||2013-05-02|2013-05-03|Estimate|August 2009||2009-08-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation|Coronary CT Angiography Using 320-Row Volume CT in Patients With Atrial Fibrillation|Completed|||54|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-06-01 00:38:32.832621|2018-06-01 00:38:32.832621
NCT00968266|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2015-06-05|2009-08-27|2009-08-28|Estimate|||||||2015-06-05|2015-06-09|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|||Improving Beliefs About Medication in Patients With Rheumatoid Arthritis|Improving Beliefs About Medication in Patients With Rheumatoid Arthritis: Randomized Controlled Study Into the Effect of a Motivational Patient-centered Intervention for Non-adherent Patients Compared to Usual Care Controls|Completed||N/A|120|Actual|Sint Maartenskliniek||2|||f||||t||||||||||2018-06-01 00:38:32.95059|2018-06-01 00:38:32.95059
NCT00968253|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2016-12-22||2018-05-01|2009-08-27|2009-08-28|Estimate|2018-05-01|2018-05-31|Estimate||||2018-05-01|2018-05-31|Estimate|November 2009||2009-11-30|May 2018|2018-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia|Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)|Completed||Phase 1/Phase 2|24|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 00:38:33.059996|2018-06-01 00:38:33.059996
NCT00968240|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2015-04-20|2009-08-27|2009-08-28|Estimate|||||||2015-04-20|2015-04-22|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)|Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma|Completed||Phase 1|30|Anticipated|Northwell Health|||||f||||f||||||||||2018-06-01 00:38:33.676491|2018-06-01 00:38:33.676491
NCT00968227|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2017-03-05||2017-03-05|2009-08-27|2009-08-28|Estimate|2017-03-05|2017-04-17|Actual||||2017-03-05|2017-04-17|Actual|November 2007||2007-11-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage|Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage|Completed||Phase 1/Phase 2|56|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 00:38:33.764926|2018-06-01 00:38:33.764926
NCT00968214|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2017-08-07|2009-08-27|2009-08-28|Estimate|||||||2017-08-07|2017-08-08|Actual|September 2008||2008-09-30|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27|A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.|Active, not recruiting|||364|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 00:38:33.941792|2018-06-01 00:38:33.941792
NCT00968201|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2009-09-15||2015-04-23|2009-08-27|2009-08-28|Estimate|2010-07-06|2010-08-03|Estimate||||2015-04-23|2015-05-12|Estimate|December 1997||1997-12-31|April 2015|2015-04-30|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )|A Multicenter, Double-Blind, Randomized, Parallel-Group Chronic Asthma Study Comparing Montelukast With Placebo in 2- to 5-Year-Old Patients|Completed||Phase 3|689|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:38:34.046614|2018-06-01 00:38:34.046614
NCT00968188|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2009-09-28|2009-08-27|2009-08-28|Estimate|||||||2009-09-28|2009-09-29|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|June 2011|Anticipated|2011-06-30|January 2010|Anticipated|2010-01-31||Interventional|KIU||Internet-based HIV/STI Prevention for Young MSM Receiving HIV Testing|A Randomized Control Trial of an Internet-based HIV/STI Prevention for Young MSM Receiving HIV Testing.|Unknown status|Enrolling by invitation|N/A|80|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 00:38:34.93817|2018-06-01 00:38:34.93817
NCT00968175|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2014-06-02|2009-08-27|2009-08-28|Estimate|||||||2014-06-02|2014-06-04|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer|EUS Guided-Celiac Plexus Neurolysis (CPN) for Patients With Unresectable Pancreatic Cancer: A Multi-Center, Randomized, Single-Blinded Controlled Trial|Completed||N/A|60|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 00:38:35.011731|2018-06-01 00:38:35.011731
NCT00968162|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2017-07-24|2009-08-27|2009-08-28|Estimate|||||||2017-07-24|2017-07-25|Actual|February 2009||2009-02-28|July 2017|2017-07-31|January 11, 2016|Actual|2016-01-11|March 2014|Actual|2014-03-31||Interventional|||Sickle Cell Disease Conditioning for Bone Marrow Transplant|Toward a Less Toxic Yet Highly Effective Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Children and Adolescents With Severe Sickle Cell Disease: A Pilot Study|Completed||Phase 1|8|Actual|Emory University||1|||f||||t||||||||||2018-06-01 00:38:35.095341|2018-06-01 00:38:35.095341
NCT00968149|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2009-09-15||2016-04-07|2009-08-27|2009-08-28|Estimate|2009-11-11|2009-12-11|Estimate||||2016-04-07|2016-04-08|Estimate|March 2001||2001-03-31|April 2016|2016-04-30|July 2001|Actual|2001-07-31|June 2001|Actual|2001-06-30||Interventional|||A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Age 2 Through 14 Years With Seasonal Allergic Rhinitis|Completed||Phase 3|413|Actual|Merck Sharp & Dohme Corp.|Efficacy endpoints are exploratory.|2|||f||||f||||||||||2018-06-01 00:38:35.222354|2018-06-01 00:38:35.222354
NCT00968136|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2009-08-27|2009-08-27|2009-08-28|Estimate|||||||2009-08-27|2009-08-28|Estimate||||August 2009|2009-08-31||||||||Observational|||Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study||Completed|||||Yonsei University|||2||f||||||||||||||2018-06-01 00:38:35.738981|2018-06-01 00:38:35.738981
NCT00968123|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2013-04-08|2009-08-27|2009-08-28|Estimate|||||||2013-04-08|2013-04-09|Estimate||||April 2013|2013-04-30||||||||Observational|||Consecutive Series Outcomes Review of Patients Undergoing a New Single Portal Technique for Endoscopic Carpal Tunnel Release|Consecutive Series Outcomes Review of Patients Undergoing a New Single Portal Technique for Endoscopic Carpal Tunnel Release|Unknown status|Active, not recruiting||||Rothman Institute Orthopaedics|||||f||||f||||||||||2018-06-01 00:38:35.799339|2018-06-01 00:38:35.799339
NCT00968110|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2017-07-20|2009-08-27|2009-08-28|Estimate|||||||2017-07-20|2017-07-24|Actual|March 2009||2009-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Xolair Treatment for Milk Allergic Children|Xolair (Omalizumab) Enhances Oral Tolerance Induction in Milk Allergic Children|Active, not recruiting||Early Phase 1|10|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-06-01 00:38:35.853153|2018-06-01 00:38:35.853153
NCT00968097|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-08-27|2009-08-27|2009-08-28|Estimate|||||||2009-08-27|2009-08-28|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition|Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Terminated||Phase 1|12|Actual|Institute for Neurodegenerative Disorders||||Early Phase I study of [123I]MNI-340 did not evidence as marker of disease|f||||f||||||||||2018-06-01 00:38:35.926985|2018-06-01 00:38:35.926985
NCT00968084|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2017-10-26|2009-08-27|2009-08-28|Estimate|||||||2017-10-26|2017-10-27|Actual|August 6, 2009||2009-08-06|October 25, 2017|2017-10-25|October 25, 2017||2017-10-25|||||Observational|||Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols|Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols|Completed|||587|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:38:35.989005|2018-06-01 00:38:35.989005
NCT00968071|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2013-02-04||2013-02-04|2009-08-26|2009-08-28|Estimate|2013-02-04|2013-03-08|Estimate||||2013-02-04|2013-03-08|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome|A Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 2|71|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:38:36.071837|2018-06-01 00:38:36.071837
NCT00968058|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2012-05-03|2009-08-27|2009-08-28|Estimate|||||||2012-05-03|2012-05-04|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Leak Pressure of Uncuffed Pediatric Endotracheal Tubes|Temporal Variation of the Leak Pressure of Uncuffed Pediatric Endotracheal Tubes Following Intubation: A Prospective Observational Study|Completed|||40|Anticipated|Oregon Health and Science University|||||f||||||||||||||2018-06-01 00:38:36.234124|2018-06-01 00:38:36.234124
NCT00968045|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2015-05-19|2009-08-27|2009-08-28|Estimate|||||||2015-05-19|2015-05-20|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|February 2012|Actual|2012-02-29||Interventional|Fibro-3||Fibrinogen and Bleeding After Cardiac Surgery|Fibrinogen and Bleeding After Cardiac Surgery|Completed||Phase 2|52|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-06-01 00:38:36.285316|2018-06-01 00:38:36.285316
NCT00968032|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2011-01-27||2011-05-30|2009-08-27|2009-08-28|Estimate|2011-02-14|2011-03-09|Estimate||||2011-05-30|2011-06-02|Estimate|July 2009||2009-07-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|09k003||Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System|Single-center Non-comparative, Prospective Interventional Clinical Investigation on the Procedural Success and Safety of the Nit-Occlud® PFO Closure Device and Its Application System.|Completed||N/A|63|Actual|pfm medical ag|||||f||||f||||||||||2018-06-01 00:38:36.351471|2018-06-01 00:38:36.351471
NCT00968019|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2013-01-15||2013-03-05|2009-08-27|2009-08-28|Estimate|2013-01-24|2013-03-06|Estimate||||2013-03-05|2013-03-13|Estimate|April 2009||2009-04-30|March 2013|2013-03-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Observational|||Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion Stent|A Multicenter Postmarket Surveillance Registry Evaluating the Performance and Long Term Safety of the Presillion Stent in de Novo Native Coronary Artery Lesions. Iberian Registry|Completed|||318|Actual|Johnson and Johnson, S.A.|since the difference with the performance goal is this large; the possibility of underreporting of adverse events is something that needs to be considered.||1||f||||t||||||||||2018-06-01 00:38:36.504271|2018-06-01 00:38:36.504271
NCT00968006|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2010-04-02|2009-08-27|2009-08-28|Estimate|||||||2010-04-02|2010-04-05|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Sitagliptin on Endothelial Progenitor Cells|Effects of 4-week Sitagliptin Therapy on Endothelial Progenitor Cells in Type 2 Diabetic Patients. A Non-randomized Controlled Open-label Pilot Trial.|Completed||Phase 4|40|Actual|University of Padova||2|||f||||f||||||||||2018-06-01 00:38:36.823584|2018-06-01 00:38:36.823584
NCT00967993|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2014-10-04||2014-11-19|2009-08-27|2009-08-28|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-19|2014-12-05|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease|A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)|Completed|||22|Actual|Keryx Biopharmaceuticals|||1||f||||f||||||||||2018-06-01 00:38:36.895455|2018-06-01 00:38:36.895455
NCT00967980|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2010-09-23|2009-08-27|2009-08-28|Estimate|||||||2010-09-23|2010-09-24|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Femoral Versus Psoas Continuous Peripheral Nerve Blocks Following Hip Arthroplasty|Femoral Versus Psoas Continuous Peripheral Nerve Blocks Following Hip Arthroplasty|Completed||Phase 4|50|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 00:38:37.066359|2018-06-01 00:38:37.066359
NCT00967967|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2013-05-24|2009-08-27|2009-08-28|Estimate|||||||2013-05-24|2013-05-27|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|RCSS||Validation of the Rhinitis Control Scoring System (RCSS)|Validation of a Rhinitis Control Tool : the Rhinitis Control Scoring System (RCSS)|Suspended||N/A|50|Anticipated|Laval University||1||Awaiting results from sub analysis to decide if study continuesé|f||||f||||||||||2018-06-01 00:38:37.168576|2018-06-01 00:38:37.168576
NCT00967954|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2014-01-09|2009-08-27|2009-08-28|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2008||2008-09-30|August 2009|2009-08-31||||August 2013|Anticipated|2013-08-31||Interventional|||Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer|A Study of Changes in the Prostate Following Androgen Deprivation to Investigate Therapy Response and Resistance in Clinical Prostate Cancer|Unknown status|Recruiting|N/A|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:38:37.25048|2018-06-01 00:38:37.25048
NCT00967941|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2012-07-31|2009-08-27|2009-08-28|Estimate|||||||2012-07-31|2012-08-02|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|August 2010|Actual|2010-08-31|June 2009|Actual|2009-06-30||Interventional|||Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis|Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis|Completed||Phase 4|201|Actual|CAMC Health System||3|||f||||f||||||||||2018-06-01 00:38:37.48609|2018-06-01 00:38:37.48609
NCT00967928|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2014-02-13|2009-08-27|2009-08-28|Estimate|||||||2014-02-13|2014-02-14|Estimate|December 2009||2009-12-31|February 2014|2014-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer|Phase I Everolimus Dose Finding Study for the Treatment of Stage IV or Recurrent, Non-resectable, Cervical Cancer With Standard Whole Pelvic Radiation Therapy in Combination With Weekly Cisplatin and Daily Everolimus|Withdrawn||Phase 1|0|Actual|Accelerated Community Oncology Research Network||1||Lack of enrollment|f||||f||||||||||2018-06-01 00:38:37.567528|2018-06-01 00:38:37.567528
NCT00967915|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2009-08-27|2009-08-27|2009-08-28|Estimate|||||||2009-08-27|2009-08-28|Estimate|November 2007||2007-11-30|August 2009|2009-08-31||||July 2009|Actual|2009-07-31||Interventional|||Efficacy of Neonatal Release of Ankyloglossia|Efficacy of Neonatal Release of Ankyloglossia|Completed||N/A|58|Actual|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-06-01 00:38:37.646478|2018-06-01 00:38:37.646478
NCT00967902|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2016-03-28|2009-08-27|2009-08-28|Estimate|||||||2016-03-28|2016-03-29|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|July 2011|Actual|2011-07-31||Interventional|REMEDEE||Safety and Effectiveness Study of Combo Bio-engineered Sirolimus Eluting Stent|The REMEDEE Study: A Prospective, Randomized Study to Evaluate the Safety and Efficacy of an Abluminal Sirolimus Coated Bio-engineered Stent (Combo Bio-engineered Sirolimus Eluting Stent)|Completed||Phase 2|180|Actual|OrbusNeich||2|||f||||t||||||||||2018-06-01 00:38:37.720848|2018-06-01 00:38:37.720848
NCT00967889|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2013-08-09|2009-08-27|2009-08-28|Estimate|||||||2013-08-09|2013-08-12|Estimate|January 2002||2002-01-31|August 2009|2009-08-31||||June 2011|Anticipated|2011-06-30||Observational|||Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer|Molecular Mechanisms of Disease Progression and the Development of Novel Treatment Strategies in Advanced Prostate Cancer (Northern Prostate Cancer Collaborative (ProMPT))|Unknown status|Recruiting||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:38:37.81351|2018-06-01 00:38:37.81351
NCT00967876|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2014-07-22|2009-08-27|2009-08-28|Estimate|||||||2014-07-22|2014-07-23|Estimate|April 2009||2009-04-30|July 2014|2014-07-31||||November 2011|Actual|2011-11-30||Observational|CARS-320||Coronary Artery Stent Evaluation With 320-slice Computed Tomography - The CArS 320 Study|Coronary Artery Stent Evaluation With 320-slice Computed Tomography - The CArS 320 Study|Completed|||90|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 00:38:37.881489|2018-06-01 00:38:37.881489
NCT00967863|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2017-11-02|2009-08-27|2009-08-28|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2008||2008-10-31|November 2017|2017-11-30|October 2026|Anticipated|2026-10-31|October 2013|Actual|2013-10-31||Interventional|||Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)|Phase III Study Comparing Irradiation at a Dose of 80 Gy to Irradiation at 70 Gy in Unfavorable Prostate Cancers Associated With Prolonged Hormonal Therapy|Active, not recruiting||N/A|500|Anticipated|UNICANCER||2|||f||||f|f|f||||||||2018-06-01 00:38:37.942247|2018-06-01 00:38:37.942247
NCT00967850|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2014-03-18|2009-08-27|2009-08-28|Estimate|||||||2014-03-18|2014-03-19|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia|Phase III Study of Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia|Completed||Phase 3|56|Actual|Instituto Universitario de Oftalmobiología Aplicada||2|||f||||f||||||||||2018-06-01 00:38:38.124201|2018-06-01 00:38:38.124201
NCT00967837|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-08-08|2009-08-27|2009-08-28|Estimate|||||||2016-08-08|2016-08-10|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|September 2012|Actual|2012-09-30|January 2012|Actual|2012-01-31||Interventional|wounds||Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics|Effects of Pulsatile Intravenous Insulin Therapy on Diabetic Subjects With Non Healing Wounds|Terminated||Phase 2/Phase 3|152|Actual|Florida Atlantic University||1||Administrative|f||||t||||||||||2018-06-01 00:38:38.244417|2018-06-01 00:38:38.244417
NCT00967824|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2011-03-22|2009-08-27|2009-08-28|Estimate|||||||2011-03-22|2011-03-24|Estimate|October 2005||2005-10-31|March 2011|2011-03-31||||August 2008|Actual|2008-08-31||Interventional|||Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer|Developing and Testing a Tamoxifen Prophylaxis Decision Aid|Completed||Phase 1/Phase 2|1683|Anticipated|University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 00:38:38.368694|2018-06-01 00:38:38.368694
NCT00967811|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27||2011-06-17|2013-09-16|2009-08-27|2009-08-28|Estimate||||2011-06-27|2011-06-29|Estimate|2013-09-16|2013-09-19|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG|An Open-Label, Phase 2 Study of Different Formulations (E1 and E2) of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)|Completed||Phase 2|83|Actual|Mati Therapeutics Inc.||2|||f||||f||||||||||2018-06-01 00:38:38.442717|2018-06-01 00:38:38.442717
NCT00967798|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2018-01-16|2009-08-27|2009-08-28|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2010||2010-05-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|March 31, 2017|Actual|2017-03-31||Interventional|Prevent||Prevention of Cystic Fibrosis Diabetes|A Randomized, Double-blind, Placebo-controlled Study to Determine Whether Chronic Treatment of Cystic Fibrosis Subjects With Impaired Glucose Tolerance Using Sitagliptin (Januvia) Prevents the Development of Diabetes|Terminated||Phase 3|30|Actual|Emory University||2||Could not achieve target enrollment|f||||t|t|f||||||Undecided||2018-06-01 00:38:38.51879|2018-06-01 00:38:38.51879
NCT00967785|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2018-03-27|2009-08-27|2009-08-28|Estimate|||||||2018-03-27|2018-03-29|Actual|August 4, 2009||2009-08-04|July 11, 2017|2017-07-11|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||A Phase I Study of Mozobil in the Treatment of Patients With WHIMS|A Phase I Study of Mozobil (TM) in the Treatment of Patients With WHIMS|Recruiting||Phase 1|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:38:38.618196|2018-06-01 00:38:38.618196
NCT00967772|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2014-09-30|2009-08-27|2009-08-28|Estimate|||||||2014-09-30|2014-10-01|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional|||The Safety/Tolerability and Pharmacokinetics (PKs) of Naftopidil in Korean Healthy Male Volunteers|A Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics of Naftopidil After Oral Administration in Korean Healthy Male Volunteers|Completed||Phase 1|16|Actual|Dong-A ST Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:38:38.709016|2018-06-01 00:38:38.709016
NCT00967759|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2016-10-18|2009-08-27|2009-08-28|Estimate|||||||2016-10-18|2016-10-19|Estimate||||October 2016|2016-10-31||||||||Interventional|||Study Comparing 3 Formulations to Evaluate the Efficacy and Safety of the Inflammatory Symptoms of the Upper Respiratory Tract, in Children Between 2 and 6 Years Old|A Double Blind, Randomized, Multicenter Phase III Study Comparing 3 Formulations: Dose Fixed Combination of Bronpheniramine and Fenilefrine, Bronpheniramine Isolated and Fenilefrine Isolated, to Evaluate the Efficacy and Safety of the Treatment of the Inflammatory Symptoms of Upper Respiratory Tract, in Children Between 2 and 6 Years Old.|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||3||The study was designed again in compliance with the regulatory agency.|f||||f||||||||||2018-06-01 00:38:38.782515|2018-06-01 00:38:38.782515
NCT00967746|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2015-08-26|2009-08-27|2009-08-28|Estimate|||||||2015-08-26|2015-08-27|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|July 2011|Actual|2011-07-31|November 2010|Actual|2010-11-30||Interventional|||An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)|A Randomized, Multicenter, Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Doses of an Etonogestrel-releasing Medicated Intrauterine System (ENG-MIUS) Versus a Copper-releasing Intrauterine Device (IUD)|Completed||Phase 2|84|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 00:38:38.859376|2018-06-01 00:38:38.859376
NCT00967733|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2013-07-18|2009-08-27|2009-08-28|Estimate|||||||2013-07-18|2013-07-19|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Alpha-Linolenic Acid and Inflammatory Markers|Effect of Alpha-Linolenic Acid on Blood Markers of Inflammation|Completed||N/A|130|Actual|Harvard School of Public Health||4|||f||||f||||||||||2018-06-01 00:38:38.931589|2018-06-01 00:38:38.931589
NCT00967720|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2017-11-17|2009-08-26|2009-08-28|Estimate|||||||2017-11-17|2017-11-21|Actual|March 2008||2008-03-31|November 2017|2017-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|ADEPT||Barriers to Adherence to Asthma Controller Meds in Low Income Urban Minority Adolescents|Qualitative Analysis of the Barriers to Adherence With Asthma Controller Medication Among Inner City African American Adolescents as Identified Through Focus Group Data|Completed|||4|Actual|Rush University Medical Center|||1||f||||f||||||||||2018-06-01 00:38:38.998404|2018-06-01 00:38:38.998404
NCT00967707|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2011-10-11|2009-08-27|2009-08-28|Estimate|||||||2011-10-11|2011-10-12|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain|Population Pharmacokinetic and Pharmacodynamic Modeling of Gabapentin in Neuropathic Pain - Effect of Adjuvant Pharmacotherapy|Completed||Phase 2|30|Anticipated|Uppsala University||2|||f||||t||||||||||2018-06-01 00:38:39.048395|2018-06-01 00:38:39.048395
NCT00967694|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2014-04-24||2014-09-15|2009-08-27|2009-08-28|Estimate|2014-09-15|2014-09-23|Estimate||||2014-09-15|2014-09-23|Estimate|August 2009||2009-08-31|September 2014|2014-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Volunteers recruited via locally placed posters, research opportunities website and email servers. Power calculations estimated 20 subjects would be needed to detect a 2.8mmHg difference in IOP. 26 subjects began nitrous oxide administration, with 6 choosing to withdraw. Baseline analysis based on the 20 participants completing the study.|Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers|Effect of N2O on Intraocular Pressure in Healthy Volunteers|Completed||Phase 4|20|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 00:38:39.12223|2018-06-01 00:38:39.12223
NCT00967681|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2012-05-02|2009-08-27|2009-08-28|Estimate|||||||2012-05-02|2012-05-04|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease|Efficacy and Safety of Nutritional Supplement ONCOXIN in Patients With Breast Fibrocystic Disease|Completed||Phase 3|200|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 00:38:39.263546|2018-06-01 00:38:39.263546
NCT00967668|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2014-07-29||2015-04-06|2009-08-26|2009-08-28|Estimate|2014-08-19|2014-08-29|Estimate||||2015-04-06|2015-04-24|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|October 2012|Actual|2012-10-31||Interventional|ASPIRE|Number of participants randomized to each arm|Coaching Veterans to Healthy Weights and Wellness|ASPIRE: Coaching Veterans to Healthy Weights and Wellness|Completed||N/A|481|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 00:38:39.329255|2018-06-01 00:38:39.329255
NCT00967655|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2014-01-09|2009-08-27|2009-08-28|Estimate|||||||2014-01-09|2014-01-10|Estimate|July 2009||2009-07-31|September 2009|2009-09-30||||July 2012|Anticipated|2012-07-31||Interventional|||Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer|A Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Radiation in Combination With Capecitabine & Paniumumab With and Without Irinotecan in Patients With Localized Rectal Cancer|Unknown status|Recruiting|Phase 2|54|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 00:38:39.848399|2018-06-01 00:38:39.848399
NCT00967642|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2009-08-27|2009-08-27|2009-08-28|Estimate|||||||2009-08-27|2009-08-28|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|April 2009|Actual|2009-04-30|July 2008|Actual|2008-07-31||Interventional|||Intravenous Insulin in Patients With Diabetes After Percutaneous Coronary Intervention (PCI)|Intravenous Insulin for 24 Hours in Patients With Diabetes Mellitus Submitted to Percutaneous Coronary Intervention With Stent: Effects Upon Oxidative Stress and Inflammatory Markers|Terminated||N/A|70||Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 00:38:39.946725|2018-06-01 00:38:39.946725
NCT00967629|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2011-11-16|2009-08-27|2009-08-28|Estimate|||||||2011-11-16|2011-11-18|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy|Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy|Completed||Phase 1|20|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 00:38:40.010767|2018-06-01 00:38:40.010767
NCT00967616|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27||2014-05-07|2014-05-07|2009-08-27|2009-08-28|Estimate||||2014-05-07|2014-05-23|Estimate|2014-05-07|2014-05-23|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy|Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy|Completed||Phase 2|100|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 00:38:40.085705|2018-06-01 00:38:40.085705
NCT00967603|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2012-01-31|2009-08-27|2009-08-28|Estimate|||||||2012-01-31|2012-02-01|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PACT-12||Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer|Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer: a Phase II Randomized Trial.|Completed||Phase 2|56|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-06-01 00:38:40.196081|2018-06-01 00:38:40.196081
NCT00967590|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2016-08-23|2009-08-27|2009-08-28|Estimate|||||||2016-08-23|2016-08-24|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|August 2010|Anticipated|2010-08-31|||||Interventional|||A Study of RO5036505 in Patients With Moderate to Severe Asthma|A Multi-center, Randomized, Double-Blind, Multiple-Dose, Placebo-controlled Asthma Control Study Evaluating the Efficacy, Safety, and Tolerability of RO5036505 in Subjects With Moderate-to-Severe Asthma|Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche||2||No patients dosed|f||||||||||||||2018-06-01 00:38:40.268964|2018-06-01 00:38:40.268964
NCT00967577|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2018-01-26|2009-08-26|2009-08-28|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2009|Actual|2009-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors|177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study|Recruiting||N/A|50|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-06-01 00:38:40.351271|2018-06-01 00:38:40.351271
NCT00967564|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2014-04-24|2009-08-27|2009-08-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Survey on QUality of Life In myeloDisplasia (SQUID)|QUALITY OF LIFE ASSESSMENT IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROME|Completed|||160|Actual|Janssen-Cilag S.p.A.|||1||f||||||||||||||2018-06-01 00:38:40.421544|2018-06-01 00:38:40.421544
NCT00967551|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2013-01-24||2013-04-05|2009-08-27|2009-08-28|Estimate|2013-03-01|2013-04-08|Estimate||||2013-04-05|2013-04-11|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Micronutrient Sprinkles in a Daycare Center|The Impact of the Use of Zinc Supplementation and Other Micronutrients on the Occurence of Diarrhea Diseases and Respiratory Infections in Children of Daycare Centers|Completed||Phase 3|143|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:38:40.480905|2018-06-01 00:38:40.480905
NCT00967538|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2014-07-23|2009-08-27|2009-08-28|Estimate|||||||2014-07-23|2014-07-24|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments|Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab|Completed||Phase 4|89|Actual|Innovaderm Research Inc.||1|||f||||f||||||||||2018-06-01 00:38:40.68466|2018-06-01 00:38:40.68466
NCT00967525|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-11-26|2009-08-27|2009-08-28|Estimate|||||||2013-11-26|2013-11-27|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Intraosseous Infusion of Unrelated Cord Blood Grafts|A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts|Terminated||N/A|5|Actual|Emory University||1||poor enrollment|f||||t||||||||||2018-06-01 00:38:40.763832|2018-06-01 00:38:40.763832
NCT00967512|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2014-09-16|2009-08-27|2009-08-28|Estimate|||||||2014-09-16|2014-09-18|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course|Aezea (Cenersen) in Combination With Chemotherapy for Treatment of Acute Myelogenous Leukemia Subjects ≥55 Years of Age With No Response to Single Frontline Induction Course in a Randomized Double-Blind Placebo-Controlled Multi-Center Study|Withdrawn||Phase 2|0|Actual|Eleos, Inc.||2||Study Was Terminated due to lack of Funding.|f||||f||||||||||2018-06-01 00:38:40.822538|2018-06-01 00:38:40.822538
NCT00967499|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2010-05-06|2009-08-27|2009-08-28|Estimate|||||||2010-05-06|2010-05-07|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)|A Multi-Center, Open-Label, 2-Arm, Randomized, Stratified, Parallel, Pilot Study to Assess Palonosetron vs. Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)|Completed||Phase 2|300|Anticipated|Eisai Inc.||2|||f||||||||||||||2018-06-01 00:38:41.863936|2018-06-01 00:38:41.863936
NCT00967486|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2012-07-31||2013-08-19|2009-08-27|2009-08-28|Estimate|2013-08-19|2013-10-24|Estimate||||2013-08-19|2013-10-24|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Selective Versus Routine Shunting in Carotid Endarterectomy Patients|Selective Shunting in Appropriately Selected Patients Undergoing Carotid Endarterectomy Based on Stump Pressure|Completed||N/A|200|Actual|CAMC Health System||2|||f||||f||||||||||2018-06-01 00:38:41.961002|2018-06-01 00:38:41.961002
NCT00967473|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2011-06-23||2016-11-18|2009-08-26|2009-08-27|Estimate|2011-06-23|2011-07-22|Estimate||||2016-11-18|2017-01-09|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||ACRYSOF® Toric NATURAL T9 Intraocular Lens (IOL)||Completed||N/A|15|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:38:42.160776|2018-06-01 00:38:42.160776
NCT00967460|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2011-01-27|2009-08-26|2009-08-27|Estimate|||||||2011-01-27|2011-01-28|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Youp'là bouge||Effect of a Physical-activity-promoting Environment on Motor Skills, Physical Activity and Quality of Life of Children in Childcare Settings|Effect of a Physical-activity-promoting Environment on Motor Skills, Physical Activity, Quality of Life and BMI of Children in Childcare Settings (Youp'là Bouge)|Completed||N/A|1764|Actual|University of Lausanne Hospitals||2|||f||||t||||||||||2018-06-01 00:38:42.316374|2018-06-01 00:38:42.316374
NCT00967447|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2012-01-05||2014-02-24|2009-08-26|2009-08-27|Estimate|2012-03-05|2012-04-05|Estimate||||2014-02-24|2014-03-19|Estimate|February 2009||2009-02-28|February 2014|2014-02-28||||January 2010|Actual|2010-01-31||Observational|||Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery|Incidence of Symptomatic Venous Thromboembolic Events and Major Bleeding Events After Dabigatran Etexilate in Patients Subject to Subject to Elective Total Hip or Knee Replacement Surgery.|Terminated|||2|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 00:38:42.393175|2018-06-01 00:38:42.393175
NCT00967434|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2011-10-24|2009-08-26|2009-08-27|Estimate|||||||2011-10-24|2011-10-26|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|STAR-VaS||Statin Drugs to Prevent Complications During Surgery|Short Term Atorvastatin Regime for Vasculopathic Surgical (STAR-VaS) Patients Study|Unknown status|Active, not recruiting|N/A|60|Anticipated|Ottawa Hospital Research Institute||3|||f||||t||||||||||2018-06-01 00:38:42.655622|2018-06-01 00:38:42.655622
NCT00967421|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2017-09-28|2009-08-26|2009-08-27|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2009|Actual|2009-09-30|September 2017|2017-09-30|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|VALIDAD||Development of a Valid Test Battery for Assessing Driving Ability When Influenced by Drugs.|Development of a Valid Test Battery for Assessing Driving Ability When Influenced by Drugs.|Completed||N/A|20|Actual|St. Olavs Hospital||3|||f||||f|f|f||||||||2018-06-01 00:38:42.744483|2018-06-01 00:38:42.744483
NCT00967408|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|October 2011|Anticipated|2011-10-31|July 2010|Anticipated|2010-07-31||Interventional|||Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients|Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke|Unknown status|Recruiting|Phase 4|200|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||f||||||||||2018-06-01 00:38:42.825257|2018-06-01 00:38:42.825257
NCT00967395|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2012-01-05|2009-08-26|2009-08-27|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|January 2009|Actual|2009-01-31||Interventional|RAhealing||Effect of Healing on Rheumatoid Arthritis|Effect of Healing on Rheumatoid Arthritis: a Three-arm Double-blind, Randomized, Controlled Trial|Completed||N/A|90|Anticipated|Frederiksberg University Hospital||3|||f||||f||||||||||2018-06-01 00:38:42.923021|2018-06-01 00:38:42.923021
NCT00967382|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2014-05-16|2009-08-26|2009-08-27|Estimate|||||||2014-05-16|2014-05-19|Estimate|July 2000||2000-07-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|TIPPS||TIPPS: Thrombophilia in Pregnancy Prophylaxis Study|TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.|Completed||Phase 3|292|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 00:38:43.006622|2018-06-01 00:38:43.006622
NCT00967369|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2018-05-07|2009-08-25|2009-08-27|Estimate|||||||2018-05-07|2018-05-11|Actual|August 24, 2009|Actual|2009-08-24|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02||Interventional|||Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma|A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma|Completed||Phase 2|20|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 00:38:43.119423|2018-06-01 00:38:43.119423
NCT00967356|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-11-11|2009-08-26|2009-08-27|Estimate|||||||2009-11-11|2009-11-13|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|November 2009|Anticipated|2009-11-30|||||Interventional|||AZD5985 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD5985 in Healthy Male Subjects|Terminated||Phase 1|72|Anticipated|AstraZeneca||2||Terminated (halted prematurely) due to tolerability issues.|f||||f||||||||||2018-06-01 00:38:43.227536|2018-06-01 00:38:43.227536
NCT00967343|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26||2013-03-22|2013-03-22|2009-08-26|2009-08-27|Estimate||||2013-03-22|2013-04-01|Estimate|2013-03-22|2013-04-01|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor|An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor|Terminated||Phase 2/Phase 3|40|Actual|Kiadis Pharma||1|||f||||t||||||||||2018-06-01 00:38:43.300748|2018-06-01 00:38:43.300748
NCT00967330|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2015-10-20||2015-10-20|2009-08-26|2009-08-27|Estimate|2015-10-20|2015-11-20|Estimate||||2015-10-20|2015-11-20|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The randomized (RND) population was defined to include all participants randomized.|A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma||Completed||Phase 2|182|Actual|Hoffmann-La Roche|Data for time to treatment failure were not collected as this outcome was removed as per changes in planned analysis.|2|||f||||||||||||||2018-06-01 00:38:43.47074|2018-06-01 00:38:43.47074
NCT00967317|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-08-25|2009-08-25|2009-08-27|Estimate|||||||2009-08-25|2009-08-27|Estimate|December 2009||2009-12-31|August 2009|2009-08-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|E02OSMAS0108||Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.|Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.|Unknown status|Not yet recruiting|Phase 3|188|Anticipated|Laboratorios Osorio de Moraes Ltda.||2|||f||||f||||||||||2018-06-01 00:38:44.594415|2018-06-01 00:38:44.594415
NCT00967304|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2016-08-31|2009-08-26|2009-08-27|Estimate|||||||2016-08-31|2016-09-01|Estimate|November 2008||2008-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Interventional|REVERSEII||Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism|"REVERSEII: Validation of the Men and HERDOO2- A Clinical Decision Rule to Identify Patients With Unprovoked Venous Thromboembolism Who Can Discontinue Anticoagulants After 6 Months of Treatment."|Completed||Phase 4|2779|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 00:38:44.673652|2018-06-01 00:38:44.673652
NCT00967291|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2012-01-31|2009-08-26|2009-08-27|Estimate|||||||2012-01-31|2012-02-01|Estimate|March 2006||2006-03-31|August 2009|2009-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|PACT-11||Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer|Mitomycin and Ifosfamide (MI) as Salvage Therapy for Metastatic Pancreatic Adenocarcinoma: a Phase II Study.|Terminated||Phase 2|21|Actual|IRCCS San Raffaele||||lack of activity and G3-4 toxicity at interim analysis|f||||f||||||||||2018-06-01 00:38:44.789028|2018-06-01 00:38:44.789028
NCT00967278|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-31|2009-08-26|2009-08-27|Estimate|||||||2009-08-31|2009-09-01|Estimate||||August 2009|2009-08-31||||||||Observational|||Hemodynamic Changes in Off-pump Coronary Artery Bypass Grafting|Hemodynamic Changes in Off-pump Coronary Artery Bypass Grafting|Completed|||||University of Sao Paulo|||1||f||||f||||||||||2018-06-01 00:38:44.854332|2018-06-01 00:38:44.854332
NCT00967265|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2017-06-12|2009-08-26|2009-08-27|Estimate|||||||2017-06-12|2017-06-14|Actual|June 2009||2009-06-30|June 2017|2017-06-30|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional|||Introduction Seminar About Patient Participation and Treatment Options for Psychiatric Patients on Waiting List|Introduction Seminar About Patient Participation and Treatment Options for Patients on Waiting List in a Community Mental Health Centre - Development, Effect, Experiences and Costs|Completed||N/A|92|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 00:38:44.90725|2018-06-01 00:38:44.90725
NCT00967252|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2011-07-19|2009-08-26|2009-08-27|Estimate|||||||2011-07-19|2011-07-21|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|STAR-VaS2||Impact of Chronic Statin Use During Surgery on Inflammation and Infection Rates|An Observational Trial of Perioperative Atorvastatin on Inflammatory and Endothelial Function in Patients Undergoing Vascular Surgery (STAR-VaS 2)|Completed|||50|Anticipated|Ottawa Hospital Research Institute|||5||f||||t||||||||||2018-06-01 00:38:45.068967|2018-06-01 00:38:45.068967
NCT00967239|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2015-05-06|2009-08-26|2009-08-27|Estimate|||||||2015-05-06|2015-05-08|Estimate|April 2009||2009-04-30|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Observational|||Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2|The Pharmacogenomics of Breast Cancer Prevention: A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2|Unknown status|Active, not recruiting||1881|Anticipated|NSABP Foundation Inc|||||f||||f||||||None Retained|"~     DNA extracted from stored lymphocytes~   "|||2018-06-01 00:38:45.176502|2018-06-01 00:38:45.176502
NCT00967226|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2014-03-14||2016-01-27|2009-08-26|2009-08-27|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Interventional||Infants 2 weeks - 6 months of age with symptomatic, proliferating, infantile hemangiomas|Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas|Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study|Terminated||Phase 2|19|Actual|Children's Research Institute|Not every enrolled participant had an adverse event and some had more than one. The prednioslone participants who had adverse events warranting early withdrawal had severe failure to thrive (<5th percentile), a serious adverse event.|2||"Serious adverse events with prednisolone, primarily temporary growth retardation, <5th~   percentile."|f||||f||||||||||2018-06-01 00:38:45.270692|2018-06-01 00:38:45.270692
NCT00967213|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2016-04-21|2009-08-26|2009-08-27|Estimate|||||||2016-04-21|2016-04-22|Estimate|August 2006||2006-08-31|April 2016|2016-04-30||||February 2008|Actual|2008-02-29||Interventional|||Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration|Changes in Preferential Hyperacuity Perimeter (PHP) and Fundus Autofluorescence (FAF) in Patients With Neovascular Age-related Macular Degeneration Receiving Combination of Ranibizumab and Verteporfin Therapy|Completed||Phase 3|10|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:38:45.889779|2018-06-01 00:38:45.889779
NCT00967200|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2015-11-23|2009-08-26|2009-08-27|Estimate|||||||2015-11-23|2015-11-24|Estimate|November 2003||2003-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|July 2009|Actual|2009-07-31||Observational|||Study of Tissue Samples From Patients With Glioma or Other Brain Tumors|Identification of Genes Involved in the Pathogenesis of Gliomas by Transcriptome Analysis|Completed|||180|Actual|University Hospital, Montpellier|||||f||||f||||||||||2018-06-01 00:38:45.9682|2018-06-01 00:38:45.9682
NCT00967187|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-01-04|2009-08-25|2009-08-27|Estimate|||||||2010-01-04|2010-01-06|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.|A Phase II Multicenter, Open-label, Randomized, Parallel Group, Study of Bevirimat in HIV-1 Positive Patients to Evaluate the Safety, Efficacy, and Pharmacokinetics of MPC-4326 Administered as Monotherapy for 14 Days and as Part of an Optimized Background Regimen for up to 72 Weeks.|Completed||Phase 2|32|Anticipated|Myrexis Inc.||2|||f||||t||||||||||2018-06-01 00:38:46.069972|2018-06-01 00:38:46.069972
NCT00967174|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-07-06|2009-08-25|2009-08-27|Estimate|||||||2012-07-06|2012-07-10|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Cumulative Skin Irritation Potential of a New 25 mg Nicotine Patch|Study on the Cumulative Skin Irritation Potential of a Newly Developed 25 mg Nicotine Transdermal Therapeutic System. A Double Blind, Randomized, Repeat Patch Test, Single Center Study in 42 Healthy Male and Female Subjects|Completed||Phase 1|42|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:38:46.162243|2018-06-01 00:38:46.162243
NCT00967161|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2015-11-17|2009-08-26|2009-08-27|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Motion Analysis of EMP Knee Versus Posterior Stabilized Knee Arthroplasty for Osteoarthritis|3D Motion Analysis of Evolution Medial Pivot Knee VS Posterior Stabilized Knee Arthroplasty for Osteoarthritis of the Knee.Feasibility Pilot for a Prospective Randomized Controlled Trial.|Completed||N/A|50|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 00:38:46.237226|2018-06-01 00:38:46.237226
NCT00967148|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2014-10-21|2009-08-26|2009-08-27|Estimate|||||||2014-10-21|2014-10-22|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PERI-OP||Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer|The Use of Extended Perioperative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colon Cancer: A Pilot Randomized Controlled Trial|Completed||N/A|18|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 00:38:46.314234|2018-06-01 00:38:46.314234
NCT00967135|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2012-04-11|2009-08-26|2009-08-27|Estimate|||||||2012-04-11|2012-04-12|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.|Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.|Completed||N/A|110|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 00:38:46.395202|2018-06-01 00:38:46.395202
NCT00967122|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-09-26|2009-08-26|2009-08-27|Estimate|||||||2012-09-26|2012-09-27|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Band Holiday Study|The Effect of Lap Band Adjustment on Satiety Peptides|Completed||Phase 1|15|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-06-01 00:38:46.46945|2018-06-01 00:38:46.46945
NCT00967109|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-02-24|2009-08-26|2009-08-27|Estimate|||||||2011-02-24|2011-02-25|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Establishment of Optimal Transfusion Threshold During Spine Surgery|Establishment of Optimal Transfusion Threshold During Spine Surgery|Completed||N/A|60|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 00:38:46.535849|2018-06-01 00:38:46.535849
NCT00967096|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-11-26|2009-08-26|2009-08-27|Estimate|||||||2013-11-26|2013-11-27|Estimate|April 2007||2007-04-30|November 2013|2013-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)|Rifaximin for Preventing Acute Graft Versus Host Disease|Completed||Phase 1|20|Actual|Emory University||1|||f||||t||||||||||2018-06-01 00:38:46.599789|2018-06-01 00:38:46.599789
NCT00967083|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2014-12-10|2009-08-26|2009-08-27|Estimate|||||||2014-12-10|2014-12-11|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Support Needs and Preferences of Family Caregivers of Lung Cancer Patients|Support Needs and Preferences of Family Caregivers of Lung Cancer Patients|Completed|||53|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 00:38:46.66703|2018-06-01 00:38:46.66703
NCT00967070|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-07-06|2009-08-25|2009-08-27|Estimate|||||||2012-07-06|2012-07-10|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Skin Sensitization Potential of a New Nicotine Patch|Study on the Skin Sensitization Potential of a New Nicotine Transdermal Therapeutic System (TTS). A Double Blind, Randomized, Repeat Patch Test, Single Center Phase I Study|Completed||Phase 1|257|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:38:46.737695|2018-06-01 00:38:46.737695
NCT00967057|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2013-08-09|2009-08-26|2009-08-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|October 2002||2002-10-31|January 2011|2011-01-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|||Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL)|Completed||Phase 3|470|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:38:46.814317|2018-06-01 00:38:46.814317
NCT00967044|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2014-09-02||2015-02-09|2009-08-25|2009-08-27|Estimate|2014-09-02|2014-09-10|Estimate||||2015-02-09|2015-02-26|Estimate|November 2009||2009-11-30|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||A total of 30 patients were evaluated in intention to treat based response analysis.|Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma|Phase I/II of Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma|Completed||Phase 1/Phase 2|31|Actual|M.D. Anderson Cancer Center|Initially intended to proceed to phase II at MTD, treatment interruptions were frequently required in participants treated at MTD for Grade 3/4 Thrombocytopenia so study amended to obtain more detailed safety data at MTD in expanded phase I study.|1|||f||||f||||||||||2018-06-01 00:38:46.927546|2018-06-01 00:38:46.927546
NCT00967031|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2013-01-17|2009-08-26|2009-08-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|April 2009||2009-04-30|January 2013|2013-01-31||||February 2012|Actual|2012-02-29||Interventional|||Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases|A Multicenter Phase II Clinical Trial Assessing the Efficacy of the Combination of Lapatinib and Capecitabine in Patients With Non Pretreated Brain Metastasis From HER2 Positive Breast Cancer|Completed||Phase 2|45|Actual|UNICANCER||1|||f||||f||||||||||2018-06-01 00:38:47.258254|2018-06-01 00:38:47.258254
NCT00967018|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2012-11-23||2013-01-02|2009-08-26|2009-08-27|Estimate|2012-11-23|2012-12-24|Estimate||||2013-01-02|2013-01-03|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||A Long Term Safety Study of Degarelix in Patients With Prostate Cancer|A Phase IIIb, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients With Prostate Cancer|Completed||Phase 3|77|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:38:47.360527|2018-06-01 00:38:47.360527
NCT00967005|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2017-04-03||2017-06-29|2009-08-26|2009-08-27|Estimate|2017-06-29|2017-07-07|Actual||||2017-06-29|2017-07-07|Actual|September 2009||2009-09-30|June 2017|2017-06-30|August 2014|Actual|2014-08-31|September 2012|Actual|2012-09-30||Interventional|||N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers|N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers|Completed||Phase 2|28|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 00:38:47.714749|2018-06-01 00:38:47.714749
NCT00966823|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2015-07-03||2017-05-23|2009-08-26|2009-08-27|Estimate|2017-05-23|2017-05-30|Actual||||2017-05-23|2017-05-30|Actual|September 2008||2008-09-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Fetal Tracheal Balloon Study in Diaphragmatic Hernia|Phase 2 Fetal Tracheal Balloon (IDE G080077) Study in Diaphragmatic Hernia|Terminated||Phase 2|3|Actual|Rhode Island Hospital||1||Device no longer available|f||||t||||||||||2018-06-01 00:38:55.401012|2018-06-01 00:38:55.401012
NCT00966992|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2015-08-10||2015-08-10|2009-08-26|2009-08-27|Estimate|2015-08-10|2015-09-09|Estimate||||2015-08-10|2015-09-09|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer|Randomized Phase II Study of Zoledronic Acid vs Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer|Terminated||Phase 2|3|Actual|Washington University School of Medicine||2||Lack of enrollment|f||||f||||||||||2018-06-01 00:38:48.251214|2018-06-01 00:38:48.251214
NCT00966979|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2018-04-26|2009-08-25|2009-08-27|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2010||2010-01-31|April 2018|2018-04-30|June 2028|Anticipated|2028-06-30|June 2028|Anticipated|2028-06-30||Interventional|PKR||Triathlon® Partial Knee Replacement (PKR) Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Triathlon® Partial Knee Resurfacing (PKR) Unicondylar Knee System|Recruiting||N/A|184|Anticipated|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:38:48.507782|2018-06-01 00:38:48.507782
NCT00966966|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2010-08-18|2009-08-26|2009-08-27|Estimate|||||||2010-08-18|2010-08-20|Estimate|September 2009||2009-09-30|August 2010|2010-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered|An Open-Label, Nonrandomized Study To Evaluate The Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, A Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally To Healthy Young Adult Subjects|Completed||Phase 1|17|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 00:38:48.609012|2018-06-01 00:38:48.609012
NCT00966953|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2009-09-14|2009-07-20|2009-08-27|Estimate|2009-07-20|2009-08-27|Estimate||||2009-09-14|2009-09-22|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.|Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.|Completed||Phase 3|25|Actual|Colgate Palmolive||4|||f||||f||||||||||2018-06-01 00:38:48.690826|2018-06-01 00:38:48.690826
NCT00966940|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2011-02-09||2012-05-18|2009-08-26|2009-08-27|Estimate|2012-05-18|2012-06-20|Estimate||||2012-05-18|2012-06-20|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension|The Efficacy and Safety of Travoprost, 0.004% Versus Tafluprost, 0.0015% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients|Completed||Phase 4|51|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:38:49.026173|2018-06-01 00:38:49.026173
NCT00966927|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|November 2009|Anticipated|2009-11-30|||||Observational|||Assessment of Functional Independence and Quality of Life in Adolescents With Spina Bifid|Assessment of Functional Independence and Quality of Life in Italian Population of Adolescents With Spina Bifid|Unknown status|Recruiting||100|Anticipated|Arcispedale Santa Maria Nuova-IRCCS|||1||f||||t||||||||||2018-06-01 00:38:49.287697|2018-06-01 00:38:49.287697
NCT00966914|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-09-20|2009-08-25|2009-08-27|Estimate|||||||2017-09-20|2017-09-21|Actual|April 2010||2010-04-30|September 2017|2017-09-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin|Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin|Completed||Phase 3|540|Actual|BioNumerik Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 00:38:49.37454|2018-06-01 00:38:49.37454
NCT00966901|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-07-06|2009-08-25|2009-08-27|Estimate|||||||2012-07-06|2012-07-10|Estimate|August 2005||2005-08-31|July 2012|2012-07-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Photoirritation and Photoallergic Potential of a New Nicotine Patch|Assessment of Photoirritation and Photoallergic Potential of a Newly Developed Nicotine Transdermal Therapeutic System (TTS) After Single and Multiple Application and Multiple UV Exposure in Healthy Subjects. A Standard Photocontact Allergenicity Assay.|Completed||Phase 1|43|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:38:49.56692|2018-06-01 00:38:49.56692
NCT00966888|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2013-08-09|2009-08-26|2009-08-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|January 2006||2006-01-31|August 2009|2009-08-31||||June 2010|Anticipated|2010-06-30||Interventional|||Radiation Therapy or Standard Therapy in Treating Women With Stage II Breast Cancer Who Have Undergone Mastectomy|Selective Use of Postoperative Radiotherapy AftEr MastectOmy - SUPREMO|Unknown status|Recruiting|Phase 3|3500|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:38:49.645948|2018-06-01 00:38:49.645948
NCT00966875|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2016-04-20|2011-08-09|2016-04-20|2009-08-25|2009-08-27|Estimate|2016-04-20|2016-05-26|Estimate|2011-08-09|2011-08-15|Estimate|2016-04-20|2016-05-26|Estimate|August 2009||2009-08-31|April 2016|2016-04-30|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional||Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug.|A Study in Patients With Rheumatoid Arthritis|A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients With Active Rheumatoid Arthritis on Concomitant DMARD Therapy|Completed||Phase 2|448|Actual|Eli Lilly and Company||9|||f||||f||||||||||2018-06-01 00:38:49.844639|2018-06-01 00:38:49.844639
NCT00966862|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|September 2009||2009-09-30|May 2009|2009-05-31|May 2010||2010-05-31|February 2010|Anticipated|2010-02-28||Interventional|||The Glycemic Effect of Taking a Supplementation of Orange Juice With Fibers||Unknown status|Not yet recruiting|Phase 1/Phase 2|||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 00:38:55.169489|2018-06-01 00:38:55.169489
NCT00966849|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2015-12-22|2009-08-26|2009-08-27|Estimate|||||||2015-12-22|2015-12-23|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Manicaland Cash Transfer Trial|The Scientific Evaluation of a Cash Transfer Pilot Project to Support Orphans and Vulnerable Children (OVC) in Manicaland, Zimbabwe|Completed||N/A|4043|Actual|Imperial College London||3|||f||||f||||||||||2018-06-01 00:38:55.229788|2018-06-01 00:38:55.229788
NCT00966836|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|April 2009||2009-04-30|August 2009|2009-08-31||||April 2012|Anticipated|2012-04-30||Interventional|PROTECT||Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy|Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy|Unknown status|Recruiting|Phase 3|100|Anticipated|University of Bologna||4|||f||||f||||||||||2018-06-01 00:38:55.314418|2018-06-01 00:38:55.314418
NCT00966810|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|December 1999||1999-12-31|January 2009|2009-01-31|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion|Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion and Preemptive Donor Lymphocyte Infusion.|Unknown status|Active, not recruiting|Phase 2/Phase 3|40|Actual|Rambam Health Care Campus||1|||f||||f||||||||||2018-06-01 00:38:55.592924|2018-06-01 00:38:55.592924
NCT00966784|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||The Effect of 2 Months Daily Supplementation of Orange Juice With Fibers|The Effect of 2 Months Daily Supplementation of Orange Juice With Fibers|Unknown status|Not yet recruiting|Phase 1/Phase 2|50|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 00:38:55.768321|2018-06-01 00:38:55.768321
NCT00966771|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-02-02|2009-08-26|2009-08-27|Estimate|||||||2017-02-02|2017-02-06|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|IUD EC||The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception|Preventing Future Pregnancy After Choosing the Copper IUD vs. Oral Levonorgestrel for Emergency Contraception|Completed|||548|Actual|University of Utah|||2||f||||t||||||||No||2018-06-01 00:38:55.823848|2018-06-01 00:38:55.823848
NCT00966758|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2010-09-15|2009-08-26|2009-08-27|Estimate|||||||2010-09-15|2010-09-16|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Open, Prospective Pilot Study to Obtain Aerosol Distribution in Asthmatic Patients Using Single Photon Emission Computed Tomography (SPECT) for Comparison With Functional Imaging Using Computer Methods|Open, Prospective Pilot Study to Obtain Aerosol Distribution in Asthmatic Patients Using SPECT-CT for Comparison With Functional Imaging Using Computer Methods|Completed||N/A|6|Actual|University Hospital, Antwerp||1|||f||||f||||||||||2018-06-01 00:38:55.905995|2018-06-01 00:38:55.905995
NCT00966745|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Milrinone During Living Donor Hepatectomy|Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique|Completed||N/A|38|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:38:55.963403|2018-06-01 00:38:55.963403
NCT00966732|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2014-10-14|2009-08-26|2009-08-27|Estimate|||||||2014-10-14|2014-10-16|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Yoga for Fibromyalgia|Yoga of Awareness Program for Fibromyalgia: A Randomized Clinical Trial|Completed||N/A|68|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 00:38:56.018648|2018-06-01 00:38:56.018648
NCT00966719|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2016-01-28|2009-08-26|2009-08-27|Estimate|||||||2016-01-28|2016-01-29|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Breastfeeding Support Intervention in Jaundiced Infants|The Impact of a Breastfeeding Support Intervention on Breastfeeding Duration in Jaundiced Infants Admitted to a Tertiary Care Centre: a Randomized Controlled Trial.|Completed||N/A|99|Actual|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-06-01 00:38:56.082689|2018-06-01 00:38:56.082689
NCT00966706|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2012-01-31|2009-08-26|2009-08-27|Estimate|||||||2012-01-31|2012-02-01|Estimate|June 2005||2005-06-30|August 2009|2009-08-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|PACT-9||Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer|PEXG (Cisplatin, Epirubicin, Capecitabine, Gemcitabine) Versus PDXG (Cisplatin, Docetaxel, Capecitabine, Gemcitabine) in Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial|Completed||Phase 2|105|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-06-01 00:38:56.218734|2018-06-01 00:38:56.218734
NCT00966693|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2017-07-06|2009-08-26|2009-08-27|Estimate|||||||2017-07-06|2017-07-11|Actual|August 2009|Actual|2009-08-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Lenalidomide, Thalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|64|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:38:56.306755|2018-06-01 00:38:56.306755
NCT00966680|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2014-03-14|2009-08-26|2009-08-27|Estimate|||||||2014-03-14|2014-03-17|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||How Fast Are we? Speed of General Versus Spinal Anesthesia for Emergency Cesarean Delivery: A Simulation Based Study|Speed of General Versus Spinal Anesthesia for Emergency Cesarean Delivery: A Simulation Based Study|Completed|||19|Actual|University of British Columbia|||1||f||||t||||||None Retained|"~     16 anesthesiologists will be recruited for the simulation part. 100 women having elective~     cesarean delivery will be timed in the clinical part.~   "|||2018-06-01 00:38:56.399381|2018-06-01 00:38:56.399381
NCT00966667|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2017-11-15|2009-08-26|2009-08-27|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2009||2009-11-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer|Health Behaviors Among Individuals Diagnosed With Colorectal Cancer|Active, not recruiting|||222|Anticipated|Rutgers, The State University of New Jersey|||1||f||||f||||||||||2018-06-01 00:38:56.466354|2018-06-01 00:38:56.466354
NCT00966654|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2017-05-01||2017-06-29|2009-08-26|2009-08-27|Estimate|2017-06-29|2017-07-12|Actual||||2017-06-29|2017-07-12|Actual|September 2008|Actual|2008-09-30|June 2017|2017-06-30|September 2012|Actual|2012-09-30|August 2009|Actual|2009-08-31||Interventional|GLP-1 CABG|Although 12 participants were enrolled in this study, their assignment to study arm/group, if any, is unknown. The P.I. has left the institution and neither he, nor further data (if any), are available.|Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery|Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass Surgery|Terminated||Phase 2|12|Actual|Johns Hopkins University||2||PI left JHU|f||||f||||||||||2018-06-01 00:38:56.843291|2018-06-01 00:38:56.843291
NCT00966641|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2015-06-22||2015-08-06|2009-08-25|2009-08-27|Estimate|2015-08-06|2015-09-07|Estimate||||2015-08-06|2015-09-07|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults|"A Single-Dose Crossover Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adult Volunteers in the Fasted State"|Completed||Phase 1/Phase 2|34|Actual|PLx Pharma||2|||f||||t||||||||||2018-06-01 00:38:56.994882|2018-06-01 00:38:56.994882
NCT00767533|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2016-07-20|2008-10-06|2008-10-07|Estimate|||||||2016-07-20|2016-07-22|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Immunobiology of Cancer|Immunobiology of Cancer|Terminated|||84|Actual|Stanford University||||PI left|f||||t||||||Samples With DNA|"~     peripheral blood mononuclear cells~   "|||2018-06-01 01:41:44.770252|2018-06-01 01:41:44.770252
NCT00966628|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-27|2009-08-26|2009-08-27|Estimate|||||||2009-08-27|2009-08-28|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)|The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients|Unknown status|Active, not recruiting|Phase 3|50|Actual|Innogene Kalbiotech Pte. Ltd||2|||f||||f||||||||||2018-06-01 00:38:57.13702|2018-06-01 00:38:57.13702
NCT00966615|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2014-09-04|2009-08-26|2009-08-27|Estimate|||||||2014-09-04|2014-09-08|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition|The Effect of Neutral Peritoneal Dialysis Solution With Minimal Glucose-Degradation-Product on the Fluid Status and Body Composition - A Randomized Control Trial|Completed||Phase 4|68|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:38:57.228059|2018-06-01 00:38:57.228059
NCT00966602|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-01-02|2009-08-25|2009-08-27|Estimate|||||||2010-01-02|2010-01-05|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects|Completed||Phase 1|24|Anticipated|Vertex Pharmaceuticals Incorporated||3|||f||||f||||||||||2018-06-01 00:38:57.302547|2018-06-01 00:38:57.302547
NCT00966589|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2017-03-07|2009-08-26|2009-08-27|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2008||2008-01-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Surgical or Conservative Treatment of Sportsman Hernia|Chronic Groin Pain and Sportsman Hernia of Athletes: Randomized Study Between Conservative Treatment and Laparoscopic Hernioplasty (TEP)|Completed||N/A|50|Actual|Kuopio University Hospital||2|||f||||t||||||||Undecided||2018-06-01 00:38:57.446856|2018-06-01 00:38:57.446856
NCT00966576|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2016-11-18|2009-08-26|2009-08-27|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy|The Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (Azarga®) to Prostaglandin Monotherapy|Completed||Phase 4|47|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:38:57.529414|2018-06-01 00:38:57.529414
NCT00966563|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2013-07-15|2009-08-26|2009-08-27|Estimate|||||||2013-07-15|2013-07-16|Estimate|December 2009||2009-12-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|MANAMI||Mangafodipir as an Adjunct to Percutaneous Coronary Intervention|Mangafodipir as an Adjunct to Percutaneous Coronary Intervention in Acute Myocardial Infarction (MANAMI)|Completed||Phase 2|20|Actual|PledPharma AB||2|||f||||f||||||||||2018-06-01 00:38:57.613526|2018-06-01 00:38:57.613526
NCT00966550|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|2014-08-20||2017-02-03|2009-08-26|2009-08-27|Estimate|2014-10-13|2014-10-16|Estimate||||2017-02-03|2017-03-14|Actual|August 2009||2009-08-31|February 2017|2017-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|TOM|A total of twenty five subjects completed the crossover study (n = 12 females, n = 13 males).|A Study of Tomato Products and Disease Risk|Tomato Products and Postprandial Oxidation and Inflammation: a Clinical Trial in Healthy Weight Men and Women|Completed||N/A|25|Actual|Institute for Food Safety and Health, United States|Acute study; Chronic effect should be investigated.|2|||f||||f||||||||Undecided||2018-06-01 00:38:57.694641|2018-06-01 00:38:57.694641
NCT00966537|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-26|2009-08-26|2009-08-27|Estimate|||||||2009-08-26|2009-08-27|Estimate|May 2008||2008-05-31|August 2009|2009-08-31||||||||Observational|||The 3-Dimensional Ultrasound for Fetal Anomaly Scan|The 3-Dimensional Ultrasound for Fetal Anomaly Scan.|Unknown status|Recruiting||600|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 00:38:57.876921|2018-06-01 00:38:57.876921
NCT00966524|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-06-10|2009-08-25|2009-08-27|Estimate|||||||2010-06-10|2010-06-11|Estimate|January 2010||2010-01-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Learning and Retention of Tracheal Intubation by Medical Students: Comparison of Standard Intubation Teaching Against Video-guided Intubation Teaching.|Learning and Retention of Tracheal Intubation by Medical Students: Comparison of Standard Intubation Teaching Against Video-guided Intubation Teaching.|Completed||N/A|18|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 00:38:57.973695|2018-06-01 00:38:57.973695
NCT00966511|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2011-02-08|2009-08-26|2009-08-27|Estimate|||||||2011-02-08|2011-02-09|Estimate|June 2009||2009-06-30|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Vibration Response Imaging (VRI) in Patients Who Are Potential Candidates for Surgical Resection|Vibration Response Imaging (VRI) in Patients Who Are Potential Candidates for Surgical Resection|Unknown status|Enrolling by invitation||200|Anticipated|Deep Breeze|||1||f||||t||||||||||2018-06-01 00:38:58.05438|2018-06-01 00:38:58.05438
NCT00966498|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-12-09|2009-08-25|2009-08-27|Estimate|||||||2013-12-09|2013-12-11|Estimate|May 2003||2003-05-31|December 2013|2013-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors|Peripheral Blood Stem Cell Transplantation in Children With High-Risk or Recurrent Solid Tumors|Terminated||N/A|3|Actual|Emory University||1||poor enrollment|f||||t||||||||||2018-06-01 00:38:58.1333|2018-06-01 00:38:58.1333
NCT00966485|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-25|2009-08-25|2009-08-27|Estimate|||||||2009-08-25|2009-08-27|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting||Completed||N/A|106|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:38:58.200074|2018-06-01 00:38:58.200074
NCT00966472|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2017-04-26|2009-08-26|2009-08-27|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2009||2009-03-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC|A Phase I, Dose Finding Study of the Combination of High-dose Statin Agent (Rosuvastatin) With Erlotinib in Patients With Advanced Solid Malignancies, With a Focus on Squamous Cell Carcinomas and NSCLC.|Completed||Phase 1|24|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-06-01 00:38:58.270421|2018-06-01 00:38:58.270421
NCT00966459|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-26|||2009-08-31|2009-08-26|2009-08-27|Estimate|||||||2009-08-31|2009-09-01|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Computed Tomography (CT) and Lung Function Data Collection for Computational Fluid Dynamics (CFD) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Computed Tomography (CT) and Lung Function Data Collection for Computational Fluid Dynamics (CFD) in COPD Patients|Completed||N/A|20|Actual|University Hospital, Antwerp||1|||f||||f||||||||||2018-06-01 00:38:58.339834|2018-06-01 00:38:58.339834
NCT00966446|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2015-12-01||2018-02-05|2009-08-26|2009-08-27|Estimate|2016-05-20|2016-06-29|Estimate||||2018-02-05|2018-02-07|Actual|September 2009||2009-09-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community|Epidemiology and Prevention of MRSA Transmission in the Community|Completed||N/A|223|Actual|University of Pennsylvania||3|||f||||t||||||||No||2018-06-01 00:38:58.407463|2018-06-01 00:38:58.407463
NCT00966433|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-11-02|2009-08-26|2009-08-27|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2009||2009-08-31|November 2017|2017-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Comparison of Different Ventilation Strategies in Children Using the Proseal™ Laryngeal Mask Airway|A Comparison of Different Ventilation Strategies in Children Using the Proseal™ Laryngeal Mask Airway|Completed||N/A|33|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||No||2018-06-01 00:38:58.857639|2018-06-01 00:38:58.857639
NCT00966420|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-03-27|2009-08-25|2009-08-27|Estimate|||||||2010-03-27|2010-03-30|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|TAEMR||Traction Assisted Polypectomy of the Intestine|Traction Assisted Endoscopic Mucosa Resection (TAEMR)|Completed||N/A|7|Actual|St John of God Hospital, Vienna||1|||f||||f||||||||||2018-06-01 00:38:59.061859|2018-06-01 00:38:59.061859
NCT00966407|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-02-08|2009-08-24|2009-08-26|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2007|Actual|2007-02-28|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|AIMMY||Assessing Inherited Markers of Metabolic Syndrome in the Young|Assessing Inherited Markers of Metabolic Syndrome in the Young|Completed|||700|Actual|Children's Research Institute|||1||f||||f||||||Samples With DNA|"~     Blood samples are obtained for DNA extraction and measuring various biomarkers (including~     fasting glucose, insulin, lipid profile, and hemoglobin A1c)~   "|||2018-06-01 00:38:59.146854|2018-06-01 00:38:59.146854
NCT00966394|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-05-25|2009-08-25|2009-08-26|Estimate|||||||2010-05-25|2010-05-26|Estimate|November 2009||2009-11-30|August 2009|2009-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|ADHD||Salivary Bacteria and Oral Health Status in Children With ADHD|Changes in Salivary Bacteria and Oral Health Status in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Completed|||150|Anticipated|Hadassah Medical Organization|||3||f||||f||||||None Retained|"~     saliva~   "|||2018-06-01 00:38:59.210647|2018-06-01 00:38:59.210647
NCT00966381|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-08-25|2009-08-25|2009-08-26|Estimate|||||||2009-08-25|2009-08-26|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|BEHIP||Breastfeeding and Exercise for Healthy Infants and Postpartum Moms Too!|Breastfeeding and Exercise for Healthy Infants and Postpartum Moms Too!|Unknown status|Recruiting|N/A|44|Anticipated|University of North Carolina, Greensboro||2|||f||||t||||||||||2018-06-01 00:38:59.269803|2018-06-01 00:38:59.269803
NCT00966368|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2015-09-24|2009-08-25|2009-08-26|Estimate|||||||2015-09-24|2015-09-28|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of Two NN1250 Formulations in Healthy Volunteers|A Trial to Test for Bioequivalence Between Two NN1250 Formulations in Healthy Subjects|Completed||Phase 1|27|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:38:59.357259|2018-06-01 00:38:59.357259
NCT00966355|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2013-04-23||2017-08-22|2009-08-25|2009-08-26|Estimate|2017-08-22|2018-03-19|Actual||||2017-08-22|2018-03-19|Actual|September 2006||2006-09-30|August 2017|2017-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding|RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide|Completed||Phase 4|1034|Actual|Korea University||3|||f||||f||||||||||2018-06-01 00:38:59.444061|2018-06-01 00:38:59.444061
NCT00966342|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-10-21|2009-08-24|2009-08-26|Estimate|||||||2009-10-21|2009-10-23|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Interventional|||Rapid Evaluation of Seasonal Influenza Vaccine|Post-marketing Surveillance of Annual Influenza Vaccines: Extended Vaccine Safety and Immunogenicity Evaluation|Withdrawn||Phase 1|300|Anticipated|University of British Columbia||1||New studies are being offered|f||||f||||||||||2018-06-01 00:38:59.713636|2018-06-01 00:38:59.713636
NCT00966329|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2013-01-23|2009-08-25|2009-08-26|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects|Pilot Study to Assess the Safety and Efficacy of Switching the Nnrti or pi to Maraviroc in Hiv-1-infected Subjects With Persistent Viremia Suppression|Completed||Phase 4|30|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 00:38:59.838588|2018-06-01 00:38:59.838588
NCT00966316|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2011-05-14|2009-08-25|2009-08-26|Estimate|||||||2011-05-14|2011-05-17|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|PAIS||Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke|Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke|Completed||Phase 4|314|Actual|Guangzhou University of Traditional Chinese Medicine||1|||f||||t||||||||||2018-06-01 00:38:59.912663|2018-06-01 00:38:59.912663
NCT00966303|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-10-05|2009-08-25|2009-08-26|Estimate|||||||2009-10-05|2009-10-06|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Cardiac Rehabilitation in Cardiomyopathies|The Effectiveness of a Cardiac Rehabilitation in Patients With Cardiomyopathy|Completed||N/A|9|Actual|Fortaleza University||1|||f||||t||||||||||2018-06-01 00:38:59.9937|2018-06-01 00:38:59.9937
NCT00966290|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2009-08-25|2009-08-25|2009-08-26|Estimate|||||||2009-08-25|2009-08-26|Estimate|February 2003||2003-02-28|August 2009|2009-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|COMPARE||Anticoagulant Clinics and Vitamin K Antagonists|Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study|Completed||Phase 4|1006|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-06-01 00:39:00.065743|2018-06-01 00:39:00.065743
NCT00966277|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2016-07-12||2016-10-20|2009-08-25|2009-08-26|Estimate|2016-10-20|2016-12-12|Estimate||||2016-10-20|2016-12-12|Estimate|April 2010||2010-04-30|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients|Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.|Completed||Phase 4|87|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:39:00.154484|2018-06-01 00:39:00.154484
NCT00966264|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2009-01-20||2009-08-26|2009-07-24|2009-08-26|Estimate|2009-07-24|2009-08-26|Estimate||||2009-08-26|2009-09-02|Estimate|October 1994||1994-10-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|VUOKKO||Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia|Hysterectomy and Levonorgestrel-releasing IUS in the Treatment of Menorrhagia|Completed||Phase 3|236|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 00:39:00.456401|2018-06-01 00:39:00.456401
NCT00966251|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-10-22|2009-08-25|2009-08-26|Estimate|||||||2012-10-22|2012-10-23|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma|Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|2|Actual|CureTech Ltd||1||The study was stopped because of slow accrual|f||||f||||||||||2018-06-01 00:39:00.692675|2018-06-01 00:39:00.692675
NCT00966238|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2011-06-13||2014-09-22|2009-08-24|2009-08-26|Estimate|2011-06-13|2011-07-14|Estimate||||2014-09-22|2014-10-02|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age|A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults ≥65 Years of Age|Completed||Phase 2|120|Actual|VaxInnate Corporation||1|||f||||f||||||||||2018-06-01 00:39:00.774613|2018-06-01 00:39:00.774613
NCT00966225|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2012-01-26|2009-08-24|2009-08-26|Estimate|||||||2012-01-26|2012-01-31|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||LIP-01 in Hypercholesterolemia|An Open-label Dose-finding Study of LIP-01 in Otherwise Healthy Individuals With Hypercholesterolemia|Completed||Phase 1|40|Actual|Afexa Life Sciences Inc||3|||f||||f||||||||||2018-06-01 00:39:01.239829|2018-06-01 00:39:01.239829
NCT00966212|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-06-29|2009-08-25|2009-08-26|Estimate|||||||2012-06-29|2012-07-03|Estimate|September 2003||2003-09-30|June 2012|2012-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Parent Education for Young Teen Females|Reducing Alcohol & Risks Among Young Females|Completed||Phase 2/Phase 3|500|Actual|Education Development Center, Inc.||2|||f||||f||||||||||2018-06-01 00:39:01.295753|2018-06-01 00:39:01.295753
NCT00966199|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-25|2009-08-25|2009-08-26|Estimate|||||||2009-08-25|2009-08-26|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|MBRACE||The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population|Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Radboud University||1|||f||||f||||||||||2018-06-01 00:39:01.347932|2018-06-01 00:39:01.347932
NCT00966186|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2010-01-04||2010-07-21|2009-08-24|2009-08-26|Estimate|2010-07-21|2010-08-16|Estimate||||2010-07-21|2010-08-16|Estimate|November 2008||2008-11-30|July 2010|2010-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||The Rotational Insertion Technique for ProSeal Laryngeal Mask Airway|The 90-degree Rotational Insertion Technique for the Large Size ProSeal Laryngeal Mask Airway|Completed||N/A|120|Actual|Seoul National University Hospital|First, as the PLMAs were inserted by two anesthesiologists who were experts in PLMA insertion, these results may not apply to novices. Second, the insertion technique was impossible to blind the anesthesiologists, which might be a source of bias.|2|||f||||t||||||||||2018-06-01 00:39:01.41902|2018-06-01 00:39:01.41902
NCT00966173|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-08-10|2009-08-25|2009-08-26|Estimate|||||||2010-08-10|2010-08-11|Estimate|December 2005||2005-12-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||International Melanoma Algorithm Training Study - IMATS|An International, Multicenter, Prospective, Non-controlled, Non-randomised, Clinical Study to Collect Impedance Data of Potentially Malignant Pigmented Nevi and Histological Diagnoses|Completed||N/A|1800|Anticipated|SciBase AB|||||f||||f||||||||||2018-06-01 00:39:01.609374|2018-06-01 00:39:01.609374
NCT00966160|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-09-28|2009-08-25|2009-08-26|Estimate|||||||2009-09-28|2009-09-29|Estimate|January 1999||1999-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes|Phase 3, Single Center, Controlled, Investigator-blinded, Randomized Matched Pair Design Study of CD4 Cell Recovery in HIV-1 Patients With Sustained Virologic Response Comparing Protease Inhibitor and Non-nucleoside Reverse Transcriptase Inhibitor Based Treatment Regimes|Completed||Phase 3|215|Actual|University of Cologne||2|||f||||||||||||||2018-06-01 00:39:01.654597|2018-06-01 00:39:01.654597
NCT00966147|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-08-25|2009-08-25|2009-08-26|Estimate|||||||2009-08-25|2009-08-26|Estimate|October 2009||2009-10-31|July 2009|2009-07-31||||||||Interventional|||Advanced Hemodynamic Monitoring for Goal-directed Hemodynamic Management During Radical Cystectomy|Advanced Hemodynamic Monitoring for Goal-directed Hemodynamic Management During Radical Cystectomy|Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 00:39:01.717079|2018-06-01 00:39:01.717079
NCT00966134|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-02-22|2009-08-25|2009-08-26|Estimate|||||||2010-02-22|2010-02-23|Estimate|April 2002||2002-04-30|August 2009|2009-08-31|September 2005|Actual|2005-09-30|||||Observational|||Ghrelin, Growth Hormone and Growth Factors at High Altitude||Completed|||||Medical University of Vienna|||1||f||||||||||||||2018-06-01 00:39:01.914273|2018-06-01 00:39:01.914273
NCT00966121|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-08-22|2009-08-25|2009-08-26|Estimate|||||||2017-08-22|2017-08-23|Actual|August 2008||2008-08-31|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Endoscopic Band Ligation (EBL) Versus Endoscopic Band Ligation and Propranolol for the Prevention of Variceal Rebleeding|RCT Comparing the Efficacies of Endoscopic Variceal Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding|Recruiting||Phase 4|180|Anticipated|Korea University||2|||f||||f||||||||||2018-06-01 00:39:01.968895|2018-06-01 00:39:01.968895
NCT00966108|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-02-03|2009-08-24|2009-08-26|Estimate|||||||2010-02-03|2010-02-04|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|09/02||SENSIMED Triggerfish Discomfort During IOP Monitoring|Evaluation of SENSIMED Triggerfish for 24 Hour IOP Monitoring in Healthy Subjects and Glaucoma Patients|Completed|||40|Actual|Sensimed AG|||2||f||||f||||||||||2018-06-01 00:39:02.041578|2018-06-01 00:39:02.041578
NCT00966095|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-11-23|2009-08-24|2009-08-26|Estimate|||||||2010-11-23|2010-11-25|Estimate|December 2009||2009-12-31|November 2010|2010-11-30||||||||Observational|PReCISE||PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy|A Prospective, Multi-Center PRostate Cancer Individual Signature Evaluation Trial (PReCISE) in Patients Undergoing Scheduled Prostate Biopsy|Unknown status|Active, not recruiting||1200|Anticipated|Source MDx|||1||f||||f||||||Samples Without DNA|"~     whole blood for gene expression analysis~      serum~      plasma~   "|||2018-06-01 00:39:02.107216|2018-06-01 00:39:02.107216
NCT00966082|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-08-21|2009-08-25|2009-08-26|Estimate|||||||2017-08-21|2017-08-22|Actual|August 2008||2008-08-31|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||EBL Versus EBL and Propranolol for the Prevention of Variceal Rebleeding in Pts With Previous Variceal Treatment|RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment|Recruiting||Phase 4|180|Anticipated|Korea University||2|||f||||f||||||||||2018-06-01 00:39:02.190529|2018-06-01 00:39:02.190529
NCT00966069|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2016-03-16|2009-08-25|2009-08-26|Estimate|||||||2016-03-16|2016-03-17|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|ReSPeCT||A Comparison of Respiratory Sample Collection by a Parent or by a Healthcare Worker|ReSPeCT: An Unblinded, Randomised, Controlled Trial to Compare Respiratory Sample Collection by a Parent or by a Healthcare Worker at a Home Visit|Completed||N/A|64|Actual|Queensland Children's Medical Research Institute||2|||f||||f||||||||No||2018-06-01 00:39:02.258026|2018-06-01 00:39:02.258026
NCT00966056|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2011-07-07|2009-08-25|2009-08-26|Estimate|||||||2011-07-07|2011-07-08|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|||Study of Mitomycin C and Nasal Splint to Treat Nasal Synechiae|Comparative Study of Mitomycin C and Internal Nasal Septal Splint in the Treatment of Nasal Synechiae|Completed||Phase 2|60|Actual|Karnataka Institute of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:39:02.383242|2018-06-01 00:39:02.383242
NCT00966043|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-10-27|2009-08-24|2009-08-26|Estimate|||||||2015-10-27|2015-10-28|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|CYPTAMBRUT-3||Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes|Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes, in Postmenopausal ER-positive Breast Cancer Patients According to Uterine and Biochemical Changes and Tolerability of Tamoxifen.|Completed|||158|Actual|Vlaamse Vereniging voor Obstetrie en Gynaecologie|||||f||||t||||||||||2018-06-01 00:39:02.471243|2018-06-01 00:39:02.471243
NCT00966030|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-07-03|2009-08-24|2009-08-26|Estimate|||||||2015-07-03|2015-07-07|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042)|An Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate Vs. a Single Dose of the Reference MK0974 Liquid Filled Capsule in Healthy Subjects|Completed||Phase 1|50|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:39:02.549905|2018-06-01 00:39:02.549905
NCT00966017|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-12-23|2009-08-24|2009-08-26|Estimate|||||||2009-12-23|2009-12-29|Estimate|July 2009||2009-07-31|December 2009|2009-12-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia|Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia|Unknown status|Recruiting||108|Anticipated|National Institute on Aging (NIA)|||2||f||||t||||||||||2018-06-01 00:39:02.618145|2018-06-01 00:39:02.618145
NCT00966004|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-02-14|2009-08-24|2009-08-26|Estimate|||||||2017-02-14|2017-02-16|Actual|July 2009||2009-07-31|February 2017|2017-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder|Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder|Completed||Phase 3|1139|Actual|Astellas Pharma Inc||3|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:39:02.699659|2018-06-01 00:39:02.699659
NCT00965991|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-06-23|2009-08-24|2009-08-26|Estimate|||||||2010-06-23|2010-06-25|Estimate|July 2003||2003-07-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Metformin Compared to Glyburide in Gestational Diabetes|A Randomized Prospective Trial of Metformin Compared to Glyburide in Gestational Diabetes|Completed||N/A|149|Actual|University of New Mexico||2|||f||||f||||||||||2018-06-01 00:39:02.794146|2018-06-01 00:39:02.794146
NCT00965978|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-10-01|2009-08-25|2009-08-26|Estimate|||||||2009-10-01|2009-10-05|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation|A Study to Evaluate Food Effect on Pharmacokinetics Parameters After Administration of ONO-5920/YM529 Intermittent Formulation|Completed||Phase 1|48|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:39:02.878567|2018-06-01 00:39:02.878567
NCT00965965|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2012-04-26|2009-08-24|2009-08-26|Estimate|||||||2012-04-26|2012-04-27|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Comprehensibility of Colorectal Cancer Screening Educational Materials: Effects on Patient Knowledge and Motivation|Effects of Comprehensibility of Colorectal Cancer Screening Educational Materials on Patient Knowledge and Motivation: A Randomized Controlled Trial|Completed||N/A|60|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 00:39:02.95048|2018-06-01 00:39:02.95048
NCT00965952|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2010-02-09|2009-08-25|2009-08-26|Estimate|||||||2010-02-09|2010-02-10|Estimate|July 2009||2009-07-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A Surgical Simulation Study to Evaluate the Safety of a Device Mechanism as Treatment for Vaginal Apical Prolapse|A Prospective, Observational Surgical Simulation Study to Evaluate the Safety of the VFIX Device Mechanism as Treatment for Vaginal Apical Prolapse|Completed|||49|Actual|Ethicon, Inc.|||||f||||f||||||||||2018-06-01 00:39:03.029308|2018-06-01 00:39:03.029308
NCT00965939|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-10-27|2009-08-24|2009-08-26|Estimate|||||||2015-10-27|2015-10-28|Estimate|February 2009||2009-02-28|October 2015|2015-10-31||||December 2014|Actual|2014-12-31||Observational|CYPTAMBRUT-2||An Observational Study to Assess Response to Tamoxifen in Breast Cancer Patients|Study to Assess Response to Tamoxifen in (cT3)/ Inoperable Locally Advanced / Metastatic ER-positive Breast Cancer by the 'Tamoxifen Activity Score' Based on Drug Interaction and Polymorphisms in Genes Coding for Tam. Metabolising Enzymes.|Completed|||300|Actual|Vlaamse Vereniging voor Obstetrie en Gynaecologie|||||f||||t||||||||||2018-06-01 00:39:03.095775|2018-06-01 00:39:03.095775
NCT00965926|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-07-15|2009-08-24|2009-08-26|Estimate|||||||2013-07-15|2013-07-17|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers|A Pharmacokinetic Study in Healthy Non-elderly Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of YM178|Completed||Phase 1|72|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:39:03.167186|2018-06-01 00:39:03.167186
NCT00765167|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2008-10-02|2008-09-30|2008-10-02|Estimate|||||||2008-10-02|2008-10-03|Estimate|November 2007||2007-11-30|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Training and Calibration of Dental Examiners|Training and Calibration of Dental Examiners|Completed||Phase 3|18|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 01:42:15.519109|2018-06-01 01:42:15.519109
NCT00965913|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-06-27|2009-08-25|2009-08-26|Estimate|||||||2012-06-27|2012-06-29|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|June 2005|Actual|2005-06-30|May 2005|Actual|2005-05-31||Interventional|||Cumulative Skin Irritation Potential of a New 15 mg Nicotine Patch|Study on the Cumulative Skin Irritation Potential of a Newly Developed 15 mg Nicotine Transdermal Therapeutic System. A Double Blind, Randomized, Repeat Patch Test, Single Center Study in 42 Healthy Male and Female Subjects|Completed||Phase 1|42|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:39:03.235442|2018-06-01 00:39:03.235442
NCT00965900|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2017-08-22|2009-08-25|2009-08-26|Estimate|||||||2017-08-22|2017-08-23|Actual|September 2006||2006-09-30|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding|Randomized Controlled Trial Comparing Propranolol, Endoscopic Banding Ligation, and Combined Treatment to Prevent First Variceal Hemorrhage in Patients With Liver Cirrhosis|Recruiting||Phase 4|288|Anticipated|Korea University||3|||f||||f||||||||||2018-06-01 00:39:03.309161|2018-06-01 00:39:03.309161
NCT00965887|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-07-03|2009-08-24|2009-08-26|Estimate|||||||2015-07-03|2015-07-07|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Bioequivalence of Two Tablet Forms of MK0974 (0974-045)|An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate vs. a Single Dose of a Tablet Form of MK0974 Hydrate in Healthy Subjects|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:39:03.386651|2018-06-01 00:39:03.386651
NCT00965874|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2018-04-18|2009-08-25|2009-08-26|Estimate|||||||2018-04-18|2018-04-20|Actual|November 2009|Actual|2009-11-30|April 2018|2018-04-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation|Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation : Randomised Controlled Double Blind Study (LOMAGHI Study)|Completed||Phase 3|450|Actual|University of Monastir||3|||f||||f||||||||Yes||2018-06-01 00:39:03.444899|2018-06-01 00:39:03.444899
NCT00965861|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-08-27|2009-08-25|2009-08-26|Estimate|||||||2013-08-27|2013-08-28|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||SCRI Tissue Testing Registry|SCRI Tissue Testing Registry|Terminated|||20|Actual|SCRI Development Innovations, LLC|||1|Replaced by a study with a similar design.|f||||f||||||Samples With DNA|"~     Potential retention of tissue blocks for future study.~   "|||2018-06-01 00:39:03.512128|2018-06-01 00:39:03.512128
NCT00965848|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2013-03-12||2013-09-27|2009-08-25|2009-08-26|Estimate|2013-07-25|2013-08-28|Estimate||||2013-09-27|2013-10-30|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||For Baseline characteristics, age and gender, number of participants evaluable was 264.|A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections|A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections|Completed||Phase 4|270|Actual|Janssen-Cilag Ltd.,Thailand||3|||f||||f||||||||||2018-06-01 00:39:03.594871|2018-06-01 00:39:03.594871
NCT00965835|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-12-23|2009-08-24|2009-08-26|Estimate|||||||2009-12-23|2009-12-29|Estimate|August 2009||2009-08-31|December 2009|2009-12-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome|Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome|Unknown status|Recruiting||40|Anticipated|National Institute on Aging (NIA)|||2||f||||t||||||||||2018-06-01 00:39:04.304759|2018-06-01 00:39:04.304759
NCT00965822|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-08-30|2009-08-25|2009-08-26|Estimate|||||||2012-08-30|2012-08-31|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population|A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population|Completed||Phase 2|293|Actual|Afexa Life Sciences Inc||2|||f||||f||||||||||2018-06-01 00:39:04.389702|2018-06-01 00:39:04.389702
NCT00965809|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2012-10-28|2009-08-25|2009-08-26|Estimate|||||||2012-10-28|2012-10-30|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Interventional|THC_PTSD||Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD)|Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD|Unknown status|Active, not recruiting|Phase 4|70|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 00:39:04.464609|2018-06-01 00:39:04.464609
NCT00965796|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-25|2009-08-25|2009-08-26|Estimate|||||||2009-08-25|2009-08-26|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Intraoperative Intravenous Lidocaine|Effect of Intraoperative Intravenous Lidocaine on Pain After Hysterectomy|Completed||N/A|40|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-06-01 00:39:04.526088|2018-06-01 00:39:04.526088
NCT00965783|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2013-09-04|2009-08-25|2009-08-26|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SDBO||Predictors of the Metabolic Effect of Sleep Loss|Predictors of the Metabolic Effect of Sleep Loss|Completed||N/A|30|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 00:39:04.593974|2018-06-01 00:39:04.593974
NCT00965770|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2018-05-01|2009-08-25|2009-08-26|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2011||2011-05-31|May 2018|2018-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Post Abortion IUD & Recurrent Abortion 2001-2004|Preventing Repeat Abortion: Is the Immediate Insertion of Intrauterine Devices Post-abortion a Cost-effective Option Associated With Fewer Repeat Abortions? Findings From 2001-2004 Data|Terminated|||1101|Actual|University of British Columbia|||1|This study is a retrospective chart review study, not a clinical trial.|f||||f||||||||||2018-06-01 00:39:04.65154|2018-06-01 00:39:04.65154
NCT00965757|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|2014-08-08||2015-11-19|2009-08-25|2009-08-26|Estimate|2015-06-15|2015-06-19|Estimate||||2015-11-19|2015-12-21|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Baseline characteristics are presented based on full analysis set, defined as all randomized patients who received at least one dose of study drug and from whom at least one assessment of efficacy under double-blind medication was available.|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|Completed||Phase 3|253|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 00:39:04.733617|2018-06-01 00:39:04.733617
NCT00965744|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2009-08-26|2009-08-25|2009-08-26|Estimate|||||||2009-08-26|2009-08-27|Estimate|January 2006||2006-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension||Completed||Phase 4|60|Actual|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-06-01 00:39:06.242375|2018-06-01 00:39:06.242375
NCT00965731|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2012-12-07||2015-10-06|2009-08-24|2009-08-26|Estimate|2012-12-07|2013-01-14|Estimate||||2015-10-06|2015-10-28|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|December 2011|Actual|2011-12-31||Interventional|||Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer|Phase 1/2, Open Label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Erlotinib With Or Without Pf 02341066 In Patients With Advanced Non Small Cell Adenocarcinoma Of The Lung.|Completed||Phase 1|27|Actual|Pfizer|The sponsor terminated phase 2 of this study; no data was collected during phase 2, leading to phase 2 outcomes not analyzed. The decision was based on strategic considerations regarding the clinical program only; there were no safety concerns.|2|||f||||f||||||||||2018-06-01 00:39:06.377999|2018-06-01 00:39:06.377999
NCT00965718|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2014-06-25||2017-10-31|2009-08-25|2009-08-26|Estimate|2014-09-14|2014-09-16|Estimate||||2017-10-31|2017-12-05|Actual|September 2009||2009-09-30|September 2014|2014-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer|"Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Activated T-lymphocyte (Immuncell-LC) Cell Therapy in Gemcitabine Refractory Advanced Pancreatic Cancer"|Completed||Phase 2|20|Actual|Green Cross Cell Corporation|||||f||||f||||||||||2018-06-01 00:39:08.110167|2018-06-01 00:39:08.110167
NCT00965705|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2018-04-18|2009-08-25|2009-08-26|Estimate|||||||2018-04-18|2018-04-20|Actual|June 2009|Actual|2009-06-30|April 2018|2018-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Stepped Care Treatment for Binge-Eating|Dialectical Behavior Therapy for Early Non-Responders to CBT|Completed||N/A|109|Actual|Temple University||3|||f||||t||||||||||2018-06-01 00:39:08.787918|2018-06-01 00:39:08.787918
NCT00965679|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-06-30|2009-08-24|2009-08-25|Estimate|||||||2017-06-30|2017-07-02|Actual|August 6, 2009||2009-08-06|May 27, 2010|2010-05-27|May 27, 2010||2010-05-27|||||Observational|||X-ray Fluoroscopy Fused With Computed Tomography (XFC) Technical Development|X-ray Fluoroscopy Fused With Computed Tomography (XFC) Technical Development|Completed|||1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:39:08.916857|2018-06-01 00:39:08.916857
NCT00965666|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2012-03-07|2009-08-24|2009-08-25|Estimate|||||||2012-03-07|2012-03-08|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia|Etanercept (Enbrel) in Children With Fanconi Anemia and Early Bone Marrow Failure: A Pilot Study|Completed||N/A|3|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 00:39:09.01925|2018-06-01 00:39:09.01925
NCT00965653|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2016-11-01|2009-08-21|2009-08-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|July 2011||2011-07-31|||||Interventional|||A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis|Open-label, Multicenter, Randomized, Parallel Study to Investigate pk, pd, Efficacy and Safety of Tocilizumab (TCZ, RO4877533) Following Subcutaneous Administration of TCZ 162 mg Weekly or Every Other Week in Combination With Methotrexate in Patients With Rheumatoid Arthritis|Completed||Phase 1|29|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:39:09.193958|2018-06-01 00:39:09.193958
NCT00965640|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-24|2009-08-24|2009-08-25|Estimate|||||||2009-08-24|2009-08-25|Estimate|December 2002||2002-12-31|August 2009|2009-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Treatment of Male Pattern Baldness With Botulinum Toxin|A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia|Completed||Phase 2|||The Crown Institute|||||f||||f||||||||||2018-06-01 00:39:09.335348|2018-06-01 00:39:09.335348
NCT00965627|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-08-27|2009-08-24|2009-08-25|Estimate|||||||2009-08-27|2009-08-28|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Observational|||Biology of Thymic Tumors|Biological Analysis of a Series of Thymoma and Thymic Carcinoma: Genetic Aberrations and Potential Therapy Targets.|Completed|||134|Actual|Istituto Clinico Humanitas|||||f||||f||||||Samples With DNA|"~     paraffin-embedded tumor specimens of patients~   "|||2018-06-01 00:39:09.501418|2018-06-01 00:39:09.501418
NCT00965614|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2012-12-20|2009-08-24|2009-08-25|Estimate|||||||2012-12-20|2012-12-21|Estimate||||November 2012|2012-11-30||||||||Expanded Access|||To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia|To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia|Available|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 00:39:09.626335|2018-06-01 00:39:09.626335
NCT00965601|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2012-04-05|2009-08-24|2009-08-25|Estimate|||||||2012-04-05|2012-04-06|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|NFR||A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia|A Pilot Study on the Use of Nociceptive Flexion Reflex for Fibromyalgia|Completed||Phase 4|30|Actual|Indiana University||2|||f||||f||||||||||2018-06-01 00:39:09.689326|2018-06-01 00:39:09.689326
NCT00965588|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-08-22|2009-08-24|2009-08-25|Estimate|||||||2011-08-22|2011-08-23|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease|A Phase I, Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of the UBITh AD Immunotherapeutic Vaccine (UB 311) in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|19|Actual|United Biomedical||1|||f||||t||||||||||2018-06-01 00:39:09.93661|2018-06-01 00:39:09.93661
NCT00965575|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2014-06-17|2009-08-24|2009-08-25|Estimate|||||||2014-06-17|2014-06-18|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pilot Study of Melatonin and Epilepsy|Melatonin and Sleep in Patients With Epilepsy|Completed||Phase 2|10|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 00:39:10.109833|2018-06-01 00:39:10.109833
NCT00965562|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2013-07-02||2015-03-03|2009-08-24|2009-08-25|Estimate|2015-02-10|2015-02-26|Estimate||||2015-03-03|2015-03-23|Estimate|September 2000||2000-09-30|February 2015|2015-02-28|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional||Participants with at least 2 follow up visits were included in analysis.|Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)|A Double-blind, Parallel Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)|Completed||N/A|49|Actual|Donaghue Medical Research Foundation|small sample size|3|||f||||t||||||||||2018-06-01 00:39:10.354334|2018-06-01 00:39:10.354334
NCT00965549|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-01-07|2009-08-24|2009-08-25|Estimate|||||||2013-01-07|2013-01-08|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|LanScape||Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients|Comparison of a Basal Plus One Insulin Regimen (Insulin Glargine/Insulin Glulisine) With a Biphasic Insulin Regimen (Insulin Aspart/Insulin Aspart Protamine 30/70) in Type 2 Diabetes Patients Following Basal Insulin Optimisation|Completed||Phase 4|463|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:39:14.613305|2018-06-01 00:39:14.613305
NCT00965536|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-02-15|2009-08-24|2009-08-25|Estimate|||||||2011-02-15|2011-02-16|Estimate|August 2009||2009-08-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Nis Register Study Comparing Seroquel and Seroquel Prolong|A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.|Completed|||200|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 00:39:15.112018|2018-06-01 00:39:15.112018
NCT00965523|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2011-12-22||2013-07-14|2009-08-24|2009-08-25|Estimate|2013-07-14|2013-08-15|Estimate||||2013-07-14|2013-08-15|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional||Demographic data were reported for 80 subjects, the Full Analysis Set, which is the primary efficacy analysis set in this study.|Study of E7389 for Advanced or Metastatic Breast Cancer|Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|81|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 00:39:15.321092|2018-06-01 00:39:15.321092
NCT00965510|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-09-29|2009-08-24|2009-08-25|Estimate|||||||2011-09-29|2011-09-30|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||SeaCare's Care Coordination for Diabetes Management in a Primary Care Office|Improved Management of Type II Diabetes in a Primary Care Office With Targeted Case Management|Terminated||N/A|50|Actual|SeaCare Health Services||2||insufficient recruitment of control and study patients|f||||t||||||||||2018-06-01 00:39:15.743657|2018-06-01 00:39:15.743657
NCT00965497|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2011-04-19||2011-08-04|2009-08-24|2009-08-25|Estimate|2011-08-04|2011-09-07|Estimate||||2011-08-04|2011-09-07|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Escitalopram (Lexapro) for Depression MS or ALS|An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis|Completed||Phase 3|13|Actual|University of South Carolina||1|||f||||t||||||||||2018-06-01 00:39:15.856502|2018-06-01 00:39:15.856502
NCT00965484|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|2010-12-02||2011-01-26|2009-08-21|2009-08-25|Estimate|2010-12-02|2010-12-23|Estimate||||2011-01-26|2011-01-28|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Genotropin Study Assessing Use of Injection Pen|Multicenter, Open-Label Study Assessing Dyad (Subject And Caregiver) Perception Of Convenience And Preference Of The Newly Developed Mark VII Injection Pen|Completed||Phase 3|136|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:39:16.418608|2018-06-01 00:39:16.418608
NCT00965471|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-24|2009-08-24|2009-08-25|Estimate|||||||2009-08-24|2009-08-25|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Interventional|||Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease|Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease|Completed||N/A|940|Anticipated|Guangzhou University of Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:39:17.162789|2018-06-01 00:39:17.162789
NCT00965458|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-22|2014-12-19|2014-08-12|2017-06-12|2009-08-22|2009-08-25|Estimate|2014-12-23|2015-01-07|Estimate|2014-08-12|2014-08-15|Estimate|2017-06-12|2017-07-06|Actual|March 2011||2011-03-31|June 2017|2017-06-30|April 2014|Actual|2014-04-30|March 2013|Actual|2013-03-31||Interventional|T1DAL||Inducing Remission in Type 1 Diabetes With Alefacept|Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept (Amevive®)|Terminated||Phase 2|49|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Enrollment ended early with 49 subjects (instead of the planned 66) as a result of the decision, unrelated to safety reasons, made by Astellas Pharma US, Inc. to discontinue manufacturing Amevive® (alefacept).|2||Manufacturer discontinued production of Amevive®: business decision.|f||||t||||||||Yes|Participant level data access and additional relevant materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.|2018-06-01 00:39:17.935291|2018-06-01 00:39:17.935291
NCT00965445|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-23|||2009-08-24|2009-08-23|2009-08-25|Estimate|||||||2009-08-24|2009-08-26|Estimate|March 2007||2007-03-31|August 2009|2009-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||The Comparison of Oxidative Stress Between Inhalation Anesthetics|The Comparison of Oxidative Stress Between Inhalation Anesthetics|Completed|||60|Actual|Chang Gung Memorial Hospital|||1||f||||t||||||Samples Without DNA|"~     thirty milliliters of urine was collected from urine bag of patients at the following times:~     baseline before anesthesia, 30 minutes before cardiopulmonary bypass, during cardiopulmonary~     bypass, after the end of cardiopulmonary bypass.~   "|||2018-06-01 00:39:19.096553|2018-06-01 00:39:19.096553
NCT00965432|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-02-05|2009-08-24|2009-08-25|Estimate|||||||2010-02-05|2010-02-08|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107|A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy, Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107|Completed||Phase 1|40|Anticipated|Seaside Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 00:39:19.240683|2018-06-01 00:39:19.240683
NCT00965419|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2018-02-17|2015-09-03|2018-03-26|2009-08-24|2009-08-25|Estimate|2018-03-26|2018-04-27|Actual|2015-09-03|2015-09-18|Estimate|2018-03-26|2018-04-27|Actual|September 2009||2009-09-30|March 2018|2018-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder|Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder|Terminated||Phase 2/Phase 3|267|Actual|Eli Lilly and Company|Terminated due to low 5 year completer number and not meeting primary objective.|1||Terminated due to low 5 year completer number and not meeting primary objective.|f||||f||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-06-01 00:39:19.514034|2018-06-01 00:39:19.514034
NCT00965406|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-04-28|2009-08-24|2009-08-25|Estimate|||||||2017-04-28|2017-05-02|Actual|August 2010||2010-08-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone|Glucose Insulin Potassium With Intensive Insulin Therapy and (GIK2) Versus GIK Alone in the Early Management of Acute Coronary Syndrome: Randomised Controlled Study|Completed||Phase 3|772|Actual|University of Monastir||3|||f||||f||||||||||2018-06-01 00:39:21.230962|2018-06-01 00:39:21.230962
NCT00965393|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-10-22|2009-08-24|2009-08-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|August 2009||2009-08-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway|The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:39:21.390908|2018-06-01 00:39:21.390908
NCT00965380|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2014-04-07|2009-08-21|2009-08-25|Estimate|||||||2014-04-07|2014-04-08|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|November 2014|Anticipated|2014-11-30|June 2014|Anticipated|2014-06-30||Observational|TLF||Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)|A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells (Trinity Evolution™ Viable Cryopreserved Cellular Bone Matrix) in Posterior Lumbar or Transforaminal Lumbar Interbody Fusion (PLIF or TLIF)|Unknown status|Active, not recruiting||200|Anticipated|Orthofix Inc.|||||f||||f||||||||||2018-06-01 00:39:21.661282|2018-06-01 00:39:21.661282
NCT00965367|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-24|2009-08-24|2009-08-25|Estimate|||||||2009-08-24|2009-08-25|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Postoperative Nausea and Vomiting and Acupuncture/Acupressure|Can Acustimulation Attenuate Postoperative Nausea and Vomiting in Children Who Have Undergone Tonsillectomy/Adenoidectomy?|Completed||Phase 2/Phase 3|154|Actual|National Research Centre of Complementary and Alternative Medicine, Norway||2|||f||||f||||||||||2018-06-01 00:39:21.815284|2018-06-01 00:39:21.815284
NCT00965354|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-06-03|2009-08-24|2009-08-25|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|MOSAIC||Mechanisms of Severe Acute Influenza Consortium (MOSAIC)|Mechanisms of Severe Acute Influenza Consortium (MOSAIC)|Completed|||257|Actual|Imperial College London|||1||f||||f||||||Samples With DNA|"~     A) Swabs and secretions from the nose and throat B) Blood C) Sputum D) Urine E) Stool~      In addition, if the patients are having further respiratory sample collection as part of~     their routine care, for example tracheal aspirates, bronchial lavage and other samples then~     we would like to take an additional amount of these samples for our research.~   "|||2018-06-01 00:39:22.066109|2018-06-01 00:39:22.066109
NCT00965341|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|2016-06-15||2016-07-26|2009-08-24|2009-08-25|Estimate|2016-07-26|2016-09-13|Estimate||||2016-07-26|2016-09-13|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients|A Preliminary Trial of Testosterone Replacement for Fatigue in Male Hypogonadic Patients With Advanced Cancer.|Completed||Phase 3|53|Actual|M.D. Anderson Cancer Center|The study has several limitations; the follow-up visits at two weekly intervals were burdensome for many patients. Others did not want to enroll in a placebo-controlled trial, and many patients regarded the intramuscular injections as too painful.|2|||f||||t||||||||||2018-06-01 00:39:22.262547|2018-06-01 00:39:22.262547
NCT00965328|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-24|2009-08-24|2009-08-25|Estimate|||||||2009-08-24|2009-08-25|Estimate|February 2007||2007-02-28|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration|Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates|Completed||Phase 4|14|Actual|Onze Lieve Vrouwe Gasthuis||2|||f||||t||||||||||2018-06-01 00:39:23.065024|2018-06-01 00:39:23.065024
NCT00965315|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2012-12-20|2009-08-24|2009-08-25|Estimate|||||||2012-12-20|2012-12-21|Estimate||||November 2012|2012-11-30||||||||Expanded Access|||A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome|A Multicenter, Randomized, Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome|Available|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 00:39:23.533147|2018-06-01 00:39:23.533147
NCT00965302|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-01-12|2009-08-24|2009-08-25|Estimate|||||||2015-01-12|2015-01-13|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|September 2014|Actual|2014-09-30|December 2012|Actual|2012-12-31||Interventional|||Sleeve Gastrectomy Versus Medical Management for Remission of Diabetes in Mild to Moderately Obese Patients|Sleeve Gastrectomy vs Medical Management for Remission of Diabetes in Mild to Moderately Obese Patients|Completed||N/A|50|Actual|Wilford Hall Medical Center||2|||f||||t||||||||||2018-06-01 00:39:23.891985|2018-06-01 00:39:23.891985
NCT00965289|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-25|2009-08-24|2009-08-25|Estimate|||||||2009-08-25|2009-08-26|Estimate|April 2002||2002-04-30|August 2009|2009-08-31|June 2009|Actual|2009-06-30|May 2003|Actual|2003-05-31||Interventional|||High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma|Front-line High-dose Chemotherapy (HDT) Combined With Rituximab for Adults With Aggressive Large B-cell Lymphoma (DLBCL) : Goelams 074 Trial.|Completed||Phase 2|42|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-06-01 00:39:24.129826|2018-06-01 00:39:24.129826
NCT00965276|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-06-30|2009-08-24|2009-08-25|Estimate|||||||2017-06-30|2017-07-02|Actual|January 13, 2004||2004-01-13|December 14, 2010|2010-12-14|December 14, 2010||2010-12-14|||||Observational|||Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer|Levels of Phosphorylated AKT in Patients With Node-Positive Breast Cancer: Correlation With Disease-Free and Overall Survival|Completed|||2500|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:39:24.244659|2018-06-01 00:39:24.244659
NCT00965263|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2017-08-03||2017-11-06|2009-08-24|2009-08-25|Estimate|2017-11-06|2017-12-11|Actual||||2017-11-06|2017-12-11|Actual|March 2003||2003-03-31|September 2017|2017-09-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional||Overall, 10 volunteers participated in this study.|Therapeutic Cocaine Vaccine: Human Laboratory Study|Tests of a Therapeutic Cocaine Vaccine|Completed||Phase 2|15|Actual|New York State Psychiatric Institute|There was no placebo TA-CD condition, due to the substantial study demands.|2|||f||||f||||||||||2018-06-01 00:39:24.385028|2018-06-01 00:39:24.385028
NCT00965068|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-10-05|2009-08-24|2009-08-25|Estimate|||||||2017-10-05|2017-10-06|Actual|July 28, 2009||2009-07-28|June 8, 2015|2015-06-08|November 14, 2013|Actual|2013-11-14|||||Interventional|||Cholesterol in ASD: Characterization and Treatment|Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment|Completed||Phase 1/Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:39:32.971765|2018-06-01 00:39:32.971765
NCT00965250|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2012-10-12||2016-10-31|2009-08-24|2009-08-25|Estimate|2012-10-12|2012-11-14|Estimate||||2016-10-31|2016-12-23|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|March 2012|Actual|2012-03-31||Interventional|||Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy|Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy|Completed||Phase 2|49|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||No||2018-06-01 00:39:27.879767|2018-06-01 00:39:27.879767
NCT00965237|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2011-01-21||2012-06-26|2009-08-24|2009-08-25|Estimate|2011-02-17|2011-03-14|Estimate||||2012-06-26|2012-07-10|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|GARM||Multifocal Contact Lens Use in Previous Contact Lens Wearers With Near Vision Demands|P/331/09/C: Multifocal Pilot Study: Refitting Drop Outs (GARM)|Completed||N/A|16|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:39:30.152662|2018-06-01 00:39:30.152662
NCT00965224|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-07-11|2009-08-24|2009-08-25|Estimate|||||||2013-07-11|2013-07-12|Estimate|January 2010||2010-01-31|July 2013|2013-07-31||||December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma|Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial|Unknown status|Enrolling by invitation|Phase 2|50|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||||2018-06-01 00:39:30.282895|2018-06-01 00:39:30.282895
NCT00965211|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2012-01-04|2009-08-24|2009-08-25|Estimate|||||||2012-01-04|2012-01-05|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome|Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome.|Unknown status|Recruiting|N/A|20|Anticipated|Shalvata Mental Health Center|||||f||||t||||||||||2018-06-01 00:39:30.356419|2018-06-01 00:39:30.356419
NCT00965198|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-11-19|2009-08-22|2009-08-25|Estimate|||||||2013-11-19|2013-11-21|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Comparison of Infection Rates Among Patients Using Two Catheter Access Devices|Comparison of a Novel Silver-Coated Catheter Access Device and a Standard Catheter Access Device: A Dual Center Cross-Over Study|Completed|||10000|Actual|Emory University|||4||f||||f||||||Samples Without DNA|"~     Samples for biofilm analysis may be banked for further study.~   "|||2018-06-01 00:39:30.5471|2018-06-01 00:39:30.5471
NCT00965185|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2015-01-30||2017-11-09|2009-08-24|2009-08-25|Estimate|2015-02-17|2015-02-26|Estimate||||2017-11-09|2017-12-11|Actual|September 2009||2009-09-30|November 2017|2017-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Statin Therapy to Improve Atherosclerosis in HIV Patients|Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients|Completed||N/A|40|Actual|Massachusetts General Hospital|FDG-PET scan data was interpretable in only a limited subset of participants as a result of technical problems with manual co-registration (outcome 1). We were unable to collect data for endothelial function due to equipment malfunction (outcome 3).|2|||f||||t||||||||||2018-06-01 00:39:30.625228|2018-06-01 00:39:30.625228
NCT00965172|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2012-03-20|2009-08-21|2009-08-25|Estimate|||||||2012-03-20|2012-03-22|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Caphosol in Sarcoma Patients With Mucositis|A Phase II Study to Evaluate the Preliminary Efficacy Assessment of Caphosol in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide or Cisplatin|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 00:39:31.122586|2018-06-01 00:39:31.122586
NCT00965146|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2012-11-09||2017-10-16|2009-08-21|2009-08-25|Estimate|2013-02-12|2013-02-15|Estimate||||2017-10-16|2017-11-17|Actual|June 2001||2001-06-30|April 2013|2013-04-30||||July 23, 2009|Actual|2009-07-23||Interventional|||Scorpio® Cruciate Retaining (CR) Outcomes Study|An Open Label, Post-market, Non-randomized, Multi-center Study of the Outcomes of the Scorpio® Cruciate Retaining (CR) Total Knee System|Terminated||N/A|215|Actual|Stryker Orthopaedics|This study was terminated early due to lagging follow up prior to the 15 year endpoint.|1||Terminated due to lagging follow-up.|f||||f||||||||||2018-06-01 00:39:31.286179|2018-06-01 00:39:31.286179
NCT00965133|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-06-10|2009-08-24|2009-08-25|Estimate|||||||2013-06-10|2013-06-11|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Endurance Training in Young Persons With Cerebral Palsy; Evaluation of Training Method and Effect|Enthusiasm - Sweat - Satisfaction! In Youngster With CP|Completed||N/A|24|Actual|Reidun Lauglo||1|||f||||f||||||||||2018-06-01 00:39:31.459701|2018-06-01 00:39:31.459701
NCT00965120|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2010-10-22|2009-08-24|2009-08-25|Estimate|||||||2010-10-22|2010-10-25|Estimate|August 2009||2009-08-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway|The Effect of Ischaemic-Reperfusion in Man - A Bradykinin Dependent Pathway|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:39:31.523557|2018-06-01 00:39:31.523557
NCT00965107|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-03-08|2009-08-24|2009-08-25|Estimate|||||||2010-03-08|2010-03-09|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Onset Time of Thiopental Versus Propofol in the Elderly|Onset Time of Thiopental Versus Propofol in the Elderly|Completed||Phase 4|78|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 00:39:31.604258|2018-06-01 00:39:31.604258
NCT00965094|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2014-05-30||2014-08-14|2009-08-24|2009-08-25|Estimate|2014-08-14|2014-08-15|Estimate||||2014-08-14|2014-08-15|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Enrolled patient population included all patients who signed an informed consent regardless whether renal transplanation as performed or not.|Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients|Efficacy and Safety of Certican® (Everolimus) in Combination With Myfortic® (EC-MPS, Enteric-coated Mycophenolate Sodium) After Early CNI Elimination Versus Myfortic® in Combination With Prograf® in Renal Transplant Recipients|Completed||Phase 4|36|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:39:31.744664|2018-06-01 00:39:31.744664
NCT00965081|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2011-09-28||2011-09-28|2009-08-24|2009-08-25|Estimate|2011-09-28|2011-11-03|Estimate||||2011-09-28|2011-11-03|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|HMGG||A Study for Adult Patients With Fibromyalgia|A Randomized, Double-Blind Comparison of Duloxetine 30 mg QD and Placebo in Adult Patients With Fibromyalgia|Completed||Phase 4|308|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:39:32.323828|2018-06-01 00:39:32.323828
NCT00965055|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-01-25|2009-08-24|2009-08-25|Estimate|||||||2013-01-25|2013-01-28|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Ezetimibe in Patients Hypo-responsive to Statins|Atorvastatin vs. Atorvastatin/Ezetimibe in Patients With Hypo-response to Initial Dose Statin Therapy|Terminated||Phase 3|2|Actual|University of California, San Diego||2||"The study was terminated due to inability to recruit subjects. A total of 2/100 anticipated~   were radomized."|f||||t||||||||||2018-06-01 00:39:33.040854|2018-06-01 00:39:33.040854
NCT00965042|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2012-07-27|2009-08-21|2009-08-25|Estimate|||||||2012-07-27|2012-07-30|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Effect of Ceftobiprole on Human Intestinal Microflora|Effect of Ceftobiprole on the Intestinal Human Microflora Following Multiple-dose Administration in Healthy Female and Male Subjects|Completed||Phase 1|12|Actual|Basilea Pharmaceutica||1|||f||||f||||||||||2018-06-01 00:39:33.100069|2018-06-01 00:39:33.100069
NCT00965029|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-04-04|2009-08-24|2009-08-25|Estimate|||||||2011-04-04|2011-04-05|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Spirometry in Mechanically Ventilated Chronic Obstructive Pulmonary Disease (COPD) Patients|Spirometry in Mechanically Ventilated COPD Patients: Correlation of Lung Function Tests to Successful Weaning From Mechanical Ventilation|Unknown status|Not yet recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 00:39:33.156033|2018-06-01 00:39:33.156033
NCT00965016|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-23|||2009-08-23|2009-08-23|2009-08-25|Estimate|||||||2009-08-23|2009-08-25|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Induced Hypothermia in Cardiac Arrest Patients Rescued by Extracorporeal Cardiopulmonary Resuscitation.|The Therapeutic Effect of Induced Hypothermia in Cardiac Arrest Patients Rescued by Extracorporeal Cardiopulmonary Resuscitation (ECPR).|Unknown status|Recruiting|Early Phase 1|45|Anticipated|Min-Sheng General Hospital||3|||f||||f||||||||||2018-06-01 00:39:33.209382|2018-06-01 00:39:33.209382
NCT00965003|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2017-10-03|2009-08-21|2009-08-25|Estimate|||||||2017-10-03|2017-10-05|Actual|July 2009||2009-07-31|October 2017|2017-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||MRI Laryngeal Imaging With a Surface Coil|High Resolution MRI in the Evaluation of Laryngeal Neoplasia|Terminated||Early Phase 1|3|Actual|Stanford University||1||Absence of key personnel to conduct study|f||||t||||||||||2018-06-01 00:39:33.275005|2018-06-01 00:39:33.275005
NCT00964990|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21||2012-04-26|2016-03-29|2009-08-21|2009-08-25|Estimate||||2012-04-26|2012-04-30|Estimate|2016-03-29|2016-05-02|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-traumatic Neuralgia, Followed by a Double Blind Safety Extension and an Open-label Safety Extension|Terminated||Phase 2|112|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Logistic reasons associated with the FDA-imposed clinical hold.|f||||t||||||||||2018-06-01 00:39:33.359603|2018-06-01 00:39:33.359603
NCT00964977|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2012-11-15|2009-08-24|2009-08-25|Estimate|||||||2012-11-15|2012-11-16|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|December 2018|Anticipated|2018-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.|Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state)|Recruiting||Phase 3|560|Anticipated|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-06-01 00:39:33.584366|2018-06-01 00:39:33.584366
NCT00964964|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-11-26|2009-08-24|2009-08-25|Estimate|||||||2013-11-26|2013-11-27|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics|A Trial Assessing the Number of Hypoglycaemic Episodes and Glycaemic Variability During Two Different Regimens of SIBA 200 U/ml in Subjects With Type 1 Diabetes|Completed||Phase 1|18|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:39:33.837965|2018-06-01 00:39:33.837965
NCT00964951|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2010-08-26|2009-08-20|2009-08-25|Estimate|||||||2010-08-26|2010-08-27|Estimate||||October 2009|2009-10-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a CSL H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant|Withdrawn||Phase 2|800|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 00:39:33.920637|2018-06-01 00:39:33.920637
NCT00964938|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2012-03-24|2009-08-24|2009-08-25|Estimate|||||||2012-03-24|2012-03-27|Estimate|August 2009||2009-08-31|March 2012|2012-03-31||||April 2011|Actual|2011-04-30||Interventional|||Multisite Pacing With a Quadripolar Lead|Multisite Pacing With a Quadripolar Left Heart Lead in Cardiovascular Resynchronization Therapy (CRT) Patients|Completed||Phase 4|35|Actual|St. Jude Medical|||||f||||f||||||||||2018-06-01 00:39:34.012329|2018-06-01 00:39:34.012329
NCT00964912|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-01-24|2009-08-24|2009-08-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|July 2008||2008-07-31|January 2011|2011-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Single Dose Study of BMS-820836|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Subjects|Completed||Phase 1|68|Actual|Bristol-Myers Squibb||11|||f||||f||||||||||2018-06-01 00:39:34.092097|2018-06-01 00:39:34.092097
NCT00964886|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2016-11-23||2016-11-23|2009-08-24|2009-08-25|Estimate|2016-11-23|2016-11-29|Estimate||||2016-11-23|2016-11-29|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional||Demographic characteristics of participants randomized at baseline to one of the four study arms (selected information on three participants missing)|Efficacy of Antidepressants in Chronic Back Pain|Efficacy of Antidepressants in Chronic Back Pain|Completed||Phase 2|142|Actual|VA Office of Research and Development|Failure to attain recruitment goals and attrition resulted in lack of power to detect an effect. A strong active placebo control condition (benztropine) and frequent follow up visits may have led to improvement in all groups over time.|4|||f||||t||||||||Yes|Available in SPSS format from the investigators.|2018-06-01 00:39:34.25388|2018-06-01 00:39:34.25388
NCT00964873|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2014-09-17|2009-08-24|2009-08-25|Estimate|||||||2014-09-17|2014-09-18|Estimate|August 2009||2009-08-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia|Completed||Phase 1|29|Actual|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-06-01 00:39:34.925664|2018-06-01 00:39:34.925664
NCT00964860|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2012-06-28||2012-10-02|2009-08-21|2009-08-25|Estimate|2012-10-02|2012-10-31|Estimate||||2012-10-02|2012-10-31|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing|A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing|Completed||Phase 3|60|Actual|Procter and Gamble||2|||f||||f||||||||||2018-06-01 00:39:35.052934|2018-06-01 00:39:35.052934
NCT00964847|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-02-13|2009-08-24|2009-08-25|Estimate|||||||2017-02-13|2017-02-15|Actual|August 2009||2009-08-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LIMBS||Lifestyle Modification and Blood Pressure Study|Lifestyle Modification and Blood Pressure Study|Completed||Phase 2|147|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 00:39:35.298699|2018-06-01 00:39:35.298699
NCT00964834|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-08-09|2009-08-24|2009-08-25|Estimate|||||||2010-08-09|2010-08-10|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Ph1 Study of Valortim and Doxycycline in Humans|A Phase I, Single Blind, Randomized, Placebo Controlled, Drug Interaction Study of Intravenous (IV) Valortim® and Intravenous (IV) Doxycycline in Healthy Normal Subjects|Terminated||Phase 1|24|Anticipated|PharmAthene, Inc.||3||"Sister trial has SAE investigation underway - sponsor elected to withdraw as study expected to~   be repeated later"|f||||t||||||||||2018-06-01 00:39:35.384764|2018-06-01 00:39:35.384764
NCT00964821|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-22|||2017-11-03|2009-08-22|2009-08-25|Estimate|||||||2017-11-03|2017-11-07|Actual|January 2007||2007-01-31|November 2017|2017-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant|Influenza Specific Humoral and Cellular Immunity After Vaccination in Recipients of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation|Completed|||459|Actual|City of Hope Medical Center|||2||f||||t||||||||||2018-06-01 00:39:35.496235|2018-06-01 00:39:35.496235
NCT00964808|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2014-12-05|2009-08-24|2009-08-25|Estimate|||||||2014-12-05|2014-12-08|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur|Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur|Completed||Phase 4|76|Actual|Vejle Hospital||2|||f||||t||||||||||2018-06-01 00:39:35.623593|2018-06-01 00:39:35.623593
NCT00964795|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2014-08-28||2015-03-10|2009-08-24|2009-08-25|Estimate|2015-03-10|2015-03-23|Estimate||||2015-03-10|2015-03-23|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Randomized participants included all participants who were enrolled in the study. The data were used to analyze the safety and efficacy parameters to characterize the long-term effect of Intravitreal Aflibercept Injection treatment. The average study duration for all enrolled participants was 116.9 weeks.|"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (Wet) Age-related Macular Degeneration (AMD)"|An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration|Completed||Phase 3|323|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:39:35.794975|2018-06-01 00:39:35.794975
NCT00964782|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2010-07-21|2009-08-24|2009-08-25|Estimate|||||||2010-07-21|2010-07-22|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation|The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation|Unknown status|Recruiting|Phase 4|30|Anticipated|Penn State University||2|||f||||t||||||||||2018-06-01 00:39:36.349769|2018-06-01 00:39:36.349769
NCT00964769|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-24|2009-08-24|2009-08-25|Estimate|||||||2009-08-24|2009-08-25|Estimate|April 2005||2005-04-30|August 2009|2009-08-31|June 2005|Actual|2005-06-30|May 2005|Actual|2005-05-31||Interventional|||Study of Evaluation Indexes for Antibody Production in Sera After Immunization|A Study of Evaluation Indexes for Antibody Production in Sera After Immunization|Completed||Phase 4|70|Actual|Ewha Womans University||1|||f||||t||||||||||2018-06-01 00:39:36.436991|2018-06-01 00:39:36.436991
NCT00964756|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2013-02-11|2009-08-24|2009-08-25|Estimate|||||||2013-02-11|2013-02-13|Estimate|August 2009||2009-08-31|February 2013|2013-02-28|April 2012|Actual|2012-04-30|December 2010|Actual|2010-12-31||Interventional|||A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers|A Phase I Study of AD5.SSTR/TK.RGD; A Tropism Modified Adenovirus Vector for Intraperitoneal Delivery of Therapeutic Genes and Additional Capability of Noninvasive Imaging of Gene Transfer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (Infectivity Enhanced Adenoviral Vectors for Ovarian CA)|Completed||Phase 1|11|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 00:39:37.523057|2018-06-01 00:39:37.523057
NCT00964743|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2012-01-19||2013-09-04|2009-08-24|2009-08-25|Estimate|2012-03-27|2012-04-19|Estimate||||2013-09-04|2013-09-09|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Depocyt® With Sorafenib in Neoplastic Meningitis|A Single Arm Pilot Study of Intrathecally Administered DepoCyt® With Systemic Sorafenib in the Treatment of Neoplastic Meningitis From Solid Tumors|Terminated||N/A|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|The study closed early due to low accrual of 2 of 10 expected patients. Neither patient completed 8 weeks of treatment as outlined in the protocol. Both patients expired before reaching the 6 month Progression Free Survival endpoint.|1||Low Accrual|f||||t||||||||||2018-06-01 00:39:37.607658|2018-06-01 00:39:37.607658
NCT00964730|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2010-04-06|2009-08-24|2009-08-25|Estimate|||||||2010-04-06|2010-04-07|Estimate|October 2009||2009-10-31|April 2010|2010-04-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm|A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers|Completed||Phase 1|135|Anticipated|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 00:39:37.839016|2018-06-01 00:39:37.839016
NCT00964717|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2012-01-27|2009-08-24|2009-08-25|Estimate|||||||2012-01-27|2012-01-31|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|CBNP||Chiropractic for Back and Neck Pain in an Emergency Department Setting|Efficacy of an Integrative Approach Utilizing Chiropractic as an Add On Therapy for the Treatment Back and Neck Pain in an Emergency Department Setting - A Comparative Randomized Controlled Trial|Completed||Phase 1/Phase 2|52|Actual|Assaf-Harofeh Medical Center||3|||f||||t||||||||||2018-06-01 00:39:37.913587|2018-06-01 00:39:37.913587
NCT00964704|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2016-11-01|2009-08-24|2009-08-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer|A Single Arm, Open-label Study to Evaluate the Efficacy on Tumor Response and the Safety of Bevacizumab and Trastuzumab Combination and Sequential Capecitabine in Patients With HER2 +Ive Locally Recurrent or Metastatic Breast Cancer After Early Relapse to Adjuvant Trastuzumab-containing Therapy|Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche||1||No patients have been recruited therefore study has been cancelled|f||||||||||||||2018-06-01 00:39:37.998572|2018-06-01 00:39:37.998572
NCT00964691|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-07-05|2009-08-24|2009-08-25|Estimate|||||||2010-07-05|2010-07-07|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|IPTpRCT||A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands|Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine Versus Weekly Chloroquine Prophylaxis During Pregnancy in Solomon Islands: a Randomized Controlled Trial|Terminated||Phase 4|2504|Anticipated|Ministry of Health and Medical Services, Solomon Islands||2||"Low prevalence of malaria, high prevalence of reported allergy to sulphur drugs, high~   proportion of women not meeting the inclusion criterea."|f||||t||||||||||2018-06-01 00:39:38.074289|2018-06-01 00:39:38.074289
NCT00964678|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2015-12-10||2017-06-06|2009-08-24|2009-08-25|Estimate|2017-06-06|2017-06-08|Actual||||2017-06-06|2017-06-08|Actual|June 2010||2010-06-30|June 2017|2017-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Patients had pulmonary arterial hypertension, on pulmonary vasodilator therapy at baseline|Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension|Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension|Completed||Phase 1/Phase 2|10|Actual|Virginia Commonwealth University|Small number of patients enrolled. This study is hypothesis generating and was meant to lead to larger studies of carvedilol in pulmonary hypertension|1|||f||||f||||||||No|IPD will not be shared|2018-06-01 00:39:38.266242|2018-06-01 00:39:38.266242
NCT00964665|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2011-01-05|2009-08-24|2009-08-25|Estimate|||||||2011-01-05|2011-01-06|Estimate|July 2009||2009-07-31|January 2011|2011-01-31||||November 2010|Actual|2010-11-30||Interventional|||Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects|A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.|Terminated||Phase 1/Phase 2|141|Actual|Novartis||5|||f||||||||||||||2018-06-01 00:39:38.632879|2018-06-01 00:39:38.632879
NCT00964652|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2009-08-24|2009-08-24|2009-08-25|Estimate|||||||2009-08-24|2009-08-25|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Treadmill Training With Additional Body Load: Effects on Gait of Subjects With Parkinson´s Disease||Completed||N/A|9|Actual|Universidade Federal de Sao Carlos||1|||f||||||||||||||2018-06-01 00:39:38.791643|2018-06-01 00:39:38.791643
NCT00964639|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2013-01-25|2009-08-24|2009-08-25|Estimate|||||||2013-01-25|2013-01-28|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies|Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies. A Prospective, Randomized and Double-blinded Study|Completed||Phase 4|12|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:39:38.861089|2018-06-01 00:39:38.861089
NCT00964626|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-22|||2013-08-23|2009-08-22|2009-08-25|Estimate|||||||2013-08-23|2013-08-26|Estimate|April 2009||2009-04-30|August 2009|2009-08-31||||April 2011|Anticipated|2011-04-30||Interventional|||Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer|A Phase II Study of Efficacy and Safety of Paclitaxel and Cisplatin Every 2 Weeks as the First-line Treatment of Patients With Ovarian Cancer Stage Ic-IV.|Unknown status|Recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:39:38.954044|2018-06-01 00:39:38.954044
NCT00964613|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-08-06|2009-08-24|2009-08-25|Estimate|||||||2015-08-06|2015-08-07|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|Capsulotomy||Pars Plana Surgical Capsulotomy for Posterior Capsular Opacification|Pars Plana Surgical Capsulotomy for Posterior Capsular Opacification|Completed|||176|Actual|Dow University of Health Sciences|||||f||||t||||||||||2018-06-01 00:39:39.024539|2018-06-01 00:39:39.024539
NCT00964600|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2010-11-17|2009-08-23|2009-08-25|Estimate|||||||2010-11-17|2010-11-18|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|October 2009|Anticipated|2009-10-31|September 2009|Anticipated|2009-09-30||Interventional|TAP||Bilateral Transversus Abdominis Plane Block and Postoperative Pain Intensity After Elective Cesarean Delivery|Evaluation of the Effect of Bilateral Transversus Abdominis Plane Block on Postoperative Pain Intensity and Analgesia Consumption After Elective Cesarean Delivery|Unknown status|Recruiting|N/A|60|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:39:39.072138|2018-06-01 00:39:39.072138
NCT00964587|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2015-05-11|2009-08-24|2009-08-25|Estimate|||||||2015-05-11|2015-05-12|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|DECIDE||Cardiovascular Disease Education and Problem-Solving Training in People With Type 2 Diabetes|Randomized Trial of CVD Education and Problem-Solving Training in Urban Diabetics|Completed||N/A|382|Actual|Johns Hopkins University||4|||f||||t||||||||||2018-06-01 00:39:39.215808|2018-06-01 00:39:39.215808
NCT00964574|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2012-07-16|2009-08-24|2009-08-25|Estimate|||||||2012-07-16|2012-07-17|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PORTAL 1||Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus|Multicentre, Open, Non-randomised Controlled Phase IV Clinical Trial of Efficacy and Safety for Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine|Completed||Phase 4|68|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:39:39.31712|2018-06-01 00:39:39.31712
NCT00962455|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-19|2009-08-19|2009-08-20|Estimate|||||||2009-08-19|2009-08-20|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|FRESCO||Feedback Reports and e-Learning in Primary Care Spirometry|Feedback Reports and E-learning to Support Spirometry Test Performance in Dutch Family Practices|Completed||Phase 4|1135|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 00:40:19.544221|2018-06-01 00:40:19.544221
NCT00964561|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-22|||2010-08-09|2009-08-22|2009-08-25|Estimate|||||||2010-08-09|2010-08-10|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|February 2010|Anticipated|2010-02-28||Interventional|||Ph1 Study of Valortim and Ciprofloxacin in Humans|A Phase I, Single Blind, Randomized, Placebo Controlled, Drug Interaction Study of Intravenous (IV) Valortim® and Intravenous (IV) Ciprofloxacin in Healthy, Normal Subjects|Suspended||Phase 1|26|Anticipated|PharmAthene, Inc.||3||On partial hold for clinical investigation into AE and SAE reported.|f||||t||||||||||2018-06-01 00:39:39.391215|2018-06-01 00:39:39.391215
NCT00964548|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-23|2011-11-18||2012-04-25|2009-08-23|2009-08-25|Estimate|2012-04-25|2012-05-25|Estimate||||2012-04-25|2012-05-25|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage|Dantrolene in the Treatment of Cerebral Vasospasm After Subarachnoid Hemorrhage - a Phase 1 Study|Completed||Phase 1/Phase 2|10|Actual|University of Massachusetts, Worcester|Limitations of this trial include the small n. No power analysis was performed, but rather a convenience sample was chosen as this was a proof-of-concept study. Transcranial Doppler measurements are operator dependent.|2|||f||||f||||||||||2018-06-01 00:39:39.488034|2018-06-01 00:39:39.488034
NCT00964535|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2010-02-12|2009-08-24|2009-08-25|Estimate|||||||2010-02-12|2010-02-15|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|KINECO||Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics|Bioequivalence Study Comparing Two Budesonide/Formoterol Fumarate Dihydrate Device-metered Dry Powder Inhalers, Budesonide/Formoterol Easyhaler 200/6 µg/Inhalation and Symbicort Turbohaler 200 µg/6 µg/Inhalation|Completed||Phase 1/Phase 2|87|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-06-01 00:39:39.857011|2018-06-01 00:39:39.857011
NCT00964522|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2011-06-21|2009-08-24|2009-08-25|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2007||2007-01-31|April 2010|2010-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Trial of the Effectiveness of a Nurse Education and Care Program for Breast Cancer Patients Treated With Chemotherapy|Randomized Trial of the Effectiveness of a Nurse Education and Care Program for Breast Cancer Patients Treated With Chemotherapy|Completed||N/A|266|Actual|Instituto de Salud Carlos III||2|||f||||f||||||||||2018-06-01 00:39:39.952841|2018-06-01 00:39:39.952841
NCT00964496|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2009-08-26||2015-11-17|2009-08-24|2009-08-25|Estimate|2010-04-08|2010-04-30|Estimate||||2015-11-17|2015-12-17|Estimate|November 2004||2004-11-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|November 2007|Actual|2007-11-30||Interventional|||Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation|Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study|Completed||Phase 2|55|Actual|Shanghai Jiao Tong University School of Medicine|Single center, open-label study; lack of placebo pills, make it impossible on equality of dosages between two groups; lack of dose response assessment either in patients or assays of serum vascular endothelial growth factor.|2|||f||||f||||||||||2018-06-01 00:39:40.094394|2018-06-01 00:39:40.094394
NCT00964483|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-11-06|2009-08-24|2009-08-25|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2010||2010-01-31|March 2017|2017-03-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Translating Dietary Trials Into the Community|Translating the Dietary Approaches to Stop Hypertension (DASH)Diet Into an Urban, African-American Community in Winston-Salem, North Carolina|Completed||N/A|25|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||Undecided||2018-06-01 00:39:40.904587|2018-06-01 00:39:40.904587
NCT00964470|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-23|||2010-06-21|2009-08-24|2009-08-25|Estimate|||||||2010-06-21|2010-06-22|Estimate|August 2009||2009-08-31|September 2009|2009-09-30||||December 2010|Anticipated|2010-12-31||Interventional|AWBAT-D||Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery|Multi-Center, Prospective, Randomized, Comparison of AWBAT™-D vs. Xeroform™ or Glucan II™ for Treatment of Donor Sites in Burn Surgery|Unknown status|Recruiting|N/A|60|Anticipated|Aubrey Inc.|||||f||||f||||||||||2018-06-01 00:39:40.983732|2018-06-01 00:39:40.983732
NCT00964457|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2009-08-24|2009-08-24|2009-08-25|Estimate|||||||2009-08-24|2009-08-25|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|July 2017|Anticipated|2017-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients|Treatment of Patient With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before Under and After Radiation and With Adding Cetuximab to K_RAS Wild-type Patients.|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-06-01 00:39:41.071038|2018-06-01 00:39:41.071038
NCT00964444|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2010-06-17||2010-07-22|2009-08-24|2009-08-25|Estimate|2010-07-22|2010-08-19|Estimate||||2010-07-22|2010-08-19|Estimate|April 2009||2009-04-30|July 2010|2010-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Demonstration of a New Device to Measure the Force of Delivering a Baby|Demonstration of a New Device to Measure the Force of Delivering a Baby|Completed|||10|Actual|Pinnacle Health System|The trial was limited to singleton term pregnancy (37-42 weeks) patients in active labor. The study was only designed to prove that the device works and not to determine the normal range of force exerted on a fetus as it was delivered.||||f||||f||||||None Retained|"~     No biospecimens~   "|||2018-06-01 00:39:41.162142|2018-06-01 00:39:41.162142
NCT00964431|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|2011-11-22||2012-05-15|2009-08-24|2009-08-25|Estimate|2012-03-02|2012-03-30|Estimate||||2012-05-15|2012-05-22|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2 Study of Indomethacin Capsules to Treat Dental Pain|A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Indomethacin Test Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars|Completed||Phase 2|203|Actual|Iroko Pharmaceuticals, LLC||4|||f||||f||||||||||2018-06-01 00:39:41.318417|2018-06-01 00:39:41.318417
NCT00964418|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-24|||2017-01-19|2009-08-24|2009-08-25|Estimate|||||||2017-01-19|2017-01-20|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 in Young and Geriatric Subjects With Type 1 Diabetes|Completed||Phase 1|27|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:39:41.628796|2018-06-01 00:39:41.628796
NCT00964405|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-08-01|2009-08-20|2009-08-24|Estimate|||||||2017-08-01|2017-08-03|Actual|September 20, 2008|Actual|2008-09-20|August 2017|2017-08-31|December 20, 2008|Actual|2008-12-20|December 20, 2008|Actual|2008-12-20||Interventional|||Phase I Study of GSK233705 in Healthy Japanese Male Subjects|Phase I Study of GSK233705- A Randomised, Double Blind, Placebo-controlled, 2-parts Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Inhaled Doses of GSK233705 From a Novel Dry Powder Device in Healthy Japanese Male Subjects -|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:39:41.746768|2018-06-01 00:39:41.746768
NCT00964392|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2016-03-10||2017-08-22|2009-08-21|2009-08-24|Estimate|2017-03-16|2017-04-26|Actual||||2017-08-22|2017-09-20|Actual|September 2009||2009-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2013|Actual|2013-09-30||Interventional|AF Registry|Enrolled subjects who have been assigned to MEP/LEP groups|NAVISTAR® THERMOCOOL® Catheter Post Approval Registry|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation - Post Approval Registry|Active, not recruiting||Phase 4|437|Actual|Biosense Webster, Inc.||2|||f||||f||||||||No||2018-06-01 00:39:41.908346|2018-06-01 00:39:41.908346
NCT00964379|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-11-11|2009-08-20|2009-08-24|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 1988||1988-01-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Intraperitoneal Versus Extraperitoneal Colostomy|Prospective Randomized Trial of Intraperitoneal Versus Extraperitoneal Techniques for Construction of Terminal Iliac Fossa Colostomies|Completed||Phase 3|81|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:39:43.00445|2018-06-01 00:39:43.00445
NCT00964366|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2010-04-13||2017-05-25|2009-08-21|2009-08-24|Estimate|2012-03-06|2012-04-03|Estimate||||2017-05-25|2017-05-30|Actual|July 2009||2009-07-31|May 2017|2017-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications|Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Clindamycin and Benzoyl Peroxide to Dapsone Gel Topical Acne Medications|Completed||Phase 4|53|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:39:43.103566|2018-06-01 00:39:43.103566
NCT00964353|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-01-24|2009-08-21|2009-08-24|Estimate|||||||2017-01-24|2017-01-25|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|August 2012|Actual|2012-08-31||Interventional|||Clinical and Economic Implications of Genetic Testing for Warfarin Management|The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management|Active, not recruiting||Phase 4|268|Anticipated|University of Chicago||2|||f||||t||||||||||2018-06-01 00:39:43.447643|2018-06-01 00:39:43.447643
NCT00964340|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2017-06-14|2009-08-20|2009-08-24|Estimate|||||||2017-06-14|2017-06-16|Actual|October 1, 2009|Actual|2009-10-01|June 2017|2017-06-30|April 27, 2010|Actual|2010-04-27|April 27, 2010|Actual|2010-04-27||Interventional|||A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days|A Randomized, Placebo-Controlled, Double-Blind, Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days|Completed||Phase 1|24|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:39:43.513983|2018-06-01 00:39:43.513983
NCT00964327|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2011-05-18|2009-08-20|2009-08-24|Estimate|||||||2011-05-18|2011-05-19|Estimate|August 2001||2001-08-31|April 2010|2010-04-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains|A Phase IIa Open-label, Randomized Trial to Determine the Antiviral Activity in 60 HIV Positive Subjects With Multiple PI Resistant Strains, Receiving Either Control Treatment or a Daily Dose of 800, 1600, 2400 or 3600 mg TMC114 (Darunavir) for 13 Days Followed by a Single Dose on Day 14|Completed||Phase 2|42|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 00:39:43.614608|2018-06-01 00:39:43.614608
NCT00964314|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2012-04-19|2009-08-21|2009-08-24|Estimate|||||||2012-04-19|2012-04-23|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Traditional Chinese Medicine Five Elements Music Therapy Improving Quality of Life in Patients With Advanced Cancer|Prospective Study With RCT Designed for Evaluation of TCM Five Elements Music Therapy Improving Quality of Life in Patients With Advanced Cancer|Completed||N/A|146|Actual|Ministry of Science and Technology of the People´s Republic of China||3|||f||||t||||||||||2018-06-01 00:39:43.677746|2018-06-01 00:39:43.677746
NCT00964301|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2017-09-11|2009-08-21|2009-08-24|Estimate|||||||2017-09-11|2017-09-12|Actual|August 2009||2009-08-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|July 2012|Actual|2012-07-31||Interventional|||Telemedicine Education for Rural Children With Asthma|Telemedicine Education for Rural Children With Asthma|Completed||N/A|106|Actual|Arkansas Children's Hospital Research Institute||2|||f||||t||||||||No|There is no plan to share individual participant data.|2018-06-01 00:39:43.763006|2018-06-01 00:39:43.763006
NCT00964288|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2017-10-25|2009-08-20|2009-08-24|Estimate|||||||2017-10-25|2017-10-26|Actual|July 31, 2009|Actual|2009-07-31|October 2017|2017-10-31|November 30, 2009|Actual|2009-11-30|November 30, 2009|Actual|2009-11-30||Interventional|||Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects|A Double Blind, Double Dummy, Placebo Controlled Cross Over Study With a Positive Control to Investigate the Effect of a GSK Drug on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects|Terminated||Phase 1|16|Actual|Biogen||4||"During treatment session 3, a subject had a pattern of AEs of severe intensity, suggestive of~   brainstem toxicity/encephalopathy during lidocaine/saline infusion"|f||||f||||||||||2018-06-01 00:39:43.831221|2018-06-01 00:39:43.831221
NCT00964275|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2014-12-05|2009-08-21|2009-08-24|Estimate|||||||2014-12-05|2014-12-08|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|MVTEP||Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein|Study of Positron Emission Tomography With 18-fluorodeoxyglucose in Detecting Cancer in Patients With Idiopathic Venous Thromboembolism|Completed||N/A|400|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-06-01 00:39:44.012275|2018-06-01 00:39:44.012275
NCT00964262|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2013-07-18|2009-08-21|2009-08-24|Estimate|||||||2013-07-18|2013-07-19|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide|A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of SR Exenatide (PT302) After Subcutaneous Injection in Healthy Male Volunteers|Completed||Phase 1|34|Actual|Peptron, Inc.||1|||f||||t||||||||||2018-06-01 00:39:44.093606|2018-06-01 00:39:44.093606
NCT00964249|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-08-01|2009-08-20|2009-08-24|Estimate|||||||2017-08-01|2017-08-03|Actual|September 20, 2008|Actual|2008-09-20|August 2017|2017-08-31|December 1, 2008|Actual|2008-12-01|December 1, 2008|Actual|2008-12-01||Interventional|||Phase I Study of GW642444M in Healthy Japanese Male Subjects|Phase I Study of GW642444M- A Randomized, Double Blind, Placebo Controlled, Parallel-group, 7 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose of GW642444M From a Novel Dry Powder Device in Healthy Japanese Male Subjects -|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:39:44.178614|2018-06-01 00:39:44.178614
NCT00964236|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2018-01-02|2009-08-21|2009-08-24|Estimate|||||||2018-01-02|2018-01-04|Actual|August 2009||2009-08-31|January 2018|2018-01-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Observational|||The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)|The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)|Completed|||20|Actual|University of Missouri-Columbia|||2||f||||f||||||||||2018-06-01 00:39:44.283275|2018-06-01 00:39:44.283275
NCT00964223|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2010-09-07||2016-10-11|2009-08-21|2009-08-24|Estimate|2011-07-25|2011-08-25|Estimate||||2016-10-11|2016-11-23|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne|A Single-blind, Randomized, Comparative Split-face Study Evaluating the Tolerability of Clindamycin and Benzoyl Peroxide Gel to Benzoyl Peroxide/Adapalene Gel in the Treatment of Acne Vulgaris.|Completed||Phase 4|28|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:39:44.42342|2018-06-01 00:39:44.42342
NCT00964210|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2011-04-14|2009-08-21|2009-08-24|Estimate|||||||2011-04-14|2011-04-15|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|HPV||Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination|Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result|Completed||Phase 3|240|Anticipated|Murdoch Childrens Research Institute|||||f||||t||||||||||2018-06-01 00:39:45.25752|2018-06-01 00:39:45.25752
NCT00964197|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2017-04-06|2009-08-21|2009-08-24|Estimate|||||||2017-04-06|2017-04-10|Actual|November 2008||2008-11-30|April 2017|2017-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Purpose of This Study is to Look at Pelvic Support Problems, Also Commonly Known as Pelvic Organ Prolapse|FemmeJock: A Pilot Study to Assess Patient Satisfaction and Improvement of Pelvic Floor Symptoms Using a Pelvic Floor Support Girdle in Women With Uterovaginal Prolapse.|Completed||N/A|100|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 00:39:45.333678|2018-06-01 00:39:45.333678
NCT00964184|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2015-08-05|2009-08-21|2009-08-24|Estimate|||||||2015-08-05|2015-08-06|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phenotypic and Genetic Correlates of Diabetes (Non-Type 1) in Young Non-Obese Asian Indians in North India and A Study to Evaluate the Efficacy of Sitagliptin (DPP-4 Inhibitor) in a Sub-group of the Study Population||Completed||Phase 4|133|Actual|Diabetes Foundation, India||2|||f||||f||||||||||2018-06-01 00:39:45.614253|2018-06-01 00:39:45.614253
NCT00964171|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2010-04-06|2009-08-21|2009-08-24|Estimate|||||||2010-04-06|2010-04-07|Estimate|August 2008||2008-08-31|April 2010|2010-04-30||||December 2010|Anticipated|2010-12-31||Interventional|||Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas.|Unknown status|Recruiting|Phase 2|72|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:39:45.729781|2018-06-01 00:39:45.729781
NCT00964158|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2017-07-31|2010-12-10|2017-07-31|2009-08-20|2009-08-24|Estimate|2017-07-31|2018-02-19|Actual|2010-12-10|2010-12-16|Estimate|2017-07-31|2018-02-19|Actual|September 10, 2009||2009-09-10|October 2016|2016-10-31|November 27, 2010|Actual|2010-11-27|November 27, 2010|Actual|2010-11-27||Interventional|||Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)|Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years|Completed||Phase 3|210|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:39:45.982182|2018-06-01 00:39:45.982182
NCT00964145|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2011-06-27|2009-08-21|2009-08-24|Estimate|||||||2011-06-27|2011-06-28|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Effects of Age on the Levator Ani Muscle of Nulliparous Women|Effects of Age on the Levator Ani Muscle of Nulliparous Women|Completed|||80|Anticipated|University of Oklahoma|||1||f||||t||||||||||2018-06-01 00:39:47.871045|2018-06-01 00:39:47.871045
NCT00964132|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-09-02|2009-08-21|2009-08-24|Estimate|||||||2009-09-02|2009-09-03|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|March 2010|Anticipated|2010-03-31||Interventional|||Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|A Multiple-Center, Open-Label, Study of the Safety and Efficacy of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Active, not recruiting|Phase 2|48|Anticipated|NuRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:39:47.932022|2018-06-01 00:39:47.932022
NCT00964119|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|2014-12-05||2015-02-11|2009-08-21|2009-08-24|Estimate|2015-02-11|2015-02-23|Estimate||||2015-02-11|2015-02-23|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|August 2013|Actual|2013-08-31|February 2010|Actual|2010-02-28||Observational||Adolescents and young adults treated with systemic isotretinoin for recalcitrant inflammatory or nodular cystic acne.|Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population|An Interdisciplinary Study of Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population|Terminated|||15|Actual|University of Wisconsin, Madison||||Principal Investigator has left Sponsoring Instiution|f||||||||||||||2018-06-01 00:39:48.035797|2018-06-01 00:39:48.035797
NCT00964106|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2018-01-02|2009-08-20|2009-08-24|Estimate|||||||2018-01-02|2018-01-04|Actual|August 26, 2009|Actual|2009-08-26|January 2018|2018-01-31|August 29, 2011|Actual|2011-08-29|August 29, 2011|Actual|2011-08-29||Interventional|||Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation|An Open-label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Cytochrome P450 Probe Drugs in Healthy Adult Subjects|Completed||Phase 1|87|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:39:48.167544|2018-06-01 00:39:48.167544
NCT00964093|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2015-03-12|2009-08-21|2009-08-24|Estimate|||||||2015-03-12|2015-03-17|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants|The Efficacy of Silver Alginate (Algidex®) Dressing in Reducing Central Line Infections in Very Low Birth Weight (VLBW) Infants: A Multicenter Collaborative Randomized Controlled Trial.|Unknown status|Enrolling by invitation|N/A|300|Anticipated|Baylor Research Institute||1|||f||||t||||||||||2018-06-01 00:39:48.277794|2018-06-01 00:39:48.277794
NCT00964080|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2014-11-28|2009-08-20|2009-08-24|Estimate|||||||2014-11-28|2014-12-02|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|April 2015|Anticipated|2015-04-30|October 2012|Actual|2012-10-31||Interventional|||Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma|A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|62|Anticipated|Mebiopharm Co., Ltd||1|||f||||f||||||||||2018-06-01 00:39:48.443368|2018-06-01 00:39:48.443368
NCT00964067|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2017-03-20|2009-08-21|2009-08-24|Estimate|||||||2017-03-20|2017-03-22|Actual|September 2009|Actual|2009-09-30|March 2017|2017-03-31|July 2012|Actual|2012-07-31|April 2011|Actual|2011-04-30||Interventional|||Aerobic Interval Training in Cardiac Rehabilitation|Effect of High Intensity Aerobic Interval Training in Cardiac Rehabilitation|Completed||N/A|90|Actual|Norwegian University of Science and Technology||3|||f||||f|f|f||||||||2018-06-01 00:39:48.515383|2018-06-01 00:39:48.515383
NCT00964054|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-03-13|2009-08-20|2009-08-24|Estimate|||||||2013-03-13|2013-03-14|Estimate|September 2012||2012-09-30|April 2012|2012-04-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|DOSE||Depression Outcomes Study of Exercise|Adapting Exercise Treatment for Depression to Adolescents: A Pilot Study|Completed||Phase 1|9|Actual|National Institute of Mental Health (NIMH)||2|||f||||t||||||||||2018-06-01 00:39:48.586115|2018-06-01 00:39:48.586115
NCT00964041|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-11-19|2009-08-20|2009-08-24|Estimate|||||||2013-11-19|2013-11-20|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Once Weekly D-cycloserine for Schizophrenia|Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia.|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:39:48.681933|2018-06-01 00:39:48.681933
NCT00964028|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2017-02-24|2013-03-14|2017-04-14|2009-08-21|2009-08-24|Estimate|2017-02-24|2017-04-10|Actual|2013-03-14|2013-03-20|Estimate|2017-04-14|2017-05-19|Actual|December 1, 2009||2009-12-01|February 2017|2017-02-28|April 12, 2010|Actual|2010-04-12|April 12, 2010|Actual|2010-04-12||Interventional|||Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)|Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) in Infants|Completed||Phase 3|50|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:39:48.780998|2018-06-01 00:39:48.780998
NCT00964015|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2012-01-03|2009-08-21|2009-08-24|Estimate|||||||2012-01-03|2012-01-04|Estimate|August 2009||2009-08-31|December 2011|2011-12-31||||||||Interventional|SSACS||Starch or Saline After Cardiac Surgery|Short-term Outcomes of Fluid Replacement and Resuscitation Strategy in the Cardiac Surgery Patient: A Randomized, Controlled Trial|Unknown status|Active, not recruiting|N/A|300|Anticipated|London Health Sciences Centre||2|||f||||t||||||||||2018-06-01 00:39:49.125502|2018-06-01 00:39:49.125502
NCT00964002|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2009-09-04|2009-08-21|2009-08-24|Estimate|||||||2009-09-04|2009-09-07|Estimate|May 2008||2008-05-31|September 2009|2009-09-30||||December 2009|Anticipated|2009-12-31||Interventional|||Efavirenz in Treating Patients With Metastatic Prostate Cancer|A Phase II Trial to Assess the Efficacy of Efavirenz in Metastatic Patients With Androgen-independent Prostate Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:39:49.207916|2018-06-01 00:39:49.207916
NCT00963989|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2016-09-26|2009-08-21|2009-08-24|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|START||Imaging Guided Patient Selection for Interventional Revascularization Therapy|The START Trial: Clinical Outcome in Acute Stroke Treatment After Imaging Guided Patient Selection for Interventional Revascularization Therapy|Completed||Phase 4|146|Actual|Penumbra Inc.||1|||f||||f||||||||||2018-06-01 00:39:49.286046|2018-06-01 00:39:49.286046
NCT00963976|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2012-02-24|2009-08-21|2009-08-24|Estimate|||||||2012-02-24|2012-02-28|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|ICH ADAPT||Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial|Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial|Completed||Phase 2|74|Actual|University of Alberta||2|||f||||t||||||||||2018-06-01 00:39:49.402217|2018-06-01 00:39:49.402217
NCT00963963|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2018-01-30|2009-08-21|2009-08-24|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2006|Actual|2006-04-30|January 2018|2018-01-31|April 30, 2013|Actual|2013-04-30|April 30, 2013|Actual|2013-04-30||Interventional|||Reducing HIV Risks in African American Teens|Reducing HIV Risks in African American Teens in High Poverty Urban Settings|Completed||N/A|1200|Actual|Education Development Center, Inc.||3|||f||||f||||||||||2018-06-01 00:39:49.474071|2018-06-01 00:39:49.474071
NCT00963950|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2018-01-12|2009-08-21|2009-08-24|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2009||2009-08-31|January 2018|2018-01-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Transvaginal Cholecystectomy Versus Laparoscopic Cholecystectomy in Patients With Biliary Colic|Transvaginal Cholecystectomy|Completed||N/A|30|Actual|Yale University||2|||f||||t|f|f||||||||2018-06-01 00:39:49.547294|2018-06-01 00:39:49.547294
NCT00963937|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2011-07-28||2016-11-30|2009-08-20|2009-08-24|Estimate|2011-07-28|2011-08-26|Estimate||||2016-11-30|2017-01-18|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents|A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents|Completed||Phase 3|178|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:39:49.62825|2018-06-01 00:39:49.62825
NCT00963924|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2014-06-23||2018-01-09|2009-08-20|2009-08-24|Estimate|2014-07-31|2014-08-20|Estimate||||2018-01-09|2018-02-06|Actual|August 2009||2009-08-31|January 2018|2018-01-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia|A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia|Completed||N/A|54|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:39:50.287905|2018-06-01 00:39:50.287905
NCT00963911|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2011-05-12|2009-08-21|2009-08-24|Estimate|||||||2011-05-12|2011-05-13|Estimate|June 2008||2008-06-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Interventional|||Questionnaire in Screening Older Patients With Cancer|Validation of a Screening Tool in Geriatric Oncology|Completed||N/A|1650|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:39:50.973701|2018-06-01 00:39:50.973701
NCT00963898|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-08-21|2009-08-21|2009-08-24|Estimate|||||||2009-08-21|2009-08-24|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|ACDS||Accurate Controlled Dental Sedation|The Clinical Efficacy of the Combination Target Controlled Infusion With Bispectral Index Monitor in Propofol Sedation for Dental Patients With Mental Retardation|Completed||N/A|40|Actual|Okayama University||1|||f||||f||||||||||2018-06-01 00:39:51.030724|2018-06-01 00:39:51.030724
NCT00963885|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18||2016-07-07|2016-11-01|2009-08-21|2009-08-24|Estimate||||2016-07-07|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection|A Randomized, Partially-blind Study on the Safety, Tolerability and Effect on Virological Response of Treatment With the HCV Protease Inhibitor RO5190591 in Combination With Pegasys and Copegus, Versus Pegasys and Copegus Alone, in Treatment-Naïve Patients With Hepatitis C Genotype 1 Virus Infectio|Completed||Phase 2|229|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 00:39:51.093556|2018-06-01 00:39:51.093556
NCT00963872|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|2015-04-22||2017-12-03|2009-08-21|2009-08-24|Estimate|2015-10-13|2015-11-10|Estimate||||2017-12-03|2017-12-28|Actual|March 2010||2010-03-31|December 2017|2017-12-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional||Two patients were unevaluable because 1 bag broke so only 1 cord was available. One subject never received the C3a.|Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer|MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)|Terminated||Phase 1/Phase 2|31|Actual|Masonic Cancer Center, University of Minnesota||2||Lack of efficacy after interim analysis|f||||t||||||||||2018-06-01 00:39:51.36938|2018-06-01 00:39:51.36938
NCT00963859|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2012-06-28||2013-04-10|2009-08-20|2009-08-24|Estimate|2013-04-10|2013-05-21|Estimate||||2013-04-10|2013-05-21|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder|Phase II Evaluation of Robotic-assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder|Completed||Phase 2|11|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:39:51.924519|2018-06-01 00:39:51.924519
NCT00963846|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-02-28|2009-08-21|2009-08-24|Estimate|||||||2013-02-28|2013-03-01|Estimate|March 2010||2010-03-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Huperzine for Cognitive and Functional Impairment in Schizophrenia|Huperzine for Cognitive and Functional Impairment in Schizophrenia|Completed||Phase 2|56|Actual|Biomedisyn Corporation||4|||f||||f||||||||||2018-06-01 00:39:52.154404|2018-06-01 00:39:52.154404
NCT00963833|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-21|||2017-07-10|2009-08-21|2009-08-24|Estimate|||||||2017-07-10|2017-07-12|Actual|December 17, 2009|Actual|2009-12-17|July 2017|2017-07-31|September 1, 2016|Actual|2016-09-01|April 12, 2016|Actual|2016-04-12||Observational|||Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis|Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis|Completed|||68|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:39:52.255633|2018-06-01 00:39:52.255633
NCT00963820|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2015-05-29||2017-12-12|2009-08-21|2009-08-24|Estimate|2015-07-30|2015-08-28|Estimate||||2017-12-12|2018-01-10|Actual|October 2009||2009-10-31|December 2017|2017-12-31|January 2014|Actual|2014-01-31|September 2012|Actual|2012-09-30||Interventional||Safety Population|Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and Refractory Multiple Myeloma|Completed||Phase 1|60|Actual|Takeda||12|||f||||f||||||||||2018-06-01 00:39:52.405354|2018-06-01 00:39:52.405354
NCT00963807|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2016-10-17||2017-01-27|2009-08-21|2009-08-24|Estimate|2017-01-27|2017-03-17|Actual||||2017-01-27|2017-03-17|Actual|September 2009||2009-09-30|January 2017|2017-01-31|November 2014|Actual|2014-11-30|August 2012|Actual|2012-08-31||Interventional|||A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC|Phase II Single-Arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess the Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Cell Lung Cancer|Completed||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||Undecided||2018-06-01 00:39:53.596999|2018-06-01 00:39:53.596999
NCT00963794|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-08-21|2009-08-21|2009-08-24|Estimate|||||||2009-08-21|2009-08-24|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Diagnosis of Rectal Cancer by Electromagnetic Device|Clinical Investigation on a Device for the Diagnosis of Rectal Cancer|Completed||N/A|442|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-06-01 00:39:53.792845|2018-06-01 00:39:53.792845
NCT00963781|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2012-12-20|2009-08-21|2009-08-24|Estimate|||||||2012-12-20|2012-12-24|Estimate|August 2009||2009-08-31|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|SEASIDE||Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)|A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent|Unknown status|Active, not recruiting|Phase 4|900|Anticipated|Scripps Health||1|||f||||t||||||||||2018-06-01 00:39:53.88572|2018-06-01 00:39:53.88572
NCT00963768|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2014-04-22|2009-08-21|2009-08-24|Estimate|||||||2014-04-22|2014-04-23|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of JNJ-28431754 in Type 2 Diabetes Mellitus Patients|Completed||Phase 1|116|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||5|||f||||f||||||||||2018-06-01 00:39:54.135293|2018-06-01 00:39:54.135293
NCT00963755|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2016-11-13|2009-08-20|2009-08-21|Estimate|||||||2016-11-13|2016-11-15|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer|Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer|Recruiting|||60|Anticipated|University of Lausanne Hospitals|||2||f||||f||||||Samples With DNA|"~     Surgical specimen for total prostatectomy~   "|No||2018-06-01 00:39:54.354349|2018-06-01 00:39:54.354349
NCT00963742|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2014-03-17|2009-08-20|2009-08-21|Estimate|||||||2014-03-17|2014-03-18|Estimate|December 2006||2006-12-31|March 2014|2014-03-31|April 2010|Actual|2010-04-30|July 2009|Actual|2009-07-31||Interventional|||Lenstec Softec HD Posterior Chamber Intraocular Lens Clinical Investigational Protocol|Lenstec Softec HD Posterior Chamber Intraocular Lens (PCIOL) Clinical Investigational Protocol|Completed||N/A|390|Actual|Lenstec Incorporated||1|||f||||f||||||||||2018-06-01 00:39:54.420019|2018-06-01 00:39:54.420019
NCT00963729|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-08-09|2009-08-20|2009-08-21|Estimate|||||||2013-08-09|2013-08-12|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery|A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal Patients With Primary Breast Cancer|Completed||Phase 3|756|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:39:54.508232|2018-06-01 00:39:54.508232
NCT00963716|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2009-08-20|2009-08-20|2009-08-21|Estimate|||||||2009-08-20|2009-08-21|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Hot and Cold Biopsy Forceps in the Diagnosis of Endobronchial Lesions|Hot and Cold Biopsy Forceps in the Diagnosis of Endobronchial Lesions|Completed||N/A|168|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-06-01 00:39:54.604709|2018-06-01 00:39:54.604709
NCT00963703|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2012-03-19|2009-08-20|2009-08-21|Estimate|||||||2012-03-19|2012-03-20|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis|Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis Using Rituximab: A Pilot Study Evaluating Synovial Outcomes|Completed||N/A|15|Anticipated|University of Manitoba||1|||f||||t||||||||||2018-06-01 00:39:54.716787|2018-06-01 00:39:54.716787
NCT00963690|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-01-30|2009-08-20|2009-08-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2009|Actual|2009-08-31|January 2017|2017-01-31|May 30, 2013|Actual|2013-05-30|April 30, 2013|Actual|2013-04-30||Interventional|||Evaluation of the CloSys Closure System as an Adjunct to Standard Compression|CloSys Hemostatic Device U.S. Multi-Center Clinical Investigation|Terminated||N/A|30|Actual|CloSys Corporation||2||Lack of funding|f||||t||||||||||2018-06-01 00:39:54.789277|2018-06-01 00:39:54.789277
NCT00963677|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2010-05-26||2012-05-01|2009-08-20|2009-08-21|Estimate|2012-05-01|2012-05-03|Estimate||||2012-05-01|2012-05-03|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|SOS||Nasotracheal Intubation Using Shikani Optical Stylet|Shikani Optical Stylet for Nasotracheal Intubation Undergoing Oral and Maxillofacial Surgery, a Prospective Evaluation|Completed||N/A|55|Actual|Central South University||2|||f||||t||||||||||2018-06-01 00:39:54.866287|2018-06-01 00:39:54.866287
NCT00963664|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-09-04|2009-08-20|2009-08-21|Estimate|||||||2009-09-04|2009-09-09|Estimate|December 2009||2009-12-31|September 2009|2009-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma|Phase 2 Study of Interferon Alfa-2b and Lovastatin Combination Therapy for Patients With High-risk Resected or Unresectable Malignant Melanoma|Withdrawn||Phase 2|250|Anticipated|NeoPlas Innovation||1||Modifications will be necessary before full IRB approval will be secured.|f||||f||||||||||2018-06-01 00:39:55.073941|2018-06-01 00:39:55.073941
NCT00963651|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-07-23|2009-08-20|2009-08-21|Estimate|||||||2013-07-23|2013-07-24|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||GE Healthcare VolumeRAD Lung Nodule Detection Study|GE Healthcare VolumeRAD Lung Nodule Detection Study|Completed|||187|Actual|American College of Radiology - Image Metrix|||1||f||||f||||||||||2018-06-01 00:39:55.151776|2018-06-01 00:39:55.151776
NCT00963638|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2011-04-19||2012-09-19|2009-08-20|2009-08-21|Estimate|2011-05-12|2011-06-13|Estimate||||2012-09-19|2012-10-01|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Beneficial Effects of Magnesium Supplementation On Idiopathic Muscle Cramps|Beneficial Effects of Magnesium Supplementation On Idiopathic Muscle Cramps|Completed||N/A|40|Actual|William Beaumont Hospitals||2|||f||||f||||||||||2018-06-01 00:39:55.221874|2018-06-01 00:39:55.221874
NCT00963625|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-10-08|2009-08-20|2009-08-21|Estimate|||||||2010-10-08|2010-10-13|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients|Comparison of Transfers of Fresh and Thawed Embryos in Normal Responder Patients|Completed||N/A|100|Anticipated|Fertility Center of Las Vegas||2|||f||||f||||||||||2018-06-01 00:39:55.415797|2018-06-01 00:39:55.415797
NCT00963612|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-09-28|2009-08-19|2009-08-21|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2009||2009-09-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Non-invasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)|Non-Invasive Prediction of Microvascular Invasion (MVI) in Hepatocellular Carcinoma (HCC) by Assessment of Tumor Oxygenation by Blood Oxygen Level-Dependent Magnetic Resonance Imaging (BOLD MRI)|Completed||N/A|80|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 00:39:56.513009|2018-06-01 00:39:56.513009
NCT00963599|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2009-08-31||2015-02-24|2009-08-20|2009-08-21|Estimate|2010-05-14|2010-06-16|Estimate||||2015-02-24|2015-03-13|Estimate|September 1999||1999-09-30|February 2015|2015-02-28|November 1999|Actual|1999-11-30|November 1999|Actual|1999-11-30||Interventional|||Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Combination Montelukast/Loratadine in Patients With Seasonal Allergic Rhinitis-Fall Study|Completed||Phase 3|907|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 00:39:56.600976|2018-06-01 00:39:56.600976
NCT00963586|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2010-06-24|2009-08-20|2009-08-21|Estimate|||||||2010-06-24|2010-06-25|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Observational|||Quality of Life in Patients Treated for Head and Neck Cancer|Quality of Life in Patients Treated for Head and Neck Cancer|Completed|||456|Actual|Maastricht Radiation Oncology|||2||f||||f||||||||||2018-06-01 00:39:57.183269|2018-06-01 00:39:57.183269
NCT00963573|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2015-04-20|2009-08-20|2009-08-21|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2003||2003-09-30|April 2015|2015-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)|Efficacy and Safety of Loratadine-Betamethasone Oral Solution (1 mg/0.05 mg/1 mL) for Initial Treatment of Severe Perennial Allergic Rhinitis in School Age Children|Completed||Phase 4|100|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:39:57.334511|2018-06-01 00:39:57.334511
NCT00963560|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2011-07-13||2011-07-13|2009-08-20|2009-08-21|Estimate|2011-07-13|2011-08-09|Estimate||||2011-07-13|2011-08-09|Estimate|August 2009||2009-08-31|July 2011|2011-07-31||||March 2011|Actual|2011-03-31||Interventional|||Presbyopia-Correcting Intraocular Lenses (IOLs)|A Randomized, Subject-masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting IOLs|Completed||Phase 4|132|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 00:39:57.408326|2018-06-01 00:39:57.408326
NCT00962442|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2009-08-19|2009-08-19|2009-08-20|Estimate|||||||2009-08-19|2009-08-20|Estimate|September 2000||2000-09-30|August 2009|2009-08-31||||January 2006|Actual|2006-01-31||Interventional|||N-Acetylcysteine in Severe Acute Alcoholic Hepatitis|N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial|Completed||Phase 3|44|Actual|Erasme University Hospital||2|||f||||t||||||||||2018-06-01 00:40:19.662717|2018-06-01 00:40:19.662717
NCT00963547|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2015-02-03|2009-08-20|2009-08-21|Estimate|||||||2015-02-03|2015-02-04|Estimate|September 2009||2009-09-30|February 2015|2015-02-28|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (2206-015)|A Phase I Investigation of the Combination of MK2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:39:57.611119|2018-06-01 00:39:57.611119
NCT00963534|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2018-03-09|2009-08-20|2009-08-21|Estimate|||||||2018-03-09|2018-03-12|Actual|September 2009|Actual|2009-09-30|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|LENA-BERIT||Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.|Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma - a Nordic Lymphoma Group Trial|Completed||Phase 1/Phase 2|51|Actual|Lund University Hospital||1|||f||||f||||||||||2018-06-01 00:39:57.689737|2018-06-01 00:39:57.689737
NCT00963521|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2011-05-12|2009-08-20|2009-08-21|Estimate|||||||2011-05-12|2011-05-13|Estimate|June 2008||2008-06-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Interventional|||Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission|Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission|Completed||Phase 1|10|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:39:57.786334|2018-06-01 00:39:57.786334
NCT00963508|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2014-01-31||2014-05-14|2009-08-20|2009-08-21|Estimate|2014-05-14|2014-06-13|Estimate||||2014-05-14|2014-06-13|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice|A Multi-Center Phase III Study to Evaluate Malathion Gel 0.5% Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects With Pediculosis Capitis|Completed||Phase 3|403|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:39:57.894598|2018-06-01 00:39:57.894598
NCT00963495|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2015-06-19|2009-08-20|2009-08-21|Estimate|||||||2015-06-19|2015-06-22|Estimate|August 2009||2009-08-31|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy|Phase 1 Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy|Terminated||Phase 1|11|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:39:58.169796|2018-06-01 00:39:58.169796
NCT00963482|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2012-02-01||2015-03-09|2009-08-20|2009-08-21|Estimate|2012-03-19|2012-04-13|Estimate||||2015-03-09|2015-03-27|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|August 2011|Actual|2011-08-31|January 2010|Actual|2010-01-31||Interventional|||Smoking Cessation in Alcoholics|Secondary Prevention of Tobacco Dependence in Alcohol-dependent Patients - a Randomized, Controlled Trial|Completed||N/A|103|Actual|University Hospital, Basel, Switzerland|Originally two recruiting centers were planned, what failed. Though less subjects than expected.|2|||f||||f||||||||||2018-06-01 00:39:58.25637|2018-06-01 00:39:58.25637
NCT00963469|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2009-09-16||2015-06-22|2009-08-20|2009-08-21|Estimate|2010-05-12|2010-06-09|Estimate||||2015-06-22|2015-07-15|Estimate|August 2001||2001-08-31|June 2015|2015-06-30|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001|Completed||Phase 3|1079|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 00:39:58.521522|2018-06-01 00:39:58.521522
NCT00963443|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2014-12-04|2009-08-20|2009-08-21|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold|A Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Acetylsalicylic Acid Combined With Pseudoephedrine, Compared With Acetylsalicylic Acid Alone, and Pseudoephedrine Alone, on Symptoms of Pain.|Completed||Phase 3|833|Actual|Bayer||4|||f||||f||||||||||2018-06-01 00:39:58.995506|2018-06-01 00:39:58.995506
NCT00963430|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2011-04-21||2012-11-29|2009-08-20|2009-08-21|Estimate|2011-04-21|2011-05-16|Estimate||||2012-11-29|2012-12-03|Estimate|September 2009||2009-09-30|April 2010|2010-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||H1N1 Vaccine in Pregnant Women|A Phase II Study in Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels|Completed||Phase 2|120|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 00:39:59.119229|2018-06-01 00:39:59.119229
NCT00963417|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2017-08-08|2009-08-20|2009-08-21|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2009||2009-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TEXT-Bone||Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02|TEXT-Bone: A Substudy of the TEXT Trial to Evaluate Serial Bone Markers for Bone Remodeling, Serial Growth Factors, and Bone Mineral Density|Active, not recruiting||N/A|119|Actual|International Breast Cancer Study Group||2|||f||||t||||||||No||2018-06-01 00:39:59.8558|2018-06-01 00:39:59.8558
NCT00963404|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2018-05-02|2009-08-20|2009-08-21|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2009||2009-08-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Image-Guided Tumorboost of Bladder Cancer|Image-guided Tumorboost of Localized Unifocal Bladder Cancer: A Phase I/II Study|Completed||Phase 1/Phase 2|19|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 00:39:59.982464|2018-06-01 00:39:59.982464
NCT00963391|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-08-20|2009-08-20|2009-08-21|Estimate|||||||2009-08-20|2009-08-21|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||"Alcohol Based Hand Sanitizers for the Prevention of Acute Diarrheal Disease and Acute Respiratory Infection in Children Under 5 Attending Childcare Centers in Bogotá, Cundinamarca and Tolima, in Colombia: a Cluster Randomized Control Trial"|"Alcohol Based Hand Sanitizers for the Prevention of Acute Diarrheal Disease and Acute Respiratory Infection in Children Under 5 Attending Childcare Centers in Bogotá, Cundinamarca and Tolima, in Colombia: a Cluster Randomized Control Trial"|Completed||N/A|1727|Actual|Fundación Santa Fe de Bogota||2|||f||||f||||||||||2018-06-01 00:40:00.070462|2018-06-01 00:40:00.070462
NCT00963196|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2010-06-02|2009-08-20|2009-08-21|Estimate|||||||2010-06-02|2010-06-04|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|SADFAT||Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response|Supplementation of Antidepressants With Fatty Acid Therapy|Withdrawn||N/A|78|Anticipated|University of Virginia||3||End of allotted time for subject recruiting.|f||||f||||||||||2018-06-01 00:40:03.504964|2018-06-01 00:40:03.504964
NCT00963365|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2014-10-10|2009-08-20|2009-08-21|Estimate|||||||2014-10-10|2014-10-13|Estimate|November 2008||2008-11-30|October 2014|2014-10-31|March 2010|Anticipated|2010-03-31|February 2009|Anticipated|2009-02-28||Interventional|||AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)|Pt. A: Ph I, Sngl-Blind, Randomized, Pcbo-Controlled 3-Way Crossover Study Followed by an Open-label Food Effect Study to Assess the PK of IV and Oral AZD6765 in Healthy Male and Female Subjects Pt.B: Ph I, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and PK of AZD6765 When Administered in Multiple Ascending Doses to Healthy Subjects|Withdrawn||Phase 1|0|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:40:00.153267|2018-06-01 00:40:00.153267
NCT00963352|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-08-26|2009-08-20|2009-08-21|Estimate|||||||2010-08-26|2010-08-27|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|December 2010|Anticipated|2010-12-31|August 2009|Actual|2009-08-31||Observational|||Colon Cancer Prognosis After Radical Surgery|Prognosis of Colon Cancer. Clinical and Pathological-anatomical Factors Concerned With Radical Surgery|Unknown status|Recruiting||300|Anticipated|Haraldsplass Deaconess Hospital|||1||f||||f||||||Samples With DNA|"~     Biopsies. 1) fresh frozen 2) sampled in RNA later 3) archival formalin~   "|||2018-06-01 00:40:00.226504|2018-06-01 00:40:00.226504
NCT00963339|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2010-09-22|2009-08-20|2009-08-21|Estimate|||||||2010-09-22|2010-09-23|Estimate|September 2009||2009-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Observational|AMD||Age-Related Macular Degeneration (AMD) - Usability Study|Age-Related Macular Degeneration (AMD) - Usability Study|Completed|||54|Actual|Notal Vision Ltd|||1||f||||t||||||||||2018-06-01 00:40:00.300468|2018-06-01 00:40:00.300468
NCT00963326|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2011-02-25|2009-08-20|2009-08-21|Estimate|||||||2011-02-25|2011-02-28|Estimate|June 2008||2008-06-30|February 2011|2011-02-28||||July 2010|Anticipated|2010-07-31||Observational|||Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer|Morphological and Molecular Characterization of Tumors of the Aero-digestive Tract in Patients Who Have no Risk Factors Such as Alcohol, Smoking, or Occupation|Unknown status|Recruiting||60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:40:00.387367|2018-06-01 00:40:00.387367
NCT00963313|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2014-09-22|2009-08-20|2009-08-21|Estimate|||||||2014-09-22|2014-09-23|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Observational|||A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis|A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis|Completed|||29|Actual|Instituto de Investigacion Biomedica de A Coruna|||1||f||||f||||||Samples Without DNA|"~     Samples recollected for analysing IL6 and MMP3 from patients blood serum.~   "|||2018-06-01 00:40:00.465911|2018-06-01 00:40:00.465911
NCT00963300|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2011-02-18|2009-08-20|2009-08-21|Estimate|||||||2011-02-18|2011-02-21|Estimate|September 2009||2009-09-30|August 2009|2009-08-31||||September 2010|Anticipated|2010-09-30||Interventional|||MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy|Hypoxia Assessment in Localized Prostate Cancer: A Companion Protocol to a Phase II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer|Unknown status|Not yet recruiting|N/A|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:40:00.556174|2018-06-01 00:40:00.556174
NCT00963287|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2016-04-18|2009-08-20|2009-08-21|Estimate|||||||2016-04-18|2016-04-19|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Trial of Chinese Prescription on Ulcerative Colitis||Completed||N/A|200|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:40:00.755511|2018-06-01 00:40:00.755511
NCT00963274|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2018-04-19|2009-08-20|2009-08-21|Estimate|||||||2018-04-19|2018-04-23|Actual|April 26, 2010|Actual|2010-04-26|April 2018|2018-04-30|April 13, 2018|Actual|2018-04-13|July 17, 2014|Actual|2014-07-17||Interventional|||Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma|Completed||Phase 1|18|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 00:40:00.910301|2018-06-01 00:40:00.910301
NCT00963261|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2010-06-24|2009-08-20|2009-08-21|Estimate|||||||2010-06-24|2010-06-25|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|April 2012|Anticipated|2012-04-30|February 2011|Anticipated|2011-02-28||Interventional|||Quality of Life and Psychological Well-being in Patients With Malignant Melanoma|Side-effect Management for Patients With Malignant Melanoma Undergoing Treatment With Interferon Alpha (IFN-α)- Diagnosis and Therapy -|Unknown status|Recruiting|N/A|600|Anticipated|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 00:40:01.041138|2018-06-01 00:40:01.041138
NCT00963248|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2015-04-10|2009-08-20|2009-08-21|Estimate|||||||2015-04-10|2015-04-13|Estimate|July 2003||2003-07-31|April 2015|2015-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients|Surveillance of EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients - a Multicenter Prospective Study|Completed|||106|Actual|Klinik für Kinder- und Jugendmedizin|||||f||||t||||||Samples Without DNA|"~     EDTA plasma for EB viral load, serum for differentiated serology and sodium heparine~     whole-blood for EBV-specific t cells~   "|||2018-06-01 00:40:01.156782|2018-06-01 00:40:01.156782
NCT00963235|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2013-04-17||2013-04-17|2009-08-20|2009-08-21|Estimate|2013-04-17|2013-06-10|Estimate||||2013-04-17|2013-06-10|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Safety population included participants who received at least 1 dose of study vaccine.|Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS|A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine|Completed||Phase 3|331|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 00:40:01.32195|2018-06-01 00:40:01.32195
NCT00963222|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2012-06-02|2009-08-20|2009-08-21|Estimate|||||||2012-06-02|2012-06-05|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|September 2011|Actual|2011-09-30||Interventional|||The Study of the Effects of Vitamin A on Immune System in Patients With Atherosclerosis|The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Atherosclerosis|Unknown status|Enrolling by invitation|Phase 4|60|Anticipated|Tehran University of Medical Sciences||4|||f||||t||||||||||2018-06-01 00:40:03.315036|2018-06-01 00:40:03.315036
NCT00963209|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-07-31|2009-08-20|2009-08-21|Estimate|||||||2013-07-31|2013-08-02|Estimate|June 2009||2009-06-30|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Tamoxifen Citrate in Patients With Breast Cancer|Tamoxifen Metabolism and the Impact of Tamoxifen Dose on the Level of the Active Metabolites in Endocrine Sensitive Breast Cancer Patients|Unknown status|Recruiting|Phase 3|140|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||||2018-06-01 00:40:03.407769|2018-06-01 00:40:03.407769
NCT00963183|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2015-01-13|2009-08-20|2009-08-21|Estimate|||||||2015-01-13|2015-01-14|Estimate|August 2009||2009-08-31|November 2014|2014-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||AZD5423 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD5423 After Single Ascending Doses in Healthy Male Subjects|Completed||Phase 1|72|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:40:03.635233|2018-06-01 00:40:03.635233
NCT00963157|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|2011-11-10||2014-12-04|2009-08-20|2009-08-21|Estimate|2011-11-10|2011-12-14|Estimate||||2014-12-04|2014-12-24|Estimate|September 2009||2009-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of a Sanofi Pasteur H1N1 Influenza Vaccine Administered at Different Dose Levels Given With and Without GlaxoSmithKline AS03 Adjuvant|Completed||Phase 2|789|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 00:40:03.767236|2018-06-01 00:40:03.767236
NCT00963144|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2010-10-20|2009-08-20|2009-08-21|Estimate|||||||2010-10-20|2010-10-21|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|GQS||Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study|Diagnosis and Response to Treatment Using a Reliable Gerd Questionnaire-an In Clinical Practise Study|Completed|||250|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:40:05.709053|2018-06-01 00:40:05.709053
NCT00963131|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2009-12-29|2009-08-20|2009-08-21|Estimate|||||||2009-12-29|2009-12-30|Estimate|December 2004||2004-12-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||High-dose Antioxidants for Central Serous Chorioretinopathy|High-dose Antioxidants for Central Serous Chorioretinopathy|Completed||Phase 2|60|Anticipated|Prince of Songkla University||2|||f||||t||||||||||2018-06-01 00:40:05.775562|2018-06-01 00:40:05.775562
NCT00963118|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2017-04-24|2009-08-20|2009-08-21|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2009||2009-06-30|April 2017|2017-04-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|Biogreen||Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability|Bioactive Plant Foods: Effects on Functional Bioavailability and Genomic Stability|Completed||N/A|36|Actual|Tufts University||4|||f||||f||||||||||2018-06-01 00:40:05.852171|2018-06-01 00:40:05.852171
NCT00963105|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2017-10-02|2009-08-20|2009-08-21|Estimate|||||||2017-10-02|2017-10-03|Actual|October 19, 2009|Actual|2009-10-19|October 2017|2017-10-31|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Interventional|||Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|104|Actual|Celgene||3|||f||||t||||||||||2018-06-01 00:40:05.937668|2018-06-01 00:40:05.937668
NCT00963092|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-20|||2013-08-09|2009-08-20|2009-08-21|Estimate|||||||2013-08-09|2013-08-12|Estimate|August 2002||2002-08-31|July 2011|2011-07-31||||December 2010|Anticipated|2010-12-31||Observational|||Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer|Stomach and Oesophageal Cancer Study (SOCS)|Unknown status|Recruiting||4000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:40:06.079101|2018-06-01 00:40:06.079101
NCT00963079|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-07-12|2009-08-20|2009-08-21|Estimate|||||||2010-07-12|2010-07-13|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients|Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients|Completed||N/A|100|Anticipated|Fertility Center of Las Vegas||2|||f||||f||||||||||2018-06-01 00:40:06.181529|2018-06-01 00:40:06.181529
NCT00963066|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2010-03-02|2009-08-20|2009-08-21|Estimate|||||||2010-03-02|2010-03-03|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||NAV-ALI: Neurally Adjusted Ventilatory Assist in Patients Recovering Spontaneous Breathing After Acute Lung Injury|NAV-ALI: Effects of Different Levels of Neurally Adjusted Ventilatory Assist (NAVA) in Patients Recovering Spontaneous Breathing After Acute Lung Injury: A Physiological Evaluation.|Completed||N/A|15|Anticipated|University Hospital, Caen||3|||f||||f||||||||||2018-06-01 00:40:06.308185|2018-06-01 00:40:06.308185
NCT00963053|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17||2014-05-06|2014-05-06|2009-08-20|2009-08-21|Estimate||||2014-05-06|2014-05-22|Estimate|2014-05-06|2014-05-22|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept|A Randomised, Double Blind, Placebo Controlled, Multicentre, Cross Over Proof of Concept Study to Investigate the Efficacy and Safety of Pre Emptive Administration of Repeated, Oral Doses of VA111913 TS for the Alleviation of Dysmenorrhoea|Completed||Phase 2|146|Actual|Vantia Ltd||2|||f||||f||||||||||2018-06-01 00:40:06.388571|2018-06-01 00:40:06.388571
NCT00963040|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2011-09-08|2009-08-19|2009-08-20|Estimate|||||||2011-09-08|2011-09-09|Estimate|November 2009||2009-11-30|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache|The Effect of Intranasal Oxytocin on Headache Intensity and Headache-associated Symptoms in Patients Suffering From Chronic Daily Headache|Completed||N/A|40|Actual|MedVadis Research Corporation||2|||f||||f||||||||||2018-06-01 00:40:06.47185|2018-06-01 00:40:06.47185
NCT00963027|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-03-05|2009-08-19|2009-08-20|Estimate|||||||2010-03-05|2010-03-08|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil|An Evaluation of Single Dose UT-15C SR (Treprostinil Diethanolamine) Pharmacokinetics Following Repeated Dosing With the Proton Pump Inhibitor Esomeprazole in Healthy Adult Volunteers|Completed||Phase 1|30|Anticipated|United Therapeutics|||||f||||f||||||||||2018-06-01 00:40:06.550583|2018-06-01 00:40:06.550583
NCT00963001|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-03-05|2009-08-19|2009-08-20|Estimate|||||||2010-03-05|2010-03-08|Estimate|September 2009||2009-09-30|March 2010|2010-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Food on the Pharmacokinetics of Oral Treprostinil|Effect of Different Meal Types on the Pharmacokinetics of a Single 1 mg Oral Dose of UT-15C (Treprostinil Diethanolamine) Sustained Release Tablets in Healthy Volunteers|Completed||Phase 1|32|Anticipated|United Therapeutics|||||f||||f||||||||||2018-06-01 00:40:06.639696|2018-06-01 00:40:06.639696
NCT00962793|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2009-08-19|2009-08-19|2009-08-20|Estimate|||||||2009-08-19|2009-08-20|Estimate||||August 2009|2009-08-31||||||||Observational|||Diagnosis of Latent Tuberculosis(TB) Infection in Health Care Workers Using TST and Whole Blood Interferon-γ Assay||Completed|||||Yonsei University|||||f||||||||||||||2018-06-01 00:40:08.67823|2018-06-01 00:40:08.67823
NCT00962988|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2015-04-14|2009-08-19|2009-08-20|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease|Efficacy and Cost-effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease|Completed||Phase 4|194|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-06-01 00:40:06.737562|2018-06-01 00:40:06.737562
NCT00962975|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2014-04-07|2009-08-19|2009-08-20|Estimate|||||||2014-04-07|2014-04-08|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies||Completed||Phase 1|29|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:40:06.845688|2018-06-01 00:40:06.845688
NCT00962962|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2014-07-14|2009-08-19|2009-08-20|Estimate|||||||2014-07-14|2014-07-15|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|STRRIDE-PD||Exercise Dose-Response Effects in Prediabetes|Exercise Dose-Response Effects in Prediabetes: Responses and Mechanisms|Completed||N/A|288|Actual|Duke University||4|||f||||f||||||||||2018-06-01 00:40:06.915214|2018-06-01 00:40:06.915214
NCT00962949|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2017-10-03|2009-08-19|2009-08-20|Estimate|||||||2017-10-03|2017-10-06|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Renin-Aldosterone Axis in Postural Tachycardia Syndrome|The Renin-Aldosterone Axis in Postural Tachycardia Syndrome|Completed||N/A|35|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 00:40:07.001906|2018-06-01 00:40:07.001906
NCT00962936|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2014-08-28|2009-08-19|2009-08-20|Estimate|||||||2014-08-28|2014-08-29|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection|Phase I/II Study to Evaluate the Safety and Tolerability of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection|Terminated||Phase 1/Phase 2|13|Actual|CureTech Ltd||1|||f||||f||||||||||2018-06-01 00:40:07.078455|2018-06-01 00:40:07.078455
NCT00962923|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2009-08-19|2009-08-19|2009-08-20|Estimate|||||||2009-08-19|2009-08-20|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Allogeneic Mesenchymal Stem Cells Transplantation for Systemic Sclerosis (SSc)||Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||||f||||t||||||||||2018-06-01 00:40:07.151304|2018-06-01 00:40:07.151304
NCT00962910|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2017-10-12|2009-08-19|2009-08-20|Estimate|||||||2017-10-12|2017-10-13|Actual|May 2009||2009-05-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|May 2014|Actual|2014-05-31||Interventional|EQCP-PFF||European Quality of Care Pathways Study on Proximal Femur Fracture (EQCP-PFF)|"The European Quality of Care Pathways Study: The Impact of a Care Pathway for Proximal Femur Fracture (PFF) : an International Cluster Randomized Controlled Trial. (Www.E-P-A.Org)"|Completed||N/A|514|Actual|European Pathway Association||2|||f||||t||||||||||2018-06-01 00:40:07.22361|2018-06-01 00:40:07.22361
NCT00962897|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2009-08-19|2009-08-19|2009-08-20|Estimate|||||||2009-08-19|2009-08-20|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|May 2007|Actual|2007-05-31||Observational|||Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusion|A Retrospective Review of Randomized Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusion With Four Years Followup|Completed|||100|Actual|Texas Vascular Associates|||2||f||||t||||||||||2018-06-01 00:40:07.305127|2018-06-01 00:40:07.305127
NCT00962884|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2018-02-27|2009-08-19|2009-08-20|Estimate|||||||2018-02-27|2018-03-01|Actual|December 2010||2010-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Breathing Device for Orthostatic Hypotension (OH)|Assessment of Inspiratory Breathing Devices to Improve Orthostatic Tolerance in Neurogenic Orthostatic Hypotension|Active, not recruiting||N/A|30|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 00:40:07.395719|2018-06-01 00:40:07.395719
NCT00962871|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2015-12-09||2016-01-14|2009-08-19|2009-08-20|Estimate|2015-12-09|2016-01-13|Estimate||||2016-01-14|2016-02-08|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both|An Open-label, Randomized Study to Evaluate the Acute Immunologic Responses in Asian Subjects With E Antigen Positive Chronic Hepatitis B Following Initiation of Therapy for Hepatitis B With Pegasys, Nucleoside Analogues, or Both.|Completed||Phase 1|30|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 00:40:07.501409|2018-06-01 00:40:07.501409
NCT00962845|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2017-02-02|2009-08-19|2009-08-20|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2010||2010-09-30|February 2017|2017-02-28|May 30, 2013|Actual|2013-05-30|May 30, 2013|Actual|2013-05-30||Interventional|||Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery|A Phase 0 Trial of Hydroxychloroquine, an Inhibitor of Autophagy, in Patients With Stage III or IV Resectable Melanoma|Completed||Early Phase 1|20|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 00:40:08.126579|2018-06-01 00:40:08.126579
NCT00962832|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19||2016-08-10|2016-08-10|2009-08-19|2009-08-20|Estimate||||2016-08-10|2016-08-12|Estimate|2016-08-10|2016-08-12|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|August 2013|Actual|2013-08-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus|A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus|Completed||Phase 2|238|Actual|Genentech, Inc.||5|||f||||||||||||||2018-06-01 00:40:08.22231|2018-06-01 00:40:08.22231
NCT00962819|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2014-03-04|2009-08-19|2009-08-20|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Measles, Mumps, and Rubella (MMR) Immunity in College Students|Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine|Completed|||74|Actual|Emory University|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:40:08.512949|2018-06-01 00:40:08.512949
NCT00962806|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2012-04-25|2009-08-19|2009-08-20|Estimate|||||||2012-04-25|2012-04-27|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Intensive Exercise to Improve Mitochondrial Dysfunction in Pediatric Obesity|Intensive Exercise to Improve Mitochondrial Dysfunction in Pediatric Obesity|Unknown status|Active, not recruiting|N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 00:40:08.610974|2018-06-01 00:40:08.610974
NCT00962780|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2014-03-17||2014-11-13|2009-08-19|2009-08-20|Estimate|2014-11-13|2014-11-17|Estimate||||2014-11-13|2014-11-17|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Safety population included all enrolled participants who received at least 1 dose of investigational product.|Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine|A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine|Completed||Phase 3|303|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 00:40:08.875661|2018-06-01 00:40:08.875661
NCT00962767|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2009-08-19|2009-08-19|2009-08-20|Estimate|||||||2009-08-19|2009-08-20|Estimate|May 2002||2002-05-31|August 2009|2009-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission|A Randomized Study of Two Doses Gemtuzumab Ozogamicin vs. A Two-year Maintenance With Atra Plus Chemotherapy as Post-consolidation Treatment for Intermediate and High-risk Adult Patients With Acute Promyelocytic Leukemia (Apl)|Completed||Phase 3|168|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 00:40:11.38297|2018-06-01 00:40:11.38297
NCT00962754|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2012-01-04||2014-04-08|2009-08-19|2009-08-20|Estimate|2014-04-08|2014-05-07|Estimate||||2014-04-08|2014-05-07|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Fluid Balance Study in Sick Neonates|Reliability and Utility of Fluid Balance Charting in Neonates Admitted to the Pediatric Ward.|Completed||Phase 4|170|Actual|Princess Amalia Children's Clinic|"lack of a more reliable assessment method of fluid status, for example central venous pressure or body impedance measurements~moderate disease severity~unequal distribution of premature infants amongst the study groups"|2|||f||||f||||||||||2018-06-01 00:40:11.468301|2018-06-01 00:40:11.468301
NCT00962741|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2012-06-14||2014-05-29|2009-08-19|2009-08-20|Estimate|2012-06-14|2012-07-19|Estimate||||2014-05-29|2014-06-10|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|June 2011|Actual|2011-06-30||Interventional|CLIPPER||Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis|A 2-Part Open-Label Study to Assess the Clinical Benefit and Long-Term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis|Completed||Phase 3|127|Actual|Pfizer|Results include data for Part 1 (up to Week 12) and Part 2 (up to week 96) of the study.|1|||f||||t||||||||||2018-06-01 00:40:11.924305|2018-06-01 00:40:11.924305
NCT00962728|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2018-02-15|2009-08-19|2009-08-20|Estimate|||||||2018-02-15|2018-02-19|Actual|October 2009||2009-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)|Assessment of Inspiratory Breathing Devices to Improve Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome|Active, not recruiting||N/A|30|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 00:40:14.265347|2018-06-01 00:40:14.265347
NCT00962715|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2012-08-02|2009-08-19|2009-08-20|Estimate|||||||2012-08-02|2012-08-03|Estimate|April 2011||2011-04-30|August 2012|2012-08-31||||||||Interventional|||Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia|A Randomized, Phase I/II Clinical Trial Evaluating the Safety, Reactogenicity, and Immunogenicity of Licensed Trivalent Influenza Vaccine Administered With Recombinant Interferon Alpha Among Patients With Chronic Lymphocytic Leukemia|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-06-01 00:40:14.359031|2018-06-01 00:40:14.359031
NCT00962702|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2009-08-19|2009-08-19|2009-08-20|Estimate|||||||2009-08-19|2009-08-20|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|October 2010|Anticipated|2010-10-31|December 2009|Anticipated|2009-12-31||Interventional|||Exclusion of the Left Atrial Appendage (LAA) With the LAAx, Inc. TigerPaw System|Exclusion of the Left Atrial Appendage With the LAAx, Inc., TigerPaw™ System During Elective, Non-Endoscopic Cardiac Surgery Procedures|Unknown status|Recruiting|Phase 2|60|Anticipated|LAAx, Inc.||1|||f||||f||||||||||2018-06-01 00:40:14.449083|2018-06-01 00:40:14.449083
NCT00962689|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2017-04-27|2009-08-19|2009-08-20|Estimate|||||||2017-04-27|2017-04-28|Actual|August 2009|Actual|2009-08-31|April 2017|2017-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Clinical Study to Improve Diagnosis and Treatment of Sinusitis|Improving Patient Care Via Proteomics Based, Microbe-Specific Detection of Chronic Rhinosinusitis|Completed|||38|Actual|Ohio State University|||2||f||||f||||||Samples With DNA|"~     whole blood nasal secretions nasal mucosa nasal polyps~   "|No||2018-06-01 00:40:14.535245|2018-06-01 00:40:14.535245
NCT00962676|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2012-01-31|2009-08-19|2009-08-20|Estimate|||||||2012-01-31|2012-02-02|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients||Completed|||140|Actual|Yonsei University|||2||f||||||||||||||2018-06-01 00:40:14.590325|2018-06-01 00:40:14.590325
NCT00962663|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2012-09-27|2009-08-19|2009-08-20|Estimate|||||||2012-09-27|2012-09-28|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of ICA-105665 Using the Intradermal Capsaicin and Ultraviolet B (UV-B) Models in Healthy Male Subjects|A Randomized, Placebo-Controlled, 3-way Crossover Study to Investigate the Pharmacodynamic Effects of ICA-105665 Using the Intradermal Capsaicin and UV-B Models in Healthy Male Subjects|Completed||Phase 1|25|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:40:14.641612|2018-06-01 00:40:14.641612
NCT00962650|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2010-12-20||2012-03-01|2009-08-18|2009-08-20|Estimate|2012-03-01|2012-03-29|Estimate||||2012-03-01|2012-03-29|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|NOTES||Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance|A Feasibility Trial to Evaluate Natural Orifice Transgastric Endoscopic Diagnostic Peritoneoscopy With Laparoscopic Assistance.|Completed||N/A|7|Actual|Ethicon Endo-Surgery|Ten male and female subjects indicated for Diagnostic Peritoneoscopy in advance of Roux-en Y Gastic Bypass procedure, who had a history of previous abdominal surgery, and met study Inclusion Criteria, were enrolled in the study.|1|||f||||f||||||||||2018-06-01 00:40:14.712217|2018-06-01 00:40:14.712217
NCT00962637|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2010-02-10|2009-08-19|2009-08-20|Estimate|||||||2010-02-10|2010-02-11|Estimate|March 2006||2006-03-31|February 2010|2010-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Open-Label, Active-Controlled Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism|Completed||Phase 3|194|Actual|Repros Therapeutics Inc.||4|||f||||f||||||||||2018-06-01 00:40:14.849123|2018-06-01 00:40:14.849123
NCT00962624|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2012-03-27|2009-08-19|2009-08-20|Estimate|||||||2012-03-27|2012-03-28|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|MenOccy||Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults|A Phase 2, Open-label Study of the Safety, Tolerability and Immunogenicity of a Meningococcal B Vaccine When Administered at a 0, 2, 6 Months and of a Single Dose of Meningococcal ACWY Conjugate Vaccine in Healthy Adults Aged 18-65 Years|Completed||Phase 2|38|Actual|Public Health England|||||f||||f||||||||||2018-06-01 00:40:15.995805|2018-06-01 00:40:15.995805
NCT00962611|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2017-10-05|2009-08-19|2009-08-20|Estimate|||||||2017-10-05|2017-10-06|Actual|November 19, 2009|Actual|2009-11-19|October 2017|2017-10-31|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Interventional|||BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer|An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Maximum Tolerated Dose and Biomarker Response After Intravenous Administration of Weekly BAY80-6946 to Patients With Advanced Cancer|Completed||Phase 1|57|Actual|Bayer||1|||f||||t||||||||||2018-06-01 00:40:16.079316|2018-06-01 00:40:16.079316
NCT00962598|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2017-04-17||2018-04-20|2009-08-19|2009-08-20|Estimate|2017-04-17|2017-05-24|Actual||||2018-04-20|2018-04-24|Actual|January 2006||2006-01-31|April 2018|2018-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Role Of Omega-3 Fatty Acids In Adolescent Depression|The Role Of Omega-3 Fatty Acids In Adolescent Depression|Completed||Phase 2|16|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||||2018-06-01 00:40:16.171736|2018-06-01 00:40:16.171736
NCT00962585|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2013-05-07||2014-03-11|2009-08-19|2009-08-20|Estimate|2014-03-11|2014-04-08|Estimate||||2014-03-11|2014-04-08|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients|Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients|Completed||Phase 2|169|Actual|Ausio Pharmaceuticals, LLC|Per-protocol, an ANOVA model was to be used for the primary efficacy analysis. However using statistical adjustment of baseline values, ANCOVA could be more a more powerful analysis (Vickers AJ. BMC Med Res Methodology. 2001;1:6. Epub 2001 Jun 28).|4|||f||||f||||||||||2018-06-01 00:40:16.451235|2018-06-01 00:40:16.451235
NCT00962572|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2012-04-06|2009-08-19|2009-08-20|Estimate|||||||2012-04-06|2012-04-09|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Observational|||The Effects of Aggressive Patient Management on Cancer Therapy Management|The Effects of Aggressive Patient Management on Cancer Therapy Management|Withdrawn|||0|Actual|University of Mississippi Medical Center||||Investigator decided not to pursue|f||||f||||||||||2018-06-01 00:40:18.772879|2018-06-01 00:40:18.772879
NCT00962559|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-02-16|2009-08-19|2009-08-20|Estimate|||||||2010-02-16|2010-02-17|Estimate|February 2008||2008-02-29|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Hypopituitarism After Aneurismal Subarachnoid Hemorrhage|Endocrine and Neuropsychological Changes After Aneurismal Subarachnoid Hemorrhage.|Completed|||26|Anticipated|Universitätsmedizin Mannheim|||||f||||f||||||||||2018-06-01 00:40:18.836323|2018-06-01 00:40:18.836323
NCT00962546|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2014-12-08|2009-08-19|2009-08-20|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage|Computed Tomographic Perfusion and Computed Tomographic Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage|Completed|||4|Actual|Washington University School of Medicine|||1||f||||t||||||||||2018-06-01 00:40:18.894746|2018-06-01 00:40:18.894746
NCT00962533|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2013-01-29|2009-08-19|2009-08-20|Estimate|||||||2013-01-29|2013-01-31|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|EFFORT||EFFicacy Optimization Research of Telbivudine Therapy|A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study)|Completed||Phase 4|606|Actual|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-06-01 00:40:18.962382|2018-06-01 00:40:18.962382
NCT00962520|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2016-04-05|2009-08-18|2009-08-20|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2009||2009-04-30|March 2016|2016-03-31||||April 2018|Anticipated|2018-04-30||Interventional|||Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer|Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 00:40:19.102234|2018-06-01 00:40:19.102234
NCT00962507|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2013-02-13|2009-08-19|2009-08-20|Estimate|||||||2013-02-13|2013-02-15|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma|A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma|Completed||Phase 1|11|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:40:19.251541|2018-06-01 00:40:19.251541
NCT00962494|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2013-02-05|2009-08-19|2009-08-20|Estimate|||||||2013-02-05|2013-02-07|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors|Cancer Survivors Online Self-Management Workshop|Completed||Phase 2|585|Actual|Stanford University||1|||f||||||||||||||2018-06-01 00:40:19.329372|2018-06-01 00:40:19.329372
NCT00962481|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-01-05|2009-08-19|2009-08-20|Estimate|||||||2010-01-05|2010-01-06|Estimate||||January 2010|2010-01-31||||||||Interventional|||Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia|A Double-blind, Placebo Controlled, Randomized, Cross-over, Phase IIa Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia in Healthy Subjects|Completed||Phase 2|18|Anticipated|Revotar Biopharmaceuticals AG||2|||f||||||||||||||2018-06-01 00:40:19.404559|2018-06-01 00:40:19.404559
NCT00962468|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2017-10-12|2009-08-19|2009-08-20|Estimate|||||||2017-10-12|2017-10-13|Actual|May 2009||2009-05-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|March 2014|Actual|2014-03-31||Interventional|EQCP-COPD||European Quality of Care Pathways Study on Chronic Obstructive Pulmonary Disease (COPD)|"The European Quality of Care Pathways Study: The Impact of a Care Pathway for Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) : an International Cluster Randomized Controlled Trial. (Www.E-P-A.Org)"|Completed||N/A|342|Actual|European Pathway Association||2|||f||||t||||||||||2018-06-01 00:40:19.466608|2018-06-01 00:40:19.466608
NCT00962429|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2013-01-30|2009-08-19|2009-08-20|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy|Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study|Completed||Phase 2|8|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 00:40:19.730716|2018-06-01 00:40:19.730716
NCT00962416|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2016-03-29|2009-08-19|2009-08-20|Estimate|||||||2016-03-29|2016-03-30|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2012|Actual|2012-01-31||Interventional|COMFORTABLE||Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI)|Comparison of Biolimus Eluted From an Erodable Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction and In Vivo 3-Vessel Assessment of Time-Related Changes of Culprit and Non-Culprit Lesions by IVUS/OCT in AMI|Completed||Phase 4|1161|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 00:40:19.811498|2018-06-01 00:40:19.811498
NCT00962403|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2013-03-19|2009-08-18|2009-08-20|Estimate|||||||2013-03-19|2013-03-20|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|EYIPTSD||Evaluation of a Yoga Intervention for Post-Traumatic Stress Disorder|Evaluation of a Yoga Intervention for Post-Traumatic Stress Disorder|Completed||N/A|108|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 00:40:19.913191|2018-06-01 00:40:19.913191
NCT00962390|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|2017-01-18||2017-04-12|2009-08-19|2009-08-20|Estimate|2017-04-12|2017-05-19|Actual||||2017-04-12|2017-05-19|Actual|June 2009||2009-06-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Participants who took at least one (1) dose of investigational product were included in the baseline analysis population.|Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia|Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia|Completed||Phase 2|116|Actual|Ausio Pharmaceuticals, LLC||4|||f||||f||||||||||2018-06-01 00:40:20.160575|2018-06-01 00:40:20.160575
NCT00962377|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2010-12-20|2009-08-19|2009-08-20|Estimate|||||||2010-12-20|2010-12-21|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|EIMAGE||A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation|Early Invasive Monitoring Attenuation Through Gene Expression (EIMAGE) Trial|Unknown status|Active, not recruiting|N/A|40|Actual|XDx||2|||f||||f||||||||||2018-06-01 00:40:21.372572|2018-06-01 00:40:21.372572
NCT00962364|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2017-03-20|2009-08-19|2009-08-20|Estimate|||||||2017-03-20|2017-03-21|Actual|October 2001||2001-10-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Observational|BMC registry||Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease|Long-term Evaluation and Follow-up Care of Patients Receiving Intracoronary Bone Marrow-derived Cell Administration for Heart Disease|Active, not recruiting|||1500|Anticipated|Johann Wolfgang Goethe University Hospital|||3||f||||f||||||Samples With DNA|"~     Serum and plasma from peripheral blood and bone marrow may me retained~   "|||2018-06-01 00:40:21.472837|2018-06-01 00:40:21.472837
NCT00962351|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2015-08-14|2009-08-19|2009-08-20|Estimate|||||||2015-08-14|2015-08-17|Estimate|October 2003||2003-10-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2010|Actual|2010-10-31||Interventional|||Metal Ion Release From an FDA-Approved Metal-on-Metal Total Hip Replacement Implant|Metal Ion Release From an FDA Approved Metal-on-Metal Hip Replacement Implant: A Multi-Center, Randomized Clinical Trial|Completed||N/A|120|Actual|Anderson Orthopaedic Research Institute||3|||f||||t||||||||||2018-06-01 00:40:21.568041|2018-06-01 00:40:21.568041
NCT00962338|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2011-08-19|2009-08-19|2009-08-20|Estimate|||||||2011-08-19|2011-08-22|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|Lap-Lyske||Pain and Convalescence After Laparoscopic Groin Hernia Repair|Pain and Convalescence After Laparoscopic Groin Hernia Repair|Completed|||210|Actual|Zealand University Hospital|||1||f||||t||||||||||2018-06-01 00:40:21.654689|2018-06-01 00:40:21.654689
NCT00962325|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2016-03-14|2009-08-19|2009-08-20|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Interventional|||Increasing Physical Activity Among Inactive Bariatric Surgery Patients (Bari-Active)|Increasing Physical Activity Among Inactive Bariatric Surgery Patients|Completed||N/A|80|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-06-01 00:40:21.736502|2018-06-01 00:40:21.736502
NCT00962312|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-19|||2014-12-30|2009-08-19|2009-08-20|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2009||2009-01-31|October 2012|2012-10-31||||December 2010|Actual|2010-12-31||Interventional|||Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Study of Lapatinib and Capecitabine in the Treatment of Metastatic Pancreatic Cancer.|Completed||Phase 2|9|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 00:40:21.817329|2018-06-01 00:40:21.817329
NCT00962299|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2018-01-03|2009-08-18|2009-08-19|Estimate|||||||2018-01-03|2018-01-04|Actual|May 2010||2010-05-31|January 2018|2018-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ICS@ADP||Effectiveness of Inhaled Corticosteroids in Preschool Children With Acute Dyspnea and Wheeze|Effectiveness of Inhaled Corticosteroids in Preschool Children Following Hospital Admission for Acute Dyspnea and Wheeze|Terminated||Phase 4|7|Actual|Princess Amalia Children's Clinic||2||recruitment was unsuccesfull, only 7 patient have been included untill 2012|f||||f||||||||||2018-06-01 00:40:21.918486|2018-06-01 00:40:21.918486
NCT00962286|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2011-08-03|2009-08-18|2009-08-19|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration||Terminated||N/A|3|Actual|Rabin Medical Center||1||The blood pressure did not decrease following furosemide administration|f||||f||||||||||2018-06-01 00:40:21.995455|2018-06-01 00:40:21.995455
NCT00962273|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2010-08-17|2009-08-18|2009-08-19|Estimate|||||||2010-08-17|2010-08-19|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||The Pandemic Stress Vaccine: A Resource to Enhance the Resilience of Healthcare Workers Facing an Infectious Outbreak|The Pandemic Stress Vaccine: Randomized Controlled Trial of an Educational Resource to Enhance the Resilience of Healthcare Workers Facing an Infectious Outbreak|Terminated||N/A|118|Actual|Mount Sinai Hospital, Canada||3||low participation and retention rates|f||||f||||||||||2018-06-01 00:40:22.062906|2018-06-01 00:40:22.062906
NCT00962260|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2013-08-13|2009-08-18|2009-08-19|Estimate|||||||2013-08-13|2013-08-14|Estimate||||August 2013|2013-08-31||||||||Expanded Access|||Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease|An Open-label Expanded Access Trial of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease Who Require Enzyme Replacement Therapy|No longer available|||||Protalix|||||||||||||||||||2018-06-01 00:40:22.139688|2018-06-01 00:40:22.139688
NCT00962247|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2016-11-11||2017-07-25|2009-08-18|2009-08-19|Estimate|2017-07-25|2017-08-24|Actual||||2017-07-25|2017-08-24|Actual|July 2006||2006-07-31|July 2017|2017-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|Effects||Effect of Changing Sedentary Behavior in Youth|Effect of Changing Sedentary Behavior in Youth|Completed||N/A|61|Actual|State University of New York at Buffalo||1|||f||||t||||||||No||2018-06-01 00:40:22.262801|2018-06-01 00:40:22.262801
NCT00962234|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2016-02-24|2009-08-18|2009-08-19|Estimate|||||||2016-02-24|2016-02-26|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Metabolism of Lipids in Advanced Cancer|Metabolism of Lipids in Advanced Cancer|Terminated|||12|Actual|AHS Cancer Control Alberta|||1|ethics approval not renewed by Study Group|f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:40:22.494374|2018-06-01 00:40:22.494374
NCT00962221|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2016-09-07|2009-08-18|2009-08-19|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Observational|LPSH||Lipids Profile in Subclinical Hypothyroidism|Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Subclinical Hypothyroidism|Terminated|||100|Actual|HaEmek Medical Center, Israel|||1|Recruiting difficulties|f||||f||||||||||2018-06-01 00:40:22.707215|2018-06-01 00:40:22.707215
NCT00962208|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2013-07-17||2013-09-21|2009-08-18|2009-08-19|Estimate|2013-07-17|2013-09-20|Estimate||||2013-09-21|2013-10-28|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|ROMIO||Retardation of Myopia in Orthokeratology|Orthokeratology for Myopic Control in Chinese Children - a Randomized Clinical Trial|Completed||N/A|102|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-06-01 00:40:22.798372|2018-06-01 00:40:22.798372
NCT00962195|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2010-04-13|2009-08-18|2009-08-19|Estimate|||||||2010-04-13|2010-04-14|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effect of Purple Sweet Potato (PSP)-Juice on Liver Enzymes and Blood Pressure|The Effect of Purple Sweet Potato (PSP)-Juice on Liver Enzymes and Blood Pressure|Completed||N/A|40|Actual|TNO||2|||f||||f||||||||||2018-06-01 00:40:23.016345|2018-06-01 00:40:23.016345
NCT00962182|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2018-03-04|2009-08-18|2009-08-19|Estimate|||||||2018-03-04|2018-03-06|Actual|August 2008||2008-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of Enzyme Supplements to Treat Celiac Disease|Effect of a Cocktail of Two Common Enzyme Supplements on Celiac Disease Patients With Persistent Seropositivity|Completed||Phase 1/Phase 2|38|Actual|Heim Pal Children's Hospital||3|||f||||t||||||||||2018-06-01 00:40:23.103649|2018-06-01 00:40:23.103649
NCT00962169|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-18|2009-08-18|2009-08-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|GIPhT||Guideline Implementation in Physiotherapy|Development and Pilot Testing of an Implementation Strategy to Increase Physiotherapists'Adherence to Evidence-based Guideline for Patients With Low Back Pain: a Planned, Systematic and Theory-based Approach|Unknown status|Recruiting|N/A|30|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 00:40:23.184768|2018-06-01 00:40:23.184768
NCT00962156|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2012-07-09|2009-08-18|2009-08-19|Estimate|||||||2012-07-09|2012-07-10|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|6S||Scandinavian Starch for Severe Sepsis/Septic Shock Trial|Effects of Hydroxyethyl Starch 130/0.4 Compared With Balanced Crystalloid Solution on Mortality and Kidney Failure in Patients With Severe Sepsis|Completed||Phase 3|804|Actual|Scandinavian Critical Care Trials Group||2|||f||||t||||||||||2018-06-01 00:40:23.333966|2018-06-01 00:40:23.333966
NCT00962143|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2017-04-04|2009-08-18|2009-08-19|Estimate|||||||2017-04-04|2017-04-05|Actual|June 2008||2008-06-30|April 2017|2017-04-30|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|||Acute Achilles Repair With or Without OrthADAPT Augmentation|Prospective, Randomized, Multi-center: Acute Achilles Repair With or Without OrthADAPT Augmentation|Withdrawn||N/A|0|Actual|Baxter Healthcare Corporation||2||Funding withdrawn|f||||f||||||||||2018-06-01 00:40:23.441427|2018-06-01 00:40:23.441427
NCT00962130|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2018-03-16|2009-08-18|2009-08-19|Estimate|||||||2018-03-16|2018-03-20|Actual|August 2009||2009-08-31|March 2018|2018-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Glucose Monitoring in Tissue Transfers|Glucose Monitoring in Tissue Transfers|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||1||No patients enrolled.|f||||f||||||||||2018-06-01 00:40:23.510172|2018-06-01 00:40:23.510172
NCT00962117|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2012-06-12|2009-08-18|2009-08-19|Estimate|||||||2012-06-12|2012-06-13|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Relationship Between Dopamine Genetics, Food Reinforcement, Energy Intake and Obesity|Food Reinforcement Genotype Interactions and Eating|Completed|||310|Actual|State University of New York at Buffalo|||1||f||||t||||||Samples With DNA|"~     Saliva DNA samples will be collected from all participants~   "|||2018-06-01 00:40:23.57491|2018-06-01 00:40:23.57491
NCT00962104|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2012-02-06||2012-08-10|2009-08-18|2009-08-19|Estimate|2012-08-10|2012-09-11|Estimate||||2012-08-10|2012-09-11|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder|A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|391|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:40:23.659803|2018-06-01 00:40:23.659803
NCT00962091|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2013-07-01|2009-08-18|2009-08-19|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Study of MLN8237 in Patients With Advanced Solid Tumors|An Open-label, Phase 1 Study of the Relative Bioavailability, Food Effect, Safety and Tolerability of MLN8237 in Patients With Advanced Solid Tumors|Completed||Phase 1|53|Actual|Millennium Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 00:40:24.408749|2018-06-01 00:40:24.408749
NCT00962078|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2011-11-10|2009-08-18|2009-08-19|Estimate|||||||2011-11-10|2011-11-11|Estimate|July 2008||2008-07-31|November 2011|2011-11-30||||October 2010|Actual|2010-10-31||Interventional|||Pulmonary Rehabilitation in Patients Before Lung Transplantation (LTx)|Effects of a Complex Pulmonary Rehabilitation Program on Patients With End Stage Lung Diseases Undergoing Evaluation for Lung Transplantation (Pre-LTx)|Completed||N/A|60|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-06-01 00:40:24.479393|2018-06-01 00:40:24.479393
NCT00962065|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2011-02-04||2011-02-04|2009-08-18|2009-08-19|Estimate|2011-02-04|2011-03-03|Estimate||||2011-02-04|2011-03-03|Estimate|August 2009||2009-08-31|February 2011|2011-02-28||||December 2009|Actual|2009-12-31||Interventional|||Study of LX4211 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX4211 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|36|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:40:24.549067|2018-06-01 00:40:24.549067
NCT00962052|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2010-09-12|2009-08-18|2009-08-19|Estimate|||||||2010-09-12|2010-09-14|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Biomarker Discovery and Application in Bladder Cancer|Biomarker Discovery and Application in Bladder Cancer: Identification and Detection of Gene Methylation, Tumor Specific Antigenes Markers of BCG Treatment.|Unknown status|Recruiting||250|Anticipated|Wolfson Medical Center|||||f||||f||||||Samples With DNA|"~     blood, first void urine, bladder tumors and healthy tissue~   "|||2018-06-01 00:40:25.014245|2018-06-01 00:40:25.014245
NCT00962039|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2009-08-18|2009-08-18|2009-08-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|July 2004||2004-07-31|March 2009|2009-03-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Anxiety and Recurrent Abdominal Pain in Children|Anxiety and Recurrent Abdominal Pain in Children|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|National Institute of Mental Health (NIMH)||1|||f||||t||||||||||2018-06-01 00:40:25.060717|2018-06-01 00:40:25.060717
NCT00962026|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2014-02-21|2009-08-17|2009-08-19|Estimate|||||||2014-02-21|2014-02-24|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|RID-A||Rilonacept in Diabetes Mellitus Type 1: Safety Study|A Phase I, Open-label, Safety Study of Anti-inflammatory Therapy With Rilonacept in Adolescents and Adults With Type 1 Diabetes Mellitus|Completed||Phase 1|13|Actual|University of Texas Southwestern Medical Center||1|||f||||||||||||||2018-06-01 00:40:25.154244|2018-06-01 00:40:25.154244
NCT00962013|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2014-04-04||2017-02-10|2009-08-17|2009-08-19|Estimate|2014-07-24|2014-08-15|Estimate||||2017-02-10|2017-03-29|Actual|January 2004||2004-01-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Includes participants who received the Restoration® Modular Hip System and were not censored from analysis.|Restoration® Modular Revision Hip System Post Market Study|A Prospective Open-Label Evaluation of the Restoration® Modular System|Completed||N/A|137|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:40:25.364269|2018-06-01 00:40:25.364269
NCT00962000|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2011-06-22||2017-04-04|2009-08-18|2009-08-19|Estimate|2011-06-22|2011-07-21|Estimate||||2017-04-04|2017-05-10|Actual|September 2009||2009-09-30|April 2017|2017-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate|Effect of Dialysate Flow Rate on Delivered Dose of Dialysis (Kt/Vurea)|Completed||N/A|42|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 00:40:25.624602|2018-06-01 00:40:25.624602
NCT00961987|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2009-08-18|2009-08-18|2009-08-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|October 2009||2009-10-31|August 2009|2009-08-31||||June 2010|Anticipated|2010-06-30||Interventional|||Innovation to Providing Interprofessional Maternity Care|Innovation to the Provision of Maternity Care in Hamilton: An Inter- and Intraprofessional Collaboration|Unknown status|Not yet recruiting|N/A|700|Anticipated|McMaster University||2|||f||||||||||||||2018-06-01 00:40:25.901526|2018-06-01 00:40:25.901526
NCT00961974|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2018-04-20|2009-08-18|2009-08-19|Estimate|||||||2018-04-20|2018-04-23|Actual|April 2002||2002-04-30|April 2018|2018-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Intensive Care Program for Youth With Diabetes|Intensive Care Program for Youth With Diabetes|Completed||N/A|154|Actual|Joslin Diabetes Center||3|||f||||t||||||||||2018-06-01 00:40:26.022543|2018-06-01 00:40:26.022543
NCT00961961|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2017-08-08|2009-08-18|2009-08-19|Estimate|||||||2017-08-08|2017-08-10|Actual|July 1, 2009|Actual|2009-07-01|August 2017|2017-08-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Prevention of Relapse & Recurrence of Bipolar Depression|Prevention of Relapse & Recurrence of Bipolar Depression|Completed||Phase 4|184|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 00:40:26.110574|2018-06-01 00:40:26.110574
NCT00961948|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2013-02-26|2009-08-18|2009-08-19|Estimate|||||||2013-02-26|2013-02-27|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Indigo Carmine Staining and Narrow Band Imaging (NBI) of Colonic Mucosa for Detection of Dysplasia in Ulcerative Colitis|A Pilot Study for the Determination of Inter-observer Variation for Abnormalities Detected by Indigo Carmine Staining and Narrow Band Imaging Among Patients Undergoing Surveillance Colonoscopy for Ulcerative Colitis|Completed|||60|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 00:40:26.21151|2018-06-01 00:40:26.21151
NCT00961935|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2016-01-12|2009-08-18|2009-08-19|Estimate|||||||2016-01-12|2016-01-13|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||Pediatric Bipolar Disorder Study at UCLA|Examining Neurocognitive Profiles of Bipolar Disorder and Attention-Deficit Hyperactivity Disorder|Completed|||50|Actual|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 00:40:26.291337|2018-06-01 00:40:26.291337
NCT00961922|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2012-10-03|2009-08-18|2009-08-19|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|July 2014|Anticipated|2014-07-31|October 2013|Anticipated|2013-10-31||Interventional|PRISMA||Pediatric Research on Improving Speed, Memory and Attention|The Efficacy of Neurofeedback to Improve Processing Speed, Attention and Memory in Childhood Brain Tumour Survivors: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|105|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||t||||||||||2018-06-01 00:40:26.401754|2018-06-01 00:40:26.401754
NCT00961909|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2016-11-01|2009-08-18|2009-08-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus|A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group, 2-Part Study to Investigate the Safety, Tolerability, PK, and PD of Once Weekly RO5095932 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin|Completed||Phase 1|122|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 00:40:26.469021|2018-06-01 00:40:26.469021
NCT00961896|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2015-08-19||2015-10-05|2009-08-18|2009-08-19|Estimate|2015-08-19|2015-09-21|Estimate||||2015-10-05|2015-11-03|Estimate|July 2009||2009-07-31|October 2015|2015-10-31||||August 2010|Actual|2010-08-31||Interventional|||A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients|A Double-blind, Randomized, Vehicle-controlled Proof of Concept (PoC) Study to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Topical Administrations of LDE225 (a Specific Smoothened Inhibitor) on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients Followed by an Open Label, Randomized Expansion Group to Test Two Different Strengths of an Improved LDE225 Formulation for Extended Treatment Durations|Completed||Phase 2|18|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:40:26.610516|2018-06-01 00:40:26.610516
NCT00961883|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2013-09-04|2009-08-17|2009-08-19|Estimate|||||||2013-09-04|2013-09-06|Estimate|August 2009||2009-08-31|September 2013|2013-09-30||||January 2013|Actual|2013-01-31||Interventional|||Safety of and Immune Response to Prime/Boost Vaccine Regimens in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adults|A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime/Boost Vaccine Regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adult Participants|Completed||Phase 1|80|Actual|HIV Vaccine Trials Network||4|||f||||t||||||||||2018-06-01 00:40:27.071454|2018-06-01 00:40:27.071454
NCT00961870|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2013-08-12|2009-08-17|2009-08-19|Estimate|||||||2013-08-12|2013-08-13|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|ERAMNE||Effect of Radius on Alpha Motor Neuron Excitability|Effect of Radius Subjecting to Mechanical Loading on Alpha Motor Neuron Excitability|Completed||N/A|80|Actual|Vakif Gureba Training and Research Hospital||4|||f||||t||||||||||2018-06-01 00:40:27.163562|2018-06-01 00:40:27.163562
NCT00961857|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2015-08-18|2009-08-18|2009-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|December 2005||2005-12-31|August 2015|2015-08-31|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)|An Open-label, Randomized Two-Part, Two-Period Crossover Study to Demonstrate the Definitive Bioequivalence After Administration of Final Market Image (FMI) Sitagliptin /Metformin 50/500 mg and 50/1000 mg Fixed Dose Combination (FDC) and Concomitant Administration of 50 mg Doses of Sitagliptin and 500 or 1000 mg Doses of Metformin as Individual Tablets|Completed||Phase 1|48|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 00:40:27.232054|2018-06-01 00:40:27.232054
NCT00961844|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2014-08-22|2009-08-17|2009-08-19|Estimate|||||||2014-08-22|2014-08-25|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma|Phase I/II Trial for Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma|Terminated||Phase 1/Phase 2|15|Actual|Oslo University Hospital||1||Logistical problems|f||||f||||||||||2018-06-01 00:40:27.295083|2018-06-01 00:40:27.295083
NCT00961831|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2014-02-19|2009-08-18|2009-08-19|Estimate|||||||2014-02-19|2014-02-20|Estimate|April 2009||2009-04-30|February 2014|2014-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients|Open-label, Multicenter Study for an Evaluation of Radiation Dosimetry, Metabolism, Safety and Tolerability of the [F18] Labeled PET (Positron Emission Tomography) Tracer BAY 85-8050 Following a Single Intravenous Administration in Healthy Volunteers, as Well as the Investigation of Safety, Tolerability and Diagnostic Performance of the Tracer in PET/CT (Computer Tomography) in Patients|Completed||Phase 1|20|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:40:27.359506|2018-06-01 00:40:27.359506
NCT00961818|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2009-08-18|2009-08-18|2009-08-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|||Immediate Effect Analysis of Vocal Techniques|Perceptual, Acoustic and Laryngological Analysis of Vocal Techniques Immediate Effect|Completed|||32|Actual|Tuiuti University of Paraná|||||f||||t||||||||||2018-06-01 00:40:27.423801|2018-06-01 00:40:27.423801
NCT00961805|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2009-04-30||2009-08-19|2009-08-18|2009-08-19|Estimate|2009-08-18|2009-08-19|Estimate||||2009-08-19|2009-08-25|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|November 2008|Actual|2008-11-30|September 2007|Actual|2007-09-30||Interventional|||Effectiveness of Dance on Patients With Fibromyalgia|Effectiveness of Dance on Patients With Fibromyalgia|Completed||N/A|80|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 00:40:27.490323|2018-06-01 00:40:27.490323
NCT00961792|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2017-10-25|2009-08-18|2009-08-19|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2004||2004-03-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CSDP||Chicago Social Drinking Project|Individual Differences After Consumption of Alcohol and Other Common Substances and Long-Term Follow-Up of Social Drinking, Young Adults|Active, not recruiting||N/A|400|Anticipated|University of Chicago||5|||f||||f|f|f||||||||2018-06-01 00:40:27.929289|2018-06-01 00:40:27.929289
NCT00961779|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2014-10-03|2009-08-18|2009-08-19|Estimate|||||||2014-10-03|2014-10-07|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Safety Study of NNZ-2566 in Healthy Female Subjects|A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability and PK of NNZ-2566 in Healthy Females, When Administered as a Loading Dose (10-Min), and as a Loading Dose Followed by a Maintenance Dose (72-Hr).|Completed||Phase 1|39|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||||2018-06-01 00:40:27.996894|2018-06-01 00:40:27.996894
NCT00961766|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2014-10-24|2009-08-18|2009-08-19|Estimate|||||||2014-10-24|2014-10-28|Estimate|August 2009||2009-08-31|October 2014|2014-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants|Phase 1: A Single-Center, Randomized, Blinded, Placebo-Controlled, Single-Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants|Completed||Phase 1|48|Actual|Biogen||2|||f||||t||||||||||2018-06-01 00:40:28.068487|2018-06-01 00:40:28.068487
NCT00961753|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2014-01-25|2009-08-18|2009-08-19|Estimate|||||||2014-01-25|2014-01-28|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|OIDS||Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates|Safety and Efficacy of an Optimized Ibuprofen Dosing Regimen Versus Standard Dosing for Pharmacologic Closure of Patent Ductus Arteriosus|Terminated||Phase 4|10|Actual|OSF Healthcare System||2||FDA drug recall on July 30, 2010|f||||t||||||||||2018-06-01 00:40:28.269003|2018-06-01 00:40:28.269003
NCT00961740|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2014-05-25|2009-08-18|2009-08-19|Estimate|||||||2014-05-25|2014-05-28|Estimate|February 2007||2007-02-28|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Childhood Obesity- Characteristics and Treatment|Cognitive Behavioural Treatment for Childhood Obesity- A Clinical Trial.|Completed||N/A|44|Actual|University of Bergen||2|||f||||f||||||||||2018-06-01 00:40:28.345466|2018-06-01 00:40:28.345466
NCT00961727|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2015-05-28|2009-08-18|2009-08-19|Estimate|||||||2015-05-28|2015-06-01|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Implementation of Bedside Pediatric Early Warning Systems (PEWS)|Implementation of Bedside PEWS at Credit Valley Hospital|Completed|||200|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-06-01 00:40:28.424676|2018-06-01 00:40:28.424676
NCT00961714|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2014-01-07|2009-08-18|2009-08-19|Estimate|||||||2014-01-07|2014-01-09|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|OsseoFix||OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture|Evaluation of Safety and Effectiveness of the OsseoFix™ Spinal Fracture Reduction System in Treating Spinal Compression Fracture|Terminated||Phase 2/Phase 3|15|Actual|Alphatec Spine, Inc.||1||Withdrew study|f||||t||||||||||2018-06-01 00:40:28.496967|2018-06-01 00:40:28.496967
NCT00961701|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2016-09-07|2009-08-18|2009-08-19|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2010|Actual|2010-10-31||Observational|LPHP||Lipids Profile in Primary Hyperparathyroidism|Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Primary Hyperparathyroidism|Terminated|||100|Actual|HaEmek Medical Center, Israel||||sample size was not enrolled|f||||f||||||||||2018-06-01 00:40:28.590186|2018-06-01 00:40:28.590186
NCT00961688|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2010-02-01|2009-08-17|2009-08-19|Estimate|||||||2010-02-01|2010-02-03|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|PCOS||The Impact of Polycystic Ovary Syndrome (PCOS) on Quality of Life and Healthcare Beliefs|The Impact of PCOS on Quality of Life and Healthcare Beliefs|Completed|||600|Anticipated|Georgia Reproductive Specialists|||||f||||f||||||||||2018-06-01 00:40:28.651658|2018-06-01 00:40:28.651658
NCT00961675|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18||2012-09-05|2015-09-14|2009-08-18|2009-08-19|Estimate||||2012-09-05|2012-09-10|Estimate|2015-09-14|2015-09-30|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||FST-201 in the Treatment of Acute Otitis Externa|A Phase III Clinical Study Evaluating the Efficacy Of FST-201 Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa|Completed||Phase 3|70|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:40:28.763818|2018-06-01 00:40:28.763818
NCT00961662|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2013-12-05||2014-11-01|2009-08-18|2009-08-19|Estimate|2014-11-01|2014-11-06|Estimate||||2014-11-01|2014-11-06|Estimate|February 2008||2008-02-29|November 2014|2014-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)|Dose Ranging Effects of Three Low-doses of Naturlose™ (Tagatose) on Glycemic Control and Safety of Naturlose™ (Tagatose) Over Six Months in Subjects With Mild Type 2 Diabetes Mellitus Under Control With Diet and Exercise.|Completed||Phase 2|161|Actual|Spherix Incorporated||3|||f||||f||||||||||2018-06-01 00:40:28.857456|2018-06-01 00:40:28.857456
NCT00961649|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2013-05-17|2012-07-17|2013-05-17|2009-08-18|2009-08-19|Estimate|2013-05-17|2013-07-04|Estimate|2012-07-17|2012-07-25|Estimate|2013-05-17|2013-07-04|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||This reporting group includes all randomized subjects, as treated.|Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination|Safety and IOP-Lowering Efficacy of Brinzolamide/Brimonidine Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma and/or Ocular Hypertension|Terminated||Phase 2|195|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 00:40:29.190963|2018-06-01 00:40:29.190963
NCT00961636|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2012-01-14||2015-01-29|2009-08-18|2009-08-19|Estimate|2012-01-14|2012-02-17|Estimate||||2015-01-29|2015-02-16|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia|Completed||Phase 3|1152|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 00:40:29.573912|2018-06-01 00:40:29.573912
NCT00961623|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2011-06-10|2009-08-18|2009-08-19|Estimate|||||||2011-06-10|2011-06-13|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Characterizing Knee Pain and Response to Surgery Using Local Biomarkers|Characterizing Knee Pain and Response to Surgery Using Local Biomarkers|Unknown status|Recruiting||150|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     Synovial fluid lavage.~   "|||2018-06-01 00:40:30.076844|2018-06-01 00:40:30.076844
NCT00961610|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-18|2009-08-18|2009-08-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|April 2004||2004-04-30|August 2009|2009-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Internet-based Support in Cancer Rehabilitation|Internet-based Support in the Rehabilitation of Danish Cancer Survivors|Completed|||794|Actual|Danish Cancer Society|||2||f||||t||||||||||2018-06-01 00:40:30.135047|2018-06-01 00:40:30.135047
NCT00961597|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2014-12-10|2009-08-18|2009-08-19|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Assessment of Outcome of Meniscus Repair With or Without Platelet Rich Plasma|Repair of Human Meniscus Complex Red/White Tears With or Without Platelet-Rich Plasma|Withdrawn||N/A|0|Actual|Cincinnati Sportsmedicine Research and Education Foundation||2|||f||||t||||||||||2018-06-01 00:40:30.195085|2018-06-01 00:40:30.195085
NCT00961571|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2017-03-11||2018-03-06|2009-08-18|2009-08-19|Estimate|2017-03-11|2017-04-21|Actual||||2018-03-06|2018-04-03|Actual|August 2009||2009-08-31|December 2017|2017-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||metastatic colon cancer who has not received 1st line systemic chemotherapy|Sunitinib and Capecitabine for First Line Colon Cancer|A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|50|Actual|Georgetown University||1||Unanticipated side effects and futility|f||||t||||||||No||2018-06-01 00:40:30.293338|2018-06-01 00:40:30.293338
NCT00961558|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2012-05-24|2009-08-18|2009-08-19|Estimate|||||||2012-05-24|2012-05-28|Estimate||||August 2011|2011-08-31||||||||Interventional|CVI||Canadian Varicocelectomy Initiative (CVI): Effects on Male Fertility and Testicular Function of Varicocelectomy|A Prospective, Multi-Centre, Randomized Controlled Study Comparing Varicocelectomy to Observation in Infertile Men With Clinical Varicoceles|Terminated||N/A|300|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-06-01 00:40:30.479917|2018-06-01 00:40:30.479917
NCT00961532|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2014-07-16||2014-08-11|2009-08-18|2009-08-19|Estimate|2014-08-11|2014-08-28|Estimate||||2014-08-11|2014-08-28|Estimate|December 2010||2010-12-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|IMPACT||Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept|Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept|Completed||Phase 2|14|Actual|Northwestern University||1|||f||||||||||||||2018-06-01 00:40:30.65585|2018-06-01 00:40:30.65585
NCT00961519|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2016-04-12|2009-08-18|2009-08-19|Estimate|||||||2016-04-12|2016-04-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:40:30.815857|2018-06-01 00:40:30.815857
NCT00961506|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2009-08-18|2009-08-18|2009-08-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Prospective Evaluation of Laparoendoscopic Single Site Versus Laparoscopic Cholecystectomy|Prospective Evaluation of Laparoendoscopic Single Site Versus Laparoscopic Cholecystectomy|Completed||Phase 2|40|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 00:40:30.871422|2018-06-01 00:40:30.871422
NCT00762528|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2012-03-05||2015-08-27|2008-09-26|2008-09-30|Estimate|2012-03-05|2012-04-03|Estimate||||2015-08-27|2015-09-10|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Compare Anti-inflammatory Dentifrices|Compare Anti-inflammatory Dentifrices|Completed||Phase 4|49|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:42:58.396609|2018-06-01 01:42:58.396609
NCT00961493|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2013-06-17|2009-08-18|2009-08-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2007||2007-03-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||RCT of an Acceptance-based Behavior Therapy for GAD|Randomized Controlled Trial of an Acceptance-based Behavior Therapy for Generalized Anxiety Disorder|Completed||N/A|81|Actual|University of Massachusetts, Boston||2|||f||||t||||||||||2018-06-01 00:40:30.948397|2018-06-01 00:40:30.948397
NCT00961480|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2015-06-08|2009-08-18|2009-08-19|Estimate|||||||2015-06-08|2015-06-09|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)|A 3-Part, Open-Label, Randomized, 2-Period Crossover Study to Demonstrate the Definitive Bioequivalence After Administration of the FMI Sitagliptin/Metformin 50/500 mg, 50/850 mg and 50/1000 mg FDC Tablet and Co-administration of Corresponding Doses of Sitagliptin and Metformin as Individual Tablets|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:40:31.016188|2018-06-01 00:40:31.016188
NCT00961467|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2016-05-09|2009-08-18|2009-08-19|Estimate|||||||2016-05-09|2016-05-10|Estimate|February 2007||2007-02-28|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2008|Actual|2008-03-31||Interventional|RMPT||RMPT for Relapsed/Refractory Multiple Myeloma|Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|44|Actual|Fondazione Neoplasie Sangue Onlus||2|||f||||f||||||||||2018-06-01 00:40:31.0985|2018-06-01 00:40:31.0985
NCT00961454|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2009-08-18|2009-08-18|2009-08-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression|A Pilot Study to Evaluate the Ability of Photobiomodulation to Alter Cerebral Blood Flow in the Frontal Poles and to Affect the Emotional Status of Patients With Major Depression|Completed||Phase 1|10|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 00:40:31.178525|2018-06-01 00:40:31.178525
NCT00961441|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2011-03-15||2015-07-10|2009-08-18|2009-08-19|Estimate|2011-04-21|2011-05-25|Estimate||||2015-07-10|2015-08-06|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy|An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epilepsy|Completed||Phase 2|25|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 00:40:31.247234|2018-06-01 00:40:31.247234
NCT00961428|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|||2012-12-04|2009-08-18|2009-08-19|Estimate|||||||2012-12-04|2012-12-05|Estimate|December 2007||2007-12-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Motivation to Exercise in People With Anorexia Nervosa|Behavioral Assessment of the Reinforcing Effects of Exercise in Patients With Anorexia Nervosa|Completed|||60|Actual|New York State Psychiatric Institute|||||f||||t||||||Samples Without DNA|"~     fasting blood draws to measure cortison and leptin levels~   "|||2018-06-01 00:40:31.592609|2018-06-01 00:40:31.592609
NCT00961415|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2015-11-30||2016-01-24|2009-08-18|2009-08-19|Estimate|2016-01-24|2016-02-22|Estimate||||2016-01-24|2016-02-22|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||The Intent-to-treat (ITT) population included all the participants that were randomized.|AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer|Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN®) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 3|376|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:40:32.730854|2018-06-01 00:40:32.730854
NCT00961402|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-18|2015-11-11||2016-08-03|2009-08-18|2009-08-19|Estimate|2016-06-17|2016-07-29|Estimate||||2016-08-03|2016-09-15|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||The Effect of Exercise on Preventing PostPartum Depression|Efficacy of an Exercise Intervention for the Prevention of PostPartum Depression|Completed||Phase 2|130|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-06-01 00:40:34.152135|2018-06-01 00:40:34.152135
NCT00961389|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-10-26|2009-08-18|2009-08-19|Estimate|||||||2009-10-26|2009-10-27|Estimate|May 2009||2009-05-31|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|September 2009|Anticipated|2009-09-30||Observational|||Validating a Delirium Prediction Model for Critically Ill Patients|Validating a Delirium Prediction Model for Critically Ill Patients|Unknown status|Recruiting||650|Anticipated|Radboud University|||2||f||||f||||||Samples With DNA|"~     blood, urine~   "|||2018-06-01 00:40:34.609728|2018-06-01 00:40:34.609728
NCT00961376|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2015-09-25|2009-08-17|2009-08-19|Estimate|||||||2015-09-25|2015-09-29|Estimate|July 2009||2009-07-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|January 2015|Actual|2015-01-31||Interventional|||Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)|Vaccination of Chemotherapy Induced Lymphopenic Unresectable Stage III or Stage IV Melanoma Patients Following Reconstitution With Total or CD25-depleted PBMC|Terminated||Phase 2|5|Actual|Providence Health & Services||2||PI Discretion|f||||f||||||||||2018-06-01 00:40:34.698009|2018-06-01 00:40:34.698009
NCT00961363|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2010-03-19|2009-08-16|2009-08-18|Estimate|||||||2010-03-19|2010-03-22|Estimate|December 2009||2009-12-31|March 2010|2010-03-31||||June 2011|Anticipated|2011-06-30||Interventional|||Effect of Sitagliptin in Impaired Glucose Tolerance|The Effect of Sitagliptin on Postprandial Glycemia and Endothelial Function in Chinese Subjects With Impaired Glucose Tolerance|Unknown status|Recruiting|Phase 2|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 00:40:34.771369|2018-06-01 00:40:34.771369
NCT00961350|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2015-10-22|2012-10-31|2016-01-20|2009-08-17|2009-08-18|Estimate|2015-12-15|2016-01-21|Estimate|2012-10-31|2012-11-02|Estimate|2016-01-20|2016-02-18|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers|A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers|Completed||Phase 3|530|Actual|POZEN||2|||f||||t||||||||||2018-06-01 00:40:34.876253|2018-06-01 00:40:34.876253
NCT00961337|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Evaluation of a School-based Influenza Vaccination Program|Evaluation of a School-based Influenza Vaccination Program|Completed||Phase 4|7854|Actual|Centers for Disease Control, Taiwan||2|||f||||t||||||||||2018-06-01 00:40:35.29887|2018-06-01 00:40:35.29887
NCT00961324|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2017-10-06|2009-08-17|2009-08-18|Estimate|||||||2017-10-06|2017-10-09|Actual|July 27, 2009|Actual|2009-07-27|October 2017|2017-10-31|October 26, 2009|Actual|2009-10-26|October 26, 2009|Actual|2009-10-26||Interventional|||A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes|A Randomised, Single-centre, Double-blind, Parallelgroup, Multiple Dose Trial Comparing the Within-subject Variability of SIBA and Insulin Glargine With Respect to Pharmacodynamic Response at Steady State Conditions in Subjects With Type 1 Diabetes|Completed||Phase 1|54|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:40:35.376317|2018-06-01 00:40:35.376317
NCT00961311|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2011-01-27||2011-10-21|2009-08-17|2009-08-18|Estimate|2011-04-12|2011-04-14|Estimate||||2011-10-21|2011-10-26|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Sprinter Legend Balloon Catheter|Evaluation of Acute Safety and Efficacy of the Medtronic Sprinter Legend 1.25mm Balloon Dilation Catheter Utilized for Enlarging Coronary Luminal Diameters During PCI Procedures|Completed||N/A|51|Actual|Medtronic Vascular||1|||f||||f||||||||||2018-06-01 00:40:35.45328|2018-06-01 00:40:35.45328
NCT00961298|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2014-03-14||2014-06-08|2009-08-17|2009-08-18|Estimate|2014-06-08|2014-07-09|Estimate||||2014-06-08|2014-07-09|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder|An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder|Completed||Phase 4|17|Actual|West Penn Allegheny Health System|A limitation of this pilot study was its small sample size and open label design. Another limitation may be that the patient sample is not representative of a true cross section of the GAD population as a whole.|1|||f||||f||||||||||2018-06-01 00:40:35.632079|2018-06-01 00:40:35.632079
NCT00961285|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2010-11-29|2009-08-17|2009-08-18|Estimate|||||||2010-11-29|2010-11-30|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|GALL||Genotyping Analysis of Acute Lymphoblastic Leukemia|High Resolution Genome Wide-Copy Number Profiling and Pharmacogenomic Analysis in Acute Lymphoblastic Leukemia by Single Nucleotide Polymorphism (SNP) Arrays|Unknown status|Recruiting||1000|Anticipated|University of Bologna|||||f||||f||||||Samples With DNA|"~     extracted DNA or cryopreserved cells in Guanidine isothiocyanate or fresh peripheral blood~     (10 ml) and/or bone marrow samples (at least 2 ml) in EDTA.~   "|||2018-06-01 00:40:35.84606|2018-06-01 00:40:35.84606
NCT00961272|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2014-02-27|2009-08-17|2009-08-18|Estimate|||||||2014-02-27|2014-02-28|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women|An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women|Completed|||6|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-06-01 00:40:35.980302|2018-06-01 00:40:35.980302
NCT00961259|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2009-08-20||2012-06-01|2009-08-17|2009-08-18|Estimate|2009-10-20|2009-11-05|Estimate||||2012-06-01|2012-06-08|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Fasted Pharmacokinetic and Bioequivalency Study of Fenofibric Acid|Open-Label, Randomized, Single-Dose, 3-Arm, Crossover Pharmacokinetic and Bioequivalence Study of One 35 mg Fenofibric Acid Tablet and Three 35 mg Fenofibric Acid Tablets Versus One 105 mg Fenofibric Acid Tablet Under Fasting Conditions|Completed||Phase 1|54|Actual|Mutual Pharmaceutical Company, Inc.||3|||f||||f||||||||||2018-06-01 00:40:36.075719|2018-06-01 00:40:36.075719
NCT00961246|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|||2013-09-23|2009-08-17|2009-08-18|Estimate|||||||2013-09-23|2013-09-25|Estimate|March 2008||2008-03-31|September 2013|2013-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|WEBABC||Web-Based Active Balance Childhood Study in Chinese-American|Web-Based Active Balance Childhood Study in Chinese-American (Web ABC Study): A Randomized Clinical Trial|Completed||Phase 2|70|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:40:36.458634|2018-06-01 00:40:36.458634
NCT00961233|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2012-09-04||2012-11-02|2009-08-17|2009-08-18|Estimate|2012-10-04|2012-11-05|Estimate||||2012-11-02|2012-11-06|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)|Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE): Esophageal Medication Distribution, Treatment Response, and Effect on the Adrenal Axis.|Completed||N/A|25|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:40:36.534648|2018-06-01 00:40:36.534648
NCT00961220|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|2015-03-11||2018-04-23|2009-08-16|2009-08-18|Estimate|2015-03-11|2015-03-23|Estimate||||2018-04-23|2018-05-22|Actual|February 1, 2010|Actual|2010-02-01|April 2018|2018-04-30|April 8, 2014|Actual|2014-04-08|April 8, 2012|Actual|2012-04-08||Interventional||Intention to treat|O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma|A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma|Completed||Phase 1/Phase 2|17|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 00:40:36.753832|2018-06-01 00:40:36.753832
NCT00961207|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2013-10-24|2009-08-17|2009-08-18|Estimate|||||||2013-10-24|2013-10-28|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients|Study of Triple Blockade of the Renin Angiotensin Aldosterone System (RAAS) in Diabetic (Type 1&2) Proteinuric Patients With (ACE-, ARB, DRI)|Terminated||Phase 4|2|Actual|John H. Stroger Hospital||2||Altitude trial which used similar drugs was terminated due to increased ADR.|f||||t||||||||||2018-06-01 00:40:37.067334|2018-06-01 00:40:37.067334
NCT00961194|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2014-12-01|2009-08-17|2009-08-18|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|KETACLUD||Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain|Evaluation of the Analgesic Effect of Orally Administrated Ketamine in Peripheral Neuropathic Pain Disease: Comparison of Three Doses Versus Placebo.|Completed||Phase 2|22|Actual|University Hospital, Toulouse||4|||f||||f||||||||||2018-06-01 00:40:37.15306|2018-06-01 00:40:37.15306
NCT00961181|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2013-03-19||2013-05-02|2009-08-17|2009-08-18|Estimate|2013-03-19|2013-05-03|Estimate||||2013-05-02|2013-05-06|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|PEPPER||Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis|Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis A Prospective, Multi-centre, Non-randomized Clinical Trial With Follow-up Investigations at 1, 6 and 12 Months|Completed||N/A|81|Actual|Biotronik AG|Single arm design. Optimal time point for a quantitative angiographic follow up should be scheduled after 12 months, as recommended by the Academic Research Consortium guidelines for DES.|1|||f||||t||||||||||2018-06-01 00:40:37.243929|2018-06-01 00:40:37.243929
NCT00961168|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|||2015-03-03|2009-08-17|2009-08-18|Estimate|||||||2015-03-03|2015-03-05|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|WOBALI||Work of Breathing and Mechanical Ventilation in Acute Lung Injury|Prospective Study on the Effects of Artificial Breathing Patterns on Work of Breathing in Patients With Acute Lung Injury.|Withdrawn||N/A|0|Actual|University of California, San Francisco||1||Budgetary restrictions|f||||f||||||||||2018-06-01 00:40:37.523066|2018-06-01 00:40:37.523066
NCT00961155|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2013-12-09|2009-08-17|2009-08-18|Estimate|||||||2013-12-09|2013-12-10|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With Asthma|Usefulness of Exhaled Breath Condensate and FENO for Evaluation of Markers of Airway Inflammation in Children With Asthma|Unknown status|Recruiting|Phase 2|200|Anticipated|Medical Universtity of Lodz||4|||f||||f||||||||||2018-06-01 00:40:37.602744|2018-06-01 00:40:37.602744
NCT00961142|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2018-05-02|2009-08-17|2009-08-18|Estimate|||||||2018-05-02|2018-05-08|Actual|June 2009||2009-06-30|May 2018|2018-05-31|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional|CD3/CD19 Haplo||Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia|Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia|Terminated||Phase 2|23|Actual|University Hospital Tuebingen||||slow recruitment|f||||t||||||||||2018-06-01 00:40:37.701938|2018-06-01 00:40:37.701938
NCT00961129|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|||2010-04-11|2009-08-17|2009-08-18|Estimate|||||||2010-04-11|2010-04-13|Estimate|March 2009||2009-03-31|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|April 2010|Actual|2010-04-30||Observational|||The Continuing Care Needs in Colorectal Cancer Patients in Different Stages|The Continuing Care Needs From Receiving Treatment to Survival in Colorectal Cancer Patients in Different Stages|Unknown status|Recruiting||269|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 00:40:37.779004|2018-06-01 00:40:37.779004
NCT00961116|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2009-08-24||2009-10-27|2009-08-17|2009-08-18|Estimate|2009-08-24|2009-10-01|Estimate||||2009-10-27|2009-11-03|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Bioequivalence Study of Fenofibric Acid Versus Tricor® (Fenofibrate)|A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg Tricor® (Fenofibrate) Tablets Under Fasting Conditions.|Completed||Phase 1|54|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:40:37.847905|2018-06-01 00:40:37.847905
NCT00961103|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Observational|||Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)|Assessment of Motor Development Related to Use of Orthoses in SMA II and III|Unknown status|Not yet recruiting||70|Anticipated|Arcispedale Santa Maria Nuova-IRCCS|||1||f||||t||||||||||2018-06-01 00:40:38.088656|2018-06-01 00:40:38.088656
NCT00961090|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2015-09-21|2009-08-17|2009-08-18|Estimate|||||||2015-09-21|2015-09-22|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery|A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.|Completed||Phase 2|150|Actual|Allegheny Singer Research Institute|||||f||||t||||||||||2018-06-01 00:40:38.150487|2018-06-01 00:40:38.150487
NCT00961077|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer|A Prospective Phase II Study of Attenuated S-1 and Oxaliplatin(Attenuated SOX) as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|Soonchunhyang University Hospital|||||f||||t||||||||||2018-06-01 00:40:38.299779|2018-06-01 00:40:38.299779
NCT00961064|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-15|||2018-05-22|2009-08-15|2009-08-18|Estimate|||||||2018-05-22|2018-05-23|Actual|July 24, 2009||2009-07-24|May 11, 2018|2018-05-11|December 30, 2021|Anticipated|2021-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)|A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:40:38.359226|2018-06-01 00:40:38.359226
NCT00961051|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2013-05-16||2013-12-06|2009-08-17|2009-08-18|Estimate|2013-12-06|2014-01-07|Estimate||||2013-12-06|2014-01-07|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Evaluation of an Investigational Multi-Purpose Solution (MPS)|Evaluation of an Investigational MPS|Completed||Phase 3|270|Actual|Abbott Medical Optics||2|||f||||f||||||||||2018-06-01 00:40:38.4492|2018-06-01 00:40:38.4492
NCT00961038|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2014-03-31|2009-08-17|2009-08-18|Estimate|||||||2014-03-31|2014-04-01|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Randomized, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Tolerability, the Pulmonary Deposition and Pharmacokinetics of Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLD II - III), Following Inhalation of Ciprofloxacin PulmoSphere® Inhalation Powder|Completed||Phase 1|19|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:40:38.765719|2018-06-01 00:40:38.765719
NCT00961025|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-08-20|2009-08-17|2009-08-18|Estimate|||||||2009-08-20|2009-08-24|Estimate|May 2009||2009-05-31|August 2009|2009-08-31|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|||A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Phase 1 Study to Investigate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of DA-1229 in Healthy Male Subjects|Unknown status|Recruiting|Phase 1|110|Anticipated|Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-06-01 00:40:38.847585|2018-06-01 00:40:38.847585
NCT00961012|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-11-21|2009-08-17|2009-08-18|Estimate|||||||2011-11-21|2011-11-23|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Big Squeeze (Lessening the Big Squeeze: The Effect of the Trunk Release on Interface Pressures of Individuals Seated in a High Fowler's Positions)|Lessening the Big Squeeze: The Effect of the Trunk Release on Interface Pressures of Individuals Seated in a High Fowler's Positions|Completed||N/A|129|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 00:40:38.92082|2018-06-01 00:40:38.92082
NCT00960999|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|2014-10-29||2017-05-18|2009-08-16|2009-08-18|Estimate|2014-10-29|2014-11-04|Estimate||||2017-05-18|2017-06-14|Actual|November 2009|Actual|2009-11-30|May 2017|2017-05-31||||August 2012|Actual|2012-08-31||Interventional||Eligible patients who started protocol treatment.|Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer|A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|94|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 00:40:39.031328|2018-06-01 00:40:39.031328
NCT00960986|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2012-01-17||2014-12-08|2009-08-17|2009-08-18|Estimate|2012-03-23|2012-04-17|Estimate||||2014-12-08|2014-12-31|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive Disorder|A Phase 4 Comparison of Duloxetine Dosing Strategies in the Treatment of Korean Patients With Major Depressive Disorder|Completed||Phase 4|249|Actual|Eli Lilly and Company|Large number of protocol violations; bias due to unblinded, open-label design (participants were predisposed to expect an outcome of nausea as the primary endpoint); use of emetogenic medications; incorrect reporting and intake of food and drug.|4|||f||||f||||||||||2018-06-01 00:40:39.389671|2018-06-01 00:40:39.389671
NCT00960973|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|||2011-08-09|2009-08-17|2009-08-18|Estimate|||||||2011-08-09|2011-08-10|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of Vitamin K Supplementation on Glucose Metabolism|The Effect of Vitamin K Supplementation on Glucose Metabolism|Completed||Phase 4|42|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 00:40:40.3668|2018-06-01 00:40:40.3668
NCT00960960|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2016-12-14|2009-08-17|2009-08-18|Estimate|||||||2016-12-14|2016-12-15|Estimate|August 2009||2009-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent Or Metastatic Breast Cancer|Completed||Phase 1|71|Actual|Genentech, Inc.||11|||f||||||||||||||2018-06-01 00:40:40.434119|2018-06-01 00:40:40.434119
NCT00960947|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-08-15|2009-08-15|2009-08-18|Estimate|||||||2009-08-15|2009-08-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:40:40.532963|2018-06-01 00:40:40.532963
NCT00960934|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2012-08-14||2015-02-01|2009-08-17|2009-08-18|Estimate|2012-10-02|2012-10-10|Estimate||||2015-02-01|2015-02-18|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)|A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women With Osteoporosis|Terminated||Phase 2|383|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:40:40.658109|2018-06-01 00:40:40.658109
NCT00960921|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2017-05-12|2009-08-17|2009-08-18|Estimate|||||||2017-05-12|2017-05-15|Actual||||May 2017|2017-05-31||||||||Interventional|||Study of the Effects of Iron on Lung Blood Pressure at High Altitude|Study of the Effects of Iron Supplementation on High Altitude Pulmonary Hypertension.|Withdrawn||Phase 2|0|Actual|University of Oxford||2||Study never started.|f||||f||||||||||2018-06-01 00:40:42.18601|2018-06-01 00:40:42.18601
NCT00960908|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate|January 2009||2009-01-31|August 2009|2009-08-31||||January 2012|Anticipated|2012-01-31||Observational|||Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent|RESOLUTE-KOREA Registry - Registry to Evaluate the Efficacy of Zotarolimus-eluting Stent|Unknown status|Recruiting||4000|Anticipated|Seoul National University Hospital|||2||f||||f||||||||||2018-06-01 00:40:42.282764|2018-06-01 00:40:42.282764
NCT00960895|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2011-10-26|2009-08-17|2009-08-18|Estimate|||||||2011-10-26|2011-10-27|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|LAM-PH||Pulmonary Hypertension in Lymphangioleiomyomatosis|Observational Study of Patients With Lymphangioleiomyomatosis and Pulmonary Hypertension|Completed|||20|Actual|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|||||f||||f||||||||||2018-06-01 00:40:42.439141|2018-06-01 00:40:42.439141
NCT00960882|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2018-01-26|2009-08-14|2009-08-18|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2007||2007-06-30|January 2018|2018-01-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Gastric Tolerability and Pharmacokinetics of DMMET-01|Gastric Tolerability and Pharmacokinetics of DMMET-01. Daily Intake for 30 Days, in Normal Alimentation Conditions, in Healthy Volunteers.|Completed||Phase 1|12|Actual|Laboratorios Silanes S.A. de C.V.||1|||f||||t||||||||Undecided||2018-06-01 00:40:42.495685|2018-06-01 00:40:42.495685
NCT00960869|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2015-10-22|2012-10-31|2016-01-20|2009-08-17|2009-08-18|Estimate|2016-01-20|2016-02-17|Estimate|2012-10-31|2012-11-02|Estimate|2016-01-20|2016-02-17|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Intent to Treat (ITT) Population|Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers|A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers|Completed||Phase 3|519|Actual|POZEN||2|||f||||t||||||||||2018-06-01 00:40:42.577405|2018-06-01 00:40:42.577405
NCT00960856|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2009-08-27||2009-10-16|2009-08-17|2009-08-18|Estimate|2009-10-12|2009-10-14|Estimate||||2009-10-16|2009-10-20|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Four Arm Food Effect Study of Fenofibric Acid Tablets|A Four Arm, Single-Dose, Food Effect Evaluation With 105 mg Fenofibric Acid Tablets Administered in a Fasted State and Three Different Fed Conditions, Low-Fat/Low Calorie Meal, Standard Meal, and High-Fat/High Calorie Meal|Completed||Phase 1|40|Actual|Mutual Pharmaceutical Company, Inc.||4|||f||||f||||||||||2018-06-01 00:40:42.94442|2018-06-01 00:40:42.94442
NCT00960843|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2011-11-02||2012-08-14|2009-08-17|2009-08-18|Estimate|2012-03-06|2012-04-03|Estimate||||2012-08-14|2012-08-20|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Six-month Study to Compare the Effects of Volume- and Pressure-Guided Adjustments on Weight Loss and Satiety|A Randomized, Controlled, 6-month Study to Compare the Effects of Volume- and Pressure-guided Adjustments on Weight Loss and Satiety in Patients Implanted With the Swedish Adjustable Gastric Band|Completed||N/A|51|Actual|Ethicon Endo-Surgery||2|||f||||f||||||||||2018-06-01 00:40:43.274109|2018-06-01 00:40:43.274109
NCT00960830|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|||Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety|Mirtazapine Reduces ICD Appropriate Shocks in Cardioverter Implanted Patients With Depression and Anxiety|Completed||N/A|40|Actual|Universidad Nacional de Rosario||2|||f||||t||||||||||2018-06-01 00:40:43.549004|2018-06-01 00:40:43.549004
NCT00960817|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate||||August 2009|2009-08-31||||||||Interventional|||"Normal Coronary Artery With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up"|"Normal Coronary Artery With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up"|Unknown status|Not yet recruiting|Early Phase 1|||Hillel Yaffe Medical Center||2|||f||||||||||||||2018-06-01 00:40:43.635181|2018-06-01 00:40:43.635181
NCT00960804|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17||2012-01-27|2013-09-17|2009-08-17|2009-08-18|Estimate||||2012-08-23|2012-08-30|Estimate|2013-09-17|2013-09-23|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients|A Phase 3, Double-Blind, Placebo-Controlled, Multicenter, Long-Term Safety Study Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip|Terminated||Phase 3|21|Actual|Pfizer||3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:40:43.707118|2018-06-01 00:40:43.707118
NCT00960791|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-09-15|2009-08-17|2009-08-18|Estimate|||||||2009-09-15|2009-09-16|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|||||Interventional|ADME||Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)|An Open, Single-centre, Single Group, Phase I Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of AZD1656 After Oral Administration of 14C-labelled AZD1656 to Type II Diabetes Mellitus Patients|Completed||Phase 1|6|Anticipated|AstraZeneca||1|||f||||||||||||||2018-06-01 00:40:43.849805|2018-06-01 00:40:43.849805
NCT00960778|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-10-31|2009-08-17|2009-08-18|Estimate|||||||2012-10-31|2012-11-01|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|BIRCWH||Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes|Gender Differences in Response to Nicotine Replacement Therapy and De-Nicotinized Cigarettes|Completed||N/A|31|Actual|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 00:40:43.925955|2018-06-01 00:40:43.925955
NCT00960765|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2016-01-27|2009-08-17|2009-08-18|Estimate|||||||2016-01-27|2016-01-28|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics|Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus|Completed|||15|Actual|CPL Associates|||4||f||||f||||||Samples Without DNA|"~     Serum, urine, stool~   "|||2018-06-01 00:40:43.996597|2018-06-01 00:40:43.996597
NCT00960752|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2018-01-08|2009-08-17|2009-08-18|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2010|Actual|2010-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist|Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist|Active, not recruiting||Phase 2|71|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-06-01 00:40:44.057433|2018-06-01 00:40:44.057433
NCT00960739|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|||2016-08-05|2009-08-16|2009-08-18|Estimate|||||||2016-08-05|2016-08-08|Estimate|November 2008||2008-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|MIITOP||Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma|Phase II Study of the Association of Iodobenzylguanidine Meta-I131 (I131 MIBG) and Topotecan in the Treatment of Refractory or Relapsed Metastatic Neuroblastoma|Completed||Phase 2|30|Actual|Centre Oscar Lambret||1|||f||||f||||||||No||2018-06-01 00:40:44.216217|2018-06-01 00:40:44.216217
NCT00960726|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2012-07-27|2009-08-17|2009-08-18|Estimate|||||||2012-07-27|2012-07-30|Estimate||||July 2012|2012-07-31||||||||Interventional|||NOV-002 in Myelodysplastic Syndrome (MDS)|Phase 2 Study of NOV-002 in Low and Intermediate-1 Risk Myelodysplastic Syndrome|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Study withdrawn at sponsor request.|f||||f||||||||||2018-06-01 00:40:44.298154|2018-06-01 00:40:44.298154
NCT00960713|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2012-10-22|2009-08-17|2009-08-18|Estimate|||||||2012-10-22|2012-10-23|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|RITAI||The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders|The RITAI Cohort. An Observational Study on Serious Adverse Events Occuring After Rituximab Off-label Use for Auto-immune Disorders|Completed|||35|Actual|University Hospital, Toulouse|||1||f||||t||||||Samples With DNA|"~     A biological collection will be constituted to allow pharmaco- immunological studies.~   "|||2018-06-01 00:40:44.379545|2018-06-01 00:40:44.379545
NCT00960700|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2013-02-07|2009-08-17|2009-08-18|Estimate|||||||2013-02-07|2013-02-08|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||A Multi Focal Visual Outcome Study Using Different Near Additions|Clinical Investigational Plan of the Rayner M-flex Multifocal Intraocular Lens (IOL) With Different Near Additions|Terminated|||52|Actual|Rayner Intraocular Lenses Limited|||||f||||t||||||||||2018-06-01 00:40:44.464774|2018-06-01 00:40:44.464774
NCT00960687|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2009-08-27||2009-10-16|2009-08-17|2009-08-18|Estimate|2009-10-08|2009-10-14|Estimate||||2009-10-16|2009-10-20|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate)|A Single-Dose, Bioequivalence Study of 105 mg Fenofibric Acid Tablets Versus 145 mg TriCor® (Fenofibrate) Tablets Under Fed Conditions(Standard Meal)|Completed||Phase 1|54|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:40:44.56476|2018-06-01 00:40:44.56476
NCT00960674|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2013-04-17|2009-08-17|2009-08-18|Estimate|||||||2013-04-17|2013-04-18|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Tactile Massage in Type 2 Diabetes|Effects on Type 2 Diabetes by Tactile Massage Compared to Relaxation With Relaxation Tape|Completed||Phase 3|53|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 00:40:45.317448|2018-06-01 00:40:45.317448
NCT00960505|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2016-01-11|2009-08-14|2009-08-17|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Alternate Day Fasting for Weight Loss, Weight Maintenance and Cardio-protection|Alternate Day Fasting for Weight Loss, Weight Maintenance and Cardio-protection|Completed||N/A|100|Actual|University of Illinois at Chicago||3|||f||||t||||||||||2018-06-01 00:40:50.152131|2018-06-01 00:40:50.152131
NCT00960661|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2013-09-05||2015-03-19|2009-08-17|2009-08-18|Estimate|2013-11-21|2013-12-17|Estimate||||2015-03-19|2015-04-07|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||per protocol population|A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes|A Randomized Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Who Were Previously Treated by Basal Insulin Glargine With Either Metformin or Metformin and Sulfonylurea|Completed||Phase 3|1036|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:40:45.416288|2018-06-01 00:40:45.416288
NCT00960648|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2010-06-28|2009-08-17|2009-08-18|Estimate|||||||2010-06-28|2010-06-29|Estimate|April 2009||2009-04-30|June 2010|2010-06-30||||April 2011|Anticipated|2011-04-30||Observational|||Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting|EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry|Unknown status|Active, not recruiting||4000|Anticipated|Seoul National University Hospital|||2||f||||f||||||||||2018-06-01 00:40:46.424554|2018-06-01 00:40:46.424554
NCT00960635|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate|June 2001||2001-06-30|August 2009|2009-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Immunointervention With Calcitriol in New-Onset Type 1 Diabetes|Immunointervention With 1,25-dihydroxy-vitamin D3 in New-onset Type 1 Diabetes|Completed||Phase 2|||Institut fur Diabetesforschung, Munich, Germany||2|||f||||f||||||||||2018-06-01 00:40:46.588293|2018-06-01 00:40:46.588293
NCT00960622|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|2011-09-21||2013-01-25|2009-08-17|2009-08-18|Estimate|2013-01-25|2013-03-04|Estimate||||2013-01-25|2013-03-04|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|TRU||Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects|Effect of Substituting Truvada for Combivir or Trizivir vs Continuing Combivir or Trizivir on Physiologic Correlates of Mitochondrial Function in Subjects Infected With Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy|Completed||Phase 4|17|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-06-01 00:40:46.662563|2018-06-01 00:40:46.662563
NCT00960609|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2009-08-17|2009-08-17|2009-08-18|Estimate|||||||2009-08-17|2009-08-18|Estimate|January 2008||2008-01-31|August 2009|2009-08-31||||||||Observational|||Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study|Communicating Veins Between Adjacent Hepatic Veins: Rare, Exceptional or Frequent? An Intra-operative Ultrasound Study|Completed|||||University of Milan|||1||f||||||||||||||2018-06-01 00:40:46.921326|2018-06-01 00:40:46.921326
NCT00960596|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-16|||2009-08-24|2009-08-17|2009-08-18|Estimate|||||||2009-08-24|2009-08-25|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Preventive Medicine Study of Childhood Atopic Diseases|Preventive Medicine Study of Childhood Atopic Diseases|Unknown status|Enrolling by invitation|N/A|100|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 00:40:47.014173|2018-06-01 00:40:47.014173
NCT00960583|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2016-05-10|2009-08-17|2009-08-18|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2005||2005-01-31|May 2016|2016-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Economic Evaluation of an Exercise Program After Multidisciplinary Rehabilitation in Patients With Chronic Low Back Pain|Cost-utility Analysis of a 3-month Exercise Program vs. Routine Follow-up in Patients Having Completed Multidisciplinary Rehabilitation: a Randomized Controlled Trial|Completed||N/A|105|Actual|University of Lausanne||2|||f||||f||||||||||2018-06-01 00:40:47.078093|2018-06-01 00:40:47.078093
NCT00960570|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2009-08-20||2012-07-31|2009-08-17|2009-08-18|Estimate|2009-10-12|2009-10-14|Estimate||||2012-07-31|2012-08-07|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz|An Open-Label Drug Interaction Study to Investigate the Effects of Steady State Fenofibric Acid on the Single-Dose Pharmacokinetics of Efavirenz in Healthy Volunteers|Completed||Phase 1|30|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:40:47.163014|2018-06-01 00:40:47.163014
NCT00960557|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-08-22|2009-08-17|2009-08-18|Estimate|||||||2011-08-22|2011-08-23|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|OXi4503||Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden|A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden|Completed||Phase 1|16|Actual|Mateon Therapeutics||1|||f||||f||||||||||2018-06-01 00:40:47.444567|2018-06-01 00:40:47.444567
NCT00960544|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-17|||2018-04-11|2009-08-17|2009-08-18|Estimate|||||||2018-04-11|2018-04-13|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism|Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism Using a Limited Pharmacokinetic Sampling Plan|Not yet recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-06-01 00:40:47.530988|2018-06-01 00:40:47.530988
NCT00960531|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2014-12-18||2016-03-02|2009-08-14|2009-08-17|Estimate|2016-03-02|2016-04-01|Estimate||||2016-03-02|2016-04-01|Estimate|July 2009||2009-07-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||160 participants were randomized and included in analysis. Of these, 1 participant was not treated: at screening, the site felt that Mini-Mental State Examination (MMSE) score was artificially low due to language issue. Hence, study enrollment was approved. Later, participant discontinued from study, which was recorded as major protocol deviation.|A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease|A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease|Terminated||Phase 2|160|Actual|Pfizer|In 2013 the sponsor decided that ACC-001 would not be further developed in mild to moderate Alzheimer's disease, study drug administration was discontinued, and remaining participants were followed for safety for up to 6 months after last injection.|3|||f||||t||||||||||2018-06-01 00:40:47.661989|2018-06-01 00:40:47.661989
NCT00960518|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2009-08-14|2009-08-14|2009-08-17|Estimate|||||||2009-08-14|2009-08-17|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2015|Anticipated|2015-08-31|August 2012|Anticipated|2012-08-31||Interventional|TACE||TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)|Combination Therapy With TACE and Adefovir Compared With TACE Alone for HBV-related Unresectable Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|216|Anticipated|Tongji University||2|||f||||t||||||||||2018-06-01 00:40:50.056453|2018-06-01 00:40:50.056453
NCT00960492|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2014-09-19|2009-08-14|2009-08-17|Estimate|||||||2014-09-19|2014-09-22|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|||Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma|A Phase 1 Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination With Temozolomide and Radiation Therapy in the First Line Treatment of Subjects With Glioblastoma|Completed||Phase 1|26|Actual|Exelixis||3|||f||||f||||||||||2018-06-01 00:40:50.295395|2018-06-01 00:40:50.295395
NCT00960479|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-03-27|2009-08-14|2009-08-17|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2001||2001-01-31|August 2009|2009-08-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions|A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Fasting Conditions.|Completed||Phase 1|38|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:40:50.39127|2018-06-01 00:40:50.39127
NCT00960466|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2014-04-01|2009-08-14|2009-08-17|Estimate|||||||2014-04-01|2014-04-02|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|DiTIT||Distress Thermometer Intervention Trial|Evaluating the Effect of Monitoring Cancer Patients Using the Distress Thermometer on Levels of Distress and Health Service Costs - a Randomised Controlled Trial|Completed||Phase 3|220|Actual|University Hospitals Bristol NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:40:50.452267|2018-06-01 00:40:50.452267
NCT00960453|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-02-19|2009-08-14|2009-08-17|Estimate|||||||2011-02-19|2011-02-23|Estimate|December 2008||2008-12-31|February 2011|2011-02-28||||September 2009|Actual|2009-09-30||Interventional|||Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin|Multiple-dose, Dose Escalation Study to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin in Healthy Male Volunteers|Completed||Phase 1|12|Anticipated|Seoul National University Hospital||3|||f||||f||||||||||2018-06-01 00:40:50.522804|2018-06-01 00:40:50.522804
NCT00960440|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2012-12-06|2012-11-05|2012-12-06|2009-08-14|2009-08-17|Estimate|2012-12-06|2013-01-10|Estimate|2012-11-05|2012-11-07|Estimate|2012-12-06|2013-01-10|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors|Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors|Completed||Phase 3|399|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 00:40:50.706112|2018-06-01 00:40:50.706112
NCT00960427|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2013-04-12|2009-08-14|2009-08-17|Estimate|||||||2013-04-12|2013-04-16|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery|Colorectal Cancer Stem Cells Marker Expression in Rectal Cancer Patients Undergoing Chemoradiotherapy-A Pilot Study|Withdrawn||Phase 1|0|Actual|Barbara Ann Karmanos Cancer Institute||||No surgeon available to perfrom gastroscopy|f||||t||||||||||2018-06-01 00:40:53.526448|2018-06-01 00:40:53.526448
NCT00960414|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2014-05-05|2009-08-13|2009-08-17|Estimate|||||||2014-05-05|2014-05-06|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SHINE||Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons|Supporting Health by Integrating Nutrition and Exercise (SHINE)|Completed||Phase 2|194|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 00:40:53.622383|2018-06-01 00:40:53.622383
NCT00960401|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2012-08-13|2009-08-14|2009-08-17|Estimate|||||||2012-08-13|2012-08-15|Estimate|August 2005||2005-08-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|May 2007|Actual|2007-05-31||Observational|ABCART||A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer|"Pilot Study A Study of Atherosclerosis in Patients After Radiation Treatment for Breast Cancer"|Unknown status|Active, not recruiting||20|Actual|Winthrop University Hospital|||2||f||||f||||||||||2018-06-01 00:40:53.707781|2018-06-01 00:40:53.707781
NCT00960375|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2015-06-05||2015-07-28|2009-08-14|2009-08-17|Estimate|2015-06-05|2015-06-23|Estimate||||2015-07-28|2015-08-18|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional||179 participants were randomized: 92 to BTSCS and 87 to StSST.|Smoking Cessation for Veterans With Severe and Persistent Mental Illness|Randomized Trial of a Smoking Cessation Program for Persons With SMI|Completed||Phase 2/Phase 3|179|Actual|VA Office of Research and Development|The sample was mostly male, African-American, and recruited at VAMCs; it is unclear if findings would generalize to community settings. Many declined to participate; the sample represents persons with SMI who are interested in quitting.|2|||f||||t||||||||||2018-06-01 00:40:53.801212|2018-06-01 00:40:53.801212
NCT00960362|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-01-26|2009-08-14|2009-08-17|Estimate|||||||2012-01-26|2012-01-30|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)|A Randomised, Double-blind, Placebo-controlled, and Single Dose-escalation Trial of AGS-009 Administered in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|13|Actual|Argos Therapeutics||7|||f||||f||||||||||2018-06-01 00:40:54.351029|2018-06-01 00:40:54.351029
NCT00960349|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-06-13|2009-08-14|2009-08-17|Estimate|||||||2011-06-13|2011-06-14|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|January 2010|Actual|2010-01-31||Interventional|||Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients|A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric Cancer|Completed||Phase 1|14|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:40:54.442357|2018-06-01 00:40:54.442357
NCT00960336|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2014-10-28|2009-08-14|2009-08-17|Estimate|||||||2014-10-28|2014-10-29|Estimate|March 2008||2008-03-31|October 2014|2014-10-31||||May 2011|Actual|2011-05-31||Interventional|||Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer|Multicenter Study of PEGylated Liposomal Doxorubicin in Geriatric Oncology - Metastatic Breast Cancer - First-line Treatment PEGylated Liposomal Doxorubicin in Patients Older Than 70 Years, Breast Cancer Metastasis|Completed||Phase 2|59|Actual|ARCAGY/ GINECO GROUP||1|||f||||f||||||||||2018-06-01 00:40:54.533822|2018-06-01 00:40:54.533822
NCT00958204|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2014-06-05|2009-08-12|2009-08-13|Estimate|||||||2014-06-05|2014-06-06|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression|Light and Ion Treatment to Enhance Medication Efficacy in Depression|Completed||Phase 3|134|Actual|University of British Columbia||4|||f||||t||||||||||2018-06-01 00:41:30.736708|2018-06-01 00:41:30.736708
NCT00960323|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2010-02-22||2010-03-22|2009-08-14|2009-08-17|Estimate|2010-02-22|2010-03-16|Estimate||||2010-03-22|2010-03-30|Estimate|February 2009||2009-02-28|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Drug-Drug Interaction Study Between Colchicine and Atorvastatin|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Atorvastatin on the Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:40:54.627605|2018-06-01 00:40:54.627605
NCT00960310|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-03-27|2009-08-14|2009-08-17|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2006||2006-06-30|August 2009|2009-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions|Randomized, Open-Label, 1-Way Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex (Reference) Following a 50 mg Dose in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:40:54.885499|2018-06-01 00:40:54.885499
NCT00960297|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2013-08-27||2013-11-08|2009-08-14|2009-08-17|Estimate|2013-08-27|2013-11-08|Estimate||||2013-11-08|2013-12-04|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC|Phase II Trial of Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III Non-Small Cell Lung Cancer|Terminated||Phase 2|4|Actual|SCRI Development Innovations, LLC||1||Study was terminated due to slow accrual|f||||f||||||||||2018-06-01 00:40:54.949678|2018-06-01 00:40:54.949678
NCT00960284|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-01-12|2009-08-14|2009-08-17|Estimate|||||||2012-01-12|2012-01-13|Estimate|June 2003||2003-06-30|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PACT-7||Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer|Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil|Completed||Phase 2/Phase 3|102|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-06-01 00:40:55.1605|2018-06-01 00:40:55.1605
NCT00960271|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2013-01-17|2009-08-14|2009-08-17|Estimate|||||||2013-01-17|2013-01-18|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|EVIEPEB||Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC)|Medico-economic Evaluation of a Preoperative Algorithm Including EBUS for NSCLC Initial Staging|Completed|||363|Actual|University Hospital, Rouen|||1||f||||t||||||||||2018-06-01 00:40:55.231097|2018-06-01 00:40:55.231097
NCT00960258|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2017-09-26|2009-08-14|2009-08-17|Estimate|||||||2017-09-26|2017-09-27|Actual|July 1, 2009|Actual|2009-07-01|September 2017|2017-09-30|November 11, 2013|Actual|2013-11-11|April 26, 2010|Actual|2010-04-26||Interventional|||Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.|Phase I, Uncontrolled, Open-label, Non-randomized Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Advanced, Refractory Solid Tumors|Completed||Phase 1|15|Actual|Bayer||1|||f||||t||||||||||2018-06-01 00:40:55.293367|2018-06-01 00:40:55.293367
NCT00960245|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-03-27|2009-08-14|2009-08-17|Estimate|||||||2017-03-27|2017-03-28|Actual|July 1994||1994-07-31|August 2009|2009-08-31|July 1994|Actual|1994-07-31|July 1994|Actual|1994-07-31||Interventional|||Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions|A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.|Completed||Phase 1|34|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:40:55.47105|2018-06-01 00:40:55.47105
NCT00960232|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-09-03|2009-08-14|2009-08-17|Estimate|||||||2012-09-03|2012-09-05|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Vitamin D, Blood Pressure, Lipids, Infection and Depression|Vitamin D, Blood Pressure, Lipids, Infection and Depression|Completed||Phase 3|250|Actual|University of Tromso||2|||f||||f||||||||||2018-06-01 00:40:55.529384|2018-06-01 00:40:55.529384
NCT00960219|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-07-07|2009-08-14|2009-08-17|Estimate|||||||2011-07-07|2011-07-11|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia|D-amino Acid Oxidase Inhibition for NMDA Modulation in Schizophrenia|Completed||Phase 2|52|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-06-01 00:40:55.611427|2018-06-01 00:40:55.611427
NCT00960206|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2013-06-07||2016-12-08|2009-08-14|2009-08-17|Estimate|2014-07-24|2014-08-15|Estimate||||2016-12-08|2017-02-03|Estimate|March 2003||2003-03-31|December 2016|2016-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||Baseline characteristics are reported by hip for each arm.|ABC/Trident® Ceramic Post Approval Study|Post-Approval Study of the ABC and Trident® Systems|Completed||N/A|413|Actual|Stryker Orthopaedics||3|||f||||f||||||||||2018-06-01 00:40:55.739236|2018-06-01 00:40:55.739236
NCT00960193|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2010-02-22||2011-06-06|2009-08-14|2009-08-17|Estimate|2010-02-22|2010-03-16|Estimate||||2011-06-06|2011-06-08|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Drug-Food Interaction Study of Seville Orange Juice and Colchicine|A One-Directional, Open-Label Drug-Food Interaction Study to Investigate the Effects of Multiple-Daily Consumptions of Seville Orange Juice on the Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 00:40:56.135723|2018-06-01 00:40:56.135723
NCT00960180|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2014-01-09|2009-08-14|2009-08-17|Estimate|||||||2014-01-09|2014-01-13|Estimate|July 2010||2010-07-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Evaluating Single Ascending Doses of MR1817|A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Doses of Orally Administered MR1817 in Healthy Adult Subjects|Completed||Phase 1|64|Anticipated|Mochida Pharmaceutical Company, Ltd.||2|||f||||f||||||||||2018-06-01 00:40:56.363538|2018-06-01 00:40:56.363538
NCT00960167|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-10-13|2009-08-14|2009-08-17|Estimate|||||||2009-10-13|2009-10-15|Estimate|September 2009||2009-09-30|October 2009|2009-10-31||||August 2011|Anticipated|2011-08-31||Interventional|||A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)|A Phase I Dose Escalation Trial of Conformal Hypofractionated Radiation Therapy for Patients With Hepatitis B Virus-Related Child A Cirrhosis and Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1|20|Anticipated|National Taiwan University Hospital||4|||f||||t||||||||||2018-06-01 00:40:56.423178|2018-06-01 00:40:56.423178
NCT00959829|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2010-06-10|2009-08-14|2009-08-17|Estimate|||||||2010-06-10|2010-06-11|Estimate|February 2004||2004-02-29|August 2009|2009-08-31|September 2005|Actual|2005-09-30|March 2005|Actual|2005-03-31||Interventional|||Use of Music and Voice Stimulus on Coma Patients|Use of Music and Vocal Stimulus in Patients in Coma State - Relations Between Auditory Stimulus, Vital Signs, Face Expression and Glasgow Coma Scale or Ramsay Scale|Completed||N/A|30|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 00:41:03.263826|2018-06-01 00:41:03.263826
NCT00960154|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2012-11-29||2013-01-03|2009-08-14|2009-08-17|Estimate|2012-11-29|2013-01-03|Estimate||||2013-01-03|2013-01-08|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|PRECISE||PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy|A Prospective, Randomized, Controlled Study to Evaluate Use of the PEAK PlasmaBladeTM 4.0 in Breast Lumpectomy|Terminated||N/A|50|Actual|Medtronic Surgical Technologies|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.|2||Termination due to acquisition of PEAK Surgical by Medtronic|f||||f||||||||||2018-06-01 00:40:56.503461|2018-06-01 00:40:56.503461
NCT00960141|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2009-08-31||2015-02-24|2009-08-14|2009-08-17|Estimate|2010-05-17|2010-06-09|Estimate||||2015-02-24|2015-03-13|Estimate|August 2000||2000-08-31|February 2015|2015-02-28|November 2000|Actual|2000-11-30|October 2000|Actual|2000-10-31||Interventional|||A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Fall Study|Completed||Phase 3|829|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 00:40:56.688585|2018-06-01 00:40:56.688585
NCT00960128|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-10-11|2009-08-14|2009-08-17|Estimate|||||||2017-10-11|2017-10-12|Actual|April 1, 2006|Actual|2006-04-01|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Observational Prospective Study on Patients Treated With Norditropin®|NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®|Completed|||21249|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 00:40:58.160089|2018-06-01 00:40:58.160089
NCT00960115|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2015-09-21||2015-09-21|2009-08-14|2009-08-17|Estimate|2015-09-21|2015-10-21|Estimate||||2015-09-21|2015-10-21|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|May 2014|Actual|2014-05-31||Interventional||Intention to Treat (ITT) analysis set included all subjects randomly allocated to a treatment (tecemotide [L-BLP25] or placebo)|Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy|Combined Phase I/II Clinical Study of EMD531444(L-BLP25 or BLP25 Liposome Vaccine) in Subjects With Stage III Unresectable Non-small Cell Lung Cancer Following Primary Chemoradiotherapy|Completed||Phase 1/Phase 2|178|Actual|Merck KGaA||2|||f||||t||||||||||2018-06-01 00:40:58.340543|2018-06-01 00:40:58.340543
NCT00960102|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2015-08-05|2009-08-14|2009-08-17|Estimate|||||||2015-08-05|2015-08-07|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|FinBiCI||Children's Bilateral Cochlear Implantation in Finland|Children's Bilateral Cochlear Implantation in Finland: a Prospective, Controlled, Multicenter Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Kuopio University Hospital||3|||f||||f||||||||||2018-06-01 00:40:58.825543|2018-06-01 00:40:58.825543
NCT00960089|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2016-01-26|2009-08-14|2009-08-17|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|CT001||Efficacy Study of LIQUICURE™ to Treat Toe Nail Fungus|Evaluation of the Efficacy of Chesson Labs LIQUICURE™ for Treatment of Onychomycosis|Completed||N/A|63|Actual|Chesson Laboratory Associates, Inc||1|||f||||t||||||||||2018-06-01 00:40:58.937278|2018-06-01 00:40:58.937278
NCT00960076|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2011-06-30||2011-08-22|2009-08-14|2009-08-17|Estimate|2011-08-22|2011-09-27|Estimate||||2011-08-22|2011-09-27|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|SCORE||An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes|18-Week, Multicenter, Randomized, Double-Blind 3b Trial to Evaluate Efficacy/Safety of Saxagliptin in Combo With Metformin XR 1500mg vs Metformin Uptitrated to 2000mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control After Diet/Exercise and a Stable Dose of Metformin XR 1500mg|Completed||Phase 3|282|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:40:59.05233|2018-06-01 00:40:59.05233
NCT00960063|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2015-11-19||2017-05-19|2009-08-14|2009-08-17|Estimate|2016-01-07|2016-02-10|Estimate||||2017-05-19|2017-06-14|Actual|November 11, 2009|Actual|2009-11-11|May 2017|2017-05-31|December 22, 2010|Actual|2010-12-22|December 22, 2010|Actual|2010-12-22||Interventional|||A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)|A Phase 1/1B Dose-Escalation Study to Determine the Safety and Tolerability of SCH 717454 Administered in Combination With Chemotherapy in Pediatric Subjects With Advanced Solid Tumors (Protocol No. 05883)|Terminated||Phase 1|4|Actual|Merck Sharp & Dohme Corp.||3||Study was terminated for business reasons.|f||||f||||||||||2018-06-01 00:40:59.464272|2018-06-01 00:40:59.464272
NCT00960037|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2012-06-14|2009-08-14|2009-08-17|Estimate|||||||2012-06-14|2012-06-18|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Trial to Assess Response to Oral Vitamin D3 Supplementation in Obese Individuals|The Vitamin D Dose Response Curve in Obesity|Completed||N/A|57|Actual|Winthrop University Hospital||2|||f||||f||||||||||2018-06-01 00:40:59.943805|2018-06-01 00:40:59.943805
NCT00960024|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2009-08-14|2009-08-14|2009-08-17|Estimate|||||||2009-08-14|2009-08-17|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|December 2015|Anticipated|2015-12-31|February 2011|Anticipated|2011-02-28||Interventional|||Supported Employment in a Swedish Context|Supported Employment for People With Severe Mental Illness in a Swedish Context- A Randomised Controlled Trial|Unknown status|Active, not recruiting|Phase 2|120|Actual|Vardalinstitutet The Swedish Institute for Health Sciences||2|||f||||t||||||||||2018-06-01 00:41:00.005191|2018-06-01 00:41:00.005191
NCT00960011|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-08-17|2009-08-14|2009-08-17|Estimate|||||||2009-08-17|2009-08-19|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|January 2011|Anticipated|2011-01-31|May 2010|Anticipated|2010-05-31||Interventional|||Comparative Study on Self-adhesive Mesh for Open Inguinal Hernia Repair|Comparison of Self Gripping Semi-resorbable Mesh (PROGRIP) With Polypropylene Mesh in Open Inguinal Hernia Repair - a Randomized Study|Unknown status|Recruiting|Phase 4|100|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:41:00.170105|2018-06-01 00:41:00.170105
NCT00959998|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-06-22|2009-08-14|2009-08-17|Estimate|||||||2012-06-22|2012-06-26|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Acupressure for Post-Treatment Cancer Fatigue||Completed||Phase 2|43|Actual|University of Michigan||3|||f||||f||||||||||2018-06-01 00:41:00.270155|2018-06-01 00:41:00.270155
NCT00959816|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2010-11-01|2009-08-14|2009-08-17|Estimate|||||||2010-11-01|2010-11-02|Estimate|August 2009||2009-08-31|September 2010|2010-09-30||||August 2009|Actual|2009-08-31||Interventional|||A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans||Completed||Phase 1|8|Actual|Abbott||2|||f||||f||||||||||2018-06-01 00:41:03.338909|2018-06-01 00:41:03.338909
NCT00959985|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2017-01-04||2017-04-26|2009-08-14|2009-08-17|Estimate|2017-03-15|2017-04-27|Actual||||2017-04-26|2017-05-30|Actual|August 2009||2009-08-31|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer|Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer: A Randomized Trial|Terminated||N/A|23|Actual|Massachusetts General Hospital|This trial was terminated due to slow accrual and small number of subjects for whom data was collected (23 out of expected 334). Study did not reach statistical power to conduct detailed analysis, results should be interpreted with this in mind|4||low accrual|f||||t||||||||Undecided||2018-06-01 00:41:00.354129|2018-06-01 00:41:00.354129
NCT00959972|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-04-27|2009-08-14|2009-08-17|Estimate|||||||2011-04-27|2011-04-29|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease|Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial|Completed||Phase 4|50|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-06-01 00:41:00.801567|2018-06-01 00:41:00.801567
NCT00959959|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2014-01-08|2009-08-14|2009-08-17|Estimate|||||||2014-01-08|2014-01-09|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|ARMOR1||ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer|ARMOR1: Phase 1, Open Label, Dose Escalation Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer|Completed||Phase 1|49|Actual|Novus Therapeutics, Inc||8|||f||||t||||||||||2018-06-01 00:41:00.89452|2018-06-01 00:41:00.89452
NCT00959946|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2012-10-04|2012-04-17|2013-01-18|2009-08-14|2009-08-17|Estimate|2013-01-18|2013-02-22|Estimate|2012-04-17|2012-04-19|Estimate|2013-01-18|2013-02-22|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer|A Phase 1/2, Open-Label Study Of Bosutinib Administered In Combination With Capecitabine In Subjects With Solid Tumor And ErbB2 Negative Locally Advanced Or Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|32|Actual|Pfizer|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.|1|||f||||f||||||||||2018-06-01 00:41:01.054682|2018-06-01 00:41:01.054682
NCT00959933|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-03-27|2009-08-14|2009-08-17|Estimate|||||||2017-03-27|2017-03-28|Actual|April 2001||2001-04-30|August 2009|2009-08-31|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions|A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Non-Fasting Conditions.|Completed||Phase 1|24|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:41:01.933829|2018-06-01 00:41:01.933829
NCT00959920|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2012-04-24||2017-05-17|2009-08-14|2009-08-17|Estimate|2012-04-24|2012-05-23|Estimate||||2017-05-17|2017-05-19|Actual|July 2009||2009-07-31|May 2017|2017-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SOFT||Bladder Drainage During Labor: A Randomized Controlled Study of Obstetric Foley Therapy|Study of Obstetric Foley Therapy (SOFT Trial)|Completed||N/A|139|Actual|Loyola University|The are not limitations or caveats to disclose.|2|||f||||t||||||||No||2018-06-01 00:41:01.983666|2018-06-01 00:41:01.983666
NCT00959907|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2009-04-23||2009-12-09|2009-07-02|2009-08-17|Estimate|2009-07-02|2009-08-17|Estimate||||2009-12-09|2009-12-15|Estimate|May 2005||2005-05-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Comparison of Two Commercial Preparations of Botulinum Toxin Type A|A Phase iv Controlled Randomized Blinded Study on the Anhydrotic Action Halos and Muscle Activity of Two Commercial Preparations Type a Botulinum Toxin (Dysport® and Botox® ) Administered to the Upper Third of the Face|Completed||Phase 4|29|Actual|Brazilan Center for Studies in Dermatology|The field of muscular effects of the studied toxins was objectively measured by EMG and it is not very precise. However, there is no more precise objective measurement to currently evaluate the field effects in muscles than EMG.|2|||f||||f||||||||||2018-06-01 00:41:02.163241|2018-06-01 00:41:02.163241
NCT00959894|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2015-03-27||2016-04-29|2009-08-14|2009-08-17|Estimate|2015-05-11|2015-05-13|Estimate||||2016-04-29|2016-06-06|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional||All participants who received at least one dose of study medication (etravirine 400 mg given once daily with with one tablet of fixed dose tenofovir/emtricitabine).|Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection|Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection|Completed||Phase 2|80|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-06-01 00:41:02.452455|2018-06-01 00:41:02.452455
NCT00959881|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-04-01|2009-08-14|2009-08-17|Estimate|||||||2011-04-01|2011-04-04|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study Evaluating The Coadministration of Begacestat And Donepezil|Combined Administration Of Begacestat And Donepezil: A Multiple-Dose Study In Healthy Subjects|Completed||Phase 1|47|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 00:41:02.898106|2018-06-01 00:41:02.898106
NCT00959868|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2012-02-10|2009-08-14|2009-08-17|Estimate|||||||2012-02-10|2012-02-13|Estimate|July 2009||2009-07-31|February 2012|2012-02-29||||December 2012|Anticipated|2012-12-31||Interventional|||A Study for Treatment of Superficial Bladder Cancer Using OGX-427|A Phase I Clinical Trial Assessing Intravesical Antisense Oligonucleotide Targeting Heat Shock Protein 27 for the Treatment of Superficial Bladder Cancer|Unknown status|Recruiting|Phase 1|36|Anticipated|Vancouver Coastal Health|||||f||||t||||||||||2018-06-01 00:41:02.984957|2018-06-01 00:41:02.984957
NCT00959855|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2010-05-25|2009-08-14|2009-08-17|Estimate|||||||2010-05-25|2010-05-26|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2014|Anticipated|2014-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Long-term Impact of Pulmonary Rehabilitation|Long-term Evaluation of Activity and Health Status Pre and Post Pulmonary Rehabilitation - A Multi-Centred Trial.|Suspended||N/A|120|Anticipated|Beaumont Hospital||2||Pending modifications|f||||f||||||||||2018-06-01 00:41:03.088461|2018-06-01 00:41:03.088461
NCT00959842|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2014-11-17|2009-08-14|2009-08-17|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|ELLF||Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia|Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia|Completed||Phase 1/Phase 2|15|Actual|Sanford Research||1|||f||||f||||||||||2018-06-01 00:41:03.177117|2018-06-01 00:41:03.177117
NCT00959803|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-12-03|2009-08-14|2009-08-17|Estimate|||||||2009-12-03|2009-12-07|Estimate|August 2009||2009-08-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study Of Single Ascending And Multiple Doses Of PF-04447943 In Japanese Subjects.|An Investigator- And Subject-Blind Phase 1 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04447943 After Administration Of Single Oral Doses To Healthy Young Adult Japanese Subjects And Multiple Oral Doses To Healthy Elderly Japanese Subjects|Completed||Phase 1|17|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:41:03.428456|2018-06-01 00:41:03.428456
NCT00959790|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2012-02-27|2009-08-14|2009-08-17|Estimate|||||||2012-02-27|2012-02-28|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|8374||Vegetable Consumption in Relation to Health|Beneficial Effects of Vegetable Consumption and a Diet Intervention on Health in Lean and Obese Men.|Completed||N/A|32|Actual|TNO||3|||f||||f||||||||||2018-06-01 00:41:03.504122|2018-06-01 00:41:03.504122
NCT00959777|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2014-09-29|2009-08-14|2009-08-17|Estimate|||||||2014-09-29|2014-10-01|Estimate||||September 2014|2014-09-30||||||||Interventional|||Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating DA-3031 (PEG-G-CSF) to Filgrastim (Dong-A) in Healthy Volunteers||Completed||Phase 1|||Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:41:03.588088|2018-06-01 00:41:03.588088
NCT00959764|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2012-10-26||2013-09-16|2009-08-14|2009-08-17|Estimate|2013-09-16|2013-11-19|Estimate||||2013-09-16|2013-11-19|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|ORACAL||A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women|A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48-Week, Study of Oral Recombinant Salmon Calcitonin (rsCT) Compared to Salmon Calcitonin (sCT) Nasal Spray in Postmenopausal Osteoporotic Women|Completed||Phase 3|565|Actual|Tarsa Therapeutics, Inc.||3|||f||||t||||||||||2018-06-01 00:41:03.688482|2018-06-01 00:41:03.688482
NCT00959751|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2013-05-08||2014-07-12|2009-08-14|2009-08-17|Estimate|2014-06-10|2014-07-11|Estimate||||2014-07-12|2014-07-23|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional||Of the 195 subjects randomized, 174 subjects received study drug: the 174 subjects constitute the Safety Population.|Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura|Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura|Completed||Phase 2|195|Actual|NeurAxon Inc.||2|||f||||f||||||||||2018-06-01 00:41:04.225177|2018-06-01 00:41:04.225177
NCT00959738|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2014-11-13|2009-08-14|2009-08-17|Estimate|||||||2014-11-13|2014-11-14|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|ROLLI||Diverting Loop Ileostomy: With or Without Rod|A Prospective Multicenter Randomized Controlled Clinical Trial to Compare the Method of Protective Diverting Loop Ileostomy With or Without the Support of a Plastic Rod|Terminated||N/A|121|Actual|University Hospital Inselspital, Berne||2||Difference found in interim analysis, not ethical to continue|f||||f||||||||||2018-06-01 00:41:04.705511|2018-06-01 00:41:04.705511
NCT00959725|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2009-08-14|2009-08-14|2009-08-17|Estimate|||||||2009-08-14|2009-08-17|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema|Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-06-01 00:41:04.773138|2018-06-01 00:41:04.773138
NCT00959712|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2011-11-07|2009-08-14|2009-08-17|Estimate|||||||2011-11-07|2011-11-08|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Computer Agents to Promote Walking in the Elderly|Computer Agents to Promote Walking in Older Adults With Low Health Literacy|Completed||N/A|263|Actual|Boston Medical Center||2|||f||||t||||||||||2018-06-01 00:41:04.91285|2018-06-01 00:41:04.91285
NCT00959699|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2013-05-08||2017-03-09|2009-08-14|2009-08-17|Estimate|2013-07-26|2013-08-30|Estimate||||2017-03-09|2017-04-07|Actual|November 2009||2009-11-30|March 2017|2017-03-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)|A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (Protocol No. P05411)|Completed||Phase 2|99|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:41:04.988508|2018-06-01 00:41:04.988508
NCT00959686|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|||2013-02-11|2009-08-14|2009-08-17|Estimate|||||||2013-02-11|2013-02-12|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|February 2013|Actual|2013-02-28|June 2011|Actual|2011-06-30||Interventional|BENTLY||Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma|"Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma. A Phase II Multicenter Study BENTLY"|Completed||Phase 2|45|Anticipated|French Innovative Leukemia Organisation||1|||f||||t||||||||||2018-06-01 00:41:05.603072|2018-06-01 00:41:05.603072
NCT00959660|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-14|2018-01-26||2018-03-13|2009-08-14|2009-08-17|Estimate|2018-03-13|2018-04-11|Actual||||2018-03-13|2018-04-11|Actual|February 2009|Actual|2009-02-28|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 15, 2012|Actual|2012-08-15||Interventional|SECRET||Exercise Intolerance in Elderly Patients With Diastolic Heart Failure|Study of the Effect of Caloric Restriction and Exercise Training in Patients With Heart Failure and a Normal Ejection Fraction.(SECRET)|Completed||N/A|100|Actual|Wake Forest University Health Sciences||4|||f||||t||||||||||2018-06-01 00:41:05.707552|2018-06-01 00:41:05.707552
NCT00959647|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2014-12-23||2014-12-23|2009-08-12|2009-08-14|Estimate|2014-12-23|2015-01-07|Estimate||||2014-12-23|2015-01-07|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety population: All participants who had received at least 1 dose of study medication.|A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study|An Open-label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study|Completed||Phase 2|19|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 00:41:06.266976|2018-06-01 00:41:06.266976
NCT00959634|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2010-11-02|2009-08-13|2009-08-14|Estimate|||||||2010-11-02|2010-11-03|Estimate|August 2009||2009-08-31|September 2010|2010-09-30||||September 2009|Actual|2009-09-30||Interventional|||Pharmacokinetic Study of ABT-126 in Healthy Volunteers||Completed||Phase 1|20|Actual|Abbott||3|||f||||f||||||||||2018-06-01 00:41:06.506922|2018-06-01 00:41:06.506922
NCT00958217|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2015-06-26||2016-02-22|2009-08-11|2009-08-13|Estimate|2016-02-22|2016-03-24|Estimate||||2016-02-22|2016-03-24|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Intervention for Veterans With Depression, Substance Disorder, and Trauma|Intervention for Veterans With Depression, Substance Disorder, and Trauma|Completed||N/A|154|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 00:41:30.394722|2018-06-01 00:41:30.394722
NCT00959621|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-08-13|2009-08-13|2009-08-14|Estimate|||||||2009-08-13|2009-08-14|Estimate|January 2002||2002-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2004|Actual|2004-12-31||Interventional|HABENOX||Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion|Role of LMWH (Enoxaparine) With or Without Aspirin in the Prevention of Habitual Abortion; Special Attention to the Thrombophilic Status of the Mother|Completed||Phase 3|220|Actual|Helsinki University||3|||f||||f||||||||||2018-06-01 00:41:06.56672|2018-06-01 00:41:06.56672
NCT00959608|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2016-08-15|2009-08-13|2009-08-14|Estimate|||||||2016-08-15|2016-08-17|Estimate|June 2006||2006-06-30|August 2016|2016-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|Think Health!||Think Health! A Personal Weight Management Program|Modeling Effective Obesity Treatment to Reduce Disparities Through Primary Care|Completed||N/A|261|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:41:06.641414|2018-06-01 00:41:06.641414
NCT00959595|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2013-12-13|2009-08-13|2009-08-14|Estimate|||||||2013-12-13|2013-12-16|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Improvement of Sensibility in the Foot in Diabetic Patients Induced by EMLA-application to the Lower Leg|Improvement of Sensibility in the Sole of the Foot in Diabetic Patients, Induced by EMLA-application to the Lower Leg - a Double Blind Study|Completed||Phase 3|32|Actual|Lund University Hospital||2|||f||||t||||||||||2018-06-01 00:41:06.704701|2018-06-01 00:41:06.704701
NCT00959582|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-01-21|2009-08-13|2009-08-14|Estimate|||||||2015-01-21|2015-01-22|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)|A Multicenter Trial to Measure Early Patterns of Change in [18F]-Fluorodeoxyglucose Uptake by PET/CT in Relapsed Ovarian Cancer Patients|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:41:06.772254|2018-06-01 00:41:06.772254
NCT00959569|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2018-04-05|2009-08-13|2009-08-14|Estimate|||||||2018-04-05|2018-04-06|Actual|August 2009||2009-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|BREVI||Esmolol in Cardiac Surgery|Esmolol in Cardiac Surgery. A Randomized Controlled Trial With Clinical|Recruiting||Phase 4|200|Anticipated|Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-06-01 00:41:06.829342|2018-06-01 00:41:06.829342
NCT00959556|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2011-01-07|2009-08-13|2009-08-14|Estimate|||||||2011-01-07|2011-01-10|Estimate|November 2007||2007-11-30|August 2009|2009-08-31||||December 2011|Anticipated|2011-12-31||Observational|||Study of Blood Samples in Patients With Breast Cancer|Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting|Unknown status|Recruiting||900|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:41:06.894091|2018-06-01 00:41:06.894091
NCT00959543|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2011-07-06|2009-08-13|2009-08-14|Estimate|||||||2011-07-06|2011-07-07|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||MRI Findings in Throwing Shoulders of Waterpolo Players|MRI Findings in Throwing Shoulders of Waterpolo Players Abnormalities in Professional Waterpolo Players|Completed||N/A|45|Actual|Cantonal Hospital of St. Gallen||2|||f||||f||||||||||2018-06-01 00:41:07.012838|2018-06-01 00:41:07.012838
NCT00959530|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-03-27|2009-08-13|2009-08-14|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2007||2007-11-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|September 2009|Actual|2009-09-30||Interventional|denture||Comparison of Lingualized and Full Bilaterally Balanced Articulation|A Randomized Clinical Trial Comparing Lingualized and Full Bilaterally Balanced Articulation for Complete Dentures|Completed||N/A|60|Actual|Nihon University||2|||f||||f||||||||||2018-06-01 00:41:07.077499|2018-06-01 00:41:07.077499
NCT00959517|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-08-13|2009-08-13|2009-08-14|Estimate|||||||2009-08-13|2009-08-14|Estimate|July 2001||2001-07-31|August 2009|2009-08-31|August 2006|Actual|2006-08-31|June 2005|Actual|2005-06-30||Interventional|||Trial of Artesunate Combination Therapy in Pakistan|Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan|Completed||Phase 2|588|Actual|London School of Hygiene and Tropical Medicine||6|||f||||t||||||||||2018-06-01 00:41:07.152035|2018-06-01 00:41:07.152035
NCT00959504|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2011-06-07|2009-08-13|2009-08-14|Estimate|||||||2011-06-07|2011-06-09|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Detection of Factor V Leiden G1691A and Factor II (Prothrombin) G20210A Point Mutations in DNA|VeraCode Genotyping Test for Factor V and Factor II on the BeadXpress System|Completed|||275|Actual|Illumina, Inc.|||||f||||t||||||||||2018-06-01 00:41:07.227635|2018-06-01 00:41:07.227635
NCT00959491|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2010-10-19|2009-08-13|2009-08-14|Estimate|||||||2010-10-19|2010-10-20|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Observational|RLHV||A Prospective Study of a New Immunological Fecal Occult Blood Test|A Prospective Study of a New Immunological Fecal Occult Blood Test in Patients Referred for Colonoscopy|Unknown status|Active, not recruiting||160|Anticipated|National Institute of Gastroenterology, Cuba|||1||f||||t||||||Samples Without DNA|"~     One fecal sample~   "|||2018-06-01 00:41:07.261279|2018-06-01 00:41:07.261279
NCT00959478|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2014-01-29|2009-08-13|2009-08-14|Estimate|||||||2014-01-29|2014-01-30|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|ProjectCODE||Emergency Department Brief Intervention to Increase Carbon Monoxide Detector Use|Emergency Department Brief Intervention to Increase Carbon Monoxide Detector Use|Completed||N/A|300|Actual|Nationwide Children's Hospital||1|||f||||t||||||||||2018-06-01 00:41:07.371738|2018-06-01 00:41:07.371738
NCT00959465|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2015-10-07|2009-08-13|2009-08-14|Estimate|||||||2015-10-07|2015-10-09|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||A/H1N1 Immunogenicity and Safety in Adults|An Open Label Phase 1/2 Study to Assess Immunogenicity and Safety of Different Dose Levels of H1N1 Pandemic Influenza Vaccine in Healthy Adults Aged 18 Years and Older|Completed||Phase 1/Phase 2|408|Actual|Ology Bioservices||3|||f||||t||||||||||2018-06-01 00:41:07.455687|2018-06-01 00:41:07.455687
NCT00959452|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2018-05-01|2009-08-13|2009-08-14|Estimate|||||||2018-05-01|2018-05-02|Actual|January 1997||1997-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2010|Actual|2010-12-31||Interventional|||Follow up of Patients Treated With Cognitive Behavioural Therapy for Hypochondria From 1997 to 2007|Follow up of Patients Treated With Cognitive Behavioural Therapy at Clinic for Hypochondriacs, Haraldsplass Deaconal Hospital, From 1997 to 2007|Active, not recruiting||N/A|250|Anticipated|University of Bergen||1|||f||||t||||||||||2018-06-01 00:41:07.521798|2018-06-01 00:41:07.521798
NCT00959439|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-03-27|2009-08-13|2009-08-14|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2002||2002-03-31|March 2017|2017-03-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Relative Bioavailability Study of Naproxen Delayed-Release Tablets (375 mg)|A Comparative Bioavailability Study of Naproxen Delayed-Release Tablets, 375mg.|Completed||Phase 1|34|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:41:07.592249|2018-06-01 00:41:07.592249
NCT00959426|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2010-06-03|2009-08-13|2009-08-14|Estimate|||||||2010-06-03|2010-06-07|Estimate|August 2009||2009-08-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Multiple Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Adult Subjects|Completed||Phase 1|71|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:41:07.663764|2018-06-01 00:41:07.663764
NCT00959413|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-03-17|2009-08-13|2009-08-14|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load|Assessment of HIV-1-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV-1 Viral Load|Completed|||328|Actual|AIDS Clinical Trials Group|||4||f||||f||||||Samples With DNA|"~     Samples of saliva and blood will be kept~   "|||2018-06-01 00:41:07.742317|2018-06-01 00:41:07.742317
NCT00959400|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2015-07-15|2009-08-13|2009-08-14|Estimate|||||||2015-07-15|2015-07-16|Estimate|November 2009||2009-11-30|July 2015|2015-07-31||||June 2011|Actual|2011-06-30||Interventional|||Efficacy and Safety Study of Fentanyl Transdermal (Fentanest®)||Withdrawn||Phase 3|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||1|||f||||||||||||||2018-06-01 00:41:07.820029|2018-06-01 00:41:07.820029
NCT00959387|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-03-22|2009-08-13|2009-08-14|Estimate|||||||2014-03-22|2014-03-26|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|November 2010|Actual|2010-11-30||Interventional|||Induction Chemotherapy for Advanced Head and Neck Cancer|Induction Chemotherapy (IC) With Paclitaxel and Cisplatin (PC) Followed by Concomitant Chemoradiotherapy (CCRT) in Patient With Advanced Squamous Carcinoma of the Head and Neck (SSCHN).|Completed||Phase 2|60|Actual|Barretos Cancer Hospital||1|||f||||t||||||||||2018-06-01 00:41:07.888799|2018-06-01 00:41:07.888799
NCT00959374|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2012-08-29||2013-03-06|2009-08-13|2009-08-14|Estimate|2013-03-06|2013-04-17|Estimate||||2013-03-06|2013-04-17|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|May 2011|Actual|2011-05-31||Interventional|||Evaluation of Dermal Closure With an Absorbable Barbed Suture as Compared to a Conventional Absorbable Suture|A Prospective, Randomized Study to Evaluate Dermal Closure With an Absorbable Barbed Suture (V-Loc 180 Absorbable Wound Closure Device or V-Loc 90 Absorbable Wound Closure Device) as Compared to a Conventional Absorbable Suture|Completed||N/A|229|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-06-01 00:41:07.992555|2018-06-01 00:41:07.992555
NCT00959361|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-09-28|2009-08-13|2009-08-14|Estimate|||||||2009-09-28|2009-09-29|Estimate|June 2006||2006-06-30|August 2009|2009-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PC-HIV||Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy|Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy - Randomized Clinical Trial|Completed||N/A|332|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:41:08.301751|2018-06-01 00:41:08.301751
NCT00959348|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-09|||2009-08-12|2009-08-12|2009-08-14|Estimate|||||||2009-08-12|2009-08-14|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Effect of Inhaled Steroids on Glucose Regulation in Asthma Patients|The Effect of Inhaled Corticosteroids on the Risk of Diabetes, Impaired Glucose Tolerance and Characteristics of Glucose Regulation in Adults With Asthma : a Population Based Matched Controlled Study|Completed|||1394|Actual|The University of Hong Kong|||2||f||||f||||||Samples With DNA|"~     Plasma, serum and DNA~   "|||2018-06-01 00:41:08.387696|2018-06-01 00:41:08.387696
NCT00959335|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-03-27|2009-08-13|2009-08-14|Estimate|||||||2017-03-27|2017-03-28|Actual|August 2006||2006-08-31|March 2017|2017-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions|Randomized, Open-Label, 1-Way Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex (Reference) Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:41:08.45996|2018-06-01 00:41:08.45996
NCT00959322|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2009-10-12|2009-08-13|2009-08-14|Estimate|||||||2009-10-12|2009-10-14|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||A Prospective Single Center Clinical Study for Capsulotomy Using the LenSx 550 Laser|A Prospective Single Center Clinical Study for Capsulotomy Using the LenSx 550 Laser|Completed||N/A|60|Actual|LenSx Lasers Inc.|||||f||||f||||||||||2018-06-01 00:41:08.524176|2018-06-01 00:41:08.524176
NCT00959309|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-11-08|2009-08-13|2009-08-14|Estimate|||||||2017-11-08|2017-11-13|Actual|October 2007||2007-10-31|November 2017|2017-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Media Use in Preschooler Study (MUPS)|Media Use in Preschooler Study (MUPS) An Office Based Intervention to Improve Media Use in Preschool Children: a Randomized Controlled Trial|Completed||Phase 4|160|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:41:08.585699|2018-06-01 00:41:08.585699
NCT00959296|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-04-20|2009-08-13|2009-08-14|Estimate|||||||2017-04-20|2017-04-21|Actual|August 2003||2003-08-31|April 2017|2017-04-30|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Observational|ISPR||Implantable Systems Performance Registry|Implantable Systems Performance Registry|Completed|||10981|Actual|MedtronicNeuro|||1||f||||f||||||||||2018-06-01 00:41:08.842675|2018-06-01 00:41:08.842675
NCT00959283|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-07-24|2009-08-13|2009-08-14|Estimate|||||||2017-07-24|2017-07-25|Actual|February 2009||2009-02-28|July 2017|2017-07-31|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Study of Blood Samples From Newborns With Down Syndrome|Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)|Active, not recruiting|||180|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 00:41:09.015093|2018-06-01 00:41:09.015093
NCT00959270|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2017-11-11|2009-08-13|2009-08-14|Estimate|||||||2017-11-11|2017-11-14|Actual|May 2009||2009-05-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|PCLS||Pennington Center Longitudinal Study (PCLS)|Pennington Center Longitudinal (PCLS)|Recruiting|||30000|Anticipated|Pennington Biomedical Research Center|||||f||||f||||||Samples With DNA|"~     Serum, plasma, buffy coat, whole blood~   "|||2018-06-01 00:41:09.376156|2018-06-01 00:41:09.376156
NCT00959257|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-09|||2009-08-12|2009-08-12|2009-08-14|Estimate|||||||2009-08-12|2009-08-14|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||The Effect of Long Term Inhaled Corticosteroids on the Risk of Cardiovascular Morbidities|The Effect of Long Term Inhaled Corticosteroids on the Risk of Cardiovascular Morbidities in Adults With Asthma :a Population Based Matched Controlled Study|Completed|||1394|Actual|The University of Hong Kong|||2||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum and DNA~   "|||2018-06-01 00:41:09.458126|2018-06-01 00:41:09.458126
NCT00959244|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2010-06-10|2009-08-13|2009-08-14|Estimate|||||||2010-06-10|2010-06-11|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105|1) Effects of Therapeutic Agents on Estrogens in the Breast 2) Utilizing the Resources of the Breast Cancer Collaborative Registry (BCCR)|Completed|||100|Anticipated|University of Nebraska|||||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-06-01 00:41:09.53362|2018-06-01 00:41:09.53362
NCT00959231|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2013-08-23|2009-08-13|2009-08-14|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2009||2009-01-31|April 2010|2010-04-30||||August 2012|Anticipated|2012-08-31||Interventional|||Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease|Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Haematological Diseases Using a Reduced Intensity Conditioning Regimen|Unknown status|Recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:41:09.612277|2018-06-01 00:41:09.612277
NCT00959218|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2012-02-02|2009-08-13|2009-08-14|Estimate|||||||2012-02-02|2012-02-03|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis|Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain|Completed||Phase 3|240|Actual|Bionorica Research GmbH||2|||f||||t||||||||||2018-06-01 00:41:09.707497|2018-06-01 00:41:09.707497
NCT00959205|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2010-05-19|2009-08-13|2009-08-14|Estimate|||||||2010-05-19|2010-05-20|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|February 2011|Anticipated|2011-02-28|June 2010|Anticipated|2010-06-30||Interventional|CARTOAF&VT||The Efficacy and Safety of CARTO 3D Mapping System Versus Conventional Method in AF and VT|Phase Ⅳ Study of CARTO 3D Mapping System vs Conventional Method in AF & VT|Unknown status|Enrolling by invitation|Phase 4|160|Anticipated|Korea University||2|||f||||t||||||||||2018-06-01 00:41:09.805518|2018-06-01 00:41:09.805518
NCT00959192|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2014-05-09||2015-11-30|2009-08-13|2009-08-14|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease|Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 Withqs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.|Completed||Phase 2|32|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:41:09.915382|2018-06-01 00:41:09.915382
NCT00959179|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2009-08-13|2009-08-13|2009-08-14|Estimate|||||||2009-08-13|2009-08-14|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|REFORM||The Registry Evaluating Functional Outcomes of Resynchronization Management|The Registry Evaluating Functional Outcomes of Resynchronization Management|Unknown status|Active, not recruiting||100|Actual|Saint Luke's Health System|||2||f||||f||||||||||2018-06-01 00:41:10.761602|2018-06-01 00:41:10.761602
NCT00959166|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2016-02-19|2009-08-13|2009-08-14|Estimate|||||||2016-02-19|2016-02-22|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Observational|||Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection - A Positron Emission Tomography (PET) Study|A Prospective Case-control Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-infection - a PET Study|Completed|||24|Actual|Imperial College London|||3||f||||f||||||||||2018-06-01 00:41:10.818878|2018-06-01 00:41:10.818878
NCT00959153|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-05-31|2009-08-13|2009-08-14|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2010||2010-06-30|May 2011|2011-05-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney|Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney (Renal Pelvis)|Unknown status|Active, not recruiting|Phase 3|20|Anticipated|Advance Shockwave Technology GmbH||1|||f||||f||||||||||2018-06-01 00:41:10.873351|2018-06-01 00:41:10.873351
NCT00959140|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-11-01|2009-08-12|2009-08-14|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors|Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants From Matched Related Donors|Recruiting||N/A|30|Anticipated|University of Alabama at Birmingham||1|||f||||t|f|t|t|f||||No||2018-06-01 00:41:11.026752|2018-06-01 00:41:11.026752
NCT00959127|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2013-02-12|2009-08-13|2009-08-14|Estimate|||||||2013-02-12|2013-02-13|Estimate|August 2009||2009-08-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer||Completed||Phase 1|93|Actual|Array BioPharma||1|||f||||f||||||||||2018-06-01 00:41:11.124096|2018-06-01 00:41:11.124096
NCT00959114|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13||2012-07-13|2012-07-30|2009-08-13|2009-08-14|Estimate||||2012-07-30|2012-08-06|Estimate|2012-07-30|2012-08-06|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Safety and Efficacy of ALV003 for the Treatment of Celiac Disease|A Phase 2a, Double-Blind, Placebo Controlled Study of the Efficacy, Safety and Tolerability of 6-weeks Treatment With ALV003 In Patients With Well-Controlled Celiac Disease|Completed||Phase 2|74|Actual|Alvine Pharmaceuticals Inc.||2|||f||||f||||||||||2018-06-01 00:41:11.202473|2018-06-01 00:41:11.202473
NCT00959101|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2015-03-23|2009-08-13|2009-08-14|Estimate|||||||2015-03-23|2015-03-24|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers|A Randomised, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Male Volunteers|Completed||Phase 1|42|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 00:41:11.284087|2018-06-01 00:41:11.284087
NCT00959088|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2013-04-09|2009-08-12|2009-08-14|Estimate|||||||2013-04-09|2013-04-11|Estimate|August 2009||2009-08-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|FASTER||Faster Identification of TB and Evaluation of Drug Resistance in HIV-infected People|Faster AFB Identification, Speciation of TB, and Evaluation of Drug Resistance in HIV-Infected Persons Initiating TB Treatment|Completed|||641|Actual|AIDS Clinical Trials Group|||1||f||||t||||||Samples With DNA|"~     samples of sputum and blood may be retained~   "|||2018-06-01 00:41:11.360994|2018-06-01 00:41:11.360994
NCT00959075|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2018-02-26|2009-08-13|2009-08-14|Estimate|||||||2018-02-26|2018-02-27|Actual|September 2009||2009-09-30|February 2018|2018-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Trial of Thiamin Supplementation in Patients With Heart Failure|A Randomized Controlled Trial of the Effect of Thiamin Supplementation on Heart Function in Ambulatory Patients With Heart Failure|Completed||Phase 4|70|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-06-01 00:41:11.447053|2018-06-01 00:41:11.447053
NCT00959062|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2014-08-11|2009-08-13|2009-08-14|Estimate|||||||2014-08-11|2014-08-13|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|NAPS Pilot||Adjunctive Clonidine in the Sedation of Mechanically Ventilated Children|New Approaches to Pediatric Sedation: Adjunctive Clonidine in the Sedation of Mechanically Ventilated Children (NAPS Pilot Trial)|Completed||Phase 4|50|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 00:41:11.534977|2018-06-01 00:41:11.534977
NCT00959049|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2011-07-03||2017-04-16|2009-08-13|2009-08-14|Estimate|2011-07-03|2011-07-29|Estimate||||2017-04-16|2017-05-16|Actual|September 2009||2009-09-30|April 2017|2017-04-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population|A Phase III, Randomized, Observer-blind, Multi-center, Noninferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Trivalent Inactivated Split-Virion Influenza Vaccine in a Pediatric Population Aged Greater Than or Equal to 6 Months to Less Than 18 Years.|Completed||Phase 3|1474|Actual|Seqirus||6|||f||||t||||||||||2018-06-01 00:41:11.74419|2018-06-01 00:41:11.74419
NCT00959036|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13||2013-01-15|2013-01-28|2009-08-13|2009-08-14|Estimate||||2013-01-15|2013-01-24|Estimate|2013-01-28|2013-01-30|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis|A Seamless, Phase 1/2, Multiple Ascending Dose, Proof Of Concept Study Of ATN-103 Administered To Subjects With Active Rheumatoid Arthritis On A Background Of Methotrexate|Completed||Phase 1/Phase 2|252|Actual|Ablynx||6|||f||||t||||||||||2018-06-01 00:41:13.326506|2018-06-01 00:41:13.326506
NCT00959023|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2013-08-23|2009-08-13|2009-08-14|Estimate|||||||2013-08-23|2013-08-26|Estimate|June 1993||1993-06-30|August 2009|2009-08-31||||||||Observational|||Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer|UK Genetic Prostate Cancer Study|Unknown status|Recruiting||21000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:41:13.494141|2018-06-01 00:41:13.494141
NCT00959010|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2015-10-20|2009-08-13|2009-08-14|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2008||2008-10-31|October 2015|2015-10-31||||June 2011|Actual|2011-06-30||Interventional|||Omega 3 Supplementation in Cystic Fibrosis Patients|Biochemical Effects of a Long-term Supplementation With Omega-3 Polyunsaturated Fatty Acids in Cystic Fibrosis|Completed||Phase 3|15|Actual|Queen Fabiola Children's University Hospital||2|||f||||||||||||||2018-06-01 00:41:13.953484|2018-06-01 00:41:13.953484
NCT00958997|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2012-07-20|2009-08-13|2009-08-14|Estimate|||||||2012-07-20|2012-07-23|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Observational|||Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients|Quantitative PET Imaging of Pancreatic Beta-cell Mass in Healthy and Type 1 Diabetic Patients With 18F-FP-DTBZ (AV-133)|Completed|||16|Actual|Yale University|||2||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|||2018-06-01 00:41:14.014952|2018-06-01 00:41:14.014952
NCT00958984|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2014-12-16|2009-08-13|2009-08-14|Estimate|||||||2014-12-16|2014-12-18|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Observational|||Continuous Hemoglobin Monitoring in Pediatric Transplant|Continuous Hemoglobin and Plethysmograph Variability Index Monitoring May Provide Superior Assessment During Visceral Solid Organ Transplantation in Children: a Prospective Cohort Study|Completed|||21|Actual|University of Nebraska|||||f||||f||||||||||2018-06-01 00:41:14.087255|2018-06-01 00:41:14.087255
NCT00958971|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11||2013-02-09|2013-02-09|2009-08-12|2009-08-14|Estimate||||2013-02-09|2013-02-12|Estimate|2013-02-09|2013-02-12|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer|A Multi-center, Open Label Phase II Trial of TKI258 in FGFR1 Amplified and Non-amplified Metastatic or Advanced HER2 Negative Breast Cancer|Completed||Phase 2|165|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:41:14.138466|2018-06-01 00:41:14.138466
NCT00958958|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2012-02-25|2009-08-13|2009-08-14|Estimate|||||||2012-02-25|2012-02-28|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|BRIDGE||Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes|Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes|Completed||N/A|1150|Actual|Hospital do Coracao||2|||f||||t||||||||||2018-06-01 00:41:14.241788|2018-06-01 00:41:14.241788
NCT00958945|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2009-08-13|2009-08-13|2009-08-14|Estimate|||||||2009-08-13|2009-08-14|Estimate|September 2009||2009-09-30|August 2009|2009-08-31||||||||Observational|||Retrospective Chart Analysis in the Effective Use of FloSeal in Post-Operative Joint Replacements|Retrospective & Prospective Evaluation/Analysis of Hb/Hct in Patients Having Received FloSeal (5ml &10ml) When Undergoing Total Knee or Total Hip Arthroplasty|Unknown status|Not yet recruiting||500|Anticipated|Desert Orthopedic Center Medical Research Foundation|||5||f||||f||||||||||2018-06-01 00:41:15.366814|2018-06-01 00:41:15.366814
NCT00958932|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|||2011-07-19|2009-08-13|2009-08-14|Estimate|||||||2011-07-19|2011-07-20|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|TEAM||Telecommunication Enhanced Asthma Management|Telecommunication Enhanced Asthma Management|Unknown status|Active, not recruiting|Early Phase 1|1000|Anticipated|National Jewish Health||2|||f||||t||||||||||2018-06-01 00:41:15.434712|2018-06-01 00:41:15.434712
NCT00958919|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-13|2012-11-05||2013-03-01|2009-08-13|2009-08-14|Estimate|2013-03-01|2013-04-11|Estimate||||2013-03-01|2013-04-11|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)|The Role of Endorphins in the Perception of Dyspnea With Resistive Loading in Patients With COPD|Completed||N/A|14|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-06-01 00:41:15.540451|2018-06-01 00:41:15.540451
NCT00958906|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-06-21|2009-08-12|2009-08-13|Estimate|||||||2011-06-21|2011-06-23|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|October 2009|Actual|2009-10-31|||||Interventional|||Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema|Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema|Withdrawn||Phase 1/Phase 2|10|Anticipated|Icahn School of Medicine at Mount Sinai||1||PI left institution (there are no data results for this study)|f||||f||||||||||2018-06-01 00:41:15.770786|2018-06-01 00:41:15.770786
NCT00958893|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2014-06-25||2014-08-08|2009-08-12|2009-08-13|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-08|2014-08-25|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated|An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext|An Open-Label Extension Study Evaluating Safety and Efficacy of Proellex® In Women With Leiomyomata Who Have Previously Completed ZPU 003 Ext|Terminated||Phase 2|4|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|1||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2018-06-01 00:41:15.860437|2018-06-01 00:41:15.860437
NCT00958880|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2013-05-30||2013-09-06|2009-08-12|2009-08-13|Estimate|2013-09-06|2013-11-11|Estimate||||2013-09-06|2013-11-11|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety|Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia|Completed||Phase 3|40|Actual|Southern Methodist University||2|||f||||f||||||||||2018-06-01 00:41:16.02931|2018-06-01 00:41:16.02931
NCT00958867|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2017-10-01|2009-08-12|2009-08-13|Estimate|||||||2017-10-01|2017-10-04|Actual|August 2009||2009-08-31|October 2017|2017-10-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||EXCEL: Exercise for Cognition and Everyday Living for Seniors With Memory Complaints|Enhancing Cognition and Functional Independence in Senior Women With Mild Cognitive Impairment: A Randomized Trial of Aerobic vs. Resistance Training|Completed||N/A|86|Actual|University of British Columbia||3|||f||||t||||||||||2018-06-01 00:41:16.415687|2018-06-01 00:41:16.415687
NCT00958854|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2013-08-23|2009-08-12|2009-08-13|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2006||2006-01-31|August 2009|2009-08-31||||March 2012|Anticipated|2012-03-31||Interventional|||Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma|Phase II Trial of Fludarabine & Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic Lymphoma|Unknown status|Recruiting|Phase 2|37|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:41:16.49809|2018-06-01 00:41:16.49809
NCT00958841|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2016-04-05||2016-06-15|2009-08-11|2009-08-13|Estimate|2016-06-15|2016-07-26|Estimate||||2016-06-15|2016-07-26|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||The full analysis set (FAS) consisted of all enrolled patients who received at least one dose of pasireotide LAR.|Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin|An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin|Terminated||Phase 2|118|Actual|Novartis||1||"Slow recruitment rate into this study with rare tumors of neuroendocrine origin (enrollment~   issues)"|f||||f||||||||||2018-06-01 00:41:16.654967|2018-06-01 00:41:16.654967
NCT00958828|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2010-09-23||2012-06-26|2009-08-12|2009-08-13|Estimate|2010-09-23|2010-10-19|Estimate||||2012-06-26|2012-07-10|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Clinical Evaluation of Two Daily Disposable Lenses in a Population of Daily Disposable (DD) Lens Wearers|Clinical Evaluation of Two Daily Disposable Lenses in a Population of Daily Disposable (DD) Lens Wearers|Completed||N/A|178|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 00:41:18.281503|2018-06-01 00:41:18.281503
NCT00958815|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2012-06-22|2009-08-12|2009-08-13|Estimate|||||||2012-06-22|2012-06-26|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT|Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT|Completed|||14|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||2||f||||f||||||||||2018-06-01 00:41:18.421981|2018-06-01 00:41:18.421981
NCT00958802|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2010-11-18|2009-08-12|2009-08-13|Estimate|||||||2010-11-18|2010-11-19|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies|Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies|Completed||Early Phase 1|6|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-06-01 00:41:18.489484|2018-06-01 00:41:18.489484
NCT00958789|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2017-04-11||2017-06-02|2009-08-12|2009-08-13|Estimate|2017-04-11|2017-05-19|Actual||||2017-06-02|2017-07-02|Actual|July 2009||2009-07-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 25, 2016|Actual|2016-04-25||Interventional||Participants who were censored are not included in baseline analysis.|Triathlon Total Stabilizer (TS) Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Triathlon® Total Stabilizer (TS) Total Knee System|Active, not recruiting||N/A|181|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:41:18.575284|2018-06-01 00:41:18.575284
NCT00958776|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2015-01-16|2014-07-17|2015-01-28|2009-08-12|2009-08-13|Estimate|2015-01-28|2015-02-12|Estimate|2014-07-17|2014-07-21|Estimate|2015-01-28|2015-02-12|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional||All enrolled subjects|A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza|A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza|Terminated||Phase 3|405|Actual|BioCryst Pharmaceuticals|Interim analysis of the primary efficacy endpoint (time to clinical resolution) performed after the end of the 2012 Southern Hemisphere influenza season lead to study termination for futility. Final enrollment was ~70% of the planned enrollment.|2||This study was terminated for futility|f||||t||||||||||2018-06-01 00:41:18.856869|2018-06-01 00:41:18.856869
NCT00958763|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2009-08-12|2009-08-12|2009-08-13|Estimate|||||||2009-08-12|2009-08-13|Estimate|March 2006||2006-03-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|NIAAA||Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)|Alcohol Use Reduction in Methadone Individuals With HCV|Completed||Phase 2|219|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-06-01 00:41:20.202635|2018-06-01 00:41:20.202635
NCT00958750|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2011-11-17|2009-08-12|2009-08-13|Estimate|||||||2011-11-17|2011-11-18|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia|Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume|Completed||Phase 3|113|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 00:41:20.339702|2018-06-01 00:41:20.339702
NCT00958737|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-02-28|2009-08-12|2009-08-13|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2009||2009-04-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|IDEA||Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer|A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer|Active, not recruiting||Phase 3|2000|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||f||||||||||2018-06-01 00:41:20.408948|2018-06-01 00:41:20.408948
NCT00958724|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2017-08-10||2017-08-10|2009-08-12|2009-08-13|Estimate|2017-08-10|2018-02-26|Actual||||2017-08-10|2018-02-26|Actual|July 2009|Actual|2009-07-31|August 2017|2017-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors|A Phase 1 Study Of Neratinib (HKI-272) In Combination With Vinorelbine In Japanese Subjects With Advanced Or Metastatic Solid Tumors|Completed||Phase 1|6|Actual|Puma Biotechnology, Inc.||1|||f||||t||||||||||2018-06-01 00:41:20.499841|2018-06-01 00:41:20.499841
NCT00958711|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2012-05-15|2009-08-12|2009-08-13|Estimate|||||||2012-05-15|2012-05-17|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer|The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer|Terminated||N/A|90|Actual|Synovis Surgical Innovations||2||Budgetary|f||||f||||||||||2018-06-01 00:41:20.808421|2018-06-01 00:41:20.808421
NCT00958698|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-08-23|2009-08-12|2009-08-13|Estimate|||||||2017-08-23|2017-08-24|Actual|January 19, 2010|Actual|2010-01-19|August 2017|2017-08-31||||January 8, 2017|Actual|2017-01-08||Interventional|||Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|NURSE-DELIVERED WRITE SYMPTOMS vs. SELF-DIRECTED WRITE SYMPTOMS vs. CARE AS USUAL FOR OPTIMAL SYMPTOM MANAGEMENT FOR WOMEN WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER|Active, not recruiting||N/A|485|Actual|Gynecologic Oncology Group||3|||f||||||||||||||2018-06-01 00:41:20.907816|2018-06-01 00:41:20.907816
NCT00958685|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-08-12|2009-08-12|2009-08-13|Estimate|||||||2009-08-12|2009-08-13|Estimate|January 2007||2007-01-31|August 2009|2009-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety Study of Feeding With Ginger Extract in Acute Respiratory Distress Syndrome|Effect of Enteral Feeding With Ginger Extract in Acute Respiratory Distress Syndrome|Completed||Phase 2|32|Actual|Shahid Beheshti University||2|||f||||t||||||||||2018-06-01 00:41:21.122459|2018-06-01 00:41:21.122459
NCT00958672|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2014-06-18|2009-08-12|2009-08-13|Estimate|||||||2014-06-18|2014-06-19|Estimate|August 2009||2009-08-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|sclero-video||Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy|Evaluation Des Anomalies Muqueuses Intestinales Par vidéocapsule Endoscopique au Cours de la sclérodermie systémique : Etude Prospective, Multicentrique et Inter-régionale|Completed|||50|Actual|University Hospital, Rouen|||||f||||t||||||||||2018-06-01 00:41:21.347268|2018-06-01 00:41:21.347268
NCT00958659|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2016-05-16|2009-08-12|2009-08-13|Estimate|||||||2016-05-16|2016-05-18|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Study of Specimens From Young Patients With Neuroblastoma|Prognostic Multigene Expression Classification of Neuroblastoma Patients|Completed|||350|Actual|Children's Oncology Group|||1||f||||t||||||||||2018-06-01 00:41:21.40566|2018-06-01 00:41:21.40566
NCT00958646|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2011-07-12|2009-08-12|2009-08-13|Estimate|||||||2011-07-12|2011-07-13|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Biomarkers of the Response to Osteopathic Manipulation|Identification of Biomarkers for Investigating Osteopathic Manipulative Treatment|Completed||N/A|40|Actual|West Virginia School of Osteopathic Medicine||2|||f||||f||||||||||2018-06-01 00:41:21.474536|2018-06-01 00:41:21.474536
NCT00958633|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2017-05-15|2009-08-12|2009-08-13|Estimate|||||||2017-05-15|2017-05-17|Actual|November 2010||2010-11-30|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.|Mood Stabilizer Plus Antidepressant Versus Mood Stabilizer Plus Placebo in the Maintenance Treatment of Bipolar Disorder|Recruiting||Phase 3|216|Anticipated|University of British Columbia||2|||f||||t||||||||No||2018-06-01 00:41:21.551038|2018-06-01 00:41:21.551038
NCT00958620|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-05-27|2009-08-12|2009-08-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2004||2004-10-31|May 2015|2015-05-31|June 2005|Actual|2005-06-30|January 2005|Actual|2005-01-31||Interventional|||Shockwave Therapy of Chronic Achilles Tendinopathy|Shockwave Therapy of Chronic Achilles Tendinopathy. A Double-blind, Randomized Clinical Trial of Efficacy|Completed||Phase 4|48|Actual|Northern Orthopaedic Division, Denmark||2|||f||||t||||||||||2018-06-01 00:41:21.650369|2018-06-01 00:41:21.650369
NCT00958607|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2014-01-20|2009-08-12|2009-08-13|Estimate|||||||2014-01-20|2014-01-22|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Optimizing Stroke Family Caregiver Support Across the Care Continuum by Improving the Timing of Intervention Delivery|Optimizing Stroke Family Caregiver Support Across the Care Continuum by Improving the Timing of Intervention Delivery|Completed||N/A|310|Actual|University of Toronto||3|||f||||f||||||||||2018-06-01 00:41:21.725975|2018-06-01 00:41:21.725975
NCT00958581|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2017-11-14||2017-12-18|2009-08-12|2009-08-13|Estimate|2017-11-14|2017-12-12|Actual||||2017-12-18|2018-01-17|Actual|December 2008||2008-12-31|December 2017|2017-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery|A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery|Completed||Phase 4|177|Actual|New York University School of Medicine||3|||f||||t|t|f|||f|||||2018-06-01 00:41:21.825252|2018-06-01 00:41:21.825252
NCT00958568|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2013-03-22||2014-02-17|2009-08-12|2009-08-13|Estimate|2014-02-17|2014-04-01|Estimate||||2014-02-17|2014-04-01|Estimate|August 2009||2009-08-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study in Relapse Prevention of Treatment-Resistant Depression|A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients With Treatment-Resistant Depression|Completed||Phase 3|892|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:41:22.272665|2018-06-01 00:41:22.272665
NCT00958555|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2014-01-13|2009-08-12|2009-08-13|Estimate|||||||2014-01-13|2014-01-14|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Study of Predictive and Prognostic Markers in Patients With Non-small Cell Lung Cancer|A Study of Predictive and Prognostic Markers in Patients With Non-small Cell Lung Cancer|Unknown status|Active, not recruiting||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 00:41:23.552702|2018-06-01 00:41:23.552702
NCT00958542|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2014-06-20|2009-08-12|2009-08-13|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Prospective Study of Cerebral Palsy Scoliosis|Prospective Study of Scoliosis in Children With Cerebral Palsy|Suspended||N/A|45|Anticipated|University of British Columbia||2||This study is coordinated by the Harms Study Group. It is already registered on this website|f||||f||||||||||2018-06-01 00:41:23.748317|2018-06-01 00:41:23.748317
NCT00958529|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-02-09|2009-08-12|2009-08-13|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2008||2008-08-31|February 2017|2017-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Gastrointestinal Toleration of Inulin Products|Effect of Two Doses of Inulin Products on Gastrointestinal Tolerance|Completed||N/A|26|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-06-01 00:41:23.845302|2018-06-01 00:41:23.845302
NCT00958516|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2013-10-24|2009-08-12|2009-08-13|Estimate|||||||2013-10-24|2013-10-25|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Assessment of the Phototoxic Potential of LEO 29102 Cream|A Phase 1 Study Evaluating the Phototoxic Potential of LEO 29102 Cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g) and the Cream Vehicle, Applied on Intact Skin of Healthy Male Subjects|Completed||Phase 1|32|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 00:41:23.952231|2018-06-01 00:41:23.952231
NCT00958503|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-03-24|2009-08-12|2009-08-13|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|April 2008|Actual|2008-04-30|September 2007|Actual|2007-09-30||Interventional|||Effect of Thiamphenicol on EAAT2 and Other Biomarkers From Nasal Biopsied Tissue|A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 14-Day Repeated-Dose Administration of Thiamphenicol (RUX 122) in Healthy Subjects|Completed||Phase 1|30|Actual|Psyadon Pharma||2|||f||||t||||||||||2018-06-01 00:41:24.013971|2018-06-01 00:41:24.013971
NCT00958490|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2011-08-13|2009-08-12|2009-08-13|Estimate|||||||2011-08-13|2011-08-16|Estimate|June 2009||2009-06-30|August 2011|2011-08-31||||June 2012|Anticipated|2012-06-30||Interventional|||Effects of a Walking Program on Functional Status of Post-Surgical Lumbar Spinal Stenosis Patients|Effects of a Physical Activity Intervention Walking Program on Quality of Life, Physical Activity Monitoring, and Functional Status of Post-Surgical Lumbar Spinal Stenosis Patients|Unknown status|Enrolling by invitation|N/A|50|Anticipated|University of Manitoba||2|||f||||||||||||||2018-06-01 00:41:24.086953|2018-06-01 00:41:24.086953
NCT00958477|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2017-01-25||2017-04-20|2009-08-12|2009-08-13|Estimate|2017-04-20|2017-08-02|Actual||||2017-04-20|2017-08-02|Actual|October 2008||2008-10-31|March 2017|2017-03-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional||Safety analysis set included all subjects who received at least 1 dose of the study medication and had at least 1 follow-up safety measure.|A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer|Phase I, Open-label Study to Investigate Safety, Tolerability, PK, and PD of EMD 525797 After Single and Repeated Dosing at Different Dose Levels in Subjects With Hormone-resistant Prostate Cancer With Bone Mets and Progressive Disease Following Prior CTX|Completed||Phase 1|26|Actual|Merck KGaA||1|||f||||f||||||||||2018-06-01 00:41:24.245966|2018-06-01 00:41:24.245966
NCT00958464|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2018-01-08|2009-08-12|2009-08-13|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2008||2008-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Effect of Perthes' Disease on Hip Cartilage|The Effect of Perthes' Disease on Hip Cartilage|Recruiting|||20|Anticipated|University of British Columbia|||1||f||||f||||||||||2018-06-01 00:41:25.94447|2018-06-01 00:41:25.94447
NCT00958451|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-03-23|2009-08-12|2009-08-13|Estimate|||||||2011-03-23|2011-03-24|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients|Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial|Completed||Phase 4|80|Anticipated|Salem Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 00:41:26.014105|2018-06-01 00:41:26.014105
NCT00958438|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2017-03-20|2011-03-10|2017-03-20|2009-08-12|2009-08-13|Estimate|2017-03-20|2017-04-28|Actual|2011-03-10|2011-03-23|Estimate|2017-03-20|2017-04-28|Actual|July 2009||2009-07-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Baseline population included all randomized participants.|PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy|Completed||Phase 3|248|Actual|Regeneron Pharmaceuticals||3|||f||||||||||||||2018-06-01 00:41:26.094131|2018-06-01 00:41:26.094131
NCT00958425|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2016-01-12|2009-08-12|2009-08-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2014||2014-01-31|January 2016|2016-01-31||||August 2016|Anticipated|2016-08-31||Interventional|||Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty|Intraoperative Hyaluronic Acid Gel Injection for Improvement of Scar Quality Following Reduction Mammaplasty: a Phase III Double-blinded, Single-centred, Randomized Controlled Study|Suspended||Phase 3|40|Anticipated|Nova Scotia Health Authority||2||Failure of funding|f||||t||||||||||2018-06-01 00:41:26.735265|2018-06-01 00:41:26.735265
NCT00958412|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2014-06-23|2009-08-12|2009-08-13|Estimate|||||||2014-06-23|2014-06-24|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study|A Randomized, Double-blind Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Premenopausal Women With Symptomatic Endometriosis-extension Study|Terminated||Phase 2|18|Actual|Repros Therapeutics Inc.||1||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2018-06-01 00:41:26.797625|2018-06-01 00:41:26.797625
NCT00958399|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2012-02-03|2009-08-12|2009-08-13|Estimate|||||||2012-02-03|2012-02-06|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers|Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers|Completed||N/A|20|Actual|University of Minnesota - Clinical and Translational Science Institute||5|||f||||f||||||||||2018-06-01 00:41:26.885951|2018-06-01 00:41:26.885951
NCT00958230|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2014-11-13|2009-08-12|2009-08-13|Estimate|||||||2014-11-13|2014-11-14|Estimate|August 2009||2009-08-31|September 2010|2010-09-30|November 2011|Actual|2011-11-30|April 2010|Actual|2010-04-30||Interventional|||dCell Vascular Patch in Peripheral Vascular Surgery Study for CE Mark Submission|An Open Arm Pilot Study to Evaluate the Safety and Performance of the dCell Vascular Patch in Reconstructive Peripheral Vascular Surgery|Completed||N/A|21|Actual|Tissue Regenix Ltd||1|||f||||f||||||||||2018-06-01 00:41:30.295112|2018-06-01 00:41:30.295112
NCT00958386|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-03-23|2009-08-12|2009-08-13|Estimate|||||||2015-03-23|2015-03-24|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|SPECTRA||Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)|Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With Irinotecan in Patients With Wild-Type KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy|Completed||Phase 2|61|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-06-01 00:41:26.957495|2018-06-01 00:41:26.957495
NCT00958373|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-05-05|2009-08-12|2009-08-13|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2006||2006-10-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Risk Factors for Psychiatric Disorders Associated With Adolescent Idiopathic Scoliosis|Risk Factors for Psychiatric Disorders Associated With Adolescent Idiopathic Scoliosis|Withdrawn|||0|Actual|University of British Columbia||||Didn't have the resources necessary to carry out the study|f||||f||||||||||2018-06-01 00:41:27.021016|2018-06-01 00:41:27.021016
NCT00958360|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2016-05-27||2016-07-14|2009-08-12|2009-08-13|Estimate|2016-07-14|2016-08-25|Estimate||||2016-07-14|2016-08-25|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|LOVIT II||Low Vision Intervention Trial II (LOVIT II)|VA Low Vision Intervention Trial (LOVIT) II|Completed||Phase 2|323|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:41:27.143238|2018-06-01 00:41:27.143238
NCT00958347|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2014-07-30||2014-07-30|2009-08-12|2009-08-13|Estimate|2014-07-30|2014-08-19|Estimate||||2014-07-30|2014-08-19|Estimate|October 1987||1987-10-31|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Omnifit Hydroxylapatite (HA) Hip Outcomes Study|Omnifit Hydroxylapatite (HA) Hip Outcomes Study|Terminated||N/A|226|Actual|Stryker Orthopaedics||1||Terminated due to lagging follow-up|f||||f||||||||||2018-06-01 00:41:27.555506|2018-06-01 00:41:27.555506
NCT00958334|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2010-08-26||2014-08-05|2009-08-12|2009-08-13|Estimate|2010-12-09|2011-01-07|Estimate||||2014-08-05|2014-08-08|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003|A Multicenter, Open-Label, Safety And Efficacy, Two Year Extension Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Pre-Menopausal Women With Symptomatic Leiomyomata Who Have Previously Completed Study ZPU 003|Completed||Phase 2|65|Actual|Repros Therapeutics Inc.||3|||f||||t||||||||||2018-06-01 00:41:27.707599|2018-06-01 00:41:27.707599
NCT00958321|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-05-23|2009-08-12|2009-08-13|Estimate|||||||2017-05-23|2017-05-24|Actual|March 2007||2007-03-31|May 2017|2017-05-31||||December 2016|Actual|2016-12-31||Interventional|||Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35|Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy|Terminated||Phase 2|40|Anticipated|Cancer Trials Ireland||1||Low levels of recruitment|f||||||||||||||2018-06-01 00:41:28.076113|2018-06-01 00:41:28.076113
NCT00958308|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2012-02-01||2012-03-09|2009-08-12|2009-08-13|Estimate|2012-02-01|2012-03-02|Estimate||||2012-03-09|2012-03-13|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection|A Double-blind, Randomized, Placebo-controlled, Single-center Study of the Efficacy and Safety of BIO-K+ CL-1285® in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection|Completed||Phase 3|255|Actual|Bio-K Plus International Inc.||3|||f||||t||||||||||2018-06-01 00:41:28.163047|2018-06-01 00:41:28.163047
NCT00958295|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-10-21|2009-08-12|2009-08-13|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|BaCyst||Epidemiology of Acute Bacterial Uncomplicated Cystitis in General Practice|Epidemiology of Acute Bacterial Uncomplicated Cystitis in General Practice: Description and Prediction by Urine Dipstick Test|Completed|||362|Actual|University Hospital, Rouen|||||f||||f||||||Samples Without DNA|"~     Bacterial strains isolated in urine cultures~   "|||2018-06-01 00:41:28.360363|2018-06-01 00:41:28.360363
NCT00958282|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2015-06-11||2015-08-13|2009-08-12|2009-08-13|Estimate|2015-08-13|2015-09-17|Estimate||||2015-08-13|2015-09-17|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Treatment of Cocaine Dependence With Lisdexamfetamine|Lisdexamfetamine Treatment for Cocaine Dependence|Completed||Phase 2|43|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 00:41:28.420734|2018-06-01 00:41:28.420734
NCT00958269|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2010-02-01|2009-08-12|2009-08-13|Estimate|||||||2010-02-01|2010-02-03|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|November 2011|Anticipated|2011-11-30|September 2011|Anticipated|2011-09-30||Interventional|||Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment|A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment Including Subjects on Hemodialysis|Terminated||Phase 3|360|Anticipated|Phenomix||5||Technical/operational issues|f||||||||||||||2018-06-01 00:41:28.671977|2018-06-01 00:41:28.671977
NCT00958256|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2015-03-31||2015-03-31|2009-08-12|2009-08-13|Estimate|2015-03-31|2015-04-13|Estimate||||2015-03-31|2015-04-13|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||One participant of 21 participants was not treated and is therefore excluded from baseline demographics.|Study of Bortezomib in Combination With Cyclophosphamide and Rituximab|Phase II Study of Bortezomib in Combination With Cyclophosphamide and Rituximab for Relapsed/Refractory Mantle Cell Lymphoma|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:41:28.977044|2018-06-01 00:41:28.977044
NCT00958243|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2011-07-13||2018-04-25|2009-08-12|2009-08-13|Estimate|2011-07-13|2011-08-09|Estimate||||2018-04-25|2018-05-23|Actual|August 2009||2009-08-31|April 2018|2018-04-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA|A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population|Completed||Phase 2|473|Actual|Seqirus||3|||f||||t||||||||||2018-06-01 00:41:29.25323|2018-06-01 00:41:29.25323
NCT00957307|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2015-07-21|2009-08-11|2009-08-12|Estimate|||||||2015-07-21|2015-07-23|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2010|Actual|2010-01-31||Observational|||Breast Computed Tomography (CT) as a Diagnostic Tool|Breast CT as a Diagnostic Tool|Completed|||16|Actual|Emory University|||||f||||f||||||||||2018-06-01 00:41:52.892209|2018-06-01 00:41:52.892209
NCT00958191|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2014-04-04||2018-01-26|2009-08-12|2009-08-13|Estimate|2014-07-11|2014-07-14|Estimate||||2018-01-26|2018-02-23|Actual|May 2005||2005-05-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|July 2012|Actual|2012-07-31||Interventional||Includes participants who received the Trident X3 polyetheylene insert and were not censored from analysis.|Trident® X3 Polyethylene Insert Study|An Open-label, Prospective, Post-market, Historically Controlled, Multi-center Clinical Evaluation of the Trident® X3 Polyethylene Acetabular Inserts.|Completed||N/A|250|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:41:30.86556|2018-06-01 00:41:30.86556
NCT00958178|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2009-08-12|2009-08-12|2009-08-13|Estimate|||||||2009-08-12|2009-08-13|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||A Novel Method of Preoxygenation Using a Bain Circuit|A Novel Method of Preoxygenation Using Partial Rebreathing Via a Coaxial Mapleson D Breathing System (Bain Circuit)|Unknown status|Recruiting|Phase 4|40|Anticipated|National Health Service, United Kingdom||2|||f||||t||||||||||2018-06-01 00:41:31.299563|2018-06-01 00:41:31.299563
NCT00958165|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2016-04-18||2016-07-27|2009-08-12|2009-08-13|Estimate|2016-06-16|2016-07-27|Estimate||||2016-07-27|2016-08-30|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional||Of the 81 enrolled participants, 72 meet all enrollment criteria and were treated. These are the evaluable baseline participants|Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic AF|Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CFEAS- AC) for the Treatment of Symptomatic Atrial Fibrillation|Completed||Phase 3|81|Actual|CardioFocus||1|||f||||f||||||||||2018-06-01 00:41:31.36377|2018-06-01 00:41:31.36377
NCT00958152|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2010-01-06|2009-08-12|2009-08-13|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2009||2009-08-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential-group, Multiple-dose, Drug-drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects|Completed||Phase 1|30|Anticipated|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-06-01 00:41:31.478253|2018-06-01 00:41:31.478253
NCT00958139|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2012-07-09|2009-08-12|2009-08-13|Estimate|||||||2012-07-09|2012-07-10|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes|Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes|Terminated||Phase 3|61|Actual|University of Minnesota - Clinical and Translational Science Institute||2||"After year 1, there was insufficient statistical power to detect a difference in the primary~   outcome measure during planned study period."|f||||f||||||||||2018-06-01 00:41:31.542559|2018-06-01 00:41:31.542559
NCT00958126|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2012-07-05||2017-10-18|2009-08-12|2009-08-13|Estimate|2012-08-31|2012-10-03|Estimate||||2017-10-18|2017-11-21|Actual|August 2009||2009-08-31|October 2017|2017-10-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA|A Phase II, Multicenter, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults Aged 18 Years and Older|Completed||Phase 2|1313|Actual|Seqirus||4|||f||||t||||||||||2018-06-01 00:41:31.649474|2018-06-01 00:41:31.649474
NCT00958113|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2015-05-26|2009-08-12|2009-08-13|Estimate|||||||2015-05-26|2015-05-28|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|February 2013|Actual|2013-02-28||Observational|||Autoimmune Thyroid Disease Genetic Study|Autoimmune Thyroid Disease Genetic Study|Completed|||199|Actual|University of Colorado, Denver|||2||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-06-01 00:41:33.391769|2018-06-01 00:41:33.391769
NCT00958100|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2015-02-03|2009-08-12|2009-08-13|Estimate|||||||2015-02-03|2015-02-04|Estimate|August 2009||2009-08-31|February 2015|2015-02-28|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|RaSTA||Raltegravir Switch for Toxicity or Adverse Events|Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Combined Antiretroviral Regimen|Completed||Phase 2|40|Actual|Catholic University of the Sacred Heart||3|||f||||f||||||||||2018-06-01 00:41:33.466901|2018-06-01 00:41:33.466901
NCT00958087|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2012-09-26|2009-08-12|2009-08-13|Estimate|||||||2012-09-26|2012-09-27|Estimate|March 2004||2004-03-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Observational|||Cardiac Sarcoidosis and FDG-PET|18F-fluorodeoxyglucose Positron Emission Tomography Imaging in Cardiac Sarcoidosis Reveals Characteristic Heterogeneity of Tracer Uptake and the Disease Activity in Myocardium|Completed|||20|Actual|Kurume University|||4||f||||t||||||||||2018-06-01 00:41:33.553868|2018-06-01 00:41:33.553868
NCT00958074|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-12-04||2014-12-11|2009-08-12|2009-08-13|Estimate|2014-12-11|2014-12-15|Estimate||||2014-12-11|2014-12-15|Estimate|July 2009||2009-07-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional|||Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma|A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated With Single Agent Targretin|Terminated||Phase 2|11|Actual|University of Washington|Early termination leading to small numbers of subjects analyzed|2||Terminated due to slow accrual|f||||f||||||||||2018-06-01 00:41:33.657807|2018-06-01 00:41:33.657807
NCT00958061|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2017-08-02|2009-08-12|2009-08-13|Estimate|||||||2017-08-02|2017-08-04|Actual|March 1, 2010|Actual|2010-03-01|August 2017|2017-08-31|August 7, 2012|Actual|2012-08-07|August 7, 2012|Actual|2012-08-07||Observational|Health ViEWS||Long Term Health Outcomes of Women Veterans' Service During the Vietnam Era|CSP #579 - Long Term Health Outcomes of Women's Service During the Vietnam Era|Completed|||4219|Actual|VA Office of Research and Development|||1||f||||t|f|f|||f|||No||2018-06-01 00:41:33.983389|2018-06-01 00:41:33.983389
NCT00958048|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2013-08-14|2009-08-12|2009-08-13|Estimate|||||||2013-08-14|2013-08-16|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effects of Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis|Effects of Early Intervention With Nocturnal Non-invasive Ventilation in Patients With Amyotrophic Lateral Sclerosis: A Randomized, Controlled Trial|Completed||N/A|70|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 00:41:34.069056|2018-06-01 00:41:34.069056
NCT00958035|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2011-11-30||2011-11-30|2009-08-12|2009-08-13|Estimate|2011-11-30|2012-01-05|Estimate||||2011-11-30|2012-01-05|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis||Completed||Phase 4|89|Actual|Allergan||2|||f||||||||||||||2018-06-01 00:41:34.140263|2018-06-01 00:41:34.140263
NCT00958022|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2017-06-21|2009-08-12|2009-08-13|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2009||2009-09-30|June 2017|2017-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer|Phase I/ II Trial of Carboplatin and Etoposide Plus LBH589 for Previously Untreated Extensive Stage Small Cell Lung Cancer|Terminated||Phase 1|7|Actual|University of Pittsburgh||1||Based on the tolerabilty challenges of the combination|f||||t||||||||||2018-06-01 00:41:34.313626|2018-06-01 00:41:34.313626
NCT00958009|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2010-12-01||2013-08-02|2009-08-12|2009-08-13|Estimate|2010-12-01|2010-12-30|Estimate||||2013-08-02|2013-08-07|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||The Multicenter, Open-label, Single-use Autoinjector Convenience Study|A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of a Ready-to-use, Single-use Autoinjector (SA) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc), Three Times a Week (Tiw)|Completed||Phase 3|109|Actual|EMD Serono|||||f||||f||||||||||2018-06-01 00:41:34.392766|2018-06-01 00:41:34.392766
NCT00957996|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2015-01-16|2012-08-06|2015-01-28|2009-08-12|2009-08-13|Estimate|2015-01-28|2015-02-12|Estimate|2012-08-06|2012-08-15|Estimate|2015-01-28|2015-02-12|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|August 2011|Actual|2011-08-31|October 2010|Actual|2010-10-31||Interventional||The Intent-to-Treat (ITT) population included all randomized subjects.|Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza|A Phase 3, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Infection|Completed||Phase 3|234|Actual|BioCryst Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:41:34.752588|2018-06-01 00:41:34.752588
NCT00957983|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2011-01-10|2009-08-12|2009-08-13|Estimate|||||||2011-01-10|2011-01-11|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model|EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model|Completed||Phase 1/Phase 2|8|Actual|Danish Headache Center||3|||f||||t||||||||||2018-06-01 00:41:35.923732|2018-06-01 00:41:35.923732
NCT00957970|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-08-12|2009-08-12|2009-08-13|Estimate|||||||2009-08-12|2009-08-13|Estimate|July 2006||2006-07-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2007|Actual|2007-07-31||Interventional|||Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components|Periprosthetic Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components|Completed||Phase 4|120|Actual|Ewha Womans University||2|||f||||t||||||||||2018-06-01 00:41:37.121911|2018-06-01 00:41:37.121911
NCT00957957|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2016-01-19|2009-08-12|2009-08-13|Estimate|||||||2016-01-19|2016-01-20|Estimate|February 2010||2010-02-28|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)|Gut Hormone Profiling in Peripheral Blood After Bariatric Surgery in Obese Patients With Type 2 Diabetes|Completed|||22|Actual|Merck Sharp & Dohme Corp.|||2||f||||||||||||||2018-06-01 00:41:37.236505|2018-06-01 00:41:37.236505
NCT00957944|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2010-07-29||2014-10-17|2009-08-12|2009-08-13|Estimate|2010-08-26|2010-09-22|Estimate||||2014-10-17|2014-10-27|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body|Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5 mg/10 cm^2) From 2 Different Manufacturing Sites.|Completed||Phase 1|40|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 00:41:37.422259|2018-06-01 00:41:37.422259
NCT00957931|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2012-12-20|2009-08-12|2009-08-13|Estimate|||||||2012-12-20|2012-12-21|Estimate|March 2009||2009-03-31|December 2012|2012-12-31||||August 2013|Anticipated|2013-08-31||Interventional|||Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs|Pilot Study MUD HCT:Pts High Risk Sickle Cell,Other Non-Malignant RBC Disorders- Reduced Intensity Preparative Regimen, HAPLO-Identical Mesenchymal Stromal Cells|Terminated||Phase 2|6|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 00:41:40.240289|2018-06-01 00:41:40.240289
NCT00957918|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11||2011-09-26|2011-09-26|2009-08-11|2009-08-13|Estimate||||2011-09-26|2011-10-05|Estimate|2011-09-26|2011-10-05|Estimate|October 2009||2009-10-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy|Randomized, Double-Blind, Parallel Group, Placebo Controlled Safety, Tolerability and Efficacy Study of NP002 in Subjects With Idiopathic Parkinson's Disease With Dyskinesias Due to Levodopa Therapy|Completed||Phase 1/Phase 2|65|Actual|Neuraltus Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:41:40.719329|2018-06-01 00:41:40.719329
NCT00957905|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|2016-03-09||2017-01-20|2009-08-12|2009-08-13|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|June 2009||2009-06-30|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors|A Non-randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors|Completed||Phase 2|36|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:41:41.170713|2018-06-01 00:41:41.170713
NCT00957892|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-12-14|2009-08-12|2009-08-13|Estimate|||||||2017-12-14|2017-12-18|Actual|May 2009||2009-05-31|December 2017|2017-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Effects of Infant Formula Composition on Infant Feeding Behaviors|Effects of Infant Formula Composition on Infant Feeding Behaviors|Completed|||55|Actual|Monell Chemical Senses Center|||||f||||f||||||Samples With DNA|"~     DNA collected for analysis of taste receptor and obesity-related genes~   "|||2018-06-01 00:41:42.604417|2018-06-01 00:41:42.604417
NCT00957879|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2012-04-18|2009-08-12|2009-08-13|Estimate|||||||2012-04-18|2012-04-19|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||Different Vitamin D Preparations & FGF23 in Humans|Effect of Different Vitamin D Preparations on Circulating FGF23 Levels in Vitamin D Deficient Caucasian and African-American Men and Women|Completed||N/A|42|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:41:42.702981|2018-06-01 00:41:42.702981
NCT00957866|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2014-05-15|2009-08-12|2009-08-13|Estimate|||||||2014-05-15|2014-05-16|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|Praire||Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity|Prospective Anti-HCV Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity: PRAIRIE Study|Completed||Phase 4|160|Anticipated|University of Manitoba|||||f||||t||||||||||2018-06-01 00:41:42.899472|2018-06-01 00:41:42.899472
NCT00957853|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-12|||2017-08-15|2009-08-12|2009-08-13|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2011|Actual|2011-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Preoperative Treatment With Cetuximab and/or IMC-A12|An Exploratory Study to Assess the Modulation of Biomarkers in Patients With Squamous Cell Carcinomas of the Head and Neck Randomized to Receive Preoperative Treatment With Cetuximab and/or IMC-A12, an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody|Active, not recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-06-01 00:41:43.014736|2018-06-01 00:41:43.014736
NCT00957840|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2015-05-05|2009-08-12|2009-08-13|Estimate|||||||2015-05-05|2015-05-06|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome|Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome|Completed||N/A|63|Actual|University of Utah||1|||f||||f||||||||||2018-06-01 00:41:43.15726|2018-06-01 00:41:43.15726
NCT00957827|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2015-12-09|2009-08-11|2009-08-12|Estimate|||||||2015-12-09|2015-12-11|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip|Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip|Terminated||N/A|10|Actual|University of Pennsylvania||2||Not enough subject enrolled|f||||f||||||||||2018-06-01 00:41:43.236627|2018-06-01 00:41:43.236627
NCT00957814|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2016-10-25|2009-08-11|2009-08-12|Estimate|||||||2016-10-25|2016-10-27|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Nutritional Orientations and Adherence, Nutritional Status, Clinical and Life Quality Parameters of Heart Failure (HF) Patients|Impact of Nutritional Orientations on Adherence to Diet and Relation to Nutritional, Clinical and Life Quality Parameters of Heart Failure Outpatients|Completed||N/A|46|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-06-01 00:41:43.300467|2018-06-01 00:41:43.300467
NCT00957801|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2018-03-08||2018-04-04|2009-08-11|2009-08-12|Estimate|2018-03-08|2018-04-04|Actual||||2018-04-04|2018-05-08|Actual|March 2009||2009-03-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men|Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men|Completed||Phase 4|29|Actual|The University of Texas Medical Branch, Galveston||4|||f||||f||||||||||2018-06-01 00:41:43.42519|2018-06-01 00:41:43.42519
NCT00957788|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-04-18|2009-08-10|2009-08-12|Estimate|||||||2013-04-18|2013-04-22|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Safety Study for NST-001 and the Neuroject Injection Set to Treat Tinnitus|Safety and Feasibility Study of NST - 001 in Inner Ear Using Neuroject Injection Set for the Treatment of Tinnitus|Terminated||Phase 1|8|Actual|NeuroSystec Corporation||4|||f||||t||||||||||2018-06-01 00:41:44.946828|2018-06-01 00:41:44.946828
NCT00957775|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2009-08-11|2009-08-11|2009-08-12|Estimate|||||||2009-08-11|2009-08-12|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Computer-delivered Psychosocial Intervention for Adolescent Substance Use Disorders|Computer-delivered Psychosocial Intervention for Adolescent Substance Use Disorders|Unknown status|Not yet recruiting|N/A|84|Anticipated|National Development and Research Institutes, Inc.||2|||f||||f||||||||||2018-06-01 00:41:45.021992|2018-06-01 00:41:45.021992
NCT00957762|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-11|2009-08-11|2009-08-12|Estimate|||||||2009-08-11|2009-08-12|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Observational|||Body Composition Assessment in Spinal Cord Injury|Body Composition Assessment in Spinal Cord Injury|Unknown status|Recruiting||170|Anticipated|Hunter Holmes Mcguire Veteran Affairs Medical Center|||1||f||||f||||||||||2018-06-01 00:41:45.09432|2018-06-01 00:41:45.09432
NCT00957749|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-01-29|2009-08-10|2009-08-12|Estimate|||||||2011-01-29|2011-02-01|Estimate|August 2009||2009-08-31|January 2011|2011-01-31||||April 2010|Anticipated|2010-04-30||Interventional|||Study of cPMP (Precusor Z) to Treat Molybdenum Cofactor Deficiency (MoCD) Type A|A Multicenter, Open-Label Study of the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered cPMP (Precursor Z) in Patients With Molybdenum Cofactor Deficiency Type A|Withdrawn||Phase 1/Phase 2|10|Anticipated|Orphatech Pharmaceuticals, GmbH||1||IND application was withdrawn, and therefore study listing is being withdrawn.|f||||f||||||||||2018-06-01 00:41:45.166867|2018-06-01 00:41:45.166867
NCT00957736|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-05-11|2009-08-11|2009-08-12|Estimate|||||||2013-05-11|2013-05-14|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant|Targeted Single Nucleotide Polymorphisms (SNPs) to Classify Subtypes of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Transplant.|Terminated|||252|Actual|Vanderbilt-Ingram Cancer Center|||1|study closed prematurely upon PI's departure from VICC|f||||t||||||Samples With DNA|"~     blood~   "|||2018-06-01 00:41:45.234498|2018-06-01 00:41:45.234498
NCT00957723|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-06-13||2018-01-13|2009-08-11|2009-08-12|Estimate|2014-03-10|2014-04-08|Estimate||||2018-01-13|2018-02-08|Actual|February 2005||2005-02-28|December 2017|2017-12-31|September 26, 2017|Actual|2017-09-26|April 2010|Actual|2010-04-30||Interventional|||Triathlon® Cruciate Retaining (CR) Total Knee System Outcomes Study|A Post-market, Non-randomized, Historical Controlled, Multi-center Study of the Outcomes of the Triathlon® Cruciate Retaining (CR) Total Knee System|Completed||N/A|419|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:41:45.347239|2018-06-01 00:41:45.347239
NCT00957710|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2015-01-26|2009-08-11|2009-08-12|Estimate|||||||2015-01-26|2015-01-27|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Language Treatment for Progressive Aphasia|Slowing Language Decline in Progressive Aphasia Through Language Rehabilitation: Treatment and Neuroimaging Study|Completed||N/A|7|Actual|Baycrest||1|||f||||f||||||||||2018-06-01 00:41:45.799285|2018-06-01 00:41:45.799285
NCT00957697|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-08-29|2009-08-11|2009-08-12|Estimate|||||||2011-08-29|2011-08-30|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Observational|||Pain After Stroke, Part 2: Clinical Characteristics and Classification of Pain in Patients After Stroke|Pain After Stroke, Part 2: Clinical Characteristics and Classification of Pain in Patients After Stroke|Completed|||52|Actual|Danish Pain Research Center|||||f||||f||||||||||2018-06-01 00:41:45.892798|2018-06-01 00:41:45.892798
NCT00957684|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-03-26||2014-06-23|2009-08-11|2009-08-12|Estimate|2013-08-02|2013-10-10|Estimate||||2014-06-23|2014-07-02|Estimate|July 2004||2004-07-31|June 2014|2014-06-30|February 2007|Actual|2007-02-28|November 2005|Actual|2005-11-30||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial.|Completed||Phase 3|402|Actual|Bial - Portela C S.A.||5|||f||||f||||||||||2018-06-01 00:41:45.951092|2018-06-01 00:41:45.951092
NCT00957671|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2018-02-01||2018-04-12|2009-08-11|2009-08-12|Estimate|2018-04-12|2018-05-15|Actual||||2018-04-12|2018-05-15|Actual|November 2003||2003-11-30|April 2018|2018-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||15 subjects with a history of mild to severe traumatic brain injury and abnormal growth hormone secretion were enrolled in this trial.|Anterior Pituitary Hormone Replacement in Traumatic Brain Injury|Anterior Pituitary Hormone Replacement in Traumatic Brain Injury|Completed||Phase 4|15|Actual|The University of Texas Medical Branch, Galveston||1|||f||||f|t|f|||f|||||2018-06-01 00:41:46.482032|2018-06-01 00:41:46.482032
NCT00957658|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-10-28||2017-07-07|2009-08-11|2009-08-12|Estimate|2014-08-13|2014-08-15|Estimate||||2017-07-07|2017-08-14|Actual|March 2006||2006-03-31|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2011|Actual|2011-05-31||Interventional||Participants who were censored protocol violations or who were enrolled but did not have surgery or age data was not available, are not included in the baseline analysis.|Accolade® TMZF® Hip Stem Outcomes Study|Accolade® TMZF® Study A Prospective, Post-market, Non-randomized, Multi-center Evaluation of the Accolade® TMZF® Hip Stem|Completed||N/A|241|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:41:47.160421|2018-06-01 00:41:47.160421
NCT00957645|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-08-29|2009-08-11|2009-08-12|Estimate|||||||2011-08-29|2011-08-30|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Observational|||Central Post-Stroke Pain - a Prospective Study|Central Post-Stroke Pain - a Prospective Study of Consecutively Admitted Patients With Recent Stroke|Completed|||275|Actual|Danish Pain Research Center|||||f||||f||||||||||2018-06-01 00:41:47.868854|2018-06-01 00:41:47.868854
NCT00957632|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-12-29|2009-08-10|2009-08-12|Estimate|||||||2009-12-29|2009-12-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:41:47.921696|2018-06-01 00:41:47.921696
NCT00957619|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2015-02-09|2009-08-11|2009-08-12|Estimate|||||||2015-02-09|2015-02-10|Estimate|March 2006||2006-03-31|February 2015|2015-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre)|Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre)|Completed||Phase 4|100|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 00:41:47.960147|2018-06-01 00:41:47.960147
NCT00957606|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-04-12|2009-08-11|2009-08-12|Estimate|||||||2011-04-12|2011-04-13|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Interventional|Osteoporosis||Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer|Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer: Symptoms, Risc Factors, and Prevention|Unknown status|Recruiting|Phase 3|100|Anticipated|Odense University Hospital|||||f||||t||||||||||2018-06-01 00:41:48.043036|2018-06-01 00:41:48.043036
NCT00957593|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2012-10-13||2013-05-28|2009-08-11|2009-08-12|Estimate|2013-05-28|2013-05-29|Estimate||||2013-05-28|2013-05-29|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Induction of Labor With Oxytocin: When Should Oxytocin be Held?|Induction of Labor With Oxytocin: When Should Oxytocin be Held?|Completed||N/A|252|Actual|Lehigh Valley Hospital||2|||f||||t||||||||||2018-06-01 00:41:48.131301|2018-06-01 00:41:48.131301
NCT00957580|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2016-07-04||2017-07-19|2009-08-11|2009-08-12|Estimate|2017-02-09|2017-03-29|Actual||||2017-07-19|2017-08-21|Actual|September 30, 2009|Actual|2009-09-30|July 2017|2017-07-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Interventional||Baseline analysis population included all the subjects who were treated with at least one administration of pimasertib.|Trial of Pimasertib in Hematological Malignancies|Phase II Trial With Safety-Run-In of MEK Inhibitor MSC1936369B in Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies|Terminated||Phase 2|81|Actual|EMD Serono|The trial has been terminated due to an estimated low probability of clinical benefit based on limited anti-leukemic effects observed in safety run-in (Part 1).|5||"The trial has been terminated due to an estimated low probability of clinical benefit based on~   limited anti-leukemic effects observed in safety run-in (Part 1)"|f||||t||||||||||2018-06-01 00:41:48.417683|2018-06-01 00:41:48.417683
NCT00957567|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-11-19|2009-08-11|2009-08-12|Estimate|||||||2013-11-19|2013-11-21|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|September 2011|Actual|2011-09-30||Observational|||Comparison Study of Breast Tomosynthesis Slice Thicknesses|A Comparison Study of Breast Tomosynthesis Images Reconstructed at 1 Millimeter and 5 Millimeter Slice Thicknesses|Completed|||182|Actual|Emory University|||||f||||f||||||||||2018-06-01 00:41:50.195707|2018-06-01 00:41:50.195707
NCT00957554|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2010-10-25|2009-08-11|2009-08-12|Estimate|||||||2010-10-25|2010-10-26|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|I-ADD||Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy|Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy|Completed||Phase 3|435|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:41:50.256093|2018-06-01 00:41:50.256093
NCT00957541|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2014-05-14|2009-08-11|2009-08-12|Estimate|||||||2014-05-14|2014-05-15|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2011|Actual|2011-04-30||Interventional|CLEPSYDRA||Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device|Clinical Evaluation of the Physiological Diagnosis Function in the Paradym CRT Device|Completed||Phase 2|520|Actual|ELA Medical, Inc.||1|||f||||t||||||||||2018-06-01 00:41:50.359139|2018-06-01 00:41:50.359139
NCT00957528|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2012-07-19||2012-09-04|2009-08-11|2009-08-12|Estimate|2012-07-19|2012-08-21|Estimate||||2012-09-04|2012-09-10|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cycled Testosterone Replacement Study|The Effects of Cyclic Testosterone Administration on Muscle Function in Older Individuals|Completed||Phase 1|26|Actual|The University of Texas Medical Branch, Galveston||3|||f||||f||||||||||2018-06-01 00:41:50.432326|2018-06-01 00:41:50.432326
NCT00957502|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-08-21|2009-08-11|2009-08-12|Estimate|||||||2012-08-21|2012-08-23|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|SSLE||ENTact™ Septal Stapler Shelf Life Extension|A Prospective, Limited-Use Evaluation of the ENTact™ Septal Stapler for Tissue Approximation Utilizing Staples With Extended Shelf Life|Completed||N/A|5|Actual|ENTrigue Surgical, Inc.||2|||f||||f||||||||||2018-06-01 00:41:51.039141|2018-06-01 00:41:51.039141
NCT00957489|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2009-08-11|2009-08-11|2009-08-12|Estimate|||||||2009-08-11|2009-08-12|Estimate|January 2007||2007-01-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Prospective Randomized Controlled Trial to Evaluate the Effectiveness of the Two Different Appliances in the Treatment of Class II Division 1 Malocclusion||Terminated||N/A|64|Actual|University of Manchester||1||Study stopped due to increased harm and slow progress in the intervention group.|f||||t||||||||||2018-06-01 00:41:51.10986|2018-06-01 00:41:51.10986
NCT00957476|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2018-05-01|2009-08-11|2009-08-12|Estimate|||||||2018-05-01|2018-05-03|Actual|September 2009||2009-09-30|May 2018|2018-05-31|June 2013|Actual|2013-06-30|March 2012|Actual|2012-03-31||Interventional|||Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy|Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy|Completed||N/A|72|Actual|MetroHealth Medical Center||2|||f||||t||||||||Yes|when data analysis completed|2018-06-01 00:41:51.187262|2018-06-01 00:41:51.187262
NCT00957463|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2014-12-29|2009-08-11|2009-08-12|Estimate|||||||2014-12-29|2014-12-30|Estimate|June 2008||2008-06-30|December 2014|2014-12-31||||December 2011|Actual|2011-12-31||Observational|||Effects of Obstructive Sleep Apnea and/or Cigarette Smoking on Endothelial Function|Effects of Intermittent Hypoxia and/or Cigarette Smoking on Endothelial Injury in Vivo - Relevance to Obstructive Sleep Apnea|Completed|||150|Anticipated|The University of Hong Kong|||4||f||||||||||||||2018-06-01 00:41:51.261112|2018-06-01 00:41:51.261112
NCT00957450|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2018-02-20|2009-08-11|2009-08-12|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2008||2008-02-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2017|Actual|2017-02-28||Observational|||Intra-Pelvic Organ Motion for Cervix Cancer Patient Using Imaging|Validation Study of Modeled Intra-pelvic Organ Motion During External Beam Radiotherapy for Cervix Cancer Using Frequent Magnetic Resonance Imaging|Active, not recruiting|||20|Anticipated|University Health Network, Toronto|||1||f||||t||||||||||2018-06-01 00:41:51.339367|2018-06-01 00:41:51.339367
NCT00957437|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-11-25|2009-08-11|2009-08-12|Estimate|||||||2009-11-25|2009-11-26|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|||||Interventional|||Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305|A Phase I, Randomised, Open, Single-centre Study to Evaluate the Pharmacokinetics of Different Extended-release Formulations of AZD1305 When Given as Single and Repeated Oral Doses to Healthy Male Volunteers|Completed||Phase 1|24|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:41:51.408647|2018-06-01 00:41:51.408647
NCT00957424|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|2016-10-19||2016-12-14|2009-08-11|2009-08-12|Estimate|2016-10-19|2016-12-14|Estimate||||2016-12-14|2017-02-07|Estimate|June 2009||2009-06-30|December 2016|2016-12-31|November 2011|Actual|2011-11-30|August 2009|Actual|2009-08-31||Interventional||Current smokers, aged 18+, smoke at least 10 cigarettes per day, not planning to quit smoking in the next 30 days|Acceptability of Less Harmful Alternatives to Cigarettes|International Study of the Acceptability of Less Harmful Alternatives to Cigarettes (ISALHAC) - A Pilot Study|Completed||N/A|67|Actual|Roswell Park Cancer Institute|About 1/3 of initial participants did not complete this study. The limited number of participants precludes identifying demographic predictors of willingness or patterns of substitution. Single armed study lacks comparison group.|1|||f||||||||||||||2018-06-01 00:41:51.487668|2018-06-01 00:41:51.487668
NCT00957411|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2017-04-04|2009-08-11|2009-08-12|Estimate|||||||2017-04-04|2017-04-06|Actual|March 2009||2009-03-31|April 2017|2017-04-30|October 2014|Actual|2014-10-31|November 2013|Actual|2013-11-30||Interventional|CETUXICOL||Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer|Phase II Randomized Assessing Pelvic Irradiation Combined With Cisplatin Alone or Cisplatin Plus Cetuximab in Patients With Carcinoma of the Cervix Stage IB2, II and III|Completed||Phase 2|76|Actual|Institut Curie||2|||f||||||||||||||2018-06-01 00:41:51.691035|2018-06-01 00:41:51.691035
NCT00957398|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2012-05-09|2009-08-11|2009-08-12|Estimate|||||||2012-05-09|2012-05-10|Estimate|August 2009||2009-08-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Comparing of the Gastrointestinal Motility in Irritable Bowel Syndrome (IBS) Patients With Healthy Volunteers|Comparing of the Gastrointestinal Motility in Irritable Bowel Syndrome (IBS) Patients With Healthy Volunteers Using Magnetic Tracking System (MTS)|Terminated|||10|Actual|University of Aarhus|||2|Not possible to include patients.|f||||t||||||||||2018-06-01 00:41:51.767725|2018-06-01 00:41:51.767725
NCT00957385|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2015-06-17|2009-08-11|2009-08-12|Estimate|||||||2015-06-17|2015-06-19|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients|A Randomized Phase II Study of Lenalidomide Maintenance Therapy in AML Patients Aged > 60 Years in CR1 or Higher and < 60 Years in CR2 or Higher|Completed||Phase 2|24|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 00:41:51.825254|2018-06-01 00:41:51.825254
NCT00957372|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-03-26||2014-06-23|2009-08-11|2009-08-12|Estimate|2013-08-01|2013-08-05|Estimate||||2014-06-23|2014-07-02|Estimate|December 2004||2004-12-31|June 2014|2014-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy|Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Clinical Trial|Completed||Phase 3|253|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-06-01 00:41:51.915628|2018-06-01 00:41:51.915628
NCT00957359|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2018-04-04|2009-08-11|2009-08-12|Estimate|||||||2018-04-04|2018-04-06|Actual|February 2009|Actual|2009-02-28|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|October 2014|Actual|2014-10-31||Interventional|||Psilocybin Cancer Anxiety Study|Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients|Active, not recruiting||Phase 1/Phase 2|32|Anticipated|New York University School of Medicine||2|||f||||t|t|f||||||||2018-06-01 00:41:52.365024|2018-06-01 00:41:52.365024
NCT00957346|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-11-05|2009-08-11|2009-08-12|Estimate|||||||2011-11-05|2011-11-08|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP)|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP): A Randomized-controlled Double-blinded Trial|Terminated||Phase 3|20|Anticipated|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 00:41:52.456864|2018-06-01 00:41:52.456864
NCT00957333|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2015-12-08||2015-12-08|2009-08-11|2009-08-12|Estimate|2015-12-08|2016-01-14|Estimate||||2015-12-08|2016-01-14|Estimate|March 2009||2009-03-31|November 2010|2010-11-30|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Observational|||Effects of Ketamine on Human Bladders and Its Possible Mechanisms|Effects of Ketamine on Human Bladders and Its Possible Mechanisms|Completed|||44|Actual|Taipei Medical University WanFang Hospital|||1||f||||f||||||Samples Without DNA|"~     1.Urine 2.Blood 3.Biopsy~   "|||2018-06-01 00:41:52.547297|2018-06-01 00:41:52.547297
NCT00957320|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-11-30|2009-08-11|2009-08-12|Estimate|||||||2013-11-30|2013-12-03|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)|A Phase I Study of Sirolimus With PEG-Asparaginase in Multiple Recurrent or Refractory Childhood Acute Lymphoblastic Leukemia|Withdrawn||Phase 1|0|Actual|Emory University||1||no patients enrolled, decided not to pursue study|f||||t||||||||||2018-06-01 00:41:52.766026|2018-06-01 00:41:52.766026
NCT00957294|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-12-02|2009-08-11|2009-08-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Metabolic Syndrome in Patients With First-episode Schizophrenia|The Metabolic Syndrome in Patients With First-episode Schizophrenia - Prognosis and Prediction.|Completed|||203|Actual|University of Aarhus|||3||f||||f||||||||||2018-06-01 00:41:52.972112|2018-06-01 00:41:52.972112
NCT00957281|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-09|||2009-08-11|2009-08-11|2009-08-12|Estimate|||||||2009-08-11|2009-08-12|Estimate|September 2008||2008-09-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||The Effect of Asthma on Systemic Inflammation, Oxidative Stress and Cardiovascular Morbidity|The Association of Asthma With Systemic Inflammation and Oxidative Stress, and Its Effect on the Risk of Cardiovascular Morbidity in Adult With Stable Asthma|Completed|||748|Actual|The University of Hong Kong|||1||f||||f||||||Samples With DNA|"~     Plasma, serum, DNA and exhaled breath condensate~   "|||2018-06-01 00:41:53.057538|2018-06-01 00:41:53.057538
NCT00957268|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2014-11-21||2015-01-26|2009-08-11|2009-08-12|Estimate|2015-01-26|2015-01-29|Estimate||||2015-01-26|2015-01-29|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Safety set: All enrolled participants who received at least 1 dose of study drug.|Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus|A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults With Type 2 (Non-Insulin Dependent) Diabetes Mellitus|Completed||Phase 1|46|Actual|Takeda||5|||f||||f||||||||||2018-06-01 00:41:53.185915|2018-06-01 00:41:53.185915
NCT00957255|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2017-04-04|2009-08-11|2009-08-12|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2009||2009-03-31|April 2017|2017-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Rotator Cuff Repair (RCR) With and Without OrthoADAPT Augmentation|Rotator Cuff Repair (RCR) With and Without OrthoADAPT Augmentation|Withdrawn||N/A|0|Actual|Baxter Healthcare Corporation||2||Funding withdrawn|f||||f||||||||||2018-06-01 00:41:54.72968|2018-06-01 00:41:54.72968
NCT00957242|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-03-04||2014-07-14|2009-08-10|2009-08-12|Estimate|2013-08-09|2013-10-21|Estimate||||2014-07-14|2014-07-23|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ACE-IPF||AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis|AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF)|Terminated||Phase 3|145|Actual|Duke University||2||Excess of mortality in the treatment group created safety concerns.|f||||t||||||||||2018-06-01 00:41:54.837311|2018-06-01 00:41:54.837311
NCT00957229|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2016-06-02|2009-08-11|2009-08-12|Estimate|||||||2016-06-02|2016-06-06|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|GDC-0449||To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)|A Randomized, Phase II Multicenter Trial Evaluating the Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS)|Completed||Phase 2|41|Actual|Children's Hospital & Research Center Oakland||2|||f||||t||||||||No||2018-06-01 00:41:55.536139|2018-06-01 00:41:55.536139
NCT00957216|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-04-15|2009-08-11|2009-08-12|Estimate|||||||2010-04-15|2010-04-16|Estimate|April 2008||2008-04-30|April 2010|2010-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CoQATAX||Coenzyme Q10 in Adult-Onset Ataxia|Safety and Tolerability of Coenzyme Q10 in Adult-Onset Sporadic Spinocerebellar Ataxia|Completed||Phase 1|1|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-06-01 00:41:55.618304|2018-06-01 00:41:55.618304
NCT00957203|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2012-08-30|2009-08-11|2009-08-12|Estimate|||||||2012-08-30|2012-08-31|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|6002-010||Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients|Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)|Completed||Phase 3|308|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 00:41:55.688042|2018-06-01 00:41:55.688042
NCT00957190|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2017-03-23|2009-08-11|2009-08-12|Estimate|||||||2017-03-23|2017-03-27|Actual|May 4, 2009|Actual|2009-05-04|March 2017|2017-03-31|February 2012|Actual|2012-02-29|September 14, 2011|Actual|2011-09-14||Interventional|DIOXXACT||The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)|Change in Optic Nerve Head Blood Flow,Optic Nerve Topography and Diurnal Fluctuation of Intraocular Pressure and Pulsatile Ocular Blood Flow in Glaucoma:Cosopt and Xalatan vs Xalatan Alone|Completed||Phase 4|25|Actual|Maisonneuve-Rosemont Hospital||1|||f||||t||||||||No||2018-06-01 00:41:55.764571|2018-06-01 00:41:55.764571
NCT00957177|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2011-05-26|2009-08-11|2009-08-12|Estimate|||||||2011-05-26|2011-05-27|Estimate|April 2009||2009-04-30|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|PregabaNeph||Analgetic Effect of Preoperative Pregabalin in Patients Undergoing Nephrectomy|Effect of Preoperative Pregabalin Administration on the Postoperative Opioid Consumption in Patients Undergoing Nephrectomy|Completed||Phase 3|20|Anticipated|Medical University of Graz||2|||f||||t||||||||||2018-06-01 00:41:55.873016|2018-06-01 00:41:55.873016
NCT00957164|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2014-01-29|2009-08-11|2009-08-12|Estimate|||||||2014-01-29|2014-01-31|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Treatment of Post-Traumatic Stress Disorder (PTSD) and Chronic Pain After Traumatic Orthopedic Injury|Treatment of PTSD and Chronic Pain After Traumatic Orthopedic Injury: A Randomized Clinical Trial|Completed||N/A|51|Actual|The University of Texas at Arlington||4|||f||||t||||||||||2018-06-01 00:41:55.94231|2018-06-01 00:41:55.94231
NCT00957151|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2009-08-11|2009-08-11|2009-08-12|Estimate|||||||2009-08-11|2009-08-12|Estimate|April 2004||2004-04-30|August 2009|2009-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis|Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis|Completed||Phase 4|12|Anticipated|Hospital Avicenne|||||f||||||||||||||2018-06-01 00:41:56.021761|2018-06-01 00:41:56.021761
NCT00957138|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2016-07-20|2009-08-11|2009-08-12|Estimate|||||||2016-07-20|2016-07-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:41:56.081695|2018-06-01 00:41:56.081695
NCT00957125|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2016-09-06|2009-08-11|2009-08-12|Estimate|||||||2016-09-06|2016-09-08|Estimate|September 2008||2008-09-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|November 2011|Actual|2011-11-30||Interventional|PROMIX||A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early|PROMIX - Preoperative Treatment of Breast Cancer With a Combination of Epirubicin, Docetaxel and Bevacizumab. A Translational Trial on Molecular Markers and Functional Imaging to Predict Response Early. A Phase 2 Study.|Active, not recruiting||Phase 2|151|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-06-01 00:41:56.135738|2018-06-01 00:41:56.135738
NCT00957112|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-08-23|2009-08-11|2009-08-12|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|February 2013|Actual|2013-02-28|October 2010|Actual|2010-10-31||Interventional|||Acupuncture or Self-Acupuncture in Managing Cancer-Related Fatigue in Women Who Have Received Chemotherapy for Stage I, Stage II, or Stage IIIA Breast Cancer|The Efficacy of Acupuncture and Self-acupuncture in Managing Cancer-related Fatigue in Breast Cancer Patients: a Pragmatic Randomised Trial|Completed||Phase 3|320|Anticipated|National Cancer Institute (NCI)||5|||f||||||||||||||2018-06-01 00:41:56.255147|2018-06-01 00:41:56.255147
NCT00957099|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2013-09-11|2009-08-11|2009-08-12|Estimate|||||||2013-09-11|2013-09-12|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Observational|||Comparison Study of Breast Computed Tomography (CT) With Magnetic Resonance Imaging (MRI)|A Comparison Study of Contrast Enhanced Breast CT With MRI On Known Malignancies For Detection of Multifocal/Multicentric Disease|Completed|||2|Actual|Emory University|||1||f||||f||||||||||2018-06-01 00:41:56.335986|2018-06-01 00:41:56.335986
NCT00957086|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2018-03-28|2009-08-11|2009-08-12|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2009||2009-08-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer|Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer|Recruiting||Phase 3|710|Anticipated|National Cancer Centre, Singapore||2|||f||||t||||||||||2018-06-01 00:41:56.413473|2018-06-01 00:41:56.413473
NCT00957073|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10||2016-04-13|2018-02-27|2009-08-11|2009-08-12|Estimate||||2016-04-13|2016-05-12|Estimate|2018-02-27|2018-03-01|Actual|August 2009||2009-08-31|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|October 2012|Actual|2012-10-31||Interventional|HOPE4HF||Rheos HOPE4HF (Health Outcomes Prospective Evaluation for Heart Failure With Ejection Fraction (EF) ≥ 40%) Trial|Health Outcomes Prospective Evaluation for Heart Failure With EF ≥ 40%|Active, not recruiting||Phase 2/Phase 3|19|Actual|CVRx, Inc.||2|||f||||t||||||||||2018-06-01 00:41:57.556869|2018-06-01 00:41:57.556869
NCT00957060|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-11|||2010-11-26|2009-08-11|2009-08-12|Estimate|||||||2010-11-26|2010-11-30|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|SUMER||Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients|A Multicenter, Open, Randomized, 24 Weeks Study to Evaluate the Superiority of Glimepiride Over Sitagliptin for the Treatment of naïve Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|400|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:41:57.656025|2018-06-01 00:41:57.656025
NCT00957047|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-03-26||2014-06-23|2009-08-11|2009-08-12|Estimate|2013-08-01|2013-08-05|Estimate||||2014-06-23|2014-07-02|Estimate|July 2004||2004-07-31|June 2014|2014-06-30|January 2008|Actual|2008-01-31|August 2006|Actual|2006-08-31||Interventional|||Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy|Efficacy and Safety of BIA 2-093 as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial|Completed||Phase 3|395|Actual|Bial - Portela C S.A.||5|||f||||f||||||||||2018-06-01 00:41:57.755629|2018-06-01 00:41:57.755629
NCT00957034|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2011-08-03||2011-12-06|2009-08-11|2009-08-12|Estimate|2011-12-06|2012-01-13|Estimate||||2011-12-06|2012-01-13|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|CORDELIA||Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure|A Placebo-controlled Study to Determine the Efficacy and Safety of 300 and 450 µg/Day Transdermal Testosterone in Female Patients With Low Ejection Fraction and Symptomatic Heart Failure|Terminated||Phase 2|17|Actual|Warner Chilcott||3||Due to difficult patient enrollment.|f||||f||||||||||2018-06-01 00:41:58.520348|2018-06-01 00:41:58.520348
NCT00957021|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-09-05||2016-11-29|2009-08-11|2009-08-12|Estimate|2013-11-12|2013-12-05|Estimate||||2016-11-29|2017-01-25|Estimate|December 2005||2005-12-31|November 2016|2016-11-30|January 2014|Actual|2014-01-31|March 2011|Actual|2011-03-31||Interventional||Participants who were censored protocol violations or who were enrolled, but did not have surgery and age data was not available, are not included in the baseline analysis.|Triathlon® Posteriorly Stabilized (PS) Total Knee System - Outcomes Study|A Prospective, Post-market, Multi-center Study of the Outcomes of the Triathlon® Posteriorly Stabilized (PS) Total Knee System|Completed||N/A|409|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 00:41:58.947565|2018-06-01 00:41:58.947565
NCT00957008|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2011-02-21||2018-01-04|2009-08-10|2009-08-11|Estimate|2011-02-21|2011-03-23|Estimate||||2018-01-04|2018-01-30|Actual|February 2008||2008-02-29|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|LEAN||Lifestyle Education for Activity and Nutrition for a Leaner You|Use of Electronic Feedback on Diet and Physical Activity to Enhance Weight Management|Completed||N/A|197|Actual|University of South Carolina|Large attrition rate due to time commitment; mostly female and highly educated sample; short intervention; GWL did not perform well|4|||f||||t||||||||||2018-06-01 00:41:59.29877|2018-06-01 00:41:59.29877
NCT00956982|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|December 2004||2004-12-31|August 2009|2009-08-31|December 2012|Anticipated|2012-12-31|July 2008|Actual|2008-07-31||Interventional|||PEG-IFN Plus Ribavirin Combination Therapy for Older Patients|Pegylated Interferon Alpha-2b Plus Ribavirin Combination Treatment for Older Patients With Chronic Hepatitis C|Unknown status|Recruiting|N/A|1251|Anticipated|Kyushu University|||||f||||t||||||||||2018-06-01 00:41:59.731098|2018-06-01 00:41:59.731098
NCT00956969|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-06-13|2009-08-10|2009-08-11|Estimate|||||||2013-06-13|2013-06-17|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Stress Management for Chronic Headaches|Emotional Awareness and Expression Training and Relaxation Training for People With Chronic Headaches|Completed||N/A|147|Actual|Wayne State University||3|||f||||f||||||||||2018-06-01 00:41:59.803994|2018-06-01 00:41:59.803994
NCT00956956|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2010-01-05|2009-08-10|2009-08-11|Estimate|||||||2010-01-05|2010-01-07|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects|A Phase I, Randomized, Placebo Controlled, Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects|Completed||Phase 1|36|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:41:59.887392|2018-06-01 00:41:59.887392
NCT00956943|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2013-01-14||2014-08-12|2009-08-10|2009-08-11|Estimate|2013-02-14|2013-03-18|Estimate||||2014-08-12|2014-08-15|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|HDP||Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine|Assessment of High Dose Transdermal Nicotine for Fast Metabolizers of Nicotine|Completed||Phase 2|87|Actual|University of Pennsylvania|This was a proof of concept trial and, as such, was inadequately powered to detect statistically significant treatment arm effects and did not include a long-term follow-up assessment.|2|||f||||f||||||||||2018-06-01 00:41:59.96626|2018-06-01 00:41:59.96626
NCT00956930|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|||2016-09-07|2009-08-08|2009-08-11|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery|An Investigator Initiated Multicenter Prospective Randomized Study of Chemoembolization Versus Radioembolization for the Treatment of Hepatocellular Carcinoma (PREMIERE Trial)|Completed||Phase 2|45|Actual|Northwestern University||2|||f||||t||||||||No|Data will be published in medical journals.|2018-06-01 00:42:00.212927|2018-06-01 00:42:00.212927
NCT00956917|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|May 2009||2009-05-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparison Study for Bioelectrical Impedance Device to Measure Human Body Composition|Comparison of Impedance Components and Estimated Body Composition Variables Determined by Using Bioelectrical Impedance Devices Manufactured by Akern SRL and RJL Systems|Completed||N/A|109|Actual|Akern USA LLC||2|||f||||f||||||||||2018-06-01 00:42:00.296072|2018-06-01 00:42:00.296072
NCT00956904|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-06-18|2009-08-10|2009-08-11|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy|Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy|Terminated||Early Phase 1|50|Actual|Johns Hopkins University||1||IRB approval expired.|f||||t||||||||||2018-06-01 00:42:00.375858|2018-06-01 00:42:00.375858
NCT00956891|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2010-12-06|2009-08-10|2009-08-11|Estimate|||||||2010-12-06|2010-12-07|Estimate|May 2005||2005-05-31|August 2009|2009-08-31|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Observational|||Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation|Therapeutic Effects Including Short-term Changes And Long-term Outcomes of Liver Failure Patients Caused by Chronic Hepatitis B After Single Transplantation With Autologous Bone Marrow Mesenchymal Stem Cells.|Completed|||158|Actual|Sun Yat-sen University|||2||f||||t||||||||||2018-06-01 00:42:00.45452|2018-06-01 00:42:00.45452
NCT00956878|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2014-12-23|2009-08-10|2009-08-11|Estimate|||||||2014-12-23|2014-12-24|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Cancer Pain Single Nucleotide Polymorphisms (SNPs)|Storage and Analysis of Patient Blood-samples for Cancer Pain Research|Completed|||243|Actual|Erasmus Medical Center|||1||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 00:42:00.528973|2018-06-01 00:42:00.528973
NCT00956865|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2016-11-26|2009-08-10|2009-08-11|Estimate|||||||2016-11-26|2016-11-29|Estimate|September 2002||2002-09-30|November 2016|2016-11-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Community Glaucoma Screening Follow-up|Community Glaucoma Screenings: Assessment of Interventions to Improve Follow-up|Completed||N/A|100|Actual|Wills Eye||3|||f||||f||||||||Undecided||2018-06-01 00:42:00.596351|2018-06-01 00:42:00.596351
NCT00956852|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-09|||2016-05-11|2009-08-10|2009-08-11|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Study on Systemic and Airway Cytokines and Oxidative Stress in Lung Cancer Patients Undergoing Surgery|Study on Systemic and Airway Cytokines and Oxidative Stress in Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Surgical Lung Resections|Terminated|||45|Actual|The University of Hong Kong|||1|Poor subject recruitment|f||||f||||||Samples Without DNA|"~     Plasma, buffy coat, red blood cell and exhaled breath condensate samples.~   "|||2018-06-01 00:42:00.6731|2018-06-01 00:42:00.6731
NCT00956839|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2012-07-23||2013-02-10|2009-08-10|2009-08-11|Estimate|2013-02-10|2013-03-14|Estimate||||2013-02-10|2013-03-14|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis|Double-blind Randomized Study to Determine the Efficacy of Intramuscular Vitamin D3 Supplementation in Tropical Calcific Pancreatitis|Completed||Phase 4|40|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||3|||f||||f||||||||||2018-06-01 00:42:00.747507|2018-06-01 00:42:00.747507
NCT00956826|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|April 2010|Anticipated|2010-04-30||Interventional|||Continuous Fetal Monitoring During Vacuum Delivery|Continuous Fetal Monitoring During Vacuum Delivery an Addition of a New Device|Unknown status|Not yet recruiting|Early Phase 1|30|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 00:42:01.118119|2018-06-01 00:42:01.118119
NCT00956813|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|2016-11-29||2017-02-16|2009-08-08|2009-08-11|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|October 2009||2009-10-31|February 2017|2017-02-28|May 2013|Actual|2013-05-31|October 2010|Actual|2010-10-31||Interventional||All patients that registered are included in baseline characteristics for the Flaxseed and Placebo Period. Patients who continued treatment during the Optional Continuation Period were a subset of the original 210 patients and are reported separately.|Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy|Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes|Completed||Phase 3|210|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 00:42:01.245057|2018-06-01 00:42:01.245057
NCT00956800|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2011-06-23|2009-08-10|2009-08-11|Estimate|||||||2011-06-23|2011-06-27|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Remote Management of Diabetic Patients Via Data Transmission by Accu-Chek 360 Software|Remote Management of Diabetic Patients Via Data Transmission by Accu-Chek 360 Software|Completed||N/A|100|Actual|Columbus Research Foundation||2|||f||||f||||||||||2018-06-01 00:42:01.946834|2018-06-01 00:42:01.946834
NCT00956787|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2014-06-23|2009-08-10|2009-08-11|Estimate|||||||2014-06-23|2014-06-24|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)|Phase 2 Study of AR-67 (DB-67) in Myelodysplastic Syndrome(MDS)|Unknown status|Recruiting|Phase 2|25|Anticipated|Arno Therapeutics||1|||f||||f||||||||||2018-06-01 00:42:02.024547|2018-06-01 00:42:02.024547
NCT00956774|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-02-13|2009-08-10|2009-08-11|Estimate|||||||2013-02-13|2013-02-15|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Comparison of Three Cannulas for Hysterosalpingography|Comparison of Three Cannulas for Hysterosalpingography: A Prospective, Randomized Study|Completed||N/A|114|Actual|Carolinas Healthcare System||3|||f||||f||||||||||2018-06-01 00:42:02.128566|2018-06-01 00:42:02.128566
NCT00956397|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-10-22|2009-08-10|2009-08-11|Estimate|||||||2012-10-22|2012-10-24|Estimate|August 2007||2007-08-31|October 2012|2012-10-31||||March 2012|Actual|2012-03-31||Interventional|||Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia|Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia|Completed||N/A|55|Actual|New Mexico VA Healthcare System||3|||f||||t||||||||||2018-06-01 00:42:06.273864|2018-06-01 00:42:06.273864
NCT00956761|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|2015-12-21||2015-12-21|2009-08-10|2009-08-11|Estimate|2015-12-21|2016-01-27|Estimate||||2015-12-21|2016-01-27|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Baseline analysis population was defined as all participants who were enrolled.|Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2009-2010, When Administered to Elderly Subjects|Completed||Phase 2|63|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:42:02.224221|2018-06-01 00:42:02.224221
NCT00956748|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-04-24|2009-08-10|2009-08-11|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2018|Anticipated|2018-06-30|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media|N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media|Not yet recruiting||Phase 4|30|Anticipated|St. Paul's Hospital, Canada||2|||f||||f|f|f||||||No||2018-06-01 00:42:02.487546|2018-06-01 00:42:02.487546
NCT00956735|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-12-13|2009-08-10|2009-08-11|Estimate|||||||2013-12-13|2013-12-16|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Pistachio||Effects of Pistachios on Cardiovascular Responses to Stress in Type 2 Diabetes|Effects of Pistachios on Cardiovascular Responses to Stress in Type 2 Diabetes: A Novel Intervention for a High Risk Population|Completed||N/A|30|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 00:42:02.59649|2018-06-01 00:42:02.59649
NCT00956722|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-08-27|2009-08-10|2009-08-11|Estimate|||||||2012-08-27|2012-08-28|Estimate|January 2012||2012-01-31|June 2011|2011-06-30|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy|Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy|Withdrawn||Phase 1|0|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 00:42:02.689959|2018-06-01 00:42:02.689959
NCT00956709|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2014-07-07||2016-10-03|2009-08-10|2009-08-11|Estimate|2014-07-07|2014-08-01|Estimate||||2016-10-03|2016-10-05|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|SCIALERO||Regional Anesthesia for Major Surgery of the Foot. Levobupivacaïne Ropivacaine 0.5% Versus 0.5% in the Sciatic Block Through médiofémorale||Terminated||Phase 4|35|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 00:42:02.797978|2018-06-01 00:42:02.797978
NCT00956696|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|May 2009||2009-05-31|August 2009|2009-08-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Observational|||Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study|Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study|Unknown status|Recruiting||50|Anticipated|Chinese University of Hong Kong|||1||f||||t||||||||||2018-06-01 00:42:03.171626|2018-06-01 00:42:03.171626
NCT00956683|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|January 2006||2006-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Dual Endpoint Nerve Stimulation Versus Ultrasound in Infraclavicular Block for Hand Surgery|A Randomized Controlled Study Comparing Dual Endpoint Nerve Stimulation With Ultrasound-guided Infraclavicular Block for Hand Surgery.|Completed||N/A|106|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:42:03.280692|2018-06-01 00:42:03.280692
NCT00956670|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|||2017-05-03|2009-08-08|2009-08-11|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2012||2012-06-30|May 2017|2017-05-31||||April 2015|Actual|2015-04-30||Interventional|LEG||Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer|The LymphEdema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients|Active, not recruiting||N/A|1055|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 00:42:03.430303|2018-06-01 00:42:03.430303
NCT00956657|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2010-03-11||2010-04-22|2009-08-10|2009-08-11|Estimate|2010-04-22|2010-05-12|Estimate||||2010-04-22|2010-05-12|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Improving Cardiac Rehabilitation Session Attendance: A Randomised Controlled Trial|Improving Cardiac Rehabilitation Session Attendance Using the Self-Regulatory Model and Motivational Interviewing: A Randomised Controlled Trial|Completed||N/A|31|Actual|NHS Greater Glasgow and Clyde|The small sample size of this study does not allow definitive conclusions to be drawn about the success or failure or this intervention approach.||||f||||f||||||||||2018-06-01 00:42:03.878293|2018-06-01 00:42:03.878293
NCT00956644|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2010-10-25|2009-08-10|2009-08-11|Estimate|||||||2010-10-25|2010-10-26|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|I-COMBINE||Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy|Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy|Completed||Phase 3|406|Anticipated|Sanofi||2|||f||||||||||||||2018-06-01 00:42:04.094842|2018-06-01 00:42:04.094842
NCT00956631|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2013-01-04||2013-02-21|2009-08-07|2009-08-11|Estimate|2013-02-21|2013-04-04|Estimate||||2013-02-21|2013-04-04|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|MiDAS I||MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study|Completed||Phase 4|78|Actual|Vertos Medical, Inc.||1|||f||||t||||||||||2018-06-01 00:42:04.287353|2018-06-01 00:42:04.287353
NCT00956618|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2010-05-17|2009-08-10|2009-08-11|Estimate|||||||2010-05-17|2010-05-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:42:04.499931|2018-06-01 00:42:04.499931
NCT00956605|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|CATS||A Trial of Computer-based Attention-training Systems in Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Randomized Trial of Computer-based Attention-training Systems With and Without Neurofeedback in Children With ADHD|Completed||N/A|35|Actual|Tufts Medical Center||3|||f||||f||||||||||2018-06-01 00:42:04.536928|2018-06-01 00:42:04.536928
NCT00956592|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2011-01-25||2018-04-03|2009-08-10|2009-08-11|Estimate|2011-02-14|2011-03-09|Estimate||||2018-04-03|2018-04-05|Actual|October 2009||2009-10-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Evaluation of the Storz CMAC Laryngoscope|A Randomized Control Trial to Determine First Attempt Intubation Success With the CMAC Laryngoscope vs. Macintosh Blade in Airways Predicted to be Difficult|Completed||N/A|300|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 00:42:04.620515|2018-06-01 00:42:04.620515
NCT00956579|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2010-05-03|2009-08-10|2009-08-11|Estimate|||||||2010-05-03|2010-05-04|Estimate|September 2005||2005-09-30|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|||Sensory and Connectivity Abnormalities in Autism and Language Disorders|Psychophysics and Neurodynamic MEG/EEG Imaging of Sensory and Connectivity Abnormalities in Neurodevelopmental Disorders.|Unknown status|Recruiting||260|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 00:42:04.907074|2018-06-01 00:42:04.907074
NCT00956566|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-07-27|2009-08-10|2009-08-11|Estimate|||||||2012-07-27|2012-07-30|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|B-SMART||Comparison of Low Fat and Low Carbohydrate Diets With Respect to Weight Loss and Metabolic Effects|Randomized Parallel Group Comparison on the Influence of a Low Carbohydrate and a Low Fat Hypocaloric 6 Months Diet on Body Weight Reduction, Metabolic and Cardiovascular Variables in Obese Healthy Women and Men.|Completed||N/A|170|Actual|Hannover Medical School||2|||f||||f||||||||||2018-06-01 00:42:04.974339|2018-06-01 00:42:04.974339
NCT00956553|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2014-03-19|2009-08-10|2009-08-11|Estimate|||||||2014-03-19|2014-03-20|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|HPV CSP01||Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls|A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines|Completed||Phase 4|400|Actual|Public Health England||2|||f||||f||||||||||2018-06-01 00:42:05.041169|2018-06-01 00:42:05.041169
NCT00956540|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2011-07-01||2011-08-19|2009-08-10|2009-08-11|Estimate|2011-08-19|2011-09-27|Estimate||||2011-08-19|2011-09-27|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Does Deflating the Tracheal Cuff Shorten Weaning Time?|Effect of Deflating the Tracheal Cuff During Ventilatory Disconnections on Weaning Time|Completed||Phase 4|195|Actual|Hospital Virgen de la Salud||4|||f||||t||||||||||2018-06-01 00:42:05.128254|2018-06-01 00:42:05.128254
NCT00956527|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-06-18|2009-08-10|2009-08-11|Estimate|||||||2013-06-18|2013-06-20|Estimate|May 2006||2006-05-31|June 2013|2013-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Martial Arts as Early Intervention for Teen Drug Abuse|Martial Arts as Early Intervention for Teen Drug Abuse|Completed||N/A|31|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-06-01 00:42:05.435247|2018-06-01 00:42:05.435247
NCT00956514|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2013-02-04|2009-08-10|2009-08-11|Estimate|||||||2013-02-04|2013-02-06|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder|Neurophysiologic Predictors of Outcome With rTMS Treatment of Major Depressive Disorder|Completed||Phase 4|50|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-06-01 00:42:05.500552|2018-06-01 00:42:05.500552
NCT00956501|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2013-07-31|2009-08-10|2009-08-11|Estimate|||||||2013-07-31|2013-08-02|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Observational|||Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)|Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)|Completed|||35|Actual|Carolinas Healthcare System|||||f||||f||||||||||2018-06-01 00:42:05.577951|2018-06-01 00:42:05.577951
NCT00956488|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-07-31|2009-08-10|2009-08-11|Estimate|||||||2013-07-31|2013-08-02|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis|Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis|Completed||Phase 1/Phase 2|9|Actual|Carolinas Healthcare System||1|||f||||f||||||||||2018-06-01 00:42:05.633074|2018-06-01 00:42:05.633074
NCT00956475|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|||2011-08-23|2009-08-08|2009-08-11|Estimate|||||||2011-08-23|2011-08-24|Estimate|October 2008||2008-10-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|September 2010|Actual|2010-09-30||Observational|||Quality of Life in Younger Leukemia and Lymphoma Survivors|Quality of Life in Young Adult Survivors of Hematologic Malignancies|Completed|||48|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 00:42:05.70491|2018-06-01 00:42:05.70491
NCT00956462|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-08-07|2009-08-07|2009-08-11|Estimate|||||||2009-08-07|2009-08-11|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Steroids Versus Non-steroidal Anti-inflammatory Drugs Following Glaucoma Surgery|Topical Steroids Versus Topical Non-steroidal Anti-inflammatory Drugs Following Ahmed Valve Glaucoma Drainage Device Surgery|Unknown status|Recruiting|N/A|36|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 00:42:05.807257|2018-06-01 00:42:05.807257
NCT00956449|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|||2017-03-24|2009-08-10|2009-08-11|Estimate|||||||2017-03-24|2017-03-28|Actual|June 2009||2009-06-30|March 2017|2017-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects|A Phase II, Single Center, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine [Ph.Eur], Formulation 2009/2010, When Administered to Non-Elderly Adult and Elderly Subjects|Completed||Phase 2|126|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:42:05.901834|2018-06-01 00:42:05.901834
NCT00956436|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2013-09-12|2009-08-10|2009-08-11|Estimate|||||||2013-09-12|2013-09-16|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)|A Phase 1b, Open-Label Study of Sorafenib With BIIB022 in Subjects With Advanced Hepatocellular Carcinoma|Completed||Phase 1|40|Actual|Biogen||2|||f||||t||||||||||2018-06-01 00:42:05.968303|2018-06-01 00:42:05.968303
NCT00956423|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2011-11-22|2009-08-07|2009-08-11|Estimate|||||||2011-11-22|2011-11-24|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Physical Activity Regimens as Treatments for Obstructive Sleep Apnea|Exercise: A Novel Treatment for Obstructive Sleep Apnea|Completed||Phase 1/Phase 2|43|Actual|University of South Carolina||2|||f||||f||||||||||2018-06-01 00:42:06.046019|2018-06-01 00:42:06.046019
NCT00956410|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2011-11-16|2009-08-10|2009-08-11|Estimate|||||||2011-11-16|2011-11-17|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients|An Open-label Extension to a 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in Patients With Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106|Completed||Phase 2|21|Actual|Novartis||1|||f||||t||||||||||2018-06-01 00:42:06.203897|2018-06-01 00:42:06.203897
NCT00956384|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2018-02-27|2009-08-10|2009-08-11|Estimate|||||||2018-02-27|2018-03-01|Actual|September 2009||2009-09-30|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|AllodermRCT||One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure|Acellular Dermal Matrix in One-Stage Breast Reconstruction: A RCT|Completed||N/A|198|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:42:06.354852|2018-06-01 00:42:06.354852
NCT00956371|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-06-12|2009-08-10|2009-08-11|Estimate|||||||2012-06-12|2012-06-14|Estimate|August 2009||2009-08-31|June 2012|2012-06-30||||March 2010|Actual|2010-03-31||Interventional|||ONO-7746 Study in Healthy Adult Subjects|A Double-Blind, Placebo-Controlled, SIngle Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Healthy Adult Subjects|Completed||Phase 1|48|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 00:42:06.44069|2018-06-01 00:42:06.44069
NCT00956358|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-09|||2016-05-11|2009-08-10|2009-08-11|Estimate|||||||2016-05-11|2016-05-12|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation|Study on Systemic and Airway Cytokines and Oxidative Stress in Patients Undergoing Haemopoietic Stem Cell Transplantation (HSCT)|Completed|||228|Actual|The University of Hong Kong|||3||f||||f||||||Samples Without DNA|"~     Plasma, buffy coat, red blood cell and exhaled breath condensate samples.~   "|||2018-06-01 00:42:06.496443|2018-06-01 00:42:06.496443
NCT00956345|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2017-01-19|2009-08-10|2009-08-11|Estimate|||||||2017-01-19|2017-01-20|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B|A Multi-Centre, Multi-National, Open-Label, Dose Escalation Trial Evaluating Safety and Pharmacokinetics of Ascending Intravenous Doses of 40K Pegylated Recombinant FIX in Non-Bleeding Patients With Haemophilia B.|Completed||Phase 1|18|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 00:42:06.554219|2018-06-01 00:42:06.554219
NCT00956332|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-09|||2015-03-04|2009-08-10|2009-08-11|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2010||2010-02-28|March 2015|2015-03-31|May 2026|Anticipated|2026-05-31|August 2011|Actual|2011-08-31||Interventional|||Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia|Phase I/IIa Safety, Two-dose Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia|Active, not recruiting||Phase 1/Phase 2|28|Actual|MultiGene Vascular Systems Ltd.||2|||f||||t||||||||||2018-06-01 00:42:06.666933|2018-06-01 00:42:06.666933
NCT00956319|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-09|||2011-10-05|2009-08-09|2009-08-11|Estimate|||||||2011-10-05|2011-10-06|Estimate|May 2009||2009-05-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients|A Randomized, Open-Label, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Zolpidem Modified Release (MR) in Patients With Primary Insomnia|Completed||Phase 4|42|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:42:06.767145|2018-06-01 00:42:06.767145
NCT00956306|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-11-22|2009-08-10|2009-08-11|Estimate|||||||2012-11-22|2012-11-27|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|udenafil||A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function|A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function|Completed||Phase 1|18|Actual|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-06-01 00:42:06.840336|2018-06-01 00:42:06.840336
NCT00956293|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2014-03-26||2014-05-23|2009-08-10|2009-08-11|Estimate|2014-04-11|2014-05-12|Estimate||||2014-05-23|2014-06-06|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Senator||Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program|6-month, Open-label, Randomized, Multicenter, Prospective, Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program|Terminated||Phase 4|207|Actual|Novartis||2||"The study was terminated because the required sample size of 240-260 de novo senior renal~   transplant patients was not achieved within a reasonable time."|f||||||||||||||2018-06-01 00:42:06.942629|2018-06-01 00:42:06.942629
NCT00956280|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2010-05-11|2009-08-10|2009-08-11|Estimate|||||||2010-05-11|2010-05-13|Estimate|September 2009||2009-09-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer|Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer|Completed|||100|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 00:42:07.433111|2018-06-01 00:42:07.433111
NCT00956267|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Letrozole or Laparoscopic Ovarian Diathermy for Women With CC Resistant Polycystic Ovary Syndrome.|Letrozole Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome|Completed||N/A|260|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:42:07.494346|2018-06-01 00:42:07.494346
NCT00956254|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|2013-06-25||2013-06-25|2009-08-08|2009-08-11|Estimate|2013-06-25|2013-09-05|Estimate||||2013-06-25|2013-09-05|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||Safety population: All subjects who received study drug.|Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis|Evaluate Safety and Tolerability and Compare Absorption/Distribution Kinetics of a Single 100 Mcg Dose of Fentanyl Sublingual Spray (Fentanyl SL Spray) in Cancer Subjects With or Without Oral Mucositis|Completed||Phase 3|18|Actual|INSYS Therapeutics Inc||1|||f||||||||||||||2018-06-01 00:42:07.573224|2018-06-01 00:42:07.573224
NCT00956241|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|April 2002||2002-04-30|August 2009|2009-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||J-pouch Versus Side-to-end Coloanal Anastomosis After Preoperative Radiotherapy and Total Mesorectal Excision for Rectal Cancer|J-pouch Versus Side-to-end Coloanal Anastomosis After Preoperative Radiotherapy and Total Mesorectal Excision for Rectal Cancer: a Multicenter Randomized Trial|Completed||N/A|127|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-06-01 00:42:07.728437|2018-06-01 00:42:07.728437
NCT00956228|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2011-02-23|2009-08-10|2009-08-11|Estimate|||||||2011-02-23|2011-02-25|Estimate|October 2006||2006-10-31|February 2011|2011-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer|Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer|Completed||Phase 1/Phase 2|72|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:42:07.801053|2018-06-01 00:42:07.801053
NCT00956215|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2012-02-14|2009-08-10|2009-08-11|Estimate|||||||2012-02-14|2012-02-16|Estimate|May 2010||2010-05-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PONV||Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients|A Randomized and Placebo-Controlled Evaluation of Aprepitant for Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients|Completed||N/A|125|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 00:42:07.860169|2018-06-01 00:42:07.860169
NCT00956202|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-01-10|2009-08-10|2009-08-11|Estimate|||||||2014-01-10|2014-01-14|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years|Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years|Completed||Phase 2|303|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 00:42:07.933949|2018-06-01 00:42:07.933949
NCT00956189|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-01-02|2009-08-10|2009-08-11|Estimate|||||||2013-01-02|2013-01-03|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome|Easy Identification, Treatment Response Prediction, and Molecular Mechanism Exploration of Antipsychotic-related Metabolic Syndrome|Completed||N/A|132|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 00:42:08.051406|2018-06-01 00:42:08.051406
NCT00956176|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2012-09-05|2009-08-10|2009-08-11|Estimate|||||||2012-09-05|2012-09-07|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||September 2014|Anticipated|2014-09-30||Interventional|||Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis|Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:42:08.11935|2018-06-01 00:42:08.11935
NCT00956163|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2014-07-01|2009-08-10|2009-08-11|Estimate|||||||2014-07-01|2014-07-02|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|May 2014|Actual|2014-05-31|January 2011|Actual|2011-01-31||Interventional|||Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer|F-18 NaF PET for Detection of Bone Metastases in Men With Prostate Cancer: Exploratory Study|Completed||Early Phase 1|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:42:08.18416|2018-06-01 00:42:08.18416
NCT00956150|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2013-04-30|2009-08-10|2009-08-11|Estimate|||||||2013-04-30|2013-05-01|Estimate|April 2009||2009-04-30|April 2013|2013-04-30||||March 2014|Anticipated|2014-03-31||Interventional|||Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex|Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex|Unknown status|Recruiting|Phase 1|210|Anticipated|New Mexico VA Healthcare System||3|||f||||t||||||||||2018-06-01 00:42:08.264527|2018-06-01 00:42:08.264527
NCT00956137|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2017-11-30|2009-08-07|2009-08-11|Estimate|||||||2017-11-30|2017-12-04|Actual|May 2009||2009-05-31|January 2010|2010-01-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Ultrasound-assisted Spinal Anaesthesia in Patients With Difficult Anatomical Landmarks|A Randomised Controlled Trial of Ultrasound-assisted Spinal Anaesthesia in Patients With Difficult Anatomical Landmarks.|Completed||N/A|180|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:42:08.338795|2018-06-01 00:42:08.338795
NCT00956124|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2017-04-24|2009-08-10|2009-08-11|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2010||2010-10-31|April 2017|2017-04-30|June 1, 2016|Actual|2016-06-01|October 2011|Actual|2011-10-31||Observational|||Autofluorescence in Uveitic and Diabetic Macular Edema||Withdrawn|||0|Actual|St. Franziskus Hospital|||2|Technical issue|f||||||||||||||2018-06-01 00:42:08.397025|2018-06-01 00:42:08.397025
NCT00956111|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-10-28|2009-08-10|2009-08-11|Estimate|||||||2009-10-28|2009-10-30|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||A Clinical Trial With Influenza A/H1N1 Vaccines|A Double-blind, Randomized, Stratified and Controlled Clinical Trial With Split-virion and Whole-virion, Adjuvanted and Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders, Adolescents and Children|Completed||Phase 4|1614|Actual|Sinovac Biotech Co., Ltd||7|||f||||t||||||||||2018-06-01 00:42:08.446152|2018-06-01 00:42:08.446152
NCT00956098|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|February 2006||2006-02-28|August 2009|2009-08-31|February 2007||2007-02-28|||||Interventional|||Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Multicenter Trial of Oltipraz for the Evaluation of Efficacy and Safety in the Patients With Liver Fibrosis and Cirrhosis Induced by Chronic Hepatitis Type B or C|Completed||Phase 2|81||CJ HealthCare Corporation||2|||f||||||||||||||2018-06-01 00:42:08.516705|2018-06-01 00:42:08.516705
NCT00956085|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2016-11-29||2017-06-20|2009-08-10|2009-08-11|Estimate|2017-03-30|2017-05-10|Actual||||2017-06-20|2017-06-21|Actual|August 2009||2009-08-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder|Open -Label Trial on the Effects of Memantine in Adults With Obsessive-Compulsive Disorder After a Single Ketamine Infusion|Completed||Phase 2|12|Actual|New York State Psychiatric Institute||1|||f||||f||||||||No||2018-06-01 00:42:08.585676|2018-06-01 00:42:08.585676
NCT00956072|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|||2012-09-20|2009-08-08|2009-08-11|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2009||2009-05-31|September 2012|2012-09-30||||March 2011|Actual|2011-03-31||Interventional|||Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate|A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients With Metastatic Gastro-intestinal Stromal Tumor Responding to Imatinib Mesylate.|Terminated||Phase 3|12|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||low accrual|f||||||||||||||2018-06-01 00:42:08.8205|2018-06-01 00:42:08.8205
NCT00956059|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2009-08-10|2009-08-10|2009-08-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis|Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis|Unknown status|Not yet recruiting|N/A|40|Anticipated|Health Science Center of Xi’an Jiaotong University||2|||f||||f||||||||||2018-06-01 00:42:08.897355|2018-06-01 00:42:08.897355
NCT00956046|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-01-10|2009-08-10|2009-08-11|Estimate|||||||2014-01-10|2014-01-14|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months|Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months|Completed||Phase 2|401|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 00:42:08.995218|2018-06-01 00:42:08.995218
NCT00956033|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|||2014-12-23|2009-08-10|2009-08-11|Estimate|||||||2014-12-23|2014-12-24|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Skin Biopsies in Chemotherapy-Induced Neuropathy|Skin Biopsies in Chemotherapy-induced Neuropathy|Completed|||26|Actual|Erasmus Medical Center|||1||f||||f||||||Samples Without DNA|"~     skin biopsy~   "|||2018-06-01 00:42:09.120572|2018-06-01 00:42:09.120572
NCT00956020|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-10|2013-05-02||2015-11-11|2009-08-10|2009-08-11|Estimate|2015-11-11|2015-12-16|Estimate||||2015-11-11|2015-12-16|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation|Evaluation of the Mechanism of Action of Platelet Rich Fibrin Matrix (PRFM) in Producing Skin Volume Augmentation|Completed||Phase 1/Phase 2|4|Actual|The New York Eye & Ear Infirmary||1|||f||||f||||||||||2018-06-01 00:42:09.216104|2018-06-01 00:42:09.216104
NCT00956007|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-08|||2018-03-28|2009-08-08|2009-08-11|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2009|Actual|2009-11-30|March 2018|2018-03-31|August 2026|Anticipated|2026-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer|A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer|Active, not recruiting||Phase 3|703|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 00:42:09.564903|2018-06-01 00:42:09.564903
NCT00955994|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2011-03-22|2009-08-07|2009-08-10|Estimate|||||||2011-03-22|2011-03-23|Estimate|January 2005||2005-01-31|March 2011|2011-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome|A Randomized, Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of On-demand Treatment With Asimadoline in Patients With Irritable Bowel Syndrome Over 4 Weeks|Completed||Phase 2|100||Mayo Clinic|||||||||||||||||||2018-06-01 00:42:10.011619|2018-06-01 00:42:10.011619
NCT00955981|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07||2014-01-07|2014-02-05|2009-08-07|2009-08-10|Estimate||||2014-02-05|2014-03-07|Estimate|2014-02-05|2014-03-07|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|September 2011|Actual|2011-09-30|March 2010|Actual|2010-03-31||Interventional|||Gout Dose Response Study|Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout|Completed||Phase 2|123|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-06-01 00:42:10.071822|2018-06-01 00:42:10.071822
NCT00955968|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2017-08-30||2018-02-21|2009-08-07|2009-08-10|Estimate|2018-01-19|2018-02-16|Estimate||||2018-02-21|2018-03-20|Actual|January 2010|Actual|2010-01-31|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||All the participants who were randomized to the study with the exception of one participant who was excluded as she withdrew from the study on the day she was randomized|IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women|IMPAACT 1077HS: HAART Standard Version of the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study|Completed||Phase 4|1653|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||2|||f||||t||||||||No||2018-06-01 00:42:10.210784|2018-06-01 00:42:10.210784
NCT00955955|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2012-10-31||2017-03-28|2009-08-07|2009-08-10|Estimate|2012-12-11|2013-01-18|Estimate||||2017-03-28|2017-04-28|Actual|July 2009||2009-07-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|TRD-2||Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder|TRD - 2: A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF Among SSRI-Resistant Outpatients With Major Depressive Disorder (MDD)|Completed||Phase 4|75|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-06-01 00:42:11.090382|2018-06-01 00:42:11.090382
NCT00955942|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2016-02-09|2009-08-07|2009-08-10|Estimate|||||||2016-02-09|2016-02-10|Estimate|December 2007||2007-12-31|February 2016|2016-02-29||||July 2012|Actual|2012-07-31||Interventional|||Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy|A Phase I Blinded, Randomized Feasibility Trial of Dietary Flaxseed Administration in Non-Small Cell Lung Cancer Patients Receiving Definitive Thoracic Chemoradiotherapy|Unknown status|Active, not recruiting|Phase 1|48|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-06-01 00:42:12.312017|2018-06-01 00:42:12.312017
NCT00955929|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-09-05|2009-08-07|2009-08-10|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2009||2009-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy|A Randomized Trial of Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy|Active, not recruiting||N/A|100|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||t||||||||||2018-06-01 00:42:12.396612|2018-06-01 00:42:12.396612
NCT00955916|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2013-11-25||2014-06-17|2009-08-07|2009-08-10|Estimate|2013-11-25|2014-01-14|Estimate||||2014-06-17|2014-06-27|Estimate|August 2009||2009-08-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|December 2012|Actual|2012-12-31||Interventional|||CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 2|38|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 00:42:12.496263|2018-06-01 00:42:12.496263
NCT00955903|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2017-04-17||2017-08-01|2009-08-07|2009-08-10|Estimate|2017-04-17|2017-06-28|Actual||||2017-08-01|2017-09-05|Actual|June 2010||2010-06-30|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CROSSROADS||Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults|Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults|Completed||Phase 3|167|Actual|University of Alabama at Birmingham|This trial was completed in older adults (age 65+) with at least one major risk factor for heart disease.|3|||f||||f||||||||||2018-06-01 00:42:12.758866|2018-06-01 00:42:12.758866
NCT00955890|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2012-02-27|2009-08-07|2009-08-10|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|cardioprotec||Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer|Randomized Phase II Trial Of Interventional Therapy Investigate Cardiac Protection of Dexrazoxane In Women With Breast Cancer Having Experienced Grade 1 Cardiotoxicity During Prior Anthracycline-based Chemotherapy.|Terminated||Phase 2|12|Actual|Fudan University||3||Enrolled too slow|f||||t||||||||||2018-06-01 00:42:13.926075|2018-06-01 00:42:13.926075
NCT00955708|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2018-05-30|2009-08-07|2009-08-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 4, 2009|Actual|2009-08-04|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Longitudinal Surveillance Registry (LSR) of ACUITY Spiral|Condition of Approval Study: Longitudinal Surveillance Registry of the ACUITY Spiral Lead|Completed|||1308|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-06-01 00:42:19.262397|2018-06-01 00:42:19.262397
NCT00955877|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-11-01|2009-08-07|2009-08-10|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2010||2010-03-31|November 2017|2017-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children|Randomized, Double-Blinded Placebo Controlled Trial of Epidural, Sustained-relief Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children|Completed||N/A|13|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 00:42:14.055489|2018-06-01 00:42:14.055489
NCT00955864|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-10-05|2009-08-07|2009-08-10|Estimate|||||||2017-10-05|2017-10-06|Actual|July 15, 2009||2009-07-15|September 1, 2016|2016-09-01|September 1, 2016||2016-09-01|||||Observational|||Non-Invasive Non-Ionizing Polarized Imaging System to Assess Structure of Cervix|Non-Invasive Non-Ionizing Polarized Imaging System to Assess Structure of Cervix|Terminated|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:42:14.288717|2018-06-01 00:42:14.288717
NCT00955851|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2010-07-29|2009-08-07|2009-08-10|Estimate|||||||2010-07-29|2010-07-30|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine|A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine|Completed|||25|Anticipated|George Washington University|||1||f||||f||||||||||2018-06-01 00:42:14.377308|2018-06-01 00:42:14.377308
NCT00955838|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-08-07|2009-08-07|2009-08-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Brain Computer Interface (BCI) Based Robotic Rehabilitation for Stroke|Brain Computer Interface (BCI) Based Robotic Rehabilitation for Stroke|Unknown status|Recruiting|N/A|40|Anticipated|National Neuroscience Institute||2|||f||||t||||||||||2018-06-01 00:42:14.494911|2018-06-01 00:42:14.494911
NCT00955825|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2016-01-25||2016-04-12|2009-08-07|2009-08-10|Estimate|2016-04-12|2016-05-19|Estimate||||2016-04-12|2016-05-19|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||The Full Analysis Set (FAS) includes all patients who received at least one dose of the investigational product and had at least one Combined Score while on treatment during the pollen period. The FAS was regarded as primary for the efficacy evaluations.|Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis|A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From Grass Pollen Rhinoconjunctivitis|Completed||Phase 3|473|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-06-01 00:42:14.844286|2018-06-01 00:42:14.844286
NCT00955812|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2013-02-11|2009-08-07|2009-08-10|Estimate|||||||2013-02-11|2013-02-12|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||STAT3 Inhibitor for Solid Tumors|A Phase I, Open-label, Dose Escalation, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity, and Maximum Tolerated Dose of OPB-31121 in Subjects With Advanced Solid Tumors|Completed||Phase 1|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:42:16.426723|2018-06-01 00:42:16.426723
NCT00955799|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06||2012-11-27|2012-11-27|2009-08-07|2009-08-10|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus|A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus|Completed||Phase 3|455|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 00:42:16.712275|2018-06-01 00:42:16.712275
NCT00955786|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-08-07|2009-08-07|2009-08-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|July 2007|Actual|2007-07-31||Interventional|||Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas|A Phase I, Multicenter, Open-label, Dose-Escalation, Safety and Tolerance, and Pharmacokinetic Study of Intravenously Administered CX-3543,on a Daily x 5, Repeated Every 3 Weeks Schedule, in Patients With Advanced Solid Tumors or Lymphomas|Completed||Phase 1|48|Actual|Cylene Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:42:16.929456|2018-06-01 00:42:16.929456
NCT00955773|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-11-07|2009-08-06|2009-08-10|Estimate|||||||2017-11-07|2017-11-09|Actual|August 17, 2009|Actual|2009-08-17|November 2017|2017-11-30|November 8, 2011|Actual|2011-11-08|November 8, 2011|Actual|2011-11-08||Interventional|Cancer||A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects|An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination With Oral Everolimus in Subjects With Solid Tumors|Completed||Phase 1|64|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 00:42:16.99863|2018-06-01 00:42:16.99863
NCT00955760|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2011-02-07|2009-08-07|2009-08-10|Estimate|||||||2011-02-07|2011-02-08|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate|A Single Center, Open-Label, Three Periods, Fixed Sequence Design Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate|Completed||Phase 1|||Merz Pharmaceuticals GmbH|||||f||||||||||||||2018-06-01 00:42:17.200219|2018-06-01 00:42:17.200219
NCT00955747|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2013-12-05||2014-11-18|2009-08-07|2009-08-10|Estimate|2014-11-18|2014-11-19|Estimate||||2014-11-18|2014-11-19|Estimate|April 2007||2007-04-30|November 2014|2014-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|NEET||Naturlose (D-Tagatose) Efficacy Evaluation Trial|Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects With Type 2 Diabetes Under Diet Control and Exercise|Completed||Phase 3|494|Actual|Spherix Incorporated||2|||f||||f||||||||||2018-06-01 00:42:17.366864|2018-06-01 00:42:17.366864
NCT00955734|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2015-06-26|2009-08-07|2009-08-10|Estimate|||||||2015-06-26|2015-06-29|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Early Motion After Volar Fixation for Distal Radius Fractures|Early Motion After Volar Fixation for Distal Radius Fractures: A Prospective Trial|Completed||N/A|25|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 00:42:18.003657|2018-06-01 00:42:18.003657
NCT00955721|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2015-01-28||2017-12-03|2009-08-07|2009-08-10|Estimate|2015-01-28|2015-02-13|Estimate||||2017-12-03|2018-01-03|Actual|August 2009||2009-08-31|December 2017|2017-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer|A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer|Terminated||Phase 1/Phase 2|9|Actual|University of Miami|Study terminated due to lack of funding prior to the opening of the Phase 2 arm. Minimum required enrollment of 18 evaluable participants for Phase 1 not met.|2||Lack of Funding|f||||t||||||||||2018-06-01 00:42:18.262803|2018-06-01 00:42:18.262803
NCT00955695|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2013-08-01|2009-08-07|2009-08-10|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2009||2009-05-31|January 2010|2010-01-31||||||||Interventional|||Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib|Unknown status|Not yet recruiting|Phase 3|242|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:42:19.575217|2018-06-01 00:42:19.575217
NCT00955682|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06||2012-11-16|2016-08-08|2009-08-06|2009-08-10|Estimate||||2012-11-16|2012-11-21|Estimate|2016-08-08|2016-08-09|Estimate|August 2009||2009-08-31|August 2016|2016-08-31|September 2012|Actual|2012-09-30|December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612|Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers|Completed||Phase 3|342|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:42:19.643325|2018-06-01 00:42:19.643325
NCT00955669|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2010-11-30|2009-08-07|2009-08-10|Estimate|||||||2010-11-30|2010-12-01|Estimate|August 2009||2009-08-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparison of Autologous Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer|Comparison of Autologous Transplantation of Bone Marrow Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer|Completed||Phase 1|40|Actual|Third Military Medical University||1|||f||||t||||||||||2018-06-01 00:42:20.170085|2018-06-01 00:42:20.170085
NCT00955656|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-09-11|2009-08-07|2009-08-10|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2009||2009-07-31|September 2017|2017-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Delta Primary Care Provider (PCP) Survey on Asthma Management|Delta Primary Care Provider (PCP) Survey on Asthma Management|Completed|||6|Actual|Arkansas Children's Hospital Research Institute|||1||f||||t||||||||No|There is no plan to share individual participant data.|2018-06-01 00:42:20.252267|2018-06-01 00:42:20.252267
NCT00955643|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2009-08-07|2009-08-07|2009-08-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|March 2002||2002-03-31|August 2009|2009-08-31|April 2003|Actual|2003-04-30|||||Interventional|||Periodontal Treatment Associated With Hyperbaric Oxygen Therapy|Periodontal Therapy in Severe Cases of Periodontitis: Preliminary Findings of Non-surgical Instrumentation With or Without Hyperbaric Oxygen Therapy (HBOT)|Completed||N/A|20|Actual|Escola Bahiana de Medicina e Saude Publica||2|||f||||f||||||||||2018-06-01 00:42:20.333917|2018-06-01 00:42:20.333917
NCT00955630|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2009-08-07|2009-08-07|2009-08-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|August 2009||2009-08-31|August 2009|2009-08-31||||August 2010|Anticipated|2010-08-31||Interventional|IVL for OHS||Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome|Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Retina Associates of Kentucky||2|||f||||t||||||||||2018-06-01 00:42:20.432466|2018-06-01 00:42:20.432466
NCT00955617|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2012-08-08||2012-10-05|2009-08-07|2009-08-10|Estimate|2012-10-05|2012-11-02|Estimate||||2012-10-05|2012-11-02|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases|Intra-individual Efficacy Evaluation of DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in the Diagnosis of Clinically Significant Abdominal or Lower Limb Arterial Diseases|Completed||Phase 4|20|Actual|Guerbet|Limitation of the study: descriptive study|2|||f||||t||||||||||2018-06-01 00:42:20.665155|2018-06-01 00:42:20.665155
NCT00955604|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-02-02|2009-08-07|2009-08-10|Estimate|||||||2017-02-02|2017-02-06|Estimate|July 2009||2009-07-31|February 2017|2017-02-28|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Observational|STACCATO||Azilect + Antidepressant Chart Review|Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review|Completed|||1500|Anticipated|Teva Pharmaceutical Industries|||3||f||||f||||||||||2018-06-01 00:42:21.001761|2018-06-01 00:42:21.001761
NCT00955591|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-02-15|2009-08-07|2009-08-10|Estimate|||||||2017-02-15|2017-02-17|Actual|March 12, 2009|Actual|2009-03-12|September 2016|2016-09-30|October 14, 2016|Actual|2016-10-14|December 12, 2011|Actual|2011-12-12||Interventional|||Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men|Comparison of Flocked vs. Dacron Swab for Anal Cytology, Correspondence With High Resolution Anoscopy|Completed||N/A|48|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:42:21.106077|2018-06-01 00:42:21.106077
NCT00955578|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2009-09-01|2009-08-07|2009-08-10|Estimate|||||||2009-09-01|2009-09-03|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Observational|||Genetic Identification (ID) of Segmental Dysplastic Nevi|Identification of the Genetic Mutation Responsible for Segmental Dysplastic Nevi|Unknown status|Not yet recruiting||1|Anticipated|Nova Scotia Health Authority|||1||f||||f||||||Samples With DNA|"~     The participant will be involved in the study for the length of time required to obtain 5 to~     6 skin biopsiesThe laboratory testing that will be performed includes a genetic analysis of~     the tissue obtained from biopsy. The genetic analysis will take place in the genetics lab of~     Dr. Hensin Tsao, Massachusetts General Hospital, Bartlett 622, 48 Blossom Street, Boston MA,~     02114.~   "|||2018-06-01 00:42:21.231846|2018-06-01 00:42:21.231846
NCT00955565|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2010-01-06|2009-08-07|2009-08-10|Estimate|||||||2010-01-06|2010-01-07|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Accuracy of Navigation in Placement of Sacroiliac Screw|Accuracy of Navigation in Placement of Sacroiliac Screw. Multicenter Randomized Controlled Trial|Completed||Phase 4|150|Actual|AO Clinical Investigation and Documentation||2|||f||||f||||||||||2018-06-01 00:42:21.372822|2018-06-01 00:42:21.372822
NCT00955552|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-03-03|2009-08-07|2009-08-10|Estimate|||||||2010-03-03|2010-03-04|Estimate|April 2010||2010-04-30|August 2009|2009-08-31|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Interventional|Artico||Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee|A Multi-center, Randomized, Double Blind, Comparative of Efficacy and Safety From Association of Capsules Glucosamine and Chondroitin Sulfate (Eurofarma) Versus Condroflex (Zodiac) to Patients Treatment With Osteoarthrosis of the Knee Study|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Eurofarma Laboratorios S.A.||2|||f||||f||||||||||2018-06-01 00:42:21.507328|2018-06-01 00:42:21.507328
NCT00950040|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2017-04-10|2009-07-30|2009-07-31|Estimate|||||||2017-04-10|2017-04-12|Actual|July 2009||2009-07-31|April 2016|2016-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|SUGAR||Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics|Brief Alcohol Intervention to Reduce At-Risk Drinking Among Type 2 Diabetics|Completed||N/A|92|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-06-01 00:44:07.214817|2018-06-01 00:44:07.214817
NCT00955539|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2011-10-04|2009-08-07|2009-08-10|Estimate|||||||2011-10-04|2011-10-06|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Viability and Cardiac Resynchronization Therapy|The Importance of Viability for Response to Cardiac Resynchronization Therapy|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-06-01 00:42:21.742258|2018-06-01 00:42:21.742258
NCT00955526|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2012-08-28|2009-08-07|2009-08-10|Estimate|||||||2012-08-28|2012-08-29|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|6002-009||Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|Placebo-Controlled, Double-Blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3)|Completed||Phase 3|373|Actual|Kyowa Hakko Kirin Co., Ltd||3|||f||||f||||||||||2018-06-01 00:42:22.035695|2018-06-01 00:42:22.035695
NCT00955513|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2010-12-01||2012-04-18|2009-08-07|2009-08-10|Estimate|2011-01-07|2011-01-26|Estimate||||2012-04-18|2012-04-20|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Placebo-controlled, 3-treatment Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Twice or Three Times Daily in Patients With Acute Ankle Sprain|Completed||Phase 3|242|Actual|Novartis||3|||f||||f||||||||||2018-06-01 00:42:22.167659|2018-06-01 00:42:22.167659
NCT00955500|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-08-07|2009-08-07|2009-08-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|January 2003||2003-01-31|August 2009|2009-08-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy|Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study|Completed||Phase 4|116|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-06-01 00:42:22.865185|2018-06-01 00:42:22.865185
NCT00955487|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2017-04-14||2017-05-22|2009-08-06|2009-08-10|Estimate|2017-04-14|2017-05-23|Actual||||2017-05-22|2017-06-15|Actual|January 2007||2007-01-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns|Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns|Completed||Phase 2|124|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 00:42:23.063452|2018-06-01 00:42:23.063452
NCT00955474|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2014-04-04||2017-04-18|2009-08-07|2009-08-10|Estimate|2016-03-25|2016-03-28|Estimate||||2017-04-18|2017-04-20|Actual|September 2008||2008-09-30|April 2017|2017-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Seroquel|Thirty-two patients were consented and 25 participants were randomized. The remaining 7 participants withdrew consent prior to randomization and the collection of any baseline data.|Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms|The Efficacy and Tolerability of Seroquel XR Combined With a Selective Serotonin Re-Uptake Inhibitor Versus Seroquel XR Monotherapy in the Acute Treatment of Major Depressive Disorder With Psychotic Features|Terminated||Phase 4|32|Actual|Massachusetts General Hospital||2||AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012|f||||f|t|f|||f|||Yes||2018-06-01 00:42:24.131136|2018-06-01 00:42:24.131136
NCT00955461|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2012-11-27|2009-08-07|2009-08-10|Estimate|||||||2012-11-27|2012-11-28|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System|Post-Market, Randomized, Single Blind, Split-Faced Comparison of the RevLite Nd:YAG Laser System Versus a Non-Ablative, Mid Infra-red, Fractionated Type Laser System for Skin Rejuvenation|Completed||N/A|12|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-06-01 00:42:25.440124|2018-06-01 00:42:25.440124
NCT00955448|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2016-08-29|2009-08-07|2009-08-10|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Anterior SIS||Trial of Small Intestine Submucosa (SIS) Mesh for Anterior Repair: A Pilot Study|Randomized Controlled Trial of SIS Mesh for Anterior Repair: A Pilot Study|Completed||Phase 3|57|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 00:42:25.572424|2018-06-01 00:42:25.572424
NCT00955435|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-05-23|2009-08-07|2009-08-10|Estimate|||||||2017-05-23|2017-05-24|Actual|September 2005||2005-09-30|May 2017|2017-05-31||||October 2012|Actual|2012-10-31||Observational|||Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15|Proteomic Analysis of the Combined Hormonal Therapy and Radiation Therapy for Localized Prostate Cancer|Active, not recruiting|||60|Anticipated|Cancer Trials Ireland|||||f||||||||||||||2018-06-01 00:42:25.758542|2018-06-01 00:42:25.758542
NCT00955422|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-10-05|2009-08-07|2009-08-10|Estimate|||||||2017-10-05|2017-10-06|Actual|July 31, 2009||2009-07-31|July 6, 2017|2017-07-06|July 6, 2017||2017-07-06|||||Observational|||Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease|Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease|Completed|||197|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:42:25.867016|2018-06-01 00:42:25.867016
NCT00955409|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2014-01-29|2009-08-07|2009-08-10|Estimate|||||||2014-01-29|2014-01-31|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease|A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease|Completed||Phase 2|50|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 00:42:25.931068|2018-06-01 00:42:25.931068
NCT00955396|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-10-13|2009-08-06|2009-08-10|Estimate|||||||2017-10-13|2017-10-16|Actual|July 31, 2009|Actual|2009-07-31|October 2017|2017-10-31|December 31, 2009|Actual|2009-12-31|December 31, 2009|Actual|2009-12-31||Interventional|||Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure|A Randomized, Double-blind, Placebo-controlled Cross-over Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure|Completed||Phase 1|60|Actual|Biogen||2|||f||||||||||||||2018-06-01 00:42:26.080774|2018-06-01 00:42:26.080774
NCT00955240|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2011-07-08|2009-08-07|2009-08-10|Estimate|||||||2011-07-08|2011-07-11|Estimate|March 2009||2009-03-31|July 2011|2011-07-31||||||||Interventional|||Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer|Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer|Unknown status|Active, not recruiting|Phase 2|77|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:42:32.048133|2018-06-01 00:42:32.048133
NCT00955383|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-06-13|2009-08-06|2009-08-10|Estimate|||||||2017-06-13|2017-06-14|Actual|August 14, 2009|Actual|2009-08-14|June 2017|2017-06-30|October 12, 2009|Actual|2009-10-12|October 12, 2009|Actual|2009-10-12||Interventional|||GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects|A Single Centre, Randomised, Double-blind, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2190915 in Healthy Japanese Subjects.|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:42:26.160007|2018-06-01 00:42:26.160007
NCT00955370|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-06-30|2009-08-07|2009-08-10|Estimate|||||||2017-06-30|2017-07-02|Actual|August 4, 2009||2009-08-04|April 10, 2012|2012-04-10|April 10, 2012||2012-04-10|||||Observational|||The Experience of Uncertainty in Parents of Children With an Undiagnosed Medical Condition|The Experience of Uncertainty in Parents of Children With an Undiagnosed Medical Condition|Completed|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:42:26.288586|2018-06-01 00:42:26.288586
NCT00955357|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2014-03-28||2017-07-28|2009-08-07|2009-08-10|Estimate|2014-03-28|2014-05-01|Estimate||||2017-07-28|2017-08-28|Actual|August 2009||2009-08-31|July 2017|2017-07-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional||The Baseline Analysis Population refers to the Safety Set (SS) which includes all enrolled subjects who took at least one dose of study medication. 5 subjects at one site were excluded from the Safety Set due to significant study conduct deficiencies.|Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures|An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures|Completed||Phase 4|461|Actual|UCB Pharma|This study was intended to assess the efficacy outcomes in the First Add-On Group and the Later Add-On Group individually relative to historical data. Comparisons between the 2 groups should not be attempted and conclusions should not be drawn.|2|||f||||f||||||||||2018-06-01 00:42:26.398821|2018-06-01 00:42:26.398821
NCT00955344|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-08-15|2009-08-07|2009-08-10|Estimate|||||||2016-08-15|2016-08-17|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Increasing Primary Care Physician Colorectal Cancer Screening Rates|Increasing Primary Care Physician Colorectal Cancer Screening Rates|Completed||N/A|134|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:42:27.32912|2018-06-01 00:42:27.32912
NCT00955331|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2015-01-12|2009-08-07|2009-08-10|Estimate|||||||2015-01-12|2015-01-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:42:27.428771|2018-06-01 00:42:27.428771
NCT00955318|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2017-03-14|2009-08-07|2009-08-10|Estimate|||||||2017-03-14|2017-03-15|Actual|July 2009||2009-07-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|December 2010|Actual|2010-12-31||Interventional|||Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease|Phase 3 Study of KW-6500 (Safety Study for Long-Term Self-Administration at Home in Patients With Parkinson's Disease|Completed||Phase 3|58|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||||||||||||2018-06-01 00:42:27.482928|2018-06-01 00:42:27.482928
NCT00955305|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|2016-07-26||2016-09-12|2009-08-07|2009-08-10|Estimate|2016-07-26|2016-09-08|Estimate||||2016-09-12|2016-10-24|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|January 2016|Actual|2016-01-31||Interventional||Eligible and treated patients|Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer|A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab With or Without IMC-A12 in Patients With Advanced Non-squamous, Non-small Cell Lung Cancer|Terminated||Phase 2|175|Actual|National Cancer Institute (NCI)||2||"The study was closed to accrual due to the end of the clinical development program with~   cixutumumab."|f||||f||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 00:42:27.629676|2018-06-01 00:42:27.629676
NCT00955292|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2009-08-07|2009-08-07|2009-08-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|July 2007||2007-07-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas|A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Quarfloxin Administered Intravenously Weekly for Three Weeks of a Four Week Cycle in Patients With Advanced Solid Tumors or Lymphomas|Terminated||Phase 1|12|Actual|Cylene Pharmaceuticals||1||Modified dose schedule presented no advantage over previously studied schedule|f||||f||||||||||2018-06-01 00:42:28.745382|2018-06-01 00:42:28.745382
NCT00955279|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2014-06-18|2013-04-25|2014-06-18|2009-08-06|2009-08-10|Estimate|2014-06-18|2014-07-17|Estimate|2013-04-25|2013-05-03|Estimate|2014-06-18|2014-07-17|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis|A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis|Completed||Phase 2|173|Actual|Centocor, Inc.||3|||f||||t||||||||||2018-06-01 00:42:28.965194|2018-06-01 00:42:28.965194
NCT00955266|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2017-01-27||2017-04-10|2009-08-06|2009-08-10|Estimate|2017-04-10|2017-05-22|Actual||||2017-04-10|2017-05-22|Actual|July 2009||2009-07-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass|A Randomized Double-Blind Placebo-Controlled Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass|Terminated||Phase 4|8|Actual|Brigham and Women's Hospital|Data storage location sustained significant water intrusion and mold contamination in June 2016. Environmental contractor has advised contents of location need to be destroyed. As a result, data is not available for results reporting.|2||Inadequate recruitment|f||||t||||||||||2018-06-01 00:42:30.568258|2018-06-01 00:42:30.568258
NCT00955253|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2015-06-03|2009-08-07|2009-08-10|Estimate|||||||2015-06-03|2015-06-04|Estimate|April 2010||2010-04-30|June 2011|2011-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|GASNIV||Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance|A Trial of Guanfacine, an Alpha 2 Adrenergic Agonist, for Spatial Neglect and Impaired Vigilance Following Stroke and Focal Brain Damage|Completed||Phase 2|13|Actual|Imperial College London||1|||f||||t||||||||||2018-06-01 00:42:31.746858|2018-06-01 00:42:31.746858
NCT00955227|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-05-10|2009-08-07|2009-08-10|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2009||2009-07-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|May 2011|Actual|2011-05-31||Interventional|||Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels|Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels|Completed||N/A|60|Actual|University of Manitoba||4|||f||||f||||||||Yes|Results in press in 2016 Clinical Nutrition Blackwood et. al|2018-06-01 00:42:32.158761|2018-06-01 00:42:32.158761
NCT00955214|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2010-06-09|2009-08-07|2009-08-10|Estimate|||||||2010-06-09|2010-06-10|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|August 2012|Anticipated|2012-08-31|August 2010|Anticipated|2010-08-31||Interventional|SACRA||Small Coronary Artery Treated by TAXUS Liberté Registry in Japan|Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease|Unknown status|Enrolling by invitation|Phase 4|250|Actual|Society for Advancement of Coronary Intervention Research||1|||f||||t||||||||||2018-06-01 00:42:32.491285|2018-06-01 00:42:32.491285
NCT00955201|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2015-04-10|2009-08-07|2009-08-10|Estimate|||||||2015-04-10|2015-04-13|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|November 2014|Actual|2014-11-30||Interventional|||Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy|Exercise-Facilitated NeuroRehabilitation in Diabetic Neuropathy|Unknown status|Active, not recruiting|N/A|100|Anticipated|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 00:42:32.79116|2018-06-01 00:42:32.79116
NCT00955188|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-07|||2012-12-19|2009-08-07|2009-08-10|Estimate|||||||2012-12-19|2012-12-21|Estimate|August 2004||2004-08-31|December 2012|2012-12-31|May 2008|Actual|2008-05-31|April 2007|Actual|2007-04-30||Observational|||Computer-Based Tailored or Standard Information for Colorectal Cancer Screening|Evaluating a Preference-tailored Intervention to Increase CRC Screening in Primary Care Settings|Completed|||345|Actual|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 00:42:33.010132|2018-06-01 00:42:33.010132
NCT00955175|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-02-15|2009-08-06|2009-08-07|Estimate|||||||2016-02-15|2016-02-17|Estimate|November 2000||2000-11-30|February 2016|2016-02-29||||June 2009|Actual|2009-06-30||Interventional|||Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09|Radiation Dose Escalation For Non-Small Cell Lung Cancer Using Hypofractionated 3-Dimensional Conformal Radiation Therapy|Completed||Phase 2|60|Anticipated|Cancer Trials Ireland||3|||f||||||||||||||2018-06-01 00:42:33.131855|2018-06-01 00:42:33.131855
NCT00955162|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-11-28|2009-08-06|2009-08-07|Estimate|||||||2012-11-28|2012-11-30|Estimate|August 2009||2009-08-31|January 2010|2010-01-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|RIME||"Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France (RIME)"|A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France|Completed||Phase 4|270|Actual|Indivior Inc.||2|||f||||f||||||||||2018-06-01 00:42:33.20296|2018-06-01 00:42:33.20296
NCT00955149|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2014-01-09|2009-08-06|2009-08-07|Estimate|||||||2014-01-09|2014-01-10|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)|An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7|Completed||Phase 1|6|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:42:33.443332|2018-06-01 00:42:33.443332
NCT00955136|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2014-06-26|2009-08-06|2009-08-07|Estimate|||||||2014-06-26|2014-06-30|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|April 2015|Anticipated|2015-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes|Utilization of Diagnostic Ultrasound in the Detection and Therapy of Acute Coronary Syndromes|Withdrawn||N/A|0|Actual|University of Nebraska||1||The study was withdrawn due to many implementation difficulties.|f||||f||||||||||2018-06-01 00:42:33.529961|2018-06-01 00:42:33.529961
NCT00955123|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2012-10-11|2009-08-05|2009-08-07|Estimate|||||||2012-10-11|2012-10-12|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|||||Observational|||Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Active Inflammatory Bowel Disease|Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Patients With Active Ulcerative Colitis and Crohn's Disease|Completed|||40|Actual|University of Aarhus|||1||f||||f||||||Samples Without DNA|"~     Serum, plasma and urine.~   "|||2018-06-01 00:42:33.59855|2018-06-01 00:42:33.59855
NCT00955110|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2011-01-31||2017-09-07|2009-08-06|2009-08-07|Estimate|2011-07-05|2011-07-14|Estimate||||2017-09-07|2017-10-05|Actual|June 2009||2009-06-30|September 2017|2017-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)|An Exploratory, Single-Dose, Double-Blind, Randomized, Placebo-Controlled Crossover Study to Evaluate The Subjective and Objective Effects of Extended-Release Oxymorphone Compared to Controlled-Release Oxycodone in Healthy Non-Dependent Recreational Opioid Users|Completed||Phase 4|78|Actual|Endo Pharmaceuticals||5|||f||||f||||||||||2018-06-01 00:42:33.860795|2018-06-01 00:42:33.860795
NCT00955097|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2013-10-18|2009-08-06|2009-08-07|Estimate|||||||2013-10-18|2013-10-21|Estimate|May 2008||2008-05-31|October 2013|2013-10-31|May 2010|Actual|2010-05-31|June 2009|Actual|2009-06-30||Interventional|Definity®||Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors|Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors|Terminated||Phase 1|6|Actual|University of Louisville||1||No funding for this study|f||||f||||||||||2018-06-01 00:42:34.494903|2018-06-01 00:42:34.494903
NCT00955084|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-09-23|2009-08-06|2009-08-07|Estimate|||||||2010-09-23|2010-09-24|Estimate|August 2008||2008-08-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Maintenance Study on the Long Term Safety of XL999|A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies|Completed||Phase 1|2|Actual|Symphony Evolution, Inc.|||||f||||f||||||||||2018-06-01 00:42:35.548037|2018-06-01 00:42:35.548037
NCT00955071|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2013-08-01|2009-08-05|2009-08-07|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Exercise on Abdominal Obesity and Risk Factors for Cardiovascular Disease|Dose-response Effects of Exercise on Abdominal Obesity and Risk Factors for CVD in Men and Women.|Completed||N/A|320|Anticipated|Queen's University||4|||f||||t||||||||||2018-06-01 00:42:35.721262|2018-06-01 00:42:35.721262
NCT00955058|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2009-09-01|2009-08-06|2009-08-07|Estimate|||||||2009-09-01|2009-09-03|Estimate|February 2007||2007-02-28|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|February 2007|Anticipated|2007-02-28||Interventional|PSA||Evaluation of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients|Study of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients|Unknown status|Enrolling by invitation|Phase 2/Phase 3|60|Anticipated|Shahid Beheshti University||2|||f||||t||||||||||2018-06-01 00:42:35.811655|2018-06-01 00:42:35.811655
NCT00954889|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-10-31|2009-08-06|2009-08-07|Estimate|||||||2011-10-31|2011-11-01|Estimate|August 2009||2009-08-31|October 2011|2011-10-31||||November 2011|Anticipated|2011-11-30||Interventional|||Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg|Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg|Unknown status|Active, not recruiting|N/A|220|Actual|Samsung Medical Center||2|||f||||||||||||||2018-06-01 00:42:37.961324|2018-06-01 00:42:37.961324
NCT00955045|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2016-07-12|2009-08-05|2009-08-07|Estimate|||||||2016-07-12|2016-07-13|Estimate|August 2002||2002-08-31|July 2016|2016-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy|A Long-Term, Multicenter, Open-Label, Safety Study With a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy|Completed||Phase 2/Phase 3|||Kyowa Kirin Pharmaceutical Development, Inc.||1|||||||||||||||||2018-06-01 00:42:35.878941|2018-06-01 00:42:35.878941
NCT00955032|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2011-12-05||2013-04-19|2009-08-06|2009-08-07|Estimate|2012-01-17|2012-02-20|Estimate||||2013-04-19|2013-04-26|Estimate|April 2007||2007-04-30|September 2012|2012-09-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|ReStore||Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Apathy in Parkinson's Disease.|Completed||N/A|24|Actual|University of Florida|Due to recruiting difficulties, only 24 participants completed study participation. Despite this, the investigators still had significant power to examine effects of interest.|2|||f||||f||||||||||2018-06-01 00:42:35.950214|2018-06-01 00:42:35.950214
NCT00955019|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-09-14|2009-08-06|2009-08-07|Estimate|||||||2009-09-14|2009-09-16|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Observational|||Novel Method of Surveillance in Barrett's Esophagus|Novel Method of Surveillance in Barrett's Esophagus|Completed|||180|Anticipated|Mayo Clinic|||||f||||t||||||Samples Without DNA|"~     cytology specimens~   "|||2018-06-01 00:42:36.422193|2018-06-01 00:42:36.422193
NCT00955006|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2018-03-05|2009-08-06|2009-08-07|Estimate|||||||2018-03-05|2018-03-07|Actual|May 2011||2011-05-31|March 2018|2018-03-31|November 22, 2017|Actual|2017-11-22|September 2013|Actual|2013-09-30||Interventional|||Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals|A Phase 1b Clinical Trial to Evaluate Mucosal Immune Responses to a DNA Plasmid Vaccine Prime Followed by an HIV-1 Adenoviral Vector Boost in Healthy Adenovirus Type 5 Seronegative HIV-1-uninfected Adults|Completed||Phase 1|17|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 00:42:36.569173|2018-06-01 00:42:36.569173
NCT00954993|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2014-09-26||2017-03-03|2009-08-06|2009-08-07|Estimate|2014-09-26|2014-09-29|Estimate||||2017-03-03|2017-03-31|Actual|January 2010||2010-01-31|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)|A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK-7009 in Hepatitis C Infected Patients|Terminated||Phase 1|3|Actual|Merck Sharp & Dohme Corp.||1||"This study was stopped for business and program changes. At no time was the safety of any~   participants at risk."|f||||f||||||||||2018-06-01 00:42:36.671494|2018-06-01 00:42:36.671494
NCT00954980|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2016-11-02|2009-08-06|2009-08-07|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|December 2012|Actual|2012-12-31||Observational|||Evaluation of Endovenous Sclerotherapy for Treatment of Varicose Veins|Evaluation of Clinical Characteristics of Endovenous Sclerotherapy of Varicose Veins|Completed|||100|Actual|University of Oklahoma|||1||f||||f||||||Samples Without DNA|"~     blood samples will be obtained for measurement of D-dimer, fibrin monomer, and total~     microparticles.~   "|Undecided||2018-06-01 00:42:36.942009|2018-06-01 00:42:36.942009
NCT00954967|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-08-06|2009-08-06|2009-08-07|Estimate|||||||2009-08-06|2009-08-07|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|September 2011|Anticipated|2011-09-30|January 2011|Anticipated|2011-01-31||Interventional|ITADI||Trial for Tobacco Cessation With Intensive Advice in Diabetic Patients: the ITADI Project|Community Intervention Trial for Smoking Cessation With Intensive Advice in Diabetic Patients in Primary Health Care|Unknown status|Not yet recruiting|N/A|546|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-06-01 00:42:37.013944|2018-06-01 00:42:37.013944
NCT00954954|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-06|2009-08-06|2009-08-07|Estimate|||||||2009-08-06|2009-08-07|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|June 2007|Actual|2007-06-30||Interventional|||Outcomes After Standard and High-Flexion Posterior Stabilized Rotating-Platform Mobile-Bearing Total Knee Arthroplasty|Outcomes After Standard and High-Flexion Posterior Stabilized Rotating-Platform Mobile-Bearing Total Knee Arthroplasty: A Prospective Randomized Comparative Study|Completed||Phase 4|170|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:42:37.11644|2018-06-01 00:42:37.11644
NCT00954941|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2013-11-26||2015-05-28|2009-08-06|2009-08-07|Estimate|2013-11-26|2014-01-13|Estimate||||2015-05-28|2015-06-25|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2013|Actual|2013-04-30||Interventional||Registered eligible participants who received one dose of study medication were evaluable for toxicity but had to receive at least five doses to be evaluable for response. Only 90 participants (46 on Group 1 and 44 on Group 2) had one or more doses of study medication.|Ondansetron Versus Aprepitant Plus Ondansetron for Emesis|Comparative Trial Ondansetron Alone Versus Combination of Ondansetron Plus Aprepitant for Prevention of Nausea and Vomiting With Hematologic Malignancies Receiving Regimens Containing High-dose Cytarabine|Completed||Phase 2|100|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:42:37.221618|2018-06-01 00:42:37.221618
NCT00954928|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2015-06-26|2009-08-06|2009-08-07|Estimate|||||||2015-06-26|2015-06-29|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Safety of Hand Surgery in the Anticoagulated Patient|The Safety of Hand Surgery in the Anticoagulated Patient|Completed|||398|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 00:42:37.642832|2018-06-01 00:42:37.642832
NCT00954915|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2012-03-27||2012-08-20|2009-08-06|2009-08-07|Estimate|2012-03-27|2012-04-19|Estimate||||2012-08-20|2012-08-30|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis|A Phase 2a, Open Label, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Teplizumab in Adults With Moderate or More Severe Psoriasis|Terminated||Phase 1/Phase 2|1|Actual|MacroGenics|This study was terminated, with only 1 subject enrolled, due to meeting the study criteria for discontinuation regarding local or regional injection site reactions.|1||Injection site reaction met protocol-defined stopping criteria.|f||||f||||||||||2018-06-01 00:42:37.7418|2018-06-01 00:42:37.7418
NCT00954902|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2018-01-23|2009-08-06|2009-08-07|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2009||2009-08-31|January 2018|2018-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Spice||Effects of Antioxidants on Cardiovascular Risk Measures (Spice Study)|Development of a Dynamic Model of Inflammation for Studying the Anti-inflammatory Effects of Culinary Spices in Human Participants|Completed||N/A|32|Actual|Penn State University||4|||f||||f||||||||||2018-06-01 00:42:37.891875|2018-06-01 00:42:37.891875
NCT00954876|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2012-01-27|2009-08-06|2009-08-07|Estimate|||||||2012-01-27|2012-01-31|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer|Phase II, Multi-Center, Open-Label, Prospective Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type KRAS Colorectal Cancer Who Are Considered Nonoptimal Candidates or Are Intolerant to a First-Line Oxaliplatin/Irinotecan Regimen|Withdrawn||Phase 2|0|Actual|Translational Drug Development||||Study has been terminated due to lack of accrual.|f||||f||||||||||2018-06-01 00:42:38.19701|2018-06-01 00:42:38.19701
NCT00954863|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-09-28|2009-08-06|2009-08-07|Estimate|||||||2009-09-28|2009-09-29|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||Genotypic Resistant HIV Strains in Taiwan|Identification and Characterization of Genotypic Resistant HIV Strains in Taiwan|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 00:42:38.261989|2018-06-01 00:42:38.261989
NCT00954850|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-08-23|2009-08-06|2009-08-07|Estimate|||||||2012-08-23|2012-08-24|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|CSAN||A National Program for Severe Asthma: The Canadian Severe Asthma Network|A National Program for Severe Asthma: The Canadian Severe Asthma Network|Withdrawn|||0|Actual|University of Alberta|||2|"Subjects not entered into electronic database due to current construct of database and~   associated privacy legislations within Alberta."|f||||f||||||Samples Without DNA|"~     If consented to by the patient, extra clinical specimens - sputum plugs, sputum supernatant,~     blood and urine will be stored. If patients undergo a clinical bronchoscopy, mucosal biopsies~     x 2 and bronchoalveolar lavage will be stored.~   "|||2018-06-01 00:42:38.389744|2018-06-01 00:42:38.389744
NCT00954837|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2013-05-24|2009-08-06|2009-08-07|Estimate|||||||2013-05-24|2013-05-27|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|CYT2THYR||Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer|Utility of a Second Ultrasound-guided Fine Needle Aspiration for the Detection of Thyroid Cancer in the Management of Single Thyroid Nodules or Multinodular Goitre.|Withdrawn||N/A|0|Actual|Assistance Publique - Hôpitaux de Paris||1||administrative delays too long|f||||f||||||||||2018-06-01 00:42:38.453561|2018-06-01 00:42:38.453561
NCT00954824|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2015-08-17||2017-03-28|2009-08-06|2009-08-07|Estimate|2015-12-21|2016-01-28|Estimate||||2017-03-28|2017-03-30|Actual|August 2003||2003-08-31|March 2017|2017-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|LPS||Inflammation and the Metabolic Syndrome in Humans|Inflammation and the Metabolic Syndrome in Humans|Completed||N/A|50|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-06-01 00:42:38.575553|2018-06-01 00:42:38.575553
NCT00954811|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2010-01-07|2009-08-06|2009-08-07|Estimate|||||||2010-01-07|2010-01-08|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|January 2008|Anticipated|2008-01-31||Interventional|||Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)|A Phase IV Study on the Effect of Luteal Supplementation With Rec-LH on the Pregnancy Rate After Ovulation Triggering With GnRH-agonist Instead of HCG in IVF Protocol;Proof of Concept|Unknown status|Recruiting|Phase 4|40|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-06-01 00:42:38.714415|2018-06-01 00:42:38.714415
NCT00954798|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-01-10|2009-08-06|2009-08-07|Estimate|||||||2014-01-10|2014-01-14|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly|Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly Subjects|Completed||Phase 2|450|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 00:42:38.809761|2018-06-01 00:42:38.809761
NCT00954785|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2013-06-19|2009-08-06|2009-08-07|Estimate|||||||2013-06-19|2013-06-20|Estimate|November 2009||2009-11-30|August 2009|2009-08-31|July 2011|Anticipated|2011-07-31|December 2010|Anticipated|2010-12-31||Interventional|||Etoricoxib in Acute Ankle Ligament Sprains|The Efficacy and Safety of Administration of the COX-2 Selective NSAID, Etoricoxib (120mg od. for 7 Days) Compared to Diclofenac (50 mg Tds. for 7 Days) and Placebo as Adjunct Treatment in the First 7 Days of Treatment of Acute Grade II Lateral Ankle Ligaments Sprains: A Clinical Trial|Withdrawn||Phase 4|0|Actual|University of Cape Town||3||The study was terminated by Merck USA. The company did not supply drugs for the study.|f||||t||||||||||2018-06-01 00:42:39.035375|2018-06-01 00:42:39.035375
NCT00954772|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-11-30|2009-08-06|2009-08-07|Estimate|||||||2011-11-30|2011-12-02|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|MOST||Mood and Subthalamic Nucleus (STN) Deep Brain Stimulation|Mood and STN Deep Brain Stimulation|Completed|||91|Actual|University of Florida|||2||f||||f||||||||||2018-06-01 00:42:39.16004|2018-06-01 00:42:39.16004
NCT00954759|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2012-11-06|2009-08-06|2009-08-07|Estimate|||||||2012-11-06|2012-11-07|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect of Chiropractic Treatment on Infantile Colic A Randomized, Controlled Trial|The Effect of Chiropractic Treatment on Infantile Colic A Randomized, Controlled Trial|Terminated||N/A|29|Actual|Nordic Institute of Chiropractic and Clinical Biomechanics||2||Abandoned due to poor recruitment|f||||f||||||||||2018-06-01 00:42:39.230712|2018-06-01 00:42:39.230712
NCT00954746|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2015-06-12|2009-08-06|2009-08-07|Estimate|||||||2015-06-12|2015-06-16|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859|CORDLESS- Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study|Completed|||645|Actual|Endo Pharmaceuticals|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:42:39.324794|2018-06-01 00:42:39.324794
NCT00954733|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2014-06-25||2014-06-25|2009-08-06|2009-08-07|Estimate|2014-06-25|2014-07-24|Estimate||||2014-06-25|2014-07-24|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||42 possible participants between 18-65 years of age were approached to participate in the study . 40 gave written informed consent.|A Comparison of the Detection of Hypoventilation During Deep Sedation Utilizing Nasal End Title CO@ Versus Transcutaneous CO2 Measurement Techniques|A Comparison of the Detection of Hypoventilation During Deep Sedation Utilizing Nasal End Title CO@ Versus Transcutaneous CO2 Measurement Techniques|Completed||N/A|40|Actual|Northwestern University|We only included healthy, female subjects without significant co-morbidities which limit our ability to generalize our findings to elderly and sicker patients who bay benefit the most from this monitoring.|1|||f||||f||||||||||2018-06-01 00:42:39.458519|2018-06-01 00:42:39.458519
NCT00954720|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2013-02-26|2009-08-06|2009-08-07|Estimate|||||||2013-02-26|2013-02-28|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Observational|||Observational Study of Iron Overload in Stem Cell Transplantation|A Prospective Observational Study of Iron Overload in Patients With Acute Leukemia or Myelodysplastic Syndromes Undergoing Myeloablative Allogeneic Stem Cell Transplantation|Completed|||45|Actual|Dana-Farber Cancer Institute|||1||f||||f||||||Samples With DNA|"~     Banked serum and mononuclear cells~   "|||2018-06-01 00:42:39.622992|2018-06-01 00:42:39.622992
NCT00954707|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2013-04-26||2014-01-13|2009-08-06|2009-08-07|Estimate|2013-07-29|2013-10-09|Estimate||||2014-01-13|2014-02-07|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|March 2016|Anticipated|2016-03-31|January 2012|Actual|2012-01-31||Interventional||Enrolled subjects were those who signed the informed consent and had met all of the inclusion and none of the exclusion criteria, and the target lesion had been successfully crossed with the intracoronary guidewire which was positioned intraluminally in the distal vessel. Enrolled subjects were also Intent to Treat (ITT).|CYPRESS - CYPHER for Evaluating Sustained Safety|A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent)|Unknown status|Active, not recruiting|Phase 4|2509|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 00:42:39.738354|2018-06-01 00:42:39.738354
NCT00954694|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-06|2009-08-06|2009-08-07|Estimate|||||||2009-08-06|2009-08-07|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Analysis of the NuStep as an Introductory Fitness Regimen|Assessing the Impact of an Introductory Exercise Regimen: An Analysis of the Consequent Effects of NuStep in Relation to Physical Activity and Lifestyle Adjustment in Adults With Type 1 and Type 2 Diabetes|Unknown status|Not yet recruiting|N/A|30|Anticipated|University of Nebraska||1|||f||||f||||||||||2018-06-01 00:42:40.169691|2018-06-01 00:42:40.169691
NCT00954681|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2017-08-07||2017-08-07|2009-08-06|2009-08-07|Estimate|2017-08-07|2017-09-06|Actual||||2017-08-07|2017-09-06|Actual|August 2009||2009-08-31|August 2017|2017-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|STUC||Study of Quetiapine Treatment for Cannabis Dependence|Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence|Completed||Phase 2|15|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-06-01 00:42:40.243625|2018-06-01 00:42:40.243625
NCT00954668|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2010-06-24|2009-08-06|2009-08-07|Estimate|||||||2010-06-24|2010-06-25|Estimate||||September 2009|2009-09-30||||||||Interventional|IDEAL NSTEMI||ImmeDiate Versus EArLy Invasive Approach in Non-ST-Elevation Myocardial Infarction (IDEAL NSTEMI)|ImmeDiate Versus EArLy Invasive Approach in Non-ST-Elevation Myocardial Infarction (IDEAL NSTEMI)|Withdrawn||Phase 4|2100|Anticipated|University of Leipzig||2||No funding|f||||t||||||||||2018-06-01 00:42:40.479978|2018-06-01 00:42:40.479978
NCT00954655|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-08-07|2009-08-06|2009-08-07|Estimate|||||||2017-08-07|2017-08-08|Actual|December 2008||2008-12-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001|Genetic Risk Factors for Gastrointestinal Stromal Tumors (GIST)|Recruiting|||374|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||||||||||||2018-06-01 00:42:40.558186|2018-06-01 00:42:40.558186
NCT00954642|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2017-05-15|2009-08-05|2009-08-07|Estimate|||||||2017-05-15|2017-05-17|Actual|August 2009|Actual|2009-08-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|24|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 00:42:40.654709|2018-06-01 00:42:40.654709
NCT00954629|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2010-03-22|2009-08-06|2009-08-07|Estimate|||||||2010-03-22|2010-03-24|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||A Study of the Efficacy and Safety of 2PX in Patients With Pain Due to Osteoarthritis of the Knee|A 26 Week Placebo-controlled, Randomised, Double-blind, Parallel Group Study of the Efficacy and Safety of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Pain Due to Osteoarthritis of the Knee|Unknown status|Recruiting|Phase 3|300|Anticipated|Smerud Medical Research International AS||2|||f||||f||||||||||2018-06-01 00:42:40.744875|2018-06-01 00:42:40.744875
NCT00954616|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2014-03-19|2009-08-05|2009-08-07|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Observational|MIDA||Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly|Inappropriate Medications and Alzheimer Disease: Prevalence and Associated Factors in Elderly Patients Treated With Anticholinesterase and/or Memantine. MIDA Study.|Completed|||636|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 00:42:40.851287|2018-06-01 00:42:40.851287
NCT00954603|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2011-06-22|2009-08-06|2009-08-07|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|July 2012|Anticipated|2012-07-31|April 2011|Actual|2011-04-30||Interventional|QHdelirium||A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium|Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium|Terminated||Phase 3|52|Actual|Chiang Mai University||2||few delirious patients were enrolled.|f||||t||||||||||2018-06-01 00:42:40.921427|2018-06-01 00:42:40.921427
NCT00954590|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06||2016-09-24|2016-09-24|2009-08-06|2009-08-07|Estimate||||2016-09-24|2016-09-27|Estimate|2016-09-24|2016-09-27|Estimate|October 2009||2009-10-31|September 2016|2016-09-30||||August 2010|Actual|2010-08-31||Interventional|CONTACT||A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease|CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease|Terminated||Phase 3|89|Actual|Medivation, Inc.||2|||f||||t||||||||||2018-06-01 00:42:41.01631|2018-06-01 00:42:41.01631
NCT00954577|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-06|2009-08-06|2009-08-07|Estimate|||||||2009-08-06|2009-08-07|Estimate|July 2006||2006-07-31|August 2009|2009-08-31|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Observational|ROAD||Reduce Obesity and Diabetes|The Pathogenesis of Type 2 Diabetes in Children and Utility of a School-based Intervention to Reduce Obesity and Diabetes in Children|Unknown status|Recruiting||1000|Anticipated|Academy for Medical Development and Collaboration, New York|||||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 00:42:41.104538|2018-06-01 00:42:41.104538
NCT00954018|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2017-07-31|2009-08-05|2009-08-06|Estimate|||||||2017-07-31|2017-08-02|Actual|August 2009||2009-08-31|July 2017|2017-07-31||||||||Observational|||Microbial Community Composition and Metabolism in Cystic Fibrosis|Respiratory Microbial Community Composition and Metabolism in Cystic Fibrosis|Recruiting|||120|Anticipated|Boston Children’s Hospital|||3||f||||f||||||Samples Without DNA|"~     throat swabs or sputum~   "|||2018-06-01 00:42:50.310032|2018-06-01 00:42:50.310032
NCT00954564|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2017-03-30|2009-08-06|2009-08-07|Estimate|||||||2017-03-30|2017-04-04|Actual|June 2009||2009-06-30|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors|Arthralgia and Medication Adherence in Women With Early Stage Breast Cancer Taking Aromatase Inhibitors: The Breast Cancer Adjuvant Therapy (BCAT) Longitudinal Cohort Study.|Completed|||351|Actual|Vanderbilt University Medical Center|||||f||||f||||||||||2018-06-01 00:42:41.198227|2018-06-01 00:42:41.198227
NCT00954551|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-06-06|2009-08-06|2009-08-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Serum Procalcitonin|Utility of Serum Procalcitonin Levels to Distinguish Systemic Inflammatory Response From Systemic Infection in Febrile Subarachnoid Hemorrhage Patients|Completed|||40|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 00:42:41.290233|2018-06-01 00:42:41.290233
NCT00954538|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2013-12-18||2015-11-02|2009-08-06|2009-08-07|Estimate|2013-12-18|2014-02-05|Estimate||||2015-11-02|2015-11-03|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)|A Three Part Study to Evaluate the Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK-3328, a Radiotracer for Use in Positron Emission Tomography|Completed||Phase 1|19|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 00:42:41.471064|2018-06-01 00:42:41.471064
NCT00954525|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2012-01-17|2009-08-05|2009-08-07|Estimate|||||||2012-01-17|2012-01-18|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer|Phase I, Open Label, Dose Escalating Study of Intravenous Ascorbic Acid in Combination With Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer|Completed||Phase 1|14|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 00:42:41.74867|2018-06-01 00:42:41.74867
NCT00954512|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2015-11-18||2017-05-16|2009-08-05|2009-08-07|Estimate|2015-11-18|2015-12-22|Estimate||||2017-05-16|2017-06-14|Actual|September 25, 2009|Actual|2009-09-25|May 2017|2017-05-31|June 7, 2011|Actual|2011-06-07|June 7, 2011|Actual|2011-06-07||Interventional|||Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)|A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722)|Terminated||Phase 1/Phase 2|15|Actual|Merck Sharp & Dohme Corp.||6||This study was terminated for business reasons.|f||||f||||||||||2018-06-01 00:42:41.8368|2018-06-01 00:42:41.8368
NCT00954499|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-02-28|2009-08-05|2009-08-07|Estimate|||||||2011-02-28|2011-03-01|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Reducing Pain in Four- to Six-month Old Infants Undergoing Immunization Using a Multi-modal Approach|Reducing Pain in Four- to Six-month Old Infants Undergoing Immunization Using a Multi-modal Approach|Completed||N/A|120|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-06-01 00:42:42.539427|2018-06-01 00:42:42.539427
NCT00954486|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2016-03-23|2009-08-06|2009-08-07|Estimate|||||||2016-03-23|2016-03-24|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia|An Open-Label, Single-Arm Pilot Study of the Efficacy of Erythropoietin Alfa in Improving Peak Oxygen Consumption in Elderly Subjects With Unexplained Anemia|Withdrawn||N/A|0|Actual|Stanford University||1||Difficulty in identifying interested subjects.|f||||f||||||||No||2018-06-01 00:42:42.614895|2018-06-01 00:42:42.614895
NCT00954473|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-05-17|2009-08-06|2009-08-07|Estimate|||||||2016-05-17|2016-05-19|Estimate|January 2009||2009-01-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Study of Blood Samples From Patients With Osteosarcoma|Retrospective Study of Genetic Risk Factors for Osteosarcoma|Completed|||1000|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 00:42:42.681378|2018-06-01 00:42:42.681378
NCT00954460|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2014-02-19|2009-08-06|2009-08-07|Estimate|||||||2014-02-19|2014-02-21|Estimate||||February 2014|2014-02-28||||||||Expanded Access|||Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease|Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease|Approved for marketing|||||Shire|||||||||||||||||||2018-06-01 00:42:42.827074|2018-06-01 00:42:42.827074
NCT00954447|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2012-08-28||2013-12-04|2009-08-06|2009-08-07|Estimate|2012-08-28|2012-09-27|Estimate||||2013-12-04|2013-12-30|Estimate|August 2009||2009-08-31|October 2012|2012-10-31||||September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy|Completed||Phase 3|1263|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:42:42.961706|2018-06-01 00:42:42.961706
NCT00954434|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2016-05-16|2009-08-06|2009-08-07|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effects of Red Wine on Cardiovascular Risk Factors in Humans||Completed||Phase 1/Phase 2|44|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-06-01 00:42:44.045271|2018-06-01 00:42:44.045271
NCT00954421|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2014-04-15||2014-07-21|2009-08-05|2009-08-07|Estimate|2014-06-25|2014-06-27|Estimate||||2014-07-21|2014-07-25|Estimate|November 2006||2006-11-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||Use of Two Deep Brain Stimulation (DBS) Electrodes to Treat Post-Traumatic Tremor|Use of Two DBS Electrodes to Treat Post-Traumatic Tremor|Completed||N/A|16|Actual|University of Florida||1|||f||||t||||||||||2018-06-01 00:42:44.115311|2018-06-01 00:42:44.115311
NCT00954408|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-09-16|2009-08-06|2009-08-07|Estimate|||||||2011-09-16|2011-09-19|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|FID||Fatigue in Dystonia (a Single Session, Questionnaire-based Study of Fatigue in Dystonia)|Fatigue in Dystonia (IRB No. 108-2008)|Completed|||123|Actual|University of Florida|||1||f||||f||||||||||2018-06-01 00:42:44.340077|2018-06-01 00:42:44.340077
NCT00954395|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2012-08-31|2009-08-06|2009-08-07|Estimate|||||||2012-08-31|2012-09-05|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Observational|DULCIS||DULCIS (D-dimer and ULtrasonography in Combination Italian Study)|Optimizing the Duration of Anticoagulation in Venous Thromboembolism: the DULCIS Study|Completed|||1100|Actual|St. Orsola Hospital|||2||f||||t||||||Samples With DNA|"~     platelet poor plasma and whole blood for Dna~   "|||2018-06-01 00:42:44.398704|2018-06-01 00:42:44.398704
NCT00954382|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-03-16|2009-08-06|2009-08-07|Estimate|||||||2010-03-16|2010-03-18|Estimate|May 2009||2009-05-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Observational|||Trends in Intellectual Development in Down Syndrome|Trends in Intellectual Development, and Diverging Verbal and Non-verbal Abilities in the Down Syndrome Phenotype|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 00:42:44.471965|2018-06-01 00:42:44.471965
NCT00954369|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-08-21|2009-08-06|2009-08-07|Estimate|||||||2012-08-21|2012-08-22|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Exploratory and Safety Study of [F-18]W372|A Phase 0, Open Label, Non-randomized, Multi-center, Exploratory and Safety Study of [F-18]W372|Completed||Early Phase 1|24|Actual|Siemens Molecular Imaging||1|||f||||f||||||||||2018-06-01 00:42:44.549847|2018-06-01 00:42:44.549847
NCT00954356|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2012-01-31||2012-07-10|2009-08-05|2009-08-07|Estimate|2012-05-28|2012-06-29|Estimate||||2012-07-10|2012-07-16|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction|Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Safety, PK, & Efficacy of a Single Oral Dose of XPF-001 in the Treatment of Pain Related to Third Molar/Wisdom Tooth Extraction.|Completed||Phase 2|61|Actual|Xenon Pharmaceuticals Inc.|This model is best suited for drugs with rapid onset of action (e.g. NSAIDs). XPF-001 does not have a rapid onset.|2|||f||||f||||||||||2018-06-01 00:42:44.630046|2018-06-01 00:42:44.630046
NCT00954343|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2013-03-18|2009-08-06|2009-08-07|Estimate|||||||2013-03-18|2013-03-19|Estimate|August 2009||2009-08-31|March 2013|2013-03-31||||||||Interventional|STUF||Shockwave Treatment of Diabetic Foot Ulcer: Step I|Shockwave Treatment of Diabetic Foot Ulcer. A Prospective, Controlled, Randomized Trial. Step 1|Withdrawn||N/A|0|Actual|Technische Universität München||5|||f||||f||||||||||2018-06-01 00:42:45.025819|2018-06-01 00:42:45.025819
NCT00954330|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-08-06|2009-08-06|2009-08-07|Estimate|||||||2009-08-06|2009-08-07|Estimate|February 1991||1991-02-28|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Surgical Versus Functional Treatment for Acute Ruptures of the Lateral Ligament Complex of the Ankle in Young Males - A Randomized Controlled Trial With a Mean of 14 Years Follow-up|Surgical Versus Functional Treatment for Acute Ruptures of the Lateral Ligament Complex of the Ankle in Young Males - A Randomized Controlled Trial With a Mean of 14 Years Follow-up|Completed||N/A|51|Actual|Finnish Defense Forces||2|||f||||f||||||||||2018-06-01 00:42:45.11493|2018-06-01 00:42:45.11493
NCT00954317|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-11-29|2009-08-06|2009-08-07|Estimate|||||||2012-11-29|2012-11-30|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Do Epidurals Placed at a Lower Level Improve Labor Analgesia?|Do Epidurals Placed at a Lower Level Improve Labour Analgesia|Unknown status|Recruiting|N/A|100|Anticipated|Royal Victoria Hospital, Canada||2|||f||||f||||||||||2018-06-01 00:42:45.197419|2018-06-01 00:42:45.197419
NCT00954304|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2010-09-10|2009-08-06|2009-08-07|Estimate|||||||2010-09-10|2010-09-13|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|PGP inhibitor||Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet|Clinical Trial to Investigate the Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet in Healthy Male Subjects : An Open, Parallel Dose Group Design|Completed||Phase 1|30|Anticipated|Hanmi Pharmaceutical Company Limited||5|||f||||f||||||||||2018-06-01 00:42:45.318866|2018-06-01 00:42:45.318866
NCT00954291|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2010-09-03|2009-08-06|2009-08-07|Estimate|||||||2010-09-03|2010-09-06|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Observational|Granisetron||An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects|An Open-label, Single Dose Pharmacokinetic Study of 14 mg Granisetron Patch in Healthy Subjects|Unknown status|Recruiting||8|Anticipated|Taipei Medical University WanFang Hospital|||1||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 00:42:45.424477|2018-06-01 00:42:45.424477
NCT00954278|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2018-02-08|2009-08-06|2009-08-07|Estimate|||||||2018-02-08|2018-02-09|Actual|July 2009||2009-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer|A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|24|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 00:42:45.573752|2018-06-01 00:42:45.573752
NCT00954265|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-12-23|2009-08-06|2009-08-07|Estimate|||||||2009-12-23|2009-12-24|Estimate|August 2005||2005-08-31|August 2009|2009-08-31|September 2010|Anticipated|2010-09-30|December 2007|Anticipated|2007-12-31||Interventional|||Pregnancy Rates in IVF After Ovulation Triggering With Recombinant or Urinary Human Chorionic Gonadotrophin (HCG)|Phase III Study on the Effects of Recombinant HCG Ovulation Triggering on Stimulation, Embryonic and Pregnancy Parameters in an IVF Program|Unknown status|Active, not recruiting|Phase 3|130|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-06-01 00:42:45.684049|2018-06-01 00:42:45.684049
NCT00954252|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2015-02-09|2009-08-06|2009-08-07|Estimate|||||||2015-02-09|2015-02-10|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|CT01||Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects|Completed||Phase 1|84|Actual|CERESPIR||2|||f||||t||||||||||2018-06-01 00:42:45.763293|2018-06-01 00:42:45.763293
NCT00954226|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2018-05-01|2009-08-06|2009-08-07|Estimate|||||||2018-05-01|2018-05-03|Actual|August 2009|Actual|2009-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Erlotinib Prior to Surgery in Patients With Head and Neck Cancer|Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer|Active, not recruiting||Phase 1|55|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 00:42:46.011326|2018-06-01 00:42:46.011326
NCT00954213|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2010-07-22|2009-08-06|2009-08-07|Estimate|||||||2010-07-22|2010-07-26|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|DIR||A Study of a Developmental,Individual-Difference,Relationship-Bases/Floortime Intervention for Children With Autistic|A One-year Prospective Follow-up Study of a DIR/ Floortime Parent Training Intervention for Pre-school Children With Autistic Spectrum Disorders|Completed||N/A|40|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 00:42:46.337425|2018-06-01 00:42:46.337425
NCT00954200|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-26|||2011-07-24|2009-08-06|2009-08-07|Estimate|||||||2011-07-24|2011-07-26|Estimate||||July 2009|2009-07-31||||||||Interventional|||Ibuprofen as a Possible Preventer of Post Bronchoscopy Fever|Ibuprofen as a Possible Preventer of Post Bronchoscopy Fever|Unknown status|Recruiting|Phase 2|50|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-06-01 00:42:46.417196|2018-06-01 00:42:46.417196
NCT00954187|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2014-09-18||2016-11-18|2009-08-06|2009-08-07|Estimate|2014-09-18|2014-09-25|Estimate||||2016-11-18|2017-01-09|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional||No subjects were randomized and assigned treatment so Baseline Characteristics were not collected|Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy|Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.|Terminated||N/A|8|Actual|Loma Linda University||2||PI left institution|f||||f||||||||||2018-06-01 00:42:46.50376|2018-06-01 00:42:46.50376
NCT00954174|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2018-01-09|2009-08-06|2009-08-07|Estimate|||||||2018-01-09|2018-01-10|Actual|August 17, 2009|Actual|2009-08-17|August 2017|2017-08-31||||November 1, 2018|Anticipated|2018-11-01||Interventional|||Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer|A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary|Active, not recruiting||Phase 3|603|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 00:42:46.79387|2018-06-01 00:42:46.79387
NCT00954161|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2011-05-02|2009-08-06|2009-08-07|Estimate|||||||2011-05-02|2011-05-03|Estimate|September 2009||2009-09-30|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bystander Helping Behaviour for Myocardial Infarction Following First Aid Training|Bystander Helping Behaviour for Acute Myocardial Infarction Following a First Aid Training Programme That Draws Attention to the Barriers to Providing Help - Protocol for a Randomized Controlled Trial|Completed||N/A|144|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 00:42:48.369132|2018-06-01 00:42:48.369132
NCT00954148|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-06-29|2009-08-06|2009-08-07|Estimate|||||||2010-06-29|2010-06-30|Estimate|September 2009||2009-09-30|May 2010|2010-05-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors|Defining the Utility of PET/CT in the Follow-up of Patients With Solid Tumors|Terminated||N/A|53|Actual|Dallas VA Medical Center||2||1st years Enrollment #s showed study was not going to meet criteria randomization.|f||||f||||||||||2018-06-01 00:42:48.444204|2018-06-01 00:42:48.444204
NCT00954135|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2009-08-06|2009-08-06|2009-08-07|Estimate|||||||2009-08-06|2009-08-07|Estimate|September 2007||2007-09-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients|Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 2|190|Anticipated|University of Turin, Italy||2|||f||||t||||||||||2018-06-01 00:42:48.516102|2018-06-01 00:42:48.516102
NCT00954122|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|2011-05-18||2013-01-07|2009-08-06|2009-08-07|Estimate|2013-01-07|2013-01-08|Estimate||||2013-01-07|2013-01-08|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia|A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia|Completed||Phase 4|35|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:42:48.607342|2018-06-01 00:42:48.607342
NCT00954109|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2015-01-08||2015-04-03|2009-08-05|2009-08-07|Estimate|2015-04-03|2015-04-06|Estimate||||2015-04-03|2015-04-06|Estimate|August 2009||2009-08-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Acute Cardiovascular and Metabolic Effects of Exercise Training in Individuals With Insulin Resistance|Physical Inactivity and Insulin Resistance in Skeletal Muscle|Completed||N/A|11|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 00:42:48.804091|2018-06-01 00:42:48.804091
NCT00954096|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-10-23|2009-08-05|2009-08-06|Estimate|||||||2009-10-23|2009-10-27|Estimate|October 2002||2002-10-31|October 2009|2009-10-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Nicotine Patch, Blood Flow and Oxidative Stress Study|The Effect Of Nicotine On Indices Of Arterial Function And Oxidative Stress|Completed||N/A|55|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-06-01 00:42:49.783326|2018-06-01 00:42:49.783326
NCT00954083|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|June 2007||2007-06-30|August 2009|2009-08-31|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional|DIR||A Pilot Trial of a Developmental, Individual-Difference, Relationship-Bases (DIR)/Floortime for Children With Autistic Spectrum Disorders|A Pilot Randomized Controlled Trial of a DIR/ Floortime Parent Training Intervention for Pre-school Children With Autistic Spectrum Disorders|Completed||N/A|32|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 00:42:49.851273|2018-06-01 00:42:49.851273
NCT00954070|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-12-26|2009-08-05|2009-08-06|Estimate|||||||2012-12-26|2012-12-28|Estimate|August 2009||2009-08-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Detection of Minimal Change Esophagitis Using Confocal Laser Endomicroscopy|Detection of Minimal Change Esophagitis Using Confocal Laser Endomicroscopy|Terminated|||6|Actual|National University Hospital, Singapore|||2|Difficulty in recruiting subjects for study|f||||f||||||||||2018-06-01 00:42:49.912353|2018-06-01 00:42:49.912353
NCT00954057|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04||2015-03-05|2015-03-05|2009-08-05|2009-08-06|Estimate||||2015-03-05|2015-03-26|Estimate|2015-03-05|2015-03-26|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED)|A Single-masked, Placebo Controlled, Multi-center Pilot Study to Determine the Safety and Efficacy of Orbital Injections of a Fixed Dose of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease|Completed||Phase 2|11|Actual|Neothetics, Inc||2|||f||||f||||||||||2018-06-01 00:42:49.987434|2018-06-01 00:42:49.987434
NCT00954044|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2014-04-10|2009-08-05|2009-08-06|Estimate|||||||2014-04-10|2014-04-11|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses|Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses|Completed||N/A|128|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 00:42:50.07616|2018-06-01 00:42:50.07616
NCT00954031|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2013-01-30|2009-08-05|2009-08-06|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|APA||Impact of Anti-inflammatory and Antibiotic Therapy on the Emergence of Peri-tonsillar Abscess|Impact of Anti-inflammatory and Antibiotic Therapy on the Emergence of Peri-tonsillar Abscess|Terminated|||711|Anticipated|Nantes University Hospital|||2||f||||f||||||||||2018-06-01 00:42:50.144555|2018-06-01 00:42:50.144555
NCT00954005|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2015-08-17|2009-08-04|2009-08-06|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2003||2003-01-31|August 2015|2015-08-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|R-GO||Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma|Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma|Terminated||Phase 1/Phase 2|56|Actual|German Low Grade Lymphoma Study Group||1||Predefined termination criterion of > 10 patients without CR or PR was matched.|f||||f||||||||||2018-06-01 00:42:50.381082|2018-06-01 00:42:50.381082
NCT00953992|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2017-08-30|2009-08-05|2009-08-06|Estimate|||||||2017-08-30|2017-08-31|Actual|April 2009||2009-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Etiology, Epidemiology and Prognostics of Acute Kidney Injury (AKI)|The Study of Etiology, Epidemiology and Prognostic Factors of Acute Kidney Injury|Recruiting|||600|Anticipated|Huashan Hospital|||||f||||t||||||Samples Without DNA|"~     1ml whole blood and 1ml serum will obtained within 24 hour after AKI for hematological and~     biochemistry analyze.~   "|||2018-06-01 00:42:50.460224|2018-06-01 00:42:50.460224
NCT00953979|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-01-18|2009-08-05|2009-08-06|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis|A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial|Completed||Phase 4|126|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 00:42:50.533384|2018-06-01 00:42:50.533384
NCT00953966|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-24|2009-08-05|2009-08-06|Estimate|||||||2009-08-24|2009-08-25|Estimate|June 2007||2007-06-30|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Metabolic Changes Induced by Genetically Modified Potatoes||Unknown status|Recruiting|N/A|50|Anticipated|Charite University, Berlin, Germany||7|||f||||f||||||||||2018-06-01 00:42:50.606933|2018-06-01 00:42:50.606933
NCT00953953|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-01-25|2009-08-05|2009-08-06|Estimate|||||||2012-01-25|2012-01-26|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Study of Left Ventricular Dyssynchrony in Heart Failure Patients|Study of the Phenomenon of Dynamic Left Ventricular Dyssynchrony in Heart Failure Patients and Its Clinical Significance.|Completed|||16|Actual|Albert Einstein Healthcare Network|||4||f||||f||||||||||2018-06-01 00:42:50.689162|2018-06-01 00:42:50.689162
NCT00953940|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2011-06-30|2009-08-05|2009-08-06|Estimate|||||||2011-06-30|2011-07-04|Estimate|June 2005||2005-06-30|August 2009|2009-08-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Prevention of Perioperative Acute Renal Failure|Prevention of Perioperative Acute Renal Failure in Abdominal Surgery|Terminated||Phase 4|600|Anticipated|Hospital Universitario Ramon y Cajal||2||An external board recommended to close the study for futility after the interin analysis|f||||f||||||||||2018-06-01 00:42:50.761427|2018-06-01 00:42:50.761427
NCT00953927|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2013-10-23||2016-04-25|2009-08-04|2009-08-06|Estimate|2013-10-23|2013-12-12|Estimate||||2016-04-25|2016-05-24|Estimate|July 2009||2009-07-31|April 2016|2016-04-30||||October 2012|Actual|2012-10-31||Interventional||Intent to treat population|A Study of MVA85A in Healthy Infants|Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants|Completed||Phase 2|2797|Actual|Aeras||2|||f||||t||||||||||2018-06-01 00:42:50.849586|2018-06-01 00:42:50.849586
NCT00953914|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2011-07-06|2009-08-05|2009-08-06|Estimate|||||||2011-07-06|2011-07-07|Estimate|March 2005||2005-03-31|July 2011|2011-07-31|May 2010|Actual|2010-05-31|July 2009|Actual|2009-07-31||Interventional|||Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients|Pyridostigmine and Its Effects on Autonomic Modulation in Diabetic Patients With Autonomic Neuropathy|Completed||N/A|40|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:42:51.306696|2018-06-01 00:42:51.306696
NCT00953901|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2009-11-13|2009-08-05|2009-08-06|Estimate|||||||2009-11-13|2009-11-16|Estimate|July 2006||2006-07-31|November 2009|2009-11-30|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Is Plasma Transfusion Beneficial Prior to Low-Risk Procedures in Hospitalized Patients With Blood Clotting Abnormalities?|Restrictive Versus Liberal Fresh Frozen Plasma Transfusion Prior to Low-Risk Invasive Procedures in Hospitalized Patients.|Completed||Phase 3|2|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 00:42:51.404097|2018-06-01 00:42:51.404097
NCT00953888|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2015-06-24|2009-08-05|2009-08-06|Estimate|||||||2015-06-24|2015-06-25|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 After Single Ascending Doses in Healthy Male and/or Female Subjects|Completed||Phase 1|203|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 00:42:51.547244|2018-06-01 00:42:51.547244
NCT00953862|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2013-04-11||2016-03-07|2009-08-05|2009-08-06|Estimate|2016-03-07|2016-03-28|Estimate||||2016-03-07|2016-03-28|Estimate|July 2005||2005-07-31|March 2016|2016-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||This number is the total number who were found eligible for the treatment.|Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility|Efficacy of Atomoxetine in Adults With ADHD and Substance Abuse Disorder Being Treated in a Residential Treatment Facility|Completed||N/A|18|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-06-01 00:42:51.666831|2018-06-01 00:42:51.666831
NCT00953849|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2016-09-06||2017-01-23|2009-08-05|2009-08-06|Estimate|2016-10-27|2016-12-21|Estimate||||2017-01-23|2017-03-07|Actual|November 2009||2009-11-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity|Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity|Completed||Phase 1/Phase 2|21|Actual|VA Office of Research and Development|Difficulty in recruiting subjects that are eligible for the combination Celecoxib + Calcitriol treatment.|4|||f||||t||||||||Yes|Publication of deidentified results.|2018-06-01 00:42:51.866478|2018-06-01 00:42:51.866478
NCT00953836|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Observational|Rye-kinetics||Plasma Pharmacokinetics of Alkylresorcinol Metabolites; New Candidate Biomarkers for Whole Grain Rye and Wheat Intake|Kinetic Study of Two Known Alkylresorcinol Metabolites in Human Subjects After the Intake of Rye Fiber, the Most Abundant Source of Alkylresorcinols in Diet.|Completed|||15|Actual|Helsinki University|||||f||||||||||||||2018-06-01 00:42:52.339592|2018-06-01 00:42:52.339592
NCT00953823|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2012-12-21|2009-08-05|2009-08-06|Estimate|||||||2012-12-21|2012-12-24|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||The Prevalence of Thiamin Deficiency in Ambulatory Patients With Heart Failure|The Prevalence of Thiamin Deficiency in Ambulatory Patients With Heart Failure|Completed|||110|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||Samples Without DNA|"~     Blood test~   "|||2018-06-01 00:42:52.392101|2018-06-01 00:42:52.392101
NCT00953810|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|April 2004||2004-04-30|August 2009|2009-08-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|ZOPAN||Educational Intervention in Heart Failure Patients|RandomiZed AmbulatOry Interventional ProgrAm in Heart Failure PatieNts (ZOPAN)|Completed||N/A|822|Actual|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-06-01 00:42:52.464757|2018-06-01 00:42:52.464757
NCT00953797|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-01-25|2009-08-05|2009-08-06|Estimate|||||||2012-01-25|2012-01-26|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|EECP||Role of Enhanced External Counterpulsation (EECP) Therapy in Patients With Resistant Hypertension|Role of EECP Therapy in Patients With Resistant Hypertension|Withdrawn||N/A|0|Actual|Albert Einstein Healthcare Network|||||f||||f||||||||||2018-06-01 00:42:52.547|2018-06-01 00:42:52.547
NCT00953784|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-06-29|2009-08-05|2009-08-06|Estimate|||||||2010-06-29|2010-06-30|Estimate|April 2007||2007-04-30|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery|Minimization of Surgical Site Infections for Pts Undergoing Colorectal Surgery|Completed||N/A|197|Actual|Dallas VA Medical Center||2|||f||||f||||||||||2018-06-01 00:42:52.607824|2018-06-01 00:42:52.607824
NCT00953771|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2017-04-19|2009-08-05|2009-08-06|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2008||2008-10-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TTP||Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)|Phase II Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura|Recruiting||Phase 2|25|Anticipated|Beth Israel Medical Center||1|||f||||f||||||||||2018-06-01 00:42:52.709508|2018-06-01 00:42:52.709508
NCT00953758|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2013-12-08|2009-08-05|2009-08-06|Estimate|||||||2013-12-08|2013-12-10|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||A Study Of PF-04449913 In Select Hematologic Malignancies|A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies|Completed||Phase 1|47|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:42:52.806628|2018-06-01 00:42:52.806628
NCT00953745|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2016-01-20||2018-04-17|2009-08-05|2009-08-06|Estimate|2018-04-17|2018-04-19|Actual||||2018-04-17|2018-04-19|Actual|May 2009||2009-05-31|April 2018|2018-04-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression|Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression: A Raclopride/F-DOPA Positron Emission Tomography and Functional MRI Study|Completed||N/A|43|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 00:42:52.913921|2018-06-01 00:42:52.913921
NCT00953732|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2015-03-25|2009-08-05|2009-08-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies|A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on the Head (Face or Scalp) Who Have Completed Day 57 in Studies PEP005-016 or PEP005-025 (REGION IIa and IIb)|Completed|||117|Actual|Peplin|||1||f||||f||||||||||2018-06-01 00:42:53.204381|2018-06-01 00:42:53.204381
NCT00953719|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2014-05-13||2018-04-09|2009-08-05|2009-08-06|Estimate|2014-08-19|2014-08-29|Estimate||||2018-04-09|2018-05-08|Actual|April 1, 2003|Actual|2003-04-01|February 2018|2018-02-28|July 1, 2013|Actual|2013-07-01|August 1, 2008|Actual|2008-08-01||Interventional||The baseline analysis population consists of all enrolled subjects who were implanted with either the investigational or control device. One subject who was randomized to receive the investigational device was exlcuded because of an intra-operative ceramic liner fracture, and hence did not receive the investigational device.|36 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement|Delta Ceramax 36 mm Ceramic-on-Ceramic Acetabular Cup Prosthesis Study|Completed||N/A|243|Actual|DePuy Orthopaedics|At study inception, information on whether or not an adverse event was deemed to be serious was not collected. Because of this caveat, the Sponsor has reported all adverse events that occurred in this study.|2|||f||||f||||||||||2018-06-01 00:42:53.442324|2018-06-01 00:42:53.442324
NCT00953706|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2012-02-27|2011-09-21|2015-08-27|2009-08-05|2009-08-06|Estimate|2012-07-18|2012-08-21|Estimate|2011-09-21|2011-09-26|Estimate|2015-08-27|2015-09-11|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|May 2013|Actual|2013-05-31|July 2010|Actual|2010-07-31||Interventional|DISCOVER||Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation|Terminated||Phase 2|140|Actual|Vertex Pharmaceuticals Incorporated|In Part B, the treatment duration was 96 weeks; however, due to early study termination all analysis were performed up to Week 64, as planned.|2||"Following review of results obtained from a pre-specified 6-month analysis of Part B data the~   study was terminated on the basis of futility."|f||||t||||||||||2018-06-01 00:42:54.009263|2018-06-01 00:42:54.009263
NCT00953693|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2012-12-25|2009-08-05|2009-08-06|Estimate|||||||2012-12-25|2012-12-27|Estimate|April 2009||2009-04-30|April 2010|2010-04-30|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Observational|||Patient Specific Induced Pluripotency Stem Cells (PSiPS)|Patient Specific Induced Pluripotency Stem Cells (PSiPS)|Completed|||15|Anticipated|Royan Institute|||||f||||t||||||||||2018-06-01 00:42:55.680331|2018-06-01 00:42:55.680331
NCT00953680|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2010-05-13||2016-01-21|2009-08-04|2009-08-06|Estimate|2010-06-17|2010-07-16|Estimate||||2016-01-21|2016-01-22|Estimate|April 2004||2004-04-30|January 2016|2016-01-31|July 2004|Actual|2004-07-31|May 2004|Actual|2004-05-31||Interventional|||Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)|An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence After Administration of a Losartan 100-mg/Hydrochlorothiazide 12.5-mg Combination Tablet and the Coadministration of a Currently Marketed COZAAR™ 100-mg Tablet and MICROZIDE™ 12.5 mg Capsule in Healthy Adults|Completed||Phase 1|77|Actual|Merck Sharp & Dohme Corp.|PK analyses included complete data from 75 subjects. 3 losartan/E-3174 concentrations from 3 different subjects were excluded from analyses due to gross deviations; 75 minutes-Treatment B, 75 minutes-Treatment A, & 15 minutes-Treatment A.|2|||f||||||||||||||2018-06-01 00:42:55.747582|2018-06-01 00:42:55.747582
NCT00953667|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2015-07-29||2016-02-23|2009-08-05|2009-08-06|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|June 2007||2007-06-30|January 2016|2016-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|GENE||The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study|The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study|Completed||N/A|400|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:42:56.085993|2018-06-01 00:42:56.085993
NCT00953654|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2010-08-17||2016-07-29|2009-08-04|2009-08-06|Estimate|2010-09-13|2010-09-29|Estimate||||2016-07-29|2016-09-09|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Exercise Training for the Treatment of Generalized Anxiety Disorder|Exercise Training for the Treatment of Generalized Anxiety Disorder: A Randomized Controlled Trial Comparing Endurance and Strength Training Among Sedentary Women With Generalized Anxiety Disorder.|Completed||N/A|30|Actual|University of Georgia|One limitation of this trial was the small sample size. Although the research design was sufficiently powered to detect a statistically significant effect for the primary outcome, a larger trial is warranted.|3|||f||||||||||||||2018-06-01 00:42:56.33658|2018-06-01 00:42:56.33658
NCT00953641|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2012-08-11|2009-08-05|2009-08-06|Estimate|||||||2012-08-11|2012-08-14|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy|Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy|Withdrawn||Phase 3|0|Actual|University of Saskatchewan||4||Principle Investigator retired, Resident moved away|f||||f||||||||||2018-06-01 00:42:56.891915|2018-06-01 00:42:56.891915
NCT00953628|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2015-12-01|2009-08-05|2009-08-06|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2005||2005-08-31|December 2015|2015-12-31|December 2008||2008-12-31|December 2006|Actual|2006-12-31||Interventional|||Endometrial Advancement After Rec or u-HCG Triggering|Endometrial Advancement After Rec or u-HCG Triggering|Completed||Phase 4|130|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-06-01 00:42:56.995912|2018-06-01 00:42:56.995912
NCT00953615|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2011-08-08||2012-01-24|2009-08-05|2009-08-06|Estimate|2012-01-24|2012-02-27|Estimate||||2012-01-24|2012-02-27|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)|Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis|Terminated||Phase 2|1|Actual|Mayo Clinic|Only one subject was enrolled, so study was terminated.|1||Lack of enrollment|f||||t||||||||||2018-06-01 00:42:57.106153|2018-06-01 00:42:57.106153
NCT00953602|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-24|2009-08-05|2009-08-06|Estimate|||||||2009-08-24|2009-08-25|Estimate|April 2009||2009-04-30|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Long Time Metabolic Changes Induced by Genetically Modified Potatoes||Unknown status|Recruiting|N/A|20|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 00:42:57.355211|2018-06-01 00:42:57.355211
NCT00953589|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2012-02-01|2009-08-05|2009-08-06|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|May 2010|Actual|2010-05-31||Interventional|480S||480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)|480 STUDY: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin Given Bi-Weekly to PEG-Intron™ Plus Ribavirin Given Weekly|Completed||Phase 2|74|Actual|Biolex Therapeutics, Inc.||4|||f||||t||||||||||2018-06-01 00:42:57.42519|2018-06-01 00:42:57.42519
NCT00953576|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2017-01-25|2009-08-05|2009-08-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|August 2009||2009-08-31|January 2017|2017-01-31||||April 2017|Anticipated|2017-04-30||Interventional|KHLAD||Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer|A Phase I/II Trial of Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Castration Resistant Prostate Cancer With Pre- and Post-therapy Tumor Biopsies|Terminated||Phase 1/Phase 2|11|Actual|Dana-Farber Cancer Institute||1||drug toxicity|f||||t||||||||||2018-06-01 00:42:57.523395|2018-06-01 00:42:57.523395
NCT00953563|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-04-04|2009-08-04|2009-08-06|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2009||2009-03-31|April 2017|2017-04-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers|The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers|Withdrawn||N/A|0|Actual|Baxter Healthcare Corporation||2||Budgetary|f||||f||||||||||2018-06-01 00:42:57.599516|2018-06-01 00:42:57.599516
NCT00953550|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-03-01|2009-08-05|2009-08-06|Estimate|||||||2011-03-01|2011-03-02|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine|Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine|Completed||Phase 4|61|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 00:42:57.675986|2018-06-01 00:42:57.675986
NCT00953537|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2015-02-08|2009-08-05|2009-08-06|Estimate|||||||2015-02-08|2015-02-10|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Predicting Response to Capecitabine in Women With Metastatic Breast Cancer|Multicentric Pilot Study of Dihydropyrimidine Dehydrogenase (DPD) Deficiency for Predicting Capecitabine Toxicity in Breast Cancer Patients|Completed||N/A|303|Actual|Centre Antoine Lacassagne||1|||f||||||||||||||2018-06-01 00:42:57.749118|2018-06-01 00:42:57.749118
NCT00953524|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2011-06-08||2014-02-06|2009-08-04|2009-08-06|Estimate|2011-06-08|2011-07-11|Estimate||||2014-02-06|2014-03-10|Estimate|August 2009||2009-08-31|February 2014|2014-02-28|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly|Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects|Completed||Phase 2|849|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 00:42:57.858384|2018-06-01 00:42:57.858384
NCT00953511|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2016-10-19|2009-08-05|2009-08-06|Estimate|||||||2016-10-19|2016-10-21|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|CERP||Cologne Esophageal Response Prediction Study (CERP-Study)|Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer|Completed||N/A|80|Actual|University of Cologne||1|||f||||t||||||||No||2018-06-01 00:42:58.956337|2018-06-01 00:42:58.956337
NCT00953498|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2013-08-30|2009-08-05|2009-08-06|Estimate|||||||2013-08-30|2013-09-02|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins|Influence of Glitazones on the Vasodilatory Effect of HDL Lipoproteins and on Phospholipase A2|Completed||Phase 4|40|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-06-01 00:42:59.02988|2018-06-01 00:42:59.02988
NCT00953485|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2009-08-19|2009-08-04|2009-08-06|Estimate|||||||2009-08-19|2009-08-20|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS)|Clinical Trial of Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome - Phase Ⅰ/Ⅱ|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||||f||||t||||||||||2018-06-01 00:42:59.126562|2018-06-01 00:42:59.126562
NCT00953472|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2011-10-10|2009-08-05|2009-08-06|Estimate|||||||2011-10-10|2011-10-12|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||B-type Natriuretic Peptide (BNP) in Human Hypertension|Clinical Proteomics and Protein Therapeutics in Human Hypertension (BNP in Human Hypertension - Phase 1)|Terminated||Phase 1|8|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 00:42:59.220002|2018-06-01 00:42:59.220002
NCT00953459|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2013-01-14|2009-08-05|2009-08-06|Estimate|||||||2013-01-14|2013-01-15|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|September 2012|Actual|2012-09-30|July 2010|Actual|2010-07-31||Interventional|||Sunitinib Malate in Treating Patients With Small Cell Lung Cancer|"Phase II Study of Sunitinib (SU011248) in Patients With Small Cell Lung Cancer Who Are Either Chemo-naïve (Extensive Disease) or Have a Sensitive Relapse"|Terminated||Phase 2|9|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||poorly recruiting|f||||||||||||||2018-06-01 00:42:59.305715|2018-06-01 00:42:59.305715
NCT00953446|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-11-18|2009-08-05|2009-08-06|Estimate|||||||2010-11-18|2010-11-19|Estimate|August 2009||2009-08-31|November 2010|2010-11-30||||August 2011|Anticipated|2011-08-31||Interventional|||Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma|Suspended||N/A|20|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 00:42:59.369436|2018-06-01 00:42:59.369436
NCT00953433|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2011-08-23|2009-08-05|2009-08-06|Estimate|||||||2011-08-23|2011-08-24|Estimate|April 2010||2010-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Laryngeal Morbidity After Endotracheal Intubation - Endoflex-tube Versus Use of Stylet|Laryngeal Morbidity After Endotracheal Intubation - Endoflex-tube Versus Use of Stylet|Completed||N/A|130|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 00:42:59.435251|2018-06-01 00:42:59.435251
NCT00953420|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04||2015-08-26|2017-08-17|2009-08-05|2009-08-06|Estimate||||2015-08-26|2015-09-09|Estimate|2017-08-17|2017-08-18|Actual|November 2009||2009-11-30|August 2017|2017-08-31|July 2015|Actual|2015-07-31|June 2014|Actual|2014-06-30||Interventional|CADEN||Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes|Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients With Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma(CADEN)|Completed||Phase 2|20|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-06-01 00:42:59.501748|2018-06-01 00:42:59.501748
NCT00953407|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2010-09-16||2012-06-26|2009-08-04|2009-08-06|Estimate|2010-10-07|2010-11-01|Estimate||||2012-06-26|2012-07-10|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparative Clinical Evaluation of Daily Disposable Lenses in Symptomatic Lens Wearers||Completed||N/A|128|Actual|Alcon Research||5|||f||||||||||||||2018-06-01 00:42:59.593852|2018-06-01 00:42:59.593852
NCT00953394|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|February 2002||2002-02-28|August 2009|2009-08-31|December 2006|Actual|2006-12-31|February 2006|Actual|2006-02-28||Interventional|||5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors|Continuous 5-fluorouracil Infusion Plus Long Acting Octreotide in Advanced Well Differentiated Neuroendocrine Carcinomas. A Phase II Trial of the Piemonte Oncology Network.|Completed||Phase 2|29|Actual|University of Turin, Italy||1|||f||||t||||||||||2018-06-01 00:42:59.90048|2018-06-01 00:42:59.90048
NCT00953381|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|October 2004||2004-10-31|August 2009|2009-08-31|May 2005|Actual|2005-05-31|March 2005|Actual|2005-03-31||Interventional|||Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)|Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase2 Trial in China|Completed||Phase 2|235|Actual|Livzon Pharmaceutical Group Inc.||4|||f||||t||||||||||2018-06-01 00:42:59.997091|2018-06-01 00:42:59.997091
NCT00953368|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Effect of Remote Ischemic Preconditioning on Cognitive Function After Off-Pump Coronary Artery Bypass Graft|Effect of Remote Ischemic Preconditioning on Cognitive Function After Off-Pump Coronary Artery Bypass Graft|Unknown status|Not yet recruiting|Phase 1|270|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-06-01 00:43:00.085568|2018-06-01 00:43:00.085568
NCT00953355|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2010-11-02|2009-08-05|2009-08-06|Estimate|||||||2010-11-02|2010-11-03|Estimate|January 2004||2004-01-31|August 2009|2009-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients|Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome|Completed||Phase 4|50|Actual|University Magna Graecia||2|||f||||t||||||||||2018-06-01 00:43:00.188239|2018-06-01 00:43:00.188239
NCT00953342|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2018-02-09|2009-08-05|2009-08-06|Estimate|||||||2018-02-09|2018-02-12|Actual|January 2010||2010-01-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|Ex-Asthma||Impact of Aerobic Exercise on Asthma Morbidity|Impact of Aerobic Exercise on Asthma Morbidity|Completed||Phase 3|66|Actual|Hopital du Sacre-Coeur de Montreal||2|||f||||f||||||||||2018-06-01 00:43:00.260035|2018-06-01 00:43:00.260035
NCT00953329|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2012-10-18||2013-02-20|2009-08-05|2009-08-06|Estimate|2013-01-14|2013-02-15|Estimate||||2013-02-20|2013-02-22|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy|An Open-Label Study to Determine the Safety and Efficacy of Alefacept as Monotherapy in Subjects With Chronic Plaque Psoriasis Who Have Failed to Respond to Anti-TNF Therapy|Terminated||Phase 4|1|Actual|Duke University|Early termination due to one patient enrolled . The patient stopped the study because she was not improved and desired alternative treatment.|1||Subjects declined enrollment; sponsor/PI elected to close study.|f||||f||||||||||2018-06-01 00:43:00.340523|2018-06-01 00:43:00.340523
NCT00953316|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2017-05-09|2009-08-05|2009-08-06|Estimate|||||||2017-05-09|2017-05-11|Actual|April 2008||2008-04-30|May 2017|2017-05-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Observational|||Infant Transition From Car Bed to Car Safety Seat|A Prospective Examination of Infant Transition From Car Bed to Car Safety Seat|Completed|||96|Actual|Boston Children’s Hospital|||1||f||||f||||||||||2018-06-01 00:43:00.508982|2018-06-01 00:43:00.508982
NCT00953303|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2012-02-19|2009-08-05|2009-08-06|Estimate|||||||2012-02-19|2012-02-22|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure|The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure|Completed||Phase 2/Phase 3|102|Actual|Hebei Medical University||2|||f||||t||||||||||2018-06-01 00:43:00.562995|2018-06-01 00:43:00.562995
NCT00953290|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2011-02-17||2011-05-06|2009-08-05|2009-08-06|Estimate|2011-03-15|2011-04-18|Estimate||||2011-05-06|2011-05-10|Estimate|January 2009||2009-01-31|May 2011|2011-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Thigh Circumference Reduction Study|Cutera Radio Frequency Device for Thigh Circumference Reduction|Terminated||N/A|4|Actual|Cutera Inc.|Early termination of the study resulting in analysis of small numbers of subjects, and technical issues with repeatability and reproducibility of circumference measurements leading to termination.|2||The study was terminated because the preliminary data did not indicate efficacy.|f||||f||||||||||2018-06-01 00:43:00.64459|2018-06-01 00:43:00.64459
NCT00953277|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2015-05-20|2009-08-05|2009-08-06|Estimate|||||||2015-05-20|2015-05-21|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer|A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy|Completed||Phase 4|12|Actual|AxoGen, Inc||1|||f||||f||||||||||2018-06-01 00:43:00.857979|2018-06-01 00:43:00.857979
NCT00953264|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2017-12-14|2009-08-05|2009-08-06|Estimate|||||||2017-12-14|2017-12-15|Actual|December 2007||2007-12-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Hormonal and Metabolic Effects of Weight Loss|Hormonal and Metabolic Effects of Weight Loss|Completed||N/A|290|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 00:43:00.969167|2018-06-01 00:43:00.969167
NCT00953251|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||TnThs Predicting Evolving Non-STEMI|High Sensitive Cardiac Troponin T for Early Prediction of Evolving Non-ST Segment Elevation Myocardial Infarction in Patients With Suspected Acute Coronary Syndrome and Negative Troponin Result on Admission|Completed|||115|Actual|Heidelberg University|||2||f||||f||||||Samples Without DNA|"~     Blood samples were collected on admission and ideally every hour within the initial 6 hours~     after admission, unless the patient refused the blood draw, or venipuncture was not feasible~     due to technical reasons.~      After collection, blood samples were centrifuged immediately and serum stored at -80°C until~     analysis. The laboratory staff responsible for measurements was blinded to patient data.~   "|||2018-06-01 00:43:01.024797|2018-06-01 00:43:01.024797
NCT00953225|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2015-02-10||2017-09-08|2009-08-05|2009-08-06|Estimate|2015-03-23|2015-04-06|Estimate||||2017-09-08|2017-10-09|Actual|January 7, 2010|Actual|2010-01-07|September 2017|2017-09-30|October 30, 2014|Actual|2014-10-30|December 15, 2013|Actual|2013-12-15||Interventional|vit D & PCa||Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer|Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer|Completed||Phase 2|83|Actual|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-06-01 00:43:01.093511|2018-06-01 00:43:01.093511
NCT00953212|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2018-01-22||2018-03-28|2009-08-05|2009-08-06|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-28|2018-04-26|Actual|August 2009||2009-08-31|March 2018|2018-03-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery|A Randomized Controlled Trial to Compare Prophylaxis With Oral Ascorbic Acid, Oral Amiodarone or Both in Combination With Beta Blockers to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery|Completed||Phase 3|304|Actual|Maine Medical Center||4|||f||||t||||||||||2018-06-01 00:43:01.374069|2018-06-01 00:43:01.374069
NCT00953199|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2017-01-19||2017-09-06|2009-08-05|2009-08-06|Estimate|2017-09-06|2017-10-03|Actual||||2017-09-06|2017-10-03|Actual|March 2010||2010-03-31|September 2017|2017-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Adult patients send for ERCP with a chance of contrast injection into the pancreatic duct|Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis|A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis|Completed||N/A|506|Actual|Milton S. Hershey Medical Center||2|||f||||||||||||No||2018-06-01 00:43:02.165585|2018-06-01 00:43:02.165585
NCT00953186|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2011-11-07|2009-08-05|2009-08-06|Estimate|||||||2011-11-07|2011-11-08|Estimate|June 2002||2002-06-30|August 2009|2009-08-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|HODFU||Hyperbaric Oxygen Therapy as Adjunctive Treatment of Chronic Diabetic Foot Ulcers|Hyperbaric Oxygen Therapy as Adjunctive Treatment in Diabetics With Chronic Foot Ulcers|Completed||Phase 4|94|Actual|Mrs. Thelma Zoegas Foundation||2|||f||||t||||||||||2018-06-01 00:43:02.413944|2018-06-01 00:43:02.413944
NCT00953173|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2017-08-07||2018-02-08|2009-08-05|2009-08-06|Estimate|2017-08-07|2018-02-09|Actual||||2018-02-08|2018-03-08|Actual|December 2009||2009-12-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Observational|||HERO Study: Helping Evaluate Reduction in Obesity||Completed|||671|Actual|Apollo Endosurgery, Inc.|||1||f||||f||||||||||2018-06-01 00:43:02.519812|2018-06-01 00:43:02.519812
NCT00953160|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2011-02-25||2013-06-21|2009-08-05|2009-08-06|Estimate|2011-02-25|2011-03-17|Estimate||||2013-06-21|2013-07-02|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Radio Frequency (RF) Device for Reduction in Size of Localized Areas of the Body|Pilot Study to Evaluate the Cutera RF Device for Reduction in Size of Localized Areas of the Body, Including, But Not Limited to, Areas on the Abdomen, Leg, and Arm|Terminated||N/A|76|Actual|Cutera Inc.|Early termination of the study resulting in analysis of small numbers of subjects, and technical issues with repeatability and reproducibility of circumference measurements leading to termination.|1||The preliminary data from this pilot study did not indicate efficacy.|f||||f||||||||||2018-06-01 00:43:02.755272|2018-06-01 00:43:02.755272
NCT00953147|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2012-02-15|2010-09-17|2012-06-07|2009-08-05|2009-08-06|Estimate|2012-05-04|2012-06-07|Estimate|2010-09-17|2010-09-21|Estimate|2012-06-07|2012-06-13|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older|A 6-Month Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Once Daily Ciclesonide HFA Nasal Aerosol (80 and 160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older|Completed||Phase 3|1110|Actual|Sunovion|This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg|3|||f||||f||||||||||2018-06-01 00:43:03.034325|2018-06-01 00:43:03.034325
NCT00953134|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2010-04-14|2009-08-05|2009-08-06|Estimate|||||||2010-04-14|2010-04-15|Estimate|February 2007||2007-02-28|August 2009|2009-08-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Periconceptional Iron Supplementation in Rural Bangladesh|Periconceptional Iron Supplementation on Iron and Folate Indicators Among Pregnant and Non-pregnant Women in Rural Bangladesh.|Completed||Early Phase 1|273|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:43:04.277928|2018-06-01 00:43:04.277928
NCT00953121|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2013-06-21||2013-09-05|2009-08-05|2009-08-06|Estimate|2013-06-21|2013-09-04|Estimate||||2013-09-05|2013-09-16|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)|Phase II Study of Bevacizumab Plus Irinotecan and Carboplatin for Recurrent Malignant Glioma Patients|Completed||Phase 2|104|Actual|Duke University||3|||f||||f||||||||||2018-06-01 00:43:04.42353|2018-06-01 00:43:04.42353
NCT00953108|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2013-02-11|2009-08-05|2009-08-06|Estimate|||||||2013-02-11|2013-02-12|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients|Impact of Quetiapine Prolong and Escitalopram on the Hypothalamic-pituitary-adrenocortical (HPA)-Axis Activity in Depressed Patients|Completed||Phase 3|60|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-06-01 00:43:04.979139|2018-06-01 00:43:04.979139
NCT00953095|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2014-09-22|2009-08-05|2009-08-06|Estimate|||||||2014-09-22|2014-09-25|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Social and Communication Outcomes for Young Children With Autism|Optimizing Social and Communication Outcomes for Young Children With Autism|Completed||N/A|112|Actual|Health Resources and Services Administration (HRSA)||2|||f||||f||||||||||2018-06-01 00:43:05.034905|2018-06-01 00:43:05.034905
NCT00953056|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2011-03-25||2015-10-30|2009-08-05|2009-08-06|Estimate|2011-03-25|2011-04-15|Estimate||||2015-10-30|2015-11-02|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine in Chinese Healthy Adults, Children and Infants|Completed||Phase 1|144|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:43:05.110234|2018-06-01 00:43:05.110234
NCT00953043|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2012-01-09||2012-02-23|2009-08-05|2009-08-06|Estimate|2012-01-09|2012-02-09|Estimate||||2012-02-23|2012-02-27|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||Lubiprostone, Colonic Motility and Sensation|The Effect of Lubiprostone, a Chloride Channel Activator, on Colonic Sensorimotor Functions in Healthy Subjects. A Phase IV, Placebo-Controlled, Parallel Group Study|Completed||Phase 4|60|Actual|Mayo Clinic|This study was conducted in healthy subjects and needs replication in patients with Irritable Bowel Syndrome.|2|||f||||t||||||||||2018-06-01 00:43:05.493072|2018-06-01 00:43:05.493072
NCT00953030|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|September 2004||2004-09-30|August 2009|2009-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Cost Effective Health Promotion for Older Adults|Cost Effective Health Promotion for Older Adults|Completed||N/A|423|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-06-01 00:43:06.690181|2018-06-01 00:43:06.690181
NCT00953017|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|2012-09-06||2012-11-01|2009-08-05|2009-08-06|Estimate|2012-11-01|2012-11-30|Estimate||||2012-11-01|2012-11-30|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy|A Randomized, Blinded Trial Comparing Miralax With Amitiza Pretreatment Versus Miralax With Dulcolax Pretreatment Versus Miralax Alone Without Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy|Completed||Phase 4|425|Actual|Brooke Army Medical Center|Indication for colonoscopy was restricted to colorectal cancer screening. Patients admitted to the hospital were not included. Polyp detection rates could have been influenced by unequal randomization of high-risk and low-risk patients for adenomas.|4|||f||||t||||||||||2018-06-01 00:43:06.757192|2018-06-01 00:43:06.757192
NCT00953004|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2010-11-10|2009-08-05|2009-08-06|Estimate|||||||2010-11-10|2010-11-11|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|July 2009|Actual|2009-07-31||Interventional|HØRFRØ||Flax Mucilage and Apparent Nutrient Digestibility|Effect of Flaxseed and Flaxseed Mucilage on Energy Digestibility, Lipid Profile and Appetite|Unknown status|Active, not recruiting|N/A|16|Anticipated|University of Copenhagen||3|||f||||f||||||||||2018-06-01 00:43:07.174624|2018-06-01 00:43:07.174624
NCT00952991|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2011-03-22|2009-08-05|2009-08-06|Estimate|||||||2011-03-22|2011-03-23|Estimate|May 2005||2005-05-31|March 2011|2011-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||The Effects of LAF237 on Gastric Function in Type 2 Diabetes|A Double Blind, Cross Over, Placebo Controlled, Multiple-dose Study to Evaluate the Effects of LAF237 on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes.|Completed||Phase 3|18||Mayo Clinic|||||||||||||||||||2018-06-01 00:43:07.282871|2018-06-01 00:43:07.282871
NCT00952978|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|May 2006|Actual|2006-05-31|February 2006|Actual|2006-02-28||Interventional|||Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)|Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase3 Trial in China|Completed||Phase 3|496|Actual|Livzon Pharmaceutical Group Inc.||2|||f||||t||||||||||2018-06-01 00:43:07.443316|2018-06-01 00:43:07.443316
NCT00952965|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|April 2009||2009-04-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|WBPMCT||Wrist-used Blood Pressure Monitor Clinical Test (Cuff Range: 14cm-25cm)|Clinical Testing Report for Wrist-used Electronic Blood Pressure Monitor|Completed|||86|Actual|Andon Health Co., Ltd|||2||f||||f||||||||||2018-06-01 00:43:07.517611|2018-06-01 00:43:07.517611
NCT00952952|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2011-05-20|2009-08-05|2009-08-06|Estimate|||||||2011-05-20|2011-05-24|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Trial of Mesalamine for the Treatment of Active Microscopic Colitis|A Randomized, Dose Ranging Trial of Mesalmine for the Treatment of Active Microscopic Colitis.|Completed||Phase 2/Phase 3|70|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 00:43:07.578204|2018-06-01 00:43:07.578204
NCT00952939|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-05|||2015-01-28|2009-08-05|2009-08-06|Estimate|||||||2015-01-28|2015-01-30|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|September 2012|Actual|2012-09-30||Observational|||Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye|Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH)|Completed|||150|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 00:43:07.644535|2018-06-01 00:43:07.644535
NCT00952926|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-11-15|2009-08-03|2009-08-06|Estimate|||||||2017-11-15|2017-11-17|Actual|October 2009|Actual|2009-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|January 2014|Actual|2014-01-31||Observational|||Watchful Waiting. An Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy|A Prospective Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy|Active, not recruiting|||100|Anticipated|Vejle Hospital|||||f||||t||||||||||2018-06-01 00:43:07.740737|2018-06-01 00:43:07.740737
NCT00952913|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2011-04-18|2009-08-04|2009-08-06|Estimate|||||||2011-04-18|2011-04-19|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects|A Study to Examine The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib When Administered Concomitantly To Healthy Subjects|Completed||Phase 1|24|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 00:43:07.812126|2018-06-01 00:43:07.812126
NCT00952900|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-06-03|2009-08-04|2009-08-06|Estimate|||||||2015-06-03|2015-06-08|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|October 2013|Actual|2013-10-31||Interventional|||An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)|An Implementation and Biobehavioral Study of TMJMD|Completed||N/A|456|Actual|The University of Texas at Arlington||3|||f||||t||||||||||2018-06-01 00:43:07.884614|2018-06-01 00:43:07.884614
NCT00952887|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2011-03-22|2009-08-04|2009-08-06|Estimate|||||||2011-03-22|2011-03-23|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ACE-031 (ActRIIB-IgG1) in Healthy Postmenopausal Women|Completed||Phase 1|70|Actual|Acceleron Pharma, Inc.||2|||f||||t||||||||||2018-06-01 00:43:07.953698|2018-06-01 00:43:07.953698
NCT00952874|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2010-06-24|2009-08-05|2009-08-06|Estimate|||||||2010-06-24|2010-06-25|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Observational|||Molecular Biology of Anal Cancer in HIV-Positive Patients|Microsatellite Instability in Anal Squamous Cell Carcinomas of HIV-Positive Versus HIV-Negative Patients|Completed|||30|Anticipated|University Hospital, Geneva|||||f||||t||||||Samples With DNA|"~     Biosie of anal cancer~   "|||2018-06-01 00:43:08.034708|2018-06-01 00:43:08.034708
NCT00952861|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2010-08-10|2009-08-03|2009-08-06|Estimate|||||||2010-08-10|2010-08-11|Estimate|October 2009||2009-10-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|TAExaCOP||Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)|Antibiotic Treatment of Patients Admitted to Hospital With Acute Exacerbation of COPD. Effect of 1 Day of Antibiotic Therapy Compared to 6 Days of Therapy in Patients Who Are Stable After 24 Hours|Withdrawn||Phase 4|140|Anticipated|Odense University Hospital||2||Stopped due to poor recruitment|f||||f||||||||||2018-06-01 00:43:08.094183|2018-06-01 00:43:08.094183
NCT00952848|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2012-11-30||2017-02-27|2009-08-05|2009-08-06|Estimate|2013-02-15|2013-03-22|Estimate||||2017-02-27|2017-03-29|Actual|June 12, 2009||2009-06-12|February 2017|2017-02-28|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Interventional|||Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy|"The Efficacy of MC5-A (Scrambler) Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase II Pilot Trial"|Completed||Phase 2|18|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 00:43:08.179457|2018-06-01 00:43:08.179457
NCT00952835|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2013-06-18|2009-08-03|2009-08-06|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2009||2009-07-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Evaluation of Different Disease Control Indices in Children With Asthma and Rhinitis|Evaluation of Different Disease Control Indices in Children With Asthma and Rhinitis|Unknown status|Recruiting||1000|Anticipated|Universita di Verona|||1||f||||f||||||||||2018-06-01 00:43:08.368557|2018-06-01 00:43:08.368557
NCT00952822|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2010-10-28||2017-10-19|2009-08-04|2009-08-06|Estimate|2011-06-23|2011-07-21|Estimate||||2017-10-19|2017-11-22|Actual|September 2008||2008-09-30|June 2011|2011-06-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection|A Phase 1, Prospective, Randomized, Crossover Study to Compare the Pharmacokinetics and Safety of rAHF-PFM Reconstituted in 2 mL Versus 5 mL SWFI in Previously Treated Severe Hemophilia A Patients|Completed||Phase 1|52|Actual|Shire||2|||f||||t||||||||||2018-06-01 00:43:08.497742|2018-06-01 00:43:08.497742
NCT00952796|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2011-08-01|2009-08-04|2009-08-06|Estimate|||||||2011-08-01|2011-08-02|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections|A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections|Completed||Phase 4|100|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||||||||||||2018-06-01 00:43:09.113229|2018-06-01 00:43:09.113229
NCT00952783|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2015-03-25|2009-08-04|2009-08-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study|A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Areas (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-020|Completed|||98|Actual|Peplin|||1||f||||f||||||||||2018-06-01 00:43:09.191823|2018-06-01 00:43:09.191823
NCT00952770|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2009-08-04|2009-08-04|2009-08-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|July 2009||2009-07-31|August 2009|2009-08-31||||July 2010|Anticipated|2010-07-31||Interventional|||Effect of Statins on the Radial Intima-media Thickness After Transradial Angioplasty|Effect of Statins on the Progression of the Intima-media Thickness of the Radial Artery After Radial Angioplasty|Unknown status|Recruiting|Phase 4|140|Anticipated|Chungnam National University||2|||f||||f||||||||||2018-06-01 00:43:09.284757|2018-06-01 00:43:09.284757
NCT00952757|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-08-05|2009-08-04|2009-08-06|Estimate|||||||2009-08-05|2009-08-07|Estimate|June 2007||2007-06-30|August 2009|2009-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine|Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine: a Naturalistic, Prospective, Multicentric Observational Study of 6 Months Follow-up|Completed|||35|Actual|Investigaciones Médicas Montejo S.L.|||1||f||||t||||||||||2018-06-01 00:43:09.395598|2018-06-01 00:43:09.395598
NCT00952744|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-01-16|2009-08-04|2009-08-06|Estimate|||||||2012-01-16|2012-01-18|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Observational|CHOPIN||Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction|Copeptin Helps in the Early Detection Of Patients With Acute Myocardial|Completed|||2071|Actual|Brahms AG|||||f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-06-01 00:43:09.512443|2018-06-01 00:43:09.512443
NCT00952731|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2015-05-27||2015-07-18|2009-08-04|2009-08-06|Estimate|2015-07-18|2015-07-21|Estimate||||2015-07-18|2015-07-21|Estimate|December 2009||2009-12-31|July 2015|2015-07-31||||September 2011|Actual|2011-09-30||Interventional|||4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ|Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast|Completed||Phase 2|27|Actual|Northwestern University|The study was originally designed to enroll 112 participants, unfortunately, the shelf-life of the study drug expired which resulted in early closure of the study after only 31 participants.|2|||f||||t||||||||||2018-06-01 00:43:09.619845|2018-06-01 00:43:09.619845
NCT00952718|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-08-03|2009-08-04|2009-08-06|Estimate|||||||2015-08-03|2015-08-05|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Inspiratory Muscle Training in Patients With Bronchiectasis|Effects of Inspiratory Muscle Training in Patients With Bronchiectasis|Completed||N/A|38|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-06-01 00:43:10.114404|2018-06-01 00:43:10.114404
NCT00952705|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2011-06-28||2018-04-06|2009-08-05|2009-08-06|Estimate|2011-12-09|2012-01-13|Estimate||||2018-04-06|2018-05-03|Actual|August 2009||2009-08-31|December 2011|2011-12-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|MI-CP206||A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age|A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age|Completed||Phase 3|1800|Actual|MedImmune LLC||3|||f||||t||||||||||2018-06-01 00:43:10.239685|2018-06-01 00:43:10.239685
NCT00952692|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04||2012-11-15|2012-11-15|2009-08-04|2009-08-06|Estimate||||2012-11-15|2012-11-20|Estimate|2012-11-15|2012-11-20|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|July 2011|Actual|2011-07-31||Interventional|||Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer|A Monocentric, Open-label Phase I/II Study to Assess dHER2+AS15 Cancer Immunotherapeutic Given in Combination With Lapatinib to Patients With ErbB2 Overexpressing Metastatic Breast Cancer Refractory to Trastuzumab|Completed||Phase 1/Phase 2|12|Actual|Duke University|||||f||||f||||||||||2018-06-01 00:43:10.978137|2018-06-01 00:43:10.978137
NCT00952679|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-08-04|2009-08-04|2009-08-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|December 2011|Anticipated|2011-12-31|January 2009|Anticipated|2009-01-31||Interventional|||Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients|Computed Tomography (CT) Based Lymphatic Mapping and Localization of Sentinel Lymph Node in Breast Cancer Patients|Unknown status|Recruiting|Phase 3|50|Anticipated|Fudan University||1|||f||||f||||||||||2018-06-01 00:43:11.057606|2018-06-01 00:43:11.057606
NCT00952666|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2010-09-10|2009-08-05|2009-08-06|Estimate|||||||2010-09-10|2010-09-13|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy|Transrectal Ultrasound (TRUS) Imaging of the Prostate Gland and Neurovascular Bundles (NVB) During Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP)|Terminated||Early Phase 1|6|Anticipated|Johns Hopkins University||1||The number of participants needed for this study has been met.|f||||t||||||||||2018-06-01 00:43:11.127878|2018-06-01 00:43:11.127878
NCT00952653|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2011-07-06||2011-08-09|2009-08-04|2009-08-06|Estimate|2011-07-06|2011-08-02|Estimate||||2011-08-09|2011-08-15|Estimate|June 2010||2010-06-30|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam|An Open-Label, Two-Period, Sequential Drug Interaction Study to Evaluate the Effect of Multiple Doses of Desvenlafaxine Succinate Sustained Release (DVS SR) on the Pharmacokinetics of Midazolam When Coadministered in Healthy Subjects|Completed||Phase 4|28|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:43:11.223652|2018-06-01 00:43:11.223652
NCT00952640|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2012-10-09|2009-08-04|2009-08-06|Estimate|||||||2012-10-09|2012-10-11|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Making Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and Inflammation|Making Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and Inflammation.|Completed||N/A|400|Anticipated|Institut de Recherche pour le Developpement||2|||f||||f||||||||||2018-06-01 00:43:11.586944|2018-06-01 00:43:11.586944
NCT00952627|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2013-12-14|2009-08-04|2009-08-06|Estimate|||||||2013-12-14|2013-12-17|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects|Mechanism of the Anti-remodeling Activity of the Over-the-counter Dietary Supplement, Pycnogenol, on Age-dependent Process of Cardiac Fibrosis in Aged Hypertensive Subjects With Echocardiographic Evidence of Grade I/II Diastolic Dysfunction|Terminated||Phase 2|9|Actual|University of Arizona||2||Not able to recruit qualified patents|f||||f||||||||||2018-06-01 00:43:11.655595|2018-06-01 00:43:11.655595
NCT00952614|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2013-08-06||2014-08-01|2009-08-04|2009-08-06|Estimate|2014-05-28|2014-06-30|Estimate||||2014-08-01|2014-08-06|Estimate|October 2002||2002-10-31|August 2014|2014-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||Twenty nine participants were consented. Of the 29 consented (30 eyes; one subject consented twice), 23 participants were studied and 24 eyes. Both eyes of one participant were studied|A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion|A Pilot Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion|Completed||N/A|29|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:43:11.73197|2018-06-01 00:43:11.73197
NCT00952601|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2010-07-14|2009-08-04|2009-08-06|Estimate|||||||2010-07-14|2010-07-15|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pilot Study of the Modified Atkins Diet for Tourette Syndrome|Pilot Study of the Modified Atkins Diet for Tourette Syndrome|Terminated||Phase 1|20|Anticipated|Johns Hopkins University||1||Insufficient interest and recruitment - study ended prematurely by investigators|f||||f||||||||||2018-06-01 00:43:11.875039|2018-06-01 00:43:11.875039
NCT00952588|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2013-02-01||2014-02-13|2009-08-04|2009-08-06|Estimate|2014-02-13|2014-03-31|Estimate||||2014-02-13|2014-03-31|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SPARK-AML1||Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients|A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)|Completed||Phase 2/Phase 3|74|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 00:43:11.963751|2018-06-01 00:43:11.963751
NCT00952575|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2011-09-12|2009-08-04|2009-08-06|Estimate|||||||2011-09-12|2011-09-13|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dose-finding Study of LFB-R593, A Monoclonal Anti-RhD Antibody, in Healthy RhD Negative Volunteers|A Phase II, Open-label, Randomised, Dose-finding Study to Compare the Efficacy (in Terms of Clearance of RhD-positive RBCs) and Safety of LFB-R593, a Monoclonal Anti-RhD Antibody vs a Polyclonal Anti-RhD Immunoglobulin in Healthy RhD Negative Volunteers|Completed||Phase 2|78|Actual|Laboratoire français de Fractionnement et de Biotechnologies||2|||f||||t||||||||||2018-06-01 00:43:12.487816|2018-06-01 00:43:12.487816
NCT00952562|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2011-08-23|2009-08-04|2009-08-06|Estimate|||||||2011-08-23|2011-08-24|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals|The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals. A Randomised Double Blinded Placebo Controlled Trial.|Completed||N/A|40|Anticipated|Zealand University Hospital||2|||f||||f||||||||||2018-06-01 00:43:12.618632|2018-06-01 00:43:12.618632
NCT00952549|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2018-01-24|2009-08-04|2009-08-06|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2009||2009-08-31|January 2018|2018-01-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Facial Yoga Toning Program - A Pilot Study|Facial Yoga Toning Program - A Pilot Study|Withdrawn||Early Phase 1|0|Actual|The Cleveland Clinic||1||Investigator no longer at Cleveland Clinic|f||||t||||||||No||2018-06-01 00:43:12.699343|2018-06-01 00:43:12.699343
NCT00952536|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-02-13|2009-08-04|2009-08-06|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2005||2005-02-28|February 2017|2017-02-28|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|BHAM-NSA-05-01||Effect of Dietary Intake of Dried Whole Food Concentrates (Juice Plus) on Clinical Outcomes Following Periodontal Therapy: A Pilot Study|The Effect of Daily Dietary Intake of Dried Whole Food Concentrates of Fruit, Vegetables and Berries (Juice Plus+) in Improving Clinical Outcomes Following Non-surgical Periodontal Therapy: a Pilot Study.|Completed||Phase 2|60|Actual|Birmingham Community Healthcare NHS||3|||f||||f||||||||||2018-06-01 00:43:12.759627|2018-06-01 00:43:12.759627
NCT00952523|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2010-01-26||2012-02-14|2009-08-05|2009-08-06|Estimate|2010-04-08|2010-04-09|Estimate||||2012-02-14|2012-02-15|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face|An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products (Retin-A Micro Gel, 0.04% Pump and Epiduo Gel) Using a Split-Face Model|Completed||Phase 4|162|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 00:43:12.84624|2018-06-01 00:43:12.84624
NCT00952510|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2011-04-19|2009-08-05|2009-08-06|Estimate|||||||2011-04-19|2011-04-20|Estimate|September 2009||2009-09-30|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|MaNeS||Maastricht Neck Study: Cervical Range of Motion in Whiplash Patients|MaNeS (Maastricht Neck Study): Development of Chronic Disability in Neck Pain Patients After a Motor Vehicle Accident|Terminated|||100|Anticipated|Maastricht University Medical Center|||1|Respond was to low.|f||||t||||||||||2018-06-01 00:43:13.027972|2018-06-01 00:43:13.027972
NCT00952497|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2012-02-07|2009-08-03|2009-08-06|Estimate|||||||2012-02-07|2012-02-08|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer|A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination With Chemotherapy as First-Line Therapy in Subjects With Advanced Gastric Cancer|Completed||Phase 2|48|Actual|ACT Biotech, Inc||1|||f||||f||||||||||2018-06-01 00:43:13.08455|2018-06-01 00:43:13.08455
NCT00952484|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2011-05-14||2016-03-29|2009-08-05|2009-08-06|Estimate|2011-06-28|2011-07-26|Estimate||||2016-03-29|2016-05-02|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)|A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Historical Control Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)|Completed||Phase 2|13|Actual|Alexion Pharma GmbH||2|||f||||t||||||||||2018-06-01 00:43:13.182365|2018-06-01 00:43:13.182365
NCT00952471|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2015-05-19|2009-08-04|2009-08-06|Estimate|||||||2015-05-19|2015-05-21|Estimate|September 2004||2004-09-30|May 2015|2015-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Reduction in Clinical Variance Using Targeted Design Changes in Computerized Provider Order Entry Order (CPOE) Sets|Reduction in Clinical Variance Using Targeted Design Changes in Computerized Provider Order Entry Order (CPOE) Sets|Completed||Phase 3|458|Actual|Children's Research Institute||2|||f||||f||||||||||2018-06-01 00:43:13.682084|2018-06-01 00:43:13.682084
NCT00952458|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-02|||2012-08-23|2009-08-03|2009-08-06|Estimate|||||||2012-08-23|2012-08-24|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|EndoBISs||Bispectral Index Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography|Bispectral Index Monitoring as an Adjunct to Standard Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography|Completed||N/A|144|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 00:43:13.742451|2018-06-01 00:43:13.742451
NCT00952445|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2009-08-05|2009-08-05|2009-08-06|Estimate|||||||2009-08-05|2009-08-06|Estimate|December 2003||2003-12-31|August 2009|2009-08-31|June 2004|Actual|2004-06-30|||||Interventional|||A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|70|Actual|InteKrin Therapeutics, Inc.||3|||||||f||||||||||2018-06-01 00:43:13.807426|2018-06-01 00:43:13.807426
NCT00952432|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2011-04-11|2009-08-04|2009-08-06|Estimate|||||||2011-04-11|2011-04-12|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Compare the Efficacy of Acupuncture Therapy and Carbamazepine Oral Dosage in Patients With Carpal Tunnel Syndrome by Multiple Excitability Test|A Single-center, Prospective, Randomized, Positive Controlled, Parallel Design Trial to Compare the Efficacy of Acupuncture Therapy and Carbamazepine Oral Dosage in Patients With Carpal Tunnel Syndrome by Multiple Excitability Test|Unknown status|Recruiting|N/A|80|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-06-01 00:43:13.894433|2018-06-01 00:43:13.894433
NCT00952419|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2011-06-08||2016-04-12|2009-08-04|2009-08-06|Estimate|2011-06-08|2011-07-11|Estimate||||2016-04-12|2016-04-14|Estimate|August 2009||2009-08-31|April 2016|2016-04-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years|Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years|Completed||Phase 2|474|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 00:43:14.03003|2018-06-01 00:43:14.03003
NCT00952406|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2015-12-10|2009-08-05|2009-08-06|Estimate|||||||2015-12-10|2015-12-14|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||A Multi Center Study to Validate a Condition-specific Measure of Sexual Health in Women With Pelvic Floor Disorders|A Multi Center Study to Validate a Condition-specific Measure of Sexual Health in Women With Pelvic Floor Disorders|Completed|||877|Actual|International Urogynecological Society|||1||f||||f||||||None Retained|"~     No Biospecimens are to be retained.~   "|||2018-06-01 00:43:14.963534|2018-06-01 00:43:14.963534
NCT00952393|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2015-11-25||2016-01-06|2009-08-04|2009-08-06|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||This is a collection of volunteers from the health science community who responded to approved advertisements.|Nicotinic Receptors and Schizophrenia|Nicotinic Receptors and Schizophrenia|Completed||Phase 1|10|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 00:43:15.041169|2018-06-01 00:43:15.041169
NCT00952380|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2018-04-09|2009-08-04|2009-08-06|Estimate|||||||2018-04-09|2018-04-11|Actual|August 20, 2009|Actual|2009-08-20|April 2018|2018-04-30|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Interventional|||Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients|A Three Month Prospective Open Label Study Of Therapy With Fragmin(Registered) (Dalteparin Sodium Injection) In Children With Venous Thromboembolism With Or Without Malignancies|Completed||Phase 2|38|Actual|Pfizer||1|||f||||f||||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-06-01 00:43:15.26039|2018-06-01 00:43:15.26039
NCT00952367|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2012-03-12||2012-03-12|2009-08-03|2009-08-06|Estimate|2012-03-12|2012-04-23|Estimate||||2012-03-12|2012-04-23|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China|Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children Aged 12-18 Months in Six Cities of China|Completed|||3641|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||Samples Without DNA|"~     Nasopharyngeal swab~   "|||2018-06-01 00:43:15.418567|2018-06-01 00:43:15.418567
NCT00952354|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-08-04|2009-08-04|2009-08-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|August 2009|Anticipated|2009-08-31|April 2009|Actual|2009-04-30||Observational|||Oral Language in Children With Down Syndrome|Oral Language in Children With Down Syndrome: Lexical, Syntactic and Semantic Aspects|Unknown status|Active, not recruiting||60|Anticipated|University of Sao Paulo|||1||f||||t||||||||||2018-06-01 00:43:15.917637|2018-06-01 00:43:15.917637
NCT00952341|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2011-07-01|2011-04-01|2017-05-02|2009-08-05|2009-08-06|Estimate|2011-08-23|2011-09-27|Estimate|2011-04-22|2011-04-29|Estimate|2017-05-02|2017-06-02|Actual|August 25, 2009|Actual|2009-08-25|May 2017|2017-05-31|May 5, 2010|Actual|2010-05-05|April 4, 2010|Actual|2010-04-04||Interventional|||Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)|A Phase III, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Safety, Tolerability and Efficacy of MK0869/Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With High-Dose Cisplatin|Completed||Phase 3|421|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:43:16.014793|2018-06-01 00:43:16.014793
NCT00952328|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-04-09|2009-08-03|2009-08-06|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2009||2009-08-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|ELF||Effect of Early Limited Formula Use on Breastfeeding Outcomes|Effect of Early Limited Formula Use on Breastfeeding Outcomes|Completed||N/A|40|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:43:16.431294|2018-06-01 00:43:16.431294
NCT00952315|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-02-14|2009-08-04|2009-08-06|Estimate|||||||2017-02-14|2017-02-16|Actual|August 2009||2009-08-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery|Randomized Controlled Trial Comparing Three Different Modalities of Newer Lithotrites For Intracorporeal Lithotripsy|Completed||N/A|270|Actual|Indiana Kidney Stone Institute||3|||f||||f||||||||No||2018-06-01 00:43:16.49233|2018-06-01 00:43:16.49233
NCT00952302|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2009-08-04|2009-08-04|2009-08-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of the Effects of Iron Levels on the Lungs at High Altitude|Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension|Completed||N/A|33|Actual|University of Oxford||4|||f||||f||||||||||2018-06-01 00:43:16.569336|2018-06-01 00:43:16.569336
NCT00952289|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|2011-12-16|2010-06-18|2018-02-12|2009-08-05|2009-08-06|Estimate|2011-12-16|2012-01-24|Estimate|2010-06-18|2010-06-22|Estimate|2018-02-12|2018-03-12|Actual|August 2009||2009-08-31|February 2018|2018-02-28|October 2015|Actual|2015-10-31|November 2010|Actual|2010-11-30||Interventional|||COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial|A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis|Completed||Phase 3|309|Actual|Incyte Corporation||2|||f||||t||||||||||2018-06-01 00:43:16.715292|2018-06-01 00:43:16.715292
NCT00952276|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2011-08-26||2011-08-26|2009-08-03|2009-08-06|Estimate|2011-08-26|2011-10-03|Estimate||||2011-08-26|2011-10-03|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly|Immunogenicity and Safety of Multiple Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adult and Elderly Subjects|Completed||Phase 2|548|Actual|Sanofi||5|||f||||f||||||||||2018-06-01 00:43:17.582327|2018-06-01 00:43:17.582327
NCT00952263|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2016-09-14|2009-08-04|2009-08-06|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MBL-HCV1||Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C|Open-Label, Dose Escalation Phase I Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (MBL-HCV1) Against Hepatitis C E2 Glycoprotein|Completed||Phase 1|31|Actual|MassBiologics||1|||f||||f||||||||||2018-06-01 00:43:19.418112|2018-06-01 00:43:19.418112
NCT00952250|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2011-12-01|2009-08-04|2009-08-06|Estimate|||||||2011-12-01|2011-12-02|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Targeted Feedback Reports to Improve Acute Coronary Syndromes (ACS) Care|Personalized and Targeted Feedback in the ACTION-Registry-GWTG|Completed||N/A|149|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:43:19.489485|2018-06-01 00:43:19.489485
NCT00952237|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2018-04-23|2009-08-04|2009-08-06|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2003||2003-01-31|May 2016|2016-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF|Completed||Phase 1|13|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 00:43:19.568589|2018-06-01 00:43:19.568589
NCT00952224|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-08-04|2009-08-04|2009-08-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|November 2006||2006-11-30|August 2009|2009-08-31|March 2009|Actual|2009-03-31|May 2008|Actual|2008-05-31||Observational|||Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome|Prognostic Significance and Determinants of Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance in Acute Reperfused Myocardial Infarction|Completed|||267|Actual|University of Leipzig|||1||f||||f||||||||||2018-06-01 00:43:19.672179|2018-06-01 00:43:19.672179
NCT00952211|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2016-01-27||2016-03-07|2009-08-03|2009-08-06|Estimate|2016-03-07|2016-04-04|Estimate||||2016-03-07|2016-04-04|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|BOSAST||Burden of Obstructive Sleep Apnea in Stroke (BOSAST)|Burden of Obstructive Sleep Apnea in Stroke (BOSAST)|Terminated||Phase 4|3|Actual|University of California, San Diego||2||problems with recruitment|f||||t||||||||No||2018-06-01 00:43:19.793607|2018-06-01 00:43:19.793607
NCT00952198|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2012-08-29|2009-08-04|2009-08-06|Estimate|||||||2012-08-29|2012-08-30|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Safety Study of ARRY-403 in Patients With Type 2 Diabetes||Completed||Phase 1|128|Actual|Array BioPharma||2|||f||||f||||||||||2018-06-01 00:43:19.984069|2018-06-01 00:43:19.984069
NCT00952185|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2015-06-03|2009-08-04|2009-08-06|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers|Clinical Correlates of Immunologic Responses to the Flu Vaccine|Terminated||N/A|9|Actual|City of Hope Medical Center||||Very low enrollment and follow-up, cannot meet study objectives|f||||t||||||||||2018-06-01 00:43:20.067647|2018-06-01 00:43:20.067647
NCT00952172|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-08-04|2009-08-04|2009-08-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Stair Stepping Exercise Training in Patients With Obstructive Sleep Apnea Syndrome|Effectiveness of Stair Stepping Exercise Training on Cardiopulmonary Fitness and Sleep Situation in Patients With Obstructive Sleep Apnea Syndrome|Completed||Phase 2|47|Actual|Chang Gung Memorial Hospital|||||f||||t||||||||||2018-06-01 00:43:20.169499|2018-06-01 00:43:20.169499
NCT00952159|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2011-07-01|2009-08-04|2009-08-06|Estimate|||||||2011-07-01|2011-07-04|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|CYTRAM||CYTRAM (Cytochrome P450, Tramadol)|Validation of a New Method to Detect CYP2D6 Poor Metabolizers by Monitoring Seric Concentrations of O-demethyl-tramadol and Tramadol to Make a Ratio in Comparison With Genotyping in Post-operative Patients Treated With Intravenous Tramadol|Completed|||301|Actual|University Hospital, Caen|||2||f||||f||||||Samples With DNA|"~     We propose to phenotype CYP2D6 in post-operative patients treated by tramadol by monitoring~     seric concentrations of O-demethyl tramadol and tramadol to make a ratio in comparision with~     genotype, and to find a threeshold to determine poor metabolizers. As already described,~     genotyping CYP2D6 will use a rapid detection method of the alleles implicated in poor~     metabolizer status (CYP2D6*3, *4, *5 et *6) in a caucasian population~   "|||2018-06-01 00:43:20.221614|2018-06-01 00:43:20.221614
NCT00952146|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-08-04|2009-08-04|2009-08-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Transgastric Peritoneoscopy and Appendectomy|Transgastric Diagnostic Peritoneoscopy (Laparoscopy) and Appendectomy - A Pilot Study|Unknown status|Recruiting|N/A|30|Anticipated|Sodra Alvsborgs Hospital||1|||f||||f||||||||||2018-06-01 00:43:20.289956|2018-06-01 00:43:20.289956
NCT00952133|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2012-06-22||2015-03-30|2009-08-03|2009-08-04|Estimate|2014-02-13|2014-03-31|Estimate||||2015-03-30|2015-04-17|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|July 2010|Actual|2010-07-31||Interventional|PONV||Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV|Randomized Double Blind Study to Evaluate the Efficacy of IV Palo w/ IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed Post-Operative Nausea/Vomiting in Subj Undergoing Laparoscopic Surgeries w/a High Emetogenic Risk|Completed||Phase 4|118|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 00:43:20.371008|2018-06-01 00:43:20.371008
NCT00952120|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2015-07-17||2015-08-24|2009-08-03|2009-08-04|Estimate|2015-08-24|2015-09-24|Estimate||||2015-08-24|2015-09-24|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional||104 unique patients were enrolled with a total of 157 wounds (80 of the wounds received GSUC and 77 of the wounds received vacuum-assisted closure).|Comparison of Two Methods of Securing Skin Grafts Using Negative Pressure Wound Therapy: Vacuum Assisted Closure (VAC) and Gauze Suction (GSUC)|Comparison of Two Methods of Securing Skin Grafts Using Negative Pressure Wound Therapy: VAC and GSUC|Completed||Phase 3|104|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 00:43:20.595728|2018-06-01 00:43:20.595728
NCT00952107|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2012-06-11|2009-08-03|2009-08-04|Estimate|||||||2012-06-11|2012-06-13|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Objective Flap Assessment During Reconstructive Surgery|Objective Flap Assessment During Reconstructive Surgery|Completed||Early Phase 1|6|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-06-01 00:43:20.828013|2018-06-01 00:43:20.828013
NCT00952094|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-02|||2009-08-03|2009-08-03|2009-08-04|Estimate|||||||2009-08-03|2009-08-04|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493|Randomized, Open Clinical Trial to Evaluate Pharmacokinetic, Pharmacodynamic and Safety Profiles After Single Oral Administration of KRN1493 in Healthy Korean Male Subjects|Completed||Phase 1|39|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-06-01 00:43:20.899389|2018-06-01 00:43:20.899389
NCT00952081|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2012-06-22||2015-01-26|2009-08-03|2009-08-04|Estimate|2013-08-23|2013-10-30|Estimate||||2015-01-26|2015-02-09|Estimate|July 2009||2009-07-31|January 2015|2015-01-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients|A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients|Completed||Phase 4|22|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 00:43:20.977031|2018-06-01 00:43:20.977031
NCT00952068|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2009-04-16||2012-04-25|2009-06-18|2009-08-04|Estimate|2009-06-18|2009-08-04|Estimate||||2012-04-25|2012-04-30|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day|A Pharmacodynamic/Pharmacokinetic Study to Determine the Onset of Analgesic Effect and Plasma Levels of Tramadol in Patients With Acute Low Back Pain Receiving a Single 200 mg Dose of Tramadol Contramid® Once-a-Day|Completed||Phase 2|47|Actual|Labopharm Inc.||1|||f||||f||||||||||2018-06-01 00:43:21.268604|2018-06-01 00:43:21.268604
NCT00952055|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2015-01-15|2009-08-03|2009-08-04|Estimate|||||||2015-01-15|2015-01-16|Estimate|July 2003||2003-07-31|January 2015|2015-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin|Effects of Standard Treatment of Acute Coronary Syndromes on Macrophage Activity as Measured by Serum Neopterin|Terminated|||152|Actual|Winthrop University Hospital|||1|"1) A delay in obtaining immunoassays to measure serum neopterin 2)altered relevance of the~   expected experimental results to clinical practice"|f||||f||||||||||2018-06-01 00:43:21.520988|2018-06-01 00:43:21.520988
NCT00952042|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-07-18|2009-08-03|2009-08-04|Estimate|||||||2014-07-18|2014-07-21|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Resistance Training as Treatment of Achilles Tendinopathy|Heavy Slow Resistance Versus Eccentric Training in the Treatment of Achilles Tendinopathy. A Randomized Controlled Trial.|Completed||N/A|47|Actual|University of Copenhagen||2|||f||||t||||||||||2018-06-01 00:43:21.595191|2018-06-01 00:43:21.595191
NCT00952029|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|||2016-12-27|2009-08-01|2009-08-04|Estimate|||||||2016-12-27|2016-12-28|Estimate|March 2010||2010-03-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer|Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer|Active, not recruiting||Phase 2/Phase 3|492|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||||2018-06-01 00:43:21.685227|2018-06-01 00:43:21.685227
NCT00952016|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2016-10-13|2009-08-03|2009-08-04|Estimate|||||||2016-10-13|2016-10-14|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MESH||Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency|A Non-randomised Phase II Trial of Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency|Terminated||Phase 2|2|Actual|Royal Marsden NHS Foundation Trust||||Lack of recruitment - only 2 patients recruited.|f||||t||||||||||2018-06-01 00:43:21.909848|2018-06-01 00:43:21.909848
NCT00952003|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-05-29|2009-08-03|2009-08-04|Estimate|||||||2017-05-29|2017-05-31|Actual|July 2009||2009-07-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|October 22, 2014|Actual|2014-10-22||Interventional|||Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients|Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients|Active, not recruiting||Phase 2|40|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||||2018-06-01 00:43:21.974234|2018-06-01 00:43:21.974234
NCT00951990|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-02|||2016-04-04|2009-08-03|2009-08-04|Estimate|||||||2016-04-04|2016-04-06|Estimate|January 2005||2005-01-31|April 2016|2016-04-30|August 2008|Actual|2008-08-31|April 2006|Actual|2006-04-30||Interventional|||Ergometer Cycling After Replacement of the Hip or Knee Joint|A Multicenter Randomized Controlled Trail of Ergometer Cycling After Hip and Knee Replacement Surgery|Completed||Phase 1/Phase 2|457|Actual|Verein zur Förderung der Rehabilitationsforschung in Schleswig-Holstein|||||f||||t||||||||||2018-06-01 00:43:22.068383|2018-06-01 00:43:22.068383
NCT00951977|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2017-03-10|2009-08-03|2009-08-04|Estimate|||||||2017-03-10|2017-03-14|Actual|October 2009||2009-10-31|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study|Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study|Completed|||7029|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||||Yes||2018-06-01 00:43:22.145554|2018-06-01 00:43:22.145554
NCT00951964|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-05-06|2009-08-03|2009-08-04|Estimate|||||||2014-05-06|2014-05-07|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)|Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)|Completed||Phase 2|18|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 00:43:22.240502|2018-06-01 00:43:22.240502
NCT00951951|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2015-06-25|2009-08-03|2009-08-04|Estimate|||||||2015-06-25|2015-06-26|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Gait Analysis of Anterior Versus Posterior Approach in Performance of Total Hip Arthroplasty|Gait Analysis of Anterior vs. Posterior Approach in Performance of Total Hip Arthroplasty: A Multi-Centre, Prospective Trial|Completed||N/A|64|Actual|Medacta USA||2|||f||||t||||||||||2018-06-01 00:43:22.315528|2018-06-01 00:43:22.315528
NCT00951938|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2014-04-07|2009-08-03|2009-08-04|Estimate|||||||2014-04-07|2014-04-08|Estimate|August 2009||2009-08-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Trinity Evolution in Anterior Cervical Disectomy and Fusion (ACDF)|A Radiographic and Clinical Study Evaluating a Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem Cells (Trinity Evolution™ Viable Cryopreserved Cellular Bone Matrix) in Patients Undergoing Anterior Cervical Discectomy and Fusion|Completed|||200|Actual|Orthofix Inc.|||||f||||f||||||||||2018-06-01 00:43:22.394641|2018-06-01 00:43:22.394641
NCT00951925|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2018-03-15|2009-08-03|2009-08-04|Estimate|||||||2018-03-15|2018-03-19|Actual|June 2005||2005-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Protocol to Obtain Bone Marrow for Research|Protocol to Obtain Bone Marrow for Research|Active, not recruiting|||28|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||Samples With DNA|"~     5cc of bone marrow aspirate~   "|||2018-06-01 00:43:22.516672|2018-06-01 00:43:22.516672
NCT00951912|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2012-06-26||2012-10-16|2009-08-03|2009-08-04|Estimate|2012-09-15|2012-10-16|Estimate||||2012-10-16|2012-10-17|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids|The Study of the Effects of Soy Isoflavones on the Metabolism of Glucose and Lipids in Postmenopausal Chinese Women With Impaired Glucose Regulation|Completed||N/A|165|Actual|Sun Yat-sen University|A relative long time of recruitment leading to a little different in dietary intakes among subjects;The menstrual period will leading to different estradiol;The different severity of the diabetes leading to the different dropout percentage.|3|||f||||t||||||||||2018-06-01 00:43:22.598|2018-06-01 00:43:22.598
NCT00951899|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2013-04-26||2013-10-17|2009-08-03|2009-08-04|Estimate|2013-06-04|2013-08-15|Estimate||||2013-10-17|2013-11-11|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional||Baseline characteristics are reported for only the randomized subjects (19/19).|The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics|The Effect of Colesevelam Hydrochloride on Disposition Index and Incretin Concentrations in Subjects With Type 2 Diabetes Using a Double-blind, Placebo-controlled, Parallel-group Study Design|Completed||Phase 4|38|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:43:23.361715|2018-06-01 00:43:23.361715
NCT00951886|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-02|||2009-08-03|2009-08-03|2009-08-04|Estimate|||||||2009-08-03|2009-08-04|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|July 2009|Anticipated|2009-07-31|||||Observational|||The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally|The Validity of Forced Expiratory Maneuvers in Ataxia Teleangiectasia Studied Longitudinally|Unknown status|Active, not recruiting||28|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 00:43:23.722154|2018-06-01 00:43:23.722154
NCT00951873|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2016-05-12|2009-07-31|2009-08-04|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2009||2009-07-31|May 2016|2016-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers|A Single-centre, Randomised, Placebo-controlled, Double-blind Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Local Tolerability of Ascending Subcutaneous Doses of Long Acting-rFVIIa in Healthy Male Subjects|Completed||Phase 1|38|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 00:43:23.780468|2018-06-01 00:43:23.780468
NCT00951860|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-09-22|2009-08-03|2009-08-04|Estimate|||||||2014-09-22|2014-09-23|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|AUBE||Assessment of Autonomic Maturation in Neonatal Period and Early Neural Development From a Longitudinal Prospective Cohort|Assessment of Autonomic Maturation in Neonatal Period and Early Neural Development From a Longitudinal Prospective Cohort : the AuBE Study|Completed|||302|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-06-01 00:43:23.876492|2018-06-01 00:43:23.876492
NCT00951847|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2009-08-03|2009-08-03|2009-08-04|Estimate|||||||2009-08-03|2009-08-04|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Oxcarbazepine 300 mg/5mL Oral Suspension of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc.) With Trileptal® 300 mg/5mL Oral Suspension (Containing Oxcarbazepine 300 mg/5mL) of Novartis Pharmaceutical Corporation in Healthy, Adult, Male, Human Subjects Under Fed Condition|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 00:43:23.956104|2018-06-01 00:43:23.956104
NCT00951834|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-12-21|2009-08-03|2009-08-04|Estimate|||||||2017-12-21|2017-12-22|Actual|October 2009||2009-10-31|December 2017|2017-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SUN-AK||Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease|Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease|Completed||Phase 2/Phase 3|21|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:43:24.027481|2018-06-01 00:43:24.027481
NCT00951821|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2015-02-20||2015-08-04|2009-08-03|2009-08-04|Estimate|2015-08-04|2015-08-31|Estimate||||2015-08-04|2015-08-31|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Concurrent Treatment for Depressed Parents and DepressedAdolescents|Concurrent Treatment for Parents and Adolescents Who Attempt Suicide|Completed||N/A|24|Actual|Brown University|The outcome data from this study must be considered within the context of its limitations including the small sample size which reduces both the power to detect differences between groups as well as the stability of findings.|2|||f||||t||||||||||2018-06-01 00:43:24.130654|2018-06-01 00:43:24.130654
NCT00951808|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2012-04-25||2013-04-16|2009-07-31|2009-08-04|Estimate|2013-02-22|2013-04-05|Estimate||||2013-04-16|2013-04-24|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|PROACTIVE|The randomization trial has been terminated due to the lack of enrollment. Therefore, the results were not reported by Arm and the total number of subjects (237) enrolled in the feasibility study was used.|Preventing Acute Chest Syndrome by Transfusion Feasibility Study|Preventing Acute Chest Syndrome by Transfusion Feasibility Study( PROACTIVE Feasibility Study)|Completed||N/A|237|Actual|New England Research Institutes|The feasibility study has been completed, but the randomization trial has been terminated early due to the lack of enrollment. Therefore, the results were reported with the subjects who completed the feasibility study and were not reported by Arm.|3|||f||||t||||||||||2018-06-01 00:43:24.416682|2018-06-01 00:43:24.416682
NCT00951795|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-07-20|2009-08-03|2009-08-04|Estimate|||||||2015-07-20|2015-07-21|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|September 2009||2009-09-30|September 2009|Anticipated|2009-09-30||Observational|||Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts|Clinical Evaluation of the Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts|Withdrawn|||0|Actual|Biosite|||2||f||||f||||||||||2018-06-01 00:43:24.610285|2018-06-01 00:43:24.610285
NCT00951782|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2013-12-19|2009-08-03|2009-08-04|Estimate|||||||2013-12-19|2013-12-20|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|TMS||Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation|Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2/Phase 3|115|Actual|BeerYaakov Mental Health Center||6|||f||||f||||||||||2018-06-01 00:43:24.663881|2018-06-01 00:43:24.663881
NCT00951769|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-01-14|2009-08-03|2009-08-04|Estimate|||||||2015-01-14|2015-01-15|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Algorithms in a Simulated Difficult Intubation Scenario|A Comparison of the Difficult Airway Society (UK) and Australian Patient Safety Foundation Crisis Algorithms for Difficult Intubation in a Simulated Difficult Intubation Scenario|Completed|||30|Actual|Aintree University Hospitals NHS Foundation Trust|||3||f||||f||||||||||2018-06-01 00:43:24.757036|2018-06-01 00:43:24.757036
NCT00951756|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2013-06-22|2009-08-03|2009-08-04|Estimate|||||||2013-06-22|2013-06-25|Estimate|July 2009||2009-07-31|June 2013|2013-06-30|August 2011|Actual|2011-08-31|January 2010|Actual|2010-01-31||Interventional|CaFE||Controlled Feeding Experiment|Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Composition|Completed||N/A|10|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:43:24.870163|2018-06-01 00:43:24.870163
NCT00951743|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2009-08-07|2009-08-03|2009-08-04|Estimate|||||||2009-08-07|2009-08-11|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|May 2010|Anticipated|2010-05-31||Interventional|||Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)|Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in the Blood Cellular Reservoir (PBMCs) of HIV Patients With Suppressed Plasma Viral Load.|Unknown status|Recruiting|Phase 2|40|Anticipated|Rapid Laboratories Inc.||2|||f||||||||||||||2018-06-01 00:43:24.929844|2018-06-01 00:43:24.929844
NCT00951730|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-07-03|2009-08-03|2009-08-04|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|SAOS/T21||Evaluation of a Simplified Method for Diagnosis of Sleep Apnea in Children and Adults With Down Syndrome|Evaluation of a Simplified Method for Diagnosis of Sleep Apnea in Children and Adults With Down Syndrome|Completed|||97|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-06-01 00:43:25.010522|2018-06-01 00:43:25.010522
NCT00951717|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2011-11-18|2009-08-03|2009-08-04|Estimate|||||||2011-11-18|2011-11-22|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Using a Preparation and Education Intervention to Reduce Postpartum Depression Among New Mothers (The MADE IT 2 Study)|Preparation and Patient Education to Reduce Postpartum Depressive Symptoms|Completed||N/A|590|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 00:43:25.093492|2018-06-01 00:43:25.093492
NCT00951704|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2017-11-27|2009-08-03|2009-08-04|Estimate|||||||2017-11-27|2017-11-28|Actual|November 2008||2008-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluation of the Quality of Cardio-Pulmonary Resuscitation (CPR) in Cardiac Arrest Patients|Evaluating the Quality of Prehospital and In-hospital Cardio-pulmonary Resuscitation - Comparing the Compressions to Concurrent Vital Signs (Invasive Blood Pressure, Cerebral Oxygen Saturation, EtCO2) and Iatrogenic Injuries Associated to Chest Compressions.|Active, not recruiting|||1000|Anticipated|Tampere University Hospital|||1||f||||t||||||||||2018-06-01 00:43:25.206443|2018-06-01 00:43:25.206443
NCT00951691|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-03-18|2009-08-03|2009-08-04|Estimate|||||||2014-03-18|2014-03-19|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Enhanced Medical Rehabilitation for Disablement|Enhanced Acute Medical Rehabilitation for Disablement|Completed||Phase 2|25|Actual|Washington University School of Medicine||2|||f||||||||||||||2018-06-01 00:43:25.294159|2018-06-01 00:43:25.294159
NCT00951678|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-04-29|2009-08-03|2009-08-04|Estimate|||||||2015-04-29|2015-04-30|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Determination of Anatomic Variations of the Internal Jugular and Femoral Veins Using Ultrasound in the Emergency Department|Determination of Anatomic Variations of the Internal Jugular and Femoral Veins Using Ultrasound in the Emergency Department|Unknown status|Recruiting||500|Anticipated|Tampa General Hospital|||1||f||||f||||||||||2018-06-01 00:43:25.365206|2018-06-01 00:43:25.365206
NCT00951665|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2016-01-04||2016-05-17|2009-08-03|2009-08-04|Estimate|2016-05-17|2016-06-24|Estimate||||2016-05-17|2016-06-24|Estimate|August 2009||2009-08-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|February 2012|Actual|2012-02-29||Interventional|||A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer|A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|107|Actual|Genentech, Inc.|Given the small sample size in the different patient subsets, no formal hypothesis testing was performed, and all statistical analyses should be considered descriptive and hypothesis-generating only.|6|||f||||||||||||||2018-06-01 00:43:25.481799|2018-06-01 00:43:25.481799
NCT00951652|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-11-03|2009-08-03|2009-08-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|July 1998||1998-07-31|November 2015|2015-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Efficacy of Adding Interpersonal and Emotional Processing Therapy Techniques to Cognitive Behavioral Therapy to Treat Generalized Anxiety Disorder|Cognitive and Interpersonal Therapies for Generalized Anxiety|Completed||N/A|83|Actual|Penn State University||2|||f||||||||||||||2018-06-01 00:43:27.013051|2018-06-01 00:43:27.013051
NCT00951639|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-08-03|2009-08-03|2009-08-04|Estimate|||||||2009-08-03|2009-08-04|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Cassia Cinnamon for Glucose Uptake in Young Women|Cassia Cinnamon and Acute Endurance Exercise for the Enhancement of Glucose Uptake in Healthy Young Women|Completed||N/A|10|Actual|Baylor University||3|||f||||f||||||||||2018-06-01 00:43:27.084054|2018-06-01 00:43:27.084054
NCT00951626|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|||2015-06-03|2009-08-01|2009-08-04|Estimate|||||||2015-06-03|2015-06-08|Estimate|September 2005||2005-09-30|June 2015|2015-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Standardized Nursing Intervention Protocol for HCT Patients|A Standardized Nursing Intervention Protocol for HCT Patients|Completed||N/A|282|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:43:27.149611|2018-06-01 00:43:27.149611
NCT00951613|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2013-03-18|2009-08-02|2009-08-04|Estimate|||||||2013-03-18|2013-03-20|Estimate|July 2009||2009-07-31|March 2013|2013-03-31||||January 2012|Actual|2012-01-31||Interventional|||A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC)|Completed||Phase 2|72|Actual|Nippon Kayaku Co.,Ltd.|||||f||||t||||||||||2018-06-01 00:43:27.243557|2018-06-01 00:43:27.243557
NCT00951600|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2009-08-03|2009-08-03|2009-08-04|Estimate|||||||2009-08-03|2009-08-04|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioavailability Study Comparing Oxcarbazepine 300 mg/5mL Oral Suspension of OHM Laboratories (a Subsidiary of Ranbaxy Pharmaceuticals Inc) With Trileptal® 300 mg/5mL Oral Suspension (Containing Oxcarbazepine 300 mg/5mL) of Novartis Pharmaceutical Corporation in Healthy, Adult, Male, Human Subjects Under Fasting Condition.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 00:43:27.331336|2018-06-01 00:43:27.331336
NCT00951587|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-02|||2010-03-10|2009-08-03|2009-08-04|Estimate|||||||2010-03-10|2010-03-11|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Night Procedure|Completed||Phase 3|49|Actual|Given Imaging Ltd.||1|||f||||f||||||||||2018-06-01 00:43:27.457109|2018-06-01 00:43:27.457109
NCT00951574|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2012-01-31|2009-08-03|2009-08-04|Estimate|||||||2012-01-31|2012-02-01|Estimate|October 2003||2003-10-31|January 2012|2012-01-31|July 2008|Actual|2008-07-31|May 2007|Actual|2007-05-31||Interventional|||Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)|Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.|Completed||Phase 3|1166|Actual|Italfarmaco||2|||f||||t||||||||||2018-06-01 00:43:27.534268|2018-06-01 00:43:27.534268
NCT00951561|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2010-09-30||2011-06-14|2009-08-03|2009-08-04|Estimate|2010-09-30|2010-10-04|Estimate||||2011-06-14|2011-06-16|Estimate|November 2006||2006-11-30|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen|A Randomized Four-Way Crossover Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen|Completed||N/A|115|Actual|Another Way Products||2|||f||||f||||||||||2018-06-01 00:43:27.676336|2018-06-01 00:43:27.676336
NCT00951548|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-02|||2009-08-03|2009-08-03|2009-08-04|Estimate|||||||2009-08-03|2009-08-04|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|||||Interventional|||Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis|Food Supplementation With the Probiotic Preparation VSL#3 as a Support to Standard Pharmaceutical Therapy in Patients With Mild to Moderate Active Ulcerative Colitis. A Double-blind, Randomized, Placebo Controlled Study|Completed||N/A|144|Actual|VSL Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:43:27.90037|2018-06-01 00:43:27.90037
NCT00951535|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|||2016-10-05|2009-08-01|2009-08-04|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|September 2026|Anticipated|2026-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17|A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0M0 Prostate Cancer|Active, not recruiting||Phase 2|251|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 00:43:27.974692|2018-06-01 00:43:27.974692
NCT00951522|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-09-24|2009-08-03|2009-08-04|Estimate|||||||2009-09-24|2009-09-25|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers|Completed||Phase 1|15|Anticipated|Gilead Sciences||5|||f||||f||||||||||2018-06-01 00:43:28.058304|2018-06-01 00:43:28.058304
NCT00951509|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|2014-11-07||2015-07-28|2009-08-03|2009-08-04|Estimate|2015-07-28|2015-08-24|Estimate||||2015-07-28|2015-08-24|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Virtual Reality Based Testing of Power Wheelchair Driving Skills|Computer-based and Virtual Assessment of Power Wheelchair Mobility|Completed|||31|Actual|VA Office of Research and Development|||5||f||||f||||||||||2018-06-01 00:43:28.127789|2018-06-01 00:43:28.127789
NCT00951496|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|2017-10-04||2018-04-19|2009-08-01|2009-08-04|Estimate|2018-04-19|2018-05-18|Actual||||2018-04-19|2018-05-18|Actual|July 2009||2009-07-31|April 2018|2018-04-30|March 15, 2022|Anticipated|2022-03-15|January 2016|Actual|2016-01-31||Interventional|||Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma|Active, not recruiting||Phase 3|1560|Actual|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-06-01 00:43:28.445447|2018-06-01 00:43:28.445447
NCT00951483|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2015-04-20||2016-08-27|2009-08-03|2009-08-04|Estimate|2016-08-27|2016-10-24|Estimate||||2016-08-27|2016-10-24|Estimate|July 2009||2009-07-31|August 2016|2016-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Baseline analysis were conducted on all individuals who signed an informed consent document (N = 91)|Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients|Cardiovascular Biomarkers During Quetiapine Treatment of Depression|Completed||Phase 4|91|Actual|Loyola University||2|||f||||f||||||||No||2018-06-01 00:43:31.60218|2018-06-01 00:43:31.60218
NCT00951470|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2012-09-05|2009-08-03|2009-08-04|Estimate|||||||2012-09-05|2012-09-07|Estimate|October 2012||2012-10-31|September 2012|2012-09-30||||October 2016|Anticipated|2016-10-31||Interventional|||Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema|Lymphedema in Patients With Oral Cavity and Oropharyngeal Cancer: Prevalence, Functional Effects, and Treatment Outcomes|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 00:43:32.229564|2018-06-01 00:43:32.229564
NCT00951457|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-12-06|2009-08-03|2009-08-04|Estimate|||||||2017-12-06|2017-12-07|Actual|March 2009||2009-03-31|December 2017|2017-12-31|August 6, 2012|Actual|2012-08-06|August 6, 2012|Actual|2012-08-06||Interventional|||Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)|Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) - A Phase I/II Trial With Concomitant Evaluation of Safety and Efficacy|Completed||Phase 1/Phase 2|20|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||t||||||||||2018-06-01 00:43:32.317188|2018-06-01 00:43:32.317188
NCT00951444|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|||2016-07-01|2009-08-01|2009-08-04|Estimate|||||||2016-07-01|2016-07-06|Estimate||||July 2016|2016-07-31||||||||Interventional|||Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without MK-0646 as First-Line Therapy in Advanced Squamous Non-Small Cell Lung Carcinoma|Withdrawn||Phase 2|0|Actual|Alliance for Clinical Trials in Oncology||2||The study was not activated.|f||||||||||||||2018-06-01 00:43:32.401183|2018-06-01 00:43:32.401183
NCT00951431|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2011-02-18|2009-08-03|2009-08-04|Estimate|||||||2011-02-18|2011-02-21|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Gastric Functions & Proton Pump Inhibitor( PPI) Study|Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia|Unknown status|Recruiting|Phase 4|60|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:43:32.483902|2018-06-01 00:43:32.483902
NCT00951418|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2013-09-11|2009-08-03|2009-08-04|Estimate|||||||2013-09-11|2013-09-12|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|September 2013|Actual|2013-09-30|March 2010|Actual|2010-03-31||Observational|||Serum Clozapine and Cognition|Serum Clozapine and Cognition|Completed|||10|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 00:43:32.573527|2018-06-01 00:43:32.573527
NCT00951054|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2015-02-12|2009-08-02|2009-08-04|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2009||2009-02-28|February 2015|2015-02-28|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer|A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients With Triple Negative Phenotype|Completed||Phase 2|61|Anticipated|Nippon Kayaku Co.,Ltd.|||||f||||t||||||||||2018-06-01 00:43:38.018047|2018-06-01 00:43:38.018047
NCT00951405|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-06-26|2009-08-03|2009-08-04|Estimate|||||||2014-06-26|2014-06-27|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors|An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of Prophylactic Administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients With Inhibitors|Completed||Phase 2|23|Actual|Novo Nordisk A/S||3|||f||||t||||||||||2018-06-01 00:43:32.638234|2018-06-01 00:43:32.638234
NCT00951392|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2010-03-08|2009-08-03|2009-08-04|Estimate|||||||2010-03-08|2010-03-09|Estimate|May 2009||2009-05-31|March 2010|2010-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|COMPALICLAMP||Implication of Metabolic and Genomic Modifications in Elderly Subjects|Implication of Metabolic and Genomic Modifications in Elderly Subjects|Completed||N/A|35|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 00:43:32.746724|2018-06-01 00:43:32.746724
NCT00951379|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2015-10-20||2016-03-29|2009-08-03|2009-08-04|Estimate|2016-03-29|2016-04-06|Estimate||||2016-03-29|2016-04-06|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pioglitazone for Oral Premalignant Lesions|Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions an Inter-consortium Collaborative Study|Terminated||Phase 2|52|Actual|National Cancer Institute (NCI)||2||Due to slow accrual.|f||||t||||||||||2018-06-01 00:43:32.86472|2018-06-01 00:43:32.86472
NCT00951366|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-08-01|2009-08-03|2009-08-04|Estimate|||||||2017-08-01|2017-08-03|Actual|June 2008||2008-06-30|August 2017|2017-08-31||||January 1, 2099|Anticipated|2099-01-01|21 Years|Observational [Patient Registry]|CHILD||Bronchopulmonary Disease (BPD) Patient Registry|The Center for Healthy Infant Development (Child) Clinic Patient Registry|Recruiting|||500|Anticipated|Boston Children’s Hospital|||1||f||||f||||||Samples With DNA|"~     Buccal swabs~   "|||2018-06-01 00:43:33.640418|2018-06-01 00:43:33.640418
NCT00951353|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2017-02-02|2009-08-03|2009-08-04|Estimate|||||||2017-02-02|2017-02-06|Estimate|July 2009||2009-07-31|February 2017|2017-02-28|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Observational|||Immune Development in Pediatric Transplantation (IMPACT)|Immune Development and Alloimmunity in Pediatric Renal Transplant Recipients|Completed|||75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t|f|f||||||||2018-06-01 00:43:33.699329|2018-06-01 00:43:33.699329
NCT00951340|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2017-09-18|2009-08-03|2009-08-04|Estimate|||||||2017-09-18|2017-09-20|Actual|July 1996||1996-07-31|September 2017|2017-09-30|December 1998|Actual|1998-12-31|July 1998|Actual|1998-07-31||Interventional|||Desensitization and Cognitive Therapy in General Anxiety.|Desensitization and Cognitive Therapy in General Anxiety.|Completed||Phase 1|21|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 00:43:33.762202|2018-06-01 00:43:33.762202
NCT00951327|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2010-08-03|2009-08-03|2009-08-04|Estimate|||||||2010-08-03|2010-08-04|Estimate|November 2008||2008-11-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)|Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing ERCP.|Completed|||30|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 00:43:33.825823|2018-06-01 00:43:33.825823
NCT00951314|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|||2017-10-05|2009-08-01|2009-08-04|Estimate|||||||2017-10-05|2017-10-06|Actual|July 14, 2009||2009-07-14|March 19, 2013|2013-03-19|March 19, 2013||2013-03-19|||||Observational|||Brain Glutamate Receptors and Cocaine Dependence|Cocaine Dependence, Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Density, Genetics and Craving|Terminated|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:43:33.876647|2018-06-01 00:43:33.876647
NCT00951301|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2016-03-14|2009-08-03|2009-08-04|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2009||2009-07-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MRI-AF||Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation|Mangosteen Effects on Inflammatory Markers in Atrial Fibrillation Trial|Terminated||Phase 1|143|Actual|Mayo Clinic||2||Significantly lower accrual rate than anticipated, time constraints.|f||||t||||||||No||2018-06-01 00:43:34.054917|2018-06-01 00:43:34.054917
NCT00951288|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-07-31|2009-08-03|2009-08-04|Estimate|||||||2015-07-31|2015-08-03|Estimate|June 2009||2009-06-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|safAMD||Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration|Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration|Unknown status|Enrolling by invitation|Phase 1/Phase 2|30|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 00:43:34.123856|2018-06-01 00:43:34.123856
NCT00951275|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2014-06-04||2017-06-28|2009-07-31|2009-08-04|Estimate|2014-07-22|2014-08-12|Estimate||||2017-06-28|2017-08-03|Actual|October 31, 2009|Actual|2009-10-31|June 2017|2017-06-30|July 22, 2011|Actual|2011-07-22|July 22, 2011|Actual|2011-07-22||Interventional||Intent-to-Treat (ITT) population: all enrolled participants who recieved at least 1 dose of study medication.|A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Single Arm, Open-label Study of Early Improvement of Anemia and Fatigue During Treatment With Tocilizumab (TCZ) in Combination With DMARDs, in Adult Patients With Moderate to Severe Active Rheumatoid Arthritis.|Completed||Phase 3|105|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:43:34.249138|2018-06-01 00:43:34.249138
NCT00951262|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-02-10|2009-08-03|2009-08-04|Estimate|||||||2014-02-10|2014-02-11|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Intervention Study on Life Review Among Advanced Cancer Patients in Fuzhou, China|Development and Evaluation of a Life Review Program for Advanced Cancer Patients in Fuzhou, China|Completed||Phase 4|80|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-06-01 00:43:34.713863|2018-06-01 00:43:34.713863
NCT00951249|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2012-05-09|2009-07-31|2009-08-04|Estimate|||||||2012-05-09|2012-05-11|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Feasibility Study of a Multi-Component Intervention for Black Men Who Have Sex With Men|Feasibility Study of a Community-Level, Multi-Component Intervention for Black Men Who Have Sex With Men|Completed||N/A|1553|Actual|HIV Prevention Trials Network||1|||f||||||||||||||2018-06-01 00:43:34.770368|2018-06-01 00:43:34.770368
NCT00951236|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2014-02-10|2009-08-03|2009-08-04|Estimate|||||||2014-02-10|2014-02-12|Estimate|May 2009||2009-05-31|February 2014|2014-02-28||||||||Interventional|||Study Comparing One Versus Two Cortisone Injections for Trigger Finger|A Prospective, Randomized Study Comparing One vs. Two Cortisone Injections for Trigger Finger|Unknown status|Recruiting|N/A|392|Anticipated|Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-06-01 00:43:35.72374|2018-06-01 00:43:35.72374
NCT00951223|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-09-01|2009-08-03|2009-08-04|Estimate|||||||2015-09-01|2015-09-03|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Observational|REACHSVR||Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C|Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen® (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus|Withdrawn|||0|Actual|Kadmon Pharmaceuticals|||1|Lack of Enrollment|f||||t||||||||||2018-06-01 00:43:35.822945|2018-06-01 00:43:35.822945
NCT00951210|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-05-24|2009-08-03|2009-08-04|Estimate|||||||2015-05-24|2015-05-27|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|January 2011|Actual|2011-01-31||Interventional|||Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)|Phase I Study of Intramuscular (IM) Injections of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-Like Stromal Cells Derived From a Full Term Placenta.|Completed||Phase 1|12|Actual|Pluristem Ltd.||2|||f||||t||||||||||2018-06-01 00:43:35.885965|2018-06-01 00:43:35.885965
NCT00951197|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-04-27|2009-08-03|2009-08-04|Estimate|||||||2012-04-27|2012-04-30|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|AMIMAGE||Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects|Estimation of Microstructure Alteration by MRI in Dementia Among Elderly Subjects Retired From Agricultural Profession and Living in Rural Area in Gironde - Participants From the AMI Cohort.|Completed|||318|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-06-01 00:43:35.947188|2018-06-01 00:43:35.947188
NCT00951184|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-01|||2015-03-17|2009-08-01|2009-08-04|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2009||2009-05-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|October 2011|Actual|2011-10-31||Observational|||Depression Screening in Patients Undergoing Radiation Therapy For Cancer|Efficiency of Screening for Depression in Cancer Patients Receiving Radiotherapy|Completed|||463|Actual|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 00:43:36.015346|2018-06-01 00:43:36.015346
NCT00951171|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2012-07-10||2012-08-27|2009-08-03|2009-08-04|Estimate|2012-08-27|2012-08-28|Estimate||||2012-08-27|2012-08-28|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Cervical Occlusion During Intrauterine Insemination (IUI)|Evaluation of the Effect of Cervical Occlusion During Infertility Treatment by Intrauterine Insemination|Terminated||Phase 3|93|Actual|Women and Infants Hospital of Rhode Island|Randomization method found to be faulty|2||Randomization flawed. Results were poor in the innovative catheter group|f||||f||||||||||2018-06-01 00:43:36.125001|2018-06-01 00:43:36.125001
NCT00951158|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2015-05-11|2009-08-03|2009-08-04|Estimate|||||||2015-05-11|2015-05-12|Estimate|March 2010||2010-03-31|March 2012|2012-03-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors|A Molecular Pharmacodynamic Dose-titration Trial of Conjugated Linoleic Acid (CLA; Clarinol®) in Patients With Advanced Solid Tumors|Terminated||Phase 1|4|Actual|Dartmouth-Hitchcock Medical Center||1||Administrative suspension. PI/grant holder transferred to new institution.|f||||t||||||||||2018-06-01 00:43:37.076958|2018-06-01 00:43:37.076958
NCT00951145|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2013-04-08|2009-08-03|2009-08-04|Estimate|||||||2013-04-08|2013-04-09|Estimate||||April 2013|2013-04-30||||||||Observational|||Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem|Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem|Unknown status|Active, not recruiting||||Rothman Institute Orthopaedics|||||f||||f||||||||||2018-06-01 00:43:37.14456|2018-06-01 00:43:37.14456
NCT00951132|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2009-09-08|2009-08-03|2009-08-04|Estimate|||||||2009-09-08|2009-09-09|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|DECAMERONE||Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy|Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy|Unknown status|Recruiting|Phase 2|40|Anticipated|University Hospital, Akershus||2|||f||||t||||||||||2018-06-01 00:43:37.197753|2018-06-01 00:43:37.197753
NCT00951119|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2012-10-23|2009-08-03|2009-08-04|Estimate|||||||2012-10-23|2012-10-24|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|Reperate3||Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients|The Effect of Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients With Hypertension (Resperate-3) A Randomized, Double-blind Controlled Trial|Completed||Phase 3|48|Actual|Medical Research Foundation, The Netherlands||2|||f||||f||||||||||2018-06-01 00:43:37.272196|2018-06-01 00:43:37.272196
NCT00951106|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2010-07-26|2009-08-03|2009-08-04|Estimate|||||||2010-07-26|2010-07-27|Estimate|January 1998||1998-01-31|July 2010|2010-07-31|August 2009|Actual|2009-08-31|June 1999|Actual|1999-06-30||Interventional|||Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon|Therapeutic Efficacy Study of Pyrimethamine / Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon|Completed||N/A|||Walter Reed Army Institute of Research (WRAIR)||1|||f||||f||||||||||2018-06-01 00:43:37.334268|2018-06-01 00:43:37.334268
NCT00951093|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-02|2013-12-04||2014-02-25|2009-08-03|2009-08-04|Estimate|2014-02-25|2014-04-04|Estimate||||2014-02-25|2014-04-04|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational||"Patients were enrolled irrespective of GERD symptoms according to the following criteria:~age between 18 and 70 years,~BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 combined with significant comorbidities,~absence of gastroesophageal surgery, and~consent to undergo open GBP"|Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass|The Impact of Gastric Bypass on Gastroesophageal Reflux Disease in Patients With Morbid Obesity: a Prospective Study Based on Montreal Consensus|Completed|||53|Actual|Clinica Gastrobese|||1||f||||f||||||||||2018-06-01 00:43:37.415739|2018-06-01 00:43:37.415739
NCT00951080|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2013-04-05|2009-08-03|2009-08-04|Estimate|||||||2013-04-05|2013-04-09|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||SNaP Wound Care System Versus Traditional NPWT Device for Treatment of Chronic Wounds|Lower Extremity Venous and Diabetic Ulcer Negative Pressure Wound Therapy Trial.|Completed||Phase 2|132|Actual|Spiracur, Inc.||2|||f||||f||||||||||2018-06-01 00:43:37.809139|2018-06-01 00:43:37.809139
NCT00951067|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2014-01-30|2009-08-03|2009-08-04|Estimate|||||||2014-01-30|2014-01-31|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|PCD-LYMPH||Pneumatic Compression Treatment For Upper Extremity Acquired Lymphedema|Trial to Compare Pneumatic Compression Treatments for Upper Extremity Acquired Lymphedema|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||5||Funding not available to continue with study.|f||||f||||||||||2018-06-01 00:43:37.919101|2018-06-01 00:43:37.919101
NCT00951041|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31||2010-12-23|2017-01-16|2009-07-31|2009-08-04|Estimate||||2010-12-23|2010-12-30|Estimate|2017-01-16|2017-01-18|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults|Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years|Completed||Phase 2|130|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:43:38.103394|2018-06-01 00:43:38.103394
NCT00951028|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-03|||2013-06-17|2009-08-03|2009-08-04|Estimate|||||||2013-06-17|2013-06-18|Estimate|September 2008||2008-09-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Therapy Targeting Depression and HIV Treatment Adherence (The TRIAD Study)|Efficacy of CBT for Adherence and Depression in HIV Care Settings|Completed||N/A|240|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 00:43:38.213119|2018-06-01 00:43:38.213119
NCT00951015|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2013-08-22|2011-03-17|2017-12-14|2009-07-30|2009-08-03|Estimate|2013-08-22|2013-11-11|Estimate|2011-03-17|2011-03-28|Estimate|2017-12-14|2018-01-16|Actual|July 30, 2009||2009-07-30|April 2017|2017-04-30|December 22, 2016|Actual|2016-12-22|February 26, 2010|Actual|2010-02-26||Interventional|ING112276||A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects|A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects|Completed||Phase 2|208|Actual|ViiV Healthcare||4|||f||||f||||||||||2018-06-01 00:43:38.532309|2018-06-01 00:43:38.532309
NCT00951002|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2013-11-25|2009-07-31|2009-08-03|Estimate|||||||2013-11-25|2013-11-27|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||The Efficacy of Human Acellular Dermal Matrix in the Treatment of Anal Fistula|A Multicenter Clinical Trial to Evaluate the Efficacy of Human Acellular Dermal Matrix in the Treatment of Anal Fistula|Unknown status|Recruiting||1000|Anticipated|Beijing Chao Yang Hospital|||1||f||||t||||||||||2018-06-01 00:43:42.048024|2018-06-01 00:43:42.048024
NCT00950989|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30||2013-11-14|2016-09-01|2009-07-30|2009-08-03|Estimate||||2013-11-14|2013-12-06|Estimate|2016-09-01|2016-09-05|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate|A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|Completed||Phase 2|240|Actual|Amgen||4|||f||||||||||||||2018-06-01 00:43:42.193837|2018-06-01 00:43:42.193837
NCT00950976|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2012-04-24|2009-07-30|2009-08-03|Estimate|||||||2012-04-24|2012-04-25|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||Dose-response Enteral Citrulline for Normal Healthy Volunteers and Surgery Patients|Clinical Trial of Enteral Citrulline in Volunteers With Surgical Repair of Ventral Hernias|Completed||N/A|14|Actual|Nestlé||2|||f||||f||||||||||2018-06-01 00:43:42.265799|2018-06-01 00:43:42.265799
NCT00950963|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2009-01-12||2015-04-23|2009-06-22|2009-08-03|Estimate|2009-06-22|2009-08-03|Estimate||||2015-04-23|2015-04-28|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|June 2008|Actual|2008-06-30|May 2007|Actual|2007-05-31||Interventional|NATCHOS||Nurse Telephone Management of Cholesterol in Diabetes|Nurse-run, Telephone-based Intervention to Improve Lipids in Diabetics|Completed||N/A|762|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||||2018-06-01 00:43:42.331803|2018-06-01 00:43:42.331803
NCT00950950|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-02-03|2009-07-31|2009-08-03|Estimate|||||||2011-02-03|2011-02-04|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate the Effect of AMG 785 on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Effect of AMG 785 on Parameters of Bone Quality of the Forearm Using pQCT in Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 1|24|Actual|Amgen||2|||f||||||||||||||2018-06-01 00:43:42.714556|2018-06-01 00:43:42.714556
NCT00950937|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2009-02-16||2009-08-04|2009-06-25|2009-08-03|Estimate|2009-06-25|2009-08-03|Estimate||||2009-08-04|2009-08-11|Estimate|June 2006||2006-06-30|August 2009|2009-08-31|July 2008|Actual|2008-07-31|January 2007|Actual|2007-01-31||Observational|||Exercise, Oxidative Stress and HIV|A Case-control Study to Test the Effects of a Bout of Aerobic Exercise Followed by Resistance Training on Antioxidant System in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV Subjects|Completed|||28|Actual|Hospital de Clinicas de Porto Alegre|||2||f||||t||||||||||2018-06-01 00:43:42.788151|2018-06-01 00:43:42.788151
NCT00950924|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2017-11-24|2009-07-31|2009-08-03|Estimate|||||||2017-11-24|2017-11-28|Actual|January 2015||2015-01-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|ODSEEH||Optical Defocus to Stimulate Eye Elongation in Hyperopia|Use of Multifocal Contact Lenses to Stimulate Axial Elongation in Axial Hyperopia|Active, not recruiting||N/A|30|Anticipated|Aller, Thomas A., OD||2|||f||||t||||||||||2018-06-01 00:43:43.189064|2018-06-01 00:43:43.189064
NCT00950911|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2012-12-17||2013-12-19|2009-07-30|2009-08-03|Estimate|2013-12-19|2014-02-11|Estimate||||2013-12-19|2014-02-11|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma|Completed||Phase 3|35|Actual|Amgen||1|||f||||||||||||||2018-06-01 00:43:43.406805|2018-06-01 00:43:43.406805
NCT00950898|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2009-07-31|2009-07-31|2009-08-03|Estimate|||||||2009-07-31|2009-08-03|Estimate|November 2006||2006-11-30|July 2009|2009-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||The Acute Effects of Coffee on Glucose Metabolism|Human Trial of the Acute Effects of Coffee on Glucose Metabolism|Completed||N/A|11|Actual|Brooklyn College of the City University of New York|||||f||||f||||||||||2018-06-01 00:43:43.994882|2018-06-01 00:43:43.994882
NCT00950885|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22||2017-03-07|2017-03-07|2009-07-31|2009-08-03|Estimate||||2017-03-07|2017-03-08|Actual|2017-03-07|2017-03-08|Actual|September 2009||2009-09-30|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Melatonin Treatment for Induced Transient Insomnia|Efficacy of Melatonin Treatment in a Phase Advance Model of Transient Insomnia|Completed||N/A|42|Actual|Brigham and Women's Hospital||3|||f||||t||||||||Yes|Per the NIH Policy on Resource Sharing, we will make the datasets collected in this grant available following publication of the final study results. Such datasets will not contain identifying information per the regulations outlined in HIPAA, and written permission will be obtained from those requesting the datasets.|2018-06-01 00:43:44.333881|2018-06-01 00:43:44.333881
NCT00949858|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2017-07-26|2009-07-28|2009-07-30|Estimate|||||||2017-07-26|2017-07-31|Actual|July 2009||2009-07-31|July 2017|2017-07-31|January 22, 2014|Actual|2014-01-22|January 2014|Actual|2014-01-31||Observational|||New Data Analysis Methods for Actigraphy in Sleep Medicine|New Data Analysis Methods for Actigraphy in Sleep Medicine|Completed|||635|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 00:44:14.357612|2018-06-01 00:44:14.357612
NCT00950872|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2013-12-17||2014-03-31|2009-07-31|2009-08-03|Estimate|2014-03-31|2014-05-01|Estimate||||2014-03-31|2014-05-01|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||number of subjects consented|Safety and Efficacy Study of Duet TRS|A Prospective, Single-Center Investigation of the Safety and Performance of the ENDO GIA Staplers With ENDO GIA Single Use Loading Units With DUET TRS TM in a Gastric Bypass Procedure|Completed||N/A|29|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-06-01 00:43:44.444869|2018-06-01 00:43:44.444869
NCT00950859|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2013-08-15|2010-08-12|2015-11-05|2009-07-30|2009-08-03|Estimate|2013-08-15|2013-10-21|Estimate|2010-10-01|2010-10-05|Estimate|2015-11-05|2015-12-04|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|November 2010|Actual|2010-11-30||Interventional|||A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir|A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance|Completed||Phase 2|51|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-06-01 00:43:44.980626|2018-06-01 00:43:44.980626
NCT00950846|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2018-01-19|2009-07-31|2009-08-03|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2009||2009-07-31|January 2018|2018-01-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|UCB||Umbilical Cord Blood Transplant for Congenital Pediatric Disorders|Umbilical Cord Blood Transplant for Congenital Pediatric Disorders|Recruiting||N/A|60|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 00:43:48.090305|2018-06-01 00:43:48.090305
NCT00950833|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2017-04-18|2010-12-07|2017-04-25|2009-07-30|2009-08-03|Estimate|2017-04-25|2017-08-07|Actual|2010-12-07|2010-12-10|Estimate|2017-04-25|2017-08-07|Actual|August 10, 2009|Actual|2009-08-10|April 2017|2017-04-30|October 27, 2010|Actual|2010-10-27|September 16, 2010|Actual|2010-09-16||Interventional|||Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children|Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children|Completed||Phase 3|467|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:43:48.381084|2018-06-01 00:43:48.381084
NCT00950820|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2013-03-01|2009-07-31|2009-08-03|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|VOXEL||Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer|An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX Alone for Second-line Treatment of Patients With Metastatic Colorectal Cancer (VOXEL-Study)|Terminated||Phase 2|9|Actual|AIO-Studien-gGmbH||3||Recruitment rate to low; changed environment made protocol in its current state obsolete|f||||t||||||||||2018-06-01 00:43:50.561456|2018-06-01 00:43:50.561456
NCT00950807|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2014-01-16|2012-03-22|2017-10-09|2009-07-30|2009-08-03|Estimate|2014-01-16|2014-03-04|Estimate|2012-03-22|2012-03-29|Estimate|2017-10-09|2017-11-08|Actual|September 1, 2009||2009-09-01|October 2017|2017-10-31|March 15, 2010|Actual|2010-03-15|March 1, 2010|Actual|2010-03-01||Interventional|||GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects With COPD|Completed||Phase 2|176|Actual|GlaxoSmithKline||10|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:43:50.925022|2018-06-01 00:43:50.925022
NCT00950794|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2009-08-06|2009-07-30|2009-08-03|Estimate|||||||2009-08-06|2009-08-07|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Study of Salmeterol (SN408D) for Adult Asthma|Study of Salmeterol (SN408D) for Adult Asthma - Clinical Study of Salmeterol Compared With Hokunalin (Tulobuterol) Tape -|Completed||Phase 4|367|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:43:52.087432|2018-06-01 00:43:52.087432
NCT00950781|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2017-11-17|2009-07-31|2009-08-03|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2009||2009-01-31|November 2017|2017-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997|"Cortisol Levels on Menopausal Vasomotor Symptoms - an Ancillary (Addendum) Study to the Impact of Traditional Acupuncture on Menopausal Vasomotor Symptoms, Psychological Stress and the Hypothalamic Pituitary Adrenal (HPA) - Sympathetic Nervous System (SNS) Axis: A Randomized, Controlled Trial"|Completed|||45|Actual|Cedars-Sinai Medical Center|||1||f||||f||||||||Yes||2018-06-01 00:43:52.219161|2018-06-01 00:43:52.219161
NCT00950768|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2009-07-31|2009-07-31|2009-08-03|Estimate|||||||2009-07-31|2009-08-03|Estimate|February 2002||2002-02-28|July 2009|2009-07-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients|GISMM2001: Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients: a Prospective, Multi-center Phase III Study|Completed||Phase 3|298|Actual|Azienda Ospedaliera San Giovanni Battista||2|||f||||||||||||||2018-06-01 00:43:52.284033|2018-06-01 00:43:52.284033
NCT00950755|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2012-02-16||2016-11-30|2009-07-30|2009-08-03|Estimate|2012-07-26|2012-08-29|Estimate||||2016-11-30|2017-01-18|Estimate|June 1998||1998-06-30|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology|Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology|Completed||Phase 2|41|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:43:52.374576|2018-06-01 00:43:52.374576
NCT00950742|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2013-08-08||2015-07-01|2009-07-31|2009-08-03|Estimate|2013-08-08|2013-10-17|Estimate||||2015-07-01|2015-07-24|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Treated set|Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.|Phase I Open Label Trial to Assess Safety of BIBW 2992 in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.|Completed||Phase 1|18|Actual|Boehringer Ingelheim|MTD was determined at 20mg afatinib when 1/6 pat. had DLT (3+3 design). Upon expansion of MTD cohort to 18 pat. recruitment was stopped when 4/13 pat. had DLT. No lower afatinib dose could be tested as 20mg was the lowest dose formulation available.|1|||f||||||||||||||2018-06-01 00:43:53.10642|2018-06-01 00:43:53.10642
NCT00949845|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|January 2007||2007-01-31|July 2009|2009-07-31||||||||Interventional|||Cytokine-Associated Depression and Social Pain|An fMRI Study of Cytokine-Associated Depression and Social Pain|Completed||Early Phase 1|||University of California, Los Angeles|||||||||||||||||||2018-06-01 00:44:14.4218|2018-06-01 00:44:14.4218
NCT00950729|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2009-03-02||2015-06-18|2009-06-16|2009-08-03|Estimate|2009-06-16|2009-08-03|Estimate||||2015-06-18|2015-07-15|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||The Effects of Lower Right Limb Orthopedic Immobilization on Driving Performance|The Effects of Lower Right Limb Orthopedic Immobilization on Driving Performance: an Experimental Study During Simulated Driving in Healthy Volunteers.|Completed||N/A|48|Actual|Université de Sherbrooke||3|||f||||f||||||||||2018-06-01 00:43:53.572395|2018-06-01 00:43:53.572395
NCT00950716|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2015-08-23|2009-07-31|2009-08-03|Estimate|||||||2015-08-23|2015-08-25|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PEARL||PEARL Program: Empowerment Program for Patients With Type 2 Diabetes (HK4)|Peer Support, Empowerment and Remote Communication Linked by Information Technology (PEARL): A Multi-Component Program to Improve Community-Based Diabetes Care|Completed||N/A|632|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 00:43:53.801877|2018-06-01 00:43:53.801877
NCT00950703|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2015-10-13|2009-07-31|2009-08-03|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|PARADIGM||Primary Care Audit of Global Risk Management|Primary Care Audit of Global Risk Management|Completed|||3015|Actual|Canadian Collaborative Research Network|||||f||||f||||||Samples Without DNA|"~     Blood serum.~   "|||2018-06-01 00:43:53.989665|2018-06-01 00:43:53.989665
NCT00950690|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2009-03-31||2011-02-18|2009-06-24|2009-08-03|Estimate|2009-06-24|2009-08-03|Estimate||||2011-02-18|2011-02-23|Estimate|July 2005||2005-07-31|February 2011|2011-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|A6111128||Efficacy and Tolerability of Xalatan in Patients|Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.|Completed|||1289|Actual|Pfizer|Efficacy data were not summarized or analyzed because data collection did not permit clear identification of IOP & visual field data in this non-monitored observational study. Consequently, data were not sufficiently interpretable.||1||f||||f||||||||||2018-06-01 00:43:54.137348|2018-06-01 00:43:54.137348
NCT00950677|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2017-04-21|2009-07-31|2009-08-03|Estimate|||||||2017-04-21|2017-04-24|Actual|July 2009||2009-07-31|April 2017|2017-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|T2DM||The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes|The Effect of the Glucagon Suppressors Pramlintide and Exenatide on Postprandial Glucose Metabolism in Children With Type 2 Diabetes Mellitus|Completed||Phase 4|16|Actual|Baylor College of Medicine||2|||f||||t|t|f||||||No||2018-06-01 00:43:54.368966|2018-06-01 00:43:54.368966
NCT00950664|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2013-02-08||2017-06-13|2009-07-30|2009-08-03|Estimate|2013-08-05|2013-10-11|Estimate||||2017-06-13|2017-07-05|Actual|August 2009||2009-08-31|June 2017|2017-06-30|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional||All analyses were performed on the modified intention-to-treat (mITT) basis, with all subjects included in the two treatment challenges.|A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia|A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® in Comparison With Botox®, Assuming a Bioequivalence Ratio of 2.5:1 Units, in the Cervical Dystonia|Completed||Phase 4|103|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-06-01 00:43:54.470625|2018-06-01 00:43:54.470625
NCT00950651|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2009-04-14||2012-04-25|2009-06-18|2009-08-03|Estimate|2009-06-18|2009-08-03|Estimate||||2012-04-25|2012-04-30|Estimate|March 2002||2002-03-31|April 2012|2012-04-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee|A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol HCl / Contramid® Tablets to Twice Daily Tramadol HCl (SR) for the Treatment of Osteoarthritis of the Knee.|Completed||Phase 3|431|Actual|Labopharm Inc.||2|||f||||||||||||||2018-06-01 00:43:54.916348|2018-06-01 00:43:54.916348
NCT00950638|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2017-08-23|2009-07-31|2009-08-03|Estimate|||||||2017-08-23|2017-08-24|Actual|July 2009||2009-07-31|August 2017|2017-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration|A Phase I Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration|Completed||Phase 1|47|Actual|Ophthotech Corporation||2|||f||||f||||||||||2018-06-01 00:43:55.430051|2018-06-01 00:43:55.430051
NCT00950625|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2011-01-24|2009-07-31|2009-08-03|Estimate|||||||2011-01-24|2011-01-25|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Intraperitoneal Analgesia After Laparoscopic Cholecystectomy|Comparison of Analgesic Efficacy of Intra-peritoneal Lignocaine With Bupivacaine After Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial|Completed||N/A|200|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-06-01 00:43:55.484364|2018-06-01 00:43:55.484364
NCT00950612|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2016-11-09|2010-12-24|2016-11-09|2009-07-30|2009-08-03|Estimate|2016-11-09|2017-01-09|Estimate|2010-12-24|2010-12-30|Estimate|2016-11-09|2017-01-09|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents|Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy HIV-negative Adolescents Living in a TB Endemic Region|Completed||Phase 2|60|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:43:55.587758|2018-06-01 00:43:55.587758
NCT00950599|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|2009-08-28||2015-03-16|2009-07-31|2009-08-03|Estimate|2010-02-04|2010-02-23|Estimate||||2015-03-16|2015-04-03|Estimate|May 2003||2003-05-31|March 2015|2015-03-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Study of Multiple Doses of Saxagliptin (BMS-477118)|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-477118 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 2|423|Actual|AstraZeneca||7|||f||||t||||||||||2018-06-01 00:43:56.861648|2018-06-01 00:43:56.861648
NCT00950586|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2017-07-11|2009-07-30|2009-08-03|Estimate|||||||2017-07-11|2017-07-13|Actual|August 24, 2009|Actual|2009-08-24|July 2017|2017-07-31|December 24, 2009|Actual|2009-12-24|December 24, 2009|Actual|2009-12-24||Interventional|||Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702|A Placebo-controlled, Single-blind, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Drug Interaction of GSK1034702 After Repeat Doses in Healthy Subjects|Completed||Phase 1|48|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:44:01.982552|2018-06-01 00:44:01.982552
NCT00950235|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2015-05-28||2015-06-11|2009-07-30|2009-07-31|Estimate|2015-06-11|2015-07-09|Estimate||||2015-06-11|2015-07-09|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|Healthy Moms||Weight Management for Improved Pregnancy Outcomes|Weight Management for Improved Pregnancy Outcomes|Completed||N/A|118|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 00:44:05.549632|2018-06-01 00:44:05.549632
NCT00950573|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-31|||2017-02-07|2009-07-31|2009-08-03|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2010||2010-01-31|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Observational|NOCTX||Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis|Is Progression of Arteriosclerosis in ESRD Patients Inhibited by Nocturnal Hemodialysis or Renal Transplantation?|Active, not recruiting|||184|Actual|Dianet Dialysis Centers|||4||f||||f|f|f||||Samples Without DNA|"~     1x 4,5 ml citrate plasma~      1x 10 ml EDTA plasma~   "|Undecided||2018-06-01 00:44:02.067505|2018-06-01 00:44:02.067505
NCT00950560|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-04-22|2009-07-31|2009-08-03|Estimate|||||||2011-04-22|2011-04-26|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||An Empirical Study of Perceived Hospital Service Quality: A Comparison of Inpatient, Outpatient and Emergence Patient|An Empirical Study of Perceived Hospital Service Quality: A Comparison of Inpatient, Outpatient and Emergence Patient|Completed|||2|Actual|Taipei Medical University WanFang Hospital|||3||f||||f||||||||||2018-06-01 00:44:02.12122|2018-06-01 00:44:02.12122
NCT00950547|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2010-01-04|2009-07-30|2009-07-31|Estimate|||||||2010-01-04|2010-01-05|Estimate|August 2009||2009-08-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||ICU Cell Saver to Reduce Blood Transfusions in Cardiac|Routinely Use of CardioPAT Cell Saver in Cardiac Surgery: A Prospective Randomized Study Focused on Allogenic Blood Transfusion and Clinical Outcome|Completed||N/A|350|Actual|Cardiochirurgia E.H.||2|||f||||t||||||||||2018-06-01 00:44:02.165565|2018-06-01 00:44:02.165565
NCT00950534|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-11-09|2009-07-30|2009-07-31|Estimate|||||||2011-11-09|2011-11-10|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|RELIANCE||Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care|A Randomised, Multicentre, Open-Label, Parallel-Group, 24-Week Phase IV Study Comparing the Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care: General Practitioner Initiation of Insulin Glargine Versus the Usual Standard of Care|Terminated||Phase 4|25|Actual|Sanofi||2||due to poor recruitment|f||||||||||||||2018-06-01 00:44:02.325703|2018-06-01 00:44:02.325703
NCT00950521|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-04-20|2009-07-30|2009-07-31|Estimate|||||||2011-04-20|2011-04-21|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy Study of CD34 Stem Cell in Chronic Stroke Patients|Phase II Study of Autologous Peripheral Blood CD34 Stem Cell Implantation in Chronic Stroke Patients|Completed||Phase 2|30|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-06-01 00:44:02.396522|2018-06-01 00:44:02.396522
NCT00950508|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-11-04|2009-07-30|2009-07-31|Estimate|||||||2014-11-04|2014-11-05|Estimate|June 1998||1998-06-30|November 2014|2014-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of the Effect of Plasmaexchange in Patients With Acute Liver Failure|European Multicenter Plasma Exchange Trial (Empet): A Controlled, Open, Randomised, Multicenter Study In Patients With Acute Liver Failure|Completed||N/A|183|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 00:44:02.474235|2018-06-01 00:44:02.474235
NCT00950495|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2014-12-24|2009-07-30|2009-07-31|Estimate|||||||2014-12-24|2014-12-25|Estimate|October 2003||2003-10-31|December 2014|2014-12-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|||Oral Appliance Therapy in Obstructive Sleep Apnea|Effects of an Oral Appliance on Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial|Completed||N/A|64|Actual|VU University of Amsterdam||3|||f||||t||||||||||2018-06-01 00:44:02.555415|2018-06-01 00:44:02.555415
NCT00950482|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2017-11-17|2009-07-30|2009-07-31|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2009||2009-01-31|November 2017|2017-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Pilot Study - Impact of Traditional Acupuncture on Menopause|Pilot Study - The Impact of Traditional Acupuncture on Menopausal Vasomotor Symptoms, Psychological Stress and the Hypothalamic Pituitary Adrenal (HPA) - Sympathetic Nervous System (SNS) Axis: A Randomized, Controlled Trial|Completed||N/A|45|Actual|Cedars-Sinai Medical Center||3|||f||||f||||||||Yes||2018-06-01 00:44:02.649554|2018-06-01 00:44:02.649554
NCT00950469|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2009-07-30|2009-07-30|2009-07-31|Estimate|||||||2009-07-30|2009-07-31|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||TnThs for Identification Myocardial Infarction|Comparison of the New High Sensitive Cardiac Troponin T With the 4th Generation Troponin-T, Myoglobin, Heart-type Fatty Acid Binding Protein for Early Identification of Myocardial Necrosis in Patients With Suspected Acute Coronary Syndrome|Completed|||94|Actual|Heidelberg University|||1||f||||f||||||Samples Without DNA|"~     Blood samples (serum) were collected at presentation and after 6 hours. After collection,~     serum was centrifuged immediately and stored at -80°C until analysis.~      The laboratory staff responsible for measurements was blinded to patient data.~   "|||2018-06-01 00:44:02.718949|2018-06-01 00:44:02.718949
NCT00950456|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2015-10-07|2009-07-30|2009-07-31|Estimate|||||||2015-10-07|2015-10-09|Estimate|November 2009||2009-11-30|May 2011|2011-05-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine|A Prospective Non-Interventional Observational Study to Assess the Safety of Two Vaccinations of a Vero Cell-Derived, Whole Virus H1N1 Pandemic Influenza Vaccine in Subjects Exposed to the Vaccine Through Policies by Governments or Health Authorities|Completed|||3216|Actual|Ology Bioservices|||1||f||||f||||||||||2018-06-01 00:44:02.776465|2018-06-01 00:44:02.776465
NCT00950443|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-12-26|2009-07-30|2009-07-31|Estimate|||||||2011-12-26|2011-12-29|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|MAVAS||Acoustic Reflection Method and Work of Breathing|Acoustic Reflection Method and Work of Breathing : Two New Methods to Measure Children's Upper Airway Obstruction|Terminated||N/A|38|Actual|Assistance Publique - Hôpitaux de Paris||2||No inclusion|f||||f||||||||||2018-06-01 00:44:02.857937|2018-06-01 00:44:02.857937
NCT00950430|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2018-04-12|2009-07-30|2009-07-31|Estimate|||||||2018-04-12|2018-04-13|Actual|April 2008||2008-04-30|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Imaging of Brain Amyloid Plaques in the Aging Population|Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia|Enrolling by invitation||Phase 4|2500|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:44:02.939725|2018-06-01 00:44:02.939725
NCT00950417|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2015-08-17|2009-07-30|2009-07-31|Estimate|||||||2015-08-17|2015-08-19|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|November 2012|Actual|2012-11-30|July 2010|Actual|2010-07-31||Interventional|||Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer|Phase I Study of Nimotuzumab in Combination With Simultaneous Chemotherapy and Radiation for Patients With Locally Advanced Esophageal Cancer|Completed||Phase 1|11|Actual|Biotech Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-06-01 00:44:03.168043|2018-06-01 00:44:03.168043
NCT00950404|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2009-10-05|2009-07-30|2009-07-31|Estimate|||||||2009-10-05|2009-10-07|Estimate|August 2009||2009-08-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet|An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of Three Orally Disintegrating Tablet Formulations Of Sildenafil Without Water Relative To Viagra Conventional Oral Tablet With Water.|Completed||Phase 1|16|Anticipated|Pfizer||4|||f||||f||||||||||2018-06-01 00:44:03.252457|2018-06-01 00:44:03.252457
NCT00950391|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2018-02-09|2009-07-30|2009-07-31|Estimate|||||||2018-02-09|2018-02-13|Actual|August 2010||2010-08-31|February 2018|2018-02-28|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus|Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus|Withdrawn||Phase 1/Phase 2|0|Actual|Washington University School of Medicine||1||PI unable to secure funding for the project so study was not pursued.|f||||t||||||||||2018-06-01 00:44:03.339773|2018-06-01 00:44:03.339773
NCT00950378|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2013-05-24|2009-07-30|2009-07-31|Estimate|||||||2013-05-24|2013-05-29|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Observational|||Non-Invasive Management of Chronic Venous Insufficiency|Non-Invasive Management of Chronic Venous Insufficiency|Completed|||10|Actual|University of Utah|||2||f||||t||||||||||2018-06-01 00:44:03.415102|2018-06-01 00:44:03.415102
NCT00950365|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2009-07-30|2009-07-30|2009-07-31|Estimate|||||||2009-07-30|2009-07-31|Estimate|May 2006||2006-05-31|July 2009|2009-07-31||||May 2011|Anticipated|2011-05-31||Interventional|||Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed and Erlotinib Versus Single Agent Pemetrexed in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 2|82|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-06-01 00:44:03.486749|2018-06-01 00:44:03.486749
NCT00950352|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2015-01-12||2015-02-09|2009-07-30|2009-07-31|Estimate|2015-02-09|2015-02-11|Estimate||||2015-02-09|2015-02-11|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Citicoline Treatment of Methamphetamine Dependence|Citicoline Treatment of Methamphetamine Dependence|Completed||Phase 3|104|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 00:44:03.589076|2018-06-01 00:44:03.589076
NCT00950339|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-19|||2016-07-06|2009-07-30|2009-07-31|Estimate|||||||2016-07-06|2016-07-07|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine|Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine|Completed||Phase 4|63|Actual|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||No||2018-06-01 00:44:03.874992|2018-06-01 00:44:03.874992
NCT00950326|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-30|2009-07-30|2009-07-31|Estimate|||||||2009-07-30|2009-07-31|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||A Comparison of Kneipp Hydrotherapy With Conventional Physiotherapy in the Treatment of Osteoarthritis of the Hip or Knee: Protocol of a Prospective Randomised Controlled Clinical Trial|A Comparison of Kneipp Hydrotherapy With Conventional Physiotherapy in the Treatment of Osteoarthritis of the Hip or Knee: Protocol of a Prospective Randomised Controlled Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|180|Anticipated|Kneippsche Stiftungen||3|||f||||t||||||||||2018-06-01 00:44:03.959269|2018-06-01 00:44:03.959269
NCT00950313|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2014-11-12|2009-07-30|2009-07-31|Estimate|||||||2014-11-12|2014-11-13|Estimate|April 2011||2011-04-30|July 2009|2009-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ATTEND||Assessment of Response Rates and Yields for Two Tools for Early Detection of Non-diabetic Hyperglycaemia and Diabetes|Assessment of Response Rates and Yields for Two Tools for Early Detection of Non-diabetic Hyperglycaemia and Diabetes|Completed||N/A|432|Actual|University of Leicester||2|||f||||t||||||||||2018-06-01 00:44:04.049242|2018-06-01 00:44:04.049242
NCT00950300|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|2016-11-04||2017-12-21|2009-07-30|2009-07-31|Estimate|2016-11-22|2017-01-23|Estimate||||2017-12-21|2018-01-23|Actual|October 16, 2009|Actual|2009-10-16|December 2017|2017-12-31|January 24, 2017|Actual|2017-01-24|July 12, 2011|Actual|2011-07-12||Interventional||Intent-to-Treat (ITT) Population: All participants with at least one efficacy assessment after administration of the first treatment cycle.|A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer|A Phase III, Randomized Open-Label Study to Compare the Pharmacokinetics, Efficacy, and Safety of Subcutaneous (SC) Trastuzumab With Intravenous (IV) Trastuzumab Administered in Women With HER2-Positive Early Breast Cancer (EBC)|Completed||Phase 3|596|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:44:04.183642|2018-06-01 00:44:04.183642
NCT00950287|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2013-03-07|2009-07-30|2009-07-31|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|INTEM||Detection of Neonatal Bradycardia|Early Detection of Severe Apnea-bradycardia in Preterm Infants Using Algorithm Fusion|Completed|||54|Anticipated|Rennes University Hospital|||1||f||||f||||||||||2018-06-01 00:44:05.218689|2018-06-01 00:44:05.218689
NCT00950274|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2016-09-13|2009-07-30|2009-07-31|Estimate|||||||2016-09-13|2016-09-14|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|PERFECT||Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery|Intramyocardial Transplantation of Bone Marrow Stem Cells for Improvement of Post-infarct Myocardial Regeneration in Addition to CABG Surgery: a Controlled, Prospective, Randomized, Double Blinded Multicenter Trial (PERFECT)|Terminated||Phase 3|81|Actual|Miltenyi Biotec GmbH||2||Recruitment stopped due to slow recruitment|f||||t||||||||||2018-06-01 00:44:05.318973|2018-06-01 00:44:05.318973
NCT00950261|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2014-05-07|2009-07-30|2009-07-31|Estimate|||||||2014-05-07|2014-05-09|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients|Phase II Clinical Trial for Adjuvant Concurrent Chemoradiation Therapy in Post-operative Cervical Cancer Patients|Unknown status|Recruiting|Phase 2|72|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||||2018-06-01 00:44:05.39803|2018-06-01 00:44:05.39803
NCT00950248|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2018-05-05|2009-07-30|2009-07-31|Estimate|||||||2018-05-05|2018-05-08|Actual|July 22, 2009||2009-07-22|August 3, 2017|2017-08-03|August 1, 2018|Anticipated|2018-08-01|April 30, 2018|Actual|2018-04-30||Interventional|||Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS)|Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis|Active, not recruiting||Phase 1/Phase 2|85|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:44:05.47659|2018-06-01 00:44:05.47659
NCT00950222|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2012-07-25|2009-07-30|2009-07-31|Estimate|||||||2012-07-25|2012-07-26|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|IMPACT||Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic|Impact of Imipenem With Amikacin Pharmacokinetic and Pharmacodynamic|Completed||N/A|70|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:44:05.903638|2018-06-01 00:44:05.903638
NCT00950209|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2014-02-24|2009-07-30|2009-07-31|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2008||2008-04-30|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients|Acute Effect of Intensive Insulin Infusion on Intestinal Triglyceride-rich-lipoprotein-apoB48 Metabolism in Type 2 Diabetic Patients|Completed||N/A|20|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 00:44:06.007923|2018-06-01 00:44:06.007923
NCT00950196|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-06-26|2009-07-30|2009-07-31|Estimate|||||||2011-06-26|2011-06-28|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia|The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia|Completed||Phase 4|30|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 00:44:06.088601|2018-06-01 00:44:06.088601
NCT00950183|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2013-03-11||2016-07-21|2009-07-30|2009-07-31|Estimate|2014-10-28|2014-11-04|Estimate||||2016-07-21|2016-08-22|Estimate|February 2007||2007-02-28|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Motorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures|Motorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures: An Evaluation of Narcotic Consumption, Pain, Wound Healing, and Patient Satisfaction|Terminated||Phase 4|36|Actual|OrthoCarolina Research Institute, Inc.|The study was stopped due to poor enrollment. No results are available|1||recruitment feasability|f||||t||||||||||2018-06-01 00:44:06.180229|2018-06-01 00:44:06.180229
NCT00950170|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2016-12-28|2009-07-30|2009-07-31|Estimate|||||||2016-12-28|2016-12-29|Estimate|February 2010||2010-02-28|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting|An Open-label Study Of The Safety And Efficacy Of Refacto Af In Previously Untreated Patients In Usual Care Settings|Completed||Phase 4|23|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:44:06.319689|2018-06-01 00:44:06.319689
NCT00950157|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2010-06-04|2009-07-30|2009-07-31|Estimate|||||||2010-06-04|2010-06-07|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Testing the Effect of a Caution for Drugs Approved on Surrogate Outcomes Alone|Testing the Effect of a Caution for Drugs Approved on Surrogate Outcomes Alone|Completed||N/A|2944|Actual|White River Junction Veterans Affairs Medical Center||3|||f||||f||||||||||2018-06-01 00:44:06.431137|2018-06-01 00:44:06.431137
NCT00950144|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-02-28|2009-07-30|2009-07-31|Estimate|||||||2011-02-28|2011-03-02|Estimate|December 2008||2008-12-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Studying Pain and Symptom Distress in Patients With Advanced Colon Cancer, Rectal Cancer, Pancreatic Cancer, or Liver Cancer|Illness Perception, Pain and Symptom Distress in Gastrointestinal Cancers|Completed|||123|Anticipated|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:44:06.493876|2018-06-01 00:44:06.493876
NCT00950131|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2010-04-08|2009-07-30|2009-07-31|Estimate|||||||2010-04-08|2010-04-09|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Testing the Effect of a Warning About New Drugs|Testing the Effect of a Warning About New Drugs|Completed||N/A|2944|Actual|White River Junction Veterans Affairs Medical Center||3|||f||||f||||||||||2018-06-01 00:44:06.560669|2018-06-01 00:44:06.560669
NCT00950118|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2018-01-25|2009-07-30|2009-07-31|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2005||2005-06-30|January 2018|2018-01-31|November 2025|Anticipated|2025-11-30|November 2025|Anticipated|2025-11-30||Observational|DHREAMS||Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science|Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science|Recruiting|||2020|Anticipated|Columbia University|||2||f||||f||||||Samples With DNA|"~     whole blood, tissue, saliva~   "|Undecided||2018-06-01 00:44:06.622002|2018-06-01 00:44:06.622002
NCT00950105|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2012-08-22|2009-07-30|2009-07-31|Estimate|||||||2012-08-22|2012-08-23|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)|A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Oral CPSI-2364 in Healthy Subjects|Completed||Phase 1|30|Actual|Ferring Pharmaceuticals||5|||f||||f||||||||||2018-06-01 00:44:06.739385|2018-06-01 00:44:06.739385
NCT00950092|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-04-02|2009-07-30|2009-07-31|Estimate|||||||2014-04-02|2014-04-03|Estimate|October 2009||2009-10-31|September 2013|2013-09-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF|Numeris-AF Tethered Coagulation System With VisiTrax Indicated For Treatment of Persistent and Longstanding Persistent Atrial Fibrillation|Terminated||N/A|5|Actual|nContact Surgical Inc.||1|||f||||t||||||||||2018-06-01 00:44:06.823553|2018-06-01 00:44:06.823553
NCT00950079|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-30|2009-07-30|2009-07-31|Estimate|||||||2009-07-30|2009-07-31|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|January 2010|Anticipated|2010-01-31|August 2009|Anticipated|2009-08-31||Interventional|||Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography|Preventive Strategies of REnal Insufficiency in Patients With Diabetes Undergoing InterVENTion or Arteriography(PREVENT Trial)|Unknown status|Recruiting|Phase 4|368|Anticipated|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 00:44:06.899423|2018-06-01 00:44:06.899423
NCT00950066|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2011-01-04|2009-07-30|2009-07-31|Estimate|||||||2011-01-04|2011-01-05|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|I-COMBO||Irbesartan and Amlodipine Combination in Controlling Blood Pressure|Study to Evaluate the Safety and Efficacy of Two Fixed Dose Combinations of Irbesartan / Amlodipine and Monotherapy After Eight Weeks of Treatment in Subjects With Uncomplicated Mild to Moderate Essential Hypertension|Completed||Phase 2|270|Actual|Sanofi||6|||f||||||||||||||2018-06-01 00:44:07.02199|2018-06-01 00:44:07.02199
NCT00950053|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2013-03-11|2009-07-30|2009-07-31|Estimate|||||||2013-03-11|2013-03-13|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer|Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer: A Prospective, Randomized, Controlled Trial|Completed||Phase 4|52|Actual|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-06-01 00:44:07.141677|2018-06-01 00:44:07.141677
NCT00950027|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2012-07-04|2009-07-30|2009-07-31|Estimate|||||||2012-07-04|2012-07-06|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SPIRIT-ICU||Study of Povidone Iodine to Reduce Pulmonary Infection in Head Trauma and Cerebral Hemorrhage in Intensive Care Unit|Prospective Randomized Double Blind Study Comparing the Effect of Oropharyngeal Decontamination by Povidone-iodine to Placebo on Ventilator-associated Pneumonia in Patients With Head Trauma or Cerebral Hemorrhage|Terminated||Phase 3|179|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-06-01 00:44:07.280954|2018-06-01 00:44:07.280954
NCT00950014|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2010-04-08|2009-07-30|2009-07-31|Estimate|||||||2010-04-08|2010-04-09|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Testing Numeric Formats for Presenting Data About Treatment Benefits and Harms|Testing Numeric Formats for Presenting Data About Treatment Benefits and Harms|Completed||N/A|2944|Actual|White River Junction Veterans Affairs Medical Center||5|||f||||f||||||||||2018-06-01 00:44:07.366217|2018-06-01 00:44:07.366217
NCT00950001|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2018-02-26|2009-07-30|2009-07-31|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2009|Actual|2009-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Resection Bed Post-Surgical Stereotactic Radiosurgery (SRS)|Efficacy of Post-Surgical Stereotactic Radiosurgery for Metastatic Brain Disease: A Randomized Trial|Active, not recruiting||Phase 3|132|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|||||||||2018-06-01 00:44:07.423349|2018-06-01 00:44:07.423349
NCT00949988|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2011-05-02|2009-07-30|2009-07-31|Estimate|||||||2011-05-02|2011-05-03|Estimate|May 2009||2009-05-31|September 2010|2010-09-30||||June 2014|Anticipated|2014-06-30||Interventional|BMS-CA180105||A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia|A Phase I/II Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia|Unknown status|Active, not recruiting|Phase 1/Phase 2|28|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-06-01 00:44:07.622213|2018-06-01 00:44:07.622213
NCT00949975|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2012-01-24||2012-06-19|2009-07-30|2009-07-31|Estimate|2012-06-19|2012-08-03|Estimate||||2012-06-19|2012-08-03|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium|A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium|Completed||Phase 2|838|Actual|AstraZeneca||4|||f||||t||||||||||2018-06-01 00:44:07.808358|2018-06-01 00:44:07.808358
NCT00949962|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2014-07-03|2009-07-30|2009-07-31|Estimate|||||||2014-07-03|2014-07-04|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Post-operative or Early Salvage XRT and ADT for High Risk PCa|Immediate or Early Salvage Post-operative External Radiotherapy Combined With Concomitant and Adjuvant Hormonal Treatment Versus Immediate or Early Salvage Postoperative External Radiotherapy Alone in pT3a-b R0-1 cN0M0 / pT2R1 cN0M0, Gleason Score 5-10 Prostatic Carcinoma. A Phase III Study|Terminated||Phase 3|87|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||Poorly recruiting|f||||t||||||||||2018-06-01 00:44:09.137642|2018-06-01 00:44:09.137642
NCT00949949|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2017-01-11|2009-07-30|2009-07-31|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy|Phase I Trial of Everolimus, Gemcitabine, and Cisplatin for Patients With Solid Tumors Refractory to Standard Therapy|Completed||Phase 1|38|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 00:44:09.215199|2018-06-01 00:44:09.215199
NCT00949936|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-30|||2010-10-14|2009-07-30|2009-07-31|Estimate|||||||2010-10-14|2010-10-15|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|||||Interventional|DISCERN||Safety and Performance Study of the CAdiscTM-L Lumbar Spinal Disc Replacement Device For CE Marking|Debilitating Low Back paIn: Multi-centre Safety and performanCe invEstigation Of CAdiscTM-L, Total Disc ReplacemeNt Therapy|Completed||N/A|||Ranier Technology Limited|||||f||||f||||||||||2018-06-01 00:44:09.291353|2018-06-01 00:44:09.291353
NCT00949923|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2018-03-28|2009-07-30|2009-07-31|Estimate|||||||2018-03-28|2018-03-30|Actual|May 7, 2008|Actual|2008-05-07|March 2018|2018-03-31|June 6, 2016|Actual|2016-06-06|December 14, 2010|Actual|2010-12-14||Interventional|||Green Tea in Breast Cancer Patients|Green Tea Supplement in Women With Incident Breast Cancer|Completed||N/A|41|Actual|University of Southern California||2|||f||||f|f|f||||||||2018-06-01 00:44:09.348675|2018-06-01 00:44:09.348675
NCT00949910|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2016-08-09||2016-10-04|2009-07-30|2009-07-31|Estimate|2016-08-09|2016-10-04|Estimate||||2016-10-04|2016-10-05|Estimate|November 2004||2004-11-30|October 2016|2016-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Intent-to-Treat (ITT)/Safety Population: All participants who received at least one dose of erlotinib.|An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)|An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 4|6586|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:44:09.596002|2018-06-01 00:44:09.596002
NCT00949897|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2013-03-11|2009-07-29|2009-07-31|Estimate|||||||2013-03-11|2013-03-13|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparison Study of Biofoam Porous Metal Versus Allograft to Treat Adult Acquired Flatfoot|A Randomized, Prospective, Controlled Trial for Lateral Column Lengthening in Adult Acquired Flatfoot Using Biofoam Porous Metal Compared With Allograft|Withdrawn||Phase 4|0|Actual|OrthoCarolina Research Institute, Inc.||2||Funding terminated|f||||t||||||||||2018-06-01 00:44:12.279719|2018-06-01 00:44:12.279719
NCT00949884|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2011-01-31||2011-03-07|2009-07-29|2009-07-30|Estimate|2011-01-31|2011-02-28|Estimate||||2011-03-07|2011-03-09|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Olmesartan Comparison to Losartan in Hypertensive Subjects|A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects|Completed||Phase 4|941|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-06-01 00:44:12.477274|2018-06-01 00:44:12.477274
NCT00949871|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2015-06-03|2009-07-29|2009-07-30|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Support Groups for African-American Breast Cancer Survivors|Sister Survivor: African American Breast Cancer Coalition|Completed||N/A|74|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:44:14.294678|2018-06-01 00:44:14.294678
NCT00949819|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2017-08-24|2009-07-29|2009-07-30|Estimate|||||||2017-08-24|2017-08-28|Actual|June 4, 2009|Actual|2009-06-04|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|June 4, 2019|Anticipated|2019-06-04||Observational|ASCaP||Active Surveillance for Cancer of the Prostate (ASCaP)|The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.|Recruiting|||462|Anticipated|Jonsson Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Serum, plasma, buffy coat, prostate tissue cores and urine.~   "|No||2018-06-01 00:44:14.579515|2018-06-01 00:44:14.579515
NCT00949806|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2012-07-18|2009-07-29|2009-07-30|Estimate|||||||2012-07-18|2012-07-19|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|SOXIS||Restless Legs Syndrome Treatment With Botulinum Toxin|Phase II Non Comparative, Open Study to Assess the Efficacy and Safety of the Botulinum Toxin Type A in Patients With Restless Legs Syndrome (RLS)|Completed||Phase 2|27|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-06-01 00:44:14.660636|2018-06-01 00:44:14.660636
NCT00949793|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-11-09|2009-07-29|2009-07-30|Estimate|||||||2009-11-09|2009-11-10|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||In Vivo Confocal Endomicroscopy of the Brain|In Vivo Confocal Endomicroscopy of the Brain|Completed||Phase 1|30|Anticipated|Carl Zeiss Surgical GmbH||1|||f||||f||||||||||2018-06-01 00:44:14.7444|2018-06-01 00:44:14.7444
NCT00949780|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-07-30|2009-07-29|2009-07-30|Estimate|||||||2009-07-30|2009-07-31|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|October 2008|Actual|2008-10-31|March 2008|Actual|2008-03-31||Interventional|||Chloral Hydrate to Perform Auditory Brainstem Response (ABR)|Use of Chloral Hydrate to Perform Auditory Brainstem Response (ABR)|Completed||Phase 2|41|Actual|Pontificia Universidade Catolica de Sao Paulo||1|||f||||f||||||||||2018-06-01 00:44:14.814008|2018-06-01 00:44:14.814008
NCT00949767|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2011-01-24|2009-07-29|2009-07-30|Estimate|||||||2011-01-24|2011-01-25|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects|Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-866949 in Healthy Subjects|Completed||Phase 1|64|Actual|Bristol-Myers Squibb||7|||f||||f||||||||||2018-06-01 00:44:14.873114|2018-06-01 00:44:14.873114
NCT00949754|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-05-04|2009-07-29|2009-07-30|Estimate|||||||2010-05-04|2010-05-05|Estimate|October 2009||2009-10-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|HBV||Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation|A Multi-Center, Randomized, Double Blind, Active-Controlled, Parallel Group Clinical Study to Evaluate the Dose Effect of Intradermal Injections of Apitox vs. Histamine in Subjects With Osteoarthritis Symptoms of the Knee|Completed||Phase 2|40|Actual|Apimeds, Inc.||2|||f||||f||||||||||2018-06-01 00:44:15.027176|2018-06-01 00:44:15.027176
NCT00949741|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2013-10-21|2009-07-29|2009-07-30|Estimate|||||||2013-10-21|2013-10-22|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Observational|CFM||Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients|Observational Retrospective Multicenter Study for the Citofluorimetric Analysis of Cerebrospinal Fluid Vs Conventional Method in Patients With Aggressive Non-Hodgkin's Lymphoma Without Leptomeningeal Disease|Completed|||175|Actual|Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie|||||f||||f||||||||||2018-06-01 00:44:15.117343|2018-06-01 00:44:15.117343
NCT00949728|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|August 2008|Actual|2008-08-31||Interventional|||Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia|Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia|Completed||N/A|151|Actual|Hospital de Olhos Sadalla Amin Ghanem||1|||f||||t||||||||||2018-06-01 00:44:15.200001|2018-06-01 00:44:15.200001
NCT00949715|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2013-03-11||2018-01-18|2009-07-28|2009-07-30|Estimate|2013-07-23|2013-10-01|Estimate||||2018-01-18|2018-02-15|Actual|September 2009||2009-09-30|January 2018|2018-01-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|ORVFUP||Optimize RV Follow-up Selective Site Pacing Clinical Trial|Optimize RV Follow-up Selective Site Pacing Clinical Trial|Completed||N/A|67|Actual|Medtronic Cardiac Rhythm and Heart Failure|Since the enrollment goal of the study (n=160) was not met (it was decided to stop enrollments after 67 due to slow enrollments), the results of the study were not powered and the results for the primary objective are inconclusive at this time.|2|||f||||f||||||||||2018-06-01 00:44:15.292995|2018-06-01 00:44:15.292995
NCT00949702|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2011-07-29||2017-06-26|2009-07-29|2009-07-30|Estimate|2011-11-17|2011-12-22|Estimate||||2017-06-26|2017-07-25|Actual|September 30, 2009|Actual|2009-09-30|June 2017|2017-06-30|June 3, 2014|Actual|2014-06-03|September 27, 2010|Actual|2010-09-27||Interventional|||A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma|An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma|Completed||Phase 2|132|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:44:15.617429|2018-06-01 00:44:15.617429
NCT00949689|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2012-11-14|2009-07-29|2009-07-30|Estimate|||||||2012-11-14|2012-11-15|Estimate|September 2009||2009-09-30|October 2011|2011-10-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|YATSS||Young Adult and Teen Sleep Study|Development and Piloting of CBT for Insomnia in Youth With Comorbid Depression|Completed||Phase 2|41|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 00:44:16.006853|2018-06-01 00:44:16.006853
NCT00949676|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2013-09-20|2009-07-29|2009-07-30|Estimate|||||||2013-09-20|2013-09-23|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Observational|DECIDE-HF||DECIDE-HF: Heart Rate Variability in Heart Failure Patients|DECIDE-HF - Heart Rate Variability in Heart Failure Patients|Unknown status|Active, not recruiting||60|Anticipated|Medtronic BRC|||1||f||||f||||||||||2018-06-01 00:44:16.076806|2018-06-01 00:44:16.076806
NCT00949663|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2014-07-21|2009-07-28|2009-07-30|Estimate|||||||2014-07-21|2014-07-22|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function|Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function|Completed||Phase 1|38|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 00:44:16.26259|2018-06-01 00:44:16.26259
NCT00949650|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2013-08-08||2018-03-09|2009-07-29|2009-07-30|Estimate|2013-10-25|2013-11-19|Estimate||||2018-03-09|2018-04-06|Actual|August 14, 2009|Actual|2009-08-14|March 2018|2018-03-31|March 16, 2017|Actual|2017-03-16|February 9, 2012|Actual|2012-02-09||Interventional||Randomised Set (RS): The randomised set includes all patients who were randomised to receive treatment, whether treated or not.|BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation|A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation|Completed||Phase 3|345|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:44:16.434077|2018-06-01 00:44:16.434077
NCT00949637|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-03-07|2009-07-29|2009-07-30|Estimate|||||||2017-03-07|2017-03-09|Actual|October 2007||2007-10-31|March 2017|2017-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|SNAP||Scouting Nutrition and Activity Program|A Site-Randomized Controlled Trial for Health Promotion in Girl Scouts: Healthier Troops in a SNAP|Completed||N/A|76|Actual|Kansas State University||2|||f||||f||||||||||2018-06-01 00:44:17.499054|2018-06-01 00:44:17.499054
NCT00949624|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2012-01-18|2009-07-28|2009-07-30|Estimate|||||||2012-01-18|2012-01-19|Estimate|December 2005||2005-12-31|August 2011|2011-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors|Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors|Completed||Phase 1|50|Actual|Arog Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 00:44:17.575864|2018-06-01 00:44:17.575864
NCT00949611|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2016-02-01|2009-07-29|2009-07-30|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Wiser Choices in Osteoporosis Choice II: A Decision Aid for Patients and Clinicians|Wiser Choices In Osteoporosis Choice II|Completed||N/A|79|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 00:44:17.656835|2018-06-01 00:44:17.656835
NCT00949598|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2015-08-03|2009-07-29|2009-07-30|Estimate|||||||2015-08-03|2015-08-05|Estimate|December 2008||2008-12-31|August 2015|2015-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer|Randomized Double-blind Study to Compare Two Neo-adjuvant Treatments: an Anti-aromatase vs SERM for Postmenopausal Women With ER+ Breast Adenocarcinoma: Effect on Intermediate Predictive Biological Response to Treatment.|Completed||Phase 3|177|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||t||||||||||2018-06-01 00:44:17.720755|2018-06-01 00:44:17.720755
NCT00949585|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2012-09-18|2009-07-29|2009-07-30|Estimate|||||||2012-09-18|2012-09-19|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CKD-K||Potassium Intake in Patients With Chronic Kidney Disease|Potassium Intake in Patients With Chronic Kidney Disease|Completed||N/A|29|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:44:17.796961|2018-06-01 00:44:17.796961
NCT00949572|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2011-01-26|2009-07-29|2009-07-30|Estimate|||||||2011-01-26|2011-01-27|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|January 2011|Actual|2011-01-31|June 2010|Actual|2010-06-30||Interventional|||Measuring Responses to Sublingual Antigens|Characterisation of Human Disseminated Cellular and Humoral Immune Responses Following Sublingual or Intramuscular Deposition of Antigens|Completed||N/A|18|Actual|St George's, University of London||2|||f||||f||||||||||2018-06-01 00:44:17.85963|2018-06-01 00:44:17.85963
NCT00949559|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2012-04-03|2009-07-29|2009-07-30|Estimate|||||||2012-04-03|2012-04-04|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pharmacodynamics (PD) and Pharmacokinetics (PK) Study of EP-100 in Advanced Solid Tumors|A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumors|Completed||Phase 1|38|Actual|Esperance Pharmaceuticals Inc|||||f||||||||||||||2018-06-01 00:44:17.931784|2018-06-01 00:44:17.931784
NCT00949546|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2017-11-21|2009-07-29|2009-07-30|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2005||2005-04-30|November 2017|2017-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Treatment of Hidradenitis Suppurativa Using Etanercept|Treatment of Hidradenitis Suppirativa With Etanercept Injection|Completed|||20|Actual|Penn State University|||1||f||||f||||||||||2018-06-01 00:44:17.982328|2018-06-01 00:44:17.982328
NCT00949533|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|2016-04-29||2016-06-27|2009-07-29|2009-07-30|Estimate|2016-06-27|2016-08-08|Estimate||||2016-06-27|2016-08-08|Estimate|August 2009||2009-08-31|June 2016|2016-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||Intention-to-treat (ITT) population included all enrolled participants who received at least one dose of the study drug.|A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza|A Phase IIIb, Open-label, Comparative, Randomized Study on Resistance of Influenza A/H1N1 2009 Virus to Treatment With Oseltamivir at Standard Dose Versus Double Dose|Completed||Phase 3|37|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:44:18.153557|2018-06-01 00:44:18.153557
NCT00949520|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-02-24|2009-07-29|2009-07-30|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2009||2009-07-31|February 2014|2014-02-28||||November 2011|Actual|2011-11-30||Interventional|||Stress Multidetector Computed Tomography (MDCT) an New Diagnostic Tool for Myocardial Disease|Dual Source Computed Tomography (DSCT) During Injection of Dipyridamole : a New Technique for Myocardial Ischemia Assessment|Completed||N/A|17|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 00:44:18.435163|2018-06-01 00:44:18.435163
NCT00949507|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2013-05-24|2009-07-29|2009-07-30|Estimate|||||||2013-05-24|2013-05-27|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Comparison of Two Regimens of Anesthesia for Children Undergoing Magnetic Resonance Imaging (MRI) in General Anesthesia|Comparison of Two Regimens of Anesthesia for Children Undergoing MRI in General Anesthesia. Advantages, Disadvantages and Time Consumption Regarding the Two Regimens.|Completed|||120|Actual|Glostrup University Hospital, Copenhagen|||2||f||||t||||||||||2018-06-01 00:44:18.492723|2018-06-01 00:44:18.492723
NCT00949494|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|February 2009|Actual|2009-02-28|June 2008|Actual|2008-06-30||Interventional|||Effects of Synvisc on Cartilage in Knee Osteoarthritis (OA)|Pilot Trial of Effects of Intra-articular Synvisc Therapy on Cartilage Determined by dGEMRIC in Patients With OA of the Knee|Completed||Phase 1|30|Actual|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-06-01 00:44:18.54511|2018-06-01 00:44:18.54511
NCT00949481|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2012-08-15|2009-07-29|2009-07-30|Estimate|||||||2012-08-15|2012-08-16|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Increasing Family Planning Uptake Among Postpartum Women|Increasing Family Planning Uptake Among Postpartum Women: Testing Supply and Demand Solutions|Completed||N/A|14050|Actual|FHI 360||3|||f||||f||||||||||2018-06-01 00:44:18.619653|2018-06-01 00:44:18.619653
NCT00949468|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|June 2008||2008-06-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||Microbiological Keratitis in a Countryside City of Brazil|Epidemiologic Characteristics, Predisposing Factors and Microbiological Profile of Infectious Corneal Ulcers in Two Referral Centers in a Countryside City of Brazil|Completed|||74|Actual|Sao Jose do Rio Preto Medical School|||2||f||||f||||||Samples With DNA|"~     Corneal scrapes~   "|||2018-06-01 00:44:18.758516|2018-06-01 00:44:18.758516
NCT00949455|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2015-04-14|2009-07-29|2009-07-30|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2009||2009-03-31|April 2015|2015-04-30||||July 2015|Anticipated|2015-07-31||Interventional|LaMB||A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium|A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB]|Unknown status|Active, not recruiting|Phase 2/Phase 3|204|Anticipated|Queen Mary University of London||2|||f||||t||||||||||2018-06-01 00:44:18.818029|2018-06-01 00:44:18.818029
NCT00949442|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2012-08-20|2009-07-29|2009-07-30|Estimate|||||||2012-08-20|2012-08-21|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|LANCELOT||Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment|Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled|Completed||Phase 4|708|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:44:18.937999|2018-06-01 00:44:18.937999
NCT00949429|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2011-07-21|2009-07-29|2009-07-30|Estimate|||||||2011-07-21|2011-07-22|Estimate|July 2009||2009-07-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Quality of Postoperative Pain Management in Cardiac Surgical Patients|Quality of Postoperative Pain Management in Cardiac Surgical Patients|Completed|||300|Actual|Mahidol University|||||f||||t||||||||||2018-06-01 00:44:19.115616|2018-06-01 00:44:19.115616
NCT00949416|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Observational|SBSS||Risk Factors of Incidence of Type 2 Diabetes and Cardiovascular Diseases---Shanghai Baoshan Study|Risk Factors of Incidence of Type 2 Diabetes and Cardiovascular Diseases|Unknown status|Enrolling by invitation||3000|Anticipated|Shanghai Jiao Tong University School of Medicine|||||f||||t||||||||||2018-06-01 00:44:19.172039|2018-06-01 00:44:19.172039
NCT00949403|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2018-02-05|2009-07-29|2009-07-30|Estimate|||||||2018-02-05|2018-02-07|Actual|July 2010||2010-07-31|February 2018|2018-02-28|January 19, 2018|Actual|2018-01-19|January 2018|Actual|2018-01-31||Observational|Liver||Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease|An Interdisciplinary Approach to the Study of Non-alcoholic Fatty Liver Disease|Completed|||9|Actual|Washington University School of Medicine|||1||f||||t||||||Samples With DNA|"~     Blood Samples.~   "|No|There is no plan to make individual participant data available to other researchers|2018-06-01 00:44:19.218096|2018-06-01 00:44:19.218096
NCT00949390|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2016-04-06|2009-07-29|2009-07-30|Estimate|||||||2016-04-06|2016-04-07|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials|Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials|Completed|||309|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 00:44:19.281728|2018-06-01 00:44:19.281728
NCT00949377|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2015-10-13|2009-07-29|2009-07-30|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?|Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?|Withdrawn||Phase 4|0|Actual|Beth Israel Medical Center||2||Unable to recruit enough patients at a single center.|f||||f||||||||||2018-06-01 00:44:19.346351|2018-06-01 00:44:19.346351
NCT00949364|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2017-09-21|2009-07-29|2009-07-30|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2009||2009-12-31|September 2017|2017-09-30|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|||Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage|Multi-Center Phase II Study With Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage|Completed||Phase 2|103|Actual|University of Ulm||1|||f||||f||||||||||2018-06-01 00:44:19.421743|2018-06-01 00:44:19.421743
NCT00949351|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|September 2010|Anticipated|2010-09-30|July 2010|Anticipated|2010-07-31||Interventional|||Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy|Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Lerdsin General Hospital||1|||f||||t||||||||||2018-06-01 00:44:19.507582|2018-06-01 00:44:19.507582
NCT00949338|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-12-30|2009-07-29|2009-07-30|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2006||2006-03-31|January 2014|2014-01-31||||June 2010|Actual|2010-06-30||Interventional|||Comparing Two Sets of Bladder-Filling Instructions in Treating Patients Undergoing Radiation Therapy For Prostate Cancer. ICORG 05-04|A Randomised Trial Comparing The Bladder Volume Consistency Achieved With Two Bladder-Filling Protocols in Prostate Conformal Radiotherapy|Completed||N/A|183|Anticipated|Cancer Trials Ireland||2|||f||||||||||||||2018-06-01 00:44:19.817707|2018-06-01 00:44:19.817707
NCT00949325|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2014-11-25|2009-07-29|2009-07-30|Estimate|||||||2014-11-25|2014-11-26|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma|Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas|Completed||Phase 1/Phase 2|24|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-06-01 00:44:19.901739|2018-06-01 00:44:19.901739
NCT00949312|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2018-02-05|2009-07-29|2009-07-30|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2009|Actual|2009-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Studying Lymph Nodes in Patients With Stage II Colon Cancer|Ultrastaging of Early Colon Cancer|Recruiting|||300|Anticipated|John Wayne Cancer Institute|||1||f||||t|f|f||||Samples With DNA|"~     Paraffin-embedded primary tumor and lymph node sections~   "|Undecided||2018-06-01 00:44:20.049801|2018-06-01 00:44:20.049801
NCT00949299|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-03-14|2009-07-29|2009-07-30|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Buprenorphine on Ulnar Nerve Motor Block|Effects of Buprenorphine on Ulnar Nerve Motor Block|Terminated||Phase 4|20|Anticipated|University of Zurich||||Not enough could be recruted|f||||t||||||||||2018-06-01 00:44:20.14573|2018-06-01 00:44:20.14573
NCT00949286|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2014-05-15|2009-07-28|2009-07-30|Estimate|||||||2014-05-15|2014-05-19|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|ADVANCE-ON||Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study|Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study|Completed|||8494|Actual|The George Institute|||||f||||f||||||||||2018-06-01 00:44:20.261724|2018-06-01 00:44:20.261724
NCT00949273|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2013-11-26|2009-07-29|2009-07-30|Estimate|||||||2013-11-26|2013-11-28|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||Safety and Efficacy Study of Cylindrical Abdominoperineal Resection to Treat Rectal Cancer|A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Cylindrical Abdominoperineal Resection in the Treatment of Advanced Very Low Rectal Cancer|Unknown status|Recruiting||300|Anticipated|Beijing Chao Yang Hospital|||2||f||||t||||||Samples Without DNA|"~     circumferential resection margin; bowel perforation; cross sectional tissue area outside the~     internal sphincter; mean distance from the internal sphincter to the anterior, posterior and~     lateral circumferential resection margins~   "|||2018-06-01 00:44:20.640853|2018-06-01 00:44:20.640853
NCT00949260|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2010-03-25|2009-07-29|2009-07-30|Estimate|||||||2010-03-25|2010-03-26|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Hemodynamic Assessment of Healthy and Hypertensive Pregnant Women by Non-Invasive Bio-Reactance|Hemodynamic Assessment of Healthy and Hypertensive Pregnant Women by Non-invasive Bio-reactance|Completed|||30|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||3||f||||f||||||||||2018-06-01 00:44:20.818867|2018-06-01 00:44:20.818867
NCT00949247|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2018-05-14|2009-07-29|2009-07-30|Estimate|||||||2018-05-14|2018-05-15|Actual|December 2009||2009-12-31|May 2018|2018-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases|Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases|Completed||Early Phase 1|20|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:44:20.950059|2018-06-01 00:44:20.950059
NCT00949234|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2017-10-02||2017-12-15|2009-07-29|2009-07-30|Estimate|2017-12-15|2017-12-18|Actual||||2017-12-15|2017-12-18|Actual|March 2010||2010-03-31|December 2017|2017-12-31|August 2011|Actual|2011-08-31|June 2010|Actual|2010-06-30||Interventional|||Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV|A Pilot Project to Operationalize the Prevention Strategy of Post Exposure Prophylaxis Following Sexual Exposure to HIV in Combination With Educational Programming and Behavioral Risk Reduction Strategies in Los Angeles County|Completed||Phase 2|267|Actual|University of California, Los Angeles|Open label clinical trial of deploying PEP regimens at community based sites. Non-randomized and guidelines have subsequently evolved.|1|||f||||t||||||||||2018-06-01 00:44:21.118688|2018-06-01 00:44:21.118688
NCT00949221|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2012-07-26|2009-07-29|2009-07-30|Estimate|||||||2012-07-26|2012-07-27|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|START-IN||Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!)|Evaluation of Long-term Efficacy of 2 Strategies of Real Time Continuous Glucose Monitoring, Compared to Self BG-monitoring in Children and Adolescent With Type 1 Diabetes: a Randomized, Multicenter, Open Trial|Completed||Phase 2/Phase 3|150|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-06-01 00:44:21.711208|2018-06-01 00:44:21.711208
NCT00949208|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2016-08-04|2009-07-29|2009-07-30|Estimate|||||||2016-08-04|2016-08-05|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Development of Applications of the Given® Diagnostic System and Evaluation of Their Performance|Development of Applications of the Given® Diagnostic System and Evaluation of Their Performance|Completed|||1225|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-06-01 00:44:21.786315|2018-06-01 00:44:21.786315
NCT00949195|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2011-07-20|2009-07-29|2009-07-30|Estimate|||||||2011-07-20|2011-07-21|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|December 2011|Anticipated|2011-12-31|December 2009||2009-12-31||Observational|PAPCOPDHS||Pulmonary Arterial Pressure Response During Exercise|Pulmonary Arterial Pressure Response During Exercise in COPD and Healthy Subjects|Unknown status|Recruiting||80|Anticipated|Szeged University|||2||f||||t||||||None Retained|"~     Blood sample is taken to analyse the systemic inflammatory marker (hsCRP) level from serum.~     We measure the samples and than we don't store it.~   "|||2018-06-01 00:44:21.843606|2018-06-01 00:44:21.843606
NCT00949182|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-01-13|2009-07-29|2009-07-30|Estimate|||||||2014-01-13|2014-01-14|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery|Micro and Macro Arteriolar Blockade of Hepatocellular Carcinoma (HCC): Treatment With Sorafenib Before and After Hepatic Arterial Embolization (HAE) Therapy for Liver Cancer.|Completed||Phase 2|20|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 00:44:21.928405|2018-06-01 00:44:21.928405
NCT00949169|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|April 2006||2006-04-30|July 2009|2009-07-31|July 2007|Actual|2007-07-31|||||Observational|||Carotid Intima-media Thickness (IMT) and Large-vessel Atherosclerosis by Multidetector Computed Tomography (MDCT)|Association of Carotid IMT and Large-vessel Atherosclerosis by MDCT in Korean Type 2 Diabetic Patients|Completed|||71|Actual|Eulji University Hospital|||1||f||||t||||||||||2018-06-01 00:44:21.999419|2018-06-01 00:44:21.999419
NCT00949156|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-09-14|2009-07-29|2009-07-30|Estimate|||||||2010-09-14|2010-09-15|Estimate|September 1997||1997-09-30|September 2010|2010-09-30|December 2015|Anticipated|2015-12-31|October 2009|Actual|2009-10-31||Observational|||Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma|Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma|Unknown status|Active, not recruiting||238|Anticipated|Southern Medical University, China|||2||f||||t||||||||||2018-06-01 00:44:22.051739|2018-06-01 00:44:22.051739
NCT00949143|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2011-03-25|2009-07-29|2009-07-30|Estimate|||||||2011-03-25|2011-03-28|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effects of Axle Positions on Wheelchair Skills in Manual Wheelchair Users|Effects of Axle Positions on Wheelchair Skills in Manual Wheelchair Users|Completed||N/A|15|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-06-01 00:44:22.118588|2018-06-01 00:44:22.118588
NCT00949130|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2010-03-17|2009-07-29|2009-07-30|Estimate|||||||2010-03-17|2010-03-18|Estimate|November 2009||2009-11-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|A Multicenter,Investigator-blinded,Randomized, Comparative Study to Evaluate the Efficacy and Safety of Oral NXL103 Versus Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Completed||Phase 2|180|Actual|Novexel Inc||2|||f||||f||||||||||2018-06-01 00:44:22.189327|2018-06-01 00:44:22.189327
NCT00937144|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-02-28|2009-07-09|2009-07-10|Estimate|||||||2010-02-28|2010-03-02|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|February 2010|Anticipated|2010-02-28|September 2009|Anticipated|2009-09-30||Interventional|||Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil||Withdrawn||Phase 4|15|Anticipated|The Baruch Padeh Medical Center, Poriya||2||we didnt recieved the medicine|f||||t||||||||||2018-06-01 00:48:05.813285|2018-06-01 00:48:05.813285
NCT00949117|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2013-07-08||2014-03-04|2009-07-29|2009-07-30|Estimate|2014-01-30|2014-03-04|Estimate||||2014-03-04|2014-04-02|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer|An Open Label Randomized Phase II Study of an Appetite Stimulant, Cyproheptadine Hydrochloride, With and Without a Nutritional Supplement, in Children With Cancer/Treatment-Related Weight Loss|Terminated||Phase 2|9|Actual|University of South Florida|Study closed early due to slow accrual and lack of feasibility Only 1 subject completed protocol and considered in the outcome measures. Subject too young to complete PedsFAACT & did not have prealbumin drawn at 24 week visit so outcomes not assessed|2||study not feasible with low accrual. DSMB recommended closure|f||||t||||||||||2018-06-01 00:44:22.419067|2018-06-01 00:44:22.419067
NCT00949104|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Role of Oral Sucrose in Reducing the Pain to Orogastric Tube Insertion in Preterm Neonates|A Study to Assess the Role of Oral Sucrose in Reducing the Pain to Orogastric Tube Insertion in Preterm Neonates|Completed||Phase 2/Phase 3|120|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-06-01 00:44:22.685214|2018-06-01 00:44:22.685214
NCT00949091|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-06-09|2009-07-28|2009-07-30|Estimate|||||||2010-06-09|2010-06-11|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes|A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes|Completed||Phase 1|60|Actual|Takeda||1|||f||||f||||||||||2018-06-01 00:44:22.760436|2018-06-01 00:44:22.760436
NCT00949078|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|2017-02-22||2017-06-12|2009-07-29|2009-07-30|Estimate|2017-06-12|2017-07-12|Actual||||2017-06-12|2017-07-12|Actual|July 2009||2009-07-31|June 2017|2017-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Omalizumab in the Treatment of Peanut Allergy|Effects of Omalizumab on Peanut Allergen Induced Cellular and Clinical Responses in Peanut Allergic Adults|Completed||Phase 2|51|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:44:22.861897|2018-06-01 00:44:22.861897
NCT00949065|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-07-29|2009-07-29|2009-07-30|Estimate|||||||2009-07-29|2009-07-30|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Interventional|PAINLESS||Intravenous Immunoglobulins in Complex-regional Pain Syndrome|Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck)|Unknown status|Not yet recruiting|Phase 3|36|Anticipated|University of Giessen||2|||f||||t||||||||||2018-06-01 00:44:23.263726|2018-06-01 00:44:23.263726
NCT00949052|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2017-05-24|2009-07-29|2009-07-30|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2009|Actual|2009-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2014|Actual|2014-12-31|1 Day|Observational [Patient Registry]|||Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer|Radiation Sensitivity, DNA Repair, and Second Cancers.|Active, not recruiting|||1000|Actual|Vanderbilt-Ingram Cancer Center|||||f||||f||||||||||2018-06-01 00:44:23.357867|2018-06-01 00:44:23.357867
NCT00949039|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-03-11|2009-07-29|2009-07-30|Estimate|||||||2015-03-11|2015-03-12|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer||Completed||Phase 3|101|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||||||||||||2018-06-01 00:44:23.450442|2018-06-01 00:44:23.450442
NCT00949026|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2013-11-19|2009-07-29|2009-07-30|Estimate|||||||2013-11-19|2013-11-21|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|May 2010||2010-05-31|May 2010||2010-05-31||Interventional|||Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis|Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis|Withdrawn||Phase 1|0|Actual|Emory University||1||No accrual|f||||t||||||||||2018-06-01 00:44:23.523288|2018-06-01 00:44:23.523288
NCT00949013|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2014-05-23|2009-07-29|2009-07-30|Estimate|||||||2014-05-23|2014-05-26|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313|Evaluation of the Expression of the Cancer Stem Cell Marker ALDH1 as a Predictor of Adjuvant Chemotherapy Response in Breast Cancers of High Risk Women in SWOG-9313|Completed|||1600|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:44:23.611514|2018-06-01 00:44:23.611514
NCT00949000|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2011-02-22|2009-07-29|2009-07-30|Estimate|||||||2011-02-22|2011-02-23|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||AnalyST Treadmill Study|Clinical Evaluation of ST Segment Deviation Detection by SJM AnalyST and Analyst Accel Implantable Cardiac Defibrillators|Completed||N/A|50|Anticipated|St. Jude Medical||1|||f||||f||||||||||2018-06-01 00:44:23.678407|2018-06-01 00:44:23.678407
NCT00948987|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2009-10-14|2009-07-29|2009-07-30|Estimate|||||||2009-10-14|2009-10-15|Estimate|September 2004||2004-09-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Mechanism Based Resistance to Aspirin|Mechanism Based Resistance to Aspirin|Completed||Phase 1|400|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:44:23.751773|2018-06-01 00:44:23.751773
NCT00948974|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-29|||2016-01-21|2009-07-29|2009-07-30|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Variations of Cognitive Behavior Therapy for Social Anxiety Disorder|Variations of Cognitive Behavior Therapy for Social Anxiety Disorder|Completed||N/A|132|Actual|Drexel University||2|||f||||f||||||||||2018-06-01 00:44:23.823005|2018-06-01 00:44:23.823005
NCT00948961|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28||2016-02-16|2016-06-22|2009-07-29|2009-07-30|Estimate||||2016-02-16|2016-03-15|Estimate|2016-06-22|2016-06-27|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|February 2014|Actual|2014-02-28|June 2012|Actual|2012-06-30||Interventional|||A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1|A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1|Completed||Phase 1/Phase 2|70|Actual|Celldex Therapeutics|||||f||||f||||||||||2018-06-01 00:44:23.938385|2018-06-01 00:44:23.938385
NCT00948948|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2013-04-03|2009-07-28|2009-07-29|Estimate|||||||2013-04-03|2013-04-05|Estimate||||April 2013|2013-04-30||||||||Expanded Access|Adjunct||Mentor Adjunct Study for Silicone Gel-Filled Mammary Prosthesis|Mentor Adjunct Study for Silicone Gel-Filled Mammary Prosthesis|Approved for marketing|||||Mentor Worldwide, LLC|||||f||||||||||||||2018-06-01 00:44:24.019362|2018-06-01 00:44:24.019362
NCT00948935|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2016-09-23|2009-07-28|2009-07-29|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2009||2009-04-30|September 2016|2016-09-30||||September 2014|Actual|2014-09-30||Interventional|||Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma|Phase II Combination of Gemcitabine (Fixed Dose-rate Infusion, FDR), Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma|Active, not recruiting||Phase 2|36|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:44:24.074818|2018-06-01 00:44:24.074818
NCT00948922|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2018-02-13|2009-07-28|2009-07-29|Estimate|||||||2018-02-13|2018-02-15|Actual|June 18, 2009|Actual|2009-06-18|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma|Evaluation of Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma After Cytoreductive Therapy|Active, not recruiting||Phase 2|124|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-06-01 00:44:24.143531|2018-06-01 00:44:24.143531
NCT00948909|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24||2011-11-22|2013-01-29|2009-07-28|2009-07-29|Estimate||||2011-11-22|2011-11-24|Estimate|2013-01-29|2013-01-31|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease|Completed||Phase 2|274|Actual|AbbVie||4|||f||||||||||||||2018-06-01 00:44:24.230354|2018-06-01 00:44:24.230354
NCT00948896|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2015-04-30||2015-10-26|2009-07-28|2009-07-29|Estimate|2015-07-07|2015-08-04|Estimate||||2015-10-26|2015-11-24|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PROMOTE-Chemop|Convenience sampling was used to enroll a cohort of 600 infants 4–5 mo of age from the Tororo District Hospital Maternal and Child Health Clinic between June 2010 and July 2011. The baseline characteristics were taken at enrollment.|Chemopreventive Therapy for Malaria in Ugandan Children|A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria|Completed||Phase 3|600|Actual|University of California, San Francisco||4|||f||||t||||||||||2018-06-01 00:44:24.353274|2018-06-01 00:44:24.353274
NCT00948883|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2013-04-03|2009-07-28|2009-07-29|Estimate|||||||2013-04-03|2013-04-04|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|K-GREF||Study of Cancers After Solid Organs Transplants|Epidemiological, Immunological, Pathological and Pharmacogenetic Study of Cancers Occuring After Solid Organs Transplants|Completed|||330|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||Samples With DNA|"~     Whole blood, frozen tissue~   "|||2018-06-01 00:44:25.469322|2018-06-01 00:44:25.469322
NCT00948870|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2013-03-06|2009-07-28|2009-07-29|Estimate|||||||2013-03-06|2013-03-07|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Trial of Chinese Prescription Shugan Decoction on Irritable Bowel Syndrome（Diarrhea Type）||Completed||N/A|200|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:44:25.651175|2018-06-01 00:44:25.651175
NCT00948857|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2012-08-02||2012-09-04|2009-07-28|2009-07-29|Estimate|2012-08-02|2012-09-05|Estimate||||2012-09-04|2012-09-10|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|DHEAFert2||Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)|A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Premature Ovarian Failure (POF).|Terminated||Phase 2/Phase 3|5|Actual|Center for Human Reproduction|Termination due to lack of consenting participants.|2||Lack of recruitment.|f||||f||||||||||2018-06-01 00:44:25.720836|2018-06-01 00:44:25.720836
NCT00948844|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2009-07-28|2009-07-28|2009-07-29|Estimate|||||||2009-07-28|2009-07-29|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|August 2011|Anticipated|2011-08-31|August 2010|Anticipated|2010-08-31||Observational|||Automatic Detection of Falls and Near Falls|Automatic Detection of Falls and Near Falls|Unknown status|Not yet recruiting||90|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 00:44:25.930015|2018-06-01 00:44:25.930015
NCT00948831|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2015-04-17|2009-07-28|2009-07-29|Estimate|||||||2015-04-17|2015-04-21|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF)|Osteocel® Plus in Anterior Lumbar Interbody Fusion (ALIF): Evaluation of Radiographic and Patient Outcomes|Completed|||51|Actual|NuVasive|||||f||||f||||||||||2018-06-01 00:44:25.987021|2018-06-01 00:44:25.987021
NCT00948818|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2012-09-28|2011-09-30|2012-12-19|2009-07-28|2009-07-29|Estimate|2012-12-19|2013-01-30|Estimate|2011-09-30|2011-10-05|Estimate|2012-12-19|2013-01-30|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Irritable Bowel Syndrome With Constipation|Completed||Phase 3|803|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:44:26.121796|2018-06-01 00:44:26.121796
NCT00948805|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-28|2009-07-28|2009-07-29|Estimate|||||||2009-07-28|2009-07-29|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|July 2010|Anticipated|2010-07-31|December 2009|Anticipated|2009-12-31||Interventional|||Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment|Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment|Unknown status|Recruiting|Phase 3|25|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 00:44:26.917639|2018-06-01 00:44:26.917639
NCT00948792|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2011-02-21||2011-06-13|2009-07-28|2009-07-29|Estimate|2011-06-13|2011-07-12|Estimate||||2011-06-13|2011-07-12|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of the Effect of Differing Platelet Transfusion Times in Neonates|The Effect of Variable Platelet Transfusion Durations on Platelet Count in Thrombocytopenic Newborns|Completed||N/A|21|Actual|University of Oklahoma||2|||f||||f||||||||||2018-06-01 00:44:27.012881|2018-06-01 00:44:27.012881
NCT00948779|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2012-07-26|2009-07-28|2009-07-29|Estimate|||||||2012-07-26|2012-07-27|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ACHEEN||Antibiotic Education for Children in an Emergency Care Unit|Therapeutic Education About Intake of Oral Solutions of Antibiotics in Children Under 6 Year-old at the Emergency Department in Robert Debré Hospital|Completed||N/A|300|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:44:27.186554|2018-06-01 00:44:27.186554
NCT00948766|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2013-01-08||2013-08-19|2009-07-28|2009-07-29|Estimate|2013-01-08|2013-02-11|Estimate||||2013-08-19|2013-08-28|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|ACTION||Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44|A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44|Completed||Phase 4|716|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:44:27.300365|2018-06-01 00:44:27.300365
NCT00948753|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2016-09-23|2009-07-28|2009-07-29|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2009||2009-06-30|September 2016|2016-09-30||||February 2013|Actual|2013-02-28||Interventional|||Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation|Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation|Active, not recruiting||Phase 1/Phase 2|38|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 00:44:28.34748|2018-06-01 00:44:28.34748
NCT00948740|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2017-01-06|2009-07-28|2009-07-29|Estimate|||||||2017-01-06|2017-01-09|Estimate|August 2009||2009-08-31|January 2017|2017-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||The Effect of Vitamin D on Urinary Calcium Excretion in Kidney Stone Formers With High Urinary Calcium|Phase III Study of the Effect of Vitamin D Repletion on Urinary Calcium Excretion in Kidney Stone Formers With Vitamin D Deficiency and High Urinary Calcium|Withdrawn||Phase 2/Phase 3|0|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-06-01 00:44:28.429643|2018-06-01 00:44:28.429643
NCT00948727|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-09-30|2009-07-28|2009-07-29|Estimate|||||||2009-09-30|2009-10-01|Estimate|January 2004||2004-01-31|July 2009|2009-07-31|June 2008|Actual|2008-06-30|September 2006|Actual|2006-09-30||Interventional|CALCICLO||Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation|Reduction of Acute and Chronic Graft-versus-host Disease After Allogeneic Hematopoietic Stem-cell Transplantation by Adapting Cyclosporine Doses According to Calcineurin Activity : a Proof-of-concept Trial|Completed||Phase 2|39|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:44:28.545865|2018-06-01 00:44:28.545865
NCT00948714|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2017-07-19|2009-07-28|2009-07-29|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2008||2008-05-31|July 2017|2017-07-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Support for Cardiovascular Health in African American Primary Care Patients|Peer and Health Educator Support for Cardiovascular Health in African-American Primary Care Patients|Completed||N/A|130|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 00:44:28.66051|2018-06-01 00:44:28.66051
NCT00948701|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2012-12-03|2009-07-28|2009-07-29|Estimate|||||||2012-12-03|2012-12-04|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|MFT2||Community Volunteers Promoting Physical Activity Among Cancer Survivors|Community Volunteers Promoting Physical Activity Among Cancer Survivors|Unknown status|Active, not recruiting|N/A|108|Anticipated|The Miriam Hospital||2|||f||||t||||||||||2018-06-01 00:44:28.745364|2018-06-01 00:44:28.745364
NCT00948688|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2017-01-27||2017-03-30|2009-07-28|2009-07-29|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|August 2009||2009-08-31|March 2017|2017-03-31|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|||Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas|Phase 1/2 Study of Vorinostat in Combination With Radiation Therapy and Infusional 5-FU in Patients With Locally Advanced Adenocarcinoma of the Pancreas|Terminated||Phase 1/Phase 2|10|Actual|Massachusetts General Hospital|Only 10 participants were enrolled on this trial that planned for 50. Phase II portion of the study was not reached and therefore endpoint analysis is severely limited by sample size.|1||Funding was withdrawn after only 10 participants were enrolled|f||||t||||||||No||2018-06-01 00:44:28.854197|2018-06-01 00:44:28.854197
NCT00948675|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2014-01-14||2017-10-11|2009-07-28|2009-07-29|Estimate|2014-03-04|2014-04-02|Estimate||||2017-10-11|2017-11-13|Actual|September 2009||2009-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2013|Actual|2013-01-31||Interventional||All randomized participants.|Study of Participants With Advanced Non-Small Cell Lung Cancer|A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquamous Histology|Active, not recruiting||Phase 3|361|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:44:29.239082|2018-06-01 00:44:29.239082
NCT00948662|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2013-02-21|2009-07-28|2009-07-29|Estimate|||||||2013-02-21|2013-02-25|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study Evaluating The Safety And Tolerability Of Administration Of Single Oral Doses Of SAM-760 To Healthy Subjects|Ascending Single Dose Study Of The Safety, Tolerability And Pharmacokinetics Of SAM-760 Administered Orally To Healthy Young And Healthy Elderly Subjects|Completed||Phase 1|124|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:44:31.875606|2018-06-01 00:44:31.875606
NCT00948649|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-08-16|2009-07-28|2009-07-29|Estimate|||||||2010-08-16|2010-08-17|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Effects of Chantix on Relapse Prevention for Smoking Cessation|Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence|Completed||Phase 4|62|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:44:31.952559|2018-06-01 00:44:31.952559
NCT00948636|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2017-06-13|2009-07-28|2009-07-29|Estimate|||||||2017-06-13|2017-06-14|Actual|January 2010||2010-01-31|July 2016|2016-07-31|September 2016|Actual|2016-09-30|August 2015|Actual|2015-08-31||Observational|RDSafe||Stem Cell Related Donor Safety Study|A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life|Completed|||1812|Actual|Center for International Blood and Marrow Transplant Research|||1||f||||t||||||||||2018-06-01 00:44:32.052177|2018-06-01 00:44:32.052177
NCT00948623|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-07-29|2009-07-28|2009-07-29|Estimate|||||||2009-07-29|2009-07-30|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|PAC||Physical Activity Counseling During Pulmonary Rehabilitation|Physical Activity Counseling During Pulmonary Rehabilitation: Does it Improve Daily Physical Activity Levels|Unknown status|Recruiting|N/A|70|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 00:44:32.172877|2018-06-01 00:44:32.172877
NCT00947908|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2010-01-12|2009-07-27|2009-07-28|Estimate|||||||2010-01-12|2010-01-13|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy|Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy|Unknown status|Active, not recruiting|N/A|20|Anticipated|University of Rostock||1|||f||||f||||||||||2018-06-01 00:44:45.285977|2018-06-01 00:44:45.285977
NCT00948610|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2017-03-24||2017-10-26|2009-07-28|2009-07-29|Estimate|2017-08-11|2017-09-12|Actual||||2017-10-26|2017-12-02|Actual|November 2008||2008-11-30|October 2017|2017-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy|Sleep & Immune Mechanisms in Rheumatoid Arthritis: Remicade Substudy|Completed||N/A|20|Actual|University of California, Los Angeles|A number of limitations exist: the sample size was relatively small; only women were included; and the exclusive use of infliximab limits generalizability to other TNF antagonists, due to differing biochemical and mechanistic profiles.|2|||f||||t||||||||||2018-06-01 00:44:32.34531|2018-06-01 00:44:32.34531
NCT00948597|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2014-01-08|2009-07-28|2009-07-29|Estimate|||||||2014-01-08|2014-01-09|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Observational|||Development of PK/PD Model for Individualized Propofol Dosing|A Non-Interventional Study to Develop a Pharmacokinetic - Pharmacodynamic Model for Individualized Propofol Dosing|Completed|||26|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||Samples With DNA|"~     Participation involves the collection of one blood sample (3.0 ml) in an EDTA (lavender top)~     tube for pharmacogenetic testing. Genomic DNA will be extracted using standard procedures.~     Participation in pharmacogenetic testing is optional and requires additional consent;~     subjects who refuse pharmacogenetifc testing may still be enrolled in this study.~   "|||2018-06-01 00:44:32.561223|2018-06-01 00:44:32.561223
NCT00948584|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-07-28|2009-07-28|2009-07-29|Estimate|||||||2009-07-28|2009-07-29|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Insulin Dose Titration System Using a Short Messaging Service (SMS) Automatically Produced by a Knowledge Matrix|Insulin Dose Titration System in Diabetic Patients Using a Short Messaging Service Automatically Produced by a Knowledge Matrix|Completed||N/A|100|Actual|Hallym University Medical Center||1|||f||||f||||||||||2018-06-01 00:44:32.63151|2018-06-01 00:44:32.63151
NCT00948571|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2011-06-27|2009-07-28|2009-07-29|Estimate|||||||2011-06-27|2011-06-28|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|February 2012|Anticipated|2012-02-29|October 2011|Anticipated|2011-10-31||Observational|||Influence of Posture and Gas Insufflation on Perioperative Lung Function|Influence of Posture, Anesthesia and Surgical Technique on Airway Resistance of the Upper and Lower Airway and Lung Function.|Unknown status|Recruiting||60|Anticipated|Kliniken Essen-Mitte|||3||f||||f||||||||||2018-06-01 00:44:32.708465|2018-06-01 00:44:32.708465
NCT00948558|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-08-04|2009-07-28|2009-07-29|Estimate|||||||2009-08-04|2009-08-06|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|September 2011|Anticipated|2011-09-30|December 2010|Anticipated|2010-12-31||Observational|||Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT|Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).|Unknown status|Recruiting||40|Anticipated|Huashan Hospital|||||f||||f||||||||||2018-06-01 00:44:32.841609|2018-06-01 00:44:32.841609
NCT00948545|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2012-11-06|2009-07-28|2009-07-29|Estimate|||||||2012-11-06|2012-11-07|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Observational|||Autonomic Nervous System Function Following Bariatric Surgery|Autonomic Nervous System Function and Novel Determinants of Glucose Homeostasis Following Bariatric Surgery|Completed|||37|Actual|Christiana Care Health Services|||1||f||||f||||||Samples Without DNA|"~     Serum, plasma, urine~   "|||2018-06-01 00:44:32.910762|2018-06-01 00:44:32.910762
NCT00948532|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2015-04-17|2009-07-27|2009-07-29|Estimate|||||||2015-04-17|2015-04-21|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®)|Osteocel® Plus in eXtreme Lateral Interbody Fusion (XLIF®): Evaluation of Radiographic and Patient Outcomes|Completed|||104|Actual|NuVasive|||||f||||f||||||||||2018-06-01 00:44:32.981476|2018-06-01 00:44:32.981476
NCT00948519|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2011-07-21|2009-07-28|2009-07-29|Estimate|||||||2011-07-21|2011-07-22|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents|Laser Microbial Killing With Photo Activated Agents|Unknown status|Recruiting|N/A|40|Anticipated|New York Head & Neck Institute||2|||f||||f||||||||||2018-06-01 00:44:33.072159|2018-06-01 00:44:33.072159
NCT00948506|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2011-07-21||2012-03-16|2009-07-28|2009-07-29|Estimate|2012-01-23|2012-02-24|Estimate||||2012-03-16|2012-03-19|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Trial of Topical Cidofovir for the Prevention of Hair Growth|A Phase II, Randomized, Double-blind, Placebo-controlled, Single-center Proof of Concept Study of Topical Cidofovir for the Prevention of Hair Growth|Completed||Phase 2|20|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 00:44:33.166987|2018-06-01 00:44:33.166987
NCT00948493|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2013-03-18|2009-07-28|2009-07-29|Estimate|||||||2013-03-18|2013-03-20|Estimate||||March 2013|2013-03-31||||||||Expanded Access|||Treatment Use of Generex Oral-lyn™ in Patients With Diabetes|An Open-Label Treatment Investigational New Drug (IND) for the Use of Generex Oral-lyn™ in Patients With Type 1 or Type 2 Diabetes Mellitus|No longer available|||||Generex Biotechnology Corp.|||||||||||||||||||2018-06-01 00:44:33.407269|2018-06-01 00:44:33.407269
NCT00948480|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2016-07-13|2009-07-28|2009-07-29|Estimate|||||||2016-07-13|2016-07-15|Estimate|October 2000||2000-10-31|July 2016|2016-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|DCVaccineMel||Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells|Vaccine Biotherapy Of Cancer: Autologous Tumor Cells and Dendritic Cells as Active Specific Immunotherapy in Patients With Metastatic Melanoma|Completed||Phase 2|56|Actual|Hoag Memorial Hospital Presbyterian|||||f||||f||||||||||2018-06-01 00:44:33.457812|2018-06-01 00:44:33.457812
NCT00948467|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2013-07-01|2009-07-28|2009-07-29|Estimate|||||||2013-07-01|2013-07-02|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies|Completed||Phase 1|51|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 00:44:33.566197|2018-06-01 00:44:33.566197
NCT00948454|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-10-23|2009-07-28|2009-07-29|Estimate|||||||2009-10-23|2009-10-27|Estimate|January 2003||2003-01-31|October 2009|2009-10-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Observational|||Research Study on the Effects of Smoking on Arteries|The Dose Effect Of Cigarette-Smoking On Indices Of Arterial Function And Oxidative Stress|Completed|||105|Actual|University of Pennsylvania|||3||f||||f||||||Samples With DNA|"~     Buffy coat from 4ml of blood will be stored for future genomic and proteomic analysis. Blood~     will also be collected for telemore length. This will be performed at an outside institution.~     Identifiers will be stripped from the samples prior to send out.~   "|||2018-06-01 00:44:33.704061|2018-06-01 00:44:33.704061
NCT00948441|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2016-02-19||2016-03-18|2009-07-27|2009-07-29|Estimate|2016-02-19|2016-03-21|Estimate||||2016-03-18|2016-04-18|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Children meeting the inclusion and exclusion criteria who received care at Children's Hospital of Pittsburgh were enrolled.|Pediatric Ethanol Lock Therapy Study.|Ethanol Lock Therapy for the Prevention of Catheter Related Blood Stream Infections|Completed||N/A|16|Actual|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-06-01 00:44:33.776311|2018-06-01 00:44:33.776311
NCT00948428|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-08-13|2009-07-28|2009-07-29|Estimate|||||||2010-08-13|2010-08-17|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis|A Multicenter, Double-Blind, Randomized, Parallel Group, Vehicle-Controlled Study to Determine the Clinical Equivalence of a Generic Imiquimod Cream, 5% and Aldara™ Cream in Subjects With Actinic Keratosis|Completed||Phase 3|462|Actual|Actavis Inc.||3|||f||||f||||||||||2018-06-01 00:44:34.123124|2018-06-01 00:44:34.123124
NCT00948415|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2014-07-07|2009-07-28|2009-07-29|Estimate|||||||2014-07-07|2014-07-08|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of the Shape Up Rhode Island Campaign Study 5|Evaluation of the Shape Up Rhode Island Campaign Study 5: Does Adding Behavioral Weight Control Information to Shape-Up Rhode Island Improve Outcomes?|Completed||N/A|128|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-06-01 00:44:34.232859|2018-06-01 00:44:34.232859
NCT00948402|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-10-13|2009-07-28|2009-07-29|Estimate|||||||2009-10-13|2009-10-14|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|January 2009|Actual|2009-01-31|December 2006|Actual|2006-12-31||Interventional|||PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives|Effects of Metformin Versus Oral Contraceptives on PED/PEA-15 Protein Expression in Obese Women With Polycystic Ovary Syndrome|Completed||Phase 3|20|Actual|Federico II University||2|||f||||f||||||||||2018-06-01 00:44:34.304811|2018-06-01 00:44:34.304811
NCT00948389|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2012-07-25||2012-08-27|2009-07-28|2009-07-29|Estimate|2012-07-25|2012-08-28|Estimate||||2012-08-27|2012-08-31|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)|Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma|Terminated||Phase 1/Phase 2|28|Actual|Bristol-Myers Squibb||2||Inability to meet protocol objectives|f||||f||||||||||2018-06-01 00:44:34.427811|2018-06-01 00:44:34.427811
NCT00948376|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2011-12-12|2009-07-28|2009-07-29|Estimate|||||||2011-12-12|2011-12-13|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|DTJ||Natural History of Asphyxiating Thoracic Dystrophy (DTJ)|Clinical and Molecular Study, Natural History of Asphyxiating Thoracic Dystrophy (DTJ)|Completed|||50|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     phenotype-genotype~   "|||2018-06-01 00:44:37.006701|2018-06-01 00:44:37.006701
NCT00948363|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2017-06-28|2009-07-28|2009-07-29|Estimate|||||||2017-06-28|2017-06-29|Actual|August 2009||2009-08-31|June 2017|2017-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of Kiwi on Blood Pressure, Endothelial Function, Antioxidant Capacity and Gene Expression|The Effect of Kiwi on Blood Pressure, Endothelial Function, Antioxidant Capacity and Gene Expression in Mildly Hypertensive Subjects|Completed||N/A|118|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 00:44:37.28802|2018-06-01 00:44:37.28802
NCT00948350|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2015-04-17|2009-07-28|2009-07-29|Estimate|||||||2015-04-17|2015-04-20|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Anesthesia for Awake Fiberoptic Intubation|"Anesthesia for Awake Fiberoptic Intubation in Patients With Cervical Instability - Comparison of Translaryngeal Injection and Spray as You go-Technique"|Completed||N/A|120|Actual|Klinikum St. Georg gGmbH||2|||f||||f||||||||||2018-06-01 00:44:37.548029|2018-06-01 00:44:37.548029
NCT00948337|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-02-25|2009-07-28|2009-07-29|Estimate|||||||2010-02-25|2010-02-26|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||A Study With Health Educational Material on Health Promotion in Cancer Survivors|A Randomized Controlled Trial on the Effect of Intervention With Health Educational Material on Knowledge, Attitude, and Behavior in Cancer Survivors|Unknown status|Active, not recruiting|Phase 2|326|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 00:44:37.816455|2018-06-01 00:44:37.816455
NCT00948324|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2017-10-01|2009-07-28|2009-07-29|Estimate|||||||2017-10-01|2017-10-03|Actual|June 2008||2008-06-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes|Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes|Suspended||Phase 4|400|Anticipated|Sun Yat-sen University||4|||f||||t||||||||||2018-06-01 00:44:38.229275|2018-06-01 00:44:38.229275
NCT00948311|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2016-02-17|2009-07-28|2009-07-29|Estimate|||||||2016-02-17|2016-02-19|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes.|Development of an Instrument to Screen for Eating Disorder Symptoms in Persons With Type 1 Diabetes|Completed|||279|Actual|HealthPartners Institute|||||f||||t||||||||Yes|Papers have been published on the study.|2018-06-01 00:44:38.483402|2018-06-01 00:44:38.483402
NCT00948298|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2017-04-18|2009-07-28|2009-07-29|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2009||2009-07-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Vitamin D3 on Vascular Function|The Effect of Cholecalciferol (Vitamin D3) on Vascular Function and Cardiovascular Risk Factors|Completed||N/A|130|Actual|Charles Drew University of Medicine and Science||1|||f||||t||||||||||2018-06-01 00:44:38.709896|2018-06-01 00:44:38.709896
NCT00948285|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2018-01-03|2009-07-28|2009-07-29|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2009||2009-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|BSMART||Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer|Breast Cancer Staging MAgnetic Resonance for Treatment (B-SMART)|Recruiting||N/A|400|Anticipated|Texas Tech University Health Sciences Center||2|||f||||f||||||||||2018-06-01 00:44:38.975834|2018-06-01 00:44:38.975834
NCT00948272|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2014-05-27|2009-07-28|2009-07-29|Estimate|||||||2014-05-27|2014-05-28|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults|Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults|Completed||Phase 2|384|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:44:39.304812|2018-06-01 00:44:39.304812
NCT00948259|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-11-10|2009-07-28|2009-07-29|Estimate|||||||2009-11-10|2009-11-11|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease|Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.|Completed||Phase 1/Phase 2|30|Actual|Noscira SA||2|||f||||f||||||||||2018-06-01 00:44:39.601829|2018-06-01 00:44:39.601829
NCT00948246|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2012-06-27||2014-10-06|2009-07-28|2009-07-29|Estimate|2012-10-26|2012-11-26|Estimate||||2014-10-06|2014-10-13|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||European Union (EU) Post-Market Study on Easyband®|EU Post-Market Study on Easyband®|Completed|||112|Actual|Allergan|||1||f||||||||||||||2018-06-01 00:44:39.952087|2018-06-01 00:44:39.952087
NCT00948233|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2016-07-20|2009-07-28|2009-07-29|Estimate|||||||2016-07-20|2016-07-21|Estimate|June 2009||2009-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Project COMBAT: Combating Tobacco Use in the United States Army|Combating Tobacco Use in the United States Army|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||2|Military related changes led to to no initiation of recruitment.|f||||f||||||Samples Without DNA|"~     Saliva samples at the 12-month follow-up visit to measure level of cotinine, a chemical~     related to tobacco use.~   "|||2018-06-01 00:44:40.823755|2018-06-01 00:44:40.823755
NCT00948220|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2011-06-06|2009-07-28|2009-07-29|Estimate|||||||2011-06-06|2011-06-07|Estimate|July 2003||2003-07-31|May 2011|2011-05-31|March 2008|Actual|2008-03-31|January 2007|Actual|2007-01-31||Interventional|||Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C|Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1|Completed||Phase 4|26|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 00:44:41.055179|2018-06-01 00:44:41.055179
NCT00948207|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2016-02-03|2009-07-28|2009-07-29|Estimate|||||||2016-02-03|2016-02-05|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Online and Narrative Interventions for Advanced Cancer Patients|Online Narrative Interventions and Family Support for Advanced Cancer Patients|Completed||N/A|117|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:44:41.133137|2018-06-01 00:44:41.133137
NCT00948194|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2016-05-05|2009-07-28|2009-07-29|Estimate|||||||2016-05-05|2016-05-09|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation|Investigation of the Effect of Nitric Oxide on Ischemic Reperfusion Injury During Extended Donor Criteria Liver Transplantation|Completed||N/A|16|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 00:44:41.208081|2018-06-01 00:44:41.208081
NCT00948181|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-07-28|2009-07-28|2009-07-29|Estimate|||||||2009-07-28|2009-07-29|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|September 2010|Anticipated|2010-09-30|July 2010|Anticipated|2010-07-31||Observational|||Evaluation of Plasma Catecholamine Concentration During Surgery|Evaluation of Stress Hormone Concentration During the Resection of Pheochromocytoma. Comparison of Surgeon - Anesthesiologist - Patient|Unknown status|Active, not recruiting||8|Anticipated|Kliniken Essen-Mitte|||3||f||||f||||||Samples Without DNA|"~     Venous blood will be drawn from the surgeon, anesthesiologist and from 8 patients to~     determine plasma catecholamine concentrations. Only plasma will be used for measurements.~   "|||2018-06-01 00:44:41.335211|2018-06-01 00:44:41.335211
NCT00948168|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-07-30|2009-07-28|2009-07-29|Estimate|||||||2009-07-30|2009-07-31|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes|6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients|Completed||Phase 4|34|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-06-01 00:44:41.39243|2018-06-01 00:44:41.39243
NCT00948155|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2013-01-14||2014-12-15|2009-07-28|2009-07-29|Estimate|2014-12-15|2014-12-16|Estimate||||2014-12-15|2014-12-16|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Measuring Smoking Behaviors While Using Varenicline|Assessment of Smoking Topography and Behaviors During Response to Varenicline|Completed||Phase 4|48|Actual|University of Pennsylvania|Attrition rates were high. The final sample consisted primarily of Caucasian males, which may limit the generalizability of the present findings.|2|||f||||t||||||||||2018-06-01 00:44:41.468669|2018-06-01 00:44:41.468669
NCT00948142|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28||2011-02-23|2016-01-26|2009-07-28|2009-07-29|Estimate||||2011-02-23|2011-03-01|Estimate|2016-01-26|2016-02-25|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections|A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections|Completed||Phase 2|198|Actual|Cempra Inc||3|||f||||f||||||||||2018-06-01 00:44:42.191096|2018-06-01 00:44:42.191096
NCT00948129|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2018-01-08|2009-07-28|2009-07-29|Estimate|||||||2018-01-08|2018-01-10|Actual|June 2010|Actual|2010-06-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Smoking Cessation for Low-Income Adults|Enhancing Cancer Outreach for Low-income Adults With Innovative Smoking Cessation|Active, not recruiting||N/A|756|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-06-01 00:44:42.671775|2018-06-01 00:44:42.671775
NCT00948116|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-07-26|2009-07-28|2009-07-29|Estimate|||||||2010-07-26|2010-07-27|Estimate|July 2009||2009-07-31|March 2009|2009-03-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Observational|BIOMARKERS||Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes|Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing Coronary Revascularisation|Unknown status|Recruiting||250|Anticipated|Barts & The London NHS Trust|||1||f||||t||||||Samples Without DNA|"~     Blood and urine samples will be retained for the duration of the study~   "|||2018-06-01 00:44:42.892064|2018-06-01 00:44:42.892064
NCT00948103|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2014-11-05|2009-07-28|2009-07-29|Estimate|||||||2014-11-05|2014-11-06|Estimate|September 2008||2008-09-30|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PROTOTOX||The Interest of the Nitrous Oxide During Intravesical Injection of Botulinum Toxin A|Nitrous Oxide (KALINOX®) Inhalation and Tolerance of Intravesical Botulinum Neurotoxin A Injection: a Double-blind Randomized Controlled Study|Completed||Phase 3|33|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:44:42.969238|2018-06-01 00:44:42.969238
NCT00948090|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2014-05-21||2014-07-01|2009-07-28|2009-07-29|Estimate|2014-07-01|2014-07-31|Estimate||||2014-07-01|2014-07-31|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients|A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually- Optimized Conditioning Using Pharmacokinetics [PK]-Directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects With Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma|Completed||Phase 2|207|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-06-01 00:44:43.073682|2018-06-01 00:44:43.073682
NCT00948077|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2011-04-11|2009-07-28|2009-07-29|Estimate|||||||2011-04-11|2011-04-12|Estimate|July 2009||2009-07-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|TBPK||Pharmacokinetic Study for Anti-tuberculosis Drugs|A Single-Center, Open-Label, Randomized, Crossover Design Study to Evaluate the Effect of Dietary Status on Pharmacokinetic Profile of Orally Administered First-Line Anti-TB Drugs in Subjects With Pulmonary Tuberculosis|Unknown status|Recruiting|N/A|16|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-06-01 00:44:43.759776|2018-06-01 00:44:43.759776
NCT00948064|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|2015-05-29||2017-01-10|2009-07-28|2009-07-29|Estimate|2015-06-30|2015-07-02|Estimate||||2017-01-10|2017-02-28|Actual|September 2009||2009-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|April 2015|Actual|2015-04-30||Interventional|||Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)|A Phase 2 Trial of Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Who Are Ineligible for Other Leukemia Protocols|Active, not recruiting||Phase 2|110|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 00:44:43.891119|2018-06-01 00:44:43.891119
NCT00948051|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2011-04-12|2009-07-28|2009-07-29|Estimate|||||||2011-04-12|2011-04-13|Estimate|March 2009||2009-03-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of follow-on Formula Enriched on Short-chain Fructooligosaccharides (scFOS) on Immune Response in Healthy Infants|A Placebo-controlled, Double-blind Randomized Study to Evaluate the Efficacy of a follow-on Milk Formula Supplemented With Fructo-oligosaccharides on Immune Response in Healthy Infants|Completed||N/A|60|Anticipated|Syral||2|||f||||||||||||||2018-06-01 00:44:44.490804|2018-06-01 00:44:44.490804
NCT00948038|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-07-28|2009-07-28|2009-07-29|Estimate|||||||2009-07-28|2009-07-29|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Dairy Modulation of Oxidative and Inflammatory Stress in Overweight and Obese Subjects||Completed||N/A|20|Actual|University of Tennessee||2|||f||||f||||||||||2018-06-01 00:44:44.545737|2018-06-01 00:44:44.545737
NCT00948025|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2015-05-20|2009-07-28|2009-07-29|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CHANGE||A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options|A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance Nerve Graft Evaluating Recovery Outcomes of Nerve Repair in the Hand. (CHANGE)|Completed||Phase 4|32|Actual|AxoGen, Inc||2|||f||||||||||||||2018-06-01 00:44:44.620075|2018-06-01 00:44:44.620075
NCT00948012|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2009-07-28|2009-07-28|2009-07-29|Estimate|||||||2009-07-28|2009-07-29|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|November 2007|Actual|2007-11-30|December 2006|Actual|2006-12-31||Observational|||Exercise-induced Pulmonary Hypertension in Patients With Sickle-cell Anemia|Exercise-induced Pulmonary Hypertension in Patients With Sickle-cell Anemia: an Echocardiographic Study.|Completed|||44|Actual|Federal University of São Paulo|||2||f||||f||||||||||2018-06-01 00:44:44.697022|2018-06-01 00:44:44.697022
NCT00947999|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2013-06-04|2009-07-28|2009-07-29|Estimate|||||||2013-06-04|2013-06-06|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Neurofeedback Treatment of Pain in Persons With Spinal Cord Injury (SCI)|Neurofeedback Treatment of Pain in Persons With SCI: Phase 1|Completed|||93|Actual|University of Washington|||3||f||||f||||||||||2018-06-01 00:44:44.750875|2018-06-01 00:44:44.750875
NCT00947986|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-28|||2010-03-18|2009-07-28|2009-07-29|Estimate|||||||2010-03-18|2010-03-22|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Mucociliary Clearance Time in Chronic Rhinosinusitis (CRS) Patients After Sinus Surgery|Effect of Baby Shampoo Nasal Irrigation on Mucociliary Clearance Time in Patients After Sinus Surgery|Completed||N/A|60|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-06-01 00:44:44.805389|2018-06-01 00:44:44.805389
NCT00947973|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2016-12-15|2009-07-27|2009-07-28|Estimate|||||||2016-12-15|2016-12-16|Estimate|July 2010||2010-07-31|December 2016|2016-12-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder|Multisite Study of School Based Treatment Approaches for ADHD Adolescents|Completed||Phase 2|315|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-06-01 00:44:44.861525|2018-06-01 00:44:44.861525
NCT00947960|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2018-03-01|2009-07-27|2009-07-28|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2009||2009-06-30|March 2018|2018-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease|A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study|Completed||Phase 2|23|Actual|Baylor Research Institute||2|||f||||f||||||||||2018-06-01 00:44:44.998596|2018-06-01 00:44:44.998596
NCT00947947|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2013-11-13|2009-07-27|2009-07-28|Estimate|||||||2013-11-13|2013-11-15|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|TIPSS||Computerized HIV/Sexually Transmitted Disease (STD) Prevention Program|Enhancing Message Design in Tailored, Computerized HIV/STI Interventions|Completed||Phase 2|274|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:44:45.082016|2018-06-01 00:44:45.082016
NCT00947934|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2011-12-07|2009-07-27|2009-07-28|Estimate|||||||2011-12-07|2011-12-08|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|August 2012|Anticipated|2012-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of the Brain Stimulation Effect on Memory Impairment in Alzheimer Disease|Study of the Effect of the Chronic Electric Stimulation of the Hypothalamus/Fornix on Memory Impairment in Alzheimer Disease.|Unknown status|Recruiting|N/A|5|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||t||||||||||2018-06-01 00:44:45.150604|2018-06-01 00:44:45.150604
NCT00947921|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2018-01-24|2009-07-27|2009-07-28|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2009||2009-08-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|POP||Plasty or Prosthesis to Treat Functional Mitral Regurgitation|POP Study: Plasty or Prosthesis to Treat Functional Mitral Regurgitation in Low Ejection Fraction Patients; a Randomized Prospective Controlled Study|Terminated||N/A|20|Actual|Cardiochirurgia E.H.||2|||f||||t||||||||||2018-06-01 00:44:45.225716|2018-06-01 00:44:45.225716
NCT00947895|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2016-03-21|2009-07-27|2009-07-28|Estimate|||||||2016-03-21|2016-03-22|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|RECLAIM||Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone|Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study|Terminated||Phase 2/Phase 3|30|Actual|Neurologique Foundation, Inc.||2||"Study reached halfway point in approximately one year time period and was halted to analyze~   data."|f||||f||||||||||2018-06-01 00:44:45.408666|2018-06-01 00:44:45.408666
NCT00947882|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2014-04-22|2012-03-09|2015-05-13|2009-07-27|2009-07-28|Estimate|2015-04-28|2015-05-14|Estimate|2012-03-09|2012-03-14|Estimate|2015-05-13|2015-06-08|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|DELUTS|FAS. The efficacy analyses were based on the “as planned” treatment. Three patients deviated from the planned dosing and were included in the planned treatment groups in the FAS (i.e. not in the actual treatment groups as for the Safety Analysis Set).|A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)|A Dose-Finding, Multi-Centre, Double-Blind, Randomised, Parallel, Placebo-Controlled Trial to Investigate Efficacy and Safety of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)|Completed||Phase 2|404|Actual|Ferring Pharmaceuticals|Following the planned 6-month interim analysis when all patients had completed the visit scheduled 6 months after dosing, a decision was taken to stop the trial since the primary efficacy endpoint was not met.|4|||f||||t||||||||||2018-06-01 00:44:45.523781|2018-06-01 00:44:45.523781
NCT00947869|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate|April 2009||2009-04-30|July 2009|2009-07-31||||||||Observational|||Contrast Sensitivity in Glaucoma|Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)|Unknown status|Recruiting||30|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||||||||||||2018-06-01 00:44:46.529522|2018-06-01 00:44:46.529522
NCT00947856|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2014-03-21||2016-12-07|2009-07-24|2009-07-28|Estimate|2014-04-30|2014-05-26|Estimate||||2016-12-07|2017-02-02|Estimate|July 2009||2009-07-31|December 2016|2016-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All participants who received treatment|A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study|Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study|Completed||Phase 2|110|Actual|Seattle Genetics, Inc.||2|||t||||f||||||||||2018-06-01 00:44:46.635434|2018-06-01 00:44:46.635434
NCT00947843|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-25|||2016-10-12|2009-07-27|2009-07-28|Estimate|||||||2016-10-12|2016-10-13|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents|Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 4|306|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-06-01 00:44:47.391925|2018-06-01 00:44:47.391925
NCT00947830|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2013-01-10|2009-07-27|2009-07-28|Estimate|||||||2013-01-10|2013-01-11|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|OCT-1||Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia|A Study Investigating the Predictive Value of Intracellular and Plasma Imatinib Levels in Newly Diagnosed Patients With Chronic Myeloid Leukemia|Completed|||81|Actual|McMaster University|||||f||||f||||||Samples With DNA|"~     Blood cells~   "|||2018-06-01 00:44:47.453306|2018-06-01 00:44:47.453306
NCT00947817|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-08-21|2009-07-27|2009-07-28|Estimate|||||||2015-08-21|2015-08-24|Estimate|September 2008||2008-09-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Impact of Endothelial Cell Activation and Modifications of Haemostasis Induced by Infective Endocarditis on the Risk of Embolism|Impact of Endothelial Cell Activation and Modifications of Haemostasis Induced by Infective Endocarditis on the Risk of Embolism.|Completed||N/A|77|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 00:44:47.500205|2018-06-01 00:44:47.500205
NCT00947804|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-26|||2013-04-05|2009-07-27|2009-07-28|Estimate|||||||2013-04-05|2013-04-08|Estimate|August 2009||2009-08-31|December 2012|2012-12-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Observational|SACS Score||Study to Validate Simple Acute Coronary Syndrome Score|Phase 1 - Pilot Study to Validate the Simple Acute Coronary Syndrome Score; an Acute Coronary Syndrome (ACS) Risk Stratification Tool|Unknown status|Enrolling by invitation||200|Anticipated|St. Joseph's Hospital, Florida|||2||f||||t||||||||||2018-06-01 00:44:47.553078|2018-06-01 00:44:47.553078
NCT00947791|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2017-04-11||2017-04-11|2009-07-27|2009-07-28|Estimate|2017-04-11|2017-05-17|Actual||||2017-04-11|2017-05-17|Actual|July 2009||2009-07-31|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Based on confidentiality concerns, 0 participants analyzed.|Treatment Study of Bipolar Depression|Intravenous Ketamine in Treatment-Resistant Bipolar Depression|Terminated||Phase 4|1|Actual|Icahn School of Medicine at Mount Sinai||2||Change in available resources for study procedures|f||||t|t|f||||||||2018-06-01 00:44:47.610608|2018-06-01 00:44:47.610608
NCT00947778|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2014-02-24|2009-07-27|2009-07-28|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Analysis of Language and Auditory Abilities in Cochlear Implanted Children|Analysis of Language and Auditory Abilities in Cochlear Implanted Children: Assessment by an Auditory Learning Programmed Method|Completed||N/A|22|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 00:44:47.857558|2018-06-01 00:44:47.857558
NCT00947765|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2010-05-27||2010-07-27|2009-07-27|2009-07-28|Estimate|2010-06-30|2010-07-23|Estimate||||2010-07-27|2010-07-28|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis|Phase 2/Phase 3 of the Randomized Control Trial to Evaluate the Efficacy of Autologous Blood Injection Versus Local Corticosteroid Injection for Treatment of Lateral Epicondylitis.|Completed||Phase 2/Phase 3|60|Actual|Dojode, Chetan M., MBBS, MS||2|||f||||t||||||||||2018-06-01 00:44:47.935094|2018-06-01 00:44:47.935094
NCT00947570|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2012-12-27|2009-07-27|2009-07-28|Estimate|||||||2012-12-27|2012-12-31|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Neural Functioning Underlying Anxiety and Its Treatment (The INSULA Study)|Neural Substrates of Anticipation and Interoception in Anxiety Disorders|Completed||N/A|60|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-06-01 00:44:49.848512|2018-06-01 00:44:49.848512
NCT00947752|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-25|2010-09-28||2017-02-02|2009-07-27|2009-07-28|Estimate|2011-05-10|2011-06-09|Estimate||||2017-02-02|2017-03-14|Actual|July 2009||2009-07-31|February 2017|2017-02-28|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|Song||Safety of New Formulation of Glatiramer Acetate|An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection|Completed||Phase 3|147|Actual|Teva Pharmaceutical Industries|Blinding in this study was not possible due to the subjects' ability to detect difference in the volume of each formulation. The lack of blinding was a known limitation.|2|||f||||f||||||||||2018-06-01 00:44:48.417576|2018-06-01 00:44:48.417576
NCT00947739|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2015-06-16|2009-07-27|2009-07-28|Estimate|||||||2015-06-16|2015-06-18|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|March 2014|Actual|2014-03-31|December 2012|Actual|2012-12-31||Interventional|||Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma|Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma|Completed||Phase 1|43|Actual|New Mexico Cancer Care Alliance||15|||f||||t||||||||||2018-06-01 00:44:48.651667|2018-06-01 00:44:48.651667
NCT00947726|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2011-04-18|2009-07-27|2009-07-28|Estimate|||||||2011-04-18|2011-04-20|Estimate|July 2009||2009-07-31|April 2011|2011-04-30||||October 2009|Actual|2009-10-31||Interventional|||Ceramide Containing Multivesicular Emulsion Application . . .|Ceramide Containing Multivesicular Emulsion Application as a Skin Hydration Treatment for Feet of Subjects With Non-insulin Dependent Diabetes Mellitus.|Completed||N/A|30|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 00:44:48.763653|2018-06-01 00:44:48.763653
NCT00947713|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-25|||2011-07-14|2009-07-27|2009-07-28|Estimate|||||||2011-07-14|2011-07-15|Estimate|August 2009||2009-08-31|April 2010|2010-04-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome|Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With HMG in PCOs Patients With Previous Clomiphene Citrate (CC)-Resistant Anovulation|Completed||Phase 1/Phase 2|10|Actual|Royan Institute||2|||f||||t||||||||||2018-06-01 00:44:48.827935|2018-06-01 00:44:48.827935
NCT00947700|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-04-18|2009-07-27|2009-07-28|Estimate|||||||2017-04-18|2017-04-20|Actual|January 2008||2008-01-31|April 2017|2017-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Early Connections, Early Detection and Intervention in Infants at Risk for Autism|UW ACE Project II, Early Detection and Intervention in Infants at Risk for Autism|Completed||N/A|100|Actual|University of Washington||2|||f||||f|f|f||||||No|Participant level data was submitted to NDAR.|2018-06-01 00:44:48.923685|2018-06-01 00:44:48.923685
NCT00947687|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-09-18|2009-07-27|2009-07-28|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2009||2009-07-31|September 2017|2017-09-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects|A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Pulmatrix Inc.||2|||f||||f||||||||||2018-06-01 00:44:49.015904|2018-06-01 00:44:49.015904
NCT00947674|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2012-12-05|2009-07-27|2009-07-28|Estimate|||||||2012-12-05|2012-12-06|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|January 2012|Actual|2012-01-31||Interventional|||A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)|Prospective, Randomized, Double-Blind, Sham Treatment Controlled Multicenter Study to Evaluate Efficacy and Safety of Cellsorba™EX Used for Leukocytapheresis (LCAP) in Patients With Steroid-Free, Active Ulcerative Colitis|Terminated||Phase 4|52|Actual|Asahi Kasei Medical Co., Ltd.||2||short of enrollment|f||||f||||||||||2018-06-01 00:44:49.098297|2018-06-01 00:44:49.098297
NCT00947661|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2015-12-14||2016-09-23|2009-07-24|2009-07-28|Estimate|2016-04-21|2016-05-30|Estimate||||2016-09-23|2016-10-27|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|578|Actual|Sun Pharma Advanced Research Company Limited||2|||f||||||||||||||2018-06-01 00:44:49.20032|2018-06-01 00:44:49.20032
NCT00947648|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2014-06-12|2009-07-27|2009-07-28|Estimate|||||||2014-06-12|2014-06-13|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Outpatient Neutropenic Diet Study|Are Neutropenic Diets Beneficial to Improve Outcome?|Terminated||Phase 2|30|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||t||||||||||2018-06-01 00:44:49.414817|2018-06-01 00:44:49.414817
NCT00947635|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-24|2009-07-24|2009-07-28|Estimate|||||||2009-07-24|2009-07-28|Estimate|November 2005||2005-11-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention|Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention|Completed||Phase 1/Phase 2|46|Actual|University of Alberta||3|||f||||f||||||||||2018-06-01 00:44:49.48672|2018-06-01 00:44:49.48672
NCT00947622|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Interventional|||Occipital Transcranial Direct Current Stimulation in Fibromyalgia|Occipital Transcranial Direct Current Stimulation in Fibromyalgia|Unknown status|Recruiting|Phase 1/Phase 2|35|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||||2018-06-01 00:44:49.570626|2018-06-01 00:44:49.570626
NCT00947609|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2012-06-05|2009-07-27|2009-07-28|Estimate|||||||2012-06-05|2012-06-06|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|TB Px||Improving Latent Tuberculosis (TB) Diagnosis in Thai Children|Improving the Diagnosis and Management of Latent Tuberculosis in Thai Children|Completed|||158|Actual|South East Asia Research Collaboration with Hawaii|||1||f||||f||||||||||2018-06-01 00:44:49.652422|2018-06-01 00:44:49.652422
NCT00947596|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2010-08-10|2009-07-27|2009-07-28|Estimate|||||||2010-08-10|2010-08-12|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||A Study of Inhaled Atropine Sulfate in Healthy Adults|Development of an Inhaled, Dry Powder Delivery System for the Administration of Atropine Sulfate|Completed||Phase 1|18|Anticipated|MicroDose Defense Products L.L.C.||2|||f||||t||||||||||2018-06-01 00:44:49.714038|2018-06-01 00:44:49.714038
NCT00947583|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2014-01-07|2009-07-27|2009-07-28|Estimate|||||||2014-01-07|2014-01-08|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Osteocel® Plus in Transforaminal Lumbar Interbody Fusion (TLIF)|Osteocel® Plus in Transforaminal Lumbar Interbody Fusion (TLIF): Evaluation of Radiographic and Patient Outcomes|Completed|||19|Actual|NuVasive|||||f||||f||||||||||2018-06-01 00:44:49.786572|2018-06-01 00:44:49.786572
NCT00947557|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23||2011-09-09|2011-09-09|2009-07-27|2009-07-28|Estimate||||2011-09-09|2011-09-21|Estimate|2011-09-09|2011-09-21|Estimate|July 2009||2009-07-31|September 2011|2011-09-30||||July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin|A Phase III, Randomized, Double-Blind, Placebo-controlled, Multicenter Study To Evaluate The Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus on Background Treatment With Glimepiride With or Without Metformin|Terminated||Phase 3|677|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:44:49.959553|2018-06-01 00:44:49.959553
NCT00947544|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2013-04-30||2017-01-13|2009-07-27|2009-07-28|Estimate|2013-11-26|2013-12-25|Estimate||||2017-01-13|2017-01-16|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders|A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age With Urea Cycle Disorders, With a Long-Term Safety Extension|Completed||Phase 2|17|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||t||||||||||2018-06-01 00:44:50.233694|2018-06-01 00:44:50.233694
NCT00947531|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2009-04-20||2009-09-24|2009-06-10|2009-07-28|Estimate|2009-06-10|2009-07-28|Estimate||||2009-09-24|2009-09-30|Estimate|October 2006||2006-10-31|September 2009|2009-09-30|August 2007|Actual|2007-08-31|||||Interventional|VascDem||A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia|Completed||Phase 4|242|Actual|Ever Neuro Pharma GmbH||2|||f||||f||||||||||2018-06-01 00:44:50.504965|2018-06-01 00:44:50.504965
NCT00947518|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2009-04-20||2009-07-27|2009-07-27|2009-07-28|Estimate|2009-07-27|2009-07-28|Estimate||||2009-07-27|2009-07-28|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Safety of Skin Cleansing With Chlorhexidine in Preterm Low Birth Weight Infants|Does Skin Cleansing With Chlorhexidine Affect Skin Condition, Temperature and Colonization in Hospitalized Preterm Low Birth Weight Infants?: A Randomized Clinical Trial|Completed||N/A|60|Actual|All India Institute of Medical Sciences, New Delhi||3|||f||||f||||||||||2018-06-01 00:44:50.771114|2018-06-01 00:44:50.771114
NCT00947505|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2011-01-06||2012-06-21|2009-07-27|2009-07-28|Estimate|2012-06-21|2012-07-30|Estimate||||2012-06-21|2012-07-30|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Treatment of Androgenetic Alopecia in Males|A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 7 Beam Model: For the Treatment of Androgenetic Alopecia in Males|Completed||N/A|49|Actual|Lexington International, LLC||2|||f||||f||||||||||2018-06-01 00:44:50.988042|2018-06-01 00:44:50.988042
NCT00947492|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2014-08-27|2009-07-27|2009-07-28|Estimate|||||||2014-08-27|2014-08-28|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs|Monitoring EBV Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs ; Orencia* (Abatacept) and RoActemra* (Tocilizumab).|Unknown status|Active, not recruiting|N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 00:44:51.145183|2018-06-01 00:44:51.145183
NCT00947479|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate|February 2009||2009-02-28|July 2009|2009-07-31|July 2011|Anticipated|2011-07-31|June 2010|Anticipated|2010-06-30||Interventional|OSA-AKI||Effect of Obstructive Sleep Apnea on Central Blood Pressure and Kidney and Endothelial Function|Effect of Correction of Obstructive Sleep Apnea With Positive Airway Pressure on Central Blood Pressure and Kidney and Endothelial Function|Unknown status|Recruiting|N/A|50|Anticipated|Medical Universtity of Lodz||1|||f||||t||||||||||2018-06-01 00:44:51.204378|2018-06-01 00:44:51.204378
NCT00947466|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2015-09-25|2009-07-27|2009-07-28|Estimate|||||||2015-09-25|2015-09-28|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|BUP1501||A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain|A Multi Centre Open Label Single Therapy Dose Ranging Study to Characterise the Pharmacokinetics & Tolerability of BTDS 5-20 ug/h in Children Who Require Opioid Analgesia for Moderate to Severe Mouth Pain Secondary to Chemotherapy Induced Mucositis.|Terminated||Phase 1/Phase 2|25|Actual|Mundipharma Research Limited||1||"25 patients have been recruited and it was considered that further recruitment would add no~   extra PK information"|f||||t||||||||||2018-06-01 00:44:52.18556|2018-06-01 00:44:52.18556
NCT00947453|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2012-08-22|2009-07-27|2009-07-28|Estimate|||||||2012-08-22|2012-08-23|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Sputum Matrix Metalloproteinases (MMP) mRNA and Montelukast|The Effect of Montelukast Therapy on mRNA Profile of Matrix Metalloproteinases and Their Inhibitors in the Sputum of Patients With Asthma|Completed||Phase 2|15|Actual|University of East Anglia||1|||f||||f||||||||||2018-06-01 00:44:52.25422|2018-06-01 00:44:52.25422
NCT00947440|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2010-10-19|2009-07-27|2009-07-28|Estimate|||||||2010-10-19|2010-10-21|Estimate|July 2009||2009-07-31|September 2010|2010-09-30||||August 2009|Actual|2009-08-31||Interventional|||Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation|An Open-Label, Randomized, Crossover Study to Evaluate the Bioavailability of Two Candidate Tablet Formulations of ABT-072 With Reference to the Capsule Formulation|Completed||Phase 1|18|Actual|Abbott||2|||f||||f||||||||||2018-06-01 00:44:52.327378|2018-06-01 00:44:52.327378
NCT00947427|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2016-05-12||2016-08-24|2009-07-24|2009-07-28|Estimate|2016-08-24|2016-10-18|Estimate||||2016-08-24|2016-10-18|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|anti IL-1||Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes|Effects of Canakinumab On The Progression of Type 1 Diabetes In New Onset Subjects|Completed||Phase 2|71|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 00:44:52.404312|2018-06-01 00:44:52.404312
NCT00947414|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2011-12-01|2009-07-27|2009-07-28|Estimate|||||||2011-12-01|2011-12-02|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Cellulite and Extracorporeal Shock Wave|Cellulite and Extracorporeal Shock Wave - a Randomized Trial|Completed||N/A|100|Anticipated|Hannover Medical School||2|||f||||f||||||||||2018-06-01 00:44:52.623686|2018-06-01 00:44:52.623686
NCT00947401|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-26|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Observational|||Fluid Management After Surgery in the Post-Anesthetic Care Unit (PACU)|The Practice of Fluid Management in the Post-anesthetic Care Unit (PACU) of Shaare Zedek Medical Center in Patients Undergoing Elective Surgery: an Observational Study|Unknown status|Not yet recruiting||1000|Anticipated|Shaare Zedek Medical Center|||1||f||||f||||||||||2018-06-01 00:44:53.496829|2018-06-01 00:44:53.496829
NCT00947388|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2013-08-20|2009-07-27|2009-07-28|Estimate|||||||2013-08-20|2013-08-22|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia|Terminated||Phase 1|9|Actual|Case Comprehensive Cancer Center||1||No more eligible patients|f||||t||||||||||2018-06-01 00:44:53.584499|2018-06-01 00:44:53.584499
NCT00947375|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate|January 2005||2005-01-31|July 2009|2009-07-31|January 2007|Actual|2007-01-31|January 2006|Actual|2006-01-31||Interventional|CMCOBaku||Lamictal TM, Haloperidol Decanoate in Schizophrenia|The Effect of Lamictal TM Augmentation of Haloperidol Decanoate in the Treatment of Resistant Schizophrenia Predominantly by Verbal Resistant Hallucinosis: Randomized, Double-blind, Placebo-controlled, Study|Terminated||Phase 4|335|Actual|Central Mental Clinic for Outpatients of Baku City||2||All of the mentioned aim and objectives were achieved before the February 2007|f||||t||||||||||2018-06-01 00:44:53.667245|2018-06-01 00:44:53.667245
NCT00947362|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate|August 2004||2004-08-31|July 2009|2009-07-31|December 2007||2007-12-31|||||Interventional|rtt-ACL||Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul|Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055)|Completed||Phase 2/Phase 3|134|Actual|Waisenmedizin e. V. Promoting Access to Essential Medicine||2|||f||||t||||||||||2018-06-01 00:44:53.753796|2018-06-01 00:44:53.753796
NCT00947349|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2015-01-22|2014-07-10|2015-07-03|2009-07-27|2009-07-28|Estimate|2015-07-03|2015-07-07|Estimate|2014-07-10|2014-07-11|Estimate|2015-07-03|2015-07-07|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||The treated set (TS) consisted of all patients who were given study medication and were documented to have taken at least one dose of investigational products regardless of randomisation.|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients|Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naïve and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin|Completed||Phase 2|22|Actual|Boehringer Ingelheim|"Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information."|4|||f||||||||||||||2018-06-01 00:44:53.923458|2018-06-01 00:44:53.923458
NCT00947336|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate|April 2005||2005-04-30|July 2009|2009-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of Safety & Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis (SBP) in Cirrhotics|Evaluation of Safety and Efficacy of Synbiotic on the Incidence and Recurrence of Spontaneous Bacterial Peritonitis in Cirrhotics: A Randomized, Double Blind Placebo Controlled Trial|Completed||Phase 3|110|Actual|Govind Ballabh Pant Hospital||2|||f||||||||||||||2018-06-01 00:44:55.694923|2018-06-01 00:44:55.694923
NCT00947323|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2010-09-24|2009-07-27|2009-07-28|Estimate|||||||2010-09-24|2010-09-27|Estimate|January 2006||2006-01-31|September 2010|2010-09-30|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|STED||Simvastatin for Treating Erectile Dysfunction|The Effect of Simvastatin in the Penile Erection: a Randomized, Double-blind Clinical Trial|Completed||Phase 3|41|Actual|Santa Casa de Porto Alegre||2|||f||||t||||||||||2018-06-01 00:44:55.760262|2018-06-01 00:44:55.760262
NCT00947310|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2013-03-04||2013-03-04|2009-07-27|2009-07-28|Estimate|2013-03-04|2013-04-18|Estimate||||2013-03-04|2013-04-18|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|MADIT-RIT||Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy|IDE-Exempt: Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy|Completed||Phase 4|1500|Actual|Boston Scientific Corporation||3|||f||||t||||||||||2018-06-01 00:44:55.842753|2018-06-01 00:44:55.842753
NCT00947297|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2013-04-30||2017-01-13|2009-07-27|2009-07-28|Estimate|2013-07-15|2013-08-15|Estimate||||2017-01-13|2017-01-16|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)|A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)|Completed||Phase 3|60|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||t||||||||||2018-06-01 00:44:56.612073|2018-06-01 00:44:56.612073
NCT00947284|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2013-08-14||2016-05-19|2009-07-24|2009-07-28|Estimate|2013-10-21|2013-10-23|Estimate||||2016-05-19|2016-05-20|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity|Effect of Kappa Opioid Agonist-Antagonists in the Heat/Capsaicin Sensitization Model|Terminated||N/A|3|Actual|University of California, San Francisco|The lead investigator passed away and co-investigators could not find complete data on his computer. The experimental model for skin sensitivity did not work in the first 3 participants, and the study was terminated without collecting outcomes data.|2||Experimental pain model didn't work as anticipated.|f||||t||||||||||2018-06-01 00:44:56.869226|2018-06-01 00:44:56.869226
NCT00947271|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2014-08-25||2014-09-10|2009-07-27|2009-07-28|Estimate|2014-09-10|2014-09-17|Estimate||||2014-09-10|2014-09-17|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic|HIV Prevention for STD Clinic Patients|Completed||Phase 3|1010|Actual|The Miriam Hospital||4|||f||||f||||||||||2018-06-01 00:44:57.019579|2018-06-01 00:44:57.019579
NCT00947258|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2009-07-27|2009-07-27|2009-07-28|Estimate|||||||2009-07-27|2009-07-28|Estimate||||July 2009|2009-07-31||||||||Interventional|||Influence of Stretching on Muscle Performance|Influence of Stretching Hamstring and Quadriceps Femoral Muscles on Peak Torque and the Maximum Power of the Knee|Completed||Phase 4|15||Fortaleza University|||||f||||f||||||||||2018-06-01 00:44:57.549335|2018-06-01 00:44:57.549335
NCT00947245|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|||2013-07-17|2009-07-27|2009-07-28|Estimate|||||||2013-07-17|2013-07-18|Estimate|October 2014||2014-10-31|July 2013|2013-07-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Japanese Bridging Study Conducted in the United States|A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||6|||f||||f||||||||||2018-06-01 00:44:57.619862|2018-06-01 00:44:57.619862
NCT00947232|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-05-02|2009-07-27|2009-07-28|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2009||2009-10-31|May 2017|2017-05-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|inMotion||Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI|The Effectiveness of Physical Activity for Major Depression in People Aging With Multiple Sclerosis or Spinal Cord Injury|Completed||N/A|123|Actual|University of Washington||2|||f||||f||||||||Undecided||2018-06-01 00:44:57.788777|2018-06-01 00:44:57.788777
NCT00947219|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-27|2011-01-06||2012-12-21|2009-07-27|2009-07-28|Estimate|2012-12-21|2013-01-31|Estimate||||2012-12-21|2013-01-31|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Treatment of Androgenic Alopecia in Males|A Randomized, Double-Blind, Control Device Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 9 & 12 Beam Models: For the Treatment of Androgenetic Alopecia in Males|Completed||N/A|79|Actual|Lexington International, LLC||3|||f||||t||||||||||2018-06-01 00:44:57.876178|2018-06-01 00:44:57.876178
NCT00947206|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2014-05-06|2009-07-27|2009-07-28|Estimate|||||||2014-05-06|2014-05-08|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans|Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans|Completed||N/A|909|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:44:58.17023|2018-06-01 00:44:58.17023
NCT00947193|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2011-10-31|2009-07-24|2009-07-27|Estimate|||||||2011-10-31|2011-11-01|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Study of Ataluren (PTC124®) in Hemophilia A and B|A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B|Suspended||Phase 2|24|Anticipated|PTC Therapeutics|||||f||||f||||||||||2018-06-01 00:44:58.251263|2018-06-01 00:44:58.251263
NCT00947180|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-10-16|2009-07-24|2009-07-27|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2000||2000-10-31|March 2010|2010-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Gastrointestinal Biopsychosocial Research Center|Randomized Controlled Trial Comparing Biofeedback, Electrogalvanic Stimulation, and Massage for the Treatment of Chronic Proctalgia|Completed||N/A|157|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||f|f|f||||||||2018-06-01 00:44:58.335132|2018-06-01 00:44:58.335132
NCT00947167|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2017-01-12||2017-01-12|2009-07-24|2009-07-27|Estimate|2017-01-12|2017-03-03|Actual||||2017-01-12|2017-03-03|Actual|March 2009||2009-03-31|January 2017|2017-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors|A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors|Terminated||Phase 2|4|Actual|Stanford University|Early termination due to toxicity, thus small number of patients analyzed and limited statistical power.|1||Extreme toxicity of Pertuzumab and Erlotinib combination|f||||t||||||||||2018-06-01 00:44:58.41788|2018-06-01 00:44:58.41788
NCT00947154|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2015-04-19||2015-05-31|2009-07-24|2009-07-27|Estimate|2015-05-31|2015-06-16|Estimate||||2015-05-31|2015-06-16|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Trial of Aripiprazole in Trichotillomania|Open Label Trial of Aripiprazole in Trichotillomania.|Completed||N/A|12|Actual|Stanford University||1|||f||||f||||||||||2018-06-01 00:44:58.577061|2018-06-01 00:44:58.577061
NCT00947141|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2017-10-25|2009-07-24|2009-07-27|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2003||2003-02-28|October 2017|2017-10-31|February 2013|Actual|2013-02-28|December 2011|Actual|2011-12-31||Interventional|||Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)|Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring|Completed||Phase 4|165|Actual|University College, London||2|||f||||f||||||||||2018-06-01 00:44:58.738361|2018-06-01 00:44:58.738361
NCT00947128|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2004||2004-09-30|July 2009|2009-07-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|26|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:44:58.807713|2018-06-01 00:44:58.807713
NCT00947115|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2011-02-10||2017-01-09|2009-07-23|2009-07-27|Estimate|2011-03-31|2011-05-02|Estimate||||2017-01-09|2017-02-23|Actual|September 2009||2009-09-30|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Some subjects who came for the Year 5 timepoint did not return for the Year 6, 7, 8 or 9 timepoints, hence the numbers of subjects starting each year (based on the actual rate of return for visits) do not correspond to the ones of the previous years.|Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects|Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects|Completed||Phase 4|525|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:44:58.918173|2018-06-01 00:44:58.918173
NCT00947102|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2010-01-12|2009-07-24|2009-07-27|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2009||2009-02-28|July 2009|2009-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|GEMSTHER||Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer|Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma|Unknown status|Recruiting||||Blood Transfusion Centre of Slovenia|||1||f||||f||||||||||2018-06-01 00:44:59.898685|2018-06-01 00:44:59.898685
NCT00947089|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|December 2003||2003-12-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ORC||"Role of Oxidized Regenerated Cellulose (ORC) Applied to Dirty Surgical Wounds"|The Role of Oxidized Regenerated Cellulose in Preventing Infections at the Surgical Site: Prospective, Randomized Study in 98 Patients Affected by a Dirty Wound|Completed||Phase 4|98|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 00:44:59.963398|2018-06-01 00:44:59.963398
NCT00947076|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2001||2001-02-28|July 2009|2009-07-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg|A Comparative Bioavailability Study of Fluoxetine Hydrochloride Capsules, 40 mg|Completed||Phase 1|30|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:00.033408|2018-06-01 00:45:00.033408
NCT00947063|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2004||2004-07-31|July 2009|2009-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||To Demonstrate the Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Promethazine HCl 50 mg Tablets Under Fasting Conditions|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:00.091525|2018-06-01 00:45:00.091525
NCT00947050|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2010-10-25|2009-07-24|2009-07-27|Estimate|||||||2010-10-25|2010-10-26|Estimate|April 2005||2005-04-30|October 2010|2010-10-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Prompt Human Coronary Collateral Vasomotor Function Induced by Dynamic Physical Exercise|Prompt Human Coronary Collateral Vasomotor Function Induced by Dynamic Physical Exercise|Completed||N/A|30|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 00:45:00.157496|2018-06-01 00:45:00.157496
NCT00947037|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2015-11-23|2009-07-24|2009-07-27|Estimate|||||||2015-11-23|2015-11-24|Estimate|August 2012||2012-08-31|September 2012|2012-09-30||||August 2012|Actual|2012-08-31||Interventional|||Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study|An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects|Withdrawn||Phase 2|0|Actual|Intec Pharma Ltd.||1||The sponsor decided to postpone the performance of this study to after phase 3|f||||t||||||||||2018-06-01 00:45:00.295689|2018-06-01 00:45:00.295689
NCT00947024|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|November 1993||1993-11-30|July 2009|2009-07-31|November 1993|Actual|1993-11-30|November 1993|Actual|1993-11-30||Interventional|||To Demonstrate the Effect of Food on the Bioavailability of Glipizide|The Effect of Food on the Bioavailability of Glipizide|Completed||Phase 1|18|Actual|Sandoz||3|||f||||||||||||||2018-06-01 00:45:00.36732|2018-06-01 00:45:00.36732
NCT00947011|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2017-05-01||2017-06-29|2009-07-24|2009-07-27|Estimate|2017-06-29|2017-07-12|Actual||||2017-06-29|2017-07-12|Actual|March 2009|Actual|2009-03-31|June 2017|2017-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Although 12 participants were enrolled in this study, their assignment to a specific Arm/Group is unknown, as the PI has left the institution and no further data (if any) is available.|Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)|The Effect of Dipeptidyl Peptidase-4 Inhibition on GLP-1 Induced Insulin Secretion and Glucose Turnover During Mild Stable Hyperglycemia in Young and Old Normal Volunteers|Terminated||Phase 2|12|Actual|Johns Hopkins University||2||PI left JHU|f||||f||||||||||2018-06-01 00:45:00.43655|2018-06-01 00:45:00.43655
NCT00946998|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2018-01-12||2018-02-09|2009-07-23|2009-07-27|Estimate|2018-01-12|2018-01-30|Actual||||2018-02-09|2018-03-09|Actual|February 8, 2010|Actual|2010-02-08|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 23, 2016|Actual|2016-11-23||Interventional|CAST||Chronic Kidney Disease Antidepressant Sertraline Trial|Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease|Completed||Phase 3|201|Actual|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-06-01 00:45:00.744014|2018-06-01 00:45:00.744014
NCT00946985|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2011-03-08||2012-09-03|2009-07-24|2009-07-27|Estimate|2012-06-12|2012-07-16|Estimate||||2012-09-03|2012-09-10|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years|A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate With Oral Risperidone in Adults With Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse|Terminated||Phase 4|163|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|No efficacy analysis was performed due to early termination of the study (only 2 patients were randomized at the time of study termination).|2||The recruitment rate for the study was inadequate to achieve its enrollment goals.|f||||t||||||||||2018-06-01 00:45:02.1052|2018-06-01 00:45:02.1052
NCT00946972|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2010-03-04|2009-07-23|2009-07-27|Estimate|||||||2010-03-04|2010-03-05|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|November 2009|Actual|2009-11-30|||||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus|Multiple Dose Study in T2DM|Terminated||Phase 1|33|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"No safety signals were noted. The study completed the main phase, additional potential study~   cohorts not required."|f||||f||||||||||2018-06-01 00:45:02.958371|2018-06-01 00:45:02.958371
NCT00946959|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2016-11-08|2009-07-24|2009-07-27|Estimate|||||||2016-11-08|2016-11-09|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|COGCAR||Characterization of Factors Influencing the Cognitive Decline in Patients With Coronary Artery Disease|Characterization of Factors Influencing the Occurrence of Cognitive Decline in Patients With Coronary Artery Disease and Undergoing Cardiac Surgery and Coronary Angioplasty|Completed||N/A|155|Actual|University Hospital, Lille||2|||f||||f||||||||No||2018-06-01 00:45:03.151427|2018-06-01 00:45:03.151427
NCT00946946|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2012-06-25|2009-07-24|2009-07-27|Estimate|||||||2012-06-25|2012-06-26|Estimate|February 2002||2002-02-28|June 2012|2012-06-30|July 2009|Actual|2009-07-31|May 2007|Actual|2007-05-31||Interventional|||Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine|Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study on the Efficacy and Safety of Azathioprine Versus Mesalazine for Prevention of Clinical Relapses in Crohn's Disease Patients With Postoperative Moderate or Severe Endoscopic Recurrence|Completed||Phase 3|78|Actual|Dr. Falk Pharma GmbH||2|||f||||f||||||||||2018-06-01 00:45:03.325976|2018-06-01 00:45:03.325976
NCT00946933|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-12-14|2009-07-24|2009-07-27|Estimate|||||||2012-12-14|2012-12-17|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Chronic Acid-Base Changes on Ventilatory and Perceptual Responses|Effects of Chronic Acid-Base Changes on the Ventilatory and Perceptual Response to Hypercapnia, Hypoxia and Exercise in Healthy Older Adults|Completed||N/A|20|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 00:45:03.566635|2018-06-01 00:45:03.566635
NCT00946920|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|2014-02-14|2012-03-09|2014-05-02|2009-07-24|2009-07-27|Estimate|2014-05-02|2014-06-02|Estimate|2012-03-09|2012-03-14|Estimate|2014-05-02|2014-06-02|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||FAS|A Trial of Degarelix in Patients With Prostate Cancer|An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen With Goserelin Acetate in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy|Completed||Phase 3|859|Actual|Ferring Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:45:03.709442|2018-06-01 00:45:03.709442
NCT00946218|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-10-03|2009-07-23|2009-07-24|Estimate|||||||2011-10-03|2011-10-05|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Diagnosis and Characterization of Dengue Fever in Children|Diagnosis and Characterization of Dengue Fever in Children|Completed|||258|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||||||2018-06-01 00:45:30.492484|2018-06-01 00:45:30.492484
NCT00946907|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2011-12-20|2009-07-24|2009-07-27|Estimate|||||||2011-12-20|2011-12-21|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|pericardite||Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin|Benign Acute Pericarditis: Brief Versus Longer Treatment. Randomized, Multicentric, Double Blind, Non Inferiority Trial|Terminated||Phase 4|34|Actual|University Hospital, Brest||2||"This study was suspended by principal investigator's decision. All the sites were not opened,~   and the recruitment was so slow."|f||||t||||||||||2018-06-01 00:45:07.165267|2018-06-01 00:45:07.165267
NCT00946894|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|January 2000||2000-01-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2003|Actual|2003-12-31||Interventional|||Outcomes of Different Thyroid Resections for Multinodular Non-toxic Goiter|Five-year Follow up of a Randomized Clinical Trial of Total Thyroidectomy Versus Dunhill Operation Versus Bilateral Subtotal Thyroidectomy for Multinodular Non-toxic Goiter.|Completed||N/A|600|Actual|Jagiellonian University||3|||f||||t||||||||||2018-06-01 00:45:07.56312|2018-06-01 00:45:07.56312
NCT00946881|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2016-04-20||2017-10-02|2009-07-24|2009-07-27|Estimate|2017-10-02|2017-11-06|Actual||||2017-10-02|2017-11-06|Actual|July 2009||2009-07-31|October 2017|2017-10-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional||All 30 patients were males suffering from low risk prostate cancer.|Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer|A Prospective, Multicenter Phase I/II Safety and Tolerability Study of Unilateral Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer|Completed||Phase 1/Phase 2|30|Actual|Steba Biotech S.A.||1|||f||||t||||||||Undecided|The data are available in case report form for each patient|2018-06-01 00:45:08.098279|2018-06-01 00:45:08.098279
NCT00946868|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-23|2009-07-23|2009-07-27|Estimate|||||||2009-07-23|2009-07-27|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication|Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication|Completed|||170|Actual|University of Sao Paulo|||1||f||||f||||||||||2018-06-01 00:45:09.905898|2018-06-01 00:45:09.905898
NCT00946855|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Observational|SOCCERLAB||Effect of Elite Soccer Training on Routine Laboratory Parameters|Laboratory Values in Elite Soccer Players|Completed|||467|Actual|Saarland University|||1||f||||f||||||Samples Without DNA|"~     iced serum samples~   "|||2018-06-01 00:45:10.383923|2018-06-01 00:45:10.383923
NCT00946842|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2013-03-18|2009-07-23|2009-07-27|Estimate|||||||2013-03-18|2013-03-19|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants|A Phase I, Two-Panel, Open-Label, Randomized, 3-way Crossover Trial in Healthy Subjects to Determine the Relative Oral Bioavailability of TMC207 After Single Dose Administration of TMC207 100 mg as the Phase II Clinical Trial Tablet Formulation and as a Newly Developed Tablet Formulation, Under Fed and Fasted Conditions|Completed||Phase 1|28|Actual|Tibotec BVBA||12|||f||||f||||||||||2018-06-01 00:45:10.99909|2018-06-01 00:45:10.99909
NCT00946829|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|January 2003||2003-01-31|July 2009|2009-07-31||||May 2007|Actual|2007-05-31||Observational|||Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise|Study of Hypertensive Population Under Treatment With Micardis in Real Clinical Conditions With the Goal to Control the Early Morning BP Rise|Completed|||18299|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 00:45:12.498495|2018-06-01 00:45:12.498495
NCT00946816|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-11-13|2009-07-21|2009-07-27|Estimate|||||||2012-11-13|2012-11-14|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Effects of Dietary Intervention on Gastrointestinal Function in Patients With Anorexia Nervosa and Obesity|The Effects of Dietary Intervention on Gastrointestinal Motility, Hormonal Feedback, Visceral Sensation and Satiety in Patients With Anorexia Nervosa and Obesity|Completed||N/A|60|Actual|University of Zurich||3|||f||||||||||||||2018-06-01 00:45:13.288192|2018-06-01 00:45:13.288192
NCT00946803|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2014-04-29|2009-07-24|2009-07-27|Estimate|||||||2014-04-29|2014-04-30|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Patient-Controlled Cognitive-Behavioral Intervention for Cancer Symptoms|A Patient-Controlled Cognitive-Behavioral Intervention for Cancer Symptoms|Completed||N/A|86|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:45:13.806865|2018-06-01 00:45:13.806865
NCT00946790|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|July 1993||1993-07-31|July 2009|2009-07-31|December 1993|Actual|1993-12-31|December 1993|Actual|1993-12-31||Interventional|||To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets|Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets|Completed||Phase 1|72|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:14.594311|2018-06-01 00:45:14.594311
NCT00946777|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2016-11-17|2009-07-24|2009-07-27|Estimate|||||||2016-11-17|2016-11-18|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days|Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 Days|Completed||N/A|19|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:45:15.122895|2018-06-01 00:45:15.122895
NCT00946764|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2005||2005-07-31|July 2009|2009-07-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||To Demonstrate the Relative Bioavailability of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and Tyco Healthcare (Tofranil) 50 mg Imipramine Hydrochloride Tablets In Healthy Adults Volunteers Under Fasting Conditions|Completed||Phase 1|48|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:15.707375|2018-06-01 00:45:15.707375
NCT00946751|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2004||2004-03-31|July 2009|2009-07-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions|Completed||Phase 1|20|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:16.851115|2018-06-01 00:45:16.851115
NCT00946738|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|October 2004||2004-10-31|July 2009|2009-07-31||||March 2008|Actual|2008-03-31||Interventional|||The Effect of Physical Therapy on Raynaud`s Phenomenon Secondary to Systemic Sclerosis|A Prospective Randomized Controlled Study Analyzing the Effect of Biofeedback and Deep Oscillation on Raynaud´s Phenomenon Secondary to Systemic Sclerosis|Completed||N/A|28||Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 00:45:18.095115|2018-06-01 00:45:18.095115
NCT00946725|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|November 2000||2000-11-30|July 2009|2009-07-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg|A Comparative Bioavailability Study of Atenolol Tablets, 100 mg|Completed||Phase 1|28|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:18.443957|2018-06-01 00:45:18.443957
NCT00946712|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-10-03|2009-07-24|2009-07-27|Estimate|||||||2017-10-03|2017-10-05|Actual|July 2009||2009-07-31|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer|A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|1546|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 00:45:18.859279|2018-06-01 00:45:18.859279
NCT00946699|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2014-11-11|2009-07-24|2009-07-27|Estimate|||||||2014-11-11|2014-11-13|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of the Safety and Tolerability of MEDI-551 in Scleroderma|A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma|Completed||Phase 1|50|Actual|MedImmune LLC||6|||f||||t||||||||||2018-06-01 00:45:20.969456|2018-06-01 00:45:20.969456
NCT00946686|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2002||2002-09-30|July 2009|2009-07-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions|A Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions|Completed||Phase 1|52|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:22.060263|2018-06-01 00:45:22.060263
NCT00946673|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2017-10-04|2009-07-24|2009-07-27|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2009||2009-06-30|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|||Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer|A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer|Completed||Phase 1|17|Actual|Stanford University||1|||f||||||||||||||2018-06-01 00:45:22.13272|2018-06-01 00:45:22.13272
NCT00946660|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2012-06-01|2009-07-24|2009-07-27|Estimate|||||||2012-06-01|2012-06-05|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|CTA||Non-Treatment Study of Factors Affecting Cocaine Drug Choice|Human Laboratory Model of Cocaine Treatment: Behavioral Economic Analysis: Study 1|Completed|||16|Anticipated|Wayne State University|||||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 00:45:22.344217|2018-06-01 00:45:22.344217
NCT00946647|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2017-12-15|2009-07-24|2009-07-27|Estimate|||||||2017-12-15|2017-12-19|Actual|December 2, 2009|Actual|2009-12-02|December 2017|2017-12-31|December 17, 2018|Anticipated|2018-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|||A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).|A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).|Active, not recruiting||Phase 1|112|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:45:22.441152|2018-06-01 00:45:22.441152
NCT00946634|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2011-10-02|2009-07-24|2009-07-27|Estimate|||||||2011-10-02|2011-10-04|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2009|Actual|2009-03-31||Interventional|||Ozone Therapy in Endodontic Practice, in Vivo Study|Phase 4 - Ozone Therapy in Endodontic Practice, in Vivo Study|Completed||Phase 2|60|Anticipated|University of Sao Paulo||3|||f||||t||||||||||2018-06-01 00:45:22.734756|2018-06-01 00:45:22.734756
NCT00946621|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2004||2004-10-31|July 2009|2009-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions|A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions|Completed||Phase 1|48|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:22.92676|2018-06-01 00:45:22.92676
NCT00946608|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2005||2005-06-30|July 2009|2009-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets|Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Sandoz Inc. and Schering (Claritin) 10 mg Loratadine Tablets In Healthy Adult Male Volunteers Under Fed and Fasting Conditions|Completed||Phase 1|30|Actual|Sandoz||3|||f||||||||||||||2018-06-01 00:45:23.000353|2018-06-01 00:45:23.000353
NCT00946595|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2014-06-23|2009-07-24|2009-07-27|Estimate|||||||2014-06-23|2014-06-24|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|ANRS 140 DREAM||Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients|A Study Comparing Efficacy and Tolerance of Two Maintenance Strategies : a Monotherapy With Lopinavir/Ritonavir or a Single-tablet Triple Therapy by Efavirenz/Emtricitabin/Tenofovir in HIV-1 Infected Patients With HIV RNA Below 50 cp/mL|Completed||Phase 2/Phase 3|420|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 00:45:23.276389|2018-06-01 00:45:23.276389
NCT00946582|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||The Therapeutic Effects of Barkley's Parenting Management Program for Taiwanese School-Aged Children With Attention Deficit/Hyperactivity Disorder (ADHD)|The Therapeutic Effects of Barkley's Parenting Management Program for Taiwanese School-aged Children With Attention Deficit/Hyperactivity Disorder|Unknown status|Recruiting|Phase 1|30|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 00:45:23.660221|2018-06-01 00:45:23.660221
NCT00946569|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23||2011-09-27|2014-03-31|2009-07-23|2009-07-27|Estimate||||2011-09-27|2011-10-05|Estimate|2014-03-31|2014-04-29|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Exploratory Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults With Persistent Asthma|Completed||Phase 2|116|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||t||||||||||2018-06-01 00:45:23.948039|2018-06-01 00:45:23.948039
NCT00946556|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-03-21|2009-07-24|2009-07-27|Estimate|||||||2012-03-21|2012-03-22|Estimate|April 2010||2010-04-30|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix|Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix.|Completed||N/A|30|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 00:45:24.405576|2018-06-01 00:45:24.405576
NCT00946543|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2013-08-23|2009-07-24|2009-07-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2000||2000-03-31|July 2009|2009-07-31||||March 2010|Anticipated|2010-03-31||Interventional|||Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer|A Phase I Dose Escalation Study of the Use of Intensity Modulated Radiotherapy (IMRT) to Treat Prostate and Pelvic Nodes in Patients With Prostate Cancer - Pelvic IMRT for Prostate Cancer|Unknown status|Recruiting|Phase 1|198|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:45:24.474066|2018-06-01 00:45:24.474066
NCT00946530|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2013-12-05||2017-02-09|2009-07-24|2009-07-27|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|September 2004||2004-09-30|December 2016|2016-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Memory impaired older adults and their caregivers|Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease|Light Treatment for Sleep/Wake Disturbances in Alzheimer's Disease|Completed||N/A|118|Actual|Stanford University||2|||f||||f||||||||No|This was not required at the time.|2018-06-01 00:45:24.554897|2018-06-01 00:45:24.554897
NCT00946517|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2015-05-14|2009-07-24|2009-07-27|Estimate|||||||2015-05-14|2015-05-15|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Impaired Family Dynamics Leads to Non Compliance in Type I Diabetes|Impaired Family Dynamics Leads to Non Compliance in Type I Diabetes|Terminated|||20|Actual|Nationwide Children's Hospital|||2|PI left the institution|f||||f||||||||||2018-06-01 00:45:25.264836|2018-06-01 00:45:25.264836
NCT00946504|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|October 1992||1992-10-31|July 2009|2009-07-31|October 1992|Actual|1992-10-31|October 1992|Actual|1992-10-31||Interventional|||To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets|A Two-Way Crossover Bioequivalence Study Comparing Single 10 mg Doses of Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets|Completed||Phase 1|28|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:25.351003|2018-06-01 00:45:25.351003
NCT00946491|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|April 1987||1987-04-30|July 2009|2009-07-31|May 1987|Actual|1987-05-31|May 1987|Actual|1987-05-31||Interventional|||To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers|An Open-Label, Single-Dose, Crossover Study to Determine the Bioequivalency of Generic Haloperidol Tablets vs. Haldol in Normal Volunteers.|Completed||Phase 1|30|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:26.449422|2018-06-01 00:45:26.449422
NCT00946478|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2013-12-10||2014-01-27|2009-07-24|2009-07-27|Estimate|2014-01-27|2014-03-10|Estimate||||2014-01-27|2014-03-10|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema|A Three-week, Double-blind, Randomized Study to Evaluate the Effect of Pimecrolimus Cream 1% on Cathelicidin Expression in the Skin of Subjects With Atopic Dermatitis|Completed||N/A|40|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 00:45:26.518165|2018-06-01 00:45:26.518165
NCT00946465|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2004||2004-10-31|July 2009|2009-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions|A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions|Completed||Phase 1|48|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:26.800724|2018-06-01 00:45:26.800724
NCT00946452|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2010-03-17|2009-07-24|2009-07-27|Estimate|||||||2010-03-17|2010-03-18|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Symbicort SMART Satisfaction From Patient Perspective 2009|Symbicort SMART Satisfaction From Patient Perspective 2009|Completed|||205|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:45:26.866473|2018-06-01 00:45:26.866473
NCT00946439|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|September 2004||2004-09-30|July 2009|2009-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|WART||Wheel Assisted Running Training (WART) in Children With Cerebral Palsy|Wheel Assisted Running Training in Children With Cerebral Palsy: A Controlled Clinical Trial|Completed||N/A|30|Actual|Israel Sport Center for the Disabled|||||f||||t||||||||||2018-06-01 00:45:26.921964|2018-06-01 00:45:26.921964
NCT00946426|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2015-05-14|2009-07-24|2009-07-27|Estimate|||||||2015-05-14|2015-05-15|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Insulin Resistance in Type I Diabetes in Pediatric Care|Insulin Resistance in Type I Diabetes in Pediatric Care|Withdrawn|||0|Actual|Nationwide Children's Hospital|||1|PI left institution|f||||f||||||||||2018-06-01 00:45:26.986332|2018-06-01 00:45:26.986332
NCT00946413|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Application and Evaluation of Group Cognitive Intervention for Depressed Adolescents|Application and Evaluation of Group Cognitive Intervention for Depressed Adolescents|Completed||Early Phase 1|31|Actual|Taipei Medical University Hospital||2|||f||||f||||||||||2018-06-01 00:45:27.072112|2018-06-01 00:45:27.072112
NCT00946400|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|August 2009||2009-08-31|July 2009|2009-07-31||||||||Observational|||Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)|Prospectively Validating the 4Ts and Chong Score for Heparin Induced Thrombocytopenia|Unknown status|Not yet recruiting||500|Anticipated|Washington Hospital Center|||1||f||||f||||||Samples Without DNA|"~     Serum will be collected to perform a serotonin release assay as confirmatory testing for the~     presence of HIT.~   "|||2018-06-01 00:45:28.005551|2018-06-01 00:45:28.005551
NCT00946387|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2017-03-27|2009-07-24|2009-07-27|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2004||2004-09-30|July 2009|2009-07-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions|Completed||Phase 1|26|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:45:28.122995|2018-06-01 00:45:28.122995
NCT00946374|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2009-07-24|2009-07-24|2009-07-27|Estimate|||||||2009-07-24|2009-07-27|Estimate|July 2004||2004-07-31|July 2009|2009-07-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|HD-MCL2003||Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma|A Prospective Phase II Trial on R-CHOP Followed by High-dose BEAM and Autologous SCT and HLA-identical Allogenic SCT After Dose-reduced Conditioning in Patients Age < 55 Years With Primary Mantle-Cell-Lymphoma|Unknown status|Recruiting|Phase 2|20|Anticipated|Heidelberg University|||||f||||t||||||||||2018-06-01 00:45:28.214447|2018-06-01 00:45:28.214447
NCT00946361|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2015-05-14|2009-07-24|2009-07-27|Estimate|||||||2015-05-14|2015-05-15|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Impaired Insulin-like Growth Factor-1 (IGF-1) Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease|Impaired IGF-1 Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease|Terminated|||1|Actual|Nationwide Children's Hospital|||1|PI left institution|f||||f||||||||||2018-06-01 00:45:28.39133|2018-06-01 00:45:28.39133
NCT00946348|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|2014-04-09||2018-03-12|2009-07-24|2009-07-27|Estimate|2014-09-26|2014-09-29|Estimate||||2018-03-12|2018-03-14|Actual|December 2009||2009-12-31|March 2018|2018-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||52 subjects consented; 15 were in a pilot study to determine the dose of dronabinol and strength of the marijuana cigarette and 14 were health controls (who received no drug)for comparison. The remaining 23 subjects consented to the Main Study and 12 were met eligibility criteria and were randomized to receive dronabinol or a marijuana cigarette.|Cannabis and Schizophrenia: Self-Medication and Agonist Treatment|Cannabis and Schizophrenia: Self-Medication and Agonist Treatment|Completed||Phase 1|12|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 00:45:28.478378|2018-06-01 00:45:28.478378
NCT00946335|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-24|||2014-07-07|2009-07-24|2009-07-27|Estimate|||||||2014-07-07|2014-07-09|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|October 2011|Actual|2011-10-31||Interventional|||ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors|A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors|Completed||Phase 1|31|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:45:28.728749|2018-06-01 00:45:28.728749
NCT00946322|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2015-12-08||2016-01-12|2009-07-24|2009-07-27|Estimate|2015-12-08|2016-01-13|Estimate||||2016-01-12|2016-02-08|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|CTAP||Couple-Based Treatment for Alcohol Use Disorders and Post-Traumatic Stress Disorder|Couple-Based Treatment for Alcohol Use Disorders and PTSD|Completed||Phase 1|13|Actual|VA Office of Research and Development|Study was an initial open-trial pilot study. A causal relationship cannot be determined between study interventions and outcomes due to lack of a comparison condition.|1|||f||||f||||||||||2018-06-01 00:45:28.928924|2018-06-01 00:45:28.928924
NCT00946309|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2015-08-20||2016-09-24|2009-07-24|2009-07-27|Estimate|2016-09-24|2016-11-15|Estimate||||2016-09-24|2016-11-15|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|PHASE|One participant enrolled to the placebo arm was determined to be ineligible, and was withdrawn from the study Two additional participants enrolled to the placebo arm became ineligible after enrollment, and were withdrawn from the study|Effects of Sulforaphane on Normal Prostate Tissue|In Vivo Effects of Sulforaphane Supplementation on Normal Human Prostate|Completed||Phase 1/Phase 2|45|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 00:45:29.282593|2018-06-01 00:45:29.282593
NCT00946296|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2015-10-09||2015-11-10|2009-07-23|2009-07-24|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|April 2005||2005-04-30|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease|Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease|Completed||Phase 4|36|Actual|University of Massachusetts, Worcester|Difficulty in enrolling subjects related to national shortages of potassium iodine which limited drug availability and contributed to delayed accrual as did decreased eligible patients and waning interest over time.|2|||f||||f||||||||||2018-06-01 00:45:29.767534|2018-06-01 00:45:29.767534
NCT00946283|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2017-02-02|2009-07-23|2009-07-24|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2010||2010-03-31|February 2017|2017-02-28|October 14, 2015|Actual|2015-10-14|May 2013|Actual|2013-05-31||Interventional|||Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome|Probiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)|Terminated||N/A|30|Actual|Rutgers, The State University of New Jersey||1||slow accrual|f||||t||||||||||2018-06-01 00:45:29.952717|2018-06-01 00:45:29.952717
NCT00946270|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2018-01-08|2009-07-23|2009-07-24|Estimate|||||||2018-01-08|2018-01-10|Actual|July 2009|Actual|2009-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pomalidomide for Myelofibrosis Patients|A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF)|Active, not recruiting||Phase 2|70|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:45:30.039337|2018-06-01 00:45:30.039337
NCT00946257|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2017-05-31|2009-07-23|2009-07-24|Estimate|||||||2017-05-31|2017-06-01|Actual|July 8, 2009|Actual|2009-07-08|May 2017|2017-05-31|June 25, 2013|Actual|2013-06-25|August 1, 2011|Actual|2011-08-01||Interventional|RAO112438||Subcutaneous Administration of Otelixizumab to T1DM Patients|A Randomised, Single-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Ascending Administration of Otelixizumab in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|33|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:45:30.120991|2018-06-01 00:45:30.120991
NCT00946244|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-02-21|2009-07-23|2009-07-24|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2009||2009-08-31|November 2009|2009-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||A Longitudinal Study of Effectiveness of Early Intervention for Preterm Infants|A Longitudinal Study of Effectiveness of Early Intervention for Preterm Infants|Completed|||183|Actual|National Taiwan University Hospital|||4||f||||t||||||||||2018-06-01 00:45:30.236618|2018-06-01 00:45:30.236618
NCT00946231|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-08-30|2009-07-23|2009-07-24|Estimate|||||||2012-08-30|2012-08-31|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Observational|HABIT||Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home|HF Assessment With BNP In The Home|Completed|||187|Actual|Biosite|||1||f||||f||||||Samples Without DNA|"~     Plasma and Urine~   "|||2018-06-01 00:45:30.39069|2018-06-01 00:45:30.39069
NCT00946205|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2015-07-08|2009-07-23|2009-07-24|Estimate|||||||2015-07-08|2015-07-09|Estimate|September 2006||2006-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Laparoscopic Rectopexy for Rectal Prolapse|Laparoscopic Posterior Rectopexy Without Mesh vs. Laparoscopic Anterior Mesh Rectopexy for Rectal Prolapse - a Prospective, Double-blind, Randomised Study|Completed||N/A|75|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-06-01 00:45:30.563132|2018-06-01 00:45:30.563132
NCT00946192|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-03-01|2009-07-23|2009-07-24|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2009|Actual|2009-05-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes|Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes|Recruiting||Phase 3|230|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 00:45:30.658774|2018-06-01 00:45:30.658774
NCT00946179|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-01-16|2009-07-23|2009-07-24|Estimate|||||||2014-01-16|2014-01-17|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intramuscular Route)|Completed||Phase 2|130|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:45:30.809024|2018-06-01 00:45:30.809024
NCT00946166|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2015-04-20|2009-07-23|2009-07-24|Estimate|||||||2015-04-20|2015-04-22|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Impact of Statins on Cytokine Expression in Pneumonia|Impact of Statins on Cytokine Expression in Pneumonia|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center at San Antonio||2||Investigator left institution.|f||||f||||||||||2018-06-01 00:45:30.891656|2018-06-01 00:45:30.891656
NCT00946153|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2018-03-13|2009-07-23|2009-07-24|Estimate|||||||2018-03-13|2018-03-15|Actual|July 31, 2009|Actual|2009-07-31|March 2018|2018-03-31|August 13, 2015|Actual|2015-08-13|June 15, 2014|Actual|2014-06-15||Interventional|||Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)|Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 1/Phase 2|66|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 00:45:30.973835|2018-06-01 00:45:30.973835
NCT00946140|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2013-10-23|2009-07-23|2009-07-24|Estimate|||||||2013-10-23|2013-10-24|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study|Motion Correction in Dynamic Contrast Enhanced MRI in Ovarian Cancer: A Pilot Study|Completed|||2|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 00:45:31.055849|2018-06-01 00:45:31.055849
NCT00946127|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-10-01|2009-07-23|2009-07-24|Estimate|||||||2012-10-01|2012-10-03|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||ETV Versus Shunt Surgery in Normal Pressure Hydrocephalus|Endoscopic Third Ventriculostomy (ETV) Versus Ventriculoperitoneal Shunting (VPS) for the Surgical Management of Normal Pressure Hydrocephalus|Terminated|||13|Actual|Johns Hopkins University|||2|Unable to recruit patients and lack of efficacy in ETV arm|f||||f||||||||||2018-06-01 00:45:31.125956|2018-06-01 00:45:31.125956
NCT00946114|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2010-03-29||2013-02-12|2009-07-23|2009-07-24|Estimate|2010-03-29|2010-04-16|Estimate||||2013-02-12|2013-02-15|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks|A Local, Multi-Centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For One Hundred Twelve Weeks / Prior To Reimbursement And Availability For Patients In Poland.|Completed|||32|Actual|Pfizer|||||f||||f||||||||||2018-06-01 00:45:31.216419|2018-06-01 00:45:31.216419
NCT00946101|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2010-06-09||2011-07-15|2009-07-23|2009-07-24|Estimate|2011-07-15|2011-08-11|Estimate||||2011-07-15|2011-08-11|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|MI-CP217||A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of MEDI3414 in Children|Completed||Phase 4|326|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 00:45:31.600944|2018-06-01 00:45:31.600944
NCT00946088|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2016-10-24||2017-02-07|2009-07-23|2009-07-24|Estimate|2016-12-15|2017-02-08|Estimate||||2017-02-07|2017-03-16|Actual|October 2009||2009-10-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|February 2013|Actual|2013-02-28||Interventional|||Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial|Progesterone for Maintenance Tocolysis: A Randomized Placebo Controlled Trial|Terminated||Phase 2/Phase 3|7|Actual|Stanford University|Very limited enrollment, study terminated early.|2||lower than expected enrollment|f||||f||||||||No||2018-06-01 00:45:32.498731|2018-06-01 00:45:32.498731
NCT00946075|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-10-01|2009-07-23|2009-07-24|Estimate|||||||2014-10-01|2014-10-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:45:33.102341|2018-06-01 00:45:33.102341
NCT00946062|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2013-11-14|2009-07-23|2009-07-24|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2007||2007-11-30|November 2013|2013-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Evaluation of a Standardised Orientation and Mobility Training in Older Adults With Low Vision|The Impact of Orientation and Mobility Training on Mobility, Participation and Quality of Life in Older Adults With Visual Impairments: a Randomised Controlled Trial|Completed||N/A|190|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:45:33.144122|2018-06-01 00:45:33.144122
NCT00946049|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|March 2005||2005-03-31|July 2009|2009-07-31|February 2008|Actual|2008-02-29|June 2007|Actual|2007-06-30||Interventional|||Oral Bacteria on Suture Materials - Clinical Comparison of an Antibacterial-coated and a Non-coated Suture Material|Oral Bacteria on Suture Materials - Clinical Comparison of an Antibacterial-coated and a Non-coated Suture Material (VICRYL PLUS® vs. VICRYL®, Ethicon) in Intraoral Dentoalveolar Surgery|Completed||N/A|||University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 00:45:33.231249|2018-06-01 00:45:33.231249
NCT00946036|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate||||July 2009|2009-07-31||||||||Interventional|||Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed Conditions||Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:45:33.297851|2018-06-01 00:45:33.297851
NCT00946023|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2013-09-20|2009-07-22|2009-07-24|Estimate|||||||2013-09-20|2013-09-24|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|August 2015|Anticipated|2015-08-31|July 2013|Actual|2013-07-31||Interventional|||Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab|Nonmyeloablative BMT With Post-transplant Cyclophosphamide, Rituximab and Optimized Donor Selection for B-cell Lymphomas|Terminated||Phase 2|135|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 00:45:33.352635|2018-06-01 00:45:33.352635
NCT00946010|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-01-20|2009-07-23|2009-07-24|Estimate|||||||2011-01-20|2011-01-24|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Observational|||Investigation of Hepatitis B and Hepatitis C in Taiwan|Investigation of Hepatitis B and Hepatitis C in Taiwan|Completed|||6228|Actual|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     10ml blood was sampled and then serum was be retained.~   "|||2018-06-01 00:45:33.457726|2018-06-01 00:45:33.457726
NCT00945997|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|October 2000||2000-10-31|July 2009|2009-07-31|March 2005|Actual|2005-03-31|September 2004|Actual|2004-09-30||Interventional|MIMIS||Misoprostol for Second Trimester Termination of Pregnancy|Mifepristone (RU 486) and Misoprostol for Second Trimester Termination of Pregnancy. A Comparison of Two Different Dose Regimens.|Completed||N/A|176|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-06-01 00:45:33.527827|2018-06-01 00:45:33.527827
NCT00945984|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-25|2009-07-23|2009-07-24|Estimate|||||||2009-07-25|2009-07-28|Estimate|March 2009||2009-03-31|July 2009|2009-07-31||||||||Observational|LESS||Laparoendoscopic Single-site Radical Nephrectomy for Localized Renal Cell Carcinoma|Comparison of Laparoendoscopic Single-site Radical Nephrectomy With Conventional Laparoscopic Radical Nephrectomy for Localized Renal Cell Carcinoma|Unknown status|Active, not recruiting||36|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-06-01 00:45:33.603076|2018-06-01 00:45:33.603076
NCT00945971|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2018-03-21|2009-07-23|2009-07-24|Estimate|||||||2018-03-21|2018-03-23|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Exercise Effects in Children With Attention Deficit Hyperactivity Disorder|Catecholamine and Cognitive Response to Exercise in Children With Attention Deficit Hyperactivity Disorder|Not yet recruiting||N/A|45|Anticipated|Meir Medical Center||1|||f||||f|f|f||||||||2018-06-01 00:45:33.671216|2018-06-01 00:45:33.671216
NCT00945958|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2015-12-28||2016-05-23|2009-07-23|2009-07-24|Estimate|2016-04-01|2016-05-05|Estimate||||2016-05-23|2016-06-24|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||A total of 161 subjects enrolled in the study. Subjects received their first dose of the study drug at Visit 1 (Baseline Visit). A total of 149 subjects completed Study Visit 7 (End-of-Evaluations), which met FDA’s recommendation of providing safety data for at least 100 subjects.|Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|161|Actual|Sun Pharma Advanced Research Company Limited||1|||f||||f||||||||||2018-06-01 00:45:33.755384|2018-06-01 00:45:33.755384
NCT00945945|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2011-02-11||2011-02-11|2009-07-23|2009-07-24|Estimate|2011-02-11|2011-03-08|Estimate||||2011-02-11|2011-03-08|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study of Duloxetine in Patients With Osteoarthritis Knee Pain|A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by Osteoarthritis of the Knee, in a 13-week, Double-blind, Randomized Study|Completed||Phase 3|424|Actual|Eli Lilly and Company|Due to a package labeling error, study drug was incorrectly administered to all patients in both treatment groups. This compromised the integrity of the entire study and rendered planned comparisons between duloxetine and placebo invalid.|2|||f||||f||||||||||2018-06-01 00:45:33.960954|2018-06-01 00:45:33.960954
NCT00945932|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2016-10-11|2009-07-23|2009-07-24|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate Asthmatics|A Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Determine the Efficacy of Repeat Inhaled Doses of GW870086X on FEV1 in Mild to Moderate Asthmatics|Completed||Phase 2|37|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:45:34.496118|2018-06-01 00:45:34.496118
NCT00945919|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|May 2011|Anticipated|2011-05-31|December 2010|Anticipated|2010-12-31||Interventional|||A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone|A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone|Unknown status|Recruiting|N/A|12|Anticipated|Icahn School of Medicine at Mount Sinai|||||f||||f||||||||||2018-06-01 00:45:34.585404|2018-06-01 00:45:34.585404
NCT00945906|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2012-09-12||2012-09-12|2009-07-23|2009-07-24|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency|A Prospective, Multicenter, Open Enrollment Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency|Completed||Phase 3|61|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 00:45:34.658418|2018-06-01 00:45:34.658418
NCT00945893|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2011-06-17||2011-09-06|2009-07-23|2009-07-24|Estimate|2011-08-04|2011-09-05|Estimate||||2011-09-06|2011-09-12|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|MI-CP215||A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of MEDI3414 in Adults|Completed||Phase 4|300|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 00:45:35.036025|2018-06-01 00:45:35.036025
NCT00945880|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2011-02-24|2009-07-23|2009-07-24|Estimate|||||||2011-02-24|2011-02-28|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|CLEAN-1||Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive|A Phase 1b, Open Label Study of the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of 100 mg Clemizole Hydrochloride Administered Orally Twice a Day for 28 Days Immediately Prior to Initiation of Treatment With HCV Standard of Care Therapy in Treatment-Naïve Subjects Chronically Infected With HCV|Completed||Phase 1|12|Anticipated|Eiger BioPharmaceuticals|||||f||||f||||||||||2018-06-01 00:45:35.946433|2018-06-01 00:45:35.946433
NCT00945867|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-04-04|2009-07-23|2009-07-24|Estimate|||||||2011-04-04|2011-04-05|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|August 2010|Anticipated|2010-08-31|March 2010|Anticipated|2010-03-31||Observational|||Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy|The Use of CYP 450 2D6 Genotype as a Predictor of Flecainide Efficacy in the Treatment of Patients With Atrial Fibrillation|Unknown status|Not yet recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 00:45:36.017526|2018-06-01 00:45:36.017526
NCT00945854|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2014-04-17||2014-05-26|2009-07-23|2009-07-24|Estimate|2014-05-26|2014-06-26|Estimate||||2014-05-26|2014-06-26|Estimate|March 2008||2008-03-31|May 2014|2014-05-31|December 2010|Actual|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Wholegrain Cereal Diet and Insulin Sensitivity|Effect of Whole Grain Rich Diet on Insulin Sensitivity in Individuals With Metabolic Syndrome|Completed||N/A|60|Actual|Federico II University||2|||f||||f||||||||||2018-06-01 00:45:36.116127|2018-06-01 00:45:36.116127
NCT00945841|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-04-05|2009-07-23|2009-07-24|Estimate|||||||2017-04-05|2017-04-07|Actual|June 2009||2009-06-30|April 2017|2017-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010 When Administered to Adult and Elderly Subjects|Completed||Phase 3|126|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:45:36.341746|2018-06-01 00:45:36.341746
NCT00945828|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2012-03-06|2009-07-23|2009-07-24|Estimate|||||||2012-03-06|2012-03-08|Estimate|January 2003||2003-01-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors|Assessing Implementation and Effectiveness of Individual Education Plans for Children With Chronic Illness|Completed||N/A|62|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 00:45:36.418751|2018-06-01 00:45:36.418751
NCT00945815|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2013-11-13||2017-10-03|2009-07-23|2009-07-24|Estimate|2013-11-13|2014-01-03|Estimate||||2017-10-03|2017-11-06|Actual|September 2010||2010-09-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|March 2013|Actual|2013-03-31||Interventional||Eligible patients who began protocol therapy were included in this analysis.|S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|S0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination With Cytarabine and Clofarabine for Patients With Relapsed or Refractory Ph- Negative Precursor B-Cell Acute Lymphoblastic Leukemia|Completed||Phase 2|35|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 00:45:36.577074|2018-06-01 00:45:36.577074
NCT00945802|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23||2012-09-05|2015-09-14|2009-07-23|2009-07-24|Estimate||||2012-09-05|2012-09-10|Estimate|2015-09-14|2015-09-30|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||FST-201 In The Treatment of Acute Otitis Externa|A Multi-Center, Randomized, Double-Masked Clinical Study Evaluating the Efficacy Of FST-201 (Dexamethasone 0.1%) Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex (Ciprofloxacin 0.3%, Dexamethasone 0.1%) Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa|Terminated||Phase 3|5|Actual|Shire||2|||f||||||||||||||2018-06-01 00:45:37.064078|2018-06-01 00:45:37.064078
NCT00945789|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-09-24|2009-07-23|2009-07-24|Estimate|||||||2009-09-24|2009-09-28|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)|Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial|Completed||Phase 1/Phase 2|45|Actual|Tanta University||3|||f||||t||||||||||2018-06-01 00:45:37.183304|2018-06-01 00:45:37.183304
NCT00945776|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Weekly Phone Calls Versus Brief Patient Education to Improve Continuous Positive Airway Pressure (CPAP) Compliance|Weekly Phone Calls vs. Brief Patient Education to Improve CPAP Compliance: A Randomized Controlled Trial|Completed||Phase 2|128|Actual|CAMC Health System||3|||f||||f||||||||||2018-06-01 00:45:37.272702|2018-06-01 00:45:37.272702
NCT00945763|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23||2011-06-24|2011-11-28|2009-07-23|2009-07-24|Estimate||||2011-11-28|2011-12-02|Estimate|2011-11-28|2011-12-02|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Adaptive Design, Single-Dose Study of Intravenous N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery|Completed||Phase 2|230|Actual|Alkermes, Inc.||5|||f||||f||||||||||2018-06-01 00:45:37.343124|2018-06-01 00:45:37.343124
NCT00945750|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2015-08-17||2017-01-30|2009-07-22|2009-07-24|Estimate|2015-11-04|2015-12-09|Estimate||||2017-01-30|2017-03-10|Actual|August 2006||2006-08-31|January 2017|2017-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)|A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine 20 mg Film-Coated Tablets (FCT) Compared to Famotidine 20 mg Chewable Tablets (CT) Without Water and Famotidine 20 mg Chewable Tablets (CTw) With Water (Protocol 144)|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:45:37.436028|2018-06-01 00:45:37.436028
NCT00945737|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2012-06-06|2009-07-23|2009-07-24|Estimate|||||||2012-06-06|2012-06-07|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PRV-08009||A Study on the Effects of Soy Protein on Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia|A Randomized, Controlled Parallel Study to Evaluate the Effects of a Non-Commercial Soy Protein Product on Fecal Bile Acids and Blood Lipids in Men and Women With Mild to Moderate Hypercholesterolemia|Completed||N/A|60|Actual|Solae, LLC||2|||f||||f||||||||||2018-06-01 00:45:38.067912|2018-06-01 00:45:38.067912
NCT00945724|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2018-02-27|2009-07-23|2009-07-24|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2009||2009-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2017|Actual|2017-07-31||Interventional|IELSG30||Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis|A Phase II Study of R-CHOP With Intensive CNS Prophylaxis and Scrotal Irradiation in Patients With Primary Testicular Diffuse Large B-cell Lymphoma|Recruiting||Phase 2|35|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||1|||f||||||||||||||2018-06-01 00:45:38.144811|2018-06-01 00:45:38.144811
NCT00945711|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2015-11-30|2009-07-23|2009-07-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Characteristics of Persons With an Eating Disorder and Type 1 Diabetes|Characteristics of Persons With an Eating Disorder and Type 1 Diabetes and Psychological Comparisons to Persons With an Eating Disorder and No Diabetes|Completed|||154|Actual|HealthPartners Institute|||2||f||||f||||||||||2018-06-01 00:45:38.278667|2018-06-01 00:45:38.278667
NCT00945698|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-05-26|2009-07-21|2009-07-24|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Interventional|iLiNS-DOSE||Prevention of Linear Growth Failure in Infants and Young Children With Lipid-based Nutrient Supplements (iLiNS-DOSE)|A Two-centre, Randomised, Single-blind, Parallel Group Controlled Trial, Testing the Growth Promoting Effect of Long-term Complementary Feeding of Infants With Different Doses and Formulations of Lipid-based Nutrient Supplements (LNS)|Completed||Phase 3|1920|Anticipated|University of Tampere||6|||f||||t||||||||||2018-06-01 00:45:38.35474|2018-06-01 00:45:38.35474
NCT00945204|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-08-07|2009-07-23|2009-07-24|Estimate|||||||2012-08-07|2012-08-08|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ICCD||Evaluation of Intermediate Care Clinics for Diabetes|Evaluation of Intermediate Care Clinics for Diabetes|Completed||N/A|1997|Actual|University Hospitals, Leicester||2|||f||||f||||||||||2018-06-01 00:45:43.109583|2018-06-01 00:45:43.109583
NCT00945685|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Evaluation of Safety and Efficacy of Using Imagine™ Computerized Radiofrequency System for Skin Tightening|Evaluation of Safety and Efficacy of Using Imagine™ Computerized Radiofrequency System for Skin Tightening|Completed||N/A|30|Actual|Endymion Medical Ltd||1|||f||||f||||||||||2018-06-01 00:45:38.469725|2018-06-01 00:45:38.469725
NCT00945672|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22||2016-04-08|2016-04-08|2009-07-23|2009-07-24|Estimate||||2016-04-08|2016-05-05|Estimate|2016-04-08|2016-05-05|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease|A Phase 2 Double-Blinded, Randomized, Placebo-Controlled, Multicenter Study Evaluating The Safety, Tolerability And Pharmacokinetics/ Pharmacodynamics Of PF-04360365 In Mild To Moderate Alzheimer's Disease Patients|Completed||Phase 2|36|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 00:45:38.537312|2018-06-01 00:45:38.537312
NCT00945659|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2017-02-08|2009-07-23|2009-07-24|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2009||2009-08-31|February 2017|2017-02-28|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|CGM-Teens||Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control|Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control|Completed||N/A|121|Actual|Nemours Children's Clinic||3|||f||||t||||||||||2018-06-01 00:45:38.618334|2018-06-01 00:45:38.618334
NCT00945646|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23||2012-09-05|2015-09-14|2009-07-23|2009-07-24|Estimate||||2012-09-05|2012-09-10|Estimate|2015-09-14|2015-09-30|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||FST-201 In The Treatment of Acute Fungal Otitis Externa|A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Clinical Study Evaluating the Efficacy Of FST-201 (Dexamethasone 0.1%) Otic Suspension in Subjects With Acute Fungal Otitis Externa|Terminated||Phase 3|6|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:45:38.695583|2018-06-01 00:45:38.695583
NCT00945633|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2018-02-22|2009-07-23|2009-07-24|Estimate|||||||2018-02-22|2018-02-26|Actual|June 2008||2008-06-30|February 2018|2018-02-28|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Observational|InSight||Dietary, Physiological, Genetic, and Behavioral Predictors of Health in a Young, Ethnically-Mixed Population|Dietary, Physiological, Genetic, and Behavioral Predictors of Health in a Young, Ethnically-Mixed Population|Active, not recruiting|||90|Actual|Pennington Biomedical Research Center|||||f||||f||||||Samples With DNA|"~     Archival repository~   "|No||2018-06-01 00:45:38.777769|2018-06-01 00:45:38.777769
NCT00945620|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2015-06-04|2009-07-23|2009-07-24|Estimate|||||||2015-06-04|2015-06-08|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Trans-Abdominis Plane Block Efficacy for Post-Cesarean Section Pain|Trans-Abdominis Plane Block Efficacy for Post-Cesarean Section Pain: A Randomized Double-Blinded Case Control Trial|Withdrawn||N/A|0|Actual|Vanderbilt University||2||PI was unable to locate appropriate population|f||||f||||||||||2018-06-01 00:45:38.847212|2018-06-01 00:45:38.847212
NCT00945607|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-07-21|2009-07-23|2009-07-24|Estimate|||||||2011-07-21|2011-07-25|Estimate|July 2009||2009-07-31|July 2011|2011-07-31||||July 2013|Anticipated|2013-07-31||Interventional|09-IM-01||Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer|Guided Relaxation Training for the Reduction of Self-Reported Stress in Individuals With Newly Diagnosed Breast Cancer|Unknown status|Active, not recruiting|Early Phase 1|40|Anticipated|Trinitas Comprehensive Cancer Center||2|||f||||f||||||||||2018-06-01 00:45:38.930259|2018-06-01 00:45:38.930259
NCT00945594|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2013-10-29|2009-07-23|2009-07-24|Estimate|||||||2013-10-29|2013-10-30|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females|Randomized Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females|Completed||N/A|100|Actual|University of Oklahoma||2|||f||||t||||||||||2018-06-01 00:45:39.005543|2018-06-01 00:45:39.005543
NCT00945581|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2011-03-28|2009-07-23|2009-07-24|Estimate|||||||2011-03-28|2011-03-29|Estimate|November 2009||2009-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery|Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery|Completed||Phase 1/Phase 2|36|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-06-01 00:45:39.083989|2018-06-01 00:45:39.083989
NCT00945568|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|KMS||Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life|Preoperative Oral Supplementation With Carbohydrate and Branched-chain Amino Acid-enriched Nutrient Improves Postoperative Quality of Life in Patients Undergoing a Hepatectomy|Completed||N/A|100|Actual|Kochi University||2|||f||||t||||||||||2018-06-01 00:45:39.154593|2018-06-01 00:45:39.154593
NCT00945555|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2011-09-23||2017-03-07|2009-07-23|2009-07-24|Estimate|2011-09-23|2011-11-03|Estimate||||2017-03-07|2017-04-05|Actual|June 2009||2009-06-30|March 2017|2017-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options|Multi-Center, Non-Interventional, Observational Study To Evaluate The Antibacterial Therapeutical Options In Febrile Neutropenia Patients|Completed|||264|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:45:39.283073|2018-06-01 00:45:39.283073
NCT00945542|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-12-01|2009-07-23|2009-07-24|Estimate|||||||2011-12-01|2011-12-02|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TRFL||The Trauma- Formula-Driven Versus Lab-Guided Study (TRFL Study)|Formula-driven vs Laboratory-guided Transfusion Practices in Bleeding Trauma Patients: A Feasibility Randomized Controlled Study|Completed||Phase 1/Phase 2|70|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 00:45:39.714752|2018-06-01 00:45:39.714752
NCT00945529|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-05-02|2009-07-23|2009-07-24|Estimate|||||||2012-05-02|2012-05-04|Estimate|August 2006||2006-08-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effects of Inhaled Nitric Oxide After Fontan Operation|The Effects of Inhaled Nitric Oxide on Patient Morbidity and Length of Hospital Stay Following Fontan Operation|Completed||Phase 2/Phase 3|21|Actual|Nemours Children's Clinic|||||f||||t||||||||||2018-06-01 00:45:39.803987|2018-06-01 00:45:39.803987
NCT00945516|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2010-10-18|2009-07-23|2009-07-24|Estimate|||||||2010-10-18|2010-10-19|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture|Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture: Prospective Randomized Study|Completed||Phase 3|60|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-06-01 00:45:39.87604|2018-06-01 00:45:39.87604
NCT00945503|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2017-07-13|2009-07-23|2009-07-24|Estimate|||||||2017-07-13|2017-07-18|Actual|May 19, 2008|Actual|2008-05-19|July 2017|2017-07-31|December 22, 2008|Actual|2008-12-22|December 22, 2008|Actual|2008-12-22||Interventional|||Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.|An Adaptive PET Study in Healthy Volunteers Using [11C]GSK931145 to Establish the Relationship of Glycine Transporter 1 Occupancy by GSK1018921 to Plasma Concentrations Over Time.|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:45:39.945155|2018-06-01 00:45:39.945155
NCT00945490|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22||2017-03-09|2017-03-09|2009-07-22|2009-07-24|Estimate||||2017-03-09|2017-03-10|Actual|2017-03-09|2017-03-10|Actual|May 2009||2009-05-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018|Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0018|Completed||Phase 3|500|Actual|Nymox Corporation||2|||f||||f||||||||||2018-06-01 00:45:40.035587|2018-06-01 00:45:40.035587
NCT00945477|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2012-10-24||2013-10-25|2009-07-23|2009-07-24|Estimate|2013-10-25|2013-11-18|Estimate||||2013-10-25|2013-11-18|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade|A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.|Terminated||Phase 2|11|Actual|Illinois CancerCare, P.C.|Because of slow enrollment, the study was terminated. The study planned enrollment of 34 subjects, 11 were enrolled.|1||Slow enrollment|f||||f||||||||||2018-06-01 00:45:40.142138|2018-06-01 00:45:40.142138
NCT00945464|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2015-10-14|2009-07-23|2009-07-24|Estimate|||||||2015-10-14|2015-10-16|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PINK||Scripps Polster Breast Care Center Investigational GeneBank|Scripps Polster Breast Care Center Investigational GeneBank|Completed|||1136|Actual|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Approximately 19.5 mls of blood will be collected from volunteers. The blood from each~     subject will be collected via venipuncture. If subject is unable/unwilling to provide blood~     sample, we can also collect 2 mls of saliva.~   "|||2018-06-01 00:45:40.285373|2018-06-01 00:45:40.285373
NCT00945451|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2018-02-02|2009-07-23|2009-07-24|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2009||2009-01-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|November 17, 2016|Actual|2016-11-17||Interventional|||Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer|Study of Doses Escalation on Efficacy on Cyberknife After Docetaxel-Cisplatin Concomitant Radiotherapy for Non Small Cells Lung Cancer Stage III|Recruiting||N/A|40|Anticipated|Centre Antoine Lacassagne||1|||f||||f||||||||||2018-06-01 00:45:40.422946|2018-06-01 00:45:40.422946
NCT00945438|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-01-10|2009-07-23|2009-07-24|Estimate|||||||2014-01-10|2014-01-14|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)|Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)|Completed||Phase 2|131|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:45:40.496382|2018-06-01 00:45:40.496382
NCT00945425|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2011-02-15|2009-07-23|2009-07-24|Estimate|||||||2011-02-15|2011-02-16|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|November 2009|Anticipated|2009-11-30|||||Interventional|JMAD||AZD7325 Japan Multiple Ascending Dose (MAD) Study|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7325 When Given in Multiple Ascending Oral Doses in Healthy Male Japanese Subjects|Terminated||Phase 1|48|Anticipated|AstraZeneca||4||Decided to stop development of this compound globally|f||||||||||||||2018-06-01 00:45:40.578903|2018-06-01 00:45:40.578903
NCT00945412|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2017-01-05|2009-07-23|2009-07-24|Estimate|||||||2017-01-05|2017-01-06|Estimate|July 2009||2009-07-31|December 2010|2010-12-31|September 2011|Anticipated|2011-09-30|June 2011|Anticipated|2011-06-30||Interventional|||Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding|Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding|Withdrawn||Phase 3|0|Actual|Massachusetts Eye and Ear Infirmary||2||PI moving to another institution|f||||f||||||||||2018-06-01 00:45:40.671762|2018-06-01 00:45:40.671762
NCT00945399|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2015-04-25|2009-07-23|2009-07-24|Estimate|||||||2015-04-25|2015-04-28|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|July 2012|Actual|2012-07-31||Interventional|||Comparison of Microfracture Treatment and CARTIPATCH® Chondrocyte Graft Treatment in Femoral Condyle Lesions|Phase III Protocol Comparing a Microfracture Treatment to a CARTIPATCH® Chondrocyte Graft Treatment in Femoral Condyle Lesions|Terminated||Phase 3|40|Actual|TBF Genie Tissulaire||2||Manufacturing stopped|f||||||||||||||2018-06-01 00:45:40.767722|2018-06-01 00:45:40.767722
NCT00945386|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|August 2010|Anticipated|2010-08-31|||||Observational|||The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission|The Effect of Continuous, Various Dosages of Furosemide Drip on Hearing as Measured by Acoustic Emission|Unknown status|Not yet recruiting||60|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 00:45:40.843916|2018-06-01 00:45:40.843916
NCT00945373|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2011-06-21|2009-07-23|2009-07-24|Estimate|||||||2011-06-21|2011-06-22|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Combination Therapy for the Treatment of Rosacea|Combination Therapy for the Treatment of Erythematotelangiectatic Rosacea|Completed||Phase 1|6|Actual|Marmur, Ellen, M.D.|||||f||||f||||||||||2018-06-01 00:45:40.924456|2018-06-01 00:45:40.924456
NCT00945360|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-07-12|2009-07-23|2009-07-24|Estimate|||||||2012-07-12|2012-07-13|Estimate|March 2011||2011-03-31|July 2009|2009-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Aromatase Inhibitors for Treatment of Uterine Leiomyomas|Aromatase Inhibitors for the Prevention of the Growth of Uterine Leiomyomas in Perimenopausal Women: A Pilot Study|Withdrawn||Phase 1|0|Actual|American University of Beirut Medical Center||1||Inability to recruit patients|f||||t||||||||||2018-06-01 00:45:41.059954|2018-06-01 00:45:41.059954
NCT00945191|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22||2013-02-01|2013-02-01|2009-07-23|2009-07-24|Estimate||||2013-02-01|2013-02-05|Estimate|2013-02-01|2013-02-05|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer|Phase 2 Study of CS-1008 in Combination With Chemotherapy (Paclitaxel/Carboplatin) in Locally Advanced or Metastatic Ovarian Cancer|Completed||Phase 2|24|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 00:45:43.173237|2018-06-01 00:45:43.173237
NCT00945347|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2011-08-09|2009-07-23|2009-07-24|Estimate|||||||2011-08-09|2011-08-10|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?|Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind Placebo-controlled Study.|Completed||Phase 2|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||f||||||||||2018-06-01 00:45:41.165211|2018-06-01 00:45:41.165211
NCT00945334|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2015-02-25||2015-07-17|2009-07-23|2009-07-24|Estimate|2015-07-17|2015-08-10|Estimate||||2015-07-17|2015-08-10|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|C-IBS||Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome|Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome|Completed||N/A|37|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-06-01 00:45:41.264488|2018-06-01 00:45:41.264488
NCT00945321|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|2010-04-22||2015-01-16|2009-07-23|2009-07-24|Estimate|2010-05-26|2010-06-30|Estimate||||2015-01-16|2015-01-28|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)|A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 00:45:41.581018|2018-06-01 00:45:41.581018
NCT00945308|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|ICE||Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients|Effectiveness of Intracoronary Injection of Eptifibatide as Adjunctive Antiplatelet Therapy in Primary Coronary Intervention in Patients With ST Segment Elevation Acute Myocardial Infarction.|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 00:45:41.99923|2018-06-01 00:45:41.99923
NCT00945295|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2013-08-20||2013-08-20|2009-07-23|2009-07-24|Estimate|2013-08-20|2013-11-01|Estimate||||2013-08-20|2013-11-01|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity|Open-label, Parallel Study to Determine the Efficacy and Safety of Botulinum Neurotoxin A Paired With Rehabilitation Therapy vs. Botulinum Neurotoxin A Alone for the Treatment of Post-stroke Upper Limb Spasticity|Completed||N/A|31|Actual|Biomedical Research Institute of New Mexico|This has a single-blind design. Admittedly, a double-blind design is best, but the participants could not be blind to the assignment of rehabilitation. Secondly, the study involved a relatively small sample size and limited follow-up duration.|2|||f||||f||||||||||2018-06-01 00:45:42.08856|2018-06-01 00:45:42.08856
NCT00945282|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23||2012-03-08|2013-05-30|2009-07-23|2009-07-24|Estimate||||2012-03-08|2012-03-13|Estimate|2013-05-30|2013-06-07|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.|A Proof of Concept Study for GSK2248761 (An Extension of NV-05A-002: A Phase I/IIa Double-Blind Study to Evaluate the Safety and Tolerability, Antiretroviral Activity, Pharmacokinetics and Pharmacodynamics of IDX12899 in Antiretroviral Treatment-Naive HIV-1 Infected Subjects, Completed by Idenix)|Completed||Phase 2|8|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-06-01 00:45:42.31095|2018-06-01 00:45:42.31095
NCT00945269|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23||2011-12-02|2011-12-02|2009-07-23|2009-07-24|Estimate||||2011-12-02|2011-12-08|Estimate|2011-12-02|2011-12-08|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma|Phase I/II Study To Evaluate The Safety Of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following CD25 Lymphodepletion For Patients With Metastatic Melanoma|Terminated||Phase 1/Phase 2|3|Actual|Fred Hutchinson Cancer Research Center||1||"ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer be~   supporting clinical trials that utilize this drug."|f||||t||||||||||2018-06-01 00:45:42.386507|2018-06-01 00:45:42.386507
NCT00945256|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2013-03-28||2016-01-05|2009-07-23|2009-07-24|Estimate|2015-11-30|2016-01-05|Estimate||||2016-01-05|2016-02-03|Estimate|May 2003||2003-05-31|April 2014|2014-04-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Muscle Perfusion and Protein Metabolism in Elderly|A Phase I Trial Examining Muscle Perfusion and Protein Metabolism in Elderly and Young|Completed||Phase 1|62|Actual|The University of Texas Medical Branch, Galveston||5|||f||||f||||||||||2018-06-01 00:45:42.469072|2018-06-01 00:45:42.469072
NCT00945243|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2016-11-17||2017-10-03|2009-07-23|2009-07-24|Estimate|2016-11-17|2017-01-13|Estimate||||2017-10-03|2017-11-06|Actual|July 1, 2009|Actual|2009-07-01|September 2017|2017-09-30|December 1, 2011|Actual|2011-12-01|December 1, 2011|Actual|2011-12-01||Interventional||Number of subjects enrolled and treated per protocol|Clinical Outcomes Study Evaluating the Zero-P PEEK|Prospective, Multi-Center Clinical Outcomes Study Evaluating the Zero-P PEEK for Anterior Cervical Interbody Fusion in the Treatment of Cervical Degenerative Disc Disease|Terminated||N/A|11|Actual|Synthes USA HQ, Inc.||1||This study was terminated early due to lower than expected enrollment rates.|f||||f||||||||No||2018-06-01 00:45:42.815618|2018-06-01 00:45:42.815618
NCT00945230|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2009-07-23|2009-07-23|2009-07-24|Estimate|||||||2009-07-23|2009-07-24|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Actigraphic Measurement of a Neurosurgical Procedure|Analysis of Post Surgical Response in A Fifty-Six Year Old Female With An Incidental Large Left Anterior Cranial Fossa Meningioma|Completed||N/A|1|Actual|Child Psychopharmacology Institute||1|||f||||f||||||||||2018-06-01 00:45:42.965797|2018-06-01 00:45:42.965797
NCT00945217|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2011-12-05|2009-07-22|2009-07-24|Estimate|||||||2011-12-05|2011-12-06|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Observational|MOSAH-S2||The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women|Genetic Probes of Atherogenic Dyslipidemia: The Roles of the SAH Gene Family (Study 2. Postmenopausal Women)|Unknown status|Recruiting||660|Anticipated|Taipei Veterans General Hospital, Taiwan|||1||f||||f||||||Samples With DNA|"~     Samples With DNA - samples retained, with potential for extraction of DNA from buffy coats~   "|||2018-06-01 00:45:43.045283|2018-06-01 00:45:43.045283
NCT00945178|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2010-12-08|2009-07-23|2009-07-24|Estimate|||||||2010-12-08|2010-12-10|Estimate|August 2009||2009-08-31|December 2009|2009-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Two-part Study to Assess Safety, Tolerability, Pharmacokinetics of Orally Administered AZD1386|Terminated||Phase 1|11|Actual|AstraZeneca||4||The study was terminated due to results in another study (NCT00878501).|f||||t||||||||||2018-06-01 00:45:43.235395|2018-06-01 00:45:43.235395
NCT00945165|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-23|||2012-10-24|2009-07-23|2009-07-24|Estimate|||||||2012-10-24|2012-10-25|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Exercise and Glycemic Control in Type 2 Diabetes|Defining the Optimal Exercise Program to Improve Glycemic Control in Various Stages of Type 2 Diabetes.|Completed||N/A|124|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:45:44.271492|2018-06-01 00:45:44.271492
NCT00945152|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-08-29|2009-07-22|2009-07-23|Estimate|||||||2017-08-29|2017-08-30|Actual|July 2011||2011-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Vancogel(R)||Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)|Topical MRSA Bactericidal Gel to Eliminate MRSA and Promote Accelerated Healing of cSSTI of Open Wounds|Recruiting||Phase 2|100|Anticipated|Robert S Berman MD||2|||f||||f||||||||||2018-06-01 00:45:44.341108|2018-06-01 00:45:44.341108
NCT00945139|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2014-06-30||2015-07-06|2009-07-22|2009-07-23|Estimate|2015-06-06|2015-07-07|Estimate||||2015-07-06|2015-07-31|Estimate|March 2007||2007-03-31|July 2015|2015-07-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)|Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer|Completed||Phase 2|46|Actual|New Mexico Cancer Care Alliance||1|||f||||t||||||||||2018-06-01 00:45:44.457015|2018-06-01 00:45:44.457015
NCT00945126|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-09-28|2009-07-22|2009-07-23|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2006||2006-12-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk Diseases|Allogeneic Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells of Related or Unrelated Haploidentical Donors in Pediatric Patients With Malignant and Non-malignant Diseases|Terminated||Phase 2|68|Actual|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-06-01 00:45:44.764569|2018-06-01 00:45:44.764569
NCT00945113|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-10-07|2009-07-22|2009-07-23|Estimate|||||||2015-10-07|2015-10-12|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pilot: Group Therapy for Children Who Stammer|A Pilot Randomised Controlled Trial of the Effectiveness of Intensive Group Speech and Language Therapy as a Treatment for Older Children Who Stammer|Completed||N/A|6|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||f||||||||||2018-06-01 00:45:44.919214|2018-06-01 00:45:44.919214
NCT00945100|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2013-09-06||2016-07-12|2009-07-21|2009-07-23|Estimate|2013-09-06|2013-11-13|Estimate||||2016-07-12|2016-07-13|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ATS15||Increasing Patching for Amblyopia in Children 3 to < 8 Years Old|Increasing Patching for Amblyopia in Children 3 to < 8 Years Old|Completed||Phase 3|169|Actual|Jaeb Center for Health Research|A potential study limitation is that compliance with patching was based on discussions with the parent and by reviewing study calendars maintained by the parent, which not an objective measure of compliance.|2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website at http://pedig.jaeb.org/Studies.aspx?RecID=29|2018-06-01 00:45:45.0828|2018-06-01 00:45:45.0828
NCT00945087|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2013-09-05|2009-07-21|2009-07-23|Estimate|||||||2013-09-05|2013-09-06|Estimate|December 2005||2005-12-31|August 2013|2013-08-31||||||||Interventional|||Experimental Phage Therapy of Bacterial Infections|Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections|Unknown status|Recruiting|N/A|||Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences|||||f||||||||||||||2018-06-01 00:45:46.705862|2018-06-01 00:45:46.705862
NCT00945074|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2016-09-21|2009-07-22|2009-07-23|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|Acu/MoxaIBS||Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)|Protocol- vs. Patient-Oriented TCM Practices: A RCT for IBS Symptom Management|Active, not recruiting||Phase 2|171|Anticipated|New York University||3|||f||||f||||||||||2018-06-01 00:45:46.787133|2018-06-01 00:45:46.787133
NCT00945061|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2018-01-26|2009-07-22|2009-07-23|Estimate|||||||2018-01-26|2018-01-30|Actual|September 23, 2008|Actual|2008-09-23|January 2018|2018-01-31|May 22, 2018|Anticipated|2018-05-22|May 22, 2018|Anticipated|2018-05-22||Interventional|||Radiation Therapy in Treating Patients With Recurrent Breast Cancer|Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation|Active, not recruiting||N/A|13|Actual|Case Comprehensive Cancer Center||2|||f||||t|f|t|f|f|f|||||2018-06-01 00:45:46.871258|2018-06-01 00:45:46.871258
NCT00945048|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2013-01-15|2009-07-21|2009-07-23|Estimate|||||||2013-01-15|2013-01-16|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Non-Invasive Determination of Cardiac Output by Electrical Velocimetry|Non-Invasive Determination of Cardiac Output by Electrical Velocimetry Compared With Magnetic Resonance Tomography and Inert Gas Rebreathing Method|Completed|||220|Actual|Universitätsmedizin Mannheim|||||f||||||||||||||2018-06-01 00:45:47.006876|2018-06-01 00:45:47.006876
NCT00945035|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2009-10-13||2015-06-05|2009-07-22|2009-07-23|Estimate|2009-10-13|2009-11-17|Estimate||||2015-06-05|2015-07-03|Estimate|November 2002||2002-11-30|June 2015|2015-06-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)|An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of the 20% and 30% Etoricoxib (MK0663) Formulations|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:45:47.084697|2018-06-01 00:45:47.084697
NCT00945022|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2011-06-08|2009-07-22|2009-07-23|Estimate|||||||2011-06-08|2011-06-09|Estimate|October 2011||2011-10-31|July 2009|2009-07-31|April 2012|Anticipated|2012-04-30|February 2012|Anticipated|2012-02-29||Interventional|||Evaluation of Safety and Efficacy of Using Lipsus Device for Oral Wetting|Evaluation of Safety and Efficacy of Using Lipsus Device for Oral Wetting|Unknown status|Not yet recruiting|N/A|100|Anticipated|IMD Tech Ltd||1|||f||||f||||||||||2018-06-01 00:45:47.320334|2018-06-01 00:45:47.320334
NCT00945009|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-11-30|2009-07-22|2009-07-23|Estimate|||||||2017-11-30|2017-12-04|Actual|July 2009||2009-07-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor|Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor|Active, not recruiting||Phase 3|249|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 00:45:47.441292|2018-06-01 00:45:47.441292
NCT00944996|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|||2012-07-25|2009-07-22|2009-07-23|Estimate|||||||2012-07-25|2012-07-26|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|June 2010|Actual|2010-06-30||Interventional|||Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression|Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression|Completed||N/A|100|Actual|Tirat Carmel Mental Health Center||2|||f||||t||||||||||2018-06-01 00:45:47.803353|2018-06-01 00:45:47.803353
NCT00944983|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2014-05-06|2009-07-22|2009-07-23|Estimate|||||||2014-05-06|2014-05-07|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Clinical Validation of the Tiba Medical Ambulo 2400 ABPM According to the ISO 80601-2-30 Standard in Adults, Adolescents, and Children|Clinical Validation of the Tiba Medical Ambulo 2400 ABPM According to the ISO 80601-2-30 Standard in Adults, Adolescents, and Children|Completed|||105|Actual|Tiba Medical, Inc.|||||f||||t||||||None Retained|"~     Only blood pressure measurements are retained~   "|||2018-06-01 00:45:47.883603|2018-06-01 00:45:47.883603
NCT00944970|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17||2010-01-05|2012-05-24|2009-07-22|2009-07-23|Estimate||||2010-01-05|2010-01-07|Estimate|2012-05-24|2012-06-01|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|VISION-305||Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia|Vasodilator Induced Stress In CONcordance With Adenosine (VISION-305)|Completed||Phase 3|578|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 00:45:47.950338|2018-06-01 00:45:47.950338
NCT00944957|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-01-11|2009-07-22|2009-07-23|Estimate|||||||2010-01-11|2010-01-12|Estimate|November 2009||2009-11-30|July 2009|2009-07-31|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Interventional|Switch-ER||Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz|Patient Preference, Sleep Quality, and Anxiety/Depression: Comparison of Raltegravir and Efavirenz|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-06-01 00:45:48.036421|2018-06-01 00:45:48.036421
NCT00944944|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2010-01-29|2009-07-22|2009-07-23|Estimate|||||||2010-01-29|2010-02-01|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema|A Pilot Study Using the Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema|Completed|||58|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 00:45:48.131978|2018-06-01 00:45:48.131978
NCT00944931|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-06-30|2009-07-22|2009-07-23|Estimate|||||||2017-06-30|2017-07-02|Actual|July 20, 2009||2009-07-20|February 9, 2012|2012-02-09|April 5, 2011|Actual|2011-04-05|April 5, 2011|Actual|2011-04-05||Interventional|||High-Density Direct Current Brain Polarization|High-Density Direct Current Brain Polarization|Completed||Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:45:48.208848|2018-06-01 00:45:48.208848
NCT00944918|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-08-26|2009-07-22|2009-07-23|Estimate|||||||2011-08-26|2011-08-29|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)|A Partially-blind Phase III Randomised Trial of Fulvestrant (Faslodex) With or Without Concomitant Anastrozole (Arimidex) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-steroidal Aromatase Inhibitors|Completed||Phase 3|25|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:45:48.275798|2018-06-01 00:45:48.275798
NCT00944905|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2013-05-21|2009-07-22|2009-07-23|Estimate|||||||2013-05-21|2013-05-22|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)|A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma|Completed||Phase 1|46|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:45:48.357529|2018-06-01 00:45:48.357529
NCT00944892|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21||2011-03-17|2011-12-01|2009-07-22|2009-07-23|Estimate||||2011-03-17|2011-03-28|Estimate|2011-12-01|2011-12-08|Estimate|August 2009||2009-08-31|December 2011|2011-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee|A Randomized,Double Blind,Placebo-controlled,Parallel Group,Repeat Dose Study of the Safety and Efficacy of REGN475 in Patients With Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|200|Actual|Regeneron Pharmaceuticals||4|||f||||||||||||||2018-06-01 00:45:48.461553|2018-06-01 00:45:48.461553
NCT00944879|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-08-14|2009-07-22|2009-07-23|Estimate|||||||2009-08-14|2009-08-17|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Observational|CATSA||Preparing for Adolescent HIV Vaccine Trials in South Africa:|Preparing for Adolescent HIV Vaccine Trials in South Africa: a Multi-centre Study to Evaluate Acceptability of the HPV Vaccine in Adolescents|Unknown status|Not yet recruiting||1400|Anticipated|Desmond Tutu HIV Centre|||2||f||||t||||||Samples Without DNA|"~     Blood for HIV, syphilis and pregnancy testing~   "|||2018-06-01 00:45:48.536572|2018-06-01 00:45:48.536572
NCT00944866|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-22|2009-07-22|2009-07-23|Estimate|||||||2009-07-22|2009-07-23|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|||Effects of Cox-II Inhibitor on Biochemical Markers in Cardiovascular-related Adverse Effects||Unknown status|Active, not recruiting||30|Anticipated|National Chung Hsing University|||2||f||||||||||||||2018-06-01 00:45:48.617805|2018-06-01 00:45:48.617805
NCT00944853|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-02-22|2009-07-21|2009-07-23|Estimate|||||||2017-02-22|2017-02-24|Actual|August 2009||2009-08-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Effects of Liquid Zinc Supplementation and Dispersible Zinc Tablets on Plasma Zinc Concentration|The Effect of Zinc Supplementation, Provided as Either a Liquid Zinc Solution or Dispersible Tablets, on Plasma Zinc Concentration Among Young Burkinabe Children|Completed||N/A|462|Actual|University of California, Davis||3|||f||||t|f|f||||||||2018-06-01 00:45:48.661638|2018-06-01 00:45:48.661638
NCT00944840|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-01-25|2009-07-22|2009-07-23|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2008||2008-09-30|January 2017|2017-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia|A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia|Completed||Phase 3|1312|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-06-01 00:45:48.756594|2018-06-01 00:45:48.756594
NCT00944827|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-12-02|2009-07-22|2009-07-23|Estimate|||||||2010-12-02|2010-12-03|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|GTE-Stat||Combination Treatment With Green Tea Extract and Statins in Patients With Hypercholesterolemia|The Effects of Catechin Supplementation (Green Tea Extract), in Combination With the Classic Treatment for the Reduction of Hypercholesterolemia (Statin Therapy) on the Treatment's Effectiveness and in the Reduction of Classic Side Effects.|Completed||Phase 2|40|Anticipated|University of Thessaly||2|||f||||f||||||||||2018-06-01 00:45:48.857752|2018-06-01 00:45:48.857752
NCT00944814|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-02-21|2009-07-21|2009-07-23|Estimate|||||||2017-02-21|2017-02-23|Actual|July 2009||2009-07-31|February 2017|2017-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Acceptability of Zinc-fortified Lipid-based Nutrient Supplements|Assessment of the Acceptability of Zinc-fortified Lipid Based Nutrient (LNS) Prepared for Young Burkinabe Children|Completed||N/A|36|Actual|University of California, Davis||2|||f||||t|f|f||||||Undecided||2018-06-01 00:45:48.939627|2018-06-01 00:45:48.939627
NCT00944801|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-07-21|2009-07-21|2009-07-23|Estimate|||||||2009-07-21|2009-07-23|Estimate|July 2002||2002-07-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma|RNOP-09: Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma - a Phase II Study|Completed||Phase 1/Phase 2|63|Actual|University of Regensburg||1|||f||||t||||||||||2018-06-01 00:45:49.019561|2018-06-01 00:45:49.019561
NCT00944788|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2013-06-12|2009-07-22|2009-07-23|Estimate|||||||2013-06-12|2013-06-13|Estimate|July 2009||2009-07-31|June 2013|2013-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Structured Qi-gong Program for Hospitalized Older Adults|Feasibility and Impact on Quality of Life and Depressive Symptoms of a Structured Qi-gong Program for Hospitalized Older Adults. A Pilot Study.|Completed||N/A|58|Actual|Fundacio Salut i Envelliment UAB||2|||f||||||||||||||2018-06-01 00:45:49.094588|2018-06-01 00:45:49.094588
NCT00944775|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-10-25|2009-07-22|2009-07-23|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2007||2007-08-31|October 2017|2017-10-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Exercise and Cardiac Measures in Dialysis Patients|Effects of Exercise Training on Non-invasive Cardiac Measures in Patients Undergoing Long-term Hemodialysis: A Randomized Controlled Trial|Completed||N/A|63|Actual|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-06-01 00:45:49.170146|2018-06-01 00:45:49.170146
NCT00944762|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-02-17|2009-07-22|2009-07-23|Estimate|||||||2017-02-17|2017-02-23|Actual|May 1, 2009|Actual|2009-05-01|February 2017|2017-02-28|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Ecosystem Focused Therapy for Treating Older Depressed Stroke Survivors|Ecosystem Focused Therapy for Depressed Stroke Survivors|Completed||N/A|40|Actual|Weill Medical College of Cornell University||2|||f||||t|f|f||||||No||2018-06-01 00:45:49.245429|2018-06-01 00:45:49.245429
NCT00944749|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2016-12-30||2017-08-24|2009-07-22|2009-07-23|Estimate|2016-12-30|2017-02-23|Actual||||2017-08-24|2017-09-25|Actual|July 2009||2009-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment|Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment|Completed||Phase 2|23|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 00:45:49.309804|2018-06-01 00:45:49.309804
NCT00944736|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-03-06|2009-07-22|2009-07-23|Estimate|||||||2014-03-06|2014-03-10|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease|Effect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in Remission|Completed||Phase 3|12|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-06-01 00:45:49.563366|2018-06-01 00:45:49.563366
NCT00944723|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-02-18|2009-07-22|2009-07-23|Estimate|||||||2010-02-18|2010-02-19|Estimate|August 2009||2009-08-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Impact of Mass Zinc Fortification Programs on Plasma Zinc Concentration|Evaluation of the Use of Plasma Zinc Concentration for Assessing the Impact of Targeted and Mass Zinc Fortification Programs|Completed||Phase 4|132|Actual|University of California, Davis||4|||f||||f||||||||||2018-06-01 00:45:49.6405|2018-06-01 00:45:49.6405
NCT00944710|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2014-10-09||2016-07-07|2009-07-21|2009-07-23|Estimate|2014-10-22|2014-10-24|Estimate||||2016-07-07|2016-07-13|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|ATS16||Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old|Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old|Completed||Phase 3|73|Actual|Jaeb Center for Health Research|A potential study limitation is that compliance with patching was based on discussions with the parent and by reviewing study calendars maintained by the parent, which not an objective measure of compliance.|2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website at http://pedig.jaeb.org/Studies.aspx?RecID=30|2018-06-01 00:45:49.788015|2018-06-01 00:45:49.788015
NCT00944697|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2011-11-22||2012-08-09|2009-07-22|2009-07-23|Estimate|2012-01-26|2012-02-28|Estimate||||2012-08-09|2012-08-17|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy|An Exploratory, Randomised, Double-blind, Single-dummy, Placebo Controlled, Parallel Group Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy|Completed||Phase 2|98|Actual|Mundipharma Research GmbH & Co KG||2|||f||||f||||||||||2018-06-01 00:45:51.182982|2018-06-01 00:45:51.182982
NCT00944515|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2016-03-15|2009-07-22|2009-07-23|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children|Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children : A Prospective, Randomized, Double-blind, Placebo Controlled Trial.|Completed||N/A|40|Actual|Mahidol University||2|||f||||t||||||||No||2018-06-01 00:45:53.344229|2018-06-01 00:45:53.344229
NCT00944684|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-11-10|2009-07-21|2009-07-23|Estimate|||||||2011-11-10|2011-11-11|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||High Dose Ribavirin in the Treatment of Chronic Hepatitis C|Prospective, Open-label, Randomised Controlled Trial on Efficacy and Tolerability of PegIFN-alpha 2a + Serum Level-adapted RBV vs. PegIFN-alpha 2a + Weight-based RBV in Treatment-naive Patients With Chronic Hepatitis C Genotype 1|Completed||Phase 2|32|Actual|University of Bern||2|||f||||f||||||||||2018-06-01 00:45:51.42925|2018-06-01 00:45:51.42925
NCT00944671|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|2014-10-27||2015-06-19|2009-07-22|2009-07-23|Estimate|2015-06-19|2015-06-24|Estimate||||2015-06-19|2015-06-24|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets Compared to Famotidine/Antacid EZ Chew Tablets (0208C-145)(COMPLETED)|A Single-Dose, Open-Label, Three-Period Crossover Study to Assess the Bioequivalence of Famotidine/Antacid Combination Tablets (FACT) Compared to Famotidine/Antacid EZ Chew Tablet Without Water and Famotidine/Antacid EZ Chew Tablet With Water|Completed||Phase 1|24|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||||||||||||2018-06-01 00:45:51.546727|2018-06-01 00:45:51.546727
NCT00944658|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2011-09-29|2009-07-22|2009-07-23|Estimate|||||||2011-09-29|2011-09-30|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|START||Spondylitis Trial of Apremilast for Better Rheumatic Therapy|Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS)|Completed||Phase 2|38|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 00:45:52.076821|2018-06-01 00:45:52.076821
NCT00944645|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2009-10-20||2015-05-25|2009-07-22|2009-07-23|Estimate|2009-10-20|2009-11-25|Estimate||||2015-05-25|2015-06-19|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||MK0524A Bioequivalence Study (0524A-059)|An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets|Completed||Phase 1|188|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:45:52.176691|2018-06-01 00:45:52.176691
NCT00944632|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-02-19|2009-07-22|2009-07-23|Estimate|||||||2014-02-19|2014-02-21|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis|Double-blind, Randomized, Dose Escalation Study of the Efficacy and Safety of ZK 245186 Ointment in Concentrations of 0.01%, 0.03%, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis|Completed||Phase 2|64|Actual|Bayer||4|||f||||f||||||||||2018-06-01 00:45:52.495987|2018-06-01 00:45:52.495987
NCT00944619|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-05-10|2009-07-21|2009-07-23|Estimate|||||||2010-05-10|2010-05-12|Estimate|September 2009||2009-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ANGELA02||Closing the Loop in Adults With Type 1 Diabetes - Alcohol Consumption|Randomised, Two-Period Crossover Study to Assess the Efficacy of Overnight Computer-based Glucose Control Compared With Conventional Pump Therapy Following the Consumption of Alcohol in Adults With Type 1 Diabetes|Completed||N/A|12|Actual|University of Cambridge||2|||f||||f||||||||||2018-06-01 00:45:52.573576|2018-06-01 00:45:52.573576
NCT00944606|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2012-02-29|2009-07-22|2009-07-23|Estimate|||||||2012-02-29|2012-03-01|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Vitamin D Versus Placebo in the Treatment of Vague Musculoskeletal Pain in Children|Vitamin D vs Placebo in the Treatment of Vague Musculoskeletal Pain in Children|Withdrawn||N/A|0|Actual|University of New Mexico||2||inability to recruit subjects|f||||t||||||||||2018-06-01 00:45:52.641354|2018-06-01 00:45:52.641354
NCT00944593|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-04-02|2009-07-21|2009-07-23|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|January 2011||2011-01-31|||||Interventional|||Gastric vs Jejunal Feeding in Diabetic Gastroparesis|A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers|Withdrawn||Phase 4|0|Actual|University of Zurich||2||"Principle Investigator moved to another institution. Research funds transferred. Study to be~   performed at new institution"|f||||||||||||||2018-06-01 00:45:52.710217|2018-06-01 00:45:52.710217
NCT00944580|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-11-21|2009-07-22|2009-07-23|Estimate|||||||2017-11-21|2017-11-24|Actual|June 2009||2009-06-30|November 2017|2017-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Vaccine Study for High Risk Cancers|A Phase 1 Study to Determine the Immunologic Effects of a MAGE- A1, MAGE- A3, NY-ESO-1 Vaccine in Patients With High Risk Neuroblastoma, Osteogenic Sarcoma, and Rhabdomyosarcoma|Withdrawn||Phase 1|0|Actual|Penn State University||1||unexpectedly low screening results leading to poor accrual|f||||t||||||||||2018-06-01 00:45:52.78468|2018-06-01 00:45:52.78468
NCT00944567|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-08-11|2009-07-22|2009-07-23|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2007||2007-01-31|August 2017|2017-08-31|February 27, 2017|Actual|2017-02-27|May 2011|Actual|2011-05-31||Observational|||A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma|A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma|Completed|||125|Actual|International Extranodal Lymphoma Study Group (IELSG)|||||f||||f|||||||"~     tissue~   "|||2018-06-01 00:45:52.852961|2018-06-01 00:45:52.852961
NCT00944554|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2017-04-20||2017-07-28|2009-07-22|2009-07-23|Estimate|2017-06-19|2017-06-23|Actual||||2017-07-28|2017-08-03|Actual|October 2008||2008-10-31|July 2017|2017-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|0815||Relapse Prevention With Varenicline|Relapse Prevention With Varenicline|Completed||Phase 4|104|Actual|Johns Hopkins University|Experimental model of relapse used in non-treatment seeking smokers. Results may not generalize to all smokers.|2|||f||||t||||||||||2018-06-01 00:45:52.931985|2018-06-01 00:45:52.931985
NCT00944541|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-12-21|2009-07-22|2009-07-23|Estimate|||||||2011-12-21|2011-12-22|Estimate|September 2009||2009-09-30|December 2011|2011-12-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|145 MARIMUNO||Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration|Pilot Study Evaluating Maraviroc (Celsentri®)Intensification Benefit in HIV Infected Patients Presenting Insufficient Immune Restoration Despite Controlled Viral Load With Antiretroviral Treatment. ANRS 145 MARIMUNO|Completed||Phase 2|60|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 00:45:53.187821|2018-06-01 00:45:53.187821
NCT00944528|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2017-12-07|2009-07-22|2009-07-23|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2010||2010-01-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|April 4, 2016|Actual|2016-04-04||Interventional|RSU||Single Dose Partial Breast Radiotherapy|Single Dose Partial Breast Radiotherapy Using Extra-cranial Radiosurgery in Patients With Early Stage Breast Cancer - a Phase I Dose Escalation Study|Active, not recruiting||Phase 1|32|Anticipated|Duke University||3|||f||||f||||||||||2018-06-01 00:45:53.267037|2018-06-01 00:45:53.267037
NCT00944502|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-23|2009-07-22|2009-07-23|Estimate|||||||2009-07-23|2009-07-24|Estimate|October 2009||2009-10-31|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins|Multicenter Clinical Study, Phase III, Prospective, Randomized, Double-blind, Comparative to Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins|Unknown status|Not yet recruiting|Phase 3|104|Anticipated|Bunker Industria Farmaceutica Ltda.||2|||f||||t||||||||||2018-06-01 00:45:53.415515|2018-06-01 00:45:53.415515
NCT00944489|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2010-12-06|2009-07-22|2009-07-23|Estimate|||||||2010-12-06|2010-12-07|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|ADHERENCE||To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension|Hypertension and Health-Related Quality of Life Adherence: Cross- Sectional Observational Study in Ambulatory Patients|Completed|||1150|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:45:53.487511|2018-06-01 00:45:53.487511
NCT00944476|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-05-13|2009-07-22|2009-07-23|Estimate|||||||2014-05-13|2014-05-15|Estimate|July 2009||2009-07-31|May 2014|2014-05-31||||May 2014|Actual|2014-05-31||Observational|||Application of Magnetic Resonance Fat-Free Imaging|Application of Magnetic Resonance Fat-Free Imaging|Terminated|||2|Actual|Memorial Sloan Kettering Cancer Center|||1|Software issues not resolved.|f||||||||||||||2018-06-01 00:45:53.541904|2018-06-01 00:45:53.541904
NCT00944463|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-02-15|2009-07-22|2009-07-23|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2008|Actual|2008-10-31|February 2017|2017-02-28|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Trial of Simvastatin and Gemcitabine in Pancreatic Cancer Patients|Randomized Double-blinded, Placebo-controlled Phase II Trial of Simvastatin and Gemcitabine in Advanced Pancreatic Cancer Patients|Completed||Phase 2|106|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 00:45:53.602031|2018-06-01 00:45:53.602031
NCT00944450|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2010-02-24||2015-08-18|2009-07-21|2009-07-23|Estimate|2010-04-06|2010-04-27|Estimate||||2015-08-18|2015-08-19|Estimate|August 2004||2004-08-31|August 2015|2015-08-31|November 2004|Actual|2004-11-30|September 2004|Actual|2004-09-30||Interventional|||Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)|An Open-Label, Randomized, 2-Period, Single-Dose, Balanced, Crossover Study in Healthy Subjects to Establish the Bioequivalence of Tablet Formulations Containing the Anhydrous and Monohydrate (FMI) Forms of MK0431|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:45:53.780024|2018-06-01 00:45:53.780024
NCT00944437|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2013-11-04|2009-07-22|2009-07-23|Estimate|||||||2013-11-04|2013-11-05|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Continuous Positive Airway Pressure (CPAP) Ventilation Using a Novel Full-Face Mask Versus Conventional Helmet|Noninvasive Ventilation For Postoperative Acute Respiratory Failure: Comparison of Conventional Helmet With a Novel Full-Face Mask.|Terminated||N/A|23|Actual|University of Parma||2||Failed to reach expected enrollment by anticipated dates.|f||||f||||||||||2018-06-01 00:45:53.978853|2018-06-01 00:45:53.978853
NCT00944424|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2011-12-11|2009-07-22|2009-07-23|Estimate|||||||2011-12-11|2011-12-13|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|GORG-002||Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca|GORG - 002 Randomized Phase III Trial to Determine the Effectiveness of High Dose Versus Standard Dose of Vitamin D2 (Ergocalciferol) Given With Docetaxel in Patients With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 3|260|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||f||||||||||2018-06-01 00:45:54.060648|2018-06-01 00:45:54.060648
NCT00944411|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2010-09-01|2009-07-22|2009-07-23|Estimate|||||||2010-09-01|2010-09-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:45:54.151967|2018-06-01 00:45:54.151967
NCT00944398|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-02-18|2009-07-22|2009-07-23|Estimate|||||||2010-02-18|2010-02-19|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Impact of Targeted Zinc Fortification Programs on Plasma Zinc Concentration|Evaluation of the Use of Plasma Zinc Concentration for Assessing the Impact of Targeted and Mass Zinc Fortification Programs|Completed||Phase 4|98|Actual|University of California, Davis||3|||f||||f||||||||||2018-06-01 00:45:54.186366|2018-06-01 00:45:54.186366
NCT00944385|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2011-05-26|2009-07-22|2009-07-23|Estimate|||||||2011-05-26|2011-05-27|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement|Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement|Completed||Phase 4|||Yonsei University||2|||f||||||||||||||2018-06-01 00:45:54.265056|2018-06-01 00:45:54.265056
NCT00944372|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2016-09-08|2009-07-22|2009-07-23|Estimate|||||||2016-09-08|2016-09-09|Estimate|July 2003||2003-07-31|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors|An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patients Referred for Scintigraphy of All Solid Tumors With a High Suspicion of Containing Somatostatin Receptor Positive Tissue|Terminated||Phase 4|150|Actual|Mallinckrodt||10||Enrollment was difficult|f||||f||||||||||2018-06-01 00:45:54.502476|2018-06-01 00:45:54.502476
NCT00944359|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2012-12-07|2009-07-21|2009-07-23|Estimate|||||||2012-12-07|2012-12-11|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children|Community-based Intervention Trial to Compare the Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children in Burkina Faso|Completed||Phase 4|7680|Actual|University of California, Davis||5|||f||||f||||||||||2018-06-01 00:45:54.646498|2018-06-01 00:45:54.646498
NCT00944346|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-07-22|2009-07-22|2009-07-23|Estimate|||||||2009-07-22|2009-07-23|Estimate||||July 2009|2009-07-31||||||||Interventional|||Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects||Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:45:54.726713|2018-06-01 00:45:54.726713
NCT00943696|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2010-06-24|2009-07-20|2009-07-22|Estimate|||||||2010-06-24|2010-06-28|Estimate|August 2009||2009-08-31|June 2010|2010-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effects of White Wine vs. Tea Intake During and an Alcoholic Digestive Following a High Fat, High Calorie Cheese Fondue Meal on Gastric Emptying and Abdominal Symptoms in Healthy Volunteers||Completed||Phase 4|12|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 00:46:09.645719|2018-06-01 00:46:09.645719
NCT00944333|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2014-08-04|2009-07-22|2009-07-23|Estimate|||||||2014-08-04|2014-08-05|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||"Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy"|"Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy"|Terminated||Phase 3|1378|Actual|Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS||2||"STOP due to recent data in literature questioning the need to continue DAP beyond six months in~   patients with stable coronary artery stenting with DES."|f||||f||||||||||2018-06-01 00:45:54.770212|2018-06-01 00:45:54.770212
NCT00944320|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-22|2009-07-22|2009-07-23|Estimate|||||||2009-07-22|2009-07-23|Estimate|February 2006||2006-02-28|July 2009|2009-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Pharmacogenetics of Antifolate Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis in Taiwan||Completed|||||National Chung Hsing University|||||f||||t||||||||||2018-06-01 00:45:54.832643|2018-06-01 00:45:54.832643
NCT00944307|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2017-06-26|2009-07-21|2009-07-23|Estimate|||||||2017-06-26|2017-06-28|Actual|July 2009||2009-07-31|June 2017|2017-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Antacids on the Pharmacokinetics of Raltegravir|Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers|Completed||Phase 1|17|Actual|University of Colorado, Denver||2|||f||||f|t|f|||f|||||2018-06-01 00:45:54.887277|2018-06-01 00:45:54.887277
NCT00944294|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17||2010-01-05|2012-05-24|2009-07-22|2009-07-23|Estimate||||2010-01-05|2010-01-07|Estimate|2012-05-24|2012-06-01|Estimate|February 2004||2004-02-29|May 2012|2012-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|VISION-302||Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia|Vasodilator Induced Stress In CONcordance With Adenosine (VISION-302)|Completed||Phase 3|419|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:45:54.96657|2018-06-01 00:45:54.96657
NCT00944281|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-05-27|2009-07-22|2009-07-23|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS)|A Randomized, Double-blind, Controlled Trial in Rural Burkina Faso to Determine the Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS). Part of the iLiNS Study|Completed||Phase 4|3220|Actual|University of California, Davis||5|||f||||f||||||||||2018-06-01 00:45:55.075419|2018-06-01 00:45:55.075419
NCT00944268|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-23|2009-07-22|2009-07-23|Estimate|||||||2009-07-23|2009-07-24|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|E01ATCAL0308||Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety|Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety|Unknown status|Not yet recruiting|Phase 3|124|Anticipated|Ativus Farmaceutica Ltda||1|||f||||t||||||||||2018-06-01 00:45:55.171369|2018-06-01 00:45:55.171369
NCT00944255|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2009-07-22|2009-07-22|2009-07-23|Estimate|||||||2009-07-22|2009-07-23|Estimate|February 2007||2007-02-28|July 2009|2009-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Pharmacogenetics of Antifolate Drugs in Autoimmune Diseases in Taiwan||Completed|||||National Chung Hsing University|||2||f||||||||||||||2018-06-01 00:45:55.238795|2018-06-01 00:45:55.238795
NCT00944242|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-07-22|2009-07-22|2009-07-23|Estimate|||||||2009-07-22|2009-07-23|Estimate||||July 2009|2009-07-31||||||||Interventional|||Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fasting Conditions||Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:45:55.312062|2018-06-01 00:45:55.312062
NCT00944229|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2016-03-23||2016-04-26|2009-07-22|2009-07-23|Estimate|2016-03-23|2016-04-22|Estimate||||2016-04-26|2016-05-25|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure|Salutary Effects of Dietary Supplementation With OMEGA 3 on Exercise Performance and Endothelial Function in Patients With Congestive Heart Failure. A Matter of Lipid Oxidation ?|Terminated||Phase 3|58|Actual|Columbia University||2||PI left the institution|f||||f||||||||||2018-06-01 00:45:55.391994|2018-06-01 00:45:55.391994
NCT00944216|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-01-19|2009-07-22|2009-07-23|Estimate|||||||2010-01-19|2010-01-20|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|January 2010||2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study|Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study|Terminated||Phase 4|10|Anticipated|Wright State University||1||terminated due to administrative reasons.|f||||t||||||||||2018-06-01 00:45:55.57246|2018-06-01 00:45:55.57246
NCT00944203|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-22|||2018-03-20|2009-07-22|2009-07-23|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2009||2009-07-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Efficacy of Ipomea Pes-caprae Ointment as an add-on Therapy in Patient With Jellyfish Dermatitis|Efficacy of Ipomea Pes-caprae Ointment as an add-on Therapy in Patient With Jellyfish Dermatitis|Completed||Phase 2|54|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 00:45:55.662511|2018-06-01 00:45:55.662511
NCT00944190|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-04-06|2009-07-21|2009-07-23|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|TakeCharge||TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS)|Telephone Delivered Self-management Intervention for People With Multiple Sclerosis Addressing Pain, Fatigue, Depression, and Cognitive Difficulties|Completed||N/A|166|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 00:45:55.729744|2018-06-01 00:45:55.729744
NCT00944177|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-07-22|2009-07-22|2009-07-23|Estimate|||||||2009-07-22|2009-07-23|Estimate||||July 2009|2009-07-31||||||||Interventional|||Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects||Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:45:55.822103|2018-06-01 00:45:55.822103
NCT00944164|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2009-07-21|2009-07-21|2009-07-23|Estimate|||||||2009-07-21|2009-07-23|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Primary Care Obesity Prevention and Treatment|Test the Feasibility of Primary Care Obesity Prevention and Treatment - Pilot Study|Completed||N/A|176|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 00:45:55.87214|2018-06-01 00:45:55.87214
NCT00941239|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2018-01-26|2009-07-16|2009-07-17|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2007||2007-01-31|January 2018|2018-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Tolerability and Pharmacokinetics of Metformin and Metformin Extended Release (ER)|Gastric Tolerability and Pharmacokinetics of an Extended Release Metformin and an Immediate Release Metformin|Completed||Phase 1|24|Actual|Laboratorios Silanes S.A. de C.V.||2|||f||||t||||||||||2018-06-01 00:46:54.809138|2018-06-01 00:46:54.809138
NCT00944151|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2014-05-19|2009-07-22|2009-07-23|Estimate|||||||2014-05-19|2014-05-20|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia|Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia: A Randomized, Triple-Masked, Placebo-Controlled Study|Terminated||Phase 4|20|Actual|University of California, San Diego||2||lack of enrollment|f||||f||||||||||2018-06-01 00:45:55.947954|2018-06-01 00:45:55.947954
NCT00944138|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2010-07-26|2009-07-22|2009-07-23|Estimate|||||||2010-07-26|2010-07-28|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||8-week Pilot Study of Relaxation for Weight Loss in Adults With Chronic Kidney Disease|Randomized 8-week Pilot Study of Relaxation Methods for Weight Loss in Adults With Chronic Kidney Disease|Completed||Phase 3|20|Anticipated|Edward Hines Jr. VA Hospital||2|||f||||||||||||||2018-06-01 00:45:56.039986|2018-06-01 00:45:56.039986
NCT00944125|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2015-02-25||2016-03-02|2009-07-22|2009-07-23|Estimate|2016-03-02|2016-03-21|Estimate||||2016-03-02|2016-03-21|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|DIVA|Includes both randomized groups, Group A: Randomized to Dual LV pacing for three months then crossed over to Standard BiV pacing for three months, then programmed at the physician discretion. Group B: Randomized to Standard BiV pacing for three months then crossed over to Dual LV pacing for three months, then programmed to physician discretion.|Dual Site Left Ventricular (LV) Pacing|Dual Site LV Pacing Study: Prospective Randomized Blinded Crossover Study of Patients Meeting Current CRT-D Indication to be Implanted With Dual LV Pacing Leads and Paced Chronically for at Least 6 Months Post-implant.|Terminated||N/A|50|Actual|Aurora Health Care|Study terminated early form administrative reasons (no safety concerns), no analysis was completed.|2||for administrative reasons (no safety concerns), no analysis completed|f||||f||||||||||2018-06-01 00:45:56.119578|2018-06-01 00:45:56.119578
NCT00944112|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2011-03-07|2009-07-21|2009-07-23|Estimate|||||||2011-03-07|2011-03-08|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|RELIEVE||Restrictive and Liberal Transfusion Strategies in Intensive Care|A Feasibility Randomized Trial Comparing Restrictive and Liberal Blood Transfusion Strategies in Patients Requiring Four or More Days in Intensive Care|Completed||N/A|100|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:45:56.346852|2018-06-01 00:45:56.346852
NCT00944099|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2018-04-03|2009-07-22|2009-07-23|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|LEAP||Lifestyle, Eating, and Activity Patterns|Eating Frequency Prescription for a Behavioral Weigh Loss Intervention|Completed||N/A|50|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-06-01 00:45:56.419774|2018-06-01 00:45:56.419774
NCT00944086|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-08-03|2009-07-21|2009-07-22|Estimate|||||||2009-08-03|2009-08-06|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Oxygen Concentration Should be Kept at the Lowest Possible Level During Recruitment|A Prospective Randomized Clinical Study:Oxygen Concentration Should be Kept at the Lowest Possible Level During Recruitment Manoeuvres|Completed|||||Istanbul University|||1||f||||||||||||||2018-06-01 00:45:56.495829|2018-06-01 00:45:56.495829
NCT00944073|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2011-03-17||2015-01-29|2009-07-21|2009-07-22|Estimate|2011-03-17|2011-04-13|Estimate||||2015-01-29|2015-02-18|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels|A Phase II Study in Infants (Greater Than or Equal to 6 - Less Than 36 Months), Children (Greater Than or Equal to 36 Months - 9 Years) and Adolescents (10 - 17 Years) to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels|Completed||Phase 2|583|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|To limit blood draws, the younger 2 age strata were assigned varying blood draw schedules and there were deviations from the schedules, reducing the size of subsets on the same schedule, such uniformity being optimal for longitudinal comparisons.|2|||f||||||||||||||2018-06-01 00:45:56.573784|2018-06-01 00:45:56.573784
NCT00944060|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2010-01-14|2009-07-20|2009-07-22|Estimate|||||||2010-01-14|2010-01-15|Estimate||||January 2010|2010-01-31||||||||Interventional|||A Pilot Study of Diabetes Risk Reduction Program With WIC Mothers(The Special Supplemental Nutrition Program for Women, Infants, and Children) Overweight WIC Mothers|A Pilot Study of Diabetes Risk Reduction Program With Overweight WIC Mothers|Completed||Phase 3|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||f||||||||||2018-06-01 00:45:57.449034|2018-06-01 00:45:57.449034
NCT00944047|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2018-03-21||2018-03-21|2009-07-21|2009-07-22|Estimate|2018-03-21|2018-04-23|Actual||||2018-03-21|2018-04-23|Actual|July 2009||2009-07-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|May 2014|Actual|2014-05-31||Interventional|||Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression|Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)|Completed||Phase 2|32|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 00:45:57.529609|2018-06-01 00:45:57.529609
NCT00944034|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2015-02-16||2017-07-12|2009-07-21|2009-07-22|Estimate|2015-10-07|2015-11-10|Estimate||||2017-07-12|2017-08-14|Actual|July 2009||2009-07-31|July 2017|2017-07-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|||Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12|A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12|Completed||Phase 2/Phase 3|1588|Actual|Novartis|None reported|12|||f||||||||||||||2018-06-01 00:45:57.929453|2018-06-01 00:45:57.929453
NCT00944021|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2014-02-19||2017-03-15|2009-07-21|2009-07-22|Estimate|2016-02-11|2016-03-09|Estimate||||2017-03-15|2017-04-12|Actual|August 2009||2009-08-31|January 2017|2017-01-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)|A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|Completed||Phase 2|69|Actual|Global Alliance for TB Drug Development||5|||f||||f||||||||||2018-06-01 00:46:00.093492|2018-06-01 00:46:00.093492
NCT00941226|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2009-07-17|2009-07-16|2009-07-17|Estimate|||||||2009-07-17|2009-07-20|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Observational|||The Quality Of Life Of Cerebral Palsy Child Carers|Evaluation of the Quality of Life of Cerebral Palsy Child Carers|Completed|||1|Actual|Centro de Estudos Superiores de Maceio|||1||f||||f||||||||||2018-06-01 00:46:54.872597|2018-06-01 00:46:54.872597
NCT00944008|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2015-05-07|2009-07-21|2009-07-22|Estimate|||||||2015-05-07|2015-05-08|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|2009-009422-92||PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia|PROCEDYTE: An Open, Prospective, Multicentre Clinical Trial With Historic Control to Determine Efficacy and Safety of Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration of Patients Between 16 and 30 Years Old With Standard Risk Acute Lymphoblastic Leukemia (ALL|Terminated||Phase 3|7|Actual|PETHEMA Foundation||1|||f||||t||||||||||2018-06-01 00:46:00.743939|2018-06-01 00:46:00.743939
NCT00943995|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-05-04|2009-07-21|2009-07-22|Estimate|||||||2015-05-04|2015-05-05|Estimate|July 2010||2010-07-31|May 2015|2015-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis|TIW Growth Hormone Therapy in Children on Hemodialysis|Completed||Phase 3|3|Actual|Nationwide Children's Hospital||1|||f||||t||||||||||2018-06-01 00:46:00.838661|2018-06-01 00:46:00.838661
NCT00943982|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-06-30|2009-07-21|2009-07-22|Estimate|||||||2017-06-30|2017-07-02|Actual|July 17, 2009||2009-07-17|June 24, 2010|2010-06-24|June 24, 2010|Actual|2010-06-24|June 24, 2010|Actual|2010-06-24||Interventional|||The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma|The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:46:00.923607|2018-06-01 00:46:00.923607
NCT00943969|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-12-14|2009-07-21|2009-07-22|Estimate|||||||2015-12-14|2015-12-16|Estimate|April 2009||2009-04-30|December 2015|2015-12-31|January 2010|Actual|2010-01-31|May 2009|Actual|2009-05-31||Interventional|OBEMO||Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass|Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass|Completed||Phase 4|31|Actual|Hopital Lariboisière||1|||f||||f||||||||||2018-06-01 00:46:00.984451|2018-06-01 00:46:00.984451
NCT00943956|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2016-05-24|2009-07-21|2009-07-22|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer|A Phase I Trial to Evaluate Acute and Late Toxicities of Concurrent Treatment With Everolimus (RAD001) and Radio-Hormonotherapy in High-risk Prostate Cancer.(RHOMUS)|Completed||Phase 1|30|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||t||||||||||2018-06-01 00:46:01.059977|2018-06-01 00:46:01.059977
NCT00943943|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2017-03-27|2009-07-21|2009-07-22|Estimate|||||||2017-03-27|2017-03-29|Actual|October 29, 2010|Actual|2010-10-29|March 2017|2017-03-31|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations|G-CSF and Plerixafor With Sorafenib for Acute Myelogenous Leukemia With FLT3 Mutations|Completed||Phase 1|33|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:46:02.086765|2018-06-01 00:46:02.086765
NCT00943930|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2016-04-26|2009-07-21|2009-07-22|Estimate|||||||2016-04-26|2016-04-28|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|DDC||Marijuana Drug Discrimination and Self-Administration|Smoked Marijuana Discrimination and Marijuana Choice in Humans: A Laboratory Mode|Completed|||29|Actual|Wayne State University|||1||f||||||||||||||2018-06-01 00:46:02.177158|2018-06-01 00:46:02.177158
NCT00943917|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2012-02-24||2015-03-23|2009-07-21|2009-07-22|Estimate|2012-05-01|2012-05-03|Estimate||||2015-03-23|2015-04-13|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Interventional|||Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus|Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|155|Actual|Intarcia Therapeutics|8 subjects (4 in 20, 1 in 40 and 3 in ex inj)completed StI but not randomized to St II; 3 subjects (2 in 20/20 & 1 in 40/80) who completed St I, randomized to St II but not given study drug. St II Cont was optional, so not all pts elected to continue|9|||f||||f||||||||||2018-06-01 00:46:02.309119|2018-06-01 00:46:02.309119
NCT00943904|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2013-07-18|2009-07-21|2009-07-22|Estimate|||||||2013-07-18|2013-07-22|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparison of Motor and Sensory Response With Interstim Stimulation|Comparison of Motor and Sensory Response With Interstim Stimulation for Overactive Bladder and Urgency-Frequency Syndrome|Completed||N/A|30|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 00:46:03.630103|2018-06-01 00:46:03.630103
NCT00943891|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2014-01-21|2009-07-21|2009-07-22|Estimate|||||||2014-01-21|2014-01-22|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer|A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer|Unknown status|Active, not recruiting||500||National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     CRC and NPC tumor specimens will be obtained.~   "|||2018-06-01 00:46:03.715148|2018-06-01 00:46:03.715148
NCT00943878|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2011-04-14||2012-07-26|2009-07-21|2009-07-22|Estimate|2011-04-14|2011-05-10|Estimate||||2012-07-26|2012-08-01|Estimate|August 2009||2009-08-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Sanofi H1N1 + TIV - Adults and Elderly|Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Healthy Adult and Elderly Populations|Completed||Phase 2|805|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 00:46:03.867505|2018-06-01 00:46:03.867505
NCT00943865|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-07-21|2009-07-21|2009-07-22|Estimate|||||||2009-07-21|2009-07-22|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Three Lifestyle Interventions on Endothelial Function and Cardiometabolic Risk in Obese Patients With Metabolic Syndrome|Effect of Three Lifestyle Interventions on Endothelial Function, Anthropometric Parameters and Cardiometabolic Profile in Obese Patients With Metabolic Syndrome: a Randomized Controlled Trial .|Completed||N/A|76|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-06-01 00:46:05.308911|2018-06-01 00:46:05.308911
NCT00943683|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2009-07-27||2015-06-22|2009-07-21|2009-07-22|Estimate|2010-05-18|2010-06-17|Estimate||||2015-06-22|2015-07-15|Estimate|August 2000||2000-08-31|June 2015|2015-06-30|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing Montelukast With Placebo in Pediatric Patients Aged 6 to 24 Months With Asthma|Completed||N/A|256|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:46:09.723019|2018-06-01 00:46:09.723019
NCT00943852|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2010-04-27||2015-04-06|2009-07-21|2009-07-22|Estimate|2010-06-21|2010-07-15|Estimate||||2015-04-06|2015-04-28|Estimate|August 2006||2006-08-31|April 2015|2015-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)|A Double-Blind, Randomized, Placebo-Controlled, 5-Period Crossover Study to Evaluate the Effects of a Single Dose of Losartan, a Single Dose of Isosorbide Mononitrate (ISMN), and Single Doses of Losartan + ISMN on Central Blood Pressure Measurements in Mildly Hypertensive Patients|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.|Due to lower than expected Blood Pressure's in individual patients, an interim analysis was undertaken after 11 patients had completed 3 to 5 of the study periods; enough data was already collected to meet objectives, so the trial was stopped early.|5|||f||||||||||||||2018-06-01 00:46:05.426441|2018-06-01 00:46:05.426441
NCT00943839|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2016-11-09|2009-07-21|2009-07-22|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2009||2009-02-28|November 2015|2015-11-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Sunitinib Malate in Treating Patients With Kidney Cancer|Effects of Sunitinib in the Expression of VEGF and of Interleukin 6 and CXCL7 - CXCL5 Cytokins : Explanation of Anti-angiogenic Effects.|Completed||N/A|60|Anticipated|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-06-01 00:46:05.820988|2018-06-01 00:46:05.820988
NCT00943826|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2013-03-29||2017-08-25|2009-07-21|2009-07-22|Estimate|2013-03-29|2013-05-20|Estimate||||2017-08-25|2017-09-25|Actual|June 29, 2009|Actual|2009-06-29|August 2017|2017-08-31|September 9, 2015|Actual|2015-09-09|February 28, 2013|Actual|2013-02-28||Interventional||Intent to treat population included all randomized participants.|A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma|Completed||Phase 3|921|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:46:05.936544|2018-06-01 00:46:05.936544
NCT00943813|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2016-08-15|2009-07-21|2009-07-22|Estimate|||||||2016-08-15|2016-08-16|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Assessment of Comskil Training Through Videorecording and Patient Surveys|Assessment of Comskil Training Through Videorecording and Patient Surveys|Completed|||55|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 00:46:07.098377|2018-06-01 00:46:07.098377
NCT00943800|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2017-11-28|2009-07-21|2009-07-22|Estimate|||||||2017-11-28|2017-11-30|Actual|October 9, 2006|Actual|2006-10-09|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Combined Haploidentical-Cord Blood Transplantation for Adults and Children|Combined Haploidentical-Cord Blood Transplantation for Adults and Children|Active, not recruiting||N/A|100|Anticipated|University of Chicago||3|||f||||t||||||||||2018-06-01 00:46:07.184812|2018-06-01 00:46:07.184812
NCT00943787|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2014-08-08||2014-08-26|2009-07-21|2009-07-22|Estimate|2014-08-26|2014-09-08|Estimate||||2014-08-26|2014-09-08|Estimate|January 2006||2006-01-31|August 2014|2014-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|BPK003||Counter-Regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus|Counter-regulatory Impairment and the Effect of Microvascular Insulin Transfer in Type 1 Diabetes Mellitus|Completed||N/A|41|Actual|University of Virginia||1|||f||||||||||||||2018-06-01 00:46:07.29116|2018-06-01 00:46:07.29116
NCT00943774|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2016-01-05|2009-07-20|2009-07-22|Estimate|||||||2016-01-05|2016-01-06|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||High Resolution Phenotyping in Healthy Humans|Blood Pressure Variability, Baroreflex Sensitivity, and Cardiovascular Responses to Sympathoexcitation in Healthy Normotensive Humans|Completed|||300|Actual|Mayo Clinic|||1||f||||t||||||Samples With DNA|"~     serum, white cells~   "|||2018-06-01 00:46:07.467842|2018-06-01 00:46:07.467842
NCT00943761|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2014-09-26||2017-03-03|2009-07-21|2009-07-22|Estimate|2014-09-26|2014-09-29|Estimate||||2017-03-03|2017-03-31|Actual|October 2009||2009-10-31|March 2017|2017-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)|A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials|Completed||Phase 2|45|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:46:07.558924|2018-06-01 00:46:07.558924
NCT00943748|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-08-31|2009-07-21|2009-07-22|Estimate|||||||2012-08-31|2012-09-03|Estimate|October 2009||2009-10-31|July 2009|2009-07-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|FAIR-PARK-I||Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease|Efficacy and Safety of the Iron Chelator Deferiprone on Iron Overload in the Brain in Parkinson's Disease|Completed||Phase 2/Phase 3|40|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-06-01 00:46:07.898978|2018-06-01 00:46:07.898978
NCT00943735|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2011-11-16||2012-02-10|2009-07-21|2009-07-22|Estimate|2012-02-10|2012-03-15|Estimate||||2012-02-10|2012-03-15|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||"This Is An Open-Label Study To Evaluate Fesoterodine Plus Your Way Patient Support Plan In Patients With Symptoms Of Overactive Bladder"|"A 13-Week, Single-Arm, Open-Label, Multicenter Study To Evaluate Refill Adherence And Satisfaction With Fesoterodine Plus Your Way Patient Support Plan In Patients With Symptoms Of Overactive Bladder."|Completed|||774|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:46:08.000697|2018-06-01 00:46:08.000697
NCT00943722|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2014-12-12||2017-10-13|2009-07-21|2009-07-22|Estimate|2015-01-12|2015-01-13|Estimate||||2017-10-13|2017-10-16|Actual|August 27, 2009|Actual|2009-08-27|October 2017|2017-10-31|December 3, 2020|Anticipated|2020-12-03|April 30, 2011|Actual|2011-04-30||Interventional|||A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)|A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)|Active, not recruiting||Phase 3|3074|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 00:46:08.57418|2018-06-01 00:46:08.57418
NCT00943709|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2013-08-29|2009-07-21|2009-07-22|Estimate|||||||2013-08-29|2013-08-30|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia|Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia|Withdrawn||Phase 3|0|Actual|Rutgers, The State University of New Jersey||2||lack of accrual|f||||t||||||||||2018-06-01 00:46:09.553028|2018-06-01 00:46:09.553028
NCT00943670|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|2013-03-12||2013-05-23|2009-07-20|2009-07-22|Estimate|2013-03-12|2013-05-01|Estimate||||2013-05-23|2013-05-27|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression|A Phase II, Open-Label Study to Evaluate Corrected QT Interval Effects of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and to Evaluate the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression While Receiving T-DM1 Alone|Completed||Phase 2|51|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 00:46:10.01352|2018-06-01 00:46:10.01352
NCT00943657|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-10-07|2009-07-21|2009-07-22|Estimate|||||||2015-10-07|2015-10-09|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Yearly Strain Variation Study, 2009/2010|An Open-Label Phase 3 Study to Assess the Immunogenicity and Safety of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult and Elderly Population|Completed||Phase 3|110|Anticipated|Ology Bioservices|||||f||||f||||||||||2018-06-01 00:46:10.894483|2018-06-01 00:46:10.894483
NCT00943644|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2011-12-14|2009-07-21|2009-07-22|Estimate|||||||2011-12-14|2011-12-16|Estimate|August 2005||2005-08-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Pre-biopsy With Dynamic Acquisitions|Determination of Sensitivity of a Dual-Headed Small Field of View Gamma Camera for the Detection of Small Breast Lesions|Completed|||185|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 00:46:10.965726|2018-06-01 00:46:10.965726
NCT00943631|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2011-03-17||2012-10-25|2009-07-21|2009-07-22|Estimate|2011-03-17|2011-04-13|Estimate||||2012-10-25|2012-10-31|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine Administered at Two Dose Levels|Completed||Phase 2|406|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 00:46:11.098764|2018-06-01 00:46:11.098764
NCT00943618|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2018-04-12|2009-07-20|2009-07-22|Estimate|||||||2018-04-12|2018-04-13|Actual|May 2010|Actual|2010-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Combining Varenicline and Bupropion for Smoking Cessation|Effectiveness of Varenicline vs. Varenicline Plus Bupropion or Placebo for Smoking Cessation|Active, not recruiting||Phase 3|385|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-06-01 00:46:11.803058|2018-06-01 00:46:11.803058
NCT00943605|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2012-11-29||2013-01-03|2009-07-21|2009-07-22|Estimate|2012-11-29|2013-01-03|Estimate||||2013-01-03|2013-01-08|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|PRECISE||PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Mastectomy|A Prospective, Randomized, Controlled Superiority Study to Evaluate Use of the PEAK PlasmaBlade™ 4.0 in Mastectomy|Terminated||N/A|60|Actual|Medtronic Surgical Technologies|Upon Medtronic's acquisition of PEAK surgical, a study integrity audit was undertaken. Results of the audit showed that patient's rights and safety were maintained, but the source data, including baseline demographics, were unverifiable.|2||Termination due to acquisition of PEAK Surgical by Medtronic|f||||f||||||||||2018-06-01 00:46:11.91958|2018-06-01 00:46:11.91958
NCT00943592|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2013-09-17||2014-01-09|2009-07-21|2009-07-22|Estimate|2014-01-09|2014-02-27|Estimate||||2014-01-09|2014-02-27|Estimate|March 2006||2006-03-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|April 2011|Actual|2011-04-30||Interventional|||Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies|Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies|Completed||Phase 1/Phase 2|82|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 00:46:12.150445|2018-06-01 00:46:12.150445
NCT00943579|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2013-01-16||2018-04-30|2009-07-20|2009-07-22|Estimate|2013-07-02|2013-07-04|Estimate||||2018-04-30|2018-05-02|Actual|August 2009||2009-08-31|April 2018|2018-04-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Open-Label Extension Study of Kuvan for Autism|Kuvan® (Sapropterin) as a Treatment for Autistic Disorder: An Open Label Extension Protocol|Completed||Phase 2/Phase 3|41|Actual|The Children's Health Council||1|||f||||f||||||||||2018-06-01 00:46:12.387331|2018-06-01 00:46:12.387331
NCT00943566|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-09-14|2009-07-21|2009-07-22|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|||A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer|A Multicenter, Open-label, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Sufentanil Transdermal System (TDS) With Sustained-Release Morphine Sulfate in Patients With Chronic Pain Due to Cancer|Withdrawn||Phase 2|0|Actual|Labtec GmbH||2||funding for project discontinued|f||||f||||||||||2018-06-01 00:46:12.650919|2018-06-01 00:46:12.650919
NCT00943553|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-04-10|2009-07-21|2009-07-22|Estimate|||||||2015-04-10|2015-04-13|Estimate|June 2010||2010-06-30|April 2015|2015-04-30||||August 2011|Actual|2011-08-31||Interventional|||A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects|A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects.|Withdrawn||Phase 2|0|Actual|Eisai Inc.||2||Terminated by Sponsor|f||||f||||||||||2018-06-01 00:46:12.703784|2018-06-01 00:46:12.703784
NCT00943540|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2011-01-07|2009-07-21|2009-07-22|Estimate|||||||2011-01-07|2011-01-10|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|PRADA||Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients|Pharmacokinetic and Safety Pilotstudy of RAltegravir and Atazanavir in a Once DAily Dose Regimen in HIV-1 Infected Patients (PRADA)|Completed||Phase 2|20|Anticipated|Radboud University||1|||f||||f||||||||||2018-06-01 00:46:12.769505|2018-06-01 00:46:12.769505
NCT00943527|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-01-23|2009-07-21|2009-07-22|Estimate|||||||2012-01-23|2012-01-25|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Observational|||Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast|Molecular Breast Imaging: Effect of Menstrual Cycle, Hormone Therapy, and Tamoxifen on Tc-99m Sestamibi Uptake in the Breast.|Completed|||110|Actual|Mayo Clinic|||3||f||||f||||||||||2018-06-01 00:46:12.833169|2018-06-01 00:46:12.833169
NCT00943514|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2018-05-22|2009-07-21|2009-07-22|Estimate|||||||2018-05-22|2018-05-23|Actual|July 20, 2009||2009-07-20|May 15, 2018|2018-05-15||||||||Observational|||Natural History of Bronchiectasis|Natural History of Bronchiectasis & Bronchiectasis Patient Registry|Recruiting|||900|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:46:12.908739|2018-06-01 00:46:12.908739
NCT00943501|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2017-01-25|2009-07-21|2009-07-22|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2009||2009-11-30|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes|Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes|Completed||Phase 1|21|Actual|Novo Nordisk A/S||4|||f||||t||||||||||2018-06-01 00:46:12.973132|2018-06-01 00:46:12.973132
NCT00943488|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2011-03-10||2012-10-25|2009-07-21|2009-07-22|Estimate|2011-03-10|2011-04-11|Estimate||||2012-10-25|2012-10-31|Estimate|August 2009||2009-08-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations|A Phase II Study in Healthy Adult and Elderly Populations to Assess the Safety and Immunogenicity of an Unadjuvanted CSL H1N1 Influenza Vaccine Administered at Two Dose Levels|Completed||Phase 2|408|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 00:46:13.089924|2018-06-01 00:46:13.089924
NCT00943475|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-07-21|2009-07-21|2009-07-22|Estimate|||||||2009-07-21|2009-07-22|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Assessment of Hemodynamic Response in Surgery of Circumcision in Children|Assessment of Hemodynamic Response and Pos-operatory Pain in Surgery of Circumcision in Children|Completed||Phase 4|40|Actual|Federal University of Juiz de Fora||1|||f||||t||||||||||2018-06-01 00:46:14.632854|2018-06-01 00:46:14.632854
NCT00943462|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2011-04-26|2009-07-21|2009-07-22|Estimate|||||||2011-04-26|2011-04-27|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM|Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme|Withdrawn|||20|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||1|No eligible patients could be recruited.|f||||f||||||||||2018-06-01 00:46:14.723357|2018-06-01 00:46:14.723357
NCT00943449|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2014-01-15|2009-07-21|2009-07-22|Estimate|||||||2014-01-15|2014-01-16|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|June 2012|Actual|2012-06-30||Interventional|Shelter||4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma|A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment|Completed||Phase 2|57|Actual|4SC AG||2|||f||||||||||||||2018-06-01 00:46:14.789746|2018-06-01 00:46:14.789746
NCT00943436|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2010-07-02||2011-06-13|2009-07-21|2009-07-22|Estimate|2011-06-13|2011-07-13|Estimate||||2011-06-13|2011-07-13|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Effects of Exercise on Dietary Intake|The Effects of Exercise on Energy Balance and Macronutrient Intake in College-aged Males|Completed||N/A|20|Actual|University of Tennessee||2|||f||||f||||||||||2018-06-01 00:46:14.886805|2018-06-01 00:46:14.886805
NCT00943423|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2018-05-01|2009-07-21|2009-07-22|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2003||2003-07-31|May 2018|2018-05-31|December 2030|Anticipated|2030-12-31|July 2014|Actual|2014-07-31||Interventional|RAPID||PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma|A Randomised Phase III Trial to Determine the Role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease|Active, not recruiting||Phase 3|602|Actual|University College, London||2|||f||||t||||||||||2018-06-01 00:46:15.266192|2018-06-01 00:46:15.266192
NCT00943410|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2012-08-14|2009-07-21|2009-07-22|Estimate|||||||2012-08-14|2012-08-15|Estimate|March 2000||2000-03-31|August 2012|2012-08-31|July 2009|Actual|2009-07-31|January 2006|Actual|2006-01-31||Interventional|||Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer|Phase II Trial of Herceptin Concurrent With External Beam Radiation Following Neoadjuvant Chemotherapy for the Treatment of HER2 Over-Expressing Breast Cancer|Completed||Phase 2|19|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 00:46:15.351871|2018-06-01 00:46:15.351871
NCT00943397|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2009-07-27||2015-07-01|2009-07-21|2009-07-22|Estimate|2010-05-18|2010-06-17|Estimate||||2015-07-01|2015-07-23|Estimate|April 2001||2001-04-30|July 2015|2015-07-31|November 2001|Actual|2001-11-30|October 2001|Actual|2001-10-31||Interventional|||Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)|A Multicenter, Open-Label, Controlled, Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma|Completed||Phase 3|190|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:46:15.45114|2018-06-01 00:46:15.45114
NCT00943384|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2014-10-21||2014-11-18|2009-07-21|2009-07-22|Estimate|2014-11-18|2014-11-26|Estimate||||2014-11-18|2014-11-26|Estimate|July 2009||2009-07-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Number of subjects treated per protocol|Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate|Prospective, Multi-Center Clinical Outcomes Study Evaluating the chronOS Strip Combined With Bone Marrow Aspirate Plus Local Bone for Posterolateral Lumbar Interbody Fusion or Lumbosacral Interbody Fusion|Completed||N/A|104|Actual|Synthes USA HQ, Inc.|Limitations included lack of control arm, no hypothesis for primary endpoint, & qualitative sample size estimate. chronOS Strip was used according to its FDA-cleared labeling; other usage was outside the study scope and was not evaluated clinically.|1|||f||||f||||||||||2018-06-01 00:46:15.76552|2018-06-01 00:46:15.76552
NCT00943371|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2015-08-26|2009-07-21|2009-07-22|Estimate|||||||2015-08-26|2015-08-27|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|May 2009|Actual|2009-05-31|September 2007|Actual|2007-09-30||Interventional|||A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)|A Double-Blind, Randomized, Placebo-Controlled, Single and Divided Rising-Dose, Sequential Panel Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK6349 in Subjects With Type 2 Diabetes|Terminated||Phase 1|28|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:46:16.049598|2018-06-01 00:46:16.049598
NCT00943358|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-08-07|2009-07-21|2009-07-22|Estimate|||||||2012-08-07|2012-08-08|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults|Safety and Immunogenicity of Cell-culture Non-adjuvanted and MF59-adjuvanted Influenza H1N1 Vaccines in Healthy Adults|Completed||Phase 1|175|Actual|University Hospitals, Leicester||2|||f||||t||||||||||2018-06-01 00:46:16.110103|2018-06-01 00:46:16.110103
NCT00943345|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2011-11-07|2009-07-21|2009-07-22|Estimate|||||||2011-11-07|2011-11-08|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|Permeability||Validation of New Tests for Gastrointestinal (GI) Permeability|Dubbelblind Crossover Study for Validation of New Tests for Gastrointestinal (GI) Permeability|Unknown status|Enrolling by invitation|Early Phase 1|34|Anticipated|Maastricht University Medical Center||4|||f||||t||||||||||2018-06-01 00:46:16.175719|2018-06-01 00:46:16.175719
NCT00943319|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2018-01-30|2009-07-21|2009-07-22|Estimate|||||||2018-01-30|2018-02-01|Actual|March 2012||2012-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies|A Phase I-II Study of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies|Active, not recruiting||Phase 1/Phase 2|51|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 00:46:16.431826|2018-06-01 00:46:16.431826
NCT00943306|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2016-02-29||2018-04-06|2009-07-21|2009-07-22|Estimate|2018-04-06|2018-05-10|Estimate||||2018-04-06|2018-05-10|Estimate|October 29, 2009|Actual|2009-10-29|April 2018|2018-04-30|December 1, 2014|Actual|2014-12-01|September 17, 2012|Actual|2012-09-17||Interventional||Baseline from initiation of treatment in Study 733-005/UP1002 (Safety Population)|Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia|A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia|Completed||Phase 3|19|Actual|Aegerion Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:46:16.584612|2018-06-01 00:46:16.584612
NCT00943293|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2014-03-14|2009-07-21|2009-07-22|Estimate|||||||2014-03-14|2014-03-17|Estimate|May 2003||2003-05-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies|A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies|Terminated||Phase 1|1|Actual|University of Chicago||1||Poor accrual; did not enter phase 2|f||||t||||||||||2018-06-01 00:46:17.445925|2018-06-01 00:46:17.445925
NCT00943280|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-01-04|2009-07-20|2009-07-22|Estimate|||||||2012-01-04|2012-01-06|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Barrett's Esophagus in Olmsted County|Population Based Screening for Barrett's Esophagus in Olmsted County : A Pilot Study|Completed|||60|Actual|Mayo Clinic|||3||f||||f||||||Samples With DNA|"~     Gastric, GE junction and esophagus tissue samples collected.~   "|||2018-06-01 00:46:17.512859|2018-06-01 00:46:17.512859
NCT00943267|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2011-03-15|2009-07-21|2009-07-22|Estimate|||||||2011-03-15|2011-03-16|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Interventional|||Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)|Effect of Intrapulmonary Administration of Recombinant Human Activated Protein C on Local Coagulation and Inflammation After Bronchial Instillation of Lipopolysaccharide in Humans|Completed||N/A|52|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-06-01 00:46:17.571043|2018-06-01 00:46:17.571043
NCT00943254|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2010-10-13|2009-07-20|2009-07-22|Estimate|||||||2010-10-13|2010-10-15|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Metabolic Syndrome Diagnosis and Education Trial|Metabolic Syndrome: Impact of Receiving the Diagnosis and Education Intervention on Cardiovascular Risk Factor Modification and Willingness to Change|Completed||N/A|74|Actual|Mayo Clinic||3|||f||||||||||||||2018-06-01 00:46:17.666581|2018-06-01 00:46:17.666581
NCT00943241|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2013-02-12|2009-07-20|2009-07-22|Estimate|||||||2013-02-12|2013-02-13|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Screening in Myocardial Perfusion Patients|Screening for Breast Cancer in Patients Undergoing Myocardial Perfusion Imaging|Completed|||322|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 00:46:17.733427|2018-06-01 00:46:17.733427
NCT00943228|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-08-08|2009-07-21|2009-07-22|Estimate|||||||2012-08-08|2012-08-09|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation|Intensified Dosing of Cellcept in Kidney Transplantation Trial|Completed||Phase 4|40|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-06-01 00:46:17.788119|2018-06-01 00:46:17.788119
NCT00943215|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2016-01-13|2009-07-21|2009-07-22|Estimate|||||||2016-01-13|2016-01-14|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|CALERIE2-FU||How Participants Behave and Respond on Their Own After Completing a 2-year Intervention of Calorie Restriction|The Proposed Study Entails a Follow-up of All the Completers for 2 Years With Visits Timed 3, 6, 12 and 24 Months After Completion of the 2-year CALERIE II Intervention.|Completed|||42|Actual|Pennington Biomedical Research Center|||||f||||f||||||||||2018-06-01 00:46:17.854692|2018-06-01 00:46:17.854692
NCT00943202|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2011-04-28||2013-04-11|2009-07-21|2009-07-22|Estimate|2011-04-28|2011-05-26|Estimate||||2013-04-11|2013-04-22|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Sanofi Pasteur, TIV + H1N1, Pediatric Population|Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Previously Primed Infants and Toddlers (Greater Than or Equal to 6 - <36 Months), Children (Greater Than or Equal to 36 Months - 9 Years), and Adolescents (10 - 17 Years)|Completed||Phase 2|531|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Due to difficulties identifying children in the youngest age stratum who were previously primed, enrollment in this stratum was closed prior to meeting the planned number of participants.|4|||f||||||||||||||2018-06-01 00:46:17.981579|2018-06-01 00:46:17.981579
NCT00943189|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-11-19|2009-07-21|2009-07-22|Estimate|||||||2009-11-19|2009-11-20|Estimate|June 2008||2008-06-30|November 2009|2009-11-30||||||||Observational|||Fetal Anomalies Scan at the Time of Nuchal Translucency Study|Fetal Anomalies Scan at the Time of Nuchal Translucency Study|Unknown status|Recruiting||600|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 00:46:20.028132|2018-06-01 00:46:20.028132
NCT00943176|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2012-01-13|2009-07-20|2009-07-22|Estimate|||||||2012-01-13|2012-01-18|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PBC||Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC)|Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis|Completed||Phase 1|40|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:46:20.085242|2018-06-01 00:46:20.085242
NCT00943163|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|||2009-07-21|2009-07-21|2009-07-22|Estimate|||||||2009-07-21|2009-07-22|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Observational|||Evaluation of Position-induced Cyclorotation Between Wavefront Measurement and Refractive Surgery by the Iris Registration Method|Evaluation of Position-induced Cyclorotation Between Wavefront Measurement and Refractive Surgery by the Iris Registration Method|Completed|||93|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 00:46:20.158754|2018-06-01 00:46:20.158754
NCT00943150|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2012-11-29||2012-11-29|2009-07-21|2009-07-22|Estimate|2012-11-29|2013-01-01|Estimate||||2012-11-29|2013-01-01|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PRECISE||PEAK PlasmaBlade™ vs. Traditional Electrosurgery in Abdominoplasty|A Prospective, Randomized, Controlled Two-arm Superiority Study to Evaluate Use of the PEAK PlasmaBlade™ 4.0 in Abdominoplasty|Completed||N/A|20|Actual|Medtronic Surgical Technologies||2|||f||||f||||||||||2018-06-01 00:46:20.225992|2018-06-01 00:46:20.225992
NCT00943137|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2015-06-17|2009-07-21|2009-07-22|Estimate|||||||2015-06-17|2015-06-19|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer|The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer|Unknown status|Active, not recruiting|Phase 2|55|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-06-01 00:46:20.659171|2018-06-01 00:46:20.659171
NCT00943124|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2009-10-09||2015-05-22|2009-07-21|2009-07-22|Estimate|2009-12-03|2010-01-06|Estimate||||2015-05-22|2015-06-19|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||MK0524B Bioequivalence Study (0524B-070)|An Open-Label, Definitive Bioequivalence Study to Compare the Pharmacokinetics of the Simvastatin, Nicotinic Acid, and MK0524 (Laropiprant) Components of a Formulation of MK0524B With That of Zocor™ and MK0524A Tablets|Completed||Phase 1|220|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:46:20.741693|2018-06-01 00:46:20.741693
NCT00943111|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2014-08-22|2014-03-07|2016-10-11|2009-07-21|2009-07-22|Estimate|2014-08-22|2014-09-04|Estimate|2014-03-07|2014-04-04|Estimate|2016-10-11|2016-11-25|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|November 2012|Actual|2012-11-30||Interventional|ENCORE|Full analysis set (FAS) for PAP: included all participants who signed informed consent and received at least 1 dose of study drug (Imiglucerase or eliglustat).|A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)|A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)|Completed||Phase 3|160|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:46:21.164315|2018-06-01 00:46:21.164315
NCT00943098|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-21|2012-11-16||2012-12-17|2009-07-21|2009-07-22|Estimate|2012-12-17|2013-01-28|Estimate||||2012-12-17|2013-01-28|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of the Efficacy and Safety of Diclofenac HPBCD 75mg/ml in Treatment of Pain Following Dental Surgery|Efficacy and Safety of a Single s.c. Diclofenac HPBCD 75mg/1ml Injection as Compared to a Single i.m. Voltarol® 75mg/3ml, in the Treatment of Acute Moderate-to-severe Post-surgical Pain Following Dental Surgery (Impacted 3rd Molar Removal).|Completed||Phase 3|142|Actual|IBSA Institut Biochimique SA||2|||f||||f||||||||||2018-06-01 00:46:21.865709|2018-06-01 00:46:21.865709
NCT00943085|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2014-03-24|2009-07-20|2009-07-21|Estimate|||||||2014-03-24|2014-03-26|Estimate|April 2007||2007-04-30|March 2014|2014-03-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Early Family-Focused Treatment for Youth at Risk for Bipolar Disorder|Family-Focused Therapy as Early Treatment for Youth at Risk for Bipolar Disorder|Completed||N/A|52|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 00:46:22.221117|2018-06-01 00:46:22.221117
NCT00943072|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2012-10-19|2011-05-09|2013-04-16|2009-07-20|2009-07-21|Estimate|2013-04-16|2013-05-27|Estimate|2011-05-09|2011-05-16|Estimate|2013-04-16|2013-05-27|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|October 2010|Actual|2010-10-31||Interventional|||Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)|A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion|Completed||Phase 3|189|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:46:22.400863|2018-06-01 00:46:22.400863
NCT00943059|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2013-05-13|2009-07-20|2009-07-21|Estimate|||||||2013-05-13|2013-05-14|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ACP||Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function|The Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function|Completed||N/A|31|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:46:23.74486|2018-06-01 00:46:23.74486
NCT00943046|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-02-12|2009-07-20|2009-07-21|Estimate|||||||2010-02-12|2010-02-15|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Master Study for the Investigation of Safety and Efficacy of the SIELLO Pacemaker Leads|Master Study of the SIELLO Pacemaker Leads|Unknown status|Recruiting|Phase 4|160|Anticipated|Biotronik SE & Co. KG|||||f||||||||||||||2018-06-01 00:46:23.837153|2018-06-01 00:46:23.837153
NCT00943033|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-09-19|2009-07-20|2009-07-21|Estimate|||||||2012-09-19|2012-09-21|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MBCT||Study of Mindfulness-Based Cognitive Therapy|Toward Identifying the Mechanisms of Action in Mindfulness-Based Cognitive Therapy|Completed||N/A|48|Actual|Binghamton University||2|||f||||f||||||||||2018-06-01 00:46:23.96409|2018-06-01 00:46:23.96409
NCT00943020|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-11-15|2009-07-20|2009-07-21|Estimate|||||||2009-11-15|2009-11-17|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effects of Glutamine on Gastric Emptying|The Effects of Supplementing Glutamine on the Gastric Emptying Time of a Preoperative Metabolic Conditioning Drink in Healthy Volunteers: a Randomized Crossover Pilot Study|Completed||Phase 4|15|Anticipated|University of Nottingham||3|||f||||f||||||||||2018-06-01 00:46:24.030828|2018-06-01 00:46:24.030828
NCT00943007|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2015-04-09|2009-07-20|2009-07-21|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|RACING||Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors|Randomized Assessment of Conventional Neuronavigation Versus Intraoperative MRI for the Neurosurgical Treatment of Glioblastomas|Completed||N/A|14|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 00:46:24.116591|2018-06-01 00:46:24.116591
NCT00942825|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2017-03-14||2017-04-25|2009-07-20|2009-07-21|Estimate|2017-04-25|2017-05-24|Actual||||2017-04-25|2017-05-24|Actual|April 2009||2009-04-30|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|CBP08-02||Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)|Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|195|Actual|CanBas Co. Ltd.||2|||f||||f|t|f||||||No||2018-06-01 00:46:27.023419|2018-06-01 00:46:27.023419
NCT00942994|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|2011-03-29||2011-05-16|2009-07-20|2009-07-21|Estimate|2011-03-29|2011-04-27|Estimate||||2011-05-16|2011-06-08|Estimate|June 2009||2009-06-30|May 2011|2011-05-31||||March 2010|Actual|2010-03-31||Interventional|ASCENT||Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension|An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren/Amlodipine/HCTZ Compared to Aliskiren/Amlodipine in US Minority Patients With Stage 2 Hypertension|Completed||Phase 4|412|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:46:24.210398|2018-06-01 00:46:24.210398
NCT00942981|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-18|||2018-03-27|2009-07-18|2009-07-21|Estimate|||||||2018-03-27|2018-03-29|Actual|July 17, 2009||2009-07-17|September 29, 2017|2017-09-29||||||||Observational|||Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography|Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography|Recruiting|||330|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:46:24.524557|2018-06-01 00:46:24.524557
NCT00942968|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2017-01-04||2017-01-04|2009-07-20|2009-07-21|Estimate|2017-01-04|2017-02-24|Actual||||2017-01-04|2017-02-24|Actual|June 2009||2009-06-30|January 2017|2017-01-31|June 2013|Actual|2013-06-30|March 2012|Actual|2012-03-31||Interventional||Safety population included all participants who received at least 1 treatment with dalteparin sodium.|Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer|FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism|Completed||Phase 4|338|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:46:24.661055|2018-06-01 00:46:24.661055
NCT00942955|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-07-20|2009-07-20|2009-07-21|Estimate|||||||2009-07-20|2009-07-21|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Point-Of-Care Chemistry Test (POCT) Effect on the Emergency Department (ED)|A Randomized Controlled Multi-center Trial of a Point-Of-Care Chemistry Test for Reduction of Turnaround and Clinical Decision Time in the Emergency Department|Completed|||||Seoul National University Hospital|||2||f||||f||||||||||2018-06-01 00:46:25.674117|2018-06-01 00:46:25.674117
NCT00942942|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-01-31|2009-07-20|2009-07-21|Estimate|||||||2011-01-31|2011-02-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:46:25.729978|2018-06-01 00:46:25.729978
NCT00942929|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-07-20|2009-07-20|2009-07-21|Estimate|||||||2009-07-20|2009-07-21|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|||||Observational|||Lung Function Tests in Adolescents With Anorexia Nervosa|Lung Function Tests in Adolescents With Anorexia Nervosa|Unknown status|Recruiting||15|Anticipated|Bnai Zion Medical Center|||2||f||||t||||||||||2018-06-01 00:46:25.763603|2018-06-01 00:46:25.763603
NCT00942916|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|||2012-08-28|2009-07-20|2009-07-21|Estimate|||||||2012-08-28|2012-08-30|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Serum Inflammatory Marker in Patients With Diagnosis of Nontuberculous Mycobacterial Pulmonary Infection|Serum Inflammatory Marker in Patients With Diagnosis of Nontuberculous Mycobacterial Pulmonary Infection|Completed|||50|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 00:46:25.824479|2018-06-01 00:46:25.824479
NCT00942903|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2010-08-04||2010-10-13|2009-07-20|2009-07-21|Estimate|2010-08-04|2010-08-30|Estimate||||2010-10-13|2010-10-22|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|N08HME||Short-term Clinical Feasibility of the Provox XtraHMEs for Pulmonary Rehabilitation After Total Laryngectomy|Phase 1 Study. Short-term Feasibility of the Next Generation Provox HMEs for Pulmonary Rehabilitation After Total Laryngectomy|Completed||Phase 1|20|Actual|Atos Medical AB||1|||f||||f||||||||||2018-06-01 00:46:25.880913|2018-06-01 00:46:25.880913
NCT00942890|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|2016-10-11||2018-03-14|2009-07-20|2009-07-21|Estimate|2018-03-14|2018-04-10|Actual||||2018-03-14|2018-04-10|Actual|April 2009||2009-04-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Strength, Pain and Function in Operation Iraqi Freedom/Operation Enduring Freedom Amputees: A Nurse-Managed Program|Strength, Pain and Function in Operation Iraqi Freedom/Operation Enduring Freedom Amputees: A Nurse-Managed Program|Completed||N/A|44|Actual|University of Tennessee|The limitations of the the study was that it was not powered to detect a small or moderate difference between the two treatment groups. The sample was small and limited to military service members.|2|||f||||t||||||||No||2018-06-01 00:46:26.027319|2018-06-01 00:46:26.027319
NCT00942877|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-18|||2018-05-22|2009-07-18|2009-07-21|Estimate|||||||2018-05-22|2018-05-23|Actual|July 18, 2009||2009-07-18|May 17, 2018|2018-05-17|July 31, 2019|Anticipated|2019-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma|Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma|Active, not recruiting||Phase 2|53|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 00:46:26.580386|2018-06-01 00:46:26.580386
NCT00942864|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2016-09-27|2009-07-20|2009-07-21|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)|An Open-label, Nonrandomized, Phase IIIb, Single Dose Study to Evaluated the Changes in Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) After Intravitreal Injection of Lucentis® in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)|Completed||Phase 3|40|Actual|Novartis|||||f||||||||||||||2018-06-01 00:46:26.65508|2018-06-01 00:46:26.65508
NCT00942851|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-18|2012-05-29||2012-08-03|2009-07-18|2009-07-21|Estimate|2012-08-03|2012-09-06|Estimate||||2012-08-03|2012-09-06|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm|A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm|Completed||Phase 1/Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 00:46:26.715792|2018-06-01 00:46:26.715792
NCT00942838|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2013-07-23|2009-07-20|2009-07-21|Estimate|||||||2013-07-23|2013-07-24|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|WAR||Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity|Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity: A Phase I Trial|Withdrawn||Phase 1|0|Actual|University of Utah||||PI decision due to under accrual.|f||||t||||||||||2018-06-01 00:46:26.936478|2018-06-01 00:46:26.936478
NCT00942812|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2011-08-09|2009-07-20|2009-07-21|Estimate|||||||2011-08-09|2011-08-10|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack|A Community Based Intervention and Evaluation of the Impact of Social Marketing of a Diarrhea Management Pack(Comprising of Low Osmolality ORS, Zinc Tablets, Water Purification Tablets and Pictorial Chart) on Childhood Diarrhea.|Completed||Phase 4|7200|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 00:46:27.551831|2018-06-01 00:46:27.551831
NCT00942799|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2014-03-17|2009-07-17|2009-07-21|Estimate|||||||2014-03-17|2014-03-19|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors|A Phase I, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|87|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:46:27.627032|2018-06-01 00:46:27.627032
NCT00942786|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-18|2015-01-26||2015-06-09|2009-07-20|2009-07-21|Estimate|2015-06-09|2015-06-29|Estimate||||2015-06-09|2015-06-29|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|||Natriuretic Peptides - Predictors of In-hospital and Long-term Major Adverse Cardiac Events After Emergency Surgery?|Prospective Study to Evaluate the Predictive Value of Brain Natriuretic Peptides for Adverse Long-term Cardiac Outcome|Completed|||297|Actual|Medical University of Graz|||1||f||||t||||||Samples Without DNA|"~     one vial of serum per patient is retained~   "|||2018-06-01 00:46:27.708746|2018-06-01 00:46:27.708746
NCT00942773|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-03-02|2009-07-20|2009-07-21|Estimate|||||||2010-03-02|2010-03-04|Estimate|December 2008||2008-12-31|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Influence of CYP2C19 Genotype on the Pharmacokinetics (PK) of Voriconazole|Clinical Trials to Evaluate the Influence of CYP2C19 Genotype and Drug-drug Interactions on the Pharmacokinetics of Voriconazole in Healthy Korean Male Volunteers (Part A)|Completed||Phase 1|18|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-06-01 00:46:27.852867|2018-06-01 00:46:27.852867
NCT00942760|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2013-05-07|2009-07-20|2009-07-21|Estimate|||||||2013-05-07|2013-05-08|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Observational|||Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas|DMS-0901: Multimodal Magnetic Resonance Protocol to Distinguish Tumor Recurrence From Treatment-Related Necrosis in Patients With High Grade Gliomas|Completed|||12|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||||||2018-06-01 00:46:27.918712|2018-06-01 00:46:27.918712
NCT00942747|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2013-04-15|2009-07-20|2009-07-21|Estimate|||||||2013-04-15|2013-04-17|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma|Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma|Unknown status|Recruiting|Phase 2|37|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 00:46:27.984767|2018-06-01 00:46:27.984767
NCT00942734|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|2015-11-24||2016-01-05|2009-07-20|2009-07-21|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma|Phase II Clinical Trial of the Combination of RAD001 and Erlotinib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|49|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:46:28.100838|2018-06-01 00:46:28.100838
NCT00942721|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2013-11-21|2009-07-20|2009-07-21|Estimate|||||||2013-11-21|2013-11-25|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Cognitive Behavioral Therapy Delivered Over the Internet for Women With Postpartum Depression|Web-Based Cognitive Behavioral Intervention for Women With Postpartum Depression|Completed||Phase 1|53|Actual|Oregon Research Institute||1|||f||||t||||||||||2018-06-01 00:46:28.254882|2018-06-01 00:46:28.254882
NCT00942708|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|||2015-06-10|2009-07-20|2009-07-21|Estimate|||||||2015-06-10|2015-06-12|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension|Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension|Completed||Phase 2|6|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 00:46:28.320639|2018-06-01 00:46:28.320639
NCT00942695|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-02-08|2009-07-20|2009-07-21|Estimate|||||||2011-02-08|2011-02-09|Estimate|October 2009||2009-10-31|February 2011|2011-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Energy Value of Macronutrients From Pistachio Nuts and Mechanisms of Nutrient Action|Energy Value of Macronutrients From Pistachio Nuts and Mechanisms of Nutrient Action|Completed||N/A|15|Anticipated|USDA Beltsville Human Nutrition Research Center||3|||f||||t||||||||||2018-06-01 00:46:28.389528|2018-06-01 00:46:28.389528
NCT00942682|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2014-04-27|2009-07-20|2009-07-21|Estimate|||||||2014-04-27|2014-04-29|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors|Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors|Completed||Phase 1|21|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:46:28.455341|2018-06-01 00:46:28.455341
NCT00942669|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-11|||2012-06-06|2009-07-19|2009-07-21|Estimate|||||||2012-06-06|2012-06-07|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Comparing the Sleep Strip OTC™ Accuracy in Screening for Sleep Apnea Syndrome Against the Reference Method, an In-lab Full Night Polysomnographic (PSG)|A Prospective, Single Center, Open, Equivalence, Two Phase Study Comparing the Sleep Strip OTC™ Accuracy in Screening for Sleep Apnea Syndrome Against the Reference Method, an In-lab Full Night Polysomnographic (PSG) Study.|Completed||Phase 1/Phase 2|80|Actual|Scientific Laboratory Products, Ltd.||1|||f||||t||||||||||2018-06-01 00:46:28.522277|2018-06-01 00:46:28.522277
NCT00942656|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-02-08|2009-07-17|2009-07-21|Estimate|||||||2011-02-08|2011-02-09|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effect of Trans Fatty Acids From Ruminant Sources on Risk Factors for Cardiovascular Disease|Effect of Trans Fatty Acids From Ruminant Sources on Risk Factors for Cardiovascular Disease|Completed||N/A|120|Anticipated|USDA Beltsville Human Nutrition Research Center|||||f||||t||||||||||2018-06-01 00:46:28.718235|2018-06-01 00:46:28.718235
NCT00942643|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2012-07-03|2009-07-20|2009-07-21|Estimate|||||||2012-07-03|2012-07-04|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Endothelial Damage and Atherosclerosis in Obstructive Sleep Apnea|Endothelial Damage and Atherosclerosis in Obstructive Sleep Apnea: the Role of Advanced Glycation End-products|Terminated||N/A|10|Actual|The University of Hong Kong||2||Poor patient recruitment|f||||t||||||||||2018-06-01 00:46:28.779048|2018-06-01 00:46:28.779048
NCT00942630|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2011-10-07|2009-07-20|2009-07-21|Estimate|||||||2011-10-07|2011-10-10|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Observational|||Value of Percutaneous Cholangioscopy After Placement of a Percutaneous Transhepatic Biliary Drainage|Percutaneous Cholangioscopy After Placement of a Percutaneous Transhepatic Biliary Drainage (PTBD) - a Prospective Study on Endoscopic Findings and Clinical Impact|Completed|||40|Anticipated|Hannover Medical School|||||f||||f||||||||||2018-06-01 00:46:28.845233|2018-06-01 00:46:28.845233
NCT00942617|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2015-12-04|2009-07-20|2009-07-21|Estimate|||||||2015-12-04|2015-12-07|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Measurement of Platelet Dense Granule Release in Healthy Volunteers|Measurement of Platelet Dense Granule Release in Healthy Volunteers|Withdrawn||N/A|0|Actual|Vanderbilt University||1||funding issue|f||||f||||||||||2018-06-01 00:46:28.890589|2018-06-01 00:46:28.890589
NCT00942604|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|2012-02-21|2010-09-22|2015-02-18|2009-07-19|2009-07-21|Estimate|2012-02-21|2012-03-19|Estimate|2010-09-22|2010-09-27|Estimate|2015-02-18|2015-03-06|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05%, In Patients With Actinic Keratoses on Non-head Locations (REGION-Ib)|Completed||Phase 3|203|Actual|Peplin||2|||f||||f||||||||||2018-06-01 00:46:28.963881|2018-06-01 00:46:28.963881
NCT00942591|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-07-20|2009-07-20|2009-07-21|Estimate|||||||2009-07-20|2009-07-21|Estimate|May 2005||2005-05-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|SWABIMS||Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b|Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.|Completed||Phase 2|77|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 00:46:29.426127|2018-06-01 00:46:29.426127
NCT00942578|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-18|||2017-08-01|2009-07-18|2009-07-21|Estimate|||||||2017-08-01|2017-08-02|Actual|July 16, 2009||2009-07-16|July 31, 2017|2017-07-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer|A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer|Completed||Phase 2|63|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 00:46:29.509341|2018-06-01 00:46:29.509341
NCT00942565|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2013-01-31|2009-07-20|2009-07-21|Estimate|||||||2013-01-31|2013-02-01|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|October 2008|Actual|2008-10-31||Interventional|||Adjuvant Analgesic Effects of Low Dose Tramadol/Acetaminophen Combination After Open Gynaecological Surgery||Completed||Phase 4|60|Actual|The University of Hong Kong||2|||f||||||||||||||2018-06-01 00:46:29.593707|2018-06-01 00:46:29.593707
NCT00942539|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-18|||2014-05-05|2009-07-20|2009-07-21|Estimate|||||||2014-05-05|2014-05-06|Estimate|July 2009||2009-07-31|July 2010|2010-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Midazolam Sedation for Neonatal Lumbar Puncture|Midazolam Sedation for Neonatal Lumbar Puncture in the Emergency Department: A Randomized Controlled Trial|Terminated||Phase 2|12|Actual|Rambam Health Care Campus||1|||f||||f||||||||||2018-06-01 00:46:29.661109|2018-06-01 00:46:29.661109
NCT00942526|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-07-20|2009-07-20|2009-07-21|Estimate|||||||2009-07-20|2009-07-21|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Oral Anti-Infective Agent for Esophageal Anastomotic Leakage|The Correlation of Oral Anti-Infective Agent With Anastomotic Leakage in Reconstruction Surgery for Esophageal Cancer|Unknown status|Recruiting|Phase 2|120|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-06-01 00:46:29.726711|2018-06-01 00:46:29.726711
NCT00942513|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-02-08|2009-07-17|2009-07-21|Estimate|||||||2011-02-08|2011-02-09|Estimate||||February 2011|2011-02-28||||||||Interventional|||Effect of Lactose, Fructose, Sucrose, Whey Protein, and Soy Protein on Substrate Absorption and Oxidation: a Pilot Study|Effect of Lactose, Fructose, Sucrose, Whey Protein, and Soy Protein on Substrate Absorption and Oxidation: a Pilot Study|Completed||N/A|9|Actual|USDA Beltsville Human Nutrition Research Center|||||f||||t||||||||||2018-06-01 00:46:30.036818|2018-06-01 00:46:30.036818
NCT00942500|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-10-31|2009-07-20|2009-07-21|Estimate|||||||2012-10-31|2012-11-01|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|POST||Effects of Postconditioning On Myocardial Reperfusion|Effects of Postconditioning On Myocardial Reperfusion in Patients With ST-segment Elevation Myocardial Infarction|Completed||N/A|700|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:46:30.101568|2018-06-01 00:46:30.101568
NCT00942487|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-19|||2009-07-20|2009-07-20|2009-07-21|Estimate|||||||2009-07-20|2009-07-21|Estimate|April 2005||2005-04-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|ENESYS||Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol|Effects of NEbivolol on Subclinical Left Ventricular dYSfunction. A Comparative Study Against Metoprolol. The ENESYS Study. A Phase 3, Randomised, Parallel, Active-controlled, Open Label Study|Completed||Phase 3|60|Actual|Berlin-Chemie Menarini||2|||f||||f||||||||||2018-06-01 00:46:30.172407|2018-06-01 00:46:30.172407
NCT00942474|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2014-02-18|2009-07-20|2009-07-21|Estimate|||||||2014-02-18|2014-02-19|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Nerve Access Tool Study|A Prospective, Non Randomized, Single-center, Non-blinded Feasibility Study Examining the Use of a Nerve Access Tool|Withdrawn||N/A|0|Actual|MedtronicNeuro||1||Medtronic made a business decision to discontinue the study and withdraw the IDE.|f||||f||||||||||2018-06-01 00:46:30.242736|2018-06-01 00:46:30.242736
NCT00942461|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-20|||2009-07-20|2009-07-20|2009-07-21|Estimate|||||||2009-07-20|2009-07-21|Estimate|October 2008||2008-10-31|July 2009|2009-07-31||||June 2009|Actual|2009-06-30||Interventional|||Inflammatory Response in Laparoscopic and Open Colectomy|Contribution to the Study of Inflammatory Response in Laparoscopic vs Open Colon Cancer Surgery|Completed||Phase 4|40|Actual|G. Hatzikosta General Hospital||2|||f||||t||||||||||2018-06-01 00:46:30.300096|2018-06-01 00:46:30.300096
NCT00942448|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2012-11-16||2012-12-17|2009-07-20|2009-07-21|Estimate|2012-12-17|2013-01-28|Estimate||||2012-12-17|2013-01-28|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery|Efficacy and Safety Study of Diclofenac HPBCD 25, 50 mg/ml Administered as Single s.c. Dose, in the Treatment of Acute Moderate-to-severe Post-surgical Pain From Dental Surgery (Impacted 3rd Molar Extraction)|Completed||Phase 3|306|Actual|IBSA Institut Biochimique SA|No limitations of the trial have been detected|4|||f||||f||||||||||2018-06-01 00:46:30.397569|2018-06-01 00:46:30.397569
NCT00942435|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2010-06-14|2009-07-16|2009-07-20|Estimate|||||||2010-06-14|2010-06-16|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery|A Randomized, Open Label Parallel Group Mechanical Prophylaxis Controlled Comparison Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery|Completed||Phase 3|156|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:46:31.004474|2018-06-01 00:46:31.004474
NCT00942422|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2015-02-03||2015-03-18|2009-07-17|2009-07-20|Estimate|2015-03-18|2015-03-27|Estimate||||2015-03-18|2015-03-27|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma|The Clinical and Biologic Evaluation of Polyphenon E, an Extract of Green Tea Containing EGCG, in Plasma Cell Dyscrasias - Pilot Study|Terminated||Phase 2|8|Actual|Barbara Ann Karmanos Cancer Institute|Low accrual and early termination limits the conclusions one could draw. Although no pts on this trial met the primary endpoint of a 25% or greater M-protein reduction, the small number of pts enrolled prohibits formal statistical analysis.|1||Low accrual and early termination|f||||t||||||||||2018-06-01 00:46:31.094411|2018-06-01 00:46:31.094411
NCT00942409|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2015-08-24||2015-11-30|2009-07-17|2009-07-20|Estimate|2015-10-19|2015-11-20|Estimate||||2015-11-30|2015-12-30|Estimate|June 2009||2009-06-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2009|Actual|2009-07-31||Interventional|||Study of Repeat Intranodal Injections of Ad-ISF35|A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD154 (Ad-ISF35) in Patients With Non-Hodgkin's Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)|Terminated||Phase 2|5|Actual|University of California, San Diego||1||drug supply was no longer available|f||||t||||||||||2018-06-01 00:46:31.343413|2018-06-01 00:46:31.343413
NCT00942396|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2011-06-07|2009-07-17|2009-07-20|Estimate|||||||2011-06-07|2011-06-09|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography|Study to Compare the Diagnostic Accuracy of Nuance Full-Field Digital Mammography to Screen-Film Mammography|Withdrawn||Phase 3|250|Anticipated|Planmed Oy||1||FDA changed classification of device and no longer requires this type of clinical data|f||||f||||||||||2018-06-01 00:46:31.498959|2018-06-01 00:46:31.498959
NCT00942383|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-08-05|2009-07-17|2009-07-20|Estimate|||||||2011-08-05|2011-08-08|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|September 2013|Anticipated|2013-09-30|September 2011|Anticipated|2011-09-30||Interventional|IOUS||Freehand Ultrasound Elasticity Imaging in Liver Surgery|Application of Novel, High Resolution, and Freehand Ultrasound Elasticity Imaging in Liver Surgery|Unknown status|Recruiting|N/A|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 00:46:31.612745|2018-06-01 00:46:31.612745
NCT00942370|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2016-09-14|2009-07-17|2009-07-20|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|EMG-MMG||Electromyographic (EMG) and Mechanomyographic (MMG) Comparison|Comparison of Electromyographic With Mechanomyographic Signals of Rectus Abdominis|Completed|||16|Actual|University Hospital, Grenoble|||1||f||||t||||||||||2018-06-01 00:46:31.722856|2018-06-01 00:46:31.722856
NCT00942357|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2018-01-09|2009-07-17|2009-07-20|Estimate|||||||2018-01-09|2018-01-10|Actual|June 29, 2009|Actual|2009-06-29|August 2017|2017-08-31||||March 9, 2017|Actual|2017-03-09||Interventional|||Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer|A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma|Active, not recruiting||Phase 3|807|Actual|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 00:46:32.212106|2018-06-01 00:46:32.212106
NCT00942344|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-07-17|2009-07-17|2009-07-20|Estimate|||||||2009-07-17|2009-07-20|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension|An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension.|Completed||Phase 2|320|Actual|Hanmi Pharmaceutical Company Limited|||||f||||f||||||||||2018-06-01 00:46:33.863349|2018-06-01 00:46:33.863349
NCT00942331|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2018-05-24|2009-07-17|2009-07-20|Estimate|||||||2018-05-24|2018-05-25|Actual|July 15, 2009|Actual|2009-07-15|April 2018|2018-04-30||||June 30, 2019|Anticipated|2019-06-30||Interventional|||Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer|A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma|Active, not recruiting||Phase 3|500|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:46:34.267422|2018-06-01 00:46:34.267422
NCT00942318|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-12-10|2009-07-17|2009-07-20|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes|Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes: a One Year, Randomised, Parallel Study|Completed||Phase 4|52|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 00:46:36.417252|2018-06-01 00:46:36.417252
NCT00942305|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2012-01-16|2009-07-17|2009-07-20|Estimate|||||||2012-01-16|2012-01-18|Estimate|October 2009||2009-10-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control Cytomegalovirus (CMV) Infection in R+ Hematopoietic Stem Cell Transplant Recipients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients|Completed||Phase 2|150|Anticipated|Chimerix||2|||f||||t||||||||||2018-06-01 00:46:36.491614|2018-06-01 00:46:36.491614
NCT00942292|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-06-24|2009-07-17|2009-07-20|Estimate|||||||2013-06-24|2013-06-25|Estimate|May 2007||2007-05-31|June 2013|2013-06-30|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||The Effect of Fish Oils on Human Hepatic Colorectal Metastases|Randomised Controlled Trial of the Effects of Fish Oil Emulsion in Total Parenteral Nutrition Upon Tumour Vascularity in Patients With Hepatic Colorectal Metastases|Completed||Phase 2|20|Actual|University Hospitals, Leicester||2|||f||||t||||||||||2018-06-01 00:46:36.584282|2018-06-01 00:46:36.584282
NCT00942266|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2013-12-26||2014-05-22|2009-07-17|2009-07-20|Estimate|2014-05-22|2014-06-23|Estimate||||2014-05-22|2014-06-23|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional||All treated and eligible patients; per protocol|Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment|A Randomized Phase II Study of Two Dose-Levels of Vorinostat in Combination With 5-FU and Leucovorin in Patients With Refractory Metastatic Colorectal Cancer|Completed||Phase 2|58|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 00:46:36.843644|2018-06-01 00:46:36.843644
NCT00942253|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2010-07-02|2009-07-17|2009-07-20|Estimate|||||||2010-07-02|2010-07-05|Estimate|September 2006||2006-09-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|HDRLS||Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)|The Effects of Exercise Training in Combination With Dopamine Agonist to Physical Fitness Parameters and Quality of Life in Dialysis Patients With the Restless Legs Syndrome.|Completed||Phase 2|46|Anticipated|University of Thessaly||2|||f||||f||||||||||2018-06-01 00:46:37.384257|2018-06-01 00:46:37.384257
NCT00942240|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2012-01-09|2009-07-17|2009-07-20|Estimate|||||||2012-01-09|2012-01-10|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects|A Phase I, Double-Masked, Multiple Rising Dose Study of ACU-4429 in Healthy Male and Female Subjects|Completed||Phase 1|40|Actual|Acucela Inc.||2|||f||||t||||||||||2018-06-01 00:46:37.457393|2018-06-01 00:46:37.457393
NCT00942227|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-01-11|2009-07-17|2009-07-20|Estimate|||||||2013-01-11|2013-01-14|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Value of Traction in Treatment of Lumbar Radiculopathy|The Value of Traction in Treatment of Lumbar Radiculopathy.|Completed||Phase 3|120|Actual|Intermountain Health Care, Inc.||2|||f||||f||||||||||2018-06-01 00:46:37.52516|2018-06-01 00:46:37.52516
NCT00942214|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2011-03-29|2009-07-17|2009-07-20|Estimate|||||||2011-03-29|2011-03-30|Estimate|June 2009||2009-06-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|Bionat2||Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment|Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study|Completed||Phase 4|300|Actual|University Hospital, Toulouse|||||f||||f||||||||||2018-06-01 00:46:37.59973|2018-06-01 00:46:37.59973
NCT00942201|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-07-17|2009-07-17|2009-07-20|Estimate|||||||2009-07-17|2009-07-20|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Oral Dexamethasone Doses in Asthma Exacerbation|Comparison of Single Dose Versus Two Doses of Oral Dexamethasone in the Management of Acute Asthma Exacerbations in the Pediatric Emergency Department.|Completed||N/A|125|Actual|Rady Children's Hospital, San Diego||2|||f||||f||||||||||2018-06-01 00:46:37.672812|2018-06-01 00:46:37.672812
NCT00942188|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2017-10-21|2011-04-05|2018-03-16|2009-07-17|2009-07-20|Estimate|2018-02-12|2018-03-13|Actual|2011-04-05|2011-04-13|Estimate|2018-03-16|2018-04-12|Actual|June 2009||2009-06-30|October 2017|2017-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of LY2189102 in Patients With Type 2 Diabetes|Phase 2 Randomized, Double-blind, Placebo Controlled, Parallel Design Study in Patients With Type 2 Diabetes Mellitus Who Are Stable on Diet and Exercise, With or Without Metformin Monotherapy.|Completed||Phase 2|106|Actual|Eli Lilly and Company||4|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 00:46:37.764687|2018-06-01 00:46:37.764687
NCT00942175|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2011-05-31||2012-02-01|2009-07-17|2009-07-20|Estimate|2011-08-03|2011-09-07|Estimate||||2012-02-01|2012-02-03|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.|A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects|Completed||Phase 1|160|Actual|Takeda||5|||f||||f||||||||||2018-06-01 00:46:39.547034|2018-06-01 00:46:39.547034
NCT00942162|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09||2013-04-11|2015-07-30|2009-07-16|2009-07-20|Estimate||||2013-04-11|2013-04-18|Estimate|2015-07-30|2015-08-20|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|June 2012|Actual|2012-06-30||Interventional|PREDICT||A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma|GSK2132231A Antigen-Specific Cancer Immunotherapeutic as First-line Treatment of Patients With Unresectable Metastatic Melanoma|Completed||Phase 2|125|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 00:46:40.368767|2018-06-01 00:46:40.368767
NCT00942149|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2012-10-18||2013-07-01|2009-07-17|2009-07-20|Estimate|2012-11-15|2012-12-12|Estimate||||2013-07-01|2013-07-15|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants|An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants|Completed||Phase 1|20|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:46:40.550142|2018-06-01 00:46:40.550142
NCT00942136|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2009-10-08|2009-07-16|2009-07-20|Estimate|||||||2009-10-08|2009-10-09|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study|The Official Study Title Exceeds the 300 Character Limit for This Field. See Detailed Study Description Section for Official Study Title.|Completed||Phase 1|24|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 00:46:40.701193|2018-06-01 00:46:40.701193
NCT00942123|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-09-26|2009-07-17|2009-07-20|Estimate|||||||2013-09-26|2013-09-27|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Observational|||Study On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis|On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis|Completed|||10|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||f||||||||||2018-06-01 00:46:40.786751|2018-06-01 00:46:40.786751
NCT00942110|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2012-03-05|2009-07-17|2009-07-20|Estimate|||||||2012-03-05|2012-03-06|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Alterations in Postprandial Glucose and Lipid Metabolism in Patients With Obstructive Sleep Apnea|Examination of Association Between Glucose, Lipid Metabolism and Obstructive Sleep Apnea|Completed||N/A|58|Actual|Kyoto University, Graduate School of Medicine||1|||f||||t||||||||||2018-06-01 00:46:40.852197|2018-06-01 00:46:40.852197
NCT00942097|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-05-08|2009-07-17|2009-07-20|Estimate|||||||2013-05-08|2013-05-13|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder|Homeopathic Treatment in Pregnant Women With Overweight and Mental Disorder: a Double Blinded Controlled Clinical Trial|Completed||Phase 2/Phase 3|134|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 00:46:40.941154|2018-06-01 00:46:40.941154
NCT00942084|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2013-08-27||2013-11-19|2009-07-17|2009-07-20|Estimate|2013-11-19|2014-01-08|Estimate||||2013-11-19|2014-01-08|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)|An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants|Completed||Phase 1|32|Actual|Duke University||4|||f||||t||||||||||2018-06-01 00:46:41.074914|2018-06-01 00:46:41.074914
NCT00942071|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2012-11-28|2009-07-17|2009-07-20|Estimate|||||||2012-11-28|2012-11-29|Estimate|August 2008||2008-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults|A Phase I Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults|Completed||Phase 1|58|Actual|University of Oxford||3|||f||||t||||||||||2018-06-01 00:46:41.459438|2018-06-01 00:46:41.459438
NCT00942058|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2014-01-28|2009-07-17|2009-07-20|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|CA9CRM||Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer|Serum Carbonic Anhydrase 9 (CA9) Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer : a Pilot Study|Terminated|||16|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1|Difficult for recruiting|f||||f||||||Samples Without DNA|"~     Blood, urine~   "|||2018-06-01 00:46:41.543874|2018-06-01 00:46:41.543874
NCT00942045|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2014-01-07|2009-07-17|2009-07-20|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Osteocel® Plus in Anterior Cervical Discectomy and Fusion (ACDF)|Osteocel® Plus in Anterior Cervical Discectomy and Fusion (ACDF): Evaluation of Radiographic and Patient Outcomes|Completed|||182|Actual|NuVasive|||||f||||f||||||||||2018-06-01 00:46:41.652248|2018-06-01 00:46:41.652248
NCT00942032|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-04-06|2009-07-17|2009-07-20|Estimate|||||||2011-04-06|2011-04-07|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Clinical Experience With the Hindfoot Arthrodesis Nail for the Surgical Treatment of Ankle and Hindfoot Pathologies|Clinical Experience With the Hindfoot Arthrodesis Nail (HAN) for the Surgical Treatment of Ankle and Hindfoot Pathologies. A Retrospective Case Series.|Completed|||39|Actual|AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-06-01 00:46:41.743969|2018-06-01 00:46:41.743969
NCT00942019|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2010-07-02|2009-07-17|2009-07-20|Estimate|||||||2010-07-02|2010-07-05|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Study of Bronchial Inflammation in Adolescent Smokers With and Without Obesity|Bronchial Inflammation in Adolescent Smokers With and Without Obesity|Completed|||110|Actual|Johann Wolfgang Goethe University Hospital|||4||f||||f||||||Samples With DNA|"~     serum: total IgE, RAST urin: cotinine, leukotrienes sputum: leukotrienes, white cells whole~     blood~   "|||2018-06-01 00:46:41.811857|2018-06-01 00:46:41.811857
NCT00942006|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2009-07-17|2009-07-17|2009-07-20|Estimate|||||||2009-07-17|2009-07-20|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|November 2011|Anticipated|2011-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis|Doxycycline and Ceftriaxone in Patients With Suspected Early Lyme Neuroborreliosis and Normal CSF Cell Count.|Unknown status|Not yet recruiting|N/A|200|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-06-01 00:46:41.881727|2018-06-01 00:46:41.881727
NCT00941993|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2014-07-02||2014-07-02|2009-07-17|2009-07-20|Estimate|2014-07-02|2014-08-04|Estimate||||2014-07-02|2014-08-04|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|IONTO||Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to External Auditory Apparatus|First in Man Evaluation of the Anesthetic Effect of Lidocaine/Epinephrine Solution Delivered Via Iontophoresis to the External Auditory Apparatus (FIM Iontophoresis Study)|Completed||N/A|109|Actual|Acclarent||1|||f||||f||||||||||2018-06-01 00:46:41.97181|2018-06-01 00:46:41.97181
NCT00941980|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2014-01-07|2009-07-17|2009-07-20|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF)|Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF): Evaluation of Radiographic and Patient Outcomes|Completed|||28|Actual|NuVasive|||||f||||f||||||||||2018-06-01 00:46:42.134381|2018-06-01 00:46:42.134381
NCT00941967|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2010-04-07|2009-07-17|2009-07-20|Estimate|||||||2010-04-07|2010-04-08|Estimate|December 2008||2008-12-31|July 2009|2009-07-31||||December 2010|Anticipated|2010-12-31||Interventional|||Sorafenib Tosylate With or Without Gemcitabine Hydrochloride and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer|Randomized Phase II Trial Assessing the Combination of Nexavar® (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic) Hepatocellular Carcinoma.|Unknown status|Recruiting|Phase 2|78|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:46:42.200899|2018-06-01 00:46:42.200899
NCT00941954|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2015-09-07|2009-07-17|2009-07-20|Estimate|||||||2015-09-07|2015-09-09|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Walking Away: Structured Education Versus Written Information for Individuals With High Risk of Developing Type 2 Diabetes|Walking Away From Type 2 Diabetes: a Cluster Randomized Controlled Trial to Investigate the Effect of Structured Education on Walking Activity in Those With a High Risk of Developing Type 2 Diabetes|Completed||N/A|833|Actual|University Hospitals, Leicester||2|||f||||t||||||||||2018-06-01 00:46:42.27777|2018-06-01 00:46:42.27777
NCT00941941|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-11|||2009-07-16|2009-07-16|2009-07-20|Estimate|||||||2009-07-16|2009-07-20|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|IHR||Non-Mesh Versus Mesh Method for Inguinal Hernia Repair|Comparison of Non-mesh (Desarda) and Mesh (Lichtenstein) Methods for Inguinal Hernia Repair at Mulago Hospital: a Double-blind Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|98|Anticipated|Makerere University||2|||f||||t||||||||||2018-06-01 00:46:42.363992|2018-06-01 00:46:42.363992
NCT00941772|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2010-12-01|2009-07-17|2009-07-20|Estimate|||||||2010-12-01|2010-12-02|Estimate|July 2009||2009-07-31|December 2010|2010-12-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Confirmation of Nasogastric Tube Placement Via Ultrasonography|Confirmation of Nasogastric Tube Placement Via Ultrasonography|Completed||N/A|50|Anticipated|Oklahoma State University Center for Health Sciences|||||f||||f||||||||||2018-06-01 00:46:45.957379|2018-06-01 00:46:45.957379
NCT00941928|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2013-05-22||2014-05-19|2009-07-17|2009-07-20|Estimate|2013-08-27|2013-08-28|Estimate||||2014-05-19|2014-05-22|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)|Adoptive Transfer of Haploidentical NK Cells in Combination With Epratuzumab for the Treatment of Relapsed Acute Lymphoblastic Leukemia|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Slow accrual|f||||f||||||||||2018-06-01 00:46:42.453063|2018-06-01 00:46:42.453063
NCT00941915|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2018-03-22|2009-07-17|2009-07-20|Estimate|||||||2018-03-22|2018-03-23|Actual|November 9, 2009|Actual|2009-11-09|March 2018|2018-03-31|February 2025|Anticipated|2025-02-28|February 2017|Actual|2017-02-28||Interventional|SMART||Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer|A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Continuous Real-time Evaluation of Prostate Motion and IMRT Plan Reoptimization Based on the Anatomy of the Day|Active, not recruiting||N/A|60|Anticipated|Duke University||1|||f||||f|f|f||||||||2018-06-01 00:46:42.613641|2018-06-01 00:46:42.613641
NCT00941902|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2011-05-16|2009-07-17|2009-07-20|Estimate|||||||2011-05-16|2011-05-17|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Observational|||A Potential Novel Marker for Liver Fibrosis in NASH: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor|A Potential Novel Marker for Liver Fibrosis in Nonalcoholic Steatohepatitis: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor Non-interventional Study.|Completed|||148|Actual|Ziv Hospital|||1||f||||t||||||||||2018-06-01 00:46:42.690262|2018-06-01 00:46:42.690262
NCT00941889|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2013-08-20||2016-06-13|2009-07-17|2009-07-20|Estimate|2016-06-13|2016-07-25|Estimate||||2016-06-13|2016-07-25|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Baseline characteristics were reported (age, gender, region of enrollment). Five of 17 patients in the placebo group completed study follow-up through at least 6 months and received all three study injections. Seven of 15 patients in the Gardasil group completed study follow-up through at least 6 months and received all three study injections.|The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata|The Effect of Human Papillomavirus Vaccination on Recurrence Rates in HIV Positive Patients Treated for Anal Condylomata|Completed||N/A|32|Actual|Washington University School of Medicine|Compliance with follow up was an ongoing issue.|2|||f||||f||||||||No|No outcomes data were collected or analyzed due to lack of participant follow-up.|2018-06-01 00:46:42.745713|2018-06-01 00:46:42.745713
NCT00941876|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2011-08-10|2009-07-17|2009-07-20|Estimate|||||||2011-08-10|2011-08-11|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Integration of Family Planning and HIV Services in Tanzania|An Evaluation of Integration of Family Planning Into HIV/AIDS Care and Treatment Clinics in Tanzania|Completed||N/A|864|Actual|FHI 360||1|||f||||f||||||||||2018-06-01 00:46:42.938137|2018-06-01 00:46:42.938137
NCT00941863|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2010-02-03||2016-02-24|2009-07-16|2009-07-20|Estimate|2010-09-21|2010-10-08|Estimate||||2016-02-24|2016-03-22|Estimate|July 2002||2002-07-31|February 2016|2016-02-29|April 2008|Actual|2008-04-30|May 2005|Actual|2005-05-31||Interventional|||Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)|Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors|Completed||Phase 1|158|Actual|Bayer||5|||f||||f||||||||||2018-06-01 00:46:43.174982|2018-06-01 00:46:43.174982
NCT00941850|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2015-12-07|2009-07-17|2009-07-20|Estimate|||||||2015-12-07|2015-12-08|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TRIVENT||A Study of Triple-site Ventricular Pacing in Patients Who Have Not Responded to Conventional Dual Ventricular Site Cardiac Resynchronization Therapy|TRIple-site VENTricular Pacing in Non-responders to Conventional Dual Ventricular Site Cardiac Resynchronization Therapy|Completed||Phase 4|20|Actual|University Hospitals, Leicester||2|||f||||||||||||||2018-06-01 00:46:44.748326|2018-06-01 00:46:44.748326
NCT00941837|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2011-06-05|2009-07-17|2009-07-20|Estimate|||||||2011-06-05|2011-06-08|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|October 2010|Actual|2010-10-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Dietary Fat Type in Combination With High Protein on Plasma Homocysteine Levels|Effect of Dietary Fat Type in Combination With High Protein on Plasma Homocysteine Levels and Selected Markers of Cardiovascular Heart Disease Risk in Human Volunteers|Completed||N/A|45|Actual|Malaysia Palm Oil Board||3|||f||||f||||||||||2018-06-01 00:46:44.81007|2018-06-01 00:46:44.81007
NCT00941824|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2010-03-24|2009-07-16|2009-07-20|Estimate|||||||2010-03-24|2010-03-25|Estimate|February 2009||2009-02-28|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus Post Kidney Transplant: The Myfortic Study|Pharmacokinetic Evaluation of an Intensified and Decreasing Dosing Regimen of Mycophenolate Sodium in Combination With Tacrolimus During the First 3 Months Post Kidney Transplant (the myFORTic Study)|Completed||Phase 4|15|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||||f||||f||||||||||2018-06-01 00:46:44.865961|2018-06-01 00:46:44.865961
NCT00941811|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2015-06-14|2009-07-17|2009-07-20|Estimate|||||||2015-06-14|2015-06-16|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment|An Explorative, Single Center and Controlled Study to Analyze the Immune Escape Mechanisms of HPV-associated Lesions and to Evaluate the Efficiency and Mechanisms of Imiquimod Treatment of Vulvar Intraepithelial Neoplasias 2/3 (VIN) and Anogenital Warts|Completed||Phase 2|5|Actual|Medical University of Vienna|||||f||||t||||||||||2018-06-01 00:46:44.916939|2018-06-01 00:46:44.916939
NCT00941798|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2012-05-03||2012-08-21|2009-07-17|2009-07-20|Estimate|2012-05-03|2012-06-05|Estimate||||2012-08-21|2012-08-31|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma|A Randomized, Multi-center, Parallel Group, Double Blind, Study to Assess the Safety of QMF Twisthaler® (500/400 µg) and Mometasone Furoate Twisthaler® (400 µg) in Adolescent and Adult Patients With Persistent Asthma|Completed||Phase 2|2283|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:46:45.111687|2018-06-01 00:46:45.111687
NCT00941785|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-03-18|2009-07-17|2009-07-20|Estimate|||||||2011-03-18|2011-03-21|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso|Randomized Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of Dihydroartemisinin-piperaquine for Seasonal IPT to Prevent Malaria in Children Under 5 Years|Completed||Phase 2/Phase 3|1500|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:46:45.88733|2018-06-01 00:46:45.88733
NCT00941759|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2017-09-06|2009-07-17|2009-07-20|Estimate|||||||2017-09-06|2017-09-07|Actual|July 2009||2009-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer|A Prospective Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer|Active, not recruiting|||100|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Blood and tissue collection~   "|||2018-06-01 00:46:46.175151|2018-06-01 00:46:46.175151
NCT00941746|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2011-06-03|2009-07-17|2009-07-20|Estimate|||||||2011-06-03|2011-06-07|Estimate|August 2009||2009-08-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain|A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in Patients With Pain Attributed to Osteoarthritis of the Knee|Completed||Phase 1|56|Actual|Abbott||9|||f||||f||||||||||2018-06-01 00:46:46.276878|2018-06-01 00:46:46.276878
NCT00941733|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2014-08-29||2018-01-31|2009-07-17|2009-07-20|Estimate|2014-10-24|2014-10-27|Estimate||||2018-01-31|2018-02-28|Actual|September 2009||2009-09-30|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|August 2013|Actual|2013-08-31||Interventional|INPACT-DEEP|The total sample size for the study was planned to be 357 subjects, which was intended to fully power the trial for the endpoints of LLL and the composite safety endpoint based on initial estimates of event rates and effect sizes. The endpoint of 12-month TLR was powered to 65% with the indicated sample size.|Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia|Randomized Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA (Percutaneous Transluminal Angioplasty) for the Treatment of Below the Knee Critical Limb Ischemia|Completed||N/A|358|Actual|Medtronic Endovascular||2|||f||||t||||||||||2018-06-01 00:46:46.441283|2018-06-01 00:46:46.441283
NCT00941720|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|2014-02-13||2018-05-02|2009-07-17|2009-07-20|Estimate|2014-02-19|2014-04-02|Estimate||||2018-05-02|2018-05-31|Estimate|June 11, 2009|Actual|2009-06-11|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|February 28, 2013|Actual|2013-02-28||Interventional|||Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Study of Outcomes and Toxicity of Busulfex as Part of a High Dose Chemotherapy Preparative Regimen in Autologous Hematopoietic Stem Cell Transplantation for Patients With Plasma Cell Myeloma|Active, not recruiting||Phase 2|71|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-06-01 00:46:47.956211|2018-06-01 00:46:47.956211
NCT00941707|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-04-22|2009-07-17|2009-07-20|Estimate|||||||2013-04-22|2013-04-23|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis|A Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy With Synovial Biopsy Substudy|Terminated||Phase 2|86|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Due to a single, unexpected serious event, the trial was stopped.|f||||t||||||||||2018-06-01 00:46:48.250745|2018-06-01 00:46:48.250745
NCT00941694|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-17|||2013-01-15|2009-07-17|2009-07-20|Estimate|||||||2013-01-15|2013-01-16|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Asthma Self-Management in Older Adults|Asthma Self-Management in Older Adults|Completed||N/A|70|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:46:48.567956|2018-06-01 00:46:48.567956
NCT00941681|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|2010-10-29||2013-02-06|2009-07-16|2009-07-17|Estimate|2010-11-22|2010-12-21|Estimate||||2013-02-06|2013-02-12|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure|An Open Label Study to Investigate the Pharmacokinetics of CK-1827452 Administered Orally to Patients With Stable Heart Failure|Completed||Phase 2|35|Actual|Cytokinetics||3|||f||||f||||||||||2018-06-01 00:46:48.834533|2018-06-01 00:46:48.834533
NCT00941668|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2015-08-18|2009-06-03|2009-07-17|Estimate|2009-06-03|2009-07-17|Estimate||||2015-08-18|2015-08-27|Estimate|January 2007||2007-01-31|August 2015|2015-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Evaluate Inflammation Caused by Gingivitis in Adults|Evaluate Inflammation Caused by Gingivitis in Adults|Completed||Phase 4|49|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 00:46:49.147719|2018-06-01 00:46:49.147719
NCT00941655|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2013-04-25||2017-09-06|2009-07-16|2009-07-17|Estimate|2013-07-09|2013-07-11|Estimate||||2017-09-06|2017-10-03|Actual|July 22, 2009|Actual|2009-07-22|September 2017|2017-09-30|June 18, 2012|Actual|2012-06-18|July 14, 2011|Actual|2011-07-14||Interventional|||Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial|Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial|Completed||Phase 3|15|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f||||||No||2018-06-01 00:46:49.614537|2018-06-01 00:46:49.614537
NCT00941642|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-06-09|2009-07-16|2009-07-17|Estimate|||||||2010-06-09|2010-06-10|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease|Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease|Unknown status|Recruiting|Phase 4|40|Anticipated|Huntington Medical Research Institutes||2|||f||||f||||||||||2018-06-01 00:46:50.192345|2018-06-01 00:46:50.192345
NCT00941629|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-09-30|2009-07-16|2009-07-17|Estimate|||||||2015-09-30|2015-10-02|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Comparison of Videoconference and Face-to-Face Delivery of Cognitive Processing Therapy for Posttraumatic Stress Disorder|Randomized Controlled Equivalence Trial Comparing Videoconference and Face-to-Face Delivery of Cognitive Processing Therapy for PTSD|Completed||Phase 3|90|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:46:50.313507|2018-06-01 00:46:50.313507
NCT00941616|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2017-10-02|2009-07-15|2009-07-17|Estimate|||||||2017-10-02|2017-10-03|Actual|June 2009||2009-06-30|October 2017|2017-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease|An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Biostate® in Subjects With Von Willebrand Disease.|Completed||Phase 2/Phase 3|22|Actual|CSL Behring||4|||f||||t||||||||||2018-06-01 00:46:50.403909|2018-06-01 00:46:50.403909
NCT00941252|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2011-01-21|2009-07-16|2009-07-17|Estimate|||||||2011-01-21|2011-01-24|Estimate|July 2009||2009-07-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|ITIC||ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial|Topical Imiquimod in Treating Patients With Grade 2/3 Cervical Intraepithelial Neoplasia|Completed||Phase 2/Phase 3|60|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:46:54.749917|2018-06-01 00:46:54.749917
NCT00941603|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2016-03-14|2010-04-13|2017-05-10|2009-07-16|2009-07-17|Estimate|2016-03-14|2016-04-12|Estimate|2010-04-13|2010-04-15|Estimate|2017-05-10|2017-06-12|Actual|June 29, 2009|Actual|2009-06-29|May 2017|2017-05-31|February 22, 2010|Actual|2010-02-22|February 22, 2010|Actual|2010-02-22||Interventional|||Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)|A Phase 2 Randomized, Double-Blind, Dose-Response Efficacy and Safety Study of SCH 900271 Compared to Placebo in Subjects With Primary Hypercholesterolemia (Familial and Nonfamilial) or Mixed Hyperlipidemia|Completed||Phase 2|619|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 00:46:50.576778|2018-06-01 00:46:50.576778
NCT00941590|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2009-07-16|2009-07-16|2009-07-17|Estimate|||||||2009-07-16|2009-07-17|Estimate|July 2009||2009-07-31|July 2009|2009-07-31||||October 2010|Anticipated|2010-10-31||Observational|||Postencephalitic Symptoms After Tick Borne Encephalitis|Postencephalitic Symptoms After Tick Borne Encephalitis|Unknown status|Not yet recruiting||200|Anticipated|University Medical Centre Ljubljana|||1||f||||f||||||||||2018-06-01 00:46:51.541031|2018-06-01 00:46:51.541031
NCT00941577|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-07-21|2009-07-16|2009-07-17|Estimate|||||||2010-07-21|2010-07-23|Estimate|October 2009||2009-10-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma|A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Bronchial Allergen Challenge Study to Assess the Safety, Tolerability, and Efficacy of Inhaled AIR645 in Subjects With Mild Allergic Asthma|Completed||Phase 2|30|Actual|Altair Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 00:46:51.600876|2018-06-01 00:46:51.600876
NCT00941564|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-11-24|2009-07-16|2009-07-17|Estimate|||||||2010-11-24|2010-11-25|Estimate|March 2010||2010-03-31|November 2010|2010-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparative Ca Absorption and Tolerance in Healthy Term Infants Fed Milk-based Formulas With Different Fat Blends|"Comparative Calcium Absorption and Gastrointestinal Tolerance in Healthy Term Infants Fed Milk-based Formulas With Different Fat Blends"|Completed||Phase 4|33|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-06-01 00:46:51.694702|2018-06-01 00:46:51.694702
NCT00941551|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2009-07-16|2009-07-16|2009-07-17|Estimate|||||||2009-07-16|2009-07-17|Estimate|January 2000||2000-01-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2003|Actual|2003-12-31||Observational|||Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively|Five-year Follow up of a Randomized Clinical Trial of Unilateral Thyroid Lobectomy With or Without Levothyroxine Treatment Postoperatively|Completed|||150|Actual|Jagiellonian University|||2||f||||t||||||||||2018-06-01 00:46:51.757002|2018-06-01 00:46:51.757002
NCT00941538|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2009-07-21|2009-07-16|2009-07-17|Estimate|||||||2009-07-21|2009-07-23|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|July 2019|Anticipated|2019-07-31|July 2012|Anticipated|2012-07-31||Observational|||Screening for Nasopharyngeal Carcinoma in High Risk Populations|Screening for Nasopharyngeal Carcinoma (NPC) on the High Risk Area and Evaluation on the Project of Early Diagnosis and Treatment|Recruiting|||30000|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     Whole blood, Serum, White cells, pathological tissue~   "|||2018-06-01 00:46:51.877919|2018-06-01 00:46:51.877919
NCT00941525|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-07-02|2009-07-15|2009-07-17|Estimate|||||||2015-07-02|2015-07-07|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CCT-IOP||Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure|Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure|Completed||Phase 4|174|Actual|Aristotle University Of Thessaloniki||1|||f||||f||||||||||2018-06-01 00:46:51.973123|2018-06-01 00:46:51.973123
NCT00941512|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2009-07-15|2009-07-15|2009-07-17|Estimate|||||||2009-07-15|2009-07-17|Estimate|April 2005||2005-04-30|July 2009|2009-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||High Resolution Digital Imaging of the Uterine Cervix|Investigation to Correlate High Resolution Digital Images of the Uterine Cervix With Histopathology|Completed|||112|Actual|STI-Medical Systems|||||f||||f||||||Samples Without DNA|"~     Uterine Cervix tissue~   "|||2018-06-01 00:46:52.225801|2018-06-01 00:46:52.225801
NCT00941499|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-11-16|2009-07-15|2009-07-17|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab|Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Bevacizumab With/Without Cetuximab by K-RAS Mutational Status and Liver Function for Advanced Cancers Metastatic to the Liver|Completed||Phase 1|140|Actual|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-06-01 00:46:52.302433|2018-06-01 00:46:52.302433
NCT00941486|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15||2012-09-05|2015-09-14|2009-07-16|2009-07-17|Estimate||||2012-09-05|2012-09-10|Estimate|2015-09-14|2015-09-30|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis||Terminated||Phase 2|30|Actual|Shire||2|||f||||||||||||||2018-06-01 00:46:52.425696|2018-06-01 00:46:52.425696
NCT00941473|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2012-03-15|2009-07-16|2009-07-17|Estimate|||||||2012-03-15|2012-03-16|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Epidural Steroid Injection on Bone Mineral Density in Postmenopausal Women|Effect of Epidural Steroid Injection on Bone Mineral Density In Postmenopausal Women|Completed||Phase 4|28|Actual|Henry Ford Health System||1|||f||||t||||||||||2018-06-01 00:46:52.501355|2018-06-01 00:46:52.501355
NCT00941460|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2014-08-13|2009-07-16|2009-07-17|Estimate|||||||2014-08-13|2014-08-15|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|DIRECTOR||Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma|Dose-intensified Rechallenge With Temozolomide, One Week On One Week Off Versus Three Weeks On One Week Off in Patients With Progressive or Recurrent Glioblastoma|Completed||Phase 2|105|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 00:46:52.576509|2018-06-01 00:46:52.576509
NCT00941447|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2018-04-03|2009-07-16|2009-07-17|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2009||2009-04-30|April 2018|2018-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Development of Self-Regulation in Individuals With Type 2 Diabetes||Completed||N/A|15|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-06-01 00:46:52.688591|2018-06-01 00:46:52.688591
NCT00941434|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2011-07-07|2009-07-16|2009-07-17|Estimate|||||||2011-07-07|2011-07-08|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Community Based Management of Malnutrition|Community Based Management of Malnutrition. A Proposal for Pakistan Initiative for Mothers and Newborns|Completed||N/A|800|Actual|Aga Khan University||1|||f||||||||||||||2018-06-01 00:46:52.826788|2018-06-01 00:46:52.826788
NCT00935415|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|TEMPE||Time-Effect of Montelukast Protection|Time-Effect of Montelukast on Protection Against Exercise-Induced Bronchoconstriction|Completed||Phase 4|69|Actual|Universita di Verona||2|||f||||f||||||||||2018-06-01 00:48:41.726514|2018-06-01 00:48:41.726514
NCT00941421|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-06-11|2009-07-16|2009-07-17|Estimate|||||||2013-06-11|2013-06-12|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|VCO-VO||Value of Oesophagal Videocapsul and Oeso-gastro-duodenal Fiber Endoscopy for the Screening of Oesophagal Varix for Cirrhotic Patients|"Comparision of Diagnostic Value of Oesophagal Videocapsul (VCO) and Oeso-gastro-duodenal Fiber Endoscopy (OGDFE) for the Screening of Oesophagal Varix (OV) for Cirrhotic Patients"|Terminated||N/A|310|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-06-01 00:46:52.898698|2018-06-01 00:46:52.898698
NCT00941408|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2014-01-13|2009-07-16|2009-07-17|Estimate|||||||2014-01-13|2014-01-14|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Biomarker Study of Breast Tumors|Biomarker Study of Breast Tumors|Unknown status|Recruiting||400||National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     During the diagnostic tumor core biopsy, 3-4 additional tumor samples will be obtained~     through the same needle track for the purpose of this study. The tumor cores will be stored~     in liquid nitrogen for subsequent histopathological analysis; DNA, RNA and protein will be~     extracted from tumor cores for genetic, gene expression and proteomics studies.~   "|||2018-06-01 00:46:52.974246|2018-06-01 00:46:52.974246
NCT00941395|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2017-06-21|2009-07-15|2009-07-17|Estimate|||||||2017-06-21|2017-06-22|Actual|June 30, 2009|Actual|2009-06-30|June 2017|2017-06-30|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||College Students and Smoking Cessation|Enhanced Smoking Cessation for University Students|Completed||N/A|39|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 00:46:53.054452|2018-06-01 00:46:53.054452
NCT00941382|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-15|2009-07-15|2009-07-17|Estimate|||||||2009-07-15|2009-07-17|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|||Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients|Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|Laboratorios Silanes S.A. de C.V.||3|||f||||t||||||||||2018-06-01 00:46:53.135122|2018-06-01 00:46:53.135122
NCT00941369|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2012-11-21|2009-07-16|2009-07-17|Estimate|||||||2012-11-21|2012-11-22|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients|Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-naive Type 2 Diabetes Patients Uncontrolled on Oral Hypoglycemic Agent Treatment Initiating Basal Insulin Therapy With Either Insulin Glargine or NPH Insulin|Completed||Phase 4|345|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:46:53.235644|2018-06-01 00:46:53.235644
NCT00941356|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2016-01-14|2009-07-16|2009-07-17|Estimate|||||||2016-01-14|2016-01-15|Estimate|January 2010||2010-01-31|January 2016|2016-01-31||||July 2016|Anticipated|2016-07-31||Interventional|MRSA||Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients|A Single Center, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients|Suspended||Phase 2|146|Anticipated|Bio-K Plus International Inc.||2||Unable to recruit patients to continue on with the study.|f||||f||||||||||2018-06-01 00:46:53.307749|2018-06-01 00:46:53.307749
NCT00941343|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2010-03-29|2009-07-16|2009-07-17|Estimate|||||||2010-03-29|2010-03-30|Estimate|September 2006||2006-09-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Benign Prostatic Hyperplasia in Taiwan|Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin|Completed||N/A|362|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:46:53.386152|2018-06-01 00:46:53.386152
NCT00941330|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|2016-12-07|2016-04-26|2017-02-24|2009-07-16|2009-07-17|Estimate|2017-02-24|2017-04-10|Actual|2016-04-26|2016-05-26|Estimate|2017-02-24|2017-04-10|Actual|July 2009||2009-07-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers|Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)|Completed||Phase 2|31|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:46:53.473894|2018-06-01 00:46:53.473894
NCT00941317|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2011-03-25|2009-07-16|2009-07-17|Estimate|||||||2011-03-25|2011-03-28|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Single-blind Evaluation of Device to Nail Micro-drilling in Onychomycosis|A Single-blind Evaluation of Device Performance and Tolerability to Nail Micro-drilling in Subjects With Onychomycosis|Completed||Phase 1|25|Actual|Galderma|||||f||||f||||||||||2018-06-01 00:46:53.766633|2018-06-01 00:46:53.766633
NCT00941304|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|2015-11-04|2015-02-24|2017-01-12|2009-07-16|2009-07-17|Estimate|2016-01-04|2016-02-03|Estimate|2015-02-24|2015-03-17|Estimate|2017-01-12|2017-02-27|Actual|August 2009||2009-08-31|January 2017|2017-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||Analysis is based on Safety population; all subjects who received at least 1 dose of study drug.|Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain|A Double-Blind, Double-Dummy, Placebo- and Active Controlled Evaluation of the Efficacy, Safety and Tolerability of Buprenorphine HCl Buccal Film in the Treatment of Pain Associated With Third Molar Extraction|Completed||Phase 2|153|Actual|BioDelivery Sciences International||5|||f||||f||||||||||2018-06-01 00:46:53.844176|2018-06-01 00:46:53.844176
NCT00941291|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-07-16|2009-07-16|2009-07-17|Estimate|||||||2009-07-16|2009-07-17|Estimate|January 2002||2002-01-31|July 2009|2009-07-31|January 2005|Actual|2005-01-31|||||Observational|||Outcome of Idiopathic Macular Hole|Long-term Outcome of Idiopathic Macular Hole Surgery|Completed|||135|Actual|Centre Hospitalier Universitaire Dijon|||4||f||||f||||||||||2018-06-01 00:46:54.588796|2018-06-01 00:46:54.588796
NCT00941278|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-07-02|2009-07-16|2009-07-17|Estimate|||||||2010-07-02|2010-07-07|Estimate|July 2009||2009-07-31|July 2010|2010-07-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis||Completed||Phase 2|30|Anticipated|Provectus Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:46:54.640588|2018-06-01 00:46:54.640588
NCT00941265|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2014-12-02|2009-07-16|2009-07-17|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2007||2007-02-28|December 2014|2014-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Dopaminergic Medication on Recovery of Aphasia|Effect of Dopaminergic Medication on Recovery of Aphasia|Completed||N/A|12|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-06-01 00:46:54.68955|2018-06-01 00:46:54.68955
NCT00935402|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-02-22|2009-07-08|2009-07-09|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|Sleep||Sleep Deprivation and Energy Balance|Sleep Deprivation and Energy Balance|Completed||N/A|30|Anticipated|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-06-01 00:48:41.879664|2018-06-01 00:48:41.879664
NCT00941213|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2010-06-24|2009-07-16|2009-07-17|Estimate|||||||2010-06-24|2010-06-25|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|Harmonic||Monopolar Electrosurgery Versus Ultrasound Scissors in Thoracoscopic Ventral Spondylodesis|Comparison of the Quantity of Bleeding and the Duration of Operation in Thoracoscopic Ventral Spondylodesis During Preparation With Monopolar Electrosurgery Compared to Ultrasound Scissors.|Unknown status|Recruiting|Phase 4|40|Anticipated|University of Cologne||2|||f||||f||||||||||2018-06-01 00:46:54.921874|2018-06-01 00:46:54.921874
NCT00941200|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2014-01-13|2009-07-16|2009-07-17|Estimate|||||||2014-01-13|2014-01-14|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Pharmacogenetic DNA Bank|Pharmacogenetic DNA Bank|Unknown status|Recruiting||5000||National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 00:46:54.995261|2018-06-01 00:46:54.995261
NCT00941187|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2013-11-06|2009-07-16|2009-07-17|Estimate|||||||2013-11-06|2013-11-07|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|VcEP||Evolution of Pulmonary Capillary Blood Volume|Evolution of Pulmonary Capillary Blood Volume (Vc) in Patients After a First Episode of Pulmonary Embolism.|Completed|||50|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-06-01 00:46:55.155571|2018-06-01 00:46:55.155571
NCT00941174|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2013-12-30|2009-07-16|2009-07-17|Estimate|||||||2013-12-30|2013-12-31|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Folate Absorption Across the Large Intestine|Folate Absorption Across the Large Intestine, Study #2: Capsule Study|Completed||Phase 1|9|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:46:55.220132|2018-06-01 00:46:55.220132
NCT00941161|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-05-17|2009-07-16|2009-07-17|Estimate|||||||2010-05-17|2010-05-18|Estimate|February 2009||2009-02-28|May 2010|2010-05-31||||May 2010|Actual|2010-05-31||Interventional|||Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus|Effect of Oral Combination Therapy of Metformin Extended Release Over Glimepiride in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus With Failure of Monotherapy|Completed||Phase 4|28|Anticipated|Laboratorios Silanes S.A. de C.V.||3|||f||||t||||||||||2018-06-01 00:46:55.289173|2018-06-01 00:46:55.289173
NCT00941148|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2009-07-16|2009-07-16|2009-07-17|Estimate|||||||2009-07-16|2009-07-17|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin|Impact of Insulin (I.)Glargine Compared to NPH I. and to I. Detemir in Combination With Metformin on Prandial ß-cell Function and Overall Metabolic Control in Type 2 Diabetic Patients With Insufficient Metabolic Control During OAD Treatment|Completed||Phase 4|30|Actual|ikfe-CRO GmbH||3|||f||||t||||||||||2018-06-01 00:46:55.367578|2018-06-01 00:46:55.367578
NCT00941135|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2011-09-28|2009-07-16|2009-07-17|Estimate|||||||2011-09-28|2011-09-29|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab|"Phase II Study of TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab Boost Concomitant With Cetuximab in Patients With Local Advanced Larynx/Hypolarynx Carcinoma"|Terminated||Phase 2|70|Anticipated|Fundacion Miguel Servet|||||f||||f||||||||||2018-06-01 00:46:55.434705|2018-06-01 00:46:55.434705
NCT00941122|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2011-07-19|2009-07-16|2009-07-17|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2009||2009-07-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Observational|MRSA VRE||Comparison of Elution Swab (ESwab) and Amies Transport Swabs for Screening Patients for Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant Enterococci (VRE) Colonization|Comparison of Elution Swab (ESwab) and Amies Transport Swabs for Screening Patients for Methicillin Resistant Staphylococcus Aureus (MRSA) and Vancomycin Resistant Enterococci (VRE) Colonization|Completed|||30|Actual|McMaster University|||1||f||||f||||||||||2018-06-01 00:46:55.490606|2018-06-01 00:46:55.490606
NCT00941109|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2016-05-05|2009-07-16|2009-07-17|Estimate|||||||2016-05-05|2016-05-09|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)|A Phase 1 Open-Label, Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)|Completed||Phase 1|12|Actual|Eisai Inc.||4|||f||||f||||||||||2018-06-01 00:46:55.564012|2018-06-01 00:46:55.564012
NCT00941096|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2010-11-29|2009-07-16|2009-07-17|Estimate|||||||2010-11-29|2010-11-30|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed Combination|Efficacy Of The Bimatoprost/Timolol Fixed Combination In Patients Treated With Bimatoprost for Primary Open Angle Glaucoma, Exfoliation Glaucoma or Ocular Hypertension.|Completed||Phase 4|30|Anticipated|Larissa University Hospital|||||f||||||||||||||2018-06-01 00:46:55.700205|2018-06-01 00:46:55.700205
NCT00941083|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-09-09|2009-07-16|2009-07-17|Estimate|||||||2009-09-09|2009-09-10|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|ODIS||Simplification From Protease Inhibitors to Raltegravir|Pilot, Open-label, Randomized, Single-center Study to Asses a Simplification Strategy From Protease Inhibitors to Raltegravir: Once Daily Isentress (ODIS)|Unknown status|Recruiting|Phase 4|240|Anticipated|Hospital Carlos III, Madrid||3|||f||||t||||||||||2018-06-01 00:46:55.768464|2018-06-01 00:46:55.768464
NCT00941070|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2013-03-20||2017-10-16|2009-07-16|2009-07-17|Estimate|2013-03-20|2013-05-13|Estimate||||2017-10-16|2017-11-17|Actual|July 2009||2009-07-31|October 2017|2017-10-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional||Baseline demographic characteristics include all 26 patients. Study specific characteristics only include the 25 patients that received treatment.|Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer|A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer|Completed||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:46:55.882572|2018-06-01 00:46:55.882572
NCT00940732|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-06-24|2009-07-15|2009-07-16|Estimate|||||||2015-06-24|2015-06-26|Estimate|November 2009||2009-11-30|June 2015|2015-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|TEAMS||The Elite Athlete Mental Health Strategy Trial|The Elite Athlete Mental Health Strategy: A Randomised Controlled Trial of an Online Intervention for the Mental Health Help-Seeking of Elite Athletes|Completed||N/A|59|Actual|Australian National University||4|||f||||t||||||||||2018-06-01 00:47:02.078131|2018-06-01 00:47:02.078131
NCT00941057|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2016-07-29|2009-07-16|2009-07-17|Estimate|||||||2016-07-29|2016-08-01|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium|Open-label, Randomized, Cross-over Study to Investigate the Bioequivalence of Estradiol Valerate (EV), Dienogest (DNG) and Levomefolate Calcium After Single Oral Administration of a Tablet Formulation Containing 2 mg Estradiol Valerate and 3 mg Dienogest Without and With 0.451 mg Levomefolate Calcium and a Tablet Formulation Containing 0.451 mg Levomefolate Calcium in 42 Healthy Postmenopausal Women|Completed||Phase 1|43|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:46:56.471255|2018-06-01 00:46:56.471255
NCT00941044|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2010-02-04|2009-07-16|2009-07-17|Estimate|||||||2010-02-04|2010-02-05|Estimate|July 2009||2009-07-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Non-invasive Neurally Adjusted Ventilatory Assist in Healthy Volunteers|Unloading of the Respiratory Muscles Using Non-invasive Neurally Adjusted Ventilatory Assist in Healthy, Resistively Loaded Volunteers|Completed||Phase 1|16|Anticipated|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 00:46:56.567763|2018-06-01 00:46:56.567763
NCT00941031|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2015-01-30|2012-05-31|2015-07-30|2009-07-16|2009-07-17|Estimate|2015-03-23|2015-03-27|Estimate|2012-05-31|2012-06-06|Estimate|2015-07-30|2015-08-20|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis|A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 2|404|Actual|Novartis||4|||f||||f||||||||||2018-06-01 00:46:56.683773|2018-06-01 00:46:56.683773
NCT00941018|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-12-01|2009-07-16|2009-07-17|Estimate|||||||2009-12-01|2009-12-02|Estimate|June 2009||2009-06-30|December 2009|2009-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers|A Randomized, Double Blind, Placebo Controlled, Ascending Single and Multiple Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Food Effect Study of RX-10001 in Healthy Volunteers|Completed||Phase 1|56|Anticipated|Resolvyx Pharmaceuticals, Inc||6|||f||||f||||||||||2018-06-01 00:46:57.658554|2018-06-01 00:46:57.658554
NCT00941005|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2009-07-16|2009-07-16|2009-07-17|Estimate|||||||2009-07-16|2009-07-17|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of Electroacustimulation on Postoperative Nausea, Vomiting and Pain in Outpatient Plastic Surgery Patients|The Effect of Electroacustimulation on Postoperative Nausea, Vomiting and Pain in Outpatient Plastic Surgery Patients: A Prospective, Randomized, Blinded Clinical Trial|Completed||N/A|122|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 00:46:57.721059|2018-06-01 00:46:57.721059
NCT00940992|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2014-12-18||2014-12-31|2009-07-16|2009-07-17|Estimate|2014-12-31|2015-01-09|Estimate||||2014-12-31|2015-01-09|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|SGTDER45EV||A Study of DER 45-EV Gel to Treat Rosacea|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Range Study of DER 45 EV Gel, 1% and 5%, and Vehicle Gel in the Treatment of Rosacea|Completed||Phase 2|92|Actual|Sol-Gel Technologies, Ltd.||3|||f||||t||||||||||2018-06-01 00:46:57.894403|2018-06-01 00:46:57.894403
NCT00940979|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2014-01-10|2009-07-16|2009-07-17|Estimate|||||||2014-01-10|2014-01-13|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|ITT||Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities|Prospective Randomised Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities|Terminated||N/A|450|Anticipated|Rijnstate Hospital||2||Interim analyses showed insufficient result. Termination for reasons of futility|f||||||||||||||2018-06-01 00:46:58.198788|2018-06-01 00:46:58.198788
NCT00940966|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-02-02|2009-07-16|2009-07-17|Estimate|||||||2015-02-02|2015-02-03|Estimate|July 2006||2006-07-31|February 2015|2015-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome|A Pilot Study to Determine the Efficacy of a Low Carbohydrate Diet in Treatment of Adolescents With Metabolic Syndrome|Completed||N/A|40|Anticipated|CAMC Health System||3|||f||||f||||||||||2018-06-01 00:46:58.257585|2018-06-01 00:46:58.257585
NCT00940953|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2012-10-02|2009-07-16|2009-07-17|Estimate|||||||2012-10-02|2012-10-04|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study Comparing Relative Efficacy of CE Budesonide+Azelastine & Rhinocort Aqua+Astelin Nasal Sprays Against Placebo in the Treatment of AR in an EEC Model|Completed||Phase 2|108|Actual|Ligand Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:46:58.319904|2018-06-01 00:46:58.319904
NCT00940940|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-05-26|2009-07-16|2009-07-17|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation|Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 00:46:58.382758|2018-06-01 00:46:58.382758
NCT00940927|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2009-02-03||2015-04-14|2009-05-28|2009-07-17|Estimate|2009-05-28|2009-07-17|Estimate||||2015-04-14|2015-05-05|Estimate|July 1993||1993-07-31|April 2015|2015-04-30|October 1994|Actual|1994-10-31|October 1994|Actual|1994-10-31||Interventional|||Dose-response of Albuterol in Asthmatics|Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule|Completed||Phase 4|81|Actual|Nemours Children's Clinic|||||f||||f||||||||||2018-06-01 00:46:58.442446|2018-06-01 00:46:58.442446
NCT00940914|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2011-03-29|2009-07-16|2009-07-17|Estimate|||||||2011-03-29|2011-03-30|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Dopaminergic Loss and Pain in Parkinson's Disease|Evaluation of Radioligand Uptake (FP-CIT) of Dopamine Transporters in Patients Suffering From Parkinson's Disease With or Without Pain|Completed||Phase 2|20|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 00:46:58.55665|2018-06-01 00:46:58.55665
NCT00940901|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|2016-09-20||2017-03-02|2009-07-16|2009-07-17|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Interventional|||Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia|Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia|Completed||Phase 2|13|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:46:58.624039|2018-06-01 00:46:58.624039
NCT00940888|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2017-01-12||2017-10-30|2009-07-15|2009-07-16|Estimate|2017-05-02|2017-08-14|Actual||||2017-10-30|2017-12-05|Actual|June 2009||2009-06-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational||Participants had an approved indication, as per ACC/AHA/HRS guidelines, for implantation of an ICD or CRT-D system for treatment of heart failure or life-threatening ventricular tachyarrhythmia(s) and will be implanted with a St. Jude Medical SJ4 system and had given informed consent prior to enrollment.|SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients|SJ4 Post Approval Study|Completed|||1701|Actual|St. Jude Medical|||1||f||||f||||||||No||2018-06-01 00:46:58.902603|2018-06-01 00:46:58.902603
NCT00940875|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2014-12-19||2015-04-01|2009-07-15|2009-07-16|Estimate|2015-04-01|2015-04-02|Estimate||||2015-04-01|2015-04-02|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Full Analysis Set (FAS) (following an intent-to-treat principle): all randomized participants.|A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Open-label Study of the Effect of First Line Treatment With Tarceva in Sequential Combination With Gemcitabine, Compared to Gemcitabine Monotherapy, on Progression-free Survival in Elderly or ECOG PS of 2 Patients With Advanced Non-small Cell Lung Cancer.|Terminated||Phase 2|54|Actual|Hoffmann-La Roche|Due to slower than expected recruitment, this study was stopped after 54 patients had been enrolled.|2||Study was stopped due to slower than expected recruitment.|f||||||||||||||2018-06-01 00:47:00.138266|2018-06-01 00:47:00.138266
NCT00940862|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-10-27|2009-07-15|2009-07-16|Estimate|||||||2011-10-27|2011-10-28|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis|Pilot Study on the Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 4|30|Actual|Innovaderm Research Inc.||2|||f||||f||||||||||2018-06-01 00:47:00.884162|2018-06-01 00:47:00.884162
NCT00940849|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2014-11-11|2009-07-15|2009-07-16|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Gastric Emptying and Gallbladder Motility Study|Gastric Emptying of Plant Sterol-containing Mini Drinks in Different Meal Intake Scenarios and Their Effect on Gallbladder Emptying|Completed||N/A|18|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 00:47:00.983898|2018-06-01 00:47:00.983898
NCT00940836|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2009-07-15|2009-07-15|2009-07-16|Estimate|||||||2009-07-15|2009-07-16|Estimate|June 2009||2009-06-30|July 2009|2009-07-31||||November 2009|Anticipated|2009-11-30||Interventional|||Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome|Phase III Clinical Trial - Efficacy and Safety Assessment of a Compound Acetaminophen, Chlorpheniramine and Phenylephrine Combination in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome in Adults|Unknown status|Recruiting|Phase 3|146|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:47:01.059469|2018-06-01 00:47:01.059469
NCT00940823|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|2016-08-21||2018-03-08|2009-07-15|2009-07-16|Estimate|2018-03-08|2018-03-13|Actual||||2018-03-08|2018-03-13|Actual|July 2005||2005-07-31|March 2018|2018-03-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma|The Ahmed Versus Baerveldt (AVB) Study: Prospective, Multicenter Trial Comparing the Ahmed-FP7 Valve With the Baerveldt-350 Implant in Treating Refractory Glaucoma|Completed||N/A|238|Actual|Credit Valley EyeCare|"Using predetermined IOP cutoffs may not reflect individual patient outcomes.~Visual field progression was not an outcome criteria due to the poor baseline vision of patients.~Results can only be applied to patients with advanced glaucoma."|2|||f||||f||||||||||2018-06-01 00:47:01.171294|2018-06-01 00:47:01.171294
NCT00940810|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-08-25|2009-07-15|2009-07-16|Estimate|||||||2015-08-25|2015-08-26|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Plasma Disc Decompression Versus Conservative Care|A Prospective, Randomized, Controlled, Multi Center, Clinical Study With Plasma Disc Decompression Versus Conservative Care|Completed||N/A|46|Actual|ArthroCare Corporation||2|||f||||f||||||||||2018-06-01 00:47:01.538042|2018-06-01 00:47:01.538042
NCT00940797|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-15|2009-07-15|2009-07-16|Estimate|||||||2009-07-15|2009-07-16|Estimate|July 2008||2008-07-31|July 2009|2009-07-31||||February 2009|Actual|2009-02-28||Interventional|DMMETclamp||Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients (CLAMP)|Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients by Glucose CLAMP Technique|Completed||Phase 2|20|Actual|Laboratorios Silanes S.A. de C.V.||2|||f||||f||||||||||2018-06-01 00:47:01.594093|2018-06-01 00:47:01.594093
NCT00940784|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2014-11-24|2009-07-15|2009-07-16|Estimate|||||||2014-11-24|2014-11-26|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|ISCLAP||Clopidogrel and Aspirin for the Treatment of Polycythemia Vera|MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera|Withdrawn||Phase 2|0|Actual|Icahn School of Medicine at Mount Sinai||2||Could not get drug|f||||t||||||||||2018-06-01 00:47:01.75773|2018-06-01 00:47:01.75773
NCT00940771|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2015-10-21|2009-07-15|2009-07-16|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens|Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels|Unknown status|Active, not recruiting|Phase 4|10|Anticipated|Phoenix Children's Hospital||1|||f||||f||||||||||2018-06-01 00:47:01.828872|2018-06-01 00:47:01.828872
NCT00940758|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2017-04-04|2009-07-15|2009-07-16|Estimate|||||||2017-04-04|2017-04-06|Actual|June 2009|Actual|2009-06-30|April 2017|2017-04-30|June 2014|Actual|2014-06-30|May 2012|Actual|2012-05-31||Interventional|||Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy|Phase I and Pharmacokinetic Study of Biweekly PEP02 (Liposome Irinotecan) in Patients With Metastatic Colorectal Cancer Refractory to First-line Oxaliplatin-based Chemotherapy|Completed||Phase 1|18|Actual|PharmaEngine||1|||f||||f||||||||||2018-06-01 00:47:01.925213|2018-06-01 00:47:01.925213
NCT00940745|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2009-07-15|2009-07-15|2009-07-16|Estimate|||||||2009-07-15|2009-07-16|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|MSATIH||Modified Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage:a Multi-center Controlled Study|Modified Stereotactic Aspiration and Thrombolysis of Spontaneous Intracerebral Hemorrhage|Unknown status|Not yet recruiting|N/A|400|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-06-01 00:47:01.988182|2018-06-01 00:47:01.988182
NCT00940719|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-08-10|2009-07-15|2009-07-16|Estimate|||||||2010-08-10|2010-08-11|Estimate|August 2009||2009-08-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)|The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot Study|Completed||N/A|15|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 00:47:02.147296|2018-06-01 00:47:02.147296
NCT00940706|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2011-09-27|2009-07-15|2009-07-16|Estimate|||||||2011-09-27|2011-09-28|Estimate|March 2010||2010-03-31|July 2009|2009-07-31|September 2013|Anticipated|2013-09-30|April 2012|Anticipated|2012-04-30||Interventional|||Promotion of a Physically Active Lifestyle in Cerebral Palsy|"Promotion of a Physically Active Lifestyle in Large Populations of Children and Teenagers With Cerebral Palsy in the Middle East"|Unknown status|Enrolling by invitation|Phase 1|120|Anticipated|Assaf-Harofeh Medical Center||3|||f||||t||||||||||2018-06-01 00:47:02.293848|2018-06-01 00:47:02.293848
NCT00940693|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-12-13|2009-07-15|2009-07-16|Estimate|||||||2010-12-13|2010-12-14|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pilot Study of Duloxetine in Adult Attention Deficit Hyperactivity Disorder(ADHD)|Pilot Study of the Efficacy of Duloxetine in Treating Adults With Attention Deficit Hyperactivity Disorder: a Randomized, Controlled Trial.|Completed||Phase 2|40|Anticipated|Université de Montréal||2|||f||||f||||||||||2018-06-01 00:47:02.382734|2018-06-01 00:47:02.382734
NCT00940680|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2009-07-15|2009-07-15|2009-07-16|Estimate|||||||2009-07-15|2009-07-16|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension|A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 100mg Versus Losartan 100mg in Patients With Essential Hypertension Not Controlled on Losartan Monotherapy|Completed||Phase 3|142|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-06-01 00:47:02.465015|2018-06-01 00:47:02.465015
NCT00940667|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-10-10|2009-07-15|2009-07-16|Estimate|||||||2016-10-10|2016-10-12|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension|A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy|Completed||Phase 3|185|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-06-01 00:47:02.600599|2018-06-01 00:47:02.600599
NCT00940654|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-05-18|2009-07-15|2009-07-16|Estimate|||||||2010-05-18|2010-05-19|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|FACE||The Fever and Antipyretic in Critically Illness Evaluation Study|The Fever and Antipyretic in Critically Illness Evaluation Study|Completed|||1426|Actual|Japanese Society of Intensive Care Medicine|||2||f||||f||||||||||2018-06-01 00:47:02.715192|2018-06-01 00:47:02.715192
NCT00940641|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2011-01-21|2009-07-15|2009-07-16|Estimate|||||||2011-01-21|2011-01-24|Estimate|August 2009||2009-08-31|January 2011|2011-01-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration|A Phase 1, Open, Two Period, Single-Centre, Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) After Intravenous and 14C-labelled Oral Administration of AZD7325 to Healthy Male Volunteers|Suspended||Phase 1|8|Anticipated|AstraZeneca||2||Study withdrawn prior to enrollment due to AZ business decision unrelated to safety.|f||||f||||||||||2018-06-01 00:47:02.870747|2018-06-01 00:47:02.870747
NCT00940628|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-04-02|2009-07-15|2009-07-16|Estimate|||||||2016-04-02|2016-04-05|Estimate|April 2008||2008-04-30|April 2016|2016-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of Xenical (Orlistat) in Overweight and Obese Adolescents|Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents|Completed||Phase 3|60|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:47:02.982824|2018-06-01 00:47:02.982824
NCT00940615|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-06-25|2009-07-15|2009-07-16|Estimate|||||||2015-06-25|2015-06-26|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Aerobic Exercise on Mild Traumatic Brain Injury|Aerobic Exercise in TBI: White Matter Integrity and Cognition|Terminated||N/A|24|Anticipated|VA Office of Research and Development||2||Primary Investigator is no longer employeed by the VA|f||||f||||||||||2018-06-01 00:47:03.12495|2018-06-01 00:47:03.12495
NCT00940602|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2017-09-11|2009-07-15|2009-07-16|Estimate|||||||2017-09-11|2017-09-12|Actual|March 22, 2010|Actual|2010-03-22|September 2017|2017-09-30|February 2, 2018|Anticipated|2018-02-02|February 2, 2018|Anticipated|2018-02-02||Interventional|TELESTO||Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study|A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload|Active, not recruiting||Phase 2|224|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:47:03.232631|2018-06-01 00:47:03.232631
NCT00940589|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2013-07-15|2009-07-15|2009-07-16|Estimate|||||||2013-07-15|2013-07-16|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor|A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor|Completed||Phase 2|73|Actual|Neurim Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 00:47:03.560361|2018-06-01 00:47:03.560361
NCT00940576|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|2009-07-17||2015-05-05|2009-07-15|2009-07-16|Estimate|2015-04-01|2015-04-20|Estimate||||2015-05-05|2015-05-25|Estimate|July 2000||2000-07-31|May 2015|2015-05-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases|Dietetic Effects of Mare's Milk in Patients With Chronic Inflammatory Bowel Diseases (IBD) - a Double Blind Placebo Controlled Cross-over Study.|Completed||N/A|17|Actual|University of Jena||2|||f||||t||||||||||2018-06-01 00:47:03.663718|2018-06-01 00:47:03.663718
NCT00940563|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2011-06-30|2009-07-15|2009-07-16|Estimate|||||||2011-06-30|2011-07-01|Estimate|March 2002||2002-03-31|June 2011|2011-06-30||||August 2004|Actual|2004-08-31||Interventional|||A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors|STI571 (Imatinib) in KIT-expressing Gastrointestinal Stromal Tumors (GIST): a Prospective, Open-label, Multicenter Study on Best Clinical Use in the Advanced Disease.|Completed||Phase 2|135|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:47:03.845372|2018-06-01 00:47:03.845372
NCT00940550|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2011-08-05|2009-07-15|2009-07-16|Estimate|||||||2011-08-05|2011-08-08|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women|A Randomised, Double-Blind, Placebo-Controlled Four-Way Cross-Over Trial to Study the Effects of Prolonged-Release Melatonin, Temazepam and Zolpidem on the Spectral Composition of the EEG During Nocturnal Sleep in Healthy Middle-Aged Men and Women|Completed||Phase 1|16|Actual|University of Surrey||4|||f||||f||||||||||2018-06-01 00:47:03.952623|2018-06-01 00:47:03.952623
NCT00940537|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2010-04-13||2010-07-02|2009-07-15|2009-07-16|Estimate|2010-04-13|2010-05-13|Estimate||||2010-07-02|2010-07-07|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|NAFLD||Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)|MRS Validation Study of Hepatic Triglyceride Content in Non-alcoholic Fatty Liver Disease (NAFLD)Subjects Pre- and Post-Prandial|Completed|||14|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 00:47:04.043746|2018-06-01 00:47:04.043746
NCT00940524|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2014-04-09|2009-07-15|2009-07-16|Estimate|||||||2014-04-09|2014-04-10|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia|Phase I Study of Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): ALL-6 Protocol|Completed||Phase 1|7|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 00:47:04.31088|2018-06-01 00:47:04.31088
NCT00940511|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-03-14|2009-07-15|2009-07-16|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Coordinated Care for Disabled Medicaid Recipients|Effects of Coordinated Care for Disabled Medicaid Recipients|Completed||N/A|2618|Actual|MDRC||2|||f||||f||||||||No||2018-06-01 00:47:04.397764|2018-06-01 00:47:04.397764
NCT00940498|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2012-11-08|2009-07-15|2009-07-16|Estimate|||||||2012-11-08|2012-11-12|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|August 2011|Actual|2011-08-31||Interventional|B2151001||Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors|A Phase 1 Study Of PF-05212384 (Also Known as PKI-587) Administered As An Intravenous Infusion To Subjects With Solid Tumors|Completed||Phase 1|78|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:47:04.484494|2018-06-01 00:47:04.484494
NCT00940485|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2016-01-24||2016-02-26|2009-07-15|2009-07-16|Estimate|2016-01-24|2016-02-22|Estimate||||2016-02-26|2016-03-25|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Full analysis set (FAS) included all randomized subjects who had baseline evaluations and at least one efficacy evaluation.|A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B|A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir|Completed||Phase 4|200|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:47:04.61471|2018-06-01 00:47:04.61471
NCT00940472|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-05-17|2009-07-15|2009-07-16|Estimate|||||||2010-05-17|2010-05-18|Estimate|March 2009||2009-03-31|May 2010|2010-05-31||||December 2009|Actual|2009-12-31||Interventional|DMMET2||Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients|Randomized, Double-Blind, Efficacy and Safety, Controlled Study, Between DMMET-01 and Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetics Patients.|Completed||Phase 2/Phase 3|20|Anticipated|Laboratorios Silanes S.A. de C.V.||2|||f||||f||||||||||2018-06-01 00:47:04.971927|2018-06-01 00:47:04.971927
NCT00940459|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-11-15|2009-07-15|2009-07-16|Estimate|||||||2016-11-15|2016-11-16|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Subjective and Conjunctival Response to Edge Design of Different Silicone Hydrogels|Subjective and Conjunctival Response to Edge Design of Different Silicone Hydrogels|Completed||N/A|30|Actual|Alcon Research||5|||f||||f||||||||||2018-06-01 00:47:05.03949|2018-06-01 00:47:05.03949
NCT00940446|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2017-04-03||2018-01-04|2009-07-15|2009-07-16|Estimate|2018-01-04|2018-01-30|Actual||||2018-01-04|2018-01-30|Actual|July 2007||2007-07-31|January 2018|2018-01-31|April 30, 2010|Actual|2010-04-30|April 30, 2010|Actual|2010-04-30||Interventional|||A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement|A Comparison of INSORB Staples With Metal Staples in Total Hip Replacement|Completed||N/A|60|Actual|Orthopaedic Research Foundation||2|||f||||t||||||||||2018-06-01 00:47:05.111534|2018-06-01 00:47:05.111534
NCT00940433|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-01-14|2009-07-15|2009-07-16|Estimate|||||||2010-01-14|2010-01-15|Estimate|February 2008||2008-02-29|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Hernia Repair Four Arm Comparative Study|Four Arm Randomised Trial Comparing Laparoscopic And Open Hernia Repairs|Completed||N/A|100|Actual|Faculty of Medicine, University of Alexandria||4|||f||||f||||||||||2018-06-01 00:47:05.339749|2018-06-01 00:47:05.339749
NCT00940420|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2016-11-01|2009-07-15|2009-07-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2002||2002-10-31|November 2016|2016-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C|Safety and Tolerability of Ribavirin (Ro 20-9963) in Combination With Peginterferon Alfa in Patients With Chronic Hepatitis C|Completed||Phase 4|2695|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:47:05.414069|2018-06-01 00:47:05.414069
NCT00940407|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2011-11-16|2009-07-15|2009-07-16|Estimate|||||||2011-11-16|2011-11-18|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TORPA||Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration|A Pilot Study to Evaluate Clinical Outcomes of Photobiomodulation in Patients With Age Related Macular Degeneration of the Dry Type.|Completed||Phase 2|18|Actual|Merry, Graham, M.D.|||||f||||t||||||||||2018-06-01 00:47:05.56264|2018-06-01 00:47:05.56264
NCT00940394|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2014-08-19|2009-07-15|2009-07-16|Estimate|||||||2014-08-19|2014-08-21|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|MSG||Effectiveness of Family Group Interventions for People With Schizophrenia|Evaluation of the Effects of Mutual Support and Psycho-educational Group Interventions for Family Caregivers of People With Schizophrenia|Completed||Phase 2|128|Actual|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-06-01 00:47:05.64487|2018-06-01 00:47:05.64487
NCT00940381|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-11-16|2009-07-14|2009-07-16|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Sirolimus and Cetuximab in Advanced Malignancies|A Phase I Trial of Sirolimus and Cetuximab in Patients With Advanced Malignancies|Completed||Phase 1|165|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:47:05.735409|2018-06-01 00:47:05.735409
NCT00940368|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2009-07-24|2009-07-15|2009-07-16|Estimate|||||||2009-07-24|2009-07-28|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|||A Study to Assess the Anti-Emetic Efficacy of Ginger in Children and Adolescents Receiving Chemotherapy|A Study to Evaluate the Anti-Emetic Effect of Ginger Powder Vs Placebo as an Add-on Therapy in Children and Adolescents Receiving Chemotherapy : A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 00:47:05.812029|2018-06-01 00:47:05.812029
NCT00940355|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2010-01-19|2009-07-15|2009-07-16|Estimate|||||||2010-01-19|2010-01-20|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Secondary Prevention of Problems in Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Secondary Prevention of Problems in Health Status in Patients With COPD by Early Detection, Motivational Intervention to Engage in Treatment by the Patient, and by Individualized Treatment|Completed||N/A|303|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 00:47:05.904428|2018-06-01 00:47:05.904428
NCT00940342|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2017-02-15|2009-07-15|2009-07-16|Estimate|||||||2017-02-15|2017-02-17|Actual|August 12, 2004|Actual|2004-08-12|February 2017|2017-02-28|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|||Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia|Rituximab In Combination With Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|119|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-06-01 00:47:05.992987|2018-06-01 00:47:05.992987
NCT00940329|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2016-12-01|2009-07-15|2009-07-16|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2004||2004-04-30|September 2016|2016-09-30|December 2004|Actual|2004-12-31|July 2004|Actual|2004-07-31||Interventional|||Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol|Investigation on the Cardiovascular and Pharmacokinetic Interaction Between Oral Roflumilast and Inhaled Formoterol in Healthy Subjects|Completed||Phase 1|27|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 00:47:06.086264|2018-06-01 00:47:06.086264
NCT00940316|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-15|||2018-01-10|2009-07-15|2009-07-16|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2009||2009-07-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer|A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|96|Anticipated|Northwestern University||3|||f||||t||||||||||2018-06-01 00:47:06.171941|2018-06-01 00:47:06.171941
NCT00940303|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2016-11-01|2009-07-15|2009-07-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer|An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study)|Completed||Phase 2|97|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:47:06.273268|2018-06-01 00:47:06.273268
NCT00940290|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-12-09||2010-01-12|2009-07-15|2009-07-16|Estimate|2009-12-09|2010-01-13|Estimate||||2010-01-12|2010-01-20|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Practice Guidelines Grading Systems|Different Grading Systems to Grade Evidence and Recommendations in Clinical Practice Guidelines: Does it Influence the Clinicians´ Behavior?|Completed||N/A|216|Actual|Instituto Tecnologico y de Estudios Superiores de Monterey|The outcome was measured in only one topic and could be not expanded to other areas of pediatrics or even other specialties in medicine.|4|||f||||f||||||||||2018-06-01 00:47:06.38099|2018-06-01 00:47:06.38099
NCT00940277|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-02-02|2009-07-14|2009-07-15|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Couple-Focused Intervention for Breast Cancer Patients|Couple-Focused Group Intervention for Women With Early-Stage Breast Cancer|Completed||N/A|611|Actual|Fox Chase Cancer Center||2|||f||||t||||||||||2018-06-01 00:47:06.636258|2018-06-01 00:47:06.636258
NCT00940264|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2012-02-10|2009-07-14|2009-07-15|Estimate|||||||2012-02-10|2012-02-13|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Laparoscopic Transvaginal Hybrid Cholecystectomy: a Prospective Data Collection.||Completed|||200|Actual|Cantonal Hospital of St. Gallen|||1||f||||f||||||||||2018-06-01 00:47:06.710637|2018-06-01 00:47:06.710637
NCT00940251|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-14|2009-07-14|2009-07-15|Estimate|||||||2009-07-14|2009-07-15|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs|Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs|Completed||Phase 2|26|Actual|Jyoti Clinical and Pathological Laboratory||2|||f||||t||||||||||2018-06-01 00:47:06.773356|2018-06-01 00:47:06.773356
NCT00940238|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2017-10-20|2009-07-14|2009-07-15|Estimate|||||||2017-10-20|2017-10-24|Actual||||October 2017|2017-10-31||||||||Interventional|||Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:47:06.83583|2018-06-01 00:47:06.83583
NCT00940225|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-12|||2015-02-18|2009-07-13|2009-07-15|Estimate|||||||2015-02-18|2015-02-19|Estimate|August 2009||2009-08-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|||Study of Cabozantinib (XL184) in Adults With Advanced Malignancies|A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors|Completed||Phase 2|730|Actual|Exelixis||4|||f||||t||||||||||2018-06-01 00:47:06.887251|2018-06-01 00:47:06.887251
NCT00940212|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-12-08|2009-07-14|2009-07-15|Estimate|||||||2010-12-08|2010-12-10|Estimate|July 2009||2009-07-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|SAD||Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 After Single Ascending Doses in Healthy Male and Female Volunteers Without Childbearing Potential|Completed||Phase 1|80|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:47:07.003371|2018-06-01 00:47:07.003371
NCT00940199|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-14|2009-07-14|2009-07-15|Estimate|||||||2009-07-14|2009-07-15|Estimate|August 2006||2006-08-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|PassionP||PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial|Prospective Randomized Trial of Standard Versus pH-adjusted Radiocolloid for Patients Undergoing Sentinel Lymph Node Mapping and Biopsy for Breast Cancer PASSION - P Trial: Ph Adjusted Sulfur-Colloid, Sentinel Initiative ON Pain Trial|Completed|||140|Actual|Walter Reed Army Medical Center|||4||f||||t||||||||||2018-06-01 00:47:07.062227|2018-06-01 00:47:07.062227
NCT00940186|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-14|2009-07-14|2009-07-15|Estimate|||||||2009-07-14|2009-07-15|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|||||Observational|||Clinical Pharmacokinetics Study on Pikamilone|Clinical Pharmacokinetics Study on Pikamilone|Completed|||30|Actual|Chinese Academy of Sciences|||3||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 00:47:07.143215|2018-06-01 00:47:07.143215
NCT00940173|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-12|||2017-10-18|2009-07-14|2009-07-15|Estimate|||||||2017-10-18|2017-10-20|Actual|July 2009||2009-07-31|October 2017|2017-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) in Patients With Type I Diabetes Mellitus|A Phase I/IIa Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type I Diabetes Mellitus|Completed||Phase 1/Phase 2|16|Actual|Diatranz Otsuka Limited||4|||f||||t||||||||||2018-06-01 00:47:07.192493|2018-06-01 00:47:07.192493
NCT00940160|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-01-20|2009-07-14|2009-07-15|Estimate|||||||2010-01-20|2010-01-21|Estimate|July 2009||2009-07-31|January 2010|2010-01-31||||January 2010|Actual|2010-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients|A Randomized, Double Blind, Placebo Controlled, Study To Compare The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of Intravenous Administration Of QAX576 In Controlled Or Partially Controlled Asthma Patients|Completed||Phase 1/Phase 2|30|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:47:07.283764|2018-06-01 00:47:07.283764
NCT00940147|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2013-06-05|2009-07-14|2009-07-15|Estimate|||||||2013-06-05|2013-06-06|Estimate|January 2007||2007-01-31|June 2013|2013-06-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Observational|OAC||Early Endoscopic Indicators for OACs After Lung Transplantation: Development of a Novel Mucosal Healing Score|Early Indicators for Obstructive Airway Complications After Lung|Completed|||180|Actual|Hannover Medical School|||2||f||||t||||||||||2018-06-01 00:47:07.357286|2018-06-01 00:47:07.357286
NCT00940134|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2012-06-14|2009-07-14|2009-07-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|INGEAR-1||Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.|INGEAR-1: Effects of INtravenous Infusions of PYY3-36 and GLP-1, as Monoinfusion and in Combination, on ad Libitum Energy Intake, Appetite Sensation, and Energy Expenditure in Healthy Obese Subjects.|Completed||N/A|24|Actual|University of Copenhagen||4|||f||||f||||||||||2018-06-01 00:47:07.407807|2018-06-01 00:47:07.407807
NCT00940121|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2013-07-01|2009-07-14|2009-07-15|Estimate|||||||2013-07-01|2013-07-03|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron|A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Assess the Pharmacokinetics of Mirabegron OCAS Formulations With Different Release Rates Versus IV Infusion in Healthy Volunteers|Completed||Phase 1|91|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 00:47:07.524158|2018-06-01 00:47:07.524158
NCT00940108|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2013-07-09||2017-10-23|2009-07-14|2009-07-15|Estimate|2013-10-28|2013-11-20|Estimate||||2017-10-23|2017-11-27|Actual|August 2009||2009-08-31|October 2017|2017-10-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children|A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months to < 9 Years.|Completed||Phase 2|370|Actual|Seqirus||2|||f||||t||||||||||2018-06-01 00:47:07.653001|2018-06-01 00:47:07.653001
NCT00940095|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13||2011-03-22|2015-04-28|2009-07-14|2009-07-15|Estimate||||2011-03-22|2011-03-28|Estimate|2015-04-28|2015-05-15|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|CONSCIOUS-3||Clazosentan in Aneurysmal Subarachnoid Hemorrhage|A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Endovascular Coiling.|Terminated||Phase 3|577|Actual|Actelion||3||Lack of efficacy data from the Phase 3 clinical study (AC-054-301; CONSCIOUS-2)|f||||t||||||||||2018-06-01 00:47:08.792107|2018-06-01 00:47:08.792107
NCT00940082|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2011-09-11|2009-07-14|2009-07-15|Estimate|||||||2011-09-11|2011-09-13|Estimate|June 2007||2007-06-30|September 2011|2011-09-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Observational|||The Cardiopathic Features and Analysis of Risk Factors in the Elderly Diabetic|The Cardiopathic Features and Analysis of Risk Factors in the Elderly Diabetic|Unknown status|Recruiting||400|Anticipated|Third Military Medical University|||4||f||||t||||||Samples Without DNA|"~     Take the fasting blood more than 12 hours overnight~   "|||2018-06-01 00:47:09.081717|2018-06-01 00:47:09.081717
NCT00940069|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-02-19|2009-07-14|2009-07-15|Estimate|||||||2016-02-19|2016-02-22|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|June 2013|Actual|2013-06-30||Interventional|TPEIAL||TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer|A Multicenter, Open Clinical Trial of Using TS Gene Polymorphism to Predict Effect in Patients of Advanced Lung Adenocarcinoma to Pemetrexed Combining With Cisplatin Regiment as First-line Treatment|Completed||Phase 2|60|Actual|Hunan Province Tumor Hospital||2|||f||||t||||||||No||2018-06-01 00:47:09.154682|2018-06-01 00:47:09.154682
NCT00940056|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-09-02|2009-07-14|2009-07-15|Estimate|||||||2016-09-02|2016-09-05|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|TEA||Totally Endoscopic Ablation of Atrial Fibrillation|Totally Endoscopic Ablation of Atrial Fibrillation|Completed||N/A|36|Actual|Region Örebro County||2|||f||||t||||||||||2018-06-01 00:47:09.236314|2018-06-01 00:47:09.236314
NCT00940043|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2013-01-15|2009-07-14|2009-07-15|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Observational|EFFARM||Monitoring of the Inflammatory Response of Patients With Premature Rupture of Membranes With Bedside Tests|Monitoring of Women With Preterm Premature Rupture of Membranes (PPROM) Between 28 and 33 Weeks of Gestation With Repetitive Immunochromatographic Bedside Test to Detect Inflammatory Protein in Vaginal Secretions.|Completed|||60|Actual|Université de Sherbrooke|||1||f||||f||||||Samples Without DNA|"~     vaginal secretions~   "|||2018-06-01 00:47:09.313652|2018-06-01 00:47:09.313652
NCT00940030|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-08-09|2009-07-14|2009-07-15|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|MBP||Comparison of Mechanical Bowel Preparation Versus Enema for Candidates to Colorectal Resection for Adenocarcinoma|Effect of Mechanical Bowel Preparation With Polyethylene Glycol Plus Bowel Enema (Glycerine 5%) vs Bowel Enema Alone in Patients Candidates to Colorectal Resection for Malignancy. Prospective, Randomized Clinical Trial|Recruiting||Phase 3|440|Anticipated|European Institute of Oncology||2|||f||||f||||||||||2018-06-01 00:47:09.370243|2018-06-01 00:47:09.370243
NCT00940017|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-10-20||2010-01-05|2009-07-14|2009-07-15|Estimate|2010-01-05|2010-02-09|Estimate||||2010-01-05|2010-02-09|Estimate|September 2008||2008-09-30|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects|A Phase 4, Open Label Study To Assess The Bronchopulmonary Pharmacokinetics Of Anidulafungin And Voriconazole Following Intravenous Administration In Healthy Subjects|Completed||Phase 4|24|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:47:09.456976|2018-06-01 00:47:09.456976
NCT00940004|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2017-04-13|2009-07-14|2009-07-15|Estimate|||||||2017-04-13|2017-04-17|Actual|June 2009||2009-06-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients|TLR Ligand Matured Dendritic Cell Vaccination in Melanoma Patients: the Key Towards a More Potent Immune Induction?|Completed||Phase 1/Phase 2|20|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 00:47:10.649237|2018-06-01 00:47:10.649237
NCT00939991|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2013-05-03||2013-05-03|2009-07-14|2009-07-15|Estimate|2013-05-03|2013-06-24|Estimate||||2013-05-03|2013-06-24|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|January 2012|Actual|2012-01-31||Interventional|||Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas|Phase I/II Study of Bevacizumab Plus Daily Temozolomide and Vorinostat for Recurrent Malignant Glioma Patients|Completed||Phase 1/Phase 2|48|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:47:10.754064|2018-06-01 00:47:10.754064
NCT00939978|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-10-06|2009-07-14|2009-07-15|Estimate|||||||2010-10-06|2010-10-07|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery||Completed||N/A|74|Actual|Yonsei University||2|||f||||||||||||||2018-06-01 00:47:11.109318|2018-06-01 00:47:11.109318
NCT00939965|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2013-08-09|2009-07-14|2009-07-15|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2009||2009-02-28|July 2009|2009-07-31||||||||Interventional|||Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma|Pilot Study to Investigate the Feasibility of 13-cis-retinoic Acid Pharmacokinetic Monitoring in High-risk Neuroblastoma Patients|Unknown status|Recruiting|N/A|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:47:11.172113|2018-06-01 00:47:11.172113
NCT00939952|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2012-07-25||2013-01-22|2009-07-14|2009-07-15|Estimate|2013-01-22|2013-02-26|Estimate||||2013-01-22|2013-02-26|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis|Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis|Completed||Phase 4|7|Actual|Albany College of Pharmacy and Health Sciences||1|||f||||f||||||||||2018-06-01 00:47:11.371653|2018-06-01 00:47:11.371653
NCT00939939|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2011-06-24|2009-07-14|2009-07-15|Estimate|||||||2011-06-24|2011-06-27|Estimate|March 2010||2010-03-31|July 2009|2009-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Sitagliptin on Postprandial Lipoprotein Metabolism||Terminated||Phase 4|3|Actual|Ludwig-Maximilians - University of Munich||2||Recruitment failure|f||||f||||||||||2018-06-01 00:47:11.591943|2018-06-01 00:47:11.591943
NCT00939926|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-10-20|2009-07-14|2009-07-15|Estimate|||||||2017-10-20|2017-10-24|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited, India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions|Bioequivalence Study of Risperidone 1 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:47:11.676655|2018-06-01 00:47:11.676655
NCT00939913|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-09-17|2009-07-14|2009-07-15|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|NAC||Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy|N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes|Unknown status|Recruiting|Phase 4|400|Anticipated|Ochsner Health System||2|||f||||t||||||||||2018-06-01 00:47:11.732631|2018-06-01 00:47:11.732631
NCT00939900|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2015-05-18||2015-06-07|2009-07-14|2009-07-15|Estimate|2015-06-07|2015-07-02|Estimate||||2015-06-07|2015-07-02|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EZAPCOFH||Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head|Multicenter, Open-labeled, Randomized Clinical Trial to Determine the Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head|Completed||Phase 3|110|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:47:11.816484|2018-06-01 00:47:11.816484
NCT00939887|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2010-02-04|2009-07-14|2009-07-15|Estimate|||||||2010-02-04|2010-02-08|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)|A Phase 1, Healthy Volunteer Qualification Of Ligand [11C] PF-04767135 And Randomized Determination Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET|Terminated||Phase 1|12|Actual|Pfizer||1||"This study was terminated on January 6, 2010, due to toxicology findings in animals exposed to~   PF-04455242 for three months."|f||||f||||||||||2018-06-01 00:47:11.99879|2018-06-01 00:47:11.99879
NCT00939874|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2015-01-13||2015-05-28|2009-07-14|2009-07-15|Estimate|2015-05-28|2015-06-12|Estimate||||2015-05-28|2015-06-12|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|June 2012|Actual|2012-06-30||Interventional|TROP||Switch From Tenofovir to Raltegravir for Low Bone Mineral Density|Switch From Tenofovir to Raltegravir for Low Bone Mineral Density|Completed||Phase 4|52|Actual|St Vincent's Hospital, Sydney||1|||f||||t||||||||||2018-06-01 00:47:12.091191|2018-06-01 00:47:12.091191
NCT00939861|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-14|2009-07-14|2009-07-15|Estimate|||||||2009-07-14|2009-07-15|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Laparoscopy Versus Laparotomy for Colorectal Endometriosis|Study Comparing Laparoscopy Versus Laparotomy in the Treatment of Colorectal Endometriosis|Unknown status|Active, not recruiting|Phase 3|52|Actual|Tenon Hospital, Paris||2|||f||||f||||||||||2018-06-01 00:47:12.268058|2018-06-01 00:47:12.268058
NCT00939848|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2014-10-24|2009-07-14|2009-07-15|Estimate|||||||2014-10-24|2014-10-27|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|September 2014|Actual|2014-09-30|September 2012|Actual|2012-09-30||Interventional|ABC-03||Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers|Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers|Completed||Phase 2/Phase 3|124|Actual|University College, London||2|||f||||t||||||||||2018-06-01 00:47:12.331219|2018-06-01 00:47:12.331219
NCT00939835|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2017-10-20|2009-07-14|2009-07-15|Estimate|||||||2017-10-20|2017-10-24|Actual||||October 2017|2017-10-31||||||||Interventional|||Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition|A Randomized, Single Dose, Open Label, Bioequivalence Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:47:12.399836|2018-06-01 00:47:12.399836
NCT00939822|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2017-03-27|2009-07-14|2009-07-15|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2009||2009-03-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2013|Actual|2013-09-30||Interventional|SHARP||Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease|"Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for AD: Statins in Healthy, At-Risk Adults: Impact on Amyloid and Regional Perfusion (SHARP) Study"|Active, not recruiting||Phase 2|88|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:47:12.529606|2018-06-01 00:47:12.529606
NCT00939809|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2014-02-03||2015-02-27|2009-07-14|2009-07-15|Estimate|2014-06-17|2014-07-17|Estimate||||2015-02-27|2015-03-19|Estimate|July 2009||2009-07-31|February 2015|2015-02-28||||July 2012|Actual|2012-07-31||Interventional|||A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|31|Actual|Gynecologic Oncology Group|Note: due to the limited activity of this agent, it was decided not to expend resources assaying the PBMCs.|1|||f||||||||||||||2018-06-01 00:47:12.642834|2018-06-01 00:47:12.642834
NCT00939796|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2014-05-07||2014-09-26|2009-07-14|2009-07-15|Estimate|2014-05-07|2014-06-09|Estimate||||2014-09-26|2014-10-06|Estimate|March 2009||2009-03-31|September 2014|2014-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|inVENT||Clinical Study of the Tympanostomy Tube Delivery System|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System For the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media (inVENT)|Completed||N/A|16|Actual|Acclarent||1|||f||||f||||||||||2018-06-01 00:47:12.97562|2018-06-01 00:47:12.97562
NCT00939783|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2012-10-11|2011-09-08|2012-10-11|2009-07-14|2009-07-15|Estimate|2012-10-11|2012-11-14|Estimate|2011-09-08|2011-09-12|Estimate|2012-10-11|2012-11-14|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease|An Open Label Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon (PF 01913539) In Patients With Alzheimer's Disease|Terminated||Phase 3|649|Actual|Pfizer|This safety study did not specify primary or secondary outcome measures. Relevant summaries of all safety assessments are thus provided. Urine blood abnormalities seen are deemed due to interference with dipstick test by a metabolite of dimebon.|1||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:47:13.223267|2018-06-01 00:47:13.223267
NCT00939770|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2017-06-20|2009-07-14|2009-07-15|Estimate|||||||2017-06-20|2017-06-21|Actual|September 2009||2009-09-30|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma|A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|122|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 00:47:13.710734|2018-06-01 00:47:13.710734
NCT00939757|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2013-06-24|2009-07-14|2009-07-15|Estimate|||||||2013-06-24|2013-06-26|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study of the Effect of Food on the Pharmacokinetics of Mirabegron|A Phase 1, Open-Label, Randomized, Single Oral Dose, Three-Way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Mirabegron|Completed||Phase 1|76|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:47:13.907293|2018-06-01 00:47:13.907293
NCT00939744|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-03-03|2009-07-14|2009-07-15|Estimate|||||||2015-03-03|2015-03-04|Estimate|May 2009||2009-05-31|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Observational|EAU2||Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation|Study of the Effect of Eicosanoids on Contractile Activity of Pregnant Human Myometrium in Pathological Situation.|Unknown status|Recruiting||130|Anticipated|Université de Sherbrooke|||1||f||||f||||||Samples Without DNA|"~     uterus biopsy~   "|||2018-06-01 00:47:13.984979|2018-06-01 00:47:13.984979
NCT00939731|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2011-09-12||2011-10-20|2009-07-14|2009-07-15|Estimate|2011-09-12|2011-10-18|Estimate||||2011-10-20|2011-10-24|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Relative Drug Exposures Of Two Formulations of PF-02341066|A Phase I Relative Bioavailability Study To Compare The Powder-In-Capsule And Immediate Release Tablet Of PF-02341066 In Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:47:14.069018|2018-06-01 00:47:14.069018
NCT00939718|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-05-28|2009-07-14|2009-07-15|Estimate|||||||2010-05-28|2010-05-31|Estimate|April 2009||2009-04-30|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||Comparison of Vitamin B12 Supplementation to Selective Serotonin Reuptake Inhibitor (SSRI) Versus SSRI Antidepressant Treatment Alone|Comparison of Vitamin B12 Supplementation and SSRI to SSRI Monotherapy in Treating Depression With Low Normal B12: A Randomized Open Label trialComparison of Vitamin B12 Supplementation to SSRI Versus SSRI Antidepressant Treatment Alone|Unknown status|Active, not recruiting|N/A|268|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-06-01 00:47:14.354028|2018-06-01 00:47:14.354028
NCT00939705|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-07-22||2011-09-08|2009-07-14|2009-07-15|Estimate|2011-09-08|2011-10-10|Estimate||||2011-09-08|2011-10-10|Estimate||||September 2011|2011-09-30||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions|Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Topiramate (2 x 25 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Topamax®, Ortho-McNeil Neurologics, Inc.) in Fed, Healthy, Adult Subjects|Completed||Phase 1|18|Actual|Torrent Pharmaceuticals Limited||2|||f||||||||||||||2018-06-01 00:47:14.451796|2018-06-01 00:47:14.451796
NCT00939692|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-07-22||2013-07-12|2009-07-14|2009-07-15|Estimate|2013-07-12|2013-07-16|Estimate||||2013-07-12|2013-07-16|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions|Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Topiramate (2 x 25 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Topamax®, Ortho-McNeil Neurologics, Inc.)in Fasted, Healthy, Adult Subjects|Completed||Phase 1|26|Actual|Torrent Pharmaceuticals Limited||2|||f||||||||||||||2018-06-01 00:47:14.737541|2018-06-01 00:47:14.737541
NCT00939679|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2013-08-01|2009-07-14|2009-07-15|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ERGEM||Effect of Gastric Bypass Surgery on Energy Metabolism|ERGEM: Effect of Roux-en-Y Gastric Bypass Surgery on Energy Metabolism.|Completed||N/A|32|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 00:47:14.971388|2018-06-01 00:47:14.971388
NCT00939666|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2017-03-22|2009-07-14|2009-07-15|Estimate|||||||2017-03-22|2017-03-24|Actual|July 1, 2009||2009-07-01|March 2017|2017-03-31|September 1, 2014|Actual|2014-09-01|September 1, 2014|Actual|2014-09-01||Interventional|||Minimal Invasive Strategies for Good and Complete Response to Chemoradiation in Rectal Cancer|Minimal Invasive Treatment for Patients With Good Response to Chemoradiation With Selection and Follow-up by MRI: a Single Arm Phase-II Feasibility Study in Rectal Cancer|Completed||N/A|28|Actual|Maastricht University Medical Center||1|||f||||t|f|f||||||Undecided|Pooling of data is expected in the future|2018-06-01 00:47:15.045501|2018-06-01 00:47:15.045501
NCT00939653|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-03-07|2009-07-14|2009-07-15|Estimate|||||||2012-03-07|2012-03-09|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)|T2007-002 A Phase II Study of Clofarabine With Etoposide and Cyclophosphamide in Relapsed/Refractory AML (IND 104,650)|Terminated||Phase 2|7|Actual|Therapeutic Advances in Childhood Leukemia Consortium||||Study lost funding and it was decided that it could not meet it's accrual goals.|f||||t||||||||||2018-06-01 00:47:15.117372|2018-06-01 00:47:15.117372
NCT00939640|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-09-07|2009-07-14|2009-07-15|Estimate|||||||2010-09-07|2010-09-08|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|DASH-DHF||Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure|Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet on Ventriculovascular Function in Heart Failure With Preserved Systolic Function|Unknown status|Recruiting|N/A|20|Anticipated|University of Michigan||1|||f||||f||||||||||2018-06-01 00:47:15.211618|2018-06-01 00:47:15.211618
NCT00939627|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2014-07-28||2017-12-28|2009-07-14|2009-07-15|Estimate|2015-08-03|2015-09-01|Estimate||||2017-12-28|2018-01-23|Actual|July 2009||2009-07-31|December 2017|2017-12-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional||Baseline participant measures are based on total eligible, consented, patients. Three of 55 consenting patients did not receive treatment. One patient had disease progression before treatment and 2 patients withdrew before treatment, resulting in 52 patients on treatment.|Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab|Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)|Accrual ended early based on planned interim analysis, but the study was completed with existing participants.|2|||f||||||||||||||2018-06-01 00:47:15.372778|2018-06-01 00:47:15.372778
NCT00939614|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2017-10-23|2009-07-14|2009-07-15|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Interventional|||Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited, India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.|A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited., India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:47:15.872427|2018-06-01 00:47:15.872427
NCT00939601|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-14|2009-07-14|2009-07-15|Estimate|||||||2009-07-14|2009-07-15|Estimate||||July 2009|2009-07-31||||||||Interventional|BREATHE||Evaluating Behavioral Treatments to Improve Adherence to CPAP in People With Obstructive Sleep Apnea|Evaluating Behavioral Treatments to Improve Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in People With Obstructive Sleep Apnea|Completed||N/A|||Brown University||3|||f||||||||||||||2018-06-01 00:47:15.915009|2018-06-01 00:47:15.915009
NCT00939588|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2016-11-16|2009-07-14|2009-07-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|July 2009||2009-07-31|November 2016|2016-11-30||||December 2009|Actual|2009-12-31||Interventional|||Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients|An 8 Week, Double-blind, Randomized, Parallel-group Study to Compare the Effect of Aliskiren 300mg + Valsartan 320mg vs. Telmisartan 80mg + Ramipril 10mg on Biomarkers of the Renin-angiotensin-aldosterone System in Moderate Hypertension|Completed||Phase 2|88|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:47:15.96099|2018-06-01 00:47:15.96099
NCT00939575|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-03-03|2009-07-14|2009-07-15|Estimate|||||||2015-03-03|2015-03-04|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Observational|GEM-1||Pre-eclampsia and Metabolomics|Feasibility Study to Develop Analysis of the Metabolomics Patterns of Women With Hypertensive Disorders During Pregnancy.|Unknown status|Active, not recruiting||50|Anticipated|Université de Sherbrooke|||2||f||||f||||||Samples Without DNA|"~     Whole blood and urine are collected~   "|||2018-06-01 00:47:16.104302|2018-06-01 00:47:16.104302
NCT00939562|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2009-11-19||2009-11-19|2009-07-14|2009-07-15|Estimate|2009-11-19|2009-12-23|Estimate||||2009-11-19|2009-12-23|Estimate|November 2008||2008-11-30|November 2009|2009-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate|An Open-Label, Two-Treatment, Two-Period, Randomized Cross-Over Study To Assess The Bioequivalence Between Commercial Doxycycline Carragenate And Monohydrate Tablet Formulations In Normal Healthy Male Subjects|Completed||Phase 4|24|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:47:16.165375|2018-06-01 00:47:16.165375
NCT00939549|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2010-11-08|2009-07-14|2009-07-15|Estimate|||||||2010-11-08|2010-11-09|Estimate|March 2011||2011-03-31|November 2010|2010-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|HiCy||High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis|Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis|Suspended||Phase 2|12|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||Suspended for revisions to the protocol.|f||||t||||||||||2018-06-01 00:47:16.385197|2018-06-01 00:47:16.385197
NCT00939536|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-07-22||2013-08-15|2009-07-14|2009-07-15|Estimate|2013-08-15|2013-10-22|Estimate||||2013-08-15|2013-10-22|Estimate|June 2005||2005-06-30|August 2013|2013-08-31|July 2005|Actual|2005-07-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fasted Conditions|Studies in Fasted Healthy, Normal Subjects to Compare the Single Dose Bio-availability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets|Completed||Phase 1|24|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||||2018-06-01 00:47:16.462552|2018-06-01 00:47:16.462552
NCT00939523|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2018-01-24|2009-07-14|2009-07-15|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2009||2009-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy|Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy|Recruiting||Phase 2|21|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-06-01 00:47:16.679363|2018-06-01 00:47:16.679363
NCT00939510|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2012-04-26||2013-01-24|2009-07-14|2009-07-15|Estimate|2012-06-11|2012-07-12|Estimate||||2013-01-24|2013-01-31|Estimate|July 2005||2005-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|October 2009|Actual|2009-10-31||Interventional|||Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer|Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer|Completed||Phase 1/Phase 2|32|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:47:16.766264|2018-06-01 00:47:16.766264
NCT00939497|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-10-20|2009-07-14|2009-07-15|Estimate|||||||2017-10-20|2017-10-24|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions|Bioequivalence Study of Risperidone 1.0 mg Tablets of Torrent Pharmaceuticals Limited., India and Risperdal® (Risperidone) 1.0 mg Tablets of Janssen Pharmaceutical Products, LP, USA, in Healthy Human Adult Subjects, Under Fasting Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:47:16.971333|2018-06-01 00:47:16.971333
NCT00939484|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2015-12-10||2016-01-28|2009-07-14|2009-07-15|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|August 2015|Actual|2015-08-31|May 2013|Actual|2013-05-31||Interventional||One patient in Stratum B was ineligible for the study and thus was not included in the baseline table.|Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma|A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma|Completed||Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:47:17.038406|2018-06-01 00:47:17.038406
NCT00939471|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2011-07-20||2017-08-04|2009-07-14|2009-07-15|Estimate|2012-07-10|2012-08-17|Estimate||||2017-08-04|2017-09-05|Actual|April 1, 2007|Actual|2007-04-01|August 2017|2017-08-31|May 1, 2010|Actual|2010-05-01|July 1, 2009|Actual|2009-07-01||Interventional|INTACT||Safety and Efficacy of Balloon Sinuplasty in Pediatric Sinusitis|Clinical Evaluation of Confirm the Safety and Efficacy of Balloon Sinuplasty Devices in the Treatment of Pediatric Sinusitis|Completed||N/A|44|Actual|Acclarent||1|||f||||t||||||||||2018-06-01 00:47:17.707219|2018-06-01 00:47:17.707219
NCT00939458|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2017-10-23|2009-07-14|2009-07-15|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Interventional|||Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects, Under Fed Conditions|A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2 x 25 mg IR Tablets of Torrent Pharmaceuticals Pvt., Ltd., India and Lamictal ® (Lamotrigine) 2 x 25 mg Tablets of Glaxo-SmithKline, USA, in Healthy Human Adult Subjects,Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:47:17.875768|2018-06-01 00:47:17.875768
NCT00939445|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-12-13|2009-07-14|2009-07-15|Estimate|||||||2015-12-13|2015-12-15|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SHD||Short Daily Hemodialysis and Online HDF: Which One is Better?|Short Daily Hemodialysis and Online HDF: Which One is Better?|Completed||Phase 3|10|Actual|Bangkok Metropolitan Administration Medical College and Vajira Hospital||2|||f||||t||||||||||2018-06-01 00:47:17.925421|2018-06-01 00:47:17.925421
NCT00939432|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-14|2009-07-14|2009-07-15|Estimate|||||||2009-07-14|2009-07-15|Estimate|November 2005||2005-11-30|July 2009|2009-07-31|April 2007|Actual|2007-04-30|April 2006|Actual|2006-04-30||Observational|||Taboo Perception of Incontinence, Depression and Cancer|The Greatest Taboo- Urinary Incontinence, Depression and Cancer|Completed|||150|Actual|Medical University of Vienna|||3||f||||f||||||||||2018-06-01 00:47:17.988633|2018-06-01 00:47:17.988633
NCT00939419|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2009-07-15|2009-07-14|2009-07-15|Estimate|||||||2009-07-15|2009-07-16|Estimate|January 2005||2005-01-31|July 2009|2009-07-31|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|||The Effectiveness of Health Facility-based and Community-based Care for Tuberculosis|A Randomised Control Trial on the Effectiveness of Three Modalities of Tuberculosis Treatment Supervision Under DOTS Strategy in Ethiopia.|Completed||Phase 4|924|Actual|University of Leeds||3|||f||||t||||||||||2018-06-01 00:47:18.054458|2018-06-01 00:47:18.054458
NCT00939406|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2012-12-19|2009-07-14|2009-07-15|Estimate|||||||2012-12-19|2012-12-20|Estimate|November 2009||2009-11-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Hyalospine||Clinical Trial to Evaluate Safety and Efficacy of Hyalospine® in Lumbar Laminectomy or Laminotomy|A Multi-center Prospective Randomized Phase II Clinical Trial to Evaluate Safety and Efficacy of Hyalospine® in Lumbar Laminectomy or Laminotomy|Completed||Phase 2/Phase 3|45|Actual|AO Clinical Investigation and Documentation||2|||f||||f||||||||||2018-06-01 00:47:18.124031|2018-06-01 00:47:18.124031
NCT00939393|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|2014-05-06||2017-09-21|2009-07-14|2009-07-15|Estimate|2014-09-29|2014-10-03|Estimate||||2017-09-21|2017-10-23|Actual|April 1, 2008|Actual|2008-04-01|September 2017|2017-09-30|July 1, 2010|Actual|2010-07-01|June 1, 2009|Actual|2009-06-01||Interventional|ORIOS||Balloon Sinus Dilation In Office or OR|ESS Performed in Operating Room Versus Clinician's Office|Completed||N/A|72|Actual|Acclarent||2|||f||||f|f|t|f|||||No||2018-06-01 00:47:18.191632|2018-06-01 00:47:18.191632
NCT00939380|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-03-09|2009-07-14|2009-07-15|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|P-SCIP||Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial|Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial|Completed||N/A|212|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 00:47:18.509272|2018-06-01 00:47:18.509272
NCT00939016|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2018-04-03|2009-07-10|2009-07-14|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2008||2008-09-30|April 2018|2018-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Influence of Factors on Accuracy of Reported Dietary Intake|The Influence of Dietary Restraint, Social Desirability and Food Type on Accuracy of Reported Dietary Intake|Completed||N/A|40|Actual|The University of Tennessee, Knoxville||4|||f||||f||||||||||2018-06-01 00:47:22.940513|2018-06-01 00:47:22.940513
NCT00939367|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-07-22||2017-10-23|2009-07-14|2009-07-15|Estimate|2013-10-22|2013-11-14|Estimate||||2017-10-23|2017-11-27|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Zolpidem Tartrate Tablets Under Fed Conditions|Randomized, Two Period Crossover Studies in Fed Healthy, Normal Subjects to Compare the Single Dose Bioavailability of Torrent's Zolpidem Tartrate Tablets 10 mg and Sanofi-Synthelabo's Ambien® 10 mg Tablets|Completed||Phase 1|30|Actual|Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-06-01 00:47:18.59617|2018-06-01 00:47:18.59617
NCT00939354|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-10-28|2009-07-14|2009-07-15|Estimate|||||||2015-10-28|2015-10-29|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Asthma in the Elderly: The Role of Exhaled Nitric Oxide Measurements|Asthma in the Elderly: The Role of Exhaled Nitric Oxide Measurements|Completed|||30|Actual|Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.|||||f||||f||||||||||2018-06-01 00:47:18.770546|2018-06-01 00:47:18.770546
NCT00939341|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2011-08-11||2012-01-12|2009-07-14|2009-07-15|Estimate|2011-10-20|2011-11-28|Estimate||||2012-01-12|2012-01-16|Estimate|July 2009||2009-07-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|SMARTASIA||Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia|Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy (SMART) in Asthma Patients Across Asia: SMARTASIA|Completed||Phase 4|862|Actual|AstraZeneca|The design of the study does not allow for any conclusion regarding the effect of Symbicort SMART, it being a within-group comparison|1|||f||||f||||||||||2018-06-01 00:47:18.845051|2018-06-01 00:47:18.845051
NCT00939328|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-03-05|2009-07-14|2009-07-15|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment|S0902, Phase II Study of Bendamustine Plus Rituximab for the Treatment of Refractory B-Cell Chronic Lymphocytic Leukemia|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||||question was no longer committee priority|f||||t||||||||||2018-06-01 00:47:19.193401|2018-06-01 00:47:19.193401
NCT00939315|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2016-01-24|2009-07-14|2009-07-15|Estimate|||||||2016-01-24|2016-01-26|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|Gliomes-FLP||Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy|Impact of Multimodal Diagnostic Assessment of Cerebral Gliomas With F-18-fluoroethyl-L-tyrosine PET/CT, F-18-fluorocholine PET/CT and Magnetic Resonance Imaging and Spectroscopy|Completed|||51|Actual|University of Lausanne Hospitals|||||f||||f||||||||No||2018-06-01 00:47:19.252189|2018-06-01 00:47:19.252189
NCT00939289|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-12|||2010-02-02|2009-07-13|2009-07-14|Estimate|||||||2010-02-02|2010-02-03|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Observational|||Concurrent Use of Two Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus (T1DM)|Pilot Study of Concurrent Use of the SEVEN® and FreeStyle Navigator® Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus|Completed|||14|Actual|DexCom, Inc.|||1||f||||f||||||||||2018-06-01 00:47:19.314669|2018-06-01 00:47:19.314669
NCT00939276|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10||2012-09-27|2012-10-18|2009-07-13|2009-07-14|Estimate||||2012-09-27|2012-10-01|Estimate|2012-10-18|2012-10-23|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Macular Edema Incidence/Severity Reduction With Nevanac||Terminated||Phase 3|175|Actual|Alcon Research||2||Patient recruitment difficulties|f||||f||||||||||2018-06-01 00:47:19.37979|2018-06-01 00:47:19.37979
NCT00939263|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2015-09-15|2009-07-13|2009-07-14|Estimate|||||||2015-09-15|2015-09-16|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Observational|EEsAI||Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index|Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index: A Prospective Multicenter Study|Unknown status|Recruiting||650|Anticipated|University Hospital Inselspital, Berne|||2||f||||t||||||||||2018-06-01 00:47:19.460796|2018-06-01 00:47:19.460796
NCT00939250|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2010-09-21|2009-07-13|2009-07-14|Estimate|||||||2010-09-21|2010-09-23|Estimate|October 2009||2009-10-31|September 2010|2010-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care|A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care|Unknown status|Recruiting|Phase 4|48|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 00:47:19.583905|2018-06-01 00:47:19.583905
NCT00939237|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13||2013-08-01|2014-08-15|2009-07-13|2009-07-14|Estimate||||2014-08-15|2014-08-19|Estimate|2014-08-15|2014-08-19|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease|Trial of Ateronon for Carotid Atherosclerosis and Biomarkers in Patients With Stable Coronary Heart Disease|Completed||Phase 3|213|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 00:47:19.659484|2018-06-01 00:47:19.659484
NCT00939224|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-08-23|2009-07-10|2009-07-14|Estimate|||||||2011-08-23|2011-08-25|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Study of Non-Invasive Regional Oxygen Saturations in Pediatric Patients Undergoing Cardiac Catheterization|Calibration and Validation of the a Non-Invasive Regional Oxygen Saturation Device in Neonates, Infants and Children Undergoing Cardiac Catheterization|Completed|||100|Actual|Nonin Medical, Inc|||1||f||||f||||||||||2018-06-01 00:47:19.726541|2018-06-01 00:47:19.726541
NCT00939211|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2011-07-08||2011-07-08|2009-07-13|2009-07-14|Estimate|2011-07-08|2011-08-05|Estimate||||2011-07-08|2011-08-05|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|LaCrossE||The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease|A Double-blind, Double-dummy, Placebo-controlled, Randomised, Multi-centre, 5-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of Inhaled AZD9164 Compared to Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|25|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 00:47:19.795943|2018-06-01 00:47:19.795943
NCT00939198|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2014-01-06|2009-07-13|2009-07-14|Estimate|||||||2014-01-06|2014-01-07|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil|Determination of Prevalence and Intensity of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Northeastern Minas Gerais, Brazil|Completed||N/A|87|Actual|Albert B. Sabin Vaccine Institute||1|||f||||f||||||||||2018-06-01 00:47:20.196594|2018-06-01 00:47:20.196594
NCT00939185|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-12-17||2010-03-25|2009-07-13|2009-07-14|Estimate|2010-01-25|2010-03-18|Estimate||||2010-03-25|2010-03-30|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|COMPAS||Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections|Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections|Completed|||400|Actual|Pfizer|Only 1 subject received tablet; therefore, no suspension versus tablet efficacy data is displayed as initially planned.||1||f||||f||||||||||2018-06-01 00:47:20.283834|2018-06-01 00:47:20.283834
NCT00939172|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2012-07-27|2009-07-10|2009-07-14|Estimate|||||||2012-07-27|2012-07-31|Estimate|March 2010||2010-03-31|July 2012|2012-07-31||||||||Interventional|||TTP607 in Refractory Solid Malignancies|An Open Label, Phase I, Single Group Assignment Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TTP607 Administered in Cycles of Five Daily One to Four Hour Infusions to Patients With Advanced Refractory Solid Malignancies|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:47:20.493009|2018-06-01 00:47:20.493009
NCT00939159|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2015-06-03||2015-06-03|2009-07-13|2009-07-14|Estimate|2015-06-03|2015-06-18|Estimate||||2015-06-03|2015-06-18|Estimate|August 2009||2009-08-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Phase II Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome|Terminated||Phase 2|17|Actual|M.D. Anderson Cancer Center|Early termination leading to small numbers of subjects analyzed.|1||Low Accrual|f||||f||||||||||2018-06-01 00:47:20.555465|2018-06-01 00:47:20.555465
NCT00939146|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2014-02-06|2009-07-10|2009-07-14|Estimate|||||||2014-02-06|2014-02-07|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Outlook: An Intervention to Improve Quality of Life in Serious Illness|Outlook: An Intervention to Improve Quality of Life in Serious Illness|Completed||N/A|154|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:47:20.682212|2018-06-01 00:47:20.682212
NCT00939133|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-11|||2015-02-09|2009-07-13|2009-07-14|Estimate|||||||2015-02-09|2015-02-10|Estimate|July 2009||2009-07-31|February 2015|2015-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin|Double Blinded Vehicle Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Non-inflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients Post Oral Isotretinoin Use|Completed||Phase 4|20|Actual|Dermatrials Research||2|||f||||f||||||||||2018-06-01 00:47:20.754792|2018-06-01 00:47:20.754792
NCT00939120|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2015-03-16||2015-04-15|2009-07-13|2009-07-14|Estimate|2015-04-15|2015-05-01|Estimate||||2015-04-15|2015-05-01|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|LUTS|Number of patients randomized into control or experimental groups.|Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)|A Randomized, Double-blind, Placebo-controlled, Study of Safety and Efficacy of Dutasteride in Combination With Tolterodine ER or Placebo in Men With Lower Urinary Tract Symptoms (LUTS) Including Urgency and Frequency|Completed||Phase 4|46|Actual|Siami, Paul F., M.D.||2|||f||||t||||||||||2018-06-01 00:47:20.838803|2018-06-01 00:47:20.838803
NCT00939107|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2009-08-13||2009-11-09|2009-07-13|2009-07-14|Estimate|2009-11-09|2009-11-19|Estimate||||2009-11-09|2009-11-19|Estimate|September 2003||2003-09-30|November 2009|2009-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||The McKenzie Method Versus Manipulation for Patients With Chronic Low Back Pain|The Effect of the McKenzie Method as Compared With That of Manipulation When Applied Adjunctive to Information and Advice for Patients With Clinical Signs of Disc-related Chronic Low Back Pain: Randomized Controlled Trial.|Completed||N/A|350|Actual|Back and Rehabilitation Center, Copenhagen||2|||f||||f||||||||||2018-06-01 00:47:21.525177|2018-06-01 00:47:21.525177
NCT00939094|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2012-08-28||2012-08-28|2009-07-13|2009-07-14|Estimate|2012-08-28|2012-09-27|Estimate||||2012-08-28|2012-09-27|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|NP-MH||AZD2066 Neuropathic Pain - Mechanical Hypersensitivity|A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2066 Compared to Placebo in Peripheral Neuropathic Pain Patients With Mechanical Hypersensitivity|Terminated||Phase 2|87|Actual|AstraZeneca|Early termination of study for safety reasons leading to fewer subjects analyzed than originally planned.|2|||f||||||||||||||2018-06-01 00:47:21.891323|2018-06-01 00:47:21.891323
NCT00939081|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2014-07-28|2009-07-13|2009-07-14|Estimate|||||||2014-07-28|2014-07-29|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|April 2011|Actual|2011-04-30||Interventional|||Community Based Obesity Prevention Among Blacks|Community Based Obesity Prevention Among Blacks|Completed||N/A|50|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:47:22.242947|2018-06-01 00:47:22.242947
NCT00939068|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2009-10-13|2009-07-13|2009-07-14|Estimate|||||||2009-10-13|2009-10-14|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|November 2010|Anticipated|2010-11-30|July 2010|Anticipated|2010-07-31||Interventional|||Efficacy and Safety Study of Telbivudine to Prevent Perinatal Transmission|A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection|Unknown status|Enrolling by invitation|Phase 4|180|Anticipated|Southeast University, China||2|||f||||t||||||||||2018-06-01 00:47:22.324908|2018-06-01 00:47:22.324908
NCT00939055|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2014-03-24||2014-05-28|2009-07-10|2009-07-14|Estimate|2014-05-28|2014-06-05|Estimate||||2014-05-28|2014-06-05|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||A total of 112 patients entered the study. 73 patients were randomized to the treatment study arm while 39 patients were randomized to the control study arm. 4 patients discontinued participation prior to receiving the study procedure. Therefore, 108 patients were eligible for follow-up.|StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight|A Randomized Controlled Trial of StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight|Terminated||Phase 2/Phase 3|112|Actual|EndoGastric Solutions||2||Based on futility analysis, study would not meet primary endpoint.|f||||f||||||||||2018-06-01 00:47:22.402698|2018-06-01 00:47:22.402698
NCT00939042|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2018-04-05|2009-07-13|2009-07-14|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2009|Actual|2009-01-31|April 2011|2011-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Alster Stem Cells - Intramyocardial Stem Therapy|Percutaneous Intramyocardial Cell Therapy After Acute Myocardial Infarction Using Bone Marrow Mononuclear Cells|Terminated||N/A|40|Actual|Asklepios proresearch||2||PI left institution|f||||f||||||||||2018-06-01 00:47:22.604762|2018-06-01 00:47:22.604762
NCT00939029|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2014-03-25||2014-05-08|2009-07-13|2009-07-14|Estimate|2014-03-25|2014-04-25|Estimate||||2014-05-08|2014-05-19|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Intention to treat analysis|Highdose Nicotine Patch Therapy for Smokeless Tobacco Use|Highdose Nicotine Patch Therapy for Smokeless Tobacco Use|Completed||Phase 2/Phase 3|52|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:47:22.685873|2018-06-01 00:47:22.685873
NCT00939003|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2012-02-02||2014-09-04|2009-07-13|2009-07-14|Estimate|2012-02-02|2012-03-06|Estimate||||2014-09-04|2014-09-09|Estimate|July 2009||2009-07-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|February 2011|Actual|2011-02-28||Interventional||Full analysis set, defined as all participants who received at least one dose of blinded study drug excluding seven participants from one site due to investigator non-compliance.|Study of Adalimumab in Patients With Axial Spondyloarthritis|A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Axial Spondyloarthritis|Completed||Phase 3|192|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 00:47:23.052752|2018-06-01 00:47:23.052752
NCT00938990|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2011-11-30|2009-07-13|2009-07-14|Estimate|||||||2011-11-30|2011-12-01|Estimate||||November 2011|2011-11-30||||||||Interventional|||The Effect of Etomidate on Outcomes of Trauma Patients|The Effect of Etomidate on Outcomes of Trauma Patients|Withdrawn||N/A|0|Actual|Advocate Hospital System||2|||f||||f||||||||||2018-06-01 00:47:23.683711|2018-06-01 00:47:23.683711
NCT00938977|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2009-07-13|2009-07-13|2009-07-14|Estimate|||||||2009-07-13|2009-07-14|Estimate|June 2003||2003-06-30|July 2009|2009-07-31||||June 2006|Actual|2006-06-30||Interventional|||The Obesity-hypoventilation Syndrome Study of Clinical Characteristics and Predictive Factors of Response to Treatment|The Obesity-Hypoventilation Syndrome: A Study Of Clinical Characteristics And Predictive Factors Of Response To Treatment With Continuous Positive Airway Pressure (CPAP) And Non-Invasive Ventilation (NIV)|Completed||N/A|110|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-06-01 00:47:23.734475|2018-06-01 00:47:23.734475
NCT00938964|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2017-07-18||2017-09-05|2009-07-13|2009-07-14|Estimate|2017-08-23|2017-08-24|Actual||||2017-09-05|2017-10-04|Actual|July 2009|Actual|2009-07-31|July 2017|2017-07-31|May 23, 2017|Actual|2017-05-23|July 18, 2016|Actual|2016-07-18||Interventional||Number of participants who completed the study are included in the baseline analysis population.|Lidocaine For Neuroprotection During Cardiac Surgery|Lidocaine For Neuroprotection During Cardiac Surgery|Completed||N/A|550|Actual|Duke University||2|||f||||t||||||||||2018-06-01 00:47:23.817759|2018-06-01 00:47:23.817759
NCT00938951|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-02-08|2009-07-13|2009-07-14|Estimate|||||||2012-02-08|2012-02-09|Estimate|June 2009||2009-06-30|February 2012|2012-02-29||||July 2009|Actual|2009-07-31||Interventional|||Evaluate the Ability of Systane Ultra to Improve Subjective Symptoms of Ocular Irritation Post 60 Min. Athletic Performance.||Completed||N/A|16|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:47:25.505407|2018-06-01 00:47:25.505407
NCT00938938|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2010-04-20|2009-07-10|2009-07-14|Estimate|||||||2010-04-20|2010-04-21|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Testing the Effect of Press Guides on Health Journalists|Testing the Effect of Press Guides on Health Journalists|Unknown status|Enrolling by invitation|N/A|50|Anticipated|White River Junction Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 00:47:25.562056|2018-06-01 00:47:25.562056
NCT00938925|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2014-12-03|2009-07-13|2009-07-14|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2009||2009-10-31|March 2010|2010-03-31|March 2017|Anticipated|2017-03-31|December 2013|Actual|2013-12-31||Interventional|EPOCAON||Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)|Effectiveness of Supplementation With Nail Debridement in Ungual Lacquer Treatment in Podiatry Care on Onychomycosis: Pilot Study of Randomized Control Trial|Suspended||Phase 1|64|Anticipated|University of Malaga||2||No funds|f||||t||||||||||2018-06-01 00:47:25.642678|2018-06-01 00:47:25.642678
NCT00938912|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2018-05-24|2009-07-10|2009-07-14|Estimate|||||||2018-05-24|2018-05-25|Actual|December 2009|Actual|2009-12-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|June 2022|Anticipated|2022-06-30||Interventional|||An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy|An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy|Enrolling by invitation||Phase 2|300|Anticipated|UCB Pharma||1|||f||||f||||||||||2018-06-01 00:47:25.75105|2018-06-01 00:47:25.75105
NCT00938899|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-05-18|2009-07-10|2009-07-14|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2007||2007-01-31|April 2010|2010-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing|Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.|Completed||Phase 1|55|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 00:47:25.96137|2018-06-01 00:47:25.96137
NCT00938886|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2017-02-22||2017-04-06|2009-07-13|2009-07-14|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|October 2009||2009-10-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment|Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment|Completed||Phase 2|150|Actual|Brown University||2|||f||||t||||||||||2018-06-01 00:47:26.042241|2018-06-01 00:47:26.042241
NCT00938873|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-02-27|2009-07-13|2009-07-14|Estimate|||||||2012-02-27|2012-02-29|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Observational|||Understanding the Impact of Meditative Homework on Metacognitive Processes in the Context of Mindfulness Based Cognitive Therapy (MBCT)|Understanding the Impact of Meditative Homework on Metacognitive Processes in the Context of Mindfulness Based Cognitive Therapy (MBCT)|Completed|||7|Actual|Lahtinen, Marika|||1||f||||f||||||||||2018-06-01 00:47:26.42994|2018-06-01 00:47:26.42994
NCT00938860|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2014-04-25||2015-05-05|2009-07-13|2009-07-14|Estimate|2014-04-25|2014-05-26|Estimate||||2015-05-05|2015-05-22|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SUSTAIN|"Intent-to-Treat (ITT) population:~The ITT population consisted of all randomized patients."|Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C|A Multi-center, Randomized, Open Label, Controlled Study to Compare the Sustained Virological Response During Treatment With Neoral or Tacrolimus in Maintenance Liver Transplant Recipients Treated With Pegylated Interferon and Ribavirin for Recurrent Hepatitis C|Completed||Phase 4|92|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:47:26.54671|2018-06-01 00:47:26.54671
NCT00938847|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2009-07-13|2009-07-13|2009-07-14|Estimate|||||||2009-07-13|2009-07-14|Estimate|February 2006||2006-02-28|July 2009|2009-07-31|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|||Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration|Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration in Early Left Ventricular Dysfunction After Acute Myocardial Infarction And Successful Percutaneous Coronary Intervention|Completed||Phase 3|20|Actual|Asklepios proresearch|||||f||||f||||||||||2018-06-01 00:47:27.233534|2018-06-01 00:47:27.233534
NCT00938821|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-11-17|2009-07-13|2009-07-14|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2010||2010-01-31|November 2017|2017-11-30|December 11, 2012|Actual|2012-12-11|December 11, 2012|Actual|2012-12-11||Observational|||Very Low Dose Caudal Morphine for Postoperative Pain Management|The Use of Very Low Dose Caudal Morphine for Postoperative Pain Management in Out Patients|Completed|||33|Actual|University of Oklahoma|||1||f||||t||||||||||2018-06-01 00:47:27.360318|2018-06-01 00:47:27.360318
NCT00938808|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2016-01-15|2009-07-13|2009-07-14|Estimate|||||||2016-01-15|2016-01-18|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LIGH T||Long-term Intervention With Weight Loss in Patients With Concomitant Obesity and Knee Osteoarthritis. The LIGHT Study|Long-term Intervention With Weight Loss in Patients With Concomitant Obesity and Knee Osteoarthritis. The LIGHT Study|Completed||N/A|154|Actual|Frederiksberg University Hospital||2|||f||||f||||||||||2018-06-01 00:47:27.443298|2018-06-01 00:47:27.443298
NCT00938795|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2014-02-06|2009-07-10|2009-07-14|Estimate|||||||2014-02-06|2014-02-07|Estimate|February 2010||2010-02-28|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Uncertainty Management Intervention|Uncertainty Management Intervention for Patients Awaiting Liver Transplant|Completed||N/A|288|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:47:27.530772|2018-06-01 00:47:27.530772
NCT00938782|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2015-01-23||2015-02-09|2009-07-13|2009-07-14|Estimate|2015-02-09|2015-02-19|Estimate||||2015-02-09|2015-02-19|Estimate|July 2006||2006-07-31|February 2015|2015-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Surgical patients older than 65 years of age receiving beta-adrenergic blockers for a minimum of 24 hours preoperatively were randomized to two groups.|Using the SEDLine for the Titration of Sevoflurane in Elderly Patients Recovery Using the SEDLine TM for the Titration of Sevoflurane in Elderly Patients Undergoing Non-Cardiac Surgery After Beta-Adrenergic Blockade|A Prospective, Randomized, Double-Blinded Study of the Effect on Improved Recovery Using the SEDLine TM for the Titration of Sevoflurane in Elderly Patients Undergoing Non-Cardiac Surgery After Beta-Adrenergic Blockade|Completed||Phase 4|67|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 00:47:27.611958|2018-06-01 00:47:27.611958
NCT00938769|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2014-02-06|2009-07-13|2009-07-14|Estimate|||||||2014-02-06|2014-02-07|Estimate|August 2009||2009-08-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Enhanced Self-Efficacy Training|Enhanced Self-Efficacy Training For Informal Cancer Caregivers|Completed||N/A|358|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:47:27.791423|2018-06-01 00:47:27.791423
NCT00938756|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-11|||2010-04-06|2009-07-11|2009-07-14|Estimate|||||||2010-04-06|2010-04-07|Estimate|April 2008||2008-04-30|April 2010|2010-04-30||||May 2009|Anticipated|2009-05-31||Interventional|||Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome|Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer|Unknown status|Recruiting|N/A|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:47:27.851971|2018-06-01 00:47:27.851971
NCT00938743|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2011-01-19|2009-07-13|2009-07-14|Estimate|||||||2011-01-19|2011-01-20|Estimate|January 2008||2008-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|DrivPerfATX||Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine|Driving Ability in Adults With ADHD Before and After 10-weeks of Treatment With 40-80mg Atomoxetine vs. Untreated Adults With ADHD|Completed||Phase 4|50|Anticipated|Central Institute of Mental Health, Mannheim||2|||f||||t||||||||||2018-06-01 00:47:27.909429|2018-06-01 00:47:27.909429
NCT00938730|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2011-01-18|2009-07-13|2009-07-14|Estimate|||||||2011-01-18|2011-01-20|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|OPAL-2||A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation|A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of YM150 in Subjects With Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability With Warfarin|Completed||Phase 2|1280|Actual|Astellas Pharma Inc||7|||f||||t||||||||||2018-06-01 00:47:27.995394|2018-06-01 00:47:27.995394
NCT00938717|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-12|2012-09-28||2013-10-09|2009-07-13|2009-07-14|Estimate|2012-12-19|2013-01-30|Estimate||||2013-10-09|2013-11-05|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 26 Weeks in Patients With Irritable Bowel Syndrome With Constipation|Completed||Phase 3|805|Actual|Ironwood Pharmaceuticals, Inc.||2|||f||||||||||||||2018-06-01 00:47:28.398494|2018-06-01 00:47:28.398494
NCT00938704|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2011-09-22||2011-09-22|2009-07-10|2009-07-14|Estimate|2011-09-22|2011-10-31|Estimate||||2011-09-22|2011-10-31|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms||Completed||Phase 4|71|Actual|Allergan||2|||f||||f||||||||||2018-06-01 00:47:29.373544|2018-06-01 00:47:29.373544
NCT00938691|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2009-07-13|2009-07-13|2009-07-14|Estimate|||||||2009-07-13|2009-07-14|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Optimal Suture Choice for Improved Scar Outcomes||Unknown status|Active, not recruiting|N/A|25|Actual|Dallas VA Medical Center||2|||f||||t||||||||||2018-06-01 00:47:30.102209|2018-06-01 00:47:30.102209
NCT00938678|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-03-16|2009-07-10|2009-07-14|Estimate|||||||2017-03-16|2017-03-20|Actual|June 2009||2009-06-30|June 2015|2015-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers|A Phase I, Randomized, Single Dose, Crossover Study Evaluating the Pharmacokinetics and Pharmacodynamics of Pegfilgrastim Hospira Compared to Neulasta (Amgen) Following Subcutaneous Administration to Healthy Volunteers|Completed||Phase 1|71|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 00:47:30.43659|2018-06-01 00:47:30.43659
NCT00938496|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2014-02-19|2009-07-13|2009-07-14|Estimate|||||||2014-02-19|2014-02-20|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Non-Interventional Study of Zoladex in Endometriosis|A Non-interventional Study of Postoperative Treatment With Goserelin Acetate (Zoladex) in Moderate to Severe Endometriosis Patient|Completed|||408|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:47:35.387262|2018-06-01 00:47:35.387262
NCT00938483|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-14|2009-07-13|2009-07-14|Estimate|||||||2009-07-14|2009-07-15|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Tolerability and Safety of An Infant Formula|A Multicenter, Single-blind, Randomized, Phase II Study of the Tolerability and Safety of NPS-202 in Infants With Clinically Diagnosed Cow's Milk Allergy|Completed||N/A|108|Actual|Perrigo Nutritionals||2|||f||||f||||||||||2018-06-01 00:47:35.501167|2018-06-01 00:47:35.501167
NCT00938665|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2014-03-06|2009-07-13|2009-07-14|Estimate|||||||2014-03-06|2014-03-10|Estimate|December 2010||2010-12-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|COGNISION™||Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.|Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.|Completed|||204|Actual|Neuronetrix, Inc.|||2||f||||f||||||Samples Without DNA|"~     1. These lab tests will be performed from a standard blood draw:~             1. B12~             2. TSH~             3. CRP~             4. ALT~             5. HGB~             6. Hgb1AC~             7. T4~             8. K~             9. Cl~            10. CO2~            11. ApoE~            12. Platelet Count~            13. INR~            14. PT~        2. MRI- INCLUDING VOLUMETRY~        3. CSF 5ML (Optional)~   "|||2018-06-01 00:47:30.60884|2018-06-01 00:47:30.60884
NCT00938652|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10||2012-12-21|2013-09-13|2009-07-13|2009-07-14|Estimate||||2012-12-21|2012-12-28|Estimate|2013-09-13|2013-09-19|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer|A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer|Completed||Phase 3|519|Actual|Sanofi||2|||t||||t||||||||||2018-06-01 00:47:30.907069|2018-06-01 00:47:30.907069
NCT00938639|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2013-07-24||2017-10-23|2009-07-13|2009-07-14|Estimate|2013-10-28|2013-11-21|Estimate||||2017-10-23|2017-11-27|Actual|July 2009||2009-07-31|October 2017|2017-10-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults|A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.|Completed||Phase 2|240|Actual|Seqirus||2|||f||||t||||||||||2018-06-01 00:47:31.433671|2018-06-01 00:47:31.433671
NCT00938626|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-11|||2013-09-20|2009-07-11|2009-07-14|Estimate|||||||2013-09-20|2013-09-23|Estimate|October 2009||2009-10-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|October 2011|Actual|2011-10-31||Interventional|||Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma|Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).|Completed||Phase 1|12|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 00:47:33.410867|2018-06-01 00:47:33.410867
NCT00938613|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-10-02|2009-07-13|2009-07-14|Estimate|||||||2012-10-02|2012-10-04|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Compare the Relative Efficacy of Budesonide Administered Via CE Budesonide Nasal Solution & Rhinocort Aqua in the Treatment of the Symptoms of AR in an EEC Model|Completed||Phase 2|65|Actual|Ligand Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:47:33.559471|2018-06-01 00:47:33.559471
NCT00938600|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2012-08-16|2009-07-13|2009-07-14|Estimate|||||||2012-08-16|2012-08-17|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|AViDD-1||Antenatal Vitamin D3 Dose-finding and Safety Study|Antenatal Vitamin D Supplementation to Improve Neonatal Health Outcomes in Dhaka, Bangladesh: Preliminary Dose-finding and Safety Study|Completed||Phase 1|75|Actual|Johns Hopkins Bloomberg School of Public Health||5|||f||||t||||||||||2018-06-01 00:47:33.753957|2018-06-01 00:47:33.753957
NCT00938587|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13||2011-10-29|2011-10-29|2009-07-13|2009-07-14|Estimate||||2011-10-29|2011-11-01|Estimate|2011-10-29|2011-11-01|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis|A Phase 2a, Randomized, Double-Blind, Active And Placebo-Controlled Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis|Completed||Phase 2|86|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:47:33.96869|2018-06-01 00:47:33.96869
NCT00938574|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2013-04-08|2009-07-13|2009-07-14|Estimate|||||||2013-04-08|2013-04-09|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Study With Atu027 in Patients With Advanced Solid Cancer|A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer|Completed||Phase 1|34|Actual|Silence Therapeutics GmbH||1|||f||||t||||||||||2018-06-01 00:47:34.206642|2018-06-01 00:47:34.206642
NCT00938561|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2016-07-12|2009-07-12|2009-07-14|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Observational|||Evaluation of New Markers to Assess Kidney Function|Validity and Reliability of a Novel GFR Marker|Withdrawn|||0|Actual|Tufts Medical Center|||1|Non availability of funding|f||||f|||||||"~     Blood and urine will be retained for future testing~   "|||2018-06-01 00:47:34.32383|2018-06-01 00:47:34.32383
NCT00938548|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|2010-03-29||2010-05-17|2009-07-13|2009-07-14|Estimate|2010-04-27|2010-05-14|Estimate||||2010-05-17|2010-05-25|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Perioperative Administration of Pregabalin for Pain After Mastectomy|Perioperative Administration of Pregabalin for Pain After Mastectomy|Completed||Phase 4|70|Actual|Severance Hospital||2|||f||||t||||||||||2018-06-01 00:47:34.417483|2018-06-01 00:47:34.417483
NCT00938535|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2014-07-28|2009-07-13|2009-07-14|Estimate|||||||2014-07-28|2014-07-29|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|October 2012|Actual|2012-10-31||Interventional|||Community Based Obesity Prevention Among Black Women|Community Based Obesity Prevention Among Black Women|Completed||N/A|194|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:47:34.821626|2018-06-01 00:47:34.821626
NCT00938522|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2009-07-20|2009-07-13|2009-07-14|Estimate|||||||2009-07-20|2009-07-21|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|October 2011|Anticipated|2011-10-31|December 2010|Anticipated|2010-12-31||Interventional|PRECEDE||Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention|PREtreatment of Cilostazol Loading in Elective Percutaneous Coronary Intervention to Decrease Adverse Events|Unknown status|Not yet recruiting|Phase 4|400|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:47:34.99402|2018-06-01 00:47:34.99402
NCT00938509|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-13|||2009-07-21|2009-07-13|2009-07-14|Estimate|||||||2009-07-21|2009-07-22|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Ibuprofen Suppositories Administration in Infants and Children|Ibuprofen Suppositories Administration for Fever Treatment in Infants and Children|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Soroka University Medical Center|||||f||||t||||||||||2018-06-01 00:47:35.290643|2018-06-01 00:47:35.290643
NCT00938470|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2017-01-03||2018-03-02|2009-07-10|2009-07-13|Estimate|2017-02-27|2017-04-10|Actual||||2018-03-02|2018-03-29|Actual|January 2010||2010-01-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2013|Actual|2013-12-31||Interventional||Eligible randomized participants who initiated first cycle of protocol treatment.|Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia|Completed||Phase 2|73|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 00:47:35.648769|2018-06-01 00:47:35.648769
NCT00938457|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2012-06-04||2016-04-19|2009-07-10|2009-07-13|Estimate|2012-06-04|2012-07-09|Estimate||||2016-04-19|2016-05-19|Estimate|July 2009||2009-07-31|October 2015|2015-10-31||||April 2011|Actual|2011-04-30||Interventional|||Stereotactic Radiation Therapy in Treating Patients With Liver Metastases|A Phase I/II Dose-Finding Study of Single-Fraction Stereotactic Body Radiotherapy (SF-SBRT) for the Treatment of Liver Metastases|Terminated||Phase 1/Phase 2|3|Actual|Mayo Clinic||1||poor accrual|f||||t||||||||||2018-06-01 00:47:36.774274|2018-06-01 00:47:36.774274
NCT00938444|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-07-13|2009-07-10|2009-07-13|Estimate|||||||2011-07-13|2011-07-14|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Evaluation of the BRADA and ABILHAND Questionnaires|Prospective, Multicenter, Non-interventional Study in RA Patients Treated With Tocilizumab - Evaluation of the BRADA and ABILHAND Questionnaires|Completed|||80|Actual|University Hospital, Ghent|||1||f||||f||||||||||2018-06-01 00:47:37.012844|2018-06-01 00:47:37.012844
NCT00938431|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2015-06-29||2017-07-28|2009-07-10|2009-07-13|Estimate|2015-11-10|2015-12-15|Estimate||||2017-07-28|2017-08-28|Actual|November 2009||2009-11-30|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The analysis group for Baseline Characteristics is the Safety Set (SS). The SS is all subjects who signed the informed consent form and took at least 1 dose of Lacosamide (LCM) in SP0847.|A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures|A Multicenter, Open-Label Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Lacosamide (LCM) Oral Solution (Syrup) As Adjunctive Therapy In Children With Partial-Onset Seizures|Completed||Phase 2|47|Actual|UCB Pharma||5|||f||||f||||||||||2018-06-01 00:47:37.169233|2018-06-01 00:47:37.169233
NCT00938418|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-07-10|2009-07-10|2009-07-13|Estimate|||||||2009-07-10|2009-07-13|Estimate|July 2009||2009-07-31|July 2009|2009-07-31||||July 2011|Anticipated|2011-07-31||Interventional|||Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer|Phase II Study on Dose Escalated, Accelerated Hypofractionated Intensity Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer With Concurrent Chemotherapy|Unknown status|Recruiting|Phase 2|43|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 00:47:37.877619|2018-06-01 00:47:37.877619
NCT00938405|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2014-05-19|2009-07-10|2009-07-13|Estimate|||||||2014-05-19|2014-05-20|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus|Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus|Completed||N/A|45|Actual|University of Colorado Denver School of Medicine Barbara Davis Center||2|||f||||f||||||||||2018-06-01 00:47:37.953745|2018-06-01 00:47:37.953745
NCT00938392|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2012-04-19|2009-11-10|2016-10-06|2009-07-09|2009-07-13|Estimate|2012-04-19|2012-05-17|Estimate|2009-11-10|2009-11-11|Estimate|2016-10-06|2016-11-16|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly|Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Adults.|Completed||Phase 3|726|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:38.071807|2018-06-01 00:47:38.071807
NCT00938379|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-07-13|2009-07-10|2009-07-13|Estimate|||||||2009-07-13|2009-07-14|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR|Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR|Unknown status|Recruiting|Phase 3|5000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:47:38.626188|2018-06-01 00:47:38.626188
NCT00938366|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2015-09-21||2016-03-15|2009-07-10|2009-07-13|Estimate|2015-09-21|2015-10-20|Estimate||||2016-03-15|2016-04-14|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||Baseline analysis population included all randomized subjects.|Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects|An Open-label, Cross Over Study, to Assess the Interactions of Pantoprazole (Proton Pump Inhibitor) With Oral Cladribine Administered in Subjects With Multiple Sclerosis|Completed||Phase 1|18|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:47:38.719332|2018-06-01 00:47:38.719332
NCT00938353|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-04-28|2009-07-10|2009-07-13|Estimate|||||||2011-04-28|2011-04-29|Estimate|April 2010||2010-04-30|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup|Multicentre, Randomized, Double-blind, Placebo-controlled, Two-arm Parallel Groups Study Design to Demonstrate the Efficacy and Tolerability of a Single Dose of BDP Suspension for Nebulisation 1600 µg vs Placebo in the Treatment of Children Aged 6 Months to 3 Years With a Clinical Diagnosis of Moderate Croup|Terminated||Phase 3|6|Actual|Chiesi Farmaceutici S.p.A.||2||possibility to discriminate the active drug from placebo|f||||f||||||||||2018-06-01 00:47:38.960346|2018-06-01 00:47:38.960346
NCT00938340|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-07-10|2009-07-10|2009-07-13|Estimate|||||||2009-07-10|2009-07-13|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction|Postprandial Effects of Walnut Components vs Whole Walnuts on Oxidative Stress, Inflammation, Platelet Function, and Endothelial Function in Volunteers With Moderate Hypercholesterolemia|Completed||N/A|20|Actual|Penn State University||1|||f||||t||||||||||2018-06-01 00:47:39.021529|2018-06-01 00:47:39.021529
NCT00938327|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2011-02-17||2017-12-07|2009-07-09|2009-07-13|Estimate|2011-02-17|2011-03-16|Estimate||||2017-12-07|2018-01-02|Actual|August 3, 2009||2009-08-03|February 2016|2016-02-29|April 23, 2010|Actual|2010-04-23|February 20, 2010|Actual|2010-02-20||Observational|||Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants|Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered According to the Prescribing Information to Indian Infants|Completed|||332|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 00:47:39.234504|2018-06-01 00:47:39.234504
NCT00938314|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2011-09-01||2011-11-24|2009-07-10|2009-07-13|Estimate|2011-11-04|2011-11-09|Estimate||||2011-11-24|2011-11-29|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|REGENESIS-LED||Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)|Terminated||Phase 2|96|Actual|Stem Cell Therapeutics Corp.|The trial was terminated after 96 of a planned 128 patients were enrolled, thus limiting opportunities to demonstrate a clear statistical benefit of active therapy compared to placebo.|4||Slow Enrollment|f||||t||||||||||2018-06-01 00:47:39.467241|2018-06-01 00:47:39.467241
NCT00938301|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2009-10-15|2009-07-09|2009-07-13|Estimate|||||||2009-10-15|2009-10-16|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers|A Phase 1, Placebo-Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 After First-Time Administration Of Single Ascending Doses To Healthy Adult Subjects|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:47:40.20088|2018-06-01 00:47:40.20088
NCT00938288|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-06-15|2009-07-10|2009-07-13|Estimate|||||||2011-06-15|2011-06-17|Estimate|April 2009||2009-04-30|March 2011|2011-03-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||A Study of KW-3357 in Congenital Antithrombin Deficiency|A Phase I Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of a Single Dose (50IU/kg) of KW-3357 in Subjects With Congenital Antithrombin Deficiency.|Completed||Phase 1|16|Anticipated|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-06-01 00:47:40.28326|2018-06-01 00:47:40.28326
NCT00938275|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-07-18|2009-07-09|2009-07-13|Estimate|||||||2017-07-18|2017-07-21|Actual|January 20, 2009|Actual|2009-01-20|July 2017|2017-07-31|March 27, 2009|Actual|2009-03-27|March 27, 2009|Actual|2009-03-27||Interventional|||A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers|Gender vs. Fed/Fasted State vs. Capsule/Liquid Suspension Formulation Study|Completed||Phase 1|20|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:40.373576|2018-06-01 00:47:40.373576
NCT00938262|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-10-07|2009-07-10|2009-07-13|Estimate|||||||2009-10-07|2009-10-08|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|An Open-label, Three-treatment, Three-period, One-sequence, Crossover Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boryung Pharmaceutical Co., Ltd||1|||f||||t||||||||||2018-06-01 00:47:40.461207|2018-06-01 00:47:40.461207
NCT00938249|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2010-04-23|2009-07-10|2009-07-13|Estimate|||||||2010-04-23|2010-04-26|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effects of Monascus Garlic Fermented Extract on Serum Triglyceride Level|Effects of Monascus Garlic Fermented Extract on Serum Triglyceride Level: a Double-Blind, Randomized Controlled Trial|Completed||N/A|55|Actual|Hiroshima University||2|||f||||||||||||||2018-06-01 00:47:40.516934|2018-06-01 00:47:40.516934
NCT00938236|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2012-09-13|2009-07-10|2009-07-13|Estimate|||||||2012-09-13|2012-09-17|Estimate|December 2009||2009-12-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|CIS002||CIS001 Extension Study of Cyclosporine Inhalation Solution|CIS002: An Open-Label, Multi-Center, Extension Study of Cyclosporine Inhalation Solution in Subjects Previously Enrolled in the APT Study CIS001|Terminated||Phase 3|17|Actual|APT Pharmaceuticals, Inc.||1||Parent study CIS001 was completed|f||||t||||||||||2018-06-01 00:47:40.579874|2018-06-01 00:47:40.579874
NCT00938223|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2018-04-30|2009-07-10|2009-07-13|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2000||2000-08-31|April 2018|2018-04-30||||November 2003|Actual|2003-11-30||Interventional|MEL39||Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma|This is an Open-label, Phase II Study of a Vaccine Comprising Melanoma Peptides and a Tetanus Helper Peptide, Administered in GM-CSF-in-adjuvant. Patients Will be Randomized to Receive One of Two Different Vaccine Regimens. Patients Will be Stratified by Stage of Disease (IIB vs. III vs. IV).|Completed||Phase 2|51|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 00:47:40.664773|2018-06-01 00:47:40.664773
NCT00938210|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2012-08-07|2009-07-10|2009-07-13|Estimate|||||||2012-08-07|2012-08-08|Estimate|May 2009||2009-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||Rehabilitation Following Laparoscopic Colonic Surgery|Changes in Fatigue and Physical Function Following Laparoscopic Colonic Surgery|Completed||N/A|50|Actual|Aarhus University Hospital||1|||f||||f||||||||||2018-06-01 00:47:40.729448|2018-06-01 00:47:40.729448
NCT00938197|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-10-07|2009-07-10|2009-07-13|Estimate|||||||2009-10-07|2009-10-08|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers|An Open-label, Multiple-dosing, and Crossover Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers|Completed||Phase 1|34|Anticipated|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-06-01 00:47:40.794833|2018-06-01 00:47:40.794833
NCT00938184|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2018-05-17|2009-07-09|2009-07-13|Estimate|||||||2018-05-17|2018-05-18|Actual|July 14, 2009|Actual|2009-07-14|May 2018|2018-05-31|September 2, 2009|Actual|2009-09-02|September 2, 2009|Actual|2009-09-02||Interventional|||Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects|An Open Label, Randomized, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Doses of the Controlled-release Paroxetine Tablets at the Dose Levels of 12.5, 25 and 50mg in Healthy Japanese Male Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:40.857049|2018-06-01 00:47:40.857049
NCT00938171|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-07-10|2009-07-10|2009-07-13|Estimate|||||||2009-07-10|2009-07-13|Estimate|June 2008||2008-06-30|July 2009|2009-07-31|July 2013|Anticipated|2013-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Comparing Local Anesthesia With General Anesthesia for Breast Cancer Surgery|A Comparison of Local Anesthesia and General Anesthesia for Breast Cancer Surgery, a Prospective Randomized Trial|Unknown status|Recruiting|Phase 3|40|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:47:40.956588|2018-06-01 00:47:40.956588
NCT00938158|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-07-18|2009-07-09|2009-07-13|Estimate|||||||2017-07-18|2017-07-21|Actual|August 5, 2009|Actual|2009-08-05|July 2017|2017-07-31|April 12, 2011|Actual|2011-04-12|April 12, 2011|Actual|2011-04-12||Interventional|||A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.|An Adaptive Design Study for the Assessment of the Pharmacokinetics of Albiglutide in Subjects With Normal Renal Function and Subjects With Moderate-to-severe Renal Impairment and Hemodialysis.|Completed||Phase 1|75|Actual|GlaxoSmithKline||7|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:41.059062|2018-06-01 00:47:41.059062
NCT00938145|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-09-21|2009-07-10|2009-07-13|Estimate|||||||2017-09-21|2017-09-25|Actual|May 2009||2009-05-31|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||3 Tesla MRI in Patients With Bladder Cancer|Imaging of Bladder Cancer Using Clinical 3 Tesla MRI and EX-VIVO Ultra-High-Field MRI.|Recruiting||N/A|65|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 00:47:41.173402|2018-06-01 00:47:41.173402
NCT00938132|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-10-07|2009-07-10|2009-07-13|Estimate|||||||2009-10-07|2009-10-08|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers|A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers|Completed||Phase 1|15|Anticipated|Boryung Pharmaceutical Co., Ltd||1|||f||||||||||||||2018-06-01 00:47:41.24927|2018-06-01 00:47:41.24927
NCT00938119|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2013-06-27|2009-07-10|2009-07-13|Estimate|||||||2013-06-27|2013-06-28|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Observational|||Care China-Diabetes|The Care China-Diabetes Registry A 12-month, Multi-centre, Prospective, Observational Registry Study to Investigate the Efficacy and Safety of CYPHER Select TM+ Sirolimus-eluting Coronary Stent Among Chinese Diabetic Patients With Coronary Artery Disease in Routine Clinical Practice|Terminated|||1603|Actual|Johnson & Johnson Medical, China|||1|the product was delisted.|f||||t||||||None Retained|"~     Diabetes patient~   "|||2018-06-01 00:47:41.322929|2018-06-01 00:47:41.322929
NCT00938106|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-09-21|2009-07-10|2009-07-13|Estimate|||||||2017-09-21|2017-09-25|Actual|May 2008||2008-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|December 2016|Actual|2016-12-31||Interventional|||Optimized Magnetic Resonance Brachytherapy (MR BT) in Cervix Cancer|Implementation of Optimized Magnetic Resonance Image-guided Intra-uterine Brachytherapy in Cervical Cancer|Active, not recruiting||Phase 2|60|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:47:41.610545|2018-06-01 00:47:41.610545
NCT00938093|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-11-06|2009-07-10|2009-07-13|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2006||2006-03-31|April 2017|2017-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Treatment of Late-life Anxiety in Primary Care Settings|Treatment of Late-life Anxiety in Primary Care Settings|Completed||N/A|60|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 00:47:41.687687|2018-06-01 00:47:41.687687
NCT00938080|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2014-01-06|2009-07-10|2009-07-13|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck|A Phase 1b, Multi-center, Single Blinded, Placebo-controlled, Sequential Dose Escalation Study to Assess the Safety and Tolerability of Topically Applied AG013 in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck|Completed||Phase 1|25|Actual|ActoGeniX N.V.||6|||f||||t||||||||||2018-06-01 00:47:41.767573|2018-06-01 00:47:41.767573
NCT00938067|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2012-06-19|2009-07-10|2009-07-13|Estimate|||||||2012-06-19|2012-06-20|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional|||Staying Connected: Trauma Center to Tribal Community Linkage for Physically Injured American Indian Patients|American Indian and Alaska Native Health Disparities Staying Connected: Trauma Center to Tribal Community Linkage for Physically Injured American Indian Patients|Completed||N/A|30|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 00:47:41.875845|2018-06-01 00:47:41.875845
NCT00938054|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-10-05|2009-07-10|2009-07-13|Estimate|||||||2017-10-05|2017-10-06|Actual|June 25, 2009||2009-06-25|October 9, 2012|2012-10-09|October 9, 2012||2012-10-09|||||Observational|||Identification of Characteristics Associated With Symptom Remission in Autism|Characterization of Autism Spectrum Disorder in School Aged Children|Completed|||37|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:47:42.024935|2018-06-01 00:47:42.024935
NCT00938041|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2014-02-27||2016-11-18|2009-07-09|2009-07-13|Estimate|2014-02-27|2014-04-08|Estimate||||2016-11-18|2017-01-09|Estimate|April 1998||1998-04-30|November 2016|2016-11-30|June 2013|Actual|2013-06-30|May 2003|Actual|2003-05-31||Interventional|||Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody|Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody|Completed||Phase 2|32|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:42.144631|2018-06-01 00:47:42.144631
NCT00938028|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2009-07-17|2009-07-10|2009-07-13|Estimate|||||||2009-07-17|2009-07-21|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|MicroMet||Metabolome and Microbiomic in Fecal Samples|Fecal Samples for Metabolomic and Microbiomic Studies: Effects of Preparation and Storage|Completed|||4|Actual|Massachusetts General Hospital|||1||f||||f||||||None Retained|"~     Stool samples~   "|||2018-06-01 00:47:42.680579|2018-06-01 00:47:42.680579
NCT00938015|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2013-03-27||2013-03-27|2009-07-10|2009-07-13|Estimate|2013-03-27|2013-05-27|Estimate||||2013-03-27|2013-05-27|Estimate|October 2004||2004-10-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|PROVE||Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis|A Post-Marketing Surveillance For Safety And Adherence To Treatment Of Enbrel In Adults With Psoriatic Arthritis In Belgium|Completed|||303|Actual|Pfizer|||2||f||||f||||||||||2018-06-01 00:47:42.83632|2018-06-01 00:47:42.83632
NCT00938002|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-08-01|2009-07-10|2009-07-13|Estimate|||||||2017-08-01|2017-08-03|Actual|July 2009||2009-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Study to Determine Quicker Methods of Diagnosing Pneumonia Caused by a Breathing Machine in Critically Ill Patients|Rapid Bacterial Identification and Antibiotic Resistance Testing in Critically Ill Adults at Risk for Ventilator Acquired Pneumonia (VAP).|Active, not recruiting|||37|Actual|Denver Health and Hospital Authority|||||f||||f||||||Samples With DNA|"~     DNA collected from whole blood~   "|No||2018-06-01 00:47:43.623033|2018-06-01 00:47:43.623033
NCT00937989|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2015-06-03|2009-07-10|2009-07-13|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Barriers to Beginning and Finishing Treatment for Patients With Breast Cancer|Patient Navigation in Breast Cancer Care; Addressing Barriers to Treatment Initiation, Completion, and Follow Up|Completed||N/A|52|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:47:43.709958|2018-06-01 00:47:43.709958
NCT00937976|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2012-05-04|2009-07-10|2009-07-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|August 2008||2008-08-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|KPU||Treatment for Periodontal Disease in Dialysis Patients|Impact of Periodontal Therapy on Metabolic and Inflammatory Markers in Chronic Kidney Disease Patients|Completed||N/A|60|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:47:43.765548|2018-06-01 00:47:43.765548
NCT00937963|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2017-05-26|2009-07-10|2009-07-13|Estimate|||||||2017-05-26|2017-05-31|Actual|February 2009||2009-02-28|May 2017|2017-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|FAT||Healthy Fatty Acids in Transition|Healthy FAT (Fatty Acids in Transition) Study|Completed||N/A|20|Anticipated|Penn State University||1|||f||||t||||||||||2018-06-01 00:47:43.821857|2018-06-01 00:47:43.821857
NCT00937950|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2015-01-08||2015-10-29|2009-07-09|2009-07-13|Estimate|2015-01-08|2015-01-15|Estimate||||2015-10-29|2015-12-04|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects|Gynaecological Follow-up of a Subset of 580299/008 Study Subjects|Completed||Phase 3|2022|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 00:47:43.907395|2018-06-01 00:47:43.907395
NCT00937937|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2015-10-22||2018-04-20|2009-07-10|2009-07-13|Estimate|2016-06-22|2016-07-22|Estimate||||2018-04-20|2018-04-24|Actual|July 1, 2009|Actual|2009-07-01|April 2018|2018-04-30||||October 22, 2013|Actual|2013-10-22||Interventional||Include all the patients that have received the treatment and been adverse event evaluable.|Dinaciclib in Treating Patients With Stage IV Melanoma|A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma|Active, not recruiting||Phase 2|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:47:44.713093|2018-06-01 00:47:44.713093
NCT00937924|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2011-02-10|2009-07-10|2009-07-13|Estimate|||||||2011-02-10|2011-02-11|Estimate|February 2008||2008-02-29|February 2011|2011-02-28|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Adjunct Sedatives in Procedures Involving Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP)|A Randomized, Double-Blinded, Placebo-Controlled Trial of Promethazine and Diphenhydramine as Adjunct Sedatives for Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP)|Unknown status|Recruiting|N/A|465|Anticipated|University of California, Irvine||3|||f||||t||||||||||2018-06-01 00:47:45.372198|2018-06-01 00:47:45.372198
NCT00937911|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2010-06-14|2009-07-10|2009-07-13|Estimate|||||||2010-06-14|2010-06-16|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities|YM150 Phase III Study - An Open-label, Multi-center Study in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities|Completed||Phase 3|101|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:47:45.454436|2018-06-01 00:47:45.454436
NCT00937898|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2013-05-13|2009-07-10|2009-07-13|Estimate|||||||2013-05-13|2013-05-15|Estimate|August 2007||2007-08-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|BOLD||Beef in an Optimal Lean Diet (BOLD) Effects on Cardiovascular Disease (CVD) Risk|BOLD (Beef in an Optimal Lean Diet) Effects on Established and Emerging Cardiovascular Disease (CVD) Risk Factors|Completed||N/A|40|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 00:47:45.520274|2018-06-01 00:47:45.520274
NCT00937885|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-09|2009-07-09|2009-07-13|Estimate|||||||2009-07-09|2009-07-13|Estimate|August 2005||2005-08-31|July 2009|2009-07-31|June 2008|Actual|2008-06-30|September 2007|Actual|2007-09-30||Interventional|||Consequences From Use of Reminiscence: a Randomised Intervention Study in Ten Danish Nursing Homes||Completed||N/A|||University of Southern Denmark||2|||f||||t||||||||||2018-06-01 00:47:45.574931|2018-06-01 00:47:45.574931
NCT00937872|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-06-02|2009-07-09|2009-07-13|Estimate|||||||2017-06-02|2017-06-05|Actual|November 22, 2008|Actual|2008-11-22|June 2017|2017-06-30|December 22, 2008|Actual|2008-12-22|December 22, 2008|Actual|2008-12-22||Interventional|||A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects|A Phase I Study to Evaluate the Intravenous Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension in Healthy Subjects|Completed||Phase 1|9|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 00:47:45.632558|2018-06-01 00:47:45.632558
NCT00937859|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09||2013-12-19|2014-04-24|2009-07-10|2009-07-13|Estimate||||2014-01-27|2014-02-28|Estimate|2014-04-24|2014-05-13|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Treatment of Patients With Nocturia|A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia|Completed||Phase 3|301|Actual|Serenity Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:47:45.805738|2018-06-01 00:47:45.805738
NCT00937846|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2017-06-26|2009-07-09|2009-07-13|Estimate|||||||2017-06-26|2017-06-27|Actual|July 15, 2009|Actual|2009-07-15|June 2017|2017-06-30|August 28, 2009|Actual|2009-08-28|August 28, 2009|Actual|2009-08-28||Interventional|||Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study|An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [Carbonyl-11C] GSK1034702 in Healthy Subjects|Completed||Phase 1|4|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:45.882732|2018-06-01 00:47:45.882732
NCT00937833|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2014-10-01||2014-12-23|2009-07-10|2009-07-13|Estimate|2014-11-05|2014-11-13|Estimate||||2014-12-23|2014-12-29|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2013|Actual|2013-10-31||Interventional||147 patients were treated with the study procedure.|Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling|Randomized Controlled Trial Examining the Return of Urinary Continence After Robot-assisted Radical Prostatectomy With or Without a Urethrovesical Sling|Completed||N/A|150|Actual|Cook Group Incorporated||2|||f||||||||||||||2018-06-01 00:47:45.98791|2018-06-01 00:47:45.98791
NCT00937820|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2011-01-05|2009-07-10|2009-07-13|Estimate|||||||2011-01-05|2011-01-06|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism|YM150 Long Term Study - Long-term Study in Patients With a History of Venous Thromboembolism|Completed||Phase 3|87|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:47:46.183389|2018-06-01 00:47:46.183389
NCT00937807|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2010-06-29|2009-07-10|2009-07-13|Estimate|||||||2010-06-29|2010-06-30|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Hemodynamic Stability During Carotid Endarterectomy.Comparison of LENOXe™ (Xenon 100% v/v) Versus Sevoflurane|Hemodynamic Stability During Carotid Endarterectomy Under General Anesthesia in Elderly Patients: Comparison LENOXe™ (xénon 100% v/v) Versus SEVOFLURANE|Completed||Phase 4|84|Anticipated|Air Liquide Santé International||2|||f||||f||||||||||2018-06-01 00:47:46.253451|2018-06-01 00:47:46.253451
NCT00937794|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2015-12-18||2016-04-11|2009-07-10|2009-07-13|Estimate|2016-04-11|2016-05-16|Estimate||||2016-04-11|2016-05-16|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®|A Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System Involvement and Who Are Currently Receiving Treatment With Elaprase®|Completed|||33|Actual|Shire|||1||f||||f||||||||||2018-06-01 00:47:46.335883|2018-06-01 00:47:46.335883
NCT00937781|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-05-16|2009-07-10|2009-07-13|Estimate|||||||2017-05-16|2017-05-17|Actual|February 8, 2011|Actual|2011-02-08|May 2017|2017-05-31|August 8, 2011|Actual|2011-08-08|August 8, 2011|Actual|2011-08-08||Observational|||Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690|Molecular Prognostic Factor Analysis in Melanoma|Completed|||307|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:47:46.460318|2018-06-01 00:47:46.460318
NCT00937768|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2013-10-08||2015-12-11|2009-07-10|2009-07-13|Estimate|2013-10-08|2013-12-06|Estimate||||2015-12-11|2016-01-14|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy|Phase II Trial of Temporary Androgen Deprivation Therapy in High Risk Prostate Cancer Following Radical Prostatectomy|Terminated||Phase 2|16|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:47:46.515987|2018-06-01 00:47:46.515987
NCT00937755|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-07-10|2009-07-10|2009-07-13|Estimate|||||||2009-07-10|2009-07-13|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Observational|||The Study of Atypical Antipsychotics-induced Metabolic Disturbances|The Study of Atypical Antipsychotics-induced Metabolic Disturbances|Completed|||80|Actual|Taipei Medical University Hospital|||3||f||||f||||||||||2018-06-01 00:47:46.712981|2018-06-01 00:47:46.712981
NCT00937742|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-05-26|2009-07-10|2009-07-13|Estimate|||||||2017-05-26|2017-05-31|Actual|January 2008||2008-01-31|May 2017|2017-05-31|April 2009|Actual|2009-04-30|September 2008|Actual|2008-09-30||Interventional|TOMATO||The Effect of Processed Tomato Products on CVD Risks|The Effect of Processed Tomatoes on Endothelium- and Platelet- Function|Completed||N/A|32|Actual|Penn State University||1|||f||||f||||||||||2018-06-01 00:47:46.777592|2018-06-01 00:47:46.777592
NCT00937729|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2012-02-14|2009-07-10|2009-07-13|Estimate|||||||2012-02-14|2012-02-16|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Observational|AMPHORE||Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules|Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment Containing Enfuvirtide (Fuzeon) Associated With Two Active Molecules|Terminated|||4|Actual|University Hospital, Rouen|||1|difficult to include patients|f||||t||||||||||2018-06-01 00:47:46.835605|2018-06-01 00:47:46.835605
NCT00937716|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2018-03-16|2009-07-10|2009-07-13|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2008||2008-10-31|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies|Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies|Active, not recruiting|||75|Anticipated|University of Alabama at Birmingham|||2||f||||t||||||Samples With DNA|"~     Specimens will be tested for dopamine, serotonin, norepinephrine, and glutamine-related~     genes. In previous studies, all of these neurotransmitters have been associated with~     schizophrenia and/or schizoaffective disorder.~   "|No||2018-06-01 00:47:47.864778|2018-06-01 00:47:47.864778
NCT00937703|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2013-12-12|2009-07-10|2009-07-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|December 2008||2008-12-31|March 2010|2010-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TELEDIAB-2||Multicentric Evaluation of Two Telematics Systems in Type 2 Diabetic Patients in Failure of Oral Treatment and Having to Start Treatment by Basal Insulin|Multicentric Evaluation of Two Telematics Systems (PDA Phone and IVS)in Type 2 Diabetics Patients in Failure of Oral Treatment and Having to Start a Treatment by Basal Insulin, Compared to a Conventional Care. National, Multicentric, Comparative Randomized Study|Completed||N/A|180|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||3|||f||||f||||||||||2018-06-01 00:47:47.94262|2018-06-01 00:47:47.94262
NCT00937690|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2014-12-19|2009-07-10|2009-07-13|Estimate|||||||2014-12-19|2014-12-23|Estimate|March 2008||2008-03-31|December 2014|2014-12-31||||September 2009|Actual|2009-09-30||Observational|MEL49||Pilot Study of Infrared Imaging of Cutaneous Melanoma|Pilot Study of Infrared Imaging of Cutaneous Melanoma|Completed|||74|Actual|University of Virginia|||1||f||||t||||||||||2018-06-01 00:47:48.064673|2018-06-01 00:47:48.064673
NCT00937677|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2011-09-06|2009-07-10|2009-07-13|Estimate|||||||2011-09-06|2011-09-07|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|November 2010|Actual|2010-11-30|December 2009|Actual|2009-12-31||Observational|||Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study|Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.|Completed|||85|Actual|University at Buffalo|||2||f||||f||||||||||2018-06-01 00:47:48.122649|2018-06-01 00:47:48.122649
NCT00937664|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2011-02-04|2009-07-10|2009-07-13|Estimate|||||||2011-02-04|2011-02-07|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine|A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies|Terminated||Phase 1|24|Actual|AstraZeneca||1||"Termination of the study was made after a full review of program data and assessment of the~   current risk-benefit profile."|f||||t||||||||||2018-06-01 00:47:48.210613|2018-06-01 00:47:48.210613
NCT00758329|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-06-16|2008-09-23|2008-09-25|Estimate|||||||2017-06-16|2017-06-19|Actual|April 2004||2004-04-30|June 2017|2017-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Retrospective Data Review of ReCap Total Hip Resurfacing|Retrospective Data Review of ReCap Total Hip Resurfacing|Withdrawn|||0|Actual|Zimmer Biomet|||1|No further contact with the site|f||||f||||||||||2018-06-01 01:44:17.604304|2018-06-01 01:44:17.604304
NCT00937651|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-07-10|2009-07-10|2009-07-13|Estimate|||||||2009-07-10|2009-07-13|Estimate|April 2005||2005-04-30|July 2009|2009-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|Fimasartan||Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)|Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Antihypertensive Efficacy, Safety, Tolerability, and Pharmacodynamic/Pharmacokinetic Profiles After 4 Weeks of Oral Administration of Fimasartan(BR-A-657) at 20-180mg in Patients With Essential Hypertension|Completed||Phase 2|81|Actual|Boryung Pharmaceutical Co., Ltd||4|||f||||t||||||||||2018-06-01 00:47:48.290582|2018-06-01 00:47:48.290582
NCT00937638|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2014-05-20|2009-07-10|2009-07-13|Estimate|||||||2014-05-20|2014-05-21|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|BOLD-X||Beef in an Optimal Lean Diet (BOLD) Effects on Metabolic Syndrome|BOLD (Beef in an Optimal Lean Diet) Effects on Established and Emerging Cardiovascular Disease (CVD) Risk Factors: Effects on Metabolic Syndrome (BOLD-X)|Completed||N/A|63|Actual|Penn State University||3|||f||||f||||||||||2018-06-01 00:47:48.38883|2018-06-01 00:47:48.38883
NCT00937625|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2015-08-17|2009-07-10|2009-07-13|Estimate|||||||2015-08-17|2015-08-18|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||T-cell Based Immunotherapy for of Melanoma|T-cell Based Immunotherapy for Treatment of Patients With Disseminated Melanoma.|Completed||Phase 1/Phase 2|31|Actual|Herlev Hospital|||||f||||t||||||||||2018-06-01 00:47:48.538301|2018-06-01 00:47:48.538301
NCT00937612|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-02-06|2009-07-10|2009-07-13|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2008||2008-06-30|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2011|Actual|2011-03-31||Interventional|||Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk|A Phase II Trial of Postoperative Concurrent Chemoradiation for Head and Neck Squamous Cell Carcinoma Patients With Multiple Risk Factors of Recurrence|Terminated||N/A|10|Actual|Chang Gung Memorial Hospital||1||Study group showed better results. Poor Accrual.|f||||t||||||||||2018-06-01 00:47:48.610752|2018-06-01 00:47:48.610752
NCT00937599|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-07-13|2009-07-10|2009-07-13|Estimate|||||||2009-07-13|2009-07-14|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Brazil Nut Consumed on the Metabolic Profile, Oxidative Stress and Nutritive Microcirculatory Patterns|The Effect of Brazil Nut Consumed on the Metabolic Profile, Oxidative Stress and Skin Microcirculatory Patterns in Obese Female Adolescents|Completed||N/A|18|Actual|Rio de Janeiro State University||1|||||||||||||||||2018-06-01 00:47:48.69845|2018-06-01 00:47:48.69845
NCT00937586|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2018-04-02|2009-07-10|2009-07-13|Estimate|||||||2018-04-02|2018-04-03|Actual|May 2000||2000-05-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Prostate Cancer Prospective Cohort|Prostate Cancer Prospective Cohort|Recruiting|||4100|Anticipated|Washington University School of Medicine|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, white cells, prostate tissue.~   "|||2018-06-01 00:47:48.76372|2018-06-01 00:47:48.76372
NCT00937573|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-11-02|2009-07-10|2009-07-13|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2009||2009-07-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Xience V at Wake Forest University Baptist Medical Center (WFUBMC)|Xience V at WFUBMC: Real World Outcomes Using Second Generation DES|Completed|||59|Actual|Wake Forest University Health Sciences|||5||f||||f||||||||||2018-06-01 00:47:48.836093|2018-06-01 00:47:48.836093
NCT00937560|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2015-02-09||2017-10-05|2009-07-10|2009-07-13|Estimate|2015-02-09|2015-02-24|Estimate||||2017-10-05|2017-11-06|Actual|June 25, 2009|Actual|2009-06-25|October 2017|2017-10-31|July 1, 2013|Actual|2013-07-01|July 31, 2012|Actual|2012-07-31||Interventional||Intent-to-treat population: All enrolled participants who received at least 1 dose of any study medication (bevacizumab, carboplatin or paclitaxel).|A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer|A Single-arm Phase II Clinical Study Investigating the Addition of Bevacizumab to Carboplatin and Weekly Paclitaxel as First-line Treatment in Patients With Epithelial Ovarian Cancer|Completed||Phase 2|190|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:47:48.941381|2018-06-01 00:47:48.941381
NCT00937547|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2012-06-06||2012-11-30|2009-07-10|2009-07-13|Estimate|2012-10-09|2012-11-08|Estimate||||2012-11-30|2012-12-04|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|HPI||Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela|Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma.|Completed|||329|Actual|Instituto Oncologico Luis Razetti|||||f||||f||||||Samples With DNA|"~     4.1. Collection of cervical samples:~      1. Previous ethics committe approval (Instituto Venezolano de Investigaciones Cientificas and~     Instituto de Oncología Luis Razetti), we are going to collect paraffin bloks of 300 patients~     with hystologic diagnosis of CIN 2/3 or Stage I cervical cancer.~      The samples will be obtained from archives of the Pathology Units of the following medical~     centers in Venezuela: Instituto de Oncología Luis Razetti, Anatomía Patológica Universidad~     Central de Venezuela, Hospital Oncológico Pérez Carreño (Valencia), Maracaibo, Barquisimeto,~     Ciudad Bolívar, Puerto La Cruz, Mérida and Barinas.~   "|||2018-06-01 00:47:49.310658|2018-06-01 00:47:49.310658
NCT00937534|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-11-02|2009-07-10|2009-07-13|Estimate|||||||2009-11-02|2009-11-04|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|Fimasartan||Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers|An Open Label, Single-dosing, and Parallel Study in Healthy Elderly and Young Male Volunteers.|Completed||Phase 1|22|Anticipated|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-06-01 00:47:49.772829|2018-06-01 00:47:49.772829
NCT00937521|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2015-02-13||2015-03-17|2009-07-10|2009-07-13|Estimate|2015-02-13|2015-03-04|Estimate||||2015-03-17|2015-04-07|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|February 2012|Actual|2012-02-29|November 2010|Actual|2010-11-30||Interventional|||Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants|A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants|Completed||Phase 2|1507|Actual|Novartis||8|||f||||||||||||||2018-06-01 00:47:49.963691|2018-06-01 00:47:49.963691
NCT00937508|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2010-04-07|2009-07-10|2009-07-13|Estimate|||||||2010-04-07|2010-04-08|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|July 2010|Anticipated|2010-07-31||Interventional|||Smoking Cessation Program in the Preadmission Clinic|A Double Blind Randomized Placebo Controlled Study, for Smoking Cessation in Preadmission Clinic. the Use of a Teachable Moment|Unknown status|Recruiting|Phase 4|290|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 00:47:54.143551|2018-06-01 00:47:54.143551
NCT00937495|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2013-09-11||2014-04-25|2009-07-10|2009-07-13|Estimate|2013-09-11|2013-11-21|Estimate||||2014-04-25|2014-05-14|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Interventional|||Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma|A Phase II Study of Suberoylanilide Hydroxamic Acid and Bortezomib in Advanced Soft Tissue Sarcomas|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:47:54.277805|2018-06-01 00:47:54.277805
NCT00937482|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2013-03-07|2009-07-10|2009-07-13|Estimate|||||||2013-03-07|2013-03-08|Estimate|August 2009||2009-08-31|March 2013|2013-03-31||||March 2011|Actual|2011-03-31||Interventional|||Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer|A Phase 1 Study of AZD2171 and WBRT in Patients With Brain Metastases|Terminated||Phase 1|18|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 00:47:54.703906|2018-06-01 00:47:54.703906
NCT00937469|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-08-04|2009-07-10|2009-07-13|Estimate|||||||2011-08-04|2011-08-08|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SOSTRA-ADHD||Social Skills Training and Standard Treatment Versus Standard Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|Social Skills Training and Standard Treatment Versus Standard Treatment of Children With ADHD - Attention Deficit Hyperactivity Disorder. Attachment Problems Among Children With ADHD|Completed||N/A|55|Actual|Region Zealand||2|||f||||t||||||||||2018-06-01 00:47:54.824368|2018-06-01 00:47:54.824368
NCT00937456|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2015-08-13|2009-07-10|2009-07-13|Estimate|||||||2015-08-13|2015-08-14|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|October 2011|Actual|2011-10-31||Interventional|||Open Versus Laparoscopically-assisted Esophagectomy for Cancer|Open vs Laparoscopically-assisted Esophagectomy for Cancer: A Multicentric Phase III Prospective Randomized Controlled Trial|Completed||Phase 3|207|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-06-01 00:47:54.913324|2018-06-01 00:47:54.913324
NCT00937443|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-03-30|2009-07-10|2009-07-13|Estimate|||||||2017-03-30|2017-04-04|Actual|July 2009|Actual|2009-07-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|EPCCHFWalk||Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure|Effectiveness of a Walking Program Modulating Cardioreparative Factors in Heart Failure|Completed|||9|Actual|Vanderbilt University Medical Center|||1||f||||f||||||Samples With DNA|"~     60 ml of blood will be used to measure baseline levels of EPC's, NRG-1, VEGF, and SDF-1.~     Repeat venipuncture will be done at Week 12. Approximately 60 ml of blood for the measurement~     of EPC's, NRG1, VEGF, and SDF-1.~   "|||2018-06-01 00:47:55.021138|2018-06-01 00:47:55.021138
NCT00937430|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2014-02-17|2009-07-10|2009-07-13|Estimate|||||||2014-02-17|2014-02-19|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Bowel Preparation and Pelvic Organ Prolapse Surgery|Bowel Preparation and Return of Bowel Function After Pelvic Organ Prolapse Surgery.|Completed||N/A|40|Actual|TriHealth Inc.||2|||f||||t||||||||||2018-06-01 00:47:55.10908|2018-06-01 00:47:55.10908
NCT00937417|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2017-04-20|2009-07-10|2009-07-13|Estimate|||||||2017-04-20|2017-04-24|Actual|September 2008||2008-09-30|April 2017|2017-04-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|Southwest Oncology Group||1||Withdrawn because SWOG no longer pursuing this study at this time|f||||f|f|f||||||No||2018-06-01 00:47:55.204121|2018-06-01 00:47:55.204121
NCT00937404|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-05-26|2009-07-09|2009-07-13|Estimate|||||||2017-05-26|2017-05-30|Actual|August 4, 2009|Actual|2009-08-04|May 2017|2017-05-31|November 13, 2009|Actual|2009-11-13|November 13, 2009|Actual|2009-11-13||Interventional|||Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix™) in Infants|An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.|Completed||Phase 1|25|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:55.284484|2018-06-01 00:47:55.284484
NCT00937391|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|2011-09-08||2015-10-19|2009-07-10|2009-07-13|Estimate|2011-09-08|2011-10-13|Estimate||||2015-10-19|2015-11-18|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Contrast-enhanced MRI in Children 2 Months to <2 Years|Open-label, Multi-center, Two-stage, Age Stratified, Pharmacokinetic, Safety, and Efficacy Study in Children 2 Months to < 2 Years of Age Undergoing Magnevist Injection Enhanced MRI|Completed||Phase 3|54|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:47:55.801676|2018-06-01 00:47:55.801676
NCT00937378|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09||2013-12-19|2014-04-17|2009-07-10|2009-07-13|Estimate||||2014-01-27|2014-02-28|Estimate|2014-04-17|2014-05-07|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Treatment of Patients With Nocturia (Non-PK Study)|A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)|Completed||Phase 3|326|Actual|Serenity Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:47:57.228207|2018-06-01 00:47:57.228207
NCT00937365|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2010-07-21|2009-07-10|2009-07-13|Estimate|||||||2010-07-21|2010-07-22|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Pregnancy-Related Low Back Pain and Complementary and Alternative Medicine (CAM) Treatment|A Pilot Randomized Controlled Trial for Complementary and Alternative Medicine Treatment of Pregnancy-Related Low Back Pain.|Unknown status|Recruiting|Phase 2|90|Anticipated|Oregon Health and Science University||3|||f||||f||||||||||2018-06-01 00:47:57.342527|2018-06-01 00:47:57.342527
NCT00937352|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07||2013-10-30|2013-11-26|2009-07-09|2009-07-13|Estimate||||2013-10-30|2013-11-25|Estimate|2013-11-26|2013-12-20|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease|A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.|Terminated||Phase 3|896|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||2|||f||||||||||||||2018-06-01 00:47:57.543508|2018-06-01 00:47:57.543508
NCT00937339|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2013-04-01|2009-07-10|2009-07-13|Estimate|||||||2013-04-01|2013-04-04|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Whole Body Vibration in People With Chronic Stroke|The Effects of Exercise and Whole Body Vibration Training on Bone Health, Physical Fitness, and Neuromotor Performance in Individuals With Chronic Stroke: A Randomized Controlled Trial.|Completed||N/A|82|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-06-01 00:47:58.072296|2018-06-01 00:47:58.072296
NCT00937326|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2017-08-31||2017-08-31|2009-07-09|2009-07-13|Estimate|2017-08-31|2018-04-09|Actual||||2017-08-31|2018-04-09|Actual|August 19, 2009|Actual|2009-08-19|August 2017|2017-08-31|September 18, 2010|Actual|2010-09-18|September 18, 2010|Actual|2010-09-18||Interventional|||Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects|A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects|Completed||Phase 2|227|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:47:58.550187|2018-06-01 00:47:58.550187
NCT00937313|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2009-07-10|2009-07-10|2009-07-13|Estimate|||||||2009-07-10|2009-07-13|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|September 2008|Actual|2008-09-30|February 2008|Actual|2008-02-29||Observational|||The Pharmacokinetics and Potential Health Effects of Champagne Wine in Human Subjects|The Pharmacokinetics and Potential Health Effects of Champagne Wine in Human Subjects|Completed|||15|Actual|University of Reading|||2||f||||f||||||Samples Without DNA|"~     plasma serum urine~   "|||2018-06-01 00:48:04.302443|2018-06-01 00:48:04.302443
NCT00937300|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-10|||2011-11-22|2009-07-10|2009-07-13|Estimate|||||||2011-11-22|2011-11-23|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||T-cell Based Immunotherapy for Head and Neck Cancer|T-cell Based Immunotherapy for Treatment of Patients Squamous Cell Carcinoma in the Oral Cavity. A Pilot Study.|Withdrawn||Phase 1|0|Actual|Herlev Hospital||||The patients eligible for this trial do not exist anymore due to change in procedures.|f||||t||||||||||2018-06-01 00:48:04.371937|2018-06-01 00:48:04.371937
NCT00937287|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2013-08-12|2009-07-09|2009-07-10|Estimate|||||||2013-08-12|2013-08-14|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|April 2011|Actual|2011-04-30||Observational|||Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters|Understanding HPV Vaccination Among Rural African American Primary Caregivers and Daughters|Completed|||410|Actual|University of Georgia|||1||f||||f||||||||||2018-06-01 00:48:04.441765|2018-06-01 00:48:04.441765
NCT00937274|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2013-11-12|2009-07-09|2009-07-10|Estimate|||||||2013-11-12|2013-11-13|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution|Randomized, Double Blind Placebo-controlled Studies to Evaluate the Effect of an Orally-fed Escherichia Coli (E. Coli) Phage in the Management of ETEC and EPEC Induced Diarrhea in Children|Terminated||N/A|120|Actual|Nestlé||3|||f||||f||||||||||2018-06-01 00:48:04.571782|2018-06-01 00:48:04.571782
NCT00937261|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-10-27|2009-07-08|2009-07-10|Estimate|||||||2010-10-27|2010-10-28|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|January 2011|Anticipated|2011-01-31|July 2010|Anticipated|2010-07-31||Interventional|||Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning|Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning|Unknown status|Recruiting|Phase 4|96|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-06-01 00:48:04.646162|2018-06-01 00:48:04.646162
NCT00937248|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2017-09-21|2009-07-09|2009-07-10|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2009||2009-04-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Cone Beam Computed Tomography (CT) (CBCT) With and Without a Customized Vacuum Immobilization Device (CVID)|A Randomized Study Evaluating Set-up Reproducibility Using Cone Beam CT (CBCT) With and Without a Customized Vacuum Immobilization Device (CVID) in Rectal Cancer Patients Treated With Preoperative Pelvic Radiation Therapy|Active, not recruiting||N/A|20|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 00:48:04.761212|2018-06-01 00:48:04.761212
NCT00937235|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2017-03-28||2017-10-11|2009-07-08|2009-07-10|Estimate|2017-08-07|2017-09-07|Actual||||2017-10-11|2017-11-14|Actual|January 2009||2009-01-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Treatment of Smoking Among Individuals With PTSD|Treatment of Smoking Among Individuals With PTSD: A Phase II, Randomized Study of Varenicline and Cognitive Behavioral Therapy|Completed||Phase 2|142|Actual|University of Pennsylvania|"PPA verified by CO/cotinine was only assessed at two time-points (post-treatment, and follow-up)~medication adherence for varenicline was measured using pill count by the study nurse"|2|||f||||t||||||||||2018-06-01 00:48:04.841015|2018-06-01 00:48:04.841015
NCT00937222|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-06-19|2009-07-09|2009-07-10|Estimate|||||||2012-06-19|2012-06-20|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes|Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults Ith Type 2 Diabetes|Completed||N/A|60|Actual|Loma Linda University|||||f||||t||||||||||2018-06-01 00:48:05.183299|2018-06-01 00:48:05.183299
NCT00937196|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2013-08-09|2009-07-09|2009-07-10|Estimate|||||||2013-08-09|2013-08-13|Estimate|August 2006||2006-08-31|August 2013|2013-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Placebo Effects on Blood Pressure Induced by Expectancy Manipulation|Effects of Placebos and Verbal Suggestions on Blood Pressure - Randomized Controlled Trial|Completed||N/A|45|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-06-01 00:48:05.247304|2018-06-01 00:48:05.247304
NCT00937183|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2016-12-06|2009-07-08|2009-07-10|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2003||2003-09-30|June 2011|2011-06-30||||June 2010|Anticipated|2010-06-30||Interventional|||Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma|Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center|||||f||||||||||||||2018-06-01 00:48:05.31014|2018-06-01 00:48:05.31014
NCT00937170|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2011-01-20|2009-07-09|2009-07-10|Estimate|||||||2011-01-20|2011-01-21|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study Comparing Traditional and Gender-specific Total Knee Replacement Designs|A Prospective, Randomized, Control Trial Comparing Total Knee Arthroplasty With Traditional and Gender-Specific Designs|Withdrawn||N/A|0|Actual|UConn Health||3|||f||||f||||||||||2018-06-01 00:48:05.384009|2018-06-01 00:48:05.384009
NCT00937157|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2014-12-02||2014-12-02|2009-07-09|2009-07-10|Estimate|2014-12-02|2014-12-09|Estimate||||2014-12-02|2014-12-09|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|April 2011|Actual|2011-04-30|July 2010|Actual|2010-07-31||Interventional|||Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)|Comparison of Standard 1.5 Versus 3T Optimized Protocols in Patients Treated With Glatiramer Acetate. A Conventional and Non-conventional MRI Study|Completed||N/A|12|Actual|University at Buffalo||1|||f||||f||||||||||2018-06-01 00:48:05.452272|2018-06-01 00:48:05.452272
NCT00937131|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2009-07-09|2009-07-09|2009-07-10|Estimate|||||||2009-07-09|2009-07-10|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)|A Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) in Combination With Plasma Exchange (PEX) in Patients With Acute Thrombotic Thrombocytopenic Purpura (TTP)|Unknown status|Active, not recruiting|Phase 2|40|Actual|University College, London|||||f||||f||||||||||2018-06-01 00:48:05.877871|2018-06-01 00:48:05.877871
NCT00937118|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2012-05-04||2013-05-13|2009-07-09|2009-07-10|Estimate|2013-05-13|2013-08-12|Estimate||||2013-05-13|2013-08-12|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Damage Control for Duodenal and Combined Duodenal-Pancreatic Injuries|Damage Control for Severe Duodenal and Combined Duodenal-Pancreatic Injuries: A Retrospective Review|Completed|||43|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-06-01 00:48:05.950978|2018-06-01 00:48:05.950978
NCT00937105|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2013-07-01||2014-01-27|2009-07-09|2009-07-10|Estimate|2014-01-27|2014-03-10|Estimate||||2014-01-27|2014-03-10|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|DWCIE|The baseline measures refer to the entire cohort of 218 participants that were randomized, stratified by solution group|Daily Wear Corneal Infiltrative Event Study|Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study)|Completed||Phase 4|218|Actual|University Hospitals Cleveland Medical Center|Mostly asymptomatic CIE events occurred which limited the ability to retrieve the lens worn (for culture) precisely at the time of CIE development; this may have hindered our ability to capture bioburden at the time of the adverse event.|2|||f||||t||||||||||2018-06-01 00:48:06.105397|2018-06-01 00:48:06.105397
NCT00937092|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2010-05-25|2009-07-09|2009-07-10|Estimate|||||||2010-05-25|2010-05-26|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|July 2012|Anticipated|2012-07-31|January 2010|Anticipated|2010-01-31||Interventional|DAD-HF||Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial|Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure|Unknown status|Recruiting|Phase 4|300|Anticipated|Larissa University Hospital||2|||f||||f||||||||||2018-06-01 00:48:06.470151|2018-06-01 00:48:06.470151
NCT00937079|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2015-01-08|2009-07-08|2009-07-10|Estimate|||||||2015-01-08|2015-01-09|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients|The Physiology of Glucagon-like-peptide-1 Receptor Expression in Patients With Endogenous Hyperinsulinism - Correlation With Histopathology|Completed|||30|Actual|University Hospital, Basel, Switzerland|||||f||||t||||||Samples Without DNA|"~     Tumor tissue~   "|||2018-06-01 00:48:06.572551|2018-06-01 00:48:06.572551
NCT00937066|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2011-01-21|2009-07-09|2009-07-10|Estimate|||||||2011-01-21|2011-01-24|Estimate||||January 2011|2011-01-31||||||||Observational|||Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)|Management of Patients With Moderate to Severe Asthma Uncontrolled When Treated With Low Dose Inhaled Corticosteroids: Cost-effectiveness of Three Therapeutics Alternatives|Completed|||1000|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:48:06.645757|2018-06-01 00:48:06.645757
NCT00937053|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2010-08-03|2009-07-09|2009-07-10|Estimate|||||||2010-08-03|2010-08-04|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|June 2015|Anticipated|2015-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Maintaining a Higher Level of Haemoglobin: Effect on the White Cells After Bone Marrow Transplantation in Children.|The Effect of Maintaining a Higher Haemoglobin Level on Neutropenia Duration After Bone Marrow Transplantation in Children.|Terminated||Phase 2|6|Actual|St. Justine's Hospital||2||3 unexpected Serious Adverse Events (veno-occlusive disease (VOD))|f||||t||||||||||2018-06-01 00:48:06.716467|2018-06-01 00:48:06.716467
NCT00937040|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2011-02-28||2013-07-23|2009-07-09|2009-07-10|Estimate|2011-07-08|2011-08-05|Estimate||||2013-07-23|2013-07-30|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate|Completed||Phase 4|357|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC||2|||f||||f||||||||||2018-06-01 00:48:06.828464|2018-06-01 00:48:06.828464
NCT00937027|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-11-01|2009-07-09|2009-07-10|Estimate|||||||2012-11-01|2012-11-05|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis|A Randomized Phase 1 Study Comparing The Safety and Oral Pharmacokinetics Of 0.25 mg and 1.0 mg Aminopterin Tablets In Human Subjects With Psoriasis|Completed||Phase 1|22|Actual|Syntrix Biosystems, Inc.||2|||f||||t||||||||||2018-06-01 00:48:07.499542|2018-06-01 00:48:07.499542
NCT00937014|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2013-06-24|2009-07-09|2009-07-10|Estimate|||||||2013-06-24|2013-06-26|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Assessment of Growth of Infants Fed a New Formula|Assessment of Growth of Infants Fed a Starter Formula With a Whey-Isolate Enriched in Lactoferrin|Completed||N/A|180|Actual|Nestlé||2|||f||||f||||||||||2018-06-01 00:48:07.558683|2018-06-01 00:48:07.558683
NCT00937001|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2018-02-28|2009-07-09|2009-07-10|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2008||2008-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|January 2010|Actual|2010-01-31||Interventional|MUSIC Plus||Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness|Investigating the Histopathological and Clinical Significance of Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness|Active, not recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||1|||f||||t||||||||||2018-06-01 00:48:07.615492|2018-06-01 00:48:07.615492
NCT00936988|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2013-05-06|2009-07-09|2009-07-10|Estimate|||||||2013-05-06|2013-05-08|Estimate|November 2000||2000-11-30|May 2013|2013-05-31|December 2005|Actual|2005-12-31|June 2005|Actual|2005-06-30||Interventional|||A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism|A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism|Completed||Phase 2|45|Actual|Amgen||1|||f||||||||||||||2018-06-01 00:48:07.674713|2018-06-01 00:48:07.674713
NCT00936819|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2018-02-05|2009-07-08|2009-07-10|Estimate|||||||2018-02-05|2018-02-07|Actual|July 2013||2013-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ENACT-AMI||The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial|A Phase IIb, Randomized, Double-blind, Placebo Controlled Study Using Transplantation of Autologous Early Endothelial Progenitor Cells(EPCs) for Patients Who Have Suffered Acute Myocardial Infarction|Recruiting||Phase 2|100|Anticipated|Ottawa Hospital Research Institute||3|||f||||t||||||||||2018-06-01 00:48:09.94224|2018-06-01 00:48:09.94224
NCT00936975|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2015-02-20||2015-06-22|2009-07-09|2009-07-10|Estimate|2015-06-22|2015-07-16|Estimate||||2015-06-22|2015-07-16|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional||18 participants meeting the eligibility criteria were accrued to the trial and received the baseline PET scan|Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases|A Phase 2, Multicenter Evaluation of 18F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant Prostate Cancer and Bone Metastases (BMS #180-279)|Completed||Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:48:07.73916|2018-06-01 00:48:07.73916
NCT00936962|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2015-07-14|2009-07-09|2009-07-10|Estimate|||||||2015-07-14|2015-07-15|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of Meningococcal C Vaccine Programmes in Canadian Children|Evaluation of Meningococcal C Vaccine Programmes in Canadian (BC, NS, Alta.) Children During Peak Years of Risk (0-<5 Years of Age)|Completed||Phase 4|452|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 00:48:08.101622|2018-06-01 00:48:08.101622
NCT00936949|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2013-03-07|2009-07-08|2009-07-10|Estimate|||||||2013-03-07|2013-03-08|Estimate|July 2003||2003-07-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Posterolateral Surgical Approach Compared With Modified Lateral Approach|Posterolateral Surgical Approach Compared With Modified Lateral Approach: A Prospective, Randomised Trial|Completed||N/A|196|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 00:48:08.176827|2018-06-01 00:48:08.176827
NCT00936936|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2017-09-14|2009-07-09|2009-07-10|Estimate|||||||2017-09-14|2017-09-15|Actual|June 2009|Actual|2009-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors|High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors|Recruiting||Phase 2|67|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-06-01 00:48:08.253069|2018-06-01 00:48:08.253069
NCT00936923|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2015-05-19|2009-07-09|2009-07-10|Estimate|||||||2015-05-19|2015-05-21|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients|Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients|Withdrawn||Phase 3|0|Actual|Sun Yat-sen University||3||The study was withdrawn prior to enrollment of first participant.|f||||t||||||||||2018-06-01 00:48:08.355921|2018-06-01 00:48:08.355921
NCT00936910|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2016-01-15||2017-09-10|2009-07-08|2009-07-10|Estimate|2017-09-10|2017-10-10|Actual||||2017-09-10|2017-10-10|Actual|September 2006||2006-09-30|September 2017|2017-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Antifungal Locks to Treat Fungal-related Central Line Infections|The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients|Completed||Phase 4|13|Actual|University of Pittsburgh||1|||f||||f||||||||Yes|The entire data for all patients from the clinical trial has been published. The reference is: McGhee W, Michaels M, Martin, J, et al. Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial. Journal of the Pediatric Infectious Diseases Society. 2016;5 (1): 80-4.|2018-06-01 00:48:08.440484|2018-06-01 00:48:08.440484
NCT00936897|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2012-10-31||2013-02-05|2009-07-09|2009-07-10|Estimate|2012-10-31|2012-11-29|Estimate||||2013-02-05|2013-02-11|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates|A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates|Completed||Phase 3|833|Actual|Amgen||2|||f||||f||||||||||2018-06-01 00:48:08.699962|2018-06-01 00:48:08.699962
NCT00936884|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2013-11-07|2009-07-09|2009-07-10|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study Evaluating The Efficacy And Safety Of Subcutaneous MOA-728 For The Treatment Of Opioid-Induced-Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, And Parallel-Group Study Of Subcutaneous MOA-728 For The Treatment Of Opioid-Induced Constipation In Adult Subjects|Completed||Phase 3|51|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 00:48:09.293253|2018-06-01 00:48:09.293253
NCT00936871|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07||2010-03-26|2010-09-01|2009-07-08|2009-07-10|Estimate||||2010-03-26|2010-03-30|Estimate|2010-09-01|2010-09-06|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects|A Phase 1, Randomized, Single Dose, Placebo And Active Controlled, 3-Way Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects|Completed||Phase 1|66|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 00:48:09.398603|2018-06-01 00:48:09.398603
NCT00936858|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2018-01-26|2009-07-09|2009-07-10|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2009||2009-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||RAD001 for Patients With Radioiodine Refractory Thyroid Cancer|A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer|Active, not recruiting||Phase 2|33|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:48:09.559299|2018-06-01 00:48:09.559299
NCT00936845|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2012-12-06|2009-07-09|2009-07-10|Estimate|||||||2012-12-06|2012-12-10|Estimate|April 2005||2005-04-30|December 2012|2012-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study|Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study|Completed|||22|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 00:48:09.649015|2018-06-01 00:48:09.649015
NCT00936832|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2014-03-03|2009-07-08|2009-07-10|Estimate|||||||2014-03-03|2014-03-04|Estimate|April 2009||2009-04-30|July 2009|2009-07-31||||||||Interventional|||Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery|Front-line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study. (SUREMETS)|Withdrawn||Phase 2|0|Actual|Federation Francophone de Cancerologie Digestive||||because the sunitinib showed futility in anotehr trial|f||||||||||||||2018-06-01 00:48:09.753707|2018-06-01 00:48:09.753707
NCT00936312|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2012-12-06|2009-07-09|2009-07-10|Estimate|||||||2012-12-06|2012-12-10|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study|Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study|Completed|||200|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-06-01 00:48:29.054047|2018-06-01 00:48:29.054047
NCT00936806|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2014-01-27|2009-07-09|2009-07-10|Estimate|||||||2014-01-27|2014-01-28|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|VISTA||Observational Study of the Differences in Characteristics of the Spontaneous Electroencephalogram, Derived From the Left and Right Hemisphere in Patients With Unilateral Intracranial Tumor During Routine Anesthesia: Comparison With a Control Group Without Intracranial Pathology|Observational Study of the Differences in Characteristics of the Spontaneous Electroencephalogram, Derived From the Left and Right Hemisphere in Patients With Unilateral Intracranial Tumor During Routine Anesthesia. Comparison With a Control Group Without Intracranial Pathology.|Completed|||80|Actual|University Hospital, Ghent|||2||f||||f||||||||||2018-06-01 00:48:10.07195|2018-06-01 00:48:10.07195
NCT00936793|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-06-30|2009-07-09|2009-07-10|Estimate|||||||2017-06-30|2017-07-02|Actual|July 6, 2009||2009-07-06|February 9, 2012|2012-02-09|June 10, 2011|Actual|2011-06-10|June 10, 2011|Actual|2011-06-10||Interventional|||Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers|Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers|Completed||Phase 1|53|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:48:10.151847|2018-06-01 00:48:10.151847
NCT00936780|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-08-22|2009-07-09|2009-07-10|Estimate|||||||2012-08-22|2012-08-23|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions|Safety and Efficacy of the Infinnium-Core™ Paclitaxel-Eluting Coronary Stent System for the Treatment of Patients With De Novo Coronary Lesions|Terminated||Phase 4|67|Actual|Sahajanand Medical Technologies Pvt. Ltd.||1||market demand from paclitaxel to sirolimus drug-eluting stent|f||||f||||||||||2018-06-01 00:48:10.269506|2018-06-01 00:48:10.269506
NCT00936767|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2010-10-08|2009-07-09|2009-07-10|Estimate|||||||2010-10-08|2010-10-11|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|AMOS||Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia|Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western|Withdrawn||Phase 2/Phase 3|75|Anticipated|University of Oxford||2||Did not get approval|f||||t||||||||||2018-06-01 00:48:10.450375|2018-06-01 00:48:10.450375
NCT00936754|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2010-01-18|2009-07-09|2009-07-10|Estimate|||||||2010-01-18|2010-01-20|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|ICAST||Safety and Efficacy of a Single Dose of a Polyphenol-enriched Brown Seaweed Powder in Human|Safety and Efficacy of a Unique Dose of a Brown Seaweeds Powder Enriched in Polyphenols on Human|Completed||Phase 1|23|Anticipated|innoVactiv Inc.||2|||f||||f||||||||||2018-06-01 00:48:10.584354|2018-06-01 00:48:10.584354
NCT00936741|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2013-09-18||2014-02-19|2009-07-09|2009-07-10|Estimate|2014-02-19|2014-04-02|Estimate||||2014-02-19|2014-04-02|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome|An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome|Completed||Phase 3|30|Actual|Corcept Therapeutics||1|||f||||f||||||||||2018-06-01 00:48:10.775689|2018-06-01 00:48:10.775689
NCT00936728|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2018-02-05|2009-07-09|2009-07-10|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2009|Actual|2009-07-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||White Wine or Nutritional Supplement in Improving Appetite in Patients With Cancer|White Wine for Appetite Loss: A Randomized, Controlled, Non-Blinded Trial|Active, not recruiting||N/A|140|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:48:11.508382|2018-06-01 00:48:11.508382
NCT00936715|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2016-11-18||2017-05-02|2009-07-09|2009-07-10|Estimate|2017-05-02|2017-06-02|Actual||||2017-05-02|2017-06-02|Actual|August 2009|Actual|2009-08-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Full Analysis Set: participants who were enrolled into the study and received study drug|Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States|A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study|Completed||Phase 2|24|Actual|Gilead Sciences||1|||f||||f|t|||||||||2018-06-01 00:48:11.674|2018-06-01 00:48:11.674
NCT00936702|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2016-12-27||2017-02-16|2009-07-08|2009-07-10|Estimate|2016-12-27|2017-02-16|Actual||||2017-02-16|2017-03-21|Actual|September 2009||2009-09-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional||All participants.|Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary|A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)|Completed||Phase 2|46|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 00:48:11.972207|2018-06-01 00:48:11.972207
NCT00936689|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2012-12-21|2009-07-09|2009-07-10|Estimate|||||||2012-12-21|2012-12-24|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|PRECISION-IT||Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE|Treatment of Hepatocellular Carcinoma (HCC)by Selective Traditional Chemoembolization(TACE)Versus Selective TACE Via Microspheres Loaded With Doxorubicin: a Multicentre,Randomized,Open Label,Controlled Study.|Completed||Phase 4|178|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 00:48:12.9449|2018-06-01 00:48:12.9449
NCT00936676|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2016-04-08|2009-07-09|2009-07-10|Estimate|||||||2016-04-08|2016-04-11|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects|An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study|Completed|||684|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-06-01 00:48:13.141434|2018-06-01 00:48:13.141434
NCT00936663|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2018-02-08||2018-03-22|2009-07-09|2009-07-10|Estimate|2018-03-22|2018-04-24|Actual||||2018-03-22|2018-04-24|Actual|July 2009||2009-07-31|March 2018|2018-03-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation|A Randomized, Placebo-Controlled Double-Blind Trial Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation: A Pilot Study|Terminated||Phase 4|3|Actual|University of Nebraska|We did not reach the target number of participants needed to achieve target power and statistically reliable results as the funding was not renewed by the sponsor.|2||lack of funding|f||||t||||||||||2018-06-01 00:48:13.407668|2018-06-01 00:48:13.407668
NCT00936650|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2013-05-06|2009-07-09|2009-07-10|Estimate|||||||2013-05-06|2013-05-08|Estimate|November 1999||1999-11-30|May 2013|2013-05-31|June 2001|Actual|2001-06-30|March 2001|Actual|2001-03-31||Interventional|||A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Dose-Titration Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT)|Completed||Phase 2|78|Actual|Amgen||2|||f||||||||||||||2018-06-01 00:48:14.626083|2018-06-01 00:48:14.626083
NCT00936637|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-07-09|2009-07-09|2009-07-10|Estimate|||||||2009-07-09|2009-07-10|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects on Growth of an Extensively Hydrolyzed Formula Fed to Term|A 16-Week Growth Study of an Extensively Hydrolyzed Infant Formula, 3 Months Treatment and 1 Month Follow-up for a Duration of 4 Months.|Completed||N/A|35|Actual|Perrigo Nutritionals||1|||f||||f||||||||||2018-06-01 00:48:14.834544|2018-06-01 00:48:14.834544
NCT00936624|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2013-12-17|2009-07-09|2009-07-10|Estimate|||||||2013-12-17|2013-12-19|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma|A 12 Week, Multi-center,Randomized, Double Blinded, Parallel Group, Placebo-controlled, 4-arm, Dose Finding Trial to Assess the Efficacy and Safety of SOTB07 in Persistent Asthma|Completed||Phase 2|245|Actual|SK Chemicals Co.,Ltd.||4|||f||||t||||||||||2018-06-01 00:48:14.946145|2018-06-01 00:48:14.946145
NCT00936611|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-08-25|2009-07-09|2009-07-10|Estimate|||||||2017-08-25|2017-08-28|Actual|June 2009||2009-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia|Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia|Active, not recruiting||Phase 2|37|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:48:15.421423|2018-06-01 00:48:15.421423
NCT00936598|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2012-06-15||2014-04-04|2009-07-09|2009-07-10|Estimate|2012-06-15|2012-07-20|Estimate||||2014-04-04|2014-04-24|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Sleep and Endometrial Cancer|Surgery for Endometrial Cancer: Biobehavioral Analysis of Sleep, Stress and Pain|Terminated||N/A|6|Actual|University of Pittsburgh||2||Investigator-initiated termination of approval due to problems with recruitment.|f||||t||||||||||2018-06-01 00:48:16.02022|2018-06-01 00:48:16.02022
NCT00936585|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2013-04-24||2015-12-07|2009-07-09|2009-07-10|Estimate|2015-12-07|2016-01-11|Estimate||||2015-12-07|2016-01-11|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease|NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease|Terminated||N/A|2|Actual|National Institutes of Health Clinical Center (CC)|The NIH sub study ended earlier than anticipated as the Novartis main study was terminated for futility. As a result, not enough patients were enrolled to perform any analysis of data.|1||Study halted by the sponsor|f||||t||||||||||2018-06-01 00:48:17.671163|2018-06-01 00:48:17.671163
NCT00936572|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-09|2009-07-09|2009-07-10|Estimate|||||||2009-07-09|2009-07-10|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Probiotics In Colorectal Cancer Patients|A Randomized Double-Blind Trial of Perioperative Administration of Probiotics in Colorectal Cancer Patients.|Completed||Phase 2|35|Actual|University of Milano Bicocca||3|||f||||t||||||||||2018-06-01 00:48:18.428561|2018-06-01 00:48:18.428561
NCT00936559|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-04-12|2009-07-09|2009-07-10|Estimate|||||||2012-04-12|2012-04-13|Estimate|September 2010||2010-09-30|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair|Randomized, Single-Blind, Standard Of Care Control, Dose-Escalating, Multicenter, Safety Study Of BMP-655/ACS As An Adjuvant Therapy For Treatment Of Full Thickness Rotator Cuff Tears Treated By Means Of An Open Surgical Procedure|Terminated||Phase 1|13|Actual|Pfizer||3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:48:18.579617|2018-06-01 00:48:18.579617
NCT00936546|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2014-02-06|2009-07-09|2009-07-10|Estimate|||||||2014-02-06|2014-02-07|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy|A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 00:48:18.68308|2018-06-01 00:48:18.68308
NCT00936533|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-03-08|2009-07-09|2009-07-10|Estimate|||||||2011-03-08|2011-03-09|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita|Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita - a Double-blind Placebo-controlled Phase II Proof of Concept Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Uppsala University|||||f||||f||||||||||2018-06-01 00:48:18.740309|2018-06-01 00:48:18.740309
NCT00936520|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-05-09|2009-07-09|2009-07-10|Estimate|||||||2017-05-09|2017-05-10|Actual|August 2009||2009-08-31|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy|A Phase 1b, Randomized, Uncontrolled, Single-masked, Safety, Tolerability, and Pharmacokinetic Study of Multiple Doses of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Human Subjects Undergoing Elective Pars Plana Vitrectomy (PPV)|Terminated||Phase 1|30|Actual|Johns Hopkins University||3||Preliminary analysis showed little or no bioactivity.|f||||f||||||||||2018-06-01 00:48:18.865201|2018-06-01 00:48:18.865201
NCT00936507|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2018-04-03|2009-07-09|2009-07-10|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2008|Actual|2008-09-30|April 2018|2018-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Does Portion Size Influence Intake of Low-Energy-Dense Foods in Preschool-aged Children?||Completed||N/A|17|Actual|The University of Tennessee, Knoxville||4|||f||||||||||||||2018-06-01 00:48:18.976644|2018-06-01 00:48:18.976644
NCT00936494|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2016-10-05|2009-07-09|2009-07-10|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Inferior Turbinate Reduction in Pediatric Population Failing Surgery for Sleep Disordered Breathing|Inferior Turbinate Reduction in Pediatric Population Failing Tonsillectomy and Adenoidectomy for Sleep Disordered Breathing (Randomized, Prospective, Controlled Study)|Terminated||N/A|2|Actual|University of Missouri-Columbia||2||Lack of enrollment|f||||t||||||||No||2018-06-01 00:48:19.190192|2018-06-01 00:48:19.190192
NCT00936481|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2013-06-12||2013-08-19|2009-07-08|2009-07-10|Estimate|2013-08-19|2013-10-25|Estimate||||2013-08-19|2013-10-25|Estimate|February 2008||2008-02-29|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea|Variability of Fibrinolytic Markers and Endothelial Function in Obstructive Sleep Apnea|Completed|||34|Actual|Vanderbilt University|||2||f||||f||||||Samples With DNA|"~     Blood samples to measure plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen~     activator (t-PA)levels, endothelial function,fasting lipid profile and glucose levels.~   "|||2018-06-01 00:48:19.522823|2018-06-01 00:48:19.522823
NCT00936468|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2011-02-10|2009-07-09|2009-07-10|Estimate|||||||2011-02-10|2011-02-14|Estimate|September 2009||2009-09-30|February 2011|2011-02-28|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Safety, Tolerability and Immunogenicity of Fluzone® With and Without JVRS-100 in Elderly Subjects|Randomized, Double Blind, Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With and Without JVRS-100 Adjuvant in Subjects 65 Years and Older|Completed||Phase 2|472|Actual|Colby Pharmaceutical Company||4|||f||||t||||||||||2018-06-01 00:48:19.943374|2018-06-01 00:48:19.943374
NCT00936455|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|2011-08-29||2012-04-24|2009-07-09|2009-07-10|Estimate|2012-03-29|2012-04-24|Estimate||||2012-04-24|2012-04-30|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|STRokE DOC-LTO||Stroke Team Remote Evaluation Using a Digital Observation Camera- Long Term Outcomes(STRokE DOC-LTO)|"An Observational Study to Evaluate the Long Term Outcomes of Patients Previously Enrolled in the STRokE DOC (STRokE DOC Trial (NCT00283868)) Telemedicine Clinical Trial."|Completed|||75|Actual|University of California, San Diego|This is an observational trial where patients were contacted by telephone for data collection only. No adverse event information was collected.||2||f||||f||||||||||2018-06-01 00:48:21.253752|2018-06-01 00:48:21.253752
NCT00936442|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-02-13|2009-07-09|2009-07-10|Estimate|||||||2012-02-13|2012-02-14|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|ARTEMIS||Arimidex Therapy Compliance Electronic Monitoring System|ARimidex Therapy Compliance Electronic MonitorIng System. A Study to Evaluate the Impact of Educational Material on the Adherence to Treatment With Adjuvant Anastrozole for Postmenopausal Women With Hormone Sensitive Early Breast Cancer|Completed|||104|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 00:48:21.908941|2018-06-01 00:48:21.908941
NCT00936429|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-02-03|2009-07-09|2009-07-10|Estimate|||||||2011-02-03|2011-02-07|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Study of HBV-001 D1 in Healthy Adults|Phase 1, Placebo-Controlled, Double-Blind, Safety Study of HBV-001 D1 in Healthy Adults|Completed||Phase 1|16|Actual|Hawaii Biotech, Inc.||3|||f||||t||||||||||2018-06-01 00:48:22.091783|2018-06-01 00:48:22.091783
NCT00936416|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-01-13|2009-07-09|2009-07-10|Estimate|||||||2012-01-13|2012-01-18|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Assessment of Renal Physiology by Magnetic Resonance Imaging (MRI) in Normal Volunteers|Assessment of Renal Physiology (Glomerular Filtration Rate and Blood Flow) by MRI With Validation by Inulin and Para-Aminohippuric Acid Clearance in Normal Volunteers|Completed||N/A|24|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 00:48:22.391965|2018-06-01 00:48:22.391965
NCT00936403|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2017-02-06|2009-07-09|2009-07-10|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 2009||2009-08-31|February 2017|2017-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone|A Randomised, Open-labelled, Single Dose, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin NordiFlex® in Growth Hormone Deficient Children|Completed||Phase 2|31|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:48:22.578585|2018-06-01 00:48:22.578585
NCT00936390|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2017-12-21|2009-07-08|2009-07-10|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2009||2009-09-30|December 2017|2017-12-31|May 2027|Anticipated|2027-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer|A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer|Active, not recruiting||Phase 3|1538|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 00:48:23.971503|2018-06-01 00:48:23.971503
NCT00936377|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2016-03-09||2016-04-07|2009-07-09|2009-07-10|Estimate|2016-04-07|2016-05-12|Estimate||||2016-04-07|2016-05-12|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|DATA||Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal|A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal|Completed||N/A|24|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-06-01 00:48:26.038105|2018-06-01 00:48:26.038105
NCT00936364|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2018-05-01|2009-07-09|2009-07-10|Estimate|||||||2018-05-01|2018-05-03|Actual|July 9, 2009|Actual|2009-07-09|May 2018|2018-05-31|July 9, 2020|Anticipated|2020-07-09|July 9, 2019|Anticipated|2019-07-09||Interventional|||Short-Term Fasting: Impact on Toxicity|Short-Term Fasting Prior To Platinum-based Chemotherapy: Feasibility and Impact on Toxicity|Recruiting||N/A|70|Anticipated|University of Southern California||4|||f||||t|f|f||||||||2018-06-01 00:48:28.159597|2018-06-01 00:48:28.159597
NCT00936351|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2015-01-16||2015-03-26|2009-07-09|2009-07-10|Estimate|2015-03-26|2015-04-10|Estimate||||2015-03-26|2015-04-10|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia|Mindfulness as a Rehabilitation Strategy in Schizophrenia|Completed||N/A|34|Actual|VA Office of Research and Development|The sample was middle-aged males with chronic schizophrenia, not representative of the broader population. Raters of work quality were not blinded to condition. Mindfulness and support conditions were not equally matched on intensity of intervention.|2|||f||||f||||||||||2018-06-01 00:48:28.324513|2018-06-01 00:48:28.324513
NCT00936338|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2009-07-09|2009-07-09|2009-07-10|Estimate|||||||2009-07-09|2009-07-10|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Randomized Clinical Trial of Treatment for Temporomandibular Joint (TMJ) Disc Displacement||Completed||N/A|44|Actual|Tokyo Medical and Dental University||2|||f||||||||||||||2018-06-01 00:48:28.862432|2018-06-01 00:48:28.862432
NCT00936325|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2018-05-23|2009-07-09|2009-07-10|Estimate|||||||2018-05-23|2018-05-24|Actual|July 8, 2009||2009-07-08|July 11, 2017|2017-07-11||||||||Observational|||Studies in the Pathogenesis of Systemic Capillary Leak Syndrome|Studies in the Pathogenesis of Systemic Capillary Leak Syndrome|Recruiting|||210|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:48:28.951789|2018-06-01 00:48:28.951789
NCT00936286|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-03-09|2009-07-09|2009-07-10|Estimate|||||||2010-03-09|2010-03-10|Estimate|January 2009||2009-01-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Respiratory Muscle Training in Obstructive Sleep Apnea Syndrome (OSAS) Patients|The Impact of Respiratory Muscle Training on the Therapy of Obstructive Sleep Apnea Syndrome (OSAS) Patients|Completed||N/A|10|Anticipated|Idiag AG||1|||f||||f||||||||||2018-06-01 00:48:29.312492|2018-06-01 00:48:29.312492
NCT00936273|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2009-07-09|2009-07-09|2009-07-10|Estimate|||||||2009-07-09|2009-07-10|Estimate|June 2009||2009-06-30|July 2009|2009-07-31||||||||Observational|DLI||Sleep Apnea and Periodic Breathing|Screening for Sleep Apnea Using Home Recording of the Double Loop Gain as a Measure of Periodic Breathing|Unknown status|Recruiting||50|Anticipated|Medical Center Alkmaar|||1||f||||f||||||||||2018-06-01 00:48:29.452849|2018-06-01 00:48:29.452849
NCT00936260|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-09|||2009-07-09|2009-07-09|2009-07-10|Estimate|||||||2009-07-09|2009-07-10|Estimate|January 1998||1998-01-31|January 1998|1998-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis|Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis|Completed||N/A|228|Actual|Ciudad Universitaria, Spain||8|||f||||f||||||||||2018-06-01 00:48:29.534704|2018-06-01 00:48:29.534704
NCT00936247|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2010-09-27|2009-07-08|2009-07-09|Estimate|||||||2010-09-27|2010-09-28|Estimate|November 2009||2009-11-30|September 2010|2010-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)|Prospective, Controlled, Single-blind, Bicentric, Randomized Study on the Safety of HES 130/0.42 Combined With a Bal. Electr. Sol. vs 5% Albumin Comb. With an Unbal. Electr. Sol. (NaCl 0.9%) in Pat. With Compensated Renal Failure|Terminated||Phase 4|2|Actual|B. Braun Melsungen AG||2||organizational reasons at sites: low recruitment|f||||f||||||||||2018-06-01 00:48:29.647767|2018-06-01 00:48:29.647767
NCT00936234|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-06-21|2009-07-08|2009-07-09|Estimate|||||||2011-06-21|2011-06-22|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|November 2012|Anticipated|2012-11-30|September 2011|Anticipated|2011-09-30||Interventional|FINNjA-DM||Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).|Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-06-01 00:48:29.71738|2018-06-01 00:48:29.71738
NCT00936221|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2015-11-04|2013-08-22|2016-02-11|2009-07-08|2009-07-09|Estimate|2015-11-04|2015-12-09|Estimate|2013-08-22|2013-08-30|Estimate|2016-02-11|2016-03-14|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2011|Actual|2011-11-30||Interventional|||Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients|A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma|Completed||Phase 2|385|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 00:48:29.83172|2018-06-01 00:48:29.83172
NCT00936208|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2012-04-19||2014-03-12|2009-07-08|2009-07-09|Estimate|2012-05-23|2012-07-02|Estimate||||2014-03-12|2014-04-10|Estimate|May 2009||2009-05-31|March 2014|2014-03-31||||November 2010|Actual|2010-11-30||Observational|||PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg|To Evaluate the Safety, Efficacy, and Protection of Micardis 80 mg/Micardis Plus 80/12.5 mg From Cardiovascular Risks in a 24 Weeks Observational Study in Patients With Essential Hypertension Who Have at Least One Other Known Cardio-vascular Risk Factor|Completed|||3184|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 00:48:30.484233|2018-06-01 00:48:30.484233
NCT00936195|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-02-14|2009-07-08|2009-07-09|Estimate|||||||2012-02-14|2012-02-15|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|UMA||Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial|Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent mother-to Child Transmission of HIV-1 o, Resource-limited Settings: A Multicentre Randomized Phase 3 Clinical Trial|Withdrawn||Phase 3|0|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2||faillure to obtain insurance because of refusal from insurance companies|f||||t||||||||||2018-06-01 00:48:31.00205|2018-06-01 00:48:31.00205
NCT00936182|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|July 2011|Anticipated|2011-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Study of Fluconazole in Children With Autism Spectrum Disorder|A Double-Blind, Placebo-Controlled Study of the Efficacy of Fluconazole as a Treatment for Autism Spectrum Disorder|Unknown status|Recruiting|N/A|50|Anticipated|The Center for Autism and Related Disorders||2|||f||||||||||||||2018-06-01 00:48:31.089702|2018-06-01 00:48:31.089702
NCT00936169|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-02-20|2009-07-08|2009-07-09|Estimate|||||||2012-02-20|2012-02-22|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|July 2011|Actual|2011-07-31|June 2009|Actual|2009-06-30||Interventional|AVIO||Angiography Versus (vs) IVUS Optimisation|Angiography vs. IVUS Optimisation: A Multi-Centre European Study of Drug Eluting Stent Implantation|Completed||N/A|284|Actual|Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS||2|||f||||f||||||||||2018-06-01 00:48:31.197798|2018-06-01 00:48:31.197798
NCT00936156|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2016-08-01|2009-07-08|2009-07-09|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years||Completed||Phase 2|67|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||||||||||||2018-06-01 00:48:31.260878|2018-06-01 00:48:31.260878
NCT00936143|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2016-01-24|2009-07-08|2009-07-09|Estimate|||||||2016-01-24|2016-01-26|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis|An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis|Completed||Phase 4|70|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-06-01 00:48:31.337846|2018-06-01 00:48:31.337846
NCT00936130|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2015-12-03|2009-07-07|2009-07-09|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|BARIA||Bariatric Surgery and Weight Loss on Energy Metabolism and Insulin Sensitivity|"Effect of Bariatric Surgery and Weight Loss on Energy Metabolism and Insulin Sensitivity BARIA"|Completed|||48|Actual|Pennington Biomedical Research Center|||2||f||||f||||||Samples Without DNA|"~     Blood draw, urine, stool, fat and muscle biopsies.~   "|||2018-06-01 00:48:31.398867|2018-06-01 00:48:31.398867
NCT00936117|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2015-05-28||2015-08-24|2009-07-07|2009-07-09|Estimate|2015-08-24|2015-09-24|Estimate||||2015-08-24|2015-09-24|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia|Phase II Study of the Pharmacokinetics of Posaconazole Prophylaxis in Relapsed or Refractory Patients With Acute Leukemia|Completed||Phase 2|25|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:48:31.476303|2018-06-01 00:48:31.476303
NCT00936104|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2012-07-01|2009-07-08|2009-07-09|Estimate|||||||2012-07-01|2012-07-03|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)|Prognostic and Therapeutic Relevance of the 'Side Population' in Pancreatic Cancer|Completed|||20|Actual|University Hospital, Gasthuisberg|||1||f||||||||||Samples With DNA|"~     Pancreatic cancer tissue specimen~   "|||2018-06-01 00:48:31.652138|2018-06-01 00:48:31.652138
NCT00936091|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2009-08-03|2009-07-08|2009-07-09|Estimate|||||||2009-08-03|2009-08-04|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effects of Vitamin A Supplementation on Intestinal Parasitic Reinfections|Effects of Vitamin A Supplementation on Intestinal Parasitic Reinfections, Growth, Iron Status and Educational Achievement Among Orang Asli Schoolchildren in Pos Betau, Pahang, Malaysia|Completed||N/A|250|Actual|Sana'a University||2|||f||||f||||||||||2018-06-01 00:48:31.702551|2018-06-01 00:48:31.702551
NCT00936078|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2018-02-22|2009-07-07|2009-07-09|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2009||2009-06-30|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|LKD||Living Kidney Donor Study|Long-term Effects of Becoming a Living Kidney Donor Study|Recruiting|||600|Anticipated|Lawson Health Research Institute|||2||f||||t||||||Samples With DNA|"~     Serum Urine~   "|||2018-06-01 00:48:31.823296|2018-06-01 00:48:31.823296
NCT00936065|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2012-03-12||2012-03-12|2009-07-07|2009-07-09|Estimate|2012-03-12|2012-04-09|Estimate||||2012-03-12|2012-04-09|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis|A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis|Completed||Phase 4|60|Actual|Pfizer|One of the protocol-defined endpoints was change from baseline in the participant's assessment of general health, however data was collected and analyzed for change from baseline in the participant's assessment of joint pain.|3|||f||||f||||||||||2018-06-01 00:48:32.078084|2018-06-01 00:48:32.078084
NCT00936052|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-07-15|2009-07-08|2009-07-09|Estimate|||||||2010-07-15|2010-07-16|Estimate|December 2008||2008-12-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|HBO||Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma|Phase II Pilot Trial of Hyperbaric Hyperoxygenation in Conjunction With Radiotherapy and Temozolomide In Adults With Newly Diagnosed Glioblastomas|Unknown status|Recruiting|Phase 2|20|Anticipated|Neurological Surgery, P.C.|||||f||||t||||||||||2018-06-01 00:48:34.224919|2018-06-01 00:48:34.224919
NCT00936039|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-07-01|2009-07-08|2009-07-09|Estimate|||||||2013-07-01|2013-07-02|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Effects of Unloading on Muscle Mass|The Effect of Immobilization on Myocellular Characteristics in Healthy, Young Males|Completed||N/A|15|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 00:48:34.307131|2018-06-01 00:48:34.307131
NCT00936026|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-02-07|2009-07-08|2009-07-09|Estimate|||||||2011-02-07|2011-02-08|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane||Completed||Phase 1|||Merz Pharmaceuticals GmbH|||||f||||||||||||||2018-06-01 00:48:34.372799|2018-06-01 00:48:34.372799
NCT00936013|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-11-01|2009-07-08|2009-07-09|Estimate|||||||2009-11-01|2009-11-02|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study|Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Pneumonia: Multi-centre, Prospective, Randomized Controlled Study|Unknown status|Recruiting|Phase 4|400|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-06-01 00:48:34.437504|2018-06-01 00:48:34.437504
NCT00936000|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2013-02-05|2009-07-08|2009-07-09|Estimate|||||||2013-02-05|2013-02-07|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Antioxidant Replacement Therapy in Patients With Alcohol Abuse|Double Blinded Placebo Controlled Trial of Protandim for Individuals With a History of Alcohol Abuse|Completed||Phase 2|38|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 00:48:34.549397|2018-06-01 00:48:34.549397
NCT00935987|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07||2013-04-25|2013-11-08|2009-07-08|2009-07-09|Estimate||||2013-04-25|2013-05-03|Estimate|2013-11-08|2013-12-04|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)|A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis.|Completed||Phase 1/Phase 2|166|Actual|Gilead Sciences||1|||f||||||||||||||2018-06-01 00:48:34.633825|2018-06-01 00:48:34.633825
NCT00935974|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-07|2009-07-07|2009-07-09|Estimate|||||||2009-07-07|2009-07-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:48:34.7369|2018-06-01 00:48:34.7369
NCT00935961|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2013-08-07|2009-07-08|2009-07-09|Estimate|||||||2013-08-07|2013-08-09|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer|A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer|Completed||Phase 1|18|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 00:48:34.781255|2018-06-01 00:48:34.781255
NCT00935948|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|April 2008||2008-04-30|July 2009|2009-07-31||||May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety Evaluation of the Imescard Compound Water Smartweed Ointment|Phase 3 Clinical Trial - Efficacy and Safety Evaluation of the Drug Imescard Compound Water Smartweed, Adrenalin and Hamamelis Ointment|Unknown status|Active, not recruiting|Phase 3|60|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:48:34.871067|2018-06-01 00:48:34.871067
NCT00935935|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-08-01|2009-07-08|2009-07-09|Estimate|||||||2012-08-01|2012-08-03|Estimate|December 2009||2009-12-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Study of Bone Disease in Older HIV-infected Adults|A Pilot Study on the Immunopathogenesis of Bone Disease in Older HIV-infected Adults|Completed|||101|Actual|Ruth M. Rothstein CORE Center|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-06-01 00:48:34.947521|2018-06-01 00:48:34.947521
NCT00935922|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2012-10-25|2009-07-08|2009-07-09|Estimate|||||||2012-10-25|2012-10-29|Estimate|February 2009||2009-02-28|July 2009|2009-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||CCRC: Understanding the Effects of Omega-3 Fatty Acids Versus Lignans in Flaxseed on Metabolic and Inflammatory Markers Leading to Diabetes and Cardiovascular Disease|CCRC: Understanding the Effects of Omega-3 Fatty Acids vs. Lignans in Flaxseed on Metabolic and Inflammatory Markers Leading to Diabetes and Cardiovascular Disease.|Completed||N/A|36|Actual|University of California, Davis||3|||f||||t||||||||||2018-06-01 00:48:35.028029|2018-06-01 00:48:35.028029
NCT00935909|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2013-06-19|2009-07-08|2009-07-09|Estimate|||||||2013-06-19|2013-06-21|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Use of Vein Viewer for Insertion of Peripheral Venous Cannula in Pediatric Patients With Difficult Intravenous Access|Use of Vein Viewer for Insertion of Peripheral Venous Cannula in Pediatric Patients With Difficult Intravenous Access.|Completed|||603|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 00:48:35.099446|2018-06-01 00:48:35.099446
NCT00935896|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate||||July 2009|2009-07-31||||||||Interventional|Normallung||High Tidal Volume Induces Inflammation In Normal Lungs|Mechanical Ventilation With High Tidal Volume Induces Inflammation In Patients Without Lung Disease|Completed||N/A|20|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-06-01 00:48:35.161572|2018-06-01 00:48:35.161572
NCT00935883|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2014-12-04||2017-04-29|2009-07-07|2009-07-09|Estimate|2015-01-20|2015-01-26|Estimate||||2017-04-29|2017-05-30|Actual|July 2009||2009-07-31|April 2017|2017-04-30|August 2013|Actual|2013-08-31|June 2012|Actual|2012-06-30||Interventional|COMPLETE||Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)|Eculizumab for the Treatment of Non-Exudative Age-Related Macular Degeneration: An Exploratory Study to Evaluate the Effects of C5 Inhibition on Drusen and Geographic Atrophy|Completed||Phase 2|60|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 00:48:35.255467|2018-06-01 00:48:35.255467
NCT00935870|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|June 2008|Actual|2008-06-30||Observational|||Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study|Bioactive Glass (S53P4) as Bone Graft Substitute in Operative Treatment of Depressed Lateral Condyle Fractures, Benign Bone Tumour Cavities and in Spinal Fusion - a 10 Years Follow-up and Bone Density Study.|Completed|||63|Actual|Vivoxid Ltd|||3||f||||f||||||||||2018-06-01 00:48:35.496159|2018-06-01 00:48:35.496159
NCT00935857|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2012-12-03||2014-09-23|2009-07-07|2009-07-09|Estimate|2014-09-23|2014-09-25|Estimate||||2014-09-23|2014-09-25|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||An interim analysis was performed at 30 patients as described in initial protocol. The study was terminated at the interim analysis.|Balloon Colonoscopy for Incomplete Colonoscopy|Balloon Colonoscopy Versus Repeat Standard Colonoscopy for Prior Incomplete Colonoscopy: A Randomized Controlled Trial|Terminated||N/A|30|Actual|Northwestern University|Early termination due to interim analysis showing statistical difference; single operator.|2||Significant difference at interim analysis|f||||f||||||||||2018-06-01 00:48:35.562226|2018-06-01 00:48:35.562226
NCT00935844|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2011-12-07|2009-07-08|2009-07-09|Estimate|||||||2011-12-07|2011-12-08|Estimate|October 2009||2009-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma|An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|20|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:48:35.789746|2018-06-01 00:48:35.789746
NCT00935831|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2017-07-25|2009-07-08|2009-07-09|Estimate|||||||2017-07-25|2017-07-27|Actual|August 12, 2009|Actual|2009-08-12|July 2017|2017-07-31|April 27, 2010|Actual|2010-04-27|April 27, 2010|Actual|2010-04-27||Interventional|||Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment|A Phase I, Single-Dose, Randomized and Single-Blind (Part 1), Fixed Sequence and Open-Label (Part 2), Studyto Evaluate the Safety, Pharmacokinetics, andPharmacodynamics of 1278863A in Subjects With RenalImpairment and Matched Healthy Volunteers|Completed||Phase 1|12|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 00:48:35.852535|2018-06-01 00:48:35.852535
NCT00935818|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2014-03-21||2014-04-25|2009-07-07|2009-07-09|Estimate|2014-03-21|2014-04-24|Estimate||||2014-04-25|2014-05-09|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CHANBAN|Smokers from the local community who smoked 10 cigarettes or more per day for the 6 months prior to study entry.|Varenicline and Bupropion for Smoking Cessation|Combination Therapy With Varenicline and Bupropion for Smoking Cessation|Completed||Phase 2/Phase 3|506|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:48:35.939863|2018-06-01 00:48:35.939863
NCT00935805|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-10-25|2009-07-08|2009-07-09|Estimate|||||||2011-10-25|2011-10-26|Estimate|July 2006||2006-07-31|July 2011|2011-07-31|July 2012|Anticipated|2012-07-31|January 2012|Anticipated|2012-01-31||Observational|||Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy|ANALYSIS OF THE EFFECTIVENESS OF A STAGED MANAGEMENT PROGRAM AIMED AT CONTROLLING BLOOD PRESSURE AND BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENTS USING EXCLUSIVELY THE RESOURCES AVAILABLE IN A PRIMARY CARE SETTING IN BRAZIL|Unknown status|Active, not recruiting||124|Anticipated|Hospital de Clinicas de Porto Alegre|||1||f||||f||||||||||2018-06-01 00:48:36.374676|2018-06-01 00:48:36.374676
NCT00935792|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2016-04-29||2017-08-28|2009-07-07|2009-07-09|Estimate|2016-10-19|2016-12-12|Estimate||||2017-08-28|2017-09-26|Actual|July 2009||2009-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study|Completed||Phase 1/Phase 2|28|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 00:48:36.469492|2018-06-01 00:48:36.469492
NCT00935779|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|October 2002||2002-10-31|July 2009|2009-07-31|December 2004|Actual|2004-12-31|July 2004|Actual|2004-07-31||Observational|||Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer|Ultra Structure of Peritoneum at Electronic Microscopy in Control Subjects and Patients With Gastric Cancer|Completed|||18|Actual|University of Chile|||2||f||||f||||||||||2018-06-01 00:48:36.863502|2018-06-01 00:48:36.863502
NCT00935766|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2014-02-11||2014-09-23|2009-07-08|2009-07-09|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries|Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation|Terminated||Phase 3|76|Actual|Denver Health and Hospital Authority|The study was discontinued early due to lack of funding and slow enrollment|2||The study was discontinued early due to lack of funding and slow enrollment|f||||f||||||||||2018-06-01 00:48:36.918383|2018-06-01 00:48:36.918383
NCT00935753|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2010-03-15|2009-07-08|2009-07-09|Estimate|||||||2010-03-15|2010-03-16|Estimate||||March 2010|2010-03-31||||||||Interventional|||Trial of Kuvan in Lesch-Nyhan Disease|Trial of Kuvan™ (Sapropterin) Treatment in Patients With Lesch Nyhan Disease|Withdrawn||Phase 2/Phase 3|8|Anticipated|University of California, San Diego||1||Contractual issues|f||||f||||||||||2018-06-01 00:48:37.130512|2018-06-01 00:48:37.130512
NCT00935740|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-07-07|2009-07-07|2009-07-09|Estimate|||||||2009-07-07|2009-07-09|Estimate|December 1996||1996-12-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|TFHF||Tissue Factor Expression in Stage C Heart Failure|Tissue Factor Expression in Stage C Heart Failure|Completed|||75|Actual|University of Utah|||2||f||||f||||||Samples Without DNA|"~     50 ml of Serum~   "|||2018-06-01 00:48:37.195958|2018-06-01 00:48:37.195958
NCT00935727|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-07-07|2009-07-07|2009-07-09|Estimate|||||||2009-07-07|2009-07-09|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Elastorenal||Elastographic Imaging of Renal Transplants|Pilot Study to Define Parameters of Elastography Compared to Color Flow Doppler Ultrasound in Renal Transplants|Terminated||Phase 1|10|Actual|The University of Texas Health Science Center, Houston||3||images obtained were non-diagnostic|f||||f||||||||||2018-06-01 00:48:38.216999|2018-06-01 00:48:38.216999
NCT00935714|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-08-18|2009-07-08|2009-07-09|Estimate|||||||2009-08-18|2009-08-19|Estimate|August 2009||2009-08-31|August 2009|2009-08-31||||January 2010|Anticipated|2010-01-31||Interventional|||Exercise and Breast Cancer Related Lymphedema: Influence of Muscle Group and Sequence on Volume Change in Swollen and Normal Arms||Unknown status|Recruiting|N/A|18|Anticipated|Hillel Yaffe Medical Center||2|||f||||||||||||||2018-06-01 00:48:38.29186|2018-06-01 00:48:38.29186
NCT00935701|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2014-03-10||2017-03-22|2009-07-08|2009-07-09|Estimate|2014-09-25|2014-09-26|Estimate||||2017-03-22|2017-04-18|Actual|July 2009||2009-07-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Acupressure and Acupuncture as an Intervention With Children With Autism II|Investigating the Use of Acupressure and Acupuncture With Children With Autism II|Completed||N/A|10|Actual|Johns Hopkins University|There were no limitations to this study.|1|||f||||f||||||||||2018-06-01 00:48:38.380042|2018-06-01 00:48:38.380042
NCT00935688|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2014-02-06|2009-07-08|2009-07-09|Estimate|||||||2014-02-06|2014-02-07|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area|An Examination of ACT Strategy in South-central Asia on Falciparum Malaria in a Context Where Vivax is the Major Species|Completed||Phase 4|4200|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-06-01 00:48:38.62284|2018-06-01 00:48:38.62284
NCT00935675|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-09-01|2009-07-08|2009-07-09|Estimate|||||||2009-09-01|2009-09-02|Estimate||||July 2009|2009-07-31||||||||Interventional|||Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment||Unknown status|Recruiting|Phase 3|100|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||||||||||||2018-06-01 00:48:38.691697|2018-06-01 00:48:38.691697
NCT00935662|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-09-10|2009-07-08|2009-07-09|Estimate|||||||2010-09-10|2010-09-13|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses|A Randomised, Single-blind, Placebo-controlled, Two-centre Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD8329 After Single Ascending Oral Doses|Completed||Phase 1|119|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:48:38.854795|2018-06-01 00:48:38.854795
NCT00935649|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2013-04-08||2013-04-08|2009-07-07|2009-07-09|Estimate|2013-04-08|2013-04-09|Estimate||||2013-04-08|2013-04-09|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||PinPointe FootLaser for the Treatment of Onychomycosis|Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis)|Completed||Phase 2/Phase 3|134|Actual|PathoLase, Inc.||2|||f||||t||||||||||2018-06-01 00:48:38.940407|2018-06-01 00:48:38.940407
NCT00935636|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2013-06-19|2009-07-07|2009-07-09|Estimate|||||||2013-06-19|2013-06-21|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||An Evaluation of Efficacy of the GlideScope Cobalt Video Baton for Intubation on Children Weighing Less Than 10 Kilograms|An Evaluation of Efficacy of the GlideScope Cobalt Video Baton for Intubation on Children Weighing Less Than 10 Kilograms|Completed|||200|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 00:48:39.100237|2018-06-01 00:48:39.100237
NCT00935623|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2012-06-19|2009-07-08|2009-07-09|Estimate|||||||2012-06-19|2012-06-20|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|Pvivax||Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans|Development of a Safe and Reproducible Human Sporozoite Challenge Model for Plasmodium Vivax in Healthy Adults in the United States|Completed||Phase 1|12|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-06-01 00:48:39.169421|2018-06-01 00:48:39.169421
NCT00935610|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-01-16|2009-07-08|2009-07-09|Estimate|||||||2015-01-16|2015-01-21|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Immunocal® With Exercise Versus Casein With Exercise on Aging Processes in Elderly Persons|Effect of the Cysteine-rich Whey Protein Isolate (Immunocal®) in Combination With Physical Exercise on Muscle Function, Body Composition and Inflammatory Cytokine Levels in Elderly Persons: A Randomized, Double-blind Study|Completed||Phase 2|99|Actual|Immunotec Inc.||2|||f||||f||||||||||2018-06-01 00:48:39.252277|2018-06-01 00:48:39.252277
NCT00935597|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-10-28|2009-07-08|2009-07-09|Estimate|||||||2010-10-28|2010-10-29|Estimate|August 2009||2009-08-31|October 2010|2010-10-31||||July 2013|Anticipated|2013-07-31||Interventional|||Host Dendritic Cells in Allograft Patients|A Phase I Trial of Host Dendritic Cell Infusion After Allogeneic Stem Cell Transplant for Prevention or for Treatment of Relapsed Disease in Patients With Advanced Hematologic Malignancies|Unknown status|Recruiting|Phase 1|25|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 00:48:39.341554|2018-06-01 00:48:39.341554
NCT00935584|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2014-01-31||2015-10-07|2009-07-08|2009-07-09|Estimate|2015-10-07|2015-11-06|Estimate||||2015-10-07|2015-11-06|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|PACECPRS|Our primary analysis is based on 126 patients/clinic visits (Of the 128 visits, 2 visits had no data). The total number of enrollments were 151 (128 patients + 23 providers).|Patient Centered Evaluation of Computerized Patient Records System|Patient Centered Evaluation of Computerized Patient Records System|Completed||N/A|151|Actual|VA Office of Research and Development|Study limitations include inability to capture EHR activity outside the visit, study only primary care providers at a single organization (VA) and only one EHR system, this limits generalizability of the findings to other setting.|1|||f||||f||||||||||2018-06-01 00:48:39.441871|2018-06-01 00:48:39.441871
NCT00935571|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Observational|||Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia|Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia|Unknown status|Active, not recruiting||400|Anticipated|Asan Medical Center|||1||f||||f||||||||||2018-06-01 00:48:39.713071|2018-06-01 00:48:39.713071
NCT00935558|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2012-05-30|2009-07-08|2009-07-09|Estimate|||||||2012-05-30|2012-05-31|Estimate|July 2009||2009-07-31|May 2012|2012-05-31||||May 2012|Actual|2012-05-31||Interventional|||Dendritic Cell Based Therapy for Breast Cancer Patients|Evaluation of p53peptide-pulsed Dendritic Cells in Combination With an Aromatase Inhibitor as a Treatment for Patients With Breast Cancer With Disease Recurrence After Adjuvant or First Line Endocrine Therapy.|Withdrawn||Phase 2|0|Actual|Herlev Hospital||2||no patients enrolled|f||||t||||||||||2018-06-01 00:48:39.786097|2018-06-01 00:48:39.786097
NCT00935545|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2016-01-25|2009-07-08|2009-07-09|Estimate|||||||2016-01-25|2016-01-26|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors|A Phase I Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide ISA-51VG in Pediatric Patients With Recurrent or Refractory Central Nervous System Tumors|Completed||Phase 1|15|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 00:48:39.863503|2018-06-01 00:48:39.863503
NCT00935532|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|2012-02-14|2011-06-17|2015-05-21|2009-07-08|2009-07-09|Estimate|2012-09-24|2012-10-24|Estimate|2011-06-17|2011-06-27|Estimate|2015-05-21|2015-06-15|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|September 2010|Actual|2010-09-30||Interventional|||Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus|Parallel Group Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus Treated With Oral Antidiabetic(s)|Completed||Phase 3|427|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:48:40.053866|2018-06-01 00:48:40.053866
NCT00935519|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2016-10-16|2009-07-08|2009-07-09|Estimate|||||||2016-10-16|2016-10-18|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|December 2030|Anticipated|2030-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cementless New Alumina-zirconia Ceramic Bearing Total Hip Arthroplasty (THA) in Asian Patients|Cementless New Alumina-zirconia(4th Generation Ceramic Bearing) Composite Ceramic Bearing Total Hip Arthroplasty (THA) in Asian Patients : a 5 Year Minimum Follow-up Study|Active, not recruiting||N/A|310|Anticipated|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-06-01 00:48:40.668161|2018-06-01 00:48:40.668161
NCT00935506|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-02-22|2009-07-08|2009-07-09|Estimate|||||||2011-02-22|2011-02-23|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Ex Vivo Human Thrombosis Chamber Study|Evaluation of an Experimental EX Vivo Thrombosis Chamber Model in Healthy Male Subjects|Completed||Phase 1|15|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:48:40.770258|2018-06-01 00:48:40.770258
NCT00935493|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2014-06-18||2014-08-10|2009-07-07|2009-07-09|Estimate|2014-07-23|2014-08-11|Estimate||||2014-08-10|2014-08-13|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||The baseline population consists of the 123 participants (out of 154) that met eligibility requirements and consented to participate in the study.|Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects|Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects|Completed||N/A|154|Actual|Yale University||3|||f||||t||||||||||2018-06-01 00:48:40.902342|2018-06-01 00:48:40.902342
NCT00935480|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2017-05-11|2009-07-08|2009-07-09|Estimate|||||||2017-05-11|2017-05-12|Actual|October 2010|Actual|2010-10-31|May 2017|2017-05-31|August 8, 2014|Actual|2014-08-08|November 12, 2010|Actual|2010-11-12||Interventional|IntensVIH||IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients|IMPACT OF THERAPY INTENSIFICATION BY AN INTEGRASE INHIBITOR +/- CCR5 INHIBITOR ON THE LYMPHOID RESERVOIR FOR HIV-1 IN CHRONICALLY INFECTED PATIENTS|Completed||Phase 3|17|Actual|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer||2|||f||||f||||||||||2018-06-01 00:48:41.419851|2018-06-01 00:48:41.419851
NCT00935467|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2015-05-04|2009-07-08|2009-07-09|Estimate|||||||2015-05-04|2015-05-05|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects|A Study to Characterize the Steady-State Pharmacokinetics and Pharmacodynamics of 2.5 mg Saxagliptin Administered Twice Daily With Meals to Healthy Subjects|Completed||Phase 1|12|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:48:41.486461|2018-06-01 00:48:41.486461
NCT00935454|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-04-11|2009-07-08|2009-07-09|Estimate|||||||2011-04-11|2011-04-12|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|March 2012|Anticipated|2012-03-31|September 2011|Anticipated|2011-09-30||Interventional|HMI||Hepatocyte Matrix Implant Study|Intracorporeal Autologous Hepatocyte Matrix Implant: A New Tissue Engineering Procedure for Treatment of Hepatic Disease.|Unknown status|Recruiting|Phase 1|10|Anticipated|Baermed|||||f||||t||||||||||2018-06-01 00:48:41.548113|2018-06-01 00:48:41.548113
NCT00935441|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-09-14|2009-07-08|2009-07-09|Estimate|||||||2011-09-14|2011-09-16|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Case-Management Using Home Monitoring on Diabetes and Blood Pressure Outcomes|Effect of Nurse-Based, Protocol-Driven, Case-Management Utilizing Home Telemonitoring and Home HbA1c Measurement on Diabetes and Blood Pressure Outcomes|Completed||N/A|460|Anticipated|Minneapolis Veterans Affairs Medical Center||2|||f||||||||||||||2018-06-01 00:48:41.606004|2018-06-01 00:48:41.606004
NCT00935428|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2011-06-07|2009-07-07|2009-07-09|Estimate|||||||2011-06-07|2011-06-09|Estimate|June 2009||2009-06-30|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Causes and Circumstances of Horse Related Injuries and Impact on Quality of Life|Causes and Circumstances of Horse Related Injuries and Impact on Quality of Life|Completed|||250|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-06-01 00:48:41.661185|2018-06-01 00:48:41.661185
NCT00935389|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2011-08-01|2009-07-08|2009-07-09|Estimate|||||||2011-08-01|2011-08-02|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria|Prospective Control Study of TW in the Treatment of LN Type V With Gross Proteinuria|Completed||N/A|44|Actual|Nanjing University School of Medicine||1|||f||||f||||||||||2018-06-01 00:48:41.951859|2018-06-01 00:48:41.951859
NCT00935376|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2017-04-14|2009-07-07|2009-07-09|Estimate|||||||2017-04-14|2017-04-18|Actual|May 2009||2009-05-31|April 2017|2017-04-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Sleep Management in Cancer Survivors|A Pilot Study of Three Short-term Intervention Programs for Sleep Management in Cancer Survivors|Completed||N/A|57|Actual|University of Utah||3|||f||||t||||||||No||2018-06-01 00:48:42.020265|2018-06-01 00:48:42.020265
NCT00935363|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-01-12|2009-07-08|2009-07-09|Estimate|||||||2015-01-12|2015-01-14|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK)||Withdrawn||Phase 1|0|Actual|University of California, San Francisco||4|||f||||f||||||||||2018-06-01 00:48:42.096101|2018-06-01 00:48:42.096101
NCT00935350|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|||Reduction of the Glycemic Index by a Novel Viscous Polysaccharide|Effect of Adding the Novel Fiber, PGX®,to Commonly Consumed Foods on Glycemic Response and Glycemic Index: A Practical and Effective Strategy for Reducing Post Prandial Blood Glucose Levels.|Completed||Phase 2/Phase 3|10|Actual|Glycemic Index Laboratories, Inc||15|||f||||f||||||||||2018-06-01 00:48:42.162473|2018-06-01 00:48:42.162473
NCT00935337|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-11-23|2009-07-08|2009-07-09|Estimate|||||||2011-11-23|2011-11-24|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Follow-up of a Study Examining Sleep Management in United States Veterans|A Pilot Study of Two Contrasting Intervention Programs for Sleep Management - Part II|Completed||Phase 1/Phase 2|34|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 00:48:42.241953|2018-06-01 00:48:42.241953
NCT00935324|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|February 2009||2009-02-28|July 2009|2009-07-31|May 2011|Anticipated|2011-05-31|March 2011|Anticipated|2011-03-31||Observational|||The Role of CK18F in Predicting Graft-Versus-Host Disease (GvHD)|CK18-Fragments as Tools for Evaluating Diagnosis, Biological Activity, and Prognosis of Graft-Versus-Host Disease|Unknown status|Recruiting||120|Anticipated|Heidelberg University|||2||f||||t||||||Samples With DNA|"~     Group A (patients scheduled for allo-SCT): 5ml serum (~25 times), 7,5ml EDTA (~25 times)~     Group B (healthy volunteers): 30ml blood once~   "|||2018-06-01 00:48:42.30684|2018-06-01 00:48:42.30684
NCT00935311|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2013-11-01|2011-11-22|2014-03-10|2009-07-08|2009-07-09|Estimate|2014-01-22|2014-03-07|Estimate|2011-11-22|2011-11-24|Estimate|2014-03-10|2014-04-08|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction|A Randomized, Multicenter, Single-blind, Placebo-controlled Study Comparing the Analgesic Efficacy and Safety of Hydrocodone/ Acetaminophen Extended-release Tablets and Hydrocodone/Acetaminophen (NORCO) to Placebo in Subjects With Acute Pain Following Third Molar Tooth Extraction|Completed||Phase 2|122|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 00:48:42.391409|2018-06-01 00:48:42.391409
NCT00935298|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2011-12-21|2009-07-08|2009-07-09|Estimate|||||||2011-12-21|2011-12-22|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|PSIDRTG||Initial Dosage Range of Tacrolimus by Genotyping in Chinese Renal Transplantation|Prospective Study:Clinical Trial on the Tacrolimus Dosage Range in Chinese Renal Transplant Recipients With Different Genetic Phenotypes of Drug Metabolizing Enzymes(CYP3A5)|Completed||Phase 4|145|Actual|The Second Artillery General Hospital||1|||f||||t||||||||||2018-06-01 00:48:42.715919|2018-06-01 00:48:42.715919
NCT00935285|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-08|||2009-07-08|2009-07-08|2009-07-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU)|Immune Response in Patients Who Develop Ventilator-Associated Pneumonia (VAP) in Intensive Care Unit (ICU) and the Role of Toll-Like Receptors(TLR2,TLR4,TLR9).|Unknown status|Active, not recruiting||300|Anticipated|University of Thessaly|||||f||||f||||||||||2018-06-01 00:48:42.803869|2018-06-01 00:48:42.803869
NCT00935272|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2011-11-02||2011-12-22|2009-07-07|2009-07-09|Estimate|2011-12-22|2012-01-30|Estimate||||2011-12-22|2012-01-30|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Safety/Efficacy Study of Restylane® in Lip Augmentation|A Randomized, Evaluator-Blinded, No-Treatment-Controlled Study of the Effectiveness and Safety of Restylane® in the Augmentation of Soft Tissue Fullness of the Lips|Completed||N/A|180|Actual|Medicis Global Service Corporation||2|||f||||f||||||||||2018-06-01 00:48:42.877843|2018-06-01 00:48:42.877843
NCT00935259|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2010-12-17||2015-10-07|2009-07-07|2009-07-08|Estimate|2012-01-17|2012-02-20|Estimate||||2015-10-07|2015-10-08|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)|A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:48:43.205711|2018-06-01 00:48:43.205711
NCT00935246|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-12-30|2009-07-07|2009-07-08|Estimate|||||||2015-12-30|2015-12-31|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2011|Actual|2011-10-31||Interventional|||Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning|Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning|Unknown status|Active, not recruiting|N/A|202|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:48:43.515069|2018-06-01 00:48:43.515069
NCT00935233|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2013-08-09|2009-07-07|2009-07-08|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2008||2008-07-31|July 2009|2009-07-31||||July 2010|Anticipated|2010-07-31||Observational|||Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy Volunteers|ICICLE- A Study to Investigate the genetiCs of In Situ Carcinoma of the ductaL subtypE|Unknown status|Recruiting||6000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:48:43.590879|2018-06-01 00:48:43.590879
NCT00934687|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-08-13|2009-07-07|2009-07-08|Estimate|||||||2013-08-13|2013-08-14|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Botulinum Toxin for the Treatment of Depression|Clostridium Botulinum Type A Neurotoxin Complex for Adjuvant Treatment of Depressive Disorders - a Randomized Controlled Pilot Study|Completed||Phase 2|30|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 00:48:51.142673|2018-06-01 00:48:51.142673
NCT00935220|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2011-08-22||2014-06-17|2009-07-07|2009-07-08|Estimate|2011-10-05|2011-11-10|Estimate||||2014-06-17|2014-06-27|Estimate|June 2009||2009-06-30|February 2014|2014-02-28||||August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients|An Open Label, Phase I Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Linagliptin (BI 1356) 5 mg After Single and Multiple Oral Administration in Patients With Type 2 Diabetes Mellitus of African American Origin for 7 Days|Completed||Phase 1|41|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:48:43.700591|2018-06-01 00:48:43.700591
NCT00935207|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2013-05-02|2009-07-07|2009-07-08|Estimate|||||||2013-05-02|2013-05-03|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Study of the Impact of a Pain Diary in Pediatric Patients|The Impact of a Pain Diary on the Communication of Pain in Pediatric Patients|Terminated|||8|Actual|University of Mississippi Medical Center|||1|Poor enrollment and data collection|f||||f||||||||||2018-06-01 00:48:44.020854|2018-06-01 00:48:44.020854
NCT00935194|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-11-30|2009-07-07|2009-07-08|Estimate|||||||2009-11-30|2009-12-01|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study|Antiviral and Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) Virus Infection: Multi-centre, Prospective, Randomized Controlled Study|Completed||Phase 4|102|Actual|Capital Medical University||4|||f||||t||||||||||2018-06-01 00:48:44.086087|2018-06-01 00:48:44.086087
NCT00935181|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2006|Actual|2006-12-31||Interventional|||Respiratory Muscle Stretching in Chronic Obstructive Pulmonary Disease (COPD)|Respiratory Muscle Stretching in Patients With Chronic Obstructive Pulmonary Disease Submitted a Pulmonary Rehabilitation Program|Completed||Phase 4|26|Actual|Faculdade Evangelica do Parana||1|||f||||f||||||||||2018-06-01 00:48:44.175437|2018-06-01 00:48:44.175437
NCT00935168|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2012-11-14|2009-07-07|2009-07-08|Estimate|||||||2012-11-14|2012-11-16|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|CHEST||Crystalloid Versus Hydroxyethyl Starch Trials|A Multi-centre Randomized Controlled Trial of Fluid Resuscitation With Starch (6%Hydroxyethyl Starch 130/0.4) Compared to Saline (0.9% Sodium Chloride) in Intensive Care Patients on Mortality|Completed||Phase 3|7000|Actual|The George Institute||2|||f||||t||||||||||2018-06-01 00:48:44.253845|2018-06-01 00:48:44.253845
NCT00935155|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2012-02-07|2009-07-07|2009-07-08|Estimate|||||||2012-02-07|2012-02-08|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|March 2012|Anticipated|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Effectiveness of Acupuncture as an Adjunct to Rehabilitation After Knee Arthroplasty|Effectiveness of Acupuncture as an Adjunct to Rehabilitation After Knee Arthroplasty. A Randomized Controlled Trial.|Unknown status|Recruiting|N/A|170|Anticipated|Back and Rehabilitation Center, Copenhagen||2|||f||||f||||||||||2018-06-01 00:48:44.354622|2018-06-01 00:48:44.354622
NCT00935142|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2013-01-24|2009-07-07|2009-07-08|Estimate|||||||2013-01-24|2013-01-25|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|[18F]VM4-037||Non-invasive Imaging With [18F]VM4-037|Non Invasive Imaging of [18F]VM4-037 With Positron-Emission-Tomography (PET): A Phase I Trial|Withdrawn||Phase 1|0|Actual|Maastricht Radiation Oncology|||||f||||t||||||||||2018-06-01 00:48:44.436385|2018-06-01 00:48:44.436385
NCT00935129|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-05-06|2009-07-06|2009-07-08|Estimate|||||||2012-05-06|2012-05-08|Estimate|August 2009||2009-08-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Treatment Satisfaction of Using OmniPod System Compared With Conventional Insulin Pump in Adults With Type 1 Diabetes|Treatment Satisfaction of Using OmniPod System Compared With Conventional Insulin Pump in Adults With Type 1 Diabetes|Completed||N/A|30|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 00:48:44.499044|2018-06-01 00:48:44.499044
NCT00935116|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Etoricoxib for Postoperative Pain After Thyroid Surgery|Effect of the Administration of Etoricoxib on Postoperative Pain and Quality of Recovery in Patients Undergoing Thyroid Surgery|Unknown status|Not yet recruiting|Phase 4|70|Anticipated|Hospital Padre Hurtado||1|||f||||f||||||||||2018-06-01 00:48:44.571463|2018-06-01 00:48:44.571463
NCT00935103|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-08-24|2009-07-07|2009-07-08|Estimate|||||||2015-08-24|2015-08-26|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Effectiveness of Skill-Based HIV Psychoeducation in IV-Drug Abuser for Reducing High-risk Behavior|The Effectiveness of Skill-Based HIV Psychoeducation in IV-Drug Abuser for Reducing High-risk Behavior|Completed||Phase 1/Phase 2|120|Actual|Iran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:48:44.625413|2018-06-01 00:48:44.625413
NCT00935090|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2017-12-05|2009-07-07|2009-07-08|Estimate|||||||2017-12-05|2017-12-07|Actual|September 2009||2009-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer|Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)|Recruiting||N/A|80|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 00:48:44.687647|2018-06-01 00:48:44.687647
NCT00935077|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2014-07-09|2009-07-07|2009-07-08|Estimate|||||||2014-07-09|2014-07-10|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities|A Collaborative Model to Improve BP Control and Minimize Racial Disparities-CCC|Completed||Phase 3|1441|Actual|University of Iowa||4|||f||||t||||||||||2018-06-01 00:48:44.819205|2018-06-01 00:48:44.819205
NCT00935064|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2012-12-31||2016-07-07|2009-07-07|2009-07-08|Estimate|2013-02-13|2013-04-01|Estimate||||2016-07-07|2016-08-09|Estimate|June 2009||2009-06-30|July 2016|2016-07-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||The Effect of Renin Inhibition on Nerve Function in Diabetes|Effect of Renin Inhibition on Cardiovascular Autonomic Nerve Function in Diabetes|Completed||N/A|60|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-06-01 00:48:44.943245|2018-06-01 00:48:44.943245
NCT00935051|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2013-12-17|2009-07-07|2009-07-08|Estimate|||||||2013-12-17|2013-12-18|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|DIAB-MMP2||Matrix Metalloproteinase-1/Tissue Inhibitor of Metalloproteinase-1 (MMP-1/TIMP-1) Ratio and Diabetic Foot Ulcers|Assessment of the MMP-1/TIMP-1 Ratio as a Predictor of Wound Healing in Diabetic Foot Ulcers|Completed||Early Phase 1|59|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-06-01 00:48:45.234644|2018-06-01 00:48:45.234644
NCT00935025|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-12-06|2009-07-06|2009-07-08|Estimate|||||||2010-12-06|2010-12-07|Estimate|July 2009||2009-07-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|JMAD||AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects|A Single-center, Single-blind, Randomized, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Oral Doses of AZD1305 Extended-release Capsules in Healthy Male Japanese and Caucasian Subjects|Terminated||Phase 1|45|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:48:45.309974|2018-06-01 00:48:45.309974
NCT00935012|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2017-11-30|2009-07-07|2009-07-08|Estimate|||||||2017-11-30|2017-12-04|Actual|September 2009|Actual|2009-09-30|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy|Open-label Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-type Transthyretin (Ttr) Amyloid Cardiomyopathy|Active, not recruiting||Phase 3|32|Actual|Pfizer||1|||f||||t|t|f||||||||2018-06-01 00:48:45.374992|2018-06-01 00:48:45.374992
NCT00934999|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2016-03-18|2009-07-07|2009-07-08|Estimate|||||||2016-03-18|2016-03-22|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of Burch Urethropexy and Mid-urethral Sling Performed Concomitantly With a Sacral Colpopexy|A Randomized Comparison of Concomitant Incontinence Procedures Performed With Abdominal Sacral Colpopexy: the Burch Versus Mid-urethral Sling Trial|Completed||Phase 4|113|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:48:45.440921|2018-06-01 00:48:45.440921
NCT00934986|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2011-09-13|2009-07-06|2009-07-08|Estimate|||||||2011-09-13|2011-09-14|Estimate|March 2008||2008-03-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|LLC-NK||Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia|Study of Natural Killer Cells Function in Untreated Patients With Chronic Lymphocytic Leukemia|Completed||N/A|70|Anticipated|Institut Paoli-Calmettes|||||f||||f||||||||||2018-06-01 00:48:45.52721|2018-06-01 00:48:45.52721
NCT00934973|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-01-16|2009-07-07|2009-07-08|Estimate|||||||2013-01-16|2013-01-17|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|MIBS||Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)|Management of Irritable Bowel Syndrome in Primary Care: Feasibility Randomised Controlled Trial of Mebeverine, Methylcellulose, Placebo and a Patient Self-management Cognitive Behavioural Therapy Website. (MIBS Trial)|Completed||Phase 4|135|Actual|University of Southampton||9|||f||||f||||||||||2018-06-01 00:48:45.603828|2018-06-01 00:48:45.603828
NCT00934960|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-11-17|2009-07-07|2009-07-08|Estimate|||||||2009-11-17|2009-11-18|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Multifocals and Accommodating/Bilateral Implantation of Different Multifocal Intraocular Lens (IOLs)|Distance, Intermediate and Near Visual Outcomes, Range of Vision and Patient Satisfaction After Bilateral Implantation of Different Multifocal IOLs|Terminated|||9|Actual|Medical University of South Carolina||||PI separated employment from the university.|f||||f||||||||||2018-06-01 00:48:45.693683|2018-06-01 00:48:45.693683
NCT00934947|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2012-05-07||2017-10-16|2009-07-07|2009-07-08|Estimate|2012-09-25|2012-10-29|Estimate||||2017-10-16|2017-11-17|Actual|July 2009||2009-07-31|September 2017|2017-09-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|BURN HELP||Burn Healing and Analgesia With Propranolol|The BURN HELP Trial: BURN Healing and AnaLgesia With Propranolol|Completed||Phase 2|45|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:48:45.764864|2018-06-01 00:48:45.764864
NCT00934934|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2018-01-24|2009-07-07|2009-07-08|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2010||2010-04-30|January 2018|2018-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|CANTREAT||Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment|Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study|Terminated||Phase 2|60|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||2||slow enrollment|f||||f||||||||||2018-06-01 00:48:46.054224|2018-06-01 00:48:46.054224
NCT00934921|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2009-07-08||2009-07-08|2009-07-07|2009-07-08|Estimate|2009-07-08|2009-08-25|Estimate||||2009-07-08|2009-08-25|Estimate|February 2003||2003-02-28|July 2009|2009-07-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 8 mg Orally Disintegrating Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:48:46.292846|2018-06-01 00:48:46.292846
NCT00934908|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine|Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine|Unknown status|Recruiting|N/A|48|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 00:48:46.521937|2018-06-01 00:48:46.521937
NCT00934895|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2017-02-18|2009-07-07|2009-07-08|Estimate|||||||2017-02-18|2017-02-23|Actual|July 15, 2009|Actual|2009-07-15|February 2017|2017-02-28|August 12, 2015|Actual|2015-08-12|January 7, 2014|Actual|2014-01-07||Interventional|||Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca|Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)|Terminated||Phase 1/Phase 2|27|Actual|Rutgers, The State University of New Jersey||1||Closed early due to slow accrual|f||||f||||||||||2018-06-01 00:48:46.587911|2018-06-01 00:48:46.587911
NCT00934882|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2014-05-30|2009-07-07|2009-07-08|Estimate|||||||2014-05-30|2014-06-02|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI|Phase I, Open-label, Non-placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI as First or Second Line Therapy in Patients With Metastatic Colorectal.|Completed||Phase 1|45|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:48:46.748716|2018-06-01 00:48:46.748716
NCT00934869|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-03-21|2009-07-07|2009-07-08|Estimate|||||||2013-03-21|2013-03-22|Estimate|August 2009||2009-08-31|March 2013|2013-03-31||||March 2015|Anticipated|2015-03-31||Observational|||Swelling or Malrotation of Metacarpal Shaft Fractures in the Evaluation of Rotational Deformity|Swelling or Malrotation of Metacarpal Shaft Fractures in the Evaluation of Rotational Deformity|Unknown status|Recruiting||||Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 00:48:46.850501|2018-06-01 00:48:46.850501
NCT00934856|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2017-02-20||2017-02-20|2009-07-07|2009-07-08|Estimate|2017-02-20|2017-04-06|Actual||||2017-02-20|2017-04-06|Actual|July 2009|Actual|2009-07-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All participants who received at least one dose of study medication were included.|A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer|An Open-Label, Multi-Center Phase I/II Study of the Safety and Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) With Docetaxel, and Potentially Pertuzumab, for Treatment for Patients With Advanced Breast Cancer|Completed||Phase 1/Phase 2|98|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 00:48:46.999106|2018-06-01 00:48:46.999106
NCT00934843|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2011-09-29||2011-11-07|2009-07-07|2009-07-08|Estimate|2011-11-07|2011-12-09|Estimate||||2011-11-07|2011-12-09|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass|Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass|Completed||N/A|77|Actual|Medical University of South Carolina|Limitations of the current study include the lack of a true placebo group. Thus recommendations for or against intraoperative MP can not be made. The results of our trial do not preclude the efficacy of other glucocorticoid regimens.|2|||f||||f||||||||||2018-06-01 00:48:49.010428|2018-06-01 00:48:49.010428
NCT00934830|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-10-28|2009-07-07|2009-07-08|Estimate|||||||2013-10-28|2013-10-29|Estimate|January 2005||2005-01-31|October 2013|2013-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Antibiotics Versus Therapeutic Ultrasound for Sinusitis|Antibiotics Versus Therapeutic Ultrasound for Treatment of Sinusitis: a Randomized Clinical Trial|Completed||Phase 3|48|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 00:48:49.304708|2018-06-01 00:48:49.304708
NCT00934817|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg|An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M 1mg/500mg and 2mg/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Subjects|Completed||Phase 1|36|Actual|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:48:49.382352|2018-06-01 00:48:49.382352
NCT00934804|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2016-05-03|2009-07-07|2009-07-08|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|Galilei||Accuracy of the Galilei Analyzer to Calculate the Effective Corneal Power After Corneal Refractive Surgery|Accuracy of the Galilei Analyzer to Calculate the Effective Corneal Power After Corneal Refractive Surgery|Terminated||N/A|7|Actual|Medical University of South Carolina||1||Principal Investigator separating employment from University.|f||||f||||||||||2018-06-01 00:48:49.442931|2018-06-01 00:48:49.442931
NCT00934791|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2013-02-04||2013-02-04|2009-07-07|2009-07-08|Estimate|2013-02-04|2013-03-08|Estimate||||2013-02-04|2013-03-08|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Polycystic Liver Disease in Kidney Transplant|Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease|Terminated||N/A|2|Actual|Mayo Clinic|This study was terminated due to inadequate enrollment, no data was collected on the participant.|2||Terminated due to inadequate enrollment|f||||f||||||||||2018-06-01 00:48:49.507808|2018-06-01 00:48:49.507808
NCT00934778|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2016-11-24|2009-07-07|2009-07-08|Estimate|||||||2016-11-24|2016-11-28|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Minimally Invasive Endoscopy in Diffuse Lung Disease|Evaluation of Two Minimally Invasive Endoscopic Techniques for the Diagnosis of the Diffuse Lung Diseases.|Completed||N/A|100|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||1|||f||||f||||||||||2018-06-01 00:48:50.65378|2018-06-01 00:48:50.65378
NCT00934765|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-04-20|2009-07-07|2009-07-08|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2008||2008-09-30|March 2014|2014-03-31||||June 2016|Anticipated|2016-06-30||Observational|||Effect of Weight Loss on Reproductive Function in Overweight Men|Effect of Weight Loss on Reproductive Function in Overweight Men.|Unknown status|Recruiting||300|Anticipated|Oslo University College|||||f||||f||||||Samples With DNA|"~     Whole blood, semen~   "|||2018-06-01 00:48:50.716437|2018-06-01 00:48:50.716437
NCT00934752|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2017-01-13|2009-07-07|2009-07-08|Estimate|||||||2017-01-13|2017-01-16|Estimate|July 2009||2009-07-31|January 2017|2017-01-31|January 2012|Actual|2012-01-31|April 2010|Actual|2010-04-30||Interventional|||De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions|An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions.|Completed||Phase 1/Phase 2|24|Actual|C. R. Bard||1|||f||||t||||||||||2018-06-01 00:48:50.786667|2018-06-01 00:48:50.786667
NCT00934739|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-02-23|2009-07-07|2009-07-08|Estimate|||||||2015-02-23|2015-02-25|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of High-Risk Oral Cavity Cancer|Multicentre，A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer|Terminated||Phase 2/Phase 3|150|Actual|National Health Research Institutes, Taiwan||3|||f||||t||||||||||2018-06-01 00:48:50.864948|2018-06-01 00:48:50.864948
NCT00934726|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2011-09-22|2009-07-07|2009-07-08|Estimate|||||||2011-09-22|2011-09-23|Estimate|July 2009||2009-07-31|September 2011|2011-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|PASQAL||Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia|Patient Satisfaction and Quality of Life Under Treatment With Seroquel XR|Completed|||150|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:48:50.938057|2018-06-01 00:48:50.938057
NCT00934713|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|September 2004||2004-09-30|October 2003|2003-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|Montelukast||The Effect of Montelukast Treatment in Wheezy Infants|The Effect of Montelukast Therapy on Respiratory Symptoms, Lung Function and Airway Responsiveness in Wheezy Very Young Children|Completed||Phase 4|112|Actual|Helsinki University||1|||f||||f||||||||||2018-06-01 00:48:50.992336|2018-06-01 00:48:50.992336
NCT00934700|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2014-10-27|2009-07-07|2009-07-08|Estimate|||||||2014-10-27|2014-10-28|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|TOBYXe||Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia|Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia|Completed||Phase 1/Phase 2|92|Actual|Imperial College London||2|||f||||t||||||||||2018-06-01 00:48:51.06576|2018-06-01 00:48:51.06576
NCT00934674|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-09-01|2009-07-07|2009-07-08|Estimate|||||||2009-09-01|2009-09-02|Estimate|July 2009||2009-07-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Comparing Two Different Tablet Formulations Of Bosutinib|A Single Dose Bioequivalence Study Comparing the Commercial Tablet Formulation to the Clinical Tablet of Bosutinib in Healthy Subjects|Completed||Phase 1|30|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 00:48:51.337838|2018-06-01 00:48:51.337838
NCT00934661|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2017-11-16||2017-12-14|2009-07-07|2009-07-08|Estimate|2017-12-14|2018-01-16|Actual||||2017-12-14|2018-01-16|Actual|January 2010||2010-01-31|December 2017|2017-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing|Low Dose Extended-release Epidural Morphine in Conjunction With Lumbar Plexus Block Versus Lumbar Plexus Block Alone for Total Hip Resurfacing Arthroplasty: A Randomized Controlled Trial.|Terminated||Phase 4|40|Actual|Wake Forest University Health Sciences||2||Drug was discontinued by manufacturer|f||||f|t|f||||||||2018-06-01 00:48:51.444672|2018-06-01 00:48:51.444672
NCT00934648|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2014-05-07||2014-06-09|2009-07-06|2009-07-08|Estimate|2014-06-09|2014-06-10|Estimate||||2014-06-09|2014-06-10|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Intent-to-Treat (ITT) population: all participants who received any part of an infusion.|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate|Completed||Phase 4|15|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:48:51.841617|2018-06-01 00:48:51.841617
NCT00934635|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2010-12-13||2014-01-14|2009-07-07|2009-07-08|Estimate|2010-12-13|2011-01-11|Estimate||||2014-01-14|2014-02-11|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls|"The Therapeutic Window of the Atypical Antipsychotic Paliperidone Extended Release (ER)-A Positron Emission Tomography Study With [18F]Fallypride as the Radiotracer"|Terminated||Phase 4|2|Actual|Janssen-Cilag G.m.b.H|Two subjects enrolled, both completed study per protocol. Study was prematurely terminated, data obtained were not submitted to further statistical analysis and will not be applicable for scientific analysis due to the low number of subjects.|9|||f||||f||||||||||2018-06-01 00:48:52.138366|2018-06-01 00:48:52.138366
NCT00934622|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2010-03-25||2010-05-05|2009-07-07|2009-07-08|Estimate|2010-05-05|2010-05-06|Estimate||||2010-05-05|2010-05-06|Estimate|November 2007||2007-11-30|May 2010|2010-05-31||||March 2009|Actual|2009-03-31||Interventional|||Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL|Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric Intraocular Lens (IOL)|Completed||Phase 4|76|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:48:52.812374|2018-06-01 00:48:52.812374
NCT00934609|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-09-17|2009-07-07|2009-07-08|Estimate|||||||2009-09-17|2009-09-18|Estimate||||September 2009|2009-09-30||||||||Interventional|CHF||Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure|Effects of 12-weeks Endurance Training in Patients With Chronic Heart Failure Due to Dilated Cardiomyopathy|Completed||N/A|66|Actual|Saarland University||2|||f||||f||||||||||2018-06-01 00:48:52.965001|2018-06-01 00:48:52.965001
NCT00934596|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2013-06-27||2013-10-07|2009-07-07|2009-07-08|Estimate|2013-10-07|2013-12-04|Estimate||||2013-10-07|2013-12-04|Estimate|June 2009||2009-06-30|October 2013|2013-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||CO2 Versus Lund De-airing Technique in Heart Surgery|CO2 Insufflation vs Lund De-airing Technique For Open Left Heart Surgery - Safety and Efficacy|Completed||N/A|20|Actual|Lund University|This study included a total of 20 patients randomized to one of two groups with ten patients in each arms. The small number of study objects might be a potential limitation.|2|||f||||f||||||||||2018-06-01 00:48:53.138584|2018-06-01 00:48:53.138584
NCT00934583|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-06-05|2009-07-06|2009-07-08|Estimate|||||||2012-06-05|2012-06-07|Estimate|August 2009||2009-08-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Testing an Internet-Based Intervention for Preventing Eating Disorders|Preventing Eating Disorders and Reducing Comorbidity|Completed||N/A|549|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 00:48:53.583161|2018-06-01 00:48:53.583161
NCT00934570|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-10-03|2009-07-07|2009-07-08|Estimate|||||||2012-10-03|2012-10-04|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|REACH||Activity and Metformin Intervention in Obese Adolescents|Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease|Completed||Phase 4|60|Anticipated|Lawson Health Research Institute||4|||f||||f||||||||||2018-06-01 00:48:53.683993|2018-06-01 00:48:53.683993
NCT00934557|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|March 2008||2008-03-31|July 2009|2009-07-31||||||||Interventional|ATG FRES||Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation|Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 3|42||IRCCS Policlinico S. Matteo||8|||f||||t||||||||||2018-06-01 00:48:53.779589|2018-06-01 00:48:53.779589
NCT00934544|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2011-12-15||2016-03-17|2009-07-07|2009-07-08|Estimate|2012-04-23|2012-05-30|Estimate||||2016-03-17|2016-04-15|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial|A Randomized Study of INC424 (INCB018424) Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis|Completed||Phase 3|219|Actual|Novartis||2|||f||||t||||||||||2018-06-01 00:48:54.029997|2018-06-01 00:48:54.029997
NCT00934531|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2017-01-04|2009-07-07|2009-07-08|Estimate|||||||2017-01-04|2017-01-06|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Donepezil and the Risk of Falls in Seniors With Cognitive Impairment|Can Cognitive Enhancers Reduce the Risk of Falls in Older People With Mild Cognitive Impairment? A Randomized Controled Trial|Active, not recruiting||N/A|60|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 00:48:54.808361|2018-06-01 00:48:54.808361
NCT00933998|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2014-01-28|2009-07-07|2009-07-08|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2006||2006-06-30|January 2014|2014-01-31||||October 2008|Actual|2008-10-31||Interventional|||Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®|Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®|Completed||N/A|20|Actual|Carolina Musculoskeletal Institute||1|||f||||f||||||||||2018-06-01 00:49:00.481087|2018-06-01 00:49:00.481087
NCT00934518|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-07-28|2009-07-07|2009-07-08|Estimate|||||||2010-07-28|2010-07-29|Estimate|July 2009||2009-07-31|July 2009|2009-07-31||||July 2016|Anticipated|2016-07-31||Interventional|||Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma|Image Guided Intensity Modulated Reirradiation With Concurrent Cetuximab in the Treatment of Locoregionally Confined Relapsed Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|30|Anticipated|Penn State University||1||Inadequate patient accrual|f||||t||||||||||2018-06-01 00:48:54.888126|2018-06-01 00:48:54.888126
NCT00934505|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2012-05-24|2009-07-07|2009-07-08|Estimate|||||||2012-05-24|2012-05-25|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|April 2014|Anticipated|2014-04-30|March 2013|Anticipated|2013-03-31||Observational|RTEP3||Predictive Value of Pet Scan With Fdg Performed During Irradiation in Patients Treated for Oesaphagus Carcinoma|Predictive Value of FDG-TEP During Exclusive Chemo-Radiotherapy (CRT) in Patients With Oesophageal Carcinoma Cancer on the One-Year Survival (RTEP3)|Unknown status|Recruiting||100|Anticipated|Centre Henri Becquerel|||||f||||t||||||||||2018-06-01 00:48:54.94742|2018-06-01 00:48:54.94742
NCT00934492|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2014-08-15|2009-07-07|2009-07-08|Estimate|||||||2014-08-15|2014-08-18|Estimate|November 2009||2009-11-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CTX||Cotrimoxazole Prophylaxis in Severely Malnourished Children|Randomized, Placebo Controlled Trial of Cotrimoxazole Prophylaxis Amongst HIV-uninfected Children With Severe Malnutrition|Completed||Phase 3|1781|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 00:48:55.111463|2018-06-01 00:48:55.111463
NCT00934479|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-07-15|2009-07-07|2009-07-08|Estimate|||||||2013-07-15|2013-07-17|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Intestinal Microecology in Chronic Constipation|The Intestinal Microecology in Chronic Constipation|Completed||Phase 1|21|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:48:55.203087|2018-06-01 00:48:55.203087
NCT00934466|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2015-06-23|2009-07-07|2009-07-08|Estimate|||||||2015-06-23|2015-06-24|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)|A Randomized Clinical Trial to Assess the Effects of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability in Healthy Subjects|Completed||Phase 1|15|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 00:48:55.280383|2018-06-01 00:48:55.280383
NCT00934453|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2017-01-10|2009-07-07|2009-07-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Healthy Volunteers|A Phase I, Randomized Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Healthy Volunteers|Completed||Phase 1|50|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 00:48:55.35847|2018-06-01 00:48:55.35847
NCT00934440|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2017-01-12||2017-05-09|2009-07-07|2009-07-08|Estimate|2017-05-09|2017-06-14|Actual||||2017-05-09|2017-06-14|Actual|June 2009||2009-06-30|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|5-AZ||A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma|A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|11|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 00:48:55.442477|2018-06-01 00:48:55.442477
NCT00934427|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2010-07-19|2009-07-06|2009-07-08|Estimate|||||||2010-07-19|2010-07-20|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms|A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|MediQuest Therapeutics||2|||f||||f||||||||||2018-06-01 00:48:55.711517|2018-06-01 00:48:55.711517
NCT00934414|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|August 2004||2004-08-31|July 2009|2009-07-31|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes|A Parallel, Controlled, Multi-Center, Single-Dose, One-Period Euglycemic Clamp Study Comparing Prandial Inhalation of Technosphere Insulin in Smokers and Non-Smokers With Type 2 Diabetes|Completed||Phase 2|24|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-06-01 00:48:55.826096|2018-06-01 00:48:55.826096
NCT00934401|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2016-07-07|2009-07-07|2009-07-08|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2009||2009-07-31|July 2016|2016-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer|Positron Emission Mammography With 3'-Deoxy-3'-[18F] Fluorothymidine (FLT PEM) for Evaluation of Response to Neoadjuvant Chemotherapy in Breast Cancer|Withdrawn|||0|Actual|University of Iowa||||poor accrual|f||||t||||||||||2018-06-01 00:48:55.892239|2018-06-01 00:48:55.892239
NCT00934388|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2010-03-15|2009-07-07|2009-07-08|Estimate|||||||2010-03-15|2010-03-16|Estimate|January 2011||2011-01-31|March 2010|2010-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Randomised, Blinded Study on Laparoscopic Mesh Reinforcement for Chronic Groin Pain|A Randomised, Blinded Study on Laparoscopic Mesh Reinforcement for Chronic Groin Pain.|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Royal Hobart Hospital||2|||f||||f||||||||||2018-06-01 00:48:55.949733|2018-06-01 00:48:55.949733
NCT00934375|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-07-25||2013-12-12|2009-05-14|2009-07-08|Estimate|2009-05-14|2009-07-08|Estimate||||2013-12-12|2014-01-14|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment|A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment|Completed||Phase 4|145|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 00:48:56.063527|2018-06-01 00:48:56.063527
NCT00934362|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2012-06-11||2017-01-31|2009-07-07|2009-07-08|Estimate|2013-01-17|2013-02-20|Estimate||||2017-01-31|2017-03-13|Actual|October 2008||2008-10-31|January 2013|2013-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease|A Double Blind, Cross-Over Study Comparing Aerosolized Lucinactant and Vehicle on Mucociliary Clearance for Cystic Fibrosis Lung Disease|Completed||Phase 2|16|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:48:56.346215|2018-06-01 00:48:56.346215
NCT00933621|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-07-06|2009-07-06|2009-07-07|Estimate|||||||2009-07-06|2009-07-07|Estimate|April 2003||2003-04-30|July 2009|2009-07-31|December 2003|Actual|2003-12-31|May 2003|Actual|2003-05-31||Interventional|||Intracoronary Injection of Autologous Bone Marrow Cells in Patients With Chronic Heart Failure: Five Years Follow up|Intracoronary Injection of Autologous Bone Marrow Cells in Patients With Chronic Heart Failure: Five Years Follow up|Completed||Phase 2|8|Actual|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-06-01 00:49:03.78439|2018-06-01 00:49:03.78439
NCT00934349|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|June 2009||2009-06-30|July 2009|2009-07-31||||||||Observational|MABECO||Study of Dry Beriberi in Mayotte, Comoro Archipelago|Determination Study of Dry Beriberi in Patients Native to the Comoro Archipelago, in Mayotte (MABECO).|Unknown status|Recruiting||200|Anticipated|Groupe Hospitalier Sud Reunion|||2||f||||t||||||Samples Without DNA|"~     Blood samples drawn for thiamine status, vit B1 dosage will be centrifuged and a serum sample~     will be frozen at -20°C, transferred to Regional Hospital of Reunion Island - GHSR and~     retained in virology laboratory of Dr MICHAULT after end of study for further explorations on~     beriberi~   "|||2018-06-01 00:48:56.585312|2018-06-01 00:48:56.585312
NCT00934336|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2015-08-05|2009-07-07|2009-07-08|Estimate|||||||2015-08-05|2015-08-07|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ITOPOS||Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention|Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention|Completed||N/A|50|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-06-01 00:48:56.656665|2018-06-01 00:48:56.656665
NCT00934323|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||Dose Proportionality Study About Amaryl M Slow Release (SR) 1/500 mg|An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M SR 1/500mg and 2/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Male Subjects|Completed||Phase 1|33|Actual|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:48:56.725951|2018-06-01 00:48:56.725951
NCT00934310|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2017-10-03|2009-07-07|2009-07-08|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2009||2009-05-31|October 2017|2017-10-31|April 2012|Actual|2012-04-30|January 2010|Actual|2010-01-31||Observational|||Introduction of the Surgical Safety Checklist|Patient Safety: Introduction of the Surgical Safety Checklist and Patient Outcome Assessment in an Academic Ambulatory Hospital|Completed|||1000|Actual|Sunnybrook Health Sciences Centre|||2||f||||f||||||||||2018-06-01 00:48:56.79647|2018-06-01 00:48:56.79647
NCT00934297|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2011-07-27|2009-07-07|2009-07-08|Estimate|||||||2011-07-27|2011-07-28|Estimate|July 2009||2009-07-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Observational|||Visualization Tool for Investigation of Breast Lesions|Evaluation of a New Multi-modality Visualization Tool for Investigation of Breast Lesions|Terminated|||10|Anticipated|Sunnybrook Health Sciences Centre|||1|The study was terminated as the PI left the institution.|f||||f||||||||||2018-06-01 00:48:56.859759|2018-06-01 00:48:56.859759
NCT00934284|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effectiveness Study of Physical Therapy as an Adjunct to a Lumbar Therapeutic Selective Nerve Root Block|Effectiveness of Physical Therapy as an Adjunct to a Selective Nerve Root Block in the Treatment of Lumbar Radicular Pain From Disk Herniation|Completed||Phase 2|44|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 00:48:56.91405|2018-06-01 00:48:56.91405
NCT00934271|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2014-10-26|2009-07-07|2009-07-08|Estimate|||||||2014-10-26|2014-10-28|Estimate|January 2002||2002-01-31|October 2014|2014-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Fractionated Stereotactic Radiotherapy in Patients With Acromegaly|Fractionated Stereotactic Radiotherapy in Patients With Acromegaly. Single Centre Experience|Completed|||34|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-06-01 00:48:56.991907|2018-06-01 00:48:56.991907
NCT00934258|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-12-20|2009-07-07|2009-07-08|Estimate|||||||2012-12-20|2012-12-21|Estimate||||November 2012|2012-11-30||||||||Expanded Access|||Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia|Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia|Available|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 00:48:57.051659|2018-06-01 00:48:57.051659
NCT00934245|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-02-21|2009-07-06|2009-07-08|Estimate|||||||2013-02-21|2013-02-22|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Direct and Indirect Protection by Influenza Vaccine Given to Children in India|Direct and Indirect Protection by Influenza Vaccine Given to Children in India|Completed||Phase 4|4598|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-06-01 00:48:57.135644|2018-06-01 00:48:57.135644
NCT00934232|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2017-05-19|2009-07-07|2009-07-08|Estimate|||||||2017-05-19|2017-05-23|Actual|August 2009|Actual|2009-08-31|May 2017|2017-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Busulfan in Multiple Myeloma|A Phase I Open Label Study of IV Busulfan (Busulfex®) in Multiple Myeloma Patients 65 Years of Age or Older, or With Renal Insufficiency Undergoing Autologous Transplantation|Terminated||Phase 1|13|Actual|University of Iowa||1||PI left the institution|f||||t||||||||No||2018-06-01 00:48:57.301785|2018-06-01 00:48:57.301785
NCT00934219|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2009-07-07|2009-07-07|2009-07-08|Estimate|||||||2009-07-07|2009-07-08|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Interventional|TGLL||Triglyceride Lowering Study|Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza.|Unknown status|Recruiting|Phase 4|25|Anticipated|Jewish Hospital, Cincinnati, Ohio||2|||f||||t||||||||||2018-06-01 00:48:57.380091|2018-06-01 00:48:57.380091
NCT00934206|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2011-08-25|2009-07-07|2009-07-08|Estimate|||||||2011-08-25|2011-08-26|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Predictors of Individual Training Effectiveness in Preventive Exercise|Pilot Study to Find Predictors of Individual Training Effectiveness in Preventive Exercise|Completed||N/A|15|Anticipated|Saarland University||1|||f||||f||||||||||2018-06-01 00:48:57.460743|2018-06-01 00:48:57.460743
NCT00934193|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2015-12-15|2009-07-07|2009-07-08|Estimate|||||||2015-12-15|2015-12-16|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Does Peri-Operative Gabapentin Reduce Chronic Post-Thoracotomy Pain?|Does Peri-Operative Gabapentin Reduce Chronic Post-Thoracotomy Pain?|Withdrawn||Phase 3|0|Actual|University of Kansas Medical Center||2|||f||||||||||||||2018-06-01 00:48:57.534823|2018-06-01 00:48:57.534823
NCT00934180|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2009-07-08||2009-07-08|2009-07-07|2009-07-08|Estimate|2009-07-08|2009-08-25|Estimate||||2009-07-08|2009-08-25|Estimate|December 2002||2002-12-31|July 2009|2009-07-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions|A Relative Bioavailability Study of Ondansetron HCl 8 mg Orally Disintegrating Tablets Under Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:48:57.606603|2018-06-01 00:48:57.606603
NCT00932243|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-07-02|2009-07-02|2009-07-03|Estimate|||||||2009-07-02|2009-07-03|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Observational|||Bacteremia in Intensive Care Unit (ICU)|Bacteremia in Intensive Care Unit (ICU) and the Role of Toll-Like-Receptors (TLRs)|Unknown status|Active, not recruiting||300|Anticipated|University of Thessaly|||||f||||f||||||||||2018-06-01 00:49:29.243203|2018-06-01 00:49:29.243203
NCT00934167|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2010-10-26|2009-07-07|2009-07-08|Estimate|||||||2010-10-26|2010-10-27|Estimate|May 2010||2010-05-31|February 2010|2010-02-28|September 2011|Anticipated|2011-09-30|November 2010|Anticipated|2010-11-30||Interventional|||Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients|NON CLINICAL INFERIORITY OF HEPARIN SODIUM PRODUCED BY HIPOLABOR FARMACEUTICA LTDA COMPARED TO THE HEPARIN SODIUM PRODUCED BY APP PHARMACEUTICALS IN VENOUS THROMBOEMBOLISM PROPHYLAXIS, IN SURGICAL PATIENTS WITH MEDIUM RISK FOR DEVELOPMENT OF THROMBOEMBOLISM.|Unknown status|Active, not recruiting|Phase 2/Phase 3|140|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:48:57.899069|2018-06-01 00:48:57.899069
NCT00934154|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-08-14|2009-07-07|2009-07-08|Estimate|||||||2013-08-14|2013-08-15|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2009|Actual|2009-09-30||Interventional|||Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma|Phase III Trial Comparing Treatment With Melphalan+Prednisolon (MP) With Melphalan+Prednisolon+Thalidomide (MPT) for Previously Untreated Elderly Patients With Multiple Myeloma|Completed||Phase 3|122|Actual|Erkim Ilac A.S.||2|||f||||t||||||||||2018-06-01 00:48:57.981785|2018-06-01 00:48:57.981785
NCT00934141|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2013-03-20||2013-07-29|2009-07-07|2009-07-08|Estimate|2013-05-17|2013-06-26|Estimate||||2013-07-29|2013-08-12|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|July 2009|Actual|2009-07-31||Interventional|NIATx 200||Evaluating Improvement Strategies in Addiction Treatment|Randomized Control Trial (RCT) Evaluating Improvement Strategies in Addiction Treatment|Completed||Phase 3|201|Actual|University of Wisconsin, Madison||4|||f||||t||||||||||2018-06-01 00:48:58.117237|2018-06-01 00:48:58.117237
NCT00934128|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|2013-06-10||2016-02-02|2009-07-07|2009-07-08|Estimate|2016-02-02|2016-03-02|Estimate||||2016-02-02|2016-03-02|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer|An Exploratory Trial of Bilevel Positive Airway Pressure Device and High Flow Oxygen for Persistent Dyspnea in Advanced Cancer Patients|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:48:58.850801|2018-06-01 00:48:58.850801
NCT00934115|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-15|2009-07-07|2009-07-08|Estimate|||||||2009-07-15|2009-07-16|Estimate|January 2008||2008-01-31|July 2009|2009-07-31||||||||Observational|||Epidemiology of Infections in Pediatric Cancer Patients|Epidemiology of Infections in Pediatric Cancer Patients: A Prospective Multicenter Study in Israel|Unknown status|Active, not recruiting||200|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 00:48:59.150997|2018-06-01 00:48:59.150997
NCT00934102|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|2010-11-01||2012-06-26|2009-07-07|2009-07-08|Estimate|2010-11-01|2010-12-01|Estimate||||2012-06-26|2012-07-10|Estimate|August 2009||2009-08-31|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|QUINCE||Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses|Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses (P/318/08/C)|Completed||N/A|57|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 00:48:59.200306|2018-06-01 00:48:59.200306
NCT00934089|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06||2010-11-11|2011-06-28|2009-07-06|2009-07-08|Estimate||||2010-11-11|2010-11-23|Estimate|2011-06-28|2011-07-01|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329|A Phase 2, Single-Masked, Randomized, Crossover Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 Alone and In Combination With Latanoprost|Completed||Phase 2|31|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:48:59.34293|2018-06-01 00:48:59.34293
NCT00934076|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2015-05-06|2009-07-06|2009-07-08|Estimate|||||||2015-05-06|2015-05-08|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|June 2015|Anticipated|2015-06-30|January 2011|Anticipated|2011-01-31||Interventional|||Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer|Phase I Study of Erlotinib (Tarceva) in Combination With AT-101 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 1|0|Actual|University of Alabama at Birmingham||1||Study was never activated|f||||t||||||||||2018-06-01 00:48:59.433162|2018-06-01 00:48:59.433162
NCT00934063|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2015-04-28|2009-07-07|2009-07-08|Estimate|||||||2015-04-28|2015-04-29|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|GET||An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®|A 24-month Prospective, Non-interventional, Observational Study on the Composite Clinical Endpoint (GET-Score) Reflecting Quality of Life, Body Composition and Cholesterol Metabolism in Patients Treated With Norditropin® (Somatropin)|Completed|||121|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 00:48:59.492729|2018-06-01 00:48:59.492729
NCT00934050|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2015-04-22||2015-05-12|2009-07-06|2009-07-08|Estimate|2015-05-12|2015-05-13|Estimate||||2015-05-12|2015-05-13|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease|A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease|Completed||Phase 2|103|Actual|Transition Therapeutics Ireland Limited||1|||f||||f||||||||||2018-06-01 00:48:59.581168|2018-06-01 00:48:59.581168
NCT00934037|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2015-09-01|2009-07-07|2009-07-08|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2009||2009-12-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2011|Actual|2011-09-30||Interventional|Core320||Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320 Detector Computed Tomography|Multi Center Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320-Detector Computed Tomography|Unknown status|Active, not recruiting|Phase 3|444|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 00:49:00.218628|2018-06-01 00:49:00.218628
NCT00934024|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-10-31|2009-07-07|2009-07-08|Estimate|||||||2012-10-31|2012-11-01|Estimate|April 2009||2009-04-30|May 2010|2010-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|GRAND||Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers|Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers (GRAND)|Completed||N/A|21|Actual|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 00:49:00.323713|2018-06-01 00:49:00.323713
NCT00934011|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2016-02-01|2009-07-07|2009-07-08|Estimate|||||||2016-02-01|2016-02-03|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections|Comparative Study of C-reactive Protein vs. Procalcitonin to Guide Antibiotic Therapy in Patients With Severe Sepsis and Septic Shock Admitted to the Intensive Care Unit.|Completed||N/A|94|Actual|Federal University of Minas Gerais||2|||f||||t||||||||Yes|Results published in the Critical Care Medicine, 2013|2018-06-01 00:49:00.400968|2018-06-01 00:49:00.400968
NCT00933985|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-07|||2014-04-30|2009-07-07|2009-07-08|Estimate|||||||2014-04-30|2014-05-01|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia|A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination With Vincristine/Doxorubicin/Dexrazoxane, in Children With Relapsed/Refractory Solid Tumors or Leukemia|Terminated||Phase 1|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:49:00.561345|2018-06-01 00:49:00.561345
NCT00933972|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2016-11-01|2009-07-07|2009-07-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment|Effect of Renal Impairment on Pharmacodynamics and Pharmacokinetics of RO4998452: A Multiple-center, Open-label, Parallel Group Study Following Single Oral Dosing of RO4998452 to Type 2 Diabetes Patients With Varying Degrees of Renal Impairment.|Completed||Phase 1|36|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 00:49:00.67961|2018-06-01 00:49:00.67961
NCT00933959|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-07-06|2009-07-06|2009-07-08|Estimate|||||||2009-07-06|2009-07-08|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pilot Study on Sleep Management for US Veterans|A Pilot Study of Two Contrasting Intervention Programs for Sleep Management|Completed||Phase 1/Phase 2|60|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 00:49:00.759911|2018-06-01 00:49:00.759911
NCT00933946|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd Silver Frutal (Lactic Acid) - Compatibility.|Study for Dermatological Evaluation of Topic Compatibility Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd Silver Frutal (Lactic Acid).|Completed||Phase 3|55|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:00.847297|2018-06-01 00:49:00.847297
NCT00933933|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2010-07-19||2011-07-05|2009-07-02|2009-07-07|Estimate|2010-07-19|2010-08-19|Estimate||||2011-07-05|2011-07-12|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Evaluation of Diagnostic HIV Ag/Ab Combo Assay|Evaluation of ARCHITECT HIV Ag/Ab Combo Assay|Completed||Phase 3|635|Actual|Abbott Diagnostics Division||3|||f||||f||||||||||2018-06-01 00:49:00.941144|2018-06-01 00:49:00.941144
NCT00933920|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-02-03|2009-07-06|2009-07-07|Estimate|||||||2010-02-03|2010-02-04|Estimate|June 2009||2009-06-30|February 2010|2010-02-28||||December 2009|Actual|2009-12-31||Interventional|||Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension|A Randomized, Single-blind, Parallel Group, Multiple Oral Dose Study to Evaluate the Effect of a Light Meal on the Pharmacokinetics and Pharmacodynamics of Aliskiren Using Market 300 mg Tablet Formulation in Subjects With Mild to Moderate Hypertension|Completed||Phase 1|124|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:49:01.422944|2018-06-01 00:49:01.422944
NCT00933907|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal|Study Title: Study for Dermatological Evaluation of Topic Compatibility Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd PH_DESILSTY_FR (Lactic Acid) .|Completed||Phase 3|55|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:01.501099|2018-06-01 00:49:01.501099
NCT00933894|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-12-16|2009-07-02|2009-07-07|Estimate|||||||2010-12-16|2010-12-17|Estimate|September 2009||2009-09-30|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram|A Phase I, Open-label, Randomized, Crossover Trial in 16 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Escitalopram at Steady-state|Completed||Phase 1|16|Actual|Tibotec BVBA|||||f||||||||||||||2018-06-01 00:49:01.571705|2018-06-01 00:49:01.571705
NCT00933881|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2016-07-13|2009-07-06|2009-07-07|Estimate|||||||2016-07-13|2016-07-14|Estimate|November 2008||2008-11-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Gestational Diabetes and Sleep-Disordered Breathing|A Pilot Study to Evaluate the Association Between Gestational Diabetes, Heart Rate Variability and Sleep-Disordered Breathing|Completed|||32|Actual|Christiana Care Health Services|||1||f||||f||||||||||2018-06-01 00:49:01.643709|2018-06-01 00:49:01.643709
NCT00933868|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-05-23|2009-07-03|2009-07-07|Estimate|||||||2012-05-23|2012-05-25|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke|Comparison of Magnesium Chloride Infusions Versus Placebo Administered Concomitantly With 100% Oxygen Given to Patients Who Have Residual Muscle Weakness From a Stroke That Occurred Three Months to Four Years Ago|Completed||Phase 2/Phase 3|81|Actual|Relox Medical, LLC||2|||f||||f||||||||||2018-06-01 00:49:01.720944|2018-06-01 00:49:01.720944
NCT00933855|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2011-11-22|2009-07-02|2009-07-07|Estimate|||||||2011-11-22|2011-11-23|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Patient Communication Training Intervention|A Feasibility Study of a Patient Communication Training Intervention|Completed|||32|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 00:49:01.793844|2018-06-01 00:49:01.793844
NCT00933842|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd PH_DESILSTY_FL (Lactic Acid) - Photo Evaluation - Stay on Floral|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DESILSTY_FL (Lactic Acid).|Completed||Phase 3|27|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:01.878292|2018-06-01 00:49:01.878292
NCT00933829|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-09-24|2009-07-06|2009-07-07|Estimate|||||||2010-09-24|2010-09-27|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Comparison of Cosmetic Outcomes of Lacerations Repaired Using Absorbable Versus Non-absorbable Sutures|Comparison of Cosmetic Outcomes of Lacerations of the Trunk and Extremity Repaired Using Absorbable Versus Non-absorbable Sutures|Completed||N/A|160|Anticipated|Temple University||2|||f||||f||||||||||2018-06-01 00:49:01.94831|2018-06-01 00:49:01.94831
NCT00933816|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2010-11-24|2009-07-06|2009-07-07|Estimate|||||||2010-11-24|2010-11-25|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|SILIUS||Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy|Phase I/II Study of Sorafenib In Combination With Low-dose FP Intraarterial Infusion Chemotherapy|Completed||Phase 1/Phase 2|37|Anticipated|Japan Liver Oncology Group||1|||f||||t||||||||||2018-06-01 00:49:02.066054|2018-06-01 00:49:02.066054
NCT00933790|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2017-04-26|2009-07-06|2009-07-07|Estimate|||||||2017-04-26|2017-04-28|Actual|September 14, 2009|Actual|2009-09-14|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis|A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis|Active, not recruiting||Phase 3|331|Actual|Tuberculosis Research Centre, India||3|||f||||t||||||||||2018-06-01 00:49:02.140288|2018-06-01 00:49:02.140288
NCT00933777|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2016-05-24|2009-07-06|2009-07-07|Estimate|||||||2016-05-24|2016-05-25|Estimate|July 2009||2009-07-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|SORAVE||SORAVE - Sorafenib and Everolimus in Solid Tumors|SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors|Completed||Phase 1|36|Actual|University of Cologne||1|||f||||t||||||||||2018-06-01 00:49:02.220773|2018-06-01 00:49:02.220773
NCT00933764|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2015-07-20|2009-07-06|2009-07-07|Estimate|||||||2015-07-20|2015-07-21|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Observational|CLEAR||Clinical Performance Evaluation of the Cholestech LDX Cardiac hsCRP Test (CLEAR)||Withdrawn|||0|Actual|Biosite|||||f||||f||||||Samples Without DNA|"~     Plasma and Serum samples will be retained for reference testing and banking.~   "|||2018-06-01 00:49:02.330863|2018-06-01 00:49:02.330863
NCT00933751|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-05|||2011-04-04|2009-07-06|2009-07-07|Estimate|||||||2011-04-04|2011-04-05|Estimate|July 2009||2009-07-31|July 2009|2009-07-31||||August 2010|Anticipated|2010-08-31||Observational|||Changes of Oxygen Saturation in Inferior Vena Cava (IVC) in Patients During and After High Risk Abdominal Surgery and Relationship to the Outcome|Changes of Oxygen Saturation in Inferior Vena Cava (IVC) in Patients During and After High Risk Abdominal Surgery and Relationship to the Outcome.|Unknown status|Not yet recruiting||20|Anticipated|Assaf-Harofeh Medical Center|||1||f||||||||||||||2018-06-01 00:49:02.376545|2018-06-01 00:49:02.376545
NCT00933738|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2011-06-21|2009-07-06|2009-07-07|Estimate|||||||2011-06-21|2011-06-22|Estimate|December 2009||2009-12-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|ECLIPSE 03||Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)||Completed|||150|Anticipated|Biosite|||||f||||f||||||Samples Without DNA|"~     Plasma samples to be retained for reference testing and banking.~   "|||2018-06-01 00:49:02.440077|2018-06-01 00:49:02.440077
NCT00933725|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-06-15|2009-07-06|2009-07-07|Estimate|||||||2012-06-15|2012-06-18|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety of Traditional Chinese Medicine Intervention for Women With Menopausal Syndrome|Efficacy and Safety of Combined Treatment of Herbs and TCM Emotion Treatment for Women With Menopausal Syndrome: A Multiple-centered Randomized Controlled Trial|Completed||Phase 3|194|Actual|Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:49:02.505357|2018-06-01 00:49:02.505357
NCT00933712|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd Silver Floral (Lactic Acid) - Compatibility.|Study for Dermatological Evaluation of Topic Compatibility. Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd Silver Floral (Lactic Acid).|Completed||Phase 3|55|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:02.643297|2018-06-01 00:49:02.643297
NCT00933699|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd PH_DESILSTY_FL (Lactic Acid) - Acceptability - Stay on Floral.|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up - Dermacyd PH_DESILSTY_FL (Lactic Acid).|Completed||Phase 3|32|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:02.693844|2018-06-01 00:49:02.693844
NCT00933686|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2013-04-15||2013-08-01|2009-07-06|2009-07-07|Estimate|2013-08-01|2013-08-02|Estimate||||2013-08-01|2013-08-02|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome|Growth Hormone Treatment of Severe Fibromyalgia Syndrome Associated With Functional Failure of Somatotropic Axis. A Multicentre, Randomized, Double-blind, Placebo-controlled Study.|Completed||Phase 3|113|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 00:49:02.76134|2018-06-01 00:49:02.76134
NCT00933673|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2012-02-16|2009-07-06|2009-07-07|Estimate|||||||2012-02-16|2012-02-20|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma|Phase II Study of L-asparaginase Plus DICE Regimen in Patients With Stage I/II NK/T-cell Lymphoma|Unknown status|Recruiting|Phase 2|76|Anticipated|Fudan University||1|||f||||f||||||||||2018-06-01 00:49:03.419083|2018-06-01 00:49:03.419083
NCT00933660|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-07-06|2009-07-06|2009-07-07|Estimate|||||||2009-07-06|2009-07-07|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|March 2009|Anticipated|2009-03-31||Interventional|||Retention and Retrieval for Three Different Training Methods|Do we Need an Instructor, or a Manikin to Learn BLS/AED, or is Web Based Training as Good as Instructor Based Training?|Unknown status|Enrolling by invitation|N/A|280|Anticipated|Doczero||4|||f||||t||||||||||2018-06-01 00:49:03.522355|2018-06-01 00:49:03.522355
NCT00933647|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-10|2009-07-06|2009-07-07|Estimate|||||||2009-07-10|2009-07-13|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Cardioprotective Effects of Green Tea Versus Maté Intake|Effects of Yerba Mate and Green Tea Consumption on Cardiovascular Risk Factors in Dyslipidemic and Overweight Subjects|Unknown status|Recruiting|Phase 3|195|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||3|||f||||t||||||||||2018-06-01 00:49:03.613046|2018-06-01 00:49:03.613046
NCT00933634|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-07-02|2009-07-02|2009-07-07|Estimate|||||||2009-07-02|2009-07-07|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation|Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation: a Randomized Controlled Trial|Completed||N/A|247|Anticipated|Valduce Hospital||2|||f||||t||||||||||2018-06-01 00:49:03.705835|2018-06-01 00:49:03.705835
NCT00932230|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2013-05-01|2009-07-02|2009-07-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Effect of Kinesio Taping on Ankle Proprioception|The Effect of Kinesio Taping on Ankle Proprioception|Completed||N/A|40|Actual|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 00:49:29.292025|2018-06-01 00:49:29.292025
NCT00933608|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2013-05-08||2014-10-20|2009-07-06|2009-07-07|Estimate|2014-10-20|2014-10-21|Estimate||||2014-10-20|2014-10-21|Estimate|July 2009||2009-07-31|October 2014|2014-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease|Effects of Memantine on the Magnetic Resonance Spectroscopy (MRS) Measures of Neuronal Integrity in Subjects at Risk for Alzheimer's Disease|Completed||Phase 4|17|Actual|New York University School of Medicine||2|||f||||||||||||||2018-06-01 00:49:03.868122|2018-06-01 00:49:03.868122
NCT00933595|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2016-08-31|2009-07-02|2009-07-07|Estimate|||||||2016-08-31|2016-09-01|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|LHIV||Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)|Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV)|Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)||1|||f||||t||||||||||2018-06-01 00:49:04.108621|2018-06-01 00:49:04.108621
NCT00933582|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-07-29|2009-07-02|2009-07-07|Estimate|||||||2010-07-29|2010-08-02|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Clinical Study to Investigate the Effect on Pain Relief of a Single Dose of JNJ-39439335 in Patients With Chronic Osteoarthritis Pain of the Knee|A Randomized, Double-Blind, Placebo-Controlled Clinical Study of Single Doses of JNJ-39439335 Versus Single and Multiple Doses of Naproxen Versus Placebo in the Treatment of Painful Osteoarthritis of the Knee: Focus on Treatment Effects and Methodological Advances|Completed||Phase 1|33|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 00:49:04.191528|2018-06-01 00:49:04.191528
NCT00933569|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd Silver Floral (Lactic Acid) - Acceptability.|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up Dermacyd Silver Floral (Lactic Acid).|Completed||Phase 3|31|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:04.250686|2018-06-01 00:49:04.250686
NCT00933556|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2015-10-06|2009-07-06|2009-07-07|Estimate|||||||2015-10-06|2015-10-08|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|March 2012|Actual|2012-03-31|October 2010|Actual|2010-10-31||Interventional|PROVE||A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE|A Pilot Randomized Trial to Determine the Efficacy of a Probiotic, VSL#3 for Reducing Colonization by Vancomycin-resistant Enterococcus (VRE)|Completed||Phase 2|90|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 00:49:04.307155|2018-06-01 00:49:04.307155
NCT00933543|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2013-03-14||2013-11-15|2009-07-06|2009-07-07|Estimate|2013-10-22|2013-11-15|Estimate||||2013-11-15|2013-12-11|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)|A Double Blinded, Prospective, Randomized, Stratified, Placebo-controlled, Multi-center Study of Photodynamic Therapy With VisonacTM Cream in Patients With Moderate to Severe Acne Vulgaris.|Completed||Phase 2|107|Actual|Photocure||2|||f||||f||||||||||2018-06-01 00:49:04.417372|2018-06-01 00:49:04.417372
NCT00933530|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2017-05-25|2009-07-02|2009-07-07|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2008||2008-05-31|May 2017|2017-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers|A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers|Completed||Phase 1|43|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-06-01 00:49:05.204385|2018-06-01 00:49:05.204385
NCT00933517|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2014-03-20|2009-07-06|2009-07-07|Estimate|||||||2014-03-20|2014-03-21|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|TVA||"Assessment of the Efficacy of the Neoadjuvant Combination: Chemotherapy-Targeted Therapy in Breast Cancer."|Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study|Completed||Phase 2|62|Actual|Centre Jean Perrin|||||f||||t||||||||||2018-06-01 00:49:05.288777|2018-06-01 00:49:05.288777
NCT00933504|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral|Study for Dermatological Evaluation of Topic Compatibility. Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd PH_DESILSTY_FL (Lactic Acid).|Completed||Phase 3|55|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:05.362013|2018-06-01 00:49:05.362013
NCT00933491|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2015-07-30||2015-10-07|2009-07-06|2009-07-07|Estimate|2015-10-07|2015-11-04|Estimate||||2015-10-07|2015-11-04|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus|Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus: A Feasibility Cohort Study|Completed|||32|Actual|University of Michigan|||2||f||||f||||||Samples Without DNA|"~     saliva and plaque biofilm~   "|||2018-06-01 00:49:05.41684|2018-06-01 00:49:05.41684
NCT00933478|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2009-07-07|2009-07-06|2009-07-07|Estimate|||||||2009-07-07|2009-07-08|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||A Trial of Clay Weight on the Ear Drum for Patulous Eustachian Tube|A Trial of Clay Weight on the Ear Drum for Patulous Eustachian Tube|Unknown status|Not yet recruiting||20|Anticipated|Nova Scotia Health Authority|||1||f||||t||||||||||2018-06-01 00:49:05.609367|2018-06-01 00:49:05.609367
NCT00933465|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2014-11-17|2009-07-06|2009-07-07|Estimate|||||||2014-11-17|2014-11-18|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Imodium Syrup Versus Imodium Tablets for Faecal Incontinence|Single Blinded Randomised Cross-over Study of Imodium Tablets Versus Imodium Syrup for the Treatment of Faecal Incontinence|Withdrawn||Phase 4|0|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:49:05.675473|2018-06-01 00:49:05.675473
NCT00933452|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-05|||2010-06-11|2009-07-06|2009-07-07|Estimate|||||||2010-06-11|2010-06-15|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects|A Open Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Safety of Duloxetine in Chinese Han Healthy Subjects|Completed||Phase 1|36|Anticipated|Shanghai Mental Health Center||3|||f||||t||||||||||2018-06-01 00:49:06.672563|2018-06-01 00:49:06.672563
NCT00929721|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2012-04-12|2009-06-26|2009-06-29|Estimate|||||||2012-04-12|2012-04-13|Estimate|December 2009||2009-12-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||A Global Active Surveillance for Community Acquired Pneumonia|Global Active Surveillance for Community-Acquired Pneumonia (CAP) in Adults 50 Years and Older|Completed||N/A|5172|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:50:19.471636|2018-06-01 00:50:19.471636
NCT00933439|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2013-08-09|2009-07-06|2009-07-07|Estimate|||||||2013-08-09|2013-08-13|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|DULOX||Assessment of Cognitive Functioning Before and After Treatment With Duloxetine|Assessment of Cognitive Functioning Before and After Treatment With Duloxetine|Completed||N/A|30|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-06-01 00:49:06.746601|2018-06-01 00:49:06.746601
NCT00933426|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2016-10-25|2009-07-03|2009-07-07|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Lenalidomide and Paclitaxel in Prostate Cancer|A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases|Terminated||Phase 1|17|Actual|M.D. Anderson Cancer Center||1||Terminated early due to slow accrual as Phase I dose escalation study.|f||||f||||||||||2018-06-01 00:49:06.818768|2018-06-01 00:49:06.818768
NCT00933413|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd Silver Frutal (Lactic Acid) - Acceptability.|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow-up (Dermacyd Silver Frutal (Lactic Acid)).|Completed||Phase 3|30|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:06.902603|2018-06-01 00:49:06.902603
NCT00933400|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-03-13|2009-07-02|2009-07-07|Estimate|||||||2012-03-13|2012-03-14|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|April 2012|Anticipated|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS|"Randomized Controlled Study of a Rapid Rule Out Strategy Using CT Coronary Angiogram Versus Traditional Care for Low- to Intermediate-Risk ED Patients With Potential Acute Coronary Syndromes"|Unknown status|Active, not recruiting|Phase 4|1365|Anticipated|American College of Radiology Imaging Network||2|||f||||t||||||||||2018-06-01 00:49:06.961334|2018-06-01 00:49:06.961334
NCT00933387|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2016-05-03|2009-07-06|2009-07-07|Estimate|||||||2016-05-03|2016-05-04|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|November 2013|Actual|2013-11-30|July 2011|Actual|2011-07-31||Interventional|||A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma|A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC)|Completed||Phase 2|47|Actual|National Health Research Institutes, Taiwan||1|||f||||t||||||||||2018-06-01 00:49:07.039564|2018-06-01 00:49:07.039564
NCT00933374|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2015-03-17|2009-07-06|2009-07-07|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|RAD001||Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma|A Single Arm, Multi-center Phase II Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma After Failure of Prior Platin-based Chemotherapy|Terminated||Phase 2|28|Actual|Heinrich-Heine University, Duesseldorf||1||delayed recruitment|f||||t||||||||||2018-06-01 00:49:07.11709|2018-06-01 00:49:07.11709
NCT00933361|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2017-07-31|2009-07-06|2009-07-07|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2009||2009-06-30|July 2017|2017-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Individual Dose-escalated Bi-daily Subcutaneously (sc) Ghrelin in Cancer Cachexia: a Phase I/II Study|Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: a Phase I/II Study|Completed||Phase 1/Phase 2|21|Actual|Cantonal Hospital of St. Gallen||1|||f||||f||||||||||2018-06-01 00:49:07.290992|2018-06-01 00:49:07.290992
NCT00933348|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-05|||2014-10-29|2009-07-06|2009-07-07|Estimate|||||||2014-10-29|2014-10-30|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers|A Randomised, Double-blind, Placebo-controlled Study of the Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers.|Suspended||Phase 2|30|Anticipated|Phoenix Eagle Company||2||Slow recruitment caused rethink on the study design|f||||f||||||||||2018-06-01 00:49:07.367459|2018-06-01 00:49:07.367459
NCT00933335|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2011-12-01||2016-11-30|2009-07-02|2009-07-07|Estimate|2012-02-09|2012-03-13|Estimate||||2016-11-30|2017-01-18|Estimate|August 1998||1998-08-31|November 2016|2016-11-30|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional|||Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab|Fludarabine Monophosphate Followed by Iodine I 131 Tositumomab for Untreated Low-grade and Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|38|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:49:07.547797|2018-06-01 00:49:07.547797
NCT00933322|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2013-07-11|2009-07-06|2009-07-07|Estimate|||||||2013-07-11|2013-07-12|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans|Randomized-controlled Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans|Terminated||N/A|142|Actual|University Hospital Inselspital, Berne||3||Recruitment problems|f||||t||||||||||2018-06-01 00:49:08.974501|2018-06-01 00:49:08.974501
NCT00933309|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2016-02-17|2009-07-06|2009-07-07|Estimate|||||||2016-02-17|2016-02-19|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Impact of Obesity and Obesity Treatments on Breast Cancer|The Impact of Obesity and Obesity Treatments on Breast Cancer: A Phase I Trial of Exemestane With Metformin and Rosiglitazone for Postmenopausal Obese Women With ER+ Metastatic Breast Cancer|Completed||Phase 1|25|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:49:09.083292|2018-06-01 00:49:09.083292
NCT00933296|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2017-09-07|2009-07-06|2009-07-07|Estimate|||||||2017-09-07|2017-09-08|Actual|July 2009||2009-07-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors|Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic|Completed|||52|Actual|University Hospital, Strasbourg, France|||2||f||||f||||||Samples With DNA|"~     White cells Serum~   "|||2018-06-01 00:49:09.239563|2018-06-01 00:49:09.239563
NCT00933283|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-11-30|2009-07-02|2009-07-07|Estimate|||||||2012-11-30|2012-12-03|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State|A Phase I, Open-Label, Single-Sequence Drug-Drug Interaction Trial in Subjects on Stable Methadone Maintenance Therapy, to Investigate the Potential Interaction Between Telaprevir 750 mg q8h and Methadone, at Steady-State|Completed||Phase 1|18|Actual|Tibotec BVBA||1|||f||||f||||||||||2018-06-01 00:49:09.349068|2018-06-01 00:49:09.349068
NCT00933270|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2014-04-08||2017-04-25|2009-07-06|2009-07-07|Estimate|2015-03-12|2015-03-25|Estimate||||2017-04-25|2017-05-30|Actual|July 2009||2009-07-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|SUPERB|The Intention-to-treat (ITT; n=264) analysis set included all subjects enrolled in the study excluding Roll-in subjects (n=61).|Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery|Comparison of the SUpera® PERipheral System to a Performance Goal Derived From Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery|Completed||N/A|325|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 00:49:09.558705|2018-06-01 00:49:09.558705
NCT00933257|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd PH_DESILSTY_FR (Lactic Acid) - Photo Evaluation - Stay on Frutal|Study Title: Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DESILSTY_FR.|Completed||Phase 3|27|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:11.26236|2018-06-01 00:49:11.26236
NCT00933244|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2015-06-16||2015-10-06|2009-07-06|2009-07-07|Estimate|2015-10-06|2015-11-10|Estimate||||2015-10-06|2015-11-10|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||All randomized subjects' baseline data is reported herein|Treatment of Vitamin D Insufficiency|Treatment of Vitamin D Insufficiency|Completed||Phase 4|230|Actual|University of Wisconsin, Madison||3|||f||||f||||||||||2018-06-01 00:49:11.359479|2018-06-01 00:49:11.359479
NCT00933231|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2018-05-14|2009-07-06|2009-07-07|Estimate|||||||2018-05-14|2018-05-15|Actual|August 17, 2009|Actual|2009-08-17|May 2018|2018-05-31|April 3, 2018|Actual|2018-04-03|May 11, 2015|Actual|2015-05-11||Interventional|||Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts|A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response|Completed||Phase 3|281|Actual|Astellas Pharma Inc||4|||f||||t||||||||Undecided||2018-06-01 00:49:11.856384|2018-06-01 00:49:11.856384
NCT00933218|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2010-10-19|2009-07-06|2009-07-07|Estimate|||||||2010-10-19|2010-10-20|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|Be-MaGIC||Beer, Marathon, Genetics, Inflammation and the Cardiovascular System: Be-MaGIC-Trial|Effects of Polyphenols on Changes of Inflammatory and Cardiovascular Status After a Marathon Run|Completed||N/A|250|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 00:49:12.034233|2018-06-01 00:49:12.034233
NCT00933205|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2016-11-29|2009-07-06|2009-07-07|Estimate|||||||2016-11-29|2016-11-30|Estimate|May 2004||2004-05-31|October 2013|2013-10-31||||June 2008|Actual|2008-06-30||Expanded Access|||An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.|An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options.|Approved for marketing|||||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 00:49:12.121655|2018-06-01 00:49:12.121655
NCT00933192|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-04-15|2009-07-06|2009-07-07|Estimate|||||||2010-04-15|2010-04-16|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||The Relationship Between Muscle Morphology and Muscle Strength|The Relationship Between Muscle Morphology and Muscle Strength|Completed|||52|Anticipated|Karl Landsteiner Institute of Remobilization and Functional Health|||2||f||||||||||||||2018-06-01 00:49:12.397046|2018-06-01 00:49:12.397046
NCT00933179|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2014-11-13|2009-07-03|2009-07-07|Estimate|||||||2014-11-13|2014-11-14|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||FC Patch Low: Metabolism Study|A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (0.03mg/0.15mg) in a 21-day Regimen on Hemostatic Parameters in 30 Women Aged 18 182 35 Years Over 3 Treatment Cycles in Each Period|Completed||Phase 2|30|Actual|Bayer||2|||f||||t||||||||||2018-06-01 00:49:12.460092|2018-06-01 00:49:12.460092
NCT00933166|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2010-12-02||2012-06-26|2009-07-06|2009-07-07|Estimate|2010-12-02|2010-12-23|Estimate||||2012-06-26|2012-07-10|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Assessing the Performance of Lotrafilcon A Lenses During a Three Month Period|Assessing the Performance of Lotrafilcon A Lenses During a Three Month Period|Completed||N/A|169|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:49:12.55117|2018-06-01 00:49:12.55117
NCT00933153|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2014-06-12|2009-07-06|2009-07-07|Estimate|||||||2014-06-12|2014-06-13|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effectiveness of Oral Nutritional Supplements (ONS) in a Meals-on-Wheels Population|Validation of the Malnutrition Screening Tool (MST) and Effectiveness of Oral Nutritional Supplements (ONS) on Weight, Nutritional Status and Quality of Life in a Meals-on-Wheels Population|Completed||N/A|91|Actual|Texas Christian University||2|||f||||t||||||||||2018-06-01 00:49:12.655997|2018-06-01 00:49:12.655997
NCT00933140|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2015-11-16|2009-07-06|2009-07-07|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2006||2006-10-31|November 2015|2015-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Anal HPV Infection and Abnormal Cytology in HIV-infected Women|Anal HPV Infection and Abnormal Cytology in HIV-infected Women|Completed|||100|Actual|Boston Medical Center|||1||f||||t||||||||||2018-06-01 00:49:12.89846|2018-06-01 00:49:12.89846
NCT00933127|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2014-07-23|2009-07-03|2009-07-07|Estimate|||||||2014-07-23|2014-07-24|Estimate|December 2008||2008-12-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone|Association of FC-Gamma Receptor Genotypes With Response and Clinical Benefit With Addition of Rituximab to CHOP Chemotherapy in Patients With Follicular Lymphoma (FL)|Completed|||142|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:49:12.962248|2018-06-01 00:49:12.962248
NCT00933114|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-04-10|2009-07-06|2009-07-07|Estimate|||||||2012-04-10|2012-04-11|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|FITT||Functional Imaging of Tumor and Normal Tissue|The Use of Functional Imaging to Quantify Tumor and Normal Tissue Physiology in Patients With Locally Advanced Head and Neck Cancer|Terminated|||21|Actual|Duke University|||1|Funding ceased|f||||f||||||||||2018-06-01 00:49:13.033704|2018-06-01 00:49:13.033704
NCT00933101|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2011-06-23|2009-07-02|2009-07-07|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2010||2010-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Vascular Inflammation in Adolescents With Type 1 Diabetes|Prevalence of Oxidative Stress, Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness (cIMT) and Biomarkers of Vascular Inflammation in Adolescents With Type-1 Diabetes Mellitus (T1DM)|Completed|||51|Actual|Children's Mercy Hospital Kansas City|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:49:13.101491|2018-06-01 00:49:13.101491
NCT00933088|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2016-06-23|2009-07-06|2009-07-07|Estimate|||||||2016-06-23|2016-06-24|Estimate|June 2008||2008-06-30|June 2016|2016-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer|Adolescent Daughters' Response and Adjustment to Maternal Breast Cancer|Terminated|||43|Actual|New York University School of Medicine||||due to slow accrual and lack of funding|f||||t||||||||||2018-06-01 00:49:13.166122|2018-06-01 00:49:13.166122
NCT00933075|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd Silver Frutal (Lactic Acid) - Photo Evaluation.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Silver Frutal (Lactic Acid).|Completed||Phase 3|27|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:13.234027|2018-06-01 00:49:13.234027
NCT00933062|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2017-07-05|2009-07-02|2009-07-07|Estimate|||||||2017-07-05|2017-07-07|Actual|March 23, 2009|Actual|2009-03-23|July 2017|2017-07-31|May 12, 2009|Actual|2009-05-12|May 12, 2009|Actual|2009-05-12||Interventional|||Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered as Single and Multiple Doses in the Fed State to Normal Healthy Male Volunteers|Completed||Phase 1|10|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:49:13.29078|2018-06-01 00:49:13.29078
NCT00933049|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-05|||2009-07-06|2009-07-06|2009-07-07|Estimate|||||||2009-07-06|2009-07-07|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months|Clinical Efficacy of Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months Attending Mulago Hospital: A Randomized Clinical Trial.|Completed||Phase 3|505|Actual|Makerere University||2|||f||||t||||||||||2018-06-01 00:49:13.446576|2018-06-01 00:49:13.446576
NCT00933036|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-05|||2014-01-21|2009-07-06|2009-07-07|Estimate|||||||2014-01-21|2014-01-23|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Evaluation of the Crosstrees Pod™ in the Treatment of Pathologic Fracture of the Vertebral Body (Levels T4 - L5) in Adult Patients|Clinical Evaluation of the Crosstrees® System for PVA in Symptomatic Adult Patients With Acute Vertebral Body Compression Fractures at T4-L5|Completed||N/A|135|Actual|Crosstrees Medical Inc.||1|||f||||t||||||||||2018-06-01 00:49:13.534394|2018-06-01 00:49:13.534394
NCT00933023|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2015-07-28|2009-07-06|2009-07-07|Estimate|||||||2015-07-28|2015-07-30|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|TopSteP||Mild Versus Potent Corticosteroids as Treatment for Phimosis in Children|A Randomised Controlled Trial of Mild Versus Potent Topical Corticosteroids as Primary Treatment for Non-retractile Foreskin in Children.|Withdrawn||Phase 4|0|Actual|Chelsea and Westminster NHS Foundation Trust||2||Patient numbers estimated to be too low to complete the trial in less than 10 years|f||||t||||||||||2018-06-01 00:49:13.634454|2018-06-01 00:49:13.634454
NCT00933010|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-10-12|2009-07-02|2009-07-07|Estimate|||||||2010-10-12|2010-10-13|Estimate|October 2009||2009-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|ORSA Umbria||Metabolic Syndrome Observation on a Regional Basis|Osservatorio Regionale Sulla Sindrome metabolicA|Completed|||1600|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 00:49:13.701262|2018-06-01 00:49:13.701262
NCT00932997|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2015-06-03|2009-07-03|2009-07-07|Estimate|||||||2015-06-03|2015-06-08|Estimate|October 2006||2006-10-31|June 2015|2015-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors|Reducing the Burden of Breast Cancer Among African American and Latina Survivors|Completed||N/A|300|Anticipated|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:49:13.765321|2018-06-01 00:49:13.765321
NCT00932984|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd Silver Floral (Lactic Acid) - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Silver Floral (Lactic Acid).|Completed||Phase 3|27|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:13.85037|2018-06-01 00:49:13.85037
NCT00932971|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2018-01-26|2009-07-06|2009-07-07|Estimate|||||||2018-01-26|2018-01-29|Actual|June 2009||2009-06-30|January 2018|2018-01-31|August 2, 2017|Actual|2017-08-02|August 2017|Actual|2017-08-31||Interventional|HIDIT-II||HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis|A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II)|Completed||Phase 2|70|Actual|HepNet Study House, German Liverfoundation||2|||f||||f||||||||||2018-06-01 00:49:13.920394|2018-06-01 00:49:13.920394
NCT00932958|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-05|||2012-12-08|2009-07-06|2009-07-07|Estimate|||||||2012-12-08|2012-12-11|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|BIGPICTURE||Physicians International Coronary Computed Tomography Angiography (CCTA) Utilization Registry|Physicians International CCTA Utilization Registry|Completed|||6000|Actual|MDDX LLC|||1||f||||t||||||||||2018-06-01 00:49:14.018356|2018-06-01 00:49:14.018356
NCT00932945|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2010-09-13|2009-07-03|2009-07-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dermacyd PH_DESILSTY_FR (Lactic Acid) - Acceptability - Stay on Frutal|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up - Dermacyd PH_DESILSTY_FR (Lactic Acid).|Completed||Phase 3|32|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:14.074835|2018-06-01 00:49:14.074835
NCT00932932|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2011-06-23|2009-07-02|2009-07-07|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|August 2010|Actual|2010-08-31|||||Observational|||Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls|11 Beta Hydroxysteroid Dehydrogenase 1 (11-beta HSD 1) Activity in Patients With Prader-Willi Syndrome and in Healthy Controls|Completed|||36|Anticipated|Children's Mercy Hospital Kansas City|||3||f||||t||||||||||2018-06-01 00:49:14.147377|2018-06-01 00:49:14.147377
NCT00932919|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2014-04-22|2009-07-06|2009-07-07|Estimate|||||||2014-04-22|2014-04-23|Estimate|October 2006||2006-10-31|April 2014|2014-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Thought Field Therapy and Cognitive Therapy for Agoraphobia|Thought Field Therapy and Cognitive Therapy for Agoraphobia - a Randomized Controlled Intervention Study Where the Efficacy of Thought Field Therapy is to be Compared to Cognitive Therapy|Completed||N/A|72|Actual|Sorlandet Hospital HF||3|||f||||f||||||||||2018-06-01 00:49:14.198399|2018-06-01 00:49:14.198399
NCT00932906|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-03|||2009-07-06|2009-07-06|2009-07-07|Estimate|||||||2009-07-06|2009-07-07|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Comparison of Different Automated External Defibrillation (AED) Training Methods|Comparison of Four Different AED Training Methods in Three Different Age Groups|Unknown status|Enrolling by invitation|N/A|396|Anticipated|Doczero||12|||f||||t||||||||||2018-06-01 00:49:14.291789|2018-06-01 00:49:14.291789
NCT00932893|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2013-03-13||2016-10-31|2009-07-02|2009-07-03|Estimate|2013-06-04|2013-06-06|Estimate||||2016-10-31|2017-01-02|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|March 2012|Actual|2012-03-31||Interventional||Full analysis set (FAS) included all participants who were randomized to study treatment.|An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene|Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus|Completed||Phase 3|347|Actual|Pfizer|No analyses of ALK fusion variants or protein expression were done due to limited slide stability of unstained tissue sections required for immunohistochemistry and no nucleic acid based assay was available to identify specific ALK gene fusion.|2|||f||||t||||||||||2018-06-01 00:49:14.556759|2018-06-01 00:49:14.556759
NCT00932880|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-15|2009-07-02|2009-07-03|Estimate|||||||2009-07-15|2009-07-16|Estimate||||July 2009|2009-07-31||||||||Interventional|||Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 18 Fed, Healthy Adult Subjects|An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets [Torrent Pharmaceuticals Limited,India] Compared to a 10 mg Dose of Norvasc®, [Pfizer, USA] in 18 Fed, Healthy Adult Subjects|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:49:18.313248|2018-06-01 00:49:18.313248
NCT00932867|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-04-19|2009-07-02|2009-07-03|Estimate|||||||2010-04-19|2010-04-20|Estimate|December 2007||2007-12-31|April 2010|2010-04-30|August 2009|Actual|2009-08-31|June 2008|Actual|2008-06-30||Observational|SONAR||Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment|Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment|Completed|||3114|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 00:49:18.362969|2018-06-01 00:49:18.362969
NCT00932854|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2011-10-17|2009-07-02|2009-07-03|Estimate|||||||2011-10-17|2011-10-18|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|October 2011|Anticipated|2011-10-31|April 2011|Actual|2011-04-30||Interventional|REMEDY||A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY)|A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of Isolated MEDiastinal lymphadenopathY (REMEDY)|Unknown status|Active, not recruiting|N/A|75|Anticipated|University College London Hospitals||1|||f||||f||||||||||2018-06-01 00:49:18.432911|2018-06-01 00:49:18.432911
NCT00932841|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-03-16|2009-07-02|2009-07-03|Estimate|||||||2012-03-16|2012-03-20|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|VSL#3||The Use of VSL#3 in Irritable Bowel Syndrome in Children|The Use of VSL#3 in Irritable Bowel Syndrome in Children|Terminated||Phase 1|15|Actual|Dayton Children's Hospital||3||PI has re-located. PI terminated FDA IND # and closed study.|f||||t||||||||||2018-06-01 00:49:18.531522|2018-06-01 00:49:18.531522
NCT00932828|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2018-02-01||2018-04-20|2009-07-02|2009-07-03|Estimate|2018-04-20|2018-05-24|Actual||||2018-04-20|2018-05-24|Actual|June 22, 2009|Actual|2009-06-22|February 2018|2018-02-28|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|DEVIL||Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study|"Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study; Grant Optimizing Tolerance Induction in Peanut Allergy: The DEVIL Study"|Completed||Phase 2|37|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-06-01 00:49:18.621707|2018-06-01 00:49:18.621707
NCT00932802|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-11-16|2009-07-02|2009-07-03|Estimate|||||||2012-11-16|2012-11-19|Estimate|February 2004||2004-02-29|November 2012|2012-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|GIANT||Greatest International Antiinfective Trial With Avelox|GIANT - Greatest International Antiinfective Trial With Avelox®|Completed|||50000|Actual|Bayer|||1||f||||t||||||||||2018-06-01 00:49:18.88637|2018-06-01 00:49:18.88637
NCT00932789|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2010-07-16|2009-07-02|2009-07-03|Estimate|||||||2010-07-16|2010-07-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:49:18.991924|2018-06-01 00:49:18.991924
NCT00932776|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-07-02|2009-07-02|2009-07-03|Estimate|||||||2009-07-02|2009-07-03|Estimate||||July 2009|2009-07-31||||||||Interventional|||Tracheobronchial Secretion Removal||Completed||N/A|||University of Milano Bicocca||2|||f||||||||||||||2018-06-01 00:49:19.024758|2018-06-01 00:49:19.024758
NCT00932763|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-15|2009-07-02|2009-07-03|Estimate|||||||2009-07-15|2009-07-17|Estimate||||July 2009|2009-07-31||||||||Interventional|||Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 22 Fasted, Healthy Adult Subjects|An Open-Label, Randomized, Two-Way Crossover, Single Dose Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited, India) Compared to a 10 mg Dose of Norvasc® (Pfizer, USA) in 22 Fasted, Healthy Adult Subjects|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-06-01 00:49:19.083758|2018-06-01 00:49:19.083758
NCT00932750|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-08-21|2009-07-02|2009-07-03|Estimate|||||||2012-08-21|2012-08-22|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|MOS||Study of Coffee Mannooligosaccharides for Weight Management|THE EFFECTS OF COFFEE MANNOOLIGOSACCHARIDES ON INDICES OF BODY WEIGHT, BODY COMPOSITION, AND SATIETY IN HUMANS|Completed||N/A|82|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-06-01 00:49:19.132372|2018-06-01 00:49:19.132372
NCT00932737|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17||2014-04-30|2014-04-30|2009-07-01|2009-07-03|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|June 2009||2009-06-30|October 2013|2013-10-31||||February 2010|Actual|2010-02-28||Interventional|||(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis|A Double-blind, Placebo-controlled, Randomized, Parallel-group Pilot Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used on Demand for the Treatment of Self-reported Functional Abdominal Pain Associated With Cramping|Completed||Phase 2|197|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:49:19.200618|2018-06-01 00:49:19.200618
NCT00932724|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2013-07-09|2009-07-02|2009-07-03|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|CY503C2||CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer|Phase II Double-blind Placebo-controlled Trial of CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Cancer|Terminated||Phase 2|77|Actual|Cytavis Biopharma GmbH||2||The sponsor declared the early termination of the study due to poor recruitment of patients.|f||||t||||||||||2018-06-01 00:49:19.301993|2018-06-01 00:49:19.301993
NCT00932711|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-07-02|2009-07-02|2009-07-03|Estimate|||||||2009-07-02|2009-07-03|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|July 2011|Anticipated|2011-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Effect of Educational Intervention in Patients With Low-Risk Chronic Obstructive Pulmonary Disease|Limited Intervention in Low Risk(Tier 3) COPD Patients|Unknown status|Enrolling by invitation|N/A|4000|Anticipated|Minneapolis Veterans Affairs Medical Center||1|||f||||f||||||||||2018-06-01 00:49:19.412778|2018-06-01 00:49:19.412778
NCT00932698|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2014-05-23|2009-07-02|2009-07-03|Estimate|||||||2014-05-23|2014-05-26|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Multiple Myeloma|An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma|Completed||Phase 1|60|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:49:19.752616|2018-06-01 00:49:19.752616
NCT00932685|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-02|2009-07-02|2009-07-03|Estimate|||||||2009-07-02|2009-07-03|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Does Distraction With a Hand Held Video Game Reduce Preoperative and Emergence Anxiety in Children?|Is Preoperative Distraction With a Hand Held Video Game Boy as Effective as Midazolam in Reducing Preoperative Anxiety Levels in Children as Weel as Emergence Agitation?|Completed||N/A|119|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 00:49:19.850254|2018-06-01 00:49:19.850254
NCT00932672|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2015-12-04|2009-07-02|2009-07-03|Estimate|||||||2015-12-04|2015-12-07|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Atkins Diet and Prostate Cancer Clinical Trial|Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer|Terminated||Phase 2|45|Actual|Duke University||2||slow recruitment, lack of funding and PI transferred|f||||f||||||||||2018-06-01 00:49:19.924858|2018-06-01 00:49:19.924858
NCT00932659|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2012-12-13||2013-04-11|2009-07-02|2009-07-03|Estimate|2013-02-19|2013-03-27|Estimate||||2013-04-11|2013-04-19|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|CARE-ESRD||Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients|Characterization of Cardiac Arrhythmias in End Stage Kidney Disease Patients on Hemodialysis Using an Implantable Continuous Cardiac Rhythm Monitoring Device: A Pilot Study|Completed|||8|Actual|Duke University|This is the 1st study of an implantable cardiac monitor in HD patients. Despite minimally invasive device implantation,collaboration between cardiology and nephrology, a large population of available subjects, we were able to enroll only 8 patients.||1||f||||t||||||||||2018-06-01 00:49:20.017404|2018-06-01 00:49:20.017404
NCT00932646|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2014-03-28||2016-01-11|2009-07-02|2009-07-03|Estimate|2014-05-27|2014-06-27|Estimate||||2016-01-11|2016-02-05|Estimate|June 2009||2009-06-30|January 2016|2016-01-31||||May 2010|Actual|2010-05-31||Interventional||Treated set, i.e. all treated patients.|Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease|Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|100|Actual|Boehringer Ingelheim|"Safety assessments are potentially confounded by both crossover and long washout periods~Comparisons of active groups for the 12 to 24 hr period overestimate the effect of Foradil (sleeping period causing an overestimation of AUC)"|4|||f||||||||||||||2018-06-01 00:49:20.213755|2018-06-01 00:49:20.213755
NCT00932633|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2016-02-08|2009-07-02|2009-07-03|Estimate|||||||2016-02-08|2016-02-10|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|CHD Brain||Magnetic Resonance Imaging (MRI) to Evaluate Brain Injury in Congenital Heart Disease|Role of Inflammatory Response in Brain Injury Following Neonatal Cardiac Surgery|Completed|||92|Actual|Emory University|||||f||||t||||||Samples With DNA|"~     dried blood spot sample~   "|Undecided||2018-06-01 00:49:20.983385|2018-06-01 00:49:20.983385
NCT00932620|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|2011-06-13||2011-08-17|2009-07-02|2009-07-03|Estimate|2011-07-19|2011-08-12|Estimate||||2011-08-17|2011-08-19|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)|THE EFFECT OF SIMVASTATIN VERSUS COMBINED SIMVASTATIN/EZETIMIBE TREATMENT ON THE CONCENTRATION OF SMALL DENSE LOW-DENSITY LIPOPROTEIN PARTICLES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA|Completed||Phase 4|100|Actual|University of Ioannina|Limitations of our study include its open-label design and the lack of clinical endpoints. However, all laboratory determinations were performed blindly with regard to treatment allocation.|2|||f||||f||||||||||2018-06-01 00:49:21.053629|2018-06-01 00:49:21.053629
NCT00932607|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-02-06|2009-07-02|2009-07-03|Estimate|||||||2012-02-06|2012-02-07|Estimate|July 2009||2009-07-31|February 2012|2012-02-29||||February 2010|Actual|2010-02-28||Interventional|||SUBLIVAC® Birch PROBE Study|SUBLIVAC® Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study|Completed||Phase 2|74|Actual|HAL Allergy||2|||f||||t||||||||||2018-06-01 00:49:21.270364|2018-06-01 00:49:21.270364
NCT00932594|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2015-05-19|2009-07-02|2009-07-03|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|December 2026|Anticipated|2026-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The New Serial Treatment of Temporomandibular Disorders|Create the New Serial Treatment of Temporomandibular Disorders|Recruiting||N/A|4|Anticipated|Sun Yat-sen University||8|||f||||t||||||||||2018-06-01 00:49:21.333128|2018-06-01 00:49:21.333128
NCT00929032|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-10-19|2009-06-25|2009-06-26|Estimate|||||||2010-10-19|2010-10-20|Estimate|September 2009||2009-09-30|October 2010|2010-10-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Liver Transplantation and Reticuloendothelial Clearance Capacity|The Impact of Liver Transplantation on Reticuloendothelial Clearance Capacity|Completed|||12|Anticipated|University of Edinburgh|||1||f||||f||||||||||2018-06-01 00:50:33.057051|2018-06-01 00:50:33.057051
NCT00932581|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2010-11-01|2009-07-02|2009-07-03|Estimate|||||||2010-11-01|2010-11-02|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|Bravura||Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties|Investigation of the Psychometric Properties of the Bradykinesia Subscale When Administered Alone Versus as a Component of the Entire Motor Examination Section of the Unified Parkinson's Disease Rating Scale|Completed|||110|Actual|Teva Pharmaceutical Industries|||2||f||||f||||||||||2018-06-01 00:49:21.406377|2018-06-01 00:49:21.406377
NCT00932555|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2012-03-13|2009-07-02|2009-07-03|Estimate|||||||2012-03-13|2012-03-14|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|||||Observational|||EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan|EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan|Completed|||82|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:49:21.460566|2018-06-01 00:49:21.460566
NCT00932542|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2012-10-08|2009-07-02|2009-07-03|Estimate|||||||2012-10-08|2012-10-10|Estimate|April 2010||2010-04-30|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|February 2011|Actual|2011-02-28||Interventional|CRT054||Eutectic Mixture for Hemorrhoidectomy Postoperative|"Topic Effects of Eutectic Mixture Use in Local Anesthetics on Hemorrhoidectomy Postoperative (Prospective Study, Randomized, Triple Blind, Placebo-controlled)"|Unknown status|Active, not recruiting|Phase 2/Phase 3|144|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-06-01 00:49:21.515266|2018-06-01 00:49:21.515266
NCT00932529|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2010-05-24|2009-07-02|2009-07-03|Estimate|||||||2010-05-24|2010-05-25|Estimate|February 2003||2003-02-28|December 2003|2003-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|BPP||Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting|Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.|Completed||Phase 4|226|Actual|University of Bergen||4|||f||||t||||||||||2018-06-01 00:49:21.70394|2018-06-01 00:49:21.70394
NCT00932516|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-07-02|2009-07-02|2009-07-03|Estimate|||||||2009-07-02|2009-07-03|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women|The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to a Traditional Calorie-Restricted Diet in Non-Diabetic Women|Completed||N/A|248|Actual|Mondelēz International, Inc.||4|||f||||f||||||||||2018-06-01 00:49:21.78437|2018-06-01 00:49:21.78437
NCT00932503|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2012-06-13|2009-07-01|2009-07-03|Estimate|||||||2012-06-13|2012-06-14|Estimate|October 2003||2003-10-31|June 2012|2012-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Antiseptic Sutures and Wound Infection|Do Triclosan Coated Sutures Reduce Wound Infections After Hepatobiliary Surgery? A Prospective Non Randomized Clinical Pathway Driven Study.|Completed||N/A|839|Actual|University Hospital, Saarland||2|||f||||f||||||||||2018-06-01 00:49:21.859761|2018-06-01 00:49:21.859761
NCT00932490|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2014-07-14|2009-07-02|2009-07-03|Estimate|||||||2014-07-14|2014-07-15|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Tailored Intervention Protocol for Oral Chemotherapy Adherence|Tailored Intervention Protocol for Oral Chemotherapy Adherence|Completed||N/A|48|Actual|Duke University||2|||f||||t||||||||||2018-06-01 00:49:21.933154|2018-06-01 00:49:21.933154
NCT00932477|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2011-11-09||2015-08-17|2009-07-02|2009-07-03|Estimate|2011-11-09|2011-12-13|Estimate||||2015-08-17|2015-08-26|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety and Tolerability of Artificial Tears in Dry Eye Subjects|Safety and Tolerability of Artificial Tears in Dry Eye Subjects|Completed||N/A|47|Actual|Allergan||3|||f||||f||||||||||2018-06-01 00:49:22.019584|2018-06-01 00:49:22.019584
NCT00932464|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2012-05-10|2009-07-01|2009-07-03|Estimate|||||||2012-05-10|2012-05-14|Estimate|August 2012||2012-08-31|May 2012|2012-05-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib|An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study To Determine The Effect Of A High-Fat Meal On The Relative Bioavailability And Pharmacokinetics Of A Single Dose Of The 240 mg Formulation Of Neratinib In Healthy Subjects|Withdrawn||Phase 1|0|Actual|Puma Biotechnology, Inc.||2||Study withdrawn as it no longer is deemed necessary per project status.|f||||f||||||||||2018-06-01 00:49:22.377817|2018-06-01 00:49:22.377817
NCT00932451|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2016-03-14||2016-11-17|2009-07-02|2009-07-03|Estimate|2016-04-28|2016-06-09|Estimate||||2016-11-17|2017-01-13|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional||An Investigational Use Only (IUO) population (N=908) was all participants whose non-small cell lung cancer (NSCLC) was Fluorescent In-Situ Hybridization (FISH) ALK (Anaplastic Lymphoma Receptor Tyrosine Kinase) (+) by the central laboratory. A non‑IUO population (N=158) was all partcipants whose NSCLC was ALK (+) by local assay testing.|An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene|Phase 2, Open-label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus|Completed||Phase 2|1069|Actual|Pfizer|Pharmacogenetic analysis of renal adverse events was not performed as no gene alleles have been identified in published literature with statistically significant association with renal toxicity to support a case control association analysis.|1|||f||||t||||||||||2018-06-01 00:49:22.567732|2018-06-01 00:49:22.567732
NCT00932438|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2013-04-17|2009-07-02|2009-07-03|Estimate|||||||2013-04-17|2013-04-18|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DEBIRI||Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic FOLFOX6|Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy|Completed||Phase 1/Phase 2|70|Actual|University of Louisville||2|||f||||t||||||||||2018-06-01 00:49:25.322871|2018-06-01 00:49:25.322871
NCT00932425|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2015-02-12||2015-02-12|2009-07-02|2009-07-03|Estimate|2015-02-12|2015-02-27|Estimate||||2015-02-12|2015-02-27|Estimate|September 2009||2009-09-30|February 2015|2015-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|CMACS|per protocol|Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)|Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS): A Pilot Randomized Trial|Completed||N/A|40|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:49:25.415025|2018-06-01 00:49:25.415025
NCT00932217|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2009-07-02|2009-07-02|2009-07-03|Estimate|||||||2009-07-02|2009-07-03|Estimate|December 2004||2004-12-31|February 2009|2009-02-28||||April 2007|Actual|2007-04-30||Interventional|||Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma|Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma|Unknown status|Active, not recruiting|Phase 3|180|Actual|University of Pisa||2|||f||||t||||||||||2018-06-01 00:49:29.351365|2018-06-01 00:49:29.351365
NCT00932412|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2016-09-20|2009-07-02|2009-07-03|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CLARA||The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)|A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA)Versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML).|Completed||Phase 2|735|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 00:49:25.629361|2018-06-01 00:49:25.629361
NCT00932399|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2014-10-02||2016-01-13|2009-07-01|2009-07-03|Estimate|2014-10-06|2014-10-07|Estimate||||2016-01-13|2016-02-08|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|August 2010|Actual|2010-08-31||Observational|||Longitudinal Study of Weight Change Following Lower Limb Amputation|Weight Change, Physical Activity and Health Promotion in Veteran Amputees|Completed|||4549|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-06-01 00:49:25.880526|2018-06-01 00:49:25.880526
NCT00932386|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2015-04-23|2009-07-02|2009-07-03|Estimate|||||||2015-04-23|2015-04-24|Estimate|July 2009||2009-07-31|April 2015|2015-04-30||||July 2011|Anticipated|2011-07-31||Interventional|||Effects of Dexmedetomidine on Tourniquet Pain Associated With Lower Extremity Surgeries Under General Anesthesia|The Effects of Dexmedetomidine on Tourniquet Pain Associated With Lower Extremity Surgeries Under General Anesthesia in Same Day Elective Patients|Withdrawn||Phase 4|0|Actual|Rutgers, The State University of New Jersey||2||unable to secure funding for analysis of laboratory data.|f||||f||||||||||2018-06-01 00:49:26.047296|2018-06-01 00:49:26.047296
NCT00932373|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2015-07-01||2015-08-13|2009-07-02|2009-07-03|Estimate|2015-07-02|2015-07-30|Estimate||||2015-08-13|2015-08-26|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||All summaries were based on data from the safety population (patients who received at least one dose of Trastuzumab-MCC-DM1). All summaries were presented for all patients and by dose level and schedule.|A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Trastuzumab-MCC-DM1 (PRO132365) Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen|Completed||Phase 1|54|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 00:49:26.167471|2018-06-01 00:49:26.167471
NCT00932360|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2010-04-21|2009-07-02|2009-07-03|Estimate|||||||2010-04-21|2010-04-22|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|TENS&FM||Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)|Transcutaneous Electrical Nerve Stimulation (TENS) and Fibromyalgia (FM)|Unknown status|Recruiting|N/A|50|Anticipated|University of Iowa||3|||f||||t||||||||||2018-06-01 00:49:27.965443|2018-06-01 00:49:27.965443
NCT00932347|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2011-07-21|2009-07-02|2009-07-03|Estimate|||||||2011-07-21|2011-07-22|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Effect of Mouthwash Containing Camellia Sinensis Extracts on Oral Malodor|Effect of Mouthwash Containing Camellia Sinensis Extracts on Oral Malodor, Plaque and Papillary Bleeding Indices in Gingivitis Patients.|Completed||Phase 2|60|Anticipated|Mahidol University||2|||f||||t||||||||||2018-06-01 00:49:28.079171|2018-06-01 00:49:28.079171
NCT00932334|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2017-12-07|2009-07-02|2009-07-03|Estimate|||||||2017-12-07|2017-12-11|Actual|February 2009||2009-02-28|December 2017|2017-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|TALK||Culturally Sensitive Behavioral Interventions to Enhance Living Kidney Donation / Living Kidney Transplantation|Culturally Sensitive Behavioral Interventions to Enhance Living Kidney Donation / Living Kidney Transplantation|Completed||N/A|145|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-06-01 00:49:28.139684|2018-06-01 00:49:28.139684
NCT00932321|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2011-02-22||2013-04-15|2009-07-01|2009-07-03|Estimate|2011-02-22|2011-03-22|Estimate||||2013-04-15|2013-04-22|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study of Safety and Efficacy of an Oral Contraceptive|Open Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate (NA) and Ethinyl Estradiol (EE)|Completed||Phase 3|938|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 00:49:28.209124|2018-06-01 00:49:28.209124
NCT00932308|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2012-02-15|2009-07-01|2009-07-03|Estimate|||||||2012-02-15|2012-02-17|Estimate|September 2006||2006-09-30|February 2012|2012-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Colorectal Inflammatory Response to a Western-Style Diet|Colorectal Inflammatory Response to a Western-Style Diet|Completed||N/A|5|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 00:49:28.596386|2018-06-01 00:49:28.596386
NCT00932295|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-02|||2016-12-12|2009-07-02|2009-07-03|Estimate|||||||2016-12-12|2016-12-13|Estimate|February 2009||2009-02-28|December 2016|2016-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.|Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.|Completed||Phase 1/Phase 2|32|Actual|Virginia Commonwealth University||4|||f||||f||||||||||2018-06-01 00:49:28.677837|2018-06-01 00:49:28.677837
NCT00932282|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2017-07-31|2012-09-14|2018-02-27|2009-07-02|2009-07-03|Estimate|2017-09-25|2017-09-26|Actual|2012-09-14|2012-09-21|Estimate|2018-02-27|2018-03-01|Actual|July 2009||2009-07-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PAIE/Xolair||Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy|Peanut OIT & Anti-IgE: Peanut Oral Immunotherapy and Anti-IgE Treatment for Peanut Allergy {NIH R21 Combined Peanut Oral Immunotherapy and Anti-IgE: Mechanistic Studies}|Completed||Phase 1/Phase 2|13|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:49:28.771237|2018-06-01 00:49:28.771237
NCT00932269|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-07-01|2009-07-01|2009-07-03|Estimate|||||||2009-07-01|2009-07-03|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|September 2011|Anticipated|2011-09-30|May 2008|Actual|2008-05-31||Observational|Sero 2007||Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease|Seroimmunity 2007. Serological Study of the Swedish Population Regarding Vaccine Preventable Diseases Within the National Immunization Program (NIP), and a Sub Study Focusing on Foreign Born 14-16 Year-Olds.|Unknown status|Active, not recruiting||5400|Anticipated|Swedish Institute for Infectious Disease Control|||2||f||||t||||||||||2018-06-01 00:49:29.036777|2018-06-01 00:49:29.036777
NCT00932256|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2010-12-06|2009-07-02|2009-07-03|Estimate|||||||2010-12-06|2010-12-08|Estimate|October 2009||2009-10-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients|STAHIST IND 105781 Phase 1 Clinical Trial|Completed||Phase 1|21|Actual|Magna Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 00:49:29.100576|2018-06-01 00:49:29.100576
NCT00757094|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2010-02-24|2008-09-19|2008-09-22|Estimate|||||||2010-02-24|2010-02-25|Estimate|September 2008||2008-09-30|February 2010|2010-02-28|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Observational|||Safety and Feasibility of Fasting While Receiving Chemotherapy|Safety and Feasibility of Fasting While Receiving Chemotherapy|Completed|||12|Actual|King Fahad Medical City|||1||f||||f||||||||||2018-06-01 01:44:35.817094|2018-06-01 01:44:35.817094
NCT00932204|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-02|2009-07-02|2009-07-03|Estimate|||||||2009-07-02|2009-07-03|Estimate|February 2007||2007-02-28|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders|A Randomized, Controlled Study of Sequentially Applied Repetitive Transcranial Magnetic Stimulation in Obsessive- Compulsive Disorders|Completed||Phase 3|21|Actual|Severance Hospital||2|||f||||t||||||||||2018-06-01 00:49:29.413543|2018-06-01 00:49:29.413543
NCT00932191|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2014-08-21|2009-07-02|2009-07-03|Estimate|||||||2014-08-21|2014-08-25|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Endothelial Cell Loss After Cataract Surgery|Endothelial Cell Loss After Cataract Surgery: Comparison of a Reduced Ultrasound Technique Versus Standard Ultrasound Technique|Terminated||Phase 2/Phase 3|39|Actual|University of California, San Francisco||2||Stopped for lack of funds|f||||f||||||||||2018-06-01 00:49:29.478632|2018-06-01 00:49:29.478632
NCT00932178|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2018-01-18|2009-07-01|2009-07-03|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2009||2009-04-30|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Calmer Life: A Worry Reduction Program for Older Adults|Calmer Life: A Worry Reduction Program for Older Adults|Completed||N/A|32|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 00:49:29.5426|2018-06-01 00:49:29.5426
NCT00932165|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2009-11-13||2010-07-13|2009-07-02|2009-07-03|Estimate|2010-05-25|2010-06-24|Estimate||||2010-07-13|2010-07-20|Estimate|December 2004||2004-12-31|July 2010|2010-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin|Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan)|Completed|||451|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:49:29.610305|2018-06-01 00:49:29.610305
NCT00932152|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2016-01-14||2017-09-18|2009-07-02|2009-07-03|Estimate|2016-07-19|2016-08-31|Estimate||||2017-09-18|2017-10-19|Actual|September 2010||2010-09-30|September 2017|2017-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer|A Phase II Randomized Trial of Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer Who Have Received First-line Platinum-based Chemotherapy With or Without Bevacizumab|Terminated||Phase 2|3|Actual|University of Pittsburgh||4||Poor enrollment/suspended to accrual; will close per AstraZeneca request|f||||t||||||||||2018-06-01 00:49:30.089548|2018-06-01 00:49:30.089548
NCT00932139|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2018-03-16|2009-07-02|2009-07-03|Estimate|||||||2018-03-16|2018-03-19|Actual|February 2003||2003-02-28|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effect of Electro-Acupuncture on Blood Pressure|Neural Mechanism of the Effect of Acupuncture on Myocardial Ischemia|Recruiting||N/A|160|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-06-01 00:49:30.350849|2018-06-01 00:49:30.350849
NCT00932126|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2012-12-11||2015-10-06|2009-07-02|2009-07-03|Estimate|2013-01-30|2013-03-06|Estimate||||2015-10-06|2015-10-28|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors|Phase 1, Open Label, Dose-Escalation, Safety, Pharmacokinetic And Pharmacodynamic Study Of Single Agent PF-03758309, An Oral PAK4 Inhibitor, In Patients With Advanced Solid Tumors|Terminated||Phase 1|35|Actual|Pfizer|The study was closed due to pharmacokinetic (PK) issues observed from initial PK data. Individual plasma concentration versus time were listed but final PK analysis and pharmacodynamic analyses were not conducted.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:49:30.503915|2018-06-01 00:49:30.503915
NCT00932113|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2016-09-27||2017-08-01|2009-07-01|2009-07-03|Estimate|2017-06-01|2017-07-02|Actual||||2017-08-01|2017-08-31|Actual|June 2009||2009-06-30|August 2017|2017-08-31|May 1, 2017|Actual|2017-05-01|December 2011|Actual|2011-12-31||Interventional|MOA||Mechanism of Action Study for Psoriasis|An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis.|Completed||Phase 4|33|Actual|Tufts Medical Center||2|||f||||f||||||||No||2018-06-01 00:49:31.6131|2018-06-01 00:49:31.6131
NCT00932100|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2012-03-01|2009-07-02|2009-07-03|Estimate|||||||2012-03-01|2012-03-02|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|RADAR||A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome|A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome|Completed||Phase 2|640|Actual|Regado Biosciences, Inc.||5|||f||||t||||||||||2018-06-01 00:49:32.941688|2018-06-01 00:49:32.941688
NCT00932087|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-04-12|2009-07-01|2009-07-02|Estimate|||||||2010-04-12|2010-04-13|Estimate|February 2009||2009-02-28|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|ECLIPSE||Characterization of Low Density Lipoprotein and Mechanism of the Pro Aggregant Effect Through Oxidant Stress and Lipid Exchange|Characterization of Low Density Lipoprotein and Mechanism of the Pro Aggregant Effect Through Oxidant Stress and Lipid Exchange|Completed|||48|Anticipated|Hospices Civils de Lyon|||4||f||||f||||||||||2018-06-01 00:49:33.707639|2018-06-01 00:49:33.707639
NCT00932074|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-04-04|2009-06-30|2009-07-02|Estimate|||||||2012-04-04|2012-04-06|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study to Determine the Safety, Tolerability and Efficacy of KP‑413 in Subjects With Atopic Dermatitis(AD)|A Phase 1/2 Study Evaluating the Safety, Tolerability and Efficacy of KP-413 Topical Ointment in Subjects With Atopic Dermatitis|Completed||Phase 1/Phase 2|58|Actual|Kaken Pharmaceutical||3|||f||||f||||||||||2018-06-01 00:49:34.011737|2018-06-01 00:49:34.011737
NCT00932061|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2013-07-18|2009-07-01|2009-07-02|Estimate|||||||2013-07-18|2013-07-19|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Biomarkers||Developing Biomarkers for Fibromyalgia|Developing Biomarkers for Fibromyalgia|Completed||N/A|105|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:49:34.311312|2018-06-01 00:49:34.311312
NCT00932048|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2013-09-05|2009-07-01|2009-07-02|Estimate|||||||2013-09-05|2013-09-06|Estimate|August 2011||2011-08-31|July 2009|2009-07-31|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|||Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes|Effect of Atorvastatin on Vascular Inflammation in Type 2 Diabetes: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography|Withdrawn||N/A|0|Actual|Korea University||2|||f||||t||||||||||2018-06-01 00:49:34.649594|2018-06-01 00:49:34.649594
NCT00930644|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2014-12-16||2015-11-10|2009-06-29|2009-06-30|Estimate|2014-12-16|2014-12-24|Estimate||||2015-11-10|2015-12-08|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)|A Long-Term, Open-Label Study With Teduglutide for Subjects With Parenteral Nutrition Dependent Short Bowel Syndrome|Completed||Phase 3|88|Actual|Shire||1|||f||||t||||||||||2018-06-01 00:50:03.673131|2018-06-01 00:50:03.673131
NCT00932035|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2016-12-09||2017-05-05|2009-06-30|2009-07-02|Estimate|2017-05-05|2017-06-07|Actual||||2017-05-05|2017-06-07|Actual|June 2009||2009-06-30|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer|Reducing Extremity Lymphedema Through Axillary Lymphatic Preservation Surgery|Terminated||Phase 1/Phase 2|39|Actual|City of Hope Medical Center|Study was terminated early due to loss of principal investigator. As a result accrual of subjects and data collection are incomplete.|2||Loss of principal investigator|f||||t||||||||||2018-06-01 00:49:34.993487|2018-06-01 00:49:34.993487
NCT00932022|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2012-12-14||2012-12-14|2009-07-01|2009-07-02|Estimate|2012-12-14|2013-01-21|Estimate||||2012-12-14|2013-01-21|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Trospium Chloride XR in Obese Female Patients With Overactive Bladder||Completed||Phase 4|127|Actual|Allergan|Due to lack of evaluable data, analysis for the secondary outcome measures was not performed.|2|||f||||f||||||||||2018-06-01 00:49:36.2516|2018-06-01 00:49:36.2516
NCT00932009|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2015-08-07|2009-06-30|2009-07-02|Estimate|||||||2015-08-07|2015-08-11|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Observational|||Prevalence and Type Distribution of Human Papillomavirus (HPV) in Tanzanian Men|Prevalence and Type Distribution of Genital Human Papillomavirus (HPV) in Tanzanian Men|Completed|||1933|Actual|Danish Cancer Society|||1||f||||f||||||Samples With DNA|"~     cell scrapes from penis~   "|||2018-06-01 00:49:36.978983|2018-06-01 00:49:36.978983
NCT00931996|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2011-11-08||2013-01-23|2009-07-01|2009-07-02|Estimate|2013-01-23|2013-01-24|Estimate||||2013-01-23|2013-01-24|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Oculomotor and Spatial Cognition Deficits in Schizophrenia|Clinical and Computational Studies of Dopamine Function in Schizophrenia|Terminated||N/A|12|Actual|University of Illinois at Chicago|Early termination leading to small numbers of subjects analyzed|1||Study was terminated due to low accrual.|f||||f||||||||||2018-06-01 00:49:37.045883|2018-06-01 00:49:37.045883
NCT00931983|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2011-12-13|2009-07-01|2009-07-02|Estimate|||||||2011-12-13|2011-12-14|Estimate|March 2009||2009-03-31|July 2011|2011-07-31||||||||Observational|||The Effect of Locomotor Training on Children With Incomplete Spinal Cord Injuries|The Effect of Locomotor Training on Children With Incomplete Spinal Cord Injuries|Withdrawn|||0|Actual|McGill University|||||f||||t||||||||||2018-06-01 00:49:37.250025|2018-06-01 00:49:37.250025
NCT00931970|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2018-03-06|2009-07-01|2009-07-02|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2009||2009-07-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Mode of Dialysis Therapy and Outcomes in End Stage Renal Disease (ESRD)|Comprehensive Prospective Study for Mode of Dialysis Therapy and Outcomes in ESRD|Recruiting|||5400|Anticipated|Clinical Research Center for End Stage Renal Disease, Korea|||1||f||||t||||||Samples With DNA|"~     Serum Whole blood Urine Dialysate~   "|No||2018-06-01 00:49:37.365174|2018-06-01 00:49:37.365174
NCT00931957|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2010-11-19|2009-06-30|2009-07-02|Estimate|||||||2010-11-19|2010-11-22|Estimate|October 2010||2010-10-31|November 2010|2010-11-30|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease|Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease|Unknown status|Recruiting|N/A|80|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:49:37.686087|2018-06-01 00:49:37.686087
NCT00931944|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30||2014-10-13|2017-12-13|2009-06-30|2009-07-02|Estimate||||2014-10-13|2014-10-22|Estimate|2017-12-13|2017-12-15|Actual|July 2009||2009-07-31|November 2017|2017-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|CL211||Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)|An Open-Label, Safety and Tolerability, Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|74|Actual|Knopp Biosciences||1|||f||||f||||||||||2018-06-01 00:49:37.786967|2018-06-01 00:49:37.786967
NCT00931931|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2018-03-19|2009-06-30|2009-07-02|Estimate|||||||2018-03-19|2018-03-21|Actual|March 2010||2010-03-31|March 2018|2018-03-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|||HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors|A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors|Completed||Phase 1|18|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-06-01 00:49:37.881257|2018-06-01 00:49:37.881257
NCT00931918|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2016-08-11||2016-11-14|2009-07-01|2009-07-02|Estimate|2016-11-14|2017-01-11|Estimate||||2016-11-14|2017-01-11|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Intent-to-treat (ITT) Population included all randomized participants who had at least 1 dose of study drug.|Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients|An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients|Completed||Phase 2|206|Actual|Takeda||2|||f||||f||||||||||2018-06-01 00:49:38.037079|2018-06-01 00:49:38.037079
NCT00931905|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-07-31|2009-06-30|2009-07-02|Estimate|||||||2009-07-31|2009-08-03|Estimate||||July 2009|2009-07-31||||||||Interventional|||Homeopathic Preparation Plumbum Metallicum for Lead Poisoning|Effectiveness of the Homeopathic Preparation Plumbum Metallicum in Decreasing Blood Levels in Exposed Workers.|Completed||Phase 4|113||Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 00:49:39.021203|2018-06-01 00:49:39.021203
NCT00931892|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2017-08-18|2009-06-30|2009-07-02|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2009|Actual|2009-04-30|August 2017|2017-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Serum Markers in Gluten Challenge|Circulating Markers of Celiac Disease Activity During Gluten Challenge - a Pilot Study.|Completed||N/A|22|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 00:49:39.087935|2018-06-01 00:49:39.087935
NCT00931879|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2016-02-04||2017-03-28|2009-06-30|2009-07-02|Estimate|2017-03-28|2017-05-09|Actual||||2017-03-28|2017-05-09|Actual|October 2009||2009-10-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||The study was powered at 0.80 for a two-tail analysis with a sensitivity of a 30% delta in blood flow in 40 subjects. The standard deviation of the measurements was calculated at 45% of the treatment group mean. This assessment of variance could accommodate for 9% attrition or data loss in the study. 44 patients will be recruited in total.|Lovaza® and Microvascular Function in Type 2 Diabetes|The Role of Lovaza® on Microvascular Function and Lipoprotein Profile in Type 2 Diabetes|Completed||Phase 4|44|Actual|Eastern Virginia Medical School||2|||f||||f||||||||||2018-06-01 00:49:39.172661|2018-06-01 00:49:39.172661
NCT00930631|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2011-10-14|2009-06-29|2009-06-30|Estimate|||||||2011-10-14|2011-10-17|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|PPA103||Study of [3H] BMS747158 in Healthy Male Subjects|Pharmacokinetics, Metabolism and Elimination of Tritiated [3H] BMS747158 in Healthy Male Subjects|Completed||Phase 1|7|Actual|Lantheus Medical Imaging|||||f||||f||||||||||2018-06-01 00:50:04.442966|2018-06-01 00:50:04.442966
NCT00931866|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2010-08-12|2009-06-30|2009-07-02|Estimate|||||||2010-08-12|2010-08-16|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries|Completed||Phase 3|407|Actual|Cerimon Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:49:39.876581|2018-06-01 00:49:39.876581
NCT00931853|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2012-10-16|2009-07-01|2009-07-02|Estimate|||||||2012-10-16|2012-10-17|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).|National Study, Phase III, Parallel, Double Blind, Placebo Comparative and Randomized to Evaluate the Therapeutic Efficacy and Tolerability of the Combination Naturetti® (Cassia Fistula + Senna Alexandrina Miller) in the Chronic Functional Constipation|Completed||Phase 3|117|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:49:39.94583|2018-06-01 00:49:39.94583
NCT00931840|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2011-09-19|2009-06-30|2009-07-02|Estimate|||||||2011-09-19|2011-09-20|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|January 2012|Anticipated|2012-01-31|October 2011|Anticipated|2011-10-31||Interventional|||A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma|A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)|Unknown status|Active, not recruiting|Phase 2|220|Anticipated|Enzon Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-06-01 00:49:40.035593|2018-06-01 00:49:40.035593
NCT00931827|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2013-12-22|2009-06-30|2009-07-02|Estimate|||||||2013-12-22|2013-12-24|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Acceptability of Long-term Progestin-only Contraception in Europe|Acceptability of Long-term Progestin-only Contraception in Europe|Completed|||436|Actual|Bayer|||2||f||||f||||||||||2018-06-01 00:49:40.19618|2018-06-01 00:49:40.19618
NCT00931814|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-06|2009-07-01|2009-07-02|Estimate|||||||2009-07-06|2009-07-07|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Effects of Exercise on Depression Symptoms, Physical Function, and Quality of Life in Community-Dwelling Elderly|Effects of Exercise on Depression Symptoms, Physical Function, and Quality of Life in Community-Dwelling Elderly|Completed||N/A|50|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:49:40.362152|2018-06-01 00:49:40.362152
NCT00931801|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2013-02-05||2017-07-18|2009-07-01|2009-07-02|Estimate|2013-02-05|2013-03-11|Estimate||||2017-07-18|2017-07-21|Actual|December 2009||2009-12-31|July 2017|2017-07-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|BATAR||BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.|A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects With Virologic Suppression on a Standard Regimen of Boosted Atazanavir, Tenofovir and Emtricitabine|Completed||Phase 4|43|Actual|Community Research Initiative of New England||3|||f||||t||||||||||2018-06-01 00:49:40.453259|2018-06-01 00:49:40.453259
NCT00931788|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2015-04-21|2009-07-01|2009-07-02|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|PREVENTION||Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack|Preventing Recurrent Vascular Events and Neurological Worsening Through Intensive Organized Case-Management (PREVENTION) Trial|Completed||Phase 4|279|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 00:49:41.295132|2018-06-01 00:49:41.295132
NCT00931775|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-01|2009-07-01|2009-07-02|Estimate|||||||2009-07-01|2009-07-02|Estimate|December 2002||2002-12-31|July 2009|2009-07-31|November 2005|Actual|2005-11-30|March 2005|Actual|2005-03-31||Interventional|CIT-PIN||Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder|Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder|Completed||Phase 2|30|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-06-01 00:49:41.398467|2018-06-01 00:49:41.398467
NCT00931762|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2016-11-16|2009-07-01|2009-07-02|Estimate|||||||2016-11-16|2016-11-18|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis|Phase II Trial of Oral Panobinostat (LBH589), a Novel Deacetylase Inhibitor (DACi) in Patients With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post- Polycythemia Vera (PV) Myelofibrosis|Completed||Phase 2|35|Actual|Novartis||1|||f||||f||||||||||2018-06-01 00:49:41.480593|2018-06-01 00:49:41.480593
NCT00931749|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2010-06-08|2009-07-01|2009-07-02|Estimate|||||||2010-06-08|2010-06-09|Estimate|September 2009||2009-09-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Effects of Ultrasound Therapy on Cartilage Healing in Patients With Knee Osteoarthritis|The Effects of Low Intensity Ultrasound on Medial Tibial Cartilage Morphology in Patients With Mild or Moderate Knee Osteoarthritis: A Double Blind, Randomized Placebo-controlled Study.|Completed||Phase 2|27|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 00:49:41.61293|2018-06-01 00:49:41.61293
NCT00931736|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2017-12-15|2009-07-01|2009-07-02|Estimate|||||||2017-12-15|2017-12-19|Actual|August 2009|Actual|2009-08-31|December 2017|2017-12-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness|A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness|Completed||Phase 3|6031|Actual|McGill University||2|||f||||t||||||||Yes||2018-06-01 00:49:41.749067|2018-06-01 00:49:41.749067
NCT00931723|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2011-11-17||2012-03-27|2009-07-01|2009-07-02|Estimate|2012-03-27|2012-04-19|Estimate||||2012-03-27|2012-04-19|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Adult Bipolar Mania|An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium Versus Placebo as an Add on to SEROQUEL XR (Quetiapine Fumarate) in Adult Patients With Acute Mania|Completed||Phase 4|356|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:49:41.864131|2018-06-01 00:49:41.864131
NCT00931710|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2011-01-13||2011-03-01|2009-07-01|2009-07-02|Estimate|2011-01-13|2011-02-04|Estimate||||2011-03-01|2011-03-07|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|EXALT||Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension|A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension|Completed||Phase 4|488|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:49:43.259267|2018-06-01 00:49:43.259267
NCT00931697|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2010-07-30|2009-06-30|2009-07-02|Estimate|||||||2010-07-30|2010-08-03|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine|A Phase I Randomised, Double-Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine|Completed||Phase 1|46|Actual|Treague Ltd||3|||f||||t||||||||||2018-06-01 00:49:43.878606|2018-06-01 00:49:43.878606
NCT00931671|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-06|2009-07-01|2009-07-02|Estimate|||||||2009-07-06|2009-07-07|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Task-Oriented Aerobic Exercise Training in Chronic Stroke Patients|Effects of Task-Oriented Aerobic Exercise Training on Cardiorespiratory Fitness and Cerebral Blood Flow in Chronic Stroke Patients|Completed||N/A|40|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:49:43.949277|2018-06-01 00:49:43.949277
NCT00931645|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-07-01|2009-07-01|2009-07-02|Estimate|||||||2009-07-01|2009-07-02|Estimate|April 2001||2001-04-30|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|Auto-LLC 2001||Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia|Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia|Completed||Phase 3|241|Actual|University Hospital, Caen||4|||f||||t||||||||||2018-06-01 00:49:44.117173|2018-06-01 00:49:44.117173
NCT00931632|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2015-07-16||2017-10-30|2009-07-01|2009-07-02|Estimate|2015-07-16|2015-08-11|Estimate||||2017-10-30|2017-12-04|Actual|November 2009||2009-11-30|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants|Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth|Completed||Phase 3|451|Actual|Mallinckrodt||2|||f||||t||||||||||2018-06-01 00:49:44.249569|2018-06-01 00:49:44.249569
NCT00931619|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2018-05-19|2009-07-01|2009-07-02|Estimate|||||||2018-05-19|2018-05-22|Actual|June 29, 2009||2009-06-29|April 2, 2013|2013-04-02|April 2, 2013||2013-04-02|||||Observational|||GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression|GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression|Completed|||29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:49:45.001879|2018-06-01 00:49:45.001879
NCT00931606|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22||2017-11-14|2017-11-14|2009-07-01|2009-07-02|Estimate||||2017-11-14|2017-11-17|Actual|2017-11-14|2017-11-17|Actual|June 1, 2009|Actual|2009-06-01|November 2017|2017-11-30|November 18, 2010|Actual|2010-11-18|November 18, 2010|Actual|2010-11-18||Interventional|||Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer|A Phase 2, Double-blind, Randomized, Placebo-Controlled Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer|Terminated||Phase 2|30|Actual|Celgene||4||administrative reasons (slow patient enrollment)|f||||t||||||||Undecided||2018-06-01 00:49:45.085041|2018-06-01 00:49:45.085041
NCT00931593|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-01|2009-07-01|2009-07-02|Estimate|||||||2009-07-01|2009-07-02|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Transient Lower Esophageal Sphincter Relaxations and High Resolution Manometry|Transient Lower Esophageal Sphincter Relaxations Detection Using High Resolution Manometry. Validation in Healthy Volunteers.|Unknown status|Recruiting|N/A|24|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-06-01 00:49:45.193576|2018-06-01 00:49:45.193576
NCT00931580|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2015-09-23|2009-07-01|2009-07-02|Estimate|||||||2015-09-23|2015-09-25|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Vitamin D Needs of Early Adolescent Children|Supplemental Vitamin D and Functional Outcomes in Early Adolescence|Completed||N/A|323|Actual|University of Georgia||5|||f||||t||||||||||2018-06-01 00:49:45.266065|2018-06-01 00:49:45.266065
NCT00931567|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-03-19|2009-07-01|2009-07-02|Estimate|||||||2012-03-19|2012-03-20|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing|Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing|Completed||Phase 2/Phase 3|80|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 00:49:45.355711|2018-06-01 00:49:45.355711
NCT00931554|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-07-01|2009-07-01|2009-07-02|Estimate|||||||2009-07-01|2009-07-02|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|April 2008|Actual|2008-04-30|||||Interventional|||Randomized Trial of Early Versus Standard Drainage Removal After Pancreatic Resections|Early Versus Standard Drainage Removal After Pancreatic Resections: Results of a Prospective Randomized Clinical Trial|Completed||N/A|114|Actual|Universita di Verona||2|||f||||f||||||||||2018-06-01 00:49:45.442532|2018-06-01 00:49:45.442532
NCT00931541|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-09-09|2009-06-30|2009-07-02|Estimate|||||||2009-09-09|2009-09-10|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|||||Interventional|||AZD6088 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD6088 After Single Ascending Doses in Healthy Male and Non-Fertile Female Volunteers|Completed||Phase 1|35|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:49:45.650569|2018-06-01 00:49:45.650569
NCT00931528|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2016-04-18||2018-01-18|2009-06-30|2009-07-02|Estimate|2016-06-14|2016-07-27|Estimate||||2018-01-18|2018-02-14|Actual|November 2009||2009-11-30|January 2018|2018-01-31|November 2014|Actual|2014-11-30|December 2012|Actual|2012-12-31||Interventional||All randomized eligible patients.|Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy|A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer|Completed||Phase 3|242|Actual|Radiation Therapy Oncology Group|"The protocol endpoint Patient-related predictors of erectile function refers to modeling of the first two outcome measures, and is therefore reported as additional statistical analyses for those outcome measures."|2|||f||||t||||||||||2018-06-01 00:49:45.81197|2018-06-01 00:49:45.81197
NCT00931359|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-28|2011-04-15||2011-06-13|2009-06-30|2009-07-02|Estimate|2011-05-13|2011-06-14|Estimate||||2011-06-13|2011-06-15|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|DRI-UP||Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis|A Prospective, Multicenter, Parallel, Randomized, Blinded Study of the Efficacy and Safety of the DTS-G2 System in Patients With Axillary Hyperhidrosis|Completed||N/A|120|Actual|Miramar Labs|Sham subjects exited the study at 6 months, so group comparisons are not possible for later timepoints.|2|||f||||t||||||||||2018-06-01 00:49:51.05538|2018-06-01 00:49:51.05538
NCT00931515|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2014-04-15||2014-05-14|2009-06-30|2009-07-02|Estimate|2014-04-15|2014-05-15|Estimate||||2014-05-14|2014-05-26|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty|A Prospective, Multi-center, Randomized, Controlled Clinical Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty|Completed||N/A|30|Actual|Pioneer Surgical Technology, Inc.|Because the study was stopped after a total of 30 patients, demonstration of non-inferiority was impossible. Results from the 2 groups were compared using the Fisher exact test for categorical variables and ANOVA for continuous variables.|2|||f||||t||||||||||2018-06-01 00:49:47.480439|2018-06-01 00:49:47.480439
NCT00931502|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2018-03-01|2009-06-30|2009-07-02|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2008||2008-04-30|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Stent Thrombosis In Acute Coronary Syndromes|Contemporary Treatment Of Stent Thrombosis In Acute Coronary Syndromes|Completed|||800|Actual|University of California, Davis|||||f||||f||||||||||2018-06-01 00:49:47.759583|2018-06-01 00:49:47.759583
NCT00931489|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2017-04-14||2017-06-26|2009-06-30|2009-07-02|Estimate|2017-06-26|2017-07-02|Actual||||2017-06-26|2017-07-02|Actual|August 2009||2009-08-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Antibody|"Acute Non-responders (Group 3) had 5 subjects at baseline but increased at 6 month timepoint because 3 subjects originally enrolled into Group 1 (Responders) were deemed non-responders (had persistent subretinal fluid on Ocular Coherence Tomography) and were moved to Group 3."|Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)|Retinal and RPE Autoimmunity in AMD: Assessment of Correlation With Degree of Response to Ranibizumab Therapy|Completed||Phase 2|131|Actual|University of California, Davis||5|||f||||f||||||||No||2018-06-01 00:49:47.834561|2018-06-01 00:49:47.834561
NCT00931476|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2017-02-23|2009-06-30|2009-07-02|Estimate|||||||2017-02-23|2017-02-27|Actual|April 6, 2000|Actual|2000-04-06|February 2017|2017-02-28|June 8, 2000|Actual|2000-06-08|June 8, 2000|Actual|2000-06-08||Interventional|||A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin|A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group, Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Norditropin® (Norditropin® PenSet® 24)|Completed||Phase 1|86|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 00:49:48.427238|2018-06-01 00:49:48.427238
NCT00931463|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2013-10-14||2014-02-12|2009-07-01|2009-07-02|Estimate|2013-12-01|2014-01-17|Estimate||||2014-02-12|2014-03-13|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|August 2013|Actual|2013-08-31|September 2012|Actual|2012-09-30||Interventional|SECOND-LINE||A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen|A Randomised Open-label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-line NNRTI/2N(t)RTI Therapy|Completed||Phase 4|558|Actual|Kirby Institute||2|||f||||t||||||||||2018-06-01 00:49:48.619565|2018-06-01 00:49:48.619565
NCT00931450|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2013-08-09|2009-07-01|2009-07-02|Estimate|||||||2013-08-09|2013-08-12|Estimate|March 2009||2009-03-31|July 2009|2009-07-31||||October 2011|Anticipated|2011-10-31||Interventional|||Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer|Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer.|Unknown status|Recruiting|Phase 1/Phase 2|70|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:49:49.25331|2018-06-01 00:49:49.25331
NCT00931437|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2010-12-15|2009-06-30|2009-07-02|Estimate|||||||2010-12-15|2010-12-16|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Vitamin K-absorption From Dairy|Absorption of Different Forms of Vitamin K From Dairy Products|Completed||N/A|12|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 00:49:49.340126|2018-06-01 00:49:49.340126
NCT00931424|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-06-30|2009-06-30|2009-07-02|Estimate|||||||2009-06-30|2009-07-02|Estimate|January 2006||2006-01-31|May 2009|2009-05-31||||December 2015|Anticipated|2015-12-31||Interventional|||The Clinical Trial for Primary Chronic Venous Insufficiency|The Clinical Research of Surgery on Primary Chronic Venous Insufficiency|Unknown status|Recruiting|N/A|400|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 00:49:49.397252|2018-06-01 00:49:49.397252
NCT00931411|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2010-08-03||2011-09-18|2009-06-30|2009-07-02|Estimate|2011-01-11|2011-02-03|Estimate||||2011-09-18|2011-09-20|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis|Double-Blind Study of Tolerance and Moisturizers Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis Under Normal Conditions of Use|Terminated||N/A|73|Actual|Cosmetique Active International||2||Patients would improve naturally due to weather conditions|f||||f||||||||||2018-06-01 00:49:49.495286|2018-06-01 00:49:49.495286
NCT00931398|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-08-23|2009-07-01|2009-07-02|Estimate|||||||2012-08-23|2012-08-24|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate|Treatment of College Students With ADHD Using OROS Methylphenidate|Withdrawn||Phase 4|0|Actual|University of Pittsburgh||2||Study was not initiated due to lack of funding by the sponsor|f||||t||||||||||2018-06-01 00:49:50.034585|2018-06-01 00:49:50.034585
NCT00931385|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2014-03-28||2014-05-29|2009-07-01|2009-07-02|Estimate|2014-05-29|2014-07-01|Estimate||||2014-05-29|2014-07-01|Estimate|June 2009||2009-06-30|May 2014|2014-05-31||||April 2010|Actual|2010-04-30||Interventional||Treated set, i.e., all treated patients.|Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease|Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil Iin Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|99|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 00:49:50.170137|2018-06-01 00:49:50.170137
NCT00931372|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-02-22|2009-06-30|2009-07-02|Estimate|||||||2012-02-22|2012-02-23|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|RESTORE||Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2|Restoration of First Phase Insulin Release in Subjects With Type 2 Diabetes Mellitus With Subcutaneous Injection of 20 µg AVE0010 in a Double-blind, Randomized, Placebo-controlled, Two-way Cross Over Intravenous Glucose Challenge Study.|Completed||Phase 1|22|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:49:50.94965|2018-06-01 00:49:50.94965
NCT00931346|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2011-08-24|2009-06-30|2009-07-02|Estimate|||||||2011-08-24|2011-08-25|Estimate|October 2009||2009-10-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa|A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa|Completed||Phase 1/Phase 2|72|Anticipated|International AIDS Vaccine Initiative||4|||f||||t||||||||||2018-06-01 00:49:51.336404|2018-06-01 00:49:51.336404
NCT00931333|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2011-11-23|2009-06-30|2009-07-02|Estimate|||||||2011-11-23|2011-11-24|Estimate|July 2009||2009-07-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|VERTEBRO-MCPC||Efficacy and Safety Study of Non-percutaneous Vertebroplasty With Macroporous Calcium Phosphate Cement (MCPC)|Non Comparative, Monocentric, Prospective, Phase II, Study of Calcium Phosphate Cement MCPC Efficacy and Safety for Bone Filling in Vertebral Site|Completed||Phase 2|4|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-06-01 00:49:51.41679|2018-06-01 00:49:51.41679
NCT00931320|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-10-23|2009-07-01|2009-07-02|Estimate|||||||2009-10-23|2009-10-27|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|||||Observational|RACHEL||Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients|Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients|Completed|||3000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:49:51.492138|2018-06-01 00:49:51.492138
NCT00931307|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2010-09-16||2012-06-26|2009-07-01|2009-07-02|Estimate|2010-09-16|2010-10-06|Estimate||||2012-06-26|2012-06-29|Estimate|May 2009||2009-05-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Evaluation of Lotrafilcon A Lenses Over a Three Month Period|Evaluation of Lotrafilcon A Lenses Over a Three Month Period|Completed||N/A|22|Actual|Alcon Research|Due to the small number of subjects successfully completing this trial, the results should be interpreted with caution.|1|||f||||||||||||||2018-06-01 00:49:51.546551|2018-06-01 00:49:51.546551
NCT00931294|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-07-01|2009-07-01|2009-07-02|Estimate|||||||2009-07-01|2009-07-02|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Saliva Testosterone Increases in Irritable Bowel Syndrome (IBS) Patients Beginning Choir Singing|Saliva Testosterone Increases in Choir Singer Beginners: a Randomised Controlled Trial to Test the Efficacy of Choir Singing in Irritable Bowel Syndrome (IBS) Patients|Completed||N/A|55|Actual|Stockholm University|||||f||||f||||||||||2018-06-01 00:49:51.737788|2018-06-01 00:49:51.737788
NCT00931281|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2010-10-11|2009-06-30|2009-07-02|Estimate|||||||2010-10-11|2010-10-13|Estimate|June 2009||2009-06-30|September 2010|2010-09-30||||September 2009|Actual|2009-09-30||Interventional|||Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir|A Blinded, Randomized, Nonfasting, Placebo-Controlled Study in Healthy Adults to Evaluate Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Ascending Doses of ABT-450 With Ritonavir|Completed||Phase 1|38|Actual|Abbott||2|||f||||f||||||||||2018-06-01 00:49:51.803025|2018-06-01 00:49:51.803025
NCT00931268|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2013-07-12||2013-11-22|2009-07-01|2009-07-02|Estimate|2013-11-22|2013-12-19|Estimate||||2013-11-22|2013-12-19|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|May 2012|Actual|2012-05-31|September 2011|Actual|2011-09-30||Interventional|||Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Macrolane|Morphological and Functional Evaluation of Buttock Lipoatrophy Treatment With Stabilized Hyaluronic Acid of Non-animal Origin (Macrolane); a Baseline-controlled Single-centre Study.|Completed||N/A|10|Actual|Q-Med AB||1|||f||||f||||||||||2018-06-01 00:49:51.892105|2018-06-01 00:49:51.892105
NCT00931255|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2014-12-31||2018-03-13|2009-06-30|2009-07-02|Estimate|2018-03-13|2018-03-16|Actual||||2018-03-13|2018-03-16|Actual|April 2009||2009-04-30|March 2018|2018-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|RAPA||Tacrolimus to Sirolimus Conversion for Delayed Graft Function|Delayed Tacrolimus to Sirolimus Conversion in Renal Transplant Recipients With Delayed Graft Function|Terminated||Phase 4|32|Actual|University of Maryland|The trial was stopped because of slow enrollment. Hence, the target enrollment number was not achieved.|2||The trial was stopped because of slow recruitment.|f||||t||||||||||2018-06-01 00:49:52.182381|2018-06-01 00:49:52.182381
NCT00931242|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2010-10-28||2010-11-23|2009-07-01|2009-07-02|Estimate|2010-11-23|2010-12-20|Estimate||||2010-11-23|2010-12-20|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Apremilast in Atopic or Contact Dermatitis|A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis|Completed||Phase 2|10|Actual|Tufts Medical Center|This was a small, single-arm open-label study with no placebo or comparison group to serve as a control.|1|||f||||f||||||||||2018-06-01 00:49:52.661418|2018-06-01 00:49:52.661418
NCT00931229|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2016-11-08|2009-06-30|2009-07-02|Estimate|||||||2016-11-08|2016-11-09|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients|Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Who Receive Rituximab-containing Chemotherapy and Are Previously Infected With Hepatitis B Virus|Unknown status|Active, not recruiting|N/A|202|Actual|National Health Research Institutes, Taiwan||1|||f||||t||||||||No||2018-06-01 00:49:53.10601|2018-06-01 00:49:53.10601
NCT00931216|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-04-06|2009-07-01|2009-07-02|Estimate|||||||2012-04-06|2012-04-10|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Integration of HIV Care and Treatment Into Antenatal Care in Migori District, Kenya|Integration of HIV Care and Treatment Into Antenatal Care in Migori District, Kenya|Completed||N/A|1172|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:49:53.203139|2018-06-01 00:49:53.203139
NCT00931203|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2016-05-03|2009-07-01|2009-07-02|Estimate|||||||2016-05-03|2016-05-04|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional|||Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer|A Phase II Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer|Completed||Phase 2|55|Actual|National Health Research Institutes, Taiwan|||||f||||t||||||||||2018-06-01 00:49:53.316738|2018-06-01 00:49:53.316738
NCT00931190|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-09-14|2009-06-30|2009-07-02|Estimate|||||||2009-09-14|2009-09-15|Estimate|February 2001||2001-02-28|September 2009|2009-09-30|November 2005|Actual|2005-11-30|||||Observational|||Use of Human Papillomavirus Persistence for Determination of Treatment Efficacy Among Women With Cervical Dysplasia|Evaluation of the Use of Human Papillomavirus Persistence for Determination of the Treatment Efficacy Among Women With Cervical Intraepithelial Neoplasia, and for Prediction of Recurrence of Cervical Disease|Completed|||195|Actual|Lund University|||||f||||f||||||Samples With DNA|"~     Cervical smear samples in physiologic saline.~   "|||2018-06-01 00:49:53.40052|2018-06-01 00:49:53.40052
NCT00931164|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2014-01-08||2014-03-03|2009-07-01|2009-07-02|Estimate|2014-03-03|2014-03-31|Estimate||||2014-03-03|2014-03-31|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|AHC-SO||Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)|Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial)|Completed||Phase 1/Phase 2|6|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 00:49:53.575643|2018-06-01 00:49:53.575643
NCT00931151|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2011-08-22|2009-07-01|2009-07-02|Estimate|||||||2011-08-22|2011-08-23|Estimate|April 2009||2009-04-30|March 2010|2010-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects of Dietary Protein on Undesirable Postprandial Events in Overweight Subjects||Completed||N/A|10|Anticipated|Institut National de la Recherche Agronomique||3|||f||||t||||||||||2018-06-01 00:49:53.801758|2018-06-01 00:49:53.801758
NCT00931138|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-06-30|2009-06-30|2009-07-02|Estimate|||||||2009-06-30|2009-07-02|Estimate|December 1999||1999-12-31|August 1999|1999-08-31|December 2006||2006-12-31|||||Interventional|ALFA 9801||Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2|Treatment of AML in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 26- ALFA 9801|Completed||Phase 3|420||Acute Leukemia French Association||3|||f||||t||||||||||2018-06-01 00:49:53.894883|2018-06-01 00:49:53.894883
NCT00931125|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2013-10-14|2009-07-01|2009-07-02|Estimate|||||||2013-10-14|2013-10-16|Estimate|March 2009||2009-03-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|September 2013|Actual|2013-09-30||Interventional|VITARM||Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone|Randomized, Double Blinded, Controlled, Two-center Study Assessing the Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|University of Debrecen||2|||f||||t||||||||||2018-06-01 00:49:53.985294|2018-06-01 00:49:53.985294
NCT00931112|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-21|2009-07-01|2009-07-02|Estimate|||||||2009-07-21|2009-07-22|Estimate|November 2006||2006-11-30|July 2009|2009-07-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Effects of Individualized Exercise Training in Patients With Peripheral Arterial Disease|Effects of Individualized Exercise Training on Arterial Function, Walking Ability and Quality of Life in Patients With Peripheral Arterial Disease Post Surgery|Completed||N/A|32|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:49:54.067324|2018-06-01 00:49:54.067324
NCT00931099|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-01|2009-07-01|2009-07-02|Estimate|||||||2009-07-01|2009-07-02|Estimate|September 2009||2009-09-30|July 2009|2009-07-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Fetal Outcome of Sleep Disordered Breathing During Pregnancy|Fetal Outcome of Sleep Disordered Breathing During Pregnancy|Unknown status|Not yet recruiting||1000|Anticipated|Tel-Aviv Sourasky Medical Center|||4||f||||||||||||||2018-06-01 00:49:54.298308|2018-06-01 00:49:54.298308
NCT00931086|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-10-29|2009-06-30|2009-07-02|Estimate|||||||2012-10-29|2012-10-31|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Expanded Access|LBRA99||Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99|An Expanded Access Trial of Belimumab Antibody (Monoclonal Anti-BLyS Antibody) in Patients With Rheumatoid Arthritis (RA) Who Were Previously Treated Under HGS Protocol LBRA99|No longer available|||||GlaxoSmithKline|||||||||f||||||||||2018-06-01 00:49:54.39568|2018-06-01 00:49:54.39568
NCT00931073|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-11-17|2009-07-01|2009-07-02|Estimate|||||||2009-11-17|2009-11-18|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers|A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects|Completed||Phase 1|24|Anticipated|Pfizer||3|||f||||f||||||||||2018-06-01 00:49:54.487122|2018-06-01 00:49:54.487122
NCT00931060|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-09-14|2009-06-30|2009-07-02|Estimate|||||||2009-09-14|2009-09-15|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects|Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects|Completed||N/A|24|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 00:49:54.599217|2018-06-01 00:49:54.599217
NCT00931034|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-06-30|2009-06-30|2009-07-02|Estimate|||||||2009-06-30|2009-07-02|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women|The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to the American Diabetic Association Diabetes Meal Plan on Body Weight and Satiety in Overweight Diabetic Women|Completed||N/A|120|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-06-01 00:49:54.661544|2018-06-01 00:49:54.661544
NCT00931021|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-07-12|2009-06-30|2009-07-02|Estimate|||||||2013-07-12|2013-07-15|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Smoking Cessation Treatment for Head and Neck Cancer Patients|Smoking Cessation Treatment for Head and Neck Cancer Patients|Terminated||Early Phase 1|7|Actual|Yale University||2|||f||||f||||||||||2018-06-01 00:49:54.77977|2018-06-01 00:49:54.77977
NCT00931008|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2013-01-22|2009-06-30|2009-07-02|Estimate|||||||2013-01-22|2013-01-24|Estimate|October 2009||2009-10-31|August 2010|2010-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study to Evaluate SID 530 Compared to Taxotere|A Randomized, Double-Blind, Two-Way Crossover, Bioequivalence Study of SID530 and Taxotere® in Study Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Platinum Therapy Failure or Study Participants With Locally Advanced or Metastatic Breast Cancer Who Have Failed At Least One Prior Chemotherapeutic Regimen|Completed||Phase 3|42|Actual|SK Chemicals Co.,Ltd.||2|||f||||||||||||||2018-06-01 00:49:54.872058|2018-06-01 00:49:54.872058
NCT00930995|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2012-04-23|2009-07-01|2009-07-02|Estimate|||||||2012-04-23|2012-04-25|Estimate||||April 2012|2012-04-30||||||||Interventional|||Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C|Angiotensin Receptor Blockade an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C|Withdrawn||Phase 2|0|Actual|Kaiser Permanente||2||Not Awarded|f||||f||||||||||2018-06-01 00:49:54.992404|2018-06-01 00:49:54.992404
NCT00930982|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2011-09-19||2014-11-28|2009-06-30|2009-07-02|Estimate|2011-12-20|2012-01-30|Estimate||||2014-11-28|2014-12-12|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis|Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis|Completed||Phase 2|124|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:49:55.241978|2018-06-01 00:49:55.241978
NCT00930969|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2011-10-27||2012-03-27|2009-06-30|2009-07-02|Estimate|2012-03-27|2012-04-20|Estimate||||2012-03-27|2012-04-20|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Observational|ST Detect||ST Segment Detection Study|ST Segment Detection Study|Terminated|||175|Actual|Medtronic Cardiac Rhythm and Heart Failure||||Low observed spontaneous coronary event rate among enrolled subjects|f||||f||||||||||2018-06-01 00:49:56.252814|2018-06-01 00:49:56.252814
NCT00930956|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2010-07-28|2009-06-30|2009-07-02|Estimate|||||||2010-07-28|2010-07-29|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Different Types of Resistant Starch|Resistant Starch Type 2 and Cross Linked Resistant Starch Type 4 on Blood Glucose|Completed||N/A|11|Actual|Kansas State University||3|||f||||f||||||||||2018-06-01 00:49:57.245137|2018-06-01 00:49:57.245137
NCT00930943|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2011-09-08|2009-06-30|2009-07-02|Estimate|||||||2011-09-08|2011-09-09|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Extended-release Oxymorphone Taking With or Without Food on Cognitive Functioning|Effect of Extended-release Oxymorphone Hydrochloride (Opana® ER), Taken Fasting Versus With Food, on Cognitive Functioning in Opioid-tolerant Subjects: a Randomized, Single-blinded, Cross-over Study|Completed||Phase 4|30|Actual|MedVadis Research Corporation|||||f||||f||||||||||2018-06-01 00:49:57.413282|2018-06-01 00:49:57.413282
NCT00930930|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|2014-10-30||2015-05-05|2009-07-01|2009-07-02|Estimate|2015-05-05|2015-05-07|Estimate||||2015-05-05|2015-05-07|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer|A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Triple-negative Locally Advanced Breast Cancer.|Completed||Phase 2|145|Actual|Vanderbilt-Ingram Cancer Center|The number of participants in each arm will not necessarily coincide with the number of participants affected in the respective arm. Some participants my have more than one event and/or some participants may not have an event at all.|2|||f||||t||||||||||2018-06-01 00:49:57.512394|2018-06-01 00:49:57.512394
NCT00930917|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2009-06-30|2009-06-30|2009-07-02|Estimate|||||||2009-06-30|2009-07-02|Estimate|December 2007||2007-12-31|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Heat Loss Prevention in Delivery Room Using a Polyethylene Cap|Heat Loss Prevention in Delivery Room: a Prospective, Randomised, Controlled Trial of Polyethylene Caps in Very Preterm Infants|Completed||Phase 3|96|Actual|University of Padova||3|||f||||f||||||||||2018-06-01 00:49:58.477054|2018-06-01 00:49:58.477054
NCT00930904|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2017-12-22|2009-06-30|2009-07-02|Estimate|||||||2017-12-22|2017-12-27|Actual|June 2009||2009-06-30|December 2017|2017-12-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Model 4196 Left Ventricular (LV) Lead Chronic Performance Study|Attain Ability® Model 4196 Left Ventricular Lead Chronic Performance Post Approval Study|Completed|||1847|Actual|Medtronic|||||f||||f||f||||||||2018-06-01 00:49:58.636075|2018-06-01 00:49:58.636075
NCT00930891|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2016-03-09|2009-07-01|2009-07-02|Estimate|||||||2016-03-09|2016-03-10|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|CPC||Bevacizumab in Extensive Small Cell Lung Cancer|Randomized Phase II-III Study of Bevacizumab 7,5 mg/kg in Combination With Chemotherapy Versus Chemotherapy in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy : PCDE (cisPlatin - Cyclophosphamide - epiDoxorubicin - Etoposide) or PE (cisPlatin - Etoposide)|Completed||Phase 2/Phase 3|143|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||||2018-06-01 00:49:58.89667|2018-06-01 00:49:58.89667
NCT00930878|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2017-02-02|2009-06-29|2009-07-02|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2008||2008-02-29|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|ProEnCy||Comparative Registry of the PROmus™, ENdeavor™ and CYpher™ Drug Eluting Stents|A Comparative Registry of the PROmus™, ENdeavor™ and CYpher™ Drug Eluting Coronary Stent Systems for the Treatment of Coronary Lesions|Completed|||1934|Actual|Boston Scientific Corporation|||3||f||||t||||||||No||2018-06-01 00:49:59.102883|2018-06-01 00:49:59.102883
NCT00930865|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2016-10-14|2009-06-30|2009-07-02|Estimate|||||||2016-10-14|2016-10-17|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects|A Randomized, Open-Label, Parallel-group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects|Completed||Phase 1|42|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:49:59.189207|2018-06-01 00:49:59.189207
NCT00930852|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2012-02-19|2009-07-01|2009-07-02|Estimate|||||||2012-02-19|2012-02-22|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||A Pilot Study of Migraine and Appetite Behaviour in Children|Migraine, Appetite Behaviour and Obesity: is There a Link?. A Pilot Study of Migraine and Appetite Behaviour in Children.|Completed|||60|Actual|Alder Hey Children's NHS Foundation Trust|||||f||||f||||||||||2018-06-01 00:49:59.279095|2018-06-01 00:49:59.279095
NCT00930839|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|||2010-03-09|2009-06-30|2009-07-02|Estimate|||||||2010-03-09|2010-03-10|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Role of Prostaglandins on Niacin-Induced Flushing|Exploring the Role of Prostaglandin D2 and the DP1 Receptor on Nicotinic Acid Induced Flushing|Completed|||30|Actual|Eastern Virginia Medical School|||1||f||||f||||||Samples Without DNA|"~     Skin biopsies and serum~   "|||2018-06-01 00:49:59.341177|2018-06-01 00:49:59.341177
NCT00930826|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-07-16|2009-07-01|2009-07-02|Estimate|||||||2010-07-16|2010-07-19|Estimate|September 2006||2006-09-30|November 2008|2008-11-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Observational|CAS||Childhood Asthma and Schooling: The Truth Unveiled|Childhood Asthma and Schooling: The Truth Unveiled|Completed|||450|Actual|Boushahri Clinic Medical Center|||||f||||t||||||||||2018-06-01 00:49:59.478538|2018-06-01 00:49:59.478538
NCT00930254|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|July 2008|Actual|2008-07-31|November 2007|Actual|2007-11-30||Interventional|||Peripheral Intravenous Puncture Guided by Vascular Ultrasound|Vascular Ultrasound During the Use of Peripheral Intravenous Catheters in Children: A Clinical, Randomized and Controlled Trial.|Completed||N/A|335|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 00:50:12.417383|2018-06-01 00:50:12.417383
NCT00930813|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-30|2014-08-05||2015-11-17|2009-06-30|2009-07-02|Estimate|2015-11-17|2015-12-21|Estimate||||2015-11-17|2015-12-21|Estimate|June 2009||2009-06-30|November 2015|2015-11-30|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional|LEVANT I||LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis|A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Catheter vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries With and Without Stenting.|Completed||Phase 1/Phase 2|101|Actual|C. R. Bard||2|||f||||t||||||||||2018-06-01 00:49:59.603425|2018-06-01 00:49:59.603425
NCT00930800|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-01|||2009-07-19|2009-07-01|2009-07-02|Estimate|||||||2009-07-19|2009-07-21|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Exercise Training in Children With Congenital Heart Defect|The Effect of Exercise Training on Exercise Capacity, Physical Activity, and Health-related Quality of Life in Children After Repair of Congenital Heart Defect|Completed||N/A|60|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:50:00.310519|2018-06-01 00:50:00.310519
NCT00930787|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2012-08-16||2013-09-17|2009-06-29|2009-06-30|Estimate|2013-09-17|2013-11-20|Estimate||||2013-09-17|2013-11-20|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|RAM2P||Hernia Repair in Multiply Morbid Patients|A Multicenter, Prospective, Randomized, Controlled, Single-Blinded Study of Strattice Reconstructive Tissue Matrix vs Proceed|Terminated||Phase 4|23|Actual|LifeCell||2||Stopped early|f||||t||||||||||2018-06-01 00:50:00.400119|2018-06-01 00:50:00.400119
NCT00930774|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2014-02-21||2014-06-03|2009-06-29|2009-06-30|Estimate|2014-06-03|2014-06-11|Estimate||||2014-06-03|2014-06-11|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|mTBI|Participants were male and female blast-exposed Veterans from the Operation Enduring Freedom/Operation Iraqi Freedom conflicts who reported difficulties hearing speech in noise/when spoken quickly/other difficult circumstances but had clinically-normal hearing.|Approaches to Auditory Rehabilitation for Mild Traumatic Brain Injury|Evaluation of Approaches to Auditory Rehabilitation for Mild TBI|Completed||N/A|99|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 00:50:00.66355|2018-06-01 00:50:00.66355
NCT00930761|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2009-07-08||2009-10-13|2009-06-29|2009-06-30|Estimate|2009-07-08|2009-08-19|Estimate||||2009-10-13|2009-10-15|Estimate|March 2004||2004-03-31|October 2009|2009-10-31|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Effects of Music Therapy on Breastfeeding Among Mothers of Premature Newborns|A Randomized Controlled Trial to Evaluate the Effects of Music Therapy on Breastfeeding Rates Among Mothers of Premature Newborns|Completed||N/A|101|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-06-01 00:50:01.832519|2018-06-01 00:50:01.832519
NCT00930748|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-06-24|2009-06-29|2009-06-30|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Evaluation of MRI for Prostate Cancer|Evaluation of the Potential of Endorectal MRI for the Staging and Recurrence of Prostate Cancer|Terminated|||40|Anticipated|Sheba Medical Center||||The MRI company forbidded additional scans with endorectal colil in this machine|f||||f||||||||||2018-06-01 00:50:02.383391|2018-06-01 00:50:02.383391
NCT00930735|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-27|||2018-04-19|2009-06-29|2009-06-30|Estimate|||||||2018-04-19|2018-04-23|Actual|January 2000||2000-01-31|April 2018|2018-04-30|July 2025|Anticipated|2025-07-31|April 30, 2020|Anticipated|2020-04-30||Observational|||The Prognostic Significance of Fibrosis Detection in Cardiomyopathy|The Prognostic Significance of Fibrosis Detection in Ischemic and Non-ischemic Cardiomyopathy|Recruiting|||3000|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Serum and plasma and myocardium~   "|||2018-06-01 00:50:02.468095|2018-06-01 00:50:02.468095
NCT00930722|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2011-04-07||2011-04-07|2009-06-29|2009-06-30|Estimate|2011-04-07|2011-05-04|Estimate||||2011-04-07|2011-05-04|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|ASSET||A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population|ASSET (Acupil® Non Interventional Study For Evaluation Of Safety Effectiveness And Tolerability)|Completed|||329|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:50:02.564315|2018-06-01 00:50:02.564315
NCT00930709|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2014-12-30|2009-06-29|2009-06-30|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|BooST||Botulinum Toxin Versus Active Strength Training in the Treatment of Lateral Epicondylitis|Botulinum Toxin Versus Active Strength Training in Treatment of the Lateral Epicondylitis - A Single-Blinded, Randomized, Controlled Trial|Completed||N/A|103|Actual|Seinajoki Central Hospital||2|||f||||f||||||||||2018-06-01 00:50:02.853064|2018-06-01 00:50:02.853064
NCT00930696|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|May 2005||2005-05-31|June 2009|2009-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Effects of Extensive Abdominal Lavage on Postoperative Inflammation Following Full Thickness Excision of Deep Endometriosis|Extensive Abdominal Lavage Following Laparoscopic Full Thickness Resection of Deep Endometriosis Involving the Bowel, Effects on Post-Operative Inflammation: a Randomised Controlled Trial|Completed||Phase 2|20|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 00:50:02.944805|2018-06-01 00:50:02.944805
NCT00930683|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2012-05-07|2009-06-29|2009-06-30|Estimate|||||||2012-05-07|2012-05-08|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|July 2011|Actual|2011-07-31|May 2010|Actual|2010-05-31||Interventional|MEDI-546||A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma|A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma|Completed||Phase 1|34|Actual|MedImmune LLC||9|||f||||f||||||||||2018-06-01 00:50:03.177072|2018-06-01 00:50:03.177072
NCT00930670|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2012-02-08|2009-06-29|2009-06-30|Estimate|||||||2012-02-08|2012-02-09|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SPICE||Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects|Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects|Completed||Phase 4|320|Actual|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||8|||f||||f||||||||||2018-06-01 00:50:03.358454|2018-06-01 00:50:03.358454
NCT00930657|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-27|||2018-05-23|2009-06-27|2009-06-30|Estimate|||||||2018-05-23|2018-05-24|Actual|June 26, 2009||2009-06-26|March 12, 2018|2018-03-12||||||||Observational|||CO2 Inhalation and Risk for Panic Disorder|CO2 Inhalation and Risk for Panic Disorder|Completed|||13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:50:03.513496|2018-06-01 00:50:03.513496
NCT00755820|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2012-10-25|2008-09-18|2008-09-19|Estimate|||||||2012-10-25|2012-10-26|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Food Exposure Therapy in Anorexia Nervosa|Food Exposure Therapy in Anorexia Nervosa|Completed|||32|Actual|New York State Psychiatric Institute|||3||f||||f||||||||||2018-06-01 01:44:53.457596|2018-06-01 01:44:53.457596
NCT00930618|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2016-12-20|2009-06-29|2009-06-30|Estimate|||||||2016-12-20|2016-12-21|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|NOCETER||Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies|NOCETER, a Multicenter Double Blind Placebo-controlled Randomized Trial: Reduction of CEsareans in Post TERm Pregnancies: Impact of Outpatient Cervical Ripening With NO Donors|Completed||Phase 3|1409|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:50:04.535844|2018-06-01 00:50:04.535844
NCT00930605|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2011-10-04|2009-06-29|2009-06-30|Estimate|||||||2011-10-04|2011-10-06|Estimate|January 2005||2005-01-31|October 2011|2011-10-31|July 2008|Actual|2008-07-31|November 2006|Actual|2006-11-30||Interventional|C+CHOP/ESHAP||The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)|A Phase II Study of Alemtuzumab in Combination With CHOP and ESHAP as First-Line Treatment in Peripheral T-Cell Lymphoma|Completed||Phase 2|16|Actual|King Chulalongkorn Memorial Hospital||1|||f||||f||||||||||2018-06-01 00:50:04.653287|2018-06-01 00:50:04.653287
NCT00930592|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2016-06-20|2009-06-29|2009-06-30|Estimate|||||||2016-06-20|2016-06-21|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Observational|||Peds Metabolic Syndrome in Psoriasis|Assessor-Blinded Study of the Metabolic Syndrome and Surrogate Markers of Increased Cardiovascular Risk in Children With Moderate to Severe Psoriasis Compared With Age Matched Population of Children With Warts|Completed|||42|Actual|Tufts Medical Center|||2||f||||f||||||Samples Without DNA|"~     Whole blood and serum~   "|No||2018-06-01 00:50:04.784003|2018-06-01 00:50:04.784003
NCT00930579|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-07-30|2009-06-29|2009-06-30|Estimate|||||||2013-07-30|2013-07-31|Estimate|October 2009||2009-10-31|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|October 2011|Actual|2011-10-31||Interventional|||Metformin Pre-Surgical Pilot Study|Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|Columbia University||1|||f||||t||||||||||2018-06-01 00:50:04.912287|2018-06-01 00:50:04.912287
NCT00930566|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-04-23|2009-06-29|2009-06-30|Estimate|||||||2013-04-23|2013-04-24|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|September 2015|Anticipated|2015-09-30|September 2011|Actual|2011-09-30||Interventional|ECP||Extracorporal Photopheresis Pilot Study|Allogenic Hematopoietic Stem Cell Transplantation (HSCT) From a Genoidentical Donor After a Reduced Intensity Conditioning Transplantation (RICT) Followed by an Early Preventive Treatment (Day 21) With Extracorporal Photopheresis After Transplantation.|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-06-01 00:50:05.016628|2018-06-01 00:50:05.016628
NCT00930553|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2017-02-16||2017-05-02|2009-06-26|2009-06-30|Estimate|2017-05-02|2017-05-15|Actual||||2017-05-02|2017-05-15|Actual|August 2009||2009-08-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab|An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab|Completed||Phase 3|1314|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:50:05.227171|2018-06-01 00:50:05.227171
NCT00930527|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2014-07-22|2009-06-29|2009-06-30|Estimate|||||||2014-07-22|2014-07-23|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors|Randomized Phase II Study of Omega-3-Fatty Acid on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients|Terminated||Phase 2|10|Actual|Columbia University||||Closed by sponsor.|f||||t||||||||||2018-06-01 00:50:09.13582|2018-06-01 00:50:09.13582
NCT00930514|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-11-01|2009-06-29|2009-06-30|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma|A Two Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Rituximab Subcutaneous (SC) Formulation in Patients With Follicular Lymphoma (FL) as Part of Maintenance Treatment|Completed||Phase 1|281|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 00:50:09.279202|2018-06-01 00:50:09.279202
NCT00930501|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-28|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Observational|Ovrescancer||Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients|Phase 1 Prospective Study of Markers of Ovarian Reserve in Young Female Cancer Patients|Unknown status|Recruiting||100|Anticipated|Hadassah Medical Organization|||1||f||||f||||||Samples Without DNA|"~     bloods~   "|||2018-06-01 00:50:09.553563|2018-06-01 00:50:09.553563
NCT00930488|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2012-11-19|2009-06-29|2009-06-30|Estimate|||||||2012-11-19|2012-11-20|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Treatment of Patients With Acute Sinusitis|Treatment of Patients With Acute Sinusitis in Daily Practice|Completed|||6777|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 00:50:09.670968|2018-06-01 00:50:09.670968
NCT00930475|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-01-25|2009-06-29|2009-06-30|Estimate|||||||2011-01-25|2011-01-26|Estimate|February 2009||2009-02-28|June 2010|2010-06-30||||December 2010|Anticipated|2010-12-31||Interventional|||Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer|Everolimus (RAD001) in Combination With Intravenous Carboplatin in Taxane- and Anthracycline-pretreated Patients With Progressive Metastatic Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|54|Anticipated|Charite University, Berlin, Germany|||||f||||t||||||||||2018-06-01 00:50:09.792309|2018-06-01 00:50:09.792309
NCT00930462|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Evaluation of the Use of Cap in Improving the Performance of Colonoscopy|A Prospective Randomised Controlled Trial Comparing Cap-Assisted Colonoscopy Versus Standard Colonoscopy|Completed||Phase 4|400|Actual|Royal Prince Alfred Hospital, Sydney, Australia||2|||f||||f||||||||||2018-06-01 00:50:09.886129|2018-06-01 00:50:09.886129
NCT00930449|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2015-05-25|2009-06-29|2009-06-30|Estimate|||||||2015-05-25|2015-05-27|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Effects Of A Computerized Working Memory Training Program On Attention, Working Memory, And Academics, In Adolescents With Severe ADHD/LD|Effects Of A Computerized Working Memory Training Program On Attention, Working Memory, And Academics, In Adolescents With Severe ADHD/LD|Completed||N/A|120|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-06-01 00:50:09.98459|2018-06-01 00:50:09.98459
NCT00929903|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-27|||2013-09-27|2009-06-27|2009-06-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|June 2009||2009-06-30|September 2013|2013-09-30||||April 2013|Actual|2013-04-30||Interventional|||Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment|A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors|Completed||Phase 1|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:50:16.537332|2018-06-01 00:50:16.537332
NCT00930436|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2012-08-22|2009-06-29|2009-06-30|Estimate|||||||2012-08-22|2012-08-23|Estimate|January 2010||2010-01-31|February 2012|2012-02-29|September 2012|Anticipated|2012-09-30|August 2012|Actual|2012-08-31||Interventional|BOSS||Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease|Evaluation of Sodium Bicarbonate to Reduce Chronic Kidney Injury in Subjects With Advanced Chronic Kidney Disease (CKD) Who Are Undergoing Angiography|Terminated||Phase 3|391|Actual|MD Scientific||2|||f||||t||||||||||2018-06-01 00:50:10.08971|2018-06-01 00:50:10.08971
NCT00930423|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2014-12-04|2009-06-29|2009-06-30|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2009||2009-08-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease|Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease.|Unknown status|Recruiting||25|Anticipated|University Hospital, Ghent|||2||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 00:50:10.322328|2018-06-01 00:50:10.322328
NCT00930410|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-27|||2013-03-19|2009-06-29|2009-06-30|Estimate|||||||2013-03-19|2013-03-20|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|EMID||Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor|Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor|Completed||N/A|50|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-06-01 00:50:10.425768|2018-06-01 00:50:10.425768
NCT00930397|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-05-24|2009-06-29|2009-06-30|Estimate|||||||2013-05-24|2013-05-27|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|PLACENTA3D||Observational Study in UTERO - Placental 3D Doppler Examination: Interest for Pre-eclampsia Screening During Pregnancy|The Evaluation of UTERO - Placental 3D Doppler Examination Potential Interest for Pre- Eclampsia Screening During Pregnancy. Observational Study in 100 Women at High Risk for Pre- Eclampsia and 70 Low Risk Women.|Completed|||146|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-06-01 00:50:10.516563|2018-06-01 00:50:10.516563
NCT00930384|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2016-06-15|2009-06-29|2009-06-30|Estimate|||||||2016-06-15|2016-06-16|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis|A Case Control Study to Evaluate the Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) Among Patients With Psoriasis|Completed|||150|Actual|George Washington University|||2||f||||f||||||||Yes||2018-06-01 00:50:10.581245|2018-06-01 00:50:10.581245
NCT00930371|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2015-12-01|2009-06-29|2009-06-30|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|DietLFAT||Effect of Diet Composition on Liver Fat and Glucose Metabolism|Effect of Diet Composition on Liver Fat and Glucose Metabolism|Completed||N/A|16|Actual|University of Washington|||||f||||f||||||||||2018-06-01 00:50:10.659618|2018-06-01 00:50:10.659618
NCT00930358|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2011-04-05|2009-06-29|2009-06-30|Estimate|||||||2011-04-05|2011-04-06|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|KALINAG||Safety Study of Colonoscopy Under Sedation|Tolerance and Acceptability of Colonoscopy Under Sedation by an Equimolar Mixture of Oxygen and Nitrous Oxide. Comparison With General Anesthesia in a Randomized, Multicentric Study.|Terminated||Phase 4|220|Actual|Assistance Publique - Hôpitaux de Paris||2||This study was stopped due to low inclusion|f||||t||||||||||2018-06-01 00:50:10.749641|2018-06-01 00:50:10.749641
NCT00930345|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2015-03-31|2009-06-29|2009-06-30|Estimate|||||||2015-03-31|2015-04-01|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|PREINSUT||Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma|A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy|Terminated||Phase 4|33|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:50:10.924713|2018-06-01 00:50:10.924713
NCT00930332|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-27|||2015-10-05|2009-06-27|2009-06-30|Estimate|||||||2015-10-05|2015-10-06|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain|A Phase I Study to Determine the Dose of Methadone as a First Line Agent in the Treatment of Chronic Neuropathic Cancer Pain|Terminated||Phase 1|8|Actual|Canadian Cancer Trials Group||2||Poor accrual|f||||t||||||||||2018-06-01 00:50:11.047723|2018-06-01 00:50:11.047723
NCT00930319|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2014-03-24|2009-06-29|2009-06-30|Estimate|||||||2014-03-24|2014-03-26|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|FAST||Effectiveness and Safety of Firmagon®|Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma|Completed|||676|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-06-01 00:50:11.228498|2018-06-01 00:50:11.228498
NCT00930306|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-10-23|2009-06-29|2009-06-30|Estimate|||||||2009-10-23|2009-10-27|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|||||Interventional|||AZD2066 Cocktail Study|A Phase I, Open Label, Multi Centre Study in Healthy Volunteers to Estimate the Effect of Multiple Doses of AZD2066 on the Activity of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 by Administering a Cocktail of Caffeine, Bupropion, Tolbutamide, Omeprazole, Metoprolol and Midazolam|Completed||Phase 1|15|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:50:11.724292|2018-06-01 00:50:11.724292
NCT00930293|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2013-12-19||2016-01-07|2009-06-26|2009-06-30|Estimate|2016-01-07|2016-02-09|Estimate||||2016-01-07|2016-02-09|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety|Personalizing Treatment of Depression Complicated by Panic Features-Pilot Study|Completed||N/A|50|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:50:11.924999|2018-06-01 00:50:11.924999
NCT00930280|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2018-02-05|2009-06-29|2009-06-30|Estimate|||||||2018-02-05|2018-02-07|Actual|July 2008||2008-07-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|GERFHS-III||Genetic and Environmental Risk Factors for Hemorrhagic Stroke-GERFHS III|Genetic and Environmental Risk Factors for Hemorrhagic Stroke|Active, not recruiting|||1260|Anticipated|University of Cincinnati|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|No||2018-06-01 00:50:12.233612|2018-06-01 00:50:12.233612
NCT00930267|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-28|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate||||June 2009|2009-06-30||||||||Observational|||Infections in Pediatric Cancer Patients|Epidemiology and Etiology of Infections in Pediatric Cancer Patients: A Prospective Study|Unknown status|Not yet recruiting||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 00:50:12.346429|2018-06-01 00:50:12.346429
NCT00930241|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-03-19|2009-06-29|2009-06-30|Estimate|||||||2013-03-19|2013-03-20|Estimate|July 2009||2009-07-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation|Prospective Randomized Trial to Compare a Twice Daily to a Once Daily Administration of the Tacrolimus in Lung Transplanted Patients|Terminated||Phase 3|25|Actual|Hannover Medical School||2||logistic reasons (insufficient funding, technical problems with MEMS)|f||||f||||||||||2018-06-01 00:50:12.556304|2018-06-01 00:50:12.556304
NCT00930228|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2018-01-18|2009-06-29|2009-06-30|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2009||2009-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CRM004||Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome|Influence of Hyperandrogenemia on the Sleep-associated Slowing of Follicular LH Frequency in Adult Polycystic Ovary Syndrome|Recruiting||Phase 1|72|Anticipated|University of Virginia||2|||f||||t|t|f||||||Undecided|We do not have current plans to share IPD|2018-06-01 00:50:12.721984|2018-06-01 00:50:12.721984
NCT00930215|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-09-09|2009-06-29|2009-06-30|Estimate|||||||2009-09-09|2009-09-10|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|||||Interventional|||Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males|Open Label, Randomized, Single Center, 2-way Crossover Bioequivalence Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule 40 mg D961H After Repeated Oral Administration in Japanese Healthy Male Subjects|Completed||Phase 1|48|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:50:12.869008|2018-06-01 00:50:12.869008
NCT00930202|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2010-09-08|2009-06-29|2009-06-30|Estimate|||||||2010-09-08|2010-09-10|Estimate|August 2009||2009-08-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury|Open Label Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury|Completed||Phase 1|10|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 00:50:12.983667|2018-06-01 00:50:12.983667
NCT00930189|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|April 2006||2006-04-30|December 2006|2006-12-31|September 2006|Anticipated|2006-09-30|||||Interventional|||Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization|Randomized, Double Blind, Controlled Study With Verteporfin Photodynamic Therapy And Intravitreal Triamcinolone(IVTA) Vs Triple Therapy With Verteporfin Photodynamic Therapy, Intravitreal Triamcinolone And Intravitreal Ranibizumab In Patients With Subfoveal Choroidal Neovascularization(CNV) Secondary To Age-Related Macular Degeneration(AMD)|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 00:50:13.119447|2018-06-01 00:50:13.119447
NCT00930176|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2014-11-25||2014-12-08|2009-06-29|2009-06-30|Estimate|2014-12-08|2014-12-12|Estimate||||2014-12-08|2014-12-12|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study Investigating Treatment Factor X in People With Factor X Deficiency|A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.|Completed||Phase 3|16|Actual|Bio Products Laboratory||1|||f||||f||||||||||2018-06-01 00:50:13.286313|2018-06-01 00:50:13.286313
NCT00930163|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29||2011-06-30|2016-11-25|2009-06-29|2009-06-30|Estimate||||2011-06-30|2011-07-13|Estimate|2016-11-25|2016-11-29|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|MILLY||A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids|Completed||Phase 2|218|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 00:50:13.735364|2018-06-01 00:50:13.735364
NCT00930150|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2011-04-15|2009-06-26|2009-06-30|Estimate|||||||2011-04-15|2011-04-19|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network|Cognitive Remediation in the Schizophrenia Trials Network|Completed||Phase 4|52|Actual|National Institute of Mental Health (NIMH)||2|||f||||t||||||||||2018-06-01 00:50:13.848617|2018-06-01 00:50:13.848617
NCT00930137|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-03-04|2009-06-29|2009-06-30|Estimate|||||||2013-03-04|2013-03-05|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|TRANSW||Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women|Ruminant Trans Fats and the Risk of Cardiovascular Disease in Women|Completed||N/A|64|Actual|Laval University||2|||f||||f||||||||||2018-06-01 00:50:13.983258|2018-06-01 00:50:13.983258
NCT00930124|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2011-09-12|2009-06-26|2009-06-30|Estimate|||||||2011-09-12|2011-09-13|Estimate|June 2002||2002-06-30|September 2011|2011-09-30|January 2008|Actual|2008-01-31|October 2004|Actual|2004-10-31||Interventional|||Cleft Orthognathic Surgery Versus Distraction Osteogenesis - Which is Better?|Distraction Versus Orthognathic Surgery - Which One is Better for Cleft Palate Patients|Completed||Phase 2|60|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:50:14.079863|2018-06-01 00:50:14.079863
NCT00930111|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2015-08-31|2009-06-29|2009-06-30|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Inpatient Attending Physician Rotation Duration Study|Inpatient Attending Physician Rotation Duration Study|Completed||N/A|62|Actual|John H. Stroger Hospital||2|||f||||f||||||||||2018-06-01 00:50:14.1962|2018-06-01 00:50:14.1962
NCT00930098|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2014-02-10|2009-06-29|2009-06-30|Estimate|||||||2014-02-10|2014-02-11|Estimate|December 2003||2003-12-31|February 2014|2014-02-28|July 2007|Actual|2007-07-31|||||Interventional|||A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia|A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia|Completed||Phase 2|74|Actual|Sanofi|||||f||||f||||||||||2018-06-01 00:50:14.28886|2018-06-01 00:50:14.28886
NCT00930085|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-09-13|2009-06-27|2009-06-30|Estimate|||||||2011-09-13|2011-09-14|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|PROTEOHSEPS||Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients|Evaluation of Predictive Proteic Profile on Mortality in the Acute Phase of Septic Shock in Cancer Patients|Completed||N/A|60|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-06-01 00:50:14.503736|2018-06-01 00:50:14.503736
NCT00930072|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2017-09-25|2009-06-29|2009-06-30|Estimate|||||||2017-09-25|2017-09-27|Actual|April 2009||2009-04-30|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage|Safety and Efficacy of Cervical Sympathetic Block in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage - Pilot Study|Terminated||Phase 2|7|Actual|University of Washington||2||Poor Enrollment|f||||t||||||||No||2018-06-01 00:50:14.611307|2018-06-01 00:50:14.611307
NCT00930059|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29||2013-04-09|2013-04-09|2009-06-29|2009-06-30|Estimate||||2013-04-09|2013-04-16|Estimate|2013-04-09|2013-04-16|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease|A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease|Completed||Phase 2|198|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:50:14.779694|2018-06-01 00:50:14.779694
NCT00930046|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2017-04-13|2009-06-29|2009-06-30|Estimate|||||||2017-04-13|2017-04-14|Actual|May 2009||2009-05-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine|The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine for the Management of Pain After Surgical Correction of Ureteropelvic Junction Stenosis|Completed||N/A|15|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 00:50:14.924235|2018-06-01 00:50:14.924235
NCT00930033|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2017-11-06|2009-06-29|2009-06-30|Estimate|||||||2017-11-06|2017-11-07|Actual|September 2009||2009-09-30|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|CARMENA||Clinical Trial to Assess the Importance of Nephrectomy|Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib|Active, not recruiting||Phase 3|452|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:50:15.043416|2018-06-01 00:50:15.043416
NCT00930020|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-05-30|2009-06-29|2009-06-30|Estimate|||||||2013-05-30|2013-06-03|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|NeuMAST||Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial|Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial, A Double-Blind, Randomized, Placebo-controlled, Multi-center Study|Terminated||Phase 4|139|Actual|Singhealth Foundation||2||interim analysis shows futility|f||||t||||||||||2018-06-01 00:50:15.18784|2018-06-01 00:50:15.18784
NCT00930007|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2018-04-11|2009-06-29|2009-06-30|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2008||2008-10-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|CRM005||Sleep-wake Changes of Luteinizing Hormone Frequency in Pubertal Girls With and Without High Testosterone|Comparison of Sleep-wake LH Frequency in Peripubertal Girls With and Without Hyperandrogenemia|Active, not recruiting|||90|Anticipated|University of Virginia|||2||f||||t|f|f||||Samples Without DNA|"~     Serum obtained during frequent sampling will be stored (in case repeat measurements are~     required), but will be discarded at the end of the study~   "|Undecided|We do not have current plans to share IPD|2018-06-01 00:50:15.316994|2018-06-01 00:50:15.316994
NCT00929994|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2015-11-11|2009-06-29|2009-06-30|Estimate|||||||2015-11-11|2015-11-13|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack|Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack|Completed|||21|Actual|Toronto Rehabilitation Institute|||1||f||||f||||||||||2018-06-01 00:50:15.482308|2018-06-01 00:50:15.482308
NCT00929981|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2011-08-03||2011-11-21|2009-06-29|2009-06-30|Estimate|2011-11-21|2011-12-26|Estimate||||2011-11-21|2011-12-26|Estimate|September 2009||2009-09-30|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Study To Assess Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Patients|Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects|Completed|||80|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:50:15.659413|2018-06-01 00:50:15.659413
NCT00929968|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29||2012-05-02|2012-05-02|2009-06-29|2009-06-30|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|June 2009||2009-06-30|May 2012|2012-05-31||||February 2011|Actual|2011-02-28||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis|A Randomized, Double-blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen|Completed||Phase 2|35|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:50:15.947723|2018-06-01 00:50:15.947723
NCT00929955|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-28|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Role of Anti-Inflammatory Agents in Patients With Schizophrenia|Study of Role of Anti-Inflammatory Agents in Patients With Schizophrenia|Unknown status|Recruiting|Phase 1|36|Anticipated|Pakistan Institute of Living and Learning||3|||f||||f||||||||||2018-06-01 00:50:16.095071|2018-06-01 00:50:16.095071
NCT00929942|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2011-07-20|2009-06-29|2009-06-30|Estimate|||||||2011-07-20|2011-07-22|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Biodegradable Stents in Lung Transplantation|Treatment of Benign Bronchial Airway Stenoses in Patients After Lung Transplantation With a Biodegradable Stent - a Proof of Concept Study|Completed||Phase 1|10|Actual|Hannover Medical School||1|||f||||f||||||||||2018-06-01 00:50:16.253143|2018-06-01 00:50:16.253143
NCT00929929|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2014-10-08|2009-06-29|2009-06-30|Estimate|||||||2014-10-08|2014-10-09|Estimate|December 2009||2009-12-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Study to Assess the Effect of Leucine Along With Resistance Exercise on Muscle Strength and Quality of Life in Elders|Randomized Double-blind, Placebo-controlled, Parallel Design, Pilot Study to Assess the Effect of a Nutritional Supplement With Leucine, Along With a Progressive Resistance Exercise Program, on Muscle Strength and Quality of Life in Elderly People.|Completed||N/A|30|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 00:50:16.326182|2018-06-01 00:50:16.326182
NCT00929916|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-03-11|2009-06-29|2009-06-30|Estimate|||||||2013-03-11|2013-03-12|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy|Efficacy of a Low Volume PEG Purgative (MoviPrep®) Administered Entirely in the Morning Compared to Split Dose (PM/AM) Administration|Completed|||125|Actual|Thomas Jefferson University|||2||f||||f||||||||||2018-06-01 00:50:16.428857|2018-06-01 00:50:16.428857
NCT00929890|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2011-10-25|2009-06-29|2009-06-30|Estimate|||||||2011-10-25|2011-10-26|Estimate|February 2009||2009-02-28|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Additional Metabolic and Vascular Effects of Exercise in Patients on Diet-based Weight Loss Programs|Effect of Weight Loss Through Dietary Energy Restriction With or Without Exercise on Vascular and Metabolic Parameters in Subjects With Obesity|Unknown status|Active, not recruiting|N/A|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 00:50:16.663899|2018-06-01 00:50:16.663899
NCT00929877|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2010-05-17|2009-06-29|2009-06-30|Estimate|||||||2010-05-17|2010-05-18|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||KRYSTAL- KetopRofen lYsinate Sore ThroAt Lozenges|A Randomised Double Blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of 2 Doses of Ketoprofen Lysinate Lozenges (6.25 mg & 12.5 mg) in Patients With Sore Throat|Completed||Phase 3|801|Actual|Sanofi||3|||f||||||||||||||2018-06-01 00:50:16.760222|2018-06-01 00:50:16.760222
NCT00929864|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|2013-11-14||2014-01-03|2009-06-29|2009-06-30|Estimate|2013-11-14|2014-01-03|Estimate||||2014-01-03|2014-02-04|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional||All randomized and treated participants who started the 12 month period.|Abatacept Versus Adalimumab Head-to-Head|A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis|Completed||Phase 3|869|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 00:50:16.873762|2018-06-01 00:50:16.873762
NCT00929851|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2017-03-28|2009-06-29|2009-06-30|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2009||2009-10-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)|"a 48-week, Double Blind, Randomized, Multinational, Multicentre, Fixed Combination Beclomethasone Dipropionate Plus Formoterol Fumarate Versus Formoterol in Patients With Severe Chronic Obstructive Pulmonary Disease"|Completed||Phase 3|1199|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||t||||||||||2018-06-01 00:50:17.774242|2018-06-01 00:50:17.774242
NCT00929838|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2015-09-24|2009-06-29|2009-06-30|Estimate|||||||2015-09-24|2015-09-25|Estimate|August 2008||2008-08-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|DM-TBSI||Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM|Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM|Unknown status|Active, not recruiting|N/A|232|Anticipated|Medical University of South Carolina||4|||f||||t||||||||||2018-06-01 00:50:17.874897|2018-06-01 00:50:17.874897
NCT00929825|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2016-08-08|2009-06-29|2009-06-30|Estimate|||||||2016-08-08|2016-08-10|Estimate|February 2008||2008-02-29|August 2016|2016-08-31|August 2011|Anticipated|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Therapies for Salivary Flux Stimulation in Patients Transplanted With Hematopoietic Stem Cells|Effects of Mechanical and Electrical Sialogogues in Stimulation of the Flow and Biochemical Composition of Saliva in Patients Transplanted With Hematopoietic Stem Cells|Withdrawn||Phase 1|0|Actual|Federal University of Minas Gerais||4||The Hospital had the Unit of Stem cells Tranplantion suspended|f||||t||||||||Yes|"Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 May;113(5):628-37. doi: 10.1016/j.oooo.2011.10.012. Epub 2012 Apr 12.~Effect of salivary stimulation therapies on salivary flow and chemotherapy-induced mucositis: a preliminary study.~Pimenta Amaral TM1, Campos CC, Moreira dos Santos TP, Leles CR, Teixeira AL, Teixeira MM, Bittencourt H, Silva TA."|2018-06-01 00:50:18.0004|2018-06-01 00:50:18.0004
NCT00929812|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|January 2008|Actual|2008-01-31||Interventional|||Glucagon Modulation of Ghrelin Secretion|The Mechanisms Underlying the Glucagon-Induced Suppression of Ghrelin Secretion|Unknown status|Active, not recruiting|Phase 3|38|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:50:18.108027|2018-06-01 00:50:18.108027
NCT00929799|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-06-29|2009-06-29|2009-06-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|November 2003||2003-11-30|June 2009|2009-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|GHGMS||Growth Hormone and Glucose Metabolism|Effects of Treatment With Human Growth Hormone on Insulin Resistance and Insulin Secretion in Adults With Growth Hormone Deficiency|Completed||Phase 4|6|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 00:50:18.223293|2018-06-01 00:50:18.223293
NCT00929786|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2009-11-09|2009-06-29|2009-06-30|Estimate|||||||2009-11-09|2009-11-10|Estimate|November 2007||2007-11-30|November 2009|2009-11-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Observational|||Anti-tuberculosis (TB) Drug Levels and Hepatotoxicity|Measurement of Drug Levels and Their Correlation With Hepatotoxicity During Antituberculosis Treatment|Completed|||72|Actual|All India Institute of Medical Sciences, New Delhi|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 00:50:18.316977|2018-06-01 00:50:18.316977
NCT00929773|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2009-07-06||2014-04-02|2009-06-26|2009-06-29|Estimate|2014-04-02|2014-05-02|Estimate||||2014-04-02|2014-05-02|Estimate|July 2000||2000-07-31|April 2014|2014-04-30|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Low Level Laser Therapy to Reduce Chronic Pain|Study of the Effect of Low Level Laser Light Therapy on the Reduction of Chronic Pain of the Neck and Shoulders|Completed||N/A|100|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-06-01 00:50:18.403429|2018-06-01 00:50:18.403429
NCT00929760|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2009-09-15|2009-06-26|2009-06-29|Estimate|||||||2009-09-15|2009-09-16|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|IMPLICATE||Impact of Specialised Renal Care in Patients With Chronic Kidney Disease|"Impact of Specialised Renal Care in Patients With Chronic Kidney Disease Stage 3-5: A Prospective Randomised Study. The Implicate Study"|Unknown status|Recruiting|N/A|400|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 00:50:18.752036|2018-06-01 00:50:18.752036
NCT00929747|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2012-04-10|2009-06-26|2009-06-29|Estimate|||||||2012-04-10|2012-04-12|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of Corneal Aberrations and Visual Outcomes in AcrySof IQ Toric Patients Versus Limbal Relaxing Incision (LRI) Patients|Comparison of Corneal Aberrations and Visual Outcomes in AcrySof IQ Toric Patients Versus LRI Patients|Withdrawn||Phase 4|0|Actual|Alcon Research||2||Management Decision|f||||f||||||||||2018-06-01 00:50:18.816853|2018-06-01 00:50:18.816853
NCT00929734|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2015-07-09||2015-09-07|2009-06-26|2009-06-29|Estimate|2015-09-07|2015-10-08|Estimate||||2015-09-07|2015-10-08|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|RODEO|Complete case population|Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease|Effect of ROsuvastatin Therapy on Peripheral Vasodilator Function, Inflammatory Markers and Pulmonary Function in Patients With StablE Chronic Obstructive Pulmonary Disease|Completed||Phase 2|99|Actual|University Hospital, Akershus||2|||f||||t||||||||||2018-06-01 00:50:18.915498|2018-06-01 00:50:18.915498
NCT00929708|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2012-12-20||2014-01-22|2009-06-26|2009-06-29|Estimate|2013-12-16|2014-01-17|Estimate||||2014-01-22|2014-02-17|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|GLAD||Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 4-week, Phase-II, Double-blind, Placebo-controlled, Randomised, Parallel-group, Multi-centre Study to Assess the Efficacy and Tolerability/Safety of Inhaled AZD3199 Once Daily Compared to 9 μg Formoterol Bid and Placebo in Patients With Moderate to Severe COPD|Completed||Phase 2|329|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 00:50:19.623443|2018-06-01 00:50:19.623443
NCT00929695|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2014-09-19||2017-07-19|2009-06-26|2009-06-29|Estimate|2014-10-08|2014-10-09|Estimate||||2017-07-19|2017-08-21|Actual|June 2009||2009-06-30|July 2017|2017-07-31|December 14, 2015|Actual|2015-12-14|July 2013|Actual|2013-07-31||Interventional||From a total enrollment of 164 patients, 150 were analyzed for the primary endpoint. Excluded from the analysis were 14 patients: 12 withdrew, died or were discharged from the Center early and did not have 42 days of cumulative prednisone dosing and 2 were stratified incorrectly.|Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease|A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease|Completed||Phase 3|164|Actual|Fred Hutchinson Cancer Research Center||2|||f||||||||||||||2018-06-01 00:50:20.142188|2018-06-01 00:50:20.142188
NCT00929682|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2013-04-02|2009-06-26|2009-06-29|Estimate|||||||2013-04-02|2013-04-04|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Levobupivacaine for Epidural Analgesia in Labour||Completed||Phase 4|136|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-06-01 00:50:21.420368|2018-06-01 00:50:21.420368
NCT00929669|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2013-12-12||2017-10-20|2009-06-26|2009-06-29|Estimate|2017-10-20|2017-11-28|Actual||||2017-10-20|2017-11-28|Actual|June 2009||2009-06-30|October 2017|2017-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|LAR||Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas|Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study|Terminated||Phase 2|2|Actual|University of Pennsylvania|This trial was terminated due to difficulty in identifying 3 subjects for completion of the study.|1||unable to identify a third subject|f||||t||||||||Undecided||2018-06-01 00:50:21.486297|2018-06-01 00:50:21.486297
NCT00929656|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2016-11-21||2017-07-12|2009-06-26|2009-06-29|Estimate|2017-04-11|2017-07-05|Actual||||2017-07-12|2017-08-21|Actual|February 1, 2013||2013-02-01|July 2017|2017-07-31|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Interventional|||Combined Neural and Behavioral Therapies to Enhance Stroke Recovery|Combining Neural and Behavioral Therapies to Enhance Stroke Recovery|Completed||N/A|22|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:50:21.648097|2018-06-01 00:50:21.648097
NCT00929643|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2012-06-27||2012-08-06|2009-06-26|2009-06-29|Estimate|2012-06-27|2012-08-06|Estimate||||2012-08-06|2012-08-10|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections|The Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections|Completed|||203|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 00:50:21.973366|2018-06-01 00:50:21.973366
NCT00929630|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-09-15|2009-06-26|2009-06-29|Estimate|||||||2009-09-15|2009-09-16|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Seton or Glue for Trans-sphincteric Anal Fistulas|Seton or Glue for Trans-sphincteric Anal Fistulas. A Prospective Randomised Clinical Trial|Terminated||Phase 3|65|Actual|Societa Italiana di Chirurgia ColoRettale||2||Evident advantages of one treatment (seton) over the other (Tissucol Glue)|f||||t||||||||||2018-06-01 00:50:22.44973|2018-06-01 00:50:22.44973
NCT00929617|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2018-01-17|2009-06-26|2009-06-29|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2009||2009-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|March 2017|Actual|2017-03-31||Interventional|BEAT||Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)|Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II)|Active, not recruiting||N/A|356|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 00:50:22.527666|2018-06-01 00:50:22.527666
NCT00929604|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2014-10-08|2009-06-26|2009-06-29|Estimate|||||||2014-10-08|2014-10-09|Estimate|December 2006||2006-12-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|May 2012|Actual|2012-05-31||Interventional|||HIV Viral Load Monitoring in Resource-Poor Settings|Effectiveness of HIV Viral Load Monitoring of Patient Outcome in Resource-Poor Settings|Completed||N/A|2112|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 00:50:22.609233|2018-06-01 00:50:22.609233
NCT00929591|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2013-01-23|2009-06-26|2009-06-29|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 1989||1989-05-31|January 2013|2013-01-31|March 2010|Actual|2010-03-31|August 2005|Actual|2005-08-31||Interventional|||SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer|Phase III Comparison of Adjuvant Chemoendocrine Therapy With CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients With Involved Axillary Lymph Nodes and Positive Receptors|Completed||Phase 3|1558|Actual|Southwest Oncology Group||3|||f||||t||||||||||2018-06-01 00:50:22.686794|2018-06-01 00:50:22.686794
NCT00929578|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2012-08-13||2017-03-02|2009-06-26|2009-06-29|Estimate|2016-06-21|2016-08-02|Estimate||||2017-03-02|2017-03-31|Actual|November 2008||2008-11-30|March 2017|2017-03-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|FP-CL2||Fluphenazine Hydrochloride for Psoriasis|Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis|Completed||Phase 2|15|Actual|Tufts Medical Center||2|||f||||f||||||||No||2018-06-01 00:50:22.803406|2018-06-01 00:50:22.803406
NCT00929565|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2012-04-05|2009-06-25|2009-06-29|Estimate|||||||2012-04-05|2012-04-09|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|October 2011|Actual|2011-10-31|June 2010|Actual|2010-06-30||Observational|||Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy|Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.|Completed|||10|Actual|University of Oklahoma|||1||f||||f||||||||||2018-06-01 00:50:23.010756|2018-06-01 00:50:23.010756
NCT00929552|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2012-09-25|2009-06-26|2009-06-29|Estimate|||||||2012-09-25|2012-09-26|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|TeenFisk||Effect of Fish Oil on Markers of the Metabolic Syndrome in Overweight Adolescent Boys|Effect of n-3 LCPUFAs on Weight Reduction and Metabolic Syndrome.|Completed||N/A|78|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 00:50:23.081181|2018-06-01 00:50:23.081181
NCT00929019|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2016-12-07|2009-06-25|2009-06-26|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients|mRNA Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients|Terminated||Phase 1/Phase 2|30|Anticipated|Radboud University||2||slow accrual|f||||f||||||||||2018-06-01 00:50:33.135272|2018-06-01 00:50:33.135272
NCT00929539|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26||2013-01-31|2013-01-31|2009-06-26|2009-06-29|Estimate||||2013-01-31|2013-02-04|Estimate|2013-01-31|2013-02-04|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients|A Phase II, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety and Tolerability of JTT-130 in Treatment-naïve, Metformin Only or Metformin Plus Sulfonylurea-treated Obese Type 2 Diabetic Patients|Completed||Phase 2|496|Actual|Akros Pharma Inc.||4|||f||||f||||||||||2018-06-01 00:50:23.161627|2018-06-01 00:50:23.161627
NCT00929526|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2012-02-16||2016-09-09|2009-06-26|2009-06-29|Estimate|2012-09-13|2012-10-15|Estimate||||2016-09-09|2016-10-20|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study|Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693|Completed||Phase 3|752|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:50:23.418435|2018-06-01 00:50:23.418435
NCT00929500|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2017-01-06||2017-11-02|2009-06-26|2009-06-29|Estimate|2017-05-03|2017-09-18|Actual||||2017-11-02|2017-11-13|Actual|July 2009||2009-07-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|May 2010|Actual|2010-05-31||Interventional|||Exercise Program in Women With Metabolic Syndrome|The Effect of Mixed Aerobic and Strength Training Program on Physical Fitness and Cerebrovascular Function in Older Women With Metabolic Syndrome: A Pilot Study With Randomized Control Trial (RCT) Design|Completed||N/A|28|Actual|Beth Israel Deaconess Medical Center|Difficulty in recruiting older women with Metabolic syndrome, unwilling to participate due to time commitment and transportation difficulties, interrupt the recruitment process due to time constraints. Results should be interpreted with caution.|2|||f||||f||||||||No||2018-06-01 00:50:23.993105|2018-06-01 00:50:23.993105
NCT00929487|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2012-09-06|2009-06-26|2009-06-29|Estimate|||||||2012-09-06|2012-09-10|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Acute Clinical Evaluation of Multi-purpose Solutions (MPS) in Soft Contact Lens Wearers|Acute Clinical Evaluation of MPS in Soft Contact Lens Wearers|Completed||N/A|278|Actual|Alcon Research||5|||f||||f||||||||||2018-06-01 00:50:24.247176|2018-06-01 00:50:24.247176
NCT00929474|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2013-06-12||2013-06-12|2009-06-26|2009-06-29|Estimate|2013-06-12|2013-08-23|Estimate||||2013-06-12|2013-08-23|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement|BOOST: Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement|Terminated||Phase 4|17|Actual|St. Jude Medical||2|||f||||||||||||||2018-06-01 00:50:24.329447|2018-06-01 00:50:24.329447
NCT00929461|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-11-24|2009-06-26|2009-06-29|Estimate|||||||2009-11-24|2009-11-25|Estimate||||November 2009|2009-11-30||||||||Interventional|||Impact of Omega-3 Fatty Acids on Lactate|Do Omega-3 Fatty Acids Have Any Impact On Serum Lactate Levels After Major Gastric Cancer Surgery?|Completed||N/A|||Ege University||2|||f||||f||||||||||2018-06-01 00:50:24.536573|2018-06-01 00:50:24.536573
NCT00929448|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2012-12-03|2009-06-26|2009-06-29|Estimate|||||||2012-12-03|2012-12-04|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||The Predictive Value of Clinical and Immunological Factors in the Development of Pneumonia After Traumatic Brain Injury|The Predictive Value of Clinical and Immunological Factors in the Development of Pneumonia After Traumatic Brain Injury|Completed|||110|Actual|Royal Alexandra Hospital|||1||f||||f||||||||||2018-06-01 00:50:24.586041|2018-06-01 00:50:24.586041
NCT00929435|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2012-04-05|2009-06-25|2009-06-29|Estimate|||||||2012-04-05|2012-04-09|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Carriage Rates in Resident Physicians|The Incidence of Methicillin Resistant Staphylococcus Aureus (MRSA) Nasal Carriage Among Resident Physicians|Terminated|||30|Actual|University of Oklahoma|||1|Minimal enrollment|f||||f||||||||||2018-06-01 00:50:24.650195|2018-06-01 00:50:24.650195
NCT00929422|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2010-11-30|2009-06-26|2009-06-29|Estimate|||||||2010-11-30|2010-12-01|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Observational|||Positron Emission Tomography (PET) in Evaluating Cerebral Glucose Metabolism and Functional Change for Patients With Spinal Cord Injury|PET in Evaluating Cerebral Glucose Metabolism and Functional Change for Patients With Spinal Cord Injury|Unknown status|Recruiting||160|Anticipated|National Taiwan University Hospital|||4||f||||f||||||||||2018-06-01 00:50:24.974838|2018-06-01 00:50:24.974838
NCT00929409|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2012-02-15|2009-06-26|2009-06-29|Estimate|||||||2012-02-15|2012-02-17|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia|A 6-week Randomised, Open Comparative, Multi-centre Study of Intravenous Ferric Carboxymaltose (Ferinject) and Oral Iron (Duroferon) for Treatment of Post Partum Anemia|Terminated||Phase 2/Phase 3|30|Actual|Norwegian University of Science and Technology||2||Stopped prematurely because too few patients were recruited.|f||||f||||||||||2018-06-01 00:50:25.057778|2018-06-01 00:50:25.057778
NCT00929396|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2013-01-18|2009-06-26|2009-06-29|Estimate|||||||2013-01-18|2013-01-21|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|THYB-02||A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis (TB) Subunit Vaccine in Purified Protein Derivative (PPD) Positive Volunteers|A Safety and Immunogenicity Phase 1 Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)Administered in PPD Positive Volunteers at 0 and 2 Months|Completed||Phase 1|20|Actual|Statens Serum Institut||2|||f||||t||||||||||2018-06-01 00:50:25.148782|2018-06-01 00:50:25.148782
NCT00929383|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2014-03-14||2014-05-15|2009-06-26|2009-06-29|Estimate|2014-05-15|2014-06-17|Estimate||||2014-05-15|2014-06-17|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|IRISS|"Prospective, open label registry. All patients meeting inclusion/exclusion at the study centers were eligible for paritcipation.~As this was an observational registry, no statistical hypothesis was stated a priori."|An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis|An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis|Completed|||82|Actual|Stryker Neurovascular|||||f||||t||||||||||2018-06-01 00:50:25.230804|2018-06-01 00:50:25.230804
NCT00754897|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2009-09-14|2008-09-17|2008-09-18|Estimate|||||||2009-09-14|2009-09-16|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Feasibility Study for PANDAS|Feasibility Study for Pediatric NeuroDevelopmental Assessment Study (PANDAS)|Completed|||72|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-06-01 01:45:09.114803|2018-06-01 01:45:09.114803
NCT00929370|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-06-25|2009-06-25|2009-06-29|Estimate|||||||2009-06-25|2009-06-29|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|GT1110791||A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.|A 4-Part Parallel Group, Randomized, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Repeat Doses of GSK1018921 in Healthy Volunteers and Stable Patients With Schizophrenia and to Evaluate Its Effects on Pharmacokinetics of Midazolam.|Terminated||Phase 1|34|Actual|GlaxoSmithKline||1||"Study has now been terminated due to changes in project strategy. Current available data will~   be analysed and reported in a synoptic study report."|f||||||||||||||2018-06-01 00:50:25.441546|2018-06-01 00:50:25.441546
NCT00929357|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2011-06-06||2011-08-04|2009-06-25|2009-06-29|Estimate|2011-06-06|2011-06-28|Estimate||||2011-08-04|2011-08-10|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment|A Retrospective Evaluation of the Radiographic Efficacy of Different Conventional Systemic Therapies and Biologics in Patients With Rheumatoid Arthritis in Routine Practice.|Completed|||156|Actual|Pfizer|||2||f||||||||||||||2018-06-01 00:50:25.523634|2018-06-01 00:50:25.523634
NCT00929344|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|2017-02-08||2017-03-30|2009-06-26|2009-06-29|Estimate|2017-02-08|2017-03-28|Actual||||2017-03-30|2017-05-04|Actual|July 2009||2009-07-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Duloxetine Versus Pregabalin for Alcohol Dependence|Duloxetine Versus Pregabalin for Alcohol Dependence|Completed||Phase 2|150|Actual|The Scripps Research Institute||3|||f||||t||||||||||2018-06-01 00:50:25.79505|2018-06-01 00:50:25.79505
NCT00929331|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2010-07-15||2016-10-07|2009-06-25|2009-06-29|Estimate|2010-07-15|2010-08-13|Estimate||||2016-10-07|2016-11-21|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years.|Completed||Phase 3|110|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:50:26.172869|2018-06-01 00:50:26.172869
NCT00929318|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2009-06-26|2009-06-26|2009-06-29|Estimate|||||||2009-06-26|2009-06-29|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Interventional|||Influence of Thyroid Hormones on the Woundhealing Process|Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound|Unknown status|Recruiting|N/A|26|Anticipated|Hannover Medical School||2|||f||||f||||||||||2018-06-01 00:50:26.603334|2018-06-01 00:50:26.603334
NCT00929305|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2009-07-07||2014-04-02|2009-06-26|2009-06-29|Estimate|2013-03-13|2013-04-22|Estimate||||2014-04-02|2014-04-21|Estimate|January 2001||2001-01-31|April 2014|2014-04-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Low Level Laser Light Therapy and Chronic Neck and Shoulder Pain|Study of the Effect of Low Level Laser Therapy on the Reduction of Chronic Pain Associated With Neck and Shoulder Pain of Musculoskeletal Origin.|Completed||N/A|100|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-06-01 00:50:26.759674|2018-06-01 00:50:26.759674
NCT00929292|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2009-06-26|2009-06-26|2009-06-29|Estimate|||||||2009-06-26|2009-06-29|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic|Study of Growth and Gastrointestinal Tolerance of an Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic.|Completed||Phase 3|66|Actual|Sodilac||2|||f||||f||||||||||2018-06-01 00:50:27.093039|2018-06-01 00:50:27.093039
NCT00929279|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2009-06-26|2009-06-26|2009-06-29|Estimate|||||||2009-06-26|2009-06-29|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|FABOLUS||Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time|Facilitation Through Abciximab By drOpping Infusion Line in Patients Undergoing Coronary Stenting. SYNergy With Clopidogrel at High Loading dOse Regimen|Completed||Phase 4|73|Actual|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-06-01 00:50:27.197425|2018-06-01 00:50:27.197425
NCT00929266|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2012-11-09|2009-06-26|2009-06-29|Estimate|||||||2012-11-09|2012-11-12|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|GRc2008||Cultured Red Blood Cells : Life Span in Vivo Study|First Pilot Study Evaluating the Life Span of Autologous Cultured Red Blood Cells (cRBC) Generated From Peripheral Stem Cells in Three Healthy Volunteers - Feasibility Study|Completed||N/A|1|Actual|Etablissement Français du Sang||1|||f||||t||||||||||2018-06-01 00:50:27.276923|2018-06-01 00:50:27.276923
NCT00929253|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2016-04-28|2009-06-26|2009-06-29|Estimate|||||||2016-04-28|2016-05-02|Estimate|September 2007||2007-09-30|April 2016|2016-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|CAT||Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)|Efficacy of Computer Delivered CRA (Bup II) Grant No. R01DA012997-10|Completed||N/A|206|Actual|Virginia Polytechnic Institute and State University||2|||f||||t||||||||No||2018-06-01 00:50:27.342229|2018-06-01 00:50:27.342229
NCT00929240|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2015-02-05||2015-03-02|2009-06-25|2009-06-26|Estimate|2015-03-02|2015-03-03|Estimate||||2015-03-02|2015-03-03|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Initial Phase Intent-to-Treat (ITT) population: all participants who were enrolled.|A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer|A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy|Completed||Phase 3|287|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 00:50:27.465768|2018-06-01 00:50:27.465768
NCT00929227|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2018-04-07|2009-06-25|2009-06-26|Estimate|||||||2018-04-07|2018-04-10|Actual|June 24, 2009||2009-06-24|April 6, 2018|2018-04-06||||||||Observational|||Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease|Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease|Suspended|||109|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:50:28.114399|2018-06-01 00:50:28.114399
NCT00929214|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2018-05-09|2009-06-25|2009-06-26|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2009|Actual|2009-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients|Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients|Active, not recruiting||Phase 2|75|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:50:28.182184|2018-06-01 00:50:28.182184
NCT00929201|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2010-01-05||2015-07-22|2009-06-25|2009-06-26|Estimate|2010-01-05|2010-02-01|Estimate||||2015-07-22|2015-08-13|Estimate|January 2008||2008-01-31|July 2015|2015-07-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)|An Open-Label, Randomized, Two-Period Crossover Definitive Bioequivalence Study With the Final Marketed Image (FMI) Sitagliptin/Metformin Fixed-Dose Combination (FDC) Tablet and Co-Administration of the Sitagliptin and Metformin Individual Tablets After Consumption of a High-Fat Meal in Healthy Adult Subjects|Completed||Phase 1|61|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:50:28.256543|2018-06-01 00:50:28.256543
NCT00929188|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25||2015-12-18|2015-12-18|2009-06-25|2009-06-26|Estimate||||2015-12-18|2016-01-22|Estimate|2015-12-18|2016-01-22|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Followed by an Open-Label Extension Phase|Completed||Phase 2|100|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-06-01 00:50:28.412294|2018-06-01 00:50:28.412294
NCT00929175|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-02-24|2009-06-25|2009-06-26|Estimate|||||||2014-02-24|2014-02-25|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Antihypertensive Effect of Continuous Positive Airway Pressure in Resistant Hypertensive Patients With Sleep Apnea|Antihypertensive Effect of Continuous Positive Airway Pressure (CPAP) in Resistant Hypertensive Patients With Sleep Apnea: Randomized Clinical Trial|Completed||Phase 4|45|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 00:50:28.525524|2018-06-01 00:50:28.525524
NCT00929162|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2012-04-26||2012-08-03|2009-06-25|2009-06-26|Estimate|2012-04-26|2012-06-06|Estimate||||2012-08-03|2012-08-07|Estimate|June 2009||2009-06-30|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer|A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 (Zibotentan) Plus Carboplatin and Paclitaxel or Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy|Terminated||Phase 2|120|Actual|AstraZeneca||2||"Primary objective of the trial was not met and so there was no benefit in collecting further~   information"|f||||f||||||||||2018-06-01 00:50:28.60201|2018-06-01 00:50:28.60201
NCT00929136|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-10-01|2009-06-25|2009-06-26|Estimate|||||||2010-10-01|2010-10-04|Estimate|June 2009||2009-06-30|October 2010|2010-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Peripheral Effects of Endotoxin on Insulin Resistance|The Effect of Regional Inflammation on Metabolism and Insulin Sensitivity in the Lower Extremity.|Completed||N/A|8|Anticipated|Aarhus University Hospital||1|||f||||f||||||||||2018-06-01 00:50:29.133524|2018-06-01 00:50:29.133524
NCT00929123|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2015-03-12|2009-06-25|2009-06-26|Estimate|||||||2015-03-12|2015-03-17|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|June 2009|Actual|2009-06-30|July 2008|Actual|2008-07-31||Interventional|||Mechanisms of Neural Mobilization in the Treatment of Chronic Pain|Mechanisms of Neural Mobilization in the Treatment of Chronic Pain|Completed||Phase 1/Phase 2|40|Actual|University of Florida||3|||f||||f||||||||||2018-06-01 00:50:29.226322|2018-06-01 00:50:29.226322
NCT00929110|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2012-06-22|2011-10-25|2012-08-09|2009-06-25|2009-06-26|Estimate|2012-06-22|2012-07-27|Estimate|2011-10-25|2011-10-31|Estimate|2012-08-09|2012-08-17|Estimate|June 2009||2009-06-30|August 2012|2012-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|GLOW2||1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)|A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1066|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:50:29.476699|2018-06-01 00:50:29.476699
NCT00929097|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-06-25|2009-06-25|2009-06-26|Estimate|||||||2009-06-25|2009-06-26|Estimate|October 2009||2009-10-31|June 2009|2009-06-30|January 2012|Anticipated|2012-01-31|July 2011|Anticipated|2011-07-31||Interventional|RISCO||Implementation of Guidelines on Hereditary or Familial Colorectal Cancer|Implementation of Guidelines on Hereditary or Familial Colorectal Cancer Risk Calculation and Risk Communication|Unknown status|Enrolling by invitation|N/A|300|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 00:50:32.520072|2018-06-01 00:50:32.520072
NCT00929084|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2017-05-11|2009-06-24|2009-06-26|Estimate|||||||2017-05-11|2017-05-12|Actual|November 2009||2009-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|January 2015|Actual|2015-01-31||Interventional|||Survivor Stories: Impact on Cancer Patients' Quality of Life and Follow-up|Survivor Stories: Impact on Cancer Patients' Quality of Life and Follow-up|Completed||N/A|227|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:50:32.586672|2018-06-01 00:50:32.586672
NCT00929071|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2013-12-16||2014-08-04|2009-06-24|2009-06-26|Estimate|2014-06-10|2014-07-11|Estimate||||2014-08-04|2014-08-07|Estimate|January 2009||2009-01-31|August 2014|2014-08-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|AD-1016||Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®|Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®|Completed||N/A|10|Actual|Weinkle, Susan H., M.D.||2|||f||||f||||||||||2018-06-01 00:50:32.658657|2018-06-01 00:50:32.658657
NCT00929058|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2010-05-17|2009-06-25|2009-06-26|Estimate|||||||2010-05-17|2010-05-18|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|BVZ1||Bevacizumab and Vasoconstriction|Bevacizumab and Vasoconstriction|Completed||N/A|10|Anticipated|Radboud University||1|||f||||||||||||||2018-06-01 00:50:32.908715|2018-06-01 00:50:32.908715
NCT00929045|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-04-12|2009-06-25|2009-06-26|Estimate|||||||2010-04-12|2010-04-14|Estimate|July 2007||2007-07-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Development|Growth Hormone and Insulin Growth Factor 1 Deficiencies in Children/Adolescents Following Traumatic Brain Injury: The Impact on Growth and Neuropsychological Recovery|Unknown status|Recruiting|Early Phase 1|8|Anticipated|University of Virginia||1|||f||||f||||||||||2018-06-01 00:50:32.970048|2018-06-01 00:50:32.970048
NCT00929006|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2018-01-18|2009-06-24|2009-06-26|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2008||2008-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CRM003||Time Course of Waking Versus Sleep-associated Luteinizing Hormone (LH) Pulse Frequency Suppression in Response to Progesterone in Late Pubertal Girls With and Without Hyperandrogenemia|Time Course of Waking vs. Sleep-associated LH Pulse Frequency Suppression in Response to Progesterone in Late Pubertal Girls With and Without Hyperandrogenemia|Recruiting||Phase 1|36|Anticipated|University of Virginia||2|||f||||t|t|f||||||Undecided|We do not have current plans to share IPD|2018-06-01 00:50:33.218678|2018-06-01 00:50:33.218678
NCT00928993|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-09-14|2009-06-25|2009-06-26|Estimate|||||||2009-09-14|2009-09-15|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Observational|||An Evaluation of Actigraphy as an Indicator of Sleep and Wake in Children|An Evaluation of Actigraphy as an Indicator of Sleep and Wake in Children|Unknown status|Not yet recruiting||80|Anticipated|Oregon Health and Science University|||1||f||||f||||||||||2018-06-01 00:50:33.299817|2018-06-01 00:50:33.299817
NCT00928980|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2013-11-07|2009-06-25|2009-06-26|Estimate|||||||2013-11-07|2013-11-08|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression|The Clinical and Cost-effectiveness of Mindfulness Based Cognitive Therapy, Maintenance Antidepressant Medication and Its Combination in the Prevention of Relapse in Patients With Recurrent Depression|Completed||N/A|317|Actual|Radboud University||3|||f||||f||||||||||2018-06-01 00:50:33.369808|2018-06-01 00:50:33.369808
NCT00928967|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2015-10-07|2009-06-25|2009-06-26|Estimate|||||||2015-10-07|2015-10-09|Estimate|May 2007||2007-05-31|October 2015|2015-10-31|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Observational|||Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients|Prospective Multicenter, Non-interventional Study to Evaluate the Impact of the Introduction of Interferon Beta-1 b Treatment on Daily Life Activities in Patients at High Risk of Developing Multiple Sclerosis After a First Clinical Demyelinating Event or Having Received a Confirmed Diagnosis of RRMS|Completed|||67|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 00:50:33.477427|2018-06-01 00:50:33.477427
NCT00928954|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2012-02-09||2016-07-28|2009-06-25|2009-06-26|Estimate|2016-07-28|2016-07-29|Estimate||||2016-07-28|2016-07-29|Estimate|February 2005||2005-02-28|July 2016|2016-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus|Investigation and Treatment of Ocular Motor Disorders: Cross-over Comparison of Gabapentin and Memantine as Treatment for Nystagmus|Completed||N/A|10|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-06-01 00:50:33.560176|2018-06-01 00:50:33.560176
NCT00928941|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2014-12-09|2009-06-24|2009-06-26|Estimate|||||||2014-12-09|2014-12-10|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Neural Correlates of Cognitive Rehabilitation in Post-Traumatic Stress Disorder (PTSD)|Neural Correlates of Cognitive Rehabilitation in PTSD|Terminated||N/A|40|Anticipated|VA Office of Research and Development||2||The PI has left the project and the VA, as of 3/2011|f||||f||||||||||2018-06-01 00:50:33.880348|2018-06-01 00:50:33.880348
NCT00928928|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-06-25|2009-06-25|2009-06-26|Estimate|||||||2009-06-25|2009-06-26|Estimate|January 2008||2008-01-31|June 2009|2009-06-30||||June 2009|Actual|2009-06-30||Interventional|||Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer|Study of the Oxidative Stress in Patients With Colorectal Cancer. Open vs Laparoscopic Approach|Completed||Phase 4|40|Actual|G. Hatzikosta General Hospital||2|||f||||t||||||||||2018-06-01 00:50:33.968662|2018-06-01 00:50:33.968662
NCT00928915|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2016-10-24|2009-06-25|2009-06-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|INCH||International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage|Multicenter, Prospective Randomized Trial on the Use of Prothrombin Complex and Fresh Frozen Plasma in Patients With Intracerebral Hemorrhage Related to Vitamin K Antagonists|Completed||Phase 4|54|Actual|Heidelberg University||2|||f||||t||||||||||2018-06-01 00:50:34.067361|2018-06-01 00:50:34.067361
NCT00928902|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-10-20|2009-06-25|2009-06-26|Estimate|||||||2010-10-20|2010-10-21|Estimate|November 1999||1999-11-30|October 2010|2010-10-31|March 2005|Actual|2005-03-31|April 2001|Actual|2001-04-30||Interventional|MEL36||Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma|Pilot Phase II Trial for the Evaluation of the Effect of Systemic Low-dose IL-2 on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant, in Patients With High Risk Melanoma|Completed||Phase 2|41|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 00:50:34.157143|2018-06-01 00:50:34.157143
NCT00928889|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2011-06-13||2012-05-07|2009-06-25|2009-06-26|Estimate|2011-06-13|2011-07-07|Estimate||||2012-05-07|2012-05-10|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ENERGY||Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors|A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients|Completed||Phase 4|160|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:50:34.390604|2018-06-01 00:50:34.390604
NCT00928876|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2010-12-16|2009-06-25|2009-06-26|Estimate|||||||2010-12-16|2010-12-17|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|July 2010|Anticipated|2010-07-31|March 2010|Anticipated|2010-03-31||Interventional|||Interleukin-1 Receptor Antagonist and Insulin Sensitivity|Effect of Interleukin-1 Receptor Antagonist on Insulin Sensitivity in Obese, Insulin Resistant Individuals|Unknown status|Active, not recruiting|Phase 2|12|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 00:50:34.748791|2018-06-01 00:50:34.748791
NCT00928863|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2013-05-22|2009-06-25|2009-06-26|Estimate|||||||2013-05-22|2013-05-24|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|Fluxim||Haemorrhagia Postpartum: an Implementation Study on the NVOG Guidelines and MOET Instructions|Haemorrhagia Postpartum: an Implementation Study on the NVOG Guidelines and MOET Instructions|Unknown status|Active, not recruiting||320|Anticipated|Radboud University|||1||f||||f||||||||||2018-06-01 00:50:34.835393|2018-06-01 00:50:34.835393
NCT00928850|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2017-07-05|2009-06-25|2009-06-26|Estimate|||||||2017-07-05|2017-07-06|Actual|June 2009||2009-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Modifications to Radical Prostatectomy: Feasibility Study|A Randomized Trial of Modifications to Radical Prostatectomy: Feasibility Study|Active, not recruiting||N/A|300|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-06-01 00:50:34.901552|2018-06-01 00:50:34.901552
NCT00928837|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2017-12-11|2009-06-25|2009-06-26|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2006||2006-03-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee|A Double-Blind,Randomized, Placebo Controlled, Parallel Group, Multi-Center Study of Flavocoxid (Limbrel) Versuss Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee|Completed||N/A|350|Actual|Primus Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:50:34.974034|2018-06-01 00:50:34.974034
NCT00928824|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-06-25|2009-06-25|2009-06-26|Estimate|||||||2009-06-25|2009-06-26|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Horenso||Can Japanese Traditional Foods Lower Blood Pressure in Healthy Volunteers|Dietary Nitrate in Japanese Traditional Foods Lowers Diastolic Blood Pressure in Healthy Volunteers.|Completed||N/A|25|Actual|Kyorin University|||||f||||t||||||||||2018-06-01 00:50:35.051313|2018-06-01 00:50:35.051313
NCT00928811|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2015-02-09|2009-06-25|2009-06-26|Estimate|||||||2015-02-09|2015-02-10|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|Simulect||Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant|One-year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-risk Kidney Transplant Recipients Treated With MPA|Terminated||Phase 2/Phase 3|5|Actual|Drexel University||2||Investigator left University 04/2010|f||||t||||||||||2018-06-01 00:50:35.10468|2018-06-01 00:50:35.10468
NCT00928798|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2012-03-07|2009-06-25|2009-06-26|Estimate|||||||2012-03-07|2012-03-08|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||Topical Rapamycin for Fibrofolliculomas|Topical Rapamycin to Treat Fibrofolliculomas in Birt-Hogg-Dubé Syndrome|Completed||Phase 3|19|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 00:50:35.18755|2018-06-01 00:50:35.18755
NCT00928785|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2017-09-08|2009-06-25|2009-06-26|Estimate|||||||2017-09-08|2017-09-11|Actual|July 2009|Actual|2009-07-31|September 2017|2017-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults|A Randomised, Comparative, Multicentre Clinical Trial of the Immunogenicity and Safety of Tdap-IPV Vaccine and a Tetanus Monovalent Vaccine in Healthy Adults 18 Years of Age and Older|Completed||Phase 3|52|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:50:35.260987|2018-06-01 00:50:35.260987
NCT00928772|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2017-04-19||2017-04-19|2009-06-25|2009-06-26|Estimate|2017-04-19|2017-04-20|Actual||||2017-04-19|2017-04-20|Actual|July 2009||2009-07-31|April 2017|2017-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety|The Effect of Cranial Electro Therapy Stimulation in Reducing Perioperative Anxiety for Patients Undergoing First Eye Cataract Surgery|Terminated||Phase 4|115|Actual|University of Oklahoma||3||Lack of efficacy|f||||f||||||||||2018-06-01 00:50:35.360621|2018-06-01 00:50:35.360621
NCT00928759|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2018-01-18|2009-06-25|2009-06-26|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2008||2008-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CRM002||Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls|Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls|Recruiting|||40|Anticipated|University of Virginia|||1||f||||f|f|f||||||Undecided|We do not have current plans to share IPD|2018-06-01 00:50:35.611524|2018-06-01 00:50:35.611524
NCT00928746|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2010-08-04||2014-06-23|2009-06-25|2009-06-26|Estimate|2010-09-08|2010-09-28|Estimate||||2014-06-23|2014-07-02|Estimate|June 2009||2009-06-30|January 2014|2014-01-31||||August 2009|Actual|2009-08-31||Interventional||Patients who were entered into this study and documented to have taken at least one dose of study medication (treated set).|Actuation Indicator Trial in Patients With COPD|ATROVENT HFA Actuation Indicator Open-Label Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|142|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:50:35.695736|2018-06-01 00:50:35.695736
NCT00928733|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2014-11-11|2009-06-25|2009-06-26|Estimate|||||||2014-11-11|2014-11-13|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Ethanol on Intestinal Permeability and Integrity|The Effect of Ethanol on Intestinal Permeability and Integrity in Healthy Individuals|Completed||N/A|17|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-06-01 00:50:36.038867|2018-06-01 00:50:36.038867
NCT00928720|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2014-06-05||2014-08-11|2009-06-25|2009-06-26|Estimate|2014-08-11|2014-08-13|Estimate||||2014-08-11|2014-08-13|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia|Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia|Completed||Phase 1/Phase 2|57|Actual|University of Virginia||3|||f||||f||||||||||2018-06-01 00:50:36.122121|2018-06-01 00:50:36.122121
NCT00928707|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2012-09-17|2009-06-25|2009-06-26|Estimate|||||||2012-09-17|2012-09-18|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|PV||Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera|Phase II Study of the Histone-deacetylase Inhibitor GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Patients With JAK2V617F Positive Polycythemia Vera Non-responder to Hydroxyurea Monotherapy.|Completed||Phase 2|45|Actual|Italfarmaco||2|||f||||f||||||||||2018-06-01 00:50:36.440036|2018-06-01 00:50:36.440036
NCT00928694|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2009-11-10||2015-08-18|2009-06-25|2009-06-26|Estimate|2009-11-10|2009-12-11|Estimate||||2015-08-18|2015-08-19|Estimate|February 2003||2003-02-28|August 2015|2015-08-31|April 2004|Actual|2004-04-30|April 2003|Actual|2003-04-30||Interventional|||Fenofibrate Bioequivalence Study (0767-031)|An Open-Label, Randomized, 2-Period, Crossover Study to Determine Definitive Bioequivalence After Administration of Single 160 mg Doses of the U.S. and UK Formulations of Fenofibrate in Healthy Adult Subjects|Completed||Phase 1|14|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 00:50:36.550288|2018-06-01 00:50:36.550288
NCT00928681|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-25|2009-06-25|2009-06-26|Estimate|||||||2009-06-25|2009-06-26|Estimate|September 2005||2005-09-30|June 2009|2009-06-30|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis|A Randomized, Double-Blind (Sponsor Open), Placebo Controlled, Dose Escalating, Parallel Group, Multi-Centre Study To Investigate The Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous/Sub-Cutaneous Doses Of PF-00547659 In Patients With Active Ulcerative Colitis.|Completed||Phase 1|80|Actual|Pfizer||12|||f||||f||||||||||2018-06-01 00:50:36.726174|2018-06-01 00:50:36.726174
NCT00928499|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-11-16|2009-06-25|2009-06-26|Estimate|||||||2010-11-16|2010-11-17|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|June 2010|Anticipated|2010-06-30|April 2010|Anticipated|2010-04-30||Interventional|||Trial of Continuous Versus Cyclic Stimulation in Interstim Therapy|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy|Unknown status|Recruiting|N/A|30|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-06-01 00:50:40.370584|2018-06-01 00:50:40.370584
NCT00928668|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2014-03-28||2014-05-29|2009-06-25|2009-06-26|Estimate|2014-05-29|2014-07-01|Estimate||||2014-05-29|2014-07-01|Estimate|January 2006||2006-01-31|May 2014|2014-05-31||||October 2006|Actual|2006-10-31||Interventional|||Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma|Randomised, Double-Blind, Placebo-Controlled, 5-Way Cross-Over Study to Assess the Efficacy (Bronchoprotection) and Safety of a Single Dose of Orally Inhaled BI 1744 CL (2, 5, 10 and 20ug) in Patients With Intermittent Asthma|Completed||Phase 2|32|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-06-01 00:50:36.879552|2018-06-01 00:50:36.879552
NCT00928655|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2014-05-18|2009-06-25|2009-06-26|Estimate|||||||2014-05-18|2014-05-20|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude|Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude|Completed||Phase 4|51|Actual|University of Zurich||2|||f||||t||||||||||2018-06-01 00:50:37.316323|2018-06-01 00:50:37.316323
NCT00928642|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2013-04-05||2014-10-20|2009-06-25|2009-06-26|Estimate|2014-10-20|2014-10-21|Estimate||||2014-10-20|2014-10-21|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer|A Phase II Trial of Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer Who Have Failed at Least Two Prior Therapies|Completed||Phase 2|8|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine|This study was terminated due to a combination of poor accrual and lack of evidence of benefit.|1|||f||||f||||||||||2018-06-01 00:50:37.396062|2018-06-01 00:50:37.396062
NCT00928629|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-11-11|2009-06-25|2009-06-26|Estimate|||||||2009-11-11|2009-11-13|Estimate|June 2009||2009-06-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|||||Interventional|ACHILLES||Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease|Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease. A Cross-sectional Multi-centre Clinical Study in Subjects With Cardiovascular Disease Risk Factors.|Completed||N/A|1000|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:50:37.571685|2018-06-01 00:50:37.571685
NCT00928616|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-06-25|2009-06-25|2009-06-26|Estimate|||||||2009-06-25|2009-06-26|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|PSE-MO||Differential Effects of a Diet Supplementation With Plant Sterol Esters on Human Monocytes|"Differential Effects of Functional Foods Supplemented With Plant Sterol Esters on Blood Cells and Serum Parameters."|Unknown status|Active, not recruiting|N/A|16|Actual|University Hospital, Saarland||2|||f||||f||||||||||2018-06-01 00:50:37.643662|2018-06-01 00:50:37.643662
NCT00928603|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2009-09-14|2009-06-25|2009-06-26|Estimate|||||||2009-09-14|2009-09-15|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2014|Anticipated|2014-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Investigative Study of the Role of Focal Therapy for Prostate Cancer Treatment|Focal Therapy for Organ Confined Prostate Cancer: an Investigative Prospective Pilot Study|Unknown status|Enrolling by invitation|Phase 1|100|Anticipated|Università Vita-Salute San Raffaele||1|||f||||t||||||||||2018-06-01 00:50:37.709644|2018-06-01 00:50:37.709644
NCT00928590|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24||2014-07-16|2014-07-16|2009-06-25|2009-06-26|Estimate||||2014-07-16|2014-07-18|Estimate|2014-07-16|2014-07-18|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Twelve-Month Open-Label Safety Study of Polyquaternium-Preserved DuoTrav APS Dosed Once Daily in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|155|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 00:50:37.782724|2018-06-01 00:50:37.782724
NCT00928577|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2018-01-26|2009-06-25|2009-06-26|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2008||2008-12-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)|A Phase IV Prospective Safety Surveillance Cohort Study Of ACAM2000® In Deploying Military Personnel|Completed|||14108|Actual|Emergent BioSolutions|||2||f||||f||||||||||2018-06-01 00:50:37.853163|2018-06-01 00:50:37.853163
NCT00928564|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2016-10-26|2009-06-25|2009-06-26|Estimate|||||||2016-10-26|2016-10-28|Estimate|April 2009||2009-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia|Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia: A Randomized Controlled Cross-over Trial|Completed||N/A|120|Actual|University of California, Irvine||2|||f||||t||||||||||2018-06-01 00:50:37.916748|2018-06-01 00:50:37.916748
NCT00928551|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-09-10|2009-06-25|2009-06-26|Estimate|||||||2009-09-10|2009-09-11|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparative Formulation Study of Vabicaserin|A Randomized, Open-Label, Single-Dose, 3-Period Crossover, Comparative Study of a Modified Formulation of Vabicaserin (SCA-136) Versus the Reference Formulation in Healthy Subjects|Completed||Phase 1|15|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 00:50:38.091239|2018-06-01 00:50:38.091239
NCT00928538|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2016-03-28|2009-06-25|2009-06-26|Estimate|||||||2016-03-28|2016-03-30|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2013|Actual|2013-05-31||Interventional|NFP2||Nurse Family Partnership (NFP) Contraceptive Study|Effectiveness of Home Based Distribution of Hormonal Contraceptives for Women at Risk for Unintended Pregnancy|Completed||Phase 4|344|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 00:50:38.147695|2018-06-01 00:50:38.147695
NCT00928525|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2018-04-18|2009-06-25|2009-06-26|Estimate|||||||2018-04-18|2018-04-19|Actual|May 2007|Actual|2007-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Basket 1||Imatinib in Patients With Desmoid Tumor and Chondrosarcoma|Open-label Trial of Imatinib in Patients With Desmoid Tumor and Chondrosarcoma|Active, not recruiting||Phase 2|35|Anticipated|Italian Sarcoma Group||1|||f||||t||||||||||2018-06-01 00:50:38.221658|2018-06-01 00:50:38.221658
NCT00928512|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2015-02-12|2012-05-31|2015-10-07|2009-06-25|2009-06-26|Estimate|2015-07-01|2015-07-30|Estimate|2012-05-31|2012-06-06|Estimate|2015-10-07|2015-10-30|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||The randomized set was defined as all subjects being randomized.|Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)|A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate|Completed||Phase 2|237|Actual|Novartis||5|||f||||f||||||||||2018-06-01 00:50:38.336202|2018-06-01 00:50:38.336202
NCT00928486|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2016-05-06||2016-05-06|2009-06-25|2009-06-26|Estimate|2016-05-06|2016-06-14|Estimate||||2016-05-06|2016-06-14|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||Safety Population = includes all participants who received at least one dose of study drug|A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma|A Safety Confirmation Study On Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma|Completed||Phase 3|25|Actual|Celgene Corporation||1|||f||||f||||||||||2018-06-01 00:50:40.455779|2018-06-01 00:50:40.455779
NCT00928473|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2017-06-27|2009-06-25|2009-06-26|Estimate|||||||2017-06-27|2017-06-28|Actual|January 2009||2009-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Danish Childhood Obesity Biobank|The Danish Childhood Obesity Biobank|Recruiting||N/A|5000|Anticipated|Zealand University Hospital||1|||f||||t||||||||||2018-06-01 00:50:40.744106|2018-06-01 00:50:40.744106
NCT00928460|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2013-07-30|2009-06-25|2009-06-26|Estimate|||||||2013-07-30|2013-07-31|Estimate||||July 2013|2013-07-31||||||||Observational|||Efficacy of Preoperative Electrocardiography|The Efficacy of Routine Preoperative Electrocardiography in Patients Undergoing Non-cardiac Surgery|Withdrawn|||0|Actual|UMC Utrecht|||2||f||||t||||||||||2018-06-01 00:50:40.814336|2018-06-01 00:50:40.814336
NCT00928447|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|||2012-09-10|2009-06-25|2009-06-26|Estimate|||||||2012-09-10|2012-09-12|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis|Completed||Phase 2|22|Actual|Halozyme Therapeutics||2|||f||||f||||||||||2018-06-01 00:50:40.887604|2018-06-01 00:50:40.887604
NCT00928434|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2016-05-09|2013-09-20|2016-10-21|2009-06-25|2009-06-26|Estimate|2016-10-21|2016-12-13|Estimate|2013-09-20|2013-09-27|Estimate|2016-10-21|2016-12-13|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Analysis population consist of Full Analysis Set (FAS), which comprised of subjects who received at least one dose of IMP and had at least one efficacy assessment after dosing.|A Study of Degarelix in Patients With Prostate Cancer|A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment|Completed||Phase 3|409|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-06-01 00:50:41.018841|2018-06-01 00:50:41.018841
NCT00928421|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2014-02-19|2011-09-14|2014-02-19|2009-06-25|2009-06-26|Estimate|2014-02-19|2014-04-02|Estimate|2011-09-14|2011-09-21|Estimate|2014-02-19|2014-04-02|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional||all patients treated with polidocanol injectable foam 0.125%|An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins|An Open-label, Single-dose Pilot Study to Evaluate the Efficacy and Safety of Varisolve® (Polidocanol Endovenous Microfoam) 0.125% [0.2%] for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence|Completed||Phase 2|16|Actual|BTG International Inc.||1|||f||||f||||||||||2018-06-01 00:50:42.693649|2018-06-01 00:50:42.693649
NCT00928408|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-25|2013-02-05||2014-07-18|2009-06-25|2009-06-26|Estimate|2013-09-10|2013-11-14|Estimate||||2014-07-18|2014-07-25|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Observational|||PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice|PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice|Completed|||305|Actual|Amgen|||1||f||||f||||||||||2018-06-01 00:50:42.857811|2018-06-01 00:50:42.857811
NCT00928395|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2013-01-24||2013-04-04|2009-06-25|2009-06-26|Estimate|2013-04-04|2013-05-16|Estimate||||2013-04-04|2013-05-16|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|STEP||Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms|Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation|Completed||Phase 4|50|Actual|Uroplasty, Inc||1|||f||||||||||||||2018-06-01 00:50:43.234342|2018-06-01 00:50:43.234342
NCT00928382|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2017-06-30|2009-06-24|2009-06-25|Estimate|||||||2017-06-30|2017-07-02|Actual|March 31, 2009||2009-03-31|April 10, 2012|2012-04-10|April 10, 2012||2012-04-10|||||Observational|||A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression|A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord Compression|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:50:43.441393|2018-06-01 00:50:43.441393
NCT00928369|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Clinical Characteristics of Patients Under the Age 21 Years Who Underwent Gynecological Surgery|Clinical Characteristics of Adnexal Masses in Korean Pediatric and Adolescent Patients Under the Age 21 Years|Unknown status|Active, not recruiting||494|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-06-01 00:50:43.493021|2018-06-01 00:50:43.493021
NCT00928356|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2018-03-22|2009-06-24|2009-06-25|Estimate|||||||2018-03-22|2018-03-23|Actual|September 2008||2008-09-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Single Center Clinical Evaluation of Same Sitting Hybrid Revascularization: Robotic Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Coronary Artery Disease|A Single Center Clinical Evaluation of Same Sitting Hybrid Revascularization: Robotic Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Coronary Artery Disease|Recruiting||N/A|350|Anticipated|Pinnacle Health Cardiovascular Institute||2|||f||||t|f|f||||||Undecided||2018-06-01 00:50:43.541621|2018-06-01 00:50:43.541621
NCT00928343|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2010-01-14|2009-06-24|2009-06-25|Estimate|||||||2010-01-14|2010-01-15|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187|Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Subcutaneous and Oral Doses of GLPG0187 in Healthy Subjects.|Completed||Phase 1|18|Actual|Galapagos NV||2|||f||||f||||||||||2018-06-01 00:50:43.624599|2018-06-01 00:50:43.624599
NCT00928005|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2013-04-01|2009-06-23|2009-06-25|Estimate|||||||2013-04-01|2013-04-04|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|SHAPE3||Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study)|Diet and Exercise in Type 2 Diabetes and Prediabetes|Completed||Phase 4|77|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:50:52.278262|2018-06-01 00:50:52.278262
NCT00928330|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2016-11-01|2009-06-24|2009-06-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy|A Phase Ib, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Activity of Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy|Completed||Phase 1|57|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 00:50:43.68179|2018-06-01 00:50:43.68179
NCT00928317|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-01-04|2009-06-24|2009-06-25|Estimate|||||||2010-01-04|2010-01-06|Estimate|April 2009||2009-04-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate|Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate|Terminated||Phase 2|13|Actual|Arana Therapeutics Ltd||4||Corporate re-prioritization|f||||t||||||||||2018-06-01 00:50:43.752737|2018-06-01 00:50:43.752737
NCT00928304|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2013-12-09|2013-05-09|2014-01-29|2009-06-24|2009-06-25|Estimate|2013-12-09|2014-01-28|Estimate|2013-05-09|2013-05-16|Estimate|2014-01-29|2014-03-05|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||All Down Syndrome subjects and healthy volunteers enrolled into the study were included in the Baseline Analysis Population|Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.|An Open-Label, Non-Randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection of Cerebral ß-Amyloid in Individuals With Down Syndrome Compared to Individuals Without Down Syndrome|Completed||Phase 2|109|Actual|Piramal Imaging SA||1|||f||||f||||||||||2018-06-01 00:50:43.867695|2018-06-01 00:50:43.867695
NCT00928291|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2011-06-22|2009-06-24|2009-06-25|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2010||2010-01-31|December 2009|2009-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Procalcitonin Protocol to Shorten the Antibiotic Therapy in Febrile Neutropenia|The Use of a Procalcitonin (PCT)-Guided Protocol to Shorten the Duration of Antibiotic Therapy in Febrile Neutropenic Patients. An Interventional Study.|Completed||N/A|60|Anticipated|Federal University of Minas Gerais||2|||f||||t||||||||||2018-06-01 00:50:44.082326|2018-06-01 00:50:44.082326
NCT00928278|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-12-18|2009-06-24|2009-06-25|Estimate|||||||2009-12-18|2009-12-21|Estimate|July 2009||2009-07-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers.|Completed||Phase 1|36|Anticipated|Pfizer||4|||f||||f||||||||||2018-06-01 00:50:44.281192|2018-06-01 00:50:44.281192
NCT00928265|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2013-05-31|2009-06-24|2009-06-25|Estimate|||||||2013-05-31|2013-06-04|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|SENAT||Safety and Efficacy of Neuroform3TM for Intracranial Aneurysm Treatment|Safety and Efficacy of Neuroform3TM for Intracranial Aneurysm Treatment|Completed|||116|Actual|Stryker Neurovascular|||||f||||f||||||||||2018-06-01 00:50:44.349171|2018-06-01 00:50:44.349171
NCT00928252|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2017-06-19||2017-07-13|2009-06-24|2009-06-25|Estimate|2017-07-13|2017-08-14|Actual||||2017-07-13|2017-08-14|Actual|June 2009||2009-06-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer|Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer|Completed||Phase 1/Phase 2|25|Actual|Queen's Medical Centre||1|||f||||f||||||||||2018-06-01 00:50:44.447124|2018-06-01 00:50:44.447124
NCT00928239|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|June 2014|Anticipated|2014-06-30|June 2011|Anticipated|2011-06-30||Interventional|MeshPlace||Laparoscopic Sacropexy: Comparison of Mesh Attachment|Laparoscopic Sacropexy: Randomized Clinical Trial to Compare Two Different Attachment Sites of the Dorsal Mesh at the Vaginal Insertion(MeshPlace)|Unknown status|Recruiting|N/A|88|Anticipated|Kantonsspital Aarau||2|||f||||f||||||||||2018-06-01 00:50:44.725783|2018-06-01 00:50:44.725783
NCT00928226|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2018-03-20|2009-06-24|2009-06-25|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2009||2009-04-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|October 31, 2017|Actual|2017-10-31||Interventional|||Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases|A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases|Active, not recruiting||N/A|120|Actual|Stanford University||4|||f||||t|f|t|f|f||||No||2018-06-01 00:50:44.808484|2018-06-01 00:50:44.808484
NCT00928213|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|August 2009||2009-08-31|June 2009|2009-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||PP13 and Doppler Study to Predict Preeclampsia|Combined Sonographic Examination and Placenta Protein 13 (PP13) to Compare the Risk for Development of Preeclampsia Among Among Pregnant Women With and Without a History of Preterm Delivery and Those Treated by Progesterone or Clexane|Unknown status|Not yet recruiting|Phase 2/Phase 3|1000|Anticipated|Ben-Gurion University of the Negev||3|||f||||f||||||||||2018-06-01 00:50:44.989365|2018-06-01 00:50:44.989365
NCT00928200|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-08-18|2009-06-24|2009-06-25|Estimate|||||||2010-08-18|2010-08-20|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)|Intravenous Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia and Allergy to E. Coli Asparaginase (IND 104224)|Terminated||Phase 1|30|Anticipated|Therapeutic Advances in Childhood Leukemia Consortium||||Study was terminated due to lack of accrual.|f||||t||||||||||2018-06-01 00:50:45.335202|2018-06-01 00:50:45.335202
NCT00928187|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2016-07-11||2017-01-12|2009-06-24|2009-06-25|Estimate|2016-09-21|2016-11-08|Estimate||||2017-01-12|2017-02-27|Actual|November 2009||2009-11-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|September 2013|Actual|2013-09-30||Interventional|2LADY||Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)|Multicentric, Non-inferiority, Randomized, Non-blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal)|Completed||Phase 3|454|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Limitations: open label design, random imbalance at baseline. Non-inferiority not shown, results influenced by the hypothesis of 80% viral success (50 copies/mL), not reached (69% in the control group). Therefore, the study power was reduced (80%).|3|||f||||t||||||||||2018-06-01 00:50:45.731738|2018-06-01 00:50:45.731738
NCT00928174|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2014-10-01||2015-10-13|2009-06-24|2009-06-25|Estimate|2014-11-07|2014-11-19|Estimate||||2015-10-13|2015-11-11|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer|Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer|Completed||Phase 1/Phase 2|27|Actual|Queen's Medical Centre||1|||f||||f||||||||||2018-06-01 00:50:46.773028|2018-06-01 00:50:46.773028
NCT00928161|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2012-09-05|2009-06-24|2009-06-25|Estimate|||||||2012-09-05|2012-09-07|Estimate|November 2012||2012-11-30|September 2012|2012-09-30||||November 2014|Anticipated|2014-11-30||Interventional|||Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy|Evaluation and Treatment of Reflux Disease in Patients With Head and Neck Cancer Undergoing Radiation Therapy That Causes Significant Mucositis in the Reflux Field and Xerostomia|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 00:50:46.966365|2018-06-01 00:50:46.966365
NCT00928148|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-23|2009-06-23|2009-06-25|Estimate|||||||2009-06-23|2009-06-25|Estimate|March 2004||2004-03-31|June 2009|2009-06-30|October 2004|Actual|2004-10-31|||||Interventional|||The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo- and Active-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder|Completed||Phase 2|86|Actual|Shire||3|||f||||||||||||||2018-06-01 00:50:47.034358|2018-06-01 00:50:47.034358
NCT00928135|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2018-04-09|2009-06-23|2009-06-25|Estimate|||||||2018-04-09|2018-04-11|Actual|January 22, 2013|Actual|2013-01-22|April 2018|2018-04-30|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects|Randomized Controlled Study of Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Hospitalized Patients With Exacerbation of Cystic Fibrosis|Completed||Phase 1/Phase 2|63|Actual|University of Iowa||2|||f||||t|t|f||||||||2018-06-01 00:50:47.103997|2018-06-01 00:50:47.103997
NCT00928122|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2010-02-07|2009-06-24|2009-06-25|Estimate|||||||2010-02-07|2010-02-09|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|December 2012|Anticipated|2012-12-31|January 2009|Actual|2009-01-31||Interventional|ISCAF||Intrastromal Correction of Ametropia by a Femtosecond Laser|Intrastromal Correction of Ametropia by a Femtosecond Laser|Unknown status|Recruiting|Phase 3|200|Anticipated|20/10 Perfect Vision||5|||f||||f||||||||||2018-06-01 00:50:47.173441|2018-06-01 00:50:47.173441
NCT00928109|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2012-11-08|2009-06-24|2009-06-25|Estimate|||||||2012-11-08|2012-11-09|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|UCAN||UCAN: Uniting Couples in the Treatment of Anorexia Nervosa|Innovative Trial for the Treatment of Anorexia Nervosa in Late Adolescence and Adulthood|Completed||N/A|40|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 00:50:47.258212|2018-06-01 00:50:47.258212
NCT00928096|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2014-10-18|2009-06-24|2009-06-25|Estimate|||||||2014-10-18|2014-10-21|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Breathing Adapted Radiotherapy for Mediastinal Lymphoma|Breathing Adapted Radiotherapy for Mediastinal Lymphoma|Completed|||22|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 00:50:47.370736|2018-06-01 00:50:47.370736
NCT00928083|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2014-11-10||2015-01-07|2009-06-24|2009-06-25|Estimate|2015-01-07|2015-01-08|Estimate||||2015-01-07|2015-01-08|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects|A Phase I Study To Investigate The Safety, Tolerability And Pharmacokinetic Profile Of OZ439 In Healthy Male and Female Subjects|Completed||Phase 1|63|Actual|Medicines for Malaria Venture||17|||f||||f||||||||||2018-06-01 00:50:47.458027|2018-06-01 00:50:47.458027
NCT00928070|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2012-12-10||2012-12-10|2009-06-24|2009-06-25|Estimate|2012-12-10|2013-01-17|Estimate||||2012-12-10|2013-01-17|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.|Completed||Phase 4|566|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:50:48.732417|2018-06-01 00:50:48.732417
NCT00928057|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2010-08-12||2010-09-24|2009-06-24|2009-06-25|Estimate|2010-09-24|2010-10-20|Estimate||||2010-09-24|2010-10-20|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles|Comparison of Glycemic Control Among Diabetics Using the 4mm x 32G BD Pen Needle Versus the 8mm x 31G BD Pen Needle and the 5mm x 31G BD Pen Needle|Completed||N/A|173|Actual|Becton, Dickinson and Company||2|||f||||f||||||||||2018-06-01 00:50:50.827186|2018-06-01 00:50:50.827186
NCT00928044|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|July 2009|Anticipated|2009-07-31|January 2009|Anticipated|2009-01-31||Observational|||The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone (AMH)|The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone|Unknown status|Active, not recruiting||330|Anticipated|Samsung Medical Center|||2||f||||f||||||Samples Without DNA|"~     Blood sample was taken before and in 1 week, 1 month and 3 months after surgery for operation~     group or at the time of screening for control group, and transvaginal ultrasonography was~     performed with AMH sampling.~      After collection of blood, serum was stored at -70ºC until the measurement of AMH level.~     Serum levels of AMH were determined by an enzyme-linked immunosorbent assay using commercial~     kit (Beckman Coulter Inc., Paris, France)~   "|||2018-06-01 00:50:51.523207|2018-06-01 00:50:51.523207
NCT00928031|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-04-23|2009-06-24|2009-06-25|Estimate|||||||2010-04-23|2010-04-26|Estimate|June 2007||2007-06-30|April 2010|2010-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|MDX010-28||Long-term Data Collection for Subjects in MDX-010 Studies|Collection of Long-Term Outcome Data for Subjects Who Have Previously Participated in Selected Ipilimumab (MDX-010) Studies in Metastatic Melanoma|Completed|||160|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-06-01 00:50:51.594999|2018-06-01 00:50:51.594999
NCT00928018|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2015-11-16||2015-12-17|2009-06-24|2009-06-25|Estimate|2015-11-16|2015-12-18|Estimate||||2015-12-17|2016-01-21|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma|A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma|Completed||Phase 3|139|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 00:50:51.695476|2018-06-01 00:50:51.695476
NCT00927992|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2012-12-20||2012-12-20|2009-06-24|2009-06-25|Estimate|2012-12-20|2013-01-30|Estimate||||2012-12-20|2013-01-30|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Study Evaluating Liver Transplantation in Haemophilia Patients in Spain|Liver Transplantation in Haemophilia Patients in Spain|Completed|||11|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|No outcomes were specified in the study protocol. Designation of outcomes as primary and secondary was based on study team’s input as study neither specifies nor prioritizes the outcomes.||1||f||||f||||||||||2018-06-01 00:50:52.445919|2018-06-01 00:50:52.445919
NCT00927979|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2011-06-26|2009-06-24|2009-06-25|Estimate|||||||2011-06-26|2011-06-28|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|PSDR||Pain Relief by Intra-Peritoneal Nebulization of Ropivacaine Under Remifentanil Anesthesia for Gynecological Laparoscopy|Phase 3 Prospective, Randomized, Controlled and Double-blinded Second Trial on Pain Relief by Continuous Intra-peritoneal Nebulization of Ropivacaine Under Remifentanil Anesthesia, During Gynecological Laparoscopic Surgery|Completed||Phase 3|40|Actual|Carmel Medical Center||2|||f||||t||||||||||2018-06-01 00:50:52.641624|2018-06-01 00:50:52.641624
NCT00927966|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2013-11-12|2009-06-24|2009-06-25|Estimate|||||||2013-11-12|2013-11-14|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms|Phase I Clinical Trial of RAD001 in Combination With CP-751,871 in Patients With Advanced Sarcomas and Other Malignant Neoplasms|Completed||Phase 1|21|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:50:52.694811|2018-06-01 00:50:52.694811
NCT00927953|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2012-04-10||2012-10-08|2009-06-24|2009-06-25|Estimate|2012-10-08|2012-11-07|Estimate||||2012-10-08|2012-11-07|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|PARADIGM||Treatment of West Nile Virus With MGAWN1|Phase 2, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MGAWN1 in Subjects With Laboratory-documented West Nile Fever or Suspected Central Nervous System Infection Due to West Nile Virus|Terminated||Phase 2|13|Actual|MacroGenics|Early termination due to the inability to enroll (only 13 of 120 subjects enrolled); leading to small numbers of subjects analyzed and therefore many pre-specified analyses were not performed.|2||Early termination due to the inability to enroll (13 of 120 subjects enrolled)|t||||t||||||||||2018-06-01 00:50:52.77606|2018-06-01 00:50:52.77606
NCT00927940|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2012-02-09||2015-04-14|2009-06-24|2009-06-25|Estimate|2012-06-06|2012-07-09|Estimate||||2015-04-14|2015-05-05|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|December 2010|Actual|2010-12-31||Interventional|RJ||RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent|The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries|Completed||N/A|100|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-06-01 00:50:53.212372|2018-06-01 00:50:53.212372
NCT00927927|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2013-04-25||2016-08-24|2009-06-24|2009-06-25|Estimate|2013-10-08|2013-10-21|Estimate||||2016-08-24|2016-10-03|Estimate|June 2009||2009-06-30|August 2016|2016-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Dose-escalation, Single and Multiple Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0142-0002 Administered Subcutaneously to Subjects With Rheumatoid Arthritis|Completed||Phase 1|65|Actual|Janssen Research & Development, LLC|Maximum tolerated dose was not reached.|15|||f||||f||||||||||2018-06-01 00:50:53.455106|2018-06-01 00:50:53.455106
NCT00927914|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24||2013-05-21|2015-11-17|2009-06-24|2009-06-25|Estimate||||2013-05-21|2013-05-29|Estimate|2015-11-17|2015-12-16|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy|A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy|Completed||Phase 2/Phase 3|800|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 00:50:54.628346|2018-06-01 00:50:54.628346
NCT00927901|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2011-07-29||2013-08-26|2009-06-24|2009-06-25|Estimate|2011-07-29|2011-08-30|Estimate||||2013-08-26|2013-09-09|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 4-way Crossover Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Indacaterol Salts (Maleate, Xinafoate, and Acetate) in Patients With Persistent Asthma|Completed||Phase 2|30|Actual|Novartis||4|||f||||||||||||||2018-06-01 00:50:54.77025|2018-06-01 00:50:54.77025
NCT00927888|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2012-12-18||2016-04-19|2009-06-24|2009-06-25|Estimate|2015-03-02|2015-03-04|Estimate||||2016-04-19|2016-05-19|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|||Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery|The Effect of Preemptive Sphenopalatine Ganglion Block on Anesthetic Requirements, Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery|Completed||Phase 4|56|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 00:50:55.054843|2018-06-01 00:50:55.054843
NCT00927875|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2013-05-31|2009-06-24|2009-06-25|Estimate|||||||2013-05-31|2013-06-03|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer|A Phase 1b Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-833923 (XL139) in Combination With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer|Completed||Phase 1|5|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:50:55.245372|2018-06-01 00:50:55.245372
NCT00927862|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2012-04-09||2012-08-24|2009-06-24|2009-06-25|Estimate|2012-08-24|2012-09-25|Estimate||||2012-08-24|2012-09-25|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|Coumagen-II||Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin|The Clinical Impact of Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin in Patients Being Initiated on Oral Anticoagulation|Completed||Phase 2/Phase 3|2415|Actual|Intermountain Health Care, Inc.||3|||f||||t||||||||||2018-06-01 00:50:55.325771|2018-06-01 00:50:55.325771
NCT00927849|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2009-03-23||2009-05-07|2009-05-07|2009-06-25|Estimate|2009-05-07|2009-06-25|Estimate||||2009-05-07|2009-06-25|Estimate|September 2002||2002-09-30|May 2009|2009-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy|Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy|Completed||N/A|63|Actual|Mansoura University||3|||f||||t||||||||||2018-06-01 00:50:55.864383|2018-06-01 00:50:55.864383
NCT00927836|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2011-12-12|2009-06-24|2009-06-25|Estimate|||||||2011-12-12|2011-12-13|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|AXIS-2||AXIS 2: AX200 for the Treatment of Ischemic Stroke|AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-controlled Phase II Trial|Completed||Phase 2|328|Actual|Sygnis Bioscience GmbH & Co KG||2|||f||||t||||||||||2018-06-01 00:50:56.091987|2018-06-01 00:50:56.091987
NCT00927823|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2014-07-18||2014-07-18|2009-06-23|2009-06-25|Estimate|2014-07-18|2014-08-12|Estimate||||2014-07-18|2014-08-12|Estimate|December 2009||2009-12-31|July 2014|2014-07-31|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|||A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients|A Phase 1, Open-Label, Dose-Escalation Study To Evaluate Safety, Pharmacokinetics, And Pharmacodynamics Of The PI3K/MTOR Inhibitor PF-04691502 In Adult Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|37|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:50:56.429066|2018-06-01 00:50:56.429066
NCT00927810|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2016-11-15|2009-06-24|2009-06-25|Estimate|||||||2016-11-15|2016-11-17|Estimate|July 2009||2009-07-31|May 2012|2012-05-31||||August 2010|Actual|2010-08-31||Interventional|||Long Term Study of Canakinumab (ACZ885) in Patients With Gout|A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Are Given Canakinumab at the Time of Gout Flare|Completed||Phase 2|300|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:50:57.923576|2018-06-01 00:50:57.923576
NCT00927797|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|February 2005||2005-02-28|June 2009|2009-06-30|January 2012|Anticipated|2012-01-31|January 2009|Anticipated|2009-01-31||Interventional|PERLL||Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)|Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas|Unknown status|Active, not recruiting|Phase 2|185|Anticipated|Heidelberg University||1|||f||||t||||||||||2018-06-01 00:50:58.040582|2018-06-01 00:50:58.040582
NCT00927784|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2013-05-15|2009-06-24|2009-06-25|Estimate|||||||2013-05-15|2013-05-17|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|February 2011|Actual|2011-02-28|May 2010|Actual|2010-05-31||Interventional|||Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD|The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Bridge to Transplant Patients|Terminated||Phase 2|10|Actual|Icahn School of Medicine at Mount Sinai||2||The enrollment has been terminated by the NHLBI for administrative reasons.|f||||t||||||||||2018-06-01 00:50:58.130508|2018-06-01 00:50:58.130508
NCT00927771|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Azelaic Acid Versus Hydroquinone in Melasma|Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma|Unknown status|Recruiting|Phase 4|30|Anticipated|Callender Center for Clinical Research||2|||f||||f||||||||||2018-06-01 00:50:58.285496|2018-06-01 00:50:58.285496
NCT00927758|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2014-04-22||2017-03-27|2009-06-24|2009-06-25|Estimate|2014-08-29|2014-09-08|Estimate||||2017-03-27|2017-03-29|Actual|June 2009||2009-06-30|April 2014|2014-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair|Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair|Completed||Phase 2|105|Actual|Sandoz||6|||f||||||||||||||2018-06-01 00:50:58.386023|2018-06-01 00:50:58.386023
NCT00927745|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|December 2002||2002-12-31|June 2009|2009-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|AFON||Clinical Evaluation of AutoFlow Mode During Mechanical Ventilation|Long Term Clinical Evaluation of AutoFlow Mode During Assist-Controlled Ventilation in ICU Patients|Completed||Phase 4|42|Actual|Centre Hospitalier Victor Dupouy||2|||f||||f||||||||||2018-06-01 00:50:58.660125|2018-06-01 00:50:58.660125
NCT00927732|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2014-11-21|2009-06-24|2009-06-25|Estimate|||||||2014-11-21|2014-11-24|Estimate|February 2009||2009-02-28|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Quidam||Hydroquinidine Versus Placebo in Patients With Brugada Syndrome|"BRD 06/2-D (Quidam) Evaluation of the Interest of Oral Hydroquinidine Administration to Treat Patients With Brugada Syndrome, High Cardiac Arrhythmic Risk and Implanted With an Implantable Cardioverter Defibrillator"|Terminated||Phase 3|64|Actual|Nantes University Hospital||2||insufficient recruitment, a lot of premature study discontinuations|f||||t||||||||||2018-06-01 00:50:58.797554|2018-06-01 00:50:58.797554
NCT00927719|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2018-01-26|2009-06-24|2009-06-25|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2008||2008-12-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Safety Surveillance Study of ACAM2000® Vaccinia Vaccine|A Phase IV Enhanced Safety Surveillance Study of ACAM2000® in Military Personnel|Completed|||897227|Actual|Emergent BioSolutions|||1||f||||f||||||||||2018-06-01 00:50:58.992943|2018-06-01 00:50:58.992943
NCT00927706|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2014-02-14|2009-06-24|2009-06-25|Estimate|||||||2014-02-14|2014-02-19|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ATUTI||Experimental Control Investigation of the Impact of Assistive Technology on the User-caregiver Dyad: a Multi-site Trial|Experimental Control Investigation of the Impact of an Assistive Technology Updating and Tune up Intervention on the User-caregiver Dyad: a Multi-site Trial|Completed||Phase 2|88|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||f||||||||||2018-06-01 00:50:59.134068|2018-06-01 00:50:59.134068
NCT00927693|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2011-09-28|2009-06-23|2009-06-25|Estimate|||||||2011-09-28|2011-09-29|Estimate|February 2001||2001-02-28|September 2011|2011-09-30|August 2010|Actual|2010-08-31|July 2009|Actual|2009-07-31||Interventional|EISNER||Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER)|Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER)|Completed||N/A|2137|Actual|Cedars-Sinai Medical Center||2|||f||||||||||||||2018-06-01 00:50:59.287427|2018-06-01 00:50:59.287427
NCT00927680|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2016-12-12|2009-06-24|2009-06-25|Estimate|||||||2016-12-12|2016-12-14|Estimate|July 2007||2007-07-31|December 2016|2016-12-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Observational|PURIFICAR||Familial Colorectal Cancer Registry in Hispanics|Familial Colorectal Cancer In Puerto Rico: A Feasibility Study|Recruiting|||5000|Anticipated|University of Puerto Rico|||2||f||||f||||||Samples With DNA|"~     Tumor blocks (colorectal tumors) and blood samples~   "|||2018-06-01 00:50:59.548475|2018-06-01 00:50:59.548475
NCT00927667|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2013-02-16|2009-06-24|2009-06-25|Estimate|||||||2013-02-16|2013-02-20|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens|A Diagnostic Interventional, Controlled, Cross-sectional Evaluation of Joint Status Using Magnetic Resonance Imaging in Subjects With Severe Hemophilia A Treated With Primary Prophylaxis, Secondary Prophylaxis, or On-demand Therapy|Completed||Phase 4|156|Actual|Bayer||5|||f||||f||||||||||2018-06-01 00:50:59.774761|2018-06-01 00:50:59.774761
NCT00927654|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2013-01-04|2009-06-24|2009-06-25|Estimate|||||||2013-01-04|2013-01-07|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Ilocard||Iloprost in High Risk Cardiac Surgical Patients|Effect of Iloprost Inhalation Before and During Extracorporeal Circulation (ECC) on Perioperative Morbidity and Outcome in High Risk Cardiac Surgical Patients|Completed||Phase 3|253|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 00:50:59.969056|2018-06-01 00:50:59.969056
NCT00927641|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24||2015-03-17|2015-05-12|2009-06-24|2009-06-25|Estimate||||2015-05-12|2015-06-04|Estimate|2015-05-12|2015-06-04|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||HKT-500 in the Treatment of Adult Patients With Ankle Sprain|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Mild to Moderate Ankle Sprain|Completed||Phase 3|240|Actual|Hisamitsu Pharmaceutical Co., Inc.||2|||f||||f||||||||||2018-06-01 00:51:00.273386|2018-06-01 00:51:00.273386
NCT00927628|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|October 1990||1990-10-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Macular Hole Reopening|Incidence and Factors Related to Macular Hole Reopening|Completed|||831|Actual|Shinjo Ophthalmologic Institute|||1||f||||t||||||||||2018-06-01 00:51:00.737656|2018-06-01 00:51:00.737656
NCT00927615|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2010-09-07|2009-06-24|2009-06-25|Estimate|||||||2010-09-07|2010-09-08|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|April 2011|Anticipated|2011-04-30|May 2010|Actual|2010-05-31||Interventional|CICERO||Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)|Coronary Versus Intravenous abCiximab Administration During Emergency Reperfusion Of ST-segment Elevation Myocardial Infarction - the CICERO Trial|Unknown status|Active, not recruiting|N/A|534|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 00:51:01.149849|2018-06-01 00:51:01.149849
NCT00927602|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2012-04-23|2009-06-24|2009-06-25|Estimate|||||||2012-04-23|2012-04-24|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency|The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency|Terminated||Phase 4|206|Actual|Università degli Studi dell'Insubria||1||study was stopped after enrolment of about 200 patients for slow recruitment|f||||t||||||||||2018-06-01 00:51:02.058506|2018-06-01 00:51:02.058506
NCT00927589|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2015-11-05||2015-11-05|2009-06-24|2009-06-25|Estimate|2015-11-05|2015-12-10|Estimate||||2015-11-05|2015-12-10|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All enrolled participants|A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer|A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer|Completed||Phase 1|59|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 00:51:02.246053|2018-06-01 00:51:02.246053
NCT00927576|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2015-03-05||2015-07-28|2009-06-24|2009-06-25|Estimate|2015-07-28|2015-07-31|Estimate||||2015-07-28|2015-07-31|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||PC-Based Cognitive Rehabilitation for Traumatic Brain Injury (TBI)|PC-Based Cognitive Rehabilitation for TBI|Completed|||265|Actual|VA Office of Research and Development|Relatively small TBI group limits strength of conclusions. Not all of the results have yet been fully analyzed and subjected to peer-review.||2||f||||f||||||||||2018-06-01 00:51:03.506125|2018-06-01 00:51:03.506125
NCT00927563|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2013-09-11||2014-01-17|2009-06-24|2009-06-25|Estimate|2014-01-17|2014-03-06|Estimate||||2014-01-17|2014-03-06|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Tolcapone Treatment of Pathological Gambling|Tolcapone Treatment of Pathological Gambling: An Open-Label Study|Completed||Phase 2|24|Actual|University of Chicago|This study did not assess treatment effects beyond an 8-week treatment period and these results may not generalize to the larger population of people with PG.|1|||f||||t||||||||||2018-06-01 00:51:04.089897|2018-06-01 00:51:04.089897
NCT00927550|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2009-09-15|2009-06-24|2009-06-25|Estimate|||||||2009-09-15|2009-09-17|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|LAST||Lithium and Standard Therapy in Resistant Depression|Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial|Unknown status|Recruiting|Phase 4|230|Anticipated|Universita di Verona||2|||f||||t||||||||||2018-06-01 00:51:04.542475|2018-06-01 00:51:04.542475
NCT00927537|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2013-09-01|2009-06-24|2009-06-25|Estimate|||||||2013-09-01|2013-09-04|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®|Data Collection on Hypertension and Its Treatment With Kinzal®/ Kinzalplus®|Completed|||2052|Actual|Bayer|||2||f||||f||||||||||2018-06-01 00:51:04.7707|2018-06-01 00:51:04.7707
NCT00927524|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2014-12-10|2009-06-24|2009-06-25|Estimate|||||||2014-12-10|2014-12-11|Estimate|April 2005||2005-04-30|December 2014|2014-12-31|December 2010|Actual|2010-12-31|April 2006|Actual|2006-04-30||Interventional|||Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls|An Open-Label, Randomized, Two-Period, Crossover Study to Characterize the Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls|Completed||N/A|24|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 00:51:05.036242|2018-06-01 00:51:05.036242
NCT00927355|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2013-07-09||2016-03-02|2009-06-24|2009-06-25|Estimate|2014-05-05|2014-06-02|Estimate||||2016-03-02|2016-03-29|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Thiazolidinediones on Human Bone|Effects of Thiazolidinediones on Human Bone Marrow Stromal Cell Differentiation Capacity:In Vitro and In Vivo- A Pilot Study|Completed||N/A|10|Actual|Emory University||2|||f||||t||||||||||2018-06-01 00:51:08.67562|2018-06-01 00:51:08.67562
NCT00927511|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2011-07-21|2009-06-24|2009-06-25|Estimate|||||||2011-07-21|2011-07-22|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|FIDeS||A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)|A Phase II Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC) (Fulvestrant Intensity Density Study - Studio FIDeS)|Unknown status|Recruiting|Phase 2|104|Anticipated|Regina Elena Cancer Institute||2|||f||||f||||||||||2018-06-01 00:51:05.211394|2018-06-01 00:51:05.211394
NCT00927498|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2013-07-10|2009-06-24|2009-06-25|Estimate|||||||2013-07-10|2013-07-11|Estimate|December 2007||2007-12-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2011|Actual|2011-07-31||Interventional|||A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old|A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old.|Completed||Phase 3|280|Actual|Acute Leukemia French Association||2|||f||||||||||||||2018-06-01 00:51:05.426321|2018-06-01 00:51:05.426321
NCT00927485|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|||2017-11-15|2009-06-24|2009-06-25|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2007||2007-11-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)|Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)|Completed||N/A|44|Actual|University of Puerto Rico||2|||f||||t||||||||||2018-06-01 00:51:05.598257|2018-06-01 00:51:05.598257
NCT00927472|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2014-01-17||2014-07-09|2009-06-24|2009-06-25|Estimate|2014-07-09|2014-08-04|Estimate||||2014-07-09|2014-08-04|Estimate|August 2009||2009-08-31|July 2014|2014-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional||Baseline characteristics were evaluated to identify differences between treatment groups which were not eliminated by randomization.|Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice|A Multi-Center Phase III Study to Evaluate Ovide Lotion 0.5% Formulation, for the Control of Head Lice in Pediatric Subjects and Adult Subjects With Pediculosis Capitis|Completed||Phase 3|254|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:51:05.745872|2018-06-01 00:51:05.745872
NCT00927459|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2010-01-21|2009-06-24|2009-06-25|Estimate|||||||2010-01-21|2010-01-22|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol|A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia|Terminated||Phase 1|23|Actual|Arbutus Biopharma Corporation||2||Potential for immune stimulation to interfere with further dose escalation.|f||||t||||||||||2018-06-01 00:51:06.371972|2018-06-01 00:51:06.371972
NCT00927446|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-10-18|2009-06-24|2009-06-25|Estimate|||||||2010-10-18|2010-10-19|Estimate|June 2009||2009-06-30|October 2010|2010-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Endoscopy Screening for Esophageal Cancer|Endoscopy Screening for Esophageal Neoplasm With Narrow Band Imaging in Patients With Head and Neck Cancer: A Controlled Tandem Endoscopy Trial|Terminated|||40|Anticipated|Lotung Poh-Ai Hospital|||1||f||||t||||||Samples Without DNA|"~     endoscopic biopsy for histopathological examination~   "|||2018-06-01 00:51:06.440109|2018-06-01 00:51:06.440109
NCT00927433|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2011-06-29|2009-06-24|2009-06-25|Estimate|||||||2011-06-29|2011-06-30|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|March 2008|Actual|2008-03-31||Interventional|||Cancer Patients' Knowledge About Fatigue|Development and Implementation of a Structured Educational Programme to Increase Patients Knowledge About Fatigue and to Evaluate the Effect of Increased Knowledge on Cancer Patients Experience of Fatigue|Unknown status|Active, not recruiting|N/A|160|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 00:51:06.517557|2018-06-01 00:51:06.517557
NCT00927420|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-10-29|2009-06-24|2009-06-25|Estimate|||||||2009-10-29|2009-10-30|Estimate|July 2009||2009-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Observational|||Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study|Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study|Completed|||300|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:51:06.58888|2018-06-01 00:51:06.58888
NCT00927407|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2013-12-21|2009-06-23|2009-06-25|Estimate|||||||2013-12-21|2013-12-24|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice|A Randomized, Single-Dose, Parallel Group, Comparative Pharmacokinetic (PK) Study to Evaluate Malathion Gel 0.5% Versus Ovide (Malathion) Lotion 0.5% in Patients With Pediculosis Capitis|Completed||Phase 1|24|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:51:06.669682|2018-06-01 00:51:06.669682
NCT00927394|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2012-10-01||2012-12-03|2009-06-24|2009-06-25|Estimate|2012-10-01|2012-10-31|Estimate||||2012-12-03|2012-12-06|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ViVID||Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus|An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus|Completed||Phase 4|1143|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:51:06.744315|2018-06-01 00:51:06.744315
NCT00927381|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-24|2009-06-24|2009-06-25|Estimate|||||||2009-06-24|2009-06-25|Estimate|January 2005||2005-01-31|June 2009|2009-06-30|December 2005|Actual|2005-12-31|||||Observational|||Retrospective Evaluation of CroFab - Efficacy in Severe Envenomation|Retrospective Evaluation of Treatments and Outcomes Associated With Antivenom Therapy For Crotaline Snakebite - A Comparison Of Severe To Mild/Moderate Envenomations|Completed|||247|Actual|BTG International Inc.|||2||f||||f||||||||||2018-06-01 00:51:07.087793|2018-06-01 00:51:07.087793
NCT00927368|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-24|2016-06-27||2017-04-06|2009-06-24|2009-06-25|Estimate|2016-06-27|2016-08-08|Estimate||||2017-04-06|2017-05-31|Actual|August 2009||2009-08-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion|Comparison Between Ultrasound Guided Femoral Nerve Block Versus Ultrasound Guided Femoral Nerve Block With the Use of Peripheral Nerve Stimulation for Patients Undergoing Total Knee Replacement.|Completed||N/A|453|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-06-01 00:51:07.158234|2018-06-01 00:51:07.158234
NCT00927342|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-23|2009-06-23|2009-06-24|Estimate|||||||2009-06-23|2009-06-24|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||BioGlue or Vivostat in the Control of Air Leak in Thoracic Surgery|A Comparison of BioGlue and Vivostat in the Prevention of Air Leak in Thoracic Surgery|Completed||N/A|103|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:51:09.069158|2018-06-01 00:51:09.069158
NCT00927329|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2017-05-02|2009-06-23|2009-06-24|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2009|Anticipated|2009-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|Dusty||Evaluation of a Nasal Allergen Challenge Procedure Using Dust Mite Extract|Evaluation of the Safety and Effect of an Allergen Challenge Procedure on Nasal Airway Inflammation in Allergic Individuals Using a Dermatophagoides Farinae Extract Nasal Allergen Challenge Protocol|Withdrawn||Phase 1|0|Actual|University of North Carolina, Chapel Hill||1||Original PI left institution.|f||||f||||||||||2018-06-01 00:51:09.160688|2018-06-01 00:51:09.160688
NCT00927316|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-11-09|2009-06-23|2009-06-24|Estimate|||||||2009-11-09|2009-11-10|Estimate|March 2003||2003-03-31|November 2009|2009-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)|Induced Asymptomatic E. Coli 83972 Bacteriuria in Patients With Recurrent Urinary Tract Infections and Bladder Dysfunction- is There a Protective Effect Against Recurrent Symptomatic Infections? A Blinded Placebo Controlled Cross-over Study.|Completed||N/A|30|Actual|Region Skane||2|||f||||f||||||||||2018-06-01 00:51:09.262615|2018-06-01 00:51:09.262615
NCT00927303|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2010-06-08|2009-06-23|2009-06-24|Estimate|||||||2010-06-08|2010-06-09|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||The Spectralis-Cirrus Study|Comparison of Quality and Reproducibility of Retinal Thickness Measurements in Two Spectral Domain OCT- Machines|Completed|||110|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||8||f||||f||||||None Retained|"~     male or femal persons age over 50 years with exudative age-related macular degeneration~   "|||2018-06-01 00:51:10.1245|2018-06-01 00:51:10.1245
NCT00927290|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2017-01-23|2009-06-23|2009-06-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 3, 2009|Actual|2009-12-03|January 2017|2017-01-31|July 6, 2012|Actual|2012-07-06|July 6, 2012|Actual|2012-07-06||Interventional|PEGLIST C||Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance|ANRS HC 22, PEGLIST-C, Multicenter, Randomized Controlled Trial of Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C, Non 2 or 3 Genotypes and Insulin Resistance|Terminated||Phase 3|40|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2||Suspension of use of medicine containing Pioglitazone by French regulatory agency|f||||t||||||||||2018-06-01 00:51:10.194668|2018-06-01 00:51:10.194668
NCT00927277|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-25|2009-06-23|2009-06-24|Estimate|||||||2009-06-25|2009-06-26|Estimate|March 2003||2003-03-31|June 2009|2009-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Low Level Laser Light Therapy as an Aid to Liposuction|Erchonia Medical, Inc., Erchonia EML Laser Liposuction Clinical Study V Protocol|Completed||N/A|70|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-06-01 00:51:10.311678|2018-06-01 00:51:10.311678
NCT00927264|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2015-09-17||2017-08-23|2009-06-23|2009-06-24|Estimate|2017-08-23|2017-08-24|Actual||||2017-08-23|2017-08-24|Actual|January 2009||2009-01-31|August 2017|2017-08-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|PRIDE|Eligible caregivers had to be the parent or legal guardian of a child aged 6 months to 6 years, who reported one or more smokers living in the home, and who spoke English. The enrolled caregiver did not have to be the smoker.|PRIDE: Preventing Respiratory Illnesses During Childhood Study|A+ Head Start Intervention for Smoke Free Homes|Completed||N/A|350|Actual|Johns Hopkins University||2|||f||||t||||||||No|We will not be sharing individual participant data|2018-06-01 00:51:10.439276|2018-06-01 00:51:10.439276
NCT00927251|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2010-06-07||2010-12-01|2009-06-23|2009-06-24|Estimate|2010-12-01|2010-12-29|Estimate||||2010-12-01|2010-12-29|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|4296||Model 4296 Left Ventricular (LV) Lead Study|Model 4296 Left Ventricular Lead Study|Completed||Phase 2|90|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-06-01 00:51:10.976924|2018-06-01 00:51:10.976924
NCT00927238|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2015-07-28|2009-06-23|2009-06-24|Estimate|||||||2015-07-28|2015-07-30|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|XL TDR||XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)|A Pivotal, Multi-Center, Clinical Trial Evaluating The Safety And Effectiveness of The Lumbar TDR Device In Patients With Single-Level Lumbar Degenerative Disc Disease|Completed||Phase 3|246|Actual|NuVasive||2|||f||||t||||||||||2018-06-01 00:51:11.268752|2018-06-01 00:51:11.268752
NCT00927225|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-23|2009-06-23|2009-06-24|Estimate|||||||2009-06-23|2009-06-24|Estimate|September 2008||2008-09-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic|Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic.|Completed||Phase 4|16|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 00:51:11.392032|2018-06-01 00:51:11.392032
NCT00927212|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2014-07-16|2009-06-23|2009-06-24|Estimate|||||||2014-07-16|2014-07-17|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Topical Application of AS101 for the Treatment of Atopic Dermatitis|Randomized Double Blind Uncontrolled Pilot Study to Compare 2% and 4% AS101 Ointment for the Treatment of Atopic Dermatitis|Terminated||Phase 2|5|Actual|BioMAS Ltd||2||The trial started and halted due sponsor's considerations.|f||||f||||||||||2018-06-01 00:51:11.479864|2018-06-01 00:51:11.479864
NCT00927199|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2013-01-31|2009-06-23|2009-06-24|Estimate|||||||2013-01-31|2013-02-01|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of High-oleic Canola and Flaxseed Oils for Hypercholesterolemia and Cardiovascular Disease Risk Factors|Efficacy of Consumption of High-oleic Canola and Flaxseed Oils in the Management of Hypercholesterolemia and Other Cardiovascular Risk Factors|Completed||Phase 2|36|Actual|University of Manitoba||3|||f||||t||||||||||2018-06-01 00:51:11.585915|2018-06-01 00:51:11.585915
NCT00927186|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2011-10-07||2013-02-21|2009-06-23|2009-06-24|Estimate|2012-01-30|2012-03-02|Estimate||||2013-02-21|2013-04-04|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|April 2012|Actual|2012-04-30|October 2010|Actual|2010-10-31||Interventional|||Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women|Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy|Completed||Phase 4|69|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:51:11.813639|2018-06-01 00:51:11.813639
NCT00927173|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2014-10-14|2009-06-23|2009-06-24|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder|A Prospective Multicenter Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Major Depression Disorder (MDD)|Completed||Phase 3|233|Actual|Brainsway||2|||f||||t||||||||||2018-06-01 00:51:13.717516|2018-06-01 00:51:13.717516
NCT00927160|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2013-06-07||2013-08-13|2009-06-22|2009-06-24|Estimate|2013-06-07|2013-08-14|Estimate||||2013-08-13|2013-08-23|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit|Evaluation of the Mobile Acute Care of the Elderly (MACE) Unit|Completed|||346|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||||||2018-06-01 00:51:13.902259|2018-06-01 00:51:13.902259
NCT00927147|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-21|||2017-01-30|2009-06-23|2009-06-24|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2009||2009-06-30|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer|Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) Combined With Anti-erbB1 Antibody Therapy in the Treatment of Locally Recurred Head and Neck Cancer: A Phase I/II Study.|Terminated||Phase 1/Phase 2|17|Actual|Boneca Corporation||1||The neutron facility closed down for financial reasons.|f||||f||||||||||2018-06-01 00:51:14.0947|2018-06-01 00:51:14.0947
NCT00927134|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-09-26|2009-06-23|2009-06-24|Estimate|||||||2011-09-26|2011-09-27|Estimate|June 2004||2004-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|XCGDinChildren||Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children|Phase I/II Gene Therapy Study for X-linked Chronic Granulomatous Disease in Children|Completed||Phase 1/Phase 2|2|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 00:51:14.176493|2018-06-01 00:51:14.176493
NCT00927121|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-04-18|2009-06-23|2009-06-24|Estimate|||||||2012-04-18|2012-04-19|Estimate||||April 2012|2012-04-30||||||||Interventional|||Clinical Investigation on the Acoustic Stimulation in the Treatment of Chronic Tinnitus|"l Prospective Clinical Investigation on the Acoustic Stimulation With the Coordinated Reset of Neural Subpopulations in the Treatment of Chronic Tinnitus"|Completed||Phase 1/Phase 2|63|Actual|ANM Adaptive Neuromodulation GmbH||5|||f||||t||||||||||2018-06-01 00:51:14.240544|2018-06-01 00:51:14.240544
NCT00927108|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-23|2009-06-23|2009-06-24|Estimate|||||||2009-06-23|2009-06-24|Estimate|July 2009||2009-07-31|June 2009|2009-06-30||||December 2011|Anticipated|2011-12-31||Interventional|RNASc||Rajavtihi Neuronal Adult Stem Cells Project|Adult Neuronal Progenitor Stem Cell Project|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Rajavithi Hospital|||||f||||t||||||||||2018-06-01 00:51:14.308249|2018-06-01 00:51:14.308249
NCT00927095|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2016-04-25||2016-07-13|2009-06-23|2009-06-24|Estimate|2016-07-13|2016-08-24|Estimate||||2016-07-13|2016-08-24|Estimate|July 2008||2008-07-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PMDD||Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)|Continuous OC Treatment in PMDD: Steroid Hormone Mechanisms|Completed||Phase 4|67|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||Undecided||2018-06-01 00:51:14.379017|2018-06-01 00:51:14.379017
NCT00927082|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2016-02-10||2016-02-10|2009-06-23|2009-06-24|Estimate|2016-02-10|2016-03-09|Estimate||||2016-02-10|2016-03-09|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The Intent-to-Treat analysis population included all participants who had received at least one dose of study medication in study WV19432 and provided informed consent for study MV22430. Participants were analyzed according to the treatment groups to which they had been randomized.|A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B|A Follow-up Study to Evaluate the Long-term Post Treatment Effects of Peginterferon Alfa-2a (PEG-IFN) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study WV19432(NEPTUNE).|Completed||Phase 4|383|Actual|Hoffmann-La Roche|"Of the responders at FU Year 5, the proportion of patients who were receiving additional anti-HBV treatment after FU Week 24 varied between groups.~The frequency of missing values (counted as non-response) was unevenly distributed between groups."|4|||f||||||||||||||2018-06-01 00:51:14.720925|2018-06-01 00:51:14.720925
NCT00927069|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2010-01-18||2011-09-01|2009-06-23|2009-06-24|Estimate|2010-07-30|2010-08-24|Estimate||||2011-09-01|2011-09-09|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept|Open Label Study to Evaluate the Efficacy and Safety of Adalimumab in Patients With Plaque Psoriasis Who Showed an Unsatisfactory Response to Etanercept|Completed||Phase 3|85|Actual|Innovaderm Research Inc.|This was an open label uncontrolled study.|4|||f||||f||||||||||2018-06-01 00:51:15.808481|2018-06-01 00:51:15.808481
NCT00927056|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-08-13|2009-06-23|2009-06-24|Estimate|||||||2011-08-13|2011-08-16|Estimate|June 2009||2009-06-30|August 2011|2011-08-31||||June 2012|Anticipated|2012-06-30||Interventional|||Evaluation of Minimally Invasive Microdiscectomy Versus Conventional Open Microdiscectomy For Lumbar Herniated Disc|Early Activity Monitoring and Pain Assessment in Minimally Invasive Microdiscectomy Versus Conventional Open Microdiscectomy For The Treatment of Lumbar Herniated Disc|Unknown status|Enrolling by invitation|N/A|50|Anticipated|University of Manitoba||2|||f||||||||||||||2018-06-01 00:51:16.062283|2018-06-01 00:51:16.062283
NCT00927043|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-11-04|2009-06-23|2009-06-24|Estimate|||||||2011-11-04|2011-11-07|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|MICRA||Study Evaluating Renal Cell Carcinoma Risk Factors|Prospective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma|Completed|||145|Actual|Pfizer|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:51:16.124671|2018-06-01 00:51:16.124671
NCT00927030|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-06-28|2009-06-23|2009-06-24|Estimate|||||||2012-06-28|2012-07-02|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|NICHD||Melatonin for Sleep in Children With Autism|Melatonin for Sleep in Children With Autism: Safety Tolerability and Dose|Completed||Phase 1|17|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 00:51:16.270301|2018-06-01 00:51:16.270301
NCT00927017|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-04-06|2009-06-23|2009-06-24|Estimate|||||||2010-04-06|2010-04-07|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect of Liquorice on Plasma Potassium|Lakritsin Vaikutus Kaliumpitoisuuteen|Terminated||N/A|9|Actual|University of Oulu||2||"When 9 subjects of targeted 12 subjects had been studied, no changes in plasma potassium were~   detected and it was deemed futile to continue with enrolment."|f||||f||||||||||2018-06-01 00:51:16.347217|2018-06-01 00:51:16.347217
NCT00927004|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2012-05-01|2009-06-23|2009-06-24|Estimate|||||||2012-05-01|2012-05-03|Estimate|August 2010||2010-08-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis|A Randomised Placebo-controlled Trail of Mechanical and Cold Hyperalgesia in Subjects With Painful Knee Osteoarthritis, Compared With Matched Controls, & Whether This Hyperalgesia Can be Modified by a 2-week Course of Etoricoxib 60mg.|Completed||Phase 4|80|Actual|Curtin University||2|||f||||f||||||||||2018-06-01 00:51:16.413202|2018-06-01 00:51:16.413202
NCT00926991|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-03-21|2009-06-23|2009-06-24|Estimate|||||||2011-03-21|2011-03-22|Estimate|August 2009||2009-08-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||Chest Wall Repair of Rib Fractures After Trauma|Chest Wall Stabilization for Traumatic Chest Wall Injuries: An Observational Study|Completed|||50|Anticipated|Vanderbilt University|||1||f||||f||||||||||2018-06-01 00:51:16.495934|2018-06-01 00:51:16.495934
NCT00926978|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-01|2009-06-22|2009-06-24|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2008||2008-12-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)|Comparison of I-124 and I-131 Radiopharmacokinetics in Patients Who Have Well-differentiated Thyroid Cancer and Are Prepared With Recombinant Human TSH Injection (rhTSH)|Recruiting||N/A|30|Anticipated|Washington Hospital Center||1|||f||||t||||||||No||2018-06-01 00:51:16.565993|2018-06-01 00:51:16.565993
NCT00926965|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-02|||2009-06-23|2009-06-23|2009-06-24|Estimate|||||||2009-06-23|2009-06-24|Estimate|January 2003||2003-01-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|TD||Tardive Dyskinesia and Cognitive Function|Tardive Dyskinesia and Cognitive Function|Completed||Phase 4|80|Actual|Taipei Veterans General Hospital, Taiwan||3|||f||||f||||||||||2018-06-01 00:51:16.656028|2018-06-01 00:51:16.656028
NCT00926952|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2011-01-21||2011-09-01|2009-06-23|2009-06-24|Estimate|2011-01-21|2011-02-17|Estimate||||2011-09-01|2011-09-09|Estimate|July 2009||2009-07-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion|Safety and Efficacy of Photodynamic Therapy With Short Incubation Methylaminolevulinate Without Occlusion in the Treatment of Actinic Keratoses.|Completed||Phase 3|20|Actual|Innovaderm Research Inc.||1|||f||||f||||||||||2018-06-01 00:51:16.750611|2018-06-01 00:51:16.750611
NCT00926939|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2015-04-13|2009-06-23|2009-06-24|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Technological Innovations in Behavioral Treatments for Cigarette Smoking|Technological Innovations in Behavioral Treatments for Cigarette Smoking|Completed||N/A|96|Actual|National Development and Research Institutes, Inc.||2|||f||||f||||||||||2018-06-01 00:51:16.99599|2018-06-01 00:51:16.99599
NCT00926926|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-10-05|2009-06-23|2009-06-24|Estimate|||||||2012-10-05|2012-10-08|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects of Oxybutynin Topical Gel on Gastric Emptying|Effect of Oxybutynin Chloride Topical Gel on Gastric Emptying, Using the Acetaminophen Absorption Test|Completed||Phase 1|23|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:51:17.071795|2018-06-01 00:51:17.071795
NCT00926913|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2015-04-03|2009-06-23|2009-06-24|Estimate|||||||2015-04-03|2015-04-06|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|March 2015|Actual|2015-03-31||Observational|||Investigating Optical and Neural Causes of Vision Loss|Investigating Optical and Neural Causes of Vision Loss|Withdrawn|||0|Actual|VA Office of Research and Development|||1|Project has ended|f||||f||||||||||2018-06-01 00:51:17.131674|2018-06-01 00:51:17.131674
NCT00926900|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-11-24|2009-06-23|2009-06-24|Estimate|||||||2011-11-24|2011-11-28|Estimate|March 2009||2009-03-31|November 2011|2011-11-30||||April 2012|Anticipated|2012-04-30||Interventional|SFB636D6||The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes|The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Central Institute of Mental Health, Mannheim||2|||f||||t||||||||||2018-06-01 00:51:17.196735|2018-06-01 00:51:17.196735
NCT00926887|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2009-06-26||2014-04-01|2009-06-23|2009-06-24|Estimate|2011-06-09|2011-07-06|Estimate||||2014-04-01|2014-04-17|Estimate|September 2005||2005-09-30|April 2014|2014-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Low Level Laser Therapy to Reduce Pain After Breast Augmentation Surgery|A Double-Blind, Randomized, Placebo-Controlled Evaluation of the Effect of the Erchonia(R) EML Laser on Reducing Pain Following Breast Augmentation Surgery|Completed||N/A|104|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-06-01 00:51:17.289969|2018-06-01 00:51:17.289969
NCT00926874|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-08-21|2009-06-23|2009-06-24|Estimate|||||||2009-08-21|2009-08-25|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Observational|AVC/SCA||Comparative Study of Arterial Properties After an Ischaemic Stroke or an Acute Coronary Syndrome|A Comparative Study of Structural and Functional Arterial Properties After an Ischaemic Stroke or an Acute Coronary Syndrome|Unknown status|Recruiting||150|Anticipated|University Hospital, Grenoble|||2||f||||f||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-06-01 00:51:17.535331|2018-06-01 00:51:17.535331
NCT00926861|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2010-06-08|2009-06-23|2009-06-24|Estimate|||||||2010-06-08|2010-06-09|Estimate|July 2009||2009-07-31|June 2010|2010-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|PAM||Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative Age Related Macular Degeneration (AMD) to Develop Exudative AMD|Posterior Macular Adhesion: A Potential Risk Factor for Non-exudative AMD to Develop Exudative AMD|Unknown status|Recruiting||320|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||1||f||||f||||||||||2018-06-01 00:51:17.599692|2018-06-01 00:51:17.599692
NCT00926848|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-01-11|2009-06-23|2009-06-24|Estimate|||||||2010-01-11|2010-01-12|Estimate|July 2009||2009-07-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|PaTH||Reducing Risk in Cardiac Rehabilitation: Partners Together in Health (PaTH) Intervention Study|Reducing Risk in Cardiac Rehabilitation: Partners Together in Health (PaTH) Intervention Study|Unknown status|Recruiting|N/A|120|Anticipated|University of Nebraska|||||f||||f||||||||||2018-06-01 00:51:17.682897|2018-06-01 00:51:17.682897
NCT00926835|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2015-09-01|2009-06-23|2009-06-24|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients|A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients|Terminated||Phase 4|692|Actual|Ministry of Health & Welfare, Korea||9||due to patient recruitment difficulties|f||||t||||||||||2018-06-01 00:51:17.773846|2018-06-01 00:51:17.773846
NCT00926809|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-24|2009-06-23|2009-06-24|Estimate|||||||2009-06-24|2009-06-25|Estimate|September 2008||2008-09-30|June 2009|2009-06-30|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection|Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial|Unknown status|Recruiting|Phase 4|232|Anticipated|Korean College of Helicobacter and Upper Gastrointestinal Research||2|||f||||t||||||||||2018-06-01 00:51:17.853426|2018-06-01 00:51:17.853426
NCT00926796|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|2013-11-25||2015-07-23|2009-06-23|2009-06-24|Estimate|2014-01-30|2014-03-20|Estimate||||2015-07-23|2015-08-19|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional||Per protocol population. See participant flow.|Efficacy of Combination Therapies for Gonorrhea Treatment|Randomized Clinical Trial Evaluating the Efficacy of Gentamicin/Azithromycin and Gemifloxacin/Azithromycin Combination Therapies as an Alternative Regimen for Uncomplicated Urogenital Gonorrhea|Completed||Phase 4|614|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|After the SMC meeting held during August 2012, the SMC recommended halting trial enrollment because continued participant accrual to targeted enrollment of 500 infected participants would be highly unlikely to alter the results.|2|||f||||||||||||||2018-06-01 00:51:17.946853|2018-06-01 00:51:17.946853
NCT00926783|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2014-03-24||2014-06-05|2009-06-23|2009-06-24|Estimate|2014-05-06|2014-06-03|Estimate||||2014-06-05|2014-06-10|Estimate|August 2009||2009-08-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|November 2011|Actual|2011-11-30||Interventional|SELECT-AF|Baseline analysis population is based on enrolled subjects (86) who had demographic information. Four subjects, who didn't have demographic data, were excluded from baseline analysis.|Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation|Selective CFAE Targeting for Atrial Fibrillation (SELECT-AF)|Completed||Phase 4|86|Actual|Biosense Webster, Inc.||2|||f||||f||||||||||2018-06-01 00:51:18.365102|2018-06-01 00:51:18.365102
NCT00926770|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2009-06-23|2009-06-23|2009-06-24|Estimate|||||||2009-06-23|2009-06-24|Estimate|November 2008||2008-11-30|June 2009|2009-06-30||||||||Observational|||Cerebral Near Infrared Spectroscopy During Blood Sampling From a Peripheral Artery Catheter in Preterm Infants|Measurement of Cerebral Oxygenation With Near Infrared Spectroscopy During Blood Sampling From a Peripheral Artery Catheter in Preterm Infants With Gestational Age <37+0|Unknown status|Recruiting||20|Anticipated|University of Cologne|||1||f||||f||||||||||2018-06-01 00:51:18.830084|2018-06-01 00:51:18.830084
NCT00926757|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2013-05-27|2009-06-23|2009-06-24|Estimate|||||||2013-05-27|2013-05-29|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|HBVNHL||Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B|Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial|Completed||Phase 4|80|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-06-01 00:51:18.94034|2018-06-01 00:51:18.94034
NCT00926744|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-23|||2017-03-27|2009-06-23|2009-06-24|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2006|Actual|2006-04-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|April 2014|Actual|2014-04-30||Interventional|NEXIS||Nutrition and Exercise Intervention Study|Large-Scale Randomized Intervention Trial of Effects of Physical Activity on Incidence and Risk Factors of Cardiovascular Diseases in Healthy People|Active, not recruiting||N/A|1085|Actual|National Institute of Health and Nutrition||3|||f||||t||||||||||2018-06-01 00:51:19.022279|2018-06-01 00:51:19.022279
NCT00926731|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-06-15|2009-06-23|2009-06-24|Estimate|||||||2011-06-15|2011-06-16|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|August 2010|Actual|2010-08-31||Interventional|||Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)|A Phase I, Open-label, Multi-centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML)|Completed||Phase 1|4|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 00:51:19.107655|2018-06-01 00:51:19.107655
NCT00926718|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|June 2009||2009-06-30|June 2009|2009-06-30||||June 2010|Anticipated|2010-06-30||Interventional|||The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy|The Effect of Rocuronium on the Response of CVI to Laryngoscopy|Unknown status|Recruiting|N/A|80|Anticipated|St. Vincent's Medical Center||6|||f||||f||||||||||2018-06-01 00:51:19.196809|2018-06-01 00:51:19.196809
NCT00926705|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|January 2009|Actual|2009-01-31|||||Interventional|||Dexmedetomidine Infusion in Hypospadias Surgery|An Intraoperative Infusion of Dexmedetomidine Reduces the Opioid Requirements for Pediatric Patients Undergoing Hypospadias Surgery|Completed||Phase 3|48|Actual|University of Jordan||2|||f||||t||||||||||2018-06-01 00:51:19.28999|2018-06-01 00:51:19.28999
NCT00926692|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2015-08-24|2009-06-22|2009-06-23|Estimate|||||||2015-08-24|2015-08-26|Estimate|April 2009||2009-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Investigations Regarding B-cell Subsets in Humans|Investigations Regarding B-cell Subsets in Humans|Completed|||249|Actual|Northwell Health|||1||f||||t||||||||||2018-06-01 00:51:19.384498|2018-06-01 00:51:19.384498
NCT00926666|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-08-03|2009-06-22|2009-06-23|Estimate|||||||2009-08-03|2009-08-04|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||A Dose Finding Study for Pain Relief of a Broken Hip|A Dose Finding Study for Ultrasound Guided Anterior Psoas Compartment Blocks in Patients With a Fractured Neck of Femur?|Unknown status|Not yet recruiting|Phase 4|48|Anticipated|NHS Greater Glasgow and Clyde|||||f||||t||||||||||2018-06-01 00:51:19.463288|2018-06-01 00:51:19.463288
NCT00926653|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2015-08-10|2009-06-22|2009-06-23|Estimate|||||||2015-08-10|2015-08-11|Estimate|July 2005||2005-07-31|August 2015|2015-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Assessing Anterior Cingulate Brain Activity in People With Late-Life Depression|Anterior Cingulate Activation in Geriatric Depression|Completed|||76|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-06-01 00:51:19.559018|2018-06-01 00:51:19.559018
NCT00926640|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-20|||2018-04-21|2009-06-20|2009-06-23|Estimate|||||||2018-04-21|2018-04-24|Actual|July 1, 2009||2009-07-01|April 20, 2018|2018-04-20|April 20, 2018|Actual|2018-04-20|June 16, 2017|Actual|2017-06-16||Interventional|||A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers|A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin|Completed||Phase 1|28|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 00:51:19.635171|2018-06-01 00:51:19.635171
NCT00926627|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2016-09-14|2009-06-22|2009-06-23|Estimate|||||||2016-09-14|2016-09-15|Estimate|April 2009||2009-04-30|September 2016|2016-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|BOPSAC||Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis|A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis|Terminated||Phase 2|32|Actual|Medical University of Vienna||2||Not enough patients with the specified criteria could not|f||||f||||||||||2018-06-01 00:51:19.722623|2018-06-01 00:51:19.722623
NCT00926614|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-02-13|2009-06-22|2009-06-23|Estimate|||||||2012-02-13|2012-02-14|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba|48 Week Pilot Trial Assessing the Efficacy of Pioglitazone, Atorvastatin, Pegasys and Weight Based Ribavirin in Chronic Hepatitis C, Genotype 1 Patients Who Have Previously Relapsed or Did Not Respond to PegInterferon /Ribavirin Therapy|Completed||Phase 4|20|Actual|Brooke Army Medical Center||1|||f||||f||||||||||2018-06-01 00:51:19.798785|2018-06-01 00:51:19.798785
NCT00926601|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-20|||2012-06-13|2009-06-20|2009-06-23|Estimate|||||||2012-06-13|2012-06-14|Estimate|June 2009||2009-06-30|June 2012|2012-06-30||||||||Observational|||Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis|Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuberculosis|Unknown status|Enrolling by invitation||100|Anticipated|Seoul National University Hospital|||||f||||f||||||Samples Without DNA|"~     Sera of TB patient~   "|||2018-06-01 00:51:19.878325|2018-06-01 00:51:19.878325
NCT00926588|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2014-11-07||2015-07-17|2009-06-22|2009-06-23|Estimate|2014-12-10|2014-12-19|Estimate||||2015-07-17|2015-08-07|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|SCOPE||Stepped Care to Optimize Pain Care Effectiveness|Stepped Care to Optimize Pain Care Effectiveness (SCOPE)|Completed||Phase 3|250|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:51:19.938446|2018-06-01 00:51:19.938446
NCT00926575|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2013-07-12||2013-10-10|2009-06-22|2009-06-23|Estimate|2013-10-10|2013-12-06|Estimate||||2013-10-10|2013-12-06|Estimate|October 2009||2009-10-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|SUPPORTS|DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.|Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD|Terminated||Phase 3|140|Actual|Soligenix|DSMB terminated study for futility; no safety concerns during analysis of patient population. Overall, 1 SAE considered possibly related to study drug, all others were not related to study drug.|2||An independent Data Safety Monitoring Board recommended the study be stopped due to futility|f||||t||||||||||2018-06-01 00:51:20.265115|2018-06-01 00:51:20.265115
NCT00926562|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2011-06-24|2009-06-22|2009-06-23|Estimate|||||||2011-06-24|2011-06-27|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|DIRECT||A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients|A Randomized, Double-blinded Comparison of Iopromide and Iodixanol in Renally Impaired Patients Undergoing Cardiac Catheterization|Completed||Phase 4|592|Actual|Chinese PLA General Hospital||2|||f||||f||||||||||2018-06-01 00:51:20.822739|2018-06-01 00:51:20.822739
NCT00926549|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-06-19|2009-06-19|2009-06-23|Estimate|||||||2009-06-19|2009-06-23|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Ocular Imaging With Spectral Domain Optical Coherence Tomography|Posterior and Anterior Ocular Imaging With Spectral Domain Optical Coherence Tomography|Unknown status|Recruiting|N/A|300|Anticipated|Yonsei University||1|||f||||t||||||||||2018-06-01 00:51:20.902479|2018-06-01 00:51:20.902479
NCT00926536|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2014-12-04||2016-03-10|2009-06-22|2009-06-23|Estimate|2016-03-10|2016-04-04|Estimate||||2016-03-10|2016-04-04|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Only patients completing the study are represented here. The three patients that were excluded by the physician is because the patients disease had progressed by the time of the study|Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance|Impact of C-arm CT in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transhepatic Arterial Chemoembolization (TACE): Optimal Imaging Guidance|Completed||N/A|84|Actual|Stanford University|This is an imaging study looking at two different modalities of imaging. There is no long term follow up or A/Es associated with this type of a study|2|||f||||t||||||||||2018-06-01 00:51:20.971349|2018-06-01 00:51:20.971349
NCT00926523|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2011-05-26|2009-06-19|2009-06-23|Estimate|||||||2011-05-26|2011-05-27|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Biomarkers in the Evaluation of Chronic Lung Disease|Biomarkers in the Evaluation of Chronic Lung Disease|Completed|||67|Actual|Northwell Health|||2||f||||t||||||Samples Without DNA|"~     Exhaled breathe condensate.~   "|||2018-06-01 00:51:21.155831|2018-06-01 00:51:21.155831
NCT00926510|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-10-10|2009-06-22|2009-06-23|Estimate|||||||2011-10-10|2011-10-12|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Interventional|||The Use of a Language Toolkit for Toddlers|Two to Talk: The Use of a Language Toolkit for Toddlers|Completed||N/A|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:51:21.217552|2018-06-01 00:51:21.217552
NCT00926497|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2009-01-16||2009-05-04|2009-05-04|2009-06-23|Estimate|2009-05-04|2009-06-23|Estimate||||2009-05-04|2009-06-23|Estimate|June 2005||2005-06-30|May 2009|2009-05-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis|Use of Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis: Prospective Randomized Intervention Trial|Completed||N/A|121|Actual|Luzerner Kantonsspital|The samll sample size does not allow to prove the safety of our Procalcitonin-guided strategy. Second, because of our single center setting, our results cannot be easily be extrapolated.|2|||f||||t||||||||||2018-06-01 00:51:21.272317|2018-06-01 00:51:21.272317
NCT00926484|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Observational|||Tooth Mousse and Fluoride in Dentin Hypersensitivity Treatment|Combined Tooth Mousse and Fluoride Varnish in Dentin Hypersensitivity Treatment|Completed|||30|Actual|Huazhong University of Science and Technology|||3||f||||f||||||||||2018-06-01 00:51:21.455601|2018-06-01 00:51:21.455601
NCT00926471|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2013-11-06|2009-06-22|2009-06-23|Estimate|||||||2013-11-06|2013-11-07|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|January 2013|Actual|2013-01-31|May 2011|Actual|2011-05-31||Interventional|||Social Skills and Anxiety Reduction Treatment for Children and Adolescents With Autism Spectrum Disorders|A Cognitive-Behavioral Intervention for Children With Autism Spectrum Disorders|Completed||Phase 1|30|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-06-01 00:51:21.514656|2018-06-01 00:51:21.514656
NCT00926458|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|NONCAD||NON-Invasive Examinations of Coronary Artery Disease|NON-Invasive Examinations of Coronary Artery Disease|Unknown status|Recruiting||200|Anticipated|Herning Hospital|||||f||||f||||||||||2018-06-01 00:51:21.571544|2018-06-01 00:51:21.571544
NCT00926445|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|November 2008||2008-11-30|June 2009|2009-06-30||||||||Observational|||Neonatal Pain- and Distress Experiences and Later Pain Behavior of Former Preterm and Critically Ill Newborn Infants|Effect of Neonatal Pain- and Distress Experiences on Later Pain Behaviour of Former Preterm and Critically Ill Newborn Infants|Unknown status|Recruiting||120|Anticipated|University of Cologne|||3||f||||f|||||||"~     Saliva for measuring cortisol levels~   "|||2018-06-01 00:51:21.62606|2018-06-01 00:51:21.62606
NCT00926432|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2013-05-06|2009-06-22|2009-06-23|Estimate|||||||2013-05-06|2013-05-07|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|POSTURADULT||Postural Balance of the Adult|3D Evaluation of Postural Balance of the Adult Affected by Postural Trouble, Using EOS™ Images and 3D-reconstructions With Regard to Gravity Line.|Completed||N/A|26|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 00:51:21.672597|2018-06-01 00:51:21.672597
NCT00926419|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|May 2010|Anticipated|2010-05-31|November 2009|Anticipated|2009-11-30||Interventional|InjHepAVar||Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery|Serological Evaluation of Chickenpox (Varicella) and Hepatitis A Vaccines Using Disposable Needle-Free Syringe Jet Injector (DSJI) Delivery|Unknown status|Not yet recruiting|Phase 2/Phase 3|600|Anticipated|University of Sao Paulo General Hospital||10|||f||||f||||||||||2018-06-01 00:51:22.567707|2018-06-01 00:51:22.567707
NCT00926406|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-21|||2010-04-05|2009-06-22|2009-06-23|Estimate|||||||2010-04-05|2010-04-07|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Environmental Exposure to Lead and Its Health Effects on Patients With Maintenance Hemodialysis||Unknown status|Recruiting|N/A|100|Anticipated|Chang Gung Memorial Hospital|||||f||||||||||||||2018-06-01 00:51:22.681178|2018-06-01 00:51:22.681178
NCT00926393|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2010-05-04||2011-05-10|2009-06-22|2009-06-23|Estimate|2011-03-06|2011-03-31|Estimate||||2011-05-10|2011-05-11|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression|A Phase IV, Multi-center, Double-blind, Double-dummy, Randomized, Parallel-group Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (Seroquel IR) With Quetiapine Fumarate Extended Release (Seroquel XR) During Initial Dose Escalation in Patients With Bipolar Depression|Completed||Phase 4|139|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:51:22.766279|2018-06-01 00:51:22.766279
NCT00926380|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2018-03-08||2018-04-06|2009-06-22|2009-06-23|Estimate|2018-04-06|2018-05-08|Actual||||2018-04-06|2018-05-08|Actual|June 2009||2009-06-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DATA||Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis|The Denosumab And Teriparatide Administration Study (DATA)|Completed||Phase 2|94|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 00:51:23.109983|2018-06-01 00:51:23.109983
NCT00926367|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-21|2010-09-07||2015-05-01|2009-06-22|2009-06-23|Estimate|2011-07-11|2011-08-04|Estimate||||2015-05-01|2015-05-20|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications|Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Topical Antibiotic and Benzoyl Peroxide to Benzoyl Peroxide and Adapalene Topical Gel Acne Medications|Completed||Phase 4|52|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:51:23.751372|2018-06-01 00:51:23.751372
NCT00926354|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2011-06-19|2009-06-21|2009-06-23|Estimate|||||||2011-06-19|2011-06-21|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients|Phase II Open Study to Evaluate Safety and Efficacy of AS101 for the Treatment of Thrombocytopenia in Solid Tumor|Terminated||Phase 2|40|Anticipated|BioMAS Ltd||2||Sponsor's considerations|f||||f||||||||||2018-06-01 00:51:24.49781|2018-06-01 00:51:24.49781
NCT00926341|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-23|2009-06-22|2009-06-23|Estimate|||||||2009-06-23|2009-06-24|Estimate|October 2006||2006-10-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome|A Study on the Effects of Peroxisome Proliferators Activated Receptor-γ Agonists on Certain Biochemical and Inflammatory Markers in Patients With Metabolic Syndrome|Completed||Phase 4|110|Actual|Aligarh Muslim University||3|||f||||f||||||||||2018-06-01 00:51:24.562959|2018-06-01 00:51:24.562959
NCT00926328|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2013-08-08|2009-05-05|2009-06-23|Estimate|2009-05-05|2009-06-23|Estimate||||2013-08-08|2013-08-15|Estimate|June 2007||2007-06-30|August 2013|2013-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis|Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis|Completed||Phase 3|120|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 00:51:24.640674|2018-06-01 00:51:24.640674
NCT00926315|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2012-10-31|2009-06-22|2009-06-23|Estimate|||||||2012-10-31|2012-11-01|Estimate|July 2007||2007-07-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Gene Expression Profile of Breast Cancer Samples After Vitamin D Supplementation|Influence of Vitamin D on Gene Expression Profile of Breast Cancer Samples From Post-menopausal Patients|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-06-01 00:51:25.039845|2018-06-01 00:51:25.039845
NCT00926302|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||A Bioequivalence Study of Levetiracetam Versus Keppra|A Randomized, Single, Two-Way Crossover Pivotal Study to Assess the Bioequivalence Study of Levetiracetam vs. Keppra Administered Under Fasting Conditions to Healthy Adult Subject|Completed||N/A|26|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-06-01 00:51:25.130195|2018-06-01 00:51:25.130195
NCT00926289|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|2011-04-20||2014-06-17|2009-06-22|2009-06-23|Estimate|2011-04-20|2011-05-24|Estimate||||2014-06-17|2014-06-27|Estimate|June 2009||2009-06-30|December 2013|2013-12-31||||April 2010|Actual|2010-04-30||Interventional|||Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension|A Randomised, Double-blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80mg (T80) Monotherapy as First Line Therapy in Patients With Grade 2 or Grade 3 Hypertension (Systolic Blood Pressure (SBP) >=160 mmHg and Diastolic Blood Pressure (DBP) >=100 mmHg)|Completed||Phase 4|894|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:51:25.264345|2018-06-01 00:51:25.264345
NCT00926276|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2014-12-09|2009-06-22|2009-06-23|Estimate|||||||2014-12-09|2014-12-11|Estimate|June 2009||2009-06-30|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|GERD-BPD||The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia|The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD).|Completed||Phase 4|2|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 00:51:25.834125|2018-06-01 00:51:25.834125
NCT00926263|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-21|2013-01-18||2013-03-27|2009-06-21|2009-06-23|Estimate|2013-03-27|2013-05-07|Estimate||||2013-03-27|2013-05-07|Estimate|July 2009||2009-07-31|March 2013|2013-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects|A Phase 1, Open Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, And Effect On QT/QTc Interval For CP-751,871 Following Single Intravenous Administration To Healthy Adult Subjects|Terminated||Phase 1|28|Actual|Pfizer|This study was terminated prior to enrollment of participants into Cohort 3 (2 doses of 20 mg/kg on consecutive days). Therefore, endpoints relating to that cohort were not assessed.|3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 00:51:25.926288|2018-06-01 00:51:25.926288
NCT00926250|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-01-17|2009-06-22|2009-06-23|Estimate|||||||2012-01-17|2012-01-18|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PS-IPC||Effects of PS-IPC Supplementation on Muscle Mass and Functional Outcomes in Older Adults|Effects of Pro-Stat Immuno-Protein Complex (PS-IPC) Supplementation on Muscle Mass and Function, Inflammatory Markers, and Immune Function in Older Adults|Terminated||N/A|18|Actual|University of Arkansas||2||Sponsor changed their study product and halted study.|f||||f||||||||||2018-06-01 00:51:26.497477|2018-06-01 00:51:26.497477
NCT00926237|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2017-10-03|2009-06-22|2009-06-23|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2009||2009-01-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Effect of rTMS on Resting State Brain Activity in Tinnitus|Effect of rTMS on Resting State Brain Activity in Tinnitus|Recruiting||N/A|60|Anticipated|University of Arkansas||2|||f||||f||||||||||2018-06-01 00:51:26.559664|2018-06-01 00:51:26.559664
NCT00926224|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-11-15|2009-06-22|2009-06-23|Estimate|||||||2010-11-15|2010-11-16|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients|Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients|Completed||N/A|300|Anticipated|Echosens|||||f||||||||||||||2018-06-01 00:51:26.634914|2018-06-01 00:51:26.634914
NCT00926211|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2011-09-23||2012-01-03|2009-06-22|2009-06-23|Estimate|2011-11-03|2011-12-08|Estimate||||2012-01-03|2012-01-05|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Computer-Assisted Versus Manual Hair Harvest Comparative Study|Safety and Efficacy of Computer-Assisted vs. Manual Hair Follicle Harvest: A Comparative Hair Count Study|Completed||N/A|37|Actual|Restoration Robotics, Inc.||2|||f||||f||||||||||2018-06-01 00:51:26.698034|2018-06-01 00:51:26.698034
NCT00926198|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2010-09-07|2009-06-22|2009-06-23|Estimate|||||||2010-09-07|2010-09-08|Estimate|May 2009||2009-05-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Investigation of Clinical Spectrum, Bacterial Pathogens and Immune Response in Acute Pharyngotonsillitis|Frequency, Pathogen Spectrum and Specific Immune Response in Acute Pharyngotonsillitis in Children and Adolescents|Completed|||4500|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples Without DNA|"~     throat culture, blood sample~   "|||2018-06-01 00:51:26.893433|2018-06-01 00:51:26.893433
NCT00926185|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-20|2016-08-09|2013-07-02|2017-01-11|2009-06-22|2009-06-23|Estimate|2017-01-11|2017-03-06|Actual|2013-07-02|2013-07-09|Estimate|2017-01-11|2017-03-06|Actual|June 2009||2009-06-30|January 2017|2017-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||Intent-to-treat (ITT) set included all randomized participants.|A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)|A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model|Completed||Phase 2|230|Actual|Shire||4|||f||||f||||||||||2018-06-01 00:51:26.980541|2018-06-01 00:51:26.980541
NCT00926172|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-12-11|2009-06-22|2009-06-23|Estimate|||||||2009-12-11|2009-12-14|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|June 2010|Anticipated|2010-06-30|December 2008|Actual|2008-12-31||Observational|||Screening Intracranial Aneurysms With Magnetic Resonance Angiography (MRA) in China|Epidemiology of Cerebral Aneurysms With MRA in China in Middle-aged or Elder Person: a Population-based Survey|Unknown status|Recruiting||4500|Anticipated|Shanghai Jiao Tong University School of Medicine|||||f||||t||||||||||2018-06-01 00:51:27.355209|2018-06-01 00:51:27.355209
NCT00926159|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-08-03|2009-06-22|2009-06-23|Estimate|||||||2011-08-03|2011-08-04|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Observational|||Assessment of Appropriate ICD Implantation for Primary Prevention of Sudden Cardiac Death|"Assessment of Appropriate ICD Implantation for Primary Prevention of Sudden Cardiac Death"|Completed|||549|Actual|University of Minnesota Physicians Heart at Fairview|||1||f||||f||||||||||2018-06-01 00:51:27.443284|2018-06-01 00:51:27.443284
NCT00926146|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2017-01-26|2009-06-22|2009-06-23|Estimate|||||||2017-01-26|2017-01-30|Estimate|July 2009||2009-07-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Interventional|HBV||Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV|HBV Prevention for Homeless at Risk for HBV/HCV/HIV|Completed||N/A|451|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-06-01 00:51:27.510098|2018-06-01 00:51:27.510098
NCT00926133|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|November 2005||2005-11-30|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Observational|||Type 2 Diabetes and Acute Myocardial Infarction|Impaired Glucose Tolerance in Patients With Acute Myocardial Infarction.|Unknown status|Active, not recruiting||224|Actual|Ullevaal University Hospital|||1||f||||f||||||Samples Without DNA|"~     Blood samples (serum,plasma) including PaxGene tubes for mRNA sampling~   "|||2018-06-01 00:51:27.595682|2018-06-01 00:51:27.595682
NCT00926120|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-02-13|2009-06-22|2009-06-23|Estimate|||||||2012-02-13|2012-02-14|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|January 2010|Actual|2010-01-31|April 2009|Actual|2009-04-30||Interventional|PureLo||The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC|"A Phase II, Open-label, Efficacy and Safety Study to Evaluate the Effects of Mogroside Sweetener PureLo on Viral Load in Treatment Naïve, Genotype 1 Subjects With Chronic Hepatitis C"|Completed||Phase 2|10|Actual|Brooke Army Medical Center||1|||f||||f||||||||||2018-06-01 00:51:27.680394|2018-06-01 00:51:27.680394
NCT00926107|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-11-09|2009-06-22|2009-06-23|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse|Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.|Terminated||Phase 2|9|Actual|Hellenic Cooperative Oncology Group||||"The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in~   the first two years of patients enrolment"|f||||f||||||||||2018-06-01 00:51:27.760409|2018-06-01 00:51:27.760409
NCT00926094|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-21|||2011-05-11|2009-06-22|2009-06-23|Estimate|||||||2011-05-11|2011-05-12|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Prevalence of Impaired Glucose Tolerance (IGT) in Patients With Frozen Shoulder||Completed|||50|Anticipated|Hadassah Medical Organization|||2||f||||||||||||||2018-06-01 00:51:27.836098|2018-06-01 00:51:27.836098
NCT00926081|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2011-12-30|2009-06-22|2009-06-23|Estimate|||||||2011-12-30|2012-01-04|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Exercise Training Versus Best Medical Treatment Only in Peripheral Artery Disease|Exercise Training Versus Best Medical Treatment Only in Peripheral Artery Disease|Unknown status|Recruiting|N/A|120|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 00:51:27.89813|2018-06-01 00:51:27.89813
NCT00926068|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2013-04-03|2009-06-22|2009-06-23|Estimate|||||||2013-04-03|2013-04-04|Estimate|February 2010||2010-02-28|April 2013|2013-04-30||||August 2013|Anticipated|2013-08-31||Interventional|Truheal||Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers|Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers (Truheal)|Unknown status|Active, not recruiting|Phase 2|196|Anticipated|HealOr||2|||f||||t||||||||||2018-06-01 00:51:27.99782|2018-06-01 00:51:27.99782
NCT00926055|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2015-03-17|2009-06-22|2009-06-23|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2011||2011-09-30|June 2010|2010-06-30||||September 2012|Anticipated|2012-09-30||Interventional|||Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)|Effects on Atherosclerosis Regression of Ezetimibe Monotherapy or Ezetimibe Plus Simvastatin Combination Therapy: Evaluation by Fluorodeoxyglucose Positron Emission Tomography|Withdrawn||N/A|0|Actual|Korea University||3|||f||||t||||||||||2018-06-01 00:51:28.12432|2018-06-01 00:51:28.12432
NCT00926042|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2016-09-16|2009-06-22|2009-06-23|Estimate|||||||2016-09-16|2016-09-19|Estimate|February 2004||2004-02-29|September 2016|2016-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Genotype and Phenotype Registry: Enrollment of Normal Control Subjects for Current and Future Research|TAP0307: Enrollment of Normal Control Subjects for Current and Future Research|Completed|||4511|Actual|Northwell Health|||1||f||||f||||||Samples With DNA|"~     Cheek cell DNA sample will be collected~   "|Yes|available upon application and approval|2018-06-01 00:51:28.190213|2018-06-01 00:51:28.190213
NCT00926029|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-09-26||2012-02-16|2009-05-05|2009-06-23|Estimate|2009-05-05|2009-06-23|Estimate||||2012-02-16|2012-02-17|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Compare the Clinical Efficacy of Prototype Toothpastes|Compare the Clinical Efficacy of Prototype Toothpastes|Completed||Phase 3|98|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 00:51:28.253568|2018-06-01 00:51:28.253568
NCT00926016|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-02-13|2009-06-22|2009-06-23|Estimate|||||||2012-02-13|2012-02-14|Estimate|June 2006||2006-06-30|February 2012|2012-02-29|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects|Assessment of the Efficacy of Pioglitazone on Viral Kinetics, Cytokines, and Innate Immunity in a Group of Insulin Resistant, Treatment Naïve, Chronic Hepatitis C, Genotype 1 Patients|Completed||N/A|23|Actual|Brooke Army Medical Center||2|||f||||t||||||||||2018-06-01 00:51:28.511493|2018-06-01 00:51:28.511493
NCT00926003|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2009-06-22|2009-06-22|2009-06-23|Estimate|||||||2009-06-22|2009-06-23|Estimate|October 2009||2009-10-31|June 2009|2009-06-30|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|HIV CCRT||Cognitive Rehabilitation in Ugandan Children With HIV|Neuropsychological Benefits of Cognitive Training in Ugandan HIV Children|Suspended||Phase 1|60|Actual|Michigan State University||2||awaiting additional funding|f||||f||||||||||2018-06-01 00:51:28.662896|2018-06-01 00:51:28.662896
NCT00925990|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2012-02-09||2012-02-27|2009-06-22|2009-06-23|Estimate|2012-02-27|2012-03-27|Estimate||||2012-02-27|2012-03-27|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||CTS-1027 in Interferon-Naive Hepatitis C Patients|A Trial of CTS-1027 in Interferon-Naive Hepatitis C Patients|Completed||Phase 2|70|Actual|Conatus Pharmaceuticals Inc.||2|||f||||t||||||||||2018-06-01 00:51:28.763804|2018-06-01 00:51:28.763804
NCT00925977|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-06-04|2009-06-22|2009-06-23|Estimate|||||||2012-06-04|2012-06-05|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents|Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents|Terminated||N/A|44|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 00:51:29.108869|2018-06-01 00:51:29.108869
NCT00925964|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-22|||2012-03-14|2009-06-22|2009-06-23|Estimate|||||||2012-03-14|2012-03-15|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Observational|IPS||Systolic Pressure Index in Assessing the Risk of Cardiovascular Events|Interest of Measuring the Systolic Pressure Index in Assessing the Risk of Cardiovascular Events Peri-operatively in the Surgery, Settled Out of Cardiovascular Surgery|Completed|||504|Anticipated|University Hospital, Limoges|||2||f||||f||||||Samples Without DNA|"~     Blood sample to evaluate Troponin, a Cardiac biomarker~   "|||2018-06-01 00:51:29.185205|2018-06-01 00:51:29.185205
NCT00925951|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2010-01-04|2009-06-19|2009-06-22|Estimate|||||||2010-01-04|2010-01-05|Estimate|June 2009||2009-06-30|June 2009|2009-06-30||||December 2009|Actual|2009-12-31||Interventional|||The Effectiveness of Wet Cupping on Persistent Non-specific Low Back Pain|The Effectiveness of Wet Cupping on Persistent Non-specific Low Back Pain: A Randomized, Waiting-list Controlled, Open-label, Parallel-group Pilot Study|Completed||N/A|37|Anticipated|Korea Institute of Oriental Medicine||2|||f||||t||||||||||2018-06-01 00:51:29.238856|2018-06-01 00:51:29.238856
NCT00925938|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2013-10-23|2012-03-14|2014-01-20|2009-06-19|2009-06-22|Estimate|2013-10-23|2013-12-13|Estimate|2012-03-14|2012-03-15|Estimate|2014-01-20|2014-02-13|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy|A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of the Misoprostol Vaginal Priming Insert for Women Requiring Cervical Priming Prior to a Hysteroscopy|Completed||Phase 2|51|Actual|Ferring Pharmaceuticals||2|||f||||t||||||||||2018-06-01 00:51:29.33439|2018-06-01 00:51:29.33439
NCT00925925|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2015-05-11|2009-06-19|2009-06-22|Estimate|||||||2015-05-11|2015-05-12|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Epigenetic Markers of B-Cell Function in Low Birth Weight Infants|Epigenetic Markers of B-Cell Function in Low Birth Weight Infants|Completed|||64|Actual|University of Utah|||2||f||||f||||||Samples With DNA|"~     Blood will be stored as frozen mRNA isolates if parents consent to tissue banking.~   "|||2018-06-01 00:51:29.957292|2018-06-01 00:51:29.957292
NCT00925912|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|November 2007|Actual|2007-11-30|||||Interventional|||A Trial of Closed Hemorrhoidectomy Under Local Perianal Block Versus Spinal Anesthesia|A Randomized Clinical Trial of Closed Hemorrhoidectomy Under Local Perianal Block Versus Spinal Anesthesia|Completed||N/A|64|Actual|Phramongkutklao College of Medicine and Hospital||2|||f||||t||||||||||2018-06-01 00:51:30.134911|2018-06-01 00:51:30.134911
NCT00925899|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2016-10-28||2017-03-10|2009-06-19|2009-06-22|Estimate|2017-03-10|2017-04-20|Actual||||2017-03-10|2017-04-20|Actual|October 2009||2009-10-31|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer|Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer|Completed||Phase 2/Phase 3|72|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-06-01 00:51:30.278754|2018-06-01 00:51:30.278754
NCT00925886|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism|Use of Toric Intraocular Lens to Neutralize Keratometric Astigmatism|Completed||Phase 4|50|Actual|Asociación para Evitar la Ceguera en México||1|||f||||t||||||||||2018-06-01 00:51:30.735978|2018-06-01 00:51:30.735978
NCT00925873|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate|June 1996||1996-06-30|June 2009|2009-06-30|November 2004|Actual|2004-11-30|April 2000|Actual|2000-04-30||Interventional|||GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly|A Randomized Study of Fludarabine in Part of Induction and Postremission Treatment for de Novo Acute Myeloid Leukaemia in Elderly Patients|Completed||Phase 3|303|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||||2018-06-01 00:51:30.884163|2018-06-01 00:51:30.884163
NCT00925860|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate|June 2001||2001-06-30|June 2009|2009-06-30|June 2007|Actual|2007-06-30|June 2006|Actual|2006-06-30||Interventional|||Non-Positive Pressure Ventilation in Hypoxemic Patients|Non-Positive Pressure Ventilation in Hypoxemic Patients. A Randomized Study|Completed||Phase 4|64|Actual|Hospital Provincial de Castellon||2|||f||||t||||||||||2018-06-01 00:51:31.025084|2018-06-01 00:51:31.025084
NCT00925847|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2012-10-30|2009-06-19|2009-06-22|Estimate|||||||2012-10-30|2012-10-31|Estimate|June 2009||2009-06-30|March 2009|2009-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|LISLA||Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis|Open Multicenter Study of Lithium in Patients With Amyotrophic Lateral Sclerosis LISLA|Completed||Phase 2|23|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:51:31.103461|2018-06-01 00:51:31.103461
NCT00925834|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|SUGO-KO||Suggestive Effects on the Diameter of Coronary Arteries|Effects of Suggestive Components of Therapeutical Interventions on the Diameter of Coronary Arteries|Completed||N/A|60|Actual|Technische Universität München||4|||f||||f||||||||||2018-06-01 00:51:31.194677|2018-06-01 00:51:31.194677
NCT00925821|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2012-06-27|2009-06-19|2009-06-22|Estimate|||||||2012-06-27|2012-06-28|Estimate|June 2009||2009-06-30|June 2012|2012-06-30||||||||Interventional|||Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma|Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD)as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance - A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myeloma (DSMM XII)|Completed||Phase 2|146|Anticipated|Wuerzburg University Hospital||2|||f||||t||||||||||2018-06-01 00:51:31.275515|2018-06-01 00:51:31.275515
NCT00925808|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2018-01-22|2009-06-19|2009-06-22|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2009|Actual|2009-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans|A Prospective Study of Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans|Active, not recruiting|||1187|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 00:51:31.385079|2018-06-01 00:51:31.385079
NCT00925795|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2010-11-22|2009-06-19|2009-06-22|Estimate|||||||2010-11-22|2010-11-23|Estimate|September 2009||2009-09-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|EVOO_HIV||Effect of Extra Virgin Olive Oil on Atherosclerosis Biomarkers in HIV-infected Patients|Effect of Extra Virgin Olive Oil on Atherosclerosis Biomarkers in Patients Treated With Combination Antiretroviral Therapy: a Randomized, Crossover Trial|Completed||N/A|39|Actual|University Hospital for Infectious Diseases, Croatia||2|||f||||t||||||||||2018-06-01 00:51:31.451259|2018-06-01 00:51:31.451259
NCT00925782|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2013-05-08||2015-05-19|2009-06-19|2009-06-22|Estimate|2014-08-18|2014-08-20|Estimate||||2015-05-19|2015-06-12|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|A Phase IIA Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|Completed||Phase 2|24|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 00:51:31.55615|2018-06-01 00:51:31.55615
NCT00924924|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2016-10-04|2009-06-18|2009-06-19|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Act Healthy! A Controlled Trial of Worksite Health Promotion|Act Healthy! A Controlled Trial of Worksite Health Promotion|Completed||N/A|91|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 00:51:49.62926|2018-06-01 00:51:49.62926
NCT00925769|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2015-07-13||2015-07-13|2009-06-19|2009-06-22|Estimate|2015-07-13|2015-08-07|Estimate||||2015-07-13|2015-08-07|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Per-protocol population: All participants who received at least 1 evaluation period of 3 cycles of the complete study regimen (of all 3 drugs) at the recommended dose unless withdrawn from therapy earlier because of toxicity.|ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer|An Open Label Study to Evaluate the Safety and Effect on Disease Progression of Triple Combination Treatment With Erlotinib (Tarceva), Bevacizumab (Avastin), and Capecitabine (Xeloda) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer (REBECA-Trial).|Completed||Phase 1|32|Actual|Hoffmann-La Roche|Planned Part 2 of the study was not implemented and outcome measures related to Part 2 were not analyzed.|1|||f||||||||||||||2018-06-01 00:51:32.003686|2018-06-01 00:51:32.003686
NCT00925756|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2014-03-31|2009-06-19|2009-06-22|Estimate|||||||2014-03-31|2014-04-02|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery|The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression|Completed||Phase 4|28|Actual|California Collaborative Treatment Group||1|||f||||f||||||||||2018-06-01 00:51:33.400721|2018-06-01 00:51:33.400721
NCT00925743|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2013-05-15|2009-06-19|2009-06-22|Estimate|||||||2013-05-15|2013-05-16|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer|A Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Cabazitaxel In Combination With Cisplatin Administered Every 3 Weeks In Subjects With Advanced Solid Malignancies|Completed||Phase 1|76|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:51:33.522901|2018-06-01 00:51:33.522901
NCT00925730|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2016-11-16|2009-06-19|2009-06-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|March 2004||2004-03-31|November 2016|2016-11-30||||January 2006|Actual|2006-01-31||Interventional|||Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion|Non-comparative Open-label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion|Completed||Phase 4|20|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:51:33.638596|2018-06-01 00:51:33.638596
NCT00925717|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2010-01-25|2009-06-19|2009-06-22|Estimate|||||||2010-01-25|2010-01-26|Estimate|May 2009||2009-05-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|||||Observational|DART||of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).|of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).|Completed|||4045|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:51:33.756365|2018-06-01 00:51:33.756365
NCT00925704|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|2010-03-19||2011-02-09|2009-06-19|2009-06-22|Estimate|2010-04-21|2010-05-14|Estimate||||2011-02-09|2011-02-11|Estimate|June 2009||2009-06-30|February 2011|2011-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers|A Phase I, Randomized, Open-Label, Three Period Cross-Over Study to Assess the Pharmacokinetics of Oral Calcitriol (ROCALTROL®) in Healthy Volunteers When Administered Alone or When Co-Administered With Lanthanum Carbonate (FOSRENOL®) or Sevelamer Carbonate (RENVELA®)|Completed||Phase 1|41|Actual|Shire||3|||f||||||||||||||2018-06-01 00:51:33.86944|2018-06-01 00:51:33.86944
NCT00925691|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2016-08-17|2009-06-19|2009-06-22|Estimate|||||||2016-08-17|2016-08-18|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SEPTAL-PM||Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing|Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing|Completed||Phase 3|141|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-06-01 00:51:34.410492|2018-06-01 00:51:34.410492
NCT00925678|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2012-06-11|2009-06-19|2009-06-22|Estimate|||||||2012-06-11|2012-06-13|Estimate|June 2009||2009-06-30|June 2012|2012-06-30||||||||Interventional|||DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season|A Double-blind, Placebo-controlled, Randomised Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DSP-3025 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season|Completed||Phase 1|72|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||2|||f||||||||||||||2018-06-01 00:51:34.487253|2018-06-01 00:51:34.487253
NCT00925665|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2011-06-27|2009-06-19|2009-06-22|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Observational|||Intubation of Patients With Odontogenic Abcesses|Intubation of Patients With Odontogenic Abcesses Glidescope vs. Macintosh Technique|Completed|||100|Anticipated|Kliniken Essen-Mitte|||2||f||||f||||||||||2018-06-01 00:51:34.543876|2018-06-01 00:51:34.543876
NCT00925652|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2015-10-20|2009-06-19|2009-06-22|Estimate|||||||2015-10-20|2015-10-21|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ABCDE||Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer|ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer|Terminated||Phase 2|55|Actual|Dana-Farber Cancer Institute||4||Slow accrual|f||||t||||||||||2018-06-01 00:51:34.647185|2018-06-01 00:51:34.647185
NCT00925639|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate|August 2009||2009-08-31|June 2009|2009-06-30|August 2010|Anticipated|2010-08-31|January 2010|Anticipated|2010-01-31||Interventional|||Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause|Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause|Unknown status|Not yet recruiting|Phase 3|84|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 00:51:34.850061|2018-06-01 00:51:34.850061
NCT00925626|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2015-06-03|2009-06-19|2009-06-22|Estimate|||||||2015-06-03|2015-06-04|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Sub-Vastus Versus Mid-Vastus Arthrotomy for Total Knee Arthroplasty: a Randomized Clinical Trial|Sub-Vastus Versus Mid-Vastus Arthrotomy for Total Knee Arthroplasty: a Randomized Clinical Trial With One Year Follow-up|Suspended||N/A|100|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 00:51:34.925957|2018-06-01 00:51:34.925957
NCT00924404|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2017-05-31||2018-05-21|2009-06-18|2009-06-19|Estimate|2017-07-10|2017-08-09|Actual||||2018-05-21|2018-05-23|Actual|May 2009||2009-05-31|May 2018|2018-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Xylitol Versus Saline in Chronic Sinusitis|Randomized Controlled Trial of Xylitol Versus Saline Rinse For Chronic Sinusitis|Completed||N/A|53|Actual|University of Iowa||2|||f||||f||||||||||2018-06-01 00:52:02.552693|2018-06-01 00:52:02.552693
NCT00925613|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2014-04-21|2009-06-19|2009-06-22|Estimate|||||||2014-04-21|2014-04-22|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Benefits of Exchanging a Double Lumen Tube to a Proseal Laryngeal Mask or a Single Lumen Tube After a Thoracic Surgery|Exchange of a Double Lumen Tube With a Proseal Laryngeal Mask or Single Lumen Endotracheal Tube Before Emergence Following a Thoracic Surgery: a Randomized-controlled Trial.|Completed||Phase 3|60|Actual|Université de Montréal||3|||f||||t||||||||||2018-06-01 00:51:35.021144|2018-06-01 00:51:35.021144
NCT00925600|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2017-04-19||2017-04-19|2009-06-18|2009-06-22|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|November 30, 2009|Actual|2009-11-30|April 2017|2017-04-30|May 12, 2016|Actual|2016-05-12|May 12, 2016|Actual|2016-05-12||Interventional|||Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss|A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy|Completed||Phase 3|769|Actual|Amgen||2|||f||||t||||||||||2018-06-01 00:51:35.154721|2018-06-01 00:51:35.154721
NCT00925587|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2013-12-05||2014-05-15|2009-06-18|2009-06-22|Estimate|2014-05-15|2014-06-04|Estimate||||2014-05-15|2014-06-04|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional||Includes all subjects who received at least one dose of darbepoetin alfa on study. 3 subjects randomized to the Q2W arm failed to administer darbepoetin alfa|Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease|A Multicenter, Randomised, Double-Blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving Dialysis|Completed||Phase 3|358|Actual|Amgen||2|||f||||f||||||||||2018-06-01 00:51:36.876805|2018-06-01 00:51:36.876805
NCT00925574|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2017-09-01|2009-06-19|2009-06-22|Estimate|||||||2017-09-01|2017-09-05|Actual|June 4, 2009|Actual|2009-06-04|August 2017|2017-08-31|October 11, 2010|Actual|2010-10-11|October 11, 2010|Actual|2010-10-11||Interventional|||A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects and in Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|71|Actual|Centocor, Inc.|||||f||||f||f||||||||2018-06-01 00:51:38.679419|2018-06-01 00:51:38.679419
NCT00925561|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2013-06-18|2009-06-19|2009-06-22|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Examining the Genetic Predictors of Coronary Artery Calcification in African Americans|Predictors of Coronary Artery Calcification in an African American Cohort|Completed|||752|Actual|University of Michigan|||1||f||||f||||||Samples With DNA|"~     Blood to measure risk factors and stored DNA for genetic studies~   "|||2018-06-01 00:51:38.794989|2018-06-01 00:51:38.794989
NCT00925548|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2014-06-24||2014-07-23|2009-06-18|2009-06-22|Estimate|2014-07-23|2014-07-24|Estimate||||2014-07-23|2014-07-24|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|STRIDE|Safety population included all participants who received at least one dose of any study treatment (L-BLP25, placebo, cyclophosphamide, saline, or any of the three hormonal therapies).|STRIDE - STimulating Immune Response In aDvanced brEast Cancer|A Randomized, Double-blind, Controlled Phase III Study of Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-line Therapy of Post-menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer|Terminated||Phase 3|16|Actual|EMD Serono|Efficacy data were not analyzed as the trial was prematurely terminated following the clinical hold on the investigational new drug application for tecemotide (L-BLP25)|2||See termination reason in the below Purpose statement|f||||t||||||||||2018-06-01 00:51:39.036796|2018-06-01 00:51:39.036796
NCT00925535|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19||2010-09-02|2010-09-17|2009-06-19|2009-06-22|Estimate||||2010-09-02|2010-09-08|Estimate|2010-09-17|2010-09-21|Estimate|May 2010||2010-05-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)|Open-Label, Randomized, 3-Way Crossover Study To Estimate The Interaction Between Multiple Dose Rifabutin And Lersivirine (UK-453,061) In Healthy Subjects|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:51:39.477065|2018-06-01 00:51:39.477065
NCT00925522|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2016-03-09||2017-02-21|2009-06-19|2009-06-22|Estimate|2016-04-20|2016-05-27|Estimate||||2017-02-21|2017-03-24|Actual|June 2009||2009-06-30|July 2016|2016-07-31|July 2011|Actual|2011-07-31|April 2010|Actual|2010-04-30||Interventional|Ablate-VT||Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT)|Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT)|Completed||N/A|20|Actual|St. Jude Medical||1|||f||||f||||||||No||2018-06-01 00:51:39.574335|2018-06-01 00:51:39.574335
NCT00925509|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2011-06-21|2009-06-19|2009-06-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|ATIM||Application of Medical Imaging Procedures in Surgery Implanting in Cancerology With the Aim to Reduce Invasive Acts|Application of Medical Imaging Procedures in Surgery Implanting in Cancerology With the Aim to Reduce Invasive Acts|Terminated||N/A|53|Anticipated|Centre Leon Berard||||Insufficient recruitment, too much selective inclusion criteria, feasibility problems|f||||f||||||||||2018-06-01 00:51:39.876622|2018-06-01 00:51:39.876622
NCT00925496|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2018-04-30|2009-06-19|2009-06-22|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2009||2009-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|Promos||Patient Benefit From the New Modular Shoulder Prosthesis PROMOS|Patient Benefit From the New Modular Shoulder Prosthesis PROMOS - a Multicentre Cohort Study|Active, not recruiting|||240|Anticipated|Smith & Nephew, Inc.|||2||f||||t||||||||Undecided||2018-06-01 00:51:39.982568|2018-06-01 00:51:39.982568
NCT00925483|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2010-02-24|2009-06-19|2009-06-22|Estimate|||||||2010-02-24|2010-02-25|Estimate|August 2004||2004-08-31|February 2010|2010-02-28||||December 2012|Anticipated|2012-12-31||Interventional|||Decreasing Dialysis Cardiovascular Risk: Daily Versus Longer Treatments|Decreasing Dialysis Cardiovascular Risk: Daily Versus Longer Treatments|Unknown status|Recruiting|N/A|60|Anticipated|Dallas VA Medical Center||4|||f||||||||||||||2018-06-01 00:51:40.109998|2018-06-01 00:51:40.109998
NCT00925470|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-12-17|2009-06-19|2009-06-22|Estimate|||||||2009-12-17|2009-12-18|Estimate|June 2009||2009-06-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Observational|PREVENTA||Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure|Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure Without Known Cardio Vascular or Renal Disease, Stratified on Blood Pressure Control.|Completed|||1200|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:51:40.27476|2018-06-01 00:51:40.27476
NCT00925457|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2016-07-15|2009-06-19|2009-06-22|Estimate|||||||2016-07-15|2016-07-19|Estimate|March 2007||2007-03-31|July 2016|2016-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone|Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone|Completed|||1608|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||3||f||||||||||||||2018-06-01 00:51:41.131079|2018-06-01 00:51:41.131079
NCT00925444|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2013-09-17|2009-06-19|2009-06-22|Estimate|||||||2013-09-17|2013-09-18|Estimate|June 2009||2009-06-30|January 2009|2009-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SPIRAL||Staple-line Reinforcement for Prevention of Pulmonary Air Leakage|Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer.|Completed||Phase 4|380|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:51:41.357186|2018-06-01 00:51:41.357186
NCT00925431|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2017-03-15|2009-06-19|2009-06-22|Estimate|||||||2017-03-15|2017-03-17|Actual|August 2009||2009-08-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Nutrition and Coping Education for Symptom and Weight Management for Fibromyalgia|Lifestyle Modification Program for Overweight and Obese Fibromyalgia Patients|Completed||Phase 2|45|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 00:51:41.543032|2018-06-01 00:51:41.543032
NCT00925418|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2011-09-13|2009-06-19|2009-06-22|Estimate|||||||2011-09-13|2011-09-14|Estimate|September 2006||2006-09-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|September 2010|Actual|2010-09-30||Interventional|CRYO1||Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer|Randomized Trial Evaluating the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Patient Treated for Breast or Prostate Cancer.|Completed||Phase 3|168|Anticipated|Institut Paoli-Calmettes||2|||f||||f||||||||||2018-06-01 00:51:41.646943|2018-06-01 00:51:41.646943
NCT00925405|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-11-07|2009-06-19|2009-06-22|Estimate|||||||2011-11-07|2011-11-08|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy|Breast MRI Screening in High-Risk Women After Mantle Radiation Therapy for Lymphoma|Terminated|||10|Actual|M.D. Anderson Cancer Center|||1|Low accrual|f||||f||||||||||2018-06-01 00:51:41.839842|2018-06-01 00:51:41.839842
NCT00925392|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2013-03-12|2009-06-19|2009-06-22|Estimate|||||||2013-03-12|2013-03-14|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects|Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects|Completed||Phase 1|40|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 00:51:42.017622|2018-06-01 00:51:42.017622
NCT00925379|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2014-07-25|2009-06-19|2009-06-22|Estimate|||||||2014-07-25|2014-07-28|Estimate|April 2009||2009-04-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|April 2013|Actual|2013-04-30||Observational|HDR||Renal HYPODYSPLASIA : Genetic and Familial Assessment|Renal HYPODYSPLASIA;Study of Familial Cases and Search for Predisposing Genes|Completed|||342|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     DNA collection from the propositus and its parents and in case of families with more than one~     affected member, collection of DNA from the all family.~   "|||2018-06-01 00:51:42.091857|2018-06-01 00:51:42.091857
NCT00925366|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-07-28|2009-06-19|2009-06-22|Estimate|||||||2009-07-28|2009-07-29|Estimate|September 2003||2003-09-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|September 2007|Actual|2007-09-30||Interventional|COIFFE||Which is the Most Reliable Radiologic Examination for the Diagnosis of Rotator Cuff Tendon Tear?|Comparative Performances of CT-arthrography, MRI and MR-arthrography in the Preoperative Assessment of the Rotator Cuff Tendon Tears, Surgical Observations Being Used as a Standard.|Completed||N/A|64|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 00:51:42.153372|2018-06-01 00:51:42.153372
NCT00925353|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2012-04-26||2013-12-20|2009-06-18|2009-06-22|Estimate|2013-12-20|2013-12-23|Estimate||||2013-12-20|2013-12-23|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Pharmacokinetics of 4% Lidocaine Gel When Applied Topically to the Breasts|The Pharmacokinetics of 4% Lidocaine Gel When Applied Topically to the Breasts|Completed||Phase 4|13|Actual|Mountain States Tumor and Medical Research Institute|No placebo comparison group; limited sample size; healthy subjects; lack of variation in doses.|1|||f||||f||||||||||2018-06-01 00:51:42.261224|2018-06-01 00:51:42.261224
NCT00925340|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2014-07-28|2009-06-19|2009-06-22|Estimate|||||||2014-07-28|2014-07-29|Estimate|September 2008||2008-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Family Check-Up for Adolescents and Siblings|Effects of the Family Check-Up on Adolescents With Alcohol-Related Events and Their Siblings|Completed||Phase 1|104|Actual|Brown University||2|||f||||t||||||||||2018-06-01 00:51:42.635998|2018-06-01 00:51:42.635998
NCT00925327|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate||||June 2009|2009-06-30||||||||Interventional|CXL||Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus||Unknown status|Not yet recruiting|Phase 2|7|Anticipated|Peschke Meditrade, GmbH||1|||||||t||||||||||2018-06-01 00:51:42.791971|2018-06-01 00:51:42.791971
NCT00925314|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2012-02-09|2009-06-19|2009-06-22|Estimate|||||||2012-02-09|2012-02-13|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|July 2014|Anticipated|2014-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma|A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Cosmo Bioscience||1|||f||||f||||||||||2018-06-01 00:51:42.908724|2018-06-01 00:51:42.908724
NCT00925301|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19||2013-09-25|2016-03-31|2009-06-19|2009-06-22|Estimate||||2013-09-25|2013-10-25|Estimate|2016-03-31|2016-05-02|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|July 2012|Actual|2012-07-31||Interventional|||Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamics of AT1001 in Patients With Fabry Disease and AT1001-Responsive GLA Mutations|Completed||Phase 3|67|Actual|Amicus Therapeutics||2|||f||||t||||||||||2018-06-01 00:51:43.052093|2018-06-01 00:51:43.052093
NCT00924950|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2011-08-04||2012-11-08|2009-06-18|2009-06-19|Estimate|2012-11-08|2012-12-05|Estimate||||2012-11-08|2012-12-05|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis|An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Taclonex Ointment With Hydrogel Patch Occlusion to Taclonex Ointment Without Occlusion in the Treatment of Plaque-Type Psoriasis|Completed||Phase 4|30|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 00:51:49.072468|2018-06-01 00:51:49.072468
NCT00925288|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2012-07-03||2012-09-10|2009-06-19|2009-06-22|Estimate|2012-09-10|2012-10-11|Estimate||||2012-09-10|2012-10-11|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Girasol||Acceptability of Human Papillomavirus (HPV) Vaccine in Female Sex Workers|Acceptability and Feasibility of a Modified HPV Vaccine Schedule in Brothel Based Female Sex Workers in Peru|Completed||Phase 4|200|Actual|Johns Hopkins Bloomberg School of Public Health|Small time difference between study arms (0,2,6 and 0,3,6 months); We cannot distinguish between antibodies resulting from vaccination and antibodies resulting from natural HPV infection;|2|||f||||t||||||||||2018-06-01 00:51:43.211027|2018-06-01 00:51:43.211027
NCT00925275|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2010-04-30|2009-06-19|2009-06-22|Estimate|||||||2010-04-30|2010-05-04|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors|A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists|Completed||Phase 1|9|Anticipated|Cellectar, Inc||1|||f||||f||||||||||2018-06-01 00:51:43.788678|2018-06-01 00:51:43.788678
NCT00925262|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2013-05-01|2009-06-19|2009-06-22|Estimate|||||||2013-05-01|2013-05-03|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|February 2010|Actual|2010-02-28||Interventional|||Controlled Trial of Mental Health Interventions for Torture Survivors in Kurdistan|A Controlled Trial of Mental Health Interventions for Common Mental Health Problems Experienced by Torture Survivors Living in Kurdistan, Iraq.|Completed||N/A|530|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||||2018-06-01 00:51:43.886021|2018-06-01 00:51:43.886021
NCT00925249|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-12-11|2009-06-19|2009-06-22|Estimate|||||||2009-12-11|2009-12-14|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Observational|||Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy|Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy|Unknown status|Recruiting||90|Anticipated|Walter Reed Army Medical Center|||2||f||||t||||||||||2018-06-01 00:51:44.018282|2018-06-01 00:51:44.018282
NCT00925236|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2015-07-27|2009-06-19|2009-06-22|Estimate|||||||2015-07-27|2015-07-29|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|MAGIC-MYH9||Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia|Phenotypic and Genotypic Identification and Characterization of MYH9-related Constitutional Thrombocytopenia|Completed|||360|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 00:51:44.146271|2018-06-01 00:51:44.146271
NCT00925223|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-10-13|2009-06-19|2009-06-22|Estimate|||||||2009-10-13|2009-10-14|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|November 2009|Anticipated|2009-11-30|August 2009|Anticipated|2009-08-31||Observational|||Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients|Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients|Unknown status|Enrolling by invitation||30|Anticipated|Shandong University|||2||f||||t||||||Samples With DNA|"~     two mucosal biospecimens will be obtained from the rectosigmoid junction from each patient.~   "|||2018-06-01 00:51:44.408063|2018-06-01 00:51:44.408063
NCT00925210|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2010-09-10|2009-06-19|2009-06-22|Estimate|||||||2010-09-10|2010-09-14|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach|Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach Using Peripheral Endobronchial Ultrasonography and Electromagnetic Navigation Bronchoscopy|Completed||Phase 2|60|Actual|University of Calgary||1|||f||||f||||||||||2018-06-01 00:51:44.535947|2018-06-01 00:51:44.535947
NCT00925197|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-19|2009-06-19|2009-06-22|Estimate|||||||2009-06-19|2009-06-22|Estimate|May 2004||2004-05-31|June 2009|2009-06-30|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Patient International Normalised Ratio (INR) Self-Testing Program|Patient INR Self-Testing Program Improves the Quality of Oral Anticoagulant Therapy After Mechanical Heart Valve Replacement|Completed||Phase 3|206|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:51:44.749954|2018-06-01 00:51:44.749954
NCT00925184|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2010-11-18|2009-06-19|2009-06-22|Estimate|||||||2010-11-18|2010-11-19|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|November 2009|Anticipated|2009-11-30|July 2009|Anticipated|2009-07-31||Observational|||Students' View: Survey of Medical Education in Taiwan|Students' View: Survey of Medical Education in Taiwan|Unknown status|Enrolling by invitation||370|Anticipated|Taipei Medical University WanFang Hospital|||1||f||||f||||||||||2018-06-01 00:51:44.938619|2018-06-01 00:51:44.938619
NCT00925171|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-19|||2011-08-03|2009-06-19|2009-06-22|Estimate|||||||2011-08-03|2011-08-04|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|||Maintenance Schedules Following Pulmonary Rehabilitation|The Effects of Maintenance Schedules Following Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Active, not recruiting|Phase 2|128|Anticipated|University of East Anglia||2|||f||||f||||||||||2018-06-01 00:51:45.047638|2018-06-01 00:51:45.047638
NCT00925158|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2012-07-23|2009-06-18|2009-06-19|Estimate|||||||2012-07-23|2012-07-24|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|DAME||Dissector Assisted Malar Elevation for Rhytidoplasty|Non-randomized Clinical Trial for Evaluation of the Dissector Assisted Malar Elevation in Videoendoscopic Rhytidoplasty.|Unknown status|Active, not recruiting|N/A|30|Anticipated|Federal University of São Paulo||1|||f||||f||||||||||2018-06-01 00:51:45.194769|2018-06-01 00:51:45.194769
NCT00925145|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-06-01|2009-06-18|2009-06-19|Estimate|||||||2011-06-01|2011-06-03|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||Single Incision Laparoscopic Appendectomy in the Community Utilizing Conventional Instruments|Single Incision Laparoscopic Appendectomy in the Community Utilizing Conventional Instruments|Completed|||32|Anticipated|University of British Columbia|||1||f||||f||||||||||2018-06-01 00:51:45.303801|2018-06-01 00:51:45.303801
NCT00924937|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2018-03-14|2009-06-18|2009-06-19|Estimate|||||||2018-03-14|2018-03-15|Actual|November 2009|Actual|2009-11-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|CORDIOPREV||CORonary Diet Intervention With Olive Oil and Cardiovascular PREVention|Randomized Clinical Trial on the Effects of Mediterranean Diet (Rich on Olive Oil) in the Reduction of Coronary Events of Patients With Coronary Disease|Active, not recruiting||N/A|1002|Actual|Hospital Universitario Reina Sofia de Cordoba||2|||f||||t||||||||No||2018-06-01 00:51:49.459214|2018-06-01 00:51:49.459214
NCT00925132|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2017-02-15||2017-06-05|2009-06-18|2009-06-19|Estimate|2017-06-05|2017-07-02|Actual||||2017-06-05|2017-07-02|Actual|December 2009|Actual|2009-12-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|November 2014|Actual|2014-11-30||Interventional||Patients with the diagnosis of metastatic melanoma from any site. These include untreated patients or those treated with chemotherapy or biochemotherapy.|Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat|Phase Ib/II: Epigenetic Modification of Chemosensitivity and Apoptosis in Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine, Temozolomide and Panobinostat|Terminated||Phase 1/Phase 2|39|Actual|University of Iowa|This study was closed to enrollment early as there was a change in the number of approved drugs for metastatic melanoma, making Temozolomide as a chemotherapy agent, an unlikely treatment for metastatic melanoma.|1||Change in the number of approved drugs for metastatic melanoma|f||||t||||||||No||2018-06-01 00:51:45.40207|2018-06-01 00:51:45.40207
NCT00925119|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-04-21||2017-12-22|2009-06-17|2009-06-19|Estimate|2017-11-28|2017-12-22|Actual||||2017-12-22|2018-01-23|Actual|December 2009||2009-12-31|December 2017|2017-12-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes|Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-Blockers|Terminated||Phase 4|31|Actual|University of Maryland||1|||f||||t||||||||No||2018-06-01 00:51:45.795567|2018-06-01 00:51:45.795567
NCT00925106|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2010-08-19|2009-06-18|2009-06-19|Estimate|||||||2010-08-19|2010-08-23|Estimate|July 2009||2009-07-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetics Of Celecoxib Test Formulations|A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Celecoxib Formulations D1, D2 And D3 In Healthy Volunteers|Completed||Phase 1|16|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:51:46.018047|2018-06-01 00:51:46.018047
NCT00925093|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2015-01-23|2009-06-18|2009-06-19|Estimate|||||||2015-01-23|2015-01-26|Estimate|September 2011||2011-09-30|June 2009|2009-06-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection|Antibiotics in Cerebrospinal Fluid Following Intravenous Injection|Withdrawn||Phase 1|0|Actual|Aarhus University Hospital||3||Primary investigator left institution|f||||f||||||||||2018-06-01 00:51:46.103959|2018-06-01 00:51:46.103959
NCT00925080|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2010-02-02|2009-06-18|2009-06-19|Estimate|||||||2010-02-02|2010-02-03|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|||Pivotal Study of the Intravenous Blood Glucose (IVBG) System, In-Clinic Setting||Completed|||50|Anticipated|DexCom, Inc.|||1||f||||f||||||||||2018-06-01 00:51:46.212817|2018-06-01 00:51:46.212817
NCT00925067|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-18|2009-06-18|2009-06-19|Estimate|||||||2009-06-18|2009-06-19|Estimate|April 2003||2003-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|October 2007|Actual|2007-10-31||Interventional|||Effects of Lightweight Meshes in Laparoscopic Inguinal Hernia Repair on Quality of Life and Male Fertility Aspects|Effects of Lightweight Meshes in Laparoscopic Inguinal Hernia Repair on Quality of Life and Male Fertility Aspects|Completed||N/A|59|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-06-01 00:51:46.367907|2018-06-01 00:51:46.367907
NCT00925054|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17||2017-08-17|2017-08-17|2009-06-18|2009-06-19|Estimate||||2017-08-17|2017-08-21|Actual|2017-08-17|2017-08-21|Actual|September 2009||2009-09-30|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU|Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous (SC) Doses of rAvPAL-PEG in Subjects With PKU|Completed||Phase 2|40|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||No||2018-06-01 00:51:46.464425|2018-06-01 00:51:46.464425
NCT00925041|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2015-06-22|2009-06-18|2009-06-19|Estimate|||||||2015-06-22|2015-06-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:51:46.583944|2018-06-01 00:51:46.583944
NCT00925028|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2010-03-04|2009-06-17|2009-06-19|Estimate|||||||2010-03-04|2010-03-08|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Warfarin Patient Self-Monitoring|THE FEASIBILITY OF PATIENT SELF-MANAGEMENT OF WARFARIN THERAPY IN THE CANADIAN PRIMARY CARE SETTING|Completed||N/A|25|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:51:46.639991|2018-06-01 00:51:46.639991
NCT00925015|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-04-24||2017-04-24|2009-06-18|2009-06-19|Estimate|2017-04-24|2017-08-02|Actual||||2017-04-24|2017-08-02|Actual|June 17, 2009|Actual|2009-06-17|April 2017|2017-04-30|December 6, 2010|Actual|2010-12-06|July 28, 2010|Actual|2010-07-28||Interventional|||Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)|A Phase I Study of MK-0646 in Combination With Cetuximab and Irinotecan in Patients With Advanced or Metastatic Colorectal Cancer|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 00:51:46.774609|2018-06-01 00:51:46.774609
NCT00925002|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-03-23|2009-06-17|2009-06-19|Estimate|||||||2018-03-23|2018-03-27|Actual|August 5, 2009|Actual|2009-08-05|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis|Open-label Safety And Efficacy Evaluation Of Fx-1006a In Subjects With Transthyretin (Ttr) Amyloidosis|Active, not recruiting||Phase 3|93|Actual|Pfizer||1|||f||||f|t|f||||||||2018-06-01 00:51:48.153735|2018-06-01 00:51:48.153735
NCT00924989|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17||2013-07-10|2013-07-10|2009-06-18|2009-06-19|Estimate||||2013-07-10|2013-07-12|Estimate|2013-07-10|2013-07-12|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|GALACCTIC||A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma|Completed||Phase 3|139|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 00:51:48.486367|2018-06-01 00:51:48.486367
NCT00924976|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2011-05-10|2009-06-18|2009-06-19|Estimate|||||||2011-05-10|2011-05-12|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families|Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families|Completed||N/A|303|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:51:48.882922|2018-06-01 00:51:48.882922
NCT00924963|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-10-17|2009-06-18|2009-06-19|Estimate|||||||2011-10-17|2011-10-18|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion|Comparison of J-Tip® Jet Injection of 1% Buffered Lidocaine, 4% Lidocaine Topical Cream, and J-Tip® Jet Injection of Placebo Prior to Venipuncture and Peripheral Intravenous Catheter Insertion in a Pediatric Emergency Department|Terminated||N/A|132|Anticipated|Children's Hospital Medical Center, Cincinnati||3||Study ended due to lack of funding.|f||||t||||||||||2018-06-01 00:51:48.977914|2018-06-01 00:51:48.977914
NCT00924911|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2017-06-23|2009-06-18|2009-06-19|Estimate|||||||2017-06-23|2017-06-26|Actual|April 27, 2009|Actual|2009-04-27|June 2017|2017-06-30|July 9, 2009|Actual|2009-07-09|July 9, 2009|Actual|2009-07-09||Interventional|PDF112034||Relative Bioavailability Study in Healthy Subjects|A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:51:49.771567|2018-06-01 00:51:49.771567
NCT00924898|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-02-08||2017-04-06|2009-06-18|2009-06-19|Estimate|2017-04-06|2017-05-16|Actual||||2017-04-06|2017-05-16|Actual|January 2005||2005-01-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)|CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis|Completed||Phase 4|92|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-06-01 00:51:49.95449|2018-06-01 00:51:49.95449
NCT00924885|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2013-10-28|2009-06-18|2009-06-19|Estimate|||||||2013-10-28|2013-10-29|Estimate|June 2009||2009-06-30|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Experience of Pain During Oocyte Retrieval- a Comparison Between Two Aspiration Needles|Experience of Pain During Oocyte Retrieval- a Comparison Between Two Aspiration Needles|Completed||N/A|280|Anticipated|Vitrolife||2|||f||||f||||||||||2018-06-01 00:51:50.524015|2018-06-01 00:51:50.524015
NCT00924872|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2012-08-31|2009-06-18|2009-06-19|Estimate|||||||2012-08-31|2012-09-03|Estimate|June 2009||2009-06-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Power Mobility Training for Persons With Stroke|Power Mobility Training for Persons With Stroke: A Randomized Control Trial|Completed||N/A|27|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-06-01 00:51:50.598767|2018-06-01 00:51:50.598767
NCT00924859|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-09-27|2009-06-18|2009-06-19|Estimate|||||||2017-09-27|2017-09-28|Actual|September 2009|Actual|2009-09-30|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis (CVT)|The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis|Recruiting|||300|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-06-01 00:51:50.70333|2018-06-01 00:51:50.70333
NCT00924846|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-19|2009-06-18|2009-06-19|Estimate|||||||2009-06-19|2009-06-22|Estimate|April 2005||2005-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|April 2008|Actual|2008-04-30||Interventional|||High-Frequency Oscillatory Ventilation Associated With Inhaled Nitric Oxide in Children|High-Frequency Oscillatory Ventilation Associated With Inhaled Nitric Oxide in Children: Randomized, Crossover Study|Completed||Phase 3|24|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||f||||||||||2018-06-01 00:51:50.807962|2018-06-01 00:51:50.807962
NCT00924833|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2009-02-19||2009-09-01|2009-05-11|2009-06-19|Estimate|2009-05-11|2009-06-19|Estimate||||2009-09-01|2009-09-02|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.|Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects.|Completed||Phase 4|27|Actual|Istituto Auxologico Italiano|We used standard doses of both beta blockers and observed similar HR reductions. We could not individually titrate drug doses. The degree of beta blockade might have been different in each subject.|3|||f||||t||||||||||2018-06-01 00:51:50.904475|2018-06-01 00:51:50.904475
NCT00924820|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2015-11-17|2009-06-18|2009-06-19|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Pilot Study of Bevacizumab for Neoplastic Meningitis|A Pilot Study of Systemically Administered Bevacizumab in Patients With Neoplastic Meningitis (NM)|Completed||Phase 1/Phase 2|20|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:51:51.326055|2018-06-01 00:51:51.326055
NCT00924807|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2015-01-13||2015-03-04|2009-06-18|2009-06-19|Estimate|2015-03-04|2015-03-17|Estimate||||2015-03-04|2015-03-17|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer|Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer|Terminated||Phase 1/Phase 2|4|Actual|Beth Israel Medical Center|"Data of zero (0) participants were analyzed due to lack of funding and prematurely terminating the study by sponsor. All subjects are following up in the clinic off the study. Early termination leading to small number of subjects analyzed."|1||Sponsor closed the trial|f||||f||||||||||2018-06-01 00:51:51.468972|2018-06-01 00:51:51.468972
NCT00924794|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2015-04-16|2009-06-18|2009-06-19|Estimate|||||||2015-04-16|2015-04-20|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway|A Retrospective Epidemiological Study of Natural History of HPV Infections in Women Aged 18 Years and Above With Recurrent Conization Following a Primary Conization for High Grade Lesions/ Microinvasive Cervical Carcinomas, in Norway|Terminated|||410|Actual|GlaxoSmithKline|||1|"This complex study included a pilot and a main part. As the results of the pilot study were~   satisfying and conclusive, the main study was not performed."|f||||||||||||||2018-06-01 00:51:52.13193|2018-06-01 00:51:52.13193
NCT00924781|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2011-10-25||2015-10-30|2009-06-18|2009-06-19|Estimate|2012-02-28|2012-03-29|Estimate||||2015-10-30|2015-11-02|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)|A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease Who Are on Hemodialysis.|Terminated||Phase 2|39|Actual|Merck Sharp & Dohme Corp.|"Cohort 3 (MK2578 1mcg/200U) was not initiated because the study was prematurely~terminated by the sponsor. All randomized participants received at least one dose of study medication. Data presented are for Cohort 1 and Cohort 2, where applicable."|6|||f||||f||||||||||2018-06-01 00:51:52.449752|2018-06-01 00:51:52.449752
NCT00924768|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2013-08-03|2009-06-18|2009-06-19|Estimate|||||||2013-08-03|2013-08-06|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|IRB 09-0259||A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers|A Study of Inhalation of 20,000 EU CCRE and MCC in Otherwise Healthy Individuals Who Are Current Cigarette Smokers|Completed||Phase 1|12|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 00:51:53.494128|2018-06-01 00:51:53.494128
NCT00924755|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2010-10-01|2009-06-18|2009-06-19|Estimate|||||||2010-10-01|2010-10-04|Estimate|June 2009||2009-06-30|October 2010|2010-10-31|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Interventional|||Study of Surgical Mesh for Inguinal Hernia Repair|Early Outcome of Inguinal Hernia Repair With Biomerix Surgical Mesh Using the Lichtenstein Technique|Unknown status|Active, not recruiting|Phase 4|25|Anticipated|Biomerix|||||f||||f||||||||||2018-06-01 00:51:53.616237|2018-06-01 00:51:53.616237
NCT00924742|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-18|2009-06-18|2009-06-19|Estimate|||||||2009-06-18|2009-06-19|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Single-Dose Pharmacokinetics Study of Tapimycin Injection|A Single-Dose Pharmacokinetics Study of Tapimycin Injection(Piperacillin 4 g + Tazobactam 0.5 g Powder for Injection) Administered Under Fasting Conditions to Healthy Adult Subjects|Completed||N/A|12|Actual|Tri-Service General Hospital||1|||f||||t||||||||||2018-06-01 00:51:53.786288|2018-06-01 00:51:53.786288
NCT00924729|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2010-02-24||2017-09-21|2009-06-17|2009-06-19|Estimate|2010-02-24|2010-03-11|Estimate||||2017-09-21|2017-10-24|Actual|September 2009||2009-09-30|September 2017|2017-09-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Study of Ocular Penetration of Topically Administered Fluoroquinolones|Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery|Completed||Phase 4|50|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 00:51:54.012529|2018-06-01 00:51:54.012529
NCT00924716|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-18|2009-06-18|2009-06-19|Estimate|||||||2009-06-18|2009-06-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:51:54.665309|2018-06-01 00:51:54.665309
NCT00924703|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2017-01-30|2009-06-18|2009-06-19|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)|Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU|Active, not recruiting||Phase 2|68|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||No||2018-06-01 00:51:54.730726|2018-06-01 00:51:54.730726
NCT00924690|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2010-07-06|2009-06-18|2009-06-19|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2009||2009-06-30|July 2010|2010-07-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Colon Cancer Prevention Study|Disparities in Colorectal Cancer Prevention Behaviors|Completed||N/A|207|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:51:54.860313|2018-06-01 00:51:54.860313
NCT00924677|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-18|2009-06-18|2009-06-19|Estimate|||||||2009-06-18|2009-06-19|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||The Effect of Therapeutic Methods for Chronic Knee Osteoarthritis Pain|Phase 1 Study of Therapeutic Methods for Chronic Knee Osteoarthritis Pain|Completed||N/A|38|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 00:51:54.935942|2018-06-01 00:51:54.935942
NCT00924664|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18||2012-01-27|2012-08-23|2009-06-18|2009-06-19|Estimate||||2012-08-23|2012-08-30|Estimate|2012-08-23|2012-08-30|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Long Term Safety Study of Tanezumab in Chronic Low Back Pain|A Randomized, Multicenter, Long Term Study of the Safety of Tanezumab in Patients With Chronic Low Back Pain|Terminated||Phase 2/Phase 3|849|Actual|Pfizer||2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:51:55.102368|2018-06-01 00:51:55.102368
NCT00924651|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2017-02-23||2017-07-05|2009-06-18|2009-06-19|Estimate|2017-07-05|2017-08-08|Actual||||2017-07-05|2017-08-08|Actual|September 2009||2009-09-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|February 2016|Actual|2016-02-29||Interventional|EXCAP||Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy|A Study of the Effects of Exercise on Cancer-Related Fatigue|Completed||N/A|693|Actual|University of Rochester||2|||f||||t||||||||No||2018-06-01 00:51:56.410117|2018-06-01 00:51:56.410117
NCT00924638|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2014-06-26||2014-06-26|2009-06-18|2009-06-19|Estimate|2014-06-26|2014-07-28|Estimate||||2014-06-26|2014-07-28|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|CRYSTAL-AF|Intention-to-treat (ITT) population (all randomized subjects)|Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke|CRYptogenic STroke And underLying AF Trial|Completed||Phase 4|447|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-06-01 00:51:57.26197|2018-06-01 00:51:57.26197
NCT00924625|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2014-09-09|2009-06-18|2009-06-19|Estimate|||||||2014-09-09|2014-09-10|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis|The Use of Neuromuscular Electrical Stimulation to Reverse Muscle Atrophy in Patients With Rheumatoid Arthritis|Completed||N/A|64|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:51:58.469871|2018-06-01 00:51:58.469871
NCT00924612|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17||2010-08-17|2010-08-23|2009-06-18|2009-06-19|Estimate||||2010-08-17|2010-08-19|Estimate|2010-08-23|2010-08-27|Estimate|July 2009||2009-07-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|September 2009|Actual|2009-09-30||Interventional|||Study to Determine the Effect of Food on the Absorption of an Oral Testosterone Undecanoate Formulation|Phase II Study of the Effect of Food With Various Levels of Fat on the Pharmacokinetics of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men|Completed||Phase 2|16|Actual|Clarus Therapeutics, Inc.||5|||f||||f||||||||||2018-06-01 00:51:58.586539|2018-06-01 00:51:58.586539
NCT00924599|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2016-07-25|2009-06-18|2009-06-19|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2009||2009-06-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Pilot Study Using Weightloss and Exercise to Prevent Recurring Gestational Diabetes in Obese Women|Prevention of Gestational Diabetes Pilot Study|Completed||N/A|12|Actual|California Polytechnic State University-San Luis Obispo||4|||f||||f||||||||||2018-06-01 00:51:58.704258|2018-06-01 00:51:58.704258
NCT00924586|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2012-06-12|2009-06-18|2009-06-19|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2009||2009-06-30|June 2012|2012-06-30||||February 2010|Actual|2010-02-28||Interventional|||Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT)|Study of ONO-1101 in Patients Scheduled for Multi-Slice Computed Tomography (CT), a Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study|Completed||Phase 3|258|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 00:51:58.790353|2018-06-01 00:51:58.790353
NCT00924573|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-08-30|2009-06-18|2009-06-19|Estimate|||||||2011-08-30|2011-08-31|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride|Double-blinded Comparative Study to Investigate the Efficacy and Safety of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride in Patients With T2DM Inadequately Treated With Constant Dose of Glimepiride|Completed||Phase 3|189|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 00:51:59.026247|2018-06-01 00:51:59.026247
NCT00924560|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|2014-10-03|2013-04-10|2014-10-10|2009-06-18|2009-06-19|Estimate|2014-10-03|2014-10-09|Estimate|2013-04-10|2013-04-16|Estimate|2014-10-10|2014-10-22|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females|A Multicenter, Open-Label, Randomized, Controlled Study to Compare the Effects on Bone Mineral Density of DR-105 and a 28-Day Cycle Oral Contraceptive Regimen in Healthy, Postmenarchal, Adolescent Females|Completed||Phase 2|1361|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 00:51:59.176339|2018-06-01 00:51:59.176339
NCT00924547|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2015-07-20|2009-06-17|2009-06-19|Estimate|||||||2015-07-20|2015-07-21|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis|Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma|Completed||Phase 2|17|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 00:52:00.147335|2018-06-01 00:52:00.147335
NCT00924534|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2011-12-30|2009-06-18|2009-06-19|Estimate|||||||2011-12-30|2012-01-04|Estimate|December 2009||2009-12-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes|A Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV337 in Patients With Type 2 Diabetes on Metformin Monotherapy|Completed||Phase 2|61|Actual|Abbott||4|||f||||f||||||||||2018-06-01 00:52:00.251543|2018-06-01 00:52:00.251543
NCT00924521|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2012-11-29|2009-06-18|2009-06-19|Estimate|||||||2012-11-29|2012-11-30|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|GRAIN||Grains Reduce Adiposity and Improve Nutrition Study|Grains Reduce Adiposity and Improve Nutrition Study (GRAINS) Increased Whole Grain Intake - Beneficial Effects on Visceral Adiposity, Vascular Function and Glucose Metabolism/Insulin Resistance|Completed||N/A|54|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 00:52:00.347083|2018-06-01 00:52:00.347083
NCT00924508|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2013-09-18||2013-12-30|2009-06-18|2009-06-19|Estimate|2013-09-18|2013-11-25|Estimate||||2013-12-30|2014-01-31|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Interventional|||Hydrogel Patch for the Treatment of Eczema|A Study to Compare the Efficacy of Triamcinolone 0.1% Cream Occluded With Hydrogel Patch to Triamcinolone 0.1% Cream Without Occlusion in the Treatment of Eczema|Terminated||N/A|23|Actual|University of California, San Francisco|Due to loss of funding, enrollment was terminated prior to intended accrual of 30 participants.|1||Loss of Funding|f||||f||||||||||2018-06-01 00:52:00.421764|2018-06-01 00:52:00.421764
NCT00924495|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2013-02-10|2009-06-18|2009-06-19|Estimate|||||||2013-02-10|2013-02-12|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study Comparing Cortical Function and Dysfunction Tests in Low Back Pain|Regulatory Central Mechanisms in Chronic Nonspecific Low Back Pain With Lumbar Dysfunction|Completed||N/A|80|Actual|Kuopio University Hospital||2|||f||||||||||||||2018-06-01 00:52:00.59582|2018-06-01 00:52:00.59582
NCT00924482|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2010-09-23||2013-08-29|2009-06-18|2009-06-19|Estimate|2013-08-29|2013-09-02|Estimate||||2013-08-29|2013-09-02|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|ECOM|Study analyses included the final n=101 who had the approved clinical electronics and clinical tube; no changes in tube, algorithm or electronic design were allowed during this part of the study. Experimental electronics and version of the tube were used to test and finalize the design and algorithm during enrollment of the earlier patient group.|Impedance Cardiography: Clinical Evaluation of Endotracheal Cardiac Output Monitor (ECOM)|Impedance Cardiography: Clinical Evaluation of Endotracheal Cardiac Output Monitor (ECOM)|Completed||Phase 2/Phase 3|261|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:52:00.661595|2018-06-01 00:52:00.661595
NCT00924469|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2013-03-06||2013-03-06|2009-06-18|2009-06-19|Estimate|2013-03-06|2013-04-17|Estimate||||2013-03-06|2013-04-17|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer|A Phase 2 Open-Label, Randomized, Multi-center Study of Neoadjuvant Abiraterone Acetate (CB7630) Plus Leuprolide Acetate and Prednisone Versus Leuprolide Acetate Alone in Men With Localized High Risk Prostate Cancer|Completed||Phase 2|58|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-06-01 00:52:00.900268|2018-06-01 00:52:00.900268
NCT00924456|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-11-27|2009-06-18|2009-06-19|Estimate|||||||2009-11-27|2009-11-30|Estimate|January 2006||2006-01-31|November 2009|2009-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Clinical Trial of the Transcendental Meditation (TM) Program on Blood Pressure, Psychological Distress, and Coping|A Randomized Controlled Trial of the Transcendental Meditation Program on Blood Pressure, Psychological Distress, and Coping in Young Adults|Completed||Phase 2|296|Actual|Maharishi University of Management||1|||f||||f||||||||||2018-06-01 00:52:01.511467|2018-06-01 00:52:01.511467
NCT00924443|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2015-03-20||2015-03-30|2009-06-18|2009-06-19|Estimate|2015-03-30|2015-04-01|Estimate||||2015-03-30|2015-04-01|Estimate|June 2004||2004-06-30|March 2015|2015-03-31|March 2008|Actual|2008-03-31|June 2006|Actual|2006-06-30||Interventional||Baseline Characteristics provided for Full Analysis Set (FAS) population, defined as all participants with a confirmed diagnosis of AML who received at least one dose of clofarabine|A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable|A Phase II Trial of Clofarabine in Older Patients With Acute Myeloid Leukemia for Whom Intensive Chemotherapy is Not Considered Suitable|Completed||Phase 2|69|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:52:01.673321|2018-06-01 00:52:01.673321
NCT00924430|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-09-04|2009-06-18|2009-06-19|Estimate|||||||2009-09-04|2009-09-09|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Interaction Study SLV337/Simvastatin|A Drug Interaction Study to Investigate the Effects of SLV337 on the Pharmacokinetics of Simvastatin and Simvastatin Acid in Healthy Male Volunteers|Completed||Phase 1|16|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:52:02.414858|2018-06-01 00:52:02.414858
NCT00924417|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-18|||2009-06-18|2009-06-18|2009-06-19|Estimate|||||||2009-06-18|2009-06-19|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||A Distraction Protocol for Peripheral Intravenous (IV) Placement in the Pediatric Emergency Department|A Distraction Protocol for Peripheral IV Placement in the Pediatric Emergency Department|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-06-01 00:52:02.484417|2018-06-01 00:52:02.484417
NCT00924391|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|August 2008|Actual|2008-08-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans|Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans Study 1|Completed||Phase 2|30|Actual|University of Manitoba||2|||f||||t||||||||||2018-06-01 00:52:02.734629|2018-06-01 00:52:02.734629
NCT00924365|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-19|2009-06-17|2009-06-18|Estimate|||||||2018-05-19|2018-05-22|Actual|February 1, 2007||2007-02-01|April 22, 2014|2014-04-22|April 22, 2014||2014-04-22|||||Observational|||Natural History Study of HIV Acquired in Infancy or Childhood|A Natural History Study of HIV Acquired in Infancy or Childhood|Completed|||54|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:02.79351|2018-06-01 00:52:02.79351
NCT00924352|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2014-09-22||2014-10-03|2009-06-17|2009-06-18|Estimate|2014-09-22|2014-09-29|Estimate||||2014-10-03|2014-10-13|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer|Phase I/II Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer|Completed||Phase 1/Phase 2|56|Actual|Accelerated Community Oncology Research Network||1|||f||||f||||||||||2018-06-01 00:52:02.881264|2018-06-01 00:52:02.881264
NCT00924339|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|September 2009||2009-09-30|June 2009|2009-06-30|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|SOYFIT||Soy Food Intervention Trial|The Soy Food Intervention Trial (SOY FIT) for the Treatment of Children and Adolescents With Familial Hypercholesterolaemia - Beneficial Effect of a Soy-Substituted Diet Confirmed by Assessment of Urinary Isoflavone Excretion as Compliance Markers|Unknown status|Not yet recruiting|N/A|30|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:52:03.42842|2018-06-01 00:52:03.42842
NCT00924326|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-23|2009-06-17|2009-06-18|Estimate|||||||2018-05-23|2018-05-24|Actual|February 17, 2009||2009-02-17|April 3, 2018|2018-04-03|December 31, 2020|Anticipated|2020-12-31|September 30, 2015|Actual|2015-09-30||Interventional|||CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma|Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma|Active, not recruiting||Phase 1|43|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 00:52:03.50609|2018-06-01 00:52:03.50609
NCT00924313|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2012-07-12||2017-06-14|2009-06-17|2009-06-18|Estimate|2012-07-12|2012-08-17|Estimate||||2017-06-14|2017-07-11|Actual|September 10, 2008|Actual|2008-09-10|June 2017|2017-06-30|April 19, 2011|Actual|2011-04-19|April 19, 2011|Actual|2011-04-19||Interventional|||Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer|A Pilot Study of 11C-Acetate Positron Emission Tomography (PET) and 3 Telsa Magnetic Resonance Imaging (MRI) in Men With Prostate Cancer Undergoing Prostatectomy|Completed||Phase 1/Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 00:52:03.640722|2018-06-01 00:52:03.640722
NCT00924300|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2018-01-29|2009-06-17|2009-06-18|Estimate|||||||2018-01-29|2018-01-31|Actual|July 7, 2009|Actual|2009-07-07|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Study to Test the Usefulness of Magnetoencephalography (MEG) Imaging of Cognition in Children and Adolescents|Magnetoencephalography (MEG) and Magnetic Resonance Imaging (MRI) Studies of Typical and Atypical Cognitive Processes in Children and Adolescents|Completed|||36|Actual|University of Nebraska|||2||f||||f||||||||||2018-06-01 00:52:03.953755|2018-06-01 00:52:03.953755
NCT00924287|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2012-01-05||2015-10-06|2009-06-17|2009-06-18|Estimate|2012-01-05|2012-02-14|Estimate||||2015-10-06|2015-10-28|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses Her-2 Using Lymphodepleting Conditioning Followed by Infusion of Anti-Her-2 Gene Engineered Lymphocytes|Terminated||Phase 1/Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated after the first patient on study died as a result of the treatment.|1||"This study was terminated after the first patient treated on study died as a result of the~   treatment."|f||||t||||||||||2018-06-01 00:52:04.033027|2018-06-01 00:52:04.033027
NCT00924274|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Effect of Rapeseed Oil and Sunflower Oil|Effect of a Diet With Rapeseed Oil /Sunflower Oil on Lipoprotein in Children and Adolescents With Familial Hypercholesterolemia|Unknown status|Recruiting|N/A|24|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:52:04.280305|2018-06-01 00:52:04.280305
NCT00924261|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-09-03|2009-06-17|2009-06-18|Estimate|||||||2009-09-03|2009-09-04|Estimate|February 2007||2007-02-28|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Age-Related Gait Changes and Hip Flexibility|Age-Related Gait Changes and Hip Flexibility|Unknown status|Active, not recruiting|N/A|250|Anticipated|University of Virginia||2|||f||||t||||||||||2018-06-01 00:52:04.35886|2018-06-01 00:52:04.35886
NCT00924248|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2012-09-18|2009-06-17|2009-06-18|Estimate|||||||2012-09-18|2012-09-19|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|May 2011|Actual|2011-05-31|||||Observational|||Primovist Regulatory Post Marketing Surveillance (PMS)|Primovist Regulatory Post Marketing Surveillance|Completed|||4358|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 00:52:04.435949|2018-06-01 00:52:04.435949
NCT00924222|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2011-10-11|2009-06-17|2009-06-18|Estimate|||||||2011-10-11|2011-10-12|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Organ Protection With Sevoflurane Postconditioning After Cardiac Surgery With Cardiopulmonary Bypass||Completed||N/A|120|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 00:52:04.522721|2018-06-01 00:52:04.522721
NCT00924209|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2012-07-19||2012-08-21|2009-06-17|2009-06-18|Estimate|2012-07-19|2012-08-21|Estimate||||2012-08-21|2012-08-30|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer|Phase II Study of Neoadjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2), Non-Squamous Cell Non-Small Cell Lung Cancer|Terminated||Phase 2|7|Actual|National Institutes of Health Clinical Center (CC)|No primary or secondary goals were met because of low accrual for which the study was closed.|1||Study was terminated due to poor accrual.|f||||f||||||||||2018-06-01 00:52:04.616002|2018-06-01 00:52:04.616002
NCT00924196|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-18|2009-06-17|2009-06-18|Estimate|||||||2018-05-18|2018-05-21|Actual|February 26, 2008||2008-02-26|December 27, 2017|2017-12-27||||||||Observational|||Natural History Study of Patients With Neurofibromatosis Type I|Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:04.877036|2018-06-01 00:52:04.877036
NCT00924183|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2011-03-22|2009-06-16|2009-06-18|Estimate|||||||2011-03-22|2011-03-23|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Measuring Response to Depression Treatment|Measuring Response to Depression Treatment: A Study Comparing the Sensitivity of Multiple Outcome Measures to Change|Unknown status|Active, not recruiting||70|Anticipated|Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.|||1||f||||f||||||Samples With DNA|"~     Plasma and white blood cells will be isolated from whole blood samples and will be stored for~     future analysis.~   "|||2018-06-01 00:52:04.950278|2018-06-01 00:52:04.950278
NCT00924170|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-06-01||2017-08-08|2009-06-17|2009-06-18|Estimate|2017-08-08|2017-09-08|Actual||||2017-08-08|2017-09-08|Actual|October 31, 2008|Actual|2008-10-31|August 2017|2017-08-31|January 1, 2019|Anticipated|2019-01-01|January 2, 2016|Actual|2016-01-02||Interventional|||Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia|Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia|Active, not recruiting||Phase 1/Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 00:52:05.08873|2018-06-01 00:52:05.08873
NCT00924157|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2012-05-23|2009-06-17|2009-06-18|Estimate|||||||2012-05-23|2012-05-25|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Ile-Pro-Pro (IPP) on Endothelial Function in Patients With Coronary Artery Disease|Effect of a Protein Hydrolysate Rich in Lacto-tripeptide (IPP) on Hyperemic Blood Flow and Flow-mediated Dilation in Patients With Coronary Artery Disease|Completed||N/A|54|Actual|Boston University|||||f||||f||||||||||2018-06-01 00:52:06.701622|2018-06-01 00:52:06.701622
NCT00924131|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-06-30|2009-06-17|2009-06-18|Estimate|||||||2017-06-30|2017-07-02|Actual|April 17, 2009||2009-04-17|May 26, 2010|2010-05-26|May 26, 2010||2010-05-26|||||Observational|||Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial|Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial|Completed|||157|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:06.771738|2018-06-01 00:52:06.771738
NCT00924118|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-07-28||2018-04-11|2009-06-17|2009-06-18|Estimate|2017-08-25|2017-09-25|Actual||||2018-04-11|2018-05-14|Actual|July 2009||2009-07-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Sodium Nitrite in Acute Myocardial Infarction|A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Prevention of Ischemia-Reperfusion Injury Associated With Acute Myocardial Infarction.|Completed||Phase 2|30|Actual|Johns Hopkins University|The primary and secondary outcomes of this study were limited by too few subjects undergoing these studies.|2|||f||||t||||||||No||2018-06-01 00:52:06.855181|2018-06-01 00:52:06.855181
NCT00924105|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2012-02-10|2009-06-17|2009-06-18|Estimate|||||||2012-02-10|2012-02-13|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes|A Two-Stage Randomized Placebo-controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 Beta Vaccine (CYT013-IL1bQb) in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|48|Actual|Cytos Biotechnology AG||2|||f||||t||||||||||2018-06-01 00:52:07.120266|2018-06-01 00:52:07.120266
NCT00924092|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-23|2009-06-17|2009-06-18|Estimate|||||||2018-05-23|2018-05-24|Actual|March 13, 2009||2009-03-13|May 20, 2014|2014-05-20|August 2, 2012|Actual|2012-08-02|||||Interventional|||An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...|Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-Expressing Carcinoma|Completed||Phase 1|25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:07.20505|2018-06-01 00:52:07.20505
NCT00924079|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-18|2009-06-17|2009-06-18|Estimate|||||||2009-06-18|2009-06-19|Estimate|September 2008||2008-09-30|June 2009|2009-06-30||||November 2009|Anticipated|2009-11-30||Interventional|NAL||The Development of Oral Nalbuphine Dosage Form|Pharmacokinetic Study of Oral Nalbuphine in Normal Healthy Subjects|Unknown status|Recruiting|N/A|60|Anticipated|Tri-Service General Hospital||1|||f||||t||||||||||2018-06-01 00:52:07.287308|2018-06-01 00:52:07.287308
NCT00924066|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2014-03-13||2014-05-12|2009-06-17|2009-06-18|Estimate|2014-05-12|2014-06-09|Estimate||||2014-05-12|2014-06-09|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Ixabepilone to Treat Cervical Cancer|A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer|Completed||Phase 2|41|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 00:52:07.389447|2018-06-01 00:52:07.389447
NCT00924053|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2010-10-25||2015-03-04|2009-06-16|2009-06-18|Estimate|2011-07-21|2011-08-17|Estimate||||2015-03-04|2015-03-24|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes|A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of EGT0001474 in Subjects With Type 2 Diabetes|Completed||Phase 1|24|Actual|Theracos||2|||f||||t||||||||||2018-06-01 00:52:07.774455|2018-06-01 00:52:07.774455
NCT00924040|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2011-09-20||2015-10-07|2009-06-17|2009-06-18|Estimate|2012-04-04|2012-05-01|Estimate||||2015-10-07|2015-10-29|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia|Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|The study of BL22 has expired and MedImmune, the sponsor, is not interested in producing any new supply. All data has been analyzed and reviewed. All patients have been taken off study.|1||"The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new~   supply."|f||||f||||||||||2018-06-01 00:52:08.259456|2018-06-01 00:52:08.259456
NCT00924027|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-18|2009-06-17|2009-06-18|Estimate|||||||2018-05-18|2018-05-21|Actual|March 17, 2009||2009-03-17|October 27, 2017|2017-10-27|November 1, 2025|Anticipated|2025-11-01|November 1, 2024|Anticipated|2024-11-01||Interventional|||A Study of Patients Receiving High-Dose Rate Brachytherapy|A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch|Recruiting||Phase 2|112|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-06-01 00:52:08.496953|2018-06-01 00:52:08.496953
NCT00922844|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2015-04-18|2009-06-16|2009-06-17|Estimate|||||||2015-04-18|2015-04-21|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|ESIVAN||The Effect of Sevoflurane Versus Isoflurane on Vasopressor Need|The Effect of Sevoflurane Versus Isoflurane on Vasopressor Need|Terminated||Phase 4|10|Actual|UMC Utrecht||2||too slow recruitment; lack of funding|f||||t||||||||||2018-06-01 00:52:32.186206|2018-06-01 00:52:32.186206
NCT00924014|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure|Comparative Effects of Conivaptan and Loop Diuretics on Plasma Neurohormones and Systemic and Renal Hemodynamics in Subjects With Chronic Congestive Heart Failure|Unknown status|Not yet recruiting|N/A|8|Anticipated|Hennepin County Medical Center, Minneapolis||3|||f||||f||||||||||2018-06-01 00:52:08.590638|2018-06-01 00:52:08.590638
NCT00924001|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2011-12-22||2012-10-18|2009-06-17|2009-06-18|Estimate|2012-05-07|2012-06-07|Estimate||||2012-10-18|2012-10-25|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma|Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma|Terminated||Phase 1/Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)||1||study was stopped due to low accrual|f||||t||||||||||2018-06-01 00:52:08.68268|2018-06-01 00:52:08.68268
NCT00923988|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-08-10|2009-06-17|2009-06-18|Estimate|||||||2009-08-10|2009-08-11|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Passive Smoking on Platelet Function and Endothelial Function|Acute Effects of Short-term Exposure to Secondhand Smoke on Platelet Activation and Endothelial Function|Completed||N/A|40|Anticipated|Kantonsspital Graubünden|||||f||||||||||||||2018-06-01 00:52:08.878712|2018-06-01 00:52:08.878712
NCT00923975|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2010-06-10||2016-01-29|2009-06-17|2009-06-18|Estimate|2010-09-16|2010-10-08|Estimate||||2016-01-29|2016-02-29|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluation of DIDGET TM World Reports|Evaluation of Avatar Web Reports|Completed||N/A|51|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-06-01 00:52:08.938315|2018-06-01 00:52:08.938315
NCT00923962|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2012-09-17|2009-06-17|2009-06-18|Estimate|||||||2012-09-17|2012-09-18|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus|Endothelial and Metabolic Effects of GLP-1 in Coronary Circulation in Patients With Type 2 Diabetes Mellitus|Completed||N/A|35|Actual|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-06-01 00:52:10.125319|2018-06-01 00:52:10.125319
NCT00923949|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2012-01-11||2015-09-29|2009-06-17|2009-06-18|Estimate|2012-01-11|2012-02-14|Estimate||||2015-09-29|2015-09-30|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer|Pilot Trial of Pioglitazone in Adults Undergoing Surgical Resection of Non-Small Cell Lung Cancer|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|Study never published; terminated early due to low accrual.|1||Study never published; terminated early due to low accrual.|f||||f||||||||||2018-06-01 00:52:10.217916|2018-06-01 00:52:10.217916
NCT00923936|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-04-14||2017-06-14|2009-06-17|2009-06-18|Estimate|2017-06-14|2017-06-16|Actual||||2017-06-14|2017-06-16|Actual|April 23, 2009|Actual|2009-04-23|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|May 13, 2015|Actual|2015-05-13||Interventional|||Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma|Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma|Active, not recruiting||Phase 2|16|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||t|||No||2018-06-01 00:52:10.492408|2018-06-01 00:52:10.492408
NCT00923923|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2016-12-12|2009-06-16|2009-06-18|Estimate|||||||2016-12-12|2016-12-14|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Stress Reactivity in Veterans Receiving Pharmacological Treatment for PTSD and Alcohol Dependence|Stress Reactivity in Veterans Receiving Pharmacological Treatment for Post-traumatic Stress Disorder (PTSD) and Alcohol Dependence|Completed||N/A|57|Actual|Yale University||1|||f||||t||||||||||2018-06-01 00:52:11.287289|2018-06-01 00:52:11.287289
NCT00923910|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2014-04-07||2017-03-01|2009-06-17|2009-06-18|Estimate|2014-04-07|2014-05-08|Estimate||||2017-03-01|2017-04-12|Actual|February 22, 2008|Actual|2008-02-22|March 2017|2017-03-31|November 15, 2016|Actual|2016-11-15|October 18, 2013|Actual|2013-10-18||Interventional|||Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood|A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies|Completed||Phase 1/Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f||||||No||2018-06-01 00:52:11.42593|2018-06-01 00:52:11.42593
NCT00923897|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2014-06-24|2009-06-17|2009-06-18|Estimate|||||||2014-06-24|2014-06-25|Estimate|February 2007||2007-02-28|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)(COLD 4)|Phase II Trial of Palliative Radiotherapy for Locally Advanced Hepatocellular Carcinoma and Hepatic Metastases|Completed||Phase 2|40|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:52:12.116623|2018-06-01 00:52:12.116623
NCT00923884|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-04-21|2009-06-17|2009-06-18|Estimate|||||||2018-04-21|2018-04-24|Actual|March 18, 2009||2009-03-18|April 20, 2018|2018-04-20|April 20, 2018||2018-04-20|||||Observational|||Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer|Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer|Completed|||546|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:12.179358|2018-06-01 00:52:12.179358
NCT00923871|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2017-05-04|2009-06-17|2009-06-18|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2009||2009-06-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Automating Breast Radiation Therapy (RT)|Automating the Breast Radiation Therapy Process to Improve Efficiency|Active, not recruiting||N/A|160|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:52:12.23314|2018-06-01 00:52:12.23314
NCT00923858|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2018-04-04|2009-06-17|2009-06-18|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2005||2005-07-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|May 2021|Anticipated|2021-05-31||Observational|||The Natural History of Asymptomatic Rotator Cuff Tears|Asymptomatic Cuff Tears: A Model for Pain Development - Part B|Enrolling by invitation|||550|Anticipated|Washington University School of Medicine|||2||f||||f||||||||No||2018-06-01 00:52:12.382677|2018-06-01 00:52:12.382677
NCT00923403|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|August 2008||2008-08-31|June 2009|2009-06-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II|Efficacy of Sterol-Fortified Low Fat Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans - Study II|Completed||Phase 1/Phase 2|33|Actual|University of Manitoba||2|||f||||t||||||||||2018-06-01 00:52:15.517806|2018-06-01 00:52:15.517806
NCT00923845|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2015-11-16||2017-09-01|2009-06-17|2009-06-18|Estimate|2015-11-16|2015-12-21|Estimate||||2017-09-01|2017-09-29|Actual|March 1, 2008|Actual|2008-03-01|September 2017|2017-09-30|June 22, 2017|Actual|2017-06-22|June 1, 2015|Actual|2015-06-01||Interventional|||Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer|Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells|Completed||Phase 2|25|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f||||||No||2018-06-01 00:52:12.524409|2018-06-01 00:52:12.524409
NCT00923832|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-06-30|2009-06-17|2009-06-18|Estimate|||||||2017-06-30|2017-07-02|Actual|March 30, 2009||2009-03-30|November 23, 2009|2009-11-23|November 23, 2009||2009-11-23|||||Observational|||Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis|Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:13.261828|2018-06-01 00:52:13.261828
NCT00923819|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-04-26|2009-06-17|2009-06-18|Estimate|||||||2018-04-26|2018-04-30|Actual|June 2009||2009-06-30|April 2018|2018-04-30|December 2027|Anticipated|2027-12-31|December 2020|Anticipated|2020-12-31||Interventional|4XL||4XL Study - Obesity Surgery in Adolescence|4XL-Study - Obesity Surgery in Adolescence|Recruiting||N/A|120|Anticipated|Sykehuset i Vestfold HF||2|||f||||f||||||||||2018-06-01 00:52:13.323534|2018-06-01 00:52:13.323534
NCT00923806|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2015-10-18|2009-06-17|2009-06-18|Estimate|||||||2015-10-18|2015-10-20|Estimate|December 2008||2008-12-31|October 2015|2015-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer|Phase I/II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes|Terminated||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)||1||Study was terminated due to poor accrual.|f||||t||||||||||2018-06-01 00:52:13.4085|2018-06-01 00:52:13.4085
NCT00923793|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2015-05-20|2009-06-17|2009-06-18|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Comparison of Individual Computer Aided Design/Manufactured (CAD/CAM) - Based Implants Consisting on Hydroxylapatite and Titanium to be Used in Cranioplasty|Comparison of Individual CAD/CAM-based Implants Consisting on Hydroxylapatite and Titanium to be Used in Cranioplasty - a Randomized Multicenter Clinical Trial|Terminated||Phase 3|53|Actual|University of Leipzig||2||Recruitment was stopped, due to slow recruitment rate|f||||f||||||||||2018-06-01 00:52:13.494316|2018-06-01 00:52:13.494316
NCT00923780|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-06-30|2009-06-17|2009-06-18|Estimate|||||||2017-06-30|2017-07-02|Actual|January 5, 2007||2007-01-05|September 28, 2009|2009-09-28||||September 28, 2009|Actual|2009-09-28||Observational|||Evaluation of Blood Vessel Formation in Endocrine Tumors|Prospective Evaluation of Tumor Angiogenesis in Endocrine Neoplasms|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:13.575357|2018-06-01 00:52:13.575357
NCT00923741|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-10-05|2009-06-17|2009-06-18|Estimate|||||||2017-10-05|2017-10-06|Actual|June 19, 2008||2008-06-19|November 6, 2012|2012-11-06|February 1, 2010|Actual|2010-02-01|February 1, 2010|Actual|2010-02-01||Interventional|||Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer|An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:13.628591|2018-06-01 00:52:13.628591
NCT00923728|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2014-01-08|2009-06-17|2009-06-18|Estimate|||||||2014-01-08|2014-01-10|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors|A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors|Withdrawn||N/A|0|Actual|Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 00:52:13.696585|2018-06-01 00:52:13.696585
NCT00923702|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2016-08-31|2009-06-17|2009-06-18|Estimate|||||||2016-08-31|2016-09-01|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India|Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India|Active, not recruiting||Phase 4|20000|Anticipated|International Agency for Research on Cancer||2|||f||||t||||||||||2018-06-01 00:52:13.763569|2018-06-01 00:52:13.763569
NCT00923676|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2015-11-17|2009-06-17|2009-06-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|April 2008||2008-04-30|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Treatment of Hyperlipidemia and Sexual Dysfunction|Effect of Fenofibrate and Rosuvastatin on Sexual Dysfunction in Hyperlipidemic Patients. A Randomized Trial|Unknown status|Active, not recruiting|Phase 4|300|Actual|"University of Campania Luigi Vanvitelli"||3|||f||||f||||||||||2018-06-01 00:52:13.836453|2018-06-01 00:52:13.836453
NCT00923663|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2010-09-27|2009-06-17|2009-06-18|Estimate|||||||2010-09-27|2010-09-28|Estimate|July 2009||2009-07-31|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|Unknown status|Recruiting|Phase 2|16|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-06-01 00:52:13.906317|2018-06-01 00:52:13.906317
NCT00923650|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-06-30|2009-06-17|2009-06-18|Estimate|||||||2017-06-30|2017-07-02|Actual|December 9, 2008||2008-12-09|February 2, 2010|2010-02-02|February 2, 2010||2010-02-02|||||Observational|||Informed Consent in Pediatric Cancer Trials|Informed Consent in Pediatric Phase I Cancer Trials|Completed|||1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:14.073121|2018-06-01 00:52:14.073121
NCT00923637|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer|Feasibility of Administering Adjuvant Chemotherapy of Pemetrexed Followed by Pemetrexed/Oxaliplatin Immediately Post-VATS in Patients With Completely Resected NSCLC|Unknown status|Recruiting|Phase 2|75|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||||f||||t||||||||||2018-06-01 00:52:14.135018|2018-06-01 00:52:14.135018
NCT00923624|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-10-11|2009-06-17|2009-06-18|Estimate|||||||2017-10-11|2017-10-13|Actual|June 2009||2009-06-30|October 2017|2017-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Patient Portal to Support Treatment Adherence|Patient Portal to Support Treatment Adherence|Completed||N/A|304|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 00:52:14.223579|2018-06-01 00:52:14.223579
NCT00923611|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel Grouped, Clinical Study to Evaluate the Antihypertensive Efficacy and Tolerability and to Determine the Adequate Antihypertensive Dosage of Fimasartan(BR-A-657-K) in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 2|182|Anticipated|Boryung Pharmaceutical Co., Ltd||5|||f||||t||||||||||2018-06-01 00:52:14.299675|2018-06-01 00:52:14.299675
NCT00923598|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2012-06-12|2009-06-17|2009-06-18|Estimate|||||||2012-06-12|2012-06-14|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks|Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks|Completed||Phase 4|48|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 00:52:14.373067|2018-06-01 00:52:14.373067
NCT00923572|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2015-11-10|2009-06-17|2009-06-18|Estimate|||||||2015-11-10|2015-11-11|Estimate|December 2007||2007-12-31|November 2015|2015-11-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|||Yasmin Post Marketing Surveillance|Yasmin Regulatory Post Marketing Surveillance|Completed|||777|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:52:14.449254|2018-06-01 00:52:14.449254
NCT00923559|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|October 2005||2005-10-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MIPPS||Mother-Infant Psychoanalysis Project of Stockholm|A Randomized Controlled Trial of Mother-Infant Psychoanalytic Treatment and Treatment As Usual at Child Health Centres|Completed||Phase 3|80|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 00:52:14.533073|2018-06-01 00:52:14.533073
NCT00923533|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-10-07|2009-06-17|2009-06-18|Estimate|||||||2009-10-07|2009-10-08|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers|An Open-label, Multiple-dosing, Crossover, and Parallel Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers|Completed||Phase 1|34|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-06-01 00:52:14.632207|2018-06-01 00:52:14.632207
NCT00923520|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-08|2009-06-17|2009-06-18|Estimate|||||||2018-05-08|2018-05-09|Actual|March 25, 2009||2009-03-25|April 26, 2018|2018-04-26|May 12, 2016|Actual|2016-05-12|May 12, 2016|Actual|2016-05-12||Interventional|||A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies|A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies|Completed||Phase 1|60|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 00:52:14.698036|2018-06-01 00:52:14.698036
NCT00923507|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-26|2009-06-17|2009-06-18|Estimate|||||||2018-05-26|2018-05-30|Actual|April 8, 2008||2008-04-08|May 22, 2018|2018-05-22||||||||Observational|||Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)|Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lmphoplasmacytic Lymphoma(LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma(SMZL)|Recruiting|||550|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:14.779584|2018-06-01 00:52:14.779584
NCT00923494|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2017-01-19|2009-06-17|2009-06-18|Estimate|||||||2017-01-19|2017-01-20|Estimate|May 2009|Actual|2009-05-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effectiveness of Ultrasound (US) Guided Supraclavicular Block|Effectiveness of Ultrasound Guided Supraclavicular Brachial Plexus Block With 20, 30, or 40 ml of Ropivacaine 0.5%|Withdrawn||N/A|0|Actual|Baylor College of Medicine||3||Unable to enroll. Change in patient population.|f||||t||||||||||2018-06-01 00:52:14.854648|2018-06-01 00:52:14.854648
NCT00923481|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2012-07-25||2015-09-29|2009-06-17|2009-06-18|Estimate|2012-07-25|2012-08-29|Estimate||||2015-09-29|2015-09-30|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|April 2009|Actual|2009-04-30||Interventional|||A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...|A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors|Completed||Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 00:52:14.944696|2018-06-01 00:52:14.944696
NCT00923468|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-06-30|2009-06-17|2009-06-18|Estimate|||||||2017-06-30|2017-07-02|Actual|September 23, 2008||2008-09-23|August 31, 2009|2009-08-31||||August 31, 2009|Actual|2009-08-31||Observational|||Pharmacokinetic Studies Participation Survey|ADVL08N1: A Pharmacokinetic Participation Questionnaire Study|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:15.240198|2018-06-01 00:52:15.240198
NCT00923442|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-03-07|2009-06-17|2009-06-18|Estimate|||||||2018-03-07|2018-03-08|Actual|January 22, 2004||2004-01-22|September 28, 2017|2017-09-28||||||||Observational|||Biology Studies of Hematologic Cancers|Hematologic Malignancy Biology Study|Enrolling by invitation|||178|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:15.307603|2018-06-01 00:52:15.307603
NCT00923429|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|January 1994||1994-01-31|June 2009|2009-06-30|December 2000|Actual|2000-12-31|December 1998|Actual|1998-12-31||Interventional|Justina||Trial on Subacute Low Back Pain|A Randomized Controlled Clinical Trial of Stay-Active Care and Manual Therapy Versus Stay-Active Care Only in Subacute Low Back Pain in a Primary Health Care Setting. The Gotland Low Back Pain Study|Completed||N/A|160|Actual|Uppsala University||4|||f||||f||||||||||2018-06-01 00:52:15.381537|2018-06-01 00:52:15.381537
NCT00923416|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2012-12-18|2009-06-17|2009-06-18|Estimate|||||||2012-12-18|2012-12-19|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Trans-Rectal Ultrasound-Guided (TRUS) Adverse Events|A Prospective Quantification of Patient-Reported Adverse Events Following Trans-Rectal Ultrasound-Guided Intra-Prostatic Marker Insertion|Completed|||240|Actual|University Health Network, Toronto|||1||f||||f||||||||||2018-06-01 00:52:15.459832|2018-06-01 00:52:15.459832
NCT00923390|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-02-13|2009-06-17|2009-06-18|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2, 2009||2009-03-02|August 24, 2012|2012-08-24|August 24, 2012|Actual|2012-08-24|August 24, 2012|Actual|2012-08-24||Interventional|||Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor|Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor|Terminated||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:15.592397|2018-06-01 00:52:15.592397
NCT00923377|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-06-30|2009-06-17|2009-06-18|Estimate|||||||2017-06-30|2017-07-02|Actual|March 23, 2007||2007-03-23|May 11, 2010|2010-05-11|May 11, 2010||2010-05-11|||||Observational|||Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer|Pilot Trial to Identify and Characterize Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer|Completed|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:15.665272|2018-06-01 00:52:15.665272
NCT00923364|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-05-03||2017-10-17|2009-06-17|2009-06-18|Estimate|2017-10-17|2017-11-30|Actual||||2017-10-17|2017-11-30|Actual|March 5, 2009|Actual|2009-03-05|October 2017|2017-10-31|July 11, 2017|Actual|2017-07-11|June 12, 2014|Actual|2014-06-12||Interventional||Data were not collected separately for donors and recipients.|Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC|Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients With GATA2 Mutations|Completed||Phase 2|19|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||No||2018-06-01 00:52:15.743679|2018-06-01 00:52:15.743679
NCT00923351|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2013-07-09||2018-03-30|2009-06-17|2009-06-18|Estimate|2013-07-09|2013-09-20|Estimate||||2018-03-30|2018-05-02|Actual|June 2, 2007|Actual|2007-06-02|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|March 19, 2013|Actual|2013-03-19||Interventional|||Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma|A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors|Active, not recruiting||Phase 1/Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)|Re: Reason stopped: Of 30 pts who have received immunotherapy,12 remain on F/U, are stable or without evidence of disease,11 died of PD, 7 are currently receiving additional therapy (NOT ON THIS PROTOCOL) for PD.|2|||f||||t|t|f||||||No||2018-06-01 00:52:16.32021|2018-06-01 00:52:16.32021
NCT00923338|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2015-12-29|2009-06-17|2009-06-18|Estimate|||||||2015-12-29|2015-12-31|Estimate|September 2009||2009-09-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|VVP||Clinical Evaluation of the Surgisis Biodesign Vesico-Vaginal Fistula Plug|Clinical Evaluation of the Surgisis Biodesign Vesico-Vaginal Fistula Plug|Completed||N/A|20|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-06-01 00:52:16.874909|2018-06-01 00:52:16.874909
NCT00923325|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-19|2009-06-17|2009-06-18|Estimate|||||||2018-05-19|2018-05-22|Actual|December 9, 2008||2008-12-09|May 18, 2017|2017-05-18|May 18, 2017||2017-05-18|||||Observational|||Blood and Tissue Study of Patients in NIH Protocol 08-C-0800|A Group Wide Biology and Banking Study for Phase II Study of R1507|Completed|||8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:16.950925|2018-06-01 00:52:16.950925
NCT00923312|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2018-03-19|2009-06-16|2009-06-18|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2009||2009-05-31|October 2013|2013-10-31|May 2014|Actual|2014-05-31|February 2012|Actual|2012-02-29||Interventional|||Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|Safety and Efficacy Phase I/IIa Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|46|Actual|CureVac AG||1|||f||||t||||||||||2018-06-01 00:52:17.034825|2018-06-01 00:52:17.034825
NCT00923299|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-20|2009-06-17|2009-06-18|Estimate|||||||2009-06-20|2009-06-23|Estimate|December 2008||2008-12-31|June 2009|2009-06-30||||April 2010|Anticipated|2010-04-30||Interventional|||Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine|Phase I-II Study Evaluating Combined Treatment of Cetuximab and Trastuzumab in Metastatic Pancreatic Cancer Patients Progressing After Gemcitabine Based Chemotherapy.|Unknown status|Recruiting|Phase 1/Phase 2|67|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:52:17.160242|2018-06-01 00:52:17.160242
NCT00923273|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2013-05-24||2015-10-01|2009-06-17|2009-06-18|Estimate|2013-10-18|2013-10-23|Estimate||||2015-10-01|2015-10-02|Estimate|February 2008||2008-02-29|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer|A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC|Completed||Phase 1/Phase 2|42|Actual|National Institutes of Health Clinical Center (CC)||5|||f||||f||||||||||2018-06-01 00:52:17.291158|2018-06-01 00:52:17.291158
NCT00923260|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2009-01-28||2009-11-24|2009-04-30|2009-06-18|Estimate|2009-04-30|2009-06-18|Estimate||||2009-11-24|2009-12-07|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|July 2008|Actual|2008-07-31|October 2007|Actual|2007-10-31||Interventional|||Omentectomy and Metabolic Syndrome|Effect of Omentectomy on Metabolic Syndrome, Acute Phase Reactants & Inflammatory Mediators in Patients Undergoing LRYGBP: A Randomized Trial|Completed||N/A|24|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|An important limitation of our study is the small number of studied patients.|2|||f||||f||||||||||2018-06-01 00:52:18.741419|2018-06-01 00:52:18.741419
NCT00923247|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-01-23||2018-04-06|2009-06-17|2009-06-18|Estimate|2017-04-13|2017-05-17|Actual||||2018-04-06|2018-05-04|Actual|February 19, 2009|Actual|2009-02-19|April 2018|2018-04-30|January 19, 2017|Actual|2017-01-19|March 11, 2016|Actual|2016-03-11||Interventional|||A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)|A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)|Terminated||Phase 1/Phase 2|22|Actual|National Institutes of Health Clinical Center (CC)||3||Terminated due to slow accrual,primary endpoint reached & investigator left NIH.|f||||f|t|f||||||No||2018-06-01 00:52:20.696593|2018-06-01 00:52:20.696593
NCT00923234|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2013-12-17|2009-06-17|2009-06-18|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|AZALE||Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes|A Phase I Study of a Combination of 5-azacitidine Followed by Lenalidomide in High-risk MDS or Relapsed/Refractory AML Patients With Cytogenetic Abnormalities Including -5 or Del(5q)|Terminated||Phase 1|||Technische Universität Dresden||1||The primary objective has already been answered with the number of recruited patients.|f||||t||||||||||2018-06-01 00:52:21.433518|2018-06-01 00:52:21.433518
NCT00923195|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2012-10-04||2015-10-06|2009-06-17|2009-06-18|Estimate|2012-10-04|2012-11-05|Estimate||||2015-10-06|2015-10-28|Estimate|December 2008||2008-12-31|October 2015|2015-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma|Phase II Study of Metastatic Melanoma Using a Chemoradiation Lymphodepleting Conditioning Regimen Followed by Infusion of Anti-Mart-1 and Anti-gp100 TCR-Gene Engineered Lymphocytes and Peptide Vaccines|Completed||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 00:52:21.578722|2018-06-01 00:52:21.578722
NCT00923182|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2015-04-29|2009-06-17|2009-06-18|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Japanese Phase I Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 1|6|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 00:52:22.055217|2018-06-01 00:52:22.055217
NCT00923169|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-23|2009-06-17|2009-06-18|Estimate|||||||2018-05-23|2018-05-24|Actual|July 9, 2006||2006-07-09|June 29, 2012|2012-06-29|January 20, 2010|Actual|2010-01-20|January 20, 2010|Actual|2010-01-20||Interventional|||Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)|A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti-Transforming Growth Factor-Beta (TGFBeta) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:22.160048|2018-06-01 00:52:22.160048
NCT00923156|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2012-02-01||2012-07-19|2009-06-17|2009-06-18|Estimate|2012-02-01|2012-03-05|Estimate||||2012-07-19|2012-07-26|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|ESCAPE-SHF||Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure|ESCAPE-SHF: A Double-blind, Double-dummy, Randomized, Multicenter, Parallel Group Study to Evaluate the Effects of Aliskiren, Ramipril and Combination Treatment on Plasma Concentration of Angiotensin II in Patients With Decompensated Systolic Heart Failure|Completed||Phase 2|123|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:52:22.261937|2018-06-01 00:52:22.261937
NCT00923130|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2016-09-16||2018-03-15|2009-06-17|2009-06-18|Estimate|2017-05-22|2017-06-27|Actual||||2018-03-15|2018-04-17|Actual|January 7, 2009|Actual|2009-01-07|March 2018|2018-03-31|June 2016|Actual|2016-06-30|March 1, 2016|Actual|2016-03-01||Interventional|||Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer|A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma|Completed||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 00:52:22.999484|2018-06-01 00:52:22.999484
NCT00923117|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2013-05-03||2015-09-29|2009-06-17|2009-06-18|Estimate|2013-05-03|2013-06-25|Estimate||||2015-09-29|2015-09-30|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Sunitinib to Treat Recurrent Brain Cancer|A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas|Terminated||Phase 2|87|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated based on results of an interim analysis for futility.|2||The study was terminated based on results of an interim analysis for futility.|f||||t||||||||||2018-06-01 00:52:23.826521|2018-06-01 00:52:23.826521
NCT00923104|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-02-13|2009-06-17|2009-06-18|Estimate|||||||2018-02-13|2018-02-14|Actual|April 9, 2009||2009-04-09|January 5, 2018|2018-01-05||||||||Observational|||An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin|An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin|Completed|||61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:24.563862|2018-06-01 00:52:24.563862
NCT00923091|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2012-01-30||2012-04-06|2009-06-16|2009-06-18|Estimate|2012-03-09|2012-04-06|Estimate||||2012-04-06|2012-04-13|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension|Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension|Completed||Phase 3|2689|Actual|Daiichi Sankyo, Inc.||8|||f||||f||||||||||2018-06-01 00:52:24.731697|2018-06-01 00:52:24.731697
NCT00923078|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2017-02-01||2017-12-21|2009-06-17|2009-06-18|Estimate|2017-12-18|2017-12-20|Actual||||2017-12-21|2017-12-22|Actual|November 2010||2010-11-30|December 2017|2017-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Neurophysiological Targets for Cognitive Training in Schizophrenia|Neurophysiological Targets for Cognitive Training in Schizophrenia|Completed||N/A|60|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-06-01 00:52:27.770063|2018-06-01 00:52:27.770063
NCT00923065|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2017-11-22|2009-06-17|2009-06-18|Estimate|||||||2017-11-22|2017-11-24|Actual|April 20, 2004||2004-04-20|November 13, 2017|2017-11-13||||||||Observational|||Cancer Care in the National Cancer Institute Center for Cancer Research|Care of the Adult Oncology Patient, CCR, NCI|Enrolling by invitation|||782|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:28.371232|2018-06-01 00:52:28.371232
NCT00923052|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-19|2009-06-17|2009-06-18|Estimate|||||||2018-05-19|2018-05-22|Actual|February 9, 2009||2009-02-09|May 7, 2015|2015-05-07|May 7, 2015||2015-05-07|||||Observational|||The Natural History of Solid Organ Cancer Stem Cells (SOCSC)|The Natural History of Solid Organ Cancer Stem Cells (SOCSC)|Terminated|||190|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:28.568329|2018-06-01 00:52:28.568329
NCT00923039|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-17|2009-06-17|2009-06-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|June 2009||2009-06-30|June 2009|2009-06-30||||||||Observational|||The Early Origins of Cardiovascular Disease|The Early Origins of Cardiovascular Disease : the Consequence of Growth Restriction During Foetal Life and Infancy on Cardiovascular Structure and Function in Adulthood|Unknown status|Not yet recruiting||200|Anticipated|Danone Institute International|||1||f||||||||||||||2018-06-01 00:52:28.674431|2018-06-01 00:52:28.674431
NCT00923026|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-05-26|2009-06-17|2009-06-18|Estimate|||||||2018-05-26|2018-05-30|Actual|June 3, 2009||2009-06-03|August 1, 2017|2017-08-01||||||||Observational|||Follow Up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies|Follow Up Protocol for Subjects Previously Enrolled in NCI Surgery Branch Studies|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:28.75797|2018-06-01 00:52:28.75797
NCT00922831|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2018-04-10|2009-06-16|2009-06-17|Estimate|||||||2018-04-10|2018-04-12|Actual|August 2008||2008-08-31|April 2018|2018-04-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Progression of Cognitive and Physical Symptoms in Multiple Sclerosis|Progression of Cognitive, Affective, and Physical Symptoms in Multiple Sclerosis.|Withdrawn|||0|Actual|MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute||||Funding not available|f||||f||||||||||2018-06-01 00:52:32.390882|2018-06-01 00:52:32.390882
NCT00923013|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-02-13|2009-06-17|2009-06-18|Estimate|||||||2018-02-13|2018-02-14|Actual|October 7, 2008||2008-10-07|January 19, 2018|2018-01-19|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia|Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease|Recruiting||Phase 2|177|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 00:52:28.866126|2018-06-01 00:52:28.866126
NCT00923000|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2009-06-18|2009-06-17|2009-06-18|Estimate|||||||2009-06-18|2009-06-19|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs|Herb Drug Interaction of Traditional Chinese Herb and Commonly Used Drugs|Unknown status|Recruiting|Phase 1|50|Anticipated|Tri-Service General Hospital||5|||f||||t||||||||||2018-06-01 00:52:28.982426|2018-06-01 00:52:28.982426
NCT00922987|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|2011-05-31||2011-07-19|2009-06-17|2009-06-18|Estimate|2011-05-31|2011-06-21|Estimate||||2011-07-19|2011-07-22|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Clinical Study With Lyrica In Patients Suffering From Epilepsy|Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency|Completed|||286|Actual|Pfizer|On review of blinded data it was decided that an additional analysis set, MFAS was required. MFAS was created for analysis of seizure data. The outcomes related to seizure data were therefore analyzed for MFAS population and not FAS population.||1||f||||f||||||||||2018-06-01 00:52:29.176644|2018-06-01 00:52:29.176644
NCT00922974|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-17|||2018-04-09|2009-06-17|2009-06-18|Estimate|||||||2018-04-09|2018-04-11|Actual|November 2009|Actual|2009-11-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2018|Actual|2018-01-31||Interventional|||Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis|Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis|Active, not recruiting||Phase 2/Phase 3|399|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 00:52:30.577245|2018-06-01 00:52:30.577245
NCT00922961|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2012-07-20|2009-06-16|2009-06-17|Estimate|||||||2012-07-20|2012-07-23|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|MAMMOSITE2||Research for Predictive Biologic Parameters of Cutaneous Hypersensitivity After Brachytherapy in Breast Cancer|Research for Predictive Biologic Parameters of Cutaneous Hypersensitivity After Brachytherapy in Breast Cancer|Completed||N/A|25|Actual|Centre Oscar Lambret||1|||f||||f||||||||||2018-06-01 00:52:30.77094|2018-06-01 00:52:30.77094
NCT00922948|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-07-26|2009-06-16|2009-06-17|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Cryoablation Versus Radiofrequency Ablation for Small Renal Masses|A Prospective Randomized Pilot Trial of Cryoablation (CA) Versus Radio Frequency Ablation (RFA) for the Management of Small Renal Masses|Withdrawn||Phase 2|0|Actual|St. Joseph's Healthcare Hamilton||2||"Cryoablation is no longer offered at our hospital, and likely won't be offered in the near~   future."|f||||f||||||||||2018-06-01 00:52:30.928408|2018-06-01 00:52:30.928408
NCT00922935|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2011-06-13||2016-03-03|2009-06-16|2009-06-17|Estimate|2011-06-13|2011-07-12|Estimate||||2016-03-03|2016-03-31|Estimate|October 2004||2004-10-31|March 2016|2016-03-31|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|||Comparison of Early and Late Loading in the Edentulous Upper Jaw Using Cresco Prosthetic System on Straumann Implants|A 3 Arm Controlled Randomised Study: Comparison of Early and Late Loading Protocols in Full Arch Reconstructions in the Edentulous Maxilla, Using The Cresco Prosthetic System on Straumann Implants|Completed||Phase 4|36|Actual|Institut Straumann AG||3|||f||||f||||||||No||2018-06-01 00:52:31.073831|2018-06-01 00:52:31.073831
NCT00922922|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-08-31|2009-06-15|2009-06-17|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2009||2009-04-30|August 2017|2017-08-31|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Observational|EI||Duration and Direct Cost of Behavioral Health Concerns in Pediatric Primary Care|Duration and Direct Cost of Behavioral Health Concerns in Pediatric Primary Care|Completed|||228|Actual|University of Nebraska|||||f||||f||||||||||2018-06-01 00:52:31.560441|2018-06-01 00:52:31.560441
NCT00922909|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2014-02-24|2009-06-16|2009-06-17|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2009||2009-06-30|February 2014|2014-02-28||||June 2010|Actual|2010-06-30||Interventional|||Executive Control Analysis in Patients Suffering From Parkinson Disease and Treated by Deep Brain Stimulation|Executive Control Analysis in Patients Suffering From Parkinson Disease and Treated by Deep Brain Stimulation (Chronometric and Electromyographic Approach During a Simon Task)|Completed||N/A|16|Actual|Assistance Publique Hopitaux De Marseille||4|||f||||f||||||||||2018-06-01 00:52:31.635785|2018-06-01 00:52:31.635785
NCT00922896|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-11-18|2009-06-16|2009-06-17|Estimate|||||||2012-11-18|2012-11-20|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|May 2011|Actual|2011-05-31|August 2010|Actual|2010-08-31||Interventional|||Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer|A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer|Completed||Phase 2|22|Actual|Gyeongsang National University Hospital||1|||f||||f||||||||||2018-06-01 00:52:31.704832|2018-06-01 00:52:31.704832
NCT00922883|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2017-10-18|2009-06-16|2009-06-17|Estimate|||||||2017-10-18|2017-10-19|Actual|May 29, 2009||2009-05-29|November 3, 2016|2016-11-03|December 31, 2020|Anticipated|2020-12-31|May 7, 2013|Actual|2013-05-07||Interventional|||A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia|A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia|Active, not recruiting||Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:31.819115|2018-06-01 00:52:31.819115
NCT00922870|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-04-04|2009-06-16|2009-06-17|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2009||2009-04-30|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Cascade||Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock|Evaluation of Hemodynamic Effects of Cascade Hemofiltration in Septic Shock|Completed||N/A|60|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 00:52:32.02467|2018-06-01 00:52:32.02467
NCT00922857|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2014-07-23|2009-06-16|2009-06-17|Estimate|||||||2014-07-23|2014-07-24|Estimate|April 2005||2005-04-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|INSPIRE||Influence of Muscular Atrophy on Biological and Functional Benefit of Respiratory Rehabilitation in Patients With Chronic Respiratory Failure|Influence of Muscular Atrophy on Biological and Functional Benefit of Respiratory Rehabilitation in Patients With Chronic Respiratory Failure|Completed||N/A|32|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 00:52:32.107768|2018-06-01 00:52:32.107768
NCT00922818|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Observational|RPP||Study of Anatomic Nerve Sparing Radical Perineal Prostatectomy|Clinical Outcomes for Anatomic Nerve Sparing Radical Perineal Prostatectomy|Unknown status|Recruiting||30|Anticipated|Maimonides Medical Center|||1||f||||f||||||||||2018-06-01 00:52:32.467143|2018-06-01 00:52:32.467143
NCT00922805|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2014-01-14|2009-06-16|2009-06-17|Estimate|||||||2014-01-14|2014-01-15|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Fiber Use in Pediatric Short Bowel Syndrome|Soluble Fiber Use in Pediatric Short Bowel Syndrome|Withdrawn||N/A|0|Actual|Arkansas Children's Hospital Research Institute||2|||f||||f||||||||||2018-06-01 00:52:32.604845|2018-06-01 00:52:32.604845
NCT00922792|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-05-12|2009-06-16|2009-06-17|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B|An Open, Non-Randomised Single and Multiple Dose Trial Investigating the Safety and Pharmacokinetics of Intravenous Administration of Long Acting rFVIIa (LA-rFVIIa) in Patients With Haemophilia A and B|Completed||Phase 1|8|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:52:32.764146|2018-06-01 00:52:32.764146
NCT00922779|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2015-12-11||2015-12-11|2009-06-16|2009-06-17|Estimate|2015-12-11|2016-01-20|Estimate||||2015-12-11|2016-01-20|Estimate|June 2002||2002-06-30|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Baseline population included all enrolled participants.|A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C|Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C|Completed||Phase 4|6661|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:52:32.973871|2018-06-01 00:52:32.973871
NCT00922766|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2011-10-07||2012-01-19|2009-06-16|2009-06-17|Estimate|2011-10-07|2011-11-11|Estimate||||2012-01-19|2012-01-23|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice|Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice|Completed|||618|Actual|Pfizer|||1||f||||t||||||||||2018-06-01 00:52:33.596832|2018-06-01 00:52:33.596832
NCT00922753|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-17|2009-06-16|2009-06-17|Estimate|||||||2009-06-17|2009-06-18|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Inspiratory Support Improves Preoxygenation in Healthy Subjects|The Efficacy and Tolerability of Different Levels of Inspiratory Support and PEEP During Preoxygenation. A Randomized Controlled Trial.|Completed||N/A|20|Actual|Maisonneuve-Rosemont Hospital||3|||f||||f||||||||||2018-06-01 00:52:33.963342|2018-06-01 00:52:33.963342
NCT00922740|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2018-05-21|2009-06-16|2009-06-17|Estimate|||||||2018-05-21|2018-05-23|Actual|June 2009||2009-06-30|May 2018|2018-05-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||VA106483 Dose Response Study in Elderly Males|An Open Label, Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Elderly Male Subjects|Completed||Phase 1|10|Actual|Vantia Ltd||4|||f||||||||||||||2018-06-01 00:52:34.127682|2018-06-01 00:52:34.127682
NCT00922727|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2018-01-23|2009-06-16|2009-06-17|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2009||2009-10-31|January 2018|2018-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults|Phase I Safety and Tolerance of Lactobacillus Reuteri in Adults|Completed||Phase 1|40|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 00:52:34.224493|2018-06-01 00:52:34.224493
NCT00922714|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-17|Estimate|||||||2009-06-15|2009-06-17|Estimate|October 2003||2003-10-31|June 2009|2009-06-30|August 2009|Anticipated|2009-08-31|May 2007|Actual|2007-05-31||Interventional|||Scandinavian Intensive Care Unit (ICU) Glutamine Study|Glutamine to Intensive Care Patients - a Prospective, Double-Blind, Placebo-Controlled Multicenter Study in the Scandinavian Countries|Terminated||Phase 4|1000|Anticipated|Scandinavian Critical Care Trials Group||2||Slow recruitment, stopped after 4 years|f||||f||||||||||2018-06-01 00:52:34.360896|2018-06-01 00:52:34.360896
NCT00922701|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2009-02-11||2010-02-16|2009-04-30|2009-06-17|Estimate|2009-04-30|2009-06-17|Estimate||||2010-02-16|2010-02-23|Estimate|June 2004||2004-06-30|February 2010|2010-02-28|December 2004|Actual|2004-12-31|October 2004|Actual|2004-10-31||Interventional|||L-Carnitine in Peritoneal Dialysis|Phase 2 Study of Dialysis Efficiency and Tolerability of Nocturnal Peritoneal Dialysis Solution Containing Glucose Plus L-carnitine|Completed||Phase 2|4|Actual|Iperboreal Pharma Srl||1|||f||||f||||||||||2018-06-01 00:52:34.457389|2018-06-01 00:52:34.457389
NCT00922688|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2011-07-20|2009-06-16|2009-06-17|Estimate|||||||2011-07-20|2011-07-21|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|AIRCo||Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients|Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients|Unknown status|Recruiting|N/A|30|Anticipated|Medical Center Alkmaar||3|||f||||f||||||||||2018-06-01 00:52:34.664277|2018-06-01 00:52:34.664277
NCT00922675|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-09-26|2009-06-16|2009-06-17|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|POSTEMI||Postconditioning in ST-elevation Myocardial Infarction|Postconditioning in ST-elevation Myocardial Infarction Treated With Primary PCI|Completed||N/A|272|Actual|Oslo University Hospital||2|||f||||t||||||||No||2018-06-01 00:52:34.803678|2018-06-01 00:52:34.803678
NCT00922662|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2016-09-13|2009-06-16|2009-06-17|Estimate|||||||2016-09-13|2016-09-14|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|CTDATABASE||Database of Patients Undergoing Cardiac Computed Tomographic Angiography at William Beaumont Hospital (CT DATABASE)|Database of Patients Undergoing Cardiac Computed Tomographic Angiography (CCTA)at William Beaumont Hospital|Completed|||10000|Actual|William Beaumont Hospitals|||||f||||f||||||||No||2018-06-01 00:52:34.897763|2018-06-01 00:52:34.897763
NCT00922649|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2017-09-20|2009-06-16|2009-06-17|Estimate|||||||2017-09-20|2017-09-21|Actual|February 1, 2008|Actual|2008-02-01|September 2017|2017-09-30|January 1, 2009|Actual|2009-01-01|December 1, 2008|Actual|2008-12-01||Interventional|||Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes|Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes|Completed||N/A|58|Actual|Animas Corporation||3|||f||||f||||||||||2018-06-01 00:52:34.972699|2018-06-01 00:52:34.972699
NCT00922311|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-14|||2015-07-02|2009-06-16|2009-06-17|Estimate|||||||2015-07-02|2015-07-03|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade|Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study|Completed||Phase 4|25|Actual|The University of Hong Kong||1|||f||||f||||||||||2018-06-01 00:52:42.421936|2018-06-01 00:52:42.421936
NCT00922636|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2013-09-26|2010-12-09|2014-07-29|2009-06-16|2009-06-17|Estimate|2014-07-29|2014-08-18|Estimate|2010-12-09|2010-12-15|Estimate|2014-07-29|2014-08-18|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder|A Fixed-Dose, Randomized, Double-Blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder|Completed||Phase 2/Phase 3|340|Actual|Eli Lilly and Company|Some sites may have received data with identifying information from the central lab; data from 69 participants were excluded from efficacy analyses. Data were excluded from efficacy analyses for a participant randomized before study site approval.|5|||f||||t||||||||||2018-06-01 00:52:35.286577|2018-06-01 00:52:35.286577
NCT00922623|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2011-12-22|2011-10-12|2013-04-19|2009-06-12|2009-06-17|Estimate|2011-12-22|2012-01-30|Estimate|2011-10-12|2011-10-21|Estimate|2013-04-19|2013-04-26|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI|A Multicenter Study of The Safety and Effectiveness of Dermal Filler, Belotero®, After Mid-to-Deep Dermal Implantation for Correction of Moderate to Severe Facial Wrinkles (Such as Nasolabial Folds) Over 24 Weeks in Subjects With Fitzpatrick Phototype Scores of IV, V, and VI.|Completed||N/A|93|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-06-01 00:52:37.812344|2018-06-01 00:52:37.812344
NCT00922610|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-11-01|2009-06-16|2009-06-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients|An Open-label Study of the Effect of Mircera on Hemoglobin Levels in Filipino Chronic Kidney Disease Patients|Completed||Phase 4|28|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 00:52:38.106238|2018-06-01 00:52:38.106238
NCT00922597|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2015-04-17|2009-06-16|2009-06-17|Estimate|||||||2015-04-17|2015-04-20|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|September 2011|Actual|2011-09-30|||||Observational|NO PEACKS||Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery|Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery - NO PEACKS|Completed|||26|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:52:38.1746|2018-06-01 00:52:38.1746
NCT00922584|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2013-08-19|2009-06-16|2009-06-17|Estimate|||||||2013-08-19|2013-08-21|Estimate|December 2008||2008-12-31|August 2013|2013-08-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor|A Phase II Study of Sorafenib (BAY 43-9006®) in Patients With Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)Treatment|Completed||Phase 2|65|Actual|Chinese Society of Lung Cancer||1|||f||||t||||||||||2018-06-01 00:52:38.265417|2018-06-01 00:52:38.265417
NCT00922571|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16||2014-05-16|2016-08-01|2009-06-16|2009-06-17|Estimate||||2014-07-07|2014-07-09|Estimate|2016-08-01|2016-08-03|Estimate|June 2009||2009-06-30|August 2016|2016-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Cataract Surgery With the Femtosecond Laser|A Study of Cataract Surgery With the Assistance of the Femtosecond Laser|Terminated||N/A|100|Actual|Abbott Medical Optics||1||Sponsor decided not to pursue market release of prototype device used in this study|f||||f||||||||||2018-06-01 00:52:38.371813|2018-06-01 00:52:38.371813
NCT00922558|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2010-10-18|2009-06-16|2009-06-17|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2010||2010-07-31|June 2009|2009-06-30|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Interventional|tetrax1||Evaluation of Postural Control in Children Using Tetra Axial Posturography|Evaluation of Postural Control in Children Using Tetra Axial Posturography|Unknown status|Recruiting|N/A|480|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-06-01 00:52:38.489117|2018-06-01 00:52:38.489117
NCT00922545|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-10-08|2009-06-16|2009-06-17|Estimate|||||||2009-10-08|2009-10-09|Estimate|April 2004||2004-04-30|October 2009|2009-10-31|December 2010|Anticipated|2010-12-31|December 2007|Anticipated|2007-12-31||Interventional|||Evaluation of a Combined Strategy Addressed to Practitioners and Chronic Obstructive Pulmonary Disease (COPD) Patients to Improve Clinical Control and Quality of Life|Evaluation of a Combined Strategy Addressed to Practitioners and COPD Patients: Information Feed-back and Health Education, to Improve Clinical Control and Quality of Life|Unknown status|Active, not recruiting|N/A|801|Actual|Jordi Gol i Gurina Foundation|||||f||||t||||||||||2018-06-01 00:52:38.752728|2018-06-01 00:52:38.752728
NCT00922532|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-09-08|2009-06-16|2009-06-17|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure|Inhaled Nitric Oxide For The Treatment Of Hypoxic Respiratory Failure With Pulmonary Hypertension In Preterm Infants|Withdrawn||Phase 3|0|Actual|Mallinckrodt||2||Company decision not to pursue prior to submission|f||||||||||||||2018-06-01 00:52:38.865209|2018-06-01 00:52:38.865209
NCT00922519|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2014-10-01|2009-06-16|2009-06-17|Estimate|||||||2014-10-01|2014-10-03|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body Positron Emission Tomography (PET) Scans for Imaging Bone|An Observational Pilot Study of 18F-Sodium Fluoride (Na18F) Whole Body PET Scans in Patients for Whom 99m Tc MDP Bone Scans Would Normally be Indicated.|Unknown status|Recruiting||9999|Anticipated|AHS Cancer Control Alberta|||1||f||||f||||||||||2018-06-01 00:52:38.95207|2018-06-01 00:52:38.95207
NCT00922506|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2015-02-12|2009-06-16|2009-06-17|Estimate|||||||2015-02-12|2015-02-16|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)|"Comparison of the Efficacy and Safety of Combination Treatment With Doxazosin Plus TolterodineSR 2 mg vs Doxazosin Plus TolterodineSR 4 mg in Men With an OAB/BPO: Randomized Controlled Study"|Unknown status|Recruiting|Phase 4|260|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 00:52:39.124632|2018-06-01 00:52:39.124632
NCT00922493|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-17|2009-06-16|2009-06-17|Estimate|||||||2009-06-17|2009-06-18|Estimate|December 2007||2007-12-31|June 2009|2009-06-30|November 2008|Actual|2008-11-30|||||Interventional|IMT||Inspiratory Muscle Training in Weaning|Weaning Process in Elderly Intubated Patients Submitted to Inspiratory Muscle Training|Completed||Phase 4|||Euro-American Network of Human Kinetics|||||f||||f||||||||||2018-06-01 00:52:39.377715|2018-06-01 00:52:39.377715
NCT00922324|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2013-05-16|2009-06-16|2009-06-17|Estimate|||||||2013-05-16|2013-05-17|Estimate|March 2010||2010-03-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Tolerability of STP206 in Healthy Adult Subjects|A Single-Center Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial to Assess the Safety and Tolerability of Single and Multiple Daily Oral Administration of STP206 Live Biotherapeutic in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Leadiant Biosciences, Inc.||2|||f||||f||||||||||2018-06-01 00:52:42.313053|2018-06-01 00:52:42.313053
NCT00922480|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2018-01-16||2018-03-15|2009-06-16|2009-06-17|Estimate|2018-01-16|2018-02-13|Actual||||2018-03-15|2018-04-10|Actual|December 2008||2008-12-31|March 2018|2018-03-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional||As ITT group, these are subjects who have been randomly assigned and have at least one primary end point.|Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients|A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 3|506|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-06-01 00:52:39.576304|2018-06-01 00:52:39.576304
NCT00922467|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-09-22|2009-06-16|2009-06-17|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Interventional|||Influence of Esmolol on a Closed-Loop Anesthesia System|Closed-loop Delivery of Propofol and Remifentanil: Sparing Effect of Esmolol|Terminated||Phase 3|15|Actual|Hopital Foch||2||lack of effectiveness|f||||f||||||||||2018-06-01 00:52:40.244143|2018-06-01 00:52:40.244143
NCT00922454|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Acute Technical Outcomes of the Talent Abdominal Aortic Aneurysm (AAA) Stent-Graft Versus Cook Zenith Stent-Graft|Acute Technical Outcomes of the Talent AAA Stent -Graft vs. Cook Zenith Stent- Graft: A Case-Control Study|Unknown status|Recruiting|N/A|200|Anticipated|Center for Vascular Awareness, Albany, New York||2|||f||||f||||||||||2018-06-01 00:52:40.361083|2018-06-01 00:52:40.361083
NCT00922441|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2018-01-16||2018-02-19|2009-06-16|2009-06-17|Estimate|2018-01-16|2018-02-13|Actual||||2018-02-19|2018-03-15|Actual|December 2008||2008-12-31|February 2018|2018-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Valsartan-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657•K) During 24hours by Dose in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 2|92|Actual|Boryung Pharmaceutical Co., Ltd||3|||f||||t||||||||||2018-06-01 00:52:40.481493|2018-06-01 00:52:40.481493
NCT00922428|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2013-05-16||2015-04-16|2009-06-16|2009-06-17|Estimate|2015-04-16|2015-05-04|Estimate||||2015-04-16|2015-05-04|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|157||PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders|PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders: A Non-interventional Observational Study.|Completed|||1389|Actual|Pascoe Pharmazeutische Praeparate GmbH|||1||f||||f||||||||||2018-06-01 00:52:40.888019|2018-06-01 00:52:40.888019
NCT00922415|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2010-12-15|2009-06-16|2009-06-17|Estimate|||||||2010-12-15|2010-12-16|Estimate|August 2009||2009-08-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Observational|||Fecal Calprotectin as a Marker for Macroscopic Recurrence of Crohn's Disease After Intestinal Resection|Use of Fecal Calprotectin as a Surrogate Marker for Macroscopic Recurrence of Disease in Patients With Crohn's Disease After Intestinal Resection|Unknown status|Recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     At all follow-up visits, they will undergo the following tests; CBC, ESR, CRP, and fecal~     calprotectin. Sera will be stored for antibodies such as ASCA or anti glycan antibodies.~      During colonoscopy, disease recurrence will be evaluated by two scores, the Rutgeerts score~     and the CDEIS score, both containing 4 grades. Recurrence will be assessed by histological~     findings as well.~   "|||2018-06-01 00:52:41.395209|2018-06-01 00:52:41.395209
NCT00922402|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2016-03-23|2009-06-16|2009-06-17|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Heart & Diabetes - Feasibility Study|Heart & Diabetes - Feasibility Study|Withdrawn||N/A|0|Actual|Medtronic Bakken Research Center||1|||f||||f||||||||||2018-06-01 00:52:41.487604|2018-06-01 00:52:41.487604
NCT00922389|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|||A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia|A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.|Unknown status|Not yet recruiting|Phase 1/Phase 2|36|Anticipated|Beike Biotech India Pvt.ltd||3|||f||||t||||||||||2018-06-01 00:52:41.602824|2018-06-01 00:52:41.602824
NCT00922376|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2012-04-09|2009-06-16|2009-06-17|Estimate|||||||2012-04-09|2012-04-10|Estimate|June 2010||2010-06-30|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|T+||Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management|Assessment of the Clinical Efficacy and Acceptability of the Think Positive (T+) Diabetes Management System in Insulin Requiring Diabetes|Completed||N/A|86|Actual|University College London Hospitals||2|||f||||f||||||||||2018-06-01 00:52:41.739091|2018-06-01 00:52:41.739091
NCT00922363|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2013-01-18|2009-06-16|2009-06-17|Estimate|||||||2013-01-18|2013-01-21|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers|An Open Phase I, Dose-escalating, Clinical Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers|Completed||Phase 1|38|Actual|Statens Serum Institut||4|||f||||t||||||||||2018-06-01 00:52:41.858128|2018-06-01 00:52:41.858128
NCT00922350|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Heliox and Posture in Patients With Asthma|Heliox and Posture Optimize Action of Nebulization With Bronchodilators for Asthma Attacks. Randomized Trial.|Completed||N/A|59|Actual|Universidade Federal de Pernambuco||4|||f||||t||||||||||2018-06-01 00:52:42.093384|2018-06-01 00:52:42.093384
NCT00922337|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2014-03-05|2009-06-16|2009-06-17|Estimate|||||||2014-03-05|2014-03-06|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||The Israeli MGuard Registry|A Prospective, Observational, Multicenter Registry To Evaluate the 'Real World' Clinical Performance of the MGuard Coronary Stent System|Completed|||86|Actual|InspireMD|||1||f||||t||||||||||2018-06-01 00:52:42.20793|2018-06-01 00:52:42.20793
NCT00922285|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2015-06-03|2009-06-16|2009-06-17|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2008||2008-06-30|June 2015|2015-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Art Therapy for Caregivers of Young Patients Undergoing Bone Marrow Transplant for Cancer|Art Therapy Interventions With Caregivers Supporting Pediatric Patients Who Are Undergoing Bone Marrow Transplantation for Cancer|Completed||N/A|11|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 00:52:42.535043|2018-06-01 00:52:42.535043
NCT00922272|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|2011-12-06||2015-03-03|2009-06-16|2009-06-17|Estimate|2012-01-17|2012-02-20|Estimate||||2015-03-03|2015-03-23|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms|A Phase 2, Multicenter Study With Open-label & Randomized Double-blind Placebo-controlled Withdrawal Phases to Evaluate the Efficacy, Safety, & Tolerability of SPD489 in Adults With Schizophrenia & Predominant Negative Symptoms Who Are Clinically Stable & Taking Stable Doses of Atypical Antipsychotic Medication|Completed||Phase 2|92|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:52:42.689479|2018-06-01 00:52:42.689479
NCT00922259|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-02-12|2009-06-16|2009-06-17|Estimate|||||||2013-02-12|2013-02-13|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7|Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H7N7 (6-2) AA ca Recombinant (A/Netherlands/219/03 (H7N7) x A/Ann Arbor/ 6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N7 Infection in the Event of a Pandemic|Completed||Phase 1|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-06-01 00:52:44.11332|2018-06-01 00:52:44.11332
NCT00922246|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||Insoles in Prevention of Lower Limb Injuries|Prevention of Lower Limb Overuse Injuries by Using Custom Made Insoles: A Randomized Controlled Trial of 230 Patients|Completed||N/A|||Finnish Defense Forces||2|||f||||f||||||||||2018-06-01 00:52:44.305798|2018-06-01 00:52:44.305798
NCT00922233|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2013-05-24||2013-08-22|2009-06-16|2009-06-17|Estimate|2013-08-22|2013-10-29|Estimate||||2013-08-22|2013-10-29|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pericoital Oral Contraception With Levonorgestrel|Pericoital Oral Contraception With Levonorgestrel: A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Acceptability|Completed||Phase 3|72|Actual|FHI 360||1|||f||||f||||||||||2018-06-01 00:52:44.428548|2018-06-01 00:52:44.428548
NCT00922220|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-12-21|2009-06-16|2009-06-17|Estimate|||||||2011-12-21|2011-12-22|Estimate|October 2004||2004-10-31|June 2009|2009-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of a Potential Mechanisms of Spinal Manipulation in the Treatment of Low Back Pain|Immediate Effect of Physical Interventions for Low Back Pain|Completed||Phase 1|94|Actual|University of Florida||3|||f||||f||||||||||2018-06-01 00:52:45.029992|2018-06-01 00:52:45.029992
NCT00922207|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2015-10-20||2017-03-10|2009-06-16|2009-06-17|Estimate|2015-10-20|2015-11-20|Estimate||||2017-03-10|2017-04-10|Actual|May 7, 2010|Actual|2010-05-07|March 2017|2017-03-31|September 29, 2014|Actual|2014-09-29|September 29, 2014|Actual|2014-09-29||Interventional||Intent-to-treat (ITT) analysis population included all randomized participants who received at least one dose of study medication.|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B|A Randomized, Open-label Study of the Effect of Peginterferon Alfa-2a (40KD)(PEGASYS) in Combination With Adefovir or Entecavir on HBeAg Seroconversion in Patients With HBeAg Positive Chronic Hepatitis B|Completed||Phase 4|280|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:52:45.30133|2018-06-01 00:52:45.30133
NCT00922194|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2009-02-17||2010-03-15|2009-06-16|2009-06-17|Estimate|2009-06-16|2009-06-17|Estimate||||2010-03-15|2010-03-23|Estimate|February 2006||2006-02-28|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Metformin in Overweight Type 2 Diabetes Mellitus|Metformin Monotherapy Significantly Improves Anthropometric and Glycemic Values in Overweight Type 2 Diabetes Mellitus: One Year or More Prospective Study.|Completed||N/A|102|Actual|Era's Lucknow Medical College|||||f||||t||||||||||2018-06-01 00:52:47.191845|2018-06-01 00:52:47.191845
NCT00922181|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-11-13|2009-06-16|2009-06-17|Estimate|||||||2009-11-13|2009-11-16|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|LiverMWA1||Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer|Single-probe Microwave Ablation of Metastatic Liver Cancer is Highly Variable and Irreproducible|Completed||N/A|19|Actual|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-06-01 00:52:47.48488|2018-06-01 00:52:47.48488
NCT00922168|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2014-02-05|2009-06-16|2009-06-17|Estimate|||||||2014-02-05|2014-02-06|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Pre-operative Polysomnography Assessment of Cardiac Surgery Inpatients|Pre-operative PSG Assessment of Cardiac Surgery Inpatients|Completed|||146|Actual|Cleveland Medical Devices Inc|||1||f||||f||||||||||2018-06-01 00:52:47.591332|2018-06-01 00:52:47.591332
NCT00922155|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-17|Estimate|||||||2009-06-15|2009-06-17|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Diagnosis of Lung Lesions by Endobronchial Ultrasound With an Alternative Guide Sheath|Clinical Effectiveness of a Balloon Covered Sheath as a Guide Sheath in Endobronchial Ultrasound Guided Diagnosis of Peripheral Lung Lesions|Completed||N/A|180|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:52:47.71827|2018-06-01 00:52:47.71827
NCT00922142|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2011-07-19|2009-06-16|2009-06-17|Estimate|||||||2011-07-19|2011-07-20|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Observational|||Cesarean Postoperative Pain Satisfaction|Cesarean Postoperative Pain Satisfaction With Intravenous Patient-Controlled Analgesia Intravenous, Oral, or Epidural Method|Completed|||120|Actual|Saint Elizabeth Regional Medical Center|||||f||||t||||||Samples Without DNA|"~     no biospecimens to be retained~   "|||2018-06-01 00:52:47.814514|2018-06-01 00:52:47.814514
NCT00922129|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2014-01-13|2009-06-16|2009-06-17|Estimate|||||||2014-01-13|2014-01-14|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer|A Prospective Randomized Pilot Study Examining the Role and Effectiveness of Conversion to Sirolimus Versus CNI Reduction in Renal Transplant Patients With Prostate Cancer|Withdrawn||Phase 2/Phase 3|0|Actual|St. Joseph's Healthcare Hamilton||2||Study did not start up as planned.|f||||f||||||||||2018-06-01 00:52:47.902023|2018-06-01 00:52:47.902023
NCT00922116|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2015-11-04||2017-06-15|2009-06-16|2009-06-17|Estimate|2015-11-04|2015-12-09|Estimate||||2017-06-15|2017-07-13|Actual|April 30, 2009|Actual|2009-04-30|May 2017|2017-05-31|November 30, 2010|Actual|2010-11-30|November 30, 2010|Actual|2010-11-30||Interventional||Safety population defined as all participants who participated in the trial.|A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera® for the Maintenance of Haemoglobin Levels in Patients With Chronic Renal Anaemia Who Are Not on Dialysis|Completed||Phase 4|191|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-06-01 00:52:48.058436|2018-06-01 00:52:48.058436
NCT00922103|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-09-10|2009-06-15|2009-06-17|Estimate|||||||2010-09-10|2010-09-13|Estimate|June 2005||2005-06-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Investigate the Ileo Neo Rectal Anastomosis Compared to the Ileo Pouch Anal Anastomosis for Patients With Ulcerative Colitis|A Historical Cohort Study, to Investigate Morbidity, Functional and Physiological Outcome, as Well as Endoscopic and Histological Aspects and the Quality of Life, of the Ileo Neo Rectal Anastomosis (INRA) Compared to the Ileo Pouch Anal Anastomosis (IPAA), for Patients With Ulcerative Colitis (UC)|Completed||N/A|100|Anticipated|Elisabeth-TweeSteden Ziekenhuis||2|||f||||f||||||||||2018-06-01 00:52:48.417506|2018-06-01 00:52:48.417506
NCT00922090|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-03-11|2009-06-16|2009-06-17|Estimate|||||||2010-03-11|2010-03-12|Estimate|July 2009||2009-07-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|CLIMAX||A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended|A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended-Release Tablets (SEROQUEL XRâ) in Subjects With Schizophrenia-An Observational, Multicentric Prospective Study|Completed|||1494|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:52:48.533094|2018-06-01 00:52:48.533094
NCT00922077|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Individualized Neurodevelopmental Treatment|Individualized Neurodevelopmental Treatment|Completed||Phase 3|1|Actual|Hellenic Society for Disabled Children|||||f||||t||||||||||2018-06-01 00:52:48.64774|2018-06-01 00:52:48.64774
NCT00922064|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2011-11-15|2009-06-16|2009-06-17|Estimate|||||||2011-11-15|2011-11-16|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effects of Electroconvulsive Therapy (ECT) on Serotonin-1A Receptor Binding|Effects of Electroconvulsive Therapy on Serotonin-1A Receptor Binding in Major Depression|Completed||Phase 4|12|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 00:52:48.699012|2018-06-01 00:52:48.699012
NCT00922051|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Acute Effects of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Forced Expiratory Flow Volume in One Second (FEV1) and Blood β-Endorphin Level in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Acute Effects of Acu-TENS on FEV1 and Blood β-Endorphin Level in Subjects With COPD|Completed||N/A|44|Actual|The Hong Kong Polytechnic University||2|||f||||||||||||||2018-06-01 00:52:48.782541|2018-06-01 00:52:48.782541
NCT00922038|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|February 2009||2009-02-28|June 2009|2009-06-30||||||||Interventional|RESPECT||Rewarding Sexually Transmitted Infection (STI) Prevention and Control in Tanzania|Encouraging Safe Sexual Practices Among Youth Using Cash Rewards: A Randomized Trial in the Kilombero/Ulanga Districts, Tanzania|Completed||N/A|2411|Actual|University of California, Berkeley||3|||f||||t||||||||||2018-06-01 00:52:48.856401|2018-06-01 00:52:48.856401
NCT00922025|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2011-09-26|2009-06-16|2009-06-17|Estimate|||||||2011-09-26|2011-09-27|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients|A Multi-centre, Naturalistic Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of EGFR TKI in Male Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer of Adeno Histology Failed 1st Line Chemotherapy|Completed|||186|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:52:49.046495|2018-06-01 00:52:49.046495
NCT00922012|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2011-05-10|2009-06-16|2009-06-17|Estimate|||||||2011-05-10|2011-05-12|Estimate|November 2007||2007-11-30|May 2011|2011-05-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome|Efficacy of Electromagnetic Stimulation Therapy for the Treatment of Chronic Prostatitis or Chronic Pelvic Pain Syndrome|Completed||N/A|50|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 00:52:49.113488|2018-06-01 00:52:49.113488
NCT00921999|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2018-02-13|2009-06-16|2009-06-17|Estimate|||||||2018-02-13|2018-02-14|Actual|June 15, 2009||2009-06-15|January 8, 2015|2015-01-08|January 8, 2015||2015-01-08|||||Observational|||Immune Response to Varicella-Zoster Vaccination and Infection|Immune Responses to Varicella-Zoster Virus Vaccination and Infection|Completed|||19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:49.186494|2018-06-01 00:52:49.186494
NCT00921986|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-07-21|2009-06-16|2009-06-17|Estimate|||||||2017-07-21|2017-07-25|Actual|March 2009|Actual|2009-03-31|July 2017|2017-07-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|||Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic|Cleveland Clinic Arrhythmia Biospecimen Repository (Cleveland Clinic Arrhythmia BioBank)|Recruiting|||2000|Anticipated|The Cleveland Clinic|||2||f||||t|f|f||||Samples With DNA|"~     Biospecimens to be collected: DNA, RNA, plasma, & serum. Also tissue may be collected.~   "|No||2018-06-01 00:52:49.247088|2018-06-01 00:52:49.247088
NCT00921973|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2014-09-22|2009-06-16|2009-06-17|Estimate|||||||2014-09-22|2014-09-23|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults|A Multicenter, Double-Blinded, Randomized, Placebo Controlled Study to Investigate the Safety and Immunogenicity of VAX102 When Given in the Same Arm With the Standard Influenza Vaccine in Healthy Adults|Completed||Phase 1|80|Actual|VaxInnate Corporation||2|||f||||f||||||||||2018-06-01 00:52:49.325842|2018-06-01 00:52:49.325842
NCT00921960|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2012-12-11|2009-06-16|2009-06-17|Estimate|||||||2012-12-11|2012-12-13|Estimate|January 2005||2005-01-31|December 2012|2012-12-31|July 2017|Anticipated|2017-07-31|December 2012|Anticipated|2012-12-31||Interventional|STOP-HF||St. Vincent's Screening To Prevent Heart Failure Study|St. Vincent's Screening To Prevent Heart Failure (STOP-HF) Study Using Natriuretic Peptides to Identify and Prevent Progression of Left Ventricular Dysfunction in Community Based, Asymptomatic, At-risk Individuals.|Unknown status|Recruiting|Phase 4|1500|Anticipated|St Vincent's University Hospital, Ireland||2|||f||||t||||||||||2018-06-01 00:52:49.399035|2018-06-01 00:52:49.399035
NCT00921947|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|2011-06-13||2011-08-22|2009-06-15|2009-06-17|Estimate|2011-07-25|2011-08-22|Estimate||||2011-08-22|2011-08-24|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults|A Phase II, Randomized, Open-Label Study to Evaluate the Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) in Healthy Adults|Completed||Phase 1/Phase 2|60|Actual|VaxInnate Corporation||2|||f||||f||||||||||2018-06-01 00:52:49.485873|2018-06-01 00:52:49.485873
NCT00921934|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|2012-08-01||2017-11-23|2009-06-16|2009-06-17|Estimate|2012-09-25|2012-10-26|Estimate||||2017-11-23|2017-12-21|Actual|April 2009||2009-04-30|November 2017|2017-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|168||Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles|PASCORBIN 7.5g in the Treatment of Viral Infection, Especially Varicella Zoster Infection: An Observational Cohort Study|Completed|||68|Actual|Pascoe Pharmazeutische Praeparate GmbH|||1||f||||f||||||||||2018-06-01 00:52:49.751864|2018-06-01 00:52:49.751864
NCT00921921|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2012-06-11|2009-06-16|2009-06-17|Estimate|||||||2012-06-11|2012-06-12|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?|Does Extra-fine HFA-BDP Suppress Small Airways Inflammation in COPD?|Completed||Phase 4|16|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 00:52:50.043153|2018-06-01 00:52:50.043153
NCT00921908|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-16|||2009-06-16|2009-06-16|2009-06-17|Estimate|||||||2009-06-16|2009-06-17|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Multihole or Epidural Catheter for Local Anesthetic in the Wound|Multihole or Epidural Catheter for Local Anesthetic in the Wound|Completed|||16|Actual|Hvidovre University Hospital|||2||f||||f||||||||||2018-06-01 00:52:50.108897|2018-06-01 00:52:50.108897
NCT00921895|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-14|2012-08-22||2015-10-26|2009-06-15|2009-06-16|Estimate|2012-08-22|2012-08-24|Estimate||||2015-10-26|2015-11-24|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis|A Comparison of the Sensitivity and Specificity of the RPS Adeno Detector IV™ at Detecting the Presence of Adenovirus to Viral Cell Culture.|Completed||N/A|128|Actual|Rapid Pathogen Screening||1|||f||||f||||||||||2018-06-01 00:52:50.168548|2018-06-01 00:52:50.168548
NCT00921882|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2018-05-02|2009-06-15|2009-06-16|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2008|Actual|2008-06-30|May 2018|2018-05-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Observational|DG4||Is it Possible to Screen for Type 2 Diabetes at Day 2 in Gestational Diabetes Mellitus Patients Postpartum?|Is it Possible to Screen for Type 2 Diabetes at Day 2 Gestational Diabetes Mellitus Postpartum?|Completed|||51|Actual|Université de Sherbrooke|||1||f||||f||||||||||2018-06-01 00:52:51.276508|2018-06-01 00:52:51.276508
NCT00921869|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-12-21|2009-06-15|2009-06-16|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2009|Actual|2009-10-31|December 2017|2017-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors|A Phase I Dose-finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors.|Completed||Phase 1|16|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 00:52:51.336538|2018-06-01 00:52:51.336538
NCT00921856|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2017-04-26|2009-06-12|2009-06-16|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2007||2007-11-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ACOVA||Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)|Abnormal Coronary Vasomotion in Patients With Suspected CAD But Normal Coronary Arteries|Recruiting||N/A|320|Anticipated|Robert Bosch Medical Center||2|||f||||f||||||||||2018-06-01 00:52:51.399736|2018-06-01 00:52:51.399736
NCT00921843|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2017-05-08|2009-06-15|2009-06-16|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2009|Actual|2009-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Methadone in Pediatric Anesthesia|Methadone in Pediatric Anesthesia|Completed||N/A|31|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 00:52:51.470029|2018-06-01 00:52:51.470029
NCT00921830|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-10-04|2009-06-15|2009-06-16|Estimate|||||||2011-10-04|2011-10-06|Estimate|April 2004||2004-04-30|October 2011|2011-10-31|November 2004|Actual|2004-11-30|July 2004|Actual|2004-07-31||Interventional|||Pharmacokinetics of 3 Formulations of Ibuprofen Suppositories|A Single-dose, Randomised, Crossover Study to Compare the Rate and Extent of Absorption of Three Formulations of Ibuprofen in Healthy, Fasting Male and Female Volunteers|Completed||Phase 1|25|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:52:51.530582|2018-06-01 00:52:51.530582
NCT00921817|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2010-02-10|2009-06-15|2009-06-16|Estimate|||||||2010-02-10|2010-02-12|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Body Composition in Infants and Children|Validation of a Body Composition Method for Infants and Children|Completed|||120|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||t||||||Samples Without DNA|"~     two urine samples are collected during the study visit~   "|||2018-06-01 00:52:51.602395|2018-06-01 00:52:51.602395
NCT00921804|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-06-29|2009-06-15|2009-06-16|Estimate|||||||2010-06-29|2010-06-30|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients|A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Active-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD8529 in Adult Schizophrenia Patients|Completed||Phase 2|296|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 00:52:51.656594|2018-06-01 00:52:51.656594
NCT00921791|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|April 2006||2006-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|MONITOR||Efficacy of Home Blood Pressure Monitoring (MONITOR Study)|Efficacy of Home Blood Pressure Monitoring to Improve Blood Pressure Control: a Randomized Controlled Trial With Ambulatory Blood Pressure Measurement|Completed||N/A|136|Actual|Hospital de Clinicas de Porto Alegre||4|||f||||f||||||||||2018-06-01 00:52:51.826958|2018-06-01 00:52:51.826958
NCT00921778|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|LSH-LAPCONE||Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern|Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern|Unknown status|Recruiting|N/A|140|Anticipated|Ullevaal University Hospital|||||f||||f||||||||||2018-06-01 00:52:51.930552|2018-06-01 00:52:51.930552
NCT00921765|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2018-04-03|2009-06-15|2009-06-16|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2009||2009-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Reversal of Ketamine Pharmacodynamic Effects With Naloxone|Naloxone Block of Low-dose (Analgetic Dose) Ketamine|Terminated||Phase 4|3|Actual|Oslo University Hospital||4||Problems with patient recruitment|f||||f||||||||No||2018-06-01 00:52:52.016605|2018-06-01 00:52:52.016605
NCT00921752|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-12-03|2009-06-15|2009-06-16|Estimate|||||||2009-12-03|2009-12-04|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|||||Observational|C2 -CORVUS||C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)|C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)|Completed|||1500|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:52:52.138463|2018-06-01 00:52:52.138463
NCT00921739|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2018-03-15|2009-06-15|2009-06-16|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2009||2009-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|ESIMRT||Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies|Phase I Dose Escalation Study of Accelerated Fractionation With Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esophageal Injury|Active, not recruiting||Phase 1|25|Anticipated|Duke University||1|||f||||f||||||||||2018-06-01 00:52:52.266415|2018-06-01 00:52:52.266415
NCT00921726|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-03-18|2009-06-12|2009-06-16|Estimate|||||||2010-03-18|2010-03-19|Estimate|July 2009||2009-07-31|May 2009|2009-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults|Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects|Completed||Phase 1|17|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 00:52:52.352812|2018-06-01 00:52:52.352812
NCT00921713|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2017-10-11|2009-06-15|2009-06-16|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2008||2008-09-30|October 2017|2017-10-31|August 2013|Actual|2013-08-31|July 2011|Actual|2011-07-31||Interventional|||Testing an Optimal Model of Patient-Centered Cancer Care|Testing an Optimal Model of Patient-Centered Cancer Care|Completed||N/A|300|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 00:52:52.440302|2018-06-01 00:52:52.440302
NCT00921700|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2016-03-29|2009-06-15|2009-06-16|Estimate|||||||2016-03-29|2016-03-30|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||Analgesic Effect of Paracetamol, Paracetamol + Codeine, Ibuprofen and Their Combination|Analgesic Effect of Ibuprofen 400 mg/Paracetamol 1000 mg, Ibuprofen 400 mg/ Paracetamol 1000 mg/60 mg Codeine, and Paracetamol 1000 mg/Codeine 60 mg: A Single-dose, Randomized, Placebo-controlled and Double-blind Study|Completed||Phase 4|200|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-06-01 00:52:52.499554|2018-06-01 00:52:52.499554
NCT00921687|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|2012-07-30||2013-05-22|2009-06-15|2009-06-16|Estimate|2013-04-16|2013-05-23|Estimate||||2013-05-22|2013-05-27|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study|Chronic Kidney Disease Guideline Adherence - a Cluster Randomized Controlled Quality Improvement Study|Completed||N/A|781|Actual|Louis Stokes VA Medical Center||2|||f||||f||||||||||2018-06-01 00:52:52.593128|2018-06-01 00:52:52.593128
NCT00921674|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-10-04|2009-06-15|2009-06-16|Estimate|||||||2011-10-04|2011-10-06|Estimate|February 2005||2005-02-28|October 2011|2011-10-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Ivermectin Solution Bioequivalence Study - With Food|A Single-dose, Randomised, Crossover Study to Compare the Rate and Extent of Absorption of Two Formulations of Ivermectin in Healthy Male and Female Volunteers After Food|Completed||Phase 1|24|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:52:52.846301|2018-06-01 00:52:52.846301
NCT00921661|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2012-11-08|2009-06-15|2009-06-16|Estimate|||||||2012-11-08|2012-11-09|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer|A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer|Completed||Phase 1|16|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 00:52:52.913033|2018-06-01 00:52:52.913033
NCT00921648|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Clinical Findings in General Paresis|Xijing HOSPITAL, Fourth Military Medical University, China|Completed|||6|Actual|Xijing Hospital|||5||f||||t||||||||||2018-06-01 00:52:53.091203|2018-06-01 00:52:53.091203
NCT00921635|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-18|2009-06-15|2009-06-16|Estimate|||||||2009-06-18|2009-06-19|Estimate|April 2008||2008-04-30|June 2009|2009-06-30||||May 2011|Anticipated|2011-05-31||Interventional|HOSTT||A Study to Evaluate the Impact of Maintaining Hemoglobin Levels in Anemic Patients With Carcinoma of the Cervix|A Phase III Study to Evaluate the Impact of Maintaining Haemoglobin Levels Above 120g/L Verses Above 100g/L in Anaemic Patients With Carcinoma of the Cervix Receiving Concurrent Cisplatin and Radiation Therapy|Suspended||Phase 3|2|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-06-01 00:52:53.167028|2018-06-01 00:52:53.167028
NCT00921622|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-08-15|2009-06-15|2009-06-16|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2009||2009-06-30|August 2017|2017-08-31|June 2011|Actual|2011-06-30|October 2009|Actual|2009-10-31||Interventional|||Vitamin Deficiency and Blood Pressure in Hospitalized Jewish General Hospital (JGH) Patients|Vitamin Deficiency and Blood Pressure in Hospitalized JGH Patients|Completed||Phase 2|50|Actual|Jewish General Hospital||2|||f||||f|f|f||||||No||2018-06-01 00:52:53.244006|2018-06-01 00:52:53.244006
NCT00921609|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2018-01-24|2009-06-15|2009-06-16|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2006||2006-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Study Examining the Peri- and Post-operative Dynamics of the Growth Hormone (GH) - IGF-1 Axis in Subjects With Acromegaly During the First Year After Surgical Resection|A Study Examining the Peri- and Post-operative Dynamics of the GH-IGF-1 Axis in Subjects With Acromegaly During the First Year After Surgical Resection|Recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||1||f||||||||||||||2018-06-01 00:52:53.325562|2018-06-01 00:52:53.325562
NCT00921596|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-06-14|2009-06-14|2009-06-16|Estimate|||||||2009-06-14|2009-06-16|Estimate|January 2000||2000-01-31|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|CPB||Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass (CPB)|Cardiac Operation Under Totally Endoscope and Cardiopulmonary Bypass, a Single Center's Experience|Unknown status|Recruiting|Phase 1/Phase 2|800|Anticipated|Xijing Hospital||1|||f||||t||||||||||2018-06-01 00:52:53.403748|2018-06-01 00:52:53.403748
NCT00921583|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-04-12|2009-06-15|2009-06-16|Estimate|||||||2012-04-12|2012-04-13|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Long-term Examination of Titanium Dental Implants With a TPS Surface: A Prospective 20-year Case Series Study|Long-term Examination of Titanium Dental Implants With a TPS Surface: A Prospective 20-year Case Series Study|Completed|||67|Actual|University of Bern|||1||f||||f||||||||||2018-06-01 00:52:53.493023|2018-06-01 00:52:53.493023
NCT00921570|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-16|2009-06-15|2009-06-16|Estimate|||||||2009-06-16|2009-06-17|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension|The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension|Completed||Phase 4|105|Actual|Gulhane School of Medicine||3|||f||||||||||||||2018-06-01 00:52:53.569937|2018-06-01 00:52:53.569937
NCT00921557|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2016-12-15||2017-06-21|2009-06-12|2009-06-16|Estimate|2017-02-08|2017-03-28|Actual||||2017-06-21|2017-07-21|Actual|November 2009|Actual|2009-11-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional||Includes participants who took at least one dose of study treatment (alendronate/placebo)|Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents|Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density|Completed||Phase 2|52|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||No||2018-06-01 00:52:53.748378|2018-06-01 00:52:53.748378
NCT00921544|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|August 2008||2008-08-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Sucrose Analgesia for the Reduction of Pain During Retinopathy of Prematurity Screening|Sucrose and Non Nutritive Suck as Analgesia for Babies Undergoing Retinopathy of Prematurity Screening; a Randomised Placebo Controlled Trial|Completed||Phase 4|40|Actual|Coombe Women and Infants University Hospital||2|||f||||f||||||||||2018-06-01 00:52:55.637399|2018-06-01 00:52:55.637399
NCT00921531|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-04-18|2009-06-15|2009-06-16|Estimate|||||||2011-04-18|2011-04-19|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma|Phase Ⅲ Study of Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 3|200|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 00:52:55.743608|2018-06-01 00:52:55.743608
NCT00921518|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|2014-01-28||2014-03-19|2009-06-15|2009-06-16|Estimate|2014-01-28|2014-03-11|Estimate||||2014-03-19|2014-04-15|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Prevention of Acute Kidney Injury in Cardiac Surgery Patients|Prevention of Acute Kidney Injury in Cardiac Surgery Patients|Completed||Phase 2|92|Actual|Community Medical Center, Scranton, PA||2|||f||||t||||||||||2018-06-01 00:52:55.840712|2018-06-01 00:52:55.840712
NCT00921505|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-07-03|2009-06-15|2009-06-16|Estimate|||||||2011-07-03|2011-07-06|Estimate|May 2009||2009-05-31|March 2009|2009-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Ibuprofen, Paracetamol and Their Combination on Radical Oxygen Species (ROS) Production|The Effect of Ibuprofen, Paracetamol and Their Combination on Reactive Oxygen Species (ROS)- Production in Leukocytes and Platelet Activation|Completed||Phase 4|7|Anticipated|Oslo University Hospital||4|||f||||f||||||||||2018-06-01 00:52:56.032523|2018-06-01 00:52:56.032523
NCT00921492|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2011-10-06|2009-06-15|2009-06-16|Estimate|||||||2011-10-06|2011-10-07|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|PCOSLFEA||Acupuncture and Gonadotropin-releasing Hormone Pulse Generator and Stress Axis in Polycystic Ovary Syndrome|Does Low-frequency Electro-acupuncture Restore Sensitivity of the Gonadotropin-releasing Hormone Pulse Generator and Stress Axis in Polycystic Ovary Syndrome|Completed||N/A|28|Anticipated|Göteborg University||2|||f||||f||||||||||2018-06-01 00:52:56.129032|2018-06-01 00:52:56.129032
NCT00921479|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2017-09-18|2009-06-15|2009-06-16|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2005||2005-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Postoperative Course Following Wisdom Tooth Surgery|Postoperative Course and Quality of Life Following Surgical Removal of the Mandibular 3. Molar|Recruiting|||300|Anticipated|Oslo University Hospital|||2||f||||f||||||||No||2018-06-01 00:52:56.205382|2018-06-01 00:52:56.205382
NCT00921466|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Observational|e-SSRS-IVR||Pilot Study to Assess Feasibility, Reliability and Validity of the e-SSRS-IVR|Pilot Study to Assess Feasibility, Reliability and Validity of the e-SSRS-IVR|Unknown status|Enrolling by invitation||20|Actual|Rogers Center for Research & Training, Inc.|||2||f||||f||||||||||2018-06-01 00:52:56.287107|2018-06-01 00:52:56.287107
NCT00921453|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Tailored Internet Information Supply for Patients - Part 2|Quality of Self-Diagnosis by Headache Patients Getting Tailored Internet Information - Part 2|Completed|||140|Actual|Health & Life Sciences University, Tryol|||4||f||||t||||||||||2018-06-01 00:52:56.358284|2018-06-01 00:52:56.358284
NCT00921440|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|August 2007||2007-08-31|June 2009|2009-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Computed Tomography Coronary Angiography (CTCA) and Coronary Flow in Stenosis Analysis|CT Coronary Angiography: Coronary Flow Quantification Supplements Morphological Stenosis Analysis|Completed|||50|Actual|University of Cologne|||||f||||t||||||||||2018-06-01 00:52:56.429739|2018-06-01 00:52:56.429739
NCT00921427|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-14|||2012-03-20|2009-06-15|2009-06-16|Estimate|||||||2012-03-20|2012-03-21|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|December 2010|Actual|2010-12-31||Interventional|||The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy||Completed||Early Phase 1|20|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 00:52:56.479244|2018-06-01 00:52:56.479244
NCT00921414|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2018-04-26|2009-06-15|2009-06-16|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2008||2008-09-30|April 2018|2018-04-30|February 2017|Actual|2017-02-28|September 2008|Actual|2008-09-30||Interventional|||Mantel Cell Lymphoma Efficacy of Rituximab Maintenance|"Manteau 2007 SJ LYMA Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL"|Completed||Phase 3|299|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||No||2018-06-01 00:52:56.545228|2018-06-01 00:52:56.545228
NCT00921401|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2013-05-06|2009-06-15|2009-06-16|Estimate|||||||2013-05-06|2013-05-07|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|December 2011|Actual|2011-12-31||Interventional|||Improving the Quality of Asthma Care Using the Internet|Improving the Quality of Asthma Care Using the Internet|Completed||Phase 2/Phase 3|408|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 00:52:56.617862|2018-06-01 00:52:56.617862
NCT00921388|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-10-27|2009-06-15|2009-06-16|Estimate|||||||2017-10-27|2017-10-31|Actual|March 2009||2009-03-31|October 2017|2017-10-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|||Exercise or Relaxation for Smoking Cessation|Exercise for Smoking Cessation in Postmenopausal Women|Completed||N/A|301|Actual|UConn Health||2|||f||||t||||||||No||2018-06-01 00:52:56.685786|2018-06-01 00:52:56.685786
NCT00921375|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-23|||2014-12-11|2009-06-14|2009-06-16|Estimate|||||||2014-12-11|2014-12-12|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia|Efficacy and Safety of TULY in Prevention and Treatment of Malignancy-associated Hyperuricemia|Completed||Phase 3|100|Actual|Virchow Group||1|||f||||f||||||||||2018-06-01 00:52:56.759047|2018-06-01 00:52:56.759047
NCT00921362|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|January 2007|Actual|2007-01-31|||||Observational|||Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme|Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme|Completed|||1387|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:52:56.882655|2018-06-01 00:52:56.882655
NCT00921349|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|December 2004||2004-12-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis|A Randomized, Controlled Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis|Completed||Phase 4|140|Actual|National Science Council, Taiwan||2|||f||||t||||||||||2018-06-01 00:52:56.939779|2018-06-01 00:52:56.939779
NCT00921336|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2010-09-09|2009-06-15|2009-06-16|Estimate|||||||2010-09-09|2010-09-10|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor|Open-Label, Sequential, Ascending, Multi-Dose, Phase 1 Study of KW-2450 as Monotherapy in Subjects With Previously Treated Advanced Solid Tumor|Completed||Phase 1|72|Anticipated|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-06-01 00:52:57.003281|2018-06-01 00:52:57.003281
NCT00921323|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2012-11-29|2009-06-15|2009-06-16|Estimate|||||||2012-11-29|2012-12-03|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Use of Pedometers as an Adjunctive Tool in a School-based Pediatric Weight Management Program|The Use of Pedometers as an Adjunctive Tool in a School-based Pediatric Weight Management Program|Completed||N/A|50|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 00:52:57.075288|2018-06-01 00:52:57.075288
NCT00921310|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|2016-08-10||2016-10-19|2009-06-15|2009-06-16|Estimate|2016-10-19|2016-12-13|Estimate||||2016-10-19|2016-12-13|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|January 2013|Actual|2013-01-31||Interventional|||Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer|A Phase I/II Trial of Temsirolimus and Pemetrexed in Recurrent/Refractory Non Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1/Phase 2|12|Actual|Washington University School of Medicine||3||Withdrawal of funding from sponsor|f||||f||||||||||2018-06-01 00:52:57.220565|2018-06-01 00:52:57.220565
NCT00921297|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2017-11-07|2009-06-15|2009-06-16|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2009||2009-06-30|November 2017|2017-11-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Cataract Removal and Alzheimer's Disease|Therapeutic Effects of Cataract Removal in Alzheimer's Disease|Completed||N/A|122|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 00:52:57.642249|2018-06-01 00:52:57.642249
NCT00921284|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-13|||2016-09-22|2009-06-13|2009-06-16|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Influence of Dexmedetomidine on a Closed-Loop Anesthesia System|Closed-Loop Delivery of Propofol and Remifentanil: Sparing Effect of Dexmedetomidine|Completed||Phase 3|66|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 00:52:57.723586|2018-06-01 00:52:57.723586
NCT00921271|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-09-20|2009-06-15|2009-06-16|Estimate|||||||2011-09-20|2011-09-21|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||The Application of Near Infrared Spectroscopy (NIRS) in the Detection of Lower Limb Compartment Syndrome|The Application of Near Infrared Spectroscopy (NIRS) in the Detection of Lower Limb Compartment Syndrome|Completed|||120|Anticipated|University Hospital Birmingham NHS Foundation Trust|||1||f||||f||||||||||2018-06-01 00:52:57.80055|2018-06-01 00:52:57.80055
NCT00921258|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2015-06-03|2009-06-15|2009-06-16|Estimate|||||||2015-06-03|2015-06-04|Estimate|December 2007||2007-12-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|SURACAP||Active Control of Prostatic Cancer With Criteria of Latence|Active Control of Prostatic Cancer With Criteria of Latence. Impact on Specific 10 Years Survival.|Terminated|||100|Actual|Clinique Mutualiste Chirurgicale de la Loire|||1|Financial problem (not enough budget to continue the study)|f||||f||||||||||2018-06-01 00:52:57.882667|2018-06-01 00:52:57.882667
NCT00921245|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2015-04-17|2009-06-15|2009-06-16|Estimate|||||||2015-04-17|2015-04-20|Estimate|June 2007||2007-06-30|April 2015|2015-04-30|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Observational|FREEDOM||FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period|First REal-life Evaluation of Darifenacin in Overactive Bladder Patients During 3 Months|Completed|||9|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:52:57.985698|2018-06-01 00:52:57.985698
NCT00921232|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2012-07-20|2009-06-15|2009-06-16|Estimate|||||||2012-07-20|2012-07-23|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|RAPSODIE||Assessment of the Burden Within the Dyad Patient/Caregiver|Crossed Assessment of the Burden Within the Dyad Patient/Caregiver: Analysis of Explanatory Factors and Consequences for Return at Home of the Life-ending Patient|Completed||N/A|139|Actual|Centre Oscar Lambret||1|||f||||f||||||||||2018-06-01 00:52:58.074492|2018-06-01 00:52:58.074492
NCT00921219|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-10-04|2009-06-15|2009-06-16|Estimate|||||||2011-10-04|2011-10-06|Estimate|September 2005||2005-09-30|October 2011|2011-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Ivermectin Solution Bioequivalence Study - With Food (Repeat)|Ivermectin Solution Bioequivalence Study - With Food (Repeat)|Completed||Phase 1|34|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:52:58.149846|2018-06-01 00:52:58.149846
NCT00921206|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2014-09-22|2009-06-15|2009-06-16|Estimate|||||||2014-09-22|2014-09-23|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults|Open-label Study to Investigate the Humoral and Cellular Immune Response to Two Doses of VAX102 Influenza Vaccine in Healthy Adults|Completed||Phase 1|21|Actual|VaxInnate Corporation||2|||f||||f||||||||||2018-06-01 00:52:58.23768|2018-06-01 00:52:58.23768
NCT00921193|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-03-29|2009-06-15|2009-06-16|Estimate|||||||2011-03-29|2011-03-30|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer|Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer|Completed||N/A|20|Actual|Navotek Medical, Ltd.|||||f||||f||||||||||2018-06-01 00:52:58.315603|2018-06-01 00:52:58.315603
NCT00921180|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2012-12-19|2009-06-15|2009-06-16|Estimate|||||||2012-12-19|2012-12-20|Estimate|February 2007||2007-02-28|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B|Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B|Unknown status|Recruiting|Phase 4|148|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 00:52:58.388876|2018-06-01 00:52:58.388876
NCT00921167|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-13|||2013-12-03|2009-06-13|2009-06-16|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas|A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme|Completed||Phase 2|32|Anticipated|Clinical Research Center for Solid Tumor, Korea||1|||f||||f||||||||||2018-06-01 00:52:58.506369|2018-06-01 00:52:58.506369
NCT00921154|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-10-04|2009-06-15|2009-06-16|Estimate|||||||2011-10-04|2011-10-06|Estimate|March 2005||2005-03-31|October 2011|2011-10-31|September 2005|Actual|2005-09-30|May 2005|Actual|2005-05-31||Interventional|||Ivermectin Solution Bioequivalence Study - Fasted|A Single-dose, Randomised, Crossover Study to Compare the Rate and Extent of Absorption of Two Formulations of Ivermectin in Healthy, Fasting Male and Female Volunteers|Completed||Phase 1|24|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 00:52:58.575764|2018-06-01 00:52:58.575764
NCT00921141|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2012-07-20|2009-06-15|2009-06-16|Estimate|||||||2012-07-20|2012-07-23|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|April 2007|Actual|2007-04-30||Observational|CCI||Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports|Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports : Cohort and Prospective Study|Completed|||815|Actual|Centre Oscar Lambret|||1||f||||f||||||||||2018-06-01 00:52:58.669926|2018-06-01 00:52:58.669926
NCT00921128|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-13|||2017-10-05|2009-06-13|2009-06-16|Estimate|||||||2017-10-05|2017-10-06|Actual|June 2, 2009||2009-06-02|September 1, 2016|2016-09-01|September 1, 2016|Actual|2016-09-01|||||Interventional|||Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease|Convection Enhanced Delivery of Muscimol to Study the Pathophysiology Underlying the Clinical Features of Parkinson's Disease|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:52:58.727896|2018-06-01 00:52:58.727896
NCT00921115|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2017-04-12||2017-04-12|2009-06-15|2009-06-16|Estimate|2017-04-12|2017-05-18|Actual||||2017-04-12|2017-05-18|Actual|May 2009||2009-05-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|April 2015|Actual|2015-04-30||Interventional|||Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.|Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer|Active, not recruiting||Phase 2|42|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 00:52:58.798163|2018-06-01 00:52:58.798163
NCT00921102|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-15|2009-06-15|2009-06-16|Estimate|||||||2009-06-15|2009-06-16|Estimate|May 2007||2007-05-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia for Caesarean Section|Intrathecal Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia With Morphine for Elective Caesarean Section: a Randomized Controlled Trial|Completed||Phase 4|216|Actual|University of Parma||3|||f||||f||||||||||2018-06-01 00:52:58.984729|2018-06-01 00:52:58.984729
NCT00921089|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-06-16|2009-06-15|2009-06-16|Estimate|||||||2009-06-16|2009-06-17|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Observational|||Vascular Calcification, Inflammation and Coronary Flow Velocity in Hemodialysis Patients|The Association Among Vascular Calcification, Inflammation and Coronary Flow Velocity in Hemodialysis Patients|Completed|||103|Actual|Istanbul University|||2||f||||f||||||||||2018-06-01 00:52:59.14135|2018-06-01 00:52:59.14135
NCT00921076|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2012-12-12|2009-06-15|2009-06-16|Estimate|||||||2012-12-12|2012-12-13|Estimate|June 2002||2002-06-30|July 2009|2009-07-31||||January 2014|Anticipated|2014-01-31||Interventional|||Gait Analysis of Ankle Arthroplasty and Arthrodesis|Gait Analysis of Patients Undergoing Total Ankle Arthroplasty, Ankle Arthrodesis, Tibiotalocalcaneal or Pantalar Fusion.|Unknown status|Recruiting|Phase 4|200|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 00:52:59.209941|2018-06-01 00:52:59.209941
NCT00921063|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2010-02-17|2009-06-15|2009-06-16|Estimate|||||||2010-02-17|2010-02-19|Estimate|November 2005||2005-11-30|February 2010|2010-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 5-Week Trial To Assess The Efficacy And Safety Of PD 0332334 Compared To Placebo And Alprazolam Extended-Release In Patients With Generalized Anxiety Disorder|Completed||Phase 2|222|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:52:59.271449|2018-06-01 00:52:59.271449
NCT00921050|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2012-06-27|2009-06-15|2009-06-16|Estimate|||||||2012-06-27|2012-06-28|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Subclinical Hypothyroidism and Mind in the Elderly|Randomized Double Blind Levothyroxine vs Placebo, Mind (NEUROPSI) Improvement in Elderly With Persistent TSH 4-10 mUI/L|Completed||Phase 2/Phase 3|70|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||||2018-06-01 00:52:59.336285|2018-06-01 00:52:59.336285
NCT00921037|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2011-07-11|2009-06-15|2009-06-16|Estimate|||||||2011-07-11|2011-07-13|Estimate|April 2006||2006-04-30|June 2009|2009-06-30|November 2012|Anticipated|2012-11-30|January 2012|Anticipated|2012-01-31||Interventional|||First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas|First Clinical Study of Erbium-YAG Laser Vaporisation of Cutaneous Neurofibromas|Unknown status|Recruiting|Phase 2/Phase 3|12|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-06-01 00:52:59.477331|2018-06-01 00:52:59.477331
NCT00921024|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2015-01-09||2018-03-28|2009-06-12|2009-06-16|Estimate|2015-01-09|2015-01-15|Estimate||||2018-03-28|2018-04-26|Actual|June 30, 2009|Actual|2009-06-30|March 2018|2018-03-31|March 11, 2010|Actual|2010-03-11|February 25, 2010|Actual|2010-02-25||Interventional|||Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections|A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis|Completed||Phase 2|129|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||||2018-06-01 00:52:59.650249|2018-06-01 00:52:59.650249
NCT00921011|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2018-04-03|2009-06-15|2009-06-16|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2009||2009-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Observational|||Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis|Iron and Atherosclerosis: Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis|Completed|||177|Actual|Ohio State University|||1||f||||t||||||Samples Without DNA|"~     Serum, plasma~   "|||2018-06-01 00:52:59.944653|2018-06-01 00:52:59.944653
NCT00920998|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2009-07-16|2009-06-15|2009-06-16|Estimate|||||||2009-07-16|2009-07-20|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Food Intake on Pharmacokinetic Profiles of Z-338|A Pharmacokinetics Study to Evaluate the Effect of Food Intake on PK Profile of Z-338 in Healthy Volunteers|Completed||Phase 1|30|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 00:53:00.001731|2018-06-01 00:53:00.001731
NCT00920985|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15||2015-09-23|2015-09-23|2009-06-15|2009-06-16|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||US Cycle Control and Blood Pressure Study|Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women|Completed||Phase 3|346|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:53:00.08196|2018-06-01 00:53:00.08196
NCT00920972|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-15|||2018-05-04|2009-06-15|2009-06-16|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2001||2001-12-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases|A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime|Recruiting||Phase 1/Phase 2|220|Anticipated|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 00:53:00.19681|2018-06-01 00:53:00.19681
NCT00920959|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2016-09-13|2009-06-12|2009-06-15|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2001||2001-11-30|September 2016|2016-09-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Advair Pediatric Once-Daily|A Stratified, Randomized, Double-blind, Placebo-controlled, Parallel-group, 12 Week Trial Evaluating the Safety and Efficacy of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg Once Daily Versus Fluticasone Propionate DISKUS 100mcg Once Daily and Placebo in Symptomatic Pediatric Subjects (4-11 Years) With Asthma|Completed||Phase 3|908|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:00.379117|2018-06-01 00:53:00.379117
NCT00920946|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12||2016-10-11|2016-10-11|2009-06-12|2009-06-15|Estimate||||2016-10-11|2016-10-12|Estimate|2016-10-11|2016-10-12|Estimate|July 2009||2009-07-31|October 2016|2016-10-31||||July 2011|Actual|2011-07-31||Interventional|HORIZON||A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington Disease|Completed||Phase 3|403|Actual|Medivation, Inc.||2|||f||||t||||||||||2018-06-01 00:53:00.664807|2018-06-01 00:53:00.664807
NCT00920933|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-04-08|2009-06-12|2009-06-15|Estimate|||||||2010-04-08|2010-04-09|Estimate|January 2009||2009-01-31|April 2010|2010-04-30||||November 2009|Actual|2009-11-30||Interventional|||Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy Subjects|Double Blind, Placebo Controlled, Parallel Group Study With an Open Label Reference Arm to Assess the Effects of Intravenously Administered AIN457 on Ozone Induced Neutrophilia Compared to Placebo & Oral Corticosteroid in Healthy Volunteers|Completed||Phase 1/Phase 2|24|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:53:00.782119|2018-06-01 00:53:00.782119
NCT00920920|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-06-15|2009-06-12|2009-06-15|Estimate|||||||2009-06-15|2009-06-16|Estimate|July 2008||2008-07-31|June 2009|2009-06-30||||December 2013|Anticipated|2013-12-31||Observational|EMBRACE||An International Study on Magnetic Resonance Imaging (MRI)-Guided Brachytherapy in Locally Advanced Cervical Cancer|A International Study on MRI-Guided Brachytherapy in Locally Advanced Cervical Cancer|Unknown status|Recruiting||600|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-06-01 00:53:00.849555|2018-06-01 00:53:00.849555
NCT00920907|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2013-11-25||2014-05-20|2009-06-12|2009-06-15|Estimate|2014-01-21|2014-03-06|Estimate||||2014-05-20|2014-06-20|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|April 2010|Actual|2010-04-30||Interventional|||Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma|A Randomized, Parallel, Open-Label Study to Compare the Pharmacokinetics of Ipilimumab (BMS-734016) Process C to Process B in Subjects With Advanced Melanoma|Completed||Phase 1|99|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 00:53:01.020622|2018-06-01 00:53:01.020622
NCT00920894|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-11-04|2009-06-12|2009-06-15|Estimate|||||||2009-11-04|2009-11-05|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Plant Stanol Esters on Blood Lipids|The Effect of Plant Stanol Esters on Serum Total and Lipoproteins Lipids, Non-cholesterol Sterols and Apolipoproteins in Subjects With Elevated Blood Lipid Concentration|Completed||N/A|112|Anticipated|Clinical Life Sciences Ltd.||2|||f||||||||||||||2018-06-01 00:53:02.43419|2018-06-01 00:53:02.43419
NCT00920881|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2009-06-11|2009-06-11|2009-06-15|Estimate|||||||2009-06-11|2009-06-15|Estimate|November 2005||2005-11-30|June 2009|2009-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Clinical Evaluation of the Accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System|Protocol #TS05-066 Clinical Evaluation of the Accuracy of the FreeStyle Navigator Continuous Glucose Monitoring System|Completed|||58|Actual|Abbott Diabetes Care|||1||f||||f||||||||||2018-06-01 00:53:02.558597|2018-06-01 00:53:02.558597
NCT00920868|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2016-02-02|2009-06-11|2009-06-15|Estimate|||||||2016-02-02|2016-02-03|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|May 2010|Actual|2010-05-31||Interventional|XAD||XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib|A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.|Completed||Phase 1|22|Actual|Duke University||1|||f||||t||||||||||2018-06-01 00:53:02.649098|2018-06-01 00:53:02.649098
NCT00920855|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2012-08-15||2012-09-20|2009-06-12|2009-06-15|Estimate|2012-08-15|2012-09-17|Estimate||||2012-09-20|2012-10-04|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma|An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|40|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 00:53:02.824697|2018-06-01 00:53:02.824697
NCT00920842|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2012-11-29|2009-06-12|2009-06-15|Estimate|||||||2012-11-29|2012-12-03|Estimate|April 2005||2005-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|July 2011|Actual|2011-07-31||Observational|||Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant|Metabolic Syndrome Following Transplant for Leukemia|Completed|||244|Actual|Fred Hutchinson Cancer Research Center|||||f||||t||||||||||2018-06-01 00:53:03.672385|2018-06-01 00:53:03.672385
NCT00920829|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2016-05-03|2009-06-11|2009-06-15|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism|Genetic and Brain Mechanisms of Naltrexone?s Treatment Efficacy for Alcoholism|Completed||Phase 4|152|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 00:53:03.732608|2018-06-01 00:53:03.732608
NCT00920816|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2013-07-26||2018-02-12|2009-06-11|2009-06-15|Estimate|2013-12-31|2014-02-04|Estimate||||2018-02-12|2018-03-09|Actual|August 25, 2009|Actual|2009-08-25|February 2018|2018-02-28|May 30, 2021|Anticipated|2021-05-30|July 27, 2012|Actual|2012-07-27||Interventional|||Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer|Ag-013736 (Axitinib) For The Treatment Of Metastatic Renal Cell Cancer|Active, not recruiting||Phase 3|492|Actual|Pfizer|The objective of the statistical analysis for secondary endpoints was to summarize data using descriptive statistics without performing any hypothesis testing.|2|||f||||t||||||||||2018-06-01 00:53:03.928718|2018-06-01 00:53:03.928718
NCT00920803|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2017-06-13|2009-06-12|2009-06-15|Estimate|||||||2017-06-13|2017-06-14|Actual|August 19, 2008|Actual|2008-08-19|June 2017|2017-06-30|November 11, 2009|Actual|2009-11-11|November 11, 2009|Actual|2009-11-11||Interventional|||A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases|A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases|Completed||Phase 1|9|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:07.332506|2018-06-01 00:53:07.332506
NCT00920790|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2012-07-09||2017-02-28|2009-06-12|2009-06-15|Estimate|2012-08-24|2012-09-25|Estimate||||2017-02-28|2017-03-29|Actual|June 2009||2009-06-30|February 2017|2017-02-28|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma|Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma|Completed||Phase 2|28|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 00:53:07.466237|2018-06-01 00:53:07.466237
NCT00920777|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2015-06-09|2009-06-12|2009-06-15|Estimate|||||||2015-06-09|2015-06-10|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|||Survey and Cognitive Behavior Therapy for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|A RCT Study on the Effect of Short and Long Cognitive Behaviour Therapy (CBT) in CFS/ME Patients|Completed||N/A|234|Actual|Norwegian University of Science and Technology||3|||f||||t||||||||||2018-06-01 00:53:07.762282|2018-06-01 00:53:07.762282
NCT00920764|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11||2011-08-18|2013-03-26|2009-06-12|2009-06-15|Estimate||||2011-08-18|2011-08-23|Estimate|2013-03-26|2013-04-02|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors|A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor|Completed||Phase 2|92|Actual|AbbVie||4|||f||||f||||||||||2018-06-01 00:53:07.850916|2018-06-01 00:53:07.850916
NCT00920751|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2009-06-12|2009-06-12|2009-06-15|Estimate|||||||2009-06-12|2009-06-15|Estimate|March 2009||2009-03-31|June 2009|2009-06-30||||||||Interventional|||Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance|Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance|Unknown status|Recruiting|N/A|100|Anticipated|East Bay Institute for Research and Education||2|||f||||t||||||||||2018-06-01 00:53:07.968598|2018-06-01 00:53:07.968598
NCT00920738|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2014-08-21|2009-06-12|2009-06-15|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2005||2005-04-30|August 2014|2014-08-31|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Observational|||Metabolic Syndrome in Childhood Cancer Survivors|Metabolic Syndrome in Childhood Cancer Survivors|Completed|||512|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||Samples With DNA|"~     A 22 gauge intravenous polyethylene catheter will be inserted into an antecubital vein of one~     arm and the necessary blood for all baseline laboratory studies will be obtained and~     processed as per standard protocol.~   "|||2018-06-01 00:53:08.050568|2018-06-01 00:53:08.050568
NCT00920725|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2012-08-14|2009-06-12|2009-06-15|Estimate|||||||2012-08-14|2012-08-16|Estimate|January 2005||2005-01-31|August 2012|2012-08-31|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|DKA||Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA|Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis|Completed||N/A|50|Actual|Rush University Medical Center||3|||f||||t||||||||||2018-06-01 00:53:08.131498|2018-06-01 00:53:08.131498
NCT00920712|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2016-04-18|2009-06-12|2009-06-15|Estimate|||||||2016-04-18|2016-04-19|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Study of the Chinese Prescription Weiqi Decoction on Chronic Atrophic Gastritis||Completed||N/A|200|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:53:08.361834|2018-06-01 00:53:08.361834
NCT00920699|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2017-08-25||2017-08-25|2009-06-12|2009-06-15|Estimate|2017-08-25|2017-09-25|Actual||||2017-08-25|2017-09-25|Actual|February 2010||2010-02-28|August 2017|2017-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PREQUEL|one subject no longer met eligibility criteria in the 1200 mg arm|Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)|A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's Disease|Completed||Phase 2|90|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-06-01 00:53:08.472427|2018-06-01 00:53:08.472427
NCT00920686|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2013-05-08||2014-07-20|2009-06-12|2009-06-15|Estimate|2014-07-20|2014-08-11|Estimate||||2014-07-20|2014-08-11|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Safety population|Study of NXN 188 for the Treatment of Migraine With Aura|A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura|Completed||Phase 2|239|Actual|NeurAxon Inc.||3|||f||||f||||||||||2018-06-01 00:53:08.939313|2018-06-01 00:53:08.939313
NCT00920673|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-02-24|2009-06-12|2009-06-15|Estimate|||||||2014-02-24|2014-02-25|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Age Influence on the Modifications of the Oral, Pharyngeal and Laryngeal Axis Alignment in Children Induced by Head Extension: an MRI Study|Age Influence on the Modifications of the Oral, Pharyngeal and Laryngeal Axis Alignment in Children Induced by Head Extension: an MRI Study|Completed||N/A|150|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 00:53:09.710463|2018-06-01 00:53:09.710463
NCT00920660|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2017-07-05|2009-06-12|2009-06-15|Estimate|||||||2017-07-05|2017-07-07|Actual|April 6, 2009|Actual|2009-04-06|July 2017|2017-07-31|June 12, 2009|Actual|2009-06-12|June 12, 2009|Actual|2009-06-12||Interventional|||Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Multi-way Crossover Study to Assess the Effects of Single Oral Doses of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers|Completed||Phase 1|20|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:09.772786|2018-06-01 00:53:09.772786
NCT00920647|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2013-10-31||2015-10-06|2009-06-12|2009-06-15|Estimate|2014-04-17|2014-05-16|Estimate||||2015-10-06|2015-10-28|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®|A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment|Completed||Phase 1/Phase 2|16|Actual|Shire|"Untreated control group were not implanted with IDDD.~Concentration of idursulfase in all CSF samples post single dose of idursulfase-IT were below LLOQ(Lower limit of quantitation) of the bioanalytical method therefore no results are reported."|4|||f||||t||||||||||2018-06-01 00:53:09.945241|2018-06-01 00:53:09.945241
NCT00920634|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2015-02-04|2009-06-12|2009-06-15|Estimate|||||||2015-02-04|2015-02-05|Estimate|July 2007||2007-07-31|February 2015|2015-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)|Protocol for Drug Use Investigation of Follistim Injection|Completed|||384|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:53:11.013713|2018-06-01 00:53:11.013713
NCT00920621|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2017-02-28||2018-02-13|2009-06-11|2009-06-15|Estimate|2017-07-12|2017-07-14|Actual||||2018-02-13|2018-03-13|Actual|September 2009||2009-09-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|January 21, 2015|Actual|2015-01-21||Interventional|VDAART||Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)|Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)|Active, not recruiting||Phase 3|876|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 00:53:11.150054|2018-06-01 00:53:11.150054
NCT00920608|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-12-02|2009-06-12|2009-06-15|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|September 2009|Anticipated|2009-09-30|||||Interventional|||A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients|A Phase I, Multi-centre, Open-label, Fixed-sequence Study to Assess the Pharmacokinetics of Methotrexate Alone and When Co-administered With AZD9056 in Subjects With Rheumatoid Arthritis|Withdrawn||Phase 1|12|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:53:11.651126|2018-06-01 00:53:11.651126
NCT00920595|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2012-08-14|2009-06-12|2009-06-15|Estimate|||||||2012-08-14|2012-08-16|Estimate|June 2009||2009-06-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors|An Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP-1 and PARP-2 Inhibitor) as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors|Completed||Phase 1|26|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 00:53:11.727599|2018-06-01 00:53:11.727599
NCT00920582|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12||2013-02-28|2013-02-28|2009-06-12|2009-06-15|Estimate||||2013-02-28|2013-03-07|Estimate|2013-02-28|2013-03-07|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus|Completed||Phase 3|254|Actual|MacroGenics||4|||f||||t||||||||||2018-06-01 00:53:11.839935|2018-06-01 00:53:11.839935
NCT00920569|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2016-05-25|2009-06-12|2009-06-15|Estimate|||||||2016-05-25|2016-05-27|Estimate|May 2006||2006-05-31|May 2016|2016-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Recirculation, Oxygenator Blood Volume and Cardiac Output Measurements During Extracorporeal Membrane Oxygenation|Measurement of Recirculation, Oxygenator Blood Volume and Cardiac Output in ECMO Using a Modified Transonic Systems (tm) HD02 Monitoring System|Terminated|||8|Actual|Transonic Systems Inc.||||Study site collaborators withdrew from participating due to time constraints.|f||||f||||||||No||2018-06-01 00:53:12.141978|2018-06-01 00:53:12.141978
NCT00920556|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2016-11-30|2009-06-12|2009-06-15|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma|A Phase II, Open-Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma|Terminated||Phase 2|24|Actual|GlaxoSmithKline||1||Study terminated.24 subjects enrolled;provided adequate data for decision making.|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:12.285569|2018-06-01 00:53:12.285569
NCT00919685|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2014-08-28|2009-06-11|2009-06-12|Estimate|||||||2014-08-28|2014-08-29|Estimate|May 2009||2009-05-31|August 2014|2014-08-31||||March 2013|Actual|2013-03-31||Interventional|||Investigations of New Markers in Patients With Shock|Investigations of New Markers in Patients With Shock|Completed||N/A|50|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 00:53:30.446443|2018-06-01 00:53:30.446443
NCT00920543|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2016-08-31|2009-06-12|2009-06-15|Estimate|||||||2016-08-31|2016-09-01|Estimate|February 2003||2003-02-28|August 2016|2016-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||GSK BHR Study (Sont)|A Multicenter, Randomized, Double-blind, Parallel Group, 40-week Comparison of Asthma Control Using Bronchial Hyperresponsiveness as an Additional Guide to Long-term Treatment in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Twice Daily or Fluticasone Propionate DISKUS Twice Daily (or Placebo BID if Asymptomatic)|Completed||Phase 4|464|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:12.506295|2018-06-01 00:53:12.506295
NCT00920530|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-17|2009-06-12|2009-06-15|Estimate|||||||2009-06-17|2009-06-18|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Observational|BBFAST||Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study|Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage at Delivery : a Medico-Economic and Feasibility Study|Completed|||224|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     Vaginal swab~   "|||2018-06-01 00:53:12.858512|2018-06-01 00:53:12.858512
NCT00920517|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2012-12-31|2009-06-11|2009-06-15|Estimate|||||||2012-12-31|2013-01-03|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine|Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine With Boosting at 4 Versus 6 Months|Completed||Phase 1|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 00:53:12.954006|2018-06-01 00:53:12.954006
NCT00920504|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2012-02-08|2009-06-12|2009-06-15|Estimate|||||||2012-02-08|2012-02-09|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PEINCA||Pilot Study to Test the Feasibility and the Efficacy of the German Language Adapted PRO-SELF© Plus Pain Control Program|Pilot Study to Test the Feasibility and the Efficacy of the German Language Adapted PRO-SELF© Plus Pain Control Program, an Educational Intervention Directed at Patients and Their Family Caregivers to Reduce Cancer Pain and Related Symptoms|Completed||N/A|39|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 00:53:13.072015|2018-06-01 00:53:13.072015
NCT00920491|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2014-12-12|2009-06-12|2009-06-15|Estimate|||||||2014-12-12|2014-12-15|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|BANC4||Biomarker-enhanced ED Disposition Decisions|BANC4 (BASEL NON - SPECIFIC COMPLAINTS 4) Biomarker-enhanced Disposition Decisions|Completed|||400|Actual|University Hospital, Basel, Switzerland|||1||f||||t||||||Samples Without DNA|"~     whole blood (MR-proADM)~   "|||2018-06-01 00:53:13.198221|2018-06-01 00:53:13.198221
NCT00920478|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2009-09-09|2009-06-11|2009-06-15|Estimate|||||||2009-09-09|2009-09-10|Estimate|September 2009||2009-09-30|September 2009|2009-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|TaSER||Targeting Synovitis in Early Rheumatoid Arthritis|Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments|Unknown status|Recruiting|Phase 4|110|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-06-01 00:53:13.267916|2018-06-01 00:53:13.267916
NCT00920465|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2011-05-24|2009-06-12|2009-06-15|Estimate|||||||2011-05-24|2011-05-25|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Treatment Regimens for Mifegyne and Cytotec|Comparison of the Effectiveness of Abortive Measures From the Administration of Mifegyne and Cytotec at One and Two Visits|Unknown status|Recruiting|Phase 3|200|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-06-01 00:53:13.352091|2018-06-01 00:53:13.352091
NCT00920452|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2012-12-03|2009-06-12|2009-06-15|Estimate|||||||2012-12-03|2012-12-05|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|4-SITE FF||The 4-SITE Field Following Study (4-SITE FF)|RELIANCE QUADRIPOLAR DEFIBRILLATION LEADS (4-SITE)FIELD FOLLOWING The 4-SITE Field Following Study (4-SITE FF)|Completed|||430|Actual|Guidant Corporation|||||f||||f||||||||||2018-06-01 00:53:13.471865|2018-06-01 00:53:13.471865
NCT00920439|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2017-04-19||2017-12-20|2009-06-12|2009-06-15|Estimate|2017-05-26|2017-10-19|Actual||||2017-12-20|2018-01-19|Actual|June 1, 2009|Actual|2009-06-01|May 2017|2017-05-31|August 3, 2009|Actual|2009-08-03|August 3, 2009|Actual|2009-08-03||Interventional|||Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers|An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.|Completed||Phase 3|26|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:13.54165|2018-06-01 00:53:13.54165
NCT00920426|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2017-07-18|2010-08-12|2017-11-02|2009-06-12|2009-06-15|Estimate|2017-11-02|2017-12-06|Actual|2010-08-12|2010-08-17|Estimate|2017-11-02|2017-12-06|Actual|June 9, 2009|Actual|2009-06-09|September 2017|2017-09-30|August 13, 2009|Actual|2009-08-13|August 13, 2009|Actual|2009-08-13||Interventional|||Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)|A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)|Completed||Phase 2|9|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-06-01 00:53:13.85708|2018-06-01 00:53:13.85708
NCT00920413|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-06-12|2009-06-12|2009-06-15|Estimate|||||||2009-06-12|2009-06-15|Estimate|March 2002||2002-03-31|June 2009|2009-06-30||||||||Interventional|||Oral Vitamin C for Correction of Anemia in Patients Receiving Peritoneal Dialysis|Randomized, Double-Blind, Placebo-Controlled Trial of Oral Vitamin C on Correction of Anemia in Patients Receiving Peritoneal Dialysis|Completed||Phase 3|32|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 00:53:15.291526|2018-06-01 00:53:15.291526
NCT00920400|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-01-11|2009-06-12|2009-06-15|Estimate|||||||2010-01-11|2010-01-12|Estimate|March 2008||2008-03-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Observational|||Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract|Value of Fecal Calprotectin in Upper Gastrointestinal Disease|Completed|||287|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     Biopsy samples (stomach, duodenum) will be stored by the Department of Pathology at the~     University Hospital Basel~   "|||2018-06-01 00:53:15.359443|2018-06-01 00:53:15.359443
NCT00917345|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|May 2009|Anticipated|2009-05-31|January 2009|Anticipated|2009-01-31||Observational|||Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity||Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 00:54:16.312112|2018-06-01 00:54:16.312112
NCT00920387|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12||2013-10-23|2014-04-16|2009-06-12|2009-06-15|Estimate||||2013-10-23|2013-11-15|Estimate|2014-04-16|2014-05-07|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety|LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study|Completed||Phase 2|12|Actual|Multidisciplinary Association for Psychedelic Studies||2|||f||||f||||||||||2018-06-01 00:53:15.407124|2018-06-01 00:53:15.407124
NCT00920374|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2010-04-22||2016-10-11|2009-06-12|2009-06-15|Estimate|2010-06-29|2010-07-27|Estimate||||2016-10-11|2016-11-23|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in People Aged 18 Years or Above|Completed||Phase 3|118|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:15.487185|2018-06-01 00:53:15.487185
NCT00920361|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2015-02-04|2009-06-12|2009-06-15|Estimate|||||||2015-02-04|2015-02-05|Estimate|November 2005||2005-11-30|February 2015|2015-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)|Designated Drug Use Investigation 1 of Follistim Injection|Completed|||1664|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:53:15.961848|2018-06-01 00:53:15.961848
NCT00920348|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2013-11-04|2009-06-12|2009-06-15|Estimate|||||||2013-11-04|2013-11-05|Estimate|January 2010||2010-01-31|November 2013|2013-11-30|March 2017|Anticipated|2017-03-31|March 2014|Anticipated|2014-03-31||Observational|CanCOLD||The Canadian Cohort Obstructive Lung Disease|The Canadian Cohort Obstructive Lung Disease|Unknown status|Recruiting||1500|Anticipated|McGill University|||4||f||||t||||||Samples With DNA|"~     Blood sampling~        -  Biomarkers:IL-6, CRP, CC-16, SP-D~        -  DNA for genetics, epigenetic and RNA for transcriptomics~        -  Markers for cardiovascular diseases: LDL, LDL and HDL sizes, Apo B, Apo A1, CRP, IL6,~          TNF alpha, Adiponectine, Leptine, Glucose and Insulin.~   "|||2018-06-01 00:53:16.015821|2018-06-01 00:53:16.015821
NCT00920335|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2014-02-24|2009-06-12|2009-06-15|Estimate|||||||2014-02-24|2014-02-25|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Adult Intracranial Ependymoma|Adult Intracranial Ependydomas : Prognostic and Diagnostic Factors Assessment and Molecular Characterization|Completed||N/A|192|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 00:53:16.107162|2018-06-01 00:53:16.107162
NCT00920322|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2011-07-19|2009-06-12|2009-06-15|Estimate|||||||2011-07-19|2011-07-21|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) in Depression|A Randomised Study of rTMS in Depression|Terminated||Phase 4|40|Anticipated|Northside Clinic, Australia||2||Technical issues impeded recruitment.|f||||t||||||||||2018-06-01 00:53:16.240766|2018-06-01 00:53:16.240766
NCT00920309|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2013-08-29||2014-03-07|2009-06-12|2009-06-15|Estimate|2014-03-07|2014-04-14|Estimate||||2014-03-07|2014-04-14|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy|Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy|Terminated||Phase 2/Phase 3|21|Actual|Yale University||2||"This study was stopped after larger studies published in the NEJM failed to show a benefit in~   treating ADPKD"|f||||t||||||||||2018-06-01 00:53:16.314624|2018-06-01 00:53:16.314624
NCT00920296|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-08-30|2009-06-12|2009-06-15|Estimate|||||||2010-08-30|2010-08-31|Estimate|July 2009||2009-07-31|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||DDI Study of Etravirine and GSK1265744|A Phase I, Open Label Crossover Study to Evaluate the Effect of Etravirine on GSK1265744 Pharmacokinetics in Healthy Adult Subjects|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 00:53:16.579978|2018-06-01 00:53:16.579978
NCT00920283|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2018-05-02|2009-06-12|2009-06-15|Estimate|||||||2018-05-02|2018-05-07|Actual|July 2009|Actual|2009-07-31|May 2018|2018-05-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|COMPETE||COMPETE: A Clinical Evaluation of Chrono Carbostent Carbofilm™ Coated Stent|Randomized Comparison Between Two Cobalt-Chromium Balloon Expandable Stents for the Treatment of De Novo Coronary Artery Lesions|Completed||N/A|205|Actual|CID - Carbostent & Implantable Devices||2|||f||||t||||||||||2018-06-01 00:53:16.669165|2018-06-01 00:53:16.669165
NCT00920270|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2009-06-11|2009-06-11|2009-06-15|Estimate|||||||2009-06-11|2009-06-15|Estimate|June 2006||2006-06-30|June 2006|2006-06-30||||March 2010|Anticipated|2010-03-31||Interventional|||Nebulized Colistin for Hospital-Acquired Pneumonia|Efficacy and Safety of Nebulized Colistin for Adjunctive Therapy of Hospital-Acquired Pneumonia Caused by Gram Negative Bacteria|Unknown status|Enrolling by invitation|Phase 3|140|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 00:53:16.7549|2018-06-01 00:53:16.7549
NCT00920257|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2017-11-08|2009-06-12|2009-06-15|Estimate|||||||2017-11-08|2017-11-13|Actual|June 16, 2009|Actual|2009-06-16|November 2017|2017-11-30|April 17, 2013|Actual|2013-04-17|April 17, 2013|Actual|2013-04-17||Interventional|||A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795|A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas|Completed||Phase 1|77|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 00:53:16.825107|2018-06-01 00:53:16.825107
NCT00920244|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2015-04-23|2009-06-12|2009-06-15|Estimate|||||||2015-04-23|2015-04-24|Estimate|August 2009||2009-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||In-hospital Cardiac Arrest - Dynamics and State Transitions|Dynamics and State Transitions During Resuscitation in In-hospital Cardiac Arrest|Completed|||285|Actual|St. Olavs Hospital|||||f||||f||||||||||2018-06-01 00:53:16.932351|2018-06-01 00:53:16.932351
NCT00920231|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2015-01-14||2015-12-18|2009-06-12|2009-06-15|Estimate|2015-03-31|2015-04-02|Estimate||||2015-12-18|2016-01-22|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|December 2013|Actual|2013-12-31||Interventional||a representative population for the VA of both sexes and ranging from 21 to 70. And they have a diverse set of reasons for blindness. But they all had sight once.|Computer Vision System for the Blind Veteran|Computer Vision System for the Blind Veteran|Completed||Phase 1|16|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:53:17.023798|2018-06-01 00:53:17.023798
NCT00912197|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2011-12-22|2009-06-02|2009-06-03|Estimate|||||||2011-12-22|2011-12-23|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Oligofructose on Appetite in Overweight Subjects|Effect of Oligofructose on Appetite, Gut Hormones and Body Composition in Healthy Overweight Subjects|Completed||N/A|22|Actual|Imperial College London||2|||f||||t||||||||||2018-06-01 00:55:45.784269|2018-06-01 00:55:45.784269
NCT00920218|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2017-08-04|2011-06-01|2017-11-10|2009-06-12|2009-06-15|Estimate|2017-11-10|2017-12-12|Actual|2011-06-01|2011-06-07|Estimate|2017-11-10|2017-12-12|Actual|July 14, 2009|Actual|2009-07-14|August 2017|2017-08-31|March 21, 2012|Actual|2012-03-21|April 26, 2011|Actual|2011-04-26||Interventional|||Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A|Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A|Completed||Phase 2|121|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 00:53:17.411595|2018-06-01 00:53:17.411595
NCT00920205|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2011-10-13|2009-06-12|2009-06-15|Estimate|||||||2011-10-13|2011-10-14|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments|Phase 1 Study of MCP-3100 in Patients With Refractory or Relapsed Cancer|Completed||Phase 1|26|Actual|Myrexis Inc.|||||f||||f||||||||||2018-06-01 00:53:20.893777|2018-06-01 00:53:20.893777
NCT00920192|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2017-07-14|2009-06-12|2009-06-15|Estimate|||||||2017-07-14|2017-07-18|Actual|August 12, 2009|Actual|2009-08-12|July 2017|2017-07-31|March 24, 2015|Actual|2015-03-24|March 7, 2012|Actual|2012-03-07||Interventional|||Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer|A Phase 1/2, Open-Label, Multicenter Study of GSK1363089Gin Adult Subjects With Hepatocellular Carcinoma|Completed||Phase 1|45|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:53:20.974821|2018-06-01 00:53:20.974821
NCT00920179|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-06-12|2009-06-12|2009-06-15|Estimate|||||||2009-06-12|2009-06-15|Estimate|October 2007||2007-10-31|June 2009|2009-06-30||||December 2010|Anticipated|2010-12-31||Observational|||Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome|The Application of In Vivo Confocal Scanning Laser Microscopy in the Evaluation of the Secretory Glands in Patients With Sjögren's Syndrome|Unknown status|Enrolling by invitation||30|Anticipated|Keio University|||2||f||||f||||||||||2018-06-01 00:53:21.075327|2018-06-01 00:53:21.075327
NCT00920166|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2009-06-12|2009-06-12|2009-06-15|Estimate|||||||2009-06-12|2009-06-15|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Pétunia||Evaluation of Safety, Growth, Tolerance and Effects on the Intestinal Fora of a New Milk for Healthy Infants|Growth and Tolerance in New Born Fed Formula Supplemented With Alpha-Lactalbumin and Containing a Symbiotic|Completed||Phase 3|97|Actual|Sodilac||2|||f||||f||||||||||2018-06-01 00:53:21.139935|2018-06-01 00:53:21.139935
NCT00920153|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2016-09-15|2009-06-12|2009-06-15|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2008||2008-05-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma|Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma|Terminated||Phase 3|442|Actual|French Innovative Leukemia Organisation||3||Other new drugs|f||||t||||||||Undecided||2018-06-01 00:53:21.229771|2018-06-01 00:53:21.229771
NCT00920140|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|2013-11-21||2014-03-06|2009-06-12|2009-06-15|Estimate|2014-01-28|2014-02-28|Estimate||||2014-03-06|2014-04-02|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias|An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias|Completed||Phase 2|97|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:53:21.41812|2018-06-01 00:53:21.41812
NCT00920127|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2011-08-04|2009-06-12|2009-06-15|Estimate|||||||2011-08-04|2011-08-05|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|February 2012|Anticipated|2012-02-29|February 2011|Actual|2011-02-28||Interventional|TAKL||Treatment With AKL1 in Obstructive Airways Disease (The TAKL Study)|An Investigation of the Safety and Efficacy of Oral AKL1 in Patients Diagnosed With Obstructive Lung Disease|Unknown status|Active, not recruiting|Phase 2/Phase 3|164|Anticipated|University of East Anglia||2|||f||||t||||||||||2018-06-01 00:53:22.54246|2018-06-01 00:53:22.54246
NCT00920114|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2012-03-12|2009-06-12|2009-06-15|Estimate|||||||2012-03-12|2012-03-13|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|LU-PUCE||Estimate of the Activity and the Forecast of the Lupus Disease of the Adult by a Transcriptomic Score (STUDY LU-PUCE)||Completed||N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 00:53:22.613022|2018-06-01 00:53:22.613022
NCT00920101|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2013-03-11|2009-06-12|2009-06-15|Estimate|||||||2013-03-11|2013-03-12|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging|Effect of Atorvastatin on Inflammatory Atherosclerotic Plaques Assessed by FDG-PET Imaging|Unknown status|Recruiting|Phase 4|30|Anticipated|National Defense Medical College, Japan||2|||f||||f||||||||||2018-06-01 00:53:22.682943|2018-06-01 00:53:22.682943
NCT00920088|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-12|||2010-11-02|2009-06-12|2009-06-15|Estimate|||||||2010-11-02|2010-11-03|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs|A Phase I Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 Pharmacokinetics and to Assess the Effect of GSK2248761 on CYP450 Probe Drugs in Healthy Adult Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 00:53:22.768849|2018-06-01 00:53:22.768849
NCT00920075|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2010-11-09||2010-11-09|2009-06-12|2009-06-15|Estimate|2010-11-09|2010-12-10|Estimate||||2010-11-09|2010-12-10|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|September 2009|Actual|2009-09-30||Observational|||Alendronate in Juvenile Osteoporosis|Phase II Study of Alendronate Sodium in Juvenile Osteoporosis (IND# 60,017)-Post Study Evaluation of Participants From Phase IIa and Phase IIb Clinical Study.|Completed|||11|Actual|Medical University of South Carolina|||1||f||||t||||||||||2018-06-01 00:53:22.842797|2018-06-01 00:53:22.842797
NCT00920062|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2016-05-25|2009-06-12|2009-06-15|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Measurement of Recirculation During Venovenous Extracorporeal Membrane Oxygenation (VV ECMO)|Ultrasound Dilution Measurement of Recirculation During Venovenous Extracorporeal Membrane Oxygenation|Completed|||16|Actual|Transonic Systems Inc.|||||f||||f||||||||||2018-06-01 00:53:22.986316|2018-06-01 00:53:22.986316
NCT00920049|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2017-06-30|2009-06-10|2009-06-12|Estimate|||||||2017-06-30|2017-07-02|Actual|June 5, 2009||2009-06-05|March 29, 2012|2012-03-29|March 29, 2012|Actual|2012-03-29|March 29, 2012|Actual|2012-03-29||Interventional|||Preventing Motor Vehicle Crashes Among Young Drivers: Evaluation of the Checkpoints Program Presented by the American Automobile Association|Preventing Motor Vehicle Crashes Among Young Drivers: Evaluation of the AAA Checkpoints Program|Completed||Phase 1/Phase 2|830|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:53:23.055966|2018-06-01 00:53:23.055966
NCT00920036|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2014-07-11|2009-06-11|2009-06-12|Estimate|||||||2014-07-11|2014-07-14|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|September 2012|Actual|2012-09-30|August 2011|Actual|2011-08-31||Interventional|ABIOP||Adjunctive Biofeedback Intervention for Operation Iraqi Freedom/Operation Enduring Freedom (OIF-OEF) Post Traumatic Stress Disorder (PTSD)|Adjunctive Biofeedback Intervention for OIF-OEF PTSD|Completed||N/A|8|Actual|Central Arkansas Veterans Healthcare System||2|||f||||f||||||||||2018-06-01 00:53:23.114734|2018-06-01 00:53:23.114734
NCT00920023|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2017-03-21||2017-06-26|2009-06-11|2009-06-12|Estimate|2017-06-26|2017-07-25|Actual||||2017-06-26|2017-07-25|Actual|July 2008||2008-07-31|June 2017|2017-06-30|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Interventional|||Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)|Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)|Completed||Phase 4|35|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:53:24.326917|2018-06-01 00:53:24.326917
NCT00920010|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-02-05|2009-06-11|2009-06-12|Estimate|||||||2015-02-05|2015-02-06|Estimate|September 2000||2000-09-30|February 2015|2015-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||S9925: Collecting and Storing Samples From Patients With Lung Cancer|Lung Cancer Specimen Repository Protocol, Ancillary|Completed|||2264|Actual|Southwest Oncology Group|||||f||||f||||||Samples With DNA|"~     Fixed tissue in paraffin blocks or slides, slides of buccal brushings, fresh frozen tissue~     peripheral blood, serum, plasma, white blood cells, and sputum.~   "|||2018-06-01 00:53:24.593778|2018-06-01 00:53:24.593778
NCT00919997|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-10-01|2009-06-11|2009-06-12|Estimate|||||||2015-10-01|2015-10-05|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Human Papilloma Virus Infection in HIV-Positive Indian Men Who Have Sex With Men|HPV Infection in Indian HIV-Seropositive Men Who Have Sex With Men (MSM)|Completed|||302|Actual|AIDS Malignancy Consortium|||1||f||||f||||||Samples With DNA|"~     Anal cytology Penile cytology Saliva Blood~   "|||2018-06-01 00:53:25.505928|2018-06-01 00:53:25.505928
NCT00919984|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-07|||2014-05-07|2009-06-11|2009-06-12|Estimate|||||||2014-05-07|2014-05-09|Estimate|May 2007||2007-05-31|May 2014|2014-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer|Phase II Clinical Trial of Intravenous Paclitaxel and Carboplatin Plus Intraperitoneal Paclitaxel as an Adjuvant Chemotherapy in Patients With Optimally Debulked Advanced Epithelial Ovarian Carcinoma|Terminated||Phase 2|22|Actual|Korea Cancer Center Hospital||1||This study stopped due to slow accrual.|f||||f||||||||||2018-06-01 00:53:25.626007|2018-06-01 00:53:25.626007
NCT00919971|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2011-10-18|2009-06-11|2009-06-12|Estimate|||||||2011-10-18|2011-10-19|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|OHBIS||Bispectral Index (BIS) on Ventilated Patients in the Prehospital Setting|Use of Bispectral Index to Assess Depth of Sedation in Ventilated Patients in the Prehospital Setting|Completed|||120|Anticipated|Beaujon Hospital|||||f||||f||||||||||2018-06-01 00:53:25.747393|2018-06-01 00:53:25.747393
NCT00919958|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2012-06-17|2009-06-11|2009-06-12|Estimate|||||||2012-06-17|2012-06-19|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia|Phase I Study of Intramuscular (IM) Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia. PLX-PAD Are Mesenchymal-like Stromal Cells Derived From a Full Term Placenta. These Placental Adherent Stromal Cells (ASCs) Are Expanded in the Company's Proprietary PluriXTM 3D Bioreactor System. PLX Cells Are Immune Privileged and Possess Immunomodulatory Properties.|Completed||Phase 1|15|Actual|Pluristem Ltd.||3|||f||||t||||||||||2018-06-01 00:53:25.851769|2018-06-01 00:53:25.851769
NCT00919945|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2014-05-12|2009-06-11|2009-06-12|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn|Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn|Terminated||Phase 2|42|Actual|The Hospital for Sick Children||2||Reduced enrollment rate for SV patients due to high competition for studies|f||||t||||||||||2018-06-01 00:53:25.931472|2018-06-01 00:53:25.931472
NCT00919932|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2016-01-18||2016-01-18|2009-06-11|2009-06-12|Estimate|2016-01-18|2016-02-15|Estimate||||2016-01-18|2016-02-15|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework|Using a Text-message System to Engage Depressed Adolescents in Cognitive-behavioral Therapy Homework.|Completed||N/A|9|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:53:26.0425|2018-06-01 00:53:26.0425
NCT00919919|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-11|2009-06-11|2009-06-12|Estimate|||||||2009-06-11|2009-06-12|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|November 2010|Anticipated|2010-11-30|September 2010|Anticipated|2010-09-30||Interventional|||Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen|Efficacy & Tolerability of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Replacement Therapy - Phase II Comparative Study|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 00:53:26.299262|2018-06-01 00:53:26.299262
NCT00919906|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-10-27|2009-06-11|2009-06-12|Estimate|||||||2010-10-27|2010-10-28|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||My Scrivener® - Measuring Effectiveness and Dose Response in Children|My Scrivener® - Measuring Effectiveness and Dose Response in Children|Completed||Phase 1/Phase 2|176|Anticipated|Obslap Research LLC||2|||f||||f||||||||||2018-06-01 00:53:26.479763|2018-06-01 00:53:26.479763
NCT00919893|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2009-02-10||2009-06-15|2009-04-27|2009-06-12|Estimate|2009-04-27|2009-06-12|Estimate||||2009-06-15|2009-06-17|Estimate|December 1999||1999-12-31|June 2009|2009-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)|Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome|Completed||Phase 3|139|Actual|University of Giessen||2|||f||||t||||||||||2018-06-01 00:53:26.561142|2018-06-01 00:53:26.561142
NCT00919880|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2014-08-12|2009-06-11|2009-06-12|Estimate|||||||2014-08-12|2014-08-15|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer|A Phase II Randomized Clinical Trial of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast Cancer|Completed||Phase 2|148|Actual|Peking University||2|||f||||t||||||||||2018-06-01 00:53:27.109467|2018-06-01 00:53:27.109467
NCT00919867|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2010-07-01||2014-01-07|2009-06-11|2009-06-12|Estimate|2010-07-01|2010-08-02|Estimate||||2014-01-07|2014-02-06|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers|A Phase 1, Open-label, Randomized, Three-period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and VYVANSE, Administered Alone and in Combination in Healthy Adult Volunteers|Completed||Phase 1|42|Actual|Shire||3|||f||||||||||||||2018-06-01 00:53:27.237367|2018-06-01 00:53:27.237367
NCT00919854|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2011-08-03||2014-04-03|2009-06-11|2009-06-12|Estimate|2013-04-18|2013-06-24|Estimate||||2014-04-03|2014-04-23|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Interventional|||A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children|A Phase II, Open Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DRV in Combination With Low-Dose Ritonavir (DRV/Rtv) in Treatment-Experienced HIV-1 Infected Children From 3 Years to Below 6 Years of Age|Completed||Phase 2|27|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||t||||||||||2018-06-01 00:53:28.113191|2018-06-01 00:53:28.113191
NCT00919841|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2010-05-01|2009-06-11|2009-06-12|Estimate|||||||2010-05-01|2010-05-04|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|3DUT||Sequential Volume Measurement of Postpartum Uterus Using 3-dimensional Sonographies|Sequential Volume Measurement of Postpartum Uterus Using 3-dimensional Sonographies|Completed|||80|Actual|Mahidol University|||1||f||||f||||||||||2018-06-01 00:53:28.383646|2018-06-01 00:53:28.383646
NCT00919828|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-02-02|2009-06-11|2009-06-12|Estimate|||||||2010-02-02|2010-02-04|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|ACUTE||Monitor Patients With Acute Heart Failure|Adherent Monitoring of Congestive Heart Failure During Therapy for Excess Fluid Study|Completed|||60|Anticipated|Corventis, Inc.|||||f||||f||||||||||2018-06-01 00:53:28.468815|2018-06-01 00:53:28.468815
NCT00919815|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-03-21|2009-06-11|2009-06-12|Estimate|||||||2015-03-21|2015-03-24|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Ciclosporin in the Management of New Type 1 Reactions in Leprosy|A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions|Completed||Phase 2/Phase 3|73|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:53:28.531069|2018-06-01 00:53:28.531069
NCT00919802|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2016-12-27||2017-04-23|2009-06-11|2009-06-12|Estimate|2017-04-23|2017-05-23|Actual||||2017-04-23|2017-05-23|Actual|June 2010||2010-06-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis|Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis|Completed||Phase 4|25|Actual|University of Alabama at Birmingham||2|||f||||t|t|f||||||Yes|De-identified raw data will be made available on request by contacting contact investigator at tness@uabmc.edu|2018-06-01 00:53:28.642668|2018-06-01 00:53:28.642668
NCT00919776|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-03-25|2009-06-11|2009-06-12|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum|A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only.|Completed||Phase 2|20|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:53:28.839667|2018-06-01 00:53:28.839667
NCT00919763|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2012-01-19||2012-05-29|2009-06-09|2009-06-12|Estimate|2012-04-04|2012-05-01|Estimate||||2012-05-29|2012-06-04|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Efficacy and Safety Study of CD2027 Ointment 3 Mcg/g Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis|A Four-Week, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CD2027 Ointment 3 Mcg/g Twice Daily in the Treatment of Adults With at Least Moderate Atopic Dermatitis|Completed||Phase 2|102|Actual|Galderma||2|||f||||f||||||||||2018-06-01 00:53:28.920778|2018-06-01 00:53:28.920778
NCT00919750|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2017-12-11|2009-06-11|2009-06-12|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2005||2005-03-31|December 2017|2017-12-31|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors|A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens|Active, not recruiting|||5000|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     brain tumor tissue, blood~   "|||2018-06-01 00:53:29.149803|2018-06-01 00:53:29.149803
NCT00919737|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2013-10-29|2009-06-11|2009-06-12|Estimate|||||||2013-10-29|2013-10-30|Estimate|June 2009||2009-06-30|October 2013|2013-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme|A Phase 1/2, Multicenter, Non-Randomized, Open Label Clinical Trial of NPC-08 Implant in Patients Undergoing Surgery for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme.|Completed||Phase 1/Phase 2|24|Actual|Nobelpharma||1|||f||||t||||||||||2018-06-01 00:53:29.509783|2018-06-01 00:53:29.509783
NCT00919724|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2014-05-28||2014-07-01|2009-06-11|2009-06-12|Estimate|2014-05-28|2014-06-30|Estimate||||2014-07-01|2014-07-15|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Observational|||Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People|A Comparison of Endothelial Function Between HIV-infected Subjects Not Receiving Antiretroviral Therapy and Matched HIV-uninfected Control Subjects|Completed|||89|Actual|Indiana University|||2||f||||t||||||Samples Without DNA|"~     Plasma, serum, urine~   "|||2018-06-01 00:53:29.586349|2018-06-01 00:53:29.586349
NCT00919711|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2012-11-15||2014-07-14|2009-06-11|2009-06-12|Estimate|2012-11-15|2012-12-12|Estimate||||2014-07-14|2014-07-23|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy|A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel® Therapies in Postmenopausal Women Transitioned From Weekly or Daily Alendronate Therapy|Completed||Phase 3|870|Actual|Amgen||2|||f||||f||||||||||2018-06-01 00:53:29.86033|2018-06-01 00:53:29.86033
NCT00919698|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2014-12-02|2009-06-10|2009-06-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Delirium in Mechanically Ventilated Patients|An Assessment of Delirium in Mechanically Ventilated Patients Undergoing Daily Awakening From Sedation|Completed|||102|Actual|University of Chicago|||1||f||||f||||||||||2018-06-01 00:53:30.368132|2018-06-01 00:53:30.368132
NCT00919672|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2018-05-16|2009-06-11|2009-06-12|Estimate|||||||2018-05-16|2018-05-17|Actual|April 2009||2009-04-30|May 2018|2018-05-31|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|||Treatment of Irritable Bowel Syndrome (IBS) With Sacral Nerve Stimulation|Treatment of Irritable Bowel Syndrome (IBS) With Sacral Nerve Stimulation. A Blinded, Randomized Crossover Study|Completed||N/A|21|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:53:30.509268|2018-06-01 00:53:30.509268
NCT00919659|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-11|2009-06-11|2009-06-12|Estimate|||||||2009-06-11|2009-06-12|Estimate|January 2002||2002-01-31|June 2009|2009-06-30|May 2004|Actual|2004-05-31|January 2004|Actual|2004-01-31||Interventional|||Parenteral Nutrition Support for Patients With Pancreatic Cancer|Parenteral Nutrition Support for Patients With Pancreatic Cancer. A Phase II Study.|Completed||Phase 2|32|Actual|CONKO-Studiengruppe||1|||f||||f||||||||||2018-06-01 00:53:30.573158|2018-06-01 00:53:30.573158
NCT00919646|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-02-02|2009-06-11|2009-06-12|Estimate|||||||2010-02-02|2010-02-04|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|ADAM||Monitoring Arrhythmia Patients in in Hospital Monitoring|Arrhythmia Detection With Adherent Patient Monitoring Study|Completed|||30|Anticipated|Corventis, Inc.|||||f||||f||||||||||2018-06-01 00:53:30.641245|2018-06-01 00:53:30.641245
NCT00919633|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2014-03-28||2014-03-28|2009-06-10|2009-06-12|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|COPE-HCV||Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C|COPE-HCV: Continuous Interferon Delivery Via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV|Completed||Phase 2|116|Actual|Medtronic Corporate Technologies and New Ventures||4|||f||||t||||||||||2018-06-01 00:53:30.711175|2018-06-01 00:53:30.711175
NCT00919620|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-01-13|2009-06-10|2009-06-12|Estimate|||||||2010-01-13|2010-01-15|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Stage-specific Case Management for Early Psychosis|Outcome of Stage-specific Early Intervention for Psychosis in Hong Kong: A Randomized Controlled Study|Unknown status|Recruiting|N/A|500|Anticipated|The University of Hong Kong||3|||f||||f||||||||||2018-06-01 00:53:31.592265|2018-06-01 00:53:31.592265
NCT00919607|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2010-03-25|2009-06-11|2009-06-12|Estimate|||||||2010-03-25|2010-03-26|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients||Completed||Phase 1|31|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 00:53:31.690264|2018-06-01 00:53:31.690264
NCT00919594|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2017-07-14|2009-06-11|2009-06-12|Estimate|||||||2017-07-14|2017-07-19|Actual|August 2009||2009-08-31|July 2017|2017-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|IPT-MOMS||Psychotherapy for Depressed Mothers of Psychiatrically Ill Children|Psychotherapy for Depressed Mothers of Psychiatrically Ill|Completed||N/A|348|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-06-01 00:53:31.771654|2018-06-01 00:53:31.771654
NCT00919581|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2017-04-24|2009-06-11|2009-06-12|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2009||2009-05-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury|Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury|Completed|||149|Actual|Northwell Health|||2||f||||f||||||||||2018-06-01 00:53:31.843036|2018-06-01 00:53:31.843036
NCT00919568|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-02-02|2009-06-11|2009-06-12|Estimate|||||||2010-02-02|2010-02-04|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Monitoring Arrhythmia Patients (IMPACT)|Arrhythmia Detection With Adherent Patient Monitoring|Completed|||28|Actual|Corventis, Inc.|||||f||||f||||||||||2018-06-01 00:53:31.908006|2018-06-01 00:53:31.908006
NCT00919555|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-11-29|2009-06-11|2009-06-12|Estimate|||||||2012-11-29|2012-11-30|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|November 2009|Actual|2009-11-30||Interventional|PNA||Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)|Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis|Completed||Phase 1/Phase 2|28|Actual|Phoenix Neurological Associates, LTD||2|||f||||t||||||||||2018-06-01 00:53:31.95447|2018-06-01 00:53:31.95447
NCT00919542|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-03-21|2009-06-11|2009-06-12|Estimate|||||||2015-03-21|2015-03-24|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Ciclosporin in the Management of New Erythema Nodosum Leprosum|A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.|Completed||Phase 2|12|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:53:32.039561|2018-06-01 00:53:32.039561
NCT00919516|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2014-12-10|2009-06-11|2009-06-12|Estimate|||||||2014-12-10|2014-12-11|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Autologous Bone Marrow Mononuclear Cell Implantation for Moderate to Severe Peripheral Arterial Disease|Use of Autologous Bone-Marrow Mononuclear Cell Implantation Therapy as a Limb Salvage Procedure in Patients With Moderate to Severe Peripheral Arterial Disease|Completed||N/A|49|Actual|The Vascular and Vein Center, Columbus, OH||1|||f||||f||||||||||2018-06-01 00:53:32.125173|2018-06-01 00:53:32.125173
NCT00919503|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2018-04-23|2009-06-11|2009-06-12|Estimate|||||||2018-04-23|2018-04-25|Actual|July 31, 2009|Actual|2009-07-31|April 2018|2018-04-30||||February 1, 2019|Anticipated|2019-02-01||Interventional|||Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders|Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen|Recruiting||Phase 2|120|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 00:53:32.200033|2018-06-01 00:53:32.200033
NCT00919490|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2010-10-22|2009-06-11|2009-06-12|Estimate|||||||2010-10-22|2010-10-25|Estimate|June 2009||2009-06-30|September 2010|2010-09-30||||August 2009|Actual|2009-08-31||Interventional|||A Study of Single Dose of ABT-333 in Healthy Male Adults|A Double-blind, Randomized, Placebo-controlled Phase 1 Study in Healthy Male Adults to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Dose of ABT-333|Completed||Phase 1|39|Actual|Abbott||5|||f||||||||||||||2018-06-01 00:53:32.351483|2018-06-01 00:53:32.351483
NCT00919477|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2013-01-21|2009-06-11|2009-06-12|Estimate|||||||2013-01-21|2013-01-23|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|CAMON||Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg|Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg|Completed|||712|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 00:53:32.438187|2018-06-01 00:53:32.438187
NCT00919464|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2013-02-13|2009-06-09|2009-06-12|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2006||2006-04-30|February 2013|2013-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Natural History of Anterior Compartment Pressures of the Thigh Following Femur Fracture|Natural History of Anterior Compartment Pressures of the Thigh Following Femur|Terminated||N/A|7|Actual|CAMC Health System||||low enrollment|f||||f||||||||||2018-06-01 00:53:32.787463|2018-06-01 00:53:32.787463
NCT00919451|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-03-24|2009-06-11|2009-06-12|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy|A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone.|Completed||Phase 2|16|Actual|London School of Hygiene and Tropical Medicine||1|||f||||t||||||||||2018-06-01 00:53:32.83928|2018-06-01 00:53:32.83928
NCT00919438|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-02-02|2009-06-11|2009-06-12|Estimate|||||||2010-02-02|2010-02-04|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|FARM||Non Invasive External Monitoring in Dialysis Patients|Fluid Removal During Adherent Renal Monitoring|Completed|||25|Anticipated|Corventis, Inc.|||1||f||||f||||||||||2018-06-01 00:53:32.908703|2018-06-01 00:53:32.908703
NCT00919425|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-03-05|2009-06-11|2009-06-12|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 1999||1999-04-30|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer|S9910, Leukemia Centralized Reference Laboratories and Tissue Repositories - Ancillary|Completed|||1294|Actual|Southwest Oncology Group|||||f||||f||||||Samples With DNA|"~     Blood and bone marrow~   "|||2018-06-01 00:53:33.034526|2018-06-01 00:53:33.034526
NCT00919412|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2016-05-17|2009-06-11|2009-06-12|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|PTMARKER||Non Invasive Biomarkers to Identify Subjects at Risk for Preterm Delivery|Non-Invasive Biomarkers To Identify Subjects At Risks For Preterm Delivery|Terminated|||32|Actual|Winthrop University Hospital|||2|Original Principal Investigator, G. Ashmead, MD left the Institution|f||||f||||||Samples With DNA|"~     Maternal blood Maternal cervical secretions Fetal umbilical cord blood Placenta~   "|||2018-06-01 00:53:33.84815|2018-06-01 00:53:33.84815
NCT00919399|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2009-06-11|2009-06-11|2009-06-12|Estimate|||||||2009-06-11|2009-06-12|Estimate|January 2002||2002-01-31|June 2009|2009-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|TAMARO||Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant|Phase II Study Evaluating the Effectiveness of the Exemestane (Aromasin) With Tamoxifen on the Rate of Clinical Response Menopausal in Patients With Locally Advanced Breast Tumors|Completed||Phase 2|15|Actual|Institut Claudius Regaud|||||f||||f||||||||||2018-06-01 00:53:33.972411|2018-06-01 00:53:33.972411
NCT00919386|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2015-07-30|2009-06-11|2009-06-12|Estimate|||||||2015-07-30|2015-07-31|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Ureteral Stent Size Measurement Study|Three Methods of Ureteral Stent Measurement: Which Method Improves Quality of Life After Ureteral Stenting?|Completed|||17|Actual|CAMC Health System|||3||f||||f||||||||||2018-06-01 00:53:34.115501|2018-06-01 00:53:34.115501
NCT00919373|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2013-07-26|2009-06-11|2009-06-12|Estimate|||||||2013-07-26|2013-07-29|Estimate|July 2002||2002-07-31|July 2013|2013-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|VTACH||Substrate Modification in Stable Ventricular Tachycardia in Addition to Implantable Cardioverter Defibrillator (ICD) Therapy|Substrate Modification in Stable Ventricular Tachycardia in Addition to ICD Therapy|Completed||N/A|110|Actual|St. Jude Medical||2|||f||||f||||||||||2018-06-01 00:53:34.36322|2018-06-01 00:53:34.36322
NCT00919360|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2015-10-19|2009-06-10|2009-06-12|Estimate|||||||2015-10-19|2015-10-21|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Gene Expression In Pregnancies Complicated by Preeclampsia|Expression of Vascular Endothelial Growth Factor and Its Effectors in Preeclampsia|Terminated|||125|Actual|University of Rochester|||2|"PI is no longer at University of Rochester, has moved to University of Florida, Gainesville. PI~   email now homonq@ufl.edu. Phone is 352-273-7675"|f||||f||||||Samples With DNA|"~     serum, placental and decidual tissue~   "|||2018-06-01 00:53:34.774184|2018-06-01 00:53:34.774184
NCT00919347|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-05-25|2009-06-11|2009-06-12|Estimate|||||||2012-05-25|2012-05-28|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction|The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction in Diabetic Patients Undergoing Retinal Surgery|Completed|||100|Anticipated|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 00:53:35.088447|2018-06-01 00:53:35.088447
NCT00919334|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2014-07-02|2009-06-11|2009-06-12|Estimate|||||||2014-07-02|2014-07-03|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Myopia Control With Simultaneous Vision Approach|Control of Myopia Progression in Myopic Children Using Simultaneous Vision Approach|Completed||Phase 1|100|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-06-01 00:53:35.767809|2018-06-01 00:53:35.767809
NCT00919321|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2014-02-17|2009-06-11|2009-06-12|Estimate|||||||2014-02-17|2014-02-19|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|KLL2||The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL||Completed||Phase 4|32|Actual|Tampere University Hospital||1|||f||||f||||||||||2018-06-01 00:53:36.462945|2018-06-01 00:53:36.462945
NCT00919308|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-11|2009-06-11|2009-06-12|Estimate|||||||2009-06-11|2009-06-12|Estimate|August 2006||2006-08-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|September 2008|Actual|2008-09-30||Observational|||Simulation Training for Ultrasound Guided Central Venous Catheter Insertion|Simulation Training for Ultrasound Guided Central Venous Catheter Insertion|Completed|||184|Actual|Yale University|||2||f||||f||||||||||2018-06-01 00:53:36.545862|2018-06-01 00:53:36.545862
NCT00919295|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2012-07-24|2009-06-11|2009-06-12|Estimate|||||||2012-07-24|2012-07-25|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome|Study of Anti-nociceptive Biogenic Amine Status, Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Thai Fibromyalgia Syndrome Patients.|Completed||Phase 2|80|Actual|Mahidol University||3|||f||||f||||||||||2018-06-01 00:53:36.622127|2018-06-01 00:53:36.622127
NCT00919282|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-11|2009-06-11|2009-06-12|Estimate|||||||2009-06-11|2009-06-12|Estimate|September 1997||1997-09-30|June 2009|2009-06-30|December 2002|Actual|2002-12-31|July 2000|Actual|2000-07-31||Interventional|GFF||Gemcitabine (GFF) in Patients With Pancreatic Cancer|A Multi Center Phase II Study of 5-Fluorouracil/ Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.|Completed||Phase 2|78|Actual|CONKO-Studiengruppe||1|||f||||f||||||||||2018-06-01 00:53:36.86786|2018-06-01 00:53:36.86786
NCT00919269|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2017-12-11|2009-06-11|2009-06-12|Estimate|||||||2017-12-11|2017-12-13|Actual|March 1999||1999-03-31|December 2017|2017-12-31|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma|A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol|Active, not recruiting|||1500|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     human tumor tissue and other biological specimens (blood, serum, and bone marrow)~   "|||2018-06-01 00:53:37.30843|2018-06-01 00:53:37.30843
NCT00919243|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2010-08-31|2009-06-11|2009-06-12|Estimate|||||||2010-08-31|2010-09-01|Estimate|February 2009||2009-02-28|June 2009|2009-06-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Prednisone for Heart Failure Patients With Hyperuricemia|Prednisone Versus Allopurinol for Symptomatic Heart Failure Patients With Hyperuricemia|Completed||Phase 4|40|Anticipated|Hebei Medical University||2|||f||||t||||||||||2018-06-01 00:53:37.886308|2018-06-01 00:53:37.886308
NCT00919230|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2012-12-07|2009-06-11|2009-06-12|Estimate|||||||2012-12-07|2012-12-10|Estimate|July 2004||2004-07-31|December 2012|2012-12-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Randomised Trial Comparing Iron Supplementation Versus Placebo in the Treatment of Anaemia After Hip Fracture|Randomised Trial Comparing Iron Supplementation Versus Placebo in the Treatment of Anaemia After Hip Fracture|Completed||Phase 3|300|Actual|Peterborough and Stamford Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 00:53:38.035272|2018-06-01 00:53:38.035272
NCT00919217|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2017-04-25|2009-06-11|2009-06-12|Estimate|||||||2017-04-25|2017-04-27|Actual|August 2008||2008-08-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms|Exploratory Study on the Timing of MS Symptoms|Recruiting|||80|Anticipated|University of Louisville|||1||f||||t||||||||Undecided||2018-06-01 00:53:38.246554|2018-06-01 00:53:38.246554
NCT00919204|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2009-09-17|2009-06-11|2009-06-12|Estimate|||||||2009-09-17|2009-09-21|Estimate|August 2009||2009-08-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Axitinib Pharmacokinetics in Chinese Healthy Volunteers|An Open Label Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Healthy Chinese Volunteers|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:53:38.366047|2018-06-01 00:53:38.366047
NCT00919191|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2009-12-28||2012-02-14|2009-06-11|2009-06-12|Estimate|2010-02-24|2010-03-10|Estimate||||2012-02-14|2012-02-15|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face|An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using A Split-Face Model|Completed||Phase 4|26|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 00:53:38.498224|2018-06-01 00:53:38.498224
NCT00919178|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2012-12-31|2009-06-11|2009-06-12|Estimate|||||||2012-12-31|2013-01-03|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus|Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers.|Completed||Phase 1|70|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 00:53:38.72399|2018-06-01 00:53:38.72399
NCT00919165|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2013-06-03|2009-06-11|2009-06-12|Estimate|||||||2013-06-03|2013-06-05|Estimate|December 2007||2007-12-31|June 2013|2013-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||Assessment of Cognitive Function in Patients Undergoing Carotid Artery Stent Placement|Assessment of Cognitive Function in Patients Undergoing Carotid Artery Stent Placement: Cognitive Function in Carotid Stenting|Unknown status|Active, not recruiting||25|Anticipated|Spectrum Health Hospitals|||1||f||||f||||||||||2018-06-01 00:53:38.866599|2018-06-01 00:53:38.866599
NCT00919152|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2015-05-27|2009-06-11|2009-06-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|January 2012|Actual|2012-01-31|December 2009|Actual|2009-12-31||Observational|||Economic Outcomes of Enteral and Parenteral Proton Pump Inhibitor (PPI) Use in the Intensive Care Unit (ICU)|Correlates of Economic Outcomes of Enteral and Parenteral PPI Use in the ICU and After Discharge|Completed|||534|Actual|University of Nebraska|||||f||||f||||||||||2018-06-01 00:53:38.996246|2018-06-01 00:53:38.996246
NCT00919139|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-04-01|2009-06-11|2009-06-12|Estimate|||||||2015-04-01|2015-04-03|Estimate|November 2003||2003-11-30|April 2015|2015-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.|S0309, Myeloma Specimen Repository Protocol, Ancillary|Completed|||190|Actual|Southwest Oncology Group|||||f||||f||||||Samples With DNA|"~     bone marrow and peripheral blood~   "|||2018-06-01 00:53:39.187847|2018-06-01 00:53:39.187847
NCT00919126|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2014-06-04||2014-09-15|2009-06-11|2009-06-12|Estimate|2014-06-18|2014-07-17|Estimate||||2014-09-15|2014-09-25|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||The analysis was done in the Intention To Treat (ITT) Data Set (Randomised Patients).|General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.|An International Phase III Randomised Trial Comparing the Propofol Consumption During General Anaesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia Alone in ASA III Patients With Increased Risk of Perioperative Cardiac Complications.|Terminated||Phase 3|102|Actual|Air Liquide SA|The study has been terminated earlier due to difficulties to find patients meeting the inclusion criteria.|3||Enrollment rate|f||||f||||||||||2018-06-01 00:53:39.564397|2018-06-01 00:53:39.564397
NCT00919113|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2013-02-05||2013-05-01|2009-06-11|2009-06-12|Estimate|2013-05-01|2013-05-03|Estimate||||2013-05-01|2013-05-03|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome|A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome|Completed||Phase 2|98|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:53:41.23633|2018-06-01 00:53:41.23633
NCT00919100|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|||2015-03-09|2009-06-11|2009-06-12|Estimate|||||||2015-03-09|2015-03-10|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Buzzy Versus Vapocoolant Spray: Pediatric Needle Pain Relief|Buzzy: An Integration of Vibration, Cold, and Distraction for Pediatric Needle Pain Relief|Completed||N/A|81|Actual|Georgia State University||2|||f||||f||||||||||2018-06-01 00:53:41.839044|2018-06-01 00:53:41.839044
NCT00919087|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-02-02|2009-06-11|2009-06-12|Estimate|||||||2010-02-02|2010-02-04|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|EVE||Non Invasive Arrhythmia Detection in Hospital Settings|Evaluating Ventricular Events With Adherent Patient Monitoring Study|Completed|||25|Anticipated|Corventis, Inc.|||||f||||f||||||||||2018-06-01 00:53:42.360372|2018-06-01 00:53:42.360372
NCT00919074|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2014-12-08|2009-06-11|2009-06-12|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|January 2011|Actual|2011-01-31||Interventional|||Comparison of Double Wire Technique With Pancreatic Duct Stent Placement for Difficult Bile Duct Cannulation|Comparison of Double Wire Technique With Pancreatic Duct Stent Placement for Difficult Bile Duct Cannulation: a Randomized Clinical Trial|Completed||N/A|87|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:53:42.645817|2018-06-01 00:53:42.645817
NCT00919061|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-11|2015-10-19||2016-01-04|2009-06-11|2009-06-12|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy|A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naïve to Systemic Therapy|Completed||Phase 2|39|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:53:42.832672|2018-06-01 00:53:42.832672
NCT00919048|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2009-12-15|2009-06-11|2009-06-12|Estimate|||||||2009-12-15|2009-12-16|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Uroflow Measurements in Urogynecology Patients Compared to Healthy Female Volunteers|Uroflow Measurements in Urogynecology Patients Compared to Healthy Female Volunteers|Completed|||36|Anticipated|University of Rochester|||1||f||||f||||||||||2018-06-01 00:53:43.311318|2018-06-01 00:53:43.311318
NCT00919035|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2014-02-28||2014-06-19|2009-06-10|2009-06-11|Estimate|2014-02-28|2014-04-07|Estimate||||2014-06-19|2014-06-30|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Interventional|||Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients|Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients|Completed||Phase 2|21|Actual|Oncology Specialists, S.C.||1|||f||||t||||||||||2018-06-01 00:53:43.425744|2018-06-01 00:53:43.425744
NCT00919022|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2012-10-30|2009-06-10|2009-06-11|Estimate|||||||2012-10-30|2012-11-01|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|||||Observational|ANES||Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate|Prospective Observational Non-interventional Study of Correlation of Treatment With Androcur, Disease Stage, Testosterone Level, Age With Sexual Function and Erectile Dysfunction (Measured by IIEF-5 Validated Questionnaire)|Terminated|||194|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 00:53:43.925827|2018-06-01 00:53:43.925827
NCT00919009|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-05-29|2009-06-10|2009-06-11|Estimate|||||||2012-05-29|2012-05-30|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)|A Phase II Study of the Combination of TACE and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma in National Cancer Center Korea (COTSUN Korea Trial)|Completed||Phase 2|50|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 00:53:44.172168|2018-06-01 00:53:44.172168
NCT00918996|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2015-10-08|2009-06-09|2009-06-11|Estimate|||||||2015-10-08|2015-10-09|Estimate|March 2010||2010-03-31|October 2015|2015-10-31|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||The Bladder Flap at Cesarean Section: A Randomized Controlled Trial|The Bladder Flap at Cesarean Delivery: Establishing Evidence for Practice|Completed||N/A|258|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 00:53:44.43134|2018-06-01 00:53:44.43134
NCT00918983|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09||2014-04-01|2014-04-01|2009-06-10|2009-06-11|Estimate||||2014-04-01|2014-04-30|Estimate|2014-04-01|2014-04-30|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)|Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017|Completed||Phase 3|500|Actual|Nymox Corporation||2|||f||||f||||||||||2018-06-01 00:53:44.759631|2018-06-01 00:53:44.759631
NCT00918970|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-12|2009-06-09|2009-06-11|Estimate|||||||2009-06-12|2009-06-15|Estimate|August 2008||2008-08-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|MEANS||Interest of Real Time Measurement of Autonomous Nervous System for the Detection of Brain Death|Interest of Real Time Measurement of Autonomous Nervous System for the Detection of Brain Death: the MEANS Study|Terminated|||30|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2|Angioscanners in excess of the SNA group because of use of thiopental|f||||f||||||||||2018-06-01 00:53:45.043574|2018-06-01 00:53:45.043574
NCT00918957|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2012-05-05||2012-10-01|2009-06-10|2009-06-11|Estimate|2012-10-01|2012-10-03|Estimate||||2012-10-01|2012-10-03|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|EDIT||A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).|Completed||Phase 3|62|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:53:45.270122|2018-06-01 00:53:45.270122
NCT00918944|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2011-12-22|2009-06-09|2009-06-11|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Electronic Health Record (EHR) Decision Support to Improve Outpatient Asthma Care|EHR Decision Support to Improve Outpatient Asthma Care|Completed||N/A|12|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 00:53:47.044959|2018-06-01 00:53:47.044959
NCT00918931|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2011-03-30||2011-10-14|2009-06-10|2009-06-11|Estimate|2011-03-30|2011-04-25|Estimate||||2011-10-14|2011-11-04|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Obatoclax for Systemic Mastocytosis|Evaluation of Obatoclax Mesylate as Therapy for Patients With Systemic Mastocytosis|Terminated||Phase 2|3|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:53:47.251063|2018-06-01 00:53:47.251063
NCT00918918|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2009-11-23|2009-06-10|2009-06-11|Estimate|||||||2009-11-23|2009-11-25|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|AR23||Effect of Alcohol Consumption on Markers of Inflammation|The Effect of Moderate Alcohol Consumption on a Human in Vivo Model of Low-grade Systemic Inflammation in Young, Normal-weight Men|Completed||N/A|24|Actual|TNO||2|||f||||t||||||||||2018-06-01 00:53:48.069458|2018-06-01 00:53:48.069458
NCT00918905|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-10|2009-06-10|2009-06-11|Estimate|||||||2009-06-10|2009-06-11|Estimate|June 2007||2007-06-30|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Nurse Tele-Consultations With Discharged COPD Patients Reduce the Numbers of Readmissions|KOL-Fyn - an Explorative Study Wtih Telemedicine in COPD Patients at Home|Completed||N/A|100|Actual|Svendborg Hospital||2|||f||||f||||||||||2018-06-01 00:53:48.46178|2018-06-01 00:53:48.46178
NCT00918892|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2017-08-03|2009-06-09|2009-06-11|Estimate|||||||2017-08-03|2017-08-04|Actual|April 24, 2008|Actual|2008-04-24|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Assessment of Candidate Protein Expression in Breast Cancer Specimens|Assessment of Candidate Protein Expression in Human Breast Cancer Specimens|Recruiting|||80|Anticipated|Case Comprehensive Cancer Center|||||f||||f|f|f||||Samples With DNA|"~     Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal~     adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.~   "|||2018-06-01 00:53:48.679074|2018-06-01 00:53:48.679074
NCT00918879|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2011-06-28||2011-08-18|2009-06-10|2009-06-11|Estimate|2011-08-18|2011-09-26|Estimate||||2011-08-18|2011-09-26|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control|A 24-Week National, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase IIIb Study in India to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise|Completed||Phase 3|213|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:53:49.147841|2018-06-01 00:53:49.147841
NCT00918866|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2010-12-17||2015-03-30|2009-06-10|2009-06-11|Estimate|2011-06-13|2011-07-11|Estimate||||2015-03-30|2015-04-17|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure|A Phase IV, Open-Label Safety Evaluation of the Effect of DEFINITY® on Pulmonary Artery Hemodynamics in Patients With Normal and Increased Pulmonary Artery Pressure|Completed||Phase 4|32|Actual|Lantheus Medical Imaging||2|||f||||f||||||||||2018-06-01 00:53:51.073126|2018-06-01 00:53:51.073126
NCT00918853|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2015-03-19|2009-06-10|2009-06-11|Estimate|||||||2015-03-19|2015-03-20|Estimate|August 2008||2008-08-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|MRP||Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas|Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas.|Completed||N/A|156|Actual|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-06-01 00:53:52.080424|2018-06-01 00:53:52.080424
NCT00918840|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2013-02-07|2009-06-10|2009-06-11|Estimate|||||||2013-02-07|2013-02-08|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|PHPC-02||Antiretroviral-Sparing Concept With HIV-specific T Cell Precursors With High Proliferative Capacity (PHPC)|Antiretroviral-Sparing Concept: An Exploratory Phase II, Randomized, Single Blind Placebo-Controlled Study to Investigate the Effect of Therapeutic Immunization on the Quantity of HIV-Specific T Cell Precursors During Highly Active Antiretroviral Therapy Followed by Analytical Treatment Interruption|Completed|||16|Actual|Genetic Immunity|||2||f||||t||||||Samples With DNA|"~     peripheral blood mononuclear cells (PBMC) and plasma~   "|||2018-06-01 00:53:52.242394|2018-06-01 00:53:52.242394
NCT00918827|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2017-06-01|2009-06-09|2009-06-11|Estimate|||||||2017-06-01|2017-06-02|Actual|April 1, 2009||2009-04-01|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy|Study of Biomarkers in Tissue Samples of Patients With Stage III Colon Cancer Treated With Adjuvant Chemotherapy Comprising Fluorouracil-Based Regimens(B-CAST)|Completed|||2128|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||f||||||||||2018-06-01 00:53:52.430576|2018-06-01 00:53:52.430576
NCT00918814|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10||2015-02-17|2015-02-17|2009-06-10|2009-06-11|Estimate||||2015-02-17|2015-03-06|Estimate|2015-02-17|2015-03-06|Estimate|June 2009||2009-06-30|February 2015|2015-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Dose Ranging and Dose Frequency of LIPO-102|A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue|Completed||Phase 2|54|Actual|Neothetics, Inc||2|||f||||f||||||||||2018-06-01 00:53:52.531695|2018-06-01 00:53:52.531695
NCT00918801|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-11-09|2009-06-09|2009-06-11|Estimate|||||||2016-11-09|2016-11-10|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|December 2013|Actual|2013-12-31||Observational|ASSET||Pilot Study of Hippocampal Function in Type 1 Diabetes Mellitus (T1DM)|Pilot Study of Hippocampal Function in T1DM|Completed|||91|Actual|Washington University School of Medicine|||2||f||||f||||||||No|This was a small pilot study and consent was not obtained to share data.|2018-06-01 00:53:52.659675|2018-06-01 00:53:52.659675
NCT00918788|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2013-08-20|2009-06-10|2009-06-11|Estimate|||||||2013-08-20|2013-08-22|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Laser Spectroscopy of Breast Tissue Through a Needle Device|Laser Spectroscopy of Breast Tissue Through a Needle Device|Completed|||17|Actual|Case Comprehensive Cancer Center|||||f||||f||||||Samples With DNA|"~     This laboratory study is looking at samples of breast tissue from women who have undergone~     breast biopsy or surgery.~   "|||2018-06-01 00:53:52.755447|2018-06-01 00:53:52.755447
NCT00918775|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2018-03-27|2009-06-10|2009-06-11|Estimate|||||||2018-03-27|2018-03-29|Actual|June 9, 2009|Actual|2009-06-09|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||Metastasectomy Study in Renal Cell Carcinoma (RCC)|A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma.|Recruiting|||120|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 00:53:53.083378|2018-06-01 00:53:53.083378
NCT00918762|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-05-07|2009-06-09|2009-06-11|Estimate|||||||2014-05-07|2014-05-09|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Interventional|||Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx|A Pilot Study Assessing the Use of DA VINCI® Robotic Surgical System in Laryngeal and Pharyngeal Surgeries|Completed||Phase 1|6|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 00:53:53.210877|2018-06-01 00:53:53.210877
NCT00918749|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2011-02-23||2015-06-01|2009-06-10|2009-06-11|Estimate|2011-02-23|2011-03-24|Estimate||||2015-06-01|2015-06-29|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women|Study Assessing the Efficacy, Safety, and Pharmacokinetics of 75 and 100 mg Once-a-month Delayed-release Risedronate Formulations Compared to 150 mg Once-a-month Immediate-release Risedronate for 3 Months in Postmenopausal Women Age 45-80|Completed||Phase 2|205|Actual|Warner Chilcott||3|||f||||f||||||||||2018-06-01 00:53:53.418513|2018-06-01 00:53:53.418513
NCT00918073|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2013-05-06|2009-06-10|2009-06-11|Estimate|||||||2013-05-06|2013-05-07|Estimate|November 2007||2007-11-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Patients|Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Infected Patients|Completed|||50|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-06-01 00:54:09.02547|2018-06-01 00:54:09.02547
NCT00918736|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2009-03-16||2009-06-11|2009-04-24|2009-06-11|Estimate|2009-04-24|2009-06-11|Estimate||||2009-06-11|2009-06-17|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy of 3 Weekly Injections of Hyaluronate in Patients With Ankle Osteoarthritis|Hyaluronans in the Treatment of Ankle Osteoarthritis|Completed||Phase 2|46|Actual|Kaohsiung Veterans General Hospital.|One limitation includes the absence of a control group, thus the placebo effects associated with joint injections were not investigated.|1|||f||||t||||||||||2018-06-01 00:53:54.515627|2018-06-01 00:53:54.515627
NCT00918723|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2017-10-31||2018-01-12|2009-06-09|2009-06-11|Estimate|2018-01-12|2018-02-08|Actual||||2018-01-12|2018-02-08|Actual|June 2009|Actual|2009-06-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2016|Actual|2016-10-31||Interventional|||Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I/II Study of Fludarabine, Cyclophosphamide, Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Active, not recruiting||Phase 1/Phase 2|40|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 00:53:54.819861|2018-06-01 00:53:54.819861
NCT00918710|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2017-04-13|2009-06-09|2009-06-11|Estimate|||||||2017-04-13|2017-04-14|Actual|May 2009|Actual|2009-05-31|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|April 2014|Actual|2014-04-30||Observational|Papillophar||Human Papillomavirus and Oropharynx Carcinoma|Impact of the Human Papillomavirus (HPV) Status in Carcinologic Prognosis of Oropharynx Squamous Cell Carcinoma.|Active, not recruiting|||362|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Pieces of Oropharyngeal squamous cell carcinomas biopsies~   "|||2018-06-01 00:53:58.185188|2018-06-01 00:53:58.185188
NCT00918697|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-10-12|2009-06-10|2009-06-11|Estimate|||||||2010-10-12|2010-10-13|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|||||Interventional|||Mechanical Versus Alcohol Epithelial Debridement During Hotorefractive Keratectomy (PRK)|Mechanical Versus Alcohol-Assisted Epithelial Debridement During Photorefractive Keratectomy: A Confocal Microscopic Clinical Trial|Completed||Phase 2|33|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 00:53:58.465948|2018-06-01 00:53:58.465948
NCT00918684|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2017-02-17||2017-04-04|2009-06-10|2009-06-11|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|December 2002|Actual|2002-12-31|April 2017|2017-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|FA|All subjects who entered the treatment phase|Aging Brain Changes, Executive Dysfunction and Depression|Aging White Matter Changes, Executive Dysfunction and Depression|Completed||Phase 4|116|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||Undecided||2018-06-01 00:53:58.903415|2018-06-01 00:53:58.903415
NCT00918671|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2010-06-03||2016-09-14|2009-06-10|2009-06-11|Estimate|2010-11-30|2010-12-30|Estimate||||2016-09-14|2016-11-03|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|MOHfollowup||Medication-overuse Headache: 4 Years Follow up|Treatment of Medication-overuse Headache: 4 Years Follow up|Completed|||60|Actual|Norwegian University of Science and Technology|||1||f||||t||||||||||2018-06-01 00:53:59.399608|2018-06-01 00:53:59.399608
NCT00918658|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2015-10-08|2009-06-10|2009-06-11|Estimate|||||||2015-10-08|2015-10-09|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer|Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity|Terminated|||34|Actual|Case Comprehensive Cancer Center|||2|PI closed lab|f||||f||||||Samples With DNA|"~     To collect normal and malignant cells in bone marrow and peripheral blood samples from~     patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous~     leukemia, or multiple myeloma and from patients with no malignancy to use as target cells in~     cytotoxicity assays.~   "|||2018-06-01 00:53:59.60069|2018-06-01 00:53:59.60069
NCT00918645|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2017-01-10||2017-12-01|2009-06-10|2009-06-11|Estimate|2017-12-01|2017-12-22|Actual||||2017-12-01|2017-12-22|Actual|September 2009||2009-09-30|December 2017|2017-12-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|UCDCC#217||Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis|Measurement of Ca Kinetics in Humans With Prostate Cancer-induced Bone Disease|Terminated||N/A|13|Actual|University of California, Davis|This trial was IRB closed after accruing only 13 patients of a potential 30 due to contract period expiring. This termination prior to accrual goal achievement led to small numbers of subjects analyzed with no statistical analysis done.|1|||f||||t||||||||||2018-06-01 00:53:59.854522|2018-06-01 00:53:59.854522
NCT00918632|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-08-01|2009-06-09|2009-06-11|Estimate|||||||2009-08-01|2009-08-04|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Food Effect Study Of AG-013736 In Healthy Volunteers|A Phase I Open-Label Study In Healthy Volunteers To Compare The Plasma Pharmacokinetics of Polymorph Form XLI AG-013736 In The Fasted And Fed State|Completed||Phase 1|30|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 00:54:00.111496|2018-06-01 00:54:00.111496
NCT00918619|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2015-05-27|2009-06-09|2009-06-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|ESSCALIVER||Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection|Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-bound Fibrin Sealant During Liver Resection (ESSCALIVER)|Completed||Phase 4|128|Actual|Aesculap AG||2|||f||||f||||||||||2018-06-01 00:54:00.226062|2018-06-01 00:54:00.226062
NCT00918606|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2015-03-19|2009-06-10|2009-06-11|Estimate|||||||2015-03-19|2015-03-24|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers||Completed||Phase 1|30|Actual|Neothetics, Inc||1|||f||||||||||||||2018-06-01 00:54:00.382487|2018-06-01 00:54:00.382487
NCT00918593|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2011-09-26|2009-06-10|2009-06-11|Estimate|||||||2011-09-26|2011-09-27|Estimate|December 2009||2009-12-31|September 2011|2011-09-30|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|||Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy|Palliative Treatment of Ulcerated Cutaneous Metastases: Randomised Trial Between Electrochemotherapy and Radiotherapy|Withdrawn||Phase 2|98|Anticipated|Copenhagen University Hospital at Herlev||2||No recruitment of patients|f||||t||||||||||2018-06-01 00:54:00.484332|2018-06-01 00:54:00.484332
NCT00918255|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2011-03-02||2011-04-14|2009-06-10|2009-06-11|Estimate|2011-04-14|2011-05-09|Estimate||||2011-04-14|2011-05-09|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Interventional|||Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa|A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa|Completed||Phase 2|154|Actual|Abbott||3|||f||||f||||||||||2018-06-01 00:54:05.873822|2018-06-01 00:54:05.873822
NCT00918580|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2014-03-17||2014-03-17|2009-06-09|2009-06-11|Estimate|2014-03-17|2014-04-21|Estimate||||2014-03-17|2014-04-21|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All-available immunogenicity (AAI) population included all participants who had at least 1 valid and determinate pneumococcal assay result for the planned analysis.|Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease|A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine|Completed||Phase 3|158|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 00:54:00.71353|2018-06-01 00:54:00.71353
NCT00918567|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-10|2009-06-10|2009-06-11|Estimate|||||||2009-06-10|2009-06-11|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Strattera and Behavior Therapy on the School and Home Functioning of Elementary School Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|Effects of Strattera and Behavior Therapy on the School and Home Functioning of Elementary School Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|56|Actual|State University of New York at Buffalo||2|||f||||f||||||||||2018-06-01 00:54:02.221987|2018-06-01 00:54:02.221987
NCT00918554|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-05-30|2009-06-10|2009-06-11|Estimate|||||||2014-05-30|2014-06-02|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|UVEXATE||Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis|Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE|Terminated||Phase 4|7|Actual|Assistance Publique - Hôpitaux de Paris||2||insufficient number of inclusion|f||||f||||||||||2018-06-01 00:54:02.301766|2018-06-01 00:54:02.301766
NCT00918541|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2011-12-22|2009-06-10|2009-06-11|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Natural History of Atherosclerosis|Natural 1-year History of Atherosclerosis in Asymptomatic Patients With Mild to Moderate Carotid Stenosis|Completed|||30|Actual|University of Zurich|||1||f||||f||||||||||2018-06-01 00:54:02.369944|2018-06-01 00:54:02.369944
NCT00918528|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-10|2009-06-10|2009-06-11|Estimate|||||||2009-06-10|2009-06-11|Estimate|June 2009||2009-06-30|June 2009|2009-06-30||||||||Interventional|||Effect of Mitomycin C on Urethral Stricture Recurrence After Internal Urethrotomy||Unknown status|Not yet recruiting|Phase 1/Phase 2|||Hillel Yaffe Medical Center||2|||f||||||||||||||2018-06-01 00:54:02.431542|2018-06-01 00:54:02.431542
NCT00918515|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-08-27|2009-06-09|2009-06-11|Estimate|||||||2009-08-27|2009-08-28|Estimate|May 2009||2009-05-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|||||Interventional|||Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD3043|A Phase I, Single-Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 After Single Ascending Doses in Healthy Male Volunteers|Completed||Phase 1|53|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:54:02.593394|2018-06-01 00:54:02.593394
NCT00918502|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-02-02|2009-06-10|2009-06-11|Estimate|||||||2010-02-02|2010-02-04|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|ARMADA||Monitor Patients With Sleep Apnea|Adherent Respiratory Monitoring for Apnea Detection and Evaluation Study|Completed|||30|Anticipated|Corventis, Inc.|||||f||||f||||||||||2018-06-01 00:54:02.659935|2018-06-01 00:54:02.659935
NCT00918489|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2014-12-03|2009-06-10|2009-06-11|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|SAHA-I||Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)|A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma|Completed||Phase 2|40|Actual|Heidelberg University||1|||f||||t||||||||||2018-06-01 00:54:02.715281|2018-06-01 00:54:02.715281
NCT00918476|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2011-04-18|2009-06-10|2009-06-11|Estimate|||||||2011-04-18|2011-04-19|Estimate|June 2010||2010-06-30|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)|A Phase 1, Open Label Fixed Sequence Study To Investigate The Effects Of Multiple Oral Doses Of Filibuvir On The Steady State Pharmacokinetics Of Oral Contraceptive Steroids In Healthy Female Subjects|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:54:02.800218|2018-06-01 00:54:02.800218
NCT00918463|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2017-02-07|2009-06-09|2009-06-11|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2009|Actual|2009-06-30|February 2017|2017-02-28|May 23, 2011|Actual|2011-05-23|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase II, Single-Institution, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of a Single Agent Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Completed||Phase 2|2|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 00:54:02.912044|2018-06-01 00:54:02.912044
NCT00918450|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2010-02-25|2009-06-10|2009-06-11|Estimate|||||||2010-02-25|2010-02-26|Estimate|March 2010||2010-03-31|February 2010|2010-02-28||||December 2012|Anticipated|2012-12-31||Interventional|||Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen|A Phase 2b Monotherapy Study of ABT-263 in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|Withdrawn||Phase 2|150|Anticipated|Abbott||1||Sponsor has decided to not proceed with this study.|f||||||||||||||2018-06-01 00:54:02.975379|2018-06-01 00:54:02.975379
NCT00918437|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2011-07-03|2009-06-10|2009-06-11|Estimate|||||||2011-07-03|2011-07-06|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Observational|||Postoperative Pain Course After Uvulopalatoplasty|Characterization of the Postoperative Pain Course and Intensity After Uvulopalatoplasty With Radiofrequency Knife (RAUP)|Completed|||33|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-06-01 00:54:03.038131|2018-06-01 00:54:03.038131
NCT00918424|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2017-05-04|2009-06-10|2009-06-11|Estimate|||||||2017-05-04|2017-05-09|Actual|June 2009||2009-06-30|May 2017|2017-05-31||||||||Expanded Access|||Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects|Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy|Approved for marketing|||||Supernus Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 00:54:03.100447|2018-06-01 00:54:03.100447
NCT00918242|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2012-07-20|2009-06-10|2009-06-11|Estimate|||||||2012-07-20|2012-07-23|Estimate|June 2009||2009-06-30|July 2012|2012-07-31||||September 2012|Anticipated|2012-09-30||Observational|||Prevalence of Coronary Artery Disease in the Siblings of Premature Coronary Heart Disease|Assessment of Occult CAD: Premature CAD Sibling Study (PreCASS)|Unknown status|Recruiting||87|Anticipated|Yonsei University|||||f||||t||||||||||2018-06-01 00:54:06.413519|2018-06-01 00:54:06.413519
NCT00918411|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2015-10-09|2009-06-10|2009-06-11|Estimate|||||||2015-10-09|2015-10-12|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome|Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - A Preliminary Study to Evaluate the Co-primary Endpoint in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome|Completed||Phase 4|98|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:54:03.164136|2018-06-01 00:54:03.164136
NCT00918398|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2009-07-29|2009-06-10|2009-06-11|Estimate|||||||2009-07-29|2009-07-30|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|||||Interventional|||AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations|An Open, Single-dose, Phase I, 4-period Partly Crossover Study in Healthy Men or Women to Assess Relative Bioavailability of Oral Administration of AZD1981 Via Tablets Compared With Suspension and Basic Systemic Pharmacokinetic Parameters After Intravenous Administration|Completed||Phase 1|14|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:54:03.268172|2018-06-01 00:54:03.268172
NCT00918385|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2014-09-11||2014-10-28|2009-06-10|2009-06-11|Estimate|2014-10-28|2014-10-29|Estimate||||2014-10-28|2014-10-29|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|February 2012|Actual|2012-02-29||Interventional|ARS|64 consented but 7 screen failures, so 57 enrolled. 2 never assigned to rx (withdrew consent, clinically unstable), 33 assigned by AR activity (15 high AR to nilutamide, 18 low AR to dasatinib) and 22 QC technical failures (received dasatinib). 14 of 15 high AR and 17 of 18 low AR began protocol treatment. Analyses include the 31 treated patients.|Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer|A Phase II Trial of Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer|Terminated||Phase 2|57|Actual|Duke University||2||Permanent closure of trial to further accrual based on IDE disapproval|f||||t||||||||||2018-06-01 00:54:03.358317|2018-06-01 00:54:03.358317
NCT00918372|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2010-09-10|2009-06-10|2009-06-11|Estimate|||||||2010-09-10|2010-09-13|Estimate|May 2009||2009-05-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Coronary Artery Disease (CAD) in Women Marathon Runners|Coronary Atherosclerosis in Women Athletes: Asymptomatic Twin Cities Marathon Women Studied by MSCT Angiography|Completed|||50|Actual|Minneapolis Heart Institute Foundation|||2||f||||f||||||||||2018-06-01 00:54:04.123512|2018-06-01 00:54:04.123512
NCT00918359|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2011-06-28|2009-06-10|2009-06-11|Estimate|||||||2011-06-28|2011-06-29|Estimate|May 2009||2009-05-31|June 2011|2011-06-30||||||||Observational|||Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes|Following Study: Heat Intolerance- A Lesson From Global Genomic Response in Lymphocytes|Unknown status|Recruiting||50|Anticipated|Medical Corps, Israel Defense Force|||2||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:54:04.206714|2018-06-01 00:54:04.206714
NCT00918346|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2009-08-04||2010-12-10|2009-06-10|2009-06-11|Estimate|2009-08-04|2009-09-15|Estimate||||2010-12-10|2010-12-28|Estimate|September 2005||2005-09-30|December 2010|2010-12-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation|Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation in Patients With Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 3|43|Actual|Santen Oy||2|||f||||f||||||||||2018-06-01 00:54:04.278456|2018-06-01 00:54:04.278456
NCT00918333|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2018-04-19||2018-04-19|2009-06-09|2009-06-11|Estimate|2018-04-19|2018-05-18|Actual||||2018-04-19|2018-05-18|Actual|June 2009||2009-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 1, 2015|Actual|2015-12-01||Interventional|||Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma|A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma|Active, not recruiting||Phase 1/Phase 2|124|Actual|Mayo Clinic||1|||f||||||||||||||2018-06-01 00:54:04.748651|2018-06-01 00:54:04.748651
NCT00918320|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-01-25|2009-06-10|2009-06-11|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|October 2013|Actual|2013-10-31||Interventional|TOTEM2||Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours|Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours|Completed||Phase 2|129|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||t||||||||||2018-06-01 00:54:05.344419|2018-06-01 00:54:05.344419
NCT00918307|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-07-28|2009-06-09|2009-06-11|Estimate|||||||2014-07-28|2014-07-29|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|Inter-ACTIV||Efficacy and Safety of Varenicline Among HIV-infected Patients|Comparison of the Efficacy and Safety of Varenicline Versus Placebo for Smoking Cessation Among HIV-infected Patients. A Randomized Double Blind Controlled Trial|Completed||Phase 3|248|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 00:54:05.425694|2018-06-01 00:54:05.425694
NCT00918294|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2011-02-22|2009-06-09|2009-06-11|Estimate|||||||2011-02-22|2011-02-23|Estimate|September 2007||2007-09-30|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|QuickOpt||QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization|QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization|Completed||N/A|100|Anticipated|St. Jude Medical||1|||f||||f||||||||||2018-06-01 00:54:05.508993|2018-06-01 00:54:05.508993
NCT00918281|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2013-10-23||2014-06-06|2009-06-10|2009-06-11|Estimate|2014-06-06|2014-06-09|Estimate||||2014-06-06|2014-06-09|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional||70 Subjects enrolled. A total of 49 subjects received a least one dose of Fluciclatide administration.|Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection|A Test-retest Study to Assess Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of AH111585 (18F) Injection.|Completed||Phase 2|70|Actual|GE Healthcare||1|||f||||t||||||||||2018-06-01 00:54:05.587605|2018-06-01 00:54:05.587605
NCT00918268|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2012-04-20|2009-06-10|2009-06-11|Estimate|||||||2012-04-20|2012-04-23|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, When Administered to Non-elderly Adult and Elderly Subjects|Completed||Phase 2|130|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:54:05.787981|2018-06-01 00:54:05.787981
NCT00918229|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2018-02-01|2009-06-09|2009-06-11|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2009||2009-06-30|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects|One-arm, Multi-center, International Prospective Study to Assess the Safety and Efficacy of BioProtect Biodegradable Implantable Balloon in Prostate Cancer Subjects Undergoing Radiotherapy|Completed||N/A|5|Actual|BioProtect||1|||f||||f||||||||||2018-06-01 00:54:06.472221|2018-06-01 00:54:06.472221
NCT00918216|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2014-07-14|2009-06-10|2009-06-11|Estimate|||||||2014-07-14|2014-07-16|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Spectroscopy of Breast Tissue|Spectroscopy of Breast Tissue|Completed|||141|Actual|Case Comprehensive Cancer Center|||||f||||f||||||Samples With DNA|"~     This study will involve up to 200 female patients already undergoing needle biopsy or~     surgical excision of a breast lesion identified clinically.~   "|||2018-06-01 00:54:06.625473|2018-06-01 00:54:06.625473
NCT00918203|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2016-11-18|2014-04-25|2017-07-12|2009-06-10|2009-06-11|Estimate|2016-11-18|2017-01-16|Estimate|2014-04-25|2014-05-13|Estimate|2017-07-12|2017-08-11|Actual|January 2010||2010-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|August 2013|Actual|2013-08-31||Interventional||All phase 2 participants who were randomized and received any dose of study drug.|A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) With Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in Previously Untreated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|137|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 00:54:06.712607|2018-06-01 00:54:06.712607
NCT00918190|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2011-01-06|2009-06-10|2009-06-11|Estimate|||||||2011-01-06|2011-01-07|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Late Onset Postoperative Nausea and Vomiting|Late Onset Postoperative Nausea and Vomiting Following Strabismus Surgery in Pediatric.What Combination is Better|Completed||N/A|75|Anticipated|King Khaled Eye Specialist Hospital||3|||f||||t||||||||||2018-06-01 00:54:07.720177|2018-06-01 00:54:07.720177
NCT00918177|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2014-05-25|2009-06-09|2009-06-11|Estimate|||||||2014-05-25|2014-05-28|Estimate|July 2009||2009-07-31|February 2010|2010-02-28||||October 2012|Actual|2012-10-31||Interventional|||An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease|Dual Release Gastric Retentive AP09004, Vs. Active Control; a Pharmacokinetic/Pharmacodynamic, Comparative, Safety Evaluation in Parkinson's Patients|Completed||Phase 2|72|Anticipated|Intec Pharma Ltd.||2|||f||||t||||||||||2018-06-01 00:54:07.812836|2018-06-01 00:54:07.812836
NCT00918164|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-07-09|2009-06-09|2009-06-11|Estimate|||||||2009-07-09|2009-07-10|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects|A Randomized, Open-Label, Single Dose, Crossover Study To Evaluate The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And To Assess Food Effect In Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:54:07.895936|2018-06-01 00:54:07.895936
NCT00918151|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-08-12|2009-06-09|2009-06-11|Estimate|||||||2014-08-12|2014-08-13|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Korea|DiabCare Asia 2008 (Korea): A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia|Completed|||1932|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Capillary or venous blood will be drawn for analysing HbA1c~   "|||2018-06-01 00:54:07.963757|2018-06-01 00:54:07.963757
NCT00918138|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2011-09-02||2015-05-04|2009-06-10|2009-06-11|Estimate|2011-09-02|2011-10-06|Estimate||||2015-05-04|2015-05-21|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg|A 4-Week, Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy of Saxagliptin in Combination With Metformin XR 1500 mg Versus Up-titrated Metformin XR to 2000 mg in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise and a Stable Dose of Metformin XR 1500 mg|Completed||Phase 3|219|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:54:08.063535|2018-06-01 00:54:08.063535
NCT00918125|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|2013-01-22||2015-10-15|2009-06-10|2009-06-11|Estimate|2013-04-03|2013-04-05|Estimate||||2015-10-15|2015-10-19|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|VIVID-01||Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use|The Use of Educational Videos to Improve Patient Decision Making and Racial Disparities in the Implantation of Implantable Cardioverter Defibrillators (ICDs)|Completed|||59|Actual|Duke University|Study terminated early and thus only 59 out of the proposed 90 patients were enrolled.||3||f||||f||||||||||2018-06-01 00:54:08.596324|2018-06-01 00:54:08.596324
NCT00918112|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-11-09|2009-06-09|2009-06-11|Estimate|||||||2016-11-09|2016-11-10|Estimate|September 2004||2004-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2009|Actual|2009-09-30||Observational|MedTask||Development of a Face Valid Executive Functioning Task|Development of a Face Valid Executive Functioning Task|Completed|||20|Actual|Washington University School of Medicine|||2||f||||f||||||||No|This was a small pilot study and consent was not obtained to share data.|2018-06-01 00:54:08.792679|2018-06-01 00:54:08.792679
NCT00918099|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-10|2009-06-10|2009-06-11|Estimate|||||||2009-06-10|2009-06-11|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||The Use of Avaulta for Anterior Repair|The Use of Avaulta for Anterior Repair. A Multicenter Randomised Prospective Controlled Study|Unknown status|Recruiting|N/A|130|Anticipated|Zealand University Hospital||2|||f||||t||||||||||2018-06-01 00:54:08.868999|2018-06-01 00:54:08.868999
NCT00918086|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2014-07-10|2009-06-10|2009-06-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|September 2012|Actual|2012-09-30||Interventional|||Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment|Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment: Building Translational Research Capacity in Nutrition and Infectious Diseases in the Republic of Georgia|Completed||Phase 2|199|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:54:08.953026|2018-06-01 00:54:08.953026
NCT00918060|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2010-10-09|2009-06-10|2009-06-11|Estimate|||||||2010-10-09|2010-10-13|Estimate|February 2008||2008-02-29|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Clinical Effects of Locally-delivered Gel Containing Camella Sinensis Extracts as an Adjunct in Peridontitis Treatment|Clinical Effects of Locally-delivered Gel Containing Camella Sinensis Extracts|Unknown status|Active, not recruiting|Phase 2|48|Anticipated|Mahidol University||2|||f||||t||||||||||2018-06-01 00:54:09.080796|2018-06-01 00:54:09.080796
NCT00918047|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2017-06-29|2009-06-10|2009-06-11|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2009||2009-06-30|June 2017|2017-06-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients|Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy|Completed||Phase 1|18|Actual|Supernus Pharmaceuticals, Inc.||4|||f||||f||||||||No||2018-06-01 00:54:09.233083|2018-06-01 00:54:09.233083
NCT00918034|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2012-11-14|2009-06-10|2009-06-11|Estimate|||||||2012-11-14|2012-11-16|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|A Phase 2 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy|Completed||Phase 2|21|Actual|Light Sciences Oncology||1|||f||||f||||||||||2018-06-01 00:54:09.313369|2018-06-01 00:54:09.313369
NCT00918021|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2010-11-18|2009-06-10|2009-06-11|Estimate|||||||2010-11-18|2010-11-19|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CLOZANS||Polypharmacy in Clozapine-resistant Schizophrenia|Olanzapine Augmentation in Clozapine-resistant Schizophrenia: a Randomized Double-blind Study|Completed||Phase 4|30|Actual|Niuvanniemi Hospital||2|||f||||f||||||||||2018-06-01 00:54:09.398232|2018-06-01 00:54:09.398232
NCT00918008|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2015-03-04|2009-06-10|2009-06-11|Estimate|||||||2015-03-04|2015-03-06|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer|A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer|Terminated|||12|Actual|Memorial Sloan Kettering Cancer Center|||1|Lack of accrual|f||||||||||Samples With DNA|"~     single blood sample~   "|||2018-06-01 00:54:09.473741|2018-06-01 00:54:09.473741
NCT00917995|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2015-10-14|2009-06-10|2009-06-11|Estimate|||||||2015-10-14|2015-10-16|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|STOMAMESH||Trial Concerning the Frequency of Parastomal Hernia With or Without a Mesh|STOMAMESH Prospective Randomised Multicenter Trial Concerning the Frequency of Parastomal Hernia With or Without a Mesh|Completed||Phase 2/Phase 3|241|Actual|Norrbottens Lans Landsting||2|||f||||f||||||||||2018-06-01 00:54:09.5714|2018-06-01 00:54:09.5714
NCT00917982|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2009-06-10|2009-06-10|2009-06-11|Estimate|||||||2009-06-10|2009-06-11|Estimate||||June 2009|2009-06-30||||||||Interventional|||The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients|The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7|Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||1|||f||||||||||||||2018-06-01 00:54:09.679326|2018-06-01 00:54:09.679326
NCT00917956|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-02-25|2009-06-10|2009-06-11|Estimate|||||||2010-02-25|2010-02-26|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|Li-IBM||Lithium in Inclusion Body Myositis (IBM)|A Pilot Trial of Lithium in Inclusion Body Myositis (IBM)|Completed|||20|Anticipated|Phoenix Neurological Associates, LTD|||||f||||t||||||Samples Without DNA|"~     Muscle Biopsies will be taken at baseline and at the end of 6 months. Tissue will be frozen~     then sent out for anaylsis.~   "|||2018-06-01 00:54:09.757879|2018-06-01 00:54:09.757879
NCT00917943|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-10|||2013-04-09|2009-06-10|2009-06-11|Estimate|||||||2013-04-09|2013-04-10|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Quit for Two||Preventing Postpartum Return to Smoking|Smoking Resumption-Prevention is Postpartum Women|Completed||N/A|386|Actual|Duke University||2|||f||||f||||||||||2018-06-01 00:54:09.818328|2018-06-01 00:54:09.818328
NCT00917930|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-10|2009-06-10|2009-06-11|Estimate|||||||2009-06-10|2009-06-11|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|January 2007|Actual|2007-01-31|||||Observational|||Evaluation Rehabilitation on Glycometabolic State in Non-Diabetic Coronary Artery Disease (CAD) Patients|Effect of Cardiac Rehabilitation on Glucometabolic State in Non-Diabetic Patients With Chronic Ischemic Heart Disease|Completed|||||IRCCS San Raffaele|||1||f||||f||||||||||2018-06-01 00:54:09.887737|2018-06-01 00:54:09.887737
NCT00917917|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-07-04|2009-06-10|2009-06-11|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Physical Activity and Diet on the Treatment of Metabolic Syndrome|Role of Combined Intervention of Physical Activity and Nutrition in Metabolic Syndrome Treatment on Cardio-vascular Risk and Muscular- Skeletal Functions in Human Subject. Analysis of Patient's Compliance in Patient's Follow-up.|Completed||N/A|150|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:54:09.943685|2018-06-01 00:54:09.943685
NCT00917904|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2011-12-13|2009-06-08|2009-06-10|Estimate|||||||2011-12-13|2011-12-14|Estimate|July 2009||2009-07-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||An Expanded Safety Study of Dapivirine Gel 4789 in Africa|A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4789, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.|Completed||Phase 1/Phase 2|100|Actual|International Partnership for Microbicides, Inc.||2|||f||||t||||||||||2018-06-01 00:54:10.027336|2018-06-01 00:54:10.027336
NCT00917891|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2011-09-09|2009-06-08|2009-06-10|Estimate|||||||2011-09-09|2011-09-12|Estimate|November 2009||2009-11-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||An Expanded Safety Study of Dapivirine Gel 4759 in Africa|A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4759, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.|Completed||Phase 1/Phase 2|280|Actual|International Partnership for Microbicides, Inc.||2|||f||||t||||||||||2018-06-01 00:54:10.102538|2018-06-01 00:54:10.102538
NCT00917878|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2018-04-25|2009-06-08|2009-06-10|Estimate|||||||2018-04-25|2018-04-27|Actual|March 2009||2009-03-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Postprandial Effects of Milk and Milk Constituents|The Effects of Milk and Milk Constituents on Postprandial Inflammation in Overweight Subjects|Completed||N/A|16|Actual|Maastricht University Medical Center||4|||f||||||||||||||2018-06-01 00:54:10.177177|2018-06-01 00:54:10.177177
NCT00917865|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2013-05-08||2013-11-18|2009-06-09|2009-06-10|Estimate|2013-11-18|2014-01-07|Estimate||||2013-11-18|2014-01-07|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|January 2013|Actual|2013-01-31|April 2011|Actual|2011-04-30||Interventional|||FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer|Anti-[18F]FACBC PET-CT for the Characterization of Primary Prostate Cancer|Terminated||Phase 2|11|Actual|Emory University|A major limitation of our study is lack of step section whole mount histology at our institution which restricted the ability to ensure an exact correlation of histology to imaging.|1||"Optimal histolgic verification support such as whole mount analysis could not be made~   available."|f||||t||||||||||2018-06-01 00:54:10.27246|2018-06-01 00:54:10.27246
NCT00917852|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2012-04-04||2017-07-26|2009-06-08|2009-06-10|Estimate|2012-04-04|2012-05-01|Estimate||||2017-07-26|2017-08-25|Actual|November 2009||2009-11-30|July 2017|2017-07-31|February 28, 2017|Actual|2017-02-28|February 2011|Actual|2011-02-28||Interventional|||Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection|Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Traumatic Transection of the Descending Thoracic Aorta|Completed||N/A|51|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-06-01 00:54:10.471968|2018-06-01 00:54:10.471968
NCT00917839|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis|Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis.|Unknown status|Recruiting|Phase 2|88|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||t||||||||||2018-06-01 00:54:11.02187|2018-06-01 00:54:11.02187
NCT00917826|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08||2011-07-28|2011-07-28|2009-06-09|2009-06-10|Estimate||||2011-07-28|2011-08-01|Estimate|2011-07-28|2011-08-01|Estimate|September 2008||2008-09-30|July 2011|2011-07-31||||September 2009|Actual|2009-09-30||Interventional|||Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies|A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies|Terminated||Phase 2|1|Actual|HemaQuest Pharmaceuticals Inc.||1|||f||||f||||||||||2018-06-01 00:54:11.12584|2018-06-01 00:54:11.12584
NCT00917813|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-11-16|2009-06-09|2009-06-10|Estimate|||||||2012-11-16|2012-11-19|Estimate|September 2007||2007-09-30|November 2012|2012-11-30||||||||Interventional|||A Study of Anti-HIV Monoclonal Antibody KD-247|A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy|Completed||Phase 1|27|Anticipated|The Chemo-Sero-Therapeutic Research Institute||2|||||||t||||||||||2018-06-01 00:54:11.200207|2018-06-01 00:54:11.200207
NCT00917800|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2013-06-11|2009-06-08|2009-06-10|Estimate|||||||2013-06-11|2013-06-12|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Comparison of the HyperQ Versus Conventional Electrocardiogram (ECG) to Detect Ischemia|Diagnostic Benefits of HyperQ™ vs. Conventional ECG During Stress Test. A Comparison Study in Patients Referred for Angiography|Unknown status|Active, not recruiting||200|Anticipated|West German Heart Center Essen|||1||f||||f||||||||||2018-06-01 00:54:11.351817|2018-06-01 00:54:11.351817
NCT00917787|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2011-09-20|2009-06-09|2009-06-10|Estimate|||||||2011-09-20|2011-09-21|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|ABBA||Analysis of Blood-based Biomarkers of Asthma|Analysis of Blood-based Biomarkers of Asthma|Completed|||127|Actual|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     sputum, saliva, DNA, RNA, Plasma, serum~   "|||2018-06-01 00:54:11.416609|2018-06-01 00:54:11.416609
NCT00917774|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-11|2009-06-09|2009-06-10|Estimate|||||||2009-06-11|2009-06-12|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|January 2007|Actual|2007-01-31||Interventional|||A Gender-Specific Posterior Cruciate-Substituting High-Flexion Knee Prosthesis Does Not Improve Fit and Function|A Gender-Specific Posterior Cruciate-Substituting High-Flexion Knee Prosthesis Does Not Improve Fit and Function Compared With a Standard Posterior Cruciate-Substituting High-Flexion Knee Prostheis A Prospective, Randomized Study|Completed||Phase 4|88|Actual|Ewha Womans University||2|||f||||t||||||||||2018-06-01 00:54:11.496675|2018-06-01 00:54:11.496675
NCT00917761|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-12-19|2009-06-09|2009-06-10|Estimate|||||||2012-12-19|2012-12-20|Estimate|February 2007||2007-02-28|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B|Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Negative Chronic Hepatitis B|Unknown status|Recruiting|Phase 4|300|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-06-01 00:54:11.579686|2018-06-01 00:54:11.579686
NCT00917748|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-09-25|2009-06-09|2009-06-10|Estimate|||||||2012-09-25|2012-09-26|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)|A Prospective, Randomised, Double-Blind, Placebo-Controlled Phase III Study of Modafinil to Improve Fatigue and Quality of Life in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer|Completed||Phase 3|84|Actual|Sanofi||2|||f||||||||||||||2018-06-01 00:54:11.693049|2018-06-01 00:54:11.693049
NCT00917735|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2015-07-29||2016-01-25|2009-06-09|2009-06-10|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Green Tea and Reduction of Breast Cancer Risk|Phase II, Randomized,Double-blind, Placebo-controlled, Study of the Efficacy of Green Tea Extract on Biomarkers of Breast Cancer Risk in High Risk Women With Differing Catechol-O-methyl Transferase (COMT) Genotypes|Completed||Phase 2|1075|Actual|University of Minnesota - Clinical and Translational Science Institute|We had limited success in recruiting minority populations.|2|||f||||t||||||||||2018-06-01 00:54:11.778493|2018-06-01 00:54:11.778493
NCT00917722|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-11-09|2009-06-09|2009-06-10|Estimate|||||||2016-11-09|2016-11-10|Estimate|March 2006||2006-03-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|March 2009|Actual|2009-03-31||Observational|COVOLT||Deep Brain Stimulation of the Subthalamic Nucleus (STN) and Cognitive Control|Deep Brain Stimulation of the STN and Cognitive Control: A Pilot Study|Completed|||12|Actual|Washington University School of Medicine|||||f||||f||||||||No|This was a small pilot study and consent was not obtained to share data.|2018-06-01 00:54:12.265369|2018-06-01 00:54:12.265369
NCT00917358|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-12-19|2009-06-08|2009-06-10|Estimate|||||||2012-12-19|2012-12-20|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C|Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C|Completed||Phase 4|42|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 00:54:16.191152|2018-06-01 00:54:16.191152
NCT00917709|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2014-08-20|2009-06-09|2009-06-10|Estimate|||||||2014-08-20|2014-08-21|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|IBVM/DATSCAN||Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies|In Vivo SPECT Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies: Applying in Diagnostic and Identification of Pathological Subtypes.|Completed||N/A|34|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-06-01 00:54:12.325398|2018-06-01 00:54:12.325398
NCT00917696|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2015-07-29|2009-06-08|2009-06-10|Estimate|||||||2015-07-29|2015-07-30|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Evaluate ATP-induced Pain and ATP-induced Dermal Vasodilation by Iontophoresis (0000-118)(COMPLETED)|A Randomized, Double Blind, Placebo Controlled, Crossover Clinical Trial to Evaluate the Effects of ATP-Induced Pain (AIP) and ATP-induced Dermal Vasodilation (AIDV) by Iontophoresis in Healthy Subjects|Completed||Phase 1|44|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:54:12.40993|2018-06-01 00:54:12.40993
NCT00917683|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-04-18|2009-06-09|2009-06-10|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2009||2009-06-30|April 2016|2016-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Investigation of Neuroserpin as an Autism Candidate Gene|Investigation of Neuroserpin as an Autism Candidate Gene|Terminated|||5|Actual|State University of New York - Upstate Medical University|||2|Lack of enrollment.|f||||f||||||Samples With DNA|"~     DNA will be isolated from peripheral blood samples.~   "|||2018-06-01 00:54:12.468865|2018-06-01 00:54:12.468865
NCT00917670|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2010-07-21|2009-06-09|2009-06-10|Estimate|||||||2010-07-21|2010-07-22|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Observational|||Ultrastructural Changes of Trabeculectomy Specimens in Patients With Uveitic Secondary Glaucoma||Completed|||10|Anticipated|St. Franziskus Hospital|||||f||||f||||||Samples With DNA|"~     trabeculectomy specimens including trabecular meshwork and Schlemms canal~   "|||2018-06-01 00:54:12.530058|2018-06-01 00:54:12.530058
NCT00917657|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Photorefractive Keratectomy (PRK) for Hyperopia After Radial Keratotomy|Corneal Wavefront-Guided PRK With Adjunctive Mitomycin-C for the Treatment of Hyperopia After Radial Keratotomy|Completed||N/A|36|Actual|University of Sao Paulo|||||f||||t||||||||||2018-06-01 00:54:12.57898|2018-06-01 00:54:12.57898
NCT00917644|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2009-09-11||2009-10-15|2009-06-08|2009-06-10|Estimate|2009-09-11|2009-10-15|Estimate||||2009-10-15|2009-10-20|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet In Healthy Subjects|Completed||Phase 4|76|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:54:12.632707|2018-06-01 00:54:12.632707
NCT00917631|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-09-01|2009-06-09|2009-06-10|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|CComforT||Co-Bedding as a Comfort Measure for Twins Undergoing Painful Procedures|Co-Bedding as a Comfort Measure for Twins Undergoing Painful Procedures|Completed||N/A|134|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 00:54:12.873836|2018-06-01 00:54:12.873836
NCT00917618|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2017-10-13|2009-06-09|2009-06-10|Estimate|||||||2017-10-13|2017-10-17|Actual|January 2005||2005-01-31|June 2009|2009-06-30|September 2006|Actual|2006-09-30|May 2006|Actual|2006-05-31||Interventional|||The Effects of Group Cycling (Spinning®) With Knee Osteoarthritis: A Randomized Control Trial|The Effects of Group Cycling (Spinning®) On Gait and Pain-Related Disability in Persons With Knee Osteoarthritis: A Randomized Control Trial|Completed||N/A|37|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:54:12.969062|2018-06-01 00:54:12.969062
NCT00917605|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-07-08|2009-06-09|2009-06-10|Estimate|||||||2012-07-08|2012-07-10|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Robot-Assisted Therapy in Stroke Patients|Robot-Assisted Upper Limb Rehabilitation in Stroke|Unknown status|Recruiting|N/A|120|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 00:54:13.235372|2018-06-01 00:54:13.235372
NCT00917592|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-08|2009-06-08|2009-06-10|Estimate|||||||2009-06-08|2009-06-10|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|DANC-05||Trial Assessing the Efficacy of a Short Course of Intravenous Antibiotic Followed by Oral Antibiotic in Uncomplicated Acute Diverticulitis|Prospective Randomized Clinical Trial Assessing the Efficacy of a Short Course of Intravenous Amoxicillin Plus Clavulanic Acid Followed by Oral Antibiotic in Patients With Uncomplicated Acute Diverticulitis|Completed||Phase 4|50|Actual|Consorci Sanitari de Terrassa||2|||f||||t||||||||||2018-06-01 00:54:13.309516|2018-06-01 00:54:13.309516
NCT00917579|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2009-09-10||2009-10-16|2009-06-08|2009-06-10|Estimate|2009-09-10|2009-10-14|Estimate||||2009-10-16|2009-10-20|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet In Healthy Subjects|Completed||Phase 4|76|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:54:13.394716|2018-06-01 00:54:13.394716
NCT00917566|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-11-18|2009-06-09|2009-06-10|Estimate|||||||2009-11-18|2009-11-19|Estimate|April 2009||2009-04-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Evaluation of Airtraq in Pediatric|Evaluation of Airtraq in Pediatric Population: A Prospective Randomized Study|Completed||N/A|50|Anticipated|King Khaled Eye Specialist Hospital||2|||f||||t||||||||||2018-06-01 00:54:13.627671|2018-06-01 00:54:13.627671
NCT00917553|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-10-04|2009-06-09|2009-06-10|Estimate|||||||2012-10-04|2012-10-08|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|POC2||Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy|Proof-of-Concept 2 (POC2): Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients With Mild to Moderate Non-Proliferative Diabetic Retinopathy|Completed||Phase 2|33|Actual|Penn State University||2|||f||||t||||||||||2018-06-01 00:54:13.689796|2018-06-01 00:54:13.689796
NCT00917540|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2013-04-05|2009-06-08|2009-06-10|Estimate|||||||2013-04-05|2013-04-09|Estimate|February 2007||2007-02-28|April 2013|2013-04-30|April 2013|Anticipated|2013-04-30|||||Observational|||Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia|Prospective Collection of Biological Data of Prognostic Relevance in Patients|Unknown status|Recruiting||495|Anticipated|Gruppo Italiano Studio Linfomi|||||f||||f||||||Samples With DNA|"~     Peripheral blood~   "|||2018-06-01 00:54:13.752878|2018-06-01 00:54:13.752878
NCT00917527|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2012-07-20|2009-06-09|2009-06-10|Estimate|||||||2012-07-20|2012-07-23|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|November 2012|Anticipated|2012-11-30||Interventional|||Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease|Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease|Unknown status|Recruiting|Phase 4|77|Anticipated|Yonsei University||2|||f||||t||||||||||2018-06-01 00:54:13.909636|2018-06-01 00:54:13.909636
NCT00917514|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2010-02-25|2009-06-09|2009-06-10|Estimate|||||||2010-02-25|2010-02-26|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen|An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen During Azathioprine Treatment in Patients With Crohn's Disease or Ulcerative Colitis|Completed|||25|Actual|Medicpen AB|||||f||||t||||||||||2018-06-01 00:54:13.985587|2018-06-01 00:54:13.985587
NCT00917501|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2015-10-26||2016-05-02|2009-06-09|2009-06-10|Estimate|2016-05-02|2016-06-09|Estimate||||2016-05-02|2016-06-09|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|R34||Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania|Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania|Completed||Phase 2|55|Actual|University of Cincinnati||2|||f||||t||||||||No||2018-06-01 00:54:14.050758|2018-06-01 00:54:14.050758
NCT00917488|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2011-06-17|2009-06-09|2009-06-10|Estimate|||||||2011-06-17|2011-06-20|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).|Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).|Completed||Phase 2|27|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-06-01 00:54:14.232147|2018-06-01 00:54:14.232147
NCT00917475|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-01-27|2009-06-08|2009-06-10|Estimate|||||||2010-01-27|2010-01-29|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Socio-Emotional Development in Preterm Infants|Socio-Emotional Development in Preterm Infants|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 00:54:14.317175|2018-06-01 00:54:14.317175
NCT00917462|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2017-06-05|2009-06-08|2009-06-10|Estimate|||||||2017-06-05|2017-06-06|Actual|June 2009|Actual|2009-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer|Phase II Trial of Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer|Active, not recruiting||Phase 2|35|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:54:14.385146|2018-06-01 00:54:14.385146
NCT00917449|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|L-arginine||Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome|Interventional Pharmacological Study With L-Arginine in the Prevention of Type 2 Diabetes Mellitus in Patients With Metabolic Syndrome|Completed||Phase 3|142|Actual|IRCCS San Raffaele||2|||f||||t||||||||||2018-06-01 00:54:14.470174|2018-06-01 00:54:14.470174
NCT00917436|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-01-14|2009-06-09|2009-06-10|Estimate|||||||2010-01-14|2010-01-15|Estimate|December 2004||2004-12-31|January 2010|2010-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain|Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain|Completed||Phase 4|183|Actual|Sanofi|||||f||||||||||||||2018-06-01 00:54:14.566636|2018-06-01 00:54:14.566636
NCT00917423|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-09-22|2009-06-08|2009-06-10|Estimate|||||||2016-09-22|2016-09-23|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|June 2016|Actual|2016-06-30|February 2015|Actual|2015-02-28||Observational|||Characteristics and Importance of Physical Activity in Women With Anorexia Nervosa|Physical Activity in Anorexia Nervosa: Characteristics and Clinical Significance|Completed|||147|Actual|New York State Psychiatric Institute|||2||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 00:54:14.619028|2018-06-01 00:54:14.619028
NCT00917410|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|November 2007||2007-11-30|June 2009|2009-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Mobile Phone Text for Optimizing Asthma Treatment|Assessment of the Health Related Effects of Compliance Optimization in Asthma Through Use of SMS (Short Message System) - A Controlled Trial|Completed||N/A|244|Actual|University of Copenhagen||1|||f||||t||||||||||2018-06-01 00:54:14.684|2018-06-01 00:54:14.684
NCT00917397|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-06-17|2009-06-09|2009-06-10|Estimate|||||||2014-06-17|2014-06-18|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Outcome of Treatment of Traumatised Refugees With Psychotherapy and/or Antidepressants|The Outcome of Treatment of Traumatised Refugees With Trauma-Focused Cognitive Behavioural Therapy and / or Antidepressants - a Randomised Controlled Trial|Completed||Phase 4|280|Actual|Psykiatrisk Center Gentofte||4|||f||||t||||||||||2018-06-01 00:54:14.744038|2018-06-01 00:54:14.744038
NCT00917384|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2014-05-21|2010-07-26|2016-12-08|2009-06-09|2009-06-10|Estimate|2014-10-09|2014-10-16|Estimate|2010-07-26|2010-07-29|Estimate|2016-12-08|2017-02-03|Estimate|August 2009||2009-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|July 2012|Actual|2012-07-31||Interventional||All randomized participants.|Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma|A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy|Completed||Phase 3|355|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-06-01 00:54:14.845743|2018-06-01 00:54:14.845743
NCT00917371|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-11-23|2009-06-09|2009-06-10|Estimate|||||||2010-11-23|2010-11-24|Estimate|August 2010||2010-08-31|November 2010|2010-11-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults With Attention Deficit/Hyperactivity Disorder|The Effectiveness of Atomoxetine on Brain Imaging, Neuropsychological, and Social Functions in Adults With Attention Deficit/Hyperactivity Disorder|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||3||f||||t||||||||||2018-06-01 00:54:16.106331|2018-06-01 00:54:16.106331
NCT00917332|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|August 2009||2009-08-31|June 2009|2009-06-30|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Interventional|||Effects of Relaxation and Guided Imagery Training on Pain at Childbirth|Effects of Relaxation and Guided Imagery Training on Rate and Time of Receiving Regional Anesthesia (Epidural), and on the Experience of Childbirth|Unknown status|Not yet recruiting|N/A|110|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 00:54:16.378516|2018-06-01 00:54:16.378516
NCT00917319|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-16|2009-06-08|2009-06-10|Estimate|||||||2009-06-16|2009-06-17|Estimate|January 2009||2009-01-31|June 2009|2009-06-30||||July 2009|Anticipated|2009-07-31||Interventional|||Prevention and Control of Healthcare-Associated Infections|Randomized Controlled Study on Effectiveness of Implementing Bundling Infection Control Interventions for Prevention and Control of Healthcare-Associated Infections in General Medical Wards at Siriraj Hospital, Bangkok, Thailand|Unknown status|Active, not recruiting|N/A|2000|Anticipated|Mahidol University||1|||f||||f||||||||||2018-06-01 00:54:16.439423|2018-06-01 00:54:16.439423
NCT00917306|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08||2010-09-22|2015-03-25|2009-06-08|2009-06-10|Estimate||||2010-09-22|2010-09-27|Estimate|2015-03-25|2015-04-15|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)|A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-head Locations (Trunk and Extremities)|Completed||Phase 3|102|Actual|Peplin||1|||f||||f||||||||||2018-06-01 00:54:16.49503|2018-06-01 00:54:16.49503
NCT00917293|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2015-04-07|2009-06-09|2009-06-10|Estimate|||||||2015-04-07|2015-04-08|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia|A Randomized, Double-Blind, Placebo-Controlled, Comparative Study to Evaluate the Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia in Patients With Schizophrenia and Schizoaffective Disorders|Terminated||Phase 2|53|Actual|Medicure||2||modified formulation under investigation|f||||f||||||||||2018-06-01 00:54:16.647331|2018-06-01 00:54:16.647331
NCT00917280|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2015-06-01|2009-06-09|2009-06-10|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|Lab2Life||Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in Parkinson's Disease (PD) Without Dementia|Connecting the Lab to Everyday Life: The Relevance of Executive Dysfunction to Participation and Quality of Life in PD Without Dementia|Completed|||174|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 00:54:16.730638|2018-06-01 00:54:16.730638
NCT00917267|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2012-02-14|2011-06-17|2015-03-20|2009-06-08|2009-06-10|Estimate|2012-11-28|2012-12-31|Estimate|2011-06-17|2011-06-27|Estimate|2015-03-20|2015-04-09|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects|A Comparator-Controlled Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control (HbA1c) and Safety in Asian Subjects With Type 2 Diabetes Mellitus Managed With Oral Antidiabetic Medications|Completed||Phase 3|691|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:54:16.836438|2018-06-01 00:54:16.836438
NCT00917254|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-06-14|2009-06-08|2009-06-10|Estimate|||||||2010-06-14|2010-06-16|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery|Phase II/III Study of YM150 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients Undergoing Elective Total Knee Replacement Surgery -|Completed||Phase 2/Phase 3|369|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 00:54:17.606805|2018-06-01 00:54:17.606805
NCT00917241|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2013-05-02|2009-06-09|2009-06-10|Estimate|||||||2013-05-02|2013-05-06|Estimate|June 2004||2004-06-30|June 2009|2009-06-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone|Prevention Relapse of Graves' Disease by Treatment With Intrathyroid Injection of Dexamethasone|Completed||Phase 4|218|Actual|Nanjing Medical University||2|||f||||f||||||||||2018-06-01 00:54:17.703205|2018-06-01 00:54:17.703205
NCT00917228|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate||||June 2009|2009-06-30||||||||Observational|prevesc0001||A Wireless Lingual Feedback Device to Reduce Overpressures in Seated Posture: A Feasibility Study|A Wireless Lingual Feedback Device to Reduce Overpressures in Seated Posture: A Feasibility Study|Completed|||||TIMC-IMAG|||2||f||||||||||||||2018-06-01 00:54:17.808693|2018-06-01 00:54:17.808693
NCT00917215|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-07-29|2009-06-09|2009-06-10|Estimate|||||||2009-07-29|2009-07-30|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Effectiveness of Acupuncture for Asthma|Effectiveness of Acupuncture for Asthma: A Randomized, Sham-acupuncture and Waiting-list Controlled Trial|Completed||N/A|45|Anticipated|Korea Institute of Oriental Medicine||3|||f||||||||||||||2018-06-01 00:54:17.864872|2018-06-01 00:54:17.864872
NCT00917202|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate||||June 2009|2009-06-30||||||||Interventional|||Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8 Project of the SFB 544|Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8|Completed||Phase 2|||Heidelberg University||3|||f||||||||||||||2018-06-01 00:54:17.920005|2018-06-01 00:54:17.920005
NCT00917189|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-10-20|2009-06-08|2009-06-10|Estimate|||||||2016-10-20|2016-10-21|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Computerized Cognitive Skills Training for Adolescents With Velocardiofacial Syndrome|Computer-Based Cognitive Remediation in Adolescents With VCFS|Completed||N/A|37|Actual|State University of New York - Upstate Medical University||1|||f||||t||||||||||2018-06-01 00:54:17.977835|2018-06-01 00:54:17.977835
NCT00917176|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate||||June 2009|2009-06-30||||||||Interventional|||Occipital Nerve Stimulation in Fibromyalgia|Subcutaneous C2 Stimulation: Treatment of Fibromyalgia|Completed||Phase 2|||University Hospital, Antwerp||2|||f||||||||||||||2018-06-01 00:54:18.05559|2018-06-01 00:54:18.05559
NCT00917007|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-08-04|2009-06-09|2009-06-10|Estimate|||||||2010-08-04|2010-08-05|Estimate|June 2009||2009-06-30|August 2010|2010-08-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|||Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis|Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis in ABO-compatible and Incompatible Healthy Term Newborn Infants.|Unknown status|Recruiting||120|Anticipated|State University of New York - Upstate Medical University|||3||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 00:54:19.737607|2018-06-01 00:54:19.737607
NCT00917163|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-08-22|2009-06-09|2009-06-10|Estimate|||||||2012-08-22|2012-08-23|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent|A Randomized Comparison of the Supralimus® Stent With the Xience V™ Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions|Terminated||Phase 4|13|Actual|Sahajanand Medical Technologies Pvt. Ltd.||2||"due to unavoidable circumstances relating to logistic issues and regulatory processes in~   various countries causing unacceptable delays."|f||||t||||||||||2018-06-01 00:54:18.124211|2018-06-01 00:54:18.124211
NCT00917150|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2014-06-09|2009-06-09|2009-06-10|Estimate|||||||2014-06-09|2014-06-10|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Dose-comparison Trial of OPC-6535 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|771|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 00:54:18.387861|2018-06-01 00:54:18.387861
NCT00917137|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2010-06-22|2009-06-09|2009-06-10|Estimate|||||||2010-06-22|2010-06-23|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Transbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy|Transbronchial Needle Aspiration in the Diagnosis of Peripheral Pulmonary Malignancy: Yield and Predictors of a Positive Aspirate|Completed|||200|Anticipated|Maggiore Bellaria Hospital, Bologna|||1||f||||f||||||||||2018-06-01 00:54:18.558087|2018-06-01 00:54:18.558087
NCT00917124|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|2013-04-09||2015-06-09|2009-06-09|2009-06-10|Estimate|2013-07-04|2013-08-07|Estimate||||2015-06-09|2015-07-08|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||"Only patients underwent coronary artery bypass grafting (CABG) with cardiopulmonary bypass were included in the study.~Four participants in Control group and six participants in INVOS group were not analysed because they did not receive allocated surgical intervention (CABG), because intraoperative plan was changed."|Cerebral Oximetry and Neurocognitive Functions in Cardiosurgical Patients|Influence of Intraoperative Monitoring of Cerebral Oximetry on Neurocognitive Function After Coronary Artery Bypass Surgery: Randomized, Prospective Study|Completed||N/A|200|Actual|University of Zagreb|"number and selection of performed neurocognitive tests. MMSE test is not part of Statement of consensus on assessment of neurobehavioral outcomes after cardiac surgery~lack of blind monitoring of cerebral oximetry in control group"|2|||f||||f||||||||||2018-06-01 00:54:18.693719|2018-06-01 00:54:18.693719
NCT00917111|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08||2012-08-06|2012-08-06|2009-06-09|2009-06-10|Estimate||||2012-08-06|2012-08-15|Estimate|2012-08-06|2012-08-15|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used Four Times a Day in the Symptomatic Treatment of Seasonal Allergic Rhinitis|Completed||Phase 2|33|Actual|Capnia, Inc.||2|||f||||f||||||||||2018-06-01 00:54:19.139882|2018-06-01 00:54:19.139882
NCT00917098|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2017-07-31|2009-06-08|2009-06-10|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2008||2008-10-31|July 2017|2017-07-31|March 26, 2014|Actual|2014-03-26|March 26, 2014|Actual|2014-03-26||Interventional|||Examining Behavior Therapy for Trichotillomania in Children and Adolescents|Behavior Therapy for Pediatric Trichotillomania|Completed||N/A|61|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 00:54:19.208678|2018-06-01 00:54:19.208678
NCT00917085|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-08-07|2009-06-08|2009-06-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|July 1996||1996-07-31|August 2009|2009-08-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Is Skin-to-Skin Care Helpful for Preterm Infants and Their Mothers After Birth?|Self-Regulatory Preterm Infant Care: Adaptation Postbirth|Completed||Phase 1|100|Actual|National Institute of Nursing Research (NINR)||2|||f||||f||||||||||2018-06-01 00:54:19.298057|2018-06-01 00:54:19.298057
NCT00917072|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|I-SWITCH||Innovative Strategies Which Improve the Clinical Handoff (I-SWITCH)|Innovative Strategies Which Improve the Clinical Handoff (I-SWITCH) Phase II: Randomized Controlled Trial Evaluating Educational Modalities Including Cognitive Simulation|Completed||N/A|39|Actual|Henry Ford Health System||3|||f||||f||||||||||2018-06-01 00:54:19.3727|2018-06-01 00:54:19.3727
NCT00917059|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2013-02-04|2009-06-08|2009-06-10|Estimate|||||||2013-02-04|2013-02-06|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)|Personalized Response Indicators of SSRI Effectiveness in Major Depression|Completed||Phase 4|172|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 00:54:19.435424|2018-06-01 00:54:19.435424
NCT00917046|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2017-01-16|2009-06-09|2009-06-10|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|September 2013|Actual|2013-09-30||Interventional|SMARTEX||The SMARTEX Heart Failure Study|Study of Myocardial Recovery After Exercise Training in Heart Failure|Completed||N/A|261|Actual|Norwegian University of Science and Technology||3|||f||||t||||||||No||2018-06-01 00:54:19.501608|2018-06-01 00:54:19.501608
NCT00917033|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2010-02-23|2009-06-09|2009-06-10|Estimate|||||||2010-02-23|2010-02-24|Estimate|September 2008||2008-09-30|February 2010|2010-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy|Orotracheal Intubation of Morbidly Obese Patients. A Randomised Controlled Trial Comparing the GlideScope Videolaryngoscope to the Macintosh Direct Laryngoscope.|Completed||Phase 4|100|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-06-01 00:54:19.579156|2018-06-01 00:54:19.579156
NCT00917020|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08||2012-08-06|2012-08-06|2009-06-09|2009-06-10|Estimate||||2012-08-06|2012-08-15|Estimate|2012-08-06|2012-08-15|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis|Completed||Phase 2|32|Actual|Capnia, Inc.||2|||f||||f||||||||||2018-06-01 00:54:19.644062|2018-06-01 00:54:19.644062
NCT00916994|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-07|||2015-03-10|2009-06-09|2009-06-10|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2009||2009-07-31|June 2013|2013-06-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Prospective Study for Safety and Efficacy of InSpace™ in Rotator Cuff Tear Subjects|One-arm, International, Multi-center With Competitive Recruitment, Prospective Study to Assess the Safety and Efficacy of OrthoSpace's InSpace™ in Rotator Cuff Tear Subjects Scheduled for Surgery of the Rotator Cuff|Completed||N/A|58|Actual|OrthoSpace Ltd.||1|||f||||f||||||||||2018-06-01 00:54:20.769505|2018-06-01 00:54:20.769505
NCT00916981|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2012-02-22|2009-06-09|2009-06-10|Estimate|||||||2012-02-22|2012-02-23|Estimate|November 2008||2008-11-30|February 2012|2012-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatment of Atrophic Nonunion by Preosteoblast Cells|Treatment of Refractory Non-union Fractures by Pre-osteoblast Cells Grafting : a Pilot Study.|Completed||Phase 1/Phase 2|30|Actual|University Hospital of Liege|||||f||||f||||||||||2018-06-01 00:54:20.838317|2018-06-01 00:54:20.838317
NCT00916968|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-07-01|2009-06-09|2009-06-10|Estimate|||||||2009-07-01|2009-07-02|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2007|Actual|2007-05-31||Interventional|CR||Comparison of Function and Fit of Standard and Gender-Specific CR High-Flex Total Knee Prostheses|Comparison of Function and Fit of Standard Posterior Cruciate-Retaining High-Flexion and Gender-Specific Posterior Cruciate-Retaining High-Flexion Total Knee Prostheses A Prospective, Randomized Study|Completed||Phase 4|146|Actual|Ewha Womans University||2|||f||||t||||||||||2018-06-01 00:54:20.90532|2018-06-01 00:54:20.90532
NCT00916955|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2015-01-05|2009-06-08|2009-06-10|Estimate|||||||2015-01-05|2015-01-06|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|VCFS||Genetic Modifiers for 22q11.2 Syndrome|Genetic Modifiers for 22q11.2 Syndrome|Unknown status|Recruiting||500|Anticipated|State University of New York - Upstate Medical University|||1||f||||f||||||Samples With DNA|"~     peripheral blood~   "|||2018-06-01 00:54:20.976649|2018-06-01 00:54:20.976649
NCT00916942|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-09-03|2009-06-09|2009-06-10|Estimate|||||||2009-09-03|2009-09-09|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)|An Open-Label Study Of The Use Of Topical Lidocaine (2.5%)/Prilocaine (2.5%) Cream As Pre-Treatment For NGX-4010 In Subjects With Postherpetic Neuralgia (PHN)|Completed||Phase 2|20|Anticipated|NeurogesX||2|||f||||||||||||||2018-06-01 00:54:21.051173|2018-06-01 00:54:21.051173
NCT00916929|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2012-12-18||2013-06-21|2009-06-08|2009-06-10|Estimate|2013-05-14|2013-06-24|Estimate||||2013-06-21|2013-07-02|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional|DEFEAT-PE||Detect Fluid Early From Intra-thoracic Impedance Monitoring|Detect Fluid Early From Intra-thoracic Impedance Monitoring|Completed||N/A|162|Actual|St. Jude Medical|There were no limitations of the trial.|2|||f||||f||||||||||2018-06-01 00:54:21.148773|2018-06-01 00:54:21.148773
NCT00916916|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate||||June 2009|2009-06-30||||||||Observational|||Lanreotide Levels in Acromegaly|Lanreotide Levels in Acromegaly|Unknown status|Recruiting||||Cedars-Sinai Medical Center|||1||f||||||||||||||2018-06-01 00:54:21.561833|2018-06-01 00:54:21.561833
NCT00916903|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|October 2005||2005-10-31|June 2009|2009-06-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|||Genetic Disease Gene Identification|Genetic Disease Gene Identification|Unknown status|Enrolling by invitation||200|Anticipated|State University of New York - Upstate Medical University|||2||f||||f||||||Samples With DNA|"~     DNA will be isolated from peripheral blood or cheek scraoes.~   "|||2018-06-01 00:54:21.64|2018-06-01 00:54:21.64
NCT00916890|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2014-01-08|2009-06-09|2009-06-10|Estimate|||||||2014-01-08|2014-01-09|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|February 2015|Anticipated|2015-02-28||Interventional|||Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain|Chronic Administration of Opioids in Cancer Chronic Pain:an Open Prospective Study on Efficacy, Safety and Pharmacogenetic Factors Influence.|Suspended||Phase 4|320|Anticipated|IRCCS Policlinico S. Matteo||4||difficulties in patients enrolment|f||||f||||||||||2018-06-01 00:54:21.754336|2018-06-01 00:54:21.754336
NCT00916877|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2011-08-04|2009-06-09|2009-06-10|Estimate|||||||2011-08-04|2011-08-08|Estimate|November 2009||2009-11-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Prophylactic Cranial Irradiation in Patients With HER-2-Positive Metastatic Breast Cancer|Prophylactic Cranial Irradiation in Patients With HER-2-Positive Metastatic Breast Cancer|Completed||Phase 1|110|Anticipated|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 00:54:21.857176|2018-06-01 00:54:21.857176
NCT00916864|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2011-06-22|2009-06-09|2009-06-10|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|BE FAST!||Biomarker for Rapid Diagnosis of Hemispheric Stroke|Biomarker for Rapid Diagnosis of Hemispheric Stroke|Completed|||250|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples Without DNA|"~     Human plasma~   "|||2018-06-01 00:54:21.926264|2018-06-01 00:54:21.926264
NCT00916851|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-07-08|2009-06-09|2009-06-10|Estimate|||||||2012-07-08|2012-07-10|Estimate|August 2010||2010-08-31|April 2012|2012-04-30|July 2013|Anticipated|2013-07-31|||||Observational|||Clinical, Environmental, Neurocognitive, Brain Imaging, and Genetic Validity of Autism and ADHD|Clinical, Environmental, Neurocognitive, Brain Imaging, and Genetic Validity of Autism and Attention-deficit Hyperactivity Disorder|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments~   "|||2018-06-01 00:54:21.98727|2018-06-01 00:54:21.98727
NCT00916838|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-05-08|2009-06-09|2009-06-10|Estimate|||||||2017-05-08|2017-05-10|Actual|January 2003||2003-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|March 2006|Actual|2006-03-31||Observational|HYPO||Neurocognitive Impact of Hypoglycemia in Type 1 Diabetes|Neurocognitive Impact of Hypoglycemia in Type 1 Diabetes|Active, not recruiting|||187|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 00:54:22.062085|2018-06-01 00:54:22.062085
NCT00916825|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2010-02-02|2009-06-09|2009-06-10|Estimate|||||||2010-02-02|2010-02-03|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Effectiveness of a Rehabilitation Programme for Mothers With Breast Cancer and Their Children|Effectiveness of a Family-oriented Rehabilitation Programme for Mothers With Breast Cancer and Their Children - Quality of Life and Psychological Health of Mothers and Their Children|Unknown status|Active, not recruiting|N/A|750|Anticipated|Philipps University Marburg Medical Center||1|||f||||f||||||||||2018-06-01 00:54:22.120334|2018-06-01 00:54:22.120334
NCT00916812|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2015-01-13|2009-06-09|2009-06-10|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2009||2009-05-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|HMDR||Sensitivity of Hyomental Distance Ratio as a Single Predictor of Difficult Intubation in Obstetrics|Hyomental Distance Ratio as a Predictor for Difficult Intubation in Elective and Emergency Cesarean Section.|Completed|||188|Actual|King Khaled Eye Specialist Hospital|||||f||||t||||||||||2018-06-01 00:54:22.189171|2018-06-01 00:54:22.189171
NCT00916799|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-09|||2009-06-10|2009-06-09|2009-06-10|Estimate|||||||2009-06-10|2009-06-12|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|May 2010|Anticipated|2010-05-31|November 2009|Anticipated|2009-11-30||Interventional|||VISN 23 Chronic Obstructive Pulmonary Disease (COPD) Case Management Using Home Telehealth Equipment|VISN 23 COPD Case Management Using Home Telehealth Equipment|Unknown status|Recruiting|N/A|50|Anticipated|VA Nebraska Western Iowa Health Care System||1|||f||||f||||||||||2018-06-01 00:54:22.240505|2018-06-01 00:54:22.240505
NCT00916786|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-07-08|2009-06-09|2009-06-10|Estimate|||||||2012-07-08|2012-07-10|Estimate|August 2009||2009-08-31|April 2012|2012-04-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder|Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting||240|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-06-01 00:54:22.318088|2018-06-01 00:54:22.318088
NCT00916773|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-09|2009-06-09|2009-06-10|Estimate|||||||2009-06-09|2009-06-10|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Pulmonary Disorders During Exercise in Patients With Obstructive Sleep Apnea|Exercised-Induced Bronchoconstriction in Patients With Severe Obstructive Sleep Apnea|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 00:54:22.382309|2018-06-01 00:54:22.382309
NCT00916760|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2013-11-08|2009-06-09|2009-06-10|Estimate|||||||2013-11-08|2013-11-11|Estimate|February 2008||2008-02-29|August 2012|2012-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica|Clinical, Multi-centre, Randomised, Double-blind Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerized Extract of Parietaria Judaica Pollen on Patients With Hypersensitivity to This Pollen|Completed||Phase 3|153|Actual|Laboratorios Leti, S.L.||2|||f||||f||||||||||2018-06-01 00:54:22.565393|2018-06-01 00:54:22.565393
NCT00916747|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2018-05-23|2009-06-05|2009-06-09|Estimate|||||||2018-05-23|2018-05-25|Actual|August 2009||2009-08-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria|An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies|Enrolling by invitation||Phase 2|85|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||||2018-06-01 00:54:22.655225|2018-06-01 00:54:22.655225
NCT00916734|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2011-12-02|2009-06-08|2009-06-09|Estimate|||||||2011-12-02|2011-12-05|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Assessing Patient Response to Therapeutic Exercise Based on Clinical Prediction Rule (CPR) for Spinal Manipulation|Assessing Patient Response to Therapeutic Exercise Based on the Clinical Prediction Rule for Spinal Manipulation|Completed||Phase 3|31|Actual|Daemen College||2|||f||||t||||||||||2018-06-01 00:54:22.736977|2018-06-01 00:54:22.736977
NCT00916721|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2013-07-09||2014-09-16|2009-06-08|2009-06-09|Estimate|2014-09-16|2014-09-19|Estimate||||2014-09-16|2014-09-19|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|SCP||Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence|Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence|Completed||Phase 3|113|Actual|Massachusetts General Hospital|Subjects were asked to not smoke for 12 hrs prior propranolol.Then were permitted to smoke throughout the week prior physiologic testing.Possibly each smoking experience presented a potential opportunity for the creation of new smoking memories.|2|||f||||t||||||||||2018-06-01 00:54:22.833772|2018-06-01 00:54:22.833772
NCT00916708|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2017-04-28|2009-06-08|2009-06-09|Estimate|||||||2017-04-28|2017-05-01|Actual|September 2008||2008-09-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|TOTEM||Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients|Appropriateness Evaluation of Follow up Procedures in Gynaecology Oncology TOTEM Study: Multicentric Randomized Controlled Clinical Trial Between Two Follow up Regimens With Different Tests Intensity in Endometrial Cancer Treated Patients.|Recruiting||N/A|2300|Anticipated|Azienda Ospedaliera San Giovanni Battista||2|||f||||t||||||||No||2018-06-01 00:54:23.172862|2018-06-01 00:54:23.172862
NCT00916695|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-07-22|2009-06-08|2009-06-09|Estimate|||||||2009-07-22|2009-07-23|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Everolimus-Eluting Stent for Bifurcation Coronary Lesions: Comparison of Simple Versus Complex Techniques|Everolimus-Eluting Stent in the Treatment of Bifurcation Lesions: Comparison of Main Vessel Stent to Main Vessel and Side Branch Stent|Unknown status|Recruiting|Phase 4|332|Anticipated|Spanish Society of Cardiology||2|||f||||t||||||||||2018-06-01 00:54:23.304208|2018-06-01 00:54:23.304208
NCT00916682|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-08|2009-06-08|2009-06-09|Estimate|||||||2009-06-08|2009-06-09|Estimate|November 2007||2007-11-30|June 2009|2009-06-30||||February 2010|Anticipated|2010-02-28||Observational|||Structure and Function of Salivary Proteins|Structure and Function of Salivary Proteins|Unknown status|Recruiting||200|Anticipated|Boston Children’s Hospital|||1||f||||f||||||||||2018-06-01 00:54:23.401685|2018-06-01 00:54:23.401685
NCT00916669|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2013-05-07|2009-06-08|2009-06-09|Estimate|||||||2013-05-07|2013-05-08|Estimate|July 2008||2008-07-31|July 2010|2010-07-31||||July 2010|Anticipated|2010-07-31||Interventional|||A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)|A Randomized Phase II Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy (Cisplatin Plus Etoposide) With Respect to Time to Tumor Progression (TTP) in Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (SCLC) Without Underlying Venous Thromboembolism|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||3||sponsor withdrew funding prior to patient enrollment|f||||t||||||||||2018-06-01 00:54:23.477757|2018-06-01 00:54:23.477757
NCT00916656|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2014-05-06|2009-06-08|2009-06-09|Estimate|||||||2014-05-06|2014-05-08|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Fibrinogen Concentrate (Human) − Efficacy and Safety Study|Efficacy and Safety of Fibrinogen Concentrate (Human) (FCH) for On-demand Treatment of Acute Bleeding in Subjects With Congenital Fibrinogen Deficiency|Withdrawn||Phase 3|0|Actual|CSL Behring||2|||f||||f||||||||||2018-06-01 00:54:23.570983|2018-06-01 00:54:23.570983
NCT00916643|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|2013-07-15||2014-01-29|2009-06-08|2009-06-09|Estimate|2013-12-10|2014-01-29|Estimate||||2014-01-29|2014-03-04|Estimate|December 1999||1999-12-31|January 2014|2014-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Secura||Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy|Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy|Completed||Phase 4|113|Actual|B. Braun Medical Inc.||1|||f||||f||||||||||2018-06-01 00:54:23.65922|2018-06-01 00:54:23.65922
NCT00916630|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2015-09-21|2009-06-08|2009-06-09|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)|A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate|Completed||Phase 1|18|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:54:23.818699|2018-06-01 00:54:23.818699
NCT00916617|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2013-09-25||2017-04-27|2009-06-05|2009-06-09|Estimate|2017-04-27|2017-06-01|Actual||||2017-04-27|2017-06-01|Actual|June 2009||2009-06-30|April 2017|2017-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||All participants who received at least 1 dose of study medication in study NCT00916617 were included in the safety population.|Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab|A Multicenter, Open Label, Multiple Dose, Parallel Group Investigation Of The Long-term Safety, Tolerability, Reactogenicity, Pharmacokinetics And Pharmacodynamics Of Aab-001 Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer's Disease|Terminated||Phase 2|62|Actual|Pfizer||1||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical~   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2018-06-01 00:54:23.958462|2018-06-01 00:54:23.958462
NCT00916604|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-11-02|2009-06-08|2009-06-09|Estimate|||||||2009-11-02|2009-11-03|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|||||Interventional|JMAD||To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients|A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 00:54:24.875026|2018-06-01 00:54:24.875026
NCT00916591|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-05|2009-06-05|2009-06-09|Estimate|||||||2009-06-05|2009-06-09|Estimate|September 2009||2009-09-30|June 2009|2009-06-30||||||||Observational|prokinetics||Prokinetic Drugs and Enteral Nutrition|Effect of Prokinetic Drugs During the Administration of Enteral Nutrition|Unknown status|Not yet recruiting||60|Anticipated|Universitair Ziekenhuis Brussel|||||f||||t||||||||||2018-06-01 00:54:24.986712|2018-06-01 00:54:24.986712
NCT00916578|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2017-06-23|2009-06-05|2009-06-09|Estimate|||||||2017-06-23|2017-06-26|Actual|June 5, 2009|Actual|2009-06-05|June 2017|2017-06-30|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|||Xeloda (Capecitabine) and External Beam Radiation|A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Inflammatory or Non-Inflammatory Breast Cancer|Completed||Phase 2|33|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 00:54:25.05781|2018-06-01 00:54:25.05781
NCT00916565|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2011-08-31|2009-06-08|2009-06-09|Estimate|||||||2011-08-31|2011-09-02|Estimate|July 2009||2009-07-31|August 2011|2011-08-31||||||||Observational|||Evaluation of Cow Milk-Based Formulas - Functional Proteins|The Evaluation of Cow Milk-Based Formulas - Functional Proteins|Completed|||139|Anticipated|Mead Johnson Nutrition|||3||f||||||||||||||2018-06-01 00:54:25.146259|2018-06-01 00:54:25.146259
NCT00916552|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2012-11-08|2009-06-08|2009-06-09|Estimate|||||||2012-11-08|2012-11-09|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder|The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study|Completed||Phase 2|83|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-06-01 00:54:25.219678|2018-06-01 00:54:25.219678
NCT00916539|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2016-12-20||2017-03-01|2009-06-08|2009-06-09|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|July 2007||2007-07-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|January 2012|Actual|2012-01-31||Interventional|||Cast Immobilization for Non-Displaced Scaphoid Fractures|Non-displaced Scaphoid Fractures: A Clinical Trial of Cast Immobilization Including vs. Excluding the Thumb|Completed||N/A|62|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 00:54:25.310778|2018-06-01 00:54:25.310778
NCT00916526|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-11-23|2009-06-08|2009-06-09|Estimate|||||||2010-11-23|2010-11-24|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|MANOTOUX||Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough|Measurement of Exhaled NO and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 00:54:25.593256|2018-06-01 00:54:25.593256
NCT00916513|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2010-04-26|2009-06-08|2009-06-09|Estimate|||||||2010-04-26|2010-04-27|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|PANORAMA||Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey|Quality of Life and Treatment Satisfaction of People With Type 2 Diabetes: A European Survey|Completed|||5926|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:54:25.731212|2018-06-01 00:54:25.731212
NCT00916500|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-07|||2014-04-29|2009-06-08|2009-06-09|Estimate|||||||2014-04-29|2014-05-01|Estimate|March 2006||2006-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer|A Phase II Trial of Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer Patients|Completed||Phase 2|71|Actual|Korea Cancer Center Hospital||1|||f||||f||||||||||2018-06-01 00:54:26.27327|2018-06-01 00:54:26.27327
NCT00916487|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2010-12-17|2009-06-05|2009-06-09|Estimate|||||||2010-12-17|2010-12-20|Estimate|June 2009||2009-06-30|December 2010|2010-12-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy of Fructose Metabolizing Enzymatic Product in Fructose Malabsorption|Efficacy of Fructose Metabolizing Enzymatic Product Fructosin(R) in Patients With Fructose Malabsorption|Completed||N/A|65|Actual|Sciotec Diagnostic Technologies GmbH||1|||f||||f||||||||||2018-06-01 00:54:26.338142|2018-06-01 00:54:26.338142
NCT00916474|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2014-02-26|2009-06-05|2009-06-09|Estimate|||||||2014-02-26|2014-02-27|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Virology Follow up Study in Subjects Previously Treated With Telaprevir|EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies|Completed|||408|Actual|Vertex Pharmaceuticals Incorporated|||2||f||||f||||||||||2018-06-01 00:54:26.431082|2018-06-01 00:54:26.431082
NCT00916461|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2009-06-12|2009-06-08|2009-06-09|Estimate|||||||2009-06-12|2009-06-15|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Role of Minocycline in First Episode Psychosis|A Randomised, Double Blind Pilot Study of Minocycline and Placebo Added to Treatment-as-Usual (TAU) in First-Episode Psychosis|Completed||Phase 1/Phase 2|52|Actual|Stanley Medical Research Institute||2|||f||||f||||||||||2018-06-01 00:54:26.562353|2018-06-01 00:54:26.562353
NCT00916448|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2015-08-13|2009-06-08|2009-06-09|Estimate|||||||2015-08-13|2015-08-14|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|March 2010|Actual|2010-03-31||Interventional|||The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia|The Effects of Atazanavir-induced Hyperbilirubinemia on the Innate Immune Response During Human Endotoxemia. A Parallel Double Blind Placebo Controlled Pilot Study.|Completed||N/A|30|Actual|Radboud University||2|||f||||t||||||||||2018-06-01 00:54:26.669502|2018-06-01 00:54:26.669502
NCT00916435|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2015-04-19|2009-06-08|2009-06-09|Estimate|||||||2015-04-19|2015-04-21|Estimate|March 2005||2005-03-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|ICD-EGMs||Study of the Implantable Cardioverter Defibrillator (ICD) Intracardiac Electrograms|Prospective Observational Study of the ICD Intracardiac Electrograms for Prediction of Ventricular Tachyarrhythmias and Congestive Heart Failure|Completed|||630|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 00:54:26.770503|2018-06-01 00:54:26.770503
NCT00916422|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2014-01-28|2009-06-08|2009-06-09|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen|Clinical, Multi-centre,Randomized, Double-blind, Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerised Extract of Phleum Pratense Pollen on Patients With Hypersensitivity to Grass Pollen|Completed||Phase 3|153|Actual|Laboratorios Leti, S.L.||2|||f||||f||||||||||2018-06-01 00:54:26.866728|2018-06-01 00:54:26.866728
NCT00916409|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2017-04-07|2009-06-08|2009-06-09|Estimate|||||||2017-04-07|2017-04-10|Actual|June 2009||2009-06-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)|A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.|Completed||Phase 3|700|Anticipated|NovoCure Ltd.||2|||f||||t||||||||||2018-06-01 00:54:27.038378|2018-06-01 00:54:27.038378
NCT00916396|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-07|||2009-11-29|2009-06-08|2009-06-09|Estimate|||||||2009-11-29|2009-12-01|Estimate|June 2005||2005-06-30|November 2009|2009-11-30|December 2011|Anticipated|2011-12-31|January 2011|Anticipated|2011-01-31||Interventional|||Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder|Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder: Modulation of Sexual Libido by Androgens and Neurosteroids|Unknown status|Recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-06-01 00:54:27.373314|2018-06-01 00:54:27.373314
NCT00916383|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2016-03-24||2016-04-21|2009-06-08|2009-06-09|Estimate|2016-04-21|2016-04-22|Estimate||||2016-04-21|2016-04-22|Estimate|May 2009||2009-05-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|DTP-System||Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System|Randomized, Placebo-Controlled Study in Elderly Alzheimer's Patients on Established/Well Tolerated Dose of Aricept to Assess Skin Tolerability, Irritation, Adhesion With 3 Consecutive 7-Day Applications of 350 mg Donepezil Transdermal Patch|Completed||Phase 2|49|Actual|Teikoku Pharma USA, Inc.||3|||f||||f||||||||||2018-06-01 00:54:27.485538|2018-06-01 00:54:27.485538
NCT00916370|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2012-05-01||2015-05-12|2009-06-08|2009-06-09|Estimate|2012-05-01|2012-06-01|Estimate||||2015-05-12|2015-06-08|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|March 2011|Actual|2011-03-31||Interventional|SPIRIT PRIME|Baseline characteristics data is presented for FAS population (n=505) for this study.|SPIRIT PRIME Clinical Trial|SPIRIT PRIME Clinical Trial.|Completed||Phase 3|525|Actual|Abbott Vascular||2|||f||||t||||||||||2018-06-01 00:54:28.108341|2018-06-01 00:54:28.108341
NCT00916357|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2014-07-30||2014-07-30|2009-06-05|2009-06-09|Estimate|2014-07-30|2014-08-18|Estimate||||2014-07-30|2014-08-18|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||Participants who received at least 1 dose of Humalog, Humalog + recombinant human hyaluronidase PH20 (rHuPH20), or Humulin-R + rHuPH20 during dose-finding (DV) visits or experimental (data gathering) visits.|Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)|Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM|Completed||Phase 2|23|Actual|Halozyme Therapeutics||6|||f||||f||||||||||2018-06-01 00:54:30.222461|2018-06-01 00:54:30.222461
NCT00916344|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2011-07-27||2011-10-04|2009-06-08|2009-06-09|Estimate|2011-08-24|2011-09-30|Estimate||||2011-10-04|2011-10-07|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Master Study for the Investigation of Safety and Efficacy of the EVIA Pacemaker|Master Study of the EVIA DR-T/DR/SR-T/SR Pacemaker|Completed||N/A|175|Actual|Biotronik SE & Co. KG||1|||f||||||||||||||2018-06-01 00:54:31.028137|2018-06-01 00:54:31.028137
NCT00916331|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-06-05|2009-06-05|2009-06-09|Estimate|||||||2009-06-05|2009-06-09|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Subcutaneous Indwelling of Vacuum Drainage in Total Knee Arthroplasty|Subcutaneous Indwelling of Vacuum Drainage in Total Knee Arthroplasty: Prospective Randomized Comparisons With Intraarticular Indwelling|Completed||Phase 4|111|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:54:31.262002|2018-06-01 00:54:31.262002
NCT00916318|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-08|2009-06-08|2009-06-09|Estimate|||||||2009-06-08|2009-06-09|Estimate|August 2008||2008-08-31|May 2009|2009-05-31|November 2015|Anticipated|2015-11-30|December 2010|Anticipated|2010-12-31||Interventional|||Childhood Overweight|Overweight and Obesity in Preschool Children, Prevalence and Prevention - Family Based Health Interventions for Child Health|Unknown status|Recruiting|N/A|260|Anticipated|Vardalinstitutet The Swedish Institute for Health Sciences||4|||f||||||||||||||2018-06-01 00:54:31.360702|2018-06-01 00:54:31.360702
NCT00916305|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2016-04-04||2016-04-04|2009-06-08|2009-06-09|Estimate|2016-04-04|2016-04-05|Estimate||||2016-04-04|2016-04-05|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|gildeaf1||TUNE! Teaching the UK About Noise Exposure: A Pilot Study|Pilot Study of an Intervention Among Young People to Prevent Noise-induced Hearing Loss and Tinnitus|Completed||N/A|65|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 00:54:31.456078|2018-06-01 00:54:31.456078
NCT00916292|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2012-03-09|2009-06-05|2009-06-09|Estimate|||||||2012-03-09|2012-03-12|Estimate|November 2012||2012-11-30|March 2012|2012-03-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Safety Study of Topical Human FGF-1 for Wound Healing|A Phase 1a, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Normal Volunteers Given Punch Skin Biopsies|Unknown status|Not yet recruiting|Phase 1|8|Anticipated|Phage Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:54:31.66019|2018-06-01 00:54:31.66019
NCT00916279|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2014-08-05||2017-01-12|2009-06-05|2009-06-09|Estimate|2015-11-17|2015-12-21|Estimate||||2017-01-12|2017-02-27|Actual|June 2009||2009-06-30|January 2017|2017-01-31|December 2011|Actual|2011-12-31|October 2010|Actual|2010-10-31||Interventional|PERVIDEO I||PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis|A Prospective, Multicenter, European Registry Investigating the Lutonix Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis Within Bare-Metal Stents|Completed||Phase 1/Phase 2|41|Actual|C. R. Bard||1|||f||||t||||||||||2018-06-01 00:54:31.759486|2018-06-01 00:54:31.759486
NCT00916266|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2015-07-29|2009-06-08|2009-06-09|Estimate|||||||2015-07-29|2015-07-31|Estimate|July 2008||2008-07-31|July 2015|2015-07-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy|Phase 1 Study of Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy|Completed||Phase 1|20|Actual|Instituto do Cerebro de Brasilia||1|||f||||t||||||||||2018-06-01 00:54:32.125309|2018-06-01 00:54:32.125309
NCT00916253|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2013-04-24|2009-06-08|2009-06-09|Estimate|||||||2013-04-24|2013-04-25|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|AUTOSOP||Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies|Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment.|Completed||N/A|27|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-06-01 00:54:32.228718|2018-06-01 00:54:32.228718
NCT00916240|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2016-08-18|2009-06-05|2009-06-09|Estimate|||||||2016-08-18|2016-08-19|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Multisystemic Therapy to Reduce Health Disparities in Adolescents With Asthma|Multisystemic Therapy to Reduce Health Disparities in Adolescents With Asthma|Completed||N/A|170|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 00:54:32.321346|2018-06-01 00:54:32.321346
NCT00916227|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2014-12-27|2009-06-05|2009-06-09|Estimate|||||||2014-12-27|2014-12-30|Estimate|June 2009||2009-06-30|December 2014|2014-12-31||||January 2012|Actual|2012-01-31||Interventional|||A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome||Completed||Phase 1|45|Actual|Array BioPharma||1|||f||||||||||||||2018-06-01 00:54:32.410076|2018-06-01 00:54:32.410076
NCT00916214|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2011-06-13|2009-06-08|2009-06-09|Estimate|||||||2011-06-13|2011-06-14|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program|Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program|Completed||Phase 2|200|Anticipated|Ringkobing Love Apotek||1|||f||||f||||||||||2018-06-01 00:54:32.502263|2018-06-01 00:54:32.502263
NCT00916201|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2018-03-07|2009-06-05|2009-06-09|Estimate|||||||2018-03-07|2018-03-08|Actual|June 2019|Anticipated|2019-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|EICAS||Evaluation Study of New Compounds With Potential Use in Schizophrenia|Evaluation of Potential Central Glucoregulatory Compounds to Treat/Ameliorate the Symptoms of Schizophrenia: a Proof-of-concept Study in Healthy Volunteers.|Not yet recruiting||Phase 1|86|Anticipated|Central Institute of Mental Health, Mannheim||3|||f||||f|f|f||||||||2018-06-01 00:54:32.647573|2018-06-01 00:54:32.647573
NCT00916188|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-07-26|2009-06-08|2009-06-09|Estimate|||||||2010-07-26|2010-07-27|Estimate|October 2006||2006-10-31|June 2009|2009-06-30|November 2007|Actual|2007-11-30|December 2006|Actual|2006-12-31||Interventional|||Effects of Black Tea on Type 2 Diabetes|Effects of Black Tea Consumption on Oxidative Stress, Serum Lipid Profile and Insulin Sensitivity in Patients With Type 2 Diabetes|Completed||N/A|45|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-06-01 00:54:32.757489|2018-06-01 00:54:32.757489
NCT00916175|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2016-12-01|2009-06-08|2009-06-09|Estimate|||||||2016-12-01|2016-12-02|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Metabolic Syndrome and Functional Food|Randomized Double Blind Factorial Assay, Aloe Vera (AV) And/Or Cnidoscolus Chayamansa (CC) Versus Placebo, Reduction Of High Blood Glucose In Women With Metabolic Syndrome|Completed||Phase 2/Phase 3|125|Actual|Universidad Autonoma de Nuevo Leon||6|||f||||t||||||||||2018-06-01 00:54:32.831909|2018-06-01 00:54:32.831909
NCT00916162|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2013-05-07|2009-06-05|2009-06-09|Estimate|||||||2013-05-07|2013-05-08|Estimate|August 2006||2006-08-31|May 2013|2013-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy|A Phase II Clinical Trial of Drug Withdrawal in Women With Progressive Breast Cancer While on Aromatase Inhibitor Therapy|Completed|||24|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 00:54:32.950249|2018-06-01 00:54:32.950249
NCT00916149|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2013-01-04|2009-06-05|2009-06-09|Estimate|||||||2013-01-04|2013-01-07|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Cognitive Effects of Treatment of Interictal Discharges|Cognitive Effects of Treatment of Interictal Discharges|Unknown status|Recruiting|N/A|39|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 00:54:33.380514|2018-06-01 00:54:33.380514
NCT00916136|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2014-06-05||2017-04-27|2009-06-05|2009-06-09|Estimate|2014-06-05|2014-07-08|Estimate||||2017-04-27|2017-05-30|Actual|May 2009||2009-05-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Skeletal Versus Cutaneous Traction For Treatment of Femur Fractures|Evaluation of Skeletal Versus Cutaneous Traction for Diaphyseal Femur Fractures|Completed||N/A|66|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 00:54:33.517403|2018-06-01 00:54:33.517403
NCT00916123|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2018-02-27|2009-06-05|2009-06-09|Estimate|||||||2018-02-27|2018-03-01|Actual|May 2009|Actual|2009-05-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2013|Actual|2013-05-31||Interventional|||Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer|A Phase I Trial of Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Anti-prostate-specific Membrane Antigen Monoclonal Antibody in Patients With Metastatic, Castrate-resistant Prostate Cancer|Active, not recruiting||Phase 1|15|Actual|Weill Medical College of Cornell University||5|||f||||t||||||||No||2018-06-01 00:54:33.774479|2018-06-01 00:54:33.774479
NCT00916110|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-01-15|2009-06-08|2009-06-09|Estimate|||||||2013-01-15|2013-01-16|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|ATN-103||Study Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects|Ascending Single Dose Study Of The Safety, Tolerability, PK And PD Of ATN-103 Administered SC Or IV To Healthy Japanese Male Subjects|Completed||Phase 1|72|Actual|Ablynx||9|||f||||f||||||||||2018-06-01 00:54:33.88261|2018-06-01 00:54:33.88261
NCT00748618|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2018-03-21|2008-09-05|2008-09-08|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2008||2008-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|April 2012|Actual|2012-04-30||Interventional|||Vitamin D Replacement After Kidney Transplant|Vitamin D Replacement After Kidney Transplant|Active, not recruiting||N/A|165|Actual|University of Nebraska||2|||f||||t||||||||Undecided||2018-06-01 01:46:48.268662|2018-06-01 01:46:48.268662
NCT00916097|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-23|2009-06-05|2009-06-09|Estimate|||||||2009-06-23|2009-06-24|Estimate|July 2002||2002-07-31|June 2009|2009-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)|A Multicenter Phase II Trial of Docetaxel Combined With Cisplatin (CDDP) as a Neo-Adjuvant Chemotherapy in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)|Completed||Phase 2|66|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:54:33.995371|2018-06-01 00:54:33.995371
NCT00916084|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-08|||2010-07-26|2009-06-08|2009-06-09|Estimate|||||||2010-07-26|2010-07-27|Estimate|June 2009||2009-06-30|December 2009|2009-12-31|August 2010|Anticipated|2010-08-31|April 2010|Anticipated|2010-04-30||Interventional|||Comparative Results of Maxillary Deficiency Treatment by Fixed Tongue Appliance and Fixed Facemask in Growing Patients|This Study is to Apply the Tongue Force to Correct the Dentofacial Deformities|Unknown status|Recruiting|Phase 3|20|Anticipated|Shahid Beheshti University||2|||f||||t||||||||||2018-06-01 00:54:34.094021|2018-06-01 00:54:34.094021
NCT00916071|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2013-03-07|2009-06-05|2009-06-09|Estimate|||||||2013-03-07|2013-03-08|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders|Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders|Completed|||64|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-06-01 00:54:34.197303|2018-06-01 00:54:34.197303
NCT00916058|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2017-12-11|2009-06-08|2009-06-09|Estimate|||||||2017-12-11|2017-12-13|Actual|April 23, 2009|Actual|2009-04-23|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|March 11, 2016|Actual|2016-03-11||Interventional|||Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma|A Phase 1 Pilot Study of a Novel Conditioning Regimen of Bendamustine and Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma|Active, not recruiting||Phase 1|53|Actual|Weill Medical College of Cornell University||5|||f||||t||||||||||2018-06-01 00:54:34.271513|2018-06-01 00:54:34.271513
NCT00916045|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2015-02-10|2009-06-05|2009-06-08|Estimate|||||||2015-02-10|2015-02-11|Estimate|September 2009||2009-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pilot Study of Unrelated Cord Blood Transplantation|Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies|Terminated||Phase 2|40|Anticipated|King's College Hospital NHS Trust||3||Recruitment issues|f||||f||||||||||2018-06-01 00:54:34.379312|2018-06-01 00:54:34.379312
NCT00916032|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2013-03-31||2017-10-19|2009-06-05|2009-06-08|Estimate|2013-09-03|2013-09-05|Estimate||||2017-10-19|2017-11-22|Actual|June 2009||2009-06-30|September 2013|2013-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A|Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study|Completed||Phase 4|29|Actual|Shire||2|||f||||t||||||||||2018-06-01 00:54:34.524106|2018-06-01 00:54:34.524106
NCT00916019|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-15|2009-06-05|2009-06-08|Estimate|||||||2009-06-15|2009-06-16|Estimate|July 2002||2002-07-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Investigation of the Effects of Exercise on Gene Expression|Investigation on Gene Expression and Gene Marker Accompanied by a Single Bout of Exercise and Exercise Training|Completed||N/A|6|Actual|Fukuoka University||1|||f||||t||||||||||2018-06-01 00:54:34.962125|2018-06-01 00:54:34.962125
NCT00916006|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2012-02-21|2010-09-22|2015-03-13|2009-06-05|2009-06-08|Estimate|2012-02-21|2012-03-21|Estimate|2010-09-22|2010-09-27|Estimate|2015-03-13|2015-04-02|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIa)|Completed||Phase 3|269|Actual|Peplin||2|||f||||f||||||||||2018-06-01 00:54:35.025694|2018-06-01 00:54:35.025694
NCT00915993|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-05|2009-06-05|2009-06-08|Estimate|||||||2009-06-05|2009-06-08|Estimate|May 2009||2009-05-31|June 2009|2009-06-30||||May 2011|Anticipated|2011-05-31||Interventional|||MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer|An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic Renal Cell Carcinoma|Unknown status|Recruiting|N/A|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:54:35.304933|2018-06-01 00:54:35.304933
NCT00915980|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2011-07-06|2009-06-05|2009-06-08|Estimate|||||||2011-07-06|2011-07-08|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|October 2010|Actual|2010-10-31|May 2009|Actual|2009-05-31||Observational|||Meal Stimulating After Roux-en Y Gastric Bypass|Meal Stimulating After Roux-en Y Gastric Bypass|Completed|||8|Actual|Hvidovre University Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma and serum sampels for analysis of primarily intestinal hormones~   "|||2018-06-01 00:54:35.406034|2018-06-01 00:54:35.406034
NCT00915967|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2012-09-03|2009-06-05|2009-06-08|Estimate|||||||2012-09-03|2012-09-05|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Interventional|POWI||Prevention of Neurosurgical Wound Infections|Pilot Project: Prevention of Neurosurgical Wound Infections|Unknown status|Active, not recruiting|N/A|250|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 00:54:35.467401|2018-06-01 00:54:35.467401
NCT00915954|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-07-28|2009-06-05|2009-06-08|Estimate|||||||2009-07-28|2009-07-29|Estimate|December 2008||2008-12-31|July 2009|2009-07-31||||||||Interventional|||Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)|Growth Hormone Feedback In Patients With Acromegaly, Type 2 Diabetes Mellitus, And Healthy Adults|Unknown status|Recruiting|Phase 4|30|Anticipated|Cedars-Sinai Medical Center|||||f||||||||||||||2018-06-01 00:54:35.572659|2018-06-01 00:54:35.572659
NCT00915811|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2011-08-16|2009-06-05|2009-06-08|Estimate|||||||2011-08-16|2011-08-17|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|FB-ATG||Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin|Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin|Terminated||Phase 2|20|Anticipated|King's College Hospital NHS Trust||1||FB ATG is now a standard for sib allo MDS patients|f||||f||||||||||2018-06-01 00:54:37.589913|2018-06-01 00:54:37.589913
NCT00915941|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2011-11-10|2009-06-05|2009-06-08|Estimate|||||||2011-11-10|2011-11-11|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Observational|Pepsin||Exploratory Study of Potential Pulmonary Aspiration Markers From Bronchoalveolar Lavage Fluid|"Exploratory Study of Potential Pulmonary Aspiration Markers From Bronchoalveolar Lavage Fluid"|Completed|||300|Actual|Mayo Clinic|||||f||||t||||||Samples Without DNA|"~     BALF specimens will be collected by the MCF Biospecimen Facility at the time of the~     bronchoscopy. A minimum of 5 mL will be collected. Specimen processing will include~     centrifugation to separate the cell pellet from the supernatant. The supernatant will be~     stored in 2 mL cryovials, and stored at -70°C until time of testing for the pepsin-ELISA.~     Storage will allow retesting at another date if the assay is modified or if another substance~     of interest arises in the course of the study that requires re-testing of the specimens. The~     clinical sample will also be tested through the Mayo Clinic medical laboratory for bilirubin,~     pepsinogen, amylase, and lipase.~   "|||2018-06-01 00:54:35.633524|2018-06-01 00:54:35.633524
NCT00915928|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2014-04-07|2009-06-04|2009-06-08|Estimate|||||||2014-04-07|2014-04-08|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|KSDH||Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors|Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors|Terminated||N/A|47|Actual|Odense University Hospital||2||No effect of the ACE inhibitor evaluated halfway in the study|f||||t||||||||||2018-06-01 00:54:35.675044|2018-06-01 00:54:35.675044
NCT00915915|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2014-10-27|2009-06-05|2009-06-08|Estimate|||||||2014-10-27|2014-10-28|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Inhibition of Ovulation and Pharmacokinetics of Transdermal Ethinylestradiol (EE) and Gestodene (GSD)|Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol and Either 1.05 or 2.1 mg Gestodene in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles|Completed||Phase 2|108|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:54:35.73058|2018-06-01 00:54:35.73058
NCT00915902|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2014-04-04||2015-11-04|2009-06-05|2009-06-08|Estimate|2014-04-04|2014-05-07|Estimate||||2015-11-04|2015-12-08|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Fish Oil Study for High Triglyceride Levels in Children|Fish Oil Treatment for Dyslipidemia Associated With Children and Adolescents|Completed||Phase 2/Phase 3|42|Actual|Nemours Children's Clinic|Intrinsic variability of triglycerides is large and may have confounded analyses; 4-week washout between treatment periods may have been too short; a reduction of triglycerides in the corn oil placebo group may have compromised the results.|2|||f||||f||||||||||2018-06-01 00:54:35.793303|2018-06-01 00:54:35.793303
NCT00915889|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2015-06-03|2009-06-05|2009-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2006||2006-11-30|June 2015|2015-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors|Cervical Cancer Survivorship Among African-, European-, and Latina-American Survivors|Completed||N/A|340|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 00:54:36.005715|2018-06-01 00:54:36.005715
NCT00915876|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2016-10-07||2016-10-07|2009-06-05|2009-06-08|Estimate|2016-10-07|2016-12-02|Estimate||||2016-10-07|2016-12-02|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||One placebo group patient dropped out due to an adverse event is not included in baseline measures or in outcome measures. Assuming 35% variability in circulating ICAM-1 concentrations,46 a sample size of 18 per group is adequate to detect a 50 percentage point difference in the percent in ICAM-1 with 80% power and an = 0.05.|Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo|Effects of 19-nor-1α-dihydroxyvitamin D2 (Paricalcitol) Versus Placebo on Oxidative Stress and Vascular Reactivity in CKD Patients|Completed||N/A|41|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 00:54:37.078342|2018-06-01 00:54:37.078342
NCT00915863|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2010-01-25|2009-06-05|2009-06-08|Estimate|||||||2010-01-25|2010-01-26|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|March 2014|Anticipated|2014-03-31|October 2013|Anticipated|2013-10-31||Interventional|||Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy|A Prospective Randomized Controlled Trial Comparing Isolated Roux-en-Y Reconstruction With Billroth-II-type Reconstruction After Pancreaticoduodenectomy|Unknown status|Recruiting|N/A|150|Anticipated|Wakayama Medical University||2|||f||||t||||||||||2018-06-01 00:54:37.277873|2018-06-01 00:54:37.277873
NCT00915850|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2010-09-08|2009-06-05|2009-06-08|Estimate|||||||2010-09-08|2010-09-09|Estimate|August 2007||2007-08-31|September 2010|2010-09-30|August 2015|Anticipated|2015-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)|Phase I/II Trial of Combination Chemotherapy With Docetaxel, Cisplatin and 5-FU for Unresectable Advanced Esophageal Cancer.|Unknown status|Recruiting|Phase 1/Phase 2|32|Anticipated|Wakayama Medical University||1|||f||||t||||||||||2018-06-01 00:54:37.363182|2018-06-01 00:54:37.363182
NCT00915837|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-04|2009-06-04|2009-06-08|Estimate|||||||2009-06-04|2009-06-08|Estimate|June 2005||2005-06-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|STRIDE||Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema|Phase 1 Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema|Completed||Phase 1|31|Actual|SurModics, Inc.||2|||f||||f||||||||||2018-06-01 00:54:37.43457|2018-06-01 00:54:37.43457
NCT00915824|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-10-28|2009-06-05|2009-06-08|Estimate|||||||2009-10-28|2009-10-29|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|June 2009|Anticipated|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Prevention of Potentially Inappropriate Prescribing in Late Life Using Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) and Screening Tool to Alert Doctors to Right Treatment (START) Criteria|Prevention of Potentially Inappropriate Prescribing in Late Life Using STOPP (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions) and START (Screening Tool to Alert Doctors to Right i.e. Appropriate Indicated Treatment): A Randomized Controlled Trial.|Unknown status|Active, not recruiting|Phase 4|400|Actual|Cork University Hospital||1|||f||||f||||||||||2018-06-01 00:54:37.512634|2018-06-01 00:54:37.512634
NCT00915798|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2016-11-02||2017-01-12|2009-06-05|2009-06-08|Estimate|2017-01-12|2017-01-13|Estimate||||2017-01-12|2017-01-13|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||Association Between Smoking, Brain Activity, Genes, and ADHD|Smoking, Neurocircuitry and Genes in Adult ADHD|Completed|||89|Actual|University of California, Irvine|||4||f||||t||||||Samples With DNA|"~     Blood samples for genotyping~   "|No||2018-06-01 00:54:37.773591|2018-06-01 00:54:37.773591
NCT00915785|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2013-04-23|2009-06-05|2009-06-08|Estimate|||||||2013-04-23|2013-04-24|Estimate|November 2005||2005-11-30|April 2013|2013-04-30||||April 2013|Actual|2013-04-30||Interventional|||Azacytidine for the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukemia (MDS/AML) With High Risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities|Pilot Study of 5 Azacytidine in the Treatment of Myelodysplastic Syndromes/Acute Myeloid Leukaemia With High-risk (Chromosome 7 and or Complex) Cytogenetic Abnormalities|Completed||Phase 2|40|Actual|King's College London||1|||f||||f||||||||||2018-06-01 00:54:38.183287|2018-06-01 00:54:38.183287
NCT00915772|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2012-06-13||2014-04-29|2009-06-05|2009-06-08|Estimate|2012-06-13|2012-07-18|Estimate||||2014-04-29|2014-05-14|Estimate|June 2009||2009-06-30|April 2014|2014-04-30||||June 2011|Actual|2011-06-30||Interventional|||Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid|Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid|Completed||Phase 3|567|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 00:54:38.324098|2018-06-01 00:54:38.324098
NCT00915759|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2013-05-15||2014-07-16|2009-06-05|2009-06-08|Estimate|2013-09-19|2013-09-20|Estimate||||2014-07-16|2014-07-25|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|November 2010|Actual|2010-11-30||Interventional|||Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy|Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy|Unknown status|Active, not recruiting|N/A|40|Actual|Walter Reed National Military Medical Center||2|||f||||||||||||||2018-06-01 00:54:39.401106|2018-06-01 00:54:39.401106
NCT00915746|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2010-04-29|2009-06-04|2009-06-08|Estimate|||||||2010-04-29|2010-04-30|Estimate|November 2009||2009-11-30|April 2010|2010-04-30|December 2009|Actual|2009-12-31|||||Interventional|||A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of JNJ-31001074 in Healthy Subjects|Completed||Phase 1|14|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 00:54:39.600471|2018-06-01 00:54:39.600471
NCT00915733|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-11-09|2009-06-05|2009-06-08|Estimate|||||||2009-11-09|2009-11-10|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|ACCELAMI2C19||Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism|Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism|Completed||Phase 4|80|Actual|Gyeongsang National University Hospital||2|||f||||t||||||||||2018-06-01 00:54:39.677274|2018-06-01 00:54:39.677274
NCT00915720|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2011-07-19|2009-06-05|2009-06-08|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Observational|||Implanted Loop Recorder Post Atrial Fibrillation Ablation|Implanted Loop Recorder Surveillance of Recurrent Atrial Fibrillation After Atrial Fibrillation Ablation|Unknown status|Active, not recruiting||50|Actual|Thoracic & Cardiovascular Healthcare Foundation|||||f||||f||||||||||2018-06-01 00:54:39.769753|2018-06-01 00:54:39.769753
NCT00915707|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2013-09-04|2009-06-05|2009-06-08|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2007||2007-01-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk|Pathways Linking Reduced Sleep Duration and Quality to Obesity Risk|Completed||N/A|23|Actual|University of Chicago||3|||f||||f||||||||||2018-06-01 00:54:39.829378|2018-06-01 00:54:39.829378
NCT00915694|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2016-02-09|2009-06-05|2009-06-08|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2009||2009-04-30|February 2016|2016-02-29||||July 2011|Actual|2011-07-31||Interventional|||Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme|A Phase I Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma|Unknown status|Active, not recruiting|Phase 1|23|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 00:54:39.897802|2018-06-01 00:54:39.897802
NCT00915681|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2017-12-21|2009-06-05|2009-06-08|Estimate|||||||2017-12-21|2017-12-26|Actual|February 2010||2010-02-28|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning|Prevention and Treatment of Amatoxin Induced Hepatic Failure With Intravenous Silibinin ( Legalon® SIL): An Open Multicenter Clinical Trial|Recruiting||Phase 2/Phase 3|50|Anticipated|Madaus Inc||1|||f||||f||||||||||2018-06-01 00:54:39.961806|2018-06-01 00:54:39.961806
NCT00915668|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2016-09-19|2009-06-04|2009-06-08|Estimate|||||||2016-09-19|2016-09-20|Estimate||||November 2010|2010-11-30|March 2011|Anticipated|2011-03-31|||||Interventional|||A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women|An Open-Label, Randomized, Crossover Drug-Drug Interaction Study to Assess the Effects of Multiple Doses of JNJ-31001074 on the Pharmacokinetics of a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel|Withdrawn||Phase 1|0|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||The trial is postponed pending the completion of other ongoing pre-clinical and clinical work.|f||||f||||||||||2018-06-01 00:54:40.042365|2018-06-01 00:54:40.042365
NCT00915655|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2011-11-25||2012-08-28|2009-06-04|2009-06-08|Estimate|2011-11-25|2011-12-28|Estimate||||2012-08-28|2012-09-03|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|DIONE||A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents|A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years|Completed||Phase 2|12|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||t||||||||||2018-06-01 00:54:40.112796|2018-06-01 00:54:40.112796
NCT00915642|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-07-31|2009-06-05|2009-06-08|Estimate|||||||2009-07-31|2009-08-03|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|May 2010|Anticipated|2010-05-31|January 2010|Anticipated|2010-01-31||Observational|weightsleep||Overnight Weight Loss and Sleep Structure|Overnight Weight Loss, Sleep Structure and the Endocrine System|Unknown status|Recruiting||60|Anticipated|Associacao Fundo de Incentivo a Psicofarmcologia|||2||f||||t||||||||||2018-06-01 00:54:40.415504|2018-06-01 00:54:40.415504
NCT00915629|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2011-10-05|2009-06-04|2009-06-08|Estimate|||||||2011-10-05|2011-10-06|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|||Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®||Terminated||N/A|134|Anticipated|Pileje||1|||f||||f||||||||||2018-06-01 00:54:40.493052|2018-06-01 00:54:40.493052
NCT00915616|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-05|2009-06-05|2009-06-08|Estimate|||||||2009-06-05|2009-06-08|Estimate||||June 2009|2009-06-30||||||||Interventional|||The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease|The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease|Withdrawn||Phase 3|||Mansoura University||4|||f||||||||||||||2018-06-01 00:54:40.558342|2018-06-01 00:54:40.558342
NCT00915603|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2014-11-21||2014-12-11|2009-06-04|2009-06-08|Estimate|2014-12-11|2014-12-22|Estimate||||2014-12-11|2014-12-22|Estimate|July 2009||2009-07-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional||Includes all enrolled and randomized patients|Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)|Completed||Phase 2|113|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 00:54:40.637978|2018-06-01 00:54:40.637978
NCT00915590|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2012-10-02||2017-05-05|2009-06-04|2009-06-08|Estimate|2017-05-05|2017-05-08|Actual||||2017-05-05|2017-05-08|Actual|April 2009||2009-04-30|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Topical IL-1-Ra for Treatment of Corneal Neovascularization|Topical IL-1-Ra for Treatment of Corneal Neovascularization|Terminated||Phase 1/Phase 2|10|Actual|Massachusetts Eye and Ear Infirmary|Enrollment goal for this study was set at 20 participants (10 for each treatment arm). After an interim analysis, the Principal Investigator decided to terminate the study and stop enrollment.|2|||f||||f||||||||Yes||2018-06-01 00:54:41.182241|2018-06-01 00:54:41.182241
NCT00915577|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-05|2009-06-05|2009-06-08|Estimate|||||||2009-06-05|2009-06-08|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe|An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects|Completed||Phase 3|74|Actual|Biogen||2|||f||||f||||||||||2018-06-01 00:54:41.494748|2018-06-01 00:54:41.494748
NCT00915564|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2013-10-11|2009-06-04|2009-06-08|Estimate|||||||2013-10-11|2013-10-16|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone|A Phase I, Open-Label, Single-Sequence Drug-Drug Interaction Trial in Subjects On Stable Methadone Maintenance Therapy, to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone, at Steady-State|Completed||Phase 1|13|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||f||||||||||2018-06-01 00:54:41.569573|2018-06-01 00:54:41.569573
NCT00915551|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2012-02-21|2010-09-22|2015-02-18|2009-06-05|2009-06-08|Estimate|2012-02-21|2012-03-16|Estimate|2010-09-22|2010-09-27|Estimate|2015-02-18|2015-03-06|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIb)|Completed||Phase 3|278|Actual|Peplin||2|||f||||f||||||||||2018-06-01 00:54:41.672408|2018-06-01 00:54:41.672408
NCT00915538|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-05|2009-06-05|2009-06-08|Estimate|||||||2009-06-05|2009-06-08|Estimate|May 2008||2008-05-31|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|WSMR2||Comparing Bronchodilation of Symbicort With and With Out Valved Holding Chamber (Aerochamber Plus)|A Comparison of the Bronchodilating Activity of Symbicort pMDI 160/4.5 Used in the Conventional Manner and With a Valved Spacer Holding Chamber (Aerochamber Plus)|Unknown status|Recruiting|N/A|16|Anticipated|Western Sky Medical Research||2|||f||||f||||||||||2018-06-01 00:54:41.92253|2018-06-01 00:54:41.92253
NCT00915525|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2015-10-02||2015-11-13|2009-06-04|2009-06-08|Estimate|2015-11-13|2015-12-18|Estimate||||2015-11-13|2015-12-18|Estimate|February 2010||2010-02-28|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||BOTOX‐Treated population includes all patients enrolled in 191622-096 who received at least 1 BOTOX treatment in study 191622‐096, 191622‐095 or 191622‐520. Treatment groups reflect highest dose received (100U BOTOX includes patients who received 100U throughout the study and 150U BOTOX includes patients who received at least 1 dose of 150U).|Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence||Completed||Phase 3|829|Actual|Allergan||2|||f||||f||||||||||2018-06-01 00:54:42.294287|2018-06-01 00:54:42.294287
NCT00915512|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2013-10-09|2009-06-05|2009-06-08|Estimate|||||||2013-10-09|2013-10-10|Estimate|May 2009||2009-05-31|October 2013|2013-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia|An Open-label, Single-arm, Multicenter, Phase IV Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-release Paliperidone in Patients With Schizophrenia|Completed||Phase 4|84|Actual|Janssen-Cilag Turkey||1|||f||||f||||||||||2018-06-01 00:54:49.49006|2018-06-01 00:54:49.49006
NCT00915499|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2012-12-10||2013-02-22|2009-06-05|2009-06-08|Estimate|2013-01-18|2013-02-22|Estimate||||2013-02-22|2013-02-28|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|CompSAS||Complex Sleep Apnea Syndrome (CompSAS) Resolution Study|Is Adaptive Servo-Ventilation Therapeutically More Effective Than Continuous Positive Airway Pressure In Treating Complex Sleep Apnea Syndrome?|Completed||N/A|66|Actual|ResMed||2|||f||||f||||||||||2018-06-01 00:54:49.593934|2018-06-01 00:54:49.593934
NCT00915486|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2012-03-15|2009-06-05|2009-06-08|Estimate|||||||2012-03-15|2012-03-16|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DFU||A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers|A Randomized, Multi-center, Controlled, Parallel Group, Dose Finding Study of the Efficacy and Safety of Topically Applied I-020201 as an Adjunct to Good Standard-of-care Versus Good Standard-of-care Alone in Patients With Chronic Diabetic Foot Ulcers|Completed||Phase 2|211|Actual|Kuros Biosurgery AG||5|||f||||t||||||||||2018-06-01 00:54:49.851667|2018-06-01 00:54:49.851667
NCT00915473|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2014-01-10||2014-02-24|2009-06-05|2009-06-08|Estimate|2014-01-10|2014-02-25|Estimate||||2014-02-24|2014-03-20|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Greater Occipital Nerve Block for Migraine Prophylaxis|Greater Occipital Nerve Block for Migraine Prophylaxis|Completed||Phase 4|70|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:54:49.988402|2018-06-01 00:54:49.988402
NCT00915460|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-05|2009-06-05|2009-06-08|Estimate|||||||2009-06-05|2009-06-08|Estimate|September 1999||1999-09-30|June 2009|2009-06-30|July 2003|Actual|2003-07-31|June 2003|Actual|2003-06-30||Interventional|||Open-Label Safety Extension Study of Avonex|An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830|Completed||Phase 4|408|Actual|Biogen||3|||f||||t||||||||||2018-06-01 00:54:50.45295|2018-06-01 00:54:50.45295
NCT00915447|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2010-08-19|2009-06-05|2009-06-08|Estimate|||||||2010-08-19|2010-08-20|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|October 2010|Anticipated|2010-10-31|December 2009|Anticipated|2009-12-31||Observational|||Diesel Exhaust Particles and Leukotriene Production|Diesel Exhaust Particles and Leukotriene Production|Unknown status|Active, not recruiting||25|Anticipated|University of California, Los Angeles|||1||f||||||||||Samples Without DNA|"~     Urine, Nasal Lavage~   "|||2018-06-01 00:54:50.520848|2018-06-01 00:54:50.520848
NCT00915434|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2010-04-22|2009-06-04|2009-06-08|Estimate|||||||2010-04-22|2010-04-26|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|November 2009|Actual|2009-11-30|||||Interventional|||A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Characterize the Pharmacokinetics and the Effect of Food of JNJ-31001074 in Healthy Subjects|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||f||||||||||2018-06-01 00:54:50.575517|2018-06-01 00:54:50.575517
NCT00915421|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-05|2009-06-05|2009-06-08|Estimate|||||||2009-06-05|2009-06-08|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Observational|PRE-COOL||Pre-Hospital Cooling in Cardiac Arrest Patients|Pre-Hospital Cooling in Cardiac Arrest Patients - Feasibility Pilot Study|Unknown status|Recruiting||40|Anticipated|Emergency Medical Service of the Central Bohemian Region, Czech Republic|||1||f||||t||||||||||2018-06-01 00:54:50.636587|2018-06-01 00:54:50.636587
NCT00915408|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2015-09-01|2009-06-05|2009-06-08|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CRD||A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma|A Phase I Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma|Completed||Phase 1/Phase 2|32|Actual|King's College Hospital NHS Trust||1|||f||||f||||||||||2018-06-01 00:54:50.724049|2018-06-01 00:54:50.724049
NCT00915382|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2014-01-13|2009-06-05|2009-06-08|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SOS||Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer|Phase III Trial of 3-weekly vs. 5-weekly Schedule of S-1 Plus Cisplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer.|Completed||Phase 3|625|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 00:54:50.80466|2018-06-01 00:54:50.80466
NCT00915369|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2010-02-05|2009-06-05|2009-06-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer|A Multicentre Phase I Study Of Cremophor FreePaclitaxel Nanoparticle In Advanced Breast Cancer|Unknown status|Recruiting|Phase 1|24|Anticipated|Fresenius Kabi Oncology Ltd.|||||f||||f||||||||||2018-06-01 00:54:50.95524|2018-06-01 00:54:50.95524
NCT00915356|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2011-01-24||2012-01-02|2009-06-05|2009-06-08|Estimate|2012-01-02|2012-02-01|Estimate||||2012-01-02|2012-02-01|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305|A Double-blind, Randomised, Placebo-controlled, Multicentre, Dose-escalating Study of AZD1305 Given Intravenously for Cardioversion of Atrial Fibrillation|Completed||Phase 2|228|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 00:54:51.073371|2018-06-01 00:54:51.073371
NCT00915343|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|2015-06-08||2015-07-16|2009-06-05|2009-06-08|Estimate|2015-07-16|2015-07-20|Estimate||||2015-07-16|2015-07-20|Estimate|August 2007||2007-08-31|March 2014|2014-03-31|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|DC 06/02|Intention-To-Treat (ITT) set included all randomised participants who took at least 1 dose of study drug with assessments of any variables or with primary efficacy assessments including all pharmacokinetic (PK) samplings during any of the treatment periods.|Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency|A, Randomised, Controlled, Two-armed, Two-period Cross-over, Multi-centre Phase II/III Study to Assess the Safety and Pharmacokinetics of Once-daily Oral Modified-release Hydrocortisone in Patients With Adrenal Insufficiency|Completed||Phase 2/Phase 3|64|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:54:51.888319|2018-06-01 00:54:51.888319
NCT00915330|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2010-02-18|2009-06-05|2009-06-08|Estimate|||||||2010-02-18|2010-02-19|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Rapid On-site Cytopathologic Evaluation in the Diagnosis of Hilar/Mediastinal Adenopathy|Transbronchial Needle Aspiration With and Without Rapid On-site Cytopathologic Evaluation in the Diagnostic Approach to Hilar/Mediastinal Adenopathy: A Randomized Controlled Trial.|Completed||N/A|164||Maggiore Bellaria Hospital, Bologna||2|||f||||f||||||||||2018-06-01 00:54:53.09318|2018-06-01 00:54:53.09318
NCT00915317|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2015-03-10|2009-06-05|2009-06-08|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency|Effect of Vitamin D Supplementation on Erythropoietin Dosage in Hemodialysis Patients Who Have Vitamin D Deficiency|Withdrawn|||0|Actual|Kaiser Permanente||||"Before we could start the study, we realized that many of the patients were already getting~   ergocalciferol. Therefore, the study was closed."|f||||||||||||||2018-06-01 00:54:53.16922|2018-06-01 00:54:53.16922
NCT00915304|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2012-12-17|2009-06-05|2009-06-08|Estimate|||||||2012-12-17|2012-12-18|Estimate|June 2009||2009-06-30|December 2012|2012-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|EBMeDS||Evidence-Based Medicine Electronic Decision Support Study|Patient Specific Automatic Reminders in Primary Care - the EBMeDS Randomised Trial|Completed||Phase 1/Phase 2|12101|Actual|University of Tampere|||||f||||f||||||||||2018-06-01 00:54:53.240881|2018-06-01 00:54:53.240881
NCT00915291|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2009-06-05|2009-06-05|2009-06-08|Estimate|||||||2009-06-05|2009-06-08|Estimate|May 2007||2007-05-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluating Effectiveness of Educational Intervention to Help Physicians Address Inappropriate Patient Requests for Direct-to-Consumer Advertised Prescription Medications|Sound Prescribing Study - Assessing the Impact of Pharmaceutical Marketing and Promotional Practices on Physician Prescribing|Completed||N/A|133|Actual|American Medical Association||2|||f||||f||||||||||2018-06-01 00:54:53.313371|2018-06-01 00:54:53.313371
NCT00915109|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2012-09-18|2009-06-04|2009-06-05|Estimate|||||||2012-09-18|2012-09-19|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Gait Stability of People With Lower-limb Amputations|Gait Stability of People With Lower-limb Amputations|Completed|||50|Actual|Nova Scotia Health Authority|||3||f||||f||||||||||2018-06-01 00:54:56.471677|2018-06-01 00:54:56.471677
NCT00915278|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2014-02-25||2014-02-25|2009-06-04|2009-06-08|Estimate|2014-02-25|2014-04-04|Estimate||||2014-02-25|2014-04-04|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||The analyzed population is the total number of enrolled subjects who started treatment.|A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors|A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors|Terminated||Phase 1|33|Actual|Pfizer|This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.|1||"The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive and~   does not support further development"|f||||f||||||||||2018-06-01 00:54:53.464526|2018-06-01 00:54:53.464526
NCT00915265|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-05|||2018-01-30|2009-06-05|2009-06-08|Estimate|||||||2018-01-30|2018-01-31|Actual|October 2009||2009-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Continuous Preperitoneal Infusion of Local Anesthetic (CPA) Versus Epidural Infusion of Local Anesthetic (EA) in Fast-Track Open Colorectal Surgery|Continuous Preperitoneal Versus Epidural Infusion of Local Anesthetic for Enhanced Postoperative Recovery Following Open Colorectal Surgery|Recruiting||Phase 4|100|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:54:55.365952|2018-06-01 00:54:55.365952
NCT00915252|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2012-12-13|2009-06-04|2009-06-05|Estimate|||||||2012-12-13|2012-12-17|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AML-AZA||Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML|Completed||Phase 2|214|Actual|University Hospital Muenster||2|||f||||t||||||||||2018-06-01 00:54:55.438247|2018-06-01 00:54:55.438247
NCT00915239|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers|Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers|Completed||N/A|50|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-06-01 00:54:55.539924|2018-06-01 00:54:55.539924
NCT00915226|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2014-11-13|2009-06-04|2009-06-05|Estimate|||||||2014-11-13|2014-11-14|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure.|Withdrawn||N/A|0|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 00:54:55.609595|2018-06-01 00:54:55.609595
NCT00915213|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2016-12-16|2009-06-04|2009-06-05|Estimate|||||||2016-12-16|2016-12-19|Estimate|October 2008||2008-10-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Incidence of Antibiotic Resistant E.Coli in Patients Undergoing Repeat Prostate Biopsy|Incidence of Fluoroquinolone Resistant Enterobacteraciae in Patients Undergoing Repeat Ultrasound Guided Prostate Biopsy|Completed|||136|Actual|University of California, Irvine|||1||f||||f||||||Samples Without DNA|"~     Rectal Swab~   "|||2018-06-01 00:54:55.667879|2018-06-01 00:54:55.667879
NCT00915200|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-06-23|2009-06-04|2009-06-05|Estimate|||||||2016-06-23|2016-06-27|Estimate|October 2009||2009-10-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy|N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy.|Completed||Phase 2|114|Actual|The University of Texas Health Science Center at San Antonio||5|||f||||t||||||||||2018-06-01 00:54:55.721276|2018-06-01 00:54:55.721276
NCT00915187|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2011-10-18|2009-06-03|2009-06-05|Estimate|||||||2011-10-18|2011-10-19|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly|A Phase II Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly, a Double-blind Randomized, Controlled Single Center Study|Completed||Phase 2|130|Actual|NasVax Ltd||2|||f||||t||||||||||2018-06-01 00:54:55.904992|2018-06-01 00:54:55.904992
NCT00915174|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2011-05-05|2009-06-04|2009-06-05|Estimate|||||||2011-05-05|2011-05-06|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects||Completed||Phase 1|36|Actual|Merz Pharmaceuticals GmbH|||||f||||||||||||||2018-06-01 00:54:55.966276|2018-06-01 00:54:55.966276
NCT00915161|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Sustained Effects of Thoracocentesis in Mechanically Ventilated Patients|Sustained Effects of Thoracocentesis in Mechanically Ventilated Patients: an Observational Single Centre Cohort Study|Completed|||10|Actual|Oxford University Hospitals NHS Trust|||||f||||f||||||||||2018-06-01 00:54:56.025934|2018-06-01 00:54:56.025934
NCT00915148|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2015-08-21||2016-04-25|2009-06-04|2009-06-05|Estimate|2016-04-25|2016-04-26|Estimate||||2016-04-25|2016-04-26|Estimate|November 2008||2008-11-30|April 2016|2016-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Ultrasound Prediction of Prolonged Labour|First Stage 3D-ultrasound During Prolonged Labour.|Completed|||110|Actual|Helse Stavanger HF|||1||f||||f||||||||||2018-06-01 00:54:56.09964|2018-06-01 00:54:56.09964
NCT00915135|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2010-05-31|2009-06-03|2009-06-05|Estimate|||||||2010-05-31|2010-06-02|Estimate|May 2002||2002-05-31|May 2010|2010-05-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Efficacy and Safety of Ramelteon on Chronic Insomnia|A Double-Blind, Dose-Response, Cross-Over Study of TAK-375 With Chronic Insomnia (Phase II Study) -- Polysomnographic Evaluation|Completed||Phase 2|66|Actual|Takeda||1|||f||||t||||||||||2018-06-01 00:54:56.261969|2018-06-01 00:54:56.261969
NCT00915122|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-12-28|2009-06-04|2009-06-05|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2005||2005-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|September 2010|Actual|2010-09-30||Interventional|||Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate|A Phase I/II Study of Dose Escalated Intensity Modulated Radiation Therapy (IMRT) for the Treatment of Pelvic Lymph Nodes and Primary Tumour in Patients With Carcinoma of the Prostate|Active, not recruiting||Phase 1/Phase 2|81|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 00:54:56.330584|2018-06-01 00:54:56.330584
NCT00915096|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2010-03-14|2009-06-04|2009-06-05|Estimate|||||||2010-03-14|2010-03-16|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma|High Tumor Burden Follicular Lymphoma: Impact of [18F]-FDG Positron Emission Tomography (PET) in the Assessment of Treatment Response|Unknown status|Active, not recruiting||120|Anticipated|Lymphoma Study Association|||1||f||||f||||||Samples With DNA|"~     Burden tissue sample~   "|||2018-06-01 00:54:56.523682|2018-06-01 00:54:56.523682
NCT00915083|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2013-03-26|2009-06-04|2009-06-05|Estimate|||||||2013-03-26|2013-03-28|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.|A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.|Completed||Phase 1|24|Actual|Celgene||1|||f||||f||||||||||2018-06-01 00:54:56.611648|2018-06-01 00:54:56.611648
NCT00915070|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-08-09|2009-06-04|2009-06-05|Estimate|||||||2012-08-09|2012-08-10|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans|Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans|Completed||N/A|16|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:54:56.69855|2018-06-01 00:54:56.69855
NCT00915057|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-12-21|2009-06-03|2009-06-05|Estimate|||||||2009-12-21|2009-12-23|Estimate|March 2009||2009-03-31|December 2009|2009-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.|An Open Study to Investigate the Effects of Chronic Viral Hepatitis B or C on the Pharmacokinetics of Cholyl-lysyl-fluorescein (NRL972) Before, During and After Standard Treatment.|Completed||Phase 2|100|Anticipated|Norgine||1|||f||||f||||||||||2018-06-01 00:54:56.765878|2018-06-01 00:54:56.765878
NCT00915044|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|July 2007||2007-07-31|June 2009|2009-06-30||||July 2014|Anticipated|2014-07-31||Observational|IBD||Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in Inflammatory Bowel Disease (IBD)|Characterization of Interactions Between Immune Cells of Intestinal Mucosa or Peripheral Blood With the Extracellular Matrix in IBD|Unknown status|Recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||Samples Without DNA|"~     15 ml peripheral blood will be obtained from all participants.~   "|||2018-06-01 00:54:56.825351|2018-06-01 00:54:56.825351
NCT00915031|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2013-06-24|2009-06-03|2009-06-05|Estimate|||||||2013-06-24|2013-06-26|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|||Use of Hypothermia During Robotic Prostatectomy|Hypothermic Nerve Sparing Radical Prostatectomy|Unknown status|Enrolling by invitation|N/A|100|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-06-01 00:54:56.890372|2018-06-01 00:54:56.890372
NCT00915018|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2017-08-10|2013-11-12|2018-03-02|2009-06-04|2009-06-05|Estimate|2017-10-06|2017-11-06|Actual|2013-11-12|2013-12-05|Estimate|2018-03-02|2018-03-06|Actual|August 2009||2009-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2013|Actual|2013-08-31||Interventional|NEFERTT||Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer|A Randomized, Open-Label, Two-Arm Study Of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel As First-Line Treatment For ErbB-2-Positive Locally Recurrent Or Metastatic Breast Cancer|Active, not recruiting||Phase 2|479|Actual|Puma Biotechnology, Inc.||2|||f||||t|t|f||||||||2018-06-01 00:54:57.014914|2018-06-01 00:54:57.014914
NCT00915005|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2018-02-12|2009-06-04|2009-06-05|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2009|Actual|2009-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence|A Bayesian Randomized Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence|Active, not recruiting||Phase 2|250|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-06-01 00:54:58.33043|2018-06-01 00:54:58.33043
NCT00914992|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2014-12-05|2009-06-04|2009-06-05|Estimate|||||||2014-12-05|2014-12-08|Estimate|July 2009||2009-07-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure.|Withdrawn||N/A|0|Actual|Medical University of Vienna|||||f||||t||||||||||2018-06-01 00:54:58.422212|2018-06-01 00:54:58.422212
NCT00914979|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2015-06-21|2009-06-04|2009-06-05|Estimate|||||||2015-06-21|2015-06-23|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|ABC||AngioSculpt Scoring Balloon Catheter For Bifurcation Coronary Lesions (ABC Study)|AngioSculpt Scoring Balloon Catheter For Bifurcation Coronary Lesions (ABC Study) Prospective, Multi-center, Non-randomized, Single-arm Registry|Terminated||Phase 3|7|Actual|HaEmek Medical Center, Israel||1||Difficulties in recruiting patients|f||||t||||||||||2018-06-01 00:54:58.480168|2018-06-01 00:54:58.480168
NCT00914966|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2013-05-23||2014-03-19|2009-06-04|2009-06-05|Estimate|2013-05-23|2013-07-18|Estimate||||2014-03-19|2014-04-15|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE|A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE® (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks|Completed||Phase 4|20|Actual|Shire||1|||f||||f||||||||||2018-06-01 00:54:58.581033|2018-06-01 00:54:58.581033
NCT00914953|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2012-02-29|2009-06-04|2009-06-05|Estimate|||||||2012-02-29|2012-03-02|Estimate|February 2010||2010-02-28|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Oxytocin and Social Behavior Over the Lifespan|Oxytocin and Social Behavior Over the Lifespan: Interventional Study|Completed||Early Phase 1|41|Actual|Claremont Graduate University||1|||f||||f||||||||||2018-06-01 00:54:58.847357|2018-06-01 00:54:58.847357
NCT00914940|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2018-02-12|2009-06-04|2009-06-05|Estimate|||||||2018-02-12|2018-02-14|Actual|October 2009||2009-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD|A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD|Active, not recruiting||Phase 2|60|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 00:54:59.04702|2018-06-01 00:54:59.04702
NCT00914927|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2017-12-05|2013-05-21|2018-01-19|2009-06-04|2009-06-05|Estimate|2018-01-19|2018-01-23|Actual|2013-05-21|2013-05-29|Estimate|2018-01-19|2018-01-23|Actual|May 2009||2009-05-31|January 2018|2018-01-31|December 21, 2011|Actual|2011-12-21|November 11, 2011|Actual|2011-11-11||Interventional||Intent to Treat (ITT) population included all participants who were randomized into the study, received study medication, and had a post-treatment assessment.|Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures|A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures|Completed||Phase 2|130|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 00:54:59.214335|2018-06-01 00:54:59.214335
NCT00914914|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2014-10-27|2009-06-04|2009-06-05|Estimate|||||||2014-10-27|2014-10-28|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment|A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors|Completed||Phase 1|15|Actual|CDG Therapeutics, Inc.||1|||f||||t||||||||||2018-06-01 00:55:00.812525|2018-06-01 00:55:00.812525
NCT00914901|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Concentrations of Salmeterol in Blood and Urine|Blood and Urinary Concentrations of Inhaled Salmeterol in Asthmatic Subjects and Elite Athletes With Asthma.|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||||2018-06-01 00:55:00.892478|2018-06-01 00:55:00.892478
NCT00914888|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2012-06-05|2009-06-04|2009-06-05|Estimate|||||||2012-06-05|2012-06-07|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia|Multicenter, Randomized, And Double-Blind Study To Evaluate The Safety Of Tigecycline Versus A Ceftriaxone Regimen In The Treatment Of Complicated Intra-Abdominal Infections And Community-Acquired Pneumonia In Subjects Of 8-17 Years|Withdrawn||Phase 3|0|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 00:55:00.967227|2018-06-01 00:55:00.967227
NCT00914875|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Observational|||Kidney Function After Pneumoperitoneum and Analgesia|Kidney Function After Laparoscopic Cholecystectomy and Tramadol Anesthesia Plus Dipyrone or Ketorolac|Completed|||126|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||t||||||||||2018-06-01 00:55:01.041226|2018-06-01 00:55:01.041226
NCT00914862|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2012-03-07||2012-03-07|2009-06-03|2009-06-05|Estimate|2012-03-07|2012-04-04|Estimate||||2012-03-07|2012-04-04|Estimate|November 2009||2009-11-30|March 2012|2012-03-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults|A Comparative Single Dose Pharmacokinetic and Safety Study of 4 mg or 8 mg Ramelteon in Adolescents With Insomnia Characterized by Difficulty With Sleep Onset, Children With Insomnia Associated With ADHD, and Healthy Adults.|Completed||Phase 1|56|Actual|Takeda||5|||f||||f||||||||||2018-06-01 00:55:01.138347|2018-06-01 00:55:01.138347
NCT00914849|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2016-07-14||2017-04-06|2009-06-04|2009-06-05|Estimate|2016-07-14|2016-08-24|Estimate||||2017-04-06|2017-05-17|Actual|August 2009||2009-08-31|April 2017|2017-04-30|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional||One recipient was not transplanted because of donor withdrawal of consent to collect a second day after a failed first day apheresis attempt.|Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies|A Phase II Study Evaluating the Safety and Efficacy of Intravenous AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies|Completed||Phase 2|68|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-06-01 00:55:02.151439|2018-06-01 00:55:02.151439
NCT00914836|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2015-06-21|2009-06-04|2009-06-05|Estimate|||||||2015-06-21|2015-06-23|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Comparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful Shoulder||Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel||2||difficulties in the department|f||||t||||||||||2018-06-01 00:55:02.682153|2018-06-01 00:55:02.682153
NCT00914823|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2018-02-20|2009-06-04|2009-06-05|Estimate|||||||2018-02-20|2018-02-22|Actual|March 2009||2009-03-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Administration of Kisspeptin to Subjects With Reproductive Disorders|Kisspeptin Administration in the Adult|Recruiting||Phase 1|496|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:55:02.759331|2018-06-01 00:55:02.759331
NCT00914810|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2013-04-22||2013-06-07|2009-06-04|2009-06-05|Estimate|2013-06-07|2013-06-11|Estimate||||2013-06-07|2013-06-11|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Supplemental Vitamin D on Skeletal Muscle Function in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effect of Supplemental Vitamin D on Skeletal Muscle Function in COPD Patients.|Completed||Phase 3|39|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 00:55:02.847608|2018-06-01 00:55:02.847608
NCT00914797|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Terbutaline Concentrations in Blood and Urine|Blood and Urinary Concentrations of Terbutaline in Asthmatics and Elite Athletes With Asthma: Comparison Between Inhalation vs. Oral Administration.|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||||2018-06-01 00:55:03.100627|2018-06-01 00:55:03.100627
NCT00914784|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|August 2009||2009-08-31|June 2009|2009-06-30|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Observational|||The Incidence of TRALI in Patients Undergoing Orthopedic-Oncology Surgery|The Incidence of Transfusion-Related Acute Lung Injury (TRALI) Following Blood Product Transfusion in Patients Undergoing Elective Orthopedic-Oncology Procedures|Unknown status|Not yet recruiting||550|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||Samples With DNA|"~     blood from arterial line to test for PaO2~   "|||2018-06-01 00:55:03.194403|2018-06-01 00:55:03.194403
NCT00914615|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2017-09-19|2009-06-04|2009-06-05|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2007||2007-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) in Liver Metastasis (COLD 3)|Phase II Trial of Stereotactic Body Radiation Therapy for Unresectable Liver Metastases From Colorectal Carcinoma|Active, not recruiting||Phase 2|23|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:55:04.8725|2018-06-01 00:55:04.8725
NCT00914771|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2015-10-08|2009-06-04|2009-06-05|Estimate|||||||2015-10-08|2015-10-12|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects|A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects|Completed||Phase 2|722|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:55:03.264997|2018-06-01 00:55:03.264997
NCT00914758|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Observational|||Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)|Comparison of Alemtuzumab (Campath®) and High Dose Interferon Beta-1a (Rebif®) Treatment on Cognition in Subjects With Relapsing Forms of MS|Unknown status|Enrolling by invitation||1|Actual|Washington Neuropsychology Research Group|||3||f||||f||||||||||2018-06-01 00:55:03.382739|2018-06-01 00:55:03.382739
NCT00914745|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2011-08-05|2009-06-04|2009-06-05|Estimate|||||||2011-08-05|2011-08-08|Estimate|April 2009||2009-04-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Place Controlled Study to Treat Recurrent Herpes Labialis.|Single Center Phase I/II, Placebo Controlled, Randomized, Double-Blind Study to Treat Recurrent Herpes Labialis by Topical Treatment With Hydroxypropyl-Beta-Cyclodextrin-Ointment (HPßCD-20% Ointment)|Completed||Phase 2|40|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 00:55:03.485402|2018-06-01 00:55:03.485402
NCT00914732|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04||2011-08-10|2014-12-04|2009-06-04|2009-06-05|Estimate||||2011-08-10|2011-08-15|Estimate|2014-12-04|2014-12-24|Estimate|February 2010||2010-02-28|January 2011|2011-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally|Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals|Completed||Phase 2|524|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 00:55:03.820501|2018-06-01 00:55:03.820501
NCT00914719|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|September 2002||2002-09-30|June 2009|2009-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Alcohol Use and Sexual Risk: An Intervention|Alcohol Use and Sexual Risk: An Intervention|Completed||N/A|484||University of New Mexico||3|||f||||||||||||||2018-06-01 00:55:03.908448|2018-06-01 00:55:03.908448
NCT00914706|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2013-05-07|2009-06-04|2009-06-05|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Observational|||A Study of the Effect of a Chronic Disease Management System on Diabetes Care Within Multidisciplinary Primary Care Practices in Ontario|Challenging the Ontario Diabetes Care Quality Gap: Evaluation and Long-Term Cost-Utility Analysis of Using a Chronic Disease Management System (CDMS) in Primary Health Care Practices in Ontario (ODIAC-CDMS): A Prospective, Observational, Comparative Study of the Effect of a CDMS on Diabetes Care Within Multidisciplinary Primary Care Practices in Ontario.|Completed|||39|Actual|St. Joseph's Healthcare Hamilton|||||f||||f||||||||||2018-06-01 00:55:03.982938|2018-06-01 00:55:03.982938
NCT00914693|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-12-04|2009-06-04|2009-06-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||EU/LA Pearl Index Study - Transdermal Contraceptive Patch|Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects|Completed||Phase 3|1694|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:55:04.071673|2018-06-01 00:55:04.071673
NCT00914680|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2011-07-20|2009-06-03|2009-06-05|Estimate|||||||2011-07-20|2011-07-22|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|May 2013|Anticipated|2013-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Berlin Magnetic Seizure Therapy Depression Trial 01|Investigation of Efficacy and Tolerability of Magnetic Seizure Therapy in the Treatment of Depression|Unknown status|Recruiting|Phase 3|32|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 00:55:04.331786|2018-06-01 00:55:04.331786
NCT00914667|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2011-05-31|2009-06-03|2009-06-05|Estimate|||||||2011-05-31|2011-06-01|Estimate|July 2009||2009-07-31|May 2011|2011-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects|An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Fesoterodine On The Pharmacokinetics And Pharmacodynamics Of A Single Supratherapeutic Dose Of Warfarin In Healthy Subjects.|Completed||Phase 1|14|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 00:55:04.433767|2018-06-01 00:55:04.433767
NCT00914654|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Concentrations of Formoterol in Blood and Urine|Blood and Urinary Concentrations of Inhaled Formoterol in Asthmatic Subjects and Elite Athletes With Asthma|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||||2018-06-01 00:55:04.535429|2018-06-01 00:55:04.535429
NCT00914641|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-08-24|2009-06-03|2009-06-05|Estimate|||||||2009-08-24|2009-08-25|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers|A Randomized, Open-Label, Single Dose, Four Way Cross-Over Bioavailability Study Comparing Three Modified Release Formulations Of Apixaban Tablets To Apixaban Immediate Release Tablets In Healthy Volunteers|Completed||Phase 1|16|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:55:04.62867|2018-06-01 00:55:04.62867
NCT00914628|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2016-04-13|2009-06-04|2009-06-05|Estimate|||||||2016-04-13|2016-04-14|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia|TK008 Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia|Recruiting||Phase 3|170|Anticipated|MolMed S.p.A.||2|||f||||t||||||||No|No, only information requested by law will be released|2018-06-01 00:55:04.725674|2018-06-01 00:55:04.725674
NCT00914602|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03||2011-05-11|2011-05-18|2009-06-04|2009-06-05|Estimate||||2011-05-11|2011-05-18|Estimate|2011-05-18|2011-05-20|Estimate|May 2009||2009-05-31|May 2011|2011-05-31||||January 2010|Actual|2010-01-31||Interventional|||An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects|An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations|Completed||Phase 1/Phase 2|14|Actual|XenoPort, Inc.||1|||f||||||||||||||2018-06-01 00:55:04.958879|2018-06-01 00:55:04.958879
NCT00914589|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2014-09-22||2017-01-23|2009-06-04|2009-06-05|Estimate|2014-11-12|2014-11-13|Estimate||||2017-01-23|2017-03-07|Actual|July 2009||2009-07-31|January 2017|2017-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery|A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment With Two Different Doses of Recombinant Factor XIII Following Cardiopulmonary Bypass Surgery|Completed||Phase 2|479|Actual|Novo Nordisk A/S||3|||f||||t||||||||||2018-06-01 00:55:05.077417|2018-06-01 00:55:05.077417
NCT00914576|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2013-07-23|2009-06-04|2009-06-05|Estimate|||||||2013-07-23|2013-07-24|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Antioxidants on Oxygen Induced Vasoconstriction in Lipopolysaccharide (LPS) Induced Inflammatory Model in Humans|Effect of Antioxidants on Oxygen Induced Vasoconstriction in LPS Induced Inflammatory Model in Humans|Completed||N/A|40|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 00:55:06.527116|2018-06-01 00:55:06.527116
NCT00914563|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|FACT in BURNS||An Upgrading of the Resuscitative Patterns by Utilization of the Balanced Crystalloids and Synthetic Colloids and the Non-Invasive Hemodynamic Monitoring During Burn Shock|An Optimizing of the Resuscitative Patterns by Use of Balanced Crystalloids and Colloids and the Non-Invasive Hemodynamic Monitoring|Unknown status|Enrolling by invitation|Phase 2|20|Anticipated|Faculty Hospital Kralovske Vinohrady||2|||f||||f||||||||||2018-06-01 00:55:07.142561|2018-06-01 00:55:07.142561
NCT00914550|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2014-12-12|2009-06-04|2009-06-05|Estimate|||||||2014-12-12|2014-12-15|Estimate|June 2009||2009-06-30|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia|Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia|Completed|||47|Actual|Winthrop University Hospital|||1||f||||f||||||None Retained|"~     Serum Procalcitonin~   "|||2018-06-01 00:55:07.422788|2018-06-01 00:55:07.422788
NCT00914537|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2018-04-04|2009-06-04|2009-06-05|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2, 2009||2009-06-02|August 21, 2017|2017-08-21||||||||Observational|||Anal Cancer Screening Study|Anal Cancer Screening Study|Completed|||363|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:55:07.497136|2018-06-01 00:55:07.497136
NCT00914524|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2010-09-28|2009-06-04|2009-06-05|Estimate|||||||2010-09-28|2010-09-29|Estimate|January 2005||2005-01-31|September 2010|2010-09-30|October 2006|Actual|2006-10-31|April 2006|Actual|2006-04-30||Interventional|||Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy|An Open-label Study of Olmesartan Medoxomil (CS-866) in Normotensive Patients With Chronic Glomerulonephritis or Diabetic Nephropathy|Completed||Phase 2|49|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 00:55:07.553921|2018-06-01 00:55:07.553921
NCT00914511|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2011-01-05|2009-06-04|2009-06-05|Estimate|||||||2011-01-05|2011-01-07|Estimate|May 2009||2009-05-31|January 2011|2011-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects|A Phase I, Single-Center, Open-Label, Non-Randomized, Two-Cohort Study to Assess the Effect of Age on the Pharmacokinetics of Avanafil And To Determine Avanafil Semen Exposure and the Acute Effect of Avanafil on Sperm Function in Healthy Young Male Subjects Following a Single Oral Dose of 200 mg|Completed||Phase 1|32|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-06-01 00:55:07.63318|2018-06-01 00:55:07.63318
NCT00914498|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2009-08-23|2009-06-04|2009-06-05|Estimate|||||||2009-08-23|2009-08-25|Estimate|July 2009||2009-07-31|August 2009|2009-08-31||||December 2010|Anticipated|2010-12-31||Interventional|||The Effect of Pre-incisional Local Xylocaine Injection on Post Operative Pain and Scar Formation After Cesarean Section|The Effect of Pre-incisional Local Xylocaine Injection on Post Operative Pain and Scar Formation After Cesarean Section|Unknown status|Recruiting|N/A|120|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||f||||||||||2018-06-01 00:55:07.701721|2018-06-01 00:55:07.701721
NCT00914485|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2015-02-03||2015-04-06|2009-06-04|2009-06-05|Estimate|2015-02-23|2015-03-09|Estimate||||2015-04-06|2015-04-27|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||Patients participating in study from baseline through post-intervention.|Using Multimedia Patient Feedback to Reduce Disparities in VA Healthcare|Using Multimedia Patient Feedback to Reduce Disparities in VA Healthcare|Completed||N/A|369|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 00:55:07.790165|2018-06-01 00:55:07.790165
NCT00914472|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2010-10-26|2009-06-04|2009-06-05|Estimate|||||||2010-10-26|2010-10-27|Estimate|April 2010||2010-04-30|December 2009|2009-12-31||||March 2011|Anticipated|2011-03-31||Interventional|HEPHIP0509||Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure.|A Randomized Non-inferiority Clinical Trial of Heparin Produced by Hipolabor Laboratory(PARINEX®) in Comparation With Heparin Produced by APP PHARMACEUTICALS in Patients With Chronic Renal Failure.|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:55:08.013413|2018-06-01 00:55:08.013413
NCT00914459|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|2016-08-08||2016-12-21|2009-06-04|2009-06-05|Estimate|2016-10-28|2016-12-21|Estimate||||2016-12-21|2017-02-10|Actual|December 2009||2009-12-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional||All treated analysis set included all enrolled participants who received at least 1 dose of ReFacto AF.|Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients|A Non-randomized, Open-label Study To Evaluate The Pharmacokinetics, Safety And Efficacy Of Refacto Af In Previously Treated Pediatric Subjects Less Than Twelve Years Of Age With Severe Hemophilia A (Fviii:c <1%).|Completed||Phase 4|37|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:55:08.114004|2018-06-01 00:55:08.114004
NCT00914446|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-06-04|2009-06-04|2009-06-05|Estimate|||||||2009-06-04|2009-06-05|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Interventional|||Identification of Protective and Worsening Steatohepatitis (NASH) Factors|Identification of Protective and Worsening Steatohepatitis (NASH) Factors by Microarray in Morbid Obesity Patients|Unknown status|Recruiting|N/A|150|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-06-01 00:55:08.623958|2018-06-01 00:55:08.623958
NCT00914433|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-11-30|2009-06-03|2009-06-05|Estimate|||||||2012-11-30|2012-12-03|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled TPI 1100 in Healthy Volunteers|A Phase 1,Randomized, Double--blind, Placebo-controlled Study Assessing the Safety and Tolerability, the Pharmacodynamics and Pharmacokinetics of Single-ascending and Repeated Doses of Inhaled TPI 1100 in Healthy Subjects|Withdrawn||Phase 1|0|Actual|Pharmaxis||1||Drug development suspended|f||||t||||||||||2018-06-01 00:55:08.71537|2018-06-01 00:55:08.71537
NCT00914420|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2010-04-16|2009-06-04|2009-06-05|Estimate|||||||2010-04-16|2010-04-19|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|October 2012|Anticipated|2012-10-31|November 2010|Anticipated|2010-11-30||Interventional|OISTER||Optical Coherence Tomography (OCT) Evaluation of Re-endothelization: A Comparison of the Intrepide™ Stent Versus Taxus™|OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™|Unknown status|Recruiting|Phase 4|40|Anticipated|Clearstream Technologies Ltd.||2|||f||||t||||||||||2018-06-01 00:55:08.787524|2018-06-01 00:55:08.787524
NCT00914407|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2017-03-09|2009-06-04|2009-06-05|Estimate|||||||2017-03-09|2017-03-10|Actual|April 2010||2010-04-30|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|December 10, 2016|Actual|2016-12-10||Interventional|||Measurement of Retinal Blood Flow, Retinal Oxygenation and Retinal Oxygen Extraction in Healthy Subjects During Normoxia and Systemic Hyperoxia|Measurement of Retinal Blood Flow, Retinal Oxygenation and Retinal Oxygen Extraction in Healthy Subjects During Normoxia and Systemic Hyperoxia|Completed||N/A|48|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 00:55:08.867492|2018-06-01 00:55:08.867492
NCT00914394|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2014-11-13|2009-06-04|2009-06-05|Estimate|||||||2014-11-13|2014-11-14|Estimate|October 2010||2010-10-31|November 2014|2014-11-30||||July 2011|Actual|2011-07-31||Interventional|||Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans|Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans|Terminated||N/A|12|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 00:55:08.936005|2018-06-01 00:55:08.936005
NCT00914381|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-03|2009-06-03|2009-06-05|Estimate|||||||2009-06-03|2009-06-05|Estimate|December 1994||1994-12-31|June 2009|2009-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Behavioral Treatment for Cocaine Dependent Women|Behavioral Treatment for Cocaine Dependent Women|Completed||Phase 2|145|Actual|Yale University||4|||f||||f||||||||||2018-06-01 00:55:09.015093|2018-06-01 00:55:09.015093
NCT00914368|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2010-04-12|2009-06-04|2009-06-05|Estimate|||||||2010-04-12|2010-04-13|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|TOPAS-1||Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis|TOPAS-1, A Pharmacodynamic Phase II Study of Clopidogrel P2Y12 Platelet Inhibition|Completed||Phase 2|450|Anticipated|Uppsala University||3|||f||||f||||||||||2018-06-01 00:55:09.086078|2018-06-01 00:55:09.086078
NCT00914355|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-04|||2017-09-19|2009-06-04|2009-06-05|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2007||2007-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) Hepatocellular Carcinoma (COLD 2)|Phase II Trial of Stereotactic Body Radiation Therapy for Unresectable Hepatocellular Carcinoma|Active, not recruiting||Phase 2|47|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 00:55:09.176241|2018-06-01 00:55:09.176241
NCT00914342|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-12-24|2009-06-04|2009-06-05|Estimate|||||||2009-12-24|2009-12-29|Estimate|July 2009||2009-07-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Observational|GerdQ-Greece||Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ|A Cross-sectional Study on the Prevalence and Impact in Work Productivity of GERD in Primary Care Patients With Upper GI Symptoms Using the Novel Questionnaire GERD-Q. The Greek GERD-Q Study|Completed|||889|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:55:09.259989|2018-06-01 00:55:09.259989
NCT00914329|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2010-06-02|2009-06-04|2009-06-05|Estimate|||||||2010-06-02|2010-06-03|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|ANXIHOMEV||Gelsemium Sempervirens in Anticipatory Anxiety|Randomized Controlled Study Versus Placebo Evaluating Effectiveness of Gelsemium Sempervirens (5CH et 15CH) on Provoked Anticipatory Anxiety, in Healthy Volunteers|Completed||Phase 3|180|Anticipated|University Hospital, Grenoble||3|||f||||f||||||||||2018-06-01 00:55:09.376082|2018-06-01 00:55:09.376082
NCT00914316|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2017-04-03||2017-07-10|2009-06-03|2009-06-04|Estimate|2017-07-10|2017-08-09|Actual||||2017-07-10|2017-08-09|Actual|May 2009||2009-05-31|June 2017|2017-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|STERILE|Missing data for 4 participants in Ranolazine/Ranolazine group, and 2 participants in placebo/Ranolazine group.|Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities|Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities. THE STERILE TRIAL.|Terminated||N/A|29|Actual|William Beaumont Hospitals|Early termination due to recruitment and retention difficulties, leading to small numbers of subjects. Missing data for several subjects.|4|||f||||t||||||||No|No plan to share individual participant data|2018-06-01 00:55:09.453458|2018-06-01 00:55:09.453458
NCT00914303|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2010-04-05|2009-06-03|2009-06-04|Estimate|||||||2010-04-05|2010-04-06|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect|Completed||Phase 1|77|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 00:55:09.903199|2018-06-01 00:55:09.903199
NCT00914290|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02||2013-09-27|2017-05-05|2009-06-03|2009-06-04|Estimate||||2015-09-08|2015-09-22|Estimate|2017-05-05|2017-05-08|Actual|April 2009||2009-04-30|May 2017|2017-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis|A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis|Completed||Phase 2|23|Actual|IMPAX Laboratories, Inc.||2|||f||||f|t|f||||||No||2018-06-01 00:55:09.985375|2018-06-01 00:55:09.985375
NCT00914277|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2011-04-29|2009-06-02|2009-06-04|Estimate|||||||2011-04-29|2011-05-02|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|RHOKET||SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction|Randomized, Double-blind, Placebo and Active Controlled Study of the Activity of SAR407899A Single-dose on the Ability to Increase Duration of Penile Rigidity, Under Experimental Condition, in Patients With Mild to Moderate Erectile Dysfunction (ED).|Completed||Phase 2|24|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 00:55:10.103318|2018-06-01 00:55:10.103318
NCT00914264|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2015-02-03|2009-06-03|2009-06-04|Estimate|||||||2015-02-03|2015-02-05|Estimate|December 2008||2008-12-31|August 2010|2010-08-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Observational|||The Effects of Continuous Positive Airway Pressure on Overlap Syndrome|The Continuous Positive Airway Pressure Effects on Chronic Obstructive Pulmonary Disease Patients With Obstructive Sleep Apnea|Unknown status|Recruiting||90|Anticipated|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-06-01 00:55:10.199707|2018-06-01 00:55:10.199707
NCT00914251|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-16|2009-06-03|2009-06-04|Estimate|||||||2009-06-16|2009-06-17|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|December 2010|Anticipated|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Vascular Effects of Hesperidin in Metabolic Syndrome|Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome|Unknown status|Recruiting|Phase 2|30|Anticipated|University of Rome Tor Vergata||2|||f||||||||||||||2018-06-01 00:55:10.272778|2018-06-01 00:55:10.272778
NCT00914238|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2016-10-24|2009-06-03|2009-06-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2015|Actual|2015-06-30||Interventional|OPUSII||Extended Specialized Assertive Intervention for First Episode Psychosis|A Randomized Clinical Trial of the Effect of Five-years Versus Two-years Specialized Assertive Intervention for First Episode Psychosis - the OPUS II Trial|Completed||N/A|400|Actual|University of Copenhagen||2|||f||||t||||||||||2018-06-01 00:55:10.345573|2018-06-01 00:55:10.345573
NCT00914225|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2015-05-27|2009-06-03|2009-06-04|Estimate|||||||2015-05-27|2015-05-29|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|ITN||Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya|Effect of Long-lasting Insecticide-treated Bednets and a Point-of-use Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya|Completed|||500|Actual|University of Washington|||2||f||||f||||||Samples With DNA|"~     Plasma HIV RNA Plasma for Malaria PCR~   "|||2018-06-01 00:55:10.519043|2018-06-01 00:55:10.519043
NCT00914212|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2015-10-09|2009-06-03|2009-06-04|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2009||2009-05-31|October 2015|2015-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)|A Functional Magnetic Resonance Imaging (fMRI) Study of the Reproducibility and the Effect of Sibutramine During Fasted and Fed Conditions in Healthy Overweight and Obese Men|Completed||Phase 1|15|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:55:10.626687|2018-06-01 00:55:10.626687
NCT00914199|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2016-09-22|2009-06-03|2009-06-04|Estimate|||||||2016-09-22|2016-09-23|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|September 2008|Actual|2008-09-30||Interventional|BIF III||The Nordic Bifurcation Study III|Stenting of Coronary Artery Stenoses With Significant Side Branches. Should we, or Should we Not, Perform Dilatation of the Side Branch Through the Main Vessel Stent, if There is Acceptable Blood Flow in the Side Branch?|Active, not recruiting||Phase 4|477|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-06-01 00:55:10.722574|2018-06-01 00:55:10.722574
NCT00914186|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2011-02-28||2011-11-30|2009-06-02|2009-06-04|Estimate|2011-11-10|2011-11-17|Estimate||||2011-11-30|2011-12-01|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of TS-022 in Adult Patients With a Diagnosis of Atopic Dermatitis (AD) With Moderate to Very Severe Pruritus|Completed||Phase 2|122|Actual|Taisho Pharmaceutical R&D Inc.|Slower than expected enrollment and a higher than expected screen failure rate.|4|||f||||f||||||||||2018-06-01 00:55:10.937942|2018-06-01 00:55:10.937942
NCT00914173|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2010-01-27|2009-06-03|2009-06-04|Estimate|||||||2010-01-27|2010-01-28|Estimate|November 2008||2008-11-30|January 2010|2010-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pain Monitoring Using Plurality of Non-invasive Physiological Measurement|A Single-blind Randomized Clinical Trial to Assess the Efficacy of the Medasense's Non-Invasive Pain Monitor in Estimating the Pain Level Comparing to the Pain Stimuli and the Reported Pain Level on Healthy Subjects.|Completed||N/A|100|Anticipated|Medasense Biometrics Ltd||1|||f||||f||||||||||2018-06-01 00:55:11.569497|2018-06-01 00:55:11.569497
NCT00914160|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|August 1993||1993-08-31|June 2009|2009-06-30|September 1993|Actual|1993-09-30|September 1993|Actual|1993-09-30||Interventional|||To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions|Completed||Phase 1|18|Actual|Sandoz||3|||f||||||||||||||2018-06-01 00:55:11.65456|2018-06-01 00:55:11.65456
NCT00914147|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2018-02-11|2009-06-03|2009-06-04|Estimate|||||||2018-02-11|2018-02-13|Actual|May 2009||2009-05-31|February 2018|2018-02-28|August 23, 2012|Actual|2012-08-23|August 23, 2012|Actual|2012-08-23||Interventional|||Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors|Pulmonary Function Tests (PFT) in a Phase I Patient Population|Completed||N/A|48|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 00:55:11.731928|2018-06-01 00:55:11.731928
NCT00914134|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2011-02-23|2009-06-03|2009-06-04|Estimate|||||||2011-02-23|2011-02-24|Estimate|April 2009||2009-04-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease|Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease|Completed||Phase 4|12|Actual|Helsinki University||1|||f||||f||||||||||2018-06-01 00:55:11.960666|2018-06-01 00:55:11.960666
NCT00914121|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-09-01|2009-06-02|2009-06-04|Estimate|||||||2009-09-01|2009-09-02|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)|A Single Dose, Crossover, Placebo- and Moxifloxacin- Controlled Study of the Effects of Bosutinib on Cardiac Repolarization in Healthy Adult Subjects|Completed||Phase 1|60|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||5|||f||||f||||||||||2018-06-01 00:55:12.093514|2018-06-01 00:55:12.093514
NCT00914108|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|October 1996||1996-10-31|June 2009|2009-06-30|July 2002|Actual|2002-07-31|July 2000|Actual|2000-07-31||Interventional|||Severe Intrauterine Growth Retardation: Developmental Newborn Intensive Care Unit (NICU) Care|Family-Centered Neuropsychoeducational In-NICU Intervention for Preterm Infants With Severe Intrauterine Growth Retardation and for Their Families|Completed||N/A|30|Actual|Boston Children’s Hospital|||||f||||f||||||||||2018-06-01 00:55:12.182981|2018-06-01 00:55:12.182981
NCT00745654|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2008-11-03|2008-09-02|2008-09-03|Estimate|||||||2008-11-03|2008-11-04|Estimate|July 2008||2008-07-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Chronic Pain After Lung Transplantation, an Incidence Study|Chronic Pain After Lung Transplantation, an Incidence Study|Completed|||111|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 01:47:29.048589|2018-06-01 01:47:29.048589
NCT00914095|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-04-23|2009-06-03|2009-06-04|Estimate|||||||2012-04-23|2012-04-24|Estimate|October 2009||2009-10-31|June 2009|2009-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PARKGAIT-II||Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)|Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial|Completed||Phase 4|69|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-06-01 00:55:12.244204|2018-06-01 00:55:12.244204
NCT00914082|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2013-03-15|2009-06-03|2009-06-04|Estimate|||||||2013-03-15|2013-03-18|Estimate|April 2009||2009-04-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|August 2011|Actual|2011-08-31||Interventional|||Mental Training and Childbirth|The Effect of Mental Training on Childbirth Measured on Pain Experience and Other Birth Outcomes|Completed||N/A|1222|Actual|University of Aarhus||3|||f||||f||||||||||2018-06-01 00:55:12.317169|2018-06-01 00:55:12.317169
NCT00914069|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2016-11-14||2017-03-02|2009-06-03|2009-06-04|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|June 2009||2009-06-30|March 2017|2017-03-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter|Evaluation of the Safety and Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter for Peripheral Intravenous (PIV) Insertion in Children, Oncology Patients and Elderly: a Controlled Randomized Trial|Terminated||N/A|175|Actual|C. R. Bard||2||Funding Stopped|f||||t||||||||No||2018-06-01 00:55:12.555364|2018-06-01 00:55:12.555364
NCT00914056|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2013-03-19|2009-06-03|2009-06-04|Estimate|||||||2013-03-19|2013-03-20|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Controlled Lactulose Withdrawal|Is Continuous Lactulose Therapy Necessary for Patients With Hepatic Encephalopathy? A Prospective Study of Controlled Lactulose Withdrawal|Completed||N/A|7|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||1|||f||||f||||||||||2018-06-01 00:55:12.920978|2018-06-01 00:55:12.920978
NCT00914043|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2013-01-10|2009-06-03|2009-06-04|Estimate|||||||2013-01-10|2013-01-11|Estimate||||January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45|Biobehavioral Mechanisms of Fatigue in Patients Treated on NSABP B-45: A Phase III Clinical Trial Comparing Adjuvant Sunitinib Malate to Placebo in Women With Residual Invasive Breast Cancer Following Neoadjuvant Chemotherapy|Withdrawn|||0|Actual|NSABP Foundation Inc||||Withdrawn as NCI rescinded approval for parent study NSABP-B-45|f||||||||||||||2018-06-01 00:55:12.997706|2018-06-01 00:55:12.997706
NCT00914030|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-08-25|2009-06-03|2009-06-04|Estimate|||||||2016-08-25|2016-08-26|Estimate|June 2009||2009-06-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Visual Exploration and Attention: Studies in Patients With Schizophrenia and Autism Spectrum Disorders|Visual Exploration and Attention : Studies in Patients With Schizophrenia and Autism Spectrum Disorders|Recruiting|||140|Anticipated|University Hospital, Strasbourg, France|||6||f||||f||||||||||2018-06-01 00:55:13.083189|2018-06-01 00:55:13.083189
NCT00914017|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-02-10|2009-06-02|2009-06-04|Estimate|||||||2010-02-10|2010-02-11|Estimate|January 2005||2005-01-31|February 2010|2010-02-28||||December 2010|Anticipated|2010-12-31||Interventional|||Statins and Breast Cancer Biomarkers|Statins and Breast Cancer Biomarkers|Unknown status|Recruiting|Phase 2|100|Anticipated|University of Vermont||2|||f||||f||||||||||2018-06-01 00:55:13.193|2018-06-01 00:55:13.193
NCT00914004|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual||||June 2009|2009-06-30||||||||Interventional|||To Demonstrate the Relative Bioequivalency of Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets|A Two-Way Crossover Bioequivalency Study Comparing Single 100 mg Doses Of Cord's 50 mg Desipramine HCL Tablets To Merrell Dow's 50 mg Norpramin Tablets|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:13.329416|2018-06-01 00:55:13.329416
NCT00913991|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2010-02-24|2009-06-03|2009-06-04|Estimate|||||||2010-02-24|2010-02-26|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Mechanisms of the Relaxation Response in Elderly Hypertensives|Mechanisms of the Relaxation Response in Elderly Hypertensives|Unknown status|Recruiting|Phase 1|90|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 00:55:13.386126|2018-06-01 00:55:13.386126
NCT00913978|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-12-21|2009-06-03|2009-06-04|Estimate|||||||2017-12-21|2017-12-26|Actual|April 13, 2017|Actual|2017-04-13|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Perioperative Active Warming Techniques in Colorectal Surgeries|A Prospective Randomized Evaluation of Two Perioperative Active Warming Techniques in Maintenance of Normothermia in Colorectal Surgeries|Recruiting||N/A|160|Anticipated|Northwestern University||2|||f||||f|f|t|f|f||||No||2018-06-01 00:55:13.449123|2018-06-01 00:55:13.449123
NCT00913965|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|July 1989||1989-07-31|June 2009|2009-06-30|August 1989|Actual|1989-08-31|August 1989|Actual|1989-08-31||Interventional|||To Demonstrate the Relative Bioavailability of Atenolol Tablets|Bioavailability of Atenolol Tablets|Completed||Phase 1|24|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:13.533296|2018-06-01 00:55:13.533296
NCT00913952|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|April 1994||1994-04-30|June 2009|2009-06-30|June 1994|Actual|1994-06-30|June 1994|Actual|1994-06-30||Interventional|||To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions|Comparative, Randomized, 3-way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fed and Fasted Conditions|Completed||Phase 1|18|Actual|Sandoz||3|||f||||||||||||||2018-06-01 00:55:13.588033|2018-06-01 00:55:13.588033
NCT00913939|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-09-19|2009-06-02|2009-06-04|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2009||2009-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||High-Dose-Rate Brachytherapy|MRI-Guided HDR Brachytherapy for Prostate Cancer|Recruiting||N/A|100|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 00:55:13.646329|2018-06-01 00:55:13.646329
NCT00913926|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2015-04-21|2009-06-03|2009-06-04|Estimate|||||||2015-04-21|2015-04-22|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Effects of Wellnara on Climacteric Symptoms|Multicenter Non-interventional Study on Efficacy, Tolerability, and Acceptance of Wellnara Containing 1.03 mg Estradiol Hemihydrate (Equivalent to 1 mg Estradiol) and 0.04 mg Levonorgestrel for Treatment of Hormone Deficiency Symptoms in Postmenopausal Women During 6 Cycles of 28 Days.|Completed|||749|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:55:13.71783|2018-06-01 00:55:13.71783
NCT00913913|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2014-02-19||2015-10-28|2009-06-03|2009-06-04|Estimate|2015-10-28|2015-12-01|Estimate||||2015-10-28|2015-12-01|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Number was the actual number of patients who signed consent and received treatment on study.|Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients|A Phase II Study of VEGF Blockade With Bevacizumab Combined With Autologous Tumor/Dendritic Cell Vaccine (DC Vaccine), Interleukin-2 (IL-2) and Interferon-α-2b (IFNα-2b) in Patients With Metastatic Renal Cell Carcinoma (RCC)|Terminated||Phase 2|8|Actual|Dartmouth-Hitchcock Medical Center|This study closed early due to difficulty enrolling patients with enrollment limited due to new competing therapies. Though enrollment numbers per statistical design were not met, the primary objective may still be reviewed.|1||low accrual not allowing site to meeting statistical endpoints|f||||t||||||||||2018-06-01 00:55:14.801905|2018-06-01 00:55:14.801905
NCT00913900|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2014-12-04|2009-06-03|2009-06-04|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SCRIPT-CLI||Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease|Stem Cell Revascularization in Patients With Critical Limb Ischemia|Terminated||Phase 1|10|Actual|University of Wisconsin, Madison||2||Failure to mobilize adequate CD34+ stem cells for minimum study treatment dose.|f||||t||||||||||2018-06-01 00:55:14.976144|2018-06-01 00:55:14.976144
NCT00913887|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|April 1994||1994-04-30|June 2009|2009-06-30|May 1994|Actual|1994-05-31|May 1994|Actual|1994-05-31||Interventional|||To Demonstrate the Relative Bioavailability of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Diclofenac Sodium 75 mg Enteric-Coated Tablets Under Non-Fasting Conditions|Completed||Phase 1|18|Actual|Sandoz||3|||f||||||||||||||2018-06-01 00:55:15.045479|2018-06-01 00:55:15.045479
NCT00913874|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2005||2005-10-31|June 2009|2009-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 500 mg Delayed Release Tablets Under Fasting Conditions|Completed||Phase 1|30|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:15.108539|2018-06-01 00:55:15.108539
NCT00913861|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2014-06-02|2009-06-03|2009-06-04|Estimate|||||||2014-06-02|2014-06-03|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Non-pharmacological Intervention for Colonoscopy|Does Non-pharmacological Intervention Reduce Consumption of Propofol During Colonoscopy?|Terminated||N/A|80|Actual|University Hospital, Geneva||3||affiliation's change of the principal investigator need a new review bord|f||||f||||||||||2018-06-01 00:55:15.170299|2018-06-01 00:55:15.170299
NCT00913848|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2005||2005-10-31|June 2009|2009-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions|Completed||Phase 1|30|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:15.247018|2018-06-01 00:55:15.247018
NCT00913835|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2016-11-18|2011-09-19|2017-03-03|2009-06-03|2009-06-04|Estimate|2017-03-03|2017-04-14|Actual|2011-09-19|2011-09-26|Estimate|2017-03-03|2017-04-14|Actual|June 2009||2009-06-30|March 2017|2017-03-31|February 2014|Actual|2014-02-28|October 2011|Actual|2011-10-31||Interventional||Modified Intent to Treat (mITT) Population: All participants who were randomized and received any quantity of study drug.|A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer|Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti-Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer|Completed||Phase 2|125|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 00:55:15.455374|2018-06-01 00:55:15.455374
NCT00913822|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|December 1987||1987-12-31|June 2009|2009-06-30|December 1987|Actual|1987-12-31|December 1987|Actual|1987-12-31||Interventional|||To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets|Bioavailability of Desipramine Hydrochloride Tablets|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:16.394829|2018-06-01 00:55:16.394829
NCT00913809|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|December 1987||1987-12-31|June 2009|2009-06-30|December 1987|Actual|1987-12-31|December 1987|Actual|1987-12-31||Interventional|||To Demonstrate the Relative Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets|A Two-Way Single Dose Crossover Bioequivalency of Cord's 100 mg Desipramine HCL Tablets To Merrell Dow's 100 mg Norpramin Tablets|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:16.448289|2018-06-01 00:55:16.448289
NCT00913796|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2010-10-21|2009-06-03|2009-06-04|Estimate|||||||2010-10-21|2010-10-22|Estimate|December 2007||2007-12-31|June 2009|2009-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|MART||Metabolic Acidosis in Renal Transplant Patients|Metabolic Acidosis and Its Impact on Mineral Metabolism and Physical Performance in Renal Transplant Patients|Completed||Phase 2|30|Actual|University of Zurich||2|||f||||t||||||||||2018-06-01 00:55:16.508017|2018-06-01 00:55:16.508017
NCT00913783|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|November 1992||1992-11-30|June 2009|2009-06-30|December 1992|Actual|1992-12-31|December 1992|Actual|1992-12-31||Interventional|||To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fasted Conditions|Comparative, Randomized, 2-way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fasted Conditions|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:16.580717|2018-06-01 00:55:16.580717
NCT00913081|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2015-01-29||2015-02-19|2009-06-02|2009-06-03|Estimate|2015-02-19|2015-03-05|Estimate||||2015-02-19|2015-03-05|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|ANTI-FLUSH|All study participants|Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)|Advancing Niacin by Inhibiting FLUSHing: (ANTI-FLUSH)|Completed||Phase 4|17|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 00:55:32.695488|2018-06-01 00:55:32.695488
NCT00913770|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2015-05-11||2016-08-04|2009-06-03|2009-06-04|Estimate|2015-05-11|2015-05-28|Estimate||||2016-08-04|2016-09-15|Estimate|September 2008||2008-09-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional||Baseline population description is the number of subjects randomized to study arm|Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department|Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department|Completed||N/A|329|Actual|Yale University||3|||f||||f||||||||||2018-06-01 00:55:16.726767|2018-06-01 00:55:16.726767
NCT00913757|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2017-10-18|2009-06-03|2009-06-04|Estimate|||||||2017-10-18|2017-10-19|Actual|July 1, 2009||2009-07-01|August 15, 2017|2017-08-15||||||||Observational|||A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area|A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:55:16.954416|2018-06-01 00:55:16.954416
NCT00913744|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2014-04-02||2014-12-02|2009-06-03|2009-06-04|Estimate|2014-04-02|2014-05-05|Estimate||||2014-12-02|2014-12-17|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|MIVI-5|Full Analysis Set (FAS): All randomized subjects who have been administered trial medication and for whom data of at least one post-baseline efficacy assessment is available. One subject (ocriplasmin) was not included in the FAS because the subject withdrew consent after receiving study treatment and refused further contact.|Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion|A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (AMD)|Completed||Phase 2|100|Actual|ThromboGenics||2|||f||||t||||||||||2018-06-01 00:55:17.044739|2018-06-01 00:55:17.044739
NCT00913731|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-10-28|2009-06-03|2009-06-04|Estimate|||||||2009-10-28|2009-10-29|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Observational|FAST-O||Quality Project to Evaluate and Validate the FAST-O Rating Scale|Quality Project to Evaluate and Validate the FAST-O Rating Scale (Fast ASessment in Acute Treatment of Psychosis-Observation)|Completed|||111|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:55:17.405517|2018-06-01 00:55:17.405517
NCT00913718|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|June 1996||1996-06-30|June 2009|2009-06-30|July 1996|Actual|1996-07-31|July 1996|Actual|1996-07-31||Interventional|||To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fasting Conditions Following Administration of a 40 mg Dose|Completed||Phase 1|46|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:17.490345|2018-06-01 00:55:17.490345
NCT00913705|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2011-06-10|2009-06-03|2009-06-04|Estimate|||||||2011-06-10|2011-06-13|Estimate|September 1999||1999-09-30|June 2011|2011-06-30|June 2009|Actual|2009-06-30|December 2007|Actual|2007-12-31||Interventional|NATCH||Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer|Randomized Trial of Surgery With or Without Paclitaxel Plus Carboplatin as Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable, Non-small-cell Lung Cancer|Completed||Phase 3|624|Anticipated|Spanish Lung Cancer Group||1|||f||||t||||||||||2018-06-01 00:55:17.691167|2018-06-01 00:55:17.691167
NCT00913692|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2012-02-29||2012-05-03|2009-06-03|2009-06-04|Estimate|2012-05-03|2012-06-11|Estimate||||2012-05-03|2012-06-11|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis|A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)|The protocol was terminated early due to slow recruitment.|||Terminated due to slow recruitment.|f||||t||||||||||2018-06-01 00:55:18.00038|2018-06-01 00:55:18.00038
NCT00913679|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2011-11-03|2009-06-03|2009-06-04|Estimate|||||||2011-11-03|2011-11-04|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty|A Comparison of Two Different Surgical Techniques to Preserve the Bony Supply and Improve Implant Longevity in Hip Resurfacing Arthroplasty|Unknown status|Recruiting|N/A|50|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 00:55:18.779583|2018-06-01 00:55:18.779583
NCT00913666|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|November 2002||2002-11-30|June 2009|2009-06-30|November 2004|Actual|2004-11-30|||||Interventional|||Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers|A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects|Completed||Phase 4|121|Actual|Biogen||4|||f||||f||||||||||2018-06-01 00:55:19.288763|2018-06-01 00:55:19.288763
NCT00913653|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-11-16|2009-06-03|2009-06-04|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2009||2009-05-31|November 2016|2016-11-30||||July 2009|Actual|2009-07-31||Interventional|||Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure|An Open Label, Non-randomised Study to Explore Safety/Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure|Completed||Phase 2|30|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:55:19.471224|2018-06-01 00:55:19.471224
NCT00913640|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-07-14|2009-06-03|2009-06-04|Estimate|||||||2009-07-14|2009-07-16|Estimate||||July 2009|2009-07-31||||||||Observational|ProMem||Prospective Memory in Parkinson's Disease|Prospective Memory in Parkinson's Disease|Completed|||||Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 00:55:19.702913|2018-06-01 00:55:19.702913
NCT00913627|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2017-08-08|2012-11-09|2018-02-22|2009-06-03|2009-06-04|Estimate|2018-02-22|2018-03-22|Actual|2012-11-09|2012-11-16|Estimate|2018-02-22|2018-03-22|Actual|May 7, 2009|Actual|2009-05-07|February 2018|2018-02-28|August 5, 2009|Actual|2009-08-05|August 1, 2009|Actual|2009-08-01||Interventional|||Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain|Ibuprofen 600 Mg Extended Release (er) Single-dose Dental Pain Study|Completed||Phase 2|196|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:55:20.078267|2018-06-01 00:55:20.078267
NCT00913614|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-11-29|2009-06-02|2009-06-04|Estimate|||||||2010-11-29|2010-11-30|Estimate|June 2009||2009-06-30|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|PKiDs||Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia|Single Dose, Open Label Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Eplivanserin Doses in Children Aged 6-17 Years With Insomnia of Various Origins|Completed||Phase 1|41|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 00:55:24.157179|2018-06-01 00:55:24.157179
NCT00913601|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2014-07-02|2009-06-03|2009-06-04|Estimate|||||||2014-07-02|2014-07-03|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|SNS||Treatment of Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Stimulation Bilaterally?|Treatment of Idiopathic Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Implantation and Stimulation of Permanent Electrodes Bilaterally - a Double-blinded Randomized Cross-over Trial|Terminated||N/A|29|Actual|University of Aarhus||3||"Prematurely stopped, as no beneficial effect was evident for bilateral stimulation after~   interim analysis of the first 20 patients."|f||||t||||||||||2018-06-01 00:55:24.50292|2018-06-01 00:55:24.50292
NCT00913588|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|May 1996||1996-05-31|June 2009|2009-06-30|August 1996|Actual|1996-08-31|August 1996|Actual|1996-08-31||Interventional|||To Demonstrate the Relative Bioavailability of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Healthy Adult Males Under Fed and Fasted Conditions|Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fed and Fasted Conditions Following Administration of a 40 mg Dose|Completed||Phase 1|24|Actual|Sandoz||3|||f||||||||||||||2018-06-01 00:55:24.693194|2018-06-01 00:55:24.693194
NCT00913575|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2014-05-21|2009-06-02|2009-06-04|Estimate|||||||2014-05-21|2014-05-22|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|Omega||Effect of Pre-surgery Neuromuscular Physiotherapy (PT)|Effect of Pre-surgery Neuromuscular Physiotherapy (PT) on Functional Outcome After Total Knee Replacement (TKR): A Single-blinded Randomized Controlled Trial.|Completed||Phase 3|44|Actual|University of Zurich||2|||f||||t||||||||||2018-06-01 00:55:24.809394|2018-06-01 00:55:24.809394
NCT00913562|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2014-11-20|2009-06-03|2009-06-04|Estimate|||||||2014-11-20|2014-11-21|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma|Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma|Withdrawn||Phase 4|0|Actual|Medical University of Vienna||4|||f||||t||||||||||2018-06-01 00:55:24.945428|2018-06-01 00:55:24.945428
NCT00913549|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|December 1989||1989-12-31|June 2009|2009-06-30|January 1990|Actual|1990-01-31|January 1990|Actual|1990-01-31||Interventional|||To Demonstrate the Relative Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets|Bioequivalency Study of Dosage Forms of Clemastine 2.68 mg Tablets|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:25.120322|2018-06-01 00:55:25.120322
NCT00913536|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-12-29|2009-06-03|2009-06-04|Estimate|||||||2017-12-29|2018-01-03|Actual|November 2005||2005-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Cone Beam Computed Tomography (CT) Bladder|Cone-Beam Computed Tomography in Image-Guided Radiotherapy for Patients With Bladder Cancer|Active, not recruiting||N/A|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 00:55:25.253853|2018-06-01 00:55:25.253853
NCT00913523|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2011-04-12||2011-08-19|2009-06-03|2009-06-04|Estimate|2011-04-12|2011-05-06|Estimate||||2011-08-19|2011-08-23|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora|Vaginal Lactobacillus and Other Key Microflora During and After Menses in Women Using Tampons Containing Glycerol Monolaurate (GML) and Women Using Tampons Without GML|Completed||N/A|482|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-06-01 00:55:25.36855|2018-06-01 00:55:25.36855
NCT00913510|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2013-06-27||2014-01-03|2009-06-03|2009-06-04|Estimate|2014-01-03|2014-01-06|Estimate||||2014-01-03|2014-01-06|Estimate|December 2009||2009-12-31|January 2014|2014-01-31||||May 2012|Actual|2012-05-31||Interventional|||Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction|Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis|Terminated||N/A|24|Actual|Wellspect HealthCare||2|||f||||f||||||||||2018-06-01 00:55:26.702864|2018-06-01 00:55:26.702864
NCT00913497|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2014-04-03|2009-06-03|2009-06-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children|Phase 4 Crossover Study Comparing the Effect of Insulin Glulisine to Insulin Aspart on Breakfast Post Prandial Blood Glucose Levels in Prepubertal Children With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy|Completed||Phase 4|16|Actual|Spectrum Health Hospitals||2|||f||||f||||||||||2018-06-01 00:55:26.907703|2018-06-01 00:55:26.907703
NCT00913484|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|October 2000||2000-10-31|June 2009|2009-06-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Disulfiram for Cocaine Abuse in Buprenorphine Treatment|Disulfiram for Cocaine Abuse in Buprenorphine Treatment|Completed||Phase 2|177|Actual|Yale University||2|||f||||||||||||||2018-06-01 00:55:26.994579|2018-06-01 00:55:26.994579
NCT00913471|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2018-02-06|2009-06-03|2009-06-04|Estimate|||||||2018-02-06|2018-02-08|Actual|June 2009||2009-06-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|SCI Pain||Biomarkers for Pain in Spinal Cord Injury (SCI) Patients|Biomarkers for Pain in Spinal Cord Injury (SCI) Patients|Active, not recruiting|||120|Anticipated|The University of Texas Health Science Center, Houston|||3||f||||f||||||Samples Without DNA|"~     blood samples (120 subjects) and skin tissue biopsy (20 subjects)~   "|No|There is no plan to share individual participant data.|2018-06-01 00:55:27.068859|2018-06-01 00:55:27.068859
NCT00913458|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2013-06-10||2014-07-15|2009-06-03|2009-06-04|Estimate|2014-07-15|2014-07-17|Estimate||||2014-07-15|2014-07-17|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional||A total of 306 participants were enrolled in the study (Phase 1). Out of the 306 participants, 193 were eligible and were randomized at a ratio of 1:1:1 to Phase 2 study. Of the 193 participants from Phase 2, a total of 131 participants were eligible and were randomized to Phase 3 study.|Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis|A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate|Completed||Phase 4|306|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:55:27.22034|2018-06-01 00:55:27.22034
NCT00913445|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-06-10|2009-06-03|2009-06-04|Estimate|||||||2010-06-10|2010-06-11|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Wound Healing After Emergency Appendicectomy|Wound Healing and Cosmetic Result After Emergency Appendicectomy in Adult Patients: a Prospective, Randomised Trial Comparing Two Methods of Wound Closure|Completed||Phase 4|200|Anticipated|Tampere University Hospital||2|||f||||f||||||||||2018-06-01 00:55:29.216961|2018-06-01 00:55:29.216961
NCT00913432|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2012-09-25|2009-06-03|2009-06-04|Estimate|||||||2012-09-25|2012-09-26|Estimate|March 2007||2007-03-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|March 2009|Actual|2009-03-31||Interventional|||A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis|A 12-week With Possible Extension, Prospective, Multicenter, Randomized, Open Label, Uncontrolled, 2-parallel Group, Phase II Study to Compare Efficacy and Safety of AB1010 at 3 and 6 mg/kg/Day in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis With Inadequate Response to 1. Methotrexate or to 2. Any DMARD Including Anti TNF Alpha if Patients Previously Failed Methotrexate or to 3. Methotrexate in Combination With Any DMARD Including Anti TNF Alpha|Unknown status|Active, not recruiting|Phase 2|20|Actual|AB Science||2|||f||||t||||||||||2018-06-01 00:55:29.273411|2018-06-01 00:55:29.273411
NCT00913419|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|November 1988||1988-11-30|June 2009|2009-06-30|December 1988|Actual|1988-12-31|December 1988|Actual|1988-12-31||Interventional|||To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets|Bioavailability of Cyclobenzaprine HCl Tablets|Completed||Phase 1|30|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:29.335263|2018-06-01 00:55:29.335263
NCT00913406|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|November 2005||2005-11-30|June 2009|2009-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|S-26 Gold L||Effect of Lutein in S-26 Gold On Growth And Safety|Effect of Lutein in S-26 Gold on Growth and Safety|Completed||N/A|232|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 00:55:29.520125|2018-06-01 00:55:29.520125
NCT00913393|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-08-30|2009-06-03|2009-06-04|Estimate|||||||2012-08-30|2012-09-03|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of FG-3019 in Subjects With Type 2 DM and KD on ACEi and/or ARB Therapy|A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background ACEi and/or ARB Therapy|Terminated||Phase 2|34|Actual|FibroGen||3||Sub-optimal study design|f||||f||||||||||2018-06-01 00:55:29.60735|2018-06-01 00:55:29.60735
NCT00913380|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2011-06-27||2011-09-02|2009-06-03|2009-06-04|Estimate|2011-08-02|2011-09-02|Estimate||||2011-09-02|2011-09-12|Estimate|September 2009||2009-09-30|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT|Negative Appendectomy Rate Following Low-dose CT vs. Standard-dose CT|Completed||Phase 3|891|Actual|Seoul National University Bundang Hospital|In this diagnostic trial, participants have a variety of abdominal diseases. Events with CTCAE v4 Grade 2 or less are not considered reportable according to the Study Protocol.|2|||f||||f||||||||||2018-06-01 00:55:29.757391|2018-06-01 00:55:29.757391
NCT00913367|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2013-03-26|2009-06-02|2009-06-04|Estimate|||||||2013-03-26|2013-03-28|Estimate|May 2009||2009-05-31|March 2013|2013-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus|A Multi-center, Open, Randomized, Parallel-group, 2 Arm Study to Compare the Efficacy and Safety of Amaryl®M 1/500mg Twice Daily Versus Amaryl® 4mg Both in Combination With Lantus® Once-daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control|Completed||Phase 4|110|Anticipated|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-06-01 00:55:30.379081|2018-06-01 00:55:30.379081
NCT00913354|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|March 2009|Actual|2009-03-31|March 2007|Actual|2007-03-31||Interventional|||Acupuncture Versus Placebo Acupuncture During In Vitro Fertilization (IVF) Embryo Transfer|Acupuncture Versus Placebo Acupuncture During Ivf Embryo Transfer|Completed||N/A|635|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 00:55:30.47682|2018-06-01 00:55:30.47682
NCT00913341|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|November 1991||1991-11-30|June 2009|2009-06-30|November 1991|Actual|1991-11-30|November 1991|Actual|1991-11-30||Interventional|||To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg|Bioavailability of Alprazolam Tablets|Completed||Phase 1|30|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:30.564242|2018-06-01 00:55:30.564242
NCT00913328|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|August 2002||2002-08-31|June 2009|2009-06-30|October 2006|Actual|2006-10-31|May 2006|Actual|2006-05-31||Interventional|SINGDEN||Effect of Add-on Montelukast to Inhaled Corticosteroids on Airway Responsiveness|Effect of Add-on Montelukast to Inhaled Corticosteroids in Excessive Airway Narrowing in Adults With Asthma|Completed||Phase 4|31|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 00:55:30.627567|2018-06-01 00:55:30.627567
NCT00913315|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-04|2009-06-03|2009-06-04|Estimate|||||||2009-06-04|2009-06-05|Estimate|August 2009||2009-08-31|June 2009|2009-06-30|January 2010|Anticipated|2010-01-31|October 2009|Anticipated|2009-10-31||Interventional|ESTTFCP||Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis|Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms|Unknown status|Not yet recruiting|N/A|30|Anticipated|Chongqing Medical University||2|||f||||t||||||||||2018-06-01 00:55:30.705842|2018-06-01 00:55:30.705842
NCT00913302|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2013-07-04|2009-06-03|2009-06-04|Estimate|||||||2013-07-04|2013-07-08|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|||Effects of Cardiovascular Training in Individuals With Ankylosing Spondylitis|Effects of Cardiovascular Training on Fitness, Cardiovascular Health, Bone Health and Quality of Life in Individuals With Ankylosing Spondylitis|Completed||N/A|106|Actual|University of Zurich||1|||f||||t||||||||||2018-06-01 00:55:30.811399|2018-06-01 00:55:30.811399
NCT00913289|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2012-10-16|2009-06-03|2009-06-04|Estimate|||||||2012-10-16|2012-10-18|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells|Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells|Terminated||Phase 1|6|Actual|Kanazawa University||1|||f||||||||||||||2018-06-01 00:55:30.875494|2018-06-01 00:55:30.875494
NCT00913276|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2012-11-22|2009-06-03|2009-06-04|Estimate|||||||2012-11-22|2012-11-27|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Conditioning With Volatile Anesthetics in Liver Transplantation||Completed||N/A|98|Actual|University of Zurich||2|||f||||t||||||||||2018-06-01 00:55:30.934185|2018-06-01 00:55:30.934185
NCT00913068|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|July 2009||2009-07-31|May 2009|2009-05-31|November 2010|Anticipated|2010-11-30|August 2010|Anticipated|2010-08-31||Interventional|TAP||Postoperative Pain Control for Prostatectomy|Post Operative Analgesia Using the Transverse Abdominal Plan (TAP) Block in Patients Undergoing a Radical Retropubic Prostatectomy (RRP)|Unknown status|Not yet recruiting|N/A|100|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-06-01 00:55:32.919621|2018-06-01 00:55:32.919621
NCT00913263|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|2013-04-22||2015-01-15|2009-06-03|2009-06-04|Estimate|2015-01-15|2015-01-19|Estimate||||2015-01-15|2015-01-19|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|2-HOF||An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate|An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer|Completed||Phase 1/Phase 2|24|Actual|Lidds AB|There were no limitations of the trial|1|||f||||f||||||||||2018-06-01 00:55:31.001662|2018-06-01 00:55:31.001662
NCT00913250|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|August 2003||2003-08-31|June 2009|2009-06-30|October 2003|Actual|2003-10-31|||||Interventional|||A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers|A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of AVONEX® (Interferon Beta-1a) Solutions for Injection Produced by a Serum-Containing Manufacturing Process and by a Serum-Free Manufacturing Process|Completed||Phase 1|96|Actual|Biogen||2|||f||||f||||||||||2018-06-01 00:55:31.194177|2018-06-01 00:55:31.194177
NCT00913237|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|July 1987||1987-07-31|June 2009|2009-06-30|August 1987|Actual|1987-08-31|August 1987|Actual|1987-08-31||Interventional|||To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride 50 mg Tablets|Randomized, 2-way Crossover Bioavailability Study of Desipramine Hydrochloride 50 mg Tablets|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:31.257782|2018-06-01 00:55:31.257782
NCT00913224|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-03|2009-06-04|Estimate|||||||2017-03-27|2017-03-28|Actual|April 1993||1993-04-30|June 2009|2009-06-30|April 1993|Actual|1993-04-30|April 1993|Actual|1993-04-30||Interventional|||To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets|A Relative Bioavailability Study of Diclofenac Sodium 50 mg Enteric-Coated Tablets|Completed||Phase 1|38|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:31.30817|2018-06-01 00:55:31.30817
NCT00913211|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2011-08-30|2009-06-02|2009-06-04|Estimate|||||||2011-08-30|2011-08-31|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|rTMS||Repetitive Transcranial Magnetic Stimulation (rTMS) to Promote Hand Recovery in Stroke|rTMS and Motor Learning Training to Promote Recovery From Hemiparesis|Completed||Phase 1|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t||||||||||2018-06-01 00:55:31.361813|2018-06-01 00:55:31.361813
NCT00913198|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2012-02-09|2009-06-03|2009-06-04|Estimate|||||||2012-02-09|2012-02-10|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||A Study of CP-4126 in Patients With Advanced Pancreatic Cancer|A Phase II Study of CP-4126 in Patients With Advanced Pancreatic Cancer.|Completed||Phase 2|21|Actual|Clavis Pharma||1|||f||||f||||||||||2018-06-01 00:55:31.42801|2018-06-01 00:55:31.42801
NCT00913185|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2014-06-23|2009-06-03|2009-06-04|Estimate|||||||2014-06-23|2014-06-24|Estimate|December 2006||2006-12-31|June 2014|2014-06-30|February 2008|Actual|2008-02-29|December 2006|Actual|2006-12-31||Interventional|||Comparison Study of Topical Acne Regimens|Acne Free vs. Proactiv for the Treatment of Moderately Severe Acne Vulgaris|Completed||Phase 4|128|Anticipated|MedDerm Associates|||||f||||t||||||||||2018-06-01 00:55:31.695819|2018-06-01 00:55:31.695819
NCT00913172|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2010-05-14|2009-06-03|2009-06-04|Estimate|||||||2010-05-14|2010-05-17|Estimate|September 2006||2006-09-30|May 2009|2009-05-31|April 2008|Actual|2008-04-30|March 2007|Actual|2007-03-31||Observational|||Cost and Cost-effectiveness of PTB+ Treatment in Southern Ethiopia|Improving Community Based TB Care in Southern Ethiopia Cost and Cost Effectiveness|Completed|||229|Actual|University of Bergen|||2||f||||f||||||||||2018-06-01 00:55:31.760248|2018-06-01 00:55:31.760248
NCT00913159|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2010-10-15|2009-06-03|2009-06-04|Estimate|||||||2010-10-15|2010-10-18|Estimate|November 2009||2009-11-30|October 2010|2010-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Trial Comparing Efficacy of HM3 Versus F2 Lithotripters for Stone Fragmentation|A Randomized Controlled Trial Comparing Efficacy of HM3 vs F2 Lithotripters for Stone Fragmentation|Terminated||N/A|5|Actual|Washington University School of Medicine||2||Slow accrual|f||||f||||||||||2018-06-01 00:55:31.829943|2018-06-01 00:55:31.829943
NCT00913146|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-03|||2009-06-03|2009-06-03|2009-06-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|March 2009|Actual|2009-03-31|June 2008|Actual|2008-06-30||Observational|||Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria?|Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria? A School-Based Prospective, Exposed/Non Exposed to Fever, Study in Benin.|Completed|||484|Actual|Institut de Recherche pour le Developpement|||2||f||||f||||||Samples With DNA|"~     whole blood dried on filter papers~   "|||2018-06-01 00:55:31.901388|2018-06-01 00:55:31.901388
NCT00913133|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2012-11-30||2013-01-06|2009-06-03|2009-06-04|Estimate|2012-11-30|2013-01-03|Estimate||||2013-01-06|2013-01-10|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|DESIR-ABLE||Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis|Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)|Completed||Phase 4|516|Actual|Canyon Pharmaceuticals, Inc.|This was a multi-center, single-arm, observational safety trial. The lack of an active comparator does not allow us to make conclusions about the relative safety and efficacy of the product.|1|||f||||t||||||||||2018-06-01 00:55:31.989851|2018-06-01 00:55:31.989851
NCT00913120|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-06-08|2009-06-02|2009-06-03|Estimate|||||||2010-06-08|2010-06-09|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery|Phase II/III Study of YM150 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients Undergoing Elective Total Hip Replacement Surgery|Completed||Phase 2/Phase 3|610|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 00:55:32.397286|2018-06-01 00:55:32.397286
NCT00913107|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2010-06-27|2009-05-29|2009-06-03|Estimate|||||||2010-06-27|2010-06-29|Estimate|September 2007||2007-09-30|June 2010|2010-06-30|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia|Lamotrigine in Trigeminal Neuralgia: Efficacy and Safety in Comparison With Carbamazepine|Completed||Phase 2/Phase 3|21|Actual|University of Malaya||2|||f||||f||||||||||2018-06-01 00:55:32.510288|2018-06-01 00:55:32.510288
NCT00913094|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-09|2009-06-02|2009-06-03|Estimate|||||||2009-06-09|2009-06-11|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Observational|BETTER-HTN||Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension|Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)|Unknown status|Recruiting||200|Anticipated|CardioDynamics|||1||f||||t||||||||||2018-06-01 00:55:32.594997|2018-06-01 00:55:32.594997
NCT00913055|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2011-07-13|2009-06-01|2009-06-03|Estimate|||||||2011-07-13|2011-07-14|Estimate|February 2007||2007-02-28|July 2011|2011-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Open Label Study of Octreotide Implant in Patients With Acromegaly|An Open-Label Study to Evaluate the Pharmacokinetic and Pharmacodynamic Response of a Hydrated and Non-Hydrated 84mg Octreotide Implant in Patients With Acromegaly|Completed||Phase 2|34|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:55:33.007786|2018-06-01 00:55:33.007786
NCT00913042|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-07-25|2009-06-02|2009-06-03|Estimate|||||||2012-07-25|2012-07-26|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|HEMATOCPLUS||Assessment of New Blood Culture Methods on the Microbiological Documentation of Febrile Neutropenia|Assessment of New Blood Culture Methods on the Microbiological Documentation of Febrile Neutropenia|Completed|||120|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     bacterial inoculum in the blood~   "|||2018-06-01 00:55:33.083951|2018-06-01 00:55:33.083951
NCT00913029|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2015-05-18|2009-06-02|2009-06-03|Estimate|||||||2015-05-18|2015-05-20|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SL||Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)|A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma|Completed||Phase 4|192|Actual|Glaukos Corporation||2|||f||||t||||||||||2018-06-01 00:55:33.157581|2018-06-01 00:55:33.157581
NCT00913016|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-31|||2010-02-14|2009-06-02|2009-06-03|Estimate|||||||2010-02-14|2010-02-17|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy|Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole (Femara) as an Early Adjuvant Treatment|Unknown status|Active, not recruiting||897|Anticipated|Korean Breast Cancer Study Group|||1||f||||t||||||||||2018-06-01 00:55:33.285977|2018-06-01 00:55:33.285977
NCT00913003|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2015-01-21||2015-02-02|2009-06-02|2009-06-03|Estimate|2015-02-02|2015-02-04|Estimate||||2015-02-02|2015-02-04|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery|Analgesic Effect of Perioperative Systemic Lidocaine in Patients Undergoing Unilateral Mastectomy Surgery|Terminated||Phase 4|22|Actual|Northwestern University|This study was terminated early because the PI left the institution.|2||PI terminated employment with the University|f||||f||||||||||2018-06-01 00:55:33.364053|2018-06-01 00:55:33.364053
NCT00912990|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2010-09-28|2009-06-01|2009-06-03|Estimate|||||||2010-09-28|2010-09-29|Estimate|January 2007||2007-01-31|September 2010|2010-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet|Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet|Terminated||N/A|35|Actual|Rady Children's Hospital, San Diego||2||Adequate subjects numbers not enrolled in study timeframe.|f||||f||||||||||2018-06-01 00:55:33.560536|2018-06-01 00:55:33.560536
NCT00912977|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-09-29|2009-06-02|2009-06-03|Estimate|||||||2016-09-29|2016-09-30|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia|Prospective Evaluation of Forceplate Measured Levodopa-Induced Dyskinesia|Completed|||10|Actual|Oregon Health and Science University|||3||f||||f||||||||Undecided||2018-06-01 00:55:33.628703|2018-06-01 00:55:33.628703
NCT00912964|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2012-07-17|2011-03-31|2017-11-09|2009-06-01|2009-06-03|Estimate|2012-09-17|2012-10-17|Estimate|2011-03-31|2011-04-07|Estimate|2017-11-09|2017-12-11|Actual|April 28, 2009|Actual|2009-04-28|November 2017|2017-11-30|April 27, 2010|Actual|2010-04-27|April 27, 2010|Actual|2010-04-27||Interventional|CAPRICORN||A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder|Completed||Phase 3|2030|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 00:55:33.787589|2018-06-01 00:55:33.787589
NCT00912938|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-02-14|2009-06-02|2009-06-03|Estimate|||||||2010-02-14|2010-02-17|Estimate|December 2007||2007-12-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients|A Phase IV, Multi-center, Open Label, Single Arm Clinical Trial to Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 4|237|Anticipated|Korean Breast Cancer Study Group||1|||f||||t||||||||||2018-06-01 00:55:36.132101|2018-06-01 00:55:36.132101
NCT00912925|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2009-07-02||2015-03-19|2009-06-02|2009-06-03|Estimate|2009-07-07|2009-08-19|Estimate||||2015-03-19|2015-04-07|Estimate|December 2000||2000-12-31|March 2015|2015-03-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multinational, Clinical Study of Recombinant Human Alpha L-Iduronidase In Patients With Mucopolysaccharidosis I|Completed||Phase 3|45|Actual|Sanofi|Rare disease with limited sample size, FVC calculations less reliable for patients whose height is below the 3rd% for general population.|2|||f||||f||||||||||2018-06-01 00:55:36.226839|2018-06-01 00:55:36.226839
NCT00912912|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2015-12-21||2016-03-17|2009-06-01|2009-06-03|Estimate|2015-12-21|2016-01-27|Estimate||||2016-03-17|2016-04-15|Estimate|May 2009||2009-05-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Sunitinib Malate in Refractory Germ Cell Tumors|Phase II Study of Sunitinib Malate in Refractory Germ Cell Tumors|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-06-01 00:55:37.20713|2018-06-01 00:55:37.20713
NCT00912899|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-10-06|2009-06-02|2009-06-03|Estimate|||||||2016-10-06|2016-10-07|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1|12|Actual|Cougar Biotechnology, Inc.||1||Terminated early due to lack of clinical response.|f||||f||||||||||2018-06-01 00:55:37.598084|2018-06-01 00:55:37.598084
NCT00912886|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2013-04-10|2009-06-02|2009-06-03|Estimate|||||||2013-04-10|2013-04-11|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|STERMEM||Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease|Neuroactive Steroids and Cognition in Humans: Pregnenolone Sulfate an Early Marker of the Memory Loss Associated With Alzheimer's Disease|Completed|||90|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Plasma and serum from AD patients and from Controls~   "|||2018-06-01 00:55:37.704127|2018-06-01 00:55:37.704127
NCT00912873|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-06-18|2009-06-02|2009-06-03|Estimate|||||||2012-06-18|2012-06-19|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks|Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks|Completed||Phase 4|56|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 00:55:37.777819|2018-06-01 00:55:37.777819
NCT00912860|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-05|2009-06-02|2009-06-03|Estimate|||||||2009-06-05|2009-06-10|Estimate|January 2003||2003-01-31|June 2009|2009-06-30|January 2005|Actual|2005-01-31|December 2004|Actual|2004-12-31||Interventional|||Immunogenicity and Safety Study of Serum-Free Avonex|A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis|Completed||Phase 2|155|Actual|Biogen||1|||f||||f||||||||||2018-06-01 00:55:37.841466|2018-06-01 00:55:37.841466
NCT00912847|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-01|2009-06-01|2009-06-03|Estimate|||||||2009-06-01|2009-06-03|Estimate|October 1997||1997-10-31|June 2009|2009-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Observational|||Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma|Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma|Completed|||1018|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-06-01 00:55:37.899513|2018-06-01 00:55:37.899513
NCT00912834|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-09-22|2009-06-02|2009-06-03|Estimate|||||||2009-09-22|2009-09-23|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|November 2009|Anticipated|2009-11-30|May 2009|Anticipated|2009-05-31||Observational|||Study of Prevalence of Proteinuria, Urinary Tract Infection or Hematuria in Athletes|Urine Analysis in Different Types of Athletes|Unknown status|Active, not recruiting||300|Actual|Far Eastern Memorial Hospital|||7||f||||f||||||||||2018-06-01 00:55:37.957994|2018-06-01 00:55:37.957994
NCT00912821|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2016-10-12|2009-06-01|2009-06-03|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional|||Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients|Effect of Different Dialysis Dosage on Prognosis in Maintenance Peritoneal Dialysis Patients - A Prospective, Randomized, Controlled, Multi-center Clinical Study|Completed||Phase 4|200|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 00:55:38.00613|2018-06-01 00:55:38.00613
NCT00912808|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2011-07-20||2018-04-05|2009-06-02|2009-06-03|Estimate|2011-07-20|2011-08-15|Estimate||||2018-04-05|2018-05-08|Actual|October 2005||2005-10-31|April 2018|2018-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||23 participants were enrolled into the study. 3 participants screen failed.|Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease|A Study of Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's|Completed||N/A|23|Actual|Oregon Health and Science University|Small number of subjects and lack of objective measurement to quantify falls. The most difficult condition to exclude was co-existing freezing of gait.|2|||f||||f||||||||No||2018-06-01 00:55:39.012946|2018-06-01 00:55:39.012946
NCT00912795|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2016-03-29||2016-08-11|2009-05-31|2009-06-03|Estimate|2016-08-11|2016-10-05|Estimate||||2016-08-11|2016-10-05|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SMS Turkey||SMS Turkey: Harnessing the Power of Text Messaging to Promote Smoking Cessation|SMS Turkey: Harnessing the Power of TXT Messaging to Promote Smoking Cessation|Completed||N/A|151|Actual|Center for Innovative Public Health Research|An imbalance favoring the intervention was detected after approximately 100 participants were enrolled. To ensure a 1:1 match, the procedure was modified so that the RA pulled a slip of paper from a hat that read either “SMS Turkey” or “brochure.”|2|||f||||f||||||||No||2018-06-01 00:55:39.251372|2018-06-01 00:55:39.251372
NCT00912782|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2013-11-02||2014-06-02|2009-06-01|2009-06-03|Estimate|2014-06-02|2014-07-02|Estimate||||2014-06-02|2014-07-02|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Vitamin D and Arteriovenous Fistulae|Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients|Completed||N/A|52|Actual|Emory University||2|||f||||f||||||||||2018-06-01 00:55:39.669685|2018-06-01 00:55:39.669685
NCT00912769|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|October 2003||2003-10-31|June 2009|2009-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Observational|MISTKR||Knee Muscle Force Recovery After Minimally Invasive Surgery (MIS) Total Knee Replacement (TKR)|Outcome and Benefit After Total Knee Arthroplasty: Natural History of Muscle Power Recovery and Difference Between Different Surgical Approach|Completed|||30|Actual|Far Eastern Memorial Hospital|||2||f||||t||||||||||2018-06-01 00:55:40.024811|2018-06-01 00:55:40.024811
NCT00912756|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-07-21|2009-06-02|2009-06-03|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2009||2009-03-31|July 2010|2010-07-31|September 2012|Anticipated|2012-09-30|June 2012|Anticipated|2012-06-30||Interventional|STOP-IC||Sufficient Treatment of Peripheral Intervention by Cilostazol|Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment|Unknown status|Recruiting|Phase 4|200|Anticipated|Kansai Rosai Hospital||2|||f||||t||||||||||2018-06-01 00:55:40.088582|2018-06-01 00:55:40.088582
NCT00912743|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2015-01-13|2013-05-20|2016-09-22|2009-06-02|2009-06-03|Estimate|2016-09-22|2016-11-09|Estimate|2013-05-20|2013-05-27|Estimate|2016-09-22|2016-11-09|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status|A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status|Completed||Phase 2|33|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 00:55:40.212809|2018-06-01 00:55:40.212809
NCT00912730|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-10-20|2009-06-02|2009-06-03|Estimate|||||||2009-10-20|2009-10-21|Estimate|August 2008||2008-08-31|October 2009|2009-10-31||||||||Observational|MEL50||A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma|A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma|Completed|||20|Actual|University of Virginia|||||f||||t||||||||||2018-06-01 00:55:40.598306|2018-06-01 00:55:40.598306
NCT00744822|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-08-28|2008-08-28|2008-09-01|Estimate|||||||2008-08-28|2008-09-01|Estimate|March 2006||2006-03-31|December 2005|2005-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Vibration Response Imaging (VRI) in Lung Transplant Recipients|Vibration Response Imaging (VRI) in Lung Transplant Recipients|Completed|||55|Actual|Hannover Medical School|||||f||||t||||||||||2018-06-01 01:47:42.35287|2018-06-01 01:47:42.35287
NCT00912717|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2017-07-21|2009-06-02|2009-06-03|Estimate|||||||2017-07-21|2017-07-24|Actual|January 2004||2004-01-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PAGER||Pancreatic Adenocarcinoma Gene Environment Risk Study|The Pancreatic Adenocarcinoma Gene Environment Risk Study -A Prospective Cohort Study of Patients at Risk or Having Pancreatic Disease|Recruiting|||10000|Anticipated|University of Pittsburgh|||2||f||||t||||||Samples With DNA|"~     Blood and urine specimens~   "|||2018-06-01 00:55:40.656031|2018-06-01 00:55:40.656031
NCT00912704|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 1998||1998-03-31|April 1998|1998-04-30|December 1998|Actual|1998-12-31|March 1998|Actual|1998-03-31||Observational|Hmodialysis||Development of Early Diagnostic Techniques and Setup of Local Therapeutic Guidelines and Standards|Prevention and Treatment of Chronic Kidney Disease in Taiwan - Development of Early Diagnostic Techniques and Setup of Local Therapeutic Guidelines and Standards|Completed|||30|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 00:55:40.717202|2018-06-01 00:55:40.717202
NCT00912691|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-16|2009-06-02|2009-06-03|Estimate|||||||2017-03-16|2017-03-17|Actual|January 2010|Actual|2010-01-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CM-AT||A Trial of CM-AT in Children With Autism- Open Label Extension Study|A Phase III Open Label Extension Study of CM-AT in Children With Autism|Completed||Phase 3|165|Actual|Curemark||1|||f||||t||||||||||2018-06-01 00:55:40.769453|2018-06-01 00:55:40.769453
NCT00912678|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2002||2002-03-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|July 2006|Actual|2006-07-31||Interventional|ESP-CNI||Minimizing Immunosuppression in Old for Old Kidney Transplantation|"Prospective Randomized Controlled Trial to Compare a Calcineurin Inhibitor Free Immunosuppression With a Low Dose Tacrolimus Based Immunosuppression in Old for Old Kidney Transplantation."|Completed||Phase 4|90|Actual|University of Luebeck||2|||f||||t||||||||||2018-06-01 00:55:40.850783|2018-06-01 00:55:40.850783
NCT00912665|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-08-09|2009-06-02|2009-06-03|Estimate|||||||2012-08-09|2012-08-10|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Optic Nerve Head Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Completed||N/A|40|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 00:55:40.917005|2018-06-01 00:55:40.917005
NCT00912652|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2018-04-04|2009-06-02|2009-06-03|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2008||2008-06-30|April 2018|2018-04-30|June 2014|Actual|2014-06-30|April 2013|Actual|2013-04-30||Interventional|RuralLITE||Rural Lifestyle Intervention Treatment Effectiveness Trial|Rural Lifestyle Intervention Treatment Effectiveness Trial|Completed||N/A|612|Actual|University of Florida||4|||f||||t||||||||||2018-06-01 00:55:40.976031|2018-06-01 00:55:40.976031
NCT00912639|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-31|||2009-06-15|2009-06-02|2009-06-03|Estimate|||||||2009-06-15|2009-06-16|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|May 2011|Anticipated|2011-05-31|May 2010|Anticipated|2010-05-31||Interventional|||A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer|A Clinical Trial of Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) in Patients With Taxane-Pretreated Recurrent Breast Cancer|Unknown status|Enrolling by invitation|Phase 4|90|Anticipated|Korean Breast Cancer Study Group||1|||f||||t||||||||||2018-06-01 00:55:41.158151|2018-06-01 00:55:41.158151
NCT00912626|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2015-03-11|2009-06-01|2009-06-03|Estimate|||||||2015-03-11|2015-03-12|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Family Functioning and Child Behavior When a Sibling is Critically Ill|Family Functioning and Child Behavior When a Sibling is Critically Ill|Completed||N/A|90|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 00:55:41.237746|2018-06-01 00:55:41.237746
NCT00912613|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-01|2009-06-01|2009-06-03|Estimate|||||||2009-06-01|2009-06-03|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|RACHEL II||Intensive Care Unit (ICU) Diaries as a Therapeutic Intervention for Post Traumatic Stress Disorder (PTSD) Following Critical Illness|ICU Diaries as a Therapeutic Intervention for Post Traumatic Stress Disorder Following Critical Illness|Completed||N/A|352|Actual|University of Liverpool||2|||f||||t||||||||||2018-06-01 00:55:41.321335|2018-06-01 00:55:41.321335
NCT00912600|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-07-25|2009-06-02|2009-06-03|Estimate|||||||2012-07-25|2012-07-26|Estimate|November 2004||2004-11-30|May 2009|2009-05-31|February 2009|Actual|2009-02-28|January 2006|Actual|2006-01-31||Observational|IceCub||Intensive Care Unit (ICU) Admission Decisions in the Elderly : the ICE-CUB Study|A Prospective Multicenter Study Examining the Criteria That Determine ICU Admission of Patients Over 80 Who Present to an Emergency Department and Evaluating the Impact of ICU Admission on Short and Mid-term Vital and Functional Outcome|Completed|||2643|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-06-01 00:55:41.436552|2018-06-01 00:55:41.436552
NCT00912587|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2011-12-19|2009-06-02|2009-06-03|Estimate|||||||2011-12-19|2011-12-21|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Ghrelin on Sympathetic Nervous System|Effect of Ghrelin on Sympathetic Nervous System and Stress Reactivity|Completed||N/A|46|Anticipated|Baker IDI Heart and Diabetes Institute|||||f||||f||||||||||2018-06-01 00:55:41.501399|2018-06-01 00:55:41.501399
NCT00912574|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|June 2004||2004-06-30|June 2009|2009-06-30||||July 2008|Actual|2008-07-31||Interventional|MEL38||Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38|Evaluation of the Effects of Local GM-CSF-in-Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes|Completed||N/A|29|Actual|University of Virginia||4|||f||||f||||||||||2018-06-01 00:55:41.555817|2018-06-01 00:55:41.555817
NCT00912561|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-02-20|2009-06-02|2009-06-03|Estimate|||||||2012-02-20|2012-02-22|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|December 2011|Actual|2011-12-31||Interventional|Exercise||Effects of Intense Aerobic Exercise on the Cerebrovascular Reserve Capacity in Patients With Hemodynamically Relevant Intra- and Extracranial Stenoses|Effects of Intense Aerobic Exercise on the Cerebrovascular Reserve Capacity in Patients With Hemodynamically Relevant Intra- and Extracranial Stenoses|Terminated||N/A|50|Anticipated|Charite University, Berlin, Germany||2||slow recruiting|f||||f||||||||||2018-06-01 00:55:41.640651|2018-06-01 00:55:41.640651
NCT00912392|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2014-08-31|2009-06-02|2009-06-03|Estimate|||||||2014-08-31|2014-09-03|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)|Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study|Completed||Phase 2|138|Actual|Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-06-01 00:55:42.931002|2018-06-01 00:55:42.931002
NCT00912548|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-31|||2009-06-15|2009-06-02|2009-06-03|Estimate|||||||2009-06-15|2009-06-16|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ASTRRA||Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women|A Randomised Phase III Study for Evaluating the Role of the Addition of Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain in Premenopause or Regain Menstruation After Chemotherapy|Unknown status|Enrolling by invitation|Phase 3|1234|Anticipated|Korean Breast Cancer Study Group||5|||f||||t||||||||||2018-06-01 00:55:41.724741|2018-06-01 00:55:41.724741
NCT00912535|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-24|||2012-01-03|2009-05-31|2009-06-03|Estimate|||||||2012-01-03|2012-01-05|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms|Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Comorbid Anxiety Symptoms|Completed||Phase 4|39|Actual|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-06-01 00:55:41.796872|2018-06-01 00:55:41.796872
NCT00912522|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2015-04-20|2009-06-02|2009-06-03|Estimate|||||||2015-04-20|2015-04-22|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Magnetic Prefrontal Stimulation for Studying the Role of the Cortex in High-level Cognition Processes and Reward System|Magnetic Prefrontal Stimulation for Studying the Role of the Cortex in High-level Cognition Processes and Reward System|Completed||Early Phase 1|91|Actual|Hadassah Medical Organization||5|||f||||f||||||||||2018-06-01 00:55:41.871638|2018-06-01 00:55:41.871638
NCT00912509|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-30|2014-08-04||2017-10-19|2009-06-01|2009-06-03|Estimate|2014-08-04|2014-08-22|Estimate||||2017-10-19|2017-11-22|Actual|May 2009||2009-05-31|October 2017|2017-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||This is the number of participants who were culture-positive|Cross Linking for Treatment of Corneal Infection|A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis|Terminated||N/A|30|Actual|Price Vision Group||2||insufficient efficacy|f||||t||||||||||2018-06-01 00:55:41.951259|2018-06-01 00:55:41.951259
NCT00912496|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-05-10|2009-05-28|2009-06-03|Estimate|||||||2013-05-10|2013-05-14|Estimate|June 2010||2010-06-30|October 2011|2011-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59|Phase I Randomized Study of the Safety, Dose Escalation, and Immunogenicity of Adjuvanted Influenza A/Anhui/05 Boosting in Subjects Previously Immunized With One or Two Doses of A/Vietnam/1203/04 or in Unprimed Individuals and Compared to Placebo|Completed||Phase 1|637|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 00:55:42.178176|2018-06-01 00:55:42.178176
NCT00912483|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2013-03-27|2009-06-02|2009-06-03|Estimate|||||||2013-03-27|2013-03-29|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|January 2011|Anticipated|2011-01-31|November 2010|Anticipated|2010-11-30||Interventional|||Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients|Efficacy of Sodium Heparin 5.000 UI/0.25 mL (Blausiegel) Compared With Heparin Sodium 5.000 USP (APP Pharmaceuticals)for Venous Thromboembolism Prophylaxis In Surgical Patients With Medium Risk For The Thromboembolism Development|Withdrawn||Phase 3|0|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:55:42.266958|2018-06-01 00:55:42.266958
NCT00912470|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2014-11-20|2009-06-02|2009-06-03|Estimate|||||||2014-11-20|2014-11-21|Estimate|May 2007||2007-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Progressive Open Angle Glaucoma (OAG) and Ocular Blood Flow|Genetic Vascular Risk Factors and Ocular Blood Flow in Patients With Progressive Open Angle Glaucoma (OAG)-a Longitudinal Prospective Study|Withdrawn||N/A|0|Actual|Medical University of Vienna|||||f||||t||||||||||2018-06-01 00:55:42.32652|2018-06-01 00:55:42.32652
NCT00912457|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|doneapnea||Donepezil Treatment for Sleep Apnea Patients|Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Associacao Fundo de Incentivo a Psicofarmcologia||2|||f||||t||||||||||2018-06-01 00:55:42.393637|2018-06-01 00:55:42.393637
NCT00912444|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2016-11-19|2009-06-02|2009-06-03|Estimate|||||||2016-11-19|2016-11-22|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|May 2012|Actual|2012-05-31||Interventional|NATT||Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer|A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer|Terminated||Phase 3|102|Actual|Shanghai Jiao Tong University School of Medicine||2||"TAC treatment was associated with better survial outcome compared with TC treatment, we~   terminated recruiting and waiting for longer follow up period."|f||||t||||||||||2018-06-01 00:55:42.47068|2018-06-01 00:55:42.47068
NCT00912431|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2010-11-01|2009-06-02|2009-06-03|Estimate|||||||2010-11-01|2010-11-02|Estimate|June 2009||2009-06-30|September 2010|2010-09-30||||August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers|A Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in the Cerebrospinal Fluid (CSF) of Healthy Subjects|Completed||Phase 1|10|Actual|Abbott||2|||f||||||||||||||2018-06-01 00:55:42.563373|2018-06-01 00:55:42.563373
NCT00912418|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2013-06-17|2009-06-02|2009-06-03|Estimate|||||||2013-06-17|2013-06-19|Estimate|January 2000||2000-01-31|June 2013|2013-06-30||||||||Interventional|MEL37||Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma|Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus GM-CSF-in-adjuvant, Followed by Systemic Low-dose-IL-2 Administration, in Patients With High Risk Melanoma.|Completed||N/A|14|Actual|University of Virginia|||||f||||f||||||||||2018-06-01 00:55:42.616426|2018-06-01 00:55:42.616426
NCT00912405|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2014-10-23||2015-03-25|2009-06-02|2009-06-03|Estimate|2015-03-25|2015-04-20|Estimate||||2015-03-25|2015-04-20|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis|A Clinical Evaluation of the Steroid-Eluting Sinexus Intranasal Splint When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis|Completed||N/A|50|Actual|Intersect ENT||1|||f||||f||||||||||2018-06-01 00:55:42.760916|2018-06-01 00:55:42.760916
NCT00912210|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-05-29|2009-05-29|2009-06-03|Estimate|||||||2009-05-29|2009-06-03|Estimate|April 2009||2009-04-30|May 2009|2009-05-31||||||||Interventional|||Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women|Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women|Completed||Phase 1|31|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-06-01 00:55:45.712996|2018-06-01 00:55:45.712996
NCT00912379|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2016-09-23|2009-06-02|2009-06-03|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Hemoglobin Measured by MASIMO SpHb™ Device and Laboratory Measurement|Comparison of the Hemoglobin Results Obtained With the Masimo SpHb™ Device and the Clinical Laboratory Measurement|Completed|||300|Actual|Hopital Foch|||1||f||||f||||||||||2018-06-01 00:55:43.03688|2018-06-01 00:55:43.03688
NCT00912366|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2015-07-23|2009-06-02|2009-06-03|Estimate|||||||2015-07-23|2015-07-27|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Observational|||Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy|A Prospective, Single Center, Observational Study Comparing the Safety and Efficacy of CVATS, HVATS and Open Surgery for Subjects Diagnosed With NSCLC Scheduled to Undergo a Lobectomy|Terminated|||39|Actual|Medtronic - MITG|||2|Slow Enrollment|f||||f||||||||||2018-06-01 00:55:43.094478|2018-06-01 00:55:43.094478
NCT00912353|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2013-01-28|2009-06-02|2009-06-03|Estimate|||||||2013-01-28|2013-01-29|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|JSAD||AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects|A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7268 in Healthy Japanese Subjects|Completed||Phase 1|56|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:55:43.16969|2018-06-01 00:55:43.16969
NCT00912340|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-12-01|2009-06-02|2009-06-03|Estimate|||||||2017-12-01|2017-12-05|Actual|May 2009||2009-05-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer|Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer|Completed||Phase 2|58|Actual|Emory University||1|||f||||t||||||||||2018-06-01 00:55:43.237251|2018-06-01 00:55:43.237251
NCT00912327|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-02-14|2009-06-01|2009-06-03|Estimate|||||||2012-02-14|2012-02-15|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer|A Phase 2 Efficacy and Safety, Open-label, Multicenter Study of Imprime PGG® Injection in Combination With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer|Completed|||18|Actual|Biothera|||2||f||||t||||||Samples With DNA|"~     Tumor tissue samples from previous biopsies and blood plasma will be collected.~   "|||2018-06-01 00:55:43.426994|2018-06-01 00:55:43.426994
NCT00912314|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2010-03-19|2009-06-02|2009-06-03|Estimate|||||||2010-03-19|2010-03-22|Estimate|February 2009||2009-02-28|June 2009|2009-06-30||||||||Interventional|||Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder|A Randomized Trial of Maintenance Therapy With Posterior Tibial Nerve Stimulation for Overactive Bladder|Suspended||N/A|32|Anticipated|University of California, San Diego||2||low recruitment|f||||||||||||||2018-06-01 00:55:43.614929|2018-06-01 00:55:43.614929
NCT00912301|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2012-05-29||2012-05-29|2009-06-02|2009-06-03|Estimate|2012-05-29|2012-07-02|Estimate||||2012-05-29|2012-07-02|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|Chenotransit||Cheno Effect on Transit in Health and IBS-C|Effect of Chenodeoxycholic Acid on Gastrointestinal Transit and Colonic Functions in Health and Constipation-predominant Irritable Bowel Syndrome (IBS-C)|Completed||Phase 2|36|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 00:55:43.76702|2018-06-01 00:55:43.76702
NCT00912288|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2012-07-30|2011-09-08|2012-08-30|2009-06-01|2009-06-03|Estimate|2012-08-30|2012-10-02|Estimate|2011-09-08|2011-09-12|Estimate|2012-08-30|2012-10-02|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease|Terminated||Phase 3|86|Actual|Pfizer|Results are not summarized because of early termination of the study due to modification in the development plan of the study medication following lack of demonstration of efficacy in the completed DIM14 CONNECTION (B1451002/NCT00675623) study.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:55:44.241933|2018-06-01 00:55:44.241933
NCT00912275|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-11-15|2009-06-02|2009-06-03|Estimate|||||||2012-11-15|2012-11-16|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer|Phase I/II Study of Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|78|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:55:44.861995|2018-06-01 00:55:44.861995
NCT00912262|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|November 2008||2008-11-30|||||Interventional|||A Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of NGX-1998 in Healthy Volunteers|A Randomized, Single Blind Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Multiple Low-Concentrations of Capsaicin Topical Liquid NGX-1998 in Healthy Volunteers|Completed||Phase 1|36|Anticipated|NeurogesX||1|||f||||||||||||||2018-06-01 00:55:45.006075|2018-06-01 00:55:45.006075
NCT00912249|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|April 2009||2009-04-30|April 2009|2009-04-30||||December 2009|Anticipated|2009-12-31||Interventional|||The Clinical Application of Horticulture Therapy in Psychiatric Rehabilitation|The Clinical Application of Horticulture Therapy in Psychiatric Rehabilitation|Unknown status|Recruiting|N/A|30|Anticipated|Far Eastern Memorial Hospital||1|||f||||f||||||||||2018-06-01 00:55:45.145997|2018-06-01 00:55:45.145997
NCT00912236|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2017-04-11|2009-06-02|2009-06-03|Estimate|||||||2017-04-11|2017-04-13|Actual|June 2009|Actual|2009-06-30|April 2017|2017-04-30|March 2012|Actual|2012-03-31|June 2011|Actual|2011-06-30||Observational|||Evaluation of High-Density Lipoprotein in Obesity Study|Evaluation of High-Density Lipoprotein in Obesity Study|Terminated|||77|Actual|The Cleveland Clinic|||3|Investigator left institution|f||||f|f|f||||Samples Without DNA|"~     Plasma and serum will be collected~   "|No||2018-06-01 00:55:45.258541|2018-06-01 00:55:45.258541
NCT00912223|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2016-08-05||2017-09-27|2009-06-01|2009-06-03|Estimate|2016-09-30|2016-11-21|Estimate||||2017-09-27|2017-10-27|Actual|April 2009||2009-04-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|November 2014|Actual|2014-11-30||Interventional||Received transplant|Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)|A Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (BMT CTN #0701)|Completed||Phase 2|65|Actual|Medical College of Wisconsin||1|||f||||t||||||||Yes|Findings will be published in a manuscript.|2018-06-01 00:55:45.325979|2018-06-01 00:55:45.325979
NCT00912184|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-01-26|2009-06-01|2009-06-03|Estimate|||||||2012-01-26|2012-01-31|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Study Comparing High Cut-off Haemofiltration With Standard Haemofiltration in Acute Renal Failure|Pilot Randomised Controlled Study Comparing The Effect of High Cut-off Point Haemofiltration With Standard Haemofiltration In Patients With Acute Renal Failure|Completed||Phase 1/Phase 2|76|Actual|Austin Health||2|||f||||||||||||||2018-06-01 00:55:45.860096|2018-06-01 00:55:45.860096
NCT00912171|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2013-02-14|2009-06-01|2009-06-03|Estimate|||||||2013-02-14|2013-02-15|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|SB-OSAS||Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children|Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome (OSAS) in Children|Completed||Phase 4|45|Actual|University of Bologna||3|||f||||t||||||||||2018-06-01 00:55:45.961346|2018-06-01 00:55:45.961346
NCT00912158|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2009-04-08||2009-08-17|2009-04-09|2009-06-03|Estimate|2009-04-09|2009-06-03|Estimate||||2009-08-17|2009-09-04|Estimate|October 2003||2003-10-31|August 2009|2009-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Non Invasive Mechanical Ventilation in Acute Cardiogenic Pulmonary Edema|CPAP Versus BiPAP in Acute Cardiogenic Pulmonary Edema: Experience With 129 Patients|Completed||Phase 4|129|Actual|Assiut University||3|||f||||f||||||||||2018-06-01 00:55:46.048298|2018-06-01 00:55:46.048298
NCT00912145|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2017-03-27|2009-06-02|2009-06-03|Estimate|||||||2017-03-27|2017-03-28|Actual|February 1996||1996-02-29|June 2009|2009-06-30|February 1996|Actual|1996-02-29|February 1996|Actual|1996-02-29||Interventional|||To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg|Bioavailability of Alprazolam Tablets, 2 mg.|Completed||Phase 1|26|Actual|Sandoz||2|||f||||||||||||||2018-06-01 00:55:46.307109|2018-06-01 00:55:46.307109
NCT00912132|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-30|||2017-10-25|2009-05-30|2009-06-03|Estimate|||||||2017-10-25|2017-10-26|Actual|May 19, 2009||2009-05-19|October 2017|2017-10-31|August 25, 2013|Actual|2013-08-25|August 25, 2013|Actual|2013-08-25||Observational|||The National Standard for Normal Fetal Growth|The National Standard for Normal Fetal Growth|Completed|||2802|Actual|National Institutes of Health Clinical Center (CC)|||2||f||||||||||Samples With DNA|"~     -  Maternal blood sample (serum, plasma, white blood cells, red blood cells and PAXgene~          RNA) at enrollment, 1st, 2nd, 4th follow-up visits, and postpartum~        -  Cord blood and placenta of offspring of consenting women collected at delivery~   "|Yes|Pregnancy and postpartum data will be made accessible in documented repositories and electronic archives after completion of the studies' analytical phases.|2018-06-01 00:55:46.373165|2018-06-01 00:55:46.373165
NCT00912119|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-10-31|2009-06-02|2009-06-03|Estimate|||||||2012-10-31|2012-11-01|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Amicar Pharmacokinetics of Children Having Craniofacial Surgery|Pharmacokinetics of Epsilon-Aminocaproic Acid in Children Undergoing Craniofacial Reconstruction Surgery|Completed||Phase 1|18|Actual|Children's Hospital of Philadelphia||4|||f||||f||||||||||2018-06-01 00:55:46.454354|2018-06-01 00:55:46.454354
NCT00912106|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2009-06-02|2009-06-02|2009-06-03|Estimate|||||||2009-06-02|2009-06-03|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Observational|SFCL||Analyzing Composition and Lubrication Properties of Synovial Fluid|Boundary Lubrication of Synovial Fluid Molecules and Its Effect on the Surrounding Cells and Tissues|Completed|||55|Actual|Far Eastern Memorial Hospital|||1||f||||f||||||Samples Without DNA|"~     synovial fluid from knee joint~   "|||2018-06-01 00:55:46.538254|2018-06-01 00:55:46.538254
NCT00912093|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2014-07-11||2014-09-11|2009-06-02|2009-06-03|Estimate|2014-07-11|2014-08-06|Estimate||||2014-09-11|2014-09-22|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)|A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)|Completed||Phase 3|98|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:55:46.635028|2018-06-01 00:55:46.635028
NCT00912080|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2013-03-19|2009-06-02|2009-06-03|Estimate|||||||2013-03-19|2013-03-20|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|SA02||Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer|Utilisation of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer: A Prospective Cohort Study.|Unknown status|Active, not recruiting|N/A|375|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-06-01 00:55:47.917424|2018-06-01 00:55:47.917424
NCT00912067|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2009-06-01|2009-06-01|2009-06-03|Estimate|||||||2009-06-01|2009-06-03|Estimate|July 2009||2009-07-31|June 2009|2009-06-30||||||||Observational|||Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults|Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults|Unknown status|Enrolling by invitation||120|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 00:55:47.985335|2018-06-01 00:55:47.985335
NCT00912054|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2012-07-17|2009-06-02|2009-06-03|Estimate|||||||2012-07-17|2012-07-19|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||DuoTrav APS Versus XALACOM® in Ocular Surface Health||Terminated||Phase 3|240|Actual|Alcon Research||2||poor enrollment|f||||f||||||||||2018-06-01 00:55:48.051983|2018-06-01 00:55:48.051983
NCT00912041|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2018-03-26|2009-06-02|2009-06-03|Estimate|||||||2018-03-26|2018-03-29|Actual|May 2009||2009-05-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|BrainGate2||BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia|BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia|Recruiting||N/A|15|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:55:48.117215|2018-06-01 00:55:48.117215
NCT00912028|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2014-03-27||2017-08-21|2009-05-29|2009-06-03|Estimate|2014-03-27|2014-04-28|Estimate||||2017-08-21|2017-09-19|Actual|May 1, 2009|Actual|2009-05-01|August 2017|2017-08-31|February 1, 2010|Actual|2010-02-01|February 1, 2010|Actual|2010-02-01||Interventional||This population includes those who were qualified to be in the analysis population. Demographics are not available for those who were excluded or discontinued.|Clinical Performance Comparison of Several Different Contact Lenses|Multicenter, Single-masked, Randomized, Parallel, Controlled Study to Compare Senofilcon A Contact Lenses to Currently Used Contact Lenses|Completed||N/A|71|Actual|Johnson & Johnson Vision Care, Inc.||5|||f||||f||||||||||2018-06-01 00:55:48.265348|2018-06-01 00:55:48.265348
NCT00911833|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2017-06-30|2009-05-29|2009-06-02|Estimate|||||||2017-06-30|2017-07-02|Actual|May 19, 2009||2009-05-19|March 30, 2011|2011-03-30|March 30, 2011||2011-03-30|||||Observational|||The Roles of Trust and Respect in Patient Reactions to Race-based and Personalized Medicine Vignettes: An Experimental Study|The Roles of Trust and Respect in Patient Reactions to Race-Based and Personalized Medicine Vignettes: An Experimental Study|Completed|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:55:52.729364|2018-06-01 00:55:52.729364
NCT00912015|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2009-04-09||2012-04-25|2009-06-02|2009-06-03|Estimate|2009-06-02|2009-06-03|Estimate||||2012-04-25|2012-04-30|Estimate|March 2002||2002-03-31|April 2012|2012-04-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up|A Comparison of the Analgesic Efficacy and Safety of Once Daily Tramadol OAD Tablets to Twice Daily Tramadol BID for the Treatment of Osteoarthritis of the Knee (Extension Protocol) and Open Label Safety Follow-Up|Completed||Phase 3|238|Actual|Labopharm Inc.||4|||f||||f||||||||||2018-06-01 00:55:48.629943|2018-06-01 00:55:48.629943
NCT00912002|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2012-04-26||2015-06-08|2009-06-01|2009-06-03|Estimate|2012-04-26|2012-05-28|Estimate||||2015-06-08|2015-07-03|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)|A Study to Investigate the Absorption, Metabolism, Excretion and Mass Balance After Administration of a Single Dose of [14C]MK-0941|Completed||Phase 1|6|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 00:55:49.049495|2018-06-01 00:55:49.049495
NCT00911989|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-31|2011-10-04||2012-06-19|2009-06-02|2009-06-03|Estimate|2011-10-04|2011-11-08|Estimate||||2012-06-19|2012-06-25|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Laparoscopic Sleeve Gastrectomy With Endoscopic Visualization|Endoscopic Visualization During a Laparoscopic Sleeve Gastrectomy Procedure|Completed||N/A|4|Actual|Ethicon Endo-Surgery||1|||f||||t||||||||||2018-06-01 00:55:49.209761|2018-06-01 00:55:49.209761
NCT00911976|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2012-10-25|2009-06-02|2009-06-03|Estimate|||||||2012-10-25|2012-10-26|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SOS-Xience V||Study of the Xience V Everolimus-eluting Stent in Saphenous Vein Graft Lesions|Prospective Evaluation of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: The Stenting Of Saphenous Vein Grafts Xience V Angiographic Study (SOS-Xience V)|Completed||Phase 4|40|Actual|North Texas Veterans Healthcare System||1|||f||||t||||||||||2018-06-01 00:55:49.352372|2018-06-01 00:55:49.352372
NCT00911963|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29||2014-02-06|2014-02-06|2009-06-02|2009-06-03|Estimate||||2014-02-06|2014-03-10|Estimate|2014-02-06|2014-03-10|Estimate|April 2009||2009-04-30|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection|A Phase l b/II a, Multicenter, Randomized, Double-Blinded, and Placebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C-Infection|Completed||Phase 1/Phase 2|49|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-06-01 00:55:49.427452|2018-06-01 00:55:49.427452
NCT00911937|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|2012-07-09||2012-07-09|2009-06-02|2009-06-03|Estimate|2012-07-09|2012-08-14|Estimate||||2012-07-09|2012-08-14|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency.|Completed||Phase 4|963|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:55:49.572502|2018-06-01 00:55:49.572502
NCT00911924|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2015-05-18|2009-06-02|2009-06-03|Estimate|||||||2015-05-18|2015-05-20|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|SY||A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma|A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma|Completed||Phase 4|112|Actual|Glaukos Corporation||1|||f||||t||||||||||2018-06-01 00:55:50.655392|2018-06-01 00:55:50.655392
NCT00911911|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2012-07-30|2009-06-02|2009-06-03|Estimate|||||||2012-07-30|2012-07-31|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|SPAM||Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy|Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy|Completed||N/A|66|Actual|Centre Oscar Lambret||1|||f||||f||||||||||2018-06-01 00:55:50.736064|2018-06-01 00:55:50.736064
NCT00911898|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|2014-02-28||2014-12-30|2009-06-02|2009-06-03|Estimate|2014-09-11|2014-09-15|Estimate||||2014-12-30|2015-01-13|Estimate|June 2009||2009-06-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Monotherapy||A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers|A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers|Completed||Phase 1|20|Actual|Merrimack Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:55:50.807335|2018-06-01 00:55:50.807335
NCT00911885|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-01|||2015-03-16|2009-06-02|2009-06-03|Estimate|||||||2015-03-16|2015-03-18|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CANDO||A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome|A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome|Completed||N/A|240|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 00:55:50.933191|2018-06-01 00:55:50.933191
NCT00911872|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-06-01|2009-06-01|2009-06-02|Estimate|||||||2009-06-01|2009-06-02|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||EVOLENCE® Assessment of Recovery Time and Impact of Dermal Filler Selection: The E-ART™ Study|EVOLENCE® Assessment of Recovery Time and Impact of Dermal Filler Selection: The E-ART™ Study|Completed||N/A|30|Actual|Solish, Nowell, M.D.||1|||f||||f||||||||||2018-06-01 00:55:50.994317|2018-06-01 00:55:50.994317
NCT00911859|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2014-09-11|2014-03-03|2014-11-17|2009-05-29|2009-06-02|Estimate|2014-11-17|2014-11-18|Estimate|2014-03-03|2014-03-31|Estimate|2014-11-17|2014-11-18|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients|A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma|Completed||Phase 2|118|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-06-01 00:55:51.108623|2018-06-01 00:55:51.108623
NCT00911846|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-06-02|Estimate|||||||2009-05-28|2009-06-02|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|June 2010|Anticipated|2010-06-30|September 2009|Anticipated|2009-09-30||Observational|Att-1||Attitudes Towards Buprenorphine and Methadone|Attitudes of Patients With Opioid-Substitution and Their Therapists Towards and Buprenorphine and Methadone|Unknown status|Recruiting||180|Anticipated|Psychiatric University Hospital, Zurich|||4||f||||f||||||||||2018-06-01 00:55:52.643812|2018-06-01 00:55:52.643812
NCT00911820|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2017-08-31||2017-10-10|2009-06-01|2009-06-02|Estimate|2017-10-10|2017-11-09|Actual||||2017-10-10|2017-11-09|Actual|July 2009|Actual|2009-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|April 2012|Actual|2012-04-30||Interventional||The analysis dataset is comprised of all treated patients.|Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer|A Randomized, Multicenter, Phase II Trial of Cisplatin, Irinotecan and Bevacizumab (PCA) vs. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer|Active, not recruiting||Phase 2|88|Actual|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-06-01 00:55:52.851997|2018-06-01 00:55:52.851997
NCT00911807|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2009-04-07||2009-06-04|2009-04-07|2009-06-02|Estimate|2009-04-07|2009-06-02|Estimate||||2009-06-04|2009-06-10|Estimate|October 2004||2004-10-31|June 2009|2009-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|Combi||Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease|A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)|Completed||Phase 2|217|Actual|Ever Neuro Pharma GmbH||3|||f||||f||||||||||2018-06-01 00:55:53.707845|2018-06-01 00:55:53.707845
NCT00911794|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-06-01|2009-06-01|2009-06-02|Estimate|||||||2009-06-01|2009-06-02|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|January 2008|Actual|2008-01-31||Interventional|||Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease|Pulmonary Therapy and Supplemental Written Disclosure Therapy for Chronic Lung Disease|Completed||N/A|66|Actual|Winthrop University Hospital||2|||f||||f||||||||||2018-06-01 00:55:55.282382|2018-06-01 00:55:55.282382
NCT00911781|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2013-02-04|2009-05-29|2009-06-02|Estimate|||||||2013-02-04|2013-02-05|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Observational|||Hemangioma Growth During the First 6 Months of Life|Hemangioma Growth During the First 6 Months of Life|Completed|||36|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-06-01 00:55:55.439173|2018-06-01 00:55:55.439173
NCT00911768|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2009-03-03||2009-08-03|2009-04-07|2009-06-02|Estimate|2009-04-07|2009-06-02|Estimate||||2009-08-03|2009-08-06|Estimate|September 2007||2007-09-30|August 2009|2009-08-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Korean Red Ginseng (KRG) on Dry Mouth|PMS Clinical Study of Korean Red Ginseng Powder on Dry Mouth and Salivary Flow Rates in Xerostomatic Populations|Completed||Phase 4|100|Actual|The Korean Society of Ginseng||2|||f||||f||||||||||2018-06-01 00:55:55.556211|2018-06-01 00:55:55.556211
NCT00911755|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2014-02-18|2009-05-29|2009-06-02|Estimate|||||||2014-02-18|2014-02-19|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|VICI||Videolaryngoscopy in the Critically Ill|Randomized Controlled Trial to Evaluate the Efficacy of Video-laryngoscopy vs. Direct Laryngoscopy for Endotracheal Intubation in the Critically Ill Patients: A Pilot Study|Completed||N/A|40|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:55:55.927858|2018-06-01 00:55:55.927858
NCT00911742|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2009-04-08||2012-04-24|2009-06-01|2009-06-02|Estimate|2009-06-01|2009-06-02|Estimate||||2012-04-24|2012-04-27|Estimate|February 2004||2004-02-29|April 2012|2012-04-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg Once A Day (OAD) Formulation Versus Zytram® 200 mg|Comparative Bioavailability Between Two Tramadol Formulations: Study of the Better Controlled Release of a New 200 mg OAD Formulation Versus Zytram® 200 mg|Completed||Phase 1|26|Actual|Labopharm Inc.||2|||f||||||||||||||2018-06-01 00:55:56.057651|2018-06-01 00:55:56.057651
NCT00911729|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2013-06-07|2009-06-01|2009-06-02|Estimate|||||||2013-06-07|2013-06-10|Estimate|April 2009||2009-04-30|June 2013|2013-06-30||||||||Observational|||Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma|Content Validation of the EORTC QLQ-C30 Version 3.0, and NIH Quality of Life and Symptoms Questionnaire for Pheochromocytoma and Paraganglioma|Terminated|||24|Anticipated|Molecular Insight Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 00:55:56.590432|2018-06-01 00:55:56.590432
NCT00911716|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-30|||2015-10-20|2009-05-30|2009-06-02|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|July 2010|Actual|2010-07-31||Interventional|||TC Avastin. ICORG 08-10, V6|Pilot Evaluation of Bevacizumab, in Combination With Docetaxel and Cyclophosphamide in the Adjuvant Treatment of Patients With HER 2 Negative Breast Cancer|Completed||N/A|106|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 00:55:56.758334|2018-06-01 00:55:56.758334
NCT00911703|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2016-04-27|2009-05-29|2009-06-02|Estimate|||||||2016-04-27|2016-04-29|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|October 2015|Actual|2015-10-31|July 2014|Actual|2014-07-31||Observational|DECIDE||Determining When Patients Hospitalized With Acute Heart Failure Can Be Safely Sent Home (The DECIDE Study)|Treatment Endpoints in Acute Decompensated Heart Failure|Completed|||835|Actual|Vanderbilt University|||1||f||||f||||||||No||2018-06-01 00:55:57.095748|2018-06-01 00:55:57.095748
NCT00911690|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2016-11-03|2009-06-01|2009-06-02|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders|Establishment of a Bank of Biospecimens for the Evaluation of New Methods Facilitating Early Diagnosis and the Monitoring of Progression and Therapy of Patients With Age-related Cognitive Disorders.|Completed|||102|Actual|William Beaumont Hospitals|||2||f||||f||||||Samples With DNA|"~     Serum, Plasma, human platelet, urine (clarified), urine sediment, saliva~   "|Undecided|If IPD are shared, it will be results of genomic and proteomic testing. As this testing was done throughout the study and is ongoing, some results are already available. Anyone interested would contact the principal investigator.|2018-06-01 00:55:57.195644|2018-06-01 00:55:57.195644
NCT00911677|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-05-29|2009-05-29|2009-06-02|Estimate|||||||2009-05-29|2009-06-02|Estimate|August 2005||2005-08-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|March 2008|Actual|2008-03-31||Observational|||Does APOE-e4 Predict Delirium and Cognitive Dysfunction After Surgery?|Does Apolipoprotein E Genotype Predict Delirium and Postoperative Cognitive Dysfunction?|Completed|||100|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-06-01 00:55:57.270874|2018-06-01 00:55:57.270874
NCT00911664|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2014-06-05|2009-06-01|2009-06-02|Estimate|||||||2014-06-05|2014-06-06|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Interventional|||Vitamin D Supplementation and CD4 Count in HIV-Infected Children|Vitamin D Supplementation and CD4 Count in HIV-Infected Children|Completed||Phase 2|54|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-06-01 00:55:57.359356|2018-06-01 00:55:57.359356
NCT00910156|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate||||May 2009|2009-05-31||||||||Interventional|||Indirect Laryngoscopy for Nasal Intubation|Indirect Versus Direct Laryngoscopy for Routine Nasotracheal Intubation: a Pilot Study|Completed||Phase 4|||General Hospital Linz||3|||f||||||||||||||2018-06-01 00:56:30.875006|2018-06-01 00:56:30.875006
NCT00911651|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-06-01|2009-06-01|2009-06-02|Estimate|||||||2009-06-01|2009-06-02|Estimate|June 2008||2008-06-30|May 2009|2009-05-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients|Open, Randomized, Two-Way Crossover, Pilot Study to Assess the Effect of Salbutamol in Comparison With Ipratropium Bromide on Central and Peripheral Airway Dimensions in COPD Patients|Completed||Phase 4|6|Actual|University Hospital, Antwerp||2|||f||||t||||||||||2018-06-01 00:55:57.443194|2018-06-01 00:55:57.443194
NCT00911638|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2017-01-23|2009-05-29|2009-06-02|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2008||2008-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Ways to Prepare Patients for Decisions About Joint Replacement Surgery|Are Patient Decision Aids for Total Joint Replacement Cost-effective and do They Optimize the Surgical Referral Process From Primary Care?|Active, not recruiting||N/A|343|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-06-01 00:55:57.545168|2018-06-01 00:55:57.545168
NCT00911625|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2017-01-22||2017-03-09|2009-06-01|2009-06-02|Estimate|2017-01-22|2017-03-10|Actual||||2017-03-09|2017-04-06|Actual|January 21, 2009|Actual|2009-01-21|March 2017|2017-03-31|June 30, 2011|Actual|2011-06-30|June 30, 2011|Actual|2011-06-30||Interventional||The baseline analysis population comprises all patients who were randomized and completed all study activities|Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency|Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency|Completed||Phase 4|114|Actual|Loyola University||2|||f||||f|t|f|||f|||No|There are no plans to make individual participant data available to other researchers|2018-06-01 00:55:57.654396|2018-06-01 00:55:57.654396
NCT00911612|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2012-02-10||2012-03-29|2009-06-01|2009-06-02|Estimate|2012-02-10|2012-03-15|Estimate||||2012-03-29|2012-04-04|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|welchol||Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?|A Phase IIB Study to Evaluate the Effects of Welchol (Colesevelam Hydrochloride) on Colonic Transit, Intestinal Permeability and Bowel Function in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)|Completed||Phase 2|24|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 00:55:58.432508|2018-06-01 00:55:58.432508
NCT00911599|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2017-05-09|2009-06-01|2009-06-02|Estimate|||||||2017-05-09|2017-05-11|Actual|August 2006||2006-08-31|May 2017|2017-05-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|RCT||RCT Comparing Ion Levels and Clinical Outcomes of A-Class BFH to Metal on Polyethylene Total Hip Replacement|A Prospective Randomized Clinical Trial Comparing Ion Levels and Clinical Outcomes of the CONSERVE® A-Class Total Hip System With BFH® Technology to Metal on Polyethylene Total Hip Replacement|Completed||N/A|60|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 00:55:58.999448|2018-06-01 00:55:58.999448
NCT00911586|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29||2010-08-17|2010-08-17|2009-05-29|2009-06-02|Estimate||||2010-08-17|2010-08-19|Estimate|2010-08-17|2010-08-19|Estimate|July 2009||2009-07-31|August 2010|2010-08-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Pharmacokinetic Study to Determine Time to Steady-state|Pharmacokinetic Study to Determine Time to Steady-state of an Oral Testosterone Undecanoate Formulation in Hypogonadal Men.|Completed||Phase 2|15|Actual|Clarus Therapeutics, Inc.|||||f||||f||||||||||2018-06-01 00:55:59.103558|2018-06-01 00:55:59.103558
NCT00911573|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2012-06-05|2009-06-01|2009-06-02|Estimate|||||||2012-06-05|2012-06-07|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects|A Phase 3, Multicenter, Randomized, Double-Blind Study To Evaluate The Safety And Efficacy Of Tigecycline Versus Comparator (Clindamycin Or Vancomycin) For The Treatment Of Complicated Skin And Skin Structure Infections, Including Those Due To MRSA, In Pediatric Subject Ages 8 To 17 Years Old|Withdrawn||Phase 3|0|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 00:55:59.183234|2018-06-01 00:55:59.183234
NCT00911560|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2018-01-17|2009-05-29|2009-06-02|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2009||2009-05-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma|Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma|Recruiting||Phase 1/Phase 2|215|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:55:59.278599|2018-06-01 00:55:59.278599
NCT00911547|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2009-07-24||2015-03-13|2009-06-01|2009-06-02|Estimate|2010-05-17|2010-06-09|Estimate||||2015-03-13|2015-04-02|Estimate|March 1995||1995-03-31|March 2015|2015-03-31|May 1996|Actual|1996-05-31|April 1996|Actual|1996-04-30||Interventional|||The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Parallel-Group Study to Assess the Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients|Completed||Phase 3|642|Actual|Merck Sharp & Dohme Corp.|Efficacy over 16 weeks of treatment for Beclo and MK+Beclo groups, and last 10 weeks for Placebo and MK groups to minimize confounding effect of beclo in 1st 4 weeks of treatment and to allow beclo washout.|4|||f||||||||||||||2018-06-01 00:55:59.400656|2018-06-01 00:55:59.400656
NCT00911534|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|2015-06-08||2016-01-04|2009-05-29|2009-06-02|Estimate|2016-01-04|2016-02-02|Estimate||||2016-01-04|2016-02-02|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)|A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)|Completed||Phase 3|305|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 00:56:00.233004|2018-06-01 00:56:00.233004
NCT00911521|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2011-10-09|2009-06-01|2009-06-02|Estimate|||||||2011-10-09|2011-10-12|Estimate|October 2009||2009-10-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study|Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study|Completed||Phase 4|100|Actual|Tuen Mun Hospital||1|||f||||t||||||||||2018-06-01 00:56:00.745175|2018-06-01 00:56:00.745175
NCT00911508|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2018-02-22|2009-05-29|2009-06-02|Estimate|||||||2018-02-22|2018-02-26|Actual|November 13, 2009|Actual|2009-11-13|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|CABANA||Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial|Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial|Completed||N/A|2204|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 00:56:00.876986|2018-06-01 00:56:00.876986
NCT00911495|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|2012-09-11||2016-08-17|2009-05-29|2009-06-02|Estimate|2013-05-02|2013-05-03|Estimate||||2016-08-17|2016-09-23|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease|Phase 1/Phase 2 Study of the Safety, Pharmacokinetics, and Microvascular Effect of Titrating Doses of Intravenous GMI-1070, a Pan-Selectin Inhibitor, in Adults With Sickle Cell Disease|Completed||Phase 1/Phase 2|15|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 00:56:01.297329|2018-06-01 00:56:01.297329
NCT00911482|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2012-11-06|2009-06-01|2009-06-02|Estimate|||||||2012-11-06|2012-11-07|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Production of Free Fatty Acids From Blood Triglycerides|FFA Production From Triglyceride-Rich Lipoproteins|Completed|||16|Actual|Mayo Clinic|||4||f||||f||||||Samples Without DNA|"~     Plasma samples obtained during the study are stored for lipid analysis.~   "|||2018-06-01 00:56:01.564787|2018-06-01 00:56:01.564787
NCT00911469|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2014-08-04|2009-06-01|2009-06-02|Estimate|||||||2014-08-04|2014-08-05|Estimate|November 2007||2007-11-30|August 2014|2014-08-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement|A Randomised, Double-blind, Placebo-controlled, Multicentre, Single and Multiple Ascending Dose Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement.|Completed||Phase 1|73|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 00:56:01.718383|2018-06-01 00:56:01.718383
NCT00911456|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2012-02-15|2009-05-29|2009-06-02|Estimate|||||||2012-02-15|2012-02-17|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|IGRT||Can 3D Ultrasound Be Used Reproducibly by Radiation Therapists in Partial Breast Image-Guided Radiation Therapy|Can 3D Ultrasound Be Used Reproducibly by Radiation Therapists in Partial Breast Image-Guided Radiation Therapy?|Completed||Phase 3|27|Actual|British Columbia Cancer Agency|||||f||||t||||||||||2018-06-01 00:56:01.881819|2018-06-01 00:56:01.881819
NCT00911443|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2009-02-26||2009-07-01|2009-04-07|2009-06-02|Estimate|2009-04-07|2009-06-02|Estimate||||2009-07-01|2009-07-09|Estimate|July 2002||2002-07-31|July 2009|2009-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma|A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma|Completed||Phase 2|488|Actual|sigma-tau i.f.r. S.p.A.||5|||f||||f||||||||||2018-06-01 00:56:02.059424|2018-06-01 00:56:02.059424
NCT00911430|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2018-05-23|2009-05-29|2009-06-02|Estimate|||||||2018-05-23|2018-05-24|Actual|May 28, 2009||2009-05-28|September 17, 2014|2014-09-17|September 17, 2014||2014-09-17|||||Observational|||Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection|Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection|Terminated|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:56:03.388607|2018-06-01 00:56:03.388607
NCT00911417|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-09-02|2009-05-28|2009-06-01|Estimate|||||||2011-09-02|2011-09-05|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Collect Intravascular Ultrasound Images Before and After Treatment With the Jetstream System|The Jetstream G2 System Post-Market Peripheral Vascular IVUS Study|Completed||Phase 4|40|Anticipated|Pathway Medical Technologies Inc.|||||f||||f||||||||||2018-06-01 00:56:03.540038|2018-06-01 00:56:03.540038
NCT00911404|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2016-08-20|2009-05-28|2009-06-01|Estimate|||||||2016-08-20|2016-08-23|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|LO-CA||Carbohydrate Restriction for Gestational Diabetes Mellitus|Comparison of Two Different Diets Containing Different Proportions of Carbohydrates in the Treatment of Gestational Diabetes Mellitus: A Randomized Clinical Trial|Completed||N/A|152|Actual|Hospital Arnau de Vilanova||2|||f||||f||||||||||2018-06-01 00:56:03.704353|2018-06-01 00:56:03.704353
NCT00911391|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2011-11-25|2009-05-29|2009-06-01|Estimate|||||||2011-11-25|2011-11-29|Estimate|November 2009||2009-11-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Randomised Trial of Doppler-Optimised Fluid Balance in Elective Colectomy|Prospective, Double-Blinded, Randomised Controlled Trial of Doppler-Optimised Fluid Balance in Elective Colectomy Within an ERAS Protocol|Completed||Phase 3|85|Actual|University of Auckland, New Zealand||2|||f||||f||||||||||2018-06-01 00:56:03.839533|2018-06-01 00:56:03.839533
NCT00911378|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-06-19|2009-05-28|2009-06-01|Estimate|||||||2009-06-19|2009-06-22|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Pressure Support Reduction Versus Spontaneous Breathing Trials in Weaning From Ventilation|A Randomized Controlled Trial on Weaning by Pressure Support Reduction Versus Spontaneous Breathing Trials in a Respiratory ICU|Unknown status|Recruiting|N/A|130|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-06-01 00:56:03.910673|2018-06-01 00:56:03.910673
NCT00911365|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2011-08-02|2009-05-29|2009-06-01|Estimate|||||||2011-08-02|2011-08-04|Estimate|May 2008||2008-05-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy|A Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy|Completed||Phase 2|27|Actual|Yonsei University||2|||f||||||||||||||2018-06-01 00:56:03.981734|2018-06-01 00:56:03.981734
NCT00911352|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2012-12-03|2009-05-29|2009-06-01|Estimate|||||||2012-12-03|2012-12-05|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cryotherapy Intervention for Docetaxel-induced Nail Toxicities|Nurse-initiated Cryotherapy Intervention for Docetaxel-induced Nail Toxicities: Case-control Study|Completed||Phase 2/Phase 3|65|Actual|Princess Alexandra Hospital, Brisbane, Australia||2|||f||||f||||||||||2018-06-01 00:56:04.042479|2018-06-01 00:56:04.042479
NCT00911339|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-05-29|2009-05-29|2009-06-01|Estimate|||||||2009-05-29|2009-06-01|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|April 2010|Anticipated|2010-04-30|January 2010|Anticipated|2010-01-31||Interventional|||Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents|Mobilization of Endothelial Progenitor Cells Induced by Atorvastatin in Patients With Stable Coronary Artery Disease Treated With Anti-CD 34 Antibodies Coated Stents|Unknown status|Enrolling by invitation|Phase 3|40|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-06-01 00:56:04.151261|2018-06-01 00:56:04.151261
NCT00911326|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2014-07-08||2014-08-06|2009-05-28|2009-06-01|Estimate|2014-08-06|2014-08-08|Estimate||||2014-08-06|2014-08-08|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Of the 101 participants who enrolled in the trial, 85 were administered the study agent, Lymphoseek, and therefore this participant number is used for the baseline analysis.|Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma|A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma|Terminated||Phase 3|101|Actual|Navidea Biopharmaceuticals|The study was prospectively structured to include an interim analysis at 33.3% enrollment. The trial was terminated early based on an interim review by the Data and Safety Monitoring Committee for positive efficacy outcome and lack of safety concern.|||"The trial was terminated early based on an interim review by the Data and Safety Monitoring~   Committee for positive efficacy outcome and no safety concerns."|f||||t||||||||||2018-06-01 00:56:04.303221|2018-06-01 00:56:04.303221
NCT00911313|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-06-01|Estimate|||||||2009-05-28|2009-06-01|Estimate|June 2006||2006-06-30|May 2009|2009-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Letrozole or Combined Metformin Clomiphene Citrate (CC) for Women With CC Resistant Polycystic Ovary Syndrome|Letrozole Versus Combined Metformin and Clomiphene Citrate for Ovulation Induction in Clomiphene-Resistant Women With Polycystic Ovary Syndrome|Completed||N/A|250|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:56:04.659107|2018-06-01 00:56:04.659107
NCT00911300|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2012-08-02||2012-09-20|2009-05-28|2009-06-01|Estimate|2012-08-02|2012-09-05|Estimate||||2012-09-20|2012-10-01|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm|An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Pilot Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients With Atrial Fibrillation Undergoing Electric Cardioversion Following Transesophageal Echocardiography|Completed||Phase 2|349|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 00:56:04.812015|2018-06-01 00:56:04.812015
NCT00911287|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-09|2009-05-29|2009-06-01|Estimate|||||||2010-02-09|2010-02-10|Estimate|June 2003||2003-06-30|February 2010|2010-02-28|March 2004|Actual|2004-03-31|January 2004|Actual|2004-01-31||Interventional|||Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain|An Open-Label Effectiveness and Safety Study of Oxymorphone Extended Release in Opioid-Naive Patients With Chronic Pain.|Completed||Phase 3|129|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:56:05.823335|2018-06-01 00:56:05.823335
NCT00911274|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2009-06-01||2009-08-14|2009-05-29|2009-06-01|Estimate|2009-08-14|2009-09-23|Estimate||||2009-08-14|2009-09-23|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions|Completed||Phase 1|53|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:56:05.908671|2018-06-01 00:56:05.908671
NCT00911261|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-29|2009-06-01|Estimate|||||||2010-02-12|2010-02-15|Estimate|August 2003||2003-08-31|February 2010|2010-02-28|May 2005|Actual|2005-05-31|March 2005|Actual|2005-03-31||Interventional|||Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain|An Open-Label Long Term Effectiveness and Safety Study of Oxymorphone Extended Release Tablets in Patients With Cancer or Neuropathic Pain|Completed||Phase 3|223|Actual|Endo Pharmaceuticals||1|||f||||t||||||||||2018-06-01 00:56:06.335912|2018-06-01 00:56:06.335912
NCT00911248|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-04-06|2009-05-29|2009-06-01|Estimate|||||||2012-04-06|2012-04-09|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||PTC299 for Treatment of Neurofibromatosis Type 2|A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2|Suspended||Phase 2|25|Anticipated|PTC Therapeutics||1|||f||||f||||||||||2018-06-01 00:56:06.410411|2018-06-01 00:56:06.410411
NCT00911235|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2011-05-31|2009-05-28|2009-06-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects|An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Effect Of Fluconazole, A Moderate CYP3A4 Inhibitor, On The Single-Dose Pharmacokinetics Of Fesoterodine In Healthy Subjects.|Completed||Phase 1|28|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:56:06.492965|2018-06-01 00:56:06.492965
NCT00911222|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2014-12-23|2009-05-29|2009-06-01|Estimate|||||||2014-12-23|2014-12-24|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Observational|EMESIS||Epidemiological EMESIS-Registry|Epidemiologic Registry for the Description of Antiemetic Strategies Under Real-life Conditions.|Completed|||1035|Actual|iOMEDICO AG|||1||f||||||||||||||2018-06-01 00:56:06.564478|2018-06-01 00:56:06.564478
NCT00911209|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-10-11|2009-05-29|2009-06-01|Estimate|||||||2012-10-11|2012-10-15|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Weight Loss in Pre-Hypertensive Patients With Diastolic Dysfunction|Impact of Weight Loss on Diastolic Dysfunction in Overweight Pre-Hypertensives|Terminated||N/A|1|Actual|Ohio State University||2||Terminated because funding was not found|f||||t||||||||||2018-06-01 00:56:06.636392|2018-06-01 00:56:06.636392
NCT00911196|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-05-25|2009-05-28|2009-06-01|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2008||2008-11-30|May 2017|2017-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma|Analysis of the Incidence of Expression of Tumor Antigens and Tumor Marker in Cancer Tissue From Asian Patients With Hepatocellular Carcinoma and Evaluation of Prognostic Significance of These Tumor Antigens.|Completed|||200|Actual|GlaxoSmithKline|||1||f||||||||||None Retained|"~     This retrospective study is based upon the analysis of archived samples and patient-related~     data already available at the investigational site~   "|||2018-06-01 00:56:06.716581|2018-06-01 00:56:06.716581
NCT00911183|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-07-21|2009-05-29|2009-06-01|Estimate|||||||2009-07-21|2009-07-22|Estimate|October 2008||2008-10-31|July 2009|2009-07-31||||October 2010|Anticipated|2010-10-31||Interventional|||Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma|Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life|Unknown status|Recruiting|Phase 2|120|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:56:06.781801|2018-06-01 00:56:06.781801
NCT00911170|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2013-11-19||2017-12-05|2009-05-28|2009-06-01|Estimate|2013-11-19|2014-01-07|Estimate||||2017-12-05|2017-12-29|Actual|November 3, 2009|Actual|2009-11-03|December 2017|2017-12-31|January 2, 2015|Actual|2015-01-02|September 17, 2012|Actual|2012-09-17||Interventional|||PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study|A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)|Completed||Phase 3|847|Actual|Amgen||2|||f||||t||||||||||2018-06-01 00:56:06.90698|2018-06-01 00:56:06.90698
NCT00911157|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2010-05-13||2016-10-11|2009-05-29|2009-06-01|Estimate|2010-05-13|2010-06-10|Estimate||||2016-10-11|2016-11-23|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT)|Completed||Phase 3|39|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:56:08.070593|2018-06-01 00:56:08.070593
NCT00911144|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2011-01-06||2016-10-06|2009-05-28|2009-06-01|Estimate|2011-01-06|2011-01-19|Estimate||||2016-10-06|2016-11-16|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine|Booster Vaccination With Pneumococcal Vaccine GSK1024850A or Prevenar™ Co-administered With Hiberix™ in Children Primed With the Same Vaccines|Completed||Phase 3|450|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:56:08.568194|2018-06-01 00:56:08.568194
NCT00911131|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2015-06-18|2009-05-29|2009-06-01|Estimate|||||||2015-06-18|2015-06-19|Estimate||||June 2015|2015-06-30||||||||Interventional|||Enhancing Detection of Small Esophageal Varices by PillCam ESO|A New Technique to Enhance Detection of Small Esophageal Varices by PillCam ESO Capsule Endoscopy|Withdrawn||Phase 3|0|Actual|Medical College of Wisconsin||3||Loss of funding|f||||t||||||||||2018-06-01 00:56:09.022662|2018-06-01 00:56:09.022662
NCT00911118|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-06-01|2009-05-28|2009-06-01|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2009|Actual|2009-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer|A Phase I Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer|Active, not recruiting||Phase 1|120|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 00:56:09.196651|2018-06-01 00:56:09.196651
NCT00911105|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2016-05-04|2009-05-28|2009-06-01|Estimate|||||||2016-05-04|2016-05-05|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|April 2012|Actual|2012-04-30||Observational|||Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone|Combined Application of Lenalidomide and Desamethasone in the Palliative Therapy of Patients With Multiple Myeloma|Completed|||101|Actual|iOMEDICO AG|||1||f||||f||||||||||2018-06-01 00:56:09.315632|2018-06-01 00:56:09.315632
NCT00911092|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2011-12-30|2009-05-29|2009-06-01|Estimate|||||||2011-12-30|2012-01-02|Estimate|October 2007||2007-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|COL06-13||Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer|Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer|Completed||Phase 4|50|Actual|Centre Oscar Lambret|||||f||||f||||||||||2018-06-01 00:56:09.396365|2018-06-01 00:56:09.396365
NCT00911079|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2014-09-26|2009-05-29|2009-06-01|Estimate|||||||2014-09-26|2014-09-29|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|May 2018|Anticipated|2018-05-31|May 2015|Anticipated|2015-05-31||Interventional|08992||Pilot Study of a Catheter-based Ultrasound Hyperthermia System|Pilot Study of a Catheter-based Ultrasound Hyperthermia System|Unknown status|Active, not recruiting|N/A|24|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:56:09.461957|2018-06-01 00:56:09.461957
NCT00911066|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-12-03|2009-05-28|2009-06-01|Estimate|||||||2013-12-03|2013-12-05|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia|An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Acute Myelogenous Leukemia,Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia|Completed||Phase 1|72|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 00:56:09.520332|2018-06-01 00:56:09.520332
NCT00911053|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2014-11-04|2009-05-28|2009-06-01|Estimate|||||||2014-11-04|2014-11-06|Estimate|June 1997||1997-06-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Melatonin for Circadian Sleep Disorders in the Blind|Melatonin for Circadian Sleep Disorders in the Blind|Unknown status|Recruiting|N/A|40|Anticipated|Oregon Health and Science University||5|||f||||||||||||||2018-06-01 00:56:09.579833|2018-06-01 00:56:09.579833
NCT00911040|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2010-09-24|2009-05-29|2009-06-01|Estimate|||||||2010-09-24|2010-09-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:56:09.652705|2018-06-01 00:56:09.652705
NCT00911027|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2012-04-24|2009-05-28|2009-06-01|Estimate|||||||2012-04-24|2012-04-25|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||SonoVue Guided Prostate Biopsy|A Phase III Study to Compare SonoVue Guided Prostate Biopsy With Systematic Biopsy in the Detection of Prostate Malignant Lesions in Patients With Suspected Prostate Cancer|Terminated||Phase 3|282|Actual|Bracco Diagnostics, Inc||2||Failure to meet primary objective|f||||f||||||||||2018-06-01 00:56:09.681901|2018-06-01 00:56:09.681901
NCT00911014|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-06-01|Estimate|||||||2009-05-28|2009-06-01|Estimate|September 2005||2005-09-30|May 2009|2009-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Access to Healthcare, Patient Comprehension and Future Plans of Women Undergoing Surgery for a Vesicovaginal Fistula in Niamey, Niger|Access to Healthcare, Patient Comprehension and Future Plans of Women Undergoing Surgery for a Vesicovaginal Fistula in Niamey, Niger|Completed|||58|Actual|Ascher-Walsh, Charles, M.D.|||1||f||||t||||||||||2018-06-01 00:56:09.760943|2018-06-01 00:56:09.760943
NCT00911001|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2013-09-18|2009-05-29|2009-06-01|Estimate|||||||2013-09-18|2013-09-19|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|SALTO||SALTO - Epidemiological Study on Compliance and Treatment Satisfaction|Compliance and Treatment Satisfaction in Prophylaxis of Postsurgical Thromboembolism|Completed|||480|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:56:09.925836|2018-06-01 00:56:09.925836
NCT00910988|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2013-04-11||2013-11-26|2009-05-28|2009-06-01|Estimate|2013-11-26|2014-01-15|Estimate||||2013-11-26|2014-01-15|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone|A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers|Completed||N/A|46|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 00:56:10.037863|2018-06-01 00:56:10.037863
NCT00910975|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-09-03|2009-05-28|2009-06-01|Estimate|||||||2012-09-03|2012-09-05|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Interventional|TTG1||Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C|Tailored Treatment of Hepatitis C Genotype 1|Completed||Phase 4|100|Actual|Göteborg University||2|||f||||t||||||||||2018-06-01 00:56:11.579107|2018-06-01 00:56:11.579107
NCT00910962|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2017-08-18|2013-02-13|2017-11-02|2009-05-28|2009-06-01|Estimate|2017-09-26|2017-10-27|Actual|2013-02-13|2013-02-18|Estimate|2017-11-02|2017-12-07|Actual|October 8, 2009|Actual|2009-10-08|September 2017|2017-09-30|March 6, 2012|Actual|2012-03-06|March 6, 2012|Actual|2012-03-06||Interventional|Solstice|The race of one participant each in treatment A and treatment B were unknown.|A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation|Completed||Phase 2|526|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:56:11.821234|2018-06-01 00:56:11.821234
NCT00910949|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2010-02-01|2009-05-28|2009-06-01|Estimate|||||||2010-02-01|2010-02-02|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Sensory Perception After Thoracotomy|Chronic Pain After Thoracotomy|Completed|||48|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-06-01 00:56:15.002253|2018-06-01 00:56:15.002253
NCT00910936|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-12-18|2009-05-29|2009-06-01|Estimate|||||||2009-12-18|2009-12-21|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|February 2010|Anticipated|2010-02-28|January 2010|Anticipated|2010-01-31||Interventional|||Exercise for Patients With HIV Infections|Effects of an Exercise Program on Metabolic Parameters of Patients With a HIV Infection.|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:56:15.110393|2018-06-01 00:56:15.110393
NCT00910923|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-10-02|2009-05-28|2009-06-01|Estimate|||||||2009-10-02|2009-10-06|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers|Single Ascending Dose|Completed||Phase 1|37|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 00:56:15.321345|2018-06-01 00:56:15.321345
NCT00910910|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2015-09-23||2017-08-31|2009-05-29|2009-06-01|Estimate|2016-10-27|2016-12-21|Estimate||||2017-08-31|2017-10-02|Actual|October 13, 2009|Actual|2009-10-13|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|March 31, 2014|Actual|2014-03-31||Interventional|ORIGIN|The Intent-to-Treat (ITT) population was defined as all participants who were randomized, independent of whether they received study treatment or not.|Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)|A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)|Active, not recruiting||Phase 3|450|Actual|Celgene||2|||f||||t||||||||||2018-06-01 00:56:15.579234|2018-06-01 00:56:15.579234
NCT00910897|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2009-05-29|2009-05-29|2009-06-01|Estimate|||||||2009-05-29|2009-06-01|Estimate|March 2008||2008-03-31|May 2009|2009-05-31||||August 2009|Anticipated|2009-08-31||Interventional|||Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)|A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma|Unknown status|Active, not recruiting|Phase 3|205|Actual|Intergroupe Francophone du Myelome||2|||f||||f||||||||||2018-06-01 00:56:17.126439|2018-06-01 00:56:17.126439
NCT00910884|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2017-07-18|2009-05-29|2009-06-01|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2018|Anticipated|2018-08-31|July 2017|2017-07-31|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Observational|||Natural Supplements Special Diet: Eliminating Cancer-impacting Hormones From Sources Outside the Body in Patients With Early-Stage or Remission Breast Cancer.|Gene Expression Control Using Micro-Trace Element Compounds During C.A.M., Adjunct Therapy and Conventional Cancer Protocols|Not yet recruiting|||300|Anticipated|Brabant Research|||2||f||||t|f|f||||||||2018-06-01 00:56:17.477315|2018-06-01 00:56:17.477315
NCT00910871|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2013-01-30||2015-04-08|2009-05-28|2009-06-01|Estimate|2013-04-03|2013-05-16|Estimate||||2015-04-08|2015-04-24|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|January 2013|Actual|2013-01-31|March 2011|Actual|2011-03-31||Interventional||Intent-to-treat (ITT) population included all participants who had at least 1 dose of TMC207, regardless of their compliance with the protocol.|To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.|A Phase II, Open-label Trial With TMC207 as Part of a Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Subjects With Sputum Smear-positive Pulmonary Infection With MDR-TB.|Completed||Phase 2|241|Actual|Janssen Infectious Diseases BVBA|In Participant Flow, the 12 deaths shown are restricted to those that occurred during the trial and do not include 4 deaths reported after discontinuation in long-term survival follow-up.|1|||f||||t||||||||||2018-06-01 00:56:17.682915|2018-06-01 00:56:17.682915
NCT00910858|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2013-07-31||2013-07-31|2009-05-29|2009-06-01|Estimate|2013-07-31|2013-09-30|Estimate||||2013-07-31|2013-09-30|Estimate|January 2005||2005-01-31|July 2013|2013-07-31|May 2009|Actual|2009-05-31|April 2006|Actual|2006-04-30||Interventional|||A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes|A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes|Completed||Phase 1/Phase 2|40|Actual|Celgene||2|||f||||t||||||||||2018-06-01 00:56:18.29244|2018-06-01 00:56:18.29244
NCT00730093|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2009-08-05|2008-08-07|2008-08-08|Estimate|||||||2009-08-05|2009-08-06|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||The Absorption of Vitamin B12 Among Healthy Pregnant Women|The Absorption of Vitamin B12 Among Healthy Pregnant Women|Completed||N/A|27|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 01:52:21.315531|2018-06-01 01:52:21.315531
NCT00910845|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2013-01-29|2012-07-23|2013-01-29|2009-05-29|2009-06-01|Estimate|2013-01-29|2013-03-05|Estimate|2012-07-23|2012-07-31|Estimate|2013-01-29|2013-03-05|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence||Completed||Phase 3|557|Actual|Allergan||2|||f||||f||||||||||2018-06-01 00:56:20.429547|2018-06-01 00:56:20.429547
NCT00910832|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2014-03-18|2009-05-29|2009-06-01|Estimate|||||||2014-03-18|2014-03-19|Estimate|May 2009||2009-05-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|Eductyl||Efficacy of Eductyl® Versus Placebo for Treatment of Dyschesia|Comparative, Randomized, Double-blind Study of the Efficacy of Eductyl® Versus Placebo for Treatment of Patients With Dyschesia Treated by Rectal Rehabilitation|Completed||Phase 4|306|Actual|Laboratoires Techni Pharma||2|||f||||f||||||||||2018-06-01 00:56:21.460163|2018-06-01 00:56:21.460163
NCT00910819|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-08-18|2009-05-29|2009-06-01|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2006||2006-09-30|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|TKK||Tumour Registry Colorectal Cancer|Prospective and Retrospective Observation of the Adjuvant and Palliative Treatment Strategies in the Therapy of Colorectal Cancer in Germany|Active, not recruiting|||6500|Actual|iOMEDICO AG|||||f||||f||||||||No||2018-06-01 00:56:21.791503|2018-06-01 00:56:21.791503
NCT00910806|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2014-04-01|2009-05-28|2009-06-01|Estimate|||||||2014-04-01|2014-04-02|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)|A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects.|Completed||Phase 1|16|Actual|Tibotec BVBA||1|||f||||f||||||||||2018-06-01 00:56:21.874204|2018-06-01 00:56:21.874204
NCT00910793|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-07-09|2009-05-28|2009-06-01|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Asthmatic Patients|Open-Label, Prospective Study to Assess the Effects of Formoterol and Beclometasone Dipropionate Combination Therapy on Central and Peripheral Airway Dimensions in Asthmatic Patients|Completed||Phase 4|29|Actual|University Hospital, Antwerp||1|||f||||f||||||||||2018-06-01 00:56:21.935903|2018-06-01 00:56:21.935903
NCT00910780|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2014-03-12|2009-05-29|2009-06-01|Estimate|||||||2014-03-12|2014-03-13|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|November 2009|Anticipated|2009-11-30|November 2009|Actual|2009-11-30||Interventional|SMEAC||Metabolic Effects of Antipsychotic Substitution in Children|Metabolic Effects of Antipsychotic Substitution in Children|Withdrawn||Phase 2/Phase 3|0|Actual|Washington University School of Medicine||4||Study was not funded.|f||||t||||||||||2018-06-01 00:56:22.007374|2018-06-01 00:56:22.007374
NCT00910767|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-09-16|2009-05-29|2009-06-01|Estimate|||||||2009-09-16|2009-09-17|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ANGELA01||Closing the Loop in Adults With Type 1 Diabetes|A Randomised, 2-period Cross-over Study to Assess the Feasibility of Overnight Computer-based Glucose Control Based on Continuous Subcutaneous Glucose Monitoring, and Compare it With Conventional Pump Therapy in Adults With Type 1 Diabetes|Completed||N/A|12|Actual|University of Cambridge||2|||f||||f||||||||||2018-06-01 00:56:22.066872|2018-06-01 00:56:22.066872
NCT00910754|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-04-11|2009-05-29|2009-06-01|Estimate|||||||2013-04-11|2013-04-12|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|November 2009|Actual|2009-11-30||Interventional|||A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer|A QT/QTc and Multi-dose PK Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration- Resistant Prostate Cancer|Completed||Phase 1|33|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-06-01 00:56:22.217426|2018-06-01 00:56:22.217426
NCT00910741|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2014-01-08|2009-05-29|2009-06-01|Estimate|||||||2014-01-08|2014-01-09|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia|Phase I/II Study of the Combination Therapy With NC-6004 and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer in Asian Countries|Completed||Phase 1/Phase 2|40|Actual|NanoCarrier Co., Ltd.||1|||f||||f||||||||||2018-06-01 00:56:22.327147|2018-06-01 00:56:22.327147
NCT00910728|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2015-08-18||2017-03-13|2009-05-29|2009-06-01|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|May 2009||2009-05-31|March 2017|2017-03-31|August 2014|Actual|2014-08-31|March 2012|Actual|2012-03-31||Interventional|||Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases|A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF|Completed||Phase 1|65|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:56:22.461799|2018-06-01 00:56:22.461799
NCT00910715|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2011-10-05||2017-05-04|2009-05-29|2009-06-01|Estimate|2012-06-13|2012-07-18|Estimate||||2017-05-04|2017-06-02|Actual|June 2009||2009-06-30|May 2017|2017-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Duration of Antibiotic Treatment of Erythema Migrans|Duration of Antibiotic Treatment of Erythema Migrans. A Randomized Clinical Trial.|Completed||N/A|306|Actual|University Medical Centre Ljubljana||3|||f||||f||||||||||2018-06-01 00:56:23.841426|2018-06-01 00:56:23.841426
NCT00910702|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-04-29|2009-05-29|2009-06-01|Estimate|||||||2013-04-29|2013-04-30|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body|The Exploratory Clinical Trials for the Feasibility, Primary Safety and Efficacy of Foldable Capsular Vitreous Body|Completed||Early Phase 1|15|Actual|GuangZhou WeiShiBo Biotechnology Co., ltd||1|||f||||t||||||||||2018-06-01 00:56:24.122241|2018-06-01 00:56:24.122241
NCT00910689|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2008-11-24||2016-10-07|2009-04-17|2009-06-01|Estimate|2009-04-17|2009-06-01|Estimate||||2016-10-07|2016-11-22|Estimate|July 2001||2001-07-31|October 2016|2016-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|TSM||Drug and Non-Drug Treatment Of Severe Migraine|Drug and Non-Drug Treatment of Severe Migraine|Completed||Phase 4|232|Actual|Ohio University|No side effect reached the 5% reporting threshold at either the Month 10 or the Month 16 assessment.|4|||f||||f||||||||||2018-06-01 00:56:24.207099|2018-06-01 00:56:24.207099
NCT00909974|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2010-09-12|2009-05-28|2009-05-29|Estimate|||||||2010-09-12|2010-09-14|Estimate|February 2006||2006-02-28|September 2010|2010-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MISAME2||Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso|Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso|Completed||Phase 4|1302|Anticipated|Institute of Tropical Medicine, Belgium||2|||f||||t||||||||||2018-06-01 00:56:33.220316|2018-06-01 00:56:33.220316
NCT00910676|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2012-07-30|2009-05-29|2009-06-01|Estimate|||||||2012-07-30|2012-07-31|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|DIPROCOL||Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors|Phase II Multicentric Study About Preventive Treatment of Folliculitis Induced by the EGF-R Inhibitors in Patients With Metastatic Colorectal Cancer and Treated by Cetuximab or With Non-small-cell Lung Carcinoma Treated by Erlotinib|Completed||Phase 2|30|Actual|Centre Oscar Lambret||1|||f||||f||||||||||2018-06-01 00:56:24.81393|2018-06-01 00:56:24.81393
NCT00910663|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2009-06-01||2010-04-28|2009-05-29|2009-06-01|Estimate|2010-04-28|2010-05-17|Estimate||||2010-04-28|2010-05-17|Estimate|October 2006||2006-10-31|April 2010|2010-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Mycophenolate Mofetil Capsules Under Fed Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:56:24.899905|2018-06-01 00:56:24.899905
NCT00910650|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2018-01-10|2009-05-29|2009-06-01|Estimate|||||||2018-01-10|2018-01-12|Actual|October 13, 2009|Actual|2009-10-13|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|F5||Study of Gene Modified Immune Cells in Patients With Advanced Melanoma|Adoptive Transfer of MART-1 F5 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of MART-126•35-Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Melanoma|Recruiting||Phase 2|22|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 00:56:25.265989|2018-06-01 00:56:25.265989
NCT00910637|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2013-02-06|2009-05-29|2009-06-01|Estimate|||||||2013-02-06|2013-02-08|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles|Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects|Completed||Phase 3|1502|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:56:25.353304|2018-06-01 00:56:25.353304
NCT00910624|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2013-09-18||2017-03-09|2009-05-28|2009-06-01|Estimate|2013-09-18|2013-11-19|Estimate||||2017-03-09|2017-04-07|Actual|June 2009||2009-06-30|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PROVIDE||Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)|A Single-Arm Study to Provide Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies|Completed||Phase 3|168|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 00:56:25.524776|2018-06-01 00:56:25.524776
NCT00910611|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2010-06-24|2009-05-28|2009-06-01|Estimate|||||||2010-06-24|2010-06-25|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|July 2010|Anticipated|2010-07-31|June 2009|Actual|2009-06-30||Interventional|Buzzy||A Test of the Effectiveness of a Device for Pediatric Immunization Pain|Relieving Pediatric Immunization Pain Using A Reusable Personal Device|Unknown status|Active, not recruiting|N/A|60|Anticipated|MMJ Labs LLC||2|||f||||f||||||||||2018-06-01 00:56:25.986238|2018-06-01 00:56:25.986238
NCT00910598|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2010-02-09|2009-05-29|2009-06-01|Estimate|||||||2010-02-09|2010-02-10|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|OCTIMS||Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)|A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS|Unknown status|Recruiting|Phase 4|60|Anticipated|Amphia Hospital||2|||f||||f||||||||||2018-06-01 00:56:26.069552|2018-06-01 00:56:26.069552
NCT00910585|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-29|2009-05-29|2009-06-01|Estimate|||||||2009-05-29|2009-06-01|Estimate|January 1997||1997-01-31|May 2009|2009-05-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|Coach||Coaching in Childhood Asthma|Phase 4 Study of Case Management and Environmental Control in Asthma|Completed||Phase 3|191|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 00:56:26.206704|2018-06-01 00:56:26.206704
NCT00910572|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2011-06-30|2009-05-29|2009-06-01|Estimate|||||||2011-06-30|2011-07-01|Estimate|July 2007||2007-07-31|May 2009|2009-05-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma|Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced HCC (Hepatocellular Carcinoma) Not Eligible to Curative Approach. A Phase II-b Study.|Completed||Phase 2|60|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||||f||||f||||||||||2018-06-01 00:56:26.274415|2018-06-01 00:56:26.274415
NCT00910559|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-29|||2018-04-25|2009-05-29|2009-06-01|Estimate|||||||2018-04-25|2018-04-26|Actual|July 2008||2008-07-31|April 2018|2018-04-30|February 2024|Anticipated|2024-02-29|February 2022|Anticipated|2022-02-28||Observational|||Phenotypic and Genetic Factors in Autism Spectrum Disorders|Phenotypic and Genetic Factors in Autism Spectrum Disorders|Active, not recruiting|||1500|Anticipated|Boston Children’s Hospital|||||f||||f|f|f||||Samples With DNA|"~     Whole blood~   "|Yes|Data is available through National Database for Autism Research (NDAR) and database of Genotypes and Phenotypes (dbGaP).|2018-06-01 00:56:26.354801|2018-06-01 00:56:26.354801
NCT00910546|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-12-27|2009-05-28|2009-06-01|Estimate|||||||2012-12-27|2012-12-28|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer|Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer|Completed||N/A|15|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-06-01 00:56:26.414861|2018-06-01 00:56:26.414861
NCT00910533|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-05-04|2009-05-28|2009-06-01|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2009||2009-06-30|May 2017|2017-05-31||||June 2018|Anticipated|2018-06-30||Interventional|||Study on Early Lyme Neuroborreliosis|Clinical and Microbiological Parameters in Patients With Early Lyme Neuroborreliosis|Recruiting||N/A|50|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-06-01 00:56:26.483435|2018-06-01 00:56:26.483435
NCT00910520|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2013-01-29|2012-08-24|2013-01-29|2009-05-29|2009-06-01|Estimate|2013-01-29|2013-03-05|Estimate|2012-08-24|2012-08-31|Estimate|2013-01-29|2013-03-05|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence||Completed||Phase 3|548|Actual|Allergan||2|||f||||f||||||||||2018-06-01 00:56:26.566621|2018-06-01 00:56:26.566621
NCT00910507|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-06-01|Estimate|||||||2009-05-28|2009-06-01|Estimate|September 2007||2007-09-30|May 2009|2009-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Impact of Exercise Counseling on Exercise Behavior in People With Type 2 Diabetes: A Randomized Clinical Trial|The Impact of Physical Therapist-Directed Exercise Counseling Combined With Fitness Center-Based Exercise Training on Stage of Exercise Behavior in People With Type 2 Diabetes: A Randomized Clinical Trial|Completed||N/A|24|Actual|University of Central Arkansas||2|||f||||f||||||||||2018-06-01 00:56:26.949425|2018-06-01 00:56:26.949425
NCT00910494|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2018-04-22|2009-05-28|2009-06-01|Estimate|||||||2018-04-22|2018-04-24|Actual|January 2010||2010-01-31|April 2018|2018-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Intraoperative Radiotherapy for Rectal Cancer Using the Photon Radiosurgery System|Intraoperative Radiotherapy (IORT) for Rectal Cancer Using the Photon Radiosurgery System (PRS): A Phase I Clinical Trial|Terminated||N/A|9|Actual|University of Dundee||2||No longer practical to deliver treatment|f||||f||||||||||2018-06-01 00:56:27.013902|2018-06-01 00:56:27.013902
NCT00910481|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|December 2005||2005-12-31|May 2009|2009-05-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|BCIS-1||Balloon Pump Assisted Coronary Intervention Study|Balloon Pump Assisted Coronary Intervention Study|Unknown status|Active, not recruiting|N/A|301|Actual|British Cardiovascular Intervention Society||2|||f||||t||||||||||2018-06-01 00:56:27.075826|2018-06-01 00:56:27.075826
NCT00910468|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|July 2005||2005-07-31|May 2009|2009-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids|Robot-Assisted Laparoscopic Myomectomy Is an Improvement Over Laparotomy in Patients With a Limited Number of Fibroids|Completed|||150|Actual|Ascher-Walsh, Charles, M.D.|||2||f||||||||||||||2018-06-01 00:56:27.141118|2018-06-01 00:56:27.141118
NCT00910455|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2010-03-16|2009-05-28|2009-05-29|Estimate|||||||2010-03-16|2010-03-17|Estimate|May 2009||2009-05-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|AVN005||Study of SRX246 Capsules in Healthy Adult Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX246 Capsules in Healthy Adult Volunteers|Completed||Phase 1|49|Actual|Azevan Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:56:27.202334|2018-06-01 00:56:27.202334
NCT00910442|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|February 2002||2002-02-28|May 2009|2009-05-31|February 2009|Actual|2009-02-28|February 2007|Actual|2007-02-28||Interventional|||Glutathione and Its Precursors in HIV-Infected Patients|The Effect of Substrate Supply on Modulating Plasma GSH Levels in Treated HIV+ Patients|Completed||Phase 2|32|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||||2018-06-01 00:56:27.274424|2018-06-01 00:56:27.274424
NCT00910429|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2018-05-24|2009-05-28|2009-05-29|Estimate|||||||2018-05-24|2018-05-25|Actual|July 1, 2009|Actual|2009-07-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CHEST-2||BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension|Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).|Active, not recruiting||Phase 3|237|Actual|Bayer||1|||f||||t|t|f||||||||2018-06-01 00:56:27.343819|2018-06-01 00:56:27.343819
NCT00910416|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2016-09-22|2009-05-28|2009-05-29|Estimate|||||||2016-09-22|2016-09-23|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Comparability of Bispectral Index and Neurosense During Anesthesia|The Comparability of Bispectral Index and Neurosense During Total Intravenous Anesthesia and Balanced Anesthesia|Terminated|||40|Actual|Hopital Foch|||2|Differences between BIS and Neurosense are important. This study can be terminated.|f||||f||||||||||2018-06-01 00:56:27.489372|2018-06-01 00:56:27.489372
NCT00910403|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2011-05-24|2009-05-28|2009-05-29|Estimate|||||||2011-05-24|2011-05-26|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PresbyLASIK||Multicenter Evaluation of Safety and Effectiveness of Presbyopic LASIK for Hyperopes|A Prospective Multicenter, Study to Evaluate the Safety and Effectiveness of the Presbyopia Algorithm for Hyperopia and Hyperopic Astigmatism Using LASIK|Completed||Phase 3|80|Anticipated|Technolas Perfect Vision GmbH|||||f||||f||||||||||2018-06-01 00:56:27.596742|2018-06-01 00:56:27.596742
NCT00910390|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2016-07-25|2009-05-28|2009-05-29|Estimate|||||||2016-07-25|2016-07-26|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|May 2011|Actual|2011-05-31|October 2009|Actual|2009-10-31||Interventional|||Comparison Between Three Freezing Protocols to Preserve Human Embryos|Randomized Comparison to Freeze Human Embryos by Either Vitrification or Slow Freezing Protocols|Completed||N/A|584|Actual|Erasme University Hospital||3|||f||||f||||||||No||2018-06-01 00:56:27.685842|2018-06-01 00:56:27.685842
NCT00910377|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Adolescent Mothers, Grandmothers, Breastfeeding and Complementary Feeding|Effect of Intervention About Breastfeeding and Complementary Feeding in Adolescent Mothers and Their Grandmothers|Completed||N/A|344|Actual|Hospital de Clinicas de Porto Alegre||4|||f||||t||||||||||2018-06-01 00:56:27.780507|2018-06-01 00:56:27.780507
NCT00910364|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-04-11|2009-05-28|2009-05-29|Estimate|||||||2017-04-11|2017-04-13|Actual|October 2008||2008-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2012|Actual|2012-12-31||Interventional|EXPERT||Feasibility Study of Exercise in Patients With Leg Blood Clots|EXPERT Trial: Exercise to Prevent Post-thrombotic Syndrome Elicited by Recent Thrombosis|Completed||N/A|5|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 00:56:27.85765|2018-06-01 00:56:27.85765
NCT00910351|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-11-20|2009-05-28|2009-05-29|Estimate|||||||2013-11-20|2013-11-21|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Cipro Inhaler for Cystic Fibrosis Children Ages 6-12|A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin in Adults and Children Aged 6 - 12 Years With Cystic Fibrosis Following Inhalation of Ciprofloxacin Dry Powder|Completed||Phase 1|19|Actual|Bayer||1|||f||||t||||||||||2018-06-01 00:56:27.913071|2018-06-01 00:56:27.913071
NCT00910338|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2011-04-21|2009-05-28|2009-05-29|Estimate|||||||2011-04-21|2011-04-22|Estimate|July 2007||2007-07-31|April 2011|2011-04-30|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Extracorporeal Biofeedback|Efficacy and Safety of Extracorporeal Biofeedback Pelvic Floor Muscle Training to Treat Urodynamic Stress Incontinence|Completed||N/A|100|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 00:56:27.983268|2018-06-01 00:56:27.983268
NCT00910325|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2012-10-29|2009-05-28|2009-05-29|Estimate|||||||2012-10-29|2012-10-30|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery: Laparoscopic-Assisted Transvaginal Cholecystectomy|Terminated||Phase 1/Phase 2|3|Actual|Massachusetts General Hospital||||"The alternative laparoscopic chole, has so little morbidity very few patients opt for a~   transvaginal approach when presented with the alternative"|f||||t||||||||||2018-06-01 00:56:28.170914|2018-06-01 00:56:28.170914
NCT00910312|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2016-04-21|2009-05-28|2009-05-29|Estimate|||||||2016-04-21|2016-04-22|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ICE-CRYSTAL||ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial|Evaluation of Safety and Feasibility of the ICE-SENSE™, a Cryotherapy Device for Office-based Ultrasound-guided Treatment of Breast Fibroadenoma|Completed||N/A|54|Actual|IceCure Medical Ltd.||1|||f||||f||||||||||2018-06-01 00:56:28.228337|2018-06-01 00:56:28.228337
NCT00910299|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2012-04-10||2012-05-08|2009-05-28|2009-05-29|Estimate|2012-05-08|2012-06-08|Estimate||||2012-05-08|2012-06-08|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|TRIGGER-PCI||Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)|Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent|Terminated||Phase 2|423|Actual|Eli Lilly and Company|The study was terminated early, and no formal statistical time-to-event analysis was performed.|2||Due to the low rate of primary endpoint events experienced in the study to date|f||||t||||||||||2018-06-01 00:56:28.350909|2018-06-01 00:56:28.350909
NCT00910286|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|December 2004||2004-12-31|May 2009|2009-05-31|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Two Cycling Off Modes in Pressure Support: Study of Respiratory Mechanics, Breathing Comfort and Asynchrony Patterns|VENTILAÇÃO MECÂNICA COM PRESSÃO SUPORTE: ESTUDO DA ASSINCRONIA EXPIRATÓRIA (in Portughese)|Completed||N/A|18|Actual|Hospital de Clinicas de Porto Alegre||1|||f||||f||||||||||2018-06-01 00:56:29.048499|2018-06-01 00:56:29.048499
NCT00910273|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|2012-10-03||2015-12-08|2009-05-28|2009-05-29|Estimate|2015-12-08|2016-01-13|Estimate||||2015-12-08|2016-01-13|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CREST||Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients|Effects of Etanercept on Endothelial Function and Carotid Intima-media Thickness (IMT) in Patients With Active AS|Terminated||Phase 4|34|Actual|Pfizer|Due to early termination and few participants attending visits after Week 12, statistical analysis limited to Week 12.|1|||f||||f||||||||||2018-06-01 00:56:29.181304|2018-06-01 00:56:29.181304
NCT00910260|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2014-05-18|2009-05-28|2009-05-29|Estimate|||||||2014-05-18|2014-05-20|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Impact on UVB Narrow Band and UVA1 Therapy on Serum 25-hydroxyvitamin D Levels|Impact on UVB Narrow Band and UVA1 Therapy on Serum 25-hydroxyvitamin D Levels|Completed|||116|Actual|University of Zurich|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 00:56:29.984542|2018-06-01 00:56:29.984542
NCT00910247|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2017-04-25|2009-05-28|2009-05-29|Estimate|||||||2017-04-25|2017-04-26|Actual|August 2009||2009-08-31|April 2017|2017-04-30|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||Eslicarbazepine Acetate Monotherapy Long Term Study|Long Term Eslicarbazepine Acetate Extension Study|Completed||Phase 3|274|Actual|Sunovion||1|||f||||f||||||||||2018-06-01 00:56:30.050389|2018-06-01 00:56:30.050389
NCT00910234|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|August 2009||2009-08-31|May 2009|2009-05-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants|Early Treatment With Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants: Comparison of High and Low Dose|Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|China Medical University Hospital||3|||f||||t||||||||||2018-06-01 00:56:30.371904|2018-06-01 00:56:30.371904
NCT00910221|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-09-09|2009-05-28|2009-05-29|Estimate|||||||2012-09-09|2012-09-11|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|September 2011|Actual|2011-09-30|August 2010|Actual|2010-08-31||Interventional|CREAT||Cardiopulmonary-bypass and Reno-protective Effect of Atorvastatin Trial|A Phase II Randomised, Double-blind, Placebo-controlled Study of the Effect of Atorvastatin on Postoperative Renal Function in Patients Undergoing Elective Cardiopulmonary Bypass.|Completed||Phase 2/Phase 3|100|Actual|Austin Health||2|||f||||t||||||||||2018-06-01 00:56:30.456957|2018-06-01 00:56:30.456957
NCT00910208|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2012-07-12|2009-05-28|2009-05-29|Estimate|||||||2012-07-12|2012-07-13|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department|Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department|Completed||N/A|211|Actual|Albert Einstein College of Medicine, Inc.||3|||f||||t||||||||||2018-06-01 00:56:30.523762|2018-06-01 00:56:30.523762
NCT00910195|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2011-08-08|2009-05-28|2009-05-29|Estimate|||||||2011-08-08|2011-08-09|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Validation of a New Automatic Bi-level Algorithm in the Treatment of Sleep-disordered Breathing|Validation of a New Automatic Bi-level Algorithm in the Treatment of Sleep-disordered Breathing|Completed||N/A|150|Anticipated|Wissenschaftliches Institut Bethanien e.V||2|||f||||f||||||||||2018-06-01 00:56:30.596432|2018-06-01 00:56:30.596432
NCT00910182|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|January 2002||2002-01-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Outcome After Conservative and Surgical Treatment of Splenic Injuries After Blunt Abdominal Trauma.|Outcome After Conservative and Surgical Treatment of Splenic Injuries After Blunt Abdominal Trauma. Retrospective Study 2002-2008.|Completed|||200|Actual|University Hospital Inselspital, Berne|||3||f||||f||||||||||2018-06-01 00:56:30.665243|2018-06-01 00:56:30.665243
NCT00910169|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2012-08-06|2009-05-28|2009-05-29|Estimate|||||||2012-08-06|2012-08-07|Estimate|March 2009||2009-03-31|May 2009|2009-05-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|EVHAN||Evaluation of Hospitalization for Anorexia Nervosa (EVALuation de l'Apport de l'HOSPITalisation Pour Anorexie Mentale : EVALHOSPITAM)|Evaluation of Hospitalization for Anorexia Nervosa: Efficacy of Treatment and Predictive Factors of Outcome.|Unknown status|Active, not recruiting||300|Anticipated|Institut Mutualiste Montsouris|||1||f||||t||||||Samples Without DNA|"~     all biological analysis during hospitalisation, serotonin , tryptophan, CD4/CD8~   "|||2018-06-01 00:56:30.793956|2018-06-01 00:56:30.793956
NCT00910143|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|January 1993||1993-01-31|May 2009|2009-05-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Observational|||Introduction and Influence of Total Mesorectal Excision (TME) in the Treatment of Rectal Cancer|Introduction of Total Mesorectal Excision (TME) in the Treatment of Rectal Cancer. Influence of This New Operation Technique on Local Recurrence and Long-Time Survival. Retrospective Study: 1993-2001|Completed|||194|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 00:56:30.930101|2018-06-01 00:56:30.930101
NCT00910130|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|July 2008||2008-07-31|May 2009|2009-05-31||||||||Observational|||Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4|Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4|Unknown status|Recruiting||30|Anticipated|IRCCS Policlinico S. Matteo|||2||f||||||||||Samples With DNA|"~     Serum Subcutaneous adipose tissue~   "|||2018-06-01 00:56:30.999958|2018-06-01 00:56:30.999958
NCT00910117|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2012-02-16|2009-05-28|2009-05-29|Estimate|||||||2012-02-16|2012-02-20|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase II Study of Nimotuzumab Plus PF as Induction Chemotherapy in Patients With Locally Advanced HNSCC|Completed||Phase 2|40|Actual|Fudan University||1|||f||||f||||||||||2018-06-01 00:56:31.065396|2018-06-01 00:56:31.065396
NCT00910104|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2018-03-14|2009-05-28|2009-05-29|Estimate|||||||2018-03-14|2018-03-15|Actual|September 2004||2004-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|Reversal||Cholestasis Reversal: Efficacy of IV Fish Oil|Cholestasis Reversal: Efficacy of IV Fish Oil|Recruiting||Phase 2/Phase 3|330|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||||2018-06-01 00:56:31.130143|2018-06-01 00:56:31.130143
NCT00910091|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2015-07-17||2015-08-28|2009-05-28|2009-05-29|Estimate|2015-08-28|2015-09-30|Estimate||||2015-08-28|2015-09-30|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|July 2013|Actual|2013-07-31|January 2012|Actual|2012-01-31||Interventional|||The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer|A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer|Completed||Phase 2|73|Actual|Ipsen||2|||f||||f||||||||||2018-06-01 00:56:31.217081|2018-06-01 00:56:31.217081
NCT00910078|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate||||May 2009|2009-05-31||||||||Observational|||Serum Free Light Change in Multiple Myeloma|Serum Free Light Chain Ratio, Total Kappa/Lambda Ratio, and Immunofixation as Prognostic Factors in Multiple Myeloma.|Completed|||||Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-06-01 00:56:31.98102|2018-06-01 00:56:31.98102
NCT00910065|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2015-06-24|2009-05-28|2009-05-29|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|ACUTE||BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)|A Prospective, Randomized, Verum Controlled, Open Label, Parallel Group Multi-center Phase III Clinical Trial to Demonstrate the Superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) Treatment Versus 300 mg Aspirin® N Tablets p.o. (BAY e4465A) in Patients With Acute Coronary Syndrome, Measured by Time Dependent Thromboxane Inhibition|Completed||Phase 3|270|Actual|Bayer||3|||f||||f||||||||||2018-06-01 00:56:32.027788|2018-06-01 00:56:32.027788
NCT00910052|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|May 2003||2003-05-31|May 2009|2009-05-31|September 2008|Actual|2008-09-30|May 2006|Actual|2006-05-31||Interventional|||Fibrin Sealant in Renal Transplantation|Routine Use of Fibrin Sealant Does Not Reduce Postoperative Wound Complications in Patients Undergoing Renal Transplantation: A Randomized Controlled Trial|Completed||N/A|141|Actual|Hennepin County Medical Center, Minneapolis||2|||f||||t||||||||||2018-06-01 00:56:32.129913|2018-06-01 00:56:32.129913
NCT00910039|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2013-07-18||2014-09-25|2009-05-28|2009-05-29|Estimate|2013-09-27|2013-10-01|Estimate||||2014-09-25|2014-09-29|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|January 2012|Actual|2012-01-31||Interventional|||Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases|SUNDANCE Trial: Phase II Trial of Sunitinib as Maintenance Therapy After Stereotactic Radiosurgery in Patients With 1-3 Newly Diagnosed Brain Metastases|Terminated||Phase 2|14|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||t||||||||||2018-06-01 00:56:32.200181|2018-06-01 00:56:32.200181
NCT00910026|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2013-10-24|2009-05-28|2009-05-29|Estimate|||||||2013-10-24|2013-10-25|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|TDEBC||Study of the Influence of Various Tidal Volumes on Exhaled Breath Condensate (EBC) in Mechanically Ventilated Patients|Exhaled Breath Condensate (EBC) Collection and Analysis in Mechanically Ventilated ICU Patients: Monitoring of the Influence of Various Tidal Volumes on Lung Inflammatory Biomarkers|Completed||N/A|20|Anticipated|Larissa University Hospital||2|||f||||f||||||||||2018-06-01 00:56:32.475988|2018-06-01 00:56:32.475988
NCT00910013|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2011-02-25|2009-05-28|2009-05-29|Estimate|||||||2011-02-25|2011-02-28|Estimate|April 2006||2006-04-30|May 2009|2009-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|TKR||Femoral Block With or Without Ropivacaine for Analgesia After Total Knee Replacement (TKR)|A Randomized Trial Comparing the Efficacy on Post-operative Analgesia of Intra-articular Ropivacaine Added to a Femoral Block After Total Knee Replacement|Completed||Phase 1/Phase 2|80|Actual|Hopital de l'Enfant-Jesus||1|||f||||f||||||||||2018-06-01 00:56:32.541532|2018-06-01 00:56:32.541532
NCT00910000|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2016-03-29||2017-06-19|2009-05-28|2009-05-29|Estimate|2016-08-10|2016-10-04|Estimate||||2017-06-19|2017-07-17|Actual|June 2009||2009-06-30|June 2017|2017-06-30|October 2015|Actual|2015-10-31|January 2013|Actual|2013-01-31||Interventional|||Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer|Phase Ib/II Study of Combination of Vorinostat, Carboplatin and Gemcitabine + Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer|Terminated||Phase 1/Phase 2|15|Actual|Dana-Farber Cancer Institute|The study was terminated early for toxicities and the emergence of better tolerated and more promising biologic agents added to platinum-based chemotherapy and/or use as maintenance.|6||Terminated due to unacceptable toxicity|f||||t||||||||No||2018-06-01 00:56:32.713925|2018-06-01 00:56:32.713925
NCT00909987|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2013-10-10|2009-05-28|2009-05-29|Estimate|||||||2013-10-10|2013-10-11|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum|Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy With Selective Radiotherapy Use in Patients With Intermediate-Risk Cancer of the Rectum Defined by Magnetic Resonance Imaging|Completed||Phase 2|46|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f||||||||||2018-06-01 00:56:33.113128|2018-06-01 00:56:33.113128
NCT00909961|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-03-17|2009-05-28|2009-05-29|Estimate|||||||2017-03-17|2017-03-21|Actual|November 2009||2009-11-30|March 2017|2017-03-31|December 16, 2011|Actual|2011-12-16|December 2011|Actual|2011-12-31||Interventional|||A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years|A One Year, Local, Open Label, Multicentre Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on BMD and Biochemical Markers of Bone in PMO Pts Between the Ages of 50 and 65 Years|Completed||Phase 3|118|Actual|Novartis||1|||f||||||||||||||2018-06-01 00:56:33.305323|2018-06-01 00:56:33.305323
NCT00909948|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2018-03-26|2009-05-28|2009-05-29|Estimate|||||||2018-03-26|2018-03-29|Actual|November 2008||2008-11-30|March 2018|2018-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|RLI||Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant|Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant|Terminated||Phase 1|7|Actual|Massachusetts General Hospital||2||Slow Accrual|f||||t||||||||||2018-06-01 00:56:33.449617|2018-06-01 00:56:33.449617
NCT00909935|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-06-08|2009-05-28|2009-05-29|Estimate|||||||2017-06-08|2017-06-12|Actual|April 2011||2011-04-30|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||The Pharmacokinetics of Dexmedetomidine in Children|The Pharmacokinetics of Dexmedetomidine in Children|Terminated|||40|Anticipated|Boston Children’s Hospital||||unable to enroll enough patients|f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 00:56:33.539283|2018-06-01 00:56:33.539283
NCT00909922|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2009-05-28|2009-05-28|2009-05-29|Estimate|||||||2009-05-28|2009-05-29|Estimate|January 2006||2006-01-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Observational|||Musculoskeletal Measurements in Transfemoral Amputees|Musculoskeletal Measurements in Transfemoral Amputees|Unknown status|Recruiting||80|Anticipated|Miami VA Healthcare System|||1||f||||t||||||||||2018-06-01 00:56:33.600198|2018-06-01 00:56:33.600198
NCT00909909|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-11-15|2009-05-28|2009-05-29|Estimate|||||||2017-11-15|2017-11-17|Actual|May 13, 2009|Actual|2009-05-13|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Radiation Therapy in Treating Women With Early Stage Breast Cancer|Safety and Feasibility of Accelerated, Hypofractionated Radiotherapy in Women With Breast Cancer: A Phase II Trial|Recruiting||Phase 2|150|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-06-01 00:56:33.68203|2018-06-01 00:56:33.68203
NCT00909896|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2018-03-30|2009-05-28|2009-05-29|Estimate|||||||2018-03-30|2018-04-02|Actual|April 8, 2009|Actual|2009-04-08|March 2018|2018-03-31|January 29, 2013|Actual|2013-01-29|January 29, 2013|Actual|2013-01-29||Observational|||Study of Post Operative Pain in Endometrial Cancer Robotic Versus Laparotomy|Prospective, Double Arm, Comparative Study for the Evaluation of Postoperative Pain, QOL, and Determination of Inflammatory Markers In Patients Undergoing Robotics Versus Open Laparotomy Approach for Staging of Endometrial Cancer|Completed|||142|Actual|Ohio State University Comprehensive Cancer Center|||2||f||||f||||||||||2018-06-01 00:56:33.756767|2018-06-01 00:56:33.756767
NCT00909883|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-03-24|2009-05-28|2009-05-29|Estimate|||||||2011-03-24|2011-03-25|Estimate|September 2009||2009-09-30|March 2011|2011-03-31|September 2012|Anticipated|2012-09-30|September 2011|Anticipated|2011-09-30||Interventional|RBHP 2008||Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)|Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)|Unknown status|Recruiting|Phase 3|45|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 00:56:33.844552|2018-06-01 00:56:33.844552
NCT00909870|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2012-12-31|2012-09-18|2013-08-09|2009-05-28|2009-05-29|Estimate|2012-12-31|2013-02-04|Estimate|2012-09-18|2012-09-25|Estimate|2013-08-09|2013-08-16|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|DEVO||Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers|A Prospective, Multi-Center, Randomized, Controlled Clinical Investigation of Dermagraft(R) in Subjects With Venous Leg Ulcers DEVO-Trial|Completed||Phase 3|537|Actual|Shire Regenerative Medicine, Inc.||2|||f||||f||||||||||2018-06-01 00:56:33.966424|2018-06-01 00:56:33.966424
NCT00909857|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2011-11-15||2015-08-06|2009-05-28|2009-05-29|Estimate|2012-01-21|2012-02-27|Estimate||||2015-08-06|2015-08-24|Estimate|April 2009||2009-04-30|August 2015|2015-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effect on Primary Dysmenorrhea|A Multi-center, Double-blind, Double-dummy, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of SH T00658ID Compared to SH D593B in the Treatment of Primary Dysmenorrhea|Completed||Phase 3|507|Actual|Bayer||2|||f||||f||||||||||2018-06-01 00:56:34.643869|2018-06-01 00:56:34.643869
NCT00909844|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|2016-12-28||2017-03-17|2009-05-28|2009-05-29|Estimate|2017-03-17|2017-05-01|Actual||||2017-03-17|2017-05-01|Actual|April 2008||2008-04-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Interventional|DECAPUB|Baseline characteristics are presented for Intention-To-Treat Population (ITT) population, consisting of all enrolled patients who received at least one injection of study treatment in this follow up study. These data were not re-collected at the start of the current study and are derived from data collected at Baseline of study 2-54-52014-143.|Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study|Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With Precocious Puberty|Completed||Phase 3|35|Actual|Ipsen|Since almost no hormonal data was collected after Baseline and only limited data was collected after Baseline for all other efficacy endpoints, only limited post-Baseline data is reported for the trial overall. All data analysed has been presented.|1|||f||||f||||||||||2018-06-01 00:56:35.875975|2018-06-01 00:56:35.875975
NCT00909831|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2016-02-09|2009-05-28|2009-05-29|Estimate|||||||2016-02-09|2016-02-10|Estimate|October 2008||2008-10-31|February 2016|2016-02-29||||May 2012|Actual|2012-05-31||Interventional|||Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment|A Phase I Trial of Hydroxychloroquine in Combination With Temsirolimus in Patients With Refractory Solid Tumors|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 00:56:37.157232|2018-06-01 00:56:37.157232
NCT00909818|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2017-07-31|2009-05-28|2009-05-29|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2009||2009-05-31|July 2017|2017-07-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients|Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients: a Randomized Phase II Trial, CIRRO (The Lundbeck Foundation Center for International Research in Radiation Oncology)|Active, not recruiting||N/A|976|Anticipated|Danish Breast Cancer Cooperative Group||2|||f||||t||||||||||2018-06-01 00:56:37.226017|2018-06-01 00:56:37.226017
NCT00909805|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2018-02-01|2009-05-28|2009-05-29|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2009|Actual|2009-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Interventional|||Interest of 2-octyl-cyanoacrylate (Dermabond®) in Closing Surgical Incisions in Children Before Acquisition of Continence|Interest of 2-octyl-cyanoacrylate (Dermabond®) in Closing Surgical Incisions in Children Before Acquisition of Continence. Randomised, Prospective, Non-inferiority Study.|Active, not recruiting||N/A|89|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 00:56:37.304811|2018-06-01 00:56:37.304811
NCT00909792|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|2010-09-16||2012-06-26|2009-05-27|2009-05-28|Estimate|2010-10-06|2010-10-29|Estimate||||2012-06-26|2012-06-29|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Clinical Evaluation of Two New Silicone Hydrogel Multifocal Products|Clinical Evaluation of Two New Silicone Hydrogel Multifocal Products|Completed||N/A|259|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 00:56:37.384062|2018-06-01 00:56:37.384062
NCT00909779|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2013-06-21||2013-09-12|2009-05-27|2009-05-28|Estimate|2013-09-12|2013-11-11|Estimate||||2013-09-12|2013-11-11|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects|A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|841|Actual|Sunovion|Although LABAs other than study medication were discontinued, other medications were not controlled for. A large number of subjects discontinued after a primary event and their eventual outcomes are unknown.|2|||f||||t||||||||||2018-06-01 00:56:37.584463|2018-06-01 00:56:37.584463
NCT00909766|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22||2015-09-23|2015-10-12|2009-05-27|2009-05-28|Estimate||||2015-10-12|2015-11-04|Estimate|2015-10-12|2015-11-04|Estimate|August 2009||2009-08-31|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects|Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose and Parallel Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-830216 (Prodrug of BMS-819881) in Obese Subjects|Completed||Phase 1/Phase 2|113|Actual|Bristol-Myers Squibb||8|||f||||f||||||||||2018-06-01 00:56:39.477129|2018-06-01 00:56:39.477129
NCT00909753|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2009-06-12||2009-08-14|2009-05-27|2009-05-28|Estimate|2009-06-12|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Ursodiol 500 mg Tablets Under Fed Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500 mg Tablets Under Fed Conditions|Completed||Phase 1|92|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:56:39.593697|2018-06-01 00:56:39.593697
NCT00909740|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2012-05-08|2009-05-26|2009-05-28|Estimate|||||||2012-05-08|2012-05-09|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEGF0444A, Administered Intravenously to Patients With Advanced Solid Tumors|Completed||Phase 1|30|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 00:56:39.96368|2018-06-01 00:56:39.96368
NCT00909727|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2012-02-27|2012-01-03|2012-07-18|2009-05-26|2009-05-28|Estimate|2012-07-18|2012-08-21|Estimate|2012-01-03|2012-01-04|Estimate|2012-07-18|2012-08-21|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|ENVISION||Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation|A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years With Cystic Fibrosis and the G551D Mutation|Completed||Phase 3|52|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-06-01 00:56:40.06016|2018-06-01 00:56:40.06016
NCT00909714|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2017-06-22|2009-05-27|2009-05-28|Estimate|||||||2017-06-22|2017-06-23|Actual|July 2009||2009-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NETS||Neuroregeneration Enhanced by Transcranial Direct Current Stimulation (TDCS) in Stroke|Neuroregeneration Enhanced by TDCS in Stroke|Recruiting||N/A|140|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||Undecided||2018-06-01 00:56:40.764832|2018-06-01 00:56:40.764832
NCT00909701|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2009-07-17|2009-05-27|2009-05-28|Estimate|||||||2009-07-17|2009-07-20|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Metabolic Response Following Intake of 2 Metabolic Preconditioning Drinks|Investigating the Metabolic Response Following Intake of 2 Metabolic Preconditioning Drinks: a Randomized Double-blind Crossover Healthy Volunteer Study|Completed||N/A|15|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-06-01 00:56:40.86666|2018-06-01 00:56:40.86666
NCT00909688|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2009-10-07|2009-05-27|2009-05-28|Estimate|||||||2009-10-07|2009-10-08|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses|Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects|Terminated||Phase 1|40|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 00:56:40.943815|2018-06-01 00:56:40.943815
NCT00909662|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2015-10-01|2009-05-27|2009-05-28|Estimate|||||||2015-10-01|2015-10-02|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers|Physiology of Chemotherapy Induced Fatigue and Cognitive Dysfunction in Early Stage Breast Cancer|Terminated|||18|Actual|Case Comprehensive Cancer Center|||2|Funding unavailable|f||||t||||||||||2018-06-01 00:56:41.024844|2018-06-01 00:56:41.024844
NCT00909649|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2008-12-05||2009-05-27|2009-05-27|2009-05-28|Estimate|2009-05-27|2009-05-28|Estimate||||2009-05-27|2009-05-28|Estimate|January 2005||2005-01-31|April 2009|2009-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|MRM||Influence of Fibrin Glue on Seroma Formation After Modified Radical Mastectomy|Influence of Fibrin Glue on Seroma Formation After Modified Radical|Completed||N/A|50|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 00:56:41.119485|2018-06-01 00:56:41.119485
NCT00909636|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2010-10-11|2009-05-27|2009-05-28|Estimate|||||||2010-10-11|2010-10-13|Estimate|May 2009||2009-05-31|September 2010|2010-09-30||||July 2009|Actual|2009-07-31||Interventional|||A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet|A Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 in Healthy Adults|Completed||Phase 1|24|Actual|Abbott||3|||f||||f||||||||||2018-06-01 00:56:41.33227|2018-06-01 00:56:41.33227
NCT00909610|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2009-06-12||2009-08-14|2009-05-27|2009-05-28|Estimate|2009-06-12|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|December 2006||2006-12-31|August 2009|2009-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Ursodiol Tablets 500 mg Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500 mg Tablets Under Fasting Conditions|Completed||Phase 1|80|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:56:41.417859|2018-06-01 00:56:41.417859
NCT00909597|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27||2016-07-08|2016-11-01|2009-05-27|2009-05-28|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea|Completed||Phase 3|756|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 00:56:41.792425|2018-06-01 00:56:41.792425
NCT00909584|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2013-11-20|2009-05-27|2009-05-28|Estimate|||||||2013-11-20|2013-11-25|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia|Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia|Terminated||Phase 2|9|Actual|Telik||2||Study TLK199.2103 was terminated for business reasons.|f||||f||||||||||2018-06-01 00:56:42.107204|2018-06-01 00:56:42.107204
NCT00909571|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2010-04-15|2009-05-27|2009-05-28|Estimate|||||||2010-04-15|2010-04-16|Estimate|April 2009||2009-04-30|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus|A Phase 3 Pilot Study to Describe the Pharmacokinetics of Tacrolimus in Patients Undergoing Primary Liver Donor Liver Transplantation Treated With Prograf Injection and Modified Release Tacrolimus Based Immunosuppressive Regimen|Completed||Phase 3|10|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 00:56:42.182585|2018-06-01 00:56:42.182585
NCT00909558|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2010-02-23|2009-05-27|2009-05-28|Estimate|||||||2010-02-23|2010-02-24|Estimate|May 2009||2009-05-31|February 2010|2010-02-28||||June 2010|Anticipated|2010-06-30||Interventional|||Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer|A Phase I Open Label, Single Site, Safety and Efficacy Study of the Effects of Autologous Natural Killer and Natural Killer T Cell Immunotherapy on Malignant Disease|Suspended||Phase 1|24|Anticipated|Envita Medical Center, Inc.|||||f||||t||||||||||2018-06-01 00:56:42.252565|2018-06-01 00:56:42.252565
NCT00909545|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2012-10-02||2013-04-16|2009-05-26|2009-05-28|Estimate|2013-04-16|2013-04-17|Estimate||||2013-04-16|2013-04-17|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|STEADY-PD||Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease|A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease|Completed||Phase 2|99|Actual|Northwestern University||4|||f||||t||||||||||2018-06-01 00:56:42.394799|2018-06-01 00:56:42.394799
NCT00909532|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2012-02-27|2011-09-21|2013-01-14|2009-05-26|2009-05-28|Estimate|2012-07-18|2012-08-21|Estimate|2011-09-21|2011-09-26|Estimate|2013-01-14|2013-01-18|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|July 2010|Actual|2010-07-31||Interventional|STRIVE||Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation|Completed||Phase 3|167|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-06-01 00:56:43.997518|2018-06-01 00:56:43.997518
NCT00909519|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2011-06-16|2009-05-27|2009-05-28|Estimate|||||||2011-06-16|2011-06-17|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide|A Phase 1, Single-Center, Randomized, Parallel-group, Placebo- and Naproxen- Controlled, Double-blind Study to Evaluate the Effect of Naproxcinod 750 mg Bid Administered for 8 Days on the Renal Hemodynamics, Natriuretic and Renin Responses to a Single Bolus IV Dose of Furosemide 40 mg in Male Healthy Normotensive Volunteers|Completed||Phase 1|31|Actual|NicOx||3|||f||||f||||||||||2018-06-01 00:56:44.774119|2018-06-01 00:56:44.774119
NCT00909506|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2015-07-27|2009-05-27|2009-05-28|Estimate|||||||2015-07-27|2015-07-29|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients||Completed||Phase 2|105|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-06-01 00:56:44.834345|2018-06-01 00:56:44.834345
NCT00909493|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2011-10-31|2009-05-27|2009-05-28|Estimate|||||||2011-10-31|2011-11-02|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|NSCPCCN||Chronic Pain Care Network|Nova Scotia Chronic Pain Collaborative Care Network: A Pilot Study|Completed||N/A|20|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-06-01 00:56:44.905979|2018-06-01 00:56:44.905979
NCT00909480|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|2011-06-10||2017-01-30|2009-05-27|2009-05-28|Estimate|2011-08-19|2011-09-27|Estimate||||2017-01-30|2017-03-10|Actual|May 2009||2009-05-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|EFFICACY||Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes|A 26 Week Randomised, Multinational, Open Labelled, 2 Armed, Parallel Group, Treat-to-target Once Daily Treatment Trial With Insulin Detemir Versus Insulin Glargine, Both in Combination With Metformin in Subjects With Type 2 Diabetes|Completed||Phase 4|457|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:56:44.995884|2018-06-01 00:56:44.995884
NCT00909467|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2012-03-08|2009-05-27|2009-05-28|Estimate|||||||2012-03-08|2012-03-09|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases|Early Recognition of Pulmonary Arterial Hypertension in Myelodysplastic and Myeloproliferative Diseases|Completed|||86|Actual|Medical University of Graz|||1||f||||f||||||Samples With DNA|"~     Samples with DNA will be retained for later examinations at the Department for Genetics, if~     the patient agrees with it (specific question at the patient information).~   "|||2018-06-01 00:56:45.73569|2018-06-01 00:56:45.73569
NCT00909454|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2011-10-14|2009-05-26|2009-05-28|Estimate|||||||2011-10-14|2011-10-17|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|VIP||Vitamin D Supplement Study for Adolescents|V.I.P. Feasibility Study (Vitamin D Intake Project)|Completed||N/A|45|Actual|Augusta University||2|||f||||f||||||||||2018-06-01 00:56:45.793875|2018-06-01 00:56:45.793875
NCT00909441|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2015-02-09|2009-05-27|2009-05-28|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|SN-FNAC||Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer|Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer: A Multi-institutional Prospective Study Furthering the Treatment of Breast Cancer|Completed||N/A|153|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-06-01 00:56:45.860172|2018-06-01 00:56:45.860172
NCT00909428|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2009-08-21||2017-04-18|2009-05-27|2009-05-28|Estimate|2017-04-18|2017-05-24|Actual||||2017-04-18|2017-05-24|Actual|January 2007|Actual|2007-01-31|April 2017|2017-04-30|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional||The baseline analysis population comprises all women who signed informed consent and have a valid diagnosis of OAB|Validation of a Real-time Urodynamic Measure of Urinary Urgency|Validation of a Real-time Urodynamic Measure of Urinary Urgency as a Measure of the Success of Drug Treatment|Completed||Phase 4|51|Actual|Loyola University|The trial experienced significant attrition. Otherwise, there are no limitations or caveats to report.|1|||f||||f|t|f|||f|||No|Due to restrictions on the availability of individual participant data (IPD), IPD are not publicly available|2018-06-01 00:56:45.925733|2018-06-01 00:56:45.925733
NCT00909415|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2012-01-26|2009-05-26|2009-05-28|Estimate|||||||2012-01-26|2012-01-31|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Urodynamic Evaluation in Patients With Anorectal Malformation According to Spinal Cord Abnormalities|Urodynamic Evaluation in Patients With Anorectal Malformation According to Spinal Cord Abnormalities|Completed|||53|Actual|Yonsei University|||||f||||||||||||||2018-06-01 00:56:46.136704|2018-06-01 00:56:46.136704
NCT00909402|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2013-06-20|2009-05-27|2009-05-28|Estimate|||||||2013-06-20|2013-06-21|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas|Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination With Cisplatin and Capecitabine as First-Line Therapy in Patients With Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas|Completed||Phase 1|39|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:56:46.179663|2018-06-01 00:56:46.179663
NCT00909389|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2009-06-24||2015-05-27|2009-05-27|2009-05-28|Estimate|2011-08-31|2011-10-04|Estimate||||2015-05-27|2015-06-22|Estimate|November 2006||2006-11-30|May 2015|2015-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)|Post - Marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients|Completed|||4748|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:56:46.331912|2018-06-01 00:56:46.331912
NCT00909376|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-05-27|2009-05-27|2009-05-28|Estimate|||||||2009-05-27|2009-05-28|Estimate|July 2009||2009-07-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Is Early Second Trimester Vaginal Ultrasound Scan Associated With Adverse Perinatal Outcomes?|Is Early Second Trimester Vaginal Ultrasound Scan Associated With Adverse Perinatal Outcomes?|Unknown status|Not yet recruiting||450|Anticipated|Shaare Zedek Medical Center|||2||f||||f||||||||||2018-06-01 00:56:46.438013|2018-06-01 00:56:46.438013
NCT00909363|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2017-01-31|2009-05-27|2009-05-28|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 2009||2009-06-30|January 2017|2017-01-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|WAS||Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients|Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.|Active, not recruiting||Phase 2|19|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||Undecided||2018-06-01 00:56:46.496421|2018-06-01 00:56:46.496421
NCT00909350|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2015-02-11|2009-05-27|2009-05-28|Estimate|||||||2015-02-11|2015-02-12|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue|Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue: A Potential Target for Understanding and Preventing the Progression of Barrett's Esophagus|Completed|||10|Actual|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     biopsy tissue from proximal and distal esophagus, stomach and duodenum~   "|||2018-06-01 00:56:46.565534|2018-06-01 00:56:46.565534
NCT00909337|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2011-09-22|2009-05-27|2009-05-28|Estimate|||||||2011-09-22|2011-09-23|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Early Therapy of Pulmonary Arterial Hypertension|Early Therapy of Pulmonary Arterial Hypertension|Completed||N/A|10|Actual|Medical University of Graz||1|||f||||f||||||||||2018-06-01 00:56:46.623363|2018-06-01 00:56:46.623363
NCT00909324|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2011-01-12||2011-02-24|2009-05-26|2009-05-28|Estimate|2011-02-24|2011-03-24|Estimate||||2011-02-24|2011-03-24|Estimate|August 2009||2009-08-31|February 2011|2011-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery|Efficacy, Tolerability and Comfort of 0.3% Hypromellose Eyedrops in the Pre- and Post-Operative Treatment of Patients Undergoing LASIK Surgery|Completed||Phase 4|162|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:56:46.706177|2018-06-01 00:56:46.706177
NCT00909311|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27|||2010-10-11|2009-05-27|2009-05-28|Estimate|||||||2010-10-11|2010-10-13|Estimate|May 2009||2009-05-31|September 2009|2009-09-30||||July 2009|Actual|2009-07-31||Interventional|||Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir|Randomized, Open-label, 2-period Cross-over Study in Healthy Adults to Evaluate the Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir|Completed||Phase 1|8|Actual|Abbott||2|||f||||f||||||||||2018-06-01 00:56:46.932547|2018-06-01 00:56:46.932547
NCT00909298|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-27||2010-07-15|2011-06-08|2009-05-27|2009-05-28|Estimate||||2010-07-15|2010-07-20|Estimate|2011-06-08|2011-06-27|Estimate|June 2009||2009-06-30|June 2011|2011-06-30||||June 2010|Actual|2010-06-30||Interventional|||Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)|A Randomized Clinical Trial of Intrinsic Pathway Antagonists in Patients Undergoing Implantation of Left Ventricular Assist Devices|Terminated||Phase 2|2|Actual|vTv Therapeutics||2|||f||||t||||||||||2018-06-01 00:56:46.99605|2018-06-01 00:56:46.99605
NCT00909285|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-24|||2010-07-11|2009-05-26|2009-05-27|Estimate|||||||2010-07-11|2010-07-13|Estimate|July 2009||2009-07-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Transcranial Magnetic Stimulation (TMS) and Cognitive Training for Alzheimer Patients|Testing the Effects of TMS Stimulation and Cognitive Training for Alzheimer Patients: A Pilot Study|Completed||N/A|20|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 00:56:47.057112|2018-06-01 00:56:47.057112
NCT00909272|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2015-04-07|2009-05-22|2009-05-27|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Ultrasound Guided Diagnostic Lumbar Medial Branch Blocks|Ultrasound Guided Diagnostic Lumbar Medial Branch Blocks|Withdrawn|||0|Actual|McMaster University|||2|One of the investigators has left the institution|f||||f||||||||||2018-06-01 00:56:47.120592|2018-06-01 00:56:47.120592
NCT00909259|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2014-01-02|2009-05-22|2009-05-27|Estimate|||||||2014-01-02|2014-01-06|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|September 2010|Actual|2010-09-30||Interventional|||Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing|Feasibility Study to Determine the Effects of Phrenic Nerve Stimulation in Patients With Periodic Breathing|Completed||Phase 1|50|Anticipated|Respicardia, Inc.||1|||f||||f||||||||||2018-06-01 00:56:47.194879|2018-06-01 00:56:47.194879
NCT00909233|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2014-12-12|2009-05-26|2009-05-27|Estimate|||||||2014-12-12|2014-12-15|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|March 2010|Actual|2010-03-31||Observational|||LEVITRA® 20mg Special Drug Use Investigation (Long-term)|LEVITRA® 20mg Special Drug Use Investigation (Long-term)|Completed|||1221|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:56:47.260617|2018-06-01 00:56:47.260617
NCT00909220|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2016-09-20||2018-03-15|2009-05-26|2009-05-27|Estimate|2017-12-12|2018-01-16|Actual||||2018-03-15|2018-04-17|Actual|May 2009||2009-05-31|March 2018|2018-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Using Affective Differences to Predict Response to Behavioral Treatment for Major Depressive Disorder|Translating Affective Science to Predict Outcomes of Behavioral Treatment for MDD|Completed|||77|Actual|Northwestern University|We enrolled adults who were medication-free, which may limit the generalizability of these results to those individuals who rely on pharmacotherapy and somatic therapies.||2||f||||t||||||||Yes|Request PI (JGollan) for de-identified data at j-gollan@northwestern.edu|2018-06-01 00:56:47.343241|2018-06-01 00:56:47.343241
NCT00909207|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2014-07-10|2009-05-26|2009-05-27|Estimate|||||||2014-07-10|2014-07-14|Estimate|July 2009||2009-07-31|July 2014|2014-07-31||||June 2013|Actual|2013-06-30||Observational|||Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing|Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing|Completed|||20|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 00:56:47.564196|2018-06-01 00:56:47.564196
NCT00909194|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2018-01-19|2009-05-26|2009-05-27|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2007||2007-07-31|January 2018|2018-01-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Juvenile Primary Fibromyalgia Syndrome (JPFS) in an Adolescent Psychiatric Population|Juvenile Primary Fibromyalgia in a Female Adolescent Psychiatric Population|Completed||N/A|132|Actual|University of Kentucky||2|||f||||f||||||||||2018-06-01 00:56:47.64439|2018-06-01 00:56:47.64439
NCT00909181|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|2010-11-29||2014-06-23|2009-05-26|2009-05-27|Estimate|2010-12-16|2011-01-19|Estimate||||2014-06-23|2014-07-02|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence|A Double-Blind, Randomized, Parallel, Placebo-Controlled, Multicenter Study Evaluating the Effect of Treatment With Topically Administered Oxybutynin Gel in Patients With Urinary Frequency, and Urge and Mixed Urinary Incontinence With a Predominance of Urge Incontinence Episodes With an Open-Label Extension|Completed||Phase 3|626|Actual|Antares Pharma Inc.||3|||f||||t||||||||||2018-06-01 00:56:47.733578|2018-06-01 00:56:47.733578
NCT00909168|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2014-05-05|2009-05-26|2009-05-27|Estimate|||||||2014-05-05|2014-05-06|Estimate|March 2008||2008-03-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|May 2009|Actual|2009-05-31||Interventional|MYFLAI07||Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)|Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)|Completed||Phase 2/Phase 3|130|Actual|University Hospital, Udine, Italy||1|||f||||t||||||||||2018-06-01 00:56:48.083498|2018-06-01 00:56:48.083498
NCT00909155|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2014-12-03||2014-12-12|2009-05-22|2009-05-27|Estimate|2014-12-12|2014-12-15|Estimate||||2014-12-12|2014-12-15|Estimate|July 2002||2002-07-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|WyethKolden||Brain Imaging Techniques That Predict Antidepressant Responsiveness|Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine|Completed||N/A|50|Actual|University of Wisconsin, Madison|Relatively small number of subjects. Not powered statistically to determine if either treatment arm (fluoxetine or venlafaxine) is superior.|3|||f||||f||||||||||2018-06-01 00:56:48.147775|2018-06-01 00:56:48.147775
NCT00909142|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2012-04-05|2009-05-26|2009-05-27|Estimate|||||||2012-04-05|2012-04-06|Estimate|April 2007||2007-04-30|April 2012|2012-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|BICAM||Bonefos and the Consumption of Analgesics|Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis|Completed|||149|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:56:48.384975|2018-06-01 00:56:48.384975
NCT00909129|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-26|2009-05-26|2009-05-27|Estimate|||||||2009-05-26|2009-05-27|Estimate||||May 2009|2009-05-31||||||||Interventional|DICO||Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment|Hepatitis C Virus Dynamic and Immune Activation in HIV-1 Coinfected Patients Treated With Pegylated Interferon Alfa-2a and Ribavirin|Completed||N/A|25|Actual|Karolinska Institutet||1|||f||||t||||||||||2018-06-01 00:56:48.441698|2018-06-01 00:56:48.441698
NCT00909116|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2017-08-10|2009-05-26|2009-05-27|Estimate|||||||2017-08-10|2017-08-11|Actual|January 31, 2009|Actual|2009-01-31|August 2017|2017-08-31|April 30, 2012|Actual|2012-04-30|April 30, 2012|Actual|2012-04-30||Observational|||International Multicenter Prospective Transtar Registry|International Transtar Registry - Stapled Transanal Rectal Resection Performed With Contour Transtar Stapler in the Treatment of Obstructed Defecation Syndrome (ODS)|Completed|||100|Actual|Ethicon Endo-Surgery (Europe) GmbH|||1||f||||t|f|t|f|f|t|||Yes|via publication|2018-06-01 00:56:48.503811|2018-06-01 00:56:48.503811
NCT00909103|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2010-01-11|2009-05-26|2009-05-27|Estimate|||||||2010-01-11|2010-01-12|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|EUS-EG||Endoscopic Ultrasound Elastography in Pancreatic Masses|Computer-aided Diagnosis of Endoscopic Ultrasound Elastography Used in the Differentiation of Focal Pancreatic Masses|Completed|||285|Actual|University of Medicine and Pharmacy Craiova|||2||f||||t||||||Samples Without DNA|"~     Pathology samples obtained from duodeno-pancreatectomies or caudal pancreatectomies done with~     curative intent, as well as microhistological fragments obtained through EUS-FNA biopsy~     processed by paraffin embedding~   "|||2018-06-01 00:56:48.568304|2018-06-01 00:56:48.568304
NCT00909090|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2011-08-10|2009-05-26|2009-05-27|Estimate|||||||2011-08-10|2011-08-11|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|MP-GD||Macular Pigment and Glare Disability|Effects of Lutein and Zeaxanthin Upon MPOD and Its Effects Upon Glare Disability, Photostress Recovery, and Contrast Enhancement in Healthy Subjects: A Randomized, Double-blind Placebo-controlled Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Anticipated|University of Georgia||2|||f||||t||||||||||2018-06-01 00:56:48.655225|2018-06-01 00:56:48.655225
NCT00909077|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2015-02-11|2009-05-26|2009-05-27|Estimate|||||||2015-02-11|2015-02-12|Estimate|August 2004||2004-08-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)|A Randomised Phase III Study of the Efficacy of High Dose Dexamethasone Versus High Dose Dexamethasone in Combination With Rituximab (MabThera®)in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-06-01 00:56:48.710229|2018-06-01 00:56:48.710229
NCT00909064|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|2017-04-05||2017-04-05|2009-05-26|2009-05-27|Estimate|2017-04-05|2017-05-15|Actual||||2017-04-05|2017-05-15|Actual|June 2009||2009-06-30|May 2009|2009-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty|The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty|Completed||Phase 4|114|Actual|University of California, Davis||1|||f||||||||||||||2018-06-01 00:56:48.775687|2018-06-01 00:56:48.775687
NCT00909051|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2012-01-18|2009-05-26|2009-05-27|Estimate|||||||2012-01-18|2012-01-19|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups|Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups|Completed|||15729|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:56:48.978503|2018-06-01 00:56:48.978503
NCT00909038|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2011-03-23||2014-05-14|2009-05-26|2009-05-27|Estimate|2011-03-23|2011-04-14|Estimate||||2014-05-14|2014-06-05|Estimate|May 2009||2009-05-31|May 2014|2014-05-31||||November 2009|Actual|2009-11-30||Observational|||Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study|A Descriptive Pharmaco-epidemiological Study of a Hypertensive Patient Population Treated With a Fixed-dose Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg and of Conditions for the Management of Arterial Hypertension|Completed|||2411|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 00:56:49.157948|2018-06-01 00:56:49.157948
NCT00909025|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2017-06-30|2009-05-26|2009-05-27|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2009||2009-05-31|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer|Clinical First-in-human Single-dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-center, Phase I, Open-label, i.v. Infusion Study|Completed||Phase 1|15|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 00:56:51.225323|2018-06-01 00:56:51.225323
NCT00909012|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2014-06-19|2009-05-26|2009-05-27|Estimate|||||||2014-06-19|2014-06-20|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|July 2011|Actual|2011-07-31||Interventional|||Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria|Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria|Completed||N/A|114|Actual|Ludwig-Maximilians - University of Munich||5|||f||||f||||||||||2018-06-01 00:56:51.297999|2018-06-01 00:56:51.297999
NCT00908999|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2011-09-27|2009-05-26|2009-05-27|Estimate|||||||2011-09-27|2011-09-29|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Functional Magnetic Resonance Imaging (fMRI) of Anosognosia in Amnestic Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)|FMRI of Anosognosia in Amnestic MCI and AD: Focus on Cortical Midline Structures|Completed|||60|Anticipated|University of Wisconsin, Madison|||3||f||||||||||||||2018-06-01 00:56:51.373982|2018-06-01 00:56:51.373982
NCT00908986|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2015-05-13|2009-05-26|2009-05-27|Estimate|||||||2015-05-13|2015-05-14|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis|Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis|Withdrawn||N/A|0|Actual|Northwell Health||1||Terminated by sponsor|f||||t||||||||||2018-06-01 00:56:51.42329|2018-06-01 00:56:51.42329
NCT00908973|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2012-03-19|2009-05-26|2009-05-27|Estimate|||||||2012-03-19|2012-03-20|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Observational|RnonR||Gut Hormone Response, Appetite and Intestinal Transit Time in Good and Poor Weight Responders After Gastric Bypass|Gut Hormone Response, Appetite and Intestinal Transit Time in Good and Poor Weight Responders 1-2 Years After Gastric Bypass|Completed|||46|Actual|Hvidovre University Hospital|||3||f||||f||||||Samples Without DNA|"~     Plasma and serum specimens are retained~   "|||2018-06-01 00:56:51.482802|2018-06-01 00:56:51.482802
NCT00908960|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2013-07-22||2017-11-22|2009-05-26|2009-05-27|Estimate|2013-10-22|2013-12-12|Estimate||||2017-11-22|2017-12-19|Actual|May 2009||2009-05-31|November 2017|2017-11-30|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|MicroTEC|The analysis dataset is comprised of all evaluable patients.|Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles|A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles|Completed||Phase 2|70|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-06-01 00:56:51.549171|2018-06-01 00:56:51.549171
NCT00908947|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2017-12-18|2009-05-26|2009-05-27|Estimate|||||||2017-12-18|2017-12-20|Actual|February 2011||2011-02-28|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|December 12, 2017|Actual|2017-12-12||Interventional|CONTINUUM||CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs|CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs|Active, not recruiting||N/A|173|Actual|C. R. Bard||1|||f||||t|f|t|f|||||||2018-06-01 00:56:52.561725|2018-06-01 00:56:52.561725
NCT00908934|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2009-07-22|2009-05-26|2009-05-27|Estimate|||||||2009-07-22|2009-07-23|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|||||Interventional|||AZD9056 Relative Bioavailability Study|An Open-label, Randomized, 2 Cohort, 2 Period Crossover Study to Assess the Relative Bioavailability of the Phase III to the Phase IIb Formulation of AZD9056 in Healthy Male and Female Subjects|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:56:52.672641|2018-06-01 00:56:52.672641
NCT00717704|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2012-05-29|2008-07-16|2008-07-17|Estimate|||||||2012-05-29|2012-05-31|Estimate|July 2008||2008-07-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Solid Tumors Using Ixabepilone and Dasatinib|A Phase I Study of Ixabepilone Combined With Dasatinib in Patients With Solid Tumors|Completed||Phase 1|19|Actual|Washington Hospital Center||1|||f||||t||||||||||2018-06-01 01:56:06.492041|2018-06-01 01:56:06.492041
NCT00908921|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2012-08-07|2009-05-26|2009-05-27|Estimate|||||||2012-08-07|2012-08-08|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|GREAT||Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)|Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono- Therapy in Chinese Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 4|391|Actual|Sanofi||1|||f||||||||||||||2018-06-01 00:56:52.734061|2018-06-01 00:56:52.734061
NCT00908908|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2011-12-22||2012-03-07|2009-05-24|2009-05-27|Estimate|2011-12-22|2012-01-27|Estimate||||2012-03-07|2012-03-09|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors|An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors|Completed||Phase 1|6|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 00:56:52.808109|2018-06-01 00:56:52.808109
NCT00908895|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2009-11-12||2011-02-25|2009-05-26|2009-05-27|Estimate|2010-05-12|2010-06-07|Estimate||||2011-02-25|2011-03-01|Estimate|April 2003||2003-04-30|November 2009|2009-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Non-bridging Fixator Versus Percutaneous Pinning for Distal Radius Fractures|Non-bridging Radio-radial Fixator Compared to Percutaneous Pinning for Unstable Distal Radius Fracture. A Prospective Randomized Trial.|Completed||Phase 3|120|Actual|Hopital de l'Enfant-Jesus|Very long time between the end of the study and the manuscript preparation due to temporarily lack of statistician and the need for some national associations that the study is not published before presentation.|2|||f||||f||||||||||2018-06-01 00:56:53.083006|2018-06-01 00:56:53.083006
NCT00908882|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|2015-04-20||2015-06-08|2009-05-26|2009-05-27|Estimate|2015-06-01|2015-06-09|Estimate||||2015-06-08|2015-06-16|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional||Arm 2 - 3 participants were found to be ineligible after signing consent.|Tobacco Cessation for Veterans With Post Traumatic Stress Disorder (PTSD)|Telehealth Care Management and Tobacco Cessation for Veterans With PTSD|Completed||N/A|178|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:56:53.344973|2018-06-01 00:56:53.344973
NCT00908869|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2012-01-26|2009-05-26|2009-05-27|Estimate|||||||2012-01-26|2012-01-30|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|METRO1||"Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b ( Metronomic Chemotherapy ) for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm"|Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b for Antiangiogenic/Antivascular Effect in Adult Advanced Neoplasm|Completed||Phase 1|30|Actual|Institut Paoli-Calmettes|||||f||||t||||||||||2018-06-01 00:56:53.748353|2018-06-01 00:56:53.748353
NCT00908856|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2016-02-02|2009-05-26|2009-05-27|Estimate|||||||2016-02-02|2016-02-04|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Autologous Cell Therapy After Stroke|Safety of IV Autologous Mononuclear Cells and Marrow Stromal Cells After Stroke|Withdrawn||Phase 1|0|Actual|University of California, Irvine||3||Not funded|f||||f||||||||||2018-06-01 00:56:53.806326|2018-06-01 00:56:53.806326
NCT00908843|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2012-06-07|2009-05-26|2009-05-27|Estimate|||||||2012-06-07|2012-06-08|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|NIC||Prevention of Contrast Induced Nephropathy (NIC) by Intravenous Versus Oral Rehydration|Comparative Efficacy of the Application of an Oral/iv Hydration Protocol in the Prevention of Contrast Induced Nephropathy|Completed||N/A|167|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-06-01 00:56:53.878338|2018-06-01 00:56:53.878338
NCT00908830|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2011-08-03|2009-05-26|2009-05-27|Estimate|||||||2011-08-03|2011-08-04|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|March 2012|Anticipated|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients|Pharmacokinetics of Mycophenolic Acid in Cystic Fibrosis Lung Transplant Recipients|Unknown status|Active, not recruiting|N/A|10|Anticipated|University of Michigan||2|||f||||t||||||||||2018-06-01 00:56:54.063136|2018-06-01 00:56:54.063136
NCT00908817|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2009-05-26|2009-05-26|2009-05-27|Estimate|||||||2009-05-26|2009-05-27|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat|Triamcinolone Paste to Reduce the Incidence of Postoperative Sore Throat|Completed||N/A|150|Actual|Soonchunhyang University Hospital||2|||f||||||||||||||2018-06-01 00:56:54.226535|2018-06-01 00:56:54.226535
NCT00908804|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2009-05-26|2009-05-26|2009-05-27|Estimate|||||||2009-05-26|2009-05-27|Estimate||||May 2009|2009-05-31||||||||Interventional|||Open Versus Laparoscopic Appendectomy|Open Versus Laparoscopic Appendectomy in Suspected Acute Appendicitis - a Prospective Randomised Clinical Trial With With 10-Year Follow-up|Completed||N/A|||North Karelia Central Hospital||2|||f||||||||||||||2018-06-01 00:56:54.35709|2018-06-01 00:56:54.35709
NCT00908791|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2012-06-08|2009-05-26|2009-05-27|Estimate|||||||2012-06-08|2012-06-11|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue|An in Vivo Proof of Principle Trial to Determine Whether the Nutritional Supplement Conjugated Linoleic Acid (CLA, Clarinol™) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue|Unknown status|Active, not recruiting|Early Phase 1|24|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 00:56:54.49353|2018-06-01 00:56:54.49353
NCT00908778|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2009-10-19|2009-05-26|2009-05-27|Estimate|||||||2009-10-19|2009-10-20|Estimate|October 2008||2008-10-31|October 2009|2009-10-31||||July 2010|Anticipated|2010-07-31||Interventional|||A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects|A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.|Unknown status|Recruiting|Phase 3|160|Anticipated|Vitreoretinal Technologies, Inc.||2|||f||||f||||||||||2018-06-01 00:56:54.572641|2018-06-01 00:56:54.572641
NCT00908765|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-01-02|2009-05-26|2009-05-27|Estimate|||||||2013-01-02|2013-01-03|Estimate|August 2008||2008-08-31|January 2013|2013-01-31|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|||Effects of Aerobe Interval Training and Moderate Continuous Training in Chronic Obstructive Pulmonary Disease Patients|Effects of Aerobe Interval Training and Moderate Continuous Training in COPD Patients|Completed||N/A|20|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-06-01 00:56:54.642754|2018-06-01 00:56:54.642754
NCT00908752|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22||2015-09-23|2018-03-01|2009-05-26|2009-05-27|Estimate||||2015-09-23|2015-10-12|Estimate|2018-03-01|2018-03-05|Actual|July 20, 2009|Actual|2009-07-20|March 2018|2018-03-31|January 26, 2018|Actual|2018-01-26|September 28, 2012|Actual|2012-09-28||Interventional|BRISK TA||Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC|A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)|Completed||Phase 3|734|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 00:56:54.736844|2018-06-01 00:56:54.736844
NCT00908739|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-23|||2015-09-29|2009-05-23|2009-05-27|Estimate|||||||2015-09-29|2015-09-30|Estimate|May 2008||2008-05-31|September 2015|2015-09-30||||September 2008|Actual|2008-09-30||Observational|||Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer|Assessment of Patterns of Expression of VEGF, Matrix Metalloproteinase 2, 9 Activity, E-Cadherin Regulation and CA-9 Activity as Predictors of Aggressive Renal Cell Carcinoma Behavior|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||PI left|f||||t||||||Samples With DNA|"~     Previously collected tumor tissue samples are examined by immunohistochemistry for levels of~     expression of five different factors related to aggressive tumor behavior (i.e., VEGF~     expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic~     anhydrase 9 activity.~   "|||2018-06-01 00:56:54.92286|2018-06-01 00:56:54.92286
NCT00908726|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2012-01-18|2009-05-26|2009-05-27|Estimate|||||||2012-01-18|2012-01-20|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Population Pharmacokinetics/Pharmacodynamics (PK/PD) of Microemulsion Propofol in Healthy Volunteers|Population Pharmacokinetic and Pharmacodynamic Modeling of Microemulsion Propofol in Healthy Volunteers: Comparison With Lipid Emulsion Propofol|Completed||Phase 1|63|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 00:56:54.982226|2018-06-01 00:56:54.982226
NCT00908713|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2013-03-19|2009-05-26|2009-05-27|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2004||2004-01-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Corticoids in Severe Community-Acquired Pneumonia (CAP)|Corticoids in Severe Community-acquired Pneumonia|Completed||Phase 4|120|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 00:56:55.045468|2018-06-01 00:56:55.045468
NCT00908700|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2015-09-21|2009-05-26|2009-05-27|Estimate|||||||2015-09-21|2015-09-23|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|November 2012|Actual|2012-11-30|November 2010|Actual|2010-11-30||Interventional|LAAOSII||Left Atrial Appendage Occlusion Study II|Phase III Pilot Study - Left Atrial Appendage Occlusion Study|Completed||Phase 3|51|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-06-01 00:56:55.126872|2018-06-01 00:56:55.126872
NCT00908687|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|2014-01-30||2014-01-30|2009-05-26|2009-05-27|Estimate|2014-01-30|2014-03-13|Estimate||||2014-01-30|2014-03-13|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2011|Actual|2011-07-31|January 2010|Actual|2010-01-31||Interventional||safety population: all subjects with signed Informed Consent who have received investigational product|A/H5N1/LT Dose Ranging Study|A Randomized Blinded, LT Dose-ranging Study to Assess the Immunogenicity and Safety of Different Doses of LT Adjuvant Patch Administered in Conjunction With Different Doses of Inactivated Influenza A/H5N1 Vaccine in Healthy Adults|Completed||Phase 2|500|Actual|Intercell USA, Inc.||6|||f||||t||||||||||2018-06-01 00:56:55.213247|2018-06-01 00:56:55.213247
NCT00908674|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-04-12|2009-05-26|2009-05-27|Estimate|||||||2010-04-12|2010-04-13|Estimate|June 2008||2008-06-30|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Androcur Effects on Quality of Life|Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients|Completed|||245|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:56:55.563638|2018-06-01 00:56:55.563638
NCT00908661|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2017-03-23|2009-05-26|2009-05-27|Estimate|||||||2017-03-23|2017-03-27|Actual|November 2007||2007-11-30|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effectiveness of a Lightweight Mesh in the Laparoscopic Prevention of Parastomal Hernia|Study of the Effectiveness of a Lightweight Mesh (Polypropylene and Poliglecaprone 25 and Oxidized Cellulose) in the Prevention of Parastomal Hernia in Patients Requiring a Permanent Ostomy. Laparoscopic Approach|Completed||N/A|36|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-06-01 00:56:55.617981|2018-06-01 00:56:55.617981
NCT00908648|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2009-01-22||2009-04-02|2009-04-02|2009-05-27|Estimate|2009-04-02|2009-05-27|Estimate||||2009-04-02|2009-05-27|Estimate||||April 2009|2009-04-30||||||||Interventional|||The Use of Narrow Band Imaging in Screening Colonoscopy|The Impact of Narrow Band Imaging in Screening Colonoscopy: a Randomized Controlled Trial.|Completed||N/A|206|Actual|Valduce Hospital||2|||f||||f||||||||||2018-06-01 00:56:55.685857|2018-06-01 00:56:55.685857
NCT00908635|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2009-05-26|2009-05-26|2009-05-27|Estimate|||||||2009-05-26|2009-05-27|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Observational|||The Role of Angiopoietin, Tie-2, and Vascular Endothelial Growth Factor (VEGF) in Sepsis-Induced Multiple Organ Dysfunction Syndrome (MODS)|The Role of Angiopoietin, Angiopoietin Receptor Tie-2, and Vascular Endothelial Growth Factor in Sepsis-Induced Multi-Organ Dysfunction Syndrome|Unknown status|Recruiting||120|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 00:56:55.934509|2018-06-01 00:56:55.934509
NCT00908622|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-25|||2015-09-10|2009-05-26|2009-05-27|Estimate|||||||2015-09-10|2015-09-11|Estimate|March 2007||2007-03-31|September 2015|2015-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PERCUTANEO||Study of the Efficacy of Percutaneous Implantation of Autologous Myoblasts in Patients With Old Infarction|Phase II, Blind, Controlled, Randomised Study of the Efficacy of Percutaneous Implantation of Autologous Myoblasts in Patients With Old Infarction|Terminated||Phase 2|38|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2||Lack of enrollment|f||||f||||||||||2018-06-01 00:56:56.016783|2018-06-01 00:56:56.016783
NCT00908609|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2017-04-13|2009-05-26|2009-05-27|Estimate|||||||2017-04-13|2017-04-17|Actual|April 2007||2007-04-30|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Optical Tomography With Ultrasound Guidance|3-D Simultaneous Ultrasound and NIR Imaging for Breast Cancer Detection|Completed|||340|Actual|UConn Health|||2||f||||t||||||||||2018-06-01 00:56:56.101689|2018-06-01 00:56:56.101689
NCT00908596|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2014-07-15||2015-07-01|2009-05-26|2009-05-27|Estimate|2014-07-15|2014-08-07|Estimate||||2015-07-01|2015-07-23|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PERI||Primovist / Eovist in Renally Impaired Patients|Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Primovist/Eovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information.|Completed||Phase 4|357|Actual|Bayer|The study was stopped early since the FDA released the sponsor from completing enrollment because the NSF incidence estimate was lower than the original literature–based estimate, and since enrollment quota were not feasible.|1|||f||||f||||||||||2018-06-01 00:56:56.221808|2018-06-01 00:56:56.221808
NCT00908583|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|2015-10-21||2016-03-04|2009-05-26|2009-05-27|Estimate|2016-01-28|2016-02-26|Estimate||||2016-03-04|2016-04-01|Estimate|May 2009||2009-05-31|March 2016|2016-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||"Forty-four patients received 52 desensitization courses (7 patients enrolled in multiple phases): Phase 1 (n=20), Phase 2 (n=12), Phase 3 (n=10), Phase 4 (n=5), Phase 5 (n=5). n refers to the number of patients. Since patients were enrolled in multiple phases the numbers reported show the total enrollment of each phase."|Desensitization in Kidney Transplantation|Desensitization for Preformed Anti-HLA Antibodies in Kidney Transplantation|Completed||Phase 4|44|Actual|University of Cincinnati||5|||f||||f||||||||||2018-06-01 00:56:56.881277|2018-06-01 00:56:56.881277
NCT00908570|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2011-03-03|2009-05-26|2009-05-27|Estimate|||||||2011-03-03|2011-03-04|Estimate|June 2009||2009-06-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Topical Estriol for Vaginal Health|Topical Estriol for Vaginal Health|Completed||Phase 1|104|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 00:56:57.340953|2018-06-01 00:56:57.340953
NCT00908557|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2014-09-11|2009-05-26|2009-05-27|Estimate|||||||2014-09-11|2014-09-12|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|LISYCOM||Impact of Readability Improvements on the Comprehension of Written Information Given to Clinical Trial Patients: a RCT|Multicenter RCT to Assess the Impact of Improvements in Lexico-syntactic Readability and Good Practice in Writing on the Comprehension of Written Information Given to Patients Participating in Clinical Trials.|Completed||N/A|400|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-06-01 00:56:57.401591|2018-06-01 00:56:57.401591
NCT00908544|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2017-11-16|2009-05-26|2009-05-27|Estimate|||||||2017-11-16|2017-11-17|Actual|May 2009||2009-05-31|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|NewEra||New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients|NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0|Active, not recruiting||N/A|40|Anticipated|MUC Research GmbH||2|||f||||t||||||||No||2018-06-01 00:56:57.467581|2018-06-01 00:56:57.467581
NCT00908531|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2015-02-13|2009-05-26|2009-05-27|Estimate|||||||2015-02-13|2015-02-16|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|June 2024|Anticipated|2024-06-30|December 2013|Actual|2013-12-31||Interventional|REAL||Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer|Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.|Terminated||Phase 3|123|Actual|Danish Breast Cancer Cooperative Group||2||Poor recruitement|f||||f||||||||||2018-06-01 00:56:57.534381|2018-06-01 00:56:57.534381
NCT00908518|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2009-05-26|2009-05-26|2009-05-27|Estimate|||||||2009-05-26|2009-05-27|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|July 2011|Anticipated|2011-07-31|July 2010|Anticipated|2010-07-31||Observational|POCD||The Difference in Postoperative Cognitive Dysfunction and Myocardial Ischemia Between Propofol and Isoflurane|Postoperative Cognitive Dysfunction and Perioperative Myocardial Ischemia: Comparing Total IV Anesthesia and Inhalation Anesthesia.|Unknown status|Not yet recruiting||500|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||t||||||||||2018-06-01 00:56:57.621163|2018-06-01 00:56:57.621163
NCT00908505|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-26|2009-05-26|2009-05-27|Estimate|||||||2009-05-26|2009-05-27|Estimate|July 2009||2009-07-31|May 2009|2009-05-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Interventional|RTX||Comparison Between RTX (Biphasic Cuirass Ventilator) and Physiotherapy in Cystic Fibrosis Patients|Comparison Between bi-Phasic Negative Pressure Ventilator Therapy and Physiotherapy in Cystic Fibrosis Patients|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 00:56:57.686393|2018-06-01 00:56:57.686393
NCT00908492|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2015-04-06|2009-05-26|2009-05-27|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Supporting Caregivers of Persons With Dementia: A Pilot Study|Pilot Study of the Environmental Skill Building Program for Dementia Caregivers|Completed||Phase 2/Phase 3|38|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 00:56:57.824634|2018-06-01 00:56:57.824634
NCT00908479|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-26|||2017-05-08|2009-05-26|2009-05-27|Estimate|||||||2017-05-08|2017-05-10|Actual|September 2009||2009-09-30|May 2017|2017-05-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|||The Effect of an Inpatient Home-work Exercise Program on Leg Function After Stroke|Exercise Programs for Stroke: Effect of an Inpatient Supplementary Practice Program on Lower Extremity Function|Completed||N/A|142|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:56:57.89556|2018-06-01 00:56:57.89556
NCT00908466|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2010-05-25|2009-05-22|2009-05-25|Estimate|||||||2010-05-25|2010-05-27|Estimate|July 2009||2009-07-31|May 2010|2010-05-31|February 2013|Anticipated|2013-02-28|July 2011|Anticipated|2011-07-31||Interventional|SAVE||Sirolimus as Therapeutic Approach to Uveitis|A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis|Unknown status|Recruiting|Phase 1|30|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 00:56:57.969551|2018-06-01 00:56:57.969551
NCT00908453|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2010-05-21|2009-05-22|2009-05-25|Estimate|||||||2010-05-21|2010-05-24|Estimate|May 2009||2009-05-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin||Completed||Phase 3|40|Anticipated|Nobelpharma||3|||f||||t||||||||||2018-06-01 00:56:58.071444|2018-06-01 00:56:58.071444
NCT00908440|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2009-05-22|2009-05-22|2009-05-25|Estimate|||||||2009-05-22|2009-05-25|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Decision Aid in Veterans With Posttraumatic Stress Disorder|Decision Aid in Veterans With Posttraumatic Stress Disorder|Unknown status|Not yet recruiting|N/A|132|Anticipated|White River Junction Veterans Affairs Medical Center|||||f||||t||||||||||2018-06-01 00:56:58.13154|2018-06-01 00:56:58.13154
NCT00908427|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2009-05-22|2009-05-22|2009-05-25|Estimate|||||||2009-05-22|2009-05-25|Estimate|June 2004||2004-06-30|May 2009|2009-05-31|September 2007|Actual|2007-09-30|May 2006|Actual|2006-05-31||Interventional|||Impact of 80 W KTP Laser Vaporization Prostatectomy on Severity of Obstruction in Benign Prostatic Hyperplasia|Impact of 80 Watt KTP Photoselective Laser Vaporization Prostatectomy on Severity of Obstruction in Benign Prostatic Hyperplasia: 6-Month Results of a Nonrandomized Prospective Trial|Completed||N/A|86|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 00:56:58.20415|2018-06-01 00:56:58.20415
NCT00907764|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2014-01-22|2009-05-21|2009-05-25|Estimate|||||||2014-01-22|2014-01-23|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Stress Echocardiography Study With Regadenoson|An Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 ug Regadenoson Bolus for Pharmacological Stress Echocardiography|Terminated||Phase 2|22|Actual|Gilead Sciences||4||Slow enrollment|f||||t||||||||||2018-06-01 00:57:11.457904|2018-06-01 00:57:11.457904
NCT00908414|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2016-10-27|2009-05-21|2009-05-25|Estimate|||||||2016-10-27|2016-10-28|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.|Phase I, Double-blind, Randomized, Placebo-controlled Trial in Healthy Volunteers to Examine Safety, Tolerability, Plasma Pharmacokinetics of TMC589337&TMC589354 After Increasing Single Oral Doses & in an Open-label Part After Different Repeated Doses in Combination With Single Oral Dose of TMC310911|Withdrawn||Phase 1|0|Actual|Tibotec Pharmaceuticals, Ireland||7||strategic decision|f||||f||||||||||2018-06-01 00:56:58.280028|2018-06-01 00:56:58.280028
NCT00908401|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2009-05-22|2009-05-22|2009-05-25|Estimate|||||||2009-05-22|2009-05-25|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|BMoS||Analgesic Effect of Breastmilk for Procedural Pain in Preterm Infants|Breastmilk or Oral Sucrose Solution in Preterm Neonates for Procedural Pain: a Randomized, Controlled Study|Unknown status|Recruiting|Phase 3|42|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||f||||||||||2018-06-01 00:56:58.384844|2018-06-01 00:56:58.384844
NCT00908388|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|2013-10-24|2013-04-01|2017-09-26|2009-05-22|2009-05-25|Estimate|2014-04-15|2014-05-16|Estimate|2013-04-16|2013-04-26|Estimate|2017-09-26|2017-10-27|Actual|October 2009||2009-10-31|September 2017|2017-09-30|February 28, 2017|Actual|2017-02-28|February 2012|Actual|2012-02-29||Interventional|||Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection|Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection|Completed||N/A|50|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-06-01 00:56:58.469612|2018-06-01 00:56:58.469612
NCT00908375|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2014-05-29||2014-10-02|2009-05-22|2009-05-25|Estimate|2014-09-08|2014-09-16|Estimate||||2014-10-02|2014-10-13|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy of Pregabalin in Patients With Radicular Pain|Efficacy of Pregabalin in Patients With Radicular Pain|Completed||Phase 4|39|Actual|Northwestern University|Early subject withdrawal and lost to follow-up leading to small numbers of subjects analyzed.|2|||f||||f||||||||||2018-06-01 00:56:58.874609|2018-06-01 00:56:58.874609
NCT00908362|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2010-01-12|2009-05-22|2009-05-25|Estimate|||||||2010-01-12|2010-01-13|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers|Investigator Initiated, Placebo Controlled, Randomized Pilot Trial on the Influence of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers With COPD Stage GOLD 0 or 1.|Completed||Phase 1|45|Anticipated|University of Rostock||3|||f||||f||||||||||2018-06-01 00:56:59.13128|2018-06-01 00:56:59.13128
NCT00908349|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|2016-02-25||2017-05-01|2009-05-22|2009-05-25|Estimate|2017-05-01|2017-05-31|Actual||||2017-05-01|2017-05-31|Actual|June 2009||2009-06-30|May 2017|2017-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy|Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy|Completed||Phase 3|214|Actual|Supernus Pharmaceuticals, Inc.||1|||f||||f||||||||No||2018-06-01 00:56:59.208974|2018-06-01 00:56:59.208974
NCT00908336|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2009-05-22|2009-05-22|2009-05-25|Estimate|||||||2009-05-22|2009-05-25|Estimate|March 2009||2009-03-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Interventional|||Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen|Phase II, Multicenter, Randomized, Open Label Study of a Sequential Treatment of Intermittent Erlotinib and Docetaxel Versus Erlotinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer After Failure of a Prior Chemotherapy Regimen|Unknown status|Recruiting|Phase 2|70|Anticipated|Hospital Arnau de Vilanova||2|||f||||f||||||||||2018-06-01 00:56:59.494679|2018-06-01 00:56:59.494679
NCT00908323|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2015-03-25|2009-05-21|2009-05-25|Estimate|||||||2015-03-25|2015-03-27|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Early Immune Responses to Vaccination - A Substudy to HVTN 205|Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205|Completed|||47|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Blood samples 30 - 90 mL per visit~   "|||2018-06-01 00:56:59.591271|2018-06-01 00:56:59.591271
NCT00908310|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2014-06-17||2014-07-16|2009-05-22|2009-05-25|Estimate|2014-07-16|2014-07-17|Estimate||||2014-07-16|2014-07-17|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional||The 202 subjects that received contrast media were evaluated for safety.|Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)|A Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive OMNISCAN (Gadodiamide Injection) for Contrast-enhanced Magnetic Resonance Imaging.|Completed||Phase 4|213|Actual|GE Healthcare|As a result of the FDA reference ID: #2954949, subject enrolment was terminated at 213 subjects. All subjects (202 subjects) who received any dose of Omniscan were followed as per protocol until study completion, withdrawal, or lost-to-follow-up.|1|||f||||t||||||||||2018-06-01 00:56:59.670268|2018-06-01 00:56:59.670268
NCT00908297|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2012-04-20|2009-05-21|2009-05-25|Estimate|||||||2012-04-20|2012-04-24|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Safety and Tolerability of Coenzyme Q10 in Hemodialysis Patients|Safety, Tolerability and Efficacy of Coenzyme Q10 in Hemodialysis Patients: Aim 1|Completed||N/A|20|Actual|University of Washington|||||f||||t||||||||||2018-06-01 00:56:59.894565|2018-06-01 00:56:59.894565
NCT00908284|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2015-12-04|2009-05-22|2009-05-25|Estimate|||||||2015-12-04|2015-12-07|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV|Atherosclerotic Risk and Response to Exercise Intervention in HIV+ Children|Completed||N/A|16|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 00:56:59.962776|2018-06-01 00:56:59.962776
NCT00908271|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2016-10-14|2009-05-22|2009-05-25|Estimate|||||||2016-10-14|2016-10-17|Estimate|July 2009||2009-07-31|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects|Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects|Completed||Phase 1|7|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:57:00.040161|2018-06-01 00:57:00.040161
NCT00907569|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2016-02-18|2009-05-21|2009-05-22|Estimate|||||||2016-02-18|2016-02-22|Estimate|June 2009||2009-06-30|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer|A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer|Completed||Phase 2|2|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 00:57:13.048347|2018-06-01 00:57:13.048347
NCT00908245|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2011-12-15|2009-05-22|2009-05-25|Estimate|||||||2011-12-15|2011-12-16|Estimate|September 2003||2003-09-30|July 2011|2011-07-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Interventional|HECLA||Ischemic Preconditioning in Major Hepatectomy|Evaluation of Ischemic Preconditioning in Patients Undergoing Major Liver Resection With Intermittent Pedicular Clamping: A Multicentric Randomized Trial|Completed||Phase 3|81|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 00:57:00.10856|2018-06-01 00:57:00.10856
NCT00908232|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2012-05-04||2015-01-14|2009-05-22|2009-05-25|Estimate|2012-05-04|2012-06-08|Estimate||||2015-01-14|2015-01-15|Estimate|May 2008||2008-05-31|January 2015|2015-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SEQUENTIAL|modified Intent to Treat Population consisting of all 163 participants with at least 1 dose and 1 post baseline efficacy assessment.: Complete and Partial Responders (non-randomized), n=144. Stable Disease (randomized to VD, VDC, and VDL), n=19.|Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD|Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD|Completed||Phase 2|163|Actual|Janssen-Cilag International NV|The response rate of bortezomib in combination with dexamethasone after 4 cycles was much higher than originally assumed. Therefore the sample size of the randomized groups is too small for further statistical analysis.|4|||f||||t||||||||||2018-06-01 00:57:00.214958|2018-06-01 00:57:00.214958
NCT00908219|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2015-06-02|2009-05-21|2009-05-25|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 2009||2009-07-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of Bevacizumab to Prevent Malignant Ascites|A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||1||Accrual closed by sponsor due to lack of accrual and study progress|f||||t||||||||||2018-06-01 00:57:00.928945|2018-06-01 00:57:00.928945
NCT00908206|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2015-04-15|2009-05-21|2009-05-25|Estimate|||||||2015-04-15|2015-04-17|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects of GSK598809 on Brain Activation in Abstinent Alcoholics|A Placebo-controlled, Single-blind, Cross-over, Randomised, fMRI Study Comparing Cue-induced Brain Activation Patterns After a Single Oral Dose of GSK598809 or Placebo in Abstinent Alcoholic Subjects|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1||Study not approved by BfARM|f||||f||||||||||2018-06-01 00:57:01.014134|2018-06-01 00:57:01.014134
NCT00908193|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2013-08-01|2009-05-22|2009-05-25|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2007||2007-07-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ARTE||"Laparoscopic DA VINCI Robot Assisted Abdominal Wall Hernia Repair"|Assistance Robotics for the Surgical Treatment of the Abdominal Wall Hernia|Completed||Phase 4|70|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 00:57:01.084237|2018-06-01 00:57:01.084237
NCT00908180|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2013-08-01|2009-05-22|2009-05-25|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2009||2009-07-31|June 2009|2009-06-30||||July 2014|Anticipated|2014-07-31||Interventional|||Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma|Unknown status|Not yet recruiting|Phase 2|47|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:57:01.167231|2018-06-01 00:57:01.167231
NCT00908167|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2018-01-10|2009-05-22|2009-05-25|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2009||2009-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies|A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies|Completed||Phase 1|44|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 00:57:01.229075|2018-06-01 00:57:01.229075
NCT00908154|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2017-10-27|2009-05-21|2009-05-25|Estimate|||||||2017-10-27|2017-10-30|Actual|May 31, 2008|Actual|2008-05-31|October 2017|2017-10-31|December 31, 2008|Actual|2008-12-31|December 31, 2008|Actual|2008-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.|Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers|Completed||Phase 1|51|Actual|Biogen||4|||f||||||||||||||2018-06-01 00:57:01.305401|2018-06-01 00:57:01.305401
NCT00908141|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|2013-05-20||2013-08-15|2009-05-22|2009-05-25|Estimate|2013-05-20|2013-08-09|Estimate||||2013-08-15|2013-08-23|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||GM-CSF in Treating Patients With Relapsed Prostate Cancer|Immunologic Effects of GM-CSF (Sargramostim, Leukine®) in Patients With Biochemically-relapsed Prostate Cancer|Completed||Phase 2|17|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 00:57:01.375549|2018-06-01 00:57:01.375549
NCT00908128|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|2009-06-12||2009-08-14|2009-05-22|2009-05-25|Estimate|2009-06-12|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Mycophenolate Mofetil Tablets Under Fed Conditions|A Single-Dose, Replicate, Comparative Bioavailability Study of Two Formulations of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:57:01.768897|2018-06-01 00:57:01.768897
NCT00908115|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2009-05-28||2016-09-16|2009-05-21|2009-05-25|Estimate|2009-05-28|2009-07-17|Estimate||||2016-09-16|2016-10-20|Estimate|August 2003||2003-08-31|September 2016|2016-09-30|June 2008|Actual|2008-06-30|June 2004|Actual|2004-06-30||Observational|||Post Market Surveillance for Infanrix™|Evaluation of Safety and Efficacy Through Post Market Surveillance for Infanrix™, the DTaP Mixed Vaccine|Completed|||1258|Actual|GlaxoSmithKline|||1||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:57:02.009497|2018-06-01 00:57:02.009497
NCT00908102|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2015-03-17|2009-05-22|2009-05-25|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2001||2001-09-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|September 2008|Actual|2008-09-30||Interventional|||Managing Non-acute Low Back Symptoms in Occupational Health: Two Trials|The Prevalence of Low Back Symptoms in a Finnish Forestry Company - Effectiveness of Primary Care Interventions for Non-acute Low Back Symptoms in Occupational Health. Two Separate Randomised Controlled Trials (RCT) of Various Levels.|Unknown status|Active, not recruiting|N/A|505|Actual|Helsinki University||5|||f||||f||||||||||2018-06-01 00:57:02.233859|2018-06-01 00:57:02.233859
NCT00908089|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2015-03-31|2009-05-22|2009-05-25|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2003||2003-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|May 2007|Actual|2007-05-31||Interventional|NEO-RACo||TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis|Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis|Unknown status|Active, not recruiting|Phase 4|100|Actual|Helsinki University||2|||f||||t||||||||||2018-06-01 00:57:02.383248|2018-06-01 00:57:02.383248
NCT00908076|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2016-02-12||2018-02-19|2009-05-22|2009-05-25|Estimate|2016-07-18|2016-08-26|Estimate||||2018-02-19|2018-03-16|Actual|February 2009||2009-02-28|February 2018|2018-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|AMITIZA|Patients were included if they had PD using standard criteria, were aged 35 to 85 years, and met the ROME II criteria19 and scored at least 10 on the ROME II constipation assessment. Excluded if they had any other identifiable cause of constipation, use of opioids, anticholinergic agents, or antacids containing magnesium or aluminum salts.|Amitiza in Constipation Associated With PD (Parkinson's Disease)|Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease|Completed||Phase 4|78|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 00:57:02.541928|2018-06-01 00:57:02.541928
NCT00908063|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2014-11-11|2009-05-22|2009-05-25|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|STOP-TBI||Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI)|A Randomized, Placebo Controlled, Double-Blind, Single Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of Oxycyte in Patients With Severe Non-Penetrating Traumatic Brain Injury|Terminated||Phase 2|18|Actual|Tenax Therapeutics, Inc.||2||futility|f||||t||||||||||2018-06-01 00:57:02.75756|2018-06-01 00:57:02.75756
NCT00908050|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2011-06-23|2009-05-22|2009-05-25|Estimate|||||||2011-06-23|2011-06-27|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Study of the Safety and Efficacy of Botox in Bruxism|DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF BOTULINUM TOXIN TYPE A (BOTOX) IN BRUXISM|Unknown status|Recruiting|Phase 4|32|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 00:57:02.838503|2018-06-01 00:57:02.838503
NCT00908037|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2014-09-29||2015-03-19|2009-05-21|2009-05-25|Estimate|2014-10-27|2014-10-31|Estimate||||2015-03-19|2015-04-07|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PETIT||Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)|A Three Part, Staggered Cohort, Open-label and Double Blind, Randomized, Placebo Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Eltrombopag, a Thrombopoietin Receptor Agonist, in Previously Treated Pediatric Patients With Chronic ITP.|Completed||Phase 2|82|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 00:57:03.150495|2018-06-01 00:57:03.150495
NCT00908024|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2013-06-17|2009-05-22|2009-05-25|Estimate|||||||2013-06-17|2013-06-18|Estimate|October 2009||2009-10-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors|A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors|Terminated||Phase 1/Phase 2|54|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:57:08.401508|2018-06-01 00:57:08.401508
NCT00908011|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2015-11-30||2015-11-30|2009-05-22|2009-05-25|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|June 2009||2009-06-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets|A Prospective, Randomized Study to Determine the Effect of Ezetimibe in Addition to Rosuvastatin on Lipids in Participants With the Hypercholesterolemia Associated With HIV Antiretroviral Therapy|Completed||N/A|43|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 00:57:08.520477|2018-06-01 00:57:08.520477
NCT00907998|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2009-11-19|2009-05-22|2009-05-25|Estimate|||||||2009-11-19|2009-11-20|Estimate|June 2009||2009-06-30|November 2009|2009-11-30||||October 2009|Actual|2009-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study in Patients With Coronary Heart Disease (CHD) to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of APL180|Completed||Phase 1|104|Actual|Novartis||3|||f||||f||||||||||2018-06-01 00:57:08.719402|2018-06-01 00:57:08.719402
NCT00907985|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2017-07-18|2009-05-21|2009-05-25|Estimate|||||||2017-07-18|2017-07-21|Actual|May 15, 2009|Actual|2009-05-15|July 2017|2017-07-31|June 10, 2010|Actual|2010-06-10|June 10, 2010|Actual|2010-06-10||Interventional|||A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects|Double Blind, Double-dummy, Randomised, Placebo Controlled Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects|Terminated||Phase 1|12|Actual|GlaxoSmithKline||20||Slow recruitment; trial unlikely to reach completion|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:57:08.904932|2018-06-01 00:57:08.904932
NCT00907972|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2013-07-11|2009-05-22|2009-05-25|Estimate|||||||2013-07-11|2013-07-12|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PDVD3||The Effects of Vitamin D and Bone Loss in Parkinson's Disease|Effect of Vitamin D3 Supplementation in Parkinson's Disease Patients - A Pilot Study|Completed||Phase 2|23|Actual|Memorial Medical Center||2|||f||||f||||||||||2018-06-01 00:57:09.054591|2018-06-01 00:57:09.054591
NCT00907959|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2012-02-06|2009-05-22|2009-05-25|Estimate|||||||2012-02-06|2012-02-08|Estimate|January 2012||2012-01-31|February 2012|2012-02-29|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|||A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer|A Phase 2 Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Bionovo|||||f||||t||||||||||2018-06-01 00:57:09.12422|2018-06-01 00:57:09.12422
NCT00907946|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2011-02-09|2009-05-22|2009-05-25|Estimate|||||||2011-02-09|2011-02-11|Estimate|December 2009||2009-12-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Comparing Previously Placed Nephrostomy Tract (NT) Versus Single Stage Percutaneous Nephrolithotomy (PCNL)|A Prospective, Randomized Trial Comparing Previously Placed Nephrostomy Tract and Single Stage Percutaneous Nephrolithotomy and Its Effects on Infection and Bleeding Related Complications|Terminated||N/A|8|Actual|Washington University School of Medicine||2||Slow accrual|f||||f||||||||||2018-06-01 00:57:09.180098|2018-06-01 00:57:09.180098
NCT00907933|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-07-10|2009-05-21|2009-05-25|Estimate|||||||2017-07-10|2017-07-13|Actual|November 10, 2008|Actual|2008-11-10|July 2017|2017-07-31|February 11, 2009|Actual|2009-02-11|February 11, 2009|Actual|2009-02-11||Interventional|||Intranasal SB-705498 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Examine the Safety, Tolerability and Pharmacokinetics of a) Single, Ascending and b) Twice-daily Repeat Doses of Intranasal SB-705498|Completed||Phase 1|44|Actual|GlaxoSmithKline||9|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:57:09.2464|2018-06-01 00:57:09.2464
NCT00907920|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2015-05-12|2009-05-22|2009-05-25|Estimate|||||||2015-05-12|2015-05-13|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Studying Tumor Samples From Young Patients With Neuroblastoma|Observational - Characterizing the Frequency and Spectrum of ALK Mutations in Neuroblastoma|Completed|||1500|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Tumor Samples~   "|||2018-06-01 00:57:09.331876|2018-06-01 00:57:09.331876
NCT00907907|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|2009-06-12||2009-08-14|2009-05-22|2009-05-25|Estimate|2009-06-12|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|July 2006||2006-07-31|August 2009|2009-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Mycophenolate Mofetil Tablets Under Fasting Conditions|A Single-Dose, Replicate, Comparative Bioavailability Study of Two Formulations of Mycophenolate Mofetil 500 mg Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:57:09.402508|2018-06-01 00:57:09.402508
NCT00907894|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2012-09-26|2009-05-22|2009-05-25|Estimate|||||||2012-09-26|2012-09-27|Estimate|February 2009||2009-02-28|September 2012|2012-09-30||||March 2012|Actual|2012-03-31||Interventional|||Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B|A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LDT600) in Children and Adolescents With Chronic Hepatitis B|Completed||Phase 1|22|Actual|Novartis||3|||f||||||||||||||2018-06-01 00:57:09.638807|2018-06-01 00:57:09.638807
NCT00907881|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2011-10-20||2015-04-01|2009-05-22|2009-05-25|Estimate|2011-10-20|2011-11-24|Estimate||||2015-04-01|2015-04-21|Estimate|August 2009||2009-08-31|April 2015|2015-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||The OBSTACLE Hypoglycemia Study (MK-0000-158)|Prospective Observational Study to Assess Correlation Between Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes Treated With Sulfonylurea|Completed|||1069|Actual|Merck Sharp & Dohme Corp.|||1||f||||||||||||||2018-06-01 00:57:09.735694|2018-06-01 00:57:09.735694
NCT00907868|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2017-08-16|2009-05-22|2009-05-25|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2008|Actual|2008-11-30|August 2017|2017-08-31|October 2029|Anticipated|2029-10-31|May 2011|Actual|2011-05-31||Interventional|BONBIS||Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)|A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS|Active, not recruiting||Phase 3|1950|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f|f|f||||||||2018-06-01 00:57:10.065739|2018-06-01 00:57:10.065739
NCT00907855|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2011-11-29|2009-05-22|2009-05-25|Estimate|||||||2011-11-29|2011-11-30|Estimate|April 2009||2009-04-30|November 2011|2011-11-30||||||||Observational|DASI-08-713||Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests|Clinical Role of the Duke Activity Status Index in the Selection of the Optimal Type of Stress Myocardial Perfusion Imaging Study in Patients With Known or Suspected Ischemic Heart Disease|Completed|||200|Actual|New York University School of Medicine|||||f||||f||||||||||2018-06-01 00:57:10.128184|2018-06-01 00:57:10.128184
NCT00907842|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2013-04-05|2009-05-22|2009-05-25|Estimate|||||||2013-04-05|2013-04-08|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Hernia Prevention in Stomas|Prevention of Parastomal Hernias and Incisional Hernias in Old Stoma Wounds: a Pilot Study|Completed||N/A|10|Actual|Academisch Ziekenhuis Maastricht||1|||f||||f||||||||||2018-06-01 00:57:10.180492|2018-06-01 00:57:10.180492
NCT00907829|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2014-05-01|2009-05-22|2009-05-25|Estimate|||||||2014-05-01|2014-05-05|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Source of Hand Weakness After Stroke|Source of Neurally-Mediated Hand Weakness After Stroke|Withdrawn||Phase 2|0|Actual|VA Office of Research and Development||2||Methods unexpectedly required additional refinement that precluded subject enrollment.|f||||f||||||||||2018-06-01 00:57:10.244808|2018-06-01 00:57:10.244808
NCT00907816|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2009-05-22|2009-05-22|2009-05-25|Estimate|||||||2009-05-22|2009-05-25|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Observational|||Concurrent Electronic Order Entry Variation Reporting Impact on Ordering Behavior|Concurrent Electronic Order Entry Variation Reporting Impact on Ordering|Unknown status|Enrolling by invitation||72|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 00:57:10.312047|2018-06-01 00:57:10.312047
NCT00907803|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2010-07-29||2010-09-15|2009-05-22|2009-05-25|Estimate|2010-07-29|2010-08-27|Estimate||||2010-09-15|2010-09-21|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|246-Safety||Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246|Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Assess Safety, Tolerability, and PK of the Anti-Orthopoxvirus Compound ST-246 When Administered as a Single Daily Oral Dose for 14 Days in Volunteers in the Fed State|Completed||Phase 2|107|Actual|SIGA Technologies||3|||f||||t||||||||||2018-06-01 00:57:10.387494|2018-06-01 00:57:10.387494
NCT00907790|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2017-05-01|2009-05-22|2009-05-25|Estimate|||||||2017-05-01|2017-05-04|Actual|March 2009||2009-03-31|May 2017|2017-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Nursing Management of Irritable Bowel Syndrome (IBS) 2008|Nursing Management of IBS:Improving Outcomes|Completed||N/A|92|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 00:57:10.879252|2018-06-01 00:57:10.879252
NCT00907777|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2016-11-07|2009-11-10|2016-11-07|2009-05-21|2009-05-25|Estimate|2016-11-07|2017-01-06|Estimate|2009-11-10|2009-11-11|Estimate|2016-11-07|2017-01-06|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™|Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine|Completed||Phase 3|52|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:57:10.983763|2018-06-01 00:57:10.983763
NCT00907751|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2014-02-26|2009-05-22|2009-05-25|Estimate|||||||2014-02-26|2014-02-27|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|PTTritux||Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura|Association of Rituximab to Plasma Exchange in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura|Completed||Phase 2|12|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 00:57:11.519434|2018-06-01 00:57:11.519434
NCT00907738|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2011-06-14||2015-05-05|2009-05-21|2009-05-25|Estimate|2011-06-14|2011-07-14|Estimate||||2015-05-05|2015-05-21|Estimate|August 2005||2005-08-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)|A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers|Completed||Phase 2|27|Actual|Merck Sharp & Dohme Corp.|Non-serious adverse events were only collected if they caused drug interruption, discontinuation, or dose reduction.|1|||f||||f||||||||||2018-06-01 00:57:11.599258|2018-06-01 00:57:11.599258
NCT00907725|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-22|||2012-05-08|2009-05-22|2009-05-25|Estimate|||||||2012-05-08|2012-05-10|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?|Follow-up With Serum BhCG Simplify Medical Abortion: A Randomized Controlled Trial|Completed||N/A|376|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-06-01 00:57:11.974528|2018-06-01 00:57:11.974528
NCT00907712|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2015-06-21|2009-05-21|2009-05-22|Estimate|||||||2015-06-21|2015-06-23|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Cardiovascular Assessment Before and After Limb Amputation||Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel||1||Department difficulties|f||||t||||||||||2018-06-01 00:57:12.02774|2018-06-01 00:57:12.02774
NCT00907699|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2014-07-23|2009-05-21|2009-05-22|Estimate|||||||2014-07-23|2014-07-24|Estimate|August 2008||2008-08-31|July 2014|2014-07-31||||February 2013|Actual|2013-02-28||Observational|||Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507|Study of Epithelial Growth Factor Receptor Mutations in Tumor Specimens and Blood Samples From Patients With Non-Small Cell Lung Cancer Enrolled on Clinical Trial CASE-2507|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||Slow Accrual|f||||t||||||Samples With DNA|"~     This laboratory study is looking at biomarkers in tumor tissue and blood samples from~     patients with non-small cell lung cancer.~   "|||2018-06-01 00:57:12.077145|2018-06-01 00:57:12.077145
NCT00907686|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2015-06-25|2009-05-21|2009-05-22|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|TT-CMV||TT-CMV Observational Birth Cohort Study|Prevention of Transfusion-transmitted CMV (TT-CMV) in Lowbirth Weight Infants (LBWI; ≤1500 Grams) Using CMV Seronegative and Leukoreduced Transfusions.|Completed|||600|Actual|Emory University|||2||f||||t||||||Samples Without DNA|"~     Whole Blood, Urine, Breast Milk~   "|||2018-06-01 00:57:12.26596|2018-06-01 00:57:12.26596
NCT00907673|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2011-12-16|2009-05-21|2009-05-22|Estimate|||||||2011-12-16|2011-12-19|Estimate|May 2009||2009-05-31|December 2011|2011-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure||Completed||N/A|2|Actual|NovaShunt AG||1|||f||||f||||||||||2018-06-01 00:57:12.329226|2018-06-01 00:57:12.329226
NCT00907660|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2013-02-01|2009-05-20|2009-05-22|Estimate|||||||2013-02-01|2013-02-05|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|PCPCWLS||A Randomized Trial Comparing Two Doses of Portion-Controlled Foods Within a Primary Care Weight Loss Program|A Randomized Trial Comparing Two Doses of Portion-Controlled Foods Within a Primary Care Weight Loss Program|Completed||Phase 2/Phase 3|50|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 00:57:12.413636|2018-06-01 00:57:12.413636
NCT00907634|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2013-10-23|2009-05-21|2009-05-22|Estimate|||||||2013-10-23|2013-10-24|Estimate|February 2009||2009-02-28|October 2013|2013-10-31||||August 2011|Actual|2011-08-31||Observational|||Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™|Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™|Withdrawn|||0|Actual|Emory University||||"Study closed by IRB because a Continuing Review and/or Close-Out have not been submitted.~    Study closed by IRB"|f||||f||||||||||2018-06-01 00:57:12.480348|2018-06-01 00:57:12.480348
NCT00907621|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2013-11-22||2015-03-15|2009-05-21|2009-05-22|Estimate|2015-03-15|2015-03-17|Estimate||||2015-03-15|2015-03-17|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||We analyzed 79 crying diaries and 84 interviews. The baseline characteristics, except crying time is based on the 84 interviews where we had complete data. The crying time is based on the 79 crying diaries|Effects of Acupuncture in the Treatment of Infant Colic|Effects of Acupuncture in the Treatment of Infant Colic: A Prospective Multi-center Single Blinded Randomized Controlled Study|Completed||Phase 2|90|Actual|University of Oslo|Our choice of acupuncture points and technique could be inferior to other more potent acupuncture approaches.|2|||f||||f||||||||||2018-06-01 00:57:12.546804|2018-06-01 00:57:12.546804
NCT00907608|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2009-05-21|2009-05-21|2009-05-22|Estimate|||||||2009-05-21|2009-05-22|Estimate|December 2007||2007-12-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy|A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy|Terminated||N/A|16|Actual|Chinese University of Hong Kong||2||Due to difficulty in patient recruitment|f||||f||||||||||2018-06-01 00:57:12.769692|2018-06-01 00:57:12.769692
NCT00907595|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2012-11-02|2009-05-21|2009-05-22|Estimate|||||||2012-11-02|2012-11-06|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon|Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||unable to recruit subjects for study.Collaborator stopped funding for study as of 3/31/2010|f||||t||||||||||2018-06-01 00:57:12.901107|2018-06-01 00:57:12.901107
NCT00907582|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2014-12-01|2009-05-21|2009-05-22|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||ASCT for Relapsed APL After Molecular Remission|Autologous Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia After Relapse With Idarubicin and Busulfan Conditioning|Terminated||Phase 2|5|Actual|Shanghai Jiao Tong University School of Medicine||1||slow recruitment|f||||f||||||||||2018-06-01 00:57:12.972917|2018-06-01 00:57:12.972917
NCT00907543|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2017-08-23|2009-05-21|2009-05-22|Estimate|||||||2017-08-23|2017-08-25|Actual|April 2009||2009-04-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|QUINTETT||Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial|Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy (Cisplatin, 5-FU and Radiotherapy Followed by Surgery) to Surgery Followed by Postoperative Chemoradiation (Cisplatin, Epirubicin, 5-FU, Radiotherapy) for Esophageal Cancer|Recruiting||Phase 2/Phase 3|96|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 00:57:13.106944|2018-06-01 00:57:13.106944
NCT00907530|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2012-01-04|2009-05-21|2009-05-22|Estimate|||||||2012-01-04|2012-01-05|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|MERIT||Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain|Phase IV, Double-Blind, Multi-Center, Randomized, Crossover Study to Compare 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF GADOVIST® in Magnetic Resonance Imaging (MRI) of the Brain|Completed||Phase 4|121|Actual|Bracco Diagnostics, Inc||2|||f||||||||||||||2018-06-01 00:57:13.187407|2018-06-01 00:57:13.187407
NCT00907517|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2016-11-30||2016-11-30|2009-05-21|2009-05-22|Estimate|2016-11-30|2017-01-25|Estimate||||2016-11-30|2017-01-25|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)|A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias (Protocol No. P05247)|Terminated||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 00:57:13.278521|2018-06-01 00:57:13.278521
NCT00907504|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2014-06-16|2009-05-20|2009-05-22|Estimate|||||||2014-06-16|2014-06-17|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|ADVIGO1017||Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer|Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 3|0|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 00:57:14.203058|2018-06-01 00:57:14.203058
NCT00907491|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2011-06-08|2009-05-21|2009-05-22|Estimate|||||||2011-06-08|2011-06-09|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Accuracy of Cough Detection in Healthy Adults|Use of Objective Cough Counting Device to Assess the Accuracy of Cough Detection in Healthy Adults Simulating Cough in Different Postures, Mobility and Environmental Conditions|Completed|||54|Anticipated|KarmelSonix Ltd.|||1||f||||f||||||||||2018-06-01 00:57:14.264206|2018-06-01 00:57:14.264206
NCT00907478|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2014-12-19||2016-12-16|2009-05-21|2009-05-22|Estimate|2014-12-19|2015-01-01|Estimate||||2016-12-16|2017-02-09|Estimate|August 2009||2009-08-31|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)|A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)|Completed||Phase 4|169|Actual|Amgen||1|||f||||f||||||||||2018-06-01 00:57:14.359054|2018-06-01 00:57:14.359054
NCT00907465|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2012-12-02|2009-05-20|2009-05-22|Estimate|||||||2012-12-02|2012-12-04|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|SeBA||Sedentary Behavior in African Americans|Measurement of Sedentary Behavior in African American Adults|Completed|||25|Actual|Pennington Biomedical Research Center|||1||f||||f||||||||||2018-06-01 00:57:15.643202|2018-06-01 00:57:15.643202
NCT00907452|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-06-18|2009-05-21|2009-05-22|Estimate|||||||2011-06-18|2011-06-21|Estimate|April 2009||2009-04-30|June 2011|2011-06-30||||September 2011|Anticipated|2011-09-30||Interventional|||Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone|Pharmacogenomic Study to Predict Survival, Best Response and Toxicity in Newly Diagnosed Myeloma Patients Above the Age of 65 Treated With Either a Combination of Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone|Unknown status|Active, not recruiting|N/A|1555|Anticipated|Intergroupe Francophone du Myelome||2|||f||||f||||||||||2018-06-01 00:57:15.722916|2018-06-01 00:57:15.722916
NCT00907439|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2010-11-03|2009-05-20|2009-05-22|Estimate|||||||2010-11-03|2010-11-05|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Study of the Effect of Inhaled Anesthetics on Diastolic Heart Function Using a Doppler-derived Efficiency Index|Changes in Diastolic Dysfunction With the Onset of Volatile Anesthesia in Patients Undergoing Coronary Artery Bypass Grafting as Determined by a Load-independent Efficiency Index Derived From the Parameterized Doppler Analysis of Left Ventricular Filling|Completed|||21|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 00:57:15.89778|2018-06-01 00:57:15.89778
NCT00907426|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2012-08-21|2011-11-23|2012-08-21|2009-05-21|2009-05-22|Estimate|2012-08-21|2012-09-19|Estimate|2011-11-23|2011-12-02|Estimate|2012-08-21|2012-09-19|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin||Completed||Phase 3|368|Actual|Allergan||3|||f||||f||||||||||2018-06-01 00:57:15.975433|2018-06-01 00:57:15.975433
NCT00907413|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2015-06-01|2009-05-21|2009-05-22|Estimate|||||||2015-06-01|2015-06-03|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PDT||Photodynamic Therapy (PDT) Trial for Palliation of Cholangiocarcinoma|Photodynamic Therapy for Palliation of Unresectable Cholangiocarcinoma A Multicenter, Open Label, Randomized, Controlled Phase III Trial|Terminated||Phase 3|50|Actual|Weill Medical College of Cornell University||2||PI relocated and reopened trial in new university|f||||t||||||||||2018-06-01 00:57:16.386251|2018-06-01 00:57:16.386251
NCT00907400|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2010-12-08|2009-05-21|2009-05-22|Estimate|||||||2010-12-08|2010-12-10|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E|Phase I, Open-label, Randomized, 2-way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Naprosyn E Under Fasting and Fed Conditions in Healthy Volunteers|Completed||Phase 1|48|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:57:16.449116|2018-06-01 00:57:16.449116
NCT00907036|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2013-08-01|2009-05-21|2009-05-22|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2009||2009-07-31|June 2009|2009-06-30||||July 2015|Anticipated|2015-07-31||Interventional|||Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma|A Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET-positive Hodgkin Lymphoma|Unknown status|Not yet recruiting|Phase 2|49|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:57:21.066236|2018-06-01 00:57:21.066236
NCT00907387|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20||2010-09-23|2013-12-16|2009-05-21|2009-05-22|Estimate||||2010-09-23|2010-09-28|Estimate|2013-12-16|2014-01-17|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment Lateral Canthal Lines in Adults|Completed||Phase 2|72|Actual|Revance Therapeutics, Inc.||3|||f||||f||||||||||2018-06-01 00:57:16.518543|2018-06-01 00:57:16.518543
NCT00907374|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2012-02-09||2012-03-28|2009-05-21|2009-05-22|Estimate|2012-03-28|2012-03-30|Estimate||||2012-03-28|2012-03-30|Estimate|July 2005||2005-07-31|March 2012|2012-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|END-IT||Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria|Early Nephropathy Study in Diabetes With Inhibitory Renin-Angiotensin-Aldosterone System Therapy (END-IT)|Completed||N/A|46|Actual|Charles Drew University of Medicine and Science||2|||f||||t||||||||||2018-06-01 00:57:16.593124|2018-06-01 00:57:16.593124
NCT00907361|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2015-11-20|2009-05-21|2009-05-22|Estimate|||||||2015-11-20|2015-11-23|Estimate|April 2009||2009-04-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|MagnaSafe||The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)|The MagnaSafe Registry: Determining the Risks of MRI in the Presence of Pacemakers and Implantable Cardioverter Defibrillators|Completed|||2039|Actual|Scripps Health|||||f||||f||||||||||2018-06-01 00:57:16.840704|2018-06-01 00:57:16.840704
NCT00907348|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2011-10-12|2009-05-21|2009-05-22|Estimate|||||||2011-10-12|2011-10-13|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|January 2012|Anticipated|2012-01-31|October 2009|Actual|2009-10-31||Interventional|REAL07||Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma|Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)|Unknown status|Active, not recruiting|Phase 2|49|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-06-01 00:57:16.920988|2018-06-01 00:57:16.920988
NCT00907335|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2010-11-30||2012-02-14|2009-05-21|2009-05-22|Estimate|2011-02-15|2011-03-11|Estimate||||2012-02-14|2012-02-15|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Acne Treatment in Children Ages 9 to 11|A Multi-Center, Double Blind, Vehicle Controlled, Study of Retin-A Micro 0.04% in the Treatment of Pediatric Acne Vulgaris in Children, Ages 9 to 11 Years of Age|Completed||Phase 2|110|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 00:57:17.016136|2018-06-01 00:57:17.016136
NCT00907322|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2009-07-20|2009-05-21|2009-05-22|Estimate|||||||2009-07-20|2009-07-22|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults|A Phase 1, Investigator- And Subject-Blind (Sponsor-Open), Randomized, Crossover, Placebo-Controlled Trial To Assess The Safety, Tolerability, And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon [PF-01913539] In Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 00:57:17.593959|2018-06-01 00:57:17.593959
NCT00907309|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2016-10-06|2009-05-21|2009-05-22|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use|Dental and Medical Office Internet/Intranet Motivational Enhancement Therapy to Reduce Teen Tobacco, Alcohol, and Drug Use|Completed||Phase 1/Phase 2|121|Actual|Boston Children’s Hospital||3|||f||||t||||||||||2018-06-01 00:57:17.672632|2018-06-01 00:57:17.672632
NCT00907296|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21||2013-05-22|2013-05-22|2009-05-21|2009-05-22|Estimate||||2013-05-22|2013-06-05|Estimate|2013-05-22|2013-06-05|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Study of AMG 785 in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing|A Multi-center, Randomized, Double Blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults With a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation With an Intramedullary Nail|Completed||Phase 2|402|Actual|Amgen||10|||f||||f||||||||||2018-06-01 00:57:17.778646|2018-06-01 00:57:17.778646
NCT00907283|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2015-08-03|2009-05-21|2009-05-22|Estimate|||||||2015-08-03|2015-08-05|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)|"Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)"|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Ente Ospedaliero Ospedali Galliera||1|||f||||f||||||||||2018-06-01 00:57:18.081004|2018-06-01 00:57:18.081004
NCT00907270|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2009-05-20|2009-05-20|2009-05-22|Estimate|||||||2009-05-20|2009-05-22|Estimate|September 2009||2009-09-30|May 2009|2009-05-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Supplementation With Vitamin D Improves Leptin Resistance|Effect of Vitamin D Supplementation on Leptin Resistance, Hunger, Body Weight and Resting Energy Expenditure in Obese Women.|Unknown status|Not yet recruiting|N/A|50|Anticipated|Mexican National Institute of Public Health||2|||f||||t||||||||||2018-06-01 00:57:18.175589|2018-06-01 00:57:18.175589
NCT00907257|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2010-12-22||2012-02-14|2009-05-21|2009-05-22|Estimate|2010-12-22|2011-01-21|Estimate||||2012-02-14|2012-02-15|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of Different Use Regimens Using Two Acne Treatments|A Clinical Assessment of the Use of RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser and a 5% Benzoyl Peroxide Wash Used in the Morning Compared to the Use of RETIN-A MICRO 0.04% Pump Nightly and a 5% Benzoyl Peroxide Wash in the Morning For the Treatment of Facial Acne Vulgaris|Completed||Phase 4|247|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 00:57:18.295347|2018-06-01 00:57:18.295347
NCT00907244|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2012-10-26|2009-05-21|2009-05-22|Estimate|||||||2012-10-26|2012-10-29|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Arterial Spin Labeling Perfusion Magnetic Resonance (MR) Imaging in Pediatric Brain Tumors|CHP-901:Arterial Spin Labeling Perfusion MR Imaging in Pediatric Brain Tumors|Completed|||13|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 00:57:18.591555|2018-06-01 00:57:18.591555
NCT00907231|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2015-07-20|2009-05-21|2009-05-22|Estimate|||||||2015-07-20|2015-07-21|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Observational|ESTIMATE||Evaluation of Serial Troponin and Cardiac Multimarkers at the Point of Care in the Emergency Department||Withdrawn|||0|Actual|Biosite||||Business Decision|f||||f||||||||||2018-06-01 00:57:18.645914|2018-06-01 00:57:18.645914
NCT00907218|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2013-05-09||2017-09-20|2009-05-21|2009-05-22|Estimate|2013-07-31|2013-09-23|Estimate||||2017-09-20|2017-10-20|Actual|April 2009||2009-04-30|September 2017|2017-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)|An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking|Terminated||Phase 4|2|Actual|Massachusetts General Hospital|Extremely slow enrollment so the study was terminated early.|1||extremely slow enrollment|f||||f||||||||||2018-06-01 00:57:18.725305|2018-06-01 00:57:18.725305
NCT00907205|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2013-06-11|2009-05-21|2009-05-22|Estimate|||||||2013-06-11|2013-06-13|Estimate|April 2007||2007-04-30|June 2013|2013-06-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|SF112600106||A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors|A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors|Completed||Phase 1|44|Actual|Semafore Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:57:18.879616|2018-06-01 00:57:18.879616
NCT00907192|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2013-06-14|2009-05-21|2009-05-22|Estimate|||||||2013-06-14|2013-06-18|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Self Reported Deviations From Opioid Analgesic Prescription|The Influence of Patients' Knowledge, Attitudes and Beliefs on Self Reported Deviations From Opioid Analgesic Prescription: an Exploratory Survey|Completed|||201|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 00:57:18.957109|2018-06-01 00:57:18.957109
NCT00907179|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2015-07-20|2009-05-21|2009-05-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer|Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1|12|Actual|University of Pittsburgh||1||Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..|f||||t||||||||||2018-06-01 00:57:19.033692|2018-06-01 00:57:19.033692
NCT00907166|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2017-03-19|2009-05-21|2009-05-22|Estimate|||||||2017-03-19|2017-03-21|Actual|May 2009||2009-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients|A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients|Terminated||Phase 1/Phase 2|6|Actual|Rafael Pharmaceuticals Inc.||3||Suspended trial was not restarted.|f||||f||||||||||2018-06-01 00:57:19.110426|2018-06-01 00:57:19.110426
NCT00907153|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2017-03-10||2017-11-20|2009-05-21|2009-05-22|Estimate|2017-11-20|2017-12-19|Actual||||2017-11-20|2017-12-19|Actual|May 2009||2009-05-31|November 2017|2017-11-30|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)|Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial.|Completed||Phase 1/Phase 2|36|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 00:57:19.224793|2018-06-01 00:57:19.224793
NCT00907140|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2017-01-19|2009-05-21|2009-05-22|Estimate|||||||2017-01-19|2017-01-20|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2010|Actual|2010-11-30||Interventional|||Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study|Assessment of Changes in Pattern and Magnitude of Tumor FDG Uptake During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer|Completed||N/A|25|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 00:57:20.041917|2018-06-01 00:57:20.041917
NCT00907127|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2013-12-13|2009-05-20|2009-05-22|Estimate|||||||2013-12-13|2013-12-17|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CAN||Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome|Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome|Completed||Phase 1|50|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 00:57:20.1094|2018-06-01 00:57:20.1094
NCT00907114|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2015-03-18|2009-05-21|2009-05-22|Estimate|||||||2015-03-18|2015-03-20|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Topic Ketorolac Added to Panphotocoagulation in Proliferative Diabetic Retinopathy|Efficacy and Safety of Topic Ketorolac to Treat Center Point Thickness Secondary to Panphotocoagulation in Proliferative Diabetic Retinopathy|Completed||Phase 2|44|Actual|Hospital Juarez de Mexico||2|||f||||f||||||||||2018-06-01 00:57:20.187225|2018-06-01 00:57:20.187225
NCT00907101|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2014-08-12||2016-02-16|2009-05-21|2009-05-22|Estimate|2016-02-16|2016-03-16|Estimate||||2016-02-16|2016-03-16|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes|Evaluation of the Effectiveness of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) in Reducing Antibiotic Sensitive and Resistant Strains of P Acnes|Completed||Phase 4|30|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-06-01 00:57:20.27834|2018-06-01 00:57:20.27834
NCT00907088|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|2013-12-02||2014-03-12|2009-05-21|2009-05-22|Estimate|2014-03-12|2014-04-16|Estimate||||2014-03-12|2014-04-16|Estimate|January 2006||2006-01-31|March 2014|2014-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years|Nutritional Education and the Prevention of Iron Depletion in Children 9 Months to 2 Years: a Randomized Controlled Trial|Completed||N/A|251|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 00:57:20.507256|2018-06-01 00:57:20.507256
NCT00907075|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2012-08-21|2009-05-21|2009-05-22|Estimate|||||||2012-08-21|2012-08-22|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pilot Study to Assess Adherence to a Novel Eating System in Men and Women With Type 2 Diabetes Mellitus|Pilot Study to Assess Adherence to a Novel Eating System in Men and Women With Type 2 Diabetes Mellitus|Completed||N/A|51|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-06-01 00:57:20.848592|2018-06-01 00:57:20.848592
NCT00907062|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2010-07-07|2009-05-21|2009-05-22|Estimate|||||||2010-07-07|2010-07-08|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents|Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents: an Open Label Pilot Clinical Trial|Completed||Phase 1|12|Actual|University of Toronto||1|||f||||t||||||||||2018-06-01 00:57:20.925183|2018-06-01 00:57:20.925183
NCT00907049|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-21|||2014-03-11|2009-05-21|2009-05-22|Estimate|||||||2014-03-11|2014-03-13|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|||Association Between Neck Pain and Quality of Sleep|Study of the Association Between Neck Pain and the Quality of Sleep|Completed|||424|Actual|Kovacs Foundation|||1||f||||t||||||||||2018-06-01 00:57:21.003061|2018-06-01 00:57:21.003061
NCT00907023|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-11-08|2009-05-21|2009-05-22|Estimate|||||||2011-11-08|2011-11-10|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Observational|||Transition From Hospital to Home in Solid Organ Transplant (SOT)|The Transition From Hospital to Home in Parents of Solid Organ Transplant Recipients|Completed|||37|Actual|Medical College of Wisconsin|||1||f||||f||||||||||2018-06-01 00:57:21.132265|2018-06-01 00:57:21.132265
NCT00907010|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Observational|||Sarcopenia and Aging|Sarcopenia and Aging|Completed|||48|Actual|Universidade de Franca|||4||f||||t|||||||"~     The evaluation instruments used were: (1) Esfigmomanômetro (EM), (2) Trunk flexor in the~     supine position,, (3) Jamar Dinamômetro and (4) Preston Pinch Gauge Dinamômetro.~   "|||2018-06-01 00:57:21.196876|2018-06-01 00:57:21.196876
NCT00906997|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2015-03-31|2009-05-19|2009-05-21|Estimate|||||||2015-03-31|2015-04-01|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy|Colorectal Cancer Screening in Average-risk Population: a Multicenter, Randomized Control Trial Comparing Immunochemical Fecal Occult Blood Testing Versus Colonoscopy.|Active, not recruiting||Phase 3|55498|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 00:57:21.273129|2018-06-01 00:57:21.273129
NCT00906984|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2018-01-10|2009-05-19|2009-05-21|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2002||2002-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TheraSphere||TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma|A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma|Recruiting||N/A|130|Anticipated|University of California, Irvine||1|||f||||t||||||||||2018-06-01 00:57:21.365192|2018-06-01 00:57:21.365192
NCT00906971|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2012-09-14||2012-11-06|2009-05-20|2009-05-21|Estimate|2012-09-14|2012-10-18|Estimate||||2012-11-06|2012-11-12|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Physiotherapeutic Intervention in Children With Chronic Functional Constipation|Physiotherapeutic Intervention in Children With Chronic Functional Constipation|Completed||N/A|72|Actual|Universidade Federal de Pernambuco|The study was not designed to assess if a longer period of physiotherapy using these exercises could bring more clinical benefits to bowel habits, therefore, further studies should be undertaken to assess longer treatment periods, of 6 to 12 months.|1|||f||||t||||||||||2018-06-01 00:57:21.460596|2018-06-01 00:57:21.460596
NCT00906958|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:57:21.681378|2018-06-01 00:57:21.681378
NCT00906945|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2016-12-20||2017-02-14|2009-05-20|2009-05-21|Estimate|2017-02-14|2017-04-04|Actual||||2017-02-14|2017-04-04|Actual|February 2011||2011-02-28|February 2017|2017-02-28|September 2015|Actual|2015-09-30|November 2012|Actual|2012-11-30||Interventional|||Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia|Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|39|Actual|Washington University School of Medicine||6|||f||||t||||||||||2018-06-01 00:57:21.785077|2018-06-01 00:57:21.785077
NCT00906932|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|March 2004||2004-03-31|May 2009|2009-05-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Observational|||Comparison Study of a New Fiberoptic Intubation Device to Standard Intubation Techniques|A Prospective Study Comparing the Trachview Videoscope to Standard Direct Laryngoscopy for Orotracheal Intubation|Completed|||159|Actual|University of Texas Southwestern Medical Center|||2||f||||f||||||||||2018-06-01 00:57:23.167539|2018-06-01 00:57:23.167539
NCT00906919|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-21|Estimate|||||||2009-05-19|2009-05-21|Estimate|April 2004||2004-04-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|March 2007|Actual|2007-03-31||Interventional|||The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes|The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes|Completed||N/A|321|Actual|University of Victoria||2|||f||||t||||||||||2018-06-01 00:57:23.226313|2018-06-01 00:57:23.226313
NCT00906906|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|June 2009|Anticipated|2009-06-30|December 2008|Anticipated|2008-12-31||Observational|||Validation of Venous Cannulae Flow Ratings|Validation of Venous Cannulae Flow Ratings of the DLP Right Angle Cannulaes Utilizing Ultrasound Transit Time Technology|Unknown status|Recruiting||50|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||||2018-06-01 00:57:23.292668|2018-06-01 00:57:23.292668
NCT00906893|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2013-02-27|2009-05-20|2009-05-21|Estimate|||||||2013-02-27|2013-02-28|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|MISOGLIO||Evaluation of [18F]-FMISO for Non Operated Glioblastoma|Methodological Evaluation of Fluor 18 Labelled Fluoromisonidazole ([18F]-FMISO) Positon Emission Tomography-Computed Tomography (PET-CT) for Non Operated Glioblastoma|Completed||Phase 2|14|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-06-01 00:57:23.373249|2018-06-01 00:57:23.373249
NCT00906880|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2013-05-30|2009-05-20|2009-05-21|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|September 2010|Actual|2010-09-30||Interventional|NECT-FIELD||Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase|Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage|Completed||Phase 4|630|Actual|Drugs for Neglected Diseases|||||f||||t||||||||||2018-06-01 00:57:23.461438|2018-06-01 00:57:23.461438
NCT00906867|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2017-03-02|2009-05-20|2009-05-21|Estimate|||||||2017-03-02|2017-03-03|Actual|April 2009||2009-04-30|March 2017|2017-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Observational|VCD||Pulmonary Function Test, Bronchial Hyperresponsiveness and Quality of Life in Patients With Vocal Cord Dysfunction (VCD)|Pulmonary Function Test, Bronchial Hyperresponsiveness and Quality of Life in Patients With Vocal Cord Dysfunction (VCD)|Completed|||25|Actual|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||Samples Without DNA|"~     Serum, total IgE~   "|||2018-06-01 00:57:23.551231|2018-06-01 00:57:23.551231
NCT00906854|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Observational|||Urinary Incontinence and Practice of Physical Exercises|Urinary Incontinence and Practice of Physical Exercises Among Nulliparous and Nulligest Women|Completed|||108|Actual|Universidade de Franca|||3||f||||t||||||||||2018-06-01 00:57:23.629192|2018-06-01 00:57:23.629192
NCT00906841|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2018-04-26|2009-05-20|2009-05-21|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2007||2007-10-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|March 2016|Actual|2016-03-31||Interventional|||Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma|Phase II Study of Evaluation of Fractionated Radio-immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-cell Lymphoma|Terminated||Phase 2|75|Actual|French Innovative Leukemia Organisation||1||completed recruitment of patients on 15 december 2010|f||||t||||||||No||2018-06-01 00:57:23.682608|2018-06-01 00:57:23.682608
NCT00906828|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2010-01-15|2009-05-20|2009-05-21|Estimate|||||||2010-01-15|2010-01-18|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|DuoCOMT||Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors|Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors|Completed||Phase 4|10|Anticipated|Uppsala University||3|||f||||t||||||||||2018-06-01 00:57:23.803068|2018-06-01 00:57:23.803068
NCT00906815|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-10-14|2009-05-20|2009-05-21|Estimate|||||||2009-10-14|2009-10-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:57:23.898024|2018-06-01 00:57:23.898024
NCT00906802|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-07-22|2009-05-20|2009-05-21|Estimate|||||||2009-07-22|2009-07-23|Estimate|April 2003||2003-04-30|July 2009|2009-07-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Benefit of Roux-en-Y (R-Y) Reconstruction After Pancreaticoduodenectomy|Benefit of R-Y Reconstruction After Pancreaticoduodenectomy|Unknown status|Recruiting|N/A|40|Anticipated|Kochi University||2|||f||||t||||||||||2018-06-01 00:57:23.956064|2018-06-01 00:57:23.956064
NCT00906789|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2013-09-19||2014-08-20|2009-05-19|2009-05-21|Estimate|2014-08-20|2014-09-01|Estimate||||2014-08-20|2014-09-01|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational||Power calculation was performed to determine the number of participants|Testing of Computer Aided Detection Software for Riverain Medical Group|Testing of Computer Aided Detection Software for Riverain Medical Group|Completed|||15|Actual|Georgetown University|No adverse events occurred. Study was subject to the following potential biases: Sample bias; Majority rule bias; Referral Bias, bias from knowledge that this is an experiment; reader order bias; learning bias; Bias from use of new technology, et al||1||f||||f||||||||||2018-06-01 00:57:24.024711|2018-06-01 00:57:24.024711
NCT00906776|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2012-08-30||2016-04-04|2009-05-20|2009-05-21|Estimate|2012-10-02|2012-10-31|Estimate||||2016-04-04|2016-05-09|Estimate|April 2007||2007-04-30|April 2016|2016-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Emdogain and Straumann Bone Ceramic in Infrabony Defects|Randomised, Controlled, Clinical Study to Compare the Effect of a Combination of Enamel Matrix Proteins and Straumann Bone Ceramic With Autogenous Bone in Deep-wide Intrabony Defects|Terminated||N/A|19|Actual|Institut Straumann AG||2||Difficulty to recruit patients fulfilling inclusion criteria|f||||f||||||||No||2018-06-01 00:57:24.232979|2018-06-01 00:57:24.232979
NCT00906763|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2010-05-25|2009-05-20|2009-05-21|Estimate|||||||2010-05-25|2010-05-26|Estimate|May 2009||2009-05-31|May 2010|2010-05-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|ChocoPD||Effects of Chocolate on Motor Symptoms of Parkinson's Disease|Effects of Chocolate on Motor Symptoms of Parkinson's Disease - A Monocenter, Prospective, Observer-blinded Interventional Trial|Unknown status|Recruiting|N/A|23|Anticipated|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 00:57:25.990542|2018-06-01 00:57:25.990542
NCT00906750|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-10-12|2009-05-19|2009-05-21|Estimate|||||||2011-10-12|2011-10-13|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|FMRESP||A Study of a Live Intranasal Influenza Vaccine in Children With Cancer|A Pilot Study of Flumist, a Live Attenuated Intranasal Influenza Vaccine, and Inactivated Influenza Vaccine in Children With Cancer|Completed||Phase 1|56|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 00:57:26.085929|2018-06-01 00:57:26.085929
NCT00906737|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2014-04-07|2009-05-20|2009-05-21|Estimate|||||||2014-04-07|2014-04-09|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities|Targeted Lower Extremity Joint Training Effects on MS Gait Abnormalities|Completed||N/A|18|Actual|Mount Sinai Rehabilitation Hospital||3|||f||||f||||||||||2018-06-01 00:57:26.189083|2018-06-01 00:57:26.189083
NCT00906724|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-21|Estimate|||||||2009-05-19|2009-05-21|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Observational|3290||An Exercise Intervention Study in Insulin-Resistant Adolescents|An Exercise Intervention in Insulin-Resistant Minority Adolescents|Unknown status|Active, not recruiting||40|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||1||f||||t||||||||||2018-06-01 00:57:26.289448|2018-06-01 00:57:26.289448
NCT00906711|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Observational|||Analysis of Balance in the Aging Process|Analysis of Balance in the Aging Process|Completed|||48|Actual|Universidade de Franca|||4||f||||t|||||||"~     The evaluation instruments are the Berg Balance Scale (BBS), the Performance Oriented~     Mobility Assessment (POMA), the Unipodal Support Test, the Functional Reach Test and the~     Romberg's Test.~   "|||2018-06-01 00:57:26.353577|2018-06-01 00:57:26.353577
NCT00906698|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2014-01-10||2014-06-03|2009-05-20|2009-05-21|Estimate|2014-03-21|2014-04-17|Estimate||||2014-06-03|2014-06-09|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2|Phase I Open Label Trial to Assess Safety of BIBW 2992 With Vinorelbine in Solid Tumors Known to Overexpress HER2 and/or EGFR|Completed||Phase 1|55|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:57:26.597258|2018-06-01 00:57:26.597258
NCT00906685|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-11-21|2009-05-20|2009-05-21|Estimate|||||||2011-11-21|2011-11-22|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Bevacizumab for Central Retinal Vein Occlusion Study|A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO)|Completed||Phase 3|60|Actual|St. Erik Eye Hospital||2|||f||||f||||||||||2018-06-01 00:57:29.034536|2018-06-01 00:57:29.034536
NCT00906672|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2014-05-07|2009-05-20|2009-05-21|Estimate|||||||2014-05-07|2014-05-08|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|INTEGRA®||Medico Economic Evaluation of Dermal Substitute Integra® for Coverage of Inferior Limb Traumatic Skin Loss||Completed||Phase 3|72|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 00:57:29.132422|2018-06-01 00:57:29.132422
NCT00906659|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|January 2006||2006-01-31|May 2009|2009-05-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Observational|||Visual Function, Center Point Thickness and Macular Volume After Photocoagulation|Correlation of Visual Function, Center Point Thickness and Macular Volume Changes Three Weeks After Focal Photocoagulation for Diabetic Macular Edema|Completed|||89|Actual|Hospital Juarez de Mexico|||1||f||||f||||||||||2018-06-01 00:57:29.264363|2018-06-01 00:57:29.264363
NCT00906646|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|April 2004||2004-04-30|May 2009|2009-05-31|December 2008|Actual|2008-12-31|June 2006|Actual|2006-06-30||Interventional|MPM||Preparation of Patients for Cardiac Surgery|Preparation of Patients for Cardiac Surgery|Completed||Phase 3|117|Actual|Bayside Health||2|||f||||f||||||||||2018-06-01 00:57:29.325771|2018-06-01 00:57:29.325771
NCT00906633|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2010-01-25|2009-05-19|2009-05-21|Estimate|||||||2010-01-25|2010-01-26|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Observational|SEIFEM COMBO||Seifem Surveillance of Antifungal Combination Therapy In Hematologic Italian Centers|Seifem Observational Study of Antifungal Combination Therapy In Hematologic Italian Centers|Completed|||80|Anticipated|University Hospital, Udine, Italy|||1||f||||t||||||||||2018-06-01 00:57:29.394443|2018-06-01 00:57:29.394443
NCT00906620|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2014-03-06|2009-05-20|2009-05-21|Estimate|||||||2014-03-06|2014-03-07|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SEYLE-ISRAEL||Saving and Empowering Young Lives in Europe (Israel)|Saving and Empowering Young Lives in Europe in Israel, Evaluation, Intervention and Prevention|Completed||Early Phase 1|1247|Actual|Rabin Medical Center||4|||f||||t||||||||||2018-06-01 00:57:29.450342|2018-06-01 00:57:29.450342
NCT00906607|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Observational|||Prevalence of Urinary Incontinence in Different Age Categories|Prevalence of the Urinary Incontinence in Adolescents, Young, Adults and Aged|Completed|||78|Actual|Universidade de Franca|||4||f||||t||||||||||2018-06-01 00:57:29.525177|2018-06-01 00:57:29.525177
NCT00906594|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2015-08-15|2009-05-20|2009-05-21|Estimate|||||||2015-08-15|2015-08-18|Estimate|September 2007||2007-09-30|August 2015|2015-08-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure|Additive Intra-ocular Pressure Reduction Effect of Fixed Combination of Maleate Timolol 0.5%/Dorzolamide 2% on Monotherapy With Latanoprost in Patients With Elevated Intra-ocular Pressure: a Prospective, Four-week, Open-label, Randomized, Controlled Clinical Trial.|Completed||Phase 4|56|Actual|University of Sao Paulo||2|||f||||||||||||||2018-06-01 00:57:29.595838|2018-06-01 00:57:29.595838
NCT00906581|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2017-04-11|2009-05-20|2009-05-21|Estimate|||||||2017-04-11|2017-04-13|Actual|April 2009|Actual|2009-04-30|April 2017|2017-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Self-guided Depression Treatment on Long-duration Spaceflights: A Continuation Study|Self-guided Depression Treatment on Long-duration Spaceflights: A Continuation Study|Completed||N/A|68|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 00:57:29.658732|2018-06-01 00:57:29.658732
NCT00906568|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-02-15|2009-05-20|2009-05-21|Estimate|||||||2011-02-15|2011-02-16|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Observational|ABPA||Evaluation of Bronchial Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)|Clinical Presentation and Bronchial Inflammation of Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients With Cystic Fibrosis|Completed|||40|Actual|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||Samples With DNA|"~     serum: total Ig-E and RAST, sputum~   "|||2018-06-01 00:57:29.754278|2018-06-01 00:57:29.754278
NCT00906555|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2016-10-12|2009-05-20|2009-05-21|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Effect of Different Dosages of Solute Clearance on Outcome in Twice Weekly Hemodialysis Patients|The Effect of Different Dosages of Solute Clearance on Outcome in Twice Weekly Hemodialysis Patients-A Prospective, Randomized, Multi-center Intervention Study|Completed||Phase 4|400|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||No||2018-06-01 00:57:29.905718|2018-06-01 00:57:29.905718
NCT00906542|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2010-02-18|2009-05-20|2009-05-21|Estimate|||||||2010-02-18|2010-02-19|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|PRECAST||Predictors of Early Chest Infection in Acute Ischemic Stroke|Predictors of Early Chest Infection in Acute Ischemic Stroke|Completed|||530|Actual|University of Rostock|||1||f||||f||||||||||2018-06-01 00:57:29.961308|2018-06-01 00:57:29.961308
NCT00906529|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-05-19|2009-05-19|2009-05-21|Estimate|||||||2009-05-19|2009-05-21|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|RASCIN||Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin|RAndomized SubCutaneous Insulin in INpatients (RASCIN) Trial: Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin|Unknown status|Recruiting|Phase 4|600|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:57:30.037499|2018-06-01 00:57:30.037499
NCT00906516|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme|A Phase II Protocol for the Use of Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Bradmer Pharmaceuticals Inc.||1|||f||||f||||||||||2018-06-01 00:57:30.124293|2018-06-01 00:57:30.124293
NCT00906503|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2014-09-23||2015-03-18|2009-05-20|2009-05-21|Estimate|2014-09-23|2014-09-29|Estimate||||2015-03-18|2015-04-07|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|April 2012|Actual|2012-04-30|February 2011|Actual|2011-02-28||Interventional|||Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules|Does Ultra Short-term Steroid Therapy Increase the Accuracy of FDG-PET/CT in Evaluation of Pulmonary Nodules?|Completed||Phase 1|9|Actual|Barbara Ann Karmanos Cancer Institute|Small number of subjects.|1|||f||||f||||||||||2018-06-01 00:57:30.251108|2018-06-01 00:57:30.251108
NCT00906490|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2013-08-16|2009-05-20|2009-05-21|Estimate|||||||2013-08-16|2013-08-20|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|||Clinical Study of the Intravenous Blood Glucose System in Hospitalized Adult Elective or Non-Emergent Surgery and Medical/Surgical Intensive Care Unit Patients|Observational Clinical Study of the Intravenous Blood Glucose System in Hospitalized Adult Elective or Non-Emergent Surgery and Medical/Surgical Intensive Care Unit Patients|Completed|||100|Actual|Edwards Lifesciences|||||f||||f||||||||||2018-06-01 00:57:30.428923|2018-06-01 00:57:30.428923
NCT00906477|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2013-10-09|2009-05-20|2009-05-21|Estimate|||||||2013-10-09|2013-10-10|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|NORCIMT||Norwegian Constraint-Induced (CI) Therapy Multisite Trial|Intensive Training of Arm and Hand Function in People With Stroke - A Randomized Controlled Multisite Trial.|Terminated||Phase 3|47|Actual|University Hospital of North Norway||2||"The study was extended for 2.5 years. A further extension could not be funded. When the study~   was halted in June 2012, 47 subjects were included."|f||||f||||||||||2018-06-01 00:57:30.486677|2018-06-01 00:57:30.486677
NCT00906451|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-06-21|2009-05-20|2009-05-21|Estimate|||||||2011-06-21|2011-06-23|Estimate|November 2008||2008-11-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction|Phase 4 Study of the Effect of Simvastatin Treatment on Inflammatory Response and Endothelial Function After Myocardial Infarction|Completed||Phase 4|58|Actual|Brasilia Heart Study Group||4|||f||||f||||||||||2018-06-01 00:57:30.786267|2018-06-01 00:57:30.786267
NCT00906438|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2009-10-28|2009-05-20|2009-05-21|Estimate|||||||2009-10-28|2009-10-29|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Effects of 2006-RD-05 on Salivary and Serum Immunoglobulin A (IgA) Levels in Healthy Subjects|Effects of 2006-RD-05 on Salivary and Serum IgA Levels in Healthy Subjects|Completed||Phase 1|50|Anticipated|innoVactiv Inc.||2|||f||||||||||||||2018-06-01 00:57:30.860087|2018-06-01 00:57:30.860087
NCT00906425|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2012-06-06||2016-03-02|2009-05-19|2009-05-21|Estimate|2012-07-31|2012-08-31|Estimate||||2016-03-02|2016-03-30|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|October 2013|Actual|2013-10-31|June 2008|Actual|2008-06-30||Interventional|||Clinical Study Comparing Submerged Versus Trans-mucosal Healing of P.004 Implants in the Anterior Mandible and Maxilla|Randomized, Controlled Clinical Study Comparing Submerged vs. Trans-mucosal Placement of P.004 Implants in the Anterior Maxilla and Mandible by Evaluation of the Change in Bone Level Between 1st Stage Surgery and 6 Months Post Surgery|Completed||N/A|145|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:57:30.9526|2018-06-01 00:57:30.9526
NCT00906412|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2016-11-09|2009-05-20|2009-05-21|Estimate|||||||2016-11-09|2016-11-10|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2013|Actual|2013-09-30||Observational|WMVIM||Ventrointermediate Nucleus (VIM DBS) and Working Memory|VIM DBS and Working Memory|Completed|||10|Actual|Washington University School of Medicine|||2||f||||f||||||||No|This is a small pilot study and consent to share data was not obtained.|2018-06-01 00:57:31.71037|2018-06-01 00:57:31.71037
NCT00906399|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2014-07-28|2014-06-17|2014-09-15|2009-05-20|2009-05-21|Estimate|2014-09-15|2014-09-19|Estimate|2014-06-17|2014-06-20|Estimate|2014-09-15|2014-09-19|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|ADVANCE|Intent-to-treat population: participants who were randomized and received at least 1 dose of study treatment (peginterferon beta-1a or placebo).|Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis|Completed||Phase 3|1516|Actual|Biogen||3|||f||||t||||||||||2018-06-01 00:57:31.995489|2018-06-01 00:57:31.995489
NCT00906386|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-03-01|2009-05-19|2009-05-21|Estimate|||||||2010-03-01|2010-03-02|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|February 2011|Anticipated|2011-02-28|October 2009|Anticipated|2009-10-31||Interventional|MMTASC||Methadone Maintenance Treatment and Smoking Cessation|An Examination of the Efficacy, Safety, and Gender Differences in Using Varenicline as an Aid to Smoking Cessation in a Population of Methadone Maintained Opioid Dependent Patients (Pilot Trial)|Unknown status|Enrolling by invitation|Phase 2|112|Anticipated|Vancouver Coastal Health||2|||f||||f||||||||||2018-06-01 00:57:34.062113|2018-06-01 00:57:34.062113
NCT00906373|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20||2010-09-01|2014-06-05|2009-05-20|2009-05-21|Estimate||||2010-09-01|2010-09-06|Estimate|2014-06-05|2014-06-18|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|October 2012|Actual|2012-10-31||Interventional|||A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver|A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 2|47|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 00:57:34.139879|2018-06-01 00:57:34.139879
NCT00906360|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2013-07-01|2009-05-20|2009-05-21|Estimate|||||||2013-07-01|2013-07-02|Estimate|July 2008||2008-07-31|July 2013|2013-07-31||||September 2012|Actual|2012-09-30||Interventional|||Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck|A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX®), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-risk/Recurrent Poor Prognosis Head and Neck Cancer|Terminated||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:57:34.329607|2018-06-01 00:57:34.329607
NCT00906347|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2012-10-05||2012-11-08|2009-05-20|2009-05-21|Estimate|2012-10-05|2012-11-07|Estimate||||2012-11-08|2012-11-15|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Trial of Oral Misoprostol for Labor Augmentation|A Randomized, Controlled Trial of Oral Misoprostol for Labor Augmentation|Completed||Phase 4|350|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 00:57:34.466757|2018-06-01 00:57:34.466757
NCT00906334|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19||2014-04-10|2017-06-22|2009-05-20|2009-05-21|Estimate||||2014-04-10|2014-05-05|Estimate|2017-06-22|2017-06-26|Actual|May 2009||2009-05-31|June 2017|2017-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk|A Phase 2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Myelodysplastic Syndrome Patients With Trisomy 8 or Classified as Intermediate-1, 2 or High Risk|Completed||Phase 2|14|Actual|Onconova Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 00:57:34.763593|2018-06-01 00:57:34.763593
NCT00906321|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2017-06-30|2009-05-20|2009-05-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 18, 2009||2009-05-18|May 26, 2010|2010-05-26|May 26, 2010|Actual|2010-05-26|May 26, 2010|Actual|2010-05-26||Interventional|||Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk|Facilitating Web-Based Patient Decision Support: Decision About Medication to Lower Breast Cancer Risk|Completed||N/A|64|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:57:34.858576|2018-06-01 00:57:34.858576
NCT00906308|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2012-02-06|2009-05-20|2009-05-21|Estimate|||||||2012-02-06|2012-02-08|Estimate|October 2011||2011-10-31|February 2012|2012-02-29||||February 2013|Anticipated|2013-02-28||Interventional|HERBA||A Study of MF101 in Postmenopausal Women|A Phase 3, Double-blind, Placebo-Controlled, Randomized Clinical Trial, Assessing Safety and Efficacy of MF101 for Hot Flushes and Menopausal Symptoms in Postmenopausal Women|Unknown status|Recruiting|Phase 3|1200|Anticipated|Bionovo||3|||f||||t||||||||||2018-06-01 00:57:34.935963|2018-06-01 00:57:34.935963
NCT00906295|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-06-03|2009-05-20|2009-05-21|Estimate|||||||2011-06-03|2011-06-06|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Establishment of Optimal Transfusion Threshold After Major Orthopedic Surgery|Establishment of Optimal Transfusion Threshold After Major Orthopedic Surgery|Completed||N/A|67|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 00:57:35.128114|2018-06-01 00:57:35.128114
NCT00906282|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2016-11-07||2017-01-05|2009-05-20|2009-05-21|Estimate|2017-01-05|2017-02-24|Actual||||2017-01-05|2017-02-24|Actual|June 2009||2009-06-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer|Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients With Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer|Completed||Phase 2|46|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||No||2018-06-01 00:57:35.200349|2018-06-01 00:57:35.200349
NCT00906269|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2012-05-18|2009-05-19|2009-05-21|Estimate|||||||2012-05-18|2012-05-21|Estimate|July 2009||2009-07-31|April 2011|2011-04-30|January 2013|Anticipated|2013-01-31|July 2012|Anticipated|2012-07-31||Interventional|HBOT||Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer|Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy|Unknown status|Recruiting|Phase 4|100|Anticipated|Hartford Hospital||2|||f||||f||||||||||2018-06-01 00:57:35.626631|2018-06-01 00:57:35.626631
NCT00906256|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2010-02-11|2009-05-20|2009-05-21|Estimate|||||||2010-02-11|2010-02-12|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Clinical Pharmacology Study of AZD7295 in Healthy Subjects|A Clinical Pharmacology Study to Determine the Pharmacokinetic, Safety and Tolerability Profile of Oral Doses of AZD7295 in Healthy Subjects|Completed||Phase 1|16|Actual|Arrow Therapeutics||2|||f||||t||||||||||2018-06-01 00:57:35.715193|2018-06-01 00:57:35.715193
NCT00906243|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2012-02-29||2012-03-29|2009-05-19|2009-05-21|Estimate|2012-02-29|2012-03-30|Estimate||||2012-03-29|2012-04-04|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||RNActive®-Derived Therapeutic Vaccine|Phase I/IIa Study of RNActive®-Derived Therapeutic Vaccine in Advanced or Metastatic Hormone Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|6|Actual|University of Florida|This study was terminated early by decision of the Sponsor after 6 subjects had been enrolled in the Phase I part of the study. No efficacy evaluations were planned during the Phase I part of the study.|1||Study Closed after completion of Phase I|f||||f||||||||||2018-06-01 00:57:35.790136|2018-06-01 00:57:35.790136
NCT00906217|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-09-14|2009-05-20|2009-05-21|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Observational|||Safety, Efficacy, and Tolerance of Pico-Salax for Colon Cleansing Prior to Colonoscopy in an Elderly Population|Safety, Efficacy, and Tolerance of Pico-Salax for Colon Cleansing Prior to Colonoscopy in an Elderly Population|Completed|||50|Anticipated|Queen's University|||1||f||||f||||||||||2018-06-01 00:57:35.957398|2018-06-01 00:57:35.957398
NCT00906204|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2015-09-11||2015-11-02|2009-05-20|2009-05-21|Estimate|2015-11-02|2015-12-07|Estimate||||2015-11-02|2015-12-07|Estimate|March 2010||2010-03-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|STAT|Patients who received a kidney transplant along with the study intervention, either single-dose or divided-dose rabbit anti-thymocyte globulin.|Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation|Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Trial to Assess Safety of Single Dose vs. Traditional Administration of Thymoglobulin Induction for Renal Transplantation|Completed||Phase 2|99|Actual|Wright State University|After an interim analysis at the trial mid-point, the trial was terminated because a futility trend analysis showed a >1.72% chance of the primary endpoint rates between the two groups achieving a significant difference with further enrollment.|2|||f||||t||||||||||2018-06-01 00:57:36.038777|2018-06-01 00:57:36.038777
NCT00906191|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-08-25|2009-05-19|2009-05-21|Estimate|||||||2009-08-25|2009-08-26|Estimate|May 2009||2009-05-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects|An Open-Label, Single-Dose, Nonrandomized Study Of The Mass Balance And Metabolic Disposition Of Orally Administered 14C-Labeled SAM-531 In Healthy Male Subjects|Completed||Phase 1|6|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 00:57:36.625846|2018-06-01 00:57:36.625846
NCT00906178|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2016-03-29||2016-06-29|2009-05-20|2009-05-21|Estimate|2016-06-29|2016-08-11|Estimate||||2016-06-29|2016-08-11|Estimate|August 2007||2007-08-31|June 2016|2016-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||CyberSenga: Internet-based HIV Prevention in Uganda|CyberSenga: Harnessing the Power of the Internet to Prevent HIV in Ugandan Youth|Completed||Phase 1|366|Actual|Center for Innovative Public Health Research|Sexual activity in adolescence is a stigmatized behavior in Uganda, especially for females. Youth may have under-reported their sexual experiences, which in the intervention group would have led to them being triaged to the incorrect content.|2|||f||||f||||||||No||2018-06-01 00:57:36.73302|2018-06-01 00:57:36.73302
NCT00906165|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2016-03-03|2009-05-19|2009-05-21|Estimate|||||||2016-03-03|2016-03-04|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|November 2011|Actual|2011-11-30||Interventional|||The Role of Immediate Provisional Restorations on Bone Level Implants|The Role of Immediate Provisional Restorations on Bone Level Implants. A Randomised, Single Blind Controlled Clinical Trial|Unknown status|Active, not recruiting|N/A|24|Anticipated|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:57:37.322494|2018-06-01 00:57:37.322494
NCT00906152|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2014-03-11|2009-05-20|2009-05-21|Estimate|||||||2014-03-11|2014-03-13|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|May 2013|Actual|2013-05-31|August 2012|Actual|2012-08-31||Observational|||Association Between Low Back Pain and Quality of Sleep|Study of the Association Between Low Back Pain and the Quality of Sleep|Completed|||437|Actual|Kovacs Foundation|||1||f||||t||||||||||2018-06-01 00:57:37.384365|2018-06-01 00:57:37.384365
NCT00906139|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2009-05-22|2009-05-20|2009-05-21|Estimate|||||||2009-05-22|2009-05-25|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|November 2009|Anticipated|2009-11-30|February 2009|Anticipated|2009-02-28||Interventional|||Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients|Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients|Unknown status|Active, not recruiting|Phase 4|210|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 00:57:37.4371|2018-06-01 00:57:37.4371
NCT00906126|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|September 2008|Actual|2008-09-30||Interventional|||Oral Misoprostol for Labor Augmentation: A Pilot Study|Oral Misoprostol for Labor Augmentation: A Dose-Finding Pilot Study|Completed||Phase 1|46|Actual|University of Texas Southwestern Medical Center||5|||f||||f||||||||||2018-06-01 00:57:37.498834|2018-06-01 00:57:37.498834
NCT00906113|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2016-10-01|2009-05-20|2009-05-21|Estimate|||||||2016-10-01|2016-10-04|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intra-arterial Chemotherapy for Children With Retinoblastoma|Phase 1-2 Study of Injection of Melphalan Into the Ophthalmic Artery in Children With Retinoblastoma|Recruiting||Phase 1/Phase 2|10|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||Yes||2018-06-01 00:57:37.561236|2018-06-01 00:57:37.561236
NCT00906100|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|May 2010|Anticipated|2010-05-31|May 2009|Anticipated|2009-05-31||Observational|||Prevalence of Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients With Biventricular (BiV) Device|Prevalence of Prolonged Inter/Intra-Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients Undergoing Biventricular (BiV) Device Placement|Unknown status|Recruiting||50|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 00:57:37.623367|2018-06-01 00:57:37.623367
NCT00906087|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2017-03-17||2017-05-02|2009-05-20|2009-05-21|Estimate|2017-05-02|2017-06-02|Actual||||2017-05-02|2017-06-02|Actual|August 4, 2009|Actual|2009-08-04|May 2017|2017-05-31|July 18, 2012|Actual|2012-07-18|July 18, 2012|Actual|2012-07-18||Interventional|Myoc Gene||Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions|The Effect of Myocilin Genetic Variants on Intraocular Pressure and Blood Pressure Variation in Sitting and Supine Positions.|Completed||Phase 4|14|Actual|University of Michigan||1|||f||||t||||||||||2018-06-01 00:57:37.68371|2018-06-01 00:57:37.68371
NCT00906074|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2012-03-09||2012-05-09|2009-05-20|2009-05-21|Estimate|2012-03-09|2012-04-11|Estimate||||2012-05-09|2012-05-15|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|EURIDICE||Study Evaluating Severe Surgical Site Infections (SSIs) Following Contaminated Or Dirty-infected Abdominal Surgery|A Multicenter, Surgeon-Matched Case-Control Study of Severe Surgical Site Infections (SSIs) Following Contaminated Or Dirty-infected Abdominal Surgery|Completed|||180|Actual|Pfizer|Adverse events and serious adverse events were not collected for this epidemiology study.||2||f||||f||||||||||2018-06-01 00:57:38.167269|2018-06-01 00:57:38.167269
NCT00906061|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-21|Estimate|||||||2009-05-19|2009-05-21|Estimate|October 2007||2007-10-31|May 2009|2009-05-31|October 2011|Anticipated|2011-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients|Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2|Unknown status|Recruiting|Phase 2|76|Anticipated|Hospital Arnau de Vilanova||1|||f||||f||||||||||2018-06-01 00:57:39.082455|2018-06-01 00:57:39.082455
NCT00906048|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-02-04|2009-05-20|2009-05-21|Estimate|||||||2011-02-04|2011-02-07|Estimate|April 2009||2009-04-30|February 2011|2011-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection|A National, Multicenter, Non-comparative Study Evaluating the Efficacy of the Combination of Levofloxacin (500 mg) and Rifampicin (600 or 900 mg Depending on Weight) Administered Once Daily by Oral Route, as Replacement of Empirical Antibiotic Therapy Given Intravenously With a Total Duration of 6 Weeks of the Antibiotic Therapy, in the Treatment of OsteoArticular Prosthetic Infections (OAPI), With a Two-stage Revision of the Prosthesis.|Terminated||Phase 3|10|Actual|Sanofi||1||lack of recruitment|f||||||||||||||2018-06-01 00:57:39.197763|2018-06-01 00:57:39.197763
NCT00906035|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2016-09-01||2017-08-02|2009-05-20|2009-05-21|Estimate|2017-08-02|2017-09-05|Actual||||2017-08-02|2017-09-05|Actual|September 2002||2002-09-30|August 2017|2017-08-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)|The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)|Terminated||N/A|25|Actual|University of Pennsylvania|"Study encountered difficulty while attempting to find subjects who met all inclusion/exclusion criteria.0 indicated because no analysis was done on samples obtained. Data could not be analyzed due to insufficient number of participants enrolled."|3||Could not enroll subjects who met the stringent inclusion/exclusion criteria.|f||||f||||||||||2018-06-01 00:57:39.265778|2018-06-01 00:57:39.265778
NCT00906022|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2015-02-06|2009-05-20|2009-05-21|Estimate|||||||2015-02-06|2015-02-09|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|EXPAND||Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND)|EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months.|Completed||Phase 4|94|Actual|Biotronik AG||2|||f||||t||||||||||2018-06-01 00:57:39.553729|2018-06-01 00:57:39.553729
NCT00906009|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:57:39.617521|2018-06-01 00:57:39.617521
NCT00905996|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-20|2009-05-21|Estimate|||||||2009-05-20|2009-05-21|Estimate|August 2006||2006-08-31|May 2009|2009-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Primary Prophylaxis of Gastric Varix Bleed|A Randomized Controlled Trial Comparing Cyanoacrylate Injection Versus Beta-Blockers Versus No Treatment for Primary Prophylaxis of Gastric Variceal Bleed|Completed||N/A|74|Actual|Govind Ballabh Pant Hospital||3|||f||||f||||||||||2018-06-01 00:57:39.655126|2018-06-01 00:57:39.655126
NCT00905983|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-21|Estimate|||||||2009-05-19|2009-05-21|Estimate|October 2007||2007-10-31|May 2009|2009-05-31|September 2011|Anticipated|2011-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients|Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non Small Cell Lung Cancer (NSCLC) Patients.|Unknown status|Active, not recruiting|Phase 2|48|Actual|Hospital Arnau de Vilanova||1|||f||||f||||||||||2018-06-01 00:57:39.741456|2018-06-01 00:57:39.741456
NCT00905970|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-07-08|2009-05-19|2009-05-21|Estimate|||||||2011-07-08|2011-07-11|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|HYPDYN||Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection|Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection|Unknown status|Recruiting||105|Anticipated|Germans Trias i Pujol Hospital|||4||f||||t||||||Samples With DNA|"~     Whole blood collected on QuantiFeron-Gold-In Tube tubes. Exhaled breath collected on R-Tube~   "|||2018-06-01 00:57:39.821552|2018-06-01 00:57:39.821552
NCT00905957|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-08-17|2009-05-19|2009-05-21|Estimate|||||||2011-08-17|2011-08-18|Estimate|October 2010||2010-10-31|October 2010|2010-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Transversus Abdominis Plane Block For Renal Transplant Recipients|Transversus Abdominis Plane Block For Renal Transplant Recipients: A Randomized Controlled Double-blinded Study|Completed||N/A|52|Actual|Royal Liverpool and Broadgreen University Hospitals NHS Trust||2|||f||||f||||||||||2018-06-01 00:57:39.878643|2018-06-01 00:57:39.878643
NCT00905944|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-12-21|2009-05-20|2009-05-21|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Exercise in Patients With a Biventricular Pacemaker|Effects of an Exercise Program on the Tendance to Severe Arrhythmias in Patients With Severely Impaired Left Ventricular Function and Cardial Re-synchronisation Therapy|Unknown status|Recruiting|Phase 2/Phase 3|45|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 00:57:39.936776|2018-06-01 00:57:39.936776
NCT00905931|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2010-06-10|2009-05-19|2009-05-21|Estimate|||||||2010-06-10|2010-06-11|Estimate|September 2010||2010-09-30|June 2010|2010-06-30|October 2012|Anticipated|2012-10-31|June 2012|Anticipated|2012-06-30||Interventional|LASH||Lycopene Following Aneurysmal Subarachnoid Haemorrhage|Acute Oral Lycopene Therapy on Cerebral Autoregulation and Delayed Ischaemic Deficits Following Aneurysmal Subarachnoid Haemorrhage (LASH): A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|124|Anticipated|University of Cambridge||2|||f||||t||||||||||2018-06-01 00:57:40.001368|2018-06-01 00:57:40.001368
NCT00905918|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2014-09-26|2009-05-20|2009-05-21|Estimate|||||||2014-09-26|2014-09-30|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Vitamin E Supplements in Treating Patients Undergoing Surgery for Colorectal Cancer|A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Colon|Completed||Phase 1|14|Actual|Rutgers, The State University of New Jersey||3|||f||||f||||||||||2018-06-01 00:57:40.069784|2018-06-01 00:57:40.069784
NCT00905905|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2010-03-23|2009-05-20|2009-05-21|Estimate|||||||2010-03-23|2010-03-24|Estimate|May 2009||2009-05-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction|Additive Effect of Ezetimibe Upon Simvastatin Treatment on Systemic Inflammatory Activity and Endothelial Function During Myocardial Infarction|Completed||Phase 4|40|Anticipated|Brasilia Heart Study Group||2|||f||||f||||||||||2018-06-01 00:57:40.148363|2018-06-01 00:57:40.148363
NCT00905892|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2011-06-22|2009-05-20|2009-05-21|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2005||2005-09-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|SURNUT||Metabolic Fate Modifications of Saturated Fats After an Overfeeding|Metabolic Fate Modifications of Saturated Fats After an Overfeeding|Completed||N/A|40|Anticipated|Centre de Recherche en Nutrition Humaine Rhone-Alpe|||||f||||t||||||||||2018-06-01 00:57:40.233499|2018-06-01 00:57:40.233499
NCT00905879|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2013-04-25|2009-05-20|2009-05-21|Estimate|||||||2013-04-25|2013-04-26|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|January 2011|Actual|2011-01-31|||||Observational|||Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging|Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients|Completed|||30|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 00:57:40.290519|2018-06-01 00:57:40.290519
NCT00905866|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2011-07-20|2009-05-20|2009-05-21|Estimate|||||||2011-07-20|2011-07-22|Estimate|August 2008||2008-08-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Quality of Life in Patients Undergoing Parathyroidectomy|Evaluation of Quality of Life in Patients Undergoing Parathyroidectomy|Completed|||60|Anticipated|Mackay Memorial Hospital|||1||f||||t||||||||||2018-06-01 00:57:40.354122|2018-06-01 00:57:40.354122
NCT00905853|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2016-07-08|2009-05-20|2009-05-21|Estimate|||||||2016-07-08|2016-07-11|Estimate|May 2009||2009-05-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VANISH||Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy|Ventricular Tachycardia Ablation or Escalated aNtiarrhythmic Drugs in ISchemic Heart Disease|Completed||Phase 4|260|Actual|Nova Scotia Health Authority||2|||f||||t||||||||No||2018-06-01 00:57:40.423584|2018-06-01 00:57:40.423584
NCT00905840|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|2014-08-14||2016-03-02|2009-05-20|2009-05-21|Estimate|2014-11-18|2014-11-25|Estimate||||2016-03-02|2016-03-30|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Interventional||Patients with edentulous mandibles|A Study to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Diameter Bone Level Implants|A Randomized, Controlled, Double Blind, Clinical Trial to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Ø Bone Level Implants by Comparing Two Different Implant Alloys in Split Mouth Design.|Completed||N/A|91|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:57:40.510676|2018-06-01 00:57:40.510676
NCT00905827|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2014-12-29||2015-04-06|2009-05-20|2009-05-21|Estimate|2014-12-29|2015-01-09|Estimate||||2015-04-06|2015-04-24|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|CAMS|comparison of three arms|Patient and Provider Outcomes of E-Learning Training in Collaborative Assessment and Management of Suicidality|Patient and Provider Outcomes of E-Learning Training in Collaborative Assessment and Management of Suicidality|Completed||N/A|212|Actual|VA Office of Research and Development|Providers in this VISN may not be representative of providers in other VAMCs.|3|||f||||t||||||||||2018-06-01 00:57:40.948216|2018-06-01 00:57:40.948216
NCT00905814|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2009-11-13|2009-05-20|2009-05-21|Estimate|||||||2009-11-13|2009-11-16|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers|A Phase I Bioequivalence Study To Compare The Plasma Pharmacokinetics Of Five 1-mg And One 5-mg AG-013736 Tablets In Healthy Volunteers|Completed||Phase 1|60|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:57:41.316106|2018-06-01 00:57:41.316106
NCT00905801|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2015-10-19|2009-05-19|2009-05-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Computed Tomography (CT) Perfusion Imaging of Lung Cancer|CTP (Computed Tomography Perfusion) Imaging of Lung Cancer|Terminated||N/A|16|Actual|University of Pittsburgh||2||Co-PI left institution, PI not pursuing|f||||t||||||||||2018-06-01 00:57:41.488448|2018-06-01 00:57:41.488448
NCT00905788|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2010-04-17|2009-05-20|2009-05-21|Estimate|||||||2010-04-17|2010-04-20|Estimate|February 2008||2008-02-29|April 2010|2010-04-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Embryo Transfer: Embryo Expulsion and Outcome|Embryo Transfer: Embryo Expulsion and Outcome|Completed||Phase 1/Phase 2|134|Anticipated|Royan Institute||2|||f||||t||||||||||2018-06-01 00:57:41.588482|2018-06-01 00:57:41.588482
NCT00905775|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2015-06-24|2009-05-20|2009-05-21|Estimate|||||||2015-06-24|2015-06-25|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Renal Function in Patients Submitted to Myocardial Revascularization Surgery|Evaluation of Renal Function and Oxidative Stress in Patients Submitted to Myocardial Revascularization Surgery, With Extracorporeal Circulation, and Anesthesia With Isoflurane or Propofol|Terminated|||60|Actual|UPECLIN HC FM Botucatu Unesp|||2|Failure of recruitment|f||||t||||||||||2018-06-01 00:57:41.676615|2018-06-01 00:57:41.676615
NCT00905762|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2011-12-07|2009-05-20|2009-05-21|Estimate|||||||2011-12-07|2011-12-09|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation|A Single-Center, Randomized, Masked Study Comparing the Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After a Single Topical Instillation|Completed||Phase 1|119|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 00:57:41.829568|2018-06-01 00:57:41.829568
NCT00905749|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2015-04-06|2009-05-20|2009-05-21|Estimate|||||||2015-04-06|2015-04-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:57:41.920973|2018-06-01 00:57:41.920973
NCT00905736|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-20|||2010-06-18|2009-05-20|2009-05-21|Estimate|||||||2010-06-18|2010-06-22|Estimate|April 2009||2009-04-30|August 2009|2009-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Influence of Microcurrent Parameters on Effectiveness in Treatment of Chronic Tennis Elbow|Influence of Microcurrent Parameters on Effectiveness of Treatment of Chronic Tennis Elbow - a Preliminary Trial|Completed||Phase 2/Phase 3|24|Anticipated|University of Hertfordshire||2|||f||||f||||||||||2018-06-01 00:57:41.962123|2018-06-01 00:57:41.962123
NCT00905723|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|May 2009||2009-05-31|May 2009|2009-05-31||||May 2010|Anticipated|2010-05-31||Interventional|||The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women|Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women|Unknown status|Recruiting|Phase 3|60|Anticipated|Federal University of São Paulo||3|||f||||f||||||||||2018-06-01 00:57:42.035276|2018-06-01 00:57:42.035276
NCT00905710|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2016-05-12|2009-05-18|2009-05-20|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ChromoLynch||Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome|Chromoendoscopy in Lynch Syndrome Patients|Completed||N/A|240|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-06-01 00:57:42.289008|2018-06-01 00:57:42.289008
NCT00905697|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2018-03-12|2009-05-18|2009-05-20|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2009||2009-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Patient Reported Outcomes in Living Donor Lung Transplantation|Analysis of Patient Reported Outcomes in Living Donor Lung Transplantation|Active, not recruiting|||40|Actual|Kyoto University, Graduate School of Medicine|||1||f||||f||||||||||2018-06-01 00:57:42.376435|2018-06-01 00:57:42.376435
NCT00905684|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2012-03-06|2009-05-19|2009-05-20|Estimate|||||||2012-03-06|2012-03-07|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|||||Observational|||Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)|Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC))|Completed|||5446|Actual|Bayer|||2||f||||f||||||||||2018-06-01 00:57:42.48941|2018-06-01 00:57:42.48941
NCT00905671|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2014-09-03|2009-05-19|2009-05-20|Estimate|||||||2014-09-03|2014-09-04|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Intravascular Near Infrared Spectroscopy (NIRS) Bifurcation - Lipid Core Plaque Shift Study|Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation|Completed||Phase 4|20|Actual|InfraReDx||2|||f||||f||||||||||2018-06-01 00:57:42.601187|2018-06-01 00:57:42.601187
NCT00905658|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-07-28|2009-05-19|2009-05-20|Estimate|||||||2009-07-28|2009-07-29|Estimate|June 2008||2008-06-30|July 2009|2009-07-31||||November 2009|Anticipated|2009-11-30||Interventional|||Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer|Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study|Unknown status|Recruiting|Phase 2|120|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 00:57:42.6931|2018-06-01 00:57:42.6931
NCT00905645|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2017-05-05|2009-05-18|2009-05-20|Estimate|||||||2017-05-05|2017-05-09|Actual|November 2002||2002-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Sientra Sponsored Silimed Gel-Filled Breast Implant Core Clinical Study|Sientra Sponsored Silimed Gel-Filled Mammary Implant Clinical Study Protocol: Core Clinical Investigation|Active, not recruiting||N/A|1788|Actual|Sientra, Inc.||3|||f||||f||||||||No||2018-06-01 00:57:42.77152|2018-06-01 00:57:42.77152
NCT00905632|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2016-01-21||2016-03-17|2009-05-19|2009-05-20|Estimate|2016-03-17|2016-04-19|Estimate||||2016-03-17|2016-04-19|Estimate|May 2009||2009-05-31|March 2016|2016-03-31||||March 2011|Actual|2011-03-31||Interventional||Treated Set (TS): All patients who received at least one dose of study medication|4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients|Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA Administered in Combination With Peg-IFN and Ribavirin in Chronic HCV-infected Patients for 4 Weeks, a Randomised, Double-blind, Placebo Controlled Study|Completed||Phase 1|75|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 00:57:42.909802|2018-06-01 00:57:42.909802
NCT00905619|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2017-08-15|2009-05-19|2009-05-20|Estimate|||||||2017-08-15|2017-08-18|Actual|December 1, 2006|Actual|2006-12-01|August 2017|2017-08-31|July 20, 2017|Actual|2017-07-20|September 28, 2012|Actual|2012-09-28||Observational|||Cognitive Impairment in Kidney Disease|Functional and Cognitive Impairment in Advanced Kidney Disease|Completed|||117|Actual|VA Office of Research and Development|||3||f||||f|f|f|||f|Samples Without DNA|"~     Serum obtained and kept until end of study.~   "|Undecided||2018-06-01 00:57:44.598775|2018-06-01 00:57:44.598775
NCT00905606|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2009-05-28||2009-08-14|2009-05-19|2009-05-20|Estimate|2009-08-14|2009-09-23|Estimate||||2009-08-14|2009-09-23|Estimate|June 2001||2001-06-30|August 2009|2009-08-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Topiramate 25 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Tablets and Topamax® 25 mg Tablets Administered as 2 x 25 mg Tablets in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|30|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:57:44.661299|2018-06-01 00:57:44.661299
NCT00905086|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2015-09-29|2009-05-19|2009-05-20|Estimate|||||||2015-09-29|2015-09-30|Estimate|August 2008||2008-08-31|September 2015|2015-09-30|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Observational|||Psychosocial Adjustment After Radiation Therapy in Patients With Cancer|Psychosocial Adjustment During the Post-Radiation Treatment Transition|Completed|||80|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 00:57:56.404034|2018-06-01 00:57:56.404034
NCT00905593|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2012-07-17|2009-05-19|2009-05-20|Estimate|||||||2012-07-17|2012-07-18|Estimate|September 2008||2008-09-30|July 2012|2012-07-31||||April 2011|Anticipated|2011-04-30||Expanded Access|ENACT||Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-label, Multicenter Study Providing Continuation of Nilotinib in Adult Patients With Imatinib-(Glivec®/Gleevec®) - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|Approved for marketing|||||Novartis|||||f||||||||||||||2018-06-01 00:57:44.89118|2018-06-01 00:57:44.89118
NCT00905580|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2009-10-13||2010-01-15|2009-05-19|2009-05-20|Estimate|2009-12-07|2010-01-11|Estimate||||2010-01-15|2010-01-20|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy|Perioperative Administration of Pregabalin for Pain After Robot-assisted Endoscopic Thyroidectomy|Completed||Phase 4|99|Actual|Severance Hospital||2|||f||||t||||||||||2018-06-01 00:57:44.951003|2018-06-01 00:57:44.951003
NCT00905567|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2009-05-28||2009-08-14|2009-05-19|2009-05-20|Estimate|2009-08-14|2009-09-23|Estimate||||2009-08-14|2009-09-23|Estimate|June 2001||2001-06-30|August 2009|2009-08-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Topiramate 25 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Tablets Administered as 2 x 25 mg Tablets in Healthy Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:57:45.216775|2018-06-01 00:57:45.216775
NCT00905554|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2011-08-05||2011-09-15|2009-05-18|2009-05-20|Estimate|2011-09-15|2011-10-25|Estimate||||2011-09-15|2011-10-25|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|WW||Warm Water for Unsedated Colonoscopy|Warm Water Irrigation Versus Standard Air Insufflation for Unsedated Colonoscopy: a Randomized Controlled Trial|Completed||N/A|230|Actual|Valduce Hospital||2|||f||||f||||||||||2018-06-01 00:57:45.446564|2018-06-01 00:57:45.446564
NCT00905541|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2009-05-18|2009-05-18|2009-05-20|Estimate|||||||2009-05-18|2009-05-20|Estimate|November 1998||1998-11-30|May 2009|2009-05-31|March 2000|Actual|2000-03-31|March 1999|Actual|1999-03-31||Interventional|SVS||Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion|Influence of Simvastatin on apoB-100 Secretion in Non-Obese Subjects With Moderate Hypercholesterolemia: A Stable Isotope Study|Completed||N/A|8|Actual|University Hospital, Bonn||3|||f||||f||||||||||2018-06-01 00:57:47.230833|2018-06-01 00:57:47.230833
NCT00905528|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2015-03-24|2009-05-19|2009-05-20|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2002||2002-01-31|March 2015|2015-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus|Prospective Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus|Completed|||69|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-06-01 00:57:47.515105|2018-06-01 00:57:47.515105
NCT00905515|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2012-10-22||2013-01-04|2009-05-18|2009-05-20|Estimate|2013-01-04|2013-02-11|Estimate||||2013-01-04|2013-02-11|Estimate|August 2003||2003-08-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|OPTIMAII||Optima: Optimizing Prograf Therapy in Maintenance Allografts II|Optima: Optimizing Prograf Therapy in Maintenance Allografts II|Completed||Phase 4|63|Actual|East Carolina University||3|||f||||f||||||||||2018-06-01 00:57:47.828059|2018-06-01 00:57:47.828059
NCT00905502|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Intraoperative Fluid Management in Laparoscopic Bariatric Surgery|Intraoperative Fluid Management in Laparoscopic Bariatric Surgery - Does it Make a Difference?|Completed||N/A|107|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:57:48.299349|2018-06-01 00:57:48.299349
NCT00905489|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2013-09-23||2015-12-02|2009-05-19|2009-05-20|Estimate|2014-04-05|2014-05-07|Estimate||||2015-12-02|2016-01-07|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Full analysis set (FAS): All patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.|An Open-label, Multiple Dose, Cross-over Study to Evaluate the Steady-state Pharmacokinetic Parameters of Nevirapine Extended Release Tablets in HIV-1 Infected Children, With an Optional Extension Phase|Completed||Phase 1|85|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 00:57:48.415701|2018-06-01 00:57:48.415701
NCT00905476|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2015-04-01|2009-05-18|2009-05-20|Estimate|||||||2015-04-01|2015-04-03|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Prognosis in Patients With Chronic Respiratory Failure Receiving Domiciliary Noninvasive Positive Pressure Ventilation (NPPV)|Analysis of the Prognosis and Clinical Course in Patients With Chronic Respiratory Failure Receiving Domiciliary NPPV|Completed|||56|Actual|Kyoto University, Graduate School of Medicine|||1||f||||f||||||||||2018-06-01 00:57:48.982632|2018-06-01 00:57:48.982632
NCT00905463|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2018-03-12|2009-05-18|2009-05-20|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2009||2009-04-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Prognosis of Lung Transplant Candidates|Analysis of Prognosis and Patient Reported Outcomes in Lung Transplant Candidates|Active, not recruiting|||272|Actual|Kyoto University, Graduate School of Medicine|||1||f||||f||||||||||2018-06-01 00:57:49.071229|2018-06-01 00:57:49.071229
NCT00905450|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19||2011-04-06|2013-10-09|2009-05-19|2009-05-20|Estimate||||2011-05-04|2011-05-06|Estimate|2013-10-09|2013-11-04|Estimate|June 2009||2009-06-30|October 2013|2013-10-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery||Completed||Phase 2|415|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:57:49.148661|2018-06-01 00:57:49.148661
NCT00905437|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2013-04-25||2013-04-25|2009-05-19|2009-05-20|Estimate|2013-04-25|2013-06-11|Estimate||||2013-04-25|2013-06-11|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement|Randomized Double-Blind, Multi-Center Study Of Efficacy And Tolerability Of Pregabalin Versus Placebo As An Adjunct To Standard Of Care For Perioperative Management Of Patients Undergoing Total Hip Arthroplasty|Terminated||Phase 3|72|Actual|Pfizer|As the enrollment rate was very low, the study was prematurely terminated. The number of enrolled participants was too low for meaningful formal statistical conclusions.|2||"The Study was terminated on May 24th 2012 due to a slow recruitment rate. The study was not~   terminated for reasons of safety or efficacy."|f||||f||||||||||2018-06-01 00:57:49.235392|2018-06-01 00:57:49.235392
NCT00905424|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2011-06-15||2013-08-26|2009-05-19|2009-05-20|Estimate|2011-06-15|2011-07-14|Estimate||||2013-08-26|2013-09-09|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant|A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 Years With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant|Completed||Phase 2|246|Actual|Shire||2|||f||||f||||||||||2018-06-01 00:57:49.555235|2018-06-01 00:57:49.555235
NCT00905411|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2013-06-13|2009-05-19|2009-05-20|Estimate|||||||2013-06-13|2013-06-17|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|PacDASH||Pacific Kids DASH for Health|Pacific Kids DASH for Health|Completed||N/A|88|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 00:57:50.228409|2018-06-01 00:57:50.228409
NCT00905398|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2015-07-07|2009-05-19|2009-05-20|Estimate|||||||2015-07-07|2015-07-09|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|July 2015|Anticipated|2015-07-31|June 2012|Actual|2012-06-30||Interventional|ALLPhi||Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Estudo da eficácia do Nilotinibe Concomitante à Quimioterapia no Tratamento de Pacientes Com Leucemia linfoblástica Aguda Filadélfia Positiva recém-diagnosticada|Terminated||Phase 1/Phase 2|8|Actual|Universidade Federal do Rio de Janeiro||1||The study was terminated due to excessive toxicity and low compliance to the protocol scheme.|f||||t||||||||||2018-06-01 00:57:50.298494|2018-06-01 00:57:50.298494
NCT00905385|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18||2011-08-12|2013-04-04|2009-05-18|2009-05-20|Estimate||||2011-08-12|2011-08-17|Estimate|2013-04-04|2013-04-11|Estimate|August 2009||2009-08-31|July 2010|2010-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Nontypeable H. Influenzae in Healthy Adults|Phase I/II Single-Site, Randomized and Double-Blinded Trial to Further Characterize the HCD50, HCD90 and Transmissibility of Nontypeable Haemophilus Influenzae in a Human Colonization Model in Healthy Adults|Completed||Phase 1/Phase 2|15|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 00:57:50.369282|2018-06-01 00:57:50.369282
NCT00905372|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18||2012-09-18|2012-09-18|2009-05-18|2009-05-20|Estimate||||2012-09-18|2012-09-25|Estimate|2012-09-18|2012-09-25|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|EXPEDITION||Effect of LY2062430 on the Progression of Alzheimer's Disease|Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo|Completed||Phase 3|1000|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 00:57:50.458612|2018-06-01 00:57:50.458612
NCT00905359|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2016-04-28||2016-12-19|2009-05-19|2009-05-20|Estimate|2016-06-17|2016-07-29|Estimate||||2016-12-19|2017-02-10|Actual|January 2010||2010-01-31|December 2016|2016-12-31|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional|NICE|Per statistical analysis plan, populations excluded patients who withdrew consent during the study.|Neurogenic Intermittent Claudication Evaluation Study|A Multicenter Prospective Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Aperius™ PercLID™ System Versus Standalone Decompressive Surgery in Degenerative Lumbar Spinal Stenosis With Neurogenic Intermittent Claudication|Completed||Phase 4|163|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 00:57:50.697081|2018-06-01 00:57:50.697081
NCT00905346|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2009-06-01||2009-08-14|2009-05-19|2009-05-20|Estimate|2009-08-14|2009-09-23|Estimate||||2009-08-14|2009-09-23|Estimate|June 2002||2002-06-30|August 2009|2009-08-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Topiramate 25 mg Capsule Mixed With Applesauce Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Capsules Administered as the Content of 2 x 25 mg Capsules Mixed With Applesauce in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:57:51.610259|2018-06-01 00:57:51.610259
NCT00905333|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2010-12-06|2009-05-19|2009-05-20|Estimate|||||||2010-12-06|2010-12-07|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal|Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine in a Combination Package Compared to the Separate Intake of the Reference Brands Atacand and Splendil After a Fasting Period.|Completed||Phase 1|36|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 00:57:51.86018|2018-06-01 00:57:51.86018
NCT00905320|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2017-08-12|2009-05-19|2009-05-20|Estimate|||||||2017-08-12|2017-08-16|Actual|September 2009||2009-09-30|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|SONS||Hernia Repair With or Without Sutures|Sutures or No Sutures (SONS)|Recruiting||N/A|160|Anticipated|Indiana University||2|||f||||t||||||||No||2018-06-01 00:57:51.945231|2018-06-01 00:57:51.945231
NCT00905307|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2015-08-04|2012-05-02|2015-09-29|2009-05-19|2009-05-20|Estimate|2015-08-04|2015-09-03|Estimate|2012-05-02|2012-05-04|Estimate|2015-09-29|2015-10-20|Estimate|July 2009||2009-07-31|September 2015|2015-09-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|STEP 203||Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia|A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients With Acute Schizophrenia|Completed||Phase 2|459|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||6|||f||||t||||||||||2018-06-01 00:57:52.116368|2018-06-01 00:57:52.116368
NCT00905294|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2013-06-17|2009-05-19|2009-05-20|Estimate|||||||2013-06-17|2013-06-19|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|ADVANCE-PCI||Study of ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Coronary Artery Disease|ADAMTS-13 Activity, Von Willebrand Factor and Platelet-Monocyte Aggregation in Patients Undergoing Percutaneous Coronary Intervention|Terminated|||11|Actual|University College Cork|||1|Funding withdrawn|f||||f||||||Samples Without DNA|"~     serum, plasma~   "|||2018-06-01 00:57:52.971648|2018-06-01 00:57:52.971648
NCT00905281|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2015-02-06|2009-05-19|2009-05-20|Estimate|||||||2015-02-06|2015-02-09|Estimate|November 2008||2008-11-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||"Study of Impact of Routine Clinical Cancer Department/Supportive Care Department Consultation on the Prescription of an Additional Line of Chemotherapy"|"Randomized Controlled Trial Assessing the Impact of Routine Oncologist-supportive Care Team Consultation on the Use of an Additional Line of Chemotherapy in Metastatic Breast Cancer Patients"|Completed||N/A|100|Actual|Centre Leon Berard||2|||f||||f||||||||||2018-06-01 00:57:53.044021|2018-06-01 00:57:53.044021
NCT00905268|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2015-10-20||2016-05-19|2009-05-19|2009-05-20|Estimate|2016-05-19|2016-06-27|Estimate||||2016-05-19|2016-06-27|Estimate|April 2006||2006-04-30|May 2016|2016-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|MICONOS||A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients|A Phase III Double-blind, Randomised, Placebo-controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|Completed||Phase 3|232|Actual|Santhera Pharmaceuticals||4|||f||||t||||||||||2018-06-01 00:57:53.234365|2018-06-01 00:57:53.234365
NCT00905255|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2016-08-18|2012-02-21|2016-10-28|2009-05-18|2009-05-20|Estimate|2016-10-28|2016-12-21|Estimate|2012-02-21|2012-02-23|Estimate|2016-10-28|2016-12-21|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|GETGOAL-MONO|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)|A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes|Completed||Phase 3|69|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 00:57:54.050368|2018-06-01 00:57:54.050368
NCT00905242|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2009-05-18|2009-05-18|2009-05-20|Estimate|||||||2009-05-18|2009-05-20|Estimate|March 2006||2006-03-31|May 2009|2009-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|MPACT||Impact of Myfortic on Gastrointestinal (GI) Prophylaxis in Maintenance Renal Transplant Patients|Impact of Myfortic on GI Prophylaxis in Maintenance Renal Transplant Patients|Completed||Phase 4|61|Actual|East Carolina University|||||f||||f||||||||||2018-06-01 00:57:54.700866|2018-06-01 00:57:54.700866
NCT00905229|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2015-06-21|2009-05-19|2009-05-20|Estimate|||||||2015-06-21|2015-06-23|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Comparing Different Routes and Doses of Phytonadione (Vitamin K) for Reversing Warfarin Treated Patients With Hip Fracture Before Surgery||Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel||2||Enrollment problems|f||||t||||||||||2018-06-01 00:57:54.834464|2018-06-01 00:57:54.834464
NCT00905216|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2011-01-27|2009-05-18|2009-05-20|Estimate|||||||2011-01-27|2011-01-28|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Efficacy and Safety of Sodium Heparin in Patients Submitted to Heart Surgery Using Bypass|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass|Unknown status|Recruiting|Phase 3|104|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 00:57:54.919637|2018-06-01 00:57:54.919637
NCT00905203|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2010-07-14|2009-05-19|2009-05-20|Estimate|||||||2010-07-14|2010-07-15|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Effects of Different Exercise Training Dose on Exercise Performance and Noninvasively Estimated Muscle Oxygen Extraction in Diabetic Postmenopausal Women|Effects of Different Exercise Training Dose on Exercise Performance and Noninvasively Estimated Muscle Oxygen Extraction in Diabetic Postmenopausal Women|Unknown status|Recruiting|N/A|45|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 00:57:54.987596|2018-06-01 00:57:54.987596
NCT00905190|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2017-02-08|2009-05-19|2009-05-20|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2009||2009-02-28|February 2017|2017-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|EUR-1025||Bioavailability Study of Anti Nausea Medication With and Without Food|Single Dose Crossover Comparative Bioavailability Study To Assess the Effect of Food on the Pharmacokinetics of Ondansetron Modified-Release Capsules (EUR1025) in Healthy Male and Female Volunteers|Completed||Phase 1|22|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 00:57:55.079807|2018-06-01 00:57:55.079807
NCT00905177|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2016-05-19|2009-05-19|2009-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Predictors of Anticoagulation Control on Warfarin Therapy|Predictors of Anticoagulation Control on Warfarin Therapy|Completed|||687|Actual|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     A one time blood sample will be collected for specific genetic testing and vitamin K assay~   "|||2018-06-01 00:57:55.14857|2018-06-01 00:57:55.14857
NCT00905164|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2009-06-01||2009-08-14|2009-05-19|2009-05-20|Estimate|2009-08-14|2009-09-23|Estimate||||2009-08-14|2009-09-23|Estimate|June 2002||2002-06-30|August 2009|2009-08-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Topiramate 25 mg Capsules Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Sprinkle Capsules Administered as 2 x 25 mg Capsules in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:57:55.216825|2018-06-01 00:57:55.216825
NCT00905151|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2016-07-27||2017-02-06|2009-05-19|2009-05-20|Estimate|2016-12-12|2017-02-06|Estimate||||2017-02-06|2017-03-15|Actual|January 2009||2009-01-31|February 2017|2017-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||HIV and Kidney Function Study|Evaluation of the Performance of GFR Estimating Equations in HIV Positive Patients|Completed|||206|Actual|Tufts Medical Center|||1||f||||f||||||Samples Without DNA|"~     Whole and urine will be retained for future testing.~   "|No|N/A, this study was not funded by the NIH|2018-06-01 00:57:55.444633|2018-06-01 00:57:55.444633
NCT00905138|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2012-02-17|2009-05-19|2009-05-20|Estimate|||||||2012-02-17|2012-02-20|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||First-in-Human Single Ascending and Multiple Dose of GLPG0259|Double Blind, Placebo-controlled Trial for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0259 in Healthy Subjects|Completed||Phase 1|32|Actual|Galapagos NV||4|||f||||f||||||||||2018-06-01 00:57:55.556495|2018-06-01 00:57:55.556495
NCT00905125|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2011-02-17||2012-06-07|2009-05-18|2009-05-20|Estimate|2011-03-03|2011-04-06|Estimate||||2012-06-07|2012-06-13|Estimate|June 2009||2009-06-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Influenza Vaccine in Pregnant Women|A Randomized, Double-Blind Trial on the Safety and Immunogenicity of Inactivated Trivalent Influenza Vaccine in Pregnant Women|Completed||Phase 2|102|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|In September of 2009, the trial was closed to enrollment prior to accruing the intended 200 participants due to the availability of the 2009-2010 seasonal Influenza vaccine and onset of Influenza season.|2|||f||||||||||||||2018-06-01 00:57:55.663615|2018-06-01 00:57:55.663615
NCT00905112|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|October 2006||2006-10-31|May 2009|2009-05-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|MOMS||Musculoskeletal and Obstetric Management Study|Musculoskeletal and Obstetric Management Study (MOMS)|Unknown status|Active, not recruiting|N/A|160|Actual|Logan College of Chiropractic||2|||f||||t||||||||||2018-06-01 00:57:56.330624|2018-06-01 00:57:56.330624
NCT00905073|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-04-12|2009-05-19|2009-05-20|Estimate|||||||2011-04-12|2011-04-13|Estimate|February 1990||1990-02-28|May 2009|2009-05-31|June 1994|Actual|1994-06-30|June 1994|Actual|1994-06-30||Interventional|||Low Dose Cyclosporin and Methotrexate Therapy in Diabetes|Low Dose Cyclosporin and Methotrexate Therapy in New Onset Diabetes Mellitus|Completed||N/A|8|Actual|Georgetown University||1|||f||||f||||||||||2018-06-01 00:57:56.475271|2018-06-01 00:57:56.475271
NCT00905060|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18||2018-05-01|2018-05-01|2009-05-19|2009-05-20|Estimate||||2018-05-01|2018-05-03|Actual|2018-05-01|2018-05-03|Actual|June 2009||2009-06-30|May 2018|2018-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|HeatShock||HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM|PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|70|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 00:57:56.550847|2018-06-01 00:57:56.550847
NCT00905047|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2012-07-20|2009-05-19|2009-05-20|Estimate|||||||2012-07-20|2012-07-23|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Interventional|COLOCROSS||Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer|Open Comparative Study With a Cross-over According to Patients'Preference Receiving Xeloda or UFT With Folinic Acid in Advanced or Metastatic Colo-rectal Cancer|Completed||Phase 3|89|Actual|Centre Oscar Lambret||2|||f||||f||||||||||2018-06-01 00:57:56.624362|2018-06-01 00:57:56.624362
NCT00905034|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2015-06-09||2015-06-09|2009-05-18|2009-05-20|Estimate|2015-06-09|2015-06-29|Estimate||||2015-06-09|2015-06-29|Estimate|March 2009||2009-03-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage|Phase II Study of Methotrexate, Vincristine, Pegylated L-asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage|Completed||Phase 2|37|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:57:56.706382|2018-06-01 00:57:56.706382
NCT00905021|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2012-02-06||2017-02-02|2009-05-19|2009-05-20|Estimate|2012-04-27|2012-05-28|Estimate||||2017-02-02|2017-03-14|Actual|March 2010||2010-03-31|January 2017|2017-01-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|EXTENT||Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer|EXTENT: Exemestane (AROMASIN®) in Combination With Sunitinib (SUTENT®) in Hormone Receptor Positive Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|4|Actual|Baylor Breast Care Center||1||Sponsor withdrew support|f||||t||||||||No||2018-06-01 00:57:56.951858|2018-06-01 00:57:56.951858
NCT00905008|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|October 2006||2006-10-31|May 2009|2009-05-31||||May 2009|Anticipated|2009-05-31||Observational|FRIST||"Long-Term Safety of Drug Eluting Stents in the Real World (FReIburger STent Registry)"|"Long-Term Safety and Efficacy of Drug Eluting Stents in Real World - Results From the FReIburger STent Registry"|Unknown status|Active, not recruiting||1502|Actual|University Hospital Freiburg|||2||f||||t||||||||||2018-06-01 00:57:57.119148|2018-06-01 00:57:57.119148
NCT00904995|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2011-04-18||2012-08-01|2009-05-19|2009-05-20|Estimate|2011-04-18|2011-05-12|Estimate||||2012-08-01|2012-08-07|Estimate|May 2009||2009-05-31|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis|Kinetics of 1, 3 Beta-d- Glucan Assay in Patients With Hematologic Malignancies Receiving Voriconazole Prophylaxis|Completed||Phase 3|23|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 00:57:57.185851|2018-06-01 00:57:57.185851
NCT00904982|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2017-01-06||2017-01-27|2009-05-19|2009-05-20|Estimate|2017-01-27|2017-03-16|Actual||||2017-01-27|2017-03-16|Actual|October 2009||2009-10-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|May 2012|Actual|2012-05-31||Interventional|WIN3||Randomized Trial of Interventions to Improve Warfarin Adherence|Randomized Trial of Interventions to Improve Warfarin Adherence|Completed||N/A|268|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 00:57:57.3713|2018-06-01 00:57:57.3713
NCT00904969|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2017-01-22||2018-01-03|2009-05-19|2009-05-20|Estimate|2018-01-03|2018-01-30|Actual||||2018-01-03|2018-01-30|Actual|September 2005||2005-09-30|January 2017|2017-01-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|AMS051||A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence|A Pre-Market Study of the AMS Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence|Completed||N/A|55|Actual|American Medical Systems||1|||f||||f||||||||Yes|Data generated from this study may be used to support clinical publications, internal device documents for marketing and/or instructional manuals, etc.|2018-06-01 00:57:57.718059|2018-06-01 00:57:57.718059
NCT00904956|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2011-07-08|2009-05-18|2009-05-20|Estimate|||||||2011-07-08|2011-07-11|Estimate|November 2009||2009-11-30|November 2009|2009-11-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Observational|GRANLATHU||Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner|Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner|Unknown status|Recruiting||12|Anticipated|Germans Trias i Pujol Hospital|||||f||||f||||||||||2018-06-01 00:57:58.377472|2018-06-01 00:57:58.377472
NCT00904943|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2009-06-01||2009-08-14|2009-05-19|2009-05-20|Estimate|2009-08-14|2009-09-23|Estimate||||2009-08-14|2009-09-23|Estimate|June 2002||2002-06-30|August 2009|2009-08-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Topiramate 25 mg Capsules Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Topiramate 25 mg Capsules and Topamax® 25 mg Capsules Administered as 2 x 25 mg Capsules in Healthy Subjects Under Fed Conditions|Completed||Phase 1|18|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 00:57:58.445032|2018-06-01 00:57:58.445032
NCT00904930|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-20|2009-05-19|2009-05-20|Estimate|||||||2009-05-20|2009-05-21|Estimate||||May 2009|2009-05-31||||||||Observational|||Evaluation of the Periotest Method in Dental Traumatology|Evaluation of the Periotest Method as a Tool for Tooth Mobility Monitoring and Splint Rigidity Assessment in Dental Traumatology|Completed|||||University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-06-01 00:57:58.742359|2018-06-01 00:57:58.742359
NCT00904917|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2013-09-26||2014-10-17|2009-05-19|2009-05-20|Estimate|2014-10-17|2014-10-20|Estimate||||2014-10-17|2014-10-20|Estimate|February 2008||2008-02-29|October 2014|2014-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||The participant flow module is based on the number of mother-child dyads that completed the baseline assessment(s), while the overall number of participants is based on the number of mothers and children in the intervention and control groups.|Preventing Depression in the Children of Depressed African American Mothers|Children of Depressed Mothers: Culture & Prevention|Completed||Phase 1|34|Actual|Children's Hospital of Philadelphia|Small sample size; Inadequate power to detect changes between groups; No-intervention comparison group; Differential attrition in the two groups favoring the comparison group|2|||f||||t||||||||||2018-06-01 00:57:58.819172|2018-06-01 00:57:58.819172
NCT00904904|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2012-08-10|2009-05-19|2009-05-20|Estimate|||||||2012-08-10|2012-08-13|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery||Completed||Phase 4|120|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:57:59.195374|2018-06-01 00:57:59.195374
NCT00904891|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2014-03-10|2009-05-19|2009-05-20|Estimate|||||||2014-03-10|2014-03-12|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Testing the Effectiveness of Adolescent Depression Prevention Programs (The OregonBlues Study)|Effectiveness Trial of an Adolescent Depression Prevention Program|Completed||Phase 2/Phase 3|390|Actual|Oregon Research Institute||3|||f||||t||||||||||2018-06-01 00:57:59.278844|2018-06-01 00:57:59.278844
NCT00904878|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2016-01-04|2009-05-19|2009-05-20|Estimate|||||||2016-01-04|2016-01-06|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease|A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease|Unknown status|Recruiting||1500|Anticipated|University of California, San Francisco|||||f||||f||||||||||2018-06-01 00:57:59.36049|2018-06-01 00:57:59.36049
NCT00904865|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|February 2009||2009-02-28|May 2009|2009-05-31||||February 2011|Anticipated|2011-02-28||Interventional|||Single Port Access (SPA) Cholecystectomy Versus Standard Laparoscopic Cholecystectomy|Single Port Access Cholecystectomy Versus Standard Laparoscopic Cholecystectomy - Randomized Study|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 00:57:59.442403|2018-06-01 00:57:59.442403
NCT00904852|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme|A Phase 1, Multicenter, Open-Label, Dose Escalation Study of Tandutinib (Formerly MLN518) in Combination With Temozolomide and Bevacizumab Following Concurrent Radiation Therapy and Temozolomide in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme.|Withdrawn||Phase 1|30|Anticipated|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 00:57:59.531937|2018-06-01 00:57:59.531937
NCT00904839|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2014-11-14|2014-05-06|2015-02-03|2009-05-19|2009-05-20|Estimate|2015-02-03|2015-02-04|Estimate|2014-05-06|2014-05-21|Estimate|2015-02-03|2015-02-04|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Treated Set (TS) - The treated set includes all patients who were dispensed and were documented to have taken at least one dose of the trial drug.|BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer|A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients|Completed||Phase 2|128|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 00:57:59.667091|2018-06-01 00:57:59.667091
NCT00904826|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2013-08-30||2013-08-30|2009-05-18|2009-05-20|Estimate|2013-08-30|2013-11-04|Estimate||||2013-08-30|2013-11-04|Estimate|April 2009||2009-04-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica|An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica|Completed||Phase 1/Phase 2|14|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 00:58:00.512455|2018-06-01 00:58:00.512455
NCT00904813|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2018-03-06|2009-05-19|2009-05-20|Estimate|||||||2018-03-06|2018-03-07|Actual|November 1998||1998-11-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2015|Actual|2015-02-28||Interventional|Stockholm III||The Stockholm III Trial on Different Preoperative Radiotherapy Regimens in Rectal Cancer|A Prospective Randomized Trial on Different Preoperative Radiotherapy Regimens in Rectal Cancer, Stockholm III.|Active, not recruiting||Phase 2/Phase 3|840|Anticipated|Karolinska Institutet||3|||f||||t||||||||||2018-06-01 00:58:00.811855|2018-06-01 00:58:00.811855
NCT00904800|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-07-10|2009-05-19|2009-05-20|Estimate|||||||2009-07-10|2009-07-13|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|||||Interventional|ER J ph I||AZD0837 Extended Release (ER) Japan Study|A Single-blind, Randomised, Placebo-controlled, Parallel-group, Single Centre Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended-release Tablets AZD0837 After Single and Repeated Oral Administration to Young Healthy Male Japanese Subjects|Completed||Phase 1|36|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:58:00.918916|2018-06-01 00:58:00.918916
NCT00904787|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2011-08-03|2009-05-19|2009-05-20|Estimate|||||||2011-08-03|2011-08-04|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies|A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies|Completed||Phase 1|27|Actual|CASI Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 00:58:00.976877|2018-06-01 00:58:00.976877
NCT00904774|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|May 2009||2009-05-31|May 2009|2009-05-31||||||||Observational|GENBPD||Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants|Polymorphisms of Genes Controlling Alveolar Development and Risk of Bronchopulmonary Dysplasia|Unknown status|Enrolling by invitation||800|Anticipated|Centre Hospitalier Intercommunal Creteil|||1||f||||||||||||||2018-06-01 00:58:01.034269|2018-06-01 00:58:01.034269
NCT00904761|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2012-12-27|2009-05-19|2009-05-20|Estimate|||||||2012-12-27|2012-12-28|Estimate|October 2001||2001-10-31|November 2012|2012-11-30|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Effects of Physical Training on Heart Rate Variability and Exercise Capacity in Diabetes With Autonomic Neuropathy|Effects of Physical Training on Heart Rate Variability and Exercise Capacity in Diabetes With Autonomic Neuropathy|Completed||N/A|||National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 00:58:01.093703|2018-06-01 00:58:01.093703
NCT00904748|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|2011-03-07||2011-05-17|2009-05-19|2009-05-20|Estimate|2011-03-07|2011-04-04|Estimate||||2011-05-17|2011-05-20|Estimate|January 2010||2010-01-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|A1481272||A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate|A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate In Healthy Male Subjects, Fasting Dosing, Being The Test Formulation Sildenafil Citrate 100 Mg CT , And The Reference Formulation Sildenafil Citrate 100 Mg Film-Coated Tablets (Viagra®), Both Formulations Manufactured By Laboratórios Pfizer Ltda.|Completed||Phase 1|47|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:58:01.158414|2018-06-01 00:58:01.158414
NCT00904735|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2013-08-09|2009-05-19|2009-05-20|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2009||2009-06-30|July 2009|2009-07-31||||||||Interventional|||Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma|IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study|Unknown status|Recruiting|Phase 2|76|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 00:58:02.482216|2018-06-01 00:58:02.482216
NCT00904722|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2016-04-27||2016-04-27|2009-05-19|2009-05-20|Estimate|2016-04-27|2016-06-03|Estimate||||2016-04-27|2016-06-03|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma|Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma|Completed||Phase 2|32|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 00:58:02.591528|2018-06-01 00:58:02.591528
NCT00904709|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2017-01-30|2009-05-19|2009-05-20|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 19, 2009|Actual|2009-10-19|January 2017|2017-01-31|March 1, 2014|Actual|2014-03-01|March 1, 2014|Actual|2014-03-01||Interventional|||The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders|The Assessment of the Minimal Effective and Tolerated Dose of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders|Completed||Phase 4|249|Actual|Nova Scotia Health Authority||1|||f||||f|t|f|||f|||||2018-06-01 00:58:02.744859|2018-06-01 00:58:02.744859
NCT00904696|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2014-04-24|2009-05-19|2009-05-20|Estimate|||||||2014-04-24|2014-04-28|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome|Assessment of Tolerability & Effectiveness of Progut in Treatment of Irritable Bowel Syndrome|Completed|||50|Actual|National University Hospital, Singapore|||||f||||f||||||||||2018-06-01 00:58:02.819103|2018-06-01 00:58:02.819103
NCT00904683|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18||2012-09-18|2012-12-11|2009-05-18|2009-05-20|Estimate||||2012-09-18|2012-09-25|Estimate|2012-12-11|2012-12-13|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EXPEDITION2||Effect of LY2062430 on the Progression of Alzheimer's Disease|Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo|Completed||Phase 3|1040|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 00:58:02.923306|2018-06-01 00:58:02.923306
NCT00904670|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2014-05-27|2013-11-19|2014-05-27|2009-05-19|2009-05-20|Estimate|2014-05-27|2014-06-26|Estimate|2013-11-19|2013-12-13|Estimate|2014-05-27|2014-06-26|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Safety population included all randomized participants who received at least 1 dose of study medication (either NWP06 or matching placebo) with at least 1 post-baseline safety assessment.|Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)|NWP06 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)- A Laboratory Classroom Study|Completed||Phase 3|45|Actual|Pfizer|Results for primary outcome is presented as absolute values and not as change from pre-dose and the secondary outcomes are presented at each post-dose time-point and not pre-dose, as planned.|2|||f||||f||||||||||2018-06-01 00:58:03.270102|2018-06-01 00:58:03.270102
NCT00904657|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-12-03|2009-05-19|2009-05-20|Estimate|||||||2009-12-03|2009-12-04|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||An Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers|An Open-label One-way Explorative Study on the Pharmacokinetics and Pharmacodynamics of Sunitinib in Healthy Volunteers|Completed||Phase 1|12|Actual|University of Cologne|||||f||||t||||||||||2018-06-01 00:58:03.908717|2018-06-01 00:58:03.908717
NCT00904644|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|April 2008||2008-04-30|May 2009|2009-05-31|April 2012|Anticipated|2012-04-30|April 2010|Anticipated|2010-04-30||Observational|||Raltegravir in the Swiss HIV Cohort Study|Raltegravir Use in the Swiss HIV Cohort Study (SHCS) - Evaluation of Efficacy, Safety, Plasma Levels and Evolution of Resistance|Unknown status|Recruiting||200|Anticipated|University of Zurich|||2||f||||f||||||Samples With DNA|"~     Within the framework of the Swiss HIV Cohort Study samples are taken of all patients~     regularly every 6 months. Plasma and frozen cells (www.shcs.ch)~   "|||2018-06-01 00:58:03.951223|2018-06-01 00:58:03.951223
NCT00904631|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-19|||2009-05-19|2009-05-19|2009-05-20|Estimate|||||||2009-05-19|2009-05-20|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|August 2010|Anticipated|2010-08-31|May 2010|Anticipated|2010-05-31||Interventional|||A Prospective, Open Label, Non Randomized, Clinical Study to Evaluate the Safety and Effectiveness of the Eraser Tattoo Removal Device||Unknown status|Recruiting|N/A|20|Anticipated|Assaf-Harofeh Medical Center||1|||f||||||||||||||2018-06-01 00:58:04.02753|2018-06-01 00:58:04.02753
NCT00904618|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2009-03-11||2009-05-18|2009-05-18|2009-05-19|Estimate|2009-05-18|2009-05-19|Estimate||||2009-05-18|2009-05-19|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Study on the Implantation of the Tension-Free Vaginal Tape (TVT-Secur) Under Local Anesthesia|Better Short-Term Outcomes With The 'U-Method' Compared to the 'Hammock' Technique for the Implantation of the TVT-SECUR Under Local Anesthesia|Completed||Phase 2|48|Actual|Université de Sherbrooke|The single-surgeon single-center experience and the lack of objective outcome evaluation. A measurement bias of the 'U-Method' because of a learning curve for the cases using the ‘Hammock’ technique.|1|||f||||f||||||||||2018-06-01 00:58:04.177936|2018-06-01 00:58:04.177936
NCT00904605|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|June 2004||2004-06-30|February 2010|2010-02-28|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee|A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Pain From Osteoarthritis of the Knee|Terminated||Phase 4|||Endo Pharmaceuticals||2||Safety concerns with the COX-2 specific inhibitor class of drug.|f||||f||||||||||2018-06-01 00:58:04.366431|2018-06-01 00:58:04.366431
NCT00904592|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2012-08-20|2009-05-18|2009-05-19|Estimate|||||||2012-08-20|2012-08-21|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||A Study on Traditional Chinese Medicine (TCM) Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy|A Study on TCM Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy|Completed||N/A|480|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 00:58:04.484077|2018-06-01 00:58:04.484077
NCT00904579|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-16|||2018-01-11|2009-05-16|2009-05-19|Estimate|||||||2018-01-11|2018-01-12|Actual|July 1, 2006||2006-07-01|January 9, 2018|2018-01-09||||||||Observational|||Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease|Cancer Risk in Solid Organ Transplant Recipients and End-Stage Renal Disease: The Transplant Cancer Match Study|Recruiting|||1929901|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:58:04.574863|2018-06-01 00:58:04.574863
NCT00904566|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2015-06-22|2009-05-18|2009-05-19|Estimate|||||||2015-06-22|2015-06-23|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Validation of 70-gene MammaPrint Profile in Japanese Population|Validation 70-gene MammaPrint Profile in Japanese Population|Completed|||102|Actual|Agendia|||||f||||f||||||||||2018-06-01 00:58:04.665592|2018-06-01 00:58:04.665592
NCT00904553|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2017-08-14|2009-05-18|2009-05-19|Estimate|||||||2017-08-14|2017-08-17|Actual|January 14, 2009|Actual|2009-01-14|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Study of Resection Combined With Stereotactic Radiosurgery for 1 to 3 Brain Metastases|Pilot Study of Resection Combined With Stereotactic Radiosurgery in Patients With Limited (1-3) Brain Metastases|Active, not recruiting|||25|Anticipated|University of Rochester|||1||f||||t||||||Samples With DNA|"~     brain tissue~   "|No||2018-06-01 00:58:04.733816|2018-06-01 00:58:04.733816
NCT00904540|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-08|2009-05-18|2009-05-19|Estimate|||||||2010-02-08|2010-02-10|Estimate|March 2002||2002-03-31|February 2010|2010-02-28||||October 2002|Actual|2002-10-31||Interventional|||Topical Lidocaine Patch in Low Back Pain|Open-Label Study Assessing the Efficacy of Topical Lidocaine Patch in Treatment of Low Back Pain|Completed||Phase 4|131|Actual|Endo Pharmaceuticals||1|||f||||||||||||||2018-06-01 00:58:04.802453|2018-06-01 00:58:04.802453
NCT00904527|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2015-07-27|2009-05-18|2009-05-19|Estimate|||||||2015-07-27|2015-07-28|Estimate|June 2006||2006-06-30|July 2015|2015-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|MIGREL||Interest of Relaxation From Patients With Pain Due to Migraine|Interest of Relaxation From Patients With Pain Due to Migraine|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-06-01 00:58:04.876237|2018-06-01 00:58:04.876237
NCT00904514|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-16|||2012-02-16|2009-05-16|2009-05-19|Estimate|||||||2012-02-16|2012-02-20|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial|Request to Conduct Research for Same Use of Stored Human Samples, Specimens, or Data Collected in a Terminated NCI-IRB Protocol|Completed|||241|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:58:04.956228|2018-06-01 00:58:04.956228
NCT00904501|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2016-03-05|2009-05-18|2009-05-19|Estimate|||||||2016-03-05|2016-03-08|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|BALI||Bone Marrow Autograft in Limb Ischemia|Cell Therapy in Critical Limb Ischemia|Completed||Phase 3|40|Actual|CHU de Reims||2|||f||||t||||||||||2018-06-01 00:58:05.037807|2018-06-01 00:58:05.037807
NCT00904488|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|2017-12-08||2018-02-13|2009-05-18|2009-05-19|Estimate|2018-01-17|2018-02-13|Actual||||2018-02-13|2018-03-13|Actual|October 2008|Actual|2008-10-31|January 2018|2018-01-31|November 14, 2017|Actual|2017-11-14|May 28, 2016|Actual|2016-05-28||Interventional|||Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure|Addition of Oral Metolazone to Intermittent Intravenous Furosemide Versus Transition to Continuous Infusion Furosemide in Acute Decompensated Heart Failure Patients Experiencing an Inadequate Response to Therapy|Terminated||Phase 4|11|Actual|University of North Carolina, Chapel Hill||2||Difficult recruitment|f||||f||||||||||2018-06-01 00:58:05.160103|2018-06-01 00:58:05.160103
NCT00904475|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|April 2003||2003-04-30|February 2010|2010-02-28||||April 2003|Actual|2003-04-30||Interventional|||Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain|A Prospective, Prospective, Double-blind, Randomized, Placebo-Controlled, Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain|Completed||Phase 4|102|Actual|Endo Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:58:05.951511|2018-06-01 00:58:05.951511
NCT00904462|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-09|2009-05-18|2009-05-19|Estimate|||||||2010-02-09|2010-02-10|Estimate|August 2004||2004-08-31|February 2010|2010-02-28||||September 2005|Actual|2005-09-30||Interventional|||Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee|A Randomized, Double-Blind, Pilot Study Comparing the Efficacy and Safety of Lidocaine 5% Patch With Placebo in Patients With Pain From Osteoarthritis of the Knee|Completed||Phase 2|224|Actual|Endo Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:58:06.117573|2018-06-01 00:58:06.117573
NCT00904449|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-09|2009-05-15|2009-05-19|Estimate|||||||2010-02-09|2010-02-10|Estimate|April 2001||2001-04-30|February 2010|2010-02-28|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Open Label Assessment of Long-Term Safety and Utility|An Open-Label Assessment of the Long-Term Safety and Utility of Numorphan® for the Relief of Moderate to Severe Pain in Patients With Cancer|Completed||Phase 3|24|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:58:06.220453|2018-06-01 00:58:06.220453
NCT00904436|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-05-18|2009-05-18|2009-05-19|Estimate|||||||2009-05-18|2009-05-19|Estimate|December 1999||1999-12-31|May 2009|2009-05-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia|Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia|Completed||N/A|20|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:58:06.279623|2018-06-01 00:58:06.279623
NCT00904423|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2012-06-27||2016-12-20|2009-05-18|2009-05-19|Estimate|2016-12-20|2017-02-14|Actual||||2016-12-20|2017-02-14|Actual|April 2009||2009-04-30|December 2016|2016-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption|A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.|Terminated||Phase 1/Phase 2|8|Actual|Stanford University|Early termination secondary to low accrual.|1||Low accrual|f||||t||||||||No||2018-06-01 00:58:06.356496|2018-06-01 00:58:06.356496
NCT00904410|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2012-07-20|2009-05-18|2009-05-19|Estimate|||||||2012-07-20|2012-07-23|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|CHIMTEP||Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET|Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET|Completed||Phase 4|63|Actual|Centre Oscar Lambret||1|||f||||f||||||||||2018-06-01 00:58:06.549389|2018-06-01 00:58:06.549389
NCT00904397|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|July 2004||2004-07-31|February 2010|2010-02-28||||November 2004|Actual|2004-11-30||Interventional|||Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain|A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Chronic Axial Low Back Pain|Terminated||Phase 4|98|Actual|Endo Pharmaceuticals||2||Rofecoxib was withdrawn from the market due to safety concerns.|f||||||||||||||2018-06-01 00:58:06.647595|2018-06-01 00:58:06.647595
NCT00904384|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2011-06-09|2009-05-18|2009-05-19|Estimate|||||||2011-06-09|2011-06-10|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|HIV&COPD||Prevalence and Determinants of Chronic Obstructive Pulmonary Disease (COPD) in HIV+ Patients|Prevalencia, Factores de Riesgo y características patogénicas Diferenciales de EPOC y Enfisema en Pacientes Con infección VIH.|Completed|||350|Anticipated|Cimera|||2||f||||f||||||||||2018-06-01 00:58:06.760862|2018-06-01 00:58:06.760862
NCT00904371|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2012-06-27||2012-08-16|2009-05-18|2009-05-19|Estimate|2012-08-16|2012-08-21|Estimate||||2012-08-16|2012-08-21|Estimate|December 2009||2009-12-31|August 2012|2012-08-31||||January 2011|Actual|2011-01-31||Observational|||Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients|Evaluation of the Effect of Telmisartan on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients|Completed|||211|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 00:58:06.852214|2018-06-01 00:58:06.852214
NCT00904358|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2017-06-04|2009-05-18|2009-05-19|Estimate|||||||2017-06-04|2017-06-06|Actual|May 2009|Actual|2009-05-31|June 2017|2017-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Estimation of Internal Jugular Vein Central Venous Pressure (CVP) by Ultrasound|Validity and Reliability of Non-invasive Estimation of Central Venous Pressure by Measurement of Internal Jugular Size Using 2-dimensional Ultrasound|Completed|||130|Actual|Mahidol University|||1||f||||t||||||||||2018-06-01 00:58:07.132686|2018-06-01 00:58:07.132686
NCT00904345|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2017-07-03|2009-05-18|2009-05-19|Estimate|||||||2017-07-03|2017-07-05|Actual|February 2009||2009-02-28|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)|Phase II Study of RT Concurrent w/ Cetuximab in Patients w/ Locally Advanced Head & Neck SCC Who Do Not Qualify For Standard Chemotherapy Due To Age >70 Or Co-Morbidities|Active, not recruiting||Phase 2|23|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 00:58:07.204208|2018-06-01 00:58:07.204208
NCT00904332|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-16|||2017-06-30|2009-05-16|2009-05-19|Estimate|||||||2017-06-30|2017-07-02|Actual|May 14, 2009||2009-05-14|December 29, 2011|2011-12-29|December 29, 2011||2011-12-29|||||Observational|||Changes in the Posterior Parietal Cortex - Primary Motor Cortex Pathway Induced by Motor Training|Changes in the Posterior Parietal Cortex - Primary Motor Cortex Pathway Induced by Motor Training|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:58:07.272755|2018-06-01 00:58:07.272755
NCT00904319|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-06-24|2009-05-15|2009-05-19|Estimate|||||||2010-06-24|2010-06-25|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Aquatic Power Training|Optimizing Mobility in Older Adults With Knee Osteoarthritis: Aquatic Power Training|Completed||N/A|81|Actual|University of Iowa||1|||f||||f||||||||||2018-06-01 00:58:07.327492|2018-06-01 00:58:07.327492
NCT00904306|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2012-04-02|2009-05-18|2009-05-19|Estimate|||||||2012-04-02|2012-04-03|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|BEACh||Binge Eating and Chromium Study|Chromium Picolinate in Binge Eating Disorder: A Feasibility Study|Completed||Phase 1/Phase 2|26|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-06-01 00:58:07.391086|2018-06-01 00:58:07.391086
NCT00904293|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2016-05-05|2009-05-18|2009-05-19|Estimate|||||||2016-05-05|2016-05-06|Estimate|August 2008||2008-08-31|October 2013|2013-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|WARFPGX||Genotype-Guided Warfarin Therapy Trial|Randomized Controlled Trial of Genotype-Guided Dosing of Warfarin Therapy|Completed||N/A|109|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:58:07.467158|2018-06-01 00:58:07.467158
NCT00904280|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-18|2009-05-18|2009-05-19|Estimate|||||||2009-05-18|2009-05-19|Estimate|March 2001||2001-03-31|March 2009|2009-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy|An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy of Numorphan® CR (Oxymorphone HCL Controlled Release) in Subjects With Cancer Pain or Chronic Lower Back Pain.|Completed||Phase 3|239|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:58:07.541559|2018-06-01 00:58:07.541559
NCT00904254|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2012-02-02|2009-05-18|2009-05-19|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2015||2015-01-31|February 2012|2012-02-29|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||The Use of Anti-CD4 mAb-Fragment for Imaging of Local Inflammation in Patients With Carotid Artery Stenosis|The Use of Anti-CD4 mAb-Fragment for Imaging of Local Inflammation in Patients With Asymptomatic and Symptomatic Carotid Artery Stenosis - an Open Proof of Concept Study.|Unknown status|Not yet recruiting|Phase 2|21|Anticipated|Technische Universität Dresden||1|||f||||t||||||||||2018-06-01 00:58:07.602012|2018-06-01 00:58:07.602012
NCT00904241|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-16|||2017-04-11|2009-05-16|2009-05-19|Estimate|||||||2017-04-11|2017-04-13|Actual|November 2000||2000-11-30|April 2017|2017-04-30||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma|Neuroblastoma Biology Studies|Recruiting|||10000|Anticipated|Children's Oncology Group|||1||f||||t||||||Samples With DNA|"~     frozen tumor tissue, diagnostic bone marrow, diagnostic blood~   "|||2018-06-01 00:58:07.73853|2018-06-01 00:58:07.73853
NCT00904228|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2010-06-24|2009-05-15|2009-05-19|Estimate|||||||2010-06-24|2010-06-28|Estimate|September 2008||2008-09-30|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Plastic Hat Trial to Prevent Hypothermia in Preterm Newborns in the Delivery Room|Effectiveness of Plastic Lined Hats for Prevention of Hypothermia in Premature Newborns in the Delivery Room|Unknown status|Recruiting|N/A|260|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 00:58:08.630962|2018-06-01 00:58:08.630962
NCT00904215|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2009-05-22||2014-04-03|2009-05-18|2009-05-19|Estimate|2009-07-21|2009-08-31|Estimate||||2014-04-03|2014-04-21|Estimate|February 2005||2005-02-28|April 2014|2014-04-30||||May 2007|Actual|2007-05-31||Observational|||An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension|A Post Marketing Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension|Completed|||1095|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 00:58:08.714763|2018-06-01 00:58:08.714763
NCT00904202|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|January 2003||2003-01-31|February 2010|2010-02-28||||June 2003|Actual|2003-06-30||Interventional|||A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions|Completed||Phase 4|62|Actual|Endo Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:58:08.904868|2018-06-01 00:58:08.904868
NCT00903149|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2016-03-29|2009-05-14|2009-05-18|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2007||2007-01-31|March 2016|2016-03-31|January 2012|Actual|2012-01-31|February 2010|Actual|2010-02-28||Observational|2007/2/0150||Long-term Effect of The Mother Infant Transaction Program (MITP)|Long-term Effect of The Mother Infant Transaction Program (MITP)|Completed|||88|Actual|Oslo University Hospital|||1||f||||t||||||||||2018-06-01 00:58:26.232163|2018-06-01 00:58:26.232163
NCT00904189|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2014-12-24||2015-09-18|2009-05-18|2009-05-19|Estimate|2015-09-18|2015-10-19|Estimate||||2015-09-18|2015-10-19|Estimate|November 2007||2007-11-30|September 2015|2015-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Measurement of the Radiation Dose Cuticles Using Electron Paramagnetic Resonance (EPR)|Measurement of the Radiation Dose Cuticles Using Electron Paramagnetic Resonance (EPR) Spectroscopy|Terminated||N/A|2|Actual|University of Rochester||1||PI has relocated|f||||f||||||||||2018-06-01 00:58:09.026767|2018-06-01 00:58:09.026767
NCT00904176|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2016-10-14|2009-05-18|2009-05-19|Estimate|||||||2016-10-14|2016-10-17|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects|Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects|Completed||Phase 1|30|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:58:09.162158|2018-06-01 00:58:09.162158
NCT00904163|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2014-05-15|2009-05-18|2009-05-19|Estimate|||||||2014-05-15|2014-05-16|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa|Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa|Completed|||13|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     Skin biopsies, serum~   "|||2018-06-01 00:58:09.243654|2018-06-01 00:58:09.243654
NCT00904150|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|2013-09-08||2014-02-18|2009-05-18|2009-05-19|Estimate|2014-02-18|2014-02-24|Estimate||||2014-02-18|2014-02-24|Estimate|November 2007||2007-11-30|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Study of the Molecular Genetics of Menstrual Migraine|A Case-control Study of the Molecular Genetics of Menstrual Migraine (Pure Menstrual and Menstrually-related Migraine)|Completed|||585|Actual|The City of London Migraine Clinic|||2||f||||f||||||Samples With DNA|"~     Saliva Whole Blood~   "|||2018-06-01 00:58:09.312101|2018-06-01 00:58:09.312101
NCT00904137|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2018-01-08|2009-05-18|2009-05-19|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2009||2009-05-31|January 2018|2018-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Treatment of Type I Supracondylar Fractures of the Humerus|Taping Versus Splinting Versus Above Elbow Casting for Type I Supracondylar Fractures of the Humerus in Children: A Randomized Controlled Trial|Terminated||N/A|12|Actual|University of British Columbia||3||"We were unable to recruit the appropriate numbers as parents did not want to randomize their~   child for the treatments options."|f||||f||||||||||2018-06-01 00:58:09.622443|2018-06-01 00:58:09.622443
NCT00904124|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2010-05-10|2009-05-18|2009-05-19|Estimate|||||||2010-05-10|2010-05-11|Estimate|May 2009||2009-05-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|July 2009|Actual|2009-07-31||Interventional|||The Effect of Different Types of Dietary Fiber on Satiation|Determination of the Effect of Different Types of Isolated Dietary Fiber on ad Libitum Food Intake in Healthy Human Subjects|Completed||N/A|123|Actual|Wageningen University||6|||f||||f||||||||||2018-06-01 00:58:09.7051|2018-06-01 00:58:09.7051
NCT00904111|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2013-12-05|2009-05-18|2009-05-19|Estimate|||||||2013-12-05|2013-12-06|Estimate|August 2004||2004-08-31|February 2010|2010-02-28||||October 2005|Actual|2005-10-31||Interventional|||A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain|A Randomized, Double-blind Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain|Completed||Phase 2|215|Actual|Endo Pharmaceuticals||2|||f||||||||||||||2018-06-01 00:58:09.768018|2018-06-01 00:58:09.768018
NCT00904098|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|September 2005||2005-09-30|February 2010|2010-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine|Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment)Of Menstrual Migraine|Completed||Phase 4|192|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:58:09.886044|2018-06-01 00:58:09.886044
NCT00904085|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|April 2003||2003-04-30|February 2010|2010-02-28|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Post-operative Efficacy and Safety Study|A Randomized, Double-blind Evaluation of the Analgesic Efficacy and Safety of a Low Dose Oxymorphone Immediate Release in Patients Following Ambulatory Arthroscopic Knee Surgery|Completed||Phase 3|122|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 00:58:10.073179|2018-06-01 00:58:10.073179
NCT00904072|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2009-05-18|2009-05-18|2009-05-19|Estimate|||||||2009-05-18|2009-05-19|Estimate|February 2009||2009-02-28|May 2009|2009-05-31||||||||Observational|||Integrated Novel Clinical Decision Support System (CDSS) in a Computerized Physician Order Entry System|Integrated a Novel Clinical Decision Support System (CDSS) in a Computerized Physician Order Entry System|Unknown status|Recruiting||50000|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 00:58:10.174241|2018-06-01 00:58:10.174241
NCT00904059|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2011-01-06|2009-05-18|2009-05-19|Estimate|||||||2011-01-06|2011-01-07|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Drug-Drug Interaction Study in Healthy Subjects|Open-Label, Randomized, Multiple-Dose, Drug-Drug Interaction Study to Assess the Pharmacokinetics and Safety of BMS-790052 and BMS-650032 Co-administered in Healthy Subjects|Completed||Phase 1|28|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:58:10.259146|2018-06-01 00:58:10.259146
NCT00904046|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2018-05-18|2009-05-18|2009-05-19|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2009||2009-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|IUAN||Pathophysiology of Uric Acid Nephrolithiasis|Pathophysiology of Uric Acid Nephrolithiasis|Recruiting||N/A|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-06-01 00:58:10.351406|2018-06-01 00:58:10.351406
NCT00904033|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2018-03-16|2009-05-15|2009-05-19|Estimate|||||||2018-03-16|2018-03-19|Actual|December 1, 2008|Actual|2008-12-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Calcitriol, Physical Activity, and Bone Health in Cancer Survivors|A Pilot Study of the Effects of High-Dose Oral Calcitriol and Physical Activity on Bone Health in Breast Cancer Survivors|Completed||Phase 2|54|Actual|University of Rochester||4|||f||||t||||||||||2018-06-01 00:58:10.44151|2018-06-01 00:58:10.44151
NCT00904020|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|June 2002||2002-06-30|February 2010|2010-02-28||||November 2002|Actual|2002-11-30||Interventional|||A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain|A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain|Completed||Phase 4|107|Actual|Endo Pharmaceuticals||1|||f||||||||||||||2018-06-01 00:58:10.520724|2018-06-01 00:58:10.520724
NCT00904007|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2014-08-11||2015-04-06|2009-05-18|2009-05-19|Estimate|2014-08-11|2014-08-26|Estimate||||2015-04-06|2015-04-24|Estimate|February 2010||2010-02-28|February 2015|2015-02-28|September 2014|Actual|2014-09-30|March 2012|Actual|2012-03-31||Interventional||Participants’ baseline demographic characteristics were similar between randomized cohorts.|Interactive Spaced Education to Optimize Hypertension Management|Interactive Spaced Education to Optimize Hypertension Management|Completed||N/A|111|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 00:58:10.624984|2018-06-01 00:58:10.624984
NCT00903994|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-18|2009-05-18|2009-05-19|Estimate|||||||2009-05-18|2009-05-19|Estimate|June 2007||2007-06-30|May 2009|2009-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|KTP||A Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee|An Open-Label, Phase II, Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee|Completed||Phase 2|17|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 00:58:10.870784|2018-06-01 00:58:10.870784
NCT00903981|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|||2010-04-22|2009-05-18|2009-05-19|Estimate|||||||2010-04-22|2010-04-23|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|ALERT||Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil|A Randomized, Placebo Controlled, Double Blind, Multicenter Therapeutic Confirmatory Clinical Study for the Evaluation of the Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction|Completed||Phase 3|208|Actual|JW Pharmaceutical||3|||f||||f||||||||||2018-06-01 00:58:10.953387|2018-06-01 00:58:10.953387
NCT00903968|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-18|2017-08-31||2017-10-12|2009-05-18|2009-05-19|Estimate|2017-08-31|2017-09-29|Actual||||2017-10-12|2017-11-14|Actual|May 2009||2009-05-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|58|Actual|Dana-Farber Cancer Institute||9|||f||||t||||||||||2018-06-01 00:58:11.136863|2018-06-01 00:58:11.136863
NCT00903955|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2013-02-06|2009-05-18|2009-05-19|Estimate|||||||2013-02-06|2013-02-07|Estimate|September 2006||2006-09-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease|SCCOR in Host Factors in Chronic Lung Disease|Completed|||100|Actual|University of North Carolina, Chapel Hill|||1||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:58:12.453205|2018-06-01 00:58:12.453205
NCT00903942|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2015-04-24|2009-05-18|2009-05-19|Estimate|||||||2015-04-24|2015-04-27|Estimate|March 2008||2008-03-31|April 2015|2015-04-30||||March 2012|Anticipated|2012-03-31||Interventional|||Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)|A Modified Two Stage Phase II Study of Combination Abraxane and Radiation for Stage III Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|University of Rochester||||funding was withdrawn from Drug company|f||||f||||||||||2018-06-01 00:58:12.514991|2018-06-01 00:58:12.514991
NCT00903929|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2016-04-01||2016-04-01|2009-05-18|2009-05-19|Estimate|2016-04-01|2016-05-05|Estimate||||2016-04-01|2016-05-05|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation|Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation|Completed||Phase 1|19|Actual|University of Rochester||1|||f||||t||||||||||2018-06-01 00:58:12.573864|2018-06-01 00:58:12.573864
NCT00903916|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-17|||2012-04-02|2009-05-18|2009-05-19|Estimate|||||||2012-04-02|2012-04-03|Estimate|August 2007||2007-08-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|ADAPT||Effect of Antipsychotics on Appetite Regulation|Effect of Weight-increasing Psychotropic Medications on Appetite Regulation|Completed|||45|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma~   "|||2018-06-01 00:58:12.742613|2018-06-01 00:58:12.742613
NCT00903903|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-18|2009-05-18|2009-05-19|Estimate|||||||2009-05-18|2009-05-19|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Observational|||Computer-Assisted Quantification of the Synovial Perfusion in Patients With Arthritis Using Two-Dimensional and Three-Dimensional Power Doppler Ultrasonography|Computer-Assisted Quantification of the Synovial Perfusion in Patients With Arthritis Using Two-Dimensional and Three-Dimensional Power Doppler Ultrasonography|Unknown status|Recruiting||100|Anticipated|Taichung Veterans General Hospital|||2||f||||t||||||||||2018-06-01 00:58:12.797056|2018-06-01 00:58:12.797056
NCT00903890|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2018-01-08|2009-05-18|2009-05-19|Estimate|||||||2018-01-08|2018-01-09|Actual|August 2008||2008-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma|Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma After Radiation Therapy/Anthracycline Chemotherapy|Active, not recruiting|||32|Actual|University of Rochester|||1||f||||f||||||||No||2018-06-01 00:58:12.847082|2018-06-01 00:58:12.847082
NCT00903877|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2017-04-03||2017-06-15|2009-05-18|2009-05-19|Estimate|2017-06-15|2017-07-14|Actual||||2017-06-15|2017-07-14|Actual|May 2009||2009-05-31|June 2017|2017-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Each participant received placebo followed by 25 mcg of T3.|Study of T3 for the Treatment of Fibromyalgia|T3 for Fibromyalgia: a Pilot Double-blind Non-randomized Clinical Trial|Completed||N/A|51|Actual|Stanford University||1|||f||||||||||||||2018-06-01 00:58:12.90432|2018-06-01 00:58:12.90432
NCT00903864|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-05-18|2009-05-18|2009-05-19|Estimate|||||||2009-05-18|2009-05-19|Estimate|February 2009||2009-02-28|May 2009|2009-05-31||||April 2009|Actual|2009-04-30||Observational|||Blood Pressure Monitor Clinical Test (Cuff Range: 22 cm-30 cm)|Blood Pressure Monitor Clinical Test (Cuff Range: 22 cm-30 cm)|Completed|||85|Actual|Andon Health Co., Ltd|||2||f||||||||||||||2018-06-01 00:58:14.000881|2018-06-01 00:58:14.000881
NCT00903851|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2010-02-12|2009-05-18|2009-05-19|Estimate|||||||2010-02-12|2010-02-15|Estimate|April 2002||2002-04-30|February 2010|2010-02-28||||June 2003|Actual|2003-06-30||Interventional|||Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy|A Prospective, Open-label Trial of Lidoderm® (Lidocaine Patch 5%)in Painful Diabetic and Idiopathic Neuropathy.|Completed||Phase 4|76|Actual|Endo Pharmaceuticals||1|||f||||||||||||||2018-06-01 00:58:14.043787|2018-06-01 00:58:14.043787
NCT00903838|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2011-08-25|2009-05-15|2009-05-18|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.|A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.|Terminated||Phase 2|37|Actual|Abbott||2||The study was terminated on 31 May, 2011, due to strategic considerations.|f||||f||||||||||2018-06-01 00:58:14.118339|2018-06-01 00:58:14.118339
NCT00903825|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2010-01-13|2009-05-14|2009-05-18|Estimate|||||||2010-01-13|2010-01-14|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Duplex Guided Application of Local Anesthetic Before Femoral Artery Catheterization|Optimization of Local Anesthetic Effect With Duplex Ultrasound Guided Injection of Lidocaine Before Femoral Artery Catheterization: A Prospective Randomized Controlled Trial|Completed||Phase 2/Phase 3|200|Actual|University of Patras||2|||f||||f||||||||||2018-06-01 00:58:14.202927|2018-06-01 00:58:14.202927
NCT00903812|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2014-07-14|2009-05-14|2009-05-18|Estimate|||||||2014-07-14|2014-07-16|Estimate|February 2007||2007-02-28|July 2014|2014-07-31|March 2014|Actual|2014-03-31|December 2008|Actual|2008-12-31||Observational|||IMPACT Non Hodgkins Lymphoma (NHL) Study|A Retrospective and Prospective Observational Study Reviewing Supportive Care Management of NHL Patients Treated With CHOP-14 or 21 Chemotherapy(With or Without Rituximab) (CHOP = Cyclophosphamide, Hydroxyrubicin (Adriamycin), Oncovin (Vincristine), Prednisone Chemotherapy )|Completed|||1837|Actual|Amgen|||1||f||||||||||None Retained|"~     This is an observational study. No bio-specimens are being collected.~      Time perspective - this study enrolls both retrospective and prospective subjects~   "|||2018-06-01 00:58:14.268324|2018-06-01 00:58:14.268324
NCT00903799|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2016-05-25|2009-05-14|2009-05-18|Estimate|||||||2016-05-25|2016-05-26|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|ENTERRA||Medico-economic Evaluation of ENTERRA Therapy|Clinical Efficacy and Efficiency of Gastric Electrical Stimulation (Enterra®) for Refractory Nausea and/or Vomiting|Completed||N/A|220|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-06-01 00:58:14.335676|2018-06-01 00:58:14.335676
NCT00903786|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2017-03-17|2009-05-15|2009-05-18|Estimate|||||||2017-03-17|2017-03-21|Actual|June 17, 2009|Actual|2009-06-17|March 2017|2017-03-31|October 31, 2016|Actual|2016-10-31|August 8, 2016|Actual|2016-08-08||Interventional|||A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)|A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)|Completed||Phase 2|21|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 00:58:14.512404|2018-06-01 00:58:14.512404
NCT00903773|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2010-12-16|2009-05-14|2009-05-18|Estimate|||||||2010-12-16|2010-12-17|Estimate|June 2009||2009-06-30|December 2010|2010-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.|A Phase I Open-label Trial to Investigate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Telaprevir.|Completed||Phase 1|24|Actual|Tibotec BVBA|||||f||||||||||||||2018-06-01 00:58:14.636396|2018-06-01 00:58:14.636396
NCT00903760|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2015-06-11|2009-05-15|2009-05-18|Estimate|||||||2015-06-11|2015-06-15|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)|A Randomized Study of Decitabine Alternating With Clofarabine Versus Decitabine Until Failure in Patients With Higher Risk Myelodysplastic Syndromes (MDS)|Completed||Phase 2|42|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 00:58:14.709966|2018-06-01 00:58:14.709966
NCT00903747|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-15|2009-05-15|2009-05-18|Estimate|||||||2009-05-15|2009-05-18|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters|A Phase I Thorough QT/QTc Study To Evaluate The Effect of Therapeutic and Supratherapeutic Multiple Doses of Prucalopride on Cardiac Repolarisation in Healthy Male and Female Volunteers|Completed||Phase 1|120|Actual|Movetis||2|||f||||f||||||||||2018-06-01 00:58:14.808646|2018-06-01 00:58:14.808646
NCT00903734|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2015-07-09|2009-05-15|2009-05-18|Estimate|||||||2015-07-09|2015-07-13|Estimate|April 2009||2009-04-30|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status|An Umbrella Protocol for Histology-Independent, Phase I Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status: Using Erlotinib Alone or in Combination With Cetuximab, Bortezomib, or Dasatinib to Overcome Resistance|Completed||Phase 1|16|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 00:58:14.886816|2018-06-01 00:58:14.886816
NCT00903721|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2015-07-29|2009-05-14|2009-05-18|Estimate|||||||2015-07-29|2015-07-30|Estimate|November 2008||2008-11-30|July 2015|2015-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)|Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation|Completed|||3806|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 00:58:14.965706|2018-06-01 00:58:14.965706
NCT00903708|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2012-07-27|2009-05-15|2009-05-18|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 2006||2006-09-30|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||LY2275796 in Advanced Cancer|A Phase I Dose-Escalation, Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous LY2275796 in Patients With Advanced Cancer|Completed||Phase 1|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:58:15.036352|2018-06-01 00:58:15.036352
NCT00903695|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-07-26||2012-01-25|2009-05-15|2009-05-18|Estimate|2012-01-25|2012-01-26|Estimate||||2012-01-25|2012-01-26|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|MemoryXL||MemoryXL Effects on Mild Cognitive Impairment Patients|Nutriceutical Effects on Cognitive Status in Mild Cognitive Impairment Patients|Terminated||Phase 2|10|Actual|University of Oklahoma|Benefits of study did not appear to outweigh subject inconvenience, so study was stopped prematurely. Also, very few 'healthy' MCI subjects were recruited from the clinic population; vast majority of MCI patients had exclusionary medical problems.|2||Risk/benefit ratio did not indicate further study would be useful, or fair to future subjects.|f||||t||||||||||2018-06-01 00:58:15.135525|2018-06-01 00:58:15.135525
NCT00903682|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-02-10||2013-01-07|2009-05-14|2009-05-18|Estimate|2011-02-10|2011-03-07|Estimate||||2013-01-07|2013-01-14|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|SENSE||A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients|A Phase IIb, Multi-centre, Randomised, Double-blind, Active-controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects|Completed||Phase 2|157|Actual|Janssen-Cilag International NV||2|||f||||t||||||||||2018-06-01 00:58:15.532056|2018-06-01 00:58:15.532056
NCT00903669|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-05-14|2009-05-14|2009-05-18|Estimate|||||||2009-05-14|2009-05-18|Estimate|January 2005||2005-01-31|May 2009|2009-05-31|February 2006|Actual|2006-02-28|September 2005|Actual|2005-09-30||Observational|PF||Anthropometric Angular Measurement to Determine Muscle Tonus in Patients With Peripheral Facial Paralysis|Anthropometric Angular Measurement to Determine Muscle Tonus in Patients With Peripheral Facial Paralysis|Completed|||20|Actual|University of Campinas, Brazil|||1||f||||f||||||||||2018-06-01 00:58:16.251411|2018-06-01 00:58:16.251411
NCT00903656|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2013-12-23|2009-05-15|2009-05-18|Estimate|||||||2013-12-23|2013-12-24|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy|Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy - a Phase II Study|Terminated||Phase 2|24|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||1||Caelyx was not available anymore|f||||f||||||||||2018-06-01 00:58:16.361127|2018-06-01 00:58:16.361127
NCT00903643|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2014-07-19|2009-05-15|2009-05-18|Estimate|||||||2014-07-19|2014-07-22|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Sensory Processing in Subjects With Painful Bladder Syndrome|Sensory Processing in Subjects With Painful Bladder Syndrome|Completed|||34|Actual|University of Alabama at Birmingham|||2||f||||t||||||||||2018-06-01 00:58:16.435787|2018-06-01 00:58:16.435787
NCT00903630|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2015-04-22||2017-12-03|2009-05-15|2009-05-18|Estimate|2016-11-21|2017-01-18|Estimate||||2017-12-03|2017-12-28|Actual|April 2009||2009-04-30|December 2017|2017-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||One of the 4 subjects enrolled in the Phase 2 portion of the study was removed from the study 2 weeks after the start of treatment due to a skin rash leaving 9 evaluable subjects for the Phase 2 analysis. All 15 subjects from both the Phase 1 and Phase 2 portions of the trial were included in the Serious and Non-Serious Adverse Events analysis.|Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Phase I/II Trial of Lenalidomide in Combination With Liposomal Doxorubicin for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Terminated||Phase 1/Phase 2|15|Actual|Masonic Cancer Center, University of Minnesota||3||lack of funding|f||||t||||||||||2018-06-01 00:58:16.534416|2018-06-01 00:58:16.534416
NCT00903617|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2017-07-19|2011-03-17|2017-08-22|2009-05-14|2009-05-18|Estimate|2017-08-22|2017-09-21|Actual|2011-03-17|2011-03-28|Estimate|2017-08-22|2017-09-21|Actual|June 15, 2009|Actual|2009-06-15|August 2017|2017-08-31|February 16, 2010|Actual|2010-02-16|February 16, 2010|Actual|2010-02-16||Interventional|||Study to Test GSK256073 in Patients With Dyslipidemia|A Two Part, Multicenter Phase IIa, Placebo Controlled Study, to Examine the Safety, Tolerability, and Effects of GSK256073 on Lipids in Subjects With Dyslipidemia|Completed||Phase 2|80|Actual|GlaxoSmithKline|The study was stopped for futility at the end of Part A due to lack of a compelling PK/PD relationship between GSK256073 and lipid effects that would predict success in achieving significant HDLc raising.|8|||f||||f||||||||||2018-06-01 00:58:17.036393|2018-06-01 00:58:17.036393
NCT00903604|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2011-05-16|2009-05-15|2009-05-18|Estimate|||||||2011-05-16|2011-05-17|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Completed||Phase 2|42|Actual|Action Pharma A/S||2|||f||||t||||||||||2018-06-01 00:58:18.554468|2018-06-01 00:58:18.554468
NCT00903591|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2018-04-20|2009-05-15|2009-05-18|Estimate|||||||2018-04-20|2018-04-23|Actual|May 2009|Actual|2009-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Study of Radiation Exposure and Bilateral Breast Cancer|Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer|Active, not recruiting|||1699|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     blood sample or saliva sample~   "|||2018-06-01 00:58:18.639737|2018-06-01 00:58:18.639737
NCT00903578|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2009-12-16|2009-05-15|2009-05-18|Estimate|||||||2009-12-16|2009-12-17|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients|Impact of FGF-23 and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients|Unknown status|Active, not recruiting||200|Anticipated|Ramathibodi Hospital|||1||f||||f||||||Samples With DNA|"~     serum~   "|||2018-06-01 00:58:18.728415|2018-06-01 00:58:18.728415
NCT00903565|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2017-06-26|2009-05-15|2009-05-18|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2008||2008-09-30|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PARSC||A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint|A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint|Active, not recruiting|||1200|Anticipated|Agendia|||||f||||f||||||||||2018-06-01 00:58:18.794937|2018-06-01 00:58:18.794937
NCT00903552|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14||2013-07-16|2013-07-16|2009-05-15|2009-05-18|Estimate||||2013-07-16|2013-07-18|Estimate|2013-07-16|2013-07-18|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)|A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults|Completed||Phase 2|221|Actual|Novavax||3|||f||||f||||||||||2018-06-01 00:58:18.899018|2018-06-01 00:58:18.899018
NCT00903539|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2012-01-26|2009-05-14|2009-05-18|Estimate|||||||2012-01-26|2012-01-31|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|SecurAcath||Prospective SecurAcath Subcutaneous Securement Trial|Prospective SecurAcath Subcutaneous Securement Clinical Trial|Completed|||217|Actual|Interrad Medical|||||f||||f||||||||||2018-06-01 00:58:18.964345|2018-06-01 00:58:18.964345
NCT00903526|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-15|2009-05-15|2009-05-18|Estimate|||||||2009-05-15|2009-05-18|Estimate|March 2009||2009-03-31|May 2009|2009-05-31||||||||Observational|||Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital|Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital|Unknown status|Active, not recruiting||250|Anticipated|University of Modena and Reggio Emilia|||1||f||||||||||||||2018-06-01 00:58:19.024032|2018-06-01 00:58:19.024032
NCT00903500|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-18|2009-05-15|2009-05-18|Estimate|||||||2009-05-18|2009-05-19|Estimate|July 2007||2007-07-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Controlled Outcome Evaluations of a Daily Physical Activity Intervention for Individuals With Type 2 Diabetes|Controlled Outcome Evaluations of a Daily Physical Activity Intervention for Individuals With Type 2 Diabetes|Completed||N/A|92|Actual|University Ghent||2|||f||||f||||||||||2018-06-01 00:58:19.074769|2018-06-01 00:58:19.074769
NCT00903474|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2015-06-03|2009-05-15|2009-05-18|Estimate|||||||2015-06-03|2015-06-08|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Mindful Movement Program in Improving Quality of Life in Older Female Breast Cancer Survivors|Mindful Movement Program for Breast Cancer Survivors|Completed||N/A|49|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:58:19.150696|2018-06-01 00:58:19.150696
NCT00903461|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2017-02-14|2009-05-14|2009-05-18|Estimate|||||||2017-02-14|2017-02-15|Actual|April 2012||2012-04-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|March 2015|Actual|2015-03-31||Interventional|||Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma|Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma|Terminated||Phase 1|7|Actual|University of Pittsburgh||1||drug supply issues|f||||t|t|f||||||||2018-06-01 00:58:19.218994|2018-06-01 00:58:19.218994
NCT00903448|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2010-08-04||2010-12-22|2009-05-15|2009-05-18|Estimate|2010-10-22|2010-11-22|Estimate||||2010-12-22|2010-12-31|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression|Comparison of Prilosec OTC® Versus Prevacid ® for Gastric Acid Suppression|Completed||Phase 4|40|Actual|Procter and Gamble||2|||f||||f||||||||||2018-06-01 00:58:19.37132|2018-06-01 00:58:19.37132
NCT00903435|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2011-11-30|2009-05-15|2009-05-18|Estimate|||||||2011-11-30|2011-12-01|Estimate|May 2007||2007-05-31|November 2011|2011-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Quantitative Studies of Urinary Bladder Sensation|Quantitative Studies of Urinary Bladder Sensation|Completed|||60|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 00:58:19.551135|2018-06-01 00:58:19.551135
NCT00903422|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2017-11-08|2009-05-14|2009-05-18|Estimate|||||||2017-11-08|2017-11-13|Actual|May 14, 2009|Actual|2009-05-14|November 2017|2017-11-30|December 5, 2013|Actual|2013-12-05|June 26, 2012|Actual|2012-06-26||Interventional|||Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)|Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)|Completed||Phase 1|98|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 00:58:19.620747|2018-06-01 00:58:19.620747
NCT00903409|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2009-06-12||2017-09-08|2009-05-14|2009-05-18|Estimate|2009-06-18|2009-08-04|Estimate||||2017-09-08|2017-10-09|Actual|November 15, 2005|Actual|2005-11-15|September 2017|2017-09-30|June 27, 2008|Actual|2008-06-27|June 27, 2008|Actual|2008-06-27||Interventional|||Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects|OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects|Completed||Phase 3|188|Actual|GlaxoSmithKline|Only Adverse Experience categories with a greater than 5% occurrence in any group were reported in the AE table.|2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:58:19.786065|2018-06-01 00:58:19.786065
NCT00903396|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|2016-12-07||2017-10-20|2009-05-15|2009-05-18|Estimate|2016-12-07|2017-02-01|Estimate||||2017-10-20|2017-11-24|Actual|September 2009|Actual|2009-09-30|October 2017|2017-10-31|May 2013|Actual|2013-05-31|January 2011|Actual|2011-01-31||Interventional||Not enough patients were accrued. In order to avoid identification of patients, no results will be entered.|Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer|A Pilot Phase II, Randomized, Double Blind Trial of Palonosetron Versus Placebo to Prevent Radiation Therapy Induced Nausea and Vomiting|Terminated||Phase 2|7|Actual|Alliance for Clinical Trials in Oncology||4||Slow accrual|f||||f||||||||||2018-06-01 00:58:20.564709|2018-06-01 00:58:20.564709
NCT00903383|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-10-03||2011-11-11|2009-05-14|2009-05-18|Estimate|2011-11-11|2011-12-15|Estimate||||2011-11-11|2011-12-15|Estimate|July 2009||2009-07-31|November 2011|2011-11-30||||September 2010|Actual|2010-09-30||Interventional|||Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate|A Phase 2, Multi-center, Randomized, Double Blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy|Completed||Phase 2|208|Actual|Lexicon Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:58:20.964859|2018-06-01 00:58:20.964859
NCT00903370|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2016-09-30||2016-12-09|2009-05-15|2009-05-18|Estimate|2016-09-30|2016-11-22|Estimate||||2016-12-09|2017-02-06|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Surgical Ablation Versus No Surgical Ablation for Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery|Surgical Ablation Versus No Surgical Ablation for Patients With Persistent or Longstanding Persistent Atrial Fibrillation (AF) Undergoing Mitral Valve Surgery|Completed||Phase 2|260|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 00:58:21.38007|2018-06-01 00:58:21.38007
NCT00903357|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-07-08||2015-11-16|2009-05-14|2009-05-18|Estimate|2012-08-15|2012-09-13|Estimate||||2015-11-16|2015-12-14|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|April 2011|Actual|2011-04-30|August 2010|Actual|2010-08-31||Interventional|||The Effectiveness of Montelukast on Atopic Dermatitis in Koreans|A Double Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Koreans|Completed||N/A|54|Actual|Soonchunhyang University Hospital||2|||f||||t||||||||||2018-06-01 00:58:21.735994|2018-06-01 00:58:21.735994
NCT00903344|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2014-05-22||2014-08-04|2009-05-15|2009-05-18|Estimate|2014-08-04|2014-08-18|Estimate||||2014-08-04|2014-08-18|Estimate|December 2009||2009-12-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Impact of Vitamin D Supplementation on Lactation Associated Bone Loss|Impact of Vitamin D Supplementation on Lactation Associated Bone Loss|Completed||N/A|22|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 00:58:21.893026|2018-06-01 00:58:21.893026
NCT00903331|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2013-10-29|2012-09-27|2014-01-02|2009-05-15|2009-05-18|Estimate|2014-01-02|2014-02-17|Estimate|2012-09-27|2012-10-01|Estimate|2014-01-02|2014-02-17|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|MUSIC||Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study|A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Macitentan in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|178|Actual|Actelion||2|||f||||t||||||||||2018-06-01 00:58:22.240296|2018-06-01 00:58:22.240296
NCT00903318|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2017-02-10|2009-05-15|2009-05-18|Estimate|||||||2017-02-10|2017-02-13|Actual|May 15, 2009|Actual|2009-05-15|February 2017|2017-02-28|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Observational|||Male:Female Birth Ratios and Phthalate Levels|Male:Female Birth Ratios and Phthalate Levels Along The Rural Lower Rio Grande Valley (Hidalgo County) and in Baytown, Texas|Completed|||300|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Urine sample.~   "|||2018-06-01 00:58:22.85779|2018-06-01 00:58:22.85779
NCT00903305|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2013-01-30|2009-05-15|2009-05-18|Estimate|||||||2013-01-30|2013-02-01|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Nurse-Provided Care or Standard Care in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer|A Standard Nursing Intervention Protocol for Breast Cancer as a Chronic Illness|Withdrawn||N/A|0|Actual|City of Hope Medical Center||2|||f||||||||||||||2018-06-01 00:58:22.931517|2018-06-01 00:58:22.931517
NCT00903292|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-15|2009-05-15|2009-05-18|Estimate|||||||2009-05-15|2009-05-18|Estimate|March 2009||2009-03-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|April 2010|Anticipated|2010-04-30||Interventional|||Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma|Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma|Unknown status|Recruiting|N/A|52|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-06-01 00:58:23.007753|2018-06-01 00:58:23.007753
NCT00903279|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2017-01-30|2009-05-14|2009-05-18|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2009||2009-08-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|||||Interventional|TOPS-MRSA||Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery|Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery (TOPS-MRSA)|Withdrawn||Phase 2|0|Actual|Bay Pines VA Healthcare System||2||Funding|f||||t||||||||||2018-06-01 00:58:23.091177|2018-06-01 00:58:23.091177
NCT00903266|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2018-01-07|2009-05-15|2009-05-18|Estimate|||||||2018-01-07|2018-01-09|Actual|February 2008||2008-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia|Behavioral and Neural Correlates of Melodic-Intonation-Therapy (MIT) and Speech-Repetition-Therapy (SRT) for Patients With Non-fluent Aphasia|Recruiting||Phase 3|30|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||f||||||||||2018-06-01 00:58:23.171396|2018-06-01 00:58:23.171396
NCT00903253|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-09-08|2009-05-14|2009-05-18|Estimate|||||||2009-09-08|2009-09-10|Estimate|May 2009||2009-05-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers|A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers|Completed||Phase 1|40|Anticipated|Link Medicine Corporation|||||f||||t||||||||||2018-06-01 00:58:23.260093|2018-06-01 00:58:23.260093
NCT00903240|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2011-06-07|2009-05-15|2009-05-18|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Observational|||Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer|Phase 3 Study of Bladder Cancer Recurrence Surveillance|Completed|||1000|Anticipated|Predictive Biosciences|||||f||||f||||||Samples With DNA|"~     The specimens to be retained are urine only~   "|||2018-06-01 00:58:23.313129|2018-06-01 00:58:23.313129
NCT00903227|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2016-10-24|2009-05-14|2009-05-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis|A Proof Of Concept Study To Assess The Steroid Sparing Effect Of Combined Nasal And Inhaled Corticosteroid In Patients With Asthma And Persistent Rhinitis|Completed||Phase 4|25|Actual|University of Dundee||3|||f||||f||||||||||2018-06-01 00:58:23.384853|2018-06-01 00:58:23.384853
NCT00903214|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2013-04-25|2009-05-15|2009-05-18|Estimate|||||||2013-04-25|2013-04-29|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer|Metabotropic Glutamate Receptor-1 (mGluR1): Validation of a Serendipitously Discovered Molecular Target for Breast Cancer Treatment|Withdrawn||Phase 1|0|Actual|Barbara Ann Karmanos Cancer Institute||||Funding ended|f||||t||||||||||2018-06-01 00:58:23.47582|2018-06-01 00:58:23.47582
NCT00903201|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2017-08-31|2012-03-15|2017-10-16|2009-05-14|2009-05-18|Estimate|2017-10-16|2017-11-17|Actual|2012-03-15|2012-03-19|Estimate|2017-10-16|2017-11-17|Actual|September 28, 2009|Actual|2009-09-28|August 2017|2017-08-31|December 29, 2010|Actual|2010-12-29|December 29, 2010|Actual|2010-12-29||Interventional|||28 Day Repeat Dose in Cystic Fibrosis Patients|A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients With Cystic Fibrosis.|Completed||Phase 2|146|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:58:23.573797|2018-06-01 00:58:23.573797
NCT00903188|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2009-05-15|2009-05-15|2009-05-18|Estimate|||||||2009-05-15|2009-05-18|Estimate|October 2008||2008-10-31|May 2009|2009-05-31|April 2015|Anticipated|2015-04-30|April 2010|Anticipated|2010-04-30||Interventional|CISTCERT||Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation|Impact of Cyclosporine or Steroid Withdrawal at 3 Months Post Transplantation on Graft Function, Patient Survival and Cardiovascular Surrogate Markers the First 5 Years After Renal Transplantation.|Unknown status|Recruiting|Phase 4|152|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||||2018-06-01 00:58:24.441198|2018-06-01 00:58:24.441198
NCT00903175|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2016-05-20||2016-10-04|2009-05-14|2009-05-18|Estimate|2016-05-20|2016-06-28|Estimate||||2016-10-04|2016-11-08|Estimate|October 2009||2009-10-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RECORD-3|The Full Analysis Set (FAS) consists of all randomized patients. Following the intent-to-treat principle, patients are analyzed according to the treatment sequence and stratum they were assigned to at randomization.|Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma|An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.|Completed||Phase 2|471|Actual|Novartis|PRO Tools - completed on Days 1 & 28 of a cycle. Assessments on D1 coincided with end of a 14-day break for patients on sunitinib but not everolimus. So D1 assessments of patients in sunitinib arm may be less impacted by potential toxicity effects.|2|||f||||t||||||||||2018-06-01 00:58:24.700278|2018-06-01 00:58:24.700278
NCT00903162|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2015-06-19||2016-03-18|2009-05-15|2009-05-18|Estimate|2016-01-03|2016-02-04|Estimate||||2016-03-18|2016-04-18|Estimate|May 2009||2009-05-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional||Enrolled participants.|Extended Endocrine Therapy for Premenopausal Women With Breast Cancer|Extended Endocrine Therapy for Premenopausal Women With Breast Cancer|Completed||Phase 2|17|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 00:58:26.080498|2018-06-01 00:58:26.080498
NCT00903136|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-15|||2014-01-09|2009-05-15|2009-05-18|Estimate|||||||2014-01-09|2014-01-10|Estimate|May 2009||2009-05-31|February 2010|2010-02-28||||December 2011|Anticipated|2011-12-31||Interventional|||Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus|Screening for Barrett's Esophagus With an Ultrathin Scanning Fiber Endoscope|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:58:26.279774|2018-06-01 00:58:26.279774
NCT00903110|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2018-04-27|2009-05-14|2009-05-15|Estimate|||||||2018-04-27|2018-04-30|Actual|December 2008||2008-12-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|EuIGFD||European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry|European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database: a European Registry for Monitoring Long Term Safety and Efficacy of Increlex®. Eu-IGFD|Recruiting|||330|Anticipated|Ipsen|||||f||||t||||||None Retained|"~     Study Design Time Perspective: Retrospective and Prospective~   "|||2018-06-01 00:58:26.343859|2018-06-01 00:58:26.343859
NCT00903084|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-04-02|2009-05-13|2009-05-15|Estimate|||||||2015-04-02|2015-04-06|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Examining Hair to Determine Tenofovir Exposure|A Phase 1 Pharmacokinetic Study of Varying Dosing Patterns on Tenofovir Concentrations in Hair|Completed||Phase 1|24|Actual|Public Health Foundation Enterprises, Inc.||6|||f||||f||||||||||2018-06-01 00:58:26.403789|2018-06-01 00:58:26.403789
NCT00903071|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2014-06-12|2009-05-14|2009-05-15|Estimate|||||||2014-06-12|2014-06-16|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|December 2011|Actual|2011-12-31||Interventional|PPL||Personalized Physician Learning to Improve Hypertension Care|Personalized Physician Learning Intervention to Improve Hypertension Care|Completed||N/A|130|Actual|HealthPartners Institute||3|||f||||t||||||||||2018-06-01 00:58:26.598832|2018-06-01 00:58:26.598832
NCT00903058|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:58:26.67067|2018-06-01 00:58:26.67067
NCT00903045|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|January 2005||2005-01-31|May 2009|2009-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder|Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder: PRopiverine Study on Overactive Bladder Including Urgency Data (PROUD)|Completed||Phase 4|264|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:58:26.703823|2018-06-01 00:58:26.703823
NCT00903032|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2014-12-03||2015-04-06|2009-05-14|2009-05-15|Estimate|2014-12-29|2015-01-09|Estimate||||2015-04-06|2015-04-27|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|MEDICATION||Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization|Patient-Centered Adherence Intervention After ACS Hospitalization|Completed||N/A|253|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 00:58:26.788167|2018-06-01 00:58:26.788167
NCT00903019|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-03-20|2009-05-13|2009-05-15|Estimate|||||||2015-03-20|2015-03-23|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Feasibility of Telehealth Problem-Solving Therapy for Depressed Homebound Older Adults|Telehealth Problem-Solving Therapy for Depressed Homebound Older Adults|Completed||N/A|158|Actual|University of Texas at Austin||3|||f||||f||||||||||2018-06-01 00:58:27.073517|2018-06-01 00:58:27.073517
NCT00903006|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2014-06-27||2015-01-21|2009-05-14|2009-05-15|Estimate|2015-01-21|2015-02-02|Estimate||||2015-01-21|2015-02-02|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer|A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer|Terminated||Phase 1/Phase 2|11|Actual|M.D. Anderson Cancer Center|Study terminated early due to small sample size.|4||Low Accrual|f||||t||||||||||2018-06-01 00:58:27.153928|2018-06-01 00:58:27.153928
NCT00902993|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-09-30|2009-05-14|2009-05-15|Estimate|||||||2009-09-30|2009-10-01|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|||||Interventional|||Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Male and Non-fertile Female, Young and Elderly Healthy Volunteers, After Oral Multiple Ascending Doses|Completed||Phase 1|80|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 00:58:27.652823|2018-06-01 00:58:27.652823
NCT00902980|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2014-09-17|2009-05-14|2009-05-15|Estimate|||||||2014-09-17|2014-09-18|Estimate|April 2005||2005-04-30|September 2014|2014-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics|Regional Transplant Programs Study of Immunosuppressive Therapy Related Toxicities in Renal Transplant Recipients Managed at Regional or Satellite Community Nephrology Clinics|Completed|||264|Actual|Astellas Pharma Inc|||2||f||||f||||||||||2018-06-01 00:58:27.728552|2018-06-01 00:58:27.728552
NCT00902967|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-06-01|2009-05-14|2009-05-15|Estimate|||||||2009-06-01|2009-06-03|Estimate|July 2009||2009-07-31|June 2009|2009-06-30|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Interventional|A4S||Study To Check The Analgesic And Anti-Inflammatory Effects Of Atorvastatin In Patients Undergoing Abdominal Surgery|A Randomized Double Blind Study Of The Evaluation Of The Potential Analgesic And Anti-Inflammatory Effects Of Atorvastatin In Patients Undergoing Abdominal Surgery|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|B. J. Medical College, Pune||2|||f||||f||||||||||2018-06-01 00:58:27.803446|2018-06-01 00:58:27.803446
NCT00902954|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Interventional|LEANEX||Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer|A Randomized Trial, Phase IIIb, Open Label Study of Exemestane After Two to Three Years of Anastrozole/Letrozole Treatment of Postmenopausal Women With Hormone Receptor Positive Breast Cancer|Unknown status|Recruiting|Phase 3|540|Anticipated|Fudan University||2|||f||||f||||||||||2018-06-01 00:58:28.891012|2018-06-01 00:58:28.891012
NCT00902941|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2012-02-06|2009-05-14|2009-05-15|Estimate|||||||2012-02-06|2012-02-07|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline|Reversibility of Olfactory Loss in Patients With Idiopathic Parkinson's Disease Following Treatment With Rasagiline|Completed||Phase 4|34|Actual|Technische Universität Dresden||2|||f||||t||||||||||2018-06-01 00:58:28.965665|2018-06-01 00:58:28.965665
NCT00902928|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30||2011-08-02|2015-10-05|2009-05-14|2009-05-15|Estimate||||2011-08-02|2011-08-08|Estimate|2015-10-05|2015-10-27|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|ONYX-3||A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery|A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 Bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery|Completed||Phase 2/Phase 3|1992|Actual|Astellas Pharma Inc||5|||f||||t||||||||||2018-06-01 00:58:29.302329|2018-06-01 00:58:29.302329
NCT00902915|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2013-11-21|2009-05-14|2009-05-15|Estimate|||||||2013-11-21|2013-11-25|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure||Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Austrian Forum Against Cancer||1|||f||||||||||||||2018-06-01 00:58:29.61844|2018-06-01 00:58:29.61844
NCT00902902|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|July 2009|Anticipated|2009-07-31|December 2008|Actual|2008-12-31||Observational|||A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark|A Clinical Study of GP73 as a HCC Early Tumor Mark|Unknown status|Recruiting||0|Anticipated|Peking Union Medical College Hospital|||2||f||||f||||||Samples With DNA|"~     Human serum~   "|||2018-06-01 00:58:29.778988|2018-06-01 00:58:29.778988
NCT00902889|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2012-09-10|2009-05-14|2009-05-15|Estimate|||||||2012-09-10|2012-09-11|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease|Single Centre (Pilot) Study for Deep Brain Stimulation (DBS) of the Globus Pallidus in Huntington's Disease (HD)|Completed||Phase 1|6|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-06-01 00:58:29.843603|2018-06-01 00:58:29.843603
NCT00902876|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2012-02-06|2009-05-14|2009-05-15|Estimate|||||||2012-02-06|2012-02-07|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|MCT-Recession||A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions|A Randomized Controlled Clinical Trial to Evaluate Safety and Effectiveness of CAF + Mucograft® Compared to CAF Alone in Patients With Gingival Recessions.|Completed||N/A|45|Actual|Geistlich Pharma AG||1|||f||||t||||||||||2018-06-01 00:58:29.94274|2018-06-01 00:58:29.94274
NCT00902863|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2010-05-06|2009-05-14|2009-05-15|Estimate|||||||2010-05-06|2010-05-07|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|YOGA||Impact of a Course on Stress Reduction|The Impact of a Course on Stress Reduction Techniques on Satisfaction, Stress, Performance, and Quality of Life in Patients With Chronic Pain|Terminated||N/A|5|Actual|McMaster University||1||Unable to keep patients attending yoga sessions|f||||f||||||||||2018-06-01 00:58:30.024729|2018-06-01 00:58:30.024729
NCT00902850|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2015-02-13||2015-02-13|2009-05-14|2009-05-15|Estimate|2015-02-13|2015-03-02|Estimate||||2015-02-13|2015-03-02|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens|One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to 1-Day Acuvue TruEye Lenses|Completed||N/A|28|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 00:58:30.10965|2018-06-01 00:58:30.10965
NCT00902837|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2012-12-12|2009-05-14|2009-05-15|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects|Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee &/or Hip Taking Oxycodone Equivalent of 20 - 80 mg/Day as Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Subjects Taking Oxycodone Prolonged Release Tablets (OxyPR) Alone.|Completed||Phase 3|181|Actual|Mundipharma Research GmbH & Co KG||2|||f||||f||||||||||2018-06-01 00:58:30.302473|2018-06-01 00:58:30.302473
NCT00902824|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2013-02-08|2009-05-14|2009-05-15|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine|Phase I Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TBC-M4 (MVA Based HIV Vaccine) Alone or in a Prime-Boost Regimen With ADVAX, DNA HIV Vaccine|Completed||Phase 1|32|Actual|International AIDS Vaccine Initiative||3|||f||||t||||||||||2018-06-01 00:58:30.430225|2018-06-01 00:58:30.430225
NCT00902811|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|ACT||Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria|Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria|Unknown status|Recruiting|Phase 4|600|Anticipated|Medecins Sans Frontieres, Netherlands||5|||f||||f||||||||||2018-06-01 00:58:30.502802|2018-06-01 00:58:30.502802
NCT00902798|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2017-11-28|2009-05-13|2009-05-15|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2010|Actual|2010-08-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|April 2016|Actual|2016-04-30||Interventional|Perspectives||Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder|Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder|Completed||N/A|54|Actual|University of Pittsburgh||2|||f||||f|f|f||||||Yes|Data will be shared through the National Database for Autism Research|2018-06-01 00:58:30.613974|2018-06-01 00:58:30.613974
NCT00902785|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2010-11-09|2009-05-14|2009-05-15|Estimate|||||||2010-11-09|2010-11-10|Estimate|March 2008||2008-03-31|November 2010|2010-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||A Study Of Early Markers Of Choroidal Neovascularization|A Two-Year Exploratory, Observational, Non-Interventional Multicenter Study To Identify Early Markers Of Choroidal Neovascularization In Fellow Eyes Of Patients With Neovascular AMD In One Eye|Terminated|||100|Anticipated|Pfizer|||1||f||||f||||||||||2018-06-01 00:58:30.693302|2018-06-01 00:58:30.693302
NCT00902772|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-09-22|2009-05-14|2009-05-15|Estimate|||||||2009-09-22|2009-09-23|Estimate|May 2009||2009-05-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|||||Interventional|||Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users|A Single-Centre, Single-Dose, Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the AbusePotential of AZD7325 in Healthy Recreational CNS Depressant Users|Completed||Phase 1|100|Anticipated|AstraZeneca||7|||f||||f||||||||||2018-06-01 00:58:30.761041|2018-06-01 00:58:30.761041
NCT00902759|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2017-08-22|2009-05-14|2009-05-15|Estimate|||||||2017-08-22|2017-08-24|Actual|January 9, 2009|Actual|2009-01-09|August 2017|2017-08-31|April 15, 2015|Actual|2015-04-15|January 7, 2011|Actual|2011-01-07||Interventional|||Fatigue and Pancreas and Bile Duct Cancer Study|Fatigue, Physical Functioning, and Quality of Life in Patients With Pancreatic and Periampullary Cancers Following Surgery, Chemotherapy, and/or Radiation Therapy|Completed||Early Phase 1|100|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-06-01 00:58:30.919172|2018-06-01 00:58:30.919172
NCT00902746|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2014-04-10||2014-05-15|2009-05-14|2009-05-15|Estimate|2014-05-15|2014-06-13|Estimate||||2014-05-15|2014-06-13|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Baseline analysis were carried out on 147 patients except 1 patients who has no available data of efficacy and safety in 148 cases that study drug administration was started.|Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis|Phase3, Open-Label, Long-Term, NSAID-Add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea Associated With Endometriosis.|Completed||Phase 3|149|Actual|Nobelpharma||1|||f||||t||||||||||2018-06-01 00:58:31.011391|2018-06-01 00:58:31.011391
NCT00902733|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2010-09-29|2009-05-14|2009-05-15|Estimate|||||||2010-09-29|2010-10-01|Estimate|July 2008||2008-07-31|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer|A Standardized Nursing Intervention Protocol for Pancreatic Cancer as a Chronic Illness|Completed||N/A|125|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 00:58:31.206517|2018-06-01 00:58:31.206517
NCT00902720|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2018-01-17|2009-05-14|2009-05-15|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2009|Actual|2009-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ovarian Tissue Freezing For Fertility Preservation|Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University|Recruiting||Phase 4|25|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-06-01 00:58:31.295282|2018-06-01 00:58:31.295282
NCT00902707|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2012-06-08|2009-05-14|2009-05-15|Estimate|||||||2012-06-08|2012-06-11|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung|An Open-Label, 2-way Crossover Placebo-Controlled , Radio-Labeled Tracer Study Evaluating the Effect of MUCINEX® 1200 mg on Mucociliary and Cough Clearance From The Human Lung In Healthy, Non-Smoking Adults|Completed||Phase 1|12|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 00:58:31.411734|2018-06-01 00:58:31.411734
NCT00902694|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2014-04-23|2009-05-13|2009-05-15|Estimate|||||||2014-04-23|2014-04-25|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ACHIEVE||Randomized Trial Of Achieving Healthy Lifestyles In Psych Rehabilitation|Randomized Trial Of Achieving Healthy Lifestyles In Psychiatric Rehabilitation|Completed||N/A|291|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 00:58:31.487533|2018-06-01 00:58:31.487533
NCT00902681|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2011-05-31|2009-05-14|2009-05-15|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2009||2009-06-30|May 2011|2011-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects|An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.|Completed||Phase 1|36|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 00:58:31.569831|2018-06-01 00:58:31.569831
NCT00902668|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2013-04-11||2013-06-11|2009-05-14|2009-05-15|Estimate|2013-04-11|2013-05-30|Estimate||||2013-06-11|2013-06-20|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2011|Actual|2011-04-30||Interventional|||Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer|A Phase II Study Using Lovastatin to Improve Cosmetic Outcome After Radiation Therapy for Breast Cancer|Terminated||Phase 2|3|Actual|Virginia Commonwealth University|Early termination leading to no subjects analyzed.|1||Slow accrual|f||||t||||||||||2018-06-01 00:58:31.662343|2018-06-01 00:58:31.662343
NCT00902655|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|April 2004||2004-04-30|May 2009|2009-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity|Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity|Completed||Phase 4|103|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 00:58:31.828269|2018-06-01 00:58:31.828269
NCT00902642|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-13|2009-05-13|2009-05-15|Estimate|||||||2009-05-13|2009-05-15|Estimate|September 2004||2004-09-30|May 2009|2009-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||What is the Effect of a Course for Treatment Providers on Their Patient Outcome|Does Training in Psychosocial Methods for Treatment Providers Improve Outcome for Pain Patients at Risk of Long-Term Disability? A Randomised Controlled Trail of a Course for Physical Therapists|Completed||N/A|364|Actual|Örebro County Council||2|||f||||f||||||||||2018-06-01 00:58:31.910926|2018-06-01 00:58:31.910926
NCT00902629|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-08-10|2009-05-14|2009-05-15|Estimate|||||||2015-08-10|2015-08-13|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|epitell||Epiretinal Fibrosis, Effect of Early Surgery|Randomized Clinical Trial Investigating the Longterm Results of Early vs. Delayed Surgery for Epiretinal Fibrosis.|Completed||N/A|56|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-06-01 00:58:31.983477|2018-06-01 00:58:31.983477
NCT00902616|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2013-11-26|2009-05-13|2009-05-15|Estimate|||||||2013-11-26|2013-11-27|Estimate|June 2003||2003-06-30|May 2009|2009-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Effect of Arginine on Microcirculation in Patients With Diabetes|L-Arginine and Endothelial Dysfunction in Type 2 Diabetic Patients|Completed||Phase 4|40|Actual|Tameside Hospital NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:58:32.052717|2018-06-01 00:58:32.052717
NCT00902603|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-04-09|2009-05-13|2009-05-15|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|RESPIRE||Ventavis® Registry Protocol|Registry to Prospectively Evaluate Use of Ventavis® in Patients With Pulmonary Arterial Hypertension|Terminated|||148|Actual|Actelion|||1|low enrollment and difficulty recruiting eligible patients in adequate time|f||||f||||||||||2018-06-01 00:58:32.128401|2018-06-01 00:58:32.128401
NCT00902590|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2018-05-17|2009-05-14|2009-05-15|Estimate|||||||2018-05-17|2018-05-18|Actual|May 2009||2009-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Familial and Atypical Urothelial Cancer Registry|Familial and Atypical Urothelial Cancer Registry|Recruiting|||3200|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Cases will be invited to provide a saliva sample and tissue~   "|||2018-06-01 00:58:32.228924|2018-06-01 00:58:32.228924
NCT00902577|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2018-01-19|2009-05-14|2009-05-15|Estimate|||||||2018-01-19|2018-01-23|Actual|August 24, 2009|Actual|2009-08-24|October 2017|2017-10-31||||January 31, 2018|Anticipated|2018-01-31||Interventional|||MRI and PET Scan Using 18F-Fluoromisonidazole In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme|Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI|Active, not recruiting||Phase 2|50|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:58:32.309284|2018-06-01 00:58:32.309284
NCT00902564|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-03-14||2011-05-11|2009-05-14|2009-05-15|Estimate|2011-05-11|2011-06-10|Estimate||||2011-05-11|2011-06-10|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Escitalopram in Patients With Generalized Anxiety Disorder|Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia|Completed||Phase 4|30|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-06-01 00:58:32.493438|2018-06-01 00:58:32.493438
NCT00902551|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-11-09|2009-05-14|2009-05-15|Estimate|||||||2009-11-09|2009-11-10|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|DNACIC||DNA Cytometry for Cervical Cancer Screening in China|Comparison of DNA Image Cytometry and Conventional Cytology for Cervical Cancer Screening in China|Completed|||25000|Actual|Nanjing Medical University|||2||f||||t||||||Samples With DNA|"~     Cervical samples were taken through cervical brush. Feulgen method is used to determine the~     amount of DNA.~   "|||2018-06-01 00:58:32.737622|2018-06-01 00:58:32.737622
NCT00902538|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2011-09-06||2012-02-20|2009-05-14|2009-05-15|Estimate|2011-10-17|2011-11-22|Estimate||||2012-02-20|2012-02-22|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension|Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone|Completed||Phase 3|2204|Actual|Daiichi Sankyo, Inc.||6|||f||||f||||||||||2018-06-01 00:58:32.851696|2018-06-01 00:58:32.851696
NCT00902525|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2012-12-28|2009-05-14|2009-05-15|Estimate|||||||2012-12-28|2012-12-31|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|September 2011|Actual|2011-09-30|January 2009|Actual|2009-01-31||Interventional|||Zevalin Twice in Aggressive Non-Hodgkin Lymphoma|Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.|Terminated||Phase 2|25|Actual|Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie||1||"After enrolling 25 patients an interim analysis was done.The study was discontinued in the~   absence of the minimum number of 6 patients free of events"|f||||t||||||||||2018-06-01 00:58:33.772392|2018-06-01 00:58:33.772392
NCT00902512|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2011-05-30|2009-05-14|2009-05-15|Estimate|||||||2011-05-30|2011-06-01|Estimate|April 2009||2009-04-30|May 2011|2011-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations|Relative Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations In Healthy Volunteers Under Fasting Conditions.|Completed||Phase 4|30|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 00:58:33.845675|2018-06-01 00:58:33.845675
NCT00902499|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2010-07-23|2009-05-13|2009-05-15|Estimate|||||||2010-07-23|2010-07-26|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Evolution of Memory Related Activity|Evolution of Memory-related fMRI Activation Over the Course of MCI and AD|Unknown status|Recruiting||160|Anticipated|National Institute on Aging (NIA)|||4||f||||||||||||||2018-06-01 00:58:33.908636|2018-06-01 00:58:33.908636
NCT00902486|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13||2010-06-18|2012-01-20|2009-05-14|2009-05-15|Estimate||||2010-06-18|2010-06-22|Estimate|2012-01-20|2012-01-25|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs|A Randomized, Double-blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients With Active RA With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs (DMARD) Therapy Including Biologics|Completed||Phase 2|127|Actual|Incyte Corporation||4|||f||||f||||||||||2018-06-01 00:58:33.976286|2018-06-01 00:58:33.976286
NCT00902473|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|September 2001||2001-09-30|May 2009|2009-05-31|October 2001|Actual|2001-10-31|September 2001|Actual|2001-09-30||Interventional|||Bioequivalence Study of Topiramate Tablets 25mg Under Fed Conditions|Comparative, Randomized, Single Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Ortho-Mcneil Pharmaceutical (Topamax®) 25 mg Topiramate Tablets Following a 50 mg Dose in Healthy Adult Males Under Fed Conditions|Completed||N/A|18|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 00:58:34.172368|2018-06-01 00:58:34.172368
NCT00902460|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-08-12|2009-05-14|2009-05-15|Estimate|||||||2009-08-12|2009-08-13|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||CP-690,550 and Midazolam Drug-Drug Interaction Study|A Phase 1, Randomized, 2-Way Crossover, Multiple Dose, Open Label Study Of The Effect Of CP-690,550 On Midazolam Pharmacokinetics In Healthy Volunteers|Completed||Phase 1|25|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:58:34.244453|2018-06-01 00:58:34.244453
NCT00902447|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2017-12-13|2009-05-14|2009-05-15|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2009||2009-04-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Human Blood Cell Disorders Tissue Bank|Human Blood Cell Disorders Tissue Bank|Recruiting|||10000|Anticipated|Northwell Health|||1||f||||f||||||Samples With DNA|"~     cells, tissue, serum, saliva, etc~   "|||2018-06-01 00:58:34.314992|2018-06-01 00:58:34.314992
NCT00902434|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2014-06-30|2009-05-14|2009-05-15|Estimate|||||||2014-06-30|2014-07-01|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Observational|||Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era|Retrospective Analysis of Histologies, Pattern of Care, and Outcomes of Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era: A Report From the Chicago Lymphoma Consortium|Completed|||50|Actual|Oncology Specialists, S.C.|||||f||||f||||||||||2018-06-01 00:58:34.379985|2018-06-01 00:58:34.379985
NCT00902421|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2010-08-24|2009-05-14|2009-05-15|Estimate|||||||2010-08-24|2010-08-26|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients|Efficacy and Safety of SSRI in Overactive Bladder Patients; a 3-month, Prospective, Open-label, Comparative Study|Completed||Phase 4|40|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 00:58:34.435239|2018-06-01 00:58:34.435239
NCT00900432|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-12-02|2009-05-09|2009-05-12|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Immune Response in Peripheral Blood of Patients With Colon Cancer|Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract|Completed|||67|Actual|University of Arizona|||||f||||t||||||||||2018-06-01 00:59:03.307996|2018-06-01 00:59:03.307996
NCT00902408|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2013-11-05|2009-05-14|2009-05-15|Estimate|||||||2013-11-05|2013-11-06|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Lutein-enriched-egg Beverage on Age-Related Macular Degeneration (AMD)|The Effect of Lutein-enriched-egg Beverage on Progression of Age-related Macular Degeneration, a Randomized Trial|Completed||N/A|100|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 00:58:34.527702|2018-06-01 00:58:34.527702
NCT00902395|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-01-15|2009-05-13|2009-05-15|Estimate|||||||2015-01-15|2015-01-19|Estimate|June 2008||2008-06-30|January 2015|2015-01-31|May 2012|Actual|2012-05-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy of Moderate Sedation for Dental Treatment of Young Children|Randomized Controlled Trial of Oral Sedatives for Moderate Sedation in Young Children|Completed||Phase 4|41|Actual|Universidade Federal de Goias||3|||f||||f||||||||||2018-06-01 00:58:34.603772|2018-06-01 00:58:34.603772
NCT00902382|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2018-02-06|2009-05-14|2009-05-15|Estimate|||||||2018-02-06|2018-02-07|Actual|May 2009||2009-05-31|February 2018|2018-02-28|June 27, 2014|Actual|2014-06-27|June 27, 2014|Actual|2014-06-27||Observational|||Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications|Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications|Completed|||264|Actual|Yale University|||2||f||||t||||||Samples With DNA|"~     Mothers of newborn infants will be asked to consent to the collection of buccal cells from~     their infants for DNA testing. Fathers will also be asked to provide buccal cells via buccal~     swab smears, if blood has not been obtained from them in the course of an RMN trial. The DNA~     specimens will be available for use in other vetted studies to enable study of independent~     genetic and environmental factors and gene-environment interactions for a broad range of~     birth defects and infertility.~   "|||2018-06-01 00:58:34.68386|2018-06-01 00:58:34.68386
NCT00902369|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2016-07-21|2009-05-14|2009-05-15|Estimate|||||||2016-07-21|2016-07-25|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Interventional|||A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)||Completed||Phase 2|130|Anticipated|Asahi Kasei Pharma Corporation||3|||f||||||||||||||2018-06-01 00:58:34.764731|2018-06-01 00:58:34.764731
NCT00902356|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2010-04-01|2009-05-14|2009-05-15|Estimate|||||||2010-04-01|2010-04-02|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women|A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 167 in Healthy Men and Postmenopausal Women|Completed||Phase 1|69|Actual|Amgen||2|||f||||||||||||||2018-06-01 00:58:34.872477|2018-06-01 00:58:34.872477
NCT00902343|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-08-12|2009-05-14|2009-05-15|Estimate|||||||2015-08-12|2015-08-13|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection|A Prospective Randomized Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection|Completed||Phase 3|149|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 00:58:34.950432|2018-06-01 00:58:34.950432
NCT00902330|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2014-05-15||2015-11-19|2009-05-14|2009-05-15|Estimate|2015-03-19|2015-04-02|Estimate||||2015-11-19|2015-11-23|Estimate|April 2009||2009-04-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional||Patients who completed trial|Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer|Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer|Completed||Phase 3|161|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 00:58:35.06517|2018-06-01 00:58:35.06517
NCT00902317|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|November 2004||2004-11-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|CLASE||Prime Time for Superficial Femoral Artery (SFA) - The SFA Study|A Randomized Trial for Femoropopliteal Arteries|Terminated||N/A|130|Actual|Arizona Heart Institute||5||No funding|f||||f||||||||||2018-06-01 00:58:35.666822|2018-06-01 00:58:35.666822
NCT00902304|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2012-07-29||2012-11-30|2009-05-14|2009-05-15|Estimate|2012-07-29|2012-08-30|Estimate||||2012-11-30|2012-12-04|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|VIPER-BP||Valsartan Intensified Primary Care Reduction of Blood Pressure Study|A Phase IV Clinical Trial of Intensified Blood Pressure Management in Primary Care Using Valsartan Alone and as Combination Anti-Hypertensive Therapy|Completed||Phase 4|2337|Actual|Novartis||3|||f||||f||||||||||2018-06-01 00:58:35.77545|2018-06-01 00:58:35.77545
NCT00902291|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13||2013-05-23|2015-08-31|2009-05-13|2009-05-15|Estimate||||2013-05-23|2013-06-05|Estimate|2015-08-31|2015-09-14|Estimate|April 2009||2009-04-30|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer|A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer|Completed||Phase 2|205|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 00:58:36.528012|2018-06-01 00:58:36.528012
NCT00902278|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2017-06-01||2017-10-17|2009-05-14|2009-05-15|Estimate|2017-10-17|2017-11-20|Actual||||2017-10-17|2017-11-20|Actual|October 2008||2008-10-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Immune Responses Induced by Different Licensed Influenza Vaccines|Immune Response Induced by Different Manufacturers of Influenza Vaccines|Completed||N/A|193|Actual|University of Massachusetts, Worcester||5|||f||||f||||||||||2018-06-01 00:58:36.782074|2018-06-01 00:58:36.782074
NCT00902265|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-03-15||2011-04-15|2009-05-14|2009-05-15|Estimate|2011-03-15|2011-04-11|Estimate||||2011-04-15|2011-04-19|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)|Efficacy and Safety of Nocturin 0.1 mg Tablets in Treatment of Nocturia in Patients With Nocturnal Polyuria, Lower Urinary Tract Symptoms (LUTS) and Benign Prostate Syndrome (BPS).|Completed|||138|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-06-01 00:58:37.312429|2018-06-01 00:58:37.312429
NCT00902252|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2010-05-14|2009-05-14|2009-05-15|Estimate|||||||2010-05-14|2010-05-17|Estimate|April 2009||2009-04-30|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Multi-National Phase III Vitala™ 12-Hour Wear Test|Multi-National Phase III Vitala™ 12-Hour Wear Test|Completed||Phase 3|78|Actual|ConvaTec Inc.||1|||f||||f||||||||||2018-06-01 00:58:37.7305|2018-06-01 00:58:37.7305
NCT00902226|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|2011-03-24||2011-05-11|2009-05-14|2009-05-15|Estimate|2011-05-11|2011-06-10|Estimate||||2011-05-11|2011-06-10|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Escitalopram in Patients With Social Anxiety Disorder|Efficacy and Safety of Escitalopram in Patients With Social Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia|Completed||Phase 4|30|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-06-01 00:58:37.833421|2018-06-01 00:58:37.833421
NCT00902213|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-11-16|2009-05-14|2009-05-15|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PAQOL||Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia|Physical Activity to Modify Sequelae and Quality of Life in Childhood Acute Lymphoblastic Leukemia: A Nursing Trial|Completed||N/A|122|Actual|St. Jude Children's Research Hospital||2|||f||||t||||||||||2018-06-01 00:58:38.041522|2018-06-01 00:58:38.041522
NCT00902200|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13||2014-02-17|2014-03-25|2009-05-14|2009-05-15|Estimate||||2014-03-25|2014-04-21|Estimate|2014-03-25|2014-04-21|Estimate|May 2009||2009-05-31|March 2014|2014-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)|A Phase 2, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 Ophthalmic Solution 0.05%, 0.1% and 0.25% in Patients With Elevated Intraocular Pressure|Completed||Phase 2|89|Actual|Aerie Pharmaceuticals||4|||f||||f||||||||||2018-06-01 00:58:38.121119|2018-06-01 00:58:38.121119
NCT00902187|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-14|||2010-06-24|2009-05-14|2009-05-15|Estimate|||||||2010-06-24|2010-06-25|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects|An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™), Manufactured At Zwickau Versus Vega Baja, In Healthy Subjects.|Completed||Phase 1|36|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:58:38.195242|2018-06-01 00:58:38.195242
NCT00902174|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2013-04-16|2012-04-27|2016-02-16|2009-05-14|2009-05-15|Estimate|2013-06-12|2013-07-16|Estimate|2012-04-27|2012-05-01|Estimate|2016-02-16|2016-02-17|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|IMPRES|Age set includes all randomized participants (202). Gender set includes all treated participants (201). One participant was randomized to placebo but did not receive stuy drug.|Imatinib (QTI571) in Pulmonary Arterial Hypertension|A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)|Completed||Phase 3|202|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:58:38.294556|2018-06-01 00:58:38.294556
NCT00902161|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2012-04-10||2015-06-08|2009-05-13|2009-05-15|Estimate|2012-04-10|2012-05-08|Estimate||||2015-06-08|2015-07-03|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose Crossover Study to Assess the Safety and Tolerability of MK0893 Coadministered With Propranolol Hydrochloride in Patients With Type 2 Diabetes|Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 00:58:39.858134|2018-06-01 00:58:39.858134
NCT00902148|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-14|2009-05-14|2009-05-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|December 2003||2003-12-31|May 2009|2009-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Evaluation of Bioresorbable Sheet to Prevent Intra-Abdominal Adhesions in Colorectal Surgeries|Evaluation of Intra-Abdominal Adhesions in Ileostomy Procedures When Using a Resorbable Polylactide Film (SurgiWrap) in Colorectal Surgeries|Completed||Phase 4|19|Actual|MAST Biosurgery, AG||2|||f||||f||||||||||2018-06-01 00:58:40.126318|2018-06-01 00:58:40.126318
NCT00902135|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-07-15|2009-05-13|2009-05-14|Estimate|||||||2015-07-15|2015-07-17|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Observational|||Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)|Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH)|Completed|||702|Actual|Bayer|||3||f||||f||||||||||2018-06-01 00:58:40.204762|2018-06-01 00:58:40.204762
NCT00902122|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2012-04-06|2009-05-13|2009-05-14|Estimate|||||||2012-04-06|2012-04-09|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors|Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors|Unknown status|Recruiting|Phase 4|600|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||4|||f||||f||||||||||2018-06-01 00:58:40.281778|2018-06-01 00:58:40.281778
NCT00902109|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2016-01-31|2009-05-12|2009-05-14|Estimate|||||||2016-01-31|2016-02-02|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|TRASCO||Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients|Pilot Study to Compare the Humphrey Field Analyzer (HFA) 30-2 Swedish Interactive Threshold Algorithm (SITA) Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE), Using a New Fast GATE (German Adaptive Threshold Estimation) in Glaucoma Patients Under Topic Therapy|Unknown status|Active, not recruiting||12|Anticipated|University Hospital Tuebingen|||1||f||||f||||||||||2018-06-01 00:58:40.361757|2018-06-01 00:58:40.361757
NCT00902096|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-13|2009-05-13|2009-05-14|Estimate|||||||2009-05-13|2009-05-14|Estimate|April 2009||2009-04-30|May 2009|2009-05-31||||||||Observational|||Predictors of Cord Blood Immunoglobin E (IgE) Levels||Unknown status|Recruiting||800|Anticipated|Min-Sheng General Hospital|||1||f||||||||||||||2018-06-01 00:58:41.354412|2018-06-01 00:58:41.354412
NCT00902083|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2012-04-06|2009-05-13|2009-05-14|Estimate|||||||2012-04-06|2012-04-09|Estimate|June 2009||2009-06-30|February 2010|2010-02-28|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|rAd-p53||rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors|Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Chemotherapy, or Combination With Surgery in Subjects With Advanced Oral and Maxillofacial Malignant Tumors|Unknown status|Recruiting|Phase 4|600|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||4|||f||||f||||||||||2018-06-01 00:58:41.430432|2018-06-01 00:58:41.430432
NCT00902070|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2015-10-29|2009-05-13|2009-05-14|Estimate|||||||2015-10-29|2015-10-30|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)|Protocol for Eslax Intravenous Drug Use Investigation|Completed|||3969|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 00:58:41.532295|2018-06-01 00:58:41.532295
NCT00902057|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-13|2009-05-13|2009-05-14|Estimate|||||||2009-05-13|2009-05-14|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Desmopressin for Bleeding Related to Low Body Temperature|Effect of Desmopressin on Platelet Dysfunction Associated With Mild Hypothermia in Healthy Volunteers|Unknown status|Not yet recruiting|Phase 4|48|Anticipated|The University of Hong Kong||4|||f||||||||||||||2018-06-01 00:58:41.73472|2018-06-01 00:58:41.73472
NCT00902044|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2018-04-25|2009-05-13|2009-05-14|Estimate|||||||2018-04-25|2018-04-27|Actual|February 11, 2010||2010-02-11|April 2018|2018-04-30|July 2031|Anticipated|2031-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma|Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS)|Recruiting||Phase 1|36|Anticipated|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 00:58:42.015464|2018-06-01 00:58:42.015464
NCT00902031|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2011-04-19|2009-05-13|2009-05-14|Estimate|||||||2011-04-19|2011-04-20|Estimate|April 2006||2006-04-30|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients|Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate for Preventing/Treating Constipation in Palliative Care Patients.|Completed||N/A|70|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 00:58:42.201561|2018-06-01 00:58:42.201561
NCT00902018|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2017-01-31|2009-05-12|2009-05-14|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2009||2009-01-31|January 2017|2017-01-31|September 7, 2015|Actual|2015-09-07|September 7, 2015|Actual|2015-09-07||Interventional|||Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)|The Effect of Eltrombopag on Platelet Survival: the Role of the B-cell Lymphoma Extra Large (BcL-xL) Pathway|Completed||Phase 2|12|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 00:58:42.415244|2018-06-01 00:58:42.415244
NCT00902005|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2013-11-20|2009-05-13|2009-05-14|Estimate|||||||2013-11-20|2013-11-21|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|August 2012|Actual|2012-08-31|June 2011|Actual|2011-06-30||Observational|PSARA||Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment|Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in RA and Spondyloarthritis Patients, Treated With TNFalpha-inhibitors in Combination With Methotrexate or Methotrexate or TNFalpha-inhibitors Alone - a Prospective Study|Completed|||145|Actual|Revmatismesykehuset AS|||1||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 00:58:42.612462|2018-06-01 00:58:42.612462
NCT00901992|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2014-08-08|2009-05-12|2009-05-14|Estimate|||||||2014-08-08|2014-08-11|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|MEDIAS-2-ICT||Evaluation of a Self-management Oriented Diabetes Education Program for Intensified Insulin Therapy in Type 2 Diabetes|Evaluation of a Self-management Oriented Diabetes Education Program for the Initiation of Intensive Insulin Therapy in Type 2 Diabetic Patients|Completed||N/A|186|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||||2018-06-01 00:58:42.696568|2018-06-01 00:58:42.696568
NCT00901979|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13||2013-01-02|2013-01-03|2009-05-13|2009-05-14|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-03|2013-01-09|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)||Completed||Phase 2|693|Actual|Novartis||7|||f||||||||||||||2018-06-01 00:58:42.820258|2018-06-01 00:58:42.820258
NCT00901966|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2018-04-04|2009-05-13|2009-05-14|Estimate|||||||2018-04-04|2018-04-05|Actual|May 12, 2009||2009-05-12|January 23, 2018|2018-01-23||||||||Observational|||Sun Exposure and Melanoma in Agricultural Workers|Sun Exposure and Melanoma in Agricultural Workers|Completed|||447|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:58:43.04251|2018-06-01 00:58:43.04251
NCT00901953|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-14|2009-05-12|2009-05-14|Estimate|||||||2009-05-14|2009-05-15|Estimate|May 2007||2007-05-31|May 2009|2009-05-31|September 2009|Anticipated|2009-09-30|May 2009|Actual|2009-05-31||Observational|||Vestibular System in Migrainous Vertigo Patients|Do Migrainous Vertigo Patients Have More Hypersensitivity in Their Vestibular System Than Migraine Patients Without Vertigo?|Unknown status|Enrolling by invitation||65|Anticipated|University of Bergen|||2||f||||t||||||||||2018-06-01 00:58:43.12557|2018-06-01 00:58:43.12557
NCT00901940|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2014-12-04|2009-05-13|2009-05-14|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Understanding the Immune Response to Meningitis Vaccines|Single Centre Open-Label Randomised Trial of Meningococcal Serogroup ACYW-135 B Cell Response to Primary & Booster Doses of ACWY Conjugate Vaccine & Primary Dose of ACWY Polysaccharide With Booster Dose of ACWY Conjugate in Adults|Completed||Phase 3|150|Actual|University of Oxford||2|||f||||f||||||||||2018-06-01 00:58:43.199122|2018-06-01 00:58:43.199122
NCT00901927|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2016-05-26|2009-05-13|2009-05-14|Estimate|||||||2016-05-26|2016-05-27|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma|A Phase II Study of Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma|Terminated||Phase 2|14|Actual|M.D. Anderson Cancer Center||1||Study was closed early due to toxicity|f||||f||||||||||2018-06-01 00:58:43.28388|2018-06-01 00:58:43.28388
NCT00901914|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2013-06-26|2009-05-13|2009-05-14|Estimate|||||||2013-06-26|2013-06-27|Estimate|October 2008||2008-10-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Study of rBet v1 Tablets|A Multi-national, Randomised, DBPC, Phase II Study to Assess the Efficacy and Safety of Three Doses of SLIT Administered as rBet v 1 Tablets Once Daily to Patients Suffering From Birch Pollen Rhinoconjunctivitis|Completed||Phase 2|483|Actual|Stallergenes Greer||4|||f||||f||||||||||2018-06-01 00:58:43.364501|2018-06-01 00:58:43.364501
NCT00901901|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2013-04-10||2018-02-09|2009-05-13|2009-05-14|Estimate|2013-09-26|2013-09-30|Estimate||||2018-02-09|2018-03-09|Actual|May 21, 2009|Actual|2009-05-21|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|April 17, 2012|Actual|2012-04-17||Interventional|SEARCH||Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma|A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)|Active, not recruiting||Phase 3|732|Actual|Bayer||2|||f||||t||||||||||2018-06-01 00:58:43.557352|2018-06-01 00:58:43.557352
NCT00901888|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2010-08-09|2009-05-13|2009-05-14|Estimate|||||||2010-08-09|2010-08-10|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Interaction of Apelin and Angiotensin in the Human Forearm Circulation|Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:58:44.830613|2018-06-01 00:58:44.830613
NCT00901875|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2012-11-28|2009-05-13|2009-05-14|Estimate|||||||2012-11-28|2012-11-30|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan|An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects|Completed||Phase 4|127|Actual|Indivior Inc.||3|||f||||f||||||||||2018-06-01 00:58:44.895183|2018-06-01 00:58:44.895183
NCT00901862|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-12|2009-05-12|2009-05-14|Estimate|||||||2009-05-12|2009-05-14|Estimate|March 2007||2007-03-31|May 2009|2009-05-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Magnetic Therapy in Migraine Prophylaxis|Magnetic Therapy in Migraine Prophylaxis; Placebo-Controlled, Double-Blind, Crossed Study|Completed||Phase 1|19|Actual|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez||2|||f||||t||||||||||2018-06-01 00:58:44.980881|2018-06-01 00:58:44.980881
NCT00901849|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2014-09-12|2009-05-13|2009-05-14|Estimate|||||||2014-09-12|2014-09-16|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|October 2012|Actual|2012-10-31|July 2010|Actual|2010-07-31||Interventional|||Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)|Phase 1 Study of Tarceva and Rapamycin For Recurrent Low-Grad Gliomas in Children With or Without Neurofibromatosis Type 1 (NF1)|Completed||Phase 1|21|Actual|Children's Research Institute|||||f||||t||||||||||2018-06-01 00:58:45.044639|2018-06-01 00:58:45.044639
NCT00901836|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2017-02-09|2009-05-13|2009-05-14|Estimate|||||||2017-02-09|2017-02-10|Actual|May 2009||2009-05-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SA03||Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma|A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma|Terminated||N/A|2|Actual|University of Florida||2||Study closed due to feasability|f||||t|f|f||||||No||2018-06-01 00:58:45.122848|2018-06-01 00:58:45.122848
NCT00901823|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2016-08-30|2009-05-13|2009-05-14|Estimate|||||||2016-08-30|2016-09-01|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline|A Randomized, Open-Label, Single- and Multiple-Dose, Four-Way Parallel Study Comparing the Fed and Fasted Pharmacokinetics of Two Dose Levels of Diazoxide Choline Controlled-Release Tablet (DCCR) in Healthy VolunteersVOLUNTEERS|Withdrawn||Phase 1|0|Actual|Essentialis, Inc.||2||Did not support the planned development of DCCR in the new indication|f||||f||||||||||2018-06-01 00:58:45.274909|2018-06-01 00:58:45.274909
NCT00901810|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-12|2009-05-12|2009-05-14|Estimate|||||||2009-05-12|2009-05-14|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Interventional|||Clinical Evaluation of Working Length Determination by Electronic Apex-Locator or Radiography on Adequacy of Final Working Length|Clinical Evaluation of Working Length Determination by Electronic Apex-Locator or Radiography on Adequacy of Final Working Length|Unknown status|Recruiting|N/A|280|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 00:58:45.351454|2018-06-01 00:58:45.351454
NCT00901797|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2010-02-10|2009-05-13|2009-05-14|Estimate|||||||2010-02-10|2010-02-11|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|May 2011|Anticipated|2011-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Arthroscopic Rotator Interval Closure in Shoulder Instability Repair||Unknown status|Recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 00:58:45.454627|2018-06-01 00:58:45.454627
NCT00901784|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-06-17|2009-05-13|2009-05-14|Estimate|||||||2009-06-17|2009-06-18|Estimate|September 2001||2001-09-30|May 2009|2009-05-31|October 2001|Actual|2001-10-31|September 2001|Actual|2001-09-30||Interventional|||Bioequivalence Study of Topiramate Tablets 25mg Under Fasting Conditions|Comparative, Randomized, Single Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Ortho-McNeil Pharmaceutical (Topamax®) 25 mg Topiramate Tablets Following a 50 mg Dose in Healthy Adult Males Under Fasting Conditions|Completed||N/A|28|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 00:58:45.54615|2018-06-01 00:58:45.54615
NCT00901771|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2010-06-14|2009-05-13|2009-05-14|Estimate|||||||2010-06-14|2010-06-15|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP|A Non-randomized, Case Series Study of the Effectiveness of Provent Treatment of Obstructive Sleep Apnea Patients Who Are Non-compliant or Minimally Adherent With Positive Airway Pressure Therapy|Completed||N/A|50|Anticipated|St. Luke's Hospital, Chesterfield, Missouri|||||f||||f||||||||||2018-06-01 00:58:45.61899|2018-06-01 00:58:45.61899
NCT00901758|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2013-08-27|2009-05-13|2009-05-14|Estimate|||||||2013-08-27|2013-08-28|Estimate|March 2003||2003-03-31|August 2013|2013-08-31|February 2008|Actual|2008-02-29|October 2006|Actual|2006-10-31||Interventional|INVERT (02)||Intravenous (IV) Nitroglycerin for Versions in Multiparous Women|Intravenous (IV) Nitroglycerin for Versions in Multiparous Women|Completed||N/A|44|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 00:58:45.683441|2018-06-01 00:58:45.683441
NCT00901745|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2010-08-09|2009-05-13|2009-05-14|Estimate|||||||2010-08-09|2010-08-10|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Interaction of Apelin and Angiotensin in the Human Forearm Circulation|Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:58:45.76013|2018-06-01 00:58:45.76013
NCT00901732|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-13|2009-05-13|2009-05-14|Estimate|||||||2009-05-13|2009-05-14|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer|Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Jazz Pharmaceuticals|||||f||||t||||||||||2018-06-01 00:58:45.840532|2018-06-01 00:58:45.840532
NCT00901719|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2010-08-09|2009-05-13|2009-05-14|Estimate|||||||2010-08-09|2010-08-10|Estimate|April 2010||2010-04-30|May 2009|2009-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation|Investigating the Interaction of Apelin and Systemic Angiotensin II Peripheral Resistance Vessels and Systemic Haemodynamics in Vivo in Man|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:58:45.924221|2018-06-01 00:58:45.924221
NCT00901706|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2013-06-17|2009-05-13|2009-05-14|Estimate|||||||2013-06-17|2013-06-18|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|||Multidimensional Assessment and Intervention for Elder Self-Neglect|Multidimensional Assessment and Intervention for Elder Self-Neglect|Completed||Early Phase 1|100|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 00:58:45.996833|2018-06-01 00:58:45.996833
NCT00901693|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08||2014-04-17|2014-05-07|2009-05-13|2009-05-14|Estimate||||2014-05-07|2014-05-22|Estimate|2014-05-07|2014-05-22|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis||Terminated||Phase 2|452|Actual|Alcon Research||2||Internal business decision|f||||f||||||||||2018-06-01 00:58:46.097687|2018-06-01 00:58:46.097687
NCT00901680|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2017-01-05|2009-05-13|2009-05-14|Estimate|||||||2017-01-05|2017-01-06|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Creation of the BioBank, Early Detection and Discovery Biomarkers|Creation of the BioBank,To Establish a Multidisciplinary Research Structure That Facilitates Projects That Bridge Specialties That Normally May or May Not Interact.|Completed|||3028|Actual|William Beaumont Hospitals|||||f||||f||||||Samples With DNA|"~     Biospecimens to be retained are tissue, blood, whole blood, DNA, RNA, urine saliva,cerebral~     spinal fluid, amniotic fluid.~   "|||2018-06-01 00:58:46.160189|2018-06-01 00:58:46.160189
NCT00901667|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2011-03-05|2009-05-13|2009-05-14|Estimate|||||||2011-03-05|2011-03-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:58:46.22645|2018-06-01 00:58:46.22645
NCT00901654|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2010-01-28|2009-05-13|2009-05-14|Estimate|||||||2010-01-28|2010-01-29|Estimate|June 2009||2009-06-30|January 2010|2010-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||ACE527 Safety and Immunogenicity Study|A Phase I, Single Center, Double-Blind, Placebo-controlled Dose Finding Clinical Study to Evaluate the Safety and Immunogenicity of the Live Attenuated, Oral Vaccine ACE527|Completed||Phase 1|36|Anticipated|TD Vaccines A/S||2|||f||||t||||||||||2018-06-01 00:58:46.262295|2018-06-01 00:58:46.262295
NCT00901641|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-13|2009-05-13|2009-05-14|Estimate|||||||2009-05-13|2009-05-14|Estimate|May 2003||2003-05-31|May 2009|2009-05-31||||April 2009|Actual|2009-04-30||Interventional|||Computer-Based Cognitive Training and Sleep Quality in Older Adult Insomniacs|Computer-Based Cognitive Training and Sleep Quality in Older Adult Insomniacs|Unknown status|Active, not recruiting|N/A|51|Actual|The Max Stern Academic College Of Emek Yezreel||1|||f||||f||||||||||2018-06-01 00:58:46.348134|2018-06-01 00:58:46.348134
NCT00901628|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|2009-05-15||2012-12-15|2009-05-13|2009-05-14|Estimate|2012-12-15|2013-01-25|Estimate||||2012-12-15|2013-01-25|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Periarticular Multimodal Drug Injections in Total Knee Arthroplasty|Efficacy and Safety of Periarticular Multimodal Drug Injections in Total Knee Arthroplasty|Completed||Phase 4|101|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 00:58:46.492969|2018-06-01 00:58:46.492969
NCT00901615|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2011-03-03|2009-05-13|2009-05-14|Estimate|||||||2011-03-03|2011-03-04|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|R2CHOP-1||Lenalidomide and R-CHOP in B-cell Lymphoma|A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Lymphoma Study Association||1|||f||||t||||||||||2018-06-01 00:58:46.899169|2018-06-01 00:58:46.899169
NCT00901602|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2013-01-31|2009-05-13|2009-05-14|Estimate|||||||2013-01-31|2013-02-01|Estimate|October 2004||2004-10-31|January 2013|2013-01-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Observational|LIPSP||Lebanese Interhospital Pneumococcal Surveillance Program|Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)|Unknown status|Recruiting||300|Anticipated|American University of Beirut Medical Center|||||f||||f||||||Samples With DNA|"~     Bacterial isolates~   "|||2018-06-01 00:58:46.999824|2018-06-01 00:58:46.999824
NCT00901589|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-13|2009-05-13|2009-05-14|Estimate|||||||2009-05-13|2009-05-14|Estimate|August 2007||2007-08-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Marine n-3 Polyunsaturated Fatty Acids in Pre- and Postmenopausal Women|The Incorporation of Marine n-3 Polyunsaturated Fatty Acids in Pre- and Postmenopausal Women: a Randomized Double-Blinded Placebo-Controlled Clinical Trial|Completed||N/A|92|Actual|Aalborg Universitetshospital||4|||f||||f||||||||||2018-06-01 00:58:47.079933|2018-06-01 00:58:47.079933
NCT00901576|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|2010-04-16||2014-01-07|2009-05-13|2009-05-14|Estimate|2010-04-16|2010-05-19|Estimate||||2014-01-07|2014-02-06|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers|A Phase 1, Open-label, Randomized, Three-period Crossover Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD503 and CONCERTA, Administered Alone and in Combination in Healthy Adult Volunteers|Completed||Phase 1|38|Actual|Shire||3|||f||||||||||||||2018-06-01 00:58:47.165608|2018-06-01 00:58:47.165608
NCT00901563|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2009-05-13|2009-05-13|2009-05-14|Estimate|||||||2009-05-13|2009-05-14|Estimate|March 2009||2009-03-31|May 2009|2009-05-31||||March 2010|Anticipated|2010-03-31||Interventional|||Gap Junction Potentiation of Endothelial Function With Rotigaptide|Gap Junction Potentiation of Endothelial Function With Rotigaptide in the Human Forearm Arterial Circulation - Effects of Ischaemia Induced Endothelial Dysfunction|Unknown status|Recruiting|N/A|24|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 00:58:47.779626|2018-06-01 00:58:47.779626
NCT00901550|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-13|||2012-07-31|2009-05-13|2009-05-14|Estimate|||||||2012-07-31|2012-08-02|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ERA||The Chinese University of Hong Kong Early Arthritis Study|The Chinese University of Hong Kong Early Arthritis Study|Completed||N/A|40|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 00:58:47.898586|2018-06-01 00:58:47.898586
NCT00901537|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2018-04-13|2009-05-13|2009-05-14|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2009||2009-02-28|April 2018|2018-04-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer|Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1|8|Actual|Loma Linda University||1||Sponsor terminated due to no enrollments within last 4 months.|f||||f||||||||||2018-06-01 00:58:47.98062|2018-06-01 00:58:47.98062
NCT00901524|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2013-03-28|2009-05-12|2009-05-13|Estimate|||||||2013-03-28|2013-03-29|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ETOC||ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV|ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360μg/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, With Accompanying Measures) on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV.|Completed||Phase 2|58|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-06-01 00:58:48.079061|2018-06-01 00:58:48.079061
NCT00901511|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-07-27|2009-05-12|2009-05-13|Estimate|||||||2009-07-27|2009-07-28|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)|Whole Lung Lavage Followed by Inhaled Sargramostim in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis|Unknown status|Enrolling by invitation|Phase 2/Phase 3|18|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-06-01 00:58:48.160042|2018-06-01 00:58:48.160042
NCT00901498|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2011-01-06|2009-05-12|2009-05-13|Estimate|||||||2011-01-06|2011-01-07|Estimate|May 2009||2009-05-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease|A Bioavailability Study of Four Experimental BMS-708163 Formulations Relative to Solubilized Capsule Formulation in Healthy Young Male Subjects|Completed||Phase 1|36|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 00:58:48.261372|2018-06-01 00:58:48.261372
NCT00901485|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2012-03-21|2009-05-12|2009-05-13|Estimate|||||||2012-03-21|2012-03-23|Estimate|April 2009||2009-04-30|January 2011|2011-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Newly Diagnosed Patients|Autotitrating Non-invasive Ventilation (NIV) Versus Standard NIV; a Randomised Crossover Trial in Patients With Newly Diagnosed Hypoventilation|Completed||N/A|23|Actual|ResMed||2|||f||||||||||||||2018-06-01 00:58:48.372081|2018-06-01 00:58:48.372081
NCT00901472|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2013-09-04|2009-05-12|2009-05-13|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2007||2007-02-28|September 2013|2013-09-30|December 2009|Actual|2009-12-31|November 2008|Actual|2008-11-30||Observational|||Sleep Disordered Breathing and Diabetes|Sleep Disordered Breathing and Blood Glucose Control in Type 2 Diabetes|Completed|||105|Actual|University of Chicago|||1||f||||f||||||None Retained|"~     Blood was taken for HbA1C~   "|||2018-06-01 00:58:48.493859|2018-06-01 00:58:48.493859
NCT00901459|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2012-09-11||2012-12-17|2009-05-12|2009-05-13|Estimate|2012-12-17|2013-01-25|Estimate||||2012-12-17|2013-01-25|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|rTMS||A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers|A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers|Completed||Phase 2|21|Actual|Duke University||3|||f||||t||||||||||2018-06-01 00:58:48.561608|2018-06-01 00:58:48.561608
NCT00901446|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2010-09-13|2009-05-11|2009-05-13|Estimate|||||||2010-09-13|2010-09-14|Estimate|May 2009||2009-05-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|SAVOIR||Study of Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Combination Coronary Catheter|Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study|Completed|||10|Anticipated|InfraReDx|||1||f||||t||||||||||2018-06-01 00:58:48.756046|2018-06-01 00:58:48.756046
NCT00901433|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-06-23|2009-05-11|2009-05-13|Estimate|||||||2009-06-23|2009-06-24|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Self Operating of the Personal WheezoMeter by Intended Users - A Usability Study|Self Operating of the Personal WheezoMeter by Intended Users - A Usability Study|Completed|||30|Anticipated|KarmelSonix Ltd.|||1||f||||f||||||||||2018-06-01 00:58:48.823091|2018-06-01 00:58:48.823091
NCT00901420|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2012-07-27|2009-05-12|2009-05-13|Estimate|||||||2012-07-27|2012-07-31|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients|Comparison of Urodynamic Evaluation in Post-Radiation Salvage Prostatectomy Versus Prostatectomy-only Patients|Terminated|||2|Actual|M.D. Anderson Cancer Center|||2|Terminated due to slow accrual.|f||||f||||||||||2018-06-01 00:58:48.878405|2018-06-01 00:58:48.878405
NCT00901407|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-12|2009-05-12|2009-05-13|Estimate|||||||2009-05-12|2009-05-13|Estimate|December 2003||2003-12-31|May 2009|2009-05-31|April 2007|Actual|2007-04-30|July 2006|Actual|2006-07-31||Interventional|||Lamotrigine Augmentation in Resistant Depression|Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression|Completed||N/A|138|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||t||||||||||2018-06-01 00:58:48.938435|2018-06-01 00:58:48.938435
NCT00901394|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2017-04-26|2009-05-12|2009-05-13|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2009||2009-03-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Mini-VINO||Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia|Influence of Preoperative Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia|Completed||N/A|577|Actual|Washington University School of Medicine||3|||f||||f||||||||No||2018-06-01 00:58:49.012458|2018-06-01 00:58:49.012458
NCT00901381|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2014-01-06|2009-05-12|2009-05-13|Estimate|||||||2014-01-06|2014-01-07|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|STEMTHER||Granulocyte-colony Stimulating Factor for Stem Cells Therapy for Acute Ischemic Stroke|Open Prospective Randomized Controlled Trial of Efficacy and Safety of Granulocyte-colony Stimulating Factor Leukostim for Acute Ischemic Stroke.|Completed||Phase 2|20|Actual|Clinical Institute of the Brain, Russia||2|||f||||t||||||||||2018-06-01 00:58:49.096144|2018-06-01 00:58:49.096144
NCT00901368|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2017-03-28|2009-05-12|2009-05-13|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2009||2009-05-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|FACTO||FACTO Study (Foster® As Complete Treatment Option)|A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE® DISKUS®) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS.|Completed||Phase 4|431|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 00:58:49.16408|2018-06-01 00:58:49.16408
NCT00901355|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2015-07-29|2009-05-12|2009-05-13|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2007||2007-01-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PARTAGE||Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population|Morbidity and Mortality Based on Blood Pressure and Arterial Stiffness in Institutionalized Persons Aged 80 and Over: Study PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population).|Completed|||1130|Actual|Central Hospital, Nancy, France|||||f||||t||||||||||2018-06-01 00:58:49.377114|2018-06-01 00:58:49.377114
NCT00901342|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2017-03-01||2017-04-21|2009-05-11|2009-05-13|Estimate|2017-03-01|2017-04-12|Actual||||2017-04-21|2017-05-23|Actual|October 2009||2009-10-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer|An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer|Completed||Phase 2|104|Actual|Dendreon||1|||f||||f||||||||Undecided||2018-06-01 00:58:49.669617|2018-06-01 00:58:49.669617
NCT00901329|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-12|2009-05-12|2009-05-13|Estimate|||||||2009-05-12|2009-05-13|Estimate|May 2007||2007-05-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||NexGen Gender Fixed Bearing Knee Versus NexGen Legacy Knee Posterior Stabilized (LPS) - Flex Fixed Bearing Knee: A Study Comparing Two Different Knee Prostheses|NEXGEN Gender Fixed Bearing Knee Versus NEXGEN LPS-Flex Fixed Bearing Knee - a Prospective Randomized Study Comparing Two Different Knee Prostheses|Unknown status|Enrolling by invitation|N/A|24|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-06-01 00:58:50.714966|2018-06-01 00:58:50.714966
NCT00901316|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2016-07-20||2016-09-19|2009-05-12|2009-05-13|Estimate|2016-09-19|2016-11-07|Estimate||||2016-09-19|2016-11-07|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional||We needed to enroll 482 children in each arm to detect a 50% reduction in recurrences with 90% power, assuming a 12-month recurrence rate of 14% in the hygiene only group.|Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children|Prevention of Recurrent Infections Caused by Community-Acquired Staphylococcus in Children 3 Months to 18 Years|Completed||N/A|987|Actual|Baylor College of Medicine|We were limited in detecting decreases in recurrent MA-SSTI < 50% because of the large sample size required.|2|||f||||t||||||||||2018-06-01 00:58:50.776616|2018-06-01 00:58:50.776616
NCT00901303|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-02-13|2009-05-12|2009-05-13|Estimate|||||||2017-02-13|2017-02-14|Actual|October 2008|Actual|2008-10-31|February 2017|2017-02-28|May 23, 2011|Actual|2011-05-23|June 2010|Actual|2010-06-30||Interventional|||Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma|Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography in Hodgkin Lymphoma|Completed||N/A|6|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 00:58:50.972372|2018-06-01 00:58:50.972372
NCT00901290|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2010-12-08|2009-05-12|2009-05-13|Estimate|||||||2010-12-08|2010-12-10|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects|A Randomized, Open-Label, Two-way Crossover Study to Determine the Effects of Co-administration of AZD7325 and a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects|Suspended||Phase 1|56|Anticipated|AstraZeneca||2||suspended pending data analysis|f||||f||||||||||2018-06-01 00:58:51.037729|2018-06-01 00:58:51.037729
NCT00901277|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2014-09-05|2009-05-12|2009-05-13|Estimate|||||||2014-09-05|2014-09-08|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SPRITE||Supporting Post Myocardial Infarction (MI) Risk Modification Intervention Via Telemedicine Evaluation|Supporting Post MI Risk Modification Intervention Via Telemedicine Evaluation|Completed||N/A|416|Actual|Duke University||3|||f||||f||||||||||2018-06-01 00:58:51.114214|2018-06-01 00:58:51.114214
NCT00901264|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2012-11-12|2009-05-12|2009-05-13|Estimate|||||||2012-11-12|2012-11-14|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|MiCK||Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients|Correlation of the Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients|Completed|||300|Actual|Pierian Biosciences|||2||f||||f||||||||||2018-06-01 00:58:51.202205|2018-06-01 00:58:51.202205
NCT00901251|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2011-03-13|2009-05-12|2009-05-13|Estimate|||||||2011-03-13|2011-03-15|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|RESORT||Reproducibility Study of Over Active Bladder Symptom Score [OABSS]|Reproducibility Study of OABSS and Its Response to Treatment - Part 1: Reproducibility -|Completed|||50|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-06-01 00:58:51.278258|2018-06-01 00:58:51.278258
NCT00901238|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-12-16|2009-05-12|2009-05-13|Estimate|||||||2009-12-16|2009-12-17|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|Chemosurgery||Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma|Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma|Completed||Phase 1/Phase 2|100|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 00:58:51.34439|2018-06-01 00:58:51.34439
NCT00901225|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2013-10-30||2014-04-08|2009-05-12|2009-05-13|Estimate|2014-04-08|2014-05-07|Estimate||||2014-04-08|2014-05-07|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|August 2010|Actual|2010-08-31||Interventional|||Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant|Plerixafor Rescue Mobilization For Autologous Stem Cell Transplant Patients With Inadequate Response to G-CSF|Completed||Phase 2|21|Actual|Duke University||1|||f||||t||||||||||2018-06-01 00:58:51.449174|2018-06-01 00:58:51.449174
NCT00901212|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2012-05-06|2009-05-12|2009-05-13|Estimate|||||||2012-05-06|2012-05-08|Estimate|October 2003||2003-10-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|EARTH||Evaluation of Resynchronization Therapy for Heart Failure (EARTH)|Evaluation fo Resynchronization Therapy for Heart Failure (EARTH)|Completed||Phase 4|120|Anticipated|Montreal Heart Institute||2|||f||||t||||||||||2018-06-01 00:58:51.623507|2018-06-01 00:58:51.623507
NCT00901199|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2013-08-05|2009-05-12|2009-05-13|Estimate|||||||2013-08-05|2013-08-07|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Combo Chelation Trial|Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload|Completed||Phase 4|22|Actual|Children's Hospital & Research Center Oakland||3|||f||||t||||||||||2018-06-01 00:58:51.703894|2018-06-01 00:58:51.703894
NCT00901186|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2014-05-30||2017-02-28|2009-05-12|2009-05-13|Estimate|2014-05-30|2014-07-03|Estimate||||2017-02-28|2017-03-03|Actual|November 2009||2009-11-30|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|RED-ES||Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema|A Randomized, Open Label, Multicenter, Laser-controlled Phase II Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) vs. Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema|Completed||Phase 2|83|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:58:51.790467|2018-06-01 00:58:51.790467
NCT00901173|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2018-05-18|2009-05-12|2009-05-13|Estimate|||||||2018-05-18|2018-05-21|Actual|May 11, 2009||2009-05-11|May 18, 2017|2017-05-18||||||||Observational|||A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya|The THINKER Study: A Pilot for a Case-Control of Esophageal Squamous Cell Carcinoma in Western Kenya|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:58:52.118544|2018-06-01 00:58:52.118544
NCT00899821|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-11-08|2009-05-09|2009-05-12|Estimate|||||||2012-11-08|2012-11-09|Estimate|June 2000||2000-06-30|December 2008|2008-12-31||||December 2004|Actual|2004-12-31||Interventional|||Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer|Head And Neck Cancer Immunotherapy Using Biodegradable Microspheres|Completed||N/A|||New York University School of Medicine|||||f||||||||||||||2018-06-01 00:59:10.966143|2018-06-01 00:59:10.966143
NCT00901160|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2015-04-07|2009-05-12|2009-05-13|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|June 2011|Actual|2011-06-30|March 2009|Actual|2009-03-31||Observational|||Thromboelastography (TEG®) and Platelet Function in Patients on Anti-platelet Agents|Pilot Study for the Prediction of Post-operative Thrombotic and Bleeding Complications in Non-cardiac Surgery Using Thromboelastography (TEG®) and Platelet Mapping Assay (PMA™) in Patients on Anti-platelet Agents|Terminated|||200|Actual|McMaster University|||1|Unable to get funding|f||||f||||||||||2018-06-01 00:58:52.179667|2018-06-01 00:58:52.179667
NCT00901147|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2014-06-26|2009-05-12|2009-05-13|Estimate|||||||2014-06-26|2014-06-27|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma|An Open-label Phase 2 Study of Intravenous Bortezomib and Oral Panobinostat (LBH589) in Adult Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma After Failure of Conventional Chemotherapy|Completed||Phase 2|25|Actual|Singapore General Hospital||1|||f||||t||||||||||2018-06-01 00:58:52.251903|2018-06-01 00:58:52.251903
NCT00901134|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2011-07-21|2009-05-12|2009-05-13|Estimate|||||||2011-07-21|2011-07-22|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|March 2010|Actual|2010-03-31||Observational|J-PULSE-HYPO||Multicenter Registry Study With Therapeutic Hypothermia After Cardiac Arrest in Japan|Multicenter Registry Study With Therapeutic Hypothermia After Cardiac Arrest in Japan|Completed|||452|Actual|National Cerebral and Cardiovascular Center|||1||f||||f||||||||||2018-06-01 00:58:52.326181|2018-06-01 00:58:52.326181
NCT00901121|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2016-03-02|2009-05-11|2009-05-13|Estimate|||||||2016-03-02|2016-03-03|Estimate|July 2005||2005-07-31|March 2016|2016-03-31|March 2011|Actual|2011-03-31|April 2007|Actual|2007-04-30||Interventional|||Maxillary Sinus Elevation With Bio-Oss or Straumann BoneCeramic|Maxillary Sinus Grafting With Bio-Oss or Straumann Bone Ceramic Followed by Delayed Placement of Straumann Dental Implants: A Comparative Histomorphometric and Clinical Study|Completed||N/A|48|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:58:52.390552|2018-06-01 00:58:52.390552
NCT00901108|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2016-02-23|2009-05-12|2009-05-13|Estimate|||||||2016-02-23|2016-02-25|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma|Prospective Randomized Controlled Trial of Trabectome Versus Trabeculectomy With Mitomycin C in Patients With Open Angle Glaucoma|Terminated||Phase 3|19|Actual|University of Alberta||2||Slow study recruitment and lack of clinical equipoise over time|f||||t||||||||No||2018-06-01 00:58:52.466594|2018-06-01 00:58:52.466594
NCT00901095|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2014-03-17|2009-05-12|2009-05-13|Estimate|||||||2014-03-17|2014-03-19|Estimate|February 2010||2010-02-28|March 2014|2014-03-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Can Diet- and Exercise-Induced Weight Loss Improve Asthma Control in Adults?|Can Diet- & Exercise-induced Weight Loss Improve Asthma Control in Adults|Completed||Phase 2|330|Actual|Palo Alto Medical Foundation||2|||f||||t||||||||||2018-06-01 00:58:52.526034|2018-06-01 00:58:52.526034
NCT00901082|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2015-10-02|2009-05-12|2009-05-13|Estimate|||||||2015-10-02|2015-10-06|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|February 2012|Actual|2012-02-29|April 2011|Actual|2011-04-30||Interventional|TIRAP||The Effectiveness of Information and Relaxation on Pre-procedural Block Anxiety and Procedural Discomfort During Medial Branch Block|The Effectiveness of Information and Relaxation on Pre-procedural Block Anxiety and Procedural Discomfort During Medial Branch Block: a Randomized Controlled Trial|Completed||N/A|60|Actual|McGill University Health Center||2|||f||||f||||||||||2018-06-01 00:58:52.590014|2018-06-01 00:58:52.590014
NCT00901069|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2016-10-13|2009-05-12|2009-05-13|Estimate|||||||2016-10-13|2016-10-17|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|November 2012|Actual|2012-11-30|January 2012|Actual|2012-01-31||Interventional|||Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma|Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma: A Phase I Trial|Completed||Phase 1|12|Actual|University of Kentucky||1|||f||||t||||||||||2018-06-01 00:58:52.710356|2018-06-01 00:58:52.710356
NCT00901056|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2011-01-23|2009-05-12|2009-05-13|Estimate|||||||2011-01-23|2011-01-25|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Extracorporeal Shock Wave Therapy for the Treatment of Erectile Dysfunction|Feasibility Study to Investigate the Effect of Low Intensity Shockwaves on Patients With Erectile Dysfunction Resulted From Vascular Origin|Completed||Phase 1/Phase 2|20|Actual|Medispec||1|||f||||f||||||||||2018-06-01 00:58:52.771838|2018-06-01 00:58:52.771838
NCT00901043|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2014-12-31|2009-05-12|2009-05-13|Estimate|||||||2014-12-31|2015-01-01|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|WALNUT||Effects of Walnut Consumption on Endothelial Function in Type 2 Diabetes|Effects of Walnut Consumption on Endothelial Function in Type 2 Diabetes: A Randomized, Controlled, Cross-over Trial|Completed||N/A|24|Actual|Griffin Hospital||2|||f||||f||||||||||2018-06-01 00:58:52.835536|2018-06-01 00:58:52.835536
NCT00901030|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2015-09-21|2009-05-12|2009-05-13|Estimate|||||||2015-09-21|2015-09-23|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|October 2014|Actual|2014-10-31||Observational|||Association Between Perioperative Platelet Function and Major Adverse Perioperative Events|The Association Between Perioperative Platelet Inhibition (Function) and Major Adverse Perioperative Cardiac Events in Post Percutaneous Coronary Intervention Patients Undergoing Non-cardiac Surgery|Completed|||250|Actual|McMaster University|||1||f||||f||||||||||2018-06-01 00:58:52.901339|2018-06-01 00:58:52.901339
NCT00901017|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2012-08-30||2016-03-02|2009-05-12|2009-05-13|Estimate|2012-10-04|2012-11-05|Estimate||||2016-03-02|2016-03-30|Estimate|March 2006||2006-03-31|March 2016|2016-03-31|August 2008|Actual|2008-08-31|February 2008|Actual|2008-02-29||Interventional|||Comparison of Synthetic Bone Substitute and a Bovine-derived Xenograft in Horizontal Bone Augmentation|A Randomised Controlled Spilt-mouth Clinical Study Comparing a Synthetic Bone Substitute and a Bovine-derived Xenograft in Primarily Horizontal Bone Augmentation Procedure During Placement of Straumann Oral Implants|Completed||N/A|14|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:58:52.977763|2018-06-01 00:58:52.977763
NCT00901004|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2010-12-06|2009-05-12|2009-05-13|Estimate|||||||2010-12-06|2010-12-07|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|September 2009|Actual|2009-09-30|||||Observational|MIGHT||The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire|Non-interventional, Cross-sectional, Multi-center Study to Establish The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire (GerdQ)|Completed|||1550|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:58:53.273857|2018-06-01 00:58:53.273857
NCT00900991|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-13|2009-05-12|2009-05-13|Estimate|||||||2009-05-13|2009-05-14|Estimate||||May 2009|2009-05-31||||||||Interventional|||Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children|Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children|Completed||Phase 2|||Sinovac Biotech Co., Ltd||2|||f||||t||||||||||2018-06-01 00:58:53.357202|2018-06-01 00:58:53.357202
NCT00900978|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-09-29|2009-05-12|2009-05-13|Estimate|||||||2009-09-29|2009-09-30|Estimate|May 2009||2009-05-31|September 2009|2009-09-30|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|7vPCV||Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Jordanian Infants|Impact of the 7 Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage of S. Pneumoniae in Healthy Jordanian Infants.|Unknown status|Active, not recruiting|Phase 1/Phase 2|377|Anticipated|German-Jordanian University||1|||f||||t||||||||||2018-06-01 00:58:53.444647|2018-06-01 00:58:53.444647
NCT00900965|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-06-30|2009-05-12|2009-05-13|Estimate|||||||2009-06-30|2009-07-02|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|IBS_FBM||Effect of Electroacupuncture in Patients With Irritable Bowel Syndrome|A Pilot Study on the Effect of Electroacupuncture on Functional Brain Mapping in Patients With Irritable Bowel Syndrome|Completed||N/A|42|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 00:58:53.536201|2018-06-01 00:58:53.536201
NCT00900952|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-10-08|2009-05-12|2009-05-13|Estimate|||||||2009-10-08|2009-10-09|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Epidemiologic Study Evaluating Infections in Elderly Patients|Epidemiologic Study of Infections in Elderly Patients|Completed|||240|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 00:58:53.631592|2018-06-01 00:58:53.631592
NCT00900939|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2012-08-06|2009-05-11|2009-05-13|Estimate|||||||2012-08-06|2012-08-07|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Plant-based Dietary Intervention for Treatment of Acne|Plant-based Dietary Intervention for Treatment of Acne|Completed||N/A|43|Actual|Physicians Committee for Responsible Medicine||2|||f||||f||||||||||2018-06-01 00:58:53.717664|2018-06-01 00:58:53.717664
NCT00900913|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2011-08-05|2009-05-12|2009-05-13|Estimate|||||||2011-08-05|2011-08-08|Estimate|January 2010||2010-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral Nerve Excitability|Effect of Systemic Ropivacaine on Hyperalgesia, Flare Reaction and Peripheral|Completed||Phase 4|34|Anticipated|University of Zurich|||||f||||t||||||||||2018-06-01 00:58:53.801387|2018-06-01 00:58:53.801387
NCT00900900|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11||2012-09-10|2012-09-14|2009-05-12|2009-05-13|Estimate||||2012-09-14|2012-09-21|Estimate|2012-09-14|2012-09-21|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|DHEA||The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers|The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers|Completed||Phase 2|22|Actual|Duke University||3|||f||||t||||||||||2018-06-01 00:58:53.885314|2018-06-01 00:58:53.885314
NCT00900887|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2015-03-18|2009-05-12|2009-05-13|Estimate|||||||2015-03-18|2015-03-20|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema|Efficacy of Topic Antiinflammatory Therapy Treatment in Center Point Thickness Secondary to Selective Photocoagulation in Diabetic Macular Edema|Completed||Phase 2|84|Actual|Hospital Juarez de Mexico||3|||f||||f||||||||||2018-06-01 00:58:54.10651|2018-06-01 00:58:54.10651
NCT00900874|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-12|2009-05-12|2009-05-13|Estimate|||||||2009-05-12|2009-05-13|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Rapid Onset Action of Salbutamol Versus Formoterol|Comparing Rapid Bronchodilatory Effect of Formoterol and Salbutamol in Children Between 5-15 Years With Mild to Moderate Acute Exacerbation of Asthma- A Double Blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|78|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 00:58:54.265093|2018-06-01 00:58:54.265093
NCT00900861|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-12-03|2009-05-12|2009-05-13|Estimate|||||||2009-12-03|2009-12-04|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|||||Observational|||Asthma Control and Clinical Practice in Hungary 2009|Asthma Control and Clinical Practice in Hungary 2009|Completed|||3000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 00:58:54.40436|2018-06-01 00:58:54.40436
NCT00900848|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2009-05-11|2009-05-11|2009-05-13|Estimate|||||||2009-05-11|2009-05-13|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Posterior Tibial Artery Bypass for Iliofemoral Artery Injury Associated With Massive Blood Loss and Shock|Traumatic Disruption of Iliofemoral Arterial Segment is Often Associated With Multiple Injuries, Massive Hemorrhage, State of Shock, and Loss of Blood Supply to the Ipsilateral Lower Extremity, as Well as With High Mortality|Completed|||8|Actual|The Second Hospital of Qinhuangdao|||1||f||||t||||||||||2018-06-01 00:58:54.562598|2018-06-01 00:58:54.562598
NCT00900835|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2011-03-03|2009-05-12|2009-05-13|Estimate|||||||2011-03-03|2011-03-07|Estimate|June 2005||2005-06-30|March 2011|2011-03-31|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|||Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer|Reducing Barriers to Pain and Fatigue Management|Completed||N/A|470|Actual|City of Hope Medical Center|||||f||||f||||||||||2018-06-01 00:58:54.608302|2018-06-01 00:58:54.608302
NCT00900822|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2012-06-06||2016-03-03|2009-05-11|2009-05-13|Estimate|2012-07-31|2012-08-31|Estimate||||2016-03-03|2016-03-31|Estimate|November 2005||2005-11-30|March 2016|2016-03-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Interventional|||Straumann Bone Ceramic Versus BioOss in Sinus Elevation|Randomized, Controlled Clinical Study to Compare Bone Formation Around Micro-implants in the Maxilla After Sinus Floor Augmentation With Straumann Bone Ceramic or Bio-Oss in a Split Mouth Design|Completed||N/A|11|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:58:54.679951|2018-06-01 00:58:54.679951
NCT00900809|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2017-03-27|2009-05-12|2009-05-13|Estimate|||||||2017-03-27|2017-03-29|Actual|May 2014||2014-05-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia|Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia|Active, not recruiting||Phase 1|18|Anticipated|NantKwest, Inc.||1|||f||||t||||||||||2018-06-01 00:58:54.854987|2018-06-01 00:58:54.854987
NCT00900796|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2012-05-07||2012-05-07|2009-05-12|2009-05-13|Estimate|2012-05-07|2012-06-19|Estimate||||2012-05-07|2012-06-19|Estimate|March 2009||2009-03-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|PRETEA||Study Evaluating Predictors of Response in Patients With Ankylosing Spondylitis|Success and Failure of Biological Therapy: Predictors of Response in Patients With Active Ankylosing Spondylitis|Completed|||132|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 00:58:54.9219|2018-06-01 00:58:54.9219
NCT00900783|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12||2015-09-23|2015-09-23|2009-05-12|2009-05-13|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients With Herpes Zoster|Completed||Phase 2|350|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 00:58:55.173669|2018-06-01 00:58:55.173669
NCT00900770|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-12-23|2009-05-11|2009-05-13|Estimate|||||||2009-12-23|2009-12-29|Estimate|November 2008||2008-11-30|December 2009|2009-12-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Implications of Amyloid Pathology|Implications of Amyloid Deposition in Clinically Normal Older Individuals|Unknown status|Recruiting||100|Anticipated|National Institute on Aging (NIA)|||2||f||||||||||||||2018-06-01 00:58:55.245214|2018-06-01 00:58:55.245214
NCT00900757|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2013-12-30||2014-11-03|2009-05-12|2009-05-13|Estimate|2014-03-04|2014-04-01|Estimate||||2014-11-03|2014-11-10|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide|Phase II Study to Evaluate the Efficacy and Safety of Intravenous Palonosetron in Primary Glioma Patients Receiving Standard Radiotherapy and Concomitant Temozolomide|Completed||Phase 2|57|Actual|Duke University||1|||f||||f||||||||||2018-06-01 00:58:55.336987|2018-06-01 00:58:55.336987
NCT00900744|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2017-08-24|2009-05-12|2009-05-13|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2009||2009-01-31|August 2017|2017-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6|A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6|Completed|||121|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f|t|f||||||||2018-06-01 00:58:55.566399|2018-06-01 00:58:55.566399
NCT00900731|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|2011-07-22||2011-07-22|2009-05-12|2009-05-13|Estimate|2011-07-22|2011-08-19|Estimate||||2011-07-22|2011-08-19|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|INTENSITY||A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD|Completed||Phase 3|1598|Actual|Novartis||2|||f||||||||||||||2018-06-01 00:58:55.659606|2018-06-01 00:58:55.659606
NCT00900718|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2016-03-02|2009-05-12|2009-05-13|Estimate|||||||2016-03-02|2016-03-03|Estimate|February 2006||2006-02-28|March 2016|2016-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparison of Straumann Bone Ceramic and Bio-Oss With Guided Tissue Regeneration for Alveolar Ridge Preservation|Comparison of Straumann Bone Ceramic (SBC) and Bio-Oss in Combination With Guided Tissue Regeneration (GTR) for Volume Preservation of Alveolar Ridge After Tooth Extraction: a Randomised, Single Blind, Controlled Clinical Trial|Completed||N/A|27|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 00:58:57.355781|2018-06-01 00:58:57.355781
NCT00900705|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2016-08-29|2009-05-12|2009-05-13|Estimate|||||||2016-08-29|2016-08-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 00:58:57.42793|2018-06-01 00:58:57.42793
NCT00900692|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2013-07-10|2009-05-12|2009-05-13|Estimate|||||||2013-07-10|2013-07-11|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|SupPro Botox||Dynamic Splinting for Excessive Pronation Following CVA|Dynamic Splinting for Excessive Pronation Following CVA: A Randomized, Controlled Tial|Withdrawn||N/A|0|Actual|Dynasplint Systems, Inc.||2|||f||||t||||||||||2018-06-01 00:58:57.467921|2018-06-01 00:58:57.467921
NCT00900679|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2010-08-09|2009-05-12|2009-05-13|Estimate|||||||2010-08-09|2010-08-11|Estimate|July 2008||2008-07-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer|A Standardized Nursing Intervention Protocol for Ovarian Cancer as a Chronic Illness|Completed||N/A|110|Anticipated|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 00:58:57.543187|2018-06-01 00:58:57.543187
NCT00900666|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|2013-05-02||2013-05-02|2009-05-12|2009-05-13|Estimate|2013-05-02|2013-06-24|Estimate||||2013-05-02|2013-06-24|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury|Randomized Controlled Trial on the Effects of Botulinum Toxin Injections in the Rectus Femoris on Gait Function in Stiff Knee Gait Following Acquired Brain Injury|Terminated||N/A|19|Actual|Mary Free Bed Rehabilitation Hospital|Early termination due to difficulty identifying and recruiting participants.|2||Original subject recruitment goal was unrealistic. Study was terminated at N=19.|f||||f||||||||||2018-06-01 00:58:57.616746|2018-06-01 00:58:57.616746
NCT00900653|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-05-29|2009-05-12|2009-05-13|Estimate|||||||2009-05-29|2009-06-01|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|July 2010|Anticipated|2010-07-31|May 2010|Anticipated|2010-05-31||Interventional|||Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women|Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study|Unknown status|Enrolling by invitation|Phase 4|142|Anticipated|Yonsei University||2|||f||||f||||||||||2018-06-01 00:58:57.851176|2018-06-01 00:58:57.851176
NCT00900640|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2017-03-15|2009-05-12|2009-05-13|Estimate|||||||2017-03-15|2017-03-16|Actual|May 2009|Actual|2009-05-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Reactions to Contrast Media (CM) Administered at the Time of the Endoscopic Retrograde Cholangiopancreatography (ERCP)|Reactions to Contrast Media (CM) Administered at the Time of Endoscopic Retrograde Cholangiopancreatography (ERCP)|Completed|||27|Actual|University of Florida|||1||f||||f||||||||||2018-06-01 00:58:57.922247|2018-06-01 00:58:57.922247
NCT00900627|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|2014-01-31||2016-01-15|2009-05-12|2009-05-13|Estimate|2014-09-23|2014-09-29|Estimate||||2016-01-15|2016-01-20|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|April 2012|Actual|2012-04-30||Interventional|THYME||Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)|A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|330|Actual|AstraZeneca|"The primary statistical analysis of PFS was performed, but the planned analyses of overall survival at 50% maturity, and of PFS at 50% OS maturity, were not performed.~AEs were coded using MedDRA v14.0 (part A) and MedDRA v15.0 (part B)."|2|||f||||t||||||||||2018-06-01 00:58:58.235301|2018-06-01 00:58:58.235301
NCT00900614|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2011-06-22|2009-05-12|2009-05-13|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer|An Open-label Phase I Dose Escalating Study of APR-246 for Infusion in Patients With Refractory Hematologic Malignancies or Prostate Carcinoma|Completed||Phase 1|36|Anticipated|Aprea Therapeutics AB|||||f||||t||||||||||2018-06-01 00:59:01.547977|2018-06-01 00:59:01.547977
NCT00900601|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2017-03-15||2017-09-18|2009-05-12|2009-05-13|Estimate|2017-09-18|2018-05-28|Estimate||||2017-09-18|2018-05-28|Estimate|January 2007||2007-01-31|September 2017|2017-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma|Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma - A Study to Measure Effect of Surgery, Analysis of Clinical Tests and Detection of Sacroiliac Instability Using RSA.|Completed||N/A|9|Actual|Oslo University Hospital||1|||f||||t||||||||No||2018-06-01 00:59:01.621939|2018-06-01 00:59:01.621939
NCT00900588|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2009-08-10|2009-05-12|2009-05-13|Estimate|||||||2009-08-10|2009-08-12|Estimate||||August 2009|2009-08-31||||||||Interventional|||Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents|Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescent|Completed||Phase 2|||Sinovac Biotech Co., Ltd||4|||f||||t||||||||||2018-06-01 00:59:01.807242|2018-06-01 00:59:01.807242
NCT00900575|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2018-04-24|2009-05-11|2009-05-13|Estimate|||||||2018-04-24|2018-04-26|Actual|May 2006|Actual|2006-05-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Cervical Cancer Detection Using Optical Spectroscopy|Cervical Cancer Detection Using Optical Spectroscopy|Recruiting||N/A|350|Anticipated|Duke University||1|||f||||f||||||||||2018-06-01 00:59:01.953293|2018-06-01 00:59:01.953293
NCT00900562|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2013-01-14|2009-05-12|2009-05-13|Estimate|||||||2013-01-14|2013-01-15|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy|Phase II Clinical and Pharmacokinetic Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy|Terminated||Phase 2|19|Actual|PharmaMar||1||Slow and poor recruitment.|f||||f||||||||||2018-06-01 00:59:02.027091|2018-06-01 00:59:02.027091
NCT00900549|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-12|||2011-07-20|2009-05-12|2009-05-13|Estimate|||||||2011-07-20|2011-07-21|Estimate|October 2003||2003-10-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|EARTH||Evaluation of Resynchronization Therapy for Heart Failure|EvaluAtion of Resynchronization Therapy for Heart Failure (EARTH)|Terminated||Phase 4|120|Anticipated|Montreal Heart Institute||2||Futility reason, no difference between study groups|f||||t||||||||||2018-06-01 00:59:02.090024|2018-06-01 00:59:02.090024
NCT00900536|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-09|2009-05-09|2009-05-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2007||2007-07-31|November 2008|2008-11-30|June 2012|Actual|2012-06-30|||||Observational|||DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE|TRANSORCE (A Sub-study of SORCE)|Completed|||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:02.163925|2018-06-01 00:59:02.163925
NCT00900523|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-04-17|2009-05-09|2009-05-12|Estimate|||||||2013-04-17|2013-04-18|Estimate|November 2006||2006-11-30|April 2013|2013-04-30|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Observational|||Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer|Urine Prostaglandin-M(PGE-M) in Ovarian Cancer|Completed|||7|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||||||2018-06-01 00:59:02.220592|2018-06-01 00:59:02.220592
NCT00900510|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2017-11-02|2009-05-11|2009-05-12|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2009||2009-05-31|December 2014|2014-12-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Antibiotic Therapy After Incision and Drainage for Abscess|The Use of Adjuvant Antibiotic Therapy After Incision and Drainage for Pediatric Abscess: A Prospective, Randomized, Double-blinded, Placebo-Controlled Trial|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2||Recruitment of this population in the hospital setting not practical.|f||||t||||||||||2018-06-01 00:59:02.287469|2018-06-01 00:59:02.287469
NCT00900497|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2017-10-07|2009-05-11|2009-05-12|Estimate|||||||2017-10-07|2017-10-10|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers|A Phase I/II Study For the Use of White Blood Cells From Healthy Donor-participants To Treat Subjects With Solid Cancers|Enrolling by invitation||Phase 1/Phase 2|29|Anticipated|South Florida Bone Marrow/Stem Cell Transplant Institute||1|||f||||f||||||||||2018-06-01 00:59:02.350281|2018-06-01 00:59:02.350281
NCT00900484|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-05-17|2009-05-09|2009-05-12|Estimate|||||||2013-05-17|2013-05-20|Estimate|February 1989||1989-02-28|May 2013|2013-05-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Observational|||SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma|Central Lymphoma Repository Tissue Procurement Protocol|Completed|||458|Actual|Southwest Oncology Group|||||f||||f||||||Samples With DNA|"~     Tissue collected for patients consenting to banking on SWOG lymphoma protocols~   "|||2018-06-01 00:59:02.43228|2018-06-01 00:59:02.43228
NCT00900471|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-05-24|2009-05-09|2009-05-12|Estimate|||||||2018-05-24|2018-05-25|Actual|May 2004||2004-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors|Advanced Tumor Bank Project|Recruiting|||2500|Anticipated|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 00:59:02.947191|2018-06-01 00:59:02.947191
NCT00900458|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2015-05-06|2009-05-11|2009-05-12|Estimate|||||||2015-05-06|2015-05-07|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Exercise Induced Improvement of the Venous Reserve Capacity in Formerly Pre-eclamptic Women|Adjustment of the Venous Reserve Capacity by Aerobic Exercise in Women at Increased Risk of Hypertensive Pregnancy Complications|Completed||N/A|50|Actual|Radboud University||3|||f||||f||||||||||2018-06-01 00:59:03.096178|2018-06-01 00:59:03.096178
NCT00900445|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-05-30|2009-05-09|2009-05-12|Estimate|||||||2013-05-30|2013-05-31|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia|Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL)|Withdrawn|||0|Actual|Children's Oncology Group|||3|Poor accrual|f||||t||||||||||2018-06-01 00:59:03.177857|2018-06-01 00:59:03.177857
NCT00900419|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-29|2009-05-09|2009-05-12|Estimate|||||||2017-08-29|2017-08-30|Actual|March 2002||2002-03-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers|Biomarkers and Dysplastic Respiratory Epithelium|Recruiting|||500|Anticipated|University of Colorado, Denver|||||f||||f||||||Samples With DNA|"~     Sputum sample,Endobronchial biopsy, bronchial secretions, pulmonary labage, blood and urine,~     buccal smears,exhaled breath collection.~   "|||2018-06-01 00:59:03.372221|2018-06-01 00:59:03.372221
NCT00900406|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-11-04|2009-05-09|2009-05-12|Estimate|||||||2012-11-04|2012-11-06|Estimate|January 2007||2007-01-31|November 2012|2012-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant|Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD)|Completed|||190|Actual|Vanderbilt-Ingram Cancer Center|||3||f||||||||||Samples Without DNA|"~     Blood collection~   "|||2018-06-01 00:59:03.448763|2018-06-01 00:59:03.448763
NCT00900380|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|March 28, 2006|Actual|2006-03-28|May 2017|2017-05-31|December 30, 2013|Actual|2013-12-30|December 30, 2013|Actual|2013-12-30||Observational|||Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia|Comparison of P-gp Efflux and Accumulation Assay Results With ECOG 3999 Leukemia Samples|Completed|||40|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:03.543625|2018-06-01 00:59:03.543625
NCT00900367|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-02-14|2009-05-09|2009-05-12|Estimate|||||||2013-02-14|2013-02-15|Estimate|July 2005||2005-07-31|February 2013|2013-02-28||||December 2013|Anticipated|2013-12-31||Observational|||Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women|Nutrition Modulated Metabolism as a Disease Risk Factor|Unknown status|Active, not recruiting||1500|Actual|Brigham and Women's Hospital|||||f||||f||||||Samples Without DNA|"~     we have only plasma, NHS has DNA samples.~      Study is nested case control, so retrospective with respect to individual inclusion,~     prospective with respect to sample collected before disease. Enrollment is approximate as it~     includes samples that will be drpped, eg for QC resons~   "|||2018-06-01 00:59:03.6073|2018-06-01 00:59:03.6073
NCT00900354|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-09|2009-05-09|2009-05-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2006||2006-06-30|June 2009|2009-06-30||||||||Observational|||Pharmacokinetics of Dactinomycin in Young Patients With Cancer|Pharmacokinetics of Actinomycin D in Children With Cancer|Unknown status|Recruiting||50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:03.687071|2018-06-01 00:59:03.687071
NCT00900341|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-03-20|2009-05-09|2009-05-12|Estimate|||||||2014-03-20|2014-03-21|Estimate|August 2005||2005-08-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma|LABORATORY STUDIES OF SOFT TISSUE SARCOMAS|Completed|||27|Actual|University of Arizona|||||f||||||||||||||2018-06-01 00:59:03.784791|2018-06-01 00:59:03.784791
NCT00900328|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|September 2008||2008-09-30|August 2017|2017-08-31|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Observational|||Study of Tumor Samples From Patients With Lung Cancer|A Pilot Project to Study the Expression of c-MET and p53 in Resected Lung Adenocarcinoma Specimens|Completed|||280|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue, serum~   "|||2018-06-01 00:59:03.842769|2018-06-01 00:59:03.842769
NCT00900302|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-02-09|2009-05-09|2009-05-12|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2005||2005-04-30|February 2016|2016-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer|Study of The Examination of Sentinel Lymph Nodes for OX-40 Expression in Patients With Cancer|Completed|||98|Actual|OHSU Knight Cancer Institute|||||f||||||||||||||2018-06-01 00:59:03.905936|2018-06-01 00:59:03.905936
NCT00900289|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-02-12|2009-05-09|2009-05-12|Estimate|||||||2013-02-12|2013-02-13|Estimate|March 2002||2002-03-31|February 2013|2013-02-28||||||||Observational|||Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer|DNA Methylation as a Predictor for Response and Progression-Free Survival in Patients With Ovarian Cancer|Unknown status|Recruiting||1000|Anticipated|Cancer Research UK, Glasgow|||||f||||f||||||Samples With DNA|"~     Tissue and whole blood~   "|||2018-06-01 00:59:03.990694|2018-06-01 00:59:03.990694
NCT00900276|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-07-31|2009-05-09|2009-05-12|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2006||2006-06-30|October 2015|2015-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants|BARC: A Secreted Marker of Kidney Cancer|Completed|||5|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 00:59:04.236256|2018-06-01 00:59:04.236256
NCT00900263|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-10-06|2009-05-09|2009-05-12|Estimate|||||||2016-10-06|2016-10-07|Estimate|June 2002||2002-06-30|October 2016|2016-10-31||||April 2016|Actual|2016-04-30||Observational|||S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma|S0120, A Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasmaproliferative Disorders|Completed|||375|Actual|Southwest Oncology Group|||||f||||t||||||Samples With DNA|"~     Bone marrow/peripheral blood~   "|||2018-06-01 00:59:04.320762|2018-06-01 00:59:04.320762
NCT00900250|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-18|Actual|October 2006||2006-10-31|May 2017|2017-05-31||||January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma|Hodgkin Disease (HD) Banking Study|Active, not recruiting|||1272|Anticipated|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 00:59:04.491271|2018-06-01 00:59:04.491271
NCT00900237|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2014-12-04||2014-12-12|2009-05-11|2009-05-12|Estimate|2014-12-12|2014-12-19|Estimate||||2014-12-12|2014-12-19|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine|A Phase I, Single Centre, Open, Randomised, Parallel Study to Evaluate the Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine in Healthy Subject|Completed||Phase 1|14|Actual|Bial - Portela C S.A.||2|||f||||t||||||||||2018-06-01 00:59:04.842858|2018-06-01 00:59:04.842858
NCT00900224|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|June 2008||2008-06-30|August 2017|2017-08-31||||December 2018|Anticipated|2018-12-31||Observational|||Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia|Assessment of Novel Molecular Markers in Acute Myeloid Leukemia|Active, not recruiting|||529|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     bone marrow aspirate, whole blood, buccal cell sample and bone marrow biopsy~   "|||2018-06-01 00:59:05.111095|2018-06-01 00:59:05.111095
NCT00900211|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-23|2009-05-09|2009-05-12|Estimate|||||||2013-08-23|2013-08-26|Estimate|August 2007||2007-08-31|April 2008|2008-04-30||||March 2012|Anticipated|2012-03-31||Observational|||Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX|VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK]|Unknown status|Recruiting||400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:05.288883|2018-06-01 00:59:05.288883
NCT00900198|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-04-03|2009-05-09|2009-05-12|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 18, 2006||2006-09-18|March 23, 2018|2018-03-23|December 31, 2019|Anticipated|2019-12-31|||||Interventional|||Collection of Tissue Samples for Cancer Research|Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)|Recruiting||Phase 1|4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:59:05.375351|2018-06-01 00:59:05.375351
NCT00900185|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-04-29|2009-05-09|2009-05-12|Estimate|||||||2015-04-29|2015-04-30|Estimate||||February 2007|2007-02-28||||||||Observational|||Study of a Polymorphism in Patients With Prostate Cancer|Retrospective Analysis of Endostatin Genotype in Prostate Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (D104N) in Endostatin and Prostate Cancer|Completed|||750|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:05.439229|2018-06-01 00:59:05.439229
NCT00900172|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|March 15, 2008|Actual|2008-03-15|May 2017|2017-05-31|April 15, 2009|Actual|2009-04-15|April 15, 2009|Actual|2009-04-15||Observational|||Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel|Angiogenesis Pathway Gene Polymorphisms Associated With Clinical Outcome in Patients Enrolled in ECOG 4599|Completed|||180|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:05.483548|2018-06-01 00:59:05.483548
NCT00900159|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|2017-03-30||2017-07-31|2009-05-11|2009-05-12|Estimate|2017-07-31|2017-08-30|Actual||||2017-07-31|2017-08-30|Actual|May 2009||2009-05-31|July 2017|2017-07-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Effects of Daytime Eszopiclone Administration in Shift Workers|Effects of Daytime Eszopiclone Administration in Shift Workers on Overnight Wakefulness During a Subsequent Simulated Nightshift|Completed||N/A|24|Actual|Brigham and Women's Hospital||2|||f||||f||||||||Undecided|After publication of initial results, would require institutional data sharing agreement with Partners Inc (Brigham and Women's Hospital), and Dr. Buxton|2018-06-01 00:59:05.541515|2018-06-01 00:59:05.541515
NCT00900146|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2011-11-22||2012-01-17|2009-05-11|2009-05-12|Estimate|2012-01-17|2012-02-20|Estimate||||2012-01-17|2012-02-20|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients|Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study|Terminated||Phase 2/Phase 3|556|Actual|Novartis||5||"Numerically modest lowering of HbA1c with canakinumab in combination with metformin was~   inadequate to continue patients with T2DM into Period IV of this study."|f||||||||||||||2018-06-01 00:59:05.952527|2018-06-01 00:59:05.952527
NCT00900133|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-10-01|2009-05-09|2009-05-12|Estimate|||||||2015-10-01|2015-10-02|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|December 2006|Actual|2006-12-31|April 2006|Actual|2006-04-30||Observational|||Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer|A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer|Completed|||60|Actual|Case Comprehensive Cancer Center|||||f||||t||||||Samples With DNA|"~     Blood draw following diagnosis of breast cancer to assess levels of circulating tumor~     markers.~   "|||2018-06-01 00:59:07.211003|2018-06-01 00:59:07.211003
NCT00900120|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2011-12-08|2009-05-09|2009-05-12|Estimate|||||||2011-12-08|2011-12-12|Estimate|March 2004||2004-03-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Collecting and Storing Blood Samples From Patients With Cancer|Banking DNA for Analysis of Genetic Polymorphisms in Patients With Cancer|Withdrawn|||0|Actual|Rutgers, The State University of New Jersey||||Will be replaced by honest broker program|f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 00:59:07.275278|2018-06-01 00:59:07.275278
NCT00900107|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2016-10-25|2009-05-11|2009-05-12|Estimate|||||||2016-10-25|2016-10-27|Estimate|September 2008||2008-09-30|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals|Time Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals.|Completed||N/A|18|Actual|University of Leipzig|||||f||||f||||||||||2018-06-01 00:59:07.366078|2018-06-01 00:59:07.366078
NCT00900094|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-02-05|2009-05-09|2009-05-12|Estimate|||||||2012-02-05|2012-02-07|Estimate|June 2000||2000-06-30|February 2012|2012-02-29|October 2007|Actual|2007-10-31|December 2006|Actual|2006-12-31||Observational|IRB 2000-294||UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer|Proteomics Biomarker Development Laboratory (Aka IRB 1999-514)|Completed|||200|Actual|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 00:59:07.416444|2018-06-01 00:59:07.416444
NCT00900081|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-07-28|2009-05-09|2009-05-12|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2003|Actual|2003-05-31|October 2015|2015-10-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Observational|||Cyclooxygenase-2 Expression in Tissue Samples From Patients With a Normal Cervix, Cervical Intraepithelial Neoplasia, or Early Invasive Cervical Cancer|Evaluation of Cyclooxygenase-2 Expression in Normal Cervix, Cervical Intraepithelial Neoplasia and Early Invasive Squamous Cell Carcinoma With Correlation to Parameters of Invasion and Angiogenesis|Withdrawn|||0|Actual|Wake Forest University Health Sciences||||no accrual, PI left institution|f||||f|f|f||||||||2018-06-01 00:59:07.476411|2018-06-01 00:59:07.476411
NCT00900068|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-07|2009-05-09|2009-05-12|Estimate|||||||2017-05-07|2017-05-09|Actual|August 2008||2008-08-31|May 2017|2017-05-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Observational|||Blood Samples From Patients on a Clinical Trial to CINV During HSCT|Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation|Terminated|||9|Actual|OHSU Knight Cancer Institute|||||f||||||||||||||2018-06-01 00:59:07.534269|2018-06-01 00:59:07.534269
NCT00900055|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-01-08|2009-05-09|2009-05-12|Estimate|||||||2018-01-08|2018-01-10|Actual|June 1975||1975-06-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma|Dysregulation of Hematopoiesis in Fanconi Anemia|Active, not recruiting|||213|Actual|OHSU Knight Cancer Institute|||||f||||||||||||||2018-06-01 00:59:07.728035|2018-06-01 00:59:07.728035
NCT00900042|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-02-21|2009-05-09|2009-05-12|Estimate|||||||2014-02-21|2014-02-25|Estimate|July 1993||1993-07-31|February 2014|2014-02-28|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Observational|||SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer|Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949|Completed|||34|Actual|Southwest Oncology Group|||||f||||||||||Samples With DNA|"~     Tumor diagnostic tissue~   "|||2018-06-01 00:59:07.806324|2018-06-01 00:59:07.806324
NCT00900029|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2016-09-28||2017-06-27|2009-05-11|2009-05-12|Estimate|2016-09-28|2016-09-29|Estimate||||2017-06-27|2017-08-02|Actual|June 2009||2009-06-30|September 2016|2016-09-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Observational||Subjects and PIs remained blinded as treatment in the 802-247-09-015 study. There were no restrictions as to treatment by the PIs during this study. Blinding was maintained in order to assess the final outcomes of this study in relation to the therapy received in the prior study|Safety Follow-Up to HP 802-247-09-015|A Twenty-Four Week Non-Interventional Safety Follow-Up to HP 802-247-09-015|Completed|||206|Actual|Healthpoint|||2||f||||f||||||||No||2018-06-01 00:59:07.879744|2018-06-01 00:59:07.879744
NCT00900016|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-09-08|2009-05-09|2009-05-12|Estimate|||||||2017-09-08|2017-09-11|Actual|August 2007||2007-08-31|September 2017|2017-09-30|June 23, 2017|Actual|2017-06-23|December 2013|Actual|2013-12-31||Observational|||Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery|Pharmacodynamic Study of Fibroblast Activity Protein in Patients With Localized Pancreas Cancer Undergoing Surgical Resection|Completed|||37|Actual|Fox Chase Cancer Center|||||f||||f||||||Samples Without DNA|"~     peripheral blood sample~   "|||2018-06-01 00:59:08.53101|2018-06-01 00:59:08.53101
NCT00900003|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-12-10|2009-05-09|2009-05-12|Estimate|||||||2013-12-10|2013-12-12|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Studying Biomarkers in Patients With Pancreatic Cancer|Developing Biomarkers in Pancreatic Cancer|Completed|||53|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||||||2018-06-01 00:59:08.586218|2018-06-01 00:59:08.586218
NCT00899990|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-12-11|2009-05-09|2009-05-12|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2008||2008-02-29|December 2017|2017-12-31|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Biological Samples From Patients With Ewing Sarcoma|A COG Study for Collecting and Banking Ewing Sarcoma Specimens|Active, not recruiting|||900|Anticipated|Children's Oncology Group|||1||f||||t||||||Samples With DNA|"~     tumor specimens, bone marrow and peripheral blood~   "|||2018-06-01 00:59:08.676452|2018-06-01 00:59:08.676452
NCT00899977|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08||2011-03-15|2013-09-03|2009-05-11|2009-05-12|Estimate||||2012-07-13|2012-07-23|Estimate|2013-09-03|2013-09-13|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension|A Double-blind, Randomized, Placebo-controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension|Terminated||Phase 1/Phase 2|1|Actual|Targacept Inc.||5||Business reasons|f||||f||||||||||2018-06-01 00:59:09.961763|2018-06-01 00:59:09.961763
NCT00899964|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-03-06|2009-05-11|2009-05-12|Estimate|||||||2014-03-06|2014-03-07|Estimate|May 2009||2009-05-31|March 2014|2014-03-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||IT-based Training in Obesity|Influence of a Combined Personal and IT-based Physical Activity Intervention in an Obese, Sedentary Population on Daily Activity and Metabolic Risk Profile|Completed||N/A|184|Actual|Technische Universität München||4|||f||||f||||||||||2018-06-01 00:59:10.036938|2018-06-01 00:59:10.036938
NCT00899951|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-04-16|2009-05-09|2009-05-12|Estimate|||||||2013-04-16|2013-04-18|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Studying Fentanyl in Patients With Cancer|Pharmacokinetics of Continuous Infusion Fentanyl in Cancer Patients|Terminated|||2|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1|poor accrual|f||||t||||||||||2018-06-01 00:59:10.111071|2018-06-01 00:59:10.111071
NCT00899912|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-11-14|2009-05-09|2009-05-12|Estimate|||||||2015-11-14|2015-11-17|Estimate|June 2006||2006-06-30|November 2015|2015-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Changes in DNA After Radiation Therapy in Patients With Prostate Cancer|Investigating Markers of Radiation Outcome in Patients With Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study|Completed|||13|Actual|Radiation Therapy Oncology Group|||||f||||t||||||Samples With DNA|"~     Frozen tissue cores of prostatic biopsy specimens~   "|||2018-06-01 00:59:10.289643|2018-06-01 00:59:10.289643
NCT00899899|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-09-28|2009-05-09|2009-05-12|Estimate|||||||2015-09-28|2015-09-30|Estimate|June 1998||1998-06-30|May 2015|2015-05-31|April 2006|Actual|2006-04-30|March 2005|Actual|2005-03-31||Observational|||Resistance to Methotrexate in Patients With Acute Lymphoblastic Leukemia in Relapse or Remission|A Study of the Mechanisms of Intrinsic and Acquired Methotrexate Resistance in Acute Lymphocytic Leukemia|Completed|||135|Actual|Children's Oncology Group|||||f||||f||||||||||2018-06-01 00:59:10.382752|2018-06-01 00:59:10.382752
NCT00899873|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|April 17, 2012|Actual|2012-04-17|May 2017|2017-05-31|July 17, 2012|Actual|2012-07-17|July 17, 2012|Actual|2012-07-17||Observational|||Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997|Proposed Study of CLL Samples|Completed|||225|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:10.447682|2018-06-01 00:59:10.447682
NCT00899860|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-25|2009-05-09|2009-05-12|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2003||2003-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer|Renal Cell Cancer Tumor Markers|Terminated|||30|Actual|Wake Forest University Health Sciences|||1|PI left institution|f||||t|f|f||||||||2018-06-01 00:59:10.509367|2018-06-01 00:59:10.509367
NCT00899847|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2017-08-24||2017-09-19|2009-05-11|2009-05-12|Estimate|2017-09-19|2017-10-20|Actual||||2017-09-19|2017-10-20|Actual|May 2009||2009-05-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG|A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients|Completed||Phase 2|9|Actual|Stanford University||1|||f||||t|t||||f|||No||2018-06-01 00:59:10.592815|2018-06-01 00:59:10.592815
NCT00899834|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-07-25|2009-05-09|2009-05-12|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma|Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study|Completed|||81|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples With DNA|"~     tumor and constitutional tissue samples from patients with diffuse brainstem glioma and other~     types of brainstem gliomas~   "|||2018-06-01 00:59:10.900743|2018-06-01 00:59:10.900743
NCT00899808|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-05-27|2009-05-09|2009-05-12|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2006||2006-05-31|May 2015|2015-05-31||||May 2006|Actual|2006-05-31||Observational|||Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer|Molecular and Genetic Markers in the Local-regional Management of Patients Undergoing Radiation Therapy|Withdrawn|||0|Actual|Rutgers, The State University of New Jersey||||"not applicable clinical trial"|f||||f||||||||||2018-06-01 00:59:11.027192|2018-06-01 00:59:11.027192
NCT00899795|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-30|2009-05-09|2009-05-12|Estimate|||||||2017-11-30|2017-12-04|Actual|June 2002||2002-06-30|November 2017|2017-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers|Stromal Injury and Clonal Adaptation in Myelodysplasia|Completed|||35|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 00:59:11.079656|2018-06-01 00:59:11.079656
NCT00899782|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2004||2004-07-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer|The CALGB Lung Cancer Tissue Bank|Active, not recruiting|||500|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tumor, blood~   "|||2018-06-01 00:59:11.146545|2018-06-01 00:59:11.146545
NCT00899769|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-03-10|2009-05-09|2009-05-12|Estimate|||||||2017-03-10|2017-03-14|Actual|April 2005||2005-04-30|March 2017|2017-03-31||||||||Observational|||Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers|Serum Biomarkers for Head and Neck Cancer|Completed|||100|Anticipated|Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 00:59:11.226842|2018-06-01 00:59:11.226842
NCT00899756|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2009-07-07|2009-05-09|2009-05-12|Estimate|||||||2009-07-07|2009-07-08|Estimate|June 2006||2006-06-30|July 2009|2009-07-31||||||||Observational|||Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer|Study of Mutations of Epidermal Growth Factor Receptor in the Blood of Patients With Advanced Non Small Cell Lung Cancer|Unknown status|Recruiting||50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:11.394997|2018-06-01 00:59:11.394997
NCT00899743|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-03-05|2009-05-09|2009-05-12|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||S9333A Study of Blood and Bone Marrow Samples From Patients With Previously Untreated Primary Acute Myeloid Leukemia|Determining the Clinicopathological Significance of CaMKIIgamma Activation in AML|Completed|||132|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 00:59:11.467177|2018-06-01 00:59:11.467177
NCT00899717|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2013-04-10||2013-07-21|2009-05-11|2009-05-12|Estimate|2013-07-13|2013-07-16|Estimate||||2013-07-21|2013-07-26|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|April 2010|Actual|2010-04-30|June 2009|Actual|2009-06-30||Interventional|||Occlusal Adjustment as Treatment for Chronic Orofacial Pain|Basis for an Etiological Diagnosis and Treatment of the Chronic TMD-pain: RCT Study|Completed||Phase 1/Phase 2|21|Actual|University of Santiago de Compostela||2|||f||||t||||||||||2018-06-01 00:59:11.546074|2018-06-01 00:59:11.546074
NCT00899704|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|March 2008||2008-03-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer|Molecular Mechanisms of OSCC Tumor Invasion|Recruiting|||161|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 00:59:11.849677|2018-06-01 00:59:11.849677
NCT00899691|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-03-14|2009-05-09|2009-05-12|Estimate|||||||2012-03-14|2012-03-15|Estimate|March 2005||2005-03-31|March 2012|2012-03-31|October 2008|Actual|2008-10-31|||||Observational|||Study of Hair Samples From Patients With Cancer|Detection and Quantification of Changes in Levels of Protein Expression and Phosphorylation Status Using Human Hair Samples|Completed|||190|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:59:11.931433|2018-06-01 00:59:11.931433
NCT00899678|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2013-06-28||2015-03-03|2009-05-08|2009-05-12|Estimate|2013-09-18|2013-11-21|Estimate||||2015-03-03|2015-03-23|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|NURTURE|The Baseline characteristics refer to the Safety Set (SS) population. The Safety Population includes all subjects enrolled who received at least 1 injection of study treatment.|The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents|A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)|Terminated||Phase 2|99|Actual|UCB Pharma||2||higher than projected discontinuation rate during Maintenance Phase|f||||t||||||||||2018-06-01 00:59:12.029339|2018-06-01 00:59:12.029339
NCT00899665|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-02-10|2009-05-09|2009-05-12|Estimate|||||||2014-02-10|2014-02-11|Estimate|July 2001||2001-07-31|February 2014|2014-02-28|January 2008|Actual|2008-01-31|September 2006|Actual|2006-09-30||Observational|||Proteases in Patients With Prostate Cancer That Has Spread to the Bone|Proteases in Prostate Cancer Bone Metastasis|Completed|||31|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||f||||||||||2018-06-01 00:59:12.730714|2018-06-01 00:59:12.730714
NCT00899652|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-04-24|2009-05-09|2009-05-12|Estimate|||||||2017-04-24|2017-04-26|Actual|January 1997||1997-01-31|April 2017|2017-04-30|September 2006|Actual|2006-09-30|September 2005|Actual|2005-09-30||Observational|||DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|The Molecular Epidemiology of de Novo and Treatment Related 11q23 Leukemia in the Young|Completed|||149|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     marrow, blood, pheresis bag~   "|||2018-06-01 00:59:12.785767|2018-06-01 00:59:12.785767
NCT00899639|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-05-27|2009-05-09|2009-05-12|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer|Correlation of Oncotype Dx With Image Features and Molecular Characteristics of Breast Cancer|Withdrawn|||0|Actual|Rutgers, The State University of New Jersey||||"not applicable clinical trial"|f||||t||||||||||2018-06-01 00:59:12.842181|2018-06-01 00:59:12.842181
NCT00899626|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-01-21|2009-05-09|2009-05-12|Estimate|||||||2013-01-21|2013-01-23|Estimate|June 2002||2002-06-30|January 2013|2013-01-31||||June 2016|Anticipated|2016-06-30||Observational|||Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Patients and Healthy Participants Undergoing Colonoscopy, Endoscopy, or Surgery|Novel Colon Cancer Markers in Gastrointestinal Tissue and Biofluids|Unknown status|Recruiting||1000|Anticipated|Vanderbilt University|||||f||||t||||||Samples With DNA|"~     Blood, Tissue, Body Fluids~   "|||2018-06-01 00:59:12.919578|2018-06-01 00:59:12.919578
NCT00899431|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2017-05-30|2009-05-11|2009-05-12|Estimate|||||||2017-05-30|2017-06-01|Actual|May 2009|Actual|2009-05-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)|Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294)|Active, not recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 00:59:14.996867|2018-06-01 00:59:14.996867
NCT00899613|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2009-12-13|2009-05-09|2009-05-12|Estimate|||||||2009-12-13|2009-12-15|Estimate|April 2007||2007-04-30|July 2009|2009-07-31||||January 2010|Anticipated|2010-01-31||Observational|||Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia|Study Aiming at Researching Diagnostic Markers for the Recognition of Precancerous States, Tracking, Follow-up, and the Identification of New Therapeutic Targets for Mesothelioma in Patients With Atypical Mesothelial Hyperplasia.|Unknown status|Recruiting||270|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:13.069509|2018-06-01 00:59:13.069509
NCT00899600|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2012-11-27||2013-05-03|2009-05-11|2009-05-12|Estimate|2013-03-05|2013-04-11|Estimate||||2013-05-03|2013-05-07|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain|Intra-operative Ketamine Infusions in Patients With Chronic Lower Back Discomfort Undergoing Laminectomies.|Completed||N/A|102|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 00:59:13.151492|2018-06-01 00:59:13.151492
NCT00899587|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate||||May 2009|2009-05-31||||||||Interventional|||Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia|Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia|Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-06-01 00:59:13.401332|2018-06-01 00:59:13.401332
NCT00899574|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2012-04-12||2015-11-06|2009-05-11|2009-05-12|Estimate|2012-04-12|2012-05-11|Estimate||||2015-11-06|2015-12-07|Estimate|May 2009||2009-05-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|April 2011|Actual|2011-04-30||Interventional|||Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases|Phase II Evaluation of Imiquimod, a Topical Toll-like Receptor 7 (TLR7) Agonist in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases|Completed||Phase 2|10|Actual|New York University School of Medicine|The 20% response rate would have justified to continue; but the study was concluded and a new trial of imiquimod and local radiotherapy (NCT01421017) is open, based on preclinical findings indicating that the combination was more effective.|1|||f||||t||||||||||2018-06-01 00:59:13.478828|2018-06-01 00:59:13.478828
NCT00899561|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2012-03-16|2009-05-11|2009-05-12|Estimate|||||||2012-03-16|2012-03-19|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2010|Actual|2010-12-31||Observational|CT||Computed Tomography (CT) Score and Histopathology of the Middle Turbinate in Chronic Rhinosinusitis|Correlation Between Middle Turbinate Histopathology and Computed Tomography Staging in Chronic Rhinosinusitis|Unknown status|Recruiting||45|Anticipated|Meir Medical Center|||||f||||t||||||Samples Without DNA|"~     Middle turbinate samples of patients with limited, intermediate, and extensive chronic sinus~     disease.~   "|||2018-06-01 00:59:13.674468|2018-06-01 00:59:13.674468
NCT00899548|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-01|2009-05-09|2009-05-12|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2006||2006-09-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|June 2010|Actual|2010-06-30||Observational|||DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer|DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer|Completed|||249|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||2||f||||f||||||Samples With DNA|"~     Serum, plasma, DNA, RNA, whole blood~   "|||2018-06-01 00:59:13.750665|2018-06-01 00:59:13.750665
NCT00899535|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-06-27|2009-05-09|2009-05-12|Estimate|||||||2016-06-27|2016-06-29|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|February 2013|Actual|2013-02-28|October 2010|Actual|2010-10-31||Observational|||Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030|The Cancer Genome Atlas (TCGA) Utilizing Z0030 NSCLC Patient Samples|Completed|||70|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tumor samples from patients enrolled on Z0030.~   "|||2018-06-01 00:59:13.854829|2018-06-01 00:59:13.854829
NCT00899522|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-30|2009-05-09|2009-05-12|Estimate|||||||2017-11-30|2017-12-04|Actual|August 2005||2005-08-31|November 2017|2017-11-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|||Tissue Sample Collection From Patients With Fanconi Anemia|Fanconi Anemia Cancer Cell Repository|Completed|||8|Actual|OHSU Knight Cancer Institute|||||f||||||||||||||2018-06-01 00:59:13.935263|2018-06-01 00:59:13.935263
NCT00899509|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2000||2000-10-31|August 2017|2017-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer|Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Protocol 0148: Doxorubicin Dose Escalation, With or Without Taxol®, as Part of the CA Adjuvant Chemotherapy Regimen For Node Positive Breast Cancer: A Phase III Intergroup Study|Completed|||1500|Anticipated|Alliance for Clinical Trials in Oncology|||||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-06-01 00:59:14.02025|2018-06-01 00:59:14.02025
NCT00899496|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-25|2009-05-09|2009-05-12|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2005|Actual|2005-09-30|April 2017|2017-04-30|October 23, 2009|Actual|2009-10-23|October 23, 2009|Actual|2009-10-23||Observational|||Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants|Pilot Study of Cancer Resistance in Humans|Completed|||54|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 00:59:14.100864|2018-06-01 00:59:14.100864
NCT00899483|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|July 2009||2009-07-31|May 2009|2009-05-31||||July 2012|Anticipated|2012-07-31||Interventional|GUIDE||Can Enhanced Glycemic Control in Type II Diabetics Improve Myocardial Protection During Coronary Artery Bypass Grafting?|Can Enhanced Glycaemic Control in Type II Diabetics Improve Myocardial Protection During Coronary Artery Bypass Grafting?|Unknown status|Not yet recruiting|N/A|100|Anticipated|University Hospital Birmingham||2|||f||||||||||||||2018-06-01 00:59:14.18014|2018-06-01 00:59:14.18014
NCT00899470|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2010-12-21||2015-05-08|2009-05-11|2009-05-12|Estimate|2011-02-28|2011-03-25|Estimate||||2015-05-08|2015-06-01|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 500 mg Metformin Immediate Release (IR) Tablet Relative to 2.5 mg Saxagliptin Tablet and 500 mg Metformin IR Tablet Co-administered to Healthy Subjects in a Fasted and in a Fed State|Completed||Phase 1|24|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:59:14.277321|2018-06-01 00:59:14.277321
NCT00899457|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-06-23|2009-05-09|2009-05-12|Estimate|||||||2014-06-23|2014-06-24|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Molecular Markers in Predicting Lung Cancer Development Using Tissue Samples From Healthy Participants|Molecular Predictors of Lung Cancer Behavior: Controls|Completed|||37|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||||||||||||2018-06-01 00:59:14.932581|2018-06-01 00:59:14.932581
NCT00899418|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-04-02|2009-05-09|2009-05-12|Estimate|||||||2013-04-02|2013-04-04|Estimate|May 2006||2006-05-31|October 2008|2008-10-31||||November 2006|Actual|2006-11-30||Observational|||Studying Tumor Tissue Samples to Learn More About DNA Changes and Response in Patients With Breast Cancer Treated With Bevacizumab on Clinical Trial ECOG-2100|Differential Response of Breast Cancer Patients on E2100 Treated With Bevacizumab as a Function of Genetic Polymorphisms of VEGF and KDR|Completed|||500|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:15.076912|2018-06-01 00:59:15.076912
NCT00899405|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-01-11|2009-05-09|2009-05-12|Estimate|||||||2018-01-11|2018-01-16|Actual|May 2005||2005-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer|EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood|Recruiting|||800|Anticipated|University of California, Davis|||1||f||||t||||||Samples With DNA|"~     Archival tissue specimens and blood samples~   "|||2018-06-01 00:59:15.220586|2018-06-01 00:59:15.220586
NCT00899392|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2010-06-25||2013-07-24|2009-05-11|2009-05-12|Estimate|2013-07-24|2013-07-30|Estimate||||2013-07-24|2013-07-30|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Improving Informed Consent in Pediatric Endoscopy|Improving Informed Consent and Assent in Pediatric Endoscopy|Completed||N/A|148|Actual|Children's Hospital of Philadelphia|Subjects of study did not all complete secondary outcome measures hence some pilot data was included in 2ndary outcome analysis, New instrument used attempting to validate. Largely female, educated cohort. >60% college educated in both groups.|2|||f||||f||||||||||2018-06-01 00:59:15.295407|2018-06-01 00:59:15.295407
NCT00899379|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2009-09-26||2015-03-17|2009-05-08|2009-05-12|Estimate|2010-06-14|2010-07-15|Estimate||||2015-03-17|2015-04-03|Estimate|April 1995||1995-04-30|March 2015|2015-03-31|April 1996|Actual|1996-04-30|January 1996|Actual|1996-01-31||Interventional|||Treatment of Multiple Attacks of Acute Migraine (0462-025)|A Randomized, Triple-Blind, Placebo-Controlled, Outpatient Study to Examine the Safety and Efficacy of MK462 10 mg p.o. in the Treatment of Multiple Attacks of Migraine Headache|Completed||Phase 3|473|Actual|Merck Sharp & Dohme Corp.|Pooled Extension data for PN022- NCT00897949; PN025- NCT00899379 and PN029- NCT00897104 appears in NCT00897949|5|||f||||||||||||||2018-06-01 00:59:15.585553|2018-06-01 00:59:15.585553
NCT00899366|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|November 30, 2006|Actual|2006-11-30|May 2017|2017-05-31|March 31, 2013|Actual|2013-03-31|March 31, 2013|Actual|2013-03-31||Observational|||DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia|Molecular Mechanisms of NOTCH Induced Transformation in T-ALL|Completed|||49|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:16.166781|2018-06-01 00:59:16.166781
NCT00899353|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2013-04-29||2013-11-18|2009-05-08|2009-05-12|Estimate|2013-10-23|2013-11-18|Estimate||||2013-11-18|2013-12-12|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|||Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)|Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies|Terminated||Phase 2|16|Actual|Marshall University||1||Original Principal Investigator left the institution.|f||||f||||||||||2018-06-01 00:59:16.250532|2018-06-01 00:59:16.250532
NCT00899340|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-03-29|2009-05-09|2009-05-12|Estimate|||||||2013-03-29|2013-04-02|Estimate|May 2006||2006-05-31|March 2013|2013-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Protein Expression in Tumor Tissue Samples From Patients With Cancer of the Oropharynx|Protein Expression Profiles in Oropharyngeal Squamous Cell Carcinoma|Completed|||54|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||||||2018-06-01 00:59:16.551952|2018-06-01 00:59:16.551952
NCT00899327|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2009-07-07|2009-05-09|2009-05-12|Estimate|||||||2009-07-07|2009-07-08|Estimate|January 2007||2007-01-31|July 2009|2009-07-31||||December 2011|Anticipated|2011-12-31||Observational|||Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants|Molecular and Functional Characterisation of Bone Marrow Function in Normal Subjects, Myelodysplastic Syndromes (MDS) and Secondary Disorders of Heamatopoiesis|Unknown status|Recruiting||200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:16.612152|2018-06-01 00:59:16.612152
NCT00899301|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-25|2009-05-09|2009-05-12|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2004||2004-01-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Collecting and Storing Tissue Samples From Women With or Without Breast Cancer|Breast Tissue/Body Fluids Repository|Recruiting|||4000|Anticipated|Vanderbilt-Ingram Cancer Center|||2||f||||f||||||||||2018-06-01 00:59:16.685813|2018-06-01 00:59:16.685813
NCT00899288|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-07-26|2009-05-09|2009-05-12|Estimate|||||||2012-07-26|2012-07-27|Estimate|April 2005||2005-04-30|July 2012|2012-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Fingernails in Evaluating Bone Health in Postmenopausal Women With Breast Cancer Undergoing Hormone Therapy on Clinical Trial IBCSG-1-98|Investigating the Chemical Properties of Fingernails to Determine the Efficacy of Nail Structure for Evaluating Bone Fragility|Terminated||Phase 3|60|Anticipated|International Breast Cancer Study Group||4||Insufficient accrual|f||||t||||||||||2018-06-01 00:59:16.760719|2018-06-01 00:59:16.760719
NCT00899275|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-12-11|2009-05-09|2009-05-12|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2008||2008-02-29|December 2017|2017-12-31||||January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma|A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens|Active, not recruiting|||1000|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     serum, plasma and blood~   "|||2018-06-01 00:59:16.860655|2018-06-01 00:59:16.860655
NCT00899262|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-23|2009-05-09|2009-05-12|Estimate|||||||2013-08-23|2013-08-26|Estimate|April 2008||2008-04-30|June 2009|2009-06-30||||April 2011|Anticipated|2011-04-30||Observational|||Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy Volunteers|Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG)|Unknown status|Recruiting||300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:17.145472|2018-06-01 00:59:17.145472
NCT00899223|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|May 1996||1996-05-31|August 2017|2017-08-31||||December 2020|Anticipated|2020-12-31||Observational|||Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes|The CALGB Leukemia Tissue Bank|Active, not recruiting|||1500|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||||||||Samples With DNA|"~     -  Bone Marrow Aspirate: 5 mL of bone marrow aspirate at the time of diagnosis, relapse,~          and during remission for each CALGB leukemia or myelodysplastic syndrome treatment~          protocol.~        -  Blood: 10 mL of whole blood at the time of diagnosis, relapse, and during remission for~          each CALGB leukemia or myelodysplastic syndrome treatment protocol.~        -  Buccal Cell Sample: One buccal cell sample at time of diagnosis, but may be obtained at~          other times if not done so previously~   "|||2018-06-01 00:59:17.223621|2018-06-01 00:59:17.223621
NCT00899210|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2011-05-14|2009-05-09|2009-05-12|Estimate|||||||2011-05-14|2011-05-17|Estimate|September 2003||2003-09-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Observational|||Matrix Metalloproteinases After Surgery and/or Radiofrequency Ablation in Patients With Liver Metastases From Colorectal Cancer|Study of Diagnostic Tests Studying Kinetic Variation of Serum Matrix Metalloproteases After Surgical Treatment and/or Destruction by Radiofrequency in Patients With Hepatic Metastases From Colorectal Cancer|Completed|||75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:17.51772|2018-06-01 00:59:17.51772
NCT00899197|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-07-31|2009-05-09|2009-05-12|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2007||2007-05-31|September 2015|2015-09-30|June 2012|Actual|2012-06-30|March 2009|Actual|2009-03-31||Observational|||Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer|Tamoxifen Resistance in Breast Cancer|Terminated|||2|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 00:59:17.579369|2018-06-01 00:59:17.579369
NCT00899184|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|May 23, 2006|Actual|2006-05-23|May 2017|2017-05-31|May 30, 2007|Actual|2007-05-30|May 30, 2007|Actual|2007-05-30||Observational|||DNA Changes in Patients With Prostate Cancer|Assessment of SNP Genotypes in Men With Prostate Cancer|Completed|||646|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:17.648256|2018-06-01 00:59:17.648256
NCT00899171|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-03-05|2009-05-09|2009-05-12|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia|S9031-S9126-S9333-S9500-A, Examination of the Prognostic Significance of AML-Specific and Age-Associated Genes in AML Patients|Completed|||251|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:59:17.698464|2018-06-01 00:59:17.698464
NCT00899158|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-09-29|2009-05-09|2009-05-12|Estimate|||||||2015-09-29|2015-09-30|Estimate|June 2005||2005-06-30|September 2015|2015-09-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Observational|||Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss|Role of Caspase-3, Phosphatidylinositol-3 Kinase (PI3K), and 3-methylhistidine (3-MH) in the Pathophysiology of Skeletal Muscle Loss in Weight-losing Pancreas Cancer Patients|Completed|||44|Actual|Case Comprehensive Cancer Center|||||f||||t||||||Samples With DNA|"~     During surgery, a muscle biopsy is performed and approximately 1 cm of rectus abdominous~     muscle is obtained for analysis.~   "|||2018-06-01 00:59:17.757345|2018-06-01 00:59:17.757345
NCT00899145|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-07-11|2009-05-09|2009-05-12|Estimate|||||||2017-07-11|2017-07-13|Actual|May 2008||2008-05-31|July 2017|2017-07-31||||January 2010|Actual|2010-01-31||Observational|||Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers|Genetic Modifiers of BRCA1/BRCA2-Related Breast Cancer Risk in BRCA1/BRCA2 Mutation Carriers|Withdrawn|||0|Actual|Gynecologic Oncology Group|||1||f||||||||||||||2018-06-01 00:59:17.821038|2018-06-01 00:59:17.821038
NCT00899132|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-09-28|2009-05-09|2009-05-12|Estimate|||||||2015-09-28|2015-09-29|Estimate|February 2007||2007-02-28|September 2015|2015-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer|The Role of TAB3 Protein in Tumorigenesis|Terminated|||180|Actual|Case Comprehensive Cancer Center||||Study due for continuing review|f||||f||||||Samples With DNA|"~     Tumor tissue samples from paraffin-embedded tissue blocks.~   "|||2018-06-01 00:59:17.87894|2018-06-01 00:59:17.87894
NCT00899119|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-12-17|2009-05-09|2009-05-12|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2005||2005-11-30|January 2008|2008-01-31||||||||Observational|||Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia|Autologous Stem Cell Harvesting for Waldenstrom's Macroglobulinemia|Unknown status|Recruiting||40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:17.944169|2018-06-01 00:59:17.944169
NCT00899093|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-05-21|2009-05-09|2009-05-12|Estimate|||||||2018-05-21|2018-05-22|Actual|September 2007||2007-09-30|May 2018|2018-05-31||||June 2016|Actual|2016-06-30||Observational|||YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy|A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy|Terminated|||2500|Anticipated|Gynecologic Oncology Group|||1||f||||||||||||||2018-06-01 00:59:18.015332|2018-06-01 00:59:18.015332
NCT00899080|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|July 4, 2008|Actual|2008-07-04|May 2017|2017-05-31|August 4, 2008|Actual|2008-08-04|August 4, 2008|Actual|2008-08-04||Observational|||Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide|Screening of Cathepsin G Levels in Multiple Myeloma Patients Receiving Treatment With Thalidomide/Lenalidomide Within the ECOG Trials E1A00 and E4A03|Completed|||33|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:18.417875|2018-06-01 00:59:18.417875
NCT00899054|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2012-11-21|2009-05-11|2009-05-12|Estimate|||||||2012-11-21|2012-11-22|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|January 2011|Actual|2011-01-31||Interventional|SPARK||Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer|An Open Label, Multicenter Phase I/II Study Of Selective Cyclin Dependent Kinase Inhibitor P276-00 In Combination With Radiation In Subjects With Recurrent And/Or Locally Advanced Squamous Cell Carcinoma Of Head And Neck|Completed||Phase 1/Phase 2|23|Actual|Piramal Enterprises Limited||1|||f||||t||||||||||2018-06-01 00:59:18.538325|2018-06-01 00:59:18.538325
NCT00899041|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2013-11-07|2009-05-11|2009-05-12|Estimate|||||||2013-11-07|2013-11-08|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Functional Evaluation of a Standard and a High-flexion Knee Prosthesis Using Thigh-calf Contact Force Measurements|In-vivo Study Investigating the Difference in Functional Outcome Between Two Types of Knee Prostheses: the Sigma FB (Depuy, J&J, UK; Standard Implant) and the Sigma RP-F (Depuy, J&J, UK; High-flexion Implant)|Completed||N/A|67|Actual|Radboud University||2|||f||||||||||||||2018-06-01 00:59:18.627288|2018-06-01 00:59:18.627288
NCT00899028|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-04-19|2009-05-09|2009-05-12|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2001||2001-05-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Observational|||Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants|Identification and Validation of Molecular Markers in Lung Cancer|Completed|||689|Actual|Vanderbilt University Medical Center|||||f|||||f|f||||||||2018-06-01 00:59:18.703694|2018-06-01 00:59:18.703694
NCT00899015|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-03-14|2009-05-09|2009-05-12|Estimate|||||||2012-03-14|2012-03-16|Estimate||||March 2012|2012-03-31|February 2008|Actual|2008-02-29|||||Observational|||Assessing Arsenic Trioxide in Young Patients With Leukemia or Lymphoma Who Were Treated on Clinical Trial NCI-00-C-0070J|Sample Analysis for Terminated Protocol 00-C-0070, Pediatric Phase I Trial of Arsenic Trioxide|Completed|||23|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:59:18.771661|2018-06-01 00:59:18.771661
NCT00899002|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-04-08|2009-05-09|2009-05-12|Estimate|||||||2013-04-08|2013-04-10|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer|Molecular Analysis of Liver Cancer|Withdrawn|||0|Actual|Vanderbilt-Ingram Cancer Center||||slow accrual|f||||t||||||Samples With DNA|"~     DNA will be extracted from the tissue samples and analyzed for molecular signatures, i.e.,~     genomic and proteomic analyses.~   "|||2018-06-01 00:59:18.823281|2018-06-01 00:59:18.823281
NCT00898989|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2010-12-18|2009-05-11|2009-05-12|Estimate|||||||2010-12-18|2010-12-21|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|IBMan||Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis|Evaluation of Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis|Completed|||42|Anticipated|Institut de Myologie, France|||2||f||||f||||||||||2018-06-01 00:59:18.899799|2018-06-01 00:59:18.899799
NCT00898976|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-07-12|2009-05-09|2009-05-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|August 1998||1998-08-31|July 2016|2016-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Biomarkers in Native American Women With Breast Cancer|Molecular Markers in Native American Women With Breast Cancer|Completed|||120|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     tissue samples~   "|||2018-06-01 00:59:18.955161|2018-06-01 00:59:18.955161
NCT00898963|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|April 18, 2007|Actual|2007-04-18|May 2017|2017-05-31|December 21, 2011|Actual|2011-12-21|December 21, 2011|Actual|2011-12-21||Observational|||Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496|Identification of Biomarkers in Follicular Lymphoma|Completed|||175|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:19.017137|2018-06-01 00:59:19.017137
NCT00898950|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|August 2004||2004-08-31|May 2009|2009-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes|The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk|Completed||N/A|21|Actual|University of Portsmouth||4|||f||||f||||||||||2018-06-01 00:59:19.073879|2018-06-01 00:59:19.073879
NCT00898937|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|2018-03-05||2018-04-12|2009-05-09|2009-05-12|Estimate|2018-04-12|2018-04-13|Actual||||2018-04-12|2018-04-13|Actual|September 1999||1999-09-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|December 2014|Actual|2014-12-31||Observational|||Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast|Pilot Study for Analysis of Tumor Gene Expression by DNA Microarray Analysis in Patients Undergoing Breast Cancer Surgery or Core Biopsy Sampling|Terminated|||55|Actual|Georgetown University||||Funding ended|f||||f||||||||||2018-06-01 00:59:19.158344|2018-06-01 00:59:19.158344
NCT00898924|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-06-28|2009-05-09|2009-05-12|Estimate|||||||2016-06-28|2016-06-29|Estimate|November 2005||2005-11-30|June 2016|2016-06-30|July 2010|Actual|2010-07-31|March 2006|Actual|2006-03-31||Observational|||Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer|Evaluation of EGFR and K-ras Mutations in Patients With Stage III NSCLC Treated on CALGB 30106|Completed|||60|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     tissue, whole blood and serum samples~   "|||2018-06-01 00:59:19.369223|2018-06-01 00:59:19.369223
NCT00898911|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|July 8, 2008|Actual|2008-07-08|May 2017|2017-05-31|April 8, 2012|Actual|2012-04-08|April 8, 2012|Actual|2012-04-08||Observational|||Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer|Prediction of Overall Survival Using Mass Spectrometry Profiling in Head and Neck Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitors|Completed|||30|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:19.435224|2018-06-01 00:59:19.435224
NCT00898898|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2000||2000-05-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831|Analyses of c-Myc (MYC) and Topoisomerase II Alpha (TOP2A) Copy Number Aberrations; MYC, Insulin-like Growth Factor Receptor-1 (IGF-1R) and PTEN Protein Expressions; and Phosphatidylinositol 3' Kinase (PIK3) Gene Mutations in N9831 Primary Breast Tumors|Active, not recruiting|||1649|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||t||||||Samples With DNA|"~     Tissue (FFPE whole block sections and TMA sections)~   "|||2018-06-01 00:59:19.489182|2018-06-01 00:59:19.489182
NCT00898885|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Observational|ORALGVHD||Analysis of the Clinical and Histological Correlation of Oral Graft-Versus-Host-Disease (GVHD)|Clinical and Histological Evaluation of Chronic Graft-Versus Host Disease (cGVHD) in Oral Mucosa|Completed|||41|Actual|University of Sao Paulo|||1||f||||t||||||Samples Without DNA|"~     samples of oral mucosa and minor salivary glands stained with hematoxylin and eosin for~     visualization of the layers in optical microscope~   "|||2018-06-01 00:59:19.54175|2018-06-01 00:59:19.54175
NCT00898872|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-05-17|2009-05-09|2009-05-12|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 1993||1993-03-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial|Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease|Completed|||32|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:59:19.644842|2018-06-01 00:59:19.644842
NCT00898859|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2015-01-15|2009-05-11|2009-05-12|Estimate|||||||2015-01-15|2015-01-16|Estimate|May 2009||2009-05-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Observational|||Role of A Disintegrin and Metalloproteinase (ADAM) in Epithelial Dysfunction|Role of ADAMs in Epithelial Dysregulation in COPD. Differences Between From Non-smokers, Healthy Smokers and Patients With COPD.|Completed|||50|Actual|University Medical Center Groningen|||5||f||||f||||||Samples Without DNA|"~     Bronchial brushes~   "|||2018-06-01 00:59:19.920445|2018-06-01 00:59:19.920445
NCT00898846|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-09-26|2009-05-09|2009-05-12|Estimate|||||||2016-09-26|2016-09-28|Estimate|October 2006||2006-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Observational|||Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery|Identification of the Prognostic Factors of Stage II Colon Cancer Patients Receiving Adjuvant Chemotherapy With UFT|Completed|||1111|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||2||f||||t||||||Samples With DNA|"~     Tumor tissue samples~   "|||2018-06-01 00:59:20.021136|2018-06-01 00:59:20.021136
NCT00898833|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2003||2003-07-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583|Laboratory Studies in Hormone Refractory Prostate Cancer - A Companion Study to CALGB 9480 and 9583|Terminated|||868|Anticipated|Alliance for Clinical Trials in Oncology|||1|The proposed work could not be completed.|f||||f||||||Samples With DNA|"~     Plasma, serum, urine~   "|||2018-06-01 00:59:20.361453|2018-06-01 00:59:20.361453
NCT00898820|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-04-07|2009-05-09|2009-05-12|Estimate|||||||2014-04-07|2014-04-09|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524|Predictive Markers of Response to Pemetrexed (Companion Study to RC0524)|Completed|||80|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 00:59:20.450101|2018-06-01 00:59:20.450101
NCT00898807|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2014-03-19||2014-06-26|2009-05-11|2009-05-12|Estimate|2014-06-26|2014-06-27|Estimate||||2014-06-26|2014-06-27|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CitAD||Citalopram for Agitation in Alzheimer's Disease|A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease|Completed||Phase 3|186|Actual|JHSPH Center for Clinical Trials||2|||f||||t||||||||||2018-06-01 00:59:20.548946|2018-06-01 00:59:20.548946
NCT00898794|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-06|2009-05-09|2009-05-12|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2007||2007-10-31|June 2011|2011-06-30||||May 2009|Anticipated|2009-05-31||Observational|||Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer|Influence of Bevacizumab and VEGF on Platelet Aggregation|Unknown status|Recruiting||20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:20.956552|2018-06-01 00:59:20.956552
NCT00898781|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2011-07-18|2009-05-09|2009-05-12|Estimate|||||||2011-07-18|2011-07-19|Estimate|November 2007||2007-11-30|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer|Molecular Detection of Circulating Cancer Cells in Breast, Ovarian, Colon and Pancreatic Cancer|Terminated|||80|Anticipated|Mayo Clinic|||6|Due to poor accrual|f||||t||||||||||2018-06-01 00:59:21.022251|2018-06-01 00:59:21.022251
NCT00898768|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2014-12-08|2009-05-11|2009-05-12|Estimate|||||||2014-12-08|2014-12-09|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CELSIUS||Capsule Endoscopy to Screen for Small Bowel Neoplasia in Lynch Syndrome|Capsule Endoscopy in Lynch Syndrome for Small Intestinal Tumor Screening|Completed||Early Phase 1|200|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-06-01 00:59:21.094894|2018-06-01 00:59:21.094894
NCT00898755|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-27|2009-05-09|2009-05-12|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2007||2007-03-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Collecting and Storing Tissue From Young Patients With Cancer|Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies|Recruiting|||500|Anticipated|Children's Oncology Group|||17||f||||f||||||Samples With DNA|"~     tumor tissue~   "|||2018-06-01 00:59:21.185155|2018-06-01 00:59:21.185155
NCT00898742|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-03-29|2009-05-09|2009-05-12|Estimate|||||||2013-03-29|2013-04-02|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer|Molecular Signatures of HNSCC in Response to Targeted Therapies|Terminated|||58|Actual|Vanderbilt-Ingram Cancer Center|||1|study closed prematurely upon PI's departure from VICC|f||||||||||||||2018-06-01 00:59:21.426133|2018-06-01 00:59:21.426133
NCT00898716|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2011-11-29|2009-05-11|2009-05-12|Estimate|||||||2011-11-29|2011-11-30|Estimate|September 2009||2009-09-30|July 2010|2010-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan|Phase 1 Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan|Completed||Phase 1|15|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 00:59:21.499119|2018-06-01 00:59:21.499119
NCT00898703|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-12-13|2009-05-09|2009-05-12|Estimate|||||||2012-12-13|2012-12-17|Estimate|August 2001||2001-08-31|December 2012|2012-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer|QUANTIFICATION OF CIRCULATING ENDOTHELIAL CELLS (CEC) AND PLASMA ANGIOGENIC FACTORS IN PATIENTS WITH BREAST CANCER|Completed|||50|Actual|University of Arizona|||||f||||||||||||||2018-06-01 00:59:21.557252|2018-06-01 00:59:21.557252
NCT00898690|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-12-17|2009-05-09|2009-05-12|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2003||2003-03-31|May 2006|2006-05-31||||||||Observational|||Gene Expression in Predicting Response to Paclitaxel in Patients With Breast Cancer|Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol|Unknown status|Active, not recruiting||120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:21.607153|2018-06-01 00:59:21.607153
NCT00898677|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2009-05-21||2015-02-13|2009-05-08|2009-05-12|Estimate|2009-05-22|2009-07-14|Estimate||||2015-02-13|2015-03-04|Estimate|September 1995||1995-09-30|February 2015|2015-02-28|September 1996|Actual|1996-09-30|May 1996|Actual|1996-05-31||Interventional|||Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)|A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Examine the Safety, Tolerability, and Efficacy of Single Oral Doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for Acute Treatment of Migraine|Completed||Phase 3|1268|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 00:59:21.682108|2018-06-01 00:59:21.682108
NCT00898664|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-03-29|2009-05-09|2009-05-12|Estimate|||||||2013-03-29|2013-04-02|Estimate|June 2006||2006-06-30|March 2013|2013-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer|Genetic Analysis of Head and Neck Squamous Cell Carcinoma|Completed|||74|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||Samples With DNA|"~     Assess common genetic mutations in tumor and germline DNAs from HNSCCs and search for viral~     DNAs and relate this information to demographics, tumor characteristics and patient~     prognosis.~   "|||2018-06-01 00:59:22.406396|2018-06-01 00:59:22.406396
NCT00898456|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2006||2006-10-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia|Multidrug Resistance Protein Gene Polymorphisms in Acute Myeloid Leukemia. A CALGB Leukemia Tissue Bank Project|Active, not recruiting|||600|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 00:59:23.711652|2018-06-01 00:59:23.711652
NCT00898638|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-01-23|2009-05-09|2009-05-12|Estimate|||||||2018-01-23|2018-01-25|Actual|February 13, 2003|Actual|2003-02-13|January 2018|2018-01-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31|9999 Days|Observational [Patient Registry]|||Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants|Head and Neck Tumor Tissue Repository and Clinical Database|Recruiting|||8000|Anticipated|Vanderbilt University Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Retrospective --Pathology archives will be reviewed and those with a sufficient amount of~     formalin-fixed tumor may be enrolled. Additionally, normal tissue from upper aerodigestive~     tract tissue excised for benign conditions will be collected. A one-time collection of~     medical data will be done for these cases. Specimens and datasets may also be incorporated~     from other studies with specimens and/or useful data left over.~      Prospective -- For non-tumor volunteers: After patient has signed consent, mouth cells and/or~     saliva samples will be obtained. If the patient agrees to having a biopsy, tissue may also be~     collected.~      For tumor patients: If the patient requires surgery, biological specimens will be collected~     day of surgery. The pathologist or designated lab personnel will oversee processing of the~     specimens. If the patient is scheduled to have a bronchoscopy, a bronchial washing may be~     collected.~   "|No||2018-06-01 00:59:22.482187|2018-06-01 00:59:22.482187
NCT00898612|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-03-06|2009-05-09|2009-05-12|Estimate|||||||2014-03-06|2014-03-10|Estimate|March 2008||2008-03-31|March 2014|2014-03-31||||December 2012|Anticipated|2012-12-31||Observational|||Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant|Using the Transcriptome for Early Detection of Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation|Withdrawn|||0|Actual|Mayo Clinic||||No Patients enrolled|f||||t||||||||||2018-06-01 00:59:22.580241|2018-06-01 00:59:22.580241
NCT00898599|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2014-11-26|2009-05-11|2009-05-12|Estimate|||||||2014-11-26|2014-12-02|Estimate|April 2009||2009-04-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Interventional|||Prebiotics and Immune Function in Middle Aged Humans|Investigation of the Effects of a Prebiotic Supplement on Immune Function in Healthy Human Adults|Completed||Phase 1/Phase 2|49|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 00:59:22.652513|2018-06-01 00:59:22.652513
NCT00898573|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-10-01|2009-05-09|2009-05-12|Estimate|||||||2015-10-01|2015-10-02|Estimate|July 2008||2008-07-31|October 2015|2015-10-31||||||||Observational|||Lapatinib Resistance in Patients With Breast Cancer|Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers|Withdrawn|||0|Actual|Case Comprehensive Cancer Center|||||f||||t||||||Samples With DNA|"~     Previously collected tumor tissue samples are obtained for genetic analysis studies. Patients~     also undergo blood sample collection for extraction of DNA.~   "|||2018-06-01 00:59:22.714211|2018-06-01 00:59:22.714211
NCT00898560|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2014-12-05||2014-12-05|2009-05-11|2009-05-12|Estimate|2014-12-05|2014-12-12|Estimate||||2014-12-05|2014-12-12|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive|Effect of Repeated Administration of Eslicarbazepine Acetate (BIA 2-093) 800mg Once-daily on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Subjects|Completed||Phase 1|20|Actual|Bial - Portela C S.A.||2|||f||||t||||||||||2018-06-01 00:59:22.875415|2018-06-01 00:59:22.875415
NCT00898547|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|November 2005||2005-11-30|August 2017|2017-08-31||||March 2006|Actual|2006-03-31||Observational|||Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107|Additional Circulating Markers of Angiogenesis and Disease in Mesothelioma Patients Treated on CALGB 30107|Active, not recruiting|||47|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Samples retained from patients participating on CALGB-30107.~   "|||2018-06-01 00:59:23.166186|2018-06-01 00:59:23.166186
NCT00898534|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|November 2003||2003-11-30|May 2009|2009-05-31|January 2006|Actual|2006-01-31|September 2005|Actual|2005-09-30||Interventional|||Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus|Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus|Completed||Phase 4|234|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-06-01 00:59:23.236513|2018-06-01 00:59:23.236513
NCT00898521|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2011-05-08|2009-05-11|2009-05-12|Estimate|||||||2011-05-08|2011-05-10|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns|Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns (Children & Adults)- Protocol MW2008-09-03|Unknown status|Recruiting|Phase 2|10|Anticipated|MediWound Ltd||1|||f||||t||||||||||2018-06-01 00:59:23.327715|2018-06-01 00:59:23.327715
NCT00898508|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-12-13|2009-05-09|2009-05-12|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2005||2005-08-31|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease|Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up|Active, not recruiting|||910|Anticipated|City of Hope Medical Center|||2||f||||t||||||Samples With DNA|"~     Peripheral blood sample and biopsy tissue~   "|||2018-06-01 00:59:23.413011|2018-06-01 00:59:23.413011
NCT00898495|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|May 11, 2007|Actual|2007-05-11|May 2017|2017-05-31|December 31, 2008|Actual|2008-12-31|December 31, 2008|Actual|2008-12-31||Observational|||Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery|Single Nucleotide Polymorphisms (SNP) in Platinum-/Radiation Pathway Genes to Predict Outcome in Patients With Esophageal Adenocarcinoma Treated With Cisplatin-Based Chemoradiotherapy Followed by Surgical Resection|Completed|||118|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:23.517415|2018-06-01 00:59:23.517415
NCT00898482|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-11-17|2009-05-09|2009-05-12|Estimate|||||||2015-11-17|2015-11-20|Estimate|May 2005||2005-05-31|November 2015|2015-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants|Pancreatic Cancer Serum and Peripheral Blood Lymphocyte Repository|Completed|||88|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||3||f||||f||||||||||2018-06-01 00:59:23.577972|2018-06-01 00:59:23.577972
NCT00898469|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-05-09|2009-05-09|2009-05-12|Estimate|||||||2016-05-09|2016-05-11|Estimate|March 2005||2005-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Identifying Risk Factors for Bone Tissue Death in Young Patients With Acute Lymphoblastic Leukemia Treated on Clinical Trial CCG-1882|Study Of Pharmacogenetic Risk Factors For Avascular Necrosis CCG 1882|Completed|||671|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-06-01 00:59:23.65061|2018-06-01 00:59:23.65061
NCT00898443|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2012-04-19||2012-06-26|2009-05-08|2009-05-12|Estimate|2012-06-26|2012-08-07|Estimate||||2012-06-26|2012-08-07|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Continuous Labor Epidural Catheter for Tubal Ligation Study|Success Rate, Efficiency, and Predictors of Reactivation of a Continuous Labor Epidural Catheter for Postpartum Tubal Ligation|Terminated||N/A|18|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 00:59:23.789144|2018-06-01 00:59:23.789144
NCT00898430|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-03-29|2009-05-09|2009-05-12|Estimate|||||||2013-03-29|2013-04-02|Estimate|November 2003||2003-11-30|March 2013|2013-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy|Biomarkers of Survival in HNSCC|Terminated|||49|Actual|Vanderbilt-Ingram Cancer Center|||1|Study closed prematurely upon PI's departure|f||||t||||||||||2018-06-01 00:59:24.024169|2018-06-01 00:59:24.024169
NCT00898417|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|March 14, 2008|Actual|2008-03-14|May 2017|2017-05-31|April 14, 2008|Actual|2008-04-14|April 14, 2008|Actual|2008-04-14||Observational|||Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab|Development of a Serum Proteomic Classifier for the Prediction of Benefit From Bevacizumab in Combination With Carboplatin and Paclitaxel|Completed|||90|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:24.090847|2018-06-01 00:59:24.090847
NCT00898404|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-05-09|2009-05-09|2009-05-12|Estimate|||||||2016-05-09|2016-05-11|Estimate|November 2003||2003-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate|Molecular Correlates of Methotrexate in Childhood ALL|Completed|||150|Anticipated|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 00:59:24.147237|2018-06-01 00:59:24.147237
NCT00898391|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-05-16|2009-05-09|2009-05-12|Estimate|||||||2016-05-16|2016-05-18|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Study of DNA in Blood Samples From Patients With Neuroblastoma|Analysis of Circulating MYCN DNA in Serum Samples Obtained From Patients With Neuroblastoma|Completed|||329|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 00:59:24.219696|2018-06-01 00:59:24.219696
NCT00898378|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-09-17|2009-05-09|2009-05-12|Estimate|||||||2014-09-17|2014-09-18|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps|Cancer Care Engineering of Colorectal Cancer - OMICs Pilot Study|Completed|||551|Actual|Indiana University|||3||f||||t||||||Samples With DNA|"~     Biospecimens will be analyzed to study metabolimics, lipidomics, genomics, glycoproteomics,~     global proteomics and Vitamin D status.~   "|||2018-06-01 00:59:24.292779|2018-06-01 00:59:24.292779
NCT00898365|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-27|2009-05-09|2009-05-12|Estimate|||||||2017-11-27|2017-11-29|Actual|February 2006||2006-02-28|November 2016|2016-11-30|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Study of Kidney Tumors in Younger Patients|Renal Tumors Classification, Biology, and Banking Study|Recruiting|||5000|Anticipated|Children's Oncology Group|||1||f||||t||||||Samples With DNA|"~     Tumor tissue, blood, and urine.~   "|||2018-06-01 00:59:24.44461|2018-06-01 00:59:24.44461
NCT00898352|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2013-05-24|2009-05-09|2009-05-12|Estimate|||||||2013-05-24|2013-05-27|Estimate||||October 2009|2009-10-31||||November 1990|Actual|1990-11-30||Interventional|||Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes|Phase III Radiation Therapy vs Pelvic Node Resection for Previously Untreated Invasive Squamous Cell Carcinoma of the Vulva With Positive Groin Nodes|Completed||Phase 3|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 00:59:26.173107|2018-06-01 00:59:26.173107
NCT00898326|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-06-01|2009-05-09|2009-05-12|Estimate|||||||2017-06-01|2017-06-02|Actual|April 1, 2011|Actual|2011-04-01|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|SHIP36B||PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer|Analysis of Biopsy Results at 36 Months After Permanent I-125 Implantation Therapy Plus LHRH-agonist Therapy for Patients With Untreated Intermediate Prostate Cancer.|Completed|||198|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||t||||||||||2018-06-01 00:59:26.272908|2018-06-01 00:59:26.272908
NCT00898313|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-21|2009-05-09|2009-05-12|Estimate|||||||2017-08-21|2017-08-23|Actual|December 2003||2003-12-31|August 2017|2017-08-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2025|Anticipated|2025-01-31||Observational|||Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer|Molecular Predictors of Lung Cancer Behavior|Recruiting|||2000|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood, urine, nasal cells, sputum, bronchal epithelial cells, airway tissue, and lung tissue~   "|||2018-06-01 00:59:26.337415|2018-06-01 00:59:26.337415
NCT00898300|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-11-11|2009-05-09|2009-05-12|Estimate|||||||2015-11-11|2015-11-13|Estimate|September 2005||2005-09-30|November 2015|2015-11-30|November 2013|Actual|2013-11-30|July 2010|Actual|2010-07-31||Observational|||Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer|Establishment of a Head and Neck Cancer Tissue/Specimen Bank|Completed|||351|Actual|Radiation Therapy Oncology Group|||1||f||||f||||||Samples Without DNA|"~     1. Fresh frozen specimens of normal squamous mucosa, tumors, and pre-malignant lesions of the~     upper aerodigestive tract. 2. Paraffin-embedded tissue sections from head and neck~     premalignant and malignant lesions. 3. Serum, plasma and isolate lymphocytes from blood drawn~     from patients with head and neck cancer. 4. Buccal scrapings and saliva samples from patients~     with head and neck cancer.~   "|||2018-06-01 00:59:26.451551|2018-06-01 00:59:26.451551
NCT00898287|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2012-01-19|2009-05-11|2009-05-12|Estimate|||||||2012-01-19|2012-01-20|Estimate|May 2009||2009-05-31|January 2012|2012-01-31||||December 2010|Actual|2010-12-31||Interventional|SAVIOR||Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer|A Phase I/II Study to Evaluate Safety and Efficacy of P276-00 in Combination With Gemcitabine in Patients With Cancer of Pancreas|Completed||Phase 1/Phase 2|23|Actual|Piramal Enterprises Limited||1|||f||||t||||||||||2018-06-01 00:59:26.744658|2018-06-01 00:59:26.744658
NCT00898274|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-03-08|2009-05-09|2009-05-12|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants|Antioxidant Enzymes and Oxidative DNA Damage in Subjects With 'High-Risk' for Prostate Cancer|Completed|||40|Actual|Case Comprehensive Cancer Center|||2||f||||t||||||Samples With DNA|"~     Blood samples from patients at high risk of developing prostate cancer and from healthy male~     participants.~   "|||2018-06-01 00:59:26.824895|2018-06-01 00:59:26.824895
NCT00898261|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|October 26, 2007|Actual|2007-10-26|May 2017|2017-05-31|July 19, 2012|Actual|2012-07-19|July 19, 2012|Actual|2012-07-19||Observational|||Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia|Genetic Risk Classes in Adult Acute Lymphocytic Leukemia|Completed|||137|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:26.904498|2018-06-01 00:59:26.904498
NCT00898235|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-04-24|2009-05-09|2009-05-12|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2000|Actual|2000-01-31|April 2018|2018-04-30|February 2037|Anticipated|2037-02-28|January 2022|Anticipated|2022-01-31||Observational|||Collection of Samples and Clinical Data From Patients With Amyloid Diseases|Data, Tissue, Blood, and Urine Repository for Amyloid Diseases|Recruiting|||10000|Anticipated|Boston Medical Center|||||f||||f|f|f||||Samples With DNA|"~     blood, urine, and tissue~   "|||2018-06-01 00:59:26.978647|2018-06-01 00:59:26.978647
NCT00898222|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2014-07-16||2015-09-21|2009-05-11|2009-05-12|Estimate|2014-10-29|2014-11-04|Estimate||||2015-09-21|2015-09-25|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects|Effect of Daily Low Dose Aspirin on Exhaled Inflammatory Mediators in Normal Subjects|Completed||N/A|4|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-06-01 00:59:27.060021|2018-06-01 00:59:27.060021
NCT00898209|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-06-23|2009-05-09|2009-05-12|Estimate|||||||2014-06-23|2014-06-24|Estimate|April 2003||2003-04-30|April 2013|2013-04-30|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Observational|||Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE)|Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer|Terminated|||564|Actual|Vanderbilt-Ingram Cancer Center|||2|This study competed with another VICC study|f||||t||||||Samples With DNA|"~     Peripheral blood lymphocyte DNA, and Exhaled breath condensate~   "|||2018-06-01 00:59:27.205545|2018-06-01 00:59:27.205545
NCT00898183|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-02-12|2009-05-09|2009-05-12|Estimate|||||||2013-02-12|2013-02-15|Estimate|November 1996||1996-11-30|February 2013|2013-02-28|February 2007|Actual|2007-02-28|February 2006|Actual|2006-02-28||Observational|||S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma|Cytogenetic, Molecular and Cellular Biology Studies in Metastatic Melanoma Patients, Ancillary|Completed|||91|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:59:27.293926|2018-06-01 00:59:27.293926
NCT00898170|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Myoma Removal on Blood Pressure and Erythropoetin Level|Effect of Myoma Removal on Blood Pressure and Erythropoetin Level|Completed||N/A|28|Actual|Shiraz University of Medical Sciences||1|||f||||||||||||||2018-06-01 00:59:27.351569|2018-06-01 00:59:27.351569
NCT00898157|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|September 24, 2007|Actual|2007-09-24|May 2017|2017-05-31|September 24, 2008|Actual|2008-09-24|September 24, 2008|Actual|2008-09-24||Observational|||Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494|Analysis of E4494 Tissues to Determine the Prognostic Significance of Biomarkers in Diffuse Large B Cell Lymphoma (DLBCL) Treated With Standard Chemotherapy (CHOP) Plus Rituximab ®)1|Completed|||1600|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:27.423723|2018-06-01 00:59:27.423723
NCT00898144|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2010-11-05|2009-05-09|2009-05-12|Estimate|||||||2010-11-05|2010-11-08|Estimate|February 2008||2008-02-29|November 2010|2010-11-30||||June 2009|Anticipated|2009-06-30||Observational|||Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171|Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS)|Unknown status|Not yet recruiting||55|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:27.478324|2018-06-01 00:59:27.478324
NCT00898131|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-21|2009-05-09|2009-05-12|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2001||2001-08-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer|Specialized Program of Research Excellence (SPORE) in Breast Cancer: Tissue and Specimen Collection|Recruiting|||10000|Anticipated|Northwestern University|||||f||||f||||||Samples Without DNA|"~     Tissue from diagnostic biopsies, as well as initial or follow-up surgical procedures for the~     treatment or prevention of breast cancer. No extra tissue is taken, only what is left over~     following clinical use will be retained for banking purposes.~   "|||2018-06-01 00:59:27.529145|2018-06-01 00:59:27.529145
NCT00898118|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-09|2009-05-09|2009-05-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|April 2007||2007-04-30|April 2008|2008-04-30||||March 2013|Anticipated|2013-03-31||Observational|||Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant|Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC)|Unknown status|Recruiting||125|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:27.630352|2018-06-01 00:59:27.630352
NCT00898092|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2006||2006-05-31|August 2017|2017-08-31||||December 2012|Actual|2012-12-31||Observational|||Genetics Study of Tissue Collected From Patients With Acute Myeloid Leukemia|Molecular Genetic Studies of Acute Myeloid Leukemia (AML) With Normal Cytogenetics. A CALGB Leukemia Tissue Bank Project|Active, not recruiting|||735|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||||||||||||2018-06-01 00:59:27.794377|2018-06-01 00:59:27.794377
NCT00898079|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-12-11|2009-05-09|2009-05-12|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2003||2003-03-31|December 2017|2017-12-31|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer|A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors|Active, not recruiting|||3000|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     solid tissue (malignant and normal)~   "|||2018-06-01 00:59:27.917673|2018-06-01 00:59:27.917673
NCT00898066|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-03-05|2009-05-09|2009-05-12|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease|Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma|Completed|||37|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:59:28.25814|2018-06-01 00:59:28.25814
NCT00898053|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-05-13|2009-05-09|2009-05-12|Estimate|||||||2016-05-13|2016-05-17|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Study of Tumor Samples From Patients With Ewing Sarcoma|Observational - Prognostic Value of p53 and/or p16 Alterations in Ewing Sarcoma|Completed|||200|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tumor samples~   "|||2018-06-01 00:59:28.324376|2018-06-01 00:59:28.324376
NCT00898027|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-01-28|2009-05-09|2009-05-12|Estimate|||||||2013-01-28|2013-01-29|Estimate|May 2006||2006-05-31|January 2013|2013-01-31|February 2009|Actual|2009-02-28|March 2008|Actual|2008-03-31||Observational|||Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer|Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on Magnesium Homeostasis|Terminated|||10|Actual|Vanderbilt-Ingram Cancer Center||||slow accrual|f||||t||||||||||2018-06-01 00:59:28.464589|2018-06-01 00:59:28.464589
NCT00898014|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2011-05-12|2009-05-09|2009-05-12|Estimate|||||||2011-05-12|2011-05-13|Estimate|May 2007||2007-05-31|July 2009|2009-07-31||||April 2010|Actual|2010-04-30||Observational|||Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer|Study Evaluating the Prognostic and Predictive Value of Response to First-Line Chemotherapy by Detection of Circulating Tumor Cells (CTC) in Patients With Metastatic Breast Cancer|Completed|||216|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:28.524052|2018-06-01 00:59:28.524052
NCT00897988|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-03-10|2009-05-09|2009-05-12|Estimate|||||||2017-03-10|2017-03-14|Actual|April 2006||2006-04-30|March 2017|2017-03-31||||||||Observational|||DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx|Effect of PI3K Inhibition in HPV-Associated HNSCC|Completed|||40|Anticipated|Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 00:59:28.587278|2018-06-01 00:59:28.587278
NCT00897975|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2011-07-14|2009-05-11|2009-05-12|Estimate|||||||2011-07-14|2011-07-18|Estimate|July 2009||2009-07-31|November 2009|2009-11-30|July 2011|Actual|2011-07-31|November 2010|Actual|2010-11-30||Interventional|||Red Yeast Rice and Phytosterols In Statin Intolerance|Red Yeast Rice and Phytosterols Versus Red Yeast Rice and Placebo for the Treatment of Hyperlipidemia in Patients With Statin Intolerance: A Multi-Center Randomized Double-blind Study|Completed||Phase 2/Phase 3|200|Actual|Chestnut Hill Health System||4|||f||||t||||||||||2018-06-01 00:59:28.670173|2018-06-01 00:59:28.670173
NCT00897962|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-01-16|2009-05-09|2009-05-12|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2006||2006-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|February 2011|Actual|2011-02-28||Observational|||Blood Glycan Biomarkers in Women With Stage IV Breast Cancer|Serum Glycan Analysis in Breast Cancer|Active, not recruiting|||200|Anticipated|University of California, Davis|||3||f||||t||||||||||2018-06-01 00:59:28.756306|2018-06-01 00:59:28.756306
NCT00897949|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2009-09-26||2015-02-13|2009-05-11|2009-05-12|Estimate|2011-04-05|2011-05-04|Estimate||||2015-02-13|2015-03-04|Estimate|March 1995||1995-03-31|February 2015|2015-02-28|July 1996|Actual|1996-07-31|January 1996|Actual|1996-01-31||Interventional|||MK0462 in Treatment of Migraine With Recurrence (MK0462-022)|A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence|Completed||Phase 3|1473|Actual|Merck Sharp & Dohme Corp.|Pooled Extension data for PN022- NCT00897949; PN025- NCT00899379 and PN029- NCT00897104 appears in NCT01286207|3|||f||||||||||||||2018-06-01 00:59:28.839101|2018-06-01 00:59:28.839101
NCT00897936|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-18|2009-05-09|2009-05-12|Estimate|||||||2017-05-18|2017-05-19|Actual|March 23, 2006|Actual|2006-03-23|May 2017|2017-05-31|April 23, 2006|Actual|2006-04-23|April 23, 2006|Actual|2006-04-23||Observational|||DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia|A Pilot Study to Characterize the Genomic and Epigenomic Signature of NPM Positive Vs. NPM Negative NCL|Completed|||418|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:29.414577|2018-06-01 00:59:29.414577
NCT00897923|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-03-21|2009-05-09|2009-05-12|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2003||2003-09-30|April 2016|2016-04-30|February 10, 2012|Actual|2012-02-10|February 10, 2012|Actual|2012-02-10||Observational|||Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma|In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy|Completed|||17|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 00:59:29.495156|2018-06-01 00:59:29.495156
NCT00897910|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|2013-10-22||2015-12-09|2009-05-09|2009-05-12|Estimate|2013-10-22|2013-12-12|Estimate||||2015-12-09|2016-01-11|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|September 2012|Actual|2012-09-30|November 2009|Actual|2009-11-30||Observational|||Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma|Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC|Terminated|||6|Actual|Barbara Ann Karmanos Cancer Institute|Tis study was closed due to technical laboratory difficulty in performing the experiments proposed.|||Funding unavailable|f||||t||||||Samples Without DNA|"~     Data from flow cytometry, and Cytokine release assays for B cells and T cells from peripheral~     blood mononuclear cells (PBMCs) will be obtained.~   "|||2018-06-01 00:59:29.612735|2018-06-01 00:59:29.612735
NCT00897897|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|2011-07-05||2012-12-03|2009-05-11|2009-05-12|Estimate|2011-10-07|2011-11-11|Estimate||||2012-12-03|2012-12-04|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids|Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Completed||N/A|33|Actual|Philips Healthcare||1|||f||||t||||||||||2018-06-01 00:59:29.774272|2018-06-01 00:59:29.774272
NCT00897884|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2012-01-18|2009-05-08|2009-05-12|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer|Clinical and Biologic Effects of Metformin in Early Stage Breast Cancer|Completed||N/A|39|Actual|Mount Sinai Hospital, Canada||1|||f||||f||||||||||2018-06-01 00:59:29.965857|2018-06-01 00:59:29.965857
NCT00897871|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-09|2009-05-09|2009-05-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2007||2007-02-28|June 2009|2009-06-30||||||||Observational|||Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer|Pharmacokinetics and Pharmacogenetics of Anticancer Drugs in Infants and Young Children|Unknown status|Recruiting||60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:30.055342|2018-06-01 00:59:30.055342
NCT00897858|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-04-18|2009-05-09|2009-05-12|Estimate|||||||2013-04-18|2013-04-19|Estimate|August 2006||2006-08-31|April 2013|2013-04-30||||January 2014|Anticipated|2014-01-31||Observational|||Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors|Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children With Newly Diagnosed Central Nervous System Tumors|Withdrawn|||0|Actual|Pediatric Brain Tumor Consortium|||1|"This non-therapeutic study was registered in error. The PRS team doesn't delete studies once~   registered, so they recommended changing the status to Withdrawn"|f||||f||||||||||2018-06-01 00:59:30.18478|2018-06-01 00:59:30.18478
NCT00897663|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-01-22|2009-05-09|2009-05-12|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2006|Actual|2006-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies|Optimizing EGFR Inhibitor-Based Therapies for GBM|Completed|||56|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-06-01 00:59:32.260547|2018-06-01 00:59:32.260547
NCT00897845|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|June 17, 2008|Actual|2008-06-17|May 2017|2017-05-31|December 2, 2013|Actual|2013-12-02|December 2, 2013|Actual|2013-12-02||Observational|||Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer|Molecular Profiling of E2197 FFPE Samples Using a Custom 512 Breast Cancer Gene Set on the DASL Platform: Towards the Development of Predictive Gene Sets for Risk of Recurrence in Patients With Operable Breast Cancer Treated With Adjuvant Therapy|Completed|||2541|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:30.260014|2018-06-01 00:59:30.260014
NCT00897832|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-03-02|2009-05-09|2009-05-12|Estimate|||||||2013-03-02|2013-03-05|Estimate|January 2007||2007-01-31|March 2013|2013-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer|Developing Predictive Markers of Therapeutic Response in Pancreatic Cancer|Completed|||50|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||||||2018-06-01 00:59:30.319037|2018-06-01 00:59:30.319037
NCT00897819|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|January 3, 2007|Actual|2007-01-03|May 2017|2017-05-31|January 30, 2008|Actual|2008-01-30|January 30, 2008|Actual|2008-01-30||Observational|||Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200|Evaluation of the Association Between DNA Methylation and Shortened Survival in Patients With Advanced Colorectal Cancer Treated With 5-FU/Oxaliplatin-Based Regimens in E3200|Completed|||350|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:30.384709|2018-06-01 00:59:30.384709
NCT00897806|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-07-27|2009-05-09|2009-05-12|Estimate|||||||2012-07-27|2012-07-30|Estimate|February 2002||2002-02-28|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2006|Actual|2006-02-28||Observational|||Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Feasibility of Measuring Gene Expression Patterns Using Tissue Acquisition of Primary Stage 3 & 4 Epithelial Ovarian Cx or Primary Peritoneal Cx & Gene Expression Array Technology for Predicting Paclitaxel Chemotherapy|Terminated|||7|Actual|M.D. Anderson Cancer Center|||1|Terminated due to slow accrual.|f||||f||||||Samples With DNA|"~     Tumor samples undergo transcriptional profiling using cDNA microarrays.~   "|||2018-06-01 00:59:30.445603|2018-06-01 00:59:30.445603
NCT00897793|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-04-10|2009-05-09|2009-05-12|Estimate|||||||2013-04-10|2013-04-12|Estimate|January 2006||2006-01-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer|A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury|Completed|||25|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||Samples With DNA|"~     venous blood~   "|||2018-06-01 00:59:30.525394|2018-06-01 00:59:30.525394
NCT00897780|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-10|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|September 2009||2009-09-30|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|VR||Combined Biofeedback With Virtual Reality in the Treatment of Pediatric Headache||Unknown status|Not yet recruiting|N/A|30|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 00:59:30.615288|2018-06-01 00:59:30.615288
NCT00897767|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-12-05|2009-05-09|2009-05-12|Estimate|||||||2012-12-05|2012-12-06|Estimate|July 2004||2004-07-31|December 2012|2012-12-31||||||||Observational|||Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial|Ancillary Laboratory Protocol For the Collection of Diagnostic Material On Patients Considered For ECOG Treatment Trials For Leukemia Or Related Hematologic Disorders|Unknown status|Recruiting||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:30.724231|2018-06-01 00:59:30.724231
NCT00897754|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|July 24, 2007|Actual|2007-07-24|May 2017|2017-05-31|February 1, 2009|Actual|2009-02-01|February 1, 2009|Actual|2009-02-01||Observational|||Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab|Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy|Completed|||200|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:31.348496|2018-06-01 00:59:31.348496
NCT00897741|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-02-10|2009-05-09|2009-05-12|Estimate|||||||2014-02-10|2014-02-11|Estimate|December 2004||2004-12-31|February 2014|2014-02-28|March 2009|Actual|2009-03-31|May 2008|Actual|2008-05-31||Observational|||Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer|Gene Expression Profiles in Primary and Metastatic Pancreatic Cancer|Completed|||10|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||f||||||||||2018-06-01 00:59:31.416874|2018-06-01 00:59:31.416874
NCT00897728|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2010-11-30|2009-05-09|2009-05-12|Estimate|||||||2010-11-30|2010-12-01|Estimate|February 2008||2008-02-29|July 2009|2009-07-31||||February 2010|Anticipated|2010-02-28||Observational|||Study of Tumor and Blood Samples From Women With Breast Cancer|Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast.|Unknown status|Recruiting||180|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:31.487794|2018-06-01 00:59:31.487794
NCT00897715|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2016-02-18||2018-01-04|2009-05-11|2009-05-12|Estimate|2016-02-18|2016-03-17|Estimate||||2018-01-04|2018-01-30|Actual|January 1, 2013|Actual|2013-01-01|January 2018|2018-01-31|May 8, 2015|Actual|2015-05-08|February 25, 2015|Actual|2015-02-25||Interventional|||Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)|Inflammation in CKD and CVD - The Role of Genetics and IL-1ra|Completed||Phase 2|15|Actual|VA Office of Research and Development||2|||f||||t|t|f||||||Undecided||2018-06-01 00:59:31.578556|2018-06-01 00:59:31.578556
NCT00897702|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-12-14|2009-05-09|2009-05-12|Estimate|||||||2017-12-14|2017-12-15|Actual|January 9, 2007||2007-01-09|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer|Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer|Recruiting|||400|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     tissue and blood~   "|||2018-06-01 00:59:31.912785|2018-06-01 00:59:31.912785
NCT00897676|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2017-11-09||2017-12-19|2009-05-08|2009-05-12|Estimate|2017-12-19|2018-01-18|Actual||||2017-12-19|2018-01-18|Actual|May 2009||2009-05-31|December 2017|2017-12-31|January 2017|Actual|2017-01-31|August 26, 2016|Actual|2016-08-26||Interventional|||Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity|Role of GLP-1 in Congenital Hyperinsulinism:Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity|Completed||Phase 1/Phase 2|17|Actual|Children's Hospital of Philadelphia|For safety reasons, blood glucose levels were maintained above a safety threshold (55-60mg/dL) during the study by infusing dextrose intravenously which may limit the magnitude of the effect that we will be able to detect.|2|||f||||f||||||||No||2018-06-01 00:59:32.012969|2018-06-01 00:59:32.012969
NCT00897650|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-07-18|2009-05-09|2009-05-12|Estimate|||||||2017-07-18|2017-07-19|Actual|December 2005||2005-12-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Observational|||Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer|Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy|Completed|||204|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||Samples With DNA|"~     Lung tumor tissue and blood samples will be collected.~   "|||2018-06-01 00:59:32.339021|2018-06-01 00:59:32.339021
NCT00897637|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-05-17|2009-05-09|2009-05-12|Estimate|||||||2016-05-17|2016-05-19|Estimate|February 2004||2004-02-29|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Gene Expression Profiles to Categorize Wilms Tumors|Categorization of Wilms Tumors by Genetic Expression|Completed|||600|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 00:59:32.413771|2018-06-01 00:59:32.413771
NCT00897624|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2011-05-12|2009-05-09|2009-05-12|Estimate|||||||2011-05-12|2011-05-13|Estimate|November 2007||2007-11-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Observational|||Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma|Evaluation of the Detection of Tumor Cells in Bone Marrow and Blood in Patients With Choroid Melanoma|Completed|||15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:32.471701|2018-06-01 00:59:32.471701
NCT00897611|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-11-29|2009-05-09|2009-05-12|Estimate|||||||2012-11-29|2012-11-30|Estimate|April 2005||2005-04-30|November 2012|2012-11-30||||August 2009|Actual|2009-08-31||Interventional|||Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma|Identification of Hypermethylated Serum Tumor DNA in High Grade Glioma Patients and Correlation With Magnetic Resonance Imaging Findings|Completed||N/A|42|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 00:59:32.520437|2018-06-01 00:59:32.520437
NCT00897559|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|July 3, 2008||2008-07-03|May 2017|2017-05-31|November 11, 2009|Actual|2009-11-11|November 11, 2009|Actual|2009-11-11||Observational|||Study of Bone Marrow Samples From Patients With Acute Leukemia|Identifying the Genetic Basis of Adult AMKL|Completed|||40|Actual|Eastern Cooperative Oncology Group|||||f||||f||||||||No|Data sharing is dictated by the group's data sharing plan.|2018-06-01 00:59:32.595247|2018-06-01 00:59:32.595247
NCT00897546|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|June 1, 2007|Actual|2007-06-01|May 2017|2017-05-31|July 1, 2008|Actual|2008-07-01|July 1, 2008|Actual|2008-07-01||Observational|||Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma|Multiplex Analysis of Serum Biomarkers for Prediction Interferon Therapy Response in Melanoma Patients|Completed|||1716|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:32.648291|2018-06-01 00:59:32.648291
NCT00897533|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|April 13, 2007|Actual|2007-04-13|May 2017|2017-05-31|April 13, 2008|Actual|2008-04-13|April 13, 2008|Actual|2008-04-13||Observational|||Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer|Development of a Model to Predict Progression Free Survival After Treatment With Erlotinib in E3503|Completed|||137|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:32.705249|2018-06-01 00:59:32.705249
NCT00897520|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-17|2009-05-09|2009-05-12|Estimate|||||||2017-05-17|2017-05-19|Actual|January 14, 2008|Actual|2008-01-14|May 2017|2017-05-31|January 24, 2010|Actual|2010-01-24|January 24, 2010|Actual|2010-01-24||Observational|||Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy|PILOT-high Throughput-protein Profiling Analysis of Sera Collected From E1694 Patients Undergoing HDI (Arm B)|Completed|||40|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:32.761743|2018-06-01 00:59:32.761743
NCT00897507|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-09-08|2009-05-09|2009-05-12|Estimate|||||||2017-09-08|2017-09-12|Actual|March 2005||2005-03-31|September 2017|2017-09-30|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia|Single Nucleotide Polymorphisms and Relapse Risk in Standard Risk ALL|Active, not recruiting|||800|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-06-01 00:59:32.900202|2018-06-01 00:59:32.900202
NCT00897494|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-03-07|2009-05-09|2009-05-12|Estimate|||||||2016-03-07|2016-03-09|Estimate|February 2005||2005-02-28|March 2016|2016-03-31|April 2011|Actual|2011-04-30|November 2009|Actual|2009-11-30||Observational|||Identification of Biomarkers for Early Detection of Pancreatic Cancer|Michigan Center for Pancreatic Cancer Molecular Diagnosis: The Serum Protein Microarray Project|Completed|||75|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||f||||||Samples Without DNA|"~     Venous blood~   "|||2018-06-01 00:59:32.960659|2018-06-01 00:59:32.960659
NCT00897481|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-09|2009-05-09|2009-05-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|January 2007||2007-01-31|April 2008|2008-04-30||||September 2011|Anticipated|2011-09-30||Observational|||Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy|A Retrospective Case-Control Study of Melanoma Patients Who Have Undergone Sentinel Lymph Node Biopsy|Unknown status|Recruiting||1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:33.039265|2018-06-01 00:59:33.039265
NCT00897468|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-05-03|2009-05-09|2009-05-12|Estimate|||||||2018-05-03|2018-05-04|Actual|February 2007||2007-02-28|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Observational|||Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer|Developing In-Vivo Models of Human Breast Cancer|Completed|||26|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||||||2018-06-01 00:59:33.106321|2018-06-01 00:59:33.106321
NCT00897455|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2011-03-22|2009-05-09|2009-05-12|Estimate|||||||2011-03-22|2011-03-23|Estimate|April 2008||2008-04-30|March 2011|2011-03-31||||December 2009|Anticipated|2009-12-31||Observational|||Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers|Genetic Modifiers of BRCA1/BRCA2-Related Breast Cancer Risk in BRCA1/BRCA2 Mutation Carriers - CIMBA 5|Unknown status|Recruiting||10000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:33.184089|2018-06-01 00:59:33.184089
NCT00897442|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-10-26|2009-05-09|2009-05-12|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 1992||1992-06-30|October 2016|2016-10-31||||January 2016|Actual|2016-01-31||Observational|||Collecting Tumor Samples From Patients With Gynecological Tumors|Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer|Completed|||275|Actual|Gynecologic Oncology Group|||1||f||||||||||Samples Without DNA|"~     Tumor Samples~   "|||2018-06-01 00:59:33.279741|2018-06-01 00:59:33.279741
NCT00897429|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-09-20|2009-05-09|2009-05-12|Estimate|||||||2017-09-20|2017-09-21|Actual|July 2007||2007-07-31|September 2017|2017-09-30||||July 2100|Anticipated|2100-07-31||Observational|||Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581|Correlative Science Studies in Colon Cancer a Companion Study to CALGB 9581 and 89803|Recruiting|||902|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-06-01 00:59:33.612796|2018-06-01 00:59:33.612796
NCT00897416|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2010-11-05|2009-05-09|2009-05-12|Estimate|||||||2010-11-05|2010-11-09|Estimate|October 2001||2001-10-31|November 2010|2010-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer|Validation of a Serum Marker Panel for Early Detection of Breast Cancer in High-Risk Women|Completed|||1452|Actual|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 00:59:33.701919|2018-06-01 00:59:33.701919
NCT00897403|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-04-05|2009-05-09|2009-05-12|Estimate|||||||2017-04-05|2017-04-07|Actual|December 2006|Actual|2006-12-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|August 2015|Actual|2015-08-31||Observational|||Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy|Discovery of Candidate Biomarkers in Colon Cancer and Precancers Repository|Completed|||6446|Actual|Vanderbilt University|||||f||||||||||||||2018-06-01 00:59:33.752438|2018-06-01 00:59:33.752438
NCT00897390|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2010-08-26||2015-05-04|2009-05-11|2009-05-12|Estimate|2010-12-21|2011-01-21|Estimate||||2015-05-04|2015-05-21|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)|Bioequivalence Study of the Fixed Dose Combination of 2.5 mg Saxagliptin and 1000 mg Metformin Immediate Release (IR) Tablet Relative to 2.5 mg Saxagliptin Tablet and 1000 mg Metformin IR Tablet Co-administered to Healthy Subjects in a Fasted and in a Fed State|Completed||Phase 1|24|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 00:59:33.859663|2018-06-01 00:59:33.859663
NCT00897377|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2014-08-04|2009-05-11|2009-05-12|Estimate|||||||2014-08-04|2014-08-05|Estimate|December 2007||2007-12-31|May 2009|2009-05-31||||||||Interventional|||Treatment Strategy for Low-grade Gliomas|Treatment Strategy for Low-grade Gliomas|Terminated||Phase 3|500|Anticipated|Sun Yat-sen University||4||Difficulty in recruiting patients|f||||t||||||||||2018-06-01 00:59:34.69379|2018-06-01 00:59:34.69379
NCT00897364|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-29|2009-05-09|2009-05-12|Estimate|||||||2017-08-29|2017-08-31|Actual|May 2000||2000-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers|Analysis of Intermediate Endpoint Biomarkers in the Respiratory Epithelium of Smokers Compared to Non-Smoking Controls|Active, not recruiting|||78|Anticipated|University of Colorado, Denver|||||f||||f|f|f||||Samples With DNA|"~     endobronchial biopsies, blood, sputum, urine~   "|||2018-06-01 00:59:34.826398|2018-06-01 00:59:34.826398
NCT00897351|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|July 10, 2008|Actual|2008-07-10|May 2017|2017-05-31|February 10, 2009|Actual|2009-02-10|February 10, 2009|Actual|2009-02-10||Observational|||Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803|Evaluation of Polymorphisms, Mutations, and Protein Expression by Automated Quantitative Immunohistochemistry (AQUA) in the LapatinibTargets and Metabolic Pathway in Samples From E5803|Completed|||37|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:34.886375|2018-06-01 00:59:34.886375
NCT00897338|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-10-09|2009-05-09|2009-05-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|August 2007||2007-08-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer|A Feasibility Study of a Novel Technique to Identify Circulating Breast Cancer Cells in Patients With Metastatic Breast Cancer|Completed|||43|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-06-01 00:59:34.947392|2018-06-01 00:59:34.947392
NCT00897325|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-10-19|2009-05-09|2009-05-12|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2006||2006-09-30|October 2017|2017-10-31||||January 2100|Anticipated|2100-01-31||Observational|||Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma|A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens|Recruiting|||528|Anticipated|Children's Oncology Group|||1||f||||||||||||||2018-06-01 00:59:35.075751|2018-06-01 00:59:35.075751
NCT00897312|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-04-21|2009-05-09|2009-05-12|Estimate|||||||2016-04-21|2016-04-25|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease|Title: Evaluation of Systemic IDO Levels After Various Immunotherapeutics|Terminated|||7|Actual|Vanderbilt-Ingram Cancer Center||||slow accrual|f||||t||||||Samples Without DNA|"~     -  Serum/plasma samples will be collected from patients being treated for untreated acute~          and chronic Hepatitis C with pegylated IFN-α and ribavirin~        -  Serum/plasma samples will be collected from patients being treated for metastatic~          melanoma with CYP-206,675~        -  Serum/plasma samples previously collected~   "|||2018-06-01 00:59:35.685684|2018-06-01 00:59:35.685684
NCT00897299|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|October 7, 2005|Actual|2005-10-07|May 2017|2017-05-31|October 8, 2005|Actual|2005-10-08|October 8, 2005|Actual|2005-10-08||Observational|||Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy|Identifying Genomic Predictors of Recurrence After Adjuvant Chemotherapy|Completed|||900|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 00:59:35.752212|2018-06-01 00:59:35.752212
NCT00897286|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-09-08|2009-05-09|2009-05-12|Estimate|||||||2017-09-08|2017-09-11|Actual|November 30, 2004|Actual|2004-11-30|September 2017|2017-09-30|February 2026|Anticipated|2026-02-28|February 2026|Anticipated|2026-02-28||Observational|||Study of Stored Tumor Samples in Young Patients With Brain Tumors|Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas, Medulloblastoma/PNET and Gliomas of the Pediatric CNS|Recruiting|||500|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Fresh frozen, fixed and cultured tumor cells collected prospectively from a clinically well~     characterized patient cohort.~   "|||2018-06-01 00:59:35.81937|2018-06-01 00:59:35.81937
NCT00897273|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2010-09-15|2009-05-09|2009-05-12|Estimate|||||||2010-09-15|2010-09-16|Estimate|May 2007||2007-05-31|September 2010|2010-09-30||||May 2009|Actual|2009-05-31||Observational|||Human Papillomavirus Infection of the Mouth in Young Men and Risk Factors for Oropharyngeal Cancer|Oral HPV Infection in Young Men|Completed|||500|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||Samples With DNA|"~     Laboratory Methods:~      Oral rinse sample:~      Standard, well-validated assays will be used to detect HPV genomic DNA in oral exfoliated~     cells from the Scope oral rinse sample.~      Serum sample:~      Standard laboratory assays will be used to detect antibodies to HPV16 L1 viral capsid~     protein.~   "|||2018-06-01 00:59:35.886609|2018-06-01 00:59:35.886609
NCT00897260|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2018-01-24|2009-05-11|2009-05-12|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2009||2009-05-31|January 2018|2018-01-31|January 9, 2013|Actual|2013-01-09|January 9, 2013|Actual|2013-01-09||Interventional|||Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders|Umbilical Cord Blood Transplantation as Treatment of Adult Patients With Hematologic Disorders|Completed||N/A|27|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 00:59:35.937303|2018-06-01 00:59:35.937303
NCT00897247|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-03-04|2009-05-09|2009-05-12|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2007||2007-01-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Observational|||Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite|Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations|Completed|||494|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||f||||||||||2018-06-01 00:59:35.996034|2018-06-01 00:59:35.996034
NCT00897234|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2014-08-21|2009-05-09|2009-05-12|Estimate|||||||2014-08-21|2014-08-22|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Observational|||Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers|Plasma Quantification of Cathepsin D and FAS in Non-Small Cell Lung Cancer|Completed|||84|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||Samples With DNA|"~     Blood sample collection, one 10 ml purple top EDTA tube, will be collected from each patient~     and control via venipuncture or from a central line.~   "|||2018-06-01 00:59:36.053201|2018-06-01 00:59:36.053201
NCT00897221|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2011-06-24|2009-05-08|2009-05-12|Estimate|||||||2011-06-24|2011-06-27|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia|An Open-label, Single Treatment, Safety and Efficacy, Long-term Study of Deferiprone in Subjects With Friedreich's Ataxia|Completed||Phase 2|36|Actual|ApoPharma||2|||f||||t||||||||||2018-06-01 00:59:36.11541|2018-06-01 00:59:36.11541
NCT00897208|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2018-02-05|2009-05-09|2009-05-12|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2005|Actual|2005-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer|Estrogen-DNA Adducts in Breast, Urine and Serum as Biomarkers of Breast Cancer Risk|Active, not recruiting|||300|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 00:59:36.29878|2018-06-01 00:59:36.29878
NCT00897182|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-07-01|2009-05-09|2009-05-12|Estimate|||||||2016-07-01|2016-07-04|Estimate|May 2008||2008-05-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia|Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray|Completed|||96|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Bone marrow and/or peripheral blood obtained at diagnosis from AML patients enrolled on CALGB~     AML treatment studies.~   "|||2018-06-01 00:59:36.358753|2018-06-01 00:59:36.358753
NCT00897169|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2016-10-26|2009-05-11|2009-05-12|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects|A Trial Investigating the Possible Difference in the Development of Type 2 Diabetes in Caucasian and Japanese Subjects by a Model-based Analysis|Completed||Phase 1|271|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 00:59:36.428176|2018-06-01 00:59:36.428176
NCT00897143|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-10-08|2009-05-09|2009-05-12|Estimate|||||||2015-10-08|2015-10-09|Estimate|June 2007||2007-06-30|October 2015|2015-10-31||||||||Observational|||Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer|Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||PI Left|f||||t||||||Samples With DNA|"~     Malignant pleural effusion specimens from patients with primary lung cancer obtained from the~     Pathology Department at the University Hospitals of Cleveland.~   "|||2018-06-01 00:59:36.493939|2018-06-01 00:59:36.493939
NCT00897130|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2014-12-02|2009-05-08|2009-05-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2009|Actual|2009-12-31||Interventional|MDSAZA0706||5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs)|Clinical and Biological Effects of 5-Azacitidine Five Days/Monthly Schedule in Symptomatic Low-risk Myelodysplastic Syndromes (MDSs)|Completed||Phase 2|28|Actual|Università degli Studi di Brescia||1|||f||||t||||||||||2018-06-01 00:59:36.551623|2018-06-01 00:59:36.551623
NCT00897117|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-21|2009-05-09|2009-05-12|Estimate|||||||2017-08-21|2017-08-23|Actual|May 2001||2001-05-31|August 2017|2017-08-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Observational|||Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer|Molecular Fingerprinting of Lung Cancer|Recruiting|||1200|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||Samples With DNA|"~     Both prospective and retrospectives samples of blood and tissue.~   "|||2018-06-01 00:59:36.632765|2018-06-01 00:59:36.632765
NCT00897104|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2009-09-26||2015-02-13|2009-05-11|2009-05-12|Estimate|2010-06-22|2010-07-23|Estimate||||2015-02-13|2015-03-04|Estimate|August 1995||1995-08-31|February 2015|2015-02-28|September 1996|Actual|1996-09-30|May 1996|Actual|1996-05-31||Interventional|||MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)|A Randomized, Placebo-Controlled, Parallel-Groups, Outpatient Study to Compare the Efficacy and Safety of MK0462 5 mg p.o. and Sumatriptan 50 mg p.o. for the Acute Treatment of Migraine|Completed||Phase 3|933|Actual|Merck Sharp & Dohme Corp.|No limitations were encountered in this study.|3|||f||||||||||||||2018-06-01 00:59:36.805123|2018-06-01 00:59:36.805123
NCT00897091|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-05-28|2009-05-09|2009-05-12|Estimate|||||||2013-05-28|2013-05-30|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil|Molecular Predictors of Outcome on CAF Plus Tamoxifen Versus Tamoxifen Alone in Postmenopausal Women With Node Positive, Receptor Positive Breast Cancer [NCI Correlative Science Reference No. # 8814A-ICSC]|Completed|||750|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:59:37.415216|2018-06-01 00:59:37.415216
NCT00897078|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-06-11|2009-05-09|2009-05-12|Estimate|||||||2013-06-11|2013-06-13|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy Siblings|Health Effects After Leukemia (HEAL) Research Study|Completed|||39|Actual|Vanderbilt University|||||f||||t||||||Samples With DNA|"~     Banked DNA~   "|||2018-06-01 00:59:37.502507|2018-06-01 00:59:37.502507
NCT00897065|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-07-09|2009-05-09|2009-05-12|Estimate|||||||2013-07-09|2013-07-10|Estimate|June 2006||2006-06-30|April 2008|2008-04-30||||||||Observational|||Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17|Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort|Unknown status|Recruiting||957|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:37.594189|2018-06-01 00:59:37.594189
NCT00897052|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2012-09-07|2009-05-09|2009-05-12|Estimate|||||||2012-09-07|2012-09-10|Estimate|February 2005||2005-02-28|September 2012|2012-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Gene Expression Profiles in Predicting Survival of Patients With Head and Neck Cancer|Survival Prediction in HNSCC Based on Gene Expression Profiles From FFPE Tissues|Completed|||29|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||Samples With DNA|"~     To identify gene expression profile associated with survival from formalin-fixed paraffin~     embedded tissue samples~   "|||2018-06-01 00:59:37.672447|2018-06-01 00:59:37.672447
NCT00897039|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-09-19|2009-05-09|2009-05-12|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2006||2006-03-31|July 2009|2009-07-31||||||||Observational|||Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas|Unknown status|Recruiting||60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:37.726951|2018-06-01 00:59:37.726951
NCT00897026|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-08-07|2009-05-09|2009-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2008||2008-07-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344|ER/HER2/Ki67 Breast Cancer Subtypes as Predictive Factors for Response to Adjuvant Dose-dense Therapy, and Basal Subtypes of Double-negative Breast Cancer as Prognostic Factors in Intergroup Trial C9741|Recruiting|||1195|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 00:59:37.790491|2018-06-01 00:59:37.790491
NCT00896987|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies|An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine or Carbamazepine for Cognitive Function as Initial Monotherapy in Adult Untreated Epilepsies|Completed||Phase 4|121|Actual|Korean Epilepsy Society||2|||f||||f||||||||||2018-06-01 00:59:37.86896|2018-06-01 00:59:37.86896
NCT00896974|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-06-17|2009-05-09|2009-05-12|Estimate|||||||2015-06-17|2015-06-18|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of 9cUAB30 in Healthy Participants|A Pilot Study of the Novel Retinoid, 9cUAB30 to Determine Preliminary Pharmacokinetics|Completed||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 00:59:37.931915|2018-06-01 00:59:37.931915
NCT00896961|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-01-15|2009-05-09|2009-05-12|Estimate|||||||2013-01-15|2013-01-16|Estimate|August 2001||2001-08-31|January 2013|2013-01-31||||September 2007|Actual|2007-09-30||Interventional|||EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer|Does Hypoxia Predict Radiation/Surgical Tumor Response/A Correlative Trial of EF5, an Agent for the Detection of Tumor Hypoxia|Terminated||N/A|120|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 00:59:37.988661|2018-06-01 00:59:37.988661
NCT00896948|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-03-10|2009-05-09|2009-05-12|Estimate|||||||2017-03-10|2017-03-14|Actual|May 2005||2005-05-31|March 2017|2017-03-31||||||||Observational|||Study of Proteins in Head and Neck Cancer Cells|Novel Protein Regulator of Tumor Suppressor ARF & NF-κB|Completed|||||Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 00:59:38.06768|2018-06-01 00:59:38.06768
NCT00896935|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2015-11-30|2009-05-09|2009-05-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2006||2006-07-31|November 2015|2015-11-30||||July 2020|Anticipated|2020-07-31||Observational|||Arizona Cancer Center Biospecimen Repository|Arizona Cancer Center Biospecimen Repository|Recruiting|||10000|Anticipated|University of Arizona|||||f||||t||||||Samples With DNA|"~     Tissue will be collected and preserved from the primary organ site, from the metastases, from~     patient blood (serum and lymphocytes), from patient urine, and from related samples of other~     tissues/fluids removed by the surgeon left over after diagnostic testing.~   "|||2018-06-01 00:59:38.216521|2018-06-01 00:59:38.216521
NCT00896922|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-02-24|2009-05-09|2009-05-12|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2007||2007-01-31|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911|Assessment of MUM1 Expression, Lymphoma-Associated Macrophages, and Regulatory T-Cells in Follicular Lymphoma: Prognostic Markers in SWOG S8809 and S9800/S9911 Trials Representing Pre-and Post-Monoclonal Antibody Therapy Protocols|Completed|||180|Actual|Southwest Oncology Group|||||f||||f|f|f||||||Yes|http://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-06-01 00:59:38.336747|2018-06-01 00:59:38.336747
NCT00896909|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-16|2009-05-09|2009-05-12|Estimate|||||||2017-05-16|2017-05-17|Actual|February 2, 2006|Actual|2006-02-02|May 2017|2017-05-31|July 2, 2006|Actual|2006-07-02|July 2, 2006|Actual|2006-07-02||Observational|||HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598|Evaluation of HER2 Mutations in Patient Tumors From E2598|Completed|||44|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 00:59:38.413547|2018-06-01 00:59:38.413547
NCT00896896|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-03-29|2009-05-09|2009-05-12|Estimate|||||||2013-03-29|2013-04-02|Estimate|November 2006||2006-11-30|March 2013|2013-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Immunoreactivity to Cetuximab in Cancer Patients|Immunoreactivity to Cetuximab in Cancer Patients|Completed|||538|Actual|Vanderbilt-Ingram Cancer Center|||||f||||f||||||||||2018-06-01 00:59:38.470976|2018-06-01 00:59:38.470976
NCT00896883|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2012-08-21|2009-05-11|2009-05-12|Estimate|||||||2012-08-21|2012-08-23|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|MTI||Evaluation of the Middle Turbinate Implant for Affixing the Middle Turbinate to the Nasal Septum|A Prospective, Non-Randomized, Limited-Use Evaluation of the Middle Turbinate Implant for Affixing the Middle Turbinate to the Nasal Septum|Completed||N/A|18|Actual|ENTrigue Surgical, Inc.||1|||f||||f||||||||||2018-06-01 00:59:38.546302|2018-06-01 00:59:38.546302
NCT00896857|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-03-13|2009-05-09|2009-05-12|Estimate|||||||2017-03-13|2017-03-15|Actual|April 2004|Actual|2004-04-30|March 2017|2017-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer|Breast Cancer Prevention by Inducing Apoptosis in DCIS Using Breast Ductal Lavage|Completed|||30|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 00:59:38.6094|2018-06-01 00:59:38.6094
NCT00896844|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-05-11|2009-05-11|2009-05-12|Estimate|||||||2009-05-11|2009-05-12|Estimate|September 2001||2001-09-30|May 2009|2009-05-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Trial on the Effect of Emotional Disclosure of Traumatic Life Events on Physical Health|A Randomised Controlled Trial on the Effect of Emotional Disclosure of Traumatic Life Events on Physical Health|Completed||N/A|100|Actual|University Hospital Birmingham||2|||f||||f||||||||||2018-06-01 00:59:38.663016|2018-06-01 00:59:38.663016
NCT00896831|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-11|||2009-06-05|2009-05-11|2009-05-12|Estimate|||||||2009-06-05|2009-06-10|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|September 2010|Anticipated|2010-09-30|March 2010|Anticipated|2010-03-31||Interventional|PORTOALEGRE||Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy|Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study|Unknown status|Enrolling by invitation|Phase 4|96|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 00:59:38.715971|2018-06-01 00:59:38.715971
NCT00896818|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-08-23|2009-05-09|2009-05-12|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2005||2005-01-31|June 2009|2009-06-30||||January 2009|Anticipated|2009-01-31||Observational|||Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends|The British Breast Cancer Study - National Cancer Research Network Cohort (BBC-NCRN)|Unknown status|Recruiting||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:38.78087|2018-06-01 00:59:38.78087
NCT00896792|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-14|2009-05-09|2009-05-12|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2008|Actual|2008-10-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Nurse Practitioner Hospice Program for Patients With Terminal Metastatic Cancer and Their Families or Caregivers|The Pilot Palliative ARNP (Advanced Registered Nurse Practitioner) Liaison Program (The PAL Program): Improving Communication Between Patients, Oncologists, and Hospice, Promoting Timely Hospice Referrals and Bringing Education and Research Efforts to Hospice and Palliative Care|Active, not recruiting||N/A|100|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 00:59:38.834809|2018-06-01 00:59:38.834809
NCT00896779|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2015-05-07||2015-06-01|2009-05-11|2009-05-12|Estimate|2015-05-07|2015-05-27|Estimate||||2015-06-01|2015-06-29|Estimate|October 2009||2009-10-31|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Lucentis in Advanced Macular Degeneration|Lucentis in Advanced Macular Degeneration|Completed||Phase 2|20|Actual|Stanford University|Limitations include small number of subjects analyzed and no control group that were untreated.|2|||f||||f||||||||||2018-06-01 00:59:38.891882|2018-06-01 00:59:38.891882
NCT00896766|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-05-13|2009-05-09|2009-05-12|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2006||2006-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia|Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk ALL Pilot Project: Application of Array-Based Methods and Gene Re-Sequencing to Identify Candidate Molecular Targets for High-Risk Pediatric Acute Lymphoblastic Leukemia|Completed|||150|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-06-01 00:59:39.087923|2018-06-01 00:59:39.087923
NCT00896753|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-05-25|2009-05-09|2009-05-12|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2003||2003-09-30|September 2015|2015-09-30|May 2008|Actual|2008-05-31|September 2006|Actual|2006-09-30||Observational|||Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum|Gene Expression Profiling of Metastatic Colon Cancer (CCCWFU 89B03)|Completed|||10|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-06-01 00:59:39.142859|2018-06-01 00:59:39.142859
NCT00896740|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-30|2009-05-09|2009-05-12|Estimate|||||||2017-11-30|2017-12-04|Actual|March 2002||2002-03-31|November 2017|2017-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Gene Function in Bone Marrow Cells From Patients With Fanconi Anemia and From Healthy Participants|Analysis of Fanconi Anemia Gene Function by Microarray Analysis of Bone Marrow Cells|Terminated|||90|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 00:59:39.1905|2018-06-01 00:59:39.1905
NCT00896727|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-10-06|2009-05-09|2009-05-12|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2006||2006-07-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||S9313A Protein Expression in Predicting Response to Treatment Using Tumor Tissue Samples From Women With Stage I, Stage II, or Stage IIIA Breast Cancer Treated on Clinical Trial SWOG-9313|Prediction of Therapeutic Response Using AQUA™ Quantitative Protein Expression Analysis of ER, PgR, and HER2 of Breast Cancer Tissue Microarrays From SWOG Protocol 9313|Completed|||2100|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 00:59:40.113832|2018-06-01 00:59:40.113832
NCT00896714|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2017-03-24|2009-05-08|2009-05-12|Estimate|||||||2017-03-24|2017-03-28|Actual|May 2009||2009-05-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|May 2016|Actual|2016-05-31||Interventional|PosoAnes||Factors Influencing Anesthetic Drug Requirement|Impact of Environmental and Demographic Factors on Pre-operative Doses of Anesthetic Agents (Prospective Multicenter Study)|Recruiting||N/A|5000|Anticipated|Hopital Foch||1|||f||||f||||||||||2018-06-01 00:59:40.200588|2018-06-01 00:59:40.200588
NCT00896701|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-07-12|2009-05-09|2009-05-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2|A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemic Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated With Interleukin-2: A CALGB Leukemia Tissue Bank Project|Completed|||451|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     bone marrow blast cells peripheral blood mononuclear cells~   "|||2018-06-01 00:59:40.283405|2018-06-01 00:59:40.283405
NCT00896688|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2018-03-07|2009-05-08|2009-05-12|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2019|Anticipated|2019-01-31|September 2017|2017-09-30|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Observational|||Ultrasound Guided Diagnostic Cervical Medial Branch Block|Ultrasound Guided Diagnostic Cervical Medial Branch Block|Suspended|||25|Anticipated|McMaster University|||2|The PI has been unable to continue with the study.|f||||f||||||||||2018-06-01 00:59:40.356244|2018-06-01 00:59:40.356244
NCT00896675|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2013-03-29|2009-05-09|2009-05-12|Estimate|||||||2013-03-29|2013-04-02|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|||Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer|Proteomic Prediction of Clinical Benefit in HNSCC|Completed|||352|Actual|Vanderbilt-Ingram Cancer Center|||2||f||||t||||||||||2018-06-01 00:59:40.42491|2018-06-01 00:59:40.42491
NCT00896662|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2016-04-21|2009-05-09|2009-05-12|Estimate|||||||2016-04-21|2016-04-25|Estimate|January 2005||2005-01-31|April 2016|2016-04-30|August 2008|Actual|2008-08-31|October 2007|Actual|2007-10-31||Observational|||Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202|Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202|Completed|||9|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||Samples Without DNA|"~     50cc of peripheral blood will be collected in CPT tubes for mononuclear cell isolation and~     10cc in SST tubes for plasma collection.~   "|||2018-06-01 00:59:40.496912|2018-06-01 00:59:40.496912
NCT00896649|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|2016-05-06||2017-04-03|2009-05-09|2009-05-12|Estimate|2016-09-13|2016-10-31|Estimate||||2017-04-03|2017-05-09|Actual|February 2009||2009-02-28|April 2017|2017-04-30|January 2017|Actual|2017-01-31|July 2012|Actual|2012-07-31||Interventional||Eligible participants|Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer|Impact of Dedicated Breast Positron Emission Mammography vs. Conventional Two-View Digital Mammography on Recall Rates and Cancer Detection as a Screening Examination in Underserved Women|Completed||N/A|193|Actual|Boston Medical Center||1|||f||||t||||||||No|Individual participant data is not useful.|2018-06-01 00:59:40.57369|2018-06-01 00:59:40.57369
NCT00896636|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-11-21|2009-05-09|2009-05-12|Estimate|||||||2017-11-21|2017-11-24|Actual|May 2008||2008-05-31|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|September 2011|Actual|2011-09-30||Observational|||Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration|Gene Methylation and Estradiol Levels in Random FNA Samples as Biomarkers for Breast Cancer Risk|Active, not recruiting|||385|Actual|Northwestern University|||3||f||||t||||||Samples Without DNA|"~     Breast tissue random fine needle aspiration (rFNA) samples will be collected and levels of~     methylation and hormones will be measured in each.~   "|||2018-06-01 00:59:40.880236|2018-06-01 00:59:40.880236
NCT00896623|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-09|||2017-02-15|2009-05-09|2009-05-12|Estimate|||||||2017-02-15|2017-02-17|Actual|December 2006||2006-12-31|February 2017|2017-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897|Pharmacogenetics in Relation to Breast Cancer Outcomes in SWOG 8897|Completed|||1577|Actual|Southwest Oncology Group|||||f||||f||||||||Yes|https://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-06-01 00:59:40.964662|2018-06-01 00:59:40.964662
NCT00896610|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2018-03-27|2009-05-08|2009-05-11|Estimate|||||||2018-03-27|2018-03-29|Actual|May 4, 2009||2009-05-04|September 26, 2017|2017-09-26||||||||Observational|||Natural History of Autoimmune Diabetes and Its Complications|Natural History of Autoimmune Diabetes and Its Complications|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:59:41.045724|2018-06-01 00:59:41.045724
NCT00896597|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2010-08-06|2009-05-08|2009-05-11|Estimate|||||||2010-08-06|2010-08-09|Estimate|April 2009||2009-04-30|August 2010|2010-08-31||||December 2009|Actual|2009-12-31||Interventional|||Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With Cirrhosis|An Open, Randomised Study to Compare the Reproducibility of CTP Rating and NRL972 Pharmacokinetics in Patient Volunteers With Hepatic Cirrhosis.|Completed||Phase 1|240|Anticipated|Norgine||1|||f||||f||||||||||2018-06-01 00:59:41.12127|2018-06-01 00:59:41.12127
NCT00896584|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2010-11-17|2009-05-08|2009-05-11|Estimate|||||||2010-11-17|2010-11-18|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Exercise Pulseoximetry for Pre-flight Evaluation of Chronic Obstructive Pulmonary Disease (COPD) Patients|May Pulseoximetry During Physical Exercise Predict Hypoxemia in COPD Patients During Air Travel?|Completed|||100|Anticipated|LHL Helse|||||f||||f||||||||||2018-06-01 00:59:41.190555|2018-06-01 00:59:41.190555
NCT00896571|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2014-11-24|2009-05-08|2009-05-11|Estimate|||||||2014-11-24|2014-11-26|Estimate|July 2009||2009-07-31|November 2014|2014-11-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Transdermal Contraceptive Patch - Endometrial Effects Study|Single-center,Open-label, Uncontrolled Study to Investigate the Effects of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene on the Endometrium in a 21-day Regimen for 13 Cycles in 80 Healthy Women|Completed||Phase 2|92|Actual|Bayer||1|||f||||f||||||||||2018-06-01 00:59:41.258754|2018-06-01 00:59:41.258754
NCT00896558|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2017-06-21|2009-05-07|2009-05-11|Estimate|||||||2017-06-21|2017-06-22|Actual|May 11, 2009|Actual|2009-05-11|June 2017|2017-06-30|September 25, 2009|Actual|2009-09-25|September 25, 2009|Actual|2009-09-25||Interventional|||A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects|Completed||Phase 1|52|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:59:41.333309|2018-06-01 00:59:41.333309
NCT00896545|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2011-07-21|2009-05-08|2009-05-11|Estimate|||||||2011-07-21|2011-07-25|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Early Childhood Prevention of Childhood Overweight|Development of an Early Intervention for the Prevention of Childhood Obesity|Completed||Phase 3|100|Anticipated|Stanford University||2|||f||||t||||||||||2018-06-01 00:59:41.428259|2018-06-01 00:59:41.428259
NCT00896532|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07||2013-04-16|2018-01-18|2009-05-07|2009-05-11|Estimate||||2013-04-16|2013-04-24|Estimate|2018-01-18|2018-01-25|Actual|June 3, 2009|Actual|2009-06-03|January 2018|2018-01-31|February 18, 2016|Actual|2016-02-18|February 21, 2011|Actual|2011-02-21||Interventional|||Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density|A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 2|419|Actual|Amgen||8|||f||||f||||||||||2018-06-01 00:59:41.495339|2018-06-01 00:59:41.495339
NCT00896519|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2013-08-01|2009-05-08|2009-05-11|Estimate|||||||2013-08-01|2013-08-02|Estimate|March 2009||2009-03-31|July 2009|2009-07-31||||March 2011|Anticipated|2011-03-31||Interventional|||GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma|An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine®) Associated With RCHOP Chemotherapy and Rituximab (MabThera®) Maintenance in Patients With First-line Advanced Follicular Non Hodgkin's Lymphoma|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:41.591378|2018-06-01 00:59:41.591378
NCT00896493|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2016-10-18|2009-05-08|2009-05-11|Estimate|||||||2016-10-18|2016-10-20|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma|A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma|Recruiting||Phase 2|40|Anticipated|Stanford University||1|||f||||t||||||||||2018-06-01 00:59:41.661338|2018-06-01 00:59:41.661338
NCT00896480|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07||2013-08-22|2015-09-24|2009-05-07|2009-05-11|Estimate||||2013-08-22|2013-08-30|Estimate|2015-09-24|2015-10-15|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma|Clinical Activity, Safety and Immunogenic Properties of Cancer Immunotherapeutic GSK2132231A in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma|Completed||Phase 2|24|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 00:59:41.742281|2018-06-01 00:59:41.742281
NCT00896467|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2013-07-09|2009-05-08|2009-05-11|Estimate|||||||2013-07-09|2013-07-10|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|||Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy|Psychological and Emotional Impacts of Participation in Randomized Clinical Studies in Medical Oncology|Terminated|||200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:41.91055|2018-06-01 00:59:41.91055
NCT00896454|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2014-12-19|2014-05-08|2016-02-18|2009-05-07|2009-05-11|Estimate|2014-12-19|2015-01-01|Estimate|2014-05-08|2014-05-23|Estimate|2016-02-18|2016-03-15|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|August 2013|Actual|2013-08-31|September 2012|Actual|2012-09-30||Interventional|||Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium|A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates|Completed||Phase 2|33|Actual|Amgen||1|||f||||f||||||||||2018-06-01 00:59:42.037336|2018-06-01 00:59:42.037336
NCT00896441|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2016-10-11||2017-09-12|2009-05-08|2009-05-11|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|February 2009||2009-02-28|September 2017|2017-09-30|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional||2 participants in the Depressed arm who did not complete study per protocol are not included in the analysis.|Functional MRI Before and After Treatment for Depression|Functional MRI Before and After Treatment for Depression|Terminated||N/A|31|Actual|Stanford University||2||Funding ended|f||||f||||||||No||2018-06-01 00:59:42.804274|2018-06-01 00:59:42.804274
NCT00896428|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2013-08-13|2009-05-08|2009-05-11|Estimate|||||||2013-08-13|2013-08-14|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|REMODEL'ASTHME||Effects of Gallopamil in Severe Asthma|Effects of Gallopamil on Bronchial Smooth Muscle Remodelling in Severe Asthma: a Double Blind Study.|Completed||Phase 2|31|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 00:59:42.996715|2018-06-01 00:59:42.996715
NCT00896415|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2010-06-28|2009-05-08|2009-05-11|Estimate|||||||2010-06-28|2010-06-29|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|November 2009|Actual|2009-11-30|||||Observational|Interscanner||Interscanner Variation in Musculoskeletal Computed Tomography (CT) Measures|Inter-scanner Comparison of Muscle Attenuation Measures|Completed|||20|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 00:59:43.077453|2018-06-01 00:59:43.077453
NCT00896402|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2015-08-26|2009-05-08|2009-05-11|Estimate|||||||2015-08-26|2015-08-27|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Chlorhexidine Versus Betadine in Preventing Colonization of Femoral Nerve Catheters After Total Joint Arthroplasty (TJA)|Chlorhexidine vs. Betadine in Preventing Colonization of Continuous Femoral Catheters After Total Joint Arthroplasty|Withdrawn||N/A|0|Actual|Northwell Health||2||Funding inadequate|f||||f||||||||||2018-06-01 00:59:43.122766|2018-06-01 00:59:43.122766
NCT00896389|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2018-05-21||2018-05-29|2009-05-08|2009-05-11|Estimate|2018-05-29|2018-05-31|Estimate||||2018-05-29|2018-05-31|Estimate|October 2009||2009-10-31|May 2018|2018-05-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|SALTI||Salt Loading and Thiazide Intervention Study|The Relationship Between Serine Threonine Kinase 39 (STK39) Genotypes, Salt Sensitivity, Thiazide Diuretics-induced Blood Pressure Response|Completed||Phase 4|124|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 00:59:43.236066|2018-06-01 00:59:43.236066
NCT00896376|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2015-02-08|2009-05-08|2009-05-11|Estimate|||||||2015-02-08|2015-02-10|Estimate|December 2005||2005-12-31|February 2015|2015-02-28|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|||Trastuzumab in Treating Women With Metastatic Breast Cancer|Prospective Multicenter Study of Genetic Factors Predictive of the Pharmacodynamics of Trastuzumab in Patients With Metastatic Breast Cancer|Completed||N/A|49|Actual|Centre Antoine Lacassagne||1|||f||||||||||||||2018-06-01 00:59:43.599495|2018-06-01 00:59:43.599495
NCT00896363|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2017-04-20||2017-08-28|2009-05-07|2009-05-11|Estimate|2017-08-28|2018-03-19|Actual||||2017-08-28|2018-03-19|Actual|April 23, 2009|Actual|2009-04-23|August 2017|2017-08-31|February 9, 2010|Actual|2010-02-09|February 9, 2010|Actual|2010-02-09||Interventional|||Safety and Efficacy Study in Patients With Major Depressive Disorder|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects With Major Depressive Disorder|Completed||Phase 2|99|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:59:43.77867|2018-06-01 00:59:43.77867
NCT00896350|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2011-02-26|2009-05-08|2009-05-11|Estimate|||||||2011-02-26|2011-03-01|Estimate|October 2008||2008-10-31|March 2009|2009-03-31||||April 2010|Anticipated|2010-04-30||Interventional|||Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer|Predicting Treatment Response Based on Hypoxia in Head and Neck Cancers Using Non-Invasive Oxygen Sensitive MRI|Unknown status|Recruiting|Phase 1|10|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:45.338969|2018-06-01 00:59:45.338969
NCT00896337|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2012-04-10||2015-04-17|2009-05-08|2009-05-11|Estimate|2012-05-30|2012-07-03|Estimate||||2015-04-17|2015-05-07|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|September 2011|Actual|2011-09-30||Interventional|ORION||EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries|A Boston Scientific Trial of the EPIC™ Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries|Completed||Phase 3|125|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-06-01 00:59:45.438004|2018-06-01 00:59:45.438004
NCT00896324|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2014-05-29|2009-05-08|2009-05-11|Estimate|||||||2014-05-29|2014-05-30|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Intellectual Impairment in Women With Breast Cancer|Assessment and Treatment of Cognitive Deficits in Breast Cancer|Completed||Phase 1|50|Actual|Stanford University||3|||f||||t||||||||||2018-06-01 00:59:46.552721|2018-06-01 00:59:46.552721
NCT00896311|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2013-08-27|2009-05-08|2009-05-11|Estimate|||||||2013-08-27|2013-08-28|Estimate|March 2003||2003-03-31|August 2013|2013-08-31|February 2008|Actual|2008-02-29|October 2006|Actual|2006-10-31||Interventional|INVERT (01)||Intravenous (IV) Nitroglycerin for Versions in Nulliparous Women|INVERT: IV Nitroglycerin for Versions Trial - a Randomized Placebo-controlled Trial in Nulliparous Women|Completed||N/A|82|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 00:59:46.61966|2018-06-01 00:59:46.61966
NCT00896298|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2015-12-03|2009-05-08|2009-05-11|Estimate|||||||2015-12-03|2015-12-04|Estimate|April 2006||2006-04-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Trial of Leptin Replacement Therapy in Patients With Lipodystrophy|Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With Lipodystrophy|Completed||Phase 2/Phase 3|24|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 00:59:46.688635|2018-06-01 00:59:46.688635
NCT00896285|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2015-07-16|2009-05-08|2009-05-11|Estimate|||||||2015-07-16|2015-07-20|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TIME-1||The First Therapeutic Intervention in Malignant Pleural Effusion Trial|TIME1: A 2 X 2 Factorial Trial to Assess Whether Non-steroidal Anti-inflammatory Analgesics and Small-bore Chest Tubes Are Less Painful Than Opiate Analgesics and Large-bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion.|Completed||N/A|4|Actual|University of California, Davis||4|||f||||t||||||||||2018-06-01 00:59:46.758292|2018-06-01 00:59:46.758292
NCT00896272|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2018-05-23|2009-05-08|2009-05-11|Estimate|||||||2018-05-23|2018-05-24|Actual|May 5, 2009||2009-05-05|January 13, 2015|2015-01-13|January 13, 2015||2015-01-13|||||Observational|||Adaptation Among Adolescents and Adults With Klinefelter Syndrome|Adaptation Among Adolescents and Adults With Klinefelter Syndrome|Completed|||302|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 00:59:46.83439|2018-06-01 00:59:46.83439
NCT00896259|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2012-08-28|2009-05-08|2009-05-11|Estimate|||||||2012-08-28|2012-08-29|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Effects of a Late Phase Exercise Program Following Total Hip Arthroplasty|Effects of a Late Phase Education and Exercise Program Following Total Hip Arthroplasty: A Pilot Project|Completed|||47|Actual|Nova Scotia Health Authority|||3||f||||f||||||||||2018-06-01 00:59:46.889531|2018-06-01 00:59:46.889531
NCT00896246|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-05-11|2009-05-08|2009-05-11|Estimate|||||||2009-05-11|2009-05-12|Estimate|September 2006||2006-09-30|May 2009|2009-05-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||Scintigraphic Assessment Following Klean-Prep® or Moviprep®|Scintigraphic Assessment of Gastrointestinal Transit Following Administration of Klean-Prep® (4L) or Moviprep® (2L) to Healthy Volunteers.|Completed||Phase 1|32|Actual|Norgine||2|||f||||f||||||||||2018-06-01 00:59:47.057406|2018-06-01 00:59:47.057406
NCT00896233|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2011-01-18||2015-08-11|2009-05-08|2009-05-11|Estimate|2011-08-17|2011-09-22|Estimate||||2015-08-11|2015-08-25|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)|Test-Retest Repeatability Study of Magnetic Resonance Elastography (MRE) for Liver Fibrosis Assessment in Healthy Volunteers and Hepatitis C Virus-Infected Patients|Completed||Phase 1|10|Actual|Merck Sharp & Dohme Corp.|Since both primary objectives were met based on the Part 1 analysis, a decision was made to stop the study and not proceed to Part 2. Therefore, data from Part 1 of the study were used for outcome measures 3 and 4 instead of data from Part 2.|1|||f||||f||||||||||2018-06-01 00:59:47.124208|2018-06-01 00:59:47.124208
NCT00896220|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-10-08|2009-05-08|2009-05-11|Estimate|||||||2009-10-08|2009-10-09|Estimate|April 2006||2006-04-30|May 2009|2009-05-31|October 2012|Anticipated|2012-10-31|October 2010|Anticipated|2010-10-31||Observational|RECOVER||Towards RECOVER: Outcomes and Needs Assessment in Intensive Care Unit (ICU) Survivors of Prolonged Mechanical Ventilation and Their Caregivers|Towards RECOVER - Rehabilitation and Recovery in Survivors of Critical Illness. Long-Term Outcomes and Needs Assessment in ICU Survivors of Prolonged Mechanical Ventilation and Their Caregivers|Unknown status|Recruiting||500|Anticipated|University Health Network, Toronto|||1||f||||f||||||||||2018-06-01 00:59:47.312396|2018-06-01 00:59:47.312396
NCT00896207|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2014-10-07|2009-05-08|2009-05-11|Estimate|||||||2014-10-07|2014-10-08|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Studying Different Formulations of SR13668 in Healthy Volunteers|Single-Dose Phase 0 Exploratory Pharmacokinetic Clinical Trial Comparing Five Oral Formulations of SR13668, an Orally Active AKT Pathway Inhibitor|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||6|||f||||||||||||||2018-06-01 00:59:47.442068|2018-06-01 00:59:47.442068
NCT00896194|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2015-07-02|2009-05-08|2009-05-11|Estimate|||||||2015-07-02|2015-07-07|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|SELF||Self-Efficacy in Weight Loss Treatment|Self-Efficacy in Weight Loss Treatment|Completed||N/A|120|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 00:59:47.543049|2018-06-01 00:59:47.543049
NCT00896181|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2016-12-09|2009-05-08|2009-05-11|Estimate|||||||2016-12-09|2016-12-13|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)|A Phase 2 Study of Sequential and Concurrent Chemoradiation for Patients With Advanced Nasopharyngeal Carcinoma (NPC)|Recruiting||Phase 2|40|Anticipated|Stanford University||1|||f||||||||||||||2018-06-01 00:59:47.677498|2018-06-01 00:59:47.677498
NCT00896168|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2013-07-01||2013-09-11|2009-05-07|2009-05-11|Estimate|2013-09-11|2013-09-13|Estimate||||2013-09-11|2013-09-13|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis|A Multi-Center, Pre-Marketing Clinical Trial to Evaluate the Efficacy and Safety of Infliximab Treatment on Rheumatoid Arthritis|Completed||Phase 4|234|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-06-01 00:59:47.784511|2018-06-01 00:59:47.784511
NCT00896155|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2011-08-27|2009-05-08|2009-05-11|Estimate|||||||2011-08-27|2011-08-30|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Interventional|CONSET||Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients|A Randomized Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy to Assess the Extent of Pulmonary Fibrosis and Disease Related Control and Survival in Breast Cancer Patients|Unknown status|Recruiting|Phase 3|260|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||||2018-06-01 00:59:48.194725|2018-06-01 00:59:48.194725
NCT00896142|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2011-11-21|2009-05-08|2009-05-11|Estimate|||||||2011-11-21|2011-11-22|Estimate|October 2006||2006-10-31|November 2011|2011-11-30||||||||Observational|||Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation)|Optima CAD (Optimal Mechanical Evaluation)|Completed|||50|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 00:59:48.26686|2018-06-01 00:59:48.26686
NCT00896129|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2014-01-21|2009-05-08|2009-05-11|Estimate|||||||2014-01-21|2014-01-22|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy|Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia Patients With Complete Cytogenetic Response Treated With Imatinib as First Line Therapy: Health-Related Quality of Life, Symptom Burden and Adherence to Therapy Issues.|Completed|||448|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||||2018-06-01 00:59:48.317489|2018-06-01 00:59:48.317489
NCT00896090|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-05-08|2009-05-08|2009-05-11|Estimate|||||||2009-05-08|2009-05-11|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Observational|||Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder|Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder|Unknown status|Recruiting||||University of Texas Southwestern Medical Center|||2||f||||f||||||||||2018-06-01 00:59:48.437276|2018-06-01 00:59:48.437276
NCT00896077|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2014-07-28|2009-05-08|2009-05-11|Estimate|||||||2014-07-28|2014-07-29|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes|A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (12 mg/kg) Administration in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|8|Actual|DiaKine Therapeutics, Inc.||2|||f||||||||||||||2018-06-01 00:59:48.493734|2018-06-01 00:59:48.493734
NCT00896064|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2017-04-21|2011-11-16|2017-04-21|2009-05-07|2009-05-11|Estimate|2017-04-21|2017-07-19|Actual|2011-11-16|2011-11-21|Estimate|2017-04-21|2017-07-19|Actual|May 18, 2009||2009-05-18|January 2017|2017-01-31|August 5, 2009|Actual|2009-08-05|August 5, 2009|Actual|2009-08-05||Interventional|||Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults|A Study to Evaluate Safety and Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults|Completed||Phase 2|43|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 00:59:48.597278|2018-06-01 00:59:48.597278
NCT00896051|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2013-04-10||2013-09-27|2009-05-07|2009-05-11|Estimate|2013-09-27|2013-09-30|Estimate||||2013-09-27|2013-09-30|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients|TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects|Completed||Phase 2|50|Actual|Janssen R&D Ireland||2|||f||||t||||||||||2018-06-01 00:59:49.260151|2018-06-01 00:59:49.260151
NCT00896038|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2015-05-26||2015-10-05|2009-05-08|2009-05-11|Estimate|2015-10-05|2015-11-03|Estimate||||2015-10-05|2015-11-03|Estimate|May 2009||2009-05-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD|The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD|Completed||Phase 2|58|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 00:59:49.911225|2018-06-01 00:59:49.911225
NCT00896025|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|2013-12-11||2018-01-10|2009-05-08|2009-05-11|Estimate|2013-12-11|2014-01-29|Estimate||||2018-01-10|2018-02-06|Actual|December 2008||2008-12-31|January 2018|2018-01-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|ONAC||Study of N-Acetylcysteine in Acute Liver Failure (ALF)|A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study|Terminated||Phase 4|8|Actual|University of Texas Southwestern Medical Center|Early termination lead to zero subjects analyzed.|1||The low enrollment did not provide statistical power for any meaningful results.|f||||t||||||||||2018-06-01 00:59:50.54813|2018-06-01 00:59:50.54813
NCT00896012|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-05-08|2009-05-08|2009-05-11|Estimate|||||||2009-05-08|2009-05-11|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal|Phase 4 Study: Comparison of Myfortic and Early Rapamycin Conversion vs. Low-Dose Tacrolimus in Preventing Acute Rejection and Chronic Allograft Fibrosis: A Protocol Biopsy Directed Approach|Unknown status|Enrolling by invitation|Phase 4|120|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-06-01 00:59:50.772462|2018-06-01 00:59:50.772462
NCT00895999|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2014-03-12|2009-05-08|2009-05-11|Estimate|||||||2014-03-12|2014-03-14|Estimate|March 2007||2007-03-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Psychosocial Treatment for Women With Depression and Pain|Psychosocial Treatment for Gynecology Patients With Comorbid Depression and Pain|Completed||N/A|60|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 00:59:50.871375|2018-06-01 00:59:50.871375
NCT00895986|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2012-10-17|2009-05-07|2009-05-11|Estimate|||||||2012-10-17|2012-10-18|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Using Conversation Maps to Reinforce Self-Care|Achieving and Maintaining Glycemic Control: Using Conversation Maps to Reinforce Self-Care|Completed||N/A|134|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-06-01 00:59:50.952622|2018-06-01 00:59:50.952622
NCT00895973|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-08|||2009-05-08|2009-05-08|2009-05-11|Estimate|||||||2009-05-08|2009-05-11|Estimate|March 2009||2009-03-31|May 2009|2009-05-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||A Trial of Bed Versus Stirrups Delivery in Nulliparous Women for Prevention of Perineal Lacerations|A Randomized Trial of Bed Versus Stirrups Delivery in Nulliparous Women for Prevention of Perineal Lacerations|Unknown status|Recruiting|N/A|194|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 00:59:51.029289|2018-06-01 00:59:51.029289
NCT00895960|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2016-01-19|2009-05-08|2009-05-11|Estimate|||||||2016-01-19|2016-01-21|Estimate|May 2009||2009-05-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma|Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma|Terminated||Phase 1|16|Actual|M.D. Anderson Cancer Center||1||Sponsor withdrew support; Study did not progress to Phase II.|f||||f||||||||||2018-06-01 00:59:51.121251|2018-06-01 00:59:51.121251
NCT00895947|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2010-11-16||2011-09-12|2009-05-07|2009-05-08|Estimate|2010-12-14|2011-01-13|Estimate||||2011-09-12|2011-09-16|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu|Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia|Completed||Phase 2|200|Actual|Amarillo Biosciences, Inc.||2|||f||||t||||||||||2018-06-01 00:59:51.2419|2018-06-01 00:59:51.2419
NCT00895934|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2014-08-06||2015-01-22|2009-05-07|2009-05-08|Estimate|2015-01-22|2015-02-06|Estimate||||2015-01-22|2015-02-06|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML|A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML)|Completed||Phase 1/Phase 2|53|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 00:59:51.736616|2018-06-01 00:59:51.736616
NCT00895752|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2015-07-29||2017-03-07|2009-05-06|2009-05-08|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|April 2009||2009-04-30|March 2017|2017-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Riluzole in Fragile X Syndrome|Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay|Completed||Phase 4|6|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 00:59:57.406998|2018-06-01 00:59:57.406998
NCT00895921|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2013-08-06|2009-05-07|2009-05-08|Estimate|||||||2013-08-06|2013-08-09|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Examining the Effects of Antipsychotic Medications on Insulin Sensitivity|Acute Impact of Antipsychotics on Insulin Sensitivity: A Novel Human Model|Completed||Phase 4|32|Actual|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-06-01 00:59:52.093359|2018-06-01 00:59:52.093359
NCT00895908|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2017-03-07|2009-05-07|2009-05-08|Estimate|||||||2017-03-07|2017-03-10|Actual|July 1, 2009|Actual|2009-07-01|March 2017|2017-03-31|April 30, 2013|Actual|2013-04-30|April 30, 2012|Actual|2012-04-30||Interventional|||Reducing Attention Deficit Hyperactivity Disorder in Kindergarten and Pre-Kindergarten Children|Reducing ADHD by Promoting Social Collaboration and Self-Regulation Skills|Completed||N/A|171|Actual|Penn State University||2|||f||||f|f|f||||||No||2018-06-01 00:59:52.179536|2018-06-01 00:59:52.179536
NCT00895895|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2012-12-21||2012-12-21|2009-05-07|2009-05-08|Estimate|2012-12-21|2013-01-31|Estimate||||2012-12-21|2013-01-31|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease|A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease|Terminated||Phase 2|526|Actual|Pfizer|Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.|5||See termination reason in detailed description.|f||||t||||||||||2018-06-01 00:59:52.374852|2018-06-01 00:59:52.374852
NCT00895882|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2015-10-21|2009-05-07|2009-05-08|Estimate|||||||2015-10-21|2015-10-22|Estimate|November 2010||2010-11-30|October 2015|2015-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)|A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Virus Infection|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.||6|||f||||t||||||||||2018-06-01 00:59:55.918549|2018-06-01 00:59:55.918549
NCT00895869|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2010-02-24|2009-05-07|2009-05-08|Estimate|||||||2010-02-24|2010-02-25|Estimate|April 2004||2004-04-30|February 2010|2010-02-28|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Observational|RETCAM||Pain in Neonates During Screening for Retinopathy of Prematurity Using Two Methods|Pain in Neonates During Screening for Retinopathy of Prematurity Using Binocular Indirect Ophthalmoscopy and Wide-field Digital Retinal Imaging: a Randomized Comparison|Completed|||76|Actual|NHS Lothian|||||f||||f||||||||||2018-06-01 00:59:56.009973|2018-06-01 00:59:56.009973
NCT00895856|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-05-08|2009-05-07|2009-05-08|Estimate|||||||2009-05-08|2009-05-11|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Observational|||Functional Capacity in Institutionalized Elders|Evaluation of the Functional Capacity in Institutionalized Elders Who Do Not Receive Physiotherapic Assistance|Completed|||3|Actual|Centro de Estudos Superiores de Maceio|||1||f||||f||||||||||2018-06-01 00:59:56.090316|2018-06-01 00:59:56.090316
NCT00895843|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2009-03-24||2009-05-07|2009-03-24|2009-05-08|Estimate|2009-03-24|2009-05-08|Estimate||||2009-05-07|2009-06-01|Estimate|November 2006||2006-11-30|May 2009|2009-05-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Protective Analgesia for Postoperative Pain Relief Following Day Case Oral Surgery|Protective Analgesia Using Bupivacaine and Conventional Release Ibuprofen Versus Bupivacaine and Sustained Release Ibuprofen for Postoperative Pain Relief in Patients Undergoing Third Molar Surgery: a Randomised Controlled Trial|Completed||N/A|122|Actual|University of Manchester||2|||f||||t||||||||||2018-06-01 00:59:56.161882|2018-06-01 00:59:56.161882
NCT00895830|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2011-02-24||2011-03-25|2009-05-07|2009-05-08|Estimate|2011-02-24|2011-03-24|Estimate||||2011-03-25|2011-03-29|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)|Randomised, Double-blind, Placebo-controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-operative Nausea and Vomiting|Completed||Phase 2|257|Actual|Acacia Pharma Ltd||5|||f||||f||||||||||2018-06-01 00:59:56.38705|2018-06-01 00:59:56.38705
NCT00895817|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2012-12-28||2013-03-11|2009-05-06|2009-05-08|Estimate|2013-03-11|2013-03-12|Estimate||||2013-03-11|2013-03-12|Estimate|April 2008||2008-04-30|March 2013|2013-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis|Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis|Completed||N/A|42|Actual|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 00:59:56.911906|2018-06-01 00:59:56.911906
NCT00895804|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-06-12|2009-05-07|2009-05-08|Estimate|||||||2009-06-12|2009-06-15|Estimate|June 2001||2001-06-30|June 2009|2009-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)|Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 00:59:57.118846|2018-06-01 00:59:57.118846
NCT00895791|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|June 2009||2009-06-30|May 2009|2009-05-31|December 2015|Anticipated|2015-12-31|December 2010|Anticipated|2010-12-31||Interventional|COBRA||COmplex BifuRcation Lesions: A Comparison Between the AXXESS Device and Culotte Stenting: An Optical Coherence Tomography (OCT) Study|Comparison of Healing Responses After Treatment of Complex Bifurcation Lesions With the AXXESS Biolimus A9 Eluting Stent Versus Culotte Technique Using Everolimus-Eluting Stents: an Optical Coherence Tomography Analysis.|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital, Gasthuisberg||2|||f||||||||||||||2018-06-01 00:59:57.18895|2018-06-01 00:59:57.18895
NCT00895778|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2013-03-18|2009-05-07|2009-05-08|Estimate|||||||2013-03-18|2013-03-19|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|NISCO||Neuromuscular Blockade Improves Surgical Conditions|Neuromuscular Blockade Improves Surgical Conditions|Completed||N/A|57|Actual|Technische Universität München||2|||f||||t||||||||||2018-06-01 00:59:57.271053|2018-06-01 00:59:57.271053
NCT00895765|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|September 2008||2008-09-30|May 2009|2009-05-31|October 2009|Anticipated|2009-10-31|September 2009|Anticipated|2009-09-30||Observational|||The Follow up of Chinese Young Children With Melamine-Related-Calculus|Part 1 The Outcome of Children With Melamine-Related-Calculus|Unknown status|Enrolling by invitation||250|Anticipated|Zhejiang University|||||f||||t||||||Samples Without DNA|"~     Blood and Urine~   "|||2018-06-01 00:59:57.336727|2018-06-01 00:59:57.336727
NCT00895739|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2013-08-09|2009-05-07|2009-05-08|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2006||2006-06-30|May 2009|2009-05-31||||||||Interventional|||Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure|Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients|Unknown status|Recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 00:59:57.650368|2018-06-01 00:59:57.650368
NCT00895726|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2012-01-12|2009-05-07|2009-05-08|Estimate|||||||2012-01-12|2012-01-13|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Pilot Study of APD209 in Cancer Cachexia|Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of APD209 in Patients With Cachexia and Advanced Malignancy|Completed||Phase 2|13|Actual|Acacia Pharma Ltd||1|||f||||f||||||||||2018-06-01 00:59:57.897938|2018-06-01 00:59:57.897938
NCT00895713|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|November 2004||2004-11-30|May 2009|2009-05-31|July 2005|Actual|2005-07-31|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation|Efficacy and Safety of Intramuscular Hepatitis B Virus Immune Globulin Grifols for the Prevention of Hepatitis B Virus Recurrence After Orthotopic Liver Transplantation.|Completed||Phase 2|18|Actual|Grifols Biologicals Inc.||1|||f||||f||||||||||2018-06-01 00:59:57.964668|2018-06-01 00:59:57.964668
NCT00895700|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2012-06-18|2009-05-07|2009-05-08|Estimate|||||||2012-06-18|2012-06-19|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|February 2014|Anticipated|2014-02-28|February 2013|Anticipated|2013-02-28||Interventional|WEBCARE||Internet-based Intervention in Cardioverter-defibrillator Patients to Enhance Quality of Life|WEB-based Distress Management Program for Implantable CARdioverter dEfibrillator Patients (WEBCARE) Trial|Unknown status|Recruiting|N/A|350|Anticipated|University of Tilburg||2|||f||||f||||||||||2018-06-01 00:59:58.064636|2018-06-01 00:59:58.064636
NCT00895687|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2015-07-10|2009-05-07|2009-05-08|Estimate|||||||2015-07-10|2015-07-13|Estimate|April 2009||2009-04-30|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||Study of Erlotinib in Combination With Bortezomib|A Phase I Dose-Escalation Study of Erlotinib in Combination With Bortezomib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.|Completed||Phase 1|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 00:59:58.172584|2018-06-01 00:59:58.172584
NCT00895674|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2010-09-29|2009-05-07|2009-05-08|Estimate|||||||2010-09-29|2010-09-30|Estimate|July 2006||2006-07-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar|Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar|Completed|||2840|Actual|Bayer|||1||f||||f||||||||||2018-06-01 00:59:58.278352|2018-06-01 00:59:58.278352
NCT00895661|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2017-03-29||2017-05-09|2009-05-07|2009-05-08|Estimate|2017-03-29|2017-05-09|Actual||||2017-05-09|2017-06-09|Actual|July 2009|Actual|2009-07-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|October 2010|Actual|2010-10-31||Interventional|||High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas|Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas|Completed||Phase 2|40|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 00:59:58.429864|2018-06-01 00:59:58.429864
NCT00895648|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2017-05-03|2009-05-07|2009-05-08|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2009||2009-01-31|May 2017|2017-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma|Phase II Study of Neo-adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Malignant Pleural Mesothelioma|Terminated||Phase 2|6|Actual|University Health Network, Toronto||1||low accrual due to competing study for same group of patients|f||||f||||||||||2018-06-01 00:59:58.767919|2018-06-01 00:59:58.767919
NCT00895635|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2014-09-05|2009-05-06|2009-05-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|EXERT||Evaluating Two Exercise Training Programs to Reduce Leg Pain in People With Peripheral Arterial Disease (The EXERT Study)|Exercise Training to Reduce Claudication: Arm Ergometry Versus Treadmill Walking|Completed||Phase 3|104|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-06-01 00:59:58.837566|2018-06-01 00:59:58.837566
NCT00895622|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2017-12-18||2017-12-18|2009-05-07|2009-05-08|Estimate|2017-12-18|2018-01-19|Actual||||2017-12-18|2018-01-19|Actual|June 2009||2009-06-30|December 2017|2017-12-31||||September 2016|Actual|2016-09-30||Interventional||All eligible patients|Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma|Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas|Active, not recruiting||Phase 2|244|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-06-01 00:59:58.962927|2018-06-01 00:59:58.962927
NCT00895609|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2013-03-18|2009-05-07|2009-05-08|Estimate|||||||2013-03-18|2013-03-19|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|SUNDRO||Sugammadex and Neostigmine at Shallow Neuromuscular Blockade|Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.5)|Completed||Phase 4|99|Actual|Technische Universität München||2|||f||||t||||||||||2018-06-01 00:59:59.518768|2018-06-01 00:59:59.518768
NCT00895596|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|March 2004||2004-03-31|May 2009|2009-05-31|December 2007|Actual|2007-12-31|August 2006|Actual|2006-08-31||Interventional|||Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B|A PhaseII, Open-Label, Multinational, Multi-Centre, Sequential Group, Dose-Escalation Study to Assess the Safety and Antiviral Activity of LB80380 for 12 Weeks in Patients With Lamivudine-Refractory Chronic Hepatitis B|Completed||Phase 1/Phase 2|65|Actual|LG Life Sciences||5|||f||||f||||||||||2018-06-01 00:59:59.575948|2018-06-01 00:59:59.575948
NCT00895583|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2014-07-23||2014-09-15|2009-05-07|2009-05-08|Estimate|2014-09-15|2014-09-18|Estimate||||2014-09-15|2014-09-18|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Safety Population: all randomized participants who received at least one dose of the assigned therapy after randomization.|Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients|Planned Transition To Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy In Renal Allograft Recipients|Completed||Phase 4|254|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 00:59:59.880579|2018-06-01 00:59:59.880579
NCT00895570|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|January 2005||2005-01-31|May 2009|2009-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction|Sleep Restriction, Impaired Glucose Metabolism, and Performance: The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction|Completed||N/A|20|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:00:02.030731|2018-06-01 01:00:02.030731
NCT00895557|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2016-09-06|2009-05-07|2009-05-08|Estimate|||||||2016-09-06|2016-09-08|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Assessing the Impact of Varenicline on Brain-Behavior Vulnerability|Assessing the Impact of Varenicline on Brain-Behavior Vulnerability in Cocaine Dependence|Withdrawn||Phase 2|0|Actual|University of Pennsylvania||1||This study never started, no funding.|f||||f||||||||||2018-06-01 01:00:02.255122|2018-06-01 01:00:02.255122
NCT00895544|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2015-10-07|2009-05-07|2009-05-08|Estimate|||||||2015-10-07|2015-10-09|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Interventional|||Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults|An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years|Completed||Phase 1/Phase 2|231|Actual|Ology Bioservices||2|||f||||t||||||||||2018-06-01 01:00:02.376481|2018-06-01 01:00:02.376481
NCT00895531|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2017-04-11||2017-06-28|2009-05-07|2009-05-08|Estimate|2017-06-28|2017-07-27|Actual||||2017-06-28|2017-07-27|Actual|December 2009||2009-12-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement|Comparison of Peripheral Nerve Blocks vs. Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement: A Prospective, Randomized Study|Terminated||Phase 4|75|Actual|University of Louisville||2||Investigator left institution|f||||f||||||||||2018-06-01 01:00:02.533492|2018-06-01 01:00:02.533492
NCT00895518|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2016-09-07|2009-05-07|2009-05-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2008||2008-04-30|September 2016|2016-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Examining the Effectiveness of an Early Psychological Intervention to Prevent Post-Traumatic Stress Disorder|Effects of Early Psychological Intervention to Prevent PTSD|Completed||Phase 1|139|Actual|Emory University||2|||f||||t||||||||||2018-06-01 01:00:02.866419|2018-06-01 01:00:02.866419
NCT00895505|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|DDOAT2006||D-Dimer Guided Oral Anticoagulant Treatment (OAT)|Safety and Efficacy of a D-Dimer-Guided Strategy for Extension of Secondary Prophylaxis of Venous Thromboembolism - a Prospective and Randomized Management Trial|Unknown status|Recruiting|Phase 3|300|Anticipated|University Hospital, Bonn||2|||f||||t||||||||||2018-06-01 01:00:02.991806|2018-06-01 01:00:02.991806
NCT00895492|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2014-04-30|2009-05-07|2009-05-08|Estimate|||||||2014-04-30|2014-05-01|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Observational|||Two-year Surveillance of Rotavirus Genotypes Causing Acute Diarrhea in Children Younger Than 5 Years Requiring Emergency Room (ER) and Hospital Admission in Chile|Two Year (2009-2010) Surveillance of Rotavirus Genotypes Causing Acute Diarrhea in Children Younger Than 5 Years of Age Requiring Emergency Room and Hospital Admission in Two Large Cities in Chile.|Completed|||967|Actual|University of Chile|||2||f||||f||||||Samples With DNA|"~     stool~   "|||2018-06-01 01:00:03.309322|2018-06-01 01:00:03.309322
NCT00895479|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2010-11-18|2009-05-07|2009-05-08|Estimate|||||||2010-11-18|2010-11-19|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|AdV-VANTAGE||Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence|A Phase III, Randomized, Controlled, Open Label, Multicenter Study of the Efficacy and Safety of Trinam® (EG004); an Assessment of Primary Unassisted Patency and Survival of Vascular Access Grafts in Hemodialysis Patients With End Stage Renal Disease|Terminated||Phase 3|250|Anticipated|Ark Therapeutics Ltd||2||Strategic reasons. Seeking partner for future development.|f||||t||||||||||2018-06-01 01:00:03.405221|2018-06-01 01:00:03.405221
NCT00895466|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|October 2008||2008-10-31|May 2009|2009-05-31||||December 2009||2009-12-31||Interventional|||Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients|A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.|Unknown status|Recruiting|Phase 1/Phase 2|12|Anticipated|Pepscan Therapeutics|||||f||||t||||||||||2018-06-01 01:00:03.538037|2018-06-01 01:00:03.538037
NCT00895453|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2009-01-16||2016-09-26|2009-05-07|2009-05-08|Estimate|2009-05-07|2009-05-08|Estimate||||2016-09-26|2016-11-11|Estimate|May 2000||2000-05-31|May 2009|2009-05-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)|Monthly Itraconazole Versus Classic Homeopathy for the Treatment of Recurrent Vulvovaginal Candidiasis: a Randomised Trial|Completed||N/A|144|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-06-01 01:00:03.653511|2018-06-01 01:00:03.653511
NCT00895440|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2013-11-25|2009-05-07|2009-05-08|Estimate|||||||2013-11-25|2013-11-26|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Role of Indicator Test (Neuropad) in Detecting Diabetic Neuropathy|Neuropad Test for Detection of Sudomotor Dysfunction in Patients With Painful and Painless Diabetic Neuropathy and Charcot Neuroarthropathy|Completed|||139|Actual|Tameside Hospital NHS Foundation Trust|||5||f||||f||||||||||2018-06-01 01:00:04.077572|2018-06-01 01:00:04.077572
NCT00895427|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2011-10-07|2009-05-07|2009-05-08|Estimate|||||||2011-10-07|2011-10-12|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Observational|CACS||A Study Comparing Skin Fluorescence to Coronary Artery Calcification|A Cross-Sectional Study Comparing Noninvasive Skin Fluorescence to Coronary Artery Calcification Measured by Rapid Computed Tomography|Completed|||240|Anticipated|VeraLight, Inc.|||12||f||||f||||||||||2018-06-01 01:00:04.255991|2018-06-01 01:00:04.255991
NCT00895414|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2015-04-23|2009-05-07|2009-05-08|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|April 2014|Actual|2014-04-30||Interventional|||Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer|The Effect of Enalapril on Doxorubicin Exposure in Adjuvant Breast Cancer Treatment|Unknown status|Active, not recruiting|N/A|17|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 01:00:04.354901|2018-06-01 01:00:04.354901
NCT00895401|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2011-02-05|2009-05-07|2009-05-08|Estimate|||||||2011-02-05|2011-02-08|Estimate|April 2009||2009-04-30|February 2011|2011-02-28||||January 2011|Actual|2011-01-31||Interventional|DANSE||DaVita Assessment of Nutritional Supplement Effects (DANSE)|DaVita Assessment of Nutritional Supplement Effects|Completed||Phase 4|160|Actual|Davita Clinical Research||2|||f||||t||||||||||2018-06-01 01:00:04.48934|2018-06-01 01:00:04.48934
NCT00895388|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2011-11-02|2009-05-07|2009-05-08|Estimate|||||||2011-11-02|2011-11-03|Estimate|May 2009||2009-05-31|November 2011|2011-11-30|November 2013|Anticipated|2013-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Effects of Structured Rehabilitation Program on Quality of Life in Rectal Cancer Patients- a Randomized Controlled Trial|Effects of Structured Rehabilitation Program on Quality of Life After Surgical Treatment for Rectal Cancer- a Randomized Controlled Clinical Trial|Unknown status|Recruiting|N/A|64|Anticipated|University Hospital of North Norway||2|||f||||t||||||||||2018-06-01 01:00:04.660868|2018-06-01 01:00:04.660868
NCT00895375|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2017-11-01|2009-05-07|2009-05-08|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2009||2009-10-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|February 2011|Actual|2011-02-28||Observational|||Prevalence of Sleep Disturbances in Psoriasis|Prevalence of Sleep Disturbances in Psoriasis|Completed|||64|Actual|Wake Forest University Health Sciences|||2||f||||f||||||||||2018-06-01 01:00:04.776873|2018-06-01 01:00:04.776873
NCT00895362|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2015-07-10|2009-05-07|2009-05-08|Estimate|||||||2015-07-10|2015-07-13|Estimate|April 2009||2009-04-30|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||Erlotinib in Combination With Cetuximab|A Phase I Dose-Escalation Study of Erlotinib in Combination With Cetuximab in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.|Completed||Phase 1|65|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:00:04.889552|2018-06-01 01:00:04.889552
NCT00895349|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2016-09-12|2009-05-07|2009-05-08|Estimate|||||||2016-09-12|2016-09-13|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|October 2019|Anticipated|2019-10-31|June 2014|Actual|2014-06-30||Interventional|PET LACE||Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer (PET LACE Trial)|The Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer|Terminated||N/A|171|Actual|Ontario Clinical Oncology Group (OCOG)||2||On 30-Jun-2014 as per recommendations from Steering Committee; due to low recruitment rate.|f||||t||||||||||2018-06-01 01:00:05.035061|2018-06-01 01:00:05.035061
NCT00895336|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-02-06|2009-05-07|2009-05-08|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2011||2011-03-31|February 2017|2017-02-28|October 2012|Anticipated|2012-10-31|March 2012|Anticipated|2012-03-31||Interventional|||Lactobacillus GG in Pediatric Ulcerative Colitis (UC)|An Open Label Pilot Study of Lactobacillus GG in Pediatric Ulcerative Colitis|Withdrawn||Phase 2|0|Actual|Children's Hospital Medical Center, Cincinnati||||IND for this study remained on clinical hold|f||||t||||||||||2018-06-01 01:00:05.181788|2018-06-01 01:00:05.181788
NCT00895323|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2013-09-16|2009-05-07|2009-05-08|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 2008||2008-11-30|July 2009|2009-07-31||||March 2010|Anticipated|2010-03-31||Interventional|||Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer|Phase I Study of Preoperative Detection of Colorectal Carcinoma With Bispecific Antibody Pretargeting|Unknown status|Recruiting|Phase 1|9|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:00:05.27187|2018-06-01 01:00:05.27187
NCT00895310|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2016-12-22||2017-02-28|2009-05-07|2009-05-08|Estimate|2016-12-22|2017-02-15|Actual||||2017-02-28|2017-03-30|Actual|May 2009||2009-05-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy|Assessing PSA Response in Low Dose Ketoconazole in Hormone Refractory Prostate Cancer Patients Who Have Failed at Least One Prior Systemic Chemotherapy Regimen|Completed||Phase 2|30|Actual|University of California, Davis||1|||f||||t||||||||Undecided||2018-06-01 01:00:05.388582|2018-06-01 01:00:05.388582
NCT00895297|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2011-12-06|2009-05-07|2009-05-08|Estimate|||||||2011-12-06|2011-12-07|Estimate|February 2010||2010-02-28|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|Dasatinib||Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia|Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation|Terminated||Phase 2|50|Anticipated|European Group for Blood and Marrow Transplantation||||Slow recruitment. No safety concerns during this study.|f||||t||||||||||2018-06-01 01:00:05.662862|2018-06-01 01:00:05.662862
NCT00895284|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2013-05-09||2013-05-09|2009-05-07|2009-05-08|Estimate|2013-05-09|2013-06-28|Estimate||||2013-05-09|2013-06-28|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Trial on Laparoscopic Hysterectomy Versus Robotic Hysterectomy|Laparoscopic Hysterectomy With and Without Robotic Assistance: a Randomized Prospective Trial|Terminated||Phase 4|3|Actual|Mayo Clinic|The study was terminated due to lack of funding.|2||Lack of funding|f||||f||||||||||2018-06-01 01:00:05.773992|2018-06-01 01:00:05.773992
NCT00895271|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2018-03-27|2009-05-07|2009-05-08|Estimate|||||||2018-03-27|2018-03-29|Actual|May 6, 2009||2009-05-06|September 1, 2017|2017-09-01||||||||Observational|||Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders|Establishing Fibroblast-derived Cell Lines From Skin/Tissue Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:00:05.984667|2018-06-01 01:00:05.984667
NCT00895258|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2014-06-18|2009-05-07|2009-05-08|Estimate|||||||2014-06-18|2014-06-19|Estimate|April 2008||2008-04-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Cognitive Training to Improve Work Outcomes in Severe Mental Illness|Cognitive Training to Improve Work Outcomes in Severe Mental Illness|Completed||Phase 2|163|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 01:00:06.086349|2018-06-01 01:00:06.086349
NCT00895245|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2017-01-09||2017-04-13|2009-05-07|2009-05-08|Estimate|2017-04-13|2017-05-18|Actual||||2017-04-13|2017-05-18|Actual|February 2009||2009-02-28|April 2017|2017-04-30|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|A Phase II Clinical Trial Investigating the Efficacy of Single-Dose Fosaprepitant for the Prevention of Cisplatin-Induced Nausea and Vomiting (CINV) in Patients With Head & Neck Cancer Undergoing Concurrent Chemotherapy and Radiation|Terminated||Phase 2|6|Actual|University of Washington|This study was terminated early due to lack of efficacy.|1||Study stopped due to lack of efficacy in first 6 patients|f||||f||||||||No||2018-06-01 01:00:06.198321|2018-06-01 01:00:06.198321
NCT00895232|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2009-06-29||2018-01-22|2009-05-07|2009-05-08|Estimate|2015-06-08|2015-06-10|Estimate||||2018-01-22|2018-02-20|Estimate|November 2003||2003-11-30|January 2018|2018-01-31|November 2005|Actual|2005-11-30|August 2005|Actual|2005-08-31||Interventional|||Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments|Iron Sucrose In The Treatment of Restless Legs Syndrome (RLS): The Safety of Three Dose Regimens as Evaluated by Clinical Assessments|Completed||Phase 2|21|Actual|Luitpold Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:00:06.724043|2018-06-01 01:00:06.724043
NCT00895219|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2009-05-07|2009-05-07|2009-05-08|Estimate|||||||2009-05-07|2009-05-08|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Interventional|HVS||Physiotherapy and Dysfunctional Breathing|A Comparison of the Effects of Respiratory Physiotherapy Alone and Respiratory Physiotherapy Combined With Musculoskeletal Techniques in the Management of Dysfunctional Breathing|Unknown status|Active, not recruiting|Phase 3|60|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:00:07.129103|2018-06-01 01:00:07.129103
NCT00895206|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2016-10-12|2009-05-07|2009-05-08|Estimate|||||||2016-10-12|2016-10-13|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|CD4-01||Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study|Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study|Completed||Phase 4|128|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:00:07.222217|2018-06-01 01:00:07.222217
NCT00895193|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2014-02-03||2014-05-22|2009-05-07|2009-05-08|Estimate|2014-02-03|2014-03-17|Estimate||||2014-05-22|2014-06-05|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Alternative Options to Minimize Niacin-Induced Flushing|Alternative Options to Minimize Niacin-Induced Flushing|Completed||N/A|100|Actual|University of Kansas Medical Center|Limitations include: pilot design, small sample size, short duration of a one-time niacin dose, utilization of only one niacin formulation.|4|||f||||f||||||||||2018-06-01 01:00:07.341176|2018-06-01 01:00:07.341176
NCT00895180|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|2016-11-18||2017-11-30|2009-05-07|2009-05-08|Estimate|2017-02-13|2017-03-29|Actual||||2017-11-30|2017-12-27|Actual|July 2010||2010-07-31|November 2017|2017-11-30|March 4, 2014|Actual|2014-03-04|June 22, 2012|Actual|2012-06-22||Interventional|||Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme|An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|80|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-06-01 01:00:08.088494|2018-06-01 01:00:08.088494
NCT00895167|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2013-01-16|2009-05-07|2009-05-08|Estimate|||||||2013-01-16|2013-01-17|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|CUMAHS||The Effects of Oral Curcumin on Heme Oxygenase-1 (HO-1) in Healthy Male Subjects|The Effects of Oral Curcumin on Heme Oxygenase-1 (HO-1) in Healthy Male Subjects|Completed||Phase 1|12|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-06-01 01:00:08.865589|2018-06-01 01:00:08.865589
NCT00895154|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2014-12-10|2009-05-06|2009-05-08|Estimate|||||||2014-12-10|2014-12-12|Estimate|September 2003||2003-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study|A Rehabilitation Program in Children With Sickle Cell Disease and Cognitive Deficits: a Pilot Study|Completed||Phase 2|37|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:00:08.966742|2018-06-01 01:00:08.966742
NCT00895141|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2013-01-10|2009-05-07|2009-05-08|Estimate|||||||2013-01-10|2013-01-14|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)|Changes in LDL and HDL With Increased Intake of Saturated Fat From Dairy Foods in Individuals With Atherogenic Dyslipidemia and LDL Subclass Pattern B|Completed||N/A|53|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||||2018-06-01 01:00:09.064267|2018-06-01 01:00:09.064267
NCT00895128|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2015-07-10|2009-05-07|2009-05-08|Estimate|||||||2015-07-10|2015-07-13|Estimate|April 2009||2009-04-30|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||Study of Erlotinib in Combination With Dasatinib|A Phase I Dose-Escalation Study of Erlotinib in Combination With Dasatinib in Subjects With Advanced Cancer. Companion Study to Umbrella Protocol 2007-0638.|Completed||Phase 1|65|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:00:09.179639|2018-06-01 01:00:09.179639
NCT00895115|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2012-06-12|2009-05-07|2009-05-08|Estimate|||||||2012-06-12|2012-06-14|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer|A Randomized Study to Investigate the Presence of Tocopherol Metabolites in the Prostate|Completed||Phase 1|65|Actual|Rutgers, The State University of New Jersey||3|||f||||f||||||||||2018-06-01 01:00:09.28608|2018-06-01 01:00:09.28608
NCT00895102|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-07|||2010-10-12|2009-05-07|2009-05-08|Estimate|||||||2010-10-12|2010-10-13|Estimate|April 2009||2009-04-30|September 2010|2010-09-30||||June 2009|Actual|2009-06-30||Interventional|||Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers|An Open-Label Randomized, Crossover Study to Evaluate the Bioavailability of ABT-333 Tablets Versus Capsules, and A Double-blind, Randomized, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending Doses of ABT-333 Tablets Versus Placebo in Healthy Volunteers|Completed||Phase 1|34|Actual|Abbott||3|||f||||f||||||||||2018-06-01 01:00:09.364218|2018-06-01 01:00:09.364218
NCT00895089|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2015-12-01|2009-05-06|2009-05-07|Estimate|||||||2015-12-01|2015-12-02|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess|Prospective, Randomized, Open-Labeled, Active-Controlled Comparison of Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess: A Pilot Study|Completed||Phase 4|24|Actual|Kaohsiung Veterans General Hospital.||2|||f||||f||||||||||2018-06-01 01:00:09.461689|2018-06-01 01:00:09.461689
NCT00895076|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-06|2009-05-06|2009-05-07|Estimate|||||||2009-05-06|2009-05-07|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Study to Compare the Pharmacokinetics of a Dexamethasone Iontophoretic Patch to a Dexamethasone Injection|A Randomized, Open-Label, Single Dose, Two-Way Crossover Study to Evaluate the Pharmacokinetics and Safety of a Dexamethasone Iontophoretic Transdermal Patch Compared to Dexamethasone Injection in Healthy Adult Volunteers|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|Travanti Pharma Inc.||2|||f||||||||||||||2018-06-01 01:00:09.57566|2018-06-01 01:00:09.57566
NCT00895063|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2016-03-02|2009-05-06|2009-05-07|Estimate|||||||2016-03-02|2016-03-03|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia|Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia|Terminated||N/A|8|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 01:00:09.68184|2018-06-01 01:00:09.68184
NCT00895050|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2011-07-13|2009-05-06|2009-05-07|Estimate|||||||2011-07-13|2011-07-15|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Study Evaluating Impact of the Use of a Computer-based Tool on the Clinical Management of RA Patients|Impact of the Use of a Computer-based Tools on the Clinical Management and Evolution of Patients With Rheumatoid Arthritis.|Completed|||321|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:00:09.799373|2018-06-01 01:00:09.799373
NCT00895037|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2017-08-28|2009-05-05|2009-05-07|Estimate|||||||2017-08-28|2017-08-29|Actual|July 17, 2009|Actual|2009-07-17|August 2017|2017-08-31|October 15, 2017|Anticipated|2017-10-15|October 30, 2016|Actual|2016-10-30||Observational|||Study Evaluating Pharmacovigilance Of Refacto AF|Refacto Af (Registered) Pharmacovigilance Study|Active, not recruiting|||101|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:00:09.897316|2018-06-01 01:00:09.897316
NCT00895024|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2017-08-09|2009-05-06|2009-05-07|Estimate|||||||2017-08-09|2017-08-11|Actual|April 2009|Actual|2009-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Caregiver Assessments of the Quality of Home Hospice Care|Caregiver Assessments of the Quality of Home Hospice Care: A Comparison Across 3 Ethnic Groups (A Preliminary Study)|Active, not recruiting|||128|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:00:10.022944|2018-06-01 01:00:10.022944
NCT00895011|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2012-05-25|2011-06-06|2012-09-14|2009-05-06|2009-05-07|Estimate|2012-05-25|2012-06-28|Estimate|2011-06-06|2011-06-21|Estimate|2012-09-14|2012-10-01|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy|Completed||Phase 3|298|Actual|VIVUS, Inc.||3|||f||||f||||||||||2018-06-01 01:00:10.129962|2018-06-01 01:00:10.129962
NCT00894998|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-02-22|2009-05-06|2009-05-07|Estimate|||||||2013-02-22|2013-02-25|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Sodium Heparin in Patients (Cristália)|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass|Completed||Phase 3|104|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:00:10.657345|2018-06-01 01:00:10.657345
NCT00894985|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-02-22|2009-05-06|2009-05-07|Estimate|||||||2013-02-22|2013-02-25|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Sodium Heparin|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass|Completed||Phase 3|104|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:00:10.749069|2018-06-01 01:00:10.749069
NCT00894972|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2012-11-05|2009-05-06|2009-05-07|Estimate|||||||2012-11-05|2012-11-06|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Rehabilitation Following Lumbar Disc Surgery|Examining the Effectiveness of a Post-operative Rehabilitation Program Emphasizing Restoration of Multifidus Muscle Function for Individuals Undergoing Lumbar Discectomy: a Randomized Clinical Trial|Completed||N/A|60|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 01:00:10.83287|2018-06-01 01:00:10.83287
NCT00894959|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-02-22|2009-05-06|2009-05-07|Estimate|||||||2013-02-22|2013-02-25|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Sodium Heparin in Patients|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass|Completed||Phase 3|104|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:00:10.92053|2018-06-01 01:00:10.92053
NCT00894946|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-06|2009-05-06|2009-05-07|Estimate|||||||2009-05-06|2009-05-07|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||The In Vitro Fertilization - Lipiodol Uterine Bathing Effect Study|The in Vitro Fertilisation - Lipiodol Uterine Bathing Effect Study|Unknown status|Recruiting|Phase 3|350|Anticipated|University of Auckland, New Zealand||2|||f||||t||||||||||2018-06-01 01:00:10.996343|2018-06-01 01:00:10.996343
NCT00894933|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2017-01-22||2018-01-24|2009-05-05|2009-05-07|Estimate|2017-01-22|2017-03-13|Actual||||2018-01-24|2018-02-21|Estimate|May 2009||2009-05-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Male patients ≥ 40 years old indicated for radical prostatectomy|Performance Evaluation of the AMS CONTINUUM™ Device|Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy|Completed||N/A|33|Actual|American Medical Systems||1|||f||||f||||||||No||2018-06-01 01:00:11.186424|2018-06-01 01:00:11.186424
NCT00894920|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2015-02-26|2009-05-06|2009-05-07|Estimate|||||||2015-02-26|2015-03-02|Estimate|August 2009||2009-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Biotin Status in Pregnancy|Biotin Status in Pregnancy|Completed||N/A|124|Actual|University of Arkansas||2|||f||||f||||||||||2018-06-01 01:00:11.588652|2018-06-01 01:00:11.588652
NCT00894907|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2017-09-19|2009-05-06|2009-05-07|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2009||2009-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|EAGLE||Early Goal-directed Volume Resuscitation in Severe Acute Pancreatitis|EAGLE: Early Goal-directed Volume Resuscitation in Severe Acute Pancreatitis: A Randomised Multi-centre Study|Recruiting||N/A|190|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-06-01 01:00:11.716604|2018-06-01 01:00:11.716604
NCT00894894|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2011-12-01|2009-05-06|2009-05-07|Estimate|||||||2011-12-01|2011-12-02|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies|Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies|Completed||Phase 1|22|Actual|Astex Pharmaceuticals|||||f||||f||||||||||2018-06-01 01:00:11.834768|2018-06-01 01:00:11.834768
NCT00894881|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-06|2009-05-06|2009-05-07|Estimate|||||||2009-05-06|2009-05-07|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||The Effect of Colonoscopy on Resting Energy Expenditure|The Effect of Colonoscopy on Resting Energy Expenditure|Unknown status|Not yet recruiting||30|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-06-01 01:00:11.932691|2018-06-01 01:00:11.932691
NCT00894374|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2010-06-24|2009-05-05|2009-05-07|Estimate|||||||2010-06-24|2010-06-25|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects|A Single-Dose Bioequivalence Study Comparing Artesunate Tablet (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects|Completed||Phase 1|40|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:00:23.4149|2018-06-01 01:00:23.4149
NCT00894868|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06||2014-03-27|2014-04-24|2009-05-06|2009-05-07|Estimate||||2014-03-27|2014-04-24|Estimate|2014-04-24|2014-05-13|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure|A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure|Completed||Phase 4|798|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:00:12.078439|2018-06-01 01:00:12.078439
NCT00894855|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2014-12-30|2009-05-06|2009-05-07|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|SHADE||Skin Cancer Screening and Education at Beaches|Skin Cancer Screening and Education Program at Beaches|Completed||N/A|634|Actual|Dana-Farber Cancer Institute||4|||f||||f||||||||||2018-06-01 01:00:12.356476|2018-06-01 01:00:12.356476
NCT00894842|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2011-10-04|2009-05-06|2009-05-07|Estimate|||||||2011-10-04|2011-10-06|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia|A 10-week, Randomized, Double-Blind, Placebo-Controlled Trial of a Neurocognition Enhancing Agent(Pregnenolone) in Patients With Schizophrenia.|Completed||Phase 2/Phase 3|120|Actual|National Research Foundation, Singapore||2|||f||||t||||||||||2018-06-01 01:00:12.475107|2018-06-01 01:00:12.475107
NCT00894829|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-02-22|2009-05-06|2009-05-07|Estimate|||||||2013-02-22|2013-02-25|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety of Sodium Heparin (Eurofarma)|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass|Completed||Phase 3|104|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:00:12.589508|2018-06-01 01:00:12.589508
NCT00894816|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2017-10-24|2009-05-06|2009-05-07|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2000||2000-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2011|Actual|2011-09-30||Interventional|ELEFANT||Probiotics in Prevention of Allergies, Obesity and Caries|Effects of Feeding Lactobacillus F19 to Infants During Weaning on Allergies, Immune Programming, Gut Microbiota, Overweight and Oral Health|Active, not recruiting||N/A|171|Anticipated|Umeå University||2|||f||||f||||||||||2018-06-01 01:00:12.671744|2018-06-01 01:00:12.671744
NCT00894803|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|2013-11-27||2014-03-26|2009-05-06|2009-05-07|Estimate|2014-01-28|2014-03-17|Estimate||||2014-03-26|2014-04-17|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|CLEAR-ER||Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke|"The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER Stroke Trial)"|Completed||Phase 2|126|Actual|University of Cincinnati||2|||f||||t||||||||||2018-06-01 01:00:12.808625|2018-06-01 01:00:12.808625
NCT00894790|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2011-01-28||2011-02-25|2009-05-06|2009-05-07|Estimate|2011-01-31|2011-02-25|Estimate||||2011-02-25|2011-03-01|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident|A Phase IV Open Label Randomized Multicenter Comparative Study Of Celecoxib Efficacy And Safety Versus Standard Doses Of Oral Diclofenac In Acute Pain Due To Cervical Sprain Related To Motor Vehicle Accident|Terminated||Phase 4|8|Actual|Pfizer||2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:00:13.924644|2018-06-01 01:00:13.924644
NCT00894777|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2010-11-19|2009-05-06|2009-05-07|Estimate|||||||2010-11-19|2010-11-22|Estimate|March 2009||2009-03-31|November 2010|2010-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Study Evaluating Management of Patients With Moderate and Severe Psoriasis|Management of Patients With Moderate and Severe Psoriasis Under Treatment With Topical and/or Systemic Drugs|Completed|||469|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 01:00:14.199096|2018-06-01 01:00:14.199096
NCT00894764|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2012-05-04|2009-05-06|2009-05-07|Estimate|||||||2012-05-04|2012-05-07|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|ARI||The Study of Chest Infections in Infants Living in a Refugee Camp on the Thai-Burmese Border|A Clinical and Microbiological Study of Acute Respiratory Infections in Refugee Infants Living on the Thai-Burmese Border|Completed|||1000|Actual|University of Oxford|||2||f||||f||||||||||2018-06-01 01:00:14.272512|2018-06-01 01:00:14.272512
NCT00894751|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-06|2009-05-06|2009-05-07|Estimate|||||||2009-05-06|2009-05-07|Estimate|January 2009||2009-01-31|May 2009|2009-05-31||||January 2011|Anticipated|2011-01-31||Interventional|||Two Anesthetic Techniques in Magnetic Resonance Imaging (MRI)|A Qualitative Comparison of Two Anesthetic Techniques in Children Undergoing Magnetic Resonance Imaging|Unknown status|Recruiting|Phase 1|160|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 01:00:14.335309|2018-06-01 01:00:14.335309
NCT00894738|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2012-07-19|2009-05-06|2009-05-07|Estimate|||||||2012-07-19|2012-07-20|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures|Biomarkers of Cardiometabolic Risk in Children Treated With Antipsychotics: A Preliminary Study of Direct Measures|Completed||N/A|45|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:00:14.405587|2018-06-01 01:00:14.405587
NCT00894725|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-06|2009-05-06|2009-05-07|Estimate|||||||2009-05-06|2009-05-07|Estimate|February 2000||2000-02-29|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2004|Actual|2004-12-31||Interventional|||Laparoscopic Versus Open Left Colonic Resection|Laparoscopic vs. Open Left Colonic Resection: a Randomized Monocentric Trial|Completed||Phase 3|268|Actual|Università Vita-Salute San Raffaele||2|||f||||f||||||||||2018-06-01 01:00:14.470117|2018-06-01 01:00:14.470117
NCT00894712|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-10-02|2009-05-06|2009-05-07|Estimate|||||||2014-10-02|2014-10-03|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|November 2012|Actual|2012-11-30||Observational|||Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis|Effect of Topical Application of Sulforaphane- Containing Broccoli Sprout Extracts on Radiation Dermatitis During External-beam Radiation Therapy for Breast Cancer|Unknown status|Active, not recruiting||32|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 01:00:14.534959|2018-06-01 01:00:14.534959
NCT00894192|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-05|2009-05-05|2009-05-06|Estimate|||||||2009-05-05|2009-05-06|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Comprehensive Evaluation of Visual Function|Comprehensive Evaluation of Visual Function|Unknown status|Recruiting|N/A|300|Anticipated|The Chicago Lighthouse for People Who Are Blind or Visually Impaired||2|||f||||f||||||||||2018-06-01 01:00:26.28416|2018-06-01 01:00:26.28416
NCT00894699|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2014-01-10||2014-05-23|2009-05-06|2009-05-07|Estimate|2014-05-23|2014-06-25|Estimate||||2014-05-23|2014-06-25|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabs™ in Patients Undergoing an Elective Abdominal Liposuction Procedure|Completed||Phase 2|40|Actual|AcelRx Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 01:00:15.713447|2018-06-01 01:00:15.713447
NCT00894686|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-07-10|2009-05-06|2009-05-07|Estimate|||||||2017-07-10|2017-07-11|Actual|April 2009|Actual|2009-04-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Tick-Borne Encephalitis (TBE) Seropersistence After First Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)|Open-label Phase Iv Study To Investigate The Seropersistence Of Tick-borne Encephalitis (Tbe) Virus Antibodies After The First Booster And The Response To A Second Booster Vaccination With Fsme-immun In Children, Adolescents And Young Adults (Follow-up To Study 700401)|Completed||Phase 4|178|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 01:00:15.948123|2018-06-01 01:00:15.948123
NCT00894673|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-02-22|2009-05-06|2009-05-07|Estimate|||||||2013-02-22|2013-02-25|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|HEPSBCCV0109||Efficacy and Safety of Sodium Heparin (Hipolabor) in Patients|Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass|Completed||Phase 3|104|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:00:16.033237|2018-06-01 01:00:16.033237
NCT00894660|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2010-04-20|2009-05-05|2009-05-07|Estimate|||||||2010-04-20|2010-04-21|Estimate|June 2009||2009-06-30|April 2010|2010-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects|A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects|Completed||Phase 1|38|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:00:16.108871|2018-06-01 01:00:16.108871
NCT00894647|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2010-07-28||2010-08-23|2009-05-05|2009-05-07|Estimate|2010-07-28|2010-08-23|Estimate||||2010-08-23|2010-08-31|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery|A Phase 3b Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses|Completed||Phase 3|247|Actual|Graceway Pharmaceuticals, LLC|A treatment-emergent AE (TEAE) was an AE that began or worsened in severity after the first application of study drug. TEAEs were summarized for each treatment group by overall incidence, descending order, relationship to study drug, and severity.|2|||f||||f||||||||||2018-06-01 01:00:16.214471|2018-06-01 01:00:16.214471
NCT00894634|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-02-21|2009-05-06|2009-05-07|Estimate|||||||2013-02-21|2013-02-22|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents|A Single-Dose, Open-Label, Pharmacokinetic Study of Brompheniramine Maleate Liquid in Children and Adolescents|Completed||N/A|30|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:00:16.702414|2018-06-01 01:00:16.702414
NCT00894621|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-06|2009-05-06|2009-05-07|Estimate|||||||2009-05-06|2009-05-07|Estimate|November 2008||2008-11-30|May 2009|2009-05-31||||||||Interventional|||Norepinephrine as Early Vasopressor Therapy in Children Undergoing Mechanical Ventilation|Norepinephrine as Early Vasopressor Therapy in Children Undergoing Mechanical Ventilation|Unknown status|Active, not recruiting|Phase 4|40|Actual|Unidade de Terapia Intensiva||2|||f||||||||||||||2018-06-01 01:00:16.78845|2018-06-01 01:00:16.78845
NCT00894608|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-05-05|2009-05-05|2009-05-07|Estimate|||||||2009-05-05|2009-05-07|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Letrozole Combined With Gonadotropins (Gn) for Ovarian Stimulation Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) in Patients With Polycystic Ovary Syndrome (PCOS)|Letrozole Combined With Gn for Ovarian Hyperstimulation Undergoing IVF/ICSI in Patients With PCOS|Unknown status|Enrolling by invitation|N/A|90|Anticipated|Yunyang Medical College||2|||f||||t||||||||||2018-06-01 01:00:16.875819|2018-06-01 01:00:16.875819
NCT00894595|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2011-01-03|2009-05-06|2009-05-07|Estimate|||||||2011-01-03|2011-01-04|Estimate|August 2008||2008-08-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Preventing Knee Injuries in Adolescent Female Football Players|Preventing Knee Injuries in Adolescent Female Football Players - Protocol of a Cluster-randomized Controlled Trial|Completed||N/A|4564|Actual|Region Skane||2|||f||||f||||||||||2018-06-01 01:00:16.976744|2018-06-01 01:00:16.976744
NCT00894582|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-05-05|2009-05-05|2009-05-07|Estimate|||||||2009-05-05|2009-05-07|Estimate|January 2007||2007-01-31|May 2009|2009-05-31|December 2008||2008-12-31|December 2008|Actual|2008-12-31||Observational|||Prospective Study of Ventral Hernia Repair|Prospective Measurements of Intra-Abdominal Volume and Pulmonary Function After Repair of Massive Ventral Hernias With the Components Separation Technique|Completed|||21|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 01:00:17.062591|2018-06-01 01:00:17.062591
NCT00894569|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-05-13|2009-05-06|2009-05-07|Estimate|||||||2009-05-13|2009-05-14|Estimate|July 2009||2009-07-31|May 2009|2009-05-31|August 2011|Anticipated|2011-08-31|July 2010|Anticipated|2010-07-31||Interventional|PACET-CUP||Paclitaxel/Carboplatin With or Without Cetuximab in CUP|Open-Labeled, Randomized Multi-Center Phase II Study Evaluating the Efficacy and Safety of Paclitaxel/ Carboplatin With and Without Cetuximab as First-Line Treatment of Adeno- and Undifferentiated Carcinoma of Unknown Primary (CUP)|Unknown status|Not yet recruiting|Phase 2|150|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-06-01 01:00:17.130536|2018-06-01 01:00:17.130536
NCT00894556|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2010-09-23||2017-05-25|2009-05-06|2009-05-07|Estimate|2010-12-17|2011-01-20|Estimate||||2017-05-25|2017-06-20|Actual|June 10, 2009|Actual|2009-06-10|May 2017|2017-05-31|January 12, 2010|Actual|2010-01-12|January 12, 2010|Actual|2010-01-12||Interventional|||A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders|Completed||Phase 3|109|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:00:17.347372|2018-06-01 01:00:17.347372
NCT00894543|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2011-02-17||2013-03-05|2009-05-05|2009-05-07|Estimate|2011-03-21|2011-03-23|Estimate||||2013-03-05|2013-03-08|Estimate|July 2009||2009-07-31|March 2013|2013-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women|Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women|Completed||N/A|205|Actual|Fred Hutchinson Cancer Research Center|Although this was a community-based sample, the volunteers may be a select group motivated to seek treatment. An 8-week trial is brief, but data indicate that this interval is sufficient to determine long-term efficacy of a nonhormonal compound.|2|||f||||t||||||||||2018-06-01 01:00:18.206201|2018-06-01 01:00:18.206201
NCT00894530|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05||2010-10-29|2013-10-29|2009-05-05|2009-05-07|Estimate||||2010-10-29|2010-11-02|Estimate|2013-10-29|2013-11-21|Estimate|May 2009||2009-05-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)||Completed||Phase 2|314|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:00:18.922126|2018-06-01 01:00:18.922126
NCT00894517|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2013-07-30|2013-06-21|2013-07-30|2009-05-05|2009-05-07|Estimate|2013-07-30|2013-09-30|Estimate|2013-06-21|2013-07-01|Estimate|2013-07-30|2013-09-30|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia||Completed||Phase 1/Phase 2|61|Actual|Allergan||2|||f||||f||||||||||2018-06-01 01:00:19.085924|2018-06-01 01:00:19.085924
NCT00894504|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2014-11-21||2015-04-28|2009-05-06|2009-05-07|Estimate|2014-12-09|2014-12-15|Estimate||||2015-04-28|2015-05-15|Estimate|February 2010||2010-02-28|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer|A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer|Completed||Phase 2|71|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 01:00:19.544677|2018-06-01 01:00:19.544677
NCT00894491|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2010-10-14|2009-05-06|2009-05-07|Estimate|||||||2010-10-14|2010-10-15|Estimate|January 2006||2006-01-31|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|December 2009|Actual|2009-12-31||Observational|||Complementary and Alternative Medical Trends: A Patient Survey in a University Based Clinic|Complementary and Alternative Medical Therapy Trends: A Patient Survey in a University Based Clinic|Unknown status|Recruiting||33|Anticipated|University of California, Irvine|||||f||||t||||||||||2018-06-01 01:00:19.986754|2018-06-01 01:00:19.986754
NCT00894478|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2013-09-09|2009-05-06|2009-05-07|Estimate|||||||2013-09-09|2013-09-10|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using Diffusion Tensor Imaging|Improving Lesion Detection in Children With MRI-negative Partial Epilepsy Using Diffusion Tensor Imaging|Completed|||64|Actual|The Hospital for Sick Children|||3||f||||f||||||||||2018-06-01 01:00:20.083397|2018-06-01 01:00:20.083397
NCT00894465|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2016-01-24||2016-10-17|2009-05-06|2009-05-07|Estimate|2016-10-17|2016-12-09|Estimate||||2016-10-17|2016-12-09|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional||All participants who signed consent were included in analysis population.|Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)|A Randomized, Double-Blind, Placebo-Controlled Study Examining the Efficacy of Oral Midazolam in Reducing Anxiety in Children Undergoing Voiding Cystourethrogram|Terminated||N/A|44|Actual|Washington University School of Medicine||2||Most pts requested to be treated with versed. It was difficult to randomize pts.|f||||f||||||||No||2018-06-01 01:00:20.213326|2018-06-01 01:00:20.213326
NCT00894452|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2016-09-28|2009-05-06|2009-05-07|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Observational|METHADOSE||Variance of Oral Methadone Dosage: Description of Implicated Factors|Factors Associated With the Variance of Oral Methadone Dosage at Steady State of Maintenance Treatment: Description of Bio-markers of Phenotype and Genotype.|Completed|||210|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     serum: orosomucoid, methadone dosage, OH midazolam/midazola ratio~      DNA: CYPs, MDR1, OPRM1, COMT~   "|||2018-06-01 01:00:20.561497|2018-06-01 01:00:20.561497
NCT00894439|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2009-07-16|2009-05-06|2009-05-07|Estimate|||||||2009-07-16|2009-07-17|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study Evaluating BLI-489 and Piperacillin in Healthy Subjects|A Randomized, Open-label, Single-dose, 3-period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone.|Completed||Phase 1|24|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:00:20.658315|2018-06-01 01:00:20.658315
NCT00894426|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2010-12-02|2009-05-06|2009-05-07|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|December 2009|Actual|2009-12-31|||||Observational|SYMBOL||Patient's Perception in Symptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease|Prospective, Observational, Multi-center, Non-interventional Study to Assess Patients Perception in SYmptoms Related to Morning Activity Based on Chronic Obstructive Lung Disease|Completed|||150|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:00:20.756056|2018-06-01 01:00:20.756056
NCT00894413|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-05-12|2009-05-06|2009-05-07|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract|A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract|Completed||Phase 2|40|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-06-01 01:00:20.838971|2018-06-01 01:00:20.838971
NCT00894400|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2011-08-01|2009-05-06|2009-05-07|Estimate|||||||2011-08-01|2011-08-02|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|CAFE AF||Characterisation of Fractionated Electrograms Critical for Maintenance of Atrial Fibrillation (AF)|Characterisation of Fractionated Electrograms Critical for Maintenance of AF|Completed||N/A|20|Actual|Barts & The London NHS Trust||2|||f||||f||||||||||2018-06-01 01:00:20.941645|2018-06-01 01:00:20.941645
NCT00894387|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2013-08-02||2013-10-15|2009-05-05|2009-05-07|Estimate|2013-08-02|2013-10-10|Estimate||||2013-10-15|2013-11-07|Estimate|May 2009||2009-05-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ASTRONAUT||Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure|Completed||Phase 3|1639|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:00:21.201597|2018-06-01 01:00:21.201597
NCT00894361|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2009-03-24||2013-06-24|2009-03-24|2009-05-07|Estimate|2009-03-24|2009-05-07|Estimate||||2013-06-24|2013-07-30|Estimate|October 2001||2001-10-31|June 2013|2013-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Comparison of Mobile-Bearing and Fixed-Bearing All-Polyethylene Tibia Total Knee Designs|A Randomized Prospective Comparison of Mobile-Bearing and Fixed-Bearing (All-Polyethylene Tibia) Cruciate-Substituting Total Knee Arthroplasty (TKA) Designs|Completed||Phase 4|400|Actual|Minneapolis Veterans Affairs Medical Center|Mean 43 month followup with minimum 2 year followup; survival analysis will follow at long-term followup; multiple outcome measures also recorded other than range of motion (ROM)|2|||f||||t||||||||||2018-06-01 01:00:23.503657|2018-06-01 01:00:23.503657
NCT00894348|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2017-03-29|2009-05-06|2009-05-07|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2009||2009-01-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|ERCP||Factors Predicting Positive Yields on Biliary Brush Cytology During Endoscopic Retrograde Cholangiopancreatography|EXEMPT: Prospective Factors Predicting Positive Yields on Biliary Brush Cytology During Endoscopic Retrograde Cholangio-pancreatography (ERCP)|Completed|||200|Actual|The Cleveland Clinic|||||f||||t||||||||No||2018-06-01 01:00:23.811402|2018-06-01 01:00:23.811402
NCT00894335|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-06|||2011-06-27|2009-05-06|2009-05-07|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|July 2012|Anticipated|2012-07-31|March 2012|Anticipated|2012-03-31||Observational|||Anesthesia Management of Retroperitoneal Adrenalectomies|Anesthesiological Management of Hemodynamics and Gas Exchange for Retroperitoneal Adrenalectomies|Unknown status|Recruiting||500|Anticipated|Kliniken Essen-Mitte|||5||f||||f||||||||||2018-06-01 01:00:24.070476|2018-06-01 01:00:24.070476
NCT00894322|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2014-04-16|2013-03-06|2015-09-03|2009-05-06|2009-05-07|Estimate|2014-04-16|2014-05-14|Estimate|2013-04-24|2013-05-03|Estimate|2015-09-03|2015-09-18|Estimate|April 2009||2009-04-30|August 2015|2015-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Intent to treat (ITT) population. All randomized participants who received at least 1 dose of study medication were included in the ITT population. Totals presented are for only Cohort 2 (35 participants), not for both Cohort 1 and 2.|A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension|A Two-Cohort, Single- and Repeat Dose Study to Examine the Pharmacokinetics, Tolerability, and Safety of Ready to Use Exenatide Once Weekly in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|65|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:00:24.244719|2018-06-01 01:00:24.244719
NCT00894309|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-05-05|2009-05-05|2009-05-06|Estimate|||||||2009-05-05|2009-05-06|Estimate|May 2009||2009-05-31|May 2009|2009-05-31||||||||Observational|FRI||Validation of the Fluid Responsiveness Index in Critically Ill Patients|Evaluation of the Validity of a New Index Provided by the PiCCO2 Device for Predicting Fluid Responsiveness in Critically Ill Patients|Unknown status|Not yet recruiting||80|Anticipated|Bicetre Hospital|||||f||||f||||||||||2018-06-01 01:00:25.282407|2018-06-01 01:00:25.282407
NCT00894296|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2012-01-04|2009-05-05|2009-05-06|Estimate|||||||2012-01-04|2012-01-05|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on Treatments|Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on Treatments|Unknown status|Recruiting||50|Anticipated|Shalvata Mental Health Center|||2||f||||t||||||||||2018-06-01 01:00:25.39222|2018-06-01 01:00:25.39222
NCT00894283|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-08-06|2009-05-05|2009-05-06|Estimate|||||||2014-08-06|2014-08-07|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Pilot Study Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients|A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily With Respect to Preventing VTE After Bariatric Surgery in Obese Patients|Completed||Early Phase 1|198|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 01:00:25.490701|2018-06-01 01:00:25.490701
NCT00894270|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-05-07|2009-05-05|2009-05-06|Estimate|||||||2009-05-07|2009-05-08|Estimate|November 2008||2008-11-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees|Comparison of Vehicle Delivery Depth Using the NovoFine® 5 mm Needle With or Without a Skin Fold and Inserted at Either 45 or 90 Degrees|Completed||Phase 4|240|Anticipated|Liggins Institute|||||f||||f||||||||||2018-06-01 01:00:25.596561|2018-06-01 01:00:25.596561
NCT00894257|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2010-04-02|2009-05-05|2009-05-06|Estimate|||||||2010-04-02|2010-04-05|Estimate|May 2009||2009-05-31|March 2010|2010-03-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|EPIALHICE B||Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population|Trends in Risk of Mother-to-child Transmission of Hepatitis C Through Analysis of Prevalence of Risk Factors for Maternal Infection Among a Southern European Population|Unknown status|Recruiting||128|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||||||2018-06-01 01:00:25.700527|2018-06-01 01:00:25.700527
NCT00894244|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2012-02-07||2014-05-22|2009-05-05|2009-05-06|Estimate|2012-08-01|2012-09-03|Estimate||||2014-05-22|2014-06-04|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Quantitative Evaluation of Skin Shrinkage Caused by a Non-invasive Tightening Device|Quantitative Evaluation of Skin Shrinkage Caused by a Non-invasive Tightening Device|Completed||N/A|25|Actual|Northwestern University||1|||f||||f||||||||||2018-06-01 01:00:25.810137|2018-06-01 01:00:25.810137
NCT00894231|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-09-03|2009-05-04|2009-05-06|Estimate|||||||2009-09-03|2009-09-04|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis|Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis|Completed||Phase 4|30|Anticipated|AAADRS Clinical Research Center||2|||f||||t||||||||||2018-06-01 01:00:26.009276|2018-06-01 01:00:26.009276
NCT00894218|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2014-02-24|2009-05-05|2009-05-06|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2009||2009-04-30|February 2014|2014-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||New Tool of Subjective and Objective Functional Evaluation and the Quality of Life After Arthroplastic Surgery of the Hip and the Knee Assisted or Not by Computer and Mini-invasive Arthroplasty||Terminated||N/A|1|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 01:00:26.105811|2018-06-01 01:00:26.105811
NCT00894205|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2015-03-09|2009-05-04|2009-05-06|Estimate|||||||2015-03-09|2015-03-11|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Neuropsychological Effects of Strengthening Exercise for Older Adults|Neuropsychological and Physiological Effects of Low-Impact Exercise for Older Adults|Completed||Phase 2|29|Actual|Union College, New York||1|||f||||f||||||||||2018-06-01 01:00:26.188345|2018-06-01 01:00:26.188345
NCT00894179|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2011-06-21|2009-05-05|2009-05-06|Estimate|||||||2011-06-21|2011-06-23|Estimate|May 2009||2009-05-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|||||Observational|REGAT||Safety and Accuracy Study of Regadenoson Atropine Combination for Stress Echocardiography in Identification of Coronary Artery Disease|Feasibility, Safety and Accuracy of Regadenoson-Atropine ( REGAT) Stress Echocardiography for the Diagnosis of Coronary Artery Disease: An Angiographic Correlative Study|Unknown status|Recruiting||110|Anticipated|Henry Ford Health System|||||f||||f||||||||||2018-06-01 01:00:26.377665|2018-06-01 01:00:26.377665
NCT00894166|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2012-10-19||2013-09-19|2009-05-05|2009-05-06|Estimate|2012-11-26|2012-12-26|Estimate||||2013-09-19|2013-09-23|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|ConNic3||Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype|Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype|Completed||Phase 3|606|Actual|Duke University|The group sizes for the post quit date randomization groups was relatively small. Second, the study used a tailored dose of pre-cessation nicotine patch therapy that is not in accordance with current product labeling in the US.|7|||f||||t||||||||||2018-06-01 01:00:26.47349|2018-06-01 01:00:26.47349
NCT00894153|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2012-04-06|2009-05-05|2009-05-06|Estimate|||||||2012-04-06|2012-04-09|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage|Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage|Unknown status|Recruiting|Phase 4|1200|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||3|||f||||f||||||||||2018-06-01 01:00:27.654215|2018-06-01 01:00:27.654215
NCT00894140|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2016-09-23|2009-05-05|2009-05-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2003||2003-01-31|September 2016|2016-09-30|May 2014|Actual|2014-05-31|November 2004|Actual|2004-11-30||Interventional|||Study to Assess the Stability, Efficacy and Safety of the Silent™ Hip Prosthesis in Primary Total Hip Replacement|A Non-comparative, Two Centre, EN540, RSA, Pilot Study to Evaluate the Stability, Efficacy and Safety of the Silent Hip Prosthesis in Primary Total Hip Replacement|Completed||N/A|44|Actual|DePuy International||1|||f||||f||||||||No||2018-06-01 01:00:27.778195|2018-06-01 01:00:27.778195
NCT00894127|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2014-08-19||2014-09-19|2009-05-05|2009-05-06|Estimate|2014-09-19|2014-09-22|Estimate||||2014-09-19|2014-09-22|Estimate|March 2009||2009-03-31|September 2014|2014-09-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional||Male and female subjects aged 18 years of age and older were recruited from the pool of United States’ military veterans who responded to public advertisements and recruitment pamphlets disseminated at veteran’s events,|Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer|Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer|Completed||Phase 1/Phase 2|128|Actual|Biomoda Inc.||1|||f||||t||||||||||2018-06-01 01:00:27.880515|2018-06-01 01:00:27.880515
NCT00894114|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2015-05-27|2009-05-05|2009-05-06|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2003||2003-05-31|May 2015|2015-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)|A Probe Study of the Safety, Tolerability, and Immunogenicity of a 1-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5, or Placebo in Merck V520 Protocols 007 or 012|Completed||Phase 1|250|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 01:00:28.158617|2018-06-01 01:00:28.158617
NCT00894101|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2011-04-01|2009-05-04|2009-05-06|Estimate|||||||2011-04-01|2011-04-04|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation|A Phase II/III, Open Label, Non-Randomized, Multi-Center Study of Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation|Withdrawn||Phase 2/Phase 3|7|Anticipated|University of California, Irvine||1||"The main sponsor of this multi-center trial has submitted this protocol. A single participating~   site should not register this study."|f||||f||||||||||2018-06-01 01:00:28.241738|2018-06-01 01:00:28.241738
NCT00894088|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2018-01-19|2009-05-05|2009-05-06|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2006||2006-01-31|January 2018|2018-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fasting Conditions|Completed||N/A|38|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:00:28.316552|2018-06-01 01:00:28.316552
NCT00894075|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2013-01-24|2009-05-05|2009-05-06|Estimate|||||||2013-01-24|2013-01-25|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)|Single-Center, Case-Control Study of Safety, Efficacy and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) for Treatment of Hypophosphatasia in Children|Withdrawn||Phase 2|0|Actual|Alexion Pharma GmbH||||Withdrawn pending further review of clinical design.|f||||t||||||||||2018-06-01 01:00:28.397802|2018-06-01 01:00:28.397802
NCT00894062|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2010-03-23|2009-05-05|2009-05-06|Estimate|||||||2010-03-23|2010-03-24|Estimate|December 2008||2008-12-31|July 2009|2009-07-31||||||||Interventional|COVER OCT||Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent|ComparisiOn of Neointimal coVerage betwEen zotaRolimus Eluting Stent and Everolimus Eluting Stent Using Optical Coherence Tomography at 9 Months (COVER OCT)|Completed||Phase 4|40|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 01:00:28.509374|2018-06-01 01:00:28.509374
NCT00894049|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-12-31|2009-05-05|2009-05-06|Estimate|||||||2013-12-31|2014-01-01|Estimate|November 2002||2002-11-30|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ITAC02-01||A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation|A Multicenter Prospective Randomized Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation|Completed||Phase 2|148|Actual|Institut Paoli-Calmettes||2|||f||||t||||||||||2018-06-01 01:00:28.618874|2018-06-01 01:00:28.618874
NCT00894036|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-09-24|2009-05-04|2009-05-06|Estimate|||||||2009-09-24|2009-09-25|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Observational|||The Burden and Genetic Variability of Extended-Spectrum ß-Lactamase (ESBL) - Producing Pathogens in Swiss Children|Epidemiology of Extended-spectrum ß-lactamase (ESBL)-Producing Enteric Gram-negative Bacilli in Swiss Children|Unknown status|Recruiting||100|Anticipated|University Hospital, Geneva|||||f||||t||||||||||2018-06-01 01:00:28.707943|2018-06-01 01:00:28.707943
NCT00894023|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2013-01-03|2009-05-05|2009-05-06|Estimate|||||||2013-01-03|2013-01-04|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|IC-CLEARLY||Intracoronary Abciximab With Clearway Catheter|IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis|Terminated||Phase 3|150|Actual|University of Roma La Sapienza||2||the study was stopped because the sample size was very difficult to achieve.|f||||f||||||||||2018-06-01 01:00:28.814085|2018-06-01 01:00:28.814085
NCT00894010|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2012-03-01|2009-05-05|2009-05-06|Estimate|||||||2012-03-01|2012-03-05|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Photosensitivity Proof of Concept Trial|Assessment of Marketed AEDs in the Human Photosensitivity Proof of Concept Trial|Completed||Phase 2|6|Actual|The Epilepsy Study Consortium|||||f||||f||||||||||2018-06-01 01:00:28.917427|2018-06-01 01:00:28.917427
NCT00893997|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2011-03-17||2012-07-10|2009-05-05|2009-05-06|Estimate|2011-03-17|2011-04-12|Estimate||||2012-07-10|2012-07-16|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||PR1 Vaccination in Myelodysplastic Syndrome (MDS)|Phase 2 Study of Proteinase 3 PR1 Peptide Vaccine in Myelodysplastic Syndrome (MDS)|Terminated||Phase 2|12|Actual|M.D. Anderson Cancer Center||1||The trial was ended per sponsor due to slow accrual rates.|f||||f||||||||||2018-06-01 01:00:29.023681|2018-06-01 01:00:29.023681
NCT00893984|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-12-06|2009-05-05|2009-05-06|Estimate|||||||2013-12-06|2013-12-09|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ABBI||Alternative in Beta Blocker Intolerance: The ABBI Trial|Alternative in Beta Blocker Intolerance; the ABBI Trial|Terminated||Phase 4|6|Actual|Minneapolis Heart Institute Foundation||1||Lack of patient recruitment|f||||f||||||||||2018-06-01 01:00:29.247494|2018-06-01 01:00:29.247494
NCT00893971|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2016-05-24||2017-03-16|2009-05-05|2009-05-06|Estimate|2017-03-16|2017-04-26|Actual||||2017-03-16|2017-04-26|Actual|May 2009||2009-05-31|March 2017|2017-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||All randomized subjects|Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects|A Randomized, Double-blind, Single Dose, Four-period, Four-treatment, Cross-over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects|Completed||Phase 1|16|Actual|Pearl Therapeutics, Inc.||4|||f||||f||||||||||2018-06-01 01:00:29.394687|2018-06-01 01:00:29.394687
NCT00893958|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2018-01-19|2009-05-05|2009-05-06|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2006||2006-01-31|January 2018|2018-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 500 mg Tablets Under Fed Conditions|Completed||N/A|39|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:00:30.73036|2018-06-01 01:00:30.73036
NCT00893945|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2014-12-19|2009-05-05|2009-05-06|Estimate|||||||2014-12-19|2014-12-23|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors|A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors|Completed||Phase 1|19|Actual|Rockefeller University||1|||f||||t||||||||||2018-06-01 01:00:30.808216|2018-06-01 01:00:30.808216
NCT00893932|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-05-05|2009-05-05|2009-05-06|Estimate|||||||2009-05-05|2009-05-06|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Observational|||Leptin: a Therapeutic Option for Treating Catabolic States and Malnutrition in Critically Ill Patients||Unknown status|Recruiting||75|Anticipated|Hadassah Medical Organization|||1||f||||f||||||Samples Without DNA|"~     Blood samples for leptin levels~   "|||2018-06-01 01:00:30.905831|2018-06-01 01:00:30.905831
NCT00893919|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2018-01-19|2009-05-05|2009-05-06|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2005||2005-11-30|January 2018|2018-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fed Conditions|Completed||N/A|37|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:00:30.996307|2018-06-01 01:00:30.996307
NCT00893906|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2013-09-19|2009-05-05|2009-05-06|Estimate|||||||2013-09-19|2013-09-23|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Inactivated Influenza Vaccine Effectiveness in Tropical Africa|Assessment of the Effectiveness of Seasonal Trivalent Influenza Vaccine Among Children in Senegal|Completed||Phase 4|10000|Anticipated|PATH||2|||f||||f||||||||||2018-06-01 01:00:31.084309|2018-06-01 01:00:31.084309
NCT00893893|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2011-08-24|2009-05-05|2009-05-06|Estimate|||||||2011-08-24|2011-08-25|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Very-low-density-lipoprotein Triglyceride (VLDL-TG) Uptake in Visceral Fat|Very-low-density-lipoprotein Triglyceride(VLDL-TG) Uptake in Visceral Fat|Completed|||16|Anticipated|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Blood samples Adipose tissue samples~   "|||2018-06-01 01:00:31.212398|2018-06-01 01:00:31.212398
NCT00893880|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2012-10-18|2009-05-05|2009-05-06|Estimate|||||||2012-10-18|2012-10-22|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis|A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis|Completed||Phase 2|92|Actual|Nitric BioTherapeutics, Inc||4|||f||||f||||||||||2018-06-01 01:00:31.276897|2018-06-01 01:00:31.276897
NCT00893867|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2012-10-23|2009-05-05|2009-05-06|Estimate|||||||2012-10-23|2012-10-24|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|MACSI||Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke|A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Phase 3 Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/Day Intravenous DP-b99 Over 4 Consecutive Days Versus Placebo When Initiated Within Nine Hours of Acute Ischemic Stroke Onset|Terminated||Phase 3|446|Actual|D-Pharm Ltd.||2||The result of a pre-planned interim futility analysis|f||||t||||||||||2018-06-01 01:00:31.411003|2018-06-01 01:00:31.411003
NCT00893854|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-06|Estimate|||||||2009-05-04|2009-05-06|Estimate||||May 2009|2009-05-31||||||||Interventional|||The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema|The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema|Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-06-01 01:00:31.986199|2018-06-01 01:00:31.986199
NCT00893841|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2013-02-01|2009-05-05|2009-05-06|Estimate|||||||2013-02-01|2013-02-04|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride|A Randomized, Double-Blind, Placebo Controlled Exploratory Study of Augmentation of Seroquel XR With Pramipexole Dihydrochloride for Bipolar Depression|Completed||Phase 2|96|Actual|Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.||3|||f||||f||||||||||2018-06-01 01:00:32.089354|2018-06-01 01:00:32.089354
NCT00893828|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2017-02-16|2009-05-05|2009-05-06|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2009|Actual|2009-03-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|September 2011|Actual|2011-09-30||Observational|PAPIRUSIII||Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (PAPIRUS III)|Monitoring Pulmonary Artery Pressure by Implanted Device Responding to Ultrasonic Signal|Completed|||18|Actual|Boston Scientific Corporation|||||f||||t||||||None Retained|"~     Whole Blood~   "|Undecided||2018-06-01 01:00:32.251709|2018-06-01 01:00:32.251709
NCT00893815|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2017-06-13|2009-05-04|2009-05-06|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2009||2009-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2011|Actual|2011-06-30||Observational|||Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients|Prevalence and Predictors of Neurocognitive Impairment Among HIV-infected Patients|Active, not recruiting|||250|Anticipated|Uniformed Services University of the Health Sciences|||3||f||||t||||||||||2018-06-01 01:00:32.32534|2018-06-01 01:00:32.32534
NCT00893802|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-06|Estimate|||||||2009-05-04|2009-05-06|Estimate|August 2001||2001-08-31|May 2009|2009-05-31|September 2002|Actual|2002-09-30|August 2002|Actual|2002-08-31||Interventional|||Influence of Periodontal Treatment During Pregnancy in Adverse Pregnant Outcomes|Influence of Periodontal Treatment in Pregnant Women Attending Antenatal Care at a Public Health Center in Adverse Pregnant Outcomes: a Controlled Clinical Trial|Completed||N/A|33|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 01:00:32.423243|2018-06-01 01:00:32.423243
NCT00893789|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2013-05-09||2013-08-14|2009-05-04|2009-05-06|Estimate|2013-08-14|2013-10-18|Estimate||||2013-08-14|2013-10-18|Estimate|April 2009||2009-04-30|August 2013|2013-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (50, 150, and 250 mg/Day) as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury|Terminated||Phase 3|117|Actual|Teva Pharmaceutical Industries|The sponsor’s decision to terminate the study early resulted in a small number of study participants and related limitations to the interpretation of the study results.|4||Study has been stopped by sponsor decision.|f||||||||||||||2018-06-01 01:00:32.600084|2018-06-01 01:00:32.600084
NCT00893776|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2017-10-24|2009-05-05|2009-05-06|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2009||2009-06-30|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Bilateral Versus Unilateral Task Retraining Using the SaeboFlex Orthosis|The Effectiveness of Bilateral Versus Unilateral Task Retraining Using the SaeboFlex Orthosis in Individuals With Subacute and Chronic Stroke.|Terminated||N/A|9|Actual|University of Missouri-Columbia||2||Insufficient time for study extenuating personal circumstances of PI|f||||f||||||||Undecided||2018-06-01 01:00:34.543261|2018-06-01 01:00:34.543261
NCT00893763|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2015-06-11||2015-12-04|2009-05-04|2009-05-06|Estimate|2015-12-04|2016-01-11|Estimate||||2015-12-04|2016-01-11|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SToPP2|Adults requiring endotracheal intubation|Strategies To Prevent Pneumonia 2 (SToPP2)|Oral Care Intervention in Mechanically Ventilated Adults|Completed||Phase 2|314|Actual|University of South Florida||2|||f||||t||||||||||2018-06-01 01:00:34.646874|2018-06-01 01:00:34.646874
NCT00893750|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2010-06-30|2009-05-05|2009-05-06|Estimate|||||||2010-06-30|2010-07-01|Estimate|May 2009||2009-05-31|June 2010|2010-06-30||||June 2010|Actual|2010-06-30||Interventional|||Trauma and Truth Interventions (NET) Versus Conflict Resolution and Social Skills Trainings for Vulnerable Youths in Northern Uganda|Effects of Trauma-Therapy and Truth Education, Conflict Resolution and Social Skills Trainings and Traditional Ways of Coping in Northern Uganda|Completed||N/A|600|Anticipated|University of Konstanz||3|||f||||f||||||||||2018-06-01 01:00:35.051864|2018-06-01 01:00:35.051864
NCT00893737|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|2010-09-22||2011-01-04|2009-05-05|2009-05-06|Estimate|2011-01-04|2011-01-25|Estimate||||2011-01-04|2011-01-25|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||"Completeness of Response Following Treatment With Treximet™ for Migraine"|"An Open-label Study to Evaluate Completeness of Response Following Treatment With Treximet™ for Migraine"|Completed||Phase 4|147|Actual|Cady, Roger, M.D.||1|||f||||f||||||||||2018-06-01 01:00:35.153634|2018-06-01 01:00:35.153634
NCT00893724|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2011-07-19|2009-05-05|2009-05-06|Estimate|||||||2011-07-19|2011-07-20|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Interventional|SAINTS||Supplemental Adjuvants for Intracellular Nutrition and Treatment|The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration|Unknown status|Active, not recruiting|N/A|60|Anticipated|Mid-Atlantic Retina Consultations, Inc.||3|||f||||||||||||||2018-06-01 01:00:35.41496|2018-06-01 01:00:35.41496
NCT00893711|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2018-04-03|2009-05-05|2009-05-06|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2008||2008-03-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic|Lactobacillus Reuteri Versus Placebo in the Treatment and Prevention of Infantile Colic: a Clinical and Microbiological, Double-blind, Prospective, Randomised, Controlled Study|Recruiting||N/A|155|Anticipated|Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna||4|||f||||t|f|f||||||Yes|to partecipe to an individual partecipant data meta- analysis.|2018-06-01 01:00:36.605019|2018-06-01 01:00:36.605019
NCT00893698|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-08-28|2009-05-05|2009-05-06|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2009||2009-01-31|August 2014|2014-08-31||||January 2015|Anticipated|2015-01-31||Interventional|||Bilateral Allotransplantation of Upper Limbs||Unknown status|Recruiting|N/A|5|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 01:00:36.768019|2018-06-01 01:00:36.768019
NCT00893685|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-05-07|2009-05-05|2009-05-06|Estimate|||||||2009-05-07|2009-05-08|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|Dreaming||Randomized Controlled Trial of Home Telemonitoring for Elderly People|Elderly Friendly Alarm Handling and Monitoring (DREAMING)|Unknown status|Not yet recruiting|N/A|300|Anticipated|Health Information Management, Belgium||2|||f||||t||||||||||2018-06-01 01:00:36.867898|2018-06-01 01:00:36.867898
NCT00893672|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-05-05|2009-05-05|2009-05-06|Estimate|||||||2009-05-05|2009-05-06|Estimate|December 2006||2006-12-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|August 2007|Actual|2007-08-31||Observational|RARE||Comparison of Two Chest Radiograph Prescription Strategies in Intensive Care Unit|A Cluster-Randomized Two-Period Cross-Over Study Comparing Routine and on-Demand Prescription of Chest Radiographs in Mechanically Ventilated Adults : the RARE Study|Completed|||849|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||||||2018-06-01 01:00:37.020685|2018-06-01 01:00:37.020685
NCT00893659|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2015-07-23|2009-05-05|2009-05-06|Estimate|||||||2015-07-23|2015-07-24|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|December 2012|Actual|2012-12-31||Interventional|||Beta-glucan on Fecal Microflora in Polypectomized Patients|The Effect of Beta-glucan on Faecal Microflora in Polypectomized Patients|Completed||N/A|69|Actual|Harokopio University||2|||f||||t||||||||||2018-06-01 01:00:37.114238|2018-06-01 01:00:37.114238
NCT00893646|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2015-05-29|2009-05-04|2009-05-06|Estimate|||||||2015-05-29|2015-06-01|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|June 2012|Actual|2012-06-30||Interventional|SF-Truck||Effects of Weight Reduction on Sleep and Alertness in Long-distance Truck and Bus Drivers|Effects of Weight Reduction and Lifestyle Changes on Sleep, Alertness and Cardiometabolic Risk Factors in Overweight Professional Long-distance Drivers|Completed||N/A|113|Actual|UKK Institute||2|||f||||f||||||||||2018-06-01 01:00:37.24147|2018-06-01 01:00:37.24147
NCT00893633|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-07-09|2009-05-05|2009-05-06|Estimate|||||||2009-07-09|2009-07-10|Estimate|March 2004||2004-03-31|July 2009|2009-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Critical Illness Neuromuscular Abnormalities in Neurocritical Care Patients|Prospective Case-Only Study of Neuromuscular Pathology in Patients on Mechanical Ventilation in the Neurosurgical Intensive Care Unit|Completed|||135|Actual|Clinical Institute of the Brain, Russia|||||f||||f||||||||||2018-06-01 01:00:38.116338|2018-06-01 01:00:38.116338
NCT00893620|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-02-13|2009-05-04|2009-05-06|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2010||2010-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Zenith(R) Connection Endovascular Covered Stent Clinical Study||Terminated||N/A|1|Actual|Cook Group Incorporated||1||"Due to less than expected enrollment rates, Cook has reevaluated the need for this clinical~   study."|f||||||||||||||2018-06-01 01:00:38.224454|2018-06-01 01:00:38.224454
NCT00893607|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2009-05-05|2009-05-05|2009-05-06|Estimate|||||||2009-05-05|2009-05-06|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or Rectum|Proof of Concept Study in Healthy Volunteers to Investigate the Safety and Response to a Single Dose of 10mg Methoxamine (NRL001) Applied Locally Using a Suppository to the Anal Canal or Rectum|Completed||Phase 1|24|Actual|Norgine||2|||f||||f||||||||||2018-06-01 01:00:38.323515|2018-06-01 01:00:38.323515
NCT00893594|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2015-02-18|2009-05-05|2009-05-06|Estimate|||||||2015-02-18|2015-02-19|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy of Sumatriptan With Naprosyn in Migraine With Aura|A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura|Unknown status|Recruiting|N/A|30|Anticipated|Dent Neurologic Institute||2|||f||||f||||||||||2018-06-01 01:00:38.415079|2018-06-01 01:00:38.415079
NCT00893581|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2016-05-18|2009-05-05|2009-05-06|Estimate|||||||2016-05-18|2016-05-19|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Multimodal Neuroimaging of Treatment Effects in Adolescent Mania|Multimodal Neuroimaging of Treatment Effects in Adolescent Mania|Completed||N/A|169|Actual|University of Cincinnati||3|||f||||t||||||||No||2018-06-01 01:00:38.528944|2018-06-01 01:00:38.528944
NCT00893568|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-08-27|2009-05-05|2009-05-06|Estimate|||||||2014-08-27|2014-08-28|Estimate|April 2009||2009-04-30|August 2014|2014-08-31||||May 2012|Actual|2012-05-31||Interventional|||Post Traumatic Stress Disorder and Neural Mechanisms Involved in Its Treatment|Post Traumatic Stress Disorder and Neural Mechanisms Involved in Its Treatment|Completed||N/A|62|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 01:00:38.696294|2018-06-01 01:00:38.696294
NCT00893555|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2017-01-11|2009-05-05|2009-05-06|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|VORI911||Pharmacologic Optimization of Voriconazole|Pharmacologic Optimization of Voriconazole - a Prospective Clustered Group-randomized Cross-over Trial of Therapeutic Drug Monitoring|Completed||Phase 3|189|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-06-01 01:00:38.785804|2018-06-01 01:00:38.785804
NCT00893542|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2018-01-19|2009-05-05|2009-05-06|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2005||2005-11-30|January 2018|2018-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions|Completed||N/A|37|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:00:39.012942|2018-06-01 01:00:39.012942
NCT00893529|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2012-06-13|2009-05-04|2009-05-06|Estimate|||||||2012-06-13|2012-06-14|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DRINK||A Study of the Effect of Replacing Sugary Drinks by Low-sugar Alternatives on Body Weight and Fat Mass in Children|A Double-blind, Randomized Trial of the Efficacy of Replacing Sugary Drinks by Low-sugar Alternatives on Body Weight and Fat Mass in School Children|Completed||N/A|641|Actual|VU University of Amsterdam||2|||f||||f||||||||||2018-06-01 01:00:39.110002|2018-06-01 01:00:39.110002
NCT00893516|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-02-25|2009-05-05|2009-05-06|Estimate|||||||2013-02-25|2013-02-26|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma|A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.|Terminated||Phase 2|5|Actual|Emergent BioSolutions||2||Portfolio consolidation.|f||||f||||||||||2018-06-01 01:00:39.222263|2018-06-01 01:00:39.222263
NCT00893503|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2011-03-07|2009-05-05|2009-05-06|Estimate|||||||2011-03-07|2011-03-08|Estimate|April 2008||2008-04-30|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|SCOPE||Scope Pilot Research Study|Stop Colorectal Cancer Through Prevention and Screening|Completed|||1248|Actual|University of Alberta|||||f||||f||||||||||2018-06-01 01:00:39.322209|2018-06-01 01:00:39.322209
NCT00893490|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-06|Estimate|||||||2009-05-04|2009-05-06|Estimate||||May 2009|2009-05-31||||||||Interventional|||Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma|Ahmed Glaucoma Valve Alone,With Amniotic Membrane or With MMC for Treatment of Refractory Glaucoma|Unknown status|Recruiting|Phase 1|||Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-06-01 01:00:39.424496|2018-06-01 01:00:39.424496
NCT00893477|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-08-01|2009-05-05|2009-05-06|Estimate|||||||2013-08-01|2013-08-02|Estimate|March 2009||2009-03-31|July 2009|2009-07-31||||March 2011|Anticipated|2011-03-31||Interventional|||GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma|An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine®) Associated With Rituximab (MabThera®) in Patients With Follicular Non Hodgkin's Lymphoma With no Prior Treatment|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:00:39.526057|2018-06-01 01:00:39.526057
NCT00893464|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2015-10-12||2015-10-12|2009-05-05|2009-05-06|Estimate|2015-10-12|2015-11-11|Estimate||||2015-10-12|2015-11-11|Estimate|August 2009||2009-08-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Safety population included all participants who received at least 1 dose of ixazomib.|A Study of IXAZOMIB in Adult Patients With Lymphoma|An Open-Label, Dose-Escalation, Phase 1 Study of IXAZOMIB (MLN9708), A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma|Completed||Phase 1|31|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:00:39.723461|2018-06-01 01:00:39.723461
NCT00893451|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2011-06-09|2009-05-05|2009-05-06|Estimate|||||||2011-06-09|2011-06-10|Estimate|September 2009||2009-09-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|VitaD-CKD1||Study of Vitamin D3 Supplementation in Patients With Chronic Kidney Disease|Does Vitamin D3 (Cholecalciferol) Supplementation Change Insulin Resistance in Patients With Chronic Kidney Disease?|Completed||N/A|24|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-06-01 01:00:42.929473|2018-06-01 01:00:42.929473
NCT00893438|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2013-05-21|2009-05-05|2009-05-06|Estimate|||||||2013-05-21|2013-05-22|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|FitNet||Efficacy of Web-based Cognitive Behavioural Treatment for Adolescents With Chronic Fatigue Syndrome|Fatigue in Teenagers on the Internet (FitNet); Efficacy of Web-based Cognitive Behavioural Treatment for Adolescents With the Chronic Fatigue Syndrome|Completed||N/A|135|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 01:00:43.062596|2018-06-01 01:00:43.062596
NCT00893425|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-06-02|2009-05-05|2009-05-06|Estimate|||||||2009-06-02|2009-06-03|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria|Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria|Completed||Phase 4|78|Actual|Gulhane School of Medicine|||||f||||||||||||||2018-06-01 01:00:43.278307|2018-06-01 01:00:43.278307
NCT00893412|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-06|Estimate|||||||2009-05-04|2009-05-06|Estimate|November 2008||2008-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography|Fast-Release Orodispersible Tramadol Tablet (Tradonal Odis®) as Analgesia for Hysterosalpingography : a Randomized, Controlled, Double Blinded Study|Completed||Phase 4|128|Actual|Universitair Ziekenhuis Brussel||4|||f||||t||||||||||2018-06-01 01:00:43.366392|2018-06-01 01:00:43.366392
NCT00893399|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2018-02-27|2009-05-05|2009-05-06|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2010||2010-02-28|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation|Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation|Active, not recruiting||Phase 3|588|Anticipated|University of Ulm||2|||f||||t||||||||||2018-06-01 01:00:43.482042|2018-06-01 01:00:43.482042
NCT00893386|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2016-01-29|2009-05-04|2009-05-06|Estimate|||||||2016-01-29|2016-02-01|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Attain StarFix® 4195 Lead Extraction Study|Attain StarFix® Model 4195 LV Lead Extraction Study|Completed|||227|Actual|Medtronic Cardiac Rhythm and Heart Failure|||3||f||||f||||||||||2018-06-01 01:00:43.764357|2018-06-01 01:00:43.764357
NCT00893373|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2016-02-04|2009-05-04|2009-05-06|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|November 2011|Actual|2011-11-30||Interventional|SORAML||Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age|A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age|Completed||Phase 2|276|Actual|Technische Universität Dresden||2|||f||||t||||||||No||2018-06-01 01:00:43.919085|2018-06-01 01:00:43.919085
NCT00893360|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-05|||2014-02-10|2009-05-05|2009-05-06|Estimate|||||||2014-02-10|2014-02-12|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|CADUCEUS||CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction|A Phase I Randomized, Dose Escalation Study of the Safety and Efficacy of Intracoronary Delivery of Cardiosphere-Derived Stem Cells in Patients With Ischemic Left Ventricular Dysfunction and a Recent Myocardial Infarction|Completed||Phase 1|31|Actual|Cedars-Sinai Medical Center||3|||f||||t||||||||||2018-06-01 01:00:44.07477|2018-06-01 01:00:44.07477
NCT00893347|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2012-11-22|2009-05-05|2009-05-06|Estimate|||||||2012-11-22|2012-11-27|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||An Intervention Program to Reduce to the Risk of Persistent Symptoms After Concussion|Prevention of Persistent Post-concussion Syndrome With Cognitive-behavioural Therapy in At-risk Patients|Completed||Phase 2|28|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:00:44.189291|2018-06-01 01:00:44.189291
NCT00893334|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2014-03-06|2009-05-05|2009-05-06|Estimate|||||||2014-03-06|2014-03-07|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Evaluation of Limb-Girdle Muscular Dystrophy|Evaluation of Limb-Girdle Muscular Dystrophy|Completed|||60|Anticipated|Cooperative International Neuromuscular Research Group|||5||f||||t||||||Samples With DNA|"~     Blood samples will be collected one time for DNA analysis.Only to confirm genotype if results~     are not available prior enrollement~   "|||2018-06-01 01:00:44.298543|2018-06-01 01:00:44.298543
NCT00893321|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-06|Estimate|||||||2009-05-04|2009-05-06|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|September 2009|Anticipated|2009-09-30|May 2009|Anticipated|2009-05-31||Interventional|||Comparison of Inferior Oblique Muscle Recession and Myectomy|Comparison of Inferior Oblique Muscle Recession and Myectomy|Unknown status|Active, not recruiting|Phase 1/Phase 2|2|Anticipated|Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-06-01 01:00:44.404528|2018-06-01 01:00:44.404528
NCT00893308|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2009-05-10|2009-05-05|2009-05-06|Estimate|||||||2009-05-10|2009-05-12|Estimate||||May 2009|2009-05-31||||||||Observational|||Metabolic Viral Host Properties||Completed|||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 01:00:44.475324|2018-06-01 01:00:44.475324
NCT00893295|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-02|||2013-12-17|2009-05-02|2009-05-05|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2008||2008-02-29|July 2009|2009-07-31||||December 2011|Anticipated|2011-12-31||Interventional|||Increasing Colorectal Cancer Screening in African Americans|Increasing Colon Cancer Screening in Primary Care Among African Americans|Unknown status|Recruiting|Phase 3|896|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:00:44.545567|2018-06-01 01:00:44.545567
NCT00893282|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2009-05-04|2009-05-04|2009-05-05|Estimate|||||||2009-05-04|2009-05-05|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy|A Randomized, Controlled, Prospective, Single Blind Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy.|Completed||N/A|68|Actual|Pluromed, Inc.||2|||f||||f||||||||||2018-06-01 01:00:44.821395|2018-06-01 01:00:44.821395
NCT00893269|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2013-12-03|2009-05-04|2009-05-05|Estimate|||||||2013-12-03|2013-12-05|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep|The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep|Completed||Phase 1|36|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:00:44.949054|2018-06-01 01:00:44.949054
NCT00893256|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-05|Estimate|||||||2009-05-04|2009-05-05|Estimate|December 2004||2004-12-31|May 2009|2009-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|RIS-CIT-SCH||Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia|Prospective Double-Blind Randomized Comparison Study of Improvement in Negative Symptoms With Risperidone vs Risperidone +Citalopram Combination Therapy in Schizophrenia--a Clinical Study|Completed||Phase 4|48|Actual|National Institute of Mental Health and Neuro Sciences, India||2|||f||||t||||||||||2018-06-01 01:00:45.057319|2018-06-01 01:00:45.057319
NCT00893243|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-05|Estimate|||||||2009-05-04|2009-05-05|Estimate||||May 2009|2009-05-31||||||||Observational|||Efficacy Comparative Study Between Tears Again®, Opticol® and Optive®|Efficacy Comparative Study Between Tears Again®, o Opticol® e o Optive® in Clinical and Symptomatology Treatment of Dry Eye Syndrome in Contact Lens Wearers and/or Computers Users|Completed|||27|Actual|Hospital de Sao Sebastiao|||6||f||||f||||||||||2018-06-01 01:00:45.156815|2018-06-01 01:00:45.156815
NCT00893230|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-05|Estimate|||||||2009-05-04|2009-05-05|Estimate|January 2007||2007-01-31|May 2009|2009-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of a Probiotic in Atopic Dermatitis|"A Double-Blind, Randomized, Placebo-Controlled Intervention Study of the Efficacy and Safety of NFM proBio65 in the Atopic and Allergic Volunteers"|Completed||Phase 3|88|Actual|Chungbuk National University||2|||f||||t||||||||||2018-06-01 01:00:45.22976|2018-06-01 01:00:45.22976
NCT00893217|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-11-06|2009-05-04|2009-05-05|Estimate|||||||2009-11-06|2009-11-09|Estimate|November 2002||2002-11-30|November 2009|2009-11-30|June 2003|Actual|2003-06-30|||||Interventional|||BEYOND Pilot Study|Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS|Completed||Phase 2|71|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:00:45.341557|2018-06-01 01:00:45.341557
NCT00893191|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-03|||2009-05-04|2009-05-04|2009-05-05|Estimate|||||||2009-05-04|2009-05-05|Estimate|May 2009||2009-05-31|May 2009|2009-05-31||||||||Observational|||The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction|The Effect of Sildenafil on Sleep-Disordered Breathing in Obese Patients With Sexual Dysfunction|Unknown status|Recruiting||50|Anticipated|Assaf-Harofeh Medical Center|||2||f||||||||||||||2018-06-01 01:00:45.451399|2018-06-01 01:00:45.451399
NCT00893178|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2017-03-14|2009-05-04|2009-05-05|Estimate|||||||2017-03-14|2017-03-15|Actual|December 2007|Actual|2007-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Impact of Polymorphism on Pulmonary Pressure in Subjects With Pulmonary Hypertension of Different Cause|Impact of Different Genetic Polymorphism on the Pulmonary Pressure in Patients With Pulmonary Hypertension of Different Cause With Special Focus on Patients With Chronic Heart Failure|Active, not recruiting|||600|Anticipated|University of Leipzig|||3||f||||f||||||Samples With DNA|"~     EDTA Blood, Serum~   "|||2018-06-01 01:00:45.621718|2018-06-01 01:00:45.621718
NCT00893165|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2012-01-13|2009-05-04|2009-05-05|Estimate|||||||2012-01-13|2012-01-18|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||Does Moderate Physical Activity in Hemodialysis Patients Reduce Inflammation?|Does Moderate Physical Activity in Chronic Hemodialysis Patients Reduce Inflammation Via Inhibition of Proinflammatory Monocyte Activity?|Completed|||16|Actual|Martin-Luther-Universität Halle-Wittenberg|||1||f||||||||||Samples With DNA|"~     Serum and DNA samples~   "|||2018-06-01 01:00:45.714882|2018-06-01 01:00:45.714882
NCT00893152|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|2015-02-17||2015-03-24|2009-05-04|2009-05-05|Estimate|2015-03-10|2015-03-23|Estimate||||2015-03-24|2015-04-14|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Observational|||Family Involvement in Treatment for PTSD|Perspectives on Enhancing Family Involvement in Treatment for PTSD|Completed|||83|Actual|VA Office of Research and Development|||3||f||||f||||||||||2018-06-01 01:00:45.869752|2018-06-01 01:00:45.869752
NCT00893139|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04||2014-07-11|2014-07-11|2009-05-04|2009-05-05|Estimate||||2014-07-11|2014-07-15|Estimate|2014-07-11|2014-07-15|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye||Completed||Phase 2|765|Actual|Alcon Research||3|||f||||t||||||||||2018-06-01 01:00:46.200872|2018-06-01 01:00:46.200872
NCT00893126|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2016-10-18|2009-05-01|2009-05-05|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Observational|||Premature Coronary Artery Disease (CAD) in Severe Psoriasis|Premature Coronary Artery Disease (CAD) in Severe Psoriasis|Completed|||46|Actual|University of Michigan|||2||f||||f||||||Samples Without DNA|"~     31 ml of blood will be drawn in conjunction with this study.Lipid, Glucose and Lipoprotein~     will be drawn in one SST tube = 7 ml. Insulin (INS) will be collected in one Green top tube =~     7 ml. HSCRP- will be collected in on SSS tube = 7 ml. IL-6 will be collected in Red or~     Lavender top tube = 7 ml. An additional 3 ml will be drawn for ICAM testing. (The blood for~     the ICAM testing and IL- 6 will be drawn and frozen until funding has been obtained to run~     these tests). Specimens will be be properly disposed of after testing is completed.~   "|No||2018-06-01 01:00:46.29675|2018-06-01 01:00:46.29675
NCT00892931|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-03|||2011-10-13|2009-05-03|2009-05-05|Estimate|||||||2011-10-13|2011-10-14|Estimate|April 2009||2009-04-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme|Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|56|Actual|Myrexis Inc.|||||f||||f||||||||||2018-06-01 01:00:50.825358|2018-06-01 01:00:50.825358
NCT00893113|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2015-03-24||2018-02-09|2009-05-04|2009-05-05|Estimate|2016-06-22|2016-08-01|Estimate||||2018-02-09|2018-03-09|Actual|June 2009||2009-06-30|February 2018|2018-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms|A Phase 3, Double Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Alfuzosin in Treating Men With ED and Mild LUTS.|Completed||Phase 3|74|Actual|Chesapeake Urology Research Associates|Data compiled in this study is unable to neither prove nor disprove the objectives set. Placebo effect and recall bias may affect results. Regular sexual interaction and prior exposure to Alfuzosin were not evaluated.|2|||f||||t||||||||||2018-06-01 01:00:46.428103|2018-06-01 01:00:46.428103
NCT00893100|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-19|||2009-05-02|2009-05-02|2009-05-05|Estimate|||||||2009-05-02|2009-05-05|Estimate|October 2007||2007-10-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Pain Reduction After Hemorrhoidectomy With Use of Diltiazim Ointment 2%|Evaluation of Pain Reduction After Hemorrhoidectomy With Use of Diltiazim Ointment 2%|Completed||Phase 4|1|Actual|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 01:00:46.999098|2018-06-01 01:00:46.999098
NCT00893087|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-03|||2010-01-19|2009-05-04|2009-05-05|Estimate|||||||2010-01-19|2010-01-20|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Comparison of Pressure-, Flow- and Neurally Adjusted Ventilatory Assistance (NAVA)-Triggering in Pediatric and Neonatal Ventilatory Care|Comparison of Pressure-, Flow- and NAVA-triggering in Pediatric and Neonatal Ventilatory Care|Completed||N/A|18|Anticipated|University of Oulu||3|||f||||f||||||||||2018-06-01 01:00:47.082501|2018-06-01 01:00:47.082501
NCT00893074|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2017-04-18||2017-08-02|2009-05-04|2009-05-05|Estimate|2017-08-02|2017-08-03|Actual||||2017-08-02|2017-08-03|Actual|April 2009||2009-04-30|August 2017|2017-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effect of Prescription Medications in Marijuana Users|The Effect of Prescription Medications in Marijuana Users|Completed||Phase 1/Phase 2|24|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 01:00:47.246898|2018-06-01 01:00:47.246898
NCT00893061|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-02|||2011-01-20|2009-05-02|2009-05-05|Estimate|||||||2011-01-20|2011-01-21|Estimate|February 2009||2009-02-28|July 2009|2009-07-31||||July 2010|Anticipated|2010-07-31||Interventional|||Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer|A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer.|Unknown status|Recruiting|Phase 3|60|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:00:47.637005|2018-06-01 01:00:47.637005
NCT00893048|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2017-07-21|2009-05-04|2009-05-05|Estimate|||||||2017-07-21|2017-07-25|Actual|January 15, 2010|Actual|2010-01-15|July 2017|2017-07-31|August 31, 2010|Actual|2010-08-31|August 31, 2010|Actual|2010-08-31||Interventional|||The Use of Oral Steroids in the Treatment of Cellulitis|Utility of Prednisone in the Treatment of Cellulitis|Withdrawn||Phase 2|0|Actual|Milton S. Hershey Medical Center||2||Study never enrolled any subjects before auto-terminated by the internal IRB.|f||||f||||||||||2018-06-01 01:00:47.81921|2018-06-01 01:00:47.81921
NCT00893035|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2017-08-16|2009-05-04|2009-05-05|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2006||2006-06-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients|Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.|Active, not recruiting|||862|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle|||2||f||||t||||||||||2018-06-01 01:00:48.094875|2018-06-01 01:00:48.094875
NCT00893009|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2011-04-04|2009-05-04|2009-05-05|Estimate|||||||2011-04-04|2011-04-05|Estimate|July 2009||2009-07-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|COPD||The Effect on Small Airways of Addition of Theophylline as Inducer of Histone Deacilase Activity for Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Treated With Inhaled Steroids and Long Acting Beta Agonists||Unknown status|Not yet recruiting|N/A|30|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 01:00:48.333619|2018-06-01 01:00:48.333619
NCT00892996|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-03|||2009-05-03|2009-05-03|2009-05-05|Estimate|||||||2009-05-03|2009-05-05|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|April 2011|Anticipated|2011-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section|Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section: a Randomized Comparison of Metoclopramide or Ondansetron Alone or in the Combination With Dexamethasone.|Unknown status|Active, not recruiting|N/A|120|Actual|Mahidol University||4|||f||||t||||||||||2018-06-01 01:00:48.435049|2018-06-01 01:00:48.435049
NCT00892983|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-03|||2018-02-14|2009-05-03|2009-05-05|Estimate|||||||2018-02-14|2018-02-16|Estimate|May 2009||2009-05-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2016|Actual|2016-04-30||Interventional|POInz||Prevention of Overweight in Infancy|Primary Prevention of Rapid Weight Gain in Early Childhood: a Randomised Controlled Trial|Completed||N/A|802|Actual|University of Otago||4|||f||||t||||||||||2018-06-01 01:00:48.565414|2018-06-01 01:00:48.565414
NCT00892970|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01||2010-10-29|2011-09-20|2009-05-04|2009-05-05|Estimate||||2010-10-29|2010-11-02|Estimate|2011-09-20|2011-09-26|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period||Completed||Phase 2|313|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:00:48.780004|2018-06-01 01:00:48.780004
NCT00892957|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2012-09-13|2011-12-02|2012-10-26|2009-05-04|2009-05-05|Estimate|2012-10-26|2012-11-27|Estimate|2011-12-02|2011-12-08|Estimate|2012-10-26|2012-11-27|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||FS VH S/D 500 S-apr in Vascular Surgery|Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-apr for Hemostasis in Subjects Undergoing Vascular Surgery|Completed||Phase 3|176|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 01:00:48.963992|2018-06-01 01:00:48.963992
NCT00892944|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-10-27|2009-05-04|2009-05-05|Estimate|||||||2009-10-27|2009-10-28|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Interventional|||An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516|An Open Label Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2516 After Oral Administration to Healthy Subjects|Completed||Phase 1|6|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:00:50.625696|2018-06-01 01:00:50.625696
NCT00892918|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2009-05-04|2009-05-04|2009-05-05|Estimate|||||||2009-05-04|2009-05-05|Estimate|June 2009||2009-06-30|March 2009|2009-03-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision|A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity.|Unknown status|Not yet recruiting|N/A|40|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-06-01 01:00:51.073106|2018-06-01 01:00:51.073106
NCT00892905|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2011-02-28|2009-05-04|2009-05-05|Estimate|||||||2011-02-28|2011-03-02|Estimate|January 2008||2008-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Comparing Point of Care Clotting Tests in the OR Versus Standard Laboratory Clotting Tests|Comparison Between Point of Care INR and aPTT Hemochron Jr Whole Blood Measurement With Standard Laboratory in Patients Having Elective First Time on Pump Coronary Artery Bypass Grafting (CABG)|Completed|||20|Anticipated|McMaster University|||1||f||||f||||||||||2018-06-01 01:00:51.367921|2018-06-01 01:00:51.367921
NCT00892892|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2015-03-16|2009-05-01|2009-05-05|Estimate|||||||2015-03-16|2015-03-17|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SNS in CRF||Sympathetic Nerve Activity in Renal Failure|Role of the Sympathetic Nerve System for the Pathogenesis and Progression of Chronic Kidney Failure|Withdrawn||Phase 4|0|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-06-01 01:00:51.559583|2018-06-01 01:00:51.559583
NCT00892879|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-05-17|2009-05-01|2009-05-05|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Trial of Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy|A Randomized Trial of Single Port Laparoscopic Cholecystectomy Versus Four Port Laparoscopic Cholecystectomy|Completed||Phase 3|50|Anticipated|Providence Health & Services||2|||f||||f||||||||||2018-06-01 01:00:51.678214|2018-06-01 01:00:51.678214
NCT00892866|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-02|||2018-05-04|2009-05-02|2009-05-05|Estimate|||||||2018-05-04|2018-05-10|Estimate|February 9, 2009|Actual|2009-02-09|May 2018|2018-05-31||||May 31, 2025|Anticipated|2025-05-31||Observational|||CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells|Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)|Recruiting|||877|Anticipated|Gynecologic Oncology Group|||1||f||||t||||||||||2018-06-01 01:00:51.804916|2018-06-01 01:00:51.804916
NCT00892853|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2014-06-11|2009-05-01|2009-05-05|Estimate|||||||2014-06-11|2014-06-12|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Association of Bone Quality and Quantity With Vascular Calcification|Association of Bone Quality and Quantity With Vascular Calcification.|Withdrawn||N/A|0|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 01:00:52.354507|2018-06-01 01:00:52.354507
NCT00892840|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-02|||2011-02-10|2009-05-04|2009-05-05|Estimate|||||||2011-02-10|2011-02-11|Estimate|May 2009||2009-05-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Multiple-Ascending Dose Study|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-820836 in Healthy Subjects|Completed||Phase 1|57|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:00:52.475933|2018-06-01 01:00:52.475933
NCT00892827|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2010-09-12|2009-05-04|2009-05-05|Estimate|||||||2010-09-12|2010-09-14|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|July 2009|Anticipated|2009-07-31||Interventional|||Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia|The Efficacy and Safety of Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia. Single-arm Phase II Study. Analysis of Complement Activation Pathways.|Unknown status|Recruiting|Phase 2|10|Anticipated|Wolfson Medical Center||1|||f||||f||||||||||2018-06-01 01:00:52.654759|2018-06-01 01:00:52.654759
NCT00892814|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|||2017-07-31|2009-05-04|2009-05-05|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2009||2009-05-31|July 2017|2017-07-31|March 2026|Anticipated|2026-03-31|March 2016|Actual|2016-03-31||Interventional|||Partial Breast Versus Whole Breast Irradiation in Elderly Women Operated on for Early Breast Cancer|Partial Breast Versus Whole Breast Irradiation to Women ≥ 60 Years Operated With Breast Conservation for Early Breast Cancer: a Randomized Fase II Trial|Active, not recruiting||N/A|882|Actual|Danish Breast Cancer Cooperative Group||2|||f||||t||||||||||2018-06-01 01:00:52.751146|2018-06-01 01:00:52.751146
NCT00892801|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-02|||2012-03-09|2009-05-02|2009-05-05|Estimate|||||||2012-03-09|2012-03-12|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer|A Phase I/II Study of RAD001 and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|5|Actual|Vanderbilt-Ingram Cancer Center||1||"Terminated due to low accrual. Study was closed to accrual prematurely and did not continue on~   to Phase II."|f||||t||||||||||2018-06-01 01:00:52.911611|2018-06-01 01:00:52.911611
NCT00892788|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2011-11-17|2009-05-02|2009-05-05|Estimate|||||||2011-11-17|2011-11-21|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Behavioral Intervention for Reducing Obesity|A Behavioral Intervention for Reducing Obesity|Completed||Phase 2|56|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 01:00:53.062976|2018-06-01 01:00:53.062976
NCT00892775|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04|2017-05-05|2011-06-01|2017-05-05|2009-05-04|2009-05-05|Estimate|2017-05-05|2017-10-09|Actual|2011-06-01|2011-06-07|Estimate|2017-05-05|2017-10-09|Actual|June 3, 2009|Actual|2009-06-03|May 2017|2017-05-31|December 13, 2010|Actual|2010-12-13|September 17, 2010|Actual|2010-09-17||Interventional|||Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds|Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds|Completed||Phase 2|501|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:00:53.194474|2018-06-01 01:00:53.194474
NCT00892762|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-04||2014-07-11|2014-07-11|2009-05-04|2009-05-05|Estimate||||2014-07-11|2014-07-15|Estimate|2014-07-11|2014-07-15|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health||Completed||Phase 3|434|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:00:54.061945|2018-06-01 01:00:54.061945
NCT00892749|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2015-04-30|2009-05-01|2009-05-04|Estimate|||||||2015-04-30|2015-05-04|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis|A Phase 3, Long-term Study in Patients With Chronic Kidney Disease (CKD) and Hyperphosphatemia on Hemodialysis|Completed||Phase 3|248|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 01:00:54.259023|2018-06-01 01:00:54.259023
NCT00892736|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2017-10-13|2009-05-01|2009-05-04|Estimate|||||||2017-10-13|2017-10-16|Actual|April 20, 2009|Actual|2009-04-20|October 2017|2017-10-31||||May 1, 2011|Actual|2011-05-01||Interventional|||Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy|A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer|Active, not recruiting||Phase 1|98|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 01:00:54.458256|2018-06-01 01:00:54.458256
NCT00892723|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2012-05-17||2012-09-10|2009-04-30|2009-05-04|Estimate|2012-09-10|2012-10-11|Estimate||||2012-09-10|2012-10-11|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars|A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloids|Completed||Phase 2|59|Actual|Capstone Therapeutics||3|||f||||f||||||||||2018-06-01 01:00:54.665828|2018-06-01 01:00:54.665828
NCT00892710|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2015-04-24||2015-05-12|2009-05-01|2009-05-04|Estimate|2015-05-12|2015-05-15|Estimate||||2015-05-12|2015-05-15|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|ToPPS|Includes all patients who were enrolled (whether they recieved treatment or not)|Trial of Poor Performance Status Patients (ToPPS)|Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2|Completed||Phase 2|172|Actual|SCRI Development Innovations, LLC||3|||f||||f||||||||||2018-06-01 01:00:55.405521|2018-06-01 01:00:55.405521
NCT00892697|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2014-12-18||2015-03-09|2009-05-01|2009-05-04|Estimate|2015-03-09|2015-03-20|Estimate||||2015-03-09|2015-03-20|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)|#0810010040: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus Infection: A Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C|Completed||Phase 2|15|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-06-01 01:00:56.306436|2018-06-01 01:00:56.306436
NCT00892684|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2009-05-01|2009-05-01|2009-05-04|Estimate|||||||2009-05-01|2009-05-04|Estimate|March 2003||2003-03-31|May 2009|2009-05-31|September 2011|Anticipated|2011-09-30|June 2005|Actual|2005-06-30||Interventional|||Does Omega-3 Fatty Acid Supplementation in Pregnancy and During Lactation Protect the Child From Allergic Disease?|Omega-3 Fatty Acid Supplementation in Pregnancy and During Lactation: a Randomized, Double-Blind, Placebo Controlled Trial.|Unknown status|Active, not recruiting|N/A|146|Actual|Linkoeping University|||||f||||f||||||||||2018-06-01 01:00:56.558338|2018-06-01 01:00:56.558338
NCT00892671|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2010-08-27|2009-05-01|2009-05-04|Estimate|||||||2010-08-27|2010-08-30|Estimate|October 2008||2008-10-31|August 2010|2010-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Airway Management and Vascular Access Simulation|Airway Management and Vascular Access Simulation|Completed|||50|Anticipated|University of Alabama at Birmingham|||1||f||||f||||||||||2018-06-01 01:00:56.654172|2018-06-01 01:00:56.654172
NCT00892658|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2017-09-21|2009-05-01|2009-05-04|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2009||2009-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)|A Phase I Study of Sorafenib and Radiation Therapy in Patients With Hepatocellular Carcinoma|Active, not recruiting||Phase 1|44|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:00:56.808104|2018-06-01 01:00:56.808104
NCT00892632|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2012-02-22|2009-05-01|2009-05-04|Estimate|||||||2012-02-22|2012-02-24|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Confocal Endomicroscopy for Biliary Strictures -Phase I|A Pilot Study of Confocal Endomicroscopy for Biliary Strictures - Phase I|Terminated||N/A|12|Actual|Mayo Clinic||1||Difficult (slow) Enrollment|f||||t||||||||||2018-06-01 01:00:56.915379|2018-06-01 01:00:56.915379
NCT00892619|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2009-04-30|2009-04-30|2009-05-04|Estimate|||||||2009-04-30|2009-05-04|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|May 2010|Anticipated|2010-05-31|March 2010|Anticipated|2010-03-31||Interventional|||Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel|Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel.|Unknown status|Recruiting|N/A|||Michael Debakey Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 01:00:57.021693|2018-06-01 01:00:57.021693
NCT00892606|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2017-04-06||2017-05-16|2009-05-01|2009-05-04|Estimate|2017-04-06|2017-05-17|Actual||||2017-05-16|2017-06-14|Actual|January 2009||2009-01-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Methadone Versus Morphine for Orthopedic Surgery Patients|Effectiveness of Pre-Operative Methadone Versus Morphine for Post-Operative Analgesia in Orthopedic Surgery Patients|Completed||Phase 4|75|Actual|University of Louisville||2|||f||||f||||||||||2018-06-01 01:00:57.21162|2018-06-01 01:00:57.21162
NCT00892593|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2014-07-18|2009-05-01|2009-05-04|Estimate|||||||2014-07-18|2014-07-21|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|ASC-FIT||Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing|Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing|Recruiting||N/A|4100|Anticipated|Forsyth Medical Center||4|||f||||f||||||||||2018-06-01 01:00:57.628193|2018-06-01 01:00:57.628193
NCT00892580|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2013-07-30|2009-05-01|2009-05-04|Estimate|||||||2013-07-30|2013-07-31|Estimate|May 2009||2009-05-31|July 2013|2013-07-31||||June 2010|Actual|2010-06-30||Observational|||Biomarker and DNA Collection in Subjects Participating in Protocol 22003|Biomarker Testing and DNA Collection in Subjects Participating in an Open-Label, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Autism Spectrum Disorders|Completed|||32|Actual|Seaside Therapeutics, Inc.|||||f||||f||||||Samples With DNA|"~     DNA from blood, plasma~   "|||2018-06-01 01:00:57.77479|2018-06-01 01:00:57.77479
NCT00892567|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2016-12-15|2009-05-01|2009-05-04|Estimate|||||||2016-12-15|2016-12-16|Estimate|May 2009||2009-05-31|December 2016|2016-12-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|Breast 37||Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer|Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine|Completed||Phase 1|9|Actual|University of Virginia||1|||f||||t||||||||||2018-06-01 01:00:57.903684|2018-06-01 01:00:57.903684
NCT00892554|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2015-12-09|2009-05-01|2009-05-04|Estimate|||||||2015-12-09|2015-12-11|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|PKU&DHA||The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)|The Impact of Docosahexaenoic Acid on Neuropsychological Status in Females With Phenylketonuria|Completed||N/A|33|Actual|Emory University||2|||f||||t||||||||||2018-06-01 01:00:58.001242|2018-06-01 01:00:58.001242
NCT00892541|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2009-04-30|2009-05-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2004||2004-10-31|March 2010|2010-03-31|November 2004|Actual|2004-11-30|||||Interventional|||A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone|Investigation of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone in Healthy Male Subjects|Completed||Phase 1|30|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:00:58.111701|2018-06-01 01:00:58.111701
NCT00892515|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2016-02-17|2009-05-01|2009-05-04|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 2008||2008-10-31|February 2016|2016-02-29||||May 2012|Actual|2012-05-31||Interventional|||Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer|Women In Steady Exercise Research (WISER) Sister|Unknown status|Active, not recruiting|N/A|183|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 01:00:58.193609|2018-06-01 01:00:58.193609
NCT00892502|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2013-09-09|2009-05-01|2009-05-04|Estimate|||||||2013-09-09|2013-09-10|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Interventional|Bismuth-PBH||Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?|Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? A Clinical, Prospective, Randomized, Blinded Examination of Patients Suffering From Hematological Malignancies Treated With Intensive Chemotherapy and/or Radiotherapy.|Completed||N/A|50|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-06-01 01:00:58.293793|2018-06-01 01:00:58.293793
NCT00892489|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2011-06-06|2009-04-30|2009-05-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|December 2004|Actual|2004-12-31|||||Interventional|||A Bioequivalence Study of 15 mg ER OROS Paliperidone|Pivotal Bioequivalence Study With 15 mg ER OROS Paliperidone Comparing the Phase 3 Formulation With the To-be-marketed Formulation and Evaluation of Food Effect on the to be Marketed Formulation in Healthy Male Subjects|Completed||Phase 1|80|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:00:58.396618|2018-06-01 01:00:58.396618
NCT00892476|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2012-12-04|2009-05-01|2009-05-04|Estimate|||||||2012-12-04|2012-12-05|Estimate|February 2002||2002-02-28|July 2010|2010-07-31|December 2008|Actual|2008-12-31|June 2004|Actual|2004-06-30||Interventional|||Prevention of Myopia of Prematurity by Calcium Supplementation|Prevention of Myopia of Prematurity by Calcium Supplementation in a Randomized Controlled Pilot Trial|Completed||Phase 1|99|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 01:00:58.480765|2018-06-01 01:00:58.480765
NCT00892463|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2011-07-27|2009-05-01|2009-05-04|Estimate|||||||2011-07-27|2011-07-28|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder|Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder|Completed||Phase 4|26|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 01:00:58.591382|2018-06-01 01:00:58.591382
NCT00892450|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2014-10-02|2009-04-30|2009-05-04|Estimate|||||||2014-10-02|2014-10-03|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease|Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease: A Randomized, Double-blind, Crossover Pilot Study|Completed||N/A|12|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:00:58.705783|2018-06-01 01:00:58.705783
NCT00892437|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2014-10-23|2011-08-23|2016-01-15|2009-05-01|2009-05-04|Estimate|2014-10-23|2014-10-28|Estimate|2011-08-23|2011-08-25|Estimate|2016-01-15|2016-02-15|Estimate|May 2009||2009-05-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|December 2009|Actual|2009-12-31||Interventional||ITT Analysis Set: participants who were randomized and received at least one dose of study drug.|Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9350-boosted Atazanavir (ATV/GS-9350) Compared to Ritonavir-boosted Atazanavir (ATV/r) in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Completed||Phase 2|85|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t||||||||||2018-06-01 01:00:58.832025|2018-06-01 01:00:58.832025
NCT00892424|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2016-12-28|2009-05-01|2009-05-04|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Sorafenib-RT Treatment for Liver Metastasis (SLIM)|Phase I/II Trial of Radiation Therapy and Sorafenib for Treatment of Unresectable Liver Metastases|Active, not recruiting||Phase 1/Phase 2|54|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:00:59.828676|2018-06-01 01:00:59.828676
NCT00892411|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2015-07-16|2009-05-01|2009-05-04|Estimate|||||||2015-07-16|2015-07-17|Estimate|February 2009||2009-02-28|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Prognostic Value of Measures of the Central Hypersensitivity in Patients With Acute Low Back Pain|Prognostic Value of Measures of Central Hypersensitivity in Patients With Low Back Pain|Completed|||154|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-06-01 01:00:59.946726|2018-06-01 01:00:59.946726
NCT00892398|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2014-04-08|2009-05-01|2009-05-04|Estimate|||||||2014-04-08|2014-04-10|Estimate|March 2009||2009-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab|Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab|Completed||N/A|242|Actual|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||||2018-06-01 01:01:00.044939|2018-06-01 01:01:00.044939
NCT00892385|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2017-07-26|2009-05-01|2009-05-04|Estimate|||||||2017-07-26|2017-07-28|Actual|August 16, 2007|Actual|2007-08-16|July 2017|2017-07-31|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Interventional|||Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors|A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors|Completed||Phase 1|66|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-06-01 01:01:00.149099|2018-06-01 01:01:00.149099
NCT00892372|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2009-05-01|2009-05-01|2009-05-04|Estimate|||||||2009-05-01|2009-05-04|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Relationship Between Body Weight and Glycohemoglobin|Relationship Between Changes in Body Weight and Glycohemoglobin Levels in Patients With Type 2 Diabetes Treated With Diet or Pioglitazone.|Completed|||100|Actual|Saitama Medical University|||2||f||||t||||||||||2018-06-01 01:01:00.246685|2018-06-01 01:01:00.246685
NCT00892359|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2009-05-01|2009-05-01|2009-05-04|Estimate|||||||2009-05-01|2009-05-04|Estimate|April 2009||2009-04-30|April 2009|2009-04-30||||April 2010|Anticipated|2010-04-30||Interventional|||Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)|The Pharmacokinetics of Anidulafungin During Continuous Venovenous Hemofiltration|Unknown status|Recruiting|Phase 2|10|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-06-01 01:01:00.340943|2018-06-01 01:01:00.340943
NCT00892346|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2016-05-09|2009-05-01|2009-05-04|Estimate|||||||2016-05-09|2016-05-10|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma|Phase III Study of Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma|Suspended||Phase 3|80|Anticipated|Shanghai Jiao Tong University School of Medicine||1||No avaliability of melphlan in mainland China|f||||f||||||||No||2018-06-01 01:01:00.45707|2018-06-01 01:01:00.45707
NCT00892333|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2016-05-16|2009-04-30|2009-05-04|Estimate|||||||2016-05-16|2016-05-17|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|BRIDGE||Large Abdominal Hernia Repair With SurgiMend 3.0|Repair of Large Abdominal Hernia Defects By A Novel Biologic Mesh: A Prospective Multi-Center Observational Study|Completed|||122|Actual|Integra LifeSciences Corporation|||||f||||f||||||||||2018-06-01 01:01:00.570702|2018-06-01 01:01:00.570702
NCT00892320|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2009-04-30|2009-05-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|May 2004|Actual|2004-05-31|||||Interventional|||A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers|A Randomized, Open-label, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Subjects|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:01:00.66031|2018-06-01 01:01:00.66031
NCT00892307|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2013-11-11|2009-05-01|2009-05-04|Estimate|||||||2013-11-11|2013-11-13|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|May 2011|Actual|2011-05-31|February 2010|Actual|2010-02-28||Observational|||Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)|Coronary Anatomy and Physiology Using Multidetector Dual Source Computed Tomography With Adenosine Enhancement: Comparative Study With SPECT Imaging: Pilot Studies I/II|Completed|||34|Actual|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-06-01 01:01:00.734622|2018-06-01 01:01:00.734622
NCT00892281|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2010-10-26||2012-09-21|2009-05-01|2009-05-04|Estimate|2010-10-26|2010-11-18|Estimate||||2012-09-21|2012-10-02|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||ORCA - Oracea® for Rosacea: A Community-based Assessment|A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea|Completed||Phase 4|1421|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 01:01:00.838178|2018-06-01 01:01:00.838178
NCT00892268|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2010-04-23|2009-05-01|2009-05-04|Estimate|||||||2010-04-23|2010-04-27|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain|Acupuncture for the Treatment of Aromatase Inhibitor Associated Joint Pain in Post-Menopausal Breast Cancer Patients|Terminated||Phase 2|68|Anticipated|University of Arizona||2||Poor accural|f||||t||||||||||2018-06-01 01:01:01.206548|2018-06-01 01:01:01.206548
NCT00892255|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2012-09-12|2009-05-01|2009-05-04|Estimate|||||||2012-09-12|2012-09-14|Estimate|April 2009||2009-04-30|September 2012|2012-09-30||||April 2015|Anticipated|2015-04-30||Observational|||Microwave Ablation of Resectable Liver Tumors|Microwave Ablation of Resectable Liver Tumors|Unknown status|Recruiting||50|Anticipated|St. Joseph Hospital of Orange|||||f||||f||||||||||2018-06-01 01:01:01.31071|2018-06-01 01:01:01.31071
NCT00892242|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2014-09-19|2009-05-01|2009-05-04|Estimate|||||||2014-09-19|2014-09-22|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer|Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer|Terminated||Phase 1|24|Actual|Washington University School of Medicine||1||Principal Investigator decided to close the study early.|f||||t||||||||||2018-06-01 01:01:02.600478|2018-06-01 01:01:02.600478
NCT00892229|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2009-05-01|2009-05-01|2009-05-04|Estimate|||||||2009-05-01|2009-05-04|Estimate|March 2007||2007-03-31|May 2009|2009-05-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Buccal Versus Vaginal Misoprostol in Surgical Termination of the First Trimester Missed Abortion in Erbil|Buccal Versus Vaginal Misoprostol for Cervical Ripening Prior to Surgical Termination of the First Trimester Missed Abortion in Erbil|Completed||Phase 2|100|Actual|Hawler Medical University||3|||f||||f||||||||||2018-06-01 01:01:02.743413|2018-06-01 01:01:02.743413
NCT00892216|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2015-04-07|2009-05-01|2009-05-04|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|October 2010|Actual|2010-10-31|January 2010|Actual|2010-01-31||Interventional|||Does Acupressure Decrease Post-operative Nausea and Vomiting (PONV) After the Pectus Excavatum Correction (NUSS) Procedure?|Does Acupressure Decrease Post-operative Nausea and Vomiting After the NUSS Procedure?|Terminated||N/A|40|Actual|McMaster University||2||Not enough participants for study to be completed|f||||f||||||||||2018-06-01 01:01:02.861801|2018-06-01 01:01:02.861801
NCT00892203|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01||2016-03-28|2016-03-28|2009-05-01|2009-05-04|Estimate||||2016-03-28|2016-05-02|Estimate|2016-03-28|2016-05-02|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of BGG492 in the Treatment of Migraine|A Multi-centre, Randomized, Double-blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492|Completed||Phase 2|75|Actual|Novartis||3|||f||||f||||||||||2018-06-01 01:01:02.955606|2018-06-01 01:01:02.955606
NCT00892190|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2016-02-09|2009-05-01|2009-05-04|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome|A Phase 1, Open-label, Dose-escalation Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Completed||Phase 1|9|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:01:03.105295|2018-06-01 01:01:03.105295
NCT00891111|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2018-01-31|2009-04-30|2009-05-01|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2009||2009-05-31|January 2018|2018-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Incentives for Preventative Health Care: Increasing Completion of Health Risk Assessments|Incentives for Preventative Health Care: Increasing Completion of Health Risk Assessments|Completed||N/A|634|Actual|Carnegie Mellon University||2|||f||||f||||||||||2018-06-01 01:01:32.835525|2018-06-01 01:01:32.835525
NCT00892177|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|2017-03-13||2017-05-23|2009-05-01|2009-05-04|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|October 2009||2009-10-31|May 2017|2017-05-31||||November 2014|Actual|2014-11-30||Interventional|||Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme|Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma|Active, not recruiting||Phase 2|144|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 01:01:04.167142|2018-06-01 01:01:04.167142
NCT00892164|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2009-05-01|2009-05-01|2009-05-04|Estimate|||||||2009-05-01|2009-05-04|Estimate|August 2008||2008-08-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Thyroid Surgery With the New Harmonic Scalpel or the Electrothermal Bipolar Vessel Sealer|Thyroid Surgery With the New Harmonic Scalpel or the Electrothermal Bipolar Vessel Sealer: a Prospective Randomized Study|Completed||N/A|120|Actual|Hippocration General Hospital||2|||f||||t||||||||||2018-06-01 01:01:06.718305|2018-06-01 01:01:06.718305
NCT00892151|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|2010-04-15||2016-01-29|2009-05-01|2009-05-04|Estimate|2010-04-15|2010-05-18|Estimate||||2016-01-29|2016-02-29|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Evaluation of GLUCOFACTS® Deluxe Diabetes Management System|Evaluation of GLUCOFACTS® Deluxe Diabetes Management System In a Clinical Setting|Completed||N/A|51|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-06-01 01:01:06.847928|2018-06-01 01:01:06.847928
NCT00892138|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2014-09-23|2009-05-01|2009-05-04|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Mindfulness Training for Stress Management|Mindfulness Training for Stress Management: A Two-centre Randomised Controlled Study of Medical and Psychology Students With Long-term Follow up|Active, not recruiting||N/A|290|Actual|Norwegian Knowledge Centre for the Health Services||2|||f||||f||||||||||2018-06-01 01:01:07.156172|2018-06-01 01:01:07.156172
NCT00892125|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-05-17|2009-04-30|2009-05-04|Estimate|||||||2011-05-17|2011-05-18|Estimate|September 2006||2006-09-30|April 2010|2010-04-30|March 2007|Actual|2007-03-31|||||Interventional|||A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I Disorder|Evaluation of the Effect of Carbamazepine on the Steady-state Pharmacokinetics of Paliperidone Extended Release in Clinically Stable Subjects With Schizophrenia or Bipolar I Disorder|Completed||Phase 1|64|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:01:07.250755|2018-06-01 01:01:07.250755
NCT00892112|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2018-04-18|2009-05-01|2009-05-04|Estimate|||||||2018-04-18|2018-04-19|Actual|November 2009|Actual|2009-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy|Immunoglobulin Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Parvovirus B19 Persistence - a Prospective, Double-blind, Randomized, Placebo-controlled Clinical Trial|Recruiting||Phase 3|50|Anticipated|Sanquin||2|||f||||f||||||||||2018-06-01 01:01:07.358115|2018-06-01 01:01:07.358115
NCT00892099|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2015-05-22||2018-03-21|2009-05-01|2009-05-04|Estimate|2015-05-22|2015-06-08|Estimate||||2018-03-21|2018-04-20|Actual|November 2009||2009-11-30|March 2018|2018-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||DIVINE: Dialysis Infection and Vitamin D In New England|DIVINE: Dialysis Infection and Vitamin D In New England|Completed||N/A|105|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 01:01:07.515722|2018-06-01 01:01:07.515722
NCT00892086|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2009-05-01|2009-05-01|2009-05-04|Estimate|||||||2009-05-01|2009-05-04|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|May 2010|Anticipated|2010-05-31|January 2010|Anticipated|2010-01-31||Observational|||Prevalence and Recognition of Geriatric Syndrome in Outpatient Clinic at Srinagarind Hospital|Prevalence and Recognition of Geriatric Syndrome in Outpatient Clinic at Srinagarind Hospital|Unknown status|Recruiting||50|Anticipated|Khon Kaen University|||||f||||f||||||||||2018-06-01 01:01:08.504556|2018-06-01 01:01:08.504556
NCT00892073|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-11-13|2009-04-30|2009-05-04|Estimate|||||||2017-11-13|2017-11-17|Actual|May 2006||2006-05-31|November 2017|2017-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy|Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study|Completed||Phase 2|9|Actual|The Hospital for Sick Children||1|||f||||t||||||||||2018-06-01 01:01:08.607599|2018-06-01 01:01:08.607599
NCT00892047|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2015-12-16||2015-12-16|2009-05-01|2009-05-04|Estimate|2015-12-16|2015-12-17|Estimate||||2015-12-16|2015-12-17|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|IRL GREY||Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)|Incomplete Response in Late Life Depression: Getting to Remission|Completed||Phase 4|468|Actual|University of Pittsburgh|limited number of participants older than 75, or members of racial/ethnic minority groups; limited follow-up period|2|||f||||f||||||||||2018-06-01 01:01:08.736491|2018-06-01 01:01:08.736491
NCT00892021|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|||2009-07-17|2009-05-01|2009-05-04|Estimate|||||||2009-07-17|2009-07-20|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder|An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Subjects With Schizophrenia or Schizoaffective Disorder|Terminated||Phase 1|24|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:01:09.11973|2018-06-01 01:01:09.11973
NCT00892008|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2009-08-27||2010-01-08|2009-04-30|2009-05-01|Estimate|2009-10-09|2009-11-18|Estimate||||2010-01-08|2010-01-12|Estimate|September 2006||2006-09-30|January 2010|2010-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|PAINS||A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin|Pregabalin (Lyrica) Action In Neuropathic Pain Syndrome (PAINS): A Post Marketing Surveillance Study On Efficacy, Safety And Tolerability Of Pregabalin|Completed|||2278|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:01:09.254273|2018-06-01 01:01:09.254273
NCT00891995|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2016-01-11||2016-11-09|2009-04-30|2009-05-01|Estimate|2016-09-02|2016-10-27|Estimate||||2016-11-09|2016-12-30|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Only 48 participants in the intensive treatment group and 20 participants in the standard treatment group who show any positive autoantibody in the first year were included in the analyses.|Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes|Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes|Terminated||Phase 2/Phase 3|71|Actual|Jaeb Center for Health Research||2||Primary outcome evaluation determined lack of treatment group difference|f||||t||||||||||2018-06-01 01:01:10.468482|2018-06-01 01:01:10.468482
NCT00891982|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2010-10-06|2010-09-07|2017-05-19|2009-04-30|2009-05-01|Estimate|2011-06-23|2011-07-25|Estimate|2010-09-07|2010-09-09|Estimate|2017-05-19|2017-05-24|Actual|April 1, 2009|Actual|2009-04-01|May 2017|2017-05-31|June 5, 2009|Actual|2009-06-05|June 1, 2009|Actual|2009-06-01||Interventional|||A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash|A Phase 3B, Multicenter, Assessor-Blinded Study of the Tolerability of Clindamycin 1%-Tretinoin 0.025% Gel Used in Conjunction With Benzoyl Peroxide 4% Wash in Subjects With Mild to Moderate Facial Acne Vulgaris|Completed||Phase 3|60|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:01:11.144986|2018-06-01 01:01:11.144986
NCT00891969|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2015-11-05|2009-04-30|2009-05-01|Estimate|||||||2015-11-05|2015-11-09|Estimate|February 2009||2009-02-28|November 2015|2015-11-30|March 2013|Actual|2013-03-31|May 2010|Actual|2010-05-31||Observational|||Treatment Decision Making Between Oncologists and Women With Newly Diagnosed Breast Cancer and Their Healthy Companions|The Process and Outcomes of Treatment Decision-Making Communication Between Oncologists and Newly Diagnosed Female Breast-Cancer Patients|Terminated|||77|Actual|Rutgers, The State University of New Jersey||||Slow accrual|f||||t||||||||||2018-06-01 01:01:12.436443|2018-06-01 01:01:12.436443
NCT00891956|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2018-05-23|2009-04-30|2009-05-01|Estimate|||||||2018-05-23|2018-05-24|Actual|April 24, 2009||2009-04-24|January 13, 2016|2016-01-13|January 13, 2016||2016-01-13|||||Observational|||The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome|The Role of Family Functioning in Adaptation to Being a Caregiver of an Individual With Rett Syndrome|Completed|||426|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:01:12.53437|2018-06-01 01:01:12.53437
NCT00891943|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2010-04-08|2009-04-30|2009-05-01|Estimate|||||||2010-04-08|2010-04-09|Estimate|June 2009||2009-06-30|April 2009|2009-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||A Trial of One to One Weight Management in Primary Care|A Randomised Controlled Trial of a One to One Weight Management Intervention in Primary Care|Unknown status|Active, not recruiting|N/A|380|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-06-01 01:01:12.653669|2018-06-01 01:01:12.653669
NCT00891930|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2016-01-07|2014-01-23|2016-01-07|2009-04-30|2009-05-01|Estimate|2016-01-07|2016-02-08|Estimate|2014-01-23|2014-02-20|Estimate|2016-01-07|2016-02-08|Estimate|May 2009||2009-05-31|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab|Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab Plus AMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin-or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to Panitumumab|Completed||Phase 2|76|Actual|Amgen||1|||f||||f||||||||||2018-06-01 01:01:12.80211|2018-06-01 01:01:12.80211
NCT00891917|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2014-01-27|2009-04-30|2009-05-01|Estimate|||||||2014-01-27|2014-01-29|Estimate|January 2005||2005-01-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Liq-NOL Efficacy in Pediatric Patients With Down Syndrome|Evaluation of Coenzyme q10 (Liq-nol®) Efficacy in Pediatric Patients With Down Syndrome|Completed||Phase 2|30|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 01:01:13.750662|2018-06-01 01:01:13.750662
NCT00891904|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2014-01-29||2016-03-14|2009-04-30|2009-05-01|Estimate|2014-01-29|2014-03-12|Estimate||||2016-03-14|2016-04-14|Estimate|April 2009||2009-04-30|March 2016|2016-03-31||||July 2011|Actual|2011-07-31||Interventional||All treated and eligible patients|Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer|A Feasibility Study of Re-irradiation Using Stereotactic Body Radiation Therapy (SBRT) and Cetuximab for Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Terminated||N/A|2|Actual|Roswell Park Cancer Institute|Trial terminated early. Too few patients to analyze.|1||Low accrual|f||||t||||||||||2018-06-01 01:01:13.924557|2018-06-01 01:01:13.924557
NCT00891891|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-04-14|2009-04-30|2009-05-01|Estimate|||||||2017-04-14|2017-04-18|Actual|September 2005||2005-09-30|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|CHATS||Psychosocial Adjustment of Adolescents With Spina Bifida|Psychosocial Adjustment of Adolescents With Spina Bifida|Active, not recruiting|||140|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||1||f||||f||||||||||2018-06-01 01:01:14.247125|2018-06-01 01:01:14.247125
NCT00891878|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2016-08-12|2009-04-30|2009-05-01|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2009||2009-08-31|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction|A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction|Completed||Phase 2|12|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 01:01:14.429106|2018-06-01 01:01:14.429106
NCT00891865|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2015-05-26|2009-04-29|2009-05-01|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Viral Triggers in Pediatric Lung Transplantation|Viral Triggers of Alloimmunity and Autoimmunity in Pediatric Lung Transplantation (CTOTC-03)|Completed|||61|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Blood and nasopharyngeal samples~   "|||2018-06-01 01:01:14.954572|2018-06-01 01:01:14.954572
NCT00891852|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2009-04-30|2009-04-30|2009-05-01|Estimate|||||||2009-04-30|2009-05-01|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Non-Invasive Determination of Fetal Chromosome Abnormalities|Non-Invasive Determination of Fetal Chromosome Abnormalities|Unknown status|Recruiting||1000|Anticipated|Lenetix Medical Screening Laboratory|||||f||||t||||||Samples With DNA|"~     Plasma~   "|||2018-06-01 01:01:15.069543|2018-06-01 01:01:15.069543
NCT00891839|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2014-10-17|2013-03-06|2014-10-28|2009-04-29|2009-05-01|Estimate|2014-10-17|2014-10-22|Estimate|2013-03-06|2013-03-14|Estimate|2014-10-28|2014-11-04|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|December 2011|Actual|2011-12-31||Interventional||Safety|Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma|An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma|Completed||Phase 2|45|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 01:01:15.19061|2018-06-01 01:01:15.19061
NCT00891826|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2013-04-11|2009-04-30|2009-05-01|Estimate|||||||2013-04-11|2013-04-12|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional|||Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability|"Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability: the BIPO-3 Trial"|Completed||N/A|55|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 01:01:15.833321|2018-06-01 01:01:15.833321
NCT00891813|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2011-09-22||2011-09-22|2009-04-30|2009-05-01|Estimate|2011-09-22|2011-10-31|Estimate||||2011-09-22|2011-10-31|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose|Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose|Completed||Phase 4|100|Actual|Abbott||1|||f||||||||||||||2018-06-01 01:01:15.962073|2018-06-01 01:01:15.962073
NCT00891800|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2011-06-06|2009-04-30|2009-05-01|Estimate|||||||2011-06-06|2011-06-07|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|SIRT||Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver|A Phase II Feasibility Study to Assess the Use of SIR-Sphere in Patients With Breast Cancer Who Have Chemotherapy-Resistant Disease in the Liver|Terminated||Phase 2|50|Anticipated|St. Joseph's Hospital, Florida||1||Lack of study patients|f||||f||||||||||2018-06-01 01:01:16.23829|2018-06-01 01:01:16.23829
NCT00891787|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-10-05|2009-04-30|2009-05-01|Estimate|||||||2017-10-05|2017-10-06|Actual|April 28, 2009||2009-04-28|April 10, 2014|2014-04-10|April 6, 2011|Actual|2011-04-06|April 6, 2011|Actual|2011-04-06||Interventional|||Probiotic Ingestion and Isoagglutinin Titers|Probiotic Ingestion and Isoagglutinin Titers|Completed||Phase 1|36|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:01:16.356561|2018-06-01 01:01:16.356561
NCT00891774|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2011-04-15||2011-10-04|2009-04-30|2009-05-01|Estimate|2011-04-15|2011-05-13|Estimate||||2011-10-04|2011-10-07|Estimate|December 2008||2008-12-31|October 2011|2011-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI|An Open-label, Multi-Center, Prospective, Post Market Study to Assess the Safety and Effectiveness of EVOLENCE® in Facial Augmentation of Subjects With Fitzpatrick Skin Color Types IV, V, and VI|Completed||Phase 4|172|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|This was not a controlled trial and the company made a business decision to discontinue marketing the product in the US, so the program has been terminated. No analysis will be performed on Secondary Outcome Measures.|1|||f||||f||||||||||2018-06-01 01:01:16.459557|2018-06-01 01:01:16.459557
NCT00891761|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2015-04-15|2009-04-30|2009-05-01|Estimate|||||||2015-04-15|2015-04-17|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy|A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Cisplatin-Induced Nausea and Vomiting|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||This study has been cancelled prior to enrollment.|f||||||||||||||2018-06-01 01:01:16.822935|2018-06-01 01:01:16.822935
NCT00891748|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2010-01-15|2009-04-30|2009-05-01|Estimate|||||||2010-01-15|2010-01-18|Estimate|November 2006||2006-11-30|April 2009|2009-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety Study on AdCD40L Gene Therapy for Bladder Cancer|A Phase I/IIa Study of Dose-escalating Intravesical AdCD40L Instillation in Urinary Bladder Carcinoma|Completed||Phase 1/Phase 2|12|Anticipated|Uppsala University||1|||f||||f||||||||||2018-06-01 01:01:16.950026|2018-06-01 01:01:16.950026
NCT00891735|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2012-09-18||2012-12-11|2009-04-29|2009-05-01|Estimate|2012-12-11|2013-01-18|Estimate||||2012-12-11|2013-01-18|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|HARBOR||A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)|A Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis (PRN) in Patients With Subfoveal Neovascular Age-related Macular Degeneration|Completed||Phase 3|1097|Actual|Genentech, Inc.||4|||f||||||||||||||2018-06-01 01:01:17.154135|2018-06-01 01:01:17.154135
NCT00891722|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2013-08-23|2009-04-30|2009-05-01|Estimate|||||||2013-08-23|2013-08-26|Estimate|August 2008||2008-08-31|June 2009|2009-06-30||||||||Observational|||Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma|Translation Study for Children and Adolescents With Low Grade Glioma|Unknown status|Recruiting||900|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:01:18.910904|2018-06-01 01:01:18.910904
NCT00891709|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2016-03-02|2009-04-30|2009-05-01|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||LEO 29102 Single and Multiple Dose Study by Dermal Application|A Phase 1, First in Man, Safety, Tolerability and Pharmacokinetic Study of Single Ascending and Multiple Cutaneous Doses of LEO 29102 2.5 mg/g Cream or LEO 29102 Cream Vehicle in Healthy Male Subjects|Completed||Phase 1|64|Actual|LEO Pharma||2|||f||||f||||||||||2018-06-01 01:01:19.045515|2018-06-01 01:01:19.045515
NCT00891696|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2017-05-01|2009-04-30|2009-05-01|Estimate|||||||2017-05-01|2017-05-04|Actual|April 2009||2009-04-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Nutritional and Contractile Regulation of Muscle Growth|Nutritional and Contractile Regulation of Muscle Growth (Cycle 2)|Completed||Phase 1|144|Actual|The University of Texas Medical Branch, Galveston||14|||f||||f||||||||No||2018-06-01 01:01:19.14812|2018-06-01 01:01:19.14812
NCT00891683|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2010-05-28|2009-04-30|2009-05-01|Estimate|||||||2010-05-28|2010-05-31|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 Versus Placebo in Patients With Painful Diabetic Peripheral Neuropathy|Completed||Phase 2|128|Anticipated|Aegera Therapeutics||4|||f||||t||||||||||2018-06-01 01:01:19.305754|2018-06-01 01:01:19.305754
NCT00891670|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2009-04-30|2009-04-30|2009-05-01|Estimate|||||||2009-04-30|2009-05-01|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|ACCEL2C19||Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism|Validation of Adjunctive Cilostazol According to CYP2C19 Polymorphism: Prospective, Randomized, Single-Center Trial:|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Gyeongsang National University Hospital||2|||f||||t||||||||||2018-06-01 01:01:19.49572|2018-06-01 01:01:19.49572
NCT00891475|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2014-02-11|2009-04-30|2009-05-01|Estimate|||||||2014-02-11|2014-02-13|Estimate|May 2008||2008-05-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients|Phase II Trial of Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients With Small Primary Tumor|Completed||Phase 1/Phase 2|114|Actual|Kidney Cancer Research Bureau||3|||f||||t||||||||||2018-06-01 01:01:22.284974|2018-06-01 01:01:22.284974
NCT00891657|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2010-07-13||2017-08-07|2009-04-30|2009-05-01|Estimate|2010-08-10|2010-08-31|Estimate||||2017-08-07|2017-09-07|Actual|November 2008||2008-11-30|August 2017|2017-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy|A Randomised, Prospective, Multi-Centre Clinical Study of SprayShield™ Adhesion Barrier System as a Barrier for the Prevention of Adhesion Formation After Laparoscopic Myomectomy|Completed||N/A|15|Actual|Integra LifeSciences Corporation|The very small sample size makes it difficult to detect any real differences between the treatments, if such differences exist.|2|||f||||f||||||||||2018-06-01 01:01:19.696785|2018-06-01 01:01:19.696785
NCT00891644|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-02-27|2009-04-30|2009-05-01|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2009||2009-06-30|February 2016|2016-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Linkage to Care - Part II|HIV-Related Care Engagement: Linkage to Care and Care-Seeking for HIV-Infected Adolescents, Phase II|Completed|||59|Actual|University of North Carolina, Chapel Hill|||3||f||||t||||||||||2018-06-01 01:01:20.165553|2018-06-01 01:01:20.165553
NCT00891631|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2016-10-06|2009-04-30|2009-05-01|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Primary Care iSBIRT to Reduce Serious Teen Health Risks|Primary Care Internet/Intranet-based Screening, Brief Intervention, and Referral to Treatment (iSBIRT) System to Reduce Serious Teen Health Risks|Withdrawn||Phase 1/Phase 2|0|Actual|Boston Children’s Hospital||3||Grant application was not funded|f||||t||||||||No||2018-06-01 01:01:20.31659|2018-06-01 01:01:20.31659
NCT00891618|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2014-05-30||2016-09-14|2009-04-30|2009-05-01|Estimate|2016-09-14|2016-10-31|Estimate||||2016-09-14|2016-10-31|Estimate|April 2009||2009-04-30|September 2016|2016-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Acupuncture for Chemo-Induced Peripheral Neuropathy|Acupuncture for Chemo-induced Peripheral Neuropathy in Multiple Myeloma and Lymphoma Patients|Completed||Phase 2|27|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:01:20.457263|2018-06-01 01:01:20.457263
NCT00891605|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2017-11-17|2009-04-30|2009-05-01|Estimate|||||||2017-11-17|2017-11-21|Actual|July 2009||2009-07-31|June 2012|2012-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors|A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Paclitaxel in the Treatment of Subjects With Solid Tumors|Completed||Phase 1|19|Actual|AbbVie||1|||f||||||||||||||2018-06-01 01:01:20.722909|2018-06-01 01:01:20.722909
NCT00891592|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2016-08-17|2009-04-30|2009-05-01|Estimate|||||||2016-08-17|2016-08-19|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|November 2011|Actual|2011-11-30||Interventional|UCB||Umbilical Cord Blood Transplant for Hematological Malignancies|A Phase 1 Dose Escalation Study of Infusion of ex Vivo cd3/cd28 Costimulated Umbilical Cord Blood-derived t Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies|Completed||Phase 1|5|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 01:01:20.817359|2018-06-01 01:01:20.817359
NCT00891579|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2012-12-07|2009-04-30|2009-05-01|Estimate|||||||2012-12-07|2012-12-10|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations|Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations|Completed||Phase 2|161|Actual|Chinese Society of Lung Cancer||2|||f||||||||||||||2018-06-01 01:01:20.947228|2018-06-01 01:01:20.947228
NCT00891566|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2011-05-23|2009-04-30|2009-05-01|Estimate|||||||2011-05-23|2011-05-24|Estimate|April 2008||2008-04-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Observational|||Duration of Immobilization After Rotator Cuff Repair: Its Clinical Impact|Prolonged Versus Conventional Immobilization After Arthroscopic Repair for Medium to Large Size Rotator Cuff Tear. A Prospective Randomized Controlled Trial|Completed|||100|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-06-01 01:01:21.071877|2018-06-01 01:01:21.071877
NCT00891553|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2013-02-21|2009-04-30|2009-05-01|Estimate|||||||2013-02-21|2013-02-25|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||CR9112792, a Follow-up of Study CR9108963|Study CR9112792, a Study to Assess Bone Mineral Density Changes in Post-menopausal Osteoporotic Women Following Discontinuation of Ronacaleret or Placebo Treatment in Study CR9108963|Completed|||171|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-06-01 01:01:21.189536|2018-06-01 01:01:21.189536
NCT00891540|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2011-06-22|2009-04-30|2009-05-01|Estimate|||||||2011-06-22|2011-06-23|Estimate|July 2009||2009-07-31|April 2009|2009-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Local Infiltration Analgesia With Ropivacaine Versus Placebo in Caesarean Section|Lokal Infiltrations Analgesi Med Ropivakain 0,5 % Versus Ropivakain 0,2 % Versus Placebo Efter Sectio Caesarea: et Prospektivt, Dobbeltblindet, Placebokontrolleret Studie.|Completed||Phase 4|90|Anticipated|Hvidovre University Hospital||3|||f||||f||||||||||2018-06-01 01:01:21.334482|2018-06-01 01:01:21.334482
NCT00891527|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2017-04-18||2017-10-17|2009-04-30|2009-05-01|Estimate|2017-04-24|2017-05-31|Actual||||2017-10-17|2017-11-17|Actual|October 2008|Actual|2008-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|PVS||Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis|Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis|Active, not recruiting||Phase 1/Phase 2|50|Actual|Boston Children’s Hospital||1|||f||||t||||||||Undecided||2018-06-01 01:01:21.480217|2018-06-01 01:01:21.480217
NCT00891514|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-07-13|2009-04-30|2009-05-01|Estimate|||||||2017-07-13|2017-07-17|Actual|September 2009|Actual|2009-09-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Trial of Aerobic Exercise Training in Stroke Survivors|Aging, Inflammation and Exercise in Chronic Stroke|Recruiting||N/A|150|Anticipated|Baltimore VA Medical Center||2|||f||||t||||||||||2018-06-01 01:01:21.817364|2018-06-01 01:01:21.817364
NCT00891501|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2009-04-30|2009-04-30|2009-05-01|Estimate|||||||2009-04-30|2009-05-01|Estimate|November 2006||2006-11-30|April 2009|2009-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects|The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects|Unknown status|Recruiting|Phase 2/Phase 3|25|Anticipated|Cairo University||1|||f||||f||||||||||2018-06-01 01:01:22.005824|2018-06-01 01:01:22.005824
NCT00891488|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2010-08-02|2009-04-30|2009-05-01|Estimate|||||||2010-08-02|2010-08-03|Estimate|July 2008||2008-07-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Stress Resilience Study|Systemic and Localized Stress Resilience in Aging: Effects of Physical Fitness|Completed|||80|Anticipated|Kronos Longevity Research Institute|||2||f||||f||||||Samples With DNA|"~     Blood, saliva, and urine samples~   "|||2018-06-01 01:01:22.16185|2018-06-01 01:01:22.16185
NCT00891462|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2012-08-14|2011-09-30|2016-11-16|2009-04-30|2009-05-01|Estimate|2012-08-14|2012-09-13|Estimate|2011-09-30|2011-10-05|Estimate|2016-11-16|2017-01-06|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)|Efficacy and Safety of Aclidinium Bromide at Two Dose Levels (200 μg Twice Daily, 400 μg Twice Daily) vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|561|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:01:22.411989|2018-06-01 01:01:22.411989
NCT00891449|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2015-11-13|2009-04-30|2009-05-01|Estimate|||||||2015-11-13|2015-11-17|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|FAP||Space Flight Simulation to Study Effects of Micro-gravity Through Bed Rest|Countermeasure and Functional Testing Study (CFT-70)|Completed|||20|Actual|National Aeronautics and Space Administration (NASA)|||||f||||t||||||Samples Without DNA|"~     Blood, Urine~   "|||2018-06-01 01:01:23.375612|2018-06-01 01:01:23.375612
NCT00891436|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2012-09-14||2012-11-29|2009-04-30|2009-05-01|Estimate|2012-09-14|2012-10-18|Estimate||||2012-11-29|2012-12-03|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms|Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy|Completed||Phase 4|20|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 01:01:23.465356|2018-06-01 01:01:23.465356
NCT00891423|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2015-07-30|2009-04-30|2009-05-01|Estimate|||||||2015-07-30|2015-08-03|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|MERO001||A Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Unit (ICU) Patients|A Randomised Controlled Crossover Pilot Study of Meropenem Standard 30 Minute Infusion Versus Prolonged 3 Hour Infusion in Intensive Care Patients|Completed||N/A|10|Actual|Austin Health||2|||f||||f||||||||||2018-06-01 01:01:23.81206|2018-06-01 01:01:23.81206
NCT00891397|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2015-04-07|2009-04-30|2009-05-01|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|October 2010|Actual|2010-10-31|January 2010|Actual|2010-01-31||Interventional|PREGA||Pregabalin Versus Placebo as an Add on for Complex Regional Pain Syndrome (CPRS) of the Upper Limb Managed by Stellate Ganglion Block (The PREGA Study)|Pregabalin vs. Placebo as an Add on for Complex Regional Pain Syndrome of the Upper Limb Managed by Stellate Ganglion Block|Terminated||N/A|14|Actual|McMaster University||2||Unable to recruit patients|f||||f||||||||||2018-06-01 01:01:23.969423|2018-06-01 01:01:23.969423
NCT00891384|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2018-01-17|2009-04-30|2009-05-01|Estimate|||||||2018-01-17|2018-01-19|Actual|April 1, 2009|Actual|2009-04-01|January 2018|2018-01-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma|A Randomised Comparison of Daily 25 mg Versus 5 mg Lenalidomide as Maintenance Therapy After High-dose Therapy and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma|Completed||Phase 3|194|Actual|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||2|||f||||t||||||||||2018-06-01 01:01:24.108291|2018-06-01 01:01:24.108291
NCT00891371|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2015-07-17||2015-08-28|2009-04-30|2009-05-01|Estimate|2015-08-28|2015-09-29|Estimate||||2015-08-28|2015-09-29|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|MEDARD|The Safety population was defined as all subjects who received at least one injection of the study medication.|Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea|A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhea|Completed||Phase 2/Phase 3|42|Actual|Ipsen||1|||f||||f||||||||||2018-06-01 01:01:25.286582|2018-06-01 01:01:25.286582
NCT00891358|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2017-03-02|2009-04-30|2009-05-01|Estimate|||||||2017-03-02|2017-03-06|Actual|November 2008||2008-11-30|July 2016|2016-07-31|April 2013|Actual|2013-04-30|July 2009|Actual|2009-07-31||Interventional|||Empowerment Intervention for Young Women - Phase I|A Secondary Prevention Empowerment Intervention for Young Women Living With HIV|Completed||N/A|17|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-06-01 01:01:25.707818|2018-06-01 01:01:25.707818
NCT00891345|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2012-04-26|2009-04-30|2009-05-01|Estimate|||||||2012-04-26|2012-04-27|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ALECSAT||Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy|A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Prostate Cancer Patients - a First Dose in Man Study|Completed||Phase 1|13|Actual|CytoVac A/S|||||f||||f||||||||||2018-06-01 01:01:25.853613|2018-06-01 01:01:25.853613
NCT00891332|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2012-01-16|2009-04-30|2009-05-01|Estimate|||||||2012-01-16|2012-01-18|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer|Phase II Study of S-1 Plus LV (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic Colorectal Cancer|Completed||Phase 2|73|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:01:25.969112|2018-06-01 01:01:25.969112
NCT00891319|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2017-09-08||2017-10-03|2009-04-30|2009-05-01|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|January 2009||2009-01-31|October 2017|2017-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Electrical Stimulation for Recovery of Hand Function in Chronic Stroke Survivors|Contralaterally Controlled FES for Chronic Arm/Hand Hemiplegia: Single-Site RCT|Completed||N/A|80|Actual|MetroHealth Medical Center||2|||f||||f|f|||||||No||2018-06-01 01:01:26.181502|2018-06-01 01:01:26.181502
NCT00891306|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2011-09-28|2009-04-30|2009-05-01|Estimate|||||||2011-09-28|2011-09-29|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|April 2011|Actual|2011-04-30|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects|An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects|Completed||Phase 2/Phase 3|5|Actual|Amsterdam Molecular Therapeutics||1|||f||||t||||||||||2018-06-01 01:01:26.710194|2018-06-01 01:01:26.710194
NCT00891137|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2014-10-23|2009-04-30|2009-05-01|Estimate|||||||2014-10-23|2014-10-27|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy|A Phase I Trial to Determine Safety and Tolerability of Ex Vivo Expanded Human Myeloid Progenitor Cells (CLT-008) Infused 24 Hours Post-Transplant to Support Allogeneic Umbilical Cord Blood Transplantation for Hematologic Malignancies|Completed||Phase 1|30|Actual|Cellerant Therapeutics||4|||f||||f||||||||||2018-06-01 01:01:32.547717|2018-06-01 01:01:32.547717
NCT00891293|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2009-05-06||2011-01-22|2009-04-30|2009-05-01|Estimate|2009-06-04|2009-07-28|Estimate||||2011-01-22|2011-01-25|Estimate|March 2006||2006-03-31|November 2010|2010-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™|A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™|Completed||Phase 4|93|Actual|GlaxoSmithKline|LOV111821/OM5XX was terminated due to the lack of substantial incremental change in the primary endpoint lipid values above that reached in either the original study (LOV111859/OM5) or the first extension study (LOV111860/OM5X).|1|||f||||f||||||||||2018-06-01 01:01:26.910102|2018-06-01 01:01:26.910102
NCT00891280|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2011-06-13|2009-04-30|2009-05-01|Estimate|||||||2011-06-13|2011-06-15|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Dose-escalation Study of Oral CX-4945|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma|Unknown status|Recruiting|Phase 1|55|Anticipated|Cylene Pharmaceuticals|||||f||||f||||||||||2018-06-01 01:01:27.387558|2018-06-01 01:01:27.387558
NCT00891267|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2011-05-24|2009-04-30|2009-05-01|Estimate|||||||2011-05-24|2011-05-25|Estimate|October 2008||2008-10-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|VAMOS||Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome|Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome|Completed||Phase 3|60|Anticipated|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-06-01 01:01:27.524512|2018-06-01 01:01:27.524512
NCT00891254|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2012-10-29|2009-04-30|2009-05-01|Estimate|||||||2012-10-29|2012-10-31|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|||Long-term Follow-up of Incisional Hernia Repaired With Intraperitoneal Mesh|Randomized Study of Long-term Follow-up of Incisional Hernia Repaired With Intraperitoneal Mesh Versus On-lay Mesh Repair|Completed||Phase 1|80|Actual|Cirujanos la Serena||2|||f||||f||||||||||2018-06-01 01:01:27.653928|2018-06-01 01:01:27.653928
NCT00891241|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2011-08-17|2009-04-30|2009-05-01|Estimate|||||||2011-08-17|2011-08-18|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure|A Multi-Center, Single Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure|Completed||Phase 1|22|Anticipated|Lantheus Medical Imaging||2|||f||||t||||||||||2018-06-01 01:01:27.756431|2018-06-01 01:01:27.756431
NCT00891228|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2016-04-08||2018-04-26|2009-04-30|2009-05-01|Estimate|2018-04-26|2018-05-24|Actual||||2018-04-26|2018-05-24|Actual|May 2009||2009-05-31|April 2018|2018-04-30|November 2011|Actual|2011-11-30|May 2010|Actual|2010-05-31||Interventional|CCN007||Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men|A Multicenter, Randomized, Double-Blind Comparator Trial of the Safety and Sperm and Gonadotropin Suppression Resulting From Combined Use of Nestorone® Gel (0, 8 or 12 mg NES) and Testosterone Gel (10 g) Compared With Testosterone Gel in Normal Men|Completed||Phase 1|99|Actual|Health Decisions||3|||f||||t||||||||||2018-06-01 01:01:27.917236|2018-06-01 01:01:27.917236
NCT00891202|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2014-08-22|2012-10-12|2017-01-17|2009-04-30|2009-05-01|Estimate|2014-08-22|2014-09-03|Estimate|2012-10-12|2012-10-16|Estimate|2017-01-17|2017-03-03|Actual|November 2009||2009-11-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|July 2012|Actual|2012-07-31||Interventional||Full analysis set (FAS) for PAP: included all participants who signed informed consent and received at least one dose of study drug (placebo or eliglustat).|A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE)|Completed||Phase 3|40|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:01:29.170403|2018-06-01 01:01:29.170403
NCT00891189|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2016-09-22|2009-04-30|2009-05-01|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Determine the Relationship Between Circadian Rhythms and Nocturnal Asthma|Circadian Rhythms and Nocturnal Asthma|Completed|||20|Actual|Northwestern University|||3||f||||f||||||||||2018-06-01 01:01:29.920999|2018-06-01 01:01:29.920999
NCT00891176|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|2010-11-30||2017-08-22|2009-04-30|2009-05-01|Estimate|2010-11-30|2010-12-23|Estimate||||2017-08-22|2018-02-15|Actual|May 14, 2009||2009-05-14|September 2016|2016-09-30|November 21, 2012|Actual|2012-11-21|November 21, 2012|Actual|2012-11-21||Interventional|||Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines|Persistence of Antibodies After Full Vaccination Course With GSK Biologicals' Menitorix or MenC Conjugate Vaccine, Co-administered With DTPa or DTPa/Hib Containing Vaccine and Pneumococcal Conjugate Vaccine, in Children up to 6 Years of Age|Completed||Phase 3|582|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody when tested by ELISA.The tables show both the results obtained by ELISA and updated results following complete retesting by CLIA.|4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:01:30.095449|2018-06-01 01:01:30.095449
NCT00891163|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2009-04-30|2009-04-30|2009-05-01|Estimate|||||||2009-04-30|2009-05-01|Estimate|December 2006||2006-12-31|April 2009|2009-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Evaluate the Depth and Duration of Anesthesia|A Randomized, Double-Blind, Two-Period, Crossover Study to Evaluate the Depth and Duration of Anesthesia of Synera™ Patches Compared to Placebo Patches Applied to Healthy Adult Volunteers|Completed||Phase 4|25|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 01:01:32.238485|2018-06-01 01:01:32.238485
NCT00891150|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2013-03-05|2009-04-30|2009-05-01|Estimate|||||||2013-03-05|2013-03-06|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Oxytocin to Decrease Blood Loss During Cesarean Section|Intravenous Oxytocin Use to Decrease Blood Loss During Cesarean Section. What is the Optimal Dose: A Randomized Blinded Trial|Completed||N/A|200|Anticipated|American University of Beirut Medical Center||3|||f||||t||||||||||2018-06-01 01:01:32.418638|2018-06-01 01:01:32.418638
NCT00891124|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-11-02|2009-04-30|2009-05-01|Estimate|||||||2009-11-02|2009-11-03|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|||||Observational|PATROL||Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).|A Multi-center, Prospective, Observational Study to Assess the Effect of Patient Education Related to CV Risk Factors in Type 2 Diabetes Mellitus|Completed|||4045|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:01:32.725696|2018-06-01 01:01:32.725696
NCT00891098|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2013-06-04|2009-04-30|2009-05-01|Estimate|||||||2013-06-04|2013-06-05|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Comparing Imaginal Exposure and Imagery Rescripting in Treatment of Posttraumatic Stress Disorder (PTSD)|Comparing Imaginal Exposure (IE) and Imagery Rescripting and Reprocessing Therapy (IRRT) in the Treatment of Posttraumatic Stress Disorder (PTSD)|Completed||N/A|65|Actual|Modum Bad||2|||f||||f||||||||||2018-06-01 01:01:32.93766|2018-06-01 01:01:32.93766
NCT00891085|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-29|2009-04-29|2009-04-30|Estimate|||||||2009-04-29|2009-04-30|Estimate|October 2007||2007-10-31|April 2009|2009-04-30||||||||Observational|SOLV||Synchronized Intermittent Mechanical Ventilation Versus Open Lung Ventilation With Spontaneous Respiration|Synchronized Intermittent Mechanical Ventilation vs Open Lung Ventilation With Spontaneous Respiration|Unknown status|Recruiting||198|Anticipated|University of New Mexico|||2||f||||t||||||||||2018-06-01 01:01:33.049602|2018-06-01 01:01:33.049602
NCT00891072|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2013-01-09|2009-04-29|2009-04-30|Estimate|||||||2013-01-09|2013-01-10|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase 1 Study of R-(-)-Gossypol (Ascenta's AT-101) in Combination With Paclitaxel and Carboplatin in Solid Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:01:33.141273|2018-06-01 01:01:33.141273
NCT00891059|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-11-22|2009-04-29|2009-04-30|Estimate|||||||2010-11-22|2010-11-23|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|Cognitive||The Role Of Cognitive Impairment In The Use Of The Diskus Inhaler|The Role Of Cognitive Impairment In The Use Of The Diskus Inhaler|Completed|||40|Actual|Synergy Health Solutions|||1||f||||f||||||||||2018-06-01 01:01:33.361464|2018-06-01 01:01:33.361464
NCT00891046|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2015-10-13||2017-01-18|2009-04-29|2009-04-30|Estimate|2017-01-18|2017-03-10|Actual||||2017-01-18|2017-03-10|Actual|September 2009||2009-09-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|β-SPECIFIC 3|Safety Set: The analysis was performed in safety set (SAF), defined as all participants who received at least one dose of study drug.|An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.|An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever|Completed||Phase 3|270|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:01:33.529546|2018-06-01 01:01:33.529546
NCT00891033|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2015-02-20|2009-04-29|2009-04-30|Estimate|||||||2015-02-20|2015-02-23|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Panobinostat/Velcade in Multiple Myeloma|Phase I Exploratory Study of Panobinostat IV in Combination With Bortezomib in Relapsed/Refractory Multiple Myeloma Patients|Terminated||Phase 1|12|Actual|University of Arkansas||4||This study was terminated because the drug company stopped making the study drug|f||||t||||||||||2018-06-01 01:01:35.318259|2018-06-01 01:01:35.318259
NCT00891020|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2012-02-28||2012-10-19|2009-04-29|2009-04-30|Estimate|2012-03-23|2012-04-17|Estimate||||2012-10-19|2012-10-25|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|March 2011|Actual|2011-03-31|July 2010|Actual|2010-07-31||Interventional|||A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)|Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs and Monotherapy Who Have an Inadequate Response to Current Non-Biologic or Biologic DMARDs|Completed||Phase 3|886|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:01:35.560501|2018-06-01 01:01:35.560501
NCT00891007|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2012-07-26|2009-04-29|2009-04-30|Estimate|||||||2012-07-26|2012-07-27|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years|Partially Randomized, Controlled Phase II Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years|Completed||Phase 2|90|Actual|Bavarian Nordic||3|||f||||f||||||||||2018-06-01 01:01:37.142826|2018-06-01 01:01:37.142826
NCT00890994|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2017-03-21|2009-04-29|2009-04-30|Estimate|||||||2017-03-21|2017-03-22|Actual|January 19, 2009|Actual|2009-01-19|March 2017|2017-03-31|November 14, 2016|Actual|2016-11-14|November 14, 2014|Actual|2014-11-14||Observational|||Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)|Evaluation of Molecular Breast Imaging in Patients With a High Likelihood of Ductal Carcinoma in Situ|Completed|||200|Actual|Mayo Clinic|||1||f||||f|f|f||||||No||2018-06-01 01:01:37.262781|2018-06-01 01:01:37.262781
NCT00890981|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2011-06-30||2014-03-05|2009-04-28|2009-04-30|Estimate|2011-06-30|2011-07-28|Estimate||||2014-03-05|2014-04-02|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab|A HR-pQCT Study in Postmenopausal Women Previously Treated With Denosumab|Completed||Phase 3|79|Actual|Amgen||1|||f||||f||||||||||2018-06-01 01:01:37.403644|2018-06-01 01:01:37.403644
NCT00890968|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28||2012-03-14|2012-03-14|2009-04-28|2009-04-30|Estimate||||2012-03-14|2012-03-16|Estimate|2012-03-14|2012-03-16|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|TAC-202||Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis|A Multi-Center Randomized, Double-Blind, Placebo Controlled, Parallel Group Comparison Study of Once Daily Triamcinolone Acetonide 0.5% DuraPeel™ Versus Placebo DuraPeel in the Treatment of Hand Dermatitis|Completed||Phase 2|56|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 01:01:38.214594|2018-06-01 01:01:38.214594
NCT00890955|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2015-12-21|2009-04-29|2009-04-30|Estimate|||||||2015-12-21|2015-12-23|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies|A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies|Completed||Phase 1|36|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||||2018-06-01 01:01:38.344255|2018-06-01 01:01:38.344255
NCT00890942|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2011-07-22|2009-04-29|2009-04-30|Estimate|||||||2011-07-22|2011-07-25|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal Morphine Induced Pruritus After Cesarean Section|Efficacy of Intramuscular Naloxone 0.4mg. in Prophylaxis of Intrathecal|Completed||N/A|60|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 01:01:38.457271|2018-06-01 01:01:38.457271
NCT00890929|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2014-10-13||2014-10-13|2009-04-29|2009-04-30|Estimate|2014-10-13|2014-10-20|Estimate||||2014-10-13|2014-10-20|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)|A Phase 1-2 Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|45|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 01:01:38.586092|2018-06-01 01:01:38.586092
NCT00890916|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|2016-10-17||2018-01-04|2009-04-29|2009-04-30|Estimate|2016-12-15|2017-02-08|Estimate||||2018-01-04|2018-01-30|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 1, 2015|Actual|2015-11-01||Interventional||C5/C6 Spinal Cord Injury|Hand Function for Tetraplegia|Hand Function for Tetraplegia Using a Wireless Neuroprosthesis|Active, not recruiting||N/A|10|Actual|VA Office of Research and Development||1|||f||||f|f|t|f|f|t|||Undecided||2018-06-01 01:01:39.009721|2018-06-01 01:01:39.009721
NCT00890903|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2012-06-28|2009-04-29|2009-04-30|Estimate|||||||2012-06-28|2012-07-02|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)|Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer|Completed|||62|Actual|Pierre Fabre Pharma GmbH|||2||f||||f||||||||||2018-06-01 01:01:39.249606|2018-06-01 01:01:39.249606
NCT00890890|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29||2015-09-23|2015-09-23|2009-04-29|2009-04-30|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease|Terminated||Phase 2|263|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:01:39.339225|2018-06-01 01:01:39.339225
NCT00890877|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2010-09-01|2009-04-29|2009-04-30|Estimate|||||||2010-09-01|2010-09-02|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||OC000459 Dose Finding Study in Patients With Mild to Moderate Persistent Asthma|Dose Finding Study in Patients With Mild to Moderate Persistent Asthma: A Parallel Group, Randomised, Placebo Controlled, Double Blind Assessment of Oral Oc000459 Dosed At Three Dose Schedules for Twelve Weeks Finding Study In Patients With Mild To Moderate Persistent Asthma|Completed||Phase 2|480|Anticipated|Oxagen Ltd||4|||f||||f||||||||||2018-06-01 01:01:39.615452|2018-06-01 01:01:39.615452
NCT00890864|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2010-07-16|2009-04-29|2009-04-30|Estimate|||||||2010-07-16|2010-07-19|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Pilot Study: Age Extension of NHS Breast Screening Programme|Pilot Study of the Feasibility and Acceptability of Randomising the phasing-in of the Age Extension of the NHS Breast Screening Programme in England|Completed||N/A|36000|Anticipated|University of Oxford||2|||f||||f||||||||||2018-06-01 01:01:39.756605|2018-06-01 01:01:39.756605
NCT00890851|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2009-09-30|2009-04-29|2009-04-30|Estimate|||||||2009-09-30|2009-10-01|Estimate|March 2006||2006-03-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|EPURE||Procedure Transurethral Needle Ablation (TUNA) and Hospitalization of Short Duration|Evaluation of Procedure Tuna Within the Framework of a Hospitalization of Short Duration|Completed||N/A|53|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:01:39.869495|2018-06-01 01:01:39.869495
NCT00890838|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2014-10-01|2009-04-29|2009-04-30|Estimate|||||||2014-10-01|2014-10-02|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|IVFO-Valvular||Preoperative Intravenous Omega 3 Fatty Acids Administration in Valvular Surgery Patients|Preoperative Intravenous Omega 3 Fatty Acids Administration in Valvular Surgery Patients: A Prospective, Randomized, Open-label, Comparative Clinical Trial|Completed||Phase 4|40|Actual|Nizam's Institute of Medical Sciences University, India||2|||f||||f||||||||||2018-06-01 01:01:40.007037|2018-06-01 01:01:40.007037
NCT00890825|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29||2013-08-22|2016-11-09|2009-04-29|2009-04-30|Estimate||||2013-08-22|2013-08-30|Estimate|2016-11-09|2016-11-10|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|May 2011|Actual|2011-05-31||Interventional|||Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients|A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination With Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients With KRAS Mutation Positive Locally Advanced Metastatic Non Small Cell Lung Cancer (Stage IIIB- IV)|Completed||Phase 2|422|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:01:40.149545|2018-06-01 01:01:40.149545
NCT00890812|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2011-08-02|2009-04-29|2009-04-30|Estimate|||||||2011-08-02|2011-08-04|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Factor XI Levels in Acute Ischemic Stroke|Factor XI Levels in Acute Ischemic Stroke|Completed|||450|Actual|University of Utah|||2||f||||f||||||Samples With DNA|"~     A small 2ml vial of spun plasma~   "|||2018-06-01 01:01:40.397766|2018-06-01 01:01:40.397766
NCT00890799|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2013-02-02|2009-04-29|2009-04-30|Estimate|||||||2013-02-02|2013-02-05|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|December 2010|Actual|2010-12-31||Interventional|||Transcatheter Closure Versus Surgery of Perimembranous Ventricular Septal Defects|Clinical Evaluation of Transcatheter Closure and Surgery of Perimembranous Ventricular Septal Defects|Completed||N/A|200|Actual|Xijing Hospital||1|||f||||t||||||||||2018-06-01 01:01:40.499297|2018-06-01 01:01:40.499297
NCT00890786|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2018-05-01|2009-04-29|2009-04-30|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2009||2009-05-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas|A Pilot Study of Bevacizumab-Based Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas|Completed||Early Phase 1|27|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No||2018-06-01 01:01:40.629401|2018-06-01 01:01:40.629401
NCT00890760|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2012-11-28|2009-04-29|2009-04-30|Estimate|||||||2012-11-28|2012-11-29|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites|Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP|Completed||Phase 1/Phase 2|55|Actual|University of Oxford||10|||f||||t||||||||||2018-06-01 01:01:40.776142|2018-06-01 01:01:40.776142
NCT00890747|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2014-03-14|2009-04-29|2009-04-30|Estimate|||||||2014-03-14|2014-03-17|Estimate|August 2009||2009-08-31|September 2013|2013-09-30||||May 2011|Actual|2011-05-31||Interventional|||Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy|A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:01:40.939932|2018-06-01 01:01:40.939932
NCT00890734|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2012-02-10|2009-04-29|2009-04-30|Estimate|||||||2012-02-10|2012-02-13|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|||CYT003-QbG10 for Treatment of Allergic Asthma Bronchial|A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial|Completed||Phase 2|63|Actual|Cytos Biotechnology AG||2|||f||||f||||||||||2018-06-01 01:01:41.147251|2018-06-01 01:01:41.147251
NCT00890721|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2011-11-22|2010-08-25|2013-07-03|2009-04-28|2009-04-30|Estimate|2013-07-03|2013-08-06|Estimate|2010-08-27|2010-08-31|Estimate|2013-07-03|2013-08-06|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study of Pain Control in Hemorrhoidectomy|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy|Completed||Phase 3|189|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:01:41.263058|2018-06-01 01:01:41.263058
NCT00890708|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2012-02-18|2009-04-29|2009-04-30|Estimate|||||||2012-02-18|2012-02-22|Estimate|November 2008||2008-11-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Therapeutic Drug Monitoring of Voriconazole|Influence of Therapeutic Drug Monitoring of Voriconazole on Incidence of Drug Adverse Reaction|Completed||N/A|110|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 01:01:41.70513|2018-06-01 01:01:41.70513
NCT00890695|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2013-01-15||2017-06-30|2009-04-29|2009-04-30|Estimate|2013-06-17|2013-07-19|Estimate||||2017-06-30|2017-08-14|Actual|May 2009||2009-05-31|June 2017|2017-06-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|MODMAL||Effectiveness of Supplementary Feeding During Infection Among Moderately Malnourished Children|Randomized Controlled Trial of an Outpatient Strategy of Ready to Use Supplementary Food (RUSF) Among Moderately Malnourished Children With Acute Infection|Terminated||N/A|64|Actual|University of Oxford|The trial was forced to stop early, 65 recruited. Analysis was inadequately powered to detect the changes in WHZ score and MUAC, the analysis of which had been originally planned for a sample size of 400.|2||New provision of supplementary feeds for moderately malnourished children|f||||f||||||||||2018-06-01 01:01:41.844382|2018-06-01 01:01:41.844382
NCT00890682|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2011-11-21|2010-08-25|2013-07-02|2009-04-28|2009-04-30|Estimate|2013-07-02|2013-08-05|Estimate|2010-08-27|2010-08-31|Estimate|2013-07-02|2013-08-05|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study of Postoperative Analgesia in Bunionectomy|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing First Metatarsal Osteotomy (Bunionectomy)|Completed||Phase 3|193|Actual|Pacira Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 01:01:42.370865|2018-06-01 01:01:42.370865
NCT00890669|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-05-01|2009-04-29|2009-04-30|Estimate|||||||2009-05-01|2009-05-04|Estimate|August 2007||2007-08-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|||||Interventional|||Treadmill Training and Quality of Life in Parkinson's Disease|Treadmill Walking Training With Additional Body Load Improves Quality of Life in Subjects With Parkinson's Disease|Completed||N/A|9|Actual|Universidade Federal de Sao Carlos||1|||f||||f||||||||||2018-06-01 01:01:42.794468|2018-06-01 01:01:42.794468
NCT00890656|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|2011-07-25||2012-02-17|2009-04-29|2009-04-30|Estimate|2011-07-25|2011-08-23|Estimate||||2012-02-17|2012-02-20|Estimate|June 2003||2003-06-30|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage|Phase II Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage|Completed||Phase 2|90|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:01:42.884328|2018-06-01 01:01:42.884328
NCT00890643|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2013-09-20|2009-04-29|2009-04-30|Estimate|||||||2013-09-20|2013-09-23|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Effect of Prazosin on Neurophysiology and Cognition in Post-Traumatic Stress Disorder (PTSD)|Effect of Prazosin on Neurophysiologic Responses and Cognitive Performance in PTSD|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Primary investigator left VA employment|f||||t||||||||||2018-06-01 01:01:43.254633|2018-06-01 01:01:43.254633
NCT00890630|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-07-19|2009-04-28|2009-04-30|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2010||2010-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|IC-PROM||Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term|Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term: A Pilot Study.|Terminated||Phase 2|5|Actual|McMaster University||2||Inadequate Patient Recruitment.|f||||f||||||||||2018-06-01 01:01:43.394949|2018-06-01 01:01:43.394949
NCT00890617|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2016-03-15|2009-04-29|2009-04-30|Estimate|||||||2016-03-15|2016-03-17|Estimate|March 2009||2009-03-31|March 2016|2016-03-31||||April 2013|Actual|2013-04-30||Interventional|||Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis|A Pilot Study of Percutaneous Cryotherapy as Treatment for Stage I Lung Cancer or Solitary Metastatic Lung Cancer|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 01:01:43.523372|2018-06-01 01:01:43.523372
NCT00890604|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2017-05-03|2009-04-29|2009-04-30|Estimate|||||||2017-05-03|2017-05-08|Actual|July 2009||2009-07-31|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SNIF||Outcomes Associated With Application of a Normothermia Protocol in Patients With Severe Neurological Insult and Fever|Outcomes Associated With the Application of the Normothermia Protocol in Patients With Severe Neurological Insult and Fever|Terminated||N/A|10|Actual|University of Washington||2||Practice change created contamination of usual care arm|f||||f||||||||||2018-06-01 01:01:43.643989|2018-06-01 01:01:43.643989
NCT00890591|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2009-02-11||2009-05-27|2009-03-20|2009-04-30|Estimate|2009-03-20|2009-04-30|Estimate||||2009-05-27|2009-06-03|Estimate|August 2006||2006-08-31|May 2009|2009-05-31|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|Benibest||Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension|National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine Besylate|Completed||Phase 4|144|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 01:01:43.793506|2018-06-01 01:01:43.793506
NCT00890578|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2012-06-19|2009-04-29|2009-04-30|Estimate|||||||2012-06-19|2012-06-21|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||HISTOACRYL: A Study of Its Efficacy in Final Scar Formation|It is Our Intent to Conduct a Prospective Randomized Controlled Trial Examining the Use of Histoacryl© in the Closure of Surgical Incisions in Comparison to Subcuticular Suture and to Dermabond©.|Completed|||21|Actual|Mayo Clinic|||2||f||||||||||||||2018-06-01 01:01:44.054563|2018-06-01 01:01:44.054563
NCT00890565|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-29|||2010-09-24|2009-04-29|2009-04-30|Estimate|||||||2010-09-24|2010-09-27|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)|A Single-Blind, Randomized, Parallel Trial to Define the ECG Effects of Sancuso® (Granisetron Transdermal System) Compared to Placebo and Moxifloxacin in Healthy Men and Women|Completed||Phase 1|240|Actual|Prostrakan Pharmaceuticals||4|||f||||f||||||||||2018-06-01 01:01:44.16978|2018-06-01 01:01:44.16978
NCT00890552|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2016-04-14||2017-02-01|2009-04-29|2009-04-30|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|April 2009||2009-04-30|February 2017|2017-02-28|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional||Lenalidomide-naïve adults with biopsy-proven amyloidosis manifested as measurable disease, ECOG ≤ 3|A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis|A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis|Completed||N/A|25|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 01:01:45.265697|2018-06-01 01:01:45.265697
NCT00890539|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-11-23|2009-04-29|2009-04-30|Estimate|||||||2009-11-23|2009-11-25|Estimate|February 2009||2009-02-28|November 2009|2009-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Methacholine Challenge: Comparison of Doubling and Quadrupling Methacholine Dose Regimes Using the Tidal Volume Method|Methacholine Challenge: Comparison of Doubling and Quadrupling Methacholine Dose Regimes Using the Tidal Volume Method|Completed||N/A|15|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 01:01:45.745213|2018-06-01 01:01:45.745213
NCT00890526|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2012-06-20|2009-04-29|2009-04-30|Estimate|||||||2012-06-20|2012-06-21|Estimate|July 2002||2002-07-31|June 2012|2012-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Intervention for Reduced Sound Tolerance|Intervention for Reduced Sound Tolerance|Completed||Phase 1|36|Actual|University of Alabama, Tuscaloosa||4|||f||||f||||||||||2018-06-01 01:01:45.863713|2018-06-01 01:01:45.863713
NCT00890513|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-11-19|2009-04-27|2009-04-29|Estimate|||||||2009-11-19|2009-11-20|Estimate|April 2007||2007-04-30|November 2009|2009-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|Swiss-BEAN||Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment|Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment|Completed|||1200|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 01:01:45.995161|2018-06-01 01:01:45.995161
NCT00890500|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2013-10-07|2009-04-28|2009-04-29|Estimate|||||||2013-10-07|2013-10-08|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.|A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematological Malignancies.|Completed||Phase 1|12|Actual|Fate Therapeutics||2|||f||||t||||||||||2018-06-01 01:01:46.157801|2018-06-01 01:01:46.157801
NCT00890487|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-04-27|2009-04-27|2009-04-29|Estimate|||||||2009-04-27|2009-04-29|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Hyaluronic Acid and Vaginal Distress|Effects of Hyaluronic Acid Oral Supplementation on the Vaginal Epithelium: a Prospective, Randomized, Double-Blind, Placebo Controlled Study|Unknown status|Not yet recruiting|N/A|70|Anticipated|University of Messina||1|||f||||f||||||||||2018-06-01 01:01:46.293392|2018-06-01 01:01:46.293392
NCT00890474|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|October 2004||2004-10-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Moxibustion for Fetus in Breech Presentation|Moxibustion for Fetus in Breech Presentation|Completed||Phase 3|212|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 01:01:46.418996|2018-06-01 01:01:46.418996
NCT00890461|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2017-05-01|2009-04-28|2009-04-29|Estimate|||||||2017-05-01|2017-05-03|Actual|November 2007||2007-11-30|May 2017|2017-05-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Observational|||Reconstruction of 12-Lead Electrogram From Intracardiac Signals From Defibrillators During or After Implantation|Reconstruction of 12-Lead Electrogram From Intracardiac Signals From Defibrillators During or After Implantation|Completed|||42|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-06-01 01:01:46.541669|2018-06-01 01:01:46.541669
NCT00890448|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-05-23|2009-04-28|2009-04-29|Estimate|||||||2012-05-23|2012-05-24|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate|A Modified Case Control Study to Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate|Completed|||66|Anticipated|Takeda|||1||f||||f||||||Samples With DNA|"~     Pharmacogenomic whole blood sample~   "|||2018-06-01 01:01:46.661277|2018-06-01 01:01:46.661277
NCT00890435|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2015-10-20|2009-04-28|2009-04-29|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2008||2008-07-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|August 2009|Actual|2009-08-31||Observational|||Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial|A Pharmacokinetic Participation Questionnaire Study|Completed|||53|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 01:01:46.815688|2018-06-01 01:01:46.815688
NCT00890422|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|July 2010|Anticipated|2010-07-31|November 2009|Anticipated|2009-11-30||Interventional|immunisation||Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine|Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine|Unknown status|Active, not recruiting|Phase 2|99|Anticipated|Elisabethinen Hospital||3|||f||||f||||||||||2018-06-01 01:01:46.918726|2018-06-01 01:01:46.918726
NCT00890409|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|2009-01-02||2009-05-01|2009-04-28|2009-04-29|Estimate|2009-04-28|2009-04-29|Estimate||||2009-05-01|2009-05-28|Estimate|May 2002||2002-05-31|May 2009|2009-05-31|August 2005|Actual|2005-08-31|June 2004|Actual|2004-06-30||Interventional|||Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy|Selective Head Cooling With Mild Systemic Hypothermia After Neonatal Hypoxic-Ischemic Encephalopathy: A Multi-Center Randomized Controlled Trial in China|Completed||Phase 3|256|Actual|Fudan University||2|||f||||t||||||||||2018-06-01 01:01:47.054188|2018-06-01 01:01:47.054188
NCT00890396|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-07-24|2009-04-27|2009-04-29|Estimate|||||||2009-07-24|2009-07-27|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)|Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Study|Unknown status|Enrolling by invitation||167|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||2||f||||t||||||Samples With DNA|"~     Stored blood and urine~   "|||2018-06-01 01:01:47.357564|2018-06-01 01:01:47.357564
NCT00890383|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-11-23|2009-04-28|2009-04-29|Estimate|||||||2009-11-23|2009-11-25|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|CIST||Colloids in Severe Trauma|"Colloids in Severe Trauma: A Multi-Center Pilot Study of Crystalloid Only or Crystalloid + Colloid Volume Resuscitation in Trauma Patients (CIST)"|Completed||Phase 4|50|Anticipated|University of the Philippines||2|||f||||t||||||||||2018-06-01 01:01:47.466011|2018-06-01 01:01:47.466011
NCT00890370|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|July 1999||1999-07-31|April 2009|2009-04-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|ACT||Should Any One Airway Clearance Technique be Recommended for People With Cystic Fibrosis?|A Comparison of Five Airway Clearance Techniques in the Treatment of Adults With Cystic Fibrosis|Completed||Phase 4|75|Actual|Royal Brompton & Harefield NHS Foundation Trust||5|||f||||f||||||||||2018-06-01 01:01:47.587383|2018-06-01 01:01:47.587383
NCT00890357|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2013-03-27|2009-04-27|2009-04-29|Estimate|||||||2013-03-27|2013-03-29|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Identifying Factors Underlying the Discontinuation of Triptans|Identifying Factors Underlying the Discontinuation of Triptans|Completed|||292|Actual|Mayo Clinic|||2||f||||t||||||||||2018-06-01 01:01:47.711324|2018-06-01 01:01:47.711324
NCT00890344|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-09-29|2009-04-28|2009-04-29|Estimate|||||||2011-09-29|2011-09-30|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Body Composition Assessment in Healthy Full-term Neonates by Anthropometry, Air Displacement Plethysmography and Multiple-frequency Bio-impedance Analysis|"Body Composition Assessment in Healthy Full-term Neonates by Anthropometry, Air Displacement Plethysmography (PeaPod) and Multiple-frequency Bio-impedance Analysis (BIA)"|Completed|||40|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-06-01 01:01:47.891148|2018-06-01 01:01:47.891148
NCT00890331|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2016-01-06|2009-04-28|2009-04-29|Estimate|||||||2016-01-06|2016-01-08|Estimate|April 2007||2007-04-30|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Prevention of Self-care Deterioration in Early Adolescents With Diabetes|Family Teamwork and Coping Skills Prevention Program|Completed||Phase 1|285|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-06-01 01:01:47.974263|2018-06-01 01:01:47.974263
NCT00890318|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-10-19|2009-04-28|2009-04-29|Estimate|||||||2010-10-19|2010-10-21|Estimate|April 2009||2009-04-30|September 2010|2010-09-30||||July 2009|Actual|2009-07-31||Interventional|||A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C||Completed||Phase 1|32|Actual|Abbott||3|||f||||||||||||||2018-06-01 01:01:48.116024|2018-06-01 01:01:48.116024
NCT00890305|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28||2015-06-10|2015-06-10|2009-04-28|2009-04-29|Estimate||||2015-06-10|2015-07-08|Estimate|2015-06-10|2015-07-08|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional|||Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone|Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease|Completed||Phase 2|171|Actual|Medivation, Inc.||2|||f||||t||||||||||2018-06-01 01:01:48.26245|2018-06-01 01:01:48.26245
NCT00890292|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-04-15|2009-04-27|2009-04-29|Estimate|||||||2010-04-15|2010-04-16|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-Label, Multi-Center, Sequential Group, Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of JNJ-31001074 After a Single Dose Administration in Pediatric Subjects With Attention-Deficit/Hyperactivity Disorder, 12 to 17 Years Old|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 01:01:48.461983|2018-06-01 01:01:48.461983
NCT00890279|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-12-01|2009-04-28|2009-04-29|Estimate|||||||2009-12-01|2009-12-02|Estimate|July 2009||2009-07-31|December 2009|2009-12-31|November 2012|Anticipated|2012-11-30|June 2010|Anticipated|2010-06-30||Interventional|||Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)|Phase II Study for the Second-Line Treatment of Hypertension in Patients With Autosomal Dominant Polycystic Kidney Disease; ACEI vs. CCB|Unknown status|Recruiting|Phase 2|160|Anticipated|Ministry of Health, Labour and Welfare, Japan||2|||f||||f||||||||||2018-06-01 01:01:48.596873|2018-06-01 01:01:48.596873
NCT00890266|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-05-06|2009-04-28|2009-04-29|Estimate|||||||2010-05-06|2010-05-07|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|July 2010|Anticipated|2010-07-31|April 2010|Actual|2010-04-30||Interventional|HypotonicRibo||Corneal Collagen Cross-linking With Hypotonic Riboflavin in Corneas Thinner Than 400 Microns|Collagen Cross-linking With Riboflavin in a Hypotonic Solution, With UV Light, on Corneas Less Than 400 Microns Thick: an Exploratory Study.|Unknown status|Active, not recruiting|N/A|5|Anticipated|Moorfields Eye Hospital NHS Foundation Trust|||||f||||t||||||||||2018-06-01 01:01:48.827467|2018-06-01 01:01:48.827467
NCT00890253|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2011-09-14|2009-04-28|2009-04-29|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|CILT||Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation|A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free De-novo Immunosuppression After Liver Transplantation|Unknown status|Recruiting|Phase 2|29|Anticipated|University Medical Center Goettingen||1|||f||||t||||||||||2018-06-01 01:01:48.965541|2018-06-01 01:01:48.965541
NCT00890240|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-04-15|2009-04-27|2009-04-29|Estimate|||||||2010-04-15|2010-04-16|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-Label, Multi-Center, Sequential Group, Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of JNJ-31001074 After a Single Dose Administration in Pediatric Subjects With Attention-Deficit/Hyperactivity Disorder, 6 to 11 Years Old|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 01:01:49.165368|2018-06-01 01:01:49.165368
NCT00890227|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2018-04-05|2009-04-27|2009-04-29|Estimate|||||||2018-04-05|2018-04-09|Actual|June 2009|Actual|2009-06-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Incidence of Proximal Junctional Kyphosis (PJK) in Long Posterior Spinal Fusion: A Study Comparing Traditional Open Surgery to Minimally Invasive Percutaneous Technique at the Proximal Fusion Levels|Incidence of Proximal Junctional Kyphosis (PJK) in Long Posterior Spinal Fusion: A Prospective Controlled Randomized Study Comparing Traditional Open Surgery to Minimally Invasive Percutaneous Technique at the Proximal Fusion Levels/Levels|Active, not recruiting||N/A|68|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:01:49.290213|2018-06-01 01:01:49.290213
NCT00890214|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Prostacyclin's Effect on Platelet Responsiveness|Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.|Completed||Phase 4|23|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 01:01:49.441334|2018-06-01 01:01:49.441334
NCT00890201|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2009-07-27||2010-12-01|2009-04-28|2009-04-29|Estimate|2009-09-17|2009-10-20|Estimate||||2010-12-01|2010-12-17|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Pancreaticobiliary Reflux in Patients Without Cholelithiasis|Is Pancreaticobiliary Reflux in Patients With Cholelithiasis and Without Cholelithiasis a Normal Phenomenon?|Completed|||197|Actual|Cirujanos la Serena|||2||f||||f||||||||||2018-06-01 01:01:49.594058|2018-06-01 01:01:49.594058
NCT00890188|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-05-05|2009-04-28|2009-04-29|Estimate|||||||2009-05-05|2009-05-07|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|UFUR||Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer|The Feasibility of Combing THALIDOMIDE and UFUR in the Treatment of Advanced Colorectal Cancer After Oxaliplatin-Contained Chemotherapy|Unknown status|Recruiting|Phase 2|34|Anticipated|National Cheng-Kung University Hospital||1|||f||||f||||||||||2018-06-01 01:01:49.99275|2018-06-01 01:01:49.99275
NCT00890175|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-03-13|2009-04-28|2009-04-29|Estimate|||||||2017-03-13|2017-03-15|Actual|May 2009||2009-05-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Staccato Loxapine Pulmonary Safety in Patients With Asthma|Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Asthma|Completed||Phase 1|52|Actual|Alexza Pharmaceuticals, Inc.||2|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 01:01:50.116175|2018-06-01 01:01:50.116175
NCT00890162|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2018-05-22|2009-04-28|2009-04-29|Estimate|||||||2018-05-22|2018-05-23|Actual|April 27, 2009||2009-04-27|May 16, 2018|2018-05-16|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis|A Randomized Double-Blinded, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis|Active, not recruiting||Phase 2|19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:01:50.246927|2018-06-01 01:01:50.246927
NCT00890149|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-08-16|2009-04-27|2009-04-29|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults|Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults|Completed||Phase 2|300|Anticipated|University of Maryland||2|||f||||t||||||||||2018-06-01 01:01:50.346116|2018-06-01 01:01:50.346116
NCT00890136|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-09-29|2009-04-28|2009-04-29|Estimate|||||||2017-09-29|2017-10-03|Actual|July 2008|Actual|2008-07-31|September 2017|2017-09-30|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Observational|CODE||Chronic Obstructive Pulmonary Disease (COPD) and Domestic Endotoxin (CODE)|COpd and Domestic Endotoxin (CODE)|Completed|||84|Actual|Johns Hopkins University|||||f||||t||||||Samples Without DNA|"~     blood, sputum~   "|||2018-06-01 01:01:50.45567|2018-06-01 01:01:50.45567
NCT00890123|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2014-10-01|2009-04-28|2009-04-29|Estimate|||||||2014-10-01|2014-10-02|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Preoperative Intravenous Omega 3 Fatty Acids Administration in Elderly Patients Undergoing Hip Surgery|Preoperative Intravenous Omega 3 Fatty Acids Administration in Elderly Patients Undergoing Hip Surgery: A Prospective, Randomized, Open-label, Comparative Clinical Trial|Completed||Phase 4|40|Actual|Nizam's Institute of Medical Sciences University, India||2|||f||||f||||||||||2018-06-01 01:01:50.53918|2018-06-01 01:01:50.53918
NCT00890110|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|June 2009||2009-06-30|April 2009|2009-04-30|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|rcc||Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib|Phase1/2 Study of Vaccination With DNP Modified Autologous Renal Cell Carcinoma in Combination With Sunitinib in Stage 4 RCC|Unknown status|Not yet recruiting|Phase 1/Phase 2|13|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:01:50.650029|2018-06-01 01:01:50.650029
NCT00890097|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|2014-06-04|2013-05-09|2014-06-04|2009-04-28|2009-04-29|Estimate|2014-06-04|2014-07-03|Estimate|2013-05-09|2013-05-16|Estimate|2014-06-04|2014-07-03|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|GATE|This analysis population includes all enrolled subjects (772).|Geographic Atrophy Treatment Evaluation|The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)|Terminated||Phase 3|772|Actual|Alcon Research||3||Treatment ineffective|f||||t||||||||||2018-06-01 01:01:50.874566|2018-06-01 01:01:50.874566
NCT00890084|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2011-12-30||2014-02-28|2009-04-28|2009-04-29|Estimate|2012-04-07|2012-05-02|Estimate||||2014-02-28|2014-04-08|Estimate|April 2009||2009-04-30|February 2014|2014-02-28||||December 2009|Actual|2009-12-31||Observational|||Telmisartan Tab Hypertension|RESPECT: Observational, Prospective, Open-label, Multi-center Study Evaluating the Antihypertensive Effect of Treatment With Telmisartan (Alone or in Fixed Combination With HCTZ) in General Practitioner and Specialist Practice in Hypertensive Patients With High and Very High Cardiovascular Risk According to the ESH/ESC Guidelines 2007 Who Are Uncontrolled Under Current Treatment.|Completed|||2913|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 01:01:52.652119|2018-06-01 01:01:52.652119
NCT00890071|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Observational|||Brachial Artery Peak Velocity Variation to Predict Fluid Responsiveness|Brachial Artery Peak Velocity Variation to Predict Fluid Responsiveness in Mechanically Ventilated Patients|Completed|||38|Actual|Hospital del SAS de Jerez|||1||f||||f||||||||||2018-06-01 01:01:52.981428|2018-06-01 01:01:52.981428
NCT00890058|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2016-08-29|2009-04-28|2009-04-29|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|CIRAS||A Case Control Study to Define Clinical, Immunologic and Radiographic Features of the Aromatase Inhibitor Arthralgia Syndrome|A Case Control Study to Define Clinical, Immunologic and Radiographic Features of the Aromatase Inhibitor Arthralgia Syndrome|Completed|||48|Actual|George Washington University|||2||f||||f||||||Samples Without DNA|"~     Blood samples for cytokine measurements~   "|||2018-06-01 01:01:53.096531|2018-06-01 01:01:53.096531
NCT00890045|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2014-08-18|2009-04-28|2009-04-29|Estimate|||||||2014-08-18|2014-08-19|Estimate|July 2004||2004-07-31|August 2014|2014-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study|A Comparison Between the HeRO® Graft and Conventional Arteriovenous Grafts in Hemodialysis Patients|Completed||N/A|72|Actual|Hemosphere, Inc.||2|||f||||t||||||||||2018-06-01 01:01:53.21522|2018-06-01 01:01:53.21522
NCT00890032|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2016-10-13|2009-04-28|2009-04-29|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|October 2014|Actual|2014-10-31||Interventional|||Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme|Recurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy Trial|Completed||Phase 1|50|Anticipated|Duke University||1|||f||||t||||||||||2018-06-01 01:01:53.479919|2018-06-01 01:01:53.479919
NCT00890019|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2012-08-21|2009-04-28|2009-04-29|Estimate|||||||2012-08-21|2012-08-22|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||A Study of AdCh63 ME−TRAP Alone and With MVA ME−TRAP|A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidate AdCh63 ME-TRAP, Alone and With MVA ME-TRAP, Using a Prime-boost Delivery Schedule|Completed||Phase 1|54|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 01:01:53.593106|2018-06-01 01:01:53.593106
NCT00890006|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-12-01|2009-04-28|2009-04-29|Estimate|||||||2017-12-01|2017-12-05|Actual|September 2006||2006-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Advanced Imaging for Radiotherapy Treatment Planning and Guidance for Low-Intermediate Risk Prostate Cancer (Margin)|Low-Intermediate Risk Prostate Cancer: Improving Acute Toxicity Outcomes of Radiotherapy With the Integration of Advanced Imaging for Treatment Planning and Guidance|Active, not recruiting||N/A|99|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:01:53.732433|2018-06-01 01:01:53.732433
NCT00889993|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-03-28|2009-04-28|2009-04-29|Estimate|||||||2012-03-28|2012-03-29|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Satiety Response After Mixed Fiber Doses|Effect of Four Doses of Mixed Fiber on Satiety, Food Intake, Glucose, Insulin, and Gut Hormone Release|Completed||N/A|20|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 01:01:53.84561|2018-06-01 01:01:53.84561
NCT00889980|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2017-08-16|2009-04-28|2009-04-29|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2008||2008-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Melanoma Molecular Profiling Analysis|Sentinel Node and Non-Sentinel Lymph Nodes (SLN and Non-SLN) Procurement From Melanoma Subjects for Molecular Profiling Analysis|Recruiting|||200|Anticipated|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     Lymph nodes (less than 20% of any node), blood will be drawn at the pre study visit (serum~     and peripheral blood mononuclear cells) and appropriate lineage control tissue will be~     collected.~   "|||2018-06-01 01:01:53.963457|2018-06-01 01:01:53.963457
NCT00889967|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27||2017-01-23|2017-01-23|2009-04-28|2009-04-29|Estimate||||2017-01-23|2017-01-25|Estimate|2017-01-23|2017-01-25|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||"Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis ORBIT-1"|An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin for Inhalation Compared With Placebo for Inhalation in the Management of Pseudomonas Aeruginosa in Patients With Non Cystic Fibrosis Bronchiectasis|Completed||Phase 2|95|Actual|Aradigm Corporation||3|||f||||f||||||||||2018-06-01 01:01:54.075032|2018-06-01 01:01:54.075032
NCT00889954|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2018-04-09|2009-04-28|2009-04-29|Estimate|||||||2018-04-09|2018-04-11|Actual|May 2009||2009-05-31|April 2018|2018-04-30|June 2030|Anticipated|2030-06-30|July 2015|Actual|2015-07-31||Interventional|HERCREEM||Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy|Administration of Her2 Chimeric Receptor and TGFbeta Dominant Negative Receptor (DNR) Expressing EBV Specific Lymphocytes for Subjects With Advanced Her2 Positive Malignancy (HERCREEM)|Active, not recruiting||Phase 1|20|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-06-01 01:01:54.355473|2018-06-01 01:01:54.355473
NCT00889941|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|May 2004||2004-05-31|April 2009|2009-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK|Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK|Completed||Phase 4|51|Actual|Stanford University||3|||f||||t||||||||||2018-06-01 01:01:54.531596|2018-06-01 01:01:54.531596
NCT00889928|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2011-11-01||2011-11-01|2009-04-28|2009-04-29|Estimate|2011-11-01|2011-11-24|Estimate||||2011-11-01|2011-11-24|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|November 2010|Actual|2010-11-30||Interventional|NOTES||A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance|A Trial to Evaluate Natural Orifice Transvaginal Endoscopic Cholecystectomy With Laparoscopic Assistance|Completed||N/A|7|Actual|Ethicon Endo-Surgery|No significant limitations. Small sample size limits inference to a larger population, however it did allow to assess whether the procedure was feasible.|1|||f||||f||||||||||2018-06-01 01:01:54.655982|2018-06-01 01:01:54.655982
NCT00889915|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|2013-01-22||2013-07-30|2009-04-27|2009-04-29|Estimate|2013-07-30|2013-09-30|Estimate||||2013-07-30|2013-09-30|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)|A Randomized Controlled Trial of Methylphenidate Transdermal System (Daytrana), Lisdexamfetamine Dimesylate (Vyvanse), OROS MPH (Concerta), and Mixed Amphetamine Salts Extended Release (Adderall XR) in Children and Adolescents With ADHD|Completed||Phase 4|228|Actual|Duke University||4|||f||||t||||||||||2018-06-01 01:01:55.084547|2018-06-01 01:01:55.084547
NCT00889902|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-04-27|2009-04-27|2009-04-29|Estimate|||||||2009-04-27|2009-04-29|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|July 2011|Anticipated|2011-07-31|June 2010|Anticipated|2010-06-30||Observational|||Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis|Molecular Markers in Cervical Cancer Screening in the Feasibility of the Mathematical Markov Model Analysis|Unknown status|Not yet recruiting||200|Anticipated|Wuhan University|||||f||||t||||||Samples With DNA|"~     Cervical exfoliated cells~   "|||2018-06-01 01:01:55.686301|2018-06-01 01:01:55.686301
NCT00889889|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28||2012-01-24|2013-09-27|2009-04-28|2009-04-29|Estimate||||2012-01-24|2012-01-30|Estimate|2013-09-27|2013-10-25|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Cell-Derived Trivalent Subunit Influenza Vaccine in Subjects Aged >= 18 Years and <= 64 Years During Two Consecutive Years.|Completed||Phase 2|1270|Actual|Abbott||2|||f||||f||||||||||2018-06-01 01:01:55.779532|2018-06-01 01:01:55.779532
NCT00889876|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-02-03|2009-04-27|2009-04-29|Estimate|||||||2011-02-03|2011-02-04|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effect of Exercise or Metformin on Nocturnal Blood Pressure and Other Risk Factors for CVD Among Obese Adolescents|Effect of Exercise or Metformin on Nocturnal Blood Pressure and Other Risk Factors for Cardiovascular Disease (CVD) Among Obese Adolescents|Unknown status|Recruiting|N/A|100|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 01:01:55.909289|2018-06-01 01:01:55.909289
NCT00889863|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2012-09-12||2012-09-13|2009-04-28|2009-04-29|Estimate|2012-09-13|2012-10-16|Estimate||||2012-09-13|2012-10-16|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|β-SPECIFIC 2||Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|A Randomized, Double-blind, Placebo Controlled, Withdrawal Study of Flare Prevention of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations|Completed||Phase 3|177|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:01:56.082966|2018-06-01 01:01:56.082966
NCT00889850|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-06-22|2009-04-28|2009-04-29|Estimate|||||||2009-06-22|2009-06-23|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted and Fed Administration|Open, Randomised, Single-Dose, 2x2-Way Cross-Over Comparative Oral Bioavailability Study in Healthy Adult Male Subjects Under Fasted Conditions (Block I) and Under Fed Conditions (Block II); Comparison of 40 mg Esomeprazole Mepha Capsules (Test) With 40 mg Esomeprazole INexium MUPS Tablets (Reference)|Completed||Phase 1|100|Actual|Mepha Ltd.||4|||f||||f||||||||||2018-06-01 01:01:57.00455|2018-06-01 01:01:57.00455
NCT00889837|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-03-13|2009-04-28|2009-04-29|Estimate|||||||2017-03-13|2017-03-14|Actual|June 2009||2009-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Staccato Loxapine Pulmonary Safety in Patients With COPD|Pulmonary Safety of Staccato® Loxapine for Inhalation in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 1|53|Actual|Alexza Pharmaceuticals, Inc.||2|||f||||f|t|f|||t|||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 01:01:57.137399|2018-06-01 01:01:57.137399
NCT00889824|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|2013-06-12||2016-01-13|2009-04-28|2009-04-29|Estimate|2016-01-13|2016-02-15|Estimate||||2016-01-13|2016-02-15|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability|Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability|Completed||Phase 1|5|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 01:01:57.267447|2018-06-01 01:01:57.267447
NCT00889811|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-10-07|2009-04-28|2009-04-29|Estimate|||||||2009-10-07|2009-10-08|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Remote Preconditioning in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery|Effect of Lower Limb Remote Preconditioning on Myocardial Injury in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery|Completed||Phase 1|68|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 01:01:57.472615|2018-06-01 01:01:57.472615
NCT00889798|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2017-08-22|2009-04-28|2009-04-29|Estimate|||||||2017-08-22|2017-08-24|Actual|April 2009||2009-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|TLN-Registry||Tumor Registry of Lymphatic Neoplasia|Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin`s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.|Active, not recruiting|||3750|Anticipated|iOMEDICO AG|||||f||||f||||||||No||2018-06-01 01:01:57.577508|2018-06-01 01:01:57.577508
NCT00889785|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2013-12-16|2009-04-28|2009-04-29|Estimate|||||||2013-12-16|2013-12-18|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Situational Problem Solving in Adolescents With Type 2 Diabetes: Enhancing a Randomized Controlled Trial (RCT)|Situational Problem Solving in Adolescents With Type 2 Diabetes: Enhancing an RCT|Completed||N/A|43|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:01:57.694919|2018-06-01 01:01:57.694919
NCT00889772|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2015-09-22|2009-04-28|2009-04-29|Estimate|||||||2015-09-22|2015-09-24|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|USCTG-LIPS1||Lung Injury Prediction Study|Identifying Patients at Risk of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) at the Time of Hospital Admission: External Validation of a Lung Injury Prediction Score (LIPS)|Completed|||300|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 01:01:57.924087|2018-06-01 01:01:57.924087
NCT00889759|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-09-22|2009-04-28|2009-04-29|Estimate|||||||2009-09-22|2009-09-23|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Observational|||The Role of High Resolution-Computed Tomography (CT) in Tuberculosis (TB) Outbreak Investigation|The Role of Addition of High Resolution-CT in Outbreak Investigation of Tuberculosis|Completed|||92|Actual|Armed Forces Capital Hospital, Republic of Korea|||||f||||f||||||||||2018-06-01 01:01:58.046305|2018-06-01 01:01:58.046305
NCT00889746|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-05-05|2009-04-28|2009-04-29|Estimate|||||||2009-05-05|2009-05-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:01:58.146213|2018-06-01 01:01:58.146213
NCT00889733|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-10-06|2009-04-28|2009-04-29|Estimate|||||||2011-10-06|2011-10-07|Estimate|February 2007||2007-02-28|October 2011|2011-10-31||||July 2009|Actual|2009-07-31||Interventional|OVHM-01||Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer|A Phase I/II Trial of Intraperitoneal (IP) Cisplatin Combined With IV Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Their Initial Surgery Performed Following Neoadjuvant Intravenous Chemotherapy|Terminated||Phase 1/Phase 2|20|Anticipated|University Health Network, Toronto||||Poor recruitment|f||||t||||||||||2018-06-01 01:01:58.200842|2018-06-01 01:01:58.200842
NCT00889564|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-08-07|2009-04-28|2009-04-29|Estimate|||||||2017-08-07|2017-08-08|Actual|March 2006||2006-03-31|August 2017|2017-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||HeRO Vascular Access Device Bacteremia Study|HeRO Vascular Access Device Bacteremia Study|Completed||N/A|38|Actual|Merit Medical Systems, Inc.|||||f||||t||||||||||2018-06-01 01:02:01.269272|2018-06-01 01:02:01.269272
NCT00889720|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2011-07-27||2011-10-12|2009-04-28|2009-04-29|Estimate|2011-07-27|2011-08-25|Estimate||||2011-10-12|2011-10-17|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery|A Multicenter, Open Label Study To Investigate The Feasibility And Efficacy Of A Smoking Cessation Program With Varenicline In Patients Undergoing Elective Surgery|Completed||Phase 4|16|Actual|Pfizer|This study was terminated after 16 of 100 planned subjects were enrolled due to slow recruitment and non-compliance with the protocol; only selected efficacy listings of the surgical population and key safety data were reported.|1|||f||||f||||||||||2018-06-01 01:01:58.318285|2018-06-01 01:01:58.318285
NCT00889707|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|2013-05-28||2013-08-19|2009-04-28|2009-04-29|Estimate|2013-08-19|2013-10-28|Estimate||||2013-08-19|2013-10-28|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|TRIUMPH-1|All randomized patients who received study drug.|Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia|A Randomized, Double-blind, Placebo-controlled Phase II Study of Transperineal Intraprostatic Injection of PRX302 for the Treatment of Benign Prostatic Hyperplasia|Completed||Phase 2|92|Actual|Sophiris Bio Corp||2|||f||||f||||||||||2018-06-01 01:01:58.95923|2018-06-01 01:01:58.95923
NCT00889694|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-04-27|2009-04-27|2009-04-29|Estimate|||||||2009-04-27|2009-04-29|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Interventional|||Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis|Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis: a 12-Week, Multiple Centers, Randomized Double-Blind, Positive Drug and Placebo Controlled Clinical Trial|Unknown status|Enrolling by invitation|Phase 2/Phase 3|80|Anticipated|Sun Yat-sen University|||||f||||t||||||||||2018-06-01 01:01:59.422436|2018-06-01 01:01:59.422436
NCT00889681|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2014-02-03||2014-03-26|2009-04-28|2009-04-29|Estimate|2014-03-26|2014-04-25|Estimate||||2014-03-26|2014-04-25|Estimate|March 2009||2009-03-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CAP-AF|All enrolled subjects|Continued Access Protocol|CAP-AF: Continued Access Protocol for the Evaluation of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation|Completed||N/A|81|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||t||||||||||2018-06-01 01:01:59.522044|2018-06-01 01:01:59.522044
NCT00889668|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2012-04-29|2009-04-28|2009-04-29|Estimate|||||||2012-04-29|2012-05-01|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|CR-01-001||Evaluation of the Performance and Use of Non-Invasive Glucose Monitoring Device|Evaluation of the Performance and Use of GlucoTrack Model DF-F Non-Invasive Glucose Monitoring Device.|Unknown status|Recruiting|Phase 1/Phase 2|180|Anticipated|Integrity Applications Ltd.||1|||f||||t||||||||||2018-06-01 01:01:59.872967|2018-06-01 01:01:59.872967
NCT00889655|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely|A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of MiraLAX (PEG 3350) vs Golytely as Bowel Preparation for Screening Colonoscopy|Unknown status|Not yet recruiting|Phase 4|432|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 01:01:59.992987|2018-06-01 01:01:59.992987
NCT00889642|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-06-22|2009-04-28|2009-04-29|Estimate|||||||2009-06-22|2009-06-23|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers|A Multicenter Double-Blind Randomized Placebo Controlled Two-Arm Study Evaluating the Safety and Efficacy of the Iontophoretic Administration of Lidocaine and Epinephrine Using Lidocaine Iontophoretic Drug Delivery System (IDDS) to Provide Local Anesthesia for Venipuncture in Healthy Adult Volunteer Subjects|Completed||Phase 2|90|Anticipated|Dharma Therapeutics Inc.||2|||f||||f||||||||||2018-06-01 01:02:00.110689|2018-06-01 01:02:00.110689
NCT00889629|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|November 2008||2008-11-30|April 2009|2009-04-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients|Pilot Study: Effects of Hectorol (Doxercalciferol) Vitamin D Replacement on Proteinuria, PTH Level and Bone Turnover in Stable Kidney Transplant Recipients: a Single-Blind, Placebo-Controlled Study in Patients Receiving 25-OH Vitamin D3|Unknown status|Recruiting|Phase 4|60|Anticipated|State University of New York - Downstate Medical Center||2|||f||||f||||||||||2018-06-01 01:02:00.226115|2018-06-01 01:02:00.226115
NCT00889616|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2018-05-23|2009-04-28|2009-04-29|Estimate|||||||2018-05-23|2018-05-24|Actual|April 23, 2009||2009-04-23|July 18, 2012|2012-07-18|July 18, 2012|Actual|2012-07-18|||||Interventional|||Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali|Phase 1 Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and in Bancoumana, Mali|Completed||Phase 1|154|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:02:00.365305|2018-06-01 01:02:00.365305
NCT00889603|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|2011-01-26||2011-03-04|2009-04-28|2009-04-29|Estimate|2011-03-04|2011-03-31|Estimate||||2011-03-04|2011-03-31|Estimate|May 2009||2009-05-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Non-Interventional Study With Aricept® Evess|Non-Interventional Study With Aricept® Evess In Patients Diagnosed With Mild And Moderate Alzheimer's Disease Or Vascular Dementia|Completed|||370|Actual|Pfizer|FAQ Change from baseline not analyzed, a note to file was issued stating it was removed from protocol but erroneously remained in statistical analysis section. Patient Domain of Benefit, Week 24 LOCF not analyzed; endpoint only collected at Week 24.||1||f||||t||||||||||2018-06-01 01:02:00.464753|2018-06-01 01:02:00.464753
NCT00889590|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2016-01-25|2009-04-28|2009-04-29|Estimate|||||||2016-01-25|2016-01-26|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|HR-GCT||Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)|Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study|Terminated||Phase 2|15|Actual|Leiden University Medical Center||2||low recruitment with registration denosumab|f||||f||||||||||2018-06-01 01:02:00.929694|2018-06-01 01:02:00.929694
NCT00889577|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2015-05-06|2009-04-28|2009-04-29|Estimate|||||||2015-05-06|2015-05-08|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|March 2010|Actual|2010-03-31||Observational|||Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons|Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons|Completed|||233|Actual|Uniformed Services University of the Health Sciences|||||f||||t||||||Samples With DNA|"~     Blood samples will be obtained~   "|||2018-06-01 01:02:01.172718|2018-06-01 01:02:01.172718
NCT00889538|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2016-12-06|2009-04-28|2009-04-29|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2009||2009-04-30|December 2016|2016-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems|Double-Blind, Placebo-Controlled, Crossover Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems|Completed||N/A|24|Actual|University of Louisville||3|||f||||f||||||||||2018-06-01 01:02:01.448206|2018-06-01 01:02:01.448206
NCT00889525|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|November 2007||2007-11-30|April 2009|2009-04-30||||||||Interventional|||Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor|Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor|Completed||Phase 3|||Seth Gordhandas Sunderdas Medical College||1|||f||||||||||||||2018-06-01 01:02:01.615311|2018-06-01 01:02:01.615311
NCT00889512|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|2014-01-08||2017-10-24|2009-04-28|2009-04-29|Estimate|2014-10-22|2014-10-23|Estimate||||2017-10-24|2017-11-30|Actual|April 2009|Actual|2009-04-30|October 2017|2017-10-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||The Luveris In Vitro Fertilization Trial|The Luveris® In Vitro Fertilization Trial: The Effect of Recombinant Luteinizing Hormone on Follicular Response, Oocyte Quality, and Pregnancy in In-Vitro Fertilization Treatment Cycles in Women Without Endogenous LH Activity.|Terminated||Phase 4|14|Actual|University Reproductive Associates|Early termination leading to small numbers of subjects analyzed;|2||Drug no longer available by manufacturer|f||||f||||||||||2018-06-01 01:02:01.760596|2018-06-01 01:02:01.760596
NCT00889499|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2011-03-23|2009-04-28|2009-04-29|Estimate|||||||2011-03-23|2011-03-24|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron|Modulation of Central Hypersensitivity in Chronic Musculoskeletal Pain by Intravenous Tropisetron|Completed||Phase 2|30|Actual|University Hospital Inselspital, Berne||3|||f||||f||||||||||2018-06-01 01:02:02.166828|2018-06-01 01:02:02.166828
NCT00889486|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28||2012-12-05|2012-12-07|2009-04-28|2009-04-29|Estimate||||2012-12-05|2012-12-07|Estimate|2012-12-07|2012-12-11|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus|Completed||Phase 2|92|Actual|Tranzyme, Inc.||4|||f||||f||||||||||2018-06-01 01:02:02.300142|2018-06-01 01:02:02.300142
NCT00889473|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27||2017-09-11|2017-09-15|2009-04-28|2009-04-29|Estimate||||2017-09-15|2017-09-20|Actual|2017-09-15|2017-09-20|Actual|April 2009|Actual|2009-04-30|September 2017|2017-09-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease|A Phase IIb, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge|Completed||Phase 2|42|Actual|Innovate Biopharmaceuticals||2|||f||||f|t|f||||||No||2018-06-01 01:02:02.473368|2018-06-01 01:02:02.473368
NCT00889460|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-28|||2009-04-28|2009-04-28|2009-04-29|Estimate|||||||2009-04-28|2009-04-29|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Tolerability Study of rBet v1 SLIT Tablets|Phase I Study to re-Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Multi Dose Regimens to Subjects Sensitised to Birch Pollen|Completed||Phase 1|55|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-06-01 01:02:02.610219|2018-06-01 01:02:02.610219
NCT00889447|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2018-03-08|2009-04-28|2009-04-29|Estimate|||||||2018-03-08|2018-03-12|Actual|January 2008|Actual|2008-01-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Screening Evaluation for Studies of Chronic Obstructive Pulmonary Disease (COPD)|Screening Evaluation for Studies of COPD|Completed|||670|Actual|Johns Hopkins University|||||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-06-01 01:02:02.746656|2018-06-01 01:02:02.746656
NCT00889434|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2017-11-29|2009-04-27|2009-04-28|Estimate|||||||2017-11-29|2017-11-30|Actual|November 1, 2011|Actual|2011-11-01|February 2017|2017-02-28|April 16, 2015|Actual|2015-04-16|April 16, 2015|Actual|2015-04-16||Interventional|||Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)|Single-site, Open-label, Dose-ranging, Efficacy, and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated CF|Completed||N/A|7|Actual|Hadassah Medical Organization||3|||f||||f||||||||No||2018-06-01 01:02:02.882522|2018-06-01 01:02:02.882522
NCT00889421|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2014-06-06||2014-06-06|2009-04-24|2009-04-28|Estimate|2014-06-06|2014-07-08|Estimate||||2014-06-06|2014-07-08|Estimate|November 2009||2009-11-30|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||patients with refractory uveitis|Apremilast in the Treatment of Uveitis|An Open-label Trial to Assess the Efficacy and Safety of Apremilast in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression.|Terminated||Phase 1/Phase 2|3|Actual|Oregon Health and Science University|Study was terminated prematurely due to inefficacy in the three initial patients enrolled. Endpoints were not analyzed as participants did not make it to the 6 month time frame before discontinuing the study.|1||Investigator discretion due to lack of efficacy in three subjects enrolled|f||||||||||||||2018-06-01 01:02:03.006171|2018-06-01 01:02:03.006171
NCT00889408|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2017-11-29|2009-04-26|2009-04-28|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2, 2013|Actual|2013-12-02|November 2017|2017-11-30|July 21, 2014|Actual|2014-07-21|July 21, 2014|Actual|2014-07-21||Interventional|||DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma|A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma|Completed||Phase 1|25|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 01:02:03.339171|2018-06-01 01:02:03.339171
NCT00889395|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-05-14|2009-04-27|2009-04-28|Estimate|||||||2009-05-14|2009-05-15|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|June 2011|Anticipated|2011-06-30|April 2011|Anticipated|2011-04-30||Interventional|||Cognitive and Psychosocial Benefits of MISC Training for Ugandan Children|Cognitive and Psychosocial Benefits of Caregiver Training for Ugandan HIV Children|Unknown status|Recruiting|N/A|120|Anticipated|Makerere University||1|||f||||f||||||||||2018-06-01 01:02:03.467188|2018-06-01 01:02:03.467188
NCT00889382|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06||2014-09-22|2014-09-22|2009-04-24|2009-04-28|Estimate||||2014-09-22|2014-10-01|Estimate|2014-09-22|2014-10-01|Estimate|July 2009||2009-07-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)|A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)|Completed||Phase 1/Phase 2|152|Actual|Astellas Pharma Inc||8|||f||||f||||||||||2018-06-01 01:02:03.604784|2018-06-01 01:02:03.604784
NCT00889369|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-02-07|2009-04-27|2009-04-28|Estimate|||||||2012-02-07|2012-02-08|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|June 2012|Anticipated|2012-06-30|February 2012|Anticipated|2012-02-29||Interventional|||Duloxetine for Major Depression in Peri-/Postmenopausal Women|Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life|Unknown status|Recruiting|Phase 4|70|Anticipated|McMaster University||1|||f||||f||||||||||2018-06-01 01:02:03.798468|2018-06-01 01:02:03.798468
NCT00889356|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2009-04-27|2009-04-27|2009-04-28|Estimate|||||||2009-04-27|2009-04-28|Estimate|September 2009||2009-09-30|April 2009|2009-04-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis|Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis)|Unknown status|Not yet recruiting|Phase 3|160|Anticipated|Zodiac Produtos Farmaceuticos S.A.||2|||f||||t||||||||||2018-06-01 01:02:03.951368|2018-06-01 01:02:03.951368
NCT00889343|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2013-03-01|2009-04-27|2009-04-28|Estimate|||||||2013-03-01|2013-03-04|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|FOSCO||Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer|A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma|Terminated||Phase 2|101|Actual|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-06-01 01:02:04.086201|2018-06-01 01:02:04.086201
NCT00889330|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2011-06-24|2010-05-21|2015-02-18|2009-04-27|2009-04-28|Estimate|2011-11-02|2011-12-08|Estimate|2010-06-01|2010-06-03|Estimate|2015-02-18|2015-03-06|Estimate|April 2009||2009-04-30|February 2015|2015-02-28||||May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy Study of a Eye Drop for Eye Allergy||Completed||Phase 3|60|Actual|Vistakon Pharmaceuticals||2|||f||||||||||||||2018-06-01 01:02:04.708056|2018-06-01 01:02:04.708056
NCT00889317|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2013-01-15|2009-04-27|2009-04-28|Estimate|||||||2013-01-15|2013-01-16|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|SPIM||Sensorimotor Maps of Vowel Perception and Production|Les Cartes Sensori-motrices De La Parole : Corrélats Neuroanatomiques Des Systèmes De Perception Et De Production Des Voyelles Du Français|Completed|||54|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-06-01 01:02:05.49195|2018-06-01 01:02:05.49195
NCT00889304|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-07-21|2009-04-27|2009-04-28|Estimate|||||||2011-07-21|2011-07-22|Estimate|July 2007||2007-07-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Observational|Position HTO||Position HTO Multicenter NIS|Study on Quality of Life in Patients With Unicompartmental Arthrosis After High Tibial Osteotomy With the Position HTO(R) System|Completed|||221|Actual|Aesculap AG|||1||f||||f||||||||||2018-06-01 01:02:05.604433|2018-06-01 01:02:05.604433
NCT00889291|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-08-07|2009-04-27|2009-04-28|Estimate|||||||2017-08-07|2017-08-08|Actual|December 2008||2008-12-31|August 2017|2017-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|PPS||HeRO Vascular Access Device Post Market Procedural Survey Protocol|HeRO Vascular Access Device Post Market Procedural Survey Protocol|Completed|||77|Actual|Merit Medical Systems, Inc.|||||f||||f||||||||||2018-06-01 01:02:05.749347|2018-06-01 01:02:05.749347
NCT00889278|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2018-05-18|2009-04-24|2009-04-28|Estimate|||||||2018-05-18|2018-05-22|Actual|February 2008|Actual|2008-02-29|May 2018|2018-05-31|January 5, 2016|Actual|2016-01-05|March 1, 2012|Actual|2012-03-01||Observational|||Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation|Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation|Completed|||30|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||Samples With DNA|"~     10cc Peripheral Blood~   "|||2018-06-01 01:02:05.844037|2018-06-01 01:02:05.844037
NCT00889265|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|2014-05-05||2014-08-06|2009-04-27|2009-04-28|Estimate|2014-07-14|2014-08-07|Estimate||||2014-08-06|2014-08-11|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||CopiOs® Pericardium Membrane for Localized Alveolar Ridge Augmentation|Prospective, Multi-Center Study of CopiOs® Pericardium Membrane With Puros® Cancellous Particulate Allograft for Localized Alveolar Ridge Augmentation|Completed||N/A|51|Actual|Zimmer Biomet||1|||f||||f||||||||||2018-06-01 01:02:05.97418|2018-06-01 01:02:05.97418
NCT00889252|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2010-10-04||2015-02-18|2009-04-27|2009-04-28|Estimate|2010-10-26|2010-11-23|Estimate||||2015-02-18|2015-03-06|Estimate|April 2009||2009-04-30|February 2015|2015-02-28||||July 2009|Actual|2009-07-31||Interventional|||Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers|A Single-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers|Completed||Phase 3|250|Actual|Vistakon Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:02:06.286744|2018-06-01 01:02:06.286744
NCT00889239|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-25|||2015-05-14|2009-04-27|2009-04-28|Estimate|||||||2015-05-14|2015-05-15|Estimate|May 2004||2004-05-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Clinical Performance and Wear Mechanism of Hot-Pressed Ceramic Crowns|Clinical Performance and Wear Mechanism of Hot-Pressed Ceramic Crowns|Completed||N/A|30|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 01:02:06.980785|2018-06-01 01:02:06.980785
NCT00889226|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2013-04-02|2009-04-27|2009-04-28|Estimate|||||||2013-04-02|2013-04-04|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|January 2010|Actual|2010-01-31|May 2009|Actual|2009-05-31||Interventional|ESPRIT||Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia|A Randomized, Open Label, Dose Titration Study to Evaluate the Efficacy and Safety of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia|Completed||Phase 4|161|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-06-01 01:02:07.10174|2018-06-01 01:02:07.10174
NCT00889213|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2014-08-05|2009-04-27|2009-04-28|Estimate|||||||2014-08-05|2014-08-06|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||An Evaluation of a New Technique Utilizing a Biologic Glue and Tissue Patch to Seal the Cut Edge of the Pancreas Following Removal of the Tail of the Pancreas|A Prospective Randomized Comparison of Pancreatic Stump Closure Techniques Utilizing an Autologous Falciform Patch and Fibrin Glue Compared to Standard Closure Following Distal Pancreatectomy With or Without Splenectomy|Unknown status|Recruiting|N/A|190|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 01:02:07.223375|2018-06-01 01:02:07.223375
NCT00889200|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2013-08-21||2017-08-08|2009-04-27|2009-04-28|Estimate|2014-11-03|2014-11-04|Estimate||||2017-08-08|2017-09-08|Actual|May 2007||2007-05-31|August 2017|2017-08-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||Eszopiclone Treatment & Cortisol Responsivity|Eszopiclone Treatment & Cortisol Response to HPA Axis Tests|Completed||Phase 4|12|Actual|Butler Hospital||1|||f||||f||||||||||2018-06-01 01:02:07.362333|2018-06-01 01:02:07.362333
NCT00889187|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|2017-04-14||2018-04-12|2009-04-27|2009-04-28|Estimate|2017-06-16|2017-07-14|Actual||||2018-04-12|2018-05-11|Actual|December 2009|Actual|2009-12-31|April 2018|2018-04-30|December 30, 2011|Actual|2011-12-30|December 30, 2011|Actual|2011-12-30||Interventional|||Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer|Phase I/II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer|Terminated||Phase 1/Phase 2|10|Actual|Dana-Farber Cancer Institute|The study did not proceed to phase II due to unexpected intraoperative complications experienced by patients enrolled on phase I.|5||Excess toxicity was identified intraoperatively|f||||t|t|f||||||||2018-06-01 01:02:07.572641|2018-06-01 01:02:07.572641
NCT00889174|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-25|||2018-03-27|2009-04-25|2009-04-28|Estimate|||||||2018-03-27|2018-03-29|Actual|April 24, 2009||2009-04-24|July 24, 2017|2017-07-24||||||||Observational|||The Nosology and Etiology of Leukodystrophies of Unknown Causes|Leukodystrophies of Unknown Cause|Completed|||76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:02:08.956023|2018-06-01 01:02:08.956023
NCT00889161|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2010-06-16|2009-04-24|2009-04-28|Estimate|||||||2010-06-16|2010-06-22|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Curcumin in Pediatric Inflammatory Bowel Disease|Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study|Completed||Phase 1|11|Actual|Seattle Children's Hospital|||||f||||||||||||||2018-06-01 01:02:09.046491|2018-06-01 01:02:09.046491
NCT00889148|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-02-28|2009-04-27|2009-04-28|Estimate|||||||2011-02-28|2011-03-02|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|MOBILE||Morphine COnsumption in Joint Replacement Patients, With and Without GaBapentin Treatment, a RandomIzed ControlLEd Study|Multiple Doses of Gabapentin and Postoperative Morphine Consumption in Primary Hip Arthroplasty|Completed||N/A|103|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 01:02:09.160823|2018-06-01 01:02:09.160823
NCT00889135|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2016-10-14|2009-04-24|2009-04-28|Estimate|||||||2016-10-14|2016-10-18|Estimate|September 2004||2004-09-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Expanded Access|||Long Term Treatment With L-DOPS|Long Term Treatment With L-DOPS|Approved for marketing|||||Vanderbilt University|||||||||||||||||||2018-06-01 01:02:09.307713|2018-06-01 01:02:09.307713
NCT00889122|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-08-03|2009-04-27|2009-04-28|Estimate|||||||2010-08-03|2010-08-04|Estimate|March 2009||2009-03-31|July 2010|2010-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families|Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families|Completed||N/A|213|Actual|Maine Medical Center||1|||f||||f||||||||||2018-06-01 01:02:09.403625|2018-06-01 01:02:09.403625
NCT00889109|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2009-04-27|2009-04-27|2009-04-28|Estimate|||||||2009-04-27|2009-04-28|Estimate|July 2009||2009-07-31|April 2009|2009-04-30||||December 2009|Anticipated|2009-12-31||Observational|||Shoulder Proprioception Following Open and Arthroscopic Instability Repair|Proprioception of the Glenohumeral Joint Following Open and Arthroscopic Repair for Anterior Shoulder Instability|Unknown status|Not yet recruiting||45|Anticipated|Sheba Medical Center|||3||f||||t||||||||||2018-06-01 01:02:09.49857|2018-06-01 01:02:09.49857
NCT00889096|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2015-06-26|2009-04-27|2009-04-28|Estimate|||||||2015-06-26|2015-06-29|Estimate||||April 2009|2009-04-30||||||||Interventional|||Effects of Propranolol on the Encoding and Retrieval of Emotional Material After Single Dose Administration in Healthy Young Subjects|Effects of Propranolol on the Encoding and Retrieval of Emotional Material After Single Dose Administration in Healthy Young Subjects|Completed||Phase 1|46|Anticipated|University Medicine Greifswald||2|||f||||f||||||||||2018-06-01 01:02:09.719699|2018-06-01 01:02:09.719699
NCT00889083|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2011-06-30|2009-04-27|2009-04-28|Estimate|||||||2011-06-30|2011-07-04|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Observational|||Hepatic Mitochondrial Function in Sepsis|Evaluation of Hepatic Mitochondrial Function in Sepsis|Unknown status|Recruiting||60|Anticipated|Institut d'Anesthesiologie des Alpes Maritimes|||2||f||||f||||||Samples With DNA|"~     Liver biopsies~   "|||2018-06-01 01:02:09.851122|2018-06-01 01:02:09.851122
NCT00889070|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2009-08-06|2009-04-24|2009-04-28|Estimate|||||||2009-08-06|2009-08-07|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Respiratory Events Among Premature Infants|Respiratory Events Among Premature Infants (32-<36 w/GA) - Outcomes & Risk Tracking Study (The REPORT Study)|Completed|||50|Anticipated|MedImmune LLC|||1||f||||f||||||||||2018-06-01 01:02:09.970041|2018-06-01 01:02:09.970041
NCT00889057|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2013-03-26|2009-04-27|2009-04-28|Estimate|||||||2013-03-26|2013-03-28|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Sorafenib in Relapsed High Grade Osteosarcoma|Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-grade Osteosarcoma.|Completed||Phase 2|35|Actual|Italian Sarcoma Group||1|||f||||||||||||||2018-06-01 01:02:10.055396|2018-06-01 01:02:10.055396
NCT00889044|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2009-04-26|2009-04-26|2009-04-28|Estimate|||||||2009-04-26|2009-04-28|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI|Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI|Unknown status|Recruiting|Phase 3|30|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 01:02:10.192306|2018-06-01 01:02:10.192306
NCT00889031|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2018-03-15|2009-04-24|2009-04-28|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2009||2009-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Protocol to Obtain Blood Samples for Leukemia Research|Protocol to Obtain Blood Samples for Leukemia Research|Active, not recruiting|||50|Anticipated|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||Samples With DNA|"~     10cc of peripheral blood.~   "|||2018-06-01 01:02:10.313537|2018-06-01 01:02:10.313537
NCT00889018|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-02-07|2009-04-27|2009-04-28|Estimate|||||||2012-02-07|2012-02-09|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma|Randomized Control Trial Comparing Carboplatin 560mg/m2 With 750mg/m2 for Ocular Salvage in Groups C and D Intraocular Retinoblastoma|Unknown status|Active, not recruiting|N/A|60|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 01:02:10.459434|2018-06-01 01:02:10.459434
NCT00889005|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2012-12-03|2009-04-26|2009-04-28|Estimate|||||||2012-12-03|2012-12-05|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Prevention of Post-traumatic Stress Disorder by Telephone Based Cognitive Behavioral Therapy|Prevention of Post-traumatic Stress Disorder by Telephone Based Cognitive Behavioral Therapy|Completed||N/A|200|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:02:10.582861|2018-06-01 01:02:10.582861
NCT00888979|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2015-07-10||2016-11-10|2009-04-27|2009-04-28|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|May 2011|Actual|2011-05-31||Interventional|||Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy|Pilot Study of Nicotine Replacement for Smoking Cessation During Pregnancy|Completed||N/A|10|Actual|Hartford Hospital||1|||f||||f||||||||No||2018-06-01 01:02:10.865536|2018-06-01 01:02:10.865536
NCT00888966|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-25|||2011-06-30|2009-04-25|2009-04-28|Estimate|||||||2011-06-30|2011-07-04|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Oxidative Stress and Cardiac Arrest|Evaluation of Oxidative Stress After Out of Hospital Cardiac Arrest Treated With Moderate Hypothermia|Completed|||40|Anticipated|Institut d'Anesthesiologie des Alpes Maritimes|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:02:11.147344|2018-06-01 01:02:11.147344
NCT00888953|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2013-06-12|2009-04-27|2009-04-28|Estimate|||||||2013-06-12|2013-06-13|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|EMERCOIR||Nursing Homes Study of Fall Risk Assessment Oriented to Intervention|Estudio de Medida Del Riesgo de Caídas Orientada a la Intervención en Residencias|Completed||N/A|331|Actual|Fundacio Salut i Envelliment UAB||2|||f||||f||||||||||2018-06-01 01:02:11.235316|2018-06-01 01:02:11.235316
NCT00888940|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|2010-12-14||2015-07-21|2009-04-26|2009-04-28|Estimate|2010-12-14|2011-01-17|Estimate||||2015-07-21|2015-08-10|Estimate|June 2009||2009-06-30|July 2015|2015-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|CONSERV-2||Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery|CONSERV - 2 (Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) - A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding|Completed||Phase 2|243|Actual|Cubist Pharmaceuticals LLC||2|||f||||t||||||||||2018-06-01 01:02:11.383325|2018-06-01 01:02:11.383325
NCT00888927|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27||2013-08-26|2016-06-14|2009-04-27|2009-04-28|Estimate||||2013-08-26|2013-09-02|Estimate|2016-06-14|2016-06-16|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma|Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects With Previously Treated Peripheral T-Cell Lymphoma|Completed||Phase 1/Phase 2|42|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-06-01 01:02:12.280973|2018-06-01 01:02:12.280973
NCT00888914|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24||2010-09-23|2013-10-25|2009-04-27|2009-04-28|Estimate||||2010-09-23|2010-09-28|Estimate|2013-10-25|2013-11-19|Estimate|November 2008||2008-11-30|October 2013|2013-10-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, to Treat Moderate to Severe Lateral Canthal Lines in Adults.|Completed||Phase 2|60|Actual|Revance Therapeutics, Inc.||5|||f||||f||||||||||2018-06-01 01:02:12.425447|2018-06-01 01:02:12.425447
NCT00888901|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-04-19|2009-04-27|2009-04-28|Estimate|||||||2012-04-19|2012-04-20|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|PLATEFUN||Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag|Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag.|Completed||Phase 4|30|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-06-01 01:02:12.572967|2018-06-01 01:02:12.572967
NCT00888888|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-10-29|2009-04-27|2009-04-28|Estimate|||||||2012-10-29|2012-10-31|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Colonic Resections in Patients With Suspected Appendicitis|Risk Factors for Colonic Resections in Patients With Suspected Acute Appendicitis|Completed|||87|Actual|Cirujanos la Serena|||1||f||||f||||||||||2018-06-01 01:02:12.70909|2018-06-01 01:02:12.70909
NCT00888875|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2014-03-11|2009-04-27|2009-04-28|Estimate|||||||2014-03-11|2014-03-12|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||ILMA Fastrach Versus I-gel for Fiberoptic Tracheal Intubation|Is Fiberoptic Intubation Through the I-gel™ Equal to Fiberoptic Intubation Through the Intubating Laryngeal Mask (Fastrach)™ ?|Completed||N/A|240|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 01:02:12.816262|2018-06-01 01:02:12.816262
NCT00888862|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2012-02-07|2009-04-27|2009-04-28|Estimate|||||||2012-02-07|2012-02-08|Estimate|June 2009||2009-06-30|April 2009|2009-04-30|October 2012|Anticipated|2012-10-31|June 2012|Anticipated|2012-06-30||Interventional|DVS||Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women|Desvenlafaxine Succinate in Major Depressive Disorder: Effects on Structural and Functional Imaging, Cognition, and Functional Outcomes in Midlife Women and Men|Unknown status|Recruiting|Phase 3|90|Anticipated|McMaster University||1|||f||||f||||||||||2018-06-01 01:02:12.921423|2018-06-01 01:02:12.921423
NCT00888849|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2011-10-18||2011-11-30|2009-04-27|2009-04-28|Estimate|2011-10-18|2011-11-24|Estimate||||2011-11-30|2011-12-05|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|Tiger||An Open-label, Randomized, Prospective Study of the Effectiveness, Safety, and Clinical Outcomes of Stapled Anastomoses Versus Hand-Sutured Anastomoses in Patients Undergoing Gastrointestinal End to End or Side to Side Anastomoses|An Open-label, Randomized, Prospective Study of the Effectiveness, Safety, and Clinical Outcomes of Stapled Anastomoses Versus Hand-Sutured Anastomoses in Patients Undergoing Gastrointestinal End to End or Side to Side Anastomoses|Completed||N/A|280|Actual|Ethicon Endo-Surgery||2|||f||||||||||||||2018-06-01 01:02:13.135023|2018-06-01 01:02:13.135023
NCT00888836|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2014-07-28|2009-04-27|2009-04-28|Estimate|||||||2014-07-28|2014-07-29|Estimate|April 2009||2009-04-30|July 2014|2014-07-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|DIBASY||Diet and Medical Therapy Versus Bariatric Surgery in Type 2 Diabetes|Prospective Randomized Controlled Trial on the Effect of Gastric Bypass and Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI > 35 vs. Medical Therapy|Completed||Phase 2/Phase 3|60|Actual|Catholic University of the Sacred Heart||3|||f||||f||||||||||2018-06-01 01:02:13.596323|2018-06-01 01:02:13.596323
NCT00888823|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2016-03-14|2009-04-27|2009-04-28|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Phase I/II Study of Fractionated Stereotactic Radiotherapy for Early Stage Non-Small Cell Lung Cancer|Multicentre, Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Early Stage Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|13|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 01:02:13.746483|2018-06-01 01:02:13.746483
NCT00888810|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-04-27|2009-04-27|2009-04-28|Estimate|||||||2009-04-27|2009-04-28|Estimate|March 2008||2008-03-31|April 2009|2009-04-30||||||||Interventional|TOPO-LAPA||Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer|A Phase II Study Evaluating the Association of Topotecan and Lapatinib in Early Recurrent (Less Than 12 Months)Ovarian or Peritoneal Cancer Patients After First Line of Platinum-Based Chemotherapy|Terminated||Phase 2|39|Actual|Centre Francois Baclesse||||lack of efficacy (intermediate analysis)|f||||t||||||||||2018-06-01 01:02:13.932613|2018-06-01 01:02:13.932613
NCT00888797|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-26|||2011-07-10|2009-04-27|2009-04-28|Estimate|||||||2011-07-10|2011-07-12|Estimate|January 2010||2010-01-31|July 2011|2011-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence|Perioperative β-adrenergic Blocker and a COX2 Inhibitor in Patients Undergoing Resection for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Postoperative Immune Perturbations. A Multicenter Randomized Prospective Trial.|Unknown status|Recruiting|Phase 3|400|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 01:02:14.09585|2018-06-01 01:02:14.09585
NCT00888784|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-04-27|2009-04-27|2009-04-28|Estimate|||||||2009-04-27|2009-04-28|Estimate|August 2006||2006-08-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Secondary Prophylaxis Gastric Variceal Bleed|Endoscopic Cyanoacrylate Injection Versus Beta-Blockers for Secondary Prophylaxis of Gastric Variceal Bleed|Completed||N/A|64|Actual|Govind Ballabh Pant Hospital||2|||f||||f||||||||||2018-06-01 01:02:14.262157|2018-06-01 01:02:14.262157
NCT00888771|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2016-02-11|2009-04-27|2009-04-28|Estimate|||||||2016-02-11|2016-02-12|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Observational|DISCARD||Discard:Characterisation of Colonic Polyps in Vivo|Characterisation of Small Colonic Polyps in Vivo|Completed|||130|Actual|Imperial College London|||4||f||||f||||||||||2018-06-01 01:02:14.37722|2018-06-01 01:02:14.37722
NCT00888758|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2009-04-30|2009-04-27|2009-04-28|Estimate|||||||2009-04-30|2009-05-01|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|May 2011|Anticipated|2011-05-31|January 2011|Anticipated|2011-01-31||Interventional|ROBUST||Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction|Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up.|Unknown status|Not yet recruiting|Phase 4|400|Anticipated|Masaryk University||2|||f||||t||||||||||2018-06-01 01:02:14.486422|2018-06-01 01:02:14.486422
NCT00888745|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-11-29|2009-04-27|2009-04-28|Estimate|||||||2010-11-29|2010-12-01|Estimate|May 2009||2009-05-31|November 2010|2010-11-30||||June 2010|Actual|2010-06-30||Interventional|||A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis|Completed||Phase 1|65|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 01:02:14.637385|2018-06-01 01:02:14.637385
NCT00888732|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2011-04-27|2009-04-27|2009-04-28|Estimate|||||||2011-04-27|2011-04-28|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin|A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin in Patients With Type 1 Diabetes, A Randomised, Quadruple Crossover Trial|Completed||Phase 3|24|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 01:02:14.78485|2018-06-01 01:02:14.78485
NCT00888719|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2010-11-03|2009-04-27|2009-04-28|Estimate|||||||2010-11-03|2010-11-05|Estimate|February 2009||2009-02-28|November 2010|2010-11-30|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Therapeutic Exploratory Study of CWP-0403|A Prospective, Randomized, Double Blinded, Multicenter and Therapeutic Exploratory Study to Comparatively Assess Efficacy and Safety of CWP-0403 in Type 2 Diabetes Patients Who Are Insufficiently Controlled by Diet and Exercise.|Completed||Phase 2|145|Actual|JW Pharmaceutical||3|||f||||f||||||||||2018-06-01 01:02:14.934583|2018-06-01 01:02:14.934583
NCT00888706|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2009-04-27|2009-04-27|2009-04-28|Estimate|||||||2009-04-27|2009-04-28|Estimate|August 2002||2002-08-31|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Activities and Exercise on Sleep in Elderly Persons With Dementia|Effect of Activities and Exercise on Sleep in Dementia|Completed||Phase 2|355|Actual|National Institute of Nursing Research (NINR)||4|||f||||t||||||||||2018-06-01 01:02:15.05732|2018-06-01 01:02:15.05732
NCT00888693|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2017-11-17|2009-04-27|2009-04-28|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2008||2008-11-30|October 2010|2010-10-31||||December 2009|Actual|2009-12-31||Interventional|||A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia||Completed||Phase 1|81|Actual|AbbVie||9|||f||||f||||||||||2018-06-01 01:02:15.240525|2018-06-01 01:02:15.240525
NCT00888680|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-27|||2016-01-12|2009-04-27|2009-04-28|Estimate|||||||2016-01-12|2016-01-13|Estimate||||January 2016|2016-01-31||||||||Interventional|||Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine|A Multinational, Multi-centre, Randomised, Double-blind, Placebo-controlled, 3-way Crossover Study in Migraine Patients, Treated With Two Doses of BGC20-1531 and Placebo|Withdrawn||Phase 2|0|Actual|BTG International Inc.||3||No patients enrolled. Delay due to optimisation of drug product formulation.|f||||f||||||||||2018-06-01 01:02:15.366807|2018-06-01 01:02:15.366807
NCT00888667|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2013-06-07|2009-04-24|2009-04-27|Estimate|||||||2013-06-07|2013-06-10|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Observational|SVT Morphology||Optimal EGM Configuration for Morphology Discrimination|Optimal EGM Configuration for Morphology Discrimination|Terminated|||3|Actual|St. Jude Medical|||1|Patient population was not available|f||||f||||||||||2018-06-01 01:02:15.503064|2018-06-01 01:02:15.503064
NCT00888654|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2015-03-23||2018-03-14|2009-04-24|2009-04-27|Estimate|2015-03-23|2015-03-30|Estimate||||2018-03-14|2018-03-19|Actual|August 2009||2009-08-31|November 2017|2017-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy|Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy|Completed||Phase 2|41|Actual|Barbara Ann Karmanos Cancer Institute|There were no significant limitations.|1|||f||||f||||||||||2018-06-01 01:02:15.59968|2018-06-01 01:02:15.59968
NCT00888641|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2011-06-08|2009-04-24|2009-04-27|Estimate|||||||2011-06-08|2011-06-09|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Pilot Study of Renal Hypothermia During Partial Nephrectomy|A Pilot Study of Renal Hypothermia During Partial Nephrectomy|Completed||Phase 1|13|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:02:15.903803|2018-06-01 01:02:15.903803
NCT00888628|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2015-05-13||2017-10-24|2009-04-24|2009-04-27|Estimate|2016-11-30|2017-01-27|Estimate||||2017-10-24|2017-11-29|Actual|May 2009||2009-05-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients|Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients|Completed||Phase 1/Phase 2|7|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 01:02:16.020495|2018-06-01 01:02:16.020495
NCT00888615|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2017-05-02|2009-04-24|2009-04-27|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2010||2010-12-31|May 2017|2017-05-31||||September 2011|Actual|2011-09-30||Interventional|||Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|58|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 01:02:16.436014|2018-06-01 01:02:16.436014
NCT00888602|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2012-12-19|2009-04-24|2009-04-27|Estimate|||||||2012-12-19|2012-12-20|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study to Evaluate the Effects of Psyllium on Blood Glucose|An Open Label, Randomized, 4-Period Cross-over Study to Evaluate the Effects of Psyllium Taken Before a Meal on Postprandial Blood Glucose in Healthy Males|Completed||N/A|49|Actual|Procter and Gamble||4|||f||||f||||||||||2018-06-01 01:02:16.843739|2018-06-01 01:02:16.843739
NCT00888589|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2014-03-25|2009-04-24|2009-04-27|Estimate|||||||2014-03-25|2014-03-27|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Detection of Aggressive Breast Tumors Using Tc-99m-NC100692|Improved Sensitivity for the Detection of Aggressive Breast Tumors Using 99mTc-NC100692 and a Dual-headed Small Field of View CZT Gamma Camera.|Completed|||40|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 01:02:16.968246|2018-06-01 01:02:16.968246
NCT00888576|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2012-02-07|2009-04-24|2009-04-27|Estimate|||||||2012-02-07|2012-02-08|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan|A Registry Study to Describe the Implications of Therapeutic Management of Etanercept in Patients With Rheumatoid Arthritis|Completed|||441|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:02:17.117752|2018-06-01 01:02:17.117752
NCT00888563|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2018-05-24|2009-04-24|2009-04-27|Estimate|||||||2018-05-24|2018-05-25|Actual|April 23, 2009||2009-04-23|November 16, 2017|2017-11-16|November 16, 2017||2017-11-16|||||Observational|||Fatigue in Healthy Individuals|Fatigue in Healthy Individuals|Completed|||114|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:02:17.261262|2018-06-01 01:02:17.261262
NCT00888550|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2010-09-28|2009-04-24|2009-04-27|Estimate|||||||2010-09-28|2010-09-29|Estimate|August 2007||2007-08-31|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Splinting Versus Not Splinting of the Distal Lower Extremity After Intramedullary Nailing for Tibial Fractures|A Randomized Trial of Post-Operative Outcomes: Splinting Versus Not Splinting of the Distal Lower Extremity After Intramedullary Nailing for Tibial Fractures|Completed||N/A|20|Anticipated|Denver Health and Hospital Authority||2|||f||||||||||||||2018-06-01 01:02:17.366423|2018-06-01 01:02:17.366423
NCT00888537|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2016-03-18|2009-04-24|2009-04-27|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Wiser Choices in Acute Myocardial Infarction|Wiser Choices in Acute Myocardial Infarction|Completed||N/A|107|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:02:17.456195|2018-06-01 01:02:17.456195
NCT00888524|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-04-24|2009-04-24|2009-04-27|Estimate|||||||2009-04-24|2009-04-27|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|+DWR||Plus Deep Water Running on Low Back Pain|Evidence-Based Physiotherapy With and Without Deep Water Running on Non-Specific Low Back Pain. A Randomized Controlled Trial|Completed||N/A|46|Actual|University of Malaga||2|||f||||t||||||||||2018-06-01 01:02:17.563538|2018-06-01 01:02:17.563538
NCT00888511|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2016-05-19|2009-04-24|2009-04-27|Estimate|||||||2016-05-19|2016-05-20|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|TARLAL||Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer|Concomitant Tarceva® and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study|Completed||Phase 2|15|Actual|Odense University Hospital||1|||f||||t||||||||||2018-06-01 01:02:17.70072|2018-06-01 01:02:17.70072
NCT00888498|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2015-07-01|2009-04-24|2009-04-27|Estimate|||||||2015-07-01|2015-07-02|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|AMT||Ankle Manual Therapy for Ankle Sprains|Ankle Manual Therapy for Individuals With Post-Acute Ankle Sprains: A Randomized, Placebo-Controlled Trial|Suspended||Phase 2/Phase 3|189|Anticipated|University of the Pacific||3|||f||||f||||||||||2018-06-01 01:02:17.865131|2018-06-01 01:02:17.865131
NCT00888485|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2009-04-24|2009-04-24|2009-04-27|Estimate|||||||2009-04-24|2009-04-27|Estimate|May 1996||1996-05-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|SUPRIM||Randomized Trial of Behavioral Intervention Versus Standard Treatment|Secondary Prevention in Uppsala Primary Health Care After Myocardial Infarction, Coronary Artery CABG and PCI. Secondary Prevention After CHD (SUPRIM).|Completed||N/A|362|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 01:02:18.051197|2018-06-01 01:02:18.051197
NCT00888472|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2013-02-03|2009-04-24|2009-04-27|Estimate|||||||2013-02-03|2013-02-05|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Refractory Asthma|Safety and Efficacy of High-dose Leukocytapheresis Using a Large Filter in Patients With Refractory Asthma|Completed||N/A|6|Actual|Gunma University||1|||f||||f||||||||||2018-06-01 01:02:18.188104|2018-06-01 01:02:18.188104
NCT00888459|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2010-10-04||2011-07-14|2009-04-24|2009-04-27|Estimate|2010-10-04|2010-11-04|Estimate||||2011-07-14|2011-07-18|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Pilot Study Evaluating Nicotine Lozenges and Self Help|A Pilot Study to Assess the Effectiveness of the Nicotine Lozenge for Smokeless Tobacco Users|Completed||Phase 2|60|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:02:18.298166|2018-06-01 01:02:18.298166
NCT00888446|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-12-13|2009-04-24|2009-04-27|Estimate|||||||2012-12-13|2012-12-17|Estimate|October 2005||2005-10-31|December 2012|2012-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|TGC14F||Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid|Phase II, Placebo-controlled, Double-blind, Dose-escalation/Dose-optimization Trial to Evaluate Safety and Immunogenicity of tgAAC09, an HIV Vaccine Containing Clade C Gag-PR-ΔRT DNA in an Adeno-associated Virus (AAV) Capsid|Completed||Phase 2|91|Actual|International AIDS Vaccine Initiative||8|||f||||t||||||||||2018-06-01 01:02:18.660345|2018-06-01 01:02:18.660345
NCT00888433|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2013-09-13||2015-05-04|2009-04-24|2009-04-27|Estimate|2014-01-10|2014-02-24|Estimate||||2015-05-04|2015-05-20|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|September 2010|Actual|2010-09-30||Interventional|HTN-2||Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)|Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)|Completed||N/A|106|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-06-01 01:02:18.844229|2018-06-01 01:02:18.844229
NCT00888420|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2015-10-19|2009-04-23|2009-04-27|Estimate|||||||2015-10-19|2015-10-21|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||The Application of Performance Improvement Principles to the Patient Throughput Process in an Adult Outpatient Pain Treatment Clinic|The Application of Performance Improvement Principles to the Patient Throughput Process in an Adult Outpatient Pain Treatment Clinic|Completed|||1221|Actual|University of Alabama at Birmingham|||2||f||||||||||||||2018-06-01 01:02:19.450494|2018-06-01 01:02:19.450494
NCT00888407|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-05-24|2009-04-24|2009-04-27|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2006||2006-09-30|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Community-based Hepatitis B Interventions for Hmong Adults|Community-based Hepatitis B Interventions for Hmong Adults|Completed||N/A|1500|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 01:02:19.541754|2018-06-01 01:02:19.541754
NCT00888394|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-07-23|2009-04-24|2009-04-27|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|February 2013|Actual|2013-02-28|May 2010|Actual|2010-05-31||Interventional|EPOPLAPAIN||Effectiveness of Podiatry on Plantar Pain|Clinical Effectiveness of Quiropodiatry and Orthesis on Heel and Plantar Pain: Randomized Control Trial|Completed||Phase 4|312|Actual|University of Malaga||4|||f||||t||||||||||2018-06-01 01:02:19.682146|2018-06-01 01:02:19.682146
NCT00888381|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2012-06-13||2017-10-23|2009-04-24|2009-04-27|Estimate|2012-06-13|2012-07-18|Estimate||||2017-10-23|2017-11-27|Actual|May 2009||2009-05-31|October 2017|2017-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2009/2010 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged ≥ 18 to < 60 Years) and 'Older Adults' (Aged ≥ 60 Years).|Completed||Phase 4|120|Actual|Seqirus||2|||f||||||||||||||2018-06-01 01:02:19.811868|2018-06-01 01:02:19.811868
NCT00888368|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-07-11|2009-04-24|2009-04-27|Estimate|||||||2012-07-11|2012-07-13|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Accuracy of the Transpatellar Tendon Approach to Knee Arthrocentesis||Completed||N/A|20|Actual|Denver Health and Hospital Authority||2|||f||||||||||||||2018-06-01 01:02:20.341301|2018-06-01 01:02:20.341301
NCT00888355|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2009-05-07||2009-07-02|2009-04-24|2009-04-27|Estimate|2009-05-07|2009-06-24|Estimate||||2009-07-02|2009-07-09|Estimate|May 1992||1992-05-31|July 2009|2009-07-31|February 1993|Actual|1993-02-28|January 1993|Actual|1993-01-31||Interventional|||MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension|A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Losartan Given Once or Twice Daily in Patients With Mild to Moderate Hypertension|Completed||Phase 3|428|Actual|Merck Sharp & Dohme Corp.|"Note that deaths are not entered under drop reasons in the participant flow panel because the patients who died are already counted as dropped due to adverse event."|4|||f||||||||||||||2018-06-01 01:02:20.461652|2018-06-01 01:02:20.461652
NCT00888342|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-05-15|2009-04-24|2009-04-27|Estimate|||||||2012-05-15|2012-05-16|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in COPD Patients|A Study of Changes in Blood Gases, Disturbance of Breath During Sleep and Cardiovascular Co-morbidity in Patients With COPD in Different Stages of the Disease, and the Effect of Alcohol, Supplementary Oxygen and Zopiclone on These Changes.|Completed||N/A|150|Actual|LHL Helse||3|||f||||f||||||||||2018-06-01 01:02:21.588233|2018-06-01 01:02:21.588233
NCT00888329|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2012-02-01||2012-03-05|2009-04-24|2009-04-27|Estimate|2012-03-05|2012-03-30|Estimate||||2012-03-05|2012-03-30|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy|Prevention of Postoperative Nausea and Vomiting in a Gynecologic Surgery Population: A Randomized Placebo Controlled Trial of Aprepitant NK-1-receptor Antagonist|Terminated||Phase 4|256|Actual|Mayo Clinic|Results might have been influenced by selection bias.|2||Slow accrual.|f||||f||||||||||2018-06-01 01:02:21.739735|2018-06-01 01:02:21.739735
NCT00888316|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2017-11-29|2009-04-24|2009-04-27|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2008||2008-12-31|November 2017|2017-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Iron Overload in Patients Undergoing Donor Stem Cell Transplant|Iron Overload in Allogeneic Hematopoietic Cell Transplantation|Completed|||112|Actual|Masonic Cancer Center, University of Minnesota|||2||f||||t||||||||||2018-06-01 01:02:22.11472|2018-06-01 01:02:22.11472
NCT00888303|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-09-01|2009-04-24|2009-04-27|Estimate|||||||2012-09-01|2012-09-05|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Single Dose Steroid Before Thyroidectomy for Benign Disease to Improve Postoperative Nausea, Pain, and Vocal Function|Randomized Controlled Trial on Efficacy of Preemptive 8 mg of Dexamethasone for Reducing Pain and Postoperative Nausea and Vomit After Thyroidectomy for Benign Disease.|Unknown status|Recruiting|Phase 2|80|Anticipated|Ospedale Misericordia e Dolce||2|||f||||t||||||||||2018-06-01 01:02:22.267164|2018-06-01 01:02:22.267164
NCT00888290|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2015-02-12|2009-04-24|2009-04-27|Estimate|||||||2015-02-12|2015-02-16|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects|Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects|Completed||Phase 2/Phase 3|20|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||f||||||||||2018-06-01 01:02:22.402136|2018-06-01 01:02:22.402136
NCT00888277|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-10-31|2009-04-24|2009-04-27|Estimate|||||||2013-10-31|2013-11-04|Estimate|May 2009||2009-05-31|October 2013|2013-10-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Observational|||Bayer/Cognitive Assessments With Multiple Sclerosis Subjects|Neuropsychological Assessments in the Multiple Sclerosis Clinic|Completed|||74|Actual|University of Louisville|||||f||||f||||||||||2018-06-01 01:02:22.560355|2018-06-01 01:02:22.560355
NCT00888264|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2010-12-21|2009-04-24|2009-04-27|Estimate|||||||2010-12-21|2010-12-22|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|HARMONY||A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder|A 6 Month Observational Multicentric Prospective Study Observing the Use of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder, in the Course of a Major Depressive Episode|Completed|||152|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:02:22.680817|2018-06-01 01:02:22.680817
NCT00888238|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2010-05-24||2015-04-24|2009-04-24|2009-04-27|Estimate|2010-07-06|2010-08-03|Estimate||||2015-04-24|2015-05-13|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)|A Randomized Clinical Trial to Evaluate Glucose-Dependent Insulinotropic Effects of a Single Dose of a DPP-4 Inhibitor in Lean Healthy Males|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:02:22.923132|2018-06-01 01:02:22.923132
NCT00888225|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2009-04-24|2009-04-24|2009-04-27|Estimate|||||||2009-04-24|2009-04-27|Estimate|October 2003||2003-10-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Interventional|Epi-X||Tennis Elbow Trial|Chronic Lateral Epicondylitis. A Randomized Controlled Clinical Trial of Two Physical Training Concepts With Special Reference to Etiology and Treatment Effect|Completed||N/A|205|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 01:02:23.317916|2018-06-01 01:02:23.317916
NCT00888212|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2009-06-19|2009-04-24|2009-04-27|Estimate|||||||2009-06-19|2009-06-22|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|MITOSIS||Minimally Invasive Techniques Or Surgery In the Diagnosis of Sarcoidosis|Minimally Invasive Techniques Or Surgery In the Diagnosis of Sarcoidosis (MITOSIS-Trial)|Completed||N/A|100|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 01:02:23.414686|2018-06-01 01:02:23.414686
NCT00888199|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2009-04-24|2009-04-24|2009-04-27|Estimate|||||||2009-04-24|2009-04-27|Estimate|January 2010||2010-01-31|April 2009|2009-04-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis|Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis|Unknown status|Not yet recruiting|Phase 2/Phase 3|80|Anticipated|Tensegrity Prosthetics||2|||f||||t||||||||||2018-06-01 01:02:23.523791|2018-06-01 01:02:23.523791
NCT00888186|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2009-04-24|2009-04-24|2009-04-27|Estimate|||||||2009-04-24|2009-04-27|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|DYSK-PD-2007||Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics|Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics|Completed||Phase 4|5|Actual|Uppsala University||5|||f||||t||||||||||2018-06-01 01:02:23.656759|2018-06-01 01:02:23.656759
NCT00888173|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|2016-11-28||2017-11-02|2009-04-24|2009-04-27|Estimate|2017-10-02|2017-11-06|Actual||||2017-11-02|2017-12-06|Actual|July 6, 2009|Actual|2009-07-06|August 2017|2017-08-31|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Interventional|||Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|45|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 01:02:23.805154|2018-06-01 01:02:23.805154
NCT00888160|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2018-05-08|2009-04-24|2009-04-27|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2010|Actual|2010-09-30|March 2017|2017-03-31|January 2031||2031-01-31|October 2017|Actual|2017-10-31||Observational|||Timing of Orthopaedic Surgery in the Multiply-injured Patient: Development of a Protocol for Early Appropriate Care|Timing of Orthopaedic Surgery in the Multiply-injured Patient: Development of a Protocol for Early Appropriate Care|Completed|||360|Actual|MetroHealth Medical Center|||||f||||f||||||||||2018-06-01 01:02:25.264786|2018-06-01 01:02:25.264786
NCT00888147|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-24|||2011-09-23|2009-04-24|2009-04-27|Estimate|||||||2011-09-23|2011-09-26|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Fiber Formula Study Among Radiation Oncology Patients|"Pilot Study: Does Using a Fiber Containing Enteral Tube Feeding Formula Increase Constipation and the Use of Stool Softeners in Patients Undergoing Radiation Therapy and Have a Percutaneous Endoscopic Gastrostomy (PEG) Placed?"|Completed|||19|Actual|Mayo Clinic|||1||f||||t||||||||||2018-06-01 01:02:25.328142|2018-06-01 01:02:25.328142
NCT00888134|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2015-12-10||2015-12-10|2009-04-23|2009-04-27|Estimate|2015-12-10|2016-01-15|Estimate||||2015-12-10|2016-01-15|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Selumetinib in Cancers With BRAF Mutations|Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Cancers With BRAF Mutations Identified by Prospective Genotypic Analysis|Completed||Phase 2|28|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 01:02:25.546125|2018-06-01 01:02:25.546125
NCT00888108|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-05-18|2009-04-23|2009-04-24|Estimate|||||||2012-05-18|2012-05-22|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer|A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Taxotere® (Docetaxel) in the Treatment of Subjects With Solid Tumors|Completed||Phase 1|41|Actual|Abbott||1|||f||||||||||||||2018-06-01 01:02:25.984486|2018-06-01 01:02:25.984486
NCT00888095|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2009-07-21|2009-04-23|2009-04-24|Estimate|||||||2009-07-21|2009-07-22|Estimate|July 2010||2010-07-31|July 2009|2009-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Deep Brain Stimulation (DBS) For Parkinson's Disease: Caudal Zona Incerta Versus Subthalamic Nucleus|The Clinical Effect of Bilateral Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) Versus Bilateral Deep Brain Stimulation of the Caudal Zona Incerta (cZI-DBS) in Patients With Idiopathic Parkinson's Disease|Unknown status|Not yet recruiting|N/A|70|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 01:02:26.107005|2018-06-01 01:02:26.107005
NCT00888082|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2010-12-09|2009-04-23|2009-04-24|Estimate|||||||2010-12-09|2010-12-10|Estimate||||December 2010|2010-12-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|PROOF||Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy|Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study|Withdrawn||Phase 3|102|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:02:26.237768|2018-06-01 01:02:26.237768
NCT00888069|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2014-09-29|2009-04-23|2009-04-24|Estimate|||||||2014-09-29|2014-09-30|Estimate|May 2009||2009-05-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects|A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT|Completed||Phase 1|28|Actual|OPKO Health, Inc.||3|||f||||f||||||||||2018-06-01 01:02:26.358579|2018-06-01 01:02:26.358579
NCT00888056|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-06-26|2009-04-23|2009-04-24|Estimate|||||||2012-06-26|2012-06-27|Estimate|June 2009||2009-06-30|April 2009|2009-04-30||||||||Interventional|||Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease|Effect of Deep Brain Stimulation of the Hypothalamus/ Fornix on Memory Impairment in Patients With Alzheimer's Disease|Unknown status|Recruiting|Phase 1/Phase 2|5|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||t||||||||||2018-06-01 01:02:26.505154|2018-06-01 01:02:26.505154
NCT00888043|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2015-03-10|2009-04-23|2009-04-24|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|CNTO95/Avastin||Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors|A Phase I/Biomarker Study of Bevacizumab in Combination With CNTO 95 in Patients With Refractory Solid Tumors|Completed||Phase 1|13|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:02:26.628776|2018-06-01 01:02:26.628776
NCT00888030|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-09-05|2009-04-23|2009-04-24|Estimate|||||||2012-09-05|2012-09-06|Estimate|May 2006||2006-05-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||P-cresol: Correlation With Glomerular Filtration Rate and Outcome in Chronic Kidney Disease||Completed|||300|Actual|Chang Gung Memorial Hospital|||4||f||||t||||||Samples Without DNA|"~     Serum level of p-cresol and indoxyl sulfate~   "|||2018-06-01 01:02:26.753555|2018-06-01 01:02:26.753555
NCT00888017|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2013-01-22|2009-04-22|2009-04-24|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|PPI||Proton Pump Inhibitor Therapy and Bone Density in Premature Infants|Proton Pump Inhibitor Therapy and Bone Density in Premature Infants|Terminated|||10|Actual|University of Utah|||2|Slow enrollment|f||||f||||||||||2018-06-01 01:02:26.905637|2018-06-01 01:02:26.905637
NCT00888004|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2016-04-15|2009-04-23|2009-04-24|Estimate|||||||2016-04-15|2016-04-19|Estimate|March 2009||2009-03-31|April 2016|2016-04-30||||August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy and Tolerability of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Severe L-dopa Induced Dyskinesias|Completed||Phase 2|28|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:02:27.101301|2018-06-01 01:02:27.101301
NCT00887991|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2009-04-23|2009-04-23|2009-04-24|Estimate|||||||2009-04-23|2009-04-24|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|February 2010|Anticipated|2010-02-28|July 2009|Anticipated|2009-07-31||Observational|||A Trial Comparing Two Breast Pumps in Mothers Expressing Milk for Their Preterm Infants|Randomised Trial Comparing the Efficacy of the ISIS Duo iQ Electric Breast Pump and the Medela Symphony Electric Breast Pump in Mothers Expressing Breast Milk for Preterm Infants|Unknown status|Recruiting||176|Anticipated|Institute of Child Health|||2||f||||||||||||||2018-06-01 01:02:27.245439|2018-06-01 01:02:27.245439
NCT00887978|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2012-11-02||2012-12-07|2009-04-23|2009-04-24|Estimate|2012-12-07|2013-01-15|Estimate||||2012-12-07|2013-01-15|Estimate|June 2009||2009-06-30|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|FREEDOM-C2||Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension|A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 3|310|Actual|United Therapeutics||2|||f||||t||||||||||2018-06-01 01:02:27.425383|2018-06-01 01:02:27.425383
NCT00887965|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2011-06-30||2013-10-23|2009-04-23|2009-04-24|Estimate|2013-08-09|2013-10-17|Estimate||||2013-10-23|2013-11-15|Estimate|June 2009||2009-06-30|October 2013|2013-10-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab|A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab|Completed||Phase 2|15|Actual|Amgen||1|||f||||f||||||||||2018-06-01 01:02:28.674123|2018-06-01 01:02:28.674123
NCT00887952|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-12-29|2009-04-22|2009-04-24|Estimate|||||||2009-12-29|2009-12-30|Estimate|August 2005||2005-08-31|April 2009|2009-04-30|November 2010|Anticipated|2010-11-30|November 2008|Actual|2008-11-30||Interventional|PRCD||Partial Removal of Caries Dentines|Alternative Treatment of Deep Caries Lesions Based on Biological Evidences|Unknown status|Active, not recruiting|N/A|329|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-06-01 01:02:29.100792|2018-06-01 01:02:29.100792
NCT00887939|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2018-03-27|2009-04-23|2009-04-24|Estimate|||||||2018-03-27|2018-03-29|Actual|April 22, 2009||2009-04-22|March 7, 2018|2018-03-07||||||||Observational|||Pathogenesis of Physical Induced Urticarial Syndromes|Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:02:29.29305|2018-06-01 01:02:29.29305
NCT00887926|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-02-24|2009-04-23|2009-04-24|Estimate|||||||2012-02-24|2012-02-28|Estimate|June 2009||2009-06-30|February 2012|2012-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of EB10 in Patients With Leukemia|An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Terminated||Phase 1|26|Actual|ImClone LLC||1||Lack of efficacy|f||||f||||||||||2018-06-01 01:02:29.41457|2018-06-01 01:02:29.41457
NCT00887913|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2010-10-06||2010-11-02|2009-04-23|2009-04-24|Estimate|2010-11-02|2010-11-30|Estimate||||2010-11-02|2010-11-30|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction|Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction|Completed||N/A|69|Actual|Syneron Medical|||||f||||f||||||||||2018-06-01 01:02:29.577635|2018-06-01 01:02:29.577635
NCT00887900|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2009-04-23|2009-04-23|2009-04-24|Estimate|||||||2009-04-23|2009-04-24|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|DALK||Deep Anterior Lamellar Keratoplasty (DALK)|Deep Anterior Lamellar Keratoplasty by Big-Bubble Technique: Results and Complications|Completed||Phase 3|40|Actual|Hospital Oftalmologico de Brasilia||2|||f||||t||||||||||2018-06-01 01:02:29.811986|2018-06-01 01:02:29.811986
NCT00887887|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2014-10-13|2009-04-23|2009-04-24|Estimate|||||||2014-10-13|2014-10-15|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|June 2010|Actual|2010-06-30||Observational|||The Association Between Gene Polymorphisms and Infectious Complications After Liver Surgery|The Association Between Gene Polymorphisms in the Innate Immune Response and the Risk of Infectious Complications and Liver Failure After Partial Hepatic Resection|Completed|||100|Actual|Maastricht University Medical Center|||1||f||||t||||||Samples With DNA|"~     whole blood, fresh frozen liver tissue~   "|||2018-06-01 01:02:29.947429|2018-06-01 01:02:29.947429
NCT00887874|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2016-11-21|2009-04-23|2009-04-24|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan|DiabCare Asia 2008. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia.|Completed|||2370|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Capillary or venous blood will be drawn for analysing HbA1c.~   "|||2018-06-01 01:02:30.073505|2018-06-01 01:02:30.073505
NCT00887861|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-03-17|2009-04-23|2009-04-24|Estimate|||||||2017-03-17|2017-03-21|Actual|March 2009||2009-03-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery|A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Parallel-group Study of BGG492 as Monotherapy in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery|Completed||Phase 2|37|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:02:30.18294|2018-06-01 01:02:30.18294
NCT00887848|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2018-03-28|2009-04-23|2009-04-24|Estimate|||||||2018-03-28|2018-03-30|Actual|October 5, 2009|Actual|2009-10-05|March 2018|2018-03-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|PeLoGAIT||Effectiveness of Robotic Assisted Gait Training in Children With Cerebral Palsy|Effectiveness of Robotic Assisted Gait Training in Children With Cerebral Palsy: A Randomized Controlled Clinical Trial Including 3D Gait Analysis|Terminated||N/A|16|Actual|University Children's Hospital, Zurich||2||Recruitment problems|f||||f||||||||Undecided||2018-06-01 01:02:30.303382|2018-06-01 01:02:30.303382
NCT00887835|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-04-25|2009-04-23|2009-04-24|Estimate|||||||2012-04-25|2012-04-27|Estimate|April 2009||2009-04-30|April 2009|2009-04-30||||October 2010|Anticipated|2010-10-31||Interventional|||A Post-Market Study of Transfacet Lumbar Spine Fixation and Fusion Utilizing the PERPOS™ PLS System|A Post-Market Study of Transfacet Lumbar Spine Fixation and Fusion Utilizing the PERPOS™ PLS System|Withdrawn||N/A|0|Actual|Interventional Spine, Inc.||1|||f||||f||||||||||2018-06-01 01:02:30.429219|2018-06-01 01:02:30.429219
NCT00887822|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2016-10-31||2017-01-10|2009-04-23|2009-04-24|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|March 2009||2009-03-31|January 2017|2017-01-31|August 2014|Actual|2014-08-31|May 2011|Actual|2011-05-31||Interventional|AVATAR|Intent-to-treat (ITT) population included all randomized participants.|A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer|A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.|Completed||Phase 3|202|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:02:30.573293|2018-06-01 01:02:30.573293
NCT00887809|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2015-12-21||2015-12-21|2009-04-23|2009-04-24|Estimate|2015-12-21|2016-01-25|Estimate||||2015-12-21|2016-01-25|Estimate|April 2009||2009-04-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes|Phase II Trial Of Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes|Completed||Phase 2|47|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:02:31.35918|2018-06-01 01:02:31.35918
NCT00887783|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2016-05-19|2009-04-23|2009-04-24|Estimate|||||||2016-05-19|2016-05-20|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|August 2012|Actual|2012-08-31||Interventional|NARLAL||Navelbine And Radiotherapy in Locally Advanced Lung Cancer|Induction Chemotherapy With Carboplatin and Navelbine Oral(R) Followed by Concomitant Navelbine Oral(R) and Irradiation in Local-regionally Advanced Non-small Cell Lung Cancer. A Randomized Phase II Study.|Active, not recruiting||Phase 2|114|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-06-01 01:02:31.731725|2018-06-01 01:02:31.731725
NCT00887770|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2009-07-15|2009-04-23|2009-04-24|Estimate|||||||2009-07-15|2009-07-16|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|||||Interventional|||A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart|A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers|Completed||Phase 1|64|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:02:31.875677|2018-06-01 01:02:31.875677
NCT00887757|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-11-17|2009-04-23|2009-04-24|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2009||2009-09-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors|A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Gemzar® (Gemcitabine) in the Treatment of Subjects With Solid Tumors|Completed||Phase 1|46|Actual|AbbVie||1|||f||||||||||||||2018-06-01 01:02:32.011486|2018-06-01 01:02:32.011486
NCT00887744|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2011-04-11||2016-01-26|2009-04-23|2009-04-24|Estimate|2011-07-20|2011-08-17|Estimate||||2016-01-26|2016-01-28|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|March 2010|Actual|2010-03-31|May 2009|Actual|2009-05-31||Interventional|INCA||Intermittent Neurogenic Claudication Treatment With APERIUS®|A Multicenter, Post Marketing Clinical Follow-up Study to Evaluate the Safety and Effectiveness of the Minimally Invasive Device APERIUS® in Degenerative Lumbar Spinal Stenosis With Symptomatic Neurogenic Intermittent Claudication|Completed||Phase 4|162|Actual|Medtronic Spinal and Biologics||1|||f||||f||||||||||2018-06-01 01:02:32.203635|2018-06-01 01:02:32.203635
NCT00887731|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-09-10|2009-04-23|2009-04-24|Estimate|||||||2013-09-10|2013-09-12|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care|Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care|Terminated|||20|Actual|University of Utah|||3|slow enrollment|f||||f||||||||||2018-06-01 01:02:32.636546|2018-06-01 01:02:32.636546
NCT00887718|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2012-12-17|2009-04-23|2009-04-24|Estimate|||||||2012-12-17|2012-12-18|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Positron Emission Tomography(PET) in Lymphoma Assessment|Positron Emission Tomography for Staging, and Treatment Assessment of Response in Lymphomas (the Pet-star Lymphoma Study)|Completed||N/A|103|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:02:32.76431|2018-06-01 01:02:32.76431
NCT00887705|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2010-06-22|2009-04-23|2009-04-24|Estimate|||||||2010-06-22|2010-06-23|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||ADL- Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Activities of Daily Living (ADL)-Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|24|Actual|LHL Helse||2|||f||||f||||||||||2018-06-01 01:02:32.90957|2018-06-01 01:02:32.90957
NCT00887692|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2010-10-18|2009-04-23|2009-04-24|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Comparison of Set-up Reproducibility Between Prone and Supine Intensity Modulated Radiotherapy (IMRT) for the Adjuvant Treatment of Breast Carcinoma After Lumpectomy|Comparison of Set-up Reproducibility Between Prone and Supine Intensity Modulated Radiotherapy (IMRT) for the Adjuvant Treatment of Breast Carcinoma After Lumpectomy|Completed||N/A|10|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 01:02:33.050105|2018-06-01 01:02:33.050105
NCT00887679|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2012-11-19||2014-10-23|2009-04-23|2009-04-24|Estimate|2014-03-07|2014-03-10|Estimate||||2014-10-23|2014-10-31|Estimate|May 2009||2009-05-31|March 2014|2014-03-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS|Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder, Adherence to Antiretroviral Therapy,Cognition, and Immune Status Among Patients With HIV and AIDS: A 6-week Open-label, Prospective, Pilot Trial.|Completed||Phase 3|30|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:02:33.171878|2018-06-01 01:02:33.171878
NCT00887666|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-04-14|2009-04-23|2009-04-24|Estimate|||||||2017-04-14|2017-04-18|Actual|October 2007||2007-10-31|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure|Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure|Completed|||48|Actual|State University of New York - Downstate Medical Center|||||f||||f||||||||||2018-06-01 01:02:33.447996|2018-06-01 01:02:33.447996
NCT00887653|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2014-09-19||2014-10-08|2009-04-23|2009-04-24|Estimate|2014-10-08|2014-10-10|Estimate||||2014-10-08|2014-10-10|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|June 2012|Actual|2012-06-30||Interventional|||Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy|Changes in Lipid Profiles and Safety of Raltegravir Based Antiretroviral Therapy in HIV-1-infected Patients With Hyperlipidemia While on Current Standard Therapy|Completed||Phase 3|20|Actual|The Miriam Hospital||1|||f||||t||||||||||2018-06-01 01:02:33.561745|2018-06-01 01:02:33.561745
NCT00887640|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2013-09-04||2014-01-24|2009-04-23|2009-04-24|Estimate|2013-11-21|2014-01-10|Estimate||||2014-01-24|2014-02-26|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer|Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer|Terminated||Phase 2|11|Actual|Duke University||1|||f||||t||||||||||2018-06-01 01:02:33.845467|2018-06-01 01:02:33.845467
NCT00887627|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2014-04-30|2009-04-23|2009-04-24|Estimate|||||||2014-04-30|2014-05-02|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function|A Phase 1, Open-Label Study to Assess the Effects of Renal Impairment on the Pharmacokinetics of Intravenous Conivaptan|Completed||Phase 1|25|Actual|Cumberland Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:02:34.209556|2018-06-01 01:02:34.209556
NCT00887614|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2011-10-01|2009-04-23|2009-04-24|Estimate|||||||2011-10-01|2011-10-04|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Mindfulness, Emotional Well-being, and Sleep Quality|Mechanisms of Mindfulness: Effects on Sleep Quality, Stress Physiology and CVD Risk|Completed||N/A|372|Actual|Duke University||1|||f||||t||||||||||2018-06-01 01:02:34.343481|2018-06-01 01:02:34.343481
NCT00887601|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2015-07-29|2009-04-23|2009-04-24|Estimate|||||||2015-07-29|2015-07-30|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)|A 4-Period, Placebo-Controlled, Crossover Study to Evaluate the Utility and Feasibility of BOLD fMRI and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (Donepezil and MK3134)|Completed||Phase 1|32|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:02:34.465339|2018-06-01 01:02:34.465339
NCT00887588|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2015-07-16|2013-01-02|2015-08-12|2009-04-23|2009-04-24|Estimate|2015-07-16|2015-08-13|Estimate|2013-01-02|2013-01-04|Estimate|2015-08-12|2015-08-25|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction|A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction|Completed||Phase 2|307|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:02:34.627798|2018-06-01 01:02:34.627798
NCT00887575|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2014-11-21||2016-09-02|2009-04-23|2009-04-24|Estimate|2014-12-09|2014-12-17|Estimate||||2016-09-02|2016-09-07|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Interventional||Between June 2009 and July 2012, 54 patients were enrolled (15 in phase I and 39 additional patients in phase II). Three patients were later found to be ineligible and were excluded from the analysis. An additional patient did not receive any study treatment and is also excluded from the analysis.|Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer|Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer|Completed||Phase 1/Phase 2|54|Actual|SCRI Development Innovations, LLC||3|||f||||f||||||||||2018-06-01 01:02:36.053686|2018-06-01 01:02:36.053686
NCT00887562|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2015-12-17||2016-09-20|2009-04-23|2009-04-24|Estimate|2016-08-08|2016-08-10|Estimate||||2016-09-20|2016-10-26|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|MELAS||Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes|A Phase IIa Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis and Stroke-like Episodes|Completed||Phase 2|27|Actual|Columbia University|Clinical variability in severity of disease among participants|3|||f||||f||||||||No||2018-06-01 01:02:36.767996|2018-06-01 01:02:36.767996
NCT00887549|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2011-07-29||2012-06-07|2009-04-23|2009-04-24|Estimate|2011-07-29|2011-08-30|Estimate||||2012-06-07|2012-06-19|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer|An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression|Completed||Phase 2|70|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:02:37.450485|2018-06-01 01:02:37.450485
NCT00887536|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-05-04|2009-04-23|2009-04-24|Estimate|||||||2017-05-04|2017-05-05|Actual|May 2009||2009-05-31|April 2017|2017-04-30|January 2022|Anticipated|2022-01-31|December 2017|Anticipated|2017-12-31||Interventional|||A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer|A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer|Active, not recruiting||Phase 3|3900|Anticipated|NSABP Foundation Inc||3|||f||||t||||||||||2018-06-01 01:02:38.045526|2018-06-01 01:02:38.045526
NCT00887523|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2015-06-02|2009-04-23|2009-04-24|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis|Randomized Controlled Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis|Unknown status|Recruiting|N/A|84|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:02:39.962525|2018-06-01 01:02:39.962525
NCT00887510|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2013-06-10|2012-02-16|2014-06-12|2009-04-23|2009-04-24|Estimate|2014-06-12|2014-06-17|Estimate|2012-02-28|2012-03-01|Estimate|2014-06-12|2014-06-17|Estimate|May 2007||2007-05-31|June 2014|2014-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|MEAD||Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)|Metabolic Effects of Antihypertensive Drugs|Completed||Phase 4|24|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 01:02:40.12244|2018-06-01 01:02:40.12244
NCT00887497|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2011-09-26|2009-04-23|2009-04-24|Estimate|||||||2011-09-26|2011-09-28|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery|Ischemic Conditioning (Delay Phenomenon) in Colorectal Surgery|Terminated||Phase 4|10|Anticipated|University of California, Irvine||1||terminated due to failure to enroll patients after two years of approval|f||||t||||||||||2018-06-01 01:02:40.489971|2018-06-01 01:02:40.489971
NCT00887484|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2010-09-22||2016-10-28|2009-04-23|2009-04-24|Estimate|2012-09-07|2012-10-23|Estimate||||2016-10-28|2016-12-13|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne|A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris|Completed||Phase 4|50|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:02:40.682638|2018-06-01 01:02:40.682638
NCT00887471|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2012-06-06||2013-12-20|2009-04-23|2009-04-24|Estimate|2013-12-20|2014-02-10|Estimate||||2013-12-20|2014-02-10|Estimate|August 2006||2006-08-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Observational|||Comparison of Sleep Study Results After Partial Intracapsular Tonsillectomy Versus Total Tonsillectomy|Comparison of Polysomnography Outcomes for Microdebrider-assisted Partial Intracapsular Tonsillectomy Versus Total Tonsillectomy|Completed|||30|Actual|State University of New York - Downstate Medical Center|Selection bias, sample size limitation as it the study was not powered to detect small differences between the groups, and the use of unattended home PSG instead of laboratory-based PSG.||2||f||||f||||||||||2018-06-01 01:02:41.7954|2018-06-01 01:02:41.7954
NCT00887458|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2013-12-11||2017-09-13|2009-04-23|2009-04-24|Estimate|2013-12-11|2014-01-27|Estimate||||2017-09-13|2017-10-16|Actual|July 2009||2009-07-31|September 2017|2017-09-30|December 2013|Actual|2013-12-31|May 2011|Actual|2011-05-31||Interventional|||A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy|A Randomized Phase II Clinical Trial of Two Dose-levels of Itraconazole in Patients With Metastatic Castration-resistant Prostate Cancer|Completed||Phase 2|46|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 01:02:42.225987|2018-06-01 01:02:42.225987
NCT00887445|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2010-04-27|2009-04-23|2009-04-24|Estimate|||||||2010-04-27|2010-04-28|Estimate|July 2008||2008-07-31|April 2010|2010-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||First in Man Study With SLV341|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV341 in Young Healthy Male Subjects|Terminated||Phase 1|87|Actual|Solvay Pharmaceuticals||2||The study was terminated on June 25th, 2009 due to strategic decision|f||||f||||||||||2018-06-01 01:02:42.624023|2018-06-01 01:02:42.624023
NCT00887432|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-10-11|2009-04-23|2009-04-24|Estimate|||||||2017-10-11|2017-10-12|Actual|April 8, 2009|Actual|2009-04-08|October 2017|2017-10-31|October 21, 2020|Anticipated|2020-10-21|October 21, 2019|Anticipated|2019-10-21||Interventional|||Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation|Randomized Placebo-Controlled, Double-Blind Study of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer|Recruiting||N/A|100|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 01:02:42.739919|2018-06-01 01:02:42.739919
NCT00887419|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-06-26|2009-04-23|2009-04-24|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2008||2008-11-30|June 2017|2017-06-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|SCS||Spinal Cord Stimulator Implant Study|Pain Coping Skills Training for Spinal Cord Stimulator Implant Candidates|Completed||N/A|101|Actual|Duke University||3|||f||||f||||||||||2018-06-01 01:02:42.880425|2018-06-01 01:02:42.880425
NCT00887406|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-08-10|2009-04-23|2009-04-24|Estimate|||||||2017-08-10|2017-08-11|Actual|November 7, 2005|Actual|2005-11-07|August 2017|2017-08-31|October 4, 2006|Actual|2006-10-04|October 4, 2006|Actual|2006-10-04||Interventional|||Study of GSK961081 in Healthy Volunteer Subjects|A Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetic Profile and Pharmacodynamics of Single and Repeat Inhaled Doses of GSK961081 in Healthy Subjects|Completed||Phase 1|46|Actual|GlaxoSmithKline||10|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:02:43.034771|2018-06-01 01:02:43.034771
NCT00887393|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-06-17|2009-04-23|2009-04-24|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates|Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates|Completed||N/A|31|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 01:02:43.195545|2018-06-01 01:02:43.195545
NCT00887380|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-07-10|2009-04-23|2009-04-24|Estimate|||||||2017-07-10|2017-07-12|Actual|September 2009||2009-09-30|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|STARS||STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)|A Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Anti-oestrogen Therapy Delayed Until After Radiotherapy.|Active, not recruiting||Phase 3|2023|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||t||||||||||2018-06-01 01:02:43.289489|2018-06-01 01:02:43.289489
NCT00887367|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|||2017-07-13|2009-04-23|2009-04-24|Estimate|||||||2017-07-13|2017-07-18|Actual|September 29, 2008|Actual|2008-09-29|July 2017|2017-07-31|December 3, 2008|Actual|2008-12-03|December 3, 2008|Actual|2008-12-03||Interventional|||EtOH Interaction Study|A Study to Investigate Potential Interactions Between GSK598809 and Ethanol in Healthy Subjects|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:02:43.465453|2018-06-01 01:02:43.465453
NCT00887354|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-23|2016-07-15||2017-01-27|2009-04-23|2009-04-24|Estimate|2016-11-11|2017-01-09|Estimate||||2017-01-27|2017-03-09|Actual|April 2009||2009-04-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MOVE|Full Analysis Set (FAS): All randomized participants who received at least one dose of study drug and with at least one post-baseline efficacy measure.|A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture|Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine BMD (Bone Mineral Density) in Men and Postmenopausal Women With Low Bone Mass and a Recent Pertrochanteric Hip Fracture|Completed||Phase 4|224|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 01:02:43.640465|2018-06-01 01:02:43.640465
NCT00887341|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2014-06-26||2014-10-20|2009-04-22|2009-04-23|Estimate|2014-10-20|2014-10-22|Estimate||||2014-10-20|2014-10-22|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Intent-to-treat (ITT) Population: all participants enrolled in the study who had been randomly assigned to one of the two study treatments and received at least one dose of study drug.|A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis|Phase II Multi-centre, Randomized, Parallel Group, Pilot Trial to Compare the Incidence of Tocilizumab Related Infusion Reactions in Moderate to Severe RA Patients When Infusion is Made Over 1 Hour Against 31 Minutes|Completed||Phase 2|76|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:02:44.807521|2018-06-01 01:02:44.807521
NCT00887328|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2017-12-20|2009-04-22|2009-04-23|Estimate|||||||2017-12-20|2017-12-22|Actual|June 2010||2010-06-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|EXTEND||Extending the Time for Thrombolysis in Emergency Neurological Deficits|Extending the Time for Thrombolysis in Emergency Neurological Deficits|Recruiting||Phase 3|400|Anticipated|Neuroscience Trials Australia||2|||f||||t||||||||||2018-06-01 01:02:46.0522|2018-06-01 01:02:46.0522
NCT00887315|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2013-06-24||2013-11-13|2009-04-22|2009-04-23|Estimate|2013-11-13|2013-12-06|Estimate||||2013-11-13|2013-12-06|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|SMART||The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Trial of Docetaxel, Cisplatin, and Hypofractionated Radiotherapy Versus Docetaxel and Cisplatin for Limited Volume Stage IV Non-small Cell Lung Cancer: The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial|Terminated||Phase 2|11|Actual|University of Chicago|Funding was withdrawn before conclusions were reached so the study was terminated and no data was collected and analyzed.|2||Slow accrual and loss of sponsor|f||||t||||||||||2018-06-01 01:02:46.325686|2018-06-01 01:02:46.325686
NCT00887302|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-04-22|2009-04-22|2009-04-23|Estimate|||||||2009-04-22|2009-04-23|Estimate|May 2009||2009-05-31|April 2009|2009-04-30||||June 2010|Anticipated|2010-06-30||Observational|J&J Ethicon||Metabolics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy|Johnson and Johnson Ethicon Metabolics of RYGB With Gastrostomy|Unknown status|Not yet recruiting||120|Anticipated|East Carolina University|||3||f||||f||||||||||2018-06-01 01:02:46.707335|2018-06-01 01:02:46.707335
NCT00887289|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2010-10-12||2014-06-17|2009-04-22|2009-04-23|Estimate|2010-11-19|2010-12-15|Estimate||||2014-06-17|2014-06-27|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS)|Non-interventional Observational Study on the Influence of Pramipexole (PPX) on Sensory Symptoms of Restless Legs Syndrome (RLS)|Completed|||1504|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:02:46.90437|2018-06-01 01:02:46.90437
NCT00887276|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2014-12-16|2009-04-22|2009-04-23|Estimate|||||||2014-12-16|2014-12-17|Estimate|November 2008||2008-11-30|January 2010|2010-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|PENCAP||Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia|Prospective, Doubleblind, Randomized Multicenter Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia|Terminated||Phase 4|290|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 01:02:48.467594|2018-06-01 01:02:48.467594
NCT00887263|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2016-01-20|2009-04-22|2009-04-23|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)|Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD|Completed||Phase 3|186|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-06-01 01:02:48.591534|2018-06-01 01:02:48.591534
NCT00887250|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2009-05-07||2009-07-08|2009-04-22|2009-04-23|Estimate|2009-05-07|2009-06-24|Estimate||||2009-07-08|2009-07-14|Estimate|December 1991||1991-12-31|July 2009|2009-07-31|November 1992|Actual|1992-11-30|August 1992|Actual|1992-08-31||Interventional|||A Study to Investigate the Antihypertensive Efficacy of MK0954|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan (MK954, DuP753) in Patients With Mild to|Completed||Phase 3|366|Actual|Merck Sharp & Dohme Corp.|Safety has been reported in the literature.|3|||f||||||||||||||2018-06-01 01:02:48.712638|2018-06-01 01:02:48.712638
NCT00887237|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-07-03|2009-04-22|2009-04-23|Estimate|||||||2013-07-03|2013-07-08|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|TRIV||Triple Site Ventricular Stimulation for Cardiac Resynchronization Therapy (CRT) Candidates|Triple Site Ventricular Stimulation for CRT Candidates|Completed||Phase 3|76|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-06-01 01:02:49.33068|2018-06-01 01:02:49.33068
NCT00887068|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2018-05-03|2009-04-22|2009-04-23|Estimate|||||||2018-05-03|2018-05-07|Actual|April 21, 2009|Actual|2009-04-21|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)|Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)|Active, not recruiting||Phase 3|187|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 01:02:57.413639|2018-06-01 01:02:57.413639
NCT00887224|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2012-03-06||2014-11-06|2009-04-22|2009-04-23|Estimate|2012-05-22|2012-06-27|Estimate||||2014-11-06|2014-11-21|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder|A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|874|Actual|Pfizer|P-value from the primary analysis is different from the one testing equality of relapse rates on Double-blind day 185. Estimated percentages were provided as representative descriptive measures. Medians were not estimable due to low relapse rates.|2|||f||||f||||||||||2018-06-01 01:02:49.514448|2018-06-01 01:02:49.514448
NCT00887211|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-29|2009-04-21|2009-04-23|Estimate|||||||2009-04-29|2009-04-30|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|Prostent||ProStent Coronary Drug-Eluting Stent|Clinical Trial Program of a Medical Instrument Product|Unknown status|Recruiting|N/A|290|Anticipated|CCRF Consulting Co., Ltd.||2|||f||||t||||||||||2018-06-01 01:02:51.277681|2018-06-01 01:02:51.277681
NCT00887198|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|2015-03-30||2017-12-18|2009-04-22|2009-04-23|Estimate|2015-03-30|2015-04-09|Estimate||||2017-12-18|2018-01-17|Actual|April 28, 2009|Actual|2009-04-28|December 2017|2017-12-31|May 25, 2017|Actual|2017-05-25|March 31, 2014|Actual|2014-03-31||Interventional||Analysis population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.|Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 3|1088|Actual|Janssen Research & Development, LLC|These results are up to clinical cutoff (CCO) date (that is, 31 March 2014).|2|||f||||t||f||||||||2018-06-01 01:02:51.441244|2018-06-01 01:02:51.441244
NCT00887185|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2011-09-26|2009-04-21|2009-04-23|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2006||2006-10-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Validation/Dissemination Of A Temporal Bone Dissection Simulator|Validation/Dissemination Of A Temporal Bone Dissection Simulator|Completed||Phase 2|100|Anticipated|Ohio State University||2|||f||||t||||||||||2018-06-01 01:02:53.615058|2018-06-01 01:02:53.615058
NCT00887172|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-22|2009-04-22|2009-04-23|Estimate|||||||2009-04-22|2009-04-23|Estimate|June 2005||2005-06-30|April 2009|2009-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Trial of Chinese Herbal Medicine in the Treatment of Upper Respiratory Tract Infections (URTIs)|A Randomized Double Blind, Placebo-Controlled Clinical Trial of Chinese Herbal Medicine (CHM) in the Treatment of Acute Upper Respiratory Tract Infections|Completed||Phase 4|327|Actual|The University of Hong Kong||4|||f||||t||||||||||2018-06-01 01:02:53.73343|2018-06-01 01:02:53.73343
NCT00887159|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2015-07-01||2018-03-21|2009-04-22|2009-04-23|Estimate|2015-07-01|2015-07-29|Estimate||||2018-03-21|2018-04-20|Actual|July 16, 2009|Actual|2009-07-16|March 2018|2018-03-31|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional||Eligible and treated patients.|A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage|A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|168|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 01:02:53.990364|2018-06-01 01:02:53.990364
NCT00887146|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2018-04-06|2009-04-22|2009-04-23|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2009||2009-09-30|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma|Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma|Recruiting||Phase 3|360|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 01:02:55.939809|2018-06-01 01:02:55.939809
NCT00887133|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-22|2009-04-22|2009-04-23|Estimate|||||||2009-04-22|2009-04-23|Estimate|November 2005||2005-11-30|April 2009|2009-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Effectiveness of Western Medicine Outpatient Consultations in Primary Care|Effectiveness of Western Medicine Outpatient Consultations in Primary Care - A Comparison With Chinese Medicine Consultations|Completed|||1469|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-06-01 01:02:56.716293|2018-06-01 01:02:56.716293
NCT00887120|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-22|2009-04-22|2009-04-23|Estimate|||||||2009-04-22|2009-04-23|Estimate|April 2007||2007-04-30|April 2009|2009-04-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Dose Reduction of Lopinavir in Children|Pharmacokinetics and Efficacy of Low- or Standard-Dose of Lopinavir/Ritonavir (Kaletra®) in PI-naïve HIV-1 Infected Children|Completed||Phase 2|24|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-06-01 01:02:56.785984|2018-06-01 01:02:56.785984
NCT00887107|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-04-22|2009-04-22|2009-04-23|Estimate|||||||2009-04-22|2009-04-23|Estimate|October 2007||2007-10-31|April 2009|2009-04-30||||||||Interventional|||Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma|Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma|Completed||Phase 2|32|Actual|Leiden University Medical Center||1|||f||||f||||||||||2018-06-01 01:02:57.028231|2018-06-01 01:02:57.028231
NCT00887094|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2011-08-03|2009-04-22|2009-04-23|Estimate|||||||2011-08-03|2011-08-04|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|CGMSexercise||Aerobic Training, Aerobic-resistance Training and Glucose Profile (CGMS) in Type 2 Diabetes|Acute and Subacute Effects of Aerobic Training vs Aerobic/Resistance Training Upon Glucose Profile Evaluated Through Continuous Glucose Monitoring System in Type 2 Diabetes|Completed||N/A|14|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 01:02:57.138781|2018-06-01 01:02:57.138781
NCT00887081|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-22|2009-04-22|2009-04-23|Estimate|||||||2009-04-22|2009-04-23|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|IFNRIBAHE||Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies|Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C|Unknown status|Recruiting|Phase 4|150|Anticipated|Azienda Ospedaliera V. Cervello||1|||f||||t||||||||||2018-06-01 01:02:57.257047|2018-06-01 01:02:57.257047
NCT00887055|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2015-06-26|2009-04-22|2009-04-23|Estimate|||||||2015-06-26|2015-06-29|Estimate||||June 2015|2015-06-30||||||||Observational|||OPTIMA Bi-ventricular Capture Verification Study|Bi-ventricular Capture Verification Study|Withdrawn|||0|Actual|Guidant Corporation||||never started|f||||||||||||||2018-06-01 01:02:57.55532|2018-06-01 01:02:57.55532
NCT00887042|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2012-03-23|2009-04-22|2009-04-23|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML|Phase II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric Acute Myeloid Leukemia|Unknown status|Active, not recruiting|Phase 1/Phase 2|35|Anticipated|The Korean Society of Pediatric Hematology Oncology||1|||f||||f||||||||||2018-06-01 01:02:57.635248|2018-06-01 01:02:57.635248
NCT00887029|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2015-04-20|2009-04-22|2009-04-23|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|DVX||A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma|A 12 Week Comparison of DuoTrav and Xalacom at 24 Hours Post-Dose in the Treatment of Open-Angle Glaucoma (the DVX Study)|Completed||Phase 4|54|Actual|Ophthalmic Consultants Centres, Canada||2|||f||||t||||||||||2018-06-01 01:02:57.786425|2018-06-01 01:02:57.786425
NCT00887003|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-02-07|2009-04-22|2009-04-23|Estimate|||||||2012-02-07|2012-02-08|Estimate|May 2005||2005-05-31|July 2011|2011-07-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Epidural Study of Patients With Chronic Lower Back Pain|Effects of Volume and Dose of Local Anaesthetic Solution in Epidural Steroidal Injections for Patients With Chronic Lower Back Pain|Completed||N/A|252|Actual|McMaster University||4|||f||||f||||||||||2018-06-01 01:02:57.923499|2018-06-01 01:02:57.923499
NCT00886990|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2009-05-14|2009-04-22|2009-04-23|Estimate|||||||2009-05-14|2009-05-15|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens|Comparing the Efficacy and Safety of Single Versus Double Ritonavir-Boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens for Children Failing Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Treatment|Completed|||240|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||2||f||||f||||||||||2018-06-01 01:02:58.044697|2018-06-01 01:02:58.044697
NCT00886977|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2010-10-22|2009-04-22|2009-04-23|Estimate|||||||2010-10-22|2010-10-25|Estimate|April 2009||2009-04-30|April 2009|2009-04-30||||December 2010|Anticipated|2010-12-31||Interventional|||Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)|Pilot-Study of YAM80 in Amyotrophic Lateral Sclerosis. Evaluation of the Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|Yoshino Neurology Clinic|||||f||||f||||||||||2018-06-01 01:02:58.168032|2018-06-01 01:02:58.168032
NCT00886964|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2010-06-04|2009-04-22|2009-04-23|Estimate|||||||2010-06-04|2010-06-07|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Hepatitis B Vaccination (HBV) in HIV Infected Children|Immunogenicity and Safety of Intradermal Compare to Intramuscular Hepatitis B Vaccination in HIV Children|Completed||Phase 2|80|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-06-01 01:02:58.248805|2018-06-01 01:02:58.248805
NCT00886951|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2010-09-20|2009-04-22|2009-04-23|Estimate|||||||2010-09-20|2010-09-21|Estimate|March 2009||2009-03-31|September 2010|2010-09-30||||March 2011|Anticipated|2011-03-31||Interventional|||Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease|Evaluation of [123I] MNI-388 and 123-I MNI-390 and SPECT as Markers of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Terminated||Phase 1|2|Actual|Institute for Neurodegenerative Disorders||1||"There did not appear to be uptake of the ligand in the areas of the brain expected for~   individuals with amyloid."|f||||f||||||||||2018-06-01 01:02:58.357169|2018-06-01 01:02:58.357169
NCT00886938|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2012-03-07||2014-05-07|2009-04-22|2009-04-23|Estimate|2012-04-20|2012-05-21|Estimate||||2014-05-07|2014-05-16|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||rTMS To The Dorsolateral Prefrontal Cortex For Patients With Subjective Idiopathic Tinnitus. A Pilot Study|rTMS To The Dorsolateral Prefrontal Cortex For Patients With Subjective Idiopathic Tinnitus. A Pilot Study|Completed||Phase 2|12|Actual|Washington University School of Medicine|Open label study.|1|||f||||t||||||||||2018-06-01 01:02:58.456146|2018-06-01 01:02:58.456146
NCT00886925|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-12-14|2009-04-22|2009-04-23|Estimate|||||||2012-12-14|2012-12-17|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|ALFAE||Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis|Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy.|Completed||Phase 4|56|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-06-01 01:02:58.725115|2018-06-01 01:02:58.725115
NCT00886912|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2010-06-24|2009-04-22|2009-04-23|Estimate|||||||2010-06-24|2010-06-25|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|October 2009|Anticipated|2009-10-31|August 2008|Actual|2008-08-31||Interventional|||Training in Hypoxia to Prevent Acute Mountain Sickness|Prevention of Acute Mountain Sickness (AMS) by Intermittent Hypoxic Training|Unknown status|Recruiting|N/A|50|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-06-01 01:02:59.820004|2018-06-01 01:02:59.820004
NCT00886899|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2012-02-21||2012-03-15|2009-04-21|2009-04-23|Estimate|2012-02-21|2012-03-13|Estimate||||2012-03-15|2012-03-20|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|FAST-CTOs||Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)|Facilitated Antegrade Steering Technique in Chronic Total Occlusions|Completed||Phase 2|147|Actual|BridgePoint Medical||1|||f||||t||||||||||2018-06-01 01:02:59.9768|2018-06-01 01:02:59.9768
NCT00886886|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-01-24|2009-04-22|2009-04-23|Estimate|||||||2013-01-24|2013-01-25|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)|Pharmacological Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacological Effects and Pharmacokinetics|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-06-01 01:03:00.262531|2018-06-01 01:03:00.262531
NCT00886873|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2014-10-16|2009-04-22|2009-04-23|Estimate|||||||2014-10-16|2014-10-17|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|Mifemyo_2||Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids|Mifepristone 5 mg Versus 10 mg During 6 Months for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial.|Completed||Phase 2/Phase 3|100|Actual|Mediterranea Medica S. L.||2|||f||||t||||||||||2018-06-01 01:03:00.387601|2018-06-01 01:03:00.387601
NCT00886860|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2010-07-12|2009-04-22|2009-04-23|Estimate|||||||2010-07-12|2010-07-14|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol|The Comparison of Efficacy for Cervical Ripening in Labor Induction Between Titrated and Conventional Oral Misoprostol|Completed||Phase 4|64|Actual|Mahidol University||2|||f||||t||||||||||2018-06-01 01:03:00.508625|2018-06-01 01:03:00.508625
NCT00886847|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2016-02-17|2009-04-22|2009-04-23|Estimate|||||||2016-02-17|2016-02-19|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Endobronchial Ultrasound-Guided Biopsy Using Fine Needle Aspiration Versus Fine Needle Capillary Sampling|Specimen Adequacy and Diagnostic Agreement of Fine Needle Aspiration (FNA) VS. Fine Needle Capillary Sampling (FNC) of Endobronchial Ultrasound-Guided Biopsy of Mediastinal Lymph Nodes|Completed||N/A|120|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:03:01.445486|2018-06-01 01:03:01.445486
NCT00886834|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2011-08-05||2014-12-04|2009-04-22|2009-04-23|Estimate|2011-12-21|2011-12-22|Estimate||||2014-12-04|2014-12-22|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|MPIIN||Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women|A Randomized Control Trial of Misoprostol vs. Placebo Prior to IUD Insertion in Nulliparous Women|Completed||N/A|108|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 01:03:01.587768|2018-06-01 01:03:01.587768
NCT00886821|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2017-03-02||2017-03-06|2009-04-22|2009-04-23|Estimate|2017-03-06|2017-04-18|Actual||||2017-03-06|2017-04-18|Actual|October 2008||2008-10-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Safety population included all randomized participants who received at least 1 dose of study medication.|A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics|A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of Cvx-096 In Type 2 Diabetic Adult Subjects|Completed||Phase 1|114|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:03:02.109109|2018-06-01 01:03:02.109109
NCT00886808|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-03-21|2009-04-22|2009-04-23|Estimate|||||||2012-03-21|2012-03-22|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema|Completed||Phase 1|15|Actual|iCo Therapeutics Inc.||4|||f||||t||||||||||2018-06-01 01:03:05.061308|2018-06-01 01:03:05.061308
NCT00886795|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2015-08-31||2015-12-17|2009-04-22|2009-04-23|Estimate|2015-12-17|2016-01-25|Estimate||||2015-12-17|2016-01-25|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|TAHOE||Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy|A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.|Completed||Phase 1/Phase 2|4|Actual|Johns Hopkins University|Open Label study. Small number of patients. Outcome measures for urticaria not standardized.|1|||f||||t||||||||||2018-06-01 01:03:05.173516|2018-06-01 01:03:05.173516
NCT00886782|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22||2012-04-25|2015-09-23|2009-04-22|2009-04-23|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors|A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors|Terminated||Phase 1/Phase 2|11|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:03:05.486121|2018-06-01 01:03:05.486121
NCT00886769|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2011-11-21||2017-02-28|2009-04-22|2009-04-23|Estimate|2012-03-13|2012-04-09|Estimate||||2017-02-28|2017-03-29|Actual|July 2009||2009-07-31|February 2017|2017-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|β-SPECIFIC 1||Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)|A Randomized, Double-blind, Placebo Controlled, Single-dose Study to Assess the Initial Efficacy of Canakinumab (ACZ885) With Respect to the Adapted ACR Pediatric 30 Criteria in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations|Terminated||Phase 3|84|Actual|Novartis||2||recommendation by Data Monitoring Committee|f||||||||||||||2018-06-01 01:03:05.624082|2018-06-01 01:03:05.624082
NCT00886756|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-08-18|2009-04-22|2009-04-23|Estimate|||||||2009-08-18|2009-08-19|Estimate|April 2009||2009-04-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|||||Interventional|JSAD||AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects|A Phase I, Single-Centre, Randomised, Double-Blind, Placebo Controlled Single-Ascending Dose, Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD8529 in Healthy Male Japanese Subjects|Completed||Phase 1|48|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:03:06.215165|2018-06-01 01:03:06.215165
NCT00886743|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2016-11-14||2017-03-08|2009-04-22|2009-04-23|Estimate|2017-03-08|2017-04-19|Actual||||2017-03-08|2017-04-19|Actual|September 2009||2009-09-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All participants who had received at least 1 dose of oprelvekin.|Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia|Study Of The Effects Of Oprelvekin On Cardiac Repolarization In Subjects At Risk Of Severe Thrombocytopenia After Myelosuppressive Chemotherapy|Terminated||Phase 2|19|Actual|Pfizer||1||"Business reason, Pfizer's requested withdrawal of the Biologics License Application (BLA) .~   This study is not being discontinued for efficacy or safety reason"|f||||f||||||||||2018-06-01 01:03:06.332472|2018-06-01 01:03:06.332472
NCT00886730|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-12-13|2009-04-22|2009-04-23|Estimate|||||||2012-12-13|2012-12-17|Estimate|October 2008||2008-10-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|September 2009|Actual|2009-09-30||Interventional|Psychobabble||Primary Care Patients With Depression for Internet-Based Social Support|Feasibility Study of Methods of Referral Primary Care Patients With Depression for Internet-Based Social Support|Completed||Phase 1/Phase 2|49|Actual|University of Chicago||3|||f||||t||||||||||2018-06-01 01:03:06.821665|2018-06-01 01:03:06.821665
NCT00886717|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-08-01|2009-04-22|2009-04-23|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2008||2008-05-31|December 2009|2009-12-31||||||||Interventional|||Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer|Open-label, Multicenter, Phase I/II Trial to Evaluate Efficacy Safety of the Combination Therapy of Genexol-PM and Carboplatin as a Firstline Treatment in Subjects With Advanced Ovarian Cancer|Unknown status|Recruiting|Phase 1/Phase 2|74|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:03:06.916806|2018-06-01 01:03:06.916806
NCT00886704|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2011-06-15||2011-09-29|2009-04-22|2009-04-23|Estimate|2011-08-18|2011-09-26|Estimate||||2011-09-29|2011-10-07|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Omega-3 Fatty Acids, the Omega-3 Index, and Atherosclerosis|Influence of Dietary Omega-3 Fatty Acids in a Convenience Drink (Smartfish) on the Omega-3 Index in Patients With Atherosclerotic Disease|Completed||N/A|50|Actual|Ludwig-Maximilians - University of Munich|Single center study, too small to detect rare side effects, 8 week intervention period relatively short.|2|||f||||f||||||||||2018-06-01 01:03:07.043946|2018-06-01 01:03:07.043946
NCT00886691|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-05-28|2009-04-22|2009-04-23|Estimate|||||||2013-05-28|2013-05-30|Estimate|December 2010||2010-12-31|May 2013|2013-05-31||||June 2014|Anticipated|2014-06-30||Interventional|||Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Unknown status|Active, not recruiting|Phase 2|150|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 01:03:07.471192|2018-06-01 01:03:07.471192
NCT00886678|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2011-02-23|2009-04-22|2009-04-23|Estimate|||||||2011-02-23|2011-02-24|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|NSCLC||A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)|A Phase II Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|63|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-06-01 01:03:07.655992|2018-06-01 01:03:07.655992
NCT00886665|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-06-17|2009-04-22|2009-04-23|Estimate|||||||2009-06-17|2009-06-18|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|||The Evaluation of Safety and Efficacy of JWHGWT on Diabetic Neuropathy|The Evaluation of Safety and Efficacy of JWHGWT on Diabetic Neuropathy|Unknown status|Recruiting|Phase 3|120|Anticipated|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-06-01 01:03:07.786348|2018-06-01 01:03:07.786348
NCT00886652|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2016-02-25|2009-04-22|2009-04-23|Estimate|||||||2016-02-25|2016-02-26|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||An Aerobic Exercising Program on Respiratory Muscle Strength in Patients With Adolescent Idiopathic Scoliosis|Results of an Aerobic Exercising Program on Respiratory Muscle Strength in Patients With Adolescent Idiopathic Scoliosis: a Randomized, Controlled Trial|Completed||N/A|90|Actual|Irmandade da Santa Casa de Misericordia de Sao Paulo||2|||f||||f||||||||||2018-06-01 01:03:07.908037|2018-06-01 01:03:07.908037
NCT00886639|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2011-06-22||2011-11-02|2009-04-22|2009-04-23|Estimate|2011-06-24|2011-07-22|Estimate||||2011-11-02|2011-11-07|Estimate|December 2008||2008-12-31|November 2011|2011-11-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Effect of Oxygen-supply on 6-Minute-Walking-Distance of COPD III/IV-patients|Effect Of Oxygen-Supply On The 6-Minute-Walking-Distance in Patients With Chronic Obstructive Pulmonary Disease (COPD) GOLD Stage III/IV Before And After A Multimodal Rehabilitation|Completed||N/A|127|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-06-01 01:03:08.018947|2018-06-01 01:03:08.018947
NCT00886626|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2012-04-25||2012-10-22|2009-04-22|2009-04-23|Estimate|2012-07-09|2012-08-17|Estimate||||2012-10-22|2012-10-29|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children|GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children: A Randomized, Controlled, Pilot Study|Completed||Phase 2|12|Actual|University of Minnesota - Clinical and Translational Science Institute|Small sample size; un-blinded; crossover study design|2|||f||||t||||||||||2018-06-01 01:03:08.485451|2018-06-01 01:03:08.485451
NCT00886613|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2011-03-22||2015-10-05|2009-04-22|2009-04-23|Estimate|2011-03-22|2011-04-13|Estimate||||2015-10-05|2015-10-06|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)|A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate Biomarkers of Immunity to Varicella Zoster Virus Following Immunization With V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine or With ZOSTAVAX in Healthy Volunteers|Completed||Phase 1|120|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:03:09.265502|2018-06-01 01:03:09.265502
NCT00886600|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2009-05-21||2015-08-17|2009-04-22|2009-04-23|Estimate|2009-05-21|2009-07-14|Estimate||||2015-08-17|2015-08-27|Estimate|May 1991||1991-05-31|August 2015|2015-08-31|August 1992|Actual|1992-08-31|May 1992|Actual|1992-05-31||Interventional|||A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)|A Double-blind, Randomized, Parallel-group, Placebo-controlled Pilot Study to Investigate the Magnitude and Duration of Response and the Safety of MK0954 (50 mg Given Once or Twice Daily, or 100 mg Given Once Daily) Compared to Placebo Using Ambulatory Blood Pressure Monitoring|Completed||Phase 3|122|Actual|Merck Sharp & Dohme Corp.|Safety has been reported in the literature.|4|||f||||||||||||||2018-06-01 01:03:10.206599|2018-06-01 01:03:10.206599
NCT00886587|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2017-01-16|2014-06-04|2017-04-24|2009-04-22|2009-04-23|Estimate|2017-04-24|2017-05-23|Actual|2014-06-04|2014-06-18|Estimate|2017-04-24|2017-05-23|Actual|April 2009||2009-04-30|April 2017|2017-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||All randomized subjects.|To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children|A Double-Blind, Randomized, Active-Controlled Clinical Trial To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children|Completed||N/A|82|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 01:03:10.768613|2018-06-01 01:03:10.768613
NCT00886574|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2010-06-03|2009-04-22|2009-04-23|Estimate|||||||2010-06-03|2010-06-04|Estimate|April 2009||2009-04-30|May 2010|2010-05-31|February 2014|Anticipated|2014-02-28|February 2011|Anticipated|2011-02-28||Interventional|CAPPA||Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events|Multi-Center, Randomized, Open Label Study of the Efficacy of Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events With Korean Type 2 DM Patients|Unknown status|Active, not recruiting|Phase 4|400|Anticipated|Hanyang University||2|||f||||t||||||||||2018-06-01 01:03:11.247621|2018-06-01 01:03:11.247621
NCT00886561|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2013-11-21|2009-04-22|2009-04-23|Estimate|||||||2013-11-21|2013-11-25|Estimate|July 2007||2007-07-31|November 2013|2013-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia|HIV- Risk Reduction Behavioral Intervention for Commercial Sex Workers in Yerevan Armenia|Completed||Phase 2|120|Actual|Emory University||2|||f||||f||||||||||2018-06-01 01:03:11.371543|2018-06-01 01:03:11.371543
NCT00886548|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2016-01-11|2009-04-22|2009-04-23|Estimate|||||||2016-01-11|2016-01-12|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|May 2010||2010-05-31|May 2010||2010-05-31||Observational|||Echocardiographic Examination Performed by Nurses in Cardiac Intensive Care Unit|Echocardiographic Examination Performed by Nurses in Cardiac Intensive Care Unit. Is it Clinical Useful?|Withdrawn|||0|Actual|Levanger Hospital|||1|Delayed inclusion|f||||f||||||||||2018-06-01 01:03:11.473838|2018-06-01 01:03:11.473838
NCT00886535|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2017-01-26|2009-04-22|2009-04-23|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2010|Actual|2010-02-28|January 2017|2017-01-31|July 27, 2017|Anticipated|2017-07-27|December 2013|Actual|2013-12-31||Observational|||Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity|An Observational Trial of the Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity|Active, not recruiting|||41|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||Undecided|After determining if data is valuable|2018-06-01 01:03:11.576049|2018-06-01 01:03:11.576049
NCT00886522|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2016-04-14|2009-04-22|2009-04-23|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|IBCB||Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies|Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.|Completed||Phase 2|23|Actual|St. Orsola Hospital||1|||f||||f||||||||Undecided||2018-06-01 01:03:11.674149|2018-06-01 01:03:11.674149
NCT00886509|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2015-12-15|2009-04-22|2009-04-23|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients|Subcutaneous Administration of Pegylated Granulocyte-Colony Stimulating Factor for Long-Term Promotion of Collateral Growth in Patients With Coronary Artery Disease|Completed||N/A|50|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 01:03:11.856701|2018-06-01 01:03:11.856701
NCT00886496|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2012-06-19|2009-04-21|2009-04-23|Estimate|||||||2012-06-19|2012-06-20|Estimate|November 2006||2006-11-30|August 2007|2007-08-31|April 2011|Actual|2011-04-30|||||Interventional|||Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia|A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia|Withdrawn||Phase 1|0|Actual|Enzon Pharmaceuticals, Inc.||||No participants enrolled. IND withdrawn.|||||||||||||||2018-06-01 01:03:11.978361|2018-06-01 01:03:11.978361
NCT00886483|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|2012-07-02||2016-10-05|2009-04-22|2009-04-23|Estimate|2013-09-26|2013-11-28|Estimate||||2016-10-05|2016-11-11|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|||Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)|Pilot Explorations of Neurofeedback Issues in ADHD|Completed||N/A|39|Actual|Ohio State University|"Small sample.~Self-selection families willing to stop/delay meds.~Failure to select for high TBR.~Small/medium pre-post ES suggests particular Tx technology may not have been the most effective.~Sham NF may not have been inert."|2|||f||||f||||||||||2018-06-01 01:03:12.108002|2018-06-01 01:03:12.108002
NCT00886470|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22||2016-12-05|2016-12-05|2009-04-22|2009-04-23|Estimate||||2016-12-05|2016-12-06|Estimate|2016-12-05|2016-12-06|Estimate|June 2009||2009-06-30|December 2016|2016-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||ACCS (Amnion-derived Cellular Cytokine Solution) Versus Standard Care In Treating Partial Thickness Burns|Phase I/II Randomized Blinded Safety, Dose-determining Efficacy Trial Comparing Amnion-derived Cellular Cytokine Solution in 3 Different Regimens With Standard Care 0.9% Sodium Chloride in the Topical Treatment of Partial-thickness Burns|Terminated||Phase 1/Phase 2|16|Actual|Noveome Biotherapeutics, formerly Stemnion||3||This study was terminated early due to slow accrual of patients.|f||||t||||||||||2018-06-01 01:03:12.546922|2018-06-01 01:03:12.546922
NCT00886457|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2011-07-19|2009-04-22|2009-04-23|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates|Inhibition of DNA Methylation by 1-hr Infusion of 5-aza-2'-Deoxycytidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alfa 2B (PEG-Intron): A Phase I Study With Molecular Correlates|Terminated||Phase 1|3|Actual|Nevada Cancer Institute||1||low accrual|f||||t||||||||||2018-06-01 01:03:12.701137|2018-06-01 01:03:12.701137
NCT00886444|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2014-11-06|2009-04-22|2009-04-23|Estimate|||||||2014-11-06|2014-11-07|Estimate|March 2009||2009-03-31|November 2014|2014-11-30||||March 2010|Actual|2010-03-31||Interventional|||Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran|Comparative Evaluation of Various CMR Pulse-Sequences for Macrophage Imaging Using Ferucarbotran as Molecular Contrast Agent in Human Myocardial Infarction|Completed||Phase 2/Phase 3|20|Actual|Robert Bosch Gesellschaft für Medizinische Forschung mbH||1|||f||||f||||||||||2018-06-01 01:03:12.795952|2018-06-01 01:03:12.795952
NCT00886431|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2014-11-26|2009-04-22|2009-04-23|Estimate|||||||2014-11-26|2014-12-02|Estimate|May 2009||2009-05-31|November 2014|2014-11-30||||May 2012|Actual|2012-05-31||Interventional|||Vitrification Versus Slow Cooling of Human Cleavage Stage Embryos|A Double Blinded, Randomised Controlled Trial Comparing the Effectiveness of Vitrification to Slow Cooling in Cryopreserving Human Preimplantation Embryos|Terminated||N/A|146|Actual|UMC Utrecht||2|||f||||f||||||||||2018-06-01 01:03:12.887353|2018-06-01 01:03:12.887353
NCT00886418|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-19|||2016-09-22|2009-04-22|2009-04-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2009||2009-12-31|September 2016|2016-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Drone-Curare||Influence of Muscle Relaxation on a Closed-loop Anesthesia System|Effect of Continuous Myorelaxation on the Need for Hypnotic Agent During Surgical Procedures Which do Not Require it (Multicenter, Randomized and Prospective Study)|Completed||Phase 3|140|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 01:03:13.036859|2018-06-01 01:03:13.036859
NCT00886405|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|January 2010|Anticipated|2010-01-31|April 2009|Actual|2009-04-30||Interventional|||Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer|Phase II Study That Evaluates Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|40|Anticipated|National Institute of Cancerología||1|||f||||f||||||||||2018-06-01 01:03:13.134564|2018-06-01 01:03:13.134564
NCT00886392|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|June 2006||2006-06-30|April 2009|2009-04-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Observational|||Diabetic Macular Edema Severity at Diagnosis|Distribution of Macular Edema Severity Level at the Moment of Diagnosis|Completed|||118|Actual|Hospital Juarez de Mexico|||1||f||||f||||||||||2018-06-01 01:03:13.239817|2018-06-01 01:03:13.239817
NCT00886379|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|BSS||Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health|Blue Sky Study: Impact of Milk and Vitamin D for Child Growth and Health|Completed||Phase 2|744|Actual|Brigham and Women's Hospital||6|||f||||f||||||||||2018-06-01 01:03:13.340485|2018-06-01 01:03:13.340485
NCT00886366|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2010-12-06|2009-04-21|2009-04-22|Estimate|||||||2010-12-06|2010-12-07|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD6714 in Healthy Male Volunteers and Male Type II Diabetic Patients|Terminated||Phase 1|26|Anticipated|AstraZeneca||3||"Part A reached a predefined stopping criteria. Relevant doses for part B could not be~   established based on A and subsequently study was stopped."|f||||||||||||||2018-06-01 01:03:13.444795|2018-06-01 01:03:13.444795
NCT00886353|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-12-30|2009-04-21|2009-04-22|Estimate|||||||2009-12-30|2009-12-31|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)|Double-blind, Placebo-controlled Dose-escalation Phase I Study With Recombinant Human Soluble Angiotensin Converting Enzyme 2 (rhACE2) APN01 in Healthy Volunteers|Completed||Phase 1|22|Anticipated|Apeiron Biologics||2|||f||||t||||||||||2018-06-01 01:03:13.535077|2018-06-01 01:03:13.535077
NCT00886340|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2009-01-22||2012-04-04|2009-03-16|2009-04-22|Estimate|2009-03-16|2009-04-22|Estimate||||2012-04-04|2012-05-07|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|August 2008|Actual|2008-08-31|September 2007|Actual|2007-09-30||Interventional|||A Lifestyle Change Program to Prevent Type 2 Diabetes|A Lifestyle Change Program to Prevent Type 2 Diabetes|Completed||Phase 2|58|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 01:03:13.640017|2018-06-01 01:03:13.640017
NCT00886327|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2012-05-30|2009-04-21|2009-04-22|Estimate|||||||2012-05-30|2012-05-31|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|||Detecting Postoperative Recurrence in Crohn's Disease|Detection of Postoperative Recurrence of Crohn's Disease by Colonic Capsule-Endoscopy|Unknown status|Recruiting||70|Anticipated|Johann Wolfgang Goethe University Hospital|||1||f||||t||||||||||2018-06-01 01:03:13.954227|2018-06-01 01:03:13.954227
NCT00886314|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-10-18|2009-04-20|2009-04-22|Estimate|||||||2009-10-18|2009-10-20|Estimate|June 2009||2009-06-30|February 2009|2009-02-28||||September 2009|Anticipated|2009-09-30||Interventional|||Clown Doctors and a Sedative Premedicant for Children Undergoing Surgery||Unknown status|Not yet recruiting|N/A|80|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-06-01 01:03:14.056431|2018-06-01 01:03:14.056431
NCT00886301|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-03-29|2009-04-21|2009-04-22|Estimate|||||||2010-03-29|2010-03-30|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Fatty Liver and Ectopic Fat in Overweight and Obese Patients|Fatty Liver and Ectopic Fat in Overweight and Obese Patients|Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:03:14.162804|2018-06-01 01:03:14.162804
NCT00886288|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2009-08-27||2014-06-12|2009-04-21|2009-04-22|Estimate|2009-10-12|2009-11-18|Estimate||||2014-06-12|2014-06-17|Estimate|September 2006||2006-09-30|June 2014|2014-06-30||||April 2007|Actual|2007-04-30||Observational||Baseline characteristics are presented for patients with available information on albuminuria at baseline. Respective data were not collected for patients without information on albuminuria at baseline.|TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in Belgium|A Comparison of Telmisartan Effectiveness in Hypertensive Patients With and Without Albuminuria.|Completed|||2874|Actual|Boehringer Ingelheim|Observational study of daily medical practice, a lot of patients did not return to their GP for the second visit during the time period of 10 to 14 weeks after the first visit||2||f||||||||||||||2018-06-01 01:03:14.346111|2018-06-01 01:03:14.346111
NCT00886275|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2012-11-15|2009-04-21|2009-04-22|Estimate|||||||2012-11-15|2012-11-16|Estimate|July 2010||2010-07-31|November 2012|2012-11-30||||April 2011|Actual|2011-04-30||Interventional|||Comparing the Effect of Dexmedetomidine With Midazolam on Sedation, Oxidative Stress, and Microcirculation in Intensive Care Unit|Comparing the Effect of Dexmedetomidine With Midazolam on Sedation, Oxidative Stress, and Microcirculation in Intensive Care Unit|Completed||Phase 4|33|Actual|National Taiwan University Hospital||3|||f||||||||||||||2018-06-01 01:03:15.943304|2018-06-01 01:03:15.943304
NCT00886262|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|January 2010|Anticipated|2010-01-31|July 2009|Anticipated|2009-07-31||Interventional|||Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant|Low Dose Vasopressin for Renal Protection During Liver Transplantation|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 01:03:16.022608|2018-06-01 01:03:16.022608
NCT00886249|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-10-09|2009-04-21|2009-04-22|Estimate|||||||2009-10-09|2009-10-12|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Observational|||Depth of Focus Comparison Between Acrysof IQ and Acrysof Natural IOLs|Depth of Focus Comparison Between Acrysof IQ and Acrysof Natural IOLs|Withdrawn|||50|Anticipated|Medical University of South Carolina||||The PI has determined not to continue the study.|f||||f||||||||||2018-06-01 01:03:16.116101|2018-06-01 01:03:16.116101
NCT00886236|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study of the Effect of the Drug Gabapentin on Postoperative Pain and Incidence of Postoperative Nausea and Vomiting|The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients|Unknown status|Enrolling by invitation|N/A|150|Anticipated|Medical University of South Carolina||3|||f||||f||||||||||2018-06-01 01:03:16.195092|2018-06-01 01:03:16.195092
NCT00886223|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-06-23|2009-04-21|2009-04-22|Estimate|||||||2009-06-23|2009-06-24|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|RobPex||Laparoscopic Sacropexy With Robot-Assisted Surgical System|Laparoscopic Sacropexy: Clinical Prospective Study With Robot-Assisted Technique(da Vinci®-System)|Unknown status|Recruiting|N/A|30|Anticipated|Kantonsspital Aarau||1|||f||||f||||||||||2018-06-01 01:03:17.190418|2018-06-01 01:03:17.190418
NCT00886210|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|October 2006||2006-10-31|April 2009|2009-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Clinical Impact of Routine Abdominal Drainage After Laparoscopic Cholecystectomy|Clinical Impact of Routine Abdominal Drainage After Laparoscopic Cholecystectomy. A Prospective Randomized Study|Completed||N/A|100|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 01:03:17.358182|2018-06-01 01:03:17.358182
NCT00882544|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2017-03-16|2009-04-15|2009-04-16|Estimate|||||||2017-03-16|2017-03-20|Actual|March 2009||2009-03-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Prospective Pediatric Pyeloplasty Robotic Surgical Database|Prospective Pediatric Pyeloplasty Robotic Surgical Database|Completed|||78|Actual|Connecticut Children's Medical Center|||1||f||||f||||||||No||2018-06-01 01:04:56.203987|2018-06-01 01:04:56.203987
NCT00886197|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease|Diagnostic Efficacy of Narrow Band Imaging (NBI) in Patients With Gastroesophageal Reflux Disease (GERD)|Completed|||80|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 01:03:17.468575|2018-06-01 01:03:17.468575
NCT00886184|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-01-29|2009-04-21|2009-04-22|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HITUPPAC-BIO||Intra-arrest Therapeutic Hypothermia in Prehospital Cardiac Arrest|Intra-arrest Therapeutic Hypothermia in Prehospital Cardiac Arrest. Impact on Biomarker of Brain Damage.|Completed||N/A|244|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 01:03:17.57338|2018-06-01 01:03:17.57338
NCT00886171|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2011-09-28|2009-04-21|2009-04-22|Estimate|||||||2011-09-28|2011-09-30|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effects of Social Skills and Physical Activity Training on Recreational Activities in Youth|Effects of Social Skills and Physical Activity Training on Recreational Activities in Youth|Completed||N/A|35|Actual|University at Buffalo||2|||f||||f||||||||||2018-06-01 01:03:17.736074|2018-06-01 01:03:17.736074
NCT00886158|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2011-07-20|2009-04-21|2009-04-22|Estimate|||||||2011-07-20|2011-07-22|Estimate|June 2001||2001-06-30|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||Virus Surveillance in Pediatric Solid Organ Transplant Recipients|Virus Surveillance in Pediatric Solid Organ Transplant Recipients: Identifying Risk Factors for PTLD and Other Complications Post-Transplant|Unknown status|Recruiting||100|Anticipated|Seattle Children's Hospital|||1||f||||f||||||Samples With DNA|"~     blood, urine, kidney biopsy tissue~   "|||2018-06-01 01:03:17.962392|2018-06-01 01:03:17.962392
NCT00886145|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2016-02-24||2016-03-28|2009-04-21|2009-04-22|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Vibration Therapy on Bone in Persons With Sub-acute Spinal Cord Injury|Effect of Using Low-magnitude High Frequency Mechanical Stimulation of Bone in Persons With Subacute SCI|Completed||N/A|1|Actual|James J. Peters Veterans Affairs Medical Center|Subject recruitment was untenable due to the physiological and psychological healing necessary during the sub-acute phase of spinal cord injury.|1|||f||||f||||||||No||2018-06-01 01:03:18.096072|2018-06-01 01:03:18.096072
NCT00886132|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2015-07-22|2009-04-21|2009-04-22|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2007||2007-01-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands|A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands|Completed||Phase 2|14|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:03:19.124849|2018-06-01 01:03:19.124849
NCT00886119|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2010-09-14||2012-06-26|2009-04-21|2009-04-22|Estimate|2010-10-06|2010-10-29|Estimate||||2012-06-26|2012-06-29|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of a Multifocal Contact Lens to a Traditional Multifocal Contact Lens|Lotrafilcon B Multifocal Evaluations - Comparison to a Traditional Multifocal in Higher Spectacle Adds|Completed||N/A|48|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 01:03:19.251182|2018-06-01 01:03:19.251182
NCT00886106|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-11-17|2009-04-21|2009-04-22|Estimate|||||||2009-11-17|2009-11-18|Estimate|June 2009||2009-06-30|November 2009|2009-11-30|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|RemiAnes 1||The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers|The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers|Unknown status|Recruiting|Phase 4|24|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:03:19.547203|2018-06-01 01:03:19.547203
NCT00886093|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-06-29|2009-04-21|2009-04-22|Estimate|||||||2009-06-29|2009-07-02|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants|A Phase 1, Open Label, Randomized, Single Dose, Cross-Over Study To Evaluate The Effect Of Food On PF-04447943 Pharmacokinetics In Healthy Adult Subjects|Completed||Phase 1|10|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:03:19.709153|2018-06-01 01:03:19.709153
NCT00886080|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|October 2002||2002-10-31|April 2009|2009-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||The Effect of Arrhythmia Surgery on Quality of Life in Patients With Atrial Fibrillation Undergoing Cardiac Surgery|A Prospective Randomised Multicentre Comparison on Health Related Quality of Life: the Value of Add-on Arrhythmia Surgery in Patients With Atrial Fibrillation Undergoing Valvular and/or Coronary Bypass Surgery|Completed||N/A|150|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 01:03:19.829061|2018-06-01 01:03:19.829061
NCT00886067|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-09-09|2009-04-21|2009-04-22|Estimate|||||||2009-09-09|2009-09-10|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Positron Emission Tomography (PET) Study|An Open-label Positron Emission Tomography (PET) Study Using 2 [18F] F A85380 to Determine α4β2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-fertile Female (Non-nicotine Users) Healthy Volunteers|Completed||Phase 1|11|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:03:19.925237|2018-06-01 01:03:19.925237
NCT00886054|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-12-20|2009-04-21|2009-04-22|Estimate|||||||2009-12-20|2009-12-23|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||The Prediction of Intracranial Pressure and Clinical Outcome by Transcranial Doppler in Neurocritical Patients|The Prediction of Intracranial Pressure and Clinical Outcome by Transcranial Doppler in Neurocritical Patients|Unknown status|Active, not recruiting||30|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 01:03:20.030669|2018-06-01 01:03:20.030669
NCT00886041|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|January 2003||2003-01-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Role of Laparoscopy in Unexplained Infertility|Role of Laparoscopy in Unexplained Infertility|Completed||Phase 4|512|Actual|Mansoura University||2|||f||||f||||||||||2018-06-01 01:03:20.232439|2018-06-01 01:03:20.232439
NCT00886028|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|September 2006||2006-09-30|April 2009|2009-04-30|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Interventional|||Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma|"Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma "|Unknown status|Active, not recruiting|Phase 2|31|Actual|National Institute of Cancerología||1|||f||||||||||||||2018-06-01 01:03:20.34919|2018-06-01 01:03:20.34919
NCT00886015|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2016-08-03||2017-04-11|2009-04-21|2009-04-22|Estimate|2017-04-11|2017-05-19|Actual||||2017-04-11|2017-05-19|Actual|May 2009||2009-05-31|April 2017|2017-04-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional||1927 participants were originally enrolled. 10 participants did not undergo surgery for the following reasons: refused surgery (5), ineligible because of lower eyelid trichiasis only (4), or surgery was delayed and patient did not attend (1). The final total number of participants was 1917.|Modified Instrumentation for Surgery to Correct Trichiasis|Partnership for the Rapid Elimination of Trachoma (PRET) Clinical Trial of Evaluation of Modified Instrumentation for Surgery to Correct Trichiasis|Completed||N/A|1927|Actual|Johns Hopkins University||2|||f||||t||||||||Yes|Deidentified data will be provided to investigators through application to the data committee at Johns Hopkins University.|2018-06-01 01:03:20.500039|2018-06-01 01:03:20.500039
NCT00886002|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-06-18|2009-04-21|2009-04-22|Estimate|||||||2010-06-18|2010-06-22|Estimate|November 2004||2004-11-30|June 2010|2010-06-30|January 2005|Actual|2005-01-31|||||Interventional|||Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers.|Explorative, Double-blind Study on Dose Effectiveness of DUROGESIC D-Trans 12 Mcg/h and 25mcg/h Compared to Transtec and Placebo in Acute Pain Models in Healthy Volunteers.|Completed||Phase 1|20|Actual|Janssen-Cilag A.G., Switzerland|||||f||||||||||||||2018-06-01 01:03:21.382578|2018-06-01 01:03:21.382578
NCT00885989|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2010-01-28|2009-04-21|2009-04-22|Estimate|||||||2010-01-28|2010-01-29|Estimate|May 2009||2009-05-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers|A Placebo-Controlled, Combined Single and Multiple Rising Dose Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV338 After Intravenous Administration in Healthy Male Subjects|Completed||Phase 1|42|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:03:21.483328|2018-06-01 01:03:21.483328
NCT00885976|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-06-25|2009-04-21|2009-04-22|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||The Predictors and Patient Versus Parental Perceptions of Health-Related Quality of Life in Pediatric Chronic Pain|The Predictors and Patient Versus Parental Perceptions of Health-Related Quality of Life in Pediatric Chronic Pain|Completed|||99|Actual|University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 01:03:21.574315|2018-06-01 01:03:21.574315
NCT00885963|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-02-07|2009-04-21|2009-04-22|Estimate|||||||2014-02-07|2014-02-10|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer|A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer|Terminated||Phase 2|62|Actual|Cyclacel Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:03:21.65146|2018-06-01 01:03:21.65146
NCT00885950|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2014-02-03|2009-04-21|2009-04-22|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Observational|||Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants|Prevention of the Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-based Neoadjuvant Chemotherapy for Colorectal Liver Metastases by Means of Anticoagulants|Completed|||80|Actual|Maastricht University Medical Center|||1||f||||t||||||Samples Without DNA|"~     Paraffin embedded liver tissue~   "|||2018-06-01 01:03:21.74543|2018-06-01 01:03:21.74543
NCT00885937|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2014-06-20|2009-04-21|2009-04-22|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparative Safety Study of New Sinecort Formulation Versus Positive Control|Single-blind, Randomized, Controlled, Single Center Trial to Evaluate the Skin Irritation Potential of a New Topical Formulation by Means of an Occlusive Patch Test in Healthy Subjects.|Completed||Phase 1|33|Actual|Bayer||3|||f||||f||||||||||2018-06-01 01:03:21.891972|2018-06-01 01:03:21.891972
NCT00885924|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2015-04-07|2009-04-21|2009-04-22|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery|Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery|Terminated||Phase 4|17|Actual|St. Olavs Hospital||2||to include required number of patients took too much time|f||||f||||||||||2018-06-01 01:03:22.104326|2018-06-01 01:03:22.104326
NCT00885911|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2017-06-22|2009-04-21|2009-04-22|Estimate|||||||2017-06-22|2017-06-26|Actual|March 2009||2009-03-31|June 2017|2017-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Evaluation of the Intubating Laryngeal Airway in Children|Evaluation of the Intubating Laryngeal Airway in Children - Phase 1|Completed|||110|Actual|University of British Columbia|||1||f||||f||||||||||2018-06-01 01:03:22.489554|2018-06-01 01:03:22.489554
NCT00885898|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|March 2005||2005-03-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|January 2007|Actual|2007-01-31||Interventional|NIV||Out-of-Hospital Non-Invasive Ventilation for Patients With Acute Respiratory Failure|Out-of-Hospital Non-Invasive Ventilation in Patients With Acute Respiratory Insufficiency|Completed||N/A|51|Actual|University of Göttingen||2|||f||||f||||||||||2018-06-01 01:03:22.583616|2018-06-01 01:03:22.583616
NCT00885885|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2017-07-31|2009-04-21|2009-04-22|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2009||2009-05-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PLANET||Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases|An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-only Metastases.|Completed||Phase 2|80|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-06-01 01:03:22.750826|2018-06-01 01:03:22.750826
NCT00885872|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2010-05-26|2009-04-21|2009-04-22|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|REACH||Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)|A 104-week, Open-label, Single-group Study: Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)|Unknown status|Recruiting|Phase 4|60|Anticipated|Chinese PLA General Hospital||1|||f||||f||||||||||2018-06-01 01:03:22.924222|2018-06-01 01:03:22.924222
NCT00885859|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|June 2009||2009-06-30|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Transcutaneous Electrical Nerve Stimulation (TENS) in Chronic Pain, Responders and Non-Responders?|Is Transcutaneous Electrical Nerve Stimulation (TENS) an Effective Method to Modulate Pain Transmission and Pain Perception in Patients Suffering From Chronic Non-Specific Pain Syndromes?|Unknown status|Not yet recruiting||62|Anticipated|Maastricht University Medical Center|||2||f||||f||||||||||2018-06-01 01:03:23.054951|2018-06-01 01:03:23.054951
NCT00885846|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2009-02-05||2015-10-23|2009-04-13|2009-04-22|Estimate|2009-04-13|2009-04-22|Estimate||||2015-10-23|2015-11-16|Estimate|June 2007||2007-06-30|April 2015|2015-04-30|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Effects of Qigong on Type 2 Diabetic Patients|A Pilot Study: The Effects of Qigong Therapy on Type 2 Diabetic Patients|Completed||N/A|32|Actual|Bastyr University|Limitations to this study include high withdrawal rate from PRT group, especially during the first cohort. Also, participants from both Qigong and PRT group changed or discontinued medications. Consequently, their results were excluded from analysis.|3|||f||||||||||||||2018-06-01 01:03:23.203266|2018-06-01 01:03:23.203266
NCT00885833|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2014-07-11|2009-04-21|2009-04-22|Estimate|||||||2014-07-11|2014-07-14|Estimate|February 2007||2007-02-28|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)|Phase I/II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome|Completed||Phase 1/Phase 2|5|Anticipated|The Korean Society of Pediatric Hematology Oncology||1|||f||||f||||||||||2018-06-01 01:03:23.740637|2018-06-01 01:03:23.740637
NCT00885820|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2014-09-17|2009-04-21|2009-04-22|Estimate|||||||2014-09-17|2014-09-18|Estimate|September 2001||2001-09-30|September 2014|2014-09-30|January 2006|Actual|2006-01-31|July 2004|Actual|2004-07-31||Interventional|||Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection|The Effects of Treatment of Subclinical Rejection on Renal Histology and Graft Function in Renal Transplant Patients Receiving Tacrolimus and Mycophenolate Mofetil|Completed||Phase 4|240|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 01:03:23.857441|2018-06-01 01:03:23.857441
NCT00885807|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2011-06-17|2009-04-21|2009-04-22|Estimate|||||||2011-06-17|2011-06-20|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||A Prospective Chart Review to Validate the WFIRS (Weiss Functional Impairment Rating Scale)|Psychometric Validation of the Weiss Functional Impairment Rating Scale and the Weiss Symptom Record in Patients With Attention-Deficit Hyperactivity Disorder|Completed|||220|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 01:03:24.018669|2018-06-01 01:03:24.018669
NCT00885794|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2011-06-23|2009-04-21|2009-04-22|Estimate|||||||2011-06-23|2011-06-27|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|May 2011|Actual|2011-05-31||Interventional|MORE||Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)|Microperimetry and High-Definition-OCT in Ranibizumab Treatment for Diabetic Macular Edema (MORE-Study)|Unknown status|Active, not recruiting|Phase 2/Phase 3|40|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||||2018-06-01 01:03:24.126718|2018-06-01 01:03:24.126718
NCT00885781|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2011-10-13|2009-04-21|2009-04-22|Estimate|||||||2011-10-13|2011-10-17|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|December 2010|Actual|2010-12-31|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety Comparison Between SMOFlipid and Lipovenoes MCT|Clinical Study Comparing Safety and Efficacy of SMOFlipid, the New Generation Fat Emulsion, in Comparison With the Current Fat Emulsion Lipovenoes MCT at the Hospital|Completed||Phase 4|40|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:03:24.282919|2018-06-01 01:03:24.282919
NCT00885768|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2010-03-09||2011-05-11|2009-04-21|2009-04-22|Estimate|2010-03-09|2010-03-23|Estimate||||2011-05-11|2011-05-13|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|September 2008|Actual|2008-09-30||Observational|RAS||Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization|Prevalence of Renal Artery Stenosis in Patients Refered for Cardiac Catheterization to Heart Center Hospital in July-September 2008|Completed|||146|Actual|Imam Khomeini Hospital|||1||f||||t||||||||||2018-06-01 01:03:24.453111|2018-06-01 01:03:24.453111
NCT00885755|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2015-09-01||2018-02-28|2009-04-21|2009-04-22|Estimate|2015-09-01|2015-10-05|Estimate||||2018-02-28|2018-03-29|Actual|August 13, 2009|Actual|2009-08-13|February 2018|2018-02-28|February 18, 2013|Actual|2013-02-18|February 18, 2013|Actual|2013-02-18||Interventional||Intent-to-treat (ITT) population: All registered participants were included in the ITT population.|A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer|A Prospective Study to Evaluate Alterations in Molecular Biomarkers in HER2 Neu Positive Metastatic Breast Cancer Together With Assessment of Trastuzumab Use Beyond Progression After Initial Response to Trastuzumab-taxane Based Treatment|Completed||Phase 2|33|Actual|Hoffmann-La Roche|The study was prematurely terminated on December 31, 2012. The end of study follow-up was February 18, 2013.|1|||f||||||||||||||2018-06-01 01:03:24.819134|2018-06-01 01:03:24.819134
NCT00885742|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2012-04-30||2012-07-10|2009-04-21|2009-04-22|Estimate|2012-06-01|2012-07-04|Estimate||||2012-07-10|2012-07-16|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency|A Prospective, Multicenter, Open-label, Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency|Completed||Phase 3|41|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 01:03:26.198501|2018-06-01 01:03:26.198501
NCT00885729|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2015-10-14|2009-04-21|2009-04-22|Estimate|||||||2015-10-14|2015-10-15|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|July 2018|Anticipated|2018-07-31|July 2011|Actual|2011-07-31||Interventional|||Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects|Mesenchymal Stem Cells in a Clinical Trial to Heal Articular Cartilage Defects|Active, not recruiting||Phase 1|50|Anticipated|University Hospital, Akershus||2|||f||||f||||||||||2018-06-01 01:03:26.535881|2018-06-01 01:03:26.535881
NCT00885716|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-04-07|2009-04-21|2009-04-22|Estimate|||||||2010-04-07|2010-04-08|Estimate|May 2009||2009-05-31|April 2010|2010-04-30||||||||Interventional|||A Shared Decision Making Training for Inpatients With Schizophrenia|Shared Decision Making: Ein Kommunikationstraining für Patienten Mit Schizophrenie|Unknown status|Recruiting|N/A|80|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 01:03:26.653633|2018-06-01 01:03:26.653633
NCT00885703|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2018-01-11||2018-02-12|2009-04-20|2009-04-22|Estimate|2018-02-12|2018-03-12|Actual||||2018-02-12|2018-03-12|Actual|April 16, 2010|Actual|2010-04-16|February 2018|2018-02-28|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals|A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis|Completed||Phase 1/Phase 2|168|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 01:03:26.846248|2018-06-01 01:03:26.846248
NCT00885690|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-09-03|2009-04-21|2009-04-22|Estimate|||||||2013-09-03|2013-09-04|Estimate|April 2009||2009-04-30|September 2013|2013-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SEROLA||Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)|A Multicentre Double-blinded Randomized Head-to-head Study|Terminated||N/A|11|Actual|University of Aarhus||2||Due to recruitment problems|f||||t||||||||||2018-06-01 01:03:30.194378|2018-06-01 01:03:30.194378
NCT00885677|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2016-11-23||2017-02-17|2009-04-21|2009-04-22|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|June 2009||2009-06-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|MORE-CARE||MOnitoring REsynchronization deviCes and cARdiac patiEnts|MOnitoring REsynchronization deviCes and cARdiac patiEnts|Terminated||N/A|918|Actual|Medtronic Bakken Research Center||2||Low enrollment rate|f||||t||||||||||2018-06-01 01:03:30.340075|2018-06-01 01:03:30.340075
NCT00885664|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-05-14|2009-04-21|2009-04-22|Estimate|||||||2009-05-14|2009-05-15|Estimate|October 2005||2005-10-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection|Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection|Unknown status|Active, not recruiting|Phase 4|60|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 01:03:31.276084|2018-06-01 01:03:31.276084
NCT00885651|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|MEXICHO||Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines|A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects.|Unknown status|Enrolling by invitation|Phase 4|30|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:03:31.467906|2018-06-01 01:03:31.467906
NCT00885638|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2012-09-21||2013-12-25|2009-04-21|2009-04-22|Estimate|2012-12-07|2013-01-15|Estimate||||2013-12-25|2014-01-30|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|May 2011|Actual|2011-05-31||Interventional|||Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion|Study of the Effect of Sitagliptin on the Hormonal Responses to Macronutrient Ingestion in Healthy Volunteers|Completed||Phase 4|12|Actual|Lund University||2|||f||||f||||||||||2018-06-01 01:03:31.651071|2018-06-01 01:03:31.651071
NCT00885625|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-07-14|2009-04-21|2009-04-22|Estimate|||||||2010-07-14|2010-07-15|Estimate|March 2009||2009-03-31|June 2010|2010-06-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|PCV||7-valent Pneumococcal Conjugated Vaccination|1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection|Unknown status|Recruiting|Phase 4|350|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:03:31.921267|2018-06-01 01:03:31.921267
NCT00885612|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2010-06-28|2009-04-21|2009-04-22|Estimate|||||||2010-06-28|2010-06-29|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)|10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors|Completed|||1114|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:03:32.032829|2018-06-01 01:03:32.032829
NCT00885599|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2012-07-16|2009-04-21|2009-04-22|Estimate|||||||2012-07-16|2012-07-17|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy of a Naturally-derived Mouthrinse for Gingival Inflammation|A Randomized Multi-treatment/Controlled Double-blinded Study to Evaluate the Efficacy of a Naturally-derived Mouthrinse in the Treatment of Gingival Inflammation.|Completed||Phase 1/Phase 2|94|Actual|Shaare Zedek Medical Center||4|||f||||f||||||||||2018-06-01 01:03:32.129076|2018-06-01 01:03:32.129076
NCT00885586|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2018-03-19|2009-04-21|2009-04-22|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2008||2008-11-30|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ACUZoster||Acupuncture in Herpes Zoster Neuralgia (ACUZoster)|Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia|Active, not recruiting||Phase 4|68|Actual|Ludwig-Maximilians - University of Munich||3|||f||||t||||||||||2018-06-01 01:03:32.227963|2018-06-01 01:03:32.227963
NCT00885573|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2014-05-02|2009-04-21|2009-04-22|Estimate|||||||2014-05-02|2014-05-05|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SENSITEST||Pharyngeal Sensitivity in Diagnosis Algorithm for Sleep Apnea Syndrome|Measurement of Pharyngeal Sensitivity With the SENSITEST Device: Validation of the Diagnosis Algorithm for Sleep Disordered Breathing|Completed||N/A|52|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-06-01 01:03:32.349325|2018-06-01 01:03:32.349325
NCT00885560|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2012-09-14|2009-04-21|2009-04-22|Estimate|||||||2012-09-14|2012-09-18|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||SNAP 25 Gene Study|Do People With ADHD, Who Respond Well to Amphetamine Medication But Not to Methylphenidate, Have Allelic Variants of the SNAP 25 Gene?|Terminated|||19|Actual|University of British Columbia||||"Collecting data for the population involved was very difficult. Over 3 years, only 19~   participants were recruited."|f||||f||||||Samples With DNA|"~     Whole blood for genetic analysis.~   "|||2018-06-01 01:03:32.967974|2018-06-01 01:03:32.967974
NCT00885547|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2015-03-31|2009-04-20|2009-04-22|Estimate|||||||2015-03-31|2015-04-02|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis|Prospective Clinical Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis.|Terminated||N/A|90|Actual|Nanjing University School of Medicine||1||low-rate of enrollment|f||||f||||||||||2018-06-01 01:03:33.0537|2018-06-01 01:03:33.0537
NCT00885534|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2015-04-07||2015-04-21|2009-04-21|2009-04-22|Estimate|2015-04-21|2015-05-06|Estimate||||2015-04-21|2015-05-06|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma|Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma|Completed||Phase 2|7|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:03:33.196675|2018-06-01 01:03:33.196675
NCT00885521|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2014-03-10|2009-04-21|2009-04-22|Estimate|||||||2014-03-10|2014-03-11|Estimate|February 2009||2009-02-28|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Exercise Training in Patients With Non-cystic Fibrosis (CF) Bronchiectasis|Exercise Training in Patients With Non-CF Bronchiectasis - a Multi-centre Randomized Controlled Trial|Completed||Phase 1|39|Actual|Bayside Health||2|||f||||t||||||||||2018-06-01 01:03:33.449123|2018-06-01 01:03:33.449123
NCT00885001|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-04-20|2009-04-20|2009-04-21|Estimate|||||||2009-04-20|2009-04-21|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||The Effects of Short Arc Banding|The Effects of Short Arc Banding: A Novel Exercise Intervention in Patients With Chronic Low Back Pain|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 01:03:44.749957|2018-06-01 01:03:44.749957
NCT00885508|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2015-04-23|2009-04-21|2009-04-22|Estimate|||||||2015-04-23|2015-04-24|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|GFM-Chimio-Rev||A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q|A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q|Unknown status|Active, not recruiting|Phase 2|85|Actual|Groupe Francophone des Myelodysplasies||1|||f||||t||||||||||2018-06-01 01:03:33.588669|2018-06-01 01:03:33.588669
NCT00885495|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-21|2009-04-21|2009-04-22|Estimate|||||||2009-04-21|2009-04-22|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Interventional|||Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study|The Effects of Darunavir Plus Ritonavir on the Pharmacokinetics and Pharmacodynamics of Rosuvastatin|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 01:03:33.734139|2018-06-01 01:03:33.734139
NCT00885482|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2015-02-04||2015-02-23|2009-04-20|2009-04-22|Estimate|2015-02-04|2015-02-23|Estimate||||2015-02-23|2015-03-13|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|AtLaS||Atazanavir and Lamivudine for Treatment Simplification|Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Atazanavir/Ritonavir + Lamivudine in Patients Stably Treated With Two NRTIs + Atazanavir/Ritonavir With Optimal Virologic Response.|Completed||Phase 4|40|Actual|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-06-01 01:03:33.955436|2018-06-01 01:03:33.955436
NCT00885469|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-08-03|2009-04-21|2009-04-22|Estimate|||||||2009-08-03|2009-08-04|Estimate|December 2007||2007-12-31|August 2009|2009-08-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Observational|MA-76||PillCam® ESO 2 in Esophageal Pathologies|Evaluation of PillCam® ESO 2 in Patients With Suspected Esophageal Pathologies|Completed|||101|Actual|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 01:03:34.216321|2018-06-01 01:03:34.216321
NCT00885456|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2018-03-21|2009-04-21|2009-04-22|Estimate|||||||2018-03-21|2018-03-23|Actual|October 30, 2011|Actual|2011-10-30|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|PREVENT||Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke or Transient Ischemic Attack: A Multi-site RCT|Effectiveness of a Program of Rehabilitative Exercise and Education to Avert Vascular Events After Non-disabling Stroke: A Multi-site RCT|Completed||Phase 2|187|Actual|Nova Scotia Health Authority||2|||f||||t||||||||||2018-06-01 01:03:34.343413|2018-06-01 01:03:34.343413
NCT00885443|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2017-06-30|2009-04-21|2009-04-22|Estimate|||||||2017-06-30|2017-07-05|Actual|February 2009||2009-02-28|May 2017|2017-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Emergence Delirium in Children: Total Intravenous Anesthesia With Propofol and Remifentanil Versus Inhalational Sevoflurane Anesthesia|Emergence Delirium in Children: Total Intravenous Anesthesia With Propofol and Remifentanil Versus Inhalational Sevoflurane Anesthesia|Completed||N/A|112|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:03:34.465278|2018-06-01 01:03:34.465278
NCT00885430|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2015-09-18|2009-04-21|2009-04-22|Estimate|||||||2015-09-18|2015-09-22|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Pico-Salax Colonic Preparation Study: Quantifying Electrolyte and Volume Status Changes|Pico-Salax Colonic Preparation Study: Quantifying Electrolyte and Volume Status Changes|Completed||Phase 4|20|Actual|Queen's University||1|||f||||f||||||||||2018-06-01 01:03:34.598965|2018-06-01 01:03:34.598965
NCT00885417|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2011-04-21|2009-04-21|2009-04-22|Estimate|||||||2011-04-21|2011-04-22|Estimate|April 2009||2009-04-30|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study|The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study|Completed||Phase 4|142|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 01:03:34.718467|2018-06-01 01:03:34.718467
NCT00885404|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|||2010-02-24|2009-04-21|2009-04-22|Estimate|||||||2010-02-24|2010-02-25|Estimate|February 2009||2009-02-28|February 2010|2010-02-28|August 2010|Anticipated|2010-08-31|August 2009|Anticipated|2009-08-31||Interventional|CHLORIDE||Chloride High Level Of Resuscitation Infusion Chloride High Level Of Resuscitation Infusion Delivered Evaluation|A Prospective, Before and After Study of the Impact of Lower Chloride Intravenous Fluid Management on Patients' Acid-base Status, Renal Profile,Length of Stay and Mortality.|Unknown status|Active, not recruiting|Phase 4|7000|Anticipated|Austin Health||1|||f||||f||||||||||2018-06-01 01:03:34.826173|2018-06-01 01:03:34.826173
NCT00885391|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2014-12-09|2009-04-21|2009-04-22|Estimate|||||||2014-12-09|2014-12-11|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|DCCV||QT Variability Pre and Post Cardioversion|QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation|Completed|||219|Actual|Vanderbilt University|||||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 01:03:34.97833|2018-06-01 01:03:34.97833
NCT00885378|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-21|2011-11-02||2015-05-08|2009-04-21|2009-04-22|Estimate|2011-11-14|2011-12-16|Estimate||||2015-05-08|2015-06-01|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, Twice Daily, in Combination With Metformin IR in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin IR Alone|Completed||Phase 3|166|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:03:35.126033|2018-06-01 01:03:35.126033
NCT00885365|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2014-05-14||2014-06-19|2009-04-20|2009-04-21|Estimate|2014-06-19|2014-06-20|Estimate||||2014-06-19|2014-06-20|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|CT03 Core|Safety Population|A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®|A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Compared to TOBI® in the Treatment of Patients With Cystic Fibrosis and Chronic Infection With Pseudomonas Aeruginosa|Completed||Phase 3|324|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 01:03:36.151068|2018-06-01 01:03:36.151068
NCT00885183|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-19|||2012-05-11|2009-04-20|2009-04-21|Estimate|||||||2012-05-11|2012-05-14|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|Acubreast||Adjuvant Acupuncture Care for Breast Cancer Patients Experiencing Side Effects From Chemotherapy|Adjuvant Acupuncture Care for Breast Cancer Patients Experiencing Side Effects From Chemotherapy. A Randomised Controlled Pilot and Feasibility Study|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital of North Norway||1|||f||||f||||||||||2018-06-01 01:03:39.117516|2018-06-01 01:03:39.117516
NCT00885352|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2011-11-04||2017-04-27|2009-04-20|2009-04-21|Estimate|2011-12-27|2012-02-01|Estimate||||2017-04-27|2017-05-23|Actual|April 15, 2009|Actual|2009-04-15|April 2017|2017-04-30|November 10, 2010|Actual|2010-11-10|November 10, 2010|Actual|2010-11-10||Interventional|||Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and Pioglitazone|Completed||Phase 3|313|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:03:37.30921|2018-06-01 01:03:37.30921
NCT00885339|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-03-10|2009-04-20|2009-04-21|Estimate|||||||2010-03-10|2010-03-11|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure|Completed|||100|Anticipated|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 01:03:37.750959|2018-06-01 01:03:37.750959
NCT00885326|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2018-04-09|2009-04-18|2009-04-21|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2009||2009-12-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|April 2014|Actual|2014-04-30||Interventional|||N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma|A Phase I Study of Bevacizumab With Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children With Recurrent or Refractory Neuroblastoma|Active, not recruiting||Phase 1|36|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||1|||f||||t||||||||||2018-06-01 01:03:37.887076|2018-06-01 01:03:37.887076
NCT00885313|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2011-05-12|2009-04-20|2009-04-21|Estimate|||||||2011-05-12|2011-05-13|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|EDACN||Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)|Study of Efficacy and Tolerability of Docosahexaenoic Acid (DHA) on Children Affected by Nonalcoholic Fatty Liver Disease (NAFLD).|Completed||Phase 1/Phase 2|60|Actual|Bambino Gesù Hospital and Research Institute||3|||f||||t||||||||||2018-06-01 01:03:38.065231|2018-06-01 01:03:38.065231
NCT00885300|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-20|2009-04-20|2009-04-21|Estimate|||||||2009-04-20|2009-04-21|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients|Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients|Completed||N/A|100|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:03:38.198516|2018-06-01 01:03:38.198516
NCT00885287|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-01-15|2009-04-20|2009-04-21|Estimate|||||||2013-01-15|2013-01-16|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|InterACT||Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania|Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania|Completed||Phase 4|830|Actual|University of Copenhagen||3|||f||||t||||||||||2018-06-01 01:03:38.297516|2018-06-01 01:03:38.297516
NCT00885274|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2015-08-27|2009-04-20|2009-04-21|Estimate|||||||2015-08-27|2015-08-31|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy|A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy.|Completed||Phase 4|250|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 01:03:38.402528|2018-06-01 01:03:38.402528
NCT00885261|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-19|||2014-03-26|2009-04-20|2009-04-21|Estimate|||||||2014-03-26|2014-03-27|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|April 2012|Actual|2012-04-30|||||Observational|||The Prevalence of Metabolic Syndrome in Patients Suffering From Chronic Pain|The Prevalence of Metabolic Syndrome in Patients Suffering From Chronic Pain|Completed|||100|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 01:03:38.490366|2018-06-01 01:03:38.490366
NCT00885248|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-20|2009-04-20|2009-04-21|Estimate|||||||2009-04-20|2009-04-21|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Observational|||Integrated Positron Emission Tomography - Computed Tomography (PET-CT) in Patients With Pancreatic Cancer|Clinical Implication of Integrated PET-CT in the Patients With Pancreatic Cancer|Unknown status|Active, not recruiting||70|Anticipated|Asan Medical Center|||||f||||t||||||||||2018-06-01 01:03:38.579638|2018-06-01 01:03:38.579638
NCT00885235|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-08-02|2009-04-20|2009-04-21|Estimate|||||||2009-08-02|2009-08-04|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|||Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure|Completed|||40|Anticipated|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 01:03:38.658969|2018-06-01 01:03:38.658969
NCT00885222|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-06-02|2009-04-20|2009-04-21|Estimate|||||||2010-06-02|2010-06-03|Estimate|May 2009||2009-05-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease Patients|Antidepressant Effect of Deep Brain Stimulation (DBS) in Parkinson's Disease (PD) Patients: Relationship of Stimulation Parameters to Improvement in the Clinical Features of Depression in PD Patients.|Completed||N/A|20|Anticipated|Hadassah Medical Organization||3|||f||||||||||||||2018-06-01 01:03:38.752428|2018-06-01 01:03:38.752428
NCT00885209|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-03-10|2009-04-20|2009-04-21|Estimate|||||||2010-03-10|2010-03-11|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Observational|||Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure|Completed|||127|Actual|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 01:03:38.868445|2018-06-01 01:03:38.868445
NCT00885196|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2016-11-15|2009-04-20|2009-04-21|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2009||2009-04-30|April 2016|2016-04-30||||August 2011|Actual|2011-08-31||Interventional|||A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis|A Double Blind, Randomized, Placebo Controlled, Multicenter, Dose Finding Study of Oral AEB071 Assessing Psoriasis Area and Severity Index (PASI) Response and a Function of Dose and Treatment Duration (Primary Outcome) in Patients With Plaque Psoriasis|Completed||Phase 2|336|Actual|Novartis||4|||f||||||||||||||2018-06-01 01:03:38.969025|2018-06-01 01:03:38.969025
NCT00885170|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2017-01-03||2017-03-06|2009-04-20|2009-04-21|Estimate|2017-03-06|2017-04-18|Actual||||2017-03-06|2017-04-18|Actual|April 2009||2009-04-30|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||The baseline characteristics are displayed for the All-Participants-As-Treated Population.|A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)|A Phase IIa Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate|Completed||Phase 2|246|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 01:03:39.287994|2018-06-01 01:03:39.287994
NCT00885157|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2014-01-20|2009-04-20|2009-04-21|Estimate|||||||2014-01-20|2014-01-22|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly|Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines|Completed||Phase 2|225|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:03:40.410239|2018-06-01 01:03:40.410239
NCT00885144|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-06-23|2009-04-20|2009-04-21|Estimate|||||||2009-06-23|2009-06-24|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|iLiNS-ACCEPT-M||Trial on the Acceptability of Modified Lipid Based Nutrient Supplements Among Malawian Infants|Differential Acceptability of New Lipid Based Nutrient Supplement (LNS) Formulations for Prevention of Moderate Malnutrition|Completed||Phase 1|19|Actual|University of Tampere|||||f||||f||||||||||2018-06-01 01:03:40.551366|2018-06-01 01:03:40.551366
NCT00885131|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2018-05-02|2009-04-18|2009-04-21|Estimate|||||||2018-05-02|2018-05-03|Actual|April 15, 2009||2009-04-15|January 22, 2013|2013-01-22|January 22, 2013||2013-01-22|||||Observational|||Effect of Reward on Learning in Motor Cortex|Effects of Reward on Learning in the Motor Cortex|Completed|||64|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:03:40.700628|2018-06-01 01:03:40.700628
NCT00885118|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2014-05-16||2014-11-13|2009-04-20|2009-04-21|Estimate|2014-05-16|2014-06-16|Estimate||||2014-11-13|2014-11-25|Estimate|April 2009||2009-04-30|November 2014|2014-11-30||||October 2009|Actual|2009-10-31||Interventional|||4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)|A Phase II, Randomised, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Once Daily Oral Administration of BI 10773 (1 mg, 5 mg, 10 mg, and 25 mg) for 28 Days in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|100|Actual|Boehringer Ingelheim|Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information”.|5|||f||||||||||||||2018-06-01 01:03:40.91203|2018-06-01 01:03:40.91203
NCT00885105|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2009-09-02||2016-04-12|2009-04-20|2009-04-21|Estimate|2009-12-03|2010-01-01|Estimate||||2016-04-12|2016-04-14|Estimate|October 2005||2005-10-31|April 2016|2016-04-30|September 2007|Actual|2007-09-30|January 2006|Actual|2006-01-31||Interventional|||Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age|Evaluation of Serologic Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® Vaccine at 2 Months of Age|Completed||Phase 3|242|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:03:42.63468|2018-06-01 01:03:42.63468
NCT00885092|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2012-02-24||2012-03-21|2009-04-20|2009-04-21|Estimate|2012-02-24|2012-03-20|Estimate||||2012-03-21|2012-03-27|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Single Site Study of the Wettability of Contact Lenses With an Investigational Multi-Purpose Disinfecting Solution vs. a Marketed Multi-Purpose Solution|Wettability of Silicone Hydrogel Lenses With SiH MPDS FID 114675A vs. A Marketed Multi-Purpose Solution|Completed||N/A|40|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:03:43.379105|2018-06-01 01:03:43.379105
NCT00885079|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-19|2013-09-12||2013-11-18|2009-04-20|2009-04-21|Estimate|2013-11-18|2013-12-12|Estimate||||2013-11-18|2013-12-12|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Confirmatory Study of OPC-12759 Ophthalmic Suspension|Confirmatory Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients|Completed||Phase 3|188|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:03:43.779236|2018-06-01 01:03:43.779236
NCT00885066|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2015-02-08|2009-04-18|2009-04-21|Estimate|||||||2015-02-08|2015-02-10|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer|Phase I Study of Gemcitabine, Capecitabine, and Erlotinib Together in Advanced Pancreatic Cancers|Completed||Phase 1|30|Actual|Centre Antoine Lacassagne||1|||f||||||||||||||2018-06-01 01:03:44.219832|2018-06-01 01:03:44.219832
NCT00885053|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-01-25|2009-04-20|2009-04-21|Estimate|||||||2010-01-25|2010-01-26|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ADIPOMEGA||Fish Oil and Inflammation in Overweight Subjects|The Effect of Acute and Short-term Intervention With Fish Oil on Overweight Subjects - Focus on Inflammation|Completed||N/A|50|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-06-01 01:03:44.306011|2018-06-01 01:03:44.306011
NCT00885040|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2018-05-18|2009-04-18|2009-04-21|Estimate|||||||2018-05-18|2018-05-21|Actual|April 17, 2009||2009-04-17|February 13, 2018|2018-02-13||||||||Observational|||Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders|Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders|Recruiting|||110|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:03:44.403957|2018-06-01 01:03:44.403957
NCT00885027|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2013-11-13|2009-04-20|2009-04-21|Estimate|||||||2013-11-13|2013-11-14|Estimate|March 2009||2009-03-31|November 2013|2013-11-30||||April 2009|Actual|2009-04-30||Observational|||MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment|Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment|Completed|||1342|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:03:44.533898|2018-06-01 01:03:44.533898
NCT00885014|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2012-03-15|2009-04-20|2009-04-21|Estimate|||||||2012-03-15|2012-03-19|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Telephone Cognitive-Behavioral Therapy (CBT) for Subthreshold Depression and Presenteeism in Workplace|Telephone Cognitive-behavioral Therapy for Subthreshold Depression and Presenteeism in Workplace: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|118|Actual|Kyoto University||2|||f||||t||||||||||2018-06-01 01:03:44.645558|2018-06-01 01:03:44.645558
NCT00884988|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-19|||2012-02-19|2009-04-20|2009-04-21|Estimate|||||||2012-02-19|2012-02-22|Estimate|February 2010||2010-02-28|February 2012|2012-02-29||||December 2012|Anticipated|2012-12-31||Interventional|||Lymphomyosot for Ankle Edema Following Fracture|The Efficacy of Lymphomyosot in the Treatment of Posttraumatic Edema Following Ankle Fracture, Pending Surgery: a Randomized, Double-blind, Placebo-controlled Study.|Suspended||Phase 2|60|Anticipated|Shaare Zedek Medical Center||2||Study recruiter withdrew from study. Suspended until replacement found.|f||||f||||||||||2018-06-01 01:03:44.841926|2018-06-01 01:03:44.841926
NCT00884975|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-20|2009-04-20|2009-04-21|Estimate|||||||2009-04-20|2009-04-21|Estimate|May 2002||2002-05-31|April 2009|2009-04-30|June 2009|Anticipated|2009-06-30|March 2009|Actual|2009-03-31||Observational|||Exacerbations and Health Related Quality of Life in Chronic Obstructive Pulmonary Disease|Exacerbations and Health Related Quality of Life in Chronic Obstructive Pulmonary Disease: CRECOPD Study|Unknown status|Active, not recruiting||102|Actual|University of Thessaly|||||f||||t||||||||||2018-06-01 01:03:44.940044|2018-06-01 01:03:44.940044
NCT00884962|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2011-10-20|2009-04-20|2009-04-21|Estimate|||||||2011-10-20|2011-10-21|Estimate|December 2008||2008-12-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema||Completed||Phase 1|25|Actual|Aeris Therapeutics||1|||f||||||||||||||2018-06-01 01:03:45.011846|2018-06-01 01:03:45.011846
NCT00884949|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2014-03-13||2014-05-28|2009-04-17|2009-04-21|Estimate|2014-05-28|2014-06-30|Estimate||||2014-05-28|2014-06-30|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA|A Phase 1/2, Multicenter, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)|Completed||Phase 1/Phase 2|20|Actual|BioMarin Pharmaceutical||1|||f||||f||||||||||2018-06-01 01:03:46.234756|2018-06-01 01:03:46.234756
NCT00884936|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2015-03-30|2009-04-20|2009-04-21|Estimate|||||||2015-03-30|2015-03-31|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Observational|||Identification of Gene Biomarkers in Aging Skin|Identification of Gene Biomarkers in Aging Skin; a Blinded, Prospective, Single-center, Clinical Study|Completed|||121|Actual|Interleukin Genetics, Inc.|||3||f||||t||||||Samples With DNA|"~     A 4 mm punch biopsy taken from exposed and unexposed skin.~   "|||2018-06-01 01:03:47.494658|2018-06-01 01:03:47.494658
NCT00884910|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2010-08-02||2012-07-12|2009-04-20|2009-04-21|Estimate|2010-10-13|2010-11-03|Estimate||||2012-07-12|2012-07-16|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Long Term Use of the Provox Vega 22.5|"Amendment on Phase 1 Trial N07VEG Assessment of a Next Generation Indwelling Provox Voice Rehabilitation System (Vega). Amendment 3: Long-term Use of the Provox Vega"|Completed||Phase 2|33|Actual|Atos Medical AB|||||f||||f||||||||||2018-06-01 01:03:47.600345|2018-06-01 01:03:47.600345
NCT00884897|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2015-02-26||2017-05-02|2009-04-20|2009-04-21|Estimate|2017-05-02|2017-06-01|Actual||||2017-05-02|2017-06-01|Actual|January 2010||2010-01-31|May 2017|2017-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Baseline participants are participants that were randomized to one of the two treatment groups.|Oxytocin and Social Cognition in Schizophrenia|Oxytocin and Social Cognition in Schizophrenia|Completed||Phase 2|28|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 01:03:47.82544|2018-06-01 01:03:47.82544
NCT00884884|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2015-10-05|2009-04-20|2009-04-21|Estimate|||||||2015-10-05|2015-10-07|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|AT||Aripiprazole and Topiramate on Free-Choice Alcohol Use|Aripiprazole and Topiramate on Free-Choice Alcohol Use|Completed||Phase 2/Phase 3|90|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||9|||f||||f||||||||||2018-06-01 01:03:48.224976|2018-06-01 01:03:48.224976
NCT00884871|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-11-10|2009-04-20|2009-04-21|Estimate|||||||2009-11-10|2009-11-11|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Study of Surgically-Induced Weight Loss on Pelvic Floor Disorders|A Prospective Cohort Study of the Impact of Surgically-Induced Weight Loss on Pelvic Floor Disorders|Completed|||100|Anticipated|University of California, San Diego|||1||f||||f||||||||||2018-06-01 01:03:48.38344|2018-06-01 01:03:48.38344
NCT00884858|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-04-29|2009-04-20|2009-04-21|Estimate|||||||2013-04-29|2013-04-30|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects|Use of Maraviroc (MVC) in Immunological Non-responder HIV-1-infected Patients.|Completed||Phase 4|100|Actual|ASST Fatebenefratelli Sacco||2|||f||||f||||||||||2018-06-01 01:03:48.58339|2018-06-01 01:03:48.58339
NCT00884845|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-03-25|2009-04-20|2009-04-21|Estimate|||||||2014-03-25|2014-03-26|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors|Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|35|Actual|PharmaMar||1|||f||||f||||||||||2018-06-01 01:03:48.732918|2018-06-01 01:03:48.732918
NCT00884832|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2013-10-16||2014-01-20|2009-04-20|2009-04-21|Estimate|2014-01-20|2014-03-06|Estimate||||2014-01-20|2014-03-06|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Placebo-Controlled Study of Clonidine for Fecal Incontinence.|A Placebo-Controlled Study of Clonidine for Fecal Incontinence.|Completed||Phase 2|44|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:03:48.8761|2018-06-01 01:03:48.8761
NCT00884819|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2015-04-01|2009-04-20|2009-04-21|Estimate|||||||2015-04-01|2015-04-03|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome|Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial|Terminated||N/A|4|Actual|Lawson Health Research Institute||2||Poor recruitment|f||||f||||||||||2018-06-01 01:03:49.612246|2018-06-01 01:03:49.612246
NCT00884806|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2012-02-20||2012-03-21|2009-04-20|2009-04-21|Estimate|2012-02-20|2012-03-22|Estimate||||2012-03-21|2012-03-27|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||7-Day, Multi-Site Study of an Investigational Multi-Purpose Disinfecting Solution for Contact Lens Wearers|Corneal Staining Evaluation of SiH MPDS FID 114675A|Completed||N/A|110|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:03:49.73276|2018-06-01 01:03:49.73276
NCT00883922|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-04-17|2009-04-17|2009-04-20|Estimate|||||||2009-04-17|2009-04-20|Estimate|January 2007||2007-01-31|April 2009|2009-04-30||||||||Observational|||Central Venous Saturation (ScvO2) Monitoring in Pediatric Patients Undergoing Cardiac Surgery|Central Venous Saturation (ScvO2) Monitoring in Pediatric Patients Undergoing Cardiac Surgery|Unknown status|Recruiting||100|Anticipated|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 01:04:07.638309|2018-06-01 01:04:07.638309
NCT00884793|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2011-08-08||2012-06-18|2009-04-20|2009-04-21|Estimate|2012-06-18|2012-07-23|Estimate||||2012-06-18|2012-07-23|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|PLUS||Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut|A Prospective Longitudinal Pilot Study to Measure the Effect of Intensification With Raltegravir +/- a Protease Inhibitor (PI) or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) on HIV-1 Levels in the Gut|Completed||N/A|8|Actual|University of California, San Francisco|1) relatively small number of participants; 2) intensification may have been too short; 3)the biopsies themselves can cause inflammation/microbial leakage; 4) sampling may miss viral replication if it occurs in temporally and spatially-discrete foci|1|||f||||t||||||||||2018-06-01 01:03:50.088426|2018-06-01 01:03:50.088426
NCT00884780|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-07-30|2009-04-20|2009-04-21|Estimate|||||||2013-07-30|2013-07-31|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||Development of a New Electronic Measure of Pediatric Pain: A Pilot Study|Development of a New Electronic Measure of Pediatric Pain: A Pilot Study|Completed|||20|Actual|Children's Mercy Hospital Kansas City|||1||f||||f||||||||||2018-06-01 01:03:50.371088|2018-06-01 01:03:50.371088
NCT00884767|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2009-07-07|2009-04-18|2009-04-21|Estimate|||||||2009-07-07|2009-07-08|Estimate|September 2007||2007-09-30|July 2009|2009-07-31||||August 2009|Anticipated|2009-08-31||Interventional|||Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin|Characterization and Research of Predictive Markers of Neurotoxicity During Treatment With Oxaliplatin in Colorectal Carcinoma: a Genetic and Proteomic Approach. Phase II Multicenter Study|Unknown status|Recruiting|Phase 2|206|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:03:50.453649|2018-06-01 01:03:50.453649
NCT00884754|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|2010-12-13||2010-12-13|2009-04-20|2009-04-21|Estimate|2010-12-13|2011-01-11|Estimate||||2010-12-13|2011-01-11|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Comparison of GlideScope-Specific Rigid Stylet to Standard Malleable Stylet for GlideScope Intubation by Novice Operators|Comparison of GlideScope-Specific Rigid Stylet to Standard Malleable Stylet for GlideScope Intubation by Novice Operators|Completed||N/A|60|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 01:03:50.562144|2018-06-01 01:03:50.562144
NCT00884741|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|2015-12-18||2018-01-04|2009-04-18|2009-04-21|Estimate|2016-08-18|2016-10-12|Estimate||||2018-01-04|2018-01-30|Actual|April 15, 2009|Actual|2009-04-15|January 2018|2018-01-31|March 17, 2013|Actual|2013-03-17|March 17, 2013|Actual|2013-03-17||Interventional||All eligible patients. Note that the Pre-Randomization TMZ+RT arm only includes eligible patients that did not continue to randomization.|Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma|Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma|Completed||Phase 3|637|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 01:03:51.010986|2018-06-01 01:03:51.010986
NCT00884728|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2009-04-20|2009-04-20|2009-04-21|Estimate|||||||2009-04-20|2009-04-21|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|EAHSP||Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory|East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities|Completed|||2329|Actual|Menzies School of Health Research|||1||f||||f||||||Samples Without DNA|"~     throat swabs, pyoderma swabs and skin scrapings for tinea where individual consent was~     obtained within selected participating communities~   "|||2018-06-01 01:03:52.941619|2018-06-01 01:03:52.941619
NCT00884715|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20||2013-09-09|2013-09-17|2009-04-20|2009-04-21|Estimate||||2013-09-17|2013-09-20|Estimate|2013-09-17|2013-09-20|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome|Open Label Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome|Terminated||Phase 1/Phase 2|10|Actual|Endo Pharmaceuticals||2||Program was terminated for business reasons|f||||f||||||||||2018-06-01 01:03:53.057065|2018-06-01 01:03:53.057065
NCT00884702|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2017-10-05|2009-04-18|2009-04-21|Estimate|||||||2017-10-05|2017-10-06|Actual|April 16, 2009||2009-04-16|April 18, 2017|2017-04-18|April 18, 2017||2017-04-18|||||Observational|||Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation|Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation|Completed|||538|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:03:53.150637|2018-06-01 01:03:53.150637
NCT00884689|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2011-03-30|2009-04-20|2009-04-21|Estimate|||||||2011-03-30|2011-03-31|Estimate|April 2009||2009-04-30|March 2011|2011-03-31|June 2010|Actual|2010-06-30|||||Observational|||A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®|A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART® 1-2 Inhalations b.i.d. as Maintenance Therapy Plus Additional Inhalations As-needed, Compared to Patients Treated With a Free Combination of an Inhaled Glucocorticosteroid and an Inhaled Long Acting ß2-agonist Plus as Needed Inhalations of a Short Acting ß2 Agonist.|Completed|||500|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:03:53.225905|2018-06-01 01:03:53.225905
NCT00884676|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2015-10-08|2009-04-18|2009-04-21|Estimate|||||||2015-10-08|2015-10-09|Estimate|November 2008||2008-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|November 2013|Actual|2013-11-30||Interventional|||Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors|A Phase I Trial of Weekly and Every Three Weeks Ixabepilone and Sunitinib in Solid Tumor Patients|Completed||Phase 1|36|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 01:03:53.50359|2018-06-01 01:03:53.50359
NCT00884663|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2013-12-22|2009-04-20|2009-04-21|Estimate|||||||2013-12-22|2013-12-24|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Candesartan Versus Propranolol for Migraine Prevention|Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study|Completed||Phase 2/Phase 3|72|Actual|Norwegian University of Science and Technology||3|||f||||t||||||||||2018-06-01 01:03:53.620439|2018-06-01 01:03:53.620439
NCT00884650|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2011-06-20|2009-04-20|2009-04-21|Estimate|||||||2011-06-20|2011-06-22|Estimate|June 2005||2005-06-30|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Managing Post-operative Pain in Children With Cerebral Palsy Using a Pain Pump|Comparing the Effectiveness of an Anesthetic Continuous-infusion Device to Oral Analgesia in Orthopedic Postoperative Pain Control of Children With Cerebral Palsy|Completed||N/A|54|Actual|Children's Hospital Colorado||2|||f||||f||||||||||2018-06-01 01:03:53.737259|2018-06-01 01:03:53.737259
NCT00884637|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2014-10-02|2009-04-20|2009-04-21|Estimate|||||||2014-10-02|2014-10-03|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects|Correlation Between Visual Field Defects on Home Macular Perimeter (FORESEE HOME) and on OCT in Eyes of Patients With CNV Before and After Treatment|Completed|||15|Actual|Notal Vision Ltd|||1||f||||f||||||||||2018-06-01 01:03:53.885539|2018-06-01 01:03:53.885539
NCT00884624|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-20|||2010-03-10|2009-04-20|2009-04-21|Estimate|||||||2010-03-10|2010-03-11|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Evaluation of the PillCam™ Colon Capsule -2 System|Evaluation of the PillCam™ Colon Capsule -2 System|Completed|||255|Actual|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 01:03:53.991272|2018-06-01 01:03:53.991272
NCT00884611|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2017-08-31||2018-01-29|2009-04-20|2009-04-21|Estimate|2018-01-29|2018-02-28|Actual||||2018-01-29|2018-02-28|Actual|May 2007||2007-05-31|January 2018|2018-01-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Development of Algorithms for a Hypoglycemic Prevention Alarm: Closed Loop Study|Development of Algorithms for a Hypoglycemic Prevention Alarm|Completed||N/A|20|Actual|Stanford University||1|||f||||f||||||||||2018-06-01 01:03:54.151043|2018-06-01 01:03:54.151043
NCT00884598|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-18|||2010-04-27|2009-04-18|2009-04-21|Estimate|||||||2010-04-27|2010-04-28|Estimate|December 2008||2008-12-31|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|CIRAB||Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer|Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer - a Single-center, Open-label Phase I Study|Unknown status|Recruiting|Phase 1|21|Anticipated|Universitätsmedizin Mannheim|||||f||||t||||||||||2018-06-01 01:03:54.693601|2018-06-01 01:03:54.693601
NCT00884585|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2012-09-27|2012-01-26|2012-11-02|2009-04-17|2009-04-21|Estimate|2012-11-02|2012-11-05|Estimate|2012-01-26|2012-01-30|Estimate|2012-11-02|2012-11-05|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis||Completed||Phase 3|176|Actual|Allergan||2|||f||||f||||||||||2018-06-01 01:03:54.828491|2018-06-01 01:03:54.828491
NCT00884559|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2012-08-24|2009-04-17|2009-04-20|Estimate|||||||2012-08-24|2012-08-27|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Leadership Instructions Improve Cardiopulmonary Resuscitation in a High Fidelity Simulation|Brief Leadership Instructions Improve Cardiopulmonary Resuscitation in a High Fidelity Simulation: a Randomised Controlled Trial|Completed||N/A|237|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 01:03:55.326585|2018-06-01 01:03:55.326585
NCT00884546|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2016-09-28|2009-04-17|2009-04-20|Estimate|||||||2016-09-28|2016-09-30|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma|A Phase Ib Multiple Ascending Dose Study of BMS-833923 Alone or in Combination With Lenalidomide (Revlimid) Plus Dexamethasone or in Combination With Bortezomib (Velcade) in Subjects With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|27|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:03:55.439835|2018-06-01 01:03:55.439835
NCT00884533|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2015-04-15|2009-04-16|2009-04-20|Estimate|||||||2015-04-15|2015-04-17|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|Rosi XR||QTc Study of Rosi XR in Healthy Volunteers|A Study to Evaluate the Effect of Extended Release Rosiglitazone (RSG XR) on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||3||The whole project was terminated|f||||||||||||||2018-06-01 01:03:55.586401|2018-06-01 01:03:55.586401
NCT00884520|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2010-03-15|2009-04-17|2009-04-20|Estimate|||||||2010-03-15|2010-03-16|Estimate|April 2009||2009-04-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|VM4-037||An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037|An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037|Completed||Early Phase 1|16|Anticipated|Siemens Molecular Imaging||1|||f||||f||||||||||2018-06-01 01:03:55.710336|2018-06-01 01:03:55.710336
NCT00884507|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17||2016-07-08|2016-11-01|2009-04-17|2009-04-20|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease|A Dose-ranging, Randomized, Double-blind , Placebo-controlled Study of the Effect of RO5313534, Used as add-on Therapy to Donepezil, on Cognitive Function in Patients With Mild to Moderate Symptoms of Alzheimer's Disease|Completed||Phase 2|389|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 01:03:55.829816|2018-06-01 01:03:55.829816
NCT00884494|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-01-18|2009-04-16|2009-04-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Ghrelin and Insulin Resistance|Role of Ghrelin in the Improvement of Insulin Resistance After Roux-en-Y Gastric Bypass Surgery|Completed||Phase 1|20|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 01:03:56.230534|2018-06-01 01:03:56.230534
NCT00884481|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2015-07-09|2009-04-17|2009-04-20|Estimate|||||||2015-07-09|2015-07-13|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|TYNERGY||Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS|A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months|Completed|||200|Actual|Biogen|||1||f||||f||||||||||2018-06-01 01:03:56.347996|2018-06-01 01:03:56.347996
NCT00884468|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-05-26|2009-04-17|2009-04-20|Estimate|||||||2009-05-26|2009-05-27|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis|Anxiety and Depression in Patients With Psoriatic Arthritis: Prevalence and Characteristics|Completed|||384|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 01:03:56.468776|2018-06-01 01:03:56.468776
NCT00884455|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2017-06-01|2009-04-17|2009-04-20|Estimate|||||||2017-06-01|2017-06-02|Actual|December 2002||2002-12-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Alpha-1 Foundation DNA and Tissue Bank|Alpha-1 Foundation DNA and Tissue Bank|Enrolling by invitation|||5000|Anticipated|University of Florida|||||f||||f||||||Samples With DNA|"~     blood, liver and lung~   "|||2018-06-01 01:03:56.572677|2018-06-01 01:03:56.572677
NCT00881335|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2009-06-17||2012-06-25|2009-04-14|2009-04-15|Estimate|2012-05-17|2012-06-20|Estimate||||2012-06-25|2012-06-29|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Implemental Flutter Mucus Clearance Devices on Geriatric Lung Function|Implemental Flutter Mucus Clearance Devices on Geriatric Lung Function|Completed||N/A|60|Actual|Tongji University||2|||f||||t||||||||||2018-06-01 01:05:21.725477|2018-06-01 01:05:21.725477
NCT00884442|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-10-20|2009-04-17|2009-04-20|Estimate|||||||2009-10-20|2009-10-21|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions|Randomized, Non-blind, 4-fold Crossover Study on Safety, Tolerability and Pharmacokinetics of Nifedipine After Single Oral Doses of Adalat® LA 60 mg or of a Marketed Generic Version of Nifedipine Retard 60 mg After an Overnight Fasting or Immediately After a High-fat American Breakfast in Healthy Male Volunteers|Completed||Phase 1|28|Actual|SocraTec R&D GmbH||4|||f||||f||||||||||2018-06-01 01:03:56.663644|2018-06-01 01:03:56.663644
NCT00884429|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2012-08-28|2009-04-17|2009-04-20|Estimate|||||||2012-08-28|2012-08-30|Estimate|April 2009||2009-04-30|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|ECPAVB||Effectiveness of Chest Physiotherapy in Infants With Acute Viral Bronchiolitis|Effectiveness of Chest Physiotherapy Actual Versus Conventional Techniques in Infants With Acute Viral Bronchiolitis. Random Clinical Trial|Completed||N/A|33|Actual|Hospital Sirio-Libanes||3|||f||||t||||||||||2018-06-01 01:03:56.775565|2018-06-01 01:03:56.775565
NCT00884416|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2014-10-31|2009-04-17|2009-04-20|Estimate|||||||2014-10-31|2014-11-04|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Sorafenib in Newly Diagnosed High Grade Glioma|Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma|Completed||Phase 1|17|Actual|University Hospital, Geneva||1|||f||||t||||||||||2018-06-01 01:03:56.947502|2018-06-01 01:03:56.947502
NCT00884403|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2018-05-01|2009-04-17|2009-04-20|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2008||2008-09-30|May 2018|2018-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Gestational Age is Underestimated by Menstrual Dating Compared to Ultrasound Dating in Those Undergoing Abortion up to 20 Weeks|Gestational Age is Underestimated by Menstrual Dating Compared to Ultrasound Dating in Those Undergoing Abortion up to 20 Weeks|Terminated|||415|Actual|University of British Columbia||||This study is a retrospective chart review study, not a clinical trial.|f||||f||||||||||2018-06-01 01:03:57.065561|2018-06-01 01:03:57.065561
NCT00884390|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2014-03-20||2014-08-20|2009-04-17|2009-04-20|Estimate|2014-08-20|2014-09-01|Estimate||||2014-08-20|2014-09-01|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings|A Postauthorization Safety Surveillance Study Of Patients Switching To ReFacto AF From ReFacto Or Other Factor VIII Products In Usual Care Settings|Terminated||Phase 4|208|Actual|Pfizer|The study was terminated early by agreement with the EMA before full recruitment was attained, but this is not considered to affect the overall results and the ability of the study to address its objectives.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:03:57.20216|2018-06-01 01:03:57.20216
NCT00884377|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2017-02-13||2017-06-15|2009-04-17|2009-04-20|Estimate|2017-06-15|2017-07-14|Actual||||2017-06-15|2017-07-14|Actual|February 2004||2004-02-29|June 2017|2017-06-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis|A Phase I/II Randomized Comparison of Localized Heat Therapy Versus Sodium Stibogluconate (Pentostam) for the Treatment of Old World Cutaneous Leishmaniasis (HSRRB Log No. A-12364)|Completed||Phase 2|56|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-06-01 01:03:57.817237|2018-06-01 01:03:57.817237
NCT00884364|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-12-21|2009-04-17|2009-04-20|Estimate|||||||2009-12-21|2009-12-23|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|September 2011|Anticipated|2011-09-30|April 2011|Anticipated|2011-04-30||Interventional|||Exercise During Chemotherapy for Patients With Hematological Malignancies|Exercise During Chemotherapy for Patients With Hematological Malignancies|Unknown status|Recruiting|Phase 3|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:03:58.460914|2018-06-01 01:03:58.460914
NCT00884351|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2017-06-30|2009-04-17|2009-04-20|Estimate|||||||2017-06-30|2017-07-02|Actual|April 15, 2009||2009-04-15|June 15, 2011|2011-06-15|June 15, 2011||2011-06-15|||||Observational|||Magnetoencephalography in Absence Seizures|Magnetoencephalography in Absence Seizures|Completed|||5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:03:58.563197|2018-06-01 01:03:58.563197
NCT00884338|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-12-18|2009-04-17|2009-04-20|Estimate|||||||2009-12-18|2009-12-21|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Interventional|||Cognitive Function After Stem Cell Transplantation|Evaluation of the Cognitive Function of Patients After Stem Cell Transplantation|Unknown status|Recruiting|Phase 3|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:03:58.770516|2018-06-01 01:03:58.770516
NCT00884325|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2013-04-23||2013-08-14|2009-04-17|2009-04-20|Estimate|2013-08-14|2013-08-16|Estimate||||2013-08-14|2013-08-16|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Management of Pruritus With Xyzal in Atopic Dermatitis|Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study|Completed||Phase 4|40|Actual|Derm Research, PLLC|Small number of subjects. Of 40 subjects enrolled, only 33 completed the 4 week study.|2|||f||||f||||||||||2018-06-01 01:03:58.908588|2018-06-01 01:03:58.908588
NCT00884312|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2018-04-09||2018-04-09|2009-04-17|2009-04-20|Estimate|2018-04-09|2018-05-14|Actual||||2018-04-09|2018-05-14|Actual|April 9, 2009|Actual|2009-04-09|April 2018|2018-04-30|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional||All participants who received at least 1 dose of carfilzomib after enrollment in PX-171-010.|A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols|An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols|Completed||Phase 2|101|Actual|Amgen||1|||f||||f||||||||||2018-06-01 01:03:59.29585|2018-06-01 01:03:59.29585
NCT00884299|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-20|2009-04-17|2009-04-20|Estimate|||||||2009-04-20|2009-04-21|Estimate|January 2004||2004-01-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2008|Actual|2008-03-31||Interventional|||Nutritional Enhancement in Chronic Obstructive Pulmonary Disease (COPD)|Nutritional Enhancement in COPD: Randomized, Controlled Trial|Completed||N/A|120|Actual|University of Thessaly||2|||f||||t||||||||||2018-06-01 01:04:00.117903|2018-06-01 01:04:00.117903
NCT00884286|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2018-01-29||2018-03-28|2009-04-17|2009-04-20|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-28|2018-04-25|Actual|December 2004||2004-12-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma|A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|67|Actual|PharmaMar||1|||f||||f||||||||No||2018-06-01 01:04:00.279474|2018-06-01 01:04:00.279474
NCT00884273|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2012-02-01||2013-10-21|2009-04-17|2009-04-20|Estimate|2012-04-10|2012-04-11|Estimate||||2013-10-21|2013-11-13|Estimate|August 2009||2009-08-31|October 2013|2013-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients|A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Volume Reduction of the Prostate in Patients With Prostate Cancer Being Candidates for Medical Castration|Completed||Phase 3|182|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:04:01.212439|2018-06-01 01:04:01.212439
NCT00884260|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-08-20|2009-04-17|2009-04-20|Estimate|||||||2014-08-20|2014-08-21|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China|Multi-center, Open Label, Single Arm Study to Assess Efficacy, Safety, Bleeding Pattern and Pharmacokinetics of the Ultra Low Dose Levonorgestrel Intrauterine Contraceptive System (LCS) for a Maximum of 3 Years in Women 18 to 40 Years of Age|Completed||Phase 3|918|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:04:02.347307|2018-06-01 01:04:02.347307
NCT00884247|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2010-12-06|2009-04-17|2009-04-20|Estimate|||||||2010-12-06|2010-12-07|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|June 2009|Actual|2009-06-30|||||Observational|||Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and Productivity|A Prospective, Non Interventional Study to Evaluate the Effects on Quality of Life, Symptoms and Productivity in Patients With Gastroesophageal Reflux Disease (GERD) After 6 Weeks Structured Treatment in a Company Health Care Setting|Completed|||36|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:04:02.480146|2018-06-01 01:04:02.480146
NCT00884234|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17||2010-09-23|2013-10-25|2009-04-17|2009-04-20|Estimate||||2010-09-23|2010-09-28|Estimate|2013-10-25|2013-11-19|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines|A Phase 2, Double-Blind, Randomized, Parallel-Group, Controlled, Repeat Dose, Single Center Study to Evaluate the Safety and Efficacy of RT001, a Botulinum Toxin Type A Topical Gel, for the Treatment of Moderate to Severe Lateral Canthal Lines In Adults|Completed||Phase 2|30|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 01:04:02.553036|2018-06-01 01:04:02.553036
NCT00884221|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2012-02-14||2012-04-18|2009-04-17|2009-04-20|Estimate|2012-03-22|2012-04-18|Estimate||||2012-04-18|2012-04-20|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|MEGASET||MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer|A Randomized, Open-label, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy of MENOPUR Versus Recombinant FSH in Controlled Ovarian Stimulation Following a GnRH Antagonist Protocol and Single Embryo Transfer|Completed||Phase 3|749|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:04:02.678289|2018-06-01 01:04:02.678289
NCT00884208|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-04-17|2009-04-17|2009-04-20|Estimate|||||||2009-04-17|2009-04-20|Estimate|April 2009||2009-04-30|April 2009|2009-04-30||||||||Observational|||Fall Risk Prediction and Reduction in Community Ambulators 65 Years of Age or Older|Fall Risk Prediction and Reduction in Community Ambulators 65 Years of Age or Older|Unknown status|Recruiting||50|Anticipated|Guthrie Healthcare System|||2||f||||f||||||||||2018-06-01 01:04:03.672193|2018-06-01 01:04:03.672193
NCT00884195|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2017-07-06|2009-04-17|2009-04-20|Estimate|||||||2017-07-06|2017-07-11|Actual|January 2009|Actual|2009-01-31|July 2017|2017-07-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Journaling and Weight Loss|Journaling and Weight Loss|Completed||Phase 1|50|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-06-01 01:04:03.772128|2018-06-01 01:04:03.772128
NCT00884182|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-01-10|2009-04-17|2009-04-20|Estimate|||||||2014-01-10|2014-01-14|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children|Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children|Completed||Phase 2|350|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:04:03.886202|2018-06-01 01:04:03.886202
NCT00884169|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2010-11-02|2009-04-17|2009-04-20|Estimate|||||||2010-11-02|2010-11-03|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|December 2009||2009-12-31|||||Interventional|||Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients||Completed||Phase 2|||Maruho Co., Ltd.|||||f||||||||||||||2018-06-01 01:04:03.990534|2018-06-01 01:04:03.990534
NCT00884143|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2010-04-19|2009-04-17|2009-04-20|Estimate|||||||2010-04-19|2010-04-20|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|TIME 2 CHANGE||Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer|Retrospective Observational Triveneto Study on the Use of Adjuvant Hormonal Therapies in the Treatment of Hormone-responsive Breast Cancer in Two Successive Time Periods|Completed|||515|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:04:04.0771|2018-06-01 01:04:04.0771
NCT00884130|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-20|Estimate|||||||2009-04-16|2009-04-20|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Observational|||Cost Effectiveness of Laparoscopic Colorectal Surgery|Cost Effectiveness of Laparoscopic Colorectal Surgery|Completed|||200|Actual|University of Surrey|||2||f||||t||||||||||2018-06-01 01:04:04.158264|2018-06-01 01:04:04.158264
NCT00884117|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2016-06-08||2016-10-18|2009-04-17|2009-04-20|Estimate|2016-06-08|2016-07-19|Estimate||||2016-10-18|2016-10-19|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|IRIS|All Enrolled Healthy Participants (AEHP) Population: All otherwise healthy participants who entered the study. Due to the imbalance between healthy (n=4553) and immunocompromised participants (n=8), results from immunocompromised participants were not included in any analyses, and data obtained from healthy participants were the focus of the study.|Influenza Resistance Information Study|Influenza Resistance Information Study (IRIS)|Completed|||4561|Actual|Hoffmann-La Roche|This was a non-randomized, observational study and many comparisons were not powered to detect a true statistically significant difference between groups. Inferential analyses should be interpreted with caution.||1||f||||||||||||||2018-06-01 01:04:04.301928|2018-06-01 01:04:04.301928
NCT00884104|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2016-01-06|2009-04-16|2009-04-20|Estimate|||||||2016-01-06|2016-01-07|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks|A Prospective, Open-label, Observational, Multi-center Study for the Identification of Predictive Factors for the Solifenacin Treatment in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks and Evaluation of Efficacy and Persistency of Add on Solifenacin in Men With Residual Overactive Bladder Symptoms After Previous Monotherapy With Tamsulosin.|Completed||Phase 4|307|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 01:04:05.369728|2018-06-01 01:04:05.369728
NCT00884091|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2011-12-05|2009-04-17|2009-04-20|Estimate|||||||2011-12-05|2011-12-06|Estimate|April 2009||2009-04-30|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|IC-1-V1||A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects|A Pilot Study to Evaluate the Glucagon-Like Peptide 1 Response to the Challenge of Mixed Meals in Chinese Subjects|Completed|||21|Actual|Taipei Veterans General Hospital, Taiwan|||1||f||||f||||||Samples Without DNA|"~     Plasma samples retained, with no potential for DNA extraction from any retained samples. The~     retained samples will be destroyed after the results published.~   "|||2018-06-01 01:04:05.478509|2018-06-01 01:04:05.478509
NCT00884078|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-04-17|2009-04-17|2009-04-20|Estimate|||||||2009-04-17|2009-04-20|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Self Harm in Females of South Asian Family Origin|Exploratory RCT of Culturally Adapted Manual Assisted Problem Solving Training (C-MAP) for Self Harm in Females of South Asian Family Origin|Unknown status|Not yet recruiting|N/A|20|Anticipated|Lancashire Care NHS Foundation Trust||2|||f||||||||||||||2018-06-01 01:04:05.552578|2018-06-01 01:04:05.552578
NCT00884065|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2009-02-09||2015-03-03|2009-04-17|2009-04-20|Estimate|2009-04-17|2009-04-20|Estimate||||2015-03-03|2015-03-23|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder|Effectiveness of Diacutaneous Fibrolysis on Pain and Mobility in Patients Suffering From Painful Shoulder. A Randomized Pilot Study.|Completed||N/A|50|Actual|Jordi Gol i Gurina Foundation||2|||f||||||||||||||2018-06-01 01:04:05.749296|2018-06-01 01:04:05.749296
NCT00884052|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2012-10-21|2009-04-17|2009-04-20|Estimate|||||||2012-10-21|2012-10-23|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|March 2011|Actual|2011-03-31||Interventional|Keppra||Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures|Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures|Completed||Phase 1/Phase 2|18|Actual|University of California, San Diego||1|||f||||t||||||||||2018-06-01 01:04:06.236792|2018-06-01 01:04:06.236792
NCT00884039|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2010-09-20||2014-08-04|2009-04-17|2009-04-20|Estimate|2010-10-21|2010-11-17|Estimate||||2014-08-04|2014-08-06|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients|Compassionate Use of Anecortave Acetate: Clinical Protocol for the Treatment of Corticosteroid-induced Intraocular Pressure (IOP) Increases After Corneal Transplantation|Terminated||N/A|7|Actual|Cornea Research Foundation of America||2||Preliminary data analysis showed insufficient efficacy to justify continuation.|f||||t||||||||||2018-06-01 01:04:06.359539|2018-06-01 01:04:06.359539
NCT00884026|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2013-01-22|2009-04-17|2009-04-20|Estimate|||||||2013-01-22|2013-01-23|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Can Augmentation Index (AIx) be Used to Predict Hypotension After Spinal Anesthesia?|Pulse Wave Analysis and Augmentation Index Changes Associated With Neuraxial Anesthesia in the Parturient|Completed||N/A|56|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:04:06.677322|2018-06-01 01:04:06.677322
NCT00884013|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-17|2009-04-17|2009-04-20|Estimate|||||||2009-04-17|2009-04-20|Estimate|January 2009||2009-01-31|April 2009|2009-04-30||||||||Observational|ehearts||New York City (NYC) Health eHearts Pay for Quality Pilot|Program Evaluation of New York City Health eHearts Pay for Quality Program|Completed|||84|Anticipated|New York City Department of Health and Mental Hygiene|||6||f||||f||||||||||2018-06-01 01:04:06.799306|2018-06-01 01:04:06.799306
NCT00884000|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2012-07-16|2009-04-17|2009-04-20|Estimate|||||||2012-07-16|2012-07-17|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||A Study of Zomacton in Children With Growth Hormone Deficiency|A Randomised, Open-label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety for 12 Months of Zomacton to Genotropin in Children With Idiopathic Growth Hormone Deficiency|Completed||Phase 3|165|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:04:06.939549|2018-06-01 01:04:06.939549
NCT00883987|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-03-05|2009-04-17|2009-04-20|Estimate|||||||2014-03-05|2014-03-07|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Osteopathic Treatment of Low Back Pain|A Pilot Project to Study the Effect of Four Osteopathic Treatments on Trunk Muscle Firing Patterns and Temporospatial Parameters of Gait in Persons With Chronic Low Back Pain|Completed|||10|Actual|Nova Scotia Health Authority|||1||f||||f||||||||||2018-06-01 01:04:07.108651|2018-06-01 01:04:07.108651
NCT00883974|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-10-28|2009-04-17|2009-04-20|Estimate|||||||2009-10-28|2009-10-29|Estimate|April 2004||2004-04-30|October 2009|2009-10-31|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Interventional|||Sensitivity Training For Parents of Preterm Infants|Early Sensitivity Training for Parents of Preterm Infants: Impact on the Developing Brain|Completed||N/A|45|Actual|University of Melbourne||2|||f||||f||||||||||2018-06-01 01:04:07.192262|2018-06-01 01:04:07.192262
NCT00883961|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-12-21|2009-04-17|2009-04-20|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|September 2011|Anticipated|2011-09-30|April 2011|Anticipated|2011-04-30||Interventional|||Exercise Following Autologous Peripheral Blood Stem Cell Transplantation||Unknown status|Recruiting|Phase 3|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:04:07.288206|2018-06-01 01:04:07.288206
NCT00883948|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2016-04-12|2009-04-17|2009-04-20|Estimate|||||||2016-04-12|2016-04-13|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|EDEN||Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)|Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)|Completed||Phase 3|1000|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 01:04:07.392622|2018-06-01 01:04:07.392622
NCT00883935|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-06-18|2009-04-16|2009-04-20|Estimate|||||||2009-06-18|2009-06-22|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir|Phase I, Open Label, Randomized, Drug-Drug Interaction Study in Healthy Subjects to Investigate the Effects of Co-Administered Atazanavir/Ritonavir (300mg/100mg) or Atazanavir 400mg Administered Once Daily on the Steady-State Plasma Pharmacokinetics of GSK1349572 30mg Administered Once Daily|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:04:07.547739|2018-06-01 01:04:07.547739
NCT00883909|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-07-06|2009-04-16|2009-04-20|Estimate|||||||2017-07-06|2017-07-11|Actual|April 9, 2009||2009-04-09|July 2017|2017-07-31|December 29, 2010|Actual|2010-12-29|December 1, 2010|Actual|2010-12-01||Observational|||ARI103094-Follow-Up Study for REDUCE Study Subjects|ARI103094-Follow-Up Study for REDUCE Study Subjects|Completed|||2795|Actual|GlaxoSmithKline|||1||f||||f||||||Samples With DNA|"~     PART B: Collection of tissue blocks or unstained slides from positive biopsies.~   "|Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:04:07.730857|2018-06-01 01:04:07.730857
NCT00883896|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17||2012-11-12|2012-11-12|2009-04-17|2009-04-20|Estimate||||2012-11-12|2012-11-19|Estimate|2012-11-12|2012-11-19|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis|A Randomized, Parallel, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of ILV-094 Administered Subcutaneously To Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate|Completed||Phase 2|195|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:04:08.467034|2018-06-01 01:04:08.467034
NCT00883883|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-03-27|2009-04-17|2009-04-20|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2005||2005-04-30|April 2009|2009-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250 mg/5 ml Oral Suspension Fed Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 250mg/5 ml Cefdinir (Test Formulation) and Omnicel 250mg/5 ml Powder For Oral Suspension (Reference Formulation) Each Given as a Single Oral Dose to Forty Healthy Male and/or Female Volunteers in the Fed State|Completed||Phase 1|40|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:04:08.681299|2018-06-01 01:04:08.681299
NCT00883870|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2013-03-04|2009-04-17|2009-04-20|Estimate|||||||2013-03-04|2013-03-05|Estimate|April 2009||2009-04-30|March 2013|2013-03-31|August 2012|Actual|2012-08-31|February 2010|Actual|2010-02-28||Interventional|||Mesenchymal Stem Cells in Critical Limb Ischemia|A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)|Completed||Phase 1/Phase 2|20|Actual|Stempeutics Research Pvt Ltd||2|||f||||t||||||||||2018-06-01 01:04:08.815783|2018-06-01 01:04:08.815783
NCT00883857|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-04-17|2009-04-17|2009-04-20|Estimate|||||||2009-04-17|2009-04-20|Estimate|October 2007||2007-10-31|April 2009|2009-04-30||||||||Observational|||Comparison Endotracheal Cardiac Output Monitor (ECOM) to a Standard Device in Measuring Heart Blood Volume|Comparison Endotracheal Cardiac Output Monitor (ECOM) to a Standard Device in Measuring Heart Blood Volume|Unknown status|Recruiting||100|Anticipated|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 01:04:08.934767|2018-06-01 01:04:08.934767
NCT00883844|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2013-04-18|2009-04-17|2009-04-20|Estimate|||||||2013-04-18|2013-04-19|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|PADD||PEG-IFN in HBV Patients With Incomplete Response to NA|Lowering Viral Load With Nucleos(t)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B - a Pilot Study|Completed||Phase 4|11|Actual|Foundation for Liver Research||2|||f||||f||||||||||2018-06-01 01:04:09.035124|2018-06-01 01:04:09.035124
NCT00883831|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2010-01-22|2009-04-17|2009-04-20|Estimate|||||||2010-01-22|2010-01-25|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||The Effectiveness and the Safety of Acupuncture for Symptomatic Care of Hemodialysis Patients: A Case-series|Acupuncture for Symptomatic Care of Hemodialysis Patients: a Case-series|Completed||N/A|20|Anticipated|Korea Institute of Oriental Medicine||1|||f||||f||||||||||2018-06-01 01:04:09.195325|2018-06-01 01:04:09.195325
NCT00883818|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-07-05|2009-04-17|2009-04-20|Estimate|||||||2009-07-05|2009-07-07|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Microorganism in Overactive Bladder Patients|Detection and Treatment Benefit of Microorganism (Chlamydia Trachomatis, Mycoplasma Hominis, Ureaplasma Urealyticum) in Overactive Bladder Patients|Completed||Phase 4|84|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 01:04:09.360581|2018-06-01 01:04:09.360581
NCT00883805|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2015-09-16|2009-04-17|2009-04-20|Estimate|||||||2015-09-16|2015-09-17|Estimate|April 2009||2009-04-30|September 2015|2015-09-30||||April 2014|Actual|2014-04-30||Observational|||Investigation of Systemic Metal Ion Concentration Following a Ceramic-on-metal Total Hip Arthroplasty|Investigation of Systemic Metal Ion Concentration Following a Ceramic-on-metal Total Hip Arthroplasty|Withdrawn|||0|Actual|Northwell Health|||2|PI moved|f||||f||||||||||2018-06-01 01:04:09.518594|2018-06-01 01:04:09.518594
NCT00883792|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2017-06-16|2009-04-17|2009-04-20|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2009||2009-05-31|June 2017|2017-06-30|July 2036|Anticipated|2036-07-31|June 2026|Anticipated|2026-06-30||Interventional|NordICC||The Northern-European Initiative on Colorectal Cancer|NordICC The Northern-European Initiative on Colorectal Cancer|Active, not recruiting||Phase 3|95000|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 01:04:09.698174|2018-06-01 01:04:09.698174
NCT00883779|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2015-11-10||2015-11-10|2009-04-17|2009-04-20|Estimate|2015-11-10|2015-12-14|Estimate||||2015-11-10|2015-12-14|Estimate|April 2009||2009-04-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Full analysis set (FAS) population (Included all enrolled participants).|A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer|Completed||Phase 3|451|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:04:10.000509|2018-06-01 01:04:10.000509
NCT00883766|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2012-07-19|2009-04-17|2009-04-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1|PCOS and IVF: A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1|Terminated||N/A|172|Anticipated|Institut Universitari Dexeus||2|||f||||f||||||||||2018-06-01 01:04:11.361861|2018-06-01 01:04:11.361861
NCT00883584|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-22|2009-04-16|2009-04-17|Estimate|||||||2009-04-22|2009-04-23|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|COPD||IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study|A Phase IIa, Proof of Concept Study to Evaluate the Reduction in Inflammatory Biomarkers and Assess Airway Function Following Administration of IMD-1041 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Institute of Medicinal Molecular Design, Inc.||2|||f||||f||||||||||2018-06-01 01:04:17.237321|2018-06-01 01:04:17.237321
NCT00883753|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2014-06-18||2014-08-04|2009-04-17|2009-04-20|Estimate|2014-08-04|2014-08-06|Estimate||||2014-08-04|2014-08-06|Estimate|March 2009||2009-03-31|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy|An Extension Phase of the Multi-National Open-Label Study (MA21573) to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.|Completed||Phase 3|934|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:04:11.594652|2018-06-01 01:04:11.594652
NCT00883740|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2011-05-16||2011-07-14|2009-04-17|2009-04-20|Estimate|2011-07-14|2011-08-10|Estimate||||2011-07-14|2011-08-10|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia|Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study|Completed||Phase 3|119|Actual|Pfizer|The protocol specified analyses of secondary outcome measures (OMs) indicated OMs would use PP population; however all secondary OMs were analyzed using the ITT population in accordance with the statistical analysis plan.|2|||f||||t||||||||||2018-06-01 01:04:14.072642|2018-06-01 01:04:14.072642
NCT00883727|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2013-03-04|2009-04-17|2009-04-20|Estimate|||||||2013-03-04|2013-03-05|Estimate|April 2009||2009-04-30|March 2013|2013-03-31|August 2012|Actual|2012-08-31|May 2010|Actual|2010-05-31||Interventional|||Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI|A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intravenous ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With st Elevated Acute Myocardial Infarction (Stemi)|Completed||Phase 1/Phase 2|20|Actual|Stempeutics Research Pvt Ltd||2|||f||||t||||||||||2018-06-01 01:04:15.361106|2018-06-01 01:04:15.361106
NCT00883714|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2009-12-21|2009-04-17|2009-04-20|Estimate|||||||2009-12-21|2009-12-23|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|August 2011|Anticipated|2011-08-31|April 2011|Anticipated|2011-04-30||Interventional|||Exercise During the Allogeneic Stem Cell Transplantation|Exercise During the Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 3|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:04:15.499453|2018-06-01 01:04:15.499453
NCT00883701|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2010-04-28|2009-04-16|2009-04-20|Estimate|||||||2010-04-28|2010-04-29|Estimate|December 2002||2002-12-31|August 2009|2009-08-31|September 2009|Actual|2009-09-30|August 2008|Actual|2008-08-31||Observational|||Granzymes and Perforin at the Onset of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Granzymes and Perforin at the Onset of COPD Exacerbations|Completed|||30|Anticipated|University of Thessaly|||2||f||||t||||||Samples Without DNA|"~     sputum cells and supernatant~   "|||2018-06-01 01:04:15.718514|2018-06-01 01:04:15.718514
NCT00883688|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2015-11-17|2009-04-17|2009-04-20|Estimate|||||||2015-11-17|2015-11-18|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma|A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma|Completed||Phase 2|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:04:15.885518|2018-06-01 01:04:15.885518
NCT00883675|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|2013-10-29||2013-10-29|2009-04-17|2009-04-20|Estimate|2013-10-29|2013-12-18|Estimate||||2013-10-29|2013-12-18|Estimate|May 2009||2009-05-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer|Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer|Completed||Phase 4|133|Actual|Maestro Clinical, Inc.||1|||f||||t||||||||||2018-06-01 01:04:16.074497|2018-06-01 01:04:16.074497
NCT00883662|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2016-09-29|2009-04-17|2009-04-20|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|April 2014|Actual|2014-04-30||Observational|||Mirena Observational Program|Mirena Observational Program|Completed|||2725|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 01:04:16.431033|2018-06-01 01:04:16.431033
NCT00883649|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2012-02-16|2009-04-17|2009-04-20|Estimate|||||||2012-02-16|2012-02-20|Estimate|September 2008||2008-09-30|February 2012|2012-02-29||||December 2011|Actual|2011-12-31||Interventional|||Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye|A Randomized, Parallel-Group, Placebo-Control, Double-Blind Trial Comparing the Efficacy and Safety of Nutritional Supplementation Containing Omega 3 Fatty Acids and Gamma Linoleic Acid, for Treatment of Keratoconjunctivitis Sicca in Post-Menopausal Females|Completed||N/A|62|Actual|Virginia Eye Consultants||2|||f||||||||||||||2018-06-01 01:04:16.564355|2018-06-01 01:04:16.564355
NCT00883636|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-17|||2013-06-18|2009-04-17|2009-04-20|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 2008||2008-10-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Observational|||Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis|Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis|Terminated|||4|Actual|Northwell Health|||2|study stopped due to lack of activity|f||||f||||||Samples With DNA|"~     Blood Serum, plasma~   "|||2018-06-01 01:04:16.749826|2018-06-01 01:04:16.749826
NCT00883623|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2013-11-21|2009-04-16|2009-04-17|Estimate|||||||2013-11-21|2013-11-25|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|LEOMEX||A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis|A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis|Completed||Phase 2|50|Actual|Heidelberg University||1|||f||||t||||||||||2018-06-01 01:04:16.847392|2018-06-01 01:04:16.847392
NCT00883610|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-12-09|2009-04-16|2009-04-17|Estimate|||||||2014-12-09|2014-12-11|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers|Modulation of QT Interval by Rapid Atrial Pacing in Patients With Dual Chamber Pacemakers|Completed|||12|Actual|Vanderbilt University|||||f||||t||||||||||2018-06-01 01:04:16.964698|2018-06-01 01:04:16.964698
NCT00883597|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-01-30|2009-04-16|2009-04-17|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Sidestream Dark-Field (SDF) Imaging of the Intestinal Microcirculation|Sidestream Dark-Field Imaging of the Intestinal Microcirculation in Clinical Sepsis: The Impact of Activated Protein C Therapy|Active, not recruiting|||36|Anticipated|Nova Scotia Health Authority|||2||f||||f||||||||||2018-06-01 01:04:17.081907|2018-06-01 01:04:17.081907
NCT00883571|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-12-28|2009-04-16|2009-04-17|Estimate|||||||2009-12-28|2009-12-29|Estimate|April 2002||2002-04-30|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparative Study of the House Advancement Flap, Rhomboid Flap, and Y-V Anoplasty|Comparative Study of the House Advancement Flap, Rhomboid Flap, and Y-V Anoplasty in Treatment of Anal Stenosis: A Prospective Randomized Study|Completed||N/A|60|Actual|Mansoura University||3|||f||||t||||||||||2018-06-01 01:04:17.421328|2018-06-01 01:04:17.421328
NCT00883558|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2014-08-28||2014-08-28|2009-04-15|2009-04-17|Estimate|2014-08-28|2014-09-08|Estimate||||2014-08-28|2014-09-08|Estimate|May 2009||2009-05-31|August 2014|2014-08-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional||Participants who were randomized and received at least 1 dose of study drug.|Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus|A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes|Completed||Phase 2|48|Actual|Halozyme Therapeutics||1|||f||||f||||||||||2018-06-01 01:04:17.575466|2018-06-01 01:04:17.575466
NCT00883545|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2013-01-03|2009-04-15|2009-04-17|Estimate|||||||2013-01-03|2013-01-07|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of Adherence to Colonoscopy in Women|The Effect of a Woman Endoscopist on Adherence to Screening Colonoscopy in Women|Completed||N/A|625|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 01:04:18.055276|2018-06-01 01:04:18.055276
NCT00883532|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-08-07|2009-04-16|2009-04-17|Estimate|||||||2012-08-07|2012-08-08|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Prevention of Chronic Lung Disease (CLD) in Preterm Infants|Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen|Unknown status|Recruiting|Phase 4|300|Anticipated|China Medical University, China||2|||f||||t||||||||||2018-06-01 01:04:18.162416|2018-06-01 01:04:18.162416
NCT00883519|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2012-04-12|2009-04-16|2009-04-17|Estimate|||||||2012-04-12|2012-04-13|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Efficacy of Parent Involvement in the Treatment of Adolescent Depression|The Efficacy of Parent Involvement in the Treatment of Adolescent Depression|Completed||Phase 1/Phase 2|15|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 01:04:18.355647|2018-06-01 01:04:18.355647
NCT00883506|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-03-27|2009-04-16|2009-04-17|Estimate|||||||2017-03-27|2017-03-29|Actual|May 2000||2000-05-31|March 2009|2009-03-31|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|||To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablet Under Fasting and Fed|Randomized, 3-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions Under Fasting and Fed Conditions.|Completed||Phase 1|24|Actual|Sandoz||3|||f||||||||||||||2018-06-01 01:04:18.534803|2018-06-01 01:04:18.534803
NCT00883493|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2012-02-29||2012-07-02|2009-04-16|2009-04-17|Estimate|2012-05-28|2012-06-29|Estimate||||2012-07-02|2012-07-11|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|QUALITY||Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression|A Randomised, Multi-Centre Study to Compare the Efficacy and Safety of Extended Release Quetiapine Fumarate (Seroquel XR TM) Tablets as Mono-Therapy or in Combination With Lithium in the Treatment of Patients With Acute Bipolar Depression|Completed||Phase 3|421|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:04:18.66285|2018-06-01 01:04:18.66285
NCT00883480|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate|June 2005||2005-06-30|April 2009|2009-04-30|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|SLAT||Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma|Tratamiento Individualizado en función de Las Mutaciones en EGFR y Del Nivel de expresión de BRCA1 en Pacientes Con Adenocarcinoma de pulmón Avanzado|Completed||N/A|153|Actual|Spanish Lung Cancer Group||1|||f||||f||||||||||2018-06-01 01:04:19.418607|2018-06-01 01:04:19.418607
NCT00883467|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate|May 2008||2008-05-31|April 2009|2009-04-30||||June 2009|Anticipated|2009-06-30||Interventional|IPC in MRI||The Effects of Preconditioning on Intramuscular High-Energy Phosphate Levels During Ischemia|The Effects of Preconditioning on Intramuscular High-Energy Phosphate Levels During Ischemia|Unknown status|Active, not recruiting|N/A|16|Anticipated|Medical University of Vienna||4|||f||||||||||||||2018-06-01 01:04:19.624547|2018-06-01 01:04:19.624547
NCT00883454|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate||||April 2009|2009-04-30||||||||Observational|||Estimation of Functional Liver Reserve Using Cholinesterases|Estimation of Functional Liver Reserve in Patients With Hepatocellular Carcinoma in Cirrhosis: the Value of Preoperative Cholinesterases|Completed|||181|Actual|University of Milan|||||f||||f||||||||||2018-06-01 01:04:19.763811|2018-06-01 01:04:19.763811
NCT00883441|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2013-01-07|2009-04-16|2009-04-17|Estimate|||||||2013-01-07|2013-01-08|Estimate|July 2006||2006-07-31|January 2013|2013-01-31|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|||Implementation Research of New Dengue Vector Control Tools|Implementation Research of New Dengue Vector Control Tools|Completed||N/A|22|Actual|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-06-01 01:04:19.840772|2018-06-01 01:04:19.840772
NCT00883428|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-03-11|2009-04-16|2009-04-17|Estimate|||||||2014-03-11|2014-03-13|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Observational|||Prevalence of Low Back and Pelvic Pain in Pregnant Women|Prevalence of Low Back and Pelvic Pain in Pregnant Women and Factors Associated With a Greater Risk of Having it|Completed|||1158|Actual|Kovacs Foundation|||1||f||||t||||||||||2018-06-01 01:04:19.940598|2018-06-01 01:04:19.940598
NCT00883415|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-12-01|2009-04-16|2009-04-17|Estimate|||||||2014-12-01|2014-12-03|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease|A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease|Completed|||20|Actual|University of Maryland|||||f||||f||||||||||2018-06-01 01:04:20.121729|2018-06-01 01:04:20.121729
NCT00883402|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2017-06-13|2009-04-15|2009-04-17|Estimate|||||||2017-06-13|2017-06-14|Actual|January 2008||2008-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ACST-2||Carotid Endarterectomy Versus Carotid Artery Stenting in Asymptomatic Patients|Asymptomatic Carotid Surgery Trial-2 (ACST-2): an International Randomised Trial to Compare Carotid Endarterectomy With Carotid Artery Stenting to Prevent Stroke|Recruiting||N/A|3600|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 01:04:20.270145|2018-06-01 01:04:20.270145
NCT00883376|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Observational|StanforAIH||Classification of Stanford for Snore as Factor of Aggravation of the Apnea Hypopnea Index (AIH) in Patients With Obstructive Sleep Apnea Syndrome (OSAS)|Classification of Stanford for Snore as Factor of Aggravation of the AIH in Patients With OSAS.|Completed|||159|Actual|Irmandade da Santa Casa de Misericoridia de Limeira|||2||f||||f||||||||||2018-06-01 01:04:21.093502|2018-06-01 01:04:21.093502
NCT00883363|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2015-01-12|2009-04-15|2009-04-17|Estimate|||||||2015-01-12|2015-01-14|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PreconRAAA||Reduction of Myocardial Infarction by Preconditioning in Patients With Ruptured Abdominal Aortic Aneurysm|Reduction of Myocardial Infarction by Preconditioning in Patients With Ruptured Abdominal Aortic Aneurysm|Completed||N/A|200|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-06-01 01:04:21.217189|2018-06-01 01:04:21.217189
NCT00883350|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2016-01-15|2009-04-15|2009-04-17|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2009||2009-05-31|January 2016|2016-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|RIDE||Evaluation of the Remote Intervention for Diet and Exercise (RIDE)|Design and Evaluation of the Remote Intervention for Diet and Exercise (RIDE)|Completed||N/A|40|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-06-01 01:04:21.340341|2018-06-01 01:04:21.340341
NCT00883337|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2012-10-03||2016-05-04|2009-04-16|2009-04-17|Estimate|2012-10-03|2012-11-06|Estimate||||2016-05-04|2016-06-13|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|September 2011|Actual|2011-09-30||Interventional|TENERE||A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis|A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period|Completed||Phase 3|324|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 01:04:21.509944|2018-06-01 01:04:21.509944
NCT00883324|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2011-06-16|2009-04-15|2009-04-17|Estimate|||||||2011-06-16|2011-06-20|Estimate|March 2009||2009-03-31|June 2011|2011-06-30||||||||Observational|SpecOp||Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum|A Phase IIIB Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum|Completed|||329|Anticipated|Hologic, Inc.|||2||f||||f||||||||||2018-06-01 01:04:23.136208|2018-06-01 01:04:23.136208
NCT00883311|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15||2010-08-26|2010-08-29|2009-04-15|2009-04-17|Estimate||||2010-08-26|2010-08-30|Estimate|2010-08-29|2010-08-31|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis|A Clinical Usage Study to Evaluate the Safety and Efficacy of BRT-FC-83C in the Management of Mild to Moderate Atopic Dermatitis|Completed||Phase 2|32|Actual|Biomed Research & Technologies, Inc.|||||f||||t||||||||||2018-06-01 01:04:23.234609|2018-06-01 01:04:23.234609
NCT00883298|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-03-28|2009-04-16|2009-04-17|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2009||2009-04-30|March 2017|2017-03-31|December 1, 2014|Actual|2014-12-01|December 2014|Actual|2014-12-31||Interventional|||Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme|Phase II Study of Bi-Weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|30|Actual|Center for Neurosciences, Tucson||1|||f||||t||||||||No||2018-06-01 01:04:23.361383|2018-06-01 01:04:23.361383
NCT00883285|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2014-01-31|2009-04-16|2009-04-17|Estimate|||||||2014-01-31|2014-02-03|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Incidence and Severity of Silent and Apparent Cerebral Embolism After Conventional and Minimal-invasive Transfemoral Aortic Valve Replacement|Incidence and Severity of Silent and Apparent Cerebral Embolism After Conventional and Minimal-invasive Transfemoral Aortic Valve Replacement|Completed|||60|Anticipated|University Hospital, Bonn|||3||f||||f||||||||||2018-06-01 01:04:23.564554|2018-06-01 01:04:23.564554
NCT00883272|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2015-10-20|2009-04-16|2009-04-17|Estimate|||||||2015-10-20|2015-10-21|Estimate|January 2007||2007-01-31|October 2015|2015-10-31|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Observational|||Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women|Assessment of Femarelle (DT56a), a Novel SERM, Effect on the Clotting Time in Normal and Thrombophililic Postmenopausal Women|Completed|||32|Actual|New York University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Blood samples were collected in evacuated tubes (Vacutainer, Becton Dickinson) at baseline,~     eight weeks, and one year.~   "|||2018-06-01 01:04:23.640477|2018-06-01 01:04:23.640477
NCT00883259|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2013-04-05|2009-04-16|2009-04-17|Estimate|||||||2013-04-05|2013-04-08|Estimate|September 2013||2013-09-30|April 2013|2013-04-30||||December 2013|Anticipated|2013-12-31||Interventional|||Metformin and Gestational Diabetes in High-risk Patients: a RCTs|Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|University Magna Graecia||2|||f||||t||||||||||2018-06-01 01:04:23.788202|2018-06-01 01:04:23.788202
NCT00883246|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2015-01-23||2016-01-28|2009-04-16|2009-04-17|Estimate|2015-09-10|2015-10-09|Estimate||||2016-01-28|2016-02-01|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||800 patients were enrolled, but 1 subject’s data were excluded from all analyses due to an invalid informed consent, yielding a cohort of 799 analyzable subjects.|Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE)|Determination of Effectiveness of SilverHawk Peripheral Plaque Excision (SilverHawk Device) for the Treatment of Infrainguinal Vessels/Lower Extremities|Completed||Phase 4|800|Actual|Medtronic Endovascular|The study’s principal limitations include a lack of randomization and follow-up beyond 12 months.|1|||f||||t||||||||||2018-06-01 01:04:24.060533|2018-06-01 01:04:24.060533
NCT00883233|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2010-10-11||2010-11-11|2009-04-16|2009-04-17|Estimate|2010-11-11|2010-12-08|Estimate||||2010-11-11|2010-12-08|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|FREE||Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris|Efficacy and Safety Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|Completed||Phase 3|123|Actual|Galderma||4|||f||||f||||||||||2018-06-01 01:04:24.649819|2018-06-01 01:04:24.649819
NCT00883220|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-09-17|2009-04-15|2009-04-17|Estimate|||||||2012-09-17|2012-09-18|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Self Management in Urinary Catheter Users|Self-management of Urine Flow in Long-term Urinary Catheter Users|Completed||Phase 2|202|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 01:04:25.311025|2018-06-01 01:04:25.311025
NCT00883207|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|October 2009|Anticipated|2009-10-31|July 2007|Actual|2007-07-31||Interventional|DINADEP||Dialogical and Narrative Processes in Couple Therapy for Depression|Dialogical and Narrative Processes in Couple Therapy for Depression. Two Year Follow-up Study of the Effectiveness and Processes in Couple Therapy|Unknown status|Recruiting|Phase 2/Phase 3|65|Anticipated|University of Jyvaskyla|||||f||||f||||||||||2018-06-01 01:04:25.434068|2018-06-01 01:04:25.434068
NCT00883194|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2013-09-12|2009-04-16|2009-04-17|Estimate|||||||2013-09-12|2013-09-13|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Safety and Effectiveness Pilot Study of PRF-108 and PRF-110 in Healthy Volunteers|A Single-center, Randomized, Placebo-controlled, Double-blind, Single-dose, Efficacy of PRF-108 4% and PRF-110 4% Versus Ropivacaine Solution 0.5% in an Experimental Pain Model|Completed||Phase 1/Phase 2|15|Actual|PainReform LTD||4|||f||||f||||||||||2018-06-01 01:04:25.69093|2018-06-01 01:04:25.69093
NCT00883181|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2016-03-10||2017-02-07|2009-04-16|2009-04-17|Estimate|2016-03-10|2016-04-08|Estimate||||2017-02-07|2017-03-15|Actual|November 2006||2006-11-30|February 2017|2017-02-28|September 2014|Actual|2014-09-30|October 2009|Actual|2009-10-31||Observational|||A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy|A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors Receiving Myelotoxic Chemotherapy|Completed|||1370|Actual|Amgen|||||f||||f||||||None Retained|"~     This is an observational study. No bio-specimens are being collected.~   "|||2018-06-01 01:04:25.885441|2018-06-01 01:04:25.885441
NCT00883168|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2012-05-21|2011-06-23|2013-06-17|2009-04-16|2009-04-17|Estimate|2012-08-07|2012-09-07|Estimate|2011-07-13|2011-07-18|Estimate|2013-06-17|2013-06-24|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|1791|Actual|Meda Pharmaceuticals||4|||f||||f||||||||||2018-06-01 01:04:28.750723|2018-06-01 01:04:28.750723
NCT00883155|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-03-27|2009-04-16|2009-04-17|Estimate|||||||2017-03-27|2017-03-29|Actual|October 1998||1998-10-31|April 2009|2009-04-30|October 1998|Actual|1998-10-31|October 1998|Actual|1998-10-31||Interventional|||To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions|To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions.|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:04:29.656172|2018-06-01 01:04:29.656172
NCT00883142|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2013-06-10|2009-04-16|2009-04-17|Estimate|||||||2013-06-10|2013-06-11|Estimate|October 2006||2006-10-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Observational|||Functional and Physiological Responses to Lokomat Therapy (Pilot Study)|Functional and Physiological Responses to Lokomat Therapy (Pilot Study)|Completed|||27|Actual|VA Office of Research and Development|||1||f||||f||||||Samples With DNA|"~     Serum, plasma and for some muscle biopsy samples~   "|||2018-06-01 01:04:29.796851|2018-06-01 01:04:29.796851
NCT00883129|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2016-11-06||2017-02-06|2009-04-16|2009-04-17|Estimate|2017-02-06|2017-02-10|Actual||||2017-02-06|2017-02-10|Actual|September 2009||2009-09-30|February 2017|2017-02-28|November 2015|Actual|2015-11-30|January 2015|Actual|2015-01-31||Interventional|SLSII||Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)|Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)|Completed||Phase 2|142|Actual|University of California, Los Angeles|While the rate of premature withdrawal from taking study drug was significant, this was anticipated in the study design and addressed by the sample size and the use of the mixed model statistical analysis.|2|||f||||t||||||||No||2018-06-01 01:04:29.970012|2018-06-01 01:04:29.970012
NCT00883116|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2013-12-06||2017-01-27|2009-04-16|2009-04-17|Estimate|2014-02-12|2014-03-14|Estimate||||2017-01-27|2017-03-09|Actual|August 2009||2009-08-31|January 2017|2017-01-31|February 2014|Actual|2014-02-28|June 2012|Actual|2012-06-30||Interventional|IXAMPLE2|Baseline analyses are for randomized participants.|A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer|A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy|Terminated||Phase 3|551|Actual|R-Pharm|This study was terminated per Data Monitoring Committee. Results from an interim analysis showed that there was no favorable benefit/risk ratio with ixabepilone and that ixabepilone did not improve survival compared with control chemotherapies.|2||"Interim analysis results showed that ixabepilone did not improve survival compared with control~   chemotherapies."|f||||t||||||||||2018-06-01 01:04:31.390922|2018-06-01 01:04:31.390922
NCT00883103|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2011-07-18||2011-08-10|2009-04-16|2009-04-17|Estimate|2011-08-10|2011-09-13|Estimate||||2011-08-10|2011-09-13|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test|Double Blinded Randomized Trial Between Lidocaine Jelly And Plain Aqueous Gel For Urethral Straight Catheterization And The Q-Tip Test|Completed||Phase 4|137|Actual|Baystate Medical Center||2|||f||||t||||||||||2018-06-01 01:04:32.862506|2018-06-01 01:04:32.862506
NCT00883090|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2011-12-07||2011-12-07|2009-04-16|2009-04-17|Estimate|2011-12-07|2012-01-16|Estimate||||2011-12-07|2012-01-16|Estimate|May 2009||2009-05-31|December 2011|2011-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency|A 12 Week, Multicenter, Pharmacokinetic and Safety Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency|Completed||Phase 2|15|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 01:04:33.608798|2018-06-01 01:04:33.608798
NCT00883077|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-10-13|2009-04-15|2009-04-17|Estimate|||||||2009-10-13|2009-10-14|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Observational|||Assessment of Colonic Permeability by Confocal Laser Endomicroscopy|Combined Assessment of Colonic Permeability by Real Time Confocal Laser Endomicroscopy and Sucralose Absorption Test|Unknown status|Recruiting||30|Anticipated|Shandong University|||3||f||||t||||||Samples With DNA|"~     Biopsies during colonoscopy.~   "|||2018-06-01 01:04:34.098452|2018-06-01 01:04:34.098452
NCT00883064|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-03-27|2009-04-16|2009-04-17|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2000||2000-03-31|March 2009|2009-03-31|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Eon Labs Manufacturing Inc. (USA) and Zeneca (USA) (Zestril) 40 mg Lisinopril Tablet Administered as a 1 x 40 mg Tablet in Health Adult Males Under Fasting Conditions.|Completed||Phase 1|32|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:04:34.213177|2018-06-01 01:04:34.213177
NCT00883051|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2018-01-02|2009-04-16|2009-04-17|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2009||2009-07-31|January 2018|2018-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment|A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine|Completed||Phase 2|450|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 01:04:34.362675|2018-06-01 01:04:34.362675
NCT00883038|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2009-04-15|2009-04-15|2009-04-17|Estimate|||||||2009-04-15|2009-04-17|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Does a Low-Fat Vegetarian Diet Improve Insulin Resistance in Individuals With Type 2 Diabetes?|Does a Low-Fat Vegetarian Diet Improve Insulin Resistance in Individuals With Type 2 Diabetes?|Completed||Phase 1|70|Actual|Institute for Clinical and Experimental Medicine||2|||f||||t||||||||||2018-06-01 01:04:35.546032|2018-06-01 01:04:35.546032
NCT00883025|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate|February 2007||2007-02-28|April 2009|2009-04-30|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Observational|FriedmAIH||Correlation Between Friedman Classification and the Apnea Hypopnea Index (AIH) in a Population With Obstructive Sleep Apnea Syndrome (OSAS)|Correlation Between Friedman Classification Ande ApneaHypopnea Index in a Population With OSAS|Completed|||147|Anticipated|Irmandade da Santa Casa de Misericoridia de Limeira|||2||f||||f||||||||||2018-06-01 01:04:35.659301|2018-06-01 01:04:35.659301
NCT00883012|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-04-02|2009-04-15|2009-04-17|Estimate|||||||2012-04-02|2012-04-03|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Influenza Vaccine in HIV Infected Children|Immunogenicity, Safety and Efficacy of Influenza Vaccine in HIV Infected Children|Completed||Phase 4|412|Actual|University of Witwatersrand, South Africa||2|||f||||f||||||||||2018-06-01 01:04:35.80493|2018-06-01 01:04:35.80493
NCT00882999|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16||2011-06-13|2012-06-22|2009-04-16|2009-04-17|Estimate||||2011-06-13|2011-06-27|Estimate|2012-06-22|2012-07-02|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|February 2011|Actual|2011-02-28||Interventional|||A Study of Patients With Relapsing Remitting Multiple Sclerosis|Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|245|Anticipated|Eli Lilly and Company||7|||f||||t||||||||||2018-06-01 01:04:36.005367|2018-06-01 01:04:36.005367
NCT00882986|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2015-09-22|2009-04-16|2009-04-17|Estimate|||||||2015-09-22|2015-09-24|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Cardiovascular and Metabolic Responses to a Mixed Meal|Role of Exercise Training and Body Weight on Cardiovascular and Metabolic Responses to a Mixed Meal Tolerance Test|Completed|||20|Actual|University of Kansas Medical Center|||2||f||||f||||||||||2018-06-01 01:04:36.315268|2018-06-01 01:04:36.315268
NCT00882973|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-05-02|2009-04-16|2009-04-17|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2008|Actual|2008-09-30|May 2017|2017-05-31|November 2010|Actual|2010-11-30|August 2009|Actual|2009-08-31||Interventional|||Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer||Completed||Phase 1|18|Actual|Samyang Biopharmaceuticals Corporation||3|||f||||||||||||||2018-06-01 01:04:36.4096|2018-06-01 01:04:36.4096
NCT00882960|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2011-05-03|2009-04-16|2009-04-17|Estimate|||||||2011-05-03|2011-05-04|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Intranasal Fentanyl for Pain Management|Atomization of Fentanyl: A Randomized Comparison Study of Intranasal Versus Intravenous Fentanyl for Pre-hospital Pain Management|Unknown status|Recruiting|Phase 4|500|Anticipated|Genesys||2|||f||||||||||||||2018-06-01 01:04:36.549542|2018-06-01 01:04:36.549542
NCT00882947|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)|Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)|Completed|||38|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 01:04:36.772719|2018-06-01 01:04:36.772719
NCT00882934|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-04-15|2009-04-15|2009-04-17|Estimate|||||||2009-04-15|2009-04-17|Estimate|October 2006||2006-10-31|April 2009|2009-04-30|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|DAFA06||The Management of Erectile Dysfunction With Placebo Only|A Single-Blind, Controlled, Randomized, Parallel-Group Study of the Efficacy of Patients' Awareness on the Composition of the Experimental Drug in the Treatment of Erectile Dysfunction.|Completed||N/A|123|Actual|Rio de Janeiro State University||3|||f||||t||||||||||2018-06-01 01:04:37.108259|2018-06-01 01:04:37.108259
NCT00882921|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2014-06-23||2014-08-04|2009-04-16|2009-04-17|Estimate|2014-07-28|2014-07-30|Estimate||||2014-08-04|2014-08-07|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients|A Multi-Center Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients Enrolled in the Hunter Outcome Survey (HOS) Receiving Idursulfase Enzyme Replacement Therapy|Completed|||26|Actual|Shire|||1||f||||f||||||Samples Without DNA|"~     Blood and urine~   "|||2018-06-01 01:04:37.408461|2018-06-01 01:04:37.408461
NCT00882908|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|2013-12-18|2011-07-07|2014-05-19|2009-04-16|2009-04-17|Estimate|2014-05-19|2014-06-16|Estimate|2011-07-07|2011-07-14|Estimate|2014-05-19|2014-06-16|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|PILLAR||A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin In Treatment-Naive Genotype 1 Hepatitis C-Infected Subjects|Completed||Phase 2|386|Actual|Tibotec Pharmaceuticals, Ireland||5|||f||||t||||||||||2018-06-01 01:04:38.265581|2018-06-01 01:04:38.265581
NCT00882895|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2017-07-17|2009-04-16|2009-04-17|Estimate|||||||2017-07-17|2017-07-19|Actual|May 5, 2009|Actual|2009-05-05|July 2017|2017-07-31|January 31, 2029|Anticipated|2029-01-31|January 31, 2029|Anticipated|2029-01-31||Interventional|||Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma|Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma|Recruiting||Phase 2|25|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-06-01 01:04:40.379442|2018-06-01 01:04:40.379442
NCT00882882|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-03-27|2009-04-16|2009-04-17|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2001||2001-06-30|April 2009|2009-04-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions|A Relative Bioavailability Study of Metformin HCL 500 mg XR Tablets Under Fasting Conditions|Completed||Phase 1|16|Actual|Sandoz||4|||f||||||||||||||2018-06-01 01:04:40.52448|2018-06-01 01:04:40.52448
NCT00882869|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2011-07-12|2009-04-16|2009-04-17|Estimate|||||||2011-07-12|2011-07-13|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 1/Phase 2|75|Anticipated|Aegera Therapeutics|||||f||||f||||||||||2018-06-01 01:04:40.700112|2018-06-01 01:04:40.700112
NCT00882856|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2017-01-06|2009-04-16|2009-04-17|Estimate|||||||2017-01-06|2017-01-09|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Biscloz||Treating Clozapine-induced Sinustachycardia With Bisoprolol|Treating Clozapine-induced Sinustachycardia With Bisoprolol - a Double Blinded Placebo Controlled Cross Over Study|Completed||N/A|21|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 01:04:40.977377|2018-06-01 01:04:40.977377
NCT00882843|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2012-06-21|2009-04-16|2009-04-17|Estimate|||||||2012-06-21|2012-06-25|Estimate|September 2006||2006-09-30|June 2012|2012-06-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Observational|||Feasibility Study for the Use of Low-magnitude, High Frequency Mechanical Stimulation of Bone in Persons With Spinal Cord Injury (SCI)|Feasibility Study for the Use of Low-magnitude, High Frequency Mechanical Stimulation of Bone in Persons With SCI|Completed|||22|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-06-01 01:04:41.267174|2018-06-01 01:04:41.267174
NCT00882830|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2015-03-12|2009-04-16|2009-04-17|Estimate|||||||2015-03-12|2015-03-13|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|June 2009|Actual|2009-06-30||Interventional|||Electrical Muscle Stimulation (EMS), a Preventive and Therapeutic Tool for Critical Illness Polyneuromyopathy (CIPNM)|Electrical Muscle Stimulation (EMS), a Preventive and Therapeutic Tool for Critical Illness Polyneuromyopathy (CIPNM)- A Randomized Controlled Parallel Intervention Trial.|Unknown status|Active, not recruiting|Phase 2|52|Actual|University of Athens||2|||f||||f||||||||||2018-06-01 01:04:41.756896|2018-06-01 01:04:41.756896
NCT00882817|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2013-07-31|2009-04-15|2009-04-17|Estimate|||||||2013-07-31|2013-08-01|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Pulmonary Rehabilitation in Interstitial Lung Diseases|Effects of Pulmonary Rehabilitation in Interstitial Lung Diseases: a Prospective Randomized Controlled Trial|Completed||Phase 4|60|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 01:04:42.122686|2018-06-01 01:04:42.122686
NCT00882804|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2009-04-16|2009-04-16|2009-04-17|Estimate|||||||2009-04-16|2009-04-17|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Hemin in Healthy Subjects|Effect of Hemin on Heme-Oxygenase-1 Activity in Healthy Subjects|Completed||Phase 1|10|Actual|Mayo Clinic||2|||f||||||||||||||2018-06-01 01:04:42.440145|2018-06-01 01:04:42.440145
NCT00882791|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-16|||2012-09-14|2009-04-16|2009-04-17|Estimate|||||||2012-09-14|2012-09-17|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Basal Cell Carcinoma Recurrence After Mohs Surgery|Basal Cell Carcinoma Recurrence|Completed|||115|Actual|Northwestern University|||2||f||||f||||||||||2018-06-01 01:04:42.754811|2018-06-01 01:04:42.754811
NCT00882778|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2011-05-11||2016-11-17|2009-04-15|2009-04-16|Estimate|2011-06-24|2011-07-25|Estimate||||2016-11-17|2017-01-09|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|PROPACT||PROPACT: Retrospective Prophylaxis Patient Case Collection|Prophylactic Treatment With Recombinant Factor VIIa (rFVIIa, NovoSeven®) in Haemophilia Patients With Inhibitors|Completed|||86|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:04:43.142951|2018-06-01 01:04:43.142951
NCT00882765|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2015-10-28|2009-04-15|2009-04-16|Estimate|||||||2015-10-28|2015-10-30|Estimate|May 2009||2009-05-31|July 2012|2012-07-31||||January 2011|Actual|2011-01-31||Interventional|||Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|A Pre-Surgical, Randomized Clinical Trial of Genistein in Resectable Pancreatic Adenocarcinoma|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||2||Study has been closed due to no accrual.|f||||t||||||||||2018-06-01 01:04:45.369147|2018-06-01 01:04:45.369147
NCT00882752|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2011-09-06|2009-04-15|2009-04-16|Estimate|||||||2011-09-06|2011-09-07|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Report of a New Method Used to Identify the Bacteria Present in a Human Colon Biopsy Sample|Retrospective Study Protocol: Report of a New Method Used to Identify the Bacteria Present in a Human Colon Biopsy|Completed|||1|Actual|Southwest Regional Wound Care Center|||1||f||||t||||||Samples With DNA|"~     colon biopsy~   "|||2018-06-01 01:04:45.94782|2018-06-01 01:04:45.94782
NCT00882739|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-01-25|2009-04-15|2009-04-16|Estimate|||||||2012-01-25|2012-01-26|Estimate|April 2009||2009-04-30|January 2012|2012-01-31||||July 2011|Actual|2011-07-31||Interventional|Load & Go||Safety and Efficacy of Three Different Loading Doses of Clopidogrel, in Patients With Acute Myocardial Infarction|Safety and Efficacy of Three Different Loading Doses of Clopidogrel, Administered at First Medical Contact in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. The LOAD & GO Trial|Completed||Phase 4|168|Actual|Ospedale San Donato||3|||f||||f||||||||||2018-06-01 01:04:46.214963|2018-06-01 01:04:46.214963
NCT00882726|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2013-12-13|2009-04-14|2009-04-16|Estimate|||||||2013-12-13|2013-12-16|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus|A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Intravenous and Subcutaneous Single-Dose Study in Healthy Subjects and Ascending Subcutaneous Multiple-Dose Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immune Response of CNTO 3649|Completed||Phase 1|133|Actual|Centocor, Inc.||3|||f||||f||||||||||2018-06-01 01:04:46.645509|2018-06-01 01:04:46.645509
NCT00882713|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2016-07-02||2016-08-12|2009-04-15|2009-04-16|Estimate|2016-08-12|2016-10-07|Estimate||||2016-08-12|2016-10-07|Estimate|February 2009||2009-02-28|August 2016|2016-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||Safety population included all participants who have been treated with at least one dose of the study drug and a safety follow-up, whether withdrawn prematurely or not.|A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once- Monthly Administration of Subcutaneous CERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anemia|Completed||Phase 3|202|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:04:47.109019|2018-06-01 01:04:47.109019
NCT00878358|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2011-04-27|2009-04-07|2009-04-08|Estimate|||||||2011-04-27|2011-04-28|Estimate|June 2009||2009-06-30|April 2009|2009-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Hydrotherapy Versus Physiotherapy for Short-term Rehabilitation After Primary TKR|Hydrotherapy Versus Physiotherapy for Short-term Rehabilitation After Primary TKR|Completed||N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:06:55.333658|2018-06-01 01:06:55.333658
NCT00882700|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2017-03-27|2009-04-15|2009-04-16|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2005||2005-04-30|April 2009|2009-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and/or Female Volunteers in the Fasting State|Completed||Phase 1|28|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:04:48.000391|2018-06-01 01:04:48.000391
NCT00882687|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2015-11-06|2013-07-02|2017-01-05|2009-04-15|2009-04-16|Estimate|2017-01-05|2017-02-24|Actual|2013-07-02|2013-07-09|Estimate|2017-01-05|2017-02-24|Actual|April 2009||2009-04-30|January 2017|2017-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||Intent-to-treat (ITT) population included data from all randomized participants.|Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis|A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model|Completed||Phase 2|60|Actual|Shire||4|||f||||f||||||||||2018-06-01 01:04:48.191651|2018-06-01 01:04:48.191651
NCT00882674|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2016-11-01|2009-04-15|2009-04-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer|An Exploratory Study to Evaluate the Biological Activity of R1507, a Human Monoclonal Antibody Antagonist of the Insulin-like Growth Factor Receptor (IGF-1R) in Women With Operable Breast Cancer|Completed||Phase 1|8|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:04:49.911086|2018-06-01 01:04:49.911086
NCT00882661|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2014-08-21||2017-06-07|2009-04-15|2009-04-16|Estimate|2017-06-07|2017-06-09|Actual||||2017-06-07|2017-06-09|Actual|July 2005||2005-07-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|April 2010|Actual|2010-04-30||Interventional|||SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study|A Prospective Randomized Clinical Investigation of the SECURE-C Cervical Artificial Disc: A Pivotal Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study|Completed||N/A|380|Actual|Globus Medical Inc||2|||f||||||||||||||2018-06-01 01:04:50.247105|2018-06-01 01:04:50.247105
NCT00882648|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2013-02-19|2009-04-15|2009-04-16|Estimate|||||||2013-02-19|2013-02-21|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||The Effect of Fetal Gender on Maternal Substance Abuse Treatment|The Effect of Fetal Gender on Maternal Substance Abuse Treatment|Completed|||850|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-06-01 01:04:51.7747|2018-06-01 01:04:51.7747
NCT00882635|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-06-28|2009-04-15|2009-04-16|Estimate|||||||2012-06-28|2012-07-02|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study|The STrategic Reperfusion Early After Myocardial Infarction (STREAM) Anticoagulation With Enoxaparin vs. Unfractionated Heparin in Primary PCI Sub-study.|Completed||Phase 3|44|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 01:04:52.051411|2018-06-01 01:04:52.051411
NCT00882622|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-01-17|2009-04-15|2009-04-16|Estimate|||||||2012-01-17|2012-01-18|Estimate|February 2009||2009-02-28|January 2012|2012-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Remote Ischemic Preconditioning on Cardiac Function After Cardiac Surgery|Effect of Remote Ischemic Preconditioning on Cardiac Function After Cardiac Surgery|Withdrawn||Phase 1|0|Actual|University of Schleswig-Holstein||2||Endpoints were investigated in parallel in NCT00877305|f||||f||||||||||2018-06-01 01:04:52.43069|2018-06-01 01:04:52.43069
NCT00882609|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-11-28|2009-04-15|2009-04-16|Estimate|||||||2012-11-28|2012-11-29|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets|18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques|Unknown status|Recruiting|Phase 3|550|Anticipated|American College of Radiology - Image Metrix||2|||f||||f||||||||||2018-06-01 01:04:52.722943|2018-06-01 01:04:52.722943
NCT00882596|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2018-01-23|2009-04-15|2009-04-16|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2008||2008-05-31|January 2018|2018-01-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||"Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to Low-risk Breast Cancer Patients"|A Multi-Site, Prospective, Non-Randomized Study of the Contura™ Multi-Lumen Balloon (MLB) Catheter to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetry, Local Tumor Control, Cosmetic Outcome, and Toxicity|Completed||Phase 4|30|Actual|Cancer Center of Irvine||1|||f||||t||||||||||2018-06-01 01:04:53.483037|2018-06-01 01:04:53.483037
NCT00882583|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2017-01-04||2017-01-04|2009-04-15|2009-04-16|Estimate|2017-01-04|2017-02-23|Actual||||2017-01-04|2017-02-23|Actual|July 2009||2009-07-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|Dasatinib||A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC|A Phase I/II Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in Locally Advanced Squamous Cell Carcinoma of Head and Neck (HNSCC)|Terminated||Phase 1/Phase 2|22|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||Low accrual|f||||t||||||||||2018-06-01 01:04:53.894897|2018-06-01 01:04:53.894897
NCT00882570|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2017-03-27|2009-04-15|2009-04-16|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2005||2005-04-30|April 2009|2009-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 250mg/5 ml Cefdinir (Test Formulation) and Omnicel 250mg/5 ml Powder For Oral Suspension (Reference Formulation) Each Given as a Single Oral Dose to Forty Healthy Male and/or Female Volunteers in the Fasting State|Completed||Phase 1|40|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:04:55.172997|2018-06-01 01:04:55.172997
NCT00882557|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2011-07-19||2018-01-10|2009-04-15|2009-04-16|Estimate|2011-09-16|2011-10-25|Estimate||||2018-01-10|2018-02-06|Actual|April 29, 2009|Actual|2009-04-29|January 2018|2018-01-31|July 17, 2009|Actual|2009-07-17|July 17, 2009|Actual|2009-07-17||Interventional|||Study to Evaluate Daptomycin Given During Dialysis and After Dialysis|A Prospective, Randomized, Crossover-design Study to Evaluate the Pharmacokinetics and Safety of Daptomycin Administered at 9 mg/kg During and 6 mg/kg After Hemodialysis|Completed||Phase 1|16|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:04:55.577851|2018-06-01 01:04:55.577851
NCT00882531|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-11-16|2009-04-15|2009-04-16|Estimate|||||||2009-11-16|2009-11-17|Estimate|February 2007||2007-02-28|November 2009|2009-11-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|ISOROS||Isotretinoin in Papular-Pustular Rosacea|Evaluation of the Efficacy of Isotretinoin Versus Placebo in Terms of Response Rate Among Patients Presenting Papular-pustular Rosacea Resistant to Standard Therapy|Completed||Phase 3|156|Actual|Laboratoires Bailleul-Biorga||2|||f||||t||||||||||2018-06-01 01:04:56.349672|2018-06-01 01:04:56.349672
NCT00882518|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2011-03-07||2012-04-16|2009-04-15|2009-04-16|Estimate|2012-04-16|2012-05-15|Estimate||||2012-04-16|2012-05-15|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ESPRIT||Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients|A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode|Completed||Phase 3|388|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:04:56.495416|2018-06-01 01:04:56.495416
NCT00882505|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-09-14|2009-04-15|2009-04-16|Estimate|||||||2012-09-14|2012-09-17|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparison of 25-hydroxy Vitamin D Level in Caucasian Women Receiving Vitamin D Supplementation and Not Receiving Supplementation: a Randomized Controlled Trial.|Comparison of 25-hydroxy Vitamin D Level in Caucasian Women Receiving Vitamin D Supplementation and Not Receiving Supplementation: a Randomized Controlled Trial.|Completed||N/A|67|Actual|Northwestern University||3|||f||||f||||||||||2018-06-01 01:04:57.193515|2018-06-01 01:04:57.193515
NCT00882492|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-02-14|2009-04-15|2009-04-16|Estimate|||||||2012-02-14|2012-02-16|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|GLP||GLP 1 for Intraoperative Glycemic Control|Identifying a Novel Mechanism for Perioperative Hyperglycemia Identifying a Novel Mechanism for Perioperative Hyperglycemia in Cardiac Surgery: A Role for Incretins|Completed||Phase 1|80|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 01:04:57.340762|2018-06-01 01:04:57.340762
NCT00882479|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-06-12|2009-04-15|2009-04-16|Estimate|||||||2012-06-12|2012-06-14|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Formalizing a Conceptual Framework of Work Domain Knowledge|Formalizing a Conceptual Framework of Work Domain Knowledge|Completed|||51|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-06-01 01:04:57.475074|2018-06-01 01:04:57.475074
NCT00882466|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-04-16|2009-04-15|2009-04-16|Estimate|||||||2009-04-16|2009-04-17|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction|Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction|Completed||Phase 4|58|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-06-01 01:04:57.549831|2018-06-01 01:04:57.549831
NCT00882453|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-05-28|2009-04-15|2009-04-16|Estimate|||||||2012-05-28|2012-05-30|Estimate|August 2006||2006-08-31|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|BEGIN||Physical Activity and Fatigue in Early Multiple Sclerosis (MS)|Betaferon Treatment and Exercise Data Gathering IN Early MS|Completed|||1739|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 01:04:57.64595|2018-06-01 01:04:57.64595
NCT00882440|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2009-04-17||2015-08-17|2009-04-14|2009-04-16|Estimate|2009-04-17|2009-06-10|Estimate||||2015-08-17|2015-08-27|Estimate|December 1990||1990-12-31|August 2015|2015-08-31|January 1992|Actual|1992-01-31|August 1991|Actual|1991-08-31||Interventional|||A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)|A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954)|Completed||Phase 3|576|Actual|Merck Sharp & Dohme Corp.||7|||f||||||||||||||2018-06-01 01:04:57.79324|2018-06-01 01:04:57.79324
NCT00882427|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2010-02-04|2009-04-15|2009-04-16|Estimate|||||||2010-02-04|2010-02-05|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|Aldea_02||Blood Glucose Control Over an Extended Glucose Control Range in Postoperative Cardiac Surgery Patients in the Intensive Care Unit|Single-center, Open Study on the Performance of the Software eMPC Algorithm Used for Blood Glucose Control Over an Extended Glucose Control Range (4.4 to 8.3 mmol/L) for a Maximum of 48 Hours in Postoperative Cardiac Surgery Patients in the Intensive Care Unit|Completed||N/A|20|Actual|B. Braun Melsungen AG||1|||f||||f||||||||||2018-06-01 01:04:58.556285|2018-06-01 01:04:58.556285
NCT00882414|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2010-04-07|2009-04-15|2009-04-16|Estimate|||||||2010-04-07|2010-04-08|Estimate|December 2006||2006-12-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)|A Multi-centre, Randomized, Controlled, Single-blinded, Phase II Study to Investigate the Safety and Efficacy of Intravenous Infusions of FERINJECT® Versus Placebo in Patients With Thrombocytosis Secondary to Iron Deficiency and Chronic Inflammatory Bowel Disease|Terminated||Phase 2|26|Actual|Vifor Inc.||4||Main objective of study was met. Further recruitment was difficult.|f||||f||||||||||2018-06-01 01:04:58.643738|2018-06-01 01:04:58.643738
NCT00882401|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2011-03-21|2009-04-15|2009-04-16|Estimate|||||||2011-03-21|2011-03-22|Estimate|April 2009||2009-04-30|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Vitamin D, Chronic Kidney Disease (CKD) and the Microcirculation|The Effect of Vitamin D on the Microcirculation of Patients With Chronic Kidney Disease (CKD) and Vitamin D Deficiency|Completed||Phase 4|64|Anticipated|Barts & The London NHS Trust||2|||f||||f||||||||||2018-06-01 01:04:58.773583|2018-06-01 01:04:58.773583
NCT00882388|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2013-12-15|2009-04-15|2009-04-16|Estimate|||||||2013-12-15|2013-12-17|Estimate|March 2005||2005-03-31|December 2013|2013-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers|Phase 4 Study of the Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel|Completed||Phase 4|40|Actual|Seoul National University Hospital||5|||f||||t||||||||||2018-06-01 01:04:58.885661|2018-06-01 01:04:58.885661
NCT00882375|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-06-28|2009-04-15|2009-04-16|Estimate|||||||2012-06-28|2012-07-02|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy|Efficacy and Safety Following Use of a Novel Nicotine Replacement Therapy. A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 52 Week Study in Smokers Motivated to Quit.|Completed||N/A|479|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 01:04:58.994565|2018-06-01 01:04:58.994565
NCT00882362|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2013-12-20||2013-12-20|2009-04-15|2009-04-16|Estimate|2013-12-20|2014-02-10|Estimate||||2013-12-20|2014-02-10|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder|Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder|Completed||Phase 3|155|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:04:59.103641|2018-06-01 01:04:59.103641
NCT00882336|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-10-28|2009-04-15|2009-04-16|Estimate|||||||2009-10-28|2009-10-29|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Observational|EURIKA||European Study of Cardiovascular Risk|Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice|Completed|||7200|Anticipated|AstraZeneca|||1||f||||f||||||Samples Without DNA|"~     Whole blood Serum~   "|||2018-06-01 01:05:00.040984|2018-06-01 01:05:00.040984
NCT00882323|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-03-23|2009-04-15|2009-04-16|Estimate|||||||2012-03-23|2012-03-26|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)|Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia|Unknown status|Recruiting|Phase 2|33|Anticipated|The Korean Society of Pediatric Hematology Oncology||1|||f||||t||||||||||2018-06-01 01:05:01.652659|2018-06-01 01:05:01.652659
NCT00882310|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2016-04-26||2016-06-22|2009-04-15|2009-04-16|Estimate|2016-05-16|2016-06-22|Estimate||||2016-06-22|2016-07-25|Estimate|September 2006||2006-09-30|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer|A Phase II Study of Gemzar, Taxotere, and Xeloda (GTX) for Adjuvant Pancreatic Cancer|Completed||Phase 2|37|Actual|Columbia University||1|||f||||t||||||||Undecided||2018-06-01 01:05:01.829029|2018-06-01 01:05:01.829029
NCT00882297|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2010-01-20|2009-04-15|2009-04-16|Estimate|||||||2010-01-20|2010-01-21|Estimate|April 2009||2009-04-30|January 2010|2010-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|CATETEL||Subclavian Vein Ultrasound Guided Cannulation in Adult|Subclavian Vein Ultrasound Guided Cannulation in Adult: Transversal and Longitudinal Approach Comparison|Completed||N/A|100|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:05:02.112333|2018-06-01 01:05:02.112333
NCT00882284|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2015-07-21|2009-04-14|2009-04-16|Estimate|||||||2015-07-21|2015-07-22|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Hypotension in Neonates|Hydrocortisone Treatment of Hypotension in Term and Late Preterm Infants: An Observational Study|Completed|||820|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-06-01 01:05:02.224185|2018-06-01 01:05:02.224185
NCT00882271|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2011-11-16|2009-04-15|2009-04-16|Estimate|||||||2011-11-16|2011-11-18|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Fibromyalgia Acupuncture Study|Efficacy of Acupuncture to Improve Symptoms and Functionality for People With Fibromyalgia|Completed||N/A|50|Actual|Southern California University of Health Sciences||2|||f||||t||||||||||2018-06-01 01:05:02.335991|2018-06-01 01:05:02.335991
NCT00882258|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2014-07-03|2009-04-14|2009-04-16|Estimate|||||||2014-07-03|2014-07-08|Estimate|March 2006||2006-03-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids|A Phase II, Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Selective Progesterone Receptor Modulator Proellex (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata|Completed||Phase 2|144|Actual|Repros Therapeutics Inc.||3|||f||||t||||||||||2018-06-01 01:05:02.422883|2018-06-01 01:05:02.422883
NCT00882245|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-10-29|2009-04-15|2009-04-16|Estimate|||||||2009-10-29|2009-10-30|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis|A Phase II, Double-Blind, Vehicle Controlled Study to Determine the Efficacy, Safety and Toleration of SRD441 Ointment in Patients With Atopic Dermatitis|Completed||Phase 2|93|Actual|Serentis Ltd.||2|||f||||f||||||||||2018-06-01 01:05:02.563995|2018-06-01 01:05:02.563995
NCT00882232|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2013-02-14|2009-04-15|2009-04-16|Estimate|||||||2013-02-14|2013-02-15|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer|Transperineal Injection of Cross-linked Hyaluronan Gel Into Anterior Perirectal Fat to Reduce Rectal Toxicity From High Dose Rate Brachytherapy and/or Intensity-Modulated Radiation Therapy for Prostate Cancer|Completed||Phase 1|10|Actual|Cancer Center of Irvine||1|||f||||t||||||||||2018-06-01 01:05:02.656771|2018-06-01 01:05:02.656771
NCT00882219|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-09-05|2009-04-15|2009-04-16|Estimate|||||||2012-09-05|2012-09-06|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|March 2011|Actual|2011-03-31||Interventional|XERES||Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period|"XERES Trial: Clinical Evaluation of Patients With Everolimus-eluting Stent  Xience V®  Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period"|Completed||Phase 3|102|Actual|Abbott Vascular||1|||f||||f||||||||||2018-06-01 01:05:02.818347|2018-06-01 01:05:02.818347
NCT00882206|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2015-04-10||2017-12-03|2009-04-15|2009-04-16|Estimate|2016-09-08|2016-10-28|Estimate||||2017-12-03|2017-12-28|Actual|April 2009||2009-04-30|December 2017|2017-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia|A Therapeutic Trial of Decitabine and Vorinostat in Combination With Chemotherapy (Vincristine, Prednisone, Doxorubicin and PEG-Asparaginase) for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)|Terminated||Phase 2|15|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||t||||||||||2018-06-01 01:05:02.935464|2018-06-01 01:05:02.935464
NCT00882193|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2011-08-08|2009-04-15|2009-04-16|Estimate|||||||2011-08-08|2011-08-09|Estimate|May 2009||2009-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers|Pilot Therapy Using Betaine in Combination With Peginterferon Alpha-2a Plus Ribavirin in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Pegylated Interferon and Ribavirin|Terminated||Early Phase 1|30|Anticipated|University of Nebraska||||new medications with improved response released, nonaccrual|f||||t||||||||||2018-06-01 01:05:04.313822|2018-06-01 01:05:04.313822
NCT00882180|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2011-08-23|2009-04-15|2009-04-16|Estimate|||||||2011-08-23|2011-08-24|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement|A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients With Advanced Solid Tumors With Liver Involvement|Completed||Phase 1|41|Actual|Alnylam Pharmaceuticals|||||f||||f||||||||||2018-06-01 01:05:04.440064|2018-06-01 01:05:04.440064
NCT00882167|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2016-11-23|2009-04-15|2009-04-16|Estimate|||||||2016-11-23|2016-11-25|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Cine-magnetic Resonance Imaging (MRI) Detecting Intra Abdominal Adhesions|Sensitivity and Predictive Value of Functional Cine Magnetic Resonance Imaging (MRI) Detecting Intra-abdominal Adhesions|Recruiting|||100|Anticipated|Radboud University|||1||f||||f||||||||||2018-06-01 01:05:04.558372|2018-06-01 01:05:04.558372
NCT00882154|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2017-03-27|2009-04-15|2009-04-16|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2005||2005-04-30|April 2009|2009-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions|A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and/or Female Volunteers in the Fed State|Completed||Phase 1|28|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:05.45342|2018-06-01 01:05:05.45342
NCT00882141|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2010-01-11|2009-04-15|2009-04-16|Estimate|||||||2010-01-11|2010-01-13|Estimate|March 2002||2002-03-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Race, Menopause and Metabolism After Exercise and Diet|Menopause, Genes and Metabolism After Weight Loss and Exercise|Completed||N/A|103|Actual|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 01:05:05.527842|2018-06-01 01:05:05.527842
NCT00882128|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2009-11-13|2009-04-15|2009-04-16|Estimate|||||||2009-11-13|2009-11-17|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|||||Observational|SAISON||Evaluation of the Control Level of Asthmatic Patients With Seasonal Increase of Respiratory Symptoms (High and/or Low)|Evaluation of the Control Level (GINA) of Asthmatic Patients Consulting Their General Practitioner for a Seasonal Increase of Respiratory Symptoms (High and / or Low), Whether an Inhaled Corticotherapy is Taken or Not|Completed|||3300|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:05:05.839547|2018-06-01 01:05:05.839547
NCT00882115|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2017-05-03|2009-04-14|2009-04-16|Estimate|||||||2017-05-03|2017-05-08|Actual|August 2009||2009-08-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose|Broccoli Sprout Extract Effects on the Inflammatory Response to Diesel Exhaust Particles in the Nose|Completed||N/A|35|Actual|University of California, Los Angeles||1|||f||||t||||||||No|There is no plan to share IPD with other researchers.|2018-06-01 01:05:07.609598|2018-06-01 01:05:07.609598
NCT00882102|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|2013-06-06||2013-09-03|2009-04-15|2009-04-16|Estimate|2013-06-06|2013-08-09|Estimate||||2013-09-03|2013-09-13|Estimate|April 2009||2009-04-30|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)|Phase II Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome|Completed||Phase 2|43|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:05:07.708834|2018-06-01 01:05:07.708834
NCT00882089|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2018-01-23|2009-04-15|2009-04-16|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2007||2007-10-31|July 2013|2013-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients|Registry Study of the Contura™ Multi-Lumen Balloon (MLB) Applicator for Accelerated Partial Breast Irradiation in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients|Completed||Phase 4|13|Actual|Cancer Center of Irvine||1|||f||||t||||||||||2018-06-01 01:05:07.913811|2018-06-01 01:05:07.913811
NCT00882076|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2014-12-04|2009-04-15|2009-04-16|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias|Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias|Completed||Phase 1|22|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-06-01 01:05:08.039213|2018-06-01 01:05:08.039213
NCT00882063|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2012-11-20|2009-04-15|2009-04-16|Estimate|||||||2012-11-20|2012-11-21|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|November 2009|Actual|2009-11-30||Interventional|||Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma|An Open Label, Multicenter Phase I/II Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Relapsed and/or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|19|Actual|Piramal Enterprises Limited||1|||f||||t||||||||||2018-06-01 01:05:08.173114|2018-06-01 01:05:08.173114
NCT00882050|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2016-08-17|2009-04-15|2009-04-16|Estimate|||||||2016-08-17|2016-08-19|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Intravenous Exenatide (Byetta) During Surgery|Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial|Completed||Phase 1/Phase 2|12|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 01:05:08.249157|2018-06-01 01:05:08.249157
NCT00882037|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2017-08-31|2009-04-15|2009-04-16|Estimate|||||||2017-08-31|2017-09-01|Actual|August 2008||2008-08-31|August 2017|2017-08-31|December 15, 2010|Actual|2010-12-15|December 15, 2010|Actual|2010-12-15||Observational|||Risk and Protective Factors for Rural Methamphetamine Dependence|Risk and Protective Factors for Rural Methamphetamine Dependence|Completed|||133|Actual|University of Nebraska|||1||f||||f||||||||||2018-06-01 01:05:08.460052|2018-06-01 01:05:08.460052
NCT00882024|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2011-01-05|2009-04-15|2009-04-16|Estimate|||||||2011-01-05|2011-01-06|Estimate|March 2009||2009-03-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)|A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast With Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients With Active Rheumatoid Arthritis (RA)|Completed||Phase 2|250|Anticipated|Nuon Therapeutics, Inc.||3|||f||||t||||||||||2018-06-01 01:05:08.628846|2018-06-01 01:05:08.628846
NCT00881140|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-12-18|2009-04-14|2009-04-15|Estimate|||||||2012-12-18|2012-12-19|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids|The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa)|Completed||Phase 2|30|Actual|BioPro Medical Ltd||1|||f||||f||||||||||2018-06-01 01:05:24.265722|2018-06-01 01:05:24.265722
NCT00882011|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-15|||2011-10-12|2009-04-15|2009-04-16|Estimate|||||||2011-10-12|2011-10-13|Estimate|April 2009||2009-04-30|October 2011|2011-10-31|April 2019|Anticipated|2019-04-30|April 2014|Anticipated|2014-04-30||Observational|||Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters|Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy-pathological Parameters|Recruiting|||100|Anticipated|Fondazione Italiana Linfomi ONLUS|||1||f||||f||||||Samples With DNA|"~     Involved lymph nodes biopsy; biopsies performed in other areas affected by lymphoma; bone~     marrow blood; peripheral blood.~   "|||2018-06-01 01:05:08.836748|2018-06-01 01:05:08.836748
NCT00881998|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2009-04-15|2009-04-15|2009-04-16|Estimate|||||||2009-04-15|2009-04-16|Estimate||||April 2009|2009-04-30||||||||Interventional|||Study of Two Surgical Approaches for Total Hip Arthroplasty|Prospective, Randomized Study of Two Surgical Approaches for Total Hip Arthroplasty|Completed||N/A|100|Actual|Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-06-01 01:05:08.994271|2018-06-01 01:05:08.994271
NCT00881985|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2018-05-18|2009-04-15|2009-04-16|Estimate|||||||2018-05-18|2018-05-22|Actual|March 2009||2009-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Continuous Positive Airway Pressure for Treatment of Obstructive Sleep Apnea on Resistant Hypertension|Effect of Continuous Positive Airway Pressure for Treatment of Obstructive Sleep Apnea on Drug-resistant Hypertension : A Randomized Controlled Trial|Recruiting||N/A|64|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-06-01 01:05:09.160385|2018-06-01 01:05:09.160385
NCT00881972|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2015-09-23|2009-04-14|2009-04-16|Estimate|||||||2015-09-23|2015-09-24|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Physical Activity and Glycemic Control|Physical Activity and Glycemic Control|Completed||N/A|12|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 01:05:09.289622|2018-06-01 01:05:09.289622
NCT00881959|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2015-05-07||2015-05-07|2009-04-14|2009-04-15|Estimate|2015-05-07|2015-05-27|Estimate||||2015-05-07|2015-05-27|Estimate|August 2009||2009-08-31|May 2015|2015-05-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Study of Root Coverage With Acellular Dermal Matrix: Puros® Dermis Versus Alloderm®|Multi-center, Post-market, Prospective, Randomized, Examiner-Only-Masked Study of Root Coverage With Acellular Dermal Matrix: Puros® Dermis Versus Alloderm®|Completed||N/A|80|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:05:09.399824|2018-06-01 01:05:09.399824
NCT00881946|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2012-04-03|2009-04-14|2009-04-15|Estimate|||||||2012-04-03|2012-04-04|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Repeat Dose Safety Study for Compound to Treat Hematologic Cancer|A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy|Completed||Phase 1/Phase 2|73|Actual|Accenture||1|||f||||f||||||||||2018-06-01 01:05:09.691206|2018-06-01 01:05:09.691206
NCT00881933|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-03-23|2009-04-14|2009-04-15|Estimate|||||||2012-03-23|2012-03-26|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)|Phase I/II Study of Fludarabine, Cyclophosphamide Plus TBI Conditioning Regimen for Double Units Cord Blood Transplantation in Severe Aplastic Anemia|Unknown status|Recruiting|Phase 1/Phase 2|5|Anticipated|The Korean Society of Pediatric Hematology Oncology||1|||f||||t||||||||||2018-06-01 01:05:09.789319|2018-06-01 01:05:09.789319
NCT00881920|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2018-02-27|2009-04-14|2009-04-15|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2009|Actual|2009-07-31|February 2018|2018-02-28|July 2034|Anticipated|2034-07-31|July 2019|Anticipated|2019-07-31||Interventional|CHARKALL||Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL|Phase I Study of Adoptive Transfer of Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobulin Expressed in Patients With CLL, B-Cell Lymphoma or Multiple Myeloma|Recruiting||Phase 1|54|Anticipated|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 01:05:09.905218|2018-06-01 01:05:09.905218
NCT00881907|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2016-02-04|2009-04-14|2009-04-15|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Tissue Characterization in Teeth Treated With a Regeneration Protocol|Tissue Characterization in Teeth Treated With a Regeneration Protocol|Completed||Early Phase 1|1|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-06-01 01:05:10.097176|2018-06-01 01:05:10.097176
NCT00881894|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|2009-11-20||2014-10-17|2009-04-14|2009-04-15|Estimate|2009-11-20|2009-12-25|Estimate||||2014-10-17|2014-10-27|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.|Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm^2) From 2 Different Manufacturing Processes|Completed||Phase 1|52|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 01:05:10.231587|2018-06-01 01:05:10.231587
NCT00881881|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2009-04-14|2009-04-14|2009-04-15|Estimate|||||||2009-04-14|2009-04-15|Estimate|December 2006||2006-12-31|April 2009|2009-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Study Evaluating the Clinical and Therapeutic Management of Rheumatoid Arthritis in Spain|Clinical and Therapeutic Management of the Rheumatoid Arthritis in Spain|Completed|||360|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 01:05:10.772473|2018-06-01 01:05:10.772473
NCT00881868|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|2010-12-16||2012-09-21|2009-04-14|2009-04-15|Estimate|2010-12-16|2010-12-23|Estimate||||2012-09-21|2012-10-02|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp|A Multi-Center, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Clobetasol Propionate Spray Versus Vehicle for the Management of Moderate to Severe Plaque Psoriasis of the Scalp|Completed||Phase 4|81|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 01:05:10.907261|2018-06-01 01:05:10.907261
NCT00881855|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2004||2004-03-31|April 2009|2009-04-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fed Conditions.|Completed||Phase 1|35|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:11.404343|2018-06-01 01:05:11.404343
NCT00881842|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2011-08-24|2009-04-14|2009-04-15|Estimate|||||||2011-08-24|2011-08-26|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 09/10 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2009/2010. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects|Completed||Phase 3|120|Actual|Abbott||1|||f||||f||||||||||2018-06-01 01:05:11.493025|2018-06-01 01:05:11.493025
NCT00881829|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2016-08-10|2009-04-14|2009-04-15|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Oxitone Blood Validation|Accuracy Validation of the Oxitone SpO2 System|Recruiting|||10000|Anticipated|Clinimark, LLC|||1||f||||t||||||||||2018-06-01 01:05:11.585486|2018-06-01 01:05:11.585486
NCT00881816|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2009-04-14|2009-04-14|2009-04-15|Estimate|||||||2009-04-14|2009-04-15|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma|Phase I Clinical Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|Nanjing Sike Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:05:11.747175|2018-06-01 01:05:11.747175
NCT00881803|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2012-05-21|2009-04-14|2009-04-15|Estimate|||||||2012-05-21|2012-05-23|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Iron & Vitamin C Study|Implications of Concurrent Iron and Ascorbic Acid Supplementation on Iron Status in Persons With Spinal Cord Injury|Completed|||60|Anticipated|VA Office of Research and Development|||3||f||||f||||||Samples With DNA|"~     Blood samples will be obtained for analysis.~   "|||2018-06-01 01:05:11.882508|2018-06-01 01:05:11.882508
NCT00881790|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2013-01-09|2009-04-14|2009-04-15|Estimate|||||||2013-01-09|2013-01-10|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Observational|BEHAVE||The Behaviour of Dental Nurses Applying Fluoride Varnish to Young Children|The Behavioural Engagement of Dental Nurses Applying the Fluoride Varnish to Young Children: the BEHAVE Study|Completed|||509|Actual|University of St Andrews|||1||f||||t||||||||||2018-06-01 01:05:11.987671|2018-06-01 01:05:11.987671
NCT00881777|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2011-07-12|2009-04-14|2009-04-15|Estimate|||||||2011-07-12|2011-07-14|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|RECOVER||Feasibility Study of Radiofrequency Heating of Cardiac Infarction Scar to Treat Heart Failure|Radiofrequency Energy Use in Cardiomyopathy and Ventricular Enlargement (RECOVER)|Terminated||Phase 1/Phase 2|3|Actual|CoRepair, Inc.||2||Unable to recruit suitable subjects within a reasonable time period.|f||||f||||||||||2018-06-01 01:05:12.289767|2018-06-01 01:05:12.289767
NCT00881764|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2016-02-01|2009-04-14|2009-04-15|Estimate|||||||2016-02-01|2016-02-03|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Observational|||PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study|Anesthesia Exposure and Neurodevelopment in Infants and Children: Pediatric Anesthesia & NeuroDevelopment (PANDA) Study|Completed|||369|Actual|Columbia University|||2||f||||f||||||||Undecided||2018-06-01 01:05:12.398079|2018-06-01 01:05:12.398079
NCT00881751|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2017-06-13||2017-08-09|2009-04-14|2009-04-15|Estimate|2017-08-09|2017-09-11|Actual||||2017-08-09|2017-09-11|Actual|March 2009||2009-03-31|October 2015|2015-10-31|February 2017|Actual|2017-02-28|May 2016|Actual|2016-05-31||Interventional||Any subjects who were enrolled to either Arm 1 or Arm 2|Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer|A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 2|95|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 01:05:12.545425|2018-06-01 01:05:12.545425
NCT00881738|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2002||2002-06-30|April 2009|2009-04-30|July 2002|Actual|2002-07-31|June 2002|Actual|2002-06-30||Interventional|||To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions|A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:13.397665|2018-06-01 01:05:13.397665
NCT00881725|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-06-18|2009-04-14|2009-04-15|Estimate|||||||2012-06-18|2012-06-19|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional|ANIMATE||A Study of Pre-operative Metformin in Prostate Cancer|A Phase II, Open Label Assessment of Neoadjuvant Intervention With Metformin Against Tumour Expression of Signaling|Terminated||Phase 2|24|Actual|University Health Network, Toronto||1||Slow Accrual|f||||t||||||||||2018-06-01 01:05:13.519632|2018-06-01 01:05:13.519632
NCT00881712|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|2015-05-28||2017-08-10|2009-04-13|2009-04-15|Estimate|2015-05-28|2015-06-16|Estimate||||2017-08-10|2017-09-11|Actual|June 2009||2009-06-30|August 2017|2017-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|LU02||Proton Therapy With Chemotherapy for Stage III Non-Small Cell Lung Cancer (LU02)|A Phase II Trial of 3 Dimensional Proton Radiotherapy With Concomitant Chemotherapy for Patients With Initially Unresectable Stage III Non-Small Cell Lung Cancer|Terminated||N/A|15|Actual|University of Florida||3||projected enrollment rate not feasible|f||||t|f|f||||||||2018-06-01 01:05:13.710378|2018-06-01 01:05:13.710378
NCT00881699|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-03-08|2009-04-14|2009-04-15|Estimate|||||||2012-03-08|2012-03-09|Estimate|September 2006||2006-09-30|March 2012|2012-03-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Testing an HIV Prevention Intervention for Psychiatric Patients in Brazil|Randomized Clinical Trial of a Brazilian HIV Prevention Intervention for the Severely Mentally Ill|Completed||Phase 3|460|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 01:05:14.146389|2018-06-01 01:05:14.146389
NCT00881686|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2009-04-14|2009-04-14|2009-04-15|Estimate|||||||2009-04-14|2009-04-15|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Myocardial Protection With Adenosine Preconditioning|Study of Myocardial Protection in Pediatric Cardiac Surgery With Adenosine Preconditioning|Completed||Phase 1/Phase 2|238|Actual|Xijing Hospital||1|||f||||t||||||||||2018-06-01 01:05:14.249962|2018-06-01 01:05:14.249962
NCT00881673|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-03-03|2009-04-14|2009-04-15|Estimate|||||||2012-03-03|2012-03-06|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge|A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge (CAC)|Withdrawn||Phase 2|0|Actual|Alcon Research||3||Management decision|f||||t||||||||||2018-06-01 01:05:14.330155|2018-06-01 01:05:14.330155
NCT00881660|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2018-05-09|2009-04-14|2009-04-15|Estimate|||||||2018-05-09|2018-05-15|Actual|March 2010||2010-03-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|FETO||Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia|A Prospective Study of the Effectiveness of Fetal Endotracheal Occlusion (FETO) in the Management of Severe and Extremely Severe Congenital Diaphragmatic Hernia|Recruiting||N/A|20|Anticipated|Baylor College of Medicine||1|||f||||t|f|t|t|f||||No||2018-06-01 01:05:14.406286|2018-06-01 01:05:14.406286
NCT00881647|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2014-01-07||2014-02-20|2009-04-14|2009-04-15|Estimate|2014-01-07|2014-02-21|Estimate||||2014-02-20|2014-03-17|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||per protocol|Treating People With Post-Traumatic Stress Disorder With Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Treatment of Insomnia in Posttraumatic Stress Disorder|Completed||N/A|45|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:05:14.61192|2018-06-01 01:05:14.61192
NCT00881634|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2005||2005-06-30|April 2009|2009-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release Tablets Under Fed Conditions|Completed||Phase 1|40|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:15.242744|2018-06-01 01:05:15.242744
NCT00881621|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|2015-03-15||2017-01-17|2009-04-14|2009-04-15|Estimate|2017-01-17|2017-03-06|Actual||||2017-01-17|2017-03-06|Actual|August 2009||2009-08-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer|Phase II Study of Lapatinib and Capecitabine in 2nd Line Treatment of Locally Advanced/Metastatic Pancreatic Cancer|Terminated||Phase 2|17|Actual|Georgetown University||1||slow enrollment|f||||t||||||||No||2018-06-01 01:05:15.345767|2018-06-01 01:05:15.345767
NCT00881608|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2014-06-26||2014-08-08|2009-04-14|2009-04-15|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-08|2014-08-25|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated, no data available|Study to Evaluate Menses Induction in Women Administered Proellex|An Open-Label, Escalating Dose, Single Center, Cross-over Design, Phase I Study to Evaluate Menses Induction in Women Administered Proellex|Terminated||Phase 1|11|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|5||Repros stopped study for safety and the FDA put the study on hold for safety.|f||||f||||||||||2018-06-01 01:05:15.62223|2018-06-01 01:05:15.62223
NCT00881595|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-02-09|2009-04-14|2009-04-15|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2009||2009-02-28|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SA02||Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas|A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas|Withdrawn||Phase 2|0|Actual|University of Florida||3||No patients accrued since study opened|f||||t|f|f|||f|||||2018-06-01 01:05:15.93749|2018-06-01 01:05:15.93749
NCT00881582|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-09-13|2009-04-14|2009-04-15|Estimate|||||||2012-09-13|2012-09-14|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients|Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients|Completed||Phase 4|32|Actual|King Abdulaziz Medical City||1|||f||||t||||||||||2018-06-01 01:05:16.120493|2018-06-01 01:05:16.120493
NCT00881569|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-09-05|2009-04-14|2009-04-15|Estimate|||||||2012-09-05|2012-09-06|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Extended Use Protocol for Subjects With Cancer to Receive Continued Treatment With CS-7017|Extended Use of CS 7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Subjects With Cancer|Completed||Phase 1|2|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 01:05:16.278871|2018-06-01 01:05:16.278871
NCT00881556|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-02-14|2009-04-14|2009-04-15|Estimate|||||||2012-02-14|2012-02-15|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|RDEB||Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)|A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)|Unknown status|Active, not recruiting|Early Phase 1|20|Anticipated|Columbia University||1|||f||||t||||||||||2018-06-01 01:05:16.359954|2018-06-01 01:05:16.359954
NCT00881543|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-05-24|2009-04-14|2009-04-15|Estimate|||||||2012-05-24|2012-05-28|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|October 2011|Actual|2011-10-31|June 2010|Actual|2010-06-30||Interventional|||"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"|"Effect of Dipeptidyl Peptidase IV Inhibitors on Glycemia, Insulin, Glucagon, C Peptide, Glp 1 and Lipids After Isocaloric Meals With Different Nutritional Composition in Patients With Type 2 Diabetes näive of Treatment"|Completed||N/A|45|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-06-01 01:05:16.441883|2018-06-01 01:05:16.441883
NCT00881530|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2014-05-16||2014-05-16|2009-04-14|2009-04-15|Estimate|2014-05-16|2014-06-16|Estimate||||2014-05-16|2014-06-16|Estimate|March 2009||2009-03-31|May 2014|2014-05-31||||May 2011|Actual|2011-05-31||Interventional||Treated set including all patients treated with at least 1 dose of study drug.|Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension|A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 10773 as Monotherapy or in Combination With Metformin in Type 2 Diabetic Patients|Completed||Phase 2|660|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 01:05:16.579149|2018-06-01 01:05:16.579149
NCT00881517|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2011-12-07|2009-04-14|2009-04-15|Estimate|||||||2011-12-07|2011-12-08|Estimate|June 2009||2009-06-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CHIP||Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection|Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection|Completed||Phase 2/Phase 3|124|Actual|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-06-01 01:05:18.278943|2018-06-01 01:05:18.278943
NCT00880958|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2009-10-28|2009-04-13|2009-04-14|Estimate|||||||2009-10-28|2009-10-29|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|||||Interventional|||Effects of Supplement Containing Various Probiotics and Fermentation Products on Obesity|Effects of Supplement Containing Various Probiotics and Fermentation Products on Obesity: a Double-Blind, Randomized Controlled Trial|Completed||N/A|30|Anticipated|Hiroshima University||2|||f||||f||||||||||2018-06-01 01:05:25.701546|2018-06-01 01:05:25.701546
NCT00881504|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|2014-09-05||2014-10-16|2009-04-14|2009-04-15|Estimate|2014-10-16|2014-10-20|Estimate||||2014-10-16|2014-10-20|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional||3 males; 5 females. Average age, 68.1 years.|A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma|A Single-Center, Open-Labeled, Phase II Trial of Modified FOLFOX6 With Bevacizumab in Patients With Advanced Biliary System Carcinoma|Terminated||Phase 2|9|Actual|Georgetown University||1||It was not possible to get insurance companies to cover bevacizumab.|f||||t||||||||||2018-06-01 01:05:18.417326|2018-06-01 01:05:18.417326
NCT00881491|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2016-02-04|2009-04-14|2009-04-15|Estimate|||||||2016-02-04|2016-02-05|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste|Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste|Completed||Early Phase 1|10|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||No|No data to be shared|2018-06-01 01:05:18.717598|2018-06-01 01:05:18.717598
NCT00881478|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2014-08-29|2009-04-14|2009-04-15|Estimate|||||||2014-08-29|2014-09-03|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|FOCUS||Family Intervention for Obese Children Using Portion Control Strategy for Weight Control|Family Intervention for Obese Children Using Portion Control Strategy (F.O.C.U.S.) for Weight Control- A Randomized Controlled Trial|Completed||N/A|102|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 01:05:18.812395|2018-06-01 01:05:18.812395
NCT00881465|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2015-04-07||2015-05-15|2009-04-14|2009-04-15|Estimate|2015-05-14|2015-05-15|Estimate||||2015-05-15|2015-06-11|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|Completed||Phase 2|31|Actual|University of South Florida|Use of a non-active control condition.|2|||f||||f||||||||||2018-06-01 01:05:18.92799|2018-06-01 01:05:18.92799
NCT00881452|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13||2013-03-04|2018-04-17|2009-04-14|2009-04-15|Estimate||||2013-03-11|2013-03-18|Estimate|2018-04-17|2018-04-19|Actual|May 2009||2009-05-31|April 2018|2018-04-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|CM-AT||A Trial of CM-AT in Children With Autism|A Phase III Randomized Double Blind Placebo Controlled Trial of CM-AT in Children With Autism|Completed||Phase 3|182|Actual|Curemark||2|||f||||f||||||||||2018-06-01 01:05:19.231009|2018-06-01 01:05:19.231009
NCT00881439|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2013-05-16|2009-04-14|2009-04-15|Estimate|||||||2013-05-16|2013-05-17|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|ARIANA-CHF-RD||Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment|A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction|Terminated||Phase 2|41|Actual|University Medical Center Groningen||2||Futility|f||||t||||||||||2018-06-01 01:05:19.356343|2018-06-01 01:05:19.356343
NCT00881426|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2004||2004-03-31|April 2009|2009-04-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fasting Conditions|Completed||Phase 1|26|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:19.436849|2018-06-01 01:05:19.436849
NCT00881413|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2015-04-07|2009-04-13|2009-04-15|Estimate|||||||2015-04-07|2015-04-08|Estimate||||April 2009|2009-04-30||||||||Interventional|||Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding|Clinical Effectiveness of Intravenous Esomeprazole Versus Pantoprazole in Preventing Peptic Ulcer Recurrent Bleeding: a Double-Blind Randomized Trial|Withdrawn||Phase 4|0|Actual|Lotung Poh-Ai Hospital||2||problems in funding|f||||f||||||||||2018-06-01 01:05:19.514554|2018-06-01 01:05:19.514554
NCT00881400|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2004||2004-06-30|April 2009|2009-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb Company (Cefzil) 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose In Healthy Adults Volunteers Under Fed Conditions|Completed||Phase 1|24|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:19.710168|2018-06-01 01:05:19.710168
NCT00881387|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2016-12-14|2009-04-14|2009-04-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|February 2009||2009-02-28|December 2016|2016-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment|A Pilot Study of Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma|Withdrawn||Phase 2|0|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 01:05:19.795233|2018-06-01 01:05:19.795233
NCT00881374|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2009-04-14|2009-04-14|2009-04-15|Estimate|||||||2009-04-14|2009-04-15|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dermacyd Infantile (Lactic Acid)- Compatibility.|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermic Irritability, Dermic Sensitivity) of Dermacyd Infantile (Lactic Acid).|Completed||Phase 4|50|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:05:20.002823|2018-06-01 01:05:20.002823
NCT00881361|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2017-08-07|2009-04-14|2009-04-15|Estimate|||||||2017-08-07|2017-08-09|Actual|July 2009|Actual|2009-07-31|August 2017|2017-08-31||||November 2012|Actual|2012-11-30||Interventional|||Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer|A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women With Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis|Active, not recruiting||Phase 2|756|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 01:05:20.142727|2018-06-01 01:05:20.142727
NCT00881348|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2009-04-14|2009-04-14|2009-04-15|Estimate|||||||2009-04-14|2009-04-15|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dermacyd Infantile (Lactic Acid) - Photo Evaluation.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Infantile (Lactic Acid).|Completed||Phase 4|25|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:05:21.569685|2018-06-01 01:05:21.569685
NCT00879320|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2013-10-21|2009-04-09|2009-04-10|Estimate|||||||2013-10-21|2013-10-22|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Healthy Lifestyle in Adults With Attention Deficit Hyperactivity Disorder|Healthy Lifestyle in Adults With ADHD|Completed|||253|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 01:06:18.234987|2018-06-01 01:06:18.234987
NCT00881322|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2009-09-29|2009-04-14|2009-04-15|Estimate|||||||2009-09-29|2009-09-30|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult|A Prospective, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial to Evaluate the Effects of Gas Defense On Intestinal Gas Symptoms in Otherwise Healthy Adults|Completed||N/A|61|Actual|Miami Research Associates||2|||f||||f||||||||||2018-06-01 01:05:22.212005|2018-06-01 01:05:22.212005
NCT00881309|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2011-05-17|2009-04-14|2009-04-15|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis|To Compare the Efficacy and Safety of Tripterygium (TW) vs Aza in the Maintenance Therapy for Lupus Nephritis|Completed||N/A|94|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 01:05:22.460563|2018-06-01 01:05:22.460563
NCT00881296|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2011-09-05|2009-04-14|2009-04-15|Estimate|||||||2011-09-05|2011-09-07|Estimate|March 2008||2008-03-31|May 2010|2010-05-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|GEEP||Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer|Randomized Phase II Study of Biweekly Chemotherapy With Gemcitabine and Carboplatin in Elder Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|60|Actual|Hamamatsu University||2|||f||||t||||||||||2018-06-01 01:05:22.619955|2018-06-01 01:05:22.619955
NCT00881283|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-01-19|2009-04-13|2009-04-15|Estimate|||||||2017-01-19|2017-01-20|Estimate|September 8, 2008|Actual|2008-09-08|April 2015|2015-04-30|March 30, 2010|Actual|2010-03-30|March 30, 2010|Actual|2010-03-30||Observational|||Long-term Cardiovascular Risk in Cured Cushing's Patients|Role of Adipokines in Long-term Cardiovascular Risk in Cured Cushing's Patients|Terminated|||1|Actual|Massachusetts General Hospital|||1|Decision made to close study early.|f||||f||||||Samples With DNA|"~     serum, urine~   "|||2018-06-01 01:05:22.728764|2018-06-01 01:05:22.728764
NCT00881270|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2009-09-25|2009-04-14|2009-04-15|Estimate|||||||2009-09-25|2009-09-28|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dermacyd Infantile - Acceptability.|Safety Dermatological Evaluation: Acceptability With Paediatric Follow up Dermacyd Infantile (Lactic Acid).|Completed||Phase 4|31|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:05:22.818123|2018-06-01 01:05:22.818123
NCT00881257|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2013-06-19|2009-04-14|2009-04-15|Estimate|||||||2013-06-19|2013-06-20|Estimate|August 2007||2007-08-31|June 2013|2013-06-30|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System|Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System|Terminated||Phase 2/Phase 3|78|Actual|Vessix Vascular, Inc||1||Data was inconclusive|f||||t||||||||||2018-06-01 01:05:22.91667|2018-06-01 01:05:22.91667
NCT00881244|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2009-04-14|2009-04-14|2009-04-15|Estimate|||||||2009-04-14|2009-04-15|Estimate|September 2003||2003-09-30|April 2009|2009-04-30|February 2007|Actual|2007-02-28|June 2006|Actual|2006-06-30||Interventional|||Study of AS1411 in Advanced Solid Tumours|Phase I Open Label Study of AS1411 in Advanced Solid Tumours|Completed||Phase 1|30|Actual|Antisoma Research||1|||||||t||||||||||2018-06-01 01:05:23.027551|2018-06-01 01:05:23.027551
NCT00881231|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2004||2004-01-31|April 2009|2009-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Eon and Otsuka (Pletal) 50 mg Cilostazol Tablets In Healthy Adults Volunteers Under Fasting Conditions|Completed||Phase 1|26|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:23.123468|2018-06-01 01:05:23.123468
NCT00881218|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2012-04-08|2009-04-14|2009-04-15|Estimate|||||||2012-04-08|2012-04-10|Estimate|June 2009||2009-06-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson|Feasibility of Detecting Myocardial Ischemia by First-pass Contrast MRI Using Regadenoson|Completed||Early Phase 1|50|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 01:05:23.211359|2018-06-01 01:05:23.211359
NCT00881205|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|2012-01-20||2012-03-08|2009-04-14|2009-04-15|Estimate|2012-01-20|2012-02-24|Estimate||||2012-03-08|2012-03-12|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|EXCITING||Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment|A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase|Terminated||Phase 4|86|Actual|Novartis|This study was terminated early due to low recruitment numbers. This study did not have the anticipated 80% power.|2||Termination of study due to low enrollment|f||||||||||||||2018-06-01 01:05:23.332991|2018-06-01 01:05:23.332991
NCT00881192|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2012-05-09|2009-04-14|2009-04-15|Estimate|||||||2012-05-09|2012-05-10|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Perioperative Intra-Aortic Balloon Pump (IABP) in Coronary Artery Bypass Grafting (CABG) Operations in Patients With Severely Depressed Left Ventricular Function|Perioperative IABP in CABG Operations in Patients With Severely Depressed Left Ventricular Function: a Randomized, Controlled Trial|Completed||N/A|160|Actual|IRCCS Policlinico S. Donato||2|||f||||f||||||||||2018-06-01 01:05:23.71756|2018-06-01 01:05:23.71756
NCT00881179|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-28|Actual|May 2002||2002-05-31|April 2009|2009-04-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:23.93663|2018-06-01 01:05:23.93663
NCT00881166|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2012-10-31|2009-04-14|2009-04-15|Estimate|||||||2012-10-31|2012-11-02|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SGI-0470-02||Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors|Safety and Dose Finding Study of Oral MP470, a Multi-targeted Tyrosine Kinase Inhibitor, in Combination With Standard-of-Care Chemotherapy Regimens|Completed||Phase 1|101|Actual|Astex Pharmaceuticals||5|||f||||f||||||||||2018-06-01 01:05:24.057176|2018-06-01 01:05:24.057176
NCT00881153|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-29|Actual|May 2004||2004-05-31|April 2009|2009-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb Company (Cefzil) 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose In Healthy Adults Volunteers Under Fasting Conditions.|Completed||Phase 1|20|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:24.182743|2018-06-01 01:05:24.182743
NCT00881127|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-03-27|2009-04-14|2009-04-15|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2005||2005-07-31|April 2009|2009-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions|A Single-Dose Comparative Bioavailability Study of Two Formulations of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:05:24.355703|2018-06-01 01:05:24.355703
NCT00881114|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2015-03-26|2009-04-14|2009-04-15|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|June 2013|Anticipated|2013-06-30|June 2009|Actual|2009-06-30||Interventional|PGx-SELECT||Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer|A Prospective Phase II Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer|Withdrawn||Phase 2|0|Actual|Georgetown University||2||Investigator decided it was not feasible to conduct this study|f||||t||||||||||2018-06-01 01:05:24.425749|2018-06-01 01:05:24.425749
NCT00881101|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2009-04-14|2009-04-14|2009-04-15|Estimate|||||||2009-04-14|2009-04-15|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Clinical Study of Liposomal Paclitaxel in Chinese Patients|Dose Escalation Study of Liposomal Paclitaxel in Chinese Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|Nanjing Sike Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:05:24.514818|2018-06-01 01:05:24.514818
NCT00881088|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2012-12-15|2009-04-14|2009-04-15|Estimate|||||||2012-12-15|2012-12-18|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|PROTECT||Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures|Prophylaxis of Venous Thromboembolism in Patients With a Nonsurgical Fracture of the Lower Extremity Immobilised in a Below-Knee Plaster Cast|Unknown status|Recruiting|Phase 2/Phase 3|669|Anticipated|Red Cross Hospital Beverwijk||3|||f||||f||||||||||2018-06-01 01:05:24.612718|2018-06-01 01:05:24.612718
NCT00881075|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2016-02-03|2009-04-14|2009-04-15|Estimate|||||||2016-02-03|2016-02-04|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy of SeeMore (TM) in Heart Patients|An Open-label, Baseline-Controlled Study of the Safety and Efficacy of SeeMore (TM) (EVP 1001-1 Injection) in Heart Patients|Completed||Phase 2|24|Actual|Eagle Vision Pharmaceutical Corp.||1|||f||||f||||||||||2018-06-01 01:05:24.782658|2018-06-01 01:05:24.782658
NCT00881062|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-14|||2014-07-03|2009-04-14|2009-04-15|Estimate|||||||2014-07-03|2014-07-08|Estimate|April 2009||2009-04-30|July 2014|2014-07-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose Administration in Healthy Female Subjects|Completed||Phase 1|6|Actual|Repros Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 01:05:24.887983|2018-06-01 01:05:24.887983
NCT00881049|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2011-01-14|2009-04-13|2009-04-14|Estimate|||||||2011-01-14|2011-01-17|Estimate|December 2008||2008-12-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma|Phase II Trial of Imatinib(Gleevec®) in Selected Patients With Metastatic Melanoma|Completed||Phase 2|1|Anticipated|Peking University|||||f||||f||||||||||2018-06-01 01:05:25.000601|2018-06-01 01:05:25.000601
NCT00881036|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2015-09-02|2009-04-13|2009-04-14|Estimate|||||||2015-09-02|2015-09-03|Estimate|August 2006||2006-08-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients|Activation of HBV Under Immunosuppression in HBsAg-negative But Anti-HBc-positive Patients With Hematological Malignancies|Completed|||33|Actual|Kyoto University|||||f||||f||||||||||2018-06-01 01:05:25.084622|2018-06-01 01:05:25.084622
NCT00881023|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10||2016-02-25|2016-08-01|2009-04-13|2009-04-14|Estimate||||2016-03-24|2016-04-25|Estimate|2016-08-01|2016-08-03|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CAIS||Cartilage Autograft Implantation System (CAIS) for the Repair of Knee Cartilage Through Cartilage Regeneration|A Multicenter, Randomized, Pivotal Study to Evaluate the Safety and Efficacy of the Cartilage Autograft Implantation System (CAIS) for the Surgical Treatment of Articular Cartilage Lesions of the Knee|Terminated||N/A|75|Actual|DePuy Mitek||3||Study was terminated because of very low enrollment rate.|f||||f||||||||No|These data will not be used in support of an FDA submission, and the product will not be commercialized. As such, there is no plan to share the IPD.|2018-06-01 01:05:25.17258|2018-06-01 01:05:25.17258
NCT00881010|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-08-24|2009-04-13|2009-04-14|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2009|Actual|2009-02-28|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Automated Pain Intervention for Underserved Minority Breast Cancer Patients|Automated Pain Intervention for Underserved Minority Breast Cancer Patients|Active, not recruiting|||60|Anticipated|M.D. Anderson Cancer Center|||2||f||||t||||||||||2018-06-01 01:05:25.312567|2018-06-01 01:05:25.312567
NCT00880997|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2012-10-22|2009-04-13|2009-04-14|Estimate|||||||2012-10-22|2012-10-24|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||The Efficacy of Doxazosin for Cocaine Users|Doxazosin, An Alpha-1 Adrenergic Antagonist, for Cocaine Dependence: Pilot Study|Completed||Phase 1|35|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 01:05:25.414924|2018-06-01 01:05:25.414924
NCT00880984|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2010-01-06|2009-04-13|2009-04-14|Estimate|||||||2010-01-06|2010-01-07|Estimate|June 2008||2008-06-30|July 2009|2009-07-31||||September 2009|Actual|2009-09-30||Interventional|||Compression Anastomosis Using the Compression Anastomosis Ring (CAR™ 27)|Compression Anastomosis Using the CAR™ 27|Completed||N/A|15|Anticipated|Aristotle University Of Thessaloniki|||||f||||f||||||||||2018-06-01 01:05:25.522608|2018-06-01 01:05:25.522608
NCT00880971|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-12-28|2009-04-13|2009-04-14|Estimate|||||||2017-12-28|2018-01-02|Actual|January 2009||2009-01-31|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||To Evaluate Postoperative 3D Conform Radiotherapy in Patients With IIIA (N2) Non-small Cell Lung Cancer|Phase III Comparison of Postoperative 3D Conform Radiotherapy After Chemotherapy and Chemotherapy Alone in Patients With Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer|Recruiting||Phase 3|500|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:05:25.592164|2018-06-01 01:05:25.592164
NCT00879125|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-09-10|2009-04-08|2009-04-09|Estimate|||||||2009-09-10|2009-09-14|Estimate|November 1999||1999-11-30|September 2009|2009-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Effect of Gastric Bypass on Patients With Type 2 Diabetes and/or Dyslipidemia|Effect of Gastric Bypass on Type 2 Diabetes and/or Dyslipidemia|Completed|||219|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 01:06:20.98638|2018-06-01 01:06:20.98638
NCT00880945|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2009-04-13|2009-04-13|2009-04-14|Estimate|||||||2009-04-13|2009-04-14|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|May 2010|Anticipated|2010-05-31|April 2010|Anticipated|2010-04-30||Observational|||Conventional Bronchoscopy Plus Rose Versus Electromagnetic Navigation (EMN) Plus Rose in Small Peripheral Lesions|Comparison of the Electromagnetic Navigation System and Rapid on Site Evaluation Versus Conventional Bronchoscopy and Rapid on Site Evaluation: Improved Yield in Small Peripheral Lung Lesions(Original Investigation)|Unknown status|Not yet recruiting||40|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita|||1||f||||f||||||||||2018-06-01 01:05:25.876177|2018-06-01 01:05:25.876177
NCT00880932|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2009-04-13|2009-04-13|2009-04-14|Estimate|||||||2009-04-13|2009-04-14|Estimate|August 2006||2006-08-31|April 2009|2009-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert|The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID|Completed||N/A|1865|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 01:05:25.962448|2018-06-01 01:05:25.962448
NCT00880919|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2014-04-16||2017-01-26|2009-04-13|2009-04-14|Estimate|2016-11-01|2016-12-28|Estimate||||2017-01-26|2017-03-09|Actual|June 2008||2008-06-30|January 2017|2017-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)|Seroquel XR for the Management of Borderline Personality Disorder (BPD)|Completed||Phase 3|95|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||No||2018-06-01 01:05:26.085808|2018-06-01 01:05:26.085808
NCT00880906|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2014-03-27||2017-10-04|2009-04-13|2009-04-14|Estimate|2014-04-29|2014-05-26|Estimate||||2017-10-04|2017-11-06|Actual|August 2008||2008-08-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EOE||Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis|Prospective, Single-Blinded, Randomized Controlled Trial With Sham Comparing Standard Therapy With or Without Esophageal Dilatation in Patients With Eosinophilic Esophagitis|Completed||N/A|50|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 01:05:26.95514|2018-06-01 01:05:26.95514
NCT00880893|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2015-08-17|2009-04-13|2009-04-14|Estimate|||||||2015-08-17|2015-08-19|Estimate|April 2009||2009-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|||Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore|Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore|Completed||Phase 2|1198|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:05:27.280838|2018-06-01 01:05:27.280838
NCT00880880|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2015-10-01|2009-04-13|2009-04-14|Estimate|||||||2015-10-01|2015-10-05|Estimate|August 2007||2007-08-31|April 2009|2009-04-30||||August 2008|Actual|2008-08-31||Interventional|||Improving Women's Health by Using an Electronic Pelvic Floor Questionnaire|Improving the Assessment of Women's Health Through the Use of a Computerized Pelvic Floor Questionnaire|Completed||N/A|284|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 01:05:27.404312|2018-06-01 01:05:27.404312
NCT00880867|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2011-07-19|2009-04-13|2009-04-14|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|April 2011|Actual|2011-04-30|May 2010|Actual|2010-05-31||Interventional|||Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma|A Phase I Study of Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma|Terminated||Phase 1|3|Actual|Nevada Cancer Institute||1||Low enrollment|f||||t||||||||||2018-06-01 01:05:27.519861|2018-06-01 01:05:27.519861
NCT00880854|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2015-09-30|2009-04-13|2009-04-14|Estimate|||||||2015-09-30|2015-10-02|Estimate|June 2009||2009-06-30|September 2015|2015-09-30||||February 2011|Actual|2011-02-28||Interventional|||Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer|Phase I Dose-escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) for Patients With BCG-resistant Localized Transitional Cell Carcinoma of the Bladder|Withdrawn||Phase 1|0|Actual|University of Wisconsin, Madison||1||Lack of accrual|f||||t||||||||||2018-06-01 01:05:27.628366|2018-06-01 01:05:27.628366
NCT00880841|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2017-06-21|2009-04-13|2009-04-14|Estimate|||||||2017-06-21|2017-06-23|Actual|April 2009||2009-04-30|June 2017|2017-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone|A Single-Dose, 1-Period, 1-Treatment Pilot Study of an Investigational Capsule Formulation of 2 mg/.05 mg Buprenorphine/Naloxone Under Fasting Conditions|Completed|||6|Actual|NanoSHIFT LLC|||1||f||||f||||||||||2018-06-01 01:05:27.721983|2018-06-01 01:05:27.721983
NCT00880828|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2010-09-23|2009-04-13|2009-04-14|Estimate|||||||2010-09-23|2010-09-24|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|October 2011|Anticipated|2011-10-31|April 2011|Anticipated|2011-04-30||Interventional|||Comparing Two Different Cervical Collars for the Treatment in Patient With Cervical Radiculopathy and Radicular Pain|A Single-Center, Prospective, Randomized, Active Controlled, Single Blind, Parallel Design, Three Arms Trial Comparing Two Different Cervical Collar Combine With Acetaminophen and Acetaminophen Along for the Treatment in Patient With Cervical Radiculopathy and Radicular Pain|Unknown status|Active, not recruiting|N/A|72|Anticipated|Taipei Medical University WanFang Hospital||3|||f||||f||||||||||2018-06-01 01:05:27.815428|2018-06-01 01:05:27.815428
NCT00880815|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2018-01-08|2009-04-13|2009-04-14|Estimate|||||||2018-01-08|2018-01-10|Actual|February 2009|Actual|2009-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies|Fludarabine, Bendamustine and Rituximab (FBR) Non-myeloablative Allogeneic Conditioning for Patients With Lymphoid Malignancies|Active, not recruiting||Phase 1|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:05:27.930785|2018-06-01 01:05:27.930785
NCT00880802|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-11|||2010-01-08|2009-04-13|2009-04-14|Estimate|||||||2010-01-08|2010-01-12|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Observational|FAST-TRAC||Finding Acute Coronary Syndromes (ACS) With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms|Finding ACS With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms|Unknown status|Active, not recruiting||1500|Anticipated|Nanosphere, Inc.|||||f||||f||||||Samples Without DNA|"~     Plasma samples.~   "|||2018-06-01 01:05:28.071571|2018-06-01 01:05:28.071571
NCT00880789|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2014-10-13|2009-04-13|2009-04-14|Estimate|||||||2014-10-13|2014-10-15|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|ACT-CAT||Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus|Adoptive Transfer of Cord Blood T Cells To Prevent and Treat CMV and Adenovirus Infections After Transplantation|Completed||Phase 1|9|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 01:05:28.191633|2018-06-01 01:05:28.191633
NCT00880763|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2014-09-26||2017-03-03|2009-04-10|2009-04-14|Estimate|2014-09-26|2014-09-29|Estimate||||2017-03-03|2017-03-31|Actual|April 2009||2009-04-30|March 2017|2017-03-31|February 2012|Actual|2012-02-29|June 2010|Actual|2010-06-30||Interventional||All randomized participants|A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)|A Phase II Randomized Placebo-controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Japanese Treatment-Experienced Patients With Chronic Hepatitis C Infection|Completed||Phase 2|90|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:05:28.334052|2018-06-01 01:05:28.334052
NCT00880750|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|2010-02-19||2015-03-03|2009-04-13|2009-04-14|Estimate|2010-02-19|2010-03-11|Estimate||||2015-03-03|2015-03-23|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults|A Phase I Pharmacodynamic Equivalence Study Comparing Urinary Phosphate Excretion and Plasma Lanthanum Pharmacokinetics for a Lanthanum Carbonate Granule Formulation and Chewable Tablets Administered to Healthy Adult Subjects|Completed||Phase 1|72|Actual|Shire||2|||f||||f||||||||||2018-06-01 01:05:29.248086|2018-06-01 01:05:29.248086
NCT00880737|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2011-06-14|2009-04-13|2009-04-14|Estimate|||||||2011-06-14|2011-06-15|Estimate|February 2009||2009-02-28|February 2010|2010-02-28||||June 2011|Actual|2011-06-30||Observational|PROTECT||Prognostic Value of Computed Tomography (CT) Scan in Hemodynamically Stable Patients With Acute Symptomatic Pulmonary Embolism||Completed|||850|Anticipated|Carlos III Health Institute|||1||f||||t||||||||||2018-06-01 01:05:29.750531|2018-06-01 01:05:29.750531
NCT00880724|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2017-05-05|2009-04-13|2009-04-14|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2007||2007-03-31|June 2009|2009-06-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|IBV||European Multi-center Post Market Study of the IBV Valve System|European Post Market Study: A Prospective, Randomized, Controlled, Multicenter Study to Evaluate the Performance of the IBV Valve System for the Treatment of Severe Emphysema|Completed||N/A|100|Anticipated|Spiration, Inc.||1|||f||||f||||||||||2018-06-01 01:05:29.826847|2018-06-01 01:05:29.826847
NCT00880711|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2011-11-29|2009-04-13|2009-04-14|Estimate|||||||2011-11-29|2011-11-30|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|FIONA||Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)|Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer|Completed|||57|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:05:29.93241|2018-06-01 01:05:29.93241
NCT00880698|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2015-06-22|2014-10-30|2015-07-17|2009-04-10|2009-04-14|Estimate|2015-07-17|2015-07-22|Estimate|2014-10-30|2014-11-05|Estimate|2015-07-17|2015-07-22|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Includes all participants 'as randomized'|Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers|Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers|Completed||Phase 2|202|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study was closed to enrollment prematurely so statistical power to detect differences was reduced.|4|||f||||t||||||||||2018-06-01 01:05:30.06374|2018-06-01 01:05:30.06374
NCT00880685|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2013-08-19||2018-01-12|2009-04-10|2009-04-14|Estimate|2014-01-17|2014-03-05|Estimate||||2018-01-12|2018-02-07|Actual|March 2009||2009-03-31|January 2018|2018-01-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Memantine in the Treatment of Kleptomania|Memantine Treatment of Kleptomania: An Open-Label Study|Completed||Phase 2|12|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 01:05:31.156018|2018-06-01 01:05:31.156018
NCT00880672|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2013-06-10|2009-04-13|2009-04-14|Estimate|||||||2013-06-10|2013-06-12|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate|Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride|Completed||Phase 4|40|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 01:05:31.398313|2018-06-01 01:05:31.398313
NCT00880659|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-11|||2010-12-29|2009-04-13|2009-04-14|Estimate|||||||2010-12-29|2010-12-30|Estimate|June 2009||2009-06-30|May 2010|2010-05-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Bangladesh Secondary Transmission Handwashing Protocol|Prevention of Secondary Transmission of Human Influenza by Promoting Handwashing With Soap: The Bangladesh Interruption of Secondary Transmission of Influenza Study (BISTIS)|Completed||Phase 2|6600|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 01:05:31.537955|2018-06-01 01:05:31.537955
NCT00880646|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2009-10-28|2009-04-13|2009-04-14|Estimate|||||||2009-10-28|2009-10-29|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Interventional|||Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity|Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity: a Double-Blind, Randomized Controlled Trial|Completed||N/A|70|Anticipated|Hiroshima University||2|||f||||f||||||||||2018-06-01 01:05:31.639808|2018-06-01 01:05:31.639808
NCT00880633|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2011-02-16|2009-04-13|2009-04-14|Estimate|||||||2011-02-16|2011-02-17|Estimate|April 2007||2007-04-30|February 2011|2011-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Observational|||Endoscopic Ultrasound Staging of Periampullary Neoplasms: Retrospective|EUS Staging Accuracy of Periampullary Neoplasms: a Retrospective Review|Completed|||||Indiana University|||||f||||f||||||||||2018-06-01 01:05:31.714959|2018-06-01 01:05:31.714959
NCT00880620|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|2015-12-07|2013-09-27|2017-08-16|2009-04-13|2009-04-14|Estimate|2016-01-25|2016-02-22|Estimate|2013-09-27|2013-10-28|Estimate|2017-08-16|2017-08-17|Actual|April 2009||2009-04-30|August 2017|2017-08-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|APEX-PD|Baseline Analysis Population is all treated|A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease|A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease|Completed||Phase 3|381|Actual|IMPAX Laboratories, Inc.||4|||f||||f||||||||No||2018-06-01 01:05:31.806742|2018-06-01 01:05:31.806742
NCT00880607|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2015-05-26|2009-04-13|2009-04-14|Estimate|||||||2015-05-26|2015-05-28|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|April 2011|Actual|2011-04-30||Interventional|IT Morphine||The Use of Intraoperative Intrathecal Morphine Versus Epidural Extended Release Morphine for Postoperative Pain Control in Pediatric Patients Undergoing Posterior Spinal Fusion|The Use of Intraoperative Intrathecal Morphine Versus Epidural Extended Release Morphine for Postoperative Pain Control in Pediatric Patients Undergoing Posterior Spinal Fusion|Completed||Phase 4|70|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 01:05:32.909407|2018-06-01 01:05:32.909407
NCT00877786|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2018-03-26|2009-04-07|2009-04-08|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2008||2008-04-30|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CBT4BN||Online Cognitive Behavioral Therapy for Bulimia Nervosa|Optimizing Technology in the Treatment of Bulimia Nervosa|Completed||N/A|196|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 01:07:20.565179|2018-06-01 01:07:20.565179
NCT00880594|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-13|||2018-02-02|2009-04-13|2009-04-14|Estimate|||||||2018-02-02|2018-02-06|Actual|February 2009||2009-02-28|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine|The Modulation of Cerebral Pain Responses Using Desipramine in the Treatment of Irritable Bowel Syndrome (IBS)|Active, not recruiting||N/A|200|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 01:05:33.051991|2018-06-01 01:05:33.051991
NCT00880581|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2016-04-23||2017-01-24|2009-04-13|2009-04-14|Estimate|2017-01-24|2017-03-14|Actual||||2017-01-24|2017-03-14|Actual|January 2009||2009-01-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|September 2011|Actual|2011-09-30||Interventional|||A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas|A Phase 2 Study of Intratumoral Injection PF-3512676 in Combination With Local Radiation in Low-Grade B-Cell Lymphomas|Completed||Phase 2|30|Actual|Stanford University||1|||f||||t|t|f||||||No||2018-06-01 01:05:33.16016|2018-06-01 01:05:33.16016
NCT00880568|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2012-09-25||2015-02-02|2009-04-13|2009-04-14|Estimate|2012-10-25|2012-10-26|Estimate||||2015-02-02|2015-02-19|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)|A Phase I Dose Escalation Study of MK1496 in Patients With Advanced Solid Tumor|Completed||Phase 1|27|Actual|Merck Sharp & Dohme Corp.||9|||f||||f||||||||||2018-06-01 01:05:33.462617|2018-06-01 01:05:33.462617
NCT00880555|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2015-11-10||2016-02-24|2009-04-10|2009-04-13|Estimate|2016-02-24|2016-03-24|Estimate||||2016-02-24|2016-03-24|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|CASL|Seventy-eight individuals underwent the baseline assessment, but four were removed from the analysis and were not asked to follow up because the consensus panel did not feel that they met criteria for any of the three arms (MCI, control, mild AD). This left 74 individuals at baseline who were eligible to continue in the study.|Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)|Semantic Memory, Financial Capacity and Brain Perfusion in MCI|Completed|||78|Actual|VA Office of Research and Development|This trial did not involve an intervention. Technical problems limited the analysis of the MRI scans. Lack of a designated rater for the study negatively impacted participant retention.||3||f||||f||||||None Retained|"~     N/A- no biospecimens~   "|No||2018-06-01 01:05:34.723781|2018-06-01 01:05:34.723781
NCT00880542|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2011-04-13||2015-10-28|2009-04-10|2009-04-13|Estimate|2011-04-13|2011-05-10|Estimate||||2015-10-28|2015-11-24|Estimate|August 2008||2008-08-31|July 2012|2012-07-31||||November 2010|Actual|2010-11-30||Interventional|||Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery|A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma|Terminated||Phase 2|7|Actual|Jonsson Comprehensive Cancer Center|This study lost funding and was not able to enroll enough participants to do a complete review.|1||The study lost funding.|f||||t||||||||||2018-06-01 01:05:35.489095|2018-06-01 01:05:35.489095
NCT00880529|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2013-02-26|2009-04-10|2009-04-13|Estimate|||||||2013-02-26|2013-02-27|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ON-Q||Pain Relief for Ventilated Patients With Multiple Rib Fractures Using the ON-Q Pain Relief System|Does Continuous Subcutaneous Paravertebral Infusion of Bupivicaine With the ON-Q Pain Relief System vs. Standard IV Pain Management Decrease Ventilator Dependence in Trauma Patients With Multiple Rib Fractures|Terminated||Phase 4|2|Actual|The Cooper Health System||2||low enrollment, 2 pts enrolled no data every analyzed investigator left the institution|f||||f||||||||||2018-06-01 01:05:35.770189|2018-06-01 01:05:35.770189
NCT00880516|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2016-08-25|2009-04-10|2009-04-13|Estimate|||||||2016-08-25|2016-08-26|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Genetic Factors in Chronic Sinusitis|Genetic Factors in Chronic Sinusitis|Recruiting|||1200|Anticipated|University of Chicago|||2||f||||f||||||Samples With DNA|"~     peripheral blood for DNA~   "|||2018-06-01 01:05:35.855427|2018-06-01 01:05:35.855427
NCT00880503|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2018-05-24|2009-04-10|2009-04-13|Estimate|||||||2018-05-24|2018-05-25|Actual|December 19, 2003||2003-12-19|February 8, 2018|2018-02-08|February 8, 2018||2018-02-08|||||Observational|||Collection of Tissue Samples for Study of Multidrug Resistance|Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute|Completed|||325|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:05:35.925334|2018-06-01 01:05:35.925334
NCT00880490|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09||2010-10-05|2010-10-11|2009-04-10|2009-04-13|Estimate||||2010-10-05|2010-10-06|Estimate|2010-10-11|2010-10-13|Estimate|November 2008||2008-11-30|October 2010|2010-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Five-period, Placebo and Active-controlled,Cross-over, Multi-centre, Study Evaluating Single Administration of Three Doses of Inhaled PT005 in Patients With Moderate-to-Severe COPD, Compared to Open- Label Marketed Formoterol (FORADIL® AEROLIZER®) as an Active Control|Completed||Phase 1/Phase 2|34|Actual|Pearl Therapeutics, Inc.||5|||f||||f||||||||||2018-06-01 01:05:36.086658|2018-06-01 01:05:36.086658
NCT00880477|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2016-09-06|2009-04-09|2009-04-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2001||2001-01-31|September 2016|2016-09-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine|Immunogenicity and Safety of GSK Biological's DTPa-HBV-IPV/Hib Vaccine or DTPa-IPV/Hib Co-administered With HBV Vaccine as Primary and Booster Vaccination in Healthy Infants Born to Hepatitis B Surface Antigen Negative Mothers|Completed||Phase 3|140|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:05:36.185336|2018-06-01 01:05:36.185336
NCT00880464|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2017-09-18|2009-04-10|2009-04-13|Estimate|||||||2017-09-18|2017-09-20|Actual|April 2009||2009-04-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer|A Phase Ib Study of Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete GM-CSF Following Preoperative Chemotherapy in Women With Operable Breast Cancer|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:05:36.305233|2018-06-01 01:05:36.305233
NCT00880451|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2009-04-10|2009-04-10|2009-04-13|Estimate|||||||2009-04-10|2009-04-13|Estimate|March 2009||2009-03-31|October 2008|2008-10-31||||||||Observational|||Development and Decline of Brain and Cognition Through the Life Span|Development and Decline of Brain and Cognition Through the Life Span|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:05:36.459194|2018-06-01 01:05:36.459194
NCT00880425|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2010-10-22||2011-01-04|2009-04-10|2009-04-13|Estimate|2010-10-22|2010-10-29|Estimate||||2011-01-04|2011-01-07|Estimate|April 2009||2009-04-30|January 2011|2011-01-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||Do Patients With Chronic Daily Headache Have Continuous Headache or Moments of Headache Relief?|Do Patients With Chronic Daily Headache Have Continuous Headache or Moments of Headache Relief?|Completed|||45|Actual|Thomas Jefferson University|||2||f||||f||||||||||2018-06-01 01:05:36.528474|2018-06-01 01:05:36.528474
NCT00880412|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2009-09-18|2009-04-10|2009-04-13|Estimate|||||||2009-09-18|2009-09-21|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|EHT0202/002||A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease|A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)|Completed||Phase 2|197|Actual|Exonhit||3|||f||||t||||||||||2018-06-01 01:05:36.777556|2018-06-01 01:05:36.777556
NCT00880399|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2017-04-20|2012-02-23|2017-08-09|2009-04-09|2009-04-13|Estimate|2017-08-09|2017-09-12|Actual|2012-02-23|2012-02-27|Estimate|2017-08-09|2017-09-12|Actual|March 1, 2009||2009-03-01|April 2017|2017-04-30|June 16, 2010|Actual|2010-06-16|June 1, 2010|Actual|2010-06-01||Interventional|orvepitant MDD||A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|Terminated||Phase 2|328|Actual|GlaxoSmithKline|The study was terminated early upon recommendation of IDMC that was reviewing data from this trial and two other ongoing trials with same drug. When the trial was terminated 331 participants were randomized, compared to a target of 348 participants.|3||To allow assessment of isolated events of seizure during program|f||||t||||||||||2018-06-01 01:05:36.95957|2018-06-01 01:05:36.95957
NCT00880386|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2017-05-01|2009-04-10|2009-04-13|Estimate|||||||2017-05-01|2017-05-02|Actual|March 2009||2009-03-31|May 2017|2017-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer|A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients With Non-Small Cell Lung Cancer|Withdrawn||N/A|0|Actual|University of South Florida||1||Study concept was not approved by NCI. Study was never activated. No enrollment|f||||f||||||||||2018-06-01 01:05:38.780589|2018-06-01 01:05:38.780589
NCT00880373|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2012-12-03|2009-04-10|2009-04-13|Estimate|||||||2012-12-03|2012-12-04|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|March 2014|Anticipated|2014-03-31||Interventional|SWIM||Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine|An Evaluation of the Effectiveness of Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease: a Double-blind, Placebo-controlled Randomised Trial|Terminated||Phase 4|320|Anticipated|London North West Healthcare NHS Trust||2||"The funding withdrawal and early termination of the trial is based upon lack of suitable~   recruitment figures in order to reach the required trial endpoints."|f||||t||||||||||2018-06-01 01:05:38.885164|2018-06-01 01:05:38.885164
NCT00880360|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2012-08-13||2018-02-27|2009-04-10|2009-04-13|Estimate|2012-09-19|2012-10-19|Estimate||||2018-02-27|2018-03-27|Actual|February 2007||2007-02-28|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|ONTAK||A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer|A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy|Completed||Phase 2|19|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-06-01 01:05:39.0106|2018-06-01 01:05:39.0106
NCT00880347|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2011-03-30|2009-04-10|2009-04-13|Estimate|||||||2011-03-30|2011-03-31|Estimate|February 2008||2008-02-29|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia|Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia : A Prospective Study for a Blood Diagnostic Test in Alzheimer's Disease - (Protocol n° EHTAD/002).|Completed||N/A|550|Anticipated|Exonhit||3|||f||||f||||||||||2018-06-01 01:05:39.27347|2018-06-01 01:05:39.27347
NCT00880334|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2014-04-15||2016-10-24|2009-04-10|2009-04-13|Estimate|2014-05-14|2014-06-04|Estimate||||2016-10-24|2016-12-06|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|December 2013|Actual|2013-12-31||Interventional||The analysis dataset is comprised of all eligible and treated patients.|Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC|Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC|Completed||Phase 2|149|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 01:05:39.402201|2018-06-01 01:05:39.402201
NCT00880321|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-11-08|2009-04-09|2009-04-13|Estimate|||||||2017-11-08|2017-11-13|Actual|June 4, 2009|Actual|2009-06-04|November 2017|2017-11-30|March 20, 2012|Actual|2012-03-20|March 25, 2011|Actual|2011-03-25||Interventional|||A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors|A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors|Completed||Phase 1|170|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:05:40.117238|2018-06-01 01:05:40.117238
NCT00880308|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2014-12-27|2009-04-10|2009-04-13|Estimate|||||||2014-12-27|2014-12-30|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors|Completed||Phase 1|103|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:05:40.263978|2018-06-01 01:05:40.263978
NCT00880295|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2017-11-21|2009-04-10|2009-04-13|Estimate|||||||2017-11-21|2017-11-24|Actual|March 23, 2009|Actual|2009-03-23|November 2017|2017-11-30|July 26, 2016|Actual|2016-07-26|July 26, 2016|Actual|2016-07-26||Interventional|||Patient Outcomes With Endoscopic Versus Open Carpal Tunnel Release|Endoscopic vs Open Carpal Tunnel Release: Comparison of Patient Satisfaction, Outcomes, and Complications|Completed||N/A|38|Actual|Penn State University||2|||f||||t||||||||||2018-06-01 01:05:40.342507|2018-06-01 01:05:40.342507
NCT00878592|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2017-10-09|2009-04-08|2009-04-09|Estimate|||||||2017-10-09|2017-10-10|Actual|October 2008||2008-10-31|April 2009|2009-04-30||||June 2010|Actual|2010-06-30||Interventional|||Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity|Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity|Terminated||N/A|||University of Pittsburgh||2||PI left institution|f||||t||||||||||2018-06-01 01:06:44.866947|2018-06-01 01:06:44.866947
NCT00880282|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2014-04-28|2009-04-10|2009-04-13|Estimate|||||||2014-04-28|2014-04-29|Estimate|April 2009||2009-04-30|April 2013|2013-04-30||||October 2012|Actual|2012-10-31||Interventional|||Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment|A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors|Completed||Phase 1|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:05:40.441746|2018-06-01 01:05:40.441746
NCT00880269|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2016-07-21||2017-01-08|2009-04-10|2009-04-13|Estimate|2016-07-21|2016-09-09|Estimate||||2017-01-08|2017-02-23|Actual|August 2009||2009-08-31|January 2017|2017-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)|A Phase II Study of Oral Single Agent Panobinostat in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)|Completed||Phase 2|59|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:05:40.69581|2018-06-01 01:05:40.69581
NCT00880256|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2011-11-25||2012-01-20|2009-04-10|2009-04-13|Estimate|2012-01-20|2012-02-27|Estimate||||2012-01-20|2012-02-27|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data|Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data|Completed||N/A|93|Actual|Seattle Institute for Biomedical and Clinical Research||1|||f||||f||||||||||2018-06-01 01:05:41.434063|2018-06-01 01:05:41.434063
NCT00880243|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-04-10|2009-04-10|2009-04-13|Estimate|||||||2009-04-10|2009-04-13|Estimate|March 1999||1999-03-31|April 2009|2009-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)|Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML|Completed||Phase 3|473|Actual|Acute Leukemia French Association||4|||f||||t||||||||||2018-06-01 01:05:41.60865|2018-06-01 01:05:41.60865
NCT00880230|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2013-02-01||2016-01-28|2009-04-10|2009-04-13|Estimate|2013-05-02|2013-06-10|Estimate||||2016-01-28|2016-02-26|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|June 2011|Actual|2011-06-30||Interventional|INTENSE||Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)|INTENSE: Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent|Completed||N/A|141|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 01:05:41.759861|2018-06-01 01:05:41.759861
NCT00880217|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09||2011-08-22|2013-02-27|2009-04-09|2009-04-13|Estimate||||2011-08-22|2011-08-25|Estimate|2013-02-27|2013-03-04|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-31001074 in the Treatment of Adult Subjects With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 2|430|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||6|||f||||t||||||||||2018-06-01 01:05:42.288823|2018-06-01 01:05:42.288823
NCT00880204|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2009-05-13|2009-04-10|2009-04-13|Estimate|||||||2009-05-13|2009-05-14|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|November 2009|Anticipated|2009-11-30|August 2009|Anticipated|2009-08-31||Interventional|||Evaluation of Essential Surgical Skills-Emergency Maternal and Child Health (ESS-EMCH) Training by Assessing the Doctors' Practices|Evaluation of Essential Surgical Skills-Emergency Maternal and Child Health (ESS-EMCH) Training by Assessing the Doctors' Practices in Pakistan|Unknown status|Recruiting|N/A|24|Anticipated|Child Advocacy International||2|||f||||t||||||||||2018-06-01 01:05:42.477112|2018-06-01 01:05:42.477112
NCT00880191|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2015-04-13||2016-07-01|2009-04-10|2009-04-13|Estimate|2015-05-20|2015-05-21|Estimate||||2016-07-01|2016-07-06|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|March 2011|Actual|2011-03-31||Interventional|||Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy|Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy|Completed||Phase 3|430|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 01:05:42.652464|2018-06-01 01:05:42.652464
NCT00880178|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2018-05-08|2009-04-10|2009-04-13|Estimate|||||||2018-05-08|2018-05-14|Actual|May 2008||2008-05-31|February 2018|2018-02-28|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|HDL Proteomics||Plaque Inflammation and Dysfunctional HDL in AIM-HIGH|Plaque Inflammation and Dysfunctional HDL in AIM-HIGH|Completed|||324|Actual|University of Washington|||2||f||||t||||||Samples Without DNA|"~     Plasma for HDL isolation~   "|||2018-06-01 01:05:43.76766|2018-06-01 01:05:43.76766
NCT00880165|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2014-01-08||2014-03-18|2009-04-10|2009-04-13|Estimate|2014-03-18|2014-04-21|Estimate||||2014-03-18|2014-04-21|Estimate|November 2006||2006-11-30|March 2014|2014-03-31|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|VSATT|Veterans referred to the participating sleep centers for evaluation of obstructive sleep apnea|Cost Effectiveness of Ambulatory Management for Veterans With Sleep Apnea|Cost Effective Strategy to Evaluate Veterans With Sleep Apnea|Completed||N/A|296|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:05:43.926866|2018-06-01 01:05:43.926866
NCT00880152|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2010-09-23|2009-04-10|2009-04-13|Estimate|||||||2010-09-23|2010-09-24|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MBSRforPTSD||Mindfulness Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study|Mindfulness-Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study|Completed||N/A|50|Anticipated|Seattle Institute for Biomedical and Clinical Research||2|||f||||f||||||||||2018-06-01 01:05:44.302385|2018-06-01 01:05:44.302385
NCT00880139|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-11-13|2009-04-10|2009-04-13|Estimate|||||||2014-11-13|2014-11-14|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|||Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes|A Cross-sectional Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes|Terminated|||33|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 01:05:44.405915|2018-06-01 01:05:44.405915
NCT00880126|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2009-04-10|2009-04-10|2009-04-13|Estimate|||||||2009-04-10|2009-04-13|Estimate|September 2006||2006-09-30|February 2009|2009-02-28|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Community Development Teams to Scale-Up Multidimensional Treatment Foster Care (MTFC) in California|Community Development Teams to Scale-Up MTFC in California|Unknown status|Enrolling by invitation|Phase 2/Phase 3|350|Anticipated|Center for Research to Practice||1|||f||||t||||||||||2018-06-01 01:05:44.520577|2018-06-01 01:05:44.520577
NCT00880113|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2012-06-04|2009-04-10|2009-04-13|Estimate|||||||2012-06-04|2012-06-05|Estimate|May 2009||2009-05-31|June 2012|2012-06-30||||December 2013|Anticipated|2013-12-31||Observational|DUST||The Dutch Acute Stroke Trial (DUST): Prediction of Outcome With Computed Tomography (CT) - Perfusion and CT-angiography|The Dutch Acute Stroke Trial (DUST): Prediction of Outcome With CT-perfusion and CT-angiography|Unknown status|Recruiting||1500|Anticipated|UMC Utrecht|||1||f||||||||||||||2018-06-01 01:05:44.606206|2018-06-01 01:05:44.606206
NCT00880100|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2014-03-05||2017-02-08|2009-04-09|2009-04-13|Estimate|2015-02-17|2015-02-19|Estimate||||2017-02-08|2017-03-16|Actual|April 2009||2009-04-30|February 2017|2017-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||Safety population included patients who signed an informed consent form (ICF), completed the baseline phase and started the treatment phase by taking at least one dose of the study treatment.|Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)|Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old|Completed||Phase 3|49|Actual|Forest Laboratories||1|||f||||t||||||||||2018-06-01 01:05:44.731925|2018-06-01 01:05:44.731925
NCT00880087|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2016-05-11|2009-04-10|2009-04-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|THAPCA-IH||Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial|Therapeutic Hypothermia After Pediatric Cardiac Arrest (In Hospital)|Completed||Phase 3|329|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:05:45.125363|2018-06-01 01:05:45.125363
NCT00880074|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-12-27|2009-04-10|2009-04-13|Estimate|||||||2017-12-27|2017-12-29|Actual|April 2009|Actual|2009-04-30|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Clinical Response to Chemotherapy With Fluoro-L-Thymidine With Positron Emission Tomography (FLT-PET)|Early Prediction of Clinical Response to Chemotherapy With FLT-PET {[F-18]-Fluoro-L-thymidine (FLT) With Positron Emission Tomography (PET)}|Active, not recruiting||N/A|16|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:05:45.306894|2018-06-01 01:05:45.306894
NCT00880061|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2018-02-13|2009-04-10|2009-04-13|Estimate|||||||2018-02-13|2018-02-14|Actual|April 7, 2009||2009-04-07|June 5, 2015|2015-06-05|June 5, 2015|Actual|2015-06-05|June 5, 2015|Actual|2015-06-05||Interventional|||An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma|An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma|Terminated||Phase 1|7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:05:45.425585|2018-06-01 01:05:45.425585
NCT00880048|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2017-08-09|2012-02-23|2017-09-12|2009-04-09|2009-04-13|Estimate|2017-09-12|2017-10-13|Actual|2012-02-23|2012-02-27|Estimate|2017-09-12|2017-10-13|Actual|March 11, 2009|Actual|2009-03-11|August 2017|2017-08-31|June 21, 2010|Actual|2010-06-21|June 21, 2010|Actual|2010-06-21||Interventional|Orvepitant MDD||A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder|Terminated||Phase 2|343|Actual|GlaxoSmithKline|The study was terminated early upon the recommendation of an Independent Data Monitoring Committee. At the time the trial was terminated 343 participants had been randomized, compared to a target of 348 participants.|3||To allow assessment of isolated events of seizure during program|f||||t||||||||||2018-06-01 01:05:45.606529|2018-06-01 01:05:45.606529
NCT00880035|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2009-04-20|2009-04-10|2009-04-13|Estimate|||||||2009-04-20|2009-04-22|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|MUSIC||Efficacy of Music on Reduction of Sedative Drugs in Mechanically Ventilated Intensive Care Unit Patients|M.U.S.I.C (MUSicotherapy in the Intensive Care) Interventional, Pilot, Cross-Over, in Mechanically-Ventilated Patients on ICU Ward|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Université de Sherbrooke||2|||f||||t||||||||||2018-06-01 01:05:48.067257|2018-06-01 01:05:48.067257
NCT00880022|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2012-08-14||2017-11-01|2009-04-10|2009-04-13|Estimate|2012-08-14|2012-09-13|Estimate||||2017-11-01|2017-12-05|Actual|May 2009||2009-05-31|November 2017|2017-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer|Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer|Completed||N/A|47|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:05:48.183032|2018-06-01 01:05:48.183032
NCT00880009|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2012-10-04|2012-03-29|2012-10-04|2009-04-10|2009-04-13|Estimate|2012-10-04|2012-11-05|Estimate|2012-03-29|2012-04-02|Estimate|2012-10-04|2012-11-05|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer|A Phase 2, Randomized, Open-Label Study Of Bosutinib Administered In Combination With Letrozole Versus Letrozole Alone As First Line Therapy In Post-Menopausal Women With Locally Advanced Or Metastatic ER+/PgR+/ErbB2- Breast Cancer|Terminated||Phase 2|16|Actual|Pfizer|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:05:48.53402|2018-06-01 01:05:48.53402
NCT00879996|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2012-03-21||2012-08-03|2009-04-10|2009-04-13|Estimate|2012-06-04|2012-07-09|Estimate||||2012-08-03|2012-08-07|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients|A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients|Completed||Phase 4|54|Actual|State University of New York at Buffalo|small subject number not a double-blind study|2|||f||||f||||||||||2018-06-01 01:05:49.105141|2018-06-01 01:05:49.105141
NCT00879983|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2010-06-11|2009-04-10|2009-04-13|Estimate|||||||2010-06-11|2010-06-14|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects|An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:05:49.481167|2018-06-01 01:05:49.481167
NCT00876213|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-03|2009-04-03|2009-04-06|Estimate|||||||2009-04-03|2009-04-06|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|June 2008|Actual|2008-06-30|||||Observational|||Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans|Amylin and GLP-1: Influence on Gastric Emptying, Appetite and Food Intake in Humans.|Completed|||23|Actual|Hvidovre University Hospital|||||f||||f||||||||||2018-06-01 01:08:13.138057|2018-06-01 01:08:13.138057
NCT00879970|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2011-11-10||2017-03-21|2009-04-09|2009-04-13|Estimate|2011-11-10|2011-12-13|Estimate||||2017-03-21|2017-04-18|Actual|May 2009||2009-05-31|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TIDE||Thiazolidinedione Intervention With Vitamin D Evaluation|AVANDIA CV Outcomes Study: Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk For Cardiovascular Disease|Terminated||Phase 4|1332|Actual|GlaxoSmithKline|The intended duration of this study was approximately 5.5 years. However, the trial was stopped prematurely because of regulatory concerns after a mean of 162 days without consideration of the accrued data.|5||FDA has placed the trial on full clinical hold.|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:05:49.750499|2018-06-01 01:05:49.750499
NCT00879957|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2015-04-14|2009-04-10|2009-04-13|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|May 2011|Actual|2011-05-31|March 2011|Anticipated|2011-03-31||Interventional|||Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates|Comparison of Heparin vs. no Heparin on Duration of Peripherally Inserted Central Catheter Patency in Neonates|Withdrawn||N/A|0|Actual|The University of Texas Health Science Center at San Antonio||2||A study was published regarding the same question this study had.|f||||t||||||||||2018-06-01 01:05:52.802355|2018-06-01 01:05:52.802355
NCT00879944|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2015-04-10|2009-04-10|2009-04-13|Estimate|||||||2015-04-10|2015-04-14|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index|Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis|Completed|||409|Actual|Northwestern University|||3||f||||t||||||||||2018-06-01 01:05:52.916297|2018-06-01 01:05:52.916297
NCT00879931|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2014-12-04|2009-04-10|2009-04-13|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Influence of Corticoids on Renal Function in Cardiac Surgery|Influence of Corticoids on Renal Function in Cardiac Surgery|Unknown status|Recruiting|Phase 2|80|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:05:53.061946|2018-06-01 01:05:53.061946
NCT00879918|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2013-05-23|2009-04-10|2009-04-13|Estimate|||||||2013-05-23|2013-05-24|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|5075-AAPK1||Pharmacogenetics of Nicotine Metabolism in African-Americans|Pharmacogenetics of Nicotine Metabolism in African-Americans|Completed||Phase 1|70|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:05:53.155533|2018-06-01 01:05:53.155533
NCT00879905|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2012-10-18|2009-04-10|2009-04-13|Estimate|||||||2012-10-18|2012-10-19|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors|A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally in Adult Patients With Advanced Solid Malignancies|Completed||Phase 1|64|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:05:53.319106|2018-06-01 01:05:53.319106
NCT00879892|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2015-01-16|2009-04-10|2009-04-13|Estimate|||||||2015-01-16|2015-01-19|Estimate|May 2009||2009-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Xe-hypotheca||Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients|Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients|Completed||Phase 2|110|Actual|Turku University Hospital||2|||f||||t||||||||||2018-06-01 01:05:53.419187|2018-06-01 01:05:53.419187
NCT00879879|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2013-08-09||2013-08-09|2009-04-10|2009-04-13|Estimate|2013-08-09|2013-10-14|Estimate||||2013-08-09|2013-10-14|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis|Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project|Completed||N/A|20|Actual|University of South Florida||1|||f||||t||||||||||2018-06-01 01:05:53.535506|2018-06-01 01:05:53.535506
NCT00879866|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2014-06-20|2009-04-10|2009-04-13|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|September 2012|Actual|2012-09-30|February 2011|Actual|2011-02-28||Interventional|||EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)|An Open-label, Phase Ib, Dose-escalation Trial on the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Biological Effects and Antitumor Activity of EMD 521873 in Combination With Local Irradiation (20 Gy) of Primary Tumors or Metastases in Subjects With Non-small Cell Lung Cancer Stage IIIb With Malignant Pleural Effusion or Stage IV With Disease Control (Partial Response or Stable Disease) After Application of 4 Cycles of Platinum-based, First-line Chemotherapy|Completed||Phase 1|15|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 01:05:53.759061|2018-06-01 01:05:53.759061
NCT00879853|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2009-04-10|2009-04-10|2009-04-13|Estimate|||||||2009-04-10|2009-04-13|Estimate||||April 2009|2009-04-30||||||||Interventional|||Trial of Mental Health Treatment for Darfur Refugees in Cairo|Randomized Controlled Trial of Mental Health Treatment for Darfur Refugees in Cairo|Completed||N/A|||University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:05:53.857513|2018-06-01 01:05:53.857513
NCT00879840|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|||2018-05-17|2009-04-10|2009-04-13|Estimate|||||||2018-05-17|2018-05-18|Actual|April 9, 2009||2009-04-09|October 25, 2017|2017-10-25||||||||Observational|||Assessment of Screening Modalities for Gynecologic Cancers|Assessment of Screening Modalities for Gynecologic Cancers|Active, not recruiting|||118|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:05:53.96004|2018-06-01 01:05:53.96004
NCT00879827|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2016-09-06|2009-04-09|2009-04-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2000||2000-09-30|September 2016|2016-09-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants|Immunogenicity and Reactogenicity of GSK Biologicals' DTPa-HBV-IPV and Hib Vaccines When Administered Concomitantly to Healthy Infants Administered as a Three-dose Primary Vaccination Course at the Age of 1.5, 3.5 and 6 Months|Completed||Phase 3|60|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:05:54.042697|2018-06-01 01:05:54.042697
NCT00878579|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2013-02-19|2009-04-08|2009-04-09|Estimate|||||||2013-02-19|2013-02-21|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Percutaneous Dynamic Stabilization (PDS) System Versus Fusion for Treating Degenerative Disc Disease|A Study to Evaluate the Safety and Effectiveness of the PDS System to Treat Back Pain Associated With Degenerative Disc Disease|Terminated||Phase 2|20|Actual|Interventional Spine, Inc.||2||Sponsor Termination|f||||f||||||||||2018-06-01 01:06:45.209545|2018-06-01 01:06:45.209545
NCT00879814|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-10|2014-11-17||2015-07-15|2009-04-10|2009-04-13|Estimate|2014-11-17|2014-11-25|Estimate||||2015-07-15|2015-08-06|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Safety population included all randomized participants who received at least 1 vaccination.|Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults|A Phase 1 Randomized, Open-label, Parallel-group, Active- And Placebo-controlled Study To Assess Safety And Tolerability Of 60, 120, And 200 Mcg Meningococcal Group B Rlp2086 Vaccine In Healthy Adult Subjects|Completed||Phase 1|48|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:05:54.219146|2018-06-01 01:05:54.219146
NCT00879801|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2009-04-09|2009-04-09|2009-04-10|Estimate|||||||2009-04-09|2009-04-10|Estimate|January 2003||2003-01-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|GENFIEV||Genetic Physiopathology and Evolution of Type 2 Diabetes|Evaluation of Genetic, Biochemical and Clinical Determinants of Type 2 Diabetes Progression in Subjects at High Risk|Completed|||1017|Actual|University of Pisa|||1||f||||t||||||Samples With DNA|"~     Serum and plasma sample, DNA~   "|||2018-06-01 01:05:56.450016|2018-06-01 01:05:56.450016
NCT00879788|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2009-04-09|2009-04-09|2009-04-10|Estimate|||||||2009-04-09|2009-04-10|Estimate|October 2006||2006-10-31|April 2009|2009-04-30|March 2007|Actual|2007-03-31|November 2006|Actual|2006-11-30||Interventional|||Bioequivalence Study of Ramipril 10 mg Capsules Under Fed Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study Comparing Ramipril 10 mg Capsules of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc.), With Altace® Capsule 10 mg (Containing Ramipril 10 mg) of Monarch Pharmaceuticals Inc, USA in Healthy, Adult, Male, Human Subjects Under Fed Conditions.|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:05:56.674579|2018-06-01 01:05:56.674579
NCT00879775|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2011-01-11||2011-03-03|2009-04-09|2009-04-10|Estimate|2011-03-03|2011-03-29|Estimate||||2011-03-03|2011-03-29|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Efficacy of Caffeine Injection as an Adjuvant to Opioid Therapy in Cancer Pain|Efficacy of Caffeine as an Adjuvant to Opioid Therapy in Cancer Pain: a Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2|41|Actual|Korea Research Foundation||2|||f||||f||||||||||2018-06-01 01:05:56.965441|2018-06-01 01:05:56.965441
NCT00879762|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09||2012-10-17|2012-12-06|2009-04-09|2009-04-10|Estimate||||2012-10-17|2012-10-19|Estimate|2012-12-06|2012-12-10|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||High Dose IMVAMUNE® in Vaccinia-Naive Individuals|Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals|Completed||Phase 2|91|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 01:05:58.413098|2018-06-01 01:05:58.413098
NCT00879749|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2011-04-05|2009-04-09|2009-04-10|Estimate|||||||2011-04-05|2011-04-07|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Safety Study of Nexvax2 in Subjects With Coeliac Disease|A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet|Completed||Phase 1|34|Actual|Nexpep Pty Ltd||2|||f||||f||||||||||2018-06-01 01:05:58.754904|2018-06-01 01:05:58.754904
NCT00879736|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2011-08-19|2009-04-09|2009-04-10|Estimate|||||||2011-08-19|2011-08-22|Estimate|March 2009||2009-03-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of the Effect of Patient Education (Talking Health Together) in Improving Doctor-patient Communication|A Multi-centre, Randomised Trial in Ontario to Evaluate the Efficacy of Talking Health Together T.M. (T.H.T. in Practice), a Communication Education Intervention for Primary Care Patients With Chronic Disease.|Completed||N/A|322|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:05:58.958321|2018-06-01 01:05:58.958321
NCT00879723|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2015-08-25|2009-04-09|2009-04-10|Estimate|||||||2015-08-25|2015-08-26|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Burn Micronutrient Repletion Pilot Study|Burn Micronutrient Repletion Pilot Study: Characterizing Relationships Between Vitamin and Mineral Supplementation and Health Outcomes of Adult Burn Patients|Completed||Phase 1|28|Actual|Southern Illinois University||2|||f||||f||||||||||2018-06-01 01:05:59.234814|2018-06-01 01:05:59.234814
NCT00879710|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2015-08-25||2016-03-16|2009-04-09|2009-04-10|Estimate|2016-03-16|2016-04-18|Estimate||||2016-03-16|2016-04-18|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Diabetes Mellitus on Cholesterol Metabolism|Effect of Diabetes Mellitus on Cholesterol Absorption, Synthesis and Statin Efficacy|Completed||N/A|57|Actual|Medical College of Wisconsin|"Smaller than desirable sample size due to difficulty in recruitment.~Could not evaluate the effect of duration of the diabetes mellitus as independent confirmation of the duration could not be done.~Apolipoprotein levels were not measured."|2|||f||||f||||||||||2018-06-01 01:05:59.561247|2018-06-01 01:05:59.561247
NCT00879697|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2009-01-27||2016-10-24|2009-03-09|2009-04-10|Estimate|2009-03-09|2009-04-10|Estimate||||2016-10-24|2016-12-15|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Strength Training in Walking Tolerance in Intermittent Claudication Patients|Effects of Strength Training and Walking Training on Physical Fitness of Patients With Intermittent Claudication|Completed||Phase 3|34|Actual|University of Sao Paulo|Our sample was composed of patients with many diseases and taking different medications.|2|||f||||t||||||||No||2018-06-01 01:06:00.54455|2018-06-01 01:06:00.54455
NCT00879684|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2015-01-15||2015-01-15|2009-04-09|2009-04-10|Estimate|2015-01-15|2015-01-26|Estimate||||2015-01-15|2015-01-26|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Safety population included all enrolled participants in the study who received any study medication.|Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors|Completed||Phase 1|34|Actual|Pfizer|Designation of outcomes as primary, secondary was based on study team’s input as study did not specify them as primary or secondary.|1|||f||||f||||||||||2018-06-01 01:06:01.627694|2018-06-01 01:06:01.627694
NCT00879671|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2014-11-13|2009-04-09|2009-04-10|Estimate|||||||2014-11-13|2014-11-14|Estimate|November 2006||2006-11-30|November 2014|2014-11-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration|Effects of Lutein Supplementation on Macular Pigment Optical Density and Visual Acuity in Patients With Age-related Macular Degeneration|Completed||N/A|126|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:06:05.383246|2018-06-01 01:06:05.383246
NCT00879658|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09||2012-07-24|2018-02-28|2009-04-09|2009-04-10|Estimate||||2012-07-24|2012-08-01|Estimate|2018-02-28|2018-03-02|Actual|March 2009||2009-03-31|February 2018|2018-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis|A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.|Completed||Phase 2|296|Actual|Novartis||6|||f||||||||||||||2018-06-01 01:06:05.675036|2018-06-01 01:06:05.675036
NCT00879645|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2010-10-07||2016-10-18|2009-04-09|2009-04-10|Estimate|2010-10-07|2010-11-04|Estimate||||2016-10-18|2016-11-28|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function|A Phase I Study to Assess the Pharmacokinetics of IK-1001 (Sodium Sulfide) in Subjects With Impaired Renal Function Following a Continuous 3-hour Intravenous Infusion|Terminated||Phase 1|28|Actual|Mallinckrodt||4||unable to develop a rapid & reliable assay to detect sulfide concentrations|f||||t||||||||||2018-06-01 01:06:06.172995|2018-06-01 01:06:06.172995
NCT00879632|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2011-02-15|2009-04-09|2009-04-10|Estimate|||||||2011-02-15|2011-02-16|Estimate|March 2009||2009-03-31|February 2011|2011-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania|Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up Study|Unknown status|Recruiting||200|Anticipated|Hospital de Clinicas de Porto Alegre|||2||f||||f||||||Samples With DNA|"~     SERUM, DNA, PLASMA~   "|||2018-06-01 01:06:07.700882|2018-06-01 01:06:07.700882
NCT00879619|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2013-04-19||2016-12-06|2009-04-09|2009-04-10|Estimate|2013-04-19|2013-06-06|Estimate||||2016-12-06|2017-02-01|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients|A Pilot Phase I/II Study to Evaluate the Effects of Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients With Biochemical Relapse|Terminated||Phase 1/Phase 2|4|Actual|University of California, Irvine|The study was terminated due to slow accrual. Zero subjects were analyzed.|1||Terminated due to slow accrual.|f||||t||||||||||2018-06-01 01:06:08.012305|2018-06-01 01:06:08.012305
NCT00879606|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08||2014-01-14|2015-03-20|2009-04-08|2009-04-10|Estimate||||2014-01-14|2014-02-11|Estimate|2015-03-20|2015-04-10|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome|Efficacy and Safety Evaluation of ALT-836 in Patients With Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome|Completed||Phase 2|150|Actual|Altor BioScience||2|||f||||t||||||||||2018-06-01 01:06:08.651707|2018-06-01 01:06:08.651707
NCT00879593|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-01-25|2009-04-09|2009-04-10|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|June 2014|Actual|2014-06-30||Interventional|||Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)|Potential Role for Nocturnal PtcCO2 Monitoring in the Close Follow up of ALS Patients.|Completed||N/A|66|Actual|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||1|||f||||f||||||||||2018-06-01 01:06:09.00044|2018-06-01 01:06:09.00044
NCT00879580|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-10-10|2009-04-09|2009-04-10|Estimate|||||||2013-10-10|2013-10-11|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|ESAT||Enterprise Stent Aneurysm Treatment (ESAT) Study - France|"Prospective Multicenter Observational Study for the Evaluation of the Efficacy of the Cordis Enterprise(TM) Self-expanding Intracranial Stent: Enterprise Stent Aneurysm Treatment (ESAT) Study"|Completed|||133|Actual|Codman & Shurtleff|||2||f||||f||||||||||2018-06-01 01:06:09.568851|2018-06-01 01:06:09.568851
NCT00879554|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2010-12-10|2009-04-09|2009-04-10|Estimate|||||||2010-12-10|2010-12-13|Estimate|February 2007||2007-02-28|December 2010|2010-12-31|November 2010|Actual|2010-11-30|March 2009|Actual|2009-03-31||Interventional|CVX-045-101||A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors|A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors|Completed||Phase 1|40|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:06:09.869091|2018-06-01 01:06:09.869091
NCT00879541|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2011-02-10|2009-04-09|2009-04-10|Estimate|||||||2011-02-10|2011-02-11|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A|A Phase II, Multicentre, Double-blinded, Randomised, Cross-over Study to Evaluate Efficacy, Safety and Pharmacokinetics of Biostate® in Subjects With Haemophilia A.|Completed||Phase 2|81|Actual|CSL Behring||3|||f||||t||||||||||2018-06-01 01:06:10.16957|2018-06-01 01:06:10.16957
NCT00879528|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2016-08-16|2009-04-09|2009-04-10|Estimate|||||||2016-08-16|2016-08-17|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|May 2010|Actual|2010-05-31||Observational|||Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory|Consolidation PET-based and Donor-based After Salvage Therapy in Patients With Hodgkin Lymphoma in Relapse or Refractory|Terminated|||264|Actual|Fondazione Italiana Linfomi ONLUS||||Failure of accrual achievement|f||||f||||||||||2018-06-01 01:06:10.534687|2018-06-01 01:06:10.534687
NCT00879515|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-05-25|2009-04-09|2009-04-10|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2005||2005-10-31|May 2017|2017-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Examining Social, Emotional, and Cognitive Functioning in People With Fragile X and Down Syndromes|Genetics and Physiology of Social Anxiety in Fragile X|Completed|||511|Actual|University of California, Davis|||4||f||||t||||||Samples With DNA|"~     Saliva samples collected at four time periods~   "|||2018-06-01 01:06:11.051985|2018-06-01 01:06:11.051985
NCT00879502|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-05-25|2009-04-09|2009-04-10|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2007||2007-06-30|May 2017|2017-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Examining Physiology and Brain Function in People With the Fragile X Premutation|Limbic System Function in Carriers of the Fragile X Premutation|Completed|||110|Actual|University of California, Davis|||3||f||||t||||||Samples With DNA|"~     Saliva and blood samples~   "|||2018-06-01 01:06:11.303387|2018-06-01 01:06:11.303387
NCT00879489|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2011-02-23|2009-04-09|2009-04-10|Estimate|||||||2011-02-23|2011-02-25|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|||Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer|Phase I/II Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Anticipated|Quantum Immunologics, Inc.|||||f||||f||||||||||2018-06-01 01:06:11.584539|2018-06-01 01:06:11.584539
NCT00879476|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2009-04-09|2009-04-09|2009-04-10|Estimate|||||||2009-04-09|2009-04-10|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Bioequivalence Study of Ramipril 10 mg Capsules Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioavailability Study Comparing Ramipril 10 mg Capsules of OHM Laboratories Inc (a Subsidiary of Ranbaxy Pharmaceuticals Inc) With ALTACE® 10 mg Capsules (Containing Ramipril 10 mg) of King Pharmaceuticals Inc, in Healthy, Adult, Male Human Subjects Under Fasting Condition.|Completed||N/A|68|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:06:11.868761|2018-06-01 01:06:11.868761
NCT00879463|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2012-07-24|2009-04-09|2009-04-10|Estimate|||||||2012-07-24|2012-07-25|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|December 2010|Actual|2010-12-31||Interventional|INVOS||Brain Tissue Oxygen Saturation and Blood Transfusion in Cardiac Surgery|The Impact of Brain Tissue Oxygen Saturation Monitoring in Reducing the Use of Red Blood Cells in Cardiac Surgery|Completed||N/A|150|Actual|Larissa University Hospital||2|||f||||f||||||||||2018-06-01 01:06:12.120249|2018-06-01 01:06:12.120249
NCT00879450|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2011-07-19|2009-04-09|2009-04-10|Estimate|||||||2011-07-19|2011-07-21|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Evaluating the Impact of a New Complement to Physiotherapy Intervention for Positional Torticollis in Infants|Evaluating the Impact of a New Complement to Physiotherapy Intervention for Positional Torticollis in Infants|Terminated||N/A|160|Anticipated|McGill University Health Center||2||Clinical department where study was held was unable to continue collaboration|f||||t||||||||||2018-06-01 01:06:12.412213|2018-06-01 01:06:12.412213
NCT00879437|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-08-25|2009-04-09|2009-04-10|Estimate|||||||2017-08-25|2017-08-28|Actual|July 2009||2009-07-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|||Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma|A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas|Active, not recruiting||Phase 2|38|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 01:06:13.24141|2018-06-01 01:06:13.24141
NCT00879424|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2016-12-20|2009-04-09|2009-04-10|Estimate|||||||2016-12-20|2016-12-22|Estimate|February 2009||2009-02-28|December 2016|2016-12-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Vitamin D Supplementation in Childhood Atopic Dermatitis|Randomized Trial of Vitamin D Supplementation in Winter-related, Childhood Atopic Dermatitis|Completed||N/A|107|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:06:13.616232|2018-06-01 01:06:13.616232
NCT00879411|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2012-01-18||2014-02-28|2009-04-09|2009-04-10|Estimate|2012-04-16|2012-05-15|Estimate||||2014-02-28|2014-03-28|Estimate|April 2009||2009-04-30|February 2014|2014-02-28||||January 2010|Actual|2010-01-31||Observational|||Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients|24h BP Under Micardis in Daily Practice|Completed|||670|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 01:06:13.955716|2018-06-01 01:06:13.955716
NCT00879398|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2015-08-06||2015-09-30|2009-04-09|2009-04-10|Estimate|2015-08-06|2015-09-04|Estimate||||2015-09-30|2015-10-21|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||Safety Analysis Set: regardless of treatment period, all participants who received study drug once or more, including dropouts due to adverse event (AE), were included in the safety analysis set. Participants who started Toviaz prior to the contract date or violated usage of maximum daily dose of 8 mg were excluded from the safety analysis set.|Toviaz Post Marketing Surveillance Study|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Toviaz (Registered)|Completed|||3000|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:06:14.592221|2018-06-01 01:06:14.592221
NCT00879385|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2014-10-29|2009-04-08|2009-04-10|Estimate|||||||2014-10-29|2014-10-31|Estimate|December 2009||2009-12-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||KRAS Wild-type Metastatic Colorectal Cancer Trial|Targeted Demethylation to Enhance Response or Overcome Resistance to EGFR Blocking Agents in KRAS Wild-type Metastatic Colorectal Cancer Patients Using Sequential Decitabine and Panitumumab|Completed||Phase 1|21|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:06:15.989712|2018-06-01 01:06:15.989712
NCT00879372|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2013-10-05|2009-04-09|2009-04-10|Estimate|||||||2013-10-05|2013-10-08|Estimate|March 2009||2009-03-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression|Double Blind,Randomized, Placebo Controlled Trial of Adjunctive Tianeptine in the Treatment of Bipolar Depression|Unknown status|Active, not recruiting|Phase 3|13|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:06:16.150378|2018-06-01 01:06:16.150378
NCT00879359|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|2017-01-10||2017-03-16|2009-04-09|2009-04-10|Estimate|2017-03-16|2017-04-26|Actual||||2017-03-16|2017-04-26|Actual|December 2007||2007-12-31|March 2017|2017-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer|A Phase II Trial of a Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody, AVASTIN, in Combination With Cytotoxic Chemotherapy CARBOPLATIN and PACLITAXEL for Recurrent/Advanced Endometrial Cancer|Completed||Phase 2|15|Actual|The Cleveland Clinic|Accrual to the study was discontinued due to the initiation of a national randomized phase II trial which included paclitaxel, carboplatin and bevacivumab with maintanence bevacizumab as one of the study arms.|1|||f||||t||||||||||2018-06-01 01:06:16.27483|2018-06-01 01:06:16.27483
NCT00879346|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-10-22|2009-04-09|2009-04-10|Estimate|||||||2009-10-22|2009-10-23|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|||||Interventional|||A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets|A Randomised, Open-label, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets in Healthy Subjects|Completed||Phase 1|24|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:06:16.61801|2018-06-01 01:06:16.61801
NCT00879333|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2015-01-28||2015-10-08|2009-04-09|2009-04-10|Estimate|2015-04-02|2015-04-06|Estimate||||2015-10-08|2015-11-03|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|GRANITE-1||Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)|A Randomized, Double-blind, Multi-center Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on 1 or 2 Prior Systemic Chemotherapy|Completed||Phase 3|656|Actual|Novartis|4 randomized patients, 2 patients each from the everolimus and placebo arms were excluded from the safety analyses as they did not receive any dose of study treatment.|2|||f||||t||||||||||2018-06-01 01:06:16.74546|2018-06-01 01:06:16.74546
NCT00879307|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2011-02-15|2009-04-09|2009-04-10|Estimate|||||||2011-02-15|2011-02-16|Estimate|March 2009||2009-03-31|February 2011|2011-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR|Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR|Unknown status|Recruiting|Phase 3|100|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f||||||||||2018-06-01 01:06:18.320192|2018-06-01 01:06:18.320192
NCT00879294|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-09|||2017-11-02|2009-04-09|2009-04-10|Estimate|||||||2017-11-02|2017-11-06|Actual||||July 2017|2017-07-31||||||||Interventional|||The Effect of Gum Chewing on Postoperative Ileus|The Effect of Gum Chewing on Postoperative Ileus|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||3|||f||||f|f|t||||||||2018-06-01 01:06:18.415767|2018-06-01 01:06:18.415767
NCT00879281|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2011-02-23|2009-04-08|2009-04-09|Estimate|||||||2011-02-23|2011-02-24|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|ACZiE||Action Plan to Enhance Self-management and Early Detection of Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients|Action Plan to Enhance Self-management and Early Detection of Exacerbations in COPD Patients; A Multicenter RCT (ACZiE)|Completed||N/A|233|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 01:06:18.509958|2018-06-01 01:06:18.509958
NCT00879268|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-04-07|2009-04-07|2009-04-09|Estimate|||||||2009-04-07|2009-04-09|Estimate|July 2004||2004-07-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Phase 1 Study of Liver Machine Preservation With Vasosol Solution|Completed||Phase 1|20|Actual|Polyak, Maximilian|||||f||||||||||||||2018-06-01 01:06:18.602638|2018-06-01 01:06:18.602638
NCT00879255|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2014-11-12||2015-04-23|2009-04-08|2009-04-09|Estimate|2015-02-27|2015-03-02|Estimate||||2015-04-23|2015-05-12|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|CPTVTEL|Male combat veterans with posttraumatic stress disorder (PTSD).|Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With Posttraumatic Stress Disorder|Telemental Health and Cognitive Processing Therapy for Rural Combat Veterans With PTSD|Completed||Phase 3|125|Actual|VA Office of Research and Development|For patients in rural areas, their local mental health facilities may not have access to videoteleconferencing technology.There were no women veterans as study participants. Participants with acute safety concerns or current substances were excluded.|2|||f||||f||||||||||2018-06-01 01:06:18.680462|2018-06-01 01:06:18.680462
NCT00879242|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2016-12-08|2009-04-08|2009-04-09|Estimate|||||||2016-12-08|2016-12-12|Estimate|February 2009||2009-02-28|November 2011|2011-11-30||||May 2011|Actual|2011-05-31||Interventional|||Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec|Multicenter, Open Label, Prospective Study to Evaluate the Efficacy and Safety of Deferasirox 30 mg/kg/Day for 52 Weeks, in Transfusion-dependent Beta-thalassemic Patients With Cardiac MRI T2* < 20 Msec|Completed||Phase 2|20|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:06:19.103223|2018-06-01 01:06:19.103223
NCT00879229|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2013-08-09||2014-05-05|2009-04-08|2009-04-09|Estimate|2014-03-18|2014-04-22|Estimate||||2014-05-05|2014-05-15|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|ARTEMIS-PH|Full Analysis Set: participants who were randomized and received at least one dose of study drug|ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension|Terminated||Phase 3|40|Actual|Gilead Sciences|Study GS-US-300-0128 was terminated early with enrollment of 40 of 225 planned subjects.|2|||f||||t||||||||||2018-06-01 01:06:19.23651|2018-06-01 01:06:19.23651
NCT00879216|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-11-24|2009-04-08|2009-04-09|Estimate|||||||2009-11-24|2009-11-25|Estimate|April 2009||2009-04-30|November 2009|2009-11-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||VA106483 and Alpha Blocker Interaction Study in Elderly Males|A Single Centre, Double-blind, Placebo Controlled Crossover Study in Elderly Male Subjects to Investigate the Plarmacodynamic Interaction of VA106483 Administered Concomitanctly With Alpha-blocker Therapy|Completed||Phase 1|12|Actual|Vantia Ltd||2|||f||||f||||||||||2018-06-01 01:06:20.078752|2018-06-01 01:06:20.078752
NCT00879203|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2016-10-31|2009-04-08|2009-04-09|Estimate|||||||2016-10-31|2016-11-02|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|November 2013|Actual|2013-11-30||Observational|LO5/HY5||Glycemic Control, Brain Structure and Cognition in Youth With Type 1 Diabetes (T1DM)|Glycemic Control, Brain Structure and Cognition in Youth With T1DM|Completed|||230|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 01:06:20.184561|2018-06-01 01:06:20.184561
NCT00879190|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2016-10-31||2018-04-18|2009-04-08|2009-04-09|Estimate|2017-01-24|2017-03-15|Actual||||2018-04-18|2018-05-18|Actual|May 2009|Actual|2009-05-31|April 2018|2018-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Chorioamnionitis|Comparison of Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|92|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 01:06:20.274807|2018-06-01 01:06:20.274807
NCT00879177|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2017-04-06|2009-04-08|2009-04-09|Estimate|||||||2017-04-06|2017-04-10|Actual|April 2009||2009-04-30|April 2017|2017-04-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|VANQUISH||Smoking Study With Behavioral Therapy for Hypertensive Patients|Contingency Management for Initiating Smoking Abstinence in Patients With Hypertension|Completed||Phase 4|203|Actual|UConn Health||2|||f||||f|f|f||||||No||2018-06-01 01:06:20.607997|2018-06-01 01:06:20.607997
NCT00879164|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2014-10-15|2009-04-08|2009-04-09|Estimate|||||||2014-10-15|2014-10-17|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Stellate Ganglion Nerve Block in Treating Women With Hot Flashes|Pilot Evaluation of a Stellate Ganglion Block for the Treatment of Hot Flashes|Completed||Early Phase 1|10|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 01:06:20.729178|2018-06-01 01:06:20.729178
NCT00879151|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2015-05-21|2009-04-08|2009-04-09|Estimate|||||||2015-05-21|2015-05-25|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Treatment for Adolescents With Bulimia Nervosa|Treatment of Bulimic Adolescents|Completed||N/A|130|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 01:06:20.812512|2018-06-01 01:06:20.812512
NCT00879138|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-04-08|2009-04-08|2009-04-09|Estimate|||||||2009-04-08|2009-04-09|Estimate|August 2008||2008-08-31|April 2009|2009-04-30||||||||Interventional|||Efficacy and Safety of VA106483 in Elderly Males|A Double-Blind, Placebo-Controlled Dose Response Study to Investigate Pharmacodynamics and Pharmacokinetics of Single and Repeated Oral Doses of VA106483 in Elderly Male Subjects|Completed||Phase 1/Phase 2|27|Actual|Vantia Ltd|||||f||||f||||||||||2018-06-01 01:06:20.915561|2018-06-01 01:06:20.915561
NCT00879112|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2011-08-10|2009-04-08|2009-04-09|Estimate|||||||2011-08-10|2011-08-12|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study of MB07811 in Subjects With Hypercholesterolemia|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of MB07811 for 12 Weeks Followed by a 6-Week Off Drug Phase in Subjects With Primary Hypercholesterolemia|Withdrawn||Phase 2|80|Anticipated|Ligand Pharmaceuticals||4||Study terminated prior to initiation|f||||f||||||||||2018-06-01 01:06:21.060567|2018-06-01 01:06:21.060567
NCT00879099|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2010-01-27|2009-04-08|2009-04-09|Estimate|||||||2010-01-27|2010-01-28|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Interaction Study of Timolol Eye Drops and Paroxetine Capsules|The Effect of Paroxetine on the Plasma Levels of Timolol Using Ophthalmic 0.5% Timolol Eye Drops and 0.1% Timolol Eye Gel in Healthy Volunteers|Completed||Phase 1|12|Anticipated|Santen Oy||4|||f||||f||||||||||2018-06-01 01:06:21.173132|2018-06-01 01:06:21.173132
NCT00879086|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2014-07-22|2009-04-08|2009-04-09|Estimate|||||||2014-07-22|2014-07-23|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer|A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer|Completed||Phase 2|104|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 01:06:21.293903|2018-06-01 01:06:21.293903
NCT00879073|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2012-12-17|2009-04-08|2009-04-09|Estimate|||||||2012-12-17|2012-12-18|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors|Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors|Terminated||Phase 1|12|Actual|H. Lee Moffitt Cancer Center and Research Institute||3||Principal Investigator is leaving Moffitt|f||||t||||||||||2018-06-01 01:06:21.461875|2018-06-01 01:06:21.461875
NCT00879060|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-04-08|2009-04-08|2009-04-09|Estimate|||||||2009-04-08|2009-04-09|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|November 2012|Anticipated|2012-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy|Clinical and Therapeutic Implications of Fibrosis in Hypertrophic|Unknown status|Recruiting|Phase 4|95|Anticipated|Tufts Medical Center||1|||f||||t||||||||||2018-06-01 01:06:21.576952|2018-06-01 01:06:21.576952
NCT00879047|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2014-05-02|2009-04-08|2009-04-09|Estimate|||||||2014-05-02|2014-05-06|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection|Interaction of Alcohol & HAART in HIV/AIDS and HIV/AIDS With HCV Co-Infection|Completed||Phase 1|30|Actual|University of California, San Francisco||5|||f||||t||||||||||2018-06-01 01:06:21.681304|2018-06-01 01:06:21.681304
NCT00879034|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2017-05-24||2018-04-08|2009-04-08|2009-04-09|Estimate|2017-07-27|2017-07-31|Actual||||2018-04-08|2018-04-10|Actual|March 2009||2009-03-31|April 2018|2018-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria|A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies|Completed||Phase 2|5|Actual|Boston Children’s Hospital|This was an open label clinical trial on a very rare disease population. Patient numbers are small, though 5 participants represents a small but significant portion of the world's population of children with HGPS.|1|||f||||t||||||||||2018-06-01 01:06:21.943993|2018-06-01 01:06:21.943993
NCT00879021|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2013-07-29|2009-04-08|2009-04-09|Estimate|||||||2013-07-29|2013-07-30|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Pregabalin in the Prevention of Central Neuropathic Pain in Acute Spinal Cord Injury|Can Pregabalin Prevent the Development of Neuropathic Pain Following Spinal Cord Injury? A Double-Blind, Randomized, Placebo Controlled Trial.|Terminated||Phase 3|5|Actual|Nova Scotia Health Authority||2||lack of funding and patients|f||||f||||||||||2018-06-01 01:06:22.255261|2018-06-01 01:06:22.255261
NCT00879008|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2014-06-20|2009-04-08|2009-04-09|Estimate|||||||2014-06-20|2014-06-23|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|SYMPROVE III||SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)|SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB|Completed|||345|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a.~   "|||2018-06-01 01:06:22.391528|2018-06-01 01:06:22.391528
NCT00878995|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2017-09-26||2018-03-08|2009-04-08|2009-04-09|Estimate|2018-03-08|2018-03-12|Actual||||2018-03-08|2018-03-12|Actual|June 3, 2009|Actual|2009-06-03|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma|Nutrition and Anabolic Interventions in Squamous Cell Carcinoma|Completed||Phase 1|28|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-06-01 01:06:22.543444|2018-06-01 01:06:22.543444
NCT00878982|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2013-02-06|2009-04-08|2009-04-09|Estimate|||||||2013-02-06|2013-02-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:06:23.924972|2018-06-01 01:06:23.924972
NCT00878969|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2015-11-20||2016-01-18|2009-04-08|2009-04-09|Estimate|2016-01-18|2016-02-15|Estimate||||2016-01-18|2016-02-15|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3|Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3|Terminated||Phase 3|78|Actual|Vanderbilt University||3||insufficient enrollment and retention|f||||t||||||||||2018-06-01 01:06:24.006618|2018-06-01 01:06:24.006618
NCT00878956|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2012-07-31|2009-04-08|2009-04-09|Estimate|||||||2012-07-31|2012-08-01|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||Bicarbonate in Cardiac Surgery|A Phase IIb Multiple Blind Randomized Controlled Trial of Sodium Bicarbonate in Cardiac Surgery at High-risk of Acute Kidney Injury|Terminated||Phase 2|427|Actual|Austin Health||2|||f||||t||||||||||2018-06-01 01:06:24.513638|2018-06-01 01:06:24.513638
NCT00878943|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2017-12-28|2009-04-08|2009-04-09|Estimate|||||||2017-12-28|2018-01-02|Actual||||December 2017|2017-12-31||||||||Expanded Access|UK 92480||Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study|A Local, Multi-centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study In India Or Ongoing In A1481269 Study Who Continue To Receive Benefit From Sildenafil Therapy.|No longer available|||||Pfizer|||||f||||||||||||||2018-06-01 01:06:24.610379|2018-06-01 01:06:24.610379
NCT00878930|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2011-01-04|2009-04-08|2009-04-09|Estimate|||||||2011-01-04|2011-01-05|Estimate|April 2009||2009-04-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|FRAME||Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer|Non-interventional Report on Parameters of Acceptability, Efficacy and Compliance of Fulvestrant in Post-menopausal Patients With Advanced Breast Cancer HR Positive Who Progresses to One Prior Endocrine Therapy With Antiestrogens|Completed|||500|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:06:24.71372|2018-06-01 01:06:24.71372
NCT00878917|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2010-02-11|2009-04-08|2009-04-09|Estimate|||||||2010-02-11|2010-02-12|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Equivalence Study of Dorzolamide 2% Eye Drops Solution|Randomized, Double-Masked, Active Controlled, Crossover Phase III Equivalence Study of Dorzolamide 2% Eye Drops Solution In Subjects With Open Angle Glaucoma Or Ocular Hypertension|Completed||Phase 3|32|Actual|Alfred E. Tiefenbacher (GmbH & Co. KG)||1|||f||||t||||||||||2018-06-01 01:06:24.829009|2018-06-01 01:06:24.829009
NCT00878904|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2017-03-21|2009-04-08|2009-04-09|Estimate|||||||2017-03-21|2017-03-24|Actual|September 13, 2009|Actual|2009-09-13|March 2017|2017-03-31|October 10, 2016|Actual|2016-10-10|May 2013|Actual|2013-05-31||Interventional|||Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors|A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies|Completed||Phase 1|40|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:06:25.044581|2018-06-01 01:06:25.044581
NCT00878891|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2018-01-19|2009-04-08|2009-04-09|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2009||2009-04-30|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MARGE||Real-time Continuous Glucose Monitoring in Diabetic Cardiothoracic Surgery Patients|Real Time Continuous Glucose Monitoring With Glucoday® as an Assistant for Intensive Insulin Therapy in Diabetic Cardiothoracic Surgery Patients: a Randomized Study Comparing Blood Glucose Measurements Alone or Associated to Continue Glucose Monitoring|Terminated||N/A|45|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:06:25.139147|2018-06-01 01:06:25.139147
NCT00878878|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2012-04-04||2012-07-19|2009-04-08|2009-04-09|Estimate|2012-07-19|2012-08-24|Estimate||||2012-07-19|2012-08-24|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).|A Phase 4, Placebo Controlled, Single-blind, Cross-over Safety Study to Evaluate the Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR) as Measured by Right Heart Catheterization|Completed||Phase 4|30|Actual|GE Healthcare||2|||f||||t||||||||||2018-06-01 01:06:25.244997|2018-06-01 01:06:25.244997
NCT00878865|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-11-23|2009-04-08|2009-04-09|Estimate|||||||2009-11-23|2009-11-25|Estimate|April 2009||2009-04-30|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets|Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets; an Open, Randomised, Single Centre, Single Dose Study With Crossover Design in Healthy Subjects|Completed||Phase 1|18|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 01:06:25.894183|2018-06-01 01:06:25.894183
NCT00878852|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-05-20|2009-04-08|2009-04-09|Estimate|||||||2009-05-20|2009-05-21|Estimate|April 2009||2009-04-30|May 2009|2009-05-31||||December 2010|Anticipated|2010-12-31||Interventional|||Efficacy of Contingency Management in the Treatment of Adolescents With Cannabis Use Disorders|Efficacy of a Contingency Management Program in the Treatment of Adolescents With Cannabis Use Disorders in a Child and Adolescent Psychiatry and Psychology Department|Unknown status|Recruiting|N/A|30|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 01:06:26.010676|2018-06-01 01:06:26.010676
NCT00878839|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2012-07-31|2009-04-08|2009-04-09|Estimate|||||||2012-07-31|2012-08-02|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Investigation of Corneal Aberrations and Visual Outcomes in Patients Implanted With an AcrySof Toric Intraocular Lens (IOL)||Withdrawn||N/A|0|Actual|Alcon Research||1||Product availability|f||||f||||||||||2018-06-01 01:06:26.175157|2018-06-01 01:06:26.175157
NCT00878826|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2013-06-21||2016-10-24|2009-04-08|2009-04-09|Estimate|2013-06-21|2013-09-05|Estimate||||2016-10-24|2016-12-16|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|August 2011|Actual|2011-08-31||Interventional||All participants in study.|Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.|Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.|Completed||Phase 2/Phase 3|11|Actual|Stanford University|Small numbers of subjects|3|||f||||f||||||||No||2018-06-01 01:06:26.331502|2018-06-01 01:06:26.331502
NCT00878813|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2011-11-09|2009-04-08|2009-04-09|Estimate|||||||2011-11-09|2011-11-10|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Observational|CoRisk||Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study|Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk-study|Completed|||1102|Actual|University Hospital Inselspital, Berne|||4||f||||f||||||Samples Without DNA|"~     In all patients: 5 ml serum~      In patients undergoing intra-arterial revascularisation: 10 ml serum~   "|||2018-06-01 01:06:27.105167|2018-06-01 01:06:27.105167
NCT00878800|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2014-07-07|2013-11-29|2015-07-07|2009-04-08|2009-04-09|Estimate|2014-12-17|2014-12-29|Estimate|2013-11-29|2013-12-25|Estimate|2015-07-07|2015-07-28|Estimate|December 2006||2006-12-31|July 2015|2015-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas|A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas|Completed||Phase 1/Phase 2|41|Actual|Onxeo||1|||f||||||||||||||2018-06-01 01:06:27.25973|2018-06-01 01:06:27.25973
NCT00878787|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2014-05-28|2009-04-08|2009-04-09|Estimate|||||||2014-05-28|2014-05-30|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Theta-burst Transcranial Magnetic Stimulation|Theta-burst Transcranial Magnetic Stimulation for the Treatment of Childhood Dystonia and Spasticity|Completed||N/A|5|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 01:06:31.035433|2018-06-01 01:06:31.035433
NCT00878774|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2010-11-09|2009-04-08|2009-04-09|Estimate|||||||2010-11-09|2010-11-10|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis|An Escalating, Multiple-dose Study in Ragweed Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Ragweed|Completed||Phase 2|50|Anticipated|Circassia Limited||5|||f||||f||||||||||2018-06-01 01:06:31.346091|2018-06-01 01:06:31.346091
NCT00878566|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2015-04-25|2009-04-08|2009-04-09|Estimate|||||||2015-04-25|2015-04-28|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|RxAction||Alberta Clinical Trial in Optimizing Hypertension|Alberta Clinical Trial in Optimizing Hypertension: The RxAction Study|Completed||N/A|248|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 01:06:45.322091|2018-06-01 01:06:45.322091
NCT00878761|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2011-05-20|2009-04-08|2009-04-09|Estimate|||||||2011-05-20|2011-05-23|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)|Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)|Withdrawn||Phase 2|48|Anticipated|Stromedix, Inc.||4|||f||||t||||||||||2018-06-01 01:06:31.670826|2018-06-01 01:06:31.670826
NCT00878748|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2010-09-21|2009-04-08|2009-04-09|Estimate|||||||2010-09-21|2010-09-22|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder|An Open Label, Prospective and Multi-center Recurrence Prevention Study With Effexor XR in MDD Patients in China|Withdrawn||Phase 4|0|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 01:06:31.929123|2018-06-01 01:06:31.929123
NCT00878735|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2014-06-06|2009-04-08|2009-04-09|Estimate|||||||2014-06-06|2014-06-09|Estimate|January 2008||2008-01-31|June 2014|2014-06-30||||January 2009|Actual|2009-01-31||Interventional|Sesshin||The Effects of a Meditation Retreat on Healthy Volunteers and Cancer Patients: an fMRI Study|The Effects of an Intensive Mindfulness Practice (Sesshin) on Neural Systems: an fMRI Evaluation of Healthy Volunteers and Cancer Patients|Completed||N/A|96|Actual|Hospital Israelita Albert Einstein||2|||f||||t||||||||||2018-06-01 01:06:32.135975|2018-06-01 01:06:32.135975
NCT00878722|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2014-06-27|2012-12-18|2015-07-06|2009-04-08|2009-04-09|Estimate|2014-11-12|2014-11-13|Estimate|2012-12-18|2012-12-21|Estimate|2015-07-06|2015-07-28|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|April 2012|Actual|2012-04-30|May 2009|Actual|2009-05-31||Interventional|||Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy|A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy|Completed||Phase 1/Phase 2|41|Actual|Onxeo||2|||f||||||||||||||2018-06-01 01:06:32.655138|2018-06-01 01:06:32.655138
NCT00878709|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2017-08-10|2013-11-12|2018-05-16|2009-04-08|2009-04-09|Estimate|2017-10-06|2017-10-09|Actual|2013-11-12|2013-12-05|Estimate|2018-05-16|2018-05-18|Actual|July 9, 2009|Actual|2009-07-09|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|August 21, 2014|Actual|2014-08-21||Interventional|ExteNET|Intent to treat (ITT) population included all participants who were randomized regardless of whether they received any study treatment.|Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer|Active, not recruiting||Phase 3|2840|Actual|Puma Biotechnology, Inc.||2|||f||||t|t|f||||||||2018-06-01 01:06:36.664916|2018-06-01 01:06:36.664916
NCT00878696|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-04-08|2009-04-08|2009-04-09|Estimate|||||||2009-04-08|2009-04-09|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|April 2008|Actual|2008-04-30|September 2007|Actual|2007-09-30||Observational|||Influence of Tonic and Burst Transcranial Magnetic Stimulation (TMS) Characteristics on Acute Inhibition of Subjective Tinnitus|Influence of Tonic and Burst TMS Characteristics on Acute Inhibition of Subjective Tinnitus|Completed|||64|Actual|University Hospital, Antwerp|||1||f||||f||||||||||2018-06-01 01:06:40.287497|2018-06-01 01:06:40.287497
NCT00878683|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2015-05-01|2009-04-08|2009-04-09|Estimate|||||||2015-05-01|2015-05-05|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Novel Device for Reducing Catheter-Related Infections|Exploring the Use of a Novel Device for Reducing Catheter-Related Bloodstream Infections|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||2||Never received IRB approval; Withdrawn before enrollment ever started|f||||f||||||||||2018-06-01 01:06:40.413612|2018-06-01 01:06:40.413612
NCT00878670|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2012-01-25|2009-04-08|2009-04-09|Estimate|||||||2012-01-25|2012-01-26|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Investigation of Efficacy and Safety of EPOGAM|Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study)|Completed||Phase 4|23|Actual|Max Zeller Soehne AG|||||f||||f||||||||||2018-06-01 01:06:40.508827|2018-06-01 01:06:40.508827
NCT00878657|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2014-05-01|2009-04-08|2009-04-09|Estimate|||||||2014-05-01|2014-05-05|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer|Phase I/II Radiotherapy Dose Escalation Study in Locally Advanced Pancreatic Cancer, Using a Simultaneous Intensity Modulated Boost With Concurrent Gemcitabine|Terminated||Phase 1|8|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||f||||||||||2018-06-01 01:06:40.876532|2018-06-01 01:06:40.876532
NCT00878644|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2017-05-24||2017-07-31|2009-04-08|2009-04-09|Estimate|2017-07-31|2017-09-29|Actual||||2017-07-31|2017-09-29|Actual|September 2009||2009-09-30|July 2017|2017-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|THAPCA-OH||Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial|Therapeutic Hypothermia After Pediatric Cardiac Arrest (Out of Hospital)|Completed||Phase 3|295|Actual|University of Michigan||2|||f||||t||||||||No||2018-06-01 01:06:41.682718|2018-06-01 01:06:41.682718
NCT00878631|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-04-08|2009-04-08|2009-04-09|Estimate|||||||2009-04-08|2009-04-09|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|December 2008|Actual|2008-12-31|January 2006|Actual|2006-01-31||Interventional|TOPHR HIT||Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline|The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial|Completed||Phase 2/Phase 3|113|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 01:06:44.067825|2018-06-01 01:06:44.067825
NCT00878618|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-06-02|2009-04-08|2009-04-09|Estimate|||||||2009-06-02|2009-06-03|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|||||Interventional|||Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837|A Phase I, Single-Centre, Open, Randomized, Two-Way Crossover Study to Evaluate the Pharmacokinetics of the Extended-Release Test Formulation of AZD0837 Compared to the Extended-Release AZD0837 Reference Formulation After Repeated Dosing in Healthy Volunteers|Completed||Phase 1|36|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:06:44.165041|2018-06-01 01:06:44.165041
NCT00878605|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2014-12-17||2015-01-26|2009-04-08|2009-04-09|Estimate|2015-01-26|2015-02-11|Estimate||||2015-01-26|2015-02-11|Estimate|April 2010||2010-04-30|January 2015|2015-01-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Development of A Novel Anti-Hyperglycemic Agent|Development of A Novel Anti-Hyperglycemic Agent|Terminated||Phase 2|38|Actual|VA Office of Research and Development|This subject was terminated early and data was not analyzed due to inability to recruit and therefore small numbers of subjects to analyze leading to uninterpretable data.|4||Unable to reach accrual target.|f||||t||||||||||2018-06-01 01:06:44.261377|2018-06-01 01:06:44.261377
NCT00878553|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2013-01-07||2013-01-30|2009-04-08|2009-04-09|Estimate|2013-01-30|2013-02-01|Estimate||||2013-01-30|2013-02-01|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Study of Sleep-maintenance Activity of 3 Doses of SKP-1041|A Phase 2, Double-Blind, Placebo-Controlled, Double-Dummy, Cross-Over Study to Investigate the Hypnotic Activity of Three Doses (10mg, 15mg, 20mg) of a New Zaleplon Prototype, SKP-1041, in Adults With Primary Insomnia|Completed||Phase 2|67|Actual|Somnus Therapeutics, Inc.|Questionnaires focused on initial insomnia as opposed to middle of the night awakening, short exposure to each dose, and lengthy washout periods between doses, may not allow for ideal assessment of subjective response to treatment.|4|||f||||f||||||||||2018-06-01 01:06:45.610137|2018-06-01 01:06:45.610137
NCT00878540|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2010-09-15|2009-04-08|2009-04-09|Estimate|||||||2010-09-15|2010-09-16|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SMMS||Short-term Metabolic Effects of Mirtazapine in Healthy Subjects|Phase 1 Study of Mirtazapine in Healthy Subjects|Completed||Phase 1|12|Anticipated|Max-Planck-Institute of Psychiatry||1|||f||||f||||||||||2018-06-01 01:06:47.859989|2018-06-01 01:06:47.859989
NCT00878527|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2018-05-24|2009-04-08|2009-04-09|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2007||2007-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Performance Evaluation of CircuLite Synergy|Safety and Performance Evaluation of the CircuLite Synergy Pocket Circulatory Assist Device|Active, not recruiting||N/A|63|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||t||||||||||2018-06-01 01:06:48.087607|2018-06-01 01:06:48.087607
NCT00878514|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-11-23|2009-04-08|2009-04-09|Estimate|||||||2009-11-23|2009-11-25|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions|Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions; an Open, Randomised, Single Centre, Single Dose Study With Crossover Design in Healthy Subjects|Completed||Phase 1|18|Anticipated|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 01:06:48.576867|2018-06-01 01:06:48.576867
NCT00878501|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2011-01-27||2012-05-28|2009-04-08|2009-04-09|Estimate|2012-04-25|2012-05-28|Estimate||||2012-05-28|2012-06-04|Estimate|March 2009||2009-03-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|OA19||Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee|A Phase II Randomised, Double-blind, Parallel Group, 4-week Treatment, Adaptive Dose Finding, Multi-centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee|Terminated||Phase 2|241|Actual|AstraZeneca||3||The study was terminated after the planned interim analysis.|f||||f||||||||||2018-06-01 01:06:49.006266|2018-06-01 01:06:49.006266
NCT00878475|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2009-04-08|2009-04-08|2009-04-09|Estimate|||||||2009-04-08|2009-04-09|Estimate|January 2005||2005-01-31|April 2009|2009-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Dyspnea and Biomarkers in a Prehospital Setting|Quantitative Capnometry and Nt-proBNP in Differentiating of Acute Dyspnea in Pre-Hospital Emergency Setting|Completed|||546|Actual|Health Care Center Maribor|||2||f||||f||||||||||2018-06-01 01:06:50.099069|2018-06-01 01:06:50.099069
NCT00878462|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2017-05-29|2009-04-08|2009-04-09|Estimate|||||||2017-05-29|2017-05-31|Actual|June 29, 2005|Actual|2005-06-29|May 2017|2017-05-31|October 15, 2005|Actual|2005-10-15|October 15, 2005|Actual|2005-10-15||Interventional|||An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)|A Randomized, Crossover Study Evaluating the Acceptability of Unflavored Asenapine and Raspberry Flavored Asenapine in Stable Subjects With A Psychotic Disorder|Completed||Phase 2|174|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:06:50.563316|2018-06-01 01:06:50.563316
NCT00878449|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2013-01-24|2009-04-08|2009-04-09|Estimate|||||||2013-01-24|2013-01-25|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer|A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer|Completed||Phase 1|12|Actual|AbbVie||1|||f||||||||||||||2018-06-01 01:06:50.953605|2018-06-01 01:06:50.953605
NCT00878436|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|2016-09-01||2018-01-10|2009-04-08|2009-04-09|Estimate|2017-10-30|2017-12-04|Actual||||2018-01-10|2018-02-07|Actual|June 2009||2009-06-30|January 2018|2018-01-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration|Phase I/II Randomized Trial of LBH589 (Panobinostat) at Two Dose Levels Combined With Bicalutamide (Casodex) in Men With Castration-resistant Prostate Cancer|Completed||Phase 1/Phase 2|52|Actual|New York University School of Medicine||2|||f||||t|t|f||||||||2018-06-01 01:06:51.750819|2018-06-01 01:06:51.750819
NCT00878423|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-08|||2014-05-07|2009-04-08|2009-04-09|Estimate|||||||2014-05-07|2014-05-08|Estimate|May 2008||2008-05-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|May 2013|Actual|2013-05-31||Interventional|||Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors|A Phase I Open-label Dose Escalation Study of AT13387 in Patients With Metastatic Solid Tumors|Completed||Phase 1|62|Actual|Astex Pharmaceuticals|||||f||||f||||||||||2018-06-01 01:06:53.623791|2018-06-01 01:06:53.623791
NCT00878397|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2014-04-09|2009-04-07|2009-04-08|Estimate|||||||2014-04-09|2014-04-10|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Impact of School-based Delivery of Long Lasting Insecticide Nets|Evaluating the Impact of Delivering Long Lasting Insecticide Nets Through Schools on Household Access and the Health of School Children in North Eastern Kenya|Completed||N/A|5113|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-06-01 01:06:53.940321|2018-06-01 01:06:53.940321
NCT00878384|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2012-07-11|2009-04-07|2009-04-08|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|ARC-HF||Catheter Ablation Versus Medical Rate Control for Atrial Fibrillation in Patients With Heart Failure|A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure|Completed||N/A|52|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 01:06:54.295765|2018-06-01 01:06:54.295765
NCT00878371|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2016-06-22|2009-04-07|2009-04-08|Estimate|||||||2016-06-22|2016-06-23|Estimate|May 2009||2009-05-31|June 2016|2016-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effects of a Surgery-induced Peripheral Inflammatory Response on the Blood Brain Barrier|Identification and Quantification of the Effects of a Surgery-induced Peripheral Inflammatory Response on Changes in Drug Efflux Transporter Function in the Brain|Completed||Phase 4|35|Actual|Nova Scotia Health Authority||1|||f||||f||||||||Yes|publication in process|2018-06-01 01:06:54.741032|2018-06-01 01:06:54.741032
NCT00878345|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-11-06|2009-04-07|2009-04-08|Estimate|||||||2009-11-06|2009-11-09|Estimate||||November 2009|2009-11-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation|Dexmedetomidine Versus Pentobarbital Sedation Protocol for Non-painful Procedural Sedation in Pediatrics|Withdrawn||N/A|120|Anticipated|Washington University School of Medicine||2||Study was never opened|f||||t||||||||||2018-06-01 01:06:55.660599|2018-06-01 01:06:55.660599
NCT00878332|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-04-07|2009-04-07|2009-04-08|Estimate|||||||2009-04-07|2009-04-08|Estimate|February 2009||2009-02-28|March 2009|2009-03-31|April 2011|Anticipated|2011-04-30|April 2010|Anticipated|2010-04-30||Observational|||"Histologic Evaluation of Bone Formation After Alveolar Augmentation by Sandwich Osteotomy Procedure for Dental Implants Insertion"|"Sandwich Osteotomy Histologic Evaluation"|Unknown status|Active, not recruiting||10|Anticipated|Hadassah Medical Organization|||1||f||||t||||||Samples Without DNA|"~     Histologic slides~   "|||2018-06-01 01:06:56.132347|2018-06-01 01:06:56.132347
NCT00878319|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2018-02-12|2009-04-07|2009-04-08|Estimate|||||||2018-02-12|2018-02-14|Actual|August 19, 2009|Actual|2009-08-19|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Operative and Nonoperative Treatment of Humeral Shaft Fractures|A Randomized Prospective Trial Comparing Operative and Nonoperative Treatment of Humeral Shaft Fractures|Recruiting||N/A|180|Anticipated|McGill University Health Center||2|||f||||f||||||||No||2018-06-01 01:06:56.449512|2018-06-01 01:06:56.449512
NCT00878306|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2014-05-04|2009-04-07|2009-04-08|Estimate|||||||2014-05-04|2014-05-06|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Disulfiram Interactions With HIV Medications: Clinical Implications|Disulfiram Interactions With HIV Medications: Clinical Implications|Completed||Phase 1|40|Actual|University of California, San Francisco||4|||f||||f||||||||||2018-06-01 01:06:56.978462|2018-06-01 01:06:56.978462
NCT00878293|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-08-19|2009-04-07|2009-04-08|Estimate|||||||2010-08-19|2010-08-20|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic|A Randomized Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Pain Due to Diabetic Polyneuropathy|Completed||Phase 2|90|Actual|Grünenthal GmbH||9|||f||||f||||||||||2018-06-01 01:06:57.407508|2018-06-01 01:06:57.407508
NCT00878280|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2011-04-21|2009-04-07|2009-04-08|Estimate|||||||2011-04-21|2011-04-22|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Copy Number Variations, Inflammatory Cytokines and the Risk of Dementia|Copy Number Variations, Expression of Inflammatory Cytokines and the Risk of Dementia - A Two-stage Genome-wide Association Study|Unknown status|Recruiting||700|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 01:06:57.759286|2018-06-01 01:06:57.759286
NCT00878267|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2011-09-20|2009-04-07|2009-04-08|Estimate|||||||2011-09-20|2011-09-21|Estimate|March 2009||2009-03-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: A Qualitative Study|A Qualitative Study of Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: Integrating PROs and Decision Support Into an Electronic Record|Completed|||9|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:06:57.91327|2018-06-01 01:06:57.91327
NCT00878254|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2018-02-07|2009-04-07|2009-04-08|Estimate|||||||2018-02-07|2018-02-08|Actual|March 25, 2009|Actual|2009-03-25|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma|Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma|Recruiting||Phase 2|22|Anticipated|University of Miami||1|||f||||t|t|f|||f|||||2018-06-01 01:06:58.238592|2018-06-01 01:06:58.238592
NCT00878241|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2011-02-23|2009-04-07|2009-04-08|Estimate|||||||2011-02-23|2011-02-24|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Compression Anastomosis Using the CAR™ 27||Completed||N/A|14|Actual|Bnai Zion Medical Center|||||f||||f||||||||||2018-06-01 01:06:58.531487|2018-06-01 01:06:58.531487
NCT00878228|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2012-07-23||2013-01-28|2009-04-07|2009-04-08|Estimate|2012-07-23|2012-08-28|Estimate||||2013-01-28|2013-01-31|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|PDNV||Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy|Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy|Completed||Phase 4|98|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-06-01 01:06:58.604809|2018-06-01 01:06:58.604809
NCT00878215|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2015-10-07||2018-01-16|2009-04-07|2009-04-08|Estimate|2018-01-16|2018-02-13|Actual||||2018-01-16|2018-02-13|Actual|October 24, 2002|Actual|2002-10-24|January 2018|2018-01-31|May 25, 2011|Actual|2011-05-25|May 25, 2011|Actual|2011-05-25||Interventional|||Clinical Application of Image-Guided Liver Surgery|Clinical Application of Image-Guided Liver Surgery|Terminated||Phase 2|40|Actual|Washington University School of Medicine||4||The image-guidance system became commercially available|f||||t|f|t|f|f|f|||No||2018-06-01 01:06:59.149327|2018-06-01 01:06:59.149327
NCT00878202|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2013-02-19|2009-04-07|2009-04-08|Estimate|||||||2013-02-19|2013-02-20|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SEDIC||Therapeutic Education by Telemedicine in Chronic Heart Failure|Impact of Clinical Follow-up and Therapeutic Education by Telemedicine in Chronic Heart Failure: a Randomized Multicenter Study.|Terminated||Phase 4|100|Actual|University Hospital, Caen||2||Insufficient recruitment|f||||t||||||||||2018-06-01 01:06:59.773745|2018-06-01 01:06:59.773745
NCT00878189|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2017-04-03|2009-04-06|2009-04-08|Estimate|||||||2017-04-03|2017-04-04|Actual|June 2009|Actual|2009-06-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|January 2013|Actual|2013-01-31||Interventional|||A Trial In Patients With Advanced Cancer And Leukemia|A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma|Completed||Phase 1|72|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:07:00.071433|2018-06-01 01:07:00.071433
NCT00878176|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-09-17|2009-04-07|2009-04-08|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2009||2009-06-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Sacral Neuromodulation Test With Bilateral First Stage Tined Lead Procedure in Patients With Non-obstructive Urinary Retention: A Pilot Study|Sacral Neuromodulation Test With Bilateral First Stage Tined Lead Procedure in Patients With Non-obstructive Urinary Retention: A Pilot Study|Unknown status|Recruiting|N/A|12|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 01:07:00.288607|2018-06-01 01:07:00.288607
NCT00878163|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2018-04-20|2009-04-07|2009-04-08|Estimate|||||||2018-04-20|2018-04-23|Actual|March 31, 2009|Actual|2009-03-31|April 2018|2018-04-30||||April 1, 2012|Actual|2012-04-01||Interventional|||GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery|Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine|Active, not recruiting||Phase 1|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:07:00.710114|2018-06-01 01:07:00.710114
NCT00878150|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2013-10-16|2009-04-07|2009-04-08|Estimate|||||||2013-10-16|2013-10-18|Estimate|September 2007||2007-09-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|LIFT||Life Improvement Following Traumatic Brain Injury|Cognitive Behavioral Therapy for Depression After Traumatic Brain Injury|Completed||N/A|100|Actual|University of Washington||3|||f||||f||||||||||2018-06-01 01:07:00.95271|2018-06-01 01:07:00.95271
NCT00878137|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2012-10-12|2009-04-06|2009-04-08|Estimate|||||||2012-10-12|2012-10-15|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin|INR Determined by Plasma-based Methods Versus Newer Point-of-care Instruments in Patients With Antiphospholipid-antibody Syndrome Treated With Anticoagulants|Completed|||63|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-06-01 01:07:01.189539|2018-06-01 01:07:01.189539
NCT00878124|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2010-01-11|2009-04-07|2009-04-08|Estimate|||||||2010-01-11|2010-01-12|Estimate|June 2009||2009-06-30|January 2010|2010-01-31||||||||Interventional|CoQ10||How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome|The Influence of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome in Intrauterine Insemination|Terminated||N/A|100|Anticipated|University of Toronto||2||Very low recruitment rate|f||||f||||||||||2018-06-01 01:07:01.531808|2018-06-01 01:07:01.531808
NCT00878111|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2015-10-08|2009-04-07|2009-04-08|Estimate|||||||2015-10-08|2015-10-09|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour|NGR013: Phase I and Pharmacodynamic Study of NGR-hTNF Administered at High Doses in Patients With Advanced or Metastatic Solid Tumour|Unknown status|Active, not recruiting|Phase 1|48|Anticipated|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 01:07:01.774436|2018-06-01 01:07:01.774436
NCT00878098|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2018-05-23|2009-04-07|2009-04-08|Estimate|||||||2018-05-23|2018-05-24|Actual|June 1, 2009||2009-06-01|August 7, 2017|2017-08-07||||||||Observational|||Study of DDT and Loss of Clinically-Recognized Pregnancies in South Africa|Study of DDT and Loss of Clinically Recognized Pregnancies in South Africa|Completed|||513|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:07:02.251131|2018-06-01 01:07:02.251131
NCT00878085|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2014-02-03|2009-04-07|2009-04-08|Estimate|||||||2014-02-03|2014-02-04|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Functional Magnetic Resonance Imaging (fMRI) and Robot-Assisted Practice of Activities of Daily Living|fMRI and Robot-Assisted Practice of Activities of Daily Living|Completed||Phase 1|61|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||||2018-06-01 01:07:02.489441|2018-06-01 01:07:02.489441
NCT00878072|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2012-05-01|2009-04-07|2009-04-08|Estimate|||||||2012-05-01|2012-05-02|Estimate|March 2009||2009-03-31|May 2012|2012-05-31||||June 2010|Actual|2010-06-30||Interventional|||Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis|A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis|Completed||Phase 2/Phase 3|53|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:07:03.165518|2018-06-01 01:07:03.165518
NCT00878059|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2013-10-14|2009-04-07|2009-04-08|Estimate|||||||2013-10-14|2013-10-16|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Alzheimer's Family Research|Proxy Decision Making for Alzheimer Disease Research|Completed|||165|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-06-01 01:07:03.658135|2018-06-01 01:07:03.658135
NCT00878046|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2016-04-20|2009-04-07|2009-04-08|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|March 2009|Actual|2009-03-31||Interventional|||Multi-centre Study to Assess Long-term Safety and Efficacy of the Silent™ Hip Prosthesis in Primary THR|A Non-comparative, Multi-centre Study to Evaluate the Safety and Efficacy of the DePuy Silent™ Hip Prosthesis in Primary Total Hip Replacement|Terminated||N/A|108|Actual|DePuy International||1||The Silent Hip has been rationalized for business reasons only|f||||f||||||||||2018-06-01 01:07:03.920385|2018-06-01 01:07:03.920385
NCT00878033|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2017-03-09|2009-04-07|2009-04-08|Estimate|||||||2017-03-09|2017-03-10|Actual|April 2009||2009-04-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients|Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients|Completed|||45|Actual|Martin-Luther-Universität Halle-Wittenberg|||3||f||||f||||||Samples Without DNA|"~     Serum Samples will be frozen for later Cytokine Sampling.~   "|||2018-06-01 01:07:04.113628|2018-06-01 01:07:04.113628
NCT00878020|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2011-02-22|2009-04-07|2009-04-08|Estimate|||||||2011-02-22|2011-02-23|Estimate|May 2009||2009-05-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety Study to Evaluate BMS-830216 in Healthy Subjects|Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-830216 (Pro-Drug of BMS-819881) in Healthy Subjects|Completed||Phase 1|48|Actual|Bristol-Myers Squibb||6|||f||||f||||||||||2018-06-01 01:07:04.322854|2018-06-01 01:07:04.322854
NCT00878007|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2014-02-14|2009-04-07|2009-04-08|Estimate|||||||2014-02-14|2014-02-17|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren|Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren|Completed||N/A|5177|Actual|London School of Hygiene and Tropical Medicine||4|||f||||t||||||||||2018-06-01 01:07:04.558627|2018-06-01 01:07:04.558627
NCT00877994|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2016-05-17|2009-04-07|2009-04-08|Estimate|||||||2016-05-17|2016-05-19|Estimate|April 2008||2008-04-30|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Nurture: A Program for Mothers With Histories of Disordered Eating|Breaking the Cycle of Risk: Intervention for Mothers With Eating Disorders|Completed||N/A|28|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 01:07:04.953182|2018-06-01 01:07:04.953182
NCT00877981|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-04-07|2009-04-07|2009-04-08|Estimate|||||||2009-04-07|2009-04-08|Estimate|February 2003||2003-02-28|April 2009|2009-04-30|October 2007|Actual|2007-10-31|April 2007|Actual|2007-04-30||Interventional|||Open Versus Video-Assisted Minimal-Invasive Parathyroid Surgery|Open Compared to Video-Assisted Minimal-Invasive Parathyroid Surgery in Primary Hyperparathyroidism|Completed||N/A|143|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 01:07:05.245065|2018-06-01 01:07:05.245065
NCT00877968|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-04-07|2009-04-07|2009-04-08|Estimate|||||||2009-04-07|2009-04-08|Estimate|March 2008||2008-03-31|April 2009|2009-04-30||||May 2008|Actual|2008-05-31||Interventional|||Glycemic Responses and Sensory Characteristics of Whole Yellow Pea Flour Added to Novel Functional Foods|Glycemic Responses and Sensory Characteristics of Whole Yellow Pea Flour Added to Novel Functional Foods|Completed||Phase 2|23|Actual|University of Manitoba||8|||f||||f||||||||||2018-06-01 01:07:05.55542|2018-06-01 01:07:05.55542
NCT00877955|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2015-03-11|2009-04-07|2009-04-08|Estimate|||||||2015-03-11|2015-03-12|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation|Open-label, Randomized, Single-dose, 2-way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet|Withdrawn||Phase 1|0|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:07:05.808855|2018-06-01 01:07:05.808855
NCT00877942|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2014-05-01|2009-04-07|2009-04-08|Estimate|||||||2014-05-01|2014-05-02|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Sex Differences in Early Brain Development; Brain Development in Turner Syndrome|Sex Differences in Early Brain Development; Brain Development in Turner Syndrome|Completed|||295|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     For participating children with Turner Syndrome, subjects may participate in an optional~     blood draw for DNA extraction and hormone assays.~   "|||2018-06-01 01:07:06.054789|2018-06-01 01:07:06.054789
NCT00877929|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2011-05-13||2014-02-10|2009-04-07|2009-04-08|Estimate|2011-05-13|2011-06-07|Estimate||||2014-02-10|2014-03-12|Estimate|February 2009||2009-02-28|February 2014|2014-02-28||||May 2010|Actual|2010-05-31||Interventional|||Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus|An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 + Amlodipine 10mg Versus Amlodipine 10 mg Monotherapy as First Line Therapy in Type 2 Diabetes Patients With Hypertension.|Completed||Phase 3|706|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:07:06.335525|2018-06-01 01:07:06.335525
NCT00877916|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2010-06-15|2009-04-07|2009-04-08|Estimate|||||||2010-06-15|2010-06-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:07:10.240079|2018-06-01 01:07:10.240079
NCT00877903|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2018-03-21|2009-04-07|2009-04-08|Estimate|||||||2018-03-21|2018-03-22|Actual|March 2009||2009-03-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|December 2011|Actual|2011-12-31||Interventional|||Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)|A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction|Completed||Phase 2|220|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-06-01 01:07:10.399742|2018-06-01 01:07:10.399742
NCT00877890|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|2012-02-14|2011-06-17|2015-03-19|2009-04-07|2009-04-08|Estimate|2012-05-16|2012-06-19|Estimate|2011-06-17|2011-06-27|Estimate|2015-03-19|2015-04-07|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)|A Randomized, Open-Label, Parallel-Group, Comparator-Controlled, Multicenter Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|254|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:07:10.823783|2018-06-01 01:07:10.823783
NCT00877877|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2011-03-31||2016-09-22|2009-04-07|2009-04-08|Estimate|2011-03-31|2011-04-27|Estimate||||2016-09-22|2016-09-23|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.|Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of a HPV Vaccine (GSK 580299) in Healthy Female Subjects|Completed||Phase 3|632|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:07:14.93687|2018-06-01 01:07:14.93687
NCT00877864|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2011-08-04|2009-04-07|2009-04-08|Estimate|||||||2011-08-04|2011-08-05|Estimate|February 2010||2010-02-28|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|DEAL||Diabetes Exercise and Lifestyle Trial|Diabetes Exercise and Lifestyle Trial|Unknown status|Active, not recruiting|Early Phase 1|26|Actual|University of Calgary||6|||f||||f||||||||||2018-06-01 01:07:16.903395|2018-06-01 01:07:16.903395
NCT00877851|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2011-08-19|2009-04-07|2009-04-08|Estimate|||||||2011-08-19|2011-08-22|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|LWD||Evaluation of an Interactive CD-ROM for People With Type 2 Diabetes|Development and Evaluation of an Interactive CD-ROM for People With Type 2 Diabetes (Evaluation Phase)|Completed||N/A|100|Anticipated|Queen's University, Belfast||2|||f||||f||||||||||2018-06-01 01:07:17.238756|2018-06-01 01:07:17.238756
NCT00877838|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-07-27|2009-04-07|2009-04-08|Estimate|||||||2009-07-27|2009-07-28|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|March 2010|Anticipated|2010-03-31||Interventional|||Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura|A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura|Unknown status|Recruiting|Phase 2|40|Anticipated|Danish Headache Center|||||f||||t||||||||||2018-06-01 01:07:17.533075|2018-06-01 01:07:17.533075
NCT00877825|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-07|2009-04-07|2009-04-08|Estimate|||||||2009-04-07|2009-04-08|Estimate||||April 2009|2009-04-30|April 2000|Actual|2000-04-30|||||Interventional|||The Influence of Soy Isoflavnoids on the Hypocholesterolemic Effects of Soy|The Influence of Soy Isoflavnoids on the Hypocholesterolemic Effects of Soy|Completed||Phase 2|||University of Toronto|||||f||||||||||||||2018-06-01 01:07:17.860986|2018-06-01 01:07:17.860986
NCT00877812|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-03-25|2009-04-07|2009-04-08|Estimate|||||||2013-03-25|2013-03-27|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Vitamin B6 Dependence of One-Carbon Metabolism|Vitamin B6 Dependence of One-Carbon Metabolism|Completed||N/A|45|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 01:07:18.068949|2018-06-01 01:07:18.068949
NCT00877799|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|2012-07-24||2015-04-23|2009-04-07|2009-04-08|Estimate|2015-04-23|2015-05-12|Estimate||||2015-04-23|2015-05-12|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 During the Post-Operative Period in Subjects Undergoing Laparoscopic-Assisted Hysterectomy|Completed||Phase 2|114|Actual|Cara Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 01:07:18.527001|2018-06-01 01:07:18.527001
NCT00877773|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2016-07-15||2016-07-15|2009-04-07|2009-04-08|Estimate|2016-07-15|2016-08-25|Estimate||||2016-07-15|2016-08-25|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients|Histology-Independent Study of the mTOR Inhibitor, Temsirolimus, in Patients With Advanced Cancer|Terminated||Phase 1/Phase 2|44|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-06-01 01:07:20.884495|2018-06-01 01:07:20.884495
NCT00877760|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2014-03-27|2009-04-07|2009-04-08|Estimate|||||||2014-03-27|2014-03-28|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ARES||Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B|Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a add-on Strategy for the Treatment of HBeAg-positive Chronic Hepatitis B|Completed||Phase 4|184|Actual|Foundation for Liver Research||2|||f||||f||||||||||2018-06-01 01:07:21.369409|2018-06-01 01:07:21.369409
NCT00877747|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2015-10-16|2009-04-07|2009-04-08|Estimate|||||||2015-10-16|2015-10-19|Estimate|January 2006||2006-01-31|October 2015|2015-10-31|October 2015|Anticipated|2015-10-31|November 2014|Actual|2014-11-30||Observational|||Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma|Early Chemotherapy Intensification With BEACOPP in High-risk, Interim-PET Positive Advanced-stage Hodgkin Lymphoma:a GITIL Retrospective Multicenter Clinical Study|Unknown status|Active, not recruiting||160|Actual|Ospedale Santa Croce-Carle Cuneo|||2||f||||f||||||||||2018-06-01 01:07:21.669954|2018-06-01 01:07:21.669954
NCT00877734|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2012-09-13|2009-04-07|2009-04-08|Estimate|||||||2012-09-13|2012-09-14|Estimate|April 2005||2005-04-30|April 2011|2011-04-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Tolerability of Baclofen for Alcohol Dependence|Phase IIIa Trial of Baclofen for Alcohol Dependence|Completed||Phase 2/Phase 3|80|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 01:07:21.956703|2018-06-01 01:07:21.956703
NCT00877721|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2010-09-19|2009-04-07|2009-04-08|Estimate|||||||2010-09-19|2010-09-21|Estimate|April 2010||2010-04-30|April 2009|2009-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Self Mobility Improvement in the Elderly by Counteracting Falls (SMILING)||Completed||N/A|30|Actual|Soroka University Medical Center||1|||f||||t||||||||||2018-06-01 01:07:22.283064|2018-06-01 01:07:22.283064
NCT00877708|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2017-06-08|2009-04-07|2009-04-08|Estimate|||||||2017-06-08|2017-06-09|Actual|March 2009||2009-03-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol|Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol|Active, not recruiting|||150|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     Biologic samples (isolates) will be under the control of the principal investigator of this~     research project. All samples provided to the investigator are de-identified by the honest~     broker and will be coded with numbers. The information linking these code numbers to the~     corresponding subjects' identities will be kept in a separate, secure location that only the~     honest broker has access to. The investigator on this study will keep the samples~     indefinitely. Samples will be kept in the investigator's laboratory located in Scaife Hall,~     room 839, 3550 Terrace Street. At no time with the research investigators have access to any~     patient identifers. Medical record information and bacteria samples from facilities outside~     of UPMC will be provided to the PI de-identified. At not time will anyone on the research~     team have access to patient identifiers. All information and bacteria are collected as part~     of the patient's clinical treatment.~   "|||2018-06-01 01:07:22.587188|2018-06-01 01:07:22.587188
NCT00877695|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2013-03-01|2009-04-07|2009-04-08|Estimate|||||||2013-03-01|2013-03-04|Estimate|August 2010||2010-08-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Motiv82Change||Motiv82Change: an HIV Prevention Study for Young Latino Men|"Young Hispanic Men Entre Culturas: Navigating Culture, Identity and HIV Risk"|Completed||N/A|200|Actual|Nova Southeastern University||4|||f||||t||||||||||2018-06-01 01:07:22.876026|2018-06-01 01:07:22.876026
NCT00877682|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2018-01-29|2009-04-07|2009-04-08|Estimate|||||||2018-01-29|2018-01-31|Actual|April 6, 2009|Actual|2009-04-06|January 2018|2018-01-31|January 14, 2018|Actual|2018-01-14|January 14, 2018|Actual|2018-01-14||Interventional|||Prostate Conformal Cryotherapy|Regional Cryoablation for Localized Adenocarcinoma of the Prostate|Completed||N/A|48|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:07:23.217646|2018-06-01 01:07:23.217646
NCT00877669|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2015-02-12|2009-04-07|2009-04-08|Estimate|||||||2015-02-12|2015-02-16|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Efficacy Study of HoLEP and TURP on LUTS Secondary to BPH|The Comparison of Efficacy Between Holmium Laser Enucleation of the Prostate (HoLEP) and Transurethral Resection of the Prostate (TURP) on the Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostate Hyperplasia (BPH)|Unknown status|Recruiting|Phase 2|116|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 01:07:23.580528|2018-06-01 01:07:23.580528
NCT00877656|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2012-11-20|2009-04-07|2009-04-08|Estimate|||||||2012-11-20|2012-11-22|Estimate|August 2005||2005-08-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|January 2006|Actual|2006-01-31||Interventional|||HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma|An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma|Completed||Phase 2/Phase 3|21|Actual|Emergent BioSolutions||1|||f||||f||||||||||2018-06-01 01:07:23.920669|2018-06-01 01:07:23.920669
NCT00877643|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2016-05-12|2009-04-07|2009-04-08|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|January 2021|Anticipated|2021-01-31|January 2017|Anticipated|2017-01-31||Interventional|RACE 3||Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure|Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3|Active, not recruiting||N/A|250|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-06-01 01:07:24.172648|2018-06-01 01:07:24.172648
NCT00877630|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-04-09|2009-04-07|2009-04-08|Estimate|||||||2009-04-09|2009-04-10|Estimate|September 2006||2006-09-30|April 2009|2009-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Minimal Invasiveness of Endoscopic Thyroidectomy|Minimal Invasiveness of Endoscopic Thyroidectomy|Completed|||||Second Military Medical University|||2||f||||||||||||||2018-06-01 01:07:24.688317|2018-06-01 01:07:24.688317
NCT00877617|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2012-07-26|2009-04-07|2009-04-08|Estimate|||||||2012-07-26|2012-07-30|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Quality of Life in Men With High Risk Localized Prostate Cancer|Assessment of Quality of Life in Men With High Risk Localized Prostate Cancer Undergoing Neoadjuvant Investigational Therapy|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1|Slow accrual|f||||f||||||||||2018-06-01 01:07:24.918055|2018-06-01 01:07:24.918055
NCT00877604|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|2014-10-31||2014-11-19|2009-04-07|2009-04-08|Estimate|2014-11-19|2014-11-26|Estimate||||2014-11-19|2014-11-26|Estimate|June 2008||2008-06-30|November 2014|2014-11-30|April 2012|Actual|2012-04-30|July 2011|Actual|2011-07-31||Interventional|TUDCA-ALS||Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis|A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis|Completed||Phase 2|34|Actual|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||2|||f||||t||||||||||2018-06-01 01:07:25.289457|2018-06-01 01:07:25.289457
NCT00877591|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2014-05-02|2009-04-07|2009-04-08|Estimate|||||||2014-05-02|2014-05-06|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications|Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications|Completed||Phase 1|63|Actual|University of California, San Francisco||6|||f||||f||||||||||2018-06-01 01:07:26.179967|2018-06-01 01:07:26.179967
NCT00877578|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2013-10-15|2009-04-07|2009-04-08|Estimate|||||||2013-10-15|2013-10-16|Estimate|April 2009||2009-04-30|October 2013|2013-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Nutri-PA||Efficacy of a Special Oral Nutritional Supplement on Nutritional Status of Malnourished Elderly Patients|Efficacy of a Special Oral Nutritional Supplement on Nutritional Status of Malnourished Elderly Patients|Completed||N/A|40|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-06-01 01:07:26.531524|2018-06-01 01:07:26.531524
NCT00877565|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-07|||2009-04-07|2009-04-07|2009-04-08|Estimate|||||||2009-04-07|2009-04-08|Estimate|February 2009||2009-02-28|April 2009|2009-04-30||||||||Observational|2DSonTOEcho||Global Longitudinal Peak Systolic Strain (GLPSS) Derived From Transesophageal Echocardiography - A Reliable Measure of Systolic Function?|Is Global Longitudinal Peak Systolic Strain (GLPSS) Derived From Transesophageal Echocardiography a Reliable Measure of Systolic Function? A Multicenter-Study to Compare GLPSS With Ejection Fraction Derived From Biplane Simpson´s Method on TTE and TEE in Patients Undergoing Elective Cardiac and Non-Cardiac Surgery|Unknown status|Recruiting||400|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-06-01 01:07:26.830772|2018-06-01 01:07:26.830772
NCT00877552|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2018-01-24|2009-04-07|2009-04-08|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2002||2002-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Prospective Studies of the Pathogenesis of Schizophrenia|Prospective Studies of the Pathogenesis of Schizophrenia (Center Title) Early Brain Development in High Risk Children (Project Title) Early Brain Development in One and Two Year Olds (Associated Grant Title)|Active, not recruiting|||600|Anticipated|University of North Carolina, Chapel Hill|||4||f||||f||||||Samples With DNA|"~     MRIs, buccal swabs, prenatal ultrasounds~   "|||2018-06-01 01:07:27.061585|2018-06-01 01:07:27.061585
NCT00877539|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2010-09-27|2009-04-06|2009-04-07|Estimate|||||||2010-09-27|2010-09-28|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects|A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.|Completed||Phase 1|29|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:07:27.313916|2018-06-01 01:07:27.313916
NCT00877526|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2016-11-21|2009-04-06|2009-04-07|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia|DiabCare Asia 2008 (Malaysia): A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia|Completed|||1670|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Capillary or venous blood will be drawn for analysing HbA1c.~   "|||2018-06-01 01:07:27.589051|2018-06-01 01:07:27.589051
NCT00877513|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2014-02-07|2009-04-06|2009-04-07|Estimate|||||||2014-02-07|2014-02-11|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Insulin Resistance in Smokers Undergoing Smoking Cessation|Insulin Resistance in Smokers Undergoing Smoking Cessation|Terminated||N/A|103|Actual|Charles Drew University of Medicine and Science||1||Funding expired|f||||t||||||||||2018-06-01 01:07:27.884738|2018-06-01 01:07:27.884738
NCT00877500|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2017-08-09|2009-04-06|2009-04-07|Estimate|||||||2017-08-09|2017-08-11|Actual|April 2009|Actual|2009-04-30|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease|A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-negative Breast Cancer|Active, not recruiting||Phase 2|116|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 01:07:28.163099|2018-06-01 01:07:28.163099
NCT00877487|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2011-07-06||2012-07-31|2009-04-06|2009-04-07|Estimate|2011-07-06|2011-08-02|Estimate||||2012-07-31|2012-08-07|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder|A Phase 4, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|123|Actual|Shire||2|||f||||||||||||||2018-06-01 01:07:28.55284|2018-06-01 01:07:28.55284
NCT00877474|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2015-11-03|2009-04-06|2009-04-07|Estimate|||||||2015-11-03|2015-11-04|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors|Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors|Completed||Phase 1|30|Actual|PharmaMar||1|||f||||f||||||||||2018-06-01 01:07:29.323261|2018-06-01 01:07:29.323261
NCT00877461|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-07|2009-04-06|2009-04-07|Estimate|||||||2009-04-07|2009-04-08|Estimate|May 2005||2005-05-31|April 2009|2009-04-30|December 2005|Actual|2005-12-31|November 2005|Actual|2005-11-30||Observational|||Glucose Monitor Accuracy Investigation (Ⅰ)|Glucose Monitor Accuracy Investigation (Ⅰ)|Completed|||308|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:07:29.565903|2018-06-01 01:07:29.565903
NCT00877448|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2012-08-01||2013-02-20|2009-04-06|2009-04-07|Estimate|2013-02-20|2013-03-27|Estimate||||2013-02-20|2013-03-27|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)|A Phase I/II, Randomized, Single-Blind, Placebo-Controlled Escalating Double-Dose Safety Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers|Completed||Phase 1/Phase 2|63|Actual|BiondVax Pharmaceuticals ltd.||7|||f||||t||||||||||2018-06-01 01:07:29.784154|2018-06-01 01:07:29.784154
NCT00877435|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2015-01-28|2009-04-06|2009-04-07|Estimate|||||||2015-01-28|2015-01-29|Estimate|September 2008||2008-09-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|August 2013|Actual|2013-08-31||Interventional|||Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial|Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial|Completed||N/A|60|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 01:07:31.7525|2018-06-01 01:07:31.7525
NCT00877422|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-07|2009-04-06|2009-04-07|Estimate|||||||2009-04-07|2009-04-08|Estimate|August 2008||2008-08-31|April 2009|2009-04-30||||||||Interventional|||Vitamin D Supplementation Prevents Elderly Pneumonia|Vitamin D Supplementation Prevents Pneumonia in Institutionalized Elderly Subjects|Completed||N/A|100|Actual|Tohoku University||3|||f||||f||||||||||2018-06-01 01:07:32.087466|2018-06-01 01:07:32.087466
NCT00877409|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|ACNASE||Safety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II|A Monocentric, Single-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of the Topical Drug Acnase Creme in the Treatment of Acne Vulgaris I and II|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Zurita Laboratorio Farmaceutico Ltda.||2|||f||||f||||||||||2018-06-01 01:07:32.397331|2018-06-01 01:07:32.397331
NCT00877396|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2011-09-27|2009-04-06|2009-04-07|Estimate|||||||2011-09-27|2011-09-28|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Hutterite Influenza Prevention Study|Does Vaccinating Health Hutterite Children Against Influenza Prevent Influenza in Other Hutterite Colony Members: A Randomized Cluster Trial|Completed||Phase 4|4771|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 01:07:32.779365|2018-06-01 01:07:32.779365
NCT00877383|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|2011-07-22||2011-08-23|2009-04-06|2009-04-07|Estimate|2011-07-22|2011-08-19|Estimate||||2011-08-23|2011-08-25|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|INTRUST2||Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1142|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:07:33.174328|2018-06-01 01:07:33.174328
NCT00877370|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|2012-08-29||2012-08-29|2009-04-06|2009-04-07|Estimate|2012-08-29|2012-09-28|Estimate||||2012-08-29|2012-09-28|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis|Pharmacokinetics of Invanz® (Ertapenem) in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis|Completed||Phase 4|8|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 01:07:34.854894|2018-06-01 01:07:34.854894
NCT00877357|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-05-05|2009-04-06|2009-04-07|Estimate|||||||2009-05-05|2009-05-06|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine|Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants|Unknown status|Recruiting|Phase 4|3000|Anticipated|Shantha Biotechnics Limited||3|||f||||f||||||||||2018-06-01 01:07:35.621297|2018-06-01 01:07:35.621297
NCT00877344|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2018-05-01|2009-04-06|2009-04-07|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2009||2009-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Better Contraceptive Choices: Immediate or Delayed Insertion of IUC After Second Trimester Abortion|Better Contraceptive Choices: Immediate vs. Delayed Insertion of Intrauterine Contraception After Second Trimester Abortion|Active, not recruiting||Phase 4|534|Actual|University of British Columbia||2|||f||||f||||||||No||2018-06-01 01:07:36.038084|2018-06-01 01:07:36.038084
NCT00877331|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2014-10-17|2009-04-06|2009-04-07|Estimate|||||||2014-10-17|2014-10-20|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|October 2013|Actual|2013-10-31||Interventional|||Brief Intervention in Primary Care for Problem Drug Use and Abuse|Brief Intervention in Primary Care for Problem Drug Use and Abuse|Completed||N/A|868|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 01:07:36.399162|2018-06-01 01:07:36.399162
NCT00877318|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2016-03-17|2009-04-06|2009-04-07|Estimate|||||||2016-03-17|2016-03-18|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|READ||Cardiac Rehabilitation of Heart Failure Patients by Telemedicine|Cardiac Rehabilitation of Heart Failure Patients by Telemedicine: a Randomized Multicenter Study.|Terminated||Phase 4|64|Actual|University Hospital, Caen||2||insufficient recruitment|f||||t||||||||||2018-06-01 01:07:36.760524|2018-06-01 01:07:36.760524
NCT00877305|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2012-01-17|2009-04-06|2009-04-07|Estimate|||||||2012-01-17|2012-01-18|Estimate|October 2008||2008-10-31|January 2012|2012-01-31||||November 2010|Actual|2010-11-30||Interventional|||Effect of Remote Ischemic Preconditioning on Cognitive Function After Cardiac Surgery||Completed||Phase 1|180|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-06-01 01:07:37.039188|2018-06-01 01:07:37.039188
NCT00877292|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2015-06-01|2009-04-06|2009-04-07|Estimate|||||||2015-06-01|2015-06-03|Estimate|February 2009||2009-02-28|June 2015|2015-06-30|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Observational|RNA||A New Prenatal Blood Test for Down Syndrome|The RNA (RNA-Based Noninvasive Aneuploidy) Study|Completed|||4664|Actual|Women and Infants Hospital of Rhode Island|||1||f||||f||||||Samples With DNA|"~     Fetal RNA and DNA in maternal plasma~   "|||2018-06-01 01:07:37.326561|2018-06-01 01:07:37.326561
NCT00877279|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03||2011-10-12|2013-10-23|2009-04-06|2009-04-07|Estimate||||2011-10-12|2011-10-21|Estimate|2013-10-23|2013-11-15|Estimate|November 2007||2007-11-30|October 2013|2013-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft|A Randomized,Blinded,Controlled,Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero® Soft, After Superficial to Mid Dermal Implantation for Correction of Mild Facial Wrinkles Over 4 Weeks.|Completed||Phase 3|64|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-06-01 01:07:37.67675|2018-06-01 01:07:37.67675
NCT00877266|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|August 2007||2007-08-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Ultrasound Guidance Versus Electrical Stimulation for Perineural Catheter Insertion|Ultrasound Guidance vs. Electrical Stimulation for Perineural Catheter Insertion: A Randomized, Controlled Trial|Completed||Phase 4|180|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 01:07:37.963591|2018-06-01 01:07:37.963591
NCT00877253|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2012-06-11|2009-04-06|2009-04-07|Estimate|||||||2012-06-11|2012-06-12|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer|Open-label, Multicenter, Phase I Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin as a Firstline Treatment in Subjects With Advanced Ovarian Cancer|Completed||Phase 1|18|Actual|Samyang Biopharmaceuticals Corporation||3|||f||||f||||||||||2018-06-01 01:07:38.243762|2018-06-01 01:07:38.243762
NCT00877240|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2016-03-15|2009-04-06|2009-04-07|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||The Influence of an Intervention Program on Altering Health Behavioral Patterns Among IDF's Staff||Withdrawn||N/A|0|Actual|Medical Corps, Israel Defense Force||1||lack of complaince|f||||||||||||||2018-06-01 01:07:38.515931|2018-06-01 01:07:38.515931
NCT00877227|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-05-05|2009-04-06|2009-04-07|Estimate|||||||2009-05-05|2009-05-06|Estimate|January 2003||2003-01-31|April 2009|2009-04-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Does B Vitamin Supplementation Decrease Homocysteine Concentrations in Newborns|Does Folinic Acid Supplementation Decrease Homocysteine Concentrations in Newborns|Completed||Phase 1|37|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:07:38.769191|2018-06-01 01:07:38.769191
NCT00877214|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2018-01-11|2009-04-06|2009-04-07|Estimate|||||||2018-01-11|2018-01-12|Actual|April 1, 2009|Actual|2009-04-01|January 2018|2018-01-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|MAINTAIN||Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas|Prospective Randomized Multicenter Study in First-line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas|Active, not recruiting||Phase 3|1272|Actual|University of Giessen||2|||f||||t||||||||No||2018-06-01 01:07:38.963316|2018-06-01 01:07:38.963316
NCT00877201|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-07|2009-04-06|2009-04-07|Estimate|||||||2009-04-07|2009-04-08|Estimate|March 2007||2007-03-31|April 2009|2009-04-30||||||||Interventional|||Improvement of Accommodation With Anti-Oxidant Supplementation in Visual Display Terminal Users||Completed||N/A|||Ryogoku Eye Clinic|||||f||||t||||||||||2018-06-01 01:07:39.366036|2018-06-01 01:07:39.366036
NCT00877188|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2012-12-20|2009-04-06|2009-04-07|Estimate|||||||2012-12-20|2012-12-21|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors|Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors: Upper Extremity Function, Quality of Life and Fitness Outcomes|Completed||N/A|34|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:07:39.585843|2018-06-01 01:07:39.585843
NCT00877175|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2012-03-07|2009-04-06|2009-04-07|Estimate|||||||2012-03-07|2012-03-09|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Comparison of Instillation and Packing in Mydriasis for Premature Infants|Comparison of Conventional Instillation and Lower Conjunctival Fornix Packing in Mydriasis for Premature Infants|Completed||Phase 4|25|Actual|Khon Kaen University||2|||f||||t||||||||||2018-06-01 01:07:39.87621|2018-06-01 01:07:39.87621
NCT00877162|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2012-06-18|2009-04-06|2009-04-07|Estimate|||||||2012-06-18|2012-06-20|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||The Rocky Sleep Study|Night Waking Reduction in Canadian Infants: A Randomized Controlled Clinical Trial of a Parent-based Cognitive and Behavioural Intervention in Community Health Units.|Completed||N/A|235|Actual|University of British Columbia||1|||f||||t||||||||||2018-06-01 01:07:40.222728|2018-06-01 01:07:40.222728
NCT00877149|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2012-05-03|2009-04-06|2009-04-07|Estimate|||||||2012-05-03|2012-05-04|Estimate|March 2009||2009-03-31|May 2012|2012-05-31||||April 2011|Actual|2011-04-30||Interventional|||Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B|A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B|Completed||Phase 4|80|Anticipated|Novartis||1|||f||||||||||||||2018-06-01 01:07:40.601406|2018-06-01 01:07:40.601406
NCT00877136|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2014-10-14|2009-04-06|2009-04-07|Estimate|||||||2014-10-14|2014-10-16|Estimate|February 2009||2009-02-28|October 2014|2014-10-31|February 2016|Anticipated|2016-02-29|February 2015|Anticipated|2015-02-28||Observational|||A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®|A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®|Unknown status|Recruiting||50|Anticipated|St. Joseph Hospital of Orange|||||f||||f||||||||||2018-06-01 01:07:40.916302|2018-06-01 01:07:40.916302
NCT00877123|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2011-11-09|2009-04-06|2009-04-07|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 2009||2009-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose|Prospective, Randomized, Double Blind Placebo Controled Clinical Trial to Assess the Effect of Vitamin D Supplementation on Fasting Glucose and IL-10 in Arab Women With Impaired Fasting Glucose.|Completed||Phase 4|74|Actual|Clalit Health Services||2|||f||||f||||||||||2018-06-01 01:07:41.29004|2018-06-01 01:07:41.29004
NCT00877110|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2018-05-01|2009-04-06|2009-04-07|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2, 2009|Actual|2009-04-02|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma|Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma|Active, not recruiting||Phase 1|71|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:07:41.586747|2018-06-01 01:07:41.586747
NCT00877097|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|July 1996||1996-07-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|December 2002|Actual|2002-12-31||Interventional|Osteo||Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women|Randomized Clinical Trial on the Effectts of Estradiol 2 mg + NETA 1 mg With or Without Clodronate on Bone Mineral Density and Bone Markers of Osteoporotic Postmenopausal 167 Finnish Women.|Completed||N/A|167|Actual|Kuopio University Hospital||3|||f||||f||||||||||2018-06-01 01:07:41.909379|2018-06-01 01:07:41.909379
NCT00877084|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|January 2004||2004-01-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2005|Actual|2005-12-31||Interventional|EXTRA||Exacerbation and Training in Patients With Chronic Obstructive Pulmonary Disease|Exacerbation and Training - Study; a Randomized Controlled Study of the Effect of Resistance Training in Acute Exacerbations of COPD|Completed||N/A|40|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 01:07:42.197257|2018-06-01 01:07:42.197257
NCT00877071|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-04|2016-01-08||2016-02-08|2009-04-06|2009-04-07|Estimate|2016-01-08|2016-02-08|Estimate||||2016-02-08|2016-03-11|Estimate|November 2008||2008-11-30|February 2016|2016-02-29|April 2012|Actual|2012-04-30|May 2011|Actual|2011-05-31||Interventional|HCC||LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed|LC Drug Eluting Bead for Regional Chemoembolization to Downstage Unresectable Hepatocellular Carcinoma (HCC) to Liver Transplantation|Completed||Phase 2|2|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:07:42.561044|2018-06-01 01:07:42.561044
NCT00877058|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|2013-10-30||2014-06-11|2009-04-06|2009-04-07|Estimate|2014-06-11|2014-07-15|Estimate||||2014-06-11|2014-07-15|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||SUPPORT FOR FRAIL ELDERLY PERSONS - From Prevention to Palliation|Elderly Persons at the Risk Zone - a Randomized Controlled Trial of a Community Based Preventive Multiprofessional Program for Old Persons at Risk of Frailty|Completed||N/A|459|Actual|Vardalinstitutet The Swedish Institute for Health Sciences||3|||f||||f||||||||||2018-06-01 01:07:43.302998|2018-06-01 01:07:43.302998
NCT00877045|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-08-03|2009-04-06|2009-04-07|Estimate|||||||2010-08-03|2010-08-04|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Observational|||Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting|Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting|Completed|||200|Actual|SCRI Development Innovations, LLC|||||f||||f||||||||||2018-06-01 01:07:44.643476|2018-06-01 01:07:44.643476
NCT00877032|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|2015-03-20||2015-03-20|2009-04-06|2009-04-07|Estimate|2015-03-20|2015-03-31|Estimate||||2015-03-20|2015-03-31|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Safety analysis population included all participants who received any amount of the single dose of either study drug or placebo.|Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration|A Phase I, Double-masked, Placebo-controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Single Escalating Doses Of Rn6g In Patients With Dry, Age-related Macular Degeneration (Amd)|Completed||Phase 1|57|Actual|Pfizer|Results for pharmacodynamic parameters [Cmax, Tmax and AUC (0-65d) of A beta(1-X)], are presented as absolute values at specified time points and not as change from baseline as planned.|1|||f||||f||||||||||2018-06-01 01:07:45.003873|2018-06-01 01:07:45.003873
NCT00877019|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|August 2007||2007-08-31|April 2009|2009-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|timebrush||Time Dependent Professional Toothbrushing Study|Time Dependent Professional Toothbrushing Study Comparing Sonicare With Manual Toothbrushes|Completed||N/A|90|Actual|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 01:07:48.356155|2018-06-01 01:07:48.356155
NCT00877006|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|2014-03-25|2013-08-08|2018-01-08|2009-04-06|2009-04-07|Estimate|2014-03-25|2014-04-28|Estimate|2013-08-08|2013-08-20|Estimate|2018-01-08|2018-02-05|Actual|April 30, 2009||2009-04-30|January 2018|2018-01-31|March 31, 2012|Actual|2012-03-31|March 31, 2012|Actual|2012-03-31||Interventional|||Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study|An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)|Completed||Phase 3|447|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 01:07:48.454592|2018-06-01 01:07:48.454592
NCT00876993|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2017-05-17|2009-04-06|2009-04-07|Estimate|||||||2017-05-17|2017-05-18|Actual|September 2008||2008-09-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors|A Phase I Study Of Irinotecan and Bevacizumab With Temozolomide in Children With Recurrent/Refractory Central Nervous System Tumors|Completed||Phase 1|26|Actual|Johns Hopkins All Children's Hospital||5|||f||||t||||||||||2018-06-01 01:07:51.058102|2018-06-01 01:07:51.058102
NCT00876980|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2013-10-15|2009-04-06|2009-04-07|Estimate|||||||2013-10-15|2013-10-16|Estimate|May 2008||2008-05-31|October 2013|2013-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Obstructive Sleep Apnea and Diabetes Mellitus|The Effect of Nasal Continuous Positive Airway Pressure Treatment on Glycemic Control and Vascular Function in Patients With Obstructive Sleep Apnea and Type II Diabetes Mellitus.|Completed||N/A|64|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-06-01 01:07:51.163191|2018-06-01 01:07:51.163191
NCT00876967|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2010-03-30|2009-04-06|2009-04-07|Estimate|||||||2010-03-30|2010-03-31|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|Laryngotest||Comparison of Three Laryngoscope Blades for Orotracheal Intubation in the Operating Room|Comparison of Performance of Three Laryngoscope Blades: Plastic Single Use, Metallic Single Use and Metallic Reusable Blades.|Completed||Phase 4|1040|Anticipated|University Hospital, Caen||3|||f||||t||||||||||2018-06-01 01:07:51.339761|2018-06-01 01:07:51.339761
NCT00876954|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2016-01-20|2009-04-06|2009-04-07|Estimate|||||||2016-01-20|2016-01-21|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Preoperative Hyperthermia in Major Abdominal Surgery Patients|Preoperative Whole-Body Hyperthermia in Patients Undergoing Major Abdominal Cancer Surgery: A Randomized Pilot Study|Completed||Phase 1/Phase 2|20|Actual|Medical University of Vienna||2|||f||||f||||||||Undecided|on request|2018-06-01 01:07:51.444572|2018-06-01 01:07:51.444572
NCT00876941|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2014-10-01|2009-04-06|2009-04-07|Estimate|||||||2014-10-01|2014-10-02|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|September 2014|Actual|2014-09-30|October 2012|Actual|2012-10-31||Interventional|ASPIRE||Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use|Efficacy/Effectiveness of Unhealthy Drug Use Screening/Brief Intervention Models|Completed||Phase 3|589|Actual|Boston Medical Center||3|||f||||f||||||||||2018-06-01 01:07:51.529346|2018-06-01 01:07:51.529346
NCT00876928|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|2012-07-03||2013-04-17|2009-04-06|2009-04-07|Estimate|2013-04-17|2013-06-14|Estimate||||2013-04-17|2013-06-14|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Vitamin D in Minorities With Prediabetes|Effect of Vitamin D Supplementation on Pre-Diabetes in a Minority Population|Completed||N/A|117|Actual|Charles Drew University of Medicine and Science||2|||f||||t||||||||||2018-06-01 01:07:51.644559|2018-06-01 01:07:51.644559
NCT00876915|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2015-07-24||2015-10-28|2009-04-03|2009-04-07|Estimate|2015-09-09|2015-10-12|Estimate||||2015-10-28|2015-11-24|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|PHACS||A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients|A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients|Terminated||Phase 3|218|Actual|University of Rochester||3||slow enrollment and lack of continuing funds|f||||t||||||||||2018-06-01 01:07:52.052321|2018-06-01 01:07:52.052321
NCT00876902|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|October 2009|Anticipated|2009-10-31|March 2009|Actual|2009-03-31||Interventional|YSPSL||YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation|A Controlled, Prospective, Blinded, Randomized, Single-Center, Study of YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation|Unknown status|Active, not recruiting|Phase 2|36|Actual|Y's Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 01:07:53.075379|2018-06-01 01:07:53.075379
NCT00876889|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2017-09-11|2009-04-06|2009-04-07|Estimate|||||||2017-09-11|2017-09-12|Actual|April 2010||2010-04-30|September 2017|2017-09-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Observational|||Safety of Riluzole in Patients With Acute Spinal Cord Injury|Safety and Pharmacokinetics of Riluzole in Patients With Traumatic Acute Spinal Cord Injury|Completed|||36|Actual|The Methodist Hospital System|||||f||||f||||||Samples Without DNA|"~     plasma and cerebral spinal fluid~   "|||2018-06-01 01:07:53.180408|2018-06-01 01:07:53.180408
NCT00876876|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-11-19|2009-04-06|2009-04-07|Estimate|||||||2010-11-19|2010-11-23|Estimate|July 2009||2009-07-31|November 2010|2010-11-30|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Interventional|||International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia|International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia|Withdrawn||Phase 3|300|Anticipated|CardioKine Inc.||2||Created Extension study - This study was no longer feasible|f||||||||||||||2018-06-01 01:07:53.27825|2018-06-01 01:07:53.27825
NCT00876863|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2017-01-06|2009-04-03|2009-04-07|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease|A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 2|50|Anticipated|Sangamo Therapeutics||2|||f||||t||||||||||2018-06-01 01:07:53.349366|2018-06-01 01:07:53.349366
NCT00876850|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2012-05-08|2009-04-06|2009-04-07|Estimate|||||||2012-05-08|2012-05-09|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|August 2010|Anticipated|2010-08-31|July 2010|Anticipated|2010-07-31||Interventional|||Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)|A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection|Withdrawn||Phase 3|0|Actual|Paratek Pharmaceuticals Inc||2||Terminated|f||||f||||||||||2018-06-01 01:07:53.435748|2018-06-01 01:07:53.435748
NCT00876837|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2017-08-02|2009-04-03|2009-04-07|Estimate|||||||2017-08-02|2017-08-03|Actual|March 1998||1998-03-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Long-term Outcomes and Life Satisfaction of Adults With Pediatric-Onset Spinal Cord Injuries|Long-term Outcomes and Life Satisfaction of Adults With Pediatric-Onset Spinal Cord Injuries|Recruiting|||600|Anticipated|Shriners Hospitals for Children|||1||f||||f||||||||||2018-06-01 01:07:53.622168|2018-06-01 01:07:53.622168
NCT00876824|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2011-06-01|2009-04-06|2009-04-07|Estimate|||||||2011-06-01|2011-06-02|Estimate|July 2009||2009-07-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar|A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar)|Completed||Phase 3|500|Actual|Bharat Serums and Vaccines Limited||2|||f||||t||||||||||2018-06-01 01:07:53.774168|2018-06-01 01:07:53.774168
NCT00876811|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-10-28|2009-04-03|2009-04-07|Estimate|||||||2010-10-28|2010-10-29|Estimate|March 2009||2009-03-31|October 2010|2010-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Red Raspberry Consumption on Fasting Oxidative Stress Biomarkers|Raspberries and Human Health: A Short-term Intervention Trial Investigating the Effect of Daily Red Raspberry Consumption on Fasting Oxidative Stress Biomarkers|Completed||Phase 1|24|Actual|University of Toronto||3|||f||||f||||||||||2018-06-01 01:07:54.006092|2018-06-01 01:07:54.006092
NCT00876798|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06||2011-06-20|2011-06-20|2009-04-06|2009-04-07|Estimate||||2011-06-20|2011-06-28|Estimate|2011-06-20|2011-06-28|Estimate|June 2009||2009-06-30|November 2010|2010-11-30||||November 2010|Actual|2010-11-30||Interventional|||A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia|Completed||Phase 3|206|Actual|CardioKine Inc.||2|||f||||t||||||||||2018-06-01 01:07:54.161339|2018-06-01 01:07:54.161339
NCT00876785|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-13|2009-04-06|2009-04-07|Estimate|||||||2009-04-13|2009-04-14|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Rye Bread Breakfasts on Eight Hour Satiety Ratings|Effect of Rye Bread Breakfasts on Subjective Hunger and Satiety|Completed||N/A|32|Actual|Swedish University of Agricultural Sciences||2|||f||||f||||||||||2018-06-01 01:07:54.487975|2018-06-01 01:07:54.487975
NCT00876772|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2011-03-23|2009-04-06|2009-04-07|Estimate|||||||2011-03-23|2011-03-24|Estimate|March 2011||2011-03-31|March 2011|2011-03-31||||July 2012|Anticipated|2012-07-31||Interventional|||Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)|Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS)|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 01:07:54.665183|2018-06-01 01:07:54.665183
NCT00876759|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|July 2013|Anticipated|2013-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Whole-Brain Radiotherapy (WBRT) Versus WBRT and Integrated Boost Using Helical Tomotherapy for Multiple Brain Metastases|Whole-Brain Radiotherapy (WBRT) vs. WBRT and Integrated Boost Using Helical Tomotherapy for Patients With Multiple Brain Metastases - a Multicentre Randomized Phase II Trial|Unknown status|Recruiting|Phase 2|160|Anticipated|University Hospital, Essen||2|||f||||t||||||||||2018-06-01 01:07:54.812205|2018-06-01 01:07:54.812205
NCT00876746|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-06-14|2009-04-06|2009-04-07|Estimate|||||||2010-06-14|2010-06-15|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Optimization of Catheter Insertion Site for Continuous Peripheral Nerve Blocks|Optimization of Catheter Insertion Site for Continuous Peripheral Nerve Blocks|Completed||Phase 4|60|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 01:07:54.965533|2018-06-01 01:07:54.965533
NCT00876733|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2014-12-27||2015-01-14|2009-04-06|2009-04-07|Estimate|2015-01-14|2015-01-16|Estimate||||2015-01-14|2015-01-16|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||Treated set (TS): This patient set includes all HIV-1 infected patients who were dispensed Viramune® and were documented to have taken at least one dose of Viramune®and of a antiretroviral combination partner.|Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients|Non-Interventional Observational Study With Viramune Plus ARV in HIV Infected Patients|Completed|||605|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 01:07:55.104417|2018-06-01 01:07:55.104417
NCT00876720|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2010-11-12|2009-04-06|2009-04-07|Estimate|||||||2010-11-12|2010-11-15|Estimate|April 2009||2009-04-30|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effectiveness Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Chronic Tinnitus|Effectiveness of Combined Frontal and Temporal Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Chronic Tinnitus|Completed||N/A|100|Anticipated|University of Regensburg||2|||f||||f||||||||||2018-06-01 01:07:56.593247|2018-06-01 01:07:56.593247
NCT00876707|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-07-01|2009-04-06|2009-04-07|Estimate|||||||2010-07-01|2010-07-02|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|IOL||Wavefront Analyzes and Visual Performance of Three Multifocal Intra-ocular Lenses|Phase 1 Study of Ocular Aberrations and Visual Performance of Eyes Implanted With Three Multifocal Intra-ocular Lenses|Completed||Phase 1/Phase 2|60|Anticipated|University of Sao Paulo||3|||f||||||||||||||2018-06-01 01:07:56.709343|2018-06-01 01:07:56.709343
NCT00876694|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|2011-10-04||2011-10-04|2009-04-06|2009-04-07|Estimate|2011-10-04|2011-11-08|Estimate||||2011-10-04|2011-11-08|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Efficacy of Indacaterol (300 µg o.d.) Using Salmeterol (50 µg b.i.d.) as an Active Control in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|186|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:07:56.919054|2018-06-01 01:07:56.919054
NCT00876681|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-10-07|2009-04-06|2009-04-07|Estimate|||||||2009-10-07|2009-10-08|Estimate|April 2008||2008-04-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Ultrasound Guidance Versus Electrical Stimulation for Continuous Popliteal-Sciatic Nerve Blocks|Ultrasound Guidance Versus Electrical Stimulation for Continuous Popliteal-Sciatic Nerve Blocks: A Randomized, Controlled Trial|Completed||Phase 4|80|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 01:07:57.539878|2018-06-01 01:07:57.539878
NCT00876668|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|June 2007||2007-06-30|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|December 2008|Actual|2008-12-31||Observational|||Evaluation of the Clinical Significance of Fluorescence Videoangiography With Indocyanine-Green|Pilot-Study to Evaluate the Clinical Significance of the Fluorescence Videoangiography With Indocyanine-Green in Patients With PAD, Rutherford Classification II-V, and Relation to Common Diagnostics.|Unknown status|Active, not recruiting||25|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-06-01 01:07:57.653789|2018-06-01 01:07:57.653789
NCT00876655|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2016-05-02|2009-04-06|2009-04-07|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate|An Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Sequence, Crossover, Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of TR-701 (Torezolid Phosphate) in Normal Healthy Adults|Completed||Phase 1|12|Actual|Trius Therapeutics LLC||2|||f||||f||||||||||2018-06-01 01:07:57.737801|2018-06-01 01:07:57.737801
NCT00876642|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-05|||2009-04-06|2009-04-06|2009-04-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Trial Comparing Best Supportive Care to Aloe Vera Gel|Phase III Trial Comparing Best Supportive Care to Aloe Vera Gel as a Prophylactic Agent for Radiation Induced Skin Toxicity|Completed||Phase 3|137|Actual|Marilia Medicine School||2|||f||||t||||||||||2018-06-01 01:07:57.813408|2018-06-01 01:07:57.813408
NCT00876629|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-08-18|2009-04-06|2009-04-07|Estimate|||||||2009-08-18|2009-08-19|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|MRE_Rénale||Renal Magnetic Resonance (MR) Elastography in Healthy Volunteers|Renal MR Elastography: Normal Findings and Variability of Stiffness Measurements|Completed||N/A|10|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-06-01 01:07:57.90361|2018-06-01 01:07:57.90361
NCT00876616|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2013-08-28|2009-04-06|2009-04-07|Estimate|||||||2013-08-28|2013-08-29|Estimate|April 2009||2009-04-30|August 2013|2013-08-31|February 2012|Actual|2012-02-29|May 2011|Actual|2011-05-31||Interventional|||Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis|An Multi-site, Open, Prospective Study to Assess the Efficacy and Safety of Multi-target Therapy in the Treatment of Class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis|Completed||N/A|362|Actual|Nanjing University School of Medicine||2|||f||||t||||||||||2018-06-01 01:07:58.009083|2018-06-01 01:07:58.009083
NCT00876603|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2010-01-12|2009-04-06|2009-04-07|Estimate|||||||2010-01-12|2010-01-14|Estimate|May 2001||2001-05-31|January 2010|2010-01-31|December 2020|Anticipated|2020-12-31|December 2010|Anticipated|2010-12-31||Observational|CSM||Anterior Vs Posterior Procedures for Cervical Spondylotic Myelopathy: Prospective Randomized Clinical Trial|A Comparison of Anterior and Posterior Procedures for the Surgical Management of Cervical Spondylotic Myelopathy: Prospective Randomized Clinical Trial|Recruiting|||100|Anticipated|The University of Hong Kong|||4||f||||t||||||||||2018-06-01 01:07:58.120078|2018-06-01 01:07:58.120078
NCT00876590|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-06|||2009-04-07|2009-04-06|2009-04-07|Estimate|||||||2009-04-07|2009-04-08|Estimate|April 2006||2006-04-30|April 2009|2009-04-30|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Observational|||Glucose Monitor Accuracy Investigation (Ⅱ)|Glucose Monitor Accuracy Investigation (Ⅱ)|Completed|||319|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:07:58.240512|2018-06-01 01:07:58.240512
NCT00876577|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2012-09-07|2009-04-03|2009-04-06|Estimate|||||||2012-09-07|2012-09-10|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|VICTOR||VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis|VICTOR - Avelox® i.v. in Acute Exacerbations of Chronic Bronchitis|Completed|||1206|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 01:07:58.307006|2018-06-01 01:07:58.307006
NCT00876564|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2013-05-07|2009-04-03|2009-04-06|Estimate|||||||2013-05-07|2013-05-08|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|RTSS||Rogaland Trauma System Study|Trauma System Evolution. A Quality Improvement Study of the Trauma System at Stavanger University Hospital, Norway.|Completed||N/A|1812|Actual|Norwegian Air Ambulance Foundation||1|||f||||f||||||||||2018-06-01 01:07:58.434422|2018-06-01 01:07:58.434422
NCT00876551|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-05-25|2009-04-03|2009-04-06|Estimate|||||||2010-05-25|2010-05-26|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|EVACoIL||Endoscopic-vacuum Assisted Closure of Intrathoracic Postsurgical Leaks|Endoscopic - Vacuum Assisted Closure of Intrathoracic Postsurgical Leaks|Unknown status|Recruiting|N/A|30|Anticipated|Hannover Medical School||1|||f||||f||||||||||2018-06-01 01:07:58.52478|2018-06-01 01:07:58.52478
NCT00876538|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2016-11-21|2009-04-03|2009-04-06|Estimate|||||||2016-11-21|2016-11-22|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|CIPN||Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy|A Double Blind, Placebo Controlled Study of the Effect of 330 mg QD of TRO19622 in the Treatment of Chemotherapy Induced Peripheral Neuropathy|Completed||Phase 2|17|Actual|Hoffmann-La Roche||2|||f||||f||||||||||2018-06-01 01:07:58.652245|2018-06-01 01:07:58.652245
NCT00876525|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2016-11-30|2009-04-03|2009-04-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|December 2013|Actual|2013-12-31||Interventional|||Clinical Investigation of the Freedom SOLO Stentless Heart Valve|Clinical Investigation of the Freedom SOLO Stentless Heart Valve|Active, not recruiting||N/A|700|Anticipated|LivaNova||1|||f||||t||||||||||2018-06-01 01:07:58.775263|2018-06-01 01:07:58.775263
NCT00876512|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2014-09-08|2009-04-03|2009-04-06|Estimate|||||||2014-09-08|2014-09-10|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|CALDERA-PCI||CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study|CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study|Completed|||104|Actual|Kumamoto University|||||f||||f||||||Samples With DNA|"~     CYP2C19 gene alteration is measured by using whole blood in patients with stable effort~     angina undergoing PCI.~   "|||2018-06-01 01:07:58.917482|2018-06-01 01:07:58.917482
NCT00876499|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2015-01-07|2009-04-03|2009-04-06|Estimate|||||||2015-01-07|2015-01-09|Estimate|January 2009||2009-01-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients|Relationship Among Fatigue, Symptoms, Melatonin and Sleep in PBT Patients Undergoing Radiation Therapy|Completed|||20|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:07:58.994625|2018-06-01 01:07:58.994625
NCT00876486|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2017-04-27|2009-04-03|2009-04-06|Estimate|||||||2017-04-27|2017-05-01|Actual|December 2008|Actual|2008-12-31|April 2017|2017-04-30|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional|||Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer|A Open-label, Randomized, Parallel, Phase III Trial to Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol®(Conventional Paclitaxel With Cremorphor EL) in Subjects With Recurrent or Metastatic Breast Cancer|Completed||Phase 3|213|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||f||||||||||2018-06-01 01:07:59.090694|2018-06-01 01:07:59.090694
NCT00876473|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2015-04-27|2009-04-03|2009-04-06|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Evaluation of Different Continuous Positive Airway Pressure (CPAP) Systems in Patients With Acute Respiratory Failure|The CPAP in Patients Affected by Acute Respiratory Failure|Completed|||30|Actual|Policlinico Hospital|||1||f||||f||||||||||2018-06-01 01:07:59.201983|2018-06-01 01:07:59.201983
NCT00876460|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2014-11-14||2016-09-27|2009-04-03|2009-04-06|Estimate|2014-11-28|2014-12-04|Estimate||||2016-09-27|2016-11-17|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|September 2012|Actual|2012-09-30||Interventional||Treated set: all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment|BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I|A Phase I Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Docetaxel - a Phase I, Open-label, Dose-escalation Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy|Completed||Phase 1|43|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 01:07:59.476372|2018-06-01 01:07:59.476372
NCT00876447|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2014-06-12||2014-06-12|2009-04-03|2009-04-06|Estimate|2014-06-12|2014-07-14|Estimate||||2014-06-12|2014-07-14|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional||BOTOX-Treated population includes all patients who enrolled in this study and who received at least one BOTOX treatment, regardless of which study they received it in (study 191622-094 or their preceding study 191622-515 or 191622-516). The treatment groups are based on the first BOTOX dose that patients received.|A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis||Completed||Phase 3|397|Actual|Allergan||2|||f||||f||||||||||2018-06-01 01:08:02.051591|2018-06-01 01:08:02.051591
NCT00876434|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2017-06-30|2009-04-03|2009-04-06|Estimate|||||||2017-06-30|2017-07-02|Actual|April 1, 2009||2009-04-01|February 10, 2011|2011-02-10|February 10, 2011|Actual|2011-02-10|February 10, 2011|Actual|2011-02-10||Interventional|||Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti|Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveitis|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:08:10.372083|2018-06-01 01:08:10.372083
NCT00876421|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2012-06-12|2009-04-03|2009-04-06|Estimate|||||||2012-06-12|2012-06-14|Estimate|April 2009||2009-04-30|June 2012|2012-06-30||||April 2010|Actual|2010-04-30||Interventional|||Study of ONO-8539 in Patients With Overactive Bladder|A Randomised, Multi-Centre, Double-Blind, Placebo and Active-Controlled, 5-Way Parallel Group Study to Investigate the Efficacy, Safety and Tolerability of ONO-8539 in Patients With Overactive Bladder|Completed||Phase 2|435|Actual|Ono Pharmaceutical Co. Ltd||5|||f||||||||||||||2018-06-01 01:08:10.46677|2018-06-01 01:08:10.46677
NCT00876408|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2013-12-03|2009-04-03|2009-04-06|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Observational|||Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer|Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer: Role in Clinical Management and Primary Site Prediction|Completed|||30|Actual|SCRI Development Innovations, LLC|||||f||||f||||||||||2018-06-01 01:08:10.766033|2018-06-01 01:08:10.766033
NCT00876200|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2016-01-20|2009-04-03|2009-04-06|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|Williams||Efficacy of Minoxidil in Children With Williams-Beuren Syndrome|The Efficacy of Minoxidil in Children With Williams-Beuren Syndrome: a Randomized Clinical Trial.|Completed||Phase 2|21|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 01:08:13.36749|2018-06-01 01:08:13.36749
NCT00876395|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-05-04|2009-04-03|2009-04-06|Estimate|||||||2018-05-04|2018-05-07|Actual|September 10, 2009|Actual|2009-09-10|May 2018|2018-05-31|October 13, 2017|Actual|2017-10-13|May 30, 2014|Actual|2014-05-30||Interventional|BOLERO-1||Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer|A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer|Completed||Phase 3|719|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:08:10.878195|2018-06-01 01:08:10.878195
NCT00876382|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2013-11-12|2009-04-03|2009-04-06|Estimate|||||||2013-11-12|2013-11-14|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Observational|||Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma|Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma|Completed|||47|Actual|SCRI Development Innovations, LLC|||||f||||f||||||||||2018-06-01 01:08:11.338895|2018-06-01 01:08:11.338895
NCT00876369|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2017-08-30|2009-04-03|2009-04-06|Estimate|||||||2017-08-30|2017-09-01|Actual|September 2009||2009-09-30|August 2017|2017-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema|Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema|Completed|||50|Actual|University of Nebraska|||2||f||||f||||||||||2018-06-01 01:08:11.421765|2018-06-01 01:08:11.421765
NCT00876356|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-03|2009-04-03|2009-04-06|Estimate|||||||2009-04-03|2009-04-06|Estimate|May 2002||2002-05-31|April 2009|2009-04-30|September 2004|Actual|2004-09-30|May 2002|Actual|2002-05-31||Interventional|||The Health Benefits of Conjugated Linoleic Acid (CLA) for Asthma & Allergy|Conjugated Linoleic Acid (CLA) as Adjunctive Therapy in Mild Asthmatics: A Pilot Study.|Completed||N/A|40|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:08:11.503417|2018-06-01 01:08:11.503417
NCT00876343|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2013-12-20||2013-12-20|2009-04-03|2009-04-06|Estimate|2013-12-20|2014-02-10|Estimate||||2013-12-20|2014-02-10|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder|Placebo-Controlled, Double-Blind, Parallel Group-Comparison Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder|Completed||Phase 3|586|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-06-01 01:08:11.623435|2018-06-01 01:08:11.623435
NCT00876330|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2012-09-19|2009-04-03|2009-04-06|Estimate|||||||2012-09-19|2012-09-20|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|CERT2||Improving Antihypertensive and Lipid-Lowering Therapy|CERT-HIT: A Multimodal Intervention to Improve Antihypertensive and Lipid-lowering Therapy|Unknown status|Active, not recruiting|N/A|6000|Anticipated|VA Boston Healthcare System||2|||f||||f||||||||||2018-06-01 01:08:12.238316|2018-06-01 01:08:12.238316
NCT00876317|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2012-06-29|2009-04-03|2009-04-06|Estimate|||||||2012-06-29|2012-07-03|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder|Efficacy and Safety of Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder|Terminated||Phase 3|45|Actual|Clinica Virgen Milagrosa||2||Change in current areas of research interest of the collaborator|f||||t||||||||||2018-06-01 01:08:12.345435|2018-06-01 01:08:12.345435
NCT00876304|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-03-17|2009-04-03|2009-04-06|Estimate|||||||2010-03-17|2010-03-19|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia|Phase 1, Investigator And Subject-Blind, Placebo-Controlled, Randomized, Sequential Group, Multiple Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04802540 In Patients With Schizophrenia|Completed||Phase 1|39|Actual|Taisho Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:08:12.466946|2018-06-01 01:08:12.466946
NCT00876291|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2011-01-31|2009-04-03|2009-04-06|Estimate|||||||2011-01-31|2011-02-01|Estimate|December 2004||2004-12-31|April 2009|2009-04-30|August 2008|Actual|2008-08-31|December 2007|Actual|2007-12-31||Interventional|LGGDAR||Efficacy of Lactobacillus GG (LGG) in Children With Abdominal Pain|The Use of Lactobacillus gg in Functional Abdominal Pain in Children: a Double-blind Randomized Control Trial|Completed||N/A|140|Actual|University of Bari||2|||f||||t||||||||||2018-06-01 01:08:12.558557|2018-06-01 01:08:12.558557
NCT00876278|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2013-11-27|2009-04-03|2009-04-06|Estimate|||||||2013-11-27|2013-11-28|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|February 2010|Anticipated|2010-02-28|October 2009|Anticipated|2009-10-31||Interventional|||Night Driving Pilot|Prospective Clinical Study to Evaluate Usability of Mesotest II for Assessment of Night Driving Capacity of Pseudophakic Patients Implanted With Monofocal IOL *AT.Smart 46LC|Withdrawn||Phase 4|0|Actual|Carl Zeiss Meditec AG||1||Due to internal reasons study was not performed.|f||||f||||||||||2018-06-01 01:08:12.68738|2018-06-01 01:08:12.68738
NCT00876265|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|2011-12-13||2013-04-19|2009-04-03|2009-04-06|Estimate|2011-12-13|2012-01-19|Estimate||||2013-04-19|2013-04-26|Estimate|December 2006||2006-12-31|April 2013|2013-04-30|December 2008|Actual|2008-12-31|July 2007|Actual|2007-07-31||Interventional|||Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®.|A Randomized, Blinded, Controlled, Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero®, After Mid-to-Deep Dermal Implantation for Correction of Moderate to Severe Facial Wrinkles|Completed||Phase 3|118|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-06-01 01:08:12.786368|2018-06-01 01:08:12.786368
NCT00876252|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2012-10-18|2009-04-03|2009-04-06|Estimate|||||||2012-10-18|2012-10-19|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients|A Phase 2 Pilot Study Assessing Immunogenicity and Safety of IC43 in Intensive Care Patients|Completed||Phase 2|400|Actual|Valneva Austria GmbH||4|||f||||t||||||||||2018-06-01 01:08:12.969232|2018-06-01 01:08:12.969232
NCT00876226|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2014-05-19|2009-04-03|2009-04-06|Estimate|||||||2014-05-19|2014-05-20|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome|Study to Determine Steady-state Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome|Withdrawn||N/A|0|Actual|University of Nebraska|||||f||||t||||||||||2018-06-01 01:08:13.068835|2018-06-01 01:08:13.068835
NCT00876187|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03||2011-07-19|2011-07-19|2009-04-03|2009-04-06|Estimate||||2011-07-19|2011-07-22|Estimate|2011-07-19|2011-07-22|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||A Study of Tanezumab in Adults With Chronic Low Back Pain|A Randomized, Double-Blind, Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effects of Tanezumab in Adult Patients With Chronic Low Back Pain|Completed||Phase 2|1359|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 01:08:13.569979|2018-06-01 01:08:13.569979
NCT00876174|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2010-01-11|2009-04-03|2009-04-06|Estimate|||||||2010-01-11|2010-01-12|Estimate|May 2009||2009-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|||||Observational|||Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C|Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C|Terminated|||30|Anticipated|University of Nebraska|||2|no accrual|f||||f||||||Samples Without DNA|"~     20 ml blood for peripheral mononuclear cells~   "|||2018-06-01 01:08:13.880321|2018-06-01 01:08:13.880321
NCT00876161|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-02-02|2009-04-03|2009-04-06|Estimate|||||||2010-02-02|2010-02-03|Estimate|April 2009||2009-04-30|February 2010|2010-02-28||||December 2009|Actual|2009-12-31||Interventional|||DAS181 Single Dose Escalation Study in Healthy Adults|Phase 1 Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study in Healthy Adults|Completed||Phase 1|45|Actual|Ansun Biopharma, Inc.||2|||f||||t||||||||||2018-06-01 01:08:14.116281|2018-06-01 01:08:14.116281
NCT00876148|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-03|2009-04-03|2009-04-06|Estimate|||||||2009-04-03|2009-04-06|Estimate||||April 2009|2009-04-30||||||||Observational|||Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting|Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting|Completed|||||Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-06-01 01:08:14.20756|2018-06-01 01:08:14.20756
NCT00876135|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2013-05-09|2009-04-03|2009-04-06|Estimate|||||||2013-05-09|2013-05-13|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Role of Airway Hyperresponsiveness on Performance in Elite Swimmers.|Role of Airway Hyperresponsiveness on Performance in Elite Swimmers: Efficiency of a Bronchodilator to Prevent an Exercise-induced Bronchoconstriction|Completed||N/A|57|Actual|Laval University||1|||f||||t||||||||||2018-06-01 01:08:14.288519|2018-06-01 01:08:14.288519
NCT00876122|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2016-11-01|2009-04-03|2009-04-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable|An Open-Label, Phase I, Dose-Escalation Study of PI3-Kinase Inhibitor (GDC-0941) in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable|Completed||Phase 1|60|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:08:14.387505|2018-06-01 01:08:14.387505
NCT00876109|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2016-11-01|2009-04-03|2009-04-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|June 2012|Actual|2012-06-30||Interventional|||A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable|An Open-Label, Phase I, Dose-Escalation Study Evaluating Two Dosing Schedules of PI3-Kinase Inhibitor (GDC-0941) in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable|Completed||Phase 1|108|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 01:08:14.468008|2018-06-01 01:08:14.468008
NCT00876096|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-03|2009-04-03|2009-04-06|Estimate|||||||2009-04-03|2009-04-06|Estimate|February 2007||2007-02-28|April 2009|2009-04-30|March 2010|Anticipated|2010-03-31|July 2009|Anticipated|2009-07-31||Interventional|||Interest of Real-Time Polymerase Chain Reaction (PCR) in the Diagnosis of Fungal Infections|Development and Validation of Fungal Extraction and Real -Time PCR Assay for the Diagnosis of Medically Important Fungal Infections in Blood Samples.|Unknown status|Enrolling by invitation|N/A|480|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:08:14.553788|2018-06-01 01:08:14.553788
NCT00876083|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2011-02-25|2009-04-03|2009-04-06|Estimate|||||||2011-02-25|2011-02-28|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|IMAGE||PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination|Post-marketing Surveillance Study Ultravist®-IMAGE IoproMide (UltrAvist®) to Gain Further Information on Tolerability and Safety in X-ray Examination|Completed|||44920|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:08:14.64845|2018-06-01 01:08:14.64845
NCT00876070|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2011-11-18|2009-04-03|2009-04-06|Estimate|||||||2011-11-18|2011-11-21|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|February 2011|Actual|2011-02-28|November 2009|Actual|2009-11-30||Observational|||Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer|Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer|Completed|||198|Actual|SCRI Development Innovations, LLC|||||f||||f||||||||||2018-06-01 01:08:14.786104|2018-06-01 01:08:14.786104
NCT00876057|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2012-06-08|2009-04-03|2009-04-06|Estimate|||||||2012-06-08|2012-06-11|Estimate|March 1998||1998-03-31|June 2012|2012-06-30|April 2005|Actual|2005-04-30|April 2004|Actual|2004-04-30||Interventional|||Psychological Well-being, Recovery and Sexuality After Total and Subtotal Hysterectomy|Subtotal Versus Total Abdominal Hysterectomy- a Prospective Randomised Comparison of Medical , Psychological and Sexual Effects.|Completed||Phase 4|200|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-06-01 01:08:14.864794|2018-06-01 01:08:14.864794
NCT00876044|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2016-05-04|2009-04-03|2009-04-06|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|November 2010|Actual|2010-11-30|February 2010|Actual|2010-02-28||Interventional|QUTIE||A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients|A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc Interval in Cancer Patients Treated With Docetaxel|Completed||Phase 1|88|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:08:14.959303|2018-06-01 01:08:14.959303
NCT00876031|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-01-31|2009-04-02|2009-04-06|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2009||2009-07-31|October 2017|2017-10-31|July 2024|Anticipated|2024-07-31|July 2019|Anticipated|2019-07-31||Interventional|CWS-2007-HR||Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma|A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults|Recruiting||Phase 3|320|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-06-01 01:08:15.229967|2018-06-01 01:08:15.229967
NCT00876018|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|2017-04-25||2018-02-28|2009-04-03|2009-04-06|Estimate|2017-04-25|2017-08-03|Actual||||2018-02-28|2018-03-01|Actual|July 7, 2008|Actual|2008-07-07|February 2018|2018-02-28|December 19, 2008|Actual|2008-12-19|December 19, 2008|Actual|2008-12-19||Interventional|||Nutrition, Physical Performance & Fitness in Indian School Children|A Double Blind Randomized Controlled Trial in School Going Children, to Evaluate the Impact of a Multiple Micronutrient Fortified Nutritional Powder on Physical Performance Measures|Completed||Phase 4|300|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 01:08:15.526721|2018-06-01 01:08:15.526721
NCT00876005|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2016-10-12|2009-04-03|2009-04-06|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2006||2006-08-31|May 2016|2016-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PORSSI||Supplemental Oxygen and the Risk of Surgical Site Infection|Perioperative Supplemental Oxygen and the Risk of Surgical Site Infection|Completed||Phase 4|1202|Anticipated|Santa Clara Valley Health & Hospital System||2|||f||||t||||||||||2018-06-01 01:08:16.445688|2018-06-01 01:08:16.445688
NCT00875992|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2013-01-22|2009-04-03|2009-04-06|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Trial to Evaluate the Effectiveness of Angular Stable Locking System (ASLS) in Patients With Distal Tibial Fractures|A Randomized Controlled Trial to Evaluate the Effectiveness of Angular Stable Locking System (ASLS) in Patients With Distal Tibial Fractures Treated With Expert Tibial Nails (ETN)|Completed||N/A|141|Actual|AO Clinical Investigation and Documentation||2|||f||||f||||||||||2018-06-01 01:08:16.532506|2018-06-01 01:08:16.532506
NCT00875979|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2013-02-22||2013-12-20|2009-04-02|2009-04-06|Estimate|2013-06-13|2013-07-18|Estimate||||2013-12-20|2013-12-24|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Treated population: All patients who received at least 1 dose of study drug and had at least 1 follow-up tumor assessment.|A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab|A Phase Ib/II, Open-label Study of the Safety, Tolerability, and Efficacy of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab|Completed||Phase 1/Phase 2|67|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:08:16.649582|2018-06-01 01:08:16.649582
NCT00875966|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2017-03-27|2009-04-03|2009-04-06|Estimate|||||||2017-03-27|2017-03-29|Actual|August 2004||2004-08-31|April 2009|2009-04-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Eon and Pfizer Inc. (ZITHROMAX) 200mg/5mL Azithromycin Suspension Following a 600mg Dose in Healthy Adult Volunteers Under Fed Conditions|Completed||Phase 1|42|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:08:17.211913|2018-06-01 01:08:17.211913
NCT00875953|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2010-12-13|2009-04-03|2009-04-06|Estimate|||||||2010-12-13|2010-12-14|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Use of the Harmonic Scalpel in Neck Dissection|Harmonic Scalpel vs. Electrocautery in Modified Radical Neck Dissection: A Single Blinded Prospective Randomized Trial|Completed||N/A|34|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 01:08:17.277264|2018-06-01 01:08:17.277264
NCT00875940|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2009-04-03|2009-04-03|2009-04-06|Estimate|||||||2009-04-03|2009-04-06|Estimate|February 2008||2008-02-29|April 2009|2009-04-30||||January 2009|Actual|2009-01-31||Observational|||Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis|Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis Between Tc-99m Tetrofosmin SPECT Adn Echocardiography|Completed|||||University of Cincinnati|||1||f||||t||||||||||2018-06-01 01:08:17.359008|2018-06-01 01:08:17.359008
NCT00875927|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-04-05|2009-04-03|2009-04-06|Estimate|||||||2009-04-05|2009-04-07|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|BCHS||Effects of Breezy Candy on Halitosis|Breezy Candy Halitosis Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|75|Anticipated|Breezy Industries Ltd.||5|||f||||f||||||||||2018-06-01 01:08:17.429183|2018-06-01 01:08:17.429183
NCT00875914|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2016-06-24|2009-04-03|2009-04-06|Estimate|||||||2016-06-24|2016-06-27|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|MAGMA-AVNRT||Magnetically Navigated vs. Manually Guided Radiofrequency in Atrioventricular-node-reentry-tachycardia|Randomized Comparison Between Magnetically Navigated vs Manually Guided Radiofrequency in AV-node-reentry-tachycardia|Completed||Phase 4|300|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-06-01 01:08:17.528446|2018-06-01 01:08:17.528446
NCT00875901|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-05-22|2009-04-03|2009-04-06|Estimate|||||||2018-05-22|2018-05-23|Actual|September 2009||2009-09-30|May 2018|2018-05-31|April 2032|Anticipated|2032-04-30|June 2021|Anticipated|2021-06-30||Interventional|LU03||Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)|Hypofractionated, Image-Guided Radiation Therapy With Proton Therapy for Stage I Non-Small Cell Lung Cancer|Recruiting||N/A|23|Anticipated|University of Florida||2|||f||||t|f|f||||||Undecided||2018-06-01 01:08:17.611728|2018-06-01 01:08:17.611728
NCT00875888|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2018-03-05|2009-04-03|2009-04-06|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2004||2004-02-29|March 2018|2018-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|HICOSS||High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock|High Cut-off Continuous Venovenous Hemodialysis (CVVHD) to Improve Hemodynamic Stability and Organ Function Scores in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock|Terminated||N/A|80|Actual|Baxter Healthcare Corporation||2||"based on interim analysis statistical significance in primary endpoint cannot be achieved with~   planned sample size, no safety concerns"|f||||f|f|f||||||||2018-06-01 01:08:17.71293|2018-06-01 01:08:17.71293
NCT00875875|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2015-06-08|2009-04-03|2009-04-06|Estimate|||||||2015-06-08|2015-06-10|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|June 2009|Anticipated|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Rifaximin 600||Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea|Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center, Houston||2||No study population in Mexico (H1N1). Study withdrawn from IRB consideration.|f||||f||||||||||2018-06-01 01:08:17.804419|2018-06-01 01:08:17.804419
NCT00875706|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2014-10-10||2015-04-06|2009-04-02|2009-04-03|Estimate|2014-11-20|2014-11-24|Estimate||||2015-04-06|2015-04-24|Estimate|October 2009||2009-10-31|August 2014|2014-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Training and Coaching to Promote High Performance in Veteran Affairs (VA) Nursing Home Care|Training and Coaching to Promote High Performance in VA Nursing Home Care|Completed||N/A|45|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 01:08:20.772533|2018-06-01 01:08:20.772533
NCT00875862|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-03|||2011-04-21|2009-04-03|2009-04-06|Estimate|||||||2011-04-21|2011-04-22|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks|Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks: A Randomized, Triple-Masked, Placebo-Controlled Study|Terminated||Phase 4|4|Actual|University of California, San Diego||2||procedure no longer being done|f||||f||||||||||2018-06-01 01:08:17.878389|2018-06-01 01:08:17.878389
NCT00875849|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2014-11-20|2009-04-02|2009-04-03|Estimate|||||||2014-11-20|2014-11-21|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|December 2013|Actual|2013-12-31|February 2010|Actual|2010-02-28||Interventional|||Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer|Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor Prognosis After Complete Surgical Resection|Completed||Phase 2|53|Actual|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-06-01 01:08:17.942279|2018-06-01 01:08:17.942279
NCT00875836|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2015-09-21||2016-07-08|2009-04-02|2009-04-03|Estimate|2016-02-10|2016-03-09|Estimate||||2016-07-08|2016-08-10|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|June 2014|Actual|2014-06-30||Interventional|||Buspirone Treatment for Marijuana Dependence|Buspirone Treatment for Marijuana Dependence|Completed||Phase 4|175|Actual|Medical University of South Carolina|Limitations included significant attrition during the course of the 12-week trial, difficulty with UCT interpretation due to the long excretion half-life of marijuana in urine, and likelihood that the genetic analysis was underpowered.|2|||f||||t||||||||||2018-06-01 01:08:18.030613|2018-06-01 01:08:18.030613
NCT00875823|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2015-04-06|2009-04-02|2009-04-03|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2003||2003-09-30|April 2015|2015-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||International Registry for Primary Hyperoxaluria|International Registry for Hereditary Calcium Stone Diseases|Withdrawn|||0|Actual|Mayo Clinic|||1|Study was combined with Mayo protocol 07-003476|f||||t||||||||||2018-06-01 01:08:19.45795|2018-06-01 01:08:19.45795
NCT00875810|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2014-12-19||2016-01-26|2009-04-02|2009-04-03|Estimate|2015-03-03|2015-03-17|Estimate||||2016-01-26|2016-01-28|Estimate|April 2008||2008-04-30|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||PRESTIGE Observational Study|PRESTIGE Observational Study|Completed|||194|Actual|Medtronic Spinal and Biologics|Low patient compliance at the 6 and 12 months follow up visits||||f||||f||||||||||2018-06-01 01:08:19.564311|2018-06-01 01:08:19.564311
NCT00875797|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2013-06-27||2013-12-01|2009-04-02|2009-04-03|Estimate|2013-12-01|2014-01-16|Estimate||||2013-12-01|2014-01-16|Estimate|October 2004||2004-10-31|December 2013|2013-12-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional||mixed surgical ICU population|Enteral Versus Parenteral Glutamine Supplement|Comparison of Effect of Enteral Versus Parenteral Glutamine Supplement on Intestinal Permeability and Outcome of Critically Ill Patients|Terminated||Phase 4|90|Actual|University Medical Centre Ljubljana|Termination due to small sample size for nutritional pilot study.|2||Termination due to interim analysis results, inclusion problems in small ICUs.|f||||t||||||||||2018-06-01 01:08:19.838736|2018-06-01 01:08:19.838736
NCT00875784|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-08-03|2009-04-02|2009-04-03|Estimate|||||||2017-08-03|2017-08-04|Actual|May 6, 2008|Actual|2008-05-06|August 2017|2017-08-31|June 14, 2008|Actual|2008-06-14|June 14, 2008|Actual|2008-06-14||Interventional|||An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)|An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate) Injection 4mg Administered Using the IMITREX STATdose System® and a TREXIMA Tablet Followed by IMI|Completed||Phase 1|30|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:08:20.172938|2018-06-01 01:08:20.172938
NCT00875771|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2017-07-31|2009-04-02|2009-04-03|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2009||2009-04-30|July 2017|2017-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|AVAXIRI||Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients|Phase II Study of Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients|Completed||Phase 2|80|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-06-01 01:08:20.301172|2018-06-01 01:08:20.301172
NCT00875758|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2017-11-01|2009-04-02|2009-04-03|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2009||2009-05-31|November 2017|2017-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|LETAP||Optimizing Treatment of Post-hemorrhagic Ventricular Dilation in Preterm Infants|Phase II Study of Late- Versus Early Treatment of Post-hemorrhagic Ventricular Dilation in Preterm Infants.|Completed||N/A|7|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:08:20.410445|2018-06-01 01:08:20.410445
NCT00875745|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2014-09-17|2009-04-02|2009-04-03|Estimate|||||||2014-09-17|2014-09-18|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|May 2010|Actual|2010-05-31||Interventional|||Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)|Phase I, Open-label, Dose-escalation Study of the Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 1|15|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 01:08:20.498115|2018-06-01 01:08:20.498115
NCT00875732|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2017-07-07|2009-03-31|2009-04-03|Estimate|||||||2017-07-07|2017-07-11|Actual|September 2009||2009-09-30|July 2017|2017-07-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|CHOICE||Choosing the Right Pacing Mode in Heart Failure - The CHOICE Trial|CHOosing the rIght paCing Mode in Heart failurE : Should Heart Failure Patients With Bradycardia Receive Biventricular Pacemakers Rather Than Conventional Pacemakers?|Completed||N/A|22|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 01:08:20.595492|2018-06-01 01:08:20.595492
NCT00875719|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2011-02-15|2009-04-02|2009-04-03|Estimate|||||||2011-02-15|2011-02-16|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Oxygen Portable Concentrator During Exercises in Patients With COPD|Comparing Effectiveness of Oxygen Supplementation From a Portable Concentrator and a Liquid Oxygen Source During Walking Test in COPD Patients With Respiratory Failure|Completed||N/A|19|Actual|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||1|||f||||t||||||||||2018-06-01 01:08:20.674498|2018-06-01 01:08:20.674498
NCT00875524|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2015-01-09|2009-04-02|2009-04-03|Estimate|||||||2015-01-09|2015-01-12|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects|Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam|Completed||Phase 2|180|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:08:23.769286|2018-06-01 01:08:23.769286
NCT00875693|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-01-12|2009-04-02|2009-04-03|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2, 2009|Actual|2009-06-02|January 2018|2018-01-31|December 27, 2017|Actual|2017-12-27|June 30, 2014|Actual|2014-06-30||Interventional|||A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)|A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT)for Primary Refractory and Relapsed Acute Myelogenous Leukemia|Completed||Phase 1|47|Actual|Weill Medical College of Cornell University||2|||f||||||||||||||2018-06-01 01:08:21.336257|2018-06-01 01:08:21.336257
NCT00875680|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2012-02-09|2009-04-02|2009-04-03|Estimate|||||||2012-02-09|2012-02-10|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|June 2014|Anticipated|2014-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy of autoPPC for the Treatment of Obstructive Sleep Apnea Syndrome (OSAS)|Evaluation of the Efficacy of Autoadjusted Positive Pressure Devices for the Treatment of Obstructive Sleep Apnea Syndrome|Unknown status|Recruiting|N/A|20|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||1|||f||||f||||||||||2018-06-01 01:08:21.40856|2018-06-01 01:08:21.40856
NCT00875667|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2018-04-24|2009-04-02|2009-04-03|Estimate|||||||2018-04-24|2018-04-26|Actual|April 30, 2009|Actual|2009-04-30|April 2018|2018-04-30|July 5, 2019|Anticipated|2019-07-05|October 15, 2018|Anticipated|2018-10-15||Interventional|Sprint||A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)|A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma|Active, not recruiting||Phase 2|254|Actual|Celgene||2|||f||||t||||||||||2018-06-01 01:08:21.506431|2018-06-01 01:08:21.506431
NCT00875654|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2017-10-30|2009-04-02|2009-04-03|Estimate|||||||2017-10-30|2017-11-01|Actual|August 2010||2010-08-31|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|ISIS||Intravenous Stem Cells After Ischemic Stroke|Cell Therapy by Intravenous Injection of Mesenchymal Stem Cells After Stroke|Completed||Phase 2|31|Actual|University Hospital, Grenoble||3|||f||||t||||||||No||2018-06-01 01:08:21.829945|2018-06-01 01:08:21.829945
NCT00875641|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2017-02-07|2009-04-02|2009-04-03|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 2009||2009-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States|Safety Study of GSK Biologicals' Rotarix® (Rotavirus Vaccine, Live, Oral) Administered to a Birth Cohort in United States Health Insurance Plans|Completed|||127120|Actual|GlaxoSmithKline|||3||f||||||||||||||2018-06-01 01:08:21.920379|2018-06-01 01:08:21.920379
NCT00875628|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-10-21|2009-04-02|2009-04-03|Estimate|||||||2009-10-21|2009-10-22|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers|A Phase 1, Randomized, Double Blind (Sponsor-Open), Placebo Controlled, Dose Escalation, Multiple Dose Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers|Terminated||Phase 1|24|Actual|Pfizer||3||See Detailed Description|f||||f||||||||||2018-06-01 01:08:22.018167|2018-06-01 01:08:22.018167
NCT00875615|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2013-07-18||2016-12-14|2009-04-02|2009-04-03|Estimate|2013-08-13|2013-10-17|Estimate||||2016-12-14|2017-02-07|Estimate|December 2008||2008-12-31|December 2016|2016-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients|Completed||Phase 2|11|Actual|University of Miami||1|||f||||||||||||||2018-06-01 01:08:22.11233|2018-06-01 01:08:22.11233
NCT00875602|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2016-12-05|2009-04-02|2009-04-03|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2009||2009-04-30|October 2012|2012-10-31||||||||Interventional|||Evaluation of EverOn™ - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion|Evaluation of EverOn™ - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion|Withdrawn||N/A|0|Actual|EarlySense Ltd.||2||NO need|f||||f||||||||||2018-06-01 01:08:22.32397|2018-06-01 01:08:22.32397
NCT00875589|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2015-09-10||2015-10-15|2009-04-02|2009-04-03|Estimate|2015-09-10|2015-10-08|Estimate||||2015-10-15|2015-11-11|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|||Eye Movement Recordings in the Diagnosis of Traumatic Brain Injury|Eye-movement Recordings in the Diagnosis of Traumatic Brain Injury|Completed|||26|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-06-01 01:08:22.39898|2018-06-01 01:08:22.39898
NCT00875576|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2010-06-25|2009-04-02|2009-04-03|Estimate|||||||2010-06-25|2010-06-28|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Influence of Parents and Friends on Children and Adolescents|Influence of Parents and Friends on Children and Adolescents|Completed|||40|Anticipated|University at Buffalo|||||f||||f||||||||||2018-06-01 01:08:22.617827|2018-06-01 01:08:22.617827
NCT00875563|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2015-06-30||2016-11-20|2009-04-02|2009-04-03|Estimate|2015-08-31|2015-09-30|Estimate||||2016-11-20|2017-01-11|Estimate|January 2005||2005-01-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|February 2011|Actual|2011-02-28||Interventional|||Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study|Evaluation of the Safety and Effectiveness of the Zenith(R) Fenestrated AAA Endovascular Graft|Completed||N/A|42|Actual|Cook Group Incorporated||1|||t||||||||||||||2018-06-01 01:08:22.689269|2018-06-01 01:08:22.689269
NCT00875550|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2014-05-30|2012-01-04|2015-07-23|2009-04-02|2009-04-03|Estimate|2014-10-24|2014-10-30|Estimate|2012-01-04|2012-01-09|Estimate|2015-07-23|2015-08-14|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects|A Phase III Randomized, Double-blind, Dose-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit Subjects|Completed||Phase 3|175|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 01:08:22.948081|2018-06-01 01:08:22.948081
NCT00875537|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2017-03-11|2009-04-02|2009-04-03|Estimate|||||||2017-03-11|2017-03-14|Actual|January 2009||2009-01-31|March 2017|2017-03-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|BMS17||Neurogenic Mechanisms in Burning Mouth Syndrome|Neurogenic Mechanisms in Burning Mouth Syndrome With Focus on Localization and Desensibilization of Vanilloid Receptor TRPV1|Completed||N/A|22|Actual|University of Copenhagen||2|||f||||t||||||||||2018-06-01 01:08:23.587247|2018-06-01 01:08:23.587247
NCT00875511|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2010-06-25|2009-04-02|2009-04-03|Estimate|||||||2010-06-25|2010-06-28|Estimate|November 2008||2008-11-30|April 2009|2009-04-30|September 2009|Actual|2009-09-30|||||Observational|||Effects of a Computer Game on Activity Choices||Completed|||40|Anticipated|University at Buffalo|||||f||||f||||||||||2018-06-01 01:08:23.896994|2018-06-01 01:08:23.896994
NCT00875498|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2016-01-26|2009-04-02|2009-04-03|Estimate|||||||2016-01-26|2016-01-27|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia|Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia|Completed||N/A|22|Actual|Hôpital le Vinatier||2|||f||||t||||||||||2018-06-01 01:08:23.967158|2018-06-01 01:08:23.967158
NCT00875485|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2010-05-27||2017-01-09|2009-04-02|2009-04-03|Estimate|2010-05-27|2010-07-05|Estimate||||2017-01-09|2017-02-23|Actual|May 2009||2009-05-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™|An Open Multicentre, Multicountry Study to Evaluate Long-term Antibody Persistence and Immune Memory Between Years 11 and 15 After the Primary Study HAB-084 in Which Healthy Adolescents Were Vaccinated With Twinrix™ Adult Following a Two-dose Schedule or Twinrix™ Junior Following a Three-dose Schedule.|Completed||Phase 4|210|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).The table shows updated results following complete retesting and reanalysis.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:08:24.113529|2018-06-01 01:08:24.113529
NCT00875472|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-04-02|2009-04-02|2009-04-03|Estimate|||||||2009-04-02|2009-04-03|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Social Influences on Adolescents' Snack Purchases|Social Influences on Adolescents' Snack Purchases|Completed|||||University at Buffalo|||||f||||f||||||||||2018-06-01 01:08:25.036238|2018-06-01 01:08:25.036238
NCT00875459|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02||2015-07-28|2015-07-28|2009-04-02|2009-04-03|Estimate||||2015-07-28|2015-07-29|Estimate|2015-07-28|2015-07-29|Estimate|April 2007||2007-04-30|July 2015|2015-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus||Completed||Phase 3|233|Actual|Biodel||1|||f||||f||||||||||2018-06-01 01:08:25.095299|2018-06-01 01:08:25.095299
NCT00875446|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2017-09-19|2009-04-02|2009-04-03|Estimate|||||||2017-09-19|2017-09-20|Actual|May 13, 2009|Actual|2009-05-13|September 2017|2017-09-30|September 9, 2011|Actual|2011-09-09|September 9, 2011|Actual|2011-09-09||Interventional|||First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis|A Single and Repeat Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of GSK1223249 in ALS Patients|Completed||Phase 1|76|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:08:25.172076|2018-06-01 01:08:25.172076
NCT00875433|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2013-08-08||2013-12-05|2009-04-02|2009-04-03|Estimate|2013-10-21|2013-11-13|Estimate||||2013-12-05|2013-12-30|Estimate|March 2009||2009-03-31|October 2013|2013-10-31||||April 2011|Actual|2011-04-30||Interventional|||Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours|Phase II Open Label Trial to Assess the Efficacy and the Impact on QTcF of Continuous Oral BIBW 2992 at a Daily Dose of 50mg in Patients With Relapsed or Refractory Solid Tumours Including Patients With Brain Metastases and Those With Glioblastoma Not Amenable to Other Therapy|Completed||Phase 2|60|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 01:08:25.402719|2018-06-01 01:08:25.402719
NCT00875420|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2011-02-16||2012-02-22|2009-04-02|2009-04-03|Estimate|2012-02-22|2012-03-26|Estimate||||2012-02-22|2012-03-26|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women|A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2, Multi-Center, Dose-Finding Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 2|100|Actual|Radius Health, Inc.||5|||f||||f||||||||||2018-06-01 01:08:25.833861|2018-06-01 01:08:25.833861
NCT00875407|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2014-02-24|2009-04-02|2009-04-03|Estimate|||||||2014-02-24|2014-02-25|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot||Completed||N/A|10|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 01:08:26.57107|2018-06-01 01:08:26.57107
NCT00875394|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2009-06-12||2017-04-28|2009-04-02|2009-04-03|Estimate|2011-03-22|2011-04-20|Estimate||||2017-04-28|2017-05-30|Actual|February 1, 2007|Actual|2007-02-01|April 2017|2017-04-30|June 27, 2008|Actual|2008-06-27|June 27, 2008|Actual|2008-06-27||Interventional|||Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)|A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin|Completed||Phase 3|68|Actual|Merck Sharp & Dohme Corp.|"A limited number of participants were recruited into this open-label study. This study was conducted at a single site.~Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data."|3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:08:26.656544|2018-06-01 01:08:26.656544
NCT00875381|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2011-03-14|2009-04-02|2009-04-03|Estimate|||||||2011-03-14|2011-03-15|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin|Immunohistochemical Analysis of Melanocytes in Sun-Exposed Skin|Completed|||100|Actual|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     The proposed dog-ears excised, that were to be discarded during reconstruction, were~     evaluated for the presence of any visible lesions (i.e. ephelid, lentigo, seborrheic~     keratosis, nevi). Dog-ears with any skin lesions were excluded. The specimens were inked by~     the surgeon on the side to be cut by the histotechnician. The specimens were placed in~     formalin bottles and submitted to the pathology department at Mayo Clinic Rochester for~     processing. The tissue was cut (4 microns) along its long access and stained with routine H&~     E and Mart-1 (MelanA) immunostains.~   "|||2018-06-01 01:08:26.991491|2018-06-01 01:08:26.991491
NCT00875368|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2013-09-06|2009-04-02|2009-04-03|Estimate|||||||2013-09-06|2013-09-10|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|MIRS||Maraviroc Immune Recovery Study|Maraviroc Immune Recovery Study, A Multicenter, Randomized, Placebo-controlled, Exploratory Mechanistic Study Into the Role of Maraviroc on Immune Recovery|Completed||Phase 4|85|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 01:08:27.06218|2018-06-01 01:08:27.06218
NCT00875355|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-08-25|2009-04-02|2009-04-03|Estimate|||||||2009-08-25|2009-08-26|Estimate|November 2007||2007-11-30|July 2009|2009-07-31||||November 2009|Anticipated|2009-11-30||Interventional|||Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer|Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:08:27.185846|2018-06-01 01:08:27.185846
NCT00875342|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-05-18|2009-04-02|2009-04-03|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2008|Actual|2008-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)|D-cycloserine Enhanced Imaginal ExposureTherapy for Posttraumatic Stress Disorder (PTSD)|Recruiting||N/A|124|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 01:08:27.272604|2018-06-01 01:08:27.272604
NCT00875329|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2014-06-10||2015-06-04|2009-04-02|2009-04-03|Estimate|2014-12-10|2014-12-12|Estimate||||2015-06-04|2015-07-03|Estimate|September 2010||2010-09-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|June 2012|Actual|2012-06-30||Observational|||Traumatic Brain Injury (TBI) Screening Instruments|TBI Screening Instruments and Processes for Clinical Follow-Up|Completed|||97|Actual|VA Office of Research and Development|||1||f||||f||||||None Retained|"~     As there are no biospecimans, there is no biospeciman description.~   "|||2018-06-01 01:08:27.374528|2018-06-01 01:08:27.374528
NCT00875316|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-08-20|2009-04-02|2009-04-03|Estimate|||||||2009-08-20|2009-08-21|Estimate|April 2009||2009-04-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients|A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month|Completed||Phase 1|36|Anticipated|Phytopharm||4|||f||||f||||||||||2018-06-01 01:08:27.514522|2018-06-01 01:08:27.514522
NCT00875303|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2011-10-27|2009-04-02|2009-04-03|Estimate|||||||2011-10-27|2011-10-28|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Brief Primary Care Intervention Helps Parents With Discipline|Brief Primary Care Intervention Helps Parents With Discipline|Completed||N/A|258|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:08:27.610348|2018-06-01 01:08:27.610348
NCT00875290|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2011-08-04|2009-04-02|2009-04-03|Estimate|||||||2011-08-04|2011-08-05|Estimate|November 2008||2008-11-30|August 2011|2011-08-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|Gerber RTSA||The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children|Gerber Pump Trial: Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Real-Time Sensor Augmentation (RTSA) in 0-3 Years Old Diabetes Patients; A One Year Randomized Controlled Clinical Trial.|Unknown status|Recruiting|Phase 3|40|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||||2018-06-01 01:08:27.69538|2018-06-01 01:08:27.69538
NCT00875277|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2013-10-24|2009-04-02|2009-04-03|Estimate|||||||2013-10-24|2013-10-25|Estimate|April 2009||2009-04-30|October 2013|2013-10-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products|A Psoriasis Plaque Test Comparing LEO 29102 Cream and Its Different Combinations to Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris|Completed||Phase 2|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 01:08:27.802997|2018-06-01 01:08:27.802997
NCT00875264|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2012-07-24|2009-04-02|2009-04-03|Estimate|||||||2012-07-24|2012-07-25|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer|An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced Cancer|Completed||Phase 1|43|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 01:08:27.871933|2018-06-01 01:08:27.871933
NCT00875251|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-04-16|2009-04-02|2009-04-03|Estimate|||||||2018-04-16|2018-04-17|Actual|April 1, 2009|Actual|2009-04-01|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|December 31, 2018|Anticipated|2018-12-31||Observational|Crescer||Growth and Body Composition in Preterm Infants|Growth and Body Composition of Very Low Birth Weight Infants Compared With Infants Birth at Term|Recruiting|||60|Anticipated|Oswaldo Cruz Foundation|||2||f||||t||||||||||2018-06-01 01:08:27.939127|2018-06-01 01:08:27.939127
NCT00875238|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-02-15|2009-04-02|2009-04-03|Estimate|||||||2018-02-15|2018-02-19|Actual|June 2008||2008-06-30|February 2018|2018-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|PACE in BC||Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab|Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)|Completed|||133|Actual|Vanderbilt University Medical Center|||||f||||t||||||Samples With DNA|"~     Serum, Plasma, Mononuclear Cells~   "|||2018-06-01 01:08:28.051831|2018-06-01 01:08:28.051831
NCT00875225|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-04-02|2009-04-02|2009-04-03|Estimate|||||||2009-04-02|2009-04-03|Estimate|December 2006||2006-12-31|April 2009|2009-04-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|CSI Birmingham||Using Multimedia Technology for Hypertension Control for Low-Income African Americans|Culturally Sensitive Intervention: CSI Birmingham|Unknown status|Active, not recruiting|N/A|300|Actual|Cooper Green Mercy Hospital||2|||f||||t||||||||||2018-06-01 01:08:28.146462|2018-06-01 01:08:28.146462
NCT00875212|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2009-04-02||2009-10-13|2009-04-02|2009-04-03|Estimate|2009-09-08|2009-10-12|Estimate||||2009-10-13|2009-10-15|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|CAGP-F||Effect of Calcium Glycerophosphate (CaGP) - Fluoride Dentifrice on Dental Biofilm pH|Effect of a Dentifrice Containing Calcium Glycerophosphate and Fluoride on the pH of Dental Biofilm in Vivo|Completed||Phase 1|12|Actual|Federal University of Paraíba|pH measurements of dental biofilms were difficult after continuous use of dentifrice because of reduced biofilm mass in contrast to baseline measurements.|1|||f||||f||||||||||2018-06-01 01:08:28.247797|2018-06-01 01:08:28.247797
NCT00875199|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2011-11-17|2009-03-31|2009-04-03|Estimate|||||||2011-11-17|2011-11-21|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Contingency Management to Promote Weight Loss in Low Income Adults|Contingency Management to Promote Weight Loss in Low Income Adults|Completed||Phase 2|30|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 01:08:28.542267|2018-06-01 01:08:28.542267
NCT00875186|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-04-02|2009-04-02|2009-04-03|Estimate|||||||2009-04-02|2009-04-03|Estimate|October 2006||2006-10-31|April 2009|2009-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|AET||The Influence of Aerobic Endurance Training After Roux-en-Y-Gastric Bypass|Impact of Aerobic Physical Exercising on Body Composition and co-Morbidities in Patients After Laparoscopic Roux-en-Y Gastric Bypass|Unknown status|Recruiting||60|Anticipated|Universitätsmedizin Mannheim|||2||f||||f||||||||||2018-06-01 01:08:28.620411|2018-06-01 01:08:28.620411
NCT00875173|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-11-09|2009-04-02|2009-04-03|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31||Interventional|STCC||Selenium Treatment and Chagasic Cardiopathy (STCC)|Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease|Recruiting||Phase 3|130|Anticipated|Oswaldo Cruz Foundation||2|||f||||t||||||||||2018-06-01 01:08:28.712898|2018-06-01 01:08:28.712898
NCT00875160|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02||2010-08-17|2010-08-17|2009-04-02|2009-04-03|Estimate||||2010-08-17|2010-08-19|Estimate|2010-08-17|2010-08-19|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101|An Open-Label Study to Assess the Pharmacokinetics, Safety, and Pharmacodynamics of Repeated Doses of Orally Administered AT2101 in Adult Patients With Type 1 Gaucher Disease|Terminated||Phase 1|1|Actual|Amicus Therapeutics||1||Subject Recruitment|f||||f||||||||||2018-06-01 01:08:28.8135|2018-06-01 01:08:28.8135
NCT00875147|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2016-10-24|2009-04-02|2009-04-03|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2009||2009-04-30|January 2010|2010-01-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Observational|||Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases|Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases A Case Matched Control Study|Completed|||163|Actual|University of Zurich|||2||f||||t||||||||||2018-06-01 01:08:28.926162|2018-06-01 01:08:28.926162
NCT00875134|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-04-02|2009-04-02|2009-04-03|Estimate|||||||2009-04-02|2009-04-03|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Testing of the Apnea Prevention Device|Testing of the Apnea Prevention Device|Unknown status|Active, not recruiting|Phase 1/Phase 2|35|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:08:29.027648|2018-06-01 01:08:29.027648
NCT00875121|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-05-11|2009-04-02|2009-04-03|Estimate|||||||2009-05-11|2009-05-12|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Peer Interactions and Food Are Substitutable in Youth|Peer Interactions and Food Are Substitutable in Youth|Completed|||||University at Buffalo|||||f||||f||||||||||2018-06-01 01:08:29.123257|2018-06-01 01:08:29.123257
NCT00875108|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02||2015-07-28|2015-07-28|2009-04-02|2009-04-03|Estimate||||2015-07-28|2015-07-29|Estimate|2015-07-28|2015-07-29|Estimate|July 2007||2007-07-31|July 2015|2015-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus||Completed||Phase 3|116|Actual|Biodel||1|||f||||f||||||||||2018-06-01 01:08:29.201442|2018-06-01 01:08:29.201442
NCT00875095|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2016-09-07|2009-04-02|2009-04-03|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Impact of Sperm DNA Integrity on Artificial Reproductive Treatment (ART)|Impact of Sperm DNA Integrity on ART Treatment|Terminated|||8|Actual|Northwell Health|||2|"Study funding was withdrawn by the sponsor following agreement that slow patient recruitment~   warranted a new approach."|f||||f||||||Samples Without DNA|"~     Smears of semen samples will be stained and stored.~   "|||2018-06-01 01:08:29.313153|2018-06-01 01:08:29.313153
NCT00875082|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2013-06-18|2009-04-02|2009-04-03|Estimate|||||||2013-06-18|2013-06-19|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|April 2013|Actual|2013-04-30|September 2011|Actual|2011-09-30||Interventional|MORACH||Effect of Montelukast on Remodelling Markers in Asthmatic Children|Effect of Montelukast on Metalloproteinase (MMP)-9, MMP-12, Tissue Inhibitor Metalloproteinase-1 (TIMP-1), Procollagen Type I C-terminal Peptide (PICP) and TGF-beta1 Levels in Sputum From Mild Intermittent Asthmatic Children: a Pilot Study|Completed||Phase 4|30|Actual|Universita di Verona||2|||f||||f||||||||||2018-06-01 01:08:29.40991|2018-06-01 01:08:29.40991
NCT00875069|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2014-06-13|2009-04-02|2009-04-03|Estimate|||||||2014-06-13|2014-06-16|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|February 2013|Actual|2013-02-28|June 2011|Actual|2011-06-30||Interventional|ELVIS||Efficacy and Safety of Ethanol Lock Solution in Prevention of Catheter Related Bloodstream Infection for Patients Suffering Acute Renal Failure, and Hospitalized in Intensive Care Unit. A Multi-Center, Randomized, Versus Placebo, Double Blinded Clinical Trial|Efficacy and Safety of Ethanol Lock Solution in Prevention of Catheter Related Bloodstream Infection for Patients Suffering Acute Renal Failure, and Hospitalized in Intensive Care Unit. A Multi-Center, Randomized, Versus Placebo, Double Blinded Clinical Trial.|Completed||Phase 3|1460|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-06-01 01:08:29.47997|2018-06-01 01:08:29.47997
NCT00875056|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2018-02-08|2009-04-02|2009-04-03|Estimate|||||||2018-02-08|2018-02-09|Actual|April 15, 2009|Actual|2009-04-15|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|February 25, 2011|Actual|2011-02-25||Interventional|||Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103)|A Phase II Study of MK0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL)|Active, not recruiting||Phase 2|54|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:08:29.621866|2018-06-01 01:08:29.621866
NCT00875043|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2016-10-13|2009-04-02|2009-04-03|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2008||2008-03-31|April 2009|2009-04-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Determine the Effect of Intraocular Pressure (IOP), Optic Nerve Imaging, Venous Congestion in Volunteers Prone Position 5 Hours|A Pilot Study to Determine the Effect on Intraocular Pressure, Optic Nerve Imaging and Other Markers of Venous Congestion of Volunteer Subjects in the Prone Position for a Period of Five Hours|Completed|||10|Actual|Rutgers, The State University of New Jersey|||2||f||||f||||||||No||2018-06-01 01:08:29.709141|2018-06-01 01:08:29.709141
NCT00875030|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2010-06-07|2009-04-02|2009-04-03|Estimate|||||||2010-06-07|2010-06-09|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects|A Single-Dose Bioequivalence Study Comparing Artesunate Sachets (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects|Completed||Phase 4|40|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:08:29.809728|2018-06-01 01:08:29.809728
NCT00875017|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2010-03-03||2013-12-04|2009-04-02|2009-04-03|Estimate|2010-05-26|2010-07-02|Estimate||||2013-12-04|2013-12-30|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers|An Open-label, Phase I, One-dose, One-meal, Balance Study Comparing the Absorption of Dietary Phosphorus When Administering FOSRENOL® (Lanthanum Carbonate) or RENVELA® (Sevelamer Carbonate) in Healthy Adult Volunteers|Completed||Phase 1|31|Actual|Shire||4|||f||||f||||||||||2018-06-01 01:08:29.945857|2018-06-01 01:08:29.945857
NCT00875004|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-12-13|2009-04-02|2009-04-03|Estimate|||||||2009-12-13|2009-12-15|Estimate|December 2007||2007-12-31|July 2009|2009-07-31||||November 2009|Anticipated|2009-11-30||Interventional|||Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors|Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy|Unknown status|Recruiting|N/A|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:08:30.622649|2018-06-01 01:08:30.622649
NCT00874991|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2016-07-07|2009-04-02|2009-04-03|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Cardiac Deformation: Correlation With Conventional Echocardiographic Hemodynamic Variables (An Intraoperative Study)|Cardiac Deformation: Correlation With Conventional Echocardiographic Hemodynamic Variables. An Intraoperative Study.|Completed|||198|Actual|Weill Medical College of Cornell University|||||f||||f||||||||No|There is no plan to share IPD|2018-06-01 01:08:30.702578|2018-06-01 01:08:30.702578
NCT00874978|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2015-09-01|2009-04-02|2009-04-03|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2005||2005-01-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality|The Efficacy and Safety of Lenalidomide (Revlimid®) Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome Associated With Del (5q) Cytogenetic Abnormality|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|King's College Hospital NHS Trust||1|||f||||f||||||||||2018-06-01 01:08:30.781806|2018-06-01 01:08:30.781806
NCT00874965|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2012-10-09|2009-04-02|2009-04-03|Estimate|||||||2012-10-09|2012-10-10|Estimate|December 2006||2006-12-31|October 2012|2012-10-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|ESTIM||Electrostimulation, Skeletal Muscle Function, and Exercise Capacity in Chronic Obstructive Pulmonary Disease (COPD)|Study of the Benefits of Lower Limb Electrostimulation Training on Muscular Parameters and Minute Ventilation During Exercise in Severe and Deconditioned COPD Patients.|Completed||N/A|23|Actual|Laval University||2|||f||||f||||||||||2018-06-01 01:08:30.904786|2018-06-01 01:08:30.904786
NCT00874952|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2010-02-16|2009-04-02|2009-04-03|Estimate|||||||2010-02-16|2010-02-17|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|ORSA||Regional Observation of the Metabolic Syndrome|Regional Observation of the Metabolic Syndrome|Completed|||1600|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:08:30.996235|2018-06-01 01:08:30.996235
NCT00874939|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2015-05-26||2015-05-26|2009-04-02|2009-04-03|Estimate|2015-05-26|2015-06-08|Estimate||||2015-05-26|2015-06-08|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)|A Randomized Clinical Trial To Evaluate the Single Dose Acute Effects of MK-0249 and Donepezil On Cognitive Function In Adult Patients With Alzheimer's Disease|Terminated||Phase 1|4|Actual|Merck Sharp & Dohme Corp.||12|||f||||f||||||||||2018-06-01 01:08:31.107798|2018-06-01 01:08:31.107798
NCT00874926|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2014-01-28|2009-04-02|2009-04-03|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Observational|||EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS|Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS|Completed|||405|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:08:31.437512|2018-06-01 01:08:31.437512
NCT00874913|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2012-10-08|2009-04-02|2009-04-03|Estimate|||||||2012-10-08|2012-10-10|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Study of Ocular Blood Flow in Patients With Glaucoma and/or Obstructive Sleep Apnea Syndrome (OSAS)|Study of Ocular Blood Flow Using Laser Doppler Flowmetry in Patients With Glaucoma and/or OSAS|Unknown status|Recruiting|N/A|90|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-06-01 01:08:31.527009|2018-06-01 01:08:31.527009
NCT00874900|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2011-07-07|2009-04-02|2009-04-03|Estimate|||||||2011-07-07|2011-07-08|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|May 2013|Anticipated|2013-05-31|January 2013|Anticipated|2013-01-31||Interventional|ALP||Asthma Learning Project|Asthma Learning Project: Randomized Trial of a Computerized Asthma Game in a Pediatric Emergency Department|Unknown status|Recruiting|N/A|120|Anticipated|Seattle Children's Hospital||4|||f||||f||||||||||2018-06-01 01:08:31.601434|2018-06-01 01:08:31.601434
NCT00874887|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2011-11-16||2011-11-16|2009-04-02|2009-04-03|Estimate|2011-11-16|2011-12-19|Estimate||||2011-11-16|2011-12-19|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms||Completed||Phase 4|66|Actual|Allergan|Only a small number of resistant species were obtained at the study endpoints. Therefore, some outcome measures were not able to be analyzed.|2|||f||||||||||||||2018-06-01 01:08:31.725222|2018-06-01 01:08:31.725222
NCT00874874|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2009-12-23|2009-04-02|2009-04-03|Estimate|||||||2009-12-23|2009-12-24|Estimate|May 2008||2008-05-31|July 2009|2009-07-31||||May 2011|Anticipated|2011-05-31||Interventional|||Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery|Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery|Unknown status|Recruiting|Phase 2|96|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:08:32.002387|2018-06-01 01:08:32.002387
NCT00874861|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2015-12-04|2009-04-02|2009-04-03|Estimate|||||||2015-12-04|2015-12-08|Estimate|April 2009||2009-04-30|December 2015|2015-12-31|November 2013|Actual|2013-11-30|May 2012|Actual|2012-05-31||Interventional|||HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas|A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With Recurrent WHO Grade II Gliomas|Completed||Early Phase 1|10|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:08:32.10363|2018-06-01 01:08:32.10363
NCT00874848|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2016-07-15||2016-10-06|2009-04-02|2009-04-03|Estimate|2016-10-06|2016-11-29|Estimate||||2016-10-06|2016-11-29|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|November 2012|Actual|2012-11-30||Interventional||The safety population comprised all randomized participants who received any amount of Imprime PGG, cetuximab, paclitaxel or carboplatin.|Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer|Efficacy and Safety Study of Imprime PGG® Injection in Combination With Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer|Completed||Phase 2|90|Actual|Biothera||2|||f||||t||||||||No||2018-06-01 01:08:32.21118|2018-06-01 01:08:32.21118
NCT00874835|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2010-05-06|2009-04-02|2009-04-03|Estimate|||||||2010-05-06|2010-05-07|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Corneal Endothelium Delivery Instrument|Endothelial Graft Injector Versus Folding Forceps Insertion During Descemet's Stripping Endothelial Keratoplasty (DSEK)|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Ocular Systems, Inc.|||||f||||t||||||||||2018-06-01 01:08:34.102563|2018-06-01 01:08:34.102563
NCT00874822|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2011-10-27||2012-01-18|2009-04-01|2009-04-03|Estimate|2012-01-18|2012-01-20|Estimate||||2012-01-18|2012-01-20|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Prevalence of Sleep Apnea in Patients Presenting for Hip or Knee Replacement Surgery|Prevalence of Sleep Apnea in Patients Presenting for Hip or Knee Replacement Surgery|Completed|||216|Actual|University of Nebraska|Obstructive sleep apnea was diagnosed in only four patients due to a high rate of failure to undergo PSG by patients for whom it was indicated. A second major weakness is the use of a literature control group.||1||f||||f||||||||||2018-06-01 01:08:34.26162|2018-06-01 01:08:34.26162
NCT00874809|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-08-23|2009-04-02|2009-04-03|Estimate|||||||2013-08-23|2013-08-27|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study|A Pilot Study to Explore Basal Insulin Dosing Requirements in Patients With Type 2 Diabetes Treated With Insulin Pump Therapy|Completed||N/A|30|Actual|Diabetes Care Center||1|||f||||f||||||||||2018-06-01 01:08:34.5119|2018-06-01 01:08:34.5119
NCT00874796|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02||2014-01-03|2014-01-03|2009-04-02|2009-04-03|Estimate||||2014-01-03|2014-02-04|Estimate|2014-01-03|2014-02-04|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection|A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106)|Terminated||Phase 2|307|Actual|Gilead Sciences||3||"Reports of significant laboratory abnormalities and adverse events in a number of clinical~   study participants."|f||||t||||||||||2018-06-01 01:08:34.640509|2018-06-01 01:08:34.640509
NCT00874783|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|||2017-11-26|2009-04-02|2009-04-03|Estimate|||||||2017-11-26|2017-11-28|Actual|April 2009||2009-04-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases|Derivation of Induced Pluripotent Stem Cells From Somatic Cells Donated by Patients With Neurological Diseases for the Study of the Pathogenesis of the Disorders and Development of Novel Therapies|Recruiting|||120|Anticipated|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     donation of a skin specimen of up to 10mm in diameter from skin which will be removed in a~     surgical operation from a patient who is scheduled to undergo an operation for medical~     reasons and with no relation to the study at hand.~   "|||2018-06-01 01:08:34.921224|2018-06-01 01:08:34.921224
NCT00874770|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-02|2015-08-06||2015-09-23|2009-04-02|2009-04-03|Estimate|2015-09-23|2015-10-23|Estimate||||2015-09-23|2015-10-23|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|January 2011|Actual|2011-01-31|November 2009|Actual|2009-11-30||Interventional||The analysis was performed in the treated population defined as all participants who received at least 1 dose of study therapy.|Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)|A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1|Completed||Phase 2|74|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 01:08:35.065945|2018-06-01 01:08:35.065945
NCT00874757|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2011-08-02|2009-04-01|2009-04-02|Estimate|||||||2011-08-02|2011-08-03|Estimate|July 2009||2009-07-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects|Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of|Unknown status|Recruiting||20|Anticipated|University of Nebraska|||||f||||f||||||||||2018-06-01 01:08:36.374863|2018-06-01 01:08:36.374863
NCT00874744|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-03-31|2009-03-31|2009-04-02|Estimate|||||||2009-03-31|2009-04-02|Estimate|March 2008||2008-03-31|March 2009|2009-03-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|Tribeva-DME||Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema|Phase 2 Study of Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema.|Completed||Phase 2|13|Actual|Universidade Federal de Goias||2|||f||||f||||||||||2018-06-01 01:08:36.655203|2018-06-01 01:08:36.655203
NCT00874731|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2015-02-18|2009-04-01|2009-04-02|Estimate|||||||2015-02-18|2015-02-19|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037 AM1)|A Clinical Trial to Assess the Effect of Deforolimus (AP23573; MK-8669) on QTc Interval in Patients (Protocol 037)|Completed||Phase 1|23|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:08:36.807212|2018-06-01 01:08:36.807212
NCT00874718|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|||Impact in Life Quality of a Educational Program for Prevention of Occupational Musculoskeletal Disorders in Workers|Impact in Life Quality of a Educational Program for Prevention of Occupational Musculoskeletal Disorders in Workers.|Completed||N/A|64|Anticipated|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-06-01 01:08:36.923343|2018-06-01 01:08:36.923343
NCT00874692|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2010-06-01|2009-04-01|2009-04-02|Estimate|||||||2010-06-01|2010-06-02|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Health and Environmental Effects of Boiler Management Systems in Social Housing|Randomised Controlled Trial of Boiler Management Systems in Social Housing in Camden: An Assessment of Health, Environmental and Economic Outcomes|Completed||N/A|150|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-06-01 01:08:37.191994|2018-06-01 01:08:37.191994
NCT00874679|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2011-11-09|2009-04-01|2009-04-02|Estimate|||||||2011-11-09|2011-11-11|Estimate|March 2007||2007-03-31|November 2011|2011-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy|REal-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra® Therapy|Completed|||7293|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:08:37.295393|2018-06-01 01:08:37.295393
NCT00874666|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-11-18|2009-04-01|2009-04-02|Estimate|||||||2009-11-18|2009-11-20|Estimate|April 2009||2009-04-30|November 2009|2009-11-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Allicin Bioavailability From Garlic Supplements and Garlic Foods|Allicin Bioavailability of Garlic Products|Unknown status|Active, not recruiting|Early Phase 1|12|Anticipated|Silliker, Inc.||2|||f||||t||||||||||2018-06-01 01:08:37.498234|2018-06-01 01:08:37.498234
NCT00874640|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-02-19|2009-04-01|2009-04-02|Estimate|||||||2014-02-19|2014-02-20|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Observational|||Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)|Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)|Completed|||3711|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:08:37.84014|2018-06-01 01:08:37.84014
NCT00874627|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2012-12-10|2009-04-01|2009-04-02|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|Lactaide||Sublingual Milk Immunotherapy in Children|Sublingual Milk Immunotherapy in Children With IgE-mediated Cow Milk Protein Allergy|Completed||N/A|51|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:08:37.99395|2018-06-01 01:08:37.99395
NCT00874614|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01||2018-03-15|2018-03-15|2009-04-01|2009-04-02|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|June 4, 2009|Actual|2009-06-04|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 14, 2017|Actual|2017-02-14||Interventional|||A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma|A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma|Active, not recruiting||Phase 2|81|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||t||||t||||||||No||2018-06-01 01:08:38.202043|2018-06-01 01:08:38.202043
NCT00874601|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2011-10-04|2009-04-01|2009-04-02|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|July 2012|Anticipated|2012-07-31|July 2011|Actual|2011-07-31||Interventional|VENTURE||Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke|Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke|Unknown status|Recruiting|Phase 4|578|Anticipated|Hallym University Medical Center||2|||f||||t||||||||||2018-06-01 01:08:38.456077|2018-06-01 01:08:38.456077
NCT00874588|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-08-13|2009-04-01|2009-04-02|Estimate|||||||2013-08-13|2013-08-15|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer|Phase I Trial in Studying Peptide Vaccine Therapy Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer|Completed||Phase 1|6|Actual|Fukushima Medical University||1|||f||||t||||||||||2018-06-01 01:08:38.588135|2018-06-01 01:08:38.588135
NCT00874575|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-09-16|2009-04-01|2009-04-02|Estimate|||||||2014-09-16|2014-09-17|Estimate|November 2008||2008-11-30|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Nutritional Intervention for Age-related Muscular Function and Strength Losses|A Double Blind Study on the Efficacy of a Combination of Beta-hydroxy-beta-methylbutyrate and Vitamin D on Muscular Strength and Functionality in Older Adults.|Completed||Phase 1|76|Actual|Metabolic Technologies Inc.||4|||f||||t||||||||||2018-06-01 01:08:38.739795|2018-06-01 01:08:38.739795
NCT00874562|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2016-11-21|2009-04-01|2009-04-02|Estimate|||||||2016-11-21|2016-11-23|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|November 2009|Actual|2009-11-30||Interventional|||Rapamycin in Relapsed Acute Lymphoblastic Leukemia|Rapamycin in Relapsed Acute Lymphoblastic Leukemia|Completed||Phase 1|6|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 01:08:38.828617|2018-06-01 01:08:38.828617
NCT00874549|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2010-03-08||2013-09-12|2009-03-31|2009-04-02|Estimate|2010-03-08|2010-03-25|Estimate||||2013-09-12|2013-09-20|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|October 2008|Actual|2008-10-31|January 2008|Actual|2008-01-31||Interventional|||Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years|A Safety and Immunogenicity Evaluation of a Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) and a Meningococcal Polysaccharide Vaccine Groups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in Subjects 56 Years of Age or Older|Completed||Phase 1/Phase 2|216|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 01:08:38.965354|2018-06-01 01:08:38.965354
NCT00874536|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-07-29|2009-04-01|2009-04-02|Estimate|||||||2013-07-29|2013-07-30|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)|The Effect of Omega-3 Fatty Acid Supplementation on Behavior of Children With ADHD|Completed||N/A|40|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:08:40.396092|2018-06-01 01:08:40.396092
NCT00874523|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2012-04-10|2009-04-01|2009-04-02|Estimate|||||||2012-04-10|2012-04-12|Estimate|July 2009||2009-07-31|April 2010|2010-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SPARTA||Raltegravir and Atazanavir Dosing Strategy Study|A Randomised, Open-label, Cross-over Study to Examine the Pharmacokinetics and Short-term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-infected Patients|Completed||Phase 3|26|Actual|Kirby Institute||2|||f||||f||||||||||2018-06-01 01:08:40.475133|2018-06-01 01:08:40.475133
NCT00874510|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2014-09-15||2016-01-22|2009-04-01|2009-04-02|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|December 2013|Actual|2013-12-31|June 2011|Actual|2011-06-30||Interventional||Characteristics of control and intervention groups comprised of medicine interns participating in a randomized trial of a Year 1 5-hour and Year 2 3-hour protected nap period at the Philadelphia Veterans Administration Medical Center ( PVAMC) and the Hospital of the University of Pennsylvania|A Randomized Controlled Trial of Mandatory Naps for Physicians in Training|Interventions to Improve Fatigue Management Among Physician Trainees|Completed||Phase 3|352|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:08:40.58681|2018-06-01 01:08:40.58681
NCT00874497|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2016-08-23|2016-06-24|2017-03-03|2009-04-01|2009-04-02|Estimate|2017-03-03|2017-04-17|Actual|2016-06-24|2016-06-29|Estimate|2017-03-03|2017-04-17|Actual|March 2009||2009-03-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|EMPHASIS|The safety population included all randomized participants who had received study medication. Participants in this population were used for all demographic and safety summaries. Participants were analyzed based on the treatment which they had received.|Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema|A Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Pharmacodynamics, Efficacy and Safety of 50 mg Tetomilast Administered as Oral Tablets in Patients With Chronic Obstructive Pulmonary Disease Associated With Emphysema THIS STUDY IS CLOSED TO ENROLLMENT AND NEW SITES|Terminated||Phase 2|84|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|This trial was terminated early, not due to a safety concern, but due to a business decision to cease development of the tetolimast clinical program.|2||Sponsor Terminated|f||||||||||||||2018-06-01 01:08:40.93255|2018-06-01 01:08:40.93255
NCT00874458|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2014-11-20|2009-04-01|2009-04-02|Estimate|||||||2014-11-20|2014-11-21|Estimate|April 2007||2007-04-30|July 2009|2009-07-31|December 2013|Actual|2013-12-31|May 2011|Actual|2011-05-31||Interventional|||MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ|Ductal Carcinoma in Situ: Protocol Evaluating the Assessment of Extension of Disease by MRI|Completed||N/A|40|Actual|Centre Antoine Lacassagne||1|||f||||f||||||||||2018-06-01 01:08:42.009301|2018-06-01 01:08:42.009301
NCT00874445|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2015-06-03|2009-03-31|2009-04-02|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2009||2009-03-31|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|PROMISE||Comparison of 50% Tilt and Tuned Waveforms in Single-Coil Active Can Configuration|Prospective Comparison of 50/50% Tilt and Tuned Defibrillation Waveforms in a Single Coil Active Can Configuration|Completed|||77|Actual|St. Jude Medical|||2||f||||f||||||||||2018-06-01 01:08:42.17501|2018-06-01 01:08:42.17501
NCT00874432|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2015-10-06|2009-04-01|2009-04-02|Estimate|||||||2015-10-06|2015-10-08|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|December 2011|Actual|2011-12-31|||||Interventional|||Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease|Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease|Completed||N/A|90|Anticipated|University of Wisconsin, Madison||4|||f||||t||||||||||2018-06-01 01:08:42.267494|2018-06-01 01:08:42.267494
NCT00874419|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2014-09-23|2009-04-01|2009-04-02|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2008||2008-08-31|September 2014|2014-09-30|July 2012|Actual|2012-07-31|July 2010|Actual|2010-07-31||Interventional|ML20981||Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation|A Randomized, Open-label, Multi-center Phase III Study of Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With EGFR Exon 19 or 21 Mutation (Optimal)|Completed||Phase 3|165|Actual|Tongji University||2|||f||||t||||||||||2018-06-01 01:08:42.376908|2018-06-01 01:08:42.376908
NCT00874406|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer|Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer|Unknown status|Recruiting|Phase 4|100|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 01:08:42.465434|2018-06-01 01:08:42.465434
NCT00874393|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2017-05-23|2009-04-01|2009-04-02|Estimate|||||||2017-05-23|2017-05-25|Actual|July 2009||2009-07-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|ELGAN BP||Early Blood Pressure Management in Extremely Premature Infants|Early Blood Pressure Management in Extremely Preterm Infants Feasibility Pilot Study|Completed||Phase 1|10|Actual|NICHD Neonatal Research Network||4|||f||||t||||||||||2018-06-01 01:08:42.661349|2018-06-01 01:08:42.661349
NCT00874380|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-05-14|2009-04-01|2009-04-02|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Fiber Intake in an End Stage Renal Disease (ESRD) Population Followed Over 2 Years|Fiber Content of Hemodialysis Patients' Diet and it's Cardiovascular Implications.|Completed|||70|Actual|Northwell Health|||1||f||||f||||||||||2018-06-01 01:08:42.791353|2018-06-01 01:08:42.791353
NCT00874367|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2017-09-22|2009-04-01|2009-04-02|Estimate|||||||2017-09-22|2017-09-25|Actual|February 2006||2006-02-28|September 2017|2017-09-30|May 2011|Actual|2011-05-31|December 2009|Actual|2009-12-31||Observational|EOS||Early-Onset Sepsis Surveillance Study|Early-Onset Sepsis: an NICHD/CDC Surveillance Study|Completed|||615|Actual|NICHD Neonatal Research Network|||||f||||t||||||Samples Without DNA|"~     Samples of the isolated pathogens~   "|||2018-06-01 01:08:42.874369|2018-06-01 01:08:42.874369
NCT00874354|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-02-01|2009-04-01|2009-04-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2005||2005-07-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|REVITALIZE||Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction|REVITALIZE: Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction|Completed||Phase 1|27|Actual|Cedars-Sinai Medical Center||1|||f||||t||||||||No||2018-06-01 01:08:43.011993|2018-06-01 01:08:43.011993
NCT00874341|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2015-05-07|2009-04-01|2009-04-02|Estimate|||||||2015-05-07|2015-05-08|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|FIRST||Effect of Fruit and Vegetables on Insulin Resistance|Dose−Response Effect of Fruit and Vegetables on Insulin Resistance in Healthy People Who Are Overweight and at High Risk of Cardiovascular Disease|Completed||Phase 1|105|Actual|Queen's University, Belfast||3|||f||||f||||||||||2018-06-01 01:08:43.111598|2018-06-01 01:08:43.111598
NCT00874328|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2010-10-22|2009-04-01|2009-04-02|Estimate|||||||2010-10-22|2010-10-25|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Study of TS-1, Irinotecan and Cisplatin for Patients With Advanced or Metastatic NSLC|Unknown status|Recruiting|Phase 1/Phase 2|74|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-06-01 01:08:43.243036|2018-06-01 01:08:43.243036
NCT00874315|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2015-10-14|2009-04-01|2009-04-02|Estimate|||||||2015-10-14|2015-10-16|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.|A Multicenter Pilot Study of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation With In-vivo T-cell Depletion to Evaluate the Role of NK Cells and KIR Mis-matches in Relapsed or Refractory High-risk Neuroblastoma.|Withdrawn||Phase 2|0|Actual|Nationwide Children's Hospital||||lack of accrual|f||||t||||||||||2018-06-01 01:08:43.390557|2018-06-01 01:08:43.390557
NCT00874302|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-06-26|2009-03-31|2009-04-02|Estimate|||||||2014-06-26|2014-06-27|Estimate||||June 2014|2014-06-30||||||||Interventional|||Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms|A Phase III, Open Label, Randomized, Multicenter Study Evaluating the Safety and Efficacy of 25 mg and 50 mg Doses of Proellex to Assess Recurrence of Symptoms in the Treatment of Symptomatic Uterine Fibroids|Withdrawn||Phase 3|0|Actual|Repros Therapeutics Inc.||2||Study terminated for safety and the FDA put the study on hold for safety.|f||||t||||||||||2018-06-01 01:08:43.506033|2018-06-01 01:08:43.506033
NCT00874289|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2015-01-20|2009-04-01|2009-04-02|Estimate|||||||2015-01-20|2015-01-22|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|ANGLE-HF||Utility of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Predicting Renal Impairment, Further Decompensation and Rehospitalization in Acutely Decompensated and Chronic Heart Failure Patients|Utility of NGAL in Predicting Renal Impairment, Further Decompensation & Rehospitalization in Acutely Decompensated & Chronic Heart Failure Patients|Completed|||106|Actual|The Alfred|||2||f||||f||||||Samples Without DNA|"~     Blood and urine samples are being collected.~   "|||2018-06-01 01:08:43.611637|2018-06-01 01:08:43.611637
NCT00874276|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2013-03-11||2015-06-03|2009-04-01|2009-04-02|Estimate|2013-05-09|2013-06-20|Estimate||||2015-06-03|2015-06-04|Estimate|August 2009||2009-08-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacotoxicology of Trichloroethylene Metabolites|Pharmacotoxicology of Trichloroethylene Metabolites|Completed||N/A|21|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 01:08:43.701748|2018-06-01 01:08:43.701748
NCT00874263|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2012-06-21|2009-04-01|2009-04-02|Estimate|||||||2012-06-21|2012-06-22|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Observational|ASGE-FNDT-1||Confocal Probe-based Endoscopic Imaging, Colorectal Cancer, Gastrointestinal (GI) Pathologies|The Role of Endoscopic Confocal Microscopy in Diagnosing Colorectal Cancer and Other Gastrointestinal Pathologies in Vivo|Completed|||225|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 01:08:44.025972|2018-06-01 01:08:44.025972
NCT00874250|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2011-09-22||2017-07-26|2009-03-31|2009-04-02|Estimate|2011-11-08|2011-12-13|Estimate||||2017-07-26|2017-08-25|Actual|June 2009||2009-06-30|July 2017|2017-07-31|January 6, 2017|Actual|2017-01-06|January 2011|Actual|2011-01-31||Interventional|||Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic|An Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for the Primary Treatment of Aneurysm of the Descending Thoracic Aortic|Completed||N/A|51|Actual|W.L.Gore & Associates||1|||f||||t||||||||No||2018-06-01 01:08:44.118829|2018-06-01 01:08:44.118829
NCT00874237|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-06-18|2009-04-01|2009-04-02|Estimate|||||||2009-06-18|2009-06-22|Estimate|April 2009||2009-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Staccato Loxapine Thorough QT/QTc|Thorough QT/QTc Study of Staccato® Loxapine for Inhalation in Healthy Volunteers|Completed||Phase 1|46|Actual|Alexza Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 01:08:44.588601|2018-06-01 01:08:44.588601
NCT00874224|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2016-03-08|2009-04-01|2009-04-02|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ORANGE II||Surgical Recovery After Left Lateral Hepatic Sectionectomy: Laparoscopic Versus Open Surgery.|The ORANGE II Trial: An International Multicenter Randomised Controlled Trial of Optimised Surgical Recovery After Left Lateral Hepatic Sectionectomy: Open Versus Laparoscopic Surgery Within an Enhanced Recovery Programme|Completed||N/A|110|Anticipated|Maastricht University Medical Center||3|||f||||t||||||||||2018-06-01 01:08:44.70028|2018-06-01 01:08:44.70028
NCT00874211|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2018-01-31|2009-04-01|2009-04-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2008||2008-12-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases|S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment|Active, not recruiting|||3500|Anticipated|Southwest Oncology Group|||1||f||||t||||||Samples With DNA|"~     Serum for banking & whole blood for DNA analysis and banking.~   "|||2018-06-01 01:08:44.841235|2018-06-01 01:08:44.841235
NCT00874198|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-02|2009-04-01|2009-04-02|Estimate|||||||2009-04-02|2009-04-03|Estimate|October 2004||2004-10-31|April 2009|2009-04-30|June 2009|Anticipated|2009-06-30|March 2008|Actual|2008-03-31||Interventional|||European Study on Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus|European Multicenter Study on the Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus|Unknown status|Active, not recruiting|N/A|156|Anticipated|International Neuroscience Institute Hannover|||||f||||f||||||||||2018-06-01 01:08:45.740728|2018-06-01 01:08:45.740728
NCT00874185|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-02-12|2009-04-01|2009-04-02|Estimate|||||||2013-02-12|2013-02-13|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|TIERRA||Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk|Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.|Completed|||720|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:08:45.848596|2018-06-01 01:08:45.848596
NCT00874172|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2012-12-17|2009-04-01|2009-04-02|Estimate|||||||2012-12-17|2012-12-18|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|DREPANOX||Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy|New Analgesic Strategy Combining Nitrous Oxide, Nefopam, Acetaminophen and Morphine Compared to the Usal Antalgic Strategy (Acetaminophen and Morphine) for the Treatment of Acute Sickle Cell Disease Pain in the Emergency Room|Completed||N/A|176|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:08:45.927257|2018-06-01 01:08:45.927257
NCT00874159|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-08-12|2009-04-01|2009-04-02|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in Philippines|DiabCare Asia 2008 Philippines A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Philippines & To Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Philippines|Completed|||770|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Capillary or venous blood will be drawn for analysing HbA1c.~   "|||2018-06-01 01:08:46.02265|2018-06-01 01:08:46.02265
NCT00874146|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-09-01|2009-04-01|2009-04-02|Estimate|||||||2010-09-01|2010-09-02|Estimate|March 2009||2009-03-31|September 2010|2010-09-30|December 2009|Anticipated|2009-12-31|September 2009|Actual|2009-09-30||Observational|||Level of HER2-neu Gene Amplification an Response to Trastuzumab|Retrospective Study of the Level of HER2-neu Gene Amplification as Predictive Factor of Response in Patients With HER2-positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.|Unknown status|Recruiting||100|Anticipated|Istituto Clinico Humanitas|||1||f||||f||||||Samples With DNA|"~     FISH test performed on paraffine embedded tumor sections.~   "|||2018-06-01 01:08:46.111766|2018-06-01 01:08:46.111766
NCT00874133|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-12-05|2009-04-01|2009-04-02|Estimate|||||||2013-12-05|2013-12-06|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis|The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis|Terminated||N/A|8|Actual|Rabin Medical Center||2||Completed due to low number of eligible patients|f||||t||||||||||2018-06-01 01:08:46.181221|2018-06-01 01:08:46.181221
NCT00874120|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2010-06-02|2010-02-05|2015-02-20|2009-04-01|2009-04-02|Estimate|2010-06-02|2010-07-05|Estimate|2010-02-05|2010-03-04|Estimate|2015-02-20|2015-03-11|Estimate|December 2008||2008-12-31|February 2015|2015-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)|Randomized, Placebo-Controlled, Double-Blind, Two-Way Crossover Study to Evaluate the Effects of Phenylephrine HCl Extended-Release Tablets 30 mg Compared to Placebo on Ambulatory Blood Pressure|Completed||Phase 3|116|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:08:46.253066|2018-06-01 01:08:46.253066
NCT00874107|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2017-03-01|2009-04-01|2009-04-02|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2009||2009-06-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination With Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients With Previously Untreated Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer|Completed||Phase 2|90|Actual|Biothera||2|||f||||t||||||||||2018-06-01 01:08:46.43363|2018-06-01 01:08:46.43363
NCT00874094|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2011-07-18||2013-07-10|2009-04-01|2009-04-02|Estimate|2013-07-10|2013-07-12|Estimate||||2013-07-10|2013-07-12|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds|Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds|Completed||Phase 1/Phase 2|15|Actual|The New York Eye & Ear Infirmary||1|||f||||f||||||||||2018-06-01 01:08:46.578026|2018-06-01 01:08:46.578026
NCT00874068|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2011-02-23|2009-04-01|2009-04-02|Estimate|||||||2011-02-23|2011-02-24|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|InFat_002||The Effects of Dietary Palmitic Acid Triacylglyceride Position on Bone Strength Parameters in Infants|The Effects of Dietary Palmitic Acid Triacylglyceride Position on Anthropometric Measures, Bone Strength Parameters, Stool Characteristics and Stool Biochemistry in Preterm and Term Infants|Completed||N/A|94|Actual|Enzymotec||3|||f||||f||||||||||2018-06-01 01:08:46.736052|2018-06-01 01:08:46.736052
NCT00874055|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||The Presence of Friends Increases Food Intake in Youth|The Presence of Friends Increases Food Intake in Youth|Completed|||72|Actual|University at Buffalo|||||f||||f||||||||||2018-06-01 01:08:46.811572|2018-06-01 01:08:46.811572
NCT00874042|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2012-07-20|2009-04-01|2009-04-02|Estimate|||||||2012-07-20|2012-07-23|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|74|Actual|ArQule||1|||f||||f||||||||||2018-06-01 01:08:46.869452|2018-06-01 01:08:46.869452
NCT00874029|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2013-10-24||2014-06-03|2009-04-01|2009-04-02|Estimate|2014-06-03|2014-07-03|Estimate||||2014-06-03|2014-07-03|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|January 2012|Actual|2012-01-31||Interventional|Halt|Subjects who met the initial inclusion exclusion criteria were enrolled and treated. Two subjects were later found to have baseline bleeding volumes outside of the protocol inclusion limits. All 137 Subjects comprised the Safety Set. The Full Analysis Set excluded the two subjects that did not meet the baseline bleeding criteria.|Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids|Evaluation of the Halt System for Laparoscopic Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation|Completed||N/A|137|Actual|Acessa Health, Inc.||1|||f||||t||||||||||2018-06-01 01:08:46.949134|2018-06-01 01:08:46.949134
NCT00874016|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2010-12-15|2009-04-01|2009-04-02|Estimate|||||||2010-12-15|2010-12-16|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Airtraq Versus Standard Direct Laryngoscopy in the Pediatric Airway|A Comparison of the Airtraq and Standard Direct Laryngoscopy in the Pediatric Airway - A Randomized Trial.|Completed||N/A|50|Actual|IWK Health Centre||2|||f||||t||||||||||2018-06-01 01:08:47.232383|2018-06-01 01:08:47.232383
NCT00874003|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|April 2004||2004-04-30|March 2009|2009-03-31|February 2009|Actual|2009-02-28|July 2006|Actual|2006-07-31||Interventional|||The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers|The Effects of Mirtazapine vs Placebo on Alcohol Consumption in Male Alcohol High Consumers; a Randomized Controlled Trial|Completed||Phase 2|59|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-06-01 01:08:47.306774|2018-06-01 01:08:47.306774
NCT00873990|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|October 2009|Anticipated|2009-10-31|July 2009|Anticipated|2009-07-31||Interventional|FSRT||Fissure Sealant Retention Trial|Split Mouth Clinical Trial of Fissure Sealant Retention With Self Etching and Total Etch Bonding Agent|Unknown status|Recruiting|Phase 2/Phase 3|93|Anticipated|Aga Khan University||2|||f||||t||||||||||2018-06-01 01:08:47.393479|2018-06-01 01:08:47.393479
NCT00873977|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2011-11-30|2009-04-01|2009-04-02|Estimate|||||||2011-11-30|2011-12-01|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Treatment Adherence and Outcomes in Three Modalities of Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea|Comparison of Three Modalities of Continuous Positive Pressure Airway Treatment for Obstructive Sleep Apnea Syndrome|Completed||N/A|93|Actual|Kyoto University, Graduate School of Medicine||3|||f||||t||||||||||2018-06-01 01:08:48.463749|2018-06-01 01:08:48.463749
NCT00873964|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2012-04-26|2009-04-01|2009-04-02|Estimate|||||||2012-04-26|2012-04-30|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|July 2013|Anticipated|2013-07-31|April 2013|Anticipated|2013-04-30||Observational|||Metabolic Syndrome in an Elderly Population is More Linked to Insulin Resistance Than to Obesity|Metabolic Syndrome in an Elderly Population is More Linked to Insulin Resistance Than to Obesity|Unknown status|Active, not recruiting||156|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||Samples Without DNA|"~     Serum collected.~   "|||2018-06-01 01:08:48.556277|2018-06-01 01:08:48.556277
NCT00873951|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|January 2008|Actual|2008-01-31|November 2006|Actual|2006-11-30||Interventional|||Influence of Protein Hydrolysis on Dietary Protein Digestibility and Metabolism in Healthy Subjects|Influence of Protein Hydrolysis on Dietary Protein Digestibility and Metabolism in Healthy Subjects|Completed||N/A|26|Actual|Institut National de la Recherche Agronomique||3|||f||||t||||||||||2018-06-01 01:08:48.619276|2018-06-01 01:08:48.619276
NCT00873938|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2010-04-29|2009-04-01|2009-04-02|Estimate|||||||2010-04-29|2010-04-30|Estimate|October 2005||2005-10-31|April 2009|2009-04-30|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Observational|Compliance||Compliance to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana||Completed|||411|Actual|Kintampo Health Research Centre, Ghana|||2||f||||f||||||||||2018-06-01 01:08:48.691402|2018-06-01 01:08:48.691402
NCT00873925|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-04-01|2009-04-01|2009-04-02|Estimate|||||||2013-04-01|2013-04-04|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Cord Blood Plus Vitamin D and Omega 3s in T1D|Transfusion of Autologous Umbilical Cord Blood Plus Vitamin D and Omega 3 Fatty Acids to Preserve Beta Cell Function in Children With Recent Onset Type 1 Diabetes - A Pilot Study|Completed||Phase 1|15|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 01:08:48.76948|2018-06-01 01:08:48.76948
NCT00873912|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2010-10-08||2011-07-12|2009-04-01|2009-04-02|Estimate|2011-06-14|2011-07-13|Estimate||||2011-07-12|2011-07-14|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|MI-MA205||A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a New 6:2 Influenza Virus Reassortant in Healthy Adults|Completed||Phase 4|300|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 01:08:48.885518|2018-06-01 01:08:48.885518
NCT00873899|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|September 2010|Anticipated|2010-09-30|||||Observational|EVOLVO||Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators||Unknown status|Recruiting||200|Anticipated|Regione Lombardia|||2||f||||f||||||||||2018-06-01 01:08:49.592682|2018-06-01 01:08:49.592682
NCT00873886|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2015-09-28|2009-04-01|2009-04-02|Estimate|||||||2015-09-28|2015-09-29|Estimate|April 2009||2009-04-30|September 2015|2015-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy|A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||2||We will focus on other Tamiflu research studies. No subjects were enrolled.|f||||t||||||||||2018-06-01 01:08:49.845093|2018-06-01 01:08:49.845093
NCT00873873|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2011-11-27||2017-03-27|2009-04-01|2009-04-02|Estimate|2011-11-27|2012-01-06|Estimate||||2017-03-27|2017-04-26|Actual|September 2008||2008-09-30|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Progression of Airway Obstruction in Childhood Asthma|Progression of Airway Obstruction in Childhood Asthma|Completed|||55|Actual|National Jewish Health|We had planned to extend invitations to the remaining 55 participants in a streamlined version of this protocol after analyzing the preliminary data and an additional cycle of CAMP was funded in 2007.||4||f||||t||||||Samples Without DNA|"~     Induced sputum, urine, blood, and exhaled breath condensates~   "|||2018-06-01 01:08:50.060521|2018-06-01 01:08:50.060521
NCT00873860|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2016-08-26||2017-02-21|2009-04-01|2009-04-02|Estimate|2017-01-03|2017-02-23|Actual||||2017-02-21|2017-03-24|Actual|June 2009||2009-06-30|February 2017|2017-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||Intent-to-Treat (ITT) population included all participants who were randomized.|Study to Evaluate the Safety and Efficacy of CAT-354|A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), on Asthma Control in Adults With Uncontrolled, Moderate-to-severe, Persistent Asthma|Completed||Phase 2|357|Actual|MedImmune LLC||4|||f||||f||||||||||2018-06-01 01:08:51.288919|2018-06-01 01:08:51.288919
NCT00873847|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2017-09-22|2009-04-01|2009-04-02|Estimate|||||||2017-09-22|2017-09-26|Actual|July 2009||2009-07-31|September 2017|2017-09-30|August 2012|Actual|2012-08-31|June 2010|Actual|2010-06-30||Observational|||Cerebral Function Monitoring in Premature Infants|Cerebral Function Monitoring and Brain Injury in Preterm Infants: Correlation With Neuroimaging Abnormalities and Neurodevelopmental Impairment - a Pilot Study|Completed|||102|Actual|NICHD Neonatal Research Network|||||f||||t||||||||||2018-06-01 01:08:56.089764|2018-06-01 01:08:56.089764
NCT00873834|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2012-01-09|2009-04-01|2009-04-02|Estimate|||||||2012-01-09|2012-01-10|Estimate|September 2009||2009-09-30|April 2009|2009-04-30|November 2011|Anticipated|2011-11-30|November 2010|Anticipated|2010-11-30||Interventional|FAIR||Fluoxetine Essay in Children With Autism|Fluoxetine : Clinical and Anatomy-functional Therapeutic Effects in Children With Autism|Withdrawn||Phase 2|0|Actual|Assistance Publique - Hôpitaux de Paris||2||Withdrawn for problem of logistics with the associated laboratories|f||||t||||||||||2018-06-01 01:08:56.361745|2018-06-01 01:08:56.361745
NCT00873821|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2012-04-10||2015-02-24|2009-03-31|2009-04-02|Estimate|2012-06-06|2012-07-11|Estimate||||2015-02-24|2015-03-09|Estimate|December 2008||2008-12-31|February 2015|2015-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration in Subjects With Type 2 Diabetes|Completed||Phase 1|44|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:08:56.883746|2018-06-01 01:08:56.883746
NCT00873808|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2013-04-09|2009-04-01|2009-04-02|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307|Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)|Withdrawn|||0|Actual|Southwest Oncology Group||||lack of accrual|f||||t||||||||||2018-06-01 01:08:57.722808|2018-06-01 01:08:57.722808
NCT00873795|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|April 2007||2007-04-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression|Efficacy and Safety of Aripiprazole 2.5mg Combine Sertraline 50mg in Major Depression|Completed||N/A|41|Actual|Chimei Medical Center||2|||f||||t||||||||||2018-06-01 01:08:58.004793|2018-06-01 01:08:58.004793
NCT00873782|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2015-01-22||2015-02-27|2009-04-01|2009-04-02|Estimate|2015-02-27|2015-03-09|Estimate||||2015-02-27|2015-03-09|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy|Safety and Feasibility of Transvenous Limb Perfusion With Normal Saline in Human Muscular Dystrophy|Completed||Phase 1|16|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-06-01 01:08:58.432598|2018-06-01 01:08:58.432598
NCT00873769|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2017-03-13|2009-04-01|2009-04-02|Estimate|||||||2017-03-13|2017-03-15|Actual|April 2009||2009-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Staccato Loxapine PK in Smokers and Nonsmokers|Pharmacokinetics of Staccato® Loxapine for Inhalation in Smokers Compared to Nonsmokers|Completed||Phase 1|35|Actual|Alexza Pharmaceuticals, Inc.||2|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 01:08:59.001092|2018-06-01 01:08:59.001092
NCT00873756|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2016-11-01|2009-03-31|2009-04-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer|A Phase Ib Study of the Safety and Pharmacokinetics of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer|Completed||Phase 1|23|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:08:59.324449|2018-06-01 01:08:59.324449
NCT00873743|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2009-04-01|2009-04-01|2009-04-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|October 2009|Anticipated|2009-10-31|May 2009|Anticipated|2009-05-31||Observational|||Analgesia and Antihyperalgesia of Tramadol and Acetaminophen Per Oral After Caesarean Section|Postoperative Analgesia and Antihyperalgesia of Tramadol and Acetaminophen Per Oral After Caesarean Section -A Randomised Controlled Trial in Female O-Desmethyl 1 Metabolizers Identified by the Respective Gene-|Suspended|||120|Anticipated|Medical University of Vienna|||2|Study was stopped because of ineffectiveness of one investigated Drug|f||||t||||||Samples With DNA|"~     CYP P450 2D6 metabolizer status~   "|||2018-06-01 01:08:59.621171|2018-06-01 01:08:59.621171
NCT00873730|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|2009-06-30||2010-04-23|2009-04-01|2009-04-02|Estimate|2009-06-30|2009-08-13|Estimate||||2010-04-23|2010-04-28|Estimate|December 2006||2006-12-31|April 2010|2010-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|Loadet||Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain|A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis|Completed||Phase 4|108|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:08:59.830686|2018-06-01 01:08:59.830686
NCT00873717|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-01|||2012-07-25|2009-04-01|2009-04-02|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Nutrident||Improvement of Nutritional Status in Elderly Residents of Long-term Facilities|Improvement of Nutritional Status in Elderly Residents of Long-term Facilities: Impact of Two Strategies (Oral Care and Dietary Control)|Completed||N/A|114|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-06-01 01:09:00.66158|2018-06-01 01:09:00.66158
NCT00873704|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2015-10-11|2009-03-31|2009-04-02|Estimate|||||||2015-10-11|2015-10-14|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Supplemental Oxygen in Vascular Surgery|Supplemental Postoperative Oxygen and the Risk of Surgical Wound Infection in a Vascular Surgery Population: A Randomized Controlled Trial|Completed||N/A|274|Actual|North Karelia Central Hospital||2|||f||||f||||||||||2018-06-01 01:09:00.76736|2018-06-01 01:09:00.76736
NCT00873691|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2015-06-03|2009-03-31|2009-04-01|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2009||2009-03-31|June 2015|2015-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|Tilt & Tune||Comparison of Fixed Tilt and Tuned Waveforms in Right-sided Implants|Prospective Comparison of 50/50% Tilt and Tuned Defibrillation Waveforms in Right-Sided Implants|Completed|||129|Actual|St. Jude Medical|||2||f||||f||||||||||2018-06-01 01:09:00.863252|2018-06-01 01:09:00.863252
NCT00873678|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2010-06-02|2009-03-31|2009-04-01|Estimate|||||||2010-06-02|2010-06-03|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|JSCORS||Assessment of the Prevalence of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome|Assessment of the Prevalence and Mutational Spectrum of Genes AHI1, NPHP1 and CEP290 in Joubert Syndrome and Cerebello-oculo-renal Syndromes|Completed|||80|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Whole blood sample (10 ml)~   "|||2018-06-01 01:09:00.943006|2018-06-01 01:09:00.943006
NCT00873665|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2013-10-25|2009-03-31|2009-04-01|Estimate|||||||2013-10-25|2013-10-28|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Erectile Dysfunction Study|Exercise Training, Erectile Dysfunction, and Prostate Cancer Study.|Completed||N/A|64|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:09:01.031757|2018-06-01 01:09:01.031757
NCT00873652|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2017-12-07|2009-03-31|2009-04-01|Estimate|||||||2017-12-07|2017-12-08|Actual|February 2009||2009-02-28|December 2017|2017-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Observational Study of Immune Response to Hepatitis B Childhood Booster|An Observational Study of Children Immunised in Infancy Against Hepatitis B Virus, Evaluating the Persistence of Immunity and the Immune Response to a Scheduled Booster Dose of Hepatitis B Vaccine|Completed|||28|Actual|University of Oxford|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:09:01.147803|2018-06-01 01:09:01.147803
NCT00873639|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2016-10-13|2009-03-31|2009-04-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2009||2009-04-30|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoRapid® (Insulin Aspart) and Levemir® (Insulin Detemir) in a Basal-bolus Regimen for Treatment of Type 1 Diabetes Mellitus in Romania|Completed|||417|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:09:01.323518|2018-06-01 01:09:01.323518
NCT00873626|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-11-05|2009-03-31|2009-04-01|Estimate|||||||2014-11-05|2014-11-06|Estimate|June 2009||2009-06-30|June 2011|2011-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|DTP||Treatment's Duration of Acute Uncomplicated Pyelonephritis|Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis.|Completed||Phase 4|310|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:09:01.425055|2018-06-01 01:09:01.425055
NCT00873613|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-11-07|2009-03-31|2009-04-01|Estimate|||||||2013-11-07|2013-11-08|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Interventional|||Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine?|Digital Ocular Fundus Photography in the Emergency Department: A New Application for Telemedicine?|Completed||N/A|705|Actual|Emory University||2|||f||||f||||||||||2018-06-01 01:09:01.59102|2018-06-01 01:09:01.59102
NCT00873600|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2015-03-17|2009-03-31|2009-04-01|Estimate|||||||2015-03-17|2015-03-19|Estimate|October 2007||2007-10-31|March 2015|2015-03-31||||||||Observational|||Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer|A Randomized Controlled Trial of Outpatient Geriatric Evaluation and Management Among Older Patients With Breast and Colon Cancer|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||No accrual|f||||t||||||||||2018-06-01 01:09:01.683598|2018-06-01 01:09:01.683598
NCT00873587|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2015-10-11|2009-03-31|2009-04-01|Estimate|||||||2015-10-11|2015-10-14|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Clinical Trial Evaluating the Optimal Technique for Chest Tube Removal|Randomized Clinical Trial Evaluating the Optimal Technique for Chest Tube Removal|Completed||N/A|342|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:09:01.79578|2018-06-01 01:09:01.79578
NCT00873574|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-03-07|2009-03-31|2009-04-01|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|May 2011|Actual|2011-05-31||Observational|SMP||JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders|Molecular Study of Factors Involved in JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders|Completed|||234|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Peripheral blood samples (35 ml) and buccal swabs~   "|||2018-06-01 01:09:01.888862|2018-06-01 01:09:01.888862
NCT00873561|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-03-30|2009-03-30|2009-04-01|Estimate|||||||2009-03-30|2009-04-01|Estimate|December 2001||2001-12-31|March 2009|2009-03-31|July 2006|Actual|2006-07-31|April 2006|Actual|2006-04-30||Interventional|||A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel, Dose-Ranging Study to Evaluate The Efficacy, Safety, Tolerability, and Pharmacodynamics of NBI-6024 In Adult and Adolescent Patients With New Onset Type 1 Diabetes Mellitus|Completed||Phase 1|188|Actual|Neurocrine Biosciences||4|||f||||t||||||||||2018-06-01 01:09:01.983219|2018-06-01 01:09:01.983219
NCT00873548|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-01-24|2009-03-31|2009-04-01|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Observational|||Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation (PFNA)-Asia|Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation Asia - A Prospective Multicenter Case Series|Completed|||245|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-06-01 01:09:02.135935|2018-06-01 01:09:02.135935
NCT00873535|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2015-09-03|2009-03-31|2009-04-01|Estimate|||||||2015-09-03|2015-09-07|Estimate|October 2008||2008-10-31|September 2015|2015-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Varenicline on Reactivity to Smoking and Drinking Cues|Effect of Varenicline on Reactivity to Smoking and Drinking Cues in Individuals With Concurrent Tobacco Dependence and Alcohol Use|Completed||N/A|48|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 01:09:02.314529|2018-06-01 01:09:02.314529
NCT00873522|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-03-31|2009-03-31|2009-04-01|Estimate|||||||2009-03-31|2009-04-01|Estimate|March 2008||2008-03-31|March 2009|2009-03-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Observational|||Microbiology and Clinical Outcome of Pneumonia|Microbiology and Clinical Outcome of Community Acquired Pneumonia and Health-Care-Associated Pneumonia in Taiwan: a Multi-Center Study|Unknown status|Recruiting||2600|Anticipated|Taichung Veterans General Hospital|||2||f||||f||||||||||2018-06-01 01:09:02.445566|2018-06-01 01:09:02.445566
NCT00873509|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2016-07-25|2009-03-31|2009-04-01|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2009||2009-05-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|B-ACE||Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder|A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder|Completed||Phase 2/Phase 3|166|Actual|Chugani, Diane C.||3|||f||||t||||||||||2018-06-01 01:09:02.579004|2018-06-01 01:09:02.579004
NCT00873496|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-03-31|2009-03-31|2009-04-01|Estimate|||||||2009-03-31|2009-04-01|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Observational|||Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients|Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study.|Completed|||30|Actual|Ege University|||1||f||||f||||||||||2018-06-01 01:09:02.709553|2018-06-01 01:09:02.709553
NCT00873483|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-09-30|2009-03-31|2009-04-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||US Ovulation Inhibition Study in Obese Women|Multicenter, Open-Label, Uncontrolled Study to Investigate the Impact of Weight and BMI on Inhibition of Ovulation of a Transdermal Patch Formulation Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene in Young Female Volunteers Stratified by BMI Over a Period of 3 Treatment Cycles|Completed||Phase 2|173|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:09:02.941399|2018-06-01 01:09:02.941399
NCT00873470|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-02-07|2009-03-31|2009-04-01|Estimate|||||||2013-02-07|2013-02-08|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|WPW||Wolff-Parkinson-White Syndrome Anterograde Refractory Period of Accessory Duct|Long Term Evolution of the Anterograde Refractory Period of Accessory Duct in the Wolff-Parkinson-White Syndrome|Terminated||N/A|13|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-06-01 01:09:03.253594|2018-06-01 01:09:03.253594
NCT00873457|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2012-12-15||2013-05-19|2009-03-31|2009-04-01|Estimate|2012-12-15|2013-01-24|Estimate||||2013-05-19|2013-05-27|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|October 2011|Actual|2011-10-31||Interventional|||Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Completed||Phase 2|16|Actual|Duke University|Early termination leading to small numbers of subjects analyzed. All patients were heavily pretreated and had aggressive disease.|1|||f||||f||||||||||2018-06-01 01:09:03.52175|2018-06-01 01:09:03.52175
NCT00873444|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2016-05-09|2009-03-31|2009-04-01|Estimate|||||||2016-05-09|2016-05-11|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing|Randomised, Controlled, Prospective, Multi-Centre, Post Market Surveillance Study Comparing a Ceramic-on-Metal Bearing and a Metal-on-Metal Bearing in Subjects Requiring Primary Total Hip Arthroplasty for Non-Inflammatory Degenerative Joint Disease|Terminated||Phase 4|5|Actual|DePuy International||2||"Study progress very slow therefore terminated as other projects underway to investigate the~   same research question which will deliver results earlier"|f||||f||||||||||2018-06-01 01:09:04.318077|2018-06-01 01:09:04.318077
NCT00873431|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2012-10-18|2009-03-31|2009-04-01|Estimate|||||||2012-10-18|2012-10-19|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47|An Open-Label Phase 1 Study Assessing the Safety, Immunogenicity and Dose Response of IC47, a New Vaccine Against Streptococcus Pneumoniae, in Healthy Subjects.|Completed||Phase 1|32|Actual|Valneva Austria GmbH||4|||f||||t||||||||||2018-06-01 01:09:04.551393|2018-06-01 01:09:04.551393
NCT00873418|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2017-03-29|2009-03-31|2009-04-01|Estimate|||||||2017-03-29|2017-03-31|Actual|March 2009||2009-03-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|COPE-HF||Coping Skills and Heart Failure: Outcomes and Mechanisms|Coping Skills Training in Heart Failure: Outcomes and Mechanisms|Completed||N/A|190|Actual|Duke University||2|||f||||t||||||||No||2018-06-01 01:09:04.805947|2018-06-01 01:09:04.805947
NCT00873405|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-03-31|2009-03-31|2009-04-01|Estimate|||||||2009-03-31|2009-04-01|Estimate|June 2006||2006-06-30|March 2009|2009-03-31||||June 2009|Anticipated|2009-06-30||Interventional|||Banded Sleeve Gastrectomy Versus Banded Ring Gastric Bypass in Morbidly Obese Patients|Banded Sleeve Gastrectomy Versus Banded Ring Gastric Bypass in Morbidly Obese Patients: a Prospective Controlled Trial.|Unknown status|Active, not recruiting|N/A|65|Anticipated|Federal University of Espirito Santo||2|||f||||t||||||||||2018-06-01 01:09:05.034737|2018-06-01 01:09:05.034737
NCT00873392|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-12-29|2009-03-31|2009-04-01|Estimate|||||||2013-12-29|2013-12-31|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|NICOPARK2||Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease|Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease(One Daily Administration).A Controlled Randomised Study, in Two Parallel Groups and Single Blind in 40 Patients.|Completed||Phase 2|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:09:05.492351|2018-06-01 01:09:05.492351
NCT00873379|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-07-06|2009-03-31|2009-04-01|Estimate|||||||2009-07-06|2009-07-07|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly|Melatonin Supplementation for Delirium Prevention in Acutely Hospitalized Elderly: a Randomized, Double Blind, Placebo-Controlled Trial|Completed||Phase 3|122|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 01:09:05.70318|2018-06-01 01:09:05.70318
NCT00873366|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2017-10-12||2018-01-22|2009-03-31|2009-04-01|Estimate|2018-01-22|2018-01-23|Actual||||2018-01-22|2018-01-23|Actual|May 2009||2009-05-31|May 2017|2017-05-31|September 23, 2015|Actual|2015-09-23|September 23, 2015|Actual|2015-09-23||Observational|||Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer|¹³C - Dextromethorphan (DM) Breath Test for Determination of CYP2D6 Enzyme Activity in Patients Receiving Tamoxifen|Terminated|||92|Actual|Mayo Clinic||||Funding issues|f||||t||||||||||2018-06-01 01:09:05.924863|2018-06-01 01:09:05.924863
NCT00873353|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2010-08-17|2009-03-31|2009-04-01|Estimate|||||||2010-08-17|2010-08-18|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2008|Actual|2008-08-31||Interventional|XELTA||Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients|An Open Non-randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|32|Actual|Grupo Gallego de Investigaciones Oncologicas||1|||f||||f||||||||||2018-06-01 01:09:06.957204|2018-06-01 01:09:06.957204
NCT00873340|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-06-25|2009-03-31|2009-04-01|Estimate|||||||2014-06-25|2014-06-26|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Physical Disability in Patients Treated With Betaferon|Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice|Completed|||83|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 01:09:07.172181|2018-06-01 01:09:07.172181
NCT00873327|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2012-11-25||2013-05-29|2009-03-31|2009-04-01|Estimate|2013-05-28|2013-05-30|Estimate||||2013-05-29|2013-06-05|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates|Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates|Completed||Phase 1|32|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:09:07.368642|2018-06-01 01:09:07.368642
NCT00873314|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-31|2009-03-31|2009-04-01|Estimate|||||||2009-03-31|2009-04-01|Estimate|July 2006||2006-07-31|March 2009|2009-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Bed Rest for Threatened Preterm Labor. Pilot Study|Bed Rest for Arrested Threatened Preterm Labor. Pilot Study for the Design of a Randomized Controlled Clinical Trial.|Completed||N/A|46|Actual|Institute for Clinical Effectiveness and Health Policy||2|||f||||f||||||||||2018-06-01 01:09:07.703769|2018-06-01 01:09:07.703769
NCT00873301|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2012-03-29|2009-03-31|2009-04-01|Estimate|||||||2012-03-29|2012-04-02|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||The Effectiveness of Vestibulectomy||Completed||N/A|40|Actual|Western Galilee Hospital-Nahariya||1|||f||||f||||||||||2018-06-01 01:09:08.022358|2018-06-01 01:09:08.022358
NCT00873288|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2010-01-27|2009-03-31|2009-04-01|Estimate|||||||2010-01-27|2010-01-28|Estimate|October 2006||2006-10-31|March 2009|2009-03-31||||September 2009|Anticipated|2009-09-30||Interventional|||Personalized Letter With Cancer Information Service Support or a Standard Reminder Letter in Women Scheduled for Colposcopy After an Abnormal Pap Test|Activating Collaborative CIS Support Via Targeted Provider Mailing|Unknown status|Recruiting|N/A|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:09:08.284848|2018-06-01 01:09:08.284848
NCT00873275|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2018-02-09|2009-03-31|2009-04-01|Estimate|||||||2018-02-09|2018-02-12|Actual|March 4, 2009||2009-03-04|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer|Phase I Study of Ursodeoxycholic Acid (Ursodiol)in Combination With 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Cancer|Active, not recruiting||Phase 1|30|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:09:08.564919|2018-06-01 01:09:08.564919
NCT00873262|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2010-06-15|2009-03-31|2009-04-01|Estimate|||||||2010-06-15|2010-06-16|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|November 2010|Anticipated|2010-11-30|May 2010|Anticipated|2010-05-31||Interventional|||Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS)|A Phase II Randomized, Two-arms, Single-blind, Cross Controlled Study for Evaluation the Safety and Efficacy of Diagnosis and Treatment of Premenstrual Syndrome by Detecting Skin Reactions Followed by Desensitization to Sex Hormones|Unknown status|Recruiting|Phase 2|20|Anticipated|EVE Medical Systems Ltd.||2|||f||||t||||||||||2018-06-01 01:09:08.899894|2018-06-01 01:09:08.899894
NCT00873249|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2010-03-23|2009-03-31|2009-04-01|Estimate|||||||2010-03-23|2010-03-24|Estimate|April 2009||2009-04-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|SMS||Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia|Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia|Completed|||339|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:09:09.207516|2018-06-01 01:09:09.207516
NCT00873236|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-08-09|2009-03-31|2009-04-01|Estimate|||||||2013-08-09|2013-08-12|Estimate|April 2008||2008-04-30|March 2009|2009-03-31||||||||Interventional|||MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer|Dynamic Contrast Enhanced MRI (DCE-MRI) Assessment of the Vascular Changes Induced With Bevacizumab Alone and in Combination With Interferon-α in Patients With Advanced Renal Cell Carcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 01:09:09.378381|2018-06-01 01:09:09.378381
NCT00873223|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2017-01-25|2009-03-31|2009-04-01|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2009||2009-03-31|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir|Insulin Detemir Co-administered With Liraglutide: An Open Label Trial to Assess Insulin Detemir and Liraglutide Pharmacokinetics and Pharmacodynamics Following Liraglutide Therapy in Subjects With Type 2 Diabetes|Completed||Phase 1|33|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 01:09:09.479411|2018-06-01 01:09:09.479411
NCT00873210|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2012-11-07|2009-03-30|2009-04-01|Estimate|||||||2012-11-07|2012-11-09|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Study In Patients With Kidney Cancer Treated With Sutent|Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent|Completed|||121|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:09:09.559866|2018-06-01 01:09:09.559866
NCT00873197|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2009-05-01|2009-03-31|2009-04-01|Estimate|||||||2009-05-01|2009-05-04|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||PK, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and IV Granisetron|A Study to Assess the Pharmacokinetics, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and Intravenous Granisetron in Healthy Subjects|Completed||Phase 1|12|Actual|Prostrakan Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:09:09.807275|2018-06-01 01:09:09.807275
NCT00873184|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2013-05-29|2009-03-31|2009-04-01|Estimate|||||||2013-05-29|2013-05-30|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of Massage Therapy Within a Brain Tumor Setting|Feasibility Study of Massage Therapy Within a Brain Tumor Setting|Completed||N/A|10|Actual|Duke University||1|||f||||t||||||||||2018-06-01 01:09:09.961211|2018-06-01 01:09:09.961211
NCT00873171|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2010-04-15|2009-03-31|2009-04-01|Estimate|||||||2010-04-15|2010-04-16|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Osteopathic Manipulation Therapy in the Treatment of Interstitial Cystitis|Osteopathic Manipulation Therapy in the Treatment of Interstitial Cystitis|Completed|||24|Actual|CAMC Health System|||3||f||||f||||||||||2018-06-01 01:09:10.109433|2018-06-01 01:09:10.109433
NCT00873158|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-08-08|2009-03-31|2009-04-01|Estimate|||||||2013-08-08|2013-08-12|Estimate|January 2006||2006-01-31|August 2013|2013-08-31||||January 2014|Anticipated|2014-01-31||Interventional|DS-SDH||Dynamic Splinting for Patients With Adhesive Capsulitis|Outcomes Following Dynamic Splinting and/or Physical Therapy for Patients With Adhesive Capsulitis|Terminated||N/A|10|Actual|Dynasplint Systems, Inc.||2||Unrelated to trial|f||||t||||||||||2018-06-01 01:09:10.210041|2018-06-01 01:09:10.210041
NCT00873145|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2015-04-14|2009-03-31|2009-04-01|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2008||2008-12-31|March 2009|2009-03-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Observational|||Management of Bone Defects Around the Elbow|Modular Prosthetic Reconstruction of Major Bone Defects of the Distal Humerus.|Completed|||50|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-06-01 01:09:10.296705|2018-06-01 01:09:10.296705
NCT00873132|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2013-06-17|2009-03-31|2009-04-01|Estimate|||||||2013-06-17|2013-06-19|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||BTC Neuropsychological Database|BTC Neuropsychological Database:Prospective Study|Withdrawn|||0|Actual|Duke University|||1|No Funding|f||||f||||||||||2018-06-01 01:09:10.36476|2018-06-01 01:09:10.36476
NCT00873119|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2014-07-01|2013-12-18|2015-07-07|2009-03-31|2009-04-01|Estimate|2014-12-08|2014-12-09|Estimate|2013-12-18|2014-01-24|Estimate|2015-07-07|2015-07-28|Estimate|February 2009||2009-02-28|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary|An Open-label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary|Completed||Phase 2|89|Actual|Onxeo||2|||f||||||||||||||2018-06-01 01:09:10.469373|2018-06-01 01:09:10.469373
NCT00873106|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-09-05|2009-03-31|2009-04-01|Estimate|||||||2012-09-05|2012-09-06|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography|Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography|Completed|||20|Actual|Glostrup University Hospital, Copenhagen|||||f||||f||||||||||2018-06-01 01:09:11.161975|2018-06-01 01:09:11.161975
NCT00873093|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2016-02-09||2016-11-30|2009-03-31|2009-04-01|Estimate|2016-11-30|2017-01-27|Estimate||||2016-11-30|2017-01-27|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)|Completed||Phase 2|148|Actual|National Cancer Institute (NCI)||5|||f||||t||||||||||2018-06-01 01:09:12.514543|2018-06-01 01:09:12.514543
NCT00873080|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-04-01|Estimate|||||||2009-03-30|2009-04-01|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|SAPO||Reliability of the Angle Measurement of the Software for Photogrammetry Postural Assessment (SAPO)|Reliability of the Angle Measurement of the Software for Photogrammetry Postural Assessment|Completed|||24|Actual|Universidade Federal de Santa Maria|||||f||||f||||||||||2018-06-01 01:09:15.436328|2018-06-01 01:09:15.436328
NCT00873067|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-02-26|2009-03-31|2009-04-01|Estimate|||||||2014-02-26|2014-02-27|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|September 2013|Actual|2013-09-30|February 2012|Actual|2012-02-29||Interventional|||Benefit of Complex Fractionated Atrial Electrograms Elimination in Atrial Fibrillation Ablation|Benefit of Complex Fractionated Atrial Electrograms Elimination in Atrial Fibrillation Ablation|Completed||Phase 3|142|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 01:09:15.528698|2018-06-01 01:09:15.528698
NCT00873054|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2014-01-30|2009-03-31|2009-04-01|Estimate|||||||2014-01-30|2014-02-03|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Observational|||Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy|Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy|Completed|||32|Actual|CAMC Health System|||2||f||||f||||||||||2018-06-01 01:09:15.629591|2018-06-01 01:09:15.629591
NCT00873041|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2012-06-20||2013-05-20|2009-03-31|2009-04-01|Estimate|2012-08-22|2012-09-25|Estimate||||2013-05-20|2013-07-09|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|THALASSA||Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study|A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload|Completed||Phase 2|166|Actual|Novartis||4|||f||||||||||||||2018-06-01 01:09:15.754552|2018-06-01 01:09:15.754552
NCT00873028|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-31|2009-03-31|2009-04-01|Estimate|||||||2009-03-31|2009-04-01|Estimate|August 2004||2004-08-31|March 2009|2009-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Evaluation of Inspiratory Muscle Strength Early After Coronary Artery Bypass|Inspiratory Muscle Strength as a Determinant of Functional Capacity Early After Coronary Artery Bypass Graft Surgery|Completed||Phase 3|20|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:09:16.819966|2018-06-01 01:09:16.819966
NCT00873015|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2013-01-26||2017-05-09|2009-03-31|2009-04-01|Estimate|2013-05-06|2013-07-16|Estimate||||2017-05-09|2017-06-07|Actual|April 2010||2010-04-30|May 2017|2017-05-31|August 2012|Actual|2012-08-31|November 2010|Actual|2010-11-30||Interventional|||Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm|Safety and Pharmacokinetic Evaluation of Sodium Nitrite Injection for the Prevention of Post-Subarachnoid Hemorrhage Induced Vasospasm|Completed||Phase 2|19|Actual|Hope Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:09:16.930499|2018-06-01 01:09:16.930499
NCT00873002|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2012-03-16|2009-03-31|2009-04-01|Estimate|||||||2012-03-16|2012-03-20|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery|Phase I Study of Combination of Sorafenib and LBH589 in Hepatocellular Carcinoma|Terminated||Phase 1|3|Actual|Case Comprehensive Cancer Center||1||Dose Limiting Toxicity|f||||t||||||||||2018-06-01 01:09:17.329453|2018-06-01 01:09:17.329453
NCT00872989|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|2015-09-28||2016-10-26|2009-03-31|2009-04-01|Estimate|2016-10-26|2016-12-19|Estimate||||2016-10-26|2016-12-19|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|||S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|129|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 01:09:17.586197|2018-06-01 01:09:17.586197
NCT00872976|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2013-07-19|2009-03-31|2009-04-01|Estimate|||||||2013-07-19|2013-07-22|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia|Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||2||Business Objectives Changed|f||||f||||||||||2018-06-01 01:09:19.054529|2018-06-01 01:09:19.054529
NCT00872963|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-31|||2015-12-04|2009-03-31|2009-04-01|Estimate|||||||2015-12-04|2015-12-07|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|February 2016|Anticipated|2016-02-29||Observational|MAL059||An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial|An Extended Follow up of a Phase 2b Vaccine Trial With RTS,S/AS01E in Kilifi District, Kenya.|Unknown status|Active, not recruiting||450|Anticipated|KEMRI-Wellcome Trust Collaborative Research Program|||2||f||||t||||||Samples Without DNA|"~     Yearly cross sectional bleeds to collect blood samples.~   "|||2018-06-01 01:09:19.173109|2018-06-01 01:09:19.173109
NCT00872950|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2018-01-10|2009-03-31|2009-04-01|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2001||2001-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|LEMS||3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)|Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)|Recruiting||N/A|25|Anticipated|Lahey Clinic||1|||f||||f||||||||||2018-06-01 01:09:19.282841|2018-06-01 01:09:19.282841
NCT00872937|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2012-05-16|2009-03-30|2009-03-31|Estimate|||||||2012-05-16|2012-05-17|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|March 2009|Actual|2009-03-31||Observational|||Retrospective Study of the Relationship Between Human Papillomavirus Genotype and Cervical Epithelial Lesions|Retrospective Study of the Relationship Between Human Papillomavirus Genotype and Cervical Epithelial Lesions|Unknown status|Recruiting||800|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:09:19.421195|2018-06-01 01:09:19.421195
NCT00872924|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Bioequivalence Study of Sumatriptan 100mg Tablets Under Fasting Conditions|An Open Label, Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets (Containing 140 mg of Sumatriptan Succinate Equivalent to 100 mg Sumatriptan) Under Fasting Conditions|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:09:19.512535|2018-06-01 01:09:19.512535
NCT00872911|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2016-12-08|2009-03-27|2009-03-31|Estimate|||||||2016-12-08|2016-12-12|Estimate|March 2009||2009-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Interventional|||Nutrition and Exercise for Sarcopenia|Nutrition and Exercise to Improve Protein Metabolism and Prevent Sarcopenia in Aging|Completed||Phase 1|108|Actual|The University of Texas Medical Branch, Galveston||4|||f||||f||||||||||2018-06-01 01:09:19.728787|2018-06-01 01:09:19.728787
NCT00872898|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2013-08-01|2012-08-16|2013-11-26|2009-03-30|2009-03-31|Estimate|2013-11-26|2014-01-14|Estimate|2012-08-16|2012-08-23|Estimate|2013-11-26|2014-01-14|Estimate|April 2009||2009-04-30|November 2013|2013-11-30||||August 2012|Actual|2012-08-31||Interventional||Part One of the study enrolled 4 patients to determine a safe dosing regimen for Part Two along with data collected for 14 patients enrolled in study MEM-PK-21. One patient from Part One of the study also enrolled in Part Two. The 121 patients enrolled in Part Two were randomized after two weeks of single-blind placebo treatment.|Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism|An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism|Completed||Phase 2|124|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 01:09:19.908206|2018-06-01 01:09:19.908206
NCT00872885|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24||2010-06-11|2010-06-21|2009-03-30|2009-03-31|Estimate||||2010-06-11|2010-06-14|Estimate|2010-06-21|2010-07-19|Estimate|March 2009||2009-03-31|June 2010|2010-06-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Bunionectomy Trial With GRT6005|A Randomized, Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Moderate to Severe Pain Following Bunionectomy.|Completed||Phase 2|258|Actual|Grünenthal GmbH||5|||f||||f||||||||||2018-06-01 01:09:20.695872|2018-06-01 01:09:20.695872
NCT00872872|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2017-05-07|2009-03-30|2009-03-31|Estimate|||||||2017-05-07|2017-05-09|Actual|May 2008||2008-05-31|May 2017|2017-05-31|April 2025|Anticipated|2025-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Nevirapine Clearance After Short-term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT)|Nevirapine Plasma Level After Discontinuation of Short-term Antiretroviral Treatment for the Prevention of Mother-to-child Transmission of HIV and Development of Drug Resistant HIV-1 Variants With 1 or 2 Weeks Continuation of Zidovudine/Lamivudine in Women After Delivery|Active, not recruiting||N/A|30|Actual|Thai Red Cross AIDS Research Centre||2|||f||||f||||||||||2018-06-01 01:09:20.818059|2018-06-01 01:09:20.818059
NCT00872859|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2017-05-16|2009-03-30|2009-03-31|Estimate|||||||2017-05-16|2017-05-18|Actual|October 2008||2008-10-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|May 2011|Actual|2011-05-31||Interventional|||The BREASTrial:Breast Reconstruction Evaluation Using Acellular Dermal Matrix as a Sling Trial|The BREASTrial: Breast Reconstruction Evaluation Using Acellular Dermal Matrix as a Sling Trial|Completed||Phase 4|128|Actual|University of Utah||4|||f||||t||||||||||2018-06-01 01:09:20.937144|2018-06-01 01:09:20.937144
NCT00872833|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2014-04-09||2015-10-05|2009-03-30|2009-03-31|Estimate|2014-08-12|2014-08-27|Estimate||||2015-10-05|2015-10-07|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions|Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles|Completed|||32|Actual|New England Research Institutes|||2||f||||t||||||||||2018-06-01 01:09:21.235613|2018-06-01 01:09:21.235613
NCT00872820|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2014-12-09|2009-03-30|2009-03-31|Estimate|||||||2014-12-09|2014-12-11|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Examining Long-Term Effects and Neural Mediators of Behavioral Treatments for Social Anxiety Disorder|Neural Mediators of Behavior Therapy for Anxiety|Completed||N/A|50|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-06-01 01:09:21.759841|2018-06-01 01:09:21.759841
NCT00872807|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2014-12-11|2009-03-30|2009-03-31|Estimate|||||||2014-12-11|2014-12-12|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||The Activity School in Finnmark for Overweight Children|The Activity School in Finnmark for Overweight and Obese Children and Their Families|Completed||N/A|97|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 01:09:21.844488|2018-06-01 01:09:21.844488
NCT00872794|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2017-06-23|2009-03-30|2009-03-31|Estimate|||||||2017-06-23|2017-06-26|Actual|November 2003||2003-11-30|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Single Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery|Prospective Single-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy ASR™ Hip in Subjects With Suitable Indications for a Primary Resurfacing Hip Arthroplasty|Terminated||Phase 4|50|Actual|DePuy International||1||"DePuy discontinued this product in 4Q 2009.At the time of this decision DePuy reviewed all~   clinical studies for this product and decided to close this Study."|f||||f||||||||||2018-06-01 01:09:22.005861|2018-06-01 01:09:22.005861
NCT00872781|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study Comparing Fixed Dose Combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg Tablets of OHM Laboratories Inc (a Subsidiary of Ranbaxy Pharmaceuticals Inc) With ACCURETICTM Tablets (Containing Fixed Dose Combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg) of Parke Davis, in Healthy, Adult, Human, Male Subjects Under Fasting Condition.|Completed||N/A|64|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:09:22.077838|2018-06-01 01:09:22.077838
NCT00872755|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|January 2002||2002-01-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD)|Laparoscopic Nissen Fundoplication Combined With Posterior Gastropexy in Surgical Treatment of Gastroesophageal Reflux Disease|Completed||Phase 4|90|Actual|G. Hatzikosta General Hospital||2|||f||||f||||||||||2018-06-01 01:09:22.181034|2018-06-01 01:09:22.181034
NCT00872742|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2014-04-08|2009-03-30|2009-03-31|Estimate|||||||2014-04-08|2014-04-10|Estimate|March 2009||2009-03-31|April 2014|2014-04-30|October 2014|Anticipated|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Testing a New Therapy for Trichotillomania|Acceptance Enhanced Behavior Therapy for Trichotillomania|Unknown status|Active, not recruiting|Phase 2|84|Anticipated|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-06-01 01:09:22.27484|2018-06-01 01:09:22.27484
NCT00872729|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2012-10-05||2017-04-11|2009-03-30|2009-03-31|Estimate|2014-10-24|2014-10-28|Estimate||||2017-04-11|2017-05-19|Actual|May 2009||2009-05-31|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis|A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis|Completed||Phase 1/Phase 2|9|Actual|Horizon Pharma USA, Inc.||2|||f||||f||||||||||2018-06-01 01:09:22.371908|2018-06-01 01:09:22.371908
NCT00872716|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2011-03-30|2009-03-30|2009-03-31|Estimate|||||||2011-03-30|2011-03-31|Estimate|April 2009||2009-04-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|QUISS||Quetiapine in Specific Phobia|Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia|Completed||Phase 2|60|Actual|University Hospital Muenster||2|||f||||f||||||||||2018-06-01 01:09:23.329464|2018-06-01 01:09:23.329464
NCT00872703|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Observational|||Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?|Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?|Completed|||42|Actual|Wolfson Medical Center|||2||f||||f||||||||||2018-06-01 01:09:23.487097|2018-06-01 01:09:23.487097
NCT00872690|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2015-03-13|2009-03-27|2009-03-31|Estimate|||||||2015-03-13|2015-03-17|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Observational|||Factors Affecting Return to Work Among OEF/OIF Veterans With Polytrauma|Factors Affecting Return to Work Among OEF/OIF Veterans With Polytrauma|Completed|||7|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-06-01 01:09:23.5918|2018-06-01 01:09:23.5918
NCT00872677|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-28|||2013-04-25|2009-03-28|2009-03-31|Estimate|||||||2013-04-25|2013-04-29|Estimate|May 2004||2004-05-31|April 2013|2013-04-30|November 2008|Actual|2008-11-30|October 2006|Actual|2006-10-31||Observational|||Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors|A Culturally-Tailored Weight Loss Program|Completed|||31|Actual|Barbara Ann Karmanos Cancer Institute|||2||f||||f||||||||||2018-06-01 01:09:23.67179|2018-06-01 01:09:23.67179
NCT00872664|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2013-12-03|2009-03-30|2009-03-31|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids|Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids|Completed||N/A|36|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 01:09:23.78396|2018-06-01 01:09:23.78396
NCT00872651|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2013-03-27|2009-03-30|2009-03-31|Estimate|||||||2013-03-27|2013-03-28|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|242|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:09:23.906406|2018-06-01 01:09:23.906406
NCT00872625|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-28|||2015-02-08|2009-03-28|2009-03-31|Estimate|||||||2015-02-08|2015-02-10|Estimate|April 2007||2007-04-30|February 2015|2015-02-28|December 2010|Actual|2010-12-31|April 2009|Actual|2009-04-30||Interventional|||Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer|Phase I Study - Hypofractionated Cyberknife Radiotherapy Combined With Neoadjuvant Chemotherapy for Breast Tumors|Completed||Phase 1|26|Actual|Centre Antoine Lacassagne||1|||f||||||||||||||2018-06-01 01:09:24.425547|2018-06-01 01:09:24.425547
NCT00872612|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2015-12-04|2009-03-30|2009-03-31|Estimate|||||||2015-12-04|2015-12-07|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|GRANULOMA||Trial for the Diagnosis of Sarcoidosis|Endosonography (EUS and EBUS) vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis: a Randomized Trial|Completed||Phase 3|304|Actual|Leiden University Medical Center||2|||f||||t||||||||||2018-06-01 01:09:24.869447|2018-06-01 01:09:24.869447
NCT00872599|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2013-02-26||2013-06-19|2009-03-30|2009-03-31|Estimate|2013-05-10|2013-06-20|Estimate||||2013-06-19|2013-06-28|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Total number who completed the screening and low salt diet and were randomized.|The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans|The Effect of a PPAR Alpha Agonist on CYP Monooxygenase Activity in Humans|Completed||Phase 4|75|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 01:09:25.208762|2018-06-01 01:09:25.208762
NCT00872586|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2010-09-28|2009-03-27|2009-03-31|Estimate|||||||2010-09-28|2010-09-29|Estimate|August 2006||2006-08-31|September 2010|2010-09-30|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy|Completed||Phase 3|304|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:09:25.959817|2018-06-01 01:09:25.959817
NCT00872573|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2017-06-23|2009-03-30|2009-03-31|Estimate|||||||2017-06-23|2017-06-26|Actual|July 1, 2006|Actual|2006-07-01|June 2017|2017-06-30|October 1, 2007|Actual|2007-10-01|October 1, 2007|Actual|2007-10-01||Interventional|||A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stem™ AMT in a Total Primary Hip Replacement|Prospective, Uncontrolled, Two-centre, RSA, Post-market Surveillance Study to Evaluate the Stability of the C-Stem™ AMT Femoral Component in Primary Total Hip Arthroplasty.|Terminated||Phase 4|5|Actual|DePuy International||1||Technical issues with RSA at main site and departure of Principal Investigator|f||||f||||||||||2018-06-01 01:09:26.274118|2018-06-01 01:09:26.274118
NCT00872560|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2017-02-27|2009-03-30|2009-03-31|Estimate|||||||2017-02-27|2017-02-28|Actual|January 20, 1998|Actual|1998-01-20|February 2017|2017-02-28|July 27, 1998|Actual|1998-07-27|July 27, 1998|Actual|1998-07-27||Interventional|||Comparison of 2 NovoFine® Needles on the Reflux of Insulin|Insulin Leakage and Pain Perception in IDDM Children or Adolescents, Where the Injections Are Performed With NovoFine™ 6 x 0.30 mm Needles and NovoFine® 8 x 0.30 mm Needles: An Open, Randomized, Two-period Cross-over, Multi-centre, Phase IIIb Trial at 4 Centres|Completed||Phase 3|60|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 01:09:26.555582|2018-06-01 01:09:26.555582
NCT00872547|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2016-08-03|2009-03-30|2009-03-31|Estimate|||||||2016-08-03|2016-08-04|Estimate|September 2006||2006-09-30|July 2016|2016-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement|Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of a Large Metal-on-Metal (MoM) Bearing Comprising a DePuy ASR™ Cup in Conjunction With Either a DePuy ASR™ Hip Resurfacing Femoral Component or a DePuy ASR™ XL Head in Subjects With Indications Suitable for Either a Primary Resurfacing Arthroplasty or Primary Total Hip Arthroplasty|Terminated||Phase 4|329|Actual|DePuy International||2||"DePuy discontinued this product in 4Q2009. At the time of this decision DePuy reviewed all~   clinical studies for this product and decided to close this Study"|f||||f||||||||||2018-06-01 01:09:26.849607|2018-06-01 01:09:26.849607
NCT00872534|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2015-06-22||2015-08-05|2009-03-30|2009-03-31|Estimate|2015-08-05|2015-08-11|Estimate||||2015-08-05|2015-08-11|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers|A Randomized, Single-Blind, Endoscopic Evaluation Of Upper GI Mucosal Damage Induced By PL-2200 Versus Aspirin In Healthy Volunteers|Completed||Phase 1/Phase 2|204|Actual|PLx Pharma||2|||f||||f||||||||||2018-06-01 01:09:27.148504|2018-06-01 01:09:27.148504
NCT00872521|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2012-12-14||2014-05-07|2009-03-27|2009-03-31|Estimate|2013-03-25|2013-05-07|Estimate||||2014-05-07|2014-05-16|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma|A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance|Completed||Phase 2|107|Actual|Janssen-Cilag Pty Ltd||1|||f||||f||||||||||2018-06-01 01:09:27.5617|2018-06-01 01:09:27.5617
NCT00872495|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2018-01-10|2009-03-27|2009-03-31|Estimate|||||||2018-01-10|2018-01-11|Actual|September 2002||2002-09-30|January 2018|2018-01-31|November 2025|Anticipated|2025-11-30|October 2025|Anticipated|2025-10-31||Observational|||Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer|Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney|Recruiting|||500|Anticipated|Lahey Clinic|||2||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-06-01 01:09:29.803377|2018-06-01 01:09:29.803377
NCT00872482|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2011-06-30|2009-03-30|2009-03-31|Estimate|||||||2011-06-30|2011-07-01|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|July 2011|Anticipated|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases|A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer|Terminated||Phase 2|21|Actual|YM BioSciences||2||Study closed due to low enrollment|f||||f||||||||||2018-06-01 01:09:29.965687|2018-06-01 01:09:29.965687
NCT00872469|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2018-02-23|2009-03-30|2009-03-31|Estimate|||||||2018-02-23|2018-02-26|Actual|May 2009||2009-05-31|March 2017|2017-03-31|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|WOMAN||World Maternal Antifibrinolytic Trial|Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial|Completed||Phase 3|20060|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||Yes|Will be available at https://ctu-app.lshtm.ac.uk/freebird/ in the future|2018-06-01 01:09:30.117739|2018-06-01 01:09:30.117739
NCT00872456|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2018-01-24|2009-03-30|2009-03-31|Estimate|||||||2018-01-24|2018-01-25|Actual|March 2005||2005-03-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|ADHOC||Associations Between Diabetes Care and Haptoglobin Genotype On outComes|The ADHOC Project: Associations Between Diabetes Care and Haptoglobin Genotype On outComes|Active, not recruiting|||3054|Actual|Clalit Health Services|||||f||||t||||||||||2018-06-01 01:09:30.438349|2018-06-01 01:09:30.438349
NCT00872443|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2010-04-27|2009-03-30|2009-03-31|Estimate|||||||2010-04-27|2010-04-28|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|FOPasa||Interest of Occlusion of Permeable Foramen Ovale After a Cryptogenic Cerebrovascular Accident (CVA)|Interest of Occlusion of Permeable Foramen Ovale After a Cryptogenic Cerebrovacular Accident.|Completed|||72|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-06-01 01:09:30.550642|2018-06-01 01:09:30.550642
NCT00872430|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2008-11-06||2009-06-16|2009-03-30|2009-03-31|Estimate|2009-03-30|2009-03-31|Estimate||||2009-06-16|2009-06-17|Estimate|July 2002||2002-07-31|June 2009|2009-06-30|June 2003|Actual|2003-06-30|December 2002|Actual|2002-12-31||Interventional|||Laxative Effectiveness of a Phytotherapeutic Tea|Laxative Effectiveness of a Phytotherapeutic Tea: A Randomized Placebo-Controlled Clinical Trial|Completed||Phase 2|20|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 01:09:30.721511|2018-06-01 01:09:30.721511
NCT00872417|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients|Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients|Unknown status|Not yet recruiting|Phase 4|750|Anticipated|Peking Union Medical College||3|||f||||t||||||||||2018-06-01 01:09:31.220077|2018-06-01 01:09:31.220077
NCT00872404|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2016-04-19|2009-03-30|2009-03-31|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma|A Phase II Study of CP-751,871 in Patients With Recurrent and/or Metastatic Squamous Head and Neck Carcinoma|Terminated||Phase 2|37|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1||lack of efficacy|f||||f||||||||||2018-06-01 01:09:31.399682|2018-06-01 01:09:31.399682
NCT00872391|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|March 2009||2009-03-31|March 2009|2009-03-31||||March 2024|Anticipated|2024-03-31||Interventional|||Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma|Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea|Recruiting||N/A|155|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-06-01 01:09:31.581219|2018-06-01 01:09:31.581219
NCT00872378|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|February 2009||2009-02-28|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|AGREE||The Effects of Exenatide After Gastric Restriction|A Pilot Study of the Effects of BYETTA® (Exenatide) on Weight Loss in Morbidly Obese Non Diabetic Patients Following Adjustable Gastric Banding|Unknown status|Recruiting|Phase 2/Phase 3|28|Anticipated|Advanced Specialty Care||2|||f||||t||||||||||2018-06-01 01:09:31.712994|2018-06-01 01:09:31.712994
NCT00872365|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2011-01-08|2009-03-30|2009-03-31|Estimate|||||||2011-01-08|2011-01-11|Estimate|March 2011||2011-03-31|January 2011|2011-01-31|May 2012|Anticipated|2012-05-31|November 2011|Anticipated|2011-11-30||Interventional|||Effect of Micronutrients and Exercise During Pregnancy on Factors Related With Non-Transmissible Chronic Diseases|Effect of Micronutrients and Exercise During Pregnancy on Factors Related With Non-Transmissible Chronic Diseases|Unknown status|Not yet recruiting|Phase 2/Phase 3|320|Anticipated|Universidad del Valle, Colombia||4|||f||||t||||||||||2018-06-01 01:09:31.998548|2018-06-01 01:09:31.998548
NCT00872352|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Interventional|||Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients|Phase 3 Study to Evaluate Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients.|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Wolfson Medical Center|||||f||||f||||||||||2018-06-01 01:09:32.219082|2018-06-01 01:09:32.219082
NCT00872339|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2014-01-02||2014-05-27|2009-03-30|2009-03-31|Estimate|2014-05-27|2014-06-05|Estimate||||2014-05-27|2014-06-05|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|Pain||Assessment of Pain in People With Thalassemia|Assessment of Pain in People With Thalassemia|Completed|||252|Actual|New England Research Institutes|||3||f||||t||||||||||2018-06-01 01:09:32.460558|2018-06-01 01:09:32.460558
NCT00872326|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2014-11-13|2009-03-30|2009-03-31|Estimate|||||||2014-11-13|2014-11-14|Estimate|December 2007||2007-12-31|November 2014|2014-11-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Autologous Bone Marrow Derived Mononuclear Cells in Treating Diabetic Patients With Critical Limb Ischemia|Phase I/II Study of Regenerative Cell Therapy in Treating Diabetic Patients With Critical Limb Ischemia|Completed||Phase 1/Phase 2|20|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||1|||f||||f||||||||||2018-06-01 01:09:33.137032|2018-06-01 01:09:33.137032
NCT00872313|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2014-01-11|2009-03-30|2009-03-31|Estimate|||||||2014-01-11|2014-01-14|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|RIFPP||Risk Factors for Postpartum Psychosis|Potential Risk Factors for Postpartum Psychosis|Completed|||4000|Actual|Nanjing Medical University|||2||f||||t||||||||||2018-06-01 01:09:33.419094|2018-06-01 01:09:33.419094
NCT00872300|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30||2014-05-13|2014-05-13|2009-03-30|2009-03-31|Estimate||||2014-05-13|2014-05-28|Estimate|2014-05-13|2014-05-28|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||PHA-739358 for the Treatment of Multiple Myeloma|An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression|Terminated||Phase 2|7|Actual|Nerviano Medical Sciences||1||Low recruitment rate|f||||||||||||||2018-06-01 01:09:33.609142|2018-06-01 01:09:33.609142
NCT00872287|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pain in Single Incision Laparoscopic Surgery Cholecystectomy|Randomized Controlled Study of Different Pain Scores in Single Transumbilical Incision Laparoscopic Cholecystectomy Versus Classic Laparoscopic Cholecystectomy|Completed||Phase 4|40|Actual|G. Hatzikosta General Hospital||2|||f||||f||||||||||2018-06-01 01:09:33.973698|2018-06-01 01:09:33.973698
NCT00865956|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-11-03|2009-03-19|2009-03-20|Estimate|||||||2009-11-03|2009-11-04|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||A Comprehensive Disease Management Program for Medically-Complex Substance Users|A Comprehensive Disease Management Program for Medically-Complex Substance Users|Unknown status|Recruiting|N/A|100|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:11:27.831544|2018-06-01 01:11:27.831544
NCT00872274|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Bioequivalence Study of Sumatriptan 100mg Tablets Under Fed Conditions|An Open Label, Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets (Containing 140 mg of Sumatriptan Succinate Equivalent to 100 mg Sumatriptan) Under Fed Conditions|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:09:34.182927|2018-06-01 01:09:34.182927
NCT00872261|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2013-04-29|2009-03-30|2009-03-31|Estimate|||||||2013-04-29|2013-05-01|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Determining Characteristics and Behaviors of Adolescent Women Regarding HIV Risk and Microbicide Trial Participation|Adolescent Women & Microbicide Trials: Assessing the Challenges & Opportunities to Their Participation|Completed|||135|Actual|FHI 360|||1||f||||f||||||||||2018-06-01 01:09:34.398033|2018-06-01 01:09:34.398033
NCT00872248|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2011-07-26|2009-03-30|2009-03-31|Estimate|||||||2011-07-26|2011-07-27|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|NARELESS||Neuraxial Anesthesia and Restless Leg Syndromes in Cesarean|Correlation of Neuraxial Anesthesia and Restless Leg Syndromes in Cesarean Delivery|Completed||N/A|350|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 01:09:34.621531|2018-06-01 01:09:34.621531
NCT00872235|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|June 2005||2005-06-30|March 2009|2009-03-31|November 2005|Actual|2005-11-30|July 2005|Actual|2005-07-31||Interventional|||Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Fixed-Dose Combination of Quinapril 20 mg and Hydrochlorothiazide 25 mg Tablets of OHM Laboratories Inc.(Division of Ranbaxy Laboratories Limited) With Accuretic 20-25 mg Tablets (Fixed Dose Combination of Quinapril 20 mg and Hydrochlorothiazide 25 mg) of Parke-Davis (Division of Pfizer Inc.) in Healthy, Adult, Human, Male Subjects Under Fed Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||4|||f||||t||||||||||2018-06-01 01:09:34.839761|2018-06-01 01:09:34.839761
NCT00872222|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2016-10-06|2009-03-30|2009-03-31|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2007||2007-01-31|September 2016|2016-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Single Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle™ Acetabular Cup Prosthesis With a Ceramic-on-ceramic Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement|Terminated||Phase 4|98|Actual|DePuy International||1||Study terminated early due to business reasons|f||||f||||||||||2018-06-01 01:09:35.083507|2018-06-01 01:09:35.083507
NCT00872209|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-29|||2009-12-23|2009-03-29|2009-03-31|Estimate|||||||2009-12-23|2009-12-24|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa|Bioequivalence of Ciprofloxacin 0.3%: a Randomized, Multicenter, Parallel, Comparative Study on the Safety and Efficacy of Ciprofloxacin 0.3% in a Standard Solution or Foam Solution, in Patients With Acute External Otitis.|Completed||Phase 1/Phase 2|100|Anticipated|Otic Pharma||2|||f||||t||||||||||2018-06-01 01:09:35.416527|2018-06-01 01:09:35.416527
NCT00872196|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23||2011-09-06|2013-03-22|2009-03-27|2009-03-31|Estimate||||2011-09-06|2011-09-12|Estimate|2013-03-22|2013-04-01|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies|A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-072 After Discontinuation of ABT-072 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-072 Clinical Studies|Completed||Phase 2|5|Actual|AbbVie||1|||f||||||||||||||2018-06-01 01:09:35.664243|2018-06-01 01:09:35.664243
NCT00872183|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-28|||2017-06-30|2009-03-28|2009-03-31|Estimate|||||||2017-06-30|2017-07-02|Actual|March 25, 2009||2009-03-25|May 3, 2012|2012-05-03|May 3, 2012||2012-05-03|||||Observational|||Exploring a Motor Learning Technique Based on the Mirror Motor Neuron System|Exploring a Motor Learning Technique Based on the Mirror Motor Neuron System|Completed|||76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:09:35.915851|2018-06-01 01:09:35.915851
NCT00872170|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2013-04-24||2014-01-02|2009-03-30|2009-03-31|Estimate|2014-01-02|2014-02-21|Estimate||||2014-01-02|2014-02-21|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional||All 27 patients (14 in the Sildenafil group and 13 in the control group) who completed the baseline visit were used.|Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension|Pilot of Oral Sildenafil for the Treatment of Pulmonary Hypertension in Thalassemia With Comparison to Controls|Completed||Phase 2/Phase 3|27|Actual|New England Research Institutes|Of 14 patients in the Sildenafil arm, 4 patients with discrepant TRVs between the local site, core lab and NHLBI readings were excluded for the main analyses.|2|||f||||t||||||||||2018-06-01 01:09:36.23156|2018-06-01 01:09:36.23156
NCT00872157|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2015-10-22|2009-03-30|2009-03-31|Estimate|||||||2015-10-22|2015-10-23|Estimate|March 2009||2009-03-31|October 2015|2015-10-31||||October 2015|Actual|2015-10-31||Interventional|||BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets|A Limited, First-in-Man, Phase IB Evaluation of BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With High-Volume Osseous Metastases and no Standard Treatment Options|Completed||Phase 1|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:09:37.376577|2018-06-01 01:09:37.376577
NCT00872144|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-03-05|2009-03-30|2009-03-31|Estimate|||||||2014-03-05|2014-03-07|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Sativex for Treatment of Chemotherapy Induced Neuropathic Pain|A Double Blind Placebo Controlled Crossover Pilot Trial of Sativex With Open Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain|Completed||Phase 3|16|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-06-01 01:09:37.651513|2018-06-01 01:09:37.651513
NCT00872131|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2011-11-21|2009-03-30|2009-03-31|Estimate|||||||2011-11-21|2011-11-23|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Observational|||Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder|Neuro-Genetic Markers of SSRI Treatment Response in Social Anxiety Disorder|Completed|||200|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Saliva samples~   "|||2018-06-01 01:09:37.944587|2018-06-01 01:09:37.944587
NCT00872118|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2010-09-15|2009-03-27|2009-03-31|Estimate|||||||2010-09-15|2010-09-16|Estimate|April 2004||2004-04-30|September 2010|2010-09-30|March 2008|Actual|2008-03-31|April 2007|Actual|2007-04-30||Interventional|BISAD||Brief Intervention for Socially Anxious College Drinkers|Brief Intervention for Socially Anxious Alcohol Abusers|Completed||Phase 1|53|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 01:09:38.578988|2018-06-01 01:09:38.578988
NCT00872105|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2017-11-23|2009-03-30|2009-03-31|Estimate|||||||2017-11-23|2017-11-27|Actual|March 2009||2009-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Conservative Treatment Versus Operative Plate Fixation for Acute, Displaced Fractures of the Distal Clavicle|A Multicentre, Randomized Trial of Conservative Treatment Versus Operative Plate Fixation for Acute, Displaced Fractures of the Distal Clavicle|Active, not recruiting||N/A|59|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 01:09:38.983917|2018-06-01 01:09:38.983917
NCT00872092|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|October 1997||1997-10-31|March 2009|2009-03-31|September 1998|Actual|1998-09-30|September 1998|Actual|1998-09-30||Observational|BTO||Validation of Breath Tests in Diagnosing Small Bowel Bacterial Overgrowth|Validation of Breath Tests in Diagnosing Small Bowel Bacterial Overgrowth|Completed|||22|Actual|University Hospital, Bonn|||1||f||||f||||||Samples Without DNA|"~     Breath samples~   "|||2018-06-01 01:09:39.29974|2018-06-01 01:09:39.29974
NCT00872079|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2014-02-21||2014-02-21|2009-03-27|2009-03-31|Estimate|2014-02-21|2014-02-24|Estimate||||2014-02-21|2014-02-24|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Personalized Warfarin Dosing by Genomics and Computational Intelligence|Personalized Warfarin Dosing Using Genomics and Computational Intelligence|Terminated||N/A|175|Actual|VA Office of Research and Development||1||Lack of Funding|f||||f||||||||||2018-06-01 01:09:39.636975|2018-06-01 01:09:39.636975
NCT00872066|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2017-03-02|2009-03-30|2009-03-31|Estimate|||||||2017-03-02|2017-03-03|Actual|March 2006||2006-03-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement|A Prospective, Randomised, Uncontrolled, Single-Centre, Post-Market Surveillance Study To Evaluate The Performance Of SmartSet® HV and SmartSet® GHV Bone Cements In Primary Cemented Total Hip Arthroplasty(THA)|Completed||Phase 4|243|Actual|DePuy International||2|||f||||f||||||||||2018-06-01 01:09:40.509961|2018-06-01 01:09:40.509961
NCT00872053|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2013-09-18|2009-03-27|2009-03-31|Estimate|||||||2013-09-18|2013-09-20|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis|Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis|Completed||Phase 1/Phase 2|18|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:09:40.805831|2018-06-01 01:09:40.805831
NCT00872040|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|||2009-03-30|2009-03-30|2009-03-31|Estimate|||||||2009-03-30|2009-03-31|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Observational|||The Effect of Delivery Mode on Inter - Couple Relationship, Sexual Function and Pelvic Floor Activity|Observational Study on the Effect of Delivery Mode on Inter Personal Relationship, Sexual Function and Pelvic Floor Activity|Unknown status|Recruiting||300|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 01:09:40.967616|2018-06-01 01:09:40.967616
NCT00872027|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-30|2017-02-15||2017-11-21|2009-03-30|2009-03-31|Estimate|2017-02-15|2017-04-04|Actual||||2017-11-21|2017-12-19|Actual|April 2009||2009-04-30|November 2017|2017-11-30|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Preventing Depression in People Receiving Mechanical Ventilation in an Intensive Care Unit|Feasibility Study to Prevent Post-ICU Depression|Completed||Phase 4|15|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 01:09:41.119639|2018-06-01 01:09:41.119639
NCT00872014|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12||2015-10-22|2016-03-07|2009-03-26|2009-03-30|Estimate||||2015-10-22|2015-11-13|Estimate|2016-03-07|2016-04-04|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|October 2011|Actual|2011-10-31||Interventional|||A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer|Phase 2 Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma|Completed||Phase 2|60|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:09:41.955615|2018-06-01 01:09:41.955615
NCT00872001|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2012-11-20||2015-10-28|2009-03-27|2009-03-30|Estimate|2012-11-20|2012-12-20|Estimate||||2015-10-28|2015-10-29|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|RED-CABG||The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)|The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction in Cardiovascular Events by AcaDesine in Subjects Undergoing CABG)|Terminated||Phase 3|3080|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 01:09:42.329778|2018-06-01 01:09:42.329778
NCT00871975|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2015-09-01||2016-06-07|2009-03-27|2009-03-30|Estimate|2016-06-07|2016-07-19|Estimate||||2016-06-07|2016-07-19|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Includes both male patients suffering from LUTS, and female patients suffering from OAB.|Tetra-NIRS Clinical Study|Diagnostic Utility of Tetra-NIRS in Conjunction With Urodynamic Studies|Terminated||Phase 4|155|Actual|Laborie Medical Technologies Inc.|Early termination was due to slow recruitment exceeding trial deadlines. Technical issues resulted in several studies being excluded (8).|1||Low enrollment exceeding trial deadlines|f||||f||||||||No|Data are highly reliant on expert interpretation on a case-by-case basis.|2018-06-01 01:09:46.394253|2018-06-01 01:09:46.394253
NCT00871962|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2015-06-22|2009-03-27|2009-03-30|Estimate|||||||2015-06-22|2015-06-23|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Observational|||Long-term Oxygen Treatment (LTOT) in Chronic Obstructive Pulmonary Disease: Factors Influencing Survival|Long-term Oxygen Treatment (LTOT) in Chronic Obstructive Pulmonary Disease: Factors Influencing Survival: Survival Factors in COPD Treated by Long-term Oxygen Therapy|Unknown status|Active, not recruiting||750|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|||1||f||||t||||||Samples Without DNA|"~     Blood gaz analysis~   "|||2018-06-01 01:09:49.04287|2018-06-01 01:09:49.04287
NCT00871949|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2013-08-26|2009-03-27|2009-03-30|Estimate|||||||2013-08-26|2013-08-27|Estimate|April 2009||2009-04-30|August 2013|2013-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults|A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PNU-100480 (PF-02341272) After First Time Administration Of Ascending Oral Doses To Healthy Adult Subjects Under Fed And Fasted Conditions|Completed||Phase 1|19|Actual|Sequella, Inc.||6|||f||||f||||||||||2018-06-01 01:09:49.468749|2018-06-01 01:09:49.468749
NCT00871936|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26||2014-12-09|2015-02-02|2009-03-26|2009-03-30|Estimate||||2014-12-09|2014-12-31|Estimate|2015-02-02|2015-02-19|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes|Completed||Phase 2|82|Actual|Kadmon Corporation, LLC||2|||f||||f||||||||||2018-06-01 01:09:49.939397|2018-06-01 01:09:49.939397
NCT00871923|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2017-09-21|2009-03-27|2009-03-30|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2009|Actual|2009-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer|A Phase II Study to Determine the Efficacy of Tarceva® (Erlotinib Hydrochloride) With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:09:50.304222|2018-06-01 01:09:50.304222
NCT00871910|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-10-20|2009-03-26|2009-03-30|Estimate|||||||2017-10-20|2017-10-23|Actual|October 11, 2006|Actual|2006-10-11|October 2017|2017-10-31|February 22, 2010|Actual|2010-02-22|February 22, 2010|Actual|2010-02-22||Interventional|||Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies|Completed||Phase 1|81|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 01:09:50.772904|2018-06-01 01:09:50.772904
NCT00871897|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2016-07-28|2009-03-27|2009-03-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|CHF CaRe||Examining the Cognitive Benefits of Cardiac Rehabilitation in People With Heart Failure (The CHF CaRe Study)|Cognitive Benefits of Cardiac Rehabilitation in Heart Failure|Unknown status|Enrolling by invitation||200|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||2||f||||f||||||||||2018-06-01 01:09:51.661492|2018-06-01 01:09:51.661492
NCT00871884|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2014-01-21|2009-03-27|2009-03-30|Estimate|||||||2014-01-21|2014-01-22|Estimate|April 2008||2008-04-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of Two Treatments for Chronic Post Concussion Syndrome|The Role of Anxiety Sensitivity in the Maintenance of Chronic Post Concussion Symptoms|Terminated||Phase 1/Phase 2|10|Actual|Simon Fraser University||2||Poor enrollment, low recruitment.|f||||t||||||||||2018-06-01 01:09:52.221305|2018-06-01 01:09:52.221305
NCT00871871|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2011-02-22||2015-07-22|2009-03-27|2009-03-30|Estimate|2011-08-17|2011-09-22|Estimate||||2015-07-22|2015-07-28|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)|A Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Evaluate the Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis in Obese Patients With Hypertension|Completed||Phase 1|64|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:09:52.798716|2018-06-01 01:09:52.798716
NCT00871858|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2011-01-07|2009-03-27|2009-03-30|Estimate|||||||2011-01-07|2011-01-10|Estimate|January 2008||2008-01-31|July 2009|2009-07-31||||September 2009|Anticipated|2009-09-30||Interventional|||Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer|Response to Neoadjuvant Treatment With Anti-aromatase Anastrozole and Anti-estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response|Unknown status|Recruiting|Phase 2|114|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:09:54.744013|2018-06-01 01:09:54.744013
NCT00871845|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-03-26|2009-03-26|2009-03-30|Estimate|||||||2009-03-26|2009-03-30|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients|Effects of Dietary and Behavioral Intervention and Orlistat for Management of Obesity and Metabolic Syndrome on Response to Hepatitis C Therapy|Unknown status|Recruiting|Phase 4|222|Anticipated|University of Pittsburgh||6|||f||||t||||||||||2018-06-01 01:09:54.954113|2018-06-01 01:09:54.954113
NCT00871832|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2013-06-05|2009-03-27|2009-03-30|Estimate|||||||2013-06-05|2013-06-06|Estimate|May 2007||2007-05-31|June 2013|2013-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Pre-admission Hyperglycemia and Its Effect on Morbidity and Mortality|To Evaluate if Pre-admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit|Completed|||200|Actual|Northwell Health|||||f||||f||||||||||2018-06-01 01:09:55.163707|2018-06-01 01:09:55.163707
NCT00871819|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2012-02-13||2013-11-05|2009-03-27|2009-03-30|Estimate|2012-03-07|2012-04-04|Estimate||||2013-11-05|2013-11-27|Estimate|March 2009||2009-03-31|November 2013|2013-11-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|OP||Optimized Programming in Spinal Cord Stimulation (SCS) System|Optimized Programming in a Multiple-Independent Current Sources Spinal Cord Stimulation (SCS) System|Completed||Phase 4|20|Actual|Boston Scientific Corporation|Small number of subjects; technical outcomes not necessarily predictive of therapeutic effectiveness.|1|||f||||f||||||||||2018-06-01 01:09:55.27317|2018-06-01 01:09:55.27317
NCT00871806|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-04-22|2009-03-26|2009-03-30|Estimate|||||||2010-04-22|2010-04-23|Estimate|April 2009||2009-04-30|April 2010|2010-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water|Phase 1, Open-Label, Randomized, Single-Dose, 5-Way Crossover Pilot Bioavailability Study Comparing Eletriptan Oral Disintegrating Tablet Formulations A And B Administered With Or Without Water To Relpax® Commercial Tablets Administered With Water|Completed||Phase 1|20|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:09:55.414202|2018-06-01 01:09:55.414202
NCT00871793|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2012-06-28|2009-03-27|2009-03-30|Estimate|||||||2012-06-28|2012-07-02|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Occupational Therapy on the Function and Mobility of Elbow Fractures|Effect of Occupational Therapy on the Function and Mobility in Supracondylar Humerus Fractures: A Randomized Controlled Trial|Completed||N/A|61|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-06-01 01:09:55.493742|2018-06-01 01:09:55.493742
NCT00871442|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2015-11-17|2009-03-27|2009-03-30|Estimate|||||||2015-11-17|2015-11-18|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Parturient Controlled Epidural Analgesia (PCEA) With or Without a Basal Infusion for Early Labor|Parturient Controlled Epidural Analgesia (PCEA) With or Without a Basal Infusion for Early Labor|Withdrawn||Phase 3|0|Actual|Baystate Medical Center||2||would not substantially add to existing contributions in the literature|f||||f||||||||||2018-06-01 01:10:04.352117|2018-06-01 01:10:04.352117
NCT00871780|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2014-11-11||2017-02-14|2009-03-27|2009-03-30|Estimate|2014-11-11|2014-11-18|Estimate||||2017-02-14|2017-03-21|Actual|August 2009||2009-08-31|February 2017|2017-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|TIMER|Efficacy Analysis Population (participants who had at least 1 infusion of natalizumab and completed at least 1 on-treatment evaluation)|A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients|"A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients TIMER Study"|Completed||Phase 4|224|Actual|Biogen||1|||f||||f||||||||||2018-06-01 01:09:55.696072|2018-06-01 01:09:55.696072
NCT00871767|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-06-29|2009-03-27|2009-03-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|||||Interventional|||AZD5672 Bioavailability Study in Healthy Male and Female Subjects|An Open-Label, Randomized, 4 Period Crossover, Replicate Study to Assess the Relative Bioavailability of the Phase III and Phase IIb Formulations of AZD5672 in Healthy Male and Female Subjects|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:09:56.449034|2018-06-01 01:09:56.449034
NCT00871754|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-03-07|2009-03-27|2009-03-30|Estimate|||||||2017-03-07|2017-03-08|Actual|April 1988||1988-04-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Molecular Analysis Of Bladder Cancer|Molecular Analysis Of Bladder Cancer|Active, not recruiting|||5000|Anticipated|Lahey Clinic|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 01:09:56.52313|2018-06-01 01:09:56.52313
NCT00871741|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2017-02-16|2012-11-16|2017-04-05|2009-03-26|2009-03-30|Estimate|2017-02-16|2017-04-04|Actual|2012-11-16|2012-11-21|Estimate|2017-04-05|2017-05-11|Actual|April 1, 2009||2009-04-01|April 2017|2017-04-30|June 25, 2009|Actual|2009-06-25|June 25, 2009|Actual|2009-06-25||Interventional|||Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.|Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.|Terminated||Phase 2|16|Actual|GlaxoSmithKline||2||"Study stopped due to non-approval of IEC to proposed change in locations. Study discontinuation~   not due to safety/efficacy reasons related to the vaccine."|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:09:56.616584|2018-06-01 01:09:56.616584
NCT00871728|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2013-04-29||2013-06-24|2009-03-26|2009-03-30|Estimate|2013-04-29|2013-06-14|Estimate||||2013-06-24|2013-07-02|Estimate|January 2007||2007-01-31|June 2013|2013-06-30|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules|Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules|Completed||Phase 4|132|Actual|Janssen Korea, Ltd., Korea|Initially it was planned to assess clinical cure rate but analysis for clinical cure rate following the administration of the study drug was replaced by change in SCIO scores which was the primary endpoint.|1|||f||||f||||||||||2018-06-01 01:09:57.246441|2018-06-01 01:09:57.246441
NCT00871715|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2016-02-17||2017-04-04|2009-03-27|2009-03-30|Estimate|2016-03-23|2016-04-27|Estimate||||2017-04-04|2017-05-11|Actual|June 2009||2009-06-30|March 2016|2016-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ICARE||Arm Rehabilitation Study After Stroke|Interdisciplinary Comprehensive Arm Rehab Evaluation (ICARE) Stroke Initiative|Completed||Phase 3|361|Actual|University of Southern California||3|||f||||t||||||||||2018-06-01 01:09:57.599847|2018-06-01 01:09:57.599847
NCT00871702|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2013-07-09|2009-03-27|2009-03-30|Estimate|||||||2013-07-09|2013-07-11|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease|Infusion of Genetically Modified T Cells: A Pilot Study of Tracking and Toxicity|Completed||Phase 1|12|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 01:09:59.852323|2018-06-01 01:09:59.852323
NCT00871689|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2012-06-11||2017-12-03|2009-03-27|2009-03-30|Estimate|2012-06-11|2012-07-16|Estimate||||2017-12-03|2017-12-28|Actual|January 2009||2009-01-31|December 2017|2017-12-31|October 2011|Actual|2011-10-31|March 2010|Actual|2010-03-31||Interventional|||Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML|Haploidentical Donor NK Cell Adoptive Therapy and Double T Cell Depleted Umbilical Cord Blood Transplantation With Post-Transplant IL-2 Immune Therapy For Refractory Acute Myeloid Leukemia|Terminated||Phase 2|2|Actual|Masonic Cancer Center, University of Minnesota|Quantitative, phenotypic and functional assessment of the in vivo expanded UCB-derived NK cells on Day 72 were not performed. Patients were not well enough to provide research samples.|1||Due to graft failure.|f||||t||||||||||2018-06-01 01:09:59.998642|2018-06-01 01:09:59.998642
NCT00871676|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2016-08-15|2009-03-27|2009-03-30|Estimate|||||||2016-08-15|2016-08-17|Estimate|May 2006||2006-05-31|March 2009|2009-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Use of Chewing Gum to Facilitate Appetite Control and Weight Loss|Use of Chewing Gum to Facilitate Appetite Control and Weight Loss in Overweight Individuals Treated by Lifestyle Modification|Completed||N/A|146|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 01:10:00.317519|2018-06-01 01:10:00.317519
NCT00871663|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2015-04-17|2009-03-26|2009-03-30|Estimate|||||||2015-04-17|2015-04-20|Estimate|August 2006||2006-08-31|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Weekly in Subjects With Advanced Malignancies|Completed||Phase 1|123|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:10:00.395605|2018-06-01 01:10:00.395605
NCT00871650|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2013-01-14|2009-03-27|2009-03-30|Estimate|||||||2013-01-14|2013-01-16|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Observational|REM-P||Neurobiological Correlates of Post Traumatic Stress Disorder (PTSD) During Rapid Eye Movement (REM) Sleep|Neurobiological Correlates of PTSD During REM Sleep (REM-P)|Completed|||24|Anticipated|University of Pittsburgh|||2||f||||t||||||||||2018-06-01 01:10:00.461364|2018-06-01 01:10:00.461364
NCT00871637|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-08-30|2009-03-26|2009-03-30|Estimate|||||||2017-08-30|2017-09-01|Actual|August 2008||2008-08-31|August 2017|2017-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction|Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction|Completed|||30|Actual|University of Nebraska|||3||f||||t||||||||||2018-06-01 01:10:00.552318|2018-06-01 01:10:00.552318
NCT00870766|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-09-13|2009-03-26|2009-03-27|Estimate|||||||2010-09-13|2010-09-14|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|PRACTA||Computer Tomography (CT) Trial of Acute Abdomen||Completed||N/A|250|Anticipated|Kuopio University Hospital||2|||f||||||||||||||2018-06-01 01:10:15.873735|2018-06-01 01:10:15.873735
NCT00871624|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2014-04-07||2017-11-20|2009-03-27|2009-03-30|Estimate|2015-11-03|2015-12-07|Estimate||||2017-11-20|2017-12-18|Actual|March 2009||2009-03-31|November 2017|2017-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation|Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation for Patients With Acute Respiratory Failure: A Randomized, Double-blind, Placebo-controlled Pilot Study|Completed||Phase 2|36|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-06-01 01:10:00.679533|2018-06-01 01:10:00.679533
NCT00871611|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2011-07-27|2009-03-27|2009-03-30|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|VIEPAF||Viennese Prevalence Study of Anderson-Fabry Disease|Prevalence of Anderson - Fabry Disease in Patients With Left Ventricular Hypertrophy|Unknown status|Active, not recruiting||4000|Anticipated|Medical University of Vienna|||||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-06-01 01:10:00.982586|2018-06-01 01:10:00.982586
NCT00871598|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2010-11-15|2009-03-27|2009-03-30|Estimate|||||||2010-11-15|2010-11-16|Estimate|March 2009||2009-03-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||BTT1023 in Psoriasis|A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Plaque Psoriasis - a Double-blind Randomized Placebo-controlled Sequential Group Trial|Completed||Phase 1|26|Actual|Biotie Therapies Corp.||6|||f||||f||||||||||2018-06-01 01:10:01.055998|2018-06-01 01:10:01.055998
NCT00871585|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2010-04-14|2009-03-27|2009-03-30|Estimate|||||||2010-04-14|2010-04-15|Estimate|March 2009||2009-03-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide|Non-interventional Observational Study to Evaluate Change of PSA Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide in Combination With Medical or Surgical Castration|Completed|||340|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:10:01.150398|2018-06-01 01:10:01.150398
NCT00871572|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2018-03-24|2010-12-09|2018-03-24|2009-03-27|2009-03-30|Estimate|2018-03-24|2018-04-24|Actual|2010-12-09|2010-12-15|Estimate|2018-03-24|2018-04-24|Actual|March 2009||2009-03-31|March 2018|2018-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||All randomized participants.|A Study for Participants With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of LY2409021 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|87|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:10:01.324283|2018-06-01 01:10:01.324283
NCT00871559|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-03-24|2009-03-27|2009-03-30|Estimate|||||||2014-03-24|2014-03-26|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies|A Phase 1, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 2 or 3 Weeks in Patients With Advanced Solid Malignancies|Completed||Phase 1|83|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:10:03.289107|2018-06-01 01:10:03.289107
NCT00871546|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2015-08-06|2009-03-26|2009-03-30|Estimate|||||||2015-08-06|2015-08-07|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)|A Randomized Phase 2 Study of SCH 727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Terminated||Phase 2|8|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:10:03.377198|2018-06-01 01:10:03.377198
NCT00871533|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-08-03|2009-03-27|2009-03-30|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2009||2009-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Pilot Study of IFN α2b for Melanoma Patients|Pilot Analysis of the Effects of IFN α2b Upon the Molecular Profile of Regional Lymph Nodes in Melanoma Patients With and Without Tumor-Involved Sentinel Lymph Nodes|Terminated||Early Phase 1|50|Actual|University of Pittsburgh||5|||f||||t||||||||||2018-06-01 01:10:03.468017|2018-06-01 01:10:03.468017
NCT00871520|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2016-08-22|2009-03-27|2009-03-30|Estimate|||||||2016-08-22|2016-08-23|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|December 2011|Actual|2011-12-31||Observational|||Prognosis and Survival Estimates in Palliative Therapy|Prognosis in Palliative Therapy - a Prospective Study on Survival Prognostication in Advanced Stage Cancer Patients|Completed|||612|Actual|Heinrich-Heine University, Duesseldorf|||1||f||||f||||||||||2018-06-01 01:10:03.568283|2018-06-01 01:10:03.568283
NCT00871507|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2014-05-21|2009-03-26|2009-03-30|Estimate|||||||2014-05-21|2014-05-22|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus|SD in Subjects With T2DM|Completed||Phase 1|25|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-06-01 01:10:03.645267|2018-06-01 01:10:03.645267
NCT00871494|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2011-09-28||2011-09-28|2009-03-27|2009-03-30|Estimate|2011-09-28|2011-11-03|Estimate||||2011-09-28|2011-11-03|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan|A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Pelvic Inflammatory Disease (PID) Requiring Initial Intravenous Therapy|Completed||Phase 3|76|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:10:03.757676|2018-06-01 01:10:03.757676
NCT00871481|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27||2017-03-03|2017-04-17|2009-03-27|2009-03-30|Estimate||||2017-03-03|2017-03-07|Actual|2017-04-17|2017-04-19|Actual|February 2009||2009-02-28|April 2017|2017-04-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma|Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|10|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 01:10:04.005644|2018-06-01 01:10:04.005644
NCT00871468|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-10-11|2009-03-27|2009-03-30|Estimate|||||||2017-10-11|2017-10-13|Actual|October 2008||2008-10-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Plating Clavicle Fractures|Does Anterior-Inferior Clavicle Plating Have a Lower Rate of Soft Tissue Irritation Compared to Superior Plating? A Prospective Randomized Trial|Active, not recruiting||N/A|90|Anticipated|United States Army Institute of Surgical Research||2|||f||||f||||||||||2018-06-01 01:10:04.137761|2018-06-01 01:10:04.137761
NCT00871455|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2012-03-29|2009-03-27|2009-03-30|Estimate|||||||2012-03-29|2012-04-02|Estimate|April 2003||2003-04-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study|Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study|Completed||N/A|20|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:10:04.283156|2018-06-01 01:10:04.283156
NCT00871429|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2010-05-05||2015-02-24|2009-03-27|2009-03-30|Estimate|2010-07-14|2010-08-10|Estimate||||2015-02-24|2015-03-17|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|August 2010|Actual|2010-08-31|November 2009|Actual|2009-11-30||Interventional|||Skin Care for Cancer Patients: A Product Satisfaction Survey|Selected Skin Products for Cancer Patients: A Product Satisfaction Survey|Completed||N/A|99|Actual|Northwestern University|No limitations of the trial identified.||||f||||f||||||||||2018-06-01 01:10:04.458831|2018-06-01 01:10:04.458831
NCT00871416|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2017-02-27|2009-03-27|2009-03-30|Estimate|||||||2017-02-27|2017-02-28|Actual|April 9, 1997|Actual|1997-04-09|February 2017|2017-02-28|July 18, 1997|Actual|1997-07-18|July 18, 1997|Actual|1997-07-18||Interventional|||Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles|Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles. Furthermore, the Thickness of Cutis/Subcutis Is Measured on Recommended Insulin Injection Sites|Completed||Phase 3|48|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 01:10:04.678129|2018-06-01 01:10:04.678129
NCT00871403|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2012-01-26||2013-06-12|2009-03-26|2009-03-30|Estimate|2012-01-26|2012-02-16|Estimate||||2013-06-12|2013-06-20|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer|An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Cell Lung Cancer|Completed||Phase 2|107|Actual|GlaxoSmithKline|Efficacy data were only summarized for the pazopanib (pazo.) 800 mg + pemetrexed (peme.) 500 mg/m^2 and the cisplatin 75 mg/m^2 + peme. 500 mg/m^2 arms due to the small sample size/short treatment duration in the pazo. 600 mg + peme. 500 mg/m^2 arm.|2|||f||||f||||||||||2018-06-01 01:10:04.771069|2018-06-01 01:10:04.771069
NCT00871390|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2017-07-14|2009-03-27|2009-03-30|Estimate|||||||2017-07-14|2017-07-19|Actual|September 2006||2006-09-30|July 2017|2017-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Organization of Excitation in People With Atrial Fibrillation|Complex Electrograms in Atrial Fibrillation: Spatiotemporal Organization and Mechanistic Insights and Organization in Acute Atrial Fibrillation Post Open Heart Surgery|Completed|||146|Actual|University of Michigan|||||f||||t||||||None Retained|"~     Biopsys~   "|||2018-06-01 01:10:05.622724|2018-06-01 01:10:05.622724
NCT00871377|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2013-10-31||2014-01-09|2009-03-27|2009-03-30|Estimate|2014-01-08|2014-01-10|Estimate||||2014-01-09|2014-02-07|Estimate|May 2008||2008-05-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|FOS|16 Female, 8 Male|Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures|Pilot Randomized Double Blind Crossover Study Of Fish Oil [Eicosapentaenoic Acid (EPA) And Docosahexaenoic Acid (DHA)] For Intractable Partial Seizures|Completed||Phase 2|24|Actual|National Center for Complementary and Integrative Health (NCCIH)||3|||f||||t||||||||||2018-06-01 01:10:05.714477|2018-06-01 01:10:05.714477
NCT00871364|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-08-13|2009-03-27|2009-03-30|Estimate|||||||2010-08-13|2010-08-16|Estimate|April 2006||2006-04-30|August 2010|2010-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Actavis Group hf 50 mg Venlafaxine Hydrochloride Tablets and Wyeth Pharmaceuticals (Effexor®) 50 mg Venlafaxine Hydrochloride Tablets|Completed||Phase 1|30|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:10:05.999546|2018-06-01 01:10:05.999546
NCT00871351|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2011-05-16||2017-04-04|2009-03-27|2009-03-30|Estimate|2011-07-26|2011-08-23|Estimate||||2017-04-04|2017-05-10|Actual|February 1, 2009|Actual|2009-02-01|April 2017|2017-04-30|May 1, 2010|Actual|2010-05-01|May 1, 2010|Actual|2010-05-01||Interventional|||Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)|Ezetimibe Phase IV Clinical Study in Patients With Hypercholesterolemia|Completed||Phase 4|125|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:10:06.132158|2018-06-01 01:10:06.132158
NCT00871338|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2014-06-26|2011-11-17|2016-09-22|2009-03-26|2009-03-30|Estimate|2014-07-24|2014-07-28|Estimate|2011-11-17|2011-11-21|Estimate|2016-09-22|2016-10-20|Estimate|June 2009||2009-06-30|September 2016|2016-09-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants|Study in Healthy Children of GSK Biologicals' DTPa-IPV/Hib-MenC-TT Vaccine, GSK2197870A, Co-administered With Prevenar™ as a Three-dose Primary Vaccination Course in Infancy Followed by a Booster Dose of Menitorix™ at 12 Months of Age|Completed||Phase 2|284|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:10:06.77331|2018-06-01 01:10:06.77331
NCT00871325|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26||2012-12-27|2013-01-08|2009-03-26|2009-03-30|Estimate||||2012-12-27|2012-12-31|Estimate|2013-01-08|2013-01-14|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Effect of TU-100 on Gastrointestinal and Colonic Transit in Humans|Effect of Gastrointestinal Nerve Modulation With DAIKENCHUTO (TU-100) on Gastrointestinal and Colonic Transit in Humans|Completed||Phase 1/Phase 2|60|Actual|Tsumura USA||3|||f||||f||||||||||2018-06-01 01:10:07.848249|2018-06-01 01:10:07.848249
NCT00871312|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2014-01-08|2009-03-27|2009-03-30|Estimate|||||||2014-01-08|2014-01-10|Estimate|May 2007||2007-05-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation of Topical Wound Oxygen (two2) Therapy|A Randomized, Double-blinded, Parallel Group, Placebo-Controlled, Multi-Center Trial of Topical Wound Oxygen Therapy in the Treatment of Diabetic Lower Extremity Ulcers|Terminated||N/A|21|Actual|AOTI Ltd.||2||Low recruitment rate meaning unable to complete the study in a timely manner|f||||t||||||||||2018-06-01 01:10:07.93431|2018-06-01 01:10:07.93431
NCT00871299|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2014-12-01|2009-03-27|2009-03-30|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PATH-D||Practicing Alternative Techniques to Heal From Depression: The PATH-D Study|Applying Mindfulness-Based Cognitive Therapy to Treatment Resistant Depression|Completed||N/A|173|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:10:08.087297|2018-06-01 01:10:08.087297
NCT00871286|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2011-08-29||2012-01-17|2009-03-27|2009-03-30|Estimate|2012-01-17|2012-01-18|Estimate||||2012-01-17|2012-01-18|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Point-of-Care Computed Tomography (CT) Chronic Rhinosinusitis Study|Role of Point-of-Care CT Scanning in Patients Presenting With Symptoms of Chronic Rhinosinusitis|Completed||N/A|40|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 01:10:08.196403|2018-06-01 01:10:08.196403
NCT00871273|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2015-07-18|2009-03-27|2009-03-30|Estimate|||||||2015-07-18|2015-07-21|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma|A Pharmacokinetic Study of Capecitabine in Patients Undergoing Peri-operative Chemotherapy and a Total Gastrectomy for Adenocarcinoma of the Stomach|Terminated||Phase 4|13|Actual|Cambridge University Hospitals NHS Foundation Trust||||"1. Slow recruitment; 2. Change to clinical environment reducing the pool of potentially~   eligible patients; 3. Availability of data from another similar study"|f||||f||||||||||2018-06-01 01:10:08.506739|2018-06-01 01:10:08.506739
NCT00871260|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2016-08-23|2009-03-26|2009-03-30|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Stress Testing and Cardiac Magnetic Resonance|Stress Testing and Cardiac Magnetic Resonance|Recruiting||N/A|525|Anticipated|University of Chicago||1|||f||||f||||||||||2018-06-01 01:10:08.58632|2018-06-01 01:10:08.58632
NCT00871247|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-08-13|2009-03-27|2009-03-30|Estimate|||||||2010-08-13|2010-08-16|Estimate|November 2004||2004-11-30|August 2010|2010-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:10:08.68794|2018-06-01 01:10:08.68794
NCT00871234|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2010-12-07||2011-01-05|2009-03-27|2009-03-30|Estimate|2010-12-07|2011-01-05|Estimate||||2011-01-05|2011-01-07|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study|Effects of Etravirine (INTELENCETM) on Endothelial Function in HIV-uninfected Adults: A Pilot Study|Completed||Phase 1|28|Actual|Indiana University|||||f||||t||||||||||2018-06-01 01:10:08.804279|2018-06-01 01:10:08.804279
NCT00871208|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2015-05-11|2009-03-27|2009-03-30|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy|Randomized, Placebo-Controlled Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids vs. Low-Potency Corticosteroid Mono-therapy|Withdrawn||Phase 4|0|Actual|St. Luke's-Roosevelt Hospital Center||2||Funding withdrawn|f||||t||||||||||2018-06-01 01:10:09.029449|2018-06-01 01:10:09.029449
NCT00871195|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2012-05-09|2009-03-27|2009-03-30|Estimate|||||||2012-05-09|2012-05-10|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Observational|NAFTnet RHD||A Noninvasive Test for Fetal RHD Genotype|Evaluation Of The Performance Of A Noninvasive Test For Fetal RHD Genotype On The Sequenom MassARRAY System|Completed|||520|Actual|Sequenom, Inc.|||||f||||f||||||Samples With DNA|"~     Plasma and buffy coat.~   "|||2018-06-01 01:10:09.138177|2018-06-01 01:10:09.138177
NCT00871182|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26||2010-08-24|2013-06-12|2009-03-27|2009-03-30|Estimate||||2010-08-24|2010-08-27|Estimate|2013-06-12|2013-06-21|Estimate|March 2009||2009-03-31|June 2013|2013-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Single Dose, Four-period, Six-treatment, Placebo-controlled, Balanced, Incomplete Block, Cross-over, Study of Four Doses of Inhaled PT001 in Patients With Mild to Moderate COPD, Compared to Open Label Tiotropium|Completed||Phase 1/Phase 2|33|Actual|Pearl Therapeutics, Inc.||6|||f||||f||||||||||2018-06-01 01:10:09.248046|2018-06-01 01:10:09.248046
NCT00871169|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2016-05-06||2016-05-06|2009-03-27|2009-03-30|Estimate|2016-05-06|2016-06-14|Estimate||||2016-05-06|2016-06-14|Estimate|October 2008||2008-10-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||These enrolled patients received study treatment according to the protocol.|Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer|INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|61|Actual|New Mexico Cancer Care Alliance||1|||f||||t||||||||No||2018-06-01 01:10:09.390084|2018-06-01 01:10:09.390084
NCT00871156|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2017-06-16|2009-03-26|2009-03-30|Estimate|||||||2017-06-16|2017-06-19|Actual|March 24, 2009|Actual|2009-03-24|June 2017|2017-06-30|August 26, 2009|Actual|2009-08-26|August 26, 2009|Actual|2009-08-26||Interventional|||Tafenoquine/Chloroquine DDI Study|Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers|Completed||Phase 1|68|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:10:09.77142|2018-06-01 01:10:09.77142
NCT00871143|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|2015-04-15||2015-09-04|2009-03-27|2009-03-30|Estimate|2015-09-04|2015-10-06|Estimate||||2015-09-04|2015-10-06|Estimate|April 2009||2009-04-30|September 2015|2015-09-30|September 2012|Actual|2012-09-30|May 2011|Actual|2011-05-31||Interventional||"Inclusion criteria:~Diagnosis of BDD according to the DSM-IV diagnostic criterion~Total of >24 on the Yale-Brown Obsessive Compulsive Scale modified for BDD~>18 years old~Willing to travel to the treatment centre for weekly sessions~Not on psychotropic medication or on a dose that's been stable for at least 12 weeks"|Cognitive Behaviour Therapy (CBT) for Body Dysmorphic Disorder (BDD)|Efficacy of Cognitive Behaviour Therapy -v- Anxiety Management for Body Dysmorphic Disorder: a Randomised Controlled Trial|Completed||N/A|46|Actual|Institute of Psychiatry, London|"Small sample size: may have led to difficulty in identifying predictors of outcome.~Investigator bias: but testing blinding would be biased as it may be influenced by her rating of the outcome.~Treatment too brief to achieve sig. changes in BDD."|2|||f||||f||||||||||2018-06-01 01:10:09.886594|2018-06-01 01:10:09.886594
NCT00871130|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-27|2009-03-27|2009-03-30|Estimate|||||||2009-03-27|2009-03-30|Estimate|January 1998||1998-01-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||The Effect of Bariatric Surgery on Thyroid Function and Morphology|The Effect of Bariatric Surgery on Thyroid Function and Morphology, a Retrospective Study|Completed|||300|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 01:10:10.477487|2018-06-01 01:10:10.477487
NCT00871117|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2011-01-13||2016-09-26|2009-03-26|2009-03-30|Estimate|2011-01-13|2011-02-10|Estimate||||2016-09-26|2016-10-27|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years|Immunogenicity and Safety Study of Kinrix® Co-administered With Varivax®|Completed||Phase 3|478|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:10:10.591936|2018-06-01 01:10:10.591936
NCT00871104|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2018-03-07|2009-03-27|2009-03-30|Estimate|||||||2018-03-07|2018-03-08|Actual|July 2009||2009-07-31|March 2018|2018-03-31|April 15, 2015|Actual|2015-04-15|July 2014|Actual|2014-07-31||Interventional|||Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis|Evaluation of the Efficacy and Safety of Fosfomycin Plus Imipenem for the Treatment of Methicillin-resistant Staphylococcus Aureus (MRSA) Infective Endocarditis.|Completed||Phase 4|50|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 01:10:11.146549|2018-06-01 01:10:11.146549
NCT00871091|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-03-27|2009-03-27|2009-03-30|Estimate|||||||2009-03-27|2009-03-30|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|June 2009|Anticipated|2009-06-30|May 2009|Anticipated|2009-05-31||Interventional|||Study Investigating Tooth Movements With Conventional and Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM) Supported Fixed Appliances|Pilot Study Investigating Tooth Movements With Conventional and CAD/CAM Supported Fixed Appliances|Unknown status|Active, not recruiting|N/A|32|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-06-01 01:10:11.248138|2018-06-01 01:10:11.248138
NCT00871078|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-09-28|2009-03-27|2009-03-30|Estimate|||||||2009-09-28|2009-09-29|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Anatomic and Visual Function Assessments on Asymptomatic HIV-positive Patients|Anatomic and Visual Function Assessments on Asymptomatic HIV-positive Patients Using Optical Coherence Tomography and Frequency Doubling Technology Perimetry|Completed|||90|Anticipated|Federal University of São Paulo|||3||f||||f||||||||||2018-06-01 01:10:12.408272|2018-06-01 01:10:12.408272
NCT00871065|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-05-12|2009-03-26|2009-03-30|Estimate|||||||2017-05-12|2017-05-16|Actual|July 2009||2009-07-31|May 2017|2017-05-31|January 2011|Anticipated|2011-01-31|July 2010|Anticipated|2010-07-31||Interventional|||Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm|Safety and Efficacy Trial of Sildenafil Citrate in Attenuation of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage|Withdrawn||Phase 2|0|Actual|University of Nebraska||1||PI decision|f||||t||||||||||2018-06-01 01:10:12.478559|2018-06-01 01:10:12.478559
NCT00871052|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-10-02|2009-03-27|2009-03-30|Estimate|||||||2009-10-02|2009-10-06|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Calcipotriol and Polymorphic Light Eruption|Calcipotriol in the Prevention of Polymorphic Light Eruption|Completed||N/A|13|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 01:10:12.589097|2018-06-01 01:10:12.589097
NCT00871039|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2016-02-29|2009-03-26|2009-03-30|Estimate|||||||2016-02-29|2016-03-01|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pilot Study Evaluating Stress Response and Immune Function in Mechanically Ventilated Patients With Alcohol Use Disorders Treated With Propofol or Midazolam|Randomized Clinical Trial Comparing Propofol and Midazolam in Mechanically Ventilated Critically Ill Patients With Alcohol Use Disorders: An Open Label Pilot Study|Withdrawn||Phase 4|0|Actual|Virginia Commonwealth University||2||Due to logistical purposes|f||||f||||||||No||2018-06-01 01:10:12.666575|2018-06-01 01:10:12.666575
NCT00871026|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2009-03-27|2009-03-27|2009-03-30|Estimate|||||||2009-03-27|2009-03-30|Estimate|March 2007||2007-03-31|March 2009|2009-03-31|October 2010|Anticipated|2010-10-31|March 2010|Anticipated|2010-03-31||Interventional|||Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM) - Based Planning and Creation of Orthodontic Appliances|Randomized Controlled Clinical Study Comparing Conventional and CAD/CAM-Based Treatment With Fixed Orthodontic Appliances|Unknown status|Active, not recruiting|N/A|160|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:10:12.761078|2018-06-01 01:10:12.761078
NCT00871013|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2018-04-24|2009-03-27|2009-03-30|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2009||2009-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)|Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)|Recruiting||Phase 2|160|Anticipated|University of Arkansas||1|||f||||t||||||||||2018-06-01 01:10:12.860984|2018-06-01 01:10:12.860984
NCT00871000|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2017-03-07|2010-07-02|2017-04-21|2009-03-26|2009-03-30|Estimate|2017-03-07|2017-04-18|Actual|2010-07-02|2010-07-07|Estimate|2017-04-21|2017-05-25|Actual|April 1, 2009||2009-04-01|March 2017|2017-03-31|November 18, 2009|Actual|2009-11-18|November 18, 2009|Actual|2009-11-18||Interventional|||Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.|Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 5 to 6-year-old Children.|Completed||Phase 3|303|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:10:13.062614|2018-06-01 01:10:13.062614
NCT00870987|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-27|||2017-10-11|2009-03-27|2009-03-30|Estimate|||||||2017-10-11|2017-10-12|Actual|May 2009|Actual|2009-05-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|April 2014|Actual|2014-04-30||Interventional|DNA-Ad||Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria|Clinical Trial on Safety, Immunogenicity, and Efficacy of a Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium Falciparum Circumsporozoite Protein and Apical Membrane Antigen 1 in Healthy Malaria-Naïve Adults in the US|Active, not recruiting||Phase 1/Phase 2|26|Anticipated|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-06-01 01:10:13.929463|2018-06-01 01:10:13.929463
NCT00870974|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-01-05|2009-03-26|2009-03-27|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2009||2009-03-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|FPEB||A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions|Evaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric Conditions|Completed||Phase 1|48|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 01:10:14.008227|2018-06-01 01:10:14.008227
NCT00870961|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2013-09-13|2009-03-26|2009-03-27|Estimate|||||||2013-09-13|2013-09-16|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps|Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study|Terminated||N/A|22|Actual|Northwestern University||2||PI changed institutions and accrual was not completed.|f||||||||||||||2018-06-01 01:10:14.092715|2018-06-01 01:10:14.092715
NCT00870948|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-11-04|2009-03-26|2009-03-27|Estimate|||||||2010-11-04|2010-11-08|Estimate|January 2009||2009-01-31|September 2010|2010-09-30||||April 2009|Actual|2009-04-30||Interventional|||Phase 1 BA Study, Single Center With Healthy Volunteers||Completed||Phase 1|75|Actual|Abbott||5|||f||||f||||||||||2018-06-01 01:10:14.181635|2018-06-01 01:10:14.181635
NCT00870753|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-03-26|2009-03-26|2009-03-27|Estimate|||||||2009-03-26|2009-03-27|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Yoga in Treatment of Eating Disorders|Yoga in Treatment of Eating Disorders|Unknown status|Recruiting|Phase 1|50|Anticipated|Norwegian School of Sport Sciences||2|||f||||f||||||||||2018-06-01 01:10:15.954202|2018-06-01 01:10:15.954202
NCT00870935|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-12-02|2009-03-26|2009-03-27|Estimate|||||||2010-12-02|2010-12-03|Estimate|August 2007||2007-08-31|March 2009|2009-03-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||A Trial to Compare Three Methods of Performing Hysterosalpingography|A Prospective, Randomized Study to Compare the Efficacy and the Tolerability of Three Methods of Performing Hysterosalpingography|Completed||N/A|222|Anticipated|IRCCS Burlo Garofolo||3|||f||||f||||||||||2018-06-01 01:10:14.251344|2018-06-01 01:10:14.251344
NCT00870922|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-03-25|2009-03-25|2009-03-27|Estimate|||||||2009-03-25|2009-03-27|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Effects of Masseter Manual Therapy on Temporomandibular Dysfunction|Effects of Masseter Manual Therapy on Temporomandibular Dysfunction: A Pilot Study|Unknown status|Recruiting|Phase 1|45|Anticipated|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 01:10:14.329618|2018-06-01 01:10:14.329618
NCT00870909|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-02-28|2009-03-26|2009-03-27|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2, 2009|Actual|2009-02-02|February 2017|2017-02-28|July 20, 2016|Actual|2016-07-20|April 21, 2016|Actual|2016-04-21||Interventional|||Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia|Anodal & Cathodal tDCS for Treatment of Resistant Auditory Hallucinations in Schizophrenia|Completed||N/A|46|Actual|Hôpital le Vinatier||2|||f||||f||||||||||2018-06-01 01:10:14.482586|2018-06-01 01:10:14.482586
NCT00870896|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2012-06-13||2014-09-29|2009-03-25|2009-03-27|Estimate|2014-09-08|2014-09-15|Estimate||||2014-09-29|2014-10-01|Estimate|February 2008||2008-02-29|September 2014|2014-09-30|June 2012|Actual|2012-06-30|February 2009|Actual|2009-02-28||Interventional||Twenty male subjects between 40-80 years of age with COPD will be recruited from the USF and James A. Haley medical clinics, word of mouth, newspaper and radio advertising. We are restricting the study to men because woman have a more sensitive cough reflex and analysis of data will be more difficult when comparing as a group.|The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Tiotropium on the Cough Reflex in Patients With COPD|Completed||Early Phase 1|5|Actual|University of South Florida||1|||f||||t||||||||||2018-06-01 01:10:14.625175|2018-06-01 01:10:14.625175
NCT00870883|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2015-05-27|2009-03-25|2009-03-27|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||N-acetylcysteine Plus Deferoxamine for Patients With Hypotension|Prospective, Randomized, Double-blinded, Placebo-controlled Study of N-acetylcysteine Plus Deferoxamine for Patients With Hypotension as Prophylaxis for Acute Renal Failure|Completed||Phase 2|81|Actual|Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude||1|||f||||t||||||||||2018-06-01 01:10:14.914121|2018-06-01 01:10:14.914121
NCT00870870|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26||2010-09-03|2012-06-12|2009-03-26|2009-03-27|Estimate||||2010-09-03|2010-09-08|Estimate|2012-06-12|2012-06-14|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Patients With Lung Cancer Who Have Not Received Chemotherapy Before|Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|64|Actual|ImClone LLC||2|||f||||f||||||||||2018-06-01 01:10:15.007554|2018-06-01 01:10:15.007554
NCT00870857|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2016-10-24|2009-03-26|2009-03-27|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|October 2013|Actual|2013-10-31||Observational|MACS||Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center|Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center|Completed|||407|Actual|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     blood oral wash sputum BAL~   "|||2018-06-01 01:10:15.163481|2018-06-01 01:10:15.163481
NCT00870844|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2011-04-19|2009-03-26|2009-03-27|Estimate|||||||2011-04-19|2011-04-20|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke|A Randomised, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Patients With Acute Ischemic Stroke|Completed||Phase 1|24|Actual|H. Lundbeck A/S||4|||f||||t||||||||||2018-06-01 01:10:15.247125|2018-06-01 01:10:15.247125
NCT00870831|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2014-12-08|2009-03-26|2009-03-27|Estimate|||||||2014-12-08|2014-12-10|Estimate|October 2000||2000-10-31|December 2014|2014-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|Islet OGTT||Islet Function and Clinical Analyses of Transplant Recipients|Islet Function and Clinical Analyses if Transplant Recipients (Project 2 of JDFI Washington University Center For Islet Transplantation) (Please Note That the JDRFI Funded Has Ended|Terminated|||8|Actual|Washington University School of Medicine|||2|PI left University|f||||f||||||Samples Without DNA|"~     Serum samples are obtained during the OGTT and stored in a -20degree freezer. They are tested~     for Insulin C-peptide and glucose.~   "|||2018-06-01 01:10:15.33722|2018-06-01 01:10:15.33722
NCT00870818|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26||2012-03-01|2012-03-05|2009-03-26|2009-03-27|Estimate||||2012-03-05|2012-03-08|Estimate|2012-03-05|2012-03-08|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)|An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus|Terminated||Phase 2/Phase 3|219|Actual|MacroGenics||4|||f||||f||||||||||2018-06-01 01:10:15.426162|2018-06-01 01:10:15.426162
NCT00870805|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2013-02-26|2009-03-26|2009-03-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|UB ECT||Ultrabrief Pulsewidth Electroconvulsive Therapy (ECT)|A Controlled Study of Ultrabrief Pulsewidth ECT (Electroconvulsive Therapy)|Completed||Phase 4|150|Actual|The University of New South Wales||4|||f||||t||||||||||2018-06-01 01:10:15.541455|2018-06-01 01:10:15.541455
NCT00870792|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-01-10|2009-03-26|2009-03-27|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2002||2002-11-30|March 2009|2009-03-31|February 2005|Actual|2005-02-28|January 2005|Actual|2005-01-31||Interventional|MAP||Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals|Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals|Completed||N/A|156|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 01:10:15.678873|2018-06-01 01:10:15.678873
NCT00870779|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2018-03-13|2009-03-25|2009-03-27|Estimate|||||||2018-03-13|2018-03-15|Actual|May 2007||2007-05-31|March 2018|2018-03-31|July 2, 2013|Actual|2013-07-02|July 2, 2012|Actual|2012-07-02||Interventional|FGR||Fluorescence Guided Resection of Brain Tumors|Co-registered Fluorescence-Enhanced Resection of Brain Tumors Stage I: Correlation With MR and Biopsy|Completed||Phase 1|105|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 01:10:15.772449|2018-06-01 01:10:15.772449
NCT00870740|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2016-05-31|2014-10-13|2016-07-19|2009-03-26|2009-03-27|Estimate|2016-07-19|2016-08-30|Estimate|2014-10-13|2014-10-22|Estimate|2016-07-19|2016-08-30|Estimate|February 2009||2009-02-28|July 2016|2016-07-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|SELECTION||Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis|A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)|Completed||Phase 2|517|Actual|Biogen||6|||f||||t||||||||||2018-06-01 01:10:16.122128|2018-06-01 01:10:16.122128
NCT00870727|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02||2017-04-06|2018-03-14|2009-03-26|2009-03-27|Estimate||||2017-04-06|2017-04-11|Actual|2018-03-14|2018-03-16|Actual|February 2009||2009-02-28|March 2018|2018-03-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders|Pharmacotherapy of Pervasive Developmental Disorders|Completed||Phase 3|33|Actual|Indiana University||2|||f||||t|t|f||||||||2018-06-01 01:10:17.942796|2018-06-01 01:10:17.942796
NCT00870714|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2009-03-25|2009-03-25|2009-03-27|Estimate|||||||2009-03-25|2009-03-27|Estimate|September 2004||2004-09-30|March 2009|2009-03-31||||September 2010|Anticipated|2010-09-30||Interventional|IST 16167||Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study|Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study|Unknown status|Active, not recruiting|N/A|20|Anticipated|Kansas City Veteran Affairs Medical Center||1|||f||||t||||||||||2018-06-01 01:10:18.052543|2018-06-01 01:10:18.052543
NCT00870701|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2018-03-01|2009-03-26|2009-03-27|Estimate|||||||2018-03-01|2018-03-02|Actual|March 19, 2009|Actual|2009-03-19|March 2018|2018-03-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|||Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma|Randomised Multicentric Phase III Study Comparing Observation Versus Post-surgery Radiotherapy After Complete Exeresis With Margins Greater Than or Equal to 1 cm in Soft Tissues Members Sarcoma.|Completed||Phase 3|77|Actual|Institut Claudius Regaud||2|||f||||t||||||||||2018-06-01 01:10:18.118849|2018-06-01 01:10:18.118849
NCT00870688|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2009-01-09||2009-05-19|2009-03-26|2009-03-27|Estimate|2009-03-26|2009-03-27|Estimate||||2009-05-19|2009-05-20|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening|Non Interventional Trial of Valproate Sustained Release Minitablets Once Daily in the Evening|Completed|||82|Actual|Desitin Arzneimittel GmbH|||1||f||||f||||||||||2018-06-01 01:10:18.220219|2018-06-01 01:10:18.220219
NCT00870675|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2014-09-23|2009-03-26|2009-03-27|Estimate|||||||2014-09-23|2014-09-25|Estimate|January 1996||1996-01-31|September 2014|2014-09-30|June 2011|Actual|2011-06-30|May 2009|Actual|2009-05-31||Observational|||Magnetic Resonance Imaging (MRI) of Ventriculomegaly: Morphology and Outcome|MRI of Ventriculomegaly: Morphology and Outcome|Completed|||434|Actual|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|||1||f||||f||||||||||2018-06-01 01:10:18.453725|2018-06-01 01:10:18.453725
NCT00870662|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2011-12-16|2009-03-25|2009-03-27|Estimate|||||||2011-12-16|2011-12-19|Estimate|December 2008||2008-12-31|December 2011|2011-12-31||||December 2009|Actual|2009-12-31||Interventional|||A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal|A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal|Completed||N/A|7|Actual|NovaShunt AG||1|||f||||f||||||||||2018-06-01 01:10:18.525827|2018-06-01 01:10:18.525827
NCT00870649|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2016-11-07|2009-03-26|2009-03-27|Estimate|||||||2016-11-07|2016-11-08|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|Bilhvax3||Efficacy of Bilhvax in Association With Praziquantel for Prevention of Clinical Recurrences of Schistosoma Haematobium|Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children|Completed||Phase 3|250|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||No||2018-06-01 01:10:18.600786|2018-06-01 01:10:18.600786
NCT00870636|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-03-27|2009-03-26|2009-03-27|Estimate|||||||2009-03-27|2009-03-30|Estimate||||March 2009|2009-03-31||||||||Expanded Access|||Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)|Compassionate Use Pan-VEGF Blockade for the Treatment of ROP (Compassionate Use BLOCK-ROP) Trial|Temporarily not available|||||Children's Hospital Los Angeles|||||||||||||||||||2018-06-01 01:10:18.679909|2018-06-01 01:10:18.679909
NCT00870623|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2018-04-18|2009-03-26|2009-03-27|Estimate|||||||2018-04-18|2018-04-20|Actual|June 2009||2009-06-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections|Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections|Completed|||223|Actual|University of Nebraska|||||f||||f||||||Samples Without DNA|"~     Blood (maximum 40mL) will be collected for future use or for purposes that are not integral~     to the current research.~   "|||2018-06-01 01:10:18.773336|2018-06-01 01:10:18.773336
NCT00870610|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2015-04-27|2009-03-26|2009-03-27|Estimate|||||||2015-04-27|2015-04-28|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SjO2||Jugular Venous Oxygen Saturation During Therapeutic Hypothermia After Cardiac Arrest|Cerebral Metabolism During Therapeutic Hypothermia for Cardiac Arrest|Completed|||15|Actual|Policlinico Hospital|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:10:18.838426|2018-06-01 01:10:18.838426
NCT00870597|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-03-26|2009-03-26|2009-03-27|Estimate|||||||2009-03-26|2009-03-27|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|TSV-25G||Transconjunctival Sutureless 25-Gauge Vitrectomy|Transconjunctival Sutureless 25-Gauge Vitrectomy for Visually Significant Vitreous Floaters in Patients With Multifocal Intraocular Lens|Completed||Phase 3|14|Actual|Hospital Oftalmologico de Brasilia||2|||f||||t||||||||||2018-06-01 01:10:18.905369|2018-06-01 01:10:18.905369
NCT00870584|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2011-10-12||2011-10-12|2009-03-25|2009-03-27|Estimate|2011-10-12|2011-11-17|Estimate||||2011-10-12|2011-11-17|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma|A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma|Completed||Phase 4|271|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:10:18.983985|2018-06-01 01:10:18.983985
NCT00870207|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2011-04-29|2009-03-26|2009-03-27|Estimate|||||||2011-04-29|2011-05-03|Estimate|November 2010||2010-11-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|TSSC Worksite||Tu Salud Si Cuenta Worksite: Pilot Intervention Study|Tu Salud Si Cuenta Worksite: Pilot Intervention Study|Completed||N/A|150|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 01:10:23.136126|2018-06-01 01:10:23.136126
NCT00870571|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-08-13|2009-03-26|2009-03-27|Estimate|||||||2010-08-13|2010-08-16|Estimate|April 2005||2005-04-30|August 2010|2010-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions|Comparative, Randomized, Single Dose, 2-way Crossover Bioavailability Study of Actavis Group hf and Pfizer Inc. (Norvasc®)10 mg Amlodipine Besylate Tablets in Healthy Adult Volunteers Under Fed Conditions.|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:10:19.302708|2018-06-01 01:10:19.302708
NCT00870558|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2011-08-13|2009-03-26|2009-03-27|Estimate|||||||2011-08-13|2011-08-16|Estimate|June 2005||2005-06-30|April 2009|2009-04-30||||May 2011|Actual|2011-05-31||Interventional|||Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer|Adjuvant Treatment by Intra-arterial Injection of Lipiodol-labeled Iodine-131 in Preventing Recurrence of Hepatocellular Carcinoma After Curative Treatment|Completed||Phase 3|120|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:10:19.519087|2018-06-01 01:10:19.519087
NCT00870545|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2013-04-04||2017-06-01|2009-03-25|2009-03-27|Estimate|2013-06-03|2013-06-04|Estimate||||2017-06-01|2017-06-28|Actual|September 2009||2009-09-30|June 2017|2017-06-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Reintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study|Reintegration: The Role of Spouse Telephone BATTLEMIND Pilot Study|Completed||N/A|86|Actual|Memphis VA Medical Center|Small sample size, some of the Wounded Warrior Project spouses knew each other, pilot feasibility study and not a randomized controlled trial.|1|||f||||f||||||||||2018-06-01 01:10:19.612474|2018-06-01 01:10:19.612474
NCT00870532|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2013-11-01|2009-03-26|2009-03-27|Estimate|||||||2013-11-01|2013-11-04|Estimate|June 2008||2008-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer|A Prospective Study of Metronomic Oral Vinorelbine in Combination With Sorafenib in Advanced Non-small Cell Lung Cancer a) A Phase I Dose-finding Study of the Combination of Metronomic Oral Vinorelbine and Sorafenib b) Pharmacokinetics Profiling of the Combination of Metronomic Oral Vinorelbine and Sorafenib at MTD|Completed||Phase 1|52|Actual|National Cancer Centre, Singapore||3|||f||||f||||||||||2018-06-01 01:10:19.835905|2018-06-01 01:10:19.835905
NCT00870519|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2011-02-24|2009-03-26|2009-03-27|Estimate|||||||2011-02-24|2011-02-25|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Evaluation of [123I] MNI-168 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Terminated||Phase 1|2|Actual|Institute for Neurodegenerative Disorders||2||"Assessment of data shows inadequate brain uptake, suggesting the tracer is inadequate as an~   imaging biomarker of brain amyloid."|f||||f||||||||||2018-06-01 01:10:19.908755|2018-06-01 01:10:19.908755
NCT00870506|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-07-09|2009-03-26|2009-03-27|Estimate|||||||2010-07-09|2010-07-12|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Community Trial to Enhance Organ Donation|Community-based Intervention to Enhance Signing of Organ Donor Cards|Completed||N/A|973|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-06-01 01:10:19.96977|2018-06-01 01:10:19.96977
NCT00870493|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2012-12-03|2009-03-26|2009-03-27|Estimate|||||||2012-12-03|2012-12-04|Estimate|April 2009||2009-04-30|December 2012|2012-12-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Aliskiren for Immunoglobulin A (IgA) Nephropathy|The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study|Completed||Phase 3|22|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:10:20.125206|2018-06-01 01:10:20.125206
NCT00870480|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-08-13|2009-03-26|2009-03-27|Estimate|||||||2010-08-13|2010-08-16|Estimate|November 2004||2004-11-30|August 2010|2010-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:10:20.200723|2018-06-01 01:10:20.200723
NCT00870467|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|2012-03-09||2012-08-01|2009-03-26|2009-03-27|Estimate|2012-03-09|2012-04-05|Estimate||||2012-08-01|2012-08-07|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis|A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis|Completed||Phase 3|334|Actual|Abbott||6|||f||||||||||||||2018-06-01 01:10:20.342636|2018-06-01 01:10:20.342636
NCT00870454|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25||2013-01-15|2013-01-15|2009-03-26|2009-03-27|Estimate||||2013-01-15|2013-01-24|Estimate|2013-01-15|2013-01-24|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase|Completed||Phase 2|386|Actual|SK Life Science||4|||f||||||||||||||2018-06-01 01:10:21.145515|2018-06-01 01:10:21.145515
NCT00870441|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-02-27|2009-03-26|2009-03-27|Estimate|||||||2013-02-27|2013-02-28|Estimate|March 2009||2009-03-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Multiple Dose, Multi-Center Study to Compare the Safety of ASP2151 to Valacylcovir and Placebo in Healthy Male and Female Subjects|Terminated||Phase 1|442|Actual|Astellas Pharma Inc||3||Study terminated due to treatment-emergent serious adverse events|f||||f||||||||||2018-06-01 01:10:21.223399|2018-06-01 01:10:21.223399
NCT00870428|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-03-26|2009-03-26|2009-03-27|Estimate|||||||2009-03-26|2009-03-27|Estimate|March 2009||2009-03-31|March 2009|2009-03-31||||||||Observational|||Predicitve Use of Spot Urine Protein/Creatinine Ratios in Preeclampsia|The Predictive Use of Spot Urine Protein/Creatinine Ratios and Decreased Sample Collection Time in the Diagnosis of Preeclampsia|Unknown status|Recruiting||117|Anticipated|MemorialCare|||1||f||||f||||||||||2018-06-01 01:10:21.290774|2018-06-01 01:10:21.290774
NCT00870415|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-08-16|2009-03-26|2009-03-27|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2007||2007-04-30|August 2017|2017-08-31|December 2010|Actual|2010-12-31|April 2009|Actual|2009-04-30||Interventional|||Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer|Multicenter (Phase II) Study of Oncoplastic Surgical Techniques for Breast Conservation in Breast Cancers|Completed||Phase 2|263|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||||||||||||2018-06-01 01:10:21.345254|2018-06-01 01:10:21.345254
NCT00870402|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-03-25|2009-03-25|2009-03-27|Estimate|||||||2009-03-25|2009-03-27|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|ALDODN||Aldosterone in Diabetic Nephropathy|Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.|Unknown status|Recruiting|Phase 4|160|Anticipated|Universidad Los Andes, Chile||2|||f||||t||||||||||2018-06-01 01:10:21.41552|2018-06-01 01:10:21.41552
NCT00870376|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2017-02-09|2009-03-26|2009-03-27|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2009|Actual|2009-04-30|July 2015|2015-07-31|April 23, 2009|Actual|2009-04-23|April 2009|Actual|2009-04-30||Observational|||Studies of Biomarkers in Different Urodynamic Diagnoses of Female Patients With Lower Urinary Tract Symptoms|Studies of Biomarkers in Different Urodynamic Diagnoses of Female Patients With Lower Urinary Tract Symptoms|Withdrawn|||0|Actual|Far Eastern Memorial Hospital|||1|no budget|f||||||||||||||2018-06-01 01:10:21.587796|2018-06-01 01:10:21.587796
NCT00870363|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2017-01-12||2017-05-24|2009-03-26|2009-03-27|Estimate|2017-02-09|2017-02-10|Actual||||2017-05-24|2017-05-30|Actual|April 2009||2009-04-30|May 2017|2017-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy|A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy|Completed||Phase 4|44|Actual|University of California, Davis||4|||f||||f||||||||||2018-06-01 01:10:21.672008|2018-06-01 01:10:21.672008
NCT00870350|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-06-04|2009-03-26|2009-03-27|Estimate|||||||2010-06-04|2010-06-07|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|June 2010|Anticipated|2010-06-30|October 2009|Actual|2009-10-31||Interventional|Tdap Booster||An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster|An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age|Unknown status|Active, not recruiting|Phase 4|400|Anticipated|Swedish Institute for Infectious Disease Control||2|||f||||t||||||||||2018-06-01 01:10:22.253514|2018-06-01 01:10:22.253514
NCT00870337|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2014-10-28|2009-03-26|2009-03-27|Estimate|||||||2014-10-28|2014-10-29|Estimate|March 2008||2008-03-31|October 2014|2014-10-31||||May 2011|Actual|2011-05-31||Interventional|ENDORAD||Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer|Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer|Completed||Phase 2|44|Actual|ARCAGY/ GINECO GROUP||1|||f||||t||||||||||2018-06-01 01:10:22.351804|2018-06-01 01:10:22.351804
NCT00870324|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2015-06-03|2009-03-26|2009-03-27|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2009||2009-03-31|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|SENSE-AF||OptiSense™ Performance in Detecting Atrial Episodes|OptiSense Performance in Detecting Atrial Episodes in CRMD Device Patient Population|Completed|||50|Actual|St. Jude Medical|||2||f||||t||||||||||2018-06-01 01:10:22.433958|2018-06-01 01:10:22.433958
NCT00870311|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-03-25|2009-03-25|2009-03-27|Estimate|||||||2009-03-25|2009-03-27|Estimate|March 1996||1996-03-31|March 2009|2009-03-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients|Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients|Completed||Phase 4|28|Actual|Wayne State University||1|||f||||f||||||||||2018-06-01 01:10:22.492064|2018-06-01 01:10:22.492064
NCT00870298|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2015-12-07|2009-03-26|2009-03-27|Estimate|||||||2015-12-07|2015-12-09|Estimate|August 2006||2006-08-31|December 2015|2015-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|warf-tmp/smx||Computer Stop Order Alert to Prevent Concurrent Prescribing of Trimethoprim/Sulfamethoxazole and Warfarin|Randomized Controlled Study of a Computer Stop Order Versus Routine Practice When Trimethoprim/Sulfamethoxazole is Ordered Concurrently With Warfarin|Terminated||N/A|1971|Actual|University of Pennsylvania||2||four adverse events encountered|f||||f||||||||||2018-06-01 01:10:22.631251|2018-06-01 01:10:22.631251
NCT00870285|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2012-03-15|2009-03-26|2009-03-27|Estimate|||||||2012-03-15|2012-03-16|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Ustekinumab Plus UVB-311nm in Psoriasis|Ustekinumab Plus UVB-311nm Half-side Phototherapy in Patients With Psoriasis|Completed||N/A|10|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 01:10:22.690542|2018-06-01 01:10:22.690542
NCT00870272|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-03-26|2009-03-26|2009-03-27|Estimate|||||||2009-03-26|2009-03-27|Estimate|July 2007||2007-07-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of 400mcg Sublingual Versus 400mcg Buccal Misoprostol Following 200mg Mifepristone for Medical Abortion up to 63 Days Last Menstrual Period (LMP)|A Randomized Study of Sublingual and Buccal Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation|Completed||N/A|550|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 01:10:22.761353|2018-06-01 01:10:22.761353
NCT00870259|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2014-12-03|2009-03-26|2009-03-27|Estimate|||||||2014-12-03|2014-12-05|Estimate|February 2008||2008-02-29|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Investigating Physiological Adaptations to Weight Loss|An Investigation of Physiological Adaptations Contributing to Weight Regain After Weight Loss|Completed||N/A|50|Actual|University of Melbourne|||||f||||f||||||||||2018-06-01 01:10:22.831444|2018-06-01 01:10:22.831444
NCT00870246|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2009-05-05|2009-03-26|2009-03-27|Estimate|||||||2009-05-05|2009-05-06|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Observational|DMCOPD||Diaphragmatic Mobility and Chronic Obstructive Pulmonary Disease|Influence of Diaphragmatic Mobility on the Exercise Capacity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease|Completed|||50|Actual|University of Sao Paulo|||2||f||||f||||||||||2018-06-01 01:10:22.898651|2018-06-01 01:10:22.898651
NCT00870233|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2018-02-14|2009-03-26|2009-03-27|Estimate|||||||2018-02-14|2018-02-15|Actual|March 24, 2009|Actual|2009-03-24|March 2017|2017-03-31|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Observational|||Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life|Electronic Patient-Reported Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life|Completed|||120|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:10:22.961821|2018-06-01 01:10:22.961821
NCT00870220|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2014-03-10|2009-03-26|2009-03-27|Estimate|||||||2014-03-10|2014-03-11|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Initiating Transdermal Estradiol Therapy in Turner's Syndrome|Initiating Transdermal Estradiol Therapy in Turner's Syndrome|Terminated||Phase 1|1|Actual|University of Chicago||1||Poor accrual|f||||t||||||||||2018-06-01 01:10:23.058688|2018-06-01 01:10:23.058688
NCT00870194|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2011-04-11||2015-03-20|2009-03-26|2009-03-27|Estimate|2011-05-19|2011-06-17|Estimate||||2015-03-20|2015-04-09|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin|A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin|Completed||Phase 4|255|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:10:23.27158|2018-06-01 01:10:23.27158
NCT00870181|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2013-06-22|2009-03-26|2009-03-27|Estimate|||||||2013-06-22|2013-06-25|Estimate|January 2008||2008-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|HGG-01||ADV-TK Improves Outcome of Recurrent High-Grade Glioma|Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma|Completed||Phase 2|47|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-06-01 01:10:23.928707|2018-06-01 01:10:23.928707
NCT00870168|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2011-05-13|2009-03-26|2009-03-27|Estimate|||||||2011-05-13|2011-05-16|Estimate|January 2006||2006-01-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer|Modifications of Hormone Receptors and Biological Parameters of Metastatic Breast Cancer Treated With First-line Chemotherapy. Prospective Biological Study.|Completed||N/A|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:10:23.98929|2018-06-01 01:10:23.98929
NCT00870155|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26||2010-09-07|2010-09-07|2009-03-26|2009-03-27|Estimate||||2010-09-07|2010-09-09|Estimate|2010-09-07|2010-09-09|Estimate|February 2007||2007-02-28|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MAESTRO-02||A Study for Patients With Multiple Sclerosis|An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis|Terminated||Phase 2/Phase 3|546|Anticipated|Eli Lilly and Company||1||Negative efficacy results of the MAESTRO-01 trial|f||||f||||||||||2018-06-01 01:10:24.046942|2018-06-01 01:10:24.046942
NCT00870142|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2010-08-13|2009-03-26|2009-03-27|Estimate|||||||2010-08-13|2010-08-16|Estimate|April 2005||2005-04-30|August 2010|2010-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions|Comparative, Randomized, Single Dose, 2-way Crossover Bioavailability Study of Actavis Group hf and Pfizer Inc. (Norvasc®)10 mg Amlodipine Besylate Tablets in Healthy Adult Volunteers Under Fasting Conditions.|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:10:24.163804|2018-06-01 01:10:24.163804
NCT00870129|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-26|||2018-04-04|2009-03-26|2009-03-27|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2009|Actual|2009-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors|Using Advanced MR Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans: A Pilot Study, and to Examine Metabolite Changes in Gliomas and Other Solid Tumors|Recruiting||N/A|190|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:10:24.237658|2018-06-01 01:10:24.237658
NCT00870116|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-03-05|2009-03-25|2009-03-26|Estimate|||||||2013-03-05|2013-03-06|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|SBRT-NSCLC||Stereotactic Body Radio Therapy (SBRT) for Early-stage Non Small Cell Lung Cancer (NSCLC)|SBRT Radiotherapy for Non-operated Non-small-cell Lung Cancer (NSCLC), T1-T2, N0, M0|Unknown status|Active, not recruiting|N/A|120|Anticipated|Centre Leon Berard||3|||f||||t||||||||||2018-06-01 01:10:24.327786|2018-06-01 01:10:24.327786
NCT00870103|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-01-14||2010-03-03|2009-03-25|2009-03-26|Estimate|2010-01-21|2010-02-15|Estimate||||2010-03-03|2010-03-09|Estimate|September 2008||2008-09-30|March 2010|2010-03-31||||February 2009|Actual|2009-02-28||Interventional|||Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery|An Evaluation of the Prophylactic Efficacy and Safety of the Administration of the Combination Formulation of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops in Inflammation and Infection Post-cataract Surgery|Completed||Phase 4|64|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:10:24.43776|2018-06-01 01:10:24.43776
NCT00870077|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2012-02-23|2009-03-25|2009-03-26|Estimate|||||||2012-02-23|2012-02-24|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|PROTOB||A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver Disease|Effect of a Whey Protein Supplementation on Intrahepatic Lipids in Obese Patients With Non-alcoholic Fatty Liver Disease|Completed||N/A|11|Actual|University of Lausanne||1|||f||||f||||||||||2018-06-01 01:10:24.681673|2018-06-01 01:10:24.681673
NCT00870064|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2017-12-27|2009-03-25|2009-03-26|Estimate|||||||2017-12-27|2017-12-29|Actual|March 2010|Actual|2010-03-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PROOF||The Treatment of Type I Open Fractures in Pediatrics|The Treatment of Type I Open Fractures in Pediatrics: Evaluating the Necessity of Formal Irrigation and Debridement|Recruiting||N/A|300|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-06-01 01:10:24.758863|2018-06-01 01:10:24.758863
NCT00870051|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2018-01-26|2009-03-25|2009-03-26|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2009||2009-03-31|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|ENGAGE||Endurant Stent Graft Natural Selection Global Postmarket Registry|Endurant Stent Graft Natural Selection Global Postmarket Registry|Active, not recruiting|||1200|Anticipated|Medtronic Endovascular|||1||f||||f||||||||Undecided||2018-06-01 01:10:24.851954|2018-06-01 01:10:24.851954
NCT00870038|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2010-07-21|2009-03-25|2009-03-26|Estimate|||||||2010-07-21|2010-07-22|Estimate|December 2010||2010-12-31|March 2009|2009-03-31|January 2012|Anticipated|2012-01-31|August 2011|Anticipated|2011-08-31||Interventional|EREMUS||To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study|Early Re-Endothelialization Might Not be the Unique Solution to Prevent Restenosis. The EREMUS Study|Unknown status|Not yet recruiting|Phase 4|75|Anticipated|Ospedale della Misericordia||3|||f||||f||||||||||2018-06-01 01:10:24.924947|2018-06-01 01:10:24.924947
NCT00870025|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-25|||2015-04-21|2009-03-25|2009-03-26|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|APPE||Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients|hCG Priming Prior to COH in Poor Responder IVF Patients|Completed||Phase 4|60|Actual|IVI Madrid||2|||f||||||||||||||2018-06-01 01:10:25.004407|2018-06-01 01:10:25.004407
NCT00870012|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-02-20|2009-03-25|2009-03-26|Estimate|||||||2014-02-20|2014-02-24|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics||Completed||N/A|20|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:10:25.071054|2018-06-01 01:10:25.071054
NCT00869999|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2013-10-25||2014-10-23|2009-03-25|2009-03-26|Estimate|2014-10-23|2014-10-27|Estimate||||2014-10-23|2014-10-27|Estimate|May 2009||2009-05-31|October 2013|2013-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||26 patients enrolled, 24 evaluable|Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma|Everolimus in Combination With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma|Completed||Phase 2|26|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 01:10:25.216347|2018-06-01 01:10:25.216347
NCT00869986|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24||2010-09-07|2010-09-07|2009-03-24|2009-03-26|Estimate||||2010-09-07|2010-09-09|Estimate|2010-09-07|2010-09-09|Estimate|November 2006||2006-11-30|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MINDSET01||A Study for Patients With Relapsing Remitting Multiple Sclerosis|A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis|Completed||Phase 2/Phase 3|218|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 01:10:25.45326|2018-06-01 01:10:25.45326
NCT00869973|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-01-22|2009-03-25|2009-03-26|Estimate|||||||2013-01-22|2013-01-23|Estimate|September 2009||2009-09-30|October 2009|2009-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients|Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study|Terminated||Phase 3|580|Actual|S. Maria Hospital, Terni||2||We terminated the study after enrolling 580/900 patients due to a slow accrual|f||||f||||||||||2018-06-01 01:10:25.546404|2018-06-01 01:10:25.546404
NCT00869960|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2012-03-15||2013-08-17|2009-03-25|2009-03-26|Estimate|2012-03-15|2012-04-12|Estimate||||2013-08-17|2013-09-06|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women|Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women|Completed||Phase 4|24|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 01:10:25.654759|2018-06-01 01:10:25.654759
NCT00869947|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2013-09-18||2014-01-07|2009-03-24|2009-03-26|Estimate|2014-01-07|2014-02-25|Estimate||||2014-01-07|2014-02-25|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|June 2011|Actual|2011-06-30||Interventional|||Effects of Wearing a Powered Ankle-Foot Prosthesis on Amputee Walking|Effects of Wearing a Powered Ankle-Foot Prosthesis on Amputee Walking|Completed||N/A|16|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:10:25.893325|2018-06-01 01:10:25.893325
NCT00869934|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2013-06-28|2009-03-24|2009-03-26|Estimate|||||||2013-06-28|2013-07-02|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cognitive-Behavior Therapy for Insomnia|Cognitive-Behavior Therapy for Insomnia: Component Analysis and Treatment|Completed||Phase 4|186|Actual|Laval University||3|||f||||f||||||||||2018-06-01 01:10:26.176803|2018-06-01 01:10:26.176803
NCT00869921|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2017-12-08|2009-03-25|2009-03-26|Estimate|||||||2017-12-08|2017-12-12|Actual|March 2009||2009-03-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Model 4195 Left Ventricular (LV) Lead Chronic Performance Study|Attain StarFix® Model 4195 Left Ventricular Lead Chronic Performance Post Approval Study|Active, not recruiting|||1322|Actual|Medtronic|||||f||||f||||||||||2018-06-01 01:10:26.275798|2018-06-01 01:10:26.275798
NCT00869908|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2017-01-18|2009-03-25|2009-03-26|Estimate|||||||2017-01-18|2017-01-19|Estimate|November 2008||2008-11-30|January 2017|2017-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|A1chieve®||Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication|The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study|Completed|||66726|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:10:26.403951|2018-06-01 01:10:26.403951
NCT00869895|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2016-01-27|2009-03-25|2009-03-26|Estimate|||||||2016-01-27|2016-01-29|Estimate|March 2009||2009-03-31|November 2012|2012-11-30||||August 2012|Actual|2012-08-31||Interventional|||A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors|A Phase I Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors|Completed||Phase 1|60|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 01:10:26.502076|2018-06-01 01:10:26.502076
NCT00869882|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-10-29|2009-03-25|2009-03-26|Estimate|||||||2014-10-29|2014-10-30|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|SPONGIT||SPONGIT: Comparison of Two Surgical Approaches in the Treatment of Degenerative Spondylolysthesis|Comparison of 2 Surgical Approaches in the Treatment of Degenerative Spondylolysthesis: Posterolateral Fusion With Instrumentation (GPLI) Plus or Minus Transforaminal Lumbar Interbody Fusion (TLIF)|Completed||N/A|60|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:10:26.561101|2018-06-01 01:10:26.561101
NCT00869869|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2018-01-17|2009-03-25|2009-03-26|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2009||2009-03-31|January 2018|2018-01-31|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Melatonin Supplementation to Improve Sleep in Patients With Heart Failure|Restoration of Sleep in Heart Failure Patients|Withdrawn||Phase 2|0|Actual|Brigham and Women's Hospital||2||No subjects were enrolled in this study. Funding ran out.|f||||f||||||||||2018-06-01 01:10:26.770615|2018-06-01 01:10:26.770615
NCT00869856|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2015-06-01|2009-03-25|2009-03-26|Estimate|||||||2015-06-01|2015-06-02|Estimate|April 2009||2009-04-30|June 2015|2015-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|SWEEP||Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)|An Open Label, Single-arm, Baseline-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 Administered Once a Week (qw) and Once Every Two Weeks (q2w) in the Treatment of Anemia Associated With Chronic Kidney Disease in Pre-dialysis and Dialysis Subjects|Withdrawn||Phase 3|0|Actual|Sandoz||1||investigation of adverse events in a related clinical study|f||||t||||||||||2018-06-01 01:10:26.868377|2018-06-01 01:10:26.868377
NCT00869843|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-04-22|2009-03-25|2009-03-26|Estimate|||||||2013-04-22|2013-04-23|Estimate|October 2002||2002-10-31|April 2013|2013-04-30|March 2009|Actual|2009-03-31|October 2007|Actual|2007-10-31||Interventional|||Study of Saline Linked Monopolar Surface Radiofrequency (RF) Ablation of Hepatic Tumors|Phase I Study of Saline Linked Monopolar Surface Radiofrequency (RF) Ablation of Hepatic Tumors|Completed||Phase 1|28|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 01:10:26.959045|2018-06-01 01:10:26.959045
NCT00869830|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-03-25|2009-03-25|2009-03-26|Estimate|||||||2009-03-25|2009-03-26|Estimate|January 2007||2007-01-31|March 2009|2009-03-31||||August 2008|Actual|2008-08-31||Interventional|||The Effectiveness of Biofeedback Treatment in Constipated Patients With Idiopathic Parkinson's Disease|The Effectiveness of Biofeedback Treatment in Constipated Patients With Idiopathic Parkinson's Disease|Completed||N/A|30|Actual|Asan Medical Center||1|||f||||t||||||||||2018-06-01 01:10:27.026256|2018-06-01 01:10:27.026256
NCT00869817|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2017-09-26|2009-03-25|2009-03-26|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2009||2009-01-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|DIAN||Dominantly Inherited Alzheimer Network (DIAN)|Dominantly Inherited Alzheimer Network (DIAN)|Recruiting|||600|Anticipated|Washington University School of Medicine|||2||f||||t||||||Samples With DNA|"~     buffy coat, plasma, cerebral spinal fluid~   "|||2018-06-01 01:10:27.102239|2018-06-01 01:10:27.102239
NCT00869804|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-03-25|2009-03-25|2009-03-26|Estimate|||||||2009-03-25|2009-03-26|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|HOPE||Heading Off Peripheral Neuropathy With Exercise|Pilot Randomized Study of Aerobic and Resistance Exercise for Women Undergoing Treatment for Breast Cancer With Taxanes.|Unknown status|Not yet recruiting|N/A|200|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-06-01 01:10:27.226739|2018-06-01 01:10:27.226739
NCT00869791|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2016-01-25|2010-10-29|2017-03-31|2009-03-25|2009-03-26|Estimate|2017-03-21|2017-03-31|Actual|2010-10-29|2010-11-02|Estimate|2017-03-31|2017-05-09|Actual|November 2008||2008-11-30|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa|A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa|Completed||Phase 2|27|Actual|IMPAX Laboratories, Inc.|The limitations of this study include its relatively small size, multiple statistical testing, short study durations, and open-label design.|2|||f||||f||||||||No||2018-06-01 01:10:27.318852|2018-06-01 01:10:27.318852
NCT00869778|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2016-11-20||2017-03-03|2009-03-25|2009-03-26|Estimate|2016-11-20|2017-01-18|Estimate||||2017-03-03|2017-03-31|Actual|June 2009||2009-06-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||FAS|Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients|Completed||Phase 2|360|Actual|Chongqing Jiachen Biotechnology Ltd.||3|||f||||t||||||||Undecided||2018-06-01 01:10:27.613253|2018-06-01 01:10:27.613253
NCT00869765|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2010-09-09|2009-03-25|2009-03-26|Estimate|||||||2010-09-09|2010-09-10|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression|An Open Pilot Trial of Transcranial Direct Current Stimulation (tDCS) Augmented by D-Cycloserine as a Treatment for Depression.|Completed||Phase 2|5|Actual|The University of New South Wales||1|||f||||t||||||||||2018-06-01 01:10:29.223581|2018-06-01 01:10:29.223581
NCT00869752|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-03-06|2009-03-25|2009-03-26|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I-II Trial of MK-0646, a Monoclonal Antibody Against Insulin-Like Growth Factor-1 Receptor, in Combination With Etoposide and Cisplatin in Extensive Stage Small Cell Lung Cancer|Completed||Phase 1/Phase 2|12|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-06-01 01:10:29.302965|2018-06-01 01:10:29.302965
NCT00869739|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-02-21|2009-03-25|2009-03-26|Estimate|||||||2013-02-21|2013-02-25|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer|Prostate Cancer Recovery Enhancement for African American Men and Their Intimate Partners|Completed||N/A|112|Actual|East Carolina University|||||f||||||||||||||2018-06-01 01:10:29.38401|2018-06-01 01:10:29.38401
NCT00869726|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24||2010-05-27|2010-05-27|2009-03-24|2009-03-26|Estimate||||2010-05-27|2010-06-02|Estimate|2010-05-27|2010-06-02|Estimate|December 2004||2004-12-31|May 2010|2010-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|MAESTRO-01||A Study for Patients With Secondary Progressive Multiple Sclerosis|A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis|Completed||Phase 2/Phase 3|596|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 01:10:29.548252|2018-06-01 01:10:29.548252
NCT00869713|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2017-10-12|2009-03-25|2009-03-26|Estimate|||||||2017-10-12|2017-10-13|Actual|September 2009|Actual|2009-09-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|RVF||Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated|Long-Term Open-Label Primary Vaccination and Booster Dose Study of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) in At-Risk Adults|Enrolling by invitation||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 01:10:29.646787|2018-06-01 01:10:29.646787
NCT00869700|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2010-06-25|2009-03-25|2009-03-26|Estimate|||||||2010-06-25|2010-06-28|Estimate|June 2009||2009-06-30|June 2010|2010-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|SEACAT 2_4_2||Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults|Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults|Completed||Phase 4|18|Actual|University of Cape Town|||||f||||t||||||||||2018-06-01 01:10:29.73033|2018-06-01 01:10:29.73033
NCT00869687|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2012-06-22|2009-03-25|2009-03-26|Estimate|||||||2012-06-22|2012-06-25|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Biopsy Study for Sculptra (Poly-L-Lactic Acid)|A Single Group Study for the Characterization of Human Tissue Response to Injectable Poly-L-Lactic Acid (Sculptra) in Healthy Volunteers|Completed||Phase 2|14|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:10:29.794941|2018-06-01 01:10:29.794941
NCT00869674|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-05-29|2009-03-25|2009-03-26|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 2009||2009-02-28|June 2009|2009-06-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||GeneSearch™ Breast Lymph Node (BLN) Assay China Registration Study|一项比较GeneSearch 乳腺淋巴结（BLN）检测试剂盒和永久病理切片检测乳腺癌患者腋窝前哨淋巴结转移的前瞻性、多中心临床试验 A Prospective and Multi-center Clinical Trial By Comparing GeneSearch™ Breast Lymph Node (BLN) Test Kit To Permanent Pathological Section On Detecting Axillary Sentinel Lymph Node Metastases In Breast Cancer Patients|Terminated||Phase 3|540|Actual|Johnson & Johnson Medical, China||2||Investigational products has been suspended from the US market|f||||f||||||||||2018-06-01 01:10:29.858774|2018-06-01 01:10:29.858774
NCT00869167|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2011-06-28||2013-04-26|2009-03-24|2009-03-25|Estimate|2012-05-27|2012-06-29|Estimate||||2013-04-26|2013-05-01|Estimate|March 2008||2008-03-31|April 2013|2013-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Ramelteon for Insomnia Comorbid With Asthma|Ramelteon for Insomnia Comorbid With Asthma|Terminated||Phase 3|2|Actual|Northwestern University|Recruitment difficulties led to only 3 participants in the study. Only 2 participants finished the study.|2|||f||||f||||||||||2018-06-01 01:10:38.790838|2018-06-01 01:10:38.790838
NCT00869661|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25||2016-07-07|2016-11-01|2009-03-25|2009-03-26|Estimate||||2016-07-07|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|February 2001||2001-02-28|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4|A Randomized, Double-blind, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination With Pegasys® and Ribavirin® (SOC) Versus SOC in Treatment-Naïve Patients With HCV Genotype 1 or 4 Infection|Completed||Phase 2|413|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 01:10:29.957625|2018-06-01 01:10:29.957625
NCT00869648|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2017-03-21|2009-03-25|2009-03-26|Estimate|||||||2017-03-21|2017-03-23|Actual|April 2009||2009-04-30|March 2017|2017-03-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Head Positions to Open the Upper Airway|Head Positions to Open the Upper Airway- a Pilot Study|Completed||N/A|60|Actual|Medical University Innsbruck||3|||f||||f||||||||||2018-06-01 01:10:30.146314|2018-06-01 01:10:30.146314
NCT00869635|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-02-05|2009-03-25|2009-03-26|Estimate|||||||2014-02-05|2014-02-06|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||S-1 and Photodynamic Therapy in Cholangiocarcinoma|Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control|Completed||Phase 3|43|Actual|Asan Medical Center||3|||f||||t||||||||||2018-06-01 01:10:30.250878|2018-06-01 01:10:30.250878
NCT00869622|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2015-01-28||2015-07-23|2009-03-25|2009-03-26|Estimate|2015-07-23|2015-07-24|Estimate||||2015-07-23|2015-07-24|Estimate|June 2006||2006-06-30|July 2015|2015-07-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|ADOPT||Antiepileptic Drugs and Osteoporotic Prevention Trial|Antiepileptic Drugs and Osteoporotic Prevention Trial|Completed||Phase 4|80|Actual|Boston VA Research Institute, Inc.||2|||f||||t||||||||||2018-06-01 01:10:30.356509|2018-06-01 01:10:30.356509
NCT00869609|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2016-01-11||2016-05-19|2009-03-25|2009-03-26|Estimate|2016-01-11|2016-02-09|Estimate||||2016-05-19|2016-06-24|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Evaluation of Group Lifestyle Balance Maintenance Strategies|Evaluation of Group Lifestyle Balance Maintenance Strategies|Completed||N/A|60|Actual|University of Pittsburgh|The sample size was small and included primarily white individuals, so these results may not be generalizable to other groups. The CPC was not carbohydrate restricted and may not be directly comparable to studies that focus on carbohydrate reduction.|2|||f||||f||||||||No||2018-06-01 01:10:30.700542|2018-06-01 01:10:30.700542
NCT00869596|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2015-07-22|2009-03-25|2009-03-26|Estimate|||||||2015-07-22|2015-07-23|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Biomarkers of Airway Inflammation (0000-128)|A Randomized Clinical Trial to Assess the Effects of Inhaled Fluticasone on Sputum Neutrophils After Low-dose Inhaled Endotoxin Challenge in Healthy Subjects|Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:10:31.07415|2018-06-01 01:10:31.07415
NCT00869583|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-01-06|2009-03-25|2009-03-26|Estimate|||||||2014-01-06|2014-01-07|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Increasing Physical Activity Among Mexican American Women (The Enlace Study)|Enlace: A Partnership to Promote Physical Activity Among Mexican Immigrant Women|Completed||Phase 1/Phase 2|117|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-06-01 01:10:31.155031|2018-06-01 01:10:31.155031
NCT00869570|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2016-12-28|2009-03-25|2009-03-26|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2009||2009-03-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|May 2013|Actual|2013-05-31||Interventional|||External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer|Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.|Completed||Phase 1/Phase 2|54|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-06-01 01:10:31.253806|2018-06-01 01:10:31.253806
NCT00869557|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2012-09-20|2011-08-23|2014-05-22|2009-03-25|2009-03-26|Estimate|2012-09-20|2012-10-22|Estimate|2011-08-23|2011-08-25|Estimate|2014-05-22|2014-06-04|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|November 2009|Actual|2009-11-30||Interventional||Safety Analysis Set: participants were randomized and received at least 1 dose of study medication.|Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Atripla® (Efavirenz 600 mg/Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Completed||Phase 2|71|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 01:10:31.422235|2018-06-01 01:10:31.422235
NCT00869544|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2014-09-04|2009-03-25|2009-03-26|Estimate|||||||2014-09-04|2014-09-05|Estimate|August 2007||2007-08-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|September 2010|Actual|2010-09-30||Observational|PACT||Pneumocystis in Pathogenesis of HIV-associated Emphysema|Pneumocystis in Pathogenesis of HIV-associated Emphysema|Completed|||250|Actual|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     oral wash blood sputum BAL~   "|||2018-06-01 01:10:32.227776|2018-06-01 01:10:32.227776
NCT00869531|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-03-25|2009-03-25|2009-03-26|Estimate|||||||2009-03-25|2009-03-26|Estimate|August 2007||2007-08-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|HEALTHGRAIN||Effect of Wholegrain Wheat on Body Weight and Composition and Cardiovascular Risk|Healthgrain WP 4.4.3: Effects of Whole Grain on Weight Maintenance/Weight Reduction in Overweight Subjects|Completed||N/A|85|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 01:10:32.283951|2018-06-01 01:10:32.283951
NCT00869518|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2014-03-13||2014-04-23|2009-03-25|2009-03-26|Estimate|2014-03-13|2014-04-21|Estimate||||2014-04-23|2014-05-14|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults|Randomized, Double-Blinded Evaluation of Rifabutin Based Therapy for Eradication of Staphylococcus Aureus Carriage in HIV Infected Individuals With Prior Skin and Skin Structure Infections|Terminated||Phase 2|12|Actual|University of California, San Francisco||2||Poor enrollment|f||||f||||||||||2018-06-01 01:10:32.352413|2018-06-01 01:10:32.352413
NCT00869505|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2009-03-25|2009-03-25|2009-03-26|Estimate|||||||2009-03-25|2009-03-26|Estimate|March 2008||2008-03-31|March 2009|2009-03-31||||||||Observational|||Study of Memantine Augmentation in Severe Obsessive-Compulsive Disorder|A Chart Review of Memantine Use in the Treatment of Obsessive-Compulsive Disorder at the OCD Institute|Completed|||||Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 01:10:32.583163|2018-06-01 01:10:32.583163
NCT00869492|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-26|Estimate|||||||2009-03-24|2009-03-26|Estimate|August 2008||2008-08-31|March 2009|2009-03-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Comparison of Nadifloxacin Cream Alone and With Benzoyl Peroxide Solution in the Treatment of Acne|A Double Blind Randomised Comparison of Nadifloxacin 1% Cream Alone and Nadifloxacine %1 Cream With Benzoyl Peroxide 5% Solution in the Treatment of Mild to Moderate Facial Acne Vulgaris|Unknown status|Active, not recruiting|Phase 3|90|Anticipated|Marmara University||2|||f||||f||||||||||2018-06-01 01:10:32.758262|2018-06-01 01:10:32.758262
NCT00869479|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-12-14|2009-03-25|2009-03-26|Estimate|||||||2010-12-14|2010-12-15|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis|Validation of a Questionnaire as a Screening Tool to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis|Completed|||60|Anticipated|Massachusetts General Hospital|||4||f||||t||||||||||2018-06-01 01:10:32.850647|2018-06-01 01:10:32.850647
NCT00869466|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-04-02|2009-03-25|2009-03-26|Estimate|||||||2013-04-02|2013-04-04|Estimate|August 2008||2008-08-31|March 2009|2009-03-31|February 2011|Actual|2011-02-28|||||Observational|||Weight Control Programs in Women Who Have Undergone Surgery for Early Stage Breast Cancer|B- AHEAD Study (Breast - Activity & Healthy Eating After Diagnosis) Randomised Comparison of 3 Weight Control Programmes During Adjuvant Treatment for Early Breast Cancer.|Completed|||409|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:10:32.920931|2018-06-01 01:10:32.920931
NCT00869453|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2012-06-29|2009-03-25|2009-03-26|Estimate|||||||2012-06-29|2012-07-03|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Observational|||Gut Hormone Secretion and Macronutrients|Gut Hormone Secretion Pattern in Response to Different Macronutrients in Healthy Volunteers|Completed|||8|Actual|University of Lausanne|||1||f||||f||||||||||2018-06-01 01:10:33.003718|2018-06-01 01:10:33.003718
NCT00869440|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25||2010-09-08|2018-05-28|2009-03-25|2009-03-26|Estimate||||2010-09-08|2010-09-09|Estimate|2018-05-28|2018-05-30|Actual|March 2009||2009-03-31|May 2018|2018-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Dose-Finding Safety Study Evaluating CNS 7056 in Patients Undergoing Diagnostic Upper GI Endoscopy|A Phase IIa, Randomized, Controlled, Double-Blind, Dose-Finding Study Evaluating the Safety and Pharmacodynamics of CNS 7056 in Patients Undergoing Diagnostic Upper GI Endoscopy|Completed||Phase 2|102|Actual|Paion UK Ltd.||4|||f||||t||||||||||2018-06-01 01:10:33.120035|2018-06-01 01:10:33.120035
NCT00869427|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2010-07-02|2009-03-25|2009-03-26|Estimate|||||||2010-07-02|2010-07-05|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured|Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured|Terminated||Phase 4|40|Anticipated|Sunnaas Rehabilitation Hospital||2||Inability to recruit sufficient number of patients|f||||f||||||||||2018-06-01 01:10:33.211618|2018-06-01 01:10:33.211618
NCT00869414|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2017-04-13||2017-05-30|2009-03-25|2009-03-26|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|July 2009|Actual|2009-07-31|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||This study was prematurely terminated because the PI is deceased. The Baseline data for the specific arms is unknown since no data are available. Only the baseline data for the overall population is available and reported.|Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes|Comparison of Glycemic Response to Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes Using Continuous Glucose Monitoring|Terminated||N/A|16|Actual|Johns Hopkins University||3||PI deceased|f||||t||||||||||2018-06-01 01:10:33.29266|2018-06-01 01:10:33.29266
NCT00869401|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2016-12-12||2018-04-06|2009-03-25|2009-03-26|Estimate|2017-03-28|2017-05-08|Actual||||2018-04-06|2018-05-08|Actual|June 2009||2009-06-30|April 2018|2018-04-30||||October 2014|Actual|2014-10-31||Interventional||Per protocol, the 8 canceled patients are excluded from all analysis|Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)|Active, not recruiting||Phase 1/Phase 2|217|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 01:10:33.586993|2018-06-01 01:10:33.586993
NCT00869388|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|||2013-07-12|2009-03-25|2009-03-26|Estimate|||||||2013-07-12|2013-07-15|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors|A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors|Completed||Phase 1|12|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 01:10:35.220664|2018-06-01 01:10:35.220664
NCT00869375|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2014-04-04||2014-06-26|2009-03-25|2009-03-26|Estimate|2014-06-26|2014-07-21|Estimate||||2014-06-26|2014-07-21|Estimate|April 2009||2009-04-30|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia|Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia: A Randomized Controlled Trial|Terminated||N/A|6|Actual|University of Oklahoma|The main limitation of this trial was slow enrollment. This led to early termination leading to small numbers of subjects analyzed. This makes the results uninterpretable.|2||very low enrollment due to low access to study population|f||||t||||||||||2018-06-01 01:10:35.324637|2018-06-01 01:10:35.324637
NCT00869362|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2012-10-03||2014-10-27|2009-03-25|2009-03-26|Estimate|2012-10-03|2012-11-02|Estimate||||2014-10-27|2014-11-04|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Inpatient Diabetes Management on Outpatient Glycemic Control|Effect of Inpatient Diabetes Management on Outpatient Glycemic Control|Completed||N/A|31|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 01:10:35.571842|2018-06-01 01:10:35.571842
NCT00869349|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2014-01-23||2017-01-31|2009-03-25|2009-03-26|Estimate|2017-01-31|2017-03-20|Actual||||2017-01-31|2017-03-20|Actual|September 2008||2008-09-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2010|Actual|2010-12-31||Interventional|||Living Well With Rheumatoid Arthritis|Brigham Rheumatoid Arthritis Sequential Study B.R.A.S.S.|Completed||N/A|79|Actual|Brigham and Women's Hospital|Participants declined participation due to long time frame. The attention given to the control group was less intense than the intervention group. There was greater attrition in the intervention group.|2|||f||||f||||||||||2018-06-01 01:10:35.811249|2018-06-01 01:10:35.811249
NCT00869154|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2017-08-11|2009-03-24|2009-03-25|Estimate|||||||2017-08-11|2017-08-14|Actual|March 1, 2009|Actual|2009-03-01|August 2017|2017-08-31|March 31, 2015|Actual|2015-03-31|March 31, 2013|Actual|2013-03-31||Interventional|||Multidisciplinary Treatment in Patients With Mild Traumatic Brain Injury|Effect of Multidisciplinary Treatment in Patients With Mild Traumatic Brain Injury - a Randomized Controlled Trial|Completed||N/A|151|Actual|Haukeland University Hospital||2|||f||||t||||||||||2018-06-01 01:10:39.030782|2018-06-01 01:10:39.030782
NCT00869336|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25||2011-06-06|2011-06-06|2009-03-25|2009-03-26|Estimate||||2011-06-06|2011-06-21|Estimate|2011-06-06|2011-06-21|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)|Phase 2 Study - A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Duration Finding Study Evaluating the Efficacy and Safety of Two Week and Four Week Once Daily Treatment of Luliconazole Cream 1% in Patients With Tinea Pedis|Completed||Phase 2|147|Actual|Tinea Pharmaceuticals||4|||f||||f||||||||||2018-06-01 01:10:36.11775|2018-06-01 01:10:36.11775
NCT00869323|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-25|2017-02-20||2017-12-03|2009-03-25|2009-03-26|Estimate|2017-02-20|2017-04-05|Actual||||2017-12-03|2017-12-05|Actual|March 2009||2009-03-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|March 2013|Actual|2013-03-31||Interventional|||Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders|Phase II Trial of Bortezomib and Rituximab for Patients With Post Transplant Lymphoproliferative Disorders (PTLD)|Terminated||Phase 2|3|Actual|Masonic Cancer Center, University of Minnesota||1||Funding unavailable|f||||t||||||||||2018-06-01 01:10:36.189546|2018-06-01 01:10:36.189546
NCT00869310|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2014-01-03|2009-03-24|2009-03-25|Estimate|||||||2014-01-03|2014-01-06|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis|Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis: a Double-blind Randomized Trial|Terminated||Phase 3|303|Actual|S. Maria Hospital, Terni||2||we terminated the study before enrolling 303/560 due to a slow accrual|f||||f||||||||||2018-06-01 01:10:36.512798|2018-06-01 01:10:36.512798
NCT00869297|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2011-04-18|2009-03-24|2009-03-25|Estimate|||||||2011-04-18|2011-04-19|Estimate|March 2009||2009-03-31|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Goal Directed Fluid Therapy in Free Flap Patients|Goal Directed Fluid Therapy for Microvascular Free Flap Reconstruction Following Mastectomy: A Pilot Study|Completed||N/A|20|Actual|University of Manitoba||2|||f||||f||||||||||2018-06-01 01:10:36.60073|2018-06-01 01:10:36.60073
NCT00869284|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 1994||1994-10-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|July 1999|Actual|1999-07-31||Interventional|073||Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas|Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas|Completed||Phase 2|45|Actual|French Innovative Leukemia Organisation|||||f||||t||||||||||2018-06-01 01:10:36.675931|2018-06-01 01:10:36.675931
NCT00869271|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer|Postoperative folfox4 Only vs folfox4 Plus TAC in the Treatment Unresectable Liver Metastasis of Colorectal Cancer: a Randomized,Prospective,Control Trial|Completed||Phase 4|200|Actual|Fudan University||2|||f||||f||||||||||2018-06-01 01:10:36.733512|2018-06-01 01:10:36.733512
NCT00869258|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2016-04-19||2016-05-16|2009-03-24|2009-03-25|Estimate|2016-05-16|2016-06-22|Estimate||||2016-05-16|2016-06-22|Estimate|June 2005||2005-06-30|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar|Phase II Study for Inoperable Non-Metastatic Pancreatic Cancer (Stage IVA) With Neoadjuvant Gemzar, Taxotere and Xeloda (GTX), and Radiation With Gemzar|Completed||Phase 2|32|Actual|Columbia University||1|||f||||t||||||||Undecided|Unknown.|2018-06-01 01:10:36.869935|2018-06-01 01:10:36.869935
NCT00869245|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2017-11-06|2009-03-24|2009-03-25|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2009||2009-03-31|April 2017|2017-04-30|October 2011|Actual|2011-10-31|September 2010|Actual|2010-09-30||Interventional|||Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain|Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain|Completed||N/A|124|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 01:10:37.066607|2018-06-01 01:10:37.066607
NCT00869232|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2017-10-11|2009-03-24|2009-03-25|Estimate|||||||2017-10-11|2017-10-13|Actual|October 2008||2008-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission|UARK 2008-02, A Phase II Trial for High-risk Myeloma Evaluation Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-host-exhausting and Timely Dose-reduced MEL-80-VRD-PACE Tandem Transplants|Active, not recruiting||Phase 2|90|Actual|University of Arkansas||1|||f||||f|t|f||||||||2018-06-01 01:10:37.161691|2018-06-01 01:10:37.161691
NCT00869219|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-25|2009-03-24|2009-03-25|Estimate|||||||2009-03-25|2009-03-26|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Comparison of Pain Sensation During Single Use of Two Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)|Phase 4 Study of Topical NSAID for Ophthalmologic Use: Pain Measurement After First Drop.|Unknown status|Recruiting|Phase 4|40|Anticipated|Santa Casa de Misericordia de Santos||2|||f||||f||||||||||2018-06-01 01:10:37.296059|2018-06-01 01:10:37.296059
NCT00869206|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2016-10-04|2009-03-24|2009-03-25|Estimate|||||||2016-10-04|2016-10-05|Estimate|March 2009||2009-03-31|October 2016|2016-10-31||||June 2014|Actual|2014-06-30||Interventional|||Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement|A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer|Active, not recruiting||Phase 3|1758|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 01:10:37.442506|2018-06-01 01:10:37.442506
NCT00869193|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-08-27|2009-03-24|2009-03-25|Estimate|||||||2009-08-27|2009-08-28|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Grape Seed Extract on Blood Pressure|Effect of Grape Seed Extract High in Polyphenols on Blood Pressure in Subjects With Elevated Blood Pressure Levels|Completed||N/A|70|Actual|Unilever R&D||2|||f||||f||||||||||2018-06-01 01:10:38.48602|2018-06-01 01:10:38.48602
NCT00869180|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-01-26|2009-03-24|2009-03-25|Estimate|||||||2010-01-26|2010-01-28|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|SUPPORT 2||Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain|Completed||Phase 3|219|Actual|Cerimon Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:10:38.679809|2018-06-01 01:10:38.679809
NCT00869141|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2015-06-01||2015-11-30|2009-03-24|2009-03-25|Estimate|2015-06-01|2015-06-17|Estimate||||2015-11-30|2015-12-30|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma|Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma|Completed||Phase 4|52|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:10:39.114709|2018-06-01 01:10:39.114709
NCT00869128|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2008-12-08||2009-03-30|2009-03-24|2009-03-25|Estimate|2009-03-24|2009-03-25|Estimate||||2009-03-30|2009-05-01|Estimate|November 1995||1995-11-30|March 2009|2009-03-31|March 1997|Actual|1997-03-31|March 1997|Actual|1997-03-31||Interventional|||A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia|A Randomized Double-Blind, Crossover Study Comparing the Efficacy of Prolonged-Release Melatonin Versus Placebo in a 3 Week Treatment of Diabetic Patients Suffering From Insomnia|Completed||Phase 2|36|Actual|Neurim Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 01:10:39.393509|2018-06-01 01:10:39.393509
NCT00869115|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2014-10-21|2009-03-24|2009-03-25|Estimate|||||||2014-10-21|2014-10-23|Estimate|June 2009||2009-06-30|October 2014|2014-10-31||||||||Interventional|||Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure|A Randomized, Double-blind, Placebo-controlled Escalating Dose Phase I Interaction Study to Evaluate the Pharmacokinetics, Tolerability and Pharmacodynamics of Three Dose Levels of Debio 0614 (Istaroxime) as a 24-hour Constant Rate IV Infusion in Combination With Chronic Oral Digoxin Treatment in Patients With Controlled Cardiac Failure and Decreased Left Ventricular Systolic Function|Withdrawn||Phase 1|0|Actual|Debiopharm International SA||4||The study was not started due to a re-evaluation of the istaroxime development program|f||||t||||||||||2018-06-01 01:10:39.611648|2018-06-01 01:10:39.611648
NCT00869102|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2014-07-30|2009-03-23|2009-03-25|Estimate|||||||2014-07-30|2014-07-31|Estimate|May 2009||2009-05-31|March 2009|2009-03-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Characterization of Beta Cell Failure||Withdrawn||N/A|0|Actual|University Hospital Tuebingen||1|||f||||||||||||||2018-06-01 01:10:39.708461|2018-06-01 01:10:39.708461
NCT00869089|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2014-05-20||2016-09-27|2009-03-23|2009-03-25|Estimate|2014-05-20|2014-06-20|Estimate||||2016-09-27|2016-11-02|Estimate|September 2008||2008-09-30|September 2016|2016-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||Number of subjects enrolled in the study.|Safety and Efficacy of CC-10004 for Prurigo Nodularis|An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis|Completed||Phase 2|5|Actual|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-06-01 01:10:39.802255|2018-06-01 01:10:39.802255
NCT00869076|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|May 2006||2006-05-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pharmacists Management of Diabetes|Pharmacist Management of Diabetes Mellitus: A Randomized Controlled Trial.|Completed||Phase 4|102|Actual|Advantage Health Physician Network||2|||f||||f||||||||||2018-06-01 01:10:40.057834|2018-06-01 01:10:40.057834
NCT00869063|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-01-26|2009-03-24|2009-03-25|Estimate|||||||2010-01-26|2010-01-28|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|WIND||Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion|Completed||Phase 3|214|Actual|Cerimon Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:10:40.14396|2018-06-01 01:10:40.14396
NCT00869050|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2016-05-03||2016-06-22|2009-03-24|2009-03-25|Estimate|2016-05-16|2016-06-22|Estimate||||2016-06-22|2016-07-25|Estimate|August 2005||2005-08-31|June 2016|2016-06-30|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|||Capecitabine and Temozolomide for Neuroendocrine Cancers|Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers|Completed||Phase 2|41|Actual|Columbia University||1|||f||||t||||||||No||2018-06-01 01:10:40.232155|2018-06-01 01:10:40.232155
NCT00869037|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2011-03-23|2009-03-24|2009-03-25|Estimate|||||||2011-03-23|2011-03-24|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|February 2012|Anticipated|2012-02-29|July 2011|Anticipated|2011-07-31||Interventional|||Analgesia After Total Knee Arthroplasty|Analgesia After Total Knee Arthroplasty: Randomized Controlled Trial Comparing (a) Periarticular Multimodal Technique With (B) Continuous Femoral Nerve Block + Posterior Capsular Injection|Unknown status|Recruiting|Phase 4|90|Anticipated|University of Manitoba||2|||f||||||||||||||2018-06-01 01:10:40.477871|2018-06-01 01:10:40.477871
NCT00869024|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2017-02-07|2009-03-24|2009-03-25|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 10, 2011|Actual|2011-11-10|February 2017|2017-02-28|March 29, 2016|Actual|2016-03-29|March 29, 2016|Actual|2016-03-29||Interventional|ASSURANCE||Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement|AsseSsment of Efficacy, Safety and Utility of intRa myocardiAl iNjection of Stem Cells in Patients With End Stage Heart Failure Undergoing LVAD Implantation (ASSURANCE)|Completed||Phase 1/Phase 2|25|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 01:10:40.559677|2018-06-01 01:10:40.559677
NCT00869011|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-12-21|2009-03-24|2009-03-25|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2009||2009-12-31|December 2009|2009-12-31||||June 2011|Anticipated|2011-06-30||Interventional|||Exercise for Patients With Renal Cell Cancer Receiving Sunitinib|Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib)|Unknown status|Recruiting|Phase 3|70|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:10:40.628128|2018-06-01 01:10:40.628128
NCT00868998|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2016-04-21||2016-05-16|2009-03-23|2009-03-25|Estimate|2016-05-16|2016-05-23|Estimate||||2016-05-16|2016-05-23|Estimate|August 2005||2005-08-31|May 2016|2016-05-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||GTX Regimen for Biliary Cancers|Phase II Study of the Gemzar, Taxotere and Xeloda Regimen (GTX) for Inoperable or Metastatic Adenocarcinoma of the Biliary System|Terminated||Phase 2|4|Actual|Columbia University||1||Poor patient accrual|f||||t||||||||Undecided||2018-06-01 01:10:40.714056|2018-06-01 01:10:40.714056
NCT00868985|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2008||2008-01-31|March 2009|2009-03-31||||August 2008|Actual|2008-08-31||Interventional|||Effects of Oral PEG 3350 on Electrolyte Balance|Effects of Oral PEG 3350 on the Electrolyte Balance in Patient Volunteers With Chronic Constipation:Pharmacokinetic Evaluation|Completed||Phase 1|114|Actual|Norgine||2|||f||||f||||||||||2018-06-01 01:10:40.908632|2018-06-01 01:10:40.908632
NCT00868972|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-01-22|2009-03-24|2009-03-25|Estimate|||||||2010-01-22|2010-01-25|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|||Renal Stenting With Distal Atheroembolic Protection|Percutaneous Renal Stenting in Renovascular Disease With or Without Distal Atheroembolic Protection|Unknown status|Recruiting|Phase 2/Phase 3|150|Anticipated|Universita di Verona||2|||f||||f||||||||||2018-06-01 01:10:40.965153|2018-06-01 01:10:40.965153
NCT00868959|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2014-02-17||2016-03-15|2009-03-24|2009-03-25|Estimate|2014-02-17|2014-04-01|Estimate||||2016-03-15|2016-04-14|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Safety population - received at least one dose of study medication|Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression|A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression|Completed||Phase 3|817|Actual|Sunovion||1|||f||||t||||||||||2018-06-01 01:10:41.212055|2018-06-01 01:10:41.212055
NCT00868946|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2016-10-11|2009-03-24|2009-03-25|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|HFRS||Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany|A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in Landstuhl Regional Medical Center (Landstuhl, Germany) IND 16,666|Withdrawn||Phase 2|0|Actual|U.S. Army Medical Research and Materiel Command||1||Lack of enrollment|f||||f||||||||||2018-06-01 01:10:41.811825|2018-06-01 01:10:41.811825
NCT00868933|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2014-02-20|2009-03-24|2009-03-25|Estimate|||||||2014-02-20|2014-02-24|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease|Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial|Completed||N/A|159|Actual|Chinese University of Hong Kong||2|||f||||||||||||||2018-06-01 01:10:41.901561|2018-06-01 01:10:41.901561
NCT00868920|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2017-11-28|2009-03-24|2009-03-25|Estimate|||||||2017-11-28|2017-11-30|Actual|January 2008||2008-01-31|November 2017|2017-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Patient-Controlled Sedation Versus Anesthesiologist-Administered Sedation|A Phase IV, Randomized, Double-Blind, Controlled Study of the Effects of Patient-Controlled Sedation vs. Anesthesiologist-Administered Sedation With Propofol and Remifentanil on Rate of Disordered Breathing in Subjects Undergoing Elective Colonoscopy|Completed||N/A|50|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 01:10:41.971972|2018-06-01 01:10:41.971972
NCT00868907|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-10-07|2009-03-24|2009-03-25|Estimate|||||||2011-10-07|2011-10-12|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food|A Crossover Study to Assess the Relative BA of Delayed-release Risedronate Compared When Dosed With Either Dinner, Breakfast or Breakfast Plus a Calcium/Vitamin D Tablet|Completed||Phase 1|101|Actual|Warner Chilcott||3|||f||||f||||||||||2018-06-01 01:10:42.060429|2018-06-01 01:10:42.060429
NCT00868894|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-11-01|2009-03-23|2009-03-25|Estimate|||||||2011-11-01|2011-11-03|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension|A Randomized, Double-masked, Placebo- and Active-controlled, Multi-Center, Dose Escalation Trial of DE-104 Ophthalmic Solution in Japanese and Non-Japanese Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 1/Phase 2|49|Actual|Santen Inc.||4|||f||||||||||||||2018-06-01 01:10:42.142312|2018-06-01 01:10:42.142312
NCT00868881|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-07-10|2009-03-24|2009-03-25|Estimate|||||||2009-07-10|2009-07-13|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|||||Observational|TAPAS||Treatment of Hypertension in Primary Care in Spain|Treatment of Hypertension in Primary Care in Spain|Completed|||2160|Anticipated|AstraZeneca|||6||f||||f||||||||||2018-06-01 01:10:42.258301|2018-06-01 01:10:42.258301
NCT00868868|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||Pedometer and Exercise Study in Prostate Cancer Patients With Hormonal Therapy|Pedometer and Exercise Study: A Randomized Trial Evaluating the Use of a Pedometer and Brief Exercise Coaching in Prostate Cancer Patients Treated With Androgen Deprivation Therapy.|Unknown status|Recruiting||400|Anticipated|Groupe de recherche en Urologie de la Mauricie|||||f||||f||||||||||2018-06-01 01:10:42.503917|2018-06-01 01:10:42.503917
NCT00868855|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2017-12-11|2009-03-24|2009-03-25|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2003||2003-12-31|December 2017|2017-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease|The Intracoronary Tissue-type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events in Patients With Non-critical Coronary Artery Disease|Terminated||Phase 1|16|Actual|Vanderbilt University Medical Center||1||poor enrollment|f||||t||||||||||2018-06-01 01:10:42.576792|2018-06-01 01:10:42.576792
NCT00868842|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2014-04-10|2009-03-24|2009-03-25|Estimate|||||||2014-04-10|2014-04-14|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis|Open-label, Single-center Study of Whether Oral Penicillin Desensitization of Healthy Sensitive Subjects Results in Allergen Cross-desensitization of Mast Cells by Skin Testing and Desensitization of Peripheral Blood Basophils.|Completed|||10|Actual|Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 01:10:42.650696|2018-06-01 01:10:42.650696
NCT00868829|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-08-09|2009-03-24|2009-03-25|Estimate|||||||2011-08-09|2011-08-10|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|FOCUS||Firebird2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent Registry Trial|Firebird2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent Registry Trial|Unknown status|Recruiting|N/A|5000|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.||1|||f||||t||||||||||2018-06-01 01:10:42.71552|2018-06-01 01:10:42.71552
NCT00868816|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles|A Prospective, Randomized, Control Trial of Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles vs 12 Cycles|Completed||Phase 4|400|Actual|Fudan University||2|||f||||t||||||||||2018-06-01 01:10:42.840337|2018-06-01 01:10:42.840337
NCT00868647|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-08-28|2009-03-24|2009-03-25|Estimate|||||||2009-08-28|2009-09-01|Estimate|June 2007||2007-06-30|August 2009|2009-08-31||||June 2012|Anticipated|2012-06-30||Interventional|||Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood|Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood: A Phase II Study|Suspended||Phase 2|60|Anticipated|Seattle Children's Hospital||1|||f||||t||||||||||2018-06-01 01:10:45.788407|2018-06-01 01:10:45.788407
NCT00865943|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|July 2003||2003-07-31|August 2010|2010-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions|A Relative Bioavailability of 10 mg Citalopram Hydrobromide Tablets Under Fasting Conditions|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:27.903695|2018-06-01 01:11:27.903695
NCT00868803|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2018-01-10|2009-03-24|2009-03-25|Estimate|||||||2018-01-10|2018-01-11|Actual|April 1995||1995-04-30|January 2018|2018-01-31|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30||Observational|||Aberrant Gene Expression Prostate Carcinoma|Identification of Aberant Gene Expression in Human Prostatic Carcinoma|Active, not recruiting|||5000|Anticipated|Lahey Clinic|||||f||||f||||||Samples With DNA|"~     Surplus tissue following pathologic review requirements will be snap frozen and processed for~     extraction of RNA. mRNA will be reversed transcribed to make cDNA with the prime~     5'TCCTTAGAAC, followed by 40 cycles of palindromic PCR using the sam eprimer. Amplified cDNA~     (35 S-labled) will be analysed on a 4% polyacrylamide gel. Comparative analysis of cDNA~     amplified products will serve to identify aberrantly expressed candidate genes. Such products~     will be isolated, sequenced and evaluated as to their role in establishing the neoplastic~     pheotype and the potential utility as a marker of prostatic neoplastic progression.~   "|||2018-06-01 01:10:42.907243|2018-06-01 01:10:42.907243
NCT00868790|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2016-11-14||2017-06-05|2009-03-24|2009-03-25|Estimate|2016-11-14|2017-01-11|Estimate||||2017-06-05|2017-07-02|Actual|March 24, 2009|Actual|2009-03-24|June 2017|2017-06-30|July 13, 2010|Actual|2010-07-13|July 12, 2010|Actual|2010-07-12||Interventional|||A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)|A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Terminated||Phase 2|118|Actual|Merck Sharp & Dohme Corp.|A pre-specified interim analysis of the efficacy and safety data for the initial cohort of participants in this study (Cohort 1) determined that sufficient data had been accrued to assess the study hypotheses, thus the study was discontinued.|14||Upon interim analysis, sufficient data was accrued to assess study hypotheses.|f||||t||||||||||2018-06-01 01:10:43.003372|2018-06-01 01:10:43.003372
NCT00868777|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-09-24|2009-03-24|2009-03-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures|The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures|Completed||Phase 4|25|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 01:10:43.821921|2018-06-01 01:10:43.821921
NCT00868764|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-10-05|2009-03-24|2009-03-25|Estimate|||||||2009-10-05|2009-10-07|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron|An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron|Completed||Phase 1|60|Anticipated|Prostrakan Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:10:43.908288|2018-06-01 01:10:43.908288
NCT00868751|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2017-02-01||2017-05-09|2009-03-24|2009-03-25|Estimate|2017-05-09|2017-05-15|Actual||||2017-05-09|2017-05-15|Actual|March 2009||2009-03-31|May 2017|2017-05-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis|Single Patient Use of Tocilizumab for Treatment of Steroid Dependent, Active Systemic Onset Juvenile Idiopathic Arthritis|Terminated||N/A|1|Actual|Tufts Medical Center||1||Hyperintensities of unclear etiology on brain MRI. Follow up revealed no progression.|f||||f||||||||||2018-06-01 01:10:44.07942|2018-06-01 01:10:44.07942
NCT00868738|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2011-11-01|2009-03-24|2009-03-25|Estimate|||||||2011-11-01|2011-11-02|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Children|Evaluation of Calcium, Vitamin D, Magnesium, and Zinc Absorption in Healthy Children 4 to 8 Years of Age|Completed||N/A|60|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 01:10:44.293434|2018-06-01 01:10:44.293434
NCT00868725|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-09-30|2009-03-24|2009-03-25|Estimate|||||||2009-09-30|2009-10-01|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Detecting Lesions in the Oral Cavity With Thermal Imaging|Detecting Lesions in the Oral Cavity With Thermal Imaging|Completed|||50|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 01:10:44.409687|2018-06-01 01:10:44.409687
NCT00868712|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2010-02-02||2012-08-23|2009-03-24|2009-03-25|Estimate|2012-08-23|2012-08-24|Estimate||||2012-08-23|2012-08-24|Estimate|May 2004||2004-05-31|August 2012|2012-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|WACC||Warfarin and Coronary Calcification Project|Warfarin and Coronary Calcification Project|Completed|||70|Actual|Walter Reed Army Medical Center|Cross-sectional nature, small sample size. Initially powered for sample size of 100 subjects, our trial was stopped early after an interim analysis at 70 subjects demonstrated no trend for effect of warfarin after adjusting for standard risk factors.||3||f||||t||||||||||2018-06-01 01:10:44.493468|2018-06-01 01:10:44.493468
NCT00868699|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2013-02-14||2014-03-31|2009-03-24|2009-03-25|Estimate|2013-05-28|2013-07-02|Estimate||||2014-03-31|2014-04-17|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Intent-to-treat population is analyzed.|Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)|A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression|Completed||Phase 3|505|Actual|Sunovion||3|||f||||t||||||||||2018-06-01 01:10:44.876675|2018-06-01 01:10:44.876675
NCT00868686|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 2005||2005-10-31|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Clinical Trial Comparing Volar, Dorsal, and Custom Thermoplastic Splinting in the Treatment of Acute Mallet Finger|Blinded, Prospective, Randomized Clinical Trial Comparing Volar, Dorsal, and Custom Thermoplastic Splinting in the Treatment of Acute Mallet Finger|Completed||Phase 3|77|Actual|St. Paul's Hospital, Canada||3|||f||||||||||||||2018-06-01 01:10:45.457453|2018-06-01 01:10:45.457453
NCT00868673|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-07-08|2009-03-24|2009-03-25|Estimate|||||||2010-07-08|2010-07-09|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|||The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome|The Role Of Fructose and Uric Acid In the Development of Obesity and Metabolic Syndrome|Completed||N/A|120|Actual|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||f||||||||||2018-06-01 01:10:45.532707|2018-06-01 01:10:45.532707
NCT00868660|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2010-11-01|2009-03-24|2009-03-25|Estimate|||||||2010-11-01|2010-11-02|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose|A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission|Completed||Phase 1|66|Actual|Zealand Pharma||2|||f||||t||||||||||2018-06-01 01:10:45.600029|2018-06-01 01:10:45.600029
NCT00868634|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2016-08-29|2009-03-24|2009-03-25|Estimate|||||||2016-08-29|2016-08-31|Estimate|February 2009||2009-02-28|August 2016|2016-08-31|October 2015|Actual|2015-10-31|March 2014|Actual|2014-03-31||Interventional|CARIN||Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer|Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients|Completed||Phase 3|600|Actual|iOMEDICO AG||2|||f||||f||||||||No||2018-06-01 01:10:45.861554|2018-06-01 01:10:45.861554
NCT00868621|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-23|2009-03-23|2009-03-25|Estimate|||||||2009-03-23|2009-03-25|Estimate|March 2007||2007-03-31|March 2009|2009-03-31|June 2009|Anticipated|2009-06-30|September 2008|Actual|2008-09-30||Observational|||Urinary Cytokines in Patients With Overactive Bladder (OAB)|Identification of Urinary Cytokines in Patients With Overactive Bladder (OAB)|Unknown status|Active, not recruiting||56|Actual|Cleveland Clinic Florida|||3||f||||t||||||||||2018-06-01 01:10:45.937987|2018-06-01 01:10:45.937987
NCT00868608|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2017-07-24|2013-04-18|2017-10-27|2009-03-24|2009-03-25|Estimate|2017-10-27|2017-10-31|Actual|2013-04-18|2013-04-26|Estimate|2017-10-27|2017-10-31|Actual|July 30, 2009|Actual|2009-07-30|October 2017|2017-10-31|June 27, 2013|Actual|2013-06-27|January 10, 2012|Actual|2012-01-10||Interventional|||Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma|A Phase 2 Study Of Inotuzumab Ozogamicin (Cmc-544) In Subjects With Indolent Non-hodgkin's Lymphoma (Nhl) That Is Refractory To Or Has Relapsed After Rituximab And Chemotherapy Or Radioimmunotherapy|Completed||Phase 2|81|Actual|Pfizer|The sample size for this study was determined by clinical rather than statistical considerations.|1|||f||||f||||||||||2018-06-01 01:10:46.073596|2018-06-01 01:10:46.073596
NCT00868595|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2017-12-05|2009-03-24|2009-03-25|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2009||2009-04-30|March 2016|2016-03-31|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Interventional|||MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer|A Phase I, Non-randomized, Multiple Dose, Dose Escalation Study of the Safety, PK, PD and Efficacy of Therapeutic Vaccine, BP-GMAX-CD1, Plus Activating Agent, AP1903, in Patients With Castrate Resistant Prostate Cancer|Completed||Phase 1|18|Actual|Bellicum Pharmaceuticals||1|||f||||t||||||||Undecided||2018-06-01 01:10:46.738219|2018-06-01 01:10:46.738219
NCT00868582|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2016-01-15|2009-03-24|2009-03-25|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2006||2006-05-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Observational|NOPR||The National Oncologic PET Registry|The National Oncologic PET Registry|Unknown status|Recruiting||333000|Anticipated|American College of Radiology Imaging Network|||2||f||||f||||||||||2018-06-01 01:10:46.831262|2018-06-01 01:10:46.831262
NCT00868569|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer|TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 01:10:47.866796|2018-06-01 01:10:47.866796
NCT00868556|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-01-04|2009-03-24|2009-03-25|Estimate|||||||2010-01-04|2010-01-05|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?|fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?|Completed|||33|Actual|The Cleveland Clinic|||3||f||||f||||||||||2018-06-01 01:10:47.964178|2018-06-01 01:10:47.964178
NCT00868543|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-03-24|2009-03-24|2009-03-25|Estimate|||||||2009-03-24|2009-03-25|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|December 2015|Anticipated|2015-12-31|July 2013|Anticipated|2013-07-31||Interventional|||Long or Very Long-Limb Gastric Bypass in Superobese|Long or Very Long-Limb Gastric Bypass in Superobese|Unknown status|Recruiting|Phase 3|150|Anticipated|Kaunas University of Medicine||2|||f||||f||||||||||2018-06-01 01:10:48.046382|2018-06-01 01:10:48.046382
NCT00868530|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2010-12-03||2017-03-07|2009-03-23|2009-03-25|Estimate|2011-01-13|2011-02-08|Estimate||||2017-03-07|2017-04-05|Actual|September 2008||2008-09-30|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects|An Evaluation Of The Safety And Efficacy Of On-Demand Treatment With Xyntha (B Domain Deleted Recombinant Factor VIII, Albumin Free) In Chinese Subjects With Hemophilia A|Completed||Phase 3|53|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:10:48.139132|2018-06-01 01:10:48.139132
NCT00868517|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2014-09-22||2015-04-06|2009-03-23|2009-03-25|Estimate|2014-11-06|2014-11-17|Estimate||||2015-04-06|2015-04-28|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional||OEF/OIF Veterans with PTSD-related insomnia.|Examining the Effect of Acupuncture on Sleep Difficulties Related to Post Traumatic Stress Disorder|The Effect of Acupuncture on PTSD-Related Insomnia|Completed||N/A|35|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 01:10:48.436972|2018-06-01 01:10:48.436972
NCT00868504|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-09-29|2009-03-24|2009-03-25|Estimate|||||||2009-09-29|2009-09-30|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Observational|||Measuring Temperatures of Tissues During Endoscopy|Measuring Temperatures of Tumors and Normal Tissues in the GI Tract, Using a Thermocouple Sheathed in a Catheter, in the Work Canal of an Endoscope|Unknown status|Recruiting||50|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 01:10:49.02811|2018-06-01 01:10:49.02811
NCT00868491|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2011-10-23|2009-03-24|2009-03-25|Estimate|||||||2011-10-23|2011-10-25|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|December 2009|Actual|2009-12-31||Interventional|||Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer|Induction Chemotherapy Followed by Chemoradiation With Cetuximab and Cisplatin for Inoperable Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|30|Anticipated|Institute of Oncology Ljubljana|||||f||||t||||||||||2018-06-01 01:10:49.113437|2018-06-01 01:10:49.113437
NCT00868478|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-06-01|2009-03-24|2009-03-25|Estimate|||||||2010-06-01|2010-06-02|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|April 2012|Anticipated|2012-04-30|April 2011|Anticipated|2011-04-30||Interventional|||The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)|Phase I-II Trial of the Anti CD74 Monoclonal Antibody-Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Kaplan Medical Center|||||f||||f||||||||||2018-06-01 01:10:49.195311|2018-06-01 01:10:49.195311
NCT00868465|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2010-06-04|2009-03-24|2009-03-25|Estimate|||||||2010-06-04|2010-06-07|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TRANSACT||Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)||Completed||N/A|600|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 01:10:49.301769|2018-06-01 01:10:49.301769
NCT00868452|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2013-01-11||2014-03-31|2009-03-24|2009-03-25|Estimate|2013-02-22|2013-04-02|Estimate||||2014-03-31|2014-04-17|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional||Data for full analysis set is provided (intent-to-treat population)|Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)|A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression|Completed||Phase 3|348|Actual|Sunovion||2|||f||||t||||||||||2018-06-01 01:10:49.405339|2018-06-01 01:10:49.405339
NCT00868439|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2015-11-11|2014-11-03|2016-01-25|2009-03-24|2009-03-25|Estimate|2015-11-11|2015-12-15|Estimate|2014-11-03|2014-11-10|Estimate|2016-01-25|2016-02-25|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|PEARL-HF|One participant received one dose of patiromer and did not return to the clinic in a timely manner; the participant was terminated from the study for protocol noncompliance, and because the participant did not have post-treatment efficacy data, the participant was excluded from the Full Analysis Set but retained in the Safety Analysis Set.|Evaluation of Patiromer in Heart Failure Patients|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of Patiromer in Heart Failure Patients|Completed||Phase 2|120|Actual|Relypsa, Inc.||2|||f||||f||||||||||2018-06-01 01:10:49.970815|2018-06-01 01:10:49.970815
NCT00868426|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-08-12|2009-03-24|2009-03-25|Estimate|||||||2009-08-12|2009-08-13|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler|Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhaler, Symbicort Turbuhaler; an Open, Single Center, Single Dose Study With 3-way Crossover Design in Healthy Subjects|Completed||Phase 1|12|Actual|Orion Corporation, Orion Pharma||3|||f||||f||||||||||2018-06-01 01:10:50.35338|2018-06-01 01:10:50.35338
NCT00868413|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2013-06-05|2009-03-23|2009-03-25|Estimate|||||||2013-06-05|2013-06-07|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 1|32|Actual|AbbVie||2|||f||||||||||||||2018-06-01 01:10:50.476152|2018-06-01 01:10:50.476152
NCT00868400|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2015-03-09|2009-03-24|2009-03-25|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2009||2009-05-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Clinical Value of Preoperative Oral Carbohydrate Loading in Colorectal Surgery|Multi-centre Double-blind Randomized Trial of the Clinical Value of Preoperative Oral Carbohydrate Loading in Colorectal Surgery.|Completed||N/A|215|Actual|Gulhane School of Medicine||3|||f||||f||||||||||2018-06-01 01:10:50.56249|2018-06-01 01:10:50.56249
NCT00868387|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2017-03-21|2009-03-24|2009-03-25|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2005||2005-11-30|December 2013|2013-12-31|December 2007|Actual|2007-12-31|November 2006|Actual|2006-11-30||Interventional|||Macronutrient Relations and Weight Loss in Obese Subjects|Effects of Macronutrient Relations on Body Weight, Body Composition, and Cardiovascular Risk Markers in Overweight Patients Attending a Telemedically Guided Weight Loss Program|Completed||N/A|200|Actual|Heart and Diabetes Center North-Rhine Westfalia||2|||f||||f||||||||No||2018-06-01 01:10:50.692108|2018-06-01 01:10:50.692108
NCT00868374|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2013-11-01||2016-11-09|2009-03-24|2009-03-25|Estimate|2013-12-23|2014-02-11|Estimate||||2016-11-09|2016-12-29|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|MDD/GAD||Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder|Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder|Terminated||Phase 3|23|Actual|University Hospitals Cleveland Medical Center||2||Study terminated due to low enrollment|f||||t||||||||||2018-06-01 01:10:50.790612|2018-06-01 01:10:50.790612
NCT00868361|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|||2009-09-15|2009-03-24|2009-03-25|Estimate|||||||2009-09-15|2009-09-16|Estimate|May 2009||2009-05-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel|A Phase 1 Open-label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male|Terminated||Phase 1|10|Anticipated|Teva Pharmaceutical Industries||1||Poor recruitment of fast and slow acetylators|f||||f||||||||||2018-06-01 01:10:51.044851|2018-06-01 01:10:51.044851
NCT00868348|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-24|2013-07-10||2014-01-22|2009-03-24|2009-03-25|Estimate|2014-01-22|2014-03-10|Estimate||||2014-01-22|2014-03-10|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional||Gender, Age,|A Comparison of Naropin and Ketorolac for Postoperative Analgesia After Total Knee Arthroplasty|Local Infiltration Analgesia for Total Knee Arthroplasty: Should Ketorolac be Added|Completed||Phase 4|60|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 01:10:51.120076|2018-06-01 01:10:51.120076
NCT00868335|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2016-03-20|2009-03-23|2009-03-24|Estimate|||||||2016-03-20|2016-03-22|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Cervical Spine; Movement Before and After Anterior Cervical Discectomy, With or Without a Cervical Disc Prosthesis|Cervical Spine; Movement Before and After Anterior Cervical Discectomy, With or Without an Activ-C Cervical Disc Prosthesis.|Completed||N/A|24|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 01:10:51.439138|2018-06-01 01:10:51.439138
NCT00868309|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2008-11-06||2016-03-18|2009-03-23|2009-03-24|Estimate|2009-03-23|2009-03-24|Estimate||||2016-03-18|2016-04-18|Estimate|January 2005||2005-01-31|March 2016|2016-03-31|February 2007|Actual|2007-02-28|August 2006|Actual|2006-08-31||Interventional|||A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,|A Comparison of Anavip and CroFab in the Treatment of Subjects With Crotalinae (Pit Viper) Envenomation: A Randomized, Prospective, Open-Label, Controlled, Comparative, Multicenter Study|Completed||Phase 2|12|Actual|Instituto Bioclon S.A. de C.V.||2|||f||||f||||||||Undecided||2018-06-01 01:10:51.608993|2018-06-01 01:10:51.608993
NCT00868296|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2009-11-30|2009-03-24|2010-04-29|2009-03-23|2009-03-24|Estimate|2009-11-30|2010-01-07|Estimate|2009-11-30|2010-01-07|Estimate|2010-04-29|2010-05-04|Estimate|March 2006||2006-03-31|April 2010|2010-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)|A Muliticenter, Open Label Safety Study of 2 Doses of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed GERD|Completed||Phase 3|58|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 01:10:51.99379|2018-06-01 01:10:51.99379
NCT00868283|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-07-06|2009-03-23|2009-03-24|Estimate|||||||2011-07-06|2011-07-07|Estimate|September 2006||2006-09-30|July 2011|2011-07-31|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|CASTA||The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke|Completed||Phase 4|1071|Actual|Ever Neuro Pharma GmbH||2|||f||||t||||||||||2018-06-01 01:10:52.531035|2018-06-01 01:10:52.531035
NCT00868270|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2009-03-22|2009-03-22|2009-03-24|Estimate|||||||2009-03-22|2009-03-24|Estimate|May 2009||2009-05-31|March 2009|2009-03-31||||||||Observational|||Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis||Unknown status|Not yet recruiting||35|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-06-01 01:10:52.691248|2018-06-01 01:10:52.691248
NCT00868257|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2012-01-11|2009-03-23|2009-03-24|Estimate|||||||2012-01-11|2012-01-12|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Measurement of Adherence to ART in HIV-Infected Children in Uganda (The CHARTA Study)|Measurement of Adherence to ART in HIV-Infected School-Aged Children in Uganda|Completed|||120|Actual|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Plasma samples to repeat HIV viral load testing, in the case of processing errors. If these~     samples are not needed, they may be used for immunologic or viral resistance testing at a~     future date.~   "|||2018-06-01 01:10:52.744252|2018-06-01 01:10:52.744252
NCT00868244|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-23|2009-03-23|2009-03-24|Estimate|||||||2009-03-23|2009-03-24|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Observational|BRUXISM||Relationship of Facial Pattern With Bruxism|Relationship of Facial Pattern With Bruxism|Unknown status|Recruiting||300|Anticipated|Universidad de Guanajuato|||||f||||t||||||||||2018-06-01 01:10:52.865521|2018-06-01 01:10:52.865521
NCT00868231|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2012-08-14||2016-11-16|2009-03-23|2009-03-24|Estimate|2012-08-14|2012-09-12|Estimate||||2016-11-16|2017-01-04|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients||Completed||Phase 2|30|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 01:10:52.994967|2018-06-01 01:10:52.994967
NCT00868218|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2015-06-06||2016-10-19|2009-03-23|2009-03-24|Estimate|2016-10-19|2016-12-13|Estimate||||2016-10-19|2016-12-13|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|November 2013|Actual|2013-11-30|July 2010|Actual|2010-07-31||Interventional|PANFLUVAC|Healthy adults willing to join phase I trial|Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults|Preparing for an Influenza Pandemic: A Phase I Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults|Completed||Phase 1|60|Actual|University of Bergen||4|||f||||f||||||||||2018-06-01 01:10:53.442097|2018-06-01 01:10:53.442097
NCT00868205|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2012-02-27|2009-03-23|2009-03-24|Estimate|||||||2012-02-27|2012-02-28|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|||Coffee and In-vivo Oxidative Stress|The Relationship Between Short- and Mid-term Intake of Coffee on in Vivo Levels of Oxidative Stress Parameters in Healthy Adults.|Completed||Phase 2|180|Anticipated|TNO||3|||f||||f||||||||||2018-06-01 01:10:53.823329|2018-06-01 01:10:53.823329
NCT00868192|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2014-10-02||2014-10-10|2009-03-23|2009-03-24|Estimate|2014-10-10|2014-10-20|Estimate||||2014-10-10|2014-10-20|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma|Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma|Completed||Phase 2|38|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 01:10:53.972838|2018-06-01 01:10:53.972838
NCT00868179|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2015-05-14|2009-03-23|2009-03-24|Estimate|||||||2015-05-14|2015-05-15|Estimate|April 2009||2009-04-30|May 2009|2009-05-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days|A Cohort (Follow Up) Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax (Tablet) Post Discharge for Ten Days, Without the Need for Routine Coagulation Monitoring and Dose Adjustment|Withdrawn||Phase 4|0|Actual|Nova Scotia Health Authority||1||study never started|f||||t||||||||||2018-06-01 01:10:54.600828|2018-06-01 01:10:54.600828
NCT00868166|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2012-03-27|2009-03-23|2009-03-24|Estimate|||||||2012-03-27|2012-03-28|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|MITOTARGET||Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)|Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole|Completed||Phase 2/Phase 3|512|Actual|Trophos||2|||f||||t||||||||||2018-06-01 01:10:54.733673|2018-06-01 01:10:54.733673
NCT00868153|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2015-02-16|2009-03-23|2009-03-24|Estimate|||||||2015-02-16|2015-02-18|Estimate|August 2004||2004-08-31|February 2015|2015-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Mirena in Idiopathic Menorrhagia|Levonorgestrel Releasing Intrauterine Device (Mirena) in Idiopathic Menorrhagia|Completed|||1125|Actual|Bayer|||1||f||||f||||||None Retained|"~     Serum~   "|||2018-06-01 01:10:54.866107|2018-06-01 01:10:54.866107
NCT00868140|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|2016-02-19|2014-08-01|2016-05-02|2009-03-23|2009-03-24|Estimate|2016-05-02|2016-06-10|Estimate|2014-08-01|2014-08-06|Estimate|2016-05-02|2016-06-10|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|PCOS|A total of 32 obese (body mass index, BMI, greater than or equal to 30 kg/m2 PCOS women, between 18-40 years old, were studied during the equivalent of the follicular phase of the menstrual cycle, as documented by a serum progesterone of less than or equal to 2 ng/ml.|Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)|Determination if Indirectly Reducing Circulating Insulin by Improving Insulin Sensitivity With Pioglitazone Reduces Renal Clearance of D-chiro-inositol (DCI) Increases the Circulating Concentration of DCI and Enhances Insulin-stimulated Release of the D-chiro-inositol-containing Inositolphosphoglycan (DCI-IPG) Mediator in Obese Women With PCOS|Terminated||N/A|51|Actual|Virginia Commonwealth University||2||Lack of recruitment|f||||t||||||||No|individual data kept confidential, secured and not shared beyond authorized study staff|2018-06-01 01:10:55.007781|2018-06-01 01:10:55.007781
NCT00868127|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-05-23|2009-03-23|2009-03-24|Estimate|||||||2012-05-23|2012-05-24|Estimate|December 2005||2005-12-31|May 2012|2012-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia|An Open-Label Extension Study to Evaluate the Safety and Tolerability of Lapaquistat Acetate in Subjects With Hypercholesterolemia|Completed||Phase 3|574|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:10:55.422235|2018-06-01 01:10:55.422235
NCT00868114|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2018-03-13|2009-03-23|2009-03-24|Estimate|||||||2018-03-13|2018-03-15|Actual|July 2006||2006-07-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|July 2013|Actual|2013-07-31||Interventional|||Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer|A Phase II Study of Apoptosis Induction Through Direct Tumor Injection of TNFerade(TM)or Radiation Alone Followed by KLH-Pulsed Autologous Dendritic Cells in Patients With Unresectable Pancreatic Cancer|Terminated||Phase 2|35|Anticipated|Leo W. Jenkins Cancer Center||2||Poor recruitment|f||||t||||||||||2018-06-01 01:10:55.506789|2018-06-01 01:10:55.506789
NCT00868101|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2011-08-03||2011-12-02|2009-03-23|2009-03-24|Estimate|2011-12-02|2012-01-09|Estimate||||2011-12-02|2012-01-09|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||The Effect of Remote Ischemic Preconditioning Applied in Children the Day Before Open Heart Surgery|The Use of Remote Ischemic Preconditioning Applied in Child the Day Before Open Heart Surgery With Extracorporeal Circulation to Correct Congenital Heart Diseases (the Second Window Effect)|Completed||Phase 1/Phase 2|22|Actual|University of Sao Paulo|Small number of subjects|2|||f||||t||||||||||2018-06-01 01:10:55.589875|2018-06-01 01:10:55.589875
NCT00868088|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-07-05|2009-03-23|2009-03-24|Estimate|||||||2011-07-05|2011-07-06|Estimate|July 2009||2009-07-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip|A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip.|Completed||Phase 4|34|Anticipated|Tufts Medical Center||2|||f||||f||||||||||2018-06-01 01:10:55.868735|2018-06-01 01:10:55.868735
NCT00868075|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2011-11-04|2009-03-23|2009-03-24|Estimate|||||||2011-11-04|2011-11-08|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis|Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis|Completed||Phase 4|27|Actual|NHS Lothian||2|||f||||f||||||||||2018-06-01 01:10:55.942084|2018-06-01 01:10:55.942084
NCT00868062|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-11-15|2009-03-23|2009-03-24|Estimate|||||||2011-11-15|2011-11-16|Estimate|April 2009||2009-04-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Responses to Colloid Infusions|Do 100 kiloDaltons Matter? A Prospective Randomised Double-blind Study on the Blood Volume Expanding Effects of Two Different Colloids in Patients Undergoing Laparoscopic Cholecystectomy|Completed||Phase 3|24|Actual|University of Nottingham||1|||f||||f||||||||||2018-06-01 01:10:56.013195|2018-06-01 01:10:56.013195
NCT00868049|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-23|2009-03-23|2009-03-24|Estimate|||||||2009-03-23|2009-03-24|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Observational|SSSCDFO||Study of Stomatognathic System of the Obese Subjects|Study of Stomatognathic System,Chewing and Deglutition Functions in the Obese Subjects|Completed|||40|Actual|University of Sao Paulo|||2||f||||f||||||||||2018-06-01 01:10:56.074362|2018-06-01 01:10:56.074362
NCT00868036|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2017-05-11|2009-03-23|2009-03-24|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2008||2008-12-31|May 2017|2017-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Evaluating for Contact Allergies in Patients With Chronic Urticaria|Contact Allergens Causing Chronic Urticaria in a New England-Area Population|Completed||N/A|23|Actual|Tufts Medical Center||1|||f||||f||||||||||2018-06-01 01:10:56.143588|2018-06-01 01:10:56.143588
NCT00868023|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2017-03-28|2009-03-23|2009-03-24|Estimate|||||||2017-03-28|2017-03-30|Actual|February 2009||2009-02-28|March 2017|2017-03-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients|A Phase II, Multinational, Multicentre, Double Blind, Double Dummy, Randomised, 5-way Cross-over, Placebo and Active Controlled Clinical Study to Test the Non-inferiority of a Single Dose of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg Dry Powder) Via NEXT™ DPI 1 or 4 Inhalations Versus CHF 1535 (Beclomethasone Dipropionate 100 µg Plus Formoterol Fumarate 6 µg) pMDI With HFA-134a Propellant 1 or 4 Puffs on FEV1 AUC0-12h in Partly Controlled Adult Asthmatic Patients|Completed||Phase 2|69|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||f||||||||||2018-06-01 01:10:56.2221|2018-06-01 01:10:56.2221
NCT00868010|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2013-03-04|2009-03-23|2009-03-24|Estimate|||||||2013-03-04|2013-03-05|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|November 2013|Anticipated|2013-11-30|August 2013|Anticipated|2013-08-31||Interventional|Enhance||Enhancing Rehabilitation After Stroke|Donepezil to Promote Functional Recovery Post-stroke|Unknown status|Recruiting|Phase 3|200|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 01:10:56.313271|2018-06-01 01:10:56.313271
NCT00867997|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2012-02-27|2009-03-23|2009-03-24|Estimate|||||||2012-02-27|2012-02-29|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|||Noncarious Cervical Lesion Treatment Outcomes|Noncarious Cervical Lesion Treatment Outcomes: Randomized Clinical Trial|Completed||Phase 3|304|Actual|Pearl Network||3|||f||||t||||||||||2018-06-01 01:10:56.429974|2018-06-01 01:10:56.429974
NCT00867984|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2015-11-20|2009-03-23|2009-03-24|Estimate|||||||2015-11-20|2015-11-24|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|TORSION||Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders|Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders (TORSION). A Randomized Comparison of Torsion-imaging Guided Optimization vs. Usual Settings.|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|University of Calgary||2|||f||||t||||||||||2018-06-01 01:10:56.555259|2018-06-01 01:10:56.555259
NCT00867971|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2009-03-22|2009-03-22|2009-03-24|Estimate|||||||2009-03-22|2009-03-24|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|||Is Recombinant Growth Hormone Therapy Associated With Increased Intraoccular Pressure?||Unknown status|Active, not recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||2||f||||||||||||||2018-06-01 01:10:56.624123|2018-06-01 01:10:56.624123
NCT00867958|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2011-02-20|2009-03-23|2009-03-24|Estimate|||||||2011-02-20|2011-02-23|Estimate|September 2008||2008-09-30|May 2009|2009-05-31|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|||Compression Anastomosis Using the CAR™ 27|Compression Anastomosis Using the CAR™ 27|Completed||N/A|15|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 01:10:56.688029|2018-06-01 01:10:56.688029
NCT00867945|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2013-06-17|2009-03-23|2009-03-24|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2009||2009-03-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Pregnancy-Induced Analgesia - A Longitudinal Study of DNIC|Pregnancy-Induced Analgesia - A Longitudinal Study of DNIC|Unknown status|Recruiting||60|Anticipated|University of Washington|||3||f||||f||||||||||2018-06-01 01:10:56.743293|2018-06-01 01:10:56.743293
NCT00867256|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2009-03-19|2009-03-19|2009-03-23|Estimate|||||||2009-03-19|2009-03-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:11:04.954005|2018-06-01 01:11:04.954005
NCT00867932|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23||2017-03-09|2017-03-09|2009-03-23|2009-03-24|Estimate||||2017-03-09|2017-03-10|Actual|2017-03-09|2017-03-10|Actual|May 2009||2009-05-31|March 2017|2017-03-31|May 12, 2011|Actual|2011-05-12|May 12, 2011|Actual|2011-05-12||Interventional|||Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects|An Open Label Multi Center Study of Eculizumab in Children and Adolescents With Diagnosis of Paroxysmal Nocturnal Hemoglobinuria|Completed||Phase 4|7|Actual|Alexion Pharmaceuticals||1|||f||||t|t|||||||||2018-06-01 01:10:56.808153|2018-06-01 01:10:56.808153
NCT00867919|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2013-04-16|2009-03-23|2009-03-24|Estimate|||||||2013-04-16|2013-04-18|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Designing and Testing a Family Therapy for Adolescent Depression|Family Therapy for Adolescent Depression: Deployment Focused Development, Phase 1|Completed||Phase 1|56|Anticipated|Oregon Research Institute||2|||f||||f||||||||||2018-06-01 01:10:56.958974|2018-06-01 01:10:56.958974
NCT00867906|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-05-05|2009-03-23|2009-03-24|Estimate|||||||2010-05-05|2010-05-06|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma|A Double-blind, Randomised, Placebo-controlled Study to Assess the Safety of Cat-PAD in Cat Allergic Subjects With Controlled Asthma|Completed||Phase 2|48|Anticipated|Circassia Limited||3|||f||||f||||||||||2018-06-01 01:10:57.036993|2018-06-01 01:10:57.036993
NCT00867893|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2012-08-13|2009-03-23|2009-03-24|Estimate|||||||2012-08-13|2012-08-14|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Suggested Immobilization Test (SIT) Test for Early Detection of Restless Legs Syndrome (RLS) Augmentation - Proof of Concept|d Immobilization Test (SIT) Test for Early Detection of Restless Legs Syndrome (RLS) Augmentation - Proof of Concept|Completed|||68|Actual|Johns Hopkins University|||2||f||||f||||||||||2018-06-01 01:10:57.127943|2018-06-01 01:10:57.127943
NCT00867880|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2014-12-12|2009-03-23|2009-03-24|Estimate|||||||2014-12-12|2014-12-15|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetic Study Of Ibuprofen Injection (IVIb) In Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Crossover Study of the Pharmacokinetics, Safety and Tolerability of Ibuprofen Inejction (IVIb) In Healthy Adult Volunteers|Completed||Phase 1|12|Actual|Cumberland Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:10:57.2361|2018-06-01 01:10:57.2361
NCT00867867|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2013-07-13|2009-03-23|2009-03-24|Estimate|||||||2013-07-13|2013-07-16|Estimate|October 2003||2003-10-31|March 2009|2009-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries|The Usefulness of Ferrous Fumarate and Ferric Pyrophosphate as Food Fortificants in Developing Countries|Completed||Phase 1|235|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||t||||||||||2018-06-01 01:10:57.327113|2018-06-01 01:10:57.327113
NCT00867854|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2017-02-27|2009-03-22|2009-03-24|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2009||2009-02-28|March 2016|2016-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Treatment De-Intensification and Residual HIV-1 in Youth|Treatment De-Intensification and Residual HIV-1 in Adolescents and Young Adults: A Sub-Study of ATN 061 and ATN 071.|Completed|||34|Actual|University of North Carolina, Chapel Hill|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:10:57.427875|2018-06-01 01:10:57.427875
NCT00867841|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2016-02-24|2009-03-23|2009-03-24|Estimate|||||||2016-02-24|2016-02-25|Estimate||||February 2016|2016-02-29||||||||Observational|||A Polymerase Chain Reaction (PCR) - Based Method to Improve Antibiotic Prescribing for Pneumonia|A Polymerase Chain Reaction-based Method to Improve Antibiotic Prescribing for Children and Adolescents With Community-Acquired Pneumonia - a Pilot Study|Withdrawn|||0|Actual|Children's Hospital of Eastern Ontario|||1|funding issues and procedural problems|f||||f||||||Samples With DNA|"~     nasopharyngeal swabs blood samples (for pneumococcal PCR)~   "|||2018-06-01 01:10:57.546679|2018-06-01 01:10:57.546679
NCT00867828|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-09-30|2009-03-23|2009-03-24|Estimate|||||||2011-09-30|2011-10-03|Estimate|May 2009||2009-05-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|MNEMOSYNE||Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease (MNEMOSYNE)|Multi-Center, Double-Blind, Placebo-Controlled, Monotherapy Study of Neptune Krill Oil (NKO™) in Early Stage Alzheimer's Disease|Completed||Phase 4|175|Actual|NeuroBioPharm Inc.||3|||f||||f||||||||||2018-06-01 01:10:57.652184|2018-06-01 01:10:57.652184
NCT00867815|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2018-04-17|2009-03-23|2009-03-24|Estimate|||||||2018-04-17|2018-04-18|Actual|July 13, 2009|Actual|2009-07-13|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|December 29, 2017|Actual|2017-12-29||Interventional|||PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men With Erectile Dysfunction Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|Terminated||Phase 4|19|Actual|Bayer||1|||f||||f|t|f||||||||2018-06-01 01:10:57.769308|2018-06-01 01:10:57.769308
NCT00867802|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2017-04-13|2009-03-20|2009-03-24|Estimate|||||||2017-04-13|2017-04-17|Actual|May 2007||2007-05-31|April 2017|2017-04-30|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|MICAS||Mindfulness Intervention For Child Abuse Survivors (MICAS)|Mindfulness Intervention For Child Abuse Survivors|Completed||N/A|20|Anticipated|University of Maryland||1|||f||||f||||||||||2018-06-01 01:10:57.878477|2018-06-01 01:10:57.878477
NCT00867789|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2011-06-21|2009-03-23|2009-03-24|Estimate|||||||2011-06-21|2011-06-22|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department|Trimethoprim-sulfamethoxazole Versus Placebo in the Treatment of Cutaneous Abscesses in the Emergency Department|Unknown status|Recruiting|N/A|200|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 01:10:57.951622|2018-06-01 01:10:57.951622
NCT00867776|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2015-10-30|2009-03-23|2009-03-24|Estimate|||||||2015-10-30|2015-11-03|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Creating African-American Wellness Through Exercise|Creating African-American Wellness Through Exercise: Community Driven Strategies to Improve Health|Terminated||N/A|22|Actual|Oregon Health and Science University||1||We decided to alter the intervention.|f||||f||||||||||2018-06-01 01:10:58.060731|2018-06-01 01:10:58.060731
NCT00867763|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2010-08-10|2009-03-23|2009-03-24|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|IVM vs IVF||In Vitro Maturation With in Vitro Fertilization (IVF) Compared to Mild in Vitro Fertilization|Clinical Research Study on in Vitro Maturation With IVF Compared to Mild Stimulation IVF|Suspended||N/A|1440|Anticipated|Batzofin Fertility Services||2||investigator changed location, requires new training effort|f||||t||||||||||2018-06-01 01:10:58.138464|2018-06-01 01:10:58.138464
NCT00865930|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:11:27.982507|2018-06-01 01:11:27.982507
NCT00867750|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2012-05-04|2009-03-20|2009-03-24|Estimate|||||||2012-05-04|2012-05-07|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SIRTACE||SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma|Radioembolisation (RE) With SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC). A Comparative, Prospective, Randomised, Open, Pilot Study.|Completed||Phase 2|28|Actual|Sirtex Medical||2|||f||||t||||||||||2018-06-01 01:10:58.236641|2018-06-01 01:10:58.236641
NCT00867737|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-23|2009-03-23|2009-03-24|Estimate|||||||2009-03-23|2009-03-24|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)|Onset of Action of Advair HFA 115/21 in Comparison to Symbicort pMDI 160/4.5 Measured by Impulse Oscillometry, IOS.|Unknown status|Recruiting|Phase 4|30|Anticipated|Allergy and Asthma Center of El Paso||2|||f||||f||||||||||2018-06-01 01:10:58.335832|2018-06-01 01:10:58.335832
NCT00867724|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2017-07-30|2009-03-23|2009-03-24|Estimate|||||||2017-07-30|2017-08-01|Actual|September 2009||2009-09-30|July 2017|2017-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||"Clinical Study-evaluate Performance&Safety Aer-O-Scope in Colon of Low Risk Patients"|"A Clinical Study to Evaluate the Performance & Safety of the Aer-O-Scope Traveling Through the Colon in Low Risk Subjects"|Completed||N/A|68|Actual|GI View Ltd.||1|||f||||f||||||||No||2018-06-01 01:10:58.426834|2018-06-01 01:10:58.426834
NCT00867711|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2014-12-01|2009-03-23|2009-03-24|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients|Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma Patients|Completed|||121|Actual|Istituto Clinico Humanitas|||||f||||f||||||Samples With DNA|"~     The paraffin-embedded tumor specimens of patients will be collected. The tumor RNA and DNA~     will be extracted and genotyping, gene expression and gene copy number analyses will be~     performed with validated PCR and array-CGH techniques.~   "|||2018-06-01 01:10:58.500589|2018-06-01 01:10:58.500589
NCT00867698|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20||2013-07-26|2014-06-02|2009-03-20|2009-03-24|Estimate||||2014-06-02|2014-06-18|Estimate|2014-06-02|2014-06-18|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|ASTUTE||AST-120 Used to Treat Mild Hepatic Encephalopathy|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy|Completed||Phase 2|148|Actual|Ocera Therapeutics||4|||f||||f||||||||||2018-06-01 01:10:58.567422|2018-06-01 01:10:58.567422
NCT00867685|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-04-29|2009-03-23|2009-03-24|Estimate|||||||2009-04-29|2009-04-30|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|||||Interventional|||Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation|A Phase I, Randomized, Open Label, 2-Way Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of AZD2624 (Tablet Versus Liquid Suspension) Followed by an Additional Period to Assess the Food Effect on the Tablet|Completed||Phase 1|16|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 01:10:58.682292|2018-06-01 01:10:58.682292
NCT00867672|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2016-08-30|2009-03-23|2009-03-24|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|DECIDER||Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia|Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy|Completed||Phase 2|204|Actual|University Hospital Freiburg||4|||f||||t||||||||||2018-06-01 01:10:58.744487|2018-06-01 01:10:58.744487
NCT00867659|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-21|2012-12-27||2013-03-26|2009-03-23|2009-03-24|Estimate|2013-03-26|2013-03-27|Estimate||||2013-03-26|2013-03-27|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors|The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome in Oocyte Donors|Completed||N/A|20|Actual|Virginia Center for Reproductive Medicine|Only 20 donors were recruited because this was a pilot study to assess the benefit of Cetrotide acetate in oocyte donors in the prevention of ovarian hyperstimulation syndrome.|1|||f||||t||||||||||2018-06-01 01:10:58.883017|2018-06-01 01:10:58.883017
NCT00867646|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2009-12-14|2009-03-23|2009-03-24|Estimate|||||||2009-12-14|2009-12-15|Estimate|May 2008||2008-05-31|December 2009|2009-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Comparison Study of CoaguChek XS PT and Laboratory Innovin PT by NTUH Lab Medicine|Comparison Study of CoaguChek XS Prothrombin Time and Laboratory Innovin PT by NTUH Lab Medicine|Completed|||70|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:10:59.012078|2018-06-01 01:10:59.012078
NCT00867633|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2012-02-20|2009-03-22|2009-03-24|Estimate|||||||2012-02-20|2012-02-22|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|March 2012|Anticipated|2012-03-31|||||Observational|||Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan|Observational Study of Aristolochic Acid-DNA Adduct in Urothelial Carcinoma in Taiwan|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||3||f||||f||||||Samples With DNA|"~     DNA extracted from the resected tissue samples~   "|||2018-06-01 01:10:59.05964|2018-06-01 01:10:59.05964
NCT00867620|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2009-03-22|2009-03-22|2009-03-24|Estimate|||||||2009-03-22|2009-03-24|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|||||Observational|||Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma|Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma|Unknown status|Enrolling by invitation||82|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     These biospecimens will be keep in low-temperature (-80 degree)and then genomic DNA will be~     extracted from blood/urine samples until the detection of DNA methylation profiles.~   "|||2018-06-01 01:10:59.115546|2018-06-01 01:10:59.115546
NCT00867607|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2015-04-19|2009-03-22|2009-03-24|Estimate|||||||2015-04-19|2015-04-21|Estimate|March 2011||2011-03-31|March 2012|2012-03-31|March 2014|Actual|2014-03-31|April 2013|Actual|2013-04-30||Interventional|||Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis|A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm|Completed||Phase 1/Phase 2|13|Actual|Hadassah Medical Organization||4|||f||||t||||||||||2018-06-01 01:10:59.194619|2018-06-01 01:10:59.194619
NCT00867594|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2011-08-10|2009-03-23|2009-03-24|Estimate|||||||2011-08-10|2011-08-11|Estimate|July 2008||2008-07-31|March 2008|2008-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effectiveness of Oral Insulin in Unstable Type 1 Diabetes Patients|A Single Blind, Open-Label Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral Insulin Formulation in Type 1 Subjects|Completed||Phase 2|12|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 01:10:59.264261|2018-06-01 01:10:59.264261
NCT00867581|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-03-23|2009-03-23|2009-03-24|Estimate|||||||2009-03-23|2009-03-24|Estimate|September 2008||2008-09-30|March 2009|2009-03-31||||July 2009|Anticipated|2009-07-31||Observational|||Magnetic Resonance Imaging (MRI) Study of the Hippocampus After Infarction in the Territory of the Middle Cerebral Artery|To Observe Delayed Neuronal Death of Hippocampus After Middle Cerebral Artery Infarction Through Magnetic Resonance Imaging(MRI) Volume Measurement and Magnetic Resonance Spectroscopy(MRS) Study of Hippocampus|Unknown status|Recruiting||80|Anticipated|Huazhong University of Science and Technology|||2||f||||t||||||||||2018-06-01 01:11:00.267353|2018-06-01 01:11:00.267353
NCT00867568|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|2016-05-11||2016-09-09|2009-03-23|2009-03-24|Estimate|2016-09-09|2016-10-28|Estimate||||2016-09-09|2016-10-28|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|September 2011|Actual|2011-09-30||Interventional|||TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma|A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma|Completed||Phase 1|18|Actual|Spectrum Health Hospitals||1|||f||||t||||||||Undecided||2018-06-01 01:11:00.383161|2018-06-01 01:11:00.383161
NCT00867555|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-23|||2009-09-17|2009-03-23|2009-03-24|Estimate|||||||2009-09-17|2009-09-18|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Green Tea, High in Epigallocatechin Gallate (EGCG) and Postprandial Fat Oxidation|Effects of the Green Tea Extract TEAVIGO High in EGCG, on Postprandial Fat Oxidation in Overweight Volunteers|Completed||N/A|24|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 01:11:00.650239|2018-06-01 01:11:00.650239
NCT00867542|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-22|||2009-03-23|2009-03-23|2009-03-24|Estimate|||||||2009-03-23|2009-03-24|Estimate|June 2009||2009-06-30|March 2009|2009-03-31|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Observational|||Dental and Oral Finding in Israeli Children With Past Intrauterine Growth Retardation (IUGR)|Dental and Oral Findings in Israeli Children With Past IUGR - a Comprehensive Study|Unknown status|Not yet recruiting||45|Anticipated|Hadassah Medical Organization|||2||f||||f||||||||||2018-06-01 01:11:00.720581|2018-06-01 01:11:00.720581
NCT00867529|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2017-04-14||2017-12-05|2009-03-20|2009-03-23|Estimate|2017-04-14|2017-05-22|Actual||||2017-12-05|2018-01-02|Actual|February 2009||2009-02-28|December 2017|2017-12-31|March 26, 2015|Actual|2015-03-26|March 2015|Actual|2015-03-31||Interventional|||Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma|Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies|Completed||Phase 2|63|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 01:11:00.816606|2018-06-01 01:11:00.816606
NCT00867516|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2017-09-13|2009-03-20|2009-03-23|Estimate|||||||2017-09-13|2017-09-15|Actual|October 2008||2008-10-31|September 2017|2017-09-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|ALD518-003||Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis|A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80,160 and 320mg ALD518 Versus Placebo Administered as Multiple IV Infusions to Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|Completed||Phase 2|127|Actual|Vitaeris INC||4|||f||||f||||||||||2018-06-01 01:11:01.200929|2018-06-01 01:11:01.200929
NCT00867503|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2012-10-01||2015-12-02|2009-03-20|2009-03-23|Estimate|2012-10-30|2012-11-29|Estimate||||2015-12-02|2016-01-01|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|April 2013|Actual|2013-04-30|January 2012|Actual|2012-01-31||Interventional|||Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer|Open Label Phase II Trial of Bendamustine Hydrochloride (HCL) in Women With Advanced Ovarian Cancer|Completed||Phase 2|10|Actual|University of Arizona|The team was not able to collect fresh tumor tissue at the time of the study, so we could not examine patient tumors to determine their DNA repair capabilities.|1|||f||||t||||||||||2018-06-01 01:11:01.328777|2018-06-01 01:11:01.328777
NCT00867490|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2011-01-07||2011-05-04|2009-03-20|2009-03-23|Estimate|2011-01-07|2011-02-01|Estimate||||2011-05-04|2011-05-06|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|AMAZING||Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothiazide 25 mg|Completed||Phase 3|186|Actual|Novartis|The Phases of this study were entered in separate tables for outcomes and the Phases for SAEs and the AEs were entered all in one table.|1|||f||||||||||||||2018-06-01 01:11:01.634229|2018-06-01 01:11:01.634229
NCT00867477|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2014-08-27|2009-03-20|2009-03-23|Estimate|||||||2014-08-27|2014-08-28|Estimate|March 2009||2009-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide|A Biomarker Study Comparing the Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide in Patients Who Receive Thoracic Radiotherapy|Completed||Phase 2|163|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 01:11:01.906373|2018-06-01 01:11:01.906373
NCT00867464|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2018-05-23|2009-03-20|2009-03-23|Estimate|||||||2018-05-23|2018-05-24|Actual|March 19, 2009||2009-03-19|May 31, 2017|2017-05-31||||||||Observational|||Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls|Extended Follow-up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls|Active, not recruiting|||8670|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:11:01.988|2018-06-01 01:11:01.988
NCT00867451|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2011-09-28||2012-03-15|2009-03-20|2009-03-23|Estimate|2012-03-15|2012-03-16|Estimate||||2012-03-15|2012-03-16|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)|A Pilot Study Designed To Improve Sleep and Subsequent Daytime Functioning in Children Diagnosed With ADHD|Completed||Phase 1/Phase 2|8|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-06-01 01:11:02.085014|2018-06-01 01:11:02.085014
NCT00851812|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2018-05-23|2009-02-25|2009-02-26|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2007||2007-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Exercise for Breast Cancer Patients (EXCAP)|Aerobic and Resistance Exercise for Cancer Treatment-Related Fatigue|Active, not recruiting||N/A|114|Anticipated|University of Rochester||2|||f||||t||||||||||2018-06-01 01:16:06.995991|2018-06-01 01:16:06.995991
NCT00867438|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2009-03-24|2009-03-20|2009-03-23|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy|Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium (CB-01-05-MMX™), Administered as Add-on Therapy to Oral Mesalazine or Other 5-ASA Derivatives, in Patients With Active, Left-Sided, Mild to Moderate Ulcerative Colitis. A Multicentre Randomized, Double-Blind, Comparative Study Versus Placebo.|Completed||Phase 2|133|Actual|Cosmo Technologies Ltd||2|||f||||f||||||||||2018-06-01 01:11:02.532484|2018-06-01 01:11:02.532484
NCT00867425|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2012-04-26|2009-03-20|2009-03-23|Estimate|||||||2012-04-26|2012-04-27|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program|Translating the Diabetes Prevention Program Into a Virtual Lifestyle Management Program: A Pilot Study in a Military Community|Completed||N/A|30|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:11:02.618129|2018-06-01 01:11:02.618129
NCT00867412|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2009-03-20|2009-03-20|2009-03-23|Estimate|||||||2009-03-20|2009-03-23|Estimate|January 2002||2002-01-31|March 2009|2009-03-31|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Observational|||Randomized Study of Positron Emission Tomography - Computed Tomography (PET/CT) in Pre-Operative Staging of Lung Cancer|Randomized Study of PET/CT in Pre-Operative Staging of Lung Cancer|Completed|||189|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-06-01 01:11:02.718432|2018-06-01 01:11:02.718432
NCT00867399|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-10-31|2009-03-20|2009-03-23|Estimate|||||||2010-10-31|2010-11-02|Estimate|March 2009||2009-03-31|September 2010|2010-09-30||||May 2009|Actual|2009-05-31||Interventional|||A Safety and Tolerability Study of ABT-126 in Elderly|A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects|Completed||Phase 1|30|Actual|Abbott||2|||f||||||||||||||2018-06-01 01:11:02.809847|2018-06-01 01:11:02.809847
NCT00867386|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2014-03-11|2009-03-19|2009-03-23|Estimate|||||||2014-03-11|2014-03-13|Estimate|December 2006||2006-12-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Observational|||Desensitization for Highly Sensitized Recipients of Pancreas Transplantation|Desensitization for Highly Sensitized Recipients of Pancreas Transplantation|Completed|||7|Actual|Northwestern University|||||f||||f||||||||||2018-06-01 01:11:02.872825|2018-06-01 01:11:02.872825
NCT00867373|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2013-04-24|2009-03-20|2009-03-23|Estimate|||||||2013-04-24|2013-04-26|Estimate|May 2007||2007-05-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Parent Perceptions of Weight Status: Impact of a Pilot Intervention|Parent Perceptions of Weight Status: Impact of a Pilot Intervention to Enhance Awareness of Risk for Overweight Parents and Their Children|Completed||N/A|222|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:11:02.94891|2018-06-01 01:11:02.94891
NCT00867360|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2016-11-15||2017-02-15|2009-03-20|2009-03-23|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|August 2005||2005-08-31|February 2017|2017-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Treatment of Psychotic Major Depression With Mifepristone|Hypothalamic-Pituitary-Adrenal (HPA)/Dopamine Axis in Psychotic Depression|Terminated||Phase 3|10|Actual|Stanford University||2||Insufficient recruitment.|f||||f||||||||No||2018-06-01 01:11:03.066442|2018-06-01 01:11:03.066442
NCT00867347|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2011-07-09|2009-03-20|2009-03-23|Estimate|||||||2011-07-09|2011-07-12|Estimate|December 2006||2006-12-31|March 2009|2009-03-31||||March 2014|Anticipated|2014-03-31||Interventional|||Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer|Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study|Unknown status|Active, not recruiting|Phase 3|1015|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:11:03.352999|2018-06-01 01:11:03.352999
NCT00867334|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2014-03-11|2009-03-20|2009-03-23|Estimate|||||||2014-03-11|2014-03-12|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|NITMEC||New Individualized Therapy Trial for Metastatic Colorectal Cancer|A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay|Completed||Phase 1/Phase 2|10|Actual|Inova Health Care Services||2|||f||||f||||||||||2018-06-01 01:11:03.461053|2018-06-01 01:11:03.461053
NCT00867321|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2017-02-14||2017-05-24|2009-03-20|2009-03-23|Estimate|2017-05-24|2017-07-02|Actual||||2017-05-24|2017-07-02|Actual|April 2009||2009-04-30|May 2017|2017-05-31|May 2013|Actual|2013-05-31|April 2012|Actual|2012-04-30||Interventional||All patients were used to analyze baseline characteristics.|Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer|Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|24|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 01:11:03.624189|2018-06-01 01:11:03.624189
NCT00867308|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2016-10-14|2009-03-20|2009-03-23|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Trilineage Dysplasia (AML-TLD)|Protocol Title: Phase II Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (AML-TLD)|Active, not recruiting||Phase 2|48|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-06-01 01:11:04.618399|2018-06-01 01:11:04.618399
NCT00867295|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2010-06-01|2009-03-20|2009-03-23|Estimate|||||||2010-06-01|2010-06-02|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|TIVAD||Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device|A Randomized, Double-blind, Placebo-controlled Trial to Determine Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access Device.|Completed||Phase 3|150|Anticipated|Istanbul University||2|||f||||t||||||||||2018-06-01 01:11:04.705572|2018-06-01 01:11:04.705572
NCT00867282|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2009-07-27|2009-03-20|2009-03-23|Estimate|||||||2009-07-27|2009-07-28|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|B0871003||A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers.|Completed||Phase 1|36|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 01:11:04.812561|2018-06-01 01:11:04.812561
NCT00867269|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2018-05-26|2009-03-20|2009-03-23|Estimate|||||||2018-05-26|2018-05-30|Actual|March 19, 2009||2009-03-19|May 21, 2018|2018-05-21||||||||Observational|||Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia|Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia|Recruiting|||950|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:11:04.881501|2018-06-01 01:11:04.881501
NCT00867243|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2013-06-10|2009-03-20|2009-03-23|Estimate|||||||2013-06-10|2013-06-11|Estimate|October 2005||2005-10-31|June 2013|2013-06-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Observational|||Prediction of Hepatitis C Recurrence in Liver Transplant Recipients|Prediction of Hepatitis C Recurrence in Liver Transplant Recipients|Terminated|||24|Actual|Northwestern University|||2|This project is no longer being adequately supported to allow completion|f||||f||||||Samples With DNA|"~     Recipient specimens: Peripheral blood draws at baseline and follow-up clinic visits.~      Donor specimens: Donor cells will be isolated from lymph nodes obtained at time of harvest;~     if living donor - blood taken at time of liver resection surgery.~   "|||2018-06-01 01:11:04.988114|2018-06-01 01:11:04.988114
NCT00867230|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2012-07-31|2009-03-20|2009-03-23|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||FTS Study in Patients With Advanced Hematologic Malignancies|A Phase I Open-Label Study of S-Trans, Trans-Farnesylthiosalicylic Acid (FTS) Administered on Days 1 to 21 of a 28 Day Cycle in Patients With Advanced Hematologic Malignancies|Completed||Phase 1|18|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:11:05.09917|2018-06-01 01:11:05.09917
NCT00867217|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2016-03-14||2018-01-11|2009-03-20|2009-03-23|Estimate|2018-01-11|2018-02-09|Actual||||2018-01-11|2018-02-09|Actual|March 2009||2009-03-31|January 2018|2018-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|VITAL||Vitamin D3 for Aromatase Inhibitor Induced Arthralgias|A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).|Completed||Phase 2|160|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 01:11:05.211045|2018-06-01 01:11:05.211045
NCT00867204|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2011-09-16|2009-03-20|2009-03-23|Estimate|||||||2011-09-16|2011-09-20|Estimate|October 2004||2004-10-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|February 2008|Actual|2008-02-29||Observational|ERCP systems||Short Versus Long Wire ERCP Systems|Prospective Randomized Blinded Comparison of a Short-wire ERCP System to Traditional Long-wire Devices|Completed|||71|Actual|University of Florida|||2||f||||f||||||||||2018-06-01 01:11:05.536241|2018-06-01 01:11:05.536241
NCT00867191|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2017-03-21|2009-03-20|2009-03-23|Estimate|||||||2017-03-21|2017-03-23|Actual|February 1, 2002|Actual|2002-02-01|March 2017|2017-03-31|April 1, 2003|Actual|2003-04-01|April 1, 2003|Actual|2003-04-01||Interventional|||Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)|A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen|Completed||Phase 4|233|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:11:05.598964|2018-06-01 01:11:05.598964
NCT00867178|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2018-05-16|2009-03-20|2009-03-23|Estimate|||||||2018-05-16|2018-05-17|Actual|February 25, 2009|Actual|2009-02-25|May 2018|2018-05-31||||December 30, 2018|Anticipated|2018-12-30||Interventional|||Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System|A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System|Active, not recruiting||N/A|62|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:11:05.677829|2018-06-01 01:11:05.677829
NCT00867165|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2013-04-10||2017-04-04|2009-03-20|2009-03-23|Estimate|2013-04-10|2013-05-30|Estimate||||2017-04-04|2017-05-10|Actual|May 21, 2009|Actual|2009-05-21|April 2017|2017-04-30|April 13, 2012|Actual|2012-04-13|April 13, 2012|Actual|2012-04-13||Interventional|||Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) (Phase 3, Protocol No. P05522)|Completed||Phase 3|138|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:11:05.918485|2018-06-01 01:11:05.918485
NCT00867152|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2012-02-20|2009-03-20|2009-03-23|Estimate|||||||2012-02-20|2012-02-22|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir|A Phase I, Open Label, Randomized, Three Period, One-way, Two Cohort, Adaptive Crossover Study to Evaluate the Effect of Darunavir/Ritonavir Plus Etravirine and Lopinavir/Ritonavir Plus Etravirine on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING112934)|Completed||Phase 1|17|Actual|ViiV Healthcare||2|||f||||||||||||||2018-06-01 01:11:07.112154|2018-06-01 01:11:07.112154
NCT00867139|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2012-12-21||2013-08-08|2009-03-20|2009-03-23|Estimate|2013-04-26|2013-06-04|Estimate||||2013-08-08|2013-08-15|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients|A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients|Completed||Phase 1/Phase 2|7|Actual|Fred Hutchinson Cancer Research Center|Study was terminated. Limitations of this study include: small sample size pilot study; inability to enroll the projected number of patients for full analysis before the study was terminated.|3|||f||||t||||||||||2018-06-01 01:11:07.255693|2018-06-01 01:11:07.255693
NCT00867126|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2009-04-02|2009-03-20|2009-03-23|Estimate|||||||2009-04-02|2009-04-03|Estimate|February 2009||2009-02-28|March 2009|2009-03-31||||February 2013|Anticipated|2013-02-28||Interventional|||Pioglitazone as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Treatment With Gemcitabine|A Pilot Study of Pioglitazone as Second Line Therapy for Patients With Previously Treated Metastatic Adenocarcinoma of the Pancreas With Disease Progression After Gemcitabine Based Chemotherapy|Unknown status|Recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:11:07.759916|2018-06-01 01:11:07.759916
NCT00867113|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2017-12-15||2018-03-09|2009-03-20|2009-03-23|Estimate|2018-03-09|2018-03-14|Actual||||2018-03-09|2018-03-14|Actual|July 22, 2009|Actual|2009-07-22|March 2018|2018-03-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)|A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)|Completed||Phase 2|91|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:11:07.860567|2018-06-01 01:11:07.860567
NCT00867100|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2010-08-19|2009-03-20|2009-03-23|Estimate|||||||2010-08-19|2010-08-20|Estimate|December 2007||2007-12-31|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis|A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|84|Actual|Amgen||1|||f||||||||||||||2018-06-01 01:11:08.291612|2018-06-01 01:11:08.291612
NCT00867087|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2017-07-24|2013-11-07|2017-10-30|2009-03-20|2009-03-23|Estimate|2017-07-24|2017-08-22|Actual|2013-11-07|2013-12-03|Estimate|2017-10-30|2017-12-05|Actual|June 8, 2009|Actual|2009-06-08|October 2017|2017-10-31|October 31, 2012|Actual|2012-10-31|October 31, 2012|Actual|2012-10-31||Interventional||Safety population - included participants who received at least 1 dose of study medication (rituximab or inotuzumab ozogamicin).|Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma|An Open-label, Single-arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory Cd22-positive Diffuse Large B-cell Lymphoma, Eligible For Autologous Stem Cell Transplantation|Completed||Phase 2|64|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:11:08.378336|2018-06-01 01:11:08.378336
NCT00867061|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2017-06-22|2009-03-20|2009-03-23|Estimate|||||||2017-06-22|2017-06-23|Actual|March 2009||2009-03-31|June 2017|2017-06-30|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)|A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 5-day Continuous Intravenous Dosing Of ON 01910.Na Administered Every 2 Weeks in Patients With Intermediate-1, Intermediate-2, or High Risk Myelodysplastic Syndrome (MDS)|Withdrawn||Phase 1/Phase 2|0|Actual|Onconova Therapeutics, Inc.||||Mutual decision by site and sponsor because of difficulty recruiting Patients.|f||||f||||||||||2018-06-01 01:11:08.870603|2018-06-01 01:11:08.870603
NCT00867048|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2017-09-21|2009-03-20|2009-03-23|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2009||2009-03-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|START||Strategic Timing of Antiretroviral Treatment|Strategic Timing of AntiRetroviral Treatment|Active, not recruiting||Phase 4|4688|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 01:11:08.966599|2018-06-01 01:11:08.966599
NCT00867035|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2009-07-01||2013-05-15|2009-03-20|2009-03-23|Estimate|2013-05-15|2013-05-16|Estimate||||2013-05-15|2013-05-16|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Bad Breath Response to Tongue Scraper and Rinses|Bad Breath Response to Tongue Scraper and Rinses, a Double-blind, Randomized, Parallel Group Clinical Trial.|Completed||N/A|22|Actual|University of California, San Francisco|Total number of subjects is less than the desired 50 persons; dimethyl sulfide measures distorted by materials in syringes; accuracy of portable gas chromatograph a concern.|2|||f||||t||||||||||2018-06-01 01:11:09.540605|2018-06-01 01:11:09.540605
NCT00867022|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2009-03-20|2009-03-20|2009-03-23|Estimate|||||||2009-03-20|2009-03-23|Estimate|August 2004||2004-08-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|November 2007|Actual|2007-11-30||Observational|||Autonomic Nervous Activity in Women With Gestational Diabetes|Autonomic Nervous Activity in Women With Gestational Diabetes|Completed|||80|Actual|Helsinki University|||4||f||||f||||||||||2018-06-01 01:11:10.017123|2018-06-01 01:11:10.017123
NCT00867009|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2012-04-10||2015-05-20|2009-03-20|2009-03-23|Estimate|2012-04-18|2012-05-16|Estimate||||2015-05-20|2015-06-15|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|May 2011|Actual|2011-05-31||Interventional|||A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer|A Phase 2 Study of Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) Other Than Predominantly Squamous Cell Histology|Completed||Phase 2|113|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:11:10.130181|2018-06-01 01:11:10.130181
NCT00866996|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2011-05-20|2009-03-19|2009-03-23|Estimate|||||||2011-05-20|2011-05-24|Estimate||||March 2010|2010-03-31|December 2003|Actual|2003-12-31|||||Interventional|||Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder|A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder|Completed||Phase 4|1323|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||f||||||||||||||2018-06-01 01:11:10.764578|2018-06-01 01:11:10.764578
NCT00866983|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2013-02-11|2009-03-20|2009-03-23|Estimate|||||||2013-02-11|2013-02-12|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Expanded Access|||Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil|A Local, Multi-Centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy For Patients Who Completed A1481244 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil , Prior To Reimbursement And Availability For Patients In Brazil.|No longer available|||||Pfizer|||||f||||f||||||||||2018-06-01 01:11:10.835606|2018-06-01 01:11:10.835606
NCT00866970|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2017-09-25|2009-03-20|2009-03-23|Estimate|||||||2017-09-25|2017-09-26|Actual|September 2008||2008-09-30|September 2017|2017-09-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia|A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia|Completed||Phase 2|124|Actual|Vitaeris INC||4|||f||||t|f|f||||||||2018-06-01 01:11:10.903906|2018-06-01 01:11:10.903906
NCT00866957|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2016-09-13|2009-03-19|2009-03-23|Estimate|||||||2016-09-13|2016-09-15|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)|Human Liver Explants for HIF-1 Alpha- Analysis/Comparison|Recruiting|||500|Anticipated|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Both, samples with DNA and without: serum, plasma, genomic samples, & liver biopsy specimens~   "|||2018-06-01 01:11:11.023172|2018-06-01 01:11:11.023172
NCT00866944|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2011-11-10|2009-03-20|2009-03-23|Estimate|||||||2011-11-10|2011-11-11|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|MT201-204||Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases|A Randomized, Open-label, Controlled, Multi-center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases|Completed||Phase 2|35|Actual|Amgen Research (Munich) GmbH||3|||f||||t||||||||||2018-06-01 01:11:11.101458|2018-06-01 01:11:11.101458
NCT00866918|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2016-10-25||2017-02-13|2009-03-20|2009-03-23|Estimate|2017-02-13|2017-04-04|Actual||||2017-02-13|2017-04-04|Actual|March 2009||2009-03-31|February 2017|2017-02-28||||June 2015|Actual|2015-06-30||Interventional|||Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia|Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® IND# 103, 331) During Consolidation|Completed||Phase 3|108|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 01:11:11.408406|2018-06-01 01:11:11.408406
NCT00866905|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2014-11-21||2014-12-05|2009-03-20|2009-03-23|Estimate|2014-11-21|2014-11-27|Estimate||||2014-12-05|2014-12-31|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer|Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer|Completed||Phase 2|168|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 01:11:12.402435|2018-06-01 01:11:12.402435
NCT00866892|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2015-07-13|2009-03-20|2009-03-23|Estimate|||||||2015-07-13|2015-07-14|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Pediatric Pilot Study: Irrigation and Scrubbing in Facial and Scalp Wounds|A Pilot Study of Noncontaminated Facial and Scalp Wounds in the Pediatric Population: Getting Away Without Irrigation and Scrubbing|Withdrawn||N/A|0|Actual|Children's Hospitals and Clinics of Minnesota||2||PI left the institution|f||||f||||||||||2018-06-01 01:11:12.624665|2018-06-01 01:11:12.624665
NCT00866879|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2018-03-27|2009-03-20|2009-03-23|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2007||2007-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients|Randomized Conversion of Calcineurin-Inhibitors(Tacrolimus to Sirolimus),6-24 Months Post Transplant Prednisone-Free Immunosuppression Regimen: Impact of Incidence of Acute Cellular Rejection,Renal Allograft Function & Lymphocytes Function|Active, not recruiting||Phase 4|275|Actual|Northwestern University||3|||f||||f||||||||||2018-06-01 01:11:12.700376|2018-06-01 01:11:12.700376
NCT00866866|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2009-03-20|2009-03-20|2009-03-23|Estimate|||||||2009-03-20|2009-03-23|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Interventional|||The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms|The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Trial|Unknown status|Recruiting|Phase 4|60|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 01:11:12.796082|2018-06-01 01:11:12.796082
NCT00866853|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-04-26|2009-03-19|2009-03-23|Estimate|||||||2010-04-26|2010-04-28|Estimate|March 2009||2009-03-31|April 2010|2010-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.|A Phase I, Open Label, 2-period, Randomized, Crossover Trial in 16 Healthy Subjects to Assess the Drug Interaction Potential of TMC435 With Oral Midazolam and With a Drug Cocktail Representative of CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP2C19 Substrates.|Completed||Phase 1|16|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:11:12.865604|2018-06-01 01:11:12.865604
NCT00866840|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2013-11-18|2009-03-20|2009-03-23|Estimate|||||||2013-11-18|2013-11-19|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Phase II Trial of Riluzole in Patients With Advanced Melanoma|Completed||Phase 2|13|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 01:11:12.922408|2018-06-01 01:11:12.922408
NCT00866827|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2018-01-31|2009-03-20|2009-03-23|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2002||2002-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Airway Vascular Lesions|Airway Vascular Lesions|Active, not recruiting|||75|Anticipated|University of Arkansas|||||f||||||||||||||2018-06-01 01:11:12.987942|2018-06-01 01:11:12.987942
NCT00866814|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2012-04-19||2012-10-10|2009-03-20|2009-03-23|Estimate|2012-04-19|2012-05-21|Estimate||||2012-10-10|2012-10-12|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Study Of Hernia Repair Utilizing The Bard Ventrio Hernia Patch|A Prospective, Single Arm, Multi-Center Study Of Open Ventral Hernia Repair Utilizing The Bard Ventrio Hernia Patch|Completed|||119|Actual|C. R. Bard|This study was designed as a single arm observational trial without predefined statistical hypotheses (theories) to test; therefore, data can only be described and no treatment comparisons or conclusions can be made.||1||f||||f||||||||||2018-06-01 01:11:13.054369|2018-06-01 01:11:13.054369
NCT00866801|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|||2015-10-12|2009-03-20|2009-03-23|Estimate|||||||2015-10-12|2015-10-14|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Observational|||Coronary Blood Flow Regulation During General Anesthesia|Cardiac Sympathetic Innervation and Coronary Blood Flow Regulation During General Anesthesia|Completed|||45|Actual|VU University Medical Center|||4||f||||f||||||Samples Without DNA|"~     Frozen plasma will be retained~   "|||2018-06-01 01:11:13.243959|2018-06-01 01:11:13.243959
NCT00866788|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-20|2011-07-01||2017-06-08|2009-03-20|2009-03-23|Estimate|2011-08-08|2011-09-09|Estimate||||2017-06-08|2017-07-11|Actual|March 2009||2009-03-31|June 2017|2017-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Intent-to-Treat population|A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)|Completed||Phase 2|90|Actual|Genentech, Inc.||4|||f||||||||||||||2018-06-01 01:11:13.438236|2018-06-01 01:11:13.438236
NCT00866775|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2015-10-06|2014-08-07|2016-02-09|2009-03-19|2009-03-20|Estimate|2016-01-04|2016-02-04|Estimate|2014-08-07|2014-08-11|Estimate|2016-02-09|2016-03-11|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs|Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs|Completed||Phase 3|193|Actual|Sunovion|The comparison of active treatment to control which was used in this trial is based on a pooled analysis of comparator groups from 8 earlier trials of similar design. Limitations related to use of historical control groups are applicable.|2|||f||||f||||||||||2018-06-01 01:11:14.073815|2018-06-01 01:11:14.073815
NCT00866762|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2011-12-09|2009-03-19|2009-03-20|Estimate|||||||2011-12-09|2011-12-12|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia|A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia.|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Copenhagen University Hospital at Herlev||1|||f||||t||||||||||2018-06-01 01:11:14.93785|2018-06-01 01:11:14.93785
NCT00866749|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2018-01-08|2009-03-19|2009-03-20|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2006|Actual|2006-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma|Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|Active, not recruiting||Phase 2|125|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:11:15.036191|2018-06-01 01:11:15.036191
NCT00866736|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2015-09-14|2009-03-19|2009-03-20|Estimate|||||||2015-09-14|2015-09-15|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia|A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia|Completed||Phase 2|65|Actual|Kanto CML Study Group||1|||f||||t||||||||||2018-06-01 01:11:15.130237|2018-06-01 01:11:15.130237
NCT00866723|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2014-11-19||2018-05-17|2009-03-19|2009-03-20|Estimate|2014-11-19|2014-11-25|Estimate||||2018-05-17|2018-05-22|Actual|March 2009||2009-03-31|May 2018|2018-05-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional||The analysis dataset is comprised of all treated patients.|Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer|Phase II Study of Single-Agent Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous, Papillary Serous Endometrial or Fallopian Tube Cancer Who Have Recurred After Prior Therapy With Maintenance Avastin|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|Early termination leading to small numbers of subjects analyzed.|1||Recruitment has been terminated prematurely because of poor enrollment.|f||||t||||||||||2018-06-01 01:11:15.210801|2018-06-01 01:11:15.210801
NCT00866710|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2012-01-10|2009-03-19|2009-03-20|Estimate|||||||2012-01-10|2012-01-12|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|BETTUR PD||Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease|Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease|Completed||N/A|28|Actual|Atlanta VA Medical Center|||||f||||f||||||||||2018-06-01 01:11:15.361131|2018-06-01 01:11:15.361131
NCT00866697|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2013-07-03||2017-10-02|2009-03-19|2009-03-20|Estimate|2013-11-21|2013-12-19|Estimate||||2017-10-02|2017-11-06|Actual|May 26, 2009|Actual|2009-05-26|October 2017|2017-10-31|August 24, 2017|Actual|2017-08-24|July 8, 2012|Actual|2012-07-08||Interventional|||Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed||Phase 3|940|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:11:15.490794|2018-06-01 01:11:15.490794
NCT00866684|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2015-09-01|2009-03-19|2009-03-20|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|PROSKIN||Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|Terminated||Phase 4|44|Actual|Charite University, Berlin, Germany||2||Insufficient patient recruitment|f||||f||||||||||2018-06-01 01:11:17.332218|2018-06-01 01:11:17.332218
NCT00866671|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2015-01-12|2009-03-19|2009-03-20|Estimate|||||||2015-01-12|2015-01-14|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Observational Study of Nelarabine in Children and Young Adults|A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-Lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma|Completed|||28|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 01:11:17.531202|2018-06-01 01:11:17.531202
NCT00866658|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2016-08-18|2012-02-21|2016-08-18|2009-03-19|2009-03-20|Estimate|2016-08-18|2016-10-11|Estimate|2012-02-21|2012-02-23|Estimate|2016-08-18|2016-10-11|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|GETGOAL-L-ASIA|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)|A Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea|Completed||Phase 3|311|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:11:17.672009|2018-06-01 01:11:17.672009
NCT00866645|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-12-02|2009-03-19|2009-03-20|Estimate|||||||2010-12-02|2010-12-03|Estimate|February 2009||2009-02-28|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia|A Randomized Blind Parallel Intramuscular Haloperidol-Controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Intramuscular Levosulpiride in the Treatment of Chinese Patients With Agitation Of Schizophrenia|Completed||Phase 2/Phase 3|240|Anticipated|Shanghai Mental Health Center||2|||f||||f||||||||||2018-06-01 01:11:18.32109|2018-06-01 01:11:18.32109
NCT00866632|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-09-09|2009-03-19|2009-03-20|Estimate|||||||2010-09-09|2010-09-10|Estimate|June 2008||2008-06-30|September 2010|2010-09-30||||December 2010|Anticipated|2010-12-31||Interventional|||Improving Psychological Wellness After Acquired Brain Injury|Improving Mood, Adjustment and Coping in People With Acquired Brain Injury: A Randomized Controlled Trial to Examine the Efficacy of a Cognitive Behaviour Therapy Protocol Adapted for Brain Injury and Remote Administration of Services.|Unknown status|Recruiting|N/A|75|Anticipated|Toronto Rehabilitation Institute||4|||f||||f||||||||||2018-06-01 01:11:18.417629|2018-06-01 01:11:18.417629
NCT00866619|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2017-04-24|2009-03-19|2009-03-20|Estimate|||||||2017-04-24|2017-04-25|Actual|March 27, 2009||2009-03-27|April 2017|2017-04-30|January 31, 2014|Actual|2014-01-31|March 1, 2011|Actual|2011-03-01||Interventional|||Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa|Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa|Completed||Phase 3|15459|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:11:18.490025|2018-06-01 01:11:18.490025
NCT00866606|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2010-12-14||2011-04-01|2009-03-19|2009-03-20|Estimate|2010-12-14|2011-01-04|Estimate||||2011-04-01|2011-04-05|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects|An Evaluation Of The Safety And Efficacy Of On-Demand Treatment With BeneFIX (Nonacog Alfa, Recombinant Factor IX) In Chinese Subjects With Hemophilia B|Completed||Phase 3|35|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:11:18.629189|2018-06-01 01:11:18.629189
NCT00866593|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2013-04-01|2009-03-19|2009-03-20|Estimate|||||||2013-04-01|2013-04-04|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram in Depression|A Randomized Double-blind Parallel Innovator-Controlled Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Generic Escitalopram Oxalate Tablets in the Treatment of Chinese Patients With Depression|Completed||Phase 2/Phase 3|260|Actual|Shanghai Mental Health Center||2|||f||||f||||||||||2018-06-01 01:11:19.829194|2018-06-01 01:11:19.829194
NCT00866580|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2015-03-19|2009-03-19|2009-03-20|Estimate|||||||2015-03-19|2015-03-23|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine|Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1562902A.|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||Study was cancelled before enrolment for reasons not related to vaccine safety or efficacy.|f||||||||||||||2018-06-01 01:11:19.925575|2018-06-01 01:11:19.925575
NCT00866567|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-02-02|2009-03-19|2009-03-20|Estimate|||||||2010-02-02|2010-02-03|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Defects in Opsonophagocytosis in Premature Infants|Defects in Opsonophagocytosis in Premature Infants as a Factor for the Development of Neonatal Sepsis|Completed|||80|Anticipated|University Hospital, Geneva|||4||f||||f||||||Samples With DNA|"~     Serum cDNA~   "|||2018-06-01 01:11:20.008748|2018-06-01 01:11:20.008748
NCT00866554|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2015-04-14|2009-03-19|2009-03-20|Estimate|||||||2015-04-14|2015-04-16|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy|Phase II Study of Bicalutamide and Dutasteride for Prostate Cytoreduction Prior to Permanent Implant I-125 Prostate Brachytherapy|Unknown status|Active, not recruiting|Phase 2|88|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-06-01 01:11:20.077091|2018-06-01 01:11:20.077091
NCT00866541|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|January 2009||2009-01-31|March 2009|2009-03-31||||December 2009|Anticipated|2009-12-31||Interventional|||Flow Proportional Pressure Support in Volunteers|Flow Proportional Pressure Support as a New Mode of Spontaneous Breathing Assist - Evaluation of Objective and Subjective Measured Data in Volunteers|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital Freiburg||1|||f||||f||||||||||2018-06-01 01:11:20.182751|2018-06-01 01:11:20.182751
NCT00866528|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2017-11-08|2009-03-19|2009-03-20|Estimate|||||||2017-11-08|2017-11-13|Actual|July 9, 2009|Actual|2009-07-09|November 2017|2017-11-30|October 25, 2012|Actual|2012-10-25|October 25, 2012|Actual|2012-10-25||Interventional|||Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer|An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:11:20.34868|2018-06-01 01:11:20.34868
NCT00866515|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2017-07-13|2009-03-19|2009-03-20|Estimate|||||||2017-07-13|2017-07-18|Actual|December 22, 2008|Actual|2008-12-22|July 2017|2017-07-31|March 27, 2009|Actual|2009-03-27|March 27, 2009|Actual|2009-03-27||Interventional|||Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole|A Double-blind, Placebo-controlled, Randomised, 2-way Crossover Drug Interaction Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects Following Co-administration of GW642444M With Ketoconazole|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:11:20.465094|2018-06-01 01:11:20.465094
NCT00866502|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2015-01-09|2009-03-18|2009-03-20|Estimate|||||||2015-01-09|2015-01-12|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease|A Randomized, Double-blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed® II Pump.|Completed||Phase 1/Phase 2|12|Actual|Newron Sweden AB||2|||f||||t||||||||||2018-06-01 01:11:20.634463|2018-06-01 01:11:20.634463
NCT00866489|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-12-26|2009-03-19|2009-03-20|Estimate|||||||2010-12-26|2010-12-28|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||The Neuroprotective Effects of RPC on the Neurosurgery|Clinical Trial Cencer, Xijing Hospital, Fourth Military Medical University|Completed||Phase 1|70|Actual|Xijing Hospital||2|||f||||t||||||||||2018-06-01 01:11:20.71757|2018-06-01 01:11:20.71757
NCT00866476|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19||2017-04-20|2017-04-20|2009-03-19|2009-03-20|Estimate||||2017-04-20|2017-04-21|Actual|2017-04-20|2017-04-21|Actual|January 2010||2010-01-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa|Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIa Vaccination Study|Terminated||Phase 2|20|Actual|University of Maryland||2||Reactogenicity met study halting criteria|f||||t||||||||||2018-06-01 01:11:20.795542|2018-06-01 01:11:20.795542
NCT00865969|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2014-12-04|2009-03-19|2009-03-20|Estimate|||||||2014-12-04|2014-12-08|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PTCL||Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma|A Multicenter, Open-Label Trial of Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma|Completed||Phase 2|129|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||t||||||||||2018-06-01 01:11:27.543989|2018-06-01 01:11:27.543989
NCT00866463|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2013-02-12|2009-03-19|2009-03-20|Estimate|||||||2013-02-12|2013-02-13|Estimate|October 2008||2008-10-31|February 2013|2013-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects|An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of An Experimental Tablet Of Sildenafil With Or Without Water Relative To Viagra® Conventional Oral Tablet With Water.|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:11:20.889767|2018-06-01 01:11:20.889767
NCT00866450|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2012-01-10|2009-03-19|2009-03-20|Estimate|||||||2012-01-10|2012-01-11|Estimate|February 2009||2009-02-28|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effects of a Western-type Diet on Colorectal Inflammation|Effects of a Western-type Diet on Colorectal Inflammation, Gut Permeability and Systemic Endotoxemia|Completed||Early Phase 1|5|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 01:11:20.997542|2018-06-01 01:11:20.997542
NCT00866437|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-06-15|2009-03-19|2009-03-20|Estimate|||||||2010-06-15|2010-06-16|Estimate|April 2009||2009-04-30|February 2010|2010-02-28|November 2010|Anticipated|2010-11-30|May 2010|Anticipated|2010-05-31||Interventional|||Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel|Prospective, Controlled, Single-blinded, Longitudinal, Two-arms, Clinical Study Evaluation of Efficacy/Safety of EVE-PMS Skin-Test Panel -Detecting Sensitivity to Sex Hormones in Women With Premenstrual Syndrome|Unknown status|Recruiting|Phase 2|40|Anticipated|EVE Medical Systems Ltd.||2|||f||||t||||||||||2018-06-01 01:11:21.07777|2018-06-01 01:11:21.07777
NCT00866424|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|April 2009|Anticipated|2009-04-30|January 2009|Anticipated|2009-01-31||Interventional|||Clinical Trial of Hyperbaric Oxygen Treatment in Trigeminal Neuralgia Patients|A Prospective Study on Efficacy of Hyperbaric Oxygenation Treatment for Patients With Trigeminal Neuralgia: a Randomized, Double-Blind, Mock Hyperbaric Chamber -Controlled, Parallel-Group Trial|Unknown status|Enrolling by invitation|Phase 1/Phase 2|30|Anticipated|Xijing Hospital||1|||f||||t||||||||||2018-06-01 01:11:21.181265|2018-06-01 01:11:21.181265
NCT00866411|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|January 2010|Anticipated|2010-01-31|May 2009|Anticipated|2009-05-31||Interventional|CES||Cranial Electrotherapy Stimulation (CES) for Soldiers With Combat-Related Symptoms|Outcomes of Cranial Electrotherapy Stimulation (CES) With Soldiers for Combat-Related Symptoms|Unknown status|Recruiting|N/A|100|Anticipated|Brooke Army Medical Center|||||f||||t||||||||||2018-06-01 01:11:21.25117|2018-06-01 01:11:21.25117
NCT00866398|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2011-01-14|2009-03-19|2009-03-20|Estimate|||||||2011-01-14|2011-01-17|Estimate|December 2005||2005-12-31|January 2011|2011-01-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Observational|||Economic Evaluation German Drug-Eluting Stent Registry|Economic Evaluation German Drug-Eluting Stent Registry|Completed|||3973|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-06-01 01:11:21.333143|2018-06-01 01:11:21.333143
NCT00866385|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-06-08|2009-03-19|2009-03-20|Estimate|||||||2009-06-08|2009-06-09|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||AZD8566 Food Effect/Microtracer Study|An Open, Randomised, Phase I, 2-Period Crossover Trial to Investigate the Absolute Bioavailability and the Effect of Food on the Oral Bioavailability of AZD8566 in Healthy Volunteers|Completed||Phase 1|21|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:11:21.387645|2018-06-01 01:11:21.387645
NCT00866359|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2014-04-22|2013-05-29|2017-10-17|2009-03-19|2009-03-20|Estimate|2014-08-26|2014-08-27|Estimate|2013-05-29|2013-06-06|Estimate|2017-10-17|2017-11-17|Actual|August 1, 2009|Actual|2009-08-01|October 2017|2017-10-31|May 1, 2012|Actual|2012-05-01|May 1, 2012|Actual|2012-05-01||Interventional||The intent to treat (ITT) population was defined as all randomized participants with at least one oral ulcer evaluation (including the baseline evaluation)|A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease|Completed||Phase 2|111|Actual|Celgene|Planned sample size not reached; slow enrollment|2|||f||||t||||||||||2018-06-01 01:11:21.500301|2018-06-01 01:11:21.500301
NCT00866346|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2014-03-03|2009-03-19|2009-03-20|Estimate|||||||2014-03-03|2014-03-04|Estimate|March 2008||2008-03-31|March 2014|2014-03-31||||March 2015|Anticipated|2015-03-31||Interventional|||PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation|A Phase I Study of PR1-Specific Cytotoxic T-Lymphocyte Infusion for Patients With Recurrent CML After Allogeneic Hematopoietic Transplantation|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||"Study failed to accrue any patients due to regulatory issues with PR1 vaccine and T cell~   production."|f||||f||||||||||2018-06-01 01:11:22.346981|2018-06-01 01:11:22.346981
NCT00866333|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2016-06-29|2009-03-19|2009-03-20|Estimate|||||||2016-06-29|2016-07-01|Estimate|March 2009||2009-03-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma|A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma|Completed||Phase 2|49|Actual|Syndax Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:11:22.436065|2018-06-01 01:11:22.436065
NCT00866320|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2011-12-27||2014-07-14|2009-03-19|2009-03-20|Estimate|2011-12-27|2012-02-01|Estimate||||2014-07-14|2014-07-23|Estimate|February 2006||2006-02-28|July 2014|2014-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab|A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy|Completed||Phase 2|49|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:11:22.533313|2018-06-01 01:11:22.533313
NCT00866307|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2016-08-01||2017-02-07|2009-03-19|2009-03-20|Estimate|2016-10-13|2016-12-07|Estimate||||2017-02-07|2017-03-15|Actual|February 2009||2009-02-28|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)|Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study|Completed||N/A|104|Actual|Children's Oncology Group|The COG SDC reviewed the NLM notification related to ct.gov AE/SAE reporting. The information in ‘Additional Description’ is accurate with respect to data supplied to ct.gov.COG plans to submit data AE/SAE data consistent with the text in this field.|2|||f||||||||||||||2018-06-01 01:11:22.868511|2018-06-01 01:11:22.868511
NCT00866294|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2010-10-14||2016-12-01|2009-03-19|2009-03-20|Estimate|2010-10-14|2010-11-15|Estimate||||2016-12-01|2017-01-30|Estimate|April 2009||2009-04-30|December 2016|2016-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)|A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder|Completed||Phase 3|416|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:11:23.671303|2018-06-01 01:11:23.671303
NCT00866281|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2015-09-08||2015-11-18|2009-03-19|2009-03-20|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The analysis was performed in full analysis set (FAS) population, defined as all participants to whom study treatment was assigned.|A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia|A Phase I/II, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients With Relapsed or Refractory Leukemia|Terminated||Phase 1/Phase 2|22|Actual|Novartis|The study was terminated early since despite considerable efforts to boost recruitment, no new participants were enrolled in the final year of this study.|2||"Despite considerable efforts to boost recruitment during the final year of the study, no new~   patients were enrolled."|f||||||||||||||2018-06-01 01:11:24.443011|2018-06-01 01:11:24.443011
NCT00866268|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|May 2006||2006-05-31|March 2009|2009-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Low Versus High Pressure Suction Drainage After Total Knee Arthroplasty|"Low Versus High Pressure Suction Drainage After Total Knee Arthroplasty: a Double Blind Randomized Controlled Trial"|Completed||Phase 3|169|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-06-01 01:11:25.090311|2018-06-01 01:11:25.090311
NCT00866255|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-02-01|2009-03-19|2009-03-20|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2008||2008-01-31|March 2009|2009-03-31||||May 2009|Actual|2009-05-31||Interventional|||Continuous Measurement of Intratracheal Pressure|Continuous Measurement of Intratracheal Pressure in Mechanically Ventilated Infants|Completed||N/A|50|Anticipated|University Hospital Freiburg|||||f||||f||||||||||2018-06-01 01:11:25.170655|2018-06-01 01:11:25.170655
NCT00866242|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19||2017-04-20|2017-04-20|2009-03-19|2009-03-20|Estimate||||2017-04-20|2017-04-21|Actual|2017-04-20|2017-04-21|Actual|January 2010||2010-01-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb|Safety, Immunogenicity, and Efficacy Following Experimental Challenge of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set Shigella Flexneri 2a Live, Oral Vaccine: Phase IIb Challenge Study|Terminated||Phase 2|20|Actual|University of Maryland||1||Reactogenicity met study halting criteria|f||||t||||||||||2018-06-01 01:11:25.222782|2018-06-01 01:11:25.222782
NCT00866229|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|June 2010|Anticipated|2010-06-30|March 2010|Anticipated|2010-03-31||Interventional|||Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level|Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level|Unknown status|Recruiting|Phase 4|140|Anticipated|Ramathibodi Hospital|||||f||||t||||||||||2018-06-01 01:11:25.289938|2018-06-01 01:11:25.289938
NCT00866216|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2017-03-27|2009-03-19|2009-03-20|Estimate|||||||2017-03-27|2017-03-29|Actual|August 2003||2003-08-31|March 2009|2009-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Geneva 600mg Azithromycin Monohydrate Tablets and Pfizer Inc. (Zithromax) 600mg Azithromycin Dihydrate Tablets in Healthy Adult Volunteers Under Fasting Conditions|Completed||Phase 1|38|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:11:25.349056|2018-06-01 01:11:25.349056
NCT00866203|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|October 2000||2000-10-31|March 2009|2009-03-31|April 2008|Actual|2008-04-30|||||Interventional|||HDS Plus PBPC Transplant Vs 4 More Courses of FrontLine Therapy in Pts With Aggressive NHL in PR After Induction Therapy|A Prospective, Randomized, Multicenter Trial Comparing a Modified HDS Therapy Supported by PBPC Transplant With Additional 4 Courses of Front-Line Therapy in Adult Aggressive NHL With PR After Short Course of Up-Front Chemotherapy|Completed||Phase 3|441|Actual|Gruppo Italiano Studio Linfomi||2|||f||||f||||||||||2018-06-01 01:11:25.415766|2018-06-01 01:11:25.415766
NCT00866190|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2011-11-03|2009-03-19|2009-03-20|Estimate|||||||2011-11-03|2011-11-07|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Dose Escalation Study of SQ109 in Healthy Adult Volunteers|A Phase 1B, Randomized, Placebo-Controlled, Double-Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single-Daily Doses of SQ109 in Normal, Healthy Male and Female Volunteers|Completed||Phase 1|10|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 01:11:25.473003|2018-06-01 01:11:25.473003
NCT00866177|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2015-07-16||2015-07-16|2009-03-19|2009-03-20|Estimate|2015-07-16|2015-08-11|Estimate||||2015-07-16|2015-08-11|Estimate|March 2009||2009-03-31|June 2013|2013-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma|Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas|Completed||Phase 2|167|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:11:25.536167|2018-06-01 01:11:25.536167
NCT00866164|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-03-02|2009-03-18|2009-03-20|Estimate|||||||2012-03-02|2012-03-05|Estimate||||March 2012|2012-03-31||||||||Expanded Access|(PUMP 2)||Prometra's Utilization in Mitigating Pain II|Prometra's Utilization in Mitigating Pain II|Approved for marketing|||||Flowonix Medical|||||||||||||||||||2018-06-01 01:11:25.828782|2018-06-01 01:11:25.828782
NCT00866151|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|August 2008||2008-08-31|March 2009|2009-03-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Observational|||A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs|A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs|Unknown status|Enrolling by invitation||150|Anticipated|Interleukin Genetics, Inc.|||1||f||||f||||||Samples With DNA|"~     Buccal swabs are collected by Stanford and sent to Interleukin Genetics for genotyping.~   "|||2018-06-01 01:11:25.892821|2018-06-01 01:11:25.892821
NCT00866138|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2013-08-13|2009-03-19|2009-03-20|Estimate|||||||2013-08-13|2013-08-14|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|January 2011|Actual|2011-01-31||Interventional|||A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3|Phase II Study of AB1010 in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not Expressing FGFR3|Unknown status|Active, not recruiting|Phase 2|24|Actual|AB Science||1|||f||||f||||||||||2018-06-01 01:11:25.967142|2018-06-01 01:11:25.967142
NCT00866125|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|April 2002||2002-04-30|March 2009|2009-03-31|August 2002|Actual|2002-08-31|||||Observational|||Hand Function in Patients With Poly- or Dermatomyositis|Hand Function, Health Related Quality of Life and Activity Performance in Patients With Polymyositis or Dermatomyositis.|Completed|||31|Actual|Karolinska Institutet|||||f||||f||||||||||2018-06-01 01:11:26.028423|2018-06-01 01:11:26.028423
NCT00866112|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2012-06-13|2009-03-19|2009-03-20|Estimate|||||||2012-06-13|2012-06-15|Estimate|May 2008||2008-05-31|April 2010|2010-04-30|June 2012|Actual|2012-06-30|February 2011|Actual|2011-02-28||Interventional|||A Randomized Exercise Trial for Wheelchair Users|A Randomized Exercise Trial for Wheelchair Users|Completed||N/A|135|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 01:11:26.078142|2018-06-01 01:11:26.078142
NCT00866099|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2010-04-16|2009-03-19|2009-03-20|Estimate|||||||2010-04-16|2010-04-19|Estimate|July 2009||2009-07-31|March 2009|2009-03-31|September 2012|Anticipated|2012-09-30|May 2011|Anticipated|2011-05-31||Interventional|EVIDEM-ED||Dementia Early Recognition and Response in Primary Care|Evidence-based Interventions In Dementia EVIDEM-ED: Early Recognition and Response in Primary Care|Unknown status|Recruiting|Phase 2/Phase 3|125|Anticipated|University College, London||2|||f||||t||||||||||2018-06-01 01:11:26.153285|2018-06-01 01:11:26.153285
NCT00866086|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-04-18|2009-03-19|2009-03-20|Estimate|||||||2009-04-18|2009-04-21|Estimate|February 2009||2009-02-28|March 2009|2009-03-31||||February 2010|Anticipated|2010-02-28||Interventional|||Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors|Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors|Unknown status|Recruiting|Phase 1|10|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:11:26.232012|2018-06-01 01:11:26.232012
NCT00866073|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|April 2003||2003-04-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia|Phase II Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia Who Are Not Eligible for Standard Induction Chemotherapy|Completed||Phase 2|238|Actual|University Hospital Freiburg||1|||f||||f||||||||||2018-06-01 01:11:26.296497|2018-06-01 01:11:26.296497
NCT00866060|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2009-03-19|2009-03-19|2009-03-20|Estimate|||||||2009-03-19|2009-03-20|Estimate|February 2008||2008-02-29|March 2009|2009-03-31|June 2013|Anticipated|2013-06-30|February 2012|Anticipated|2012-02-29||Interventional|DOMINO-AD||Donepezil and Memantine in Moderate to Severe Alzheimer's Disease|Donepezil and Memantine in Moderate to Severe Alzheimer's Disease|Unknown status|Recruiting|Phase 4|800|Anticipated|King's College London||4|||f||||t||||||||||2018-06-01 01:11:26.378783|2018-06-01 01:11:26.378783
NCT00866047|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2011-09-15||2017-02-02|2009-03-19|2009-03-20|Estimate|2011-09-15|2011-10-26|Estimate||||2017-02-02|2017-03-22|Actual|March 2009||2009-03-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|August 2010|Actual|2010-08-31||Interventional|||A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma|A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)|Completed||Phase 2|58|Actual|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-06-01 01:11:26.476155|2018-06-01 01:11:26.476155
NCT00866034|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|2013-10-17||2014-02-04|2009-03-19|2009-03-20|Estimate|2013-10-17|2013-12-17|Estimate||||2014-02-04|2014-03-19|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Cetrotide Treatment Optimization|Prospective, Multicenter,Randomized Controlled Trial Towards Identifying the Optimal GnRH Antagonist Treatment Protocol|Terminated||Phase 4|617|Actual|UMC Utrecht|The study was terminated prematurely because no significant difference was observed in clinical outcome after 617 inclusions. A much larger population would be needed to detect a small significant difference in favour of either study arm.|2||Due to limited rate of patient inclusion|f||||t||||||||||2018-06-01 01:11:26.936834|2018-06-01 01:11:26.936834
NCT00866021|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2013-03-21|2009-03-19|2009-03-20|Estimate|||||||2013-03-21|2013-03-22|Estimate|February 2008||2008-02-29|March 2013|2013-03-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|PEKARI||Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r|A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent.|Completed||Phase 4|68|Actual|Fundacion SEIMC-GESIDA||2|||f||||f||||||||||2018-06-01 01:11:27.227936|2018-06-01 01:11:27.227936
NCT00866008|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2013-07-19|2009-03-19|2009-03-20|Estimate|||||||2013-07-19|2013-07-22|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)|The Impact of the Heterogeneity of the Recruited Cohort of Follicles During Ovarian Hyperstimulation for IVF on Aneuploidy Rates of Generated Embryos.|Terminated||Phase 4|34|Actual|UMC Utrecht||2||Due to a very slow inclusion rate.|f||||f||||||||||2018-06-01 01:11:27.311948|2018-06-01 01:11:27.311948
NCT00865995|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2013-10-22|2009-03-19|2009-03-20|Estimate|||||||2013-10-22|2013-10-23|Estimate|February 2008||2008-02-29|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Pepsin As A Biomarker For Aspiration|Pepsin as a Biomarker for Aspiration Due to Gastroesophageal Reflux|Completed|||76|Actual|Medical College of Wisconsin|||3||f||||f||||||Samples Without DNA|"~     Tracheal fluid~   "|||2018-06-01 01:11:27.38468|2018-06-01 01:11:27.38468
NCT00865982|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-19|||2011-08-04|2009-03-19|2009-03-20|Estimate|||||||2011-08-04|2011-08-05|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|DCXAIOCHARITE||Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer|Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal Esophagus|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Charite University, Berlin, Germany|||||f||||t||||||||||2018-06-01 01:11:27.450848|2018-06-01 01:11:27.450848
NCT00865917|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|November 2008||2008-11-30|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Cardiovascular Effects of Selective I(f)-Channel Blockade|Einfluss Selektiver I(f)-Blockade Auf Orthostase-Toleranz Und Sympathikusaktivität Bei Gesunden|Unknown status|Recruiting|Phase 2|40|Anticipated|Hannover Medical School||3|||f||||f||||||||||2018-06-01 01:11:28.033434|2018-06-01 01:11:28.033434
NCT00865904|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2015-08-01|2011-03-23|2015-08-01|2009-03-18|2009-03-19|Estimate|2015-08-01|2015-08-28|Estimate|2011-03-23|2011-03-29|Estimate|2015-08-01|2015-08-28|Estimate|March 2009||2009-03-31|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.|Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the ∆F508-CFTR Gene Mutation|Completed||Phase 2|93|Actual|Vertex Pharmaceuticals Incorporated||5|||f||||t||||||||||2018-06-01 01:11:28.15442|2018-06-01 01:11:28.15442
NCT00865891|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|July 2005||2005-07-31|August 2010|2010-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|96|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:29.228668|2018-06-01 01:11:29.228668
NCT00865878|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2011-10-20|2009-03-18|2009-03-19|Estimate|||||||2011-10-20|2011-10-21|Estimate|May 2009||2009-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients|A Randomized, Evaluator-Blinded, Parallel Group Comparison of PDT With Levulan Topical Solution + Blue Light vs Levulan Topical Solution Vehicle + Blue Light for the Treatment of AK and Reduction of New NMSC in Organ Transplant Recipients|Terminated||Phase 2|6|Actual|DUSA Pharmaceuticals, Inc.||2||Orphan Drug Designation for this indication not granted|f||||f||||||||||2018-06-01 01:11:29.296156|2018-06-01 01:11:29.296156
NCT00865865|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|May 2006||2006-05-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Computer Aided Gap Balancing Improves Sagittal Stability and Outcomes for Cruciate-Retaining Total Knee Arthroplasty|Computer Aided Gap Balancing Improves Sagittal Stability and Outcomes for Cruciate-Retaining Total Knee Arthroplasty- 2-Year Results of a Prospective Randomised Trial|Completed||N/A|140|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-06-01 01:11:29.373685|2018-06-01 01:11:29.373685
NCT00865852|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|August 2003||2003-08-31|August 2010|2010-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 750 mg Metformin Hydrochloride Extended Release Tablets Under Non-Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:29.430058|2018-06-01 01:11:29.430058
NCT00865839|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|March 2002||2002-03-31|August 2010|2010-08-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:29.493654|2018-06-01 01:11:29.493654
NCT00865826|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2015-03-17|2009-03-17|2009-03-19|Estimate|||||||2015-03-17|2015-03-18|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Observational Study of Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals|Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals|Completed|||801|Actual|AIDS Clinical Trials Group|||1||f||||||||||Samples With DNA|"~     Sputum samples and blood collection~   "|||2018-06-01 01:11:29.55977|2018-06-01 01:11:29.55977
NCT00865813|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|December 2008||2008-12-31|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Biopsy Incisional With Trepan in Periocular Lesions|Biopsy Incisional With Trepan in Periocular Lesions|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-06-01 01:11:29.722804|2018-06-01 01:11:29.722804
NCT00865787|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2011-08-10|2009-03-18|2009-03-19|Estimate|||||||2011-08-10|2011-08-12|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Effects of EGCG-Enhanced Extra Virgin Olive Oil on Endothelial Function|Effects of EGCG-Enhanced Extra Virgin Olive Oil on Endothelial Function|Completed|||83|Actual|Mayo Clinic|||2||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-06-01 01:11:29.780746|2018-06-01 01:11:29.780746
NCT00865774|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2017-11-02|2009-03-18|2009-03-19|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2009||2009-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|TM||The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients|The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients|Completed||N/A|333|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 01:11:29.83892|2018-06-01 01:11:29.83892
NCT00865761|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|September 2005||2005-09-30|August 2010|2010-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:29.909066|2018-06-01 01:11:29.909066
NCT00865748|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|January 2004||2004-01-31|August 2010|2010-08-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:29.979331|2018-06-01 01:11:29.979331
NCT00865735|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-04-16|2009-03-18|2009-03-19|Estimate|||||||2012-04-16|2012-04-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:11:30.047422|2018-06-01 01:11:30.047422
NCT00865722|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-08-16|2009-03-18|2009-03-19|Estimate|||||||2012-08-16|2012-08-17|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|RemPostCon||Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI)|Pilot Study to Test Feasibility, Safety, Molecular Mediators and Preliminary Efficacy of Remote Myocardial Postconditioning Provided With Extrinsic Cuff Compression of Lower Limb During Primary PCI|Completed||Phase 2/Phase 3|96|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-06-01 01:11:30.080369|2018-06-01 01:11:30.080369
NCT00865709|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2012-01-31||2014-11-25|2009-03-18|2009-03-19|Estimate|2012-02-15|2012-03-20|Estimate||||2014-11-25|2014-12-11|Estimate|March 2009||2009-03-31|November 2014|2014-11-30|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects|Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease|Completed||Phase 2|198|Actual|Bayer||2|||f||||t||||||||||2018-06-01 01:11:30.263556|2018-06-01 01:11:30.263556
NCT00865696|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|September 2001||2001-09-30|August 2010|2010-08-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 15 mg Mirtazapine Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:31.456036|2018-06-01 01:11:31.456036
NCT00865683|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-07-14|2009-03-17|2009-03-19|Estimate|||||||2009-07-14|2009-07-15|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||DHA Supplements to Improve Insulin Sensitivity in Obese Pregnant Women (The Omega-3 Pregnancy Study)|DHA, Inflammation, and Insulin Sensitivity|Unknown status|Recruiting|Phase 1|90|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||f||||||||||2018-06-01 01:11:31.519481|2018-06-01 01:11:31.519481
NCT00865670|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2017-03-27|2009-03-18|2009-03-19|Estimate|||||||2017-03-27|2017-03-29|Actual|August 2003||2003-08-31|March 2009|2009-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Geneva 600 mg Azithromycin Monohydrate Tablets and Pfizer Inc. (Zithromax) 600 mg Azithromycin Dihydrate Tablets in Healthy Adult Volunteers Under Fed Conditions|Completed||Phase 1|38|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:11:31.592763|2018-06-01 01:11:31.592763
NCT00865657|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|September 2005||2005-09-30|August 2010|2010-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Non-Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:31.649191|2018-06-01 01:11:31.649191
NCT00865644|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2017-01-09|2009-03-18|2009-03-19|Estimate|||||||2017-01-09|2017-01-10|Estimate|March 2009||2009-03-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|April 2010|Actual|2010-04-30||Interventional|||Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1|Pilot Study of Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1|Completed||Phase 1|11|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 01:11:31.712057|2018-06-01 01:11:31.712057
NCT00865631|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|June 1999||1999-06-30|August 2010|2010-08-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||A Limited Food Effect Study of Gabapentin 800 mg Tablets|A Limited Food Effect Study of 800 mg Gabapentin Tablets Versus 400 mg Gabapentin Capsules|Completed||Phase 1|18|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:31.775437|2018-06-01 01:11:31.775437
NCT00865618|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2017-03-27|2009-03-18|2009-03-19|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2006||2006-06-30|March 2009|2009-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fed Conditions|Comparative Bioavailability Study of Eplerenone 50 mg Tablets (Sandoz Inc., USA) and Inspra 50 mg Tablets (GD Searle LLC, USA) in Healthy Male and/or Female Volunteers Under Fed Conditions.|Completed||Phase 1|60|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:11:31.91372|2018-06-01 01:11:31.91372
NCT00865605|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|December 2003||2003-12-31|August 2010|2010-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects|A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Pivotal Bioequivalence Study|Completed||Phase 1|71|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:31.96607|2018-06-01 01:11:31.96607
NCT00865592|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-10|2009-03-17|2009-03-19|Estimate|||||||2010-08-10|2010-08-11|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|March 2011|Anticipated|2011-03-31|January 2011|Anticipated|2011-01-31||Interventional|||Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus|An Open Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety of PHX1149T/Dutogliptin in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 3|450|Anticipated|Phenomix|||||f||||f||||||||||2018-06-01 01:11:32.041955|2018-06-01 01:11:32.041955
NCT00865579|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2017-09-15|2009-03-18|2009-03-19|Estimate|||||||2017-09-15|2017-09-18|Actual|April 2009|Actual|2009-04-30|September 2017|2017-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients|Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients|Terminated||Phase 3|964|Actual|Newron Pharmaceuticals SPA||1||study terminated early due to change in Sponsorship|f||||||||||||No|No efficacy endpoints were analyzed in this trial.|2018-06-01 01:11:32.186521|2018-06-01 01:11:32.186521
NCT00865566|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2018-03-05|2009-03-18|2009-03-19|Estimate|||||||2018-03-05|2018-03-06|Actual|May 2009||2009-05-31|March 2018|2018-03-31|October 6, 2017|Actual|2017-10-06|October 6, 2017|Actual|2017-10-06||Interventional|||Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men|Phase 2b, Randomized, Placebo-Controlled Test-of-Concept Trial to Evaluate the Safety and Efficacy of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by a Multiclade HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Adenovirus Type 5 Neutralizing Antibody Negative, Circumcised Men and Male-to-Female (MTF) Transgender Persons, Who Have Sex With Men|Completed||Phase 2|2504|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:11:32.244857|2018-06-01 01:11:32.244857
NCT00865553|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2013-09-19|2009-03-18|2009-03-19|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2009||2009-03-31|March 2011|2011-03-31||||August 2010|Anticipated|2010-08-31||Interventional|||Computer-Assisted Stop-Smoking Program in Helping Doctors Counsel Patients Who Smoke Cigarettes|Clinical Testing of a Decision Support System for Tobacco Use Treatment|Unknown status|Recruiting|Phase 2|630|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:11:32.338173|2018-06-01 01:11:32.338173
NCT00865540|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2011-05-23|2009-03-18|2009-03-19|Estimate|||||||2011-05-23|2011-05-24|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies|Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies|Unknown status|Active, not recruiting|Phase 4|30|Actual|Clinica Oftamologica Zona Sul||4|||f||||t||||||||||2018-06-01 01:11:32.395132|2018-06-01 01:11:32.395132
NCT00865527|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2016-03-29|2009-03-18|2009-03-19|Estimate|||||||2016-03-29|2016-03-31|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Pilot Study of Colon Cancer Screening Tests|Randomized Comparison of Virtual Colonoscopy, Optical Colonoscopy, and Fecal Occult Blood Testing for Colorectal Cancer Screening: a Pilot Study|Terminated||N/A|198|Actual|McMaster University||3||Lack of ongoing funding|f||||f||||||||||2018-06-01 01:11:32.455843|2018-06-01 01:11:32.455843
NCT00865514|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2013-03-21||2015-06-02|2009-03-18|2009-03-19|Estimate|2013-05-09|2013-06-20|Estimate||||2015-06-02|2015-06-03|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pharmacotoxicology of Trichloroethylene Metabolites|Pharmacotoxicology of Trichloroethylene Metabolites: Short-term Effect of DCA on in Vivo Tyrosine Catabolism and MAAI Expression|Terminated||N/A|2|Actual|University of Florida||1||"Difficulty in obtaining the solution from the compounding pharmacies caused a two year delay in~   start-up; the funding ended prior to study completion."|f||||f||||||||||2018-06-01 01:11:32.526203|2018-06-01 01:11:32.526203
NCT00865501|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-07-06|2009-03-18|2009-03-19|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease|Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease|Completed||Phase 3|50|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-06-01 01:11:33.716264|2018-06-01 01:11:33.716264
NCT00865488|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-12-20|2009-03-18|2009-03-19|Estimate|||||||2009-12-20|2009-12-23|Estimate|May 2009||2009-05-31|December 2009|2009-12-31|April 2010|Anticipated|2010-04-30|February 2010|Anticipated|2010-02-28||Interventional|||Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery|A Prospective, Controlled, Randomized, Multi-Center, Pivotal Study Evaluating the Safety and Efficacy of AdhexilTM in Prevention And/Or Reduction of Adhesions in Gynecology Surgery|Suspended||Phase 3|80|Anticipated|OMRIX Biopharmaceuticals||2|||f||||t||||||||||2018-06-01 01:11:33.783865|2018-06-01 01:11:33.783865
NCT00865475|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2013-09-11|2009-03-18|2009-03-19|Estimate|||||||2013-09-11|2013-09-12|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|KALIPO||Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC|A Randomized Comparative Clinical Trial of ZDV + 3TC + ABC (Trizivir) vs Monotherapy With Lopinavir/R (Kaletra) in Patients With Viral Suppression on Previous Treatment With ZDV + 3TC + ABC (Trizivir) for Preventing Lipoatrophy|Completed||Phase 4|38|Actual|Fundacion SEIMC-GESIDA||2|||f||||f||||||||||2018-06-01 01:11:33.858028|2018-06-01 01:11:33.858028
NCT00865462|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-16|Estimate|July 2004||2004-07-31|August 2010|2010-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Normal, Healthy Man Following a Standard Meal|Completed||Phase 1|30|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:33.943499|2018-06-01 01:11:33.943499
NCT00865449|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-10-23|2009-03-18|2009-03-19|Estimate|||||||2012-10-23|2012-10-25|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis|Role of Renin Angiotensin Blockade in Peritoneal Fibrosis in Peritoneal Dialysis Patients|Completed||Phase 3|20|Actual|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||f||||||||||2018-06-01 01:11:34.019398|2018-06-01 01:11:34.019398
NCT00865436|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|April 2004||2004-04-30|August 2010|2010-08-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Fasting Conditions|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:34.09113|2018-06-01 01:11:34.09113
NCT00865423|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|February 2001||2001-02-28|August 2010|2010-08-31|March 2001|Actual|2001-03-31|February 2001|Actual|2001-02-28||Interventional|||A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Fasting Conditions|Completed||Phase 1|28|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:34.161196|2018-06-01 01:11:34.161196
NCT00865410|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-16|Estimate|August 2004||2004-08-31|August 2010|2010-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Extended-Released Tablets Formulation in Fasted, Normal, Healthy Subjects.|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:34.329689|2018-06-01 01:11:34.329689
NCT00865397|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2016-11-22|2009-03-18|2009-03-19|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|HA-BOT||Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment|Observational Study of Glycaemic Control in Type 2 Diabetic Patients Uncontrolled on Oral Antidiabetic Agents and Starting With Once Daily Levemir® (Insulin Detemir) - 24 Weeks, Prospective, Multicentre Observational Study in Hungary|Completed|||1032|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:11:34.409609|2018-06-01 01:11:34.409609
NCT00865384|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|September 2001||2001-09-30|August 2010|2010-08-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 15 mg Mirtazapine Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:34.485018|2018-06-01 01:11:34.485018
NCT00865371|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-16|Estimate|September 2004||2004-09-30|August 2010|2010-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Extended-Released Tablets Formulation in Normal, Healthy Man Following a Standard Meal|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:34.561948|2018-06-01 01:11:34.561948
NCT00865358|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2012-12-04|2009-03-18|2009-03-19|Estimate|||||||2012-12-04|2012-12-05|Estimate|February 2007||2007-02-28|December 2012|2012-12-31|January 2008|Actual|2008-01-31|July 2007|Actual|2007-07-31||Interventional|||Yoga for Chronic Low Back Pain|Yoga for Chronic Low Back Pain in a Predominantly Minority Population: A Pilot Randomized Controlled Trial|Completed||Phase 2|30|Actual|Boston Medical Center||2|||f||||f||||||||||2018-06-01 01:11:34.656858|2018-06-01 01:11:34.656858
NCT00865345|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2011-04-19||2012-11-05|2009-03-18|2009-03-19|Estimate|2012-07-23|2012-08-27|Estimate||||2012-11-05|2012-11-06|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|6-DayFU||An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance|An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance|Completed||N/A|63|Actual|Medtronic Diabetes|||||f||||t||||||||||2018-06-01 01:11:34.746145|2018-06-01 01:11:34.746145
NCT00865332|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2017-06-30|2009-03-18|2009-03-19|Estimate|||||||2017-06-30|2017-07-02|Actual|December 12, 2007||2007-12-12|December 21, 2010|2010-12-21|December 21, 2010||2010-12-21|||||Observational|||Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates|Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:11:34.909438|2018-06-01 01:11:34.909438
NCT00865319|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2013-03-20|2009-03-18|2009-03-19|Estimate|||||||2013-03-20|2013-03-22|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)|A Multicenter Phase 2 Study Comparing 99m Tc EC-DG SPECT/CT With 18F FDG PET/CT in the Evaluation of Patients With Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|22|Actual|Cell>Point LLC||2|||f||||t||||||||||2018-06-01 01:11:34.965648|2018-06-01 01:11:34.965648
NCT00865306|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2010-07-20||2010-09-22|2009-03-18|2009-03-19|Estimate|2010-09-22|2010-10-13|Estimate||||2010-09-22|2010-10-13|Estimate|March 1998||1998-03-31|September 2010|2010-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Early Intervention for Children at Risk for Anxiety|Early Intervention for Children at Risk for Anxiety|Completed||N/A|65|Actual|Massachusetts General Hospital|Wait-list control condition Use of parent report in diagnostic interviews (necessary in this young age range) Small sample size|2|||f||||f||||||||||2018-06-01 01:11:35.080823|2018-06-01 01:11:35.080823
NCT00865293|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-07-13|2009-03-18|2009-03-19|Estimate|||||||2009-07-13|2009-07-14|Estimate|July 2008||2008-07-31|July 2009|2009-07-31||||||||Observational|EFL||Expiratory Airflow Limitation in Subjects With Obesity|Obesity and Expiratory Flow Limitation (EFL)|Unknown status|Active, not recruiting||30|Anticipated|Medical Center Alkmaar|||2||f||||f||||||||||2018-06-01 01:11:35.345852|2018-06-01 01:11:35.345852
NCT00865280|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17||2013-05-20|2013-05-20|2009-03-18|2009-03-19|Estimate||||2013-05-20|2013-05-27|Estimate|2013-05-20|2013-05-27|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|CSSI||Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)|A Randomized, Evaluator-Blinded, Phase 3 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid in the Treatment of Adults With Complicated Skin and Skin Structure Infection|Terminated||Phase 3|143|Actual|Paratek Pharmaceuticals Inc||2||Terminated|f||||f||||||||||2018-06-01 01:11:35.404045|2018-06-01 01:11:35.404045
NCT00865267|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|December 2003||2003-12-31|August 2010|2010-08-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects|A Single-blind, Single Exposure Study, to Evaluate the Vasoconstriction Activity of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects: Dose Ranging Study|Completed||Phase 1|20|Actual|Actavis Inc.||1|||f||||f||||||||||2018-06-01 01:11:35.509305|2018-06-01 01:11:35.509305
NCT00865254|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2013-06-27|2009-03-17|2009-03-19|Estimate|||||||2013-06-27|2013-06-28|Estimate|August 2007||2007-08-31|June 2013|2013-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Prize Reinforcement for Smoking Cessation|Prize Reinforcement for Smoking Cessation|Completed||N/A|84|Actual|Wayne State University||3|||f||||t||||||||||2018-06-01 01:11:35.654733|2018-06-01 01:11:35.654733
NCT00865241|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|November 2002||2002-11-30|August 2010|2010-08-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Fasting Conditions|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:35.738643|2018-06-01 01:11:35.738643
NCT00865228|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-05-23|2009-03-18|2009-03-19|Estimate|||||||2012-05-23|2012-05-24|Estimate|July 2007||2007-07-31|May 2012|2012-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia|A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia|Terminated||Phase 2|224|Actual|Takeda||4||"Overall profile of the compound does not offer significant clinical advantage to patients over~   currently available lipid lowering agents"|f||||f||||||||||2018-06-01 01:11:35.834055|2018-06-01 01:11:35.834055
NCT00865215|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|April 2005||2005-04-30|August 2010|2010-08-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 160 mg Propranolol Hydrochloride Extended Release Capsules Under Fasting Conditions|Completed||Phase 1|60|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:35.968762|2018-06-01 01:11:35.968762
NCT00865202|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2014-05-27||2017-05-26|2009-03-18|2009-03-19|Estimate|2017-05-26|2017-06-01|Actual||||2017-05-26|2017-06-01|Actual|December 2008||2008-12-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||301 total study participants|A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium|A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium|Completed||Phase 3|301|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 01:11:36.077937|2018-06-01 01:11:36.077937
NCT00865189|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2017-04-13||2017-07-31|2009-03-18|2009-03-19|Estimate|2017-07-31|2017-08-04|Actual||||2017-07-31|2017-08-04|Actual|October 23, 2007|Actual|2007-10-23|July 2017|2017-07-31|March 23, 2016|Actual|2016-03-23|March 23, 2016|Actual|2016-03-23||Interventional|INOVA|Intent to treat (ITT) population included all the randomized participants who received at least one dose of treatment.|A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer|Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in Locally Advanced Resectable Rectal Cancer: A Randomized, Non-Comparative Phase II Study|Completed||Phase 2|91|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:11:36.39539|2018-06-01 01:11:36.39539
NCT00865176|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2017-03-27|2009-03-18|2009-03-19|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2006||2006-06-30|March 2009|2009-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Comparative Bioavailability Study of Eplerenone 50 mg Tablets Under Fasting Conditions|Comparative Bioavailability Study of Eplerenone 50 mg Tablets (Sandoz Inc., USA) and Inspra 50 mg Tablets (GD Searle LLC, USA) in Healthy Male and/or Female Volunteers Under Fasting Conditions.|Completed||Phase 1|60|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:11:37.003331|2018-06-01 01:11:37.003331
NCT00865163|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2016-06-16|2009-03-18|2009-03-19|Estimate|||||||2016-06-16|2016-06-17|Estimate|November 2008||2008-11-30|June 2016|2016-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|LASER||LASER: Real Life Antithrombotic Stent Evaluation Registry|LASER: Real Life Antithrombotic Stent Evaluation Registry|Completed|||915|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No||2018-06-01 01:11:37.060788|2018-06-01 01:11:37.060788
NCT00865150|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-02-28|2009-03-18|2009-03-19|Estimate|||||||2012-02-28|2012-03-01|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Observational|||Amino Acid and Acylcarnitine Profiles in Premature Neonates|How Illness and Nutritional Support Influence Amino Acid and Acylcarnitine Profiles in Premature Neonates|Completed|||1003|Actual|Mednax Center for Research, Education, Quality and Safety|||||f||||t||||||||||2018-06-01 01:11:37.12794|2018-06-01 01:11:37.12794
NCT00865137|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2014-07-17|2009-03-18|2009-03-19|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2007||2007-09-30|July 2014|2014-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients|An Open-label, Single-centre Study to Assess the Effect of Food on the Relative Bioavailability of Orally Administered Tacrolimus Modified Release Formulation, FK506E (MR4), in Stable Kidney Transplant Recipients|Completed||Phase 3|27|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 01:11:37.188619|2018-06-01 01:11:37.188619
NCT00865124|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2017-04-12||2017-05-19|2009-03-18|2009-03-19|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|September 2008||2008-09-30|May 2017|2017-05-31|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional||All participants who completed the study.|Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease|Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease|Completed||N/A|69|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-06-01 01:11:37.298143|2018-06-01 01:11:37.298143
NCT00865111|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-16|Estimate|March 2006||2006-03-31|August 2010|2010-08-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion Sustained Release Tablets in Fasted, Normal, Healthy Men.|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:37.757357|2018-06-01 01:11:37.757357
NCT00865098|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2011-06-23||2014-02-10|2009-03-18|2009-03-19|Estimate|2011-06-23|2011-07-22|Estimate||||2014-02-10|2014-03-12|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Open-label, Non-randomized, Non-controlled, Multicenter Phase II Study Investigating Cetuximab in Combination With Concomitant-boost Radiotherapy as First-line Treatment for Japanese Patients With Newly Diagnosed Locally Advanced SCCHN.|Completed||Phase 2|27|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 01:11:37.862672|2018-06-01 01:11:37.862672
NCT00865085|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|June 2003||2003-06-30|August 2010|2010-08-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting Conditions|Single Dose Crossover Comparative Bioavailability Study of Citalopram 40 mg Tablets in Healthy Male Volunteers/Fasting State|Completed||Phase 1|28|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:38.244181|2018-06-01 01:11:38.244181
NCT00865072|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|August 2003||2003-08-31|August 2010|2010-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions|A Relative Bioavailability Study of 750 mg Metformin Hydrochloride Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:38.35834|2018-06-01 01:11:38.35834
NCT00865059|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|February 2001||2001-02-28|August 2010|2010-08-31|March 2001|Actual|2001-03-31|February 2001|Actual|2001-02-28||Interventional|||A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:38.441714|2018-06-01 01:11:38.441714
NCT00865046|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2014-12-10||2015-01-22|2009-03-18|2009-03-19|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-22|2015-01-26|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PST|Community dwelling adults with advanced knee osteoarthritis and chronic pain|Periosteal Stimulation for Knee Osteoarthritis|Efficacy of Periosteal Stimulation and Boosters for Advanced Knee OA Pain|Completed||N/A|190|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 01:11:38.529269|2018-06-01 01:11:38.529269
NCT00865033|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2017-03-27|2009-03-18|2009-03-19|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2005||2005-11-30|March 2009|2009-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions|A Relative Bioavailability Study of Metformin HCL 1000 mg Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:11:39.058942|2018-06-01 01:11:39.058942
NCT00864851|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|2014-01-30||2015-03-03|2009-03-18|2009-03-19|Estimate|2014-05-19|2014-06-06|Estimate||||2015-03-03|2015-03-23|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease|A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease|Completed||Phase 3|44|Actual|Shire||3|||f||||t||||||||||2018-06-01 01:11:40.622324|2018-06-01 01:11:40.622324
NCT00865020|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2011-06-22||2011-06-22|2009-03-18|2009-03-19|Estimate|2011-06-22|2011-07-22|Estimate||||2011-06-22|2011-07-22|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ASSERTIVE||Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal|A Twelve-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Prolonged Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg in Mild to Moderate Hypertensive Patients With the 24-hour Ambulatory Blood Pressure Measurement After 1 Week of Treatment Withdrawal Study Acronym: ASSERTIVE - AliSkiren Study of Profound antihypERtensive Efficacy in hyperTensIVE Patients|Completed||Phase 4|822|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:11:39.132358|2018-06-01 01:11:39.132358
NCT00865007|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2013-03-21|2009-03-18|2009-03-19|Estimate|||||||2013-03-21|2013-03-22|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|KRETA||Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy|A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir|Completed||Phase 4|88|Actual|Fundacion SEIMC-GESIDA||2|||f||||f||||||||||2018-06-01 01:11:39.438647|2018-06-01 01:11:39.438647
NCT00864994|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-03-26|2009-03-18|2009-03-19|Estimate|||||||2010-03-26|2010-03-29|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)|COPD: Transition of Systemic Inflammation Into Multiorgan Pathology (Study 3). (De Effecten Van Ontsteking op Skeletspieren Bij COPD)|Unknown status|Not yet recruiting||60|Anticipated|Top Institute Pharma|||2||f||||t||||||Samples With DNA|"~     Blood will be retained to investigate differences in candidate genes (SNPs) for COPD and CVD~     between the different groups.~   "|||2018-06-01 01:11:39.513131|2018-06-01 01:11:39.513131
NCT00864981|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2017-03-27|2009-03-18|2009-03-19|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2005||2005-09-30|March 2009|2009-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:11:39.581899|2018-06-01 01:11:39.581899
NCT00864968|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:39.632452|2018-06-01 01:11:39.632452
NCT00864955|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-09-02|2009-03-18|2009-03-19|Estimate|||||||2009-09-02|2009-09-03|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|DIMUVA||Cutaneous DNA Damage Caused by UV-A Irradiation|Damage to DNA Caused by UV-A Irradiation: Photochemical Mechanism and Cutaneous Parameters Involved in the Formation of Cyclobutane Pyrimidine Dimers|Completed||N/A|24|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 01:11:39.697121|2018-06-01 01:11:39.697121
NCT00864942|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2015-03-12|2009-03-18|2009-03-19|Estimate|||||||2015-03-12|2015-03-13|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Phase I BLR||Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)|Phase I Clinical Trial of Bendamustine, Lenalidomide and Rituximab in B-Cell Lymphoid Malignancies|Completed||Phase 1|28|Actual|Georgetown University||4|||f||||t||||||||||2018-06-01 01:11:39.770289|2018-06-01 01:11:39.770289
NCT00864929|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2011-02-15|2009-03-18|2009-03-19|Estimate|||||||2011-02-15|2011-02-16|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice|An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice|Completed|||1500|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:11:39.942155|2018-06-01 01:11:39.942155
NCT00864916|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2014-03-10||2014-04-28|2009-03-17|2009-03-19|Estimate|2014-03-10|2014-04-16|Estimate||||2014-04-28|2014-05-12|Estimate|March 2009||2009-03-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Completed enrollment visit|Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People|A Randomized, Placebo-Controlled Trial of Pentoxifylline Plus Combination ART vs. Combination ART Alone to Improve Endothelial Dysfunction in HIV-Infected Patients|Completed||Phase 2|19|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 01:11:40.03222|2018-06-01 01:11:40.03222
NCT00864903|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2017-05-14|2009-03-18|2009-03-19|Estimate|||||||2017-05-14|2017-05-16|Actual|April 2009||2009-04-30|March 2009|2009-03-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Observational|||A New Enzymatic Assay for Rapid Diagnosing of Central Nervous System Enteroviral Infection|A Comparison Between a New Experimental Enzymatic Assay to Real Time PCR for the Diagnosing of Central Nervous System Enteroviral Infection|Withdrawn|||0|Actual|Shaare Zedek Medical Center|||1|The enzymatic assay was not sensitive nor spesific for the test.|f||||f||||||Samples With DNA|"~     Cerebrospinal Fluid~   "|||2018-06-01 01:11:40.262585|2018-06-01 01:11:40.262585
NCT00864890|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|June 2003||2003-06-30|August 2010|2010-08-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditions|Single Dose Crossover Comparative Bioavailability Study of Citalopram 40 mg Tablets in Healthy Male Volunteers/Fed State|Completed||Phase 1|32|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:40.329038|2018-06-01 01:11:40.329038
NCT00864877|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|May 2009||2009-05-31|March 2009|2009-03-31||||April 2012|Anticipated|2012-04-30||Interventional|||Comparison of Biodegradable & Metal Plates for Fixing Ankle Fracture|A Randomised, Prospective Clinical Investigation to Compare Post-Operative Fracture Healing and Complication Rate After the Fixation of Ankle Fractures Using the Inion OTPS FreedomPlate Biodegradable Fixation System Versus Conventional Metal Screws and Plates.|Unknown status|Not yet recruiting|N/A|||Inion Oy|||||f||||f||||||||||2018-06-01 01:11:40.427468|2018-06-01 01:11:40.427468
NCT00864864|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2016-07-06|2009-03-17|2009-03-19|Estimate|||||||2016-07-06|2016-07-07|Estimate|May 2007||2007-05-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2011|Actual|2011-05-31||Interventional|||Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma|Pilot Study of Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma|Completed||Early Phase 1|8|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 01:11:40.488751|2018-06-01 01:11:40.488751
NCT00864838|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab|Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection|Completed||Phase 2|56|Actual|University of Sao Paulo||4|||f||||t||||||||||2018-06-01 01:11:42.032256|2018-06-01 01:11:42.032256
NCT00864825|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-05-06|2009-03-18|2009-03-19|Estimate|||||||2012-05-06|2012-05-08|Estimate|August 2009||2009-08-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia|Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia|Completed||Phase 4|248|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 01:11:42.108205|2018-06-01 01:11:42.108205
NCT00864812|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-03-29|2009-03-18|2009-03-19|Estimate|||||||2010-03-29|2010-03-31|Estimate|March 2009||2009-03-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea|A Randomized, Open Label, Multicenter, Phase 4 Study for the Comparison of Efficacy of Tiotropium Plus Salmeterol/ Fluticasone Propionate Compared With Tiotropium Alone in COPD Patients|Completed||Phase 4|509|Actual|The Korean Academy of Tuberculosis and Respiratory Diseases||2|||f||||f||||||||||2018-06-01 01:11:42.204873|2018-06-01 01:11:42.204873
NCT00864799|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2013-07-23|2009-03-18|2009-03-19|Estimate|||||||2013-07-23|2013-07-24|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Techniques to Improve Efficacy of Second Trimester Medical Termination|Comparison of 3 Regimens Using Mifepristone and Misoprostol for Second Trimester Pregnancy Interruption.|Completed||N/A|302|Actual|King Edward Memorial Hospital||3|||f||||f||||||||||2018-06-01 01:11:42.299237|2018-06-01 01:11:42.299237
NCT00864786|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-03-20|2009-03-18|2009-03-19|Estimate|||||||2009-03-20|2009-03-23|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study|A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration, Pharmacokinetics, And Pharmacodynamics Of Multiple Inhaled Doses Of PF-03635659 In Healthy Male Subjects.|Completed||Phase 1|50|Anticipated|Pfizer||5|||f||||f||||||||||2018-06-01 01:11:42.448673|2018-06-01 01:11:42.448673
NCT00864773|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy|Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab|Unknown status|Enrolling by invitation|N/A|10|Anticipated|Hallym University Medical Center|||||f||||t||||||||||2018-06-01 01:11:42.521079|2018-06-01 01:11:42.521079
NCT00864760|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|June 1999||1999-06-30|August 2010|2010-08-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Versus 400 mg Gabapentin Capsules Under Fasting Conditions|Completed||Phase 1|30|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:42.592507|2018-06-01 01:11:42.592507
NCT00864747|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|May 2005||2005-05-31|August 2010|2010-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 160 mg Propranolol Hydrochloride Extended Release Capsules Under Non-Fasting Conditions|Completed||Phase 1|60|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:42.666075|2018-06-01 01:11:42.666075
NCT00864734|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|November 2002||2002-11-30|August 2010|2010-08-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:42.748709|2018-06-01 01:11:42.748709
NCT00864721|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2014-05-19|2009-03-18|2009-03-19|Estimate|||||||2014-05-19|2014-05-21|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Sunitinib Non Small Cell Lung Cancer Patients Over 70|Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70|Completed||Phase 2|63|Actual|US Oncology Research||1|||f||||f||||||||||2018-06-01 01:11:42.841503|2018-06-01 01:11:42.841503
NCT00864708|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2013-11-25||2014-05-07|2009-03-18|2009-03-19|Estimate|2014-05-07|2014-05-26|Estimate||||2014-05-07|2014-05-26|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||This was a feasibility study to test an RFM Gait System for re-training gait coordination. Number of participants was limited to sponsor timeline.|Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008|Enhancing Function Using the RF Microstimulator Gait System Following Stroke 2008|Terminated||N/A|1|Actual|VA Office of Research and Development|Study sponsor, Alfred Mann foundation (AMF) stopped study because “enrollment period/study duration has exceeded the AMF’s timeline”.|1||The enrollment period/study duration had exceeded The Alfred Mann Foundation's timeline.|f||||t||||||||||2018-06-01 01:11:42.969282|2018-06-01 01:11:42.969282
NCT00864695|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Role of Anesthesiologist-Patient Relationship|Role of Anesthesiologist-Patient Relationship in Changing Postoperative Perception of Patients Admitted to a Teaching Hospital|Completed|||1137|Actual|UPECLIN HC FM Botucatu Unesp|||1||f||||t||||||||||2018-06-01 01:11:43.172499|2018-06-01 01:11:43.172499
NCT00864682|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2009-03-24||2012-02-04|2009-03-18|2009-03-19|Estimate|2009-06-15|2009-08-03|Estimate||||2012-02-04|2012-02-07|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Preventing Propofol-associated Injection Pain|Propofol Mixed With Lidocaine Versus Lidocaine Pretreatment With Tourniquet for Alleviation of Pain Associated With Propofol Injection|Completed||Phase 4|156|Actual|Benaroya Research Institute||3|||f||||t||||||||||2018-06-01 01:11:43.238574|2018-06-01 01:11:43.238574
NCT00864669|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|March 2002||2002-03-31|August 2010|2010-08-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 500 mg Metformin Hydrochloride Extended Release Tablets Under Non-Fasting Conditions|Completed||Phase 1|32|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:43.582716|2018-06-01 01:11:43.582716
NCT00864656|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-18|2009-03-18|2009-03-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 10% Phenylephrine|Comparative Study of Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 1, 2 or 4 Drops of 10% Phenylephrine|Completed|||60|Actual|University of Sao Paulo|||3||f||||t||||||||||2018-06-01 01:11:43.657666|2018-06-01 01:11:43.657666
NCT00864643|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2012-05-23|2009-03-18|2009-03-19|Estimate|||||||2012-05-23|2012-05-24|Estimate|September 2004||2004-09-30|May 2012|2012-05-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 (100 mg) Vs Placebo When Coadministered With Atorvastatin (10 or 20 mg) in Subjects With Primary Hypercholesterolemia|Completed||Phase 2|172|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:11:43.723266|2018-06-01 01:11:43.723266
NCT00864630|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2011-05-23|2009-03-18|2009-03-19|Estimate|||||||2011-05-23|2011-05-24|Estimate|September 2010||2010-09-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Neuroimaging for Depression|Objective Detection, Evaluation and Countermeasures for In-flight Depression|Terminated||N/A|68|Anticipated|Massachusetts General Hospital||2||"The study upon which this project depended for subjects and the intervention was terminated~   prematurely due to lack of funds."|f||||f||||||||||2018-06-01 01:11:43.793273|2018-06-01 01:11:43.793273
NCT00864617|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|May 2005||2005-05-31|August 2010|2010-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Non-Fasting Conditions|Completed||Phase 1|84|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:43.861176|2018-06-01 01:11:43.861176
NCT00864604|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-18|||2010-08-13|2009-03-18|2009-03-19|Estimate|||||||2010-08-13|2010-08-17|Estimate|April 2007||2007-04-30|August 2010|2010-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers|Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers|Completed||Phase 1|30|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:43.933981|2018-06-01 01:11:43.933981
NCT00864591|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|October 2010|Anticipated|2010-10-31|April 2010|Anticipated|2010-04-30||Observational|||Stress Adenosine Cardiac Magnetic Resonance (MR) Comparison With Single Photon Emission Computed Tomography (SPECT) Imaging|Stress Adenosine Cardiac MR Comparison With SPECT Imaging|Unknown status|Not yet recruiting||50|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 01:11:43.998912|2018-06-01 01:11:43.998912
NCT00864578|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-06-05|2009-03-17|2009-03-18|Estimate|||||||2012-06-05|2012-06-06|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Observational|||Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy|Effects of the Oral Administration of an Association of Forskolin With Rutin and Vitamins B on Intraocular Pressure (IOP) in Patients Affected by Primary Open Angle Glaucoma (POAG) Under Maximun Tolerated Medical Therapy (MTMT)|Withdrawn|||0|Actual|Sooft Italia||||loss of interest before enrolment started|f||||t||||||||||2018-06-01 01:11:44.072441|2018-06-01 01:11:44.072441
NCT00864565|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|June 2003||2003-06-30|August 2010|2010-08-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System|Randomized, 2-way Crossover, Bioequivalence Study of Fentanyl 25 μg/h Transdermal System and Duragesic 25 μg/h Transdermal System Administrated as 1 x 25 μg/h Single Application in the Healthy Subjects|Completed||Phase 1|48|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:44.132158|2018-06-01 01:11:44.132158
NCT00864552|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-06-29|2009-03-17|2009-03-18|Estimate|||||||2009-06-29|2009-06-30|Estimate|December 2002||2002-12-31|June 2009|2009-06-30|December 2005|Actual|2005-12-31|||||Observational|||International PMS Study - KOGENATE Bayer|International PMS Study - KOGENATE Bayer|Completed|||200|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:11:44.308132|2018-06-01 01:11:44.308132
NCT00864539|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2010-07-27||2011-11-12|2009-03-17|2009-03-18|Estimate|2010-09-07|2010-09-28|Estimate||||2011-11-12|2011-11-21|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|June 2010|Actual|2010-06-30|February 2009|Actual|2009-02-28||Interventional|||Comparison of the Efficacy of Calcium-cholecalciferol Foodstuffs and Calcium-cholecalciferol Supplement|The Prevalence of Vitamin D Insufficiency in Primary School Children and Comparison of the Effect of Calcium-Vitamin D-Fortified Milk, -Orange Juice and Calcium-Vitamin D Supplement|Completed||Phase 2/Phase 3|585|Actual|National Nutrition and Food Technology Institute|Because of very cold winter, it was not possible to extend the intervention period to 12 weeks or longer. Moreover, it was impossible to fortify the foodstuffs with more than 50% of RDA(recommended daily allowance) because of legal problems.|6|||f||||f||||||||||2018-06-01 01:11:44.398355|2018-06-01 01:11:44.398355
NCT00864526|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-17|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:44.778578|2018-06-01 01:11:44.778578
NCT00864513|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2011-03-24||2015-12-07|2009-03-17|2009-03-18|Estimate|2015-12-07|2015-12-08|Estimate||||2015-12-07|2015-12-08|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study of Pemetrexed for Second-Line Pancreas Cancer|A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine|Terminated||Phase 2|17|Actual|Georgetown University|study was closed at interim analysis so only 12 subjects were evaluable for response, 15 subjects received treatment and were evaluable for adverse events|1||At interim analysis the study did not meet the response criteria to continue|f||||t||||||||||2018-06-01 01:11:44.858091|2018-06-01 01:11:44.858091
NCT00864500|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|November 2005||2005-11-30|August 2010|2010-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects|Bioequivalence of Two Clobetasol Propionate 0.05% Topical Lotions|Completed||Phase 1|224|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:45.100326|2018-06-01 01:11:45.100326
NCT00864487|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-05-10|2009-03-17|2009-03-18|Estimate|||||||2012-05-10|2012-05-14|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib|A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Neratinib When Administered Concomitantly to Healthy Subjects|Completed||Phase 1|24|Actual|Puma Biotechnology, Inc.||2|||f||||f||||||||||2018-06-01 01:11:45.176797|2018-06-01 01:11:45.176797
NCT00864474|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2018-01-22|2009-03-17|2009-03-18|Estimate|||||||2018-01-22|2018-01-24|Actual|March 31, 2010|Actual|2010-03-31|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation For Hiv Infection Patients Of Maraviroc (Regulatory Post Marketing Commitment Plan).|Active, not recruiting|||50|Anticipated|ViiV Healthcare|||1||f||||f|t|f|||f|||||2018-06-01 01:11:45.238652|2018-06-01 01:11:45.238652
NCT00864461|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2017-05-02|2009-03-17|2009-03-18|Estimate|||||||2017-05-02|2017-05-05|Actual|September 1, 2009|Actual|2009-09-01|May 2017|2017-05-31|March 31, 2010|Actual|2010-03-31|December 21, 2009|Actual|2009-12-21||Observational|||Frequency of Metabolic Syndrome in Down Syndrome Patients|Prevalence of Metabolic Syndrome in Down Syndrome Patients|Completed|||96|Actual|Universidad de Guanajuato|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|No||2018-06-01 01:11:45.304911|2018-06-01 01:11:45.304911
NCT00864448|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2004||2004-10-31|August 2010|2010-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Under Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:45.363795|2018-06-01 01:11:45.363795
NCT00864435|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2005||2005-10-31|August 2010|2010-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single Dose, Fasting, Bioequivalence Study of Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets in Normal, Healthy, Non-Smoking Male and Female Subjects|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:45.438369|2018-06-01 01:11:45.438369
NCT00864422|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Changes in Motor Cortex Following Exercises for Chronic Low Back Pain|Driving Plasticity in the Motor Brain in Chronic Back Pain|Completed||Phase 1|20|Actual|The University of Queensland||2|||f||||f||||||||||2018-06-01 01:11:45.509139|2018-06-01 01:11:45.509139
NCT00864409|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate||||March 2009|2009-03-31||||||||Interventional|||Local Infiltration Analgesia With Ropivacaine Versus Placebo in Bilateral Hip Arthroplasty||Unknown status|Recruiting|Phase 4|12|Anticipated|Hvidovre University Hospital||2|||f||||||||||||||2018-06-01 01:11:45.584415|2018-06-01 01:11:45.584415
NCT00864396|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2017-03-22|2009-03-17|2009-03-18|Estimate|||||||2017-03-22|2017-03-27|Actual|July 2005||2005-07-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux|Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux: A Double-Blind, Placebo Controlled, Randomized Clinical Trial|Completed||Phase 1|59|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 01:11:45.678177|2018-06-01 01:11:45.678177
NCT00864383|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2015-03-10||2017-02-15|2009-03-17|2009-03-18|Estimate|2015-05-07|2015-05-25|Estimate||||2017-02-15|2017-03-21|Actual|January 2008||2008-01-31|February 2017|2017-02-28|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|REMoxTB|Per protocol population|Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis|A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis|Completed||Phase 3|1931|Actual|Global Alliance for TB Drug Development||3|||f||||t||||||||||2018-06-01 01:11:45.844149|2018-06-01 01:11:45.844149
NCT00864370|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2013-11-12|2009-03-17|2009-03-18|Estimate|||||||2013-11-12|2013-11-13|Estimate|May 2005||2005-05-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|January 2011|Actual|2011-01-31||Observational|||Bipolar Disorder (BPD) in Pregnancy: Predictors of Morbidity|Bipolar Disorder in Pregnancy: Predictors of Morbidity|Completed|||237|Actual|Emory University|||||f||||t||||||Samples With DNA|"~     Plasma, serum and urine samples are processed and stored at each research visit.~   "|||2018-06-01 01:11:48.043179|2018-06-01 01:11:48.043179
NCT00864357|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-17|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting Conditions|A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:48.109677|2018-06-01 01:11:48.109677
NCT00864344|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|August 2004||2004-08-31|August 2010|2010-08-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fasting Conditions|Completed||Phase 1|30|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:48.224131|2018-06-01 01:11:48.224131
NCT00864331|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2013-08-06|2009-03-17|2009-03-18|Estimate|||||||2013-08-06|2013-08-07|Estimate|February 2008||2008-02-29|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy|Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy|Completed||Phase 3|251|Actual|International Atomic Energy Agency||4|||f||||t||||||||||2018-06-01 01:11:48.291541|2018-06-01 01:11:48.291541
NCT00864318|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2018-03-01|2009-03-17|2009-03-18|Estimate|||||||2018-03-01|2018-03-02|Actual|March 13, 2009|Actual|2009-03-13|March 2018|2018-03-31|September 2029|Anticipated|2029-09-30|September 2021|Anticipated|2021-09-30||Interventional|TICE||Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis|Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.|Active, not recruiting||Phase 2|101|Actual|Institut Claudius Regaud|||||f||||t||||||||||2018-06-01 01:11:48.45299|2018-06-01 01:11:48.45299
NCT00864305|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-17|Estimate|December 1997||1997-12-31|August 2010|2010-08-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions|A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions|Completed||Phase 1|18|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:48.554157|2018-06-01 01:11:48.554157
NCT00864292|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2011-05-02|2009-03-17|2009-03-18|Estimate|||||||2011-05-02|2011-05-03|Estimate|August 2007||2007-08-31|March 2009|2009-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Predictors of Neuro-cognitive Decline and Survival in HIV-infected Subjects||Completed|||60|Actual|South East Asia Research Collaboration with Hawaii|||2||f||||f||||||||||2018-06-01 01:11:48.647664|2018-06-01 01:11:48.647664
NCT00864279|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:48.734576|2018-06-01 01:11:48.734576
NCT00864266|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2018-01-30|2009-03-17|2009-03-18|Estimate|||||||2018-01-30|2018-01-31|Actual|March 2009||2009-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer|Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer : a Prospective Study|Active, not recruiting||N/A|70|Anticipated|European Lung Cancer Working Party||1|||f||||t||||||||Undecided||2018-06-01 01:11:48.831393|2018-06-01 01:11:48.831393
NCT00864253|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2014-04-16|2013-08-06|2017-04-24|2009-03-17|2009-03-18|Estimate|2014-05-13|2014-06-05|Estimate|2013-08-06|2013-08-12|Estimate|2017-04-24|2017-04-26|Actual|April 2009||2009-04-30|April 2017|2017-04-30|February 2014|Actual|2014-02-28|June 2012|Actual|2012-06-30||Interventional||Intent-to-Treat (ITT) Population: The ITT population consisted of all randomized participants regardless of whether the participant received any study drug or had any efficacy assessments collected.|A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma|An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma|Completed||Phase 3|529|Actual|Celgene|Participation in the PK sampling for participants randomized to the ABI-007 arm was optional; too few samples were available to support the analysis|2|||f||||t||||||||||2018-06-01 01:11:48.975263|2018-06-01 01:11:48.975263
NCT00864240|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2005||2005-10-31|August 2010|2010-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||"The Dose-response Pilot Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects"|Dose Response of Clobex 0.05% Lotion|Completed||Phase 1|15|Actual|Actavis Inc.||1|||f||||f||||||||||2018-06-01 01:11:50.034842|2018-06-01 01:11:50.034842
NCT00864227|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2015-05-20||2017-09-27|2009-03-17|2009-03-18|Estimate|2015-07-30|2015-08-28|Estimate||||2017-09-27|2017-10-27|Actual|December 2008||2008-12-31|August 2016|2016-08-31|November 2013|Actual|2013-11-30|April 2011|Actual|2011-04-30||Interventional|||Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)|A Multi-Center, Phase II Trial of Non-Myeloablative Conditioning (NST) and Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies (BMT CTN #0604)|Completed||Phase 2|54|Actual|Medical College of Wisconsin||1|||f||||t||||||||Yes|Findings will be published in a manuscript.|2018-06-01 01:11:50.117056|2018-06-01 01:11:50.117056
NCT00864214|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-01-12|2009-03-17|2009-03-18|Estimate|||||||2012-01-12|2012-01-16|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|HRT||A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone|A Pharmacokinetic Evaluation of Bioidentical Compounded Estrogen Cream and Natural Progesterone|Completed||Phase 1|40|Actual|Mayo Clinic||4|||f||||t||||||||||2018-06-01 01:11:50.593531|2018-06-01 01:11:50.593531
NCT00864201|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease|A Pilot Study to Evaluate the Effect of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease|Unknown status|Not yet recruiting|Phase 3|10|Anticipated|McMaster University||1|||f||||f||||||||||2018-06-01 01:11:50.672853|2018-06-01 01:11:50.672853
NCT00864188|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2013-05-15|2009-03-17|2009-03-18|Estimate|||||||2013-05-15|2013-05-16|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||The Influence of Probiotics in a Drinkable Yogurt on Skin Health|Phase 1 The Influence of Probiotics in a Drinkable Yogurt on Skin Health|Completed||Phase 1|207|Actual|Nestlé||5|||f||||f||||||||||2018-06-01 01:11:50.741418|2018-06-01 01:11:50.741418
NCT00864175|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26||2010-06-18|2018-01-16|2009-03-17|2009-03-18|Estimate||||2010-06-18|2010-06-22|Estimate|2018-01-16|2018-01-18|Actual|July 2007||2007-07-31|January 2018|2018-01-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer|A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|68|Actual|Incyte Corporation||4||Incyte suspended development of the compound.|f||||f||||||||||2018-06-01 01:11:50.806244|2018-06-01 01:11:50.806244
NCT00864162|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|September 2004||2004-09-30|August 2010|2010-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Under Fed Conditions|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:50.89005|2018-06-01 01:11:50.89005
NCT00864149|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2005||2005-10-31|August 2010|2010-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions|A Two-Way Crossover, Open-Label, Single Dose, Fed, Bioequivalence Study of Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets in Normal, Healthy, Non-Smoking Male and Female Subjects|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:50.955823|2018-06-01 01:11:50.955823
NCT00864136|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2015-06-30|2009-03-17|2009-03-18|Estimate|||||||2015-06-30|2015-07-01|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Mirena or Conventional Medical Treatment for Menorrhagia|MiCo - Mirena or Conventional Medical Treatment for Menorrhagia|Completed|||647|Actual|Bayer|||3||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 01:11:51.024683|2018-06-01 01:11:51.024683
NCT00864123|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2012-06-26||2012-09-14|2009-03-17|2009-03-18|Estimate|2012-09-14|2012-10-17|Estimate||||2012-09-14|2012-10-17|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder|D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder|Completed||Phase 2|30|Actual|University of South Florida||2|||f||||f||||||||||2018-06-01 01:11:51.118766|2018-06-01 01:11:51.118766
NCT00864110|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2013-03-20|2009-03-17|2009-03-18|Estimate|||||||2013-03-20|2013-03-22|Estimate|April 2010||2010-04-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)|A Multi-Center Phase 1b Pharmacokinetic and Radiation Dosimetry Study Evaluating 99mTc-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|4|Actual|Cell>Point LLC||2|||f||||t||||||||||2018-06-01 01:11:51.369469|2018-06-01 01:11:51.369469
NCT00864097|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17||2012-01-26|2015-03-04|2009-03-17|2009-03-18|Estimate||||2012-02-02|2012-02-07|Estimate|2015-03-04|2015-03-24|Estimate|August 2009||2009-08-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip|A Phase 3, Randomized, Double-Blind, Controlled, Multi-Center Study Of The Analgesic Efficacy And Safety Of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip|Terminated||Phase 3|607|Actual|Pfizer||4||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:11:51.448325|2018-06-01 01:11:51.448325
NCT00864084|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2013-09-30||2014-08-26|2009-03-17|2009-03-18|Estimate|2014-08-01|2014-08-20|Estimate||||2014-08-26|2014-09-05|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Does Pulmonary Rehabilitation Improve Balance in People With Respiratory Disease?|Does a Pulmonary Rehabilitation Program Improve Balance in Individuals With Respiratory Disease?|Completed||Phase 1|14|Actual|University of Manitoba|This sample size in this study was small. Study participants received an individualised exercise program which means that exercises given and number of pulmonary rehabilitation sessions attended were not standardized between study participants.|1|||f||||f||||||||||2018-06-01 01:11:52.573243|2018-06-01 01:11:52.573243
NCT00864071|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|November 2005||2005-11-30|August 2010|2010-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Female Subjects|Completed||Phase 1|50|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:52.849143|2018-06-01 01:11:52.849143
NCT00864058|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-17|Estimate|January 1998||1998-01-31|August 2010|2010-08-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions|A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions|Completed||Phase 1|30|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:53.749725|2018-06-01 01:11:53.749725
NCT00864045|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2013-09-19|2009-03-17|2009-03-18|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Sertindole in Asian Patients With Schizophrenia|A Randomised, Double-blind, Parallel-group, Flexible-dose Trial Evaluating the Efficacy and Safety of 12 Weeks of Treatment With Sertindole or Olanzapine in Patients With Schizophrenia in Asia|Completed||Phase 3|394|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:11:53.82399|2018-06-01 01:11:53.82399
NCT00864032|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2013-01-15||2013-04-09|2009-03-17|2009-03-18|Estimate|2013-04-09|2013-04-10|Estimate||||2013-04-09|2013-04-10|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall|Phase I/II Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall|Completed||Phase 1/Phase 2|8|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 01:11:53.907999|2018-06-01 01:11:53.907999
NCT00864019|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|August 2004||2004-08-31|August 2010|2010-08-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Sertraline 100 mg Tablets Under Fed Conditions|Completed||Phase 1|30|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:54.104739|2018-06-01 01:11:54.104739
NCT00864006|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2017-03-27|2009-03-17|2009-03-18|Estimate|||||||2017-03-27|2017-03-29|Actual|October 2006||2006-10-31|March 2009|2009-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting Conditions|Completed||Phase 1|28|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:11:54.311654|2018-06-01 01:11:54.311654
NCT00863993|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2015-02-11|2009-03-17|2009-03-18|Estimate|||||||2015-02-11|2015-02-12|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Energy Expenditure and Gastric Bypass Surgery|Energy Expenditure and Gastric Bypass Surgery|Withdrawn|||0|Actual|Mayo Clinic||||no patients enrolled.|f||||t||||||||||2018-06-01 01:11:54.395991|2018-06-01 01:11:54.395991
NCT00863616|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|August 2006||2006-08-31|March 2009|2009-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||High Frequency Chest Wall Oscillation in Chronic Obstructive Pulmonary Disease (COPD)|Self-Administered High Frequency Chest Wall Oscillation Technique for Mucus Clearance in COPD: An Exploratory Pilot Project Using the SMARTVEST Device|Completed||N/A|32|Actual|East and North Hertfordshire NHS Trust||2|||f||||t||||||||||2018-06-01 01:12:05.037149|2018-06-01 01:12:05.037149
NCT00863980|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2015-09-01|2009-03-17|2009-03-18|Estimate|||||||2015-09-01|2015-09-03|Estimate|April 2009||2009-04-30|September 2015|2015-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|KCPS||Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients|Effects of Telmisartan Compared With Candesartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients: a Multi-center, Prospective, Randomized, Open-labeled, Blinded Endpoints Trial|Terminated||N/A|1500|Actual|Kyoto Prefectural University of Medicine||2||Principle investigator resigned in 2013|f||||t||||||||||2018-06-01 01:11:54.540241|2018-06-01 01:11:54.540241
NCT00863967|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|October 2003||2003-10-31|March 2009|2009-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Early Detection of Arteriosclerosis|Prospective Observational Cohort Study for Early Detection of Arteriosclerosis|Unknown status|Active, not recruiting||269|Actual|Kantonsspital Baselland Bruderholz|||3||f||||f||||||Samples With DNA|"~     Whole blood / serum / white cells / plasma~   "|||2018-06-01 01:11:54.676936|2018-06-01 01:11:54.676936
NCT00863954|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-12-14|2009-03-17|2009-03-18|Estimate|||||||2010-12-14|2010-12-15|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Application of Magnetic Fields as Adjunctive Treatment for Type II Diabetes|A Controlled Pilot Study of the Application of Magnetic Fields Using the Resonator in Adjunctive Management of Type 2 Diabetes|Completed||Phase 1|60|Anticipated|pico-tesla Magnetic Therapies, LLC||6|||f||||t||||||||||2018-06-01 01:11:54.755053|2018-06-01 01:11:54.755053
NCT00863941|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-19|2009-03-17|2009-03-18|Estimate|||||||2010-08-19|2010-08-23|Estimate|June 2004||2004-06-30|August 2010|2010-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions|A Randomized, Single Dose Two -Way Crossover Relative Bioavailability Study of Bupropion XL Tablets Formulation in Fasted, Normal, Healthy Subjects.|Completed||Phase 1|28|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:54.823156|2018-06-01 01:11:54.823156
NCT00863928|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-05-25|2009-03-17|2009-03-18|Estimate|||||||2010-05-25|2010-05-26|Estimate||||May 2010|2010-05-31||||||||Interventional|||Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain and Morphine Consumption on Patients After Robotic Assisted Laparoscopic Radical Prostatectomy|Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain and Morphine Consumption on Patients After Robotic Assisted Laparoscopic Radical Prostatectomy|Completed||N/A|||Benaroya Research Institute|||||f||||||||||||||2018-06-01 01:11:54.906548|2018-06-01 01:11:54.906548
NCT00863915|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2004||2004-10-31|August 2010|2010-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Ramipril10 mg Capsules Administered Orally as a Sprinkle on Applesauce|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:54.987483|2018-06-01 01:11:54.987483
NCT00863902|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers|Completed||Phase 1|26|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:55.065919|2018-06-01 01:11:55.065919
NCT00863889|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2013-09-19|2009-03-17|2009-03-18|Estimate|||||||2013-09-19|2013-09-23|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome|Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|Emory University||2|||f||||f||||||||||2018-06-01 01:11:55.139218|2018-06-01 01:11:55.139218
NCT00863876|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-06-28|2009-03-17|2009-03-18|Estimate|||||||2010-06-28|2010-06-29|Estimate|March 2009||2009-03-31|June 2010|2010-06-30||||||||Observational|||Comparison of WaveLight Analyzer and Alcon LadarWave||Completed|||144|Anticipated|WaveLight AG|||9||f||||t||||||||||2018-06-01 01:11:55.22074|2018-06-01 01:11:55.22074
NCT00863863|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-08-13|2009-03-17|2009-03-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|January 2006||2006-01-31|August 2010|2010-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Female Subjects|Completed||Phase 1|40|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:11:55.27531|2018-06-01 01:11:55.27531
NCT00863850|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-04-20|2009-03-17|2009-03-18|Estimate|||||||2012-04-20|2012-04-23|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Pharmacokinetics of Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy|Open-Label Study to Investigate the Pharmacokinetics of Bendamustine Hydrochloride Following Intravenous Infusion of [14C] Bendamustine Hydrochloride in Patients With Relapsed or Refractory Malignancy|Completed||Phase 1|6|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 01:11:55.355782|2018-06-01 01:11:55.355782
NCT00863837|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Prevention of Esophageal Variceal Rebleeding||Unknown status|Enrolling by invitation|Phase 4|120|Anticipated|National Science Council, Taiwan||2|||f||||f||||||||||2018-06-01 01:11:55.424476|2018-06-01 01:11:55.424476
NCT00863824|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2017-09-09|2009-03-17|2009-03-18|Estimate|||||||2017-09-09|2017-09-12|Actual|July 2009||2009-07-31|September 2017|2017-09-30|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Observational|NNAL||NNAL Clearance in Hair and Urine|Elimination of NNAL and Cotinine From Hair and Urine|Withdrawn|||0|Actual|University of Nebraska||||Study was not funded|f||||f||||||||||2018-06-01 01:11:55.481896|2018-06-01 01:11:55.481896
NCT00863811|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-06-05|2009-03-17|2009-03-18|Estimate|||||||2012-06-05|2012-06-06|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Observational|||Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Treatment With Either Beta-blockers or Prostaglandins Eye Drops|Effects of the Oral Administration of an Association of Forskolin With Rutin and Vitamins B on Intraocular Pressure in Patients Affected by Primary Open Angle Glaucoma and Treated With Either Beta-blockers or Prostaglandin Eye Drops|Withdrawn|||0|Actual|Sooft Italia|||2|loss of interest before enrolment started|f||||t||||||||||2018-06-01 01:11:55.530482|2018-06-01 01:11:55.530482
NCT00863798|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2011-03-08||2011-04-07|2009-03-17|2009-03-18|Estimate|2011-04-07|2011-05-06|Estimate||||2011-04-07|2011-05-06|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|682|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 01:11:55.787164|2018-06-01 01:11:55.787164
NCT00863785|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-10-19|2009-03-17|2009-03-18|Estimate|||||||2009-10-19|2009-10-20|Estimate|April 2004||2004-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|HAA-NAC||Treatment of Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone|Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study.|Completed||Phase 3|174|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||t||||||||||2018-06-01 01:11:57.371363|2018-06-01 01:11:57.371363
NCT00863772|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17||2012-01-27|2012-08-20|2009-03-17|2009-03-18|Estimate||||2012-08-20|2012-08-29|Estimate|2012-08-20|2012-08-29|Estimate|May 2009||2009-05-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Tanezumab and Nerve Function In Arthritis Patients|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of Tanezumab On Peripheral Nerve Function In Patients With Osteoarthritis|Terminated||Phase 3|220|Actual|Pfizer||3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:11:57.556436|2018-06-01 01:11:57.556436
NCT00863759|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2010-07-01|2009-03-17|2009-03-18|Estimate|||||||2010-07-01|2010-07-02|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Wavefront Analysis and Contrast Sensitivity After Cataract Surgery With Akreos Advanced Optics Intraocular Lens Implantation|Wavefront Analysis and Contrast Sensitivity After Cataract Surgery With Akreos AO Intraocular Lens Implantation: Clinical Comparative Study|Completed||N/A|25|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 01:11:57.64154|2018-06-01 01:11:57.64154
NCT00863746|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2013-04-10||2015-01-07|2009-03-17|2009-03-18|Estimate|2013-06-23|2013-07-30|Estimate||||2015-01-07|2015-01-19|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|April 2013|Actual|2013-04-30|March 2012|Actual|2012-03-31||Interventional|MISSION||A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).|A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease|Completed||Phase 3|703|Actual|Bayer||2|||f||||t||||||||||2018-06-01 01:11:57.806479|2018-06-01 01:11:57.806479
NCT00863733|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|May 1996||1996-05-31|March 2009|2009-03-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|DMXAA||Study of DMXAA (Now Known as ASA404) in Solid Tumors|Phase I Trial of 5,6 Dimethylxanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors|Completed||Phase 1|63|Actual|Cancer Research UK|||||f||||f||||||||||2018-06-01 01:11:58.929973|2018-06-01 01:11:58.929973
NCT00863707|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2010-12-28||2012-05-11|2009-03-16|2009-03-18|Estimate|2010-12-28|2011-01-31|Estimate||||2012-05-11|2012-05-18|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment|A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment|Completed||Phase 4|511|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||f||||||||||2018-06-01 01:11:59.032242|2018-06-01 01:11:59.032242
NCT00863694|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2013-12-12|2009-03-17|2009-03-18|Estimate|||||||2013-12-12|2013-12-13|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Fecal Calprotectin in Cystic Fibrosis|Fecal Calprotectin in Cystic Fibrosis|Completed|||106|Actual|Medical College of Wisconsin|||||f||||f||||||Samples Without DNA|"~     stool~   "|||2018-06-01 01:11:59.671953|2018-06-01 01:11:59.671953
NCT00863681|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2018-05-03|2009-03-17|2009-03-18|Estimate|||||||2018-05-03|2018-05-04|Actual|March 12, 2009|Actual|2009-03-12|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PATENT-2||BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension|Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)|Active, not recruiting||Phase 3|396|Actual|Bayer||1|||f||||t|t|f||||||||2018-06-01 01:11:59.962861|2018-06-01 01:11:59.962861
NCT00863668|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2015-05-14|2009-03-17|2009-03-18|Estimate|||||||2015-05-14|2015-05-18|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Raltegravir Activity In Lymphoid Tissues|Decay Kinetics of HIV With the Integrase Inhibitor Raltegravir|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 01:12:00.524131|2018-06-01 01:12:00.524131
NCT00863655|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2012-07-31||2017-03-21|2009-03-17|2009-03-18|Estimate|2012-07-31|2012-08-31|Estimate||||2017-03-21|2017-05-02|Actual|June 3, 2009|Actual|2009-06-03|March 2017|2017-03-31|December 4, 2014|Actual|2014-12-04|December 4, 2014|Actual|2014-12-04||Interventional|BOLERO-2||Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole|A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole|Completed||Phase 3|724|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:12:01.110314|2018-06-01 01:12:01.110314
NCT00863642|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2011-09-25|2009-03-17|2009-03-18|Estimate|||||||2011-09-25|2011-09-27|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Early Versus Delayed Surgery for Gallstone Pancreatitis|Early Versus Delayed Surgery for Gallstone Pancreatitis: A Prospective Randomized|Completed||N/A|100|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-06-01 01:12:04.793005|2018-06-01 01:12:04.793005
NCT00863629|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-03-17|2009-03-17|2009-03-18|Estimate|||||||2009-03-17|2009-03-18|Estimate|January 2001||2001-01-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||Tight Glycemic Control Increases Cardiac Stem Cells During Acute Myocardial Infarction|Tight Glycemic Control Increases Cardiac Stem Cells and Reduces Heart Remodeling During Acute Myocardial Infarction in Hyperglycemic Patients|Completed||Phase 4|65|Actual|"University of Campania Luigi Vanvitelli"||3|||f||||t||||||||||2018-06-01 01:12:04.870912|2018-06-01 01:12:04.870912
NCT00863603|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-05-23|2009-03-16|2009-03-18|Estimate|||||||2012-05-23|2012-05-25|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||"The Effect of Oxygen on Healing an Artery From the Injury of Surgery"|Artery Wall Hypoxia and Intimal Hyperplasia|Terminated||N/A|46|Actual|University of Minnesota - Clinical and Translational Science Institute||2||"Clinical changes: graft to fistula first; enrollment of 46/132 planned. NIH approved animal~   model: supplemental oxygen/AV fistula."|f||||f||||||||||2018-06-01 01:12:05.229931|2018-06-01 01:12:05.229931
NCT00863590|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2015-08-18|2009-03-16|2009-03-18|Estimate|||||||2015-08-18|2015-08-19|Estimate|June 2004||2004-06-30|August 2015|2015-08-31|August 2008|Actual|2008-08-31|February 2005|Actual|2005-02-28||Interventional|||A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Single Oral Rising-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK0822 in Healthy Volunteers|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 01:12:05.317136|2018-06-01 01:12:05.317136
NCT00863577|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-03-17|2009-03-17|2009-03-18|Estimate|||||||2011-03-17|2011-03-18|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Pharmacokinetic Study of Two Oral Bemiparin Formulations||Completed||Phase 1|102|Actual|Rovi Pharmaceuticals Laboratories|||||f||||f||||||||||2018-06-01 01:12:05.419032|2018-06-01 01:12:05.419032
NCT00863564|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2009-11-09|2009-03-17|2009-03-18|Estimate|||||||2009-11-09|2009-11-10|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Acute Effects of Dietary Proteins on Postprandial Lipemia, Incretin Responses and Subclinical Inflammation in Obese Subjects|Acute Effects of Dietary Proteins on Postprandial Lipemia, Incretin Responses and Subclinical Inflammation in Obese Subjects|Completed||N/A|12|Anticipated|Aarhus University Hospital||4|||f||||f||||||||||2018-06-01 01:12:05.534726|2018-06-01 01:12:05.534726
NCT00863551|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2011-11-16||2016-01-28|2009-03-16|2009-03-18|Estimate|2011-11-16|2011-12-19|Estimate||||2016-01-28|2016-02-26|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial||Completed||Phase 4|12|Actual|Allergan|Due to technical problems associated with the administration of the BVMT-R test, the results were invalid, therefore, results for Outcome Measures 4 and 5 are not presented.|1|||f||||||||||||||2018-06-01 01:12:05.752312|2018-06-01 01:12:05.752312
NCT00863538|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2010-02-01|2009-03-17|2009-03-18|Estimate|||||||2010-02-01|2010-02-03|Estimate||||February 2010|2010-02-28||||||||Interventional|||Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)|An Open-label, Phase II Study of KPS-0373 in Patients With SCD|Completed||Phase 2|40|Anticipated|Kissei Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:12:06.132181|2018-06-01 01:12:06.132181
NCT00863525|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2015-08-18|2009-03-16|2009-03-18|Estimate|||||||2015-08-18|2015-08-19|Estimate|November 2004||2004-11-30|August 2015|2015-08-31|June 2006|Actual|2006-06-30|December 2004|Actual|2004-12-31||Interventional|||A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)|A Double-Blind, Randomized, 2-Period Crossover, Placebo Controlled Study to Asses the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MK0822|Completed||Phase 1|8|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:12:06.229138|2018-06-01 01:12:06.229138
NCT00863512|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2016-12-13||2017-02-07|2009-03-17|2009-03-18|Estimate|2017-02-07|2017-03-27|Actual||||2017-02-07|2017-03-27|Actual|March 2009||2009-03-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer|A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data|Terminated||Phase 3|34|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 01:12:06.374139|2018-06-01 01:12:06.374139
NCT00863499|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2016-07-20|2009-03-17|2009-03-18|Estimate|||||||2016-07-20|2016-07-22|Estimate|October 2009||2009-10-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Interventional|||International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder|International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder.|Recruiting||Phase 4|1344|Anticipated|BRC Operations Pty. Ltd.||3|||f||||f||||||||||2018-06-01 01:12:07.895753|2018-06-01 01:12:07.895753
NCT00863486|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-02-22|2009-03-17|2009-03-18|Estimate|||||||2010-02-22|2010-02-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:12:08.040196|2018-06-01 01:12:08.040196
NCT00863473|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2015-04-22|2009-03-17|2009-03-18|Estimate|||||||2015-04-22|2015-04-23|Estimate|May 2003||2003-05-31|April 2015|2015-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comminuted Proximal Humeral Fractures. A Randomised Study of Surgical Versus Conservative Treatment|Health and Cost Consequenses of Surgical Versus Conservative Treatment for a Comminuted Humerus Fracture. Do Interlocking Plate Surgery Benefit Displaced Proximal Humerus Fractures? A Randomized Clinical Trial|Completed||Phase 2|50|Actual|Oslo University Hospital||2|||f||||||||||||||2018-06-01 01:12:08.162423|2018-06-01 01:12:08.162423
NCT00863460|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2018-03-07|2009-03-17|2009-03-18|Estimate|||||||2018-03-07|2018-03-09|Actual|October 3, 2008|Actual|2008-10-03|March 2018|2018-03-31|May 2026|Anticipated|2026-05-31|May 17, 2016|Actual|2016-05-17||Interventional|PRECIS||Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients|Prospective , Multicentric, Randomized Phase II Study, Evaluating the Role of Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue After Conventional Chemotherapy for Primary Central Nervous System in Young Patients (< 60 y)|Active, not recruiting||Phase 2|140|Actual|Institut Curie||2|||f||||t|f|f||||||Undecided||2018-06-01 01:12:08.265487|2018-06-01 01:12:08.265487
NCT00863447|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-03-16|2009-03-16|2009-03-18|Estimate|||||||2009-03-16|2009-03-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:12:08.628614|2018-06-01 01:12:08.628614
NCT00863434|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2017-03-04||2017-05-04|2009-03-17|2009-03-18|Estimate|2017-05-04|2017-05-15|Actual||||2017-05-04|2017-05-15|Actual|February 2009||2009-02-28|May 2017|2017-05-31||||February 2011|Actual|2011-02-28||Interventional|||Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease|A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia|Terminated||Phase 2|2|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 01:12:08.708044|2018-06-01 01:12:08.708044
NCT00863421|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2011-06-15|2009-03-17|2009-03-18|Estimate|||||||2011-06-15|2011-06-16|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Observational|VISIFA||Sleep Disordered Breathing in Patients With Chronic Heart Failure|Prevalence, Incidence and Clinical Characteristics of Sleep Disordered Breathing in Patients With Stable Chronic Heart Failure|Unknown status|Recruiting||200|Anticipated|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|||||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 01:12:09.079594|2018-06-01 01:12:09.079594
NCT00863408|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2017-06-30|2009-03-17|2009-03-18|Estimate|||||||2017-06-30|2017-07-02|Actual|March 3, 2009||2009-03-03|March 10, 2010|2010-03-10|March 10, 2010||2010-03-10|||||Observational|||Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali|Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali (Village of Thierola in the District of Banamba)|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:12:09.353824|2018-06-01 01:12:09.353824
NCT00863395|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2014-03-28|2009-03-16|2009-03-18|Estimate|||||||2014-03-28|2014-03-31|Estimate|December 2008||2008-12-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CTCL||Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma|Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma|Terminated||Phase 1/Phase 2|6|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-06-01 01:12:09.477435|2018-06-01 01:12:09.477435
NCT00863382|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-05-04|2009-03-17|2009-03-18|Estimate|||||||2012-05-04|2012-05-07|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Comparison of External Event Recorders for Atrial Fibrillation Monitoring|Comparison of External Event Recorders With Implantable Monitor for Post Atrial Fibrillation Monitoring: Assessment of Cost and Efficacy|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 01:12:09.603825|2018-06-01 01:12:09.603825
NCT00863369|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2018-04-04|2009-03-17|2009-03-18|Estimate|||||||2018-04-04|2018-04-05|Actual|June 20, 2005||2005-06-20|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma|A Phase I/II Study of VELCADE in Combination With Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|56|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:12:09.701868|2018-06-01 01:12:09.701868
NCT00863356|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2012-10-29||2012-10-29|2009-03-17|2009-03-18|Estimate|2012-10-29|2012-11-28|Estimate||||2012-10-29|2012-11-28|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis|Completed||N/A|20|Actual|HemCon Medical Technologies, Inc||1|||f||||f||||||||||2018-06-01 01:12:09.98344|2018-06-01 01:12:09.98344
NCT00863343|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2011-08-05||2012-01-30|2009-03-16|2009-03-18|Estimate|2012-01-30|2012-03-01|Estimate||||2012-01-30|2012-03-01|Estimate|March 2010||2010-03-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Clinical Validation of the Point-of-Care MSD Influenza Test|Clinical Validation of the Point-of-Care MSD Influenza Test|Terminated|||391|Actual|Meso Scale Diagnostics, LLC.|||1|Funding of study was exhausted prior to completion of study|f||||f||||||Samples With DNA|"~     Viral transport media containing nasal swab extract.~   "|||2018-06-01 01:12:10.176625|2018-06-01 01:12:10.176625
NCT00863330|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|2014-12-03||2014-12-16|2009-03-17|2009-03-18|Estimate|2014-12-15|2014-12-17|Estimate||||2014-12-16|2015-01-06|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma|A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma|Terminated||Phase 2|14|Actual|Aurora Health Care|Study was ended early, before substantial data could be collected, due to Investigators retiring/leaving the institution.|1||administrative decision- PI retired and treating physician left the institution|f||||t||||||||||2018-06-01 01:12:10.465643|2018-06-01 01:12:10.465643
NCT00863317|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2015-06-02||2015-06-19|2009-03-16|2009-03-18|Estimate|2015-06-02|2015-06-19|Estimate||||2015-06-19|2015-07-15|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Trial of Montelukast for Treatment of Acute Bronchiolitis|A Randomized, Double Blind, Placebo Controlled Trial of Daily Montelukast for the Treatment of Viral Bronchiolitis|Completed||N/A|141|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-06-01 01:12:10.707095|2018-06-01 01:12:10.707095
NCT00863304|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13||2011-05-02|2011-05-02|2009-03-16|2009-03-17|Estimate||||2011-05-02|2011-05-05|Estimate|2011-05-02|2011-05-05|Estimate|May 2009||2009-05-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Tanezumab in Osteoarthritis of the Hip or Knee (2)|A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study of the Analgesic Efficacy And Study of Tanezumab in Patients With Osteoarthritis Of The Hip or Knee|Completed||Phase 3|849|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 01:12:11.005198|2018-06-01 01:12:11.005198
NCT00863291|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2009-03-16|2009-03-16|2009-03-17|Estimate|||||||2009-03-16|2009-03-17|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|November 2008|Anticipated|2008-11-30|||||Interventional|||A Double-Blind Study of Buprenorphine Treatment of Acute Suicidality|Phase 3 Study of the Effects of Buprenophine as Add-on Treatment to Antidepressants in Treating Acutely Suicidal Depressed Inpatients|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Abarbanel Mental Health Center||2|||f||||t||||||||||2018-06-01 01:12:11.259233|2018-06-01 01:12:11.259233
NCT00863278|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-03-23|2009-03-16|2009-03-17|Estimate|||||||2012-03-23|2012-03-26|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser|Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser; a Comparative Prospective Study|Terminated||Phase 4|20|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:12:11.348636|2018-06-01 01:12:11.348636
NCT00863265|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-05-02|2009-03-16|2009-03-17|Estimate|||||||2012-05-02|2012-05-03|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|Phyteaux-III||Phytosterols, Ezetimibe, and Cholesterol Metabolism|Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)|Completed||N/A|22|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 01:12:11.427104|2018-06-01 01:12:11.427104
NCT00863252|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2009-03-16|2009-03-16|2009-03-17|Estimate|||||||2009-03-16|2009-03-17|Estimate|March 2002||2002-03-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|June 2004|Actual|2004-06-30||Interventional|||Mycophenolate Mofetil for IgA Nephropathy|A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade|Completed||Phase 4|40|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:12:11.530616|2018-06-01 01:12:11.530616
NCT00863239|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-02-01|2009-03-16|2009-03-17|Estimate|||||||2012-02-01|2012-02-02|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|SELECT-2||Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV|Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron Plus Ribavirin Given Bi-weekly in Comparison With PEG-Intron Plus Ribavirin Given Weekly|Completed||Phase 2|116|Actual|Biolex Therapeutics, Inc.||4|||f||||t||||||||||2018-06-01 01:12:11.614729|2018-06-01 01:12:11.614729
NCT00863226|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2011-12-13|2009-03-16|2009-03-17|Estimate|||||||2011-12-13|2011-12-14|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease|A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol|Unknown status|Active, not recruiting|Phase 3|72|Anticipated|pico-tesla Magnetic Therapies, LLC|||||f||||||||||||||2018-06-01 01:12:11.750169|2018-06-01 01:12:11.750169
NCT00863213|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2013-04-25|2009-03-16|2009-03-17|Estimate|||||||2013-04-25|2013-04-26|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Interventional|SARA||Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation|Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation|Completed||Phase 4|152|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 01:12:11.8228|2018-06-01 01:12:11.8228
NCT00863200|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2018-01-08|2009-03-16|2009-03-17|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2009|Actual|2009-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Identification and Treatment of Depression|Identification and Treatment of Depression in Underserved African American and Latino Patients With Cancer|Active, not recruiting|||166|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 01:12:11.905213|2018-06-01 01:12:11.905213
NCT00863187|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|||2009-03-16|2009-03-16|2009-03-17|Estimate|||||||2009-03-16|2009-03-17|Estimate|February 2009||2009-02-28|February 2009|2009-02-28||||February 2010|Anticipated|2010-02-28||Interventional|||Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab||Unknown status|Not yet recruiting|N/A|100|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||||2018-06-01 01:12:11.974001|2018-06-01 01:12:11.974001
NCT00863174|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2016-03-08|2009-03-16|2009-03-17|Estimate|||||||2016-03-08|2016-03-09|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of SPARC_147709- Test and Reference, 2mg/ml (30 mg/m2 Dose) in Patients With Multiple Myeloma|Completed||Phase 1|24|Actual|Sun Pharma Advanced Research Company Limited||2|||f||||f||||||||||2018-06-01 01:12:12.042137|2018-06-01 01:12:12.042137
NCT00863161|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2011-01-21|2009-03-16|2009-03-17|Estimate|||||||2011-01-21|2011-01-24|Estimate|March 2009||2009-03-31|January 2011|2011-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Renal Impairment Study|A Phase I, Open Label, Non-randomized, Parallel Group, Pharmacokinetic Study in Subjects With Normal Renal Function, Moderate or Severe Renal Impairment Receiving a Single Dose of Oral 130 mg AZD3355|Completed||Phase 1|23|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:12:12.098825|2018-06-01 01:12:12.098825
NCT00863148|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-07-18|2009-03-16|2009-03-17|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2009||2009-10-31|July 2017|2017-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Cloric||Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)|A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-risk AML, MDS or ALL.|Completed||Phase 2|30|Actual|Nantes University Hospital|||||f||||t||||||||||2018-06-01 01:12:12.175681|2018-06-01 01:12:12.175681
NCT00863135|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-02-07|2009-03-16|2009-03-17|Estimate|||||||2017-02-07|2017-02-09|Estimate|December 2008||2008-12-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of CPAP on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension|Effect of Continuous Positive Airway Pressure (CPAP) Treatment on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension|Completed||N/A|68|Actual|Corporacion Parc Tauli||2|||f||||f||||||||No||2018-06-01 01:12:12.333682|2018-06-01 01:12:12.333682
NCT00863122|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2013-08-05|2009-03-16|2009-03-17|Estimate|||||||2013-08-05|2013-08-07|Estimate|June 2009||2009-06-30|August 2013|2013-08-31||||December 2013|Anticipated|2013-12-31||Interventional|||Concentration and Activity of Lapatinib in Vestibular Schwannomas|Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas|Unknown status|Recruiting|Early Phase 1|26|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-06-01 01:12:12.41571|2018-06-01 01:12:12.41571
NCT00863109|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2014-05-14||2017-03-09|2009-03-16|2009-03-17|Estimate|2014-05-14|2014-06-12|Estimate||||2017-03-09|2017-04-07|Actual|April 2009||2009-04-30|March 2017|2017-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|VIDA|Of 133 enrolled participants, Baseline Characteristics were reported for 130 evaluable participants. 3 enrolled participants who failed screening did not have Baseline Characteristics reported.|Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)|Evaluation of the Health-Related Quality of Life During Combined Treatment of Chronic Hepatitis Due to Hepatitis C Virus Under Habitual Clinical Practise Conditions.|Completed|||133|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:12:12.603423|2018-06-01 01:12:12.603423
NCT00863096|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2011-03-02|2009-03-16|2009-03-17|Estimate|||||||2011-03-02|2011-03-03|Estimate|June 2009||2009-06-30|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Human Papillomavirus Screening and Vaccine Readiness Program|Human Papillomavirus Screening and Vaccine Readiness Program|Withdrawn|||450|Anticipated|Public Health Research Institute, India|||1|Unable to get the vaccine on time to offer it to the study population.|f||||f||||||||||2018-06-01 01:12:13.074003|2018-06-01 01:12:13.074003
NCT00863083|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2010-06-17|2009-03-16|2009-03-17|Estimate|||||||2010-06-17|2010-06-22|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity|Reducing Barriers to Behavior Change Among Youth With Pediatric Overweight and Obesity|Terminated||N/A|12|Actual|Medical College of Wisconsin||2||Study was terminated due to poor enrollment.|f||||f||||||||||2018-06-01 01:12:13.160772|2018-06-01 01:12:13.160772
NCT00863070|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-03-16|2009-03-16|2009-03-17|Estimate|||||||2017-03-16|2017-03-20|Actual|April 2009||2009-04-30|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|Gait||Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy|Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy|Completed|||6|Actual|Connecticut Children's Medical Center|||1||f||||f||||||||No||2018-06-01 01:12:13.251648|2018-06-01 01:12:13.251648
NCT00863057|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2011-12-14||2017-10-30|2009-03-16|2009-03-17|Estimate|2012-03-29|2012-04-25|Estimate||||2017-10-30|2017-12-05|Actual|May 2009||2009-05-31|September 2014|2014-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Combination Pain Therapy in HIV Neuropathy|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy|Completed||Phase 2|15|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The results should be interpreted with caution since the total sample size was much lower than planned.|4|||f||||t||||||||||2018-06-01 01:12:13.359044|2018-06-01 01:12:13.359044
NCT00863044|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2016-03-15|2009-03-16|2009-03-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|VHF||High Frequency Ventilation During Off Pump Coronary Artery Bypass Graft (CABG)|Impact of High Frequency Ventilation During Coronary Anastomosis in Off Pump Coronary Artery Bypass.|Completed||Phase 4|80|Actual|Montreal Heart Institute||2|||f||||f||||||||||2018-06-01 01:12:14.223122|2018-06-01 01:12:14.223122
NCT00863031|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2009-03-16|2009-03-16|2009-03-17|Estimate|||||||2009-03-16|2009-03-17|Estimate|November 2002||2002-11-30|March 2009|2009-03-31|June 2006|Actual|2006-06-30|December 2005|Actual|2005-12-31||Interventional|||A Trial on the Effectiveness of Screening and Brief Problem-Solving Therapy (PST) for Elderly Patients With Psychological Problems|A Randomised Controlled Trail on the Effectiveness of Screening and Brief Counselling (Problem-Solving Therapy) for Elderly Patients With Psychological Problems in Primary Care.|Completed||N/A|299|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:12:14.295352|2018-06-01 01:12:14.295352
NCT00863018|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2015-07-27|2009-03-16|2009-03-17|Estimate|||||||2015-07-27|2015-07-29|Estimate|August 2003||2003-08-31|July 2015|2015-07-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Observational|||Corneal Endothelium After Glaucoma Surgery|Change in Corneal Endothelium After Glaucoma Surgery; Trabeculectomy and Glaucoma Implant Surgery|Completed|||61|Actual|Chungnam National University|||3||f||||t||||||||||2018-06-01 01:12:14.354069|2018-06-01 01:12:14.354069
NCT00863005|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-11-05|2009-03-16|2009-03-17|Estimate|||||||2009-11-05|2009-11-06|Estimate||||November 2009|2009-11-30||||||||Interventional|||Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study||Completed||Phase 1/Phase 2|||Moberg Pharma AB||2|||f||||f||||||||||2018-06-01 01:12:14.491874|2018-06-01 01:12:14.491874
NCT00862992|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2009-09-08|2009-03-15|2009-03-17|Estimate|||||||2009-09-08|2009-09-10|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia|Phase II Study of MP-214 in Patients With Schizophrenia (Exploratory Study)|Completed||Phase 2|30|Anticipated|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-06-01 01:12:14.57908|2018-06-01 01:12:14.57908
NCT00862979|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-09-06|2009-03-16|2009-03-17|Estimate|||||||2017-09-06|2017-09-07|Actual|February 24, 2009|Actual|2009-02-24|September 2017|2017-09-30|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|MANDELA||A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients|A 15-month, Multi-center, Randomized, Open-label, Parallel Group Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Regimen (Everolimus and Mycophenolic Acid) Versus a Standard Regimen (Cyclosporine A and Everolimus) in de Novo Heart Transplant Recipients|Completed||Phase 4|185|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:12:14.814756|2018-06-01 01:12:14.814756
NCT00862966|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2009-03-13|2009-03-13|2009-03-17|Estimate|||||||2009-03-13|2009-03-17|Estimate|April 2009||2009-04-30|March 2009|2009-03-31||||April 2010|Anticipated|2010-04-30||Interventional|CVCLS||Central Venous Catheter Lock Solution|Randomized Control Trial on Citrate as the Central Venous Catheter Lock Solution|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Medical Center, Tuzla||2|||f||||f||||||||||2018-06-01 01:12:14.926191|2018-06-01 01:12:14.926191
NCT00862953|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-02-19|2009-03-16|2009-03-17|Estimate|||||||2012-02-19|2012-02-22|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|LOWER||Study to Assess the Effects of High Protein Diet in Obesity, the LOWER Study|The Lifestyle, OverWeight, Energy Restriction Study|Completed||N/A|317|Actual|University Medical Center Groningen||4|||f||||f||||||||||2018-06-01 01:12:14.998211|2018-06-01 01:12:14.998211
NCT00862940|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2010-11-23||2012-08-29|2009-03-16|2009-03-17|Estimate|2011-05-05|2011-06-03|Estimate||||2012-08-29|2012-09-03|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease|A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease|Completed||Phase 4|277|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:12:15.091765|2018-06-01 01:12:15.091765
NCT00862927|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-06-19|2009-03-16|2009-03-17|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Cue Reactivity in Virtual Reality: The Role of Context|Cue Reactivity in Virtual Reality: The Role of Context|Terminated|||21|Actual|M.D. Anderson Cancer Center|||1|Slow accrual.|f||||f||||||||||2018-06-01 01:12:15.60467|2018-06-01 01:12:15.60467
NCT00862914|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-10-15|2009-03-16|2009-03-17|Estimate|||||||2012-10-15|2012-10-16|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Observational|||Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi||Completed|||30|Actual|Ruhr University of Bochum|||3||f||||f||||||Samples With DNA|"~     Paraffin embedded melanocytic skin lesion~   "|||2018-06-01 01:12:15.680283|2018-06-01 01:12:15.680283
NCT00862901|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2011-09-23|2009-03-16|2009-03-17|Estimate|||||||2011-09-23|2011-09-26|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|CLIPT||Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma|A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy|Completed||Phase 1|48|Anticipated|Tufts Medical Center||4|||f||||t||||||||||2018-06-01 01:12:15.737605|2018-06-01 01:12:15.737605
NCT00862888|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-04-07|2009-03-16|2009-03-17|Estimate|||||||2009-04-07|2009-04-08|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction|A 2-Cohort, Multi-Centre, Randomised, Double Blind, Placebo Controlled 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses Of PF-00446687 On Erectile Function In Men Suffering From Erectile Dysfunction, Using 100 Mg Sildenafil As A Positive Control.|Completed||Phase 2|39|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:12:15.811839|2018-06-01 01:12:15.811839
NCT00862875|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2014-05-06|2009-03-16|2009-03-17|Estimate|||||||2014-05-06|2014-05-07|Estimate|March 2009||2009-03-31|May 2014|2014-05-31||||April 2014|Actual|2014-04-30||Interventional|||Levemir-Body Composition and Energy Metabolism|Effects of Basal Insulin Analogue Detemir on Body Composition, Epicardial Fat and Energy Metabolism|Completed||Phase 4|42|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-06-01 01:12:15.981591|2018-06-01 01:12:15.981591
NCT00862862|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2015-05-27|2009-03-13|2009-03-17|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus|Evaluation of Pharmacodynamic Target Attainment With Vancomycin Treatment of Infections Due to Staphylococcus Aureus|Terminated|||250|Actual|University of Nebraska||||lack of enrollment|f||||f||||||||||2018-06-01 01:12:16.067978|2018-06-01 01:12:16.067978
NCT00862849|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|2014-06-10||2014-07-11|2009-03-16|2009-03-17|Estimate|2014-06-10|2014-07-11|Estimate||||2014-07-11|2014-07-22|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional||Participants who received at least one dose of insulin lispro, regular human insulin, or recombinant human hyaluronidase (rHuPH20).|Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone|Phase 1, Randomized, Double-Blind, Pharmacokinetic and Glucodynamic 6-Way Crossover Study of SC Administered Insulin Lispro With Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin With Recombinant Human Hyaluronidase (rHuPH20) Compared to Insulin Lispro Alone in Healthy Volunteers|Completed||Phase 1|22|Actual|Halozyme Therapeutics||1|||f||||f||||||||||2018-06-01 01:12:16.154094|2018-06-01 01:12:16.154094
NCT00862836|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2011-11-02|2011-03-28|2016-08-29|2009-03-16|2009-03-17|Estimate|2012-09-11|2012-10-11|Estimate|2011-04-20|2011-04-28|Estimate|2016-08-29|2016-10-10|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|ZACFAST||Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)|Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study|Terminated||Phase 1/Phase 2|15|Actual|Sanofi||1||Lack of efficacy|f||||f||||||||||2018-06-01 01:12:16.575819|2018-06-01 01:12:16.575819
NCT00862823|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|2012-02-16||2012-08-16|2009-03-16|2009-03-17|Estimate|2012-08-16|2012-09-14|Estimate||||2012-08-16|2012-09-14|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers|The Stability and Bioequivalence of Tenofovir, Emtricitabine and Efavirenz (Atripla) in an Extemporaneously Prepared Oral Liquid Formulation Compared With the Commercially Available Tablet Formulation|Completed||Phase 4|14|Actual|University of Alabama at Birmingham|Efavirenz exposure was highly variable and relative bioequivalence for efavirenz may have been more appropriately assessed with a larger sample size.|2|||f||||||||||||||2018-06-01 01:12:16.977274|2018-06-01 01:12:16.977274
NCT00862810|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|2014-09-17||2014-11-19|2009-03-16|2009-03-17|Estimate|2014-09-17|2014-09-25|Estimate||||2014-11-19|2014-11-20|Estimate|March 2009||2009-03-31|September 2014|2014-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ADS||Alternate Dosing Schedules Study for HPV Vaccine|Alternate Dosing Schedules Study for HPV Vaccine|Completed||Phase 4|72|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:12:17.195311|2018-06-01 01:12:17.195311
NCT00862797|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2010-02-01|2009-03-16|2009-03-17|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2008||2008-01-31|March 2009|2009-03-31||||May 2009|Actual|2009-05-31||Observational|||Pressure Course in the Tube Cuff During Swallowing|Pressure Course in the Tube Cuff During Swallowing|Completed|||20|Anticipated|University Hospital Freiburg|||1||f||||f||||||||||2018-06-01 01:12:17.412306|2018-06-01 01:12:17.412306
NCT00862784|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2014-05-16|2010-07-26|2014-05-16|2009-03-16|2009-03-17|Estimate|2014-05-16|2014-06-17|Estimate|2010-07-26|2010-07-29|Estimate|2014-05-16|2014-06-17|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional||All participants who received any amount of study drug.|A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer|An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|48|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 01:12:17.497634|2018-06-01 01:12:17.497634
NCT00862758|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2013-12-09|2009-03-16|2009-03-17|Estimate|||||||2013-12-09|2013-12-10|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Expanded Access|||Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab|Emergency IND for Provision of Tocilizumab|No longer available|||||University of Oklahoma|||||||||f||||||||||2018-06-01 01:12:17.906848|2018-06-01 01:12:17.906848
NCT00862745|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|2011-09-14||2011-10-19|2009-03-16|2009-03-17|Estimate|2011-10-19|2011-11-24|Estimate||||2011-10-19|2011-11-24|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|BRIDGES||Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)|A Multi-center, Randomized, Placebo-controlled Clinical Trial Comparing Fesoterodine to Placebo in Women Diagnosed With Urge Urinary Incontinence by the 3 Incontinence Questions (3IQ). Followed by a Multi-center Open Label Clinical Cohort Study of Long-term Effects of Treatment With Fesoterodine.|Completed||Phase 4|645|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:12:17.989078|2018-06-01 01:12:17.989078
NCT00862732|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-03-16|2009-03-16|2009-03-17|Estimate|||||||2009-03-16|2009-03-17|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Study to Prevent Negative Thoughts of Life|A Randomised Controlled Trial With Cognitive Behavioural Therapy for Persons With Active Suicidal Ideations|Unknown status|Not yet recruiting|N/A|68|Anticipated|Institute for Research & Development Sri Lanka||2|||f||||f||||||||||2018-06-01 01:12:18.238642|2018-06-01 01:12:18.238642
NCT00862719|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2016-06-22||2016-08-25|2009-03-16|2009-03-17|Estimate|2016-06-22|2016-08-04|Estimate||||2016-08-25|2016-10-07|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|November 2012|Actual|2012-11-30||Interventional|||Sitagliptin Umbilical Cord Blood Transplant Study|A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies|Completed||Phase 2|29|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 01:12:18.347145|2018-06-01 01:12:18.347145
NCT00862706|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2016-09-22|2009-03-16|2009-03-17|Estimate|||||||2016-09-22|2016-09-23|Estimate|April 2009||2009-04-30|September 2016|2016-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks|An Open-label, Single-arm, Multicenter, Study of Telbivudine in Nucleos(t)Ide-naïve Subjects of Black/African American or Hispanic/Latino Origin With Compensated Chronic Hepatitis B Virus (HBV) Infection|Withdrawn||Phase 4|0|Actual|Novartis||1||Stopped with Patients|f||||||||||||||2018-06-01 01:12:19.613255|2018-06-01 01:12:19.613255
NCT00862693|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2011-02-16|2009-03-16|2009-03-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|March 2011|Anticipated|2011-03-31|August 2010|Anticipated|2010-08-31||Interventional|||Calcitriol in the Treatment of Immunoglobulin A Nephropathy||Unknown status|Recruiting|Phase 4|40|Anticipated|Peking University First Hospital||2|||f||||||||||||||2018-06-01 01:12:19.717593|2018-06-01 01:12:19.717593
NCT00862680|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-07-12|2009-03-16|2009-03-17|Estimate|||||||2017-07-12|2017-07-14|Actual|March 12, 2009|Actual|2009-03-12|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis|4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis|Active, not recruiting||N/A|59|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-06-01 01:12:19.803092|2018-06-01 01:12:19.803092
NCT00862667|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-06-23|2009-03-16|2009-03-17|Estimate|||||||2009-06-23|2009-06-24|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|B0871002||A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.|An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers.|Completed||Phase 1|36|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:12:19.899653|2018-06-01 01:12:19.899653
NCT00862654|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|2011-06-15||2011-08-31|2009-03-15|2009-03-17|Estimate|2011-07-19|2011-08-12|Estimate||||2011-08-31|2011-09-01|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|Escape||Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis|Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis|Completed||Phase 3|326|Actual|Galderma||4|||f||||f||||||||||2018-06-01 01:12:20.001012|2018-06-01 01:12:20.001012
NCT00862641|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|2010-11-15||2012-09-12|2009-03-15|2009-03-17|Estimate|2010-11-15|2010-12-15|Estimate||||2012-09-12|2012-09-18|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease|A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 4|1009|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|4|||f||||f||||||||||2018-06-01 01:12:20.59531|2018-06-01 01:12:20.59531
NCT00862628|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-09-18|2009-03-16|2009-03-17|Estimate|||||||2009-09-18|2009-09-21|Estimate|October 2009||2009-10-31|September 2009|2009-09-30|October 2010|Anticipated|2010-10-31|June 2010|Anticipated|2010-06-30||Interventional|||The Effect of Rebamipide for Non-steroidal Anti-inflammatory Drugs (NSAID) - Induced Small-intestinal Injuries||Unknown status|Not yet recruiting|N/A|60|Anticipated|Nagoya University||1|||f||||||||||||||2018-06-01 01:12:21.235537|2018-06-01 01:12:21.235537
NCT00862615|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2010-09-28|2009-03-16|2009-03-17|Estimate|||||||2010-09-28|2010-09-29|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|January 2011|Anticipated|2011-01-31|July 2010|Anticipated|2010-07-31||Interventional|Compalimage||Relationships Between Quality of Ageing and Age-related Degenerated Disease (Compalimage)|Chronic Micro-inflammation and Bone and Muscular Status in Elderly|Unknown status|Recruiting|N/A|32|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:12:21.415476|2018-06-01 01:12:21.415476
NCT00862602|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-05-19|2009-03-16|2009-03-17|Estimate|||||||2017-05-19|2017-05-23|Actual|July 2009|Actual|2009-07-31|May 2017|2017-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|PEG||Pedometers for Gestational Diabetes|Type 2 Diabetes Risk in Women With Gestational Diabetes|Completed||N/A|60|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 01:12:21.478351|2018-06-01 01:12:21.478351
NCT00862589|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2009-03-17|2009-03-16|2009-03-17|Estimate|||||||2009-03-17|2009-03-18|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)|GLP-1 Suppression of Alpha Cell Secretion in T2DM|Completed||N/A|20|Actual|University Hospital, Gentofte, Copenhagen|||||f||||f||||||||||2018-06-01 01:12:21.546715|2018-06-01 01:12:21.546715
NCT00862576|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2009-03-16|2009-03-16|2009-03-17|Estimate|||||||2009-03-16|2009-03-17|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome|A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome|Completed|||55|Actual|University of California, San Francisco|||2||f||||f||||||||||2018-06-01 01:12:21.611165|2018-06-01 01:12:21.611165
NCT00862563|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|2015-03-06||2015-04-06|2009-03-16|2009-03-17|Estimate|2015-03-24|2015-04-07|Estimate||||2015-04-06|2015-04-28|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism|A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of; Levetiracetam, Zonisamide, Topiramate, and Placebo Control for the Treatment of Alcohol Dependent Subjects.|Terminated||Phase 2|85|Actual|Boston Medical Center|Early termination lead to a small number of subjects in each group being analyzed.|4||Recruitment goals could not be met before ending of funding for this project.|f||||t||||||||||2018-06-01 01:12:21.726829|2018-06-01 01:12:21.726829
NCT00862550|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-08-09|2009-03-16|2009-03-17|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2009|Actual|2009-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Xerostomia Pilot Fudan: Acupuncture for Prevention of Radiation-Induced Xerostomia|Randomized Pilot Trial of Acupuncture for Prevention of Radiation-Induced Xerostomia|Recruiting||N/A|23|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-06-01 01:12:22.402176|2018-06-01 01:12:22.402176
NCT00862537|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2011-05-13||2011-06-09|2009-03-16|2009-03-17|Estimate|2011-06-09|2011-07-08|Estimate||||2011-06-09|2011-07-08|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)|An Open-label Extension Study for Subjects Previously Treated Either in Pilot I or Pilot II Studies of the Application of Magnetic Fields Using the Resonator for the Treatment of Parkinson's Disease.|Completed|||18|Actual|pico-tesla Magnetic Therapies, LLC|||1||f||||t||||||||||2018-06-01 01:12:22.465261|2018-06-01 01:12:22.465261
NCT00862511|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2017-01-24|2009-03-16|2009-03-17|Estimate|||||||2017-01-24|2017-01-25|Estimate|March 2009|Actual|2009-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2012|Actual|2012-12-31||Interventional|||Serum Metal Ion Concentration After Total Knee Arthroplasty (TKA)|A Prospective Randomized Comparison of Serum Metal Ion Levels After Implantation of Coated and Uncoated Knee Prostheses|Completed||N/A|120|Actual|Technische Universität Dresden||2|||f||||f|f|f||||||No||2018-06-01 01:12:23.561019|2018-06-01 01:12:23.561019
NCT00862498|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2018-02-26|2009-03-16|2009-03-17|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2008|Actual|2008-08-31|February 2018|2018-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Examining Written Disclosure as a Treatment for Post-Traumatic Stress Disorder|Examining Written Disclosure as an Intervention for Posttraumatic Stress Disorder|Completed||N/A|48|Actual|Boston University||3|||f||||f|f|f||||||Undecided||2018-06-01 01:12:23.632807|2018-06-01 01:12:23.632807
NCT00862485|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-15|||2016-04-04|2009-03-16|2009-03-17|Estimate|||||||2016-04-04|2016-04-06|Estimate|March 2009||2009-03-31|April 2016|2016-04-30||||December 2013|Actual|2013-12-31||Observational|||MCA Doppler Studies in Neborns Following Exchange Transfusion||Completed|||50|Actual|Rambam Health Care Campus|||1||f||||||||||||||2018-06-01 01:12:23.715088|2018-06-01 01:12:23.715088
NCT00862472|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-16|||2012-01-13|2009-03-16|2009-03-17|Estimate|||||||2012-01-13|2012-01-18|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy Study of DuoTrav APS Versus DuoTrav||Withdrawn||Phase 3|0|Actual|Alcon Research||2||Management decision not to conduct an additional efficacy study.|f||||f||||||||||2018-06-01 01:12:23.772828|2018-06-01 01:12:23.772828
NCT00862459|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2011-09-14||2013-12-11|2009-03-16|2009-03-17|Estimate|2011-12-20|2012-01-30|Estimate||||2013-12-11|2014-01-13|Estimate|August 2005||2005-08-31|December 2013|2013-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)|Multi-center, Double-blind, Randomized, Controlled, Parallel Group, Dose Comparison Study With Corresponding Blinded Image Evaluation Following a Single Intravenous Injection of Three Different Doses of Gadobutrol 1.0 Molar (Gadavist) in Patients With Known or Suspected Focal Blood Brain Barrier Disturbances and/or Abnormal Vascularity of the Central Nervous System|Completed||Phase 2|237|Actual|Bayer|OptiMARK was used as a standard of reference in this study. A formal comparison of the efficacy of gadobutrol and OptiMARK was not specified prospectively in the statistical analysis plan. For completeness, the safety data of OptiMARK is presented.|3|||f||||f||||||||||2018-06-01 01:12:24.000603|2018-06-01 01:12:24.000603
NCT00862446|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2018-02-12|2009-03-16|2009-03-17|Estimate|||||||2018-02-12|2018-02-14|Actual|March 2009||2009-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease|Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease|Recruiting||Phase 4|60|Anticipated|Vanderbilt University Medical Center||1|||f||||t||||||||||2018-06-01 01:12:27.044259|2018-06-01 01:12:27.044259
NCT00862433|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2018-05-17|2009-03-13|2009-03-16|Estimate|||||||2018-05-17|2018-05-18|Actual|March 11, 2009||2009-03-11|December 1, 2017|2017-12-01|December 31, 2019|Anticipated|2019-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women|Vitamin E Pharmacokinetics and Biomarkers in Women|Recruiting||Phase 1|326|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 01:12:27.197417|2018-06-01 01:12:27.197417
NCT00862420|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2012-07-16|2009-03-13|2009-03-16|Estimate|||||||2012-07-16|2012-07-17|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease|A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg/Day Versus Ticlopidine 200 mg/Day in Patients With Peripheral Arterial Disease - With Extended Treatment of Clopidogrel 75 mg/Day for 40 Weeks|Completed||Phase 3|431|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:12:27.28013|2018-06-01 01:12:27.28013
NCT00862407|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2012-05-08|2009-03-13|2009-03-16|Estimate|||||||2012-05-08|2012-05-09|Estimate|October 2008||2008-10-31|May 2012|2012-05-31||||||||Observational|||Impact of Pulsatile Cardio-Pulmonary Bypass (CPB) on Vital Organ Recovery|Impact of Pulsatile CPB on Vital Organ Recovery|Unknown status|Recruiting||300|Anticipated|Penn State University|||2||f||||t||||||Samples Without DNA|"~     Blood and plasma samples~   "|||2018-06-01 01:12:27.352426|2018-06-01 01:12:27.352426
NCT00862394|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2018-04-12|2009-03-13|2009-03-16|Estimate|||||||2018-04-12|2018-04-13|Actual|February 2009||2009-02-28|April 2018|2018-04-30|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma|A 12-week, Multinational, Randomised, Double Blind, Double Dummy, 4-arm Parallel-group Study Comparing the Efficacy and Safety of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation, Via HFA Pressurised Inhalation Solution, in Moderate to Severe Symptomatic Asthmatic Patients Aged ≥ 12 Years Under Treatment With Inhaled Corticosteroids|Completed||Phase 3|783|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-06-01 01:12:27.421725|2018-06-01 01:12:27.421725
NCT00862381|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2010-07-23|2009-03-13|2009-03-16|Estimate|||||||2010-07-23|2010-07-26|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Hydrocortisone Use After Etomidate in Intensive Care|Opothérapie Par Hydrocortisone après Injection Unique d'Etomidate Chez le Patient de réanimation|Completed||Phase 3|106|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 01:12:27.49953|2018-06-01 01:12:27.49953
NCT00862368|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2012-04-24|2009-03-13|2009-03-16|Estimate|||||||2012-04-24|2012-04-25|Estimate|October 2005||2005-10-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PAQS2||Sustaining Smoking Cessation in Smokers With Kids With Asthma|Sustaining Cessation in Smokers With Kids With Asthma|Completed||Phase 3|573|Actual|The Miriam Hospital||3|||f||||t||||||||||2018-06-01 01:12:27.579754|2018-06-01 01:12:27.579754
NCT00862355|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2016-03-08|2009-03-13|2009-03-16|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer||Completed||Phase 1|24|Actual|Sun Pharma Advanced Research Company Limited||2|||f||||f||||||||||2018-06-01 01:12:27.700533|2018-06-01 01:12:27.700533
NCT00862342|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2012-07-16|2009-03-13|2009-03-16|Estimate|||||||2012-07-16|2012-07-17|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|SAFE||Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)|Efficacy and Safety of Second-line Combination Chemotherapy With Avastin in Patients With Metastatic Colorectal Cancer Who Have Received First-line Chemotherapy Plus Avastin|Completed||Phase 2|78|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 01:12:27.764857|2018-06-01 01:12:27.764857
NCT00862316|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2017-06-15|2009-03-13|2009-03-16|Estimate|||||||2017-06-15|2017-06-16|Actual|May 2009||2009-05-31|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Oxford Unicompartmental Knee Arthroplasty With and Without Navigational Unit|Outcome Analysis of the Oxford Unicompartmental Knee Arthroplasty With and Without the Assistance of a Computer Navigational Unit|Completed||N/A|48|Actual|Zimmer Biomet||2|||f||||||||||||||2018-06-01 01:12:27.908315|2018-06-01 01:12:27.908315
NCT00862303|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2011-03-07|2009-03-13|2009-03-16|Estimate|||||||2011-03-07|2011-03-08|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma|Study of Autologous Dendritic Cells (DC) Loaded With Autologous Tumor Lysate (DC-Vaccine) in Combination With Cytokine-Induced Killer Cell (CIK) in Patients With Renal Cell Cancer|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Fuzhou General Hospital||2|||f||||t||||||||||2018-06-01 01:12:27.982569|2018-06-01 01:12:27.982569
NCT00862290|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2013-05-02|2009-03-13|2009-03-16|Estimate|||||||2013-05-02|2013-05-03|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Observational|||Circulating microRNAs as Biomarkers of Sepsis|Diagnostic and Predictive Value of Circulating microRNAs During Sepsis|Completed|||100|Actual|Changhai Hospital|||3||f||||t||||||Samples Without DNA|"~     Blood of septic patients is collected on the second day when they are diagnosed with sepsis~     in ICU. Blood of SIRS patients is collected on the second day when they are diagnozed with~     SIRS after cardiac surgery with cardiopulmonary bypass.~   "|||2018-06-01 01:12:28.102263|2018-06-01 01:12:28.102263
NCT00862277|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|2010-12-11||2016-04-12|2009-03-13|2009-03-16|Estimate|2011-01-12|2011-01-13|Estimate||||2016-04-12|2016-04-14|Estimate|December 2008||2008-12-31|April 2016|2016-04-30|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Observational|||Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine|Evaluation of the Persistence of Bactericidal Antibodies in Adolescents and Adults Who Received a Single Dose of Menactra® Four to Eight Years Earlier|Completed|||763|Actual|Sanofi|||3||f||||f||||||||||2018-06-01 01:12:28.169654|2018-06-01 01:12:28.169654
NCT00862264|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2017-03-28|2009-03-13|2009-03-16|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2004||2004-08-31|March 2017|2017-03-31|September 2005|Actual|2005-09-30|||||Interventional|||Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma|A 12-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Mild to Moderate Persistent Asthma|Completed||Phase 3|286|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 01:12:28.548926|2018-06-01 01:12:28.548926
NCT00862251|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2012-02-23||2017-03-17|2009-03-13|2009-03-16|Estimate|2012-02-23|2012-03-16|Estimate||||2017-03-17|2017-04-14|Actual|April 2009||2009-04-30|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)|A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin Dose|Completed||Phase 3|808|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:12:28.721632|2018-06-01 01:12:28.721632
NCT00862238|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2013-03-21|2009-03-13|2009-03-16|Estimate|||||||2013-03-21|2013-03-25|Estimate|April 2008||2008-04-30|March 2013|2013-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An Arts Intervention for Drug-Using Homeless Youth|An Arts Intervention for Drug-Using Homeless Youth|Completed||Phase 2|156|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 01:12:29.420374|2018-06-01 01:12:29.420374
NCT00862225|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2012-01-25|2009-03-13|2009-03-16|Estimate|||||||2012-01-25|2012-01-26|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|PETRA||MOA Study of Ze 339 in Seasonal Allergic Rhinitis|Randomized, Double-blind Prospective Clinical Study to Examine the Mechanism of Action of IG-RD-001 (Ze-339) Compared to Desloratadine and Placebo in Patients With Seasonal Allergic Rhinitis Who Are Sensitized to Grasses|Completed||Phase 2|18|Actual|Max Zeller Soehne AG||3|||f||||f||||||||||2018-06-01 01:12:29.505229|2018-06-01 01:12:29.505229
NCT00862212|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2013-04-22|2009-03-13|2009-03-16|Estimate|||||||2013-04-22|2013-04-23|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting|Phased Treatment for Social Anxiety Disorder and Coping Behaviors in a Medical Setting|Completed||N/A|83|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 01:12:29.590647|2018-06-01 01:12:29.590647
NCT00862186|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2012-04-11||2013-01-11|2009-03-12|2009-03-16|Estimate|2012-04-11|2012-05-09|Estimate||||2013-01-11|2013-01-15|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Self-Management of Cancer-Related Fatigue by Adolescents|Self-Management of Cancer-Related Fatigue by Adolescents: Pilot Study of an Evidence Based Educational Resource|Completed||N/A|15|Actual|Seattle Children's Hospital|Slow enrollment resulting in low accrual - only 15 participants rather than the 60 planned - therefore unable to complete analysis.|1|||f||||f||||||||||2018-06-01 01:12:29.685667|2018-06-01 01:12:29.685667
NCT00862173|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2012-06-11|2009-03-12|2009-03-16|Estimate|||||||2012-06-11|2012-06-12|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer|Gene-expression Profile as Predictor of Central Nervous System Metastasis Development in Non-small Cell Lung Cancer: a Prospective Study|Unknown status|Recruiting||120|Anticipated|National Institute of Cancerología|||2||f||||f||||||Samples With DNA|"~     NSCLC Biopsy.~   "|||2018-06-01 01:12:29.847665|2018-06-01 01:12:29.847665
NCT00862160|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2009-10-06|2009-03-13|2009-03-16|Estimate|||||||2009-10-06|2009-10-07|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|October 2010|Anticipated|2010-10-31|April 2010|Anticipated|2010-04-30||Interventional|ROCsafeTM||Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit|Acute Cerebrovascular Events During Extracorporeal Circulation a Comparison of New Minimized Perfusion Circuit to Standard Cardiopulmonary Bypass|Unknown status|Recruiting|Phase 4|64|Anticipated|Hannover Medical School||2|||f||||t||||||||||2018-06-01 01:12:29.933232|2018-06-01 01:12:29.933232
NCT00862147|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2017-02-13|2009-03-13|2009-03-16|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2007|Actual|2007-01-31|February 2017|2017-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effectiveness Study of the International Child Development Program|The Effect of the International Child Development Program - A Randomised Controlled Trial|Terminated||N/A|35|Actual|Norwegian University of Science and Technology||2||the study was stopped due to failure to recruit sufficient participants|f||||t||||||||||2018-06-01 01:12:30.021701|2018-06-01 01:12:30.021701
NCT00862134|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2011-05-31||2013-01-08|2009-03-13|2009-03-16|Estimate|2013-01-08|2013-01-10|Estimate||||2013-01-08|2013-01-10|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II, Multi-Center, Open-Label Trial of PR104 and Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|42|Actual|Proacta, Incorporated||2||Interim analysis indicated low probability of clinically significant result|f||||||||||||||2018-06-01 01:12:30.114478|2018-06-01 01:12:30.114478
NCT00862121|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|2011-10-03||2012-03-15|2009-03-13|2009-03-16|Estimate|2012-02-09|2012-03-12|Estimate||||2012-03-15|2012-03-16|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|PEACE||A Study With Pentasa in Patients With Active Crohn's Disease|PENTASA in Active Crohn's Disease: A 10-week, Double-blind, Multi-centre Trial Comparing PENTASA Sachet 6 g/Day (Mesalazine, Mesalamine) With Placebo.|Terminated||Phase 3|20|Actual|Ferring Pharmaceuticals|Early termination led to small number of participants (20/510; actual/planned). Only the primary efficacy outcome was subject to formal statistical analysis. No conclusions could be drawn on primary and secondary efficacy analyses.|2||Terminated due to poor recruitment|f||||f||||||||||2018-06-01 01:12:30.674009|2018-06-01 01:12:30.674009
NCT00862108|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-09-20|2009-03-13|2009-03-16|Estimate|||||||2009-09-20|2009-09-22|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)|Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD|Unknown status|Recruiting|Phase 4|50|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-06-01 01:12:31.064127|2018-06-01 01:12:31.064127
NCT00862095|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2013-04-22|2009-03-13|2009-03-16|Estimate|||||||2013-04-22|2013-04-23|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Medical Therapies for Chronic Post-Traumatic Headaches|A Randomized Controlled Trial of Medical Therapies for Chronic Post-Traumatic Headaches|Terminated||Phase 4|64|Actual|Madigan Army Medical Center||4||inadequate enrollment, insufficient funds to continue enrollment|f||||t||||||||||2018-06-01 01:12:31.219984|2018-06-01 01:12:31.219984
NCT00862082|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2011-05-31||2013-07-19|2009-03-13|2009-03-16|Estimate|2013-07-19|2013-08-23|Estimate||||2013-07-19|2013-08-23|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|A Randomized Phase I/II, Multi-Center, Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|14|Actual|Proacta, Incorporated|Early termination leading to small numbers of subjects analyzed. Phase II part of study never initiated.|1||PR104 plus sorafenib was poorly tolerated in patients with advanced HCC|f||||||||||||||2018-06-01 01:12:31.355027|2018-06-01 01:12:31.355027
NCT00862056|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-11-16|2009-03-13|2009-03-16|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2009|Actual|2009-01-31|November 2017|2017-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|Decide CTA||Detection of Subclinical Atherosclerosis in Asymptomatic Individuals|Prospective Detection of Subclinical Atherosclerosis in Asymptomatic Individuals With High Likelihood of Coronary Artery Disease With a Novel, Low-Radiation Volumetric Computed Tomography Approach|Completed|||73|Actual|Piedmont Healthcare|||1||f||||f||||||Samples With DNA|"~     Whole blood for DNA and RNA analysis for genetics and genomics~   "|||2018-06-01 01:12:31.9994|2018-06-01 01:12:31.9994
NCT00862043|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2016-09-22|2009-03-13|2009-03-16|Estimate|||||||2016-09-22|2016-09-23|Estimate|April 2009||2009-04-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SIOVAC||Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease|Sildenafil for Improving Outcomes After Valvular Correction|Completed||Phase 4|200|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||||2018-06-01 01:12:32.086734|2018-06-01 01:12:32.086734
NCT00862030|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2011-08-04|2009-03-13|2009-03-16|Estimate|||||||2011-08-04|2011-08-08|Estimate|April 2009||2009-04-30|August 2011|2011-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||CT-Based Versus Conventional Simulation for Palliative Radiotherapy of Non-Small Cell Lung Cancer|Comparison of Two-versus Three-Dimensional Treatment Planning for Patients Receiving Chest Radiotherapy for Symptom Control|Completed|||20|Anticipated|AHS Cancer Control Alberta|||1||f||||f||||||||||2018-06-01 01:12:32.207883|2018-06-01 01:12:32.207883
NCT00862017|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2009-03-13|2009-03-13|2009-03-16|Estimate|||||||2009-03-13|2009-03-16|Estimate|April 2008||2008-04-30|March 2009|2009-03-31||||||||Interventional|||Effect of Monosodium Glutamate Supplementation on Gastric Emptying and Postprandial Nitrogen Kinetics|Effect of Monosodium Glutamate on Gastric Emptying and Postprandial Nitrogen in Healthy Volunteers|Completed||N/A|13|Actual|Institut National de la Recherche Agronomique||2|||f||||t||||||||||2018-06-01 01:12:32.27814|2018-06-01 01:12:32.27814
NCT00862004|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2010-02-01|2009-03-13|2009-03-16|Estimate|||||||2010-02-01|2010-02-02|Estimate|December 2008||2008-12-31|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Video-assisted Thoracoscopic Surgery for Stage IIIA Non-Small Cell Lung Cancer|Feasibility of Video-Assisted Thoracoscopic Surgery for Clinical Stage IIIA Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||||f||||t||||||||||2018-06-01 01:12:32.347785|2018-06-01 01:12:32.347785
NCT00861991|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2009-03-13|2009-03-13|2009-03-16|Estimate|||||||2009-03-13|2009-03-16|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Enhancing Empathy in Medical Communication Through Perspective-Taking|Enhancing Empathy in Medical Communication Through Perspective-Taking|Completed||N/A|608|Actual|George Washington University||2|||f||||t||||||||||2018-06-01 01:12:32.435062|2018-06-01 01:12:32.435062
NCT00861978|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2009-03-13|2009-03-13|2009-03-16|Estimate|||||||2009-03-13|2009-03-16|Estimate|December 2002||2002-12-31|March 2009|2009-03-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||St. John's Wort Extract LI 160 for the Treatment of Atypical Depression||Completed||Phase 3|201|Actual|Cassella-med GmbH & Co. KG||2|||f||||t||||||||||2018-06-01 01:12:32.506355|2018-06-01 01:12:32.506355
NCT00861965|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2015-04-01|2009-03-12|2009-03-16|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2010||2010-01-31|April 2015|2015-04-30||||November 2012|Actual|2012-11-30||Interventional|||Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match Alternative to Allogeneic Transplant for Blood Cancers|A Phase I/II Study of Polyclonally Activated, Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStimTM) in Patients With Relapsed or Refractory Hematological Malignancy Without Prior Conditioning|Withdrawn||Phase 1/Phase 2|0|Actual|Immunovative Therapies, Ltd.||1||withdrawn due to poor recruitment|f||||f||||||||||2018-06-01 01:12:32.572538|2018-06-01 01:12:32.572538
NCT00861952|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2015-03-10|2009-03-13|2009-03-16|Estimate|||||||2015-03-10|2015-03-17|Estimate|January 2010||2010-01-31|March 2015|2015-03-31||||||||Interventional|||Neuragen for Peripheral Diabetic Neuropathy|The Safety and Efficacy of Neuragen in Diabetic Peripheral Neuropathy: A Double-blind Randomized Placebo Controlled Trial|Withdrawn||Phase 3|0|Actual|The Canadian College of Naturopathic Medicine||2||"Study has received ethics approval, however funding limitations have resulted in suspending~   date of commencement."|f||||t||||||||||2018-06-01 01:12:32.665283|2018-06-01 01:12:32.665283
NCT00861939|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-03-27|2009-03-13|2009-03-16|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2004||2004-03-31|March 2009|2009-03-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions|Completed||Phase 1|28|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:12:32.741267|2018-06-01 01:12:32.741267
NCT00861926|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2017-03-28|2009-03-13|2009-03-16|Estimate|||||||2017-03-28|2017-03-30|Actual|March 2009||2009-03-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics|48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics >=18 Years of Age|Completed||Phase 3|2079|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 01:12:32.802194|2018-06-01 01:12:32.802194
NCT00861913|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|2013-11-07||2017-11-29|2009-03-13|2009-03-16|Estimate|2013-12-06|2014-01-21|Estimate||||2017-11-29|2017-11-30|Actual|April 3, 2009|Actual|2009-04-03|November 2017|2017-11-30||||September 14, 2010|Actual|2010-09-14||Interventional|||Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery|Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients|Completed||Phase 2|13|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:12:32.894676|2018-06-01 01:12:32.894676
NCT00861900|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2009-07-14|2009-03-13|2009-03-16|Estimate|||||||2009-07-14|2009-07-15|Estimate|January 1998||1998-01-31|July 2009|2009-07-31||||||||Observational|||Immune Mechanisms of Rejection in Human Lung Allografts|Immune Mechanisms of Rejection in Human Lung Allografts|Unknown status|Enrolling by invitation||360|Anticipated|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 01:12:33.142731|2018-06-01 01:12:33.142731
NCT00861887|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-13|||2016-12-13|2009-03-13|2009-03-16|Estimate|||||||2016-12-13|2016-12-14|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|January 2010|Anticipated|2010-01-31|November 2009|Anticipated|2009-11-30||Interventional|||Extended Treatment With Vancomycin for Clostridium Difficile Colitis|Comparative Study of 2 Weeks Versus 4 Weeks Treatment With Vancomycin for Clostridium Difficile Colitis|Withdrawn||N/A|0|Actual|William Beaumont Hospitals||2||Difficult enrollment|f||||t||||||||No||2018-06-01 01:12:33.209431|2018-06-01 01:12:33.209431
NCT00861874|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2012-10-08|2009-03-13|2009-03-16|Estimate|||||||2012-10-08|2012-10-10|Estimate|January 2010||2010-01-31|October 2012|2012-10-31||||September 2012|Actual|2012-09-30||Interventional|||A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 1|13|Actual|University of Rochester||1|||f||||t||||||||||2018-06-01 01:12:33.286818|2018-06-01 01:12:33.286818
NCT00861861|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2013-10-11|2009-03-13|2009-03-16|Estimate|||||||2013-10-11|2013-10-14|Estimate|September 2008||2008-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|COMPACT-CAD||Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)|Comparison of Pitavastatin With Atorvastatin in Increasing HDL-C and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease.|Completed||Phase 4|129|Actual|Kumamoto University||2|||f||||f||||||||||2018-06-01 01:12:33.348916|2018-06-01 01:12:33.348916
NCT00861848|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-09-17|2009-03-13|2009-03-16|Estimate|||||||2009-09-17|2009-09-21|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Observational|ECHOBIKE||Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging|Quantification of Ventricular Mechanics and Myocardial Blood Flow Reserve in Adolescents and Adults Ages 13-40 With Congenital or Acquired Heart Disease Using Supine Bicycle Stress With Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging|Unknown status|Enrolling by invitation||80|Anticipated|University of Nebraska|||1||f||||f||||||||||2018-06-01 01:12:33.432207|2018-06-01 01:12:33.432207
NCT00861835|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|November 2004||2004-11-30|March 2009|2009-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Trial of Rapid On-Site Evaluation of Transbronchial Needle Aspirate (TBNA)|A Randomized Prospective Trial of Rapid On-Site Evaluation of Transbronchial Needle Aspirate Specimens|Completed||N/A|||Maine Medical Center||2|||f||||t||||||||||2018-06-01 01:12:33.49933|2018-06-01 01:12:33.49933
NCT00861822|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2013-02-22|2009-03-12|2009-03-13|Estimate|||||||2013-02-22|2013-02-25|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study|Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study|Completed||Phase 1|60|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 01:12:33.548895|2018-06-01 01:12:33.548895
NCT00861809|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26||2012-03-22|2017-01-27|2009-03-12|2009-03-13|Estimate||||2012-03-22|2012-03-29|Estimate|2017-01-27|2017-01-30|Estimate|June 2009||2009-06-30|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis|A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis|Completed||Phase 2|11|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:12:33.608599|2018-06-01 01:12:33.608599
NCT00861796|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2011-06-06|2009-03-12|2009-03-13|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2008||2008-03-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Study of CYR-101 in Patients With Schizophrenia|A Multi-center, Inpatient and Ambulatory, Phase 2, Double Blind, Randomized, Placebo-controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia|Completed||Phase 2|100|Anticipated|Cyrenaic Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:12:33.712493|2018-06-01 01:12:33.712493
NCT00861783|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-06-22|2009-03-12|2009-03-13|Estimate|||||||2017-06-22|2017-06-23|Actual|June 2008||2008-06-30|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma|A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors|Completed||Phase 1|16|Actual|Onconova Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 01:12:33.772028|2018-06-01 01:12:33.772028
NCT00861770|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2017-05-09|2009-03-12|2009-03-13|Estimate|||||||2017-05-09|2017-05-11|Actual|November 2008||2008-11-30|May 2017|2017-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|TEAM UF||Utilizing Blood Volume Measurements in the Treatment of Heart Failure Patients|Prospective Protocol for Utilizing Blood Volume Measurements in the Treatment of Heart Failure Patients|Completed||N/A|30|Actual|Christiana Care Health Services||2|||f||||t||||||||||2018-06-01 01:12:33.919487|2018-06-01 01:12:33.919487
NCT00861757|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2011-05-10||2011-06-23|2009-03-12|2009-03-13|Estimate|2011-05-10|2011-06-13|Estimate||||2011-06-23|2011-06-28|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia|A Phase 3, Randomized, Double Blind, Placebo and Tamsulosin Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil Once a Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|612|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:12:34.05068|2018-06-01 01:12:34.05068
NCT00861744|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2011-07-14||2018-03-02|2009-03-12|2009-03-13|Estimate|2011-09-29|2011-11-04|Estimate||||2018-03-02|2018-03-29|Actual|June 3, 2009||2009-06-03|August 2016|2016-08-31|June 18, 2012|Actual|2012-06-18|July 21, 2010|Actual|2010-07-21||Interventional|||Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age|A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites.|Completed||Phase 2|1259|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:12:35.735573|2018-06-01 01:12:35.735573
NCT00861731|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-04-27|2009-03-12|2009-03-13|Estimate|||||||2009-04-27|2009-04-28|Estimate|November 2008||2008-11-30|April 2009|2009-04-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|VICTORY||Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy|The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Azienda Ospedaliero Universitaria di Sassari||3|||f||||t||||||||||2018-06-01 01:12:38.731698|2018-06-01 01:12:38.731698
NCT00861718|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-12-09|2009-03-12|2009-03-13|Estimate|||||||2009-12-09|2009-12-10|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|October 2009|Actual|2009-10-31|||||Interventional|||Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7268 When Given in Multiple Ascending Oral Doses in Healthy Subjects|Completed||Phase 1|40|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:12:38.805037|2018-06-01 01:12:38.805037
NCT00861705|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2015-01-12||2018-03-29|2009-03-12|2009-03-13|Estimate|2015-03-13|2015-03-23|Estimate||||2018-03-29|2018-04-27|Actual|May 2009||2009-05-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2014|Actual|2014-08-31||Interventional||Using a modified intent-to-treat approach only patients who began protocol treatment (n=443) were included in analyses for neoadjuvant treatment and toxicity. Analyses for surgical endpoints excluded 10 patients who withdrew consent prior to surgery (n=433). All analyses considered patients according to treatment assignment.|Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery|Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer|Active, not recruiting||Phase 2|454|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 01:12:39.101328|2018-06-01 01:12:39.101328
NCT00861692|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2015-11-17||2016-07-01|2009-03-12|2009-03-13|Estimate|2015-11-17|2015-12-22|Estimate||||2016-07-01|2016-08-01|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II|An Open-label, Multi-centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy|Completed||Phase 2|20|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 01:12:42.569569|2018-06-01 01:12:42.569569
NCT00861679|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-15|2009-03-12|2009-03-13|Estimate|||||||2009-03-15|2009-03-17|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|September 2014|Anticipated|2014-09-30|September 2009|Anticipated|2009-09-30||Interventional|ALL SCT BFM||Therapy Protocol Acute Lymphoblastic Leukemia Stem Cell Transplantation International|Therapy Protocol ALL SCT BFM International-Open, Multicenter, Controlled, Prospective Study for Therapy and Therapy Optimisation in Patients With Acute Lymphoblastic Leukemia (ALL) and an Indication for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Unknown status|Recruiting|Phase 1/Phase 2|552|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 01:12:42.91412|2018-06-01 01:12:42.91412
NCT00861666|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-06-01|2009-03-12|2009-03-13|Estimate|||||||2009-06-01|2009-06-03|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Forgiveness-Based Writing to Prevent Post-Traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans|Forgiveness-Based Writing to Prevent Posttraumatic Stress Disorder in OEF/OIF Veterans|Unknown status|Recruiting|N/A|20|Anticipated|South Central VA Mental Illness Research, Education & Clinical Center||1|||f||||f||||||||||2018-06-01 01:12:42.98769|2018-06-01 01:12:42.98769
NCT00861653|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2014-04-14|2009-03-12|2009-03-13|Estimate|||||||2014-04-14|2014-04-15|Estimate|October 2006||2006-10-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|August 2011|Actual|2011-08-31||Observational|APC||Atherosclerotic Plaque Characterization|Atherosclerotic Plaque Characterization Using Multispectral, Multicontrast High Resolution Cardiovascular Magnetic Resonance Imaging|Completed|||50|Actual|Piedmont Healthcare|||||f||||f||||||Samples With DNA|"~     Serum and tissue samples are collected for markers of inflammation and gene chip analysis~   "|||2018-06-01 01:12:43.075766|2018-06-01 01:12:43.075766
NCT00861640|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-07-14|2009-03-12|2009-03-13|Estimate|||||||2009-07-14|2009-07-15|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding|The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding|Unknown status|Recruiting|Phase 4|200|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-06-01 01:12:43.136257|2018-06-01 01:12:43.136257
NCT00861627|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2015-12-01|2009-03-12|2009-03-13|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation|Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors|Completed||Phase 2|37|Actual|Oncolytics Biotech|||||f||||f||||||||||2018-06-01 01:12:43.233129|2018-06-01 01:12:43.233129
NCT00861614|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2016-03-15||2016-08-04|2009-03-12|2009-03-13|Estimate|2016-03-15|2016-03-16|Estimate||||2016-08-04|2016-09-30|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|November 2012|Actual|2012-11-30||Interventional|||Study of Immunotherapy to Treat Advanced Prostate Cancer|A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel|Completed||Phase 3|988|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:12:43.512373|2018-06-01 01:12:43.512373
NCT00861601|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2010-05-11||2015-04-23|2009-03-12|2009-03-13|Estimate|2010-08-30|2010-09-23|Estimate||||2015-04-23|2015-05-12|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease|TPL111913, a Multi-centre, Open Label, Dose Ranging Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease|Completed||Phase 2|38|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 01:12:45.086255|2018-06-01 01:12:45.086255
NCT00861588|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effects of Isoflavone in Patients With Watchful Waiting Benign Prostate Hyperplasia||Completed||N/A|176|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:12:46.037801|2018-06-01 01:12:46.037801
NCT00861575|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-11-16|2009-03-12|2009-03-13|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2006||2006-02-28|November 2017|2017-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|CGR||Cardiogenomics Registry|CAD Genotype and Phenotype Cardiac Catheterization Laboratory Registry|Completed|||2601|Actual|Piedmont Healthcare|||||f||||f||||||Samples With DNA|"~     20 mL of blood are collected and aliquots of whole blood, plasma, serum and buffy coat are~     stored.~   "|||2018-06-01 01:12:46.324672|2018-06-01 01:12:46.324672
NCT00861562|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|April 2009|Anticipated|2009-04-30|October 2008|Actual|2008-10-31||Interventional|||Clinical Efficacy and Safety Evaluation of the Drug Imescard Compound Water Smartweed Pills|Clinical Efficacy and Safety Evaluation of the Drug Imescard Compound Water Smartweed Pills|Unknown status|Active, not recruiting|Phase 3|56|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:12:46.550019|2018-06-01 01:12:46.550019
NCT00861549|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2011-09-13|2009-03-12|2009-03-13|Estimate|||||||2011-09-13|2011-09-14|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers|Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers|Completed||Phase 1|30|Anticipated|PhytoHealth Corporation||3|||f||||f||||||||||2018-06-01 01:12:46.815653|2018-06-01 01:12:46.815653
NCT00861536|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2015-04-13|2009-03-12|2009-03-13|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Comparison of ATG to Thymoglobuline in Renal Transplantation|An Open, Multicenter, Randomised, Parallel Group Pilot Study to Investigate Two Different Polyclonal Rabbit Immunoglobulin Preparations for Safety and Efficacy:A Comparison of ATG-Fresenius S to Thymoglobulin in Prophylaxis for Immunological High Risk Patients Following Renal Transplantation|Completed||Phase 4|40|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 01:12:47.066369|2018-06-01 01:12:47.066369
NCT00861523|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2015-06-21|2009-03-12|2009-03-13|Estimate|||||||2015-06-21|2015-06-23|Estimate|February 2009||2009-02-28|June 2015|2015-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Does Thiamine Help Vomiting and Nausea in Pregnancy?|Comparison Between the Treatment of Thiamine and Promethazine for Improving Vomiting and Nausea in Pregnancy|Terminated||Phase 3|50|Actual|HaEmek Medical Center, Israel||2||Difficulties in recruiting patients|f||||||||||||||2018-06-01 01:12:47.468673|2018-06-01 01:12:47.468673
NCT00861510|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2018-05-23|2009-03-12|2009-03-13|Estimate|||||||2018-05-23|2018-05-24|Actual|March 5, 2009||2009-03-05|September 4, 2014|2014-09-04|October 19, 2012|Actual|2012-10-19|October 19, 2012|Actual|2012-10-19||Interventional|||A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies|A Pilot Study of the Safety and Efficacy of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies|Completed||Phase 1|16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:12:47.548421|2018-06-01 01:12:47.548421
NCT00861497|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2013-09-13|2009-03-12|2009-03-13|Estimate|||||||2013-09-13|2013-09-16|Estimate|January 2006||2006-01-31|September 2013|2013-09-30|July 2009|Actual|2009-07-31|January 2008|Actual|2008-01-31||Interventional|||Bifeprunox Extension to Extension Study in Patients With Schizophrenia|An Open-label Safety Study of Bifeprunox Investigating Flexible Doses of 20, 30, or 40mg/Day in Patients With Schizophrenia Who Have Completed Studies 10206 or 10265|Terminated||Phase 3|11|Actual|H. Lundbeck A/S||1||The study stopped after been paused (the patients were switched in the meantime)|f||||f||||||||||2018-06-01 01:12:47.621922|2018-06-01 01:12:47.621922
NCT00861484|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-06-13|2009-03-12|2009-03-13|Estimate|||||||2017-06-13|2017-06-14|Actual|November 26, 2008|Actual|2008-11-26|June 2017|2017-06-30|December 11, 2009|Actual|2009-12-11|December 11, 2009|Actual|2009-12-11||Interventional|PoM||Proof of Mechanism in ELT|A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation|Completed||Phase 1|33|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:12:47.688812|2018-06-01 01:12:47.688812
NCT00861471|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2011-04-29||2016-05-31|2009-03-12|2009-03-13|Estimate|2011-06-02|2011-06-29|Estimate||||2016-05-31|2016-06-30|Estimate|May 2005||2005-05-31|May 2016|2016-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer|Phase I/II, Open Label Study of Sequential Taxotere® (Docetaxel) and Gleevec® (Imatinib Mesylate) in Hormone Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|24|Actual|New York University School of Medicine|This study was terminated before it reached the target accrual number due to slow accrual, leading to small number of subjects analyzed (12 out of the target number of 37).|1||due to slow accrual|f||||t||||||||||2018-06-01 01:12:47.84862|2018-06-01 01:12:47.84862
NCT00861458|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-07-06|2009-03-12|2009-03-13|Estimate|||||||2009-07-06|2009-07-08|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State|A Phase 1, Open-Label, Randomized, 3-Way Crossover Study In Healthy Subjects To Estimate The Pharmacokinetics Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:12:48.1197|2018-06-01 01:12:48.1197
NCT00861445|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2014-10-17|2009-03-12|2009-03-13|Estimate|||||||2014-10-17|2014-10-20|Estimate|June 2001||2001-06-30|July 2010|2010-07-31|February 2003|Actual|2003-02-28|January 2003|Actual|2003-01-31||Interventional|||A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy|A Randomized, Double-Blind Placebo Controlled Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy|Completed||Phase 2|119|Actual|UCB Pharma||2|||f||||t||||||||||2018-06-01 01:12:48.190398|2018-06-01 01:12:48.190398
NCT00861432|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2016-09-12|2009-03-12|2009-03-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|April 2011|Actual|2011-04-30|July 2010|Actual|2010-07-31||Interventional|||Evaluation of Questionnaires of Tumor Patients With and Without Additive Homeopathic Therapy|Evaluation of Quality of Life of Tumor Patients With and Without Additive Homeopathy.|Completed||Phase 2|400|Actual|Medical University of Vienna||2|||f||||f||||||||No||2018-06-01 01:12:48.269113|2018-06-01 01:12:48.269113
NCT00861419|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-02-07|2009-03-12|2009-03-13|Estimate|||||||2017-02-07|2017-02-08|Estimate|December 2005||2005-12-31|February 2017|2017-02-28||||||||Interventional|||To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.|An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|88|Anticipated|Amgen||8|||f||||||||||||||2018-06-01 01:12:48.354854|2018-06-01 01:12:48.354854
NCT00861406|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-02-28|2009-03-12|2009-03-13|Estimate|||||||2017-02-28|2017-03-03|Actual|March 10, 2009|Actual|2009-03-10|February 2017|2017-02-28|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|||Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine|An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients With Resected Stage II and III (N1a, N2a) Melanoma|Completed||Phase 1|38|Actual|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-06-01 01:12:48.443727|2018-06-01 01:12:48.443727
NCT00861393|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|February 2009||2009-02-28|March 2009|2009-03-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|CBT||Cognitive Behavioural Therapy (CBT) For Improving Emotional Well Being in Spinal Cord Injuries (SCI)|The Impact of a Brief Cognitive Behavior Therapy Intervention Aimed at Improving Emotional Well-Being and Quality of Life for Individuals With Spinal Cord Injuries|Unknown status|Active, not recruiting|N/A|50|Anticipated|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-06-01 01:12:48.533722|2018-06-01 01:12:48.533722
NCT00861380|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12||2013-02-14|2016-08-08|2009-03-12|2009-03-13|Estimate||||2013-02-14|2013-02-18|Estimate|2016-08-08|2016-08-09|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|October 2013|Actual|2013-10-31|January 2012|Actual|2012-01-31||Interventional|FinIP||Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease|Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease|Completed||Phase 3|41188|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:12:48.602195|2018-06-01 01:12:48.602195
NCT00861367|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2016-11-17|2009-03-12|2009-03-13|Estimate|||||||2016-11-17|2016-11-21|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Prospective Double-blind Study for the Use of Aspirin During Transurethral Surgery of the Bladder or the Prostate|Prospektive Doppel-Blind-randomisierte Studie Zur Verwendung Von Aspirin Bei Transurethralen Operationen|Withdrawn||N/A|0|Actual|University Hospital, Basel, Switzerland||2||difficult enrollment, focus of study no longer of interest|f||||f||||||||||2018-06-01 01:12:48.729792|2018-06-01 01:12:48.729792
NCT00861354|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2010-01-06|2009-03-12|2009-03-13|Estimate|||||||2010-01-06|2010-01-08|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|TRIPPS||Home Monitoring for Atrial Fibrillation Using a Microlife Blood Pressure Monitor|Home Monitoring for Atrial Fibrillation Using a Microlife Blood Pressure Monitor: Trial of Regular vs Irregualr Pulse for the Prevention of Stroke (TRIPPS 2.0)|Completed|||150|Anticipated|Microlife|||||f||||f||||||||||2018-06-01 01:12:49.002001|2018-06-01 01:12:49.002001
NCT00861341|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2011-06-21||2015-12-23|2009-03-12|2009-03-13|Estimate|2015-12-23|2016-02-03|Estimate||||2015-12-23|2016-02-03|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|UHEM08014||Effects of Pioglitazone on Platelet Function|Effects of Pioglitazone on Platelet Function|Completed||Phase 2|40|Actual|University of Rochester||1|||f||||t||||||||||2018-06-01 01:12:49.13031|2018-06-01 01:12:49.13031
NCT00851461|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2015-05-20|2009-02-25|2009-02-26|Estimate|||||||2015-05-20|2015-05-21|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|November 2013|Actual|2013-11-30|November 2011|Actual|2011-11-30||Interventional|||Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy|Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai Patients|Completed||Phase 4|10|Actual|Ramathibodi Hospital|||||f||||f||||||||||2018-06-01 01:16:14.526713|2018-06-01 01:16:14.526713
NCT00861328|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-06-22|2009-03-12|2009-03-13|Estimate|||||||2017-06-22|2017-06-23|Actual|February 2008||2008-02-29|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin|A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Advanced Solid Tumors|Completed||Phase 1|18|Actual|Onconova Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 01:12:49.332246|2018-06-01 01:12:49.332246
NCT00861315|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-13|2009-03-12|2009-03-13|Estimate|||||||2009-03-13|2009-03-16|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|DARTAGNAN||Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation|Phase II Study of High Dose Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation|Unknown status|Recruiting|Phase 2/Phase 3|24|Anticipated|Association Pour La Promotion A Tours De La Reanimation Medicale||2|||f||||t||||||||||2018-06-01 01:12:49.425929|2018-06-01 01:12:49.425929
NCT00861302|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2012-06-18|2009-03-12|2009-03-13|Estimate|||||||2012-06-18|2012-06-19|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Evaluating a Chronic Pain Treatment Program|Evaluating Outcomes and Response Profiles of a Psychological Treatment for People With Chronic Pain|Completed||Phase 1|72|Actual|Wayne State University||1|||f||||f||||||||||2018-06-01 01:12:49.518867|2018-06-01 01:12:49.518867
NCT00861276|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|June 2000||2000-06-30|March 2009|2009-03-31|December 2001|Actual|2001-12-31|July 2001|Actual|2001-07-31||Interventional|SUNIC||Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit|Use of Nicotine Substitute Prescribed at Hourly Intake or ad Libitum for Heavy Smokers Willing to Quit: a Randomized Controlled Trial|Completed||Phase 4|50|Actual|University of Lausanne||2|||f||||f||||||||||2018-06-01 01:12:49.599341|2018-06-01 01:12:49.599341
NCT00861263|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2013-11-12||2014-03-07|2009-03-12|2009-03-13|Estimate|2014-03-07|2014-04-14|Estimate||||2014-03-07|2014-04-14|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Spirus||The Clinical Utility of Overtube Use at the Time of Endoscopy|The Clinical Utility of Overtube Use at the Time of Endoscopy|Completed||N/A|193|Actual|University of Florida|No limitations were found|1|||f||||f||||||||||2018-06-01 01:12:49.969151|2018-06-01 01:12:49.969151
NCT00861250|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2016-06-15|2009-03-12|2009-03-13|Estimate|||||||2016-06-15|2016-06-17|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT|Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-dexamethasone (Vel/Dex) Followed by HDT With ASCT|Completed||Phase 2/Phase 3|47|Actual|Tampere University Hospital||1|||f||||t||||||||||2018-06-01 01:12:50.147192|2018-06-01 01:12:50.147192
NCT00861237|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-08-28|2009-03-12|2009-03-13|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2008||2008-07-31|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery|Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery|Terminated||Phase 4|12|Actual|Medical University of Vienna||2||Number of patients recruited to small, no cooperation of study members|f||||f||||||||No||2018-06-01 01:12:50.306239|2018-06-01 01:12:50.306239
NCT00861224|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2010-07-15|2009-03-12|2009-03-13|Estimate|||||||2010-07-15|2010-07-16|Estimate|August 2005||2005-08-31|July 2010|2010-07-31|May 2007|Actual|2007-05-31|October 2006|Actual|2006-10-31||Observational|||Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology|The Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Completed|||10|Actual|Amgen|||1||f||||||||||None Retained|"~     No biospecimen samples were retained.~   "|||2018-06-01 01:12:50.559635|2018-06-01 01:12:50.559635
NCT00861211|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12||2011-07-07|2011-07-08|2009-03-12|2009-03-13|Estimate||||2011-07-08|2011-07-14|Estimate|2011-07-08|2011-07-14|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess The Safety and Efficacy of Two Weeks of Oral Senicapoc Administration on Allergen Challenge in Atopic Asthmatic Subjects|Completed||Phase 2|34|Actual|Icagen||2|||f||||f||||||||||2018-06-01 01:12:50.695123|2018-06-01 01:12:50.695123
NCT00861198|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|2015-06-29||2015-06-29|2009-03-12|2009-03-13|Estimate|2015-06-29|2015-07-27|Estimate||||2015-06-29|2015-07-27|Estimate|November 2006||2006-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders|The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders|Completed|||88|Actual|University of Florida|||1||f||||f||||||||||2018-06-01 01:12:50.810185|2018-06-01 01:12:50.810185
NCT00861185|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12||2011-07-07|2011-07-08|2009-03-12|2009-03-13|Estimate||||2011-07-08|2011-07-14|Estimate|2011-07-08|2011-07-14|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of Four Weeks of Oral Senicapoc Administration on Exercise-Induced Asthma|Completed||Phase 2|69|Actual|Icagen||2|||f||||f||||||||||2018-06-01 01:12:51.108724|2018-06-01 01:12:51.108724
NCT00861172|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2013-06-20|2009-03-12|2009-03-13|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|IRM 3T-SEP||Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy|Longitudinal (Weekly) Follow-up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy|Completed||N/A|6|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-06-01 01:12:51.246636|2018-06-01 01:12:51.246636
NCT00861159|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2011-01-11|2009-03-12|2009-03-13|Estimate|||||||2011-01-11|2011-01-12|Estimate|September 2011||2011-09-30|January 2011|2011-01-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||RLIP76 in Human Serum in Adults With Rheumatologic Diseases|Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.|Withdrawn|||100|Anticipated|University of North Texas Health Science Center|||1|Study withdrawn due to lack of staffing resources and subject interest|f||||t||||||||||2018-06-01 01:12:51.380034|2018-06-01 01:12:51.380034
NCT00861146|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2014-01-15||2014-02-27|2009-03-12|2009-03-13|Estimate|2014-02-27|2014-04-07|Estimate||||2014-02-27|2014-04-07|Estimate|April 2009||2009-04-30|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk|Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk|Completed||Phase 2|151|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:12:51.518963|2018-06-01 01:12:51.518963
NCT00861133|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-05-04|2009-03-12|2009-03-13|Estimate|||||||2009-05-04|2009-05-05|Estimate|March 2009||2009-03-31|May 2009|2009-05-31|May 2011|Anticipated|2011-05-31|April 2011|Anticipated|2011-04-30||Interventional|||Cryptogenic Stroke Study|Long-Term Cardiac Monitoring for Detection of Atrial Fibrillation After Cryptogenic Stroke|Unknown status|Recruiting|N/A|100|Anticipated|Transoma Medical|||||f||||t||||||||||2018-06-01 01:12:52.252536|2018-06-01 01:12:52.252536
NCT00861120|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2012-10-25|2009-03-12|2009-03-13|Estimate|||||||2012-10-25|2012-10-26|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|PaLiDo||Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type|Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-type|Completed||Phase 2|33|Anticipated|Vejle Hospital|||||f||||t||||||||||2018-06-01 01:12:52.512586|2018-06-01 01:12:52.512586
NCT00861107|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2011-06-06|2009-03-12|2009-03-13|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2009||2009-08-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation|Phase I/II Study of a Therapeutic Cancer Vacccine Created In-situ in Patients With Refractory or Metastatic Cancer|Completed||Phase 1/Phase 2|50|Anticipated|Immunovative Therapies, Ltd.|||||f||||f||||||||||2018-06-01 01:12:52.621664|2018-06-01 01:12:52.621664
NCT00861094|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2015-12-17|2009-03-12|2009-03-13|Estimate|||||||2015-12-17|2015-12-18|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|September 2011|Actual|2011-09-30||Interventional|||Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer|Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.|Completed||Phase 2/Phase 3|266|Actual|UNICANCER||2|||f||||t||||||||||2018-06-01 01:12:52.788145|2018-06-01 01:12:52.788145
NCT00861081|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2014-01-06|2009-03-12|2009-03-13|Estimate|||||||2014-01-06|2014-01-07|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|SUSTAIN||"Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to Stay Within the Guidelines"|"RCT of an Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to Stay Within the Guidelines (SUSTAIN)"|Completed||N/A|410|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:12:52.98106|2018-06-01 01:12:52.98106
NCT00861068|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2014-10-17|2009-03-12|2009-03-13|Estimate|||||||2014-10-17|2014-10-20|Estimate|February 2002||2002-02-28|March 2009|2009-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).|A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).|Completed||Phase 2|44|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 01:12:53.247772|2018-06-01 01:12:53.247772
NCT00861055|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2010-01-22|2009-03-12|2009-03-13|Estimate|||||||2010-01-22|2010-01-25|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|December 2011|Anticipated|2011-12-31|February 2011|Anticipated|2011-02-28||Observational|NSS||Neonatal Sepsis and GBS Carriage Study|A Clinical and Microbiological Study of Early Onset Neonatal Sepsis in Refugee Infants and Group B Streptococcal Carriage in Expectant Refugee Mothers Living on the Thai-Burmese Border|Unknown status|Recruiting||160|Anticipated|University of Oxford|||2||f||||f||||||||||2018-06-01 01:12:53.347748|2018-06-01 01:12:53.347748
NCT00861042|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2014-09-19|2009-03-12|2009-03-13|Estimate|||||||2014-09-19|2014-09-22|Estimate|April 2002||2002-04-30|July 2010|2010-07-31|March 2005|Actual|2005-03-31|December 2004|Actual|2004-12-31||Interventional|||An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy|An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy|Completed||Phase 2|69|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 01:12:53.673233|2018-06-01 01:12:53.673233
NCT00861029|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-11-10|2009-03-12|2009-03-13|Estimate|||||||2017-11-10|2017-11-14|Actual|March 19, 2009|Actual|2009-03-19|November 2017|2017-11-30|February 15, 2010|Actual|2010-02-15|February 15, 2010|Actual|2010-02-15||Interventional|||VEG111485: A QTc Study of Pazopanib|A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors|Completed||Phase 1|2|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:12:53.811775|2018-06-01 01:12:53.811775
NCT00861016|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|October 2005||2005-10-31|March 2009|2009-03-31|May 2006|Actual|2006-05-31|April 2006|Actual|2006-04-30||Interventional|||Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension|An Open-Label, Non-Comparative, Multi-Centre Study to Evaluate the Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet (Betaloc Zok) in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 4|310|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:12:54.021736|2018-06-01 01:12:54.021736
NCT00861003|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|August 2010|Anticipated|2010-08-31|December 2009|Anticipated|2009-12-31||Observational|MEMS-SPR||An Adherence Study of Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder|An Exploratory Study on Comparison of Electronic Monitoring and Other Measures of Adherence to Antipsychotic Medication in Outpatients With Schizophrenia or Schizoaffective Disorder|Unknown status|Not yet recruiting||57|Anticipated|Korea University Guro Hospital|||1||f||||f||||||||||2018-06-01 01:12:54.20382|2018-06-01 01:12:54.20382
NCT00860990|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2015-06-25|2009-03-11|2009-03-13|Estimate|||||||2015-06-25|2015-06-26|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|VA GI QOL||VA Gastrointestinal (GI) Quality of Life Survey|VA GI Quality of Life Survey|Terminated|||100|Anticipated|VA Office of Research and Development|||2|Outcome measures are included in another, similar study.|f||||f||||||||||2018-06-01 01:12:54.309339|2018-06-01 01:12:54.309339
NCT00860977|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2018-03-02|2009-03-11|2009-03-13|Estimate|||||||2018-03-02|2018-03-06|Actual|March 2010|Actual|2010-03-31|March 2018|2018-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|VALIDATE||Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?|VALacyclovir In Delaying Antiretroviral Treatment Entry|Completed||Phase 3|202|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 01:12:54.418751|2018-06-01 01:12:54.418751
NCT00860964|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-16|2009-03-12|2009-03-13|Estimate|||||||2009-03-16|2009-03-17|Estimate|February 1998||1998-02-28|March 2009|2009-03-31|December 2006|Actual|2006-12-31|February 2003|Actual|2003-02-28||Interventional|||A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women|A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women|Completed||Phase 4|221|Actual|Peking Union Medical College||2|||f||||f||||||||||2018-06-01 01:12:54.761289|2018-06-01 01:12:54.761289
NCT00860951|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2015-05-27||2015-06-10|2009-03-11|2009-03-13|Estimate|2015-05-27|2015-06-11|Estimate||||2015-06-10|2015-07-09|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Participants who completed the protocol.|P300 Brain Computer Interface Keyboard to Operate Assistive Technology||Completed||Phase 1/Phase 2|29|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 01:12:54.993083|2018-06-01 01:12:54.993083
NCT00860938|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2009-03-12|2009-03-12|2009-03-13|Estimate|||||||2009-03-12|2009-03-13|Estimate|April 2007||2007-04-30|March 2009|2009-03-31|May 2010|Anticipated|2010-05-31|June 2009|Anticipated|2009-06-30||Interventional|||Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD|Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Recruiting|Phase 4|100|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 01:12:55.486333|2018-06-01 01:12:55.486333
NCT00860925|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2010-03-08|2009-03-12|2009-03-13|Estimate|||||||2010-03-08|2010-03-09|Estimate|May 2009||2009-05-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|POISE2-pilot||PeriOperative ISchemic Evaluation-2 Pilot|PeriOperative ISchemic Evaluation-2 (POISE-2) Trial: A Pilot|Completed||Phase 4|90|Actual|McMaster University||4|||f||||f||||||||||2018-06-01 01:12:55.831253|2018-06-01 01:12:55.831253
NCT00860912|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-12|||2017-04-18|2009-03-12|2009-03-13|Estimate|||||||2017-04-18|2017-04-20|Actual|December 2001||2001-12-31|April 2017|2017-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Veritas Collagen Matrix Cystocele Repair Study - Postmarketing|Veritas Collagen Matrix Cystocele Repair Study - Postmarketing Protocol #CP1004|Completed||N/A|94|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 01:12:55.955356|2018-06-01 01:12:55.955356
NCT00860899|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2011-11-16|2009-03-11|2009-03-12|Estimate|||||||2011-11-16|2011-11-17|Estimate|December 2007||2007-12-31|November 2011|2011-11-30|May 2009|Actual|2009-05-31|October 2008|Actual|2008-10-31||Interventional|PPSAPACL||Postoperative Pain and SIRS After Preoperative Analgesia With Clonidine or Levobupivacaine|Postoperative Pain and Systemic Inflammatory Stress Response (SIRS) After Preoperative Analgesia With Clonidine or Levobupivacaine|Completed||Phase 4|42|Actual|University Hospital Dubrava||2|||f||||f||||||||||2018-06-01 01:12:56.052681|2018-06-01 01:12:56.052681
NCT00860886|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2018-04-04|2009-03-11|2009-03-12|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2, 2009||2009-03-02|March 6, 2018|2018-03-06||||||||Observational|||Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer|Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer|Completed|||433|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:12:56.169034|2018-06-01 01:12:56.169034
NCT00860873|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-02-22|2009-03-11|2009-03-12|Estimate|||||||2013-02-22|2013-02-25|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|||Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis|"Randomized Study of Two Dosage Forms (Oral Powder and Capsule) of Chondroitin + Glucosamine Sulfate Produced by the Laboratory EMS When Compared to the Product Condroflex (Oral Powder and Capsules) Produced by Laboratory Zodiac in the Treatment of Osteoarthrosis."|Completed||Phase 3|280|Actual|Azidus Brasil||4|||f||||f||||||||||2018-06-01 01:12:56.342182|2018-06-01 01:12:56.342182
NCT00860860|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2012-03-16|2009-03-11|2009-03-12|Estimate|||||||2012-03-16|2012-03-19|Estimate|July 2009||2009-07-31|August 2010|2010-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|PRIT2008||Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer|Phase I Clinical Study of the Feasibility of Pretargeted Radioimmunotherapy of an Anti-CEA Bispecific Antibody and Lu-177-labeled Peptide in Patients With Advanced Colorectal Cancer|Completed||Phase 1|20|Actual|Radboud University|||||f||||t||||||||||2018-06-01 01:12:56.432075|2018-06-01 01:12:56.432075
NCT00860847|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2013-01-27||2015-02-28|2009-03-11|2009-03-12|Estimate|2015-02-28|2015-03-12|Estimate||||2015-02-28|2015-03-12|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)|Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)|Completed||Phase 3|65|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-06-01 01:12:56.535003|2018-06-01 01:12:56.535003
NCT00860834|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2014-03-28|2009-03-10|2009-03-12|Estimate|||||||2014-03-28|2014-03-31|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|May 2014|Anticipated|2014-05-31|May 2013|Actual|2013-05-31||Interventional|PARTNER||Parents, Pediatricians, and Asthma Telephone Coaches Partner to Improve Control of Asthma in Children (The PARTNER Study)|Parents, Pediatricians, and Telephone Coaches Partner to Improve Control of Asthma|Unknown status|Active, not recruiting|N/A|1000|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:12:56.818548|2018-06-01 01:12:56.818548
NCT00860821|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-10-27|2009-03-11|2009-03-12|Estimate|||||||2009-10-27|2009-10-28|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Interventional|||A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)|A Randomised, Double-blind, Placebo-controlled, Two-way Crossover, Single-centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).|Completed||N/A|20|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:12:56.879798|2018-06-01 01:12:56.879798
NCT00860808|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2013-02-12|2009-03-11|2009-03-12|Estimate|||||||2013-02-12|2013-02-13|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus|Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study|Completed||Phase 2|248|Actual|Auris Medical, Inc.||3|||f||||t||||||||||2018-06-01 01:12:56.945456|2018-06-01 01:12:56.945456
NCT00860795|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2010-09-28||2018-04-29|2009-03-11|2009-03-12|Estimate|2010-10-20|2010-11-17|Estimate||||2018-04-29|2018-05-01|Actual|March 2009||2009-03-31|April 2018|2018-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Immunologic Effects of Echinacea|Study of the Immunologic Effects of Echinacea Purpurea in Adults|Completed||N/A|20|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 01:12:57.062101|2018-06-01 01:12:57.062101
NCT00860782|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2017-08-30|2009-03-10|2009-03-12|Estimate|||||||2017-08-30|2017-08-31|Actual|August 2008||2008-08-31|August 2017|2017-08-31|August 31, 2018|Anticipated|2018-08-31|May 2016|Actual|2016-05-31||Interventional|||Parent Educational Program for Children With Sickle Cell Disease|Parent Intervention to Improve Academic Success in Children With Sickle Cell Disease|Active, not recruiting||N/A|160|Anticipated|University of Miami||2|||f||||t||||||||Undecided||2018-06-01 01:12:57.78221|2018-06-01 01:12:57.78221
NCT00860769|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2016-09-26|2009-03-11|2009-03-12|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2008||2008-09-30|September 2016|2016-09-30|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional|||Asha HIV Health Promotion Intervention in India|ASHA HIV Health Promotion Intervention in India|Completed||Phase 1/Phase 2|68|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:12:58.030367|2018-06-01 01:12:58.030367
NCT00860756|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-03-11|2009-03-11|2009-03-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Sleep Disturbance in Deployed Soldiers|Sleep Disturbance in Deployed Soldiers|Unknown status|Recruiting|Early Phase 1|150|Anticipated|Brooke Army Medical Center||1|||f||||f||||||||||2018-06-01 01:12:58.393596|2018-06-01 01:12:58.393596
NCT00860743|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2014-12-10||2017-09-29|2009-03-10|2009-03-12|Estimate|2015-02-23|2015-02-25|Estimate||||2017-09-29|2017-11-01|Actual|September 2009||2009-09-30|September 2017|2017-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|RAP-IH|Overall 40 participants were enrolled in Aim 1. One OSA male and two healthy male participants were enrolled but withdrew from the study. Thus, the total number that completed Aim 1 was 37 participants.|Respiratory and Autonomic Plasticity Following Intermittent Hypoxia|Respiratory and Autonomic Plasticity Following Intermittent Hypoxia|Completed||Early Phase 1|63|Actual|VA Office of Research and Development|The primary limitation of this trial was the number of participants that required screening to recruit the participants that met the inclusion criteria for the study. However, once the participants were recruited few withdrew.|2|||f||||t||||||||||2018-06-01 01:12:58.692567|2018-06-01 01:12:58.692567
NCT00860730|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2015-05-21|2009-03-11|2009-03-12|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|October 2009|Actual|2009-10-31||Interventional|||PERCEVAL Pivotal Trial|PERCEVAL Pivotal Trial|Unknown status|Active, not recruiting|N/A|150|Actual|LivaNova||1|||f||||t||||||||||2018-06-01 01:12:59.690185|2018-06-01 01:12:59.690185
NCT00860717|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-12-12|2009-03-11|2009-03-12|Estimate|||||||2009-12-12|2009-12-15|Estimate|November 2006||2006-11-30|March 2009|2009-03-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients|Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial|Completed||N/A|25|Actual|Para Federal University||2|||f||||f||||||||||2018-06-01 01:12:59.791801|2018-06-01 01:12:59.791801
NCT00860704|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2015-04-06|2009-03-11|2009-03-12|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FLO1||Goal Directed Fluid Therapy|Intraoperative Goal Directed Fluid Therapy in Lean and Obese Patients|Completed||Phase 4|90|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:12:59.944634|2018-06-01 01:12:59.944634
NCT00860691|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2010-03-24|2009-03-11|2009-03-12|Estimate|||||||2010-03-24|2010-03-26|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|June 2010|Anticipated|2010-06-30|July 2009|Actual|2009-07-31||Interventional|||Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer|Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital Dubrava||3|||f||||t||||||||||2018-06-01 01:13:00.109736|2018-06-01 01:13:00.109736
NCT00860678|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-03-11|2009-03-11|2009-03-12|Estimate|||||||2009-03-11|2009-03-12|Estimate||||March 2009|2009-03-31||||||||Interventional|||Physical Activity in Patients After Aortic Valve Replacement (Valve-ex)|Influence of Regular Physical Activity on Exercise Capacity, Cardiac Remodeling and Endothelial Function in Patients After Aortic Valve Replacement|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Technische Universität München||2|||f||||||||||||||2018-06-01 01:13:00.213311|2018-06-01 01:13:00.213311
NCT00860665|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-03-11|2009-03-11|2009-03-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Observational|||Case Volume and Adenoma Rate During Screening Colonoscopy|Case Volume and Adenoma Detection Rates During Screening Colonoscopy|Completed|||12134|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-06-01 01:13:00.293652|2018-06-01 01:13:00.293652
NCT00860652|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2017-07-10|2009-03-11|2009-03-12|Estimate|||||||2017-07-10|2017-07-12|Actual|March 2009||2009-03-31|July 2017|2017-07-31|December 2026|Anticipated|2026-12-31|December 2021|Anticipated|2021-12-31||Interventional|RAVES||Radiotherapy - Adjuvant Versus Early Salvage|Radiotherapy - Adjuvant Versus Early Salvage. A Phase III Multi-centre Randomised Trial Comparing Adjuvant Radiotherapy (RT) With Early Salvage RT in Patients With Positive Margins or Extraprostatic Disease Following Radical Prostatectomy.|Active, not recruiting||Phase 3|333|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||t||||||||||2018-06-01 01:13:00.36265|2018-06-01 01:13:00.36265
NCT00860639|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2017-01-26|2009-03-11|2009-03-12|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2007||2007-10-31|January 2017|2017-01-31|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|LAM2006IR||Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk|Randomized Open Phase III Trial Testing Efficacy of Gemtuzumab Ozogamycin (MYLOTARG) Associated to Intensive Chemotherapy for Patients Aged Between 18-60 Years and Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk|Completed||Phase 3|327|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-06-01 01:13:01.54221|2018-06-01 01:13:01.54221
NCT00860626|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-03-11|2009-03-11|2009-03-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Interventional|||Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B|Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B|Unknown status|Recruiting|N/A|50|Anticipated|Sun Yat-sen University||3|||f||||f||||||||||2018-06-01 01:13:01.688998|2018-06-01 01:13:01.688998
NCT00860613|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-03-11|2009-03-11|2009-03-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|February 2004||2004-02-29|March 2009|2009-03-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Interventional|||Medical Nutrition Therapy Program for Pregnant Women With Diabetes|Medical Nutrition Therapy Program for Pregnant Women With Diabetes: Evaluation of Two Different Dietary Strategies on Metabolic Control, Maternal and Fetal Nutritional Status and Cost Effectiveness.|Completed||N/A|162|Actual|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||3|||f||||f||||||||||2018-06-01 01:13:01.7893|2018-06-01 01:13:01.7893
NCT00860600|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2015-11-03|2009-03-11|2009-03-12|Estimate|||||||2015-11-03|2015-11-04|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients|The Clinical Trial of PG2 in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Completed||Phase 2|14|Actual|PhytoHealth Corporation||2|||f||||f||||||||||2018-06-01 01:13:02.01224|2018-06-01 01:13:02.01224
NCT00860587|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-03-11|2009-03-11|2009-03-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Observational|Bakki||Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections|Risk Factors for Colonization and Infection With Antibiotic Resistant Bacteria Among Patients With Severe Intraabdominal Infections (IAI). An Open Observational Study|Unknown status|Active, not recruiting||200|Anticipated|University Hospital, Linkoeping|||||f||||f||||||||||2018-06-01 01:13:02.096064|2018-06-01 01:13:02.096064
NCT00860574|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11||2017-04-05|2017-04-05|2009-03-11|2009-03-12|Estimate||||2017-04-05|2017-04-07|Actual|2017-04-05|2017-04-07|Actual|February 2009||2009-02-28|April 2017|2017-04-30||||February 2013|Actual|2013-02-28||Interventional|||Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia|A Multi-Center Study of Conditioning With Treosulfan, Fludarabine and Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS), and Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2|96|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 01:13:02.31062|2018-06-01 01:13:02.31062
NCT00860561|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2014-10-09|2009-03-11|2009-03-12|Estimate|||||||2014-10-09|2014-10-10|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Faslodex Post Marketing Surveillance|Faslodex Post Marketing Surveillance|Completed|||42|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:13:02.474791|2018-06-01 01:13:02.474791
NCT00860548|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2017-04-03|2009-03-11|2009-03-12|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2005||2005-06-30|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||SCOT Scleroderma Treatment Alternative Registry (STAR Registry)|An Observational, Long-term Follow-up Study of Eligible Individuals Declining To Participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study (SCSSc-02)|Completed|||19|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||||||2018-06-01 01:13:02.55458|2018-06-01 01:13:02.55458
NCT00860535|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2011-06-28||2015-09-28|2009-03-11|2009-03-12|Estimate|2011-09-07|2011-10-10|Estimate||||2015-09-28|2015-09-30|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)|A Multicenter Phase Ib Trial to Determine Whether a Gene Expression Signature Changes in Response to Treatment With Bcr-Abl Inhibitors in Patients With Blast Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphocytic Leukemia|Terminated||Phase 1|9|Actual|Merck Sharp & Dohme Corp.|Part I aimed to have 10 evaluable patients. Due to slow enrollment, 9 patients who met the inclusion/exclusion criteria were enrolled over a period of 9 months. Part I was terminated early and Part II was cancelled due to slow enrollment.|1|||f||||f||||||||||2018-06-01 01:13:02.679048|2018-06-01 01:13:02.679048
NCT00860522|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2017-01-26|2009-03-11|2009-03-12|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2009|Actual|2009-03-31|January 2017|2017-01-31|October 19, 2017|Anticipated|2017-10-19|October 31, 2014|Actual|2014-10-31||Interventional|||JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia|A Phase I Trial of the Immunostimulant JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia|Active, not recruiting||Phase 1|23|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||Undecided|To determine if data is valuable|2018-06-01 01:13:02.842317|2018-06-01 01:13:02.842317
NCT00860509|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2012-05-02|2009-03-11|2009-03-12|Estimate|||||||2012-05-02|2012-05-03|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|Phyteaux-II||Comparison of Low and High Phytosterol Diets With Respect to Cholesterol Metabolism|Phyteaux-II- Regulation of Cholesterol Absorption: Response of LDL to Low and Naturally High Phytosterol Diets|Completed||N/A|20|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:13:02.965812|2018-06-01 01:13:02.965812
NCT00860496|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-08-12|2009-03-11|2009-03-12|Estimate|||||||2009-08-12|2009-08-13|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers|A Phase I, Open Label, Fixed-Sequence Study to Estimate the Effect of Tacrolimus and Cyclosporine on the Pharmacokinetics of CP-690,550 in Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:13:03.068706|2018-06-01 01:13:03.068706
NCT00860483|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2012-12-03|2009-03-10|2009-03-12|Estimate|||||||2012-12-03|2012-12-05|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|November 2009|Actual|2009-11-30|February 2009|Actual|2009-02-28||Interventional|||Correlation of Laparoscopic Experience and Functional Brain Activation: A PET Scan Study|GAC 0201 Correlation of Laparoscopic Experience and Functional Brain Activation: A Pet Scan Study|Completed||N/A|10|Anticipated|Northwell Health||1|||f||||f||||||||||2018-06-01 01:13:03.141513|2018-06-01 01:13:03.141513
NCT00860470|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2015-05-07||2015-05-07|2009-03-11|2009-03-12|Estimate|2015-05-07|2015-05-27|Estimate||||2015-05-07|2015-05-27|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|JiVitA-3||Antenatal Micronutrient Supplementation and Infant Survival|Antenatal Multiple Micronutrient Supplementation to Improve Infant Survival and Health in Bangladesh|Completed||Phase 3|44567|Actual|Johns Hopkins Bloomberg School of Public Health|The study was run in an area where iron deficiency rates were low.|2|||f||||t||||||||||2018-06-01 01:13:03.230406|2018-06-01 01:13:03.230406
NCT00860457|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2014-02-24||2018-04-09|2009-03-11|2009-03-12|Estimate|2014-08-04|2014-08-18|Estimate||||2018-04-09|2018-05-08|Actual|February 2008||2008-02-29|August 2014|2014-08-31|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|||Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)|Lenalidomide Following Rituximab and Fludarabine in Untreated Chronic Lymphocytic Leukemia|Completed||Phase 2|22|Actual|Georgetown University||1|||f||||t||||||||||2018-06-01 01:13:04.108124|2018-06-01 01:13:04.108124
NCT00860444|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2014-01-06|2009-03-10|2009-03-12|Estimate|||||||2014-01-06|2014-01-07|Estimate|May 2005||2005-05-31|January 2014|2014-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|HHER||Cardiovascular Risk Reduction Program Aimed at African American Women (The HHER Lifestyle Program)|The Heart Healthy and Ethnically Relevant (HHER) Lifestyle Program for Cardiovascular Risk Reduction|Completed||Phase 3|266|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-06-01 01:13:04.301254|2018-06-01 01:13:04.301254
NCT00860431|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2014-03-17|2009-03-11|2009-03-12|Estimate|||||||2014-03-17|2014-03-19|Estimate|March 2009||2009-03-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|K-STAR||Kremezin Study Against Renal Disease Progression in Korea|K-STAR (Kremezin STudy Against Renal Disease Progression in Korea) Randomized, Open-label, Controlled Study|Completed||Phase 4|578|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 01:13:04.401527|2018-06-01 01:13:04.401527
NCT00860418|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2015-08-31|2009-03-11|2009-03-12|Estimate|||||||2015-08-31|2015-09-02|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PAAL||Pediatric Asthma Alert Intervention for Minority Children With Asthma|Pediatric Asthma Alert Intervention for Minority Children|Completed||Phase 2|350|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 01:13:04.489918|2018-06-01 01:13:04.489918
NCT00860405|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2011-08-12||2011-11-01|2009-03-11|2009-03-12|Estimate|2011-08-12|2011-09-19|Estimate||||2011-11-01|2011-11-02|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Voluven® in Paediatric Patients|Efficacy and Safety of 6 % Hydroxyethyl Starch 130/0.4 (Voluven®) vs. 5% HSA in Volume Replacement Therapy During Elective Open-heart Surgery in Paediatric Patients|Completed||Phase 4|61|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 01:13:04.73649|2018-06-01 01:13:04.73649
NCT00860392|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2017-11-23|2009-03-11|2009-03-12|Estimate|||||||2017-11-23|2017-11-27|Actual|March 2, 2009|Actual|2009-03-02|November 2017|2017-11-30|July 8, 2009|Actual|2009-07-08|July 8, 2009|Actual|2009-07-08||Interventional|||A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation (0000-110)|A Comparison of Measurements of Ketone Body Flux Versus Ketone Body Concentration as a Pharmacodynamic Marker of Hepatic Fatty Acid Oxidation|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:13:05.48463|2018-06-01 01:13:05.48463
NCT00860379|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2018-04-17|2009-03-11|2009-03-12|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2009||2009-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of Selenium Supplementation Among Pediatric Patients With Burns|The Effect of Selenium Supplementation Among Pediatric Patients With Burns|Active, not recruiting||Phase 4|14|Actual|Shriners Hospitals for Children||3|||f||||t||||||||No||2018-06-01 01:13:05.538082|2018-06-01 01:13:05.538082
NCT00860366|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2015-03-09|2009-03-11|2009-03-12|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|Urico-Ictus||Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke|Randomized, Double Blind Study Assessing the Clinical Efficacy of Combined Treatment With Uric Acid and rtPA Administered Intravenously in Acute Ischemic Stroke Patients Within the First 4.5 Hours of Symptoms Onset|Completed||Phase 2/Phase 3|421|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||t||||||||||2018-06-01 01:13:05.607568|2018-06-01 01:13:05.607568
NCT00860353|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2010-12-02|2009-03-11|2009-03-12|Estimate|||||||2010-12-02|2010-12-03|Estimate|February 2009||2009-02-28|December 2010|2010-12-31|May 2009|Actual|2009-05-31|||||Interventional|||Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551|A Double Blind, Randomised, Placebo-controlled, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single, Ascending, Oral Doses of AZD2551 in Healthy Male Subjects|Terminated||Phase 1|90|Anticipated|AstraZeneca||2||"Due to portfolio and logistical issues, this study will not be re-started at the present time.~   The study is not being terminated for safety reasons."|f||||f||||||||||2018-06-01 01:13:05.714256|2018-06-01 01:13:05.714256
NCT00860340|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2014-12-09|2009-03-11|2009-03-12|Estimate|||||||2014-12-09|2014-12-10|Estimate|February 2003||2003-02-28|December 2014|2014-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Hemodynamic Effects of Spironolactone in Patients With Heart Failure|Hemodynamic Effects of Spironolactone in Patients With Heart Failure|Completed||N/A|18|Actual|University of Toledo Health Science Campus||1|||f||||f||||||||||2018-06-01 01:13:05.768463|2018-06-01 01:13:05.768463
NCT00860327|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2016-08-19|2009-03-10|2009-03-12|Estimate|||||||2016-08-19|2016-08-22|Estimate|December 2007||2007-12-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Examining Developmental Changes in Heart Contractions of Children With Congenital Heart Defects|Excitation-contraction Coupling in Human Ventricle Development|Terminated|||375|Actual|Emory University|||2||f||||f||||||Samples Without DNA|"~     Ventricular tissue, that would have been discarded, and was removed during surgery as part of~     the necessary repair for congenital heart defects~   "|||2018-06-01 01:13:05.824823|2018-06-01 01:13:05.824823
NCT00860314|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2008-11-10||2015-08-17|2009-03-11|2009-03-12|Estimate|2009-03-11|2009-03-12|Estimate||||2015-08-17|2015-08-27|Estimate|January 2005||2005-01-31|August 2015|2015-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|APOVERSAL||Antero-posterior Versus Antero-lateral Electrode Position for Electrical Cardioversion of Typical Atrial Flutter|Prospective, Randomized Single-center Study for Efficacy of Antero-posterior and Antero-lateral Electrode Position for External Electrical Cardioversion of Typical Atrial Flutter|Terminated||N/A|96|Actual|Universitätsklinikum Hamburg-Eppendorf||2||Statistical interim analysis showed valid and significant results|f||||f||||||||||2018-06-01 01:13:05.892102|2018-06-01 01:13:05.892102
NCT00860301|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2009-03-11|2009-03-11|2009-03-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Acupuncture in Infantile Colic|Acupuncture in Infantile Colic - a Randomised Controlled Double Blind Clinical Study|Completed||N/A|90|Actual|Lund University||2|||f||||f||||||||||2018-06-01 01:13:06.262067|2018-06-01 01:13:06.262067
NCT00860288|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10||2013-01-02|2013-01-03|2009-03-11|2009-03-12|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-03|2013-01-09|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes||Completed||Phase 2/Phase 3|1988|Actual|Novartis||4|||f||||||||||||||2018-06-01 01:13:06.383525|2018-06-01 01:13:06.383525
NCT00860275|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2011-01-24|2009-03-11|2009-03-12|Estimate|||||||2011-01-24|2011-01-25|Estimate|April 2009||2009-04-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole|A Study of the Effect of Concomitant Administration of Ketoconazole or Fluconazole on the Pharmacokinetics of BMS-708163 in Healthy Subjects|Completed||Phase 1|30|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 01:13:06.708905|2018-06-01 01:13:06.708905
NCT00860262|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2010-12-10||2014-05-16|2009-03-11|2009-03-12|Estimate|2010-12-10|2011-01-04|Estimate||||2014-05-16|2014-05-20|Estimate|March 2009||2009-03-31|May 2014|2014-05-31||||December 2009|Actual|2009-12-31||Interventional|||Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension|An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg & Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).|Completed||Phase 3|858|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 01:13:06.948292|2018-06-01 01:13:06.948292
NCT00860249|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2011-09-02||2011-11-30|2009-03-11|2009-03-12|Estimate|2011-10-24|2011-12-01|Estimate||||2011-11-30|2011-12-05|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|UPQUAL||Outreach for Patients That Are Newly Eligible for Colorectal Cancer Screening|Using Precision Performance Measurement To Conduct Focused Quality Improvement. Sub-study 2|Terminated||N/A|60|Actual|Northwestern University|Early termination prior to collection of primary or secondary outcome measures, hence no analyses of the primary or secondary outcomes were performed.Thus, the only results reported are baseline characteristics of enrolled participants.|3||"Lack of sufficient participants meeting the eligibility criteria to complete study in proposed~   and acceptable time frame."|f||||f||||||||||2018-06-01 01:13:08.854422|2018-06-01 01:13:08.854422
NCT00860236|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2017-03-01|2009-03-11|2009-03-12|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2009||2009-03-31|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|GIFF||Giardia Induced Fatigue and Functional Gastrointestinal Diseases|Chronic Fatigue Syndrome and Abdominal Symptoms After Giardia Infection: Clinical Evaluation, Biomarkers, Risk Factors and the Effect of Intervention|Completed||Phase 4|40|Anticipated|University of Bergen||2|||f||||f||||||||||2018-06-01 01:13:09.289825|2018-06-01 01:13:09.289825
NCT00860223|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2012-05-10|2009-03-11|2009-03-12|Estimate|||||||2012-05-10|2012-05-14|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin|An Open-Label, Nonrandomized, Crossover Study to Evaluate the Potential Effect of Multiple Doses of Neratinib on the Pharmacokinetics of a Single Dose of Digoxin When Administered Orally to Healthy Adult Subjects|Completed||Phase 1|27|Actual|Puma Biotechnology, Inc.||2|||f||||f||||||||||2018-06-01 01:13:09.379159|2018-06-01 01:13:09.379159
NCT00860210|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2010-04-09|2009-03-11|2009-03-12|Estimate|||||||2010-04-09|2010-04-12|Estimate|October 2007||2007-10-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Pilot Study Assessing the Feasibility of Treating Foot Drop With the Neurostep™ System.|Pilot Feasibility Study of the Neurostep™ System in Subjects With Gait Disorder Secondary to CNS Lesion.|Completed||Phase 1|14|Actual|Neurostream Technologies G.P.|||||f||||t||||||||||2018-06-01 01:13:09.446225|2018-06-01 01:13:09.446225
NCT00860197|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2015-11-30|2009-03-11|2009-03-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|||Immune Benefits of Coffee|Effect of Coffee Consumption on Immune and Inflammatory Status in Elderly|Completed||N/A|116|Actual|University of Chile||3|||f||||f||||||||||2018-06-01 01:13:09.526792|2018-06-01 01:13:09.526792
NCT00860184|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2011-04-13|2009-03-11|2009-03-12|Estimate|||||||2011-04-13|2011-04-14|Estimate|November 2009||2009-11-30|April 2011|2011-04-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|SmartRisk||SmartRisk Stroke Prediction by MRI of Carotid Disease|Assessment of MRI-based Prediction of Stroke and Other Cerebrovascular Symptoms Arising From Carotid Atherosclerotic Disease in Asymptomatic Individuals|Unknown status|Recruiting||300|Anticipated|VPDiagnostics|||1||f||||t||||||||||2018-06-01 01:13:09.643485|2018-06-01 01:13:09.643485
NCT00860171|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2016-10-07||2017-11-15|2009-03-11|2009-03-12|Estimate|2017-10-09|2017-10-12|Actual||||2017-11-15|2017-12-13|Actual|February 2009||2009-02-28|November 2017|2017-11-30||||March 2015|Actual|2015-03-31||Interventional|||Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma|A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies|Active, not recruiting||Phase 1|16|Actual|Fred Hutchinson Cancer Research Center|This protocol was closed to enrollment when replaced by a newer approach.|1|||f||||t||||||||||2018-06-01 01:13:09.812662|2018-06-01 01:13:09.812662
NCT00860158|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|2016-01-07||2018-02-14|2009-03-11|2009-03-12|Estimate|2016-01-07|2016-02-05|Estimate||||2018-02-14|2018-03-14|Actual|March 2009||2009-03-31|February 2018|2018-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer|A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer|Terminated||Phase 2|1|Actual|Hoosier Cancer Research Network|This study was terminated due to slow accrual and no results were analyzed.|1||Slow accrual; closed by funder|f||||t||||||||No||2018-06-01 01:13:10.078105|2018-06-01 01:13:10.078105
NCT00860145|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-11|||2018-05-07|2009-03-11|2009-03-12|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2009||2009-09-30|May 2018|2018-05-31|July 1, 2016|Actual|2016-07-01|June 1, 2016|Actual|2016-06-01||Interventional|ROSE||Radiosurgery or Open Surgery for Epilepsy Trial|Radiosurgery Versus Lobectomy for Temporal Lobe Epilepsy|Completed||N/A|61|Actual|University of California, San Francisco||2|||f||||t||||||||Yes|Preliminary report 12/2016 at the American Epilepsy Society meeting. Full paper to follow.|2018-06-01 01:13:10.294008|2018-06-01 01:13:10.294008
NCT00860132|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-03-10|2009-03-10|2009-03-11|Estimate|||||||2009-03-10|2009-03-11|Estimate|May 2009||2009-05-31|March 2009|2009-03-31||||||||Observational|||Economic Aspects Associated With the Implementation of an Orthogeriatric Setting in a General Hospital|Economic Aspects Associated With the Implementation of an Orthogeriatric Setting in a General Hospital|Unknown status|Not yet recruiting||2000|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 01:13:10.382957|2018-06-01 01:13:10.382957
NCT00860119|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-11-11|2009-03-10|2009-03-11|Estimate|||||||2009-11-11|2009-11-13|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Bioequivalence of Alprazolam Sublingual vs Oral Tablets|Open-Label, Randomized, Single-Dose, 2-Way Crossover Pivotal Bioequivalence Study Comparing Alprazolam Immediate Release (IR) Tablets (Administered Orally) And Alprazolam Sublingual (SL) Tablets (Administered Sublingually)|Completed||Phase 1|23|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:13:10.426737|2018-06-01 01:13:10.426737
NCT00860106|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2011-10-10|2009-03-10|2009-03-11|Estimate|||||||2011-10-10|2011-10-12|Estimate|March 2005||2005-03-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|VAPRED||Echo Doppler (ED )Score and D-dimer (DD) Level in the Evaluation of VTE Recurrence After Anticoagulant Treatment Cessation|Study of Predictive Echo Doppler Score and D-dimer Level in Evaluation of the Thromboembolic Event Recurrence After Anticoagulant Treatment Cessation.|Completed||Phase 4|222|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-06-01 01:13:10.501323|2018-06-01 01:13:10.501323
NCT00860093|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2017-03-21|2009-03-10|2009-03-11|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2010||2010-04-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy|A Multi-Site Placebo-Controlled Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Using MPC-5971 as Adjuvant Therapy in Subjects Undergoing Shock Wave Lithotripsy|Terminated||Phase 2|135|Actual|Mission Pharmacal||2||Sponsor Corporate Business Decision|f||||t||||||||||2018-06-01 01:13:10.713021|2018-06-01 01:13:10.713021
NCT00860080|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2010-04-22|2009-03-10|2009-03-11|Estimate|||||||2010-04-22|2010-04-23|Estimate|March 2009||2009-03-31|April 2010|2010-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety Study Investigating Local Tolerability and Pharmacokinetics of PXL01 in Healthy Volunteers|A First in Man, Phase I, Single-blind, Placebo-controlled Study Investigating the Local Tolerability, Safety and Pharmacokinetics in Three Doses of PXL01 and Placebo in 15 Healthy Volunteers|Completed||Phase 1|15|Actual|PharmaSurgics AB||2|||f||||t||||||||||2018-06-01 01:13:10.802533|2018-06-01 01:13:10.802533
NCT00860067|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2011-06-10||2011-11-30|2009-03-09|2009-03-11|Estimate|2011-07-19|2011-08-12|Estimate||||2011-11-30|2011-12-05|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|MI-CP185||A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age|A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age|Completed||Phase 2/Phase 3|1800|Actual|MedImmune LLC||3|||f||||t||||||||||2018-06-01 01:13:10.897094|2018-06-01 01:13:10.897094
NCT00860054|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2012-04-17|2009-03-10|2009-03-11|Estimate|||||||2012-04-17|2012-04-19|Estimate|March 2006||2006-03-31|April 2012|2012-04-30|October 2008|Actual|2008-10-31|September 2006|Actual|2006-09-30||Interventional|phyteaux-I||Addition of Phytosterols to a Low Phytosterol Diet|Regulation of Cholesterol Absorption: Dose Response of LDL to Phytosterols Added to a Phytosterol-Poor Diet|Completed||N/A|18|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 01:13:11.850802|2018-06-01 01:13:11.850802
NCT00860041|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2016-07-12|2009-03-10|2009-03-11|Estimate|||||||2016-07-12|2016-07-14|Estimate|February 2009||2009-02-28|July 2016|2016-07-31|May 2013|Actual|2013-05-31|April 2011|Actual|2011-04-30||Observational|||Acute Pain Caused by Paclitaxel in Patients With Cancer|Paclitaxel-Associated Acute Pain Syndrome Natural History Study|Completed|||306|Actual|Alliance for Clinical Trials in Oncology|||4||f||||f||||||||||2018-06-01 01:13:11.992634|2018-06-01 01:13:11.992634
NCT00860028|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2012-01-03||2013-01-28|2009-03-10|2009-03-11|Estimate|2013-01-28|2013-03-07|Estimate||||2013-01-28|2013-03-07|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Varenicline for Smoking Cessation in Heavy Drinking Smokers|Varenicline for Smoking Cessation in Heavy Drinking Smokers|Completed||Phase 2|30|Actual|Yale University||2|||f||||t||||||||||2018-06-01 01:13:12.499685|2018-06-01 01:13:12.499685
NCT00860015|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2012-11-01|2009-03-09|2009-03-11|Estimate|||||||2012-11-01|2012-11-02|Estimate|August 2005||2005-08-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|August 2009|Actual|2009-08-31||Interventional|||Alimta Plus Gemcitabine for Advanced Sarcoma|Alimta Plus Gemcitabine as Chemotherapy for Patients With Advanced Sarcoma: A Phase II Clinical|Completed||Phase 2|12|Actual|Columbia University||1|||f||||t||||||||||2018-06-01 01:13:12.819743|2018-06-01 01:13:12.819743
NCT00860002|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2010-06-06|2009-03-10|2009-03-11|Estimate|||||||2010-06-06|2010-06-08|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|December 2014|Anticipated|2014-12-31|December 2010|Anticipated|2010-12-31||Observational|||The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids|The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids|Unknown status|Recruiting||1200|Anticipated|Taipei Veterans General Hospital, Taiwan|||17||f||||f||||||||||2018-06-01 01:13:12.878131|2018-06-01 01:13:12.878131
NCT00859989|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2013-12-17|2009-03-10|2009-03-11|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 2004||2004-07-31|March 2009|2009-03-31||||April 2009|Anticipated|2009-04-30||Interventional|||A Weight-Loss Program in Helping Obese Black Women Lose Weight|Obesity Reduction Black Intervention Trial (ORBIT)|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:13:13.036519|2018-06-01 01:13:13.036519
NCT00859976|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2016-07-28|2009-03-10|2009-03-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2009||2009-03-31|July 2016|2016-07-31|May 2014|Actual|2014-05-31|June 2012|Actual|2012-06-30||Interventional|||Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups|Prospective Randomised Control Trial to Compare the Effect Upon Bone Density and Clinical Outcomes When Using BoneMaster HA Coated Acetabular Cups Compared With Plasma Sprayed HA Coated Cups in Patients With Total Hip Replacements|Completed||N/A|193|Actual|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-06-01 01:13:13.136539|2018-06-01 01:13:13.136539
NCT00859963|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2017-06-22|2009-03-10|2009-03-11|Estimate|||||||2017-06-22|2017-06-23|Actual|March 2009||2009-03-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Regenerex Tibial Tray Multi-Center Data Collection|Regenerex Tibial Tray Multi-Center Data Collection|Enrolling by invitation|||200|Anticipated|Zimmer Biomet|||||f||||f||||||||Undecided||2018-06-01 01:13:13.233314|2018-06-01 01:13:13.233314
NCT00859950|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2016-12-06||2017-04-06|2009-03-10|2009-03-11|Estimate|2017-04-06|2017-05-17|Actual||||2017-04-06|2017-05-17|Actual|April 2009||2009-04-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea|Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea|Completed||N/A|70|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-06-01 01:13:13.325597|2018-06-01 01:13:13.325597
NCT00859937|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2014-06-19||2018-03-21|2009-03-10|2009-03-11|Estimate|2015-04-02|2015-04-03|Estimate||||2018-03-21|2018-04-20|Actual|March 16, 2009|Actual|2009-03-16|March 2018|2018-03-31||||January 30, 2013|Actual|2013-01-30||Interventional|||Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors|Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:13:13.664983|2018-06-01 01:13:13.664983
NCT00859911|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2009-03-09|2009-03-09|2009-03-11|Estimate|||||||2009-03-09|2009-03-11|Estimate|March 2008||2008-03-31|March 2009|2009-03-31|October 2011|Anticipated|2011-10-31|March 2011|Anticipated|2011-03-31||Interventional|||The Effectiveness of Micronutrient Supplements on Growth and Educational Achievement of Schoolchildren in Bangladesh|The Effectiveness of Multiple Micronutrient Supplements Given by Teachers to School-Age Children on Growth and Educational Achievement|Unknown status|Active, not recruiting|N/A|2300|Actual|Save the Children||2|||f||||f||||||||||2018-06-01 01:13:14.269548|2018-06-01 01:13:14.269548
NCT00859898|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2014-02-04||2016-05-30|2009-03-10|2009-03-11|Estimate|2014-02-04|2014-03-20|Estimate||||2016-05-30|2016-07-07|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||All randomized participants who took at least one dose of double-blind study medication.|Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 3|1093|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:13:14.42345|2018-06-01 01:13:14.42345
NCT00859885|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2017-12-11|2009-03-10|2009-03-11|Estimate|||||||2017-12-11|2017-12-12|Actual|September 8, 2008|Actual|2008-09-08|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||International PFO Consortium|Secondary Stroke Prevention In Patients With Patent Foramen Ovale: International PFO Consortium|Recruiting|||1500|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 01:13:15.822704|2018-06-01 01:13:15.822704
NCT00859872|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-07-31|2009-03-10|2009-03-11|Estimate|||||||2009-07-31|2009-08-03|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia|Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia|Completed||Phase 4|198|Actual|Central South University||2|||f||||t||||||||||2018-06-01 01:13:15.98467|2018-06-01 01:13:15.98467
NCT00859859|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2011-07-19|2009-03-10|2009-03-11|Estimate|||||||2011-07-19|2011-07-20|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Vagus Nerve Stimulation in Rheumatoid Arthritis|Vagus Nerve Stimulation in Rheumatoid Arthritis|Terminated||Phase 1|23|Actual|Northwell Health||||"The protocol was terminated early (prior to complete enrollment) after interim analysis proved~   data to be statistically insignificant"|f||||f||||||||||2018-06-01 01:13:16.053935|2018-06-01 01:13:16.053935
NCT00859846|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2017-05-26|2009-03-10|2009-03-11|Estimate|||||||2017-05-26|2017-05-31|Actual|March 17, 2009|Actual|2009-03-17|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ultrasound Guided Arterial Line Placement in Long Axis Versus Short Axis in Pediatric Patients|Comparison of Ultrasound Guided Arterial Line Placement in Long Axis Versus Short Axis in Pediatric Patients.|Recruiting||N/A|74|Anticipated|University of Oklahoma||3|||f||||t||||||||No||2018-06-01 01:13:16.110232|2018-06-01 01:13:16.110232
NCT00859833|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2010-11-01||2011-05-20|2009-03-10|2009-03-11|Estimate|2011-05-20|2011-05-24|Estimate||||2011-05-20|2011-05-24|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Body Mass Index on the Hyperemic Response to Regadenoson|Effects of Body Mass Index on the Hyperemic Response to Regadenoson|Completed||N/A|30|Actual|University of Utah|Due to technical problems, data from two of the 30 subjects was not usable.|1|||f||||f||||||||||2018-06-01 01:13:17.120616|2018-06-01 01:13:17.120616
NCT00859807|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2010-04-20|2009-03-10|2009-03-11|Estimate|||||||2010-04-20|2010-04-21|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects|A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects|Completed||Phase 4|38|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:13:17.269447|2018-06-01 01:13:17.269447
NCT00859794|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2018-02-06|2009-03-10|2009-03-11|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2007||2007-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||An Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy|An Examination of Cognitive and Sensorimotor Processes in Patients With Epilepsy Using Electrophysiology, Cortical Mapping, and fMRI|Enrolling by invitation|||200|Anticipated|Northwell Health|||||f||||f||||||||||2018-06-01 01:13:17.349809|2018-06-01 01:13:17.349809
NCT00859781|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2018-02-27|2009-03-10|2009-03-11|Estimate|||||||2018-02-27|2018-03-01|Actual|June 2009|Actual|2009-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer|A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy|Recruiting||Phase 2|140|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-06-01 01:13:17.436269|2018-06-01 01:13:17.436269
NCT00859768|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2011-03-07|2009-03-10|2009-03-11|Estimate|||||||2011-03-07|2011-03-08|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients|The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients Treated With Radiotherapy.|Completed||N/A|568|Actual|Netherlands Open University||4|||f||||f||||||||||2018-06-01 01:13:17.553298|2018-06-01 01:13:17.553298
NCT00859755|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2012-08-29|2009-03-09|2009-03-11|Estimate|||||||2012-08-29|2012-08-30|Estimate|March 2009||2009-03-31|August 2012|2012-08-31||||July 2009|Actual|2009-07-31||Interventional|||A Safety Study of ARRY-403 in Patients With Type 2 Diabetes||Completed||Phase 1|41|Actual|Array BioPharma||2|||f||||||||||||||2018-06-01 01:13:17.638134|2018-06-01 01:13:17.638134
NCT00859742|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2018-03-29|2009-03-10|2009-03-11|Estimate|||||||2018-03-29|2018-04-02|Actual|March 2009||2009-03-31|March 2018|2018-03-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Mediastinal Re-staging of Non-small Cell Lung Cancer(NSCLC)|Endobronchial Ultrasound Guided Transbronchial Needle Aspiration for the Mediastinal Re-staging After Induction Therapy in Non-small Cell Lung Cancer. A Prospective Study|Withdrawn||N/A|0|Actual|National Cancer Center, Korea||1|||f||||t||||||||||2018-06-01 01:13:17.803407|2018-06-01 01:13:17.803407
NCT00859729|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2014-03-14|2009-03-10|2009-03-11|Estimate|||||||2014-03-14|2014-03-17|Estimate|December 2008||2008-12-31|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer|DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients With Relapsed Prostate Cancer. A Phase I/II Study|Completed||Phase 1/Phase 2|15|Actual|Uppsala University||5|||f||||t||||||||||2018-06-01 01:13:17.874813|2018-06-01 01:13:17.874813
NCT00859716|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-03-10|2009-03-10|2009-03-11|Estimate|||||||2009-03-10|2009-03-11|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|July 2009|Anticipated|2009-07-31|March 2009|Anticipated|2009-03-31||Interventional|ACE393-103VC||ACE393-103 Vaccination Challenge Study|A Randomized, Double-Blind, Placebo Controlled Vaccination-Challenge Study of ACE393 to Determine Efficacy Against the Symptoms of Moderate to Severe Campylobacter Jejuni Infection in Normal Healthy Volunteers|Unknown status|Active, not recruiting|Phase 2|72|Anticipated|TD Vaccines A/S||2|||f||||t||||||||||2018-06-01 01:13:17.965409|2018-06-01 01:13:17.965409
NCT00859703|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2013-10-30|2009-03-10|2009-03-11|Estimate|||||||2013-10-30|2013-10-31|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|RISAROS||Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer|Randomized, Double-blinded, Placebo Controlled Study to Assess Efficacy of Oral 35 mg Per Week Risedronate in Preventing Bone Loss in Postmenopausal Women With Aromatase Inhibitor Therapy for Breast Cancer.|Completed||Phase 3|20|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 01:13:18.091106|2018-06-01 01:13:18.091106
NCT00859690|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2013-07-25|2009-03-10|2009-03-11|Estimate|||||||2013-07-25|2013-07-26|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Regulation of Vascular Thrombosis in Sleep Apnea|Regulation of Vascular Thrombosis in Sleep Apnea|Completed|||14|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples With DNA|"~     A total of 15ml (approximately 1 tablespoon) of whole blood will be collected from each~     subject during his or her out-patient office visit. This sample will be retained for genomic~     analysis~   "|||2018-06-01 01:13:18.229247|2018-06-01 01:13:18.229247
NCT00859677|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2017-06-13|2009-03-10|2009-03-11|Estimate|||||||2017-06-13|2017-06-14|Actual|March 2009||2009-03-31|June 2017|2017-06-30|August 26, 2016|Actual|2016-08-26|November 2010|Actual|2010-11-30||Observational|MRSA-2||Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection|Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection|Completed|||52|Actual|Uniformed Services University of the Health Sciences|||6||f||||t||||||Samples With DNA|"~     Skin biopsy will be obtained.~   "|||2018-06-01 01:13:18.335371|2018-06-01 01:13:18.335371
NCT00859664|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-03-10|2009-03-10|2009-03-11|Estimate|||||||2009-03-10|2009-03-11|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders||Unknown status|Recruiting||500|Anticipated|Assaf-Harofeh Medical Center|||1||f||||||||||||||2018-06-01 01:13:18.454492|2018-06-01 01:13:18.454492
NCT00859651|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2016-05-05||2017-08-30|2009-03-09|2009-03-11|Estimate|2017-08-30|2017-09-27|Actual||||2017-08-30|2017-09-27|Actual|June 2009||2009-06-30|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Data for this study (NCT00859651; n=20) is combined with the data for another study (NCT00976339; n=20).|Vitamin D in Postmenopausal Women at High Risk for Breast Cancer|Effects of High-Dose Vitamin D on Circulating Vitamin D Levels and Breast Density in Postmenopausal Women at High Risk for Breast Cancer Development|Completed||Phase 2|20|Actual|Columbia University|The investigator combined the data for this study (NCT00859651; n=20) with the data for another study (NCT00976339; n=20). Therefore, the total number of participants analyzed is 40 for Outcome Measures and Adverse Events sections.|2|||f||||t|t|f||||||Undecided||2018-06-01 01:13:18.543848|2018-06-01 01:13:18.543848
NCT00859638|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2009-09-29||2010-06-17|2009-03-10|2009-03-11|Estimate|2010-05-20|2010-06-17|Estimate||||2010-06-17|2010-06-22|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||I Am Able: Population Based Rehabilitation in a Family Health Team|I Am Able: Population Based Rehabilitation in a Family Health Team|Completed||N/A|124|Actual|McMaster University|The limited duration of the study period may not allow sufficient time to show the difference in outcome measures such as self-rated health and health care utilization.|2|||f||||f||||||||||2018-06-01 01:13:18.841941|2018-06-01 01:13:18.841941
NCT00859625|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2015-01-20|2009-03-10|2009-03-11|Estimate|||||||2015-01-20|2015-01-22|Estimate|November 2008||2008-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy|The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy|Completed||N/A|500|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:13:19.104679|2018-06-01 01:13:19.104679
NCT00859612|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2017-05-02|2009-03-09|2009-03-11|Estimate|||||||2017-05-02|2017-05-05|Actual|March 2009||2009-03-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Renal Osteodystrophy: A Fresh Approach|Renal Osteodystrophy: A Fresh Approach|Completed|||464|Actual|University of Kentucky|||||f||||f||||||Samples Without DNA|"~     blood samples and bone biopsy samples~   "|||2018-06-01 01:13:19.168728|2018-06-01 01:13:19.168728
NCT00859599|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2011-06-07|2009-03-10|2009-03-11|Estimate|||||||2011-06-07|2011-06-08|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|April 2012|Anticipated|2012-04-30|December 2011|Anticipated|2011-12-31||Interventional|||Monochromatic Phototherapy on Diabetic Foot Ulcers|Monochromatic Phototherapy on Diabetic Foot Ulcers. A Twenty Weeks Prospective, Randomised, Double Blind, Multi-centre, Placebo Controlled Study|Unknown status|Recruiting|Phase 3|107|Anticipated|Biolight AB||2|||f||||f||||||||||2018-06-01 01:13:19.221037|2018-06-01 01:13:19.221037
NCT00859586|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2015-10-05||2015-10-05|2009-03-10|2009-03-11|Estimate|2015-10-05|2015-11-06|Estimate||||2015-10-05|2015-11-06|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation|Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation|Completed||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 01:13:19.437125|2018-06-01 01:13:19.437125
NCT00859573|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|2011-04-15||2017-10-18|2009-03-10|2009-03-11|Estimate|2011-06-17|2011-07-15|Estimate||||2017-10-18|2017-11-21|Actual|April 2009||2009-04-30|October 2017|2017-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Modafinil for Methamphetamine Dependence|Clinical Efficacy of Modafinil in Recently-Abstinent Methamphetamine-Dependent Volunteers|Terminated||Phase 2|9|Actual|University of Arkansas|Early termination leading to small numbers of subjects analyzed. Small number of completers leading to small numbers of subjects analyzed.|2||Terminated due to lack of funding.|f||||t||||||||||2018-06-01 01:13:19.629578|2018-06-01 01:13:19.629578
NCT00859560|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-03-10|2009-03-10|2009-03-11|Estimate|||||||2009-03-10|2009-03-11|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|||||Observational|||Retrospective Survey of Bone Fracture in Patients With Arimidex 1mg|Retrospective Survey of Bone Fracture in Post-Menopausal Breast Cancer Patients With Arimidex 1 mg as Adjuvant Therapy|Completed|||2205|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 01:13:19.862844|2018-06-01 01:13:19.862844
NCT00859547|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2011-11-03||2012-01-25|2009-03-10|2009-03-11|Estimate|2011-11-03|2011-12-08|Estimate||||2012-01-25|2012-01-26|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants|A Phase 4, Open-Label, Single-Group Safety and Immunogenicity Study of RECOTHROM® (rThrombin) in Pediatric Subjects Undergoing Synchronous Burn Wound Excision and Skin Grafting|Completed||Phase 4|30|Actual|ZymoGenetics||1|||f||||t||||||||||2018-06-01 01:13:19.94844|2018-06-01 01:13:19.94844
NCT00859534|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-09-13|2009-03-10|2009-03-11|Estimate|||||||2009-09-13|2009-09-15|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Phase II Solar Urticaria (SU) Pilot Study|A Phase II, Open Label Pilot Study to Evaluate the Safety and Efficacy of A Bioresorbable Subcutaneous Implant of CUV1647 in Patients With Solar Urticaria (SU)|Completed||Phase 2|5|Actual|Clinuvel Pharmaceuticals Limited|||||f||||f||||||||||2018-06-01 01:13:20.419595|2018-06-01 01:13:20.419595
NCT00859521|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2009-07-09||2009-07-09|2009-03-09|2009-03-11|Estimate|2009-07-09|2009-08-25|Estimate||||2009-07-09|2009-08-25|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Levetiracetam 1000 mg Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Levetiracetam 1000 mg Tablet Under Fasting Conditions|Completed||Phase 1|30|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:13:20.496083|2018-06-01 01:13:20.496083
NCT00859508|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2012-02-03|2010-08-27|2012-03-06|2009-03-10|2009-03-11|Estimate|2012-02-03|2012-03-06|Estimate|2012-01-23|2012-01-27|Estimate|2012-03-06|2012-03-08|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of SyntheCelTM Dura Replacement to Other Dura Replacements|A Prospective, Multi-Center, Randomized, Controlled Clinical Study Comparing SyntheCelTM Dura Replacement to Other Dura Replacements in Patients Requiring Dura Repair Following Cranial Surgery|Completed||N/A|99|Actual|Synthes USA HQ, Inc.||2|||f||||||||||||||2018-06-01 01:13:20.870948|2018-06-01 01:13:20.870948
NCT00859495|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2011-10-28|2009-03-10|2009-03-11|Estimate|||||||2011-10-28|2011-10-31|Estimate|February 2008||2008-02-29|October 2011|2011-10-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Trimodal Lung-Sparing Treatment of Pleural Mesothelioma|Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol|Unknown status|Recruiting|Phase 2|25|Anticipated|Columbia University||1|||f||||t||||||||||2018-06-01 01:13:21.3031|2018-06-01 01:13:21.3031
NCT00859482|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-03-10|2009-03-10|2009-03-11|Estimate|||||||2009-03-10|2009-03-11|Estimate|July 2006||2006-07-31|March 2009|2009-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Differential Immune Effects of Natalizumab|A Phase IV Study to Investigate Differential Immune Effects of Natalizumab|Completed|||27|Actual|Cantonal Hospital of St. Gallen|||||f||||f||||||Samples Without DNA|"~     full blodd~   "|||2018-06-01 01:13:21.369604|2018-06-01 01:13:21.369604
NCT00859469|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2012-01-20||2012-01-20|2009-03-10|2009-03-11|Estimate|2012-01-20|2012-02-24|Estimate||||2012-01-20|2012-02-24|Estimate|April 2004||2004-04-30|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|March 2009|Actual|2009-03-31||Interventional|||Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma|Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial|Unknown status|Active, not recruiting|Phase 2|29|Actual|Columbia University||1|||f||||t||||||||||2018-06-01 01:13:21.430795|2018-06-01 01:13:21.430795
NCT00859456|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2012-11-02|2009-03-10|2009-03-11|Estimate|||||||2012-11-02|2012-11-06|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Sunitinib in Soft Tissue Sarcoma|A Phase II, Open-label, Non-randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas|Unknown status|Active, not recruiting|Phase 2|17|Anticipated|Columbia University||1|||f||||f||||||||||2018-06-01 01:13:21.740525|2018-06-01 01:13:21.740525
NCT00859430|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2009-07-09||2009-07-09|2009-03-09|2009-03-11|Estimate|2009-07-09|2009-08-25|Estimate||||2009-07-09|2009-08-25|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Levetiracetam 1000 mg Under Non-Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalence Study of Levetiracetam 1000 mg Tablet Under Fed Conditions|Completed||Phase 1|22|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:13:21.817641|2018-06-01 01:13:21.817641
NCT00859417|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2013-11-29|2009-03-10|2009-03-11|Estimate|||||||2013-11-29|2013-12-02|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study Evaluating the Effectiveness of the Use of Prosthesis With Trans-Obturator Way for the Correction of Anterior Prolapse|PERIGEE :Randomized Study Evaluating the Effectiveness of the Use of Prosthesis With Trans-obturator Way for the Correction of Anterior Prolapse.|Completed||N/A|78|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 01:13:22.16038|2018-06-01 01:13:22.16038
NCT00859404|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-09-23|2009-03-10|2009-03-11|Estimate|||||||2009-09-23|2009-09-24|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|||A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma|A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma|Unknown status|Active, not recruiting|Phase 2|282|Anticipated|Glenmark Pharmaceuticals Europe Ltd. (R&D)||4|||f||||t||||||||||2018-06-01 01:13:22.293507|2018-06-01 01:13:22.293507
NCT00859391|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2009-06-09|2009-03-10|2009-03-11|Estimate|||||||2009-06-09|2009-06-11|Estimate|May 2008||2008-05-31|June 2009|2009-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|0801||Effects of Gluten Digestion With ALV003|A Phase 0 Study in Subjects With Well Controlled Celiac Disease to Assess the Effects of Gluten Digestion With ALV003 (a Protease Enzyme) in Vitro|Completed|||20|Actual|Alvine Pharmaceuticals Inc.|||2||f||||f||||||Samples With DNA|"~     The enzyme linked immunospot (ELISPOT) assay is used in vaccine development, cancer research,~     infectious disease diagnosis and monitoring, autoimmune disease studies and allergy and~     transplantation research. The ELISPOT enables determination of the frequency of cytokine~     secreting cells. The ELISPOT is a combination of both immunoassay and bioassay because live~     cells are cultured in plates. This enables a very high sensitivity to detect cytokine~     secretion at a single cell level as secreted cytokine does not diffuse into media but is~     immediately membrane bound.~   "|||2018-06-01 01:13:22.412522|2018-06-01 01:13:22.412522
NCT00859378|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2015-04-03|2009-03-10|2009-03-11|Estimate|||||||2015-04-03|2015-04-07|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Cemented vs Non-cemented Semiendoprosthesis in the Treatment of Proximal Femoral Fractures|A Prospective, Randomized Study Comparing Cemented and Non-cemented Semiendoprostheses in the Treatment of Proximal Femoral Fractures in the Elderly Patients|Unknown status|Active, not recruiting|N/A|400|Anticipated|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 01:13:22.485454|2018-06-01 01:13:22.485454
NCT00859365|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2012-01-27|2009-03-10|2009-03-11|Estimate|||||||2012-01-27|2012-01-31|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ABNP||Acupuncture for Back and Neck Pain in an Emergency Room Setting|Efficacy of an Integrative Approach Utilizing Acupuncture as an add-on Therapy for the Treatment of Back and Neck Pain in an Emergency Department Setting - A Comparative Randomized Controlled Trial|Completed||Phase 1/Phase 2|65|Actual|Assaf-Harofeh Medical Center||3|||f||||t||||||||||2018-06-01 01:13:22.573926|2018-06-01 01:13:22.573926
NCT00859144|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2012-03-07|2009-03-06|2009-03-10|Estimate|||||||2012-03-07|2012-03-08|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Training Community Members to Deliver HIV Prevention Programs to Urban Youth|Community Partnerships to Prevent Urban Youth Health Risks (CHAMPions)|Completed||Phase 3|901|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-06-01 01:13:25.229249|2018-06-01 01:13:25.229249
NCT00859352|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-04-09|2009-03-10|2009-03-11|Estimate|||||||2009-04-09|2009-04-10|Estimate|March 2009||2009-03-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|||||Interventional|||AZD1981 Midazolam CYP4503A Induction Study|A Phase I, Open, Randomised, Non-Comparative, Parallel Group Study of a Potential Cytochrome P450 3A Induction After Repeat Twice Daily Oral Dosing With 100 and 500 mg AZD1981 Tablets for 14 Days to Healthy Male Volunteers With Single Oral Doses of Midazolam 7.5 mg.|Completed||Phase 1|28|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:13:22.685378|2018-06-01 01:13:22.685378
NCT00859339|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2016-03-15||2016-03-15|2009-03-10|2009-03-11|Estimate|2016-03-15|2016-04-14|Estimate||||2016-03-15|2016-04-14|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC|A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123|Terminated||Phase 2|9|Actual|Hoosier Cancer Research Network|Study was terminated due to pre-defined stopping rules (patient toxicities)|1||Patient Toxicities|f||||t||||||||No||2018-06-01 01:13:22.790103|2018-06-01 01:13:22.790103
NCT00859313|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2012-01-25||2012-02-28|2009-03-09|2009-03-11|Estimate|2012-01-25|2012-02-27|Estimate||||2012-02-28|2012-03-01|Estimate|April 2009||2009-04-30|February 2012|2012-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement|An Open-Label Functionality, Safety, and Efficacy Study of the NanoTab® Delivery System/ARX-F01 15 Mcg in Patients Undergoing Elective Unilateral Knee Replacement|Completed||Phase 2|30|Actual|AcelRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:13:23.144244|2018-06-01 01:13:23.144244
NCT00859300|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2016-03-15|2009-03-10|2009-03-11|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|MAP-IDM||MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction|MAP-IDM: Identification of Molecular Markers of Sudden Death at the Acute Phase of Myocardial Infarction. A Case Control Study|Completed|||1011|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-06-01 01:13:23.30027|2018-06-01 01:13:23.30027
NCT00859287|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-07-14|2009-03-10|2009-03-11|Estimate|||||||2009-07-14|2009-07-15|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|July 2008|Actual|2008-07-31|||||Observational|OMAREE||Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis|Omepral® Tablets Mega-study to Investigate the Efficacy on Various Type of Acid Reflux Related Symptoms and QOL, and Epidemiology in Patients With Erosive Esophagitis in Daily Medical Practice|Completed|||10703|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:13:23.370918|2018-06-01 01:13:23.370918
NCT00859274|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2013-10-09|2009-03-10|2009-03-11|Estimate|||||||2013-10-09|2013-10-10|Estimate|March 2009||2009-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Saline Challenge in Monitoring Asthma Control|Saline Challenge in Monitoring Asthma Control|Completed||N/A|40|Actual|Kuopio University Hospital||1|||f||||f||||||||||2018-06-01 01:13:23.438386|2018-06-01 01:13:23.438386
NCT00859261|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2016-05-03|2009-03-09|2009-03-11|Estimate|||||||2016-05-03|2016-05-05|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound|2D Silicon Transducer-Compression Plates for Breast Ultrasound|Completed||N/A|21|Actual|University of Michigan||1|||f||||t||||||||No||2018-06-01 01:13:23.495574|2018-06-01 01:13:23.495574
NCT00859235|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-10|||2009-03-10|2009-03-10|2009-03-11|Estimate|||||||2009-03-10|2009-03-11|Estimate|May 2009||2009-05-31|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|PEG||The Influence of Oral Hygiene on Local Wound and Systemic Infection in Patients With Percutaneous Endoscopic Gastrostomy Placement|Predicting Oral Care Before Percutaneous Endoscopic Gastrostomy (PEG). The Influence of Oral Hygiene on Local Wound and Systemic Infection in Patients With PEG Placement|Unknown status|Not yet recruiting|Phase 3|50|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-06-01 01:13:23.563582|2018-06-01 01:13:23.563582
NCT00859222|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2016-03-29||2017-02-03|2009-03-09|2009-03-10|Estimate|2016-10-06|2016-11-28|Estimate||||2017-02-03|2017-03-14|Actual|March 2009||2009-03-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|September 2013|Actual|2013-09-30||Interventional||The analysis dataset is comprised of all enrolled patients.|LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma|Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma|Completed||Phase 1/Phase 2|51|Actual|Dana-Farber Cancer Institute||7|||f||||t||||||||No||2018-06-01 01:13:23.665844|2018-06-01 01:13:23.665844
NCT00859209|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2015-08-11|2009-03-09|2009-03-10|Estimate|||||||2015-08-11|2015-08-13|Estimate|December 2008||2008-12-31|March 2009|2009-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Capnography in Infants Ventilated With High Frequency Ventilation|Capnography in Infants Ventilated With High Frequency Ventilation: Prospective, Observational, Multi-Center Study|Completed|||24|Actual|Bnai Zion Medical Center|||||f||||f||||||||||2018-06-01 01:13:24.710873|2018-06-01 01:13:24.710873
NCT00859196|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2014-12-08|2009-03-09|2009-03-10|Estimate|||||||2014-12-08|2014-12-09|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries|A Randomized, Double-blind, Single Centre, Placebo-controlled Pilot Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Previously Injured Skin by Investigation of Skin Biopsies|Completed||Phase 4|15|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:13:24.862312|2018-06-01 01:13:24.862312
NCT00859183|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2009-03-09|2009-03-09|2009-03-10|Estimate|||||||2009-03-09|2009-03-10|Estimate|October 2001||2001-10-31|March 2009|2009-03-31|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|OSIRIS||Oral Sirolimus for In-Stent Restenosis|A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Impact of Oral Sirolimus on Restenosis Prevention in Patients With In-Stent Restenosis.|Completed||Phase 4|300|Actual|Deutsches Herzzentrum Muenchen||3|||f||||t||||||||||2018-06-01 01:13:24.947516|2018-06-01 01:13:24.947516
NCT00859170|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2010-01-06|2009-03-06|2009-03-10|Estimate|||||||2010-01-06|2010-01-08|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Interventional|||Use of Antiretropulsion Device in Laser Lithotripsy|Use of the Accordion Stone Management Device in Laser Lithotripsy|Terminated||N/A|100|Anticipated|Percutaneous Systems, Inc.||2||Change in priorities occurred|f||||f||||||||||2018-06-01 01:13:25.060017|2018-06-01 01:13:25.060017
NCT00859157|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-07|||2017-06-19|2009-03-07|2009-03-10|Estimate|||||||2017-06-19|2017-06-21|Actual|October 2008||2008-10-31|June 2017|2017-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer|Tumescent Mastectomy: A Prospective Comparison to Standard Mastectomy Technique|Completed|||74|Actual|University of California, Davis|||2||f||||f||||||||||2018-06-01 01:13:25.148056|2018-06-01 01:13:25.148056
NCT00859131|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2015-05-14||2016-03-23|2009-03-09|2009-03-10|Estimate|2016-03-23|2016-04-26|Estimate||||2016-03-23|2016-04-26|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|July 2014|Actual|2014-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists|Rabbit Anti-thymocyte Globulin Versus IL2 Receptor Antagonists in Combination With Tacrolimus, Corticosteroids and Mycophenolate Mofetil in a Predominantly High Risk Kidney Transplant Population.|Completed||N/A|200|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:13:25.38042|2018-06-01 01:13:25.38042
NCT00859118|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2015-03-04|2009-03-09|2009-03-10|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies|Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies|Completed||Phase 1|30|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 01:13:25.729872|2018-06-01 01:13:25.729872
NCT00859105|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2009-03-09|2009-03-09|2009-03-10|Estimate|||||||2009-03-09|2009-03-10|Estimate|February 2008||2008-02-29|March 2009|2009-03-31||||November 2008|Actual|2008-11-30||Interventional|||A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis|A Multicenter, Double-Blind, Vehical-Controlled Study Comparing Imiquimod Cream, 5% (Apotex Inc.) to Aldara™ Cream, 5%(3M Pharmaceutials, U.S.) and Aldara™ Cream, 5%(3M Pharmaceuticals, Canada) in the Treatments of Actinic Keratosis.|Completed||Phase 3|497|Actual|Apotex Inc.||4|||f||||t||||||||||2018-06-01 01:13:25.812969|2018-06-01 01:13:25.812969
NCT00859092|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2012-03-07|2009-03-09|2009-03-10|Estimate|||||||2012-03-07|2012-03-09|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional|||Promotion of Thickened Feeds to Manage Newborns With Feeding Difficulties|Promotion of Thickened Feeds to Manage Newborns With Feeding Difficulties|Completed||Phase 2|15|Anticipated|Eastern Virginia Medical School||2|||f||||f||||||||||2018-06-01 01:13:25.876609|2018-06-01 01:13:25.876609
NCT00859079|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-07|||2009-03-09|2009-03-09|2009-03-10|Estimate|||||||2009-03-09|2009-03-10|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients|Efficacy of a Continuous GLP-1 Infusion in Comparison to a Structured Insulin Infusion Protocol to Reach Normoglycemia in Non-Fasted Type 2 Diabetic Patients|Completed||Phase 4|8|Actual|Medical University of Graz||2|||f||||t||||||||||2018-06-01 01:13:25.972939|2018-06-01 01:13:25.972939
NCT00859066|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2012-04-26|2009-03-09|2009-03-10|Estimate|||||||2012-04-26|2012-04-30|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||Evaluation of Radiology Resident Anxiety When Beginning Emergency Room (ER) Call|Evaluation of Radiology Resident Anxiety When Beginning ER Call|Terminated|||19|Actual|University of Michigan|||2|Original Principal Investigator (Andrew Trout M.D.) left the University.|f||||t||||||||||2018-06-01 01:13:26.073059|2018-06-01 01:13:26.073059
NCT00859053|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2015-08-10||2015-09-09|2009-03-09|2009-03-10|Estimate|2015-09-09|2015-10-08|Estimate||||2015-09-09|2015-10-08|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||Analysis was done in safety population, defined as all the participants who received study medication.|Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment|Single-Dose Pharmacokinetics of BMS-790052 in Subjects With Hepatic Impairment Compared to Healthy Subjects|Completed||Phase 1|46|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 01:13:26.163555|2018-06-01 01:13:26.163555
NCT00859040|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2014-02-14||2017-09-26|2009-03-09|2009-03-10|Estimate|2014-04-16|2014-05-16|Estimate||||2017-09-26|2017-10-27|Actual|March 2009||2009-03-31|September 2017|2017-09-30|January 2016|Actual|2016-01-31|December 2011|Actual|2011-12-31||Interventional|||Monthly SOM230C for Recurrent or Progressive Meningioma|Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma|Completed||Phase 2|34|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:13:26.700627|2018-06-01 01:13:26.700627
NCT00859027|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-07|2012-08-22||2018-04-11|2009-03-07|2009-03-10|Estimate|2013-06-28|2013-08-01|Estimate||||2018-04-11|2018-05-01|Actual|January 2003||2003-01-31|April 2018|2018-04-30|February 2009|Actual|2009-02-28|March 2008|Actual|2008-03-31||Interventional|||Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer|The Effect Of Risedronate On Bone Turnover And Bone Mass In Older Men|Completed||Phase 4|50|Actual|UConn Health|Small number but otherwise no limitations.|2|||f||||f||||||||||2018-06-01 01:13:27.150018|2018-06-01 01:13:27.150018
NCT00859014|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2014-12-18||2014-12-31|2009-03-09|2009-03-10|Estimate|2014-12-31|2015-01-01|Estimate||||2014-12-31|2015-01-01|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Total number of study participants|Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients|Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients|Completed||Phase 1|25|Actual|The University of Texas Health Science Center, Houston|This is a Phase I safety and feasibility study, designed without a control group. Small sample size and inclusion of selected patients warrants caution in interpretation of findings. A randomized controlled study is needed.|1|||f||||t||||||||||2018-06-01 01:13:27.407534|2018-06-01 01:13:27.407534
NCT00859001|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2009-03-10|2009-03-09|2009-03-10|Estimate|||||||2009-03-10|2009-03-12|Estimate||||March 2009|2009-03-31||||||||Interventional|FM+R-Z||Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy|A Phase II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy.|Completed||Phase 2|55|Actual|University of Bologna||1|||f||||||||||||||2018-06-01 01:13:27.587838|2018-06-01 01:13:27.587838
NCT00858988|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2009-03-09|2009-03-09|2009-03-10|Estimate|||||||2009-03-09|2009-03-10|Estimate||||March 2009|2009-03-31||||||||Interventional|||Trial of Rifaximin in the Treatment of Tropical Enteropathy|A Randomized, Double-Blind, Placebo-Controlled Trial of Rifaximin, a Non-Absorbable Antibiotic, in the Treatment of Tropical Enteropathy|Completed||N/A|||Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:13:27.651748|2018-06-01 01:13:27.651748
NCT00858975|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2013-08-12|2009-03-09|2009-03-10|Estimate|||||||2013-08-12|2013-08-13|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study of Cryotherapy for Renal Tumors|Study of Cryotherapy for Renal Tumors|Withdrawn||N/A|0|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 01:13:27.718409|2018-06-01 01:13:27.718409
NCT00858962|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2012-05-31||2012-10-19|2009-03-09|2009-03-10|Estimate|2012-10-19|2012-11-21|Estimate||||2012-10-19|2012-11-21|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Buprenorphine/Raltegravir Pharmacokinetic Interaction Study|A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Raltegravir (Isentress) and Buprenorphine|Completed||N/A|12|Actual|Yale University|The sample size was small, though within the range of similar drug-drug interaction studies. This study utilized a within-subject design with patients acting as their own controls (thereby resulting in less intra-patient variability).|1|||f||||f||||||||||2018-06-01 01:13:27.818636|2018-06-01 01:13:27.818636
NCT00858949|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2016-07-18|2009-03-09|2009-03-10|Estimate|||||||2016-07-18|2016-07-20|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Costs of Postoperative Nausea and Vomiting in Ambulatory Surgery Patients|Time-Motion Study of PONV Costs in Ambulatory Surgery|Completed|||100|Actual|The Cleveland Clinic|||1||f||||f||||||||||2018-06-01 01:13:28.038045|2018-06-01 01:13:28.038045
NCT00858936|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2016-10-18|2009-03-09|2009-03-10|Estimate|||||||2016-10-18|2016-10-19|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of IK-1001 to Evaluate Safety, Pharmacokinetics and Proof-of-concept Efficacy for Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft(CABG)Surgery|Terminated||Phase 2|6|Actual|Mallinckrodt||2||Study Terminated - Company decision|f||||t||||||||||2018-06-01 01:13:28.12029|2018-06-01 01:13:28.12029
NCT00858923|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2009-04-07|2009-03-06|2009-03-10|Estimate|||||||2009-04-07|2009-04-08|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|November 2009|Anticipated|2009-11-30|July 2009|Anticipated|2009-07-31||Interventional|||Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)|Phase 1 Study of the HemoModulator System for the Treatment of Human Immunodeficiency Virus (HIV)|Unknown status|Enrolling by invitation|Phase 1|10|Actual|Energex Systems, Inc.|||||f||||t||||||||||2018-06-01 01:13:28.25198|2018-06-01 01:13:28.25198
NCT00858910|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2013-10-24|2009-03-09|2009-03-10|Estimate|||||||2013-10-24|2013-10-25|Estimate|March 2009||2009-03-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of Embedded and Added Motor Imagery Training in Patients After Stroke|Comparison of Embedded and Added Motor Imagery Training to Improve a Motor Skill in Patients After Stroke: a Pilot Randomised Controlled Trial Using a Mixed Methods Approach|Completed||Phase 2|90|Anticipated|Reha Rheinfelden||3|||f||||f||||||||||2018-06-01 01:13:28.336947|2018-06-01 01:13:28.336947
NCT00858897|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2009-07-14|2009-03-09|2009-03-10|Estimate|||||||2009-07-14|2009-07-15|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A|Regulation of Glutathione Homeostasis in Adolescents With Type 1 Diabetes - Study A|Completed||N/A|10|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-06-01 01:13:28.452118|2018-06-01 01:13:28.452118
NCT00858884|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2013-06-25|2009-03-09|2009-03-10|Estimate|||||||2013-06-25|2013-06-27|Estimate|August 2006||2006-08-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus|Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus|Completed||N/A|68|Actual|University of New Mexico||1|||f||||f||||||||||2018-06-01 01:13:28.549734|2018-06-01 01:13:28.549734
NCT00858871|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09||2015-09-23|2016-10-14|2009-03-09|2009-03-10|Estimate||||2015-09-23|2015-10-09|Estimate|2016-10-14|2016-10-17|Estimate|May 2009||2009-05-31|October 2016|2016-10-31|September 2013|Actual|2013-09-30|June 2012|Actual|2012-06-30||Interventional|BRISK FL||First Line Hepato Cellular Carcinoma (HCC)|A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 3|1714|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:13:28.694715|2018-06-01 01:13:28.694715
NCT00858858|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2014-11-07||2015-04-15|2009-03-09|2009-03-10|Estimate|2014-11-17|2014-11-24|Estimate||||2015-04-15|2015-04-30|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|March 2013|Actual|2013-03-31||Interventional|||Clinical Studies on Bile Acids in Barrett's Esophagus|Clinical Studies on Bile Acids in Barrett's Esophagus|Completed||N/A|60|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 01:13:29.080981|2018-06-01 01:13:29.080981
NCT00858845|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2013-06-19||2018-04-26|2009-03-06|2009-03-10|Estimate|2013-09-04|2013-09-09|Estimate||||2018-04-26|2018-05-24|Actual|May 2008||2008-05-31|April 2018|2018-04-30|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Interventional|||Using Clonidine to Improve Leg Weakness in People With Heart Failure|Clonidine and the Skeletal Myopathy of Heart Failure|Completed||Phase 4|11|Actual|University of California, Los Angeles|This is a small trial, but it was not terminated early, and there were no technical issues.|2|||f||||t||||||||||2018-06-01 01:13:29.245018|2018-06-01 01:13:29.245018
NCT00858832|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2012-07-05||2012-09-17|2009-03-09|2009-03-10|Estimate|2012-09-17|2012-09-19|Estimate||||2012-09-17|2012-09-19|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine|Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine|Completed||N/A|44|Actual|University of South Florida|Early termination due to lack of feasibility in completing project; full analysis was not conducted;|2|||f||||f||||||||||2018-06-01 01:13:29.51057|2018-06-01 01:13:29.51057
NCT00858819|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2015-05-28|2009-03-09|2009-03-10|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|May 2012|Actual|2012-05-31||Observational|||Clinical Trial of Osteoporosis in Ankylosing Spondylitis|Clinical Trial of Osteoporosis in Ankylosing Spondylitis|Completed|||250|Anticipated|Göteborg University|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:13:29.764655|2018-06-01 01:13:29.764655
NCT00858806|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2014-12-02|2009-03-09|2009-03-10|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2010|Actual|2010-12-31||Interventional|INTERIM0407||Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy|Phase II Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients With Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) With Standard IM Therapy|Completed||Phase 2|78|Actual|Università degli Studi di Brescia||1|||f||||t||||||||||2018-06-01 01:13:29.888744|2018-06-01 01:13:29.888744
NCT00857792|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2014-11-18||2016-05-09|2009-03-05|2009-03-09|Estimate|2014-11-24|2014-12-02|Estimate||||2016-05-09|2016-05-11|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging|Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging|Completed||N/A|120|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 01:13:53.435159|2018-06-01 01:13:53.435159
NCT00858793|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2017-05-26|2009-03-09|2009-03-10|Estimate|||||||2017-05-26|2017-05-30|Actual|November 28, 2008|Actual|2008-11-28|May 2017|2017-05-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT|High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT|Completed||Phase 1/Phase 2|5|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||t||||||||||2018-06-01 01:13:29.966854|2018-06-01 01:13:29.966854
NCT00858780|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2013-06-06||2013-08-30|2009-03-09|2009-03-10|Estimate|2013-06-06|2013-08-13|Estimate||||2013-08-30|2013-09-11|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|DOSERA||Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA|Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA)|Completed||Phase 4|91|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:13:30.104739|2018-06-01 01:13:30.104739
NCT00858767|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2010-12-15|2009-03-09|2009-03-10|Estimate|||||||2010-12-15|2010-12-16|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Arabic Gum-Absorption Study|Comparison of Absorption and Efficacy of 3 Different Menaquinone-7 Delivery Systems; Casein Powder, Arabic Gum Powder, or Linseed Oil|Completed||N/A|69|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 01:13:32.580371|2018-06-01 01:13:32.580371
NCT00858754|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2011-07-22|2009-03-09|2009-03-10|Estimate|||||||2011-07-22|2011-07-25|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects|A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Related Pain|Withdrawn||Phase 4|340|Anticipated|Valeant Pharmaceuticals International, Inc.||2||"Withdrawn [This study was terminated early by Wyeth, prior to dosing any subjects, for business~   reasons not related to safety."|f||||f||||||||||2018-06-01 01:13:32.659389|2018-06-01 01:13:32.659389
NCT00858741|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2009-03-09|2009-03-09|2009-03-10|Estimate|||||||2009-03-09|2009-03-10|Estimate||||March 2009|2009-03-31||||||||Interventional|||Palliative Radiotherapy for Bone Metastases: Single Versus Multiple Fractions.|Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions.|Completed||Phase 3|148|Actual|Marilia Medicine School||2|||f||||f||||||||||2018-06-01 01:13:32.75936|2018-06-01 01:13:32.75936
NCT00858728|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2010-07-22|2009-03-09|2009-03-10|Estimate|||||||2010-07-22|2010-07-26|Estimate|October 2006||2006-10-31|July 2010|2010-07-31|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|ADIT||Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly|Effect of Fruit and Vegetable Consumption on Immune Function in the Elderly: a Randomised Controlled Trial|Completed||Phase 3|83|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-06-01 01:13:32.905864|2018-06-01 01:13:32.905864
NCT00858715|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2012-12-11|2009-03-09|2009-03-10|Estimate|||||||2012-12-11|2012-12-12|Estimate|May 2008||2008-05-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|Vienna REACT||Resistance to Antithrombotic Therapy|Resistance to Antithrombotic Therapy in Patients Undergoing Angioplasty and Stenting for Cardiovascular Disease - Vienna REACT|Completed||N/A|46|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:13:32.970596|2018-06-01 01:13:32.970596
NCT00858702|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2009-07-16||2017-10-10|2009-03-09|2009-03-10|Estimate|2009-07-16|2009-08-26|Estimate||||2017-10-10|2017-10-11|Actual|February 2005||2005-02-28|October 2017|2017-10-31|November 2005|Actual|2005-11-30|July 2005|Actual|2005-07-31||Interventional|||Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension|Add-on Study of CCBs or Diuretics in Essential Hypertension Not Achieving Target Blood Pressure on Olmesartan Medoxomil Alone|Completed||Phase 4|105|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:13:33.064416|2018-06-01 01:13:33.064416
NCT00858689|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2013-09-01||2016-02-16|2009-03-09|2009-03-10|Estimate|2016-02-16|2016-02-18|Estimate||||2016-02-16|2016-02-18|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome|Add-on Pilot Trial of Minocycline in Fragile X Syndrome|Completed||N/A|20|Actual|FRAXA Research Foundation|This was an open-label trial. Further study in a randomized controlled trial is warranted.|1|||f||||f||||||||||2018-06-01 01:13:33.295004|2018-06-01 01:13:33.295004
NCT00858676|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2012-07-17|2009-03-09|2009-03-10|Estimate|||||||2012-07-17|2012-07-18|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)|Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation|Unknown status|Recruiting|Phase 4|150|Anticipated|Aichi Gakuin University||1|||f||||t||||||||||2018-06-01 01:13:33.499151|2018-06-01 01:13:33.499151
NCT00858663|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2013-07-23|2009-03-06|2009-03-10|Estimate|||||||2013-07-23|2013-07-25|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer|A Phase I Study of Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer|Completed||Phase 1|13|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:13:33.599075|2018-06-01 01:13:33.599075
NCT00858650|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2016-08-22|2009-03-09|2009-03-10|Estimate|||||||2016-08-22|2016-08-24|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|RHyMe||Registry of Hypogonadism in Men|Registry of Hypogonadism in Men|Completed|||999|Actual|New England Research Institutes|||1||f||||f||||||||||2018-06-01 01:13:33.684659|2018-06-01 01:13:33.684659
NCT00858637|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|2014-09-08||2014-12-08|2009-03-09|2009-03-10|Estimate|2014-10-16|2014-10-17|Estimate||||2014-12-08|2014-12-30|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis|A Phase III, Multicentre, Double-blind, Double-dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 Versus Simvastatin for the Treatment of Dyslipidaemia in Subjects With Chronic Kidney Disease on Dialysis (Incorporating a Placebo-controlled Withdrawal Phase)|Completed||Phase 3|260|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||f||||||||||2018-06-01 01:13:33.914286|2018-06-01 01:13:33.914286
NCT00858624|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2013-06-17|2009-03-09|2009-03-10|Estimate|||||||2013-06-17|2013-06-19|Estimate|February 2008||2008-02-29|June 2013|2013-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity|Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity|Completed||N/A|24|Actual|University of Manchester||2|||f||||f||||||||||2018-06-01 01:13:34.670695|2018-06-01 01:13:34.670695
NCT00858611|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-07|||2017-06-30|2009-03-07|2009-03-10|Estimate|||||||2017-06-30|2017-07-02|Actual|March 3, 2009||2009-03-03|June 21, 2010|2010-06-21|June 21, 2010|Actual|2010-06-21|June 21, 2010|Actual|2010-06-21||Interventional|||VRC 307: A Double-Blind, Randomized Phase I Study of the Safety and Immunogenicity of a Prime-Boost Schedule of the Investigational DNA Trivalent Influenza Vaccine, VRC-FLUDNA047-00-VP, Followed by the 2008/2009 Seasonal Influenza Trivalent Inactivat...|VRC 307: A D/B Randomized Ph. I Study of Safety/Immunogenicity of a Prime-Boost Schedule of an Investigational DNA Influenza Vaccine, Followed by the Seasonal Influenza Trivalent Inactivated Vaccine (TIV), Compared to TIV Alone in Healthy Adults|Completed||Phase 1|51|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:13:34.755128|2018-06-01 01:13:34.755128
NCT00858598|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2017-06-19|2009-03-09|2009-03-10|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2009||2009-12-31|June 2017|2017-06-30|January 2014|Anticipated|2014-01-31|July 2013|Anticipated|2013-07-31||Observational|PO||Pro Osteon Bone Void Filler Study|Pro Osteon Bone Void Filler Data Collection|Withdrawn|||0|Actual|Zimmer Biomet|||1|Study never started. Study suspended indefinitely.|f||||f||||||||||2018-06-01 01:13:34.829022|2018-06-01 01:13:34.829022
NCT00858585|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-07|||2017-11-30|2009-03-09|2009-03-10|Estimate|||||||2017-11-30|2017-12-04|Actual|March 2009||2009-03-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|May 2011|Actual|2011-05-31||Observational|||Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study|Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study|Active, not recruiting|||124|Actual|University of Michigan Cancer Center|||||f||||t||||||Samples With DNA|"~     Retained samples will consist of a portion of the specimens collected for this concordance~     study: peripheral blood leukocytes, lymph nodes, and tumor tissue. All retained samples will~     be completely de-identified and re-numbered.~   "|||2018-06-01 01:13:34.910659|2018-06-01 01:13:34.910659
NCT00858572|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2014-09-17|2009-03-09|2009-03-10|Estimate|||||||2014-09-17|2014-09-18|Estimate|March 2009||2009-03-31|September 2014|2014-09-30|February 2013|Actual|2013-02-28|May 2011|Actual|2011-05-31||Interventional|||STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies|Completed||Phase 1|31|Actual|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-06-01 01:13:34.986444|2018-06-01 01:13:34.986444
NCT00858559|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2017-08-03|2009-03-09|2009-03-10|Estimate|||||||2017-08-03|2017-08-04|Actual|March 2009||2009-03-31|May 2011|2011-05-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|ANVITE||Follow-up of Patients With Implantable Cardioverter Defibrillators by Home Monitoring (ANVITE)|Follow-up of Patients With Implantable Cardioverter Defibrillators by Home Monitoring (ANVITE)|Terminated||N/A|110|Actual|Biotronik SE & Co. KG||2||Stopped due to low enrollment. Patients will be followed up for 3 months.|f||||f||||||||||2018-06-01 01:13:35.071774|2018-06-01 01:13:35.071774
NCT00858546|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-08|||2009-10-15|2009-03-09|2009-03-10|Estimate|||||||2009-10-15|2009-10-16|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease|The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease|Completed||N/A|10|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 01:13:35.1394|2018-06-01 01:13:35.1394
NCT00858533|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2010-07-26|2009-03-09|2009-03-10|Estimate|||||||2010-07-26|2010-07-28|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|H@W||Trial of Health at Work Workplace Health Intervention|A Pilot Controlled Feasibility Trial of Early Health at Work Workplace Intervention|Completed||N/A|63|Actual|University of Liverpool||2|||f||||t||||||||||2018-06-01 01:13:35.202225|2018-06-01 01:13:35.202225
NCT00858520|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-09|||2013-09-02|2009-03-09|2009-03-10|Estimate|||||||2013-09-02|2013-09-04|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Serum, Plasma, DNA and Tissue Bank in Chronic Obstructive Pulmonary Disease and Lung Cancer|Serum, Plasma, DNA and Tissue Bank of Patients With Chronic Obstructive Pulmonary Disease, Lung Cancer and Smoking Controls.|Recruiting|||2000|Anticipated|Katholieke Universiteit Leuven|||3||f||||f||||||Samples With DNA|"~     Germline DNA, serum and plasma, Peripheral blood mononuclear cells, Lung tissue biopsies~   "|||2018-06-01 01:13:35.27539|2018-06-01 01:13:35.27539
NCT00858507|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2014-12-10||2016-06-09|2009-03-06|2009-03-09|Estimate|2016-06-09|2016-07-21|Estimate||||2016-06-09|2016-07-21|Estimate|October 2009||2009-10-31|June 2016|2016-06-30|March 2014|Actual|2014-03-31|October 2012|Actual|2012-10-31||Interventional|||Engaging Homeless Veterans in Primary Care|Engaging Homeless Veterans in Primary Care|Completed||N/A|221|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:13:35.36048|2018-06-01 01:13:35.36048
NCT00858494|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2010-12-27||2018-04-12|2009-03-06|2009-03-09|Estimate|2011-03-01|2011-03-03|Estimate||||2018-04-12|2018-05-14|Actual|March 2009||2009-03-31|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Homeopathic Cold Medicine for Children|Homeopathic Cold Medicine for Children|Completed||N/A|50|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 01:13:35.557725|2018-06-01 01:13:35.557725
NCT00858481|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2015-10-19|2009-03-06|2009-03-09|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Pilot Dose Ranging Study of Spinosad Creme Rinse|Efficacy and Safety of Different Strengths of Spinosad Topical Creme (0%, 0.5%, 1.0% or 2%) in Subjects With Pediculosis Capitis - a Dose Ranging Study|Completed||Phase 2|36|Actual|ParaPRO LLC||4|||f||||f||||||||||2018-06-01 01:13:35.793759|2018-06-01 01:13:35.793759
NCT00858468|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2009-04-20||2016-04-12|2009-03-05|2009-03-09|Estimate|2009-06-09|2009-07-31|Estimate||||2016-04-12|2016-04-14|Estimate|April 2005||2005-04-30|April 2016|2016-04-30|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Interventional|||Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age|Proof of Concept Study of the Safety and Immunogenicity of Influenza Virus Vaccine Fluzone® 2004-2005 Among Healthy Children 2 Months vs 6 Months of Age|Completed||Phase 1/Phase 2|394|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:13:35.900976|2018-06-01 01:13:35.900976
NCT00858455|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-06-04|2009-03-05|2009-03-09|Estimate|||||||2009-06-04|2009-06-05|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|DDI||A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572|A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Maalox® Advanced Maximum Strength and One A Day® Maximum on Pharmacokinetics of GSK1349572 in Healthy Adult Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:13:36.450003|2018-06-01 01:13:36.450003
NCT00858442|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2013-04-18||2015-01-28|2009-03-05|2009-03-09|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-28|2015-02-13|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional||Some patients received more than one graft, as it is shown in result section.|Platelet-Rich Plasma (PRP) in Reconstructive Surgery on Children With Retractable Burn Sequelae on Extremities|PRP on Children With Retractable Burn Sequelae Who Have Submitted Release of Burn Contractures and Skin Graft on Their Limbs. A Double-Blind Randomized Clinical Trial|Completed||N/A|44|Actual|Corporation for the Aid of Burned Children|Loss cases: PRP group: 3/23 and group without PRP: 1/21|2|||f||||f||||||||||2018-06-01 01:13:36.531711|2018-06-01 01:13:36.531711
NCT00858429|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2018-01-22|2009-03-06|2009-03-09|Estimate|||||||2018-01-22|2018-01-24|Actual|March 2009||2009-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases|Dose Escalating Study of Yttrium 90 Microspheres (TheraSphere) With Capecitabine (Xeloda) for Intrahepatic Cholangiocarcinoma or Metastatic Disease to the Liver|Active, not recruiting||Phase 1|30|Anticipated|Northwestern University||4|||f||||t||||||||||2018-06-01 01:13:36.802826|2018-06-01 01:13:36.802826
NCT00858416|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-06|2009-03-06|2009-03-09|Estimate|||||||2009-03-06|2009-03-09|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|KC-01||Combined Vibrations, Passive Motion and Thermotherapy for Knee Osteoarthritis|Efficacy of Combined Local Mechanical Vibrations, Continuous Passive Motion and Thermotherapy in the Management of Osteoarthritis of the Knee|Completed||Phase 4|71|Actual|Kineticure||2|||f||||f||||||||||2018-06-01 01:13:36.888209|2018-06-01 01:13:36.888209
NCT00858403|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2011-07-12||2013-12-13|2009-03-06|2009-03-09|Estimate|2011-08-05|2011-09-07|Estimate||||2013-12-13|2014-01-15|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation|Phase II Study of Dasatinib in Advanced Non-small Cell Lung Cancer With Ex Vivo and In Vivo Assessment of Tumor Target Modulation|Terminated||Phase 2|7|Actual|H. Lee Moffitt Cancer Center and Research Institute|The low accrual of 7 participants prevented us from completing the planned analysis. Target accrual was 40.|1||Slow Accrual|f||||t||||||||||2018-06-01 01:13:36.980104|2018-06-01 01:13:36.980104
NCT00858390|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2014-05-15||2014-06-13|2009-03-06|2009-03-09|Estimate|2014-05-15|2014-06-16|Estimate||||2014-06-13|2014-06-26|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Interventional|HRSA Nutrition||Nutritional Status and Enteral Absorption Capability After Brain Death|Clinical Interventions to Increase Organ Procurement Nutritional Status and Enteral Absorption Capability After Brain Death (R38OT10585)|Completed||N/A|36|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 01:13:37.290543|2018-06-01 01:13:37.290543
NCT00858377|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2018-03-12|2009-03-05|2009-03-09|Estimate|||||||2018-03-12|2018-03-14|Actual|August 10, 2009|Actual|2009-08-10|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|December 31, 2014|Actual|2014-12-31||Interventional|||A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors|A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|95|Actual|Amgen||2|||f||||t||||||||||2018-06-01 01:13:37.660795|2018-06-01 01:13:37.660795
NCT00858364|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-11-29|2009-03-05|2009-03-09|Estimate|||||||2017-11-29|2017-12-02|Actual|July 17, 2009|Actual|2009-07-17|November 2017|2017-11-30|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy|Terminated||Phase 3|2549|Actual|Amgen||2||Primary objective reached|f||||t||||||||||2018-06-01 01:13:37.852376|2018-06-01 01:13:37.852376
NCT00858351|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2015-05-08|2009-03-06|2009-03-09|Estimate|||||||2015-05-08|2015-05-12|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Thermal Biofeedback for the Treatment of Diabetic Neuropathy|A Placebo-Controlled Trial of Thermal Biofeedback Assisted Relaxation for the Treatment of Diabetic Neuropathy: An Evaluation of Outcomes and Mechanisms|Completed||N/A|32|Actual|Rosalind Franklin University of Medicine and Science||2|||f||||f||||||||||2018-06-01 01:13:39.146467|2018-06-01 01:13:39.146467
NCT00858338|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2016-03-10|2009-03-06|2009-03-09|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2002||2002-12-31|March 2016|2016-03-31|February 2012|Actual|2012-02-29|March 2007|Actual|2007-03-31||Interventional|||Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer|Phase-II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma (R0 Resection and at Least D1 Lymph-node Dissection)|Completed||Phase 2|28|Actual|New York University School of Medicine|||||f||||t||||||||||2018-06-01 01:13:39.220817|2018-06-01 01:13:39.220817
NCT00858325|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2010-01-21|2009-03-06|2009-03-09|Estimate|||||||2010-01-21|2010-01-22|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|March 2009|Actual|2009-03-31|||||Interventional|||Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China|A Two Cohort, Open Label, Single and Multiple Dose Pharmacokinetic Study of 4mg/Kg and 6mg/Kg Doses of Daptomycin in Healthy Chinese Subjects Living in China|Completed||Phase 1|24|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:13:39.329765|2018-06-01 01:13:39.329765
NCT00858312|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-10-22|2009-03-06|2009-03-09|Estimate|||||||2009-10-22|2009-10-23|Estimate|October 2006||2006-10-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Dairy Foods and Weight Loss|Role of Dairy Foods to Enhance Central Fat and Weight Loss With Moderate Energy Restriction in Overweight and Obesity Individuals|Completed||Phase 2/Phase 3|72|Anticipated|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 01:13:39.404297|2018-06-01 01:13:39.404297
NCT00858299|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-06|2009-03-06|2009-03-09|Estimate|||||||2009-03-06|2009-03-09|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria|The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria|Unknown status|Not yet recruiting|Phase 4|500|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 01:13:39.516126|2018-06-01 01:13:39.516126
NCT00858286|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2014-08-11|2009-03-05|2009-03-09|Estimate|||||||2014-08-11|2014-08-13|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.|Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.|Completed||Phase 4|56|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:13:39.584138|2018-06-01 01:13:39.584138
NCT00858273|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2012-05-02|2009-03-06|2009-03-09|Estimate|||||||2012-05-02|2012-05-04|Estimate|March 2008||2008-03-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B|Regulation of Glutathione Homeostasis in Adolescents With Type 1 Diabetes - Study B|Completed||N/A|40|Anticipated|Nemours Children's Clinic||2|||f||||f||||||||||2018-06-01 01:13:39.675452|2018-06-01 01:13:39.675452
NCT00858260|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2009-09-03|2009-03-06|2009-03-09|Estimate|||||||2009-09-03|2009-09-04|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|February 2009|Actual|2009-02-28|||||Observational|ARNOGENE||Arnogene: A Phosphocalcic Study in Dialysis|Genetic Determinants of Phosphocalcic Metabolism in Hemodialysis Patients|Completed|||1200|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     Searching for high morbi-mortality risk Klotho variants~   "|||2018-06-01 01:13:40.242784|2018-06-01 01:13:40.242784
NCT00858247|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2013-12-16||2014-05-13|2009-03-06|2009-03-09|Estimate|2014-02-04|2014-03-06|Estimate||||2014-05-13|2014-05-20|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||47 Subjects started the study, but one subject in the Vitamin D3-high dose arm only completed one visit. The baseline characteristics are reported on the 47 subjects who started the study.|Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents|Significance of Vitamin D Status in Obese Adolescents- A Pilot Study to Examine the Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors|Completed||Phase 2|51|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 01:13:40.551214|2018-06-01 01:13:40.551214
NCT00858234|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2016-01-21|2009-03-06|2009-03-09|Estimate|||||||2016-01-21|2016-01-22|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|April 2012|Actual|2012-04-30|June 2010|Actual|2010-06-30||Interventional|||Phase I Study of MK0683 in Combination With Bortezomib in Multiple Myeloma Patients (0683-098)|A Multicenter, Open-Label, Phase I Study of MK0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma|Completed||Phase 1|9|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:13:41.588369|2018-06-01 01:13:41.588369
NCT00858221|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-10-19|2009-03-06|2009-03-09|Estimate|||||||2009-10-19|2009-10-20|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Observational|||Association of Genes to Resistance to Weight Loss in Obese Patients|Association of Genetic Variants in Obesity Genes to Resistance to Weight Loss and Susceptibility to Metabolic Syndrome in Morbidly Obese Patients: A Single Center, Blinded, Retrospective Clinical Study|Completed|||824|Actual|Interleukin Genetics, Inc.|||||f||||f||||||Samples With DNA|"~     DNA to be analyzed by genotyping~   "|||2018-06-01 01:13:41.877071|2018-06-01 01:13:41.877071
NCT00858208|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2012-03-14||2012-03-14|2009-03-06|2009-03-09|Estimate|2012-03-14|2012-04-11|Estimate||||2012-03-14|2012-04-11|Estimate|March 2008||2008-03-31|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|MACULA||Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.|Long-Term Non-Interventional Study To Investigate The Efficacy And Safety Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice.|Completed|||86|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:13:42.166821|2018-06-01 01:13:42.166821
NCT00858195|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-03-27|2009-03-06|2009-03-09|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2006||2006-06-30|March 2009|2009-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules|A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules Under Fasting Conditions|Completed||Phase 1|36|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:13:43.765508|2018-06-01 01:13:43.765508
NCT00858182|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2013-03-25|2009-03-06|2009-03-09|Estimate|||||||2013-03-25|2013-03-26|Estimate|May 2009||2009-05-31|March 2013|2013-03-31|January 2013|Anticipated|2013-01-31|October 2012|Anticipated|2012-10-31||Interventional|||Study of Safety and Efficacy on New Peritoneal Dialysis Solutions|Evaluation of a New Peritoneal Dialysis Solutions Containing Glucose, Xylitol and L-carnitine Compared to Standard PD Solutions in End-stage Renal Disease (ESRD) Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)|Withdrawn||Phase 2|0|Actual|Iperboreal Pharma Srl||2|||f||||f||||||||||2018-06-01 01:13:44.054038|2018-06-01 01:13:44.054038
NCT00858169|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2015-02-12|2009-03-06|2009-03-09|Estimate|||||||2015-02-12|2015-02-13|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|3D sono in RA||Assessment of Wrist Joint and Knee Joint Inflammation in Patients With Rheumatoid Arthritis by Quantitative Three Dimensional Power Doppler Ultrasonography|Taichung Veterans General Hospital|Completed|||49|Actual|Taichung Veterans General Hospital|||||f||||f||||||||||2018-06-01 01:13:44.314124|2018-06-01 01:13:44.314124
NCT00858156|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2010-01-26|2009-03-05|2009-03-09|Estimate|||||||2010-01-26|2010-01-27|Estimate|April 2009||2009-04-30|January 2010|2010-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||BG9928 in Subjects With Hepatic Impairment|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Oral BG9928 in Subjects With Mild and Moderate Hepatic Impairment and in Healthy Subjects|Completed||Phase 1|23|Actual|Biogen|||||f||||f||||||||||2018-06-01 01:13:44.505007|2018-06-01 01:13:44.505007
NCT00858143|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2009-06-25||2009-08-24|2009-03-06|2009-03-09|Estimate|2009-06-25|2009-08-12|Estimate||||2009-08-24|2009-09-02|Estimate|January 2004||2004-01-31|March 2009|2009-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|GPOS||Non Interventional Study For Patients Treated With Somavert®|German Non Interventional Study For Patients Treated With Somavert®|Completed|||311|Actual|Pfizer|||1||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:13:44.93093|2018-06-01 01:13:44.93093
NCT00858130|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2017-03-16||2017-10-30|2009-03-06|2009-03-09|Estimate|2017-10-30|2017-11-29|Actual||||2017-10-30|2017-11-29|Actual|March 2009||2009-03-31|August 2017|2017-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|VeinoPlus||Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)|Optimal Intensity and Frequency of a Portable Electrical Muscle Stimulator (VeinoPlus) to Improve Symptoms of Postthrombotic Syndrome|Completed||N/A|12|Actual|University of North Carolina, Chapel Hill|Given its small sample size (n=12), this study provides rationale and details needed for a larger randomized, placebo controlled, and double-blinded trial.|1|||f||||t|f|t|f|f|f|||||2018-06-01 01:13:47.175354|2018-06-01 01:13:47.175354
NCT00858117|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2018-02-02|2009-03-06|2009-03-09|Estimate|||||||2018-02-02|2018-02-06|Actual|March 2005||2005-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL|A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL|Active, not recruiting||Phase 2|30|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 01:13:47.393095|2018-06-01 01:13:47.393095
NCT00858104|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2014-05-23|2009-03-06|2009-03-09|Estimate|||||||2014-05-23|2014-05-26|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|May 2013|Actual|2013-05-31|March 2010|Actual|2010-03-31||Interventional|||Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results|Multicentric Randomized Controlled Study of Percutaneous Laser Ablation Versus Follow Up in Benign Thyroid Nodules. Long Term Results|Completed||Phase 4|200|Actual|Elesta S.R.L.||2|||f||||t||||||||||2018-06-01 01:13:47.483095|2018-06-01 01:13:47.483095
NCT00858091|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2015-04-06|2009-03-05|2009-03-09|Estimate|||||||2015-04-06|2015-04-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:13:47.552|2018-06-01 01:13:47.552
NCT00858078|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2018-05-23|2009-03-06|2009-03-09|Estimate|||||||2018-05-23|2018-05-24|Actual|January 27, 2009||2009-01-27|January 10, 2018|2018-01-10||||||||Observational|||A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women|A Qualitative Exploration of the Impact of Positive BRCA 1/2 Mutation Status on the Lives of Young Women|Completed|||76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:13:47.590599|2018-06-01 01:13:47.590599
NCT00858065|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2012-12-14|2009-03-06|2009-03-09|Estimate|||||||2012-12-14|2012-12-18|Estimate|April 2005||2005-04-30|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Adolescent Family-Based Alcohol Prevention|Adolescent Family-Based Alcohol Prevention|Completed||Phase 4|1228|Actual|Pacific Institute for Research and Evaluation||5|||f||||t||||||||||2018-06-01 01:13:47.654325|2018-06-01 01:13:47.654325
NCT00858052|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05||2014-03-11|2017-03-01|2009-03-06|2009-03-09|Estimate||||2014-09-04|2014-09-12|Estimate|2017-03-01|2017-03-03|Actual|February 2009||2009-02-28|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|February 2012|Actual|2012-02-29||Interventional|||Core Study of the Safety and Effectiveness of IDEAL IMPLANT(R) Saline-filled Breast Implants|Core Study of the Safety and Effectiveness of IDEAL IMPLANT(R) Saline-filled Breast Implants in Women Who Are Undergoing Primary Breast Augmentation or Replacement of Existing Augmentation Implants|Active, not recruiting||N/A|500|Anticipated|Ideal Implant Incorporated||1|||f||||f||||||||||2018-06-01 01:13:47.736598|2018-06-01 01:13:47.736598
NCT00858039|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2014-11-04|2009-03-06|2009-03-09|Estimate|||||||2014-11-04|2014-11-05|Estimate|February 2009||2009-02-28|November 2014|2014-11-30|June 2014|Actual|2014-06-30|July 2013|Actual|2013-07-31||Observational|CATS||Cardiotoxicity of Adjuvant Trastuzumab|Prediction of Cardiotoxicity Using Serum N-terminal Pro-B-type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab|Completed|||220|Actual|Royal Prince Alfred Hospital, Sydney, Australia|||1||f||||f||||||Samples With DNA|"~     Human serum Human whole blood~   "|||2018-06-01 01:13:47.82799|2018-06-01 01:13:47.82799
NCT00858026|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2009-03-06|2009-03-06|2009-03-09|Estimate|||||||2009-03-06|2009-03-09|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Impact of a Fermented Infant Formula in Weaning Babies|Impact of a Fermented Infant Formula in Weaning Babies|Completed||N/A|91|Actual|Bledina||3|||f||||f||||||||||2018-06-01 01:13:47.894217|2018-06-01 01:13:47.894217
NCT00858013|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2017-02-14||2017-05-15|2009-03-06|2009-03-09|Estimate|2017-02-14|2017-03-31|Actual||||2017-05-15|2017-05-16|Actual|April 24, 2009|Actual|2009-04-24|May 2017|2017-05-31|June 25, 2014|Actual|2014-06-25|June 25, 2014|Actual|2014-06-25||Interventional|||Study of the Durability of Glycemic Control With Nateglinide|Multi-center, Randomized, Open Label Study of the Durability of Glycemic Control With Nateglinide Versus Glimepiride as Monotherapy in Type 2 Diabetic Patients|Completed||Phase 4|88|Actual|Ajou University School of Medicine||2|||f||||t||||||||No||2018-06-01 01:13:47.963071|2018-06-01 01:13:47.963071
NCT00858000|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-12-23|2009-03-05|2009-03-09|Estimate|||||||2009-12-23|2009-12-24|Estimate|July 2009||2009-07-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Analysis of Expression of Specific Markers in Hepatocellular Carcinoma|Analysis of the Incidence of Expression of a Specific Set of Genes and of Tumor Antigens in Cancer Tissue From Patients With Hepatocellular Carcinoma|Completed|||30|Actual|GlaxoSmithKline|||1||f||||||||||None Retained|"~     This retrospective study is based upon the analysis of archived samples and patient-related~     data already available at the investigational site~   "|||2018-06-01 01:13:48.218164|2018-06-01 01:13:48.218164
NCT00857987|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2011-01-27|2009-03-06|2009-03-09|Estimate|||||||2011-01-27|2011-01-28|Estimate|April 2010||2010-04-30|January 2011|2011-01-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Effectiveness and Safety of the of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improvement of Symptoms Resulting From Acute Respiratory Infections.|Randomized , Placebo-controlled, Clinical Trial of Efficacy and Safety Evaluation of Guaifenesin, Doxylamine Succinate and Hydrochloride Etafedrine Syrup in Improving the Signs and Symptoms of Infections of Way Upper (URI)|Unknown status|Recruiting|Phase 3|174|Anticipated|Azidus Brasil||2|||f||||t||||||||||2018-06-01 01:13:48.277895|2018-06-01 01:13:48.277895
NCT00857974|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2017-11-02|2009-03-06|2009-03-09|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2007||2007-07-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|PART||Physical Activity Program for Older Renal Transplant Candidates|Impact of a Physical Activity Intervention on Physical Function and Quality of Life in Aging Candidates for Renal Transplantation: The PART Study|Completed||N/A|25|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 01:13:48.470683|2018-06-01 01:13:48.470683
NCT00857961|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2010-12-15|2010-09-13|2011-01-06|2009-03-05|2009-03-09|Estimate|2011-01-06|2011-01-07|Estimate|2010-09-13|2010-09-15|Estimate|2011-01-06|2011-01-07|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations|A Phase II, Randomised, Four-way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered Dose (MD) Lotion® Formulations and Doses in Hypogonadal Men|Completed||Phase 2|21|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:13:48.563507|2018-06-01 01:13:48.563507
NCT00857948|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2012-03-01|2010-09-22|2012-03-01|2009-03-06|2009-03-09|Estimate|2012-03-01|2012-03-30|Estimate|2010-09-22|2010-09-27|Estimate|2012-03-01|2012-03-30|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation|A Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of 3 Strengths of Ivermectin Treatment Conditioner and Placebo in Subjects With Pediculus Humanus Capitis (Head Lice) Infestation|Completed||Phase 2|78|Actual|Topaz Pharmaceuticals Inc||4|||f||||f||||||||||2018-06-01 01:13:49.014719|2018-06-01 01:13:49.014719
NCT00857935|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-06|2009-03-06|2009-03-09|Estimate|||||||2009-03-06|2009-03-09|Estimate|March 2007||2007-03-31|March 2009|2009-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse|A Pilot Study to Test the Operational Elements of an Actual Use Study Designed to Compare the Safety and Efficacy of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months of Age or Older With Pediculosis Capitis|Completed||Phase 2|24|Actual|ParaPRO LLC||2|||f||||f||||||||||2018-06-01 01:13:49.586618|2018-06-01 01:13:49.586618
NCT00857922|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2018-02-06|2009-03-06|2009-03-09|Estimate|||||||2018-02-06|2018-02-08|Actual|March 2009||2009-03-31|February 2018|2018-02-28|August 2030|Anticipated|2030-08-31|March 2030|Anticipated|2030-03-31||Observational|NRR||Neurosciences Research Repository|Neurosciences Research Repository|Recruiting|||5000|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||t||||||Samples With DNA|"~     whole blood, plasma, white cells, saliva, tissue, CSF~   "|||2018-06-01 01:13:49.655067|2018-06-01 01:13:49.655067
NCT00857909|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2011-07-07|2009-03-06|2009-03-09|Estimate|||||||2011-07-07|2011-07-08|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SPAS||The Effect of Amiloride and Spironolactone in Healthy Persons|The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study|Completed||Phase 1|30|Actual|Regional Hospital Holstebro||3|||f||||t||||||||||2018-06-01 01:13:49.7277|2018-06-01 01:13:49.7277
NCT00857896|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2011-10-04||2011-11-20|2009-03-06|2009-03-09|Estimate|2011-10-04|2011-11-17|Estimate||||2011-11-20|2011-11-24|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years|An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years.|Completed||Phase 2|21|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 01:13:49.814012|2018-06-01 01:13:49.814012
NCT00857883|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2017-06-23|2009-03-05|2009-03-09|Estimate|||||||2017-06-23|2017-06-26|Actual|November 17, 2008|Actual|2008-11-17|June 2017|2017-06-30|August 1, 2009|Actual|2009-08-01|August 1, 2009|Actual|2009-08-01||Interventional|FTIH||A First-Time-In-Human Study in Healthy Subjects|A First-Time-In-Human, Three-Part, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1521498 in Healthy Subjects|Completed||Phase 1|56|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:13:50.073564|2018-06-01 01:13:50.073564
NCT00857870|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2012-01-10|2009-03-06|2009-03-09|Estimate|||||||2012-01-10|2012-01-11|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|GLORY||Insulin Glargine First Line vs Metformin in Type 2 Diabetic Subjects|Comparative Investigation of Efficacy and Safety of Insulin Glargine Versus Metformin as First Line Drug in Treatment of Early Type 2 Diabetes|Completed||Phase 4|96|Actual|GWT-TUD GmbH||2|||f||||||||||||||2018-06-01 01:13:50.184707|2018-06-01 01:13:50.184707
NCT00857857|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2017-04-20||2017-08-11|2009-03-05|2009-03-09|Estimate|2017-08-11|2018-02-20|Estimate||||2017-08-11|2018-02-20|Estimate|February 16, 2009|Actual|2009-02-16|August 2017|2017-08-31|November 3, 2009|Actual|2009-11-03|November 3, 2009|Actual|2009-11-03||Interventional|||A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics|A Randomised, Placebo-controlled, Incomplete Block, Three-way Cross-over Study to Evaluate the Effect of Treatment With Repeat Inhaled Doses of GW870086X on the Allergen-induced Early and Late Asthmatic Response in Subjects With Mild Asthma|Completed||Phase 2|24|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:13:50.365609|2018-06-01 01:13:50.365609
NCT00857844|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2013-05-01|2009-03-06|2009-03-09|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2007||2007-07-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|October 2008|Actual|2008-10-31||Observational|||Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers|Genetic Predisposition of Chronic Nephrotoxicity From Calcineurin Inhibitors in Liver Transplant Recipients, Potential Correlation With Urinary Biomarkers|Completed|||207|Actual|Northwestern University|||3||f||||f||||||Samples With DNA|"~     -  Urine will be collected from all patients in the 3 groups and analyzed for biomarkers of~          interstitial fibrosis and proximal tubule injury. Specific biomarkers that will be~          tested are: urinary TGF-beta1, kidney injury molecule-1 and angiotensinogen. Urinary~          biomarkers will be normalized to creatinine and analyzed using an ELISA assay.~        -  An additional 18mls of blood will be collected. This blood will be used to study organ~          transplant tolerance in subjects who are currently using immunosuppressant medications.~   "|||2018-06-01 01:13:52.686641|2018-06-01 01:13:52.686641
NCT00857831|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2012-10-02|2009-03-05|2009-03-09|Estimate|||||||2012-10-02|2012-10-03|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Vitamin D and Calcium Study|Vitamin D and Calcium Replacement/Supplementation in Subjects With Chronic Spinal Cord Injury|Completed||N/A|10|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:13:52.776594|2018-06-01 01:13:52.776594
NCT00857818|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2011-05-17||2013-11-07|2009-03-06|2009-03-09|Estimate|2011-06-22|2011-07-21|Estimate||||2013-11-07|2013-12-02|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome|A 16-Week, Randomized, Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Non-HDL Cholesterol Among Patients With Schizophrenia and Bipolar I Disorder Who Have Pre-existing Metabolic Syndrome|Terminated||Phase 3|64|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The study terminated early due to low enrollment. Mean changes from baseline in: the Clinical Global Impression-Severity Scale and the Impact of Weight on Quality of Life scores were not analyzed due to insufficient data for meaningful conclusions.|2||Slow Accrual|f||||f||||||||||2018-06-01 01:13:52.889149|2018-06-01 01:13:52.889149
NCT00857805|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-03-06|2009-03-05|2009-03-09|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2009||2009-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma|Randomized Controlled Trial of Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma|Recruiting||N/A|220|Anticipated|Loma Linda University||2|||f||||f||||||||||2018-06-01 01:13:53.348468|2018-06-01 01:13:53.348468
NCT00857779|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2013-02-07|2009-03-05|2009-03-09|Estimate|||||||2013-02-07|2013-02-08|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients|A Multicentre Randomised Phase II Clinical Trial to Demonstrate Equivalent Pharmacodynamic Efficacy and Tolerability of Two Updosing Schedules for ALK-Flex SQ|Completed||Phase 2|473|Actual|ALK-Abelló A/S||2|||f||||t||||||||||2018-06-01 01:13:53.626648|2018-06-01 01:13:53.626648
NCT00857766|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2010-12-16||2016-12-01|2009-03-05|2009-03-09|Estimate|2010-12-16|2010-12-23|Estimate||||2016-12-01|2017-01-30|Estimate|March 2009||2009-03-31|December 2016|2016-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Parallel-Group, 16-Week Study to Evaluate the Effect of Fluticasone Propionate/Salmeterol DISKUS® 250/50mcg BID and Placebo on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|249|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:13:53.833054|2018-06-01 01:13:53.833054
NCT00857753|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-03-27|2009-03-06|2009-03-09|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2006||2006-09-30|March 2009|2009-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Relative Bioavailability of a Fentanyl Patch|A Study to Evaluate the Relative Bioavailability of a Fentanyl PAtch Transdermal Delivery System (25 ug/hr) (Sandoz) Compared to Duragesic (Fentanyl Transdermal SYstem 25 ug/hr Patches (Alza)|Completed||Phase 1|40|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:13:54.370164|2018-06-01 01:13:54.370164
NCT00857740|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2010-07-07|2009-03-06|2009-03-09|Estimate|||||||2010-07-07|2010-07-08|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Influence of Painphysiolgy Education on the Pain Inhibition in Fibromyalgia|Influence of Painphysiolgy Education on the Pain Inhibition in Fibromyalgia|Completed||Early Phase 1|50|Anticipated|Vrije Universiteit Brussel|||||f||||||||||||||2018-06-01 01:13:54.425123|2018-06-01 01:13:54.425123
NCT00857727|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2015-03-03|2009-03-06|2009-03-09|Estimate|||||||2015-03-03|2015-03-04|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|DexPeds||Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children|Use of Dexmedetomidine for Emergence Delirium in Children Undergoing General Anesthesia for Endovascular Interventional Neuroradiologic Procedures|Completed||Phase 3|128|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-06-01 01:13:54.473935|2018-06-01 01:13:54.473935
NCT00857714|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|2015-06-16||2015-06-16|2009-03-06|2009-03-09|Estimate|2015-06-16|2015-07-08|Estimate||||2015-06-16|2015-07-08|Estimate|April 2009||2009-04-30|June 2015|2015-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast|Lapatinib in the Treatment of Ductal Carcinoma in Situ of the Breast|Terminated||N/A|1|Actual|Indiana University||||Terminated due to low accrual|f||||t||||||||||2018-06-01 01:13:54.572313|2018-06-01 01:13:54.572313
NCT00857701|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2013-08-08|2009-03-06|2009-03-09|Estimate|||||||2013-08-08|2013-08-12|Estimate|January 2009||2009-01-31|August 2013|2013-08-31||||May 2015|Anticipated|2015-05-31||Interventional|||Dynamic Splinting After Total Knee Arthroplasty|Dynamic Splinting After Total Knee Arthroplasty: a Randomized, Controlled Trial|Terminated||N/A|25|Actual|Dynasplint Systems, Inc.||2||Unrelated to trial|f||||t||||||||||2018-06-01 01:13:54.743264|2018-06-01 01:13:54.743264
NCT00857688|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-06|||2013-02-22|2009-03-06|2009-03-09|Estimate|||||||2013-02-22|2013-02-25|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration|Randomized Clinical Study to Evaluate the Effectiveness and Safety of the Drug Topic Bismu-Jet ® (Bismuth Tartrate, Neomycin Sulphate and Procaine Hydrochloride) Compared to Placebo in Improvement of Signs and Symptoms of Ulcerations Caused Disease.|Completed||Phase 3|100|Actual|Azidus Brasil||2|||f||||t||||||||||2018-06-01 01:13:54.81057|2018-06-01 01:13:54.81057
NCT00857675|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-04-02|2009-03-05|2009-03-09|Estimate|||||||2009-04-02|2009-04-03|Estimate|December 2002||2002-12-31|April 2009|2009-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B|A Multi-Centre, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients With HBeAg Positive Chronic Hepatitis B Followed by Long-Term (5 Years Total) Adefovir Dipivoxil Treatment. (Report on Year 1 and Year 2 Data)|Completed||Phase 3|480|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:13:54.873692|2018-06-01 01:13:54.873692
NCT00857662|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-03-01|2009-03-06|2009-03-09|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2001||2001-05-31|March 2017|2017-03-31|December 2007|Actual|2007-12-31|April 2003|Actual|2003-04-30||Interventional|||Study Comparing Onyx and TRUFILL in Brain Arteriovenous Malformations (AVMs)|U.S. Multicenter, Randomized Controlled Study Comparing the Performance fo Onyx(EVOH) and TRUFILL® (n-BCA)in Presurgical Embolization of Brain Arteriovenous Malformations (BAVMs)|Completed||Phase 2|117|Actual|Medtronic Neurovascular Clinical Affairs||2|||f||||t||||||||||2018-06-01 01:13:54.978582|2018-06-01 01:13:54.978582
NCT00857649|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2011-10-26||2013-11-12|2009-03-05|2009-03-06|Estimate|2011-12-05|2012-01-09|Estimate||||2013-11-12|2013-12-05|Estimate|December 2003||2003-12-31|November 2013|2013-11-30|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease|A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type|Terminated||Phase 3|369|Actual|H. Lundbeck A/S|Long recruitment, premature termination, substantial protocol changes; baseline imbalances (concomitant medication and severity of agitation). Variability across sites in reported events frequency (50% of agitation reports from a single site)|2|||f||||f||||||||||2018-06-01 01:13:56.059235|2018-06-01 01:13:56.059235
NCT00857636|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2015-03-31|2009-03-05|2009-03-06|Estimate|||||||2015-03-31|2015-04-02|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2011|Actual|2011-11-30||Interventional|||Behavioral Intervention Study for Better Breast and Cervical Cancer Control for Korean American Women|Better Breast and Cervical Cancer Control for Korean American Women|Completed||N/A|560|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 01:13:56.486511|2018-06-01 01:13:56.486511
NCT00857467|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-12-21|2009-03-05|2009-03-06|Estimate|||||||2009-12-21|2009-12-23|Estimate|February 2009||2009-02-28|December 2009|2009-12-31||||December 2009|Actual|2009-12-31||Interventional|||Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.|Randomised, Double-blind, Single Dose, Three-way, Cross-over Study to Investigate the Safety and Response to 1g or 2g Rectal Suppositories Containing 5 mg or 10 mg 1R,2S-methoxamine Hydrochloride [NRL001] or Matching Placebo|Completed||Phase 1|36|Anticipated|Norgine||2|||f||||f||||||||||2018-06-01 01:13:59.587626|2018-06-01 01:13:59.587626
NCT00857623|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2012-09-28||2012-11-08|2009-03-05|2009-03-06|Estimate|2012-09-28|2012-10-29|Estimate||||2012-11-08|2012-11-12|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy|A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy|Completed||Phase 2|127|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 01:13:56.581706|2018-06-01 01:13:56.581706
NCT00857610|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2018-02-20|2009-03-05|2009-03-06|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 20, 2009|Actual|2009-07-20|February 2018|2018-02-28|August 29, 2014|Actual|2014-08-29|August 29, 2014|Actual|2014-08-29||Observational|||Retinol-induced Dermatitis in Aged Skin|Molecular Analyses of Retinoid-induced Dermatitis in Aged/Photoaged Human Skin|Completed|||41|Actual|University of Michigan|||6||f||||f||||||Samples With DNA|"~     Skin biopsies will be taken; however, they are not intended to be used for DNA extraction.~   "|||2018-06-01 01:13:56.993442|2018-06-01 01:13:56.993442
NCT00857597|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2018-03-28|2009-03-04|2009-03-06|Estimate|||||||2018-03-28|2018-03-30|Actual|March 2009||2009-03-31|October 2016|2016-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TvP||Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment|A Randomized Controlled Trial of Transoral Incisionless Fundoplication (TIF) Versus Proton Pump Inhibitors (PPIs) for Treatment of GERD: The TIF vs. PPIs Study|Terminated||Phase 3|60|Actual|University of Pittsburgh||2||"Study was terminated after unplanned interim analysis of single centre data and results were~   reported"|f||||t||||||||||2018-06-01 01:13:57.05893|2018-06-01 01:13:57.05893
NCT00857584|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2012-02-06||2012-04-16|2009-03-05|2009-03-06|Estimate|2012-03-15|2012-04-10|Estimate||||2012-04-16|2012-04-18|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy|Effectiveness of Quetiapine XR Versus Sertraline in Acute Depression as add-on Therapy to Previous Mood Stabilizer Treatment: a Pilot Study|Completed||Phase 3|27|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:13:57.180526|2018-06-01 01:13:57.180526
NCT00857571|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2010-10-22|2009-03-05|2009-03-06|Estimate|||||||2010-10-22|2010-10-25|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.|An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.|Terminated||Phase 1|30|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 01:13:57.611301|2018-06-01 01:13:57.611301
NCT00857558|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2017-03-07|2009-03-05|2009-03-06|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2009||2009-01-31|March 2017|2017-03-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes|A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes|Completed||Phase 2|350|Actual|Kyowa Hakko Kirin Co., Ltd||4|||f||||f||||||||||2018-06-01 01:13:57.68231|2018-06-01 01:13:57.68231
NCT00857545|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2016-12-20||2017-09-12|2009-03-05|2009-03-06|Estimate|2017-08-07|2017-09-06|Actual||||2017-09-12|2017-09-13|Actual|July 2010||2010-07-31|December 2016|2016-12-31||||September 2015|Actual|2015-09-30||Interventional||Enrolled and randomized Participants|OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission|A Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933 ) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete Remission|Completed||Phase 2|171|Actual|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 01:13:57.813164|2018-06-01 01:13:57.813164
NCT00857532|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2012-11-30||2013-02-01|2009-03-05|2009-03-06|Estimate|2013-02-01|2013-03-11|Estimate||||2013-02-01|2013-03-11|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients|A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment|Completed||Phase 2|31|Actual|Avid Radiopharmaceuticals||3|||f||||f||||||||||2018-06-01 01:13:58.746714|2018-06-01 01:13:58.746714
NCT00857519|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2016-12-09|2009-03-04|2009-03-06|Estimate|||||||2016-12-09|2016-12-12|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|IAC-RB||A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma|Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma|Completed||N/A|10|Actual|Wills Eye||1|||f||||f||||||||No||2018-06-01 01:13:58.968098|2018-06-01 01:13:58.968098
NCT00857506|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2012-12-31||2013-03-26|2009-03-05|2009-03-06|Estimate|2013-03-26|2013-03-28|Estimate||||2013-03-26|2013-03-28|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)|Longitudinal Study of Long-term (36 Month) Cognitive Outcomes in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) Who Have Previously Had PET Imaging With 18F-AV-45 Injection.|Completed||Phase 2|152|Actual|Avid Radiopharmaceuticals|||||f||||f||||||||||2018-06-01 01:13:59.070404|2018-06-01 01:13:59.070404
NCT00857493|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2015-01-28|2009-03-05|2009-03-06|Estimate|||||||2015-01-28|2015-01-29|Estimate|June 2009||2009-06-30|January 2015|2015-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects|A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects|Completed||Phase 2|120|Actual|Bavarian Nordic||2|||f||||t||||||||||2018-06-01 01:13:59.451165|2018-06-01 01:13:59.451165
NCT00857480|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-06|2009-03-05|2009-03-06|Estimate|||||||2009-03-06|2009-03-09|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|October 2006|Actual|2006-10-31|August 2006|Actual|2006-08-31||Interventional|||Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin|A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part B: Interaction With Ursodeoxycholic Acid and Cloxacillin|Completed||Phase 1|12|Actual|Norgine||3|||f||||f||||||||||2018-06-01 01:13:59.521254|2018-06-01 01:13:59.521254
NCT00857103|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2013-06-14|2009-03-05|2009-03-06|Estimate|||||||2013-06-14|2013-06-17|Estimate|August 2006||2006-08-31|June 2013|2013-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Interactive Tailored Assessment on Patient-provider Communication|Improving Patient-Provider Communication in Cancer Care|Completed||N/A|200|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:14:04.21315|2018-06-01 01:14:04.21315
NCT00857454|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2010-12-15|2010-09-14|2010-12-15|2009-03-05|2009-03-06|Estimate|2010-12-15|2011-01-05|Estimate|2010-09-14|2010-09-16|Estimate|2010-12-15|2011-01-05|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations|A Phase III Open-label Extension of the MTE08 Trial (A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion® (Cutaneous Solution) in Hypogonadal Men) to Evaluate Skin-safety|Completed||Phase 3|71|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:13:59.695388|2018-06-01 01:13:59.695388
NCT00857441|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2015-07-16|2009-03-05|2009-03-06|Estimate|||||||2015-07-16|2015-07-20|Estimate|January 2008||2008-01-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|September 2009|Actual|2009-09-30||Interventional|DEBIUT||Drug-eluting Balloon in Bifurcations Trial|A Prospective Three-arm Multi-center Study to Investigate Procedural, Clinical and Angiographic Outcomes Using a Drug Eluting Balloon Versus a Standard Balloon in Combination With a Bare Metal Stent and a DES Stent, Following the Provisional Side Branch T-stenting Approach, in Patients With Complex Lesions|Completed||Phase 2/Phase 3|120|Actual|UMC Utrecht||3|||f||||t||||||||||2018-06-01 01:14:00.108161|2018-06-01 01:14:00.108161
NCT00857428|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2017-03-27|2009-03-05|2009-03-06|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2007||2007-11-30|March 2009|2009-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions|A Study to Evaluate the Relative Bioavailability of Oxymorphone 40 mg Extended-Release Tablets (Sandoz, Inc.) Compared to Opana ER (Oxymorphone Hydrochloride) Extended-Release Tablets, 40 mg (Endo Pharmaceuticals, Inc.) in Healthy Volunteers Under Fasted Conditions|Completed||Phase 1|50|Actual|Sandoz||2|||f||||f||||||||||2018-06-01 01:14:00.204048|2018-06-01 01:14:00.204048
NCT00857415|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2012-04-06|2011-11-21|2012-05-17|2009-03-05|2009-03-06|Estimate|2012-04-06|2012-05-07|Estimate|2011-11-21|2011-11-23|Estimate|2012-05-17|2012-05-22|Estimate|December 2008||2008-12-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain|A Phase III Study of the Correlation Between Florbetapir F 18 (18F-AV-45) PET Imaging and Amyloid Pathology|Completed||Phase 3|226|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-06-01 01:14:00.283107|2018-06-01 01:14:00.283107
NCT00857402|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|February 2004||2004-02-29|March 2009|2009-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Arginine as an Adjuvant Treatment Against Tuberculosis|Arginine Rich Food Supplementation as an Adjuvant Treatment Against Tuberculosis|Completed||N/A|180|Actual|Linkoeping University||2|||f||||f||||||||||2018-06-01 01:14:00.556936|2018-06-01 01:14:00.556936
NCT00857389|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2018-04-16|2009-03-05|2009-03-06|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2009|Actual|2009-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies|Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies|Active, not recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:14:00.631606|2018-06-01 01:14:00.631606
NCT00857376|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2012-09-27|2009-03-05|2009-03-06|Estimate|||||||2012-09-27|2012-10-01|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|Alpha||Dose Ranging Study of the Effects of Alpha Lipoic Acid on Oxidative Stress|Dose Ranging Study of the Effects of Alpha Lipoic Acid on Oxidative Stress|Completed||Phase 2|77|Actual|Johns Hopkins University||4|||f||||f||||||||||2018-06-01 01:14:00.735191|2018-06-01 01:14:00.735191
NCT00857363|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2010-01-14|2009-03-05|2009-03-06|Estimate|||||||2010-01-14|2010-01-15|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|June 2009|Anticipated|2009-06-30|May 2009|Anticipated|2009-05-31||Observational|CTT||Colonic Transit Time Validation Study|SmartPill Colonic Transit Time Validation Study in Patients With Chronic Constipation|Unknown status|Recruiting||210|Anticipated|The SmartPill Corporation|||1||f||||f||||||||||2018-06-01 01:14:00.819151|2018-06-01 01:14:00.819151
NCT00857350|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2013-07-19|2009-03-05|2009-03-06|Estimate|||||||2013-07-19|2013-07-22|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|June 2010|Actual|2010-06-30||Observational|||The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment|The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment|Completed|||60|Actual|Yale University|||1||f||||f||||||||||2018-06-01 01:14:00.939879|2018-06-01 01:14:00.939879
NCT00857324|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2017-09-05|2009-03-05|2009-03-06|Estimate|||||||2017-09-05|2017-09-06|Actual|March 2009||2009-03-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|March 2012|Actual|2012-03-31||Interventional|||Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients|A Phase I/II, Multi-Center, Open Label Study of Vorinostat Plus Melphalan and Prednisone (ZMP) in Advanced, Refractory Multiple Myeloma Patients|Terminated||Phase 1/Phase 2|18|Actual|University of Turin, Italy||1||The Phase I of the study was completed, but Phase 2 has not been activated|f||||t||||||||||2018-06-01 01:14:01.009321|2018-06-01 01:14:01.009321
NCT00857311|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2011-06-09||2015-08-11|2009-03-05|2009-03-06|Estimate|2011-06-09|2011-07-07|Estimate||||2015-08-11|2015-08-25|Estimate|May 2004||2004-05-31|August 2015|2015-08-31|May 2010|Actual|2010-05-31|January 2006|Actual|2006-01-31||Interventional|||MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 1|17|Actual|Merck Sharp & Dohme Corp.|An interim analysis of a related study, V520 Protocol 023 (NCT00095576), showed that the MRKAd5 vaccine used in Protocol 022 (NCT00857311) was not efficacious; therefore, only a high level summary of the safety data was performed.|4|||f||||t||||||||||2018-06-01 01:14:01.107497|2018-06-01 01:14:01.107497
NCT00857298|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2015-02-13|2009-03-05|2009-03-06|Estimate|||||||2015-02-13|2015-02-16|Estimate|February 2009||2009-02-28|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome|Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome|Completed||N/A|20|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:14:01.428453|2018-06-01 01:14:01.428453
NCT00857285|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2009-05-28||2009-07-22|2009-03-05|2009-03-06|Estimate|2009-07-22|2009-07-23|Estimate||||2009-07-22|2009-07-23|Estimate|May 2002||2002-05-31|July 2009|2009-07-31|September 2003|Actual|2003-09-30|August 2003|Actual|2003-08-31||Interventional|||Olmesartan Medoxomil Versus Losartan in Patients With Hypertension|"A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker Olmesartan Medoxomil Versus Losartan in Patients With Mild to Moderate Essential Hypertension"|Completed||Phase 3|130|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:14:01.505811|2018-06-01 01:14:01.505811
NCT00857272|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2010-08-09|2010-05-03|2010-09-29|2009-03-05|2009-03-06|Estimate|2010-09-08|2010-09-28|Estimate|2010-05-03|2010-05-05|Estimate|2010-09-29|2010-10-05|Estimate|February 2009||2009-02-28|September 2010|2010-09-30||||May 2009|Actual|2009-05-31||Interventional|||F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|Completed||Phase 4|308|Actual|Braintree Laboratories|Total number of patients experiencing a non-serious adverse event is based on all adverse events, not just those events above the reporting threshold of 3%|2|||f||||f||||||||||2018-06-01 01:14:01.712802|2018-06-01 01:14:01.712802
NCT00857259|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2011-07-22||2011-07-22|2009-03-05|2009-03-06|Estimate|2011-07-22|2011-08-19|Estimate||||2011-07-22|2011-08-19|Estimate|February 2009||2009-02-28|July 2011|2011-07-31||||July 2010|Actual|2010-07-31||Interventional|||The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration|A Randomized, Double-masked, Parallel Group Study to Assess the Efficacy of Oral Everolimus, Either Alone or Added to Lucentis, in Patients With Neovascular Age-related Macular Degeneration|Terminated||Phase 2|16|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:14:01.935478|2018-06-01 01:14:01.935478
NCT00857246|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2015-03-02||2015-11-06|2009-03-04|2009-03-06|Estimate|2015-03-02|2015-03-13|Estimate||||2015-11-06|2015-12-07|Estimate|July 2005||2005-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2011|Actual|2011-09-30||Interventional|||Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer|Neoadjuvant Therapy of Gastric Cancer With Irinotecan, Cisplatin and Cetuximab Followed by Surgical Resection and Adjuvant Chemoradiation|Completed||Phase 2|30|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 01:14:02.337701|2018-06-01 01:14:02.337701
NCT00857233|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2012-07-26||2012-07-26|2009-03-05|2009-03-06|Estimate|2012-07-26|2012-08-29|Estimate||||2012-07-26|2012-08-29|Estimate|June 2004||2004-06-30|July 2012|2012-07-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease|An Open-label Extension Study Examining the Safety and Tolerability of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type Having Completed Study 10158|Terminated||Phase 3|297|Actual|H. Lundbeck A/S|Long recruitment, premature termination.|1||Please see explanation in the Detailed Description field.|f||||f||||||||||2018-06-01 01:14:02.822732|2018-06-01 01:14:02.822732
NCT00857220|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2012-11-02|2012-05-01|2017-09-25|2009-03-05|2009-03-06|Estimate|2013-06-18|2013-07-22|Estimate|2012-05-03|2012-05-08|Estimate|2017-09-25|2017-10-26|Actual|May 2009||2009-05-31|September 2017|2017-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia|A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia|Completed||Phase 3|304|Actual|Sunovion|Designed to assess safety/tolerability. Efficacy endpoints evaluated w/ descriptive stats only, w/ no placebo group against which to assess the impact of therapy. ~40% completion rate typical for one year studies but limits interpretation of results.|1|||f||||t||||||||||2018-06-01 01:14:03.177037|2018-06-01 01:14:03.177037
NCT00857207|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2018-04-20|2009-03-05|2009-03-06|Estimate|||||||2018-04-20|2018-04-23|Actual|October 1, 2013|Actual|2013-10-01|April 2018|2018-04-30|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Metacognitive Training to Enhance Strategy Use in Blast-Related TBI|Metacognitive Training to Enhance Strategy Use in Blast Related TBI|Recruiting||N/A|54|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-06-01 01:14:03.637735|2018-06-01 01:14:03.637735
NCT00857194|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-06-28|2009-03-05|2009-03-06|Estimate|||||||2017-06-28|2017-07-02|Actual|March 1, 2007|Actual|2007-03-01|June 2017|2017-06-30|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Observational|||Cardiovascular Disease Study|Risk Factors for Coronary Heart Disease in Spinal Cord Injury: Conventional and Emerging|Completed|||170|Actual|VA Office of Research and Development|||1||f||||f|f|f|||f|Samples Without DNA|"~     serum and plasma~   "|Undecided||2018-06-01 01:14:03.713143|2018-06-01 01:14:03.713143
NCT00857181|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2012-03-02|2009-03-05|2009-03-06|Estimate|||||||2012-03-02|2012-03-05|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|CLC-2009||Cytokines and the Risk of Infection in Liver Cirrhosis|A Single-center, Open Study to Investigate Cytokine Levels in Patients With Hepatic Cirrhosis Before the Development of Significant Infection|Terminated|||150|Actual|Medical University of Graz|||1|Finding to be unable to reach the primary endpoint|f||||f||||||Samples Without DNA|"~     Serum and plasma samples.~   "|||2018-06-01 01:14:03.778781|2018-06-01 01:14:03.778781
NCT00857168|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-10-12|2009-03-05|2009-03-06|Estimate|||||||2009-10-12|2009-10-14|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|MTE10||To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion|A Phase I Trial to Determine the Impact of Application of Antiperspirant and Deodorant as Well as Washing the Application Site, on the Pharmacokinetics of Testosterone Following Single Dose Applications of 2% Testosterone MD-Lotion® (Cutaneous Solution)|Completed||Phase 1|36|Anticipated|Acrux DDS Pty Ltd||6|||f||||f||||||||||2018-06-01 01:14:03.845951|2018-06-01 01:14:03.845951
NCT00857155|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|February 2011|Anticipated|2011-02-28|January 2011|Anticipated|2011-01-31||Interventional|TARGET-CABG||Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to Coronary Artery Bypass Graft (CABG)||Unknown status|Recruiting|N/A|200|Anticipated|LifeBridge Health||2|||f||||f||||||||||2018-06-01 01:14:03.909848|2018-06-01 01:14:03.909848
NCT00857142|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-03-27|2009-03-05|2009-03-06|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2007||2007-11-30|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions|A Study to Evaluate the Relative Bioavaility of Oxymorphone Hydrochloride 40 mg Extended-Release Tablets(Sandoz, Inc. Compared to Opana ER (Oxymorphone Hydrochloride) Extended-Release Tablets, 40 mg (Edo Pharmaceuticals Inc.) in Healthy Volunteers Under Non-fasted COnditions|Completed||Phase 1|32|Actual|Sandoz||2|||f||||||||||||||2018-06-01 01:14:03.991537|2018-06-01 01:14:03.991537
NCT00857129|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2014-10-17|2009-03-05|2009-03-06|Estimate|||||||2014-10-17|2014-10-20|Estimate|September 2006||2006-09-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|March 2010|Actual|2010-03-31||Interventional|||Can Differentiated Birth Care Improve the Service?|Differentiated Birth Service- an Improvement?|Completed||N/A|1111|Actual|Ostfold Hospital Trust||3|||f||||f||||||||||2018-06-01 01:14:04.055036|2018-06-01 01:14:04.055036
NCT00857116|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2013-08-28|2009-03-05|2009-03-06|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Deworming Against Tuberculosis|The Impact of Deworming on Host Immunity and Clinical Outcome in Patients With Pulmonary Tuberculosis|Completed||N/A|140|Actual|Linkoeping University||2|||f||||t||||||||||2018-06-01 01:14:04.130356|2018-06-01 01:14:04.130356
NCT00857090|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04||2012-10-10|2012-10-10|2009-03-05|2009-03-06|Estimate||||2012-10-10|2012-10-12|Estimate|2012-10-10|2012-10-12|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones|Double-Blind, Placebo-Controlled, Concentration-Escalating, Pharmacokinetic Study Evaluating the Systemic Absorption, Safety, and Efficacy of OMS201 in Subjects Undergoing Ureteroscopic Treatment of Ureteral- or Renal Collecting System-Located Stones|Completed||Phase 1/Phase 2|18|Actual|Omeros Corporation||2|||f||||f||||||||||2018-06-01 01:14:04.273815|2018-06-01 01:14:04.273815
NCT00857077|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-01-25|2009-03-05|2009-03-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2000||2000-09-30|January 2017|2017-01-31|June 2004|Actual|2004-06-30|||||Interventional|||Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana|Evaluation of the Safety and Effectiveness of EPI-linked Malaria Intermittent Chemotherapy and Iron Supplementation|Completed||N/A|2485|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 01:14:04.33875|2018-06-01 01:14:04.33875
NCT00857064|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2010-12-07|2009-03-05|2009-03-06|Estimate|||||||2010-12-07|2010-12-09|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|AURA||Subjective Well Being of Schizophrenic Patients in Greece|Subjective Well Being of Schizophrenic Patients in Greece|Completed|||600|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:14:04.523224|2018-06-01 01:14:04.523224
NCT00857051|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-09-24|2009-03-05|2009-03-06|Estimate|||||||2009-09-24|2009-09-25|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Postpartum Support: Can we Facilitate the Transition to Motherhood?|Postpartum Support: Can we Facilitate the Transition to Motherhood?|Completed||N/A|552|Anticipated|American University of Beirut Medical Center||4|||f||||f||||||||||2018-06-01 01:14:04.633135|2018-06-01 01:14:04.633135
NCT00857038|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|January 2010|Anticipated|2010-01-31|August 2009|Anticipated|2009-08-31||Interventional|||Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)|Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD.|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Medical Center Alkmaar||2|||f||||f||||||||||2018-06-01 01:14:04.751935|2018-06-01 01:14:04.751935
NCT00857025|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2018-03-06|2009-03-05|2009-03-06|Estimate|||||||2018-03-06|2018-03-07|Actual|November 21, 2008|Actual|2008-11-21|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase I Study of MM-10-001 In Advanced Non Small Lung Cancer|Active, not recruiting||Phase 1|20|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:14:04.842751|2018-06-01 01:14:04.842751
NCT00857012|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2012-11-09|2009-03-05|2009-03-06|Estimate|||||||2012-11-09|2012-11-12|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|February 2012|Actual|2012-02-29|||||Observational|COMPACT||Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT)|Arimidex: Compliance and Arthralgias in Clinical Therapy (COMPACT): An in Practice Assessment of Arthralgias and Related Costs as Well as Compliance in the First Year of Anastrozole Therapy|Completed|||2313|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:14:04.972812|2018-06-01 01:14:04.972812
NCT00856999|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-04|2009-03-04|2009-03-06|Estimate|||||||2009-03-04|2009-03-06|Estimate||||March 2009|2009-03-31||||||||Interventional|||Botox Cosmetic and the Young Patient With Glabellar Furrows|Botox Cosmetic and the Young Patient With Glabellar Furrows|Completed||Phase 4|||Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:14:05.508233|2018-06-01 01:14:05.508233
NCT00856986|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2011-04-19||2017-01-25|2009-03-05|2009-03-06|Estimate|2011-04-19|2011-05-13|Estimate||||2017-01-25|2017-03-08|Actual|March 2009||2009-03-31|January 2017|2017-01-31|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|||The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes|The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extension|Completed||Phase 3|987|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-06-01 01:14:05.642454|2018-06-01 01:14:05.642454
NCT00856973|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2012-11-02|2012-05-01|2013-06-07|2009-03-04|2009-03-06|Estimate|2013-02-28|2013-04-10|Estimate|2012-05-01|2012-05-03|Estimate|2013-06-07|2013-06-17|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia|A Randomized, Placebo Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia|Completed||Phase 3|486|Actual|Sunovion|Per protocol, study did not have PSG adaptation nights at baseline and contained one PSG assessment post randomization visit|3|||f||||t||||||||||2018-06-01 01:14:09.385745|2018-06-01 01:14:09.385745
NCT00856960|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-01-21|2009-03-05|2009-03-06|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)|A Randomized, Double-Blind, Placebo-Controlled, 4-Treatment, 3-Period, Incomplete Block, Balanced Crossover Study to Evaluate the Effects of a Single Dose of Aliskiren and Losartan on Renal Blood Flow Measurements in Healthy Male Subjects|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:14:10.281101|2018-06-01 01:14:10.281101
NCT00856947|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2017-03-08|2009-03-05|2009-03-06|Estimate|||||||2017-03-08|2017-03-09|Actual|March 2009||2009-03-31|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|ABCvitaminD||Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood|Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood: An Interventional Trial in the ABC (Asthma Begins in Childhood) Cohort|Active, not recruiting||Phase 2/Phase 3|600|Anticipated|Copenhagen Studies on Asthma in Childhood||2|||f||||t||||||||||2018-06-01 01:14:10.350681|2018-06-01 01:14:10.350681
NCT00856934|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|2009-01-02||2009-02-05|2009-02-05|2009-03-06|Estimate|2009-02-05|2009-03-06|Estimate||||2009-02-05|2009-03-06|Estimate|June 2005||2005-06-30|February 2009|2009-02-28||||March 2006|Actual|2006-03-31||Interventional|||Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing|A New Model to Enhance Wound Healing Using Autologous Keratinocytes in Platelet Concentrates - a Prospective Randomized Trial.|Completed||Phase 1|45|Actual|Centre Hospitalier Universitaire Vaudois||3|||f||||f||||||||||2018-06-01 01:14:10.431018|2018-06-01 01:14:10.431018
NCT00856921|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Observational|AAAS||Genetic Evaluation of AAAS Gene in Early-Onset Achalasia and Alacrima Patients|To Find Out the Genetic Relationship Between the Early-Onset Achalasia and AAAS Gene|Completed|||19|Actual|Asan Medical Center|||||f||||t||||||Samples With DNA|"~     DNA and genetic analysis~   "|||2018-06-01 01:14:10.676972|2018-06-01 01:14:10.676972
NCT00856908|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2012-07-24||2012-11-27|2009-03-05|2009-03-06|Estimate|2012-11-22|2012-11-26|Estimate||||2012-11-27|2012-12-06|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes|A Randomised, Single-Blind, Placebo-Controlled, Phase IIa Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 During Four Weeks in T2DM Subjects Treated With Insulin|Completed||Phase 2|20|Actual|AstraZeneca|"The primary objective of the study was to assess safety and tolerability and hence the study was not sized based on statistical considerations. The most import outcome, no safety or tolerability concerns were identified, is not a numerical variable"|2|||f||||f||||||||||2018-06-01 01:14:10.744186|2018-06-01 01:14:10.744186
NCT00856895|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2017-09-22|2009-03-04|2009-03-06|Estimate|||||||2017-09-22|2017-09-25|Actual|October 2007||2007-10-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|QOL||Quality of Life in Pre and Post Renal Transplant in Hispanic and Non-Hispanic Recipients|Evaluation of Quality of Life Pre and Post Renal Transplant in Hispanic and Non-Hispanic Recipients|Enrolling by invitation|||1200|Anticipated|Northwestern University|||2||f||||f||||||||||2018-06-01 01:14:11.171028|2018-06-01 01:14:11.171028
NCT00856882|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|October 2007||2007-10-31|March 2009|2009-03-31||||April 2008|Actual|2008-04-30||Interventional|||The Effects of Soy Protein and Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors|The Effects of Soy Protein and/or Isoflavones on Glycemic Control, Insulin Sensitivity and Cardiovascular Risk Factors-a Six Months RCT Among Postmenopausal Women|Completed||N/A|||Chinese University of Hong Kong||3|||f||||t||||||||||2018-06-01 01:14:11.235605|2018-06-01 01:14:11.235605
NCT00856869|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|August 2004||2004-08-31|March 2009|2009-03-31|April 2005|Actual|2005-04-30|February 2005|Actual|2005-02-28||Interventional|||Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers|A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.|Completed||Phase 1/Phase 2|52|Actual|Norgine||7|||f||||f||||||||||2018-06-01 01:14:11.292298|2018-06-01 01:14:11.292298
NCT00856856|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-02-24|2009-03-04|2009-03-06|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|October 2015|Actual|2015-10-31||Interventional|ABSORB B||ABSORB Clinical Investigation, Cohort B|A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With de Novo Native Coronary Artery Lesions.|Unknown status|Active, not recruiting|Phase 1/Phase 2|101|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 01:14:11.386773|2018-06-01 01:14:11.386773
NCT00856843|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2010-09-03|2010-05-03|2010-10-15|2009-03-05|2009-03-06|Estimate|2010-10-15|2010-11-10|Estimate|2010-05-03|2010-05-05|Estimate|2010-10-15|2010-11-10|Estimate|February 2009||2009-02-28|October 2010|2010-10-31||||May 2009|Actual|2009-05-31||Interventional|||BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|Completed||Phase 3|136|Actual|Braintree Laboratories|As prespecified in the study protocol, expected prep related side effects (nausea, vomiting, cramping, bloating and overall discomfort) were only documented as AEs if patients rated them severely distressing on the study questionnaire.|2|||f||||f||||||||||2018-06-01 01:14:11.551021|2018-06-01 01:14:11.551021
NCT00856830|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2017-03-03||2017-06-19|2009-03-05|2009-03-06|Estimate|2017-06-19|2017-07-17|Actual||||2017-06-19|2017-07-17|Actual|April 2009||2009-04-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|||Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer|Phase I/IIa Study of the Novel Combination of Bendamustine With Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 1/Phase 2|30|Actual|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-06-01 01:14:12.083548|2018-06-01 01:14:12.083548
NCT00856817|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2011-08-10|2009-03-05|2009-03-06|Estimate|||||||2011-08-10|2011-08-11|Estimate|March 2009||2009-03-31|January 2010|2010-01-31||||||||Interventional|||Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation||Terminated||Phase 4|6|Anticipated|Radboud University||2||Recruitment faillure. Similar study published by others. Not yet entered treatment phase.|f||||||||||||||2018-06-01 01:14:12.368381|2018-06-01 01:14:12.368381
NCT00856804|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|June 2012|Anticipated|2012-06-30|June 2009|Anticipated|2009-06-30||Interventional|TRITAL||Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance|Usefulness of Adding Thalidomide to Peginterferon and Ribavirin in Patients With Hepatitis C and Resistance to Interferon. Phase II|Unknown status|Recruiting|Phase 2|10|Anticipated|Valme University Hospital||1|||f||||f||||||||||2018-06-01 01:14:12.420144|2018-06-01 01:14:12.420144
NCT00856791|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2012-11-27||2017-06-22|2009-03-04|2009-03-06|Estimate|2012-12-27|2013-01-08|Estimate||||2017-06-22|2017-07-21|Actual|March 2009||2009-03-31|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients|Phase II Single-arm Study of ON 01910.Na by 2-hr Infusion in Patients With Recurring Platinum-resistant Ovarian Cancer|Completed||Phase 2|1|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-06-01 01:14:12.488536|2018-06-01 01:14:12.488536
NCT00856778|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2013-09-27||2014-04-11|2009-03-05|2009-03-06|Estimate|2014-03-07|2014-04-14|Estimate||||2014-04-11|2014-04-29|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Virtue® Male Incontinence Sling Study|Virtue® Male Incontinence Sling Study|Completed||N/A|98|Actual|Coloplast A/S||1|||f||||t||||||||||2018-06-01 01:14:12.694582|2018-06-01 01:14:12.694582
NCT00856765|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2017-05-01|2009-03-05|2009-03-06|Estimate|||||||2017-05-01|2017-05-02|Actual|March 2009||2009-03-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|June 2011|Actual|2011-06-30||Interventional|DEB-AMI||Drug-eluting Balloon in Acute Myocardial Infarction|Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction|Completed||Phase 2/Phase 3|150|Actual|UMC Utrecht||3|||f||||t||||||||||2018-06-01 01:14:13.063235|2018-06-01 01:14:13.063235
NCT00856752|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Evaluation of the Pharmacokinetics of NRL972 Following Pre-Administration of Rifampicin and Cyclosporine|A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins. Part A: Interaction With Rifampicin and Cyclosporine|Completed||Phase 1|12|Actual|Norgine||3|||f||||f||||||||||2018-06-01 01:14:13.177497|2018-06-01 01:14:13.177497
NCT00856739|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2014-12-02||2014-12-10|2009-03-05|2009-03-06|Estimate|2014-12-10|2014-12-19|Estimate||||2014-12-10|2014-12-19|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||no self-reported chronic pain or significant injury in any of the lower extremity joints or lower back|Obesity and the Initiation of Knee Osteoarthritis|Obesity and Initiation of Osteoarthritis|Completed|||177|Actual|VA Office of Research and Development|||1||f||||f||||||Samples Without DNA|"~     One tube of blood identified with a unique number.~   "|||2018-06-01 01:14:13.261574|2018-06-01 01:14:13.261574
NCT00856726|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2017-06-05||2017-09-05|2009-03-05|2009-03-06|Estimate|2017-09-05|2017-09-11|Actual||||2017-09-05|2017-09-11|Actual|February 2009||2009-02-28|September 2017|2017-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Racial Differences in Phosphorus Metabolism|Racial Differences in Phosphorus Metabolism|Completed||N/A|26|Actual|University of Miami|It is possible that the length of the intervention needed to be longer to detect racial differences in phosphorus excretion.|1|||f||||f||||||||No||2018-06-01 01:14:13.497655|2018-06-01 01:14:13.497655
NCT00856713|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-05|2009-03-05|2009-03-06|Estimate|||||||2009-03-05|2009-03-06|Estimate|March 2006||2006-03-31|March 2009|2009-03-31||||August 2006|Actual|2006-08-31||Interventional|||Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers|A Study in Healthy Volunteers and Patients With Liver Cirrhosis to Assess the Effects of Age, Gender, and Stable Liver Disease on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) as an in-Vivo Marker of Liver Function in Man|Completed||Phase 1|72|Actual|Norgine||6|||f||||f||||||||||2018-06-01 01:14:13.716603|2018-06-01 01:14:13.716603
NCT00856700|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2013-12-10|2009-03-05|2009-03-06|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome|Effect of GLP-1 on Endothelial Function and Glucose Uptake in Patients With Metabolic Syndrome|Completed||N/A|20|Actual|University of Rome Tor Vergata||1|||f||||t||||||||||2018-06-01 01:14:13.806674|2018-06-01 01:14:13.806674
NCT00856687|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2010-01-21|2009-03-05|2009-03-06|Estimate|||||||2010-01-21|2010-01-22|Estimate|April 2009||2009-04-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects|A Randomized, Double-Blind (3rd Party Open), Double-Dummy, Placebo- And Active Controlled, 3-Way Crossover Study To Determine The Effects Of Oral PF-03893787 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.|Completed||Phase 1|12|Anticipated|Pfizer||3|||f||||f||||||||||2018-06-01 01:14:13.905195|2018-06-01 01:14:13.905195
NCT00856674|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2010-06-01|2009-03-05|2009-03-06|Estimate|||||||2010-06-01|2010-06-02|Estimate|March 2009||2009-03-31|June 2010|2010-06-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy|A Dose-Escalating Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous OPL-CCL2-LPM in Patients With IgA Nephropathy|Terminated||Phase 1|30|Anticipated|Osprey Pharmaceuticals USA, Inc.||||Study terminated due to resources and slow enrollment; not due to safety|f||||f||||||||||2018-06-01 01:14:13.973341|2018-06-01 01:14:13.973341
NCT00856661|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2015-10-06||2017-02-08|2009-03-05|2009-03-06|Estimate|2015-11-18|2015-12-22|Estimate||||2017-02-08|2017-03-16|Actual|April 2009||2009-04-30|February 2017|2017-02-28||||October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)|A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke|Terminated||Phase 3|270|Actual|H. Lundbeck A/S||2||"The recruitment into DIAS4 has been stopped as the result of DIAS 3 indicates that the study is~   unlikely to reach its primary endpoint with the current protocol"|f||||t||||||||||2018-06-01 01:14:14.080565|2018-06-01 01:14:14.080565
NCT00856648|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2012-05-21|2009-03-05|2009-03-06|Estimate|||||||2012-05-21|2012-05-23|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Observational|||SmartPill Monitoring for Assessment of GI Function in SCI|SmartPill Monitoring for Assessment of GI Function in SCI|Completed|||40|Anticipated|VA Office of Research and Development|||2||f||||f||||||None Retained|"~     No Biospecimens will be collected.~   "|||2018-06-01 01:14:14.867741|2018-06-01 01:14:14.867741
NCT00856635|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2013-07-11||2018-01-08|2009-03-05|2009-03-06|Estimate|2013-09-20|2013-09-23|Estimate||||2018-01-08|2018-02-06|Actual|February 2009||2009-02-28|January 2018|2018-01-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional||The safety analysis set included all patients who had been randomized to the study and received at least one dose of study drug.|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON)|Completed||Phase 3|44|Actual|Teva Pharmaceutical Industries|Enrollment did not meet expectations, and target sample sizes were not met.|2|||f||||||||||||||2018-06-01 01:14:14.939868|2018-06-01 01:14:14.939868
NCT00856622|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-06-03|2009-03-05|2009-03-06|Estimate|||||||2009-06-03|2009-06-04|Estimate|August 1997||1997-08-31|June 2009|2009-06-30|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients|A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension.|Completed||Phase 3|436|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:14:15.203312|2018-06-01 01:14:15.203312
NCT00856609|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2017-09-18||2017-12-12|2009-03-05|2009-03-06|Estimate|2017-12-12|2018-01-12|Actual||||2017-12-12|2018-01-12|Actual|March 3, 2009||2009-03-03|September 19, 2017|2017-09-19|September 19, 2016|Actual|2016-09-19|September 19, 2016|Actual|2016-09-19||Interventional|||The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects|The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects|Completed||Phase 3|150|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f|||t|||||2018-06-01 01:14:15.361505|2018-06-01 01:14:15.361505
NCT00856596|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|||2009-08-03|2009-03-05|2009-03-06|Estimate|||||||2009-08-03|2009-08-06|Estimate|March 2009||2009-03-31|August 2009|2009-08-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|||Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females|Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks|Unknown status|Recruiting|Phase 3|30|Anticipated|Jamaica Hospital Medical Center||1|||f||||t||||||||||2018-06-01 01:14:15.870906|2018-06-01 01:14:15.870906
NCT00856583|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-05|2011-05-04||2011-08-18|2009-03-05|2009-03-06|Estimate|2011-07-01|2011-08-01|Estimate||||2011-08-18|2011-08-19|Estimate|July 2002||2002-07-31|August 2011|2011-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|SCoP||Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use|Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study|Completed||Phase 3|9809|Actual|H. Lundbeck A/S||2|||f||||t||||||||||2018-06-01 01:14:16.028081|2018-06-01 01:14:16.028081
NCT00856570|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2013-07-01|2009-03-04|2009-03-05|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects|An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-06-01 01:14:17.225906|2018-06-01 01:14:17.225906
NCT00856557|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2014-10-27||2015-04-06|2009-03-04|2009-03-05|Estimate|2014-11-24|2014-11-25|Estimate||||2015-04-06|2015-04-24|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional||Resident physicians in primary care.|Intervening to Prevent Contextual Errors in Medical Decision Making|Intervening to Prevent Contextual Errors in Medical Decision Making|Completed||N/A|138|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:14:17.287536|2018-06-01 01:14:17.287536
NCT00856544|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2012-12-06|2012-11-05|2012-12-06|2009-03-03|2009-03-05|Estimate|2012-12-06|2013-01-10|Estimate|2012-11-05|2012-11-07|Estimate|2012-12-06|2013-01-10|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications|Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS|Completed||Phase 3|795|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 01:14:17.733489|2018-06-01 01:14:17.733489
NCT00856531|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-04|2009-03-04|2009-03-05|Estimate|||||||2009-03-04|2009-03-05|Estimate|January 2002||2002-01-31|March 2009|2009-03-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Observational|Mobius||Impairments of Oral Language in Mobius Syndrome|Impairments of Oral Language in Subjects With the Möbius Sequence|Completed|||||Fortaleza University|||15||f||||f||||||||||2018-06-01 01:14:21.868781|2018-06-01 01:14:21.868781
NCT00856518|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2016-02-26||2016-12-19|2009-03-03|2009-03-05|Estimate|2016-10-05|2016-11-29|Estimate||||2016-12-19|2017-02-10|Actual|March 2009||2009-03-31|December 2016|2016-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|EMST||Expiratory Muscle Training for Persons With Neurodegenerative Disease|Expiratory Muscle Training for Persons With Neurodegenerative Disease|Completed||Phase 2/Phase 3|42|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-06-01 01:14:21.943806|2018-06-01 01:14:21.943806
NCT00856505|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-04|2009-03-04|2009-03-05|Estimate|||||||2009-03-04|2009-03-05|Estimate|March 2008||2008-03-31|March 2009|2009-03-31|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation|Everolimus and Mycophenolate Sodium as GvHD Prophylaxis in Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|38|Anticipated|University Hospital Freiburg||1|||f||||t||||||||||2018-06-01 01:14:22.249197|2018-06-01 01:14:22.249197
NCT00856492|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2016-11-15||2017-05-23|2009-03-04|2009-03-05|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|April 2010||2010-04-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer|A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A)and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy For Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer|Completed||Phase 2|215|Actual|Southwest Oncology Group||3|||f||||t||||||||Undecided||2018-06-01 01:14:22.487933|2018-06-01 01:14:22.487933
NCT00856479|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-05-14|2009-03-04|2009-03-05|Estimate|||||||2015-05-14|2015-05-15|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|March 2013|Anticipated|2013-03-31|March 2010|Anticipated|2010-03-31||Interventional|Infuse||A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures|A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures|Withdrawn||Phase 4|0|Actual|Nova Scotia Health Authority||2||Study never started|f||||t||||||||||2018-06-01 01:14:25.239922|2018-06-01 01:14:25.239922
NCT00856453|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2017-05-25|2009-03-04|2009-03-05|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2009||2009-05-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer|Restorative Yoga for Women With Ovarian Cancer Undergoing Chemotherapy|Terminated||N/A|2|Actual|Wake Forest University Health Sciences||2||slow accrual|f||||f|f|f||||||||2018-06-01 01:14:25.322811|2018-06-01 01:14:25.322811
NCT00856440|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2010-07-15|2009-03-04|2009-03-05|Estimate|||||||2010-07-15|2010-07-16|Estimate|June 2006||2006-06-30|July 2010|2010-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Safety and Efficacy of Routine Colonoscopy Preparations|Safety and Efficacy of Routine Colonoscopy Preparations|Completed|||330|Actual|VA Office of Research and Development|||2||f||||f||||||Samples Without DNA|"~     Serum and urine samples~   "|||2018-06-01 01:14:25.405037|2018-06-01 01:14:25.405037
NCT00856427|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2013-12-18|2009-03-04|2009-03-05|Estimate|||||||2013-12-18|2013-12-20|Estimate|February 2008||2008-02-29|December 2013|2013-12-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Implantation of Markers for the Radiotherapy of Lung Cancer Patients|Implantation of Markers for the Radiotherapy of Lung Cancer Patients|Terminated||Phase 1|6|Actual|Virginia Commonwealth University||1||Slow accrual|f||||t||||||||||2018-06-01 01:14:25.491916|2018-06-01 01:14:25.491916
NCT00856414|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2011-09-22||2011-11-08|2009-03-04|2009-03-05|Estimate|2011-11-08|2011-12-12|Estimate||||2011-11-08|2011-12-12|Estimate|March 2009||2009-03-31|November 2011|2011-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines||Completed||Phase 4|45|Actual|Allergan||1|||f||||||||||||||2018-06-01 01:14:25.57798|2018-06-01 01:14:25.57798
NCT00856401|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2018-02-27|2009-03-04|2009-03-05|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2010||2010-09-30|February 2018|2018-02-28|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Interventional|||ADD-ON Study to Existing Hypoparathyroidism Studies|Phase II Trial of Parathyroid Hormone for the Treatment of Hypoparathyroidism|Active, not recruiting||Phase 3|62|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t||||||||||2018-06-01 01:14:25.737487|2018-06-01 01:14:25.737487
NCT00856388|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2016-05-05||2017-11-29|2009-03-04|2009-03-05|Estimate|2016-05-05|2016-06-13|Estimate||||2017-11-29|2017-12-26|Actual|January 14, 2009|Actual|2009-01-14|November 2017|2017-11-30|August 15, 2019|Anticipated|2019-08-15|August 9, 2012|Actual|2012-08-09||Interventional|||Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders|A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation|Active, not recruiting||N/A|62|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 01:14:25.846246|2018-06-01 01:14:25.846246
NCT00856375|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03||2014-08-13|2015-02-06|2009-03-04|2009-03-05|Estimate||||2014-08-13|2014-08-15|Estimate|2015-02-06|2015-02-25|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer|A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naive, KRAS-Mutant, Metastatic Colorectal Cancer (mCRC)|Completed||Phase 2|83|Actual|Nektar Therapeutics||2|||f||||t||||||||||2018-06-01 01:14:26.169234|2018-06-01 01:14:26.169234
NCT00856362|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2010-09-15|2009-03-04|2009-03-05|Estimate|||||||2010-09-15|2010-09-16|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects|An Open-label, Single-Dose, 4-Period, Sequential Study to Determine the Effect of Moxidectin on CYP3A4 Activity in Healthy Subjects Using Midazolam as a Probe Substrate|Completed||Phase 1|38|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:14:26.274142|2018-06-01 01:14:26.274142
NCT00856349|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2014-05-22||2014-07-01|2009-03-04|2009-03-05|Estimate|2014-07-01|2014-07-03|Estimate||||2014-07-01|2014-07-03|Estimate|April 2009||2009-04-30|July 2014|2014-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational||Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.|Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming|Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming|Completed|||4384|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||||2018-06-01 01:14:26.424976|2018-06-01 01:14:26.424976
NCT00856336|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-04|2009-03-04|2009-03-05|Estimate|||||||2009-03-04|2009-03-05|Estimate|May 2003||2003-05-31|March 2009|2009-03-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|DART||Phase I Safety Study of DMXAA in Refractory Tumors|5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.|Completed||Phase 1|15|Actual|Antisoma Research|||||f||||t||||||||||2018-06-01 01:14:26.949862|2018-06-01 01:14:26.949862
NCT00856323|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2012-08-27||2016-08-12|2009-03-04|2009-03-05|Estimate|2012-10-26|2012-11-27|Estimate||||2016-08-12|2016-09-20|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men|Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM|Completed||Phase 2|53|Actual|Friends Research Institute, Inc.||1|||f||||t||||||||No||2018-06-01 01:14:27.037913|2018-06-01 01:14:27.037913
NCT00856310|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-05-09|2009-03-03|2009-03-05|Estimate|||||||2012-05-09|2012-05-10|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Tolerability of REGN475 in Healthy Subjects|Completed||Phase 1|56|Actual|Regeneron Pharmaceuticals||7|||f||||f||||||||||2018-06-01 01:14:27.219424|2018-06-01 01:14:27.219424
NCT00856297|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2013-10-24||2017-05-17|2009-03-04|2009-03-05|Estimate|2013-12-17|2014-01-22|Estimate||||2017-05-17|2017-06-14|Actual|February 2009||2009-02-28|May 2017|2017-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Enrolled population|Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine|An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercially Available MenACWY Conjugate Vaccine|Completed||Phase 3|389|Actual|Novartis||5|||f||||||||||||||2018-06-01 01:14:27.331231|2018-06-01 01:14:27.331231
NCT00856284|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2013-09-25|2013-02-11|2013-09-25|2009-03-04|2009-03-05|Estimate|2013-09-25|2013-12-03|Estimate|2013-02-17|2013-02-21|Estimate|2013-09-25|2013-12-03|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ENDURE|The Randomized Set included all enrolled subjects who were subsequently randomized.|Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes|Completed||Phase 3|2639|Actual|Takeda|The Week 52 results summarized in herein differ from the Week 52 results summarized in an interim analysis, because the per protocol set (PPS) defined for the final analysis included fewer subjects than the PPS defined for the interim analysis.|3|||f||||t||||||||||2018-06-01 01:14:28.163939|2018-06-01 01:14:28.163939
NCT00856271|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2010-09-28|2009-03-04|2009-03-05|Estimate|||||||2010-09-28|2010-09-29|Estimate|August 2004||2004-08-31|September 2010|2010-09-30|April 2005|Actual|2005-04-30|February 2005|Actual|2005-02-28||Interventional|||Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 3|287|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:14:30.045302|2018-06-01 01:14:30.045302
NCT00856258|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-12-22|2009-03-03|2009-03-05|Estimate|||||||2009-12-22|2009-12-23|Estimate|March 2009||2009-03-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845|A Phase 1, Double Blind (Sponsor Open), Randomized, Placebo Controlled, Parallel Group, Oral Multiple Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF 03882845 In Healthy Volunteers|Terminated||Phase 1|10|Actual|Pfizer||4||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:14:30.11416|2018-06-01 01:14:30.11416
NCT00856245|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2017-01-23||2017-04-19|2009-03-04|2009-03-05|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|February 2009||2009-02-28|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma|Role of Rituximab Containing Salvage Chemotherapy and in Vivo Purging in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma or Transplant Eligible Mantle Cell Lymphoma|Completed||Phase 2|21|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 01:14:30.178682|2018-06-01 01:14:30.178682
NCT00856232|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2012-06-12||2016-03-23|2009-03-04|2009-03-05|Estimate|2013-03-22|2013-05-03|Estimate||||2016-03-23|2016-04-21|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department|Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department|Completed||N/A|91|Actual|Rutgers, The State University of New Jersey|Limited number of subjects due to difficulty with recruitment|3|||f||||f||||||||||2018-06-01 01:14:30.334947|2018-06-01 01:14:30.334947
NCT00856219|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2015-05-20|2009-03-04|2009-03-05|Estimate|||||||2015-05-20|2015-05-22|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|Feeding||Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects|Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects|Completed||Phase 1|12|Actual|Rutgers, The State University of New Jersey||3|||f||||f||||||||||2018-06-01 01:14:30.60335|2018-06-01 01:14:30.60335
NCT00856206|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-21|2017-03-20|2011-01-05|2017-03-20|2009-03-04|2009-03-05|Estimate|2017-03-20|2017-04-28|Actual|2011-01-05|2011-01-10|Estimate|2017-03-20|2017-04-28|Actual|March 2009||2009-03-31|March 2017|2017-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||Baseline population included all randomized participants.|Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy|Completed||Phase 3|1315|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:14:30.715951|2018-06-01 01:14:30.715951
NCT00856193|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2011-01-20||2016-08-02|2009-03-04|2009-03-05|Estimate|2011-04-12|2011-05-06|Estimate||||2016-08-02|2016-09-14|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, Multi-center, Two-period Crossover Study to Investigate the Bronchodilatory Effect of 50 µg NVA237 Inhaled Once Daily in Patient With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 2|33|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:14:31.507095|2018-06-01 01:14:31.507095
NCT00856180|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2016-04-13||2017-06-19|2009-03-04|2009-03-05|Estimate|2016-04-13|2016-05-17|Estimate||||2017-06-19|2017-07-17|Actual|February 2009||2009-02-28|June 2017|2017-06-30|January 2014|Actual|2014-01-31|April 2010|Actual|2010-04-30||Interventional|||Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies|Pilot Study of Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies|Completed||Phase 2|20|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 01:14:31.71303|2018-06-01 01:14:31.71303
NCT00856167|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2015-05-26|2009-03-04|2009-03-05|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2006||2006-09-30|May 2015|2015-05-31|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|TCM-TMD||Traditional Chinese Medicine (TCM) for Temporomandibular Dysfunction (TMD): A Whole Systems Multi-site Trial|TCM for TMD: A Multi-Site Whole Systems Trial|Completed||Phase 2|160|Actual|University of Arizona||2|||f||||t||||||||||2018-06-01 01:14:31.944753|2018-06-01 01:14:31.944753
NCT00856154|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-04-07|2009-03-04|2009-03-05|Estimate|||||||2009-04-07|2009-04-08|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|HIVDCVac||Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection|Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection. Phase I Trial|Completed||Phase 1|12|Actual|Statens Serum Institut|||||f||||t||||||||||2018-06-01 01:14:32.016998|2018-06-01 01:14:32.016998
NCT00856141|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-04|2009-03-04|2009-03-05|Estimate|||||||2009-03-04|2009-03-05|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|May 2006|Actual|2006-05-31|March 2006|Actual|2006-03-31||Interventional|||Set up for in-Vivo Measurement of Dynamic Intraocular Pressure (IOP)|In Vivo Evaluation of Dynamic IOP Measuring Device During Phacoemulsifcation: A Prospective Randomised Clinical Trial|Completed||N/A|20|Actual|Iladevi Cataract and IOL Research Center||2|||f||||t||||||||||2018-06-01 01:14:32.082226|2018-06-01 01:14:32.082226
NCT00856115|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2014-07-14|2009-03-04|2009-03-05|Estimate|||||||2014-07-14|2014-07-16|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|October 2010|Actual|2010-10-31||Observational|||Differences in Timely Cancer Diagnosis in African American and Caucasian Patients With Newly Diagnosed Colorectal Cancer|Appraisal Delay and Disparities in Timely Cancer Diagnosis|Completed|||84|Actual|Case Comprehensive Cancer Center|||4||f||||t||||||||||2018-06-01 01:14:32.17163|2018-06-01 01:14:32.17163
NCT00856102|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2011-01-31|2009-03-03|2009-03-05|Estimate|||||||2011-01-31|2011-02-01|Estimate|March 2009||2009-03-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Exercise and Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy|Efficacy of Exercise in Promotion Cognitive-psychosocial Functions in Men With Prostate Cancer Receiving Androgen Depletion Therapy|Completed||N/A|30|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-06-01 01:14:32.239546|2018-06-01 01:14:32.239546
NCT00856089|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2013-05-28|2009-03-04|2009-03-05|Estimate|||||||2013-05-28|2013-05-29|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization|Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization|Withdrawn||Phase 4|0|Actual|Ochsner Health System||1||Study is withdrawn and no one enrolled due to changes in personnel|f||||t||||||||||2018-06-01 01:14:32.293834|2018-06-01 01:14:32.293834
NCT00856076|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2011-10-17|2009-03-04|2009-03-05|Estimate|||||||2011-10-17|2011-10-18|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|December 2023|Anticipated|2023-12-31|December 2010|Actual|2010-12-31||Observational|VIP||Venous Thromboembolism in Pregnancy Study|Venous Thromboembolism and Intrauterine Fetal Death in Pregnancy - Epidemiology and Pathogenic Mechanisms|Recruiting|||1200|Anticipated|Oslo University Hospital|||10||f||||f||||||Samples With DNA|"~     Serum, EDTA and citrated plasma, whole blood and processed DNA~   "|||2018-06-01 01:14:32.357009|2018-06-01 01:14:32.357009
NCT00856063|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2012-07-05|2009-03-04|2009-03-05|Estimate|||||||2012-07-05|2012-07-09|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD)|Feasibility and Utility of Autonomic Correlates of Impulsivity in Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD): Extending Translational Research Skills|Completed||Phase 4|5|Actual|University of Arizona|||||f||||f||||||||||2018-06-01 01:14:32.42186|2018-06-01 01:14:32.42186
NCT00856050|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2014-01-09||2017-03-22|2009-03-04|2009-03-05|Estimate|2014-02-03|2014-03-19|Estimate||||2017-03-22|2017-04-18|Actual|February 2009||2009-02-28|March 2017|2017-03-31|March 2014|Actual|2014-03-31|January 2013|Actual|2013-01-31||Interventional||27 patients were enrolled, and 26 patients received at least one dose of study medication and were included in the analysis.|Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma|Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma|Completed||Phase 2|27|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:14:32.510277|2018-06-01 01:14:32.510277
NCT00856037|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2018-01-16|2009-03-04|2009-03-05|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2009||2009-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)|Active, not recruiting||Phase 1|22|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 01:14:32.692459|2018-06-01 01:14:32.692459
NCT00856024|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2011-10-14||2015-06-04|2009-03-04|2009-03-05|Estimate|2011-10-14|2011-11-28|Estimate||||2015-06-04|2015-07-01|Estimate|July 2008||2008-07-31|June 2015|2015-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|ATHENAS||ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)|ATHENAS - Retrospective Analysis of Compliance to Treatment of Chronic Hepatitis C With Pegylated Interferon Alpha 2b Associated to Ribavirin Until Week 12 and Correlation With Virological Response in Brazil Health Centers|Terminated|||902|Actual|Merck Sharp & Dohme Corp.|||3||f||||f||||||||||2018-06-01 01:14:32.799557|2018-06-01 01:14:32.799557
NCT00856011|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-04|2009-03-04|2009-03-05|Estimate|||||||2009-03-04|2009-03-05|Estimate|December 2003||2003-12-31|March 2009|2009-03-31|April 2008|Actual|2008-04-30|||||Observational|||Nerve Morphology in Diabetic Patients|Posterior Interosseous Nerve Pathology May Provide Novel Insights Into Both Predisposition and Potential Vascular Basis for the Development of Carpal Tunnel Syndrome in Diabetic Patients.|Completed|||46|Actual|Skane University Hospital|||2||f||||f||||||Samples Without DNA|"~     Biopsies of the posterior interosseous nerve~   "|||2018-06-01 01:14:32.986829|2018-06-01 01:14:32.986829
NCT00855998|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2010-06-02|2009-03-04|2009-03-05|Estimate|||||||2010-06-02|2010-06-03|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Observational|||Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer|Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer|Unknown status|Recruiting||300|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:14:33.048925|2018-06-01 01:14:33.048925
NCT00855985|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2011-09-24|2009-03-04|2009-03-05|Estimate|||||||2011-09-24|2011-09-27|Estimate|July 2004||2004-07-31|September 2011|2011-09-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|PG/PJ||Anastomotic Techniques in Pancreaticoduodenectomy|A Randomised Controlled Trial of Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Pancreaticoduodenectomy for Cancer|Unknown status|Active, not recruiting|N/A|312|Actual|Lakeshore Hospital||2|||f||||f||||||||||2018-06-01 01:14:33.121264|2018-06-01 01:14:33.121264
NCT00855972|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2015-12-09|2009-03-04|2009-03-05|Estimate|||||||2015-12-09|2015-12-11|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome|Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome|Withdrawn||N/A|0|Actual|Stanford University||||"The FDA IND application is paused due to additional required testing. The IRB protocol was~   closed prior to research starting."|f||||||||||||||2018-06-01 01:14:33.183768|2018-06-01 01:14:33.183768
NCT00855959|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2010-08-17||2011-02-16|2009-03-04|2009-03-05|Estimate|2011-02-16|2011-03-11|Estimate||||2011-02-16|2011-03-11|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients|An Evaluation of Efficacy and Safety of Corresponding Doses of Pulmicort Turbuhaler® and Pulmicort Respules® in Japanese Asthmatic Adult Patients (Open, Multicenter, Phase III Study)|Completed||Phase 3|108|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:14:33.246175|2018-06-01 01:14:33.246175
NCT00855946|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2013-05-07|2009-03-04|2009-03-05|Estimate|||||||2013-05-07|2013-05-09|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|PROTEORECTUM||Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy|Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy|Completed|||46|Actual|University Hospital, Bordeaux|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:14:34.457559|2018-06-01 01:14:34.457559
NCT00855933|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2012-12-03||2013-01-07|2009-03-04|2009-03-05|Estimate|2013-01-07|2013-02-08|Estimate||||2013-01-07|2013-02-08|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing|A Controlled Clinical Study to Determine the Gingivitis Benefit of Flossing|Completed||Phase 4|60|Actual|Procter and Gamble||2|||f||||f||||||||||2018-06-01 01:14:34.617576|2018-06-01 01:14:34.617576
NCT00855920|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2017-03-20|2011-01-05|2017-03-20|2009-03-03|2009-03-05|Estimate|2017-03-20|2017-04-28|Actual|2011-01-05|2011-01-10|Estimate|2017-03-20|2017-04-28|Actual|March 2009||2009-03-31|March 2017|2017-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|SURGE|Baseline population included full analysis set (FAS) comprising of all randomized participants who received any study drug and had at least 1 post-baseline assessment.|Study Utilizing Rilonacept in Gout Exacerbations|A Multi-Center, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rilonacept Administered Subcutaneously for the Treatment of an Acute Gout Flare|Completed||Phase 3|225|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-06-01 01:14:34.857909|2018-06-01 01:14:34.857909
NCT00850551|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2016-11-30|2009-02-24|2009-02-25|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis|Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis|Completed||N/A|42|Actual|University of Washington||2|||f||||f||||||||No|There is no IPD|2018-06-01 01:16:26.724385|2018-06-01 01:16:26.724385
NCT00855907|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2009-03-04|2009-03-04|2009-03-05|Estimate|||||||2009-03-04|2009-03-05|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Observational|||Fatty Liver in Inflammatory Bowel Disease (IBD) Patients|Prevalence of Fatty Liver in Inflammatory Bowel Disease (IBD) Patients and Mechanisms Related to Inflammation and Fatty Liver|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     Blood count and biochemistry tests (such as: Liver and thyroid enzimes,cholesterol,~     immunology, glucose)~   "|||2018-06-01 01:14:35.419125|2018-06-01 01:14:35.419125
NCT00855894|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|2013-03-14||2013-05-14|2009-03-04|2009-03-05|Estimate|2013-03-14|2013-05-01|Estimate||||2013-05-14|2013-05-21|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PENGUIN||A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer|An Open-label Phase II Multicenter Study of the Safety and Activity (as Measured by FDG-PET Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer|Completed||Phase 2|41|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:14:35.507175|2018-06-01 01:14:35.507175
NCT00855881|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-04|||2011-07-25|2009-03-04|2009-03-05|Estimate|||||||2011-07-25|2011-07-26|Estimate|December 2008||2008-12-31|August 2010|2010-08-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma|A Trial of Metronomic Chemotherapy With Tegafur/Uracil for Patients With Locally Advanced (Stage III~IVB) Head and Neck Squamous Cell Carcinoma (HNSCC)|Unknown status|Recruiting|Phase 2|115|Anticipated|Mackay Memorial Hospital||1|||f||||t||||||||||2018-06-01 01:14:35.764604|2018-06-01 01:14:35.764604
NCT00855868|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2012-05-04|2012-03-06|2012-06-19|2009-03-03|2009-03-05|Estimate|2012-06-19|2012-07-26|Estimate|2012-03-06|2012-03-08|Estimate|2012-06-19|2012-07-26|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals|Evaluation of the Ability of a Novel [18F] Amyloid Ligand ([18F]-AV-45) to Distinguish Patients With a Clinical Diagnosis of Alzheimer's Disease From Cognitively Normal Elderly Individuals|Completed||Phase 2|28|Actual|Avid Radiopharmaceuticals|||||f||||t||||||||||2018-06-01 01:14:35.855656|2018-06-01 01:14:35.855656
NCT00855855|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2018-02-05|2009-03-03|2009-03-04|Estimate|||||||2018-02-05|2018-02-06|Actual|February 2009|Actual|2009-02-28|February 2018|2018-02-28|July 18, 2018|Anticipated|2018-07-18|July 18, 2018|Anticipated|2018-07-18||Observational|||Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease|Surveillance for Rates of Hib Disease Among Persons 0 Through 59 Months of Age Receiving Pentacel® or Other Hib Vaccines|Active, not recruiting|||510000|Anticipated|Sanofi|||1||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available at Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-06-01 01:14:36.039683|2018-06-01 01:14:36.039683
NCT00855842|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2011-04-04||2011-06-10|2009-03-03|2009-03-04|Estimate|2011-06-10|2011-07-08|Estimate||||2011-06-10|2011-07-08|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|DAIS||Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion|Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion|Terminated||N/A|4|Actual|Boston University|The study was terminated early because the clinical facility changed and eligible patients were not seen at the facility.|1||inadequate enrollment|f||||f||||||||||2018-06-01 01:14:36.171194|2018-06-01 01:14:36.171194
NCT00855829|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2013-11-10|2009-03-03|2009-03-04|Estimate|||||||2013-11-10|2013-11-13|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||A Feasibility Study Designed to Assess the Efficacy of the ActiLady Device in Adult Female Subjects With Dysmenorrhea|A Single-Center, Randomized, Controlled, Double-Blind Feasibility Study Designed to Assess the Safety Performance of ActiLady Prototype in Adult Female Subjects With Dysmenorrhea.|Completed||Phase 1|24|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:14:36.383757|2018-06-01 01:14:36.383757
NCT00855816|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2014-10-07||2014-10-14|2009-03-03|2009-03-04|Estimate|2014-10-14|2014-10-20|Estimate||||2014-10-14|2014-10-20|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|BaRT||Post Traumatic Stress Disorder (PTSD) Hyperarousal Symptoms Treated With Physiological Stress Management|PTSD Hyperarousal Symptoms Treated With Physiological Stress Management|Completed||Phase 2/Phase 3|80|Actual|VA Office of Research and Development|Higher than anticipated withdrawal rate limited power of statistical analyses.|2|||f||||t||||||||||2018-06-01 01:14:36.449253|2018-06-01 01:14:36.449253
NCT00855803|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2018-01-24|2009-03-03|2009-03-04|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2009||2009-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis|Phase II Study of Stereotactic Body Radiation Therapy and Vertebroplasty for Localized Spinal Metastasis (SBRT Spine)|Recruiting||Phase 2|42|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-06-01 01:14:36.663252|2018-06-01 01:14:36.663252
NCT00855790|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2015-07-22|2009-03-03|2009-03-04|Estimate|||||||2015-07-22|2015-07-23|Estimate|December 2008||2008-12-31|July 2015|2015-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Comparison of Two Types of Biopsy Forceps for Obtaining Cold Biopsy Polypectomy for Small Sessile Colorectal Polyps Less Than 6 mm in Diameter|Comparison of Two Types of Biopsy Forceps for Obtaining Cold Biopsy Polypectomy for Small Sessile Colorectal Polyps Less Than 6 mm in Diameter|Completed||N/A|125|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 01:14:36.762856|2018-06-01 01:14:36.762856
NCT00855777|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-03-03|2009-03-03|2009-03-04|Estimate|||||||2009-03-03|2009-03-04|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Interventional|||Etoricoxib Versus Ibuprofen in Third Molar Extraction Pain|Evaluation of Analgesic Efficacy of Etoricoxib Compared With Ibuprofen in Third Molar Extraction Pain.|Unknown status|Not yet recruiting|Phase 4|110|Anticipated|Universita di Verona||2|||f||||f||||||||||2018-06-01 01:14:36.838223|2018-06-01 01:14:36.838223
NCT00855764|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03||2010-02-02|2010-02-02|2009-03-03|2009-03-04|Estimate||||2010-02-02|2010-02-04|Estimate|2010-02-02|2010-02-04|Estimate|October 2005||2005-10-31|October 2009|2009-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer|Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer|Completed||Phase 2|36|Anticipated|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 01:14:36.899293|2018-06-01 01:14:36.899293
NCT00855738|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2010-06-23||2010-11-23|2009-03-03|2009-03-04|Estimate|2010-06-23|2010-07-23|Estimate||||2010-11-23|2010-12-10|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice|Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice|Completed||Phase 4|111|Actual|Pfizer|This study was cancelled with 111 patients enrolled due to lack of recruitment, and inability to analyze the study by treatment groups. Seizures were analyzed by 3 month data instead of 2 month data as originally planned.|1|||f||||t||||||||||2018-06-01 01:14:36.99847|2018-06-01 01:14:36.99847
NCT00855725|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-07-08|2009-03-03|2009-03-04|Estimate|||||||2009-07-08|2009-07-09|Estimate|June 2008||2008-06-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Affective Processing in Depression and Epilepsy|Affective Processing in Depression and Epilepsy; An fMRI Study|Terminated|||14|Actual|Northwell Health||||PI wanted to discontinue study.|f||||f||||||||||2018-06-01 01:14:37.422286|2018-06-01 01:14:37.422286
NCT00855712|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03||2015-05-11|2015-05-11|2009-03-03|2009-03-04|Estimate||||2015-05-11|2015-06-03|Estimate|2015-05-11|2015-06-03|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|PROCEEDII||Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation|Prospective, Multicenter, Randomized, Clinical Investigation of TransMedics Organ Care System (OCS) for Cardiac Use|Completed||Phase 2/Phase 3|128|Actual|TransMedics||2|||f||||t||||||||||2018-06-01 01:14:37.480403|2018-06-01 01:14:37.480403
NCT00855699|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2011-01-18|2009-03-03|2009-03-04|Estimate|||||||2011-01-18|2011-01-19|Estimate|November 2009||2009-11-30|January 2011|2011-01-31|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|ADEPT||Alcohol Detoxification in Primary Care Treatment (ADEPT)|Alcohol Detoxification in Primary Care Treatment (ADEPT) - a Feasibility Study of Conducting a Randomised Trial in Primary Care Comparing Two Pharmacological Regimens.|Completed||Phase 4|36|Actual|University of Bristol|||||f||||f||||||||||2018-06-01 01:14:37.555542|2018-06-01 01:14:37.555542
NCT00855686|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2013-09-19|2009-03-03|2009-03-04|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2007||2007-01-31|September 2013|2013-09-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies|A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies|Completed||Phase 4|199|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:14:37.616921|2018-06-01 01:14:37.616921
NCT00855673|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-04|Estimate|||||||2009-03-02|2009-03-04|Estimate|January 2001||2001-01-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|FM-S1||Intermittent Mechanical Compression For Peripheral Arterial Disease|Intermittent Mechanical Compression For Peripheral Arterial Disease|Completed||Phase 4|30|Actual|Hospital Universitario Getafe||2|||f||||f||||||||||2018-06-01 01:14:37.685161|2018-06-01 01:14:37.685161
NCT00855660|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2016-01-07|2009-03-03|2009-03-04|Estimate|||||||2016-01-07|2016-01-11|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Riociguat on Bone Metabolism|Investigation of the Effect of Riociguat, Administered as 2.5 mg IR-tablets TID Over 14 Days, on Bone Metabolism in a Randomized, Placebo-controlled, Double-blind, 2-fold Cross-over Design in Healthy Male Subjects|Completed||Phase 1|17|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:14:37.824834|2018-06-01 01:14:37.824834
NCT00855647|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2010-06-01|2009-03-03|2009-03-04|Estimate|||||||2010-06-01|2010-06-03|Estimate|August 2003||2003-08-31|June 2010|2010-06-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)|Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)|Completed||Phase 2|99999|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 01:14:37.915452|2018-06-01 01:14:37.915452
NCT00855634|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2012-09-05|2009-03-03|2009-03-04|Estimate|||||||2012-09-05|2012-09-06|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|March 2012|Actual|2012-03-31|||||Interventional|PaMeViTUM||Resection in Pancreatic Cancer With Minimal Metastatic Disease or Venous Infiltration Trial at Technische Universität München|Extended Versus Standard Resection in Two Cohorts of Patients With Adenocarcinoma of the Pancreas: Minimal Metastatic Disease or Venous Infiltration - a Randomized Trial|Terminated||N/A|355|Anticipated|Technische Universität München||2||"Protocol planned interim analysis after two years showed very low recruitment in cohort 1 and~   low recruitment in cohort 2."|f||||t||||||||||2018-06-01 01:14:37.975082|2018-06-01 01:14:37.975082
NCT00855621|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2016-11-18|2009-03-03|2009-03-04|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|December 2023|Anticipated|2023-12-31|November 2014|Actual|2014-11-30||Interventional|||Effects of Deep Brain Stimulation in Parkinson's Disease|Prognostic Factors in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) - a Prospective Randomized Double-blind Study (The NORSTIM Study)|Active, not recruiting||N/A|70|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 01:14:38.047498|2018-06-01 01:14:38.047498
NCT00855608|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2011-07-20|2009-03-02|2009-03-04|Estimate|||||||2011-07-20|2011-07-22|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|ADA01||Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study|The Safety and Tolerability of Intravitreal Adalimumab in Patients With Refractory Diabetic Macular Retinopathy or Choroidal Neovascularization or Uveitis: A Pilot Study|Unknown status|Recruiting|Phase 1|15|Anticipated|Rafic Hariri University Hospital||1|||f||||t||||||||||2018-06-01 01:14:38.113847|2018-06-01 01:14:38.113847
NCT00855595|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2012-07-25||2014-01-29|2009-03-03|2009-03-04|Estimate|2012-07-25|2012-08-29|Estimate||||2014-01-29|2014-02-28|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea|An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily in Subjects With Moderate Papulopustular Rosacea|Completed||Phase 4|207|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:14:38.236951|2018-06-01 01:14:38.236951
NCT00855257|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-07-08|2009-03-03|2009-03-04|Estimate|||||||2009-07-08|2009-07-10|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|EVANACS||Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome|Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Patients Presenting a Recent Acute Coronary Syndrome.|Completed||Phase 3|93|Actual|French Cardiology Society||2|||f||||t||||||||||2018-06-01 01:14:46.70703|2018-06-01 01:14:46.70703
NCT00855582|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2011-06-01||2011-07-26|2009-03-03|2009-03-04|Estimate|2011-06-01|2011-06-30|Estimate||||2011-07-26|2011-07-28|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|COMORBID©||A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men With Both Erectile Dysfunction and Benign Prostatic Hyperplasia|Completed||Phase 3|606|Actual|Eli Lilly and Company|P-values for the peak urine flow rate outcome were corrected in this record after an error was identified.|3|||f||||f||||||||||2018-06-01 01:14:39.210621|2018-06-01 01:14:39.210621
NCT00855569|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2017-12-08|2009-03-03|2009-03-04|Estimate|||||||2017-12-08|2017-12-12|Actual|June 2008||2008-06-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|Stasilon||Hemostatic Textile to Control Bleeding at Donor Graft Sites|Use of a HemostaticTextile (StasilonTM) to Control Bleeding at Skin Graft Donor Sites (Randomized, Single-Blind)|Completed|||20|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-06-01 01:14:41.062083|2018-06-01 01:14:41.062083
NCT00855556|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2015-09-15|2009-03-03|2009-03-04|Estimate|||||||2015-09-15|2015-09-16|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Parkinson's Disease Genetics Database|Parkinson's Disease Genetics Database|Terminated|||16|Actual|Northwell Health||||"Enrollment into this registry was not as robust as investigator envisioned. Thus, the registry~   was closed."|f||||f||||||Samples With DNA|"~     DNA stored in TE buffer solution~   "|||2018-06-01 01:14:41.131506|2018-06-01 01:14:41.131506
NCT00855543|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2011-07-14|2009-03-03|2009-03-04|Estimate|||||||2011-07-14|2011-07-15|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Phospholipase A2 Producing Bacteria and Pre-Term Labor|Phospholipase A2 Producing Bacteria, Age at Gestation, Cervical Length Measurement and the Incidence of Pre-Term Labor|Completed|||60|Anticipated|CAMC Health System|||||f||||f||||||||||2018-06-01 01:14:41.198249|2018-06-01 01:14:41.198249
NCT00855530|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-03-24|2009-03-03|2009-03-04|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder|A Fifty-Two-Week Multicenter, Open-Label, Study Evaluating the Long-Term Safety and Tolerability of SR58611A 350 mg q12 in Patients With Major Depressive Disorder.|Completed||Phase 3|527|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:14:41.263729|2018-06-01 01:14:41.263729
NCT00855517|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2013-09-16|2009-03-03|2009-03-04|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma|A Partially Masked, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)|Withdrawn||Phase 2|0|Actual|Mati Therapeutics Inc.||1||Sponsor's decision|f||||f||||||||||2018-06-01 01:14:41.352583|2018-06-01 01:14:41.352583
NCT00855504|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2015-04-10|2009-03-03|2009-03-04|Estimate|||||||2015-04-10|2015-04-13|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Observational|||Association of Periodontitis and Preeclampsia During Pregnancy|Role of Cytokines in Association Between Periodontitis and Preeclampsia During Pregnancy|Completed|||528|Actual|Maulana Azad Medical College|||1||f||||f||||||||||2018-06-01 01:14:41.416594|2018-06-01 01:14:41.416594
NCT00855491|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-03-03|2009-03-03|2009-03-04|Estimate|||||||2009-03-03|2009-03-04|Estimate|July 2003||2003-07-31|March 2009|2009-03-31|November 2008|Actual|2008-11-30|September 2004|Actual|2004-09-30||Interventional|||Posterior Capsule Opacification (PCO) With AcrySof Single-Piece IOL|Prospective Evaluation of Posterior Capsule Opacification in Myopic Eyes 4 Years After AcrySof Single-Piece IOL Implantation|Completed||N/A|100|Actual|Iladevi Cataract and IOL Research Center||2|||f||||t||||||||||2018-06-01 01:14:41.481427|2018-06-01 01:14:41.481427
NCT00855478|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2010-11-25|2009-03-03|2009-03-04|Estimate|||||||2010-11-25|2010-11-29|Estimate|May 2006||2006-05-31|November 2010|2010-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|FR E-REGISTRY||French Post-Marketing Surveillance Survey|French Post-Marketing Surveillance Survey|Terminated||Phase 4|4080|Actual|Cordis Corporation||1||Early termination of patient enrollment based on business decision|f||||t||||||||||2018-06-01 01:14:41.549873|2018-06-01 01:14:41.549873
NCT00855465|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2013-11-04||2016-10-14|2009-03-03|2009-03-04|Estimate|2014-01-25|2014-03-11|Estimate||||2016-10-14|2016-11-28|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CHEST-1||A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.|Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Completed||Phase 3|262|Actual|Bayer||2|||f||||t||||||||||2018-06-01 01:14:41.706664|2018-06-01 01:14:41.706664
NCT00855452|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2015-06-10|2009-03-03|2009-03-04|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2009||2009-01-31|October 2008|2008-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|rIL-2(LAK)||Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors|rIL-2 Activated Allogeneic Lymphocytes for the Induction of Graft Versus Tumor Effect (GVT) in Metastatic Solid Tumors|Completed||Phase 2|20|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 01:14:43.112492|2018-06-01 01:14:43.112492
NCT00855439|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2015-04-23||2017-01-12|2009-03-03|2009-03-04|Estimate|2015-04-23|2015-05-12|Estimate||||2017-01-12|2017-03-01|Actual|June 2008||2008-06-30|January 2017|2017-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of Exenatide in Patients With Diabetic Neuropathy|A Single-center,Proof of Concept,Randomized,Controlled Parallel Group Clinical Trial of the Effects of Exenatide vs. a Long Acting Insulin Analog to Evaluate the Efficacy of Exenatide in Patients With Diabetic Neuropathy and Type 2 Diabetes|Completed||N/A|46|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 01:14:43.183658|2018-06-01 01:14:43.183658
NCT00855426|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2010-11-28|2009-03-03|2009-03-04|Estimate|||||||2010-11-28|2010-11-30|Estimate||||October 2010|2010-10-31||||||||Observational|||Diagnostic Protocol Of Painful Hip||Suspended|||||Hadassah Medical Organization||||the research is on susoension beacause the lack of manpower|f||||f||||||||||2018-06-01 01:14:43.5074|2018-06-01 01:14:43.5074
NCT00855244|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2015-05-14|2009-03-03|2009-03-04|Estimate|||||||2015-05-14|2015-05-18|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Metabolic Syndrome in Bone Marrow Transplant Survivors|Metabolic Syndrome in Bone Marrow Transplant Survivors|Terminated||N/A|5|Actual|Nationwide Children's Hospital||1||Principal Investigator left the institution|f||||f||||||||||2018-06-01 01:14:46.773556|2018-06-01 01:14:46.773556
NCT00855413|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2017-02-24||2017-09-12|2009-03-03|2009-03-04|Estimate|2017-09-12|2017-10-17|Actual||||2017-09-12|2017-10-17|Actual|March 2009||2009-03-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine|CID 0821 - Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected Antiretroviral Naïve Patients Treated With Darunavir/Ritonavir and Etravirine|Terminated||Phase 4|15|Actual|University of North Carolina, Chapel Hill|Early termination prior to target enrollment due to slow enrollment limited analysis involving optional procedures. Lack of paired (baseline and followup) samples from optional procedures also limited ability to perform these analyses.|1||Study halted by sponsor due to slow enrollment.|f||||t||||||||||2018-06-01 01:14:43.602554|2018-06-01 01:14:43.602554
NCT00855400|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2010-12-01|2009-03-03|2009-03-04|Estimate|||||||2010-12-01|2010-12-02|Estimate|February 2007||2007-02-28|December 2010|2010-12-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|CMN/ELA||Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis|Phase I/II Clinical Trial on the Use of Autologous Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis|Completed||Phase 1/Phase 2|11|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||1|||f||||t||||||||||2018-06-01 01:14:44.094114|2018-06-01 01:14:44.094114
NCT00855387|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2009-11-25|2009-03-03|2009-03-04|Estimate|||||||2009-11-25|2009-11-26|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Observational|||Severe Complications Triplicate the Costs of Major Surgical Procedures|Surgical Complications Dramatically Influence Overall Cost of Major Surgical Procedures|Completed|||1235|Actual|University of Zurich|||1||f||||f||||||||||2018-06-01 01:14:44.161916|2018-06-01 01:14:44.161916
NCT00855374|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2017-04-07|2009-03-03|2009-03-04|Estimate|||||||2017-04-07|2017-04-11|Actual|June 2008||2008-06-30|April 2017|2017-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||PAR Regulation of Platelet Function in Diabetic Patients|PAR Regulation of Platelet Function in Diabetic Patients|Completed|||195|Actual|Vanderbilt University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:14:44.238191|2018-06-01 01:14:44.238191
NCT00855361|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2013-04-26|2009-03-03|2009-03-04|Estimate|||||||2013-04-26|2013-04-29|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)|A Pharmacokinetic, Pharmacodynamic and Short-term Safety Study of Single and Multiple Day Doses of Rabeprazole Sodium in Neonates and Pre-term Infants With a Corrected Age of Less Than 44 Weeks With a Presumptive Diagnosis of GERD|Completed||Phase 1|69|Actual|Janssen Research & Development, LLC||1|||f||||||||||||||2018-06-01 01:14:44.290646|2018-06-01 01:14:44.290646
NCT00855348|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2014-08-01|2009-03-02|2009-03-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Observational|PRESEPT||PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening|PRESEPT Study: Prospective Evaluation of Septin 9 Performance for Colorectal Cancer Screening|Completed|||7929|Actual|Epigenomics, Inc|||1||f||||t||||||Samples With DNA|"~     Eligible consented Subjects meeting inclusion / exclusion criteria will have 40 ml of blood~     drawn prior to undergoing bowel cleansing in preparation for screening colonoscopy. Subject~     blood specimens will be processed according to Epigenomics' plasma preparation procedure~     (Blood Collection and Plasma Preparation SOP.~   "|||2018-06-01 01:14:44.373651|2018-06-01 01:14:44.373651
NCT00855335|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2017-06-30||2018-02-12|2009-03-02|2009-03-04|Estimate|2017-08-15|2017-09-15|Actual||||2018-02-12|2018-02-14|Actual|April 9, 2009|Actual|2009-04-09|February 2018|2018-02-28|August 11, 2016|Actual|2016-08-11|August 11, 2016|Actual|2016-08-11||Interventional|||A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women|A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women|Completed||Phase 3|77|Actual|Janssen Scientific Affairs, LLC||5|||f||||f||f||||||||2018-06-01 01:14:44.507423|2018-06-01 01:14:44.507423
NCT00855322|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-04|Estimate|||||||2009-03-02|2009-03-04|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Study Examining the Effect of Exercise in People With Rheumatoid Arthritis Taking Anti-TNFalpha Medication|Randomized Controlled Trial Examining The Effect Of Exercise In People With Rheumatoid Arthritis Taking Anti-TNFalpha Medication|Unknown status|Active, not recruiting|Phase 2|51|Anticipated|University College Dublin||3|||f||||f||||||||||2018-06-01 01:14:46.229469|2018-06-01 01:14:46.229469
NCT00855309|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2013-09-24||2017-12-20|2009-03-03|2009-03-04|Estimate|2013-09-24|2013-11-25|Estimate||||2017-12-20|2018-01-19|Actual|November 2008||2008-11-30|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia|Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient|Completed||Phase 3|112|Actual|Wake Forest University Health Sciences|per the protocol, only nephrotoxicities (as measured by Creatinine increase over baseline were observed.|2|||f||||t|t|f||||||||2018-06-01 01:14:46.313999|2018-06-01 01:14:46.313999
NCT00855296|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2017-04-07|2009-03-03|2009-03-04|Estimate|||||||2017-04-07|2017-04-11|Actual|September 2006||2006-09-30|April 2017|2017-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Thrombin Regulated Platelet Activation|Thrombin Regulated Platelet Activation|Completed|||69|Actual|Vanderbilt University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:14:46.499564|2018-06-01 01:14:46.499564
NCT00855283|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2013-07-23|2009-03-03|2009-03-04|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|IN NEO||Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI|Intranasal Administration of Neostigmine and Glycopyrrolate for Bowel Evacuation|Completed||Phase 2|20|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:14:46.546838|2018-06-01 01:14:46.546838
NCT00855270|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2016-05-22|2009-03-03|2009-03-04|Estimate|||||||2016-05-22|2016-05-24|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Efficacy of Single Dose IV Hydrocortisone in Post Traumatic Stress Disorder (PTSD) Prevention|The Efficacy of a Single Dose IV Hydrocortisone Given Within 6 Hours of Exposure to a Traumatic Event in PTSD Prevention|Unknown status|Recruiting|N/A|120|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 01:14:46.604497|2018-06-01 01:14:46.604497
NCT00849823|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-07-11|2009-02-23|2009-02-24|Estimate|||||||2017-07-11|2017-07-14|Actual|February 2009||2009-02-28|July 2017|2017-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||HIV Prevention Program for African American Teen Males|A Brief, Clinic-Based, HIV Prevention Program for African American Teen Males|Completed||N/A|840|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-06-01 01:16:38.456518|2018-06-01 01:16:38.456518
NCT00855231|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2017-11-22|2009-03-03|2009-03-04|Estimate|||||||2017-11-22|2017-11-27|Actual|July 2006||2006-07-31|November 2017|2017-11-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Observational|ACUTE CT||Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain|Diagnostic Accuracy of Multislice CT Angiography for Acute Chest Pain - Assessment of Chest Pain Utilizing a Triple Rule Out Evaluation With Computed Tomography (ACUTE CT) Trial|Completed|||102|Actual|University of Washington|||||f||||f||||||||||2018-06-01 01:14:46.834835|2018-06-01 01:14:46.834835
NCT00855218|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2012-08-23||2017-07-18|2009-03-03|2009-03-04|Estimate|2012-08-23|2012-09-24|Estimate||||2017-07-18|2017-08-18|Actual|March 2009||2009-03-31|July 2017|2017-07-31|February 2013|Actual|2013-02-28|July 2011|Actual|2011-07-31||Interventional|||A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).|A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).|Completed||Phase 2|307|Actual|Bayer||2|||f||||t||||||||||2018-06-01 01:14:46.933425|2018-06-01 01:14:46.933425
NCT00855205|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2013-12-09|2009-03-03|2009-03-04|Estimate|||||||2013-12-09|2013-12-11|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RIPS||Rituximab for Pulmonary Sarcoidosis|Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open-|Completed||Phase 2|10|Actual|University of Cincinnati||1|||f||||t||||||||||2018-06-01 01:14:49.599346|2018-06-01 01:14:49.599346
NCT00855192|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2010-03-17|2009-03-03|2009-03-04|Estimate|||||||2010-03-17|2010-03-18|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|ARG||Antenatal Relaxation Group for Anxiety and Depression Management|Antenatal Depression Group Research Project: The Effectiveness of Mindfulness-based Relaxation and Interpersonal Therapy to Relieve Anxiety and Depression Symptoms in Pregnant Women.|Unknown status|Enrolling by invitation|N/A|20|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 01:14:49.970566|2018-06-01 01:14:49.970566
NCT00855179|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03||2014-04-30|2014-04-30|2009-03-03|2009-03-04|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|March 2009||2009-03-31|April 2014|2014-04-30||||November 2009|Actual|2009-11-30||Interventional|||Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency|A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 720 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency|Completed||Phase 3|250|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:14:50.35168|2018-06-01 01:14:50.35168
NCT00855166|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|2013-01-21||2013-08-09|2009-03-03|2009-03-04|Estimate|2013-08-09|2013-10-14|Estimate||||2013-08-09|2013-10-14|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes|A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|Completed||Phase 3|182|Actual|AstraZeneca|For participants who did not complete 24 weeks, last observation carried forward (LOCF) was used.|2|||f||||t||||||||||2018-06-01 01:14:50.77311|2018-06-01 01:14:50.77311
NCT00855153|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2011-12-19|2009-03-03|2009-03-04|Estimate|||||||2011-12-19|2011-12-20|Estimate|May 2009||2009-05-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Virtual Reality and D-Cycloserine in Combat Related Psycological Trauma in Burn Service Members|A Pilot Study Using Gradual Virtual Reality Exposure Therapy and D-Cycloserine (DCS) for Treatment of Combat Related Psychological Trauma in Burn Service Members|Withdrawn||N/A|0|Actual|United States Army Institute of Surgical Research||1||Investigator was not able to maintain IRB approval. Study never accrued subjects.|f||||f||||||||||2018-06-01 01:14:52.259734|2018-06-01 01:14:52.259734
NCT00855140|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2017-10-05|2009-03-02|2009-03-04|Estimate|||||||2017-10-05|2017-10-09|Actual|March 2009||2009-03-31|October 2017|2017-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Acupuncture for the Treatment of Insomnia|Acupuncture for the Treatment of Insomnia - A Pilot Study|Completed||N/A|56|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:14:52.643406|2018-06-01 01:14:52.643406
NCT00855127|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2015-05-28|2009-03-03|2009-03-04|Estimate|||||||2015-05-28|2015-06-01|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients|Early Biomarkers of Acute Kidney Injury in Liver Transplant Patients|Withdrawn|||0|Actual|University of Colorado, Denver|||1|no enrollment|f||||f||||||Samples Without DNA|"~     Urine supernatent Serum~   "|||2018-06-01 01:14:53.028361|2018-06-01 01:14:53.028361
NCT00855114|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-03|||2017-11-29|2009-03-03|2009-03-04|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2008||2008-07-31|November 2017|2017-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery|A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||1||Withdrawn due to no accrual|f||||t||||||||||2018-06-01 01:14:53.178132|2018-06-01 01:14:53.178132
NCT00855101|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2010-06-11|2009-03-02|2009-03-04|Estimate|||||||2010-06-11|2010-06-14|Estimate|April 2009||2009-04-30|June 2010|2010-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults|An Open-Label, Intravenous (6/4 Mg/Kg Q12h) To Oral Switch (200 Mg Q12h), Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Healthy Male And Female Adults|Completed||Phase 1|35|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:14:53.283049|2018-06-01 01:14:53.283049
NCT00855088|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2011-05-11|2009-03-03|2009-03-04|Estimate|||||||2011-05-11|2011-05-13|Estimate|July 2009||2009-07-31|May 2011|2011-05-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|DESeRT||Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue|A Phase IV, Open Label Study in Healthy Male Subjects to Investigate the Extent of Darunavir/Ritonavir and Etravirine Exposure in Blood, Seminal Fluid, and Rectal Mucosal Tissue Following Single and Multiple Dosing of Darunavir/Ritonavir and Etravirine|Completed||Phase 1|13|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 01:14:53.560235|2018-06-01 01:14:53.560235
NCT00855075|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-07-27|2009-03-03|2009-03-04|Estimate|||||||2015-07-27|2015-07-29|Estimate|May 2008||2008-05-31|July 2015|2015-07-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|||Correlation of Cerebral State Index With the Richmond Agitation-Sedation Scale in Mechanically Ventilated ICU Patients|Correlation of the Cerebral State Index With the Richmond Agitation-Sedation Scale in ICU Patients Who Are Sedated and Mechanically Ventilated: A Pilot Study|Terminated|||3|Actual|CAMC Health System|||1|Technology used to obtain/measure cerebral state index is no longer manufactured|f||||f||||||||||2018-06-01 01:14:53.697481|2018-06-01 01:14:53.697481
NCT00855062|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2010-12-17||2011-01-28|2009-03-02|2009-03-03|Estimate|2011-01-28|2011-02-25|Estimate||||2011-01-28|2011-02-25|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Minocycline for HIV+ Cognitive Impairment in Uganda|Minocycline in the Treatment of HIV-Associated Cognitive Impairment in Uganda|Terminated||Phase 1/Phase 2|73|Actual|Johns Hopkins University|The estimated sample size was 100; however, due to early termination of the study, the total number of randomized participants was 73.|2||"The Neurologic AIDS Research Consortium Data Safety and Monitoring Board committee recommended~   to terminate the study early due to futility on 11/6/2009."|f||||t||||||||||2018-06-01 01:14:53.815223|2018-06-01 01:14:53.815223
NCT00855049|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2010-09-23|2009-02-27|2009-03-03|Estimate|||||||2010-09-23|2010-09-27|Estimate|April 2009||2009-04-30|September 2010|2010-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||A Randomized Crossover Study to Determine the Pharmacokinetics of Intranasally Administered Acetaminophen in Healthy Adults|A Randomized Crossover Study to Determine the Pharmacokinetics of Intranasally Administered Acetaminophen in Healthy Adults|Withdrawn||N/A|10|Anticipated|University of Texas Southwestern Medical Center||2||Unable to obtain FDA approval|f||||f||||||||||2018-06-01 01:14:55.800791|2018-06-01 01:14:55.800791
NCT00855036|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2017-01-23|2009-03-02|2009-03-03|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|January 2018|Anticipated|2018-01-31||Observational|||Prospective Evaluation of Blunt Renal Injury in Children|Prospective Evaluation of Blunt Renal Injury in Children|Recruiting|||100|Anticipated|Children's Mercy Hospital Kansas City|||1||f||||f||||||||||2018-06-01 01:14:56.018008|2018-06-01 01:14:56.018008
NCT00855023|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Observational|||Knee Alignment Contributions to Anterior Cruciate Ligament (ACL) Injury|Tibiofemoral Alignment: Contributing Factors to Noncontact Anterior Cruciate Ligament Injury|Suspended|||25|Actual|The Orthopaedic Center, Maryland|||1|May continue recruiting only if required by journal reviewers|f||||f||||||||||2018-06-01 01:14:56.252862|2018-06-01 01:14:56.252862
NCT00855010|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2017-08-01||2017-11-14|2009-03-02|2009-03-03|Estimate|2017-11-14|2017-12-13|Actual||||2017-11-14|2017-12-13|Actual|February 2009||2009-02-28|November 2017|2017-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pioglitazone on Pancreatic Steatosis and Bone Health|Effect of Pioglitazone on Pancreatic Steatosis and Bone Health|Completed||N/A|42|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 01:14:56.391288|2018-06-01 01:14:56.391288
NCT00854997|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-03-01|2009-03-01|2009-03-03|Estimate|||||||2009-03-01|2009-03-03|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||The Impact of Obstructive Sleep Apnea on the Outcomes in Patients of First-Time Acute Myocardial Infarction|The Impact of Obstructive Sleep Apnea on the Outcomes in Patients of First-Time Acute Myocardial Infarction|Unknown status|Recruiting||120|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     serum, plasma, RNA, DNA~   "|||2018-06-01 01:14:56.718579|2018-06-01 01:14:56.718579
NCT00854984|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2010-04-07|2009-03-02|2009-03-03|Estimate|||||||2010-04-07|2010-04-08|Estimate|February 2009||2009-02-28|April 2010|2010-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Pilot Study of a Self-help Intervention for Depression in Patients With a Chronic Disease|Pilot Study of a Practice Nurse Supported Psychological Self-help Intervention for Patients With Diabetes or Coronary Heart Disease and Co-morbid Depression|Unknown status|Recruiting|N/A|49|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:14:56.810009|2018-06-01 01:14:56.810009
NCT00854971|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-28|||2009-05-15|2009-03-02|2009-03-03|Estimate|||||||2009-05-15|2009-05-18|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Efficacy Study of TKcell in Advanced Colorectal Cancer|Evaluating the Safety and Efficacy of Combination Therapy With FOLFOX-4 and TKcell Therapy Versus FOLFOX-4 Alone in Patients With Recurrent, Unresectable and Advanced Colorectal Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|86|Anticipated|Binex||2|||f||||f||||||||||2018-06-01 01:14:56.878816|2018-06-01 01:14:56.878816
NCT00854958|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|May 2005||2005-05-31|February 2009|2009-02-28|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Observational|||The Diagnosis of Oral Allergy Syndrome Through the Use of a Structured Questionnaire|The Diagnosis of Oral Allergy Syndrome Through the Use of a Structured Questionnaire|Completed|||123|Actual|Royal Brompton & Harefield NHS Foundation Trust|||||f||||f||||||||||2018-06-01 01:14:56.968901|2018-06-01 01:14:56.968901
NCT00854945|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02||2014-10-03|2017-06-22|2009-03-02|2009-03-03|Estimate||||2014-10-03|2014-10-13|Estimate|2017-06-22|2017-06-26|Actual|January 2009||2009-01-31|June 2017|2017-06-30|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML|A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)|Completed||Phase 1/Phase 2|36|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-06-01 01:14:57.097691|2018-06-01 01:14:57.097691
NCT00854932|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2016-03-04|2009-03-02|2009-03-03|Estimate|||||||2016-03-04|2016-03-08|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|May 2015|Actual|2015-05-31||Interventional|NeoPInS||Neonatal Procalcitonin Intervention Study|Effect of Procalcitonin-guided Decision Making on Duration of Antibiotic Therapy in Suspected Neonatal Early-onset Sepsis: Multicenter Prospective Randomized Intervention Study|Unknown status|Active, not recruiting|N/A|1600|Anticipated|Luzerner Kantonsspital||2|||f||||t||||||||||2018-06-01 01:14:57.24337|2018-06-01 01:14:57.24337
NCT00854919|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|OCDDRUG||Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder|An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder|Completed||Phase 4|||Osaka City University||3|||f||||||||||||||2018-06-01 01:14:57.333915|2018-06-01 01:14:57.333915
NCT00854906|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2010-07-07||2014-10-22|2009-03-02|2009-03-03|Estimate|2010-12-28|2011-01-25|Estimate||||2014-10-22|2014-10-23|Estimate|February 2009||2009-02-28|October 2014|2014-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time|Comparison of Keratometric Tear Break Up Time (KTBUT) to Fluorescein Tear Break Up Time (FTBUT)|Completed|||26|Actual|University of Arkansas|||2||f||||f||||||||||2018-06-01 01:14:57.420376|2018-06-01 01:14:57.420376
NCT00854893|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2017-08-02|2009-03-02|2009-03-03|Estimate|||||||2017-08-02|2017-08-03|Actual|October 2009|Actual|2009-10-31|August 2017|2017-08-31|July 1, 2010|Actual|2010-07-01|January 1, 2010|Actual|2010-01-01||Interventional|||Enhance of Language Learning With Neurostimulation|Enhance of Language Learning With Neurostimulation (Transcranial Direct Current Stimulation)|Completed||N/A|70|Actual|Universitätsklinikum Hamburg-Eppendorf||3|||f||||t||||||||||2018-06-01 01:14:57.594883|2018-06-01 01:14:57.594883
NCT00854880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Comparative Phase II Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis|Completed||Phase 2|69|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 01:14:57.664219|2018-06-01 01:14:57.664219
NCT00854867|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2014-02-21|2009-03-02|2009-03-03|Estimate|||||||2014-02-21|2014-02-24|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.|Phase I Randomised Multi-centre Study to Demonstrate the Safety of WBRT Concomitant to Intrathecal Liposomal Cytarabine (DepoCyte®) Versus WBRT & Sequential Intrathecal Liposomal Cytarabine (DepoCyte®) for Treatment of STNM With or Without Brain Metastasis.|Completed||Phase 1|18|Actual|Mundipharma Research Limited||2|||f||||t||||||||||2018-06-01 01:14:57.717986|2018-06-01 01:14:57.717986
NCT00854854|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2009-05-15|2009-03-02|2009-03-03|Estimate|||||||2009-05-15|2009-05-18|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|July 2010|Anticipated|2010-07-31|January 2010|Anticipated|2010-01-31||Interventional|||Efficacy Study of TKcell in Advanced Gastric Cancer|Evaluating the Safety and Efficacy of Combination Therapy With FOLFOX-4 and TKcell Therapy Versus FOLFOX-4 Alone in Patients With Recurrent, Unresectable and Advanced Gastric Cancer|Unknown status|Enrolling by invitation|Phase 1/Phase 2|94|Actual|Binex||2|||f||||f||||||||||2018-06-01 01:14:57.797803|2018-06-01 01:14:57.797803
NCT00854841|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate||||March 2009|2009-03-31||||||||Expanded Access|||The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder|Randomized, Open Label Study of Dasatinib (100mg qd) vs. High-Dose Imatinib (600mg) in Patients With Chronic Phase CML Who Have Had Suboptimal Response After 3-18 Months of Therapy With Imatinib (400mg)|Available|||||Pusan National University Hospital|||||f||||||||||||||2018-06-01 01:14:57.873744|2018-06-01 01:14:57.873744
NCT00854828|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2017-05-08|2009-03-02|2009-03-03|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2010|Actual|2010-04-30|May 2017|2017-05-31|February 28, 2023|Anticipated|2023-02-28|December 31, 2022|Anticipated|2022-12-31||Interventional|ASLS||A Multicenter Prospective Study of Quality of Life in Adult Scoliosis|A Multicenter Prospective Study of Quality of Life in Adult Scoliosis|Active, not recruiting||N/A|300|Anticipated|Washington University School of Medicine||2|||f||||f||||||||Undecided||2018-06-01 01:14:57.93733|2018-06-01 01:14:57.93733
NCT00854815|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2012-07-31|2009-03-02|2009-03-03|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Irrigation Versus No Irrigation for Perforated Appendicitis|Irrigation Versus No Irrigation for Perforated Appendicitis|Completed||N/A|220|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 01:14:58.04285|2018-06-01 01:14:58.04285
NCT00854802|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2016-02-12|2009-03-02|2009-03-03|Estimate|||||||2016-02-12|2016-02-17|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients|A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients|Completed||N/A|290|Actual|Debiopharm International SA||4|||f||||t||||||||||2018-06-01 01:14:58.115306|2018-06-01 01:14:58.115306
NCT00854789|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2014-06-02|2009-03-02|2009-03-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|December 2002||2002-12-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer|Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Node Negative Breast Cancer Patients|Completed||Phase 1/Phase 2|95|Actual|Walter Reed Army Medical Center||2|||f||||f||||||||||2018-06-01 01:14:58.310137|2018-06-01 01:14:58.310137
NCT00854776|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2010-06-06|2009-03-02|2009-03-03|Estimate|||||||2010-06-06|2010-06-08|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor|The Occurrence of Peptic Ulcer Disease and Its Complications in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Co-prescription of Proton Pump Inhibitor|Unknown status|Recruiting|N/A|300|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-06-01 01:14:58.410217|2018-06-01 01:14:58.410217
NCT00854763|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2009-03-01|2009-03-01|2009-03-03|Estimate|||||||2009-03-01|2009-03-03|Estimate|April 2009||2009-04-30|February 2009|2009-02-28||||||||Observational|||Olmesartan on Ambulatory Blood Pressure Change|Phase 4 Study on Olmesartan, an Angiotensin Receptor Blocker, on Ambulatory Blood Pressure Change, Vitamin D Levels and Urinary Sodium Excretion of Patients With Hypertension|Unknown status|Not yet recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 01:14:58.532006|2018-06-01 01:14:58.532006
NCT00854750|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2013-04-19|2009-03-02|2009-03-03|Estimate|||||||2013-04-19|2013-04-22|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis|Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis|Terminated||Phase 4|1|Actual|University of Texas Southwestern Medical Center||4||Poor Enrollment- schedule of assessments too complex and time-consuming.|f||||t||||||||||2018-06-01 01:14:58.652366|2018-06-01 01:14:58.652366
NCT00854737|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2012-04-19|2009-02-27|2009-03-03|Estimate|||||||2012-04-19|2012-04-20|Estimate|July 2004||2004-07-31|April 2012|2012-04-30|July 2010|Actual|2010-07-31|August 2007|Actual|2007-08-31||Interventional|||Cytidine and Omega-3 Fatty Acids in Bipolar Disorder|A Combination of Cytidine and Omega-3 Fatty Acids in Bipolar Disorder: Are There Additive or Synergistic Mood Stabilizing Effects?|Completed||Phase 2|90|Actual|Mclean Hospital||3|||f||||f||||||||||2018-06-01 01:14:58.765103|2018-06-01 01:14:58.765103
NCT00854724|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2011-07-19||2011-09-01|2009-02-27|2009-03-03|Estimate|2011-07-19|2011-08-12|Estimate||||2011-09-01|2011-09-09|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|PAD||Puerarin Effects on Alcohol Drinking|Puerarin (NPI-031G) Effects on Alcohol Drinking - A Natural Settings Study|Completed||Phase 2|16|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 01:14:58.89365|2018-06-01 01:14:58.89365
NCT00854711|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2016-07-06|2009-03-02|2009-03-03|Estimate|||||||2016-07-06|2016-07-07|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|ENAMOR||Randomized Placebo-controlled Trial of Inhaled iNO in Acute ST-segment Elevation MI Treated by Primary Angioplasty|Randomized Placebo-controlled Trial of Inhaled iNO in Acute ST-segment Elevation MI Treated by Primary Angioplasty|Completed||Phase 2|7|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||No||2018-06-01 01:14:59.21085|2018-06-01 01:14:59.21085
NCT00854698|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2014-06-20|2009-03-02|2009-03-03|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2009||2009-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Long-Term Effects of Aortic Valve Mismatch|Long-Term Effects of Aortic Valve Mismatch on Functional Ability and Remodeling the Left Ventricular After Aortic Valve Replacement Mechanics|Completed||N/A|77|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 01:14:59.330067|2018-06-01 01:14:59.330067
NCT00854685|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2010-01-04|2009-03-01|2009-03-03|Estimate|||||||2010-01-04|2010-01-06|Estimate|February 2009||2009-02-28|March 2009|2009-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate|A Factorial-design, Randomised, Double-blind, Placebo-controlled, Dose Optimisation Study to Investigate the Safety, Efficacy, Immunogenicity and Pharmacokinetics of ART621 Following Multiple Dose Administration in Subjects Diagnosed With Rheumatoid Arthritis Concomitantly Taking Methotrexate|Completed||Phase 2|27|Actual|Arana Therapeutics Ltd||6|||f||||t||||||||||2018-06-01 01:14:59.450137|2018-06-01 01:14:59.450137
NCT00854672|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2012-04-05|2009-03-02|2009-03-03|Estimate|||||||2012-04-05|2012-04-06|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|August 2009|Actual|2009-08-31||Observational|||Muscle Strength and Exercise Capacity in Sarcoidosis Patients|Exercise Capacity, Muscle Strength and Fatigue in Sarcoidosis: a Two-year Follow-up Study|Completed|||124|Actual|Maastricht University Medical Center|||1||f||||t||||||||||2018-06-01 01:14:59.634587|2018-06-01 01:14:59.634587
NCT00854659|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2010-11-01|2009-03-02|2009-03-03|Estimate|||||||2010-11-01|2010-11-02|Estimate|March 2009||2009-03-31|September 2010|2010-09-30||||June 2009|Actual|2009-06-30||Interventional|||A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of ABT-102 in Healthy Subjects|Completed||Phase 1|36|Actual|Abbott||4|||f||||f||||||||||2018-06-01 01:14:59.816952|2018-06-01 01:14:59.816952
NCT00854646|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2018-01-09|2009-03-02|2009-03-03|Estimate|||||||2018-01-09|2018-01-10|Actual|October 2008||2008-10-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)|Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS|Completed||Phase 1|22|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-06-01 01:14:59.961832|2018-06-01 01:14:59.961832
NCT00854633|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2012-03-13|2009-03-02|2009-03-03|Estimate|||||||2012-03-13|2012-03-15|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|March 2012|Anticipated|2012-03-31||Interventional|||Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants|Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|Agennix||2|||f||||t||||||||||2018-06-01 01:15:00.07391|2018-06-01 01:15:00.07391
NCT00854620|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2015-01-06||2015-05-20|2009-03-02|2009-03-03|Estimate|2015-01-06|2015-01-14|Estimate||||2015-05-20|2015-06-19|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|January 2011|Actual|2011-01-31|July 2009|Actual|2009-07-31||Interventional||All subjects enrolled were included in the analysis|Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer|A Phase 2 Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma at Stanford University|Completed||Phase 2|9|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 01:15:00.267535|2018-06-01 01:15:00.267535
NCT00854607|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2012-07-24||2015-08-04|2009-02-27|2009-03-03|Estimate|2012-07-24|2012-08-28|Estimate||||2015-08-04|2015-08-21|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Observational|||An Observational Study of Fungal Biomarkers (MK-0000-089)|A Prospective, Non-Intervention, Observational Assessment of the Correlation Between Circulating Biomarkers of Fungal Bioburden and Clinical Outcome in the Setting of Invasive Aspergillosis|Completed|||116|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||Samples With DNA|"~     Blood samples are collected for 12 weeks to evaluate levels of fungal biomarkers.~   "|||2018-06-01 01:15:00.452181|2018-06-01 01:15:00.452181
NCT00854594|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2015-06-11||2015-09-02|2009-03-02|2009-03-03|Estimate|2015-09-02|2015-10-06|Estimate||||2015-09-02|2015-10-06|Estimate|September 2010||2010-09-30|September 2015|2015-09-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|ReSPECT|For providers who completed the survey once, using demographics reported; for providers who completed the survey twice, using demographics from earlier survey completion.|Interprofessional Training to Improve Diabetes Care: The ReSPECT Trial|Interprofessional Training for Improving Diabetes Care|Completed||N/A|117|Actual|VA Office of Research and Development|IRB-related delays were so significant that aspects of the research plan could not be completed. Delays have also been experienced in the collection and analysis of clinical endpoints.|2|||f||||f||||||||||2018-06-01 01:15:00.967239|2018-06-01 01:15:00.967239
NCT00854581|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-28|2014-12-22||2018-03-19|2009-02-28|2009-03-03|Estimate|2014-12-22|2015-01-06|Estimate||||2018-03-19|2018-04-17|Actual|November 2007||2007-11-30|December 2017|2017-12-31|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma|Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b|Terminated||Phase 4|13|Actual|University of Miami||4||Investigator Decision|f||||t||||||||||2018-06-01 01:15:01.928376|2018-06-01 01:15:01.928376
NCT00854568|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2014-08-19|2009-03-02|2009-03-03|Estimate|||||||2014-08-19|2014-08-20|Estimate|March 2009||2009-03-31|August 2014|2014-08-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL|A Randomized Phase III Study Comparing CHOP Versus CEOP-induced Cardiotoxicity in Patients With Aggressive B-cell Lymphoma|Completed||Phase 3|398|Actual|Fudan University||2|||f||||f||||||||||2018-06-01 01:15:03.266215|2018-06-01 01:15:03.266215
NCT00854555|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2018-05-15|2009-03-01|2009-03-03|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2008||2008-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ATLET||The ATLET Study: Can Subjects With Incomplete Spinal Cord Injury Learn to Walk?|The ATLET Study: Can Subjects With Incomplete Spinal Cord Injury Learn to Walk? A Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|North Norway Rehabilitation Center||2|||f||||f||||||||||2018-06-01 01:15:03.422115|2018-06-01 01:15:03.422115
NCT00854542|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-11-30|2009-03-02|2009-03-03|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|January 2014|Actual|2014-01-31||Interventional|||Effectiveness of Telepsychiatry-based Culturally Sensitive Collaborative Treatment of Depressed Chinese Americans|Effectiveness of Telepsychiatry-based Culturally Sensitive Collaborative Treatment of Depressed Chinese Americans|Completed||N/A|241|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 01:15:03.679713|2018-06-01 01:15:03.679713
NCT00854529|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|April 2009||2009-04-30|February 2009|2009-02-28|October 2011|Anticipated|2011-10-31|April 2011|Anticipated|2011-04-30||Interventional|||Subconjunctival Bevacizumab Effect on Bleb Vascularity|Subconjunctival Bevacizumab Injection for the Prevention of Bleb Vascularization Post Trabeculectomy|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Rabin Medical Center||3|||f||||t||||||||||2018-06-01 01:15:03.937374|2018-06-01 01:15:03.937374
NCT00854516|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2012-01-20|2009-03-02|2009-03-03|Estimate|||||||2012-01-20|2012-01-23|Estimate|February 2009||2009-02-28|October 2010|2010-10-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Open Label Clinical Study to Assess the Clinical Safety of a New Compression Device in Subjects With Peripheral Arterial Vascular Disease|Open Label Clinical Study to Assess the Clinical Safety of a New Compression Procedure in Subjects With Peripheral Arterial Vascular Disease|Completed||N/A|15|Actual|3M|||||f||||t||||||||||2018-06-01 01:15:04.146175|2018-06-01 01:15:04.146175
NCT00854503|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2011-05-11|2009-03-02|2009-03-03|Estimate|||||||2011-05-11|2011-05-12|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients||Completed||Phase 3|30|Actual|University of Rome Tor Vergata||2|||f||||||||||||||2018-06-01 01:15:04.246625|2018-06-01 01:15:04.246625
NCT00854490|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-09-18|2009-03-02|2009-03-03|Estimate|||||||2009-09-18|2009-09-21|Estimate|October 2009||2009-10-31|September 2009|2009-09-30||||||||Observational|||Follow-up Study of Small-intestinal Mucosal Injuries in Chronic Non-steroidal Anti-inflammatory Drugs (NSAIDs)-Users||Unknown status|Not yet recruiting||100|Anticipated|Nagoya University|||||f||||||||||||||2018-06-01 01:15:04.354549|2018-06-01 01:15:04.354549
NCT00854477|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2013-02-15|2009-02-27|2009-03-03|Estimate|||||||2013-02-15|2013-02-18|Estimate|November 2009||2009-11-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma|A Pharmacokinetic Study of Adjuvant Capecitabine in Patients Who Have Undergone Proximal Pancreatico-duodenectomy for Resection of Pancreatic Adenocarcinoma|Completed||Phase 4|13|Actual|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-06-01 01:15:04.448004|2018-06-01 01:15:04.448004
NCT00854464|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|August 2008||2008-08-31|March 2009|2009-03-31||||July 2011|Anticipated|2011-07-31||Observational|||Arsenic Methylation Enzymes, Cigarette Metabolites, DNA Repair Enzymes, Inflammatory Factors and Urothelial Carcinoma|Arsenic Methylation, Cigarette Smoking Exposure, Individual DNA Susceptibility Factors and Urothelial Carcinoma|Unknown status|Recruiting||420|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:15:04.53487|2018-06-01 01:15:04.53487
NCT00854451|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-03-01|2009-03-01|2009-03-03|Estimate|||||||2009-03-01|2009-03-03|Estimate|August 1996||1996-08-31|July 1996|1996-07-31|February 1998|Actual|1998-02-28|December 1997|Actual|1997-12-31||Interventional|||Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection|Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study|Completed||Phase 4|128|Actual|National Taiwan University Hospital||4|||f||||f||||||||||2018-06-01 01:15:04.721311|2018-06-01 01:15:04.721311
NCT00854438|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2015-06-18|2009-03-02|2009-03-03|Estimate|||||||2015-06-18|2015-06-19|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|PRADA||Reduction of Adverse Events of Anticholinergic Drugs by Multidisciplinary Medical Reviews in Norwegian Nursing Homes|Pharmacist-initiated Reduction of Anticholinergic Drug Activity|Completed||N/A|87|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:15:04.84843|2018-06-01 01:15:04.84843
NCT00854425|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2012-02-16|2009-03-02|2009-03-03|Estimate|||||||2012-02-16|2012-02-20|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma|Phase II Study of L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma|Completed||Phase 2|40|Actual|Fudan University||1|||f||||f||||||||||2018-06-01 01:15:04.994396|2018-06-01 01:15:04.994396
NCT00854412|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|March 1995||1995-03-31|March 2009|2009-03-31|June 1995|Actual|1995-06-30|June 1995|Actual|1995-06-30||Interventional|WLMBL||The Effect of Weight Loss on Serum Mannose-Binding Lectin(MBL) Levels|The Effect of Weight Loss on Serum Mannose-Binding Lectin (MBL) Levels|Completed||N/A|36|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 01:15:05.182411|2018-06-01 01:15:05.182411
NCT00854399|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|December 2011|Anticipated|2011-12-31|January 2006|Anticipated|2006-01-31||Interventional|||Screening and Identification of Ovarian Cancers|Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Ovarian Cancers|Unknown status|Recruiting|N/A|250|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:15:05.293159|2018-06-01 01:15:05.293159
NCT00854386|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-10-14|2009-03-02|2009-03-03|Estimate|||||||2009-10-14|2009-10-15|Estimate|May 2009||2009-05-31|October 2009|2009-10-31|September 2011|Anticipated|2011-09-30|May 2011|Anticipated|2011-05-31||Interventional|||Effect of Intraoperative Fluid Restriction on Postoperative Outcomes in Video-assisted Thoracic Surgery (VATS)|The Effect of Intraoperative Fluid Restriction on Postoperative Outcomes in Video-assisted Thoracic Surgery (VATS) for Lung Resection|Unknown status|Recruiting|N/A|200|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-06-01 01:15:05.454965|2018-06-01 01:15:05.454965
NCT00854373|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2013-05-29||2013-08-01|2009-03-02|2009-03-03|Estimate|2013-08-01|2013-08-05|Estimate||||2013-08-01|2013-08-05|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial|Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial|Completed||Phase 4|232|Actual|University of California, San Francisco|This study was powered to detect difference in fertilization instead of pregnancy outcomes, because the number of patients required to detect a 10% absolute difference in pregnancy rates was too large to be completed at our center (n=387 per group).|2|||f||||t||||||||||2018-06-01 01:15:05.674441|2018-06-01 01:15:05.674441
NCT00854360|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|2012-04-23|2011-08-25|2012-04-23|2009-03-02|2009-03-03|Estimate|2012-04-23|2012-05-22|Estimate|2011-08-25|2011-08-29|Estimate|2012-04-23|2012-05-22|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Range-Finding Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Adult and Adolescent Patients (12 Years and Older) With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|487|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-06-01 01:15:06.222182|2018-06-01 01:15:06.222182
NCT00854347|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|November 2005||2005-11-30|November 2008|2008-11-30|February 2007|Actual|2007-02-28|August 2006|Actual|2006-08-31||Observational|||Hyperglycemia in the Intensive Care Unit, a Prevalence Study|Hyperglycemia in the Intensive Care Unit Marker of Diabetes or Pre-Diabetes ?|Completed|||100|Actual|Université de Montréal|||||f||||f||||||||||2018-06-01 01:15:07.344996|2018-06-01 01:15:07.344996
NCT00854334|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2018-03-07|2009-03-02|2009-03-03|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2010||2010-09-30|March 2018|2018-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|||Co-existent Obstructive Sleep Apnea (OSA) and Obesity: Finding Non-exercise Activity Thermogenesis (NEAT) Targets for Intervention|Co-existent OSA and Obesity: Finding NEAT Targets for Intervention|Completed|||9|Actual|Katz, Sherri Lynne, M.D.|||2||f||||f||||||Samples Without DNA|"~     urine~   "|||2018-06-01 01:15:07.412389|2018-06-01 01:15:07.412389
NCT00854321|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|November 2004||2004-11-30|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|KuoRituxi1||Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital|One Centre Follow-up Study on Safety and Efficacy|Completed|||49|Actual|Kuopio University Hospital|||1||f||||f||||||||||2018-06-01 01:15:07.480877|2018-06-01 01:15:07.480877
NCT00854308|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2011-09-09||2017-03-02|2009-02-27|2009-03-03|Estimate|2011-09-09|2011-10-18|Estimate||||2017-03-02|2017-03-31|Actual|April 2009||2009-04-30|November 2012|2012-11-30|January 2012|Actual|2012-01-31|November 2010|Actual|2010-11-30||Interventional|||A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)|A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Activity of MetMAb, a Monovalent Antagonist Antibody to the Receptor Met, Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)|Completed||Phase 2|137|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 01:15:07.581006|2018-06-01 01:15:07.581006
NCT00854295|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2017-07-05|2009-02-27|2009-03-03|Estimate|||||||2017-07-05|2017-07-11|Actual|April 2009|Actual|2009-04-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee|Prospective Multicenter Post Approval Study of the LPS-Flex Mobile Bearing Knee|Active, not recruiting||N/A|400|Anticipated|Zimmer Biomet||2|||f||||f||t|f|f||||||2018-06-01 01:15:08.255683|2018-06-01 01:15:08.255683
NCT00854282|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|December 2012|Anticipated|2012-12-31|January 2009|Anticipated|2009-01-31||Interventional|Tregs||The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between Clinical Prognosis and Regulatory T Cell Expression|The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between|Unknown status|Recruiting|N/A|50|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:15:08.343104|2018-06-01 01:15:08.343104
NCT00854269|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2009-03-22|2009-03-02|2009-03-03|Estimate|||||||2009-03-22|2009-03-24|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|January 2011|Anticipated|2011-01-31|May 2008|Anticipated|2008-05-31||Interventional|||Screening and Identification of Biomarkers on Cervical Cancers|Screening and Identification of Novel Diagnostic and Prognosis Biomarkers on Cervical Cancers|Unknown status|Recruiting|N/A|250|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:15:08.428901|2018-06-01 01:15:08.428901
NCT00854256|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2013-04-12|2009-03-02|2009-03-03|Estimate|||||||2013-04-12|2013-04-15|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Trabeculectomy Versus Canaloplasty to Treat Glaucoma|Comparison of Canaloplasty and Trabeculectomy in Patients With Open Angle Glaucoma and Inadequate Local Eye Pressure Lowering Therapy - a Prospective, Randomized Study|Unknown status|Recruiting|N/A|60|Anticipated|University of Cologne||2|||f||||f||||||||||2018-06-01 01:15:08.484312|2018-06-01 01:15:08.484312
NCT00854243|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|April 2009||2009-04-30|March 2009|2009-03-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Observational|||Role of Greyscale and Power Doppler Sonography in Therapy Monitoring in Early Rheumatoid Arthritis (RA)|Therapy Monitoring in Early Rheumatoid Arthritis: The Role of Greyscale and Power Doppler Sonography A Prospective Study Of 20 Egyptian Rheumatoid Arthritis Patients|Unknown status|Not yet recruiting||20|Anticipated|Cairo University|||||f||||f||||||||||2018-06-01 01:15:08.558049|2018-06-01 01:15:08.558049
NCT00854230|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2012-03-27|2009-03-02|2009-03-03|Estimate|||||||2012-03-27|2012-03-28|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Pharmacotherapy for HIV Infected Patients With Alcohol Problems|Pharmacotherapy for HIV Infected Patients With Alcohol Problems|Withdrawn||Phase 4|0|Actual|VA Connecticut Healthcare System||2||We expanded to a bigger, multi-site study & decided to close this study.|f||||t||||||||||2018-06-01 01:15:08.606669|2018-06-01 01:15:08.606669
NCT00854217|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2011-03-02|2009-03-02|2009-03-03|Estimate|||||||2011-03-02|2011-03-03|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery||Completed||N/A|40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||||||||||||2018-06-01 01:15:08.674794|2018-06-01 01:15:08.674794
NCT00849628|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2016-07-18|2009-02-23|2009-02-24|Estimate|||||||2016-07-18|2016-07-19|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|||Use of Drugs and Constipation in Nursing Homes|Use of Drugs and Constipation in Nursing Homes|Completed|||267|Actual|Norwegian University of Science and Technology|||1||f||||f||||||||||2018-06-01 01:16:44.93132|2018-06-01 01:16:44.93132
NCT00854204|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2010-04-26|2009-02-27|2009-03-03|Estimate|||||||2010-04-26|2010-04-28|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629|Phase I, Open-label, 3-way Crossover Trial in Healthy Male Volunteers to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629|Completed||Phase 1|12|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:15:08.728976|2018-06-01 01:15:08.728976
NCT00854191|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|July 2007||2007-07-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Simulator Practice on Trainees' Endoscopic Retrograde Cholangiopancreatography (ERCP) Performance in the Early Learning Period|A RCT of Mechanical Simulator Practice and Usual Training vs. Usual Training on Novice Trainee Clinical ERCP Performance|Completed||N/A|8|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:15:08.784143|2018-06-01 01:15:08.784143
NCT00854178|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-02|||2010-01-05|2009-03-02|2009-03-03|Estimate|||||||2010-01-05|2010-01-06|Estimate|March 2008||2008-03-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Toxicogenomic and Immunocytotoxic Effects of Propofol and Isoflurane Anesthetics in Patients Undergoing Elective Surgery|Toxicogenomic and Immunocytotoxic Effects of Propofol and Isoflurane Anesthetics in Patients Undergoing Elective Surgery|Completed||Phase 4|26|Anticipated|UPECLIN HC FM Botucatu Unesp||1|||f||||f||||||||||2018-06-01 01:15:08.859081|2018-06-01 01:15:08.859081
NCT00854165|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-01|||2009-03-02|2009-03-02|2009-03-03|Estimate|||||||2009-03-02|2009-03-03|Estimate|February 2009||2009-02-28|March 2009|2009-03-31|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Observational|||Lung Transplantation in Respiratory Failure Patients|Extracorporeal Membrane Oxygenation Support for Bilateral Sequential Lung Transplantation in Respiratory Failure Patients.|Unknown status|Active, not recruiting||10|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:15:08.925061|2018-06-01 01:15:08.925061
NCT00854152|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-11-01|2009-02-27|2009-03-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma|An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma|Completed||Phase 1|121|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:15:08.988805|2018-06-01 01:15:08.988805
NCT00854139|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2018-03-14|2009-03-02|2009-03-03|Estimate|||||||2018-03-14|2018-03-15|Actual|August 2001||2001-08-31|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)|Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure|Completed||Phase 1|10|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 01:15:09.060784|2018-06-01 01:15:09.060784
NCT00854126|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-11-01|2009-02-27|2009-03-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma|An Open-label, Phase I, Dose-escalation Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors and Non-hodgkin's Lymphoma|Completed||Phase 1|38|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:15:09.2458|2018-06-01 01:15:09.2458
NCT00854113|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2010-10-25||2011-07-18|2009-02-27|2009-03-02|Estimate|2011-07-18|2011-08-12|Estimate||||2011-07-18|2011-08-12|Estimate|February 2009||2009-02-28|July 2011|2011-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers|A Phase I , Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of EGT0001474 In Healthy Volunteers|Completed||Phase 1|78|Actual|Theracos||2|||f||||f||||||||||2018-06-01 01:15:09.382678|2018-06-01 01:15:09.382678
NCT00854100|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26||2012-02-06|2012-02-06|2009-02-26|2009-03-02|Estimate||||2012-02-06|2012-02-08|Estimate|2012-02-06|2012-02-08|Estimate|June 2009||2009-06-30|February 2012|2012-02-29||||December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder|A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder|Completed||Phase 2|232|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 01:15:11.368555|2018-06-01 01:15:11.368555
NCT00854087|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2014-05-19||2014-06-18|2009-02-27|2009-03-02|Estimate|2014-05-19|2014-06-18|Estimate||||2014-06-18|2014-06-27|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis|A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis|Completed||Phase 2|118|Actual|SCTI Research Foundation||2|||f||||t||||||||||2018-06-01 01:15:11.571923|2018-06-01 01:15:11.571923
NCT00854074|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2018-02-15|2009-02-27|2009-03-02|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2009||2009-07-31|February 2018|2018-02-28|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|||Neurostimulation for the Treatment of Post-Operative Ileus|Neurostimulation for the Treatment of Post-Operative Ileus|Withdrawn||N/A|0|Actual|ElectroCore LLC||2||Withdrawn: study halted prematurely, prior to enrollment of first participant|f||||f||||||||||2018-06-01 01:15:12.024199|2018-06-01 01:15:12.024199
NCT00854061|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26||2011-09-02|2014-04-04|2009-02-26|2009-03-02|Estimate||||2011-09-02|2011-09-12|Estimate|2014-04-04|2014-05-01|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of T-PRED(TM) Compared to Pred Forte(R) II||Completed||Phase 3|135|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 01:15:12.174428|2018-06-01 01:15:12.174428
NCT00854048|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-11-29|2009-02-27|2009-03-02|Estimate|||||||2016-11-29|2016-11-30|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||The Performance of Pulse Oximeters in Pediatric Patients With Low Oxygen Saturation Levels|The Performance of Nellcor OxiMax N-560 and Masimo SET Radical Pulse Oximeters in Pediatric Patients With Low Oxygen Saturation Levels|Completed|||66|Actual|Medtronic - MITG|||||f||||t||||||||||2018-06-01 01:15:12.241944|2018-06-01 01:15:12.241944
NCT00852891|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-02-26|2009-02-26|2009-02-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|December 2005||2005-12-31|February 2009|2009-02-28|August 2007|Actual|2007-08-31|||||Observational|||Cardiorespiratory Changes in Patients Being Weaned Off Mechanical Ventilation|Cardiorespiratory Changes in Patients Being Weaned Off Mechanical Ventilation: a Randomized Crossover Clinical Trial|Completed|||24|Actual|Hospital de Clinicas de Porto Alegre|||||f||||f||||||||||2018-06-01 01:15:53.724623|2018-06-01 01:15:53.724623
NCT00854035|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2012-06-12|2009-02-27|2009-03-02|Estimate|||||||2012-06-12|2012-06-14|Estimate|February 2009||2009-02-28|June 2012|2012-06-30||||June 2010|Actual|2010-06-30||Interventional|||MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus|A Phase III, Randomized, Placebo-Controlled, Double-Blind Clinical Trial and Subsequent Open-Label, Extension Clinical Trial to Study the Efficacy and Safety of Addition of MK-0431/ONO-5435 in Japansese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Insulin Monotherapy|Completed||Phase 3|266|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 01:15:12.294986|2018-06-01 01:15:12.294986
NCT00854022|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2010-12-02|2009-02-27|2009-03-02|Estimate|||||||2010-12-02|2010-12-06|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Observational|||Genetic Susceptibility to Kidney Cancer|Genetic Susceptibility to Renal Cell Carcinoma|Unknown status|Recruiting||1600|Anticipated|Baylor College of Medicine|||2||f||||f||||||Samples With DNA|"~     We will utilize the blood collected to run several laboratory analyses that will assess DNA~     damage/repair, telomere length, telomerase activity, and other genetic instability as~     predictors of RCC risk. All information linking this unique identifier to the participant~     will be kept in a secure location under lock-and-key password protected.~      In addition, RCC tumor and adjacent normal tissue samples may be obtained from the MDACC~     Institutional Tissue Bank (ITB) for cases only. The samples obtained will be left over from~     surgical procedures, so as to prevent any additional distress to the patient.~   "|||2018-06-01 01:15:12.376374|2018-06-01 01:15:12.376374
NCT00854009|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-10-07|2009-02-27|2009-03-02|Estimate|||||||2009-10-07|2009-10-08|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Japanese Male Subjects|Terminated||Phase 1|56|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:15:12.483107|2018-06-01 01:15:12.483107
NCT00853996|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2017-01-23||2018-01-15|2009-02-26|2009-03-02|Estimate|2017-01-23|2017-03-13|Actual||||2018-01-15|2018-01-17|Actual|February 2009||2009-02-28|January 2018|2018-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer|Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer|Completed||Phase 2|25|Actual|University of Kansas Medical Center||1|||f||||f||||||||No|Individual data will not be shared; only summary assessments.|2018-06-01 01:15:12.584968|2018-06-01 01:15:12.584968
NCT00853983|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2009-05-20|2009-02-27|2009-03-02|Estimate|||||||2009-05-20|2009-05-21|Estimate|March 2009||2009-03-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|||||Interventional|||Phase I Study to Assess Absorption, Metabolism & Excretion of a Single Oral Dose [14C]AZD0530 in Healthy Male Volunteers|An Open-Label, Phase I Study to Assess Absorption, Metabolism and Excretion of a Single Oral Dose of [14C]AZD0530 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:15:14.01733|2018-06-01 01:15:14.01733
NCT00853970|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2010-11-15|2010-11-15|2013-01-11|2009-02-27|2009-03-02|Estimate|2011-01-07|2011-01-26|Estimate|2011-01-07|2011-01-26|Estimate|2013-01-11|2013-01-25|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery||Completed||Phase 3|299|Actual|Bausch & Lomb Incorporated||2|||f||||||||||||||2018-06-01 01:15:14.114596|2018-06-01 01:15:14.114596
NCT00853957|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2010-12-06||2012-04-26|2009-02-27|2009-03-02|Estimate|2010-12-22|2011-01-21|Estimate||||2012-04-26|2012-04-30|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|AACESS||Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension|An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine (150/5 mg, 300/10 mg) Versus Amlodipine Alone (5 mg, 10 mg) in African American Patients With Stage 2 Hypertension|Completed||Phase 4|443|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:15:14.345601|2018-06-01 01:15:14.345601
NCT00853944|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2017-10-27|2009-02-27|2009-03-02|Estimate|||||||2017-10-27|2017-10-30|Actual|July 2009||2009-07-31|October 2017|2017-10-31|November 1, 2013|Actual|2013-11-01|November 1, 2013|Actual|2013-11-01||Interventional|||Effect of Sitagliptin on Graft Function Following Islet Transplantation|A Randomized Controlled Trial to Determine if Sitagliptin Will Enhance Islet Graft Function When Given for 1 Year Following Transplantation|Terminated||Phase 3|12|Anticipated|University of British Columbia||2||"Sponsor withdrew funding du to lack of enrollment. Lack of enrollment was due to decrease in~   number of islet transplant procedures"|f||||f||||||||||2018-06-01 01:15:14.871076|2018-06-01 01:15:14.871076
NCT00853931|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-11-27|2009-02-27|2009-03-02|Estimate|||||||2015-11-27|2015-12-02|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Biomarker - Panitumumab Response With KRAS Wild Type MCC|An Exploratory Trial of Biomarkers for Panitumumab Response Among Previously Treated Patients With KRAS Wild Type Metastatic Colorectal Cancer.|Completed||N/A|52|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-06-01 01:15:14.953581|2018-06-01 01:15:14.953581
NCT00853918|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2017-10-04|2009-02-27|2009-03-02|Estimate|||||||2017-10-04|2017-10-06|Actual|June 1, 2009|Actual|2009-06-01|October 2017|2017-10-31|December 1, 2010|Actual|2010-12-01|June 1, 2010|Actual|2010-06-01||Interventional|||Clinical Practice Intensity: Comparing Veterans Affairs (VA) to Private Sector Physicians|Clinical Practice Intensity: Comparing VA to Private Sector Providers|Completed||N/A|1000|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 01:15:15.052503|2018-06-01 01:15:15.052503
NCT00853905|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2015-02-12||2016-11-20|2009-02-27|2009-03-02|Estimate|2016-03-02|2016-03-21|Estimate||||2016-11-20|2017-01-10|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?|The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery|Completed||Phase 2/Phase 3|77|Actual|Wills Eye||2|||f||||f||||||||No||2018-06-01 01:15:15.207472|2018-06-01 01:15:15.207472
NCT00853892|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-09-08|2009-02-27|2009-03-02|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Controlled-Release Test Tablet Formulation of Oxycodone Hydrochloride (40 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (OxyContin® 40 mg, Purdue Pharma L.P.) in Normal Human Subjects Under Fasting Conditions|Completed||Phase 1|34|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:15.668356|2018-06-01 01:15:15.668356
NCT00853879|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-05-13|2009-02-27|2009-03-02|Estimate|||||||2015-05-13|2015-05-15|Estimate|December 2006||2006-12-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease|An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease|Terminated||N/A|150|Actual|Northwell Health||3|||f||||f||||||||||2018-06-01 01:15:15.739204|2018-06-01 01:15:15.739204
NCT00853866|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2017-08-02|2009-02-27|2009-03-02|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2009||2009-01-31|August 2017|2017-08-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|STIMBOX||Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation|Entwicklung Neuronaler Repräsentationen Nach Schlaganfall: Verbesserung Motorischer Leistungen Durch Transkranielle Gleichstromstimulation Und Noradrenerge Co-Stimulation|Completed||Phase 4|12|Actual|Universitätsklinikum Hamburg-Eppendorf||4|||f||||t||||||||||2018-06-01 01:15:15.839396|2018-06-01 01:15:15.839396
NCT00853853|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2012-11-19|2009-02-27|2009-03-02|Estimate|||||||2012-11-19|2012-11-20|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||EnSeal Device Versus Ferguson Technique in Hemorrhoidectomy|Randomized Trial Comparing Standard Ferguson Technique With the EnSeal Device During Hemorrhoidectomy|Unknown status|Active, not recruiting|N/A|100|Anticipated|The Miriam Hospital||2|||f||||t||||||||||2018-06-01 01:15:15.952429|2018-06-01 01:15:15.952429
NCT00853840|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2009-05-05||2013-01-16|2009-02-27|2009-03-02|Estimate|2009-05-05|2009-06-23|Estimate||||2013-01-16|2013-01-25|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc|A Randomized, Single-Blinded, Placebo-Controlled Two-Way Crossover Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc|Completed||Phase 4|18|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-06-01 01:15:16.077195|2018-06-01 01:15:16.077195
NCT00853827|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2014-01-23||2014-05-20|2009-02-27|2009-03-02|Estimate|2014-04-07|2014-05-07|Estimate||||2014-05-20|2014-06-03|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|AQUARIUS|Randomized - All patients who received a randomization number, regardless of whether or not the patient received the trial medication|Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients|A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy|Completed||Phase 3|613|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:15:16.862187|2018-06-01 01:15:16.862187
NCT00853814|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-02-27|2009-02-27|2009-03-02|Estimate|||||||2009-02-27|2009-03-02|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Increasing Youth Physical Activity: Neighborhood Environment Influences|Increasing Youth Physical Activity: Neighborhood Environment Influences|Unknown status|Recruiting|N/A|100|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||4|||f||||f||||||||||2018-06-01 01:15:17.779089|2018-06-01 01:15:17.779089
NCT00853801|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2014-09-30|2009-02-27|2009-03-02|Estimate|||||||2014-09-30|2014-10-02|Estimate|February 2006||2006-02-28|September 2014|2014-09-30|December 2010|Actual|2010-12-31|November 2007|Actual|2007-11-30||Interventional|||Integrating Lifestyle Therapy for Diabetes Prevention Into Primary Care|Detecting and Managing Metabolic Syndrome and Pre-Diabetes in General Medicine Clinic (Feasibility)|Completed||N/A|112|Anticipated|John H. Stroger Hospital||1|||f||||t||||||||||2018-06-01 01:15:18.000928|2018-06-01 01:15:18.000928
NCT00853788|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2012-02-15|2009-02-27|2009-03-02|Estimate|||||||2012-02-15|2012-02-17|Estimate|November 2008||2008-11-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil|Genomic and Histological Analysis of Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil|Completed|||40|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||Samples Without DNA|"~     skin biopsy samples~   "|||2018-06-01 01:15:18.109719|2018-06-01 01:15:18.109719
NCT00853775|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2017-05-25|2009-02-27|2009-03-02|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2009||2009-02-28|May 2017|2017-05-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Observational|||Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups|Regulation of Lipoprotein(a) Metabolism in Humans With Reference to Ethnicity|Completed|||325|Actual|University of California, Davis|||2||f||||t||||||Samples With DNA|"~     plasma, DNA, white blood cell~   "|||2018-06-01 01:15:18.218408|2018-06-01 01:15:18.218408
NCT00853762|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2016-04-15||2017-02-12|2009-02-27|2009-03-02|Estimate|2016-04-15|2016-05-24|Estimate||||2017-02-12|2017-03-20|Actual|March 2009||2009-03-31|February 2017|2017-02-28|February 2011|Actual|2011-02-28|September 2009|Actual|2009-09-30||Interventional|ATAMS ext|Intent-to-treat (ITT) population included all randomized subjects.|Atacicept in Multiple Sclerosis Extension Study, Phase II|An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)|Terminated||Phase 2|74|Actual|EMD Serono|Sponsor voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS.|4||"EMD Serono voluntarily decided to terminate this trial after observing increased MS disease~   activity in trial 28063 ATAMS [Please refer to ATAMS]"|f||||t||||||||||2018-06-01 01:15:18.328946|2018-06-01 01:15:18.328946
NCT00853749|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2010-12-16||2010-12-16|2009-02-27|2009-03-02|Estimate|2010-12-16|2011-01-05|Estimate||||2010-12-16|2011-01-05|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|REPLAY||Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine|Revaccination With Pneumococcal Conjugate Vaccine - Characterization Of The Immune Response After Polysaccharide|Completed||Phase 3|89|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|In protocol, primary analysis based on All Available Immunogenicity Population and later modified to Evaluable Immunogenicity Population in Statistical Analysis Plan based on subsequent similar studies and suitability for primary objective.|1|||f||||f||||||||||2018-06-01 01:15:19.443084|2018-06-01 01:15:19.443084
NCT00853736|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-18|2009-02-27|2009-03-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|February 2003||2003-02-28|October 2016|2016-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Fed Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (30 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Roxicodone™, 30 mg Tablet, Roxane Laboratories, Inc.) in Normal Human Subjects Under Fed Conditions|Completed||Phase 1|23|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:20.208165|2018-06-01 01:15:20.208165
NCT00853723|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2015-07-15||2016-02-24|2009-02-27|2009-03-02|Estimate|2016-01-27|2016-02-24|Estimate||||2016-02-24|2016-03-24|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional||Postmenopausal women age 45-75 with osteoporosis or low bone density|Comparison Study of PTHrP and PTH to Treat Osteoporosis|Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis|Completed||Phase 2|105|Actual|University of Pittsburgh|This study was not double-blinded. There was no placebo group in this study. Subjects had higher than anticipated calcium intake and baseline vitamin D levels.|3|||f||||t||||||||No||2018-06-01 01:15:20.304246|2018-06-01 01:15:20.304246
NCT00853710|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2017-08-25|2009-02-27|2009-03-02|Estimate|||||||2017-08-25|2017-08-28|Actual|March 2009||2009-03-31|August 2017|2017-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Test Semiquantitative Prostate Specific Antigen (PSA)|Validation of a Semiquantitative Screening Assay for PSA|Completed||N/A|94|Actual|Institut Curie||1|||f||||f||||||||||2018-06-01 01:15:21.097377|2018-06-01 01:15:21.097377
NCT00853697|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-10-28|2009-02-26|2009-03-02|Estimate|||||||2015-10-28|2015-10-30|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer|Phase II Trial of Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer|Completed||Phase 2|6|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:15:21.188293|2018-06-01 01:15:21.188293
NCT00853684|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-09-17|2009-02-27|2009-03-02|Estimate|||||||2009-09-17|2009-09-18|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|OXCE||Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer|Phase II Study of Oxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer|Unknown status|Recruiting|Phase 2|44|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||||2018-06-01 01:15:21.292238|2018-06-01 01:15:21.292238
NCT00853671|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2010-04-30|2009-02-27|2009-03-02|Estimate|||||||2010-04-30|2010-05-04|Estimate|April 2008||2008-04-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Myocardial Stress Perfusion Imaging With Dual Source CT|Myocardial Stress Perfusion Imaging With Dual Source CT|Unknown status|Recruiting|N/A|60|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 01:15:21.375353|2018-06-01 01:15:21.375353
NCT00853658|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2016-10-03||2016-10-03|2009-02-27|2009-03-02|Estimate|2016-10-03|2016-11-25|Estimate||||2016-10-03|2016-11-25|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ATMOSPHERE|Full Analysis Set (FAS) - included all randomized patients but excluded 48 patients (22 mis-randomized but took no double blind and 26 patients due to GCP violations)|Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II - IV). The Study is Also Known as Aliskiren Trial of Minimizing OutcomeS in Patients With HEart Failure (ATMOSPHERE).|Completed||Phase 3|7064|Actual|Novartis||3|||f||||t||||||||||2018-06-01 01:15:21.691164|2018-06-01 01:15:21.691164
NCT00853645|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2017-02-14|2009-02-27|2009-03-02|Estimate|||||||2017-02-14|2017-02-16|Actual|July 2008||2008-07-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Chronic II||Initial Chronic Human Validation Study: Subcutaneous Implantable (S-ICD) System|Initial Chronic Human Validation Study: Subcutaneous Implantable (S-ICD) System|Completed||N/A|6|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 01:15:28.700899|2018-06-01 01:15:28.700899
NCT00853632|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2017-07-21|2009-02-27|2009-03-02|Estimate|||||||2017-07-21|2017-07-25|Actual|August 2007||2007-08-31|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol|Carpentier-Edwards® Perimount Magna® Mitral Pericardial Bioprostheses Models 7000/7000 TFX and Carpentier-Edwards® Perimount Magna® Mitral Ease™ Pericardial Bioprostheses Models 7200TFX and 7300/7300TFX|Active, not recruiting||N/A|250|Anticipated|Edwards Lifesciences||1|||f||||f||||||||||2018-06-01 01:15:28.772786|2018-06-01 01:15:28.772786
NCT00853619|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2012-02-27|2009-02-26|2009-03-02|Estimate|||||||2012-02-27|2012-02-29|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|CDSC||Clinical Decision Support Consortium|Clinical Decision Support Consortium for AHRQ CDS Research|Unknown status|Enrolling by invitation|N/A|70|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:15:28.878378|2018-06-01 01:15:28.878378
NCT00853606|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2012-05-25|2011-06-06|2012-08-10|2009-02-27|2009-03-02|Estimate|2012-05-25|2012-06-28|Estimate|2011-06-06|2011-06-21|Estimate|2012-08-10|2012-08-17|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction|An Open-Label, Long-Term Evaluation of the Safety and Efficacy of Avanafil in Men With Erectile Dysfunction|Completed||Phase 3|712|Actual|VIVUS, Inc.||1|||f||||f||||||||||2018-06-01 01:15:28.974767|2018-06-01 01:15:28.974767
NCT00853593|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2011-08-25|2010-05-27|2012-02-01|2009-02-27|2009-03-02|Estimate|2011-10-27|2011-12-05|Estimate|2010-05-27|2010-06-02|Estimate|2012-02-01|2012-02-03|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|August 2010|Actual|2010-08-31|July 2009|Actual|2009-07-31||Interventional|4396||Model 4396 Left Ventricular (LV) Lead Study|Model 4396 Left Ventricular Lead Study|Completed||Phase 3|197|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-06-01 01:15:29.248512|2018-06-01 01:15:29.248512
NCT00853580|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2017-09-15||2018-03-08|2009-02-27|2009-03-02|Estimate|2018-03-08|2018-03-12|Actual||||2018-03-08|2018-03-12|Actual|July 2009||2009-07-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|May 2014|Actual|2014-05-31||Interventional|STARS|Primary analyses of efficacy and safety were performed on the baseline to post-treatment data using the modified intention-to-treat population (defined as all subjects that had baseline data). Two participants from the placebo condition were excluded due to failure to complete baseline assessment.|A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1|A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1|Completed||Phase 2|146|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 01:15:30.061416|2018-06-01 01:15:30.061416
NCT00853398|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2014-05-22|2009-02-27|2009-03-02|Estimate|||||||2014-05-22|2014-05-23|Estimate|October 2004||2004-10-31|May 2014|2014-05-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|MIS GEN II||MINIMALLY INVASIVE SURGERY in Total Knee Arthroplasty|A Prospective (Non)-Randomized Controlled Multicenter Clinical Study Of the Genesis ii Total Knee System in Minimally Invasive Total Knee Arthroplasty|Terminated||Phase 4|||Smith & Nephew, Inc.||2||"The results obtained 1 year after surgery were clearly indicative of the outcome and the~   investigators decided to terminate follow-up at that point."|f||||||||||||||2018-06-01 01:15:32.735399|2018-06-01 01:15:32.735399
NCT00853567|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2014-06-25||2014-08-05|2009-02-27|2009-03-02|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated|Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids|A Phase III, Three-Arm, Parallel Design, Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids|Terminated||Phase 3|71|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2018-06-01 01:15:30.772034|2018-06-01 01:15:30.772034
NCT00853554|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-18|2009-02-26|2009-03-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2002||2002-12-31|October 2016|2016-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Hydromorphone Hydrochloride (8 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (DILAUDID®, 8 mg Tablet, Knoll Pharmaceutical Company) in Normal Human Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:31.349177|2018-06-01 01:15:31.349177
NCT00853541|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-09-22|2009-02-26|2009-03-02|Estimate|||||||2015-09-22|2015-09-24|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|October 2011|Anticipated|2011-10-31|October 2010|Anticipated|2010-10-31||Observational|CAPRICORN||Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study|Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study|Withdrawn|||0|Actual|Massachusetts General Hospital|||1|No patients enrolled.|f||||f||||||Samples Without DNA|"~     blood samples are taken~   "|||2018-06-01 01:15:31.42841|2018-06-01 01:15:31.42841
NCT00853528|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2017-07-17|2009-02-27|2009-03-02|Estimate|||||||2017-07-17|2017-07-19|Actual|January 2009|Actual|2009-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2013|Actual|2013-06-30||Interventional|||Stereotactic Radiosurgery in Treating Patients With Spinal Metastases|Cyberknife Radiosurgery for Improving Palliation of Metastatic Tumors of the Spine|Completed||Phase 1|18|Actual|Boston Medical Center||6|||f||||t|f|t|f|||||No|There is no plan to share individual participant data.|2018-06-01 01:15:31.546966|2018-06-01 01:15:31.546966
NCT00853515|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-12-08|2009-02-27|2009-03-02|Estimate|||||||2016-12-08|2016-12-09|Estimate|March 2009||2009-03-31|December 2016|2016-12-31|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Goal-directed Fluid Resuscitation in Acute Pancreatitis|A Randomized-controlled Trial of a Targeted Approach to Fluid Resuscitation in Acute Pancreatitis|Terminated||N/A|40|Actual|Brigham and Women's Hospital||4||"interim analysis incidence primary endpoint lower than anticipated. Sigicant finding based on~   secondary endpoint."|f||||t||||||||||2018-06-01 01:15:31.650543|2018-06-01 01:15:31.650543
NCT00853502|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-26|2009-02-26|2009-03-02|Estimate|||||||2016-10-26|2016-10-28|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa|The Effect of Testosterone Replacement on Bone Mineral Density and Bone Microarchitecture in Teenage Boys and Young Adult Men With Anorexia Nervosa|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||2||No recruitment|f||||t||||||||||2018-06-01 01:15:31.720365|2018-06-01 01:15:31.720365
NCT00853489|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2018-02-14||2018-03-13|2009-02-27|2009-03-02|Estimate|2018-02-14|2018-03-13|Actual||||2018-03-13|2018-04-10|Actual|August 2011||2011-08-31|March 2018|2018-03-31|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Interventional|||rhBMP-2 Versus Autograft in Critical Size Tibial Defects|RhBMP-2 vs. Autograft for Critical Size Tibial Defects: A Multicenter Randomized Trial|Terminated||Phase 4|33|Actual|St. Louis University||2||Enrollment too slow|f||||t||||||||||2018-06-01 01:15:31.829408|2018-06-01 01:15:31.829408
NCT00853476|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2011-02-16|2009-02-27|2009-03-02|Estimate|||||||2011-02-16|2011-02-18|Estimate|March 2009||2009-03-31|February 2011|2011-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test|The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test|Completed|||25|Actual|Chulalongkorn University|||||f||||f||||||||||2018-06-01 01:15:32.292645|2018-06-01 01:15:32.292645
NCT00853463|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2011-05-31|2009-02-27|2009-03-02|Estimate|||||||2011-05-31|2011-06-01|Estimate|April 2009||2009-04-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|March 2010|Actual|2010-03-31||Interventional|Discharge||Discharge ALERT: Quality Improvement Initiative|Multi-centered Discharge Alert to Prevent DVT and PE at Hospital Discharge|Completed||N/A|2515|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:15:32.360423|2018-06-01 01:15:32.360423
NCT00853450|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2009-08-18|2009-02-27|2009-03-02|Estimate|||||||2009-08-18|2009-08-19|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|July 2009|Actual|2009-07-31|||||Interventional|||Bleeding Time Study With AZD6482, Clopidogrel and ASA|A Randomised, Open-label, Single-Centre, Phase I, Crossover Study to Evaluate the Effect of AZD6482, Compared With Clopidogrel, on Bleeding Time in Healthy Volunteers Receiving Low-Dose ASA|Completed||Phase 1|28|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:15:32.463916|2018-06-01 01:15:32.463916
NCT00853437|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-05-25|2009-02-27|2009-03-02|Estimate|||||||2016-05-25|2016-05-27|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|GCH||Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Pediatric Patients|Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Pediatric Patients|Completed|||7|Actual|Transonic Systems Inc.|||||f||||f||||||||||2018-06-01 01:15:32.556185|2018-06-01 01:15:32.556185
NCT00853424|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2014-03-14|2009-02-27|2009-03-02|Estimate|||||||2014-03-14|2014-03-17|Estimate|December 2009||2009-12-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease|A Comparison of Islet Cell Transplantation With Medical Therapy on the Risk of Progression of Diabetic Retinopathy and Diabetic Macular Edema|Withdrawn||Phase 3|0|Actual|University of British Columbia||2||"We were unable to enroll any subjects in this study due to lack of interest."|f||||f||||||||||2018-06-01 01:15:32.617203|2018-06-01 01:15:32.617203
NCT00853411|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-03-21|2009-02-27|2009-03-02|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Asthma Exacerbation Study|Th2 Effects on Eicosanoid Pathways: Implications for Altered Innate Responses in Asthma|Withdrawn||N/A|0|Actual|University of Pittsburgh||||Terminated by Investigator due to lack of eligible subjects.|f||||||||||||||2018-06-01 01:15:32.684227|2018-06-01 01:15:32.684227
NCT00853385|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2012-12-04|2012-11-05|2013-01-10|2009-02-27|2009-03-02|Estimate|2012-12-04|2013-01-09|Estimate|2012-11-05|2012-11-07|Estimate|2013-01-10|2013-01-18|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis|Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate|Completed||Phase 3|717|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 01:15:32.982364|2018-06-01 01:15:32.982364
NCT00853372|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26||2015-11-02|2018-03-26|2009-02-26|2009-03-02|Estimate||||2015-11-02|2015-11-30|Estimate|2018-03-26|2018-03-29|Actual|May 28, 2009|Actual|2009-05-28|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|August 8, 2011|Actual|2011-08-08||Interventional|||AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib|Phase 2 Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 2|85|Actual|Amgen||2|||f||||f||||||||||2018-06-01 01:15:37.751993|2018-06-01 01:15:37.751993
NCT00853346|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2012-11-15|2009-02-27|2009-03-02|Estimate|||||||2012-11-15|2012-11-16|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Psychosocial Treatment of Depression in Parkinson's Disease|Psychosocial Treatment of Depression in Parkinson's Disease|Unknown status|Active, not recruiting|N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 01:15:37.834368|2018-06-01 01:15:37.834368
NCT00853333|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2013-08-23||2014-06-24|2009-02-27|2009-03-02|Estimate|2014-06-24|2014-06-26|Estimate||||2014-06-24|2014-06-26|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Sedation and Pain (The Effect of IV Sedation on Pain Perception)|Sedation and Pain (The Effect of IV Sedation on Pain Perception)|Completed||N/A|86|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-06-01 01:15:37.918879|2018-06-01 01:15:37.918879
NCT00853320|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-18|2009-02-27|2009-03-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|February 2003||2003-02-28|October 2016|2016-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (15 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Roxicodone™, 15 mg Tablet, Roxane Laboratories, Inc.) in Normal Human Subjects Under Fasting Conditions|Completed||Phase 1|38|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:38.202975|2018-06-01 01:15:38.202975
NCT00853307|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2018-01-04|2012-01-27|2018-02-27|2009-02-27|2009-03-02|Estimate|2018-02-27|2018-03-27|Actual|2012-01-27|2012-01-31|Estimate|2018-02-27|2018-03-27|Actual|March 23, 2009|Actual|2009-03-23|February 2018|2018-02-28|January 27, 2011|Actual|2011-01-27|November 23, 2009|Actual|2009-11-23||Interventional||Safety Population is defined as all participants who receive any amount of alisertib.|MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma|A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients With Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|31|Actual|Takeda||1|||f||||f|t|f||||||||2018-06-01 01:15:38.345347|2018-06-01 01:15:38.345347
NCT00853294|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-18|2009-02-27|2009-03-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2003||2003-09-30|October 2016|2016-10-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Extended Release Test Capsule Formulation of Chlorpheniramine Polistirex and Hydrocodone Polistirex Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in Normal Human Subjects Under Fasting Conditions|Completed||Phase 1|42|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:39.15741|2018-06-01 01:15:39.15741
NCT00853281|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2010-09-12|2009-02-27|2009-03-02|Estimate|||||||2010-09-12|2010-09-14|Estimate|March 2004||2004-03-31|September 2010|2010-09-30|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|||A Cluster Randomized Trial to Evaluate Long Lasting Insecticidal Hammocks to Prevent Forest Malaria in Vietnam|A Cluster Randomized Trial to Evaluate the Effectiveness of Long Lasting Insecticidal Hammocks for Controlling Forest Malaria in Central Vietnam|Completed||N/A|18646|Actual|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-06-01 01:15:39.223189|2018-06-01 01:15:39.223189
NCT00853268|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-09-08|2009-02-27|2009-03-02|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a Controlled-Release Test Tablet Formulation of Oxycodone Hydrochloride (40 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (OxyContin® 40 mg, Purdue Pharma L.P.) in Normal Human Subjects Under Fed Conditions|Completed||Phase 1|34|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:39.300085|2018-06-01 01:15:39.300085
NCT00853255|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2012-12-31|2009-02-27|2009-03-02|Estimate|||||||2012-12-31|2013-01-03|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults|Phase 1 Inpatient Study of the Safety and Immunogenicity of One Dose of Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N3 Infection in the Event of a Pandemic|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-06-01 01:15:39.365094|2018-06-01 01:15:39.365094
NCT00853242|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2015-04-15|2010-10-02|2015-04-15|2009-02-27|2009-03-02|Estimate|2015-04-15|2015-05-01|Estimate|2010-10-02|2010-10-05|Estimate|2015-04-15|2015-05-01|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|LEAP|Safety Set included all randomized participants who received at least one dose of study drug.|Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis|Completed||Phase 2|349|Actual|Sanofi||7|||f||||f||||||||||2018-06-01 01:15:39.576533|2018-06-01 01:15:39.576533
NCT00853229|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2017-01-10||2017-04-06|2009-02-27|2009-03-02|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|February 2009||2009-02-28|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||No study analysis completed due to early termination due to poor enrollment|Pregabalin for the Treatment of Vulvodynia|Pregabalin (Lyrica) for the Treatment of Vulvodynia: A Randomized, Double-blinded, Placebo-controlled Cross-over Study|Terminated||Phase 2|16|Actual|The Cleveland Clinic||2||Not feasible due to low accrual|f||||f||||||||||2018-06-01 01:15:41.517391|2018-06-01 01:15:41.517391
NCT00853216|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-18|2009-02-26|2009-03-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2003||2003-01-31|October 2016|2016-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of an Immediate Release Test Tablet Formulation of Oxycodone Hydrochloride (30 mg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Roxicodone™, 30 mg Tablet, Roxane Laboratories, Inc.) in Normal Human Subjects Under Fasting Conditions|Completed||Phase 1|38|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:41.79204|2018-06-01 01:15:41.79204
NCT00853203|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2017-09-07|2009-02-27|2009-03-02|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2009|Actual|2009-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Expressive Disclosure and Colorectal Cancer|Expressive Disclosure Program for Colorectal Cancer Patients|Active, not recruiting|||174|Anticipated|M.D. Anderson Cancer Center|||3||f||||t|f|f||||||||2018-06-01 01:15:41.906933|2018-06-01 01:15:41.906933
NCT00853190|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-18|2009-02-27|2009-03-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2003||2003-09-30|October 2016|2016-10-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension|An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Extended Release Test Capsule Formulation of Chlorpheniramine Polistirex and Hydrocodone Polistirex Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in Normal Human Subjects Under Fed Conditions|Completed||Phase 1|43|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 01:15:41.982645|2018-06-01 01:15:41.982645
NCT00853177|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-09-15|2009-02-27|2009-03-02|Estimate|||||||2012-09-15|2012-09-18|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|KALOVAL||MEOPA Breathing Analgesia for Oocyte Retrieval(KALOVAL)|MEOPA Breathing Analgesia vs Local Anesthesia for Oocyte Retrieval in ART: a Prospective, Randomized Controlled Study|Completed||Phase 4|77|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:15:42.044048|2018-06-01 01:15:42.044048
NCT00853164|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2018-05-01|2009-02-27|2009-03-02|Estimate|||||||2018-05-01|2018-05-07|Actual|July 2008|Actual|2008-07-31|May 2018|2018-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MAP-P||A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)|A Pilot Study of Physical Activity for Improving Quality of Life in Prostate Cancer Patients on Androgen Deprivation Therapy|Completed||N/A|8|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 01:15:42.166255|2018-06-01 01:15:42.166255
NCT00853151|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2011-09-15||2012-03-19|2009-02-26|2009-03-02|Estimate|2012-03-19|2012-04-13|Estimate||||2012-03-19|2012-04-13|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes|A Proof of Concept Study to Evaluate the Coadministration of TT223 Given Daily and LY2428757 Given Once-Weekly for Four Weeks in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|131|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:15:42.278935|2018-06-01 01:15:42.278935
NCT00853138|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-05-26|2009-02-26|2009-03-02|Estimate|||||||2015-05-26|2015-05-28|Estimate|May 2007||2007-05-31|May 2015|2015-05-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Web-based CBT for Children With Chronic Pain|Web-based CBT for Children With Chronic Pain|Completed||Phase 2|48|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-06-01 01:15:43.977165|2018-06-01 01:15:43.977165
NCT00853125|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2017-02-13|2009-02-27|2009-03-02|Estimate|||||||2017-02-13|2017-02-15|Actual|February 2009||2009-02-28|May 2015|2015-05-31|February 22, 2014|Actual|2014-02-22|February 22, 2014|Actual|2014-02-22||Interventional|||Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer|Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial)|Terminated||Phase 2|10|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||t||||||||||2018-06-01 01:15:44.050439|2018-06-01 01:15:44.050439
NCT00853112|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2017-08-09|2012-03-27|2017-09-20|2009-02-27|2009-03-02|Estimate|2017-09-20|2017-10-24|Actual|2012-03-27|2012-03-30|Estimate|2017-09-20|2017-10-24|Actual|April 2009|Actual|2009-04-30|September 2017|2017-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||Safety population included all randomized participants who received study medication.|A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension|A Phase 2a, Randomized, Double Blind, Placebo-controlled, Parallel Group Study Investigating The Dose-response Of Pf-00489791 On Acute Hemodynamics In Subjects With Idiopathic And Familial Pulmonary Arterial Hypertension|Terminated||Phase 2|48|Actual|Pfizer|Study was terminated prematurely as further continuation would not have meaningfully contributed to the next phase of development.|7||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:15:44.249088|2018-06-01 01:15:44.249088
NCT00853099|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|2012-10-26||2014-09-03|2009-02-27|2009-03-02|Estimate|2012-10-26|2012-11-27|Estimate||||2014-09-03|2014-09-05|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|August 2013|Actual|2013-08-31|May 2011|Actual|2011-05-31||Interventional||1 participant in the adalimumab 160 mg/80 mg arm was incorrectly treated with open-label (rescue) study drug at Week 0, and was not included in Baseline Characteristics.|A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis|A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.|Completed||Phase 3|274|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 01:15:46.334358|2018-06-01 01:15:46.334358
NCT00853086|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-27|||2016-11-15|2009-02-27|2009-03-02|Estimate|||||||2016-11-15|2016-11-16|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database|United Kingdom Haemophilia Centre Doctor's Organisation (UKHCDO) - Novo Nordisk Collaboration on NovoSeven® Post Marketing Follow-up Measures|Completed|||139|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:15:48.321903|2018-06-01 01:15:48.321903
NCT00853073|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2015-01-30||2018-03-28|2009-02-26|2009-02-27|Estimate|2015-03-11|2015-03-12|Estimate||||2018-03-28|2018-04-30|Actual|February 2009||2009-02-28|March 2018|2018-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|Avastin|5 patients withdrew; 3 from Treatment A group and 2 from Treatment B group.|Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?|Does a New Add on (or Adjunctive) Therapy Used in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?|Completed||Phase 2/Phase 3|63|Actual|Wills Eye|Small sample size which did not allow further subgroup analysis based on these patient characteristics.|2|||f||||f||||||||No||2018-06-01 01:15:49.193749|2018-06-01 01:15:49.193749
NCT00853060|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-26|2009-02-26|2009-02-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Observational|||Energy Expenditure in Weaning From Mechanical Ventilation|Energy Expenditure During Weaning From Mechanical Ventilation: Is There Any Difference Between Pressure Support and T-Tube?|Completed|||40|Actual|Hospital de Clinicas de Porto Alegre|||||f||||f||||||||||2018-06-01 01:15:49.463482|2018-06-01 01:15:49.463482
NCT00853047|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25||2016-02-04|2016-04-01|2009-02-25|2009-02-27|Estimate||||2016-02-04|2016-03-03|Estimate|2016-04-01|2016-05-03|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy||Completed||Phase 2|23|Actual|Lexicon Pharmaceuticals||6|||f||||f||||||||||2018-06-01 01:15:49.528654|2018-06-01 01:15:49.528654
NCT00853034|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-26|2009-02-26|2009-02-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|September 2007|Actual|2007-09-30|||||Interventional|||Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects|Effects of Arabinoxylan-Oligosaccharides on Colonic Metabolism and Microbial Composition Compared to Other Prebiotics in Healthy Subjects|Completed||Phase 4|20|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-06-01 01:15:49.626276|2018-06-01 01:15:49.626276
NCT00853021|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2015-07-28||2015-07-28|2009-02-26|2009-02-27|Estimate|2015-07-28|2015-08-24|Estimate||||2015-07-28|2015-08-24|Estimate|December 2005||2005-12-31|July 2015|2015-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney|Phase II Open Label Trial of rIL-2 and Bevacizumab Combination in Patients With Metastatic Clear Cell Renal Carcinoma|Completed||Phase 2|26|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:15:49.718733|2018-06-01 01:15:49.718733
NCT00853008|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2018-01-09|2009-02-26|2009-02-27|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2003||2003-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|LAL-AR/2003||Treatment of High Risk Adult Acute Lymphoblastic Leukemia|Treatment of High Risk Adult Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 4|100|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 01:15:50.177038|2018-06-01 01:15:50.177038
NCT00852995|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2016-02-15|2013-09-12|2016-09-13|2009-02-26|2009-02-27|Estimate|2016-02-15|2016-03-14|Estimate|2013-09-19|2013-09-26|Estimate|2016-09-13|2016-10-24|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||Dose Finding Study of HP802-247 in Venous Leg Ulcers|A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in Venous Leg Ulcers|Completed||Phase 2|228|Actual|Healthpoint||5|||f||||f||||||||||2018-06-01 01:15:50.427492|2018-06-01 01:15:50.427492
NCT00852982|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-02-27|2009-02-26|2009-02-27|Estimate|||||||2009-02-27|2009-03-02|Estimate|April 2006||2006-04-30|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|SMIDIG||Exercise Effects on Cardiovascular Risk Factors, Quality of Life, Muscle Function in Type 2 Diabetes and Healthy Persons|Exercise - Effects on Health Related Quality of Life, Cardiovascular Risk Factors, and Cellular Functions With Respect to Glucose Metabolism, in Type 2 Diabetes Mellitus, Impaired Glucose Tolerance and in Healthy Individuals.|Unknown status|Active, not recruiting|N/A|213|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 01:15:52.064238|2018-06-01 01:15:52.064238
NCT00852969|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2013-11-27||2014-04-03|2009-02-26|2009-02-27|Estimate|2014-04-03|2014-05-06|Estimate||||2014-04-03|2014-05-06|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||These were the number of individuals who agreed to be randomized for the study|Niacin and Endothelial Function in Early CKD|Does Raising HDL-C With Niacin Improve Endothelial Function in Early CKD?|Completed||Phase 4|30|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-06-01 01:15:52.146436|2018-06-01 01:15:52.146436
NCT00852956|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-05-03|2009-02-26|2009-02-27|Estimate|||||||2009-05-03|2009-05-05|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects|Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects|Completed||Phase 1|50|Anticipated|OBEcure Ltd.||2|||f||||f||||||||||2018-06-01 01:15:52.411137|2018-06-01 01:15:52.411137
NCT00852943|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2018-03-27|2009-02-26|2009-02-27|Estimate|||||||2018-03-27|2018-03-29|Actual|February 25, 2009||2009-02-25|December 20, 2017|2017-12-20||||||||Observational|||Screening Protocol for Genetic Diseases of Allergic Inflammation|Screening Protocol for Genetic Diseases of Allergic Inflammation|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:15:52.472351|2018-06-01 01:15:52.472351
NCT00852930|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2015-07-17||2017-04-07|2009-02-26|2009-02-27|Estimate|2015-09-30|2015-11-02|Estimate||||2017-04-07|2017-04-11|Actual|September 2009||2009-09-30|April 2017|2017-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||breast cancer survivors with known lymphedema|Low Level Laser Treatment and Breast Cancer Related Lymphedema|Low Level Laser Treatment and Breast Cancer Related Lymphedema|Completed||Phase 4|50|Actual|Vanderbilt University||3|||f||||f||||||||||2018-06-01 01:15:52.545197|2018-06-01 01:15:52.545197
NCT00852917|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2009-04-08||2012-04-25|2009-02-26|2009-02-27|Estimate|2009-04-08|2009-06-02|Estimate||||2012-04-25|2012-04-30|Estimate|January 2003||2003-01-31|April 2012|2012-04-30||||August 2003|Actual|2003-08-31||Interventional|||A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee (With 7-Day Follow-up)||Completed||Phase 3|552|Actual|Labopharm Inc.||4|||f||||||||||||||2018-06-01 01:15:53.052717|2018-06-01 01:15:53.052717
NCT00852904|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2018-05-10|2009-02-26|2009-02-27|Estimate|||||||2018-05-10|2018-05-11|Actual|February 25, 2009||2009-02-25|August 29, 2017|2017-08-29||||||||Observational|||National Children s Health Study|Vanguard Phase of the National Children s Study|Completed|||11710|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:15:53.655096|2018-06-01 01:15:53.655096
NCT00852345|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-04-02|2009-02-26|2009-02-27|Estimate|||||||2015-04-02|2015-04-03|Estimate||||March 2015|2015-03-31||||||||Expanded Access|||Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy|Clofazamine in the Long Term Treatment of Leprosy, Phase III|No longer available|||||Kaiser Permanente|||||||||||||||||||2018-06-01 01:16:00.402236|2018-06-01 01:16:00.402236
NCT00852878|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-06-19|2009-02-26|2009-02-27|Estimate|||||||2015-06-19|2015-06-23|Estimate|March 2009||2009-03-31|December 2010|2010-12-31||||January 2010|Anticipated|2010-01-31||Interventional|||The Treatment of Recurrent Abdominal Pain in Children|The Treatment of Recurrent Abdominal Pain in Children: A Comparison of Biofeedback and Behavioral Intervention|Withdrawn||N/A|0|Actual|Kaiser Permanente||2||Not enough interested participants|f||||f||||||||||2018-06-01 01:15:53.793013|2018-06-01 01:15:53.793013
NCT00852865|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-04-30|2009-02-26|2009-02-27|Estimate|||||||2009-04-30|2009-05-01|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Lactobacillus Farciminis and Hyperalgesia|Effect of a Dialy Consumption of a Probiotic (Lactobacillus Farciminis) on Hyperalgesia in Response to Thermal Stimulation|Completed||Phase 1|48|Actual|Lallemand SAS||2|||f||||f||||||||||2018-06-01 01:15:53.869062|2018-06-01 01:15:53.869062
NCT00852852|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2018-01-30|2009-02-26|2009-02-27|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2008||2008-10-31|January 2018|2018-01-31|December 2013|Actual|2013-12-31|July 2011|Actual|2011-07-31||Interventional|ESRA-C_II||Computerized Assessment for Patients With Cancer|Computerized Assessment for Patients With Cancer-ESRA-C II|Completed||N/A|779|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 01:15:53.964057|2018-06-01 01:15:53.964057
NCT00852839|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26||2011-08-04|2014-07-11|2009-02-26|2009-02-27|Estimate||||2014-07-11|2014-07-15|Estimate|2014-07-11|2014-07-15|Estimate|February 2009||2009-02-28|July 2014|2014-07-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Arm Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome|Completed||Phase 2|140|Actual|Parion Sciences||2|||f||||f||||||||||2018-06-01 01:15:54.042968|2018-06-01 01:15:54.042968
NCT00852826|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-02-26|2009-02-26|2009-02-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|November 2008||2008-11-30|||||Interventional|||Evaluation of a Hemostatic and Sealing Agent to Prevent Surgical Complications After Axillary Lymphadenectomy|Value of a Hemostatic and Sealing Agent for Preventing Seroma After Axillary Lymphadenectomy|Completed||Phase 4|60|Actual|Hospital Universitario Virgen de la Arrixaca||2|||f||||||||||||||2018-06-01 01:15:54.148659|2018-06-01 01:15:54.148659
NCT00852813|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-02-26|2009-02-26|2009-02-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|||||Interventional|||Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects|Tolerance and Prebiotic Activity of Arabinoxylan-Oligosaccharides in Healthy Subjects: a Randomized, Placebo-Controlled Cross-Over Study|Completed||Phase 4|20|Actual|Katholieke Universiteit Leuven|||||f||||t||||||||||2018-06-01 01:15:54.228516|2018-06-01 01:15:54.228516
NCT00852800|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2010-06-04|2009-02-26|2009-02-27|Estimate|||||||2010-06-04|2010-06-07|Estimate|March 2006||2006-03-31|June 2010|2010-06-30|March 2011|Anticipated|2011-03-31|August 2009|Actual|2009-08-31||Interventional|ALTERNATE||Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study|Effect of Intravenous Albumin (Standard vs Dose Reduced Regimen) On Renal Impairment and Mortality in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis: A Double Blind Randomized Clinical Trial|Unknown status|Enrolling by invitation|Phase 2|43|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:15:54.420163|2018-06-01 01:15:54.420163
NCT00852787|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2012-05-23|2009-02-26|2009-02-27|Estimate|||||||2012-05-23|2012-05-25|Estimate|April 2009||2009-04-30|December 2009|2009-12-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease|Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|National Institute on Aging (NIA)||4|||f||||f||||||||||2018-06-01 01:15:54.570436|2018-06-01 01:15:54.570436
NCT00852774|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2014-07-25|2009-02-26|2009-02-27|Estimate|||||||2014-07-25|2014-07-28|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery for Endometrial Robotics Versus Laparotomy|Effects of Steep Trendelenburg Positioning on Intra-Ocular Pressure During Surgery For Endometrial Cancer: Robotics Versus Laparotomy|Withdrawn|||0|Actual|Ohio State University Comprehensive Cancer Center|||2|terminated due to low staffing|f||||f||||||||||2018-06-01 01:15:54.699119|2018-06-01 01:15:54.699119
NCT00852761|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2010-11-04||2012-04-19|2009-02-26|2009-02-27|Estimate|2011-09-01|2011-10-04|Estimate||||2012-04-19|2012-04-23|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis|A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects.|Completed||Phase 4|34|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:15:54.818424|2018-06-01 01:15:54.818424
NCT00852748|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2010-10-07|2009-02-26|2009-02-27|Estimate|||||||2010-10-07|2010-10-08|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Observational|||Validation of Venogenic Hypothesis for Cough, Exertional and Sexual Headaches||Completed|||50|Anticipated|French Society for the Study of Migraine Headache|||||f||||f||||||||||2018-06-01 01:15:55.637438|2018-06-01 01:15:55.637438
NCT00852735|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2010-03-09|2009-02-26|2009-02-27|Estimate|||||||2010-03-09|2010-03-10|Estimate|December 2008||2008-12-31|March 2010|2010-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of the Antioxidant Micronutrients of Rapeseed Oil on the Prevention of Cardiovascular Diseases (Optim'Oils)|Effect of the Antioxidant Micronutrients of Rapeseed Oil on the Prevention of Cardiovascular Diseases|Completed||N/A|60|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:15:55.740525|2018-06-01 01:15:55.740525
NCT00852722|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-02-02|2009-02-26|2009-02-27|Estimate|||||||2015-02-02|2015-02-04|Estimate|February 2009||2009-02-28|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MS||Low Fat Diet and Multiple Sclerosis|A Randomized, Controlled Study of Diet and Multiple Sclerosis|Completed||Phase 1|61|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 01:15:55.823453|2018-06-01 01:15:55.823453
NCT00852709|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2018-02-13|2009-02-26|2009-02-27|Estimate|||||||2018-02-13|2018-02-15|Actual|September 1, 2007|Actual|2007-09-01|February 2018|2018-02-28|November 20, 2009|Actual|2009-11-20|November 20, 2009|Actual|2009-11-20||Interventional|POE07-01||Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias|Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias|Terminated||Phase 1|35|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||Lack of accrual|f||||f||||||||||2018-06-01 01:15:55.901104|2018-06-01 01:15:55.901104
NCT00852696|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2017-04-18|2009-02-26|2009-02-27|Estimate|||||||2017-04-18|2017-04-20|Actual|February 2008||2008-02-29|April 2017|2017-04-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Over Active Bladder Patients Having Sling Surgery|A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures.|Completed||Phase 4|11|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 01:15:56.008185|2018-06-01 01:15:56.008185
NCT00852683|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2014-03-05|2009-02-26|2009-02-27|Estimate|||||||2014-03-05|2014-03-07|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||The Effects of Peri-Operative Pregabalin on Post-Operative Pain Following Breast Cancer Surgery With Axillary Node Dissection: A Pilot Study||Completed||Phase 3|70|Anticipated|Nova Scotia Health Authority||2|||f||||||||||||||2018-06-01 01:15:56.091708|2018-06-01 01:15:56.091708
NCT00852670|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-11-11|2009-02-26|2009-02-27|Estimate|||||||2009-11-11|2009-11-13|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||ACT-128800 in Psoriasis|Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|66|Actual|Actelion||2|||f||||t||||||||||2018-06-01 01:15:56.160357|2018-06-01 01:15:56.160357
NCT00852657|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2018-01-19|2009-02-26|2009-02-27|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2004||2004-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of Tendon Repair and Physiotherapy in the Treatment of Small and Medium-sized Tears of the Rotator Cuff|Comparison of Surgical Treatment by Tendon Repair and Physiotherapy in the Treatment of Small and Medium-sized Tears of the Rotator Cuff|Active, not recruiting||N/A|103|Actual|Martina Hansen's Hospital||2|||f||||f||||||||||2018-06-01 01:15:56.27302|2018-06-01 01:15:56.27302
NCT00852644|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2017-02-13||2018-04-11|2009-02-26|2009-02-27|Estimate|2017-12-08|2018-01-09|Actual||||2018-04-11|2018-05-11|Actual|January 2009|Actual|2009-01-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|June 2013|Actual|2013-06-30||Interventional|||Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer|Terminated||N/A|9|Actual|Boston Medical Center|The highest tolerable dose was not established in either cohort due to early termination. There were no dose limiting toxicities experienced at 56 or 62 gray (less than 3 centimeters) or 56 gray (more than 3 centimeters) at the time of study closure|6||poor accrual|f||||t|f|t|f|||||No||2018-06-01 01:15:56.373015|2018-06-01 01:15:56.373015
NCT00852631|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2011-05-18||2012-06-12|2009-02-26|2009-02-27|Estimate|2012-06-12|2012-07-17|Estimate||||2012-06-12|2012-07-17|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Seroquel XR in Adults With Schizophrenia|Open-label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia|Terminated||Phase 3|28|Actual|AstraZeneca||||The study was prematurely terminated due to insufficient recruitment.|f||||f||||||||||2018-06-01 01:15:56.828437|2018-06-01 01:15:56.828437
NCT00852618|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2015-06-08|2009-02-26|2009-02-27|Estimate|||||||2015-06-08|2015-06-10|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|September 2008|Actual|2008-09-30|||||Observational|||Intensive Viral Dynamics Substudy of A5248|Intensive Viral Dynamics Substudy of A5248|Completed|||11|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples Without DNA|"~     Plasma samples will be collected throughout the study~   "|||2018-06-01 01:15:56.946763|2018-06-01 01:15:56.946763
NCT00852605|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-02-26|2009-02-26|2009-02-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|December 2001||2001-12-31|February 2009|2009-02-28||||August 2005|Actual|2005-08-31||Interventional|||Acute Lung Injury After Allogeneic Transplantation - Diagnosis and Early Treatment|A Randomized Clinical Trial on the Use of Early Intermittent Non-Invasive Ventilation in Patients Suffering From Acute Lung Injury After Allogeneic Transplantation|Completed||Phase 1/Phase 2|86|Actual|Technische Universität Dresden||2|||f||||||||||||||2018-06-01 01:15:57.00749|2018-06-01 01:15:57.00749
NCT00852592|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2016-02-19||2016-09-20|2009-02-26|2009-02-27|Estimate|2016-09-20|2016-11-07|Estimate||||2016-09-20|2016-11-07|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial|Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial|Completed||Phase 3|46|Actual|Northwestern University||2|||f||||t||||||||Undecided|We can share data if approached by other investigators|2018-06-01 01:15:57.077206|2018-06-01 01:15:57.077206
NCT00852579|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2011-10-18|2009-02-26|2009-02-27|Estimate|||||||2011-10-18|2011-10-19|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Macrolides on Asthma Control|Effects of Macrolides on Asthma Control, Airway Inflammation and Bacterial Colonisation in Smokers With Asthma.|Completed||Phase 3|77|Actual|University of Glasgow||2|||f||||t||||||||||2018-06-01 01:15:57.432923|2018-06-01 01:15:57.432923
NCT00852566|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2017-09-21|2009-02-26|2009-02-27|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2009|Actual|2009-03-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|February 2011|Actual|2011-02-28||Interventional|NordCML006||Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia|An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells With Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid|Completed||Phase 2|46|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 01:15:57.531776|2018-06-01 01:15:57.531776
NCT00852553|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2017-05-24|2009-02-26|2009-02-27|Estimate|||||||2017-05-24|2017-05-30|Actual|February 2003||2003-02-28|May 2017|2017-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Neurohumoral Control of Intestinal Electrical and Mechanical Activity|Neurohumoral Control of Intestinal Electrical and Mechanical Activity|Completed|||45|Actual|University of California, Davis|||||f||||f||||||Samples Without DNA|"~     jejunum~   "|||2018-06-01 01:15:57.611649|2018-06-01 01:15:57.611649
NCT00852540|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2011-07-28||2017-02-23|2009-02-26|2009-02-27|Estimate|2011-07-28|2011-08-26|Estimate||||2017-02-23|2017-03-27|Actual|April 2009||2009-04-30|February 2017|2017-02-28|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA|A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus|Completed||Phase 3|410|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:15:57.709269|2018-06-01 01:15:57.709269
NCT00852527|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2014-11-04||2015-04-06|2009-02-25|2009-02-27|Estimate|2014-11-04|2014-12-05|Estimate||||2015-04-06|2015-04-28|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|TBI|Number of participants consented and enrolled.|Evaluation of VA's Traumatic Brain Injury (TBI) Clinical Reminder and Comprehensive TBI Evaluation (CTBIE)|Evaluation of VA's TBI Clinical Reminder And Secondary Level Evaluation|Completed|||456|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-06-01 01:15:58.535256|2018-06-01 01:15:58.535256
NCT00852514|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-02-26|2009-02-26|2009-02-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|September 2006||2006-09-30|February 2009|2009-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis|The Optimization of Blood Pressure and Fluid Status Control With Eight-Polar Bioelectrical Impedance Analysis|Completed||Phase 4|132|Actual|Taipei Veterans General Hospital, Taiwan||1|||f||||t||||||||||2018-06-01 01:15:58.777563|2018-06-01 01:15:58.777563
NCT00852501|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2013-04-08|2009-02-26|2009-02-27|Estimate|||||||2013-04-08|2013-04-09|Estimate|March 2006||2006-03-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Characterization of Receptors in Non-functioning Pituitary Macroadenomas|Characterization of Receptors Present in Non-functioning Pituitary Macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR)|Unknown status|Recruiting||100|Anticipated|John H. Stroger Hospital|||1||f||||f||||||Samples Without DNA|"~     A small piece of the pituitary macradenoma removed at surgery will be frozen to perform~     RT-PCR~   "|||2018-06-01 01:15:58.846734|2018-06-01 01:15:58.846734
NCT00852488|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-04-27|2009-02-26|2009-02-27|Estimate|||||||2017-04-27|2017-05-01|Actual|March 2009||2009-03-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Medium-term Venous Access in Congenital Heart Surgery|A Medium-term Venous Access Alternative in Infants Undergoing Congenital Heart Surgery|Completed||N/A|50|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 01:15:58.939701|2018-06-01 01:15:58.939701
NCT00852475|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2014-12-22||2016-12-07|2009-02-26|2009-02-27|Estimate|2016-12-07|2017-02-02|Estimate||||2016-12-07|2017-02-02|Estimate|February 2010||2010-02-28|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MUFAPUFA||Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome|Comparative Effects of Two Popular Diets in Veterans With the Metabolic Syndrome|Completed||N/A|46|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:15:59.019162|2018-06-01 01:15:59.019162
NCT00852462|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-10-19|2009-02-26|2009-02-27|Estimate|||||||2016-10-19|2016-10-21|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|August 2012|Actual|2012-08-31||Interventional|||Lung Cancer Symptom Assessment and Management Intervention|Lung Cancer Symptom Assessment and Management Intervention|Completed||Phase 2|179|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 01:15:59.237692|2018-06-01 01:15:59.237692
NCT00852449|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2012-10-04|2009-02-26|2009-02-27|Estimate|||||||2012-10-04|2012-10-05|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Intraoperative Hypovolemia and Fluid Therapy|Restrictive Versus Liberal Intraoperative Goal-directed Fluid Management During Major Abdominal Surgery:a Prospective Randomized Study|Terminated||Phase 4|70|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-06-01 01:15:59.308825|2018-06-01 01:15:59.308825
NCT00852436|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2015-06-01|2009-02-26|2009-02-27|Estimate|||||||2015-06-01|2015-06-03|Estimate|February 2009||2009-02-28|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|Pregabalin-Dao||Pregabalin and Orofacial Neuropathic Pain|Efficacy of Pregabalin in the Treatment of Orofacial Neuropathic Pain|Terminated||Phase 2|1|Actual|University of Toronto||2||difficulty to recruit patients|f||||f||||||||||2018-06-01 01:15:59.361922|2018-06-01 01:15:59.361922
NCT00852423|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2016-03-11|2009-02-26|2009-02-27|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|October 2013|Actual|2013-10-31||Interventional|PREGACT||Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria|Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria|Completed||Phase 3|3428|Actual|Institute of Tropical Medicine, Belgium||4|||f||||t||||||||||2018-06-01 01:15:59.429143|2018-06-01 01:15:59.429143
NCT00852410|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2010-06-29|2009-02-26|2009-02-27|Estimate|||||||2010-06-29|2010-06-30|Estimate|March 2009||2009-03-31|June 2010|2010-06-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||The Hemostatic and Hemodynamic Effects of Adrenaline During Endoscopic Sinus Surgery|The Hemostatic and Hemodynamic Effects of Adrenaline During Endoscopic Sinus Surgery: Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 3|140|Anticipated|University of Toronto||2|||f||||f||||||||||2018-06-01 01:15:59.525109|2018-06-01 01:15:59.525109
NCT00852397|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|2013-06-04||2013-08-27|2009-02-26|2009-02-27|Estimate|2013-08-27|2013-08-29|Estimate||||2013-08-27|2013-08-29|Estimate|April 2009||2009-04-30|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients|A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg BID Apixaban In Combination With Standard Therapy In Patients With Recent (≤7 Days) Acute Coronary Syndrome (ACS)|Terminated||Phase 2|151|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:15:59.612106|2018-06-01 01:15:59.612106
NCT00852384|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2009-08-27|2009-02-26|2009-02-27|Estimate|||||||2009-08-27|2009-08-28|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Non Invasive Pressure Support Ventilation (NIPPV) Versus Recruitment Maneuver (RM) and Preoxygenation|Non Invasive Pressure Support Ventilation (NIPPV) Versus Conventionnal Approach and Early Recruitment Maneuver (RM) for Preoxygenation of Morbidly Obese Patient|Completed||Phase 4|60|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:16:00.07686|2018-06-01 01:16:00.07686
NCT00852371|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2017-01-25|2009-02-26|2009-02-27|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2008||2008-02-29|January 2017|2017-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Intermittent Preventive Treatment of Malaria in Schoolchildren|IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda|Completed||Phase 3|760|Anticipated|London School of Hygiene and Tropical Medicine||4|||f||||t||||||||||2018-06-01 01:16:00.128854|2018-06-01 01:16:00.128854
NCT00852358|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-01-22|2009-02-25|2009-02-27|Estimate|||||||2016-01-22|2016-01-26|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I|A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I|Completed||N/A|9|Actual|Dickson, Patricia I., M.D.||2|||f||||t||||||||No||2018-06-01 01:16:00.310808|2018-06-01 01:16:00.310808
NCT00852332|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-26|||2017-11-14|2009-02-26|2009-02-27|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2009||2009-08-31|October 2017|2017-10-31||||October 2017|Actual|2017-10-31||Interventional|||Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer|An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.|Recruiting||Phase 2|100|Anticipated|Centre Jean Perrin||2|||f||||||||||||||2018-06-01 01:16:00.465978|2018-06-01 01:16:00.465978
NCT00852319|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-01-13|2009-02-25|2009-02-27|Estimate|||||||2016-01-13|2016-01-15|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|IPC-M||Interpregnancy Care Project-Mississippi (IPC-M)|Interpregnancy Care Project-Mississippi|Completed||N/A|264|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-06-01 01:16:00.553198|2018-06-01 01:16:00.553198
NCT00852306|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2012-10-08|2009-02-25|2009-02-26|Estimate|||||||2012-10-08|2012-10-10|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|October 2012|Actual|2012-10-31|February 2011|Actual|2011-02-28||Interventional|||A Comparison of Two Freezing Techniques|A Comparison of Two Freezing Techniques|Completed||N/A|18|Actual|Northwell Health||2|||f||||f||||||||||2018-06-01 01:16:00.639276|2018-06-01 01:16:00.639276
NCT00852293|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-25|2009-02-25|2009-02-26|Estimate|||||||2009-02-25|2009-02-26|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|March 2014|Anticipated|2014-03-31|March 2010|Anticipated|2010-03-31||Observational|||The Connection Between Liver Disease and Chitinase Proteins|The Connection Between Liver Disease and Chitinase Proteins|Unknown status|Not yet recruiting||200|Anticipated|Hadassah Medical Organization|||1||f||||||||||Samples Without DNA|"~     Blood tests are taken to determin Chitinase 3 like-1 protein levels.~   "|||2018-06-01 01:16:00.721012|2018-06-01 01:16:00.721012
NCT00852280|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2012-06-06|2009-02-25|2009-02-26|Estimate|||||||2012-06-06|2012-06-07|Estimate|December 2008||2008-12-31|July 2010|2010-07-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Effects of Pulsed-Dyed Laser on Scar Formation|Effects of Pulsed-Dyed Laser on Scar Formation|Completed||N/A|17|Actual|Shriners Hospitals for Children|||||f||||f||||||||||2018-06-01 01:16:00.794777|2018-06-01 01:16:00.794777
NCT00852267|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2011-10-04|2009-02-25|2009-02-26|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Lipoprotein Effects of Substituting Beef Protein for Carbohydrate|Lipoprotein Effects of Substituting Beef Protein for Carbohydrate|Completed||N/A|40|Anticipated|Children's Hospital & Research Center Oakland||3|||f||||f||||||||||2018-06-01 01:16:00.928181|2018-06-01 01:16:00.928181
NCT00852254|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-05-25|2009-02-25|2009-02-26|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2008||2008-06-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Validation of Minimally Invasive Ultrasound Indicator Dilution Technique in Critically Ill Children|Validation of a Novel, Minimally Invasive Ultrasound Indicator Dilution Technique for Measuring Cardiac Index in Critically Ill Children|Completed|||9|Actual|Transonic Systems Inc.|||||f||||f||||||||No||2018-06-01 01:16:01.022041|2018-06-01 01:16:01.022041
NCT00852241|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2017-04-17||2018-02-05|2009-02-25|2009-02-26|Estimate|2018-02-05|2018-03-12|Actual||||2018-02-05|2018-03-12|Actual|February 2009||2009-02-28|February 2018|2018-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||The Principal Investigator left the institution and no data is available.|Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study|Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study|Completed||Phase 4|18|Actual|The Cleveland Clinic|PI left institution, no data is available.|1|||f||||||||||||No||2018-06-01 01:16:01.095578|2018-06-01 01:16:01.095578
NCT00852228|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2013-12-10|2009-02-25|2009-02-26|Estimate|||||||2013-12-10|2013-12-12|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|March 2012|Actual|2012-03-31||Interventional|OPTILIV||Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy|Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Association pour la Recherche sur le Temps Biologique et la Chronothérapie||2|||f||||t||||||||||2018-06-01 01:16:01.247605|2018-06-01 01:16:01.247605
NCT00852215|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-25|2009-02-25|2009-02-26|Estimate|||||||2009-02-25|2009-02-26|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|July 2009|Anticipated|2009-07-31||Interventional|COPE||Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion?|Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion? (COPE Study): Long-Term Follow-up Study|Unknown status|Recruiting|Phase 4|500|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-06-01 01:16:01.389357|2018-06-01 01:16:01.389357
NCT00852202|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25||2011-07-06|2011-07-06|2009-02-25|2009-02-26|Estimate||||2011-07-06|2011-07-14|Estimate|2011-07-06|2011-07-14|Estimate|June 2009||2009-06-30|July 2011|2011-07-31||||June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression|A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression|Completed||Phase 2|234|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 01:16:01.498962|2018-06-01 01:16:01.498962
NCT00852189|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2012-08-07|2009-02-25|2009-02-26|Estimate|||||||2012-08-07|2012-08-08|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Study of EC0489 for the Treatment of Refractory or Metastatic Tumors|A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle|Completed||Phase 1|65|Actual|Endocyte|||||f||||f||||||||||2018-06-01 01:16:01.617849|2018-06-01 01:16:01.617849
NCT00852176|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2017-02-06|2009-02-25|2009-02-26|Estimate|||||||2017-02-06|2017-02-08|Estimate|May 2009||2009-05-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Observational|||Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System|Best Vascular P000018 Post-approval Study: Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System|Recruiting|||200|Anticipated|Best Vascular, Inc.|||1||f||||t||||||||Undecided||2018-06-01 01:16:01.714559|2018-06-01 01:16:01.714559
NCT00852163|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2013-04-01|2009-02-25|2009-02-26|Estimate|||||||2013-04-01|2013-04-04|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen|Phase II Trial of Clofarabine With Parenteral Busulfan (Busulfex®) Followed by Allogeneic Related or Unrelated Donor Transplantation for the Treatment of Hematologic Malignancies and Diseases|Completed||Phase 2|20|Actual|Baylor Research Institute||1|||f||||t||||||||||2018-06-01 01:16:01.787762|2018-06-01 01:16:01.787762
NCT00852150|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2012-06-05|2009-02-25|2009-02-26|Estimate|||||||2012-06-05|2012-06-06|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Is a Reporting System for Gastritis or Duodenitis (Modified Lanza Scale) Reproducible?|Reproducibility of Modified Lanza Scale for the Reporting of Gastritis and Duodenitis|Completed|||200|Anticipated|Ruttonjee Hospital|||||f||||f||||||||||2018-06-01 01:16:01.87493|2018-06-01 01:16:01.87493
NCT00852137|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|2012-02-21|2010-07-13|2015-02-18|2009-02-24|2009-02-26|Estimate|2012-04-24|2012-05-28|Estimate|2010-07-13|2010-07-15|Estimate|2015-02-18|2015-03-06|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis|A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis|Completed||Phase 2|16|Actual|Peplin||2|||f||||f||||||||||2018-06-01 01:16:01.971203|2018-06-01 01:16:01.971203
NCT00852124|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2014-12-02||2018-04-17|2009-02-24|2009-02-26|Estimate|2015-06-04|2015-06-10|Estimate||||2018-04-17|2018-04-19|Actual|February 2007||2007-02-28|April 2018|2018-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Zero participants analyzed for the primary outcome due to early termination of study|Safety of VSL#3 in Adult Asthmatics|Safety of VSL#3 for Adult Asthmatics|Terminated||Phase 1/Phase 2|3|Actual|University of Maryland|Early termination due to small number of persons recruited before PI relocated.|2||Inadequate recruitment|f||||t||||||||||2018-06-01 01:16:02.287183|2018-06-01 01:16:02.287183
NCT00852111|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2018-04-03|2009-02-25|2009-02-26|Estimate|||||||2018-04-03|2018-04-04|Actual|February 24, 2009||2009-02-24|March 27, 2018|2018-03-27||||||||Observational|||Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy|Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy|Recruiting|||262|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:16:02.507321|2018-06-01 01:16:02.507321
NCT00852098|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-25|2009-02-25|2009-02-26|Estimate|||||||2009-02-25|2009-02-26|Estimate|November 1997||1997-11-30|February 2009|2009-02-28|May 2008|Actual|2008-05-31|January 2000|Actual|2000-01-31||Interventional|||Laparoscopic Nissen Fundoplication Comparing Division Versus Non-Division of Short Gastric Vessels|Randomized Clinic Trial of Total Fundoplication and Fundal Mobilization With or Without Division of Short Gastric Vessels: Long-Term Endoscopic Evaluation|Completed||N/A|2|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:16:02.5671|2018-06-01 01:16:02.5671
NCT00852085|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-25|2009-02-25|2009-02-26|Estimate|||||||2009-02-25|2009-02-26|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|RYDD||Reducing Youthful Dangerous Driving||Unknown status|Active, not recruiting|Phase 1/Phase 2|482|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-06-01 01:16:02.644692|2018-06-01 01:16:02.644692
NCT00852072|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2017-08-08|2009-02-25|2009-02-26|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2016||2016-03-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Randomized Trial Comparing Sphincteroplasty and Lithotripsy for Extraction of Large Bile Duct Stones|Randomized Trial Comparing the Use of Single-operator Peroral Cholangioscopy-guided Laser Lithotripsy (POC-LL) Versus Endoscopic Balloon Sphincteroplasty (EBS) for Removal of Difficult Bile Duct Stones|Recruiting||N/A|82|Anticipated|Florida Hospital||2|||f||||f||||||||Yes|A manuscript will be developed when the study is complete.|2018-06-01 01:16:02.720823|2018-06-01 01:16:02.720823
NCT00852059|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2014-05-06|2009-02-25|2009-02-26|Estimate|||||||2014-05-06|2014-05-07|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ASTA||Adherence to Stimulant Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) Patients (ASTA)|Effect of Methylphenidate Formulation on ADHD-patients` Adherence to Medical Treatment. A Comparison of Medikinet Retard® (ER) Once Daily and Medikinet® (IR) Twice Daily in Children and Adolescents Diagnosed With ADHD|Terminated||Phase 4|32|Actual|Johannes Gutenberg University Mainz||2||Diffculties to recruit anticipated study size, now analysis|f||||f||||||||||2018-06-01 01:16:02.789041|2018-06-01 01:16:02.789041
NCT00852046|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2011-10-05|2009-02-25|2009-02-26|Estimate|||||||2011-10-05|2011-10-06|Estimate|February 2009||2009-02-28|July 2011|2011-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Adjunct Dexmedetomidine (Precedex®) Therapy Impact on Sedative and Analgesic Requirement|Adjunct Dexmedetomidine Therapy Impact on Sedative and Analgesic|Withdrawn||Phase 4|0|Actual|Avera McKennan Hospital & University Health Center||3||PI resigned.|f||||t||||||||||2018-06-01 01:16:02.962272|2018-06-01 01:16:02.962272
NCT00852033|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-24|2009-02-24|2009-02-26|Estimate|||||||2009-02-24|2009-02-26|Estimate|January 2004||2004-01-31|February 2009|2009-02-28|July 2009|Anticipated|2009-07-31|June 2007|Actual|2007-06-30||Interventional|Transitions||Alcohol Early Intervention for Freshmen|Alcohol Early Intervention for Freshmen|Unknown status|Active, not recruiting|N/A|1014|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||4|||f||||t||||||||||2018-06-01 01:16:03.050575|2018-06-01 01:16:03.050575
NCT00852020|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2017-01-30|2009-02-25|2009-02-26|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients|Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in CHF and COPD Patients. A Randomised, Double-blind and Controlled Pilot Study.|Completed||N/A|60|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 01:16:03.136733|2018-06-01 01:16:03.136733
NCT00852007|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-09-13|2009-02-25|2009-02-26|Estimate|||||||2016-09-13|2016-09-15|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2014|Actual|2014-02-28||Interventional|MUC1||A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1|A Phase I/II Study Evaluating the Safety and Efficacy of Vaccination With Autologous Dendritic Cells Loaded With Tn-MUC1 Peptide in Patients With Non-Metastatic Androgen Independent Prostatic Adenocarcinoma.|Completed||Phase 1/Phase 2|20|Actual|McMaster University||1|||f||||f||||||||||2018-06-01 01:16:03.21388|2018-06-01 01:16:03.21388
NCT00851994|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-10-31|2009-02-25|2009-02-26|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Urine Proteome of Patients Having Surgery|Urine Proteome of Patients Undergoing Surgery|Completed|||274|Actual|Washington University School of Medicine|||1||f||||f||||||Samples With DNA|"~     We are collecting urine and blood samples.~   "|||2018-06-01 01:16:03.279329|2018-06-01 01:16:03.279329
NCT00849238|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2015-10-06|2009-02-20|2009-02-23|Estimate|||||||2015-10-06|2015-10-08|Estimate||||October 2015|2015-10-31||||||||Interventional|||Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation|Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation Following Campath-1H Induction|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||||feasibility issues|f||||||||||||||2018-06-01 01:16:48.897183|2018-06-01 01:16:48.897183
NCT00851981|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2010-09-09|2009-02-24|2009-02-26|Estimate|||||||2010-09-09|2010-09-13|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|RCT SAMe||Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease|Effect of Oral S-Adenosylmethionine Administration on Abnormalities of Hepatic Methionine Metabolism and Disease Progression in Alcoholic Liver Disease. A Randomized, Double Blind, Placebo-controlled Trial|Completed||Phase 2|60|Anticipated|Loma Linda University||2|||f||||f||||||||||2018-06-01 01:16:03.335678|2018-06-01 01:16:03.335678
NCT00851968|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2016-03-30|2009-02-25|2009-02-26|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||A Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy|A Prospective Randomized Controlled Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy|Completed||N/A|320|Actual|Eastern Hepatobiliary Surgery Hospital||3|||f||||t||||||||||2018-06-01 01:16:03.395111|2018-06-01 01:16:03.395111
NCT00851955|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-01-11|2009-02-25|2009-02-26|Estimate|||||||2016-01-11|2016-01-12|Estimate|May 2007||2007-05-31|January 2016|2016-01-31|November 2011|Actual|2011-11-30|December 2009|Actual|2009-12-31||Observational|||Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer|Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer|Completed|||150|Actual|Mayo Clinic|||3||f||||||||||||||2018-06-01 01:16:03.469745|2018-06-01 01:16:03.469745
NCT00851942|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2017-11-03|2009-02-25|2009-02-26|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2008||2008-09-30|November 2017|2017-11-30|July 28, 2012|Actual|2012-07-28|July 28, 2012|Actual|2012-07-28||Interventional|||Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test|Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test|Completed||Phase 4|165|Actual|Cardiff University||1|||f||||f||||||||||2018-06-01 01:16:03.526082|2018-06-01 01:16:03.526082
NCT00851929|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-25|2009-02-25|2009-02-26|Estimate|||||||2009-02-25|2009-02-26|Estimate|November 2008||2008-11-30|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension|Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension|Unknown status|Recruiting|Phase 2/Phase 3|24|Anticipated|Medical University of South Carolina||1|||f||||f||||||||||2018-06-01 01:16:03.591138|2018-06-01 01:16:03.591138
NCT00851916|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2017-07-18|2009-02-25|2009-02-26|Estimate|||||||2017-07-18|2017-07-21|Actual|February 2009||2009-02-28|July 2017|2017-07-31||||February 2020|Anticipated|2020-02-29||Interventional|||CyberKnife Radiosurgery for Locally Recurrent Prostate CA|VIRTUAL HDR CYBERKNIFE RADIOSURGERY FOR LOCALLY RECURRENT PROSTATIC CARCINOMA: A PHASE II STUDY|Recruiting||Phase 2|20|Anticipated|CyberKnife Centers of San Diego||1|||f||||f||||||||||2018-06-01 01:16:03.6683|2018-06-01 01:16:03.6683
NCT00851903|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2012-09-03||2012-09-03|2009-02-25|2009-02-26|Estimate|2012-09-03|2012-10-04|Estimate||||2012-09-03|2012-10-04|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial|Combination Therapy of Insulin Glargine and Sitagliptin in Patients With Type 2 Diabetes Not Adequately Controlled by a Previous Treatment With Metformin and Either Insulin Glargine or Sitagliptin|Completed||Phase 3|112|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:16:03.744484|2018-06-01 01:16:03.744484
NCT00851890|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2014-12-29|2011-08-18|2014-12-29|2009-02-24|2009-02-26|Estimate|2014-12-29|2015-01-08|Estimate|2011-08-18|2011-08-23|Estimate|2014-12-29|2015-01-08|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Baseline characteristics were summarized by treatment group for all participants who received at least 1 dose of study drug. The treatment groups were compared with 1-way analysis of variance (ANOVA).|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|30|Actual|AbbVie||4|||f||||f||||||||||2018-06-01 01:16:05.057366|2018-06-01 01:16:05.057366
NCT00851877|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2017-11-02|2009-02-25|2009-02-26|Estimate|||||||2017-11-02|2017-11-06|Actual|March 1, 2009|Actual|2009-03-01|November 2017|2017-11-30|August 3, 2015|Actual|2015-08-03|October 1, 2013|Actual|2013-10-01||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer|A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma|Completed||Phase 1/Phase 2|80|Anticipated|University of Texas Southwestern Medical Center||1|||f||||||||||||||2018-06-01 01:16:06.633264|2018-06-01 01:16:06.633264
NCT00851864|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2013-08-14|2009-02-25|2009-02-26|Estimate|||||||2013-08-14|2013-08-15|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing|Weight-Adjusted Dosing of Tinzaparin in Pregnancy|Completed||Phase 4|13|Actual|University of Calgary||1|||f||||t||||||||||2018-06-01 01:16:06.730757|2018-06-01 01:16:06.730757
NCT00851851|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-07-18|2009-02-25|2009-02-26|Estimate|||||||2016-07-18|2016-07-20|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Observational|RTMKF||New Non-invasive Methods for Real-time Monitoring of Organ Function.|New Non-invasive Methods for Real-time Monitoring of Organ Function.|Completed|||641|Actual|Washington University School of Medicine|||||f||||f||||||Samples With DNA|"~     Urine and blood samples~   "|||2018-06-01 01:16:06.805434|2018-06-01 01:16:06.805434
NCT00851838|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2013-03-25|2009-02-25|2009-02-26|Estimate|||||||2013-03-25|2013-03-26|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis|Phase 2 Study of Dialysis Efficiency and Tolerability of Peritoneal Dialysis Solution Containing Glucose Plus L-Carnitine in APD (Automated Peritoneal Dialysis) Treated Uremic Patients|Completed||Phase 2|5|Actual|Iperboreal Pharma Srl||1|||f||||f||||||||||2018-06-01 01:16:06.868264|2018-06-01 01:16:06.868264
NCT00851825|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-05-07|2009-02-25|2009-02-26|Estimate|||||||2009-05-07|2009-05-08|Estimate|March 2003||2003-03-31|May 2009|2009-05-31|June 2007|Actual|2007-06-30|||||Observational|||Heart Rate Variability During Weaning From Mechanical Ventilation|The Effect of T-Tube and Pressure Support on Cardiorespiratory Variables and Heart Rate Variability During Weaning From Mechanical Ventilation|Completed|||30|Actual|Hospital de Clinicas de Porto Alegre|||||f||||f||||||||||2018-06-01 01:16:06.935612|2018-06-01 01:16:06.935612
NCT00851799|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2015-11-04||2015-12-09|2009-02-24|2009-02-26|Estimate|2015-12-09|2016-01-13|Estimate||||2015-12-09|2016-01-13|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||All eligible participants were included in the baseline characteristics.|Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters|Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Substudy of A5257|Completed|||334|Actual|AIDS Clinical Trials Group|||3||f||||||||||Samples Without DNA|"~     Blood and urine samples will be collected and stored~   "|||2018-06-01 01:16:07.22794|2018-06-01 01:16:07.22794
NCT00851786|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2012-09-07||2018-01-08|2009-02-25|2009-02-26|Estimate|2012-09-07|2012-10-10|Estimate||||2018-01-08|2018-02-01|Actual|April 29, 2009|Actual|2009-04-29|January 2018|2018-01-31|January 3, 2012|Actual|2012-01-03|September 22, 2011|Actual|2011-09-22||Interventional|||Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy|A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX® (Zoster Vaccine Live) in Human Immunodeficiency Virus (HIV)-1-Infected Adults on Potent Combination ART With Conserved Immune Function|Completed||Phase 2|395|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:16:08.320632|2018-06-01 01:16:08.320632
NCT00851773|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2015-02-20|2009-02-25|2009-02-26|Estimate|||||||2015-02-20|2015-02-23|Estimate|February 2009||2009-02-28|February 2015|2015-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects|A Randomised, Double Blind, Placebo-controlled, Parallel-group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.|Completed||Phase 1|84|Actual|Novo Nordisk A/S||10|||f||||f||||||||||2018-06-01 01:16:09.033159|2018-06-01 01:16:09.033159
NCT00851760|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-08-03|2009-02-25|2009-02-26|Estimate|||||||2009-08-03|2009-08-04|Estimate|January 2005||2005-01-31|August 2009|2009-08-31|September 2007|Actual|2007-09-30|December 2006|Actual|2006-12-31||Interventional|||Epiretinal Macular Membrane and Cataract Extraction|Idiopathic Epiretinal Macular Membrane and Cataract Extraction : Combined vs Consecutive Surgery|Completed||N/A|174|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-06-01 01:16:09.128714|2018-06-01 01:16:09.128714
NCT00851747|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2017-04-18||2018-03-19|2009-02-25|2009-02-26|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|February 2009||2009-02-28|March 2018|2018-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||No analysis completed. PI left the institution|A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal|A Randomized, Double-Blinded, Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal|Terminated||N/A|18|Actual|The Cleveland Clinic|PI left institution, no data available.|3|||f||||||||||||No||2018-06-01 01:16:09.224075|2018-06-01 01:16:09.224075
NCT00851734|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2012-06-21|2009-02-25|2009-02-26|Estimate|||||||2012-06-21|2012-06-22|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)|A Phase 1 Dose-Escalation Study To Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed By an Open-Label Evaluation of LX214 Ophthalmic Solution in Patients With Keratoconjunctivitis Sicca|Completed||Phase 1|35|Actual|Lux Biosciences, Inc.||3|||f||||f||||||||||2018-06-01 01:16:09.41437|2018-06-01 01:16:09.41437
NCT00851721|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2014-01-30||2017-10-19|2009-02-25|2009-02-26|Estimate|2014-01-30|2014-03-14|Estimate||||2017-10-19|2017-11-22|Actual|March 2009||2009-03-31|October 2016|2016-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor|FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor|Completed||Phase 3|52|Actual|Shire||2|||f||||t||||||||||2018-06-01 01:16:09.601616|2018-06-01 01:16:09.601616
NCT00851708|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-27|2009-02-25|2009-02-26|Estimate|||||||2009-02-27|2009-03-02|Estimate||||February 2009|2009-02-28||||||||Interventional|||Impact of N-Acetylcysteine on Oxidative Stress and Renal Function in Deceased Kidney Transplant Recipients|Oxidative Stress and Postoperatory Renal Function in Deceased Kidney Transplantation|Completed||N/A|||University of Sao Paulo||2|||f||||f||||||||||2018-06-01 01:16:11.700822|2018-06-01 01:16:11.700822
NCT00851695|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2012-08-10|2009-02-25|2009-02-26|Estimate|||||||2012-08-10|2012-08-13|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Examining the Role of Vitamin D in Asthma and Chronic Obstructive Pulmonary Disease (COPD)|Vitamin D in Obstructive Lung Diseases|Completed|||2266|Actual|Brigham and Women's Hospital|||3||f||||f||||||Samples With DNA|"~     Serum samples~   "|||2018-06-01 01:16:11.764577|2018-06-01 01:16:11.764577
NCT00851682|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2015-09-08||2015-10-14|2009-02-25|2009-02-26|Estimate|2015-10-14|2015-11-11|Estimate||||2015-10-14|2015-11-11|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Feasibility Study of Prostate Tumor Localization for Focal Cryoablation of Prostate Carcinoma|Feasibility Study of Prostate Tumor Localization for Focal Cryoablation of Prostate Carcinoma|Terminated||N/A|65|Actual|Washington University School of Medicine||2||Enrollment was stopped and will not resume. Participants are no longer being examined.|f||||f||||||||||2018-06-01 01:16:11.826952|2018-06-01 01:16:11.826952
NCT00851669|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2013-07-12|2009-02-25|2009-02-26|Estimate|||||||2013-07-12|2013-07-16|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|MEADOW/Bridge||The MEADOW PROJECT (Mending the Effects of Alcohol and Depression on Women) and The Bridge Program (Connecting Recovery Treatment and Behavioral Health)|Behavioral Treatment for Alcohol Dependent Women With Co-occurring Depression|Completed||Phase 2|91|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 01:16:12.017468|2018-06-01 01:16:12.017468
NCT00851656|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-25|2009-02-25|2009-02-26|Estimate|||||||2009-02-25|2009-02-26|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||MilkScreen Home Test for Alcohol in Breast Milk|MilkScreen Home Test for Alcohol in Breast Milk Clinical Study|Completed|||48|Actual|UpSpring Baby, Ltd.|||||f||||f||||||||||2018-06-01 01:16:12.170902|2018-06-01 01:16:12.170902
NCT00850915|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2013-05-17|2009-02-24|2009-02-25|Estimate|||||||2013-05-17|2013-05-20|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|IPT||Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya|Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya|Completed||Phase 4|1259|Actual|KNCV Tuberculosis Foundation||2|||f||||f||||||||||2018-06-01 01:16:21.082206|2018-06-01 01:16:21.082206
NCT00851643|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2011-02-10||2016-02-02|2009-02-24|2009-02-26|Estimate|2011-05-20|2011-06-21|Estimate||||2016-02-02|2016-02-03|Estimate|April 2006||2006-04-30|February 2016|2016-02-29|November 2009|Actual|2009-11-30|December 2007|Actual|2007-12-31||Interventional|||Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)|A Randomized, Double-Blind, Multicenter, Biphasic, Controlled With GARDASIL™ Dose-Escalation Study of Octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and ISCOMATRIX™ (IMX)|Completed||Phase 1|158|Actual|Merck Sharp & Dohme Corp.||6|||f||||t||||||||||2018-06-01 01:16:12.249425|2018-06-01 01:16:12.249425
NCT00851630|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2009-03-15||2010-05-02|2009-02-25|2009-02-26|Estimate|2009-12-05|2010-01-08|Estimate||||2010-05-02|2010-05-04|Estimate|June 2004||2004-06-30|May 2010|2010-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|THIRST||Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)|A Pilot Study Of Open-Label Fixed Dose Combination Zidovudine/Lamivudine/Abacavir In HIV-Infected Persons With Tuberculosis In Moshi, Tanzania; Tuberculosis And HIV Immune Reconstitution Syndrome Trial (THIRST)|Completed||Phase 4|70|Actual|Duke University||2|||f||||t||||||||||2018-06-01 01:16:12.926914|2018-06-01 01:16:12.926914
NCT00851617|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-03-05|2009-02-25|2009-02-26|Estimate|||||||2009-03-05|2009-03-06|Estimate|August 2004||2004-08-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|March 2005|Actual|2005-03-31||Interventional|||Does Threshold IMT Influence Weaning?|Is Threshold IMT Useful To Accelerate Weaning From Mechanical Ventilation?|Completed||N/A|92|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:16:13.250226|2018-06-01 01:16:13.250226
NCT00851604|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2010-06-02|2009-02-25|2009-02-26|Estimate|||||||2010-06-02|2010-06-03|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|January 2011|Anticipated|2011-01-31|March 2010|Anticipated|2010-03-31||Observational|||ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors|Evaluation of Serological Markers ProGRP, CgA, NSE and TUM2-PK in Patients With Malignant Neuroendocrine Tumors|Unknown status|Recruiting||40|Anticipated|Hadassah Medical Organization|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-06-01 01:16:13.318402|2018-06-01 01:16:13.318402
NCT00851591|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2014-01-24||2017-10-31|2009-02-25|2009-02-26|Estimate|2014-06-30|2014-07-28|Estimate||||2017-10-31|2017-12-05|Actual|September 2008||2008-09-30|October 2017|2017-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|fenugreek||Effect of Fenugreek on Milk Production|Effect of Fenugreek on Milk Production|Terminated||N/A|3|Actual|Texas Tech University Health Sciences Center||2||Low enrollment; investigator chose not to continue study|f||||t||||||||||2018-06-01 01:16:13.388162|2018-06-01 01:16:13.388162
NCT00851578|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2015-01-26|2009-02-24|2009-02-26|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|December 2013|Actual|2013-12-31|February 2012|Actual|2012-02-29||Interventional|ASAP||ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology|ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology|Completed||N/A|150|Anticipated|Boston Scientific Corporation||1|||f||||t||||||||||2018-06-01 01:16:13.584051|2018-06-01 01:16:13.584051
NCT00851565|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2011-11-24|2009-02-25|2009-02-26|Estimate|||||||2011-11-24|2011-11-28|Estimate|June 2009||2009-06-30|November 2011|2011-11-30|February 2014|Anticipated|2014-02-28|February 2012|Anticipated|2012-02-29||Interventional|||Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy|Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-06-01 01:16:13.646057|2018-06-01 01:16:13.646057
NCT00851552|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2014-06-23||2014-06-23|2009-02-25|2009-02-26|Estimate|2014-06-23|2014-07-21|Estimate||||2014-06-23|2014-07-21|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||All treated and eligible patients|Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment|A Phase II Study of VDR (VELCADE™, DOXIL® and RITUXAN™) in Relapsed/Refractory Diffuse Large B-cell Lymphoma|Terminated||Phase 2|9|Actual|Roswell Park Cancer Institute|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.|||Lack of sponsor support|f||||t||||||||||2018-06-01 01:16:13.733442|2018-06-01 01:16:13.733442
NCT00851539|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2014-12-09|2009-02-25|2009-02-26|Estimate|||||||2014-12-09|2014-12-10|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|April 2011|Actual|2011-04-30|November 2008|Actual|2008-11-30||Interventional|Control||Evaluating Post-test HIV Counseling Videos for Teens|Educational Effectiveness of an HIV Pretest Video for Adolescents: A Randomized Controlled Trial|Completed||N/A|200|Actual|North Bronx Healthcare Network||2|||f||||t||||||||||2018-06-01 01:16:14.007165|2018-06-01 01:16:14.007165
NCT00851526|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2012-07-15|2009-02-25|2009-02-26|Estimate|||||||2012-07-15|2012-07-17|Estimate|January 2004||2004-01-31|July 2012|2012-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|COBIS||Coronary Bifurcation Stenting (COBIS) Registry in South Korea|Coronary Bifurcation Stenting (COBIS) Registry in South Korea|Completed|||1919|Actual|Samsung Medical Center|||1||f||||||||||||||2018-06-01 01:16:14.078377|2018-06-01 01:16:14.078377
NCT00851513|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2013-09-02|2009-02-25|2009-02-26|Estimate|||||||2013-09-02|2013-09-04|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|INFILTHERA||Therapeutic Effects Analysis of Pudendal Nerve Infiltrations After 3 Months, in Patients Suffering of Pudendal Neuralgia||Completed||Phase 4|202|Actual|Nantes University Hospital||3|||f||||||||||||||2018-06-01 01:16:14.136836|2018-06-01 01:16:14.136836
NCT00851500|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2011-08-15|2009-02-25|2009-02-26|Estimate|||||||2011-08-15|2011-08-17|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis||Completed||Phase 2|210|Anticipated|Kowa Research Institute, Inc.||3|||f||||f||||||||||2018-06-01 01:16:14.235578|2018-06-01 01:16:14.235578
NCT00851487|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-02-25|2009-02-25|2009-02-26|Estimate|||||||2009-02-25|2009-02-26|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Trial of Amoxicillin Compared With Placebo for Pneumonia in Children Aged 2-59 Months|A Randomized Multicentre Double Blind Trial of Amoxicillin Compared With Placebo for Treatment of WHO Defined Non-Severe Pneumonia in Children Aged 2-59 Months: NARIMA Study Group|Completed||N/A|900|Actual|Pakistan Institute of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:16:14.319724|2018-06-01 01:16:14.319724
NCT00851474|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2016-05-25|2009-02-25|2009-02-26|Estimate|||||||2016-05-25|2016-05-27|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|WSU||Measurement of Cardiac Output and Blood Volumes|Measurement of Cardiac Output and Blood Volumes|Withdrawn|||0|Actual|Transonic Systems Inc.||||Protocol not renewed|f||||f||||||||||2018-06-01 01:16:14.455975|2018-06-01 01:16:14.455975
NCT00851448|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2011-06-01|2009-02-25|2009-02-26|Estimate|||||||2011-06-01|2011-06-02|Estimate|October 2009||2009-10-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients|Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients. A Randomised, Double-blind, Controlled Pilot Study|Terminated||N/A|17|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 01:16:14.610685|2018-06-01 01:16:14.610685
NCT00851435|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2009-07-29|2009-02-25|2009-02-26|Estimate|||||||2009-07-29|2009-07-30|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa|A Non-comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa|Completed||Phase 1/Phase 2|15|Anticipated|Kenta Biotech Ltd||1|||f||||f||||||||||2018-06-01 01:16:14.688213|2018-06-01 01:16:14.688213
NCT00851422|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|||2012-05-30|2009-02-25|2009-02-26|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|BCM||Accurate Measurement of Cardiac Output Using the Ultrasound Dilution Technique|Accurate Measurement of Cardiac Output Using the Ultrasound Dilution Technique|Completed|||28|Actual|Transonic Systems Inc.|||||f||||f||||||||||2018-06-01 01:16:14.775132|2018-06-01 01:16:14.775132
NCT00851409|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-25|2012-11-09||2012-12-20|2009-02-25|2009-02-26|Estimate|2012-12-20|2013-01-31|Estimate||||2012-12-20|2013-01-31|Estimate|June 2009||2009-06-30|December 2012|2012-12-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|OPERA||A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration|"An Open-label Exploratory Phase II Study of the Safety and Immunogenicity of Repeated rhC1INH Administration of 50 U/Kg in Patients With Hereditary C1 Inhibitor Deficiency (HAE)"|Completed||Phase 2|25|Actual|Pharming Technologies B.V.||1|||f||||f||||||||||2018-06-01 01:16:14.879959|2018-06-01 01:16:14.879959
NCT00851396|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2011-09-09|2009-02-24|2009-02-25|Estimate|||||||2011-09-09|2011-09-12|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Assessment of Influence of Vitamin D on Insulin Secretion and Sensitivity in Obese Teenage Girls|Assessment of Influence of Vitamin D on Insulin Secretion and Sensitivity in Obese Teenage Girls (Assessment of Prevalence of Vitamin D Deficiency in Obese Teenage Girls and Influence of Vitamin D on Insulin Secretion and Sensitivity)|Completed|||30|Anticipated|University of Alabama at Birmingham|||1||f||||f||||||||||2018-06-01 01:16:15.054243|2018-06-01 01:16:15.054243
NCT00851383|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2012-04-23|2009-02-24|2009-02-25|Estimate|||||||2012-04-23|2012-04-25|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers|A Phase I Placebo-controlled, Double-blinded (in Terms of Vaccine or Placebo), Randomized Dose-escalation Trial to Evaluate the Safety and Immunogenicity of Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers. (IAVI B001)|Completed||Phase 1|56|Actual|International AIDS Vaccine Initiative||4|||f||||t||||||||||2018-06-01 01:16:15.119941|2018-06-01 01:16:15.119941
NCT00851370|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-03-27|2009-02-24|2009-02-25|Estimate|||||||2017-03-27|2017-03-29|Actual|January 2009||2009-01-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels|Exploratory Study of Xolair (Omalizumab)to Improve Outcomes in Patients With COPD and Elevated IgE Levels, and Positive RAST or Skin Prick Tests|Withdrawn||Phase 2|0|Actual|National Jewish Health||2||Unable to find eligible subjects- study closed|f||||t||||||||||2018-06-01 01:16:15.236501|2018-06-01 01:16:15.236501
NCT00851357|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2017-11-07|2009-02-24|2009-02-25|Estimate|||||||2017-11-07|2017-11-09|Actual|February 2009||2009-02-28|November 2017|2017-11-30|December 2011|Actual|2011-12-31|October 2010|Actual|2010-10-31||Interventional|||Telephone Counseling and the Distribution of Nicotine Patches to Smokers|The Efficacy of Telephone Counseling and the Centralized Distribution of Nicotine Replacement Therapy Through a Smoking Cessation Quitline|Completed||Phase 3|4200|Actual|University of California, San Diego||6|||f||||f||||||||No||2018-06-01 01:16:15.310185|2018-06-01 01:16:15.310185
NCT00851344|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2016-11-04|2009-02-24|2009-02-25|Estimate|||||||2016-11-04|2016-11-07|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo|A Randomised, Double-blind, Placebo-controlled, 4-period Incomplete Block Crossover Study of Single Oral Dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and Placebo to Evaluate the Efficacy and Safety Using an Environmental Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis|Completed||Phase 2|54|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:16:15.395127|2018-06-01 01:16:15.395127
NCT00851331|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-24|2009-02-24|2009-02-25|Estimate|||||||2009-02-24|2009-02-25|Estimate||||February 2009|2009-02-28||||||||Interventional|||Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits|Genetic Basis of Idiopathic Focal Epilepsies With Cognitif Deficits|Unknown status|Not yet recruiting|N/A|||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 01:16:15.514998|2018-06-01 01:16:15.514998
NCT00851318|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2014-09-09||2014-10-27|2009-02-24|2009-02-25|Estimate|2014-09-09|2014-09-17|Estimate||||2014-10-27|2014-11-03|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients|A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered in Combination With Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-001)|Completed||Phase 3|285|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:16:15.845672|2018-06-01 01:16:15.845672
NCT00851305|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2012-07-16|2009-02-24|2009-02-25|Estimate|||||||2012-07-16|2012-07-17|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|CLE||Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy|Comparison Confocal Laser Endomicroscopy With Conventional Endoscopy for the Detection of Early Gastric Cancers|Completed||N/A|1786|Actual|Shandong University||2|||f||||t||||||||||2018-06-01 01:16:17.140781|2018-06-01 01:16:17.140781
NCT00851292|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2011-06-21|2009-02-24|2009-02-25|Estimate|||||||2011-06-21|2011-06-22|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|BIOPRES||The BIOPRES Trial: Transrectal BIOpsies of the PRostate: End Versus Side-firing|The BIOPRES Trial; Transrectal BIOpsies of the PRostate: End Versus Side-firing|Unknown status|Recruiting|Phase 3|800|Anticipated|Amphia Hospital||2|||f||||f||||||||||2018-06-01 01:16:17.217156|2018-06-01 01:16:17.217156
NCT00851279|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2013-12-02||2015-07-27|2009-02-24|2009-02-25|Estimate|2015-07-27|2015-08-24|Estimate||||2015-07-27|2015-08-24|Estimate|June 2009||2009-06-30|July 2015|2015-07-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|STOP-VT||Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia|Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia: Data Collection of Clinical Scar-related VT Cases|Completed||Phase 4|53|Actual|Stereotaxis||1|||f||||f||||||||||2018-06-01 01:16:17.299126|2018-06-01 01:16:17.299126
NCT00851266|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2015-02-11|2009-02-23|2009-02-25|Estimate|||||||2015-02-11|2015-02-12|Estimate|October 2006||2006-10-31|February 2015|2015-02-28|January 2009|Actual|2009-01-31|August 2007|Actual|2007-08-31||Interventional|||A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults|A Dose-Escalation, Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of a Bivalent Influenza Peptide Conjugate Vaccine Formulated With Aluminum- and ISCOMATRIX(TM) Containing Adjuvants (BIPCV/IMX) Evaluated in Healthy Adults 18 to 35 Years of Age|Completed||Phase 1|187|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:16:17.490061|2018-06-01 01:16:17.490061
NCT00851253|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2017-07-10||2017-12-17|2009-02-24|2009-02-25|Estimate|2017-12-17|2018-01-17|Actual||||2017-12-17|2018-01-17|Actual|January 2009||2009-01-31|December 2017|2017-12-31|April 2017|Actual|2017-04-30|December 2014|Actual|2014-12-31||Interventional|||Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer|The Feasibility and Outcome of Cyberknife® Stereotactic Radiosurgical Boost and Salvage Therapy for Head and Neck Cancer|Completed||N/A|12|Actual|Boston Medical Center||2|||f||||t|f|t|f|f|t|||Undecided||2018-06-01 01:16:17.571748|2018-06-01 01:16:17.571748
NCT00851240|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2012-02-02|2009-02-24|2009-02-25|Estimate|||||||2012-02-02|2012-02-03|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||BTT-1023 in Rheumatoid Arthritis|A Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of Repeated Intravenous Doses of BTT-1023 in Patients With Rheumatoid Arthritis - a Double-blind Randomized Placebo-controlled Sequential Group Trial|Completed||Phase 1|24|Actual|Biotie Therapies Corp.||2|||f||||||||||||||2018-06-01 01:16:17.864766|2018-06-01 01:16:17.864766
NCT00851227|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2014-04-30|2009-02-23|2009-02-25|Estimate|||||||2014-04-30|2014-05-02|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function|A Phase 1, Open-Label Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan|Completed||Phase 1|26|Actual|Cumberland Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:16:17.921593|2018-06-01 01:16:17.921593
NCT00851214|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2010-02-17|2009-02-24|2009-02-25|Estimate|||||||2010-02-17|2010-02-18|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Use of Non Invasive Hemodynamic Cardiovascular Monitoring to Evaluate Emergency Department Patients|Assessments of Early Hemodynamics in Emergency Department Patients and Evaluation of Trends and Variability in Prediction of Life-saving Interventions|Completed|||40|Actual|Henry Ford Health System|||4||f||||f||||||||||2018-06-01 01:16:17.993299|2018-06-01 01:16:17.993299
NCT00851201|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-10-16|2009-02-23|2009-02-25|Estimate|||||||2017-10-16|2017-10-18|Actual|August 2009||2009-08-31|October 2017|2017-10-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Family Weight Management Study|Comprehensive Approach to Family Weight Management|Completed||N/A|360|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 01:16:18.21559|2018-06-01 01:16:18.21559
NCT00851188|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2012-06-12|2009-02-24|2009-02-25|Estimate|||||||2012-06-12|2012-06-13|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Internet Delivered Self-help for Insomnia||Completed||N/A|626|Actual|Utrecht University||3|||f||||t||||||||||2018-06-01 01:16:18.282346|2018-06-01 01:16:18.282346
NCT00851175|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-09-30|2009-02-24|2009-02-25|Estimate|||||||2009-09-30|2009-10-01|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?|Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?|Completed||Phase 4|8|Anticipated|Radboud University||4|||f||||f||||||||||2018-06-01 01:16:18.349267|2018-06-01 01:16:18.349267
NCT00851162|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2012-11-27|2009-02-24|2009-02-25|Estimate|||||||2012-11-27|2012-11-28|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions|Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions|Withdrawn||Phase 2/Phase 3|0|Actual|Emory University||2||Study was not continued due to lack of enrollment.|f||||f||||||||||2018-06-01 01:16:18.430238|2018-06-01 01:16:18.430238
NCT00851149|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2010-06-10|2009-02-23|2009-02-25|Estimate|||||||2010-06-10|2010-06-11|Estimate|November 2009||2009-11-30|June 2010|2010-06-30|May 2010|Anticipated|2010-05-31|February 2010|Anticipated|2010-02-28||Observational|KEEP-HB||Pro-inflammatory Cytokines in Blood From Orthopedic Surgery Compared to Abdominal Aneurysm Repair|Pro-inflammatory Cytokines (IL-1beta,IL-6, IL-8 and TNF-α) and Complement Activation (C3a) in Blood Collected From Surgery Field From Patients Undergoing Orthopedic Surgery Compared to Patients Undergoing Abdominal Aneurysm Repair.|Unknown status|Active, not recruiting||20|Anticipated|Sykehuset i Vestfold HF|||2||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 01:16:18.506473|2018-06-01 01:16:18.506473
NCT00851136|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2010-06-29|2009-02-23|2009-02-25|Estimate|||||||2010-06-29|2010-07-01|Estimate|May 2009||2009-05-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|||||Interventional|||A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)|A Phase Ib Study of the Safety and Pharmacokinetics of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer|Completed||Phase 1|9|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:16:18.578105|2018-06-01 01:16:18.578105
NCT00851123|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2014-01-03|2009-02-23|2009-02-25|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Modified Constrained - Induced Movement Therapy Compared to Intensive Bimanual Training|Modified Constrained - Induced Movement Therapy Compared to Intensive Bimanual Training for Subacute Stroke Patients. A Randomized Controlled Trial|Terminated||N/A|30|Actual|University of Bergen||2||Due to recruitment difficulties the trial was stopped after an interim analysis at 30 patients.|f||||t||||||||||2018-06-01 01:16:18.651133|2018-06-01 01:16:18.651133
NCT00851110|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-02-24|2009-02-24|2009-02-25|Estimate|||||||2009-02-24|2009-02-25|Estimate|October 2004||2004-10-31|February 2009|2009-02-28||||||||Interventional|||Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors|A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.|Terminated||Phase 2|50|Anticipated|University Medical Center Groningen|||||f||||||||||||||2018-06-01 01:16:18.798269|2018-06-01 01:16:18.798269
NCT00851084|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2013-02-19||2016-05-04|2009-02-24|2009-02-25|Estimate|2013-06-21|2013-06-25|Estimate||||2016-05-04|2016-06-07|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|AFFIRM||Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer|Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer|Completed||Phase 2|268|Actual|Sanofi|The overall survival (OS) data are severely limited due to the low number of events (<50%) in both arms, therefore median OS cannot be accurately estimated due to limitations of available data.|2|||f||||t||||||||||2018-06-01 01:16:18.921773|2018-06-01 01:16:18.921773
NCT00851071|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-12-20|2009-02-24|2009-02-25|Estimate|||||||2017-12-20|2017-12-22|Actual|February 2009|Actual|2009-02-28|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|December 2011|Actual|2011-12-31||Interventional|||Interventional Study of Anxiety Symptoms in the Implantable Cardioverter Defibrillator (ICD) Patient|"Bakken Heart Brain Institute's An Observational and Interventional Study of Anxiety Symptoms in the Implantable Cardioverter Defibrillator (ICD) Patient."|Completed||N/A|28|Actual|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-06-01 01:16:19.688613|2018-06-01 01:16:19.688613
NCT00851058|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2011-02-24|2009-02-24|2009-02-25|Estimate|||||||2011-02-24|2011-02-25|Estimate|May 2007||2007-05-31|February 2011|2011-02-28|April 2012|Anticipated|2012-04-30|March 2010|Anticipated|2010-03-31||Interventional|ROAD||Reducing Driving Offenses of Adolescent Drinkers|A Randomized Control Trial of the Effectiveness of of Group Motivational Counseling and an Emergency Department Experience in Reducing Risky Alcohol Use and Driving Behaviors.|Unknown status|Active, not recruiting|Phase 1/Phase 2|786|Anticipated|Rhode Island Hospital||3|||f||||t||||||||||2018-06-01 01:16:19.82204|2018-06-01 01:16:19.82204
NCT00851045|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23||2015-09-23|2015-09-23|2009-02-23|2009-02-25|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|October 2009||2009-10-31|September 2015|2015-09-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer|A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer|Completed||Phase 2|17|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:16:19.90115|2018-06-01 01:16:19.90115
NCT00851032|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2018-01-19|2009-02-23|2009-02-25|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2009|Actual|2009-02-28|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol|An Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial. A Molecular Profile-Based Study in Patients With Advanced Cancer Treated in the Investigational Cancer Therapeutics Program|Recruiting|||5000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Specimen obtained from MDACC Tissue Bank.~   "|||2018-06-01 01:16:20.001832|2018-06-01 01:16:20.001832
NCT00851019|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2013-03-25|2009-02-24|2009-02-25|Estimate|||||||2013-03-25|2013-03-27|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Dance Dance Revolution (DDR) in Type 2 Diabetes|Dance Dance Revolution (DDR) Exergaming in Adults With Type 2 Diabetes Mellitus|Completed||N/A|76|Actual|Charles Drew University of Medicine and Science||2|||f||||t||||||||||2018-06-01 01:16:20.077949|2018-06-01 01:16:20.077949
NCT00851006|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2014-12-09||2017-04-06|2009-02-24|2009-02-25|Estimate|2015-01-08|2015-01-13|Estimate||||2017-04-06|2017-05-12|Actual|April 2009||2009-04-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram|Adjunctive Creatine Treatment for Adolescent Females With Major Depressive Disorder Who Are Non-Responders to Fluoxetine or Escitalopram: A Magnetic Resonance Spectroscopy Study|Completed||Phase 2|13|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:16:20.14922|2018-06-01 01:16:20.14922
NCT00850993|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2013-12-06||2014-08-19|2009-02-24|2009-02-25|Estimate|2014-08-19|2014-08-29|Estimate||||2014-08-19|2014-08-29|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|June 2011|Actual|2011-06-30||Interventional|||A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia|A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia|Terminated||Phase 2|63|Actual|InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company|It should be noted that the study was discontinued before enrollment of the full 4.5 mg/kg cohort,and therefore, the stannsoporfin 4.5 mg/kg treatment group included 8 patients and the placebo group included 15 patients.|2||To redefine study population|f||||t||||||||||2018-06-01 01:16:20.356358|2018-06-01 01:16:20.356358
NCT00850980|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-02-09|2009-02-24|2009-02-25|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2009|Actual|2009-02-28|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Selective AV Nodal Vagal Stimulation For Reduction of the Ventricular Rate During Atrial Fibrillation|Selective AV Nodal Vagal Stimulation For Reduction of the Ventricular Rate During Atrial Fibrillation|Withdrawn|||0|Actual|The Cleveland Clinic||||unable to recruit|f||||f|f|f||||||No||2018-06-01 01:16:20.840232|2018-06-01 01:16:20.840232
NCT00850954|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2017-09-05|2009-02-24|2009-02-25|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2006|Actual|2006-08-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Project CASA: Promoting Smoke-Free Indoor Air Policy in Mexican American Households|Project CASA: Promoting Smoke-Free Indoor Air Policy in Mexican American Households|Recruiting|||250|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 01:16:20.892064|2018-06-01 01:16:20.892064
NCT00850941|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2018-02-01|2009-02-23|2009-02-25|Estimate|||||||2018-02-01|2018-02-05|Actual|January 26, 2009|Actual|2009-01-26|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy|Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy|Active, not recruiting|||146|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Leftover tissue from prostate surgery to be used for biomarker research.~   "|||2018-06-01 01:16:20.957821|2018-06-01 01:16:20.957821
NCT00850928|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2016-03-15|2009-02-24|2009-02-25|Estimate|||||||2016-03-15|2016-03-17|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids|Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids.|Completed|||41|Actual|New York University School of Medicine|||1||f||||f||||||Samples With DNA|"~     Serum and plasma will be collected and stored at baseline, intra-operatively, and one day~     post-operative for analysis of markers of inflammation. Plasma will be collected and stored~     at baseline, three months, and six months for analysis of Beta Amyloid levels. DNA will be~     collected and stored at baseline for analysis of Apolipoprotein E.~   "|No||2018-06-01 01:16:21.023095|2018-06-01 01:16:21.023095
NCT00850902|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-03-09|2009-02-24|2009-02-25|Estimate|||||||2009-03-09|2009-03-10|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Humidity Strategy to Decrease Morbidity and Mortality in Extremely Low Birth Weight Infants|Application of a Different Incubator Humidity Strategy at Birth to Decrease Morbidity and Mortality in Extremely Low Birth (1000 g or Less) Infants|Unknown status|Not yet recruiting|N/A|700|Anticipated|King Fahad Medical City||2|||f||||t||||||||||2018-06-01 01:16:21.244869|2018-06-01 01:16:21.244869
NCT00850889|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2011-02-24||2014-10-06|2009-02-24|2009-02-25|Estimate|2011-03-23|2011-04-21|Estimate||||2014-10-06|2014-10-13|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nasolabial Folds||Completed||Phase 4|32|Actual|Allergan||2|||f||||||||||||||2018-06-01 01:16:21.31979|2018-06-01 01:16:21.31979
NCT00850876|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2010-04-08|2009-02-24|2009-02-25|Estimate|||||||2010-04-08|2010-04-09|Estimate|September 2008||2008-09-30|April 2010|2010-04-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Observational|||Heated Humidified Continuous Positive Airway Pressure and Nasal Physiology|Randomized Cross-over Trials of the Effect of Heated Humidified CPAP Versus Non-humidified CPAP on Nasal Physiology|Completed|||20|Actual|University of Athens|||||f||||f||||||Samples Without DNA|"~     Nasal wash will be performed using a technique adapted by Hurst et al. Briefly, a 12-French~     Foley catheter (Bard, Crawley, UK), modified by removal of the tip distal to the balloon, was~     inserted into the nostril and inflated with sufficient air to form a comfortable seal~     (typically 7-10ml). With the patients head flexed 45o forward, 7ml of warmed 0.9% saline will~     be instilled through the catheter and washed in and out of the nasal cavity three times. A~     portion of the pooled wash from both nostrils will be centrifuged to yield a supernatant for~     analysis of inflammatory cytokines (IL-6, IL-8, TNF-a, IL-10).~   "|||2018-06-01 01:16:21.514935|2018-06-01 01:16:21.514935
NCT00850863|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-24|2009-02-24|2009-02-25|Estimate|||||||2009-02-24|2009-02-25|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|January 2015|Anticipated|2015-01-31|January 2013|Anticipated|2013-01-31||Observational|||Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)|Acute and Chronic Inflammatory Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD: From Specific Disease Phenotyping Towards Novel Therapy (Study 2).|Unknown status|Recruiting||240|Anticipated|Top Institute Pharma|||9||f||||t||||||||||2018-06-01 01:16:21.578585|2018-06-01 01:16:21.578585
NCT00850850|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2010-05-26|2009-02-24|2009-02-25|Estimate|||||||2010-05-26|2010-05-27|Estimate|December 2009||2009-12-31|May 2010|2010-05-31|May 2011|Anticipated|2011-05-31|March 2011|Anticipated|2011-03-31||Interventional|||Physostigmine After General Anesthesia|The Use of Physostigmine in Elderly Patients in the Postoperative Recovery-phase After General Anesthesia|Unknown status|Recruiting|N/A|50|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||||2018-06-01 01:16:21.687848|2018-06-01 01:16:21.687848
NCT00850837|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2013-12-02|2009-02-24|2009-02-25|Estimate|||||||2013-12-02|2013-12-03|Estimate|February 2009||2009-02-28|December 2013|2013-12-31||||||||Interventional|||Safety of Acidform Lubricant in HIV-Uninfected Women|Safety of Acidform Lubricant (Amphora) in Women at Low Risk for HIV-1 Infection|Completed||Phase 1|35|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:16:21.774438|2018-06-01 01:16:21.774438
NCT00850824|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2015-10-05|2009-02-23|2009-02-25|Estimate|||||||2015-10-05|2015-10-07|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|June 2011|Actual|2011-06-30||Interventional|DCAS||Community Health Workers in Diabetes Care in American Samoa|Diabetes Care in American Samoa|Completed||N/A|268|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 01:16:21.864474|2018-06-01 01:16:21.864474
NCT00850811|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2015-09-07|2009-02-24|2009-02-25|Estimate|||||||2015-09-07|2015-09-09|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers|A 4-Day, Randomized, Controlled, Open Application Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers, Using a Phototoxicity Test Design|Completed||Phase 1|30|Anticipated|Peplin||1|||f||||f||||||||||2018-06-01 01:16:21.951056|2018-06-01 01:16:21.951056
NCT00850798|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2010-07-23|2009-02-24|2009-02-25|Estimate|||||||2010-07-23|2010-07-26|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|December 2020|Anticipated|2020-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Benefits of Intensive Glycemic Control in Elderly Patients With Type 2 Diabetes||Recruiting||N/A|208|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-06-01 01:16:22.019781|2018-06-01 01:16:22.019781
NCT00850785|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2016-09-26|2009-02-24|2009-02-25|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|DRibble||Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer|A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer|Completed||Phase 1|6|Actual|Providence Health & Services|||||f||||f||||||||No||2018-06-01 01:16:22.126371|2018-06-01 01:16:22.126371
NCT00850772|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2014-06-10|2009-02-24|2009-02-25|Estimate|||||||2014-06-10|2014-06-12|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|OPEN||Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer|Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer|Completed||Phase 3|109|Actual|Queensland Centre for Gynaecological Cancer||2|||f||||t||||||||||2018-06-01 01:16:22.201938|2018-06-01 01:16:22.201938
NCT00850759|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2013-06-17||2014-12-01|2009-02-24|2009-02-25|Estimate|2013-10-28|2013-11-20|Estimate||||2014-12-01|2014-12-16|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|May 2012|Actual|2012-05-31||Interventional|||Using Virtual Reality to Train Children in Pedestrian Safety|Using Virtual Reality to Train Children in Pedestrian Safety|Completed||Phase 3|240|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-06-01 01:16:22.286853|2018-06-01 01:16:22.286853
NCT00850746|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2014-03-21|2009-02-24|2009-02-25|Estimate|||||||2014-03-21|2014-03-24|Estimate|February 2009||2009-02-28|March 2014|2014-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults|A Phase 1, Randomized, Double-Blind, Placebo- and Active- Controlled, Crossover Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Male and Female Adult Subjects|Completed||Phase 1|80|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 01:16:22.545341|2018-06-01 01:16:22.545341
NCT00850564|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2011-03-03||2011-04-15|2009-02-23|2009-02-25|Estimate|2011-03-03|2011-03-30|Estimate||||2011-04-15|2011-04-19|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men|Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men|Completed||N/A|15|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:16:25.752656|2018-06-01 01:16:25.752656
NCT00850733|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2009-09-15|2009-02-24|2009-02-25|Estimate|||||||2009-09-15|2009-09-17|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||516-BOTOX Urinary Incontinence Detrusor|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Safety and Efficacy of a Single Treatment With 2 Dose Levels of BOTOX Purified Neurotoxin Complex Followed by a Treatment With BOTOX in Patients With…|Completed|||||Veterans Medical Research Foundation|||||f||||t||||||||||2018-06-01 01:16:22.611547|2018-06-01 01:16:22.611547
NCT00850720|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2010-01-15||2013-11-18|2009-02-24|2009-02-25|Estimate|2013-11-18|2014-01-07|Estimate||||2013-11-18|2014-01-07|Estimate|March 2009||2009-03-31|November 2013|2013-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Study of Possible Brain Hormone Problems After Open Heart Surgery in Infants|Prevalence of Neuroendocrine Dysfunction in the Pediatric Cardiopulmonary Bypass Patient|Terminated|||3|Actual|Emory University|Early termination of study; Technical problems with measurement leading to unreliable or uninterpretable data.||1|Inability to recruit / logistic problems.|f||||f||||||||||2018-06-01 01:16:22.654745|2018-06-01 01:16:22.654745
NCT00850707|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-26|2009-02-24|2009-02-25|Estimate|||||||2009-02-26|2009-02-27|Estimate|January 2000||2000-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2006|Actual|2006-12-31||Observational|||Vascular Access for Hemodialysis and Inflammation|Artero-Venous Fistula, Prosthetic Polytetrafluoroethylene Grafts (AVG), Tunneled Cuffed Catheter (TCC): Impact of Vascular Access on HD Inflammation and Monocyte Activation|Completed|||458|Actual|St. Orsola Hospital|||4||f||||t||||||||||2018-06-01 01:16:22.753774|2018-06-01 01:16:22.753774
NCT00850694|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-04-07|2009-02-24|2009-02-25|Estimate|||||||2017-04-07|2017-04-10|Actual|February 2007||2007-02-28|September 2011|2011-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Vitamin D Deficiency in Obese Adolescent Girls and Influence of Vitamin D on Insulin Secretion and Sensitivity|Assessment of Prevalence of Vitamin D Deficiency in Obese Adolescent Girls and Influence of Vitamin D on Insulin Secretion and Sensitivity|Completed|||114|Actual|University of Alabama at Birmingham|||1||f||||f||||||||||2018-06-01 01:16:22.81595|2018-06-01 01:16:22.81595
NCT00850681|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2015-09-07|2009-02-23|2009-02-25|Estimate|||||||2015-09-07|2015-09-09|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers|A Randomized, Controlled Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers Using an Open Application Photoallergic Test Design|Completed||Phase 1|50|Anticipated|Peplin||1|||f||||f||||||||||2018-06-01 01:16:22.87076|2018-06-01 01:16:22.87076
NCT00850668|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2013-05-23|2009-02-24|2009-02-25|Estimate|||||||2013-05-23|2013-05-27|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults|A Phase 1 Study of Heat/Phenol-Killed, E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP 123) in Healthy Volunteers Followed by Subjects Allergic to Peanuts (CoFAR 1)|Completed||Phase 1|15|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:16:23.047002|2018-06-01 01:16:23.047002
NCT00850655|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2016-10-25|2009-02-24|2009-02-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae|Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae|Completed|||20|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||No||2018-06-01 01:16:23.117575|2018-06-01 01:16:23.117575
NCT00850642|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2017-08-09||2018-02-27|2009-02-24|2009-02-25|Estimate|2018-02-27|2018-03-01|Actual||||2018-02-27|2018-03-01|Actual|June 26, 2009|Actual|2009-06-26|August 2017|2017-08-31|June 2, 2010|Actual|2010-06-02|June 2, 2010|Actual|2010-06-02||Interventional|||GSK2190915 Moderate to Severe Asthma Study|The Efficacy of Orally Administered GSK2190915 as an add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils|Terminated||Phase 2|7|Actual|GlaxoSmithKline|The study was terminated early due to difficulties in recruiting the required participants.|2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:16:23.215062|2018-06-01 01:16:23.215062
NCT00850629|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2018-01-12|2009-02-24|2009-02-25|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2010|Actual|2010-01-31|January 2018|2018-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Hormonal Regulation of Body Weight Maintenance|Hormonal Regulation of Body Weight Maintenance|Completed||N/A|286|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||No||2018-06-01 01:16:23.710793|2018-06-01 01:16:23.710793
NCT00850616|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2015-10-30|2009-02-24|2009-02-25|Estimate|||||||2015-10-30|2015-11-02|Estimate|April 2005||2005-04-30|October 2015|2015-10-31|March 2011|Actual|2011-03-31|August 2006|Actual|2006-08-31||Interventional|||Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)|A Phase I Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and in Combination in Healthy Adults|Completed||Phase 1|147|Actual|Merck Sharp & Dohme Corp.||8|||f||||||||||||||2018-06-01 01:16:23.788077|2018-06-01 01:16:23.788077
NCT00850603|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2009-03-13||2016-04-12|2009-02-24|2009-02-25|Estimate|2009-03-13|2009-04-30|Estimate||||2016-04-12|2016-04-14|Estimate|October 2002||2002-10-31|April 2016|2016-04-30|November 2004|Actual|2004-11-30|May 2003|Actual|2003-05-31||Interventional|||Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®|Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135|Completed||Phase 4|170|Actual|Sanofi||5|||f||||f||||||||||2018-06-01 01:16:23.864575|2018-06-01 01:16:23.864575
NCT00850590|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-12-21|2009-02-24|2009-02-25|Estimate|||||||2009-12-21|2009-12-23|Estimate|February 2009||2009-02-28|December 2009|2009-12-31||||April 2009|Actual|2009-04-30||Interventional|||Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights|A Randomised, Placebo-controlled, Double-blind, Dose Escalation Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of Rectal Suppositories Containing Between 5 and 15 mg NRL001 or Matching Placebo for Two Different Sized Suppositories (1 g and 2 g).|Completed||Phase 1|48|Anticipated|Norgine||2|||f||||t||||||||||2018-06-01 01:16:25.50801|2018-06-01 01:16:25.50801
NCT00850577|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23||2015-09-23|2015-09-23|2009-02-23|2009-02-25|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer|A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology|Terminated||Phase 2|255|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:16:25.583488|2018-06-01 01:16:25.583488
NCT00850538|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2013-05-15||2015-11-02|2009-02-24|2009-02-25|Estimate|2015-11-02|2015-12-04|Estimate||||2015-11-02|2015-12-04|Estimate|July 2008||2008-07-31|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Role of Bone in Knee Osteoarthritis (OA)|The Role of Bone and Its Measurement in Knee Osteoarthritis|Completed|||101|Actual|The New England Baptist Hospital|||||f||||f||||||Samples Without DNA|"~     Tibial plateau patella fat pad synovial fluid and synovium~   "|||2018-06-01 01:16:26.826273|2018-06-01 01:16:26.826273
NCT00850512|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-24|2009-02-24|2009-02-25|Estimate|||||||2009-02-24|2009-02-25|Estimate||||February 2009|2009-02-28||||||||Interventional|CHOP21+R-Z||Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy||Completed||Phase 2|55|Actual|University of Bologna||1|||f||||||||||||||2018-06-01 01:16:26.977152|2018-06-01 01:16:26.977152
NCT00850499|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|2012-10-03||2012-12-10|2009-02-24|2009-02-25|Estimate|2012-10-03|2012-11-01|Estimate||||2012-12-10|2012-12-12|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab|A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab|Terminated||Phase 2|12|Actual|Millennium Pharmaceuticals, Inc.|Early termination leading to small numbers of subjects analyzed|2|||f||||f||||||||||2018-06-01 01:16:27.060964|2018-06-01 01:16:27.060964
NCT00850486|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-24|2009-02-24|2009-02-25|Estimate|||||||2009-02-24|2009-02-25|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography|The Diagnostic Benefits of HyperQTM vs. Conventional ECG During Stress Test. A Comparison Study in Women Referred to Angiography.|Unknown status|Recruiting|Phase 4|200|Anticipated|BSP Biological Signal Processing Ltd.|||||f||||f||||||||||2018-06-01 01:16:27.572498|2018-06-01 01:16:27.572498
NCT00850473|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2014-05-02|2009-02-24|2009-02-25|Estimate|||||||2014-05-02|2014-05-05|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|PET/CT||PET/CT Study in the Diagnosis of Coronary Plaque|x Comparison of Cardiac Positron Emission Tomography/Computed Tomography (PET/CT) With Coronary Angiography (CA) in the Diagnosis and Characterization of Coronary Artery Plaque|Completed||N/A|3|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 01:16:27.665057|2018-06-01 01:16:27.665057
NCT00850460|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2016-02-12||2016-09-21|2009-02-24|2009-02-25|Estimate|2016-09-21|2016-11-07|Estimate||||2016-09-21|2016-11-07|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Males and females 30-60 years old, taking a statin, experiencing muscle pain, weakness, cramping and not at high risk for a cardiovascular event|Quality of Life in Patients With Statin-Associated Myopathy|Quality of Life and Metabolic Alterations in Patients With Statin-Associated Myopathy|Terminated||Phase 4|14|Actual|Rockefeller University||2||Investigator left institution and no PI has been found to continue the study|f||||f||||||||||2018-06-01 01:16:27.777796|2018-06-01 01:16:27.777796
NCT00850447|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2012-02-01|2009-02-24|2009-02-25|Estimate|||||||2012-02-01|2012-02-02|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Cognitive Remediation in Posttraumatic Stress Disorder (PTSD)|Cognitive Remediation in PTSD|Completed||N/A|2|Actual|Bronx VA Medical Center||2|||f||||f||||||||||2018-06-01 01:16:28.101204|2018-06-01 01:16:28.101204
NCT00850434|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2009-02-24|2009-02-24|2009-02-25|Estimate|||||||2009-02-24|2009-02-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:16:28.169539|2018-06-01 01:16:28.169539
NCT00850421|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2013-07-10||2017-09-07|2009-02-23|2009-02-25|Estimate|2013-07-10|2013-09-18|Estimate||||2017-09-07|2017-10-06|Actual|April 2004||2004-04-30|July 2013|2013-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pilot Study of BOTOX for Migraine Headaches|A Single-Center Pharmacoeconomic Pilot Study of BOTOX® (Botulinum Toxin Type A) for the Prophylactic Treatment of Migraine Headaches|Terminated||N/A|35|Actual|HealthPartners Institute|This study was terminated and PI left organization. No results available to report|1||Recently published BOTOX efficacy data and study design deficits.|f||||f||||||||||2018-06-01 01:16:28.208553|2018-06-01 01:16:28.208553
NCT00850408|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2013-04-22|2009-02-24|2009-02-25|Estimate|||||||2013-04-22|2013-04-24|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Enhancing the Response to Rehabilitation After Stroke Using Repetitive Transcranial Magnetic Stimulation (rTMS)|Enhancing the Response to Rehabilitative Interventions After Stroke Using Transcranial Magnetic Stimulation|Terminated||Phase 2|11|Actual|McGill University Health Center||2|||f||||t||||||||||2018-06-01 01:16:28.3521|2018-06-01 01:16:28.3521
NCT00850395|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2012-09-11||2012-11-05|2009-02-24|2009-02-25|Estimate|2012-09-11|2012-10-15|Estimate||||2012-11-05|2012-11-07|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection|Non-Interventional Study Of Celsentri® In Treatment Experienced Patients Infected With CCR5 Tropic HIV-1|Completed|||79|Actual|ViiV Healthcare|Designation of outcomes as primary and secondary was based on study team input as study did not specify primary or secondary outcome measures.||1||f||||f||||||||||2018-06-01 01:16:28.450692|2018-06-01 01:16:28.450692
NCT00850382|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2016-02-29|2009-02-24|2009-02-25|Estimate|||||||2016-02-29|2016-03-01|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)|Open-Label, Multicenter Phase Ib/IIa Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolida-tion Therapy as Well as in Maintenance Therapy in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)|Completed||Phase 1/Phase 2|89|Actual|University of Ulm||1|||f||||f||||||||||2018-06-01 01:16:28.970232|2018-06-01 01:16:28.970232
NCT00850369|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2013-07-26|2009-02-24|2009-02-25|Estimate|||||||2013-07-26|2013-07-29|Estimate|February 2005||2005-02-28|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension|A Pilot Study of the Effects of Chronic Red Blood Cell Transfusion in Sickle Cell Disease On Pulmonary Hypertension in Patients With Sickle Cell Disease|Withdrawn||Phase 2|0|Actual|University of North Carolina, Chapel Hill||1||Slow accrual onto the study|f||||t||||||||||2018-06-01 01:16:29.119298|2018-06-01 01:16:29.119298
NCT00850356|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-24|||2013-05-17|2009-02-24|2009-02-25|Estimate|||||||2013-05-17|2013-05-21|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Quality of Life Outcomes and Economic Impacts of Bariatric Surgery|Alberta Population-based, Prospective Evaluation of the Quality of Life Outcomes and Economic Impacts of Bariatric Surgery|Completed|||500|Actual|University of Alberta|||3||f||||||||||||||2018-06-01 01:16:29.187745|2018-06-01 01:16:29.187745
NCT00850343|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2014-09-09||2014-10-27|2009-02-24|2009-02-25|Estimate|2014-09-09|2014-09-17|Estimate||||2014-10-27|2014-11-03|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients|A Multicenter, Open-label, Long-term Safety Study of CDP870 to Evaluate the Safety and Efficacy of CDP870 Administered Without Coadministration of Methotrexate (MTX) Over the Long Term in Patients With Active Rheumatoid Arthritis Transferred From the Efficacy Confirmatory Study (Study 275-08-003)|Completed||Phase 3|208|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:16:29.326542|2018-06-01 01:16:29.326542
NCT00850330|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2009-08-03|2009-02-24|2009-02-25|Estimate|||||||2009-08-03|2009-08-04|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|SEDDI||Study for Early Detection of Drug Interactions in Older Hospitalized Patients Using on Line Software|Transversal, Multicentric Study for Early Detection of Drug Interactions in Older Hospitalized Patients Using on Line Software in Córdoba, Argentina|Unknown status|Recruiting||3000|Anticipated|Universidad Nacional de Córdoba|||1||f||||f||||||||||2018-06-01 01:16:30.414793|2018-06-01 01:16:30.414793
NCT00850304|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-21|||2009-02-21|2009-02-21|2009-02-24|Estimate|||||||2009-02-21|2009-02-24|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide|Feasibility Study of Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide on Ambulatory Schedule|Completed||Phase 2|10|Actual|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 01:16:30.586576|2018-06-01 01:16:30.586576
NCT00850291|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-06-22|2009-02-23|2009-02-24|Estimate|||||||2017-06-22|2017-06-23|Actual|May 2008||2008-05-31|June 2017|2017-06-30|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Observational|SEAL||Economisation of Whipple Resection Using Electrosurgical Sealing Device|Prospective, Controlled, Randomized Study of Economisation of the Preparation in Partial Duodenopancreatectomy Using an Electrosurgical Sealing Device Versus Traditional Methods|Completed|||89|Actual|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||||||2018-06-01 01:16:30.679416|2018-06-01 01:16:30.679416
NCT00850278|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2012-08-31|2009-02-23|2009-02-24|Estimate|||||||2012-08-31|2012-09-03|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|FLT||Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors|Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors|Completed||N/A|50|Actual|University Hospital, Caen||1|||f||||t||||||||||2018-06-01 01:16:30.756798|2018-06-01 01:16:30.756798
NCT00850265|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-03-26|2009-02-23|2009-02-24|Estimate|||||||2009-03-26|2009-03-27|Estimate|March 2008||2008-03-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Spacer in Extrafine Formoterol-Beclomethasone Treatment to Asthma|Rol of Spacer in the Combined Treatment With Extrafine Beclomethasone-Formoterol in Stable Asthma|Completed||N/A|40|Actual|Hospital General de Requena||2|||f||||f||||||||||2018-06-01 01:16:30.84438|2018-06-01 01:16:30.84438
NCT00850252|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2013-07-15|2009-02-20|2009-02-24|Estimate|||||||2013-07-15|2013-07-17|Estimate|September 2004||2004-09-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Use of a Lifeline Graft in the A-V Shunt Model|Use of a Completely Autologous and Completely Biological Tissue Engineered Blood Vessel Lifeline as an Arteriovenous Fistula in Hemodialysis Patients - Safety and Efficacy Study.|Completed||Phase 1/Phase 2|||Cytograft Tissue Engineering||1|||f||||t||||||||||2018-06-01 01:16:30.917911|2018-06-01 01:16:30.917911
NCT00850239|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2010-08-10|2009-02-20|2009-02-24|Estimate|||||||2010-08-10|2010-08-11|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin|Terminated||Phase 3|700|Anticipated|Phenomix||2|||f||||f||||||||||2018-06-01 01:16:31.061165|2018-06-01 01:16:31.061165
NCT00850226|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2010-05-28|2009-02-23|2009-02-24|Estimate|||||||2010-05-28|2010-06-02|Estimate|February 2009||2009-02-28|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Comparing Acceptance and Commitment Therapy (ACT) and Cognitive Therapy (CT) for Test Anxiety|Comparing Acceptance and Commitment Therapy Strategies to Cognitive Therapy Strategies in Reduction of Test Anxiety|Completed||N/A|50|Anticipated|Drexel University||2|||f||||f||||||||||2018-06-01 01:16:31.291958|2018-06-01 01:16:31.291958
NCT00850213|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-03-22|2009-02-23|2009-02-24|Estimate|||||||2017-03-22|2017-03-23|Actual|February 2009||2009-02-28|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|REDES||"Assessment of Clinical Performance and Costs of the Endeavor Resolute Stent in Real Life in Spain."|"Registro Redes - Evaluación Del Comportamiento clínico y Del Coste Del Stent Coronario Endeavor Resolute de Medtronic en el Mundo Real en España"|Completed|||448|Actual|Medtronic Cardiovascular|||1||f||||t||||||||||2018-06-01 01:16:31.377066|2018-06-01 01:16:31.377066
NCT00850200|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2013-12-13||2018-01-24|2009-02-20|2009-02-24|Estimate|2014-02-04|2014-03-21|Estimate||||2018-01-24|2018-02-22|Actual|August 2009||2009-08-31|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|May 2013|Actual|2013-05-31||Interventional|HL01|20 patients were enrolled. One decided to withdrawal after being enrolled, but prior to any treatment plans being performed.|Proton Therapy for Hodgkin Lymphoma|Improving the Therapeutic Ratio by Using Proton Beam Radiation Therapy for Patients With Stage IA-IIIBX (Bulky/Non-bulky) Hodgkin Lymphoma Involving the Mediastinum Following Standard Chemotherapy|Completed||N/A|20|Actual|University of Florida||3|||f||||t|f|f||||||||2018-06-01 01:16:31.47445|2018-06-01 01:16:31.47445
NCT00850187|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-21|||2012-01-02|2009-02-23|2009-02-24|Estimate|||||||2012-01-02|2012-01-05|Estimate|August 2008||2008-08-31|April 2010|2010-04-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage|Treatment of Full-thickness Articular Cartilage Defects in the Knee of Patients With Autologous Bone-marrow Mesenchymal Stem Cells and Scaffold|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-06-01 01:16:31.751141|2018-06-01 01:16:31.751141
NCT00850174|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2009-07-02||2009-09-09|2009-02-23|2009-02-24|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|April 2005||2005-04-30|September 2009|2009-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Oxcarbazepine 600 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Oxcarbazepine 600 mg Tablets Under Fasting Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:16:31.861992|2018-06-01 01:16:31.861992
NCT00850161|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2016-02-12|2009-02-23|2009-02-24|Estimate|||||||2016-02-12|2016-02-15|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|September 2010|Anticipated|2010-09-30|August 2009|Anticipated|2009-08-31||Interventional|||Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin|Intranasal Insulin and Its Effect on Postprandial Glucose Metabolism in Comparison to Subcutaneous Insulin|Withdrawn||Phase 2|0|Actual|CPEX Pharmaceuticals Inc.||2||Business purposes.|f||||f||||||||No|There is no data; study never initiated.|2018-06-01 01:16:32.240642|2018-06-01 01:16:32.240642
NCT00850148|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2012-01-04|2009-02-23|2009-02-24|Estimate|||||||2012-01-04|2012-01-05|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Comparison of Anwar and Melles Techniques in Deep Anterior Lamellar Keratoplasty (DALK) for Keratoconus Patients||Completed||N/A|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 01:16:32.31513|2018-06-01 01:16:32.31513
NCT00850135|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2016-04-13||2016-04-13|2009-02-20|2009-02-24|Estimate|2016-04-13|2016-05-19|Estimate||||2016-04-13|2016-05-19|Estimate|February 2009||2009-02-28|April 2016|2016-04-30|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional||A total of 57 patients were enrolled from two clinical sites. One patient had no CGM data. One patient transferred care after completing the CGM study period, and thus did not have delivery data. Two patients who had an existing diagnosis of diabetes were excluded.The remaining 53 patients were analyzed.|Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes|Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes|Completed||Phase 1/Phase 2|57|Actual|Stanford University|Limited monitoring period between 24 and 28 weeks’ gestation. Sample size was under powered to detect differences in secondary outcomes of interest.|1|||f||||f||||||||No||2018-06-01 01:16:32.379367|2018-06-01 01:16:32.379367
NCT00850122|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2017-09-01|2009-02-23|2009-02-24|Estimate|||||||2017-09-01|2017-09-05|Actual|July 2013||2013-07-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates|An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates|Active, not recruiting||Phase 1|9|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:16:32.69158|2018-06-01 01:16:32.69158
NCT00850109|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2012-04-25|2009-02-23|2009-02-24|Estimate|||||||2012-04-25|2012-04-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:16:32.778774|2018-06-01 01:16:32.778774
NCT00850096|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2012-02-14||2013-11-25|2009-02-23|2009-02-24|Estimate|2012-05-14|2012-05-15|Estimate||||2013-11-25|2013-12-13|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|CPEX-011||Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus|Effects of Nasulin v.Placebo on Blood Glucose Control in Patients With Type 2 DM Treated With Basal Insulin & Oral Antidiabetic Meds, Excluding Secretagogues in Phase 2A, Randomized, Parallel, Double-Blind, Placebo-Controlled, Multi-Center Study|Completed||Phase 2|94|Actual|CPEX Pharmaceuticals Inc.||2|||f||||f||||||||||2018-06-01 01:16:32.826714|2018-06-01 01:16:32.826714
NCT00850083|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-02-23|2009-02-23|2009-02-24|Estimate|||||||2009-02-23|2009-02-24|Estimate|March 2009||2009-03-31|February 2009|2009-02-28||||December 2009|Anticipated|2009-12-31||Observational|||Accuracy of Measurement of Surface Body Temperature Using the Health e Pod Device (Card Guard) Compared to Gold Standard Equipment|Accuracy of Measurement of Surface Body Temperature Using the Health e Pod Device (Card Guard) Compared to Gold Standard Equipment|Unknown status|Not yet recruiting||400|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-06-01 01:16:33.280561|2018-06-01 01:16:33.280561
NCT00850070|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2012-08-31||2018-04-27|2009-02-23|2009-02-24|Estimate|2014-01-27|2014-02-28|Estimate||||2018-04-27|2018-05-01|Actual|March 2009||2009-03-31|April 2018|2018-04-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Sapropterin as a Treatment for Autistic Disorder|Sapropterin as a Treatment for Autistic Disorder: A Phase II Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 2|46|Actual|The Children's Health Council||2|||f||||t||||||||||2018-06-01 01:16:33.383511|2018-06-01 01:16:33.383511
NCT00850057|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2011-03-31|2009-02-20|2009-02-24|Estimate|||||||2011-03-31|2011-04-01|Estimate|February 2006||2006-02-28|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|A Phase 1, Open Label, Dose-escalation, Pharmacodynamic Study of Intranodal Injection of Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Completed||Phase 1|16|Actual|University of California, San Diego|||||f||||t||||||||||2018-06-01 01:16:33.833316|2018-06-01 01:16:33.833316
NCT00850044|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2017-11-16|2009-02-23|2009-02-24|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2009||2009-02-28|September 2010|2010-09-30||||July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1|A Double-Blind, Randomized, Placebo-Controlled, Nonfasting Study in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Doses of ABT-450 With and Without Ritonavir|Completed||Phase 1|87|Actual|AbbVie||4|||f||||f||||||||||2018-06-01 01:16:33.919047|2018-06-01 01:16:33.919047
NCT00850031|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2016-07-20||2018-01-31|2009-02-20|2009-02-24|Estimate|2016-12-13|2017-02-06|Estimate||||2018-01-31|2018-02-28|Actual|January 2009||2009-01-31|January 2018|2018-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|ACI|Patients between 45 and 60 years of age with presbyopia|Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes|A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay (ACI)™ ACI 7000PDT in Presbyopic Subjects (OUS Study)|Completed||N/A|119|Actual|AcuFocus, Inc.||1|||f||||f||||||||No||2018-06-01 01:16:34.018412|2018-06-01 01:16:34.018412
NCT00850018|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2017-02-14|2009-02-23|2009-02-24|Estimate|||||||2017-02-14|2017-02-15|Actual|December 2004||2004-12-31|February 2017|2017-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease - Pilot Intervention Study|Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Disease - A Pilot Intervention Study|Completed||Phase 1|36|Anticipated|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-06-01 01:16:34.2524|2018-06-01 01:16:34.2524
NCT00850005|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-23|2009-02-23|2009-02-24|Estimate|||||||2009-02-23|2009-02-24|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain|IVIG for Treatment of Resistant Neuropathic Pain: a Preliminary Study|Unknown status|Recruiting|Phase 2|12|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 01:16:34.369846|2018-06-01 01:16:34.369846
NCT00849992|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2017-05-12|2009-02-23|2009-02-24|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2009|Actual|2009-03-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Interventional|||Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy|Randomized Prospective Study Comparing 5% Imiquimod and Photodynamic Therapy for Actinic Cheilitis|Completed||Phase 4|53|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 01:16:34.463467|2018-06-01 01:16:34.463467
NCT00849979|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2012-07-26|2009-02-23|2009-02-24|Estimate|||||||2012-07-26|2012-07-30|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy|M.D. Anderson Symptom Inventory (MDASI-GI) Validation and Clinical Utility in Patients With Gastrointestinal Cancers Being Treated or Followed by GI Medical Oncology|Completed||N/A|184|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 01:16:34.564439|2018-06-01 01:16:34.564439
NCT00849966|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2013-04-17|2009-02-23|2009-02-24|Estimate|||||||2013-04-17|2013-04-18|Estimate|August 2009||2009-08-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Celecoxib for Pediatric Adenotonsillectomy|Celecoxib for Pediatric Adenotonsillectomy: A Randomized Controlled Double Blinded Study|Completed||Phase 2|282|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||||2018-06-01 01:16:34.669714|2018-06-01 01:16:34.669714
NCT00849953|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2011-06-27|2009-02-20|2009-02-24|Estimate|||||||2011-06-27|2011-06-28|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||FinESS Registry Study|FinESS Registry Study|Completed|||500|Anticipated|Entellus Medical, Inc.|||1||f||||f||||||||||2018-06-01 01:16:34.785876|2018-06-01 01:16:34.785876
NCT00849940|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2015-11-09||2016-12-20|2009-02-22|2009-02-24|Estimate|2016-02-24|2016-03-28|Estimate||||2016-12-20|2017-02-09|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Validation of Brain Oxygenation Monitor on Pediatric Patients|Validation of the CAS Medical System, Inc. FORE-SIGHT Near-Infrared Spectroscopy (NIRS) Monitor in Pediatric Subjects for Viscerosomatic Applications|Terminated||N/A|72|Actual|Duke University|Blood samples collected from pediatric patients undergoing cardiac catheterization. Venous blood samples taken from within IVC as close to the tissue of interest.|1|||f||||f||||||||||2018-06-01 01:16:34.865638|2018-06-01 01:16:34.865638
NCT00849927|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-21|2009-02-21|2009-02-24|Estimate|||||||2009-02-21|2009-02-24|Estimate|January 2003||2003-01-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Circumferential Lesions of the Glenoid Labrum|Circumferential Lesions of the Glenoid Labrum: A Prospective Cohort Study of Arthroscopic Repair With Minimum 2-Year Follow-up: A Multi-Center Study.|Completed|||39|Actual|Society of Military Orthopedic Surgeons|||||f||||f||||||||||2018-06-01 01:16:35.06006|2018-06-01 01:16:35.06006
NCT00849914|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2012-10-15|2009-02-23|2009-02-24|Estimate|||||||2012-10-15|2012-10-16|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer|Expression Levels of microRNA Processing Enzymes Dicer and Drosha in Epithelial Skin Cancer|Completed|||28|Actual|Ruhr University of Bochum|||3||f||||f||||||Samples With DNA|"~     Punch biopsy from tumour, punch biopsy from healthy skin~   "|||2018-06-01 01:16:35.149063|2018-06-01 01:16:35.149063
NCT00849901|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2012-02-22||2017-09-07|2009-02-20|2009-02-24|Estimate|2012-02-22|2012-03-06|Estimate||||2017-09-07|2017-09-11|Actual|March 2009||2009-03-31|September 2017|2017-09-30|October 2011|Actual|2011-10-31|March 2011|Actual|2011-03-31||Interventional|||A Study in the Treatment of Children and Adolescents With Major Depressive Disorder|A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder|Completed||Phase 3|337|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 01:16:35.26252|2018-06-01 01:16:35.26252
NCT00849888|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2014-10-27|2009-02-23|2009-02-24|Estimate|||||||2014-10-27|2014-10-29|Estimate|April 2008||2008-04-30|October 2014|2014-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SerumFree||Serum-Free Thymus Transplantation in DiGeorge Anomaly|Phase I Serum-Free Cultured Thymus Transplantation in DiGeorge Anomaly, IND9836|Terminated||Phase 1|2|Actual|Duke University||2||The sponsor decided to withdraw the study.|f||||t||||||||||2018-06-01 01:16:36.585718|2018-06-01 01:16:36.585718
NCT00849875|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2016-11-28|2015-03-12|2017-06-15|2009-02-23|2009-02-24|Estimate|2017-02-10|2017-03-30|Actual|2015-03-12|2015-04-01|Estimate|2017-06-15|2017-07-12|Actual|May 26, 2009|Actual|2009-05-26|June 2017|2017-06-30|November 17, 2014|Actual|2014-11-17|November 17, 2014|Actual|2014-11-17||Interventional|||A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients|Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Association With Chemotherapy in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma|Terminated||Phase 2|48|Actual|GlaxoSmithKline||1||"Early end of trial notification after termination of long term follow up due to lack of~   scientific justification to continue collect information."|f|||||f|f||||||||2018-06-01 01:16:36.784776|2018-06-01 01:16:36.784776
NCT00849862|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2009-06-30||2009-09-01|2009-02-20|2009-02-24|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Levetiracetam 750 mg Tablets Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Levetiracetam 750 mg Tablet and Keppra® (Reference) Following a 750 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|22|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:16:38.107591|2018-06-01 01:16:38.107591
NCT00849849|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2014-12-17|2009-02-23|2009-02-24|Estimate|||||||2014-12-17|2014-12-18|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|COPSS-GDM||Comprehensive Postpartum Screening Strategies for Women With Gestational Diabetes Mellitus (GDM)|Comprehensive Postpartum Screening Strategies for Women With Prior Gestational Diabetes (COPSS - GDM): Now is the Time for a Paradigm Shift in Clinical Practice|Completed|||214|Actual|Woman's|||1||f||||t||||||Samples Without DNA|"~     Blood samples for diabetes testing~   "|||2018-06-01 01:16:38.307359|2018-06-01 01:16:38.307359
NCT00849836|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-02-23|2009-02-23|2009-02-24|Estimate|||||||2009-02-23|2009-02-24|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|January 2010|Anticipated|2010-01-31|||||Observational|||Novel Biomarkers in Chronic Airway Diseases|The Study for The Identification of Novel Biomarkers in Chronic Airway Inflammatory Disorders|Unknown status|Recruiting||30|Anticipated|Chonbuk National University|||3||f||||||||||||||2018-06-01 01:16:38.356413|2018-06-01 01:16:38.356413
NCT00849810|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2013-03-18||2013-03-18|2009-02-23|2009-02-24|Estimate|2013-03-18|2013-03-19|Estimate||||2013-03-18|2013-03-19|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate|Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study|Terminated||N/A|1|Actual|University of Mississippi Medical Center||1||Difficulty with recruiting willing participants.|f||||t||||||||||2018-06-01 01:16:38.543395|2018-06-01 01:16:38.543395
NCT00849797|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2009-07-02||2009-09-09|2009-02-20|2009-02-24|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|July 2005||2005-07-31|September 2009|2009-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Oxcarbazepine 600 mg Tablet and Trileptal® Following a 600 mg Dose in Healthy Subjects Under Fed Conditions|Completed||Phase 1|120|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:16:38.746821|2018-06-01 01:16:38.746821
NCT00849771|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2015-11-10|2009-02-23|2009-02-24|Estimate|||||||2015-11-10|2015-11-13|Estimate|March 2008||2008-03-31|November 2015|2015-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Operative Versus Nonoperative Treatment for Scapula Fractures|Multicenter Prospective Study of Operative and Non-operative Treatment for Scapula Fractures|Withdrawn|||0|Actual|Vanderbilt University|||2|Joined another larger group of same study|f||||f||||||||||2018-06-01 01:16:39.140911|2018-06-01 01:16:39.140911
NCT00849758|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2014-12-08|2009-02-20|2009-02-24|Estimate|||||||2014-12-08|2014-12-09|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2012|Actual|2012-09-30||Observational|EBS||Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients|Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients.|Completed|||110|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples With DNA|"~     peripheral blood is collected for DNA, RNA, serum plasma, and lymphocytes~   "|||2018-06-01 01:16:39.214077|2018-06-01 01:16:39.214077
NCT00849745|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2016-06-21|2009-02-23|2009-02-24|Estimate|||||||2016-06-21|2016-06-23|Estimate|January 2003||2003-01-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases|Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases|Terminated||Phase 1|4|Actual|Duke University||2||low accrual|f||||t||||||||||2018-06-01 01:16:39.280782|2018-06-01 01:16:39.280782
NCT00849732|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2015-02-26|2009-02-20|2009-02-24|Estimate|||||||2015-02-26|2015-02-27|Estimate|June 2003||2003-06-30|February 2015|2015-02-28|February 2011|Actual|2011-02-28|October 2006|Actual|2006-10-31||Interventional|||A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)|A Worldwide, Phase I, Dose-Escalating Study of Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Healthy Adults|Completed||Phase 1|360|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:16:39.801435|2018-06-01 01:16:39.801435
NCT00849719|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-23|2009-02-23|2009-02-24|Estimate|||||||2009-02-23|2009-02-24|Estimate|April 2009||2009-04-30|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|April 2010|Anticipated|2010-04-30||Interventional|||Effects of a Combination of IV-PCA With Continuous IV Infusion of MO, Versus IV-PCA MO on Postoperative Pain|Effects of Combination of Continuous Intravenous (IV) Infusion Plus Patient-Controlled Analgesia (PCA) of Morphine (MO) vs. IV-PCA MO on Postoperative Pain Control|Unknown status|Not yet recruiting|N/A|150|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-06-01 01:16:39.872469|2018-06-01 01:16:39.872469
NCT00849706|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-23|2009-02-23|2009-02-24|Estimate|||||||2009-02-23|2009-02-24|Estimate|March 2009||2009-03-31|February 2009|2009-02-28||||March 2010|Anticipated|2010-03-31||Observational|||Effect of Work Load and Sleep Deprivation on Medical Staff's Driving Skills|Effect of Work Load and Sleep Deprivation on Medical Staff's Driving Skills|Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-06-01 01:16:39.960391|2018-06-01 01:16:39.960391
NCT00849693|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|2012-02-22||2012-03-26|2009-02-23|2009-02-24|Estimate|2012-03-26|2012-04-19|Estimate||||2012-03-26|2012-04-19|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Interventional|||A Study in the Treatment of Children and Adolescents With Major Depressive Disorder|A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder|Completed||Phase 3|463|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:16:40.103999|2018-06-01 01:16:40.103999
NCT00849680|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2011-06-09||2015-01-21|2009-02-20|2009-02-24|Estimate|2011-06-09|2011-07-07|Estimate||||2015-01-21|2015-02-02|Estimate|April 2003||2003-04-30|January 2015|2015-01-31|February 2010|Actual|2010-02-28|March 2005|Actual|2005-03-31||Interventional|||A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)|A Phase I Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in a Prime-Boost Regimen in Healthy Adults|Completed||Phase 1|317|Actual|Merck Sharp & Dohme Corp.|An interim analysis of a related study, V520 Protocol 023 (NCT00095576), showed that the MRKAd5 vaccine used in Protocol 016 (NCT00849680) was not efficacious; therefore, only a high level summary of the safety data was performed.|8|||f||||f||||||||||2018-06-01 01:16:42.542501|2018-06-01 01:16:42.542501
NCT00849667|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13||2015-06-25|2015-06-25|2009-02-20|2009-02-24|Estimate||||2015-06-25|2015-07-20|Estimate|2015-06-25|2015-07-20|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse|A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse|Completed||Phase 3|1100|Actual|Morphotek||3|||f||||t||||||||||2018-06-01 01:16:43.916576|2018-06-01 01:16:43.916576
NCT00849654|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2013-05-21|2009-02-23|2009-02-24|Estimate|||||||2013-05-21|2013-05-22|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PCYC-04753||Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma|Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma|Completed||Phase 1|66|Actual|Pharmacyclics LLC.||1|||f||||f||||||||||2018-06-01 01:16:44.775117|2018-06-01 01:16:44.775117
NCT00849641|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2009-02-20|2009-02-20|2009-02-24|Estimate|||||||2009-02-20|2009-02-24|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|March 2011|Anticipated|2011-03-31|October 2010|Anticipated|2010-10-31||Observational|||Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis|Muscle Tissue Oxygenation in Patients With Decompensated Liver Cirrhosis|Unknown status|Not yet recruiting||90|Anticipated|University of Regensburg|||3||f||||f||||||||||2018-06-01 01:16:44.856594|2018-06-01 01:16:44.856594
NCT00849615|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2016-04-05|2009-02-23|2009-02-24|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2009||2009-02-28|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2012|Actual|2012-01-31||Interventional|FLOT3||Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|Completed||Phase 2|252|Actual|Krankenhaus Nordwest||1|||f||||t||||||||||2018-06-01 01:16:44.988797|2018-06-01 01:16:44.988797
NCT00849602|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-02-23|2009-02-23|2009-02-24|Estimate|||||||2009-02-23|2009-02-24|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|May 2008|Anticipated|2008-05-31||Interventional|||The Effect of Chloroquine in the Treatment of Patients With Dengue|The Effect of Chloroquine in the Treatment of Patients With Dengue|Unknown status|Active, not recruiting|Phase 1/Phase 2|132|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:16:45.06785|2018-06-01 01:16:45.06785
NCT00849589|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2016-10-06|2009-02-23|2009-02-24|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|||Computerized Screening and Brief Physician Advice to Reduce Teen Drinking|Computerized Screening and Brief Physician Advice to Reduce Teen Drinking|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||3||Grant application was not funded|f||||t||||||||No||2018-06-01 01:16:45.154361|2018-06-01 01:16:45.154361
NCT00849576|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20||2015-07-30|2015-07-30|2009-02-23|2009-02-24|Estimate||||2015-07-30|2015-08-03|Estimate|2015-07-30|2015-08-03|Estimate|April 2008||2008-04-30|July 2015|2015-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.||Completed||Phase 3|15|Actual|Biodel||4|||f||||f||||||||||2018-06-01 01:16:45.234535|2018-06-01 01:16:45.234535
NCT00849563|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2014-04-09|2009-02-22|2009-02-24|Estimate|||||||2014-04-09|2014-04-10|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|September 2011|Actual|2011-09-30||Interventional|TDE||Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes|Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes|Completed||N/A|450|Actual|Duke University||3|||f||||f||||||||||2018-06-01 01:16:45.40072|2018-06-01 01:16:45.40072
NCT00849550|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-22|||2012-12-21|2009-02-23|2009-02-24|Estimate|||||||2012-12-21|2012-12-24|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|COBRA||Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.|A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors|Completed||Phase 1|32|Actual|Duke University||1|||f||||t||||||||||2018-06-01 01:16:45.483214|2018-06-01 01:16:45.483214
NCT00849537|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2009-02-23|2009-02-23|2009-02-24|Estimate|||||||2009-02-23|2009-02-24|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy||Unknown status|Recruiting|Phase 1/Phase 2|||Shahid Beheshti University of Medical Sciences||1|||f||||||||||||||2018-06-01 01:16:45.55737|2018-06-01 01:16:45.55737
NCT00849524|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2015-08-24||2015-11-30|2009-02-20|2009-02-24|Estimate|2015-10-19|2015-11-20|Estimate||||2015-11-30|2015-12-30|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2009|Actual|2009-07-31||Interventional|||Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma|Terminated||Phase 2|6|Actual|University of California, San Diego||1||drug supply became unavailable|f||||t||||||||||2018-06-01 01:16:45.643957|2018-06-01 01:16:45.643957
NCT00849511|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-23|||2014-09-24|2009-02-23|2009-02-24|Estimate|||||||2014-09-24|2014-09-25|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|MMP||Melatonin for Migraine Prevention|Melatonin for Migraine Prevention (The MMP-study): A Randomized, Double-blind, Cross-over, Placebo-controlled Study of Melatonin in Prophylactic Treatment of Migraine|Completed||Phase 2|48|Actual|Nordlandssykehuset HF||2|||f||||f||||||||||2018-06-01 01:16:45.892381|2018-06-01 01:16:45.892381
NCT00849485|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2009-06-30||2009-09-01|2009-02-20|2009-02-24|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|November 2005||2005-11-30|September 2009|2009-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Levetiracetam 750 mg Tablets Under Non-Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Levetiracetam 750 mg Tablet and Keppra® (Reference) Following a 750 mg Dose in Healthy Subjects Under Fed Conditions|Completed||Phase 1|22|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:16:45.985276|2018-06-01 01:16:45.985276
NCT00849472|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2012-12-06||2014-01-30|2009-02-19|2009-02-23|Estimate|2012-12-06|2013-01-09|Estimate||||2014-01-30|2014-03-04|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|December 2011|Actual|2011-12-31||Interventional|||Treatment With Pazopanib for Neoadjuvant Breast Cancer|A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently With Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women With Locally Advanced Breast Cancer|Completed||Phase 2|101|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:16:46.31116|2018-06-01 01:16:46.31116
NCT00849459|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2017-01-10|2009-02-20|2009-02-23|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Gene Therapy in Treating Women With Metastatic Breast Cancer|Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer|Completed||Phase 1|3|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-06-01 01:16:46.907332|2018-06-01 01:16:46.907332
NCT00849446|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2011-08-23|2009-02-20|2009-02-23|Estimate|||||||2011-08-23|2011-08-24|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Validity and Reliability of an Activity Monitor in Persons With a Cerebrovascular Accident||Completed|||30|Anticipated|University College of Antwerp|||2||f||||f||||||||||2018-06-01 01:16:47.097726|2018-06-01 01:16:47.097726
NCT00849433|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2015-01-15|2009-02-20|2009-02-23|Estimate|||||||2015-01-15|2015-01-16|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Observational|||Effects of Smoking on Bronchial Epithelium|Effects of Smoking on Airway Remodeling and Phenotypic Changes of the Airway Epithelium in Asthma and COPD: Strategies to Restore the Epithelial Barrier, Repair and Steroid Sensitivity.|Completed|||60|Anticipated|University Medical Center Groningen|||2||f||||f||||||Samples With DNA|"~     Bronchial biopsies Bronchial brushes Blood~   "|||2018-06-01 01:16:47.16187|2018-06-01 01:16:47.16187
NCT00849407|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2017-08-30|2009-02-20|2009-02-23|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2008||2008-10-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|M3||Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma|Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma|Recruiting|||2000|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-06-01 01:16:47.22809|2018-06-01 01:16:47.22809
NCT00849394|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2012-10-31|2009-02-20|2009-02-23|Estimate|||||||2012-10-31|2012-11-01|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Evaluation of Protein in the Urine in Patients Receiving Bevacizumab|An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab|Completed|||106|Actual|North Texas Veterans Healthcare System|||1||f||||f||||||||||2018-06-01 01:16:47.286765|2018-06-01 01:16:47.286765
NCT00849381|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2013-11-27||2014-09-04|2009-02-19|2009-02-23|Estimate|2014-08-21|2014-08-25|Estimate||||2014-09-04|2014-09-12|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female Brazilian, Taiwanese and Thai Subjects Who Had Received Control Vaccine in Study 580299/008|Completed||Phase 3|1239|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:16:47.36044|2018-06-01 01:16:47.36044
NCT00849368|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2012-02-06|2009-02-20|2009-02-23|Estimate|||||||2012-02-06|2012-02-07|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients|Dose-effect Relationship Between Allopurinol, Azathioprine and 6-thioguanine Nucleotide Levels (6-TGN) in Inflammatory Bowel Disease Patients.|Completed||Phase 1|6|Actual|University of Zurich||1|||f||||t||||||||||2018-06-01 01:16:47.642332|2018-06-01 01:16:47.642332
NCT00849355|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2009-02-20|2009-02-20|2009-02-23|Estimate|||||||2009-02-20|2009-02-23|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|November 2010|Anticipated|2010-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk|Phase II, Multicenter Trial to Evaluate the Efficacy and Safety of the Following Treatment Squeme:Ciclophosphamide, Vincristine, Lyposomal Doxorrubicine, Myocet and Prednisone,Combined With Rituximab in First Line Treatment for Patients With Aggresive No Hodgkin B Lymphoma and Cardiovascular Risk|Unknown status|Recruiting|Phase 2|44|Anticipated|Asociacion Doctor Peset Para el Estudio de la Hematología||1|||f||||f||||||||||2018-06-01 01:16:47.720051|2018-06-01 01:16:47.720051
NCT00849342|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2014-08-13|2009-02-20|2009-02-23|Estimate|||||||2014-08-13|2014-08-15|Estimate|December 2008||2008-12-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|April 2011|Actual|2011-04-30||Observational|KILOS||Observational Study on Levemir® in Obese Diabetic Patients|A Prospective, Multicentre, Non-controlled, Observational, 52-weeks Study: the Evaluation of the Body Weight Progress During the Treatment With Insulin Detemir in Type 1 or 2 Diabetes Patients, Previously Treated With Other Basal Insulins|Completed|||580|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:16:47.830604|2018-06-01 01:16:47.830604
NCT00849329|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-11-10|2009-02-19|2009-02-23|Estimate|||||||2017-11-10|2017-11-14|Actual|March 10, 2009|Actual|2009-03-10|November 2017|2017-11-30|November 24, 2009|Actual|2009-11-24|November 24, 2009|Actual|2009-11-24||Interventional|||A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer|An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:16:47.917707|2018-06-01 01:16:47.917707
NCT00849316|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2013-01-18|2009-02-20|2009-02-23|Estimate|||||||2013-01-18|2013-01-21|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Observational|||Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease|A Multicenter, Open Label, Nonrandomized, Non Interventional, Observational, Safety and Efficacy Study of NovoRapid™(Insulin Aspart) in Patients With Coexisting Diabetes and Kidney Disease in India. The NovoRapid™ Nephropathy Study|Withdrawn|||0|Actual|Novo Nordisk A/S|||1|"Due to company decision to focus resources on the finalisation of three ongoing studies in the~   region"|f||||f||||||||||2018-06-01 01:16:48.001005|2018-06-01 01:16:48.001005
NCT00849303|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2009-02-20|2009-02-20|2009-02-23|Estimate|||||||2009-02-20|2009-02-23|Estimate|January 2009||2009-01-31|February 2009|2009-02-28||||December 2011|Anticipated|2011-12-31||Interventional|||Multicenter Rehabilitation Study in Acute Stroke|Gait-Oriented Rehabilitation at Different Phases in Patients With Acute Stroke - Multicenter Randomized Controlled Trial.|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|University of Jyvaskyla||2|||f||||f||||||||||2018-06-01 01:16:48.0954|2018-06-01 01:16:48.0954
NCT00849290|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2010-05-28||2013-03-12|2009-02-19|2009-02-23|Estimate|2010-10-08|2010-10-11|Estimate||||2013-03-12|2013-03-14|Estimate|April 2004||2004-04-30|March 2013|2013-03-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)||Completed||Phase 2|113|Actual|Dendreon||1|||f||||f||||||||||2018-06-01 01:16:48.224671|2018-06-01 01:16:48.224671
NCT00849277|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2009-02-20|2009-02-20|2009-02-23|Estimate|||||||2009-02-20|2009-02-23|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of the Effect of Probiotics on Respiratory Morbidity After Influenza Vaccination of Elderly in Nursing Homes|An RCT in Nursing Homes: the Effect of a Probiotic Treatment With Lactobacillus Casei Shirota on Respiratory Morbidity After Influenza Vaccination of Elderly.|Completed||Phase 4|737|Actual|Universiteit Antwerpen|||||f||||||||||||||2018-06-01 01:16:48.523725|2018-06-01 01:16:48.523725
NCT00849264|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2016-03-30|2009-02-19|2009-02-23|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients|a Randomized Controlled Study of Surgical Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients|Completed||Phase 2|120|Actual|Eastern Hepatobiliary Surgery Hospital||3|||f||||t||||||||||2018-06-01 01:16:48.584535|2018-06-01 01:16:48.584535
NCT00849251|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2017-03-04||2017-08-07|2009-02-20|2009-02-23|Estimate|2017-08-07|2017-09-08|Actual||||2017-08-07|2017-09-08|Actual|November 2008||2008-11-30|August 2017|2017-08-31|June 2015|Actual|2015-06-30|December 2011|Actual|2011-12-31||Interventional|||Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma|Combination Pegylated Liposomal Doxorubicin, Bortezomib, Cyclophosphamide, and Dexamethasone for Multiple Myeloma (PLD-BCD)|Terminated||Phase 1/Phase 2|31|Actual|University of Washington||1||One of the study drugs is not available.|f||||t||||||||||2018-06-01 01:16:48.669037|2018-06-01 01:16:48.669037
NCT00849212|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2012-10-26||2013-01-03|2009-02-20|2009-02-23|Estimate|2013-01-03|2013-02-07|Estimate||||2013-01-03|2013-02-07|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)|A Phase II, Open-label, Ascending High-dose, add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)|Completed||Phase 2|30|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 01:16:48.940779|2018-06-01 01:16:48.940779
NCT00849199|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2017-07-20|2009-02-20|2009-02-23|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2001||2001-07-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cancer Screening and Prevention Program for High Risk Women|Cancer Screening and Prevention Program for High Risk Women|Recruiting|||2062|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||||||2018-06-01 01:16:49.240507|2018-06-01 01:16:49.240507
NCT00849186|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2015-01-22||2015-01-22|2009-02-20|2009-02-23|Estimate|2015-01-22|2015-02-06|Estimate||||2015-01-22|2015-02-06|Estimate|August 2007||2007-08-31|January 2015|2015-01-31|April 2010|Actual|2010-04-30|July 2009|Actual|2009-07-31||Interventional||All treated and eligible patients|Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer|A Pilot Study of Neoadjuvant SUNITINIB MALATE (Sunitinib) in Patients With Renal Cell Carcinoma Undergoing Nephrectomy|Completed||N/A|20|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 01:16:49.325137|2018-06-01 01:16:49.325137
NCT00849173|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2018-04-04|2009-02-20|2009-02-23|Estimate|||||||2018-04-04|2018-04-05|Actual|February 17, 2009||2009-02-17|November 26, 2012|2012-11-26|November 26, 2012||2012-11-26|||||Observational|||Global Study of Women's Health|Global Study of Women's Health|Completed|||1459|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:16:49.546137|2018-06-01 01:16:49.546137
NCT00849160|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2014-01-21|2009-02-20|2009-02-23|Estimate|||||||2014-01-21|2014-01-22|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|RADAR||Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.|Non-comparative, Opened Study, Evaluating in HIV-1 Infected Patients With Undetectable Viral Load, Treated by an Antiretroviral Combination Including a Protease Inhibitor Boosted With Ritonavir and Administered by Oral Route Twice a Day, the Substitutability of the Current Protease Inhibitor Regimen by the Association Darunavir/Ritonavir 800/100 mg Once a Day to Maintain the Viral Load Under the 50 Copies/ml Limit of Detection After 24 Weeks of Treatment.|Completed||Phase 3|100|Actual|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida||1|||f||||f||||||||||2018-06-01 01:16:49.600683|2018-06-01 01:16:49.600683
NCT00849147|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|2015-05-20||2017-11-28|2009-02-20|2009-02-23|Estimate|2015-08-05|2015-09-07|Estimate||||2017-11-28|2017-12-22|Actual|October 2008||2008-10-31|August 2016|2016-08-31|November 2013|Actual|2013-11-30|June 2011|Actual|2011-06-30||Interventional||Received transplant.|Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)|A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)|Completed||Phase 2|55|Actual|Medical College of Wisconsin||1|||f||||t||||||||Yes|Results will be published in a manuscript|2018-06-01 01:16:49.754291|2018-06-01 01:16:49.754291
NCT00849134|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-07-05|2009-02-19|2009-02-23|Estimate|||||||2017-07-05|2017-07-07|Actual|November 17, 2008|Actual|2008-11-17|July 2017|2017-07-31|April 6, 2009|Actual|2009-04-06|April 6, 2009|Actual|2009-04-06||Interventional|||First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.|A First-Time-in-Human Randomised, Single Blind Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Escalating Doses of GSK1482160, in Male and Female Healthy Subjects, and to Make a Preliminary Assessment of the Effect of Food.|Completed||Phase 1|25|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:16:50.291466|2018-06-01 01:16:50.291466
NCT00849121|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2014-08-29||2018-02-20|2009-02-20|2009-02-23|Estimate|2014-09-10|2014-09-11|Estimate||||2018-02-20|2018-03-15|Actual|March 2009||2009-03-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|February 2014|Actual|2014-02-28||Interventional|||Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer|A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer|Active, not recruiting||Phase 2|17|Actual|University of Wisconsin, Madison|Of the 17 participants enrolled, 16 received at least 6 initial immunizations with pTVG-HP vaccine and were deemed evaluable to be assessed for outcome measure 3.|2|||f||||t||||||||||2018-06-01 01:16:50.41545|2018-06-01 01:16:50.41545
NCT00849108|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2014-10-30||2015-10-12|2009-02-20|2009-02-23|Estimate|2015-01-09|2015-01-19|Estimate||||2015-10-12|2015-10-14|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Intent to treat population Cohort 1 N=33; Cohort 2 N=125 Safety population; Cohort 1 N=33; Cohort 2 N=143|Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158|A Phase 2, Open-Label, Randomized Multicenter Study for the Development of One-Day Rest/Stress Cardiac Positron Emission Tomography (PET) Perfusion Imaging Protocols of BMS747158|Completed||Phase 2|176|Actual|Lantheus Medical Imaging||2|||f||||t||||||||||2018-06-01 01:16:50.789132|2018-06-01 01:16:50.789132
NCT00849095|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2014-05-29|2009-02-20|2009-02-23|Estimate|||||||2014-05-29|2014-05-30|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma|As Needed Budesonide/Formoterol Combination Versus Regular Budesonide/Formoterol Combination Plus as Needed Terbutaline in Mild-Moderate Persistent Asthma|Completed||Phase 3|860|Actual|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-06-01 01:16:51.162761|2018-06-01 01:16:51.162761
NCT00849082|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2012-07-10|2009-02-20|2009-02-23|Estimate|||||||2012-07-10|2012-07-11|Estimate|May 1987||1987-05-31|July 2012|2012-07-31||||November 1995|Actual|1995-11-30||Interventional|||Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer|Phase III Randomized Comparison of Pelvic Radiotherapy Alone vs Pelvic Radiotherapy Plus the LHRH Analogue Goserelin and Cyproterone Acetate in Carcinoma of the Prostate at High Risk for Metastasis|Completed||Phase 3|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 01:16:51.282941|2018-06-01 01:16:51.282941
NCT00848068|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2012-02-01|2009-02-19|2009-02-20|Estimate|||||||2012-02-01|2012-02-02|Estimate|January 2009||2009-01-31|February 2012|2012-02-29||||March 2009|Actual|2009-03-31||Interventional|||Evaluation of FID 114657 on Tear Film Lipid Layer Thickness||Completed||N/A|40|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:17:12.183538|2018-06-01 01:17:12.183538
NCT00849069|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2017-10-30|2009-02-19|2009-02-23|Estimate|||||||2017-10-30|2017-10-31|Actual|March 12, 2009|Actual|2009-03-12|October 2017|2017-10-31|April 7, 2009|Actual|2009-04-07|April 7, 2009|Actual|2009-04-07||Interventional|||Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine|An Observer-blind, Safety Study of GSK Biologicals' Haemophilus Influenzae and Streptococcus Pneumoniae Candidate Vaccine in Adults.|Terminated||Phase 1|30|Anticipated|GlaxoSmithKline||2||"The study has been stopped for logistic reasons not related to the safety or efficacy of the~   vaccine."|f||||||||||||||2018-06-01 01:16:51.372265|2018-06-01 01:16:51.372265
NCT00849056|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2014-04-24|2012-04-03|2016-11-18|2009-02-19|2009-02-23|Estimate|2014-05-29|2014-07-01|Estimate|2012-04-03|2012-04-05|Estimate|2016-11-18|2017-01-09|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|November 2011|Actual|2011-11-30||Interventional|||Safety and Efficacy of Albiglutide in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|310|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:16:51.509611|2018-06-01 01:16:51.509611
NCT00849043|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2011-01-25|2009-02-20|2009-02-23|Estimate|||||||2011-01-25|2011-01-26|Estimate|February 2009||2009-02-28|January 2011|2011-01-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Observational|AERO C009E||Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopnea|A Single Arm, Open-label Extension Study to Evaluate the Long-term Durability of Treatment Response and and Safety of the Provent Professional Sleep Apnea Therapy Device for the Non-invasive Treatment of Obstructive Sleep Apnea-hypopnea|Completed|||65|Anticipated|Ventus Medical, Inc.|||1||f||||f||||||||||2018-06-01 01:16:52.834479|2018-06-01 01:16:52.834479
NCT00849030|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2012-06-05|2009-02-20|2009-02-23|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 1996||1996-07-31|June 2012|2012-06-30|April 2010|Actual|2010-04-30|June 2001|Actual|2001-06-30||Interventional|||ATAC - Arimidex, Tamoxifen Alone or in Combination|A Randomised, Double Blind Trial Comparing Arimidex Alone With Nolvadex Alone With Arimidex and Nolvadex in Combination, as Adjuvant Treatment in Post-Menopausal Women With Breast Cancer|Completed||Phase 3|9358|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 01:16:52.909369|2018-06-01 01:16:52.909369
NCT00849017|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2014-04-24|2012-06-21|2016-11-18|2009-02-19|2009-02-23|Estimate|2014-05-29|2014-06-05|Estimate|2012-06-21|2012-07-02|Estimate|2016-11-18|2017-01-09|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|November 2011|Actual|2011-11-30||Interventional|||Safety and Efficacy Study of Albiglutide in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|309|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:16:53.098467|2018-06-01 01:16:53.098467
NCT00849004|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2012-10-19|2009-02-20|2009-02-23|Estimate|||||||2012-10-19|2012-10-22|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|RCT||Prevention of Hypertrophic Scars or Keloids|Comparison of the Effectiveness in Prevention of Hypertrophic Scars or Keloids Between Silicone Sheet, Silicone Gel and Paper Steri-strip-A Randomised Controlled Trial.|Unknown status|Active, not recruiting|N/A|75|Anticipated|Kaohsiung Veterans General Hospital.||3|||f||||f||||||||||2018-06-01 01:16:55.63138|2018-06-01 01:16:55.63138
NCT00848991|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2012-02-09|2009-02-20|2009-02-23|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Comparison of Propofol to Precedex With Propofol for Emergence and Recovery in Patients Having Craniotomy Surgery|Comparison of Propofol Standard Anesthetic to Precedex With Propofol for Emergence and Recovery in Patients Having Craniotomy Surgery|Completed||Phase 3|15|Actual|The Cooper Health System||2|||f||||f||||||||||2018-06-01 01:16:55.73202|2018-06-01 01:16:55.73202
NCT00848978|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2009-02-20|2009-02-20|2009-02-23|Estimate|||||||2009-02-20|2009-02-23|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|STRONG||Strength Training in Nonagenarians|Health Enhancing Strength Training in Nonagenarians|Unknown status|Enrolling by invitation|N/A|60|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||||2018-06-01 01:16:55.834977|2018-06-01 01:16:55.834977
NCT00848965|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2012-08-23||2012-08-23|2009-02-19|2009-02-23|Estimate|2012-08-23|2012-09-24|Estimate||||2012-08-23|2012-09-24|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber|A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purpose of Investigating the Sensitivity|Completed||Phase 4|59|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 01:16:56.014715|2018-06-01 01:16:56.014715
NCT00848952|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-20|||2010-02-03|2009-02-20|2009-02-23|Estimate|||||||2010-02-03|2010-02-04|Estimate|March 2009||2009-03-31|February 2009|2009-02-28||||March 2010|Anticipated|2010-03-31||Interventional|CHIC||Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis|Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis|Unknown status|Not yet recruiting|N/A|450|Anticipated|University Hospital, Angers|||||f||||||||||||||2018-06-01 01:16:56.519204|2018-06-01 01:16:56.519204
NCT00848939|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2012-10-19|2009-02-19|2009-02-20|Estimate|||||||2012-10-19|2012-10-23|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|DISTOL-PK||Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis|An Evaluation of the Pharmacokinetics and Safety of Fixed and Escalating Doses of Oral Treprostinil Diethanolamine (UT-15C) Sustained Release Tablets in Patients With Systemic Sclerosis|Completed||Phase 1|28|Actual|United Therapeutics||1|||f||||f||||||||||2018-06-01 01:16:56.632677|2018-06-01 01:16:56.632677
NCT00848926|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2011-09-15||2017-03-09|2009-02-18|2009-02-20|Estimate|2011-09-15|2011-10-26|Estimate||||2017-03-09|2017-03-13|Actual|February 2009||2009-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|August 2010|Actual|2010-08-31||Interventional|||A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma|A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)|Completed||Phase 2|102|Actual|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-06-01 01:16:56.744149|2018-06-01 01:16:56.744149
NCT00848913|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2015-06-02|2009-02-19|2009-02-20|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Strength Training After Hip Fracture Surgery|Effect of Rehabilitation With Versus Without Progressive Strength Training Implemented in the Acute Ward After Hip Fracture Surgery: A Randomized Controlled Trial|Completed||N/A|90|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-06-01 01:16:57.27127|2018-06-01 01:16:57.27127
NCT00848900|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-11-19|2009-02-19|2009-02-20|Estimate|||||||2010-11-19|2010-11-22|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|July 2012|Anticipated|2012-07-31|April 2012|Anticipated|2012-04-30||Interventional|||Guangzhou Outdoor Activity Longitudinal Study|A Controlled Clinical Trial of the Effect of Increases Time Outdoors in the Prevention of Juvenile-onset Myopia in Chinese Children|Unknown status|Enrolling by invitation|N/A|2000|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:16:57.354085|2018-06-01 01:16:57.354085
NCT00848887|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2014-01-23|2009-02-19|2009-02-20|Estimate|||||||2014-01-23|2014-01-24|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age|A Phase Ib, Randomized, Observer-Blind, Multicenter, Factorial-Design Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Injections of Trivalent Inactivated Influenza Vaccine With or Without a Second Influenza B Strain in Combination With or Without One of Three Different Doses of Adjuvant in Healthy Children, Aged 6 to <36 Months|Completed||Phase 1|410|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:16:57.423607|2018-06-01 01:16:57.423607
NCT00848874|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|April 2010|Anticipated|2010-04-30|June 2009|Anticipated|2009-06-30||Interventional|PVGS-II||Portable Visual Guidance System Phase II|Phase II Study of a Portable Visual Guidance System for Use by AS/HFA Students in Inclusion Settings|Unknown status|Enrolling by invitation|N/A|50|Anticipated|SymTrend Inc.||1|||f||||f||||||||||2018-06-01 01:16:57.495105|2018-06-01 01:16:57.495105
NCT00848861|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Trial Comparing Propofol to Midazolam Plus Meperidine Sedation for Outpatient Colonoscopy||Completed||N/A|92|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 01:16:57.563406|2018-06-01 01:16:57.563406
NCT00848848|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2016-05-05|2009-02-19|2009-02-20|Estimate|||||||2016-05-05|2016-05-09|Estimate|October 2008||2008-10-31|May 2016|2016-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older|A Phase Ib, Multi-Center, Randomized, Observer-Blind, Proof of Concept, Dose- and Formulation-Ranging Study to Evaluate Safety, Tolerability, and Immunogenicity of One Dose of Trivalent Inactivated Influenza Vaccine in Different Presentations (Intramuscular and Intradermal Delivery), Dosages (Regular or Higher A/H3N2 Content) and Doses of Adjuvant Administered to Healthy Elderly Aged ≥ 65 Years|Completed||Phase 1|450|Actual|Seqirus||10|||f||||||||||||||2018-06-01 01:16:57.6456|2018-06-01 01:16:57.6456
NCT00848835|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-08-30|2009-02-19|2009-02-20|Estimate|||||||2010-08-30|2010-08-31|Estimate|March 2002||2002-03-31|August 2010|2010-08-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Observational|LEAD LIFE||Long Term Integrity Follow-up Evaluation|Long Term Integrity Follow-up Evaluation|Completed|||372|Actual|Guidant Corporation|||1||f||||f||||||||||2018-06-01 01:16:57.737066|2018-06-01 01:16:57.737066
NCT00848822|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-04-14|2009-02-19|2009-02-20|Estimate|||||||2011-04-14|2011-04-15|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Sleep and Glucose Regulation in Youth With Type 1 Diabetes Mellitus|Sleep and Glucose Regulation in Youth With Type 1 Diabetes Mellitus|Completed|||50|Actual|University of Arizona|||||f||||f||||||||||2018-06-01 01:16:57.798277|2018-06-01 01:16:57.798277
NCT00848809|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2015-04-21|2009-02-19|2009-02-20|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Pharmacokinetics of Vancomycin in the ICU in Renal Replacement Therapy|Pharmacokinetics of Vancomycin in Various Modalities of Renal Replacement Therapy in the Intensive Care Unit|Withdrawn|||0|Actual|Avera McKennan Hospital & University Health Center|||2|PI had difficult enrollment.|f||||f||||||None Retained|"~     Whole blood~   "|||2018-06-01 01:16:57.857383|2018-06-01 01:16:57.857383
NCT00848796|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|September 2006||2006-09-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparative Study of Two Brands of Heparin Already on the Market|Do Different Heparin Brands Influence Bleeding in Coronary Surgery|Completed||N/A|100|Actual|Southlake Regional Health Centre||1|||f||||f||||||||||2018-06-01 01:16:57.945715|2018-06-01 01:16:57.945715
NCT00848783|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2012-11-09||2017-12-05|2009-02-19|2009-02-20|Estimate|2012-11-09|2012-12-10|Estimate||||2017-12-05|2018-01-08|Actual|May 2008||2008-05-31|December 2017|2017-12-31|September 2012|Actual|2012-09-30|August 2011|Actual|2011-08-31||Interventional|||Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers|A Randomized Phase-II Study of Patients With Locally Advanced Gastric of Gastro-Esophageal Adenocarcinoma Treated With Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine, Followed by Prolonged Administration of Capecitabine|Terminated||Phase 2|8|Actual|New York University School of Medicine|Early termination leading to small numbers of subjects analyzed.|2||Due to slow accrual|f||||t||||||||||2018-06-01 01:16:58.047372|2018-06-01 01:16:58.047372
NCT00848770|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-12-30|2009-02-19|2009-02-20|Estimate|||||||2009-12-30|2009-12-31|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|MAPAS||Manipulation of Arterial Pressure in Acute Ischemic Stroke|Manipulation of Arterial Pressure Early in Non Thrombolysed Acute Ischemic Stroke: Effects on Death and Neurological Disability|Unknown status|Recruiting|N/A|240|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-06-01 01:16:58.406004|2018-06-01 01:16:58.406004
NCT00848757|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2015-07-20|2009-02-19|2009-02-20|Estimate|||||||2015-07-20|2015-07-21|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Changing Lifestyles for Better Health|Changing Lifestyles for Better Health: A Model Program for Community Health Centers|Completed||N/A|130|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:16:58.505758|2018-06-01 01:16:58.505758
NCT00842595|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2013-07-23|2009-02-11|2009-02-12|Estimate|||||||2013-07-23|2013-07-24|Estimate|December 2003||2003-12-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas|Phase II Study of Treatment of Relapsed Agressive Lymphomas|Completed||Phase 2|50|Actual|French Innovative Leukemia Organisation||1|||f||||t||||||||||2018-06-01 01:18:55.151044|2018-06-01 01:18:55.151044
NCT00848744|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2009-11-10||2018-01-31|2009-02-19|2009-02-20|Estimate|2010-06-02|2010-07-05|Estimate||||2018-01-31|2018-03-01|Actual|February 2008||2008-02-29|January 2018|2018-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Two Salicylic Acid Formulations|A Split-Face, Paired-Comparison, Pilot Study to Evaluate Safety and Efficacy of Two Topical Salicylic Acid 1.0% Creams for Mild to Moderate Acne Vulgaris|Completed||N/A|10|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 01:16:58.582118|2018-06-01 01:16:58.582118
NCT00848731|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2011-06-23|2009-02-19|2009-02-20|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism|Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism|Completed||Phase 1|25|Anticipated|Carolinas Healthcare System||1|||f||||f||||||||||2018-06-01 01:16:58.735376|2018-06-01 01:16:58.735376
NCT00848718|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2015-01-21|2009-02-19|2009-02-20|Estimate|||||||2015-01-21|2015-01-22|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|||A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5)|A Phase I Dose Escalation Study of MK-2206 in Combination With Standard Doses of Selected Chemotherapies or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|72|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:16:58.795787|2018-06-01 01:16:58.795787
NCT00848705|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2011-01-31|2009-02-19|2009-02-20|Estimate|||||||2011-01-31|2011-02-02|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|YourWay||Adolescent Self-Management of Type 1 Diabetes: an Intervention (Completed)|Adolescent Self-Management of Type 1 Diabetes: an Intervention|Completed||Early Phase 1|72|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 01:16:58.86064|2018-06-01 01:16:58.86064
NCT00848692|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2011-06-01|2009-02-19|2009-02-20|Estimate|||||||2011-06-01|2011-06-02|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|KTS-1-2008||Drug Intervention in Chronic Fatigue Syndrome|B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-blind, Placebo-controlled Study.|Completed||Phase 2/Phase 3|30|Anticipated|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 01:16:58.914902|2018-06-01 01:16:58.914902
NCT00848679|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Investigating the Novel Observation of Right-Left Difference in Uterine Artery Vascular Resistance in Pre-Eclampsia|Investigating the Novel Observation of Right-Left Difference in Uterine Artery Vascular Resistance in Pre-Eclampsia: A Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Dose-Dependent Effect of Epidural Lidocaine on Right-Left Uterine Artery Blood Flow Differences in Pre-Eclampsia, With Healthy Term Pregnant and Non-Pregnant Controls|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:16:58.972946|2018-06-01 01:16:58.972946
NCT00848666|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2009-02-23|2009-02-19|2009-02-20|Estimate|||||||2009-02-23|2009-02-24|Estimate|April 2009||2009-04-30|February 2009|2009-02-28||||April 2010|Anticipated|2010-04-30||Interventional|||Safety and Efficacy of a Novel Topical Therapy for Tinea Pedis (Athlete's Foot)||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-06-01 01:16:59.037181|2018-06-01 01:16:59.037181
NCT00848653|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|ELECTION||ELECTION - The Electrode Configuration Cardiac Resynchronization Therapy (CRT) Study (ELECTION)|The Electrode Configuration (ELECTION) CRT Study Including ELECTION Phrenic Nerve Stimulation (PNS) Sub-Study|Completed|||260|Actual|Guidant Corporation|||||f||||f||||||||||2018-06-01 01:16:59.177758|2018-06-01 01:16:59.177758
NCT00848640|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-05-25|2009-02-19|2009-02-20|Estimate|||||||2010-05-25|2010-05-26|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|MERITS||Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma|Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug|Completed||Phase 2|75|Actual|Egyptian Foundation For Cancer Research||1|||f||||t||||||||||2018-06-01 01:16:59.231225|2018-06-01 01:16:59.231225
NCT00848627|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-12-09|2009-02-19|2009-02-20|Estimate|||||||2010-12-09|2010-12-10|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|February 2015|Anticipated|2015-02-28|February 2012|Anticipated|2012-02-29||Observational|||Screening for Bladder Cancer|Screening for Bladder Cancer|Unknown status|Recruiting||1500|Anticipated|Baylor College of Medicine|||1||f||||f||||||||||2018-06-01 01:16:59.299491|2018-06-01 01:16:59.299491
NCT00848601|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2011-12-01|2009-02-19|2009-02-20|Estimate|||||||2011-12-01|2011-12-02|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma|Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Hormone and Docetaxel Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma|Terminated||Phase 1|14|Actual|Astex Pharmaceuticals||||"The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in~   patients with refractory prostate and lymphoma"|f||||f||||||||||2018-06-01 01:16:59.377749|2018-06-01 01:16:59.377749
NCT00848588|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2012-03-01|2009-02-19|2009-02-20|Estimate|||||||2012-03-01|2012-03-05|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Observational|||A Survey of Factors Associated With the Successful Recognition of Agonal Breathing and Cardiac Arrest.|A Survey of Factors Associated With the Successful Recognition of Agonal Breathing and Cardiac Arrest by 9-1-1 Call Takers.|Completed|||409|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-06-01 01:16:59.439413|2018-06-01 01:16:59.439413
NCT00848575|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2013-09-13|2009-02-19|2009-02-20|Estimate|||||||2013-09-13|2013-09-16|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|Culdo||A Preliminary Study Utilizing a Flexible Endoscope for Pelvic Culdoscopy|A Preliminary Study Utilizing a Flexible Endoscope for Pelvic Culdoscopy|Terminated|||2|Actual|University of Arkansas|||1|Low enrollment|f||||f||||||||||2018-06-01 01:16:59.497415|2018-06-01 01:16:59.497415
NCT00848562|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|January 2002||2002-01-31|February 2009|2009-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients|Oral Nicorandil to Reduce Cardiac Death After Coronary Revascularization in Hemodialysis Patients: A Randomized Trial|Completed||N/A|129|Actual|Toujinkai Hospital||1|||f||||t||||||||||2018-06-01 01:16:59.585554|2018-06-01 01:16:59.585554
NCT00848549|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2012-11-12||2015-12-21|2009-02-19|2009-02-20|Estimate|2013-01-10|2013-01-15|Estimate||||2015-12-21|2015-12-24|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures|A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures|Completed||Phase 3|295|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 01:16:59.705254|2018-06-01 01:16:59.705254
NCT00848536|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2011-02-14||2012-04-04|2009-02-19|2009-02-20|Estimate|2011-02-14|2011-03-08|Estimate||||2012-04-04|2012-04-06|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy Study of Travoprost APS Versus TRAVATAN|A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|371|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:17:00.506353|2018-06-01 01:17:00.506353
NCT00848523|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-07-15|2009-02-19|2009-02-20|Estimate|||||||2010-07-15|2010-07-16|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|April 2009|Actual|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors|Phase II Trial of LBH589 (Panobinostat) in Adult Patients With Recurrent Malignant Gliomas|Terminated||Phase 2|6|Actual|Neurological Surgery, P.C.||||insufficient accrual|f||||t||||||||||2018-06-01 01:17:00.797224|2018-06-01 01:17:00.797224
NCT00848510|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2015-07-24||2015-11-09|2009-02-19|2009-02-20|Estimate|2015-11-09|2015-12-14|Estimate||||2015-11-09|2015-12-14|Estimate|February 2009||2009-02-28|November 2015|2015-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All subjects analysis set included all subjects who entered the trial (that is, all subjects who signed informed consent).|EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases|A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With Liver Metastases After Failure of Standard Therapy|Completed||Phase 1|41|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 01:17:00.915294|2018-06-01 01:17:00.915294
NCT00848497|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2013-03-18||2015-06-02|2009-02-19|2009-02-20|Estimate|2015-06-02|2015-06-19|Estimate||||2015-06-02|2015-06-19|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Arm 1 = 2 Arm 2 = 1|Testosterone for Penile Rehabilitation After Radical Prostatectomy|Efficacy of Testosterone Replacement Therapy in Penile Rehabilitation Following Radical Prostatectomy (#: 04-07-30-01)|Terminated||Early Phase 1|3|Actual|Baylor College of Medicine|The subject that completed the study reported no adverse reactions or events.|2||Lack of volunteers who would consent to participate and lack of funding|f||||t||||||||||2018-06-01 01:17:02.262577|2018-06-01 01:17:02.262577
NCT00848484|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2010-06-11||2015-10-30|2009-02-19|2009-02-20|Estimate|2010-11-17|2010-12-15|Estimate||||2015-10-30|2015-11-02|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Add-On Therapy, 2-Period Cross-Over Clinical Trial to Evaluate the Safety and Efficacy of MK5757 for the Treatment of Cognitive Impairment in Men With Schizophrenia|Completed||Phase 2|54|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:17:02.594773|2018-06-01 01:17:02.594773
NCT00848471|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-08-18|2009-02-19|2009-02-20|Estimate|||||||2009-08-18|2009-08-19|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|Protocol Quark||Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)|Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems) for Measuring Energy Expenditure at Rest and in Dynamic Phase After a Meal in Adult Healthy and Obese Volunteers|Unknown status|Recruiting|N/A|30|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 01:17:03.112344|2018-06-01 01:17:03.112344
NCT00848458|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-07-14|2009-02-19|2009-02-20|Estimate|||||||2010-07-14|2010-07-15|Estimate|January 2009||2009-01-31|July 2010|2010-07-31||||December 2010|Anticipated|2010-12-31||Interventional|AAI||Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma|Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma - An Open Randomized, Controlled, Prospective, Single Blinded Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|70|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:17:03.185454|2018-06-01 01:17:03.185454
NCT00848445|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|October 2002||2002-10-31|February 2009|2009-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|CAFE||Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -|the Use of Atrial Fibrillation Pacing Therapies in Patients With no Previous History of Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -|Completed||Phase 4|270|Actual|Guidant Corporation||2|||f||||f||||||||||2018-06-01 01:17:03.27766|2018-06-01 01:17:03.27766
NCT00848432|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-23|2009-02-19|2009-02-20|Estimate|||||||2009-02-23|2009-02-24|Estimate|December 2002||2002-12-31|February 2009|2009-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Risperidone Maintenance Treatment in Schizophrenia|Risperidone Maintenance Treatment for Relapse Prevention in Schizophrenia|Completed||Phase 4|404|Actual|Capital Medical University||3|||f||||t||||||||||2018-06-01 01:17:03.345261|2018-06-01 01:17:03.345261
NCT00848419|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|April 2009||2009-04-30|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||A Prospective Randomized Comparison of Fentanyl, Methadone and Morphine for Epidural Analgesia in an Experimental Pain Model|A Prospective Randomized Comparison of Fentanyl, Methadone and Morphine for Epidural Analgesia in an Experimental Pain Model|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Hadassah Medical Organization||4|||f||||f||||||||||2018-06-01 01:17:03.455602|2018-06-01 01:17:03.455602
NCT00848406|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2015-01-15|2009-02-19|2009-02-20|Estimate|||||||2015-01-15|2015-01-16|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|April 2014|Actual|2014-04-30||Observational|NORM||A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects|An Observational Study to Obtain Normal Values of Inflammatory Variables in Induced Sputum, Exhaled Breath, and Bronchial Biopsies From Healthy Smoking and Non-smoking Individuals|Completed|||120|Anticipated|University Medical Center Groningen|||4||f||||f||||||Samples With DNA|"~     Blood, induced sputum, bronchial biopsies, brush and lining fluid, urine~   "|||2018-06-01 01:17:03.528684|2018-06-01 01:17:03.528684
NCT00842387|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-12-22|2009-02-11|2009-02-12|Estimate|||||||2009-12-22|2009-12-23|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Observational|||Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)|Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)|Completed|||2370|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:18:56.887581|2018-06-01 01:18:56.887581
NCT00848393|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2015-06-26|2009-02-19|2009-02-20|Estimate|||||||2015-06-26|2015-06-29|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Measures to Lower the Stress Response in Pediatric Cardiac Surgery|Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl, Low Dose Fentanyl Plus Dexmedetomidine and High Dose Fentanyl.|Completed||N/A|52|Actual|Nationwide Children's Hospital||3|||f||||t||||||||||2018-06-01 01:17:03.591211|2018-06-01 01:17:03.591211
NCT00848380|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-11-15|2009-02-19|2009-02-20|Estimate|||||||2010-11-15|2010-11-16|Estimate|February 2009||2009-02-28|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Management of Cardiovascular Risk Factors|Management of Cardiovascular Risk Factors|Completed|||1492|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:17:03.744558|2018-06-01 01:17:03.744558
NCT00848367|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2013-06-04||2014-01-10|2009-02-19|2009-02-20|Estimate|2013-10-17|2013-12-11|Estimate||||2014-01-10|2014-02-07|Estimate|April 2007||2007-04-30|January 2014|2014-01-31|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Binge Eating Disorder Treatment Study|Optimizing Outcomes for Binge Eating, Depression and Weight Loss for Obese Women With Binge Eating Disorder by Matching to Group Psychological Treatments Based on Level of Attachment Anxiety|Completed||N/A|102|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 01:17:03.863536|2018-06-01 01:17:03.863536
NCT00848354|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2012-02-02||2015-12-11|2009-02-19|2009-02-20|Estimate|2012-03-26|2012-04-19|Estimate||||2015-12-11|2016-01-18|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||The safety population included all randomized participant with documented use of at least 1 dose of test article - Baseline characteristics from Phase 1 CSR are provided.|Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy|A Randomized, Open-label Study In The Latin America Region Comparing The Safety And Efficacy Of Etanercept With Conventional Dmard Therapy In Subjects With Rheumatoid Arthritis.|Completed||Phase 4|429|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:17:04.354494|2018-06-01 01:17:04.354494
NCT00848341|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Observational|||Canadian Registry of ICD Implant Testing Procedures|Canadian Registry of ICD Implant Testing Procedures|Completed|||261|Actual|Guidant Corporation|||1||f||||t||||||||||2018-06-01 01:17:07.642177|2018-06-01 01:17:07.642177
NCT00848328|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2018-03-01|2009-02-19|2009-02-20|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2008||2008-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma|A Phase II Trial of the Combination of Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular NHL (RV 0163)|Active, not recruiting||Phase 2|30|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-06-01 01:17:07.704809|2018-06-01 01:17:07.704809
NCT00848315|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|July 2004||2004-07-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Diabetes Management in Low-Income Hispanic Patients|Diabetes Management in Low-Income Hispanic Patients|Completed||Phase 2|252|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 01:17:07.784217|2018-06-01 01:17:07.784217
NCT00848302|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-03-06|2009-02-19|2009-02-20|Estimate|||||||2017-03-06|2017-03-07|Actual|September 2009||2009-09-30|March 2017|2017-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Endothelial Function in Human Arteries|Endothelial Function in Human Arteries|Completed||Early Phase 1|25|Actual|The Cleveland Clinic||1|||f||||t||||||||No||2018-06-01 01:17:07.934273|2018-06-01 01:17:07.934273
NCT00848289|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2017-09-07|2009-02-19|2009-02-20|Estimate|||||||2017-09-07|2017-09-11|Actual|February 10, 1998|Actual|1998-02-10|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Genetic Susceptibility to Bladder Cancer|Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach|Recruiting|||4500|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples Without DNA|"~     blood (about 40 cc or 8 teaspoons), urine~   "|||2018-06-01 01:17:08.004842|2018-06-01 01:17:08.004842
NCT00848276|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2010-12-07|2009-02-19|2009-02-20|Estimate|||||||2010-12-07|2010-12-08|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Sex Hormones and Blood PCSK9 Levels|Human Studies On Gender Differences In PCSK9 Function In Lipoprotein Metabolism|Completed|||61|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:17:08.101379|2018-06-01 01:17:08.101379
NCT00848263|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2014-11-17|2009-02-19|2009-02-20|Estimate|||||||2014-11-17|2014-11-19|Estimate|February 2009||2009-02-28|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|RADIUS||Unstable Fractures of the Distal Radius: Trial of Volar Plate Versus Dorsal Nail Plate Fixation|Unstable Fractures of the Distal Radius: Randomised Controlled Trial of Volar Plate Versus Dorsal Nail Plate Fixation.|Completed||N/A|120|Actual|Sykehuset Asker og Baerum||2|||f||||f||||||||||2018-06-01 01:17:08.16844|2018-06-01 01:17:08.16844
NCT00848250|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2017-05-01||2017-06-26|2009-02-19|2009-02-20|Estimate|2017-06-26|2017-07-26|Actual||||2017-06-26|2017-07-26|Actual|September 2008||2008-09-30|June 2017|2017-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children|Effects of Angiotensin Converting Enzyme Inhibition During and After Cardiopulmonary Bypass in Infants and Children With Congenital Heart Defects|Completed||N/A|21|Actual|Vanderbilt University Medical Center|While patients were randomized to preoperative ACE inhibition, the present study was neither blinded nor placebo-controlled. However, the dose and type of ACE inhibitor were similar between the two study groups.|2|||f||||f||||||||||2018-06-01 01:17:08.268759|2018-06-01 01:17:08.268759
NCT00848237|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2015-09-11||2016-01-05|2009-02-19|2009-02-20|Estimate|2016-01-05|2016-02-05|Estimate||||2016-01-05|2016-02-05|Estimate|July 2007||2007-07-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||HALO Patient Registry: Ablation of Barrett's Esophagus|HALO Patient Registry: Ablation of Barrett's Esophagus, A Multi-Center Patient Registry|Completed||N/A|5521|Actual|Medtronic - MITG|Endoscopic clearance rate for Barrett's esophagus-Percentage of patients with no endoscopically visible Barrett's esophagus at 1 year follow-up: This endpoint is a visual and not reliable or accurate.|1|||f||||f||||||||||2018-06-01 01:17:08.713429|2018-06-01 01:17:08.713429
NCT00848224|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|September 2000||2000-09-30|February 2009|2009-02-28|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|PACT||Improving Adherence to Pharmacological Treatment|Improving Adherence to Pharmacological Treatment|Completed||N/A|689|Actual|University of Massachusetts, Worcester||1|||f||||f||||||||||2018-06-01 01:17:08.952728|2018-06-01 01:17:08.952728
NCT00848211|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2010-06-12||2011-02-17|2009-02-19|2009-02-20|Estimate|2011-01-23|2011-02-21|Estimate||||2011-02-17|2011-02-24|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|THYMON-08001||Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects|Phase I/IIA Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects|Completed||Phase 1/Phase 2|24|Actual|Thymon, LLC||4|||f||||f||||||||||2018-06-01 01:17:09.039053|2018-06-01 01:17:09.039053
NCT00848198|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2011-04-05||2016-04-13|2009-02-19|2009-02-20|Estimate|2016-03-14|2016-04-14|Estimate||||2016-04-13|2016-05-16|Estimate|February 2009||2009-02-28|April 2016|2016-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|CVS||TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease|A Prospective Study to Establish Normative Values, Demographic Variations, Referent Diagnostic Values and Disease Severity Correlations for Dry Eye Disease and TearLab Osmometry.|Completed|||314|Actual|TearLab Corporation|95/299 subjects were using topical medication at the time of measurement, potentially lowering the diagnostic performance of osmolarity (osmolarity is lowered and responds before the other tests during therapy) and compressing the referent spread.||2||f||||f||||||||Yes|Data was published in AJO May 2011 and IOVS Dec.2010.|2018-06-01 01:17:09.402716|2018-06-01 01:17:09.402716
NCT00848185|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2016-02-25||2017-03-05|2009-02-19|2009-02-20|Estimate|2017-03-05|2017-04-17|Actual||||2017-03-05|2017-04-17|Actual|June 2008||2008-06-30|March 2017|2017-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Observational||"Age between 18 and 35 years and previous pregnancy~Regular menstrual cycles (between 25 and 35 days)~Normal karyotype~Body massindex between 18 and 25 kg/m2~Negative serology for VHB, VHC and HIV~Normal cervical cytology in the past year, and a vaginal ultrasound without evidence of any pathologic conditions"|Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors|Differential Regulation of VEGF, Cadherin and Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors: Try to Explain the Lower OHSS Incidence|Completed|||96|Actual|IVI Madrid|||3||f||||t||||||Samples With DNA|"~     follicular fluid~   "|No||2018-06-01 01:17:09.809853|2018-06-01 01:17:09.809853
NCT00848172|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2012-08-06||2012-11-22|2009-02-19|2009-02-20|Estimate|2012-11-22|2012-12-27|Estimate||||2012-11-22|2012-12-27|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor|Double-Blind, Placebo Controlled Pilot-Study of Octanoic Acid in Essential Tremor|Completed||Phase 1/Phase 2|29|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 01:17:10.191904|2018-06-01 01:17:10.191904
NCT00848159|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|November 2007|Actual|2007-11-30||Observational|||Postural Assessment by Photogrammetry|Evaluation of Thoracic Kyphosis in Elderly Women Affected by Osteoporosis Through Computerized Photogrammetry|Completed|||12||Universidade de Franca|||2||f||||t|||||||"~     The two groups were photographed in the sagittal plane with right column markers fixed on two~     anatomical points. The selected images were quantified by computerized photogrametry, using~     the program Autocad-2006~   "|||2018-06-01 01:17:10.499733|2018-06-01 01:17:10.499733
NCT00848146|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2012-07-03|2009-02-19|2009-02-20|Estimate|||||||2012-07-03|2012-07-04|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|TAS-NOTES||NOTES-Assisted Laparoscopic Cholecystectomy Surgery|Natural Orifice Translumenal Endoscopic Surgery (NOTES)-Assisted Laparoscopic Cholecystectomy Surgery|Completed||N/A|4|Actual|Northwestern University||1|||f||||f||||||||||2018-06-01 01:17:10.557305|2018-06-01 01:17:10.557305
NCT00848133|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|July 2004||2004-07-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Comparison of Subvastus and Midvastus Approaches in Minimally-Invasive Total Knee Arthroplasty|A Comparison of Subvastus and Midvastus Approaches in Minimally-Invasive Total Knee Arthroplasty|Completed||Phase 4|51|Actual|Sinai Hospital of Baltimore||2|||f||||f||||||||||2018-06-01 01:17:10.618621|2018-06-01 01:17:10.618621
NCT00848120|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2014-05-05||2017-06-28|2009-02-19|2009-02-20|Estimate|2014-12-23|2015-01-07|Estimate||||2017-06-28|2017-08-03|Actual|December 31, 2008|Actual|2008-12-31|June 2017|2017-06-30|February 13, 2010|Actual|2010-02-13|February 13, 2010|Actual|2010-02-13||Interventional||"The safety population included all participants who received any part of an infusion of study drug.~Intent to Treat (ITT) Population was used for efficacy analyses. All participants who have received any part of an infusion of study medication were included in this population."|A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis|An Open Label Study to Evaluate the Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis|Completed||Phase 3|29|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:17:10.69511|2018-06-01 01:17:10.69511
NCT00848107|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2013-07-12|2013-04-01|2014-01-08|2009-02-19|2009-02-20|Estimate|2014-01-08|2014-02-07|Estimate|2013-04-01|2013-04-08|Estimate|2014-01-08|2014-02-07|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|DISTOL-EXT|Efficacy was assessed using data obtained at each visit, if available, from all subjects enrolled in this study. Assessments performed after discontinuation of study drug were excluded from the summaries. All subjects who had at least one dose of study drug documented were included in the safety analysis population.|Open-Label Study of Oral Treprostinil in Digital Ulcers|Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: An Open-label Multicenter Extension Study|Terminated||Phase 2|115|Actual|United Therapeutics|Interpretation of the change in digital ulcer status was limited by the lack of a control group and the discontinuation of the study prior to subjects completing all scheduled visits.|1||"The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled~   TDE-DU-201 study did not meet its primary efficacy objective."|f||||f||||||||||2018-06-01 01:17:11.079104|2018-06-01 01:17:11.079104
NCT00848094|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2009-02-19|2009-02-19|2009-02-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|April 2005||2005-04-30|February 2009|2009-02-28|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Radiation Dose Escalation Study for Advanced Liver Cancer|Phase I Trial of Radiation Dose Escalation for Locally Advanced Hepatocellular Carcinoma|Completed||Phase 1|40|Actual|Fudan University||2|||f||||t||||||||||2018-06-01 01:17:11.495337|2018-06-01 01:17:11.495337
NCT00848081|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2010-08-16||2010-08-16|2009-02-19|2009-02-20|Estimate|2010-08-16|2010-09-14|Estimate||||2010-08-16|2010-09-14|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1-Adrenergic Blocker Therapy|Completed||Phase 3|318|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:17:11.605173|2018-06-01 01:17:11.605173
NCT00848055|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2013-10-31|2009-02-19|2009-02-20|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2008||2008-12-31|October 2013|2013-10-31||||October 2010|Actual|2010-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single Rising, Open-label Doses of AbGn-168 Administered by Intravenous Infusion (1 Mcg/kg, 5 Mcg/kg, 25 Mcg/kg, 125 Mcg/kg, 625 Mcg/kg, 3 mg/kg, or 10 mg/kg) or Subcutaneous Injection (625 Mcg/kg) to Patients With Chronic Plaque Psoriasis|Completed||Phase 1|40|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-06-01 01:17:12.236277|2018-06-01 01:17:12.236277
NCT00848042|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2016-06-07||2016-12-19|2009-02-19|2009-02-20|Estimate|2016-06-07|2016-07-18|Estimate||||2016-12-19|2017-02-09|Estimate|April 2008||2008-04-30|December 2016|2016-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck|A Pilot Study of AuroLase(tm) Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck|Completed||N/A|11|Actual|Nanospectra Biosciences, Inc.||3|||f||||t||||||||||2018-06-01 01:17:12.314361|2018-06-01 01:17:12.314361
NCT00848029|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|||2016-11-30|2009-02-19|2009-02-20|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2008||2008-11-30|December 2011|2011-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules||Completed||Phase 3|240|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:17:12.802096|2018-06-01 01:17:12.802096
NCT00848016|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-19|2014-01-06||2014-04-17|2009-02-19|2009-02-20|Estimate|2014-01-07|2014-02-21|Estimate||||2014-04-17|2014-05-07|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery|A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)|Completed||Phase 2|29|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:17:12.879372|2018-06-01 01:17:12.879372
NCT00848003|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2013-05-17|2009-02-19|2009-02-20|Estimate|||||||2013-05-17|2013-05-20|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PHASE||Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics|Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics|Completed||Phase 1|40|Actual|Georgetown University||2|||f||||t||||||||||2018-06-01 01:17:13.130766|2018-06-01 01:17:13.130766
NCT00847990|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-09-01|2009-02-19|2009-02-20|Estimate|||||||2011-09-01|2011-09-05|Estimate|March 2009||2009-03-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Observational|||Non-Invasive Screening for Fetal Aneuploidy|Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|Completed|||5000|Anticipated|Sequenom, Inc.|||1||f||||f||||||Samples With DNA|"~     plasma, PBMCs~   "|||2018-06-01 01:17:13.225988|2018-06-01 01:17:13.225988
NCT00847977|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2013-01-30|2009-02-18|2009-02-19|Estimate|||||||2013-01-30|2013-01-31|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|IsoTC||Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic Acidosis|Intérêt d'Utiliser Des solutés de Remplissage équilibrés à la Phase précoce d'un Traumatisme crânien Grave Pour Limiter l'Acidose hyperchlorémique|Terminated||Phase 3|42|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 01:17:13.302238|2018-06-01 01:17:13.302238
NCT00847964|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-11-29|2009-02-17|2009-02-19|Estimate|||||||2012-11-29|2012-11-30|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery|SYM-08-001: A Pilot Study to Evaluate the Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With Dilated Cardiomyopathy Undergoing Open-heart Surgery|Completed||Phase 2|11|Actual|LoneStar Heart, Inc.||1|||f||||f||||||||||2018-06-01 01:17:13.360411|2018-06-01 01:17:13.360411
NCT00847951|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2017-09-18|2009-02-18|2009-02-19|Estimate|||||||2017-09-18|2017-09-19|Actual|October 2008|Actual|2008-10-31|September 2017|2017-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Ultrasound for Perfusion in Neonates|3D Ultrasound for Perfusion in Neonates|Withdrawn||N/A|0|Actual|University of Michigan||1||Study terminated at this time by investigator. Will create new protocol.|f||||f||||||||No||2018-06-01 01:17:13.414475|2018-06-01 01:17:13.414475
NCT00847938|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-11-30|2009-02-18|2009-02-19|Estimate|||||||2009-11-30|2009-12-01|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|NEODEC||Comparision of Different Dose of Neostigmine at Advanced Decurarization|Randomized, Controlled, Double-blind, Prospective Study, Comparing Different Doses of Neostigmine at Advanced Decurarization .|Completed||Phase 3|72|Anticipated|Centre Hospitalier Departemental Vendee||4|||f||||f||||||||||2018-06-01 01:17:13.464114|2018-06-01 01:17:13.464114
NCT00847925|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|November 2001||2001-11-30|February 2009|2009-02-28|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects|A Double Blind, Placebo and Standard Care Controlled, Randomised Study to Investigate the Clinical Safety and Toleration, Wound Healing and Antiscarring Potential of Two Applications of Intradermal RN1001 (Avotermin) in Healthy Male Subjects|Completed||Phase 1/Phase 2|103|Actual|Renovo||9|||f||||f||||||||||2018-06-01 01:17:13.52599|2018-06-01 01:17:13.52599
NCT00847912|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2016-11-07|2014-08-11|2018-03-23|2009-02-18|2009-02-19|Estimate|2017-01-27|2017-03-17|Actual|2014-08-11|2014-09-15|Estimate|2018-03-23|2018-04-24|Actual|June 26, 2009|Actual|2009-06-26|March 2018|2018-03-31|July 30, 2016|Actual|2016-07-30|June 28, 2013|Actual|2013-06-28||Interventional|VAKCCT||CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial|CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial|Completed||Phase 4|954|Actual|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-06-01 01:17:14.614877|2018-06-01 01:17:14.614877
NCT00847899|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-11-18|2009-02-17|2009-02-19|Estimate|||||||2009-11-18|2009-11-20|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance|Completed||Phase 2|150|Anticipated|Arete Therapeutics||4|||f||||f||||||||||2018-06-01 01:17:16.234986|2018-06-01 01:17:16.234986
NCT00847886|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2010-04-19||2010-06-01|2009-02-17|2009-02-19|Estimate|2010-06-01|2010-06-03|Estimate||||2010-06-01|2010-06-03|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis|Completed||Phase 1|15|Actual|Lexicon Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:17:16.363436|2018-06-01 01:17:16.363436
NCT00847873|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2013-11-03|2009-02-18|2009-02-19|Estimate|||||||2013-11-03|2013-11-05|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Treatment of Intimate Partner Violence and Substance Abuse in a Substance Abuse Treatment Facility|Treatment of Intimate Partner Violence and Substance Abuse in a Substance Abuse: a Randomized Controlled Trial|Completed||N/A|100|Anticipated|VU University of Amsterdam||2|||f||||f||||||||||2018-06-01 01:17:16.782361|2018-06-01 01:17:16.782361
NCT00847860|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2015-05-05|2009-02-17|2009-02-19|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|CAVAD||Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions|Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White|Completed||Phase 4|200|Actual|Peking University First Hospital||2|||f||||t||||||||||2018-06-01 01:17:16.864968|2018-06-01 01:17:16.864968
NCT00847847|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2012-11-16|2009-02-18|2009-02-19|Estimate|||||||2012-11-16|2012-11-19|Estimate|March 2009||2009-03-31|December 2009|2009-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|NETALS||Neuromuscular Transmission in Amyotrophic Lateral Sclerosis|Neuromuscular Transmission in Amyotrophic Lateral Sclerosis|Completed||N/A|14|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:17:16.950081|2018-06-01 01:17:16.950081
NCT00847834|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-09-14|2009-02-18|2009-02-19|Estimate|||||||2009-09-14|2009-09-15|Estimate|December 2003||2003-12-31|September 2009|2009-09-30||||June 2004|Actual|2004-06-30||Interventional|||Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population|Multi-center Open Label, Non-comparative Observational Study of Irbesartan-Hydrochlorothiazide in the Treatment of Hypertension in Chinese Population|Completed||Phase 4|968|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:17:17.026122|2018-06-01 01:17:17.026122
NCT00847821|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2010-09-03|2009-02-18|2009-02-19|Estimate|||||||2010-09-03|2010-09-06|Estimate|May 2009||2009-05-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene|RNA Expression Analysis Of Endometrial Biopsies Comparing Placebo, Bazedoxifene/ Conjugated Estrogens And Raloxifene|Terminated|||185|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||8|See termination reason in detailed description.|f||||f||||||Samples With DNA|"~     Endometrial biopsy blocks~   "|||2018-06-01 01:17:17.104615|2018-06-01 01:17:17.104615
NCT00847808|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2011-04-05||2012-02-01|2009-02-18|2009-02-19|Estimate|2011-04-05|2011-04-29|Estimate||||2012-02-01|2012-02-03|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy|A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy|Completed||Phase 3|178|Actual|Takeda||1|||f||||f||||||||||2018-06-01 01:17:17.234765|2018-06-01 01:17:17.234765
NCT00847795|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|September 2002||2002-09-30|February 2009|2009-02-28|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.|A Trial to Investigate the Accelerated Wound Healing and Antiscarring Potential, Safety, Toleration and Systemic Exposure of Intradermal RN1001 (Avotermin) in Male and Female Subjects Aged 60 Years and Over.|Completed||Phase 1/Phase 2|42|Actual|Renovo||5|||f||||f||||||||||2018-06-01 01:17:17.650789|2018-06-01 01:17:17.650789
NCT00847782|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-11-04|2009-02-17|2009-02-19|Estimate|||||||2009-11-04|2009-11-05|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism|An Experimental Medicine Study to Quantify PCSK9 Serum Concentrations and LDL Receptor Expression in Peripheral Blood Cells in Normal and Hypercholesterolemic Subjects|Completed||N/A|150|Anticipated|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:17:17.736432|2018-06-01 01:17:17.736432
NCT00847769|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2017-03-30|2009-02-17|2009-02-19|Estimate|||||||2017-03-30|2017-04-04|Actual|December 2008||2008-12-31|March 2017|2017-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ACE||Ankle Sprains and Corticospinal Excitability|Effect of Manual Therapy Intervention on Corticospinal Excitability in Individuals With Post-acute Ankle Sprains|Completed||Phase 1/Phase 2|27|Actual|University of Southern California||3|||f||||f||||||||||2018-06-01 01:17:17.815694|2018-06-01 01:17:17.815694
NCT00847756|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-07-19|2009-02-18|2009-02-19|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|July 2011|Anticipated|2011-07-31|September 2009|Actual|2009-09-30||Observational|OMVac||Host-pathogen Interaction in Otitis Media|Thorough Clinical Investigation of the Host-pathogen Interaction in Chronic and Recurrent Otitis Media|Unknown status|Active, not recruiting||179|Actual|Radboud University|||3||f||||f||||||Samples With DNA|"~     blood nasopharyngeal swab middle ear fluid~   "|||2018-06-01 01:17:17.904392|2018-06-01 01:17:17.904392
NCT00847743|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study on Whether Tart Cherry Juice Can Reduce Oxidative Stress and Inflammation|Effects of Tart Cherry Juice on Oxidative Stress and Inflammation in Older Men and Women|Completed||N/A|12|Actual|Kronos Longevity Research Institute|||||f||||f||||||||||2018-06-01 01:17:17.975298|2018-06-01 01:17:17.975298
NCT00847730|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2011-09-08|2009-02-18|2009-02-19|Estimate|||||||2011-09-08|2011-09-09|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negatvie Pressure Wound Therapy|A Single Arm, Prospective Clinical Trial Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabectic Foot Ulcers Receiving VAC Negative Pressure Therapy|Completed||Phase 2|75|Anticipated|KCI USA, Inc.|||||f||||f||||||||||2018-06-01 01:17:18.04654|2018-06-01 01:17:18.04654
NCT00847717|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-08-10|2009-02-18|2009-02-19|Estimate|||||||2009-08-10|2009-08-11|Estimate|August 2007||2007-08-31|August 2009|2009-08-31||||September 2009|Anticipated|2009-09-30||Interventional|||Trial of IIb Preserving Neck Dissection|Randomized Controlled Trial of IIb Preserving Neck Dissection VS Neck Dissections Involving IIb Removal (Selective/Functional) in Patients With N0 Neck With Oral Cavity Malignancies|Unknown status|Recruiting|Phase 3|100|Anticipated|Banaras Hindu University||2|||f||||f||||||||||2018-06-01 01:17:18.103212|2018-06-01 01:17:18.103212
NCT00847704|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2014-12-17||2016-11-23|2009-02-18|2009-02-19|Estimate|2016-11-23|2017-01-23|Estimate||||2016-11-23|2017-01-23|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||Stroke >1 yr prior to enrollment Able to stand independently <50% normal strength in affected leg Functioning proprioception in affected leg|Clinic-Based AMES Treatment of Stroke|Clinic-Based Ames Treatment of the Lower Extremity in Chronic Stroke Subjects|Terminated||Phase 1/Phase 2|3|Actual|Oregon Health and Science University|Early termination due to lack of funding lead to only 2 subjects treated and analyzed.|1||Funding not available.|f||||t||||||||||2018-06-01 01:17:18.245323|2018-06-01 01:17:18.245323
NCT00847691|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2012-12-17|2009-02-18|2009-02-19|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Observational|GENSARC||GENSARC 2008 : Medical Economic Evaluation of the Molecular Detection by FISH (Fluorescent in Situ Hybridization) and by PCR (Polymerase Chain Reaction) of Sarcomas Specific Translocations and Amplifications .|GENSARC 2008 : Medical Economic Evaluation of the Molecular Detection by FISH (Fluorescent in Situ Hybridization) and by PCR (Polymerase Chain Reaction) of Sarcomas Specific Translocations and Amplifications .|Completed|||350|Actual|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||Samples With DNA|"~     sarcoma biopsy~   "|||2018-06-01 01:17:18.471043|2018-06-01 01:17:18.471043
NCT00847678|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|August 2006||2006-08-31|February 2009|2009-02-28||||November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS|A Multicenter, Randomized Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS|Terminated||Phase 2|38|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:17:18.534789|2018-06-01 01:17:18.534789
NCT00847665|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2012-06-28||2013-03-09|2009-02-18|2009-02-19|Estimate|2013-03-09|2013-04-17|Estimate||||2013-03-09|2013-04-17|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PUPPAS||Pressure Ulcer Prevention in Ventilated Patients Using Two Repositioning Regimens|Comparison of Two Turning Regimens (2 Versus Every 4 Hours) in the Prevention of Pressure Ulcers in Patients on Mechanical Ventilation That Use Alternating-pressure Air Mattresses.|Completed||Phase 3|330|Actual|University Hospital Virgen de las Nieves||2|||f||||t||||||||||2018-06-01 01:17:18.615615|2018-06-01 01:17:18.615615
NCT00847639|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2014-04-02|2009-02-17|2009-02-19|Estimate|||||||2014-04-02|2014-04-04|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2013|Actual|2013-01-31||Interventional|07-REV||Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma|Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma|Completed||Phase 2|30|Actual|Center for International Blood and Marrow Transplant Research||1|||f||||t||||||||||2018-06-01 01:17:18.880899|2018-06-01 01:17:18.880899
NCT00847626|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2012-01-04||2012-01-04|2009-02-18|2009-02-19|Estimate|2012-01-04|2012-02-07|Estimate||||2012-01-04|2012-02-07|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension|A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension|Completed||Phase 3|1711|Actual|Takeda||11|||f||||f||||||||||2018-06-01 01:17:19.048402|2018-06-01 01:17:19.048402
NCT00847613|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2012-12-05|2012-11-05|2013-01-14|2009-02-17|2009-02-19|Estimate|2012-12-05|2013-01-09|Estimate|2012-11-05|2012-11-07|Estimate|2013-01-14|2013-01-18|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|April 2011|Actual|2011-04-30||Interventional|||A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate|Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate|Completed||Phase 3|800|Actual|Pfizer|Results include data of 1-year analysis.|4|||f||||t||||||||||2018-06-01 01:17:22.500576|2018-06-01 01:17:22.500576
NCT00847600|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2010-12-14|2009-02-18|2009-02-19|Estimate|||||||2010-12-14|2010-12-15|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|PREG-2008||Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia|Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-week, Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 4|60|Anticipated|Sha’ar Menashe Mental Health Center||2|||f||||f||||||||||2018-06-01 01:17:26.957739|2018-06-01 01:17:26.957739
NCT00847587|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2011-03-10||2016-03-18|2009-02-18|2009-02-19|Estimate|2011-04-29|2011-06-02|Estimate||||2016-03-18|2016-04-18|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant|Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Etonogestrel Contraceptive Implant|Completed||Phase 4|69|Actual|University of Utah|Limitations:Study was not blinded & early insertion was allowed as late as 3 days postpartum. Insertion on postpartum days 1-3 was allowed so long as lactogenesis had not already occurred to mimic normal clinical practice & improve generalizability.|2|||f||||t||||||||||2018-06-01 01:17:27.041722|2018-06-01 01:17:27.041722
NCT00847574|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-11-30|2009-02-18|2009-02-19|Estimate|||||||2011-11-30|2011-12-01|Estimate|March 2006||2006-03-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|June 2008|Actual|2008-06-30||Interventional|WORLD||The WORLD (Weight Optimization: Revamping Lifestyles Using the Dietary Guidelines) Study - Developing, Implementing, and Testing an Education Program|Development, Implementation, & Testing and Education Program to Teach Weight Loss Using the 2005 Dietary Guidelines to Pre-Menopausal Women|Completed||N/A|101|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 01:17:27.242026|2018-06-01 01:17:27.242026
NCT00847561|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2014-05-05||2017-03-23|2009-02-18|2009-02-19|Estimate|2014-05-05|2014-06-03|Estimate||||2017-03-23|2017-03-24|Actual|August 2008||2008-08-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effectiveness of a Family-Based Treatment for Preventing Anxiety Disorders in At-Risk Children|Family-Based Prevention for Childhood Anxiety|Completed||N/A|136|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 01:17:27.328112|2018-06-01 01:17:27.328112
NCT00847548|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2013-09-16|2009-02-18|2009-02-19|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting|Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting|Unknown status|Active, not recruiting|N/A|100|Anticipated|VU University of Amsterdam||2|||f||||f||||||||||2018-06-01 01:17:27.556492|2018-06-01 01:17:27.556492
NCT00847535|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2013-11-12||2015-07-29|2009-02-18|2009-02-19|Estimate|2013-11-12|2014-01-01|Estimate||||2015-07-29|2015-08-10|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence|Muscle Cell Mediated Therapy for Stress Urinary Incontinence: An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells.|Completed||Phase 2|66|Actual|Cook Group Incorporated||2|||f||||||||||||||2018-06-01 01:17:27.649575|2018-06-01 01:17:27.649575
NCT00847522|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2017-06-30||2017-11-20|2009-02-18|2009-02-19|Estimate|2017-11-20|2017-12-20|Actual||||2017-11-20|2017-12-20|Actual|February 2009||2009-02-28|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma|Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma|Completed||Phase 1/Phase 2|90|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:17:27.843002|2018-06-01 01:17:27.843002
NCT00847509|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2013-07-26||2013-07-26|2009-02-18|2009-02-19|Estimate|2013-07-26|2013-09-27|Estimate||||2013-07-26|2013-09-27|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|FLT101|A total of 49 patients were enrolled and 38 patients received investiational product.|A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation|A Phase II/III, Open Label, Non-Randomized, Multi - Center Study Of Positron Emission Tomography (PET) Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation|Completed||N/A|49|Actual|Siemens Molecular Imaging||1|||f||||f||||||||||2018-06-01 01:17:27.970582|2018-06-01 01:17:27.970582
NCT00847496|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-12-10|2009-02-18|2009-02-19|Estimate|||||||2012-12-10|2012-12-11|Estimate|December 2009||2009-12-31|December 2012|2012-12-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|Awbat||Awbat Versus Biobrane in Partial Thickness Burns|The Treatment of Partial Thickness Burns: Awbat(r) Versus Biobrane(r)|Withdrawn||Phase 2|0|Actual|The University of Texas Medical Branch, Galveston||2||Company went out of business|f||||f||||||||||2018-06-01 01:17:28.122778|2018-06-01 01:17:28.122778
NCT00847483|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2009-02-17|2009-02-17|2009-02-19|Estimate|||||||2009-02-17|2009-02-19|Estimate|January 2002||2002-01-31|February 2009|2009-02-28|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|XLT||Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US|A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-Week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan).|Completed||Phase 4|375|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:17:28.213284|2018-06-01 01:17:28.213284
NCT00847470|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2014-11-17|2009-02-18|2009-02-19|Estimate|||||||2014-11-17|2014-11-18|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||DPBRN Reasons for Placing the First Restoration on Permanent Tooth Surfaces|Reasons for Placing the First Restoration on Permanent Tooth Surfaces|Completed|||5810|Actual|Dental Practice-Based Research Network|||||f||||f||||||||||2018-06-01 01:17:28.530037|2018-06-01 01:17:28.530037
NCT00847457|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2013-06-26|2009-02-18|2009-02-19|Estimate|||||||2013-06-26|2013-06-27|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Depressed Adolescents Treated With Exercise (The DATE Study)|Exercise Treatment for Depressed Youth|Completed||N/A|40|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 01:17:28.599587|2018-06-01 01:17:28.599587
NCT00847444|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-04-17|2009-02-17|2009-02-19|Estimate|||||||2013-04-17|2013-04-19|Estimate|February 2009||2009-02-28|April 2013|2013-04-30|September 2016|Anticipated|2016-09-30|September 2011|Actual|2011-09-30||Interventional|SUCCESS-C||Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention|Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention Strategies|Unknown status|Active, not recruiting|Phase 3|3547|Anticipated|Ludwig-Maximilians - University of Munich||3|||f||||t||||||||||2018-06-01 01:17:28.677324|2018-06-01 01:17:28.677324
NCT00847431|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2016-05-03|2009-02-18|2009-02-19|Estimate|||||||2016-05-03|2016-05-04|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|MOOD-D||Mapping Mood in the Subthalamic Nucleus in Parkinson's Disease (PD)|Mapping Mood in the Subthalamic Nucleus in PD|Completed|||81|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 01:17:28.743019|2018-06-01 01:17:28.743019
NCT00847418|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2010-12-01|2009-02-18|2009-02-19|Estimate|||||||2010-12-01|2010-12-02|Estimate|February 2009||2009-02-28|December 2010|2010-12-31|October 2009|Actual|2009-10-31|||||Interventional|||Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine|Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine|Completed||Phase 1|||University Hospital, Basel, Switzerland||1|||f||||||||||||||2018-06-01 01:17:28.799384|2018-06-01 01:17:28.799384
NCT00847405|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2009-07-06||2009-09-01|2009-02-17|2009-02-19|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets Versus Imitrex® 100 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:17:28.861822|2018-06-01 01:17:28.861822
NCT00847392|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2016-09-16|2009-02-17|2009-02-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PV-BUS||Study to Determine Pediatric Bladder Volume Prior to Catheterization|Pediatric Volumetric Bladder Ultrasound Study|Withdrawn||N/A|0|Actual|McMaster University||2||Inability to obtain grant funding|f||||f||||||||||2018-06-01 01:17:29.180829|2018-06-01 01:17:29.180829
NCT00847379|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2017-05-30|2009-02-18|2009-02-19|Estimate|||||||2017-05-30|2017-06-01|Actual|January 2009|Actual|2009-01-31|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)|A Phase 2b Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy|Terminated||Phase 2/Phase 3|173|Actual|PTC Therapeutics||1|||f||||t||||||||No||2018-06-01 01:17:29.253623|2018-06-01 01:17:29.253623
NCT00847366|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17||2018-03-06|2018-03-12|2009-02-17|2009-02-19|Estimate||||2018-03-06|2018-03-08|Actual|2018-03-12|2018-03-15|Actual|May 2008||2008-05-31|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma|An Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma|Completed||N/A|10|Actual|AEterna Zentaris||5|||f||||f||||||||||2018-06-01 01:17:29.367653|2018-06-01 01:17:29.367653
NCT00847353|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2010-02-03|2009-02-18|2009-02-19|Estimate|||||||2010-02-03|2010-02-04|Estimate|February 2009||2009-02-28|February 2010|2010-02-28|June 2010|Anticipated|2010-06-30|February 2010|Anticipated|2010-02-28||Observational|||Normal Values of High Frequency ECG (HyperQ™) in Apparently Healthy Individuals and in Young and Masters Athletes|Normal Values of High Frequency ECG (HyperQ™) in Asymptomatic, Apparently Healthy Normal Weight vs. Obese Individuals and in Young and Masters Athletes|Unknown status|Recruiting||300|Anticipated|BSP Biological Signal Processing Ltd.|||||f||||f||||||||||2018-06-01 01:17:29.42999|2018-06-01 01:17:29.42999
NCT00847340|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-03-19|2009-02-17|2009-02-19|Estimate|||||||2012-03-19|2012-03-20|Estimate|December 2009||2009-12-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|GWprofamilia||Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population|Prevalence of HPV Genotypes in Genital Warts in Colombian Male and Female Population Attending Medical Services.|Completed|||342|Actual|La Fundacion para la Investigacion y el Desarrollo|||||f||||t||||||Samples With DNA|"~     Biopsies from genital warts will be taken through an excisional procedure. Homeostasis will~     be obtained by using topications of Monssell solution. Biopsy sample will be splinted in~     order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to~     the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer~     Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the~     pathology laboratory for haematoxiline - eosine paint and lecture.~   "|||2018-06-01 01:17:29.482274|2018-06-01 01:17:29.482274
NCT00847327|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2018-03-12|2009-02-17|2009-02-19|Estimate|||||||2018-03-12|2018-03-14|Actual|April 2008|Actual|2008-04-30|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|YCP||Parental Management of Young Children's Diabetes|Parenting and Control Among Young Children With Type 1 Diabetes|Completed||N/A|134|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 01:17:29.537|2018-06-01 01:17:29.537
NCT00847314|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-06-19|2009-02-18|2009-02-19|Estimate|||||||2013-06-19|2013-06-21|Estimate|June 2007||2007-06-30|June 2013|2013-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients|Efficacy and Tolerability of Testogel® / Nebido in Combination With a Standardised Exercise and Diet Programme in Hypogonadal Male Patients With Abdominal Obesity Compared With Exercise and Diet Programme|Completed|||30|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:17:29.886228|2018-06-01 01:17:29.886228
NCT00847301|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2015-06-30||2015-08-25|2009-02-18|2009-02-19|Estimate|2015-08-25|2015-09-25|Estimate||||2015-08-25|2015-09-25|Estimate|April 2009||2009-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational||The Treated set with moderate renal impairment: this patient set included all patients with CrCl (Creatinine clearance) 30 - 50 mL/min who received at least one 1 of dabigatran etexilate.|Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery|Observational Cohort Study to Evaluate Safety and Efficacy of Pradaxa (Dabigatran Etexilate) in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery|Completed|||472|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 01:17:29.983537|2018-06-01 01:17:29.983537
NCT00847288|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2012-06-05||2013-04-30|2009-02-17|2009-02-19|Estimate|2013-04-30|2013-05-03|Estimate||||2013-04-30|2013-05-03|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||OptiVol® Care Pathway|OptiVol® Care Pathway|Completed||Phase 4|1682|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-06-01 01:17:30.368719|2018-06-01 01:17:30.368719
NCT00847275|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2010-01-25|2009-02-17|2009-02-19|Estimate|||||||2010-01-25|2010-01-26|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|BCDE||Behaviour and Cognitive Evaluation for Dialysis Elderly Patients (BCDE)|Behaviour and Cognitive Evaluation for Dialysis Elderly Patients|Unknown status|Recruiting|N/A|500|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-06-01 01:17:30.89912|2018-06-01 01:17:30.89912
NCT00847262|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-12-15|2009-02-18|2009-02-19|Estimate|||||||2013-12-15|2013-12-17|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|HOT-DM||Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes|Hypertension With Obesity Trial: Diabetes Mellitus Branch|Completed||Phase 4|120|Actual|Third Military Medical University||2|||f||||t||||||||||2018-06-01 01:17:31.015238|2018-06-01 01:17:31.015238
NCT00847249|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-09-22|2009-02-18|2009-02-19|Estimate|||||||2009-09-22|2009-09-23|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|April 2009|Actual|2009-04-30|||||Interventional|||AZD9164 Single Ascending Dose Study in Healthy Male Subjects|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD9164 After Single Ascending Doses in Healthy Male Subjects|Completed||Phase 1|65|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:17:31.128737|2018-06-01 01:17:31.128737
NCT00847236|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2017-08-22|2009-02-18|2009-02-19|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2009|Actual|2009-01-31|August 2017|2017-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica|Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica|Completed|||142|Actual|Lahey Clinic|||3||f||||f||||||||||2018-06-01 01:17:31.214396|2018-06-01 01:17:31.214396
NCT00847223|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-03-03|2009-02-18|2009-02-19|Estimate|||||||2011-03-03|2011-03-04|Estimate|June 2007||2007-06-30|March 2011|2011-03-31||||March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma|A Phase II Study Evaluating the Efficacy and Safety of the Farnesyl-transferase Inhibitor ZARNESTRA® in Patients With Relapsed, Refractory or Progressive Mantle Cell Lymphoma Not Appropriate for Autologous Bone Marrow Transplantation|Terminated||Phase 2|11|Actual|Lymphoma Study Association||1||Inefficiency of treatment|f||||t||||||||||2018-06-01 01:17:31.274588|2018-06-01 01:17:31.274588
NCT00847210|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2010-09-08||2012-01-31|2009-02-18|2009-02-19|Estimate|2010-09-08|2010-10-05|Estimate||||2012-01-31|2012-02-02|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease|A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease|Completed||Phase 1|36|Actual|Takeda|For outcome measures #4, 5, 6, 7 and 8, outcomes could not be estimated for one participant in the 30 mg dose group.|2|||f||||f||||||||||2018-06-01 01:17:31.351225|2018-06-01 01:17:31.351225
NCT00847197|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2010-08-27||2015-11-19|2009-02-18|2009-02-19|Estimate|2010-08-27|2010-09-22|Estimate||||2015-11-19|2015-12-21|Estimate|June 2008||2008-06-30|November 2015|2015-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK1903 in Patients With Dyslipidemia|Completed||Phase 2|191|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:17:31.78043|2018-06-01 01:17:31.78043
NCT00847184|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Comparison of Airtraq Versus MacIntosh Intubation Via Nasal Approach|Comparison of Airtraq vs. MacIntosh Intubation Via Nasal Approach|Unknown status|Recruiting|N/A|200|Anticipated|Kliniken Essen-Mitte||2|||f||||f||||||||||2018-06-01 01:17:32.16639|2018-06-01 01:17:32.16639
NCT00847171|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2018-05-22|2009-02-18|2009-02-19|Estimate|||||||2018-05-22|2018-05-24|Actual|December 2008||2008-12-31|August 2017|2017-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer|A Safety and Bioactivity Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of Patients With High Risk/ Metastatic HER-2/Neu- Overexpressing Breast Cancer With No Evidence of Disease|Completed||Phase 2|20|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 01:17:32.243183|2018-06-01 01:17:32.243183
NCT00847158|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|December 2006||2006-12-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Clinical Trial of Phacoemulsification Versus Phacoemulsification & the iStent Implantation in POAG Patients|A Randomized, Double-Masked Clinical Trial of Phacoemulsification Compared With Phacoemulsification and Micro-Bypass Stent Implantation in Patients With POAG|Completed||N/A|36|Actual|University of Turin, Italy||2|||f||||t||||||||||2018-06-01 01:17:32.316958|2018-06-01 01:17:32.316958
NCT00847145|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2015-02-03||2015-03-02|2009-02-18|2009-02-19|Estimate|2015-03-02|2015-03-03|Estimate||||2015-03-02|2015-03-03|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers|A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13|Completed||Phase 3|2249|Actual|Novartis|None reported.|8|||f||||||||||||||2018-06-01 01:17:32.494258|2018-06-01 01:17:32.494258
NCT00847132|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2014-08-14||2017-03-21|2009-02-17|2009-02-19|Estimate|2017-03-21|2017-03-31|Actual||||2017-03-21|2017-03-31|Actual|July 2007||2007-07-31|March 2017|2017-03-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients|A Collaborative Care Program to Improve Depression Treatment in Cardiac Patients|Completed||N/A|175|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:17:34.105486|2018-06-01 01:17:34.105486
NCT00847119|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2017-08-28|2009-02-18|2009-02-19|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2007||2007-09-30|August 2017|2017-08-31|February 2015|Actual|2015-02-28|June 2011|Actual|2011-06-30||Interventional|xeberecto||Xeloda and Bevacizumab to Treat Rectal Cancer|ESTUDIO FASE II DE BEVACIZUMAB EN COMBINACIÓN CON CAPECITABINA Y RADIOTERAPIA COMO TRATAMIENTO PREOPERATORIO EN PACIENTES CON CÁNCER RECTAL LOCALMENTE AVANZADO RESECABLE|Completed||Phase 2|43|Actual|Institut Català d'Oncologia||1|||f||||f||||||||||2018-06-01 01:17:34.499703|2018-06-01 01:17:34.499703
NCT00847106|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|March 2004||2004-03-31|February 2009|2009-02-28|October 2005||2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients|Augmentation of Dendritic Cell Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells With an Anti-CD25 Monoclonal Antibody (Daclizumab). A Clinical Study.|Completed||Phase 1/Phase 2|15||Radboud University|||||f||||||||||||||2018-06-01 01:17:34.578684|2018-06-01 01:17:34.578684
NCT00847093|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-06-30|2009-02-18|2009-02-19|Estimate|||||||2011-06-30|2011-07-01|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|LMX-4||LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery|Post-Operative Pain Control in Children and Infants Undergoing Penoplasty: A Randomized Control Trial of a Local Anesthetic Cream Placebo.|Completed||Phase 4|50|Actual|Ferndale Laboratories, Inc.||1|||f||||f||||||||||2018-06-01 01:17:34.644713|2018-06-01 01:17:34.644713
NCT00847080|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-04-22|2009-02-18|2009-02-19|Estimate|||||||2011-04-22|2011-04-26|Estimate|December 2008||2008-12-31|February 2009|2009-02-28|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism|Treatment With Sitagliptin Phosphate in Patients With Reactive Hypoglycemia Secondary to Dysinsulinism. A Controlled, Randomized, Double-blind, Clinical Trial|Completed||Phase 4|20|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-06-01 01:17:34.724466|2018-06-01 01:17:34.724466
NCT00847067|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2010-06-10|2009-02-18|2009-02-19|Estimate|||||||2010-06-10|2010-06-11|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Chronic Post Breast Surgery Pain|A Prospective, Single-blinded, Randomized, Trial Evaluating the Use of Paravertebral Block to Decrease Chronic Post Breast Surgery Pain.|Terminated||N/A|40|Actual|Mayo Clinic||2||Funding not renewed|f||||f||||||||||2018-06-01 01:17:34.820438|2018-06-01 01:17:34.820438
NCT00847054|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2014-07-15|2009-02-18|2009-02-19|Estimate|||||||2014-07-15|2014-07-16|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of of MORAb-004 in Subjects With Solid Tumors|A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-004, a Humanized Monoclonal Antibody, in Subjects With Solid Tumors|Completed||Phase 1|80|Actual|Morphotek||1|||f||||f||||||||||2018-06-01 01:17:34.885771|2018-06-01 01:17:34.885771
NCT00847041|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate||||February 2009|2009-02-28||||||||Observational|||Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis.|Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis.|Completed|||||University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:17:34.985532|2018-06-01 01:17:34.985532
NCT00839137|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-05-26|2009-02-06|2009-02-09|Estimate|||||||2010-05-26|2010-05-27|Estimate|December 2003||2003-12-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|ETA||Exercise Therapy for Asthma (ETA Trial)|Exercise Therapy for Asthma (ETA Trial)|Terminated|||13|Actual|Ohio State University|||2|Study proved difficult to recruit|f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 01:19:39.722597|2018-06-01 01:19:39.722597
NCT00847028|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-19|Estimate|||||||2009-02-17|2009-02-19|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Oral Glucose Solution as Pain Relief in Newborns: Results of a Clinical Trial|Oral Glucose Solution as Pain Relief in Newborns: Results of a Clinical Trial|Unknown status|Active, not recruiting|N/A|304|Actual|Universiteit Antwerpen||4|||f||||t||||||||||2018-06-01 01:17:35.119675|2018-06-01 01:17:35.119675
NCT00847015|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2015-10-19||2016-02-01|2009-02-18|2009-02-19|Estimate|2016-02-01|2016-02-29|Estimate||||2016-02-01|2016-02-29|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer|Phase II Study of Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer|Completed||Phase 2|18|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:17:35.253072|2018-06-01 01:17:35.253072
NCT00847002|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2012-05-31||2016-09-06|2009-02-18|2009-02-19|Estimate|2012-06-20|2012-07-25|Estimate||||2016-09-06|2016-10-21|Estimate|September 2007||2007-09-30|September 2016|2016-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Flexitouch Treatment for Venous Ulcers|A Pilot Randomized Trial of Flexitouch as an Adjunctive Treatment for Venous Ulcers|Terminated||Phase 4|8|Actual|Tactile Medical||2||Lack of Enrollment|f||||f||||||||||2018-06-01 01:17:35.490519|2018-06-01 01:17:35.490519
NCT00846989|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18||2012-05-02|2013-02-11|2009-02-18|2009-02-19|Estimate||||2012-05-02|2012-05-04|Estimate|2013-02-11|2013-02-13|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension|A 4-week Multi-center, Single-masked, Randomized, Latanoprost-controlled, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of RKI983 (0.05% and 0.10%) Ophthalmic Solution Given Twice a Day Versus Once Daily Latanoprost 0.005%, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.|Completed||Phase 1/Phase 2|276|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:17:35.725837|2018-06-01 01:17:35.725837
NCT00846976|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2015-01-20|2009-02-18|2009-02-19|Estimate|||||||2015-01-20|2015-01-21|Estimate|December 1994||1994-12-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer|A Treatment Protocol to Monitor the Safety of a 200 mg Daily Dose of Bicalutamide (Casodex) in Patients With Advanced Prostate Cancer|Completed||Phase 3|101|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:17:35.829965|2018-06-01 01:17:35.829965
NCT00846963|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-09-16|2009-02-17|2009-02-19|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|URSONEONAT||Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates|Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates|Completed||Phase 2/Phase 3|26|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-06-01 01:17:35.892434|2018-06-01 01:17:35.892434
NCT00846950|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|December 2006||2006-12-31|February 2009|2009-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effects of H1-Antagonist on Cognition|Effects of H1-Antagonist on Stages of Human Information Processing|Completed||N/A|18|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 01:17:36.002932|2018-06-01 01:17:36.002932
NCT00846937|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-02-09|2009-02-18|2009-02-19|Estimate|||||||2011-02-09|2011-02-10|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|STOMA||Plant Stanol Ester Beverage and Ileostoma Patients|Effects of a Plant Stanolester Beverage on Cholesterol Metabolism Among Human Subjects With Ileostoma|Completed||N/A|10|Actual|Helsinki University|||||f||||f||||||||||2018-06-01 01:17:36.068448|2018-06-01 01:17:36.068448
NCT00846924|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2018-05-19|2009-02-18|2009-02-19|Estimate|||||||2018-05-19|2018-05-22|Actual|May 2009||2009-05-31|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|April 2014|Actual|2014-04-30||Interventional|EMBRACE||30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event|30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event: A Randomized Controlled Trial|Active, not recruiting||N/A|564|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:17:36.121837|2018-06-01 01:17:36.121837
NCT00846911|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2012-07-05|2009-02-18|2009-02-19|Estimate|||||||2012-07-05|2012-07-09|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs|AVANTI - Avelox® in Acute Exacerbations of Chronic Bronchitis|Completed|||2672|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:17:36.214693|2018-06-01 01:17:36.214693
NCT00846898|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-11-11|2009-02-18|2009-02-19|Estimate|||||||2011-11-11|2011-11-14|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|cinnamon||Is There a Metabolic Effect of Cinnamon on HbA1c, Blood Pressure and Serum Lipids in Type 2 Diabetes Mellitus?|The Effect of Dietary Supplementation of Cinnamon (Cinnamon Cassia) on HbA1c, Blood Pressure and Serum Lipid Measurements in Patients With Type 2 Diabetes Mellitus: a Randomised Placebo Controlled, Double Blind Clinical Trial|Completed||Phase 2|58|Actual|Thames Valley University||2|||f||||t||||||||||2018-06-01 01:17:36.294915|2018-06-01 01:17:36.294915
NCT00846885|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2009-07-06||2009-09-01|2009-02-17|2009-02-19|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|October 2004|Actual|2004-10-31|September 2004|Actual|2004-09-30||Interventional|||Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Sumatriptan Succinate, (100mg), Compared to and Equivalent Dose of a Commercially Available Reference Drug Product (Imitrex®, GlaxoSmithKline, USA) in 28 Fed, Healthy, Adult Subjects.|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:17:36.373338|2018-06-01 01:17:36.373338
NCT00846872|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2016-12-01|2009-02-18|2009-02-19|Estimate|||||||2016-12-01|2016-12-05|Estimate|July 2008||2008-07-31|December 2016|2016-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance|Effect of Continuous Subcutaneous GHRP-3 Infusion at 2 Dose Levels on the Physiological Secretion of the GH-IGF-I System, Blood Pressure, Glucose, Inflammatory Markers and Endothelial Function in Subjects With Insulin Resistance|Withdrawn||Phase 1/Phase 2|0|Actual|Tulane University||3||Inadequate subject recruitment|f||||t||||||||||2018-06-01 01:17:36.810585|2018-06-01 01:17:36.810585
NCT00846859|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2011-07-20|2009-02-17|2009-02-19|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?|Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?|Completed||Phase 2|162|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-06-01 01:17:36.905242|2018-06-01 01:17:36.905242
NCT00846846|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2014-05-30||2015-04-13|2009-02-18|2009-02-19|Estimate|2014-05-30|2014-07-02|Estimate||||2015-04-13|2015-05-04|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2013|Actual|2013-03-31||Interventional|PROTECT-CA||PROTECT Continued Access Post Marketing Surveillance Trial|Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial: PROTECT Continued Access Post Marketing Surveillance Trial|Completed||Phase 4|1018|Actual|Medtronic Vascular||1|||f||||f||||||||||2018-06-01 01:17:37.016103|2018-06-01 01:17:37.016103
NCT00846833|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-06-06|2009-02-18|2009-02-19|Estimate|||||||2012-06-06|2012-06-08|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|April 2012|Actual|2012-04-30|February 2011|Actual|2011-02-28||Interventional|||Haploidentical NK Cell Infusion in Malignant Melanoma|Phase I/II Study of Haploidentical Natural Killer Cell Infusion in Patients With Refractory or Relapsed Malignant Melanoma|Completed||Phase 1/Phase 2|12|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-06-01 01:17:37.295731|2018-06-01 01:17:37.295731
NCT00846820|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2014-11-21|2009-02-18|2009-02-19|Estimate|||||||2014-11-21|2014-11-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:17:37.42206|2018-06-01 01:17:37.42206
NCT00846807|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2012-07-25||2012-09-13|2009-02-18|2009-02-19|Estimate|2012-07-25|2012-08-28|Estimate||||2012-09-13|2012-09-18|Estimate|February 2009||2009-02-28|September 2012|2012-09-30||||July 2011|Actual|2011-07-31||Observational|||Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery|Observational Cohort Study to Evaluate the Safety and Efficacy of Pradaxa (Dabigatran Etexilate) for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery in a Routine Clinical Setting.|Completed|||5476|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 01:17:37.483796|2018-06-01 01:17:37.483796
NCT00846794|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2016-09-14|2009-02-17|2009-02-19|Estimate|||||||2016-09-14|2016-09-15|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||AcuGraph and Digestive Symptoms|Can AcuGraph Differentiate Between Participants With and Without Digestive Symptoms|Completed|||30|Actual|Logan College of Chiropractic|||2||f||||f||||||||||2018-06-01 01:17:37.935226|2018-06-01 01:17:37.935226
NCT00846781|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18||2011-05-20|2015-10-15|2009-02-18|2009-02-19|Estimate||||2011-05-20|2011-05-23|Estimate|2015-10-15|2015-11-06|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|DEFY||Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)||Terminated||Phase 3|308|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-06-01 01:17:37.991388|2018-06-01 01:17:37.991388
NCT00846768|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2014-03-28||2014-05-29|2009-02-18|2009-02-19|Estimate|2014-05-29|2014-07-01|Estimate||||2014-05-29|2014-07-01|Estimate|February 2009||2009-02-28|May 2014|2014-05-31||||July 2009|Actual|2009-07-31||Interventional||Treated set, includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD|Randomised, Double-Blind, Cross-over Study to Determine the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, Delivered With the Respimat Inhaler, After 3 Weeks of Once Daily or Twice Daily Administration in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|47|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:17:38.11984|2018-06-01 01:17:38.11984
NCT00846755|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2011-09-26|2009-02-18|2009-02-19|Estimate|||||||2011-09-26|2011-09-27|Estimate|March 2005||2005-03-31|September 2011|2011-09-30|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|||Thyroid Disease in Pregnancy: Case Finding Versus Universal Screening|Impact of Treating Thyroid Hormone Dysfunction During Pregnancy: A Randomized Controlled Trial of Universal Screening Versus Case Finding|Completed||N/A|4657|Actual|Ospedale V. Fazzi||2|||f||||f||||||||||2018-06-01 01:17:38.817214|2018-06-01 01:17:38.817214
NCT00846742|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2017-10-28|2009-02-18|2009-02-19|Estimate|||||||2017-10-28|2017-10-31|Actual|June 5, 2009|Actual|2009-06-05|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma|Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma|Recruiting||Phase 2|100|Anticipated|St. Jude Children's Research Hospital||1|||f||||t|t|f||||||||2018-06-01 01:17:38.877684|2018-06-01 01:17:38.877684
NCT00846729|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2018-04-26|2009-02-17|2009-02-19|Estimate|||||||2018-04-26|2018-04-30|Actual|March 2003||2003-03-31|April 2018|2018-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors|Preserving Renal Longevity in Living Kidney Donors|Completed|||120|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     1. Blood samples are obtained throughout the kidney function study. These samples are~          analyzed for Iothalamate and PAH (markers of kidney function) only.~        2. Kidney tissue obtained by biopsy at the time of surgery are used to analyze the~          structure of the kidney.~      No Tissue or Blood is used for genetic analysis.~   "|||2018-06-01 01:17:38.987335|2018-06-01 01:17:38.987335
NCT00846716|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|SHIP-DINER||Shiga Progression of Diabetes, Nephropathy and Retinopathy|Exploratory Study to Investigate the Suppressive Effect of Oral Anti-Diabetic Drug (TZD) on Progression of Diabetic Nephropathy on|Unknown status|Recruiting|N/A|400|Anticipated|Shiga University||2|||f||||t||||||||||2018-06-01 01:17:39.041871|2018-06-01 01:17:39.041871
NCT00846703|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2010-03-05|2009-02-17|2009-02-19|Estimate|||||||2010-03-05|2010-03-08|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|December 2018|Anticipated|2018-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia|Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province|Recruiting||Phase 4|600|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:17:39.266998|2018-06-01 01:17:39.266998
NCT00846690|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2009-02-18|2009-02-18|2009-02-19|Estimate|||||||2009-02-18|2009-02-19|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|May 2009|Anticipated|2009-05-31|March 2009|Anticipated|2009-03-31||Interventional|||Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel|Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel for Control of Pain of Dental Needle Insertion in the Palate|Unknown status|Recruiting|Phase 4|20|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 01:17:39.369692|2018-06-01 01:17:39.369692
NCT00846677|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-03-01|2009-02-17|2009-02-19|Estimate|||||||2012-03-01|2012-03-02|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips|A Randomized, Open-label, Cross-over Study Comparing Two Vitamin D Supplements for Infants: Liquid Versus D-Strips.|Completed||Phase 4|50|Actual|McGill University||2|||f||||f||||||||||2018-06-01 01:17:39.510624|2018-06-01 01:17:39.510624
NCT00846664|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-19|Estimate|||||||2009-02-17|2009-02-19|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Short Arc Multifidus Study|Increase in Multifidus Size By Short Arc Banding on the ATM Machine as Measure by Diagnostic Ultrasound|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 01:17:39.580024|2018-06-01 01:17:39.580024
NCT00846651|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|2013-02-04||2017-09-14|2009-02-18|2009-02-19|Estimate|2013-05-29|2013-07-03|Estimate||||2017-09-14|2017-10-16|Actual|February 2009||2009-02-28|September 2017|2017-09-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Spinal Anesthesia Induced Hypotension During Cesarean Section|Comparison of Phenylephrine Infusion With Colloids vs. Crystalloids for Reduction of Spinal-induced Hypotension During Cesarean Section|Completed||Phase 4|82|Actual|Milton S. Hershey Medical Center|technical problems for analysing fetal pH in all newborns|2|||f||||f||||||||||2018-06-01 01:17:39.662623|2018-06-01 01:17:39.662623
NCT00846638|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2010-05-06|2009-02-18|2009-02-19|Estimate|||||||2010-05-06|2010-05-07|Estimate|January 2005||2005-01-31|May 2010|2010-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|WHHS||Women's Health Habits Study|Screening and Brief Intervention for Problem Drinking Women|Completed||Phase 3|611|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:17:39.937518|2018-06-01 01:17:39.937518
NCT00846625|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2014-12-09|2009-02-18|2009-02-19|Estimate|||||||2014-12-09|2014-12-11|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SURFING||Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids|Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids Following a Periocular Steroid Injections in Patients on Steroid Sparing Agents or Low Dose Steroids|Withdrawn||Phase 2|0|Actual|University of Utah||2||Insufficient enrollment (no subjects were enrolled)|f||||t||||||||||2018-06-01 01:17:40.07257|2018-06-01 01:17:40.07257
NCT00846612|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-18|||2012-10-18|2009-02-18|2009-02-19|Estimate|||||||2012-10-18|2012-10-19|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|September 2010|Actual|2010-09-30||Interventional|||Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer|Phase II and Pharmacokinetic Study of Avastin and Doxil in the Treatment of Platinum-resistant or Refractory Ovarian Cancer|Completed||Phase 1|15|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 01:17:40.172249|2018-06-01 01:17:40.172249
NCT00846599|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2017-10-11|2009-02-17|2009-02-18|Estimate|||||||2017-10-11|2017-10-12|Actual|January 2008||2008-01-31|October 2017|2017-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|PERTH||Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men|Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men|Completed|||50|Anticipated|Tufts University|||2||f||||f||||||||||2018-06-01 01:17:40.274048|2018-06-01 01:17:40.274048
NCT00846586|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|2011-07-22||2011-07-22|2009-02-15|2009-02-18|Estimate|2011-07-22|2011-08-18|Estimate||||2011-07-22|2011-08-18|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|INTRUST1||Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Controlled, Parallel-group, 12-week Study to Compare the Efficacy and Safety of the Combination of Indacaterol 150 µg Once Daily With Open Label Tiotropium 18 µg Once Daily Versus Open Label Tiotropium 18 µg Once Daily in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1134|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:17:40.41107|2018-06-01 01:17:40.41107
NCT00846573|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2012-08-21||2012-11-08|2009-02-16|2009-02-18|Estimate|2012-10-09|2012-11-09|Estimate||||2012-11-08|2012-11-15|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders|Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders|Terminated||N/A|14|Actual|University of Massachusetts, Worcester||4||The study was halted prematurely as the PI was no longer an employee of UMass Medical School.|f||||f||||||||||2018-06-01 01:17:40.993554|2018-06-01 01:17:40.993554
NCT00846560|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|||2017-10-10|2009-02-17|2009-02-18|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2008|Actual|2008-08-31|October 2017|2017-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)|Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)|Withdrawn|||0|Actual|Rambam Health Care Campus|||2|Changes in the lab's focus and needs|f||||f||||||||||2018-06-01 01:17:41.379033|2018-06-01 01:17:41.379033
NCT00846547|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2013-02-14||2013-05-10|2009-02-17|2009-02-18|Estimate|2013-05-10|2013-06-14|Estimate||||2013-05-10|2013-06-14|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders|An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for Treatment of Irritability in Subjects With Autism Spectrum Disorders|Completed||Phase 2|32|Actual|Seaside Therapeutics, Inc.||1|||f||||t||||||||||2018-06-01 01:17:41.466251|2018-06-01 01:17:41.466251
NCT00846534|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2014-04-21|2009-02-17|2009-02-18|Estimate|||||||2014-04-21|2014-04-23|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|POAF||The Assessment of Oxidative Stress Markers and the Development of Atrial Fibrillation After Cardiac Surgery|The Assessment of Oxidative Stress Markers and the Development of Atrial Fibrillation After Cardiac Surgery|Terminated|||100|Anticipated|University of Illinois at Chicago|||1|Insufficient patient volume|f||||f||||||Samples Without DNA|"~     Approximately 10- 15 ml of blood will be drawn from subjects. Blood samples will be separated~     into plasma and serum to measure the oxidative stress markers.~   "|||2018-06-01 01:17:41.676406|2018-06-01 01:17:41.676406
NCT00846521|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2013-03-07||2013-04-29|2009-02-17|2009-02-18|Estimate|2013-04-29|2013-05-01|Estimate||||2013-04-29|2013-05-01|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Baseline analysis was only done on subjects who completed the study|Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity|Postprandial Glycemia in Association With Vascular Disease in Childhood Obesity|Terminated||Phase 4|23|Actual|Yale University||1|||f||||f||||||||||2018-06-01 01:17:41.811008|2018-06-01 01:17:41.811008
NCT00846508|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-12-31|2009-02-17|2009-02-18|Estimate|||||||2009-12-31|2010-01-05|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis|Phase III Randomized Trial of Comparing CCRT vs. RT Alone for Cervical Cancer Patients Primarily Treated by Radiotherapy and With Clinically Defined Good-prognosis|Unknown status|Enrolling by invitation|Phase 3|208|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 01:17:42.242782|2018-06-01 01:17:42.242782
NCT00846495|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2011-06-09||2012-01-11|2009-02-17|2009-02-18|Estimate|2011-07-12|2011-08-09|Estimate||||2012-01-11|2012-01-13|Estimate|August 2009||2009-08-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine|A Randomized, Single-Blind Pilot Study to Compare the Efficacy and Cost-Effectiveness of Frovatriptan vs. Topiramate for the Prevention of Migraine|Completed||Phase 4|55|Actual|Cady, Roger, M.D.||2|||f||||f||||||||||2018-06-01 01:17:42.362791|2018-06-01 01:17:42.362791
NCT00846482|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|February 2010|Anticipated|2010-02-28||Observational|||Exploratory Study Of The ERCC-1 Gene|Exploratory Study Of The ERCC-1 Gene Expression In Colorectal Cancer Cell Lines And In Patients With Colorectal Cancer|Unknown status|Recruiting||40|Anticipated|Montefiore Medical Center|||1||f||||t||||||Samples With DNA|"~     Biospecimens include blood and tumor samples.~   "|||2018-06-01 01:17:42.734852|2018-06-01 01:17:42.734852
NCT00846469|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-12-04|2009-02-17|2009-02-18|Estimate|||||||2012-12-04|2012-12-05|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Coronary Computed Tomography (CT) Angiography Versus Standard Therapy in the Emergency Room|64 Slice Coronary CT Angiography vs. Standard Therapy in the Emergency Room: Determining Cost-effectiveness and Predicting Clinical Outcome in Patients With Low and Moderate Risk for Acute Coronary Syndrome.|Completed||N/A|43|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 01:17:42.803091|2018-06-01 01:17:42.803091
NCT00846456|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|||2015-10-19|2009-02-17|2009-02-18|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma|Phase I/II Trial of Vaccine Therapy With Tumor Stem Cell Derived mRNA- Transfected Dendritic Cells in Patients Receiving Standard Therapy for Glioblastoma|Completed||Phase 1/Phase 2|20|Actual|Oslo University Hospital|||||f||||t||||||||||2018-06-01 01:17:42.85975|2018-06-01 01:17:42.85975
NCT00846443|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|January 2009||2009-01-31|February 2009|2009-02-28||||January 2010|Anticipated|2010-01-31||Interventional|||Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer|A Phase I Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer.|Unknown status|Recruiting|Phase 1|12|Anticipated|Fudan University||4|||f||||t||||||||||2018-06-01 01:17:42.909927|2018-06-01 01:17:42.909927
NCT00846430|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2015-05-20|2009-02-16|2009-02-18|Estimate|||||||2015-05-20|2015-05-21|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||"Medical Treatment of High-Risk Neurofibromas"|"Medical Treatment of High-Risk Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies"|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Spectrum Health Hospitals||1|||f||||f||||||||||2018-06-01 01:17:42.976236|2018-06-01 01:17:42.976236
NCT00846417|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2013-09-10|2009-02-17|2009-02-18|Estimate|||||||2013-09-10|2013-09-12|Estimate|July 2008||2008-07-31|September 2013|2013-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Implantable Cardioverter Defibrillator (ICD) Support Groups and Veterans|Impact of ICD Support Groups in Veterans Receiving Internal Cardioverter Defibrillators|Terminated|||3|Actual|Emory University|||2|No funding, lost support staff, no data collected/processed|f||||t||||||||||2018-06-01 01:17:43.048691|2018-06-01 01:17:43.048691
NCT00846404|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|May 2007|Anticipated|2007-05-31||Observational|ODDS||Markers of Oxidative Stress Diastolic Dysfunction|Markers of Oxidative Stress Present in Blood in Patients With Diastolic Dysfunction|Unknown status|Active, not recruiting||50|Anticipated|Emory University|||2||f||||f||||||||||2018-06-01 01:17:43.099259|2018-06-01 01:17:43.099259
NCT00846391|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2010-08-26||2016-02-04|2009-02-17|2009-02-18|Estimate|2010-08-26|2010-09-21|Estimate||||2016-02-04|2016-02-05|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)|A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK8245 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control|Terminated||Phase 2|14|Actual|Merck Sharp & Dohme Corp.|This study was terminated due to the continuing inability to recruit patients. No efficacy analysis was performed because of insufficient sample size for meaningful analysis due to early study termination and insufficient sample size.|3||Study was terminated due to inability to recruit patients.|f||||||||||||||2018-06-01 01:17:43.152194|2018-06-01 01:17:43.152194
NCT00846378|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2014-01-31|2009-02-17|2009-02-18|Estimate|||||||2014-01-31|2014-02-03|Estimate|March 2008||2008-03-31|January 2014|2014-01-31||||May 2010|Actual|2010-05-31||Interventional|PCinAMI||Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction|The Mechanism of Ischemic Post-conditioning in Humans: Minimizing Reperfusion Injury in Patients With Acute Myocardial Infarction|Suspended||Phase 1|30|Anticipated|University of Cincinnati||2||Suspended for potential change in protocol to include different imaging modalities|f||||t||||||||||2018-06-01 01:17:44.352791|2018-06-01 01:17:44.352791
NCT00846365|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2012-01-04||2012-02-09|2009-02-17|2009-02-18|Estimate|2012-02-09|2012-03-13|Estimate||||2012-02-09|2012-03-13|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension|A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension|Completed||Phase 3|1085|Actual|Takeda||3|||f||||f||||||||||2018-06-01 01:17:44.504532|2018-06-01 01:17:44.504532
NCT00846352|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2017-04-18|2009-02-17|2009-02-18|Estimate|||||||2017-04-18|2017-04-20|Actual|January 2009|Actual|2009-01-31|August 2009|2009-08-31|August 2, 2010|Actual|2010-08-02|August 2, 2010|Actual|2010-08-02||Interventional|||Early Versus Late Bronchoscopy in Bone Marrow Transplantation (BMT) Patients|Randomized Trial Comparing Early Versus Late Bronchoscopy in Hematopoietic Stem Cell Transplant Patients With Pulmonary Infiltrates.|Completed||N/A|22|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-06-01 01:17:47.091201|2018-06-01 01:17:47.091201
NCT00846339|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-14|||2011-02-19|2009-02-14|2009-02-18|Estimate|||||||2011-02-19|2011-02-23|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||PET Imaging Study on Occupancy of Dopamine D2 Receptors and Genotypes After Bupropion Administration|[11C] Raclopride PET Imaging Study That Investigates Relation Between Occupancy of Dopamine D2 Receptors and Genotypes of DRD2 After Bupropion Administration|Completed||Phase 4|12|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 01:17:47.175855|2018-06-01 01:17:47.175855
NCT00846326|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2016-10-24|2009-02-17|2009-02-18|Estimate|||||||2016-10-24|2016-10-25|Estimate||||October 2016|2016-10-31||||||||Interventional|||Preventing Tolerance to Oxymetazoline in Allergic Rhinitis|A Proof of Concept Study to Evaluate if Concomitant Topical Intranasal Steroid Prevents Tolerance and Rebound Congestion Due to Regular Oxymetazoline in Persistent Allergic Rhinitis.|Withdrawn||Phase 4|0|Actual|University of Dundee||2||The suppliers were unable to provide the investigational medicinal product (IMP)|f||||f||||||||||2018-06-01 01:17:47.335384|2018-06-01 01:17:47.335384
NCT00846313|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2015-04-07|2009-02-16|2009-02-18|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2003||2003-12-31|April 2015|2015-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|ColErn||Can Malnutrition be Prevented in Patient With Colorectal Cancer Stage Dukes D?|A Randomised Study of Dietary Counseling for Patients With Colorectal Cancer.|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||2||Study was stopped due to lack of resources (clinical dietitians)|f||||f||||||||||2018-06-01 01:17:47.426156|2018-06-01 01:17:47.426156
NCT00846300|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2015-10-07|2009-02-17|2009-02-18|Estimate|||||||2015-10-07|2015-10-08|Estimate|August 2001||2001-08-31|October 2015|2015-10-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas|An Intervention to Improve Medication Knowledge & Compliance Among Family Practice Patients in South Texas: An RRNEST Study.|Completed||N/A|150|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-06-01 01:17:47.502151|2018-06-01 01:17:47.502151
NCT00846287|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2012-06-19||2012-10-03|2009-02-17|2009-02-18|Estimate|2012-10-03|2012-11-01|Estimate||||2012-10-03|2012-11-01|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI|Assessment of Arformoterol for COPD Using Hyperpolarized 3He MRI|Completed||N/A|16|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 01:17:47.588702|2018-06-01 01:17:47.588702
NCT00846274|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|October 2008||2008-10-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III|"Single-Dose, Open Label, Randomized Comparative Clinical Trial to Evaluate the Tolerability, Safety and PK/PD of Human ATIII Products, SKATIII Injection andATIII Injection in Healthy Male Subjects"|Completed||Phase 1|20|Anticipated|SK Chemicals Co.,Ltd.||2|||f||||||||||||||2018-06-01 01:17:47.853073|2018-06-01 01:17:47.853073
NCT00846261|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-03-03|2009-02-17|2009-02-18|Estimate|||||||2009-03-03|2009-03-04|Estimate|January 2002||2002-01-31|March 2009|2009-03-31|January 2008|Actual|2008-01-31|December 2006|Actual|2006-12-31||Interventional|||The Infected Bone Nonunion and Soft Tissue Defect of Long Bone Treated Simultaneously With Ilizarov Technique|The Infected Bone Nonunion and Soft Tissue Defect of Long Bone Treated Simultaneously With Ilizarov Technique|Completed||Phase 4|22|Actual|Zhejiang University||1|||f||||t||||||||||2018-06-01 01:17:47.92294|2018-06-01 01:17:47.92294
NCT00846248|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-08-30|2009-02-17|2009-02-18|Estimate|||||||2012-08-30|2012-08-31|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2009|Actual|2009-07-31||Interventional|||Chromium and Insulin Resistance|Chromium and Insulin Resistance|Completed||N/A|75|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:17:48.002455|2018-06-01 01:17:48.002455
NCT00846235|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-10-07|2009-02-16|2009-02-18|Estimate|||||||2009-10-07|2009-10-08|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis|Clinical Evaluation of the Effect of Moisturising Cream on Skin Moisture in Atopic Dermatitis|Completed||Phase 4|24|Actual|Orion Corporation, Orion Pharma||1|||f||||f||||||||||2018-06-01 01:17:48.087327|2018-06-01 01:17:48.087327
NCT00846222|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|April 2010|Anticipated|2010-04-30||Interventional|||Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study||Unknown status|Active, not recruiting|Phase 3|10|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-06-01 01:17:48.170076|2018-06-01 01:17:48.170076
NCT00846209|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||Improving Prescription Drug Warning Labels||Completed||Phase 4|500|Actual|Northwestern University|||||f||||f||||||||||2018-06-01 01:17:48.237437|2018-06-01 01:17:48.237437
NCT00846196|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2011-10-07|2009-02-13|2009-02-18|Estimate|||||||2011-10-07|2011-10-12|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects|A Crossover Study to Assess the Bioequivalence of the Phase III and Commercial Risedronate 35 mg Delayed Release Formulations.|Completed||Phase 1|538|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 01:17:48.295739|2018-06-01 01:17:48.295739
NCT00846183|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-12-20|2009-02-17|2009-02-18|Estimate|||||||2013-12-20|2013-12-23|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Local Injury on Implantation|Effect of Local Injury to Endometrium on the Day of Oocyte Retrieval in First IVF Cycle on Implantation Rate.|Completed||Phase 2|156|Actual|Yazd Research & Clinical Center for Infertility||2|||f||||t||||||||||2018-06-01 01:17:48.366206|2018-06-01 01:17:48.366206
NCT00846170|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2015-03-08|2009-02-17|2009-02-18|Estimate|||||||2015-03-08|2015-03-10|Estimate|September 2010||2010-09-30|May 2011|2011-05-31||||March 2012|Anticipated|2012-03-31||Interventional|||Probiotics in Irritable Bowel Syndrome|"Double Blind Placebo Controlled Study of the Effect of Probiotics Co-Biotic (TM)on Symptoms and Fecal Bacterial Composition in IBS Patients"|Withdrawn||Phase 3|0|Actual|Meir Medical Center||2||sponsor decided they are not interested in the study due to finacial reasons|f||||f||||||||||2018-06-01 01:17:48.427897|2018-06-01 01:17:48.427897
NCT00846157|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|||2011-06-26|2009-02-17|2009-02-18|Estimate|||||||2011-06-26|2011-06-28|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|September 2014|Anticipated|2014-09-30|September 2011|Anticipated|2011-09-30||Interventional|NKCell||Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients|R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail|Unknown status|Enrolling by invitation|Phase 3|276|Anticipated|NKBio Co.Ltd.||2|||f||||f||||||||||2018-06-01 01:17:48.571927|2018-06-01 01:17:48.571927
NCT00845455|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|||2011-10-24|2009-02-17|2009-02-18|Estimate|||||||2011-10-24|2011-10-25|Estimate|November 2007||2007-11-30|October 2011|2011-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|TPQ BDI SSQOL||Personality Type as a Predictor to Develop Depression and Reduction in Quality of Life Among Stroke Survivals.|Personality Type as a Predictor to Develop Depression and Reduction in Quality of Life Among Stroke Survivals.|Completed|||85|Actual|Rambam Health Care Campus|||3||f||||f||||||||||2018-06-01 01:18:00.957572|2018-06-01 01:18:00.957572
NCT00846144|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|September 2009||2009-09-30|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||The Reduction in Glucose Stimulated Insulin Secretion Induced by Cytokines May be Prevented by Copper Addition - Studies in Diabetic Patients|This Study is a Small Preliminary Study to Evaluate the Possibility of Performing a Phase 1 Study.|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 01:17:48.642985|2018-06-01 01:17:48.642985
NCT00846131|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2016-09-13|2009-02-17|2009-02-18|Estimate|||||||2016-09-13|2016-09-15|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|||Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma|A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined With Therasphere in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation.|Completed||Phase 1|24|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 01:17:48.718905|2018-06-01 01:17:48.718905
NCT00846118|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2014-09-24|2009-02-17|2009-02-18|Estimate|||||||2014-09-24|2014-09-25|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|July 2014|Actual|2014-07-31||Interventional|||Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)|Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis.|Unknown status|Active, not recruiting|N/A|1550|Anticipated|Juntendo University Hospital||2|||f||||t||||||||||2018-06-01 01:17:48.814105|2018-06-01 01:17:48.814105
NCT00846105|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2010-06-14|2009-02-17|2009-02-18|Estimate|||||||2010-06-14|2010-06-15|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)|Two-Center Intervention Study to Evaluate the Impact of Rapid Molecular Screening on Nosocomial Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA).|Completed||N/A|7400|Anticipated|Erasme University Hospital||2|||f||||f||||||||||2018-06-01 01:17:48.910283|2018-06-01 01:17:48.910283
NCT00846092|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2013-09-20|2009-02-17|2009-02-18|Estimate|||||||2013-09-20|2013-09-23|Estimate|November 2007||2007-11-30|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|NIR||Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study|Phase 1 Study To Determine the Effects of Short Term Near-infrared Light (NIR) Therapy on Anatomic and Functional Abnormalities of Diabetic Macular Edema, and Assess Safety of Short Term Near-infrared Light Therapy in Eyes With Diabetic Macular Edema.|Completed||Phase 1|4|Actual|Medical College of Wisconsin||1|||f||||f||||||||||2018-06-01 01:17:48.989456|2018-06-01 01:17:48.989456
NCT00846079|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Myocardial Perfusion Assessment With Multidetector Computed Tomography|Myocardial Perfusion Assessment With Multidetector Computed Tomography|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Tennessee Heart and Vascular Institute, P.C.|||||f||||f||||||||||2018-06-01 01:17:49.068341|2018-06-01 01:17:49.068341
NCT00846066|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2009-02-19||2015-07-27|2009-02-17|2009-02-18|Estimate|2009-10-21|2009-10-22|Estimate||||2015-07-27|2015-08-14|Estimate|January 2007||2007-01-31|July 2015|2015-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Oral Health Training Program for Pediatric Residents|Effective Educational Instruction in Preventive Oral Health: Hands On Training (HOT)Versus Web Based Training (WBT): A Randomized Control Trial|Completed||N/A|56|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-06-01 01:17:49.14627|2018-06-01 01:17:49.14627
NCT00846053|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2011-03-02|2009-02-17|2009-02-18|Estimate|||||||2011-03-02|2011-03-04|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||FDG-PET Imaging in Young Cystic Fibrosis Patients|FDG-PET Imaging in Young Cystic Fibrosis Patients|Unknown status|Recruiting||28|Anticipated|Washington University School of Medicine|||1||f||||t||||||||||2018-06-01 01:17:49.405952|2018-06-01 01:17:49.405952
NCT00846040|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-14|||2018-03-27|2009-02-14|2009-02-18|Estimate|||||||2018-03-27|2018-03-29|Actual|February 13, 2009||2009-02-13|February 5, 2018|2018-02-05||||||||Observational|||Reduced Carbohydrate vs. Fat|Selective Reduction of Dietary Carbohydrate Versus Fat: Effects on Metabolism, Endocrine Physiology, Brain Activity and Reward Circuitry|Completed|||71|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:17:49.49581|2018-06-01 01:17:49.49581
NCT00846027|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2014-05-27||2014-07-09|2009-02-17|2009-02-18|Estimate|2014-05-27|2014-06-26|Estimate||||2014-07-09|2014-07-23|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional||Intent-to-treat population: All participants enrolled in the study.|A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer|An Open Label Study to Assess the Effect of First Line Treatment With Avastin in Combination With Paclitaxel and Gemcitabine in Progression-free Survival in Patients With HER-2 Negative Breast Cancer|Completed||Phase 2|90|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:17:49.594653|2018-06-01 01:17:49.594653
NCT00846014|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2012-09-18|2009-02-17|2009-02-18|Estimate|||||||2012-09-18|2012-09-20|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Asthma Exacerbation and Helium-3 MRI|Asthma Exacerbation and Helium-3 MRI|Withdrawn||N/A|0|Actual|University of Massachusetts, Worcester||1||Subjects which fit the strict inclusion criteria were not found.|f||||f||||||||||2018-06-01 01:17:49.923345|2018-06-01 01:17:49.923345
NCT00846001|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2015-07-14|2009-02-17|2009-02-18|Estimate|||||||2015-07-14|2015-07-15|Estimate|September 2007||2007-09-30|July 2015|2015-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|RESCUE||Resynchronization Surgery Combined Unified Efficacy|Study of Resynchronization and CABG Unified Efficacy in Ischemic Heart Failure Patients|Completed||Phase 3|178|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-06-01 01:17:49.998315|2018-06-01 01:17:49.998315
NCT00845988|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-14|||2013-12-04|2009-02-14|2009-02-18|Estimate|||||||2013-12-04|2013-12-05|Estimate|December 2008||2008-12-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders|Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-induced Weight Gain|Completed||Phase 4|28|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 01:17:50.067434|2018-06-01 01:17:50.067434
NCT00845650|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13||2012-11-20|2018-02-02|2009-02-13|2009-02-18|Estimate||||2012-11-20|2012-11-22|Estimate|2018-02-02|2018-02-08|Actual|February 2009||2009-02-28|January 2018|2018-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)|A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV)|Completed||Phase 1/Phase 2|129|Actual|Emergent BioSolutions||6|||f||||t||||||||||2018-06-01 01:17:57.936372|2018-06-01 01:17:57.936372
NCT00845975|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2013-04-11||2014-05-07|2009-02-17|2009-02-18|Estimate|2014-05-07|2014-06-05|Estimate||||2014-05-07|2014-06-05|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Low Level Laser Therapy and Tinnitus Relief|A Double-blind, Placebo-controlled Randomized Evaluation of the Application of Low Level Laser Light Therapy Using the Erchonia Hearing Lasers for the Relief of Tinnitus Clinical Study Protocol.|Terminated||N/A|18|Actual|Erchonia Corporation||2||New information suggested a more effective treatment protocol.|f||||t||||||||||2018-06-01 01:17:50.137515|2018-06-01 01:17:50.137515
NCT00845962|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2010-01-26|2009-02-17|2009-02-18|Estimate|||||||2010-01-26|2010-01-27|Estimate|February 2009||2009-02-28|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Comparison of Bupivacaine and 2-chloroprocaine for Spinal Anesthesia|Spinal Anesthesia With Bupivacaine or 2-chloroprocaine for Outpatient Elective Surgery: a Prospective, Randomized, Double-blind Comparison.|Completed||N/A|106|Actual|Université de Montréal||2|||f||||f||||||||||2018-06-01 01:17:50.426763|2018-06-01 01:17:50.426763
NCT00845949|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2012-05-18|2009-02-16|2009-02-18|Estimate|||||||2012-05-18|2012-05-21|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Observational|||Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes|Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes|Withdrawn|||0|Actual|Far Eastern Memorial Hospital||||NO available budget and difficulty in recruiting|f||||t||||||Samples With DNA|"~     Synovial tissue~   "|||2018-06-01 01:17:50.517181|2018-06-01 01:17:50.517181
NCT00845936|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|||2009-02-18|2009-02-17|2009-02-18|Estimate|||||||2009-02-18|2009-02-19|Estimate|May 2009||2009-05-31|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics|Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|BeerYaakov Mental Health Center||2|||f||||||||||||||2018-06-01 01:17:50.576055|2018-06-01 01:17:50.576055
NCT00845923|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16||2014-04-30|2017-02-09|2009-02-16|2009-02-18|Estimate||||2014-04-30|2014-05-19|Estimate|2017-02-09|2017-02-13|Actual|March 2009||2009-03-31|February 2017|2017-02-28|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia|Phase II Proof of Concept Trial of Civamide Patch in the Treatment of Post-herpetic Neuralgia and Post-incisional Neuralgia|Completed||Phase 2|22|Actual|Winston Laboratories||1|||f||||f||||||||||2018-06-01 01:17:50.670722|2018-06-01 01:17:50.670722
NCT00845910|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2016-11-01|2009-02-17|2009-02-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2009||2009-05-31|November 2016|2016-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer|A Phase II Trial of Evaluating Circulating Endothelial Cell as A Surrogate Marker for Monitoring Treatment Efficacy of Docetaxel Plus Capecitabine With Bevacizumab as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer|Terminated||Phase 2|22|Actual|Hoffmann-La Roche||1||To be confirmed|f||||||||||||||2018-06-01 01:17:50.761116|2018-06-01 01:17:50.761116
NCT00845897|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2011-08-11||2012-02-01|2009-02-17|2009-02-18|Estimate|2011-12-28|2012-02-02|Estimate||||2012-02-01|2012-02-03|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Botulinum Toxin Effects on Plantar Ulcer Recurrence|Botulinum Toxin Effects on Plantar Ulcer Recurrence|Completed||N/A|17|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 01:17:50.844054|2018-06-01 01:17:50.844054
NCT00845884|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2009-02-16|2009-02-16|2009-02-18|Estimate|||||||2009-02-16|2009-02-18|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer|A Phase I/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Patients With Advanced Gastric Cancer|Unknown status|Not yet recruiting|Phase 1/Phase 2|49|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-06-01 01:17:51.115064|2018-06-01 01:17:51.115064
NCT00845871|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2014-05-07|2009-02-17|2009-02-18|Estimate|||||||2014-05-07|2014-05-08|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food|A Single-arm, Open-label Study of the Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food|Completed||Phase 4|65|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:17:51.199563|2018-06-01 01:17:51.199563
NCT00845858|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2014-04-17||2014-06-17|2009-02-17|2009-02-18|Estimate|2014-05-16|2014-06-17|Estimate||||2014-06-17|2014-06-27|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Provides at least 80% power (alpha=0.05 two sided) to detect a mean difference between treatment groups of 0.5, for the GCSI-DD total score. Based on the literature, the standard deviation (SD) of the endpoint is approximately 1.1 resulting in a sample size of 77 per treatment group.|Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Clinical Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Subjects With Gastroparesis|Completed||Phase 2|287|Actual|Evoke Pharma||3|||f||||f||||||||||2018-06-01 01:17:51.349996|2018-06-01 01:17:51.349996
NCT00845845|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2013-02-06||2013-06-18|2009-02-17|2009-02-18|Estimate|2013-06-18|2013-07-24|Estimate||||2013-06-18|2013-07-24|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)|Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)|Terminated||Phase 2|12|Actual|University of Illinois at Chicago|The study was terminated on October 12, 2010 due to low enrollment. Consequently, no analyses were completed.|2||Terminated due to low enrollment.|f||||f||||||||||2018-06-01 01:17:51.910041|2018-06-01 01:17:51.910041
NCT00845663|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2009-08-25||2011-08-30|2009-02-17|2009-02-18|Estimate|2009-10-08|2009-11-17|Estimate||||2011-08-30|2011-08-31|Estimate|October 2007||2007-10-31|December 2009|2009-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)|Open Label, Randomized, Parallel Group, Single Dose, 2-way Comparison Bioequivalence Study of Certolizumab Pegol Solution Injected Either by a Pre-filled Syringe (Reference) or by an Auto-injection Device (Test) to Healthy Volunteers.|Completed||Phase 1|98|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 01:17:56.803487|2018-06-01 01:17:56.803487
NCT00845832|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2014-06-23||2014-12-15|2009-02-17|2009-02-18|Estimate|2014-12-15|2014-12-24|Estimate||||2014-12-15|2014-12-24|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Safety population: All participants who were randomized and received any part of an infusion of study medication; participants who received the incorrect therapy from that intended were summarized in the group according to the therapy actually received for the majority of the time through Week 48.|A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate|A Randomized, Active Controlled, Double-blind, Study to Compare the Safety and Reduction in Disease Activity With the Combination of Rituximab (MabThera®)and Tocilizumab (RoActemra®) Versus Tocilizumab in Patients With Active Rheumatoid Arthritis With an Incomplete Response to Methotrexate|Terminated||Phase 2|24|Actual|Hoffmann-La Roche||2||"The study was terminated early because of a related decision to stop the development of~   ocrelizumab in rheumatoid arthritis."|f||||||||||||||2018-06-01 01:17:52.187029|2018-06-01 01:17:52.187029
NCT00845819|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2015-01-20|2009-02-16|2009-02-18|Estimate|||||||2015-01-20|2015-01-21|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|EGFOM||Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies|Randomized Phase II Study of Recombinant Human Epidermal Growth Factor (rhEGF) on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies|Completed||Phase 2|138|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 01:17:53.015413|2018-06-01 01:17:53.015413
NCT00845806|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2011-11-03|2009-02-16|2009-02-18|Estimate|||||||2011-11-03|2011-11-04|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Neuronal Processing of Diacritics: An fMRI Study|Neuronal Processing of Diacritics: An fMRI Study|Completed|||12|Actual|University of Massachusetts, Worcester|||1||f||||f||||||||||2018-06-01 01:17:53.12827|2018-06-01 01:17:53.12827
NCT00845793|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|April 2009||2009-04-30|February 2009|2009-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Meal Tray as a Tool and Platform to Change Eating Habits Among Hospitalized Diabetic Patients - An Intervention Study|The Meal Tray as a Tool and Platform to Change Eating Habits Among Hospitalized Diabetic Patients - An Intervention Study|Unknown status|Not yet recruiting|N/A|500|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 01:17:53.199321|2018-06-01 01:17:53.199321
NCT00845780|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-06-23|2009-02-17|2009-02-18|Estimate|||||||2009-06-23|2009-06-24|Estimate|August 2000||2000-08-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|WISDOM||Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation|Withdrawal of Amiodarone Treatment Versus Continuation in Successfully Treated Patients With Persistent Atrial Fibrillation. A Randomized Study.|Completed||Phase 4|37|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 01:17:53.26643|2018-06-01 01:17:53.26643
NCT00845767|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-10-08|2009-02-17|2009-02-18|Estimate|||||||2009-10-08|2009-10-09|Estimate|April 2009||2009-04-30|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Cardiovascular Effects of Air Pollution: the Role of Nitric Oxide|The Cardiovascular Effects of Air Pollution: the Role of Nitric Oxide|Completed||N/A|16|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:17:53.379204|2018-06-01 01:17:53.379204
NCT00845754|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-14|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|September 1999||1999-09-30|February 2009|2009-02-28|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Post-Operative Treatment With Ketorolac After Abdominal Myomectomy|Effects of Ketorolac on Post-Operative Febrile Morbidity and Pain Management in Abdominal Myomectomy Patients|Completed||N/A|112|Actual|Ascher-Walsh, Charles, M.D.||2|||f||||||||||||||2018-06-01 01:17:53.52606|2018-06-01 01:17:53.52606
NCT00845741|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2011-01-20|2009-02-17|2009-02-18|Estimate|||||||2011-01-20|2011-01-24|Estimate|February 2009||2009-02-28|October 2010|2010-10-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|||Neutrophil Gelatinase-associated Lipocalin (NGAL) Evaluation in Emergency Department (ED) All-Comers|NGAL Evaluation in ED All-Comers|Completed|||700|Actual|Biosite|||||f||||f||||||||||2018-06-01 01:17:53.618556|2018-06-01 01:17:53.618556
NCT00845728|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|2013-07-03||2013-09-16|2009-02-17|2009-02-18|Estimate|2013-09-16|2013-11-19|Estimate||||2013-09-16|2013-11-19|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|INVIGORATE||Exacerbation Study|A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD|Completed||Phase 3|3439|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:17:53.732092|2018-06-01 01:17:53.732092
NCT00845715|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2017-04-24|2009-02-17|2009-02-18|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2008||2008-07-31|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Early Range of Motion Following Arthroscopic Rotator Cuff Repair|The Effect of Early Range of Motion on Clinical Outcomes, Patient Satisfaction, and Cuff Integrity Following Arthroscopic Rotator Cuff Repair. A Prospective Randomized Study.|Completed||N/A|73|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 01:17:56.016953|2018-06-01 01:17:56.016953
NCT00845702|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2011-09-22||2016-04-19|2009-02-17|2009-02-18|Estimate|2012-09-18|2012-09-19|Estimate||||2016-04-19|2016-05-20|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||Baseline measures were recorded for all 33 patients.|Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)|Evaluation of Dotarem-enhanced Magnetic Resonance Angiography (MRA) Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Renal Arterial Disease|Terminated||Phase 3|33|Actual|Guerbet|The study was not completed due to poor enrollment. The statistical analysis was not performed.|2||lack of recruitment.|f||||f||||||||||2018-06-01 01:17:56.100105|2018-06-01 01:17:56.100105
NCT00845689|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate||||February 2009|2009-02-28||||||||Interventional|LTR||Prevention of Liver Damage During Liver Surgery|Study on the Potential Role of Intraoperative Hepatoprotection During Liver Resections|Unknown status|Active, not recruiting|Phase 1/Phase 2|||Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-06-01 01:17:56.268227|2018-06-01 01:17:56.268227
NCT00845676|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2013-08-13||2014-04-10|2009-02-17|2009-02-18|Estimate|2013-08-13|2013-10-17|Estimate||||2014-04-10|2014-05-01|Estimate|March 2008||2008-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Acute Hepatitis C Virus in HIV Co-Infection|Treatment of Acute Hepatitis C Virus in HIV Co-Infection|Completed||Phase 4|21|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:17:56.458698|2018-06-01 01:17:56.458698
NCT00845637|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2009-02-20|2009-02-16|2009-02-18|Estimate|||||||2009-02-20|2009-02-24|Estimate|March 2004||2004-03-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Effect of Eggplant Extract on Lipid Profile During Fasting and Postprandial Period|Effect of the Oral Administration of Eggplant Extract Capsules on Lipid Profile During Fasting and Postprandial Period: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 1|59|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 01:17:58.158808|2018-06-01 01:17:58.158808
NCT00845624|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2012-06-13|2009-02-16|2009-02-18|Estimate|||||||2012-06-13|2012-06-15|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|SAT01ROP||Time Outside Target Oxygen Saturation Range in Preterm Infants and Long Term Outcomes and Preterm Infants|DURATION OF TIME OUTSIDE, BELOW, AND ABOVE THE TARGETED Oxygen SATURATION RANGE In Preterm Infants|Completed|||102|Actual|University of Virginia|||1||f||||t||||||||||2018-06-01 01:17:58.241454|2018-06-01 01:17:58.241454
NCT00845611|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-04-04|2009-02-17|2009-02-18|Estimate|||||||2012-04-04|2012-04-06|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer|Tumor Vaccine Therapy Against Advanced Gastric Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10|Completed||Phase 1|9|Actual|Kinki University|||||f||||t||||||||||2018-06-01 01:17:59.223216|2018-06-01 01:17:59.223216
NCT00845598|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-06-11|2009-02-17|2009-02-18|Estimate|||||||2012-06-11|2012-06-12|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Azelastine Fluticasone Combination vs. Fluticasone|A Proof of Concept Study to Evaluate Comparative Efficacy of an Azelastine/Fluticasone Combination Nasal Spray vs. Twice the Dose of Fluticasone in Persistent Allergic Rhinitis|Withdrawn||Phase 4|0|Actual|University of Dundee||2||Could not get IMP|f||||f||||||||||2018-06-01 01:17:59.343111|2018-06-01 01:17:59.343111
NCT00845585|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2015-07-16|2009-02-17|2009-02-18|Estimate|||||||2015-07-16|2015-07-17|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Ovine Graft (Omniflow II) Versus PTFE in Below Knee Arterial Reconstruction|Ovine Graft (Omniflow II) Versus PTFE in Below Knee Arterial Reconstruction: A Prospective Randomized Multi Centre Study|Withdrawn||N/A|0|Actual|University Hospital Inselspital, Berne||2||found not enough centers for recruitment|f||||f||||||||||2018-06-01 01:17:59.46539|2018-06-01 01:17:59.46539
NCT00845572|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-09-17|2009-02-17|2009-02-18|Estimate|||||||2012-09-17|2012-09-18|Estimate|January 2007||2007-01-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center|The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center|Completed||N/A|30|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-06-01 01:17:59.564282|2018-06-01 01:17:59.564282
NCT00845559|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2012-12-10|2009-02-16|2009-02-18|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2008||2008-08-31|December 2012|2012-12-31||||March 2010|Anticipated|2010-03-31||Interventional|||The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults|The Effects of Exenatide on Post-Prandial Glucose Excursions and Vascular Health in Obese/Pre-Diabetic Young Adults|Withdrawn||Phase 4|0|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:17:59.642717|2018-06-01 01:17:59.642717
NCT00845546|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-02-16|2009-02-16|2009-02-18|Estimate|||||||2009-02-16|2009-02-18|Estimate|June 2002||2002-06-30|February 2009|2009-02-28|November 2002|Actual|2002-11-30|August 2002|Actual|2002-08-31||Interventional|||Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D® 24 Hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets, in Healthy Adult Volunteers Under Fed Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:17:59.740452|2018-06-01 01:17:59.740452
NCT00845533|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2014-01-15|2009-02-17|2009-02-18|Estimate|||||||2014-01-15|2014-01-16|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|||Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso||Completed||Phase 4|||University of California, San Francisco|||||f||||||||||||||2018-06-01 01:17:59.927565|2018-06-01 01:17:59.927565
NCT00845520|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2017-12-12|2009-02-13|2009-02-18|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2009||2009-01-31|December 2017|2017-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)|A Prospective Multi-center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens (LAL) in Subjects Undergoing Cataract Extraction|Completed||N/A|74|Actual|Calhoun Vision, Inc.||3|||f||||f||||||||||2018-06-01 01:17:59.996227|2018-06-01 01:17:59.996227
NCT00845507|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2017-11-20||2018-03-21|2009-02-17|2009-02-18|Estimate|2018-03-21|2018-04-20|Actual||||2018-03-21|2018-04-20|Actual|December 2008||2008-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults|A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|54|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 01:18:00.202613|2018-06-01 01:18:00.202613
NCT00845494|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|October 2010|Anticipated|2010-10-31|February 2010|Anticipated|2010-02-28||Interventional|||Efficacy of a Behavioral Based Education Intervention to Decrease Medication History Errors Among Professional Nurses.|Efficacy of a Behavioral Based Education Intervention to Decrease Medication History Errors Among Professional Nurses.|Unknown status|Not yet recruiting|Early Phase 1|140|Anticipated|Waukesha Memorial Hospital||1|||f||||t||||||||||2018-06-01 01:18:00.574898|2018-06-01 01:18:00.574898
NCT00845481|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|2011-01-13||2015-03-25|2009-02-16|2009-02-18|Estimate|2011-02-14|2011-03-08|Estimate||||2015-03-25|2015-04-14|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris|A Plaque Test Comparing 4 Steroids With Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris|Completed||Phase 2|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 01:18:00.706356|2018-06-01 01:18:00.706356
NCT00845468|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|January 2006||2006-01-31|February 2009|2009-02-28||||August 2008|Actual|2008-08-31||Observational|||Coronary Flow Reserve and Glucometabolic State|Coronary Flow Velocity Reserve According to Glucometabolic State in Acute Myocardial Infarction; Relation to Ventricular Systolic and Diastolic Function|Completed|||190|Actual|Medicinsk Forsknings Afdeling|||1||f||||f||||||||||2018-06-01 01:18:00.894512|2018-06-01 01:18:00.894512
NCT00845442|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2010-01-12|2009-02-17|2009-02-18|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2006||2006-01-31|January 2010|2010-01-31|November 2010|Anticipated|2010-11-30|January 2009|Anticipated|2009-01-31||Interventional|||Dynamic Laryngeal Opening for Bilateral Vocal Fold Paralysis by an Implanted Stimulator|Dynamic Vocal Fold Abduction for Bilateral Paralysis|Unknown status|Recruiting|Phase 1|6|Anticipated|University Hospitals Cleveland Medical Center|||||f||||f||||||||||2018-06-01 01:18:01.028103|2018-06-01 01:18:01.028103
NCT00845429|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2012-11-17||2012-12-13|2009-02-13|2009-02-18|Estimate|2012-11-17|2012-12-17|Estimate||||2012-12-13|2012-12-19|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects|Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years|Completed||Phase 2|729|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 01:18:01.1955|2018-06-01 01:18:01.1955
NCT00845416|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-07-13|2009-02-17|2009-02-18|Estimate|||||||2012-07-13|2012-07-16|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population|Newborn Screening for SCID in a High-Risk Population|Completed|||1800|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:18:01.93837|2018-06-01 01:18:01.93837
NCT00845403|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2014-01-10|2009-02-16|2009-02-18|Estimate|||||||2014-01-10|2014-01-13|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Antigen-specific Immune Response to Hepatitis B Virus in Utero|Antigen-specific Immune Response to Hepatitis B Virus and Influenza A (H1N1 Strain) in Utero|Unknown status|Recruiting||60|Anticipated|National University Hospital, Singapore|||||f||||t||||||Samples Without DNA|"~     Cord Blood of HBsAg+ mothers will be collected at delivery after seeking informed consent.~     Mononuclear cells (T cells and monocytes) will be isolated.Purified populations of T cells~     will be stimulated with different mixtures of HBV peptides covering HBV proteins and~     experiments of ELISPOT or intracellular cytokine staining will be carried out to detect the~     specificty of the responsive T cell population. In addition, T cells willbe stained with~     HLA-tetramers specific for different HBV epitopes to directly analyze the frequency and~     phenotype of HBV-specific CD8+Tcells present in cord blood.~   "|||2018-06-01 01:18:02.006088|2018-06-01 01:18:02.006088
NCT00845390|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2012-04-26|2009-02-17|2009-02-18|Estimate|||||||2012-04-26|2012-04-27|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Patient Expectations After Implantable-cardioverter Defibrillator (ICD) Implantation|Patient Expectations After ICD Implantation|Completed|||100|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-06-01 01:18:02.1154|2018-06-01 01:18:02.1154
NCT00845377|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|April 2010|Anticipated|2010-04-30||Interventional|||Changing Minds - Supporting Depressed Elderly People With an Individually Tailored Service Model|Changing Minds - Studying the Effects of a Tailored Psychosocial Support Model on Depressive Mood and Quality of Life in Depressive Elderly People|Unknown status|Recruiting|Phase 2|200|Anticipated|Central Union for the Welfare of the Aged||1|||f||||t||||||||||2018-06-01 01:18:02.234466|2018-06-01 01:18:02.234466
NCT00845364|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2010-05-19|2009-02-17|2009-02-18|Estimate|||||||2010-05-19|2010-05-20|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|CASPER||Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery|Metabolic Support With Perhexiline to Protect Myocardium Undergoing Coronary Artery Surgery|Completed||Phase 2/Phase 3|290|Actual|University Hospital Birmingham||2|||f||||t||||||||||2018-06-01 01:18:02.41639|2018-06-01 01:18:02.41639
NCT00845351|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2011-05-26|2009-02-16|2009-02-18|Estimate|||||||2011-05-26|2011-05-30|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Preoperative Bexarotene Treatment for Cushing's Disease|Preoperative Bexarotene Treatment for Cushing's Disease|Unknown status|Recruiting|Phase 1/Phase 2|6|Anticipated|University of Virginia||1|||f||||f||||||||||2018-06-01 01:18:02.565453|2018-06-01 01:18:02.565453
NCT00845338|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2014-11-28|2009-02-16|2009-02-18|Estimate|||||||2014-11-28|2014-12-02|Estimate|February 2007||2007-02-28|November 2014|2014-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity|A 4-week, Open-label, Multicenter, Urodynamic Pilot Study to Explore the Efficacy, Tolerability and Safety of Darifenacin (7.5 mg With Up-titration to 15 mg) in Patients With Multiple Sclerosis and Neurogenic Detrusor Overactivity|Terminated||Phase 2|7|Actual|Bayer||1||"The enrollment rate at most centers was unlikely to result in the recruitment of the planned~   sample size of 40 evaluable subjects."|f||||f||||||||||2018-06-01 01:18:02.778586|2018-06-01 01:18:02.778586
NCT00845325|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2016-04-27|2009-02-16|2009-02-18|Estimate|||||||2016-04-27|2016-04-29|Estimate|December 2008||2008-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Early Motion Following Carpal Tunnel Release|Early Motion Following Carpal Tunnel Release, a Randomized Control Trial|Completed||N/A|16|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 01:18:02.927398|2018-06-01 01:18:02.927398
NCT00845312|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|||2011-02-13|2009-02-17|2009-02-18|Estimate|||||||2011-02-13|2011-02-15|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Observational|||Prognostic Features for Mortality in Young Adults With Pneumonia|Prognostic Features for Mortality in Adult Pneumonia Patients at the Age of Sixty and Beneath.|Completed|||1200|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-06-01 01:18:03.084247|2018-06-01 01:18:03.084247
NCT00845299|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16||2011-03-01|2013-09-16|2009-02-17|2009-02-18|Estimate||||2011-03-01|2011-03-16|Estimate|2013-09-16|2013-09-19|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma|An Open-Label, Randomized, Phase 2 Study of the Effects of Artificial Tears Preserved With Benzalkonium Chloride (AT-BAK) on the Response to the Latanoprost Punctal Plug Delivery System (L PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)|Completed||Phase 2|40|Actual|Mati Therapeutics Inc.||2|||f||||f||||||||||2018-06-01 01:18:03.340111|2018-06-01 01:18:03.340111
NCT00845286|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2016-03-16|2009-02-16|2009-02-18|Estimate|||||||2016-03-16|2016-03-17|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|MAGIC||Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial|Investigation of Myocardial Function and Vascular Adaptation in Association With Genotype in Marathon Runners|Completed||N/A|162|Actual|Technische Universität München|||||f||||t||||||||||2018-06-01 01:18:03.448783|2018-06-01 01:18:03.448783
NCT00845273|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2015-09-30|2009-02-16|2009-02-18|Estimate|||||||2015-09-30|2015-10-02|Estimate|November 2008||2008-11-30|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration|Special Investigation For Long-term Use Of Macugen (Regulatory Post Marketing Commitment Plan).|Completed|||3538|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:18:03.628356|2018-06-01 01:18:03.628356
NCT00845260|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|December 2004||2004-12-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|IP2||Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder|Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial|Completed||Phase 3|113|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 01:18:03.740398|2018-06-01 01:18:03.740398
NCT00845247|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2012-08-30|2009-02-17|2009-02-18|Estimate|||||||2012-08-30|2012-08-31|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effect of Case Management in Complex Cancer Pathways|The Effect of Case Management in Complex Cancer Pathways|Completed||N/A|280|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 01:18:03.821992|2018-06-01 01:18:03.821992
NCT00845234|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-02-25|2009-02-17|2009-02-18|Estimate|||||||2013-02-25|2013-02-26|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Establishing a Standard for Peri-operative Implantable Cardioverter Defibrillator (ICD) Patient Education|Establishing a Standard for Peri-operative ICD Patient Education: A Demonstration Project|Completed||N/A|62|Actual|East Carolina University||2|||f||||t||||||||||2018-06-01 01:18:03.902713|2018-06-01 01:18:03.902713
NCT00845221|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-16|||2016-10-10|2009-02-17|2009-02-18|Estimate|||||||2016-10-10|2016-10-11|Estimate|July 2004||2004-07-31|October 2016|2016-10-31||||November 2011|Actual|2011-11-30||Interventional|||Glivec in Pediatric Chronic Myeloid Leukemia (CML)||Completed||Phase 4|44|Actual|Poitiers University Hospital||1|||f||||||||||||||2018-06-01 01:18:03.977385|2018-06-01 01:18:03.977385
NCT00845208|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2017-07-27|2009-02-17|2009-02-18|Estimate|||||||2017-07-27|2017-08-01|Actual|March 2002||2002-03-31|July 2017|2017-07-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Network Support for Treatment of Alcohol Dependence|Network and Contingency Management for Alcohol Treatment|Completed||N/A|210|Actual|UConn Health||3|||f||||f||||||||||2018-06-01 01:18:04.049644|2018-06-01 01:18:04.049644
NCT00845195|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2010-03-25||2010-04-22|2009-02-13|2009-02-18|Estimate|2010-03-25|2010-04-21|Estimate||||2010-04-22|2010-04-27|Estimate|March 2009||2009-03-31|April 2010|2010-04-30||||May 2009|Actual|2009-05-31||Interventional|||Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid||Completed||Phase 4|150|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:18:04.177076|2018-06-01 01:18:04.177076
NCT00845182|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|2013-04-04||2017-12-18|2009-02-17|2009-02-18|Estimate|2015-03-13|2015-03-17|Estimate||||2017-12-18|2018-01-18|Actual|June 2007||2007-06-30|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PIO-EX||Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function|Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients|Completed||Phase 4|43|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-06-01 01:18:04.584085|2018-06-01 01:18:04.584085
NCT00845169|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2014-12-01|2009-02-17|2009-02-18|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Role of Nitric Oxide Synthase Isoforms in the Cardiovascular Effects of Air Pollution|The Role of Nitric Oxide Synthase Isoforms in the Cardiovascular Effects of Air Pollution|Completed||N/A|16|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:18:05.057698|2018-06-01 01:18:05.057698
NCT00845156|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-06-18|2009-02-17|2009-02-18|Estimate|||||||2013-06-18|2013-06-20|Estimate|January 2008||2008-01-31|June 2013|2013-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Alpha Lipoic Acid and Insulin Resistance|Alpha Lipoic Acid and Insulin Resistance|Completed||N/A|68|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:18:05.246148|2018-06-01 01:18:05.246148
NCT00845143|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2009-02-17|2009-02-17|2009-02-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|August 2011|Anticipated|2011-08-31|February 2011|Anticipated|2011-02-28||Observational|||Vibration Response Imaging (VRI) in the Preoperative Management in Patients With Non-Small Cell Lung Cancer|Vibration Response Imaging (VRI) in the Preoperative Management in Patients With Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting||100|Anticipated|Heidelberg University|||||f||||f||||||||||2018-06-01 01:18:05.391415|2018-06-01 01:18:05.391415
NCT00845130|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-15|2016-06-09||2018-04-02|2009-02-17|2009-02-18|Estimate|2016-06-09|2016-07-21|Estimate||||2018-04-02|2018-05-03|Actual|September 2009||2009-09-30|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes|Quantitative in Vivo Biomarkers of Oxidative Stress in Diabetes|Completed||N/A|42|Actual|University of Kansas Medical Center||2|||f||||t||||||||No|No, there is not a plan to share individual data.|2018-06-01 01:18:05.481273|2018-06-01 01:18:05.481273
NCT00845117|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-06-19|2009-02-17|2009-02-18|Estimate|||||||2013-06-19|2013-06-20|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|LECT||Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency|Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency|Unknown status|Active, not recruiting|Phase 1/Phase 2|21|Actual|University Hospital, Antwerp||1|||f||||||||||||||2018-06-01 01:18:05.836214|2018-06-01 01:18:05.836214
NCT00845104|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2015-03-04|2009-02-17|2009-02-18|Estimate|||||||2015-03-04|2015-03-06|Estimate|January 2009||2009-01-31|March 2015|2015-03-31||||||||Interventional|||Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment|A Phase II Study of Fludarabine (F), Rituxan (R) and Avastin (A) Followed by RA Maintenance in Patients With Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)|Withdrawn||Phase 2|0|Actual|Fred Hutchinson Cancer Research Center||1||No patients enrolled.|f||||t||||||||||2018-06-01 01:18:05.979158|2018-06-01 01:18:05.979158
NCT00845091|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2014-01-07|2009-02-13|2009-02-16|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CARE-E||Cardiac Autonomic Regulation Enhancement Through Exercise Trial|Cardiac Autonomic Regulation Enhancement Through Exercise Trial|Completed||Phase 1|22|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-06-01 01:18:06.250404|2018-06-01 01:18:06.250404
NCT00845078|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2017-04-25|2009-02-13|2009-02-16|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2008||2008-12-31|February 2009|2009-02-28||||||||Observational|||Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer|Prospective Outcomes After Reconstruction and Radiotherapy for Breast Cancer|Withdrawn|||0|Actual|University of Pittsburgh|||2||f||||f||||||||||2018-06-01 01:18:06.432217|2018-06-01 01:18:06.432217
NCT00845065|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2011-10-10||2017-03-09|2009-02-13|2009-02-16|Estimate|2011-12-30|2012-02-02|Estimate||||2017-03-09|2017-04-07|Actual|February 2009||2009-02-28|March 2017|2017-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)|A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin|Completed||Phase 3|202|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:18:06.59677|2018-06-01 01:18:06.59677
NCT00845052|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2017-02-02|2009-02-13|2009-02-16|Estimate|||||||2017-02-02|2017-02-06|Estimate|July 2008||2008-07-31|February 2017|2017-02-28|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Observational|||Survey of Housestaff Attitudes Toward Patient Care and Safety|Changing Housestaff Culture and Tracking Housestaff Attitudes Regarding Patient Care and Safety|Completed|||674|Actual|Weill Medical College of Cornell University|||3||f||||f||||||||No||2018-06-01 01:18:07.2796|2018-06-01 01:18:07.2796
NCT00845039|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10||2010-11-11|2012-02-02|2009-02-13|2009-02-16|Estimate||||2010-11-11|2010-11-23|Estimate|2012-02-02|2012-02-07|Estimate|May 2009||2009-05-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|FC-4||A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab|A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy|Completed||Phase 2|4|Actual|ImClone LLC||2|||f||||f||||||||||2018-06-01 01:18:07.424305|2018-06-01 01:18:07.424305
NCT00845026|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13||2011-02-25|2011-02-25|2009-02-13|2009-02-16|Estimate||||2011-02-25|2011-03-11|Estimate|2011-02-25|2011-03-11|Estimate|March 2009||2009-03-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients|A Long-Term, Phase 2, Multicenter, Randomized, Open-Label Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia|Completed||Phase 2|261|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:18:07.568169|2018-06-01 01:18:07.568169
NCT00845013|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2015-05-29|2009-02-13|2009-02-16|Estimate|||||||2015-05-29|2015-06-02|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension|Epidemiology and Pathogenesis of HIV-Associated Pulmonary Hypertension|Active, not recruiting|||125|Anticipated|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     serum, plasma, PBMCS, BAL~   "|||2018-06-01 01:18:07.724521|2018-06-01 01:18:07.724521
NCT00845000|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2016-04-18||2016-06-09|2009-02-13|2009-02-16|Estimate|2016-06-09|2016-07-21|Estimate||||2016-06-09|2016-07-21|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)|Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:18:07.809307|2018-06-01 01:18:07.809307
NCT00844987|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2010-05-26|2009-02-13|2009-02-16|Estimate|||||||2010-05-26|2010-05-27|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Hepatocyte Growth Factor (HGF) in Patients With Acute Coronary Syndrome (ACS)|The Importance of Vascular Endothelial Growth Factor (VEGF), Hepatocyte Growth Factor (HGF) and Platelet Derived Growth Factor (PDGF) as a New Indicators of Myocardial Ischemic Injury in Comparison With Commonly Used Biomarkers.|Completed|||120|Anticipated|Institute of Cardiology, Warsaw, Poland|||||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-06-01 01:18:08.329688|2018-06-01 01:18:08.329688
NCT00844974|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2013-11-14|2009-02-12|2009-02-16|Estimate|||||||2013-11-14|2013-11-18|Estimate|December 2007||2007-12-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms|Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder Depressed Type: Prevalence and Symptoms With Treating of Depressive Symptoms|Completed||N/A|33|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:18:08.436931|2018-06-01 01:18:08.436931
NCT00844961|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2011-11-08|2009-02-13|2009-02-16|Estimate|||||||2011-11-08|2011-11-09|Estimate|November 2008||2008-11-30|February 2009|2009-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effectiveness of Internet Delivered Cognitive Behavior Therapy (CBT) for Irritable Bowel Syndrome (IBS)|Study of the Effectiveness of Internet Delivered Cognitive Behavior Therapy in a Sample of Consecutively Recruited Patients Diagnosed With Irritable Bowel Syndrome|Completed||N/A|61|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 01:18:08.514545|2018-06-01 01:18:08.514545
NCT00844948|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2012-05-04|2009-02-13|2009-02-16|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Observational|Speech2||Vocal Acoustic Biomarkers in Depression|Development of a Convenient, Automated, Objective Measure of Depression|Completed|||125|Actual|Center for Psychological Research, Madison, WI|||3||f||||f||||||||||2018-06-01 01:18:08.6139|2018-06-01 01:18:08.6139
NCT00844935|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2012-03-26|2009-02-13|2009-02-16|Estimate|||||||2012-03-26|2012-03-28|Estimate|September 2011||2011-09-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients|The Value of Electrocardiographic Autonomic Nervous System Function Measures for Predicting Cardiopulmonary Recovery of Mechanically Ventilated Patients in Intensive Care|Withdrawn|||0|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:18:08.716936|2018-06-01 01:18:08.716936
NCT00844922|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2014-12-30|2009-02-13|2009-02-16|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)|Double-blind, Placebo-controlled Trial Investigating the Safety of Re-exposure to 900 mg of Org 34517, Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features), Who Participated in Trial 28130|Completed||Phase 2|16|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 01:18:08.779307|2018-06-01 01:18:08.779307
NCT00844909|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2010-04-26|2009-02-13|2009-02-16|Estimate|||||||2010-04-26|2010-04-27|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|||||Interventional|||A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers|A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of CNTO136 Following a Single Subcutaneous Administration to Healthy Japanese and Caucasian Subjects.|Completed||Phase 1|62|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 01:18:08.83979|2018-06-01 01:18:08.83979
NCT00844896|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2012-06-12||2014-10-08|2009-02-13|2009-02-16|Estimate|2014-10-08|2014-10-16|Estimate||||2014-10-08|2014-10-16|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Intervention to Reduce Stress in 0-5 Year Olds With Burns|RCT Intervention to Reduce Stress in 0-5 Year Olds With Burns|Completed||N/A|57|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:18:08.916445|2018-06-01 01:18:08.916445
NCT00844883|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2017-04-19||2017-07-24|2009-02-13|2009-02-16|Estimate|2017-07-24|2017-08-28|Actual||||2017-07-24|2017-08-28|Actual|February 2009||2009-02-28|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma|Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma|Completed||Phase 2|50|Actual|Yale University||1|||f||||t||||||||||2018-06-01 01:18:09.521381|2018-06-01 01:18:09.521381
NCT00844870|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Exploring New Approaches in Reaching Behavior Post Stroke|Training With or Without Upper Body Restraint During Reaching in Individuals Post Stroke|Completed||N/A|24|Actual|University of the Sciences in Philadelphia||2|||f||||f||||||||||2018-06-01 01:18:10.125143|2018-06-01 01:18:10.125143
NCT00844857|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2013-01-16||2013-01-16|2009-02-13|2009-02-16|Estimate|2013-01-16|2013-02-18|Estimate||||2013-01-16|2013-02-18|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression|Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder|Completed||Phase 4|291|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:18:10.275388|2018-06-01 01:18:10.275388
NCT00844844|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2014-10-21||2015-06-30|2009-02-13|2009-02-16|Estimate|2014-11-26|2014-12-03|Estimate||||2015-06-30|2015-07-23|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|September 2010|Actual|2010-09-30||Interventional|aHUS|The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 17 patients who were treated with study drug were included in the ITT population.|Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS|An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)|Completed||Phase 2|1|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-06-01 01:18:11.639609|2018-06-01 01:18:11.639609
NCT00844831|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2011-08-04||2017-06-28|2009-02-13|2009-02-16|Estimate|2017-06-28|2017-07-27|Actual||||2017-06-28|2017-07-27|Actual|May 2009||2009-05-31|June 2017|2017-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit|Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit|Completed||Phase 4|25|Actual|University of Louisville||1|||f||||f||||||||||2018-06-01 01:18:12.71063|2018-06-01 01:18:12.71063
NCT00844818|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-16|Estimate|||||||2009-02-12|2009-02-16|Estimate|February 2005||2005-02-28|February 2009|2009-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|NEWS||An Intervention to Address Parental Smoking During the Postpartum Hospitalization.|Using the Postpartum Hospital Stay to Address Mother's and Father's Smoking: the NEWS Study|Completed||N/A|101|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:18:13.110295|2018-06-01 01:18:13.110295
NCT00844805|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2012-09-20||2017-03-15|2009-02-13|2009-02-16|Estimate|2012-11-16|2012-12-17|Estimate||||2017-03-15|2017-04-12|Actual|September 2009||2009-09-30|March 2017|2017-03-31|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|INFAST||Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)|Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial|Completed||Phase 3|158|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:18:13.230769|2018-06-01 01:18:13.230769
NCT00844792|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2017-10-24|2009-02-13|2009-02-16|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2008||2008-10-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer|A Randomized, Double-Blind Study of Combination Vitamin E, Selenium and Lycopene vs. Placebo in Men Undergoing Radical Prostatectomy for Prostate Cancer|Completed||Phase 2|48|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:18:13.91647|2018-06-01 01:18:13.91647
NCT00844779|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-04-24|2009-02-13|2009-02-16|Estimate|||||||2009-04-24|2009-04-27|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Observational|||Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients|Evaluation of Non Alcoholic Metabolic Liver Diseases in Patients Harboring Central Adiposity and Insulin Resistance by Biochemical and Functional Genomic Approaches|Unknown status|Recruiting||90|Anticipated|University Hospital, Strasbourg, France|||3||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:18:14.022166|2018-06-01 01:18:14.022166
NCT00844766|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|December 2006||2006-12-31|February 2009|2009-02-28||||||||Observational|||Validation of a Home-Screening Test for Lactose Intolerance|A Study to Validate a Home-Screening Test for Lactose Intolerant People|Suspended|||40|Anticipated|University Hospitals, Leicester||||This study was stopped as no patient asked to participate was prepared to do so|f||||||||||||||2018-06-01 01:18:14.178174|2018-06-01 01:18:14.178174
NCT00844753|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2015-11-23||2016-01-05|2009-02-13|2009-02-16|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Strattera||Atomoxetine, Placebo and Parent Management Training in Autism|Atomoxetine, Placebo and Parent Management Training in Autism|Completed||Phase 4|128|Actual|University of Rochester||4|||f||||t||||||||||2018-06-01 01:18:14.264731|2018-06-01 01:18:14.264731
NCT00844740|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|February 2009||2009-02-28|February 2009|2009-02-28||||June 2010|Anticipated|2010-06-30||Interventional|CHR||Calcimimetics in Hypophosphatemic Rickets|Effect of Cinacalcet on the Long-Term Treatment of Familial Hypophosphatemic Rickets|Unknown status|Enrolling by invitation|N/A|10|Anticipated|Children's Mercy Hospital Kansas City||1|||f||||t||||||||||2018-06-01 01:18:14.745706|2018-06-01 01:18:14.745706
NCT00844727|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2011-07-03|2009-02-13|2009-02-16|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2003||2003-09-30|February 2009|2009-02-28|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Coxib-inhibition of Duodenal Polyp Growth in FAP|Coxib-inhibition of Duodenal Polyp Growth in Familial Adenomatous Polyposis|Terminated||Phase 2/Phase 3|38|Actual|Oslo University Hospital||2||Drug withdrawal|f||||f||||||||||2018-06-01 01:18:14.825966|2018-06-01 01:18:14.825966
NCT00844714|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2014-05-19||2015-05-29|2009-02-13|2009-02-16|Estimate|2014-06-19|2014-06-23|Estimate||||2015-05-29|2015-06-26|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional||per protocol, patients with active rheumatoid arthritis (RA) who had high levels of systemic inflammation|Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy|Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy|Completed||N/A|20|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:18:14.892506|2018-06-01 01:18:14.892506
NCT00844701|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-10-31|2009-02-13|2009-02-16|Estimate|||||||2012-10-31|2012-11-01|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Cue Induced Imaging in Nicotine Dependent Smokers|Validation of Cue Induced Imaging Paradigm in Nicotine Dependent Smokers|Completed|||52|Actual|Medical University of South Carolina|||2||f||||f||||||||||2018-06-01 01:18:15.103194|2018-06-01 01:18:15.103194
NCT00844688|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|HCC||Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)|A Phase II Feasibility Study of Sorafenib and Gemcitabine Combination Treatment in Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Combined Military Hospital, Pakistan||1|||f||||t||||||||||2018-06-01 01:18:15.168766|2018-06-01 01:18:15.168766
NCT00844675|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2012-10-16|2009-02-13|2009-02-16|Estimate|||||||2012-10-16|2012-10-18|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection|Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study|Completed||Phase 4|120|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-06-01 01:18:15.274937|2018-06-01 01:18:15.274937
NCT00844662|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2010-10-18|2009-02-13|2009-02-16|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|October 2011|Anticipated|2011-10-31|September 2011|Anticipated|2011-09-30||Interventional|||Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride|An Open, Randomised, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride in Haemodialysis Patients With Hyperphosphataemia|Terminated||Phase 3|1000|Anticipated|Ineos Healthcare Limited||2|||f||||t||||||||||2018-06-01 01:18:15.391923|2018-06-01 01:18:15.391923
NCT00844649|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2013-10-21||2017-01-17|2009-02-13|2009-02-16|Estimate|2013-10-21|2013-12-11|Estimate||||2017-01-17|2017-03-01|Actual|March 2009||2009-03-31|January 2017|2017-01-31|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional||For the Karnofsky Performance Status (KPS) baseline characteristic, some of the participants did not have a baseline KPS recorded by the clinical site.|Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas|A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas|Completed||Phase 3|861|Actual|Celgene||2|||f||||t||||||||||2018-06-01 01:18:15.746727|2018-06-01 01:18:15.746727
NCT00844636|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||A Trial of Blunt Needles for the Reduction of Needlestick Injuries During Cesarean Section|A Randomized Trial of Blunt Needles for the Reduction of Needlestick Injuries During Cesarean Section|Completed||N/A|197|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:18:17.480729|2018-06-01 01:18:17.480729
NCT00844623|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2013-01-15|2009-02-13|2009-02-16|Estimate|||||||2013-01-15|2013-01-16|Estimate|December 2002||2002-12-31|January 2013|2013-01-31|March 2008|Actual|2008-03-31|November 2003|Actual|2003-11-30||Interventional|||TK-based Suicide Gene Therapy for Hepatocellular Carcinoma|Phase I Clinical Trial Of Gene Therapy For Hepatocellular Carcinoma By Intratumoral Injection Of TK99UN (An Adenoviral Vector Containing The Thymidine Kinase Of Herpes Simplex Virus)|Completed||Phase 1|10|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||||f||||f||||||||||2018-06-01 01:18:17.566909|2018-06-01 01:18:17.566909
NCT00844597|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2015-06-08||2015-09-03|2009-02-12|2009-02-16|Estimate|2015-09-03|2015-10-06|Estimate||||2015-09-03|2015-10-06|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients|Clinical Study to Assess the Safety fo AVI-4658 in Subjects With Duchenne Muscular Dystrophy Due to a Frame-shift Mutation Amenable to Correction by Skipping Exon 51.|Completed||Phase 1/Phase 2|19|Actual|Sarepta Therapeutics|"Due to the small number of study participants, a single adverse event (AE) in 1 patient exceeds the reporting threshold of 5%. Refer to the Post-Hoc Outcome Measures #5 for a summary of frequent and related AEs."|6|||f||||t||||||||||2018-06-01 01:18:17.687568|2018-06-01 01:18:17.687568
NCT00844584|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-02-12|2009-02-12|2009-02-16|Estimate|||||||2009-02-12|2009-02-16|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Radiofrequency Ablation of Atrial Fibrillation Under Totally Thoracoscope|Clinical Study of Radiofrequency Ablation of Atrial Fibrillation Under Totally Thoracoscope|Unknown status|Recruiting|N/A|20|Anticipated|Xijing Hospital||1|||f||||t||||||||||2018-06-01 01:18:18.7386|2018-06-01 01:18:18.7386
NCT00844571|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-11-23|2009-02-13|2009-02-16|Estimate|||||||2009-11-23|2009-11-25|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|April 2009|Anticipated|2009-04-30||Observational|||Effect E-learning Program About Child Maltreatment|The Effectiveness of an E-learning Program About Child Maltreatment for Nurses on an A&E Department: a Randomised Controlled Trial|Unknown status|Enrolling by invitation||38|Anticipated|UMC Utrecht|||2||f||||f||||||||||2018-06-01 01:18:18.827427|2018-06-01 01:18:18.827427
NCT00844558|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2015-07-02||2016-05-02|2009-02-13|2009-02-16|Estimate|2016-05-02|2016-06-06|Estimate||||2016-05-02|2016-06-06|Estimate|August 2008||2008-08-31|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|MOVE|The objective of this study was to determine whether individualized gait training is more effective than usual care for reducing mobility disability and pain in individuals with symptomatic knee osteoarthritis.|Mobility Optimization Through Velocity Exercise|Optimizing Mobility in Older Adults With Knee Osteoarthritis|Completed||N/A|58|Actual|University of Iowa||2|||f||||f||||||||||2018-06-01 01:18:19.94104|2018-06-01 01:18:19.94104
NCT00844545|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2014-10-21||2015-06-30|2009-02-13|2009-02-16|Estimate|2014-11-26|2014-12-01|Estimate||||2015-06-30|2015-07-23|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|September 2010|Actual|2010-09-30||Interventional|aHUS|The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 17 patients who were treated with study drug were included in the ITT population.|Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS|An Open-Label, Multi-Center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant Atypical Hemolytic Uremic Syndrome (aHUS)|Completed||Phase 2|16|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-06-01 01:18:20.325428|2018-06-01 01:18:20.325428
NCT00844532|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2012-03-30|2011-12-07|2015-05-14|2009-02-13|2009-02-16|Estimate|2012-08-07|2012-09-07|Estimate|2012-02-28|2012-03-01|Estimate|2015-05-14|2015-06-09|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|March 2011|Actual|2011-03-31||Interventional|MOBILITY AP||Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.|A Prospective, Non-randomized, 2 Arm (AP Arm & Omni-Link Elite [OE] Arm-separately Posted as: NCT01396525), Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System and the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery. CAUTION: The Omnilink Elite™ Peripheral Balloon-expandable Stent System is an Investigational Device. Limited by Federal (U.S.) Law to Investigational Use Only.|Completed||Phase 3|151|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 01:18:21.192494|2018-06-01 01:18:21.192494
NCT00844519|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2014-05-19||2014-07-16|2009-02-13|2009-02-16|Estimate|2014-05-19|2014-06-19|Estimate||||2014-07-16|2014-07-24|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|December 2012|Actual|2012-12-31||Interventional||per protocol|Effect of Maraviroc on Endothelial Function in HIV-Infected Patients||Completed||Phase 3|52|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:18:22.416828|2018-06-01 01:18:22.416828
NCT00844506|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2011-02-24|2009-02-13|2009-02-16|Estimate|||||||2011-02-24|2011-02-25|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ISA-P53-CTX||p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer|p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial|Completed||Phase 2|19|Anticipated|University Medical Center Groningen|||||f||||t||||||||||2018-06-01 01:18:22.600687|2018-06-01 01:18:22.600687
NCT00844493|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2014-09-11|2009-02-13|2009-02-16|Estimate|||||||2014-09-11|2014-09-12|Estimate|February 2009||2009-02-28|April 2013|2013-04-30|June 2013|Actual|2013-06-30|February 2012|Actual|2012-02-29||Interventional|||Low-dose Challenge Model With Enterotoxigenic E Coli|Validation of Low-dose ETEC Challenge Model in U.S. Adults and Re-challenge of Immune Subjects With a Homologous ETEC Strain (H10407)|Completed||Phase 1|30|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||||2018-06-01 01:18:22.667231|2018-06-01 01:18:22.667231
NCT00844480|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2017-03-27||2017-05-16|2009-02-13|2009-02-16|Estimate|2017-03-27|2017-05-08|Actual||||2017-05-16|2017-06-14|Actual|March 2010||2010-03-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss|Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss|Terminated||Phase 2|17|Actual|Northwestern University|please see publication for discussion; small sample size major limitation|2||difficulty in enrollment|f||||f||||||||Undecided||2018-06-01 01:18:22.765419|2018-06-01 01:18:22.765419
NCT00844467|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Observational|IPD in saudi||A Retrospective Epidemiological Study on Pneumococcal Infection in Children in Ministry of Health Hospital at EHSA Region in the Eastern Province|Serotyping of Pneumococci|Unknown status|Active, not recruiting||300|Anticipated|King Saud University|||||f||||||||||||||2018-06-01 01:18:23.004331|2018-06-01 01:18:23.004331
NCT00844454|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-08-10|2009-02-13|2009-02-16|Estimate|||||||2009-08-10|2009-08-11|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|May 2011|Anticipated|2011-05-31|May 2010|Anticipated|2010-05-31||Interventional|QPEAvsRFA||Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma|Ethanol Ablation Using a Multi-pronged Needle and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma: a Randomized Clinical Trial|Unknown status|Recruiting|Phase 2|80|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:18:23.061445|2018-06-01 01:18:23.061445
NCT00844441|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2011-05-17|2009-02-13|2009-02-16|Estimate|||||||2011-05-17|2011-05-19|Estimate|December 2008||2008-12-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|Pilot Study of Feasibility, Safety, and Economics of Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Non-APL Acute Myeloid Leukemia|Completed||N/A|96|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 01:18:23.219521|2018-06-01 01:18:23.219521
NCT00844428|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2014-12-15||2015-06-30|2009-02-13|2009-02-16|Estimate|2015-01-19|2015-01-26|Estimate||||2015-06-30|2015-07-23|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|aHUS|The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 20 patients who were treated with study drug were included in the ITT population.|Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS|An Open-Label, Multi-Center Controlled Clinical Trial Of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive Atypical Hemolytic Uremic Syndrome (AHUS)|Completed||Phase 2|5|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-06-01 01:18:23.331703|2018-06-01 01:18:23.331703
NCT00844415|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2013-02-13||2014-06-03|2009-02-13|2009-02-16|Estimate|2013-02-13|2013-03-26|Estimate||||2014-06-03|2014-06-09|Estimate|June 2009||2009-06-30|December 2013|2013-12-31||||February 2012|Actual|2012-02-29||Interventional|||Safety and Tolerability of Dabigatran Etexilate in Adolescents|Open-label Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given for 3 Days at the End of Standard Anticoagulant Therapy in Children Aged 12 Years to Less Than 18 Years|Completed||Phase 2|9|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 01:18:23.952927|2018-06-01 01:18:23.952927
NCT00844402|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis|Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis|Completed||Phase 3|40|Actual|Medical University of Graz||1|||f||||f||||||||||2018-06-01 01:18:24.227092|2018-06-01 01:18:24.227092
NCT00844389|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-09-30|2009-02-13|2009-02-16|Estimate|||||||2009-09-30|2009-10-01|Estimate|April 2009||2009-04-30|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||Near to Infrared (NIR) Light Neuroprotection in Glaucomatous Optic Neuropathy|Near to Infrared Light Stimulation Effect on Ganglion Cell Function in Glaucomatous Optic Neuropathy|Unknown status|Active, not recruiting|Early Phase 1|40|Anticipated|Universidad de Valparaiso||2|||f||||f||||||||||2018-06-01 01:18:24.304371|2018-06-01 01:18:24.304371
NCT00844376|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2009-03-05||2009-10-21|2009-02-13|2009-02-16|Estimate|2009-09-18|2009-10-21|Estimate||||2009-10-21|2009-10-28|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Bioavailability Study for New Atorvastatin Formulation|An Open Label, Single Dose, Randomized 2-Way Crossover Study To Estimate The Relative Bioavailability Of Atorvastatin Commercial Tablet, And An Extemporaneous Preparation (EP) Suspension Formulation, In Healthy Subjects|Completed||Phase 4|12|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:18:24.448574|2018-06-01 01:18:24.448574
NCT00844363|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-06-29|2009-02-13|2009-02-16|Estimate|||||||2011-06-29|2011-06-30|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris|Mechanism of Action of Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris|Terminated||N/A|20|Anticipated|Rockefeller University||1||Unable to isolate sufficient cells from the skin biopsy to perform study related experiments|f||||f||||||||||2018-06-01 01:18:24.719832|2018-06-01 01:18:24.719832
NCT00844350|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||The Effect of Oxytocin (OT) and Oxytocin Plus Human Chorionic Gonadotropin (hCG), in Cycles Induced by Letrozole or Clomiphene Citrate||Completed||Phase 2|177|Actual|Tabriz University||5|||f||||f||||||||||2018-06-01 01:18:24.780847|2018-06-01 01:18:24.780847
NCT00844337|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2014-09-12|2009-02-13|2009-02-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|March 2009||2009-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh|Safety and Efficacy of Simplified Antibiotic Regimens for Outpatient Treatment of Suspected Sepsis in Neonates and Young Infants in Bangladesh|Completed||N/A|2490|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-06-01 01:18:24.846946|2018-06-01 01:18:24.846946
NCT00844324|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2010-12-06|2009-02-13|2009-02-16|Estimate|||||||2010-12-06|2010-12-07|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Bioequivalence Study in Healthy Subjects|A Single Dose, 2-Period, Cross-over, Bioequivalence Study in Healthy Subjects to Evaluate the Proposed Commercial Oral Suspension of Candesartan Cilexetil|Completed||Phase 1|36|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:18:24.922685|2018-06-01 01:18:24.922685
NCT00844311|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2010-08-03|2009-02-13|2009-02-16|Estimate|||||||2010-08-03|2010-08-04|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Supplementation With Human Chorionic Gonadotropin (hCG) During Controlled Ovarian Stimulation With Recombinant Follicle-stimulating Hormone (FSH) for In Vitro Fertilisation|Supplementation With hCG During Controlled Ovarian Stimulation With Recombinant FSH for in Vitro Fertilisation. A Randomized Controlled Clinical Study. Clinical, Embryological, Endocrine and Genetic Aspects.|Completed||Phase 4|60|Anticipated|Rigshospitalet, Denmark||4|||f||||t||||||||||2018-06-01 01:18:24.992518|2018-06-01 01:18:24.992518
NCT00844298|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2015-08-07||2015-08-07|2009-02-13|2009-02-16|Estimate|2015-08-07|2015-09-07|Estimate||||2015-08-07|2015-09-07|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|June 2012|Actual|2012-06-30||Interventional|||Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Tasigna® (Nilotinib) Plus Multi-Agent Chemotherapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|Completed||Phase 2|91|Actual|Asan Medical Center|The limitation of the current study was that this study was not performed in a randomized comparative way, and the advantages of nilotinib over other TKIs were not definitely demonstrated.|1|||f||||f||||||||||2018-06-01 01:18:25.151948|2018-06-01 01:18:25.151948
NCT00844285|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2018-04-26|2009-02-13|2009-02-16|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2009|Actual|2009-01-31|December 2017|2017-12-31|August 2025|Anticipated|2025-08-31|August 2025|Anticipated|2025-08-31||Observational|SECURE||SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry|A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease|Active, not recruiting|||3045|Actual|UCB Pharma|||2||f||||f||||||||||2018-06-01 01:18:25.340161|2018-06-01 01:18:25.340161
NCT00844272|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2015-05-27|2009-02-13|2009-02-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|Permit||Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment|Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment|Completed||Phase 4|189|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-06-01 01:18:25.640155|2018-06-01 01:18:25.640155
NCT00844259|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Functional Communicative Profile of Children With Down Syndrome|Functional Communicative Profile of Children With Down Syndrome|Completed|||15|Actual|University of Sao Paulo|||1||f||||t||||||||||2018-06-01 01:18:25.730265|2018-06-01 01:18:25.730265
NCT00844246|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2011-11-08|2009-02-13|2009-02-16|Estimate|||||||2011-11-08|2011-11-10|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|TEDS||Translating Evidence Based Developmental Screening Into Pediatric Primary Care|Translating Evidence Based Developmental Screening Into Pediatric Primary Care ( Aims 2 and 3 )|Completed||Phase 2|2314|Actual|Children's Hospital of Philadelphia||3|||f||||f||||||||||2018-06-01 01:18:25.797288|2018-06-01 01:18:25.797288
NCT00844233|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2013-03-28|2009-02-13|2009-02-16|Estimate|||||||2013-03-28|2013-03-29|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|October 2012|Actual|2012-10-31|September 2011|Actual|2011-09-30||Interventional|PARAGON-II||Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer|A Single Arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients With Resectable Liver Metastases From Colorectal Cancer|Completed||Phase 1/Phase 2|40|Actual|Biocompatibles UK Ltd||1|||f||||f||||||||||2018-06-01 01:18:25.891523|2018-06-01 01:18:25.891523
NCT00844220|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2017-07-19|2009-02-13|2009-02-16|Estimate|||||||2017-07-19|2017-07-21|Actual|February 18, 2009|Actual|2009-02-18|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2015|Actual|2015-09-30||Interventional|CAD-Man||Coronary Artery Disease Management Using Multislice Computed Tomography and Magnetic Resonance Imaging|Coronary Artery Disease Management Using Multislice Computed Tomography and Magnetic Resonance Imaging|Active, not recruiting||N/A|340|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 01:18:26.003041|2018-06-01 01:18:26.003041
NCT00844207|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-04-20|2009-02-12|2009-02-16|Estimate|||||||2009-04-20|2009-04-21|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|AZCQ||A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine|A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine In Healthy Adult Subjects|Completed||Phase 1|40|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:18:26.101532|2018-06-01 01:18:26.101532
NCT00844194|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|2011-06-07||2014-05-02|2009-02-13|2009-02-16|Estimate|2011-09-20|2011-10-31|Estimate||||2014-05-02|2014-05-15|Estimate|February 2009||2009-02-28|December 2013|2013-12-31||||June 2010|Actual|2010-06-30||Interventional||All patients receiving at least one dose of study medication (TS).|Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder|A 12 Weeks Open Label Two Parallel Groups Study to Assess the Efficacy of Orally Administered Duloxetine 60 mg and 120 mg Per Day on Treatment Outcomes in Patients With Diabetic Peripheral Neuropathic Pain With and Without Co-morbid Major Depressive Disorder. The Primary Objective of This Study is to Evaluate Whether the Efficacy of Duloxetine Given as 60 mg to 120 mg Once Daily (QD), Measured by the BPI Interference Score After 12 Weeks Shows a Clinically Relevant Improvement in the DPNP Patients With Co-morbid MDD|Completed||Phase 4|108|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 01:18:26.245701|2018-06-01 01:18:26.245701
NCT00844181|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2009-02-13|2009-02-13|2009-02-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Racial Differences in Orthostatic Tolerance|Racial Differences in Orthostatic Tolerance|Completed|||18|Actual|Yale University|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:18:28.062408|2018-06-01 01:18:28.062408
NCT00844168|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2015-03-25|2009-02-13|2009-02-16|Estimate|||||||2015-03-25|2015-03-27|Estimate|January 2009||2009-01-31|March 2015|2015-03-31||||June 2010|Actual|2010-06-30||Interventional|||Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant|Phase I Adjuvant Trial of Sorafenib in Hepatocellular Carcinoma Patients After Liver Transplantation|Completed||Phase 1|4|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 01:18:28.114902|2018-06-01 01:18:28.114902
NCT00844155|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-13|||2010-04-01|2009-02-13|2009-02-16|Estimate|||||||2010-04-01|2010-04-02|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit|A Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir (Tamiflu®) in Patients in the Intensive Care Unit|Withdrawn||N/A|0|Actual|University of Manitoba||2||Study has been withdrawn as the H1N1 epidemic made this study redundant|f||||f||||||||||2018-06-01 01:18:28.187643|2018-06-01 01:18:28.187643
NCT00844142|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)|Randomized Controlled 12 Months Trial With Etanercept (Enbrel ®) vs. Sulfasalazine in Early Axial Spondyloarthritis With Focus on Improvement of Acute Inflammatory Lesions as Detected by MRI. Amendment 4: 1-Year Extension of Study|Unknown status|Recruiting|Phase 2|80|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 01:18:28.258784|2018-06-01 01:18:28.258784
NCT00844129|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2018-04-30|2009-02-12|2009-02-13|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2006|Actual|2006-12-31|April 2018|2018-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|Spine||Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)|Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)|Completed|||112|Actual|University of Utah|||1||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-06-01 01:18:28.361795|2018-06-01 01:18:28.361795
NCT00844116|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-05-15|2009-02-12|2009-02-13|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||"Efficacy of On Line Telematic Spirometry"|"Efficacy of On Line Telematic Spirometry"|Completed||N/A|226|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||||2018-06-01 01:18:28.419808|2018-06-01 01:18:28.419808
NCT00844103|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-04-29|2009-02-12|2009-02-13|Estimate|||||||2009-04-29|2009-04-30|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.|A Phase I, Randomised, Double Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of AZD8566 in Healthy Volunteers|Completed||Phase 1|36|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:18:28.482342|2018-06-01 01:18:28.482342
NCT00844090|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2013-12-02||2014-03-18|2009-02-12|2009-02-13|Estimate|2014-03-18|2014-04-21|Estimate||||2014-03-18|2014-04-21|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional||The number of participants for analysis was 92 in total since only 92 participants completed the study.|The Role of Apathy in Glycemic Control|The Role of Apathy in Glycemic Control|Completed||N/A|106|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:18:28.571037|2018-06-01 01:18:28.571037
NCT00844077|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-12-05|2009-02-12|2009-02-13|Estimate|||||||2011-12-05|2011-12-07|Estimate|October 2007||2007-10-31|December 2011|2011-12-31||||April 2011|Actual|2011-04-30||Observational|||Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus|Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus Progression to Dysplasia and Adenocarcinoma|Completed|||255|Actual|University of Michigan|||1||f||||t||||||Samples With DNA|"~     Plasma,serum, DNA, urine, Barrett's tissue (Fixed and Frozen), Normal Esophagus tissue (Fixed~     and Frozen)~   "|||2018-06-01 01:18:28.781163|2018-06-01 01:18:28.781163
NCT00844064|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-11-18|2009-02-12|2009-02-13|Estimate|||||||2011-11-18|2011-11-21|Estimate|January 2005||2005-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2|An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-β2.|Completed||Phase 1|62|Actual|Isarna Therapeutics GmbH||1|||f||||t||||||||||2018-06-01 01:18:28.83937|2018-06-01 01:18:28.83937
NCT00844051|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2015-03-02||2016-08-01|2009-02-12|2009-02-13|Estimate|2016-06-21|2016-08-01|Estimate||||2016-08-01|2016-09-12|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Evaluate Impact of School-based Influenza Vaccination on School Populations|Prospective Study of School-based Influenza Vaccination's Impact on School Populations|Completed||N/A|4455|Actual|Children's Hospital Los Angeles||2|||f||||f||||||||||2018-06-01 01:18:28.917252|2018-06-01 01:18:28.917252
NCT00844038|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Observational|||Stevens-Johnson Syndrome Antimicrobial|Stevens-Johnson Syndrome Associated With Antimicrobial|Completed|||1|Actual|University of Pernambuco|||1||f||||t||||||||||2018-06-01 01:18:29.115601|2018-06-01 01:18:29.115601
NCT00844025|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-03-30|2009-02-12|2009-02-13|Estimate|||||||2009-03-30|2009-03-31|Estimate|February 2009||2009-02-28|March 2009|2009-03-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Pharmaceutical Care and Clinical Outcomes for the Elderly Taking Potentially Inappropriate Medication|Pharmaceutical Care and Clinical Outcomes for the Elderly Taking Potentially Inappropriate Medication: a Randomized-Controlled Trial|Unknown status|Enrolling by invitation|N/A|120|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-06-01 01:18:30.064518|2018-06-01 01:18:30.064518
NCT00844012|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-03-10|2009-02-12|2009-02-13|Estimate|||||||2009-03-10|2009-03-12|Estimate|May 2009||2009-05-31|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|May 2010|Anticipated|2010-05-31||Interventional|||Continuous Postoperative Use of Low-Dose Combined Oral Contraceptivesfor for Endometriosis-Related Chronic Pelvic Pain|Continuous Versus Cyclic Postoperative Use of Low-Dose Combined Oral Contraceptive Belara® for the Treatment of Endometriosis-Related Chronic Pelvic Pain: a Randomized Controlled Trial.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|University Magna Graecia||2|||f||||f||||||||||2018-06-01 01:18:30.137495|2018-06-01 01:18:30.137495
NCT00843986|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2010-09-09||2014-04-30|2009-02-11|2009-02-13|Estimate|2010-09-09|2010-10-01|Estimate||||2014-04-30|2014-05-15|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CONVERT-H||Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)|A Phase-3b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety and Efficacy of Conivaptan in Symptomatic Acute Decompensated Heart Failure (ADHF) Subjects With Hyponatremia|Terminated||Phase 3|9|Actual|Cumberland Pharmaceuticals|"The study was terminated because of difficulties in enrolling eligible patients per the protocol inclusion and exclusion criteria.~Outcome Measures were not analyzed due to the abbreviated enrollment at early study termination."|2||"The clinical study has been terminated based on difficulties to enroll eligible subjects per~   protocol inclusion and exclusion criteria."|f||||f||||||||||2018-06-01 01:18:30.229593|2018-06-01 01:18:30.229593
NCT00843973|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2017-06-20|2009-02-12|2009-02-13|Estimate|||||||2017-06-20|2017-06-21|Actual|June 2008||2008-06-30|June 2017|2017-06-30|December 2013|Actual|2013-12-31|October 2011|Actual|2011-10-31||Observational|||Osteogenic Cell Viability in Bone Graft|Osteogenic Cell Viability in Bone Graft Obtained Using the Reamer Irrigator Aspirator (RIA) System Versus Iliac Crest Bone Graft|Completed|||83|Actual|University of Missouri-Columbia|||2||f||||f||||||||No||2018-06-01 01:18:30.535452|2018-06-01 01:18:30.535452
NCT00843960|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-10-06|2009-02-12|2009-02-13|Estimate|||||||2009-10-06|2009-10-07|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|December 2013|Anticipated|2013-12-31|January 2010|Anticipated|2010-01-31||Interventional|||Medication Adherence Enhancement in Heart Transplant Recipients|Medication Adherence Enhancement in Heart Transplant Recipients: a Randomized Clinical Trial|Unknown status|Recruiting|N/A|150|Anticipated|Hannover Medical School||2|||f||||t||||||||||2018-06-01 01:18:30.607666|2018-06-01 01:18:30.607666
NCT00843947|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-06-26|2009-02-12|2009-02-13|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2007|Actual|2007-06-30|June 2017|2017-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan|Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan|Completed||Phase 2|8|Actual|University of California, Davis|||||f||||t||||||||||2018-06-01 01:18:30.775611|2018-06-01 01:18:30.775611
NCT00843934|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-10-17|2009-02-12|2009-02-13|Estimate|||||||2012-10-17|2012-10-19|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|February 2015|Anticipated|2015-02-28|December 2012|Anticipated|2012-12-31||Interventional|ACE500||Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma|Randomized Controlled Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2/Phase 3|450|Anticipated|Nihon University||1|||f||||t||||||||||2018-06-01 01:18:30.839841|2018-06-01 01:18:30.839841
NCT00843921|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2018-05-01|2009-02-12|2009-02-13|Estimate|||||||2018-05-01|2018-05-03|Actual|August 2008||2008-08-31|May 2018|2018-05-31|April 25, 2018|Actual|2018-04-25|April 25, 2018|Actual|2018-04-25||Interventional|||N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia|N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia|Completed||Phase 2/Phase 3|52|Actual|Children's Research Institute||1|||f||||t||||||||Yes|Individual participant data will be shared with that particular participant|2018-06-01 01:18:30.92618|2018-06-01 01:18:30.92618
NCT00843908|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-08-26|2009-02-12|2009-02-13|Estimate|||||||2009-08-26|2009-08-27|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Tension Free Vaginal Tape (TVT) Versus the Miniarc Sling|A Randomized Study of the Treatment of Urodynamic Stress Incontinence: the Tension Free Vaginal Tape (TVT) Versus the Miniarc Sling.|Completed||N/A|70|Anticipated|Medway NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:18:31.010017|2018-06-01 01:18:31.010017
NCT00843895|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-11|2009-02-11|2009-02-13|Estimate|||||||2009-02-11|2009-02-13|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|Pneumococci||Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years|Serotyping of Pneumococci|Unknown status|Not yet recruiting|N/A|400|Anticipated|King Saud University|||||f||||||||||||||2018-06-01 01:18:31.118776|2018-06-01 01:18:31.118776
NCT00843882|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2018-05-24|2009-02-12|2009-02-13|Estimate|||||||2018-05-24|2018-05-25|Actual|January 29, 2009|Actual|2009-01-29|March 2018|2018-03-31||||July 31, 2018|Anticipated|2018-07-31||Interventional|||Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia|Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia|Active, not recruiting||Phase 3|252|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 01:18:31.308044|2018-06-01 01:18:31.308044
NCT00843869|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2015-03-24|2009-02-12|2009-02-13|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Reversal of Tobacco-Related Sinusitis|Reversal of Tobacco-Related Sinusitis (Flight Attendant Medical Research Institute (FAMRI) Young Clinical Scientist Award)|Completed|||282|Actual|University of Alabama at Birmingham|||1||f||||f||||||Samples Without DNA|"~     Zinc levels and hair samples will be collected.~   "|||2018-06-01 01:18:32.137882|2018-06-01 01:18:32.137882
NCT00843856|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-03-03|2009-02-12|2009-02-13|Estimate|||||||2017-03-03|2017-03-06|Actual|February 2009||2009-02-28|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MTAC||Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG)|Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis|Active, not recruiting||Phase 4|40|Actual|Imperial College Healthcare NHS Trust||2|||f||||f||||||||||2018-06-01 01:18:32.226522|2018-06-01 01:18:32.226522
NCT00843843|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2015-11-02||2016-02-09|2009-02-12|2009-02-13|Estimate|2016-02-09|2016-03-08|Estimate||||2016-02-09|2016-03-08|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HAM||Sleep Length and Circadian Regulation in Humans|Sleep Length and Circadian Regulation in Humans|Completed||N/A|16|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 01:18:32.302068|2018-06-01 01:18:32.302068
NCT00843830|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2014-10-29||2015-11-06|2009-02-12|2009-02-13|Estimate|2014-10-29|2014-11-05|Estimate||||2015-11-06|2015-12-08|Estimate|October 2006||2006-10-31|November 2015|2015-11-30|April 2010|Actual|2010-04-30|December 2008|Actual|2008-12-31||Interventional|||A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma||Terminated||Phase 1|4|Actual|University of Michigan Cancer Center|The study was closed early secondary to inability to obtain grant funding to conduct.|1||Study closed early secondary to inability to obtain grant funding to conduct.|f||||t||||||||||2018-06-01 01:18:32.558831|2018-06-01 01:18:32.558831
NCT00843817|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-02-23|2009-02-12|2009-02-13|Estimate|||||||2017-02-23|2017-02-27|Actual|April 2009|Actual|2009-04-30|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|BioDNase||RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum|RhDNase Effect on Biodistribution of PMN Serine Proteases in Cystic Fibrosis Sputum|Completed||Phase 4|15|Actual|University Hospital, Tours||1|||f||||f|f|f||||||No||2018-06-01 01:18:32.851259|2018-06-01 01:18:32.851259
NCT00843804|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2010-06-25|2009-02-12|2009-02-13|Estimate|||||||2010-06-25|2010-06-28|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|||||Observational|Oncoped2006||Surveillance for Nosocomial Infections in Pediatric Cancer Patients|Prospective Surveillance for Nosocomial Infections and Catheter-related Thrombotic Events in Pediatric Patients|Unknown status|Recruiting||50|Anticipated|University Hospital, Bonn|||||f||||f||||||Samples With DNA|"~     Blood culture isolates~   "|||2018-06-01 01:18:32.922387|2018-06-01 01:18:32.922387
NCT00843791|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-06-04|2009-02-12|2009-02-13|Estimate|||||||2012-06-04|2012-06-06|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin|Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin|Completed||N/A|6|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 01:18:33.043276|2018-06-01 01:18:33.043276
NCT00843778|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2013-08-19||2014-01-17|2009-02-12|2009-02-13|Estimate|2013-08-19|2013-10-31|Estimate||||2014-01-17|2014-01-30|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CERTAIN 2|"One subject did not receive treatment during C87080, so it is excluded from the Full Analysis Set (FAS) and Safety Set (SS).~Full Analysis Set (FAS) consists of all subjects from the Enrolled Set who were dispensed medication.~Safety Set is identical to the FAS."|Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study|A Phase IIIB, Multi-center, Open Label Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With DMARDs in Patients With Active Rheumatoid Arthritis Who Participated in C87076.|Completed||Phase 3|131|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 01:18:33.195646|2018-06-01 01:18:33.195646
NCT00843765|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-02-13|2009-02-12|2009-02-13|Estimate|||||||2012-02-13|2012-02-15|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|February 2009|Actual|2009-02-28||Interventional|||Efficiency Study of Traditional Chinese Medicine (TCM) Versus Western Medicine (WM) on Ischemic Stroke|Program of TCM on Early Rehabilitation and Secondary Prevention of Ischemic Stroke|Completed||N/A|1151|Actual|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-06-01 01:18:33.803393|2018-06-01 01:18:33.803393
NCT00843752|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:18:33.88234|2018-06-01 01:18:33.88234
NCT00843739|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-09-16|2009-02-12|2009-02-13|Estimate|||||||2011-09-16|2011-09-20|Estimate|January 2004||2004-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|EMST||Expiratory Muscle Training in Patients With Parkinson's Disease|Expiratory Muscle Training in Patients With Parkinson's Disease|Completed||Phase 1/Phase 2|90|Actual|University of Florida||3|||f||||t||||||||||2018-06-01 01:18:33.920216|2018-06-01 01:18:33.920216
NCT00843726|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2018-03-19|2009-02-12|2009-02-13|Estimate|||||||2018-03-19|2018-03-21|Actual|September 12, 2008|Actual|2008-09-12|March 2018|2018-03-31|April 15, 2021|Anticipated|2021-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|||Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients With Node Negative, Peripheral Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|98|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 01:18:34.009187|2018-06-01 01:18:34.009187
NCT00843349|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2013-02-07||2013-05-01|2009-02-12|2009-02-13|Estimate|2013-05-01|2013-06-07|Estimate||||2013-05-01|2013-06-07|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)|Fibroblast Growth Factor-23 Reduction in Predialysis Chronic Kidney Disease|Completed||N/A|43|Actual|University of Miami||4|||f||||t||||||||||2018-06-01 01:18:39.554236|2018-06-01 01:18:39.554236
NCT00843713|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2015-01-30||2015-05-26|2009-02-12|2009-02-13|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Effect of Raltegravir on Endothelial Function in HIV-Infected Patients|A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection|Completed||Phase 4|56|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:18:34.085754|2018-06-01 01:18:34.085754
NCT00843700|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2014-01-08|2009-02-12|2009-02-13|Estimate|||||||2014-01-08|2014-01-09|Estimate|September 2007||2007-09-30|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Women's Depression Treatment Study|Effectiveness of IPT Adapted for Depressed Women With Trauma Histories in a Community Mental Health Center|Completed||Phase 2|162|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 01:18:34.296169|2018-06-01 01:18:34.296169
NCT00843687|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12||2011-06-02|2011-06-02|2009-02-12|2009-02-13|Estimate||||2011-06-02|2011-06-09|Estimate|2011-06-02|2011-06-09|Estimate|September 2005||2005-09-30|June 2011|2011-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.|Comparative Single-Dose Pharmacokinetics and Safety of Gluteal and Deltoid Intramuscular Injection of Long-Acting Injectable Risperidone in Subjects With Chronic Stable Schizophrenia|Completed||Phase 3|188|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:18:34.359674|2018-06-01 01:18:34.359674
NCT00843661|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-08-01|2009-02-12|2009-02-13|Estimate|||||||2011-08-01|2011-08-02|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients|Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study.|Unknown status|Recruiting|Phase 4|60|Anticipated|Ospedale di Circolo - Fondazione Macchi||2|||f||||||||||||||2018-06-01 01:18:34.414454|2018-06-01 01:18:34.414454
NCT00843648|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Observational|||Study of the Development of Human Immune System of Newborns by Antigen Chips||Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||4||f||||f||||||||||2018-06-01 01:18:34.477348|2018-06-01 01:18:34.477348
NCT00843635|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2015-06-03||2015-09-25|2009-02-12|2009-02-13|Estimate|2015-08-07|2015-08-13|Estimate||||2015-09-25|2015-10-19|Estimate|September 2008||2008-09-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Race/ethnicity reported for 34 of the 35 participants, specifically for 14 of the 15 participants in Arm B - Tadalafil 20mg.|Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx|Pilot Study of Phosphodiesterase-5 Inhibitor Tadalafil (Cialis) as an Immunomodulator in Patients With Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.|Completed||N/A|35|Actual|University of Miami|Race/Ethnicity baseline characteristics reported for 34 of 35 patients enrolled. Data analyzed for outcome measure for the 31 participants who completed the study.|3|||f||||t||||||||||2018-06-01 01:18:34.546853|2018-06-01 01:18:34.546853
NCT00843622|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2014-05-15||2014-05-15|2009-02-12|2009-02-13|Estimate|2014-05-15|2014-06-17|Estimate||||2014-05-15|2014-06-17|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Controlled Study of the Ability of a Smokefree Tobacco Product to Increase the Quit Rate Among Cigarette Smokers|"A Controlled Study of the Ability of a Traditional Swedish Smokeless Tobacco Product (Snus) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking"|Completed||Phase 4|250|Actual|Swedish Match AB||2|||f||||f||||||||||2018-06-01 01:18:35.566066|2018-06-01 01:18:35.566066
NCT00843609|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2010-02-04|2009-02-12|2009-02-13|Estimate|||||||2010-02-04|2010-02-05|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||International Navigator Hypoglycaemia Study|International Navigator Hypoglycaemia Study: Evaluation of the Incidence and Duration of Hypoglycaemia Using the Freestyle Navigator® Continuous Glucose Monitoring System|Completed||N/A|122|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-06-01 01:18:35.82228|2018-06-01 01:18:35.82228
NCT00843596|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-02-17|2009-02-12|2009-02-13|Estimate|||||||2012-02-17|2012-02-20|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|HEMOCARD||Surgical Bleeding Control of Extra-corporeal Circulation (ECC) by Vacuum Devices||Completed||Phase 1/Phase 2|30|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-06-01 01:18:35.923846|2018-06-01 01:18:35.923846
NCT00843583|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-05-02|2009-02-12|2009-02-13|Estimate|||||||2017-05-02|2017-05-03|Actual|February 2009||2009-02-28|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Cross-sectional Study of the Occurrence and Effect of Obstructive Sleep Apnea in Subjects With Resistant Hypertension|A Cross-sectional Study of the Occurrence and Effect of Obstructive Sleep Apnea in Subjects With Resistant Hypertension|Completed|||96|Anticipated|The University of Hong Kong|||1||f||||f||||||Samples Without DNA|"~     Blood test for glucose, lipid, vascular and metabolic markers~   "|||2018-06-01 01:18:36.030419|2018-06-01 01:18:36.030419
NCT00843570|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2013-07-24|2009-02-12|2009-02-13|Estimate|||||||2013-07-24|2013-07-25|Estimate|November 2009||2009-11-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment|A Randomised Controlled Trial of Natural Versus Hormone Replacement Therapy Cycles in Frozen Embryo Replacement IVF: a Pilot Study|Completed||Phase 4|159|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 01:18:36.113001|2018-06-01 01:18:36.113001
NCT00843557|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2016-10-25|2009-02-12|2009-02-13|Estimate|||||||2016-10-25|2016-10-27|Estimate|September 2001||2001-09-30|October 2016|2016-10-31|April 2008|Actual|2008-04-30|May 2006|Actual|2006-05-31||Observational|||Impact of Gender on Hospitalized Patients||Completed|||2400|Actual|University of Virginia|||1||f||||f||||||||||2018-06-01 01:18:36.199946|2018-06-01 01:18:36.199946
NCT00843544|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Integrative Medicine Approach to the Management of Asthma in Adults|Effect of an Integrative Medicine Approach to the Management of Asthma in Adults on Quality of Life and Clinical Outcomes|Completed||Phase 2/Phase 3|156|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-06-01 01:18:36.289193|2018-06-01 01:18:36.289193
NCT00842972|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-09-14|2009-02-11|2009-02-12|Estimate|||||||2009-09-14|2009-09-15|Estimate||||September 2009|2009-09-30||||||||Observational|||Is Carotid Intima-media Thickness Affected by A1C Variability?||Completed|||||Yonsei University|||||f||||||||||||||2018-06-01 01:18:48.163974|2018-06-01 01:18:48.163974
NCT00843531|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-06-16|2009-02-12|2009-02-13|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2009||2009-06-30|June 2017|2017-06-30|August 2016|Actual|2016-08-31|July 2013|Actual|2013-07-31||Interventional|||RAD001 and Erlotinib in Patients With Neuroendocrine Tumors|A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors|Completed||Phase 2|17|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:18:36.373266|2018-06-01 01:18:36.373266
NCT00843518|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2016-07-07|2011-09-20|2017-10-23|2009-02-12|2009-02-13|Estimate|2017-10-23|2017-11-29|Actual|2011-09-20|2011-09-26|Estimate|2017-10-23|2017-11-29|Actual|February 2009||2009-02-28|October 2017|2017-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Treatment for Aggression and Agitation in Patients With Alzheimer's Disease|Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease|Completed||Phase 2|132|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:18:36.507535|2018-06-01 01:18:36.507535
NCT00843505|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-10-04|2009-02-12|2009-02-13|Estimate|||||||2012-10-04|2012-10-05|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluating a Telemedicine Smoking Cessation Program in Rural Primary Care Practices|Telemedicine for Smoking Cessation in Rural Primary Care|Completed||Phase 3|566|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 01:18:37.223774|2018-06-01 01:18:37.223774
NCT00843492|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2012-05-24||2016-02-18|2009-02-12|2009-02-13|Estimate|2012-06-14|2012-07-18|Estimate||||2016-02-18|2016-03-16|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|FONDACAST||A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery|A Multicentre, Randomized, Open-label Study to Evaluate the Efficacy andSafety of Fondaparinux Versus Low Molecular Weight Heparin(Nadroparin) in Patients Requiring Rigid or Semi-rigid Immobilization for at Least 21 Days and up to 45 Days Because of Isolated Non-surgical Below-Knee Injury|Completed||Phase 3|1351|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:18:37.421448|2018-06-01 01:18:37.421448
NCT00843479|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2011-10-04||2013-03-07|2009-02-12|2009-02-13|Estimate|2013-03-07|2013-04-22|Estimate||||2013-03-07|2013-04-22|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly|The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly.|Completed|||24|Actual|University of Campinas, Brazil|||2||f||||f||||||Samples Without DNA|"~     Sera and plasma~   "|||2018-06-01 01:18:38.105453|2018-06-01 01:18:38.105453
NCT00843466|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2010-11-12||2017-12-06|2009-02-12|2009-02-13|Estimate|2017-01-26|2017-03-16|Actual||||2017-12-06|2018-01-02|Actual|May 2007||2007-05-31|December 2017|2017-12-31|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|||Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis|Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis|Completed||N/A|46|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-06-01 01:18:38.462536|2018-06-01 01:18:38.462536
NCT00843453|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-07-21|2009-02-12|2009-02-13|Estimate|||||||2009-07-21|2009-07-23|Estimate|November 2006||2006-11-30|July 2009|2009-07-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Long-term Use of Proton Pump Inhibitors May Cause Vitamin B12 Deficiency in the Institutionalized Elderly|Long-term Use of Proton Pump Inhibitors May Cause Vitamin B12 Deficiency in the Institutionalized Elderly|Completed||N/A|36|Actual|University of Delaware||2|||f||||t||||||||||2018-06-01 01:18:38.782145|2018-06-01 01:18:38.782145
NCT00843440|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2013-05-29|2009-02-12|2009-02-13|Estimate|||||||2013-05-29|2013-05-30|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|March 2012|Actual|2012-03-31|March 2009|Actual|2009-03-31||Interventional|METAFORE||Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study|Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study.|Completed||Phase 2|25|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-06-01 01:18:38.872099|2018-06-01 01:18:38.872099
NCT00843427|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2018-05-10|2009-02-12|2009-02-13|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2008||2008-09-30|May 2018|2018-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||fMRI of Language Recovery Following Stroke in Adults|fMRI of Language Recovery Following Stroke in Adults|Completed||N/A|24|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:18:38.959086|2018-06-01 01:18:38.959086
NCT00843414|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2016-07-05|2009-02-12|2009-02-13|Estimate|||||||2016-07-05|2016-07-07|Estimate|March 1978||1978-03-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Immunological Characterization of Bronchoalveolar Cells in Normals|Immunological Characterization of Bronchoalveolar Cells in Normals|Completed|||1232|Actual|Ohio State University|||||f||||f||||||Samples With DNA|"~     blood lung fluid (BAL)~   "|||2018-06-01 01:18:39.054185|2018-06-01 01:18:39.054185
NCT00843401|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-02-01|2009-02-12|2009-02-13|Estimate|||||||2011-02-01|2011-02-02|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Clinical Performance Evaluation of Pediatric and Neonatal Low Saturation Oximetry Sensors|Clinical Performance Evaluation of Pediatric and Neonatal Low Saturation Oximetry Sensors|Completed|||100|Anticipated|Children's Research Institute|||||f||||f||||||||||2018-06-01 01:18:39.125238|2018-06-01 01:18:39.125238
NCT00843388|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|March 2009||2009-03-31|January 2009|2009-01-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria|A Randomized Doubleblind Placebo Controlled Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Steno Diabetes Center||2|||f||||t||||||||||2018-06-01 01:18:39.233216|2018-06-01 01:18:39.233216
NCT00843375|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-03-15|2009-02-12|2009-02-13|Estimate|||||||2011-03-15|2011-03-16|Estimate|December 2005||2005-12-31|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas|Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas|Completed|||695|Actual|University of Michigan|||4||f||||t||||||Samples With DNA|"~     Tissue (normal colonic mucosa (fixed and frozen) plus adenoma or cancer), plasma, serum, FOBT~     cards, frozen stool samples, DNA and urine.~   "|||2018-06-01 01:18:39.358598|2018-06-01 01:18:39.358598
NCT00843362|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|December 2006||2006-12-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||24-Hour Vaginal Dinoprostone Pessary Versus Gel for Labour Induction|A Randomised Controlled Trial of 24-Hours Vaginal Dinoprostone Pessary vs. Gel for Induction of Labour in Term Pregnancies With a Bishop Score ≤4|Completed||Phase 4|133|Actual|Università degli Studi di Brescia||2|||f||||f||||||||||2018-06-01 01:18:39.46593|2018-06-01 01:18:39.46593
NCT00843336|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2015-09-22|2009-02-12|2009-02-13|Estimate|||||||2015-09-22|2015-09-24|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Two Internet Supported Natural Family Planning Methods|Randomized Comparison of Two Internet Supported Natural Family Planning Methods|Completed||Phase 3|358|Actual|Marquette University||2|||f||||f||||||||||2018-06-01 01:18:39.997122|2018-06-01 01:18:39.997122
NCT00843323|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2010-06-10|2009-02-12|2009-02-13|Estimate|||||||2010-06-10|2010-06-11|Estimate|December 2008||2008-12-31|June 2010|2010-06-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|PDT||Photodynamic Therapy (PDT) Effect on Large Surface Photodamaged Skin|Histological and Immunohistochemical Study of Photodamaged Skin Submitted to MAL-PDT|Completed||N/A|26|Actual|University of Sao Paulo|||||f||||t||||||||||2018-06-01 01:18:40.100036|2018-06-01 01:18:40.100036
NCT00843310|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2013-08-13||2017-06-21|2009-02-12|2009-02-13|Estimate|2013-08-13|2013-10-18|Estimate||||2017-06-21|2017-07-19|Actual|November 2008||2008-11-30|June 2017|2017-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma|Phase II Study of Revlimid (Lenalidomide), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation|Terminated||Phase 2|8|Actual|New York University School of Medicine||1||Due to slow accrual|f||||t||||||||||2018-06-01 01:18:40.243417|2018-06-01 01:18:40.243417
NCT00843297|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2010-02-01|2009-02-12|2009-02-13|Estimate|||||||2010-02-01|2010-02-02|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|COOL||COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest|Clinical and Neurological Outcome With Two Different Cooling Methods (Invasive and Non-invasive) After Sudden Cardiac Arrest|Completed||Phase 4|120|Anticipated|University of Leipzig||3|||f||||f||||||||||2018-06-01 01:18:40.531016|2018-06-01 01:18:40.531016
NCT00843284|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2009-03-11||2009-10-21|2009-02-12|2009-02-13|Estimate|2009-03-12|2009-04-16|Estimate||||2009-10-21|2009-10-28|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|NI-PMS||Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA|Assessing the Treatment of Patients With Neuropathic Pain Using LYRICA; A Non Interventional Post-marketing Study (NI-PMS)|Completed|||691|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:18:40.705209|2018-06-01 01:18:40.705209
NCT00843271|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-01-12|2009-02-12|2009-02-13|Estimate|||||||2012-01-12|2012-01-16|Estimate|October 2004||2004-10-31|January 2012|2012-01-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Observational|MESA-LUNG||Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA|Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)|Unknown status|Active, not recruiting||4359|Actual|Columbia University|||1||f||||t||||||||||2018-06-01 01:18:41.107744|2018-06-01 01:18:41.107744
NCT00843258|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-13|Estimate|||||||2009-02-11|2009-02-13|Estimate|February 1998||1998-02-28|February 2009|2009-02-28|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Treatment for Mild Hip Dysplasia in Newborns|Immediate Treatment Compared With Active Sonographic Surveillance in the Management of Mild Hip Dysplasia in Newborn Infants: A Randomized, Controlled Trial|Completed||N/A|140|Actual|University of Bergen||2|||f||||t||||||||||2018-06-01 01:18:41.274822|2018-06-01 01:18:41.274822
NCT00843245|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-06-21|2009-02-12|2009-02-13|Estimate|||||||2011-06-21|2011-06-22|Estimate|April 2009||2009-04-30|June 2011|2011-06-30||||||||Observational|BELIC||Study of Electrical Bioimpedance in Heart Failure.|Study of Electrical Bioimpedance in Heart Failure Patients Followed at the Heart Failure Unit of the Santa Creu i Sant Pau Hospital.|Unknown status|Recruiting||400|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||Samples Without DNA|"~     Blood serum obtained from routine blood test~   "|||2018-06-01 01:18:41.379297|2018-06-01 01:18:41.379297
NCT00843232|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-02-03|2009-02-12|2009-02-13|Estimate|||||||2011-02-03|2011-02-04|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Characterization of the Incretinpathy in Type 2 Diabetes Initiated After Sixty Years Old|Physiopathology of Type 2 Diabetes Initiated After Sixty Years Old: Characterization of a Diabetic-related Incretinpathy in Aging Subjects.|Completed|||24|Actual|University of Campinas, Brazil|||2||f||||f||||||Samples Without DNA|"~     Sera and plasma~   "|||2018-06-01 01:18:41.505839|2018-06-01 01:18:41.505839
NCT00843219|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2016-02-15|2009-02-12|2009-02-13|Estimate|||||||2016-02-15|2016-02-17|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating|Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating|Completed|||12|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:18:41.626745|2018-06-01 01:18:41.626745
NCT00843193|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2017-09-26|2012-02-23|2017-11-13|2009-02-12|2009-02-13|Estimate|2017-11-13|2017-12-12|Actual|2012-02-23|2012-02-27|Estimate|2017-11-13|2017-12-12|Actual|December 9, 2008|Actual|2008-12-09|November 2017|2017-11-30|July 25, 2010|Actual|2010-07-25|July 25, 2010|Actual|2010-07-25||Interventional|||Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma|A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients With Severe Asthma|Completed||Phase 2|198|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:18:41.792329|2018-06-01 01:18:41.792329
NCT00843180|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2012-02-07||2012-05-02|2009-02-12|2009-02-13|Estimate|2012-04-05|2012-05-02|Estimate||||2012-05-02|2012-05-08|Estimate|November 2008||2008-11-30|May 2012|2012-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Massage for Pediatric Oncology|Massage for Children Undergoing Bone Marrow Transplantation|Completed||N/A|23|Actual|University of California, San Francisco|"small sample size~limited number of time points for self-report assessments.~the dose of the massage intervention averaged 1.8 massages per week, while the target dose was 3 per week."|2|||f||||f||||||||||2018-06-01 01:18:42.636775|2018-06-01 01:18:42.636775
NCT00843167|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2014-12-30||2017-04-25|2009-02-12|2009-02-13|Estimate|2015-02-20|2015-02-24|Estimate||||2017-04-25|2017-04-27|Actual|August 2009||2009-08-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy|Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS)|Completed||Phase 2|54|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 01:18:42.923055|2018-06-01 01:18:42.923055
NCT00843154|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2010-06-09|2009-02-12|2009-02-13|Estimate|||||||2010-06-09|2010-06-11|Estimate|December 2005||2005-12-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|CANDHEART||Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure|Effects Of Candesartan Cilexetil vs Standard Therapy on Serum Levels of Brain Natriuretic Peptide in Patients Suffering From Chronic Heart Failure With Depressed and Preserved Systolic Function|Terminated||Phase 3|571|Actual|Takeda||2||Insufficient enrollment|f||||f||||||||||2018-06-01 01:18:43.319319|2018-06-01 01:18:43.319319
NCT00843141|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-08-15|2009-02-12|2009-02-13|Estimate|||||||2011-08-15|2011-08-16|Estimate|May 2009||2009-05-31|February 2009|2009-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Efficacy of Computerized Cognitive Training in Adults With ADHD: Change in ADHD Symptoms, Executive Functions and Quality of Life Following Three Months of Training.|ADHD Symptoms, Executive Functions and Quality of Life Following Three Months of Training.|Completed||N/A|60|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:18:43.416641|2018-06-01 01:18:43.416641
NCT00843128|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2011-04-07|2009-02-12|2009-02-13|Estimate|||||||2011-04-07|2011-04-08|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Multiple Sclerosis Patients|Phase II Study of the Effectiveness of Locomotor Therapy Using Robot-Driven Gait Orthosis System in Acute Stroke Patients: A Randomized Controlled Trial.|Completed||Phase 2|40|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:18:43.509487|2018-06-01 01:18:43.509487
NCT00843115|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2009-04-08||2014-02-11|2009-02-12|2009-02-13|Estimate|2009-04-09|2009-06-02|Estimate||||2014-02-11|2014-03-13|Estimate|February 2007||2007-02-28|February 2014|2014-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Observational Study Of Donepezil In Routine Clinical Practice|Ecological Perspective On The Efficacy And Tolerability Of Donepezil In A Routine Clinical Practice: A Patient Centered Observational Study|Terminated|||370|Actual|Pfizer|||1|See Detailed Description.|f||||f||||||||||2018-06-01 01:18:43.634305|2018-06-01 01:18:43.634305
NCT00843102|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2012-06-12|2009-02-12|2009-02-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|December 2009|Actual|2009-12-31||Observational|||Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis|Investigation of Coronary and Pulmonary Circulatory Parameters in Systemic Sclerosis|Completed|||120|Actual|University of Pecs|||||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-06-01 01:18:45.452059|2018-06-01 01:18:45.452059
NCT00843089|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2014-06-27|2009-02-12|2009-02-13|Estimate|||||||2014-06-27|2014-07-01|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Secondary Prevention After Coronary Bypass Surgery|Secondary Prevention After Coronary Bypass Surgery: A Pilot Study|Completed||N/A|115|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 01:18:45.653177|2018-06-01 01:18:45.653177
NCT00843076|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2013-11-08|2009-02-12|2009-02-13|Estimate|||||||2013-11-08|2013-11-11|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|Viro-steatosis||Impact of Hepatitis C Virus Variability on Steatosis|Impact of the Hepatitis C Virus Variability on Liver Steatosis|Terminated|||27|Actual|University Hospital, Tours|||||f||||f||||||Samples With DNA|"~     Liver biopsy~      Blood sample~   "|||2018-06-01 01:18:45.736398|2018-06-01 01:18:45.736398
NCT00843063|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2009-02-12|2009-02-12|2009-02-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|August 2004||2004-08-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion|Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study|Completed||Phase 4|161|Actual|Ruttonjee Hospital||2|||f||||t||||||||||2018-06-01 01:18:45.811147|2018-06-01 01:18:45.811147
NCT00843050|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2012-02-29||2012-06-20|2009-02-12|2009-02-13|Estimate|2012-06-20|2012-07-27|Estimate||||2012-06-20|2012-07-27|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|February 2011|Actual|2011-02-28||Interventional|||A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma|Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of P276-00 in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma|Terminated||Phase 2|13|Actual|Piramal Enterprises Limited|The Sponsor has terminated the study based on interim results. All subjects were off study at the time of termination. There are no major safety or tolerability concerns from this study. The study results published here are preliminary results.|1||"The study was terminated based on interim results and all subjects were off study at that time.~   No major safety or tolerability concerns"|f||||f||||||||||2018-06-01 01:18:45.936589|2018-06-01 01:18:45.936589
NCT00843037|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-04-03|2009-02-12|2009-02-13|Estimate|||||||2017-04-03|2017-04-04|Actual|February 2009||2009-02-28|April 2017|2017-04-30|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|SNIPP||Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma|A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma|Completed||Phase 2|25|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:18:46.230333|2018-06-01 01:18:46.230333
NCT00843024|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|2011-01-22||2016-11-30|2009-02-12|2009-02-13|Estimate|2011-04-07|2011-05-09|Estimate||||2016-11-30|2017-01-18|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Migraine Study in Adolescent Patients|TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents|Completed||Phase 3|589|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:18:46.395032|2018-06-01 01:18:46.395032
NCT00843011|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-12|||2017-07-18|2009-02-12|2009-02-13|Estimate|||||||2017-07-18|2017-07-21|Actual|August 28, 2008|Actual|2008-08-28|July 2017|2017-07-31|October 23, 2008|Actual|2008-10-23|October 23, 2008|Actual|2008-10-23||Interventional|Food/rel BA||Food and Relative Bioavailability Study|A Open-label, Randomized, Single-dose, 3-way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 2 Different Formulations of Orvepitant and the Effect of Food in Healthy Volunteers.|Completed||Phase 1|14|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:18:47.792317|2018-06-01 01:18:47.792317
NCT00842998|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-06-25|2009-02-11|2009-02-12|Estimate|||||||2009-06-25|2009-06-26|Estimate|February 2009||2009-02-28|June 2009|2009-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|HERLAP||Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer|A Phase II, Randomized Trial With Single Agent Trastuzumab or Lapatinib in Patients With Metastatic HER2-Overexpressing Breast Cancer|Unknown status|Recruiting|Phase 2|120|Anticipated|Azienda Ospedaliera Ordine Mauriziano di Torino||2|||f||||f||||||||||2018-06-01 01:18:47.87354|2018-06-01 01:18:47.87354
NCT00842985|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2011-08-05||2017-04-21|2009-02-11|2009-02-12|Estimate|2012-11-15|2012-12-17|Estimate||||2017-04-21|2017-05-30|Actual|September 2008||2008-09-30|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Dronabinol Interactions With Cognitive Enhancing Drug in Humans|Dronabinol Interactions in Humans|Completed||Early Phase 1|53|Actual|Yale University|"One dose of modafinil Brief treatment duration and use of a low dose of THC Cognitive testing assessed only two tasks. Outcome measures were limited by small sample size.~Limited generalizability because heavy cannibas users were excluded"|1|||f||||t||||||||No||2018-06-01 01:18:47.961327|2018-06-01 01:18:47.961327
NCT00842959|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2011-06-15|2009-02-11|2009-02-12|Estimate|||||||2011-06-15|2011-06-16|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|ZO Okulix||Check of Optical Features and Accuracy of the Zeiss ZO Lens After Selection and Calculation With OKULIX|Check of Optical Features and Accuracy of the Zeiss ZO Lens of the Company Carl Zeiss Meditec After Selection and Calculation With OKULIX|Completed||Phase 4|120|Anticipated|Carl Zeiss Meditec AG||1|||f||||f||||||||||2018-06-01 01:18:48.202429|2018-06-01 01:18:48.202429
NCT00842946|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2014-05-01||2014-05-01|2009-02-11|2009-02-12|Estimate|2014-05-01|2014-06-02|Estimate||||2014-05-01|2014-06-02|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety|Exposure With Acceptance-Based Versus Habituation-Based Rationale for Public Speaking Anxiety|Completed||N/A|45|Actual|Drexel University||2|||f||||f||||||||||2018-06-01 01:18:48.275524|2018-06-01 01:18:48.275524
NCT00842933|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2011-06-28|2009-02-11|2009-02-12|Estimate|||||||2011-06-28|2011-06-29|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Adrenal Insufficiency in Septic Shock|An Open-label, Prospective, Randomized, Controlled Clinical Trial of the Use of Reduced Duration Versus Standard Duration Steroid Replacement Therapy for Acute Adrenal Insufficiency in Patients With Septic Shock|Terminated||Phase 4|32|Anticipated|The Methodist Hospital System||2||Unable to meet enrollment goal prior to PI transfer|f||||t||||||||||2018-06-01 01:18:48.556592|2018-06-01 01:18:48.556592
NCT00842920|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2015-09-15|2009-02-11|2009-02-12|Estimate|||||||2015-09-15|2015-09-16|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|SIMaMCI||Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients|Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients|Recruiting||Phase 4|520|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 01:18:48.667059|2018-06-01 01:18:48.667059
NCT00842907|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2010-06-07|2009-02-11|2009-02-12|Estimate|||||||2010-06-07|2010-06-08|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|August 2010|Anticipated|2010-08-31|December 2009|Anticipated|2009-12-31||Interventional|||Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage|A Clinical, Laboratorial and Quality of Life Study to Evaluate the Efficacy and Safety of Oral Isotretinoin in the Treatment of Cutaneous Photodamage|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:18:48.801071|2018-06-01 01:18:48.801071
NCT00842894|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2014-08-13|2009-02-11|2009-02-12|Estimate|||||||2014-08-13|2014-08-15|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 26-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Macedonia|Completed|||3421|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 01:18:48.915314|2018-06-01 01:18:48.915314
NCT00842881|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-09-23|2009-02-11|2009-02-12|Estimate|||||||2009-09-23|2009-09-24|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|September 2009|Anticipated|2009-09-30|March 2009|Anticipated|2009-03-31||Interventional|Healingstone||A Trial for Evaluation of Clinical Efficacy and Safety of Healing Stone Navel Belt in Patients With Primary Dysmenorrhea|Clinical Efficacy and Safety of Healing Stone Navel Belt in Patients With Primary Dysmenorrhea|Unknown status|Enrolling by invitation|Phase 3|102|Anticipated|Healingstone Co., Ltd.||2|||f||||t||||||||||2018-06-01 01:18:48.997879|2018-06-01 01:18:48.997879
NCT00842868|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-09-16|2009-02-11|2009-02-12|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2008||2008-09-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|CASABLANCA||The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases|The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases. An Observational Biomarker Study|Completed|||1298|Actual|Massachusetts General Hospital|||||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-06-01 01:18:49.062131|2018-06-01 01:18:49.062131
NCT00842855|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2011-02-04|2009-02-11|2009-02-12|Estimate|||||||2011-02-04|2011-02-07|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|REMAIN||Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France|Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient|Completed|||275|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:18:49.128849|2018-06-01 01:18:49.128849
NCT00842842|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2015-08-17|2009-02-11|2009-02-12|Estimate|||||||2015-08-17|2015-08-19|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|July 2011|Actual|2011-07-31|June 2010|Actual|2010-06-30||Interventional|MEFIXIT||Mesh Fixation With Intraperitoneal Tisseel|A Prospective, Controlled, Randomized, Patient and Evaluator Blinded Study to Evaluate Pain and Recovery in Patients Undergoing Laparoscopic Umbilical Hernia Repair by Fixing the Mesh With Tisseel Versus Tackers|Completed||N/A|40|Actual|Herlev Hospital||2|||f||||f||||||||||2018-06-01 01:18:49.277011|2018-06-01 01:18:49.277011
NCT00842829|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2012-08-17||2012-09-19|2009-02-11|2009-02-12|Estimate|2012-08-17|2012-09-20|Estimate||||2012-09-19|2012-10-01|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients|A European Multicenter Open-Label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients|Terminated||Phase 4|330|Actual|Teva Pharmaceutical Industries||2||Recruitment stopped at the end of the recruitment timeframe|f||||f||||||||||2018-06-01 01:18:49.42842|2018-06-01 01:18:49.42842
NCT00842816|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-06-05|2009-02-11|2009-02-12|Estimate|||||||2012-06-05|2012-06-07|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease|A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®)|Completed||Phase 2|210|Actual|Sonexa Therapeutics, Inc.||4|||f||||f||||||||||2018-06-01 01:18:50.746428|2018-06-01 01:18:50.746428
NCT00842803|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-09-17|2009-02-11|2009-02-12|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2010||2010-01-31|September 2009|2009-09-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant|Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant Recipients Status 1-2. A Prospective Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|100|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-06-01 01:18:50.888851|2018-06-01 01:18:50.888851
NCT00842790|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2015-10-05|2009-02-11|2009-02-12|Estimate|||||||2015-10-05|2015-10-06|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|REMISCAN||Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging|Medical and Economical Impact of Predicting the Response to Anti-angiogenic Treatment in Metastatic Renal Cell Carcinoma Using Functional CT and MRI|Completed|||107|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 01:18:50.970674|2018-06-01 01:18:50.970674
NCT00842777|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2016-07-27|2009-02-11|2009-02-12|Estimate|||||||2016-07-27|2016-07-28|Estimate|October 2004||2004-10-31|July 2016|2016-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Childhood Obesity: a Study of Group Treatment Targeting Parents Behaviour|Childhood Obesity; a Randomized Controlled Study of Group Treatment Targeting Parents Behaviour|Completed||Phase 2|99|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 01:18:51.033111|2018-06-01 01:18:51.033111
NCT00842764|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2018-02-02|2009-02-11|2009-02-12|Estimate|||||||2018-02-02|2018-02-06|Actual|January 2009||2009-01-31|February 2018|2018-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Minimally Invasive Holmium:YAG Laser Blepharoplasty|Minimally Invasive Holmium:YAG Laser Blepharoplasty|Completed||N/A|7|Actual|University of California, Irvine||1|||f||||f||||||||||2018-06-01 01:18:51.102057|2018-06-01 01:18:51.102057
NCT00842751|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2011-03-21||2013-12-10|2009-02-10|2009-02-12|Estimate|2013-12-10|2014-01-13|Estimate||||2013-12-10|2014-01-13|Estimate|July 2009||2009-07-31|December 2013|2013-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|Oral T7|Each subject was administered each of the three treatments over a 6-week period with 1 week of no treatment (wash-out) between each of the treatment period.|Oral T7 Oral Testosterone in Man|Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride|Completed||Phase 2|11|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 01:18:51.177407|2018-06-01 01:18:51.177407
NCT00842738|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2010-01-13|2009-02-11|2009-02-12|Estimate|||||||2010-01-13|2010-01-14|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|December 2011|Anticipated|2011-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Can Alternative Treatment Have an Impact on Cervical Dysplasia?|Can Mindfulness Meditation Limit the Progression and/or Increase the Remission of Cervical Dysplasia?|Unknown status|Enrolling by invitation|Phase 4|200|Anticipated|University of Copenhagen||3|||f||||f||||||||||2018-06-01 01:18:51.392643|2018-06-01 01:18:51.392643
NCT00842712|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2014-07-31||2017-01-12|2009-02-10|2009-02-12|Estimate|2014-09-29|2014-09-30|Estimate||||2017-01-12|2017-01-13|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|CERTO|Intent-to-treat (ITT) population included all participants who were randomized to trial treatment.|Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)|Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Cilengitide Regimens in Combination With Cetuximab and Platinum-based Chemotherapy (Cisplatin/Vinorelbine or Cisplatin/Gemcitabine) Compared to Cetuximab and Platinum-based Chemotherapy Alone as First Line Treatment for Subjects With Advanced NSCLC|Completed||Phase 2|232|Actual|Merck KGaA||7|||f||||||||||||||2018-06-01 01:18:51.639873|2018-06-01 01:18:51.639873
NCT00842699|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2011-06-27|2009-02-11|2009-02-12|Estimate|||||||2011-06-27|2011-06-29|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Observational|||Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab|Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab|Completed|||40|Anticipated|Brigham and Women's Hospital|||2||f||||f||||||||||2018-06-01 01:18:53.790176|2018-06-01 01:18:53.790176
NCT00842686|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2012-03-23|2009-02-11|2009-02-12|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|August 2014|Anticipated|2014-08-31|August 2010|Actual|2010-08-31||Interventional|CRAB||Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study|Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Institute of Oncology Ljubljana|||||f||||t||||||||||2018-06-01 01:18:53.912741|2018-06-01 01:18:53.912741
NCT00842673|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-06-05|2009-02-10|2009-02-12|Estimate|||||||2012-06-05|2012-06-07|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease|A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease|Completed||Phase 2|168|Actual|Sonexa Therapeutics, Inc.||4|||f||||f||||||||||2018-06-01 01:18:54.092746|2018-06-01 01:18:54.092746
NCT00842660|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2010-01-03|2009-02-11|2009-02-12|Estimate|||||||2010-01-03|2010-01-05|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer|Phase III Trial for Primary Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in PET/CT Defined Poor-Prognostic Cervical Cancer Patients|Unknown status|Enrolling by invitation|Phase 3|172|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 01:18:54.18028|2018-06-01 01:18:54.18028
NCT00842647|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-04-07|2009-02-11|2009-02-12|Estimate|||||||2009-04-07|2009-04-08|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Observational|HCC||Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma|Diagnosis of Hepatic Tumors in Cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma|Unknown status|Recruiting||1200|Anticipated|Sun Yat-sen University|||||f||||t||||||||||2018-06-01 01:18:54.396919|2018-06-01 01:18:54.396919
NCT00842634|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2016-11-11|2009-02-11|2009-02-12|Estimate|||||||2016-11-11|2016-11-15|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Zinc-Finger||Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV|A Phase I Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 in HIV-Infected Patients|Completed||Phase 1|12|Actual|University of Pennsylvania||3|||f||||t||||||||No||2018-06-01 01:18:54.494333|2018-06-01 01:18:54.494333
NCT00842621|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2016-06-24|2009-02-11|2009-02-12|Estimate|||||||2016-06-24|2016-06-27|Estimate|March 2009||2009-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Long Term Effects of Erythrocyte Lysis|Long Term Effects of Erythrocyte Lysis|Completed|||390|Actual|St. Jude Children's Research Hospital|||3||f||||f||||||Samples With DNA|"~     Blood Serum Plasma Urine~   "|||2018-06-01 01:18:54.578086|2018-06-01 01:18:54.578086
NCT00842582|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2016-11-01|2009-02-11|2009-02-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer|Neoadjuvant Azacitidine With Carboplatin and Paclitaxel for Suboptimal Newly Diagnosed Ovarian Cancer|Withdrawn||Phase 1|0|Actual|Loyola University||1||No enrollment. Unable to recruit due to lack of eligible patients.|f||||f||||||||No||2018-06-01 01:18:55.241513|2018-06-01 01:18:55.241513
NCT00842569|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|January 2008||2008-01-31|February 2009|2009-02-28||||December 2008|Actual|2008-12-31||Observational|||Brain Electrophysiological Patterns in Obesity|ERP Study of Brain Electrophysiological Patterns in Obesity|Completed|||69|Actual|Centre de Recherche en Nutrition Humaine Rhone-Alpe|||2||f||||f||||||||||2018-06-01 01:18:55.318248|2018-06-01 01:18:55.318248
NCT00842556|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2016-10-14|2009-02-11|2009-02-12|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects|Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects|Completed||Phase 1|18|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 01:18:55.388385|2018-06-01 01:18:55.388385
NCT00842543|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2012-05-18||2013-07-16|2009-02-11|2009-02-12|Estimate|2013-07-16|2013-09-26|Estimate||||2013-07-16|2013-09-26|Estimate|July 2008||2008-07-31|July 2013|2013-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|FVJC||Fruit and Vegetable Juice Concentrate Effects on RBP4 and Antioxidant Capacity in Lean and Overweight 6-10 Year Old Boys|Effects Of A Fruit And Vegetable Juice Concentrate (FVJC) In-Vivo On Retinol Binding Protein 4 And Antioxidant Capacity In Normal And Overweight Boys -A Pilot Randomized Placebo Controlled Study|Completed||N/A|39|Actual|Nemours Children's Clinic||2|||f||||t||||||||||2018-06-01 01:18:55.470095|2018-06-01 01:18:55.470095
NCT00842530|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2014-09-18|2009-02-11|2009-02-12|Estimate|||||||2014-09-18|2014-09-19|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of Dengue Vaccine in Healthy Children|Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand|Completed||Phase 2|4002|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:18:55.813721|2018-06-01 01:18:55.813721
NCT00842517|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Long Term Maintenance of Drug Abstinence|A Behavioral Model for Maintenance of Drug Abstinence|Completed||Phase 1|166|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-06-01 01:18:55.89258|2018-06-01 01:18:55.89258
NCT00842504|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2012-02-15|2009-02-11|2009-02-12|Estimate|||||||2012-02-15|2012-02-16|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Alternate Day Micafungin: A PK Study in Pediatric Patients|Alternate Day Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients: A Pharmacokinetic Study|Completed||Phase 1|15|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-06-01 01:18:55.957598|2018-06-01 01:18:55.957598
NCT00842491|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2015-05-17|2009-02-11|2009-02-12|Estimate|||||||2015-05-17|2015-05-19|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer|A Phase II Study of Endostar (Recombinant Human Endostatin ®) With Cisplatin and Capecitabine (Xeloda) as 1st Line Treatment in the Advanced Gastric Cancer|Completed||Phase 2|45|Actual|Peking University||1|||f||||t||||||||||2018-06-01 01:18:56.033825|2018-06-01 01:18:56.033825
NCT00842478|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|May 2005||2005-05-31|February 2009|2009-02-28||||||||Interventional|RASPALL||Effectiveness of Dental Brushing for Preventing Ventilator-Associated Pneumonia|Effectiveness of Dental Brushing for Preventing Ventilator-Associated Pneumonia|Unknown status|Recruiting|Phase 2/Phase 3|400|Anticipated|Hospital Universitari Joan XXIII de Tarragona.||2|||f||||t||||||||||2018-06-01 01:18:56.115416|2018-06-01 01:18:56.115416
NCT00842465|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-11-21|2009-02-11|2009-02-12|Estimate|||||||2013-11-21|2013-11-25|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|Prolacsein||Prolactin Receptor and Breast Diseases|Characterization and Implication of Prolactin Receptor Mutants in Human Breast Diseases|Completed|||735|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples Without DNA|"~     blood collection breast Biopsy or surgery~   "|||2018-06-01 01:18:56.435992|2018-06-01 01:18:56.435992
NCT00842452|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2013-04-03|2009-02-11|2009-02-12|Estimate|||||||2013-04-03|2013-04-05|Estimate|February 2009||2009-02-28|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery|A Phase I Study of Weekly Oral Topotecan in Gynecologic Malignancies|Completed||Phase 1|26|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:18:56.515444|2018-06-01 01:18:56.515444
NCT00842439|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2016-08-17|2009-02-11|2009-02-12|Estimate|||||||2016-08-17|2016-08-19|Estimate|February 2009||2009-02-28|August 2016|2016-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HBB||Healthy Brains & Behavior: Understanding and Treating Youth Aggression|Biosocial Prediction and Intervention on Childhood Aggression|Completed||N/A|335|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 01:18:56.603343|2018-06-01 01:18:56.603343
NCT00842426|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2012-09-11|2009-02-11|2009-02-12|Estimate|||||||2012-09-11|2012-09-13|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|E-LITE||Evaluation of Lifestyle Interventions to Treat Elevated Cardiometabolic Risk in Primary Care|A Pilot of Customized Continuous Care Management of Obesity in Pre-Diabetics|Completed||Phase 2|241|Actual|Palo Alto Medical Foundation||3|||f||||t||||||||||2018-06-01 01:18:56.679326|2018-06-01 01:18:56.679326
NCT00842413|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|May 2007||2007-05-31|November 2008|2008-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Investigating the Role of the Premotor Cortex in Higher Cognitive Functions|What Part Does the Premotor Cortex Play in Subjective Visual Perception and in the Perception of Others' Actions?|Terminated|||9|Actual|Assistance Publique - Hôpitaux de Paris|||2|not enough enrollment|f||||f||||||||||2018-06-01 01:18:56.760239|2018-06-01 01:18:56.760239
NCT00842400|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-01-20|2009-02-10|2009-02-12|Estimate|||||||2010-01-20|2010-01-21|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.|A Phase I, Single-Center, Open-Label, Non-randomized, One-Sequence Crossover, Pharmacokinetic Interaction Study of the Combination Product VI-0521 (Phentermine Plus Topiramate) With Metformin, Sitagliptin or Probenecid in Healthy Subjects|Completed||Phase 1|20|Actual|VIVUS, Inc.|||||f||||f||||||||||2018-06-01 01:18:56.816559|2018-06-01 01:18:56.816559
NCT00842374|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2013-04-24|2009-02-11|2009-02-12|Estimate|||||||2013-04-24|2013-04-25|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin|Single Center Registry of Non-STEMI Acute Coronary Syndrome Patients Treated With Bivalirudin|Completed|||32|Actual|Minneapolis Heart Institute Foundation|||1||f||||f||||||||||2018-06-01 01:18:57.112671|2018-06-01 01:18:57.112671
NCT00842361|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2015-10-19|2009-11-09|2016-12-15|2009-02-11|2009-02-12|Estimate|2015-10-19|2015-11-20|Estimate|2009-11-09|2009-11-11|Estimate|2016-12-15|2017-02-09|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus|A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIAC Compared to Mix30 (NovoRapid®30Mix) on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|66|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:18:57.20068|2018-06-01 01:18:57.20068
NCT00842348|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2016-12-28||2016-12-28|2009-02-11|2009-02-12|Estimate|2016-12-28|2017-02-17|Actual||||2016-12-28|2017-02-17|Actual|February 2009||2009-02-28|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|NET729|Safety Population: All patients who received at least one dose of lanreotide Autogel in Study 729.|Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour|Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour|Completed||Phase 3|89|Actual|Ipsen||1|||f||||f||||||||||2018-06-01 01:18:57.577807|2018-06-01 01:18:57.577807
NCT00842335|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2012-12-12||2013-06-21|2009-02-11|2009-02-12|Estimate|2013-06-21|2013-06-24|Estimate||||2013-06-21|2013-06-24|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|January 2012|Actual|2012-01-31|July 2010|Actual|2010-07-31||Interventional|||A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors|A Multicenter, Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|18|Actual|Jubilant Innovation Ltd.||1|||f||||f||||||||||2018-06-01 01:18:58.153491|2018-06-01 01:18:58.153491
NCT00842322|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-12|2009-02-11|2009-02-12|Estimate|||||||2009-02-12|2009-02-13|Estimate||||February 2009|2009-02-28||||||||Interventional|||Fluid Intake in Kidney Failure|The Effect of Increased Fluid Intake on Chronic Renal Failure|Completed||N/A|76|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:18:58.594417|2018-06-01 01:18:58.594417
NCT00842309|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2018-01-25|2009-02-10|2009-02-12|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2008||2008-11-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BDD/DCS||D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder|A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder|Active, not recruiting||Early Phase 1|50|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:18:58.674376|2018-06-01 01:18:58.674376
NCT00842296|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2017-06-26||2018-02-12|2009-02-11|2009-02-12|Estimate|2017-11-07|2017-12-11|Actual||||2018-02-12|2018-03-12|Actual|April 2006||2006-04-30|February 2018|2018-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||326 patients were enrolled and 396 limbs were treated and are analyzed. Only 395 limbs provided baseline CEAP data.|ClosureFAST - Radiofrequency Great Saphenous Vein Treatment|ClosureFAST - Endovascular Radiofrequency Great Saphenous Vein Treatment Using a Catheter With an Integrated Heating Element|Completed||N/A|326|Actual|Medtronic Endovascular||1|||f||||f||||||||Yes||2018-06-01 01:18:58.79139|2018-06-01 01:18:58.79139
NCT00842283|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2018-02-12|2009-02-11|2009-02-12|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2008||2008-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target|Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target|Recruiting|||100|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-06-01 01:18:59.329334|2018-06-01 01:18:59.329334
NCT00842270|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|January 2006||2006-01-31|February 2009|2009-02-28||||July 2007|Actual|2007-07-31||Interventional|||Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent Asthma|Completed||Phase 2|44|Actual|AB Science||4|||f||||f||||||||||2018-06-01 01:18:59.403264|2018-06-01 01:18:59.403264
NCT00842257|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2017-02-10||2017-04-10|2009-02-10|2009-02-12|Estimate|2017-04-10|2017-05-16|Actual||||2017-04-10|2017-05-16|Actual|May 2009|Actual|2009-05-31|April 2017|2017-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer|A Single Arm Phase II Trial of Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer|Completed||Phase 2|20|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 01:18:59.491494|2018-06-01 01:18:59.491494
NCT00842244|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2012-02-25||2013-10-17|2009-02-11|2009-02-12|Estimate|2012-02-25|2012-03-26|Estimate||||2013-10-17|2013-11-27|Estimate|April 2009||2009-04-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|December 2009|Actual|2009-12-31||Interventional|||Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer|A Phase 1 Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer|Completed||Phase 1|22|Actual|Pfizer|AUC (0-24) was evaluated and reported for axitinib instead of AUClast as AUC0-24 was a more appropriate measure of steady-state exposure for this drug.|1|||f||||f||||||||||2018-06-01 01:18:59.750419|2018-06-01 01:18:59.750419
NCT00842231|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2010-08-11||2010-09-23|2009-02-11|2009-02-12|Estimate|2010-08-11|2010-09-08|Estimate||||2010-09-23|2010-09-28|Estimate|January 2009||2009-01-31|September 2010|2010-09-30||||March 2009|Actual|2009-03-31||Observational|||Assessment of Visual Performance in Patients With Low Levels of Astigmatism||Completed|||40|Actual|Alcon Research|||1||f||||f||||||||||2018-06-01 01:19:00.154724|2018-06-01 01:19:00.154724
NCT00842218|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|April 2009|Anticipated|2009-04-30||Observational|scoliosis||The Idiopathic Scoliosis and Its Treatment (Orthopaedic and Surgery): Effect of the Severity, the Orthosis and the Arthrodesis on the Gait|Effect of the Severity and the Treatment (Orthosis Versus Surgery)of the Idiopathic Scoliosis on the Locomotor Mechanism of the Gait.|Unknown status|Recruiting||50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||t||||||||||2018-06-01 01:19:00.31246|2018-06-01 01:19:00.31246
NCT00841503|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-03-20|2009-02-10|2009-02-11|Estimate|||||||2012-03-20|2012-03-21|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Exploring Buckwheat's Glucose Lowering Potential|A Double-Blind, Randomized, Controlled Study to Determine Buckwheat's Glucose Lowering Effects in Healthy Volunteers and Volunteers With Type 2 Diabetes|Completed|||24|Actual|St. Boniface General Hospital Research Centre|||2||f||||f||||||||||2018-06-01 01:19:09.96734|2018-06-01 01:19:09.96734
NCT00842205|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection|Role of Heme Oxygenase in the Pathogenesis od Hepatocellular Injury in Chronic HCV Infection|Unknown status|Recruiting|N/A|150|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||||2018-06-01 01:19:00.371031|2018-06-01 01:19:00.371031
NCT00842192|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2016-12-06|2009-02-11|2009-02-12|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2009||2009-04-30|December 2016|2016-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|BO2NE||An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries|A Prospective, Multicentre, Multinational, Open Label, Non-controlled, Observational, 24-week Study in Patients Using Oral Anti-Diabetic (OAD) Drugs + Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Near East Region Countries|Completed|||2155|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:19:00.44378|2018-06-01 01:19:00.44378
NCT00842179|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Groin Complications Post Percutaneous Coronary Intervention Using Either Manual Compression or PERCLOSE Device|Femoral Access Site Groin Complication Rates After 2517 Groin Punctures Undergoing Vascular Closure by Either Manual Compression or the Perclose Vascular Closure Device|Completed|||2517|Actual|Clinyx, LLC|||2||f||||f||||||||||2018-06-01 01:19:00.512214|2018-06-01 01:19:00.512214
NCT00842166|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2014-08-28|2009-02-11|2009-02-12|Estimate|||||||2014-08-28|2014-08-29|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Surveillance of Summer Febrile Syndromes of Viral Origin in South of France||Completed||N/A|90|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 01:19:00.567758|2018-06-01 01:19:00.567758
NCT00842153|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2011-12-21||2017-10-05|2009-02-11|2009-02-12|Estimate|2011-12-21|2012-01-30|Estimate||||2017-10-05|2017-10-09|Actual|November 2007||2007-11-30|October 2017|2017-10-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam|A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis|Completed||Phase 4|58|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:19:00.63028|2018-06-01 01:19:00.63028
NCT00842140|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2010-07-21|2009-02-10|2009-02-12|Estimate|||||||2010-07-21|2010-07-22|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women|Metabolic Effects of Multiple Therapies in Polycystic Ovary Syndrome (PCOS) Women|Completed||N/A|75|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-06-01 01:19:01.178442|2018-06-01 01:19:01.178442
NCT00842127|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Genetic Polymorphism and OROS-Methylphenidate Treatment in Attention Deficit Hyperactivity Disorder(ADHD)|Genetic Polymorphism of Drug Transporters in OROS-Methylphenidate Treatment in Children and Adolescents With Attention Deficit Hyperactivity Disorder(ADHD)|Completed||Phase 4|150|Actual|Bundang CHA Hospital|||||f||||t||||||||||2018-06-01 01:19:01.259967|2018-06-01 01:19:01.259967
NCT00842114|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-03-31|2009-02-11|2009-02-12|Estimate|||||||2016-03-31|2016-04-04|Estimate|February 2006||2006-02-28|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|LNH-Pro-05||Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)|Association of Rituximab to Immunochemotherapy With CVP + Interferon in Newly Diagnosed Follicular Lymphoma Patients With Intermediate-high FLIPI Score. Phase II Study.|Completed||Phase 2|50|Actual|Fundación Leucemia y Linfoma, Spain||1|||f||||f||||||||||2018-06-01 01:19:01.326207|2018-06-01 01:19:01.326207
NCT00842101|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|December 2005||2005-12-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Observational|||Compartmental Overpressures Associated to Reamed Intramedullary Nails|Effect of Reamed Intramedullary Nails in Tibial Fractures as a Factor of Rising Intracompartmental Pressures: A Clinical Study|Completed|||80|Actual|University of Andorra|||1||f||||t||||||None Retained|"~     Serum~   "|||2018-06-01 01:19:01.397333|2018-06-01 01:19:01.397333
NCT00842088|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11||2011-07-01|2011-07-28|2009-02-11|2009-02-12|Estimate||||2011-07-28|2011-08-01|Estimate|2011-07-28|2011-08-01|Estimate|March 2009||2009-03-31|July 2011|2011-07-31||||July 2010|Actual|2010-07-31||Interventional|||Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease|A Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects With Sickle Cell Disease|Completed||Phase 1/Phase 2|24|Actual|HemaQuest Pharmaceuticals Inc.||2|||f||||t||||||||||2018-06-01 01:19:01.518978|2018-06-01 01:19:01.518978
NCT00842075|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2012-09-17||2015-05-26|2009-02-11|2009-02-12|Estimate|2012-09-17|2012-10-19|Estimate||||2015-05-26|2015-06-23|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pramlintide in Adolescents With Type 1 Diabetes|Effects of Pramlintide in Adolescents With Type 1 Diabetes|Completed||N/A|10|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:19:01.611874|2018-06-01 01:19:01.611874
NCT00842062|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2015-03-23|2009-02-11|2009-02-12|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation|Study of the MyoScience Tissue Remodeling Device for Facial Rejuvenation|Completed||Phase 1/Phase 2|380|Actual|MyoScience, Inc||1|||f||||f||||||||||2018-06-01 01:19:01.873869|2018-06-01 01:19:01.873869
NCT00842049|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2011-02-22|2009-02-11|2009-02-12|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2006||2006-11-30|February 2009|2009-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|LUMAS||Lumbar Drainage in Subarachnoid Haemorrhage|Lumbar Drainage of Cerebrospinal Fluid in Aneurysmal Subarachnoid Haemorrhage: A Prospective Randomised Controlled Trial|Completed||Phase 2|210|Actual|The Leeds Teaching Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 01:19:01.955052|2018-06-01 01:19:01.955052
NCT00842036|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2010-06-24|2009-02-11|2009-02-12|Estimate|||||||2010-06-24|2010-06-25|Estimate|January 2006||2006-01-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||CRAFT Behavior Therapy: Treatment Entry Component|CRAFT Behavior Therapy Phase 2 Study: Treatment Entry Component|Completed||Phase 2|180|Anticipated|Treatment Research Institute||3|||f||||t||||||||||2018-06-01 01:19:02.063781|2018-06-01 01:19:02.063781
NCT00842023|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2012-02-03||2013-08-29|2009-02-10|2009-02-12|Estimate|2013-08-29|2013-08-30|Estimate||||2013-08-29|2013-08-30|Estimate|July 2006||2006-07-31|August 2013|2013-08-31|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|ABC-HFT||Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy|A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin.|Completed||Phase 4|89|Actual|Western University of Health Sciences||2|||f||||t||||||||||2018-06-01 01:19:02.159872|2018-06-01 01:19:02.159872
NCT00842010|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Observational|||Characteristics of Non Diabetic Hyperglycemic Inpatients|Hyperglycemic Non Diabetic (HND) Hospital Patients: Are They Different From Diabetic Hyperglycemic and Non-Hyperglycemic Non-Diabetic(NHND) Patients?|Completed|||600|Actual|John H. Stroger Hospital|||3||f||||f||||||||||2018-06-01 01:19:02.454507|2018-06-01 01:19:02.454507
NCT00841984|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Observational|SPECMET||In Vitro NMR Spectroscopy in Neurological Diseases|Evaluation of in Vitro NMR Spectroscopy to Identify Inborn Errors of Metabolism in Patients With Complex Neurological Diseases|Terminated|||271|Actual|Assistance Publique - Hôpitaux de Paris|||3|not enough enrollment|f||||f||||||Samples Without DNA|"~     urines, cerebrospinal fluid~   "|||2018-06-01 01:19:02.523637|2018-06-01 01:19:02.523637
NCT00841971|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2014-12-08||2014-12-15|2009-02-11|2009-02-12|Estimate|2014-12-15|2014-12-17|Estimate||||2014-12-15|2014-12-17|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients|Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial|Completed||Phase 4|200|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:19:02.594067|2018-06-01 01:19:02.594067
NCT00841958|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-04-23|2009-02-11|2009-02-12|Estimate|||||||2012-04-23|2012-04-24|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ESCAPE||Endocardial Stem Cells Approach Efficacy|Efficacy of the Endocardial Stem Cells Implantation in Ischemic Heart Failure Patients|Completed||Phase 3|250|Actual|Meshalkin Research Institute of Pathology of Circulation|||||f||||t||||||||||2018-06-01 01:19:02.836765|2018-06-01 01:19:02.836765
NCT00841945|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|||2017-02-20|2009-02-11|2009-02-12|Estimate|||||||2017-02-20|2017-02-23|Actual|April 2005||2005-04-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2016|Actual|2016-01-31||Interventional|||Treatment of Aggressive Localized Lymphoma|Phase III Study of the Interest of Radiotherapy After 4 or 6 Cycles of CHOP 14 Rituximab Regimen of Chemotherapy , Patients With Agressive Localized Lymphoma|Terminated||Phase 3|334|Actual|French Innovative Leukemia Organisation||2||other drugs other studies|f||||t||||||||No||2018-06-01 01:19:02.889441|2018-06-01 01:19:02.889441
NCT00841932|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-11|2009-02-11|2009-02-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Performing Fractional Flow Reserve Without Anticoagulation During Diagnostic Catheterization|Retrospective Assessment of the Safety of Performing Fractional Flow Reserve (FFR) of the Myocardium Without Anticoagulation During Diagnostic Cardiac Catheterization|Completed|||100|Actual|Clinyx, LLC|||1||f||||f||||||||||2018-06-01 01:19:02.961457|2018-06-01 01:19:02.961457
NCT00841919|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-09-08|2009-02-11|2009-02-12|Estimate|||||||2009-09-08|2009-09-09|Estimate|December 2006||2006-12-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Insulin Therapy in the Hospital Comparing Two Protocols|Basal/Bolus Insulin Therapy in the Hospital Ward Comparison of Two Protocols: Feasibility Study|Completed||Phase 4|60|Anticipated|John H. Stroger Hospital||2|||f||||f||||||||||2018-06-01 01:19:03.029719|2018-06-01 01:19:03.029719
NCT00841906|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-11|2016-07-13||2016-10-05|2009-02-11|2009-02-12|Estimate|2016-10-05|2016-11-29|Estimate||||2016-10-05|2016-11-29|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Alice PDx User/Validation Extended Trial|Alice PDx User/Validation Extended Trial|Completed||N/A|30|Actual|Philips Respironics||2|||f||||f||||||||||2018-06-01 01:19:03.109826|2018-06-01 01:19:03.109826
NCT00841893|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-10|2009-02-10|2009-02-11|Estimate|||||||2009-02-10|2009-02-11|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of a Specific Spice on Energy Metabolism|Effects of a Specific Spice on Energy Expenditure, Substrate Oxidation, Appetite and Energy Intake|Completed||N/A|16|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 01:19:03.555173|2018-06-01 01:19:03.555173
NCT00841880|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2010-08-26|2009-02-10|2009-02-11|Estimate|||||||2010-08-26|2010-08-27|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||China Medical University Hospital (CMUH) Triapin Listing|A Prospective, Open Label, Randomized, Comparative Study of Ramipril 5mg Plus Felodipine 5mg Combined Regimen and Ramipril 10mg in Uncontrolled Hypertensive Patients|Completed||Phase 4|49|Actual|Sanofi||2|||f||||||||||||||2018-06-01 01:19:03.626916|2018-06-01 01:19:03.626916
NCT00841867|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-11-16|2009-02-10|2009-02-11|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|Pilot OGTT||The Role of Pulsatile Insulin Secretion (A Study Investigating the Effects of Partial Pacreatectomy on Glucose Metabolism)|A Pilot Study Investigating the Effects of Partial Pancreatectomy on Glucose Tolerance|Completed|||24|Actual|University of California, Los Angeles|||2||f||||t||||||||||2018-06-01 01:19:03.700996|2018-06-01 01:19:03.700996
NCT00841854|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-12-04|2009-02-10|2009-02-11|Estimate|||||||2016-12-04|2016-12-06|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication|Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.|Completed||Phase 4|199|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 01:19:03.771754|2018-06-01 01:19:03.771754
NCT00841841|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2013-02-08|2009-02-10|2009-02-11|Estimate|||||||2013-02-08|2013-02-12|Estimate|March 2006||2006-03-31|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Dipyrone Versus Acetaminophen in the Control of Postoperative Pain|Dipyrone Versus Acetaminophen in the Control of Postoperative Pain|Completed||Phase 2|30|Actual|University Center of Araraquara||2|||f||||t||||||||||2018-06-01 01:19:03.859022|2018-06-01 01:19:03.859022
NCT00836589|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2017-02-16|2009-02-02|2009-02-04|Estimate|||||||2017-02-16|2017-02-20|Actual|December 2008||2008-12-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|GALAXY||Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)|GALAXY Registry: Long-term Evaluation of the Linox Family ICD Leads Registry|Completed|||1997|Actual|Biotronik, Inc.|||1||f||||f||||||||||2018-06-01 01:20:33.427489|2018-06-01 01:20:33.427489
NCT00841828|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2013-06-07|2009-02-10|2009-02-11|Estimate|||||||2013-06-07|2013-06-10|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients|A Phase II Randomised, Multicentre Compare Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Trastuzumab Versus Epirubicine and Cyclophosphamide Treatment Plus Docetaxel and Lapatinib in Women With Primary Resectable Breast Cancer or Locally Advanced Breast Cancer Positive Her 2.|Unknown status|Active, not recruiting|Phase 2/Phase 3|102|Anticipated|Spanish Breast Cancer Research Group||2|||f||||f||||||||||2018-06-01 01:19:03.941373|2018-06-01 01:19:03.941373
NCT00841815|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2009-05-06||2009-07-06|2009-02-09|2009-02-11|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|April 2003||2003-04-30|July 2009|2009-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Amlodipine 10 mg Tablets Under Fed Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Amlodipine 10 mg Tablets Versus Norvasc® 10 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:04.062462|2018-06-01 01:19:04.062462
NCT00841802|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2017-12-05|2009-02-10|2009-02-11|Estimate|||||||2017-12-05|2017-12-07|Actual|July 2008||2008-07-31|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Chronic Rhinosinusitis With or Without Nasal Polyps Steroid Study|Glucocorticosteroid Action in Inflammatory Disease|Active, not recruiting||Phase 4|50|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 01:19:04.312769|2018-06-01 01:19:04.312769
NCT00841789|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2018-04-16|2009-02-10|2009-02-11|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2009||2009-03-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|January 2018|Actual|2018-01-31||Interventional|||Etanercept in Kawasaki Disease|A Randomized, Double Blind, Placebo Controlled Study of the Effects of Etanercept in Children Presenting With Kawasaki Disease|Active, not recruiting||Phase 2|196|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||||2018-06-01 01:19:04.394607|2018-06-01 01:19:04.394607
NCT00841776|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2010-04-07||2017-05-24|2009-02-10|2009-02-11|Estimate|2010-06-29|2010-07-23|Estimate||||2017-05-24|2017-05-25|Actual|August 2007||2007-08-31|May 2017|2017-05-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne|Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Moderate to Moderately Severe Facial Acne Vulgaris|Completed||Phase 4|54|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:19:04.479658|2018-06-01 01:19:04.479658
NCT00841763|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2011-07-04||2013-01-18|2009-02-10|2009-02-11|Estimate|2012-12-11|2013-01-18|Estimate||||2013-01-18|2013-01-24|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|||Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects|A Phase III, Randomized, Controlled, Observer-blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted With MF59 (Fluad-H5N1) in Adult and Elderly Subjects|Completed||Phase 3|3647|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:19:05.936456|2018-06-01 01:19:05.936456
NCT00841750|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2011-07-19|2009-02-10|2009-02-11|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|NOTUBE||Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection|The NoTube Study: Evaluation of the Necessity of a Chest Tube After a Video-assisted Thoracoscopic Surgery Pulmonary Wedge Resection.|Unknown status|Recruiting|Phase 3|100|Anticipated|Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle||2|||f||||t||||||||||2018-06-01 01:19:07.158526|2018-06-01 01:19:07.158526
NCT00841737|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-08-05|2009-02-10|2009-02-11|Estimate|||||||2009-08-05|2009-08-06|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|April 2010|Anticipated|2010-04-30|July 2009|Actual|2009-07-31||Interventional|||Evaluation of a Psychoeducation Group Program for Mild/Moderate Depression|Evaluation of the Effectiveness and Efficiency of a Psychoeducational Group Sessions Intervention Program in the Depressive Episode Realized by Primary Health Care Center Nurses in Barcelona City.|Unknown status|Recruiting|N/A|192|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-06-01 01:19:07.242368|2018-06-01 01:19:07.242368
NCT00841724|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-05-15|2009-02-10|2009-02-11|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ITT 08-01||"Study of a Reduced-toxicity Submyeloablative Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies"|"Phase II Study of a Reduced-toxicity  Submyeloablative  Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies"|Completed||Phase 2|82|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-06-01 01:19:07.342724|2018-06-01 01:19:07.342724
NCT00841711|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-08-10|2009-02-10|2009-02-11|Estimate|||||||2016-08-10|2016-08-12|Estimate|September 2008||2008-09-30|August 2016|2016-08-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|||Transitions: Linkages From Jail To Community|Transitions: Linkages From Jail to Community|Completed||N/A|127|Actual|Yale University||1|||f||||f||||||||||2018-06-01 01:19:07.404078|2018-06-01 01:19:07.404078
NCT00841698|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2009-07-02||2009-09-09|2009-02-09|2009-02-11|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|October 2002||2002-10-31|September 2009|2009-09-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Paroxetine Hydrochloride 40 mg Film-Coated Tablets and Paxil® 40 mg Film-Coated Tablets Administered as 1 x 40 mg Film-Coated Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|50|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:07.478017|2018-06-01 01:19:07.478017
NCT00841685|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2014-12-04|2009-02-10|2009-02-11|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate|The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Ghent||5|||f||||f||||||||||2018-06-01 01:19:07.787799|2018-06-01 01:19:07.787799
NCT00841672|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2011-01-05||2011-07-05|2009-02-10|2009-02-11|Estimate|2011-05-26|2011-06-27|Estimate||||2011-07-05|2011-07-12|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension|An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients|Completed||Phase 3|485|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:19:07.875511|2018-06-01 01:19:07.875511
NCT00841659|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2009-07-02||2009-09-09|2009-02-09|2009-02-11|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|August 2002||2002-08-31|September 2009|2009-09-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Paroxetine Hydrochloride 40 mg Film-Coated Tablets and Paxil® 40 mg Film-Coated Tablets Administered as 1 x 40 mg Film-Coated Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:08.131236|2018-06-01 01:19:08.131236
NCT00841646|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-11-30|2009-02-10|2009-02-11|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2008||2008-12-31|December 2011|2011-12-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects|A Phase II, Open-label, Multi-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects|Completed||Phase 2|343|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:19:08.402437|2018-06-01 01:19:08.402437
NCT00841633|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2011-10-11|2009-02-10|2009-02-11|Estimate|||||||2011-10-11|2011-10-12|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study|Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study|Terminated||Phase 3|15|Actual|UMC Utrecht||2||"Our RCT recently started. The RCT is similar to the feasibility trial, so it was terminated to~   avoid 2 trials running simultaniously."|f||||f||||||||||2018-06-01 01:19:08.489264|2018-06-01 01:19:08.489264
NCT00841620|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2015-04-30|2009-02-10|2009-02-11|Estimate|||||||2015-04-30|2015-05-04|Estimate|September 1999||1999-09-30|April 2015|2015-04-30|April 2007|Actual|2007-04-30|January 2001|Actual|2001-01-31||Interventional|||Symptom Control 1-year After Circular Stapler Anopexy or Diathermy Excision for Prolapsed Haemorhoids|Symptom Control 1-year After Circular Stapler Anopey or Diathermy Excision for Prolapsed Haemorrhoids: an International Randomsed Trial (the STOPP-trial|Completed||Phase 4|207|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 01:19:08.55851|2018-06-01 01:19:08.55851
NCT00841607|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-10-17|2009-02-10|2009-02-11|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy|Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy|Completed||N/A|162|Actual|Tom Baker Cancer Centre||2|||f||||||||||||||2018-06-01 01:19:08.621747|2018-06-01 01:19:08.621747
NCT00841594|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2011-05-13|2009-02-10|2009-02-11|Estimate|||||||2011-05-13|2011-05-17|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison|MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects|Completed||Phase 1|12|Anticipated|MediQuest Therapeutics||2|||f||||f||||||||||2018-06-01 01:19:08.690823|2018-06-01 01:19:08.690823
NCT00841581|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2011-12-07|2009-02-09|2009-02-11|Estimate|||||||2011-12-07|2011-12-08|Estimate|December 2008||2008-12-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Lucentis to Treat Pigment Epithelial Detachment|Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED)|Completed||Phase 2|32|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-06-01 01:19:08.750362|2018-06-01 01:19:08.750362
NCT00841568|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2011-04-07|2009-02-10|2009-02-11|Estimate|||||||2011-04-07|2011-04-11|Estimate|April 2006||2006-04-30|April 2011|2011-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]|A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]|Completed||Phase 2|17|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:19:08.831413|2018-06-01 01:19:08.831413
NCT00841555|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2016-03-24||2018-04-16|2009-02-10|2009-02-11|Estimate|2016-03-24|2016-04-27|Estimate||||2018-04-16|2018-04-18|Actual|February 13, 2009|Actual|2009-02-13|April 2018|2018-04-30|November 25, 2014|Actual|2014-11-25|February 13, 2013|Actual|2013-02-13||Interventional||Glioblastoma multiforme (GBM) patients|Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma|A Phase I Trial of Hypofraction Radiotherapy + Temozolomide in the Treatment of Patients With Glioblastoma Multiforme and Anaplastic Astrocytoma of the Brain|Completed||Phase 1|9|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:19:09.025422|2018-06-01 01:19:09.025422
NCT00841542|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2009-05-06||2009-07-06|2009-02-09|2009-02-11|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|April 2003||2003-04-30|July 2009|2009-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Amlodipine 10 mg Tablets Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Amlodipine 10 mg Tablets Versus Norvasc® 10 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:09.486494|2018-06-01 01:19:09.486494
NCT00841529|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10||2012-10-01|2012-10-18|2009-02-10|2009-02-11|Estimate||||2012-10-18|2012-10-23|Estimate|2012-10-18|2012-10-23|Estimate|March 2009||2009-03-31|October 2012|2012-10-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Evaluation of the Cardioblate Closure Device in Facilitating Occlusion of the Left Atrial Appendage|Evaluation of the Cardioblate Closure Device in Facilitating Occlusion of the Left Atrial Appendage|Terminated||Phase 2|40|Actual|Medtronic Cardiovascular||||Medtronic Business Decision|f||||t||||||||||2018-06-01 01:19:09.820802|2018-06-01 01:19:09.820802
NCT00841516|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2013-11-07|2009-02-10|2009-02-11|Estimate|||||||2013-11-07|2013-11-08|Estimate|December 2007||2007-12-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|April 2011|Actual|2011-04-30||Interventional|||Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for the Immunological and Histological Evaluation of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v1-FV|Completed||Phase 2|14|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 01:19:09.891924|2018-06-01 01:19:09.891924
NCT00841490|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2017-04-12|2009-02-10|2009-02-11|Estimate|||||||2017-04-12|2017-04-14|Actual|September 2008||2008-09-30|December 2016|2016-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults|Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults|Completed|||220|Actual|University of Louisville|||2||f||||t||||||Samples With DNA|"~     Samples of dental plaque.~   "|No||2018-06-01 01:19:10.061256|2018-06-01 01:19:10.061256
NCT00841477|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2017-01-10|2009-02-10|2009-02-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2004||2004-01-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|June 2007|Actual|2007-06-30||Interventional|||An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users|An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users|Completed||Phase 3|1260|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||t||||||||||2018-06-01 01:19:10.12442|2018-06-01 01:19:10.12442
NCT00841464|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-07-09|2009-02-10|2009-02-11|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|||||Observational|||Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease|Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease|Completed|||20|Actual|Parkinson's Disease Research, Education, and Clinical Center, Philadelphia|||||f||||f||||||||||2018-06-01 01:19:10.216425|2018-06-01 01:19:10.216425
NCT00841451|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-03-22|2009-02-10|2009-02-11|Estimate|||||||2016-03-22|2016-03-23|Estimate||||March 2016|2016-03-31||||||||Expanded Access|PUFA||Pulmonary Vein Isolation Outcomes With Fish Oils|Pulmonary Vein Isolation Outcomes With Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid (DHA)|No longer available|||||St. Luke's-Roosevelt Hospital Center|||||f||||||||||||||2018-06-01 01:19:10.274108|2018-06-01 01:19:10.274108
NCT00841438|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2010-05-03|2009-02-10|2009-02-11|Estimate|||||||2010-05-03|2010-05-04|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ECLAT-STEMI||Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction|Efficacy of Clotinab in Acute Myocardial Infarction Trial- ST Elevation Myocardial Infarction|Completed||Phase 4|786|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 01:19:10.337757|2018-06-01 01:19:10.337757
NCT00841425|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-23|2009-02-10|2009-02-11|Estimate|||||||2009-02-23|2009-02-24|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|June 2009|Anticipated|2009-06-30||Observational|||Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study|Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study|Unknown status|Recruiting||33|Anticipated|Bispebjerg Hospital|||1||f||||||||||Samples Without DNA|"~     Blood (serum, whole blood) Exhaled breath condensate Induced sputum~   "|||2018-06-01 01:19:10.459895|2018-06-01 01:19:10.459895
NCT00841412|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2014-10-28||2015-04-06|2009-02-09|2009-02-11|Estimate|2014-10-28|2014-11-10|Estimate||||2015-04-06|2015-04-27|Estimate|February 2009||2009-02-28|October 2014|2014-10-31|September 2013|Actual|2013-09-30|October 2011|Actual|2011-10-31||Interventional||200 long-stay veterans completed baseline assessments.|Prevention of Weight Loss in Long Term Care Veterans|Prevention of Weight Loss in Long-Term Care Veterans|Completed||N/A|222|Actual|VA Office of Research and Development|This study was conducted in only two VA facilities in one geographic region with predominately White, male residents. All study results have been published in a series of papers.|2|||f||||t||||||||||2018-06-01 01:19:10.546018|2018-06-01 01:19:10.546018
NCT00841399|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2014-06-02|2009-02-10|2009-02-11|Estimate|||||||2014-06-02|2014-06-03|Estimate|July 2001||2001-07-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients|Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies|Completed||Phase 1/Phase 2|100|Actual|Walter Reed Army Medical Center||2|||f||||f||||||||||2018-06-01 01:19:10.715369|2018-06-01 01:19:10.715369
NCT00841386|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-10|2009-02-10|2009-02-11|Estimate|||||||2009-02-10|2009-02-11|Estimate|September 2008||2008-09-30|January 2009|2009-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Treatment of Keratoconus Using Collagen Cross-Linking|Treatment of Keratoconus Using Collagen Cross-Linking By Means of Topical Riboflavin and UV Light.|Unknown status|Recruiting|Phase 2/Phase 3|150|Anticipated|University at Buffalo||2|||f||||f||||||||||2018-06-01 01:19:10.801215|2018-06-01 01:19:10.801215
NCT00841373|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2014-11-17|2009-02-10|2009-02-11|Estimate|||||||2014-11-17|2014-11-19|Estimate|July 2007||2007-07-31|November 2014|2014-11-30|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|||Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease|Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease|Completed||Phase 1/Phase 2|1|Actual|Southern New England Retina Associates||2|||f||||t||||||||||2018-06-01 01:19:10.916489|2018-06-01 01:19:10.916489
NCT00841360|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2017-02-27|2009-02-09|2009-02-11|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2009||2009-01-31|February 2016|2016-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||ID and Testing Via Friendship Networks|A Pilot Study to Identify Undiagnosed Asymptomatic HIV Infections in Adolescent and Young Adult Women|Completed|||535|Actual|University of North Carolina, Chapel Hill|||4||f||||t||||||||||2018-06-01 01:19:10.99336|2018-06-01 01:19:10.99336
NCT00841347|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2017-08-02|2009-02-10|2009-02-11|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2009||2009-02-28|August 2017|2017-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Sleep and Obesity in Teenagers|Sleep and Obesity in Teenagers: Impact of Sleep Length and Quality on Obesity and Diabetes Risks in Teenagers.|Completed||N/A|41|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-06-01 01:19:11.060702|2018-06-01 01:19:11.060702
NCT00841334|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2013-01-22|2009-02-09|2009-02-11|Estimate|||||||2013-01-22|2013-01-24|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|May 2010|Actual|2010-05-31||Interventional|ACTION||Adolescents Committed to Nutrition and Physical Activity|Adolescents Committed to Improvement of Nutrition and Physical Activity (ACTION)|Completed||Phase 1/Phase 2|145|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 01:19:11.126542|2018-06-01 01:19:11.126542
NCT00841321|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2013-10-22||2014-05-23|2009-02-09|2009-02-11|Estimate|2014-04-03|2014-05-05|Estimate||||2014-05-23|2014-06-06|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional||Based on pilot data (compliance of 80%,dropout rate of 20%) the estimated sample size needed to power the study was 158 enrolled to yield 110 with complete observations. In this study, enrollment was stopped at 121 participants with more than 110 subjects completing the study (dropout rate less than 5%).|Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis|Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis|Completed||Phase 2|120|Actual|VA Office of Research and Development|Limitations include underrepresentation of minorities. Subjects overall had mild impairment.|2|||f||||t||||||||||2018-06-01 01:19:11.19849|2018-06-01 01:19:11.19849
NCT00841308|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-05-24|2009-02-10|2009-02-11|Estimate|||||||2012-05-24|2012-05-25|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|HBP10||Home Blood Pressure in Hypertension Management|Antihypertensive Drug Treatment Decisions Based on Home Blood Pressure Monitoring|Unknown status|Recruiting|Phase 4|150|Anticipated|University of Athens||2|||f||||f||||||||||2018-06-01 01:19:11.666475|2018-06-01 01:19:11.666475
NCT00841295|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2017-05-03|2009-02-10|2009-02-11|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2008||2008-07-31|May 2017|2017-05-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|CarniPrema||Effects of Parenteral L-carnitine Supplementation in Premature Neonates|Effects of Parenteral L-carnitine Supplementation in Premature Neonates|Completed||N/A|53|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-06-01 01:19:11.751987|2018-06-01 01:19:11.751987
NCT00841282|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-10|2009-02-10|2009-02-11|Estimate|||||||2009-02-10|2009-02-11|Estimate|October 2008||2008-10-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||RCT of Air Insufflation Versus Water Infusion Colonoscopy by Supervised Trainees|Comparison of Study Versus Conventional Method for Performing Colonoscopy by Supervised Trainees for Colorectal Cancer Screening and Surveillance|Completed||N/A|62|Actual|East Bay Institute for Research and Education||2|||f||||t||||||||||2018-06-01 01:19:11.823278|2018-06-01 01:19:11.823278
NCT00841269|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2014-12-10||2018-02-26|2009-02-09|2009-02-11|Estimate|2015-01-06|2015-01-08|Estimate||||2018-02-26|2018-03-26|Estimate|May 2009||2009-05-31|February 2018|2018-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Oral Uridine for Treatment of Bipolar Depression in Adolescents|Oral Administration of Uridine for Treatment of Bipolar Depression in Adolescents: A Magnetic Resonance Spectroscopy Study|Completed||Phase 2|42|Actual|University of Utah|Limited sample size and small percentage of underrepresented racial/ethnic minority participants.|2|||f||||t||||||||||2018-06-01 01:19:11.974514|2018-06-01 01:19:11.974514
NCT00841256|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2015-10-15|2009-02-10|2009-02-11|Estimate|||||||2015-10-15|2015-10-16|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|August 2015|Actual|2015-08-31|June 2012|Actual|2012-06-30||Interventional|||Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children|... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo|Completed||Phase 3|207|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 01:19:12.288355|2018-06-01 01:19:12.288355
NCT00841243|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-10|2009-02-10|2009-02-11|Estimate|||||||2009-02-10|2009-02-11|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|March 2010|Anticipated|2010-03-31||Interventional|||Nutritional Support During Antiviral Therapy for Hepatitis C|The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-06-01 01:19:12.391547|2018-06-01 01:19:12.391547
NCT00841230|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2009-08-10|2009-02-10|2009-02-11|Estimate|||||||2009-08-10|2009-08-11|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Deanxit and Rivotril in Tinnitus Patients|Additional Value of Deanxit in Tinnitus Patients Treated With Rivotril|Completed||Phase 4|50|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||||2018-06-01 01:19:12.465855|2018-06-01 01:19:12.465855
NCT00841217|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-10|2009-02-10|2009-02-11|Estimate|||||||2009-02-10|2009-02-11|Estimate|April 2003||2003-04-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|August 2005|Actual|2005-08-31||Interventional|||Regulation of Lipoprotein Transport in Metabolic Syndrome|Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome|Completed||Phase 4|13|Actual|The University of Western Australia||2|||f||||f||||||||||2018-06-01 01:19:12.541199|2018-06-01 01:19:12.541199
NCT00841204|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2012-02-14||2017-11-30|2009-02-10|2009-02-11|Estimate|2012-02-14|2012-03-16|Estimate||||2017-11-30|2017-12-26|Actual|February 2009||2009-02-28|November 2017|2017-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma|Phase II Trial of Sulindac in Individuals at Increased Risk for Melanoma|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:19:12.625878|2018-06-01 01:19:12.625878
NCT00841191|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2014-05-13|2009-02-09|2009-02-11|Estimate|||||||2014-05-13|2014-05-14|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors|A Phase 1/2, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-Interleukin 6 (IL-6) Monoclonal Antibody, in Subjects With Solid Tumors|Completed||Phase 1/Phase 2|84|Actual|Centocor, Inc.||7|||f||||t||||||||||2018-06-01 01:19:13.037604|2018-06-01 01:19:13.037604
NCT00841178|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2014-12-02|2009-02-10|2009-02-11|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2005||2005-10-31|December 2014|2014-12-31||||August 2011|Actual|2011-08-31||Interventional|||Endovenous Laser Therapy (EVLT) for Sapheno-Popliteal Incompetence and Short Saphenous Vein (SSV) Reflux: A RCT|A Randomised Controlled Trial of the Clinical and Cost Effectiveness of Endovenous Laser Therapy in the Treatment of Varicose Veins Secondary to Isolated Sapheno-Popliteal Incompetence and Short Saphenous Reflux|Unknown status|Active, not recruiting|N/A|106|Anticipated|University of Hull||2|||f||||f||||||||||2018-06-01 01:19:13.170291|2018-06-01 01:19:13.170291
NCT00841165|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2010-04-01|2009-02-10|2009-02-11|Estimate|||||||2010-04-01|2010-04-02|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|COMET||Carbon Monoxide Monitoring and Emergency Treatment|Randomized Trial of Carbon Monoxide Elimination Kinetics With Oxygen Delivered by Continuous Positive Airway Pressure Compared to Face Mask|Unknown status|Recruiting|N/A|40|Anticipated|University of Vermont||2|||f||||t||||||||||2018-06-01 01:19:13.239409|2018-06-01 01:19:13.239409
NCT00841152|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2017-02-10|2009-02-10|2009-02-11|Estimate|||||||2017-02-10|2017-02-13|Actual|March 2009|Actual|2009-03-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|February 2014|Actual|2014-02-28||Observational|BAGvsTCP||Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute|A National, Prospective, Randomized, Multicenter, Controlled Head-to-Head Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute in Filling of Contained Bone Defects|Active, not recruiting|||120|Actual|Turku University Hospital|||2||f||||f||||||||||2018-06-01 01:19:13.321138|2018-06-01 01:19:13.321138
NCT00841139|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2011-11-25|2009-02-10|2009-02-11|Estimate|||||||2011-11-25|2011-11-29|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Metabolic Manipulation in Chronic Heart Failure|Metabolic Manipulation in Chronic Heart Failure|Completed||Phase 2|50|Actual|University Hospital Birmingham NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 01:19:13.418089|2018-06-01 01:19:13.418089
NCT00841126|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2010-10-18|2009-02-10|2009-02-11|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2009||2009-07-31|October 2010|2010-10-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate|An Open, Randomized, Controlled, Parallel Group, Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate Together With a Randomized Placebo Controlled Double Blind Fermagate Comparison in Hemodialysis Patients With Hyperphosphatemia|Terminated||Phase 3|657|Anticipated|Ineos Healthcare Limited||3|||f||||t||||||||||2018-06-01 01:19:13.505198|2018-06-01 01:19:13.505198
NCT00841113|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-02-10|2009-02-10|2009-02-11|Estimate|||||||2009-02-10|2009-02-11|Estimate|January 1999||1999-01-31|February 2009|2009-02-28|February 2003|Actual|2003-02-28|February 2001|Actual|2001-02-28||Interventional|||Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer|Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.|Completed||Phase 3|177|Actual|Speciality European Pharma Limited||2|||f||||f||||||||||2018-06-01 01:19:13.776319|2018-06-01 01:19:13.776319
NCT00841100|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-03-10|2009-02-10|2009-02-11|Estimate|||||||2009-03-10|2009-03-12|Estimate|December 2008||2008-12-31|February 2009|2009-02-28|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response|Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response|Unknown status|Recruiting|N/A|20|Anticipated|University of Miami||1|||f||||t||||||||||2018-06-01 01:19:13.839444|2018-06-01 01:19:13.839444
NCT00841087|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2015-10-16|2009-11-09|2017-01-19|2009-02-10|2009-02-11|Estimate|2015-10-16|2015-11-16|Estimate|2009-11-09|2009-11-11|Estimate|2017-01-19|2017-03-03|Actual|January 2009||2009-01-31|January 2017|2017-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes|A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIBA Once Daily + NovoRapid® Compared to Insulin Detemir Once Daily + NovoRapid®, All in a Basal-bolus Regimen in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 2|65|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:19:13.939872|2018-06-01 01:19:13.939872
NCT00841074|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2017-04-12|2009-02-10|2009-02-11|Estimate|||||||2017-04-12|2017-04-14|Actual|January 2006||2006-01-31|December 2016|2016-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Chlorhexidine & Pneumonia in Nursing Home Residents|Effect of Topical Oral Chlorhexidine in Reducing Pneumonia in Nursing Home Residents|Completed||Phase 1|75|Actual|University of Louisville||2|||f||||t||||||||||2018-06-01 01:19:14.25884|2018-06-01 01:19:14.25884
NCT00841061|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-11|Estimate|||||||2009-02-09|2009-02-11|Estimate|July 2003||2003-07-31|January 2009|2009-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|Bfe03B||Cereals as a Source of Iron for Breastfed Infants|Breast Feeding and Iron: Comparison of Cereals Fortified With Different Forms of Iron|Completed||N/A|111|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-06-01 01:19:14.323084|2018-06-01 01:19:14.323084
NCT00841048|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2009-09-29|2009-02-10|2009-02-11|Estimate|||||||2009-09-29|2009-09-30|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|May 2009|Actual|2009-05-31|||||Interventional|MAD||Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses|A Randomised, Single-blind, Placebo-controlled, Single Centre, Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses|Completed||Phase 1|107|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:19:14.377294|2018-06-01 01:19:14.377294
NCT00841035|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2013-07-03||2017-04-17|2009-02-10|2009-02-11|Estimate|2014-09-29|2014-10-06|Estimate||||2017-04-17|2017-05-19|Actual|February 2009||2009-02-28|April 2017|2017-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients|University of Alabama at Birmingham(UAB 0808), A Phase II Study of Short-course Preoperative Erlotinib Followed by Post-operative Erlotinib-gemcitabine in Patients With Resectable Pancreatic Adenocarcinoma|Terminated||Phase 2|6|Actual|University of Alabama at Birmingham|Early termination by sponsor and No good clinical data was analyzed to the early termination of the study.|1||Sponsor stopped due to slow enrollment|f||||t||||||||||2018-06-01 01:19:14.439116|2018-06-01 01:19:14.439116
NCT00841022|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2013-10-22|2009-02-10|2009-02-11|Estimate|||||||2013-10-22|2013-10-23|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Information and Anaesthesia in Paediatrics|Effects of Comics on Anaesthesia's Anxiety in Paediatrics: A Randomized Controlled Trial|Completed||N/A|115|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 01:19:14.577052|2018-06-01 01:19:14.577052
NCT00841009|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2016-05-03|2009-02-10|2009-02-11|Estimate|||||||2016-05-03|2016-05-04|Estimate|July 2005||2005-07-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|May 2012|Actual|2012-05-31||Observational|||Effect of Gastric Bypass-induced Weight Loss on Myocardial Structure, Function and Metabolism|Effect of Gastric Bypass-induced Weight Loss on Myocardial Structure, Function and Metabolism|Completed|||18|Actual|Washington University School of Medicine|||||f||||f||||||Samples With DNA|"~     2 tubes of blood (1 tablespoon total) will be collected (with permission), tested and stored~     for a length of time~   "|||2018-06-01 01:19:14.64109|2018-06-01 01:19:14.64109
NCT00840996|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|2016-06-27||2016-10-31|2009-02-10|2009-02-11|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery|Effect of Perioperative Intravenous Lidocaine Administration or Epidural Anesthesia on Postoperative Outcomes in Complex Spine Surgery|Completed||N/A|116|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 01:19:14.712844|2018-06-01 01:19:14.712844
NCT00840983|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2015-11-27|2009-02-10|2009-02-11|Estimate|||||||2015-11-27|2015-11-30|Estimate|August 2003||2003-08-31|November 2015|2015-11-30|December 2006|Actual|2006-12-31|November 2005|Actual|2005-11-30||Interventional|||Effects of Delayed Cord Clamping in Very Low Birth Weight Infants|Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants|Completed||Phase 1|72|Actual|University of Rhode Island||2|||f||||t||||||||||2018-06-01 01:19:15.002106|2018-06-01 01:19:15.002106
NCT00840970|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2015-03-25|2009-02-10|2009-02-11|Estimate|||||||2015-03-25|2015-03-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:19:15.073905|2018-06-01 01:19:15.073905
NCT00840957|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2015-04-08|2009-02-10|2009-02-11|Estimate|||||||2015-04-08|2015-04-09|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|FAKIR||Pharmaco Kinetic Variability of Infliximab in Rheumatoid Arthritis|Pharmaco Kinetic and Pharmacokinetic-Pharmacodynamic Variability of Infliximab|Completed|||84|Actual|University Hospital, Tours|||1||f||||f||||||Samples With DNA|"~     whole blood and serum~   "|||2018-06-01 01:19:15.106633|2018-06-01 01:19:15.106633
NCT00840944|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2017-11-29|2009-02-10|2009-02-11|Estimate|||||||2017-11-29|2017-11-30|Actual|January 2008||2008-01-31|November 2017|2017-11-30|April 2023|Anticipated|2023-04-30|January 2023|Anticipated|2023-01-31||Interventional|ZomaTrip||A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height|Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height.|Active, not recruiting||Phase 4|44|Actual|Belgian Study Group for Pediatric Endocrinology||1|||f||||f||||||||||2018-06-01 01:19:15.172225|2018-06-01 01:19:15.172225
NCT00840931|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2018-04-30|2009-02-10|2009-02-11|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2, 2009|Actual|2009-02-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|February 17, 2014|Actual|2014-02-17||Interventional|||Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)|"A Phase I Pilot Study of Immunotherapy Using Lenalidomide Plus Bystander Vaccine in Patients With High-Risk Myelodysplastic Syndrome (MDS)"|Active, not recruiting||Phase 1|22|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 01:19:15.254022|2018-06-01 01:19:15.254022
NCT00840918|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2018-03-09|2009-02-10|2009-02-11|Estimate|||||||2018-03-09|2018-03-12|Actual|February 2009||2009-02-28|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Intravenous Lidocaine and Postoperative Outcomes After Cardiac Surgery|The Effect of Perioperative Intravenous Lidocaine on Postoperative Outcomes After Cardiac Surgery|Recruiting||N/A|1294|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 01:19:15.340522|2018-06-01 01:19:15.340522
NCT00840905|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2012-11-06|2009-02-10|2009-02-11|Estimate|||||||2012-11-06|2012-11-07|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Observational|||A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil|A Pilot Observational Study to Determine the Prevalence of HPV Serology in HIV Seropositive Women From Subsaharan Africa and Brasil|Completed|||487|Actual|University of Witwatersrand, South Africa|||3||f||||f||||||None Retained|"~     Blood /plasma specimen 10cc~   "|||2018-06-01 01:19:15.417361|2018-06-01 01:19:15.417361
NCT00840892|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-10|||2018-02-16|2009-02-10|2009-02-11|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2002||2002-01-31|February 2009|2009-02-28|March 2007|Actual|2007-03-31|||||Interventional|||(Cost-)Effectiveness Interdisciplinary Community-based COPD Management Program (INTERCOM)|Randomized Controlled Trial to Establish the (Cost-)Effectiveness of an Interdisciplinary Community-based COPD Management Program Relative to Usual Care.|Completed||N/A|199|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-06-01 01:19:15.478939|2018-06-01 01:19:15.478939
NCT00840879|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-30||2009-09-01|2009-02-06|2009-02-10|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Meloxicam 15 mg Tablets Under Non-Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Meloxicam 15 mg Tablets Versus Mobic® 15 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:15.551831|2018-06-01 01:19:15.551831
NCT00840866|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-18||2009-08-14|2009-02-06|2009-02-10|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Cefprozil 500 mg Tablets Under Fed Conditions|A Relative Bioavailability Study of Cefprozil 500 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|39|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:15.809976|2018-06-01 01:19:15.809976
NCT00840853|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2017-08-24|2009-02-09|2009-02-10|Estimate|||||||2017-08-24|2017-08-25|Actual|April 2009||2009-04-30|August 2017|2017-08-31|April 2031|Anticipated|2031-04-30|April 2016|Actual|2016-04-30||Interventional|MULTIPRAT||Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT|Phase I Study of the Administration of Multi-Virus-Specific Cytotoxic T Lymphocytes Expressing CD19 Chimeric Receptors for Prophylaxis or Therapy of Relapse of CD19 Positive Malignancies Post Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 1|68|Anticipated|Baylor College of Medicine||4|||f||||t||||||||||2018-06-01 01:19:16.056342|2018-06-01 01:19:16.056342
NCT00840840|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-05-18||2009-07-08|2009-02-09|2009-02-10|Estimate|2009-07-08|2009-08-25|Estimate||||2009-07-08|2009-08-25|Estimate|August 2002||2002-08-31|July 2009|2009-07-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions|An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects, Under Fed Conditions|Completed||Phase 1|48|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:16.128219|2018-06-01 01:19:16.128219
NCT00840827|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2011-03-08|2009-02-06|2009-02-10|Estimate|||||||2011-03-08|2011-03-10|Estimate|December 2008||2008-12-31|March 2011|2011-03-31||||December 2010|Actual|2010-12-31||Interventional|||Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes|A Single-Arm, Open-Label Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes|Completed||Phase 2|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 01:19:16.37609|2018-06-01 01:19:16.37609
NCT00840814|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|||2017-04-06|2009-02-07|2009-02-10|Estimate|||||||2017-04-06|2017-04-07|Actual|May 2008||2008-05-31|April 2017|2017-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Developing a Checklist of Lymphedema Symptoms in Patients With Head and Neck Cancer|Development of a Lymphedema Symptom Checklist in Head and Neck Cancer Patients|Completed|||55|Actual|Vanderbilt University|||||f||||||||||||||2018-06-01 01:19:16.440413|2018-06-01 01:19:16.440413
NCT00840801|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2015-05-20|2009-02-09|2009-02-10|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|August 2010|Actual|2010-08-31|May 2009|Actual|2009-05-31||Interventional|||Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children|Single-blind, Randomized, Phase 3B Study in Children Aged 1 - 11 Years to Investigate the Immunogenicity, Safety and Interchangeability of Two Tick-borne Encephalitis (Tbe) Vaccines Administered According to a Conventional Schedule|Completed||Phase 3|302|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 01:19:16.495328|2018-06-01 01:19:16.495328
NCT00840788|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|May 2005||2005-05-31|February 2009|2009-02-28|January 2007|Actual|2007-01-31|May 2006|Actual|2006-05-31||Interventional|||Comparison of Adhesive Glue With Skin Suture for Repair of Episiotomy|Skin Adhesive Versus Subcuticular Suture for Perineal Skin Repair After Episiotomy - a Randomized Controlled Trial.|Completed||N/A|100|Actual|Hospital Sao Joao||2|||f||||f||||||||||2018-06-01 01:19:16.643154|2018-06-01 01:19:16.643154
NCT00840775|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2018-03-25|2009-02-09|2009-02-10|Estimate|||||||2018-03-25|2018-03-27|Actual|April 2009||2009-04-30|March 2018|2018-03-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||PIONIR Study (Presillion™ and Presillion™ Plus Stent Systems)|Clinical Protocol Presillion™ and Presillion™ Plus Stent Systems|Completed||Phase 4|278|Actual|Medinol Ltd.||1|||f||||f||||||||||2018-06-01 01:19:16.717435|2018-06-01 01:19:16.717435
NCT00840762|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2010-01-25|2009-02-09|2009-02-10|Estimate|||||||2010-01-25|2010-01-26|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|July 2012|Anticipated|2012-07-31|February 2012|Anticipated|2012-02-29||Interventional|||A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication|A Randomized Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication|Unknown status|Recruiting|Phase 4|756|Anticipated|Ruth M. Rothstein CORE Center||2|||f||||f||||||||||2018-06-01 01:19:16.802044|2018-06-01 01:19:16.802044
NCT00840749|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|||2013-04-05|2009-02-09|2009-02-10|Estimate|||||||2013-04-05|2013-04-08|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|STARS||Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer|International Randomized Study to Compare CyberKnife® Stereotactic Radiotherapy With Surgical Resection in Stage I Non-small Cell Lung Cancer|Terminated||Phase 3|36|Actual|Accuray Incorporated||2||Lack of enrollment|f||||t||||||||||2018-06-01 01:19:16.912086|2018-06-01 01:19:16.912086
NCT00840736|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||LAGB Versus VBG: 7-Year Results|Laparoscopic Adjustable Gastric Banding Versus Open Vertical Banded Gastroplasty: 7-Year Results of a Prospective Randomized Trial|Completed||N/A|100|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:19:17.084032|2018-06-01 01:19:17.084032
NCT00840723|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2013-09-03|2009-02-09|2009-02-10|Estimate|||||||2013-09-03|2013-09-05|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|SCCOR Bronch||Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects|Bronchoscopy-Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects|Completed|||30|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     Whole blood, Bronchial Lavage Fluid (BALF), cytology brushings~   "|||2018-06-01 01:19:17.164113|2018-06-01 01:19:17.164113
NCT00840710|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2009-12-27|2009-02-09|2009-02-10|Estimate|||||||2009-12-27|2009-12-29|Estimate|February 2010||2010-02-28|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|||||Observational|BT||Clinical Feasibility of Birth- Track II System|Clinical Feasibility of Birth- Track II System|Unknown status|Not yet recruiting||15|Anticipated|Barnev Ltd|||||f||||f||||||||||2018-06-01 01:19:17.234294|2018-06-01 01:19:17.234294
NCT00840697|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2011-06-24|2009-02-09|2009-02-10|Estimate|||||||2011-06-24|2011-06-27|Estimate|August 2009||2009-08-31|May 2011|2011-05-31|August 2013|Anticipated|2013-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Effect of Interventions in Return to Work for Patients With Neck and Low Back Pain|Facilitating and Inhibiting Factors and Effect of Interventions in Return to Work for Patients With Neck and Low Back Pain|Unknown status|Recruiting|N/A|400|Anticipated|Oslo University Hospital||3|||f||||t||||||||||2018-06-01 01:19:17.303399|2018-06-01 01:19:17.303399
NCT00840684|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|||2011-05-12|2009-02-07|2009-02-10|Estimate|||||||2011-05-12|2011-05-13|Estimate|January 2009||2009-01-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia|A PHASE I-II MULTICENTER STUDY OF THE CLORETAZINE-DAUNORUBICIN-ARACYTINE COMBINATION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH UNFAVORABLE CYTOGENETICS|Completed||Phase 1/Phase 2|135|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:19:17.402277|2018-06-01 01:19:17.402277
NCT00840671|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2010-12-27|2009-02-09|2009-02-10|Estimate|||||||2010-12-27|2010-12-28|Estimate|October 2005||2005-10-31|December 2010|2010-12-31|July 2008|Actual|2008-07-31|March 2008|Actual|2008-03-31||Interventional|CERE-LYSE-1||Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke|A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke|Completed||Phase 3|119|Actual|Ever Neuro Pharma GmbH||2|||f||||f||||||||||2018-06-01 01:19:17.496773|2018-06-01 01:19:17.496773
NCT00840658|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|2012-07-02||2014-12-05|2009-02-09|2009-02-10|Estimate|2012-08-18|2012-09-18|Estimate||||2014-12-05|2014-12-24|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|FSW-IDU||Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico|Epidemiologic Study on Changing HIV Risks Among FSW-IDUs on the Mexico-US Border|Completed||Phase 2|584|Actual|University of California, San Diego|Observed important site differences at enrollment need to be considered in outcome analysis.|4|||f||||t||||||||||2018-06-01 01:19:17.631035|2018-06-01 01:19:17.631035
NCT00840645|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2016-01-04|2009-02-08|2009-02-10|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients|Long-term Study of YM178: Long Term Study of YM178 in Subjects With Overactive Bladder|Completed||Phase 3|204|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-06-01 01:19:17.917607|2018-06-01 01:19:17.917607
NCT00840632|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-07-06||2009-07-06|2009-02-06|2009-02-10|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|October 2004||2004-10-31|July 2009|2009-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Trandolapril 4 mg Tablet Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Trandolapril 4 mg Tablets Versus Mavik® 4 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:18.010313|2018-06-01 01:19:18.010313
NCT00840619|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:19:18.333222|2018-06-01 01:19:18.333222
NCT00840606|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|December 2001||2001-12-31|February 2009|2009-02-28|April 2002|Actual|2002-04-30|December 2001|Actual|2001-12-31||Interventional|||Buspirone Hydrochloride 30mg Tablets, Fasting|A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Fasting Conditions|Completed||Phase 1|70|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:18.362616|2018-06-01 01:19:18.362616
NCT00840593|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2011-12-07|2009-02-09|2009-02-10|Estimate|||||||2011-12-07|2011-12-08|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||A Prospective, Randomised Long-term Follow-up of Operative Versus Non-operative Treatment of Gr. 3 Acromioclavicular Dislocation|A Prospective, Randomised 18 -Year Follow-up Study of Operative and Non-operative Treatment of Acute, Total Acromioclavicular Dislocation.|Completed||N/A|39|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 01:19:18.420329|2018-06-01 01:19:18.420329
NCT00840580|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2012-07-19|2009-02-09|2009-02-10|Estimate|||||||2012-07-19|2012-07-23|Estimate|January 2009||2009-01-31|July 2012|2012-07-31||||September 2009|Actual|2009-09-30||Interventional|||Effect on Wound Healing of Vigamox Versus Cravit|Prospective, Randomized Study Comparing Effect on Wound Healing of Vigamox (Moxifloxacin 0.5% Ophthalmic Solution) and Cravit (Levofloxacin 0.5% Ophthalmic Solution) Administered Post-Surgically in Patients Undergoing Cataract Extraction|Completed||Phase 4|79|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:19:18.489316|2018-06-01 01:19:18.489316
NCT00840567|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2013-07-09|2009-02-09|2009-02-10|Estimate|||||||2013-07-09|2013-07-11|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Skin and Blood Research Samples From Healthy Volunteers and Patients With Hematologic Diseases|Acquisition of Skin Biopsies and Blood Samples From Normal Volunteers and Patients With Benign, Inherited Hematologic Diseases for Research Purposes|Terminated||N/A|7|Actual|Washington University School of Medicine||2||"Key samples protocols will be provided by a collaborator and we were not able to produce IPS~   lines from human fibroblasts."|f||||f||||||||||2018-06-01 01:19:18.559029|2018-06-01 01:19:18.559029
NCT00840554|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-07-10|2009-02-09|2009-02-10|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effects of Adding a Home Exercise Program to a Clinical Physical Therapy Program on Cancer-Related Fatigue|The Effects of Adding a Home Exercise Program (HEP) to a Clinical Physical Therapy Program (CPTP) on the Cancer-Related Fatigue Reported by Patients Undergoing Concurrent Radiation and Chemotherapy for High-Grade Glioma (HGG)|Completed||N/A|20|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 01:19:18.626157|2018-06-01 01:19:18.626157
NCT00840541|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2014-04-04|2009-02-09|2009-02-10|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2010|Actual|2010-01-31||Observational|||Phenotyping Diabetic Retinopathy|Observational Study of Type-2 Diabetic Subjects to Validate Diabetic Retinopathy Phenotypes|Completed|||80|Actual|Association for Innovation and Biomedical Research on Light and Image|||1||f||||f||||||||||2018-06-01 01:19:18.690756|2018-06-01 01:19:18.690756
NCT00840528|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2017-09-20|2009-02-06|2009-02-10|Estimate|||||||2017-09-20|2017-09-25|Actual|February 2002||2002-02-28|September 2017|2017-09-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|GARBOZ||Genetic Susceptibility TO Ozone-induced Airway Inflammation in Humans|Genetic Susceptibility TO Ozone-induced Bronchial Airway Inflammatory Responses In Humans|Completed||N/A|84|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 01:19:18.743243|2018-06-01 01:19:18.743243
NCT00840515|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|||2009-05-05|2009-02-09|2009-02-10|Estimate|||||||2009-05-05|2009-05-06|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Observational|||PraevoSkin Emulsion in the Prevention of Radiation Induced Dermatitis|A Phase 2,Double Blind Randomized Study of PraevoSkin,a Melatonin Containing Emulsion, in the Prevention of Radiation Induced Dermatitis.|Unknown status|Active, not recruiting||1|Anticipated|Pharm Olam Pharmaceuticals Ltd.|||1||f||||f||||||||||2018-06-01 01:19:18.884823|2018-06-01 01:19:18.884823
NCT00840502|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2016-02-12|2009-02-09|2009-02-10|Estimate|||||||2016-02-12|2016-02-15|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Observational|UPS||Ultrasound Study in Pregnant Women With Malaria|Impact of Malaria Infection in Pregnancy on Fetal and Newborn Growth|Recruiting|||400|Anticipated|University of Oxford|||1||f||||f||||||||||2018-06-01 01:19:18.932518|2018-06-01 01:19:18.932518
NCT00840489|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2013-01-30|2009-02-09|2009-02-10|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RIBACIR||Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis|Phase II Trial of Long-term Monotherapy With Ribavirin Against Colchicine on Progression of Chronic Hepatitis C With Advanced Fibrosis in Patients With Non-response to Standard Antiviral Therapy|Terminated||Phase 2|50|Actual|Hospital Universitario Ramon y Cajal||2||Preliminary analysis|f||||f||||||||||2018-06-01 01:19:19.000232|2018-06-01 01:19:19.000232
NCT00840476|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-30||2009-09-01|2009-02-06|2009-02-10|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-15|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Meloxicam 15 mg Tablets Under Fasting Conditions|A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Meloxicam 15 mg Tablets Versus Mobic® 15 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:19.091204|2018-06-01 01:19:19.091204
NCT00840463|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2015-06-10|2009-02-09|2009-02-10|Estimate|||||||2015-06-10|2015-06-12|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan|Safety and Efficacy Trial Using Ambrisentan for Pulmonary Hypertension Associated With Congestive Heart Failure With Preserved Left Ventricular Ejection Fraction|Terminated||Phase 4|3|Actual|University of Texas Southwestern Medical Center||2||Poor enrolment|f||||t||||||||||2018-06-01 01:19:19.334796|2018-06-01 01:19:19.334796
NCT00840450|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2011-08-18||2012-11-12|2009-02-09|2009-02-10|Estimate|2011-08-18|2011-09-26|Estimate||||2012-11-12|2012-11-19|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|April 2010|Actual|2010-04-30||Interventional|||Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin|Phase II Study of Paclitaxel With Imatinib Mesylate (Gleevec) in Taxane-pretreated Ovarian and Other Cancers of Mullerian Origin|Terminated||Phase 2|14|Actual|New York University School of Medicine|Premature closure led to small numbers of subjects analyzed (12 out of 50 targeted accrual number).|1||Due to slow accrual|f||||t||||||||||2018-06-01 01:19:19.403136|2018-06-01 01:19:19.403136
NCT00840437|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2013-12-03|2009-02-06|2009-02-10|Estimate|||||||2013-12-03|2013-12-05|Estimate|December 2008||2008-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|||Quality of Life in Patients With Refractory Angina|Health Status of Patients Enrolled in the OPTions In Myocardial Ischemic Syndrome Therapy (OPTIMIST) Program|Completed|||90|Actual|Minneapolis Heart Institute Foundation|||||f||||f||||||||||2018-06-01 01:19:19.563372|2018-06-01 01:19:19.563372
NCT00840411|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-18||2009-09-01|2009-02-09|2009-02-10|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Extended Release Tablet Formulation of Clarithromycin (500 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Biaxin® XL Filmtab) in 66 Fasted, Healthy, Adult Subjects|Completed||Phase 1|66|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:19.646242|2018-06-01 01:19:19.646242
NCT00840398|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|December 2001||2001-12-31|February 2009|2009-02-28|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Buspirone Hydrochloride 30mg Tablets, Non-Fasting|A Relative Bioavailability Study of 30 mg Buspirone Hydrochloride Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:20.832342|2018-06-01 01:19:20.832342
NCT00840385|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2010-09-14|2009-02-09|2009-02-10|Estimate|||||||2010-09-14|2010-09-15|Estimate|November 2007||2007-11-30|September 2010|2010-09-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|FAD||Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)|Phase II Study of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed PTCL|Unknown status|Recruiting|Phase 2|30|Anticipated|Fudan University||1|||f||||f||||||||||2018-06-01 01:19:20.911906|2018-06-01 01:19:20.911906
NCT00840372|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-09-28|2009-02-09|2009-02-10|Estimate|||||||2009-09-28|2009-09-29|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|Needles||Semi-blunt Needles: is Outcome Better?||Completed|||50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||2||f||||t||||||||||2018-06-01 01:19:20.985144|2018-06-01 01:19:20.985144
NCT00840359|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2011-08-15|2009-02-09|2009-02-10|Estimate|||||||2011-08-15|2011-08-16|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis|Phase 2 Study of the Efficacy of Daylight Activated Photodynamic Therapy in the Treatment of Cutaneous Leishmaniasis|Unknown status|Enrolling by invitation|Phase 2|44|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:19:21.053379|2018-06-01 01:19:21.053379
NCT00840346|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|||2016-05-16|2009-02-09|2009-02-10|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PANOBIDARA||Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)|A Phase I/II Multicenter, National, Open-Label Study of Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)|Completed||Phase 1/Phase 2|46|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-06-01 01:19:21.119359|2018-06-01 01:19:21.119359
NCT00840333|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2018-01-17|2009-02-06|2009-02-10|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2009||2009-04-30|January 2018|2018-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"|A Phase 1B, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Given Daily for 14 Days to Stable Pediatric Cystic Fibrosis Patients.|Completed||Phase 1|27|Actual|Horizon Pharma USA, Inc.||2|||f||||f||||||||||2018-06-01 01:19:21.201863|2018-06-01 01:19:21.201863
NCT00840320|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2017-06-21|2009-02-09|2009-02-10|Estimate|||||||2017-06-21|2017-06-22|Actual|March 13, 2009|Actual|2009-03-13|June 2017|2017-06-30|September 2, 2009|Actual|2009-09-02|September 2, 2009|Actual|2009-09-02||Interventional|||Repeat Dose Safety Study for Compound to Treat Anemia|A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeat Oral Doses of 1278863A in Healthy Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:19:21.273444|2018-06-01 01:19:21.273444
NCT00840307|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2017-08-14||2017-11-17|2009-02-09|2009-02-10|Estimate|2017-10-17|2017-11-20|Actual||||2017-11-17|2017-12-13|Actual|August 2008||2008-08-31|November 2017|2017-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Changes in Ectopic Fat Following Surgically Induced Weight Loss|Changes in Ectopic Fat Following Surgically Induced Weight Loss: Does it Explain the Resolution of Diabetes?|Completed|||20|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 01:19:21.448404|2018-06-01 01:19:21.448404
NCT00840294|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2014-07-07||2014-07-07|2009-02-09|2009-02-10|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Subjects with complete data are included|Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)|Randomized, Multi-Institution Trial of Ciprofloxacin Versus Observation for Men With an Elevated Prostate Specific Antigen (PSA)|Terminated||Phase 3|85|Actual|University of Chicago|Early termination due to poor accrual and interim futility analysis.|2||Combination of futility analysis and poor accrual|f||||f||||||||||2018-06-01 01:19:21.60253|2018-06-01 01:19:21.60253
NCT00840281|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-18||2009-08-14|2009-02-06|2009-02-10|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Cefprozil 500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Cefprozil 500 mg Tablets Under Fasting Conditions|Completed||Phase 1|38|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:21.943509|2018-06-01 01:19:21.943509
NCT00840268|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06||2014-07-15|2014-07-15|2009-02-09|2009-02-10|Estimate||||2014-07-15|2014-07-17|Estimate|2014-07-15|2014-07-17|Estimate|February 2009||2009-02-28|July 2014|2014-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye Patients||Completed||Phase 2|427|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:19:22.227334|2018-06-01 01:19:22.227334
NCT00840255|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2012-06-15|2009-02-09|2009-02-10|Estimate|||||||2012-06-15|2012-06-18|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|BBTIMVII||Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 2 (BBTIMVII)|Treatment of Insomnia in Military Veterans:Phase 2|Completed||N/A|40|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:19:22.305235|2018-06-01 01:19:22.305235
NCT00840242|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2012-04-24|2009-02-09|2009-02-10|Estimate|||||||2012-04-24|2012-04-25|Estimate|February 1999||1999-02-28|April 2012|2012-04-30|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Smoking Reduction or Cessation With Nicotine Replacement Therapy|Smoking Reduction or Cessation With Nicotine Replacement Therapy. A Placebo Controlled Double Blind Trial With Nicotine Gum or Inhaler.|Completed||Phase 3|314|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||||2018-06-01 01:19:22.387366|2018-06-01 01:19:22.387366
NCT00840229|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2013-11-24|2009-02-09|2009-02-10|Estimate|||||||2013-11-24|2013-11-26|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder|Rotator Interval and Intra-articular Corticosteroid Injection for Adhesive Capsulitis (Frozen Shoulder): a Randomised, Double Blind, Placebo Controlled Trial|Completed||N/A|122|Actual|Oslo University Hospital||3|||f||||f||||||||||2018-06-01 01:19:22.469056|2018-06-01 01:19:22.469056
NCT00840216|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-18||2009-09-01|2009-02-09|2009-02-10|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|August 2002||2002-08-31|September 2009|2009-09-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Extended Release Tablet Formulation of Clarithromycin (500 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Biaxin® XL Filmtab) in 22 Fed, Healthy, Adult Subjects|Completed||Phase 1|22|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:22.547614|2018-06-01 01:19:22.547614
NCT00840203|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-30||2009-09-01|2009-02-06|2009-02-10|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|May 2003||2003-05-31|September 2009|2009-09-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Mesalamine 4 gm/60 mL Rectal Enema|A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 mL Rectal Enema Formulations|Completed||Phase 1|72|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:22.890277|2018-06-01 01:19:22.890277
NCT00840190|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-11-20|2009-02-06|2009-02-10|Estimate|||||||2012-11-20|2012-11-21|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|Serenity||A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies|An Open Label, Multicenter Phase I Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies|Completed||Phase 1|29|Actual|Piramal Enterprises Limited||1|||f||||f||||||||||2018-06-01 01:19:23.238645|2018-06-01 01:19:23.238645
NCT00840177|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|||2017-10-03|2009-02-07|2009-02-10|Estimate|||||||2017-10-03|2017-10-05|Actual|August 2009||2009-08-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia|S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)|Active, not recruiting||Phase 2|115|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 01:19:23.369108|2018-06-01 01:19:23.369108
NCT00840164|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2011-10-13|2009-02-09|2009-02-10|Estimate|||||||2011-10-13|2011-10-17|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|December 2011|Anticipated|2011-12-31||Observational|||Pathology of Skin, Nerve and Vasculature in the Amputated Limb of Diabetes|Pathology of Skin, Nerve and Vasculature in the Amputated Limb of Diabetes|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     After amputation, sural nerve, posterior tibial nerve, and the accompanying vasculature will~     be harvested from the amputated leg. 3mm-puch skin will be taken from the amputated leg, 10~     cm above the lateral malleolus.~   "|||2018-06-01 01:19:23.686003|2018-06-01 01:19:23.686003
NCT00840151|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|||2014-11-06|2009-02-09|2009-02-10|Estimate|||||||2014-11-06|2014-11-10|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A SMART Design for Attendance-based Prize CM|A SMART Design for Attendance-based Prize CM|Completed||Phase 2|360|Actual|UConn Health||4|||f||||f||||||||||2018-06-01 01:19:23.748431|2018-06-01 01:19:23.748431
NCT00840138|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|January 1996||1996-01-31|February 2009|2009-02-28|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||A Comparison of Bile Duct Injuries Following Open Cholecystectomy Versus Laparoscopic Cholecystectomy|Comparison of Iatrogenic Common Bile Duct Injuries Following Open Cholecystectomy vs Laparoscopic Cholecystectomy|Unknown status|Active, not recruiting||70|Actual|Centre of Postgraduate Medical Education|||2||f||||f||||||||||2018-06-01 01:19:23.813128|2018-06-01 01:19:23.813128
NCT00840125|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2012-10-29|2009-02-09|2009-02-10|Estimate|||||||2012-10-29|2012-10-30|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment|A Phase II Open-Label Study Designed to Evaluate the Efficacy and Safety, of Erlotinib in Combination With Docetaxel in Selected Non Small Cell Lung Cancer Patients Eligible for First Line Treatment|Completed||Phase 2|4|Actual|Meir Medical Center||1|||f||||t||||||||||2018-06-01 01:19:23.882873|2018-06-01 01:19:23.882873
NCT00840112|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2015-10-20|2009-02-09|2009-02-10|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy|Vitamin E Treatment for LCHAD Associated Neuropathy|Terminated||N/A|1|Actual|Oregon Health and Science University||1||New data does not support a role of vitamin E in LCHAD associated neuropathy.|f||||f||||||||||2018-06-01 01:19:23.955928|2018-06-01 01:19:23.955928
NCT00840099|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-05-18||2009-07-08|2009-02-09|2009-02-10|Estimate|2009-07-08|2009-08-25|Estimate||||2009-07-08|2009-08-25|Estimate|August 2002||2002-08-31|July 2009|2009-07-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions|An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|48|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:24.149235|2018-06-01 01:19:24.149235
NCT00840086|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2013-11-14|2012-01-17|2017-02-09|2009-02-09|2009-02-10|Estimate|2014-09-03|2014-09-04|Estimate|2012-01-17|2012-01-19|Estimate|2017-02-09|2017-03-17|Actual|April 2009||2009-04-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|guardian™1||Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects|A Multi-centre, Open-label, Non-controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects With Haemophilia A. Sub-trial: Safety and Efficacy of N8 in Prevention and Treatment of Bleeding During Surgical Procedures in Subjects With Haemophilia A|Completed||Phase 3|150|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 01:19:24.519731|2018-06-01 01:19:24.519731
NCT00840073|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-07-06||2009-07-06|2009-02-06|2009-02-10|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|October 2004||2004-10-31|July 2009|2009-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Trandolapril 4 mg Tablet Under Non-Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Trandolapril 4 mg Tablets Under Fed Conditions.|Completed||Phase 1|50|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:24.923826|2018-06-01 01:19:24.923826
NCT00840060|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2012-04-13||2012-05-14|2009-02-09|2009-02-10|Estimate|2012-05-14|2012-05-15|Estimate||||2012-05-14|2012-05-15|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|AMALS||Efficacy of AMALS in Treating Language Impairment in Children|AMALS: Addressing Multiple Aspects of Language Simultaneously: A Randomized Clinical Trial|Completed||Phase 2|40|Actual|Lamar University|Problems with stratification according to dialect prior to randomization lead to difficulty interpreting results related to dialect|2|||f||||t||||||||||2018-06-01 01:19:25.251618|2018-06-01 01:19:25.251618
NCT00840047|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2017-05-10|2009-02-09|2009-02-10|Estimate|||||||2017-05-10|2017-05-11|Actual|July 20, 2009|Actual|2009-07-20|May 2017|2017-05-31|May 31, 2023|Anticipated|2023-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Methionine PET/CT Studies In Patients With Cancer|Methionine PET/CT Studies In Patients With Cancer|Recruiting||Phase 2|650|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-06-01 01:19:25.503861|2018-06-01 01:19:25.503861
NCT00840034|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|2018-02-17|2010-10-25|2018-03-25|2009-02-09|2009-02-10|Estimate|2018-03-25|2018-04-24|Actual|2010-10-25|2010-10-27|Estimate|2018-03-25|2018-04-24|Actual|February 2009||2009-02-28|March 2018|2018-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||All randomized participants.|A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder|A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment|Completed||Phase 2|227|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:19:25.699771|2018-06-01 01:19:25.699771
NCT00840008|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2011-08-25|2009-02-09|2009-02-10|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|REASON-II||The Dissemination of Consensus Recommendations on Upper Gastrointestinal Bleeding|The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy|Completed||Phase 4|3157|Actual|McGill University Health Center||2|||f||||f||||||||||2018-06-01 01:19:26.821901|2018-06-01 01:19:26.821901
NCT00839995|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-03-02|2009-02-09|2009-02-10|Estimate|||||||2012-03-02|2012-03-05|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|ROTEM||Use of ROTEM for Multi-level Spine Surgery|A Prospective Observational Study to Evaluate Perioperative Coagulation Profiles Using Rotational Thromboelastometry (ROTEM®) in Patients Undergoing Multi-level Spine Surgery|Completed|||41|Actual|Weill Medical College of Cornell University|||1||f||||f||||||Samples With DNA|"~     a small sample of blood will be obtained from a pre-existing arterial line.~   "|||2018-06-01 01:19:26.920529|2018-06-01 01:19:26.920529
NCT00839982|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|2017-03-07||2017-07-06|2009-02-07|2009-02-10|Estimate|2017-07-06|2017-07-11|Actual||||2017-07-06|2017-07-11|Actual|November 2008||2008-11-30|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS|Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML and High-Risk MDS Patients at Least 60 Years of Age|Completed||Phase 1/Phase 2|35|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 01:19:27.012513|2018-06-01 01:19:27.012513
NCT00839969|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding|A Randomized Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding.|Unknown status|Recruiting|N/A|30|Anticipated|Medway NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:19:27.300575|2018-06-01 01:19:27.300575
NCT00839956|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-07|2017-02-10||2017-04-01|2009-02-07|2009-02-10|Estimate|2017-02-10|2017-03-29|Actual||||2017-04-01|2017-05-09|Actual|February 2009||2009-02-28|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|August 2012|Actual|2012-08-31||Interventional|||Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant|Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma|Completed||Phase 2|31|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 01:19:27.40581|2018-06-01 01:19:27.40581
NCT00839943|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-08-24|2009-02-09|2009-02-10|Estimate|||||||2012-08-24|2012-08-27|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|OBOZ||Effect Of Obesity On Ozone-Induced Airway Inflammation|Effect Of Obesity On Ozone-Induced Airway Inflammation|Completed||N/A|40|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 01:19:27.609902|2018-06-01 01:19:27.609902
NCT00839930|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2009-06-18||2009-09-01|2009-02-09|2009-02-10|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Cilostazol 50 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 50 mg Cilostazol Tablets Under Fasting Conditions|Completed||Phase 1|30|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:27.707712|2018-06-01 01:19:27.707712
NCT00839917|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2012-09-07||2017-03-15|2009-02-09|2009-02-10|Estimate|2012-09-07|2012-10-10|Estimate||||2017-03-15|2017-04-12|Actual|February 2008||2008-02-29|March 2017|2017-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study of ProQuad™ in Healthy Children in Korea (V221-023)|A Multicenter, Randomized, Open-Label Study to Compare the Immunogenicity, Safety, and Tolerability of Measles, Mumps, Rubella, and Varicella of Combination Vaccine ProQuad With Concomitant Administration of M-M-R II and VARIVAX in Healthy Korean Children|Terminated||Phase 3|30|Actual|Merck Sharp & Dohme Corp.|Formal testing of the study hypotheses was not possible because of low enrollment|2||"Study terminated early because of insufficient enrollment before expiration date of the~   investigational vaccine lot"|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:19:27.956184|2018-06-01 01:19:27.956184
NCT00839904|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-08|||2013-07-29|2009-02-09|2009-02-10|Estimate|||||||2013-07-29|2013-07-30|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Physical Activity and Health of Children With Cancer in Remission|The Effect of Physical Activity on the Mental and Physical Health of Children With Cancer in Remission|Completed||N/A|22|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:19:28.332623|2018-06-01 01:19:28.332623
NCT00839709|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2011-03-01|2009-02-06|2009-02-09|Estimate|||||||2011-03-01|2011-03-03|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Observational|||Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion Versus Non-depletion Protocols|Peripheral Immunologic Response of Solid Organ Transplant Recipients to Depletion vs. Non-depletion Protocols|Completed|||30|Anticipated|University of Washington|||2||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 01:19:30.472461|2018-06-01 01:19:30.472461
NCT00839891|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-01-20|2009-02-09|2009-02-10|Estimate|||||||2010-01-20|2010-01-21|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|TQT||A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers|A Phase 1 Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group/Crossover Thorough QT/QTc Study to Evaluate the Effect of a Therapeutic Dose and a Supra-therapeutic Dose of VI-0521 on Cardiac Repolarization in Healthy Male and Female Volunteers|Completed||Phase 1|112|Actual|VIVUS, Inc.||1|||f||||f||||||||||2018-06-01 01:19:28.383653|2018-06-01 01:19:28.383653
NCT00839878|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2016-10-13|2009-02-09|2009-02-10|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia DiabCare Asia 2008 (Bangladesh)|Completed|||2092|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 01:19:28.529793|2018-06-01 01:19:28.529793
NCT00839865|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|November 2008||2008-11-30|February 2009|2009-02-28|March 2011|Anticipated|2011-03-31|November 2010|Anticipated|2010-11-30||Interventional|||Trial of Herb Yuyang Ointment to Diabetic Foot Ulcer|Phase 1 Study of Herb Yuyang Ointment That Expressed Good Effect in Diabetic Foot Ulcer|Unknown status|Recruiting|Phase 2|100|Anticipated|Guiyang No.1 People's Hospital||2|||t||||t||||||||||2018-06-01 01:19:28.605295|2018-06-01 01:19:28.605295
NCT00839852|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05||2011-09-13|2011-09-13|2009-02-06|2009-02-10|Estimate||||2011-09-13|2011-09-21|Estimate|2011-09-13|2011-09-21|Estimate|May 2009||2009-05-31|September 2011|2011-09-30||||August 2010|Actual|2010-08-31||Interventional|||The Purpose of the Study is to Determine Whether Cariprazine is a Safe and Tolerated Long-term Treatment in Patients With Chronic Stable Schizophrenia|A Long-Term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia|Completed||Phase 2|93|Actual|Forest Laboratories|||||f||||||||||||||2018-06-01 01:19:28.694314|2018-06-01 01:19:28.694314
NCT00839839|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2015-12-01|2009-02-09|2009-02-10|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Egg Freezing Pilot Study|Oocyte Cryopreservation in Assisted Reproduction|Completed||N/A|10|Actual|University Reproductive Associates||1|||f||||f||||||||||2018-06-01 01:19:28.821913|2018-06-01 01:19:28.821913
NCT00839826|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2014-12-15|2009-02-09|2009-02-10|Estimate|||||||2014-12-15|2014-12-17|Estimate|December 2002||2002-12-31|December 2014|2014-12-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|ODiXaHip||ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial|Oral Direct Factor Xa Inhibitor BAY 59-7939 in the Prevention of VTE in Patients Undergoing Total Hip Replacement. ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial|Completed||Phase 2|641|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:19:28.893678|2018-06-01 01:19:28.893678
NCT00839813|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2011-04-04|2009-02-09|2009-02-10|Estimate|||||||2011-04-04|2011-04-06|Estimate|November 2008||2008-11-30|April 2011|2011-04-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Efficacy of Yoga for Treatment-Resistant Posttraumatic Stress Disorder|Efficacy of Yoga for Treatment-Resistant PTSD|Unknown status|Recruiting|N/A|64|Anticipated|Justice Resource Institute||2|||f||||t||||||||||2018-06-01 01:19:29.230848|2018-06-01 01:19:29.230848
NCT00839800|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2012-02-21||2012-11-26|2009-02-09|2009-02-10|Estimate|2012-11-26|2012-11-30|Estimate||||2012-11-26|2012-11-30|Estimate|February 2009||2009-02-28|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SAKURA||Study to Investigate the Efficacy of Symbicort® SMART.|A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years|Completed||Phase 3|2091|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:19:29.363416|2018-06-01 01:19:29.363416
NCT00839787|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|December 2008||2008-12-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision|The Effect of Opiate Administration in Children With Acute Abdominal Pain and Peritoneal Signs on the Decision for Surgical Intervention|Unknown status|Active, not recruiting|N/A|500|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 01:19:30.097693|2018-06-01 01:19:30.097693
NCT00839774|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-06-18|2009-02-06|2009-02-10|Estimate|||||||2010-06-18|2010-06-22|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Pulse Fractions on Indices on Cardiovascular Disease and Diabetes Risk Factors|Effect of Pulse Fractions on Indices of Lipid, Carbohydrate and Energy Metabolism as Well as Oxidative Status in Overweight, Hyperlipidemic Individuals|Completed||Phase 2|23|Actual|University of Manitoba||3|||f||||f||||||||||2018-06-01 01:19:30.162346|2018-06-01 01:19:30.162346
NCT00839761|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-09|||2009-02-09|2009-02-09|2009-02-10|Estimate|||||||2009-02-09|2009-02-10|Estimate|December 2006||2006-12-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The Use of Ultra Rice Compared to Iron Drops Consumed by Anemic Children|Efficacy of Iron Fortified Ultra Rice Compared to Supplemental Iron Drops in Infants and Young Children|Completed||N/A|175|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-06-01 01:19:30.22603|2018-06-01 01:19:30.22603
NCT00839748|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2013-11-18|2009-02-06|2009-02-09|Estimate|||||||2013-11-18|2013-11-19|Estimate|February 2004||2004-02-29|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||The Ohio State University Asthma Registry|The Ohio State University Asthma Registry|Unknown status|Recruiting||500|Anticipated|Ohio State University|||1||f||||f||||||||||2018-06-01 01:19:30.287426|2018-06-01 01:19:30.287426
NCT00839735|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-06|2009-02-06|2009-02-09|Estimate|||||||2009-02-06|2009-02-09|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||Trefoil Peptides in Lung Diseases|Trefoil Peptides in Lung Diseases|Unknown status|Recruiting||60|Anticipated|Bispebjerg Hospital|||3||f||||||||||||||2018-06-01 01:19:30.345785|2018-06-01 01:19:30.345785
NCT00839722|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-10-12|2009-02-06|2009-02-09|Estimate|||||||2012-10-12|2012-10-15|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|EFU||Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas|Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas|Completed||Phase 2|16|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:19:30.416025|2018-06-01 01:19:30.416025
NCT00839696|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2014-12-05|2009-02-05|2009-02-09|Estimate|||||||2014-12-05|2014-12-09|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|April 2010|Actual|2010-04-30|June 2009|Actual|2009-06-30||Observational|||Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk|Total Xonoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk|Completed|||270|Actual|University of Wisconsin, Madison|||||f||||f||||||Samples Without DNA|"~     Serum Xenoestrogen~   "|||2018-06-01 01:19:30.530055|2018-06-01 01:19:30.530055
NCT00839683|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2016-10-14|2009-02-06|2009-02-09|Estimate|||||||2016-10-14|2016-10-17|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects|Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects|Completed||Phase 1|24|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 01:19:30.707522|2018-06-01 01:19:30.707522
NCT00839670|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-01-09|2009-02-06|2009-02-09|Estimate|||||||2012-01-09|2012-01-10|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|LICITE||Light Constraint Induced Therapy Experiment|Effects of a Modified Constraint Induced Therapy Intervention in Stroke Patients: A Multicenter, Randomized Controlled Trial.|Terminated||Phase 3|34|Actual|Assistance Publique - Hôpitaux de Paris||2||departure of the investigator coordinator into other country|f||||f||||||||||2018-06-01 01:19:30.787638|2018-06-01 01:19:30.787638
NCT00839657|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2016-04-19|2009-02-06|2009-02-09|Estimate|||||||2016-04-19|2016-04-20|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|COAG||Clarification of Optimal Anticoagulation Through Genetics|A Randomized, Multi-Center, Double-Blind Clinical Trial to Evaluate the Use of Clinical Plus Genetic Information to Guide Warfarin Therapy Initiation and Improve Anticoagulation Control for Patients|Completed||Phase 3|1015|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 01:19:30.86691|2018-06-01 01:19:30.86691
NCT00839644|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2012-10-01|2009-02-06|2009-02-09|Estimate|||||||2012-10-01|2012-10-02|Estimate|December 1999||1999-12-31|October 2012|2012-10-31|June 2003|Actual|2003-06-30|December 2002|Actual|2002-12-31||Interventional|||Airway Secretion Clearance in Cystic Fibrosis|Airway Secretion Clearance in Cystic Fibrosis|Terminated||N/A|166|Actual|University of Colorado, Denver||3||High dropout, problems recruiting, and smaller than expected decline in FEV1.|f||||t||||||||||2018-06-01 01:19:30.985559|2018-06-01 01:19:30.985559
NCT00839631|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-04-30|2009-02-06|2009-02-09|Estimate|||||||2012-04-30|2012-05-02|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors|A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid Tumors|Completed||Phase 1|23|Actual|Dendreon|||||f||||f||||||||||2018-06-01 01:19:31.067446|2018-06-01 01:19:31.067446
NCT00839605|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2016-10-03|2009-02-06|2009-02-09|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|Dex-One-Lung||Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedures and One-Lung Ventilation|Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedure and One-Lung Ventilation(OLV)|Completed|||25|Actual|University of Missouri-Columbia|||2||f||||f||||||||No||2018-06-01 01:19:31.118626|2018-06-01 01:19:31.118626
NCT00839592|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-01-12|2009-02-06|2009-02-09|Estimate|||||||2010-01-12|2010-01-14|Estimate|July 2006||2006-07-31|January 2010|2010-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Acupuncture for Primary Insomnia|Acupuncture Treatment of Primary Insomnia|Completed||N/A|60|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:19:31.250551|2018-06-01 01:19:31.250551
NCT00839579|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2014-03-06|2009-02-06|2009-02-09|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Cardiovascular Treatment|How Little Pain for Cardiac Gain? A Pilot Study|Completed||N/A|26|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-06-01 01:19:31.323446|2018-06-01 01:19:31.323446
NCT00839566|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2017-02-14|2009-02-06|2009-02-09|Estimate|||||||2017-02-14|2017-02-15|Actual|November 2008||2008-11-30|February 2017|2017-02-28|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|PAF-HEFT||PAF-HEFT (Permanent Atrial Fibrillation in Heart Failure Trial)|Permanent Atrial Fibrillation in Heart Failure Trial|Terminated||Phase 4|12|Actual|Medtronic Bakken Research Center||3||Number of eligible patients too small.|f||||f||||||||No|"Not applicable as NO is selected above for 'Plan to share IPD?"|2018-06-01 01:19:31.389849|2018-06-01 01:19:31.389849
NCT00839553|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-06|2009-02-06|2009-02-09|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|April 2009|Anticipated|2009-04-30|||||Interventional|||Intrapleural Minocycline After Aspiration of Spontaneous Pneumothorax|Intrapleural Minocycline After Manual Aspiration for the Prevention of Primary Spontaneous Pneumothorax. A Phase III Multicenter Prospective Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 01:19:31.459553|2018-06-01 01:19:31.459553
NCT00839540|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2012-01-23||2012-02-27|2009-02-06|2009-02-09|Estimate|2012-01-23|2012-02-24|Estimate||||2012-02-27|2012-02-28|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins|Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins in Patients With Presumptive Candidemia|Completed||Phase 4|21|Actual|Michigan State University||3|||f||||f||||||||||2018-06-01 01:19:31.531048|2018-06-01 01:19:31.531048
NCT00839527|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2014-04-24|2012-04-03|2016-11-18|2009-02-05|2009-02-09|Estimate|2014-05-29|2014-07-01|Estimate|2012-04-03|2012-04-05|Estimate|2016-11-18|2017-01-09|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|April 2013|Actual|2013-04-30|January 2012|Actual|2012-01-31||Interventional|||A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes|A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|685|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:19:31.906985|2018-06-01 01:19:31.906985
NCT00839514|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-06-06|2009-02-06|2009-02-09|Estimate|||||||2012-06-06|2012-06-07|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|TCE||Trichloroethylene (TCE) Exposure in an Industrial Population|Evaluation of Parkinson Disease Symptoms in Trichloroethylene Exposed Patients in an Industrial Population|Completed|||27|Actual|University of Kentucky|||||f||||f||||||||||2018-06-01 01:19:33.536195|2018-06-01 01:19:33.536195
NCT00839501|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2012-01-19|2009-02-06|2009-02-09|Estimate|||||||2012-01-19|2012-01-20|Estimate|December 2008||2008-12-31|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome|Therapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil Syndrome|Terminated||Phase 1|3|Actual|University of Rochester||1||Unable to recruit sufficient number of participants|f||||t||||||||||2018-06-01 01:19:33.590058|2018-06-01 01:19:33.590058
NCT00839488|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2013-10-12|2009-02-06|2009-02-09|Estimate|||||||2013-10-12|2013-10-16|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis|Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery|Terminated||Phase 4|6|Actual|Far Eastern Memorial Hospital||2||the chief of GS left the hopsital and the successor did't want to keep on this study|f||||t||||||||||2018-06-01 01:19:33.667409|2018-06-01 01:19:33.667409
NCT00839475|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2010-03-22|2009-02-05|2009-02-09|Estimate|||||||2010-03-22|2010-03-24|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|July 2009|Actual|2009-07-31|November 2008|Actual|2008-11-30||Observational|||Investigation of the Uterine Cervix Using CervicalMD|Investigational Study: Imaging the Uterine Cervix Using C30 Investigational Device|Completed|||26|Actual|STI-Medical Systems|||||f||||f||||||Samples Without DNA|"~     LEEP specimens~   "|||2018-06-01 01:19:33.738865|2018-06-01 01:19:33.738865
NCT00839462|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2013-10-18|2009-02-06|2009-02-09|Estimate|||||||2013-10-18|2013-10-21|Estimate|September 2007||2007-09-30|October 2013|2013-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy of Dexpanthenol in Thermic Erythema|Evaluation of the Effect of Bepanthen Burn Relief Foam Spray New Formula on a Thermic Erythema. Equivalence Trial. Intra-individual Design.|Completed||Phase 2|55|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:19:33.777126|2018-06-01 01:19:33.777126
NCT00839449|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-09-01|2009-02-06|2009-02-09|Estimate|||||||2009-09-01|2009-09-03|Estimate|December 2004||2004-12-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|EVAS||Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study|Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage|Completed||Phase 4|200|Actual|Yamaguchi University Hospital||2|||f||||t||||||||||2018-06-01 01:19:33.840604|2018-06-01 01:19:33.840604
NCT00839436|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2015-10-14||2015-10-14|2009-02-06|2009-02-09|Estimate|2015-10-14|2015-10-15|Estimate||||2015-10-14|2015-10-15|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)|Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)|Terminated||Phase 1/Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)||3||Bankruptcy of Drug manufacturer: Drug not available|f||||t||||||||||2018-06-01 01:19:33.93705|2018-06-01 01:19:33.93705
NCT00839423|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2013-10-28||2014-04-22|2009-02-06|2009-02-09|Estimate|2013-10-28|2013-12-17|Estimate||||2014-04-22|2014-05-13|Estimate|August 2006||2006-08-31|April 2014|2014-04-30|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults|Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder|Completed||Phase 2|426|Actual|H. Lundbeck A/S||4|||f||||f||||||||||2018-06-01 01:19:34.55011|2018-06-01 01:19:34.55011
NCT00839410|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2017-10-12|2009-02-06|2009-02-09|Estimate|||||||2017-10-12|2017-10-13|Actual|September 2003|Actual|2003-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|Melan-Cohort||Multicentric Cohort of Melanoma Patients in Ile de France Area|Multicentric Cohort of Melanoma Patients in Ile de France Area|Active, not recruiting|||1255|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     DNA,RNA,SERUM,PLASMA,PROTEOMICS~   "|||2018-06-01 01:19:35.106722|2018-06-01 01:19:35.106722
NCT00839397|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2014-03-06|2009-02-05|2009-02-09|Estimate|||||||2014-03-06|2014-03-10|Estimate|May 2002||2002-05-31|March 2014|2014-03-31|June 2005|Actual|2005-06-30|November 2004|Actual|2004-11-30||Interventional|||BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder|BRL29060A in Posttraumatic Stress Disorder|Completed||Phase 3|52|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:19:35.228007|2018-06-01 01:19:35.228007
NCT00839384|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2017-11-08|2009-02-06|2009-02-09|Estimate|||||||2017-11-08|2017-11-09|Actual|February 2009|Actual|2009-02-28|November 2017|2017-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||AdvisaTM IPG Clinical Evaluation Study|Clinical Study to Evaluate System Safety and Clinical Performance of the AdvisaTM IPG|Completed||N/A|79|Actual|Medtronic Bakken Research Center||1|||f||||f||||||||||2018-06-01 01:19:35.292563|2018-06-01 01:19:35.292563
NCT00839371|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-06|2009-02-06|2009-02-09|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Bronchoscopy and Bispectral Index (BIS) - Guided Sedation|Bronchoscopy Under Titrated Sedation With Propofol or Midazolam: a Randomized Trial.|Completed||Phase 4|84|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 01:19:35.356751|2018-06-01 01:19:35.356751
NCT00839358|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2016-08-17|2009-02-06|2009-02-09|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|MACHT||Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation|Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation|Completed||Phase 4|199|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 01:19:35.421353|2018-06-01 01:19:35.421353
NCT00839345|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-09|2009-02-06|2009-02-09|Estimate|||||||2009-02-09|2009-02-10|Estimate||||February 2009|2009-02-28||||||||Expanded Access|||Clopidogrel Resistance and the Possibility of Its Affection|Resistance to Antiplatelet Agents, Its Etiology and the Possibility of Its Affection|Temporarily not available|||||Charles University, Czech Republic|||||f||||||||||||||2018-06-01 01:19:35.516135|2018-06-01 01:19:35.516135
NCT00839332|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2018-02-17|2014-04-14|2018-03-15|2009-02-06|2009-02-09|Estimate|2018-03-15|2018-04-17|Actual|2014-04-14|2014-05-06|Estimate|2018-03-15|2018-04-17|Actual|February 2009||2009-02-28|March 2018|2018-03-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional||Participants who received at least 1 dose of study drug.|A Study for Participants With Pancreatic Cancer|A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer|Completed||Phase 1/Phase 2|157|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 01:19:35.628569|2018-06-01 01:19:35.628569
NCT00839319|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2010-10-15||2015-12-09|2009-02-06|2009-02-09|Estimate|2010-10-15|2010-11-16|Estimate||||2015-12-09|2016-01-11|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|HOP-3||HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone|Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (Short Title (HOP-3)|Completed||Phase 1/Phase 2|59|Actual|University of Washington||5|||f||||f||||||||||2018-06-01 01:19:36.990536|2018-06-01 01:19:36.990536
NCT00839306|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2015-06-08||2016-01-11|2009-02-06|2009-02-09|Estimate|2015-10-15|2015-11-16|Estimate||||2016-01-11|2016-02-08|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized Double-Blind Parallel Study of Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|240|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 01:19:37.711464|2018-06-01 01:19:37.711464
NCT00839293|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-10-14|2009-02-06|2009-02-09|Estimate|||||||2010-10-14|2010-10-15|Estimate|February 2009||2009-02-28|September 2010|2010-09-30||||March 2009|Actual|2009-03-31||Interventional|||Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules|Comparison of Fenofibric Acid Bioavailability From 45 mg and 135 mg Strength ABT-335 Capsules|Completed||Phase 1|32|Anticipated|Abbott||2|||f||||||||||||||2018-06-01 01:19:37.929864|2018-06-01 01:19:37.929864
NCT00839280|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2014-10-14|2009-02-06|2009-02-09|Estimate|||||||2014-10-14|2014-10-15|Estimate|August 2007||2007-08-31|October 2014|2014-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Moisturizing Effect of Two Dexpanthenol Formulations|Evaluation of the Moisturizing Effect of Bepanthen Burn Relief Foam Spray New Formula Versus Bepanthen Burn Relief Foam Spray (Current Formula). Equivalence Trial. Intra-individual Design.|Completed||Phase 2|19|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:19:38.019413|2018-06-01 01:19:38.019413
NCT00839267|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-09|2009-02-06|2009-02-09|Estimate|||||||2009-02-09|2009-02-10|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|||||Observational|||Clopidogrel Efficacy and Acute Coronary Syndromes|The Comparison of Clopidogrel Efficacy in Patients With Acute Myocardial Infarction and Severe Hemodynamic Instability to Patients With Hemodynamically Uncomplicated Myocardial Infarction|Completed|||40|Actual|Charles University, Czech Republic|||2||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 01:19:38.094587|2018-06-01 01:19:38.094587
NCT00839254|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05||2013-02-14|2017-01-09|2009-02-05|2009-02-09|Estimate||||2013-02-14|2013-02-18|Estimate|2017-01-09|2017-01-10|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A|Impact on Nasopharyngeal Carriage, Acute Otitis Media, Immunogenicity and Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A|Completed||Phase 3|6181|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:19:38.160378|2018-06-01 01:19:38.160378
NCT00839241|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2010-07-19||2012-09-27|2009-02-06|2009-02-09|Estimate|2010-09-15|2010-10-04|Estimate||||2012-09-27|2012-10-04|Estimate|January 2009||2009-01-31|September 2012|2012-09-30||||July 2009|Actual|2009-07-31||Interventional|||"A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood (Bank Blood)"|An Open , Prospective, Randomized, Parallel Group Study to Investigate Whether Postoperatively Collected and Transfused Autologous Whole Blood Improves the Immunological Status in Comparison to Allogenic Blood Transfusion in Patients Undergoing Total Knee Replacement|Completed||N/A|45|Actual|Wellspect HealthCare||2|||f||||f||||||||||2018-06-01 01:19:38.409042|2018-06-01 01:19:38.409042
NCT00839228|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2015-11-04|2009-02-06|2009-02-09|Estimate|||||||2015-11-04|2015-11-05|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome|Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF)|Completed||Phase 2|70|Anticipated|University of Aberdeen||2|||f||||t||||||||||2018-06-01 01:19:39.146851|2018-06-01 01:19:39.146851
NCT00839202|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2017-01-31|2009-02-06|2009-02-09|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2006||2006-09-30|January 2017|2017-01-31|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional|||Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay|Pharmacokinetic (PK) Analysis of a Novel Immunoassay in Hemophilia A|Completed||N/A|7|Actual|Children's Hospital Los Angeles||1|||f||||f||||||||No||2018-06-01 01:19:39.226622|2018-06-01 01:19:39.226622
NCT00839189|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-12-08|2009-02-06|2009-02-09|Estimate|||||||2009-12-08|2009-12-09|Estimate|October 2002||2002-10-31|December 2009|2009-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults|Safety Study To Determine the Effect of a 10,000 EU Dose of Clinical Center Reference Endotoxin in Allergic and Mildly Asthmatic Adults|Completed||Phase 1|11|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 01:19:39.296494|2018-06-01 01:19:39.296494
NCT00839176|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2013-11-18|2009-02-06|2009-02-09|Estimate|||||||2013-11-18|2013-11-19|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)|A Double-blinded, Randomized, Placebo-controlled, Dose-Exploring Study of RX-10100 When Given for Eight Consecutive Weeks to Subjects With Major Depression Disorder (MDD)|Completed||Phase 2|118|Actual|Rexahn Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 01:19:39.36525|2018-06-01 01:19:39.36525
NCT00839163|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2014-10-27|2009-02-06|2009-02-09|Estimate|||||||2014-10-27|2014-10-28|Estimate|March 2004||2004-03-31|October 2014|2014-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)|ODIXa-DVTA Prospective, Randomized, Multinational, Multicenter, Partially Blinded, Parallel-group, Open-label Active Comparator Controlled Phase II Dose Finding and Proof of Principle Trial.|Completed||Phase 2|613|Actual|Bayer||5|||f||||t||||||||||2018-06-01 01:19:39.448526|2018-06-01 01:19:39.448526
NCT00839150|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2011-09-16|2009-02-06|2009-02-09|Estimate|||||||2011-09-16|2011-09-19|Estimate|May 2005||2005-05-31|June 2009|2009-06-30|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Observational|NEURODIAB||Retinal Function in Diabetic Patients Without Retinopathy|Assessment of Retinal Functional Abnormalities in Diabetic Patients Without Retinopathy|Completed|||56|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||||||2018-06-01 01:19:39.665272|2018-06-01 01:19:39.665272
NCT00839124|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-12-04|2009-02-06|2009-02-09|Estimate|||||||2012-12-04|2012-12-05|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Endomac||A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals|A Study of Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers Compared to Allergic Asthmatic Individuals|Completed||Phase 1|32|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 01:19:39.774669|2018-06-01 01:19:39.774669
NCT00839111|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-09-14|2009-02-06|2009-02-09|Estimate|||||||2010-09-14|2010-09-15|Estimate|November 2008||2008-11-30|September 2010|2010-09-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment|A Phase Ⅱ Open Label, Non Randomized Study, in Which Sorafenib is Used in Combination With Irinotecan, Leucovorin and Fluorouracil in Patients With Advanced Colorectal Cancer After Failure of Oxaliplatin Treatment|Unknown status|Recruiting|Phase 2|43|Anticipated|Fudan University||1|||f||||f||||||||||2018-06-01 01:19:39.954808|2018-06-01 01:19:39.954808
NCT00839098|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2015-03-09||2016-01-05|2009-02-06|2009-02-09|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional||"The average age of the participants was 53.2 years old (+/- 14.0 years old). Twelve out of 28 were female (42.9%). Two of the participants were veterans, and one of them was recruited from VA Wheelchair Seating clinic.~Arm 1 (control group) was removed from the study through IRB modification because of difficulties in recruiting participants."|Powered Seating Function Usage Among Veterans - Compliance and Coaching|Powered Seating Function Usage Among Veterans - Compliance and Coaching|Completed||N/A|28|Actual|VA Office of Research and Development|It was difficult to recruit power wheelchair users to participate in the study. Participants withdrew from the study because the study wheelchair could not meet their needs, or they could not use the Virtual Seating Coach independently.|3|||f||||f||||||||||2018-06-01 01:19:40.057369|2018-06-01 01:19:40.057369
NCT00839085|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-02-09|2009-02-06|2009-02-09|Estimate|||||||2009-02-09|2009-02-10|Estimate|November 2008||2008-11-30|February 2009|2009-02-28|March 2009|Anticipated|2009-03-31|January 2009|Anticipated|2009-01-31||Interventional|||Comparison of Ascorbic Acid and Grape Seed Extract in Oxidative Stress Induced by on Pump Heart Surgery|"Effect of Ascorbic Acid and Grape Seed Extract Vitis Vinifera L. in Oxidative Stress Induced by on Pump Coronary Artery by Pass Grafting Surgery"|Unknown status|Active, not recruiting|N/A|72|Actual|Tabriz University||3|||f||||f||||||||||2018-06-01 01:19:40.469631|2018-06-01 01:19:40.469631
NCT00839072|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2010-06-22||2012-04-24|2009-02-06|2009-02-09|Estimate|2010-07-21|2010-08-16|Estimate||||2012-04-24|2012-04-27|Estimate|February 2009||2009-02-28|April 2012|2012-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers|Crossover Comparative Bioavailability Study of Trazodone Contramid(r) OAD 300 mg Extended-release Caplets and Desyrel(r) 100 mg Immediate-release Tablets in Healthy Adult Volunteers Under Fasting Conditions|Completed||Phase 1|24|Actual|Labopharm Inc.||2|||f||||f||||||||||2018-06-01 01:19:40.561401|2018-06-01 01:19:40.561401
NCT00839059|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2011-07-28|2009-02-06|2009-02-09|Estimate|||||||2011-07-28|2011-07-29|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Lenalidomide In Patients With Acute Myeloid Leukemia|Open-Label, Multi-Center Phase I Dose-Escalation Study With Lenalidomide In Patients With Acute Myeloid Leukemia|Terminated||Phase 1|14|Actual|University of Ulm||1||"Results of an interim analysis and a hardly ongoing enrolment in the last 10 months in all six~   participating centres"|f||||t||||||||||2018-06-01 01:19:40.830725|2018-06-01 01:19:40.830725
NCT00839046|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2017-07-20|2009-02-06|2009-02-09|Estimate|||||||2017-07-20|2017-07-24|Actual|August 2007||2007-08-31|July 2017|2017-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CAAA||A Community-based Participatory Research (CBPR) Intervention for Childhood Asthma Using Air Filters and Air Conditioners|A Community Based Participatory Research Intervention for Childhood Asthma Using Air Filters and Air Conditioners|Completed||N/A|126|Actual|University of Michigan||3|||f||||t|f|f||||||||2018-06-01 01:19:40.896142|2018-06-01 01:19:40.896142
NCT00839033|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2015-05-27|2009-02-06|2009-02-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|Nemucough||Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders|Evaluation of a Mechanical Insufflation-exsufflation Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders: a Prospective, Randomized, Controlled, Multicenter Study|Terminated||Phase 3|14|Actual|Assistance Publique - Hôpitaux de Paris||2||No inclusion|f||||f||||||||||2018-06-01 01:19:40.969836|2018-06-01 01:19:40.969836
NCT00839020|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2016-07-25|2009-02-06|2009-02-09|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||Minimally Invasive Versus Conventional Approaches in Navigated Total Knee Arthroplasty (TKA)|Comparison of a Minimally Invasive and a Conventional Approach in Computer Assisted Total Knee Arthroplasty.|Terminated||Phase 4|26|Actual|Aesculap AG||2||Number of patients willing to participate in the study too low|f||||f||||||||||2018-06-01 01:19:41.038416|2018-06-01 01:19:41.038416
NCT00839007|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-09-15|2009-02-06|2009-02-09|Estimate|||||||2010-09-15|2010-09-17|Estimate|June 2009||2009-06-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure|A Multi-Center, Single-Blind, Placebo-Controlled Phase 2 Study Assessing the Safety and Efficacy of Intravenous CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure|Completed||Phase 2|77|Actual|Nile Therapeutics||7|||f||||t||||||||||2018-06-01 01:19:41.111017|2018-06-01 01:19:41.111017
NCT00838994|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2010-01-12|2009-02-06|2009-02-09|Estimate|||||||2010-01-12|2010-01-14|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Acupuncture for Residual Insomnia Associated With Major Depressive Disorder|A Randomized Controlled Trial of Acupuncture for Residual Insomnia Associated With Major Depressive Disorder|Completed||N/A|78|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-06-01 01:19:42.128999|2018-06-01 01:19:42.128999
NCT00838981|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2017-05-05||2017-08-10|2009-02-06|2009-02-09|Estimate|2017-08-10|2017-09-12|Actual||||2017-08-10|2017-09-12|Actual|May 2008||2008-05-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacotherapy & CM for Opioid and Cocaine Dependence|Pharmacotherapy & CM for Opioid and Cocaine Dependence|Completed||Phase 1/Phase 2|91|Actual|Yale University||4|||f||||t||||||||No||2018-06-01 01:19:42.226322|2018-06-01 01:19:42.226322
NCT00838968|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-08-21|2009-02-06|2009-02-09|Estimate|||||||2012-08-21|2012-08-23|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|January 2013|Anticipated|2013-01-31|October 2012|Anticipated|2012-10-31||Interventional|||The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma|The Efficiency of Postoperative Interferon-alpha(IFNa) Treatment in p48 Positive Patients With Hepatocellular Carcinoma|Withdrawn||N/A|0|Actual|Fudan University||2||"we have found another marker (microRNA26) which is more sensitive to evaluate the effect of~   postoperative IFNa treatment in patients with HCC"|f||||t||||||||||2018-06-01 01:19:42.769963|2018-06-01 01:19:42.769963
NCT00838955|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-10-29|2009-02-06|2009-02-09|Estimate|||||||2012-10-29|2012-10-30|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|January 2017|Anticipated|2017-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma|Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Loyola University||1|||f||||t||||||||||2018-06-01 01:19:42.840758|2018-06-01 01:19:42.840758
NCT00838942|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2011-10-27|2009-02-06|2009-02-09|Estimate|||||||2011-10-27|2011-10-28|Estimate|December 2004||2004-12-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Observational|VIVA||Life From Vision in Alzheimer Disease|Cataract Surgery Benefice in Improvement of Behaviour, Autonomy and Mood for Alzheimer Patients.|Completed|||80|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-06-01 01:19:43.769456|2018-06-01 01:19:43.769456
NCT00838929|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|2013-03-14||2016-10-19|2009-02-06|2009-02-09|Estimate|2013-08-29|2013-11-01|Estimate||||2016-10-19|2016-11-29|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|January 2012|Actual|2012-01-31||Interventional|||Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases|Phase I Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases|Completed||Phase 1|17|Actual|Thomas Jefferson University||3|||f||||t||||||||||2018-06-01 01:19:43.883831|2018-06-01 01:19:43.883831
NCT00838916|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2014-04-17|2012-04-03|2016-11-18|2009-02-05|2009-02-09|Estimate|2014-05-22|2014-06-04|Estimate|2012-04-03|2012-04-05|Estimate|2016-11-18|2017-01-09|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|May 2013|Actual|2013-05-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes|A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.|Completed||Phase 3|779|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:19:44.328069|2018-06-01 01:19:44.328069
NCT00838903|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2014-04-17||2016-11-18|2009-02-05|2009-02-09|Estimate|2014-04-17|2014-05-16|Estimate||||2016-11-18|2017-01-09|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|April 2013|Actual|2013-04-30|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes|A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|1049|Actual|GlaxoSmithKline||4|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:19:46.527628|2018-06-01 01:19:46.527628
NCT00838890|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06||2011-06-21|2015-09-23|2009-02-06|2009-02-09|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of BMS-863233 in Patients With Hematologic Cancer|A Phase 1/2, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Refractory Hematologic Malignancies|Terminated||Phase 1/Phase 2|11|Actual|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 01:19:51.31998|2018-06-01 01:19:51.31998
NCT00838877|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2009-10-21|2009-02-06|2009-02-09|Estimate|||||||2009-10-21|2009-10-23|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Interventional|PET||Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid|Open Label Positron Emission Tomography Study With [18F]AZD4694 and [11C]AZD2184, Candidate Radioligands for AB Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease|Completed||Phase 1|26|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:19:51.62477|2018-06-01 01:19:51.62477
NCT00838864|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2015-08-28|2009-02-06|2009-02-09|Estimate|||||||2015-08-28|2015-08-31|Estimate|March 2009||2009-03-31|January 2009|2009-01-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis for Variceal Bleeding|Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding|Completed||Phase 4|79|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-06-01 01:19:51.909544|2018-06-01 01:19:51.909544
NCT00838851|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-10-05|2009-02-06|2009-02-09|Estimate|||||||2012-10-05|2012-10-08|Estimate|August 2003||2003-08-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults|Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adult|Terminated||Phase 1|26|Actual|University of North Carolina, Chapel Hill||1||no further funding|f||||f||||||||||2018-06-01 01:19:52.242778|2018-06-01 01:19:52.242778
NCT00838838|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2010-04-13|2009-02-05|2009-02-06|Estimate|||||||2010-04-13|2010-04-14|Estimate|September 2005||2005-09-30|April 2010|2010-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis|Nebido® Therapy in Hypogonadal Male Patients With Osteoporosis Associated With Paraplegia Compared With Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients With Osteoporosis Associated With Paraplegia|Completed|||26|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:19:52.539521|2018-06-01 01:19:52.539521
NCT00838825|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2016-05-06|2009-02-05|2009-02-06|Estimate|||||||2016-05-06|2016-05-10|Estimate|April 2005||2005-04-30|May 2016|2016-05-31|April 2011|Actual|2011-04-30|March 2008|Actual|2008-03-31||Interventional|||Continuous Quality Improvement for Diabetes|Continuous Quality Improvement for Diabetes: Unique Care Delivery Design's Effect on Quality of Care and Utilization of Resources|Completed||Phase 2|10|Actual|Santa Clara Valley Health & Hospital System||2|||f||||t||||||||No|Data will be shared in a peer review journal|2018-06-01 01:19:52.836692|2018-06-01 01:19:52.836692
NCT00837642|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|April 2009|Anticipated|2009-04-30||Interventional|||Vascular Dysfunction in Offspring of Assisted Reproduction Technologies|Vascular Dysfunction in Offspring of Assisted Reproduction Technologies|Unknown status|Recruiting|N/A|||University of Lausanne Hospitals|||||f||||f||||||||||2018-06-01 01:20:19.261559|2018-06-01 01:20:19.261559
NCT00838812|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2010-05-24|2009-02-05|2009-02-06|Estimate|||||||2010-05-24|2010-05-25|Estimate|March 2009||2009-03-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate|Monocentric Study, Prospective, Open and Non Controlled for to Evaluate the Effectiveness, and Tolerability the Safety of Association of Clindamycin Phosphate 1.2% and Tretinoin 0,025% in the Treatment of Acne Vulgaris Mild to Moderate, When Used Once Daily for 12 Weeks.|Completed||Phase 3|154|Actual|Igefarma Laboratorios S.A.||1|||f||||f||||||||||2018-06-01 01:19:53.106649|2018-06-01 01:19:53.106649
NCT00838799|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05||2011-07-06|2011-07-06|2009-02-05|2009-02-06|Estimate||||2011-07-06|2011-07-14|Estimate|2011-07-06|2011-07-14|Estimate|February 2009||2009-02-28|July 2011|2011-07-31||||April 2010|Actual|2010-04-30||Interventional|||Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain|Completed||Phase 2|458|Actual|Forest Laboratories||5|||f||||f||||||||||2018-06-01 01:19:53.556152|2018-06-01 01:19:53.556152
NCT00838773|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2016-04-21|2009-02-05|2009-02-06|Estimate|||||||2016-04-21|2016-04-25|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|April 2012|Actual|2012-04-30||Interventional|||International Social Network Intervention|HIV Prevention Within High-Risk Social Networks|Completed||Phase 2|1292|Actual|Medical College of Wisconsin||4|||f||||t||||||||||2018-06-01 01:19:54.00304|2018-06-01 01:19:54.00304
NCT00838760|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2010-04-26|2009-02-05|2009-02-06|Estimate|||||||2010-04-26|2010-04-28|Estimate|February 2009||2009-02-28|April 2010|2010-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir|Phase I, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Increasing Single Oral Doses of TMC558445 With and Without Food, and Increasing Repeated Oral Doses in Combination With a Single Dose of TMC310911|Completed||Phase 1|54|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:19:54.311076|2018-06-01 01:19:54.311076
NCT00838747|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2016-05-25|2009-02-05|2009-02-06|Estimate|||||||2016-05-25|2016-05-26|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Observational|||Measurement of the Folate Receptor in Blood|Measurement of the Folate Receptor in Blood|Completed|||7|Actual|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-06-01 01:19:54.564224|2018-06-01 01:19:54.564224
NCT00838734|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|||||Observational|||Compare Anterior Chamber Biometry in Healthy and Post-LASIK Patients|Compare Anterior Chamber Biometry in Healthy and Post-LASIK Pati|Unknown status|Recruiting||100|Anticipated|Far Eastern Memorial Hospital|||2||f||||t||||||||||2018-06-01 01:19:54.836949|2018-06-01 01:19:54.836949
NCT00838721|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2016-10-12|2009-02-05|2009-02-06|Estimate|||||||2016-10-12|2016-10-14|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|PLT||Evaluation of Pascal Laser Trabeculoplaty|Prospective Evaluation of the Efficacy of Pascal Trabeculoplasty: A Pilot Study|Completed||N/A|50|Actual|Santa Clara Valley Health & Hospital System|||||f||||f||||||||||2018-06-01 01:19:54.98899|2018-06-01 01:19:54.98899
NCT00838708|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-10-29|2009-02-05|2009-02-06|Estimate|||||||2009-10-29|2009-10-30|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus|A Phase II, Randomised, Double-blind, Vehicle-controlled, Cross-over Study to Determine the Anti-pruritic Efficacy, Safety and Local Dermal Toleration of SRD174 Cream in Subjects With Atopic Dermatitis.|Completed||Phase 2|62|Actual|Serentis Ltd.||2|||f||||f||||||||||2018-06-01 01:19:55.059186|2018-06-01 01:19:55.059186
NCT00838695|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-12-13|2009-02-05|2009-02-06|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2009||2009-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Variability in Adrenergic Response|Variability in Adrenergic Response|Completed||N/A|106|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 01:19:55.146914|2018-06-01 01:19:55.146914
NCT00838682|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2010-08-02||2010-08-31|2009-02-05|2009-02-06|Estimate|2010-08-31|2010-09-24|Estimate||||2010-08-31|2010-09-24|Estimate|April 2006||2006-04-30|August 2010|2010-08-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers|Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers|Terminated||Phase 4|106|Actual|The Catholic University of Korea|This was the two-center study and was stopped before the complete enrollment leading to small numbers of subjects statistically underpowered.|2||Terminated before the complete enrollment due to slow enrollment|f||||f||||||||||2018-06-01 01:19:55.621029|2018-06-01 01:19:55.621029
NCT00838669|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2011-05-17|2009-02-05|2009-02-06|Estimate|||||||2011-05-17|2011-05-18|Estimate|August 2005||2005-08-31|March 2010|2010-03-31|December 2005|Actual|2005-12-31|||||Interventional|||A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone|Evaluation of the Effect of Food and Posture on the Pharmacokinetics of Paliperidone After a Single Administration of 12 mg ER OROS Paliperidone to Healthy Men|Completed||Phase 1|74|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:19:56.453271|2018-06-01 01:19:56.453271
NCT00838656|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2013-09-16|2009-02-05|2009-02-06|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 2007||2007-10-31|June 2011|2011-06-30||||June 2009|Anticipated|2009-06-30||Interventional|||Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Randomised Feasibility Study of Extended Chemotherapy With Neoadjuvant Carboplatin, Then Surgery Followed by Adjuvant Paclitaxel and Gemcitabine Verses Neoadjuvant Gemcitabine and Carboplatin, Then Surgery, Followed by Adjuvant Paclitaxel|Unknown status|Active, not recruiting|Phase 2|88|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:19:56.520382|2018-06-01 01:19:56.520382
NCT00838643|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-06|2009-02-05|2009-02-06|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 2002||2002-05-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|June 2007|Actual|2007-06-30||Observational|||Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: an Italian Prospective Multicentre Study|Unknown status|Active, not recruiting||220|Actual|Ospedale Santa Croce-Carle Cuneo|||1||f||||f||||||||||2018-06-01 01:19:56.63925|2018-06-01 01:19:56.63925
NCT00838630|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2009-06-18||2009-09-01|2009-02-05|2009-02-06|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|November 2003||2003-11-30|September 2009|2009-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Cilostazol 100 mg Tablet Formulations Under Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Cilostazol, 100 mg, Compared to an Equivalent Dose of a Commercially Available Reference Drug Product in 36 Fasted, Healthy, Adult Subjects|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:19:56.717402|2018-06-01 01:19:56.717402
NCT00838617|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-12-10|2009-02-05|2009-02-06|Estimate|||||||2009-12-10|2009-12-11|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Muscle Ultrasound: A New Tool for Measuring Progression in Amyotrophic Lateral Sclerosis (ALS)|Muscle Ultrasound: A New Tool for Measuring Progression in ALS|Completed|||10|Actual|Vanderbilt University|||1||f||||t||||||||||2018-06-01 01:19:57.265536|2018-06-01 01:19:57.265536
NCT00838591|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05||2013-04-22|2013-09-04|2009-02-05|2009-02-06|Estimate||||2013-09-04|2013-09-05|Estimate|2013-09-04|2013-09-05|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma|MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma|Completed||Phase 2|176|Actual|MediciNova||2|||f||||t||||||||||2018-06-01 01:19:57.540868|2018-06-01 01:19:57.540868
NCT00838578|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2014-03-19||2015-11-05|2009-02-05|2009-02-06|Estimate|2015-03-09|2015-03-23|Estimate||||2015-11-05|2015-11-11|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer|Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal Cancer|Terminated||Phase 1/Phase 2|65|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1||Per protocol, the study was terminated based on interim analysis results|f||||f||||||||||2018-06-01 01:19:57.943746|2018-06-01 01:19:57.943746
NCT00838565|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2012-03-28|2009-02-04|2009-02-06|Estimate|||||||2012-03-28|2012-03-29|Estimate|May 2009||2009-05-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis|Phase I, Randomized, Patient and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PF-04236921 in Patients With Rheumatoid Arthritis Receiving Methotrexate|Completed||Phase 1|41|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:19:58.87436|2018-06-01 01:19:58.87436
NCT00838552|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2016-12-05|2009-02-05|2009-02-06|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2007||2007-10-31|December 2016|2016-12-31|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Observational|||Markers of Airway Inflammation in BAL Fluid From Children With Asthma|Prospective Analysis of Markers of Airway Inflammation and Remodeling in Bronchoalveolar Lavage Fluid From Children With Asthma.|Enrolling by invitation|||40|Anticipated|National Jewish Health|||2||f||||f||||||||||2018-06-01 01:19:58.962183|2018-06-01 01:19:58.962183
NCT00838539|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2017-08-10||2017-08-10|2009-02-05|2009-02-06|Estimate|2017-08-10|2018-02-26|Actual||||2017-08-10|2018-02-26|Actual|April 2009||2009-04-30|August 2017|2017-08-31|December 2013|Actual|2013-12-31|June 2011|Actual|2011-06-30||Interventional|||Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors|A Phase 1 Study Of Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors|Completed||Phase 1|63|Actual|Puma Biotechnology, Inc.||12|||f||||f|t|f||||||||2018-06-01 01:19:59.26992|2018-06-01 01:19:59.26992
NCT00838526|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2015-06-08||2015-10-15|2009-02-05|2009-02-06|Estimate|2015-06-08|2015-06-23|Estimate||||2015-10-15|2015-11-11|Estimate|August 2008||2008-08-31|October 2015|2015-10-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)|Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|240|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 01:20:03.654157|2018-06-01 01:20:03.654157
NCT00838513|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2014-12-15||2015-06-30|2009-02-04|2009-02-06|Estimate|2015-01-19|2015-01-26|Estimate||||2015-06-30|2015-07-23|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|aHUS|The intent-to-treat (ITT) population was defined as all patients who received any amount of eculizumab, and were considered evaluable for safety and efficacy analyses. For both the efficacy and safety analyses, all 20 patients who were treated with study drug were included in the ITT population.|Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)|An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)|Completed||Phase 2|15|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-06-01 01:20:04.115823|2018-06-01 01:20:04.115823
NCT00838500|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2012-09-28|2009-02-05|2009-02-06|Estimate|||||||2012-09-28|2012-10-01|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Interventional|||THERMES ET VEINES: Spa for Prevention of Leg Ulcers|Evaluation of the Efficacy of Spa Treatment for Prevention of Leg Ulcers in Advanced Chronic Venous Insufficiency.|Completed||Phase 3|425|Actual|Association Francaise pour la Recherche Thermale||2|||f||||t||||||||||2018-06-01 01:20:04.789502|2018-06-01 01:20:04.789502
NCT00838487|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-10-09|2009-02-05|2009-02-06|Estimate|||||||2009-10-09|2009-10-12|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|March 2010|Anticipated|2010-03-31|July 2009|Anticipated|2009-07-31||Interventional|ZD20108||Evaluate Safety & Efficacy of Condroflex in Subjects With OA|Phase 3 Study, to Evaluate Safety & Efficacy of the Association Condroflex + Therapeutic Exercises Compared to Placebo + Therapeutic Exercises, in Subjects With Knee OA|Unknown status|Recruiting|Phase 3|240|Anticipated|Zodiac Produtos Farmaceuticos S.A.||2|||f||||t||||||||||2018-06-01 01:20:04.876847|2018-06-01 01:20:04.876847
NCT00838474|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants|The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants|Completed||N/A|20|Actual|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-06-01 01:20:04.956388|2018-06-01 01:20:04.956388
NCT00838461|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-07-31|2009-02-05|2009-02-06|Estimate|||||||2009-07-31|2009-08-03|Estimate|March 2009||2009-03-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016|Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of HSD-016 Administered Orally to Healthy Subjects|Completed||Phase 1|32|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:20:05.016312|2018-06-01 01:20:05.016312
NCT00838448|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2013-06-11|2009-02-04|2009-02-06|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|January 2011|Actual|2011-01-31||Interventional|||Interactions Between Physical Activity and Cannabis Use in Adults|Interactions Between Physical Activity and Cannabis Use in Adults|Completed||N/A|30|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 01:20:05.083436|2018-06-01 01:20:05.083436
NCT00838435|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2017-04-05|2009-02-05|2009-02-06|Estimate|||||||2017-04-05|2017-04-06|Actual|February 2009||2009-02-28|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|PKU-015||Effect of Kuvan on Neurocognitive Function, Blood Phenylalanine Level, Safety, and Pharmacokinetics in Children With PKU|A Phase 3b Open-Label Study to Evaluate the Effect of Kuvan® on Neurocognitive Function, Maintenance of Blood Phenylalanine Concentrations, Safety, and Population Pharmacokinetics in Young Children With Phenylketonuria|Active, not recruiting||Phase 3|230|Anticipated|BioMarin Pharmaceutical||1|||f||||f||||||||||2018-06-01 01:20:05.154179|2018-06-01 01:20:05.154179
NCT00838422|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Observational|||Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound|Repeatability and Reproducibility of Pachymetric Mapping With Fourier Domain Optical Coherence Tomography, Ocular Response Analyzer, Confoscan 4 and Ultrasound|Unknown status|Recruiting||100|Anticipated|Far Eastern Memorial Hospital|||1||f||||t||||||||||2018-06-01 01:20:05.529008|2018-06-01 01:20:05.529008
NCT00838409|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2011-09-13|2009-02-05|2009-02-06|Estimate|||||||2011-09-13|2011-09-14|Estimate|May 2008||2008-05-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||USDA Behavior, Motivation & Nutrition Study|Examination of Metabolic Determinants of Behavior and Motivation in Obesity: Implication to the Development of New Strategies for Achieving Body Weight Health|Completed|||40|Actual|USDA, Western Human Nutrition Research Center|||1||f||||f||||||Samples With DNA|"~     Blood and saliva samples will be kept for future research purposes.~   "|||2018-06-01 01:20:05.596659|2018-06-01 01:20:05.596659
NCT00838396|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2016-09-12|2009-02-05|2009-02-06|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2005||2005-10-31|September 2016|2016-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover, Single Dose-Finding Study to Assess the Efficacy and Safety of Controlled Release XP19986 in Patients With Gastroesophageal Reflux Disease|Completed||Phase 2|58|Actual|Indivior Inc.||2|||f||||f||||||||No||2018-06-01 01:20:05.663734|2018-06-01 01:20:05.663734
NCT00838383|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05||2012-01-27|2012-02-02|2009-02-05|2009-02-06|Estimate||||2012-02-02|2012-02-07|Estimate|2012-02-02|2012-02-07|Estimate|August 2006||2006-08-31|February 2012|2012-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|FCAD02||Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery|Selective Endothelin Type A Receptor Inhibition In Cardiac Surgery Subjects With Pre-Existing Cardiovascular Risk Factors: A Dose Confirmation Study|Completed||Phase 2|29|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:20:05.743026|2018-06-01 01:20:05.743026
NCT00838370|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2014-03-03|2009-02-05|2009-02-06|Estimate|||||||2014-03-03|2014-03-04|Estimate|May 2007||2007-05-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines|Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines|Completed||Phase 1|22|Actual|The Netherlands Cancer Institute||1|||f||||t||||||||||2018-06-01 01:20:05.830684|2018-06-01 01:20:05.830684
NCT00838357|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2015-03-19|2009-02-05|2009-02-06|Estimate|||||||2015-03-19|2015-03-24|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|PREDICT||A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).|Plerixafor and G−CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non−Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) − Safety Study in a General Autologous Transplant Population|Completed||Phase 3|118|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:20:05.913908|2018-06-01 01:20:05.913908
NCT00838344|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-09-28|2009-02-05|2009-02-06|Estimate|||||||2009-09-28|2009-09-30|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|January 2010|Anticipated|2010-01-31||Interventional|MAP||The Medication Adherence Program|The Medication Adherence Program:Promoting Diabetes Self-Management Through Community Pharmacies|Unknown status|Active, not recruiting|N/A|240|Anticipated|University of Washington||2|||f||||f||||||||||2018-06-01 01:20:06.098131|2018-06-01 01:20:06.098131
NCT00838331|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2015-02-13||2015-03-04|2009-02-05|2009-02-06|Estimate|2015-03-04|2015-03-06|Estimate||||2015-03-04|2015-03-06|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|INOBA|Only the 8 volunteers who completed both arms of this study are analyzed here.|Adverse Effects of RBC Transfusions: A Unifying Hypothesis|Adverse Effects of RBC Transfusions: A Unifying Hypothesis|Completed||Phase 2|24|Actual|Emory University|Primary limitation is that we are studying transfusion effects of fresh vs stored RBCs in healthy individuals, and not sick, anemic individuals as are often encountered in the hospital.|1|||f||||t||||||||||2018-06-01 01:20:06.177799|2018-06-01 01:20:06.177799
NCT00838318|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2012-07-26|2009-02-05|2009-02-06|Estimate|||||||2012-07-26|2012-07-30|Estimate|February 2004||2004-02-29|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Colon Cancer Screening in First-Degree Relatives of Hispanic Colorectal Cancer (CRC) Patients|Colorectal Cancer (CRC) Screening in First-Degree Relatives (FDRs) of Hispanic CRC Patients|Completed|||26|Actual|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-06-01 01:20:06.342126|2018-06-01 01:20:06.342126
NCT00838305|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2013-05-29|2009-02-05|2009-02-06|Estimate|||||||2013-05-29|2013-05-31|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|August 2011|Actual|2011-08-31|December 2009|Actual|2009-12-31||Interventional|||Role of Serotonin in Acute and Subacute MDMA Effects||Completed||N/A|13|Actual|California Pacific Medical Center Research Institute||2|||f||||||||||||||2018-06-01 01:20:06.414762|2018-06-01 01:20:06.414762
NCT00838292|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-03-12|2009-02-05|2009-02-06|Estimate|||||||2009-03-12|2009-03-13|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Impacts of Food Supplementation on Malnourished HIV-Infected Adults in Kenya|Randomized Controlled Evaluation of the Impact of Food Supplements on Malnourished HIV-Infected Adult ART Clients and Malnourished, HIV-Infected Pre-ART Adults in Kenya|Completed||N/A|1049|Actual|Academy for Educational Development||4|||f||||f||||||||||2018-06-01 01:20:06.478032|2018-06-01 01:20:06.478032
NCT00838279|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2009-06-30||2009-09-01|2009-02-05|2009-02-06|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|February 2002||2002-02-28|September 2009|2009-09-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Lamotrigine 25 mg Chewable Tablets, Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Dispersible Tablets and Lamictal® 25 mg Chewable Dispersible Tablets in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:06.573474|2018-06-01 01:20:06.573474
NCT00838266|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-09-22|2009-02-05|2009-02-06|Estimate|||||||2009-09-22|2009-09-23|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|Bain de bouche||Study of Growing Biofilm by an Antiplaque Mouthrinse|A Double Blind Randomized, Placebo-controlled, Cross-over Trial to Evaluate the Efficiency of a Mouthrinse, Containing Red Grape Seed Extract and nicométhanol Fluorhydrate, in the Control of Dental Plaque Deposit in a 4-days Plaque Regrowth Model|Completed||Phase 3|50|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:20:06.847635|2018-06-01 01:20:06.847635
NCT00838253|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2014-10-21|2009-02-05|2009-02-06|Estimate|||||||2014-10-21|2014-10-23|Estimate|June 2009||2009-06-30|October 2014|2014-10-31||||||||Interventional|||Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled Staggered Dose-escalating Phase IIb Study of the Safety and Efficacy of Istaroxime Over 24 Hours at Three Doses in Acute Decompensated Heart Failure Patients (The IGNITE Trial)|Withdrawn||Phase 2|0|Actual|Debiopharm International SA||4||The study was not started due to a re-evaluation of the istaroxime development program|f||||t||||||||||2018-06-01 01:20:06.923801|2018-06-01 01:20:06.923801
NCT00838240|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2012-07-19|2009-02-05|2009-02-06|Estimate|||||||2012-07-19|2012-07-20|Estimate|November 2008||2008-11-30|July 2012|2012-07-31||||December 2012|Anticipated|2012-12-31||Interventional|AML-14A||Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia|Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial)|Unknown status|Recruiting|Phase 1/Phase 2|114|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-06-01 01:20:07.051964|2018-06-01 01:20:07.051964
NCT00838227|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2014-09-16|2009-02-05|2009-02-06|Estimate|||||||2014-09-16|2014-09-18|Estimate|February 2008||2008-02-29|September 2014|2014-09-30|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|||Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder|Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study|Withdrawn||Phase 2|0|Actual|Manhattan Psychiatric Center||1||This study was withdrawn because there was no source of funding to implement the study.|f||||t||||||||||2018-06-01 01:20:07.206852|2018-06-01 01:20:07.206852
NCT00838214|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|March 2001||2001-03-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis|Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-Blind, Randomized, Active-Controlled, Multicentre Study|Completed||Phase 2/Phase 3|208|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-06-01 01:20:07.282922|2018-06-01 01:20:07.282922
NCT00838201|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2013-07-23||2013-11-01|2009-02-05|2009-02-06|Estimate|2013-07-23|2013-09-24|Estimate||||2013-11-01|2013-11-26|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer|Completed||Phase 3|384|Actual|Amgen||1|||f||||f||||||||||2018-06-01 01:20:07.399681|2018-06-01 01:20:07.399681
NCT00838188|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|March 2008|Actual|2008-03-31|||||Observational|||Energy Expenditure in Breast and Bottle Feeding Preterm Infants Fed Their Mother's Breast Milk|Energy Expenditure in Breast and Bottle Feeding Preterm Infants Fed Their Mother's Breast Milk|Completed|||23|Actual|Tel-Aviv Sourasky Medical Center|||5||f||||f||||||Samples Without DNA|"~     Maternal breast milk~   "|||2018-06-01 01:20:08.293112|2018-06-01 01:20:08.293112
NCT00838175|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|May 2009|Anticipated|2009-05-31|February 2009|Anticipated|2009-02-28||Observational|||Characteristics Predictive of Success and Complications in the Use of Suture-Mediated Closure of Femoral Venous Access|Characteristics Predictive of Success and Complications in the Use of Suture-Mediated Closure of Femoral Venous Access|Unknown status|Active, not recruiting||250|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||||2018-06-01 01:20:08.45487|2018-06-01 01:20:08.45487
NCT00838162|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2013-01-30|2011-07-01|2013-06-03|2009-02-05|2009-02-06|Estimate|2013-01-30|2013-03-07|Estimate|2011-07-01|2011-07-14|Estimate|2013-06-03|2013-06-12|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|February 2011|Actual|2011-02-28|August 2009|Actual|2009-08-31||Interventional|||A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients|A Phase IIa, Open-label, Randomized Trial in Treatment-naive HIV-1-infected Subjects to Determine the Antiviral Activity of 14 Days of Monotherapy With 4 Different Dose Regimens of TMC310911 Coadministered With Ritonavir|Completed||Phase 2|33|Actual|Tibotec Pharmaceuticals, Ireland||4|||f||||f||||||||||2018-06-01 01:20:08.57357|2018-06-01 01:20:08.57357
NCT00838149|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Effect of Glutamine on Intestinal Permeability in Crohn's Disease|Effect of Glutamine Supplementation on the Structure and Function of the Mucosa of Small Intestine in Crohn's Disease: A Randomized Controlled Trial|Completed||Phase 1|30|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 01:20:09.303699|2018-06-01 01:20:09.303699
NCT00838136|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2009-06-30||2009-09-01|2009-02-05|2009-02-06|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|February 2002||2002-02-28|September 2009|2009-09-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Lamotrigine 25 mg Chewable Tablets, Non-Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Lamotrigine 25 mg Chewable Dispersible Tablets and Lamictal® 25 mg Chewable Dispersible Tablets in Healthy Subjects Under Fed Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:09.399376|2018-06-01 01:20:09.399376
NCT00838123|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|||||Observational|||Cognitive Functioning Related to Job Tenure Among Patients With Schizophrenia||Completed|||60|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 01:20:09.685546|2018-06-01 01:20:09.685546
NCT00838110|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2012-10-11|2011-03-14|2013-01-07|2009-02-05|2009-02-06|Estimate|2013-01-07|2013-02-08|Estimate|2011-03-14|2011-03-25|Estimate|2013-01-07|2013-02-08|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease|A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease|Completed||Phase 3|742|Actual|Pfizer|This safety study did not specify primary or secondary outcome measures. Relevant summaries of all safety assessments are thus provided. Urine blood abnormalities seen are deemed due to interference with dipstick test by a metabolite of dimebon.|4|||f||||t||||||||||2018-06-01 01:20:09.778654|2018-06-01 01:20:09.778654
NCT00838097|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2014-03-04||2014-07-29|2009-02-05|2009-02-06|Estimate|2014-06-06|2014-07-09|Estimate||||2014-07-29|2014-08-01|Estimate|February 2008||2008-02-29|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28|2 Years|Observational [Patient Registry]||Full Analysis Set: all participants who received at least 1 dose of darbepoetin alfa during the study.|European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa|A Prospective Registry Study Observing the Safety and Patterns of Use of Darbepoetin Alfa in EU Paediatric Chronic Kidney Disease Patients Receiving or Not Receiving Dialysis|Completed|||321|Actual|Amgen|||1||f||||||||||||||2018-06-01 01:20:10.898302|2018-06-01 01:20:10.898302
NCT00838084|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-07-14|2009-02-05|2009-02-06|Estimate|||||||2009-07-14|2009-07-15|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Safety Study of LY2811376 Single Doses in Healthy Subjects|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2811376 in Healthy Subjects|Completed||Phase 1|61|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 01:20:11.492505|2018-06-01 01:20:11.492505
NCT00838071|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|October 2003||2003-10-31|February 2009|2009-02-28|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation|Evaluation of Anti-Hepatitis B Antibodies Levels in Serum After the Intravenous Administration of Specific Anti-Hepatitis B Immunoglobulin (IGIV-HB Grifols) in Patients Having Previously Undergone Liver Transplantation|Completed||Phase 3|20|Actual|Grifols Biologicals Inc.||1|||f||||f||||||||||2018-06-01 01:20:11.564042|2018-06-01 01:20:11.564042
NCT00838058|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-10-10|2009-02-05|2009-02-06|Estimate|||||||2009-10-10|2009-10-14|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.|An Open-Label Two-Part Randomized, Crossover Study Of The Pharmacokinetics Of CE-224,535 Administered As Controlled And Immediate Release Formulations In Healthy Volunteers|Completed||Phase 1|11|Actual|Pfizer||8|||f||||f||||||||||2018-06-01 01:20:11.642844|2018-06-01 01:20:11.642844
NCT00838045|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2011-12-07|2009-02-05|2009-02-06|Estimate|||||||2011-12-07|2011-12-09|Estimate|September 2006||2006-09-30|December 2011|2011-12-31|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL Intraocular Lens|A Prospective, Multi-Center Clinical Investigation to Evaluate the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL (Model MI60) Intraocular Lens|Completed||Phase 4|125|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 01:20:11.772568|2018-06-01 01:20:11.772568
NCT00838032|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-03-31|2009-02-05|2009-02-06|Estimate|||||||2009-03-31|2009-04-01|Estimate|August 2008||2008-08-31|March 2009|2009-03-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia||Unknown status|Recruiting|Phase 4|70|Anticipated|Sichuan University||2|||f||||t||||||||||2018-06-01 01:20:11.858735|2018-06-01 01:20:11.858735
NCT00838019|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Intrabone Cord Blood Transplantation|Pilot Study About Viability and Efficacy of Intrabone Administration of Umbilical Cord Blood for Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 4|10|Anticipated|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-06-01 01:20:12.007675|2018-06-01 01:20:12.007675
NCT00838006|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2014-07-16|2009-02-05|2009-02-06|Estimate|||||||2014-07-16|2014-07-17|Estimate|September 2008||2008-09-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Psychophysiologic Predictors of Post-deployment Mental Health Outcomes|Identification of and At-Risk Interventions for Pre-deployment Psychophysiologic Predictors of Post-deployment Mental Health Outcomes|Completed||N/A|426|Actual|Biomedical Research Foundation||3|||f||||f||||||||||2018-06-01 01:20:12.091769|2018-06-01 01:20:12.091769
NCT00837993|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2012-12-20|2009-02-05|2009-02-06|Estimate|||||||2012-12-20|2012-12-21|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System|An Ancillary Study of Patients With Advanced Stage Serous Carcinoma of the Ovary Treated on GOG Protocol 158: A Survival Analysis Based on Reclassification to a Two-tier Grading System|Completed|||241|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:20:12.196833|2018-06-01 01:20:12.196833
NCT00837980|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|||Functional Imaging in HNC Undergoing Chemoradiation|Investigation of the Role of Functional Imaging in Characterising Radiotherapy Target Volumes and Assessing Disease Response in Patients Undergoing Chemoradiation for Head and Neck Cancer (HNC)|Unknown status|Recruiting||10|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 01:20:12.269329|2018-06-01 01:20:12.269329
NCT00837967|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2010-07-05||2012-08-27|2009-02-05|2009-02-06|Estimate|2012-08-27|2012-08-29|Estimate||||2012-08-27|2012-08-29|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients|A Comparison of Tolerability of 10 Inhalations of Symbicort® Turbuhaler® 160/4.5 μg and 10 Inhalations of Terbutaline Turbuhaler® 0.4 mg on Top of Symbicort® Turbuhaler® 160/4.5 μg 1 Inhalation Bid, Randomized, Double-blind, Cross Over, Phase III Study in Japanese Adults Asthma Patients|Completed||Phase 3|25|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:20:12.362423|2018-06-01 01:20:12.362423
NCT00837954|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2015-05-27|2009-02-05|2009-02-06|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|COBBANA||Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis|Randomized, Controlled, Prospective Trial to Evaluate the Hemostatic Effect of Lyostypt® Versus Surgicel® in Arterial Bypass Anastomosis|Completed||Phase 4|32|Actual|Aesculap AG||4|||f||||f||||||||||2018-06-01 01:20:12.625117|2018-06-01 01:20:12.625117
NCT00837941|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2015-07-24|2009-02-05|2009-02-06|Estimate|||||||2015-07-24|2015-07-27|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|||A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)|Qualification of Single Dose Administration of Analgesic Therapy in the Treatment of Chronic Neuropathic Pain in Patients With Painful Diabetic Neuropathy|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:20:12.730103|2018-06-01 01:20:12.730103
NCT00837928|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|||2018-05-14|2009-02-05|2009-02-06|Estimate|||||||2018-05-14|2018-05-17|Actual|February 19, 2009|Actual|2009-02-19|May 2018|2018-05-31|January 8, 2015|Actual|2015-01-08|January 8, 2015|Actual|2015-01-08||Interventional|||Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors|Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1- 4 Brain Metastases From Solid Malignancies|Completed||Phase 1|18|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:20:12.810807|2018-06-01 01:20:12.810807
NCT00837915|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-02-05|2009-02-05|2009-02-06|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2002||2002-06-30|February 2009|2009-02-28|November 2002|Actual|2002-11-30|August 2002|Actual|2002-08-31||Interventional|||Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D® 24 Hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets, in Healthy Adult Volunteers Under Fasting Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:20:12.886261|2018-06-01 01:20:12.886261
NCT00837902|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-12-13|2009-02-05|2009-02-06|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2009||2009-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Genetic Determinants of Response to Beta Blockade|Genetic Determinants of Response to Beta Blockade|Completed||N/A|154|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 01:20:12.948056|2018-06-01 01:20:12.948056
NCT00837889|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2010-11-04|2009-02-05|2009-02-06|Estimate|||||||2010-11-04|2010-11-05|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|May 2011|Anticipated|2011-05-31|November 2010|Actual|2010-11-30||Observational|CogImpairHF||Cognitive Impairment in Patients With Heart Failure|Cognitive Impairment and Prognosis in Patients With Decompensated Heart Failure|Unknown status|Active, not recruiting||60|Actual|University Hospital, Saarland|||3||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:20:13.014116|2018-06-01 01:20:13.014116
NCT00837876|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-05|2012-04-02||2014-06-13|2009-02-05|2009-02-06|Estimate|2012-08-23|2012-09-28|Estimate||||2014-06-13|2014-06-25|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|April 2011|Actual|2011-04-30||Interventional|||Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery|A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer|Completed||Phase 2|37|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 01:20:13.104945|2018-06-01 01:20:13.104945
NCT00837863|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-05-06|2009-02-04|2009-02-05|Estimate|||||||2009-05-06|2009-05-07|Estimate|March 2009||2009-03-31|May 2009|2009-05-31||||September 2010|Anticipated|2010-09-30||Interventional|||Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency|A Twelve Month, Phase II, Randomized, Open-Label, Multi-Center, Dose-Ranging Study of Weekly ALTU-238 (Somatropin) as Compared With Daily Nutropin AQ (Somatropin) in Prepubertal Children With Growth Hormone Deficiency|Unknown status|Recruiting|Phase 2|36|Anticipated|Altus Pharmaceuticals||4|||f||||f||||||||||2018-06-01 01:20:13.58441|2018-06-01 01:20:13.58441
NCT00837850|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2011-08-25|2009-02-04|2009-02-05|Estimate|||||||2011-08-25|2011-08-26|Estimate|October 2002||2002-10-31|August 2011|2011-08-31|October 2008|Actual|2008-10-31|October 2003|Actual|2003-10-31||Interventional|||SmartSet HV and Palacos R RSA Bone Cements in Primary Total Hip Arthroplasty|A Randomised Prospective Trial of SmartSet HV and Palacos R Bone Cements in Primary Total Hip Arthroplasty. A Radiostereometric Analysis of the Charnley Femoral Component.|Completed||N/A|35|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 01:20:13.717809|2018-06-01 01:20:13.717809
NCT00837837|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2013-02-21|2009-02-04|2009-02-05|Estimate|||||||2013-02-21|2013-02-22|Estimate|December 2008||2008-12-31|February 2013|2013-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents|A Single-Dose, Open-Label, Pharmacokinetic Study of Chlorpheniramine Maleate Liquid in Children and Adolescents|Completed||Phase 2|36|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:20:13.802567|2018-06-01 01:20:13.802567
NCT00837824|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2008-12-05||2015-03-19|2009-02-04|2009-02-05|Estimate|2009-02-04|2009-02-05|Estimate||||2015-03-19|2015-04-07|Estimate|December 2002||2002-12-31|March 2015|2015-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme|A Phase 2, Randomized, Open Label, Dose-Ranging, Multiple Dose Study of Fabrazyme® In Patients With Fabry Disease and With Severe Renal Disease|Terminated||Phase 2|20|Actual|Sanofi|The trial was terminated early due to inadequate study design, leading to small numbers of subjects analyzed.|2||The trial was terminated early due to inadequate study design.|f||||t||||||||||2018-06-01 01:20:13.960751|2018-06-01 01:20:13.960751
NCT00837629|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2011-01-21|2009-02-04|2009-02-05|Estimate|||||||2011-01-21|2011-01-24|Estimate|February 2007||2007-02-28|January 2011|2011-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)|An Open-label Non-interventional Evaluation of Efficacy of Symbicort® Forte Turbuhaler 320/9 µg (Budesonide / Formoterol) and Symbicort® Turbuhaler® 160/4,5 µg (Budesonide / Formoterol)in Functional Status Improvement of Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||743|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:20:19.335687|2018-06-01 01:20:19.335687
NCT00837811|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2018-03-24|2011-04-05|2018-03-24|2009-02-03|2009-02-05|Estimate|2018-03-24|2018-04-25|Actual|2011-04-05|2011-04-13|Estimate|2018-03-24|2018-04-25|Actual|February 2009||2009-02-28|March 2018|2018-03-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional||Baseline was defined as Week 0 in this study [which is equivalent to Week 24 of the participant's prior study: Study H9B-MC-BCDG (NCT00689728) or Study H9B-MC-BCDH (NCT00785928)]. The baseline characteristics of participants who received any amount of study drug and had at least 1 post-baseline efficacy assessment were analyzed.|An Open Label Extension Study in Participants With Rheumatoid Arthritis|An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.|Completed||Phase 2|182|Actual|Eli Lilly and Company|Data integrity issues were identified at 1 study site involving 1 participant. Therefore, this site/participant is excluded from all efficacy analyses/results.|1|||f||||f||||||||||2018-06-01 01:20:14.621314|2018-06-01 01:20:14.621314
NCT00837798|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2012-12-18|2009-02-04|2009-02-05|Estimate|||||||2012-12-18|2012-12-20|Estimate|October 2006||2006-10-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|RATE||RATE Registry - Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population|Registry of AT/AF Episodes in the CRM Device Population: RATE Registry|Completed|||5379|Actual|St. Jude Medical|||1||f||||f||||||||||2018-06-01 01:20:17.116923|2018-06-01 01:20:17.116923
NCT00837785|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2018-02-13|2009-02-04|2009-02-05|Estimate|||||||2018-02-13|2018-02-15|Actual|February 28, 2009|Actual|2009-02-28|February 2018|2018-02-28|October 31, 2009|Actual|2009-10-31|October 31, 2009|Actual|2009-10-31||Interventional|||A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS|A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With Multiple Sclerosis|Completed||Phase 1|48|Actual|Biogen||2|||f||||f||||||||||2018-06-01 01:20:17.184594|2018-06-01 01:20:17.184594
NCT00837772|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2016-04-04|2009-02-04|2009-02-05|Estimate|||||||2016-04-04|2016-04-06|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2012|Actual|2012-07-31||Interventional|||Total Knee Replacement Study Using Standard Cutting Guide vs Otismed MRI Generated Cutting Guide|Total Knee Replacement Using Standard Knee Cutting Guides vs Otismed MRI Generated Cutting Guide|Completed||N/A|120|Actual|Phoenix VA Health Care System||2|||f||||f||||||||No||2018-06-01 01:20:17.253528|2018-06-01 01:20:17.253528
NCT00837759|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2012-03-24||2012-12-31|2009-02-04|2009-02-05|Estimate|2012-09-24|2012-10-24|Estimate||||2012-12-31|2013-01-03|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes|Novel Therapy Combining Regenerative Stimuli Immunomodulation to Preserve Beta Cell Function in New Onset Type 1 Diabetes|Terminated||Phase 2|7|Actual|National Institutes of Health Clinical Center (CC)||1||Changes to study personnel.|f||||f||||||||||2018-06-01 01:20:17.340739|2018-06-01 01:20:17.340739
NCT00837746|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2013-06-03|2009-02-04|2009-02-05|Estimate|||||||2013-06-03|2013-06-05|Estimate|April 2003||2003-04-30|June 2013|2013-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate|Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Risedronate Daily or Weekly|Completed|||29|Actual|Warner Chilcott|||1||f||||f||||||||||2018-06-01 01:20:18.523582|2018-06-01 01:20:18.523582
NCT00837733|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Endometrial Local Injury and Implantation Failure|Endometrial Local Injury Improves the Pregnancy Rate Among Recurrent Implantation Failure Patients Undergoing IVF/ICSI|Completed||N/A|115|Actual|Yazd Research & Clinical Center for Infertility||1|||f||||t||||||||||2018-06-01 01:20:18.615986|2018-06-01 01:20:18.615986
NCT00837720|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-05|2009-02-04|2009-02-05|Estimate|||||||2009-02-05|2009-02-06|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|June 2007|Actual|2007-06-30|||||Observational|||Evaluation of Atacand® (Candesartan) in Daily Medical Practice|A 12-Week Open-Label Non-Interventional Evaluation of Atacand® (Candesartan) Efficacy, Tolerability, Compliance and Treatment Satisfaction in Patients With Arterial Hypertension|Completed|||750|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:20:18.696602|2018-06-01 01:20:18.696602
NCT00837707|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|February 2010|Anticipated|2010-02-28|August 2009|Anticipated|2009-08-31||Interventional|||Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia|Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study|Unknown status|Recruiting|Phase 4|25|Anticipated|Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan|||||f||||f||||||||||2018-06-01 01:20:18.778754|2018-06-01 01:20:18.778754
NCT00837694|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Snack Food Reinforcement in Obese and Non-Obese Women|Differential Effects of Daily Snack Food Intake on Reinforcing Value of Food in Obese and Non-Obese Women.|Completed|||||State University of New York at Buffalo|||6||f||||f||||||||||2018-06-01 01:20:18.869922|2018-06-01 01:20:18.869922
NCT00837681|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-02-24|2009-02-04|2009-02-05|Estimate|||||||2017-02-24|2017-02-27|Actual|October 2005||2005-10-31|July 2016|2016-07-31|July 8, 2016|Actual|2016-07-08|July 8, 2016|Actual|2016-07-08||Observational|||Pulmonary Complications of Hematopoietic Stem Cell Transplantation|Pulmonary Complications of Hematopoietic Stem Cell Transplantation|Completed|||350|Actual|Ohio State University|||1||f||||t||||||Samples With DNA|"~     Blood draw will be 10cc of blood, analysis includes % of CD8+CD57+ and CD8+CD28-. On one~     occasion, after the 6 mo. post transplant timepoint the subject will be asked to donate a~     larger amount of blood (50cc) if they are not anemic.~      ***Respiratory Specimens of extra BAL or biopsy specimens will be collected at any point a~     study patient undergoes a clinically warranted bronchoscopy or lung biopsy procedure and the~     diagnostic physician feels there is adequate specimen to use extra sample for research~     purposes.~   "|||2018-06-01 01:20:18.944778|2018-06-01 01:20:18.944778
NCT00837668|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-06-12|2009-02-04|2009-02-05|Estimate|||||||2017-06-12|2017-06-14|Actual|April 2005||2005-04-30|June 2017|2017-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Stromal Gene Expression During Pulmonary Sarcoidosis|Stromal Gene Expression During Pulmonary Sarcoidosis|Terminated|||110|Anticipated|Ohio State University|||1|Interim analysis|f||||f||||||Samples With DNA|"~     lung tissue~   "|||2018-06-01 01:20:19.005807|2018-06-01 01:20:19.005807
NCT00837655|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2012-09-25|2009-02-04|2009-02-05|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SIR||Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)|Study of the Effect of Treatment With Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure|Withdrawn||N/A|0|Actual|Karolinska Institutet||2||PI retired|f||||t||||||||||2018-06-01 01:20:19.070987|2018-06-01 01:20:19.070987
NCT00837616|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2013-05-28||2014-02-26|2009-02-04|2009-02-05|Estimate|2013-12-19|2014-02-10|Estimate||||2014-02-26|2014-03-27|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism|Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism|Completed||Phase 4|41|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-06-01 01:20:19.420272|2018-06-01 01:20:19.420272
NCT00837603|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2012-03-08|2009-02-04|2009-02-05|Estimate|||||||2012-03-08|2012-03-09|Estimate|February 2009||2009-02-28|July 2011|2011-07-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|TrainingTGA||Physical Training in Transposition of the Great Arteries|Influence of Physical Training on Cardiopulmonary Exercise Capacity and Right Ventricular Function in Patients With D-TGA and Atrial Switch Operation.|Completed||N/A|48|Anticipated|Hannover Medical School||2|||f||||t||||||||||2018-06-01 01:20:19.843131|2018-06-01 01:20:19.843131
NCT00837590|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2012-05-21|2009-02-04|2009-02-05|Estimate|||||||2012-05-21|2012-05-22|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls|Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls|Completed||N/A|14|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 01:20:19.927466|2018-06-01 01:20:19.927466
NCT00837577|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2011-08-09||2017-04-10|2009-02-03|2009-02-05|Estimate|2011-08-09|2011-09-13|Estimate||||2017-04-10|2017-05-15|Actual|February 5, 2009|Actual|2009-02-05|April 2017|2017-04-30|August 11, 2010|Actual|2010-08-11|August 11, 2010|Actual|2010-08-11||Interventional|||MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)|A Phase III, Randomized, Placebo-controlled, Double-blind Clinical Trial and Subsequent Open-label, Extension Clinical Trial to Study the Efficacy and Safety of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Voglibose Monotherapy|Completed||Phase 3|133|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:20:20.039005|2018-06-01 01:20:20.039005
NCT00837564|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2010-06-29|2009-02-04|2009-02-05|Estimate|||||||2010-06-29|2010-06-30|Estimate|February 2009||2009-02-28|July 2010|2010-07-31|April 2011|Anticipated|2011-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression|Differential Responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP)Versus Escitalopram in Chronic Major Depression With and Without Early Trauma|Unknown status|Recruiting|Phase 3|60|Anticipated|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 01:20:20.344869|2018-06-01 01:20:20.344869
NCT00837551|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-05|Estimate|||||||2009-02-03|2009-02-05|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|WBI-1001-201||Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis|A Randomized, Double-Blinded, Vehicle-Controlled Phase IIa Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Atopic Dermatitis.|Completed||Phase 1/Phase 2|36|Actual|Welichem Biotech Inc.||3|||f||||t||||||||||2018-06-01 01:20:20.420284|2018-06-01 01:20:20.420284
NCT00837538|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2011-03-18|2009-02-04|2009-02-05|Estimate|||||||2011-03-18|2011-03-21|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Screening of Instability of the Spinal Column With Spinal Mouse® and X-ray|A Comparison of Spinal Mouse® and X-ray Film to Measure a Instability of Lumbar Spine|Completed|||100|Actual|Jyväskylä Central Hospital|||1||f||||f||||||||||2018-06-01 01:20:20.592086|2018-06-01 01:20:20.592086
NCT00837525|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Validity Study of a Nasal Valve Implant|Validity of Biodegradable Injectable Implant for the Treatment of External Nasal Valve Collapse.|Unknown status|Enrolling by invitation|N/A|4|Anticipated|Nasoform, LLC|||||f||||f||||||||||2018-06-01 01:20:20.664169|2018-06-01 01:20:20.664169
NCT00837512|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2013-08-13||2013-11-20|2009-02-04|2009-02-05|Estimate|2013-11-20|2014-01-08|Estimate||||2013-11-20|2014-01-08|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Insulin Delivery Using Microneedles in Type 1 Diabetes|Insulin Delivery Using Microneedles in Type 1 Diabetes|Completed||Phase 2/Phase 3|16|Actual|Emory University||2|||f||||t||||||||||2018-06-01 01:20:20.733004|2018-06-01 01:20:20.733004
NCT00837499|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-11-22|2009-02-04|2009-02-05|Estimate|||||||2017-11-22|2017-11-27|Actual|September 2008|Actual|2008-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.|Comparative Study of Breast Cancers and Their Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.|Recruiting|||1825|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||Samples With DNA|"~     One-time blood draw (about 3 tablespoons). If blood cannot be drawn or not enough blood can~     be drawn, a saliva sample will be taken.~   "|||2018-06-01 01:20:20.920192|2018-06-01 01:20:20.920192
NCT00837486|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2015-03-13||2015-05-06|2009-02-03|2009-02-05|Estimate|2015-05-06|2015-05-28|Estimate||||2015-05-06|2015-05-28|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|April 2013|Actual|2013-04-30|December 2010|Actual|2010-12-31||Interventional||All enrolled participants are included.|Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression|Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression|Completed||Phase 2|30|Actual|MedtronicNeuro|With this 30-subject cohort, and only 29 subjects completing the blinded-treatment phase per protocol, the comparisons of response rates and improvements were not adequately powered.|2|||f||||t||||||||||2018-06-01 01:20:21.041099|2018-06-01 01:20:21.041099
NCT00837473|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2018-03-13||2018-04-26|2009-02-04|2009-02-05|Estimate|2018-04-26|2018-04-30|Actual||||2018-04-26|2018-04-30|Actual|January 2009||2009-01-31|September 2012|2012-09-30|October 2011|Actual|2011-10-31|March 2011|Actual|2011-03-31||Interventional|||Study Performance of The Plexur P™ Bone Void Filler Device in Patients Undergoing Iliac Crest Harvesting Procedures|A Prospective Pilot Study on the Performance of The Plexur P™ Bone Void Filler|Completed||N/A|15|Actual|Medtronic Spinal and Biologics||1|||f||||f||||||||||2018-06-01 01:20:21.504227|2018-06-01 01:20:21.504227
NCT00837460|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2010-03-29|2009-02-04|2009-02-05|Estimate|||||||2010-03-29|2010-03-30|Estimate|September 2006||2006-09-30|March 2010|2010-03-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Effect of Rehabilitation of Patients With a Central Nervous System Lesion||Completed||N/A|15|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-06-01 01:20:21.806273|2018-06-01 01:20:21.806273
NCT00837447|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2011-06-23||2013-03-05|2009-02-04|2009-02-05|Estimate|2013-03-05|2013-04-10|Estimate||||2013-03-05|2013-04-10|Estimate|October 2004||2004-10-31|March 2013|2013-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Range of Motion of Standard and High-Flexion Posterior Cruciate Retaining Total Knee Prostheses|Range of Motion of Standard and High-Flexion Posterior Cruciate Retaining Total Knee Prostheses A Prospective, Randomized Study|Completed||Phase 4|54|Actual|Ewha Womans University|First, the knee scoring system is prone to intraobserver variability. Second, we had no interobserver variability and this could have lead to bias in interpreting radiographic results.|2|||f||||f||||||||||2018-06-01 01:20:21.866186|2018-06-01 01:20:21.866186
NCT00837434|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2015-03-18|2015-01-30|2017-11-07|2009-02-03|2009-02-05|Estimate|2015-04-10|2015-04-14|Estimate|2015-01-30|2015-02-19|Estimate|2017-11-07|2017-12-11|Actual|March 2009||2009-03-31|November 2017|2017-11-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional||The Modified Intent-to-Treat population included all randomized subjects who received at least one dose of either etanercept or adalimumab.|Anti-TNF Agents for the Treatment of Rheumatoid Arthritis|A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis|Completed||Phase 4|63|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:20:22.008734|2018-06-01 01:20:22.008734
NCT00837421|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-01-30|2009-02-04|2009-02-05|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2006||2006-12-31|January 2017|2017-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||The Ohio State University Sepsis Registry|The Ohio State University Sepsis Registry|Terminated|||230|Actual|Ohio State University|||1|Lack of resources has prevented the study from continuation.|f||||f||||||Samples With DNA|"~     Blood~   "|No|The study was terminated and after analysis data integrity issues prohibited accurate IPD sharing. The data records have been destroyed.|2018-06-01 01:20:22.649974|2018-06-01 01:20:22.649974
NCT00837408|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2018-04-04|2009-02-04|2009-02-05|Estimate|||||||2018-04-04|2018-04-05|Actual|February 3, 2009||2009-02-03|August 30, 2017|2017-08-30||||||||Observational|||Genetics of Type 2 Diabetes Among Han Chinese|Genetics of Type 2 Diabetes Among Han Chinese|Completed|||2379|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:20:22.713384|2018-06-01 01:20:22.713384
NCT00837395|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-01-17|2009-02-04|2009-02-05|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma|Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma|Recruiting|||25|Anticipated|Ohio State University|||1||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 01:20:22.773148|2018-06-01 01:20:22.773148
NCT00837382|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2010-09-28|2009-02-03|2009-02-05|Estimate|||||||2010-09-28|2010-09-29|Estimate|January 2010||2010-01-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD)|Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD)|Terminated||N/A|7|Anticipated|VA Office of Research and Development||2||Primary investigator is no longer a part of the VA.|f||||f||||||||||2018-06-01 01:20:22.847614|2018-06-01 01:20:22.847614
NCT00837369|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-07-19|2009-02-03|2009-02-05|Estimate|||||||2012-07-19|2012-07-23|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Regadenoson R-T Perfusion Imaging Trial|Regadenoson Real Time Perfusion Imaging Trial|Completed||N/A|100|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 01:20:22.909292|2018-06-01 01:20:22.909292
NCT00837356|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-02-09|2009-02-04|2009-02-05|Estimate|||||||2017-02-09|2017-02-10|Actual|March 2009||2009-03-31|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects|A Multi-centre, Multi-national Open-label Sequential Trial Comparing Pharmacokinetics and Safety of N8 and Advate® in Subjects With Haemophilia A|Completed||Phase 1|23|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 01:20:22.983323|2018-06-01 01:20:22.983323
NCT00837343|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|December 2008||2008-12-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder|An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder|Unknown status|Recruiting|Phase 4|120|Anticipated|Guangzhou Mental Hospital||1|||f||||t||||||||||2018-06-01 01:20:23.082349|2018-06-01 01:20:23.082349
NCT00837330|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2011-11-03||2014-11-17|2009-02-04|2009-02-05|Estimate|2014-05-21|2014-06-23|Estimate||||2014-11-17|2014-12-03|Estimate|May 2006||2006-05-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||10 subjects were enrolled into each of the two ranibizumab groups (0.3 mg/ 0.5 mg)|Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy|Treatment of Polypoidal Choroidal Vasculopathy With Ranibizumab(Lucentis): A Phase I/II Safety Study.|Completed||Phase 1/Phase 2|20|Actual|Southeast Retina Center, Georgia||2|||f||||f||||||||||2018-06-01 01:20:23.172162|2018-06-01 01:20:23.172162
NCT00837317|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-05-12|2009-02-04|2009-02-05|Estimate|||||||2009-05-12|2009-05-13|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Different Oils For Frying and Endothelial Function|Comparative Effect Of Different Oils For Frying On The Endothelial Function, The Oxidative Stress And The Postprandial Inflammatory Response|Completed||N/A|26|Actual|Hospital Universitario Reina Sofia de Cordoba||1|||f||||f||||||||||2018-06-01 01:20:23.449216|2018-06-01 01:20:23.449216
NCT00837304|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2012-12-07|2009-02-04|2009-02-05|Estimate|||||||2012-12-07|2012-12-10|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Colon Capsule Endoscopy Versus Standard Colonoscopy in Ulcerative Colitis|Colon Capsule Endoscopy Versus Standard Colonoscopy in Assessing Disease Activity in Patients With Ulcerative Colitis - A Prospective Trial|Terminated|||14|Actual|University Hospital Muenster|||1||f||||t||||||||||2018-06-01 01:20:23.540142|2018-06-01 01:20:23.540142
NCT00837291|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2018-01-30|2009-02-04|2009-02-05|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2018|Anticipated|2018-11-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Daily CF101 Administered Orally for 12 Weeks to Patients With Osteoarthritis of the Knee|Withdrawn||Phase 2|0|Actual|Can-Fite BioPharma||2||The company has decided not to conduct the study|f||||t|t|f||||||||2018-06-01 01:20:23.602141|2018-06-01 01:20:23.602141
NCT00837278|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-09-17|2009-02-04|2009-02-05|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|March 2010|Anticipated|2010-03-31||Observational|||Maternal Serum Cytokine Levels and Angiogenic Factor Levels in IVF vs Spontaneously Conceived Pregnancies|Maternal Serum Cytokine Levels and Angiogenic Factor Levels in Singleton IVF Pregnancies vs Spontaneously Conceived Pregnancies|Unknown status|Recruiting||40|Anticipated|MemorialCare|||2||f||||f||||||Samples Without DNA|"~     Maternal blood draws are to be performed at four times. These are 10-15 weeks, 22-28 weeks,~     34-40 weeks, and 4-8 weeks postpartum. Additionally, placental biopsies and umbilical cord~     blood specimens are to be collected for possible future analysis.~   "|||2018-06-01 01:20:23.685531|2018-06-01 01:20:23.685531
NCT00837265|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04||2013-08-27|2016-07-19|2009-02-04|2009-02-05|Estimate||||2013-08-27|2013-09-12|Estimate|2016-07-19|2016-07-21|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|July 2010|Actual|2010-07-31|September 2009|Actual|2009-09-30||Interventional|NEUGR-002||Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel|A Randomized Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel)|Completed||Phase 2/Phase 3|334|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 01:20:23.763551|2018-06-01 01:20:23.763551
NCT00837252|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2011-04-21||2016-09-22|2009-02-04|2009-02-05|Estimate|2011-04-21|2011-05-16|Estimate||||2016-09-22|2016-09-26|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy|Completed||Phase 1/Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 01:20:23.861653|2018-06-01 01:20:23.861653
NCT00837239|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-07-10|2009-02-03|2009-02-05|Estimate|||||||2012-07-10|2012-07-12|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Huachansu & Gemcitabine in Pancreatic Cancer|A Randomized, Placebo-controlled, Blinded Phase II Study of Huachansu & Gemcitabine in Pancreatic Cancer|Completed||Phase 2|80|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 01:20:24.1684|2018-06-01 01:20:24.1684
NCT00837226|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2015-12-04|2009-02-04|2009-02-05|Estimate|||||||2015-12-04|2015-12-08|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|IOP||Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure (IOP)|The Effects of Weight Loss From Bariatric Surgery on Intraocular Pressure|Withdrawn|||0|Actual|The University of Texas Health Science Center, Houston|||2||f||||f||||||||||2018-06-01 01:20:24.243655|2018-06-01 01:20:24.243655
NCT00837213|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2010-04-07||2017-05-24|2009-02-04|2009-02-05|Estimate|2010-08-06|2010-08-31|Estimate||||2017-05-24|2017-05-25|Actual|August 2007||2007-08-31|May 2017|2017-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne|Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne|Completed||Phase 4|33|Actual|GlaxoSmithKline|Small sample size did not provide adequate power. Even with the limited sample size, total lesion counts provides a more reliable view of the study data due to the greater number of lesions to work with.|2|||f||||f||||||||||2018-06-01 01:20:24.307706|2018-06-01 01:20:24.307706
NCT00837200|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2014-05-02||2017-06-23|2009-02-04|2009-02-05|Estimate|2014-08-01|2014-08-20|Estimate||||2017-06-23|2017-07-24|Actual|March 2009||2009-03-31|June 2017|2017-06-30|October 2013|Actual|2013-10-31|January 2011|Actual|2011-01-31||Interventional|||Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies|Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies|Terminated||Phase 2|13|Actual|Milton S. Hershey Medical Center||1||PI said to close accrual do to funding|f||||t||||||||||2018-06-01 01:20:24.637071|2018-06-01 01:20:24.637071
NCT00837187|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2010-01-12|2009-02-04|2009-02-05|Estimate|||||||2010-01-12|2010-01-13|Estimate|March 2009||2009-03-31|January 2009|2009-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|INDEX||Bioavailability of Dexmedetomidine After Intranasal Administration|Bioavailability of Dexmedetomidine After Intranasal Administration in Healthy Subjects|Completed||Phase 1|7|Actual|University of Turku||2|||f||||f||||||||||2018-06-01 01:20:24.91896|2018-06-01 01:20:24.91896
NCT00837174|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2017-09-15|2009-02-04|2009-02-05|Estimate|||||||2017-09-15|2017-09-19|Actual|June 2010||2010-06-30|September 2017|2017-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|COMBOSTAT||Relapsed and/or Refractory Non-Hodgkin Lymphoma Study|Phase II Study of Combination Vorinostat and Bortezomib in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma|Withdrawn||Phase 2|0|Actual|The Methodist Hospital System||1||Study never activated/opened as funding source and other support not available.|f||||t||||||||Undecided|To be determined|2018-06-01 01:20:24.998379|2018-06-01 01:20:24.998379
NCT00837161|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2011-07-01||2012-11-30|2009-02-04|2009-02-05|Estimate|2011-10-20|2011-11-28|Estimate||||2012-11-30|2012-12-04|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids|Completed||Phase 1/Phase 2|11|Actual|Philips Healthcare||1|||f||||f||||||||||2018-06-01 01:20:25.090856|2018-06-01 01:20:25.090856
NCT00837148|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2015-10-19||2015-10-19|2009-02-04|2009-02-05|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Sorafenib and Dacarbazine in Soft Tissue Sarcoma|Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma|Completed||Phase 2|37|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:20:25.327517|2018-06-01 01:20:25.327517
NCT00837135|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2016-08-16|2009-02-04|2009-02-05|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||GI-4000 With Adoptive Transfer in Pancreatic Cancer|Pilot Study Of Safety And Feasibility Of GI-4000, An Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With Adoptive Transfer And Chemoradiation in Locally Advanced Pancreatic Cancer|Withdrawn||Phase 1|0|Actual|University of Pennsylvania||4||Withdrawn due to transfer of Investigator|f||||f||||||||||2018-06-01 01:20:25.501061|2018-06-01 01:20:25.501061
NCT00837122|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2018-05-08|2009-02-04|2009-02-05|Estimate|||||||2018-05-08|2018-05-09|Actual|February 3, 2009||2009-02-03|April 27, 2018|2018-04-27||||||||Observational|||Genetics of Type 2 Diabetes in West Africans|Genetics of Tye 2 Diabetes in Diverse Populations|Recruiting|||9000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:20:25.583603|2018-06-01 01:20:25.583603
NCT00837109|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2010-09-28|2009-02-03|2009-02-05|Estimate|||||||2010-09-28|2010-09-29|Estimate|February 2009||2009-02-28|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Randomized Clinical Trial of Imagery Rescripting Treatment In Veterans With Trauma-Related Nightmares And Posttraumatic Stress Disorder (PTSD)|Randomized Clinical Trial of Imagery Rescripting Treatment In Veterans With Trauma-Related Nightmares And Posttraumatic Stress Disorder (PTSD)|Terminated||N/A|50|Anticipated|VA Office of Research and Development||2||Primary investigator is no longer a part of the VA|f||||f||||||||||2018-06-01 01:20:25.65084|2018-06-01 01:20:25.65084
NCT00837096|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2013-10-10|2009-02-04|2009-02-05|Estimate|||||||2013-10-10|2013-10-14|Estimate|June 2007||2007-06-30|October 2013|2013-10-31||||April 2008|Actual|2008-04-30||Interventional|VAC 2006-19||A Study Comparing V.A.C. Negative Pressure Wound Therapy (NPWT) to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Amputation Wounds|A Prospective, Randomized, Multicenter, Parallel Study Comparing V.A.C. Negative Pressure Wound Therapy (NPWT) to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Amputation Wounds|Terminated||N/A|17|Actual|KCI USA, Inc.||2||Business objectives changed.|f||||t||||||||||2018-06-01 01:20:25.714305|2018-06-01 01:20:25.714305
NCT00837083|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-05|2009-02-04|2009-02-05|Estimate|||||||2009-02-05|2009-02-06|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|October 2007|Actual|2007-10-31|||||Observational|||Evaluation of Crestor® (Rosuvastatin) in Daily Practice|Open-Label Non-Interventional Evaluation of Efficacy of Crestor® (Rosuvastatin) in Reduction of LDL-Cholesterol and Cardiovascular Risk Parameters in Patients With Hypercholesterolaemia|Completed|||602|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:20:25.779682|2018-06-01 01:20:25.779682
NCT00837070|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2017-09-26|2009-02-04|2009-02-05|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2009||2009-01-31|September 2017|2017-09-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Percutaneous Rupture of Zygapophyseal Joint Cysts|Percutaneous Rupture of Zygapophyseal Joint Cysts|Completed||Phase 2|26|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-06-01 01:20:25.834612|2018-06-01 01:20:25.834612
NCT00837057|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|February 2009||2009-02-28|January 2009|2009-01-31||||January 2011|Anticipated|2011-01-31||Interventional|||Early Continuous Renal Replacement Therapies (CRRT) in Patients With Severe Sepsis or Septic Shock With Acute Kidney Injury|A Randomized Controlled Multi-Center Trial of the Early Application of CRRT in Patients With Severe Sepsis or Septic Shock|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-06-01 01:20:25.909278|2018-06-01 01:20:25.909278
NCT00837044|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|||2009-02-04|2009-02-04|2009-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|July 2009|Anticipated|2009-07-31||Interventional|||Treximet in Acute Migraine Headache: Assessing Cognitive Function|An Evaluation of Treximet in the Treatment of Acute Migraine Headache: A Placebo-Controlled, Double-Blind, Crossover Study, Assessing Cognitive Function.|Unknown status|Recruiting|N/A|30|Anticipated|Neurological Research Center||2|||f||||f||||||||||2018-06-01 01:20:25.98545|2018-06-01 01:20:25.98545
NCT00837031|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-04|2013-02-08||2013-02-08|2009-02-04|2009-02-05|Estimate|2013-02-08|2013-03-13|Estimate||||2013-02-08|2013-03-13|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|June 2012|Actual|2012-06-30|April 2010|Actual|2010-04-30||Interventional|||Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas|A Phase II Study of Lenalidomide in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas|Completed||Phase 2|72|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 01:20:26.079681|2018-06-01 01:20:26.079681
NCT00837018|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2013-03-04|2009-02-03|2009-02-04|Estimate|||||||2013-03-04|2013-03-05|Estimate|June 2005||2005-06-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2010|Actual|2010-05-31||Interventional|EXAOS||Exercise Intolerance in Obstructive Sleep Apnea Syndrome Patients|Exercise Intolerance in Obstructive Sleep Apnea Syndrome Patients: Cardiovascular and Metabolic Characterisation During Exercise. Treatments Effect.|Completed||N/A|30|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-06-01 01:20:26.277015|2018-06-01 01:20:26.277015
NCT00837005|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-03-28|2009-02-03|2009-02-04|Estimate|||||||2012-03-28|2012-04-02|Estimate|January 2005||2005-01-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|DS-Prognosis||Prognostic Value of High Dose Dobutamine Stress Magnetic Resonance Imaging|Prognostic Value of High Dose Dobutamine Stress Magnetic Resonance in Patients With Ischemic Heart Disease. Assessment of Myocardial Perfusion and Wall Motion.|Completed|||2500|Actual|Heidelberg University|||2||f||||f||||||||||2018-06-01 01:20:26.336208|2018-06-01 01:20:26.336208
NCT00836992|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2017-05-23|2009-02-03|2009-02-04|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2009|Actual|2009-01-31|May 2017|2017-05-31|July 27, 2015|Actual|2015-07-27|September 15, 2011|Actual|2011-09-15||Observational|||Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer|Assessing the Clinical Significance of Real-time Quality of Life Data in Cancer Patients Treated With Radiation Therapy|Completed|||144|Actual|Mayo Clinic|||2||f||||t||||||||||2018-06-01 01:20:26.391782|2018-06-01 01:20:26.391782
NCT00836979|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2015-04-03|2009-02-03|2009-02-04|Estimate|||||||2015-04-03|2015-04-07|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|RRISK3||Urinary Incontinence: Reproductive/Hormonal Risk Factors|Urinary Incontinence: Reproductive/Hormonal Risk Factors III|Completed|||2161|Actual|Kaiser Permanente|||||f||||f||||||Samples With DNA|"~     Sera will be banked for this cohort.~   "|||2018-06-01 01:20:26.464167|2018-06-01 01:20:26.464167
NCT00836966|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Sampling Biomarkers in Meniscus Injury to the Knee|Diagnostic Utility of Cytokine Biomarkers in the Evaluation of Acute Knee Pain|Completed|||73|Actual|Scuderi, Gaetano J., M.D.|||||f||||f||||||Samples Without DNA|"~     saline lavage from joint space~   "|||2018-06-01 01:20:26.52091|2018-06-01 01:20:26.52091
NCT00836953|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2009-07-20||2016-04-12|2009-02-03|2009-02-04|Estimate|2009-07-20|2009-08-27|Estimate||||2016-04-12|2016-04-14|Estimate|September 2003||2003-09-30|April 2016|2016-04-30|July 2004|Actual|2004-07-31|January 2004|Actual|2004-01-31||Interventional|||Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®|A Trial for the Collection of Sera in Healthy Children Receiving Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® 2003/2004|Completed||Phase 4|33|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:20:26.579132|2018-06-01 01:20:26.579132
NCT00836940|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-09-23|2009-02-03|2009-02-04|Estimate|||||||2009-09-23|2009-09-24|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|October 2009|Anticipated|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus|A 12-week Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of GRC 8200, a New Oral DPP -IV Inhibitor, in Patients With Type 2 Diabetes Mellitus.|Unknown status|Active, not recruiting|Phase 2|480|Anticipated|Glenmark Pharmaceuticals Europe Ltd. (R&D)||5|||f||||t||||||||||2018-06-01 01:20:26.817208|2018-06-01 01:20:26.817208
NCT00836927|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2018-04-03||2018-04-03|2009-02-03|2009-02-04|Estimate|2018-04-03|2018-05-03|Actual||||2018-04-03|2018-05-03|Actual|February 1, 2009|Actual|2009-02-01|April 2018|2018-04-30|July 9, 2018|Anticipated|2018-07-09|April 3, 2017|Actual|2017-04-03||Interventional|||Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)|An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer|Active, not recruiting||Phase 2|7|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-06-01 01:20:26.894366|2018-06-01 01:20:26.894366
NCT00836914|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2013-01-04|2009-02-03|2009-02-04|Estimate|||||||2013-01-04|2013-01-08|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-101 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge|Completed||Phase 1|41|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 01:20:27.926834|2018-06-01 01:20:27.926834
NCT00836901|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2009-05-07||2009-07-06|2009-02-03|2009-02-04|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|September 2003||2003-09-30|July 2009|2009-07-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Non-Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets and AUGMENTIN® 400 mg-57 mg Chewable Tablets Administered as 1 x 400 mg-57 mg Chewable Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|52|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:28.058318|2018-06-01 01:20:28.058318
NCT00836888|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2016-11-24|2009-02-03|2009-02-04|Estimate|||||||2016-11-24|2016-11-28|Estimate|January 2009||2009-01-31|April 2015|2015-04-30||||September 2010|Actual|2010-09-30||Interventional|||ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan|ONO-4538 Phase I Study - A Single Center, Open Label, Dose Escalation Single Dose, Followed by Multiple Dose Study of ONO-4538, a Fully Human mAb to PD-1, in Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|17|Actual|Ono Pharmaceutical Co. Ltd||1|||f||||||||||||||2018-06-01 01:20:28.364906|2018-06-01 01:20:28.364906
NCT00836875|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2014-05-09||2017-05-23|2009-02-03|2009-02-04|Estimate|2014-06-19|2014-06-23|Estimate||||2017-05-23|2017-06-16|Actual|May 2009|Actual|2009-05-31|May 2017|2017-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Safety population: included all participants who received at least 1 dose of study medication.|A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children|A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.|Terminated||Phase 3|31|Actual|Pfizer|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns. Interpretation of the data are limited due to the small sample size and descriptive design.|1||"This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any~   safety issues or concerns."|f||||t||||||||||2018-06-01 01:20:28.471113|2018-06-01 01:20:28.471113
NCT00836862|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2018-02-01|2009-02-03|2009-02-04|Estimate|||||||2018-02-01|2018-02-05|Actual|February 1, 2009|Actual|2009-02-01|February 2018|2018-02-28|September 7, 2017|Actual|2017-09-07|November 10, 2012|Actual|2012-11-10||Observational|||Arteriovenous Fistula Tissue Bank|Arteriovenous Fistula Tissue Bank|Completed|||43|Actual|University of Nebraska|||1||f||||f||||||Samples With DNA|"~     Serum, Whole Blood, Tissue~   "|||2018-06-01 01:20:29.065293|2018-06-01 01:20:29.065293
NCT00836849|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2002||2002-03-31|February 2009|2009-02-28|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Sertraline Hydrochloride 100 mg Tablets, Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:29.129999|2018-06-01 01:20:29.129999
NCT00836836|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2011-06-20|2009-02-03|2009-02-04|Estimate|||||||2011-06-20|2011-06-21|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|mAD||Modified Atkins Diet in Childhood Epilepsy|Evaluation Of The Efficacy Of The Modified Atkins Diet In Children With Refractory Epilepsy: A Randomized Controlled Trial.|Completed||Phase 2/Phase 3|96|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 01:20:29.191903|2018-06-01 01:20:29.191903
NCT00836823|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2010-10-18|2009-02-03|2009-02-04|Estimate|||||||2010-10-18|2010-10-20|Estimate|December 2005||2005-12-31|October 2010|2010-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Evaluation of Symptom-specific Goal Achievement|The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility|Completed||Phase 4|130|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 01:20:29.258505|2018-06-01 01:20:29.258505
NCT00836810|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2017-02-01||2017-07-13|2009-02-02|2009-02-04|Estimate|2017-07-13|2018-02-02|Estimate||||2017-07-13|2018-02-02|Estimate|October 2009||2009-10-31|July 2017|2017-07-31|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional||Fewer participants were recruited than anticipateed within the time frame of the trial.|Timed Release Tablet Prednisone in Polymyalgia Rheumatica|Circadian Variation in Cytokines and the Effect of Timed Release Tablet Prednisone in Polymyalgia Rheumatica|Completed||Phase 2/Phase 3|12|Actual|University Hospitals Bristol NHS Foundation Trust|Small number of patients not blind to study treatment which may have influenced reports of morning stiffness.|2|||f||||f||||||||No||2018-06-01 01:20:29.32548|2018-06-01 01:20:29.32548
NCT00836797|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Observational|||Radiographic Assessment of Bone Regeneration in Alveolar Sockets With PLGA Scaffold|Phase I Radiographic Assessment of Bone Regeneration in Alveolar Sockets With PLGA Bioscaffold After Teeth Extraction|Completed|||33|Actual|Bio-Scaffold International Pte Ltd|||2||f||||f||||||||||2018-06-01 01:20:30.593425|2018-06-01 01:20:30.593425
NCT00836784|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-05-04|2009-02-03|2009-02-04|Estimate|||||||2009-05-04|2009-05-05|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Comparison of New and 3-Month-Old Toothbrush in the Removal of Plaque in Children|Comparing Efficacy of Old Versus New Toothbrushes in Plaque Removal in the Hands of 7-9 Year Old Children.|Completed||N/A|93|Actual|Shahid Beheshti University||2|||f||||f||||||||||2018-06-01 01:20:30.653896|2018-06-01 01:20:30.653896
NCT00836771|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2013-07-30|2009-02-03|2009-02-04|Estimate|||||||2013-07-30|2013-07-31|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|||Infant Formula Supplemented With Probiotic Microorganisms and/or Prebiotic.|Evaluation of the Effect of Milk Based Infant Formula Supplemented Either With Probiotic Microorganisms and/or With Prebiotic on the Intestinal Microflora During the First 4 Months of Life of Healthy, Full Term Infants and it's Long Term Effect on Morbidity up to the Age of 9 Months|Unknown status|Active, not recruiting|N/A|270|Anticipated|Materna Laboratories||5|||f||||t||||||||||2018-06-01 01:20:30.719767|2018-06-01 01:20:30.719767
NCT00836758|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03||2010-07-19|2010-07-28|2009-02-03|2009-02-04|Estimate||||2010-07-28|2010-07-29|Estimate|2010-07-28|2010-07-29|Estimate|February 2009||2009-02-28|July 2010|2010-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Comparison of Breathing Event Detection by a CPAP Device to Clinical Polysomnography|Validation of Breathing Event Detection of the REMstar Auto With Aflex Compared to Clinical Polysomnography|Completed||N/A|30|Actual|Philips Respironics||1|||f||||f||||||||||2018-06-01 01:20:30.789944|2018-06-01 01:20:30.789944
NCT00836745|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2013-07-29||2013-11-26|2009-02-03|2009-02-04|Estimate|2013-11-26|2013-12-20|Estimate||||2013-11-26|2013-12-20|Estimate|March 2009||2009-03-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent|Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent|Completed|||36|Actual|Pfizer|Relatively small sample size might limit any useful interpretation and applicability of data for larger populations.||1||f||||f||||||||||2018-06-01 01:20:30.872282|2018-06-01 01:20:30.872282
NCT00836732|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2013-09-27|2009-02-03|2009-02-04|Estimate|||||||2013-09-27|2013-09-30|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|MESSAGE||Mesenchymal Stem Cells: Alterations in Genome|MESenchymal Stem Cells: Alterations in GEnome|Completed||N/A|35|Actual|Nantes University Hospital|||||f||||f||||||||||2018-06-01 01:20:31.233286|2018-06-01 01:20:31.233286
NCT00836719|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2013-04-04||2013-05-21|2009-02-03|2009-02-04|Estimate|2013-05-21|2013-06-27|Estimate||||2013-05-21|2013-06-27|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety of Polyphenon E in Multiple Sclerosis Pilot Study|Safety and Neuroprotective Effects of Polyphenon E in Multiple Sclerosis|Completed||Phase 1|10|Actual|Louisiana State University Health Sciences Center in New Orleans|The study was a pilot study with a small sample size and no control group. The primary endpoint was futility in change in NAA thus the p-values for the primary endpoint are nominal only.|1|||f||||t||||||||||2018-06-01 01:20:31.321|2018-06-01 01:20:31.321
NCT00836706|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2009-06-18||2009-09-01|2009-02-02|2009-02-04|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|July 2002||2002-07-31|September 2009|2009-09-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Clarithromycin 500 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 500 mg Clarithromycin Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:31.625516|2018-06-01 01:20:31.625516
NCT00836693|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2010-12-15||2010-12-15|2009-02-03|2009-02-04|Estimate|2010-12-15|2011-01-04|Estimate||||2010-12-15|2011-01-04|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Tadalafil Once a Day in Men With Erectile Dysfunction|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors|Completed||Phase 3|217|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:20:31.982037|2018-06-01 01:20:31.982037
NCT00836680|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-02-02|2009-02-02|2009-02-04|Estimate|||||||2009-02-02|2009-02-04|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|May 2009|Anticipated|2009-05-31||Interventional|||Clinical Study for the Evaluation of the Efficiency of a Device for the Diagnosis of an Internal Rectal Prolapse, a Pelvic Floor Ptosis and for the Determination of an Internal Hernia Into the Douglas Pouch|Study for the Evaluation of the Efficiency of a Device for the Diagnosis of an Internal Rectal Prolapse, a Pelvic Floor Ptosis and for the Determination of an Internal Hernia Into the Douglas Pouch|Unknown status|Recruiting|N/A|15|Anticipated|Gerhard Pejcl Medizintechnik GmbH|||||f||||t||||||||||2018-06-01 01:20:32.799927|2018-06-01 01:20:32.799927
NCT00836667|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2002||2002-03-31|February 2009|2009-02-28|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Sertraline Hydrochloride 100 mg Tablets, Fed|Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|18|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:32.881816|2018-06-01 01:20:32.881816
NCT00836654|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-04|2009-02-03|2009-02-04|Estimate|||||||2009-02-04|2009-02-05|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group|Two-Arm, Randomized (2:1), Open-Label Phase II/III Study in EpCAM Positive Cancer Patients With Symptomatic Malignant Ascites Using the Trifuncitonal Bispecific Antibody Removab (Anti-EpCAM x Anti-CD3) Versus an Untreated Control Group|Completed||Phase 2/Phase 3|258|Actual|Neovii Biotech||2|||f||||||||||||||2018-06-01 01:20:32.951699|2018-06-01 01:20:32.951699
NCT00836641|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2013-04-04||2013-07-30|2009-02-03|2009-02-04|Estimate|2013-07-30|2013-09-02|Estimate||||2013-07-30|2013-09-02|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|PAPSI||Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics|Prospective Randomized Controlled Phase 4 Study on the Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics|Completed||Phase 4|70|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-06-01 01:20:33.047167|2018-06-01 01:20:33.047167
NCT00836628|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2016-02-04|2009-02-03|2009-02-04|Estimate|||||||2016-02-04|2016-02-08|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study of Busulfan for Refractory Central Nervous System (CNS) Tumors|A Phase I Study Using Submyeloablative DOsing of Intravenous Busulfan (Busulfex) for Refractory Brain Tumors|Withdrawn||Phase 1|0|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||1||slow accrual|f||||t||||||||Undecided||2018-06-01 01:20:33.272681|2018-06-01 01:20:33.272681
NCT00836602|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2011-02-22|2009-02-03|2009-02-04|Estimate|||||||2011-02-22|2011-02-23|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects|Placebo-Controlled, Ascending, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects|Completed||Phase 1|25|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:20:33.337422|2018-06-01 01:20:33.337422
NCT00836576|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|February 2001||2001-02-28|February 2009|2009-02-28|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Benazepril HCl 40 mg Tablets, Fasting|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Benazepril HCl (40 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Lotensin®, Novartis Pharmaceuticals Corporation) in 40 Fasted, Healthy, Adult Subjects|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:33.576718|2018-06-01 01:20:33.576718
NCT00836563|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2018-02-01|2009-02-03|2009-02-04|Estimate|||||||2018-02-01|2018-02-05|Actual|January 10, 2009|Actual|2009-01-10|February 2018|2018-02-28|December 13, 2011|Actual|2011-12-13|December 13, 2011|Actual|2011-12-13||Observational|||Vascular Changes Following Forearm Loop Arteriovenous Graft Placement|The Natural History of Upper Arm Vessels Following Forearm Loop Arteriovenous|Completed|||10|Actual|University of Nebraska|||1||f||||f||||||||||2018-06-01 01:20:33.635198|2018-06-01 01:20:33.635198
NCT00836550|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-09-18|2009-02-03|2009-02-04|Estimate|||||||2009-09-18|2009-09-21|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Video-based Counseling & Rapid HIV Testing for Teens|An RCT to Evaluate the Effectiveness of an Emergency Department Based Multimedia HIV Testing Model in Adolescents|Completed||N/A|200|Actual|North Bronx Healthcare Network||2|||f||||t||||||||||2018-06-01 01:20:33.691934|2018-06-01 01:20:33.691934
NCT00836537|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2001||2001-03-31|February 2009|2009-02-28|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Benazepril HCl 40 mg Tablets, Fed|A Relative Bioavailability Study of 40 mg Benazepril Hydrochloride Tablets Under Non-Fasting Conditions|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:33.754049|2018-06-01 01:20:33.754049
NCT00836524|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2011-10-27|2009-02-03|2009-02-04|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2009||2009-01-31|October 2011|2011-10-31|September 2012|Anticipated|2012-09-30|November 2011|Anticipated|2011-11-30||Observational|||Is Serum YKL-40 Capable of Predicting Intrauterine Growth Restriction (IUGR) and Preeclampsia?|"Kan IUGR og præeclampsi Forudsiges ud Fra YKL-40 målt i Serum? Metoder Til at Vurdere om Den Gravide Har Risiko for at Udvikle Svangerskabsforgiftning og/Eller væksthæmning Hos Fosteret."|Unknown status|Active, not recruiting||2000|Anticipated|Zealand University Hospital|||1||f||||f||||||Samples With DNA|"~     Bloodsamples will be collected as well as placenta tissue for histology.~   "|||2018-06-01 01:20:33.846707|2018-06-01 01:20:33.846707
NCT00836498|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2011-01-12||2015-04-10|2009-02-03|2009-02-04|Estimate|2011-01-12|2011-02-04|Estimate||||2015-04-10|2015-05-01|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)|V260-027 Safety and Immunogenicity of RotaTeq™ in Elderly Subjects|Terminated||Phase 1|66|Actual|Merck Sharp & Dohme Corp.||5||Strategic business decision not to pursue indication due to lack of demonstrable medical need|f||||||||||||||2018-06-01 01:20:34.004023|2018-06-01 01:20:34.004023
NCT00836485|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-05-15|2009-02-02|2009-02-04|Estimate|||||||2009-05-15|2009-05-19|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|A Prospective, Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|Completed||Phase 2|120|Anticipated|Senju USA, Inc.||4|||f||||f||||||||||2018-06-01 01:20:34.696402|2018-06-01 01:20:34.696402
NCT00836472|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2009-06-30||2009-09-01|2009-02-03|2009-02-04|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|April 2003||2003-04-30|September 2009|2009-09-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting|Randomized, 2-Way Crossover, Bioequivalence Study of Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets and Glucovance® 5 mg/500 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:34.79522|2018-06-01 01:20:34.79522
NCT00836459|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2014-12-01|2009-02-03|2009-02-04|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2009||2009-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|Booster||Sheffield Physical Activity Booster Trial|"A Randomised Controlled Trial and Cost-effectiveness Evaluation of Booster Interventions to Sustain Increases in Physical Activity in Middle-aged Adults in Deprived Urban Neighbourhoods."|Completed||N/A|282|Actual|University of Sheffield||3|||f||||f||||||||||2018-06-01 01:20:35.172935|2018-06-01 01:20:35.172935
NCT00836446|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-03-10|2009-02-03|2009-02-04|Estimate|||||||2009-03-10|2009-03-11|Estimate|August 2008||2008-08-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Effects of Physical Activity on Cardiovascular Risk Markers in School-Aged Mexican Children|Effects of Physical Activity on Cardiovascular Risk Markers in School-Aged Mexican Children|Completed||N/A|214|Actual|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||2|||f||||f||||||||||2018-06-01 01:20:35.244945|2018-06-01 01:20:35.244945
NCT00836433|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2014-10-09||2015-04-06|2009-02-02|2009-02-04|Estimate|2014-10-23|2014-10-30|Estimate||||2015-04-06|2015-04-24|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|CONNECT||CONNECT for Better Falls Prevention in VA Community Living Centers|CONNECT for Better Falls Prevention in VA Community Living Centers|Completed||Phase 3|689|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:20:35.314786|2018-06-01 01:20:35.314786
NCT00836420|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2015-10-26|2009-02-03|2009-02-04|Estimate|||||||2015-10-26|2015-10-27|Estimate|January 2000||2000-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Cerebral Microdialysis in Patients With Fulminant Hepatic Failure|Cerebral Microdialysis in Patients With Fulminant Hepatic Failure|Completed|||50|Actual|Rigshospitalet, Denmark|||1||f||||f||||||Samples Without DNA|"~     microdialysate from the brain as part of rutine monitoring~   "|||2018-06-01 01:20:35.589751|2018-06-01 01:20:35.589751
NCT00836407|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2013-10-16||2013-10-16|2009-02-03|2009-02-04|Estimate|2013-10-16|2013-12-10|Estimate||||2013-10-16|2013-12-10|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|A Phase Ib Trial Evaluating the Safety and Feasibility of Ipilimumab (BMS-734016) Alone or in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene for the Treatment of Locally Advanced, Unresectable or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 1|30|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-06-01 01:20:35.682557|2018-06-01 01:20:35.682557
NCT00836394|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2018-05-08|2009-02-03|2009-02-04|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2009||2009-02-28|May 2018|2018-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|WBV-JIA||Effect of Whole Body Vibration Therapy in Children With Juvenile Idiopathic Arthritis|The Effect of Whole Body Vibration Therapy on Muscle Function and Joint Loading in Children With Juvenile Idiopathic Arthritis|Withdrawn||N/A|0|Actual|Children's Hospital of Eastern Ontario||2||No potential participants met entry criteria|f||||f||||||||||2018-06-01 01:20:35.966713|2018-06-01 01:20:35.966713
NCT00836381|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2013-05-29|2009-02-03|2009-02-04|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder|Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (Phase Ⅳ)|Completed||Phase 4|56|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 01:20:36.037217|2018-06-01 01:20:36.037217
NCT00836368|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2011-11-04|2009-02-03|2009-02-04|Estimate|||||||2011-11-04|2011-11-07|Estimate|December 2008||2008-12-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Gammaphil||In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics|In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics|Completed||Phase 1|25|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 01:20:36.110233|2018-06-01 01:20:36.110233
NCT00836355|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2016-02-29||2016-03-29|2009-02-03|2009-02-04|Estimate|2016-03-29|2016-04-29|Estimate||||2016-03-29|2016-04-29|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Enoxaparin and/or Minocycline in Acute Stroke|Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke|Terminated||N/A|6|Actual|New York University School of Medicine|This trial was terminated early because of logistical challenges in data collection. No outcome measures data was able to be collected.|4||Too few acute stroke patients available to meet enrollment requirements.|f||||f||||||||||2018-06-01 01:20:36.182777|2018-06-01 01:20:36.182777
NCT00836342|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2012-05-14||2012-06-24|2009-02-02|2009-02-04|Estimate|2012-06-24|2012-07-25|Estimate||||2012-06-24|2012-07-25|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer|Comparison of Skin Carotenoid Levels Between Subjects With History of Cutaneous Squamous Cell Carcinoma and Subjects With History of Basal Cell Carcinoma Versus a Control Group|Completed|||81|Actual|Massachusetts General Hospital|Limitations include a small sample size||3||f||||f||||||||||2018-06-01 01:20:36.414183|2018-06-01 01:20:36.414183
NCT00836329|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2016-07-11|2009-02-02|2009-02-04|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Improving Neurologic Outcomes in People With Diabetes Who Are Undergoing Heart Surgery|Improving Neurologic Outcomes in Diabetics Undergoing Cardiac Surgery|Completed||Phase 3|133|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 01:20:36.857911|2018-06-01 01:20:36.857911
NCT00836316|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate||||February 2009|2009-02-28||||||||Interventional|||Levobupivacaine During Cholecystectomy|Effects of Intraperitoneal Levobupivacaine on Pain After Laparoscopic Cholecystectomy: A Prospective, Randomized, Double-Blinded Study|Completed||Phase 4|40|Actual|Ege University|||||f||||||||||||||2018-06-01 01:20:36.93049|2018-06-01 01:20:36.93049
NCT00836303|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-02|2009-02-02|2009-02-04|Estimate|||||||2009-02-02|2009-02-04|Estimate|December 2005||2005-12-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening|A Randomized Controlled Trial of a Multilevel Intervention to Increase Colorectal Cancer Screening Among Latino Immigrants in a Primary Care Facility|Completed||N/A|130|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 01:20:36.984423|2018-06-01 01:20:36.984423
NCT00836290|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2015-10-19|2009-02-02|2009-02-04|Estimate|||||||2015-10-19|2015-10-21|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|Project PLUS||Positive Lifestyles Using Safety|Positive Lifestyles Using Safety|Completed||N/A|90|Actual|Yale University||3|||f||||f||||||||||2018-06-01 01:20:37.045694|2018-06-01 01:20:37.045694
NCT00836277|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2016-07-27||2016-09-23|2009-02-03|2009-02-04|Estimate|2016-09-23|2016-11-15|Estimate||||2016-09-23|2016-11-15|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Phase II Study of Irinotecan and Panitumumab|Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma|Completed||Phase 2|24|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:20:37.14409|2018-06-01 01:20:37.14409
NCT00836264|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2017-01-19|2009-02-03|2009-02-04|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2015|Actual|2015-12-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Pharmacogenomics Analysis of Morphine Pharmacokinetics in Pediatric Tonsillectomy and Adenoidectomy|Pharmacogenomic Analysis of Morphine Pharmacokinetics and Response Variability Following Pediatric Tonsillectomy and Adenoidectomy: A Genome-Wide Association Approach|Suspended|||1650|Anticipated|Children's Hospital of Philadelphia|||1|Enrollment is on hold dependent upon funding|f||||f||||||Samples Without DNA|"~     PK plasma samples will be obtained~   "|||2018-06-01 01:20:37.482793|2018-06-01 01:20:37.482793
NCT00836251|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2014-03-12|2009-02-03|2009-02-04|Estimate|||||||2014-03-12|2014-03-13|Estimate|April 2006||2006-04-30|March 2014|2014-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|DLW||Effects of Antipsychotic Medications on Energy Intake and Expenditure|Effects of Antipsychotic Medications on Energy Intake and Expenditure|Completed|||15|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-06-01 01:20:37.539337|2018-06-01 01:20:37.539337
NCT00836238|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2012-07-31|2009-02-02|2009-02-04|Estimate|||||||2012-07-31|2012-08-01|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Questionnaire and Fall Risk Assessment|A Cross-Sectional Study of the Predictability of a Questionnaire About Difficulty in Climbing Up or Down Stairs in Objective Measures of Functional Status in Elderly Patients With Prostate Cancer|Completed|||34|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:20:37.602958|2018-06-01 01:20:37.602958
NCT00836225|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2012-02-02|2009-02-02|2009-02-04|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers|A Phase I , Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 388626 Administered to Healthy Volunteers|Completed||Phase 1|103|Actual|Ionis Pharmaceuticals, Inc.||10|||f||||t||||||||||2018-06-01 01:20:37.701178|2018-06-01 01:20:37.701178
NCT00836212|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-07-21|2009-02-03|2009-02-04|Estimate|||||||2009-07-21|2009-07-23|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|TDM||Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring|Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring|Unknown status|Recruiting|Phase 4|12|Anticipated|University Hospital, Geneva||2|||f||||||||||||||2018-06-01 01:20:37.777408|2018-06-01 01:20:37.777408
NCT00836199|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-05-08|2009-02-03|2009-02-04|Estimate|||||||2012-05-08|2012-05-09|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||NicVAX/Placebo as an Aid for Smoking Cessation|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation|Completed||Phase 3|1000|Actual|Nabi Biopharmaceuticals||2|||f||||t||||||||||2018-06-01 01:20:37.860594|2018-06-01 01:20:37.860594
NCT00836186|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2017-10-05|2009-02-03|2009-02-04|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2009||2009-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Cytokine Expression During Radiation for Breast Cancer|Cytokine Expression During Radiation for Breast Cancer|Active, not recruiting||N/A|100|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||t||||||||||2018-06-01 01:20:37.956003|2018-06-01 01:20:37.956003
NCT00836173|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2016-03-14|2009-02-03|2009-02-04|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase II Study Evaluating Three Cyslces of Ifosfamide, Carboplatin, Etoposide, and Rituximab (RICE) Followed by Two Cycles of Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma MA|Withdrawn||Phase 2|0|Actual|Loyola University||1||Gallium is no longer available for the conduct of this study.|f||||t||||||||||2018-06-01 01:20:38.027355|2018-06-01 01:20:38.027355
NCT00836160|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-09-19|2009-02-03|2009-02-04|Estimate|||||||2012-09-19|2012-09-20|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy|Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy|Completed|||36|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:20:38.092221|2018-06-01 01:20:38.092221
NCT00836147|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2010-09-27|2009-02-03|2009-02-04|Estimate|||||||2010-09-27|2010-09-28|Estimate|February 2009||2009-02-28|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids|A Single-centre, Double Blind, Randomised, Exploratory Study to Explore the Efficacy and Safety of Juvista 250ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids.|Completed||Phase 1/Phase 2|20|Actual|Renovo||2|||f||||f||||||||||2018-06-01 01:20:38.136781|2018-06-01 01:20:38.136781
NCT00836134|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2014-06-10|2009-02-03|2009-02-04|Estimate|||||||2014-06-10|2014-06-12|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Ultrasound-guided Rectus Sheath Block for Post-operative Pain Control Following Umbilical Hernia Repair|Ultrasound-guided Rectus Sheath Block for Post-operative Pain Control Following Umbilical Hernia Repair|Completed||N/A|40|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-06-01 01:20:38.194064|2018-06-01 01:20:38.194064
NCT00836121|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Observational|||Anterior Mediastinum Teratoma: A Case Report|Case Report of a 39 Years Old Man That Has Been Cured by a Total Resection of a Anterior Mediastinum Teratoma.|Completed|||1|Actual|Faculdade de Medicina de Catanduva|||1||f||||t||||||||||2018-06-01 01:20:38.277916|2018-06-01 01:20:38.277916
NCT00836108|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-07-10|2009-02-03|2009-02-04|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Unsupported Arm Exercise and Breathing Strategy in Patients With Chronic Obstructive Pulmonary Disease|Unsupported Arm Exercise and Breathing Strategy in Patients With Chronic|Completed||N/A|36|Actual|West Park Healthcare Centre||3|||f||||f||||||||||2018-06-01 01:20:38.333251|2018-06-01 01:20:38.333251
NCT00836095|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2014-05-05||2016-03-17|2009-02-02|2009-02-04|Estimate|2014-05-05|2014-06-03|Estimate||||2016-03-17|2016-04-15|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Comparison of ProSeal Laryngeal Mask Airway to Laryngeal Mask Airway Supreme|A Randomized Controlled Trial Comparing the ProSeal Laryngeal Mask Airway With the Laryngeal Mask Airway Supreme in Mechanically Ventilated Patients|Completed||Phase 4|52|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-06-01 01:20:38.401654|2018-06-01 01:20:38.401654
NCT00836082|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-08-05|2009-02-03|2009-02-04|Estimate|||||||2009-08-05|2009-08-06|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers|A Phase 1, Double-Blind (Sponsor Open), Randomised, Placebo-Controlled, Parallel Group, Oral Multiple-Dose Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04457845 In Healthy Volunteers|Completed||Phase 1|41|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:20:38.70254|2018-06-01 01:20:38.70254
NCT00836069|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-05-29|2009-02-03|2009-02-04|Estimate|||||||2009-05-29|2009-06-01|Estimate|October 2008||2008-10-31|May 2009|2009-05-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder|Terminated||Phase 3|15|Anticipated|Cedars-Sinai Medical Center||4||Pfizer has terminated the execution of this protocol|f||||f||||||||||2018-06-01 01:20:38.785511|2018-06-01 01:20:38.785511
NCT00836056|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2009-06-18||2009-09-01|2009-02-03|2009-02-04|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|November 2003||2003-11-30|September 2009|2009-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Clindamycin 300 mg Capsules and Cleocin HCl Administered as 1 x 300 mg Capsule in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:38.869809|2018-06-01 01:20:38.869809
NCT00836043|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2013-12-02|2009-02-03|2009-02-04|Estimate|||||||2013-12-02|2013-12-03|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia|Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia (CLL)|Terminated|||6|Actual|Sanofi|||1|Study terminated due to low enrollment.|f||||f||||||||||2018-06-01 01:20:39.117049|2018-06-01 01:20:39.117049
NCT00836030|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2016-11-21|2009-02-03|2009-02-04|Estimate|||||||2016-11-21|2016-11-22|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore|DiabCare Asia 2008. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia|Completed|||854|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 01:20:39.205487|2018-06-01 01:20:39.205487
NCT00836017|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2014-06-19||2014-06-19|2009-02-03|2009-02-04|Estimate|2014-06-19|2014-07-17|Estimate||||2014-06-19|2014-07-17|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational||Baseline measures were based on all enrolled participants who received treatment.|CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy||Completed|||1046|Actual|Allergan|||1||f||||f||||||||||2018-06-01 01:20:39.289732|2018-06-01 01:20:39.289732
NCT00836004|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2009-06-18||2009-09-01|2009-02-03|2009-02-04|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|November 2003||2003-11-30|September 2009|2009-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Clindamycin 300 mg Capsules and Cleocin Hcl Administered as 1 x 300 mg Capsule in Healthy Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:39.614076|2018-06-01 01:20:39.614076
NCT00835991|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2009-06-30||2009-09-01|2009-02-03|2009-02-04|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|February 2003||2003-02-28|September 2009|2009-09-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed|Randomized, 2-Way Crossover, Bioequivalence Study of Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets and Glucovance® 5 mg/500 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:39.909356|2018-06-01 01:20:39.909356
NCT00835978|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2013-10-11||2017-04-18|2009-02-02|2009-02-04|Estimate|2014-04-23|2014-05-26|Estimate||||2017-04-18|2017-05-30|Actual|August 2009||2009-08-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|October 2012|Actual|2012-10-31||Interventional||The safety analysis (SA) population consists of all participants who received at least one dose of study medication.|Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer|Randomized, Double-blind Phase 2 Study Of Axitinib (Ag-013736) With Or Without Dose Titration In Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|213|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:20:40.302381|2018-06-01 01:20:40.302381
NCT00835965|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|February 2009||2009-02-28|February 2009|2009-02-28||||December 2009|Anticipated|2009-12-31||Interventional|||Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries|A Randomized, Double-Blind Comparison of Oral Aprepitant and Lower Dose Dexamethasone vs Aprepitant Alone for Preventing Postoperative Nausea and Vomiting After Elective Laparoscopic Surgeries|Unknown status|Not yet recruiting|N/A|50|Anticipated|Main Line Health||2|||f||||f||||||||||2018-06-01 01:20:41.998989|2018-06-01 01:20:41.998989
NCT00835952|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2010-01-25|2009-02-03|2009-02-04|Estimate|||||||2010-01-25|2010-01-27|Estimate|November 2008||2008-11-30|January 2010|2010-01-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|ATX-101-08-10||ATX-101 Abdominoplasty|Phase 1, Open-label Study of the Safety, Tolerability, and Histological Effect of Single Doses of ATX-101 (Sodium Deoxycholate for Injection) Administered in Abdominal Fat in Subjects Undergoing Abdominoplasty|Completed||Phase 1|14|Anticipated|Kythera Biopharmaceuticals||1|||f||||f||||||||||2018-06-01 01:20:42.098191|2018-06-01 01:20:42.098191
NCT00835939|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|September 2007||2007-09-30|February 2009|2009-02-28||||January 2010|Anticipated|2010-01-31||Interventional|||Treatment for Achilles Tendinopathy|Treatment for Achilles Tendinopathy|Unknown status|Active, not recruiting|Phase 2/Phase 3|17|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 01:20:42.31635|2018-06-01 01:20:42.31635
NCT00835926|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2009-09-23||2016-04-12|2009-02-03|2009-02-04|Estimate|2009-09-23|2009-10-26|Estimate||||2016-04-12|2016-04-14|Estimate|July 2003||2003-07-31|April 2016|2016-04-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination|Safety and Immunogenicity of Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® 2003/2004|Completed||Phase 4|121|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:20:43.372443|2018-06-01 01:20:43.372443
NCT00835913|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2015-01-16|2009-02-03|2009-02-04|Estimate|||||||2015-01-16|2015-01-19|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|SNA&Sepsis||Autonomic Nervous System Alteration Induce by Sepsis: Assessment and Prognosis Impact|Autonomic Nervous System Alteration Induce by Sepsis:Assessment and Prognosis Impact|Completed|||13|Actual|University Hospital, Grenoble|||||f||||t||||||Samples Without DNA|"~     Peptid and protein sAmple~   "|||2018-06-01 01:20:43.716634|2018-06-01 01:20:43.716634
NCT00835900|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2017-03-13||2017-04-24|2009-02-03|2009-02-04|Estimate|2017-04-24|2017-05-30|Actual||||2017-04-24|2017-05-30|Actual|March 2009||2009-03-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2010|Actual|2010-07-31||Interventional|||An Alternative Dosing Schedule of Varenicline for Smoking Cessation|Extended Varenicline for Smoking Cessation: A Pilot Study|Completed||Phase 2|60|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 01:20:43.787769|2018-06-01 01:20:43.787769
NCT00835887|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2015-09-22|2009-02-03|2009-02-04|Estimate|||||||2015-09-22|2015-09-23|Estimate||||September 2015|2015-09-30||||||||Interventional|ESRD||Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease|Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease, a Phase 2 Study|Withdrawn||Phase 2|0|Actual|RWTH Aachen University||2||no patients recruited, responsible physician left clinic|f||||f||||||||||2018-06-01 01:20:44.003188|2018-06-01 01:20:44.003188
NCT00835354|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|May 2004||2004-05-31|August 2009|2009-08-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting|A Relative Bioavailability Study of Cefprozil for Oral Suspension 250 mg/5 mL Under Non-Fasting Conditions|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:51.948266|2018-06-01 01:20:51.948266
NCT00835874|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2012-08-01|2009-02-03|2009-02-04|Estimate|||||||2012-08-01|2012-08-02|Estimate|June 2007||2007-06-30|August 2012|2012-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis|Probiotic Administartion to Mothers of Preterm Infants to Prevent Necrotizing Enterocolitis and Sepsis|Terminated||N/A|57|Actual|Tel-Aviv Sourasky Medical Center||||"Difficulty in recruitment. Mothers of infants preferred to take probiotics bought~   over-the-counter over the possibility of being in a placebo group"|f||||f||||||||||2018-06-01 01:20:44.165421|2018-06-01 01:20:44.165421
NCT00835861|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2013-08-14||2017-04-21|2009-02-02|2009-02-04|Estimate|2014-04-24|2014-05-26|Estimate||||2017-04-21|2017-04-25|Actual|August 2008||2008-08-31|April 2014|2014-04-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|MIPOD|Three women who never received the allocated treatment were excluded from the analysis.|Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes|Pilot Study of Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)|Completed||Phase 2|31|Actual|University of North Carolina, Chapel Hill|Unable to achieve enrollment goal before funding period expired because recruitment progressed more slowly than anticipated.|2|||f||||f||||||||||2018-06-01 01:20:44.25867|2018-06-01 01:20:44.25867
NCT00835848|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2015-05-04|2009-02-03|2009-02-04|Estimate|||||||2015-05-04|2015-05-05|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|December 2009|Actual|2009-12-31||Interventional|POSTCON II||Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI|Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI in Patients With STEMI|Completed||Phase 4|100|Anticipated|Rigshospitalet, Denmark||2|||f||||||||||||||2018-06-01 01:20:44.628936|2018-06-01 01:20:44.628936
NCT00835835|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2015-11-09|2009-02-03|2009-02-04|Estimate|||||||2015-11-09|2015-11-11|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|June 2013|Actual|2013-06-30|October 2011|Actual|2011-10-31||Interventional|||Lokomat Treadmill Training Effects on MS Gait|Lokomat Treadmill Training Effects on MS Gait|Completed||N/A|8|Actual|Mount Sinai Rehabilitation Hospital||2|||f||||f||||||||||2018-06-01 01:20:44.720991|2018-06-01 01:20:44.720991
NCT00835822|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-03|2009-02-03|2009-02-04|Estimate|||||||2009-02-03|2009-02-04|Estimate|May 2005||2005-05-31|February 2009|2009-02-28||||October 2006|Actual|2006-10-31||Interventional|||Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency|Multicenter, Prospective, Randomized, Double-Blind Study to Assess the Therapeutic Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency|Completed||Phase 4|216|Actual|Abbott||2|||f||||f||||||||||2018-06-01 01:20:44.803464|2018-06-01 01:20:44.803464
NCT00835809|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2010-09-06|2009-02-03|2009-02-04|Estimate|||||||2010-09-06|2010-09-08|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|BIO-IRA||Multi Marker Approach Interest in Emergency in Acute Respiratory Insufficiency Diagnostic|Multi Marker Approach Interest in Emergency in Acute Respiratory Insufficiency Diagnostic|Completed|||400|Actual|University Hospital, Grenoble|||1||f||||t||||||Samples With DNA|"~     Protein sample~   "|||2018-06-01 01:20:44.88602|2018-06-01 01:20:44.88602
NCT00835796|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2009-06-22||2009-09-01|2009-02-03|2009-02-04|Estimate|2009-06-22|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|June 2002||2002-06-30|September 2009|2009-09-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Finasteride 5 mg Tablets, Non-fasting|A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|20|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:44.959289|2018-06-01 01:20:44.959289
NCT00835783|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2014-10-26|2009-02-03|2009-02-04|Estimate|||||||2014-10-26|2014-10-28|Estimate|November 2008||2008-11-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PIN-UP||Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation|PET/CT in Infection and Inflammation Imaging: Current Utility and Future Perspectives (The PIN-UP Study)|Terminated|||30|Actual|Odense University Hospital|||3|Study logistics proved difficult and enrollment never moved beyond the pilot phase.|f||||f||||||||||2018-06-01 01:20:45.196685|2018-06-01 01:20:45.196685
NCT00835770|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2018-04-02|2009-02-03|2009-02-04|Estimate|||||||2018-04-02|2018-04-03|Actual|February 28, 2009|Actual|2009-02-28|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|ENDORSE||BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)|A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis|Active, not recruiting||Phase 3|1738|Actual|Biogen||2|||f||||f||||||||||2018-06-01 01:20:45.319723|2018-06-01 01:20:45.319723
NCT00835757|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2013-12-13|2009-02-02|2009-02-04|Estimate|||||||2013-12-13|2013-12-17|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|||Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy|"Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy"|Completed|||50|Actual|University of Michigan|||2||f||||f||||||||||2018-06-01 01:20:45.802515|2018-06-01 01:20:45.802515
NCT00835744|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2012-03-27|2009-02-03|2009-02-04|Estimate|||||||2012-03-27|2012-03-28|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|cc versus FSH||Comparison of Clomiphene Citrate and Gonadotropins in Ovulation Induction Cycles|Among Non-IVF Patients Undergoing Ovulation Induction With Clomiphene Citrate (Clomid® 50 mg), Does Administration of an Increased Dose of Clomiphene Citrate (Clomid® 100 mg) Compared With Gonadotropins, Achieve Similar Rates of Folliculogenesis?|Completed||Phase 4|40|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-06-01 01:20:45.863276|2018-06-01 01:20:45.863276
NCT00835731|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2013-06-13||2017-09-20|2009-02-03|2009-02-04|Estimate|2013-11-20|2014-01-07|Estimate||||2017-09-20|2017-10-23|Actual|January 2009||2009-01-31|September 2017|2017-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Misoprostol Versus Dilapan-S for Cervical Preparation|Cervical Preparation Before Same-day Second Trimester Abortion With Buccal Misoprostol Versus Dilapan-S: A Randomized Placebo Controlled Trial|Completed||N/A|125|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-06-01 01:20:45.956494|2018-06-01 01:20:45.956494
NCT00835718|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|||2010-03-26|2009-02-03|2009-02-04|Estimate|||||||2010-03-26|2010-03-30|Estimate|February 2009||2009-02-28|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study of MK0594 in Patients With Alcohol Dependence|A Phase II Multicenter, Randomized, Double-Blind, Two-Stage Clinical Trial to Evaluate the Efficacy and Safety of MK0594 in Patients With Alcohol Dependence|Terminated||Phase 2|162|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-06-01 01:20:46.2441|2018-06-01 01:20:46.2441
NCT00835172|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-22||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-06-22|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Glimepiride 4 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:55.304705|2018-06-01 01:20:55.304705
NCT00835705|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2009-05-07||2009-07-06|2009-02-03|2009-02-04|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|September 2003||2003-09-30|July 2009|2009-07-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets and AUGMENTIN® 400 mg-57 mg Chewable Tablets Administered as 1 x 400 mg-57 mg Chewable Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|52|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:46.327286|2018-06-01 01:20:46.327286
NCT00835692|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2009-06-18||2009-09-01|2009-02-02|2009-02-04|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Clarithromycin 500 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Clarithromycin Tablets Under Fasting COnditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:46.605897|2018-06-01 01:20:46.605897
NCT00835679|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2012-03-12||2014-05-07|2009-02-03|2009-02-04|Estimate|2012-08-07|2012-09-07|Estimate||||2014-05-07|2014-05-23|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery|A Preoperative Biological Trial of Cetuximab, Dasatinib or the Combination in Colorectal Cancer Patients With Resectable Liver Metastases|Terminated||Early Phase 1|9|Actual|National Cancer Institute (NCI)|"Due to study design and slow accrual, no drug was received, no biomarkers were determined and no data obtained. 0 data is entered in the outcomes measures database as suggested by CT.gov previously. Detailed explanations are given."|4|||f||||||||||||||2018-06-01 01:20:46.835703|2018-06-01 01:20:46.835703
NCT00835666|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-03|2009-06-22||2009-09-01|2009-02-03|2009-02-04|Estimate|2009-06-22|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|June 2002||2002-06-30|September 2009|2009-09-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Finasteride 5 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:47.218098|2018-06-01 01:20:47.218098
NCT00835653|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2016-09-22|2009-02-02|2009-02-03|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Efficacy of Median Nerve Block Performed Using Echographic Guidance|Efficacy of Median Nerve Block Performed Using Echographic Guidance|Completed|||70|Anticipated|Hopital Foch|||2||f||||f||||||||||2018-06-01 01:20:47.48919|2018-06-01 01:20:47.48919
NCT00835640|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-08-14|2009-02-02|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|January 2002||2002-01-31|August 2009|2009-08-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fed Conditions.|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:47.565713|2018-06-01 01:20:47.565713
NCT00835627|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2014-11-07|2009-01-30|2009-02-03|Estimate|||||||2014-11-07|2014-11-10|Estimate|September 2008||2008-09-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|NEST-T_1||Treatment Trial for Psychogenic Nonepileptic Seizures|Medication and Psychotherapy Treatment Trial for Psychogenic Nonepileptic Seizures|Completed||Phase 4|38|Actual|Rhode Island Hospital||4|||f||||t||||||||||2018-06-01 01:20:47.85427|2018-06-01 01:20:47.85427
NCT00835614|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|April 2004||2004-04-30|August 2009|2009-08-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Cefprozil for Oral Suspension 250 mg/5 mL, Fasting|A Relative Bioavailability Study of Cefprozil for Oral Suspension 250 mg/5 mL Under Fasting Conditions|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:47.975813|2018-06-01 01:20:47.975813
NCT00835601|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2011-05-13|2009-02-02|2009-02-03|Estimate|||||||2011-05-13|2011-05-16|Estimate|January 2009||2009-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Observational|CCD||Resistive/Cardiovascular Training Study|An Integrated Musculoskeletal Countermeasure Battery for Long-Duration Lunar Missions|Completed|||36|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:20:48.235361|2018-06-01 01:20:48.235361
NCT00835588|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2009-07-02||2009-09-09|2009-02-02|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|December 2003||2003-12-31|September 2009|2009-09-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions|A Relative Bioavailability Study of Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions|Completed||Phase 1|100|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:48.303405|2018-06-01 01:20:48.303405
NCT00835575|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-02-02|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|July 2003||2003-07-31|September 2009|2009-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||15 mg Mirtazapine Orally Disintegrating Tablets, Fasting|A Relative Bioavailability Study of 15 mg Mirtazapine Orally Disintegrating Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:48.583433|2018-06-01 01:20:48.583433
NCT00835562|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2012-06-06|2009-02-02|2009-02-03|Estimate|||||||2012-06-06|2012-06-07|Estimate|April 2009||2009-04-30|June 2012|2012-06-30||||March 2013|Anticipated|2013-03-31||Interventional|||Effect of Osteosynthesis, Primary Hemi-arthroplasty, and Non-surgical Management for Fractures of the Proximal Humerus|Effect of Osteosynthesis, Primary Hemi-arthroplasty, and Non-surgical Management for Displaced Four-part Fractures of the Proximal Humerus in Elderly: a Multi-centre, Randomised Clinical Trial|Unknown status|Recruiting|Phase 3|162|Anticipated|Herlev Hospital||3|||f||||f||||||||||2018-06-01 01:20:48.818984|2018-06-01 01:20:48.818984
NCT00835549|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|March 2005||2005-03-31|August 2009|2009-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting|A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Non-Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:48.907172|2018-06-01 01:20:48.907172
NCT00835536|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-02-02|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Ribavirin 200 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|27|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:49.158425|2018-06-01 01:20:49.158425
NCT00835523|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2012-06-13|2009-02-02|2009-02-03|Estimate|||||||2012-06-13|2012-06-14|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist|OHSS Prevention by GnRH-agonist Triggering of Final Oocyte Maturation and Cryoperservation of All Two-pronucleate Oocytes in Women Undergoing Stimulation for IVF With Gonadotrophins and GnRH-analogues: a Prospective, Observational, Multicentric, Clinical Cohort Study|Completed|||51|Actual|University of Schleswig-Holstein|||1||f||||t||||||||||2018-06-01 01:20:49.405341|2018-06-01 01:20:49.405341
NCT00835510|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-05-04||2014-01-02|2009-01-30|2009-02-03|Estimate|2009-09-03|2009-10-06|Estimate||||2014-01-02|2014-02-04|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis|Completed||Phase 1|548|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-06-01 01:20:49.546253|2018-06-01 01:20:49.546253
NCT00835497|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-09|2009-01-30|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|June 2004||2004-06-30|September 2009|2009-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting|A Relative Bioavailability Study of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets Under Fasting Conditions.|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:49.939335|2018-06-01 01:20:49.939335
NCT00835484|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Cefdinir Capsules 300 mg, Fasting|A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:50.306535|2018-06-01 01:20:50.306535
NCT00835471|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2010-07-23|2009-02-02|2009-02-03|Estimate|||||||2010-07-23|2010-07-26|Estimate|March 2009||2009-03-31|July 2010|2010-07-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|NVALT10||2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study)|Unknown status|Recruiting|Phase 2|230|Anticipated|Dutch Society of Physicians for Pulmonology and Tuberculosis||2|||f||||f||||||||||2018-06-01 01:20:50.612172|2018-06-01 01:20:50.612172
NCT00835458|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-10|2009-02-02|2009-02-03|Estimate|||||||2009-02-10|2009-02-11|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Endoscopic Treatment of Intestinal Fistulas and Perforations|Closure of Fistulas and Perforations Endoscopically to Avoid Laparoscopic or Open Surgery|Unknown status|Enrolling by invitation|N/A|5|Actual|Legacy Health System|||||f||||f||||||||||2018-06-01 01:20:50.756777|2018-06-01 01:20:50.756777
NCT00835445|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2011-01-06|2009-02-02|2009-02-03|Estimate|||||||2011-01-06|2011-01-07|Estimate|July 2007||2007-07-31|December 2010|2010-12-31|September 2009|Actual|2009-09-30|October 2008|Actual|2008-10-31||Observational|||Biopsies and Polyps|Nasal Features of Subjects With Nasal Polyposis With or Without Asthma|Completed|||25|Actual|Laval University|||2||f||||f||||||Samples Without DNA|"~     Nasal polyps (Biopsies) Normal nasal mucosa (Biopsies) Sputum~   "|||2018-06-01 01:20:50.861607|2018-06-01 01:20:50.861607
NCT00835432|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-02|2009-02-02|2009-02-03|Estimate|||||||2009-02-02|2009-02-03|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|BCP+Collagen||Morphometric, Clinical and Histological Study on One Stage Bone Augmentation Using BoneCeramic (BCP) and Collagen Membranes|Prospective Clinical, Morphometric and Histological Study on Augmentation Using BoneCeramic as Bone Substitute in Combination With Either Cross-Linked or Non Cross-Linked Collagen Membrane in Dehiscent Type of Defects .|Completed||Phase 4|40|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 01:20:50.921547|2018-06-01 01:20:50.921547
NCT00835419|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2012-12-03|2009-02-02|2009-02-03|Estimate|||||||2012-12-03|2012-12-04|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|April 2011|Actual|2011-04-30||Interventional|ENVER||Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression|An Open Label, Multicentre, Two Stage, Phase II Study To Evaluate Efficacy And Safety Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression|Completed||Phase 2|12|Actual|Piramal Enterprises Limited||1|||f||||f||||||||||2018-06-01 01:20:50.974311|2018-06-01 01:20:50.974311
NCT00835406|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-04-24||2009-06-29|2009-01-30|2009-02-03|Estimate|2009-04-24|2009-06-11|Estimate||||2009-06-29|2009-07-09|Estimate|June 2000||2000-06-30|June 2009|2009-06-30|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.|Randomized, 2-Way Crossover, Bioequivalence Study of Teva Pharmaceuticals USA and Merck Sharp & Dohme (USA) (Fosamax®) Alendronate Sodium Tablets Administered as a 1 x 70 mg in Healthy Adult Males Under Fasting Conditions|Completed||Phase 1|140|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:51.060693|2018-06-01 01:20:51.060693
NCT00835393|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-02|2009-02-02|2009-02-03|Estimate|||||||2009-02-02|2009-02-03|Estimate|December 2003||2003-12-31|January 2009|2009-01-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions|A Relative Bioavailability Replicated Crossover Study of Pantoprazole Sodium 40 mg DR Tablets Under Non-Fasting Conditions.|Completed||Phase 1|50|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:51.341076|2018-06-01 01:20:51.341076
NCT00835380|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-10-19||2017-03-16|2009-01-30|2009-02-03|Estimate|2009-12-08|2010-01-11|Estimate||||2017-03-16|2017-04-13|Actual|March 2008||2008-03-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)|A Phase III Open-Label Study of Immunogenicity, Safety, and Tolerability of 2 Doses of VAQTA™ (Formalin, Inactivated, Alum-Adjuvanted Hepatitis A Vaccine) in Healthy Children 12 to 23 Months of Age|Completed||Phase 3|80|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:20:51.448474|2018-06-01 01:20:51.448474
NCT00835367|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-05-06||2009-07-06|2009-02-02|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|March 2004||2004-03-31|July 2009|2009-07-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fed Conditions|Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|68|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:51.619881|2018-06-01 01:20:51.619881
NCT00835341|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2009-10-21||2015-05-07|2009-02-02|2009-02-03|Estimate|2010-02-01|2010-02-23|Estimate||||2015-05-07|2015-06-01|Estimate|March 2005||2005-03-31|May 2015|2015-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia|A Cohort Study on Prediction of Malignant Transformation of Oral Epithelial Dysplasia by p16 Methylation|Completed|||93|Actual|Peking University|||2||f||||t||||||Samples With DNA|"~     Tissue specimen are collected from outpatients and inpatients with oral leukoplakia by biopsy~     or surgical resection, fixed in neutral buffered formalin, and embedded in paraffin. Genomic~     DNA is extracted from tissue sections.~   "|||2018-06-01 01:20:52.191348|2018-06-01 01:20:52.191348
NCT00835328|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2018-03-07|2009-02-02|2009-02-03|Estimate|||||||2018-03-07|2018-03-09|Actual|February 2009||2009-02-28|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Exendin-(9-39) On Glucose Requirements To Maintain Euglycemia|Role of GLP-1 In Congenital Hyperinsulinism: Effect Of Exendin-(9-39)On Glucose Requirements To Maintain Euglycemia|Recruiting||Phase 1/Phase 2|20|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-06-01 01:20:52.44832|2018-06-01 01:20:52.44832
NCT00835315|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2010-08-11|2009-02-02|2009-02-03|Estimate|||||||2010-08-11|2010-08-12|Estimate|January 2008||2008-01-31|February 2009|2009-02-28||||||||Observational|||Prevalence of Psoriasis Alba in Psoriatic Patients||Unknown status|Enrolling by invitation||300|Actual|Hadassah Medical Organization|||1||f||||t||||||||||2018-06-01 01:20:52.541237|2018-06-01 01:20:52.541237
NCT00835302|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2013-01-29|2009-02-02|2009-02-03|Estimate|||||||2013-01-29|2013-01-30|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Development of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation|Development of a Clinical Prediction Rule to Identify Patients With Shoulder Pain Likely to Benefit From Cervicothoracic Manipulation|Completed||Phase 2|80|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-06-01 01:20:52.607873|2018-06-01 01:20:52.607873
NCT00835289|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-04-22|2009-02-02|2009-02-03|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|COD-Fish||The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial|The Chronic Obstructive Pulmonary Disease Fish Oil Pilot Trial|Completed||Phase 2|40|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 01:20:52.696649|2018-06-01 01:20:52.696649
NCT00835276|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-08-14|2009-02-02|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|March 2002||2002-03-31|August 2009|2009-08-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fasting Conditions.|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:52.804059|2018-06-01 01:20:52.804059
NCT00835263|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions|Randomized, 2-Way, Crossover, Bioequivalence Study of Lamotrigine 200 mg Tablets and Lamictal® 200 mg Tablets Administered as 1 x 200 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:53.133038|2018-06-01 01:20:53.133038
NCT00835250|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2013-03-11|2009-02-02|2009-02-03|Estimate|||||||2013-03-11|2013-03-12|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|April 2012|Actual|2012-04-30|May 2011|Actual|2011-05-31||Interventional|||Laparoscopic Cholecystectomy vs Hybrid Natural Orifice Translumenal Surgery|Prospective Randomized Clinical Trial Comparing Laparoscopic Cholecystectomy and Hybrid Natural Orifice Translumenal Endoscopic Surgery (NOTES)|Completed||Phase 3|60|Actual|Hospital Son Llatzer||3|||f||||f||||||||||2018-06-01 01:20:53.415761|2018-06-01 01:20:53.415761
NCT00835237|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2010-07-08||2018-04-27|2009-02-02|2009-02-03|Estimate|2010-07-08|2010-08-05|Estimate||||2018-04-27|2018-05-25|Actual|February 17, 2009||2009-02-17|October 2016|2016-10-31|October 15, 2009|Actual|2009-10-15|July 23, 2009|Actual|2009-07-23||Interventional|||Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.|Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.|Completed||Phase 3|1332|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:20:53.532464|2018-06-01 01:20:53.532464
NCT00835224|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2013-09-12||2014-03-21|2009-01-30|2009-02-03|Estimate|2014-03-21|2014-04-23|Estimate||||2014-03-21|2014-04-23|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional||30 subjects were anticipated but 34 were enrolled following an IRB approval to expand the n. Increased recruitment was due to a number of subjects withdrawing from participation for various reasons listed below.|Safety and Efficacy of L-NAME and Midodrine to Increase MAP|Safety and Efficacy of L-NAME and Midodrine to Increase MAP in Persons With Tetraplegia|Completed||Phase 2|34|Actual|VA Office of Research and Development|Study population was relatively small and were not blinded to the interventions.|3|||f||||f||||||||||2018-06-01 01:20:54.063272|2018-06-01 01:20:54.063272
NCT00835211|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|July 2003||2003-07-31|September 2009|2009-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Desmopressin Acetate 0.2 mg Tablets, Fasting|Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg Desmopressin Acetate Tablets in Healthy Adult Subjects Following a 0.8 mg Dose Under Fasting Conditions|Completed||Phase 1|48|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:54.414204|2018-06-01 01:20:54.414204
NCT00835198|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2011-09-22||2011-09-22|2009-02-02|2009-02-03|Estimate|2011-09-22|2011-10-31|Estimate||||2011-09-22|2011-10-31|Estimate|December 2008||2008-12-31|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris||Completed||Phase 4|163|Actual|Allergan||2|||f||||||||||||||2018-06-01 01:20:54.647369|2018-06-01 01:20:54.647369
NCT00835185|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2015-12-21|2010-09-29|2015-12-21|2009-02-02|2009-02-03|Estimate|2015-12-21|2016-01-29|Estimate|2010-10-04|2010-10-06|Estimate|2015-12-21|2016-01-29|Estimate|August 2007||2007-08-31|December 2015|2015-12-31|October 2010|Actual|2010-10-31|January 2010|Actual|2010-01-31||Interventional||All enrolled participants who received any quantity of study drug.|Study of IMC-11F8 in Participants With Colorectal Cancer|Open Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of IMC-11F8 in Combination With 5-FU/FA and Oxaliplatin (mFOLFOX-6) in Patients With Treatment-naïve, Locally-advanced or Metastatic Colorectal Cancer|Completed||Phase 2|44|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:20:54.89855|2018-06-01 01:20:54.89855
NCT00835159|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2013-04-12||2015-01-26|2009-02-02|2009-02-03|Estimate|2014-02-12|2014-02-13|Estimate||||2015-01-26|2015-02-09|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial|Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial|Completed||Phase 4|30|Actual|New York University School of Medicine|The study was halted prematurely because of a warning letter issued by the rivastigmine manufacturer indicating the possibility of increased mortality associated with the oral administration of the drug in critically ill patients.|2|||f||||f||||||||||2018-06-01 01:20:56.566875|2018-06-01 01:20:56.566875
NCT00835146|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-02-02|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Ribavirin 200 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Fasting Conditions|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:56.769504|2018-06-01 01:20:56.769504
NCT00835133|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-31|||2017-09-08|2009-01-31|2009-02-03|Estimate|||||||2017-09-08|2017-09-11|Actual|August 2002||2002-08-31|September 2017|2017-09-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma|Biospecimen Resource for Familial Pancreas Research, a Data and Tissue Registry (Also Known as a Bio-repository, Bio-bank, Data and Tissue Database, Data and Tissue Bank, Etc.) to Help Advance Research in Familial Pancreas Disease|Recruiting|||4000|Anticipated|Mayo Clinic|||||f||||t||||||Samples With DNA|"~     Two 10mL plasma tubes and two 10mL serum tubes collected. DNA extracted from blood~     lymphocytes. Possible saliva sample for DNA extraction. Waste tissue from previous surgery~     may be requested.~   "|||2018-06-01 01:20:56.987468|2018-06-01 01:20:56.987468
NCT00835120|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2014-10-10||2016-11-30|2009-02-02|2009-02-03|Estimate|2014-10-10|2014-10-17|Estimate||||2016-11-30|2017-01-26|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance|Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance|Completed||Phase 4|34|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-06-01 01:20:57.087877|2018-06-01 01:20:57.087877
NCT00835107|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2015-12-14|2009-02-02|2009-02-03|Estimate|||||||2015-12-14|2015-12-16|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression|An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression|Completed||Phase 4|14|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 01:20:57.472939|2018-06-01 01:20:57.472939
NCT00835094|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-03-20|2009-02-02|2009-02-03|Estimate|||||||2017-03-20|2017-03-22|Actual|October 1, 2002|Actual|2002-10-01|March 2017|2017-03-31|July 1, 2003|Actual|2003-07-01|July 1, 2003|Actual|2003-07-01||Interventional|||A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Study P02177)|A Randomized Trial Assessing the Chronobiology of Once Daily Administration of Mometasone Furoate DPI in Patients With Asthma|Completed||Phase 4|216|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:20:57.554704|2018-06-01 01:20:57.554704
NCT00835081|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|September 2004||2004-09-30|August 2009|2009-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.|A Two-Way , Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:57.648246|2018-06-01 01:20:57.648246
NCT00835068|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2014-09-11||2014-09-11|2009-02-02|2009-02-03|Estimate|2014-09-11|2014-09-17|Estimate||||2014-09-11|2014-09-17|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational||Safety population included all participants who received at least one dose of BeneFIX.|Post Marketing Observational Study of Reformulated BeneFIX|Post Marketing Observational Study Of Reformulated BeneFIX|Completed|||58|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:20:57.980288|2018-06-01 01:20:57.980288
NCT00835055|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-09-21|2009-02-02|2009-02-03|Estimate|||||||2009-09-21|2009-09-22|Estimate|April 2005||2005-04-30|September 2009|2009-09-30||||||||Observational|||Expression of Molecular Markers Before and After Neo-adjuvant Chemoradiotherapy in Rectal Cancer||Unknown status|Recruiting||100|Anticipated|St. Claraspital AG|||||f||||||||||||||2018-06-01 01:20:58.44141|2018-06-01 01:20:58.44141
NCT00835042|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-02-02|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|October 2003||2003-10-31|September 2009|2009-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:58.509372|2018-06-01 01:20:58.509372
NCT00835029|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2015-03-24|2009-02-02|2009-02-03|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches|Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis|Completed||Phase 2|13|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:20:58.929301|2018-06-01 01:20:58.929301
NCT00835016|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2015-09-19|2009-02-01|2009-02-03|Estimate|||||||2015-09-19|2015-09-22|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|LTP||Early Psychosocial Stimulation Program for Children of Depressed Mothers|Early Psychosocial Stimulation (LTP) Program for Children of Depressed Mothers: An RCT|Completed||Phase 2|260|Actual|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-06-01 01:20:59.006739|2018-06-01 01:20:59.006739
NCT00835003|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2014-06-03||2014-06-03|2009-02-02|2009-02-03|Estimate|2014-06-03|2014-07-03|Estimate||||2014-06-03|2014-07-03|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|November 2011|Actual|2011-11-30||Interventional|||Timing of Planned Caesarean Section and Morbidity of the Newborn|Timing of Elective Caesarean Section and Neonatal Morbidity - a Randomised Multicentre Study|Completed||N/A|1273|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-06-01 01:20:59.089999|2018-06-01 01:20:59.089999
NCT00834990|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-22||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-22|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Delayed-Release Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:59.328749|2018-06-01 01:20:59.328749
NCT00834977|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-05-06||2009-07-06|2009-02-02|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|April 2004||2004-04-30|July 2009|2009-07-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way, Crossover, Bioequivalence Study of Amlodipine-Benazepril 10mg-20mg Capsules and Lotrel® Administered as 1 x 10 mg-20 mg Capsule in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|48|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:59.593291|2018-06-01 01:20:59.593291
NCT00834964|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-06||2009-09-11|2009-01-30|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-15|Estimate|December 2002||2002-12-31|September 2009|2009-09-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Venlafaxine 25 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|30|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:20:59.947348|2018-06-01 01:20:59.947348
NCT00834951|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-02|2009-02-02|2009-02-03|Estimate|||||||2009-02-02|2009-02-03|Estimate|January 2003||2003-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma|A Prospective Multicenter Phase II Study of MabThera (Rituximab) Plus 2 Weekly CHOP Followed by Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma|Completed||Phase 2|40|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 01:21:00.204668|2018-06-01 01:21:00.204668
NCT00834938|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2011-08-09|2009-02-02|2009-02-03|Estimate|||||||2011-08-09|2011-08-11|Estimate|July 2007||2007-07-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2008|Actual|2008-07-31||Observational|||Comparison Between Patients With or Without Diabetes Recovery After Bariatric Surgery|Long Term Effects of Bariatric Surgery on Diabetes: Comparison Between Patients With or Without Diabetes Recovery.|Completed|||24|Actual|University of Campinas, Brazil|||2||f||||f||||||||||2018-06-01 01:21:00.251451|2018-06-01 01:21:00.251451
NCT00834925|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2011-07-25|2009-02-02|2009-02-03|Estimate|||||||2011-07-25|2011-07-26|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|August 2011|Anticipated|2011-08-31|August 2009|Actual|2009-08-31||Interventional|||Low Dose of Diltiazem for Rate Control of Atrial Fibrillation||Unknown status|Recruiting|Phase 4|380|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-06-01 01:21:00.316945|2018-06-01 01:21:00.316945
NCT00834912|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-04-09||2012-04-25|2009-02-02|2009-02-03|Estimate|2009-09-16|2009-10-19|Estimate||||2012-04-25|2012-04-30|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of Two Tramadol Contramid® OAD 300 mg Controlled-Release Tablets From Two Different Manufacturing Sites Following a 300 mg Dose in Healthy Subjects Under Fasting and Fed Conditions||Completed||Phase 1|36|Actual|Labopharm Inc.||3|||f||||||||||||||2018-06-01 01:21:00.389763|2018-06-01 01:21:00.389763
NCT00834899|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-31|2013-02-24||2013-05-22|2009-01-31|2009-02-03|Estimate|2013-05-22|2013-06-27|Estimate||||2013-05-22|2013-06-27|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Safety Study of Eptifibatide in Patients With Sickle Cell Disease|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease|Terminated||Phase 1/Phase 2|13|Actual|University of North Carolina, Chapel Hill|The study was terminated early resulting in small numbers of subjects analyzed.|2||Slow accrual and no cost extension not approved by NHLBI|f||||t||||||||||2018-06-01 01:21:00.851309|2018-06-01 01:21:00.851309
NCT00834886|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2014-08-01||2016-03-09|2009-02-02|2009-02-03|Estimate|2014-12-02|2014-12-08|Estimate||||2016-03-09|2016-03-14|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Randomized Controlled Trial on the Treatment Effects of Melatonin and Light Therapy on Delayed Sleep Phase Syndrome|Delayed Sleep Phase Syndrome in Adolescents and Young Adults. Sleep, Personality, Developmental History, Circadian Rhythm, Daytime Functioning and Treatment|Completed||Phase 4|40|Actual|University of Bergen||4|||f||||t||||||||No|Publications from the stury are reported here. IPD can be retrieved upon request to the study investigator.|2018-06-01 01:21:01.300512|2018-06-01 01:21:01.300512
NCT00834873|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-05-08||2009-09-11|2009-01-30|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-15|Estimate|December 2001||2001-12-31|September 2009|2009-09-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects|A Randomized, Two-Way Crossover, Single-Dose, Open Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Carvedilol (25 mg), Compared to an Equivalent Dose of COREG® (SmithKline Beecham Pharmaceuticals) in 24 Fed, Healthy, Adult Subjects|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:01.640143|2018-06-01 01:21:01.640143
NCT00834860|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2010-02-11|2009-02-02|2009-02-03|Estimate|||||||2010-02-11|2010-02-15|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|February 2010|Anticipated|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma|The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 4|179|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-06-01 01:21:01.889567|2018-06-01 01:21:01.889567
NCT00834847|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2009-01-30|2009-01-30|2009-02-03|Estimate|||||||2009-01-30|2009-02-03|Estimate|August 2000||2000-08-31|January 2009|2009-01-31|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Pravastatin Sodium 40 mg Tablets Food Challenge Study|A Relative Bioavailability Food Challenge Study of Pravastatin Sodium 40 mg Tablets|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||3|||f||||f||||||||||2018-06-01 01:21:01.971176|2018-06-01 01:21:01.971176
NCT00834834|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2016-10-06||2017-07-20|2009-02-02|2009-02-03|Estimate|2017-07-20|2017-08-18|Actual||||2017-07-20|2017-08-18|Actual|March 2009||2009-03-31|July 2017|2017-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder|Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change|Completed||Phase 4|84|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-06-01 01:21:02.050035|2018-06-01 01:21:02.050035
NCT00834821|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2014-01-17|2009-02-02|2009-02-03|Estimate|||||||2014-01-17|2014-01-20|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Effectiveness of a Behavioral Treatment Program for Attention Deficit Hyperactivity Disorder, Inattentive Type|Integrated Multi-setting Psychosocial Treatment for ADHD-Inattentive Type|Unknown status|Active, not recruiting|N/A|210|Anticipated|University of California, San Francisco||3|||f||||f||||||||||2018-06-01 01:21:02.289899|2018-06-01 01:21:02.289899
NCT00834808|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-04-08||2012-04-24|2009-02-02|2009-02-03|Estimate|2009-04-08|2009-06-02|Estimate||||2012-04-24|2012-04-27|Estimate|November 2002||2002-11-30|April 2012|2012-04-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers||Completed||Phase 1|27|Actual|Labopharm Inc.||3|||f||||||||||||||2018-06-01 01:21:02.38229|2018-06-01 01:21:02.38229
NCT00834795|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-05-08||2009-09-11|2009-01-30|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-15|Estimate|December 2001||2001-12-31|September 2009|2009-09-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects|A Randomized, Two-Way Crossover, Single-Dose, Open Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Carvedilol (25 mg), Compared to an Equivalent Dose of COREG® (SmithKline Beecham Pharmaceuticals) in 36 Fasted, Healthy, Adult Subjects|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:02.681861|2018-06-01 01:21:02.681861
NCT00834782|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-09-13|2009-02-02|2009-02-03|Estimate|||||||2009-09-13|2009-09-15|Estimate|May 2009||2009-05-31|September 2009|2009-09-30|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Observational|||Comparison of DCT, ORA and GAT in Eyes After Penetrating Keratoplasty|Comparison of Pascal Dynamic Contour Tonometer, Reichart Ocular Response Analyzer and Goldmann Applanation Tonometer in Eyes After Penetrating Keratoplasty|Unknown status|Recruiting||35|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 01:21:02.90353|2018-06-01 01:21:02.90353
NCT00834769|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2016-09-22|2009-02-02|2009-02-03|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Chronic Pain After Thoracotomy, an Incidence Study in a Single Surgical Center|Chronic Pain After Thoracotomy, an Incidence Study in a Single Surgical Center|Completed|||65|Actual|Hopital Foch|||||f||||f||||||||||2018-06-01 01:21:02.979119|2018-06-01 01:21:02.979119
NCT00834756|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-05-07||2009-09-11|2009-02-02|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-15|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Azithromycin 600 Mg Tablets, Fasting|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Azithromycin (600 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Zithromax®, Pfizer, Inc.) in 36 Fasted, Healthy, Adult Subjects|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:03.041436|2018-06-01 01:21:03.041436
NCT00834743|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|August 2003||2003-08-31|September 2009|2009-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Metformin ER 750 mg Tablets, Fasting|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Metformin ER 750 mg Tablets Versus Glucophage® XR 750 mg Tablets in Normal Healthy Non-smoking Male and Female Subjects|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:03.293178|2018-06-01 01:21:03.293178
NCT00834730|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2011-09-13|2009-02-01|2009-02-03|Estimate|||||||2011-09-13|2011-09-15|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|PSA||Comparison of N2O Inhalation and Ketamine in Pediatric PSA|Comparison of N2O Inhalation and Ketamine IV Injection for Sedation in the Treatment of Laceration of Pediatric Patients.|Completed||Phase 4|32|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 01:21:03.619551|2018-06-01 01:21:03.619551
NCT00834717|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|September 2005||2005-09-30|September 2009|2009-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Granisetron 1 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Granisetron 1 mg Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:03.691088|2018-06-01 01:21:03.691088
NCT00834704|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2013-03-24|2009-02-02|2009-02-03|Estimate|||||||2013-03-24|2013-03-26|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|PEG||Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors|Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Given Intravenously to Patients With Advanced Solid Tumors|Completed||Phase 1|14|Actual|Halozyme Therapeutics||1|||f||||f||||||||||2018-06-01 01:21:03.933898|2018-06-01 01:21:03.933898
NCT00834691|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2010-07-30|2009-02-02|2009-02-03|Estimate|||||||2010-07-30|2010-08-02|Estimate|January 2008||2008-01-31|July 2010|2010-07-31||||February 2010|Actual|2010-02-28||Observational|ANCHOR||An Evaluation of the Causes of Anemia in Patients With Heart Failure|Anemia in Chronic Heart Failure: Etiology, Comparisons With Renal Disease, and Relationships With Biomarkers and Left Ventricular Remodeling.|Completed|||180|Anticipated|Montreal Heart Institute|||3||f||||f||||||Samples Without DNA|"~     Plasma and serum samples for analysis of biomarkers.~   "|||2018-06-01 01:21:03.995378|2018-06-01 01:21:03.995378
NCT00834678|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-31|2014-09-26||2018-03-19|2009-01-31|2009-02-03|Estimate|2015-03-31|2015-04-22|Estimate||||2018-03-19|2018-04-17|Actual|April 2009|Actual|2009-04-30|March 2018|2018-03-31|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|||Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer|Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer|Completed||Phase 1/Phase 2|11|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-06-01 01:21:04.080926|2018-06-01 01:21:04.080926
NCT00834665|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2016-08-17|2009-02-02|2009-02-03|Estimate|||||||2016-08-17|2016-08-19|Estimate|December 2006||2006-12-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma|Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells|Active, not recruiting||Phase 1/Phase 2|56|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 01:21:04.386305|2018-06-01 01:21:04.386305
NCT00834652|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2016-08-08||2018-01-29|2009-02-02|2009-02-03|Estimate|2018-01-29|2018-02-28|Actual||||2018-01-29|2018-02-28|Actual|September 2007||2007-09-30|January 2018|2018-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight|Improving Depression Treatment Outcomes With an Insulin-Sensitizing Agent|Completed||Phase 4|206|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:21:04.466419|2018-06-01 01:21:04.466419
NCT00834639|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-22||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-22|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions|A Relative Bioavailability Study of 500 mg Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:04.746243|2018-06-01 01:21:04.746243
NCT00834626|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|2011-02-03||2012-08-30|2009-02-02|2009-02-03|Estimate|2012-07-27|2012-08-31|Estimate||||2012-08-30|2012-09-06|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|IISG||Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes|Interventional Study of Effects of Ileal Interposition With Sleeve Gastrectomy for Control of Type 2 Diabetes|Completed||N/A|30|Actual|Kirloskar Hospital|Non-availability of hormonal tests like Glucagon-Like Peptide-1 estimation pre- & post-operative.|1|||f||||t||||||||||2018-06-01 01:21:05.006216|2018-06-01 01:21:05.006216
NCT00834613|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-02-02|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|August 2003||2003-08-31|September 2009|2009-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Metformin ER 750 mg Tablets, Fed|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Metformin ER 750 mg Tablets Versus Glucophage® XR 750 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:05.18743|2018-06-01 01:21:05.18743
NCT00834600|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2012-04-18|2009-01-30|2009-02-03|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2005||2005-12-31|October 2010|2010-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Renin Profiling in Selection of Initial Antihypertensive Drug|A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug|Completed||N/A|185|Actual|The Louis & Rachel Rudin Foundation||2|||f||||t||||||||||2018-06-01 01:21:05.425452|2018-06-01 01:21:05.425452
NCT00834587|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-09|2009-01-30|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|June 2004||2004-06-30|September 2009|2009-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting|A Relative Bioavailability Study of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets Under Non-Fasting Conditions.|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:05.511241|2018-06-01 01:21:05.511241
NCT00834574|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|February 2005||2005-02-28|August 2009|2009-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Cefdinir for Oral Suspension 250 mg/5mL, Fasting|A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:05.80421|2018-06-01 01:21:05.80421
NCT00834561|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Bioequivalence Study of 200 mg Lamotrigine Tablet Under Fasting Conditions|Randomized, Two-Way Crossover, Single-Dose, Fasting Bioequivalence Study of Lamotrigine 1 x 200 mg Tablet|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:06.059656|2018-06-01 01:21:06.059656
NCT00834548|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2009-02-01|2009-02-01|2009-02-03|Estimate|||||||2009-02-01|2009-02-03|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|August 2008|Actual|2008-08-31|||||Observational|||Whole-Body MRA at 3T - A Comparison Between Two Different Scan Protocols|Whole-Body MRA at 3T - A Comparison Between Two Different Scan Protocols|Completed|||26|Anticipated|Copenhagen University Hospital at Herlev|||2||f||||t||||||||||2018-06-01 01:21:06.267292|2018-06-01 01:21:06.267292
NCT00834535|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Cefdinir Capsules 300 mg, Non-fasting|A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Non-fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:06.325529|2018-06-01 01:21:06.325529
NCT00834522|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|July 2005||2005-07-31|September 2009|2009-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Granisetron 1 mg Tablets, Non-fasting|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Granisetron 1 mg Tablets Under Fed Conditions|Completed||Phase 1|80|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:06.620309|2018-06-01 01:21:06.620309
NCT00834509|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2017-04-17|2009-02-02|2009-02-03|Estimate|||||||2017-04-17|2017-04-18|Actual|April 2008||2008-04-30|April 2017|2017-04-30|February 1, 2015|Actual|2015-02-01|February 1, 2015|Actual|2015-02-01||Observational|BOSA||Biomarkers for Obstructive Sleep Apnea|Towards a Blood Test for Diagnosis of Obstructive Sleep Apnea|Completed|||181|Actual|University of Pennsylvania|||2||f||||t||||||Samples With DNA|"~     Primary outcome variables: tumor necrosis factor alpha (TNFα); plasma norepinephrine, and~     free fatty acids. Secondary biomarkers: Interleukin 6 (IL-6), urinary norepinephrine; urinary~     normetanephrine; glucose, Intercellular Adhesion Molecule (ICAM), leptin. Monocytes will be~     separated from each blood sample (before, during and after sleep) and RNA extracted.~     Expression of key genes will be assessed by RT-PCR and microarray studies will be performed~     in a subset of subjects to assess changes in expression of all genes as a result of OSA. We~     will evaluate: a)whether individuals with comorbidities have more oxidative stress and~     inflammatory change for equivalent degrees of OSA than individuals without such~     comorbidities; b) whether individuals with comorbidities have lower levels of protective~     mechanisms—melatonin, IL-10; c) different gene variants based on a genetic association study~     using a recently developed CV SNP array.~   "|||2018-06-01 01:21:06.936032|2018-06-01 01:21:06.936032
NCT00834496|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2017-01-11|2009-02-02|2009-02-03|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2009||2009-01-31|January 2017|2017-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation|Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation|Withdrawn|||0|Actual|Thomas Jefferson University|||1||f||||t||||||||||2018-06-01 01:21:07.012521|2018-06-01 01:21:07.012521
NCT00834483|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2013-02-02||2014-09-09|2009-02-02|2009-02-03|Estimate|2014-09-09|2014-09-11|Estimate||||2014-09-09|2014-09-11|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|December 2012|Actual|2012-12-31|January 2011|Actual|2011-01-31||Interventional|||Use of Knotless Suture for Closure of Total Hip and Knee Arthroplasties|Use of Knotless Suture for Closure of Total Hip and Knee Arthroplasties: A Prospective-randomized Clinical Trial|Completed||N/A|65|Actual|Rush University Medical Center|Five patients were offered enrollment but refused to participate, however this does not alter our data as sixty others did enroll.|2|||f||||t||||||||||2018-06-01 01:21:07.102452|2018-06-01 01:21:07.102452
NCT00834457|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2014-10-29|2009-02-02|2009-02-03|Estimate|||||||2014-10-29|2014-10-30|Estimate|June 2007||2007-06-30|October 2014|2014-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe|A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe|Completed||Phase 2/Phase 3|49|Actual|Parirenyatwa Hospital||2|||f||||t||||||||||2018-06-01 01:21:07.524914|2018-06-01 01:21:07.524914
NCT00834444|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|August 2004||2004-08-31|August 2009|2009-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Famciclovir 500 mg Tablets Under Non-Fasting Conditions|A Single Dose, Comparative Bioavailability Study of Two Formulations of Famciclovir 500 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:07.645709|2018-06-01 01:21:07.645709
NCT00834431|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-30||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-30|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|August 2004||2004-08-31|August 2009|2009-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Famciclovir 500 mg Tablets Under Fasting Conditions|A Single Dose, Comparative Bioavailability Study of Two Formulations of Famciclovir 500 mg Tablets Under Fasting Conditions|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:07.952065|2018-06-01 01:21:07.952065
NCT00834418|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-09|2009-01-30|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|June 2002||2002-06-30|September 2009|2009-09-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Leflunomide 20 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 20 mg Leflunomide Tablets Under Fasting Conditions|Completed||Phase 1|84|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:08.274235|2018-06-01 01:21:08.274235
NCT00834405|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-09|2009-01-30|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|April 2002||2002-04-30|September 2009|2009-09-30|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Leflunomide 20 mg Tablets, Non-Fasting|A Relative Bioavailability, Parallel Study of Leflunomide 20 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|37|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:08.511408|2018-06-01 01:21:08.511408
NCT00834392|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2011-01-31|2009-02-02|2009-02-03|Estimate|||||||2011-01-31|2011-02-01|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Exercise in Men With Prostate Cancer|A Pilot Study of Exercise in Men With Prostate Cancer Receiving Androgen Depletion Therapy|Completed||N/A|30|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-06-01 01:21:08.728643|2018-06-01 01:21:08.728643
NCT00834379|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2009-01-30|2009-01-30|2009-02-03|Estimate|||||||2009-01-30|2009-02-03|Estimate|September 2000||2000-09-30|January 2009|2009-01-31|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Pravastatin Sodium 40 mg Tablets Under Fasting Conditions|Completed||Phase 1|58|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:08.783806|2018-06-01 01:21:08.783806
NCT00834366|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-04-06||2012-04-25|2009-02-02|2009-02-03|Estimate|2009-04-06|2009-06-08|Estimate||||2012-04-25|2012-04-30|Estimate|February 2005||2005-02-28|April 2012|2012-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions||Completed||Phase 1|26|Actual|Labopharm Inc.||2|||f||||||||||||||2018-06-01 01:21:08.847852|2018-06-01 01:21:08.847852
NCT00834353|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-02|2009-02-02|2009-02-03|Estimate|||||||2009-02-02|2009-02-03|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Observational|||Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis|Prospective Study of N-acetyltransferase2 (NAT2) Gene and Rifampicin Induced Cytochrome P-450 as Susceptible Risk Factors for Antituberculosis Drug Induced Hepatitis|Completed|||||Maulana Azad Medical College|||1||f||||t||||||||||2018-06-01 01:21:09.048513|2018-06-01 01:21:09.048513
NCT00834340|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-22||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-06-22|2009-08-04|Estimate||||2009-09-01|2009-09-11|Estimate|February 2003||2003-02-28|September 2009|2009-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Glimepiride 4 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Glimepiride 4 mg Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:09.106015|2018-06-01 01:21:09.106015
NCT00834327|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2009-10-12|2009-01-30|2009-02-03|Estimate|||||||2009-10-12|2009-10-14|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome|A Randomized, Double-Blind, Placebo-Controlled Four Week Study of the Efficacy and Safety of Four Doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of Aplindore MR Tablets vs. Placebo in Idiopathic Restless Legs Syndrome.|Terminated||Phase 2|230|Anticipated|Neurogen Corporation||5||"Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety~   concerns identified."|f||||f||||||||||2018-06-01 01:21:09.414336|2018-06-01 01:21:09.414336
NCT00834314|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2015-12-07|2009-02-02|2009-02-03|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ABDOVAC||Randomized Pilot Study Comparing Two Vacuum-wound-dressings for Open Abdomen Treatment|"Vacuum-Therapy in Open Abdomen Treatment - Randomized Pilot-trial Comparing Fascial Closure and Survival With Vacuum-Pack-Technique vs. Abdominal Dressing"|Terminated||N/A|3|Actual|Universitätsmedizin Mannheim||2||"extended obligations of amended medical device law in Germany 2010 did not allow to continue~   and complete the trial due to budget limitation"|f||||t||||||||||2018-06-01 01:21:09.496136|2018-06-01 01:21:09.496136
NCT00834301|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-02|2009-02-02|2009-02-03|Estimate|||||||2009-02-02|2009-02-03|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients|An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients|Unknown status|Recruiting|Phase 2|25|Anticipated|Nephrian||1|||f||||f||||||||||2018-06-01 01:21:09.562137|2018-06-01 01:21:09.562137
NCT00834288|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-04-08||2012-04-24|2009-02-02|2009-02-03|Estimate|2009-09-16|2009-10-19|Estimate||||2012-04-24|2012-04-27|Estimate|June 2003||2003-06-30|April 2012|2012-04-30||||August 2003|Actual|2003-08-31||Interventional|||A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions|A Study to Compare the Bioavailability of Two Tramadol Hydrochloride Tablet Products (50 mg and 200 mg, Respectively) at Steady-state Under Fasting Conditions|Completed||Phase 1|26|Actual|Labopharm Inc.||2|||f||||||||||||||2018-06-01 01:21:09.633202|2018-06-01 01:21:09.633202
NCT00834275|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-06-18||2009-08-14|2009-01-30|2009-02-03|Estimate|2009-06-18|2009-07-21|Estimate||||2009-08-14|2009-08-20|Estimate|September 2004||2004-09-30|August 2009|2009-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Cefadroxil 500 mg Capsules Under Fasting Conditions|A Two-Way Crossover, Open-Label, Single-Dose Fasting, Bioequivalence Study of Cefadroxil 500 mg Capsules Versus DURICEF® 500 mg Capsules in Normal Healthy Non-smoking Male and Female Subjects.|Completed||Phase 1|26|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:10.854916|2018-06-01 01:21:10.854916
NCT00834262|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2016-10-27|2009-02-02|2009-02-03|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2009||2009-04-30|October 2016|2016-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients|A Multi Centre, Open Label, Non-Randomized, Non Interventional, Observational Study on the Safety and Efficacy of Biphasic Insulin Aspart (NovoMix® 30, NovoMix® 50 and NovoMix® 70 or Combinations) in Type 2 Diabetes Mellitus Patients|Completed|||339|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:21:11.141177|2018-06-01 01:21:11.141177
NCT00834249|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-06||2009-09-11|2009-01-30|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-15|Estimate|December 2002||2002-12-31|September 2009|2009-09-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Venlafaxine 25 mg Tablets Under Non-Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Venlafaxine 25 mg Tablets and Effexor® 25 mg Tablets Administered as 1 x 25 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|18|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:11.232668|2018-06-01 01:21:11.232668
NCT00834236|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2015-09-30||2015-11-03|2009-02-02|2009-02-03|Estimate|2015-11-03|2015-12-07|Estimate||||2015-11-03|2015-12-07|Estimate|March 2008||2008-03-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Proteiomic Fingerprints of Gastric Juice|Diagnosis of Gastroduodenal Diseases by Proteiomic Fingerprints of Gastric Juice|Completed||N/A|76|Actual|Kaohsiung Veterans General Hospital.|The trial was performed in a single country|2|||f||||t||||||||||2018-06-01 01:21:11.621521|2018-06-01 01:21:11.621521
NCT00834223|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2011-03-31|2009-02-02|2009-02-03|Estimate|||||||2011-03-31|2011-04-01|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|May 2010|Actual|2010-05-31|September 2009|Actual|2009-09-30||Interventional|||A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)|A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)|Completed||N/A|15|Actual|OPKO Health, Inc.||1|||f||||f||||||||||2018-06-01 01:21:11.82262|2018-06-01 01:21:11.82262
NCT00834210|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2011-09-22||2011-09-22|2009-01-30|2009-02-03|Estimate|2011-09-22|2011-10-31|Estimate||||2011-09-22|2011-10-31|Estimate|December 2008||2008-12-31|September 2011|2011-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris||Completed||Phase 4|171|Actual|Allergan||2|||f||||||||||||||2018-06-01 01:21:11.89383|2018-06-01 01:21:11.89383
NCT00834197|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-02-02|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|July 2003||2003-07-31|September 2009|2009-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting|A Relative Bioavailability Study of 15 mg Mirtazapine Orally Disintegrating Tablets Under Non-Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:12.124364|2018-06-01 01:21:12.124364
NCT00834184|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2013-02-12|2009-02-02|2009-02-03|Estimate|||||||2013-02-12|2013-02-15|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety and PK of Nikkomycin Z in Healthy Subjects|Phase I, Randomized, Double-blind, Placebo Controlled, Multiple-dose Evaluation of the Safety Tolerance and Pharmacokinetics of Nikkomycin Z in Healthy Subjects|Completed||Phase 1|33|Actual|University of Arizona||4|||f||||t||||||||||2018-06-01 01:21:12.370151|2018-06-01 01:21:12.370151
NCT00834171|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2011-08-17||2011-08-17|2009-01-30|2009-02-03|Estimate|2011-08-17|2011-09-26|Estimate||||2011-08-17|2011-09-26|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin||Completed|||50|Actual|Allergan|||2||f||||||||||||||2018-06-01 01:21:12.442131|2018-06-01 01:21:12.442131
NCT00834158|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-31|||2016-03-30|2009-01-31|2009-02-03|Estimate|||||||2016-03-30|2016-04-01|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|November 2010|Actual|2010-11-30|December 2009|Actual|2009-12-31||Interventional|TACEPVE||Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC|Efficacy of Sequential Arterial and Portal Vein Embolizations on Increasing the Resectability of Hepatitis B Related Primary Hepatocellular Carcinoma|Completed||N/A|20|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:21:12.588996|2018-06-01 01:21:12.588996
NCT00834145|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2009-02-02|2009-02-02|2009-02-03|Estimate|||||||2009-02-02|2009-02-03|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure|Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure: Short- Intermediate- and Long-Term Outcomes|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hillel Yaffe Medical Center||2|||f||||||||||||||2018-06-01 01:21:12.659086|2018-06-01 01:21:12.659086
NCT00834132|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-05-07||2009-09-11|2009-02-02|2009-02-03|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-15|Estimate|July 2002||2002-07-31|September 2009|2009-09-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Azithromycin 600 Mg Tablets, Fed|A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Azithromycin (600 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Zithromax®, Pfizer, Inc.) in 24 Fed, Healthy, Adult Subjects|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:12.744038|2018-06-01 01:21:12.744038
NCT00834119|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-03-21|2009-02-02|2009-02-03|Estimate|||||||2017-03-21|2017-03-23|Actual|September 1, 2003|Actual|2003-09-01|March 2017|2017-03-31|April 1, 2004|Actual|2004-04-01|April 1, 2004|Actual|2004-04-01||Interventional|||Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)|Assessment of the Effectiveness of Regular Use of Intranasal Steroids in Alleviating Nasal Symptoms in Allergic Rhinitis When Used Alone or in Combination With Oral Antihistamine|Completed||Phase 4|72|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:21:13.064417|2018-06-01 01:21:13.064417
NCT00834106|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2017-09-12|2013-04-25|2017-10-16|2009-01-30|2009-02-03|Estimate|2017-09-12|2017-10-12|Actual|2013-04-25|2013-05-03|Estimate|2017-10-16|2017-11-17|Actual|December 31, 2008|Actual|2008-12-31|October 2017|2017-10-31|September 30, 2016|Actual|2016-09-30|May 11, 2012|Actual|2012-05-11||Interventional||All randomized participants|Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)|A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women|Completed||Phase 3|3006|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f|||t|||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:21:13.15234|2018-06-01 01:21:13.15234
NCT00834093|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2018-01-26|2009-02-02|2009-02-03|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2009||2009-01-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma|A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma|Active, not recruiting||Phase 2|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No|There are no plans to share IPD. Cumulative results will be posted and published.|2018-06-01 01:21:13.710386|2018-06-01 01:21:13.710386
NCT00834080|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|2013-05-30||2013-05-30|2009-02-02|2009-02-03|Estimate|2013-05-30|2013-07-29|Estimate||||2013-05-30|2013-07-29|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||The Safety Population, defined as all subjects who received at least 1 dose (injection) of study drug, was used for presentation and analysis of both safety and efficacy data.|ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals|Open-Label Study of the Safety and Tolerability of VIVITROL Administered to Health Care Professionals Participating in an Extended Outpatient Treatment Program for Opioid Dependence|Completed||Phase 3|38|Actual|Alkermes, Inc.|After screening 49 subjects, Alkermes made a business decision to stop enrollment, resulting in 38 total subjects enrolled.|1|||f||||f||||||||||2018-06-01 01:21:13.809091|2018-06-01 01:21:13.809091
NCT00834067|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-02||2009-09-01|2009-01-30|2009-02-03|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|October 2003||2003-10-31|September 2009|2009-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:14.034464|2018-06-01 01:21:14.034464
NCT00834054|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-02|||2016-09-22|2009-02-02|2009-02-03|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|PICCO-LungT||Measurement of Lung Water by Transpulmonary Thermodilution in Lung Transplanted Patients|Interest of Repeated Extravascular Lung Water Measurements With the PICCO Device in Lung Transplanted Patients|Completed|||15|Anticipated|Hopital Foch|||1||f||||f||||||||||2018-06-01 01:21:14.402689|2018-06-01 01:21:14.402689
NCT00834041|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2011-01-18||2011-04-15|2009-02-02|2009-02-03|Estimate|2011-04-15|2011-05-09|Estimate||||2011-04-15|2011-05-09|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age|An 8-day Open-label, Multiple-dose, Multicenter Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age|Completed||Phase 1/Phase 2|39|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:21:14.473049|2018-06-01 01:21:14.473049
NCT00834028|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-01|||2009-02-01|2009-02-01|2009-02-03|Estimate|||||||2009-02-01|2009-02-03|Estimate|February 2007||2007-02-28|November 2006|2006-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization|Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization : The Roles of VEGF, Cathepsin L, Endostatin, and Angiopoietin-2.|Completed|||60|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||f||||||Samples With DNA|"~     serum~   "|||2018-06-01 01:21:14.757231|2018-06-01 01:21:14.757231
NCT00834015|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2015-04-13|2009-01-30|2009-02-02|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Spinal Fusion and Rehabilitation Study|Outcome of Lumbar Spinal Fusion Patients and Significance of Postoperative Exercise Therapy: Randomized Controlled Trial and Spine Register Study|Completed||N/A|100|Actual|Jyväskylä Central Hospital||1|||f||||f||||||||||2018-06-01 01:21:14.905583|2018-06-01 01:21:14.905583
NCT00834002|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2010-02-05|2009-01-30|2009-02-02|Estimate|||||||2010-02-05|2010-02-09|Estimate|March 2005||2005-03-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|November 2007|Actual|2007-11-30||Interventional|CCRG 05-001||Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission|Wilms Tumor Gene (WT1) mRNA-transfected Autologous Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia (AML): a Phase I Trial|Completed||Phase 1|10|Actual|University Hospital, Antwerp|||||f||||f||||||||||2018-06-01 01:21:14.983913|2018-06-01 01:21:14.983913
NCT00833989|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2017-07-31|2012-03-15|2017-10-17|2009-01-29|2009-02-02|Estimate|2017-09-14|2017-10-16|Actual|2012-03-15|2012-03-19|Estimate|2017-10-17|2017-11-17|Actual|July 8, 2009|Actual|2009-07-08|September 2017|2017-09-30|January 31, 2011|Actual|2011-01-31|January 31, 2011|Actual|2011-01-31||Interventional|MAG111539||Safety Escalating Repeat IV, in Stroke Patients|A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke|Completed||Phase 2|42|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:21:15.170054|2018-06-01 01:21:15.170054
NCT00833976|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2015-04-14||2017-06-05|2009-01-30|2009-02-02|Estimate|2016-03-14|2016-04-04|Estimate||||2017-06-05|2017-07-02|Actual|July 2009||2009-07-31|June 2017|2017-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia|Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia|Completed||Phase 4|65|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:21:17.394766|2018-06-01 01:21:17.394766
NCT00833963|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2018-05-02|2009-01-30|2009-02-02|Estimate|||||||2018-05-02|2018-05-04|Actual|January 14, 2009|Actual|2009-01-14|May 2018|2018-05-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2025|Anticipated|2025-01-31|12 Months|Observational [Patient Registry]|MotHER||A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine|An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception|Recruiting|||100|Anticipated|Genentech, Inc.|||3||f||||f|t|f||||||||2018-06-01 01:21:17.566054|2018-06-01 01:21:17.566054
NCT00833937|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-06||2009-07-06|2009-01-30|2009-02-02|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|March 2002||2002-03-31|July 2009|2009-07-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions|A Relative Bioavailability Study of Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:17.720431|2018-06-01 01:21:17.720431
NCT00833924|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2015-12-18||2018-03-08|2009-01-30|2009-02-02|Estimate|2016-01-28|2016-01-29|Estimate||||2018-03-08|2018-04-04|Actual|May 2008||2008-05-31|March 2018|2018-03-31|June 2016|Actual|2016-06-30|October 2011|Actual|2011-10-31||Interventional|||Zenith(R) Low Profile AAA Endovascular Graft Clinical Study|Evaluation of the Safety and Effectiveness of the Zenith(R) Low Profile AAA Endovascular Graft|Completed||N/A|120|Actual|Cook Group Incorporated||1|||t||||||||||||||2018-06-01 01:21:17.998411|2018-06-01 01:21:17.998411
NCT00833911|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2009-04-08||2012-04-25|2009-01-30|2009-02-02|Estimate|2009-06-01|2009-06-02|Estimate||||2012-04-25|2012-04-30|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee|An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee|Completed||Phase 3|392|Actual|Labopharm Inc.||1|||f||||f||||||||||2018-06-01 01:21:18.377011|2018-06-01 01:21:18.377011
NCT00833898|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2015-06-08||2015-11-06|2009-01-30|2009-02-02|Estimate|2015-08-10|2015-09-10|Estimate||||2015-11-06|2015-12-09|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)|Psychoeducation For BMT Caregivers: Biobehavioral Markers and Outcome|Completed||Phase 3|298|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 01:21:18.652128|2018-06-01 01:21:18.652128
NCT00833885|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2011-04-21|2009-01-30|2009-02-02|Estimate|||||||2011-04-21|2011-04-22|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal Influenza|Tolerability and Measurability of the Efficacy of Non Pharmaceutical Measures to Prevent Seasonal Influenza|Completed||N/A|300|Anticipated|Robert Koch Institut||3|||f||||f||||||||||2018-06-01 01:21:19.464836|2018-06-01 01:21:19.464836
NCT00833872|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2016-03-02|2009-01-30|2009-02-02|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects|LEO 22811 - A Phase I, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects|Completed||Phase 1|58|Actual|LEO Pharma||2|||f||||f||||||||||2018-06-01 01:21:19.52363|2018-06-01 01:21:19.52363
NCT00833859|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2011-03-30||2017-09-08|2009-01-30|2009-02-02|Estimate|2011-04-29|2011-05-26|Estimate||||2017-09-08|2017-10-09|Actual|March 2009||2009-03-31|December 2013|2013-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery|A Phase 2 Study of GTX-SRS: Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery for Borderline Resectable Pancreatic Cancer|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|Early termination of study due to termination of funding. The study was closed to accrual on 12/17/09 and final closed on 3/12/10. The sample size goal of 33 evaluable participants could not be met.|1||Abandoned - Lack of funding after only 2 patients enrolled|f||||t||||||||||2018-06-01 01:21:19.593934|2018-06-01 01:21:19.593934
NCT00833846|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2017-06-30|2009-01-30|2009-02-02|Estimate|||||||2017-06-30|2017-07-02|Actual|January 27, 2009||2009-01-27|October 24, 2011|2011-10-24|October 24, 2011||2011-10-24|||||Observational|||Pilot Study of Mitochondrial Biology in Human Platelets|Pilot Study of Mitochondrial Biology in Human Platelets|Completed|||18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:21:19.75824|2018-06-01 01:21:19.75824
NCT00833833|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2013-03-08||2016-03-25|2009-01-30|2009-02-02|Estimate|2013-03-08|2013-04-25|Estimate||||2016-03-25|2016-04-27|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|April 2011|Actual|2011-04-30||Interventional||Intent to treat population from both phases|MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma|A Phase I/II Multicenter, Randomized, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Safety, And Efficacy Of CC-4047 Alone Or In Combination With Low-Dose Dexamethasone In Patients Wth Relapsed And Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide And Bortezomib|Completed||Phase 1/Phase 2|259|Actual|Celgene Corporation||6|||f||||t||||||||||2018-06-01 01:21:19.945665|2018-06-01 01:21:19.945665
NCT00833820|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2009-01-30|2009-01-30|2009-02-02|Estimate|||||||2009-01-30|2009-02-02|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|rTMS-ALS||Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis|Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis|Completed||Phase 2/Phase 3|20|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 01:21:23.874195|2018-06-01 01:21:23.874195
NCT00833807|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2015-11-25|2009-01-30|2009-02-02|Estimate|||||||2015-11-25|2015-11-26|Estimate|February 2009||2009-02-28|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver|Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver|Completed||Phase 1|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:21:24.025783|2018-06-01 01:21:24.025783
NCT00833794|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2009-04-09||2012-04-25|2009-01-30|2009-02-02|Estimate|2009-06-22|2009-08-10|Estimate||||2012-04-25|2012-04-30|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol HCl Once-a-Day Versus Placebo for the Treatment of Pain Due to Osteoarthritis||Completed||Phase 3|1028|Actual|Labopharm Inc.||2|||f||||||||||||||2018-06-01 01:21:24.194924|2018-06-01 01:21:24.194924
NCT00833781|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2015-10-15||2016-03-03|2009-01-29|2009-02-02|Estimate|2016-03-03|2016-03-08|Estimate||||2016-03-03|2016-03-08|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PARC002||A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects|A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy|Completed||Phase 1/Phase 2|15|Actual|Massachusetts General Hospital|The trial size is small, precluding detection of small effect sizes.|2|||f||||t||||||||||2018-06-01 01:21:25.499517|2018-06-01 01:21:25.499517
NCT00833768|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2015-03-19|2009-01-29|2009-02-02|Estimate|||||||2015-03-19|2015-03-24|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|ASPIRE||A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis|A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease (CKD) Patients Not on Dialysis|Terminated||Phase 3|5|Actual|Sanofi||2||"After an extensive review,the ASPIRE in CKD study was terminated because it was not possible to~   complete the study in an appropriate time frame."|f||||f||||||||||2018-06-01 01:21:25.798952|2018-06-01 01:21:25.798952
NCT00833755|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2016-09-20||2016-11-17|2009-01-30|2009-02-02|Estimate|2016-11-17|2017-01-16|Estimate||||2016-11-17|2017-01-16|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|May 2013|Actual|2013-05-31||Interventional|||Effect of Ketamine on Opioid-Induced Hyperalgesia|Effect of Ketamine on Opioid-Induced Hyperalgesia|Completed||N/A|79|Actual|Massachusetts General Hospital||4|||f||||t||||||||No||2018-06-01 01:21:26.012211|2018-06-01 01:21:26.012211
NCT00833742|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2009-01-30|2009-01-30|2009-02-02|Estimate|||||||2009-01-30|2009-02-02|Estimate|January 2002||2002-01-31|January 2009|2009-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|ISTDPED||Intensive Short-Term Dynamic Psychotherapy (ISTDP) in the Emergency Department|Emotion-Focused Diagnosis and Treatment of Somatization in the ED|Completed||N/A|77|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-06-01 01:21:26.44243|2018-06-01 01:21:26.44243
NCT00833729|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2010-06-25|2009-01-30|2009-02-02|Estimate|||||||2010-06-25|2010-06-28|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab|An Open Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab|Completed||Phase 4|10|Anticipated|Dermatrials Research||1|||f||||||||||||||2018-06-01 01:21:26.522414|2018-06-01 01:21:26.522414
NCT00833716|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2017-03-31|2009-01-30|2009-02-02|Estimate|||||||2017-03-31|2017-04-04|Actual|February 2, 2009|Actual|2009-02-02|March 2017|2017-03-31|July 26, 2010|Actual|2010-07-26|July 26, 2010|Actual|2010-07-26||Interventional|||Effect of Renal Impairment on the Pharmacokinetics of NN9535|An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NN9535 in Subjects With Normal Renal Function and Various Degrees of Impaired Renal Function|Completed||Phase 1|62|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 01:21:26.612343|2018-06-01 01:21:26.612343
NCT00833703|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2011-07-20||2011-08-18|2009-01-30|2009-02-02|Estimate|2011-07-20|2011-08-16|Estimate||||2011-08-18|2011-08-22|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CLARINET LT||Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation|Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age|Completed||Phase 3|49|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:21:26.830265|2018-06-01 01:21:26.830265
NCT00833690|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2013-12-26||2014-05-30|2009-01-29|2009-02-02|Estimate|2014-05-30|2014-06-05|Estimate||||2014-05-30|2014-06-05|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SURE-PD||Safety of Urate Elevation in Parkinson's Disease|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease|Completed||Phase 2|75|Actual|The Parkinson Study Group||3|||f||||t||||||||||2018-06-01 01:21:27.769027|2018-06-01 01:21:27.769027
NCT00833677|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2013-10-29|2009-01-30|2009-02-02|Estimate|||||||2013-10-29|2013-10-31|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Community Based Participatory Research With Immigrant Chinese With Diabetes|Community Based Participatory Research With Immigrant Chinese With Type 2 Diabetes: Adapting and Testing Coping Skills Training.|Completed||N/A|148|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 01:21:29.49543|2018-06-01 01:21:29.49543
NCT00833664|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-06||2009-09-11|2009-01-30|2009-02-02|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-15|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions|The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions|Completed||Phase 1|22|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:29.613688|2018-06-01 01:21:29.613688
NCT00833651|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2013-11-21|2009-01-30|2009-02-02|Estimate|||||||2013-11-21|2013-11-25|Estimate|November 2006||2006-11-30|November 2013|2013-11-30|October 2011|Actual|2011-10-31|February 2010|Actual|2010-02-28||Observational|PIP-02||Protective Immunity Project 02|A Prospective Comparison of the Magnitude and Character of the Immune Response to Influenza Vaccine in Immunosuppressed Renal Transplant Patients and Healthy Age-matched Volunteers|Completed|||97|Actual|Emory University|||3||f||||t||||||Samples Without DNA|"~     serum, PBMCs~   "|||2018-06-01 01:21:29.943343|2018-06-01 01:21:29.943343
NCT00833638|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2010-06-03||2010-08-18|2009-01-30|2009-02-02|Estimate|2010-07-20|2010-08-18|Estimate||||2010-08-18|2010-08-24|Estimate|February 2009||2009-02-28|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study in Erectile Dysfunction|Tadalafil 2.5 mg and 5 mg Once a Day Compared to Placebo in Day of Onset of Efficacy|Completed||Phase 4|372|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 01:21:30.06495|2018-06-01 01:21:30.06495
NCT00833625|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2016-10-26|2009-01-29|2009-02-02|Estimate|||||||2016-10-26|2016-10-28|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||FDG-PET-CT and Biomarkers in Esophageal Cancer|FDG-PET-CT and Biomarkers to Assess Pathologic Response in Surgical Specimens of Patients With Localized Esophageal Cancer After Chemoradiation|Completed||N/A|31|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:21:31.352849|2018-06-01 01:21:31.352849
NCT00833612|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-06-24|2009-01-30|2009-02-02|Estimate|||||||2011-06-24|2011-06-27|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|CRISP-AMI||Counterpulsation Reduces Infarct Size Pre-PCI for AMI|A Multi-center, Randomized, Controlled Study of Mechanical Left Ventricular Unloading With Counterpulsation to Reduce Infarct Size Pre-PCI for Acute Myocardial Infarction - CRISP AMI|Completed||Phase 4|339|Actual|Datascope Corp.||1|||f||||t||||||||||2018-06-01 01:21:31.49209|2018-06-01 01:21:31.49209
NCT00833443|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2014-01-10||2014-01-10|2009-01-30|2009-02-02|Estimate|2014-01-10|2014-02-26|Estimate||||2014-01-10|2014-02-26|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|BUP PGx||Study of Medical Treatment for Methamphetamine Addiction|Pharmacogenomics and Medication Development for Methamphetamine Dependence|Completed||Phase 2|84|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 01:21:36.839312|2018-06-01 01:21:36.839312
NCT00833599|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2018-05-21|2009-01-30|2009-02-02|Estimate|||||||2018-05-21|2018-05-23|Actual|January 2009||2009-01-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders|Phase I/II Combinational Investigational New Drug Application: Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders|Enrolling by invitation|||283|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f||||||Samples With DNA|"~     DNA from blood or saliva~   "|||2018-06-01 01:21:31.649521|2018-06-01 01:21:31.649521
NCT00833586|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-06||2009-09-11|2009-01-30|2009-02-02|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-11|2009-09-25|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Terbinafine HCl 250 mg Tablet Under Fasting Conditions|The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Fasting Conditions|Completed||Phase 1|28|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:31.811232|2018-06-01 01:21:31.811232
NCT00833573|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2009-11-13|2009-01-30|2009-02-02|Estimate|||||||2009-11-13|2009-11-17|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|||||Observational|RGO à trav||National Survey on GERD Patients (Adults and Children)|National Survey on GERD Patients (Adults and Children)|Completed|||4400|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:21:32.247631|2018-06-01 01:21:32.247631
NCT00833560|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2013-10-30||2014-11-11|2009-01-29|2009-02-02|Estimate|2014-01-15|2014-03-03|Estimate||||2014-11-11|2014-11-21|Estimate|March 2006||2006-03-31|November 2014|2014-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy|Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)|Completed||Phase 2|401|Actual|Janssen-Cilag G.m.b.H||1|||f||||f||||||||||2018-06-01 01:21:33.991204|2018-06-01 01:21:33.991204
NCT00833547|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2014-07-17||2014-08-26|2009-01-30|2009-02-02|Estimate|2014-08-26|2014-09-09|Estimate||||2014-08-26|2014-09-09|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia|Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia|Completed||N/A|25|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:21:34.605951|2018-06-01 01:21:34.605951
NCT00833534|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2015-03-04|2009-01-30|2009-02-02|Estimate|||||||2015-03-04|2015-03-06|Estimate|February 2009||2009-02-28|March 2015|2015-03-31||||||||Interventional|||Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant|Consolidation Therapy With Lenalidomide (Revlimid®) With or Without Rituximab Followed by Maintenance Therapy With Revlimid® After Autologous/Syngeneic Transplant for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Withdrawn||Phase 2|0|Actual|Fred Hutchinson Cancer Research Center||2||"No patient enrolled on study. Did not get patients in timely fashion. All referrals for study~   when assessed were not eligible."|f||||||||||||||2018-06-01 01:21:34.864208|2018-06-01 01:21:34.864208
NCT00833521|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2009-07-06||2009-07-06|2009-01-30|2009-02-02|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|February 2002||2002-02-28|July 2009|2009-07-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions|A Relative BioAvailability Study of Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions|Completed||Phase 1|38|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:21:35.030573|2018-06-01 01:21:35.030573
NCT00833508|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2016-02-15|2009-01-30|2009-02-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Preoperative Chemoradiotherapy on Exercise Capacity as Measured by Cardiopulmonary Exercise Testing|Effect of Preoperative Chemoradiotherapy on Exercise Capacity as Measured by Cardiopulmonary Exercise Testing|Completed||N/A|40|Actual|Imperial College London||1|||f||||f||||||||||2018-06-01 01:21:35.3521|2018-06-01 01:21:35.3521
NCT00833495|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30||2010-09-28|2012-03-08|2009-01-30|2009-02-02|Estimate||||2010-09-28|2010-10-01|Estimate|2012-03-08|2012-03-09|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation|A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (PredMild®) Compared to Prednisolone Acetate 1% Alone or Vehicle Alone in Patients With Mild Ongoing Ocular Allergic Inflammation|Completed||Phase 2|155|Actual|Fovea Pharmaceuticals SA||4|||f||||f||||||||||2018-06-01 01:21:35.435637|2018-06-01 01:21:35.435637
NCT00833482|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2012-07-23||2012-09-24|2009-01-30|2009-02-02|Estimate|2012-09-24|2012-10-25|Estimate||||2012-09-24|2012-10-25|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|February 2011|Actual|2011-02-28|July 2010|Actual|2010-07-31||Interventional|||Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants|Study to Assess the Pharmacokinetic Drug - Drug Interactions Between Atazanavir Plus Ritonavir Coadministered With Voriconazole in Healthy Subjects|Completed||Phase 1|185|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 01:21:35.599254|2018-06-01 01:21:35.599254
NCT00833469|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2014-07-11||2014-08-05|2009-01-30|2009-02-02|Estimate|2014-08-05|2014-08-06|Estimate||||2014-08-05|2014-08-06|Estimate|January 2009||2009-01-31|August 2014|2014-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|LexaproPPD|Of the 7 subjects consented, 5 were eligible to initiate study intervention. Out of these 5, 1 subject dropped prior to V1 and no baseline information is available for her.|Escitalopram (Lexapro) for the Treatment of Postpartum Depression|Escitalopram for the Treatment of Postpartum Depression|Completed||Phase 4|7|Actual|Massachusetts General Hospital|We recruited only 7 patients out of a projected 20. Patients were not referred because they were breastfeeding or preferred to receive treatment from their primary care doctor. We also suspect that many women with PPD do not seek treatment at all.|1|||f||||f||||||||||2018-06-01 01:21:36.565232|2018-06-01 01:21:36.565232
NCT00833456|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2011-10-13|2009-01-29|2009-02-02|Estimate|||||||2011-10-13|2011-10-14|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia|Non-interventional Clinical Study to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia, Treated With Atypical Antipsychotics|Completed|||106|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:21:36.761787|2018-06-01 01:21:36.761787
NCT00833417|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2012-02-23||2015-05-01|2009-01-30|2009-02-02|Estimate|2012-04-03|2012-04-30|Estimate||||2015-05-01|2015-05-20|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|April 2014|Actual|2014-04-30|November 2010|Actual|2010-11-30||Interventional|||A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma|A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma|Completed||Phase 2|104|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:21:37.366441|2018-06-01 01:21:37.366441
NCT00833404|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2011-09-09|2009-01-30|2009-02-02|Estimate|||||||2011-09-09|2011-09-12|Estimate|December 2008||2008-12-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|||Smoking Cessation and Sexual Health in Men|Effects of Smoking Cessation on Sexual Health in Men|Completed||Phase 1|80|Anticipated|University of Texas at Austin||2|||f||||f||||||||||2018-06-01 01:21:37.826866|2018-06-01 01:21:37.826866
NCT00833391|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2013-05-10|2009-01-29|2009-02-02|Estimate|||||||2013-05-10|2013-05-14|Estimate|January 2009||2009-01-31|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)|An Open-label, Randomized, Single Dose, Five-period Crossover Study to Evaluate the Relative Bioavailability of Different Formulations of GSK1838262 in Healthy Volunteers.|Completed||Phase 1|16|Actual|XenoPort, Inc.||1|||f||||||||||||||2018-06-01 01:21:38.006669|2018-06-01 01:21:38.006669
NCT00833378|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2017-11-10|2009-01-29|2009-02-02|Estimate|||||||2017-11-10|2017-11-14|Actual|January 19, 2009|Actual|2009-01-19|November 2017|2017-11-30|March 11, 2009|Actual|2009-03-11|March 11, 2009|Actual|2009-03-11||Interventional|||Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.|A Phase I, Open-label, Single Sequence, Crossover Study Evaluating the Safety and the Pharmacokinetics of Lopinavir/Ritonavir and Eltrombopag Given Alone and When Co-administered in Healthy Adult Subjects.|Completed||Phase 1|40|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 01:21:38.161704|2018-06-01 01:21:38.161704
NCT00833365|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2015-05-01||2016-05-24|2009-01-30|2009-02-02|Estimate|2016-05-24|2016-07-04|Estimate||||2016-05-24|2016-07-04|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure|Early vs. Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure and Pain/Stress Reduction|Terminated||N/A|15|Actual|University of Utah||2||Study drug not available|f||||f||||||||||2018-06-01 01:21:38.283005|2018-06-01 01:21:38.283005
NCT00833352|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2014-01-29|2009-01-30|2009-02-02|Estimate|||||||2014-01-29|2014-01-30|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SEPTAL-CRT||Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device|Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device|Completed||N/A|263|Actual|Guidant Corporation||2|||f||||f||||||||||2018-06-01 01:21:38.694414|2018-06-01 01:21:38.694414
NCT00833339|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2015-03-30|2009-01-30|2009-02-02|Estimate|||||||2015-03-30|2015-04-01|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder|Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone|Unknown status|Recruiting|Phase 2|80|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||t||||||||||2018-06-01 01:21:38.920516|2018-06-01 01:21:38.920516
NCT00833326|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2012-09-28|2009-01-30|2009-02-02|Estimate|||||||2012-09-28|2012-10-01|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer||Completed||Phase 1|27|Actual|Array BioPharma||1|||f||||f||||||||||2018-06-01 01:21:39.041916|2018-06-01 01:21:39.041916
NCT00833313|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2018-03-08|2009-01-29|2009-02-02|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2008||2008-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery|Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery|Recruiting|||240|Anticipated|Brigham and Women's Hospital|||||f||||f||||||Samples With DNA|"~     Atrial tissue sample~   "|||2018-06-01 01:21:39.271912|2018-06-01 01:21:39.271912
NCT00833300|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2012-08-02|2009-01-30|2009-02-02|Estimate|||||||2012-08-02|2012-08-03|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Haloperidol vs Olanzapine for the Management of ICU Delirium|Haloperidol vs Olanzapine for the Management of ICU Delirium: A Randomized Clinical Trial|Terminated||N/A|200|Anticipated|Nova Scotia Health Authority||2|||f||||||||||||||2018-06-01 01:21:39.361122|2018-06-01 01:21:39.361122
NCT00833287|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2012-04-05|2009-01-30|2009-02-02|Estimate|||||||2012-04-05|2012-04-06|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|ObesityRole||Immunoregulatory Dysfunction in Trauma Patients: Role of Obesity|Immunoregulatory Dysfunction in Trauma Patients: Role of Obesity|Terminated|||10|Actual|University of Mississippi Medical Center||||Enrollment process not efficient|f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 01:21:39.465103|2018-06-01 01:21:39.465103
NCT00833274|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2011-12-08|2009-01-30|2009-02-02|Estimate|||||||2011-12-08|2011-12-09|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases|Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases|Completed||N/A|70|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:21:39.515214|2018-06-01 01:21:39.515214
NCT00833261|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|||2018-04-25|2009-01-30|2009-02-02|Estimate|||||||2018-04-25|2018-04-26|Actual|December 2008|Actual|2008-12-31|April 2018|2018-04-30|May 2016|Actual|2016-05-31|September 2013|Actual|2013-09-30||Interventional|||Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer|A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck|Completed||Phase 2|50|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 01:21:39.598003|2018-06-01 01:21:39.598003
NCT00833248|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-30|2012-08-27||2012-09-27|2009-01-30|2009-02-02|Estimate|2012-08-27|2012-09-27|Estimate||||2012-09-27|2012-10-04|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer|A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)|Completed||Phase 3|246|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:21:39.701957|2018-06-01 01:21:39.701957
NCT00833222|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2017-12-21|2009-01-30|2009-02-02|Estimate|||||||2017-12-21|2017-12-26|Actual|January 2008||2008-01-31|December 2017|2017-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|PREMA||Neuroendocrine Mechanisms of Growth and Body Composition in Preterm and Term Infants|Neuroendocrine Mechanisms of Growth and Body Composition in Preterm and Term Infants|Completed|||72|Actual|University of Utah|||2||f||||f||||||Samples With DNA|"~     Saliva; Urine~   "|||2018-06-01 01:21:40.926297|2018-06-01 01:21:40.926297
NCT00833209|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2012-07-31|2009-01-29|2009-01-30|Estimate|||||||2012-07-31|2012-08-01|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|May 2012|Actual|2012-05-31|July 2011|Actual|2011-07-31||Interventional|MOH-PET||Orbitofrontal Cortex (OFC) Influence on Addictive Medication Overuse Headache (MOH) Deriving From Migraine|Orbitofrontal Cortex (OFC) Influence on Addictive Behaviour in Medication Overuse Headache (MOH) Deriving From Migraine|Completed||N/A|53|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-06-01 01:21:41.057273|2018-06-01 01:21:41.057273
NCT00833196|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2010-07-06|2009-01-29|2009-01-30|Estimate|||||||2010-07-06|2010-07-07|Estimate|February 2009||2009-02-28|July 2010|2010-07-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Observational|||Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia|Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia|Completed|||400|Anticipated|Ipsen|||||f||||f||||||||||2018-06-01 01:21:41.140668|2018-06-01 01:21:41.140668
NCT00833183|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial Acne|A Study of Safety and Efficacy of Topical Methylaminolevulinate 80mg/g With and Without Occlusion Followed by Red Light Exposure in Subjects With Facial Acne|Completed||Phase 2|44|Actual|Photocure||4|||f||||f||||||||||2018-06-01 01:21:41.252828|2018-06-01 01:21:41.252828
NCT00833170|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2018-01-24|2009-01-28|2009-01-30|Estimate|||||||2018-01-24|2018-01-26|Actual|January 28, 2002|Actual|2002-01-28|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry|Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry|Active, not recruiting|||1000|Anticipated|Connecticut Children's Medical Center|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 01:21:41.362196|2018-06-01 01:21:41.362196
NCT00833157|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|February 2005||2005-02-28|January 2009|2009-01-31|March 2009|Anticipated|2009-03-31|July 2007|Actual|2007-07-31||Interventional|||Effect of Glucosamine or Ibuprofen Combined With Physical Training in Patients With Knee-Osteoarthritis|Effect of Glucosamine or Ibuprofen Combined With Physical Training in Patients With Knee-Osteoarthritis|Unknown status|Active, not recruiting|Phase 1|36|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-06-01 01:21:41.475462|2018-06-01 01:21:41.475462
NCT00833144|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2013-12-12|2009-01-29|2009-01-30|Estimate|||||||2013-12-12|2013-12-13|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Observational|||Bedside Ultrasound Identifies Congestive Heart Failure|Emergency Physician-Performed Thoracic Ultrasound Rapidly Identifies Patients With Congestive Heart Failure|Completed|||375|Actual|Emory University|||2||f||||t||||||||||2018-06-01 01:21:41.596179|2018-06-01 01:21:41.596179
NCT00833131|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2010-04-14|2009-01-29|2009-01-30|Estimate|||||||2010-04-14|2010-04-15|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|November 2015|Anticipated|2015-11-30|November 2012|Anticipated|2012-11-30||Interventional|||The Randomised Study of Preoperative Radiotherapy With Consolidating Chemotherapy for Unresectable Rectal Cancer|Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study|Unknown status|Recruiting|Phase 3|540|Anticipated|Polish Colorectal Cancer Study Group||2|||f||||t||||||||||2018-06-01 01:21:41.704161|2018-06-01 01:21:41.704161
NCT00833118|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2010-02-11|2009-01-29|2009-01-30|Estimate|||||||2010-02-11|2010-02-12|Estimate|November 2008||2008-11-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Tongue Pull Versus Jaw Thrust|Tongue Pull Versus Jaw Thrust|Completed|||100|Actual|Mayo Clinic|||1||f||||||||||||||2018-06-01 01:21:41.825001|2018-06-01 01:21:41.825001
NCT00833105|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2014-04-28|2009-01-29|2009-01-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury|Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury (SCI)|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-06-01 01:21:41.91734|2018-06-01 01:21:41.91734
NCT00833092|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2011-07-27||2015-03-06|2009-01-28|2009-01-30|Estimate|2012-03-07|2012-04-04|Estimate||||2015-03-06|2015-03-26|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Magnesium Nutrition and Sleep Behavior in Older Adults|Magnesium Nutrition and Sleep Behavior in Older Adults|Completed||N/A|111|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 01:21:42.082463|2018-06-01 01:21:42.082463
NCT00833079|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2014-01-19|2009-01-29|2009-01-30|Estimate|||||||2014-01-19|2014-01-22|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis|A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 1|500|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-06-01 01:21:42.356606|2018-06-01 01:21:42.356606
NCT00833066|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2011-11-16|2009-01-29|2009-01-30|Estimate|||||||2011-11-16|2011-11-17|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis|Preliminary Assessment of the Clinical Tolerability, Safety and Immunogenicity of Three Different Doses of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis|Completed||Phase 1/Phase 2|54|Actual|BioTech Tools S.A.||4|||f||||t||||||||||2018-06-01 01:21:42.464921|2018-06-01 01:21:42.464921
NCT00832871|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2016-06-22||2016-06-22|2009-01-29|2009-01-30|Estimate|2016-06-22|2016-08-02|Estimate||||2016-06-22|2016-08-02|Estimate|November 2008||2008-11-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers|INST 0817: Compassionate Use of Mifepristone|Terminated||N/A|4|Actual|New Mexico Cancer Care Alliance|This is a compassionate use protocol. No statistical analysis was specified in the protocol; it states that only descriptive data will be collected. Data from only 4 patients should not be considered reliable.|1||Low accrual; 4 patients enrolled between 2008-2015|f||||f||||||||||2018-06-01 01:21:45.169794|2018-06-01 01:21:45.169794
NCT00833053|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2012-03-15||2017-03-15|2009-01-29|2009-01-30|Estimate|2012-06-19|2012-07-26|Estimate||||2017-03-15|2017-04-12|Actual|October 2009||2009-10-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|DOSE||Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)|A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis|Terminated||Phase 3|39|Actual|Merck Sharp & Dohme Corp.||2||"In Amendment 1 of P05319 [NCT 00779675], the option to enroll into this study, was discontinued~   due to low numbers of participants with suboptimal response."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:21:42.639995|2018-06-01 01:21:42.639995
NCT00833040|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2014-01-06||2014-12-18|2009-01-29|2009-01-30|Estimate|2014-12-18|2015-01-01|Estimate||||2014-12-18|2015-01-01|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain|A Multicenter, Randomized, Placebo-Controlled, Crossover Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 Compared to Placebo in the Treatment of Cancer Breakthrough Pain|Completed||Phase 2|34|Actual|AcelRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:21:42.991252|2018-06-01 01:21:42.991252
NCT00833027|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2010-08-26||2017-04-10|2009-01-28|2009-01-30|Estimate|2010-08-26|2010-09-21|Estimate||||2017-04-10|2017-05-15|Actual|March 1, 2008|Actual|2008-03-01|April 2017|2017-04-30|October 30, 2009|Actual|2009-10-30|October 30, 2009|Actual|2009-10-30||Interventional|||ALPHA Sitagliptin Add on to Metformin (0431-103)|A 24 Week, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Adding Sitagliptin 100 mg Once Daily in Patients With T2DM Who Have Inadequate Glycemic Control on Metformin Therapy|Completed||Phase 4|608|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:21:43.293058|2018-06-01 01:21:43.293058
NCT00833014|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|DYANA||Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation|Dynamic Annuloplasty System With Activation for the Treatment of Mitral Regurgitation|Unknown status|Recruiting|Phase 2|130|Anticipated|MiCardia Corporation||1|||f||||f||||||||||2018-06-01 01:21:43.641118|2018-06-01 01:21:43.641118
NCT00833001|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2014-05-05|2009-01-29|2009-01-30|Estimate|||||||2014-05-05|2014-05-06|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|December 2011|Actual|2011-12-31|November 2009|Actual|2009-11-30||Observational|||Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse|A Prospective, Multi-center Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse|Completed|||126|Actual|Ethicon, Inc.|||1||f||||f||||||||||2018-06-01 01:21:43.935662|2018-06-01 01:21:43.935662
NCT00832988|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2013-06-07|2009-01-29|2009-01-30|Estimate|||||||2013-06-07|2013-06-10|Estimate|October 2008||2008-10-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|CONFIRM||CONFIRM - Comparison of in Office Interrogation Versus Remote Measurements|Comparison of in Office Interrogation vs. Remote Measurements|Completed|||115|Actual|St. Jude Medical|||1||f||||t||||||||||2018-06-01 01:21:44.042563|2018-06-01 01:21:44.042563
NCT00832975|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2015-02-17||2016-10-21|2009-01-29|2009-01-30|Estimate|2015-02-17|2015-03-03|Estimate||||2016-10-21|2016-12-02|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Observational|AVAI|All patients|AVAI: Atrial Ventricular Arrythmia Incidence|Study of Slow Ventricular Tachycardia and Atrial Fibrillation Incidence Documented by Intracardiac Electrogram in Patients Implanted With an Implantable Cardiac Device (ICD) .|Completed|||157|Actual|St. Jude Medical|||||f||||f||||||||||2018-06-01 01:21:44.139411|2018-06-01 01:21:44.139411
NCT00832962|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2015-03-25|2009-01-28|2009-01-30|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|GENIFERH||Routine Fetal RhD Genotyping for RhD- Pregnant Women|Effectiveness of Routine Fetal RhD Genotyping for RhD- Pregnant Women|Completed|||2532|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Whole blood sample (0.5 ml)~   "|||2018-06-01 01:21:44.3108|2018-06-01 01:21:44.3108
NCT00832949|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-01-06|2009-01-29|2009-01-30|Estimate|||||||2011-01-06|2011-01-07|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (One-on-one Interviews)|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (One-on-one Interviews)|Completed|||10|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 01:21:44.441939|2018-06-01 01:21:44.441939
NCT00832923|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2014-09-10|2009-01-29|2009-01-30|Estimate|||||||2014-09-10|2014-09-12|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PEPAC||Improving Asthma Care Through Parental Empowerment|Improving Asthma Care Through Parental Empowerment: Effect on Healthcare Utilization and Parent Self-Efficacy|Completed||N/A|150|Actual|Children's Research Institute||2|||f||||f||||||||||2018-06-01 01:21:44.593285|2018-06-01 01:21:44.593285
NCT00832910|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|||||Observational|BIRA||Assessment of Body Image in Patients With Rheumatoid Arthritis|Body Image in Patients With Rheumatoid Arthritis|Completed|||82|Actual|Federal University of São Paulo|||2||f||||f||||||None Retained|"~     None Retained~   "|||2018-06-01 01:21:44.698716|2018-06-01 01:21:44.698716
NCT00832897|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2011-01-06|2009-01-29|2009-01-30|Estimate|||||||2011-01-06|2011-01-07|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|October 2010|Actual|2010-10-31|November 2008|Actual|2008-11-30||Interventional|||Evaluation of Topical Riboflavin Exposed to UVA Radiation and Implantation of Corneal Ring|"Evaluation of Topical Riboflavin Exposed to UVA Radiation and Implantation of Intrastromal Corneal Ring for Treatment of Keratoconus and Others Irregulars Astigmatisms."|Completed||N/A|31|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:21:44.803692|2018-06-01 01:21:44.803692
NCT00832884|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2014-10-13|2009-01-29|2009-01-30|Estimate|||||||2014-10-13|2014-10-15|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|||The Safety of Intravenous Lacosamide|IV Lacosamide: The Safety of Intravenous Lacosamide|Completed||Phase 4|40|Actual|Le Bonheur Children's Hospital||8|||f||||t||||||||||2018-06-01 01:21:44.947644|2018-06-01 01:21:44.947644
NCT00832845|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2017-04-12|2009-01-29|2009-01-30|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2008||2008-06-30|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|CBSST||Cognitive Behavioral Social Skills Training for Patients With Late-Life Schizophrenia: a Pilot Study|Cognitive Behavioral Social Skills Training for Patients With Late-Life Schizophrenia: a Pilot Study|Completed||N/A|80|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-06-01 01:21:45.397844|2018-06-01 01:21:45.397844
NCT00832832|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2012-09-19|2009-01-29|2009-01-30|Estimate|||||||2012-09-19|2012-09-20|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Eyelid Closure in Glaucoma Therapy|Eyelid Closure in Topical Glaucoma Therapy|Completed||N/A|60|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:21:45.652571|2018-06-01 01:21:45.652571
NCT00832819|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2015-02-21||2015-04-09|2009-01-28|2009-01-30|Estimate|2015-02-21|2015-03-06|Estimate||||2015-04-09|2015-04-30|Estimate|February 2009||2009-02-28|February 2015|2015-02-28|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)|E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|28|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 01:21:45.887311|2018-06-01 01:21:45.887311
NCT00832806|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2011-11-28|2009-01-29|2009-01-30|Estimate|||||||2011-11-28|2011-11-30|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Smoke-Free Living Study|Smoking Cessation With Varenicline (Champix) and Integrated Voice Response Technology (IVR)|Completed||Phase 1|100|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 01:21:46.507193|2018-06-01 01:21:46.507193
NCT00832793|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-01-06|2009-01-29|2009-01-30|Estimate|||||||2011-01-06|2011-01-07|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers Patient Perspectives: Perspectives of Health Care Providers|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers Patient Perspectives: Perspectives of Health Care Providers|Completed|||10|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 01:21:46.573882|2018-06-01 01:21:46.573882
NCT00832780|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2018-04-09||2018-04-09|2009-01-29|2009-01-30|Estimate|2018-04-09|2018-05-10|Estimate||||2018-04-09|2018-05-10|Estimate|January 2008||2008-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung|INST 0810: Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung|Active, not recruiting||N/A|44|Actual|New Mexico Cancer Care Alliance||1|||f||||t||||||||No||2018-06-01 01:21:46.665984|2018-06-01 01:21:46.665984
NCT00832767|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2014-11-11||2017-05-22|2009-01-29|2009-01-30|Estimate|2017-05-22|2017-12-18|Actual||||2017-05-22|2017-12-18|Actual|April 2009||2009-04-30|May 2017|2017-05-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional||202 subjects were enrolled and randomized, however 2 subjects opted not to have surgery and were removed from the study prior to the baseline visit. Therefore data is only available on 200 subjects.|SILS™ Port Laparoscopic Cholecystectomy Post Market Study|Prospective Randomized Controlled Trial of Traditional Laparoscopic Cholecystectomy Versus SILS™ Port Laparoscopic Cholecystectomy|Completed||N/A|202|Actual|Medtronic - MITG||2|||f||||t||||||||||2018-06-01 01:21:47.05463|2018-06-01 01:21:47.05463
NCT00832754|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2012-12-20|2009-01-29|2009-01-30|Estimate|||||||2012-12-20|2012-12-21|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|RDT-ACT||Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial|Effects of Restricting the Use of AS-AQ Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial|Completed||Phase 4|3063|Actual|Kintampo Health Research Centre, Ghana||2|||f||||t||||||||||2018-06-01 01:21:47.722532|2018-06-01 01:21:47.722532
NCT00832741|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus|Secretion and Significance of the Incretin Hormones on the Postprandial Glycemic Response in Type-1 Diabetes Mellitus|Completed|||30|Actual|Hvidovre University Hospital|||||f||||f||||||Samples With DNA|"~     whole blood, plasma~   "|||2018-06-01 01:21:47.829335|2018-06-01 01:21:47.829335
NCT00832728|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2012-07-24|2009-01-29|2009-01-30|Estimate|||||||2012-07-24|2012-07-25|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ELAD||Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)|Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)|Withdrawn||Phase 2|0|Actual|Vital Therapies, Inc.||2||To focus on another clinical indication.|f||||f||||||||||2018-06-01 01:21:47.929999|2018-06-01 01:21:47.929999
NCT00832715|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2016-07-18|2009-01-29|2009-01-30|Estimate|||||||2016-07-18|2016-07-20|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)|Diagnostic Utility of Endobronchial Ultrasound Guided Mediastinal Lymph Node Sampling in Clinical Stage I and II Non Small Cell Lung Cancer|Completed||Phase 1/Phase 2|120|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:21:48.038309|2018-06-01 01:21:48.038309
NCT00832702|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2017-12-19|2009-01-29|2009-01-30|Estimate|||||||2017-12-19|2017-12-21|Actual|September 17, 2008|Actual|2008-09-17|December 2017|2017-12-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction|Women's Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction|Active, not recruiting|||433|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||Samples With DNA|"~     Blood sample will be collected for future genetic studies to better understand heart artery~     disease by identifing genetic factors that contribute to heart artery disorders, and for~     extraction and creation of cell lines.~   "|Yes||2018-06-01 01:21:48.104146|2018-06-01 01:21:48.104146
NCT00832689|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2011-03-25|2009-01-29|2009-01-30|Estimate|||||||2011-03-25|2011-03-28|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer||Completed||Phase 2|39|Actual|Yonsei University||1|||f||||||||||||||2018-06-01 01:21:48.162117|2018-06-01 01:21:48.162117
NCT00832676|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-01-06|2009-01-29|2009-01-30|Estimate|||||||2011-01-06|2011-01-07|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (Focus Groups)|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Patient Perspectives (Focus Groups)|Completed|||24|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 01:21:48.214936|2018-06-01 01:21:48.214936
NCT00832663|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2010-03-15|2009-01-29|2009-01-30|Estimate|||||||2010-03-15|2010-03-16|Estimate|April 2009||2009-04-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Influence of Non-steroidal Anti-inflammatory Drugs (NSAID) on Muscle Regeneration|The Influence of Blocking Inflammatory Activity in Vivo on Skeletal Muscle Regeneration in Humans|Completed||N/A|32|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-06-01 01:21:48.275112|2018-06-01 01:21:48.275112
NCT00832650|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2010-12-02||2010-12-02|2009-01-28|2009-01-30|Estimate|2010-12-02|2010-12-24|Estimate||||2010-12-02|2010-12-24|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose Study To Investigate The Effects Of 8 Mg Fesoterodine SR Tablets And 10 Mg Solifenacin Tablet On Gastrointestinal Transit In Healthy Female Subjects.|Terminated||Phase 1|60|Actual|Pfizer|Study was terminated due to futility based on interim analysis with 60 subjects. Although the results of statistical test for the primary endpoint was interpreted, the other endpoint results were interpreted based on statistical inference.|3||"Protocol A0221057 was terminated on December 25, 2009 for futility. There were no safety~   concerns related to this decision."|f||||f||||||||||2018-06-01 01:21:48.35797|2018-06-01 01:21:48.35797
NCT00832637|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2015-06-15||2017-11-15|2009-01-29|2009-01-30|Estimate|2015-06-15|2015-07-14|Estimate||||2017-11-15|2017-12-12|Actual|August 2007||2007-08-31|November 2017|2017-11-30|March 15, 2017|Actual|2017-03-15|June 2013|Actual|2013-06-30||Interventional|Gem-ox||Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers|Gemcitabine and Cisplatin With Erlotinib in Hepatocellular Carcinoma (HCC) and Biliary Tree Cancer (BTC) (Intra- and Extra-hepatic Cholangiocarcinoma, Bile Duct Cancer, Adenocarcinoma of the Ampulla of Vater and Gallbladder Carcinoma)|Terminated||Phase 2|33|Actual|New Mexico Cancer Care Alliance||1||Low accrual|f||||t||||||||No||2018-06-01 01:21:49.93617|2018-06-01 01:21:49.93617
NCT00832624|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2010-07-06||2017-04-27|2009-01-29|2009-01-30|Estimate|2010-09-23|2010-10-11|Estimate||||2017-04-27|2017-05-23|Actual|November 26, 2008|Actual|2008-11-26|April 2017|2017-04-30|September 2, 2009|Actual|2009-09-02|September 2, 2009|Actual|2009-09-02||Interventional|||The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)|Open-label, Non Placebo-Controlled Study To Verify the Effect of Sitagliptin In Adult Patients With Type 2 Diabetes and Inadequate Glycemic Control|Terminated||Phase 4|10|Actual|Merck Sharp & Dohme Corp.|The planned 18-week study was terminated early due to reconsideration of the study design. None of the 10 patients progressed beyond the second study visit, no laboratory tests were performed, and adverse experience data were not collected.|1||Business Reasons|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:21:50.206585|2018-06-01 01:21:50.206585
NCT00832611|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2015-01-27|2009-01-29|2009-01-30|Estimate|||||||2015-01-27|2015-01-29|Estimate|November 2008||2008-11-30|January 2015|2015-01-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||Study of the Effect of the ROX AC1 on Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Study of the Effect of the ROX Percutaneous Arteriovenous Fistula System (ROX AC1) on Exercise Capacity and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|46|Actual|ROX Medical, Inc.||1|||f||||t||||||||||2018-06-01 01:21:50.426146|2018-06-01 01:21:50.426146
NCT00832598|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2018-02-22||2018-03-26|2009-01-29|2009-01-30|Estimate|2018-03-26|2018-04-27|Actual||||2018-03-26|2018-04-27|Actual|January 2009|Actual|2009-01-31|February 2018|2018-02-28|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors|18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors|Completed||N/A|13|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:21:50.517805|2018-06-01 01:21:50.517805
NCT00832585|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2010-07-09||2011-03-04|2009-01-29|2009-01-30|Estimate|2011-01-26|2011-01-28|Estimate||||2011-03-04|2011-03-10|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis|A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis|Completed||Phase 4|5|Actual|Rush University Medical Center||1|||f||||f||||||||||2018-06-01 01:21:50.784656|2018-06-01 01:21:50.784656
NCT00832572|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2013-05-28||2014-05-23|2009-01-28|2009-01-30|Estimate|2014-05-23|2014-06-30|Estimate||||2014-05-23|2014-06-30|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||All enrolled and treated participants|Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy|A Double-blind, Placebo-controlled, Cross-over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy|Terminated||Phase 4|5|Actual|Gilead Sciences|The study was stopped after 5 participants were enrolled. No outcome measure analyses were performed. Adverse events were collected and reported to the study center's Institutional Review Board.|2||Lack of enrollment|f||||f||||||||||2018-06-01 01:21:51.091954|2018-06-01 01:21:51.091954
NCT00832559|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2018-01-10|2009-01-29|2009-01-30|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2009||2009-01-31|January 2018|2018-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|VLA-X06||A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)|A Phase I, Open-label, Dosage Escalation, Study of Multiple Doses of CAVATAKTM (CVA21; Coxsackievirus A21) Administered Intratumourally in the Treatment of Squamous Cell Carcinoma of the Head and Neck Bearing ICAM-1 Receptors (VLA-X06)|Terminated||Phase 1|4|Actual|Viralytics||1||Poor recruitment rate.|f||||||||||||||2018-06-01 01:21:51.418028|2018-06-01 01:21:51.418028
NCT00832546|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers|A Double-Blind, Randomized, Placebo Controlled, Cross-Over, Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Volunteers|Completed||Phase 1|18|Actual|TorreyPines Therapeutics||3|||f||||t||||||||||2018-06-01 01:21:51.489166|2018-06-01 01:21:51.489166
NCT00832533|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2015-09-24|2009-01-29|2009-01-30|Estimate|||||||2015-09-24|2015-09-28|Estimate|November 2008||2008-11-30|September 2015|2015-09-30|January 2010|Actual|2010-01-31|February 2009|Actual|2009-02-28||Observational|||The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure|INST 0814: The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure|Completed|||9|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||Samples With DNA|"~     Blood samples and Buccal Smear~   "|||2018-06-01 01:21:51.54776|2018-06-01 01:21:51.54776
NCT00832520|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2012-07-20||2018-03-14|2009-01-29|2009-01-30|Estimate|2012-11-19|2012-12-18|Estimate||||2018-03-14|2018-04-10|Actual|November 2008||2008-11-30|March 2018|2018-03-31|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight|INST 0816: Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight|Terminated||Phase 2|13|Actual|New Mexico Cancer Care Alliance|Early termination leading to no subjects analyzed.There will be no publication, as this study was terminated after the original PI left employment with the institution.|1||Low accrual rate.|f||||t||||||||||2018-06-01 01:21:51.620093|2018-06-01 01:21:51.620093
NCT00832507|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29||2014-01-03|2014-01-03|2009-01-29|2009-01-30|Estimate||||2014-01-03|2014-02-04|Estimate|2014-01-03|2014-02-04|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 2|162|Actual|Gilead Sciences||4|||f||||t||||||||||2018-06-01 01:21:51.810573|2018-06-01 01:21:51.810573
NCT00832494|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|September 2004||2004-09-30|January 2009|2009-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer|An Open Label, Randomized, Phase I/II Study of DMXAA in Combination With Carboplatin and Paclitaxel in Patients With Locally Advanced and Metastatic Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|105|Actual|Antisoma Research|||||f||||t||||||||||2018-06-01 01:21:52.107197|2018-06-01 01:21:52.107197
NCT00832481|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-08-24|2009-01-29|2009-01-30|Estimate|||||||2009-08-24|2009-08-25|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions|Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions in Newly Diagnosed Type 2 Diabetes Patients in China|Unknown status|Recruiting|N/A|60|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-06-01 01:21:52.207719|2018-06-01 01:21:52.207719
NCT00832468|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-12-07|2009-01-29|2009-01-30|Estimate|||||||2009-12-07|2009-12-08|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||The Complementary Effect of Ear Acupressure on Older Patients With Chronic Insomnia|The Complementary Effect of Ear Acupressure on Older Patients With Chronic Insomnia and Anxiety|Completed||Phase 2|72|Actual|National Yang Ming University||2|||f||||t||||||||||2018-06-01 01:21:52.325465|2018-06-01 01:21:52.325465
NCT00832455|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2009-08-25||2017-03-10|2009-01-28|2009-01-30|Estimate|2010-01-18|2010-02-05|Estimate||||2017-03-10|2017-04-10|Actual|June 2006||2006-06-30|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)|A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma|Completed||Phase 4|445|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:21:52.437421|2018-06-01 01:21:52.437421
NCT00832442|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2012-05-08|2009-01-29|2009-01-30|Estimate|||||||2012-05-08|2012-05-09|Estimate|August 2008||2008-08-31|January 2009|2009-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|BB-META-HF||Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure|Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure|Unknown status|Enrolling by invitation||18240|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||2||f||||t||||||||||2018-06-01 01:21:52.879432|2018-06-01 01:21:52.879432
NCT00832429|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2017-11-10|2009-01-29|2009-01-30|Estimate|||||||2017-11-10|2017-11-14|Actual|February 2009|Actual|2009-02-28|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Sentinel Lymph Node (SLN) Biopsy for Sebaceous Gland Carcinoma of Eyelid|Sentinel Lymph Node Localization and Biopsy for Sebaceous Gland Carcinoma of the Eyelid|Recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:21:53.052094|2018-06-01 01:21:53.052094
NCT00832416|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2009-04-08||2012-04-25|2009-01-29|2009-01-30|Estimate|2009-06-18|2009-08-03|Estimate||||2012-04-25|2012-04-30|Estimate|January 2003||2003-01-31|April 2012|2012-04-30||||August 2003|Actual|2003-08-31||Interventional|||A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee||Completed||Phase 3|565|Actual|Labopharm Inc.||4|||f||||||||||||||2018-06-01 01:21:53.175861|2018-06-01 01:21:53.175861
NCT00832403|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|November 2006||2006-11-30|January 2009|2009-01-31||||February 2008|Actual|2008-02-29||Observational|RA||Gore Tex Implants in the Treatment of Atrophic Rhinitis|Gore Tex Implants in the Treatment of Atrophic Rhinitis|Suspended|||5|Actual|Hospital Felicio Rocho|||1|lack of new patients|f||||f||||||||||2018-06-01 01:21:53.746826|2018-06-01 01:21:53.746826
NCT00832390|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2009-06-11||2017-04-28|2009-01-29|2009-01-30|Estimate|2009-06-11|2009-07-31|Estimate||||2017-04-28|2017-05-30|Actual|February 14, 2007|Actual|2007-02-14|April 2017|2017-04-30|July 11, 2008|Actual|2008-07-11|July 11, 2008|Actual|2008-07-11||Interventional|||Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)|Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise|Completed||Phase 4|29|Actual|Merck Sharp & Dohme Corp.|"Few participants were recruited into this single-site study as the investigator preferred the use of initial combination therapy.~Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data."|1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:21:53.80668|2018-06-01 01:21:53.80668
NCT00832377|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2011-02-25||2017-08-31|2009-01-29|2009-01-30|Estimate|2011-02-25|2011-03-24|Estimate||||2017-08-31|2017-09-29|Actual|April 24, 2009|Actual|2009-04-24|August 2017|2017-08-31|March 26, 2010|Actual|2010-03-26|March 12, 2010|Actual|2010-03-12||Interventional|||COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)|Prospective, Open-label, Single-arm Study to Evaluate Efficacy and Safety of Combination Therapy of Timolol and Dorzolamide (COSOPT) as Initial Treatment for Patients With Normal Tension Glaucoma|Completed||Phase 2|37|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:21:54.120542|2018-06-01 01:21:54.120542
NCT00832364|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2015-04-20|2009-01-28|2009-01-30|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2009||2009-10-31|June 2011|2011-06-30|April 2010|Anticipated|2010-04-30|March 2010|Anticipated|2010-03-31||Interventional|||Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis|Randomized, Controlled Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||2||Business decision. No patients were enrolled|f||||f||||||||||2018-06-01 01:21:54.53921|2018-06-01 01:21:54.53921
NCT00832351|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2015-12-30|2009-01-29|2009-01-30|Estimate|||||||2015-12-30|2016-01-01|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|AKEMIS||Akershus Early Mobilisation in Stroke Study|Effect of Immediate Mobilisation After Stroke on Mortality, Morbidity and Functional Outcome|Completed||N/A|65|Actual|University Hospital, Akershus||2|||f||||f||||||||||2018-06-01 01:21:54.621307|2018-06-01 01:21:54.621307
NCT00832338|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2016-12-07||2017-08-01|2009-01-29|2009-01-30|Estimate|2017-02-24|2017-03-29|Actual||||2017-08-01|2017-08-31|Actual|April 2009||2009-04-30|August 2017|2017-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores|Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) in Patients With Hormone Receptor-Positive Cancers With Recurrence Scores ≥ 25|Terminated||Phase 2|23|Actual|Emory University||1||Funding withdrawn|f||||t||||||||||2018-06-01 01:21:54.714285|2018-06-01 01:21:54.714285
NCT00832325|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2018-01-19|2009-01-29|2009-01-30|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2009||2009-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Adolescent and Young Adult Cancer Survivors: Identity Development|Adolescent and Young Adult Cancer Survivors: Identity Development|Active, not recruiting|||300|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 01:21:54.949242|2018-06-01 01:21:54.949242
NCT00832312|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2016-07-27|2009-01-29|2009-01-30|Estimate|||||||2016-07-27|2016-07-28|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Intraarticular Ozone Therapy for Pain Control in Osteoarthritis of the Knee|Intraarticular Ozone Therapy for Pain Control in Osteoarthritis of the Knee|Terminated||Phase 2|20|Actual|Ben-Gurion University of the Negev||2||Because of technical problems (researcher moved to different city).|f||||f||||||||||2018-06-01 01:21:55.024205|2018-06-01 01:21:55.024205
NCT00832299|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2013-02-25||2018-02-01|2009-01-29|2009-01-30|Estimate|2013-03-07|2013-04-22|Estimate||||2018-02-01|2018-03-01|Actual|January 2009||2009-01-31|February 2018|2018-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Neo-Adjuvant FOLFOX for Rectal Carcinoma|A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6|Terminated||Phase 2|2|Actual|Beth Israel Medical Center||1||terminated for lack of enrollment|f||||f||||||||||2018-06-01 01:21:55.110555|2018-06-01 01:21:55.110555
NCT00832286|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2016-11-23|2009-01-29|2009-01-30|Estimate|||||||2016-11-23|2016-11-28|Estimate|July 2009||2009-07-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Longitudinal Study of the Human Intestinal Microbiome|Longitudinal Study of the Human Intestinal Microbiome Before and After Antibiotic Administration|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 01:21:55.279555|2018-06-01 01:21:55.279555
NCT00832273|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2013-09-09|2009-01-29|2009-01-30|Estimate|||||||2013-09-09|2013-09-10|Estimate||||September 2013|2013-09-30||||||||Expanded Access|||Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery|Use of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Liver Failure: Uncontrolled Treatment Protocol to Provide Expanded Access With Cost Recovery|No longer available|||||Vital Therapies, Inc.|||||||||||||||||||2018-06-01 01:21:55.355194|2018-06-01 01:21:55.355194
NCT00832260|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|2014-08-27||2014-09-25|2009-01-29|2009-01-30|Estimate|2014-08-27|2014-09-08|Estimate||||2014-09-25|2014-10-06|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|June 2011|Actual|2011-06-30||Observational|IES-ACap||IES-ACap: Influence of Atrial Pulse Width in the Behaviour of ACap™ Confirm Algorithm.|Influence of Atrial Pulse Width in the Behaviour of ACap™ Confirm Algorithm.|Completed|||70|Actual|St. Jude Medical|||||f||||f||||||||||2018-06-01 01:21:55.421475|2018-06-01 01:21:55.421475
NCT00832247|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-01-29|2009-01-29|2009-01-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|CELTHEP-02||Autologous Bone Marrow Mononuclear Cells in Liver Cirrhosis|Phase 1 Study of Autologous Bone Marrow Mononuclear Cells Infusion in Peripheral Vein in Liver Cirrhosis Due to Hepatitis C Virus|Unknown status|Recruiting|Phase 1|15|Anticipated|Universidade Federal do Rio de Janeiro|||||f||||t||||||||||2018-06-01 01:21:55.578786|2018-06-01 01:21:55.578786
NCT00832234|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2015-02-16|2009-01-29|2009-01-30|Estimate|||||||2015-02-16|2015-02-18|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2010|Actual|2010-06-30||Interventional|BDR-WM||Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia|Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network|Completed||Phase 2|59|Actual|European Myeloma Network||1|||f||||f||||||||||2018-06-01 01:21:55.694717|2018-06-01 01:21:55.694717
NCT00832221|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-09-11|2009-01-29|2009-01-30|Estimate|||||||2009-09-11|2009-09-14|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|||||Interventional|PET||Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL|An Open Label, 1-sequence Cross-over, Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Receptor Occupancy of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) in Healthy Male Volunteers|Completed||Phase 1|10|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:21:55.785737|2018-06-01 01:21:55.785737
NCT00832208|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2016-01-20|2009-01-29|2009-01-30|Estimate|||||||2016-01-20|2016-01-21|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL|Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis|Terminated||Phase 2|124|Actual|Drugs for Neglected Diseases||2|||f||||t||||||||||2018-06-01 01:21:55.861558|2018-06-01 01:21:55.861558
NCT00832195|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2014-02-17|2009-01-29|2009-01-30|Estimate|||||||2014-02-17|2014-02-19|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Footwear and Injury Prevention Study|Footwear Prevention Study: Investigating the Effects of Running Shoe Pronation Control on the Risk of Injury|Completed||Phase 3|103|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:21:55.955755|2018-06-01 01:21:55.955755
NCT00832182|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2017-02-22|2009-01-29|2009-01-30|Estimate|||||||2017-02-22|2017-02-23|Actual|December 22, 1999|Actual|1999-12-22|February 2017|2017-02-28|November 25, 2002|Actual|2002-11-25|November 25, 2002|Actual|2002-11-25||Interventional|||Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes|An Open-labelled, Non-randomized, Multi-centre, Multinational Extension Trial Assessing the Safety of Insulin Aspart in Patients With Type I Diabetes Treated With a Basal-bolus Regimen|Completed||Phase 3|75|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 01:21:56.080976|2018-06-01 01:21:56.080976
NCT00832169|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-29|||2009-04-27|2009-01-29|2009-01-30|Estimate|||||||2009-04-27|2009-04-28|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|||||Interventional|||Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386|An Open, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD1386 to Healthy Male Volunteers|Completed||Phase 1|6|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:21:56.15245|2018-06-01 01:21:56.15245
NCT00832156|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2014-06-11|2009-01-28|2009-01-29|Estimate|||||||2014-06-11|2014-06-12|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|KC||Application of Cultured Autologous Keratinocytes for Burn Wound Healing|Application of Cultured Autologous Keratinocytes in Combination With a Meshed Split Skin Autograft for Burn Wound Healing|Completed||Phase 3|40|Actual|Association of Dutch Burn Centres||2|||f||||t||||||||||2018-06-01 01:21:56.208937|2018-06-01 01:21:56.208937
NCT00832143|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2009-01-28|2009-01-28|2009-01-29|Estimate|||||||2009-01-28|2009-01-29|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|Referral Card||Effect of Referral Card on Neonatal Medical Care Seeking for Institutional Births in Urban Lucknow|Effect of Referral Card on Neonatal Medical Care Seeking for Institutional Births in Urban Lucknow|Completed||N/A|1020|Actual|King George's Medical University||2|||f||||f||||||||||2018-06-01 01:21:56.337542|2018-06-01 01:21:56.337542
NCT00832130|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2011-09-19||2011-12-05|2009-01-28|2009-01-29|Estimate|2011-11-01|2011-12-06|Estimate||||2011-12-05|2011-12-12|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye|Randomized Clinical Trial for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye|Completed||N/A|139|Actual|TearScience, Inc.||2|||f||||f||||||||||2018-06-01 01:21:56.430338|2018-06-01 01:21:56.430338
NCT00832117|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2012-02-21||2016-02-09|2009-01-28|2009-01-29|Estimate|2012-03-24|2012-03-27|Estimate||||2016-02-09|2016-03-10|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase I Combination Ixabepilone + Cisplatin|Phase 1 Study of Ixabepilone in Combination With Cisplatin in Subjects With Advanced Solid Tumors|Completed||Phase 1|30|Actual|R-Pharm||1|||f||||f||||||||||2018-06-01 01:21:56.787855|2018-06-01 01:21:56.787855
NCT00832091|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2010-01-19||2010-03-24|2009-01-28|2009-01-29|Estimate|2010-02-22|2010-03-24|Estimate||||2010-03-24|2010-03-30|Estimate|July 2006||2006-07-31|March 2010|2010-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|SSVS||Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Venous Stasis Ulcers|Completed||Phase 2|72|Actual|RegeneRx Biopharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 01:21:57.441299|2018-06-01 01:21:57.441299
NCT00832078|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2012-01-09||2012-08-02|2009-01-28|2009-01-29|Estimate|2012-08-02|2012-09-05|Estimate||||2012-08-02|2012-09-05|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|Test catheter||Test Catheter Pilot Study in Healthy Volunteers|Test Catheter Pilot Study in Healthy Volunteers|Completed||N/A|28|Actual|Coloplast A/S||2|||f||||f||||||||||2018-06-01 01:21:57.919838|2018-06-01 01:21:57.919838
NCT00832065|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2017-08-22|2009-01-28|2009-01-29|Estimate|||||||2017-08-22|2017-08-24|Actual|January 2009|Actual|2009-01-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Sexual Dysfunction And Hypotestosteronemia In Patients With Obstructive Sleep Apnea Syndrome|Sexual Dysfunction And Hypotestosteronemia In Patients With Obstructive Sleep Apnea Syndrome And Its Effects With CPAP Therapy|Withdrawn|||0|Actual|Lahey Clinic|||1|No patients enrolled in study|f||||f||||||||||2018-06-01 01:21:58.109804|2018-06-01 01:21:58.109804
NCT00832052|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-06-09|2009-01-27|2009-01-29|Estimate|||||||2009-06-09|2009-06-12|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.|An Investigator And Subject-Blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 Up To An Exposure Cap In Healthy Elderly Subjects|Completed||Phase 1|32|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:21:58.184474|2018-06-01 01:21:58.184474
NCT00832039|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2016-08-11|2009-01-28|2009-01-29|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|SISPCT||Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis|Prospective, Randomized Multicenter Trial of Adjunctive Intravenous Therapy With Sodium-selenite(Selenase®, Double-blinded) and a Procalcitonin Guided Causal Therapy (Open) of Severe Sepsis or Septic Shock.|Completed||Phase 3|1089|Actual|Kompetenznetz Sepsis||4|||f||||t||||||||||2018-06-01 01:21:58.272689|2018-06-01 01:21:58.272689
NCT00832026|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-28|2009-01-28|2009-01-29|Estimate|||||||2009-01-28|2009-01-29|Estimate|July 2004||2004-07-31|January 2009|2009-01-31||||||||Observational|TNI||Trans Nasal Insuflation for the Treatment of Snoring|Trans Nasal Insuflation for the Treatment of Snoring and Obstructive Sleep Apnea|Unknown status|Active, not recruiting||100|Anticipated|Johns Hopkins University|||1||f||||f||||||||||2018-06-01 01:21:58.410984|2018-06-01 01:21:58.410984
NCT00832000|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2012-10-02||2013-08-19|2009-01-27|2009-01-29|Estimate|2013-03-07|2013-03-11|Estimate||||2013-08-19|2013-08-23|Estimate|December 2008||2008-12-31|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia|Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia|Completed||Phase 2|59|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 01:21:58.577375|2018-06-01 01:21:58.577375
NCT00831987|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2009-07-20||2016-04-12|2009-01-28|2009-01-29|Estimate|2009-07-20|2009-08-27|Estimate||||2016-04-12|2016-04-14|Estimate|August 2004||2004-08-31|April 2016|2016-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine|Annual Study of Safety and Immunogenicity of Influenza Virus Vaccine Fluzone® 2004-2005|Completed||Phase 4|120|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:21:59.080427|2018-06-01 01:21:59.080427
NCT00831974|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2013-08-13|2009-01-28|2009-01-29|Estimate|||||||2013-08-13|2013-08-14|Estimate|October 2004||2004-10-31|January 2009|2009-01-31||||February 2007|Actual|2007-02-28||Interventional|||Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis|Phase IIa, Open-label, Randomized Study of Oral AB1010 in Patients With Systemic Indolent Mastocytosis With Handicap and Not Bearing Activating Point Mutations in the Phosphotransferase Domain of c-Kit Such as the Main Mutation Asp-816-Val (D816V)|Completed||Phase 2|23|Actual|AB Science||2|||f||||f||||||||||2018-06-01 01:21:59.519474|2018-06-01 01:21:59.519474
NCT00831961|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2015-12-07|2009-01-28|2009-01-29|Estimate|||||||2015-12-07|2015-12-09|Estimate|January 2009||2009-01-31|December 2015|2015-12-31||||November 2009|Actual|2009-11-30||Observational|ARCaNE||Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics|Prospective, Randomized, Observational Cohort Study of Antibiotic Resistance After Repeated Application of Topical Antibiotics|Completed|||24|Actual|Vanderbilt University|||4||f||||f||||||||||2018-06-01 01:21:59.603555|2018-06-01 01:21:59.603555
NCT00831948|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2009-01-28|2009-01-28|2009-01-29|Estimate|||||||2009-01-28|2009-01-29|Estimate|December 2008||2008-12-31|January 2009|2009-01-31||||||||Observational|||Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.|Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.|Unknown status|Recruiting||20|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||||||2018-06-01 01:21:59.712926|2018-06-01 01:21:59.712926
NCT00831935|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2013-04-05|2009-01-28|2009-01-29|Estimate|||||||2013-04-05|2013-04-08|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Use of Conversation and Acoustic Signals in Measuring Depression Severity|Use of Conversation and Acoustic Signals in Measuring Depression Severity|Completed|||89|Actual|Boston Medical Center|||2||f||||f||||||||||2018-06-01 01:21:59.77966|2018-06-01 01:21:59.77966
NCT00831922|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2009-08-11|2009-01-28|2009-01-29|Estimate|||||||2009-08-11|2009-08-12|Estimate|September 2004||2004-09-30|August 2009|2009-08-31||||October 2006|Actual|2006-10-31||Interventional|||Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis|A Multicenter, Open Label, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis With Inadequate Response to at Least One Disease Modifying Anti Rheumatic Drugs (DMARD)|Completed||Phase 2|43|Actual|AB Science||2|||f||||f||||||||||2018-06-01 01:21:59.84286|2018-06-01 01:21:59.84286
NCT00831909|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2010-08-09|2009-01-28|2009-01-29|Estimate|||||||2010-08-09|2010-08-10|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|EPICLIN||Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN|Epidemiological Study to Describe Non-small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Europe. Lung|Completed|||3513|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:21:59.918449|2018-06-01 01:21:59.918449
NCT00831896|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-12-01|2009-01-27|2009-01-29|Estimate|||||||2011-12-01|2011-12-02|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies|A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies|Completed||Phase 1|27|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:22:00.387141|2018-06-01 01:22:00.387141
NCT00831883|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2012-12-03|2009-01-28|2009-01-29|Estimate|||||||2012-12-03|2012-12-05|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|GET UP||Partner-Specific HIV Risk Reduction Intervention for Drug-Using Adolescents|Partner-Specific HIV Risk Reduction Intervention for Drug-Using Incarcerated Adolescents|Completed||N/A|59|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-06-01 01:22:00.445652|2018-06-01 01:22:00.445652
NCT00831870|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2012-08-29|2009-01-28|2009-01-29|Estimate|||||||2012-08-29|2012-08-30|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|||||Observational|PRICELESS||EndoSure Sensor for Long-term Follow-up After Endovascular AAA Repair|PRessure and Imaging—Using the CardioMEMS EndoSure Sensor for Long-term Follow-up After EVAR With Standard Surveillance (Prospective Registry)|Unknown status|Enrolling by invitation||900|Anticipated|CardioMEMS|||||f||||f||||||||||2018-06-01 01:22:00.512421|2018-06-01 01:22:00.512421
NCT00831857|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2015-10-01|2009-01-28|2009-01-29|Estimate|||||||2015-10-01|2015-10-02|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|Renimage||VEGF Imaging in Renal Cell Carcinoma|89Zr-bevacizumab PET Imaging in Patients With Renal Cell Carcinoma Treated With Sunitinib or Bevacizumab Plus Interferon; a Pilot Study|Completed|||26|Actual|University Medical Center Groningen|||2||f||||f||||||||||2018-06-01 01:22:00.557143|2018-06-01 01:22:00.557143
NCT00831844|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2015-03-18||2015-03-18|2009-01-28|2009-01-29|Estimate|2015-03-18|2015-03-30|Estimate||||2015-03-18|2015-03-30|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional||Group 10, Recurrent or Refractory Retinoblastoma no patients were enrolled.|Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors|Completed||Phase 2|116|Actual|National Cancer Institute (NCI)||10|||f||||t||||||||||2018-06-01 01:22:00.729821|2018-06-01 01:22:00.729821
NCT00831831|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-07-11|2009-01-28|2009-01-29|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|||Can Safety Planning Improve Perinatal Outcomes Among Pregnant Women Exposed to Intimate Partner Violence?|Can Safety Planning Improve Perinatal Outcomes Among Pregnant Women Exposed to Intimate Partner Violence?|Withdrawn||Phase 3|0|Actual|University of British Columbia||||The team wasn't able to work effectively with the social worker at the site|f||||f||||||||||2018-06-01 01:22:03.456578|2018-06-01 01:22:03.456578
NCT00831818|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2011-05-31|2009-01-28|2009-01-29|Estimate|||||||2011-05-31|2011-06-01|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Observational|||Effects of Breastfeeding on Maternal Plasma Ghrelin and Peptide Tyrosine Tyrosine (PYY) Levels|Effects of Breastfeeding on Maternal Plasma Ghrelin and PYY Levels|Completed|||20|Anticipated|Medical University of Vienna|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:22:03.518399|2018-06-01 01:22:03.518399
NCT00831805|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-01-18|2009-01-28|2009-01-29|Estimate|||||||2012-01-18|2012-01-19|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|EMG||Screening of Psycho-cognitive Troubles in Elderly Patients|Impact of a Geriatric Mobile Unit on the Screening of Psycho-cognitive Troubles in Internal Medicine Departments and Circumstances of Calling in This Unit.|Completed|||200|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 01:22:03.575635|2018-06-01 01:22:03.575635
NCT00831792|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2017-06-15|2009-01-27|2009-01-29|Estimate|||||||2017-06-15|2017-06-19|Actual|April 7, 2010|Actual|2010-04-07|June 2017|2017-06-30|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|||TKI258 in Castrate Resistant Prostate Cancer|An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma|Completed||Phase 2|46|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:22:03.62657|2018-06-01 01:22:03.62657
NCT00831779|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2016-09-30|2012-03-24|2017-03-24|2009-01-28|2009-01-29|Estimate|2017-01-10|2017-03-01|Actual|2014-06-06|2014-06-18|Estimate|2017-03-24|2017-04-24|Actual|April 2009||2009-04-30|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||All randomized participants who received at least 1 dose of study medication|Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes|Completed||Phase 2|116|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:22:03.78903|2018-06-01 01:22:03.78903
NCT00831766|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2016-02-25||2017-12-08|2009-01-28|2009-01-29|Estimate|2016-02-25|2016-03-28|Estimate||||2017-12-08|2018-01-03|Actual|January 22, 2009|Actual|2009-01-22|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|February 17, 2015|Actual|2015-02-17||Interventional||All participants enrolled, according to study phase. Outcome measure groups may vary depending on the analysis required.|Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)|A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia|Active, not recruiting||Phase 1/Phase 2|51|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-06-01 01:22:04.115897|2018-06-01 01:22:04.115897
NCT00831753|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2014-02-14||2016-04-08|2009-01-27|2009-01-29|Estimate|2014-02-14|2014-04-02|Estimate||||2016-04-08|2016-05-13|Estimate|May 2008||2008-05-31|April 2016|2016-04-30|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants|Immunogenicity Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to Infanrix®Hexa, at 2-4-6 Months of Age in Healthy Peruvian Infants|Completed||Phase 3|263|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:22:04.747083|2018-06-01 01:22:04.747083
NCT00831740|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2010-11-03|2009-01-28|2009-01-29|Estimate|||||||2010-11-03|2010-11-04|Estimate|October 2006||2006-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|ACT NoW||ACT NoW: Assessing the Effectiveness of Communication Therapy in the North West|ACT NoW: Assessing the Effectiveness of Communication Therapy in the North West: a Pragmatic, Multi-centre Randomised Controlled Trial|Completed||N/A|170|Actual|University of Manchester||2|||f||||t||||||||||2018-06-01 01:22:05.186771|2018-06-01 01:22:05.186771
NCT00831727|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2016-05-10|2009-01-28|2009-01-29|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Role of Affect Regulation and Self-presentation in the Expressive Writing Intervention|Examining Potential Moderators and Mediators in the Expressive Writing Intervention: The Role of Affect Regulation and Self-presentation.|Completed||N/A|75|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 01:22:05.255825|2018-06-01 01:22:05.255825
NCT00831714|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2017-01-19|2009-01-28|2009-01-29|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|April 2013|Actual|2013-04-30|June 2011|Actual|2011-06-30||Observational|XAMOS||Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty|Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee|Completed|||19076|Actual|Bayer|||2||f||||f||||||||||2018-06-01 01:22:05.324344|2018-06-01 01:22:05.324344
NCT00831701|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2010-01-11||2010-05-19|2009-01-28|2009-01-29|Estimate|2010-04-23|2010-05-12|Estimate||||2010-05-19|2010-05-25|Estimate|September 2006||2006-09-30|May 2010|2010-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Medical Expulsive Therapy of Single Distal Ureteral Stones|Medical Expulsive Therapy of Single Distal Ureteral Stones. A Randomised, Double-blind and Placebo-controlled Study|Completed||N/A|100|Actual|University of Zurich|Not all patients were able to record the exact time of stone passage. Thus, the secondary end point of time to stone passage is based on Kaplan-Meier estimation.|2|||f||||f||||||||||2018-06-01 01:22:05.603271|2018-06-01 01:22:05.603271
NCT00831688|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2009-04-20|2009-01-28|2009-01-29|Estimate|||||||2009-04-20|2009-04-21|Estimate|August 2005||2005-08-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy of Local Overpressure Treatment for Meniere's Disease|Phase 3 Study of Efficacy of Local Overpressure Treatment for Meniere's Disease|Completed||Phase 4|80|Anticipated|Klinikum der Universitaet Muenchen, Grosshadern||2|||f||||f||||||||||2018-06-01 01:22:05.881947|2018-06-01 01:22:05.881947
NCT00831675|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2009-07-20||2016-04-12|2009-01-28|2009-01-29|Estimate|2009-07-20|2009-08-27|Estimate||||2016-04-12|2016-04-14|Estimate|September 2004||2004-09-30|April 2016|2016-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of Safety and Immunogenicity of Fluzone® in Healthy Children|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Influenza Virus Vaccine Fluzone® 2004-2005|Completed||Phase 4|30|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:22:05.985065|2018-06-01 01:22:05.985065
NCT00831662|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27||2011-03-24|2014-12-21|2009-01-28|2009-01-29|Estimate||||2011-03-30|2011-04-07|Estimate|2014-12-21|2015-01-09|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)||Completed||Phase 3|490|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:22:06.493509|2018-06-01 01:22:06.493509
NCT00831649|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2016-06-14|2009-01-27|2009-01-29|Estimate|||||||2016-06-14|2016-06-16|Estimate|September 2004||2004-09-30|January 2009|2009-01-31||||February 2005|Actual|2005-02-28||Interventional|||A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201|A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201|Terminated||Phase 2|||Biogen||1||"The biological effect seen with natalizumab was not sufficient to warrant further development~   in RA."|||||||||||||||2018-06-01 01:22:06.564196|2018-06-01 01:22:06.564196
NCT00831636|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2013-09-12|2009-01-28|2009-01-29|Estimate|||||||2013-09-12|2013-09-13|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer|A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer|Completed||Phase 1/Phase 2|28|Actual|Clavis Pharma||1|||f||||f||||||||||2018-06-01 01:22:06.638362|2018-06-01 01:22:06.638362
NCT00831623|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2018-04-15|2009-01-28|2009-01-29|Estimate|||||||2018-04-15|2018-04-17|Actual|March 2009||2009-03-31|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer|Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-risk Prostate Cancer|Recruiting||N/A|200|Anticipated|Loma Linda University||1|||f||||t||||||||||2018-06-01 01:22:06.723677|2018-06-01 01:22:06.723677
NCT00831610|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2012-05-25|2009-01-28|2009-01-29|Estimate|||||||2012-05-25|2012-05-28|Estimate|August 2006||2006-08-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|October 2008|Actual|2008-10-31||Interventional|||Post-bariatric Abdominoplasty: Skin Sensation Evaluation|Post-bariatric Abdominoplasty: Skin Sensation Evaluation.|Completed||N/A|100|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:22:06.802237|2018-06-01 01:22:06.802237
NCT00831597|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2016-04-18|2009-01-27|2009-01-29|Estimate|||||||2016-04-18|2016-04-19|Estimate|November 2008||2008-11-30|May 2012|2012-05-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|904||Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Completed||Phase 2|61|Actual|Pharmatech||1|||f||||t||||||||||2018-06-01 01:22:06.881375|2018-06-01 01:22:06.881375
NCT00831571|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2017-08-03|2009-01-27|2009-01-29|Estimate|||||||2017-08-03|2017-08-04|Actual|February 2009||2009-02-28|August 2017|2017-08-31||||October 2012|Actual|2012-10-31||Observational|||Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin|Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin|Active, not recruiting|||200|Anticipated|Dana-Farber Cancer Institute|||2||f||||t||||||||||2018-06-01 01:22:07.010793|2018-06-01 01:22:07.010793
NCT00831545|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2017-05-08|2009-01-28|2009-01-29|Estimate|||||||2017-05-08|2017-05-09|Actual|December 1, 2000|Actual|2000-12-01|May 2017|2017-05-31|October 20, 2006|Actual|2006-10-20|October 20, 2006|Actual|2006-10-20||Interventional|||Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)|Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.|Completed||Phase 2|162|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:22:07.089832|2018-06-01 01:22:07.089832
NCT00831532|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20||2009-09-14|2009-09-14|2009-01-28|2009-01-29|Estimate||||2009-09-14|2009-09-16|Estimate|2009-09-14|2009-09-16|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function|A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function|Completed||Phase 1|23|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:22:07.169226|2018-06-01 01:22:07.169226
NCT00831519|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2017-11-29|2009-01-28|2009-01-29|Estimate|||||||2017-11-29|2017-11-30|Actual|January 2009||2009-01-31|November 2017|2017-11-30|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Observational|||The Effect of Diabetes on the Newborn|Biochemical, Hematologic, and Inflammatory Effects of Diabetes on the Newborn|Completed|||40|Actual|Western Galilee Hospital-Nahariya|||2||f||||f||||||||||2018-06-01 01:22:07.240486|2018-06-01 01:22:07.240486
NCT00831506|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-06-09|2009-01-27|2009-01-29|Estimate|||||||2009-06-09|2009-06-12|Estimate|February 2009||2009-02-28|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:22:07.288197|2018-06-01 01:22:07.288197
NCT00831493|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2012-02-13||2012-02-27|2009-01-28|2009-01-29|Estimate|2012-02-13|2012-02-24|Estimate||||2012-02-27|2012-02-28|Estimate|May 2009||2009-05-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Vorinostat Plus Radiation Therapy in Pancreatic Cancer|Phase I/II Trial of Vorinostat and Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer|Terminated||Phase 1/Phase 2|3|Actual|M.D. Anderson Cancer Center||1||Slow Accrual.|f||||f||||||||||2018-06-01 01:22:07.381946|2018-06-01 01:22:07.381946
NCT00831480|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2014-11-20||2016-02-19|2009-01-28|2009-01-29|Estimate|2016-02-19|2016-03-21|Estimate||||2016-02-19|2016-03-21|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional||Patients with clinically measurable metastatic RCC|Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal|Neoadjuvant Everolimus (RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01)|Terminated||Phase 2|15|Actual|Baylor College of Medicine||1||Difficulty in accrual and by the order of the cancer center.|f||||t||||||||Undecided||2018-06-01 01:22:07.552222|2018-06-01 01:22:07.552222
NCT00831467|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2018-03-19|2009-01-28|2009-01-29|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2009||2009-01-31|March 2018|2018-03-31|September 2013|Actual|2013-09-30|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease|Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease|Completed||Phase 1/Phase 2|48|Actual|CureVac AG||1|||f||||t||||||||||2018-06-01 01:22:07.922472|2018-06-01 01:22:07.922472
NCT00831259|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-05-19|2009-01-27|2009-01-28|Estimate|||||||2011-05-19|2011-05-20|Estimate|October 2007||2007-10-31|May 2011|2011-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Observational|ICEP||Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO)|Silent Cerebral Infarcts in Patients With Pulmonary Embolism and a Patent Foramen Ovale: a Prospective Diffusion-weighted Magnetic Resonance Imaging Study.|Completed|||70|Anticipated|University Hospital, Caen|||2||f||||t||||||||||2018-06-01 01:22:15.944004|2018-06-01 01:22:15.944004
NCT00831454|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2014-11-27|2009-01-28|2009-01-29|Estimate|||||||2014-11-27|2014-12-02|Estimate|September 2008||2008-09-30|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection|Relationship of Polymorphisms and Mutations of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors Responsiveness in Non-small-cell Lung Cancer Patients|Completed|||51|Actual|Istituto Clinico Humanitas|||||f||||f||||||Samples With DNA|"~     blood samples tissue samples~   "|||2018-06-01 01:22:08.015615|2018-06-01 01:22:08.015615
NCT00831441|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2015-12-18||2015-12-18|2009-01-28|2009-01-29|Estimate|2015-12-18|2016-01-27|Estimate||||2015-12-18|2016-01-27|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|APPRAISE-2|Randomized participants|Phase III Acute Coronary Syndrome|Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome|Terminated||Phase 3|7484|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:22:08.399135|2018-06-01 01:22:08.399135
NCT00831428|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|2011-08-11||2018-04-09|2009-01-28|2009-01-29|Estimate|2011-08-11|2011-09-23|Estimate||||2018-04-09|2018-04-10|Actual|February 2009||2009-02-28|April 2018|2018-04-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Observational|CLE004||Screening Scottish Swimmers for Asthma and Rhinitis|A Pilot Study to Identify the Prevalence of Exercise- Induced Asthma and Rhinitis in Scottish Swimmers, Using Mannitol Challenge as a Screening Tool.|Completed|||97|Actual|University of Dundee|||1||f||||f||||||||||2018-06-01 01:22:12.324792|2018-06-01 01:22:12.324792
NCT00831415|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2011-12-22||2011-12-22|2009-01-28|2009-01-29|Estimate|2011-12-22|2012-01-30|Estimate||||2011-12-22|2012-01-30|Estimate|March 2009||2009-03-31|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)|A 10-Month Open-Label Evaluation Of The Long-Term Safety Of Desvenlafaxine Succinate Sustained Release In Japanese Adults With Major Depressive Disorder|Completed||Phase 3|304|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:22:12.489936|2018-06-01 01:22:12.489936
NCT00831402|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-28|||2012-03-23|2009-01-28|2009-01-29|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|August 2008|Actual|2008-08-31|July 2007|Actual|2007-07-31||Interventional|||Thyroid Function Throughout Pregnancy With and Without Iodine Supplementation|Assessment of Thyroid Function Throughout Pregnancy With and Without Iodine Supplementation|Completed||N/A|111|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:22:13.081158|2018-06-01 01:22:13.081158
NCT00831389|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2012-06-08||2017-11-09|2009-01-26|2009-01-28|Estimate|2012-09-10|2012-10-11|Estimate||||2017-11-09|2017-12-12|Actual|January 2009||2009-01-31|November 2017|2017-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ePID-03||Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia|Effect of Closed Loop Glucose Control on Exercise-Associated Hypoglycemia|Completed||N/A|13|Actual|Medtronic Diabetes||2|||f||||f||||||||No||2018-06-01 01:22:13.168981|2018-06-01 01:22:13.168981
NCT00831376|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-06-11|2009-01-27|2009-01-28|Estimate|||||||2012-06-11|2012-06-12|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|NAI009||Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol|A Proof of Concept Study to Evaluate the Trough Bronchoprotection Conferred by Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics|Completed||Phase 4|30|Actual|University of Dundee||3|||f||||f||||||||||2018-06-01 01:22:13.505195|2018-06-01 01:22:13.505195
NCT00831363|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate||||January 2009|2009-01-31||||||||Observational|||Minimal Invasive Versus Traditional Transgluteal Approach in Total Hip Arthroplasty: a Comparative Gait Analysis|Minimal Invasive Versus Traditional Transgluteal Approach in Total Hip Arthroplasty: a Comparative Gait Analysis|Completed|||||Orthopedic Hospital Vienna Speising|||2||f||||||||||||||2018-06-01 01:22:13.570382|2018-06-01 01:22:13.570382
NCT00831350|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2017-10-26|2009-01-27|2009-01-28|Estimate|||||||2017-10-26|2017-10-30|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|PADDLE||Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations|Posterior Vitreous Detachment (PVD) Assessment During Dual RVO Lucentis Evaluations (PADDLE Study)|Completed||Phase 2|32|Actual|Barnes Retina Institute||1|||f||||f||||||||||2018-06-01 01:22:13.619599|2018-06-01 01:22:13.619599
NCT00831337|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2016-11-21|2009-01-27|2009-01-28|Estimate|||||||2016-11-21|2016-11-23|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Evaluation of Probiotics in the Treatment of Portal Hypertension|The Study of Probiotics in Liver Cirrhosis Patients With Portal Hypertension.|Completed||N/A|33|Actual|Pomeranian Medical University Szczecin||3|||f||||t||||||||||2018-06-01 01:22:13.684129|2018-06-01 01:22:13.684129
NCT00831311|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2013-09-19||2013-11-21|2009-01-27|2009-01-28|Estimate|2013-09-19|2013-11-21|Estimate||||2013-11-21|2013-12-17|Estimate|October 2004||2004-10-31|November 2013|2013-11-30|March 2007|Actual|2007-03-31|November 2005|Actual|2005-11-30||Interventional|||Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants|Phase-II Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants|Completed||Phase 2|624|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:22:13.757043|2018-06-01 01:22:13.757043
NCT00831298|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-12-08|2009-01-27|2009-01-28|Estimate|||||||2011-12-08|2011-12-09|Estimate|July 2010||2010-07-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Assessment of Sleep Disturbance in Alzheimer Disease|Assessment of Sleep Disturbance in Alzheimer Disease|Completed||N/A|70|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:22:15.344078|2018-06-01 01:22:15.344078
NCT00831285|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2010-02-18|2009-01-27|2009-01-28|Estimate|||||||2010-02-18|2010-02-22|Estimate|December 2008||2008-12-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Barley Tortillas Study in Healthy Volunteers|A Double-Blind, Randomized, Controlled Study to Examine the Glycemic Response of Barley Tortillas in Healthy Volunteers|Completed||N/A|12|Actual|University of Manitoba||6|||f||||f||||||||||2018-06-01 01:22:15.415661|2018-06-01 01:22:15.415661
NCT00831272|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2017-01-16||2017-03-29|2009-01-26|2009-01-28|Estimate|2017-03-29|2017-05-11|Actual||||2017-03-29|2017-05-11|Actual|January 5, 2009|Actual|2009-01-05|March 2017|2017-03-31|January 15, 2014|Actual|2014-01-15|December 20, 2013|Actual|2013-12-20||Interventional|||Pharmacogenetic Response to Naltrexone For Alcohol Dependence|Pharmacogenetic Response to Naltrexone for Alcohol Dependence|Completed||Phase 4|221|Actual|University of Pennsylvania|While the study did not achieve the intended sample size, it is highly unlikely that a larger sample would have resulted in the demonstration of the expected moderating effect of the Asp40 allele.|2|||f||||t||||||||No||2018-06-01 01:22:15.597856|2018-06-01 01:22:15.597856
NCT00831246|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2010-06-07|2009-01-27|2009-01-28|Estimate|||||||2010-06-07|2010-06-08|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Prevention of Ileus After Gynecologic Surgery Using Chewing Gum|Prevention of Post-Op Ileus After Gynecologic Surgery Using Chewing Gum|Completed||N/A|400|Anticipated|Aultman Health Foundation||2|||f||||f||||||||||2018-06-01 01:22:16.013869|2018-06-01 01:22:16.013869
NCT00831233|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2011-06-14||2013-10-18|2009-01-27|2009-01-28|Estimate|2011-07-28|2011-08-26|Estimate||||2013-10-18|2013-11-11|Estimate|April 2009||2009-04-30|October 2013|2013-10-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer|A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer|Terminated||Phase 3|42|Actual|Ferring Pharmaceuticals|Early termination leading to small numbers of subjects analyzed.|2||Poor recruitment due to rare targeted population|f||||f||||||||||2018-06-01 01:22:16.142684|2018-06-01 01:22:16.142684
NCT00831220|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease|Endothelial Dysfunction in Chronic Obstructive Pulmonary Disease|Completed|||99|Actual|Hospital Universitari Son Dureta|||4||f||||f||||||Samples Without DNA|"~     Plasma and serum.~   "|||2018-06-01 01:22:16.824023|2018-06-01 01:22:16.824023
NCT00831207|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|August 2004||2004-08-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|November 2005|Actual|2005-11-30||Observational|||Beta-2 Microglobulin and Serum Cytokines x HAART|Beta-2 Microglobulin and Serum Cytokines as Indicators of Antiretroviral Therapy Failure|Completed|||109|Actual|UPECLIN HC FM Botucatu Unesp|||4||f||||t||||||||||2018-06-01 01:22:16.88196|2018-06-01 01:22:16.88196
NCT00831194|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-07-31|2009-01-27|2009-01-28|Estimate|||||||2012-07-31|2012-08-02|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2010|Actual|2010-07-31||Interventional|||Stress, Dietary Lapse and Weight Loss Among Adults With Type 2 Diabetes|Stress, Dietary Lapse and Weight Loss Among Adults With Type 2 Diabetes|Completed||N/A|70|Anticipated|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||||2018-06-01 01:22:17.03059|2018-06-01 01:22:17.03059
NCT00831181|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2013-01-09||2018-02-20|2009-01-27|2009-01-28|Estimate|2018-02-20|2018-03-20|Actual||||2018-02-20|2018-03-20|Actual|July 2004||2004-07-31|February 2018|2018-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer|A Phase II Open-labeled, Prospective Study to Determine the Efficacy of Preoperative Chemoradiation With Oxaliplatin/5-FU in Locally Advanced Rectal Cancer Followed by Total Mesorectal Excision and FOLFOX6|Completed||Phase 2|27|Actual|Beth Israel Medical Center||1|||f||||f||||||||||2018-06-01 01:22:17.121073|2018-06-01 01:22:17.121073
NCT00831168|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|BEADI||BEADI - The Bliss Cluster Randomised Control Trial on the Effects of Active Dissemination of Information (BEADI)|The Bliss Cluster Randomised Control Trial on the Effects of Active Dissemination of Information on Outcomes of Premature Babies.|Unknown status|Active, not recruiting|Phase 1/Phase 2|200|Anticipated|Confidential Enquiry into Maternal and Child Health|||||f||||f||||||||||2018-06-01 01:22:17.340185|2018-06-01 01:22:17.340185
NCT00831155|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2015-04-17|2009-01-27|2009-01-28|Estimate|||||||2015-04-17|2015-04-20|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Extinction01||Extinction Based Treatment for Nicotine Dependence|Brain Substrates of Extinction Based Treatment for Nicotine Dependence|Completed||Phase 1|257|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:22:17.418635|2018-06-01 01:22:17.418635
NCT00831142|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2018-03-19|2009-01-27|2009-01-28|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2006||2006-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|January 2012|Actual|2012-01-31||Observational|||Characterization of Prostate Cancer With 3T MR|Characterization of Prostate Cancer With 3T MR|Active, not recruiting|||236|Actual|Beth Israel Deaconess Medical Center|||1||f||||f||||||||||2018-06-01 01:22:17.489193|2018-06-01 01:22:17.489193
NCT00831129|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2013-06-27||2016-12-19|2009-01-27|2009-01-28|Estimate|2013-06-27|2013-09-12|Estimate||||2016-12-19|2017-02-10|Actual|September 2006||2006-09-30|December 2016|2016-12-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|SIROCO||A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs|Effects of Simvastatin and Rosiglitazone Combination in Patients With the Metabolic Syndrome.|Completed||Phase 2/Phase 3|53|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:22:17.58279|2018-06-01 01:22:17.58279
NCT00831116|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2017-06-08|2009-01-27|2009-01-28|Estimate|||||||2017-06-08|2017-06-09|Actual|February 2009|Actual|2009-02-28|June 2017|2017-06-30|April 2017|Actual|2017-04-30|February 2016|Actual|2016-02-29||Observational|COLOR||An Observational Study of Cholesterol in Coronary Arteries|Chemometric Observation of Lipid Core Plaques of Interest in Native Coronary Arteries Registry|Completed|||2067|Actual|InfraReDx|||1||f||||t||||||||||2018-06-01 01:22:18.222201|2018-06-01 01:22:18.222201
NCT00831103|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2013-12-03|2009-01-26|2009-01-28|Estimate|||||||2013-12-03|2013-12-05|Estimate|November 2007||2007-11-30|December 2013|2013-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster|A Randomized, Double-blind, Active-controlled, Multi-center, Parallel-group Dose-ranging Study Assessing the Safety and Efficacy of EPB-348 Versus Valacyclovir Among Immunocompetent Patients With an Acute Episode of Herpes Zoster|Completed||Phase 2|373|Actual|Epiphany Biosciences||4|||f||||f||||||||||2018-06-01 01:22:18.335265|2018-06-01 01:22:18.335265
NCT00831090|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2016-04-01|2009-01-27|2009-01-28|Estimate|||||||2016-04-01|2016-04-05|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|EFVGR||Endothelial Function and Vein Graft Remodeling|Endothelial Function and Vein Graft Remodeling|Unknown status|Recruiting||60|Anticipated|University of California, San Francisco|||||f||||f||||||Samples Without DNA|"~     A segment of vein that would usually be discarded will be taken to a lab for testing of~     endothelial reactivity and quantification of endothelial coverage through CD31 staining.~   "|||2018-06-01 01:22:18.416532|2018-06-01 01:22:18.416532
NCT00831077|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-10-07|2009-01-27|2009-01-28|Estimate|||||||2009-10-07|2009-10-08|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Early Phase I Microdosing Study of ORM-14540 and ORM-12741|Pharmacokinetic Properties of ORM-14540 and ORM-12741 After Administration of a Microdose of 14C-labelled Drug; An Open, Non-randomised, Single Dose, Single Centre Study in Healthy Male Subjects|Completed||Early Phase 1|6|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 01:22:18.475261|2018-06-01 01:22:18.475261
NCT00831064|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2016-06-09|2009-01-27|2009-01-28|Estimate|||||||2016-06-09|2016-06-13|Estimate|September 2007||2007-09-30|June 2016|2016-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Trial of Four Different Bowel Cleansing Regimens Prior to Colonoscopy|A Randomized Controlled Trial of Four Different Bowel Cleansing Regimens Prior to Colonoscopy: Efficacy, Patient Tolerability and Safety|Completed||N/A|200|Actual|University of Alberta||4|||f||||f||||||||||2018-06-01 01:22:18.541198|2018-06-01 01:22:18.541198
NCT00831051|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27||2010-08-25|2012-05-15|2009-01-27|2009-01-28|Estimate||||2010-08-25|2010-08-31|Estimate|2012-05-15|2012-05-17|Estimate|December 2008||2008-12-31|May 2012|2012-05-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients|A Double-Blind, Randomized, Multi-Center, Repeat-Dose, Comparison of the Analgesic Efficacy and Safety of the Opioid Combination Q8003 to Each of the Individual Milligram Components (Oxycodone and Morphine) in the Management of Acute Moderate to Severe Pain Following Bunionectomy Surgery|Completed||Phase 2|197|Actual|QRxPharma Inc.||6|||f||||f||||||||||2018-06-01 01:22:18.62813|2018-06-01 01:22:18.62813
NCT00831038|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-11-28|2009-01-27|2009-01-28|Estimate|||||||2011-11-28|2011-11-30|Estimate|August 2008||2008-08-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Pilot Study of Pulmonary Function in Dysphagic Infants|A Pilot Study of Pulmonary Function in Dysphagic Infants|Completed||N/A|26|Actual|University of Tennessee|||||f||||f||||||||||2018-06-01 01:22:18.717682|2018-06-01 01:22:18.717682
NCT00831025|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2018-02-21|2009-01-27|2009-01-28|Estimate|||||||2018-02-21|2018-02-23|Actual|January 2008||2008-01-31|February 2018|2018-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|OLEA||Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen|Multicenter, Randomised, Double-blind Placebo-controlled, Subcutaneous Immunotherapy Clinical Trial With Depigmented and Polymerized Allergen Extract of Olea Europaea Pollen in Patients With Hypersensitivity to Olea Pollen|Completed||Phase 3|158|Actual|Laboratorios Leti, S.L.||2|||f||||f||||||||||2018-06-01 01:22:18.776561|2018-06-01 01:22:18.776561
NCT00831012|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2013-11-13|2009-01-27|2009-01-28|Estimate|||||||2013-11-13|2013-11-15|Estimate|September 2009||2009-09-30|November 2013|2013-11-30||||June 2011|Actual|2011-06-30||Interventional|||Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults|A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3|Completed||Phase 1|56|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:22:18.877093|2018-06-01 01:22:18.877093
NCT00830999|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2013-01-18|2009-01-26|2009-01-28|Estimate|||||||2013-01-18|2013-01-21|Estimate|April 2006||2006-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DEV||Fat Metabolism in Response to Acute Diet- and Exercise-induced Changes in Energy Balance|VLDL-triglyceride Metabolism in Response to Acute Diet- and Exercise-induced Changes in Energy Balance|Completed||N/A|12|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 01:22:18.943714|2018-06-01 01:22:18.943714
NCT00830986|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-04-14|2009-01-26|2009-01-28|Estimate|||||||2009-04-14|2009-04-16|Estimate|July 2005||2005-07-31|January 2009|2009-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|Minimental||Cognition Following Computer Assisted Total Knee Arthroplasty|Cognition Following Computer Assisted Total Knee Arthroplasty: A Prospective Cohort Study|Completed|||100|Actual|Rothman Institute Orthopaedics|||2||f||||f||||||||||2018-06-01 01:22:19.116918|2018-06-01 01:22:19.116918
NCT00830973|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-10-12|2009-01-27|2009-01-28|Estimate|||||||2009-10-12|2009-10-14|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|MHSLabCorp1||The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer|Tamoxifen Pharmacogenomics and the Prevention of Recurrent Breast Cancer|Completed|||184|Actual|Medco Health Solutions, Inc.|||1||f||||t||||||Samples With DNA|"~     Buccal swab~   "|||2018-06-01 01:22:19.184738|2018-06-01 01:22:19.184738
NCT00830960|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2011-06-17||2011-09-22|2009-01-27|2009-01-28|Estimate|2011-09-22|2011-11-02|Estimate||||2011-09-22|2011-11-02|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome|A Comparison of Platelet Inhibition Following Prasugrel or Clopidogrel Administration in Asian Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention|Completed||Phase 3|720|Actual|Eli Lilly and Company||6|||f||||t||||||||||2018-06-01 01:22:19.3391|2018-06-01 01:22:19.3391
NCT00830947|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2013-06-20||2013-11-05|2009-01-27|2009-01-28|Estimate|2013-11-05|2013-12-23|Estimate||||2013-11-05|2013-12-23|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement|The OrthoAccel (OATI) Celerect Device Pivotal Study - Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement|Completed||Phase 3|45|Actual|OrthoAccel Technologies Inc.||2|||f||||f||||||||||2018-06-01 01:22:21.446403|2018-06-01 01:22:21.446403
NCT00830934|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|April 2009||2009-04-30|January 2009|2009-01-31|September 2010|Anticipated|2010-09-30|March 2010|Anticipated|2010-03-31||Interventional|GRIP||Trial for the Treatment of Pelvic and Back Pain in Pregnancy|Randomised Controlled Trial for the Treatment of Pelvic Girdle Pain in Pregnancy|Unknown status|Not yet recruiting|N/A|226|Anticipated|University College Cork||2|||f||||t||||||||||2018-06-01 01:22:21.707349|2018-06-01 01:22:21.707349
NCT00830921|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-06-15|2009-01-27|2009-01-28|Estimate|||||||2012-06-15|2012-06-18|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|January 2012|Actual|2012-01-31|||||Observational|TMS||Does Transcranial Magnetic Stimulation of the Cingulate Cortex Modulate the Perception of Dyspnoea?|"A Randomised Crossover Study to Investigate the Effect of Transcranial Magnetic Stimulation of the Anterior Cingulate Cortex on Air Hunger"|Terminated|||12|Anticipated|University of Oxford|||1|Lack of patients|f||||f||||||||||2018-06-01 01:22:21.804904|2018-06-01 01:22:21.804904
NCT00830908|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2012-06-25|2009-01-27|2009-01-28|Estimate|||||||2012-06-25|2012-06-27|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis|An Open-Label Study of the HairMax LaserComb(r) in the Treatment of Seborrheic Dermatitis of the Scalp.|Completed||N/A|10|Anticipated|Lexington International, LLC||1|||f||||t||||||||||2018-06-01 01:22:21.888954|2018-06-01 01:22:21.888954
NCT00830895|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2013-04-11|2009-01-27|2009-01-28|Estimate|||||||2013-04-11|2013-04-12|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|October 2010|Actual|2010-10-31||Interventional|||RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)|A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma|Completed||Phase 2|49|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-06-01 01:22:21.964301|2018-06-01 01:22:21.964301
NCT00830882|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-06-11|2009-01-27|2009-01-28|Estimate|||||||2012-06-11|2012-06-12|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|NAI007||Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol|A Proof of Concept Study to Evaluate the Peak Bronchoprotection Conferred by Single and Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics.|Withdrawn||Phase 4|0|Actual|University of Dundee||3||Lack of funding|f||||f||||||||||2018-06-01 01:22:22.027483|2018-06-01 01:22:22.027483
NCT00830869|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2014-06-23|2009-01-26|2009-01-28|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies|An Open-Label, Dose Escalation, Phase 1 Study of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies|Completed||Phase 1|116|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:22:22.095973|2018-06-01 01:22:22.095973
NCT00830856|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2016-07-14|2009-01-27|2009-01-28|Estimate|||||||2016-07-14|2016-07-18|Estimate|October 2006||2006-10-31|July 2016|2016-07-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa|Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis.|Completed||N/A|54|Actual|University of Zimbabwe||2|||f||||t||||||||||2018-06-01 01:22:22.159689|2018-06-01 01:22:22.159689
NCT00830843|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2016-08-19|2009-01-27|2009-01-28|Estimate|||||||2016-08-19|2016-08-22|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|GAS-SAH||Inhalatorial Sedation in Patient With Subarachnoid Hemorrhage (SAH) Versus Conventional Intravenous Sedation|Inhalatorial Sedation in Patient With SAH Versus Conventional Intravenous Sedation (GAS-SAH)|Completed||Phase 4|13|Actual|Azienda Ospedaliera San Gerardo di Monza||2|||f||||f||||||||||2018-06-01 01:22:22.242013|2018-06-01 01:22:22.242013
NCT00830830|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-03-18|2009-01-27|2009-01-28|Estimate|||||||2009-03-18|2009-03-19|Estimate|December 2005||2005-12-31|March 2009|2009-03-31|October 2006|Actual|2006-10-31|||||Interventional|||TREAD-20 Extension - Treatment of Knee Pain Due to Osteoarthritis|A Double-Blind, Randomized Trial of Intra-Articular Injections of 20mg of Hyalgan for the Treatment of Knee Pain Due to Osteoarthritis (Three Injection Regimen for Efficacy and Duration - 20mg/2ml Dose) - Extension Study|Completed||Phase 4|40|Actual|Sanofi|||||f||||||||||||||2018-06-01 01:22:22.315759|2018-06-01 01:22:22.315759
NCT00830817|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Observational|WBI-1001-101||Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis|A Randomized, Double-Blind Phase I Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Psoriasis.|Completed|||36|Actual|Welichem Biotech Inc.|||||f||||t||||||Samples Without DNA|"~     Blood plasma samples retained following PK analyses.~   "|||2018-06-01 01:22:22.367812|2018-06-01 01:22:22.367812
NCT00830804|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2011-09-07||2016-01-04|2009-01-27|2009-01-28|Estimate|2011-09-07|2011-10-10|Estimate||||2016-01-04|2016-02-03|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Interventional|||Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults|A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects|Completed||Phase 2|113|Actual|AIDS Clinical Trials Group|This is a single-arm study.|1|||f||||t||||||||||2018-06-01 01:22:22.450003|2018-06-01 01:22:22.450003
NCT00830791|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2012-05-01||2015-02-09|2009-01-26|2009-01-28|Estimate|2012-06-07|2012-07-23|Estimate||||2015-02-09|2015-02-26|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)|A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Subjects With Renal Insufficiency|Terminated||Phase 1|32|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 01:22:22.85649|2018-06-01 01:22:22.85649
NCT00830778|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-09-11|2009-01-27|2009-01-28|Estimate|||||||2012-09-11|2012-09-12|Estimate|June 2009||2009-06-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy|Reduced Postoperative Pancreatic Fistula Rate Following Pancreaticoduodenectomy; Multicentric Randomized Controlled Trial on Pancreaticogastrostomy vs. Pancreaticojejunostomy|Completed||Phase 3|336|Anticipated|University Hospital, Gasthuisberg||2|||f||||t||||||||||2018-06-01 01:22:23.490228|2018-06-01 01:22:23.490228
NCT00830765|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2012-05-22||2013-01-17|2009-01-27|2009-01-28|Estimate|2013-01-17|2013-02-20|Estimate||||2013-01-17|2013-02-20|Estimate|June 2004||2004-06-30|January 2013|2013-01-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||The Use of Progesterone to Reduce Preterm Birth|The Use of Progesterone to Reduce Preterm Birth|Completed||N/A|144|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-06-01 01:22:23.574154|2018-06-01 01:22:23.574154
NCT00830752|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Observational|ALEX||Neurobiological, Neuropsychological,Linguistic and Gestural Processes and Phenomena in Individuals With Alexithymia|Understanding Alexithymia|Unknown status|Not yet recruiting||70|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-06-01 01:22:23.752658|2018-06-01 01:22:23.752658
NCT00830739|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2018-04-04|2009-01-27|2009-01-28|Estimate|||||||2018-04-04|2018-04-05|Actual|November 25, 2008||2008-11-25|February 26, 2013|2013-02-26|February 26, 2013||2013-02-26|||||Observational|||A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control|A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control|Completed|||61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:22:23.801713|2018-06-01 01:22:23.801713
NCT00830726|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-06-22|2009-01-27|2009-01-28|Estimate|||||||2011-06-22|2011-06-23|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Observational|||Water- and Salt-homeostasis in Healthy Humans, and in Patients With Heart- or Lung Disease|Water-and Salt-homeostasis in Healthy Humans, and in Patients With Heart- or Lung Disease, Evaluated by the Excretion of Aquaporin-2 and Epithelial Sodium Channels in the Urine|Unknown status|Recruiting||150|Anticipated|Kolding Sygehus|||6||f||||f||||||Samples Without DNA|"~     Plasma and Urine samples~   "|||2018-06-01 01:22:23.927357|2018-06-01 01:22:23.927357
NCT00830713|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-09-04|2009-01-27|2009-01-28|Estimate|||||||2012-09-04|2012-09-06|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|MKTP||Vitiligo Skin Transplantation|Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo|Completed||Phase 3|40|Actual|Henry Ford Health System||1|||f||||f||||||||||2018-06-01 01:22:24.029101|2018-06-01 01:22:24.029101
NCT00830700|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2014-02-07|2009-01-27|2009-01-28|Estimate|||||||2014-02-07|2014-02-11|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CATTS||Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study|Telemental Health to Improve Mental Health Care and Outcomes for Children in Underserved Areas|Completed||N/A|223|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-06-01 01:22:24.097991|2018-06-01 01:22:24.097991
NCT00830687|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-25|||2010-09-05|2009-01-27|2009-01-28|Estimate|||||||2010-09-05|2010-09-08|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Intracapsular Femoral Neck Fractures Fixation With a Dynamic Locking Plate and Screw System, Targon FN|Intracapsular Femoral Neck Fractures Fixation With a Dynamic Locking Plate and Screw System, Targon FN. Prospective and Retrospective Cohort Study.|Unknown status|Recruiting|N/A|100|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 01:22:24.185317|2018-06-01 01:22:24.185317
NCT00830674|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2013-10-18|2009-01-27|2009-01-28|Estimate|||||||2013-10-18|2013-10-21|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|December 2011|Actual|2011-12-31||Interventional|||A Study of KRN23 in X-linked Hypophosphatemia|A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia|Completed||Phase 1|42|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||t||||||||||2018-06-01 01:22:24.268032|2018-06-01 01:22:24.268032
NCT00830661|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-05-28|2009-01-27|2009-01-28|Estimate|||||||2009-05-28|2009-05-29|Estimate|March 2009||2009-03-31|May 2009|2009-05-31||||March 2012|Anticipated|2012-03-31||Interventional|LIFT vs PLUG||Ligation of Intersphincteric Fistula Tract (LIFT) Procedure Versus Use of an Anal Fistula Plug for Anal Fistula Repair|A Randomized, Prospective, Multi-Centered Study Comparing Clinical Outcomes of the Ligation of Intersphincteric Fistula Tract (LIFT)Procedure Versus Use of Anal Fistula Plug (AFP)in the Surgical Repair of Trans-Sphincteric Anal Fistulae of Cryptoglandular Origin|Unknown status|Recruiting|N/A|124|Anticipated|Colon and Rectal Surgery Associates, Ltd.||2|||f||||t||||||||||2018-06-01 01:22:24.347493|2018-06-01 01:22:24.347493
NCT00830648|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2013-06-06|2009-01-27|2009-01-28|Estimate|||||||2013-06-06|2013-06-10|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Safety of a Second Dose of Biken's Varicella Vaccine|Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina|Completed||Phase 4|122|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:22:24.431249|2018-06-01 01:22:24.431249
NCT00830635|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2015-06-12|2009-01-27|2009-01-28|Estimate|||||||2015-06-12|2015-06-16|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer|Cancer Information Service Research Consortium: Years 2006-2011 Program Narrative and Overview|Completed||N/A|1800|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-06-01 01:22:24.498602|2018-06-01 01:22:24.498602
NCT00830622|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2010-06-18|2009-01-27|2009-01-28|Estimate|||||||2010-06-18|2010-06-22|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Cell Phone Intervention to Support Antiretroviral Therapy (ART) Adherence in Kenya|A Targeted Cell Phone Intervention to Improve Patient Access to Care and Drug Adherence in Patients Taking Antiretroviral (ARV) Medications in Kenya|Completed||N/A|536|Actual|University of Manitoba||2|||f||||f||||||||||2018-06-01 01:22:24.577715|2018-06-01 01:22:24.577715
NCT00830609|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-03-12|2009-01-27|2009-01-28|Estimate|||||||2012-03-12|2012-03-13|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|DARGEN-3||High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3|Effect of High Dose vs. Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3, High Viral Load Without Rapid Virological Response|Completed||Phase 4|101|Actual|Hospital Universitario Fundación Alcorcón||3|||f||||t||||||||||2018-06-01 01:22:24.656983|2018-06-01 01:22:24.656983
NCT00830596|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2017-04-18||2017-07-21|2009-01-27|2009-01-28|Estimate|2017-07-21|2017-09-25|Actual||||2017-07-21|2017-09-25|Actual|July 2007||2007-07-31|July 2017|2017-07-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|D2P3||Effect of Spinal Manipulation on Sensorimotor Functions in Back Pain Patients|Effect of Spinal Manipulation on Sensorimotor Functions in Back Pain Patients|Completed||N/A|221|Actual|Palmer College of Chiropractic||3|||f||||t||||||||Yes|Once the resulting manuscripts have been published, data sets will be provided for public access. Potential investigators can contact one of the Co-PIs to present their hypothesis, study design, instruments and/or data on which to focus, and resources required. Depending upon the needs and desires of the requesting party, the data that are shared may include analytic tables or de-identified or limited data sets that are transmitted to the requesting parties for additional analyses.|2018-06-01 01:22:24.794976|2018-06-01 01:22:24.794976
NCT00830583|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-12-07|2009-01-27|2009-01-28|Estimate|||||||2011-12-07|2011-12-08|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|POPS||Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis|Pompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis|Completed||N/A|400|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:22:25.181209|2018-06-01 01:22:25.181209
NCT00830570|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2010-11-15|2009-01-27|2009-01-28|Estimate|||||||2010-11-15|2010-11-16|Estimate|July 2007||2007-07-31|November 2010|2010-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|MHSMayoWarf1||The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings|in Typical Community Practice Settings|Completed|||1635|Actual|Medco Health Solutions, Inc.|||3||f||||t||||||Samples With DNA|"~     Blood draw and buccal swab~   "|||2018-06-01 01:22:25.245768|2018-06-01 01:22:25.245768
NCT00830557|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2017-09-08|2009-01-27|2009-01-28|Estimate|||||||2017-09-08|2017-09-11|Actual|October 2000||2000-10-31|September 2017|2017-09-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders|Biospecimen Resource for Pancreas Research, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease|Recruiting|||7500|Anticipated|Mayo Clinic|||||f||||t||||||Samples With DNA|"~     Two 10mL plasma tubes, two 10mL serum tubes and one 10mL heparin tube collected. DNA~     extracted from lymphocytes. Possible saliva collection for DNA extraction. Waste tissue from~     prior surgery may be collected. Stool samples may be collected.~   "|||2018-06-01 01:22:25.328256|2018-06-01 01:22:25.328256
NCT00830544|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2012-07-12|2009-01-27|2009-01-28|Estimate|||||||2012-07-12|2012-07-13|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2011|Actual|2011-12-31||Interventional|Neoadjuvant||Study of Neoadjuvant Chemotherapy of Breast Cancer|Phase II Study of Neoadjuvant Chemotherapy of Breast Cancer|Unknown status|Active, not recruiting|Phase 2|54|Anticipated|Auxilio Mutuo Cancer Center||1|||f||||f||||||||||2018-06-01 01:22:25.396065|2018-06-01 01:22:25.396065
NCT00830531|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2018-04-10|2009-01-27|2009-01-28|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Pilot Study of Bumetanide for Newborn Seizures|Pilot Study of Bumetanide for Newborn Seizures: A Phase I Study of Pharmacokinetics and Safety of Bumetanide for Neonatal Seizures|Active, not recruiting||Phase 1|43|Actual|Soul, Janet , M.D.||2|||f||||t||||||||||2018-06-01 01:22:25.464779|2018-06-01 01:22:25.464779
NCT00830518|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|2018-01-04|2012-01-26|2018-04-09|2009-01-27|2009-01-28|Estimate|2018-04-09|2018-05-11|Actual|2012-01-26|2012-01-30|Estimate|2018-04-09|2018-05-11|Actual|February 10, 2009|Actual|2009-02-10|April 2018|2018-04-30|July 4, 2011|Actual|2011-07-04|February 2, 2010|Actual|2010-02-02||Interventional||Safety population was defined as all participants who received any amount of alisertib.|A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome|A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome|Completed||Phase 2|57|Actual|Takeda||1|||f||||f|t|f||||||||2018-06-01 01:22:25.566816|2018-06-01 01:22:25.566816
NCT00830505|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|CLE001||Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma|A Randomized, Double-Blind, Cross-Over Study to Demonstrate Superiority of Fluticasone/Salmeterol Over Double the Dose of Fluticasone on Methacholine Hyper-Reactivity in Patients With Persistent, Mild to Moderate Asthma|Unknown status|Not yet recruiting|Phase 4|32|Anticipated|University of Dundee||2|||f||||f||||||||||2018-06-01 01:22:26.419123|2018-06-01 01:22:26.419123
NCT00830492|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2009-01-27|2009-01-27|2009-01-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist|Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome.|Completed||Phase 4|200|Anticipated|Yazd Research & Clinical Center for Infertility||2|||f||||t||||||||||2018-06-01 01:22:26.534693|2018-06-01 01:22:26.534693
NCT00830479|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-08-11|2009-01-27|2009-01-28|Estimate|||||||2011-08-11|2011-08-12|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|STRETCH||Study of Endoscopic Versus Open Surgery for Urinary Reflux|A Randomized Trial of Endoscopic vs. Open Anti-Reflux Surgery For Treatment of Low-Grade Vesicoureteral Reflux: Surgical Treatment of Reflux: Endoscopic vs. Traditional CHoices (STRETCH) Study|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||2||unable to enroll patients for randomization|f||||t||||||||||2018-06-01 01:22:26.614045|2018-06-01 01:22:26.614045
NCT00830466|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2017-02-08|2009-01-27|2009-01-28|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2008||2008-12-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.|A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.|Completed||Phase 1|22|Actual|University of California, Irvine||1|||f||||f||||||||Undecided||2018-06-01 01:22:26.757377|2018-06-01 01:22:26.757377
NCT00830453|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-27|||2011-09-02|2009-01-27|2009-01-28|Estimate|||||||2011-09-02|2011-09-07|Estimate|November 2003||2003-11-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|HYBOBI||Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury|Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury|Completed||Phase 2|60|Anticipated|Intermountain Health Care, Inc.|||||f||||f||||||||||2018-06-01 01:22:26.855679|2018-06-01 01:22:26.855679
NCT00830440|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2016-11-01|2010-04-06|2017-04-12|2009-01-27|2009-01-28|Estimate|2017-02-24|2017-04-10|Actual|2010-04-13|2010-04-15|Estimate|2017-04-12|2017-05-17|Actual|January 2007||2007-01-31|April 2017|2017-04-30|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional||EndoBarrier subjects with a successful implant|A Multicenter Study for Pre-Surgical Weight Loss|A Multi-Center, Pilot Efficacy Study of the GI Sleeve™ for Pre-Surgical Weight Loss|Completed||N/A|43|Actual|GI Dynamics||2|||f||||f||||||||No||2018-06-01 01:22:26.954563|2018-06-01 01:22:26.954563
NCT00830427|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-03-11|2009-01-26|2009-01-27|Estimate|||||||2011-03-11|2011-03-15|Estimate|July 2009||2009-07-31|March 2011|2011-03-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|A7881006||A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects|A Phase IIb Randomised, Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of PF-00610355 Over 4 Weeks In Moderately Asthmatic Subjects.|Withdrawn||Phase 2|350|Anticipated|Pfizer||3|||f||||f||||||||||2018-06-01 01:22:27.276798|2018-06-01 01:22:27.276798
NCT00830414|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|April 2002||2002-04-30|January 2009|2009-01-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women|A Pivotal Study to Evaluate the Bioequivalence of 150 mg/1 mL Medroxyprogesterone Acetate Injection in Postmenopausal Women|Completed||Phase 1|124|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:27.368006|2018-06-01 01:22:27.368006
NCT00830401|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2015-06-03|2009-01-26|2009-01-27|Estimate|||||||2015-06-03|2015-06-04|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||The Impact of Treating Minor Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy in Unselected In Vitro Fertilization (IVF) Cases|Comparative Controlled Trial of Treatment of Minor Unexpected Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy Screening in Women Indicated for IVF|Terminated||Phase 2|700|Actual|UMC Utrecht||2||Abnormality prevalence revealed to be much lower than expected.|f||||f||||||||||2018-06-01 01:22:27.46103|2018-06-01 01:22:27.46103
NCT00830388|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2012-05-01||2012-08-21|2009-01-26|2009-01-27|Estimate|2012-08-21|2012-08-22|Estimate||||2012-08-21|2012-08-22|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Ketoconazole Foam 2% for the Treatment of Versicolor|Ketoconazole Foam 2% for the Treatment of Versicolor|Completed||Phase 4|11|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 01:22:27.572225|2018-06-01 01:22:27.572225
NCT00830375|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2012-03-01||2012-04-09|2009-01-26|2009-01-27|Estimate|2012-04-09|2012-05-04|Estimate||||2012-04-09|2012-05-04|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Memantine Treatment of Compulsive Buying|Memantine Treatment of Compulsive Buying: An Open-Label Study|Completed||Phase 2|10|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 01:22:27.748109|2018-06-01 01:22:27.748109
NCT00829855|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2013-03-04|2009-01-26|2009-01-27|Estimate|||||||2013-03-04|2013-03-05|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Echocardiographic Evaluation of Hypertensive Acute Pulmonary Edema|Echocardiographic Evaluation of Hypertensive Acute Pulmonary Edema|Completed|||51|Actual|Carol Davila University of Medicine and Pharmacy|||2||f||||t||||||||||2018-06-01 01:22:37.751743|2018-06-01 01:22:37.751743
NCT00830362|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2012-08-24||2012-10-31|2009-01-26|2009-01-27|Estimate|2012-10-31|2012-11-30|Estimate||||2012-10-31|2012-11-30|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Beta-blockade Effects on Memory for Cocaine Craving|Treatment Implications of Beta-blockade Effects on Memory for Cocaine Craving|Completed||Phase 2|50|Actual|Medical University of South Carolina|Lack of a “no retrieval” control group. Lack of determination of plasma propranolol levels following the medicated retrieval session. The sample size was insufficient to assess the more distal effects at 1-week follow-up.|2|||f||||t||||||||||2018-06-01 01:22:27.918165|2018-06-01 01:22:27.918165
NCT00830349|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|June 2001||2001-06-30|January 2009|2009-01-31|July 2004|Actual|2004-07-31|July 2001|Actual|2001-07-31||Interventional|||Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Risperidone 1 mg Tablets and Risperdal 1 mg Tablets Administered as a 1 x 1 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|30|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 01:22:28.095179|2018-06-01 01:22:28.095179
NCT00830336|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-18||2009-09-01|2009-01-26|2009-01-27|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions|A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions|Completed||Phase 1|80|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:28.165429|2018-06-01 01:22:28.165429
NCT00830323|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2010-09-29|2009-01-26|2009-01-27|Estimate|||||||2010-09-29|2010-09-30|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|Combina||Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection|Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection|Terminated||Phase 2|60|Anticipated|Hospices Civils de Lyon||3|||f||||t||||||||||2018-06-01 01:22:28.468102|2018-06-01 01:22:28.468102
NCT00830310|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2011-10-24||2014-12-08|2009-01-26|2009-01-27|Estimate|2011-10-24|2011-11-24|Estimate||||2014-12-08|2014-12-30|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|UH CAE||Customized Medication Adherence Enhancement for Adults With Bipolar Disorder|Customized Adherence Enhancement (CAE) Among Individuals With Bipolar Disorder|Completed||N/A|43|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-06-01 01:22:28.553129|2018-06-01 01:22:28.553129
NCT00830297|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2012-08-30|2009-01-26|2009-01-27|Estimate|||||||2012-08-30|2012-09-03|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|TIP||Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia|Treat-to-target Trial of Basal Insulin in Post-transplant Hyperglycemia (TIP): Efficacy and Safety of a Novel Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression|Completed||Phase 2|50|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:22:28.895403|2018-06-01 01:22:28.895403
NCT00830284|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2016-12-23||2016-12-23|2009-01-26|2009-01-27|Estimate|2016-12-23|2017-02-16|Actual||||2016-12-23|2017-02-16|Actual|November 2008||2008-11-30|December 2016|2016-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Recruitment||Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury|Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury|Completed||N/A|12|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-06-01 01:22:28.976197|2018-06-01 01:22:28.976197
NCT00830271|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-02-02|2009-01-26|2009-01-27|Estimate|||||||2015-02-02|2015-02-03|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Vicryl Plus and Monocryl Plus in Breast Surgery|Pilot Study of Vicryl Plus and Monocryl Plus in Breast Surgery|Completed||Phase 4|150|Anticipated|Cardiff and Vale University Health Board||2|||f||||t||||||||||2018-06-01 01:22:29.119097|2018-06-01 01:22:29.119097
NCT00830258|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-07-02||2009-09-09|2009-01-26|2009-01-27|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|April 2005||2005-04-30|September 2009|2009-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Pravastatin Sodium 80 mg Tablets Under Fasting Conditions|A Single-Dose, Comparative, Bioavailability Study of Two Formulations of Pravastatin Sodium 80 mg Tablets Under Fasting Conditions|Completed||Phase 1|60|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:29.191487|2018-06-01 01:22:29.191487
NCT00830245|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-24|||2011-07-25|2009-01-26|2009-01-27|Estimate|||||||2011-07-25|2011-07-26|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer||Terminated||Phase 2|20|Anticipated|Clinical Research Center for Solid Tumor, Korea||1||low accrual rate|f||||f||||||||||2018-06-01 01:22:29.491179|2018-06-01 01:22:29.491179
NCT00830232|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2013-03-08||2018-03-10|2009-01-26|2009-01-27|Estimate|2014-02-10|2014-03-27|Estimate||||2018-03-10|2018-04-06|Actual|December 2008||2008-12-31|March 2018|2018-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Effects of Carotid Stent Design on Cerebral Embolization|Effects of Carotid Stent Design on Cerebral Embolization|Completed||N/A|40|Actual|Dallas VA Medical Center|1. Small sample size 2.randomization did not eliminate all pretreatment differences between groups because of the small sample size.3.All patients underwent Stenting under ﬁlter embolic protection.|2|||f||||f||||||||||2018-06-01 01:22:29.569242|2018-06-01 01:22:29.569242
NCT00830219|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-07-06||2009-09-01|2009-01-26|2009-01-27|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-01|2009-09-15|Estimate|November 2004||2004-11-30|September 2009|2009-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions|The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions|Completed||Phase 1|46|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:29.818677|2018-06-01 01:22:29.818677
NCT00830206|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-18||2009-09-01|2009-01-26|2009-01-27|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions|A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Fasting Conditions|Completed||Phase 1|80|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:30.101057|2018-06-01 01:22:30.101057
NCT00829491|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2012-07-13|2009-01-26|2009-01-27|Estimate|||||||2012-07-13|2012-07-17|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Denver Health Cardiovascular Disease (CVD) Prevention Program|Denver Health Cardiovascular Prevention Program|Completed||N/A|340|Actual|Denver Health and Hospital Authority|||||f||||f||||||||||2018-06-01 01:22:44.255959|2018-06-01 01:22:44.255959
NCT00830193|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|August 2002||2002-08-31|January 2009|2009-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography|N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography: A Randomized Trial|Completed||Phase 2/Phase 3|45|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 01:22:31.411559|2018-06-01 01:22:31.411559
NCT00830180|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26||2014-03-03|2014-03-03|2009-01-26|2009-01-27|Estimate||||2014-03-03|2014-03-31|Estimate|2014-03-03|2014-03-31|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Open Label Extension In Cancer Patients|Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases|Completed||Phase 2|41|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 01:22:31.515455|2018-06-01 01:22:31.515455
NCT00830167|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2012-04-30||2012-04-30|2009-01-26|2009-01-27|Estimate|2012-04-30|2012-06-01|Estimate||||2012-04-30|2012-06-01|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia|Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin（CI-1008）In The Treatment Of Fibromyalgia|Completed||Phase 3|498|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 01:22:31.704077|2018-06-01 01:22:31.704077
NCT00830154|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-25||2012-08-20|2012-08-20|2009-01-26|2009-01-27|Estimate||||2012-08-20|2012-08-28|Estimate|2012-08-20|2012-08-28|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering|A 3 Arm, Double-blind, Placebo-controlled Parallel Group Study to Assess the Efficacy,Safety and Tolerability of Pagoclone for Adults With Stuttering|Completed||Phase 2/Phase 3|321|Actual|Endo Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:22:32.689411|2018-06-01 01:22:32.689411
NCT00830141|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-25|||2015-07-02|2009-01-26|2009-01-27|Estimate|||||||2015-07-02|2015-07-03|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|Ghrelin||Study of the Molecular Basis in the Pathophysiology of Food Intake and Growth in Children|Study of the Molecular Basis in the Pathophysiology of Food Intake and Growth in Children|Completed|||259|Actual|HaEmek Medical Center, Israel|||5||f||||f||||||Samples With DNA|"~     Genomic DNA will be isolated from peripheral blood by standard methods. The corresponding~     intron-exon boundaries of ghrelin and GHSR genes will be analyzed by direct sequencing using~     the ABI Prism 3100 DNA Analyzer~   "|||2018-06-01 01:22:32.759609|2018-06-01 01:22:32.759609
NCT00830128|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2012-01-23||2012-04-02|2009-01-26|2009-01-27|Estimate|2012-01-23|2012-02-14|Estimate||||2012-04-02|2012-04-04|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia|An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For The Treatment Of Fibromyalgia|Completed||Phase 3|106|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:22:32.849227|2018-06-01 01:22:32.849227
NCT00830115|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2010-07-20||2012-05-04|2009-01-26|2009-01-27|Estimate|2010-08-20|2010-09-15|Estimate||||2012-05-04|2012-05-08|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Observational|PANDA||Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders|Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders|Completed|||1045|Actual|Nycomed|||1||f||||f||||||||||2018-06-01 01:22:33.291001|2018-06-01 01:22:33.291001
NCT00830102|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26||2011-06-08|2011-06-08|2009-01-26|2009-01-27|Estimate||||2011-06-08|2011-06-23|Estimate|2011-06-08|2011-06-23|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients|A Randomized, Placebo-controlled, Double-blind, Six-way Crossover, Single-dose Exposure Study to Compare the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™100/10μg and 250/10μg) in a Single Inhaler (SkyePharma HFA MDI) With the Administration of Fluticasone (250μg) and Formoterol (12μg) Concurrently or Alone in Patients With Asthma|Completed||Phase 2|64|Actual|SkyePharma AG||6|||f||||f||||||||||2018-06-01 01:22:33.941359|2018-06-01 01:22:33.941359
NCT00830089|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-24|||2012-01-18|2009-01-26|2009-01-27|Estimate|||||||2012-01-18|2012-01-19|Estimate|September 2009||2009-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Trial of a Transversus Abdominis Plane (TAP) Block in Laparoscopic Colorectal Surgery|A Prospective Randomised Controlled Trial of the Efficacy of a Transversus Abdominis Plane Block in Laparoscopic Colorectal Surgery.|Completed||N/A|66|Actual|University of Nottingham||2|||f||||f||||||||||2018-06-01 01:22:34.032285|2018-06-01 01:22:34.032285
NCT00830076|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2011-09-29||2017-04-10|2009-01-26|2009-01-27|Estimate|2011-09-29|2011-11-03|Estimate||||2017-04-10|2017-05-15|Actual|December 2, 2008|Actual|2008-12-02|April 2017|2017-04-30|May 14, 2009|Actual|2009-05-14|April 30, 2009|Actual|2009-04-30||Interventional|||A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)|A Study to Assess the Effects of Co-Administration of Sitagliptin and Metformin on Incretin Hormone Concentrations|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:22:34.119421|2018-06-01 01:22:34.119421
NCT00830063|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23||2011-06-02|2011-06-07|2009-01-26|2009-01-27|Estimate||||2011-06-02|2011-06-07|Estimate|2011-06-07|2011-06-21|Estimate|May 2009||2009-05-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Tanezumab In Osteoarthritis Of The Knee (2)|A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee|Completed||Phase 3|848|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 01:22:34.46025|2018-06-01 01:22:34.46025
NCT00830050|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-03-10|2009-01-26|2009-01-27|Estimate|||||||2011-03-10|2011-03-14|Estimate|July 2010||2010-07-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients|A Study To Determine The Ability Of FMRI To Detect And Quantify The Effect Of Naproxen On Osteoarthritis Of The Hand|Completed||Early Phase 1|24|Actual|Pfizer||2|||f||||||||||||||2018-06-01 01:22:34.685064|2018-06-01 01:22:34.685064
NCT00830037|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2016-04-28||2016-06-09|2009-01-26|2009-01-27|Estimate|2016-06-09|2016-07-21|Estimate||||2016-06-09|2016-07-21|Estimate|August 2008||2008-08-31|June 2016|2016-06-30||||November 2014|Actual|2014-11-30||Interventional|||A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease|Pathobiology of Kidney Disease: Role of Iron|Terminated||Phase 4|136|Actual|Indiana University||2||"Terminated by the DSMB based on low chance of finding differences in mGFR slopes, but higher~   risk of serious adverse events in the IV iron group (aIRR = 1.60)"|f||||t||||||||||2018-06-01 01:22:34.79468|2018-06-01 01:22:34.79468
NCT00830024|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-18||2009-09-01|2009-01-26|2009-01-27|Estimate|2009-06-18|2009-07-21|Estimate||||2009-09-01|2009-09-11|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Non-fasting Conditions|Completed||Phase 1|36|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:35.294793|2018-06-01 01:22:35.294793
NCT00830011|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-24|||2011-07-27|2009-01-24|2009-01-27|Estimate|||||||2011-07-27|2011-07-28|Estimate|September 2004||2004-09-30|July 2011|2011-07-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Cognitive Behavioral Therapy for Painful Diabetic Neuropathy|Cognitive Behavioral Therapy for Painful Diabetic Neuropathy|Completed||N/A|80|Anticipated|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-06-01 01:22:35.571998|2018-06-01 01:22:35.571998
NCT00829998|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-07-06||2009-07-06|2009-01-26|2009-01-27|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|February 2004||2004-02-29|July 2009|2009-07-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Zaleplon 10mg Capsules Under Fasting Conditions|A Relative Bioavailability Study of Zaleplon 10mg Capsules Under Fasting Conditions|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:35.651803|2018-06-01 01:22:35.651803
NCT00829985|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2013-01-31||2017-02-14|2009-01-26|2009-01-27|Estimate|2013-01-31|2013-03-08|Estimate||||2017-02-14|2017-03-21|Actual|January 2009||2009-01-31|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)|A Biomarker-based Pilot Study of Cockroach Sublingual Immunotherapy in Cockroach Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-12)|Completed||Phase 1/Phase 2|54|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 01:22:35.920547|2018-06-01 01:22:35.920547
NCT00829972|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|November 2009|Anticipated|2009-11-30|September 2009|Anticipated|2009-09-30||Observational|||Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls|Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls|Unknown status|Recruiting||60|Anticipated|University of Chicago|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 01:22:36.230799|2018-06-01 01:22:36.230799
NCT00829959|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2016-08-03|2009-01-26|2009-01-27|Estimate|||||||2016-08-03|2016-08-04|Estimate|February 2009||2009-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)|Attitudes About Childbearing And Fertility In Women Seeking Genetic Testing For Inherited Breast And Ovarian Cancer Syndromes (HBOC)|Completed|||156|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:22:36.289612|2018-06-01 01:22:36.289612
NCT00829946|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Effects of Resistance Strength Training on Functional Capacity and Well Being of Anorexic Patients|Effects of Resistance Strength Training on Functional Capacity and Well Being of Anorexic Patients; A Randomized Controlled Trial|Completed||N/A|35|Actual|Universidad Europea de Madrid||1|||f||||t||||||||||2018-06-01 01:22:36.443029|2018-06-01 01:22:36.443029
NCT00829933|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2015-01-15||2015-02-03|2009-01-26|2009-01-27|Estimate|2015-01-15|2015-01-26|Estimate||||2015-02-03|2015-02-23|Estimate|March 2007||2007-03-31|February 2015|2015-02-28|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional||Baseline Analysis Population is based on Full Analysis Set. FAS defined as all subjects enrolled in study, but excluded those who had GCP violations, who did not receive any dose of study drug, or who did not have atrial fibrillation confirmed by ECG performed at least twice within a 1-week or longer interval within 1 year before registration|Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation|A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation|Completed||Phase 2|536|Actual|Daiichi Sankyo, Inc.||4|||f||||t||||||||||2018-06-01 01:22:36.525253|2018-06-01 01:22:36.525253
NCT00829920|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-25|||2013-06-21|2009-01-26|2009-01-27|Estimate|||||||2013-06-21|2013-06-25|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Observational|||The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease|The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease|Completed|||44|Actual|University of Colorado, Denver|||1||f||||t||||||Samples With DNA|"~     Serum from patients undergoing treatment for muscle-invasive or metastatic bladder cancer who~     are planning for surgical bladder removal or chemotherapy will be acquired.~   "|||2018-06-01 01:22:37.103975|2018-06-01 01:22:37.103975
NCT00829907|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2009-11-23|2009-01-26|2009-01-27|Estimate|||||||2009-11-23|2009-11-25|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A PET Study With ORM-12741|Effect of ORM-12741 on Receptor Occupancy Studied by Positron Emission Tomography; an Open, Single Dose, Dose Ranging Study in Healthy Males|Completed||Phase 1|26|Actual|Orion Corporation, Orion Pharma||1|||f||||t||||||||||2018-06-01 01:22:37.176421|2018-06-01 01:22:37.176421
NCT00829894|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|June 2001||2001-06-30|January 2009|2009-01-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Risperidone 1 mg Tablets Dosed in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Risperidone 1 mg Tablets and Risperdal® 1 mg Tablets Administered as a 1 x 1 mg Tablets in Subjects Under Fed Conditions|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 01:22:37.264396|2018-06-01 01:22:37.264396
NCT00829881|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2013-09-25|2009-01-26|2009-01-27|Estimate|||||||2013-09-25|2013-09-26|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder|Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder|Completed||Phase 1|16|Actual|P2D, Inc.||2|||f||||f||||||||||2018-06-01 01:22:37.3546|2018-06-01 01:22:37.3546
NCT00829868|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-07-06||2009-07-06|2009-01-26|2009-01-27|Estimate|2009-07-06|2009-08-18|Estimate||||2009-07-06|2009-08-18|Estimate|February 2004||2004-02-29|July 2009|2009-07-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Zaleplon 10 mg Capsules Under Non-Fasting Conditions|A Relative Bioavailability Study of Zaleplon 10 mg Capsules Under Non-Fasting Conditions|Completed||Phase 1|42|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:37.455511|2018-06-01 01:22:37.455511
NCT00829842|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|February 2006|Actual|2006-02-28|||||Interventional|||Oral Hygiene With Chlorhexidine and Incidence of Ventilator-Associated Pneumonia in Children Submitted to Heart Surgery|Evaluation of Oral Hygiene With 0.12% Chlorhexidine Antiseptic Solution on the Incidence of Nosocomial Pneumonia and Ventilator-Associated Pneumonia in Children Submitted to Heart Surgery|Completed||Phase 3|160|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:22:37.815856|2018-06-01 01:22:37.815856
NCT00829829|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2017-03-20|2011-01-05|2017-03-20|2009-01-26|2009-01-27|Estimate|2017-03-20|2017-04-28|Actual|2011-01-05|2011-01-10|Estimate|2017-03-20|2017-04-28|Actual|February 2009||2009-02-28|March 2017|2017-03-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|PRE-SURGE1|Baseline population included full analysis set (FAS) comprising of all randomized participants who received any study medication and was based on treatment allocated by Interactive voice response system (IVRS) at randomization (as randomized).|PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy|Completed||Phase 3|241|Actual|Regeneron Pharmaceuticals||3|||f||||||||||||||2018-06-01 01:22:37.920148|2018-06-01 01:22:37.920148
NCT00829816|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2015-11-06|2009-01-23|2009-01-27|Estimate|||||||2015-11-06|2015-11-10|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|August 2010|Actual|2010-08-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil|A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2)|Completed||Phase 1|46|Actual|Medivation, Inc.||2|||f||||f||||||||||2018-06-01 01:22:38.521486|2018-06-01 01:22:38.521486
NCT00829803|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2010-06-22|2009-01-26|2009-01-27|Estimate|||||||2010-06-22|2010-06-23|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|Precision GA||A Study to Assess Indeics of SNAP vs VISTA on Surgical Patients Undergoing General Anesthesia|A Prospective Randomized Double Blinded Study Assessing Indeics of SNAP vs VISTA on Surgical Patients Undergoing General Anesthesia|Unknown status|Recruiting|Phase 4|40|Anticipated|Stryker Instruments||2|||f||||f||||||||||2018-06-01 01:22:38.580844|2018-06-01 01:22:38.580844
NCT00829790|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-30||2009-08-14|2009-01-26|2009-01-27|Estimate|2009-06-30|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study of Doxycycline Monohydrate 25 mg as a 5mL Oral Suspension Under Fed Conditions|Completed||Phase 1|30|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 01:22:38.650069|2018-06-01 01:22:38.650069
NCT00829777|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-09-14|2009-01-26|2009-01-27|Estimate|||||||2009-09-14|2009-09-16|Estimate|March 2009||2009-03-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|AIKO-150||Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects|A Phase-I, Two-Stage, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Trial of Low Doses of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects.|Completed||Phase 1|8|Anticipated|California Pacific Medical Center Research Institute|||||f||||f||||||||||2018-06-01 01:22:38.954268|2018-06-01 01:22:38.954268
NCT00829764|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-30||2009-08-14|2009-01-26|2009-01-27|Estimate|2009-06-30|2009-08-04|Estimate||||2009-08-14|2009-08-20|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study of Doxycycline Monohydrate 25 mg as a 5 mL Oral Suspension Under Fasting Conditions|Completed||Phase 1|30|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 01:22:39.038647|2018-06-01 01:22:39.038647
NCT00829751|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2013-05-31|2009-01-26|2009-01-27|Estimate|||||||2013-05-31|2013-06-04|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Physiological Consequence of Silicone-hydrogel Care-solution Bio-incompatibility|The Physiological Consequence of Silicone-hydrogel Care-solution Bio-incompatibility|Completed||N/A|26|Actual|Southern California College of Optometry||2|||f||||f||||||||||2018-06-01 01:22:39.291|2018-06-01 01:22:39.291
NCT00829738|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2010-09-01||2012-05-04|2009-01-26|2009-01-27|Estimate|2010-09-01|2010-09-24|Estimate||||2012-05-04|2012-05-08|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Observational|PARADE||Efficacy of Pantoprazole 20/40 mg Once Daily (od) in Patients Older Than 12 Years Who Have Gastrointestinal Symptoms of Reflux Disease|Pantoprazole 20/40 mg in Reflux-Associated Complaints With Focus on Gastrointestinal Symptoms|Completed|||4188|Actual|Nycomed|||1||f||||f||||||||||2018-06-01 01:22:39.438769|2018-06-01 01:22:39.438769
NCT00829725|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-25|||2010-09-05|2009-01-26|2009-01-27|Estimate|||||||2010-09-05|2010-09-08|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Comparison Study of 3-4-screws-internal Fixation With Multi-screw-system Targon FN for Femoral Neck Fracture|Randomized, Prospective, Multi-center, Comparison Study of 3-4-screws-internal Fixation With Multi-screw-system Targon FN for Femoral Neck Fracture|Unknown status|Recruiting|Phase 4|300|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 01:22:41.015647|2018-06-01 01:22:41.015647
NCT00829712|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-22||2009-08-14|2009-01-26|2009-01-27|Estimate|2009-06-22|2009-08-04|Estimate||||2009-08-14|2009-08-19|Estimate|June 2004||2004-06-30|August 2009|2009-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Dexmethylphenidate Hydrochloride, (10 mg), Compared to and Equivalent Dose of a Commercially Available Reference Drug Product (Focalin®, Novartis Pharmaceuticals Corporation) in 24 Fasted, Healthy, Adult Subjects|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:41.114143|2018-06-01 01:22:41.114143
NCT00829699|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2017-02-09|2009-01-26|2009-01-27|Estimate|||||||2017-02-09|2017-02-10|Actual|July 2009||2009-07-31|February 2017|2017-02-28|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|||Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus|Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus, Question 3|Completed||Early Phase 1|31|Actual|University of Maryland||4|||f||||t||||||||||2018-06-01 01:22:41.427208|2018-06-01 01:22:41.427208
NCT00829686|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-05||2017-05-10|2009-01-26|2009-01-27|Estimate|2009-07-27|2009-07-28|Estimate||||2017-05-10|2017-06-09|Actual|June 2008||2008-06-30|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection|Prospective Randomized Controlled Trial of Antibiotic Treatment for Uncomplicated Skin Abscess in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection|Completed||N/A|31|Actual|Wilford Hall Medical Center||2|||f||||f||||||||||2018-06-01 01:22:41.524107|2018-06-01 01:22:41.524107
NCT00829673|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-22||2009-08-14|2009-01-26|2009-01-27|Estimate|2009-06-22|2009-08-04|Estimate||||2009-08-14|2009-08-19|Estimate|June 2004||2004-06-30|August 2009|2009-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Dexmethylphenidate Hydrochloride, (10 mg), Compared to an Equivalent Dose of a Commercially Available Reference Product (Focalin®, Novartis Pharmaceuticals Corporation) in 24 Fed, Healthy, Adult Subjects|Completed||Phase 1|24|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:41.817313|2018-06-01 01:22:41.817313
NCT00829660|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2017-07-21|2009-01-26|2009-01-27|Estimate|||||||2017-07-21|2017-07-25|Actual|February 17, 2009|Actual|2009-02-17|July 2017|2017-07-31|April 18, 2017|Actual|2017-04-18|April 11, 2017|Actual|2017-04-11||Interventional|ACE||Acarbose Cardiovascular Evaluation Trial|A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance|Completed||Phase 4|6526|Actual|University of Oxford||2|||f||||t||||||||Undecided||2018-06-01 01:22:42.202237|2018-06-01 01:22:42.202237
NCT00829647|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2017-07-14|2009-01-26|2009-01-27|Estimate|||||||2017-07-14|2017-07-19|Actual|January 2009||2009-01-31|April 2016|2016-04-30||||December 2009|Actual|2009-12-31||Interventional|||A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia|A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia|Withdrawn||Phase 1/Phase 2|0|Actual|Scripps Health||1||Unable to enroll|f||||f||||||||No|There is no data to share.|2018-06-01 01:22:42.504609|2018-06-01 01:22:42.504609
NCT00829634|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2013-05-29|2009-01-26|2009-01-27|Estimate|||||||2013-05-29|2013-05-31|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation||Completed||N/A|12|Actual|California Pacific Medical Center Research Institute||1|||f||||||||||||||2018-06-01 01:22:42.575506|2018-06-01 01:22:42.575506
NCT00829621|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2014-01-01||2016-10-02|2009-01-26|2009-01-27|Estimate|2014-01-01|2014-02-21|Estimate||||2016-10-02|2016-11-07|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|May 2012|Actual|2012-05-31||Interventional|||Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)|Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)|Completed||N/A|20|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 01:22:42.64795|2018-06-01 01:22:42.64795
NCT00829608|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2016-10-03|2009-01-26|2009-01-27|Estimate|||||||2016-10-03|2016-10-05|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis|Investigator Initiated Study of Effects of Progression of Recurrent Respiratory Papillomatosis in Patients After They Are Given Human Papillomavirus Quadrivalent Vaccine|Withdrawn||Early Phase 1|0|Actual|University of Missouri-Columbia||1||investigator has left the institution|f||||f||||||||No||2018-06-01 01:22:42.982666|2018-06-01 01:22:42.982666
NCT00829595|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|May 2005||2005-05-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease|Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease|Completed||N/A|69|Actual|Cedars-Sinai Medical Center||3|||f||||f||||||||||2018-06-01 01:22:43.068894|2018-06-01 01:22:43.068894
NCT00829582|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2017-11-09|2009-01-26|2009-01-27|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2009||2009-02-28|January 2010|2010-01-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers|Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (AnthimTM) [Elusys Protocol Number AH-102]|Completed||Phase 1|45|Anticipated|Elusys Therapeutics||2|||f||||t||||||||||2018-06-01 01:22:43.141258|2018-06-01 01:22:43.141258
NCT00829569|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2011-11-03|2009-01-26|2009-01-27|Estimate|||||||2011-11-03|2011-11-04|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|May 2004|Actual|2004-05-31||Interventional|||n-3 Fatty Acid Infusion and Type 2 Diabetes|Effects of Marine n-3 Fatty Acid Infusion on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes|Completed||N/A|11|Actual|St. Olavs Hospital||1|||f||||f||||||||||2018-06-01 01:22:43.24303|2018-06-01 01:22:43.24303
NCT00829556|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-12-18|2009-01-26|2009-01-27|Estimate|||||||2009-12-18|2009-12-21|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Efficacy of InteguSeal for Surgical Skin Preparation in Patients Undergoing Total Joint Replacement|Single-Center, Randomized Trial to Study the Efficacy of InteguSeal for Surgical Skin Preparation in Patients Undergoing|Completed||N/A|160|Anticipated|Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-06-01 01:22:43.330115|2018-06-01 01:22:43.330115
NCT00829543|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-02-02|2009-01-26|2009-01-27|Estimate|||||||2009-02-02|2009-02-03|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|February 2009|Anticipated|2009-02-28|January 2007|Actual|2007-01-31||Interventional|||Unguided Sacroiliac Injection: Effect on Refractory Buttock Pain in Patients With Spondyloarthropathies|Guide-Free Sacroiliac Injection in Spondyloarthropathies|Unknown status|Enrolling by invitation|Early Phase 1|35|Anticipated|Tabriz University||1|||f||||t||||||||||2018-06-01 01:22:43.391542|2018-06-01 01:22:43.391542
NCT00829530|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2009-07-02||2009-09-01|2009-01-26|2009-01-27|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Ramipril 10 mg Capsule in Healthy Subjects Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as 1 x 10 mg Capsule in Healthy Subjects Under Fed Conditions|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 01:22:43.547386|2018-06-01 01:22:43.547386
NCT00829517|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2012-02-15|2009-01-23|2009-01-27|Estimate|||||||2012-02-15|2012-02-17|Estimate|January 2011||2011-01-31|February 2012|2012-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Computer-Assisted Provision of Reproductive Health Care|Computer-Assisted Provision of Reproductive Health Care|Completed||N/A|814|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:22:43.861195|2018-06-01 01:22:43.861195
NCT00829504|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-07-06||2009-09-01|2009-01-26|2009-01-27|Estimate|2009-07-06|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|October 2004||2004-10-31|September 2009|2009-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Ropinirole 0.25 mg Tablets Under Fasting Conditions|The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fasting Conditions.|Completed||Phase 1|44|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:43.954103|2018-06-01 01:22:43.954103
NCT00829478|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-24|||2012-03-16|2009-01-26|2009-01-27|Estimate|||||||2012-03-16|2012-03-20|Estimate|October 2008||2008-10-31|March 2012|2012-03-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|AFIB||Improving the Quality of Care for Atrial Fibrillation by Promoting Patient-Centered Decision Making|Improving Quality of Care for Atrial Fibrillation by Promoting Patient-Centered Decision Making|Completed||Phase 1|135|Actual|VA Connecticut Healthcare System||2|||f||||t||||||||||2018-06-01 01:22:44.341841|2018-06-01 01:22:44.341841
NCT00829465|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2016-03-30|2009-01-26|2009-01-27|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma|Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma|Completed||Phase 4|400|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:22:44.420839|2018-06-01 01:22:44.420839
NCT00829452|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2009-07-02||2009-09-01|2009-01-26|2009-01-27|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions|Randomized, 2-Way Crossover Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as the Content of 1 x 10 mg Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 01:22:44.515322|2018-06-01 01:22:44.515322
NCT00829439|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2016-08-05||2016-09-29|2009-01-26|2009-01-27|Estimate|2016-09-29|2016-11-21|Estimate||||2016-09-29|2016-11-21|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome|A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome|Completed||Phase 1|16|Actual|Boston Children’s Hospital||1|||f||||t||||||||Undecided||2018-06-01 01:22:44.862125|2018-06-01 01:22:44.862125
NCT00829426|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-06-18||2009-06-18|2009-01-26|2009-01-27|Estimate|2009-06-18|2009-07-21|Estimate||||2009-06-18|2009-07-21|Estimate|June 2005||2005-06-30|June 2009|2009-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions|A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Fasting Conditions|Completed||Phase 1|32|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:45.014938|2018-06-01 01:22:45.014938
NCT00829413|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26||2014-08-18|2014-08-19|2009-01-26|2009-01-27|Estimate||||2014-08-19|2014-08-21|Estimate|2014-08-19|2014-08-21|Estimate|June 2010||2010-06-30|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization|Characterization Of Focal Liver Lesions With Sonovue®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Unenhanced Ultrasound Imaging Using Histology Or Combined Imaging/Clinical Data As Truth Standard|Completed||Phase 3|353|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-06-01 01:22:45.260561|2018-06-01 01:22:45.260561
NCT00829400|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-24|||2016-12-19|2009-01-26|2009-01-27|Estimate|||||||2016-12-19|2016-12-21|Estimate|May 2008||2008-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cognitive Training to Enhance VA Work Program Outcomes|Cognitive Training to Enhance VA Work Program Outcomes|Completed||Phase 3|77|Actual|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-06-01 01:22:45.332838|2018-06-01 01:22:45.332838
NCT00829387|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-24|2015-01-02||2015-06-01|2009-01-26|2009-01-27|Estimate|2015-06-01|2015-06-18|Estimate||||2015-06-01|2015-06-18|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Cognitive Behavioral Therapy for Diabetic Neuropathic Pain|Cognitive Behavioral Therapy for Diabetic Peripheral Neuropathic Pain|Completed||N/A|47|Actual|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-06-01 01:22:45.406192|2018-06-01 01:22:45.406192
NCT00829374|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23||2016-09-24|2016-09-24|2009-01-23|2009-01-27|Estimate||||2016-09-24|2016-09-27|Estimate|2016-09-24|2016-09-27|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CONCERT||Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil|CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil|Completed||Phase 3|1003|Actual|Medivation, Inc.||3|||f||||t||||||||||2018-06-01 01:22:45.845214|2018-06-01 01:22:45.845214
NCT00829361|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2015-11-23|2009-01-26|2009-01-27|Estimate|||||||2015-11-23|2015-11-25|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|STARR||Stroke Telemedicine for Arizona Rural Residents Trial|Stroke Telemedicine for Arizona Rural Residents Trial|Completed||N/A|447|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 01:22:46.049103|2018-06-01 01:22:46.049103
NCT00829348|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-12-29|2009-01-26|2009-01-27|Estimate|||||||2009-12-29|2009-12-30|Estimate|August 2006||2006-08-31|December 2009|2009-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Short Message Service (SMS) Impact on Patient Compliance Receiving Long Term Lipid Lowering Therapy With Statins|Short Massages Service (SMS) Impact on Patient Compliance Receiving Long Term Lipid Lowering Therapy With Statins.|Completed||N/A|120|Actual|Hillel Yaffe Medical Center||2|||f||||f||||||||||2018-06-01 01:22:46.175313|2018-06-01 01:22:46.175313
NCT00829335|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2009-01-26|2009-01-26|2009-01-27|Estimate|||||||2009-01-26|2009-01-27|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Anatomical Resection of the Liver for Hepatocellular Carcinoma: a New Ultrasound Guided Approach|Anatomical Segmental and Subsegmental Resection of the Liver for Hepatocellular Carcinoma: a New Approach by Means of Ultrasound-Guided Vessel Compression|Completed|||30|Actual|University of Milan|||1||f||||t||||||||||2018-06-01 01:22:46.254392|2018-06-01 01:22:46.254392
NCT00829322|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2013-08-16|2009-01-26|2009-01-27|Estimate|||||||2013-08-16|2013-08-19|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Modafinil for the Treatment of Fatigue in Lung Cancer V9.0|Modafinil for the Treatment of Fatigue in Lung Cancer: a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial|Completed||Phase 4|208|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 01:22:46.333428|2018-06-01 01:22:46.333428
NCT00829309|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2009-07-02||2009-09-09|2009-01-26|2009-01-27|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-09|2009-09-15|Estimate|March 2005||2005-03-31|September 2009|2009-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions|A Relative Bioavailability Study of 80 mg Pravastatin Sodium Tablets Under Non-Fasting Conditions|Completed||Phase 1|16|Actual|Teva Pharmaceuticals USA||2|||f||||f||||||||||2018-06-01 01:22:46.433817|2018-06-01 01:22:46.433817
NCT00829296|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2014-08-04||2016-01-08|2009-01-26|2009-01-27|Estimate|2014-10-29|2014-11-05|Estimate||||2016-01-08|2016-02-05|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|EFFORT||Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries|The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetics|Completed||Phase 2/Phase 3|70|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:22:46.723991|2018-06-01 01:22:46.723991
NCT00829283|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|2015-10-27||2015-12-28|2009-01-26|2009-01-27|Estimate|2015-12-28|2016-02-01|Estimate||||2015-12-28|2016-02-01|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care|Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care|Completed||N/A|191|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:22:46.999212|2018-06-01 01:22:46.999212
NCT00829270|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2012-12-17|2009-01-26|2009-01-27|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2009||2009-03-31|January 2009|2009-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Economic and Medical Evaluation of the Whole Mitochondrial DNA Screening by Surveyor and Mitochips Techniques|Economic and Medical Evaluation of the Whole Mitochondrial DNA Screening by Surveyor and Mitochips Techniques.|Completed|||550|Actual|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||Samples With DNA|"~     patients presenting clinical features of mitochondrial diseases~   "|||2018-06-01 01:22:47.250102|2018-06-01 01:22:47.250102
NCT00829257|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-26|||2012-06-11|2009-01-26|2009-01-27|Estimate|||||||2012-06-11|2012-06-12|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PAW01||Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma|A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to Fluticasone/Salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma|Completed||Phase 4|15|Actual|University of Dundee||2|||f||||t||||||||||2018-06-01 01:22:47.308499|2018-06-01 01:22:47.308499
NCT00829244|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2012-06-01||2014-01-20|2009-01-23|2009-01-26|Estimate|2012-08-07|2012-09-07|Estimate||||2014-01-20|2014-02-13|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||CONSORT Randomized Controlled Trial in Assisted Reproductive Technology|A Phase IV Prospective, Multicenter, Randomized, Open-label Trial to Assess the Efficacy and Safety of GONAL f® at a Dose Based on Subject Baseline Characteristics Determined According to the CONSORT Calculator Compared With a Standard Dose of GONAL f® 150 IU Per Day for Ovarian Stimulation in Women Undergoing Assisted Reproductive Technology (ART)|Completed||Phase 4|200|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 01:22:47.399308|2018-06-01 01:22:47.399308
NCT00829231|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2014-10-31|2009-01-23|2009-01-26|Estimate|||||||2014-10-31|2014-11-03|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Hepatic Impairment Study|Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006)|Completed||Phase 1|45|Actual|Bayer||3|||f||||f||||||||||2018-06-01 01:22:47.953249|2018-06-01 01:22:47.953249
NCT00829218|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2013-12-21|2009-01-23|2009-01-26|Estimate|||||||2013-12-21|2013-12-24|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)|A Clinical Trial Examining the Effects of the Food Additive Glutamate on Irritable Bowel Syndrome and Fibromyalgia|Completed||N/A|60|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 01:22:48.039532|2018-06-01 01:22:48.039532
NCT00829205|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2013-08-23|2009-01-23|2009-01-26|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2009||2009-01-31|July 2009|2009-07-31||||||||Interventional|||Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment|A Phase I/II Study of Methylselenocysteine (MSC) in Combination With Immunochemotherapy (R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Withdrawn||Phase 1/Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:22:48.11515|2018-06-01 01:22:48.11515
NCT00829192|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2010-12-03|2009-01-23|2009-01-26|Estimate|||||||2010-12-03|2010-12-06|Estimate|November 2007||2007-11-30|December 2010|2010-12-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Phase II AK Study in Organ Transplant Patients|A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|Clinuvel Pharmaceuticals Limited||2|||f||||t||||||||||2018-06-01 01:22:48.219432|2018-06-01 01:22:48.219432
NCT00829179|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2009-02-22||2016-01-12|2009-01-23|2009-01-26|Estimate|2009-09-17|2009-10-21|Estimate||||2016-01-12|2016-02-08|Estimate|October 2002||2002-10-31|January 2016|2016-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma|Role of RhuMab-E25 in Reducing Exhaled NO in Allergic Asthma|Completed||Phase 3|20|Actual|Duke University|Pilot study with small sample size.||||f||||f||||||||||2018-06-01 01:22:48.292436|2018-06-01 01:22:48.292436
NCT00829166|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2013-02-22||2016-09-10|2009-01-22|2009-01-26|Estimate|2013-04-22|2013-04-23|Estimate||||2016-09-10|2016-10-31|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|September 2015|Actual|2015-09-30|July 2012|Actual|2012-07-31||Interventional|EMILIA|Intent-to-treat (ITT) population included all randomized participants on the basis of the treatment assigned at randomization.|A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer|A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy|Completed||Phase 3|991|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-06-01 01:22:48.487931|2018-06-01 01:22:48.487931
NCT00829153|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2010-03-15|2009-01-23|2009-01-26|Estimate|||||||2010-03-15|2010-03-16|Estimate|January 2007||2007-01-31|March 2010|2010-03-31||||August 2010|Anticipated|2010-08-31||Interventional|||U Clip Study - Study to Compare U Clip Anastomosis With Conventional Continuous Prolene Anastomosis|A Pilot, Randomised, Blinded Study to Compare U Clip Anastomosis With Conventional Continuous Prolene Anastomosis for Creating of Autologous Arteriovenous Fistulae|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Royal Hobart Hospital||2|||f||||f||||||||||2018-06-01 01:22:50.293339|2018-06-01 01:22:50.293339
NCT00827970|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-01-22|2009-01-22|2009-01-23|Estimate|||||||2009-01-22|2009-01-23|Estimate|October 1997||1997-10-31|January 2009|2009-01-31|August 2007|Actual|2007-08-31|February 1998|Actual|1998-02-28||Interventional|||Randomized Population-Based Study on Chlamydia Trachomatis Screening|Populationbased Screening for Urogenital Chlamydia Trachomatis Infections by Use of Home-Obtained and Mailed Samples: A Randomized Study|Completed||N/A|30000|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 01:23:14.962684|2018-06-01 01:23:14.962684
NCT00829140|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2010-11-01|2009-01-23|2009-01-26|Estimate|||||||2010-11-01|2010-11-02|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|TULIP||To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake|A 56-Day , Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake in Overweight and Obese Patients (TULIP)|Completed||Phase 1|56|Anticipated|Arena Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:22:50.364988|2018-06-01 01:22:50.364988
NCT00829127|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2011-08-24|2009-01-23|2009-01-26|Estimate|||||||2011-08-24|2011-08-25|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers|Withdrawn||Phase 1|27|Anticipated|AstraZeneca||2||Due to termination of study D3801C00001, due to reports of turbid urine.|f||||f||||||||||2018-06-01 01:22:50.518184|2018-06-01 01:22:50.518184
NCT00829114|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2011-10-28|2009-01-23|2009-01-26|Estimate|||||||2011-10-28|2011-10-31|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Interactions Between Antiretrovirals (ARVs) and Combined Oral Contraceptives (COCs)|Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills|Completed||Phase 4|370|Anticipated|FHI 360||2|||f||||f||||||||||2018-06-01 01:22:50.581959|2018-06-01 01:22:50.581959
NCT00829101|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2014-07-01|2009-01-23|2009-01-26|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|APCLP||Articulation and Phonology in Children With Unilateral Cleft Lip and Palate|Articulatory and Phonological Competence at 3 and 5 Years of Age in Children With Unilateral Cleft Lip and Palate Who Have Undergone Different Methods of Primary Palatal Surgery|Completed|||30|Actual|Region Skane|||3||f||||f||||||||||2018-06-01 01:22:50.658999|2018-06-01 01:22:50.658999
NCT00829088|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-02-24|2009-01-23|2009-01-26|Estimate|||||||2009-02-24|2009-02-25|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|||||Interventional|||Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066|An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects|Completed||Phase 1|6|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:22:50.723958|2018-06-01 01:22:50.723958
NCT00829075|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-01-23|2009-01-23|2009-01-26|Estimate|||||||2009-01-23|2009-01-26|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|December 2006|Actual|2006-12-31|||||Interventional|||Impact of Three Different Gonadotrophin Regimes on Egg Donation Program|A Prospective, Randomized, Controlled Trial Comparing Three Different Gonadotrophin Regimens in Oocyte Donors: Ovarian Response and IVF Outcome|Completed||Phase 4|||Instituto Valenciano de Infertilidad, IVI VALENCIA||3|||f||||f||||||||||2018-06-01 01:22:50.789335|2018-06-01 01:22:50.789335
NCT00829062|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2010-07-29|2009-01-22|2009-01-26|Estimate|||||||2010-07-29|2010-07-30|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|July 2010|Anticipated|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Expanding Coverage of Continuous Subcutaneous Insulin Infusion in Pediatric Patients With Diabetes|Presenting Evidence Based Practice to an Insurance Provider to Expand Coverage of Continuous Subcutaneous Insulin Infusion (CSII) in Pediatric Patients With Diabetes|Withdrawn||N/A|0|Actual|Children's Mercy Hospital Kansas City||1||No participants met inclusion criteria.|f||||t||||||||||2018-06-01 01:22:50.847025|2018-06-01 01:22:50.847025
NCT00829049|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2011-09-22||2012-08-20|2009-01-22|2009-01-26|Estimate|2012-08-20|2012-09-12|Estimate||||2012-08-20|2012-09-12|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris||Terminated||Phase 4|165|Actual|Allergan|Study enrollment was terminated due to company decision before the target enrollment of 220 patients was reached.|2||"Study enrollment was terminated due to company decision before the target enrollment of 220~   patients was reached."|f||||f||||||||||2018-06-01 01:22:50.918465|2018-06-01 01:22:50.918465
NCT00829036|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2014-02-18||2014-02-18|2009-01-22|2009-01-26|Estimate|2014-02-18|2014-04-02|Estimate||||2014-02-18|2014-04-02|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Using Repeated Measures ANOVA for the 24 participants, and assuming a minimum correlation between repeated measures of .7, our analyses will be sensitive to a between factor effect size of f=.33, with power set to .80 and alpha level set to .05. This should be sufficient to reveal significant differences between baseline and device use.|Wayfinding Information Access System for People With Vision Loss|Wayfinding Information Access System for People With Vision Loss|Completed||N/A|24|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:22:51.111811|2018-06-01 01:22:51.111811
NCT00829023|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-23|2009-01-23|2009-01-26|Estimate|||||||2009-01-23|2009-01-26|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of Surgical Preparation Solutions in Shoulder Surgery|Efficacy of Surgical Preparation Solutions in Shoulder Surgery|Completed||N/A|150|Actual|Northwestern University||1|||f||||f||||||||||2018-06-01 01:22:51.269559|2018-06-01 01:22:51.269559
NCT00829010|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2012-05-08||2017-10-23|2009-01-22|2009-01-26|Estimate|2012-05-31|2012-07-06|Estimate||||2017-10-23|2017-11-27|Actual|February 17, 2009||2009-02-17|October 2017|2017-10-31|June 27, 2012|Actual|2012-06-27|June 13, 2011|Actual|2011-06-13||Interventional|||Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.|Primary and Booster Vaccination Course in Human Immunodeficiency Virus (HIV) Infected Infants, HIV Exposed Uninfected Infants and Unexposed Uninfected Infants Receiving the Pneumococcal Vaccine GSK 1024850A.|Completed||Phase 3|489|Actual|GlaxoSmithKline|The study aimed to enrol 100 HIV+/+ subjects but succeeded to enrol 83 mainly due to decrease of vertical HIV transmission in South Africa. Some subjects, HIV+ at screening, tested negative at subsequent HIV testing, were reallocated in HIV+/-Group.|5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:22:51.397939|2018-06-01 01:22:51.397939
NCT00828997|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2017-09-14|2009-01-23|2009-01-26|Estimate|||||||2017-09-14|2017-09-15|Actual|August 2008||2008-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PVA||Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar®|Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar®|Enrolling by invitation||Phase 4|500|Anticipated|Region Skane||1|||f||||t||||||||||2018-06-01 01:22:55.491305|2018-06-01 01:22:55.491305
NCT00828984|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2016-11-18||2017-03-22|2009-01-23|2009-01-26|Estimate|2016-11-18|2017-01-19|Estimate||||2017-03-22|2017-04-18|Actual|October 2009||2009-10-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer|Polyethylene Glycol for ACF Reduction and Biomarker Modulation in Individuals With CRC Risk|Completed||Phase 2|87|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 01:22:55.708687|2018-06-01 01:22:55.708687
NCT00828971|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2014-12-05|2009-01-23|2009-01-26|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|MERAK||A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs|A Prospective, Randomized, Open Label, Active Comparator, Multicenter, National Trial to Compare the Efficacy and Safety of Sequential IV/PO Moxifloxacin 400 mg Once Daily Versus IV Amoxicillin/Clavulanate 2,0/0,2 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanate 875/125 mg Every 8 Hours in the Treatment of Adult Subjects With Complicated Skin and Skin Structure Infections|Completed||Phase 3|16|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:22:56.361435|2018-06-01 01:22:56.361435
NCT00828958|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2011-05-17|2009-01-22|2009-01-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 2006||2006-02-28|March 2010|2010-03-31|September 2006|Actual|2006-09-30|||||Interventional|||Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.|Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia.|Completed||Phase 3|53|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:22:56.499423|2018-06-01 01:22:56.499423
NCT00828945|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2012-02-16||2012-02-16|2009-01-23|2009-01-26|Estimate|2012-02-16|2012-03-22|Estimate||||2012-02-16|2012-03-22|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|COLL||Compliance With Treatment For Patients With Hyperlipidemia|A Non-Randomized, Non-Controlled, Open Study In Order To Document The Compliance With Treatment, According To Clinical Praxis And National Guidelines For Patients With Hyperlipidemia. COLL: Control Of Lipid Lowering|Completed|||259|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:22:56.576812|2018-06-01 01:22:56.576812
NCT00828932|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-07-27|2009-01-23|2009-01-26|Estimate|||||||2009-07-27|2009-07-29|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment|An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment|Completed||Phase 1|24|Anticipated|Arena Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:22:56.805357|2018-06-01 01:22:56.805357
NCT00828919|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2018-04-10|2009-01-23|2009-01-26|Estimate|||||||2018-04-10|2018-04-11|Actual|March 2003|Actual|2003-03-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials|Continuing Access To The Tyrosine Kinase Inhibitor Of Vegfr 2, Ag 013736 (a406) For Patients Previously Receiving Ag 013736 In Clinical Trials|Active, not recruiting||N/A|52|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:22:56.969654|2018-06-01 01:22:56.969654
NCT00828906|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2012-09-18|2009-01-23|2009-01-26|Estimate|||||||2012-09-18|2012-09-20|Estimate|February 2009||2009-02-28|July 2012|2012-07-31||||November 2009|Actual|2009-11-30||Interventional|||DuoTrav® Eye Drops As Replacement Therapy Program||Completed||Phase 4|128|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:22:57.087201|2018-06-01 01:22:57.087201
NCT00828893|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2012-02-17|2009-01-23|2009-01-26|Estimate|||||||2012-02-17|2012-02-20|Estimate|October 2009||2009-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|CT-Nav||Navigation Guidance Gestures Carried Out Under CT|Interest of the Use of a Navigation Guidance Gestures Carried Out Under CT|Completed||Phase 2/Phase 3|120|Actual|University Hospital, Grenoble|||||f||||t||||||||||2018-06-01 01:22:57.152113|2018-06-01 01:22:57.152113
NCT00828880|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-01-23|2009-01-23|2009-01-26|Estimate|||||||2009-01-23|2009-01-26|Estimate||||January 2009|2009-01-31||||||||Observational|||Restoration of Disc Height Reduces Chronic Low Back Pain|Restoration of Disk Height Through Non-Invasive Spinal Decompression is Associated With Decreased Discogenic Low-Back Pain: A Retrospective Cohort Study|Completed|||||NEMA Research, Inc.|||1||f||||f||||||||||2018-06-01 01:22:57.209606|2018-06-01 01:22:57.209606
NCT00828867|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2017-06-19|2009-01-22|2009-01-26|Estimate|||||||2017-06-19|2017-06-20|Actual|November 14, 2008|Actual|2008-11-14|June 2017|2017-06-30|December 7, 2009|Actual|2009-12-07|December 7, 2009|Actual|2009-12-07||Interventional|||Single Dose Escalation First Time in Human PK Study|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects|Completed||Phase 1|41|Actual|GlaxoSmithKline||9|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:22:57.270369|2018-06-01 01:22:57.270369
NCT00828854|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2010-02-02|2009-01-23|2009-01-26|Estimate|||||||2010-02-02|2010-02-03|Estimate|April 2008||2008-04-30|February 2010|2010-02-28||||February 2010|Actual|2010-02-28||Interventional|||A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing|A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing|Completed||Phase 2|25|Anticipated|Syndax Pharmaceuticals||1|||f||||t||||||||||2018-06-01 01:22:57.447166|2018-06-01 01:22:57.447166
NCT00828841|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2013-08-07||2013-10-11|2009-01-23|2009-01-26|Estimate|2013-08-07|2013-10-11|Estimate||||2013-10-11|2013-11-06|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC|A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|601|Actual|Accelerated Community Oncology Research Network||3|||f||||t||||||||||2018-06-01 01:22:57.643618|2018-06-01 01:22:57.643618
NCT00828828|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-05-20|2009-01-23|2009-01-26|Estimate|||||||2009-05-20|2009-05-21|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Observational|IVS||Antibody Response to Influenza Vaccine in Patients With Sarcoidosis|Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis|Completed|||49|Actual|Shahid Beheshti University of Medical Sciences|||2||f||||t||||||||||2018-06-01 01:23:00.122131|2018-06-01 01:23:00.122131
NCT00828815|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2011-06-08|2009-01-22|2009-01-26|Estimate|||||||2011-06-08|2011-06-09|Estimate|March 2009||2009-03-31|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.|A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy.|Completed||Phase 1|22|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:23:00.226381|2018-06-01 01:23:00.226381
NCT00828802|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2013-09-06|2009-01-23|2009-01-26|Estimate|||||||2013-09-06|2013-09-09|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes|A Phase I Study of Lenalidomide in Combination With Decitabine for Patients With High Grade Myelodysplastic Syndromes|Completed||Phase 1|15|Actual|Duke University||5|||f||||f||||||||||2018-06-01 01:23:00.295805|2018-06-01 01:23:00.295805
NCT00828789|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2010-12-16|2009-01-22|2009-01-26|Estimate|||||||2010-12-16|2010-12-17|Estimate|February 2009||2009-02-28|December 2010|2010-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer|A Phase I, Open-label, Randomized, Crossover Trial in 20 Healthy Subjects to Investigate the Pharmacokinetic Interactions Between the Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir.|Completed||Phase 1|20|Actual|Tibotec BVBA|||||f||||||||||||||2018-06-01 01:23:00.368341|2018-06-01 01:23:00.368341
NCT00828776|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-01-23|2009-01-23|2009-01-26|Estimate|||||||2009-01-23|2009-01-26|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|heparin||Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure|Clinical Trial of Pharmacodynamic Effects and Non-Clinical Inferiority of the Drug Heparin Sodium Produced by the Laboratory Cristália When Compared With the Product Liquemine of Roche Laboratory in Patients With Chronic Renal Failure|Completed||Phase 2/Phase 3|62|Actual|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:23:00.434739|2018-06-01 01:23:00.434739
NCT00828763|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-06-04|2009-01-22|2009-01-26|Estimate|||||||2009-06-04|2009-06-05|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||GSK1349572 Mass Balance Study|An Open Label, Non-Randomized, Single Dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853)|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:23:00.508558|2018-06-01 01:23:00.508558
NCT00828750|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2011-09-15||2011-10-31|2009-01-22|2009-01-26|Estimate|2011-10-31|2011-12-01|Estimate||||2011-10-31|2011-12-01|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)-An Extension Study of Eltrombopag in Subjects, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study TRA108109 (NCT00540423)-<Phase III Study>|Completed||Phase 3|19|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:23:00.616848|2018-06-01 01:23:00.616848
NCT00828737|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2016-02-16|2009-01-23|2009-01-26|Estimate|||||||2016-02-16|2016-02-18|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|GRIP||Safety of Gadovist in Renally Impaired Patients|Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Gadovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information|Completed||Phase 4|927|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:23:01.264333|2018-06-01 01:23:01.264333
NCT00828724|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-01-23|2009-01-23|2009-01-26|Estimate|||||||2009-01-23|2009-01-26|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State|An Open Label, Single Dose, Cross-Over Study to Assess the Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State|Completed||Phase 1|24|Actual|Arena Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:23:01.61583|2018-06-01 01:23:01.61583
NCT00828711|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2014-01-24|2012-03-14|2014-03-10|2009-01-23|2009-01-26|Estimate|2014-03-10|2014-04-21|Estimate|2012-03-14|2012-03-15|Estimate|2014-03-10|2014-04-21|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor|A Multicenter, Randomized, Double-Blind, Dose-Ranging, Phase II Study to Assess the Efficacy and Safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert for Women Requiring Cervical Ripening and Induction of Labor|Completed||Phase 2|374|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-06-01 01:23:01.717727|2018-06-01 01:23:01.717727
NCT00828698|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2009-01-23|2009-01-23|2009-01-26|Estimate|||||||2009-01-23|2009-01-26|Estimate|January 1996||1996-01-31|January 2009|2009-01-31||||January 2000|Actual|2000-01-31||Observational|FINGER||FINGER; Finland-Germany Myocardial Infarction Study|Finnish-German Prospective, Observational Follow-up Study on Risk Assessment of Mortality After Myocardial Infarction|Completed|||||University of Oulu|||1||f||||||||||Samples With DNA|"~     DNA samples from Finnish subjects in the study have been retained.~   "|||2018-06-01 01:23:02.515251|2018-06-01 01:23:02.515251
NCT00828685|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2017-02-03|2009-01-23|2009-01-26|Estimate|||||||2017-02-03|2017-02-07|Estimate||||February 2017|2017-02-28||||||||Interventional|||Early Functional Outcomes After Closed Reduction With Pinning Versus Open Reduction Internal Fixation of Wrist Fractures|Early Functional Outcomes After Closed Reduction Percutaneous Pinning vs. Open Reduction Internal Fixation of Distal Radius Fractures: A Prospective Randomized Trial|Completed||N/A|||Beth Israel Deaconess Medical Center||2|||f||||||||||||||2018-06-01 01:23:02.633726|2018-06-01 01:23:02.633726
NCT00828672|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2017-05-02|2009-01-23|2009-01-26|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2009|Actual|2009-06-30|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2014|Actual|2014-03-31||Interventional|AXE BEAM||Phase II Study of Neo Adjuvant Treatment With Avastin, Xeloda and/or Eloxatin in Colorectal Cancer|A Randomized Phase II Study of Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin in the Preoperative Treatment of Locally Advanced Rectal Cancer|Active, not recruiting||Phase 2|80|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||No||2018-06-01 01:23:02.760959|2018-06-01 01:23:02.760959
NCT00828659|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-07-27|2009-01-23|2009-01-26|Estimate|||||||2009-07-27|2009-07-29|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users|A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users|Completed||Phase 1|35|Anticipated|Arena Pharmaceuticals||7|||f||||f||||||||||2018-06-01 01:23:02.979775|2018-06-01 01:23:02.979775
NCT00828646|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2011-01-06|2009-01-23|2009-01-26|Estimate|||||||2011-01-06|2011-01-07|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|JMAD||Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese|Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 in Healthy Male Japanese Subjects and a Comparison to Healthy Elderly Japanese Subjects|Completed||Phase 1|32|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 01:23:03.106355|2018-06-01 01:23:03.106355
NCT00828633|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2018-01-18|2009-01-23|2009-01-26|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2008||2008-08-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|December 2010|Actual|2010-12-31||Observational|||Health-Related Quality of Life in Gay Men With Localized Prostate Cancer|Patient-Reported Outcomes For Gay Men With Localized Prostate Cancer|Completed|||92|Actual|Baylor College of Medicine|||||f||||f||||||||||2018-06-01 01:23:03.245025|2018-06-01 01:23:03.245025
NCT00828620|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2012-08-09|2009-01-23|2009-01-26|Estimate|||||||2012-08-09|2012-08-10|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|October 2011|Actual|2011-10-31||Observational|||Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project|Imaging for Early Response Prediction to EGF-receptor Blocking Monoclonal Antibodies in Combination Therapy for Colorectal Cancer|Terminated|||21|Actual|Universitaire Ziekenhuizen Leuven|||1|Lack of recruitment|f||||t||||||||||2018-06-01 01:23:03.331405|2018-06-01 01:23:03.331405
NCT00828607|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2018-02-06|2009-01-23|2009-01-26|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2009||2009-01-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|||Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses|Characterization of Liver Masses With Contrast Enhanced Ultrasound (CEUS): A Comparison With Standard Institutional Contrast Enhanced CT (CECT) or MR Scan (CEMRI)|Completed|||250|Actual|Foothills Medical Centre|||1||f||||f||||||||||2018-06-01 01:23:03.450084|2018-06-01 01:23:03.450084
NCT00828594|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2013-04-09|2009-01-23|2009-01-26|Estimate|||||||2013-04-09|2013-04-11|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma|A Phase 1 Open Label/ Phase 2 Randomized, Double-blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar®) in Patients With Advanced Hepatocellular Carcinoma|Terminated||Phase 1|130|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:23:03.52429|2018-06-01 01:23:03.52429
NCT00828581|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-01-23|2009-01-23|2009-01-26|Estimate|||||||2009-01-23|2009-01-26|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects|An Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects|Completed||Phase 1|24|Actual|Arena Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:23:03.62034|2018-06-01 01:23:03.62034
NCT00828568|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2009-09-17||2013-12-21|2009-01-23|2009-01-26|Estimate|2009-10-21|2009-11-26|Estimate||||2013-12-21|2014-01-28|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Bioequivalence Study of Two Imiquimod Cream 5%|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Two Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis|Completed||Phase 1|425|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-06-01 01:23:03.70718|2018-06-01 01:23:03.70718
NCT00828555|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2012-10-15|2009-01-23|2009-01-26|Estimate|||||||2012-10-15|2012-10-16|Estimate|November 2008||2008-11-30|September 2012|2012-09-30|February 2012|Actual|2012-02-29|April 2009|Actual|2009-04-30||Observational|||Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting|Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting|Completed|||3988|Actual|Duke University|||||f||||f||||||||||2018-06-01 01:23:04.170025|2018-06-01 01:23:04.170025
NCT00828542|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2012-06-12||2017-05-01|2009-01-23|2009-01-26|Estimate|2017-05-01|2017-05-15|Actual||||2017-05-01|2017-05-15|Actual|July 2007||2007-07-31|May 2017|2017-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women|Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women|Completed||N/A|40|Actual|University of Sao Paulo|Patients were not blinded to treatment. However, this was not possible because the ENG group received a subdermal contraceptive implant, whereas, for ethical reasons, the control group could not receive a placebo implant.|2|||f||||f||||||||No||2018-06-01 01:23:04.268494|2018-06-01 01:23:04.268494
NCT00828529|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2012-08-14|2009-01-22|2009-01-26|Estimate|||||||2012-08-14|2012-08-15|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer|A Phase I, Open-label, Randomized Crossover Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Lopinavir/Ritonavir and Single-dose TMC207 in Healthy Subjects.|Completed||Phase 1|16|Actual|Tibotec BVBA|||||||||f||||||||||2018-06-01 01:23:04.541655|2018-06-01 01:23:04.541655
NCT00828516|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|2012-11-09||2012-12-07|2009-01-23|2009-01-26|Estimate|2012-12-07|2013-01-17|Estimate||||2012-12-07|2013-01-17|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|AMWELL-SL||Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema|Using Acupuncture and Moxibustion to Promote Wellbeing and Improve Quality of Life for Patients With Upper Body Lymphoedema Secondary to Cancer Treatment|Completed||N/A|56|Actual|East and North Hertfordshire NHS Trust||1|||f||||f||||||||||2018-06-01 01:23:04.60485|2018-06-01 01:23:04.60485
NCT00828503|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2012-08-30|2009-01-23|2009-01-26|Estimate|||||||2012-08-30|2012-09-03|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|Certi-CMV||Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients|Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients|Unknown status|Recruiting|Phase 2|40|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:23:04.831907|2018-06-01 01:23:04.831907
NCT00828490|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2010-03-21|2009-01-23|2009-01-26|Estimate|||||||2010-03-21|2010-03-23|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|ePRM||Electronic Pharmacotherapy Risk Management|Developing a Utah Pharmacotherapy Risk Management System With an Electronic Surveillance Tool (Utah ePRM)|Completed|||174000|Actual|University of Utah|||6||f||||f||||||||||2018-06-01 01:23:04.902655|2018-06-01 01:23:04.902655
NCT00828477|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-06-08|2009-01-23|2009-01-26|Estimate|||||||2009-06-08|2009-06-10|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)|Evaluation of Comfort With the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Xibrom (Bromfenac Ophthalmic Solution) 0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)|Completed||Phase 4|25|Anticipated|Bp Consulting, Inc||2|||f||||f||||||||||2018-06-01 01:23:05.080742|2018-06-01 01:23:05.080742
NCT00828464|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2010-04-07||2012-09-21|2009-01-22|2009-01-26|Estimate|2010-09-07|2010-09-28|Estimate||||2012-09-21|2012-10-03|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis|An Open Label Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for the Condition of Chronic Hand Dermatitis|Completed||Phase 4|30|Actual|GlaxoSmithKline|Open label study|1|||f||||f||||||||||2018-06-01 01:23:05.179589|2018-06-01 01:23:05.179589
NCT00828451|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2011-08-02||2018-03-07|2009-01-23|2009-01-26|Estimate|2018-02-07|2018-03-07|Actual||||2018-03-07|2018-04-04|Actual|May 2008||2008-05-31|March 2018|2018-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional||29 subjects were enrolled. 11 subjects did not complete the study and were not analyzed due to lack of adequate specimens.|Collaborative Research Group for Necrotizing Enterocolitis|Collaborative Research Group for Necrotizing Enterocolitis|Completed||N/A|29|Actual|Washington University School of Medicine|stable isotope labeled EGF could not be detected in the urine and thus the project was closed|1|||f||||t||||||||||2018-06-01 01:23:05.43931|2018-06-01 01:23:05.43931
NCT00828438|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-07-27|2009-01-23|2009-01-26|Estimate|||||||2009-07-27|2009-07-29|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment|A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment|Completed||Phase 1|40|Anticipated|Arena Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:23:05.677287|2018-06-01 01:23:05.677287
NCT00828425|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-23|||2010-08-17|2009-01-23|2009-01-26|Estimate|||||||2010-08-17|2010-08-18|Estimate|December 2008||2008-12-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|||||Observational|||Management of Diabetes Mellitus Patients With Retinopathy|Management of Diabetes Mellitus Patients With Retinopathy|Completed|||2500|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:23:05.756536|2018-06-01 01:23:05.756536
NCT00828412|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2013-09-17||2016-12-01|2009-01-23|2009-01-26|Estimate|2013-10-14|2013-12-09|Estimate||||2016-12-01|2017-01-30|Estimate|March 2009||2009-03-31|December 2016|2016-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis|A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis|Completed||Phase 4|100|Actual|Promius Pharma, LLC||2|||f||||f||||||||||2018-06-01 01:23:05.959585|2018-06-01 01:23:05.959585
NCT00828399|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2011-05-24|2009-01-22|2009-01-23|Estimate|||||||2011-05-24|2011-05-25|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Prevention of Acute Radiation Enteritis With Glutamine|Efficacy of Glutamine in the Prevention of Acute Radiation Enteritis Among Patients Treated With Radiation of Abdomen and Pelvis.|Completed||Phase 4|70|Actual|Castilla-León Health Service||2|||f||||f||||||||||2018-06-01 01:23:06.243093|2018-06-01 01:23:06.243093
NCT00828386|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2015-03-23|2009-01-22|2009-01-23|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|GORTEC-NPC2006||Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers|A Randomized, Multicenter, Phase III Trial Comparing Induction Chemotherapy With Docetaxel, Cisplatin and 5-Fluorouracil (TPF) Followed by Concurrent Chemoradiotherapy to Concurrent Chemoradiotherapy Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)|Terminated||Phase 3|83|Actual|Groupe Oncologie Radiotherapie Tete et Cou||2||Low accrual|f||||||||||||||2018-06-01 01:23:06.326545|2018-06-01 01:23:06.326545
NCT00828373|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2011-07-14|2009-01-22|2009-01-23|Estimate|||||||2011-07-14|2011-07-15|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|LidoRoc||The Influence of Intravenous Lidocaine on the Action of the Neuromuscular Blocker Rocuronium|The Effect of Intravenous Lidocaine on the Time Course of Rocuronium Induced Neuromuscular Block. A Randomised, Placebo-controlled, Electrophysiological Study|Completed||Phase 4|52|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 01:23:06.42029|2018-06-01 01:23:06.42029
NCT00828360|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-01-22|2009-01-22|2009-01-23|Estimate|||||||2009-01-22|2009-01-23|Estimate|July 2006||2006-07-31|January 2009|2009-01-31|September 2009|Anticipated|2009-09-30|April 2009|Anticipated|2009-04-30||Observational|LODO-CRT||Dobutamine Stress Echocardiography in Cardiac Resynchronization Therapy (CRT) Patients Selection|Efficacy Of Low-Dose Dobutamine Stress-Echocardiography To Predict Cardiac Resynchronization Therapy Response|Unknown status|Active, not recruiting||270|Anticipated|Ospedale Santa Maria di Loreto Mare|||||f||||f||||||||||2018-06-01 01:23:06.506129|2018-06-01 01:23:06.506129
NCT00828347|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2011-07-05||2015-12-16|2009-01-22|2009-01-23|Estimate|2015-12-16|2016-01-25|Estimate||||2015-12-16|2016-01-25|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)|A Study of Maintenance Therapy After Intravenous Maxacalcitol for Secondary Hyperparathyroidism|Completed||N/A|35|Actual|Kumamoto University|Sample size was small, so it will be necessary to conduct further studies in a larger number of patients.|2|||f||||t||||||||||2018-06-01 01:23:06.611622|2018-06-01 01:23:06.611622
NCT00828334|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2018-03-21|2009-01-22|2009-01-23|Estimate|||||||2018-03-21|2018-03-23|Actual|November 2002||2002-11-30|March 2018|2018-03-31|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||NIT-OCCLUD PDA Phase II Sentinel Trial|Transcatheter Occlusion of Patent Ductus Arteriosus (PDA) With the NIT-OCCLUD PDA Occlusions System|Completed||N/A|357|Actual|PFM Medical, Inc||1|||f||||t|f|t|f|f||||Undecided||2018-06-01 01:23:06.87132|2018-06-01 01:23:06.87132
NCT00828321|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2009-07-02||2009-09-01|2009-01-22|2009-01-23|Estimate|2009-07-02|2009-08-18|Estimate||||2009-09-01|2009-09-11|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions|Randomized , 2- Way Crossover, Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as 1 x 10 mg Capsule in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|40|Actual|Teva Pharmaceuticals USA||2|||f||||||||||||||2018-06-01 01:23:06.972693|2018-06-01 01:23:06.972693
NCT00828308|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2013-08-20||2017-02-13|2009-01-22|2009-01-23|Estimate|2013-08-20|2013-11-01|Estimate||||2017-02-13|2017-03-20|Actual|February 2009|Actual|2009-02-28|February 2017|2017-02-28|December 2016|Actual|2016-12-31|March 2011|Actual|2011-03-31||Interventional|BrUOG-Pros-221||Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer|BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study|Completed||Phase 2|16|Actual|Brown University||1|||f||||t||||||||||2018-06-01 01:23:07.262594|2018-06-01 01:23:07.262594
NCT00828295|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2014-06-27|2010-04-15|2015-03-17|2009-01-22|2009-01-23|Estimate|2014-07-28|2014-08-15|Estimate|2010-04-15|2010-04-16|Estimate|2015-03-17|2015-04-03|Estimate|August 2008||2008-08-31|July 2014|2014-07-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients|A Multicenter, Double-blind, Randomized, Parallel Group, Stratified Study to Assess the Safety and Efficacy of Single IV Doses of Palonosetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients|Completed||Phase 3|150|Actual|Helsinn Healthcare SA||2|||f||||f||||||||||2018-06-01 01:23:07.440153|2018-06-01 01:23:07.440153
NCT00828282|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2014-05-23|2009-01-22|2009-01-23|Estimate|||||||2014-05-23|2014-05-26|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|January 2011|Actual|2011-01-31||Interventional|||High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL|High-dose HMG-CoA Inhibitor Simvastatin for Patients With Relapsed CLL: Pilot Trial and Pharmacokinetic-pharmacodynamic Studies|Completed||Phase 1|3|Actual|University of Kentucky||1|||f||||t||||||||||2018-06-01 01:23:07.860987|2018-06-01 01:23:07.860987
NCT00828269|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-04-21|2009-01-21|2009-01-23|Estimate|||||||2015-04-21|2015-04-22|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)|Evaluation of RNA Quality and the Reproducibility of Gene Expression Profiling From Liver Tissue Obtained by Fine Needle Aspiration in Patients With Chronic Hepatitis C.|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 01:23:07.929366|2018-06-01 01:23:07.929366
NCT00828256|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-01-22|2009-01-22|2009-01-23|Estimate|||||||2009-01-22|2009-01-23|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|June 2009|Anticipated|2009-06-30|May 2009|Anticipated|2009-05-31||Observational|||Outcome of Arthroscopic Repair of Chronic Rotator Cuff Tears Between 2005-2008|Outcome Study of Arthroscopic Repair of Chronic Rotator Cuff Tears Between 2005-2008, at the Soroka University Medical Center, Beer Sheva, Israel|Unknown status|Enrolling by invitation||80|Anticipated|Soroka University Medical Center|||||f||||||||||||||2018-06-01 01:23:07.990144|2018-06-01 01:23:07.990144
NCT00828243|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2018-04-30|2009-01-22|2009-01-23|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2007||2007-11-30|April 2018|2018-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Genetic Regulation of Surfactant Deficiency|Genetic Regulation of Surfactant Deficiency in Human Newborn Infants|Completed|||773|Actual|Washington University School of Medicine|||2||f||||t||||||Samples With DNA|"~     DNA samples and tracheal aspirate samples will be retained on each study participant.~   "|||2018-06-01 01:23:08.049965|2018-06-01 01:23:08.049965
NCT00828230|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2012-01-26|2009-01-22|2009-01-23|Estimate|||||||2012-01-26|2012-01-30|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis|Randomised, Double-blind, Placebo-controlled, Multicentre, Comparative Phase II Pilot Study on the Efficacy and Tolerability of an 8-week Rectal Treatment With 2 mg Budesonide or Placebo for the Prevention of Acute Radiation Proctitis|Terminated||Phase 2|17|Actual|Dr. Falk Pharma GmbH||2||"Study was prematurely stopped due to slow recruitment after 17 of 32 anticipated patients were~   recruited."|f||||f||||||||||2018-06-01 01:23:08.138059|2018-06-01 01:23:08.138059
NCT00828217|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2010-09-23|2009-01-22|2009-01-23|Estimate|||||||2010-09-23|2010-09-24|Estimate|November 2008||2008-11-30|September 2010|2010-09-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|ACTIVHOP||Adapted Physical Activity, Health-related Quality of Life and Satisfaction With Care in Hospitalized Children|ACTIVHOP: Adapted Physical Activity, Health-related Quality of Life and Satisfaction With Care in Hospitalized Children; a Randomized Controlled Study|Unknown status|Recruiting|N/A|312|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-06-01 01:23:08.219333|2018-06-01 01:23:08.219333
NCT00828204|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2011-07-13||2014-05-08|2009-01-21|2009-01-23|Estimate|2011-07-13|2011-08-09|Estimate||||2014-05-08|2014-06-03|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional||This table presents the baseline characteristics for both the Initial Subset and Main Subset populations. As represented in the Participant Flow module, these 2 groups participated prior to and after study suspension, respectively; therefore the total column should not be interpreted as cumulative.|Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects|An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects|Completed||Phase 3|95|Actual|Biogen|The Initial Subset is too small a population from which to draw conclusions.|1|||f||||f||||||||||2018-06-01 01:23:08.306138|2018-06-01 01:23:08.306138
NCT00828191|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2012-11-26||2013-01-28|2009-01-22|2009-01-23|Estimate|2012-11-26|2012-12-26|Estimate||||2013-01-28|2013-01-31|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|||Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)|Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) Versus Vaginal Progesterone for Luteal Phase Support in Patients Undergoing In Vitro Fertilization (IVF)|Completed||Phase 3|800|Actual|IBSA Institut Biochimique SA|No limitations of the trial reported.|2|||f||||||||||||||2018-06-01 01:23:08.68284|2018-06-01 01:23:08.68284
NCT00828178|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2013-09-17||2016-09-28|2009-01-22|2009-01-23|Estimate|2016-09-28|2016-11-18|Estimate||||2016-09-28|2016-11-18|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy of Fish Oil in Lupus Patients|A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE.|Completed||Phase 4|106|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-06-01 01:23:10.006456|2018-06-01 01:23:10.006456
NCT00828165|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2012-08-29|2009-01-22|2009-01-23|Estimate|||||||2012-08-29|2012-08-30|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Safety Study of ARRY-300 in Healthy Subjects||Completed||Phase 1|12|Actual|Array BioPharma||2|||f||||f||||||||||2018-06-01 01:23:10.280073|2018-06-01 01:23:10.280073
NCT00828152|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2015-05-05|2009-01-22|2009-01-23|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|Ha1b||Internet-delivered Cognitive Behavioral Therapy (CBT) for Health Anxiety|Internet-delivered Cognitive Behavioural Therapy for Health Anxiety - a Randomized Controlled Trial|Completed||Phase 2|80|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 01:23:10.339705|2018-06-01 01:23:10.339705
NCT00828139|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2015-11-05||2017-07-21|2009-01-22|2009-01-23|Estimate|2016-03-02|2016-04-04|Estimate||||2017-07-21|2017-08-21|Actual|May 2009||2009-05-31|July 2017|2017-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)|Completed||Phase 2|189|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:23:10.527968|2018-06-01 01:23:10.527968
NCT00828126|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-03-26|2009-01-22|2009-01-23|Estimate|||||||2012-03-26|2012-03-28|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma|PET-CT in the Management of Patients With Stage III Or IV Metastatic Melanoma Considered Candidates for Surgery: Evaluation of Additive Value Following Conventional Imaging|Completed|||38|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:23:12.155946|2018-06-01 01:23:12.155946
NCT00828113|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2012-06-13||2015-10-22|2009-01-21|2009-01-23|Estimate|2012-06-13|2012-07-18|Estimate||||2015-10-22|2015-11-20|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||Long-term Varenicline Treatment for Smoking Cessation|Long-term Varenicline Treatment for Smoking Cessation|Completed||Phase 4|101|Actual|University of Wisconsin, Madison|Feasibility study with limited statistical power at baseline compounded by a significant rate of attrition during the study.|2|||f||||t||||||||||2018-06-01 01:23:12.317846|2018-06-01 01:23:12.317846
NCT00828100|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-03-05|2009-01-22|2009-01-23|Estimate|||||||2009-03-05|2009-03-06|Estimate|February 2009||2009-02-28|March 2009|2009-03-31||||May 2009|Anticipated|2009-05-31||Interventional|||Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B|Comparison of fluID Rapid Influenza and BinaxNOW® Influenza A & B|Suspended||Phase 3|650|Anticipated|Nanogen, Inc.||||Study currently suspended due to a lack of available funding.|f||||f||||||||||2018-06-01 01:23:12.574971|2018-06-01 01:23:12.574971
NCT00828087|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2015-05-18|2009-01-22|2009-01-23|Estimate|||||||2015-05-18|2015-05-19|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study|A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction.EXAMINATION Study|Completed||N/A|1504|Actual|Spanish Society of Cardiology||2|||f||||f||||||||||2018-06-01 01:23:12.644067|2018-06-01 01:23:12.644067
NCT00828074|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2016-11-04||2017-01-06|2009-01-22|2009-01-23|Estimate|2017-01-06|2017-02-27|Actual||||2017-01-06|2017-02-27|Actual|November 2008||2008-11-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer|Phase I/II Vinorelbine and Sorafenib as Salvage Therapy in Metastatic Breast Cancer|Completed||Phase 1/Phase 2|46|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:23:12.789137|2018-06-01 01:23:12.789137
NCT00828061|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2010-04-12||2015-08-04|2009-01-22|2009-01-23|Estimate|2010-04-12|2010-05-05|Estimate||||2015-08-04|2015-08-05|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of the Effects of Single Dose Corticosteroids on Response to Allergens|A Randomized Clinical Trial to Study the Effects of Single Dose of Corticosteroid on Response to Nasal Allergen Challenge in Patients|Completed||Phase 1|19|Actual|Merck Sharp & Dohme Corp.|Poor cell yields from nasal lavage significantly reduced the utility of eosinophil count data.|3|||f||||f||||||||||2018-06-01 01:23:13.472866|2018-06-01 01:23:13.472866
NCT00828048|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2017-10-16|2009-01-22|2009-01-23|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2008||2008-03-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||International Registry for Intraductal Papillary Mucinous Neoplasma|International Registry for Intraductal Papillary Mucinous Neoplasma|Active, not recruiting|||560|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-06-01 01:23:13.811676|2018-06-01 01:23:13.811676
NCT00828035|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2012-09-17|2009-01-22|2009-01-23|Estimate|||||||2012-09-17|2012-09-18|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|April 2011|Actual|2011-04-30|April 2008|Actual|2008-04-30||Interventional|||Light Endoscopic Robot Use in Laparoscopic Surgery|Light Endoscopic Robot Use in Abdominal and Urological Laparoscopic Surgery|Completed||Phase 2/Phase 3|78|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 01:23:13.89683|2018-06-01 01:23:13.89683
NCT00828022|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-01-22|2009-01-22|2009-01-23|Estimate|||||||2009-01-22|2009-01-23|Estimate|March 2009||2009-03-31|January 2009|2009-01-31||||||||Interventional|SMC4692||Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer|A Single-Institution, Open-Label, Single-Arm phase1/2 Study of Measles Vaccine as Consolidation in Patients With Measles Virus-Positive, Stage 3B/4 Non-Small Cell Lung Cancer|Unknown status|Not yet recruiting|Phase 1/Phase 2|15|Anticipated|Soroka University Medical Center|||||f||||t||||||||||2018-06-01 01:23:14.062554|2018-06-01 01:23:14.062554
NCT00828009|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2017-12-12|2009-01-22|2009-01-23|Estimate|||||||2017-12-12|2017-12-14|Actual|December 22, 2010|Actual|2010-12-22|December 2017|2017-12-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation|Active, not recruiting||Phase 2|55|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 01:23:14.164437|2018-06-01 01:23:14.164437
NCT00827996|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-22|2009-01-22|2009-01-23|Estimate|||||||2009-01-22|2009-01-23|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|August 2008||2008-08-31|November 2007|Actual|2007-11-30||Interventional|HIDRI2007||To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa|Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa|Completed||Phase 2|10|Actual|Florida Academic Dermatology Centers|||||f||||t||||||||||2018-06-01 01:23:14.40751|2018-06-01 01:23:14.40751
NCT00827983|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2012-11-26||2013-01-28|2009-01-22|2009-01-23|Estimate|2012-11-26|2012-12-26|Estimate||||2013-01-28|2013-01-31|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)|Efficacy and Tolerability of Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)|Completed||Phase 3|683|Actual|IBSA Institut Biochimique SA|no special limitations of the trial were detected.|2|||f||||||||||||||2018-06-01 01:23:14.519218|2018-06-01 01:23:14.519218
NCT00827957|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2017-02-09|2009-01-22|2009-01-23|Estimate|||||||2017-02-09|2017-02-10|Actual|October 2008||2008-10-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Hypothermia||Comparing Therapeutic Hypothermia Using External and Internal Cooling for Post-Cardiac Arrest Patients|A Phased Prospective Clinical Study Comparing Controlled Therapeutic Hypothermia Post Resuscitation After Cardiac Arrest Using External and Internal Cooling to Standard Intensive Care Unit Therapy|Completed||Phase 4|51|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-06-01 01:23:15.041625|2018-06-01 01:23:15.041625
NCT00827944|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2013-08-23||2016-11-16|2009-01-22|2009-01-23|Estimate|2016-11-16|2016-11-17|Estimate||||2016-11-16|2016-11-17|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Parietex Progrip Study|ProGrip Mesh Repair Versus Lichtenstein Mesh Repair: a Comparative Randomized Study in Primary Inguinal Hernia|Completed||Phase 4|603|Actual|Medtronic - MITG||2|||f||||f||||||||||2018-06-01 01:23:15.250184|2018-06-01 01:23:15.250184
NCT00827931|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2012-04-02||2012-04-02|2009-01-22|2009-01-23|Estimate|2012-04-02|2012-04-26|Estimate||||2012-04-02|2012-04-26|Estimate|September 2009||2009-09-30|April 2012|2012-04-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery|Prospective Randomized Phase IV Open Label Comparative Study Of Tranexamic Acid Plus Standard Of Care Vs Standard Of Care For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery|Completed||Phase 4|94|Actual|Pfizer|The intended FAS population was planned to include participants from 2 sites, however due to non-reliability of data from one of the sites, the actual FAS population included participants from a single site only.|2|||f||||t||||||||||2018-06-01 01:23:15.783081|2018-06-01 01:23:15.783081
NCT00827918|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2013-09-24||2015-10-20|2009-01-22|2009-01-23|Estimate|2013-12-18|2014-02-06|Estimate||||2015-10-20|2015-10-21|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)|A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia|Completed||Phase 2|216|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 01:23:16.354467|2018-06-01 01:23:16.354467
NCT00827905|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2010-08-04|2009-01-22|2009-01-23|Estimate|||||||2010-08-04|2010-08-06|Estimate|January 2009||2009-01-31|August 2010|2010-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Substantial Equivalence Study for Kai Sensors RSpot Non-Contact Respiratory Rate Spot Check|Remote Doppler System to Measure Heart Rate and Breathing Pattern|Completed|||20|Anticipated|Kai Medical, Inc.|||1||f||||f||||||||||2018-06-01 01:23:16.961379|2018-06-01 01:23:16.961379
NCT00827892|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-10-01|2009-01-22|2009-01-23|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|SHRINC||Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage|Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage|Completed||Phase 2|84|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 01:23:17.085237|2018-06-01 01:23:17.085237
NCT00827879|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2017-07-11|2009-01-22|2009-01-23|Estimate|||||||2017-07-11|2017-07-12|Actual|February 2009||2009-02-28|July 2017|2017-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Strength at Home Couples Program (PTSD-Focused Relationship Enhancement Therapy for Returning Veterans)|Strength at Home Couples Program (Formerly: PTSD-Focused Relationship Enhancement Therapy for Returning Veterans and Their Partners)|Completed||N/A|156|Actual|Boston VA Research Institute, Inc.||2|||f||||t||||||||||2018-06-01 01:23:17.171712|2018-06-01 01:23:17.171712
NCT00827866|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2014-11-24|2009-01-21|2009-01-23|Estimate|||||||2014-11-24|2014-11-25|Estimate|October 2008||2008-10-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Tobacco Quitline for Cancer Survivors|Efficacy of Tobacco Quitline for Cancer Survivors|Completed||N/A|946|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 01:23:17.263623|2018-06-01 01:23:17.263623
NCT00827853|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2013-11-01|2009-01-22|2009-01-23|Estimate|||||||2013-11-01|2013-11-04|Estimate|November 2008||2008-11-30|November 2013|2013-11-30|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|COBRA||Study Comparing Two Methods of Expanding Stents Placed in Legs of Diabetics With Peripheral Vascular Disease|PolarCath® Cryoplasty Versus Conventional Balloon Post-dilation of Nitinol Stents for Peripheral Vascular Interventions (COBRA)|Completed||N/A|90|Actual|North Texas Veterans Healthcare System||2|||f||||t||||||||||2018-06-01 01:23:17.361655|2018-06-01 01:23:17.361655
NCT00827840|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2011-12-22|2009-01-22|2009-01-23|Estimate|||||||2011-12-22|2011-12-23|Estimate|November 2008||2008-11-30|December 2011|2011-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia|Paliperidone ER Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia: a Randomized, Open-label, Controlled Trial|Completed||Phase 4|58|Actual|Chonnam National University Hospital||2|||f||||t||||||||||2018-06-01 01:23:17.488972|2018-06-01 01:23:17.488972
NCT00827827|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|2014-12-29||2018-01-29|2009-01-22|2009-01-23|Estimate|2015-01-12|2015-01-19|Estimate||||2018-01-29|2018-02-07|Actual|April 1, 2009|Actual|2009-04-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2013|Actual|2013-08-31||Interventional||Disabled stroke survivors|Strength Training for Skeletal Muscle Adaptation After Stroke|Strength Training for Skeletal Muscle Adaptation After Stroke|Active, not recruiting||N/A|38|Actual|VA Office of Research and Development|"Scanning results and muscle biopsy outcomes are still pending and won't be available for some time.~Numbers of participants qualifying for and agreeing to metabolic testing will be too low to yield reportable results."|2|||f||||t|f|f|||f|||No||2018-06-01 01:23:17.583606|2018-06-01 01:23:17.583606
NCT00827814|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2009-06-08|2009-01-22|2009-01-23|Estimate|||||||2009-06-08|2009-06-11|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction|Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction: A 24-Week Open-Label, Single-Arm Pilot Study|Completed||Phase 4|36|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 01:23:18.0912|2018-06-01 01:23:18.0912
NCT00827801|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2012-07-19|2009-01-22|2009-01-23|Estimate|||||||2012-07-19|2012-07-23|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program|MDASI-HF: Bridging the Symptom Management Gap in Patients With Cancer and Concurrent Heart Failure to Improve Outcomes|Completed|||26|Actual|M.D. Anderson Cancer Center|||2||f||||t||||||||||2018-06-01 01:23:18.294399|2018-06-01 01:23:18.294399
NCT00827788|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2010-11-15|2009-01-22|2009-01-23|Estimate|||||||2010-11-15|2010-11-16|Estimate|December 2008||2008-12-31|September 2009|2009-09-30||||April 2010|Actual|2010-04-30||Interventional|CONTRAST-AMI||Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI)|The Contrast Media and Nephrotoxicity Following Coronary Revascularization by Primary Angioplasty for Acute Myocardial Infarction. The CONTRAST-AMI Study.|Completed||Phase 4|432|Anticipated|Ospedale San Donato||2|||f||||f||||||||||2018-06-01 01:23:18.384014|2018-06-01 01:23:18.384014
NCT00827775|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2014-01-27|2009-01-22|2009-01-23|Estimate|||||||2014-01-27|2014-01-29|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|MATCH||Mechanisms and Treatment of Intradialytic Hypertension|Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients|Completed||Phase 4|59|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 01:23:18.461047|2018-06-01 01:23:18.461047
NCT00827762|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2013-12-03|2009-01-21|2009-01-23|Estimate|||||||2013-12-03|2013-12-05|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Behavioral Effects of Kuvan in Children With Mild Phenylketonuria|Behavioral Effects of Kuvan in Children With Mild Phenylketonuria|Terminated|||2|Actual|Washington University School of Medicine|||1|Too few participants recruited within timeframe|f||||f||||||||||2018-06-01 01:23:18.536787|2018-06-01 01:23:18.536787
NCT00827749|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2010-07-21|2009-01-22|2009-01-23|Estimate|||||||2010-07-21|2010-07-22|Estimate|November 2008||2008-11-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PRIOD||Swallowing Disorders in Geriatrics Studied With Respiratory Plethysmography by Inductance|Contribution of Respiratory Plethysmography by Inductance and of Informatic Tool for the Study of Swallowing Disorders in Geriatrics (PRIOD)|Completed||Early Phase 1|30|Anticipated|University Hospital, Grenoble|||||f||||t||||||||||2018-06-01 01:23:18.623428|2018-06-01 01:23:18.623428
NCT00827736|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-01-22|2009-01-22|2009-01-23|Estimate|||||||2009-01-22|2009-01-23|Estimate|June 2002||2002-06-30|January 2009|2009-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Comparison of Treatment Success of Botox Injection in the Internal Sphincter Versus Isosorbidedinitrate Ointment in Patients With an Anal Fissure|Botulin Toxin Versus Isosorbidedinitrate Ointment in Treatment Anal Fissure; A Prospective, Blinded, Randomized Trial|Completed||Phase 4|73|Actual|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||||2018-06-01 01:23:18.696585|2018-06-01 01:23:18.696585
NCT00827723|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2016-01-27|2009-01-22|2009-01-23|Estimate|||||||2016-01-27|2016-01-28|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma|Makuuchi Versus Barcelona Clinic of Liver Cancer Criteria in Cirrhotic Patients With Hepatocellular Carcinoma. Does Etiology of Cirrhosis Influence the Relationship Between the Portal Pressure and Quantitative Tests of Liver Function?|Unknown status|Recruiting||60|Anticipated|University of Lausanne Hospitals|||2||f||||t||||||||||2018-06-01 01:23:18.867321|2018-06-01 01:23:18.867321
NCT00827710|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2012-04-29|2009-01-21|2009-01-23|Estimate|||||||2012-04-29|2012-05-01|Estimate|December 2007||2007-12-31|April 2012|2012-04-30|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|||Automated Diabetes Registry Tools to Enhance Patient Self-Management and Provider Performance Feedback||Completed||N/A|5457|Actual|Denver Health and Hospital Authority||4|||f||||t||||||||||2018-06-01 01:23:18.955173|2018-06-01 01:23:18.955173
NCT00827697|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2016-08-15|2009-01-21|2009-01-23|Estimate|||||||2016-08-15|2016-08-17|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||A Validation Study for Detecting Chlamydia and Gonorrhea in Rectal Samples|A Validation Study of the Gen-Probe APTIMA Combo2 (AC2) for Detecting Chlamydia Trachomatis and Neisseria Gonorrhoeae in Rectal Samples.|Completed|||399|Actual|University of Pittsburgh|||||f||||f||||||||No||2018-06-01 01:23:19.058781|2018-06-01 01:23:19.058781
NCT00827684|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2011-06-07|2009-01-22|2009-01-23|Estimate|||||||2011-06-07|2011-06-08|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|TIRASMUS||Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations|Phase II Study of Temsirolimus and Irinotecan in Chemotherapy Refractory Patients With KRAS Mutated Metastatic Colorectal Cancer|Completed||Phase 2|50|Anticipated|Vejle Hospital||2|||f||||t||||||||||2018-06-01 01:23:19.132129|2018-06-01 01:23:19.132129
NCT00827671|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2018-03-07|2009-01-22|2009-01-23|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2009|Actual|2009-03-31|March 2018|2018-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|TRACC||Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma|Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab|Terminated||Phase 2|12|Actual|UMC Utrecht||1||Experimental treatment not feasible due to high rate of drop out|f||||t||||||||||2018-06-01 01:23:19.27931|2018-06-01 01:23:19.27931
NCT00827658|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2018-05-08|2009-01-22|2009-01-23|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2008||2008-02-29|May 2018|2018-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Ulnar Nerve Block for Procedural Anesthesia - Wrist Versus Palm|Ulnar Nerve Block for Procedural Anesthesia - Wrist Versus Palm|Terminated||N/A|127|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 01:23:19.368445|2018-06-01 01:23:19.368445
NCT00827645|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2018-05-18|2009-01-21|2009-01-23|Estimate|||||||2018-05-18|2018-05-22|Actual|January 1, 2009|Actual|2009-01-01|May 2018|2018-05-31|January 1, 2013|Actual|2013-01-01|January 1, 2013|Actual|2013-01-01||Observational|||Uterine Artery Embolization and Pelvic Floor Symptoms|Effect of Uterine Artery Embolization on Symptoms of Pelvic Floor Dysfunction|Withdrawn|||0|Actual|University of Texas Southwestern Medical Center|||1|never funded and never started|f||||f||||||||||2018-06-01 01:23:19.453654|2018-06-01 01:23:19.453654
NCT00827632|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2010-10-11||2012-12-11|2009-01-22|2009-01-23|Estimate|2011-05-16|2011-06-14|Estimate||||2012-12-11|2012-12-13|Estimate|July 2006||2006-07-31|December 2012|2012-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|20/30||Obesity, Oral Contraception, and Ovarian Suppression|Oral Contraception and Ovarian Suppression in Women With Different Weights|Completed||Phase 4|226|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 01:23:19.522909|2018-06-01 01:23:19.522909
NCT00827619|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2015-12-03|2009-01-22|2009-01-23|Estimate|||||||2015-12-03|2015-12-04|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2011|Actual|2011-11-30||Interventional|||Zilver® Flex™ Vascular Stent Study|Evaluation of the Zilver® Flex™ Vascular Stent in the Above-the-Knee Femoropopliteal Artery|Completed||N/A|110|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-06-01 01:23:19.93952|2018-06-01 01:23:19.93952
NCT00827606|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2014-09-11||2016-08-16|2009-01-22|2009-01-23|Estimate|2015-06-01|2015-06-02|Estimate||||2016-08-16|2016-09-22|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Full Analysis Set (FAS): all participants who took at least one dose of study drug.|Atorvastatin Three Year Pediatric Study|A Three Year, Prospective, Open-label, Study To Evaluate Clinical Efficacy, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|272|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 01:23:20.133194|2018-06-01 01:23:20.133194
NCT00827593|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2012-04-12|2009-01-22|2009-01-23|Estimate|||||||2012-04-12|2012-04-13|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Managing Obesity by Combining Behavioral Weight Loss and Commercial Approaches|Managing Obesity by Combining Behavioral Weight Loss and Commercial Approaches|Completed||N/A|144|Actual|Baruch College City University of New York||3|||f||||t||||||||||2018-06-01 01:23:22.293439|2018-06-01 01:23:22.293439
NCT00827580|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-22|||2018-05-25|2009-01-22|2009-01-23|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2009|Actual|2009-01-31|May 2018|2018-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Eniluracil Hand Foot Syndrome|A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)|Terminated||Phase 1|3|Actual|West Virginia University||1|||f||||t||||||||||2018-06-01 01:23:22.376489|2018-06-01 01:23:22.376489
NCT00827567|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2011-08-16||2013-12-11|2009-01-21|2009-01-22|Estimate|2012-03-15|2012-04-20|Estimate||||2013-12-11|2014-01-13|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Trial of RAD001 in Triple Negative Metastatic Breast Cancer|A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer|Terminated||Phase 2|6|Actual|Milton S. Hershey Medical Center||1||Slow accrual|f||||t||||||||||2018-06-01 01:23:22.482117|2018-06-01 01:23:22.482117
NCT00827554|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2016-03-30|2009-01-21|2009-01-22|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma|A Clinical Randomized Control Trial of Combination TACE With and Without Low-molecular-weight Heparin in Hepatocellular Carcinoma|Completed||Phase 2/Phase 3|100|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:23:22.643844|2018-06-01 01:23:22.643844
NCT00827541|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2011-12-23||2011-12-23|2009-01-21|2009-01-22|Estimate|2011-12-23|2012-02-01|Estimate||||2011-12-23|2012-02-01|Estimate|August 2008||2008-08-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|HORUS||Post-Authorization Study Evaluating Safety Of Tigecycline|A Phase IV Pharmacovigilance, Post-Authorization Clinical Trial To Evaluate And Assess The Safety Of Tigecycline In The Approved Indications In The Usual Health Care Setting|Completed|||115|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:23:22.813134|2018-06-01 01:23:22.813134
NCT00827528|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2012-03-22|2009-01-21|2009-01-22|Estimate|||||||2012-03-22|2012-03-26|Estimate|August 2006||2006-08-31|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||SIS Graft and Traditional Repair in Vaginal Wall Prolapse|Surgical Treatment of Anterior Vaginal Wall Prolapse: Comparison of SIS Graft and Traditional Repair.|Completed||Phase 4|56|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:23:23.366371|2018-06-01 01:23:23.366371
NCT00827515|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-03-04|2009-01-21|2009-01-22|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|May 2009|Anticipated|2009-05-31|April 2009|Anticipated|2009-04-30||Interventional|||Relative Bioavailability and Food Effect Study|A Phase 1, Randomized, Open-Label, Single Dose, 4-Way Crossover Study In Healthy Volunteers To Assess The Relative Bioavailability Of The Oral Powder In Capsule (PIC) And An Immediate Release (IR) Film-Coated Tablet Of PH-797804 In The Fed And Fasted State|Withdrawn||Phase 1|0|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:23:23.459091|2018-06-01 01:23:23.459091
NCT00827502|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2010-03-30||2011-04-25|2009-01-21|2009-01-22|Estimate|2010-05-17|2010-06-09|Estimate||||2011-04-25|2011-04-28|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections|Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections|Completed|||421|Actual|Pfizer|||||f||||f||||||||||2018-06-01 01:23:23.532717|2018-06-01 01:23:23.532717
NCT00827489|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-09-01|2009-01-21|2009-01-22|Estimate|||||||2009-09-01|2009-09-02|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Evaluating HTC-867 in Healthy Young and Elderly Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTC-867 Administered Orally to Healthy Subjects|Terminated||Phase 1|72|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:23:23.814992|2018-06-01 01:23:23.814992
NCT00827476|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|January 2015|Anticipated|2015-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Improving Human Ovarian Transplantation|Phase 1 Study to Improve Results of Human Ovarian Transplantation|Unknown status|Active, not recruiting|Early Phase 1|100|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-06-01 01:23:23.940197|2018-06-01 01:23:23.940197
NCT00827463|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2016-08-19|2009-01-21|2009-01-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|anémie||Early Detection of Anaemia During the Maternity|The Early Detection of Anaemia During the Maternity Decreases the Anaemia at the End of the Maternity.|Completed||Phase 3|80|Actual|University Hospital, Limoges||2|||f||||t||||||||||2018-06-01 01:23:24.019933|2018-06-01 01:23:24.019933
NCT00827450|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2012-02-23|2009-01-21|2009-01-22|Estimate|||||||2012-02-23|2012-02-24|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|COLIBRI||Effects of Coffee on Hepatic Steatosis Induced by a High Fructose Diet|Effects of Coffees With Various Compositions of Antioxidants on Hepatic Steatosis Induced by a High Fructose, Hypercaloric Diet|Completed||N/A|13|Actual|University of Lausanne||5|||f||||t||||||||||2018-06-01 01:23:24.098915|2018-06-01 01:23:24.098915
NCT00827437|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2012-04-20|2009-01-21|2009-01-22|Estimate|||||||2012-04-20|2012-04-23|Estimate|January 2004||2004-01-31|June 2011|2011-06-30||||November 2007|Actual|2007-11-30||Interventional|||Family-Staff Communication Intervention at the Time of Difficult Treatment Decision Making|Family-Staff Communication Intervention at the Time of Difficult Treatment Decision Making|Completed||N/A|401|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 01:23:24.230376|2018-06-01 01:23:24.230376
NCT00826696|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2010-01-26|2009-01-20|2009-01-22|Estimate|||||||2010-01-26|2010-01-28|Estimate|January 2009||2009-01-31|January 2010|2010-01-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Observational|||A Retrospective Review of the Seasonality of Pre-Eclampsia|A Retrospective Review of the Seasonality of Pre-Eclampsia|Completed|||500|Anticipated|Oklahoma State University Center for Health Sciences|||||f||||t||||||||||2018-06-01 01:23:32.972048|2018-06-01 01:23:32.972048
NCT00827424|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2010-08-23|2009-01-21|2009-01-22|Estimate|||||||2010-08-23|2010-08-24|Estimate|December 2008||2008-12-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|AWESOME||The Impact of the PACE Program Implementation on Health Services Utilization by Obese Arab Women|The Impact of the PACE Program Implementation on Health Services Utilization by Obese Arab Women (The AWESOME Study: Arab WomEn Study on Obesity Metabolism and Exercise)|Completed||N/A|100|Anticipated|Clalit Health Services||2|||f||||f||||||||||2018-06-01 01:23:24.327405|2018-06-01 01:23:24.327405
NCT00827411|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-04-11|2009-01-21|2009-01-22|Estimate|||||||2013-04-11|2013-04-12|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|March 2012|Actual|2012-03-31||Interventional|ARCTIC||Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy|Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting|Completed||Phase 4|2500|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||t||||||||||2018-06-01 01:23:24.460107|2018-06-01 01:23:24.460107
NCT00827398|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2014-11-05|2009-01-20|2009-01-22|Estimate|||||||2014-11-05|2014-11-06|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|MSCforGVHD||Treatment of Steroid Resistant GVHD by Infusion MSC|Treatment of Steroid Resistant Grade II to IV GVHD by Infusion MSCof Mesenchymal Stem Cells Expanded With Human Plasma and Platelet Lysate a Phase I/II Study|Completed||Phase 1/Phase 2|50|Actual|UMC Utrecht|||||f||||f||||||||||2018-06-01 01:23:24.552758|2018-06-01 01:23:24.552758
NCT00827385|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-02-02|2009-01-21|2009-01-22|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Intraoperative Blood Pressure and Cognitive Performance|Impact of Intraoperative Blood Pressure on Cognitive Performance in Patients With and Without Hypertension: a Prospective Observational Study|Completed|||100|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-06-01 01:23:24.64319|2018-06-01 01:23:24.64319
NCT00827372|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2014-09-02||2014-10-15|2009-01-21|2009-01-22|Estimate|2014-10-15|2014-10-16|Estimate||||2014-10-15|2014-10-16|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer|A Phase II Study of VEGF Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer|Completed||Phase 2|10|Actual|Indiana University|This study was to enroll 14-15 patients. Due to toxicity and enough patients met the definition of response, enrollment to this study was halted early, leading to a smaller number of subjects analyzed.|1|||f||||t||||||||||2018-06-01 01:23:24.717167|2018-06-01 01:23:24.717167
NCT00827359|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2017-06-28|2009-01-21|2009-01-22|Estimate|||||||2017-06-28|2017-06-29|Actual|March 2009||2009-03-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma|A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:23:25.248779|2018-06-01 01:23:25.248779
NCT00827346|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2011-04-28|2009-01-21|2009-01-22|Estimate|||||||2011-04-28|2011-04-29|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty|Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty|Completed||Phase 2/Phase 3|100|Anticipated|Ottawa Heart Institute Research Corporation||4|||f||||f||||||||||2018-06-01 01:23:25.371858|2018-06-01 01:23:25.371858
NCT00827333|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2016-07-29|2009-01-21|2009-01-22|Estimate|||||||2016-07-29|2016-08-02|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Palliative Care Teaching Sessions for Family Caregivers of Patients With Non-Small Cell Lung Cancer|Palliative Care for Quality of Life and Symptom Concerns in Family Caregivers of Lung Cancer Patients|Completed||N/A|372|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 01:23:25.67713|2018-06-01 01:23:25.67713
NCT00827320|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2018-01-19|2009-01-21|2009-01-22|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2007||2007-06-30|January 2018|2018-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions|Completed||N/A|26|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:23:25.785702|2018-06-01 01:23:25.785702
NCT00827307|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2011-08-05|2009-01-21|2009-01-22|Estimate|||||||2011-08-05|2011-08-08|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Zoladex Plus Tamoxifen in Breast Cancer|The Effects of Adjuvant Zoladex Plus Tamoxifen on Breast Density in Pre- or Peri-menopausal Women With Early-stage Breast Cancer|Completed||N/A|100|Anticipated|Zhejiang Cancer Hospital||2|||f||||f||||||||||2018-06-01 01:23:25.879431|2018-06-01 01:23:25.879431
NCT00827294|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-09-11|2009-01-20|2009-01-22|Estimate|||||||2009-09-11|2009-09-14|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Home-based Self-delivered Mirror Therapy for Phantom Limb Pain|A Pilot Study of Self-delivered Home-based Mirror Therapy for Phantom Limb Pain|Unknown status|Recruiting|Early Phase 1|16|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-06-01 01:23:25.977444|2018-06-01 01:23:25.977444
NCT00827281|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2017-04-28|2009-01-21|2009-01-22|Estimate|||||||2017-04-28|2017-05-01|Actual|August 2008|Actual|2008-08-31|April 2017|2017-04-30|July 15, 2015|Actual|2015-07-15|July 15, 2015|Actual|2015-07-15||Interventional|||D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation (DCSSmoking)|D-Cycloserine Enhancement of Exposure-Based CBT for Smoking Cessation|Withdrawn||Phase 2|0|Actual|Boston University Charles River Campus||2||Study was not funded and pilot work proved impractical.|f||||f||||||||||2018-06-01 01:23:26.052495|2018-06-01 01:23:26.052495
NCT00827268|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2017-11-28|2009-01-21|2009-01-22|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2009||2009-06-30|November 2017|2017-11-30|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|||Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes|Multimodal Treatment of Phonological Alexia: Behavioral & fMRI Outcomes|Completed||N/A|5|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:23:26.121675|2018-06-01 01:23:26.121675
NCT00827255|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2011-10-17||2012-07-16|2009-01-20|2009-01-22|Estimate|2012-07-16|2012-07-18|Estimate||||2012-07-16|2012-07-18|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Observational|||Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%||Completed|||35|Actual|Allergan|||1||f||||f||||||||||2018-06-01 01:23:26.20039|2018-06-01 01:23:26.20039
NCT00827242|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2010-10-19||2010-10-19|2009-01-20|2009-01-22|Estimate|2010-10-19|2010-11-17|Estimate||||2010-10-19|2010-11-17|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|325|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:23:26.487685|2018-06-01 01:23:26.487685
NCT00827229|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of Laborpro - a New Device for the Assessment of Progress of Labor||Completed||N/A|110|Actual|Trig Medical Inc||1|||f||||f||||||||||2018-06-01 01:23:27.56209|2018-06-01 01:23:27.56209
NCT00827216|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-06-22|2009-01-21|2009-01-22|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia|The Effect of Intravenous Erythromycin on Gastric Emptying in Patients Undergoing Rapid Sequence Intubation for Full Stomach - A Randomised, Placebo-controlled, Double-blind Study|Completed||Phase 2|132|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 01:23:27.624437|2018-06-01 01:23:27.624437
NCT00827203|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-03-06|2009-01-21|2009-01-22|Estimate|||||||2009-03-06|2009-03-09|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors|A Phase 1 Multi-Dose Dose-Escalation Study of Elesclomol Sodium, Administered Once Weekly to Subjects With Solid Tumors|Suspended||Phase 1|30|Anticipated|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-06-01 01:23:27.764408|2018-06-01 01:23:27.764408
NCT00827190|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2010-02-02|2009-01-21|2009-01-22|Estimate|||||||2010-02-02|2010-02-03|Estimate|February 2009||2009-02-28|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study Evaluating Single Ascending Doses Of ILS-920|Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of ILS-920 Administered Intravenously To Healthy Adult Subjects|Completed||Phase 1|16|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:23:27.821132|2018-06-01 01:23:27.821132
NCT00827177|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2014-01-23|2009-01-21|2009-01-22|Estimate|||||||2014-01-23|2014-01-24|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|||Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|87|Actual|ArQule||1|||f||||f||||||||||2018-06-01 01:23:27.874784|2018-06-01 01:23:27.874784
NCT00827164|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-05-09|2009-01-21|2009-01-22|Estimate|||||||2015-05-09|2015-05-12|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer|Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer|Completed||Phase 2|29|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:23:27.94435|2018-06-01 01:23:27.94435
NCT00827151|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2015-09-21|2009-01-20|2009-01-22|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|January 2015|Anticipated|2015-01-31|May 2011|Actual|2011-05-31||Interventional|838||Bone Mass Accrual in Adolescent Athletes|"2008P-00346: Bone Mass Accrual in Adolescent Athletes"|Withdrawn||Phase 3|0|Actual|Massachusetts General Hospital||2||The study was not funded|f||||t||||||||||2018-06-01 01:23:28.027566|2018-06-01 01:23:28.027566
NCT00827138|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2014-07-16|2009-01-21|2009-01-22|Estimate|||||||2014-07-16|2014-07-18|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)|A Multicenter Phase 1 Clinical and Pharmacokinetic Study of DCC-2036 in Subjects With Leukemias (Ph+CML With T315I Mutation Only)|Completed||Phase 1|57|Actual|Deciphera Pharmaceuticals LLC||1|||f||||f||||||||||2018-06-01 01:23:28.101807|2018-06-01 01:23:28.101807
NCT00827125|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2010-01-04|2009-01-21|2009-01-22|Estimate|||||||2010-01-04|2010-01-05|Estimate|March 2009||2009-03-31|January 2009|2009-01-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based, Multiple Parameters|Determination of Labor Progression Patterns Using Non-invasive, Ultrasound Based, Multiple Parameters|Unknown status|Recruiting|Phase 2|650|Anticipated|Trig Medical Inc|||||f||||f||||||||||2018-06-01 01:23:28.172714|2018-06-01 01:23:28.172714
NCT00827112|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2011-07-11||2012-06-08|2009-01-21|2009-01-22|Estimate|2011-10-19|2011-11-24|Estimate||||2012-06-08|2012-06-15|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients|Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naïve HIV-Infected Patients With R5 HIV-1|Completed||Phase 2|129|Actual|ViiV Healthcare||2|||f||||t||||||||||2018-06-01 01:23:28.401611|2018-06-01 01:23:28.401611
NCT00827099|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2011-07-28||2012-03-19|2009-01-21|2009-01-22|Estimate|2011-07-28|2011-08-03|Estimate||||2012-03-19|2012-03-23|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer|Transplantation of Two Partially Matched Umbilical Cord Blood Units Following Reduced Intensity Conditioning to Enhance Engraftment and Limit Transplant-Related Mortality in Adults With Hematologic Malignancies|Terminated||Phase 2|5|Actual|Northside Hospital, Inc.|This study was terminated early, therefore no additional data measures or outcomes are available.|||Unacceptable morbidity & mortality|f||||f||||||||||2018-06-01 01:23:29.171408|2018-06-01 01:23:29.171408
NCT00827086|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2011-07-20|2009-01-20|2009-01-22|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|July 2011|Actual|2011-07-31|||||Observational|||Influencing Factors in Uveitis|Evaluation of Influencing Factors in Uveitis|Completed|||500|Anticipated|St. Franziskus Hospital|||2||f||||f||||||||||2018-06-01 01:23:29.491809|2018-06-01 01:23:29.491809
NCT00827073|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2014-03-11||2014-07-11|2009-01-21|2009-01-22|Estimate|2014-05-20|2014-06-23|Estimate||||2014-07-11|2014-07-22|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery|The Effects on Betadine 5% Penetration When Using Lidocaine 2% Jelly Versus Topical Tetracaine 0.5% for Topical Phacoemulsification Cataract Surgery.|Completed||N/A|40|Actual|Hermann Eye Center||2|||f||||f||||||||||2018-06-01 01:23:29.571835|2018-06-01 01:23:29.571835
NCT00827060|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-27|2009-01-21|2009-01-22|Estimate|||||||2009-01-27|2009-01-28|Estimate|December 2006||2006-12-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Observational|||Observation of Initial Procalcitonin and the Clinical Course of Patients With Acute Respiratory Tract Infections|Observation of the Initial Procalcitonin Values and the Clinical Course of Patients With Acute Respiratory Tract Infections at General Medical Practices in Greater Hannover|Completed|||702|Actual|Hannover Medical School|||||f||||f||||||||||2018-06-01 01:23:29.844482|2018-06-01 01:23:29.844482
NCT00827047|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2016-03-30|2009-01-21|2009-01-22|Estimate|||||||2016-03-30|2016-04-01|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma Treatment|A Prospective Randomized Controlled Trial of Total Hemihepatic Vascular Exclusion in Hepatectomy in Hepatocellular Carcinoma Treatment|Completed||N/A|150|Actual|Eastern Hepatobiliary Surgery Hospital||3|||f||||t||||||||||2018-06-01 01:23:29.915524|2018-06-01 01:23:29.915524
NCT00827034|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-04-20|2009-01-21|2009-01-22|Estimate|||||||2009-04-20|2009-04-21|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects|A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:23:30.014401|2018-06-01 01:23:30.014401
NCT00827021|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2016-07-15|2009-01-21|2009-01-22|Estimate|||||||2016-07-15|2016-07-19|Estimate|July 2009||2009-07-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CEDOSE||The Clinical Evaluation of the Dose of Erythropoietins Trial|Effects of the Dose of Erythropoiesis Stimulating Agents on Cardiac-cerebrovascular Outcomes Quality of Life and Costs in Hemodialysis Patients. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) Trial|Completed||Phase 3|656|Actual|Consorzio Mario Negri Sud||2|||f||||t||||||||||2018-06-01 01:23:30.086067|2018-06-01 01:23:30.086067
NCT00827008|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21||2012-11-27|2012-11-27|2009-01-21|2009-01-22|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|OLLTT||Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus|An Open-Label, Long-Term Treatment Study to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane With Subjective Tinnitus|Terminated||Phase 3|821|Actual|Merz Pharmaceuticals GmbH||1|||f||||f||||||||||2018-06-01 01:23:30.239033|2018-06-01 01:23:30.239033
NCT00826995|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2015-04-20|2009-01-21|2009-01-22|Estimate|||||||2015-04-20|2015-04-22|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Video-Based Versus Written Patient Education on Melanoma|Comparison of Video-based Versus Written Patient Education on Melanoma|Completed||N/A|78|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 01:23:30.446579|2018-06-01 01:23:30.446579
NCT00826982|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2012-05-15|2009-01-21|2009-01-22|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2008||2008-01-31|May 2012|2012-05-31||||August 2011|Actual|2011-08-31||Observational|Sonoma||Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer|Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer|Completed|||90|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 01:23:30.544097|2018-06-01 01:23:30.544097
NCT00826969|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2016-12-01|2009-01-21|2009-01-22|Estimate|||||||2016-12-01|2016-12-02|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|October 2011|Actual|2011-10-31|July 2010|Actual|2010-07-31||Interventional|||Ciclesonide for the Treatment of Airway Hyperresponsiveness|Ciclesonide for the Treatment of Airway Hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A Double-blind, Randomized, Parallel Group Study.|Completed||Phase 4|64|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:23:30.593279|2018-06-01 01:23:30.593279
NCT00826956|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate||||January 2009|2009-01-31||||||||Expanded Access|||The Change of Pulmonary Blood Flow During One Lung Ventilation|The Changes of Pulmonary Blood Flow in Nondependent Lung During One Lung Ventilation|Temporarily not available|||||Sichuan University|||||f||||||||||||||2018-06-01 01:23:30.676102|2018-06-01 01:23:30.676102
NCT00826943|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2009-06-25||2014-02-19|2009-01-21|2009-01-22|Estimate|2014-02-19|2014-02-20|Estimate||||2014-02-19|2014-02-20|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Is Levocetirizine Less Sedating Than Cetirizine?|Is Levocetirizine Less Sedating Than Cetirizine? A Randomized, Double-blind, Placebo Controlled Trial.|Completed||Phase 4|30|Actual|Vanderbilt University||3|||f||||f||||||||||2018-06-01 01:23:30.818422|2018-06-01 01:23:30.818422
NCT00826930|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2010-08-11|2009-01-21|2009-01-22|Estimate|||||||2010-08-11|2010-08-12|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma|Open-label Study to Determine the Effect of Trans Sodium Crocetinate (TSC) on Intra-tumoral Oxygen Concentration, Tolerability, and Pharmacokinetics of TSC in Post-operative Patients With High Grade Glioma (HGG)|Terminated||Phase 1|1|Actual|Diffusion Pharmaceuticals Inc||8||Sponsor business decision, not based on safety or efficacy data.|f||||t||||||||||2018-06-01 01:23:31.087384|2018-06-01 01:23:31.087384
NCT00826917|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-05-31|2009-01-21|2009-01-22|Estimate|||||||2015-05-31|2015-06-02|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Observational|||Use of 3D/4D Ultrasound in the Evaluation of Fetal Anomalies|Use of 3D/4D Ultrasound in the Evaluation of Fetal Anomalies - The Use of Volumetry by Three Dimensional Ultrasound in the First Trimester|Completed|||195|Actual|The University of Hong Kong|||4||f||||t||||||||||2018-06-01 01:23:31.16755|2018-06-01 01:23:31.16755
NCT00826904|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2018-01-16|2009-01-21|2009-01-22|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2007||2007-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Regulation Of Maternal Fuel Supply And Neonatal Adiposity|Regulation Of Maternal Fuel Supply And Neonatal Adiposity|Active, not recruiting|||40|Anticipated|University of Colorado, Denver|||2||f||||t||||||||||2018-06-01 01:23:31.250988|2018-06-01 01:23:31.250988
NCT00826891|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-01-20|2009-01-20|2009-01-22|Estimate|||||||2009-01-20|2009-01-22|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Study of Cisplatin in Cervical Cancer Stage IVB|Phase II Study of Cisplatin Combined With Topotecan in Advanced (Stage IVB) Recurrent or Persistent Cervical Cancer|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Chinese Anti-Cancer Association|||||f||||f||||||||||2018-06-01 01:23:31.346814|2018-06-01 01:23:31.346814
NCT00826878|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2012-06-27|2009-01-21|2009-01-22|Estimate|||||||2012-06-27|2012-06-28|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase 1b/2a Open-Label Study to Evaluate the Safety and Activity of Once Daily Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer|Completed||Phase 1|17|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:23:31.478281|2018-06-01 01:23:31.478281
NCT00826865|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2018-01-19|2009-01-21|2009-01-22|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2005||2005-08-31|January 2018|2018-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions|Completed||N/A|27|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:23:31.553383|2018-06-01 01:23:31.553383
NCT00826852|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2010-07-26|2009-01-21|2009-01-22|Estimate|||||||2010-07-26|2010-07-27|Estimate|October 2003||2003-10-31|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax|Phase II Trial of Weekly Docetaxel and Four Weekly Carboplatin Combination in the First-line Treatment of Advanced Non-small Cell Lung Cancer|Completed||Phase 2|49|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:23:31.619167|2018-06-01 01:23:31.619167
NCT00826839|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2013-06-21|2009-01-21|2009-01-22|Estimate|||||||2013-06-21|2013-06-25|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|September 2010|Actual|2010-09-30||Interventional|OMLET||Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients|A Randomized Controlled Trial of Treatment Protocols to Optimize Outcomes in Poor Responder In Vitro Fertilization (IVF) Patients: E2 Patch/Antagonist Protocol Versus OCP/Microdose Lupron Protocol|Withdrawn||Phase 4|0|Actual|Weill Medical College of Cornell University||2||poor enrollment|f||||f||||||||||2018-06-01 01:23:31.69499|2018-06-01 01:23:31.69499
NCT00826826|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2014-03-04|2009-01-20|2009-01-22|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|AMIO-CAT||The Effect of Short Term Amiodarone Treatment After Catheter Ablation for Atrial Fibrillation|The Effect of Short Term Amiodarone Treatment on Success Rate and Quality of Life After Catheter Ablation for Atrial Fibrillation|Completed||N/A|212|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:23:31.818353|2018-06-01 01:23:31.818353
NCT00826813|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|March 2011|Anticipated|2011-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Trial Using 125I Embedded Stent in Patients With Advanced Esophageal Cancer|Phase IV Study of Self-Expandable Esophageal Stent Loaded With 125I Seeds: a Randomized Controlled Multiple Center Trial in Patients With Advanced Esophageal Cancer|Unknown status|Active, not recruiting|N/A|250|Actual|Southeast University, China||1|||f||||t||||||||||2018-06-01 01:23:31.914606|2018-06-01 01:23:31.914606
NCT00826800|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2015-04-03||2015-04-03|2009-01-20|2009-01-22|Estimate|2015-04-03|2015-04-15|Estimate||||2015-04-03|2015-04-15|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer|A Pilot Study of Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer|Terminated||N/A|2|Actual|Memorial Sloan Kettering Cancer Center|Early termination lead to small numbers of subjects analyzed.|1||Lack of accrual|f||||||||||||||2018-06-01 01:23:32.026237|2018-06-01 01:23:32.026237
NCT00826787|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2018-01-19|2009-01-21|2009-01-22|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2005||2005-08-31|January 2018|2018-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions|Completed||N/A|29|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:23:32.20848|2018-06-01 01:23:32.20848
NCT00826774|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2012-05-14|2009-01-21|2009-01-22|Estimate|||||||2012-05-14|2012-05-15|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|Power-UP||Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial)|Practice-based Opportunities for Weight Reduction Trial at University of Pennsylvania|Completed||Phase 3|390|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 01:23:32.294462|2018-06-01 01:23:32.294462
NCT00826761|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2012-06-14|2009-01-21|2009-01-22|Estimate|||||||2012-06-14|2012-06-15|Estimate|January 2009||2009-01-31|June 2012|2012-06-30||||June 2009|Actual|2009-06-30||Interventional|ProSat||ProSat - Effect of Probiotics on Satiety|Probiotics and Satiety - Acute Effects and Persistence of Acute Effects|Completed||N/A|22|Actual|University of Copenhagen||3|||f||||||||||||||2018-06-01 01:23:32.383937|2018-06-01 01:23:32.383937
NCT00826748|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2017-03-16||2018-01-02|2009-01-21|2009-01-22|Estimate|2018-01-02|2018-01-25|Actual||||2018-01-02|2018-01-25|Actual|November 2010||2010-11-30|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||The subjects included in this group underwent the screening visit and were determined eligible to undergo the baseline assessments and sample collection procedure.|Effect of Inhaled Steroids on Gene Expression in the Lungs - 2|Effect of Inhaled Steroids on Gene Expression in the Lungs of Healthy Smokers|Terminated||Phase 4|24|Actual|Weill Medical College of Cornell University|The study could not completed as designed due to a lack of funding.|3||Funding|f||||t||||||||Undecided||2018-06-01 01:23:32.464126|2018-06-01 01:23:32.464126
NCT00826735|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effect of Guided Imagery on the Third Stage of Labor|The Effect of Guided Imagery on the Third Stage of Labor|Completed||N/A|||Vanderbilt University||1|||f||||f||||||||||2018-06-01 01:23:32.716712|2018-06-01 01:23:32.716712
NCT00826722|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2018-01-19|2009-01-21|2009-01-22|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2007||2007-06-30|January 2018|2018-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Levetiracetam 1g Tablets Under Fasting Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:23:32.790845|2018-06-01 01:23:32.790845
NCT00826709|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-04-14|2009-01-21|2009-01-22|Estimate|||||||2009-04-14|2009-04-15|Estimate|February 2009||2009-02-28|April 2009|2009-04-30||||October 2009|Anticipated|2009-10-31||Interventional|||Prospective Evaluation of the Fluid Rapid Influenza Test|CLINICAL STUDY PROTOCOL for the Prospective Evaluation of the fluID Rapid Influenza Test|Suspended||Phase 3|1300|Anticipated|Nanogen, Inc.||3||The 2008-09 North American peak influenza season ended prior to study completion.|f||||f||||||||||2018-06-01 01:23:32.870084|2018-06-01 01:23:32.870084
NCT00826683|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2016-08-19|2009-01-20|2009-01-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|CBNPC:PCE||Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)|Detection of Circulating Endothelial Progenitor Cells (EPCs) in Peripheral Blood From Non-small Cell Lung Cancer Patients|Completed||Phase 3|140|Actual|University Hospital, Limoges||3|||f||||f||||||||||2018-06-01 01:23:33.045543|2018-06-01 01:23:33.045543
NCT00826670|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2012-08-06|2009-01-20|2009-01-22|Estimate|||||||2012-08-06|2012-08-07|Estimate|June 2009||2009-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study||Completed||Phase 4|58|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 01:23:33.108128|2018-06-01 01:23:33.108128
NCT00826657|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2015-05-19|2009-01-20|2009-01-22|Estimate|||||||2015-05-19|2015-05-21|Estimate|October 2004||2004-10-31|May 2015|2015-05-31|November 2006|Actual|2006-11-30|August 2005|Actual|2005-08-31||Interventional|||Vitamin B12 Supplementation Study|Assessment of Functional Vitamin B12 Deficiency in Mexican Women|Completed||N/A|180|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 01:23:33.180025|2018-06-01 01:23:33.180025
NCT00826644|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2012-01-09|2009-01-21|2009-01-22|Estimate|||||||2012-01-09|2012-01-10|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|COMBAT||Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient|A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer|Unknown status|Recruiting|Phase 3|150|Anticipated|Chonnam National University Hospital||2|||f||||f||||||||||2018-06-01 01:23:33.37413|2018-06-01 01:23:33.37413
NCT00826631|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|||How Does 4 Weeks of Increased Fast Food Intake Affect Metabolism?|How Does 4 Weeks of Increased Fast Food Intake Affect Metabolism?|Completed||N/A|36|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-06-01 01:23:33.505042|2018-06-01 01:23:33.505042
NCT00826618|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2014-08-06||2014-08-24|2009-01-20|2009-01-22|Estimate|2014-08-24|2014-08-26|Estimate||||2014-08-24|2014-08-26|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema|Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema|Completed||Phase 1|6|Actual|University of Miami|The main limitation of this study is the small number of patients.There is no comparative arm to better define the relative efficacy of ranibizumab as compared with intraocular steroids or other treatments.|1|||f||||t||||||||||2018-06-01 01:23:33.593933|2018-06-01 01:23:33.593933
NCT00826605|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2010-01-26|2009-01-20|2009-01-22|Estimate|||||||2010-01-26|2010-01-28|Estimate|January 2009||2009-01-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Observational|||Urobilinogen, Maternal Weight Loss and Impending Parturition at Term|Retrospective Investigation of Presence of Urobilinogen and Maternal Weight Loss as Indications of Impending Parturition in the Term Gravida|Completed|||200|Anticipated|Oklahoma State University Center for Health Sciences|||2||f||||t||||||||||2018-06-01 01:23:33.767517|2018-06-01 01:23:33.767517
NCT00826592|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2015-04-15|2009-01-21|2009-01-22|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis|Comparison of Video-based Versus Written Patient Education on Atopic Dermatitis|Completed||N/A|80|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 01:23:33.828953|2018-06-01 01:23:33.828953
NCT00826579|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2015-03-11|2009-01-20|2009-01-22|Estimate|||||||2015-03-11|2015-03-12|Estimate|May 2000||2000-05-31|March 2015|2015-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer|Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer|Completed||Phase 1/Phase 2|192|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 01:23:33.896864|2018-06-01 01:23:33.896864
NCT00826566|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2015-09-22|2009-01-21|2009-01-22|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|||Anti-inflammatory Effects of Caffeine in Chronic Obstructive Pulmonary Disease (COPD) Subjects|Pilot Study to Investigate the Anti-inflammatory Effects of Caffeine in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Withdrawn||N/A|0|Actual|Maastricht University Medical Center||2||Suitable subjects could not be recruited within the estimated time frame.|f||||f||||||||||2018-06-01 01:23:33.966459|2018-06-01 01:23:33.966459
NCT00826553|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2017-06-01|2009-01-21|2009-01-22|Estimate|||||||2017-06-01|2017-06-05|Actual|January 2009||2009-01-31|June 2017|2017-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|HYPNOS||How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units|Comparison of Polysomnographic Findings in Mechanically Ventilated Patients Sedated With α2 Agonists Versus GABA Agonists|Terminated||Phase 1|6|Actual|Vanderbilt University Medical Center||2||poor recruitment|f||||f||||||||||2018-06-01 01:23:34.037062|2018-06-01 01:23:34.037062
NCT00826540|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2013-11-27||2017-08-07|2009-01-21|2009-01-22|Estimate|2014-01-14|2014-03-03|Estimate||||2017-08-07|2017-09-06|Actual|September 2009|Actual|2009-09-30|August 2017|2017-08-31|February 2014|Actual|2014-02-28|January 2010|Actual|2010-01-31||Interventional|||Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of Sorafenib/Avastin® as Salvage Therapy in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|83|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 01:23:34.145937|2018-06-01 01:23:34.145937
NCT00826527|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 2007||2007-01-31|January 2009|2009-01-31||||December 2009|Anticipated|2009-12-31||Interventional|||Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)|Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH)|Unknown status|Recruiting|Phase 4|23|Anticipated|Seattle Urology Research Center|||||f||||t||||||||||2018-06-01 01:23:35.748061|2018-06-01 01:23:35.748061
NCT00826514|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21||2011-03-14|2011-03-14|2009-01-21|2009-01-22|Estimate||||2011-03-14|2011-03-25|Estimate|2011-03-14|2011-03-25|Estimate|March 2009||2009-03-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis|A Phase 2, 16 Week, Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel Group Proof-Of-Concept Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis|Completed||Phase 2|62|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:23:35.851313|2018-06-01 01:23:35.851313
NCT00826501|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2013-03-15|2009-01-20|2009-01-22|Estimate|||||||2013-03-15|2013-03-18|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|December 2009|Actual|2009-12-31||Interventional|||Randomized Trial Comparing Endoscopy and Surgery for Pancreatic Cyst-gastrostomy|Randomized Trial Comparing Endoscopy and Surgery for Pancreatic Cyst-gastrostomy|Completed||N/A|40|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:23:36.003519|2018-06-01 01:23:36.003519
NCT00826488|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2015-06-01|2009-01-21|2009-01-22|Estimate|||||||2015-06-01|2015-06-02|Estimate|March 2009||2009-03-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Comparison of Breast Tomosynthesis Mammography and Conventional Breast Imaging in the Characterization of Breast Masses|A Comparison of Breast Tomosynthesis Mammography and Conventional Breast Imaging in the Characterization of Breast Masses: A Pilot Study|Completed||Early Phase 1|136|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 01:23:36.07942|2018-06-01 01:23:36.07942
NCT00826475|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2011-08-12|2009-01-20|2009-01-22|Estimate|||||||2011-08-12|2011-08-15|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Randomized Trial to Evaluate the Effectiveness of a Mindfulness Based Intervention (MBSR) for Patients Suffering From Migraine|Randomized Trial to Evaluate the Effectiveness of a Mindfulness Based Intervention (MBSR) for Patients Suffering From Migraine|Completed||N/A|62|Actual|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 01:23:36.150408|2018-06-01 01:23:36.150408
NCT00826462|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2015-05-28|2009-01-21|2009-01-22|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2009||2009-03-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Treatment Study of Steroid Injection and Physical Therapy for Acute Lateral Epicondylitis|Physiotherapy Alone, in Combination With Corticosteroid Injection or Wait-and-see for Acute Lateral Epicondylitis in General Practice: a Randomised, Placebo-controlled Study With 12 Months Follow-up|Completed||Phase 4|177|Actual|University of Oslo||3|||f||||f||||||||||2018-06-01 01:23:36.227645|2018-06-01 01:23:36.227645
NCT00826449|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2015-09-18||2016-05-26|2009-01-20|2009-01-22|Estimate|2015-09-18|2015-10-21|Estimate||||2016-05-26|2016-06-28|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)|Phase I-II Study of Dasatinib and Erlotinib in Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|53|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:23:36.408968|2018-06-01 01:23:36.408968
NCT00826436|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-03-05|2009-01-20|2009-01-22|Estimate|||||||2009-03-05|2009-03-06|Estimate|November 2008||2008-11-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 in Japanese Postmenopausal Women|A Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of PRA-027 Administered Orally to Japanese Postmenopausal Women|Completed|||16|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:23:36.97422|2018-06-01 01:23:36.97422
NCT00826423|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2012-07-27|2009-01-21|2009-01-22|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Observational|MAC||Mycobacterium Avium Intracellulare Complex (MAC) Study|Pilot Study to Assess Safety and Efficacy of Short Course Multiple Drug Therapy for Adult Patients With Mycobacterium Avium Intracellulare Complex (MAC) Infection Associated With Mulit Focal Bronchiectasis and Multiple Small Nodules|Completed|||15|Actual|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     sputum and blood collection for analysis~   "|||2018-06-01 01:23:37.034784|2018-06-01 01:23:37.034784
NCT00826410|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-01-20|2009-01-20|2009-01-22|Estimate|||||||2009-01-20|2009-01-22|Estimate|May 2003||2003-05-31|January 2009|2009-01-31|January 2005|Actual|2005-01-31|December 2004|Actual|2004-12-31||Interventional|||Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery|Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery|Completed||Phase 3|200|Actual|University Hospital Freiburg||1|||f||||f||||||||||2018-06-01 01:23:37.101263|2018-06-01 01:23:37.101263
NCT00826397|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2017-11-03|2009-01-21|2009-01-22|Estimate|||||||2017-11-03|2017-11-06|Actual|June 2005|Actual|2005-06-30|November 2017|2017-11-30|September 2009|Actual|2009-09-30|October 2008|Actual|2008-10-31||Interventional|||Acupuncture for Aromatase Inhibitor Induced Joint Pain|Pilot Study on the Effect of Acupuncture on Joint Pain Induced by Aromatase Inhibitors in Breast Cancer Patients|Completed||N/A|40|Actual|Columbia University||2|||f||||f|f|f||||||Undecided||2018-06-01 01:23:37.183189|2018-06-01 01:23:37.183189
NCT00826384|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2016-03-30|2009-01-21|2009-01-22|Estimate|||||||2016-03-30|2016-04-01|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion|Phase 1,Single-blind, Randomized, Controlled Study to Evaluate the Safety and Effectivity of TACE Therapy of HCC(Hepatocellular Carcinoma) With Blocking Tumor Blood Temporarily and Enhancing Perfu|Completed||Phase 1/Phase 2|352|Actual|Eastern Hepatobiliary Surgery Hospital|||||f||||t||||||||||2018-06-01 01:23:37.26215|2018-06-01 01:23:37.26215
NCT00826371|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2016-11-16|2009-01-21|2009-01-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2009||2009-01-31|November 2016|2016-11-30||||July 2010|Actual|2010-07-31||Interventional|EXTEND II||Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months|Completed||Phase 3|114|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:23:37.328498|2018-06-01 01:23:37.328498
NCT00826358|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2012-09-27|2009-01-20|2009-01-22|Estimate|||||||2012-09-27|2012-09-28|Estimate|November 2008||2008-11-30|September 2012|2012-09-30||||November 2008|Actual|2008-11-30||Interventional|||Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg||Completed||Phase 1|90|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:23:37.405125|2018-06-01 01:23:37.405125
NCT00826345|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2012-06-20|2009-01-21|2009-01-22|Estimate|||||||2012-06-20|2012-06-22|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TCMAcuPilot||Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV|Patient-Oriented TCM Intervention for DSP in HIV: A Pilot Study|Completed||N/A|20|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 01:23:37.473867|2018-06-01 01:23:37.473867
NCT00824083|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2016-04-27|2009-01-15|2009-01-16|Estimate|||||||2016-04-27|2016-04-28|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment|Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment|Completed|||950|Actual|University Hospital Muenster|||2||f||||f||||||||No||2018-06-01 01:24:17.360093|2018-06-01 01:24:17.360093
NCT00826332|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|TVUSET||Transvaginal vs Transabdominal Ultrasound Guided Embryo Transfer|Transvaginal or Transabdominal Ultrasound Guided Embryo Transfer- Which is Better?|Unknown status|Recruiting|Phase 1|200|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 01:23:37.560861|2018-06-01 01:23:37.560861
NCT00826319|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2013-11-27|2009-01-21|2009-01-22|Estimate|||||||2013-11-27|2013-11-28|Estimate|June 2008||2008-06-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|CanPREDDICT||Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time|CanPREDDICT: Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time|Unknown status|Active, not recruiting||2602|Actual|University of British Columbia|||3||f||||f||||||Samples With DNA|"~     Serum,Plasma,Urine, DNA and RNA~   "|||2018-06-01 01:23:37.643065|2018-06-01 01:23:37.643065
NCT00826306|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2015-04-15|2009-01-21|2009-01-22|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Comparison Of Video-based Versus Written Patient Education on Sunscreen|Comparison of Video-based Versus Written Patient Education on Sunscreen Behavior|Completed||N/A|94|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 01:23:37.73862|2018-06-01 01:23:37.73862
NCT00826293|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2013-07-09|2009-01-21|2009-01-22|Estimate|||||||2013-07-09|2013-07-11|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||The Clinical Efficacy of Belting Stabilization for Shoulder Pain|The Clinical Efficacy of Belting Stabilization for Shoulder Pain: A Double Blinded Randomized Clinical Trial|Completed||Phase 1|64|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:23:37.872569|2018-06-01 01:23:37.872569
NCT00826280|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2011-07-08||2017-11-20|2009-01-21|2009-01-22|Estimate|2011-09-14|2011-10-21|Estimate||||2017-11-20|2017-12-18|Actual|March 24, 2009|Actual|2009-03-24|November 2017|2017-11-30|July 15, 2010|Actual|2010-07-15|July 15, 2010|Actual|2010-07-15||Interventional|||Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)|A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson|Completed||Phase 3|347|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 01:23:37.978232|2018-06-01 01:23:37.978232
NCT00826267|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2013-08-08||2013-12-05|2009-01-21|2009-01-22|Estimate|2013-08-08|2013-10-17|Estimate||||2013-12-05|2013-12-31|Estimate|January 2009||2009-01-31|August 2013|2013-08-31||||August 2011|Actual|2011-08-31||Interventional|||6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab|Randomised Phase II Study of Neoadjuvant BIBW 2992 Versus Herceptin Versus Lapatinib in Her2 Positive Breast Cancer Patients|Completed||Phase 2|29|Actual|Boehringer Ingelheim|Because of slow enrollment and a high screen-failure rate, recruitment became a challenge and the sponsor chose to terminate the trial prior to reaching the target enrollment of 120 pat. Small number of subjects lead to some shortcomings in analyses.|3|||f||||||||||||||2018-06-01 01:23:38.766296|2018-06-01 01:23:38.766296
NCT00826254|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2011-07-03|2009-01-21|2009-01-22|Estimate|||||||2011-07-03|2011-07-06|Estimate|August 2003||2003-08-31|January 2009|2009-01-31|December 2011|Anticipated|2011-12-31|April 2007|Actual|2007-04-30||Interventional|||Nutritional Problems After Lung and Heart Transplantation|Nutritional Problems After Lung and Heart Transplantation|Unknown status|Active, not recruiting|N/A|94|Actual|Oslo University Hospital|||||f||||f||||||||||2018-06-01 01:23:39.292202|2018-06-01 01:23:39.292202
NCT00826241|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2015-10-21|2009-01-21|2009-01-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|January 2009||2009-01-31|March 2015|2015-03-31||||January 2017|Anticipated|2017-01-31||Interventional|||Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma|A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 01:23:39.361314|2018-06-01 01:23:39.361314
NCT00826228|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2013-04-17||2013-06-03|2009-01-21|2009-01-22|Estimate|2013-06-03|2013-07-11|Estimate||||2013-06-03|2013-07-11|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)|Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury|Completed||Phase 4|12|Actual|Northwestern University|Small numbers of subjects analyzed with considerable between-subject variability.|1|||f||||f||||||||||2018-06-01 01:23:39.448596|2018-06-01 01:23:39.448596
NCT00826215|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2009-01-21|2009-01-21|2009-01-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Electroacupuncture for Chronic Neck Pain|A Randomized Controlled Trial of the Long-Term Efficacy of Electroacupuncture for Chronic Neck Pain|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|Hong Kong Baptist University||2|||f||||f||||||||||2018-06-01 01:23:39.59586|2018-06-01 01:23:39.59586
NCT00826202|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|2015-04-15||2017-07-07|2009-01-21|2009-01-22|Estimate|2016-12-15|2017-02-08|Estimate||||2017-07-07|2017-08-14|Actual|March 2009||2009-03-31|July 2017|2017-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Includes 35 subjects who received at least one post-baseline efficacy evaluation|D-serine for the Schizophrenia Prodrome|D-Serine vs Placebo for the Schizophrenia Prodrome|Completed||Phase 2|44|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||t||||||||||2018-06-01 01:23:39.676282|2018-06-01 01:23:39.676282
NCT00826189|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-21|||2014-01-08|2009-01-21|2009-01-22|Estimate|||||||2014-01-08|2014-01-09|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Influence of Probiotics on Atopy With Focus on Respiratory Allergic Diseases- Follow-up to 7 Years|A Follow-up Study to 7 Years of a Randomized, Double-blinded, Placebo-controlled Study on the Influence of Probiotics on Atopy With Focus on Respiratory Allergic Diseases|Completed|||253|Actual|National University Hospital, Singapore|||||f||||t||||||||||2018-06-01 01:23:40.019683|2018-06-01 01:23:40.019683
NCT00825513|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16||2013-03-19|2013-03-19|2009-01-16|2009-01-21|Estimate||||2013-03-19|2013-03-25|Estimate|2013-03-19|2013-03-25|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Safety and Effectiveness of the Akreos Toric Intraocular Lens.|Monocular Study to Evaluate the Safety and Effectiveness of the Akreos™ Toric IOL When Used to Correct Primary Aphakia With the Reduction of Astigmatism|Completed||Phase 4|198|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 01:23:49.253783|2018-06-01 01:23:49.253783
NCT00826176|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2011-08-09||2015-10-06|2009-01-16|2009-01-21|Estimate|2011-08-09|2011-09-16|Estimate||||2015-10-06|2015-10-07|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of 4.0 mg/kg Sugammadex at 1-2 PTC in Chinese and European Subjects (Study 19.4.335)(P05775AM1)(COMPLETED)|A Multi-center, Open Label Trial, to Show Efficacy and Safety of 4.0 mg.Kg-1 Sugammadex Administered at a Depth of Neuromuscular Blockade of 1-2 PTC Induced by Rocuronium in Chinese and European ASA I-III Subjects Undergoing Elective Surgery Under Propofol Anesthesia|Completed||Phase 3|164|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:23:40.143079|2018-06-01 01:23:40.143079
NCT00826163|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2013-09-10|2009-01-16|2009-01-21|Estimate|||||||2013-09-10|2013-09-11|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients|Innate Immune Responses in Chronic Obstructive Pulmonary Disease Patients|Completed||Phase 3|20|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 01:23:40.425296|2018-06-01 01:23:40.425296
NCT00826150|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-18|||2012-11-12|2009-01-18|2009-01-21|Estimate|||||||2012-11-12|2012-11-14|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer|Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer|Completed||Phase 1/Phase 2|14|Actual|BioCancell Ltd.||1|||f||||t||||||||||2018-06-01 01:23:40.499019|2018-06-01 01:23:40.499019
NCT00826137|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2012-06-13|2009-01-20|2009-01-21|Estimate|||||||2012-06-13|2012-06-14|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|WGAAD||Preventing Childhood Antibiotic-associated Diarrhea by Prebiotics|Prebiotics in the Prevention of Antibiotic-associated Diarrhea in Children|Completed||Phase 3|200|Actual|Soroka University Medical Center||2|||f||||f||||||||||2018-06-01 01:23:40.594301|2018-06-01 01:23:40.594301
NCT00826124|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2011-06-22|2009-01-20|2009-01-21|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Does Magnetic Resonance Imaging (MRI) Improve Interventional Outcomes for Lumbosacral Radiculopathy?|Does MRI Improve Interventional Outcomes for Lumbosacral Radiculopathy? A Randomized Study Comparing Epidural Steroid Injections Based on Clinical Findings Alone, or Clinical Findings and MRI|Completed||N/A|131|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 01:23:40.676575|2018-06-01 01:23:40.676575
NCT00826111|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2011-10-27||2012-06-28|2009-01-20|2009-01-21|Estimate|2012-06-28|2012-06-29|Estimate||||2012-06-28|2012-06-29|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia|The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Co-morbid Anxiety and Insomnia: A Proton MRS Study|Completed||Phase 4|19|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.|Withdrawal of support by the funding sponsor due to other priorities resulted in a very small sample size with a small placebo group. Participant withdrawal and unusable data explains discrepancies in subject numbers in some analyses.|2|||f||||f||||||||||2018-06-01 01:23:40.780809|2018-06-01 01:23:40.780809
NCT00826098|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2015-02-09|2009-01-20|2009-01-21|Estimate|||||||2015-02-09|2015-02-10|Estimate|December 2008||2008-12-31|February 2015|2015-02-28|February 2013|Actual|2013-02-28|June 2011|Actual|2011-06-30||Interventional|||Platelet Rich Plasma (PRP) in Total Knee Replacement|Platelet Rich Plasma (PRP) in Total Knee Replacement: A Prospective, Randomized, Single-blind, Single-center Clinical Study to Evaluate the Effect of Platelet Rich Plasma (PRP) on Short-term Patient Outcomes Following Total Knee Replacement|Completed||Phase 4|70|Actual|Exactech||2|||f||||f||||||||||2018-06-01 01:23:41.201036|2018-06-01 01:23:41.201036
NCT00826085|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2017-01-27|2009-01-20|2009-01-21|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 2013|Actual|2013-02-28|January 2017|2017-01-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|DIGNITY||Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall|A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer.|Completed||Phase 1/Phase 2|17|Actual|Celsion||1|||f||||f||||||||||2018-06-01 01:23:41.275803|2018-06-01 01:23:41.275803
NCT00826072|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2013-05-02|2009-01-20|2009-01-21|Estimate|||||||2013-05-02|2013-05-03|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Observational|||Inflammatory Genetic Polymorphism and Acute Lung Injury After Cardiac Surgery|Association Study of Inflammatory Genetic Polymorphism and Acute Lung Injury After Cardiac Surgery With Cardiopulmonary Bypass|Completed|||107|Actual|Changhai Hospital|||2||f||||t||||||Samples With DNA|"~     3ml blood before surgery, after surgery and 24h after surgery respectively~   "|||2018-06-01 01:23:41.341782|2018-06-01 01:23:41.341782
NCT00826059|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2018-05-25|2009-01-20|2009-01-21|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2009||2009-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ImpACT-24||Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window|A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke|Recruiting||Phase 3|1000|Anticipated|BrainsGate||2|||f||||t||||||||||2018-06-01 01:23:41.401603|2018-06-01 01:23:41.401603
NCT00826046|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2015-10-20|2009-01-20|2009-01-21|Estimate|||||||2015-10-20|2015-10-22|Estimate||||October 2015|2015-10-31||||||||Expanded Access|||Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD|Expanded Access of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD|No longer available|||||Mesoblast, Ltd.|||||||||||||||||||2018-06-01 01:23:41.51829|2018-06-01 01:23:41.51829
NCT00826033|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate||||January 2009|2009-01-31||||||||Observational|||Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer|Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy|Completed|||||Gunma University|||1||f||||f||||||||||2018-06-01 01:23:41.578129|2018-06-01 01:23:41.578129
NCT00826020|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2017-08-17|2009-01-19|2009-01-21|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2009||2009-04-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Evaluation of Omegaven™ Parenteral Nutrition in Patients With TPN-Induced Cholestasis|Prospective Evaluation of a Parenteral Omega-3 Fatty Acid Preparation (Omegaven™) in Therapy of Patients With TPN-Induced Cholestasis|Completed||Phase 2|85|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 01:23:41.637337|2018-06-01 01:23:41.637337
NCT00826007|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2013-03-26||2013-03-26|2009-01-20|2009-01-21|Estimate|2013-03-26|2013-05-27|Estimate||||2013-03-26|2013-05-27|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes|Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes|Completed|||587|Actual|William Beaumont Hospitals|Point-of-care blood glucose testing was most often the means of measurement. Frequency of glucose monitoring was not standardized. Retrospective review.||||f||||f||||||None Retained|"~     non applicable~   "|||2018-06-01 01:23:41.727025|2018-06-01 01:23:41.727025
NCT00825994|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2011-05-10||2014-08-05|2009-01-16|2009-01-21|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|November 2008||2008-11-30|August 2014|2014-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|O3Meno|24 subjects were eligible after V1.|Omega-3 for Peri- and Postmenopausal Depression|Omega-3 for Peri- and Postmenopausal Depression|Completed||N/A|31|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:23:41.985927|2018-06-01 01:23:41.985927
NCT00825981|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2010-07-22|2009-01-20|2009-01-21|Estimate|||||||2010-07-22|2010-07-23|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Observational|HEMOCOR||Primary and Secondary Hemostasis in Elective Coronary Artery Bypass Graft Surgery||Completed|||100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||||2018-06-01 01:23:42.323821|2018-06-01 01:23:42.323821
NCT00825968|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2011-09-16|2009-01-20|2009-01-21|Estimate|||||||2011-09-16|2011-09-20|Estimate|July 2008||2008-07-31|September 2011|2011-09-30|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Observational|||Data Collection and Analysis of Patients Who Have Had an Electrophysiological Procedure|Data Collection and Analysis of Patients Who Have Had an Electrophysiological Procedure Performed at the Ross Heart Hospital|Terminated|||58|Actual|Ohio State University|||1|PI stopped study to make a more substantial database.|f||||f||||||||||2018-06-01 01:23:42.384923|2018-06-01 01:23:42.384923
NCT00825955|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20||2015-09-23|2018-03-05|2009-01-20|2009-01-21|Estimate||||2015-09-23|2015-10-09|Estimate|2018-03-05|2018-03-07|Actual|February 17, 2009|Actual|2009-02-17|March 2018|2018-03-31|August 25, 2017|Actual|2017-08-25|November 15, 2011|Actual|2011-11-15||Interventional|BRISK PS||Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment|A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib: The BRISK PS Study (Brivanib Study in HCC Patients at Risk Post Sorafenib)|Completed||Phase 3|587|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:23:42.463721|2018-06-01 01:23:42.463721
NCT00825942|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2009-04-16|2009-01-19|2009-01-21|Estimate|||||||2009-04-16|2009-04-17|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Interventional|||An Open-Label Study of the Effect of an Ophthalmic Solution on Asteroid Hyalosis|An Open-Label Study of the Effect of C-KAD Ophthalmic Solution on Asteroid Hyalosis|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Chakshu Research, Inc.||1|||f||||f||||||||||2018-06-01 01:23:42.693139|2018-06-01 01:23:42.693139
NCT00825929|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2017-11-14|2009-01-20|2009-01-21|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2009||2009-02-28|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PANNA||Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.|Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)|Recruiting|||176|Anticipated|Radboud University|||1||f||||f||||||Samples Without DNA|"~     Plasma samples will be collected in Week 33 of the pregnancy and at 4-6 weeks after delivery.~     At the following time points samples will be collected: T=0 (prior to dosing), and T=1, 2, 3,~     4, 6, 8, 12 and 24h (24h sample only in case of QD regimen) post-dosing (8 or 9 samples).~      In case the infant needs post-exposure prophylaxis with at least one of the agents sparse PK~     sampling is optional.~   "|||2018-06-01 01:23:42.770856|2018-06-01 01:23:42.770856
NCT00825916|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2012-05-17||2012-09-10|2009-01-20|2009-01-21|Estimate|2012-09-10|2012-10-11|Estimate||||2012-09-10|2012-10-11|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars|A Pilot Phase 2a Blinded, Placebo Controlled, Multicenter Parallel Group, Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product Following Excision of Keloids|Completed||Phase 2|59|Actual|Capstone Therapeutics||3|||f||||f||||||||||2018-06-01 01:23:42.947941|2018-06-01 01:23:42.947941
NCT00825903|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2011-12-31|2009-01-16|2009-01-21|Estimate|||||||2011-12-31|2012-01-04|Estimate|September 2008||2008-09-30|December 2011|2011-12-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||The Effects of Exercise on Physiological and Psychological Parameters in an Asthmatic Population|The Effects of Exercise on Physiological and Psychological Parameters in an Asthmatic Population|Completed||N/A|16|Actual|Washington State University||1|||f||||t||||||||||2018-06-01 01:23:43.548481|2018-06-01 01:23:43.548481
NCT00825890|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2015-09-02|2009-01-19|2009-01-21|Estimate|||||||2015-09-02|2015-09-04|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||The High Cup/Disc Ratio in Children||Completed|||50|Actual|Kim's Eye Hospital|||||f||||||||||||||2018-06-01 01:23:43.638661|2018-06-01 01:23:43.638661
NCT00825877|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-17|||2018-05-19|2009-01-17|2009-01-21|Estimate|||||||2018-05-19|2018-05-22|Actual|January 15, 2009||2009-01-15|June 29, 2012|2012-06-29|June 29, 2012||2012-06-29|||||Observational|||Long-term Follow-up of HALT-C Sustained Virological Responders|Long-Term Follow-Up of HALT-C Sustained Virologic Responders|Completed|||140|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:23:43.697846|2018-06-01 01:23:43.697846
NCT00825864|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-18|||2009-01-18|2009-01-18|2009-01-21|Estimate|||||||2009-01-18|2009-01-21|Estimate|January 2004||2004-01-31|January 2009|2009-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Diclofenac vs Dexamethasone in Combined Surgery|Evaluation the Effect of Diclofenac Drops vs Dexamethasone Drops in Trabeculectomy and Cataract Surgery|Completed||N/A|50|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 01:23:43.76774|2018-06-01 01:23:43.76774
NCT00825851|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|August 2000||2000-08-31|January 2009|2009-01-31|January 2001|Actual|2001-01-31|December 2000|Actual|2000-12-31||Interventional|||Effect of Smoking, Abstention and Nicotine Replacement Therapy on Wound Healing|Effect of Smoking, Abstention and Nicotine Replacement Therapy on Wound Healing|Completed||N/A|78|Actual|Bispebjerg Hospital||4|||f||||f||||||||||2018-06-01 01:23:43.845958|2018-06-01 01:23:43.845958
NCT00824434|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2011-12-20||2012-08-17|2009-01-15|2009-01-16|Estimate|2012-02-03|2012-03-07|Estimate||||2012-08-17|2012-08-30|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|PLATINUM QCA||A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)|A Prospective, Multi-center Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™)|Completed||Phase 3|100|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-06-01 01:24:06.429956|2018-06-01 01:24:06.429956
NCT00825838|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-18|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|||Effect of Chili Pepper Extract on Weight and Fat Loss and Metabolism Increase|A Randomized Double-Blind Placebo-Controlled Clinical Trial of a Purified Chili Pepper Extract (CH-19 Sweet Extract) to Evaluate Its Safety and Efficacy for Weight and Fat Loss and Metabolism Change in Overweight or Obese Healthy Male and Female Adults|Completed||Phase 2|80|Actual|Ajinomoto USA, INC.||2|||f||||||||||||||2018-06-01 01:23:43.930095|2018-06-01 01:23:43.930095
NCT00825825|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2012-06-11||2015-06-16|2009-01-20|2009-01-21|Estimate|2012-07-30|2012-09-03|Estimate||||2015-06-16|2015-07-14|Estimate|May 2007||2007-05-31|June 2015|2015-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Brain Effects of Escitalopram and Citalopram Using fMRI|A Comparison of the CNS Effects of Equivalent Doses of Escitalopram and Racemic Citalopram Using BOLD fMRI|Completed||Phase 4|27|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.|Data from several subjects had to be excluded due to one or more fMRI scans with poor data quality (usually high motion) or scheduling problems that prevented a scan from occuring during the specified time window.|3|||f||||f||||||||||2018-06-01 01:23:44.022196|2018-06-01 01:23:44.022196
NCT00825812|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2011-07-22||2015-10-30|2009-01-16|2009-01-21|Estimate|2011-07-22|2011-08-18|Estimate||||2015-10-30|2015-11-02|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)|A Multi-center, Randomized, Parallel-group, Active-controlled, Safety-assessor Blinded Trial, Comparing the Efficacy and Safety of 2.0 mg.Kg-1 Sugammadex With 50 μg.Kg-1 Neostigmine Administered at Reappearance of T2 After Rocuronium in Chinese and European ASA I-III Subjects Undergoing Elective Surgery Under Propofol Anesthesia|Completed||Phase 3|308|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:23:44.350406|2018-06-01 01:23:44.350406
NCT00825799|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2014-01-02|2009-01-19|2009-01-21|Estimate|||||||2014-01-02|2014-01-03|Estimate|November 2007||2007-11-30|June 2013|2013-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Serum Markers as a Bioassay for Unipolar Depression|Validation of Serum Markers as a Bioassay for Unipolar Depression|Completed|||160|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.|||2||f||||f||||||Samples Without DNA|"~     serum, plasma~   "|||2018-06-01 01:23:44.67723|2018-06-01 01:23:44.67723
NCT00825786|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2017-04-18||2017-05-22|2009-01-16|2009-01-21|Estimate|2017-04-18|2017-05-23|Actual||||2017-05-22|2017-06-14|Actual|September 2008||2008-09-30|May 2017|2017-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Ultrasound Guided Supraclavicular Nerve Block|Ultrasound Guided Supraclavicular Nerve Block: Comparison Between a Mixture of Mepivacaine and Ropivacaine, and Sequential Injection of Mepivacaine Followed by Ropivacaine|Completed||Phase 3|103|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 01:23:44.746307|2018-06-01 01:23:44.746307
NCT00825773|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2009-01-22|2009-01-20|2009-01-21|Estimate|||||||2009-01-22|2009-01-26|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|April 2014|Anticipated|2014-04-30|April 2010|Anticipated|2010-04-30||Interventional|EVOLUTION||A Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer in the Treatment of Patients With de Novo Coronary Artery Lesions|A Randomized Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus SirOlimus ELUting Stent With Non-Biodegradable Polymer in the Treatment of PatIents With de nOvo Coronary Artery LesioNs|Unknown status|Recruiting|Phase 4|1944|Anticipated|JW Medical Systems Ltd||2|||f||||t||||||||||2018-06-01 01:23:45.203975|2018-06-01 01:23:45.203975
NCT00825760|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2013-01-23|2009-01-20|2009-01-21|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Clinical Trial to Investigate Treatment With Photodynamic Therapy to Reduce Levels of Bacteria in Leg Ulcers|Phase II Randomised, Placebo Controlled Trial to Investigate Repeat Dose Antimicrobial Photodynamic Therapy in Patients With Chronic Leg Ulcers.|Completed||Phase 2|57|Actual|Photopharmica||2|||f||||t||||||||||2018-06-01 01:23:45.412346|2018-06-01 01:23:45.412346
NCT00825747|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-18|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Evaluation of Seelens AF, an Aspheric Intra-Ocular Lens|Clinical Evaluation of the Aspheric SeeLens AF Intra-Ocular Lens.|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Hanita Lenses|||||f||||t||||||||||2018-06-01 01:23:45.551319|2018-06-01 01:23:45.551319
NCT00825734|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2014-11-21||2014-12-16|2009-01-19|2009-01-21|Estimate|2014-12-16|2014-12-22|Estimate||||2014-12-16|2014-12-22|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Interventional|||Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer|Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (MBC)|Completed||Phase 1/Phase 2|83|Actual|SCRI Development Innovations, LLC||3|||f||||f||||||||||2018-06-01 01:23:45.727315|2018-06-01 01:23:45.727315
NCT00825721|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|||Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract|A Randomized, Placebo-Controlled, Single-Masked, Dose-Ranging Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataracts|Unknown status|Active, not recruiting|Phase 2|81|Actual|Chakshu Research, Inc.||4|||f||||f||||||||||2018-06-01 01:23:46.105358|2018-06-01 01:23:46.105358
NCT00825708|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2007||2007-03-31|January 2009|2009-01-31||||March 2008|Anticipated|2008-03-31||Interventional|||Evaluation of the Effect of rTMS on Attention in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder (ADHD)|Evaluation of the Effect of rTMS on Attention in Adults Diagnosed With ADHD|Unknown status|Recruiting|N/A|20|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-06-01 01:23:46.192539|2018-06-01 01:23:46.192539
NCT00825695|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2014-04-28|2009-01-20|2009-01-21|Estimate|||||||2014-04-28|2014-04-30|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|March 2012|Actual|2012-03-31||Interventional|||Flavanol-Rich Cocoa and Cerebral Blood Flow|Flavanol-Rich Cocoa, Vascular Responses and Mechanisms|Completed||N/A|60|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:23:46.28466|2018-06-01 01:23:46.28466
NCT00825162|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2011-07-03||2018-04-25|2009-01-15|2009-01-19|Estimate|2011-07-03|2011-07-29|Estimate||||2018-04-25|2018-05-23|Actual|March 2009||2009-03-31|April 2018|2018-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years|A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years|Completed||Phase 4|1992|Actual|Seqirus||3|||f||||t||||||||||2018-06-01 01:23:53.252531|2018-06-01 01:23:53.252531
NCT00825682|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2012-07-03||2016-10-16|2009-01-20|2009-01-21|Estimate|2016-10-16|2016-12-08|Estimate||||2016-10-16|2016-12-08|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||The Effect of Reflexology on Radiation-related Fatigue in Breast Cancer Patients|The Effect of Reflexology on Radiation-related Fatigue and QOL in Breast Cancer Patients: a Pilot Study.|Completed||Phase 1/Phase 2|72|Actual|Sheba Medical Center|This was a pilot non-randomized controlled study, with a relatively small sample and a single therapist.The control group received no additional intervention.|2|||f||||f||||||||No||2018-06-01 01:23:46.367897|2018-06-01 01:23:46.367897
NCT00825669|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2016-03-30|2009-01-20|2009-01-21|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection|A Randomized Controlled Trial of Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection|Completed||N/A|100|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:23:46.634636|2018-06-01 01:23:46.634636
NCT00825656|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2009-01-21|2009-01-20|2009-01-21|Estimate|||||||2009-01-21|2009-01-23|Estimate|September 2008||2008-09-30|January 2009|2009-01-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|SMAN||Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis|SINOL + MucoAd™ (SMAN) Evaluation Trial: A Double-Blind, Cross-Over Comparison of SINOL and SMAN in Subjects With Congestion Due to Allergic Rhinitis|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|Strategic Biosciences||2|||f||||f||||||||||2018-06-01 01:23:46.70915|2018-06-01 01:23:46.70915
NCT00825643|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2017-02-10|2009-01-20|2009-01-21|Estimate|||||||2017-02-10|2017-02-13|Actual|April 2008||2008-04-30|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|SOLVE™||Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes|A Multicentre, Open Label, Observational 24-week Study to Evaluate Safety of Initiating Insulin Therapy With Levemir® (Insulin Detemir) Once-daily in Oral Antidiabetic Drug-treated Patients With Type 2 Diabetes|Completed|||18481|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:23:46.781641|2018-06-01 01:23:46.781641
NCT00825630|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2011-06-19||2012-02-15|2009-01-20|2009-01-21|Estimate|2011-09-07|2011-10-07|Estimate||||2012-02-15|2012-02-16|Estimate|November 2008||2008-11-30|February 2012|2012-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)|The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates|Completed||Phase 4|123|Actual|Exalenz Bioscience LTD.|It was hard to get people to agree to return for multiple tests within a few days, so the enrollment was difficult|4|||f||||t||||||||||2018-06-01 01:23:46.882299|2018-06-01 01:23:46.882299
NCT00825617|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1996||1996-10-31|January 2009|2009-01-31|June 2000|Actual|2000-06-30|October 1999|Actual|1999-10-31||Interventional|||Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy|Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy|Completed||N/A|16|Actual|University of Aarhus||1|||f||||t||||||||||2018-06-01 01:23:47.189239|2018-06-01 01:23:47.189239
NCT00825604|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2012-03-16|2009-01-20|2009-01-21|Estimate|||||||2012-03-16|2012-03-19|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|LOBSTR||Quality of Life and Target Achievement After Treatment of Patients With Stable Angina Pectoris|Quality of Life and Achievement of Target of Treatment After Optimized Medical Treatment, Physical Training and Smoking Cessation With or Without Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris.|Withdrawn||Phase 2|0|Actual|Göteborg University||2||Because of poor inclusion difficulties to find patient|f||||f||||||||||2018-06-01 01:23:47.263125|2018-06-01 01:23:47.263125
NCT00825591|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2011-02-07|2009-01-19|2009-01-21|Estimate|||||||2011-02-07|2011-02-08|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Biological Clock Dysfunction in Optic Nerve Hypoplasia|Identification and Treatment of Biological Clock Dysfunction in Optic Nerve Hypoplasia|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Yale University||2|||f||||f||||||||||2018-06-01 01:23:47.371898|2018-06-01 01:23:47.371898
NCT00825578|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2012-02-03|2009-01-20|2009-01-21|Estimate|||||||2012-02-03|2012-02-06|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Use of Endobronchial Valves in Non-Upper Lobe Heterogeneous Emphysema|Comparative Study of Bronchoscopic Lung Volume Reduction to Evaluate Relative Efficacy in Patients With Non-Upper Lobe Emphysema|Completed||Phase 3|32|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:23:47.440976|2018-06-01 01:23:47.440976
NCT00825565|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2012-02-22||2018-01-31|2009-01-19|2009-01-21|Estimate|2012-11-29|2013-01-01|Estimate||||2018-01-31|2018-02-28|Actual|February 2009||2009-02-28|January 2018|2018-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of Alwextin® Cream in Treating Epidermolysis Bullosa|Open-label, Pilot Study to Investigate the Safety and Tolerability of Alwextin 3.0% Cream in the Treatment of Epidermolysis Bullosa|Completed||Phase 2|8|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 01:23:47.534839|2018-06-01 01:23:47.534839
NCT00825552|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|November 2010|Anticipated|2010-11-30|January 2010|Anticipated|2010-01-31||Interventional|||Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation|Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation. An Open Trial With Risperidone.|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Federal University of Rio Grande do Sul|||||f||||t||||||||||2018-06-01 01:23:49.011361|2018-06-01 01:23:49.011361
NCT00825539|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19||2013-02-18|2013-02-21|2009-01-20|2009-01-21|Estimate||||2013-02-18|2013-02-22|Estimate|2013-02-21|2013-02-28|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia|A Single-dose, Placebo-controlled, Stratified, Randomized, Double-blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-week Multiple-dose Safety and Tolerability in People With Chronic Stable Schizophrenia.|Completed||Phase 1/Phase 2|68|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:23:49.084192|2018-06-01 01:23:49.084192
NCT00825526|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2012-05-31|2009-01-20|2009-01-21|Estimate|||||||2012-05-31|2012-06-01|Estimate|July 2008||2008-07-31|May 2012|2012-05-31||||March 2012|Actual|2012-03-31||Interventional|HARMONY||HARMONY Study (Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga)|HARMONY Study (Hypertension Analysis of Stress Reduction Using Mindfulness Meditation and Yoga)|Completed||N/A|101|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:23:49.163617|2018-06-01 01:23:49.163617
NCT00825500|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2017-03-13||2017-03-13|2009-01-20|2009-01-21|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|January 2009||2009-01-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Safety Population|Staccato Loxapine in Migraine (Out Patient)|A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Outpatients With Migraine Headache|Completed||Phase 2|366|Actual|Alexza Pharmaceuticals, Inc.||3|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 01:23:49.350471|2018-06-01 01:23:49.350471
NCT00825487|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2011-10-17|2009-01-16|2009-01-21|Estimate|||||||2011-10-17|2011-10-19|Estimate|August 2009||2009-08-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies|A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies|Completed||Phase 1|50|Actual|ArQule||1|||f||||f||||||||||2018-06-01 01:23:49.763456|2018-06-01 01:23:49.763456
NCT00825474|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2016-03-30|2009-01-17|2009-01-21|Estimate|||||||2016-03-30|2016-04-01|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma|A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma|Completed||N/A|160|Actual|Eastern Hepatobiliary Surgery Hospital||1|||f||||t||||||||||2018-06-01 01:23:49.869737|2018-06-01 01:23:49.869737
NCT00825461|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2018-01-05|2009-01-20|2009-01-21|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2009|Actual|2009-03-31|September 2009|2009-09-30|December 31, 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Ghrelin With Anorexia Nervosa|Level of Ghrelin With Anorexia Nervosa (AN) Patients. Subgroup AN: With and Without Tubefeeding.|Completed|||20|Actual|Maastricht University Medical Center|||3||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:23:49.959728|2018-06-01 01:23:49.959728
NCT00825448|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2012-03-23|2009-01-20|2009-01-21|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|January 2013|Anticipated|2013-01-31|September 2012|Anticipated|2012-09-30||Interventional|||Alcohol Addiction and Otorhinolaryngology Cancer|Impact for Care for Patients With Alcohol Addiction and Treated for ORL Cancer|Unknown status|Recruiting|N/A|115|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:23:50.031092|2018-06-01 01:23:50.031092
NCT00825435|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2008||2008-10-31|January 2009|2009-01-31||||June 2009|Anticipated|2009-06-30||Interventional|||Coronary CT Angiography in Acute Chest Pain is a Cost Effective Risk Stratification Strategy|Inclusion of Multi-Detector CT Angiography (MDCT) in Low to Intermediate Risk Chest Pain Patients Presenting to the Emergency Department; a Randomized Cost Analysis|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 01:23:50.12115|2018-06-01 01:23:50.12115
NCT00825422|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2012-06-19|2009-01-20|2009-01-21|Estimate|||||||2012-06-19|2012-06-20|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|ICALP||Local Anesthetic Infiltration to Prevent Postoperative Pain After Lumbar Surgery|Assessment of Efficacy and Safety of Continuous Wound Infiltration With Local Anesthesics Through a Parietal Paravertebral Catheter for Postoperative Analgesia After Posterior Lumbar Arthrodesis|Completed||Phase 3|50|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:23:50.206865|2018-06-01 01:23:50.206865
NCT00825396|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-06-09|2009-01-16|2009-01-21|Estimate|||||||2009-06-09|2009-06-11|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension|A Pilot, Open-Label, Controlled Clinical Trial of C-KAD Ophthalmic Solution in Reducing Intraocular Pressure in Patients With Ocular Hypertension|Completed||N/A|12|Anticipated|Chakshu Research, Inc.||1|||f||||f||||||||||2018-06-01 01:23:50.298482|2018-06-01 01:23:50.298482
NCT00825383|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2013-06-19|2009-01-20|2009-01-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|January 1993||1993-01-31|June 2013|2013-06-30|December 1995|Actual|1995-12-31|December 1995|Actual|1995-12-31||Interventional|||Effect of Dietary Fiber on Glucose & Lipids in Non Insulin Dependent Diabetes Mellitus (NIDDM)|Effect of Dietary Fiber on Glucose, Lipid, and Mineral Metabolism in Patients With Non Insulin Dependent Diabetes Mellitus|Completed||N/A|13|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 01:23:50.370471|2018-06-01 01:23:50.370471
NCT00825370|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2018-02-07||2018-04-20|2009-01-20|2009-01-21|Estimate|2018-03-20|2018-04-19|Actual||||2018-04-20|2018-05-18|Actual|October 2008|Actual|2008-10-31|April 2018|2018-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||The discrepancy between the number of patients who completed the study and the number of patients included in analysis is due to missing data (6 Protocolized and 4 Discretionary) and participants enrolled more than once (2 Protocolized). These patients completed the study but had duplicate or missing data that could not be included in analysis.|Protocolized vs Discretionary Use of Opioids in Acute Pain|Protocolized vs Discretionary Use of Opioids in Acute Pain|Completed||Phase 3|350|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 01:23:50.474066|2018-06-01 01:23:50.474066
NCT00825357|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2016-01-26|2009-01-20|2009-01-21|Estimate|||||||2016-01-26|2016-01-28|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Biological Markers to Identify Early Sepsis and Acute Lung Injury||Completed|||30|Actual|Chimei Medical Center|||||f||||f||||||||||2018-06-01 01:23:50.84717|2018-06-01 01:23:50.84717
NCT00825344|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|2013-04-12||2017-09-06|2009-01-20|2009-01-21|Estimate|2013-10-24|2013-12-13|Estimate||||2017-09-06|2017-10-05|Actual|January 2009||2009-01-31|September 2017|2017-09-30|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||Preoperative Etanercept Before Inguinal Hernia Surgery|A Randomized Controlled Study Evaluating Pre-operative Etanercept on the Severity of Postoperative Pain After Inguinal Hernia Surgery.|Completed||N/A|77|Actual|Johns Hopkins University|Only one type of surgery studied; more males than females enrolled (function of military treatment facility and type of population)|2|||f||||t||||||||||2018-06-01 01:23:50.911257|2018-06-01 01:23:50.911257
NCT00825331|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|||2015-09-22|2009-01-20|2009-01-21|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Improvement of Periprocedural Guidewire Management for Cardiac Catheterization (PTCA)|Improvement of Periprocedural Guidewire Management for Cardiac Catheterization (PTCA)Using Preprocedural Marking of the Arterial Access Site and a Graduated Scheme for Removal of the Guidewire|Withdrawn|||0|Actual|RWTH Aachen University|||4|Change of location for Investigators|f||||f||||||||||2018-06-01 01:23:51.13352|2018-06-01 01:23:51.13352
NCT00825318|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2014-02-18||2014-04-28|2009-01-19|2009-01-21|Estimate|2014-04-28|2014-05-26|Estimate||||2014-04-28|2014-05-26|Estimate|July 2009||2009-07-31|April 2014|2014-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis|Pilot Trial To Study Blood Pressure, Weight and Hydration State in Patients Undergoing A Treatment Regimen of Daily Ultrafiltration and Twice-weekly Hemodialysis As Compared to Conventional Three Times Per Week Hemodialysis|Completed||N/A|13|Actual|Renal Research Institute||1|||f||||f||||||||||2018-06-01 01:23:51.296112|2018-06-01 01:23:51.296112
NCT00825305|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-19|2010-01-25||2011-12-07|2009-01-20|2009-01-21|Estimate|2010-04-20|2010-05-19|Estimate||||2011-12-07|2011-12-13|Estimate|November 2008||2008-11-30|December 2011|2011-12-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule)|A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China|Completed||Phase 3|825|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:23:51.508753|2018-06-01 01:23:51.508753
NCT00825292|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2009-01-20|2009-01-20|2009-01-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|July 2006||2006-07-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Detection and Classification of Colon Polyps|Detection and Classification of Colon Polyps: A Comparison of High Definition White Light and Narrow Band Imaging (Endoscopic Trimodal Imaging; ETMI)|Completed||Phase 2|110|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 01:23:51.826936|2018-06-01 01:23:51.826936
NCT00825279|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-20|||2010-05-27|2009-01-20|2009-01-21|Estimate|||||||2010-05-27|2010-05-28|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|EUCATAX||A Trial Comparing a Paclitaxel Eluting Stent With Biodegradable Polymer Versus a Bare Metal Stent|Comparison Among a Paclitaxel Eluting Stent With Biodegradable Polymer Versus an Uncoated Bare Metal Stent. A Prospective, Multicentric and Randomized Study.(EUCATAX Trial)|Completed||Phase 4|300|Actual|Centro de estudios en Cardiologia Intervencionista||2|||f||||t||||||||||2018-06-01 01:23:51.926786|2018-06-01 01:23:51.926786
NCT00825266|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2016-11-21||2017-02-13|2009-01-20|2009-01-21|Estimate|2017-02-13|2017-03-31|Actual||||2017-02-13|2017-03-31|Actual|September 2008||2008-09-30|February 2017|2017-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Insulin Resistance in Pulmonary Arterial Hypertension|The Effect of Bosentan and Pioglitazone on Insulin Resistance in Pulmonary Arterial Hypertension|Terminated||Phase 2|2|Actual|Stanford University|Study terminated due to poor enrollment|2||difficulty in finding eligible subjects|f||||||||||||||2018-06-01 01:23:52.03001|2018-06-01 01:23:52.03001
NCT00825253|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2017-01-05|2009-01-16|2009-01-19|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2007||2007-03-31|January 2017|2017-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes|A Randomised, Open-labelled, 4-period Crossover Trial Characterising Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 Administered Once, Twice or Thrice Daily and Biphasic Human Insulin 30 Administered Once Daily in Subjects With Type 2 Diabetes|Completed||Phase 1|24|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 01:23:52.24957|2018-06-01 01:23:52.24957
NCT00825240|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-03-06|2009-01-15|2009-01-19|Estimate|||||||2015-03-06|2015-03-09|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Formative Study of Tailored Survivor Health Promotion|Formative Study of Tailored Survivor Health Promotion|Completed|||15|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:23:52.321632|2018-06-01 01:23:52.321632
NCT00825227|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2011-07-28||2017-10-12|2009-01-16|2009-01-19|Estimate|2012-02-09|2012-03-13|Estimate||||2017-10-12|2017-11-17|Actual|December 2008||2008-12-31|October 2017|2017-10-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Armodafinil Treatment (150 mg/Day) for Patients With Fatigue Associated With Taxane Chemotherapy Alone or in Combination With Other Agents|Terminated||Phase 2|10|Actual|Teva Pharmaceutical Industries|This trial was discontinued early after only 10 of 160 planned subjects had been recruited. No efficacy data was analyzed.|2|||f||||f||||||||||2018-06-01 01:23:52.416738|2018-06-01 01:23:52.416738
NCT00825214|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-01-16|2009-01-16|2009-01-19|Estimate|||||||2009-01-16|2009-01-19|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|February 2009|Anticipated|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Evaluation of Zapperclick Device for Relief From Mosquito Bites|Evaluation of a Piezoelectric Device (Zapperclick) for Relief From Mosquito Bites|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-06-01 01:23:52.694049|2018-06-01 01:23:52.694049
NCT00825201|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2018-01-17|2009-01-16|2009-01-19|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2009||2009-01-31|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity|Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity|Completed||Phase 1|27|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:23:52.761634|2018-06-01 01:23:52.761634
NCT00825188|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2018-05-24|2009-01-16|2009-01-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2009|Actual|2009-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives|Investigation of Reduction of Blood Pressure and Metabolic Rate in Obese Hypertensive Patients Using Eplerenone: Implications for Treatment of Hypertension and Heart Failure|Terminated||N/A|10|Actual|University of Mississippi Medical Center||2||funding to complete was inadequate|f||||t||||||||||2018-06-01 01:23:52.836164|2018-06-01 01:23:52.836164
NCT00825175|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2011-08-05||2017-10-27|2009-01-15|2009-01-19|Estimate|2013-12-09|2014-01-24|Estimate||||2017-10-27|2017-12-04|Actual|March 2006||2006-03-31|October 2017|2017-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Treadmill Training and Orthotic Use in Infants With Down Syndrome|The Effect of Treadmill Training and Orthotic Use on the Development of Walking and Upright Play in Infants With Down Syndrome|Completed||N/A|22|Actual|University of Michigan|small sample size|2|||f||||t||||||||||2018-06-01 01:23:52.909006|2018-06-01 01:23:52.909006
NCT00824798|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2014-07-10|2009-01-16|2009-01-19|Estimate|||||||2014-07-10|2014-07-11|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|||Gait Evaluation in Haemophiliac Patients|Gait Evaluation in Haemophiliac Patients|Completed|||200|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||t||||||||||2018-06-01 01:23:59.030992|2018-06-01 01:23:59.030992
NCT00825149|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2016-11-03|2009-01-16|2009-01-19|Estimate|||||||2016-11-03|2016-11-04|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|GAUDI||A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma|An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma|Completed||Phase 1|137|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 01:23:54.016386|2018-06-01 01:23:54.016386
NCT00825136|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2012-08-19|2009-01-16|2009-01-19|Estimate|||||||2012-08-19|2012-08-21|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring|A Study on Mental Health Care by Using Specific Vital Signs|Terminated||N/A|10|Actual|Chimei Medical Center||2||The main limitations were the small sample size and low completion rate.|f||||t||||||||||2018-06-01 01:23:54.177981|2018-06-01 01:23:54.177981
NCT00825123|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2011-11-07|2009-01-16|2009-01-19|Estimate|||||||2011-11-07|2011-11-09|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|December 2012|Anticipated|2012-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals|The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals|Withdrawn||Phase 4|40|Anticipated|Bayside Health||3|||f||||f||||||||||2018-06-01 01:23:54.391855|2018-06-01 01:23:54.391855
NCT00825110|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-01-16|2009-01-16|2009-01-19|Estimate|||||||2009-01-16|2009-01-19|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer|SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer|Unknown status|Recruiting||3750|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||t||||||Samples With DNA|"~     biospecimen includes formalin-fixed, paraffin embedded tissue, fresh frozen tissue and blood~     smaples~   "|||2018-06-01 01:23:54.470865|2018-06-01 01:23:54.470865
NCT00825097|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2011-12-22|2009-01-16|2009-01-19|Estimate|||||||2011-12-22|2011-12-23|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Neurotomy||Efficacy Study of Selective Tibial Neurotomy in the Treatment of the Spastic Equinovarus Foot Among Adult Hemiplegic Patients|Study of the Efficacy of the Selective Neurotomy in the Treatment of the Spastic Equinovarus Foot Among Adult Hemiplegic Patient Following the ICF Model. A Prospective, Randomized, Controlled Single Blind Study|Completed||Phase 3|16|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-06-01 01:23:54.549248|2018-06-01 01:23:54.549248
NCT00825084|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2011-04-22|2009-01-16|2009-01-19|Estimate|||||||2011-04-22|2011-04-26|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects|A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects|Completed||Phase 1|45|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:23:54.644412|2018-06-01 01:23:54.644412
NCT00825071|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2016-05-12|2009-01-15|2009-01-19|Estimate|||||||2016-05-12|2016-05-13|Estimate|November 2007||2007-11-30|May 2016|2016-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Dexamethasone for Postoperative Nausea and Vomiting|Optimizing Anesthesia Antiemetic Measures Versus Combination With Dexamethasone or Ondansetron in the Prevention of Postoperative Nausea and Vomiting.|Completed||Phase 4|180|Actual|University of Jordan||3|||f||||t||||||||||2018-06-01 01:23:54.71849|2018-06-01 01:23:54.71849
NCT00825058|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-03-24|2009-01-16|2009-01-19|Estimate|||||||2009-03-24|2009-03-25|Estimate|November 2003||2003-11-30|March 2009|2009-03-31|October 2004|Actual|2004-10-31|May 2004|Actual|2004-05-31||Interventional|||Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine|A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode.|Completed||Phase 3|317|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:23:54.793507|2018-06-01 01:23:54.793507
NCT00825045|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2017-11-28|2009-01-16|2009-01-19|Estimate|||||||2017-11-28|2017-11-30|Actual|December 2008|Actual|2008-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia|Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia|Recruiting||N/A|14|Anticipated|Centre for Addiction and Mental Health||1|||f||||f||||||||Undecided||2018-06-01 01:23:54.864726|2018-06-01 01:23:54.864726
NCT00825032|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2011-08-02|2009-01-16|2009-01-19|Estimate|||||||2011-08-02|2011-08-04|Estimate|March 2007||2007-03-31|May 2009|2009-05-31|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Interventional|UEET-COPD||Efficacy of Arm Training in COPD Patients|Effects of Unsupported Upper Extremity Exercise Training in Patients With Chronic Obstructive Pulmonary Disease: a Randomized Clinical Trial|Completed||N/A|50|Actual|Villa Pineta Hospital||2|||f||||f||||||||||2018-06-01 01:23:54.941319|2018-06-01 01:23:54.941319
NCT00825019|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-03-24|2009-01-16|2009-01-19|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2003||2003-09-30|March 2009|2009-03-31|December 2004|Actual|2004-12-31|October 2004|Actual|2004-10-31||Interventional|||Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine|A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode.|Completed||Phase 3|306|Actual|Sanofi||3|||f||||||||||||||2018-06-01 01:23:55.013915|2018-06-01 01:23:55.013915
NCT00825006|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2009-01-16|2009-01-16|2009-01-19|Estimate|||||||2009-01-16|2009-01-19|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Interventional|||The Effects of Anodal Stimulation on Echocardiographic Outcome in Patients With Cardiac Resynchronization Therapy|The Effects of Anodal Stimulation on Left Ventricular Desynchrony and Hemodynamics in Patients With a Biventricular Pacemaker|Unknown status|Recruiting|N/A|30|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 01:23:55.165464|2018-06-01 01:23:55.165464
NCT00824993|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2018-03-09||2018-04-10|2009-01-15|2009-01-19|Estimate|2018-04-10|2018-05-11|Actual||||2018-04-10|2018-05-11|Actual|December 9, 2008|Actual|2008-12-09|April 2018|2018-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional||All patient's enrolled in the study were analyzed (Intention To Treat)|Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients|A Randomized, Controlled Study of Ibandronate for the Prevention of Bone Loss in Patients Who Have Received Allogeneic Bone Marrow Transplantation for Hematological Malignancies|Completed||Phase 3|78|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-06-01 01:23:55.247639|2018-06-01 01:23:55.247639
NCT00824980|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-01-16|2009-01-16|2009-01-19|Estimate|||||||2009-01-16|2009-01-19|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis|Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis - Phase II Single Center Study|Unknown status|Recruiting|Phase 2|24|Anticipated|Immune Technologies & Medicine GmbH||2|||f||||f||||||||||2018-06-01 01:23:55.60858|2018-06-01 01:23:55.60858
NCT00824967|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2012-03-23|2009-01-16|2009-01-19|Estimate|||||||2012-03-23|2012-03-26|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Non Pharmacological Management of Behavioural Symptoms in Nursing Home|Not Pharmacologic Treatment Has Illness of Alzheimer and Pathologies Related. Application in Disturbances of Behaviour in EHPAD|Terminated||N/A|306|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:23:55.718663|2018-06-01 01:23:55.718663
NCT00824954|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2011-01-18|2009-01-16|2009-01-19|Estimate|||||||2011-01-18|2011-01-19|Estimate|June 2009||2009-06-30|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease|Evaluation of Extracorporeal Photochemotherapy in Children and Young Adults With Refractory Acute Graft Versus Host Disease After Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|30|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:23:55.799023|2018-06-01 01:23:55.799023
NCT00824941|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2018-05-18|2009-01-16|2009-01-19|Estimate|||||||2018-05-18|2018-05-21|Actual|January 15, 2009||2009-01-15|July 15, 2017|2017-07-15||||||||Observational|||Brain-Gut Interactions in Overweight and Normal Weight Patients With Chronic Abdominal Pain|Brain-Gut Interactions in Overweight and Normal Weight Patients With Chronic Abdominal Pain|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:23:55.878401|2018-06-01 01:23:55.878401
NCT00824928|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-05-26|2009-01-16|2009-01-19|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|SCORE||Salvage Cryotherapy in Recurrent Prostate Cancer|A Prospective Multicenter Registry of Salvage Cryotherapy in Recurrent Prostate Cancer Study|Terminated|||60|Actual|University of Colorado, Denver|||1|Study was ended due to low enrollment|f||||f||||||||||2018-06-01 01:23:55.953249|2018-06-01 01:23:55.953249
NCT00824915|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2018-02-28|2009-01-16|2009-01-19|Estimate|||||||2018-02-28|2018-03-02|Actual|August 2008||2008-08-31|February 2018|2018-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|RVLIA||Enhanced Surveillance of RV Lead Integrity Alert (RVLIA)|Enhanced Surveillance of RV Lead Integrity Alert (RVLIA)|Completed|||1779|Actual|Medtronic|||||f||||f||||||||||2018-06-01 01:23:56.057987|2018-06-01 01:23:56.057987
NCT00824902|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-01-07|2009-01-15|2009-01-19|Estimate|||||||2015-01-07|2015-01-09|Estimate|December 2008||2008-12-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy|A Pilot Trial Evaluation of Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer in Patients Undergoing Radical Prostatectomy|Terminated||N/A|13|Actual|M.D. Anderson Cancer Center||1||Technical Issues|f||||f||||||||||2018-06-01 01:23:56.101259|2018-06-01 01:23:56.101259
NCT00824889|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2014-08-28|2009-01-16|2009-01-19|Estimate|||||||2014-08-28|2014-08-29|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Exploratory Study of Natural Killer Cells in Human Skin|Exploratory Study of Natural Killer Cells in Human Skin|Completed||N/A|28|Actual|Assistance Publique Hopitaux De Marseille||7|||f||||f||||||||||2018-06-01 01:23:56.169288|2018-06-01 01:23:56.169288
NCT00824876|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-07-07|2009-01-16|2009-01-19|Estimate|||||||2009-07-07|2009-07-08|Estimate|January 2009||2009-01-31|July 2009|2009-07-31||||||||Observational|||Orthostatic Tolerance in Mamma Cancer Patients After Anaesthesia||Completed|||||Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 01:23:56.24333|2018-06-01 01:23:56.24333
NCT00824863|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2014-08-19|2009-01-16|2009-01-19|Estimate|||||||2014-08-19|2014-08-21|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis|An Open-Label, Proof of Concept Study to Determine the Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis|Completed||Phase 4|10|Actual|Fujita, Wayne, M.D.||1|||f||||t||||||||||2018-06-01 01:23:56.298219|2018-06-01 01:23:56.298219
NCT00824850|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2011-08-04||2011-10-05|2009-01-16|2009-01-19|Estimate|2011-10-05|2011-11-11|Estimate||||2011-10-05|2011-11-11|Estimate|January 2010||2010-01-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PILOT||Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort|Characterization of the Prevnar Infant Long-term Immune Response vs a Prevnar Naive Cohort|Completed||Phase 2|75|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:23:56.498317|2018-06-01 01:23:56.498317
NCT00824837|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-07-06|2009-01-16|2009-01-19|Estimate|||||||2009-07-06|2009-07-07|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|HiCOF||Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane|Randomised, Cross Over Pilot Study Comparing Removal of beta2-Microglobulin by Standard Haemodialysis to Haemodialysis With a Novel Dialysis Membrane (P2SH) in Chronic Dialysis Patients|Completed||Phase 1/Phase 2|8|Actual|Austin Health||2|||f||||t||||||||||2018-06-01 01:23:58.64377|2018-06-01 01:23:58.64377
NCT00824824|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2012-08-30||2017-03-31|2009-01-16|2009-01-19|Estimate|2016-10-27|2016-10-28|Estimate||||2017-03-31|2017-04-04|Actual|January 2009||2009-01-31|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||There are 14 subjects in this study whop have PAOG without RVD. There are 7 subjects with POAG with RVD. The 14 subjects without RVD did not continue in the two treament arms of this study.|Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)|Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)|Completed||N/A|21|Actual|Massachusetts Eye and Ear Infirmary|A potential limitation of this study is that no washout period occurred because the 6-week treatment periods extended beyond the typical 2-week washout period for dorzolamide and the 3-week washout period for brimonidine.|2|||f||||f||||||||No||2018-06-01 01:23:58.715154|2018-06-01 01:23:58.715154
NCT00824811|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2012-08-01|2009-01-16|2009-01-19|Estimate|||||||2012-08-01|2012-08-02|Estimate|June 2009||2009-06-30|August 2012|2012-08-31||||||||Interventional|||Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel|A Double-Blind Study Evaluating the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion 0.05% [Restasis] in Subjects With Epiphora Secondary to Docetaxel [Taxotere] Treatment for Various Cancers|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2||Slow accrual.|f||||t||||||||||2018-06-01 01:23:58.958683|2018-06-01 01:23:58.958683
NCT00824785|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2012-12-10|2009-01-16|2009-01-19|Estimate|||||||2012-12-10|2012-12-11|Estimate|May 2008||2008-05-31|December 2012|2012-12-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|REAL3||REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer|REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer|Terminated||Phase 3|574|Actual|Royal Marsden NHS Foundation Trust||2||Lack of efficacy|f||||t||||||||||2018-06-01 01:23:59.082178|2018-06-01 01:23:59.082178
NCT00824772|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2013-03-25||2013-05-26|2009-01-16|2009-01-19|Estimate|2013-03-25|2013-05-27|Estimate||||2013-05-26|2013-06-04|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Observational|||Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control|Evaluation of Pharmacogenetic Factors Contributing to Dose Requirement of Fentanyl for Postoperative Pain Control: Genetic Polymorphisms of OPRM1, ABCB1, CYP3A4 and CYP3A5|Completed|||204|Actual|Inje University|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:23:59.153657|2018-06-01 01:23:59.153657
NCT00824759|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2014-11-18|2009-01-16|2009-01-19|Estimate|||||||2014-11-18|2014-11-19|Estimate||||November 2014|2014-11-30||||||||Interventional|||Cardioprotective Effects of Increased Endogenous Erythropoietin After Normobaric Oxygen Breathing||Withdrawn||N/A|0|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2||Because it seemed not of interest based on the current literature|f||||f||||||||||2018-06-01 01:23:59.276505|2018-06-01 01:23:59.276505
NCT00824746|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2012-02-09||2013-01-22|2009-01-16|2009-01-19|Estimate|2013-01-22|2013-02-26|Estimate||||2013-01-22|2013-02-26|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|ReGaiN||Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)|Retreatment of Gefitinib in the Patients With Non-small Cell Lung Cancer (NSCLC) Previously Responded to Gefitinib A Single Arm, Open Label, Phase II Study|Completed||Phase 2|23|Actual|Chonnam National University Hospital|Our study has several limitations such as lack of generalizability outside a clinically and molecularly enriched population and the small number of repeat biopsies.|1|||f||||f||||||||||2018-06-01 01:23:59.337641|2018-06-01 01:23:59.337641
NCT00824733|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2015-08-19||2015-12-09|2009-01-16|2009-01-19|Estimate|2015-12-09|2016-01-14|Estimate||||2015-12-09|2016-01-14|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|April 2014|Actual|2014-04-30|February 2013|Actual|2013-02-28||Interventional|||Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase II Open-label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer|Terminated||Phase 2|6|Actual|Ohio State University Comprehensive Cancer Center||1||Inaccurate patient accrual for trial|f||||t||||||||||2018-06-01 01:24:00.564139|2018-06-01 01:24:00.564139
NCT00824720|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2010-04-15||2015-02-18|2009-01-15|2009-01-19|Estimate|2010-04-15|2010-05-14|Estimate||||2015-02-18|2015-03-06|Estimate|December 2008||2008-12-31|February 2015|2015-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy of a Glaucoma Drug Delivery System||Completed||Phase 2|55|Actual|Vistakon Pharmaceuticals||3|||f||||||||||||||2018-06-01 01:24:00.802723|2018-06-01 01:24:00.802723
NCT00824707|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2016-03-30|2009-01-16|2009-01-19|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer|A Randomized, Controlled Study to Evaluate the Efficacy and Significant of the Anti-virus Therapy for the Unresectable Hepatitis B Virus-related Primary Liver Cancer|Completed||N/A|200|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:24:01.133263|2018-06-01 01:24:01.133263
NCT00824694|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2011-06-21|2009-01-16|2009-01-19|Estimate|||||||2011-06-21|2011-06-23|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes|Impact of Accu-Chek 360 View on Practice Patterns and HBA1C in Veterans With Type 2 Diabetes.|Completed||N/A|348|Anticipated|Biomedical Research Institute of New Mexico||2|||f||||t||||||||||2018-06-01 01:24:01.213737|2018-06-01 01:24:01.213737
NCT00824681|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2010-07-22|2009-01-15|2009-01-19|Estimate|||||||2010-07-22|2010-07-23|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MTS3||Effect of Music Therapy on Families of Burn Patients|Sound Of Family Together (S.O.F.T.) Music Program: A Randomized-Controlled Study to Investigate the Effect of Music Therapy on the Coping and Adjustment of Children of Adults With Major Burns|Terminated||Phase 1|30|Anticipated|MetroHealth Medical Center||2||Music therapist left position.|f||||f||||||||||2018-06-01 01:24:01.395328|2018-06-01 01:24:01.395328
NCT00824668|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2017-01-05|2009-01-16|2009-01-19|Estimate|||||||2017-01-05|2017-01-06|Estimate|August 2007||2007-08-31|January 2017|2017-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes|A Randomised, Open-labelled, 2-period Crossover Trial Investigating Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 Thrice Daily and Basal-bolus Therapy With Insulin Glargine & Insulin Glulisine in Subjects With Type 2 Diabetes|Completed||Phase 1|24|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 01:24:01.480571|2018-06-01 01:24:01.480571
NCT00824655|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2011-06-17||2011-08-04|2009-01-16|2009-01-19|Estimate|2011-06-17|2011-07-18|Estimate||||2011-08-04|2011-08-10|Estimate|March 2009||2009-03-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children|A Phase 3, Open-Label Trial, Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Previously Partially Immunized With Prevenar|Completed||Phase 3|234|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:24:01.597311|2018-06-01 01:24:01.597311
NCT00824642|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2009-01-16|2009-01-16|2009-01-19|Estimate|||||||2009-01-16|2009-01-19|Estimate|May 2005||2005-05-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Acu-Transcutaneous Electrical Nerve Stimulation (TENS) on Post-Exercise Expiratory Flow Rate in Subjects With Asthma|Effect of Acu-TENS on Post-Exercise Expiratory Flow Rate in Subjects With Asthma- A Randomized Controlled Trial|Completed||N/A|30|Actual|The Hong Kong Polytechnic University||3|||f||||||||||||||2018-06-01 01:24:02.288978|2018-06-01 01:24:02.288978
NCT00824629|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2010-10-25|2009-01-16|2009-01-19|Estimate|||||||2010-10-25|2010-10-26|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Embryo Transfer: Direct Versus Afterloading Trial|"Direct Transfer vs Previous Cervical Canalization Transfer (Afterloading): Randomized Clinical Trial."|Completed||N/A|400|Anticipated|Institut Universitari Dexeus||2|||f||||f||||||||||2018-06-01 01:24:02.35983|2018-06-01 01:24:02.35983
NCT00824616|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|2012-07-17||2015-07-21|2009-01-16|2009-01-19|Estimate|2012-07-17|2012-08-21|Estimate||||2015-07-21|2015-07-28|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin|Completed||Phase 2|68|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:24:02.444149|2018-06-01 01:24:02.444149
NCT00824603|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-11-30|2009-01-16|2009-01-19|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Impact of Continuing Medical Education (CME) Insulin Program|Impact of CME Program on Self-Reported Confidence and Use of Insulin in Persons With Type 2 Diabetes|Completed|||294|Actual|HealthPartners Institute|||1||f||||f||||||||||2018-06-01 01:24:02.71434|2018-06-01 01:24:02.71434
NCT00824590|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-12-29|2009-01-16|2009-01-19|Estimate|||||||2009-12-29|2009-12-30|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function|A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function|Completed||Phase 1|20|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:24:02.77828|2018-06-01 01:24:02.77828
NCT00824577|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-16|||2010-06-28|2009-01-16|2009-01-19|Estimate|||||||2010-06-28|2010-06-29|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Observational|||Heart Rate Variability in Chronic Kidney Disease Patients|Heart Rate Variability in Chronic Kidney Disease Patients|Unknown status|Active, not recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     PD effluent and blood sample~   "|||2018-06-01 01:24:02.976286|2018-06-01 01:24:02.976286
NCT00824564|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2011-06-06||2011-06-06|2009-01-14|2009-01-16|Estimate|2011-06-06|2011-06-28|Estimate||||2011-06-06|2011-06-28|Estimate|April 2009||2009-04-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture|Prospective Randomized Phase IV Open Label Comparative Study Of Tranexamic Acid Plus Standard Of Care Versus Standard Of Care For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture|Completed||Phase 4|82|Actual|Pfizer|The data for hemoglobin levels was planned but not evaluated on the morning of Day 7 post-surgery.|2|||f||||t||||||||||2018-06-01 01:24:03.094465|2018-06-01 01:24:03.094465
NCT00824551|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2009-01-15|2009-01-15|2009-01-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|January 2009||2009-01-31|December 2008|2008-12-31||||December 2010|Anticipated|2010-12-31||Interventional|||The Effects of Hyperbaric Oxygen Therapy (HBOT) on Acute Thermal Burns|The Effects of Hyperbaric Oxygen Therapy on Acute Thermal Burns|Unknown status|Recruiting|Phase 1|80|Anticipated|Singapore General Hospital||2|||f||||t||||||||||2018-06-01 01:24:03.565095|2018-06-01 01:24:03.565095
NCT00824538|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2013-03-01||2018-03-09|2009-01-15|2009-01-16|Estimate|2014-04-10|2014-05-08|Estimate||||2018-03-09|2018-04-05|Actual|February 2009||2009-02-28|March 2018|2018-03-31|December 2013|Actual|2013-12-31|November 10, 2010|Actual|2010-11-10||Interventional|||Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow|Pilot Study to Evaluate the Effect of Sunitinib on Occult Tumor Cells in the Bone Marrow of Patients With High Risk Early Stage Breast Cancer|Terminated||Phase 2|13|Actual|University of California, San Francisco|The study closed early due to results released from a phase III metastatic breast cancer (MBC) study that demonstrated significant sunitinib toxicity without commensurate clinical benefit.|1||Closed prematurely due to emerging data on toxicity and competing trials.|f||||t||||||||||2018-06-01 01:24:03.669118|2018-06-01 01:24:03.669118
NCT00824512|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2012-10-30||2013-04-10|2009-01-15|2009-01-16|Estimate|2013-04-10|2013-05-21|Estimate||||2013-04-10|2013-05-21|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia|A Phase II, Randomised, Double Blind Study Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia|Completed||Phase 2|22|Actual|Ipsen||2|||f||||f||||||||||2018-06-01 01:24:03.95603|2018-06-01 01:24:03.95603
NCT00824499|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2009-01-15|2009-01-15|2009-01-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|February 2004||2004-02-29|January 2009|2009-01-31|June 2009|Anticipated|2009-06-30|December 2007|Actual|2007-12-31||Interventional|DPA||Development, Implementation and Evaluation of a Complex Regional Intervention for Type 2 Diabetes: Diabetes Project Aalst|Development, Implementation and Evaluation of a Complex Regional Intervention for Type 2 Diabetes.|Unknown status|Active, not recruiting|N/A|375|Actual|Universiteit Antwerpen||2|||f||||t||||||||||2018-06-01 01:24:04.582398|2018-06-01 01:24:04.582398
NCT00824486|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2009-01-15|2009-01-15|2009-01-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|June 2003||2003-06-30|January 2009|2009-01-31|March 2007|Actual|2007-03-31|||||Interventional|||Home Safety Intervention Using a Safe Home Model|A Randomized Trial of a Home Safety Intervention Using a Safe Home Model|Completed||N/A|||Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-06-01 01:24:04.646678|2018-06-01 01:24:04.646678
NCT00824473|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2009-09-30||2010-02-19|2009-01-14|2009-01-16|Estimate|2010-01-04|2010-01-28|Estimate||||2010-02-19|2010-02-23|Estimate|December 2008||2008-12-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|506|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:24:04.724699|2018-06-01 01:24:04.724699
NCT00824460|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2013-12-20|2012-07-23|2014-03-03|2009-01-14|2009-01-16|Estimate|2014-03-03|2014-04-01|Estimate|2012-07-31|2012-08-07|Estimate|2014-03-03|2014-04-01|Estimate|December 2008||2008-12-31|March 2014|2014-03-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional|PA21|For baseline characteristics data, from All Randomised patients was used.|Study of Phosphate Levels in Patients With Chronic Kidney Disease|An Open-label, Randomised, Active Controlled Multi-center Phase II Dose Finding Study to Evaluate the Ability of PA21 to Lower Serum Phosphate Levels and the Tolerability in Patients With Chronic Kidney Disease on Maintenance Hemodialysis|Completed||Phase 2|154|Actual|Vifor Inc.||6|||f||||f||||||||||2018-06-01 01:24:05.351685|2018-06-01 01:24:05.351685
NCT00824447|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2010-05-04|2009-01-15|2009-01-16|Estimate|||||||2010-05-04|2010-05-05|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Long-term Efficacy and Safety Study With Oralgen Grass Pollen|A Randomised, DB, Plcb Controlled, Multicentre, Multinat. Phase II/III FU Study to Assess Longterm Efficacy and Safety of 3 Different Dose Regimens of Oralgen® GrassPollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis|Completed||Phase 2/Phase 3|356|Actual|Artu Biologicals||4|||f||||f||||||||||2018-06-01 01:24:06.241552|2018-06-01 01:24:06.241552
NCT00824421|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2013-12-09|2011-11-23|2013-12-09|2009-01-15|2009-01-16|Estimate|2013-12-09|2014-01-24|Estimate|2011-11-23|2011-12-02|Estimate|2013-12-09|2014-01-24|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Intent-to-treat (ITT) population included all randomized participants who had received at least 1 dose of study medication.|A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1|A Phase 2B Multicenter, Randomized, Double-Blind, Comparative Trial Of UK-453,061, In Combination With Tenofovir Df And Emtricitabine Versus Efavirenz In Combination With Tenofovir DF And Emtricitabine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects|Completed||Phase 2|195|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 01:24:07.045656|2018-06-01 01:24:07.045656
NCT00824408|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2016-07-28|2014-04-30|2016-07-28|2009-01-15|2009-01-16|Estimate|2016-07-28|2016-09-20|Estimate|2014-04-30|2014-05-16|Estimate|2016-07-28|2016-09-20|Estimate|March 2009||2009-03-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|September 2012|Actual|2012-09-30||Interventional||Randomized set, which included all patients randomised in the randomisation phase, whether treated or not|Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC|A Randomised Open-label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-small Cell Lung Cancer|Completed||Phase 2|143|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:24:08.714772|2018-06-01 01:24:08.714772
NCT00824395|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2011-02-02|2009-01-15|2009-01-16|Estimate|||||||2011-02-02|2011-02-04|Estimate|January 2006||2006-01-31|February 2011|2011-02-28|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|||The Genetics of Diabetes in Southern California Chinese Americans|Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort|Unknown status|Recruiting||500|Anticipated|University of California, Irvine|||2||f||||f||||||Samples With DNA|"~     whole blood and serum~   "|||2018-06-01 01:24:10.118374|2018-06-01 01:24:10.118374
NCT00824382|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2014-03-28||2014-06-17|2009-01-15|2009-01-16|Estimate|2014-05-30|2014-06-10|Estimate||||2014-06-17|2014-06-27|Estimate|January 2009||2009-01-31|May 2014|2014-05-31||||March 2010|Actual|2010-03-31||Interventional||The treated set consisting of all randomised patients for whitch at least one investigational treatment was used.|Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD|Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL Delivered by the Respimat Inhaler in Japanese Patients With COPD|Completed||Phase 2|328|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 01:24:10.251115|2018-06-01 01:24:10.251115
NCT00824369|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2014-01-16||2014-07-31|2009-01-15|2009-01-16|Estimate|2014-07-31|2014-08-04|Estimate||||2014-07-31|2014-08-04|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1|A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1 Infected Subjects|Terminated||Phase 2|52|Actual|Pfizer||1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:24:11.162114|2018-06-01 01:24:11.162114
NCT00824356|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-06-18|2009-01-15|2009-01-16|Estimate|||||||2009-06-18|2009-06-22|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo|A Randomised, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Assess the Efficacy and Safety of Single Dose Intranasal GSK1004723 Compared With Placebo in an Allergen Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis|Completed||Phase 2|54|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 01:24:12.018059|2018-06-01 01:24:12.018059
NCT00824343|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2013-07-08|2009-01-15|2009-01-16|Estimate|||||||2013-07-08|2013-07-10|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|April 2011|Actual|2011-04-30||Interventional|MONARCH||A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer|An Open Label, Multicenter Phase II Study to Evaluate Efficacy and Safety of P276-00 in Indian Subjects With Recurrent, Metastatic or Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck|Completed||Phase 2|86|Actual|Piramal Enterprises Limited||1|||f||||f||||||||||2018-06-01 01:24:12.100741|2018-06-01 01:24:12.100741
NCT00824330|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2017-04-12|2009-01-15|2009-01-16|Estimate|||||||2017-04-12|2017-04-14|Actual|January 2009|Actual|2009-01-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|July 2013|Actual|2013-07-31||Interventional|||Home-Based Walking Study in Older Adults With Type 2 Diabetes|The Use of a Home-based Walking Program to Treat Orthostatic Hypotension in Older Adults With Type 2 Diabetes|Completed||N/A|13|Actual|University of British Columbia||1|||f||||f||||||||No||2018-06-01 01:24:12.24383|2018-06-01 01:24:12.24383
NCT00824317|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2009-01-15|2009-01-15|2009-01-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|October 2001||2001-10-31|January 2009|2009-01-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type|Stimulant Drug Treatment of AD/HD, Inattentive Type|Completed||N/A|25|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 01:24:12.327665|2018-06-01 01:24:12.327665
NCT00824304|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2013-02-14|2009-01-15|2009-01-16|Estimate|||||||2013-02-14|2013-02-18|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|July 2009|Actual|2009-07-31|January 2008|Actual|2008-01-31||Observational|FeZn_FU||Long-term Effects of Iron and Zinc Supplementation During Infancy on Cognitive Performance and Growth|Long-Term Effects of Iron and Zinc Supplementation During Infancy on Cognitive Performance and Growth 8 Years Later: A Follow-Up Study|Completed|||562|Actual|Mahidol University|||1||f||||f||||||Samples Without DNA|"~     Plasma and urine~   "|||2018-06-01 01:24:12.397263|2018-06-01 01:24:12.397263
NCT00824291|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2010-10-26||2011-03-04|2009-01-15|2009-01-16|Estimate|2010-10-26|2010-11-25|Estimate||||2011-03-04|2011-03-10|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release|Completed||Phase 3|437|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:24:12.480864|2018-06-01 01:24:12.480864
NCT00824278|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2018-05-22|2009-01-15|2009-01-16|Estimate|||||||2018-05-22|2018-05-23|Actual|January 13, 2009||2009-01-13|May 11, 2018|2018-05-11||||||||Observational|||The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study|The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory, Pilot Study|Completed|||289|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:24:13.1237|2018-06-01 01:24:13.1237
NCT00824265|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2015-08-10||2017-12-13|2009-01-15|2009-01-16|Estimate|2016-06-15|2016-07-25|Estimate||||2017-12-13|2018-01-12|Actual|March 2009||2009-03-31|December 2017|2017-12-31|October 25, 2017|Actual|2017-10-25|December 2014|Actual|2014-12-31||Interventional|||Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia|A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 3|365|Actual|Novartis||2|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:24:13.34786|2018-06-01 01:24:13.34786
NCT00824252|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2017-07-07|2009-01-15|2009-01-16|Estimate|||||||2017-07-07|2017-07-11|Actual|December 8, 2008|Actual|2008-12-08|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Spousal Support in Head and Neck Cancer|Spousal Support, Emotional Disclosure, and Adjustment to Head and Neck Cancer|Active, not recruiting|||361|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:24:16.166594|2018-06-01 01:24:16.166594
NCT00824239|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2012-06-08|2009-01-15|2009-01-16|Estimate|||||||2012-06-08|2012-06-11|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients|Randomized Trial Comparing Intermittent Sedation and Daily Interruption of Sedation in Mechanically Ventilated Patients|Completed||Phase 3|60|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-06-01 01:24:16.240504|2018-06-01 01:24:16.240504
NCT00824226|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2011-08-26|2009-01-15|2009-01-16|Estimate|||||||2011-08-26|2011-08-29|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Magnesium Treatment in Hypoparathyroidism|Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients|Completed||N/A|10|Actual|University of Tartu|||||f||||f||||||||||2018-06-01 01:24:16.325826|2018-06-01 01:24:16.325826
NCT00824213|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2017-03-01|2009-01-15|2009-01-16|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2009||2009-01-31|March 2017|2017-03-31|August 10, 2016|Actual|2016-08-10|August 10, 2016|Actual|2016-08-10||Observational|||Pilot Project: Fast Whole-body Spect Scanning to Improve the Detection of Bone Metastases in Patients With Diagnosed Cancer|Pilot Project: Fast Whole-body Spect Scanning to Improve the Detection of Bone Metastases in Patients With Diagnosed Cancer|Completed|||50|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 01:24:16.397445|2018-06-01 01:24:16.397445
NCT00824200|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2014-01-06|2009-01-15|2009-01-16|Estimate|||||||2014-01-06|2014-01-07|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|BEDTiMe||Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe)|Behavior and Exercise Versus Drug Treatment in Men With Nocturia|Unknown status|Active, not recruiting|Phase 4|200|Anticipated|Atlanta VA Medical Center||3|||f||||f||||||||||2018-06-01 01:24:16.467965|2018-06-01 01:24:16.467965
NCT00824187|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2014-04-01|2009-01-15|2009-01-16|Estimate|||||||2014-04-01|2014-04-02|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||YAZ Premenstrual Dysphoric Disorder (PMDD) in China|A Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Monophasic Oral Contraceptive YAZ (20 µg Ethinylestradiol, 3 mg Drospirenone) in the Treatment of Chinese Patients With Premenstrual Dysphoric Disorder (PMDD)|Completed||Phase 3|187|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:24:16.559709|2018-06-01 01:24:16.559709
NCT00824174|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2012-10-01|2009-01-15|2009-01-16|Estimate|||||||2012-10-01|2012-10-02|Estimate|December 2008||2008-12-31|October 2012|2012-10-31||||September 2012|Actual|2012-09-30||Observational|||Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer|Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer|Completed|||289|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:24:16.713382|2018-06-01 01:24:16.713382
NCT00824161|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2011-06-21||2012-04-20|2009-01-14|2009-01-16|Estimate|2011-07-20|2011-08-17|Estimate||||2012-04-20|2012-04-23|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer|A Phase II Study of TAS-109 Given by Continuous Intravenous 14-day Infusion in Patients With Chemotherapy-refractory Advanced Colorectal Cancer|Terminated||Phase 2|28|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-06-01 01:24:16.795315|2018-06-01 01:24:16.795315
NCT00824148|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2017-02-23|2009-01-15|2009-01-16|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2009|Actual|2009-01-31|February 2017|2017-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Use of Real-time Continuous Glucose Monitoring System in Patients With Type 1 Diabetes Mellitus|Use of Real-time Continuous Glucose Monitoring System to Control Blood Glucose in Patients With Type 1 Diabetes Mellitus|Completed||N/A|30|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-06-01 01:24:16.979752|2018-06-01 01:24:16.979752
NCT00824135|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2016-12-30|2009-01-15|2009-01-16|Estimate|||||||2016-12-30|2017-01-02|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2012|Actual|2012-10-31||Interventional|||Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies|Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies|Completed||Phase 1|34|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 01:24:17.048987|2018-06-01 01:24:17.048987
NCT00824122|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2011-10-11|2009-01-14|2009-01-16|Estimate|||||||2011-10-11|2011-10-12|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|December 2008|Actual|2008-12-31||Observational|||Vancomycin Associated Red Man Syndrome (RMS)|Genetic Polymorphisms Associated With Histamine Disposition in Children With Vancomycin Associated Red Man Syndrome (RMS)|Completed|||544|Actual|Children's Mercy Hospital Kansas City|||2||f||||f||||||Samples With DNA|"~     Frozen blood has been maintained for future genetic studies~   "|||2018-06-01 01:24:17.132598|2018-06-01 01:24:17.132598
NCT00824109|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2010-12-02|2009-01-15|2009-01-16|Estimate|||||||2010-12-02|2010-12-03|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Prospective, Multicenter Study of the Second Generation Antimicrobial Graft in the Abdominal Position|Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in the Abdominal Position|Unknown status|Recruiting|Phase 4|60|Anticipated|Datascope Corp.||1|||f||||f||||||||||2018-06-01 01:24:17.197143|2018-06-01 01:24:17.197143
NCT00824070|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2010-09-30||2011-12-07|2009-01-15|2009-01-16|Estimate|2010-09-30|2010-10-29|Estimate||||2011-12-07|2011-12-13|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects|An Open-Label, Randomized Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects After a Single Topical Dose|Completed||Phase 1|105|Actual|Bausch & Lomb Incorporated|All drug concentrations were significantly below MIC90 values for relevant staphylococcal species.|3|||f||||f||||||||||2018-06-01 01:24:17.430516|2018-06-01 01:24:17.430516
NCT00824057|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-07-30|2009-01-15|2009-01-16|Estimate|||||||2009-07-30|2009-07-31|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|||||Interventional|CYP||Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)|A Phase I Open-labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)|Completed||Phase 1|24|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:24:17.71262|2018-06-01 01:24:17.71262
NCT00824044|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2012-12-05||2017-12-07|2009-01-15|2009-01-16|Estimate|2012-12-05|2013-01-08|Estimate||||2017-12-07|2018-01-05|Actual|July 2008||2008-07-31|December 2017|2017-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression|QEEG Predictors of Response for Psychotherapy Compared to Pharmacotherapy in Depression|Completed||Phase 4|39|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:24:17.806159|2018-06-01 01:24:17.806159
NCT00824031|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2009-09-10|2009-01-15|2009-01-16|Estimate|||||||2009-09-10|2009-09-11|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|||||Observational|||Study of Mental Care in Spain|Study of Mental Care in Spain|Completed|||76|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:24:18.306338|2018-06-01 01:24:18.306338
NCT00824018|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-01-15|2009-01-15|2009-01-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:24:18.590435|2018-06-01 01:24:18.590435
NCT00824005|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2012-08-30||2015-06-02|2009-01-15|2009-01-16|Estimate|2013-02-22|2013-04-04|Estimate||||2015-06-02|2015-07-01|Estimate|March 2009||2009-03-31|June 2015|2015-06-30|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)|Randomized, Controlled, Phase II, Double-Blind Trial of Intramyocardial Injection of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Patients With Chronic Ischemic Heart Disease and Left Ventricular Dysfunction|Completed||Phase 2|92|Actual|The University of Texas Health Science Center, Houston|Sample size was small and required large improvements in order to show significant treatment effects. SPECT often underestimates reversibility and viability in those with multivessel disease. Presence of cardiac devices limited MRI evaluation.|2|||f||||t||||||||||2018-06-01 01:24:18.658449|2018-06-01 01:24:18.658449
NCT00823992|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15||2016-07-26|2016-07-26|2009-01-15|2009-01-16|Estimate||||2016-07-26|2016-07-28|Estimate|2016-07-26|2016-07-28|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy|A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Taspoglutide on Glycemic Control, and Its Safety and Tolerability, in Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy.|Completed||Phase 3|305|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:24:19.139986|2018-06-01 01:24:19.139986
NCT00823979|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2014-01-28|2013-11-19|2014-03-24|2009-01-15|2009-01-16|Estimate|2014-01-28|2014-03-14|Estimate|2013-11-19|2013-12-13|Estimate|2014-03-24|2014-04-16|Estimate|March 2009||2009-03-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Intent-to-Treat (ITT) population included all randomized participants who received at least 1 dose of study drug.|A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1|A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1|Terminated||Phase 2|105|Actual|Pfizer|The trial was terminated on 12 April, 2012 due to lack of efficacy at the Week 24 analysis. The decision to terminate the trial was not based on any safety concerns.|3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:24:19.440495|2018-06-01 01:24:19.440495
NCT00823966|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2010-03-04||2010-06-02|2009-01-15|2009-01-16|Estimate|2010-06-02|2010-07-05|Estimate||||2010-06-02|2010-07-05|Estimate|December 2003||2003-12-31|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients|Drug Use Investigation For Rescriptor (Regulatory Post Marketing Commitment Plan)|Completed|||3|Actual|Pfizer|There is not enough data to analyze on the efficacy and safety of delavirdine mesylate in the 3 subjects with HIV infection assessed during this study.||1||f||||f||||||||||2018-06-01 01:24:20.440937|2018-06-01 01:24:20.440937
NCT00823953|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2012-06-09|2009-01-15|2009-01-16|Estimate|||||||2012-06-09|2012-06-12|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Glycemic Response to Momordica Charantia in Type 2 Diabetes|The Effect of Momordica Charantia on Glycemic Control and Insulin Resistance in Type 2 Diabetes|Withdrawn||Phase 2|0|Actual|Services Hospital, Lahore||2||IP could not be made available in sufficient quantity for the expected enrollment|f||||t||||||||||2018-06-01 01:24:20.612821|2018-06-01 01:24:20.612821
NCT00823940|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2017-07-05|2009-01-15|2009-01-16|Estimate|||||||2017-07-05|2017-07-07|Actual|January 13, 2009|Actual|2009-01-13|July 2017|2017-07-31|April 27, 2009|Actual|2009-04-27|April 27, 2009|Actual|2009-04-27||Interventional|||A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects|A Single-blind, Randomized, Placebo Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Healthy Normal Subjects.|Completed||Phase 1|42|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:24:20.69421|2018-06-01 01:24:20.69421
NCT00823927|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-04-20|2009-01-15|2009-01-16|Estimate|||||||2015-04-20|2015-04-22|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|HIVE||Alveolar Macrophage Proteomics in HIV-associated Emphysema|Alveolar Macrophage Proteomics in HIV-associated Emphysema|Unknown status|Active, not recruiting||365|Actual|Ohio State University|||2||f||||t||||||Samples With DNA|"~     blood lung fluid (optional)~   "|||2018-06-01 01:24:20.786665|2018-06-01 01:24:20.786665
NCT00823914|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2017-03-23|2009-01-15|2009-01-16|Estimate|||||||2017-03-23|2017-03-24|Actual|December 2008||2008-12-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life|Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life|Completed|||116|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 01:24:20.843605|2018-06-01 01:24:20.843605
NCT00823901|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2011-04-04||2012-06-19|2009-01-15|2009-01-16|Estimate|2012-05-14|2012-06-15|Estimate||||2012-06-19|2012-06-25|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea|A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks|Completed||Phase 2/Phase 3|83|Actual|Massachusetts General Hospital|This study is limited by relatively small number of subjects. In addition, overall assessment of acne rosacea severity as determined by subjects’ self-assessment was not performed.|2|||f||||t||||||||||2018-06-01 01:24:20.901375|2018-06-01 01:24:20.901375
NCT00823888|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2011-07-19|2009-01-15|2009-01-16|Estimate|||||||2011-07-19|2011-07-20|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Mechanics of Knee Bracing|Mechanics of Knee Bracing|Completed||N/A|20|Actual|The New England Baptist Hospital|||||f||||f||||||||||2018-06-01 01:24:21.277063|2018-06-01 01:24:21.277063
NCT00823875|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2010-11-30|2009-01-15|2009-01-16|Estimate|||||||2010-11-30|2010-12-01|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject|A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject|Completed||Phase 4|200|Anticipated|Otsuka Beijing Research Institute||4|||f||||f||||||||||2018-06-01 01:24:21.369383|2018-06-01 01:24:21.369383
NCT00823862|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2018-02-27|2009-01-14|2009-01-16|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2008||2008-10-31|February 2018|2018-02-28|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection|A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study of SD-101 to Assess the Safety, Pharmacodynamics, and Preliminary Evidence of Anti-Viral Effect in Subjects Diagnosed With Chronic Hepatitis C, Genotype 1|Completed||Phase 1|34|Actual|Dynavax Technologies Corporation||1|||f||||f||||||||Undecided|3/2017 no change to status in this Phase 1 study|2018-06-01 01:24:21.44203|2018-06-01 01:24:21.44203
NCT00823849|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2010-04-21|2009-01-15|2009-01-16|Estimate|||||||2010-04-21|2010-04-22|Estimate|October 2008||2008-10-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker|A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker|Completed||Phase 4|200|Actual|Otsuka Beijing Research Institute||4|||f||||f||||||||||2018-06-01 01:24:21.522435|2018-06-01 01:24:21.522435
NCT00823836|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2011-09-01||2016-11-30|2009-01-15|2009-01-16|Estimate|2011-09-01|2011-10-07|Estimate||||2016-11-30|2017-01-18|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease|Clinical Evaluation of Ropinirole PR/XR Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease|Completed||Phase 3|302|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:24:21.709015|2018-06-01 01:24:21.709015
NCT00823823|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2014-09-02||2014-09-02|2009-01-15|2009-01-16|Estimate|2014-09-02|2014-09-09|Estimate||||2014-09-02|2014-09-09|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Randomized Trial of Casting Techniques for Displaced Forearm Fractures|Randomized Trial of Bivalved and Circumferential Casting for Displaced Forearm Fractures in Children|Completed||N/A|202|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 01:24:23.521176|2018-06-01 01:24:23.521176
NCT00823810|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2014-10-08|2009-01-15|2009-01-16|Estimate|||||||2014-10-08|2014-10-09|Estimate|December 2008||2008-12-31|October 2014|2014-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|RESCORE||Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT|Treatment Monitoring of Advanced Colorectal Cancer With 18F-FDG PET/CT|Terminated||N/A|20|Actual|Turku University Hospital||1||Recruitment promlems|f||||f||||||||||2018-06-01 01:24:23.744962|2018-06-01 01:24:23.744962
NCT00823797|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|2017-04-07||2017-06-07|2009-01-15|2009-01-16|Estimate|2017-04-07|2017-05-19|Actual||||2017-06-07|2017-07-07|Actual|October 2008||2008-10-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|December 2015|Actual|2015-12-31||Interventional|||Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma|A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)|Completed||Phase 2|45|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 01:24:23.959203|2018-06-01 01:24:23.959203
NCT00823784|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2009-01-15|2009-01-15|2009-01-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|July 2009|Anticipated|2009-07-31|January 2009|Anticipated|2009-01-31||Interventional|THD/stapler||Prospective Randomized Trial Comparing THD Versus Stapler Operation for 3rd Degree Hemorrhoids|Prospective Randomized Trial Comparing Transanal Doppler de-Arterialization (THD) Versus Stapler Operation for 3rd Degree Hemorrhoids|Unknown status|Recruiting|Phase 3|270|Anticipated|Societa Italiana di Chirurgia ColoRettale||2|||f||||f||||||||||2018-06-01 01:24:24.40434|2018-06-01 01:24:24.40434
NCT00823771|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2017-01-31|2009-01-14|2009-01-16|Estimate|||||||2017-01-31|2017-02-02|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|April 1, 2014|Actual|2014-04-01|October 2012|Actual|2012-10-31||Observational|PROFUGO||A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment|A Pilot Study in the Transfer of Follow-up Reviews to the General Practitioner for Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment|Terminated|||107|Actual|Barwon Health|||2|Data review showed that the study was underpowered to draw clear conlcusions|f||||f||||||||||2018-06-01 01:24:24.651257|2018-06-01 01:24:24.651257
NCT00823758|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2018-01-24|2009-01-15|2009-01-16|Estimate|||||||2018-01-24|2018-01-26|Actual|December 19, 2008|Actual|2008-12-19|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Understanding Patient's Knowledge and Use of Acetaminophen|Understanding Patient's Knowledge and Use of Acetaminophen|Active, not recruiting|||124|Anticipated|M.D. Anderson Cancer Center|||5||f||||f|f|f||||||||2018-06-01 01:24:24.848835|2018-06-01 01:24:24.848835
NCT00823745|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2009-03-06|2009-01-14|2009-01-16|Estimate|||||||2009-03-06|2009-03-09|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects|A Phase 1 Study To Evaluate The Metabolism And Excretion Of [14C] PF-00868554 In Healthy Adult Male Subjects|Completed||Phase 1|7|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:24:24.931693|2018-06-01 01:24:24.931693
NCT00823732|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2015-11-04|2009-01-15|2009-01-16|Estimate|||||||2015-11-04|2015-11-06|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Palliative Care for Quality of Life and Symptom Concerns in Late Stage Lung Cancer|Completed||N/A|280|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 01:24:25.008032|2018-06-01 01:24:25.008032
NCT00823719|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2012-06-21||2013-03-07|2009-01-15|2009-01-16|Estimate|2012-08-02|2012-09-05|Estimate||||2013-03-07|2013-03-12|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)|A Single Arm, Safety and Efficacy Study of Ofatumumab in Combination With ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive Lymphoma Prior to Autologous Stem Cell Transplantation|Completed||Phase 2|61|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:24:25.160364|2018-06-01 01:24:25.160364
NCT00823706|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15|||2011-04-04|2009-01-15|2009-01-16|Estimate|||||||2011-04-04|2011-04-05|Estimate|January 2009||2009-01-31|January 2009|2009-01-31||||||||Observational|||Prevalence of Angle Closure in Caucasian Hyperopes|Prevalence of Chronic Angle Closure in Caucasian Hyperopic Subjects|Unknown status|Recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 01:24:27.235287|2018-06-01 01:24:27.235287
NCT00823693|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-08-20|2009-01-15|2009-01-16|Estimate|||||||2009-08-20|2009-08-21|Estimate||||August 2009|2009-08-31||||||||Interventional|||Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis|Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Bimosiamose 5% Cream for the Treatment of Patients With Chronic Plaque Type Psoriasis|Completed||Phase 2|107|Actual|Revotar Biopharmaceuticals AG||2|||f||||||||||||||2018-06-01 01:24:27.298701|2018-06-01 01:24:27.298701
NCT00823680|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-15||2016-07-26|2016-07-26|2009-01-15|2009-01-16|Estimate||||2016-07-26|2016-07-28|Estimate|2016-07-26|2016-07-28|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin|Multi-center, Randomized, Double-blind, 5-arm Parallel Group, Placebo Controlled 4 Week Study to Investigate the Safety, Tolerability and Efficacy of Two Doses Each (Near to Maximum Tolerated Dose and Lower Dose) of RO5093151 Administered Twice Daily (BID Regimen) and RO5027838 Administered Once da|Completed||Phase 2|110|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-06-01 01:24:27.370333|2018-06-01 01:24:27.370333
NCT00823667|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2014-09-18|2009-01-14|2009-01-15|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery|Palliative Care for Quality of Life and Symptom Concerns in Early Stage Lung Cancer|Completed||N/A|198|Actual|City of Hope Medical Center||2|||f||||f||||||||||2018-06-01 01:24:28.386557|2018-06-01 01:24:28.386557
NCT00823654|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2018-02-20|2009-01-14|2009-01-15|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2009|Actual|2009-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations|Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer BRCA Mutations|Recruiting|||320|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples Without DNA|"~     blood~   "|||2018-06-01 01:24:28.499333|2018-06-01 01:24:28.499333
NCT00823641|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2013-04-12|2009-01-14|2009-01-15|Estimate|||||||2013-04-12|2013-04-15|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|HAM06||The HAM Infliximab Study|An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP|Terminated||Phase 2|3|Actual|Imperial College London||1||Higher toxicity rate than observed in studies in Rheumatoid arthritis|f||||t||||||||||2018-06-01 01:24:28.697165|2018-06-01 01:24:28.697165
NCT00823628|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2010-07-06|2009-01-14|2009-01-15|Estimate|||||||2010-07-06|2010-07-07|Estimate|February 2009||2009-02-28|April 2009|2009-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide|Comparison of Contrast-medium Induced Nephrotoxicity Between Iodixanol and Iopromide in Patients With Renal Insufficiency Undergoing Coronary Angiography|Completed||Phase 4|420|Anticipated|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-06-01 01:24:28.788463|2018-06-01 01:24:28.788463
NCT00823615|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2010-09-07||2012-06-26|2009-01-13|2009-01-15|Estimate|2010-10-06|2010-10-29|Estimate||||2012-06-26|2012-06-29|Estimate|December 2008||2008-12-31|January 2012|2012-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Comparison of Two New Silicone Hydrogel Multifocal Products|Comparison of Two New Silicone Hydrogel Multifocal Products|Completed||N/A|40|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 01:24:28.865819|2018-06-01 01:24:28.865819
NCT00823602|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-14|2009-01-14|2009-01-15|Estimate|||||||2009-01-14|2009-01-15|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|January 2009|Anticipated|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH|Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART|Unknown status|Recruiting|Phase 3|2|Anticipated|Yazd Research & Clinical Center for Infertility||2|||f||||||||||||||2018-06-01 01:24:29.07924|2018-06-01 01:24:29.07924
NCT00823589|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2014-02-24|2009-01-14|2009-01-15|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Immune Status of Elderly Population Admitted in an Acute Geriatric Unit|Immune Status of Elderly Population Admitted in an Acute Geriatric Unit|Completed||N/A|78|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 01:24:29.283328|2018-06-01 01:24:29.283328
NCT00823407|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2013-05-29|2009-01-14|2009-01-15|Estimate|||||||2013-05-29|2013-05-31|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|MDA||Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]|Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]|Completed||N/A|12|Actual|California Pacific Medical Center Research Institute||1|||f||||f||||||||||2018-06-01 01:24:31.206045|2018-06-01 01:24:31.206045
NCT00823576|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2011-05-31|2009-01-14|2009-01-15|Estimate|||||||2011-05-31|2011-06-01|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy of Ropivacaine Continuous Wound Instillation Versus Single Shot After Spine Fusion Surgery|Efficacy of Ropivacaine Continuous Wound Instillation Versus Single Shot After Spine Fusion Surgery|Terminated||Phase 4|64|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:24:29.350125|2018-06-01 01:24:29.350125
NCT00823563|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2014-07-07|2009-01-14|2009-01-15|Estimate|||||||2014-07-07|2014-07-09|Estimate|June 2007||2007-06-30|July 2014|2014-07-31||||June 2015|Anticipated|2015-06-30||Observational|||Sex Differences in Coronary Pathophysiology|Sex Differences in Symptomatic Non-Obstructive Coronary Disease: Do Women Have a Unique Coronary Pathophysiology?|Unknown status|Recruiting||126|Anticipated|Stanford University|||||f||||t||||||||||2018-06-01 01:24:29.429209|2018-06-01 01:24:29.429209
NCT00823550|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2010-12-15|2009-01-14|2009-01-15|Estimate|||||||2010-12-15|2010-12-16|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients|A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase|Unknown status|Active, not recruiting|Phase 4|462|Anticipated|Yonsei University||2|||f||||t||||||||||2018-06-01 01:24:29.520496|2018-06-01 01:24:29.520496
NCT00823537|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-01-14|2009-01-14|2009-01-15|Estimate|||||||2009-01-14|2009-01-15|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|TES||Power-Assisted Therapeutic Electrical Stimulation to Upper Extremities|Power-Assisted Therapeutic Electrical Stimulation to Upper Extremities in Acute Stroke Patients. A Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|||Fujita Health University|||||f||||f||||||||||2018-06-01 01:24:29.642202|2018-06-01 01:24:29.642202
NCT00823524|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2013-02-18|2009-01-14|2009-01-15|Estimate|||||||2013-02-18|2013-02-20|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer|Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study|Completed||Phase 1/Phase 2|47|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 01:24:29.720744|2018-06-01 01:24:29.720744
NCT00823511|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2015-01-27|2009-01-14|2009-01-15|Estimate|||||||2015-01-27|2015-01-28|Estimate|October 2006||2006-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|January 2012|Actual|2012-01-31||Observational|||The Human Papillomavirus (HPV) Transmission Pilot Study|The Human Papillomavirus (HPV) Transmission Pilot Study|Completed|||137|Actual|H. Lee Moffitt Cancer Center and Research Institute|||1||f||||f||||||||||2018-06-01 01:24:30.020261|2018-06-01 01:24:30.020261
NCT00823498|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2018-02-05|2009-01-14|2009-01-15|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2009|Actual|2009-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Physical Activity in Public Housing - II|Perceptions of School, Recreation, and Transportation Environments Among African American Families in Public Housing--II|Active, not recruiting|||84|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 01:24:30.230827|2018-06-01 01:24:30.230827
NCT00823485|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2011-12-08|2009-01-14|2009-01-15|Estimate|||||||2011-12-08|2011-12-09|Estimate|October 2005||2005-10-31|December 2011|2011-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Clinical Efficacy of In-situ Thrombolysis in Case of Intraventricular Haemorraghia by Aneurysm Rupture|Clinical Efficacy of In-situ Thrombolysis in Case of Intraventricular Haemorraghia by Aneurysm Rupture|Completed||Phase 2/Phase 3|19|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:24:30.307235|2018-06-01 01:24:30.307235
NCT00823472|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2010-11-02||2010-11-02|2009-01-13|2009-01-15|Estimate|2010-11-02|2010-12-02|Estimate||||2010-11-02|2010-12-02|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|LITE||Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)|Among IVF Patients Undergoing Fixed Antagonist Protocols With Recombinant FSH, Does Administration of Recombinant FSH From Cycle Day 5 Onwards Compared With Cycle Day 2 Onwards, Yield a Higher Number of Good Quality Embryos?|Terminated||Phase 4|147|Actual|UMC Utrecht|Early termination of the trial lead to small number of subjects to be analyzed. Only half of the expected patients were included.|2||"Inclusion of the study didn't go as fast as expected. Expect: 234 patients in 1 year in 2~   centers. After 1,5 year only 147 patients were recruited."|f||||t||||||||||2018-06-01 01:24:30.390385|2018-06-01 01:24:30.390385
NCT00823459|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2016-02-16|2009-01-14|2009-01-15|Estimate|||||||2016-02-16|2016-02-18|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|RAD001||Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma|Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma|Completed||Phase 2|58|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:24:30.679224|2018-06-01 01:24:30.679224
NCT00823446|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-06-22|2009-01-13|2009-01-15|Estimate|||||||2012-06-22|2012-06-26|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Feasibility Study to Evaluate the Safety of Topically Applied Revera in Subjects With Venous Leg Ulcers|A Feasibility, Double Blind, Randomized, Controlled Clinical Study to Evaluate the Safety of Topically Applied Revera vs. Control in Subjects With Venous Leg Ulcers.|Completed||Phase 1|13|Actual|Revalesio Corporation||2|||f||||f||||||||||2018-06-01 01:24:30.773737|2018-06-01 01:24:30.773737
NCT00823433|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2016-11-02|2009-01-13|2009-01-15|Estimate|||||||2016-11-02|2016-11-04|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood|Does Oral Penicillin Reach and Simulate Intravenous Penicillin Levels in Venous Umbilical Cord Blood of Laboring Pregnant Patients?|Terminated||Early Phase 1|25|Actual|William Beaumont Hospitals||1||Insufficient enrollment.|f||||t||||||||||2018-06-01 01:24:30.908528|2018-06-01 01:24:30.908528
NCT00823420|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2014-12-04|2009-01-13|2009-01-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2009||2009-05-31|January 2009|2009-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential|Influence of a Prematuration Culture With a PDE3-I on Embryonic Aneuploidy Rate and Developmental Potential|Terminated||Phase 1|213|Actual|Universitair Ziekenhuis Brussel||1||"The Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) has been replaced by a~   different formulation"|f||||t||||||||||2018-06-01 01:24:30.997697|2018-06-01 01:24:30.997697
NCT00823394|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2017-09-12|2009-01-14|2009-01-15|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2008|Actual|2008-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||African American Cancer Prevention Project: Establishing a Cohort to Investigate Health Disparities|African American Cancer Prevention Project: Establishing a Cohort to Investigate Health Disparities|Active, not recruiting|||1501|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:24:31.330343|2018-06-01 01:24:31.330343
NCT00823381|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-12-09|2009-01-13|2009-01-15|Estimate|||||||2013-12-09|2013-12-10|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Resvida||Effect of Resvida, a Comparison With Calorie Restriction Regimen|Effect of Resvida(tm) Dietary Supplementation on Muscle Gene Expression: A Comparison With Calorie Restriction Regimen|Completed||N/A|58|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 01:24:31.703824|2018-06-01 01:24:31.703824
NCT00823368|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-07-30|2009-01-14|2009-01-15|Estimate|||||||2013-07-30|2013-07-31|Estimate|January 2009||2009-01-31|July 2013|2013-07-31||||March 2010|Actual|2010-03-31||Observational|||Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001|Biomarker Testing and DNA Collection in Subjects Participating in a Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome|Completed|||||Seaside Therapeutics, Inc.|||2||f||||t||||||Samples With DNA|"~     DNA from blood,plasma~   "|||2018-06-01 01:24:31.875485|2018-06-01 01:24:31.875485
NCT00823355|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2013-09-20|2009-01-13|2009-01-15|Estimate|||||||2013-09-20|2013-09-23|Estimate|January 2009||2009-01-31|September 2013|2013-09-30||||August 2013|Actual|2013-08-31||Interventional|||Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies|A Phase I, Open Label, Dose Ascending Study of BCX1777 (Oral) in Patients With Recurrent or Refractory T/NK-cell Malignancies|Completed||Phase 1|24|Anticipated|Mundipharma K.K.||1|||f||||f||||||||||2018-06-01 01:24:32.063231|2018-06-01 01:24:32.063231
NCT00823342|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-05-07|2009-01-14|2009-01-15|Estimate|||||||2009-05-07|2009-05-08|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|||ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy|ANRS HB 05 : A Randomized, Double Blind, Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy|Terminated||Phase 3|150|Anticipated|French National Agency for Research on AIDS and Viral Hepatitis||3|||f||||t||||||||||2018-06-01 01:24:32.269983|2018-06-01 01:24:32.269983
NCT00823329|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-10-10|2009-01-14|2009-01-15|Estimate|||||||2012-10-10|2012-10-12|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2012||2012-10-31|October 2012||2012-10-31||Interventional|PCMMS||Calorie Balance Monitoring and Analysis of Body Composition and Hydration Status|Calorie Balance Monitoring and Analysis of Body Composition and Hydration|Suspended||Early Phase 1|10|Anticipated|Ori Diagnostic Instruments LLC||||lack of funding|f||||f||||||||||2018-06-01 01:24:32.386797|2018-06-01 01:24:32.386797
NCT00823316|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-04-20|2009-01-14|2009-01-15|Estimate|||||||2012-04-20|2012-04-23|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation|Phase 1/2 Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells Infusion for Promotion of Engraftment and Prevention of an Graft Rejection and Graft-versus-Host Disease After Unrelated Hematopoietic Stem Cell Transplantation.|Completed||Phase 1/Phase 2|10|Actual|Medipost Co Ltd.||2|||f||||t||||||||||2018-06-01 01:24:32.509748|2018-06-01 01:24:32.509748
NCT00823303|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2014-06-05||2014-08-04|2009-01-14|2009-01-15|Estimate|2014-07-07|2014-08-05|Estimate||||2014-08-04|2014-08-07|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|PACE|Stage 3 and 4 CKD with SHPT, age >18, a stable dose of phosphate binder (if receiving a binder), estimated glomerular filtration rate (eGFR) of 15-59 mL/min using the abbreviated MDRD equation, PTH >120 pg/mL, albumin-corrected calcium >8.5 mg/dL and <10.0 mg/dL, phosphorus <4.6 mg/dL.|Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)|A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism|Completed||Phase 4|110|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:24:32.684899|2018-06-01 01:24:32.684899
NCT00823290|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2010-01-11|2009-01-14|2009-01-15|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)|A Phase I Trial of Sorafenib and LBH589 in the Treatment of Advanced HCC|Unknown status|Recruiting|Phase 1|18|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 01:24:33.053103|2018-06-01 01:24:33.053103
NCT00823277|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2014-04-30|2009-01-14|2009-01-15|Estimate|||||||2014-04-30|2014-05-01|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight|Indicators for the Metabolic Syndrome as Well as the Influence of Different Gen-polymorphs on Weightloss and the Maintenance of Lower Weight Among Children in Treatment for Overweight|Completed|||517|Actual|Zealand University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood samples of Whoole Blood.~   "|||2018-06-01 01:24:33.19009|2018-06-01 01:24:33.19009
NCT00823264|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2013-08-14||2014-09-04|2009-01-14|2009-01-15|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-04|2014-09-11|Estimate|August 2008||2008-08-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|July 2010|Actual|2010-07-31||Interventional|||Phenytoin and Multidose Activated Charcoal|Prospective Randomized Study of Multidose Activated Charcoal in Supratherapeutic Phenytoin Serum Levels|Completed||N/A|17|Actual|Emory University||2|||f||||f||||||||||2018-06-01 01:24:33.359086|2018-06-01 01:24:33.359086
NCT00823251|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2017-06-06|2009-01-14|2009-01-15|Estimate|||||||2017-06-06|2017-06-07|Actual|December 2008||2008-12-31|June 2017|2017-06-30|February 2013|Actual|2013-02-28|October 2009|Actual|2009-10-31||Interventional|||IlluminOss Hand Fracture International Clinical Feasibility Study|IlluminOss Medical- Photodynamic Bone Stabilization System- International Study|Completed||Phase 1|4|Actual|IlluminOss Medical, Inc.||1|||f||||f|f|f||||||||2018-06-01 01:24:33.834842|2018-06-01 01:24:33.834842
NCT00823238|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2011-04-15|2009-01-14|2009-01-15|Estimate|||||||2011-04-15|2011-04-18|Estimate|July 2004||2004-07-31|April 2011|2011-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|CAPEC||Comparison of Antibiotics for Pseudomonas in Early CF|Comparison of Antibiotics for Pseudomonas in Early CF|Completed||Phase 1|21|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 01:24:33.96519|2018-06-01 01:24:33.96519
NCT00823225|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2015-03-12|2009-01-14|2009-01-15|Estimate|||||||2015-03-12|2015-03-13|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Urokinase Therapy in Patients With Diabetic Foot Syndrome|Low Dose Urokinase Therapy in Patients With Diabetic Foot Syndrome and Critical Limb Ischemia Versus Conventional Standard Therapy|Terminated||Phase 3|5|Actual|medac GmbH||2||Insufficient recruitment of study patients|f||||f||||||||||2018-06-01 01:24:34.043599|2018-06-01 01:24:34.043599
NCT00823212|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2011-12-21|2010-11-10|2017-02-02|2009-01-13|2009-01-15|Estimate|2011-12-21|2012-01-27|Estimate|2010-11-10|2010-11-16|Estimate|2017-02-02|2017-03-13|Actual|January 2009||2009-01-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|September 2010|Actual|2010-09-30||Interventional|PLATINUM||The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions|PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions|Completed||Phase 3|1530|Actual|Boston Scientific Corporation||2|||f||||t||||||||No|Primary endpoint data uploaded.|2018-06-01 01:24:34.232875|2018-06-01 01:24:34.232875
NCT00823199|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2012-04-25||2015-07-20|2009-01-14|2009-01-15|Estimate|2013-03-21|2013-05-03|Estimate||||2015-07-20|2015-08-10|Estimate|November 2005||2005-11-30|July 2015|2015-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia|An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia|Completed||N/A|10|Actual|Bronx Psychiatric Center||1|||f||||f||||||||||2018-06-01 01:24:37.013683|2018-06-01 01:24:37.013683
NCT00823186|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2010-01-03|2009-01-14|2009-01-15|Estimate|||||||2010-01-03|2010-01-05|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|January 2013|Anticipated|2013-01-31|January 2012|Anticipated|2012-01-31||Interventional|Chemothreapy||Dose-finding Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and Bulky IIA Cervical Cancer|Phase I Dose Escalation Study Of Weekly Paclitaxel and Cisplatin Followed by Radical Hysterectomy in FIGO IB2 and Bulky IIA Cervical Cancer|Unknown status|Enrolling by invitation|Phase 1|21|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 01:24:37.404501|2018-06-01 01:24:37.404501
NCT00823173|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2011-05-25|2009-01-14|2009-01-15|Estimate|||||||2011-05-25|2011-05-26|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis|An Open Label Exploratory Study to Assess the Safety, Tolerability and Clinical Activity of Topically Applied ESBA105 in Patients With Acute Anterior Uveitis|Completed||Phase 2|9|Actual|ESBATech AG||1|||f||||f||||||||||2018-06-01 01:24:37.508535|2018-06-01 01:24:37.508535
NCT00823160|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2011-02-18|2009-01-14|2009-01-15|Estimate|||||||2011-02-18|2011-02-21|Estimate|October 2001||2001-10-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Surgical Management of Blood in the Pericardial Sac After Penetrating Trauma|A Randomized Prospective Study of the Definitive Management of the Stable Haemopericardium Following Penetrating Cardiac Injury Utilising Subxyphoid Window and Drainage.|Completed||N/A|111|Actual|University of Cape Town||2|||f||||t||||||||||2018-06-01 01:24:37.636505|2018-06-01 01:24:37.636505
NCT00823147|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-09-11|2009-01-13|2009-01-15|Estimate|||||||2009-09-11|2009-09-14|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|June 2020|Anticipated|2020-06-30|June 2010|Anticipated|2010-06-30||Observational|||Pain Catastrophizing as a Cause for Systemic Inflammation|Pain Catastrophizing as a Cause for Systemic Inflammation|Recruiting|||60|Anticipated|Oregon Health and Science University|||2||f||||f||||||Samples With DNA|"~     Whole Blood, saliva~   "|||2018-06-01 01:24:37.727686|2018-06-01 01:24:37.727686
NCT00823134|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2011-10-31|2009-01-14|2009-01-15|Estimate|||||||2011-10-31|2011-11-02|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Evaluation of ApneaLink Plus Scoring Capabilities|Evaluation of ApneaLink Plus Scoring Capabilities|Completed|||30|Anticipated|ResMed|||||f||||f||||||||||2018-06-01 01:24:37.813093|2018-06-01 01:24:37.813093
NCT00823121|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2010-01-19|2009-01-14|2009-01-15|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|February 2009|Anticipated|2009-02-28||Interventional|||Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification|Can Fresh Embryo Transfers be Replaced by Cryopreserved-thawed Embryo Transfers in Assisted Reproductive Cycles?|Unknown status|Recruiting|Phase 1/Phase 2|500|Anticipated|Yazd Research & Clinical Center for Infertility||2|||f||||t||||||||||2018-06-01 01:24:37.883369|2018-06-01 01:24:37.883369
NCT00823108|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2011-05-31|2009-01-14|2009-01-15|Estimate|||||||2011-05-31|2011-06-01|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Rapid Administration of Insulin in Sepsis|Rapid Administration of Insulin in Sepsis: A Pilot Study|Completed||Phase 1|20|Anticipated|Carolinas Healthcare System||2|||f||||t||||||||||2018-06-01 01:24:37.991155|2018-06-01 01:24:37.991155
NCT00823095|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2013-08-02||2016-01-28|2009-01-14|2009-01-15|Estimate|2014-04-02|2014-05-05|Estimate||||2016-01-28|2016-02-26|Estimate|December 2005||2005-12-31|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Topical Nitric Oxide Trial in Chronic Non-Healing Wounds|The Observational Effects of the Topical Application of ViaNOx-H (Gaseous Nitric Oxide) on the Bio-Burden in Chronic Non-Healing Colonized Ulcers of the Lower Extremities|Terminated||Phase 2|7|Actual|Loma Linda University|No data available for this study due to dissolution of company contracted to perform study analysis.|1||Subject recuitment halted and won't resume; subjects are no longer being treated.|f||||t||||||||||2018-06-01 01:24:38.079225|2018-06-01 01:24:38.079225
NCT00823082|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2016-04-05||2016-08-10|2009-01-14|2009-01-15|Estimate|2016-06-23|2016-08-04|Estimate||||2016-08-10|2016-09-20|Estimate|June 2009||2009-06-30|August 2016|2016-08-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional||206 subjects were randomized; six were screen failures. 100 subjects in the Anbinex treatment group and 94 subjects in the control group were included in the Intent-to-treat and Per-protocol populations (6 subjects in the control group were excluded). 199 subject were included in the Safety population (100 Anbinex and 99 control).|Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass|A Prospective Randomized Pilot Study to Evaluate the Effect of Preoperative Antithrombin Supplementation on Postoperative Levels of Antithrombin in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Completed||Phase 2|200|Actual|Grifols Biologicals Inc.||2|||f||||f||||||||||2018-06-01 01:24:38.254118|2018-06-01 01:24:38.254118
NCT00823069|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2010-08-25||2010-11-01|2009-01-14|2009-01-15|Estimate|2010-11-01|2010-11-30|Estimate||||2010-11-01|2010-11-30|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Safety Study That Compares Perlane to Perlane With Lidocaine (Perlane-L) While Correcting Wrinkles in the Area Around Your Nose|A Randomized, Double-Blind Study Comparing Safety and Tolerability of Perlane® With and Without Addition of 0.3% Lidocaine HCL During Correction of Nasolabial Folds|Completed||N/A|60|Actual|Medicis Global Service Corporation||1|||f||||f||||||||||2018-06-01 01:24:39.005074|2018-06-01 01:24:39.005074
NCT00823043|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2010-08-02||2015-02-18|2009-01-14|2009-01-15|Estimate|2010-08-27|2010-09-22|Estimate||||2015-02-18|2015-03-06|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs|A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With Timolol Hemihydrate 0.5% Solution Once or Twice Daily Versus Timolol Maleate in Sorbate|Completed|||103|Actual|Vistakon Pharmaceuticals|||2||f||||f||||||||||2018-06-01 01:24:39.327383|2018-06-01 01:24:39.327383
NCT00823030|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2015-10-12|2009-01-14|2009-01-15|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis|Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis|Withdrawn||N/A|0|Actual|Northwell Health||2|||f||||f||||||||||2018-06-01 01:24:39.550285|2018-06-01 01:24:39.550285
NCT00823017|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2018-05-16|2009-01-14|2009-01-15|Estimate|||||||2018-05-16|2018-05-18|Actual|July 2006||2006-07-31|May 2018|2018-05-31|March 2, 2011|Actual|2011-03-02|July 2010|Actual|2010-07-31||Interventional|MTS2||Effect of Music on Patients in Intensive Care Units|The Effect of Patient-Preferred Music, Relaxation Music, and Standard Care Environment on Patients in Intensive Care Units|Withdrawn||Phase 1|0|Actual|MetroHealth Medical Center||3||study withdrawn from IRB|f||||f||||||||||2018-06-01 01:24:39.68677|2018-06-01 01:24:39.68677
NCT00823004|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2013-12-20|2009-01-14|2009-01-15|Estimate|||||||2013-12-20|2013-12-23|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|October 2009|Actual|2009-10-31|February 2009|Actual|2009-02-28||Interventional|||Antagonist/Letrozole in Poor Responders|GnRH Antagonist /Letrozole Versus Microdose GnRH Agonist Flare Protocol in Poor Responders Undergoing in Vitro Fertilization|Completed||Phase 1/Phase 2|120|Actual|Yazd Research & Clinical Center for Infertility||2|||f||||t||||||||||2018-06-01 01:24:39.832103|2018-06-01 01:24:39.832103
NCT00822991|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2010-12-29|2009-01-14|2009-01-15|Estimate|||||||2010-12-29|2010-12-30|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sonazoid Enhanced Liver Cancer Trial for Early Detection|Sonazoid Enhanced Liver Cancer Trial for Early Detection|Recruiting||N/A|760|Anticipated|Japan Liver Oncology Group||2|||f||||t||||||||||2018-06-01 01:24:39.994171|2018-06-01 01:24:39.994171
NCT00822978|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-02-24|2009-01-14|2009-01-15|Estimate|||||||2012-02-24|2012-02-27|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase 1 Study for Safety of ACHN-490|A Double-Blind, Randomized, Placebo-controlled, Parallel-Group, Single and Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-490 Injection Administered Intravenously in Healthy Volunteers|Completed||Phase 1|39|Actual|Achaogen, Inc.||2|||f||||f||||||||||2018-06-01 01:24:40.189969|2018-06-01 01:24:40.189969
NCT00822965|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2016-01-05|2009-01-13|2009-01-15|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Enhancing Knowledge Implantable Cardioverter-Defibrillators (ICDs)|Patient Knowledge of Pacemaker/Implantable Cardioverter-Defibrillator-Phase II|Completed|||104|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:24:40.268873|2018-06-01 01:24:40.268873
NCT00822952|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2014-03-28|2009-01-14|2009-01-15|Estimate|||||||2014-03-28|2014-03-31|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|PMI||Prostate Mechanical Imager (PMI) Clinical Bridging Study|Prostate Mechanical Imager (PMI) Clinical Bridging Study|Completed|||71|Actual|Artann Laboratories|||||f||||f||||||||||2018-06-01 01:24:40.344216|2018-06-01 01:24:40.344216
NCT00822926|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2017-04-17||2017-07-14|2009-01-14|2009-01-15|Estimate|2017-07-14|2017-08-15|Actual||||2017-07-14|2017-08-15|Actual|January 2009||2009-01-31|July 2017|2017-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial|Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial|Terminated||N/A|5|Actual|Stanford University||2|||f||||||||||||||2018-06-01 01:24:40.464243|2018-06-01 01:24:40.464243
NCT00822913|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2009-01-14|2009-01-14|2009-01-15|Estimate|||||||2009-01-14|2009-01-15|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|Botox-PD||Botulinum A Toxin in Patients With Parkinson's Disease|The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity.|Unknown status|Enrolling by invitation|Phase 4|20|Anticipated|University Of Perugia||1|||f||||t||||||||||2018-06-01 01:24:40.7286|2018-06-01 01:24:40.7286
NCT00822900|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|2015-04-01||2015-12-16|2009-01-14|2009-01-15|Estimate|2015-06-24|2015-07-03|Estimate||||2015-12-16|2016-01-20|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|ProTECT||Progesterone for the Treatment of Traumatic Brain Injury III|Phase 3 Clinical Trial to Determine if Progesterone Along With Standard Medical Care for Brain Injury is More Effective at Limiting the Amount of Damage Cause by a Traumatic Brain Injury Than Standard Medical Care Alone.|Terminated||Phase 3|882|Actual|Emory University|The trial was stopped early for futility with respect to the primary outcome.|2||futility: low conditional power to demonstrate benefit of progesterone|f||||t||||||||||2018-06-01 01:24:40.851193|2018-06-01 01:24:40.851193
NCT00822887|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-06-24|2009-01-14|2009-01-15|Estimate|||||||2013-06-24|2013-06-26|Estimate|March 2007||2007-03-31|June 2013|2013-06-30|January 2011|Actual|2011-01-31|May 2010|Actual|2010-05-31||Interventional|IRUSZACT0073||Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas|A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients With Recurrent Malignant Gliomas|Completed||Phase 1|13|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-06-01 01:24:42.305001|2018-06-01 01:24:42.305001
NCT00822874|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2014-12-02|2009-01-13|2009-01-15|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential|Influence of a Prematuration Culture With a PDE3-I on Embryonic Aneuploidy Rate and Developmental Potential - a Pilot Study|Terminated||Phase 1|115|Actual|Universitair Ziekenhuis Brussel||1||"Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) has been replaced by other~   system"|f||||t||||||||||2018-06-01 01:24:42.385877|2018-06-01 01:24:42.385877
NCT00822861|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-11-14|2009-01-14|2009-01-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma|A Single Center, Open Label, Stepwise, Dose Profiling Study to Evaluate the Efficacy and Safety of Four Dose Regimens of Inhaled TPI ASM8 in Patients With Allergic Asthma|Completed||Phase 2|14|Actual|Pharmaxis||4|||f||||t||||||||||2018-06-01 01:24:42.443811|2018-06-01 01:24:42.443811
NCT00822848|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-14|||2018-01-16|2009-01-14|2009-01-15|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2009||2009-02-28|January 2018|2018-01-31||||September 2012|Actual|2012-09-30||Interventional|||Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma|Antiangiogenic Potentiation of Preoperative Chemoradiotherapy for High Risk Extremity Soft Tissue Sarcomas: A Phase I Study of Sorafenib With Epirubicin, Ifosfamide, Hypofractionated Radiation, and Surgery|Active, not recruiting||Phase 1|18|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 01:24:42.518865|2018-06-01 01:24:42.518865
NCT00822835|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-09-17|2009-01-13|2009-01-14|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Evaluating Single Doses of ILV-095 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-095 Administered Subcutaneously to Healthy Subjects|Completed||Phase 1|48|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:24:42.622533|2018-06-01 01:24:42.622533
NCT00822822|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-11-21|2009-01-13|2009-01-14|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2006||2006-03-31|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assess|Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assessment|Completed|||17|Actual|H. Lee Moffitt Cancer Center and Research Institute|||1||f||||f||||||||||2018-06-01 01:24:42.681789|2018-06-01 01:24:42.681789
NCT00822809|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2012-10-02|2009-01-13|2009-01-14|Estimate|||||||2012-10-02|2012-10-03|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|CASIMAS||CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers|Two-arm, Randomized, Open-label, Phase IIIb Study Investigating the Safety of a 3 Hour i.p. Infusion of Catumaxomab With and Without Prednisolone Premedication in Patients With Malignant Ascites Due to Epithelial Cancer|Completed||Phase 3|230|Actual|Neovii Biotech||2|||f||||t||||||||||2018-06-01 01:24:42.773445|2018-06-01 01:24:42.773445
NCT00822796|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-07-22|2009-01-13|2009-01-14|Estimate|||||||2013-07-22|2013-07-24|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Thermogard™ Efficacy Trial|Thermogard™ Efficacy Trial|Terminated||N/A|9|Actual|Brooke Army Medical Center||2||Difficulty in obtaining surrogate consent on critically ill subjects.|f||||t||||||||||2018-06-01 01:24:42.867429|2018-06-01 01:24:42.867429
NCT00822783|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|October 2001||2001-10-31|January 2009|2009-01-31|April 2003||2003-04-30|||||Interventional|||Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients|An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis.|Completed||Phase 4|||Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:24:42.958616|2018-06-01 01:24:42.958616
NCT00822770|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2014-06-13||2014-06-13|2009-01-13|2009-01-14|Estimate|2014-06-13|2014-07-16|Estimate||||2014-06-13|2014-07-16|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin|G-CSF and Plerixafor With Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias|Completed||Phase 1/Phase 2|47|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 01:24:43.032279|2018-06-01 01:24:43.032279
NCT00822757|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2011-06-22||2015-10-01|2009-01-13|2009-01-14|Estimate|2011-10-13|2011-11-21|Estimate||||2015-10-01|2015-10-02|Estimate|August 2007||2007-08-31|October 2015|2015-10-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Single Dose of the Lyophilized Formulation of Merck Staphylococcus Aureus Vaccine (V710) in Healthy Adults|Completed||Phase 1|51|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:24:43.212418|2018-06-01 01:24:43.212418
NCT00822744|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-03-14|2009-01-13|2009-01-14|Estimate|||||||2013-03-14|2013-03-15|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|FIDELIO||An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients|An Eight-week, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Study, With Escitalopram (10 mg Daily) as Active Control, to Evaluate the Efficacy, Safety and Tolerability of Three Fixed Doses of SSR411298 (10, 50, or 200 mg Daily) in Elderly Patients With Major Depressive Disorder|Completed||Phase 2|527|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 01:24:44.413919|2018-06-01 01:24:44.413919
NCT00822731|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2012-05-22|2009-01-12|2009-01-14|Estimate|||||||2012-05-22|2012-05-23|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SMC-LCS||Samsung Medical Center-Lymphoma Cohort Study|Development of a Predictive Model for Treatment Outcome and Treatment-related Morbidity in a Prospective Cohort Study of Patients With Lymphoma|Completed||N/A|953|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 01:24:44.499136|2018-06-01 01:24:44.499136
NCT00822718|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|July 2007|Actual|2007-07-31|||||Observational|||Obestatin Change in Distal Gastrectomy||Completed|||100|Actual|Samsung Medical Center|||||f||||t||||||||||2018-06-01 01:24:44.565513|2018-06-01 01:24:44.565513
NCT00822705|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|August 2008||2008-08-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36|Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36: a Phase 1 Study|Completed||Phase 1/Phase 2|16|Actual|University Hospital, Basel, Switzerland||4|||f||||f||||||||||2018-06-01 01:24:44.627804|2018-06-01 01:24:44.627804
NCT00822692|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2009-07-29||2015-12-17|2009-01-13|2009-01-14|Estimate|2009-07-29|2009-09-03|Estimate||||2015-12-17|2015-12-21|Estimate|July 2008||2008-07-31|December 2015|2015-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection|Prospective Randomized Double Blind, Placebo-Controlled Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection on 30 Day Recurrence Rates.|Completed||N/A|139|Actual|Wilford Hall Medical Center||2|||f||||f||||||||||2018-06-01 01:24:44.715707|2018-06-01 01:24:44.715707
NCT00822679|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2016-10-26||2016-10-26|2009-01-13|2009-01-14|Estimate|2016-10-26|2016-12-20|Estimate||||2016-10-26|2016-12-20|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome|Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome|Completed||Phase 4|5|Actual|University of Arizona|Zero subjects were randomized. Many potential participants screen-failed. Study was closed due to difficulty with recruitment.|2|||f||||f||||||||||2018-06-01 01:24:44.961755|2018-06-01 01:24:44.961755
NCT00822666|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-12-10|2009-01-13|2009-01-14|Estimate|||||||2012-12-10|2012-12-11|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|CLOVIS2||Clopidogrel and Response Variability Investigation Study 2|Effect of the Genetic Variant 2C19*2 on Clopidogrel Biological Response in Patients With Premature Coronary Artery Disease|Completed||Phase 3|109|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:24:45.188535|2018-06-01 01:24:45.188535
NCT00822653|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2016-09-22|2009-01-13|2009-01-14|Estimate|||||||2016-09-22|2016-09-26|Estimate|June 2008||2008-06-30|September 2016|2016-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effects of Plantar Stimulation on Hypotension, Treatment Efficacy and Quality of Life With Adults on Hemodialysis|the Effects of Plantar Stimulation on Hypotension, Treatment Efficacy and Quality of Life|Withdrawn||N/A|0|Actual|Binghamton University||1||Original principal investigator left the university before enrollment started|f||||f||||||||Yes|Team is willing to share anonymous data with interested investigators|2018-06-01 01:24:45.268965|2018-06-01 01:24:45.268965
NCT00822640|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-05-13|2009-01-13|2009-01-14|Estimate|||||||2013-05-13|2013-05-14|Estimate|March 2004||2004-03-31|May 2013|2013-05-31|July 2008|Actual|2008-07-31|June 2007|Actual|2007-06-30||Interventional|||Comparison of Rotating vs. Fixed Platform of the COLUMBUS Knee Prosthesis|Clinical Outcome With Attention to Functional Results One Year After Fixed or Mobile Bearing Total Knee Replacement in a Randomized Controlled Trial|Completed||Phase 4|100|Actual|Aesculap AG||2|||f||||f||||||||||2018-06-01 01:24:45.334478|2018-06-01 01:24:45.334478
NCT00822627|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Influenza Vaccination in the Emergency Department|Influenza Vaccination in the Emergency Department|Completed||N/A|140|Actual|University of Arizona||2|||f||||f||||||||||2018-06-01 01:24:45.43127|2018-06-01 01:24:45.43127
NCT00822614|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|FINDS||Safety of Fentanyl TAIFUN Treatment|The Safety of Fentanyl TAIFUN Treatment After Titrated Dose Administration and the Current Breakthrough Pain Treatment for Breakthrough Pain in Cancer Patients|Unknown status|Recruiting|Phase 3|500|Anticipated|Akela Pharma, Inc.||2|||f||||f||||||||||2018-06-01 01:24:45.513267|2018-06-01 01:24:45.513267
NCT00822601|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-07-30|2009-01-13|2009-01-14|Estimate|||||||2012-07-30|2012-07-31|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|TMS-TOC||Study of Repetitive Transcranial Magnetic Stimulation Efficacy on Obsessive Compulsive Disorder (OCD)|A Controlled Study of rTMS Over Supplementary Motor Area (SMA) in Obsessive Compulsive Disorder|Completed||Phase 2|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:24:45.595977|2018-06-01 01:24:45.595977
NCT00822588|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2011-02-18||2012-09-27|2009-01-13|2009-01-14|Estimate|2011-04-01|2011-05-03|Estimate||||2012-09-27|2012-10-04|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not|A Prospective, Randomized, Controlled Trial of Retransfusion of Intra-operatively Collected Filtered Whole Blood in Total Hip Surgery|Completed||N/A|227|Actual|Wellspect HealthCare||2|||f||||f||||||||||2018-06-01 01:24:45.694487|2018-06-01 01:24:45.694487
NCT00822575|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of a Device to Relieve Mosquito Bite Itching.|Relief From Itching of Mosquito Bites Clinical Study Protocol.|Completed||N/A|60|Actual|Ecobrands, Ltd.||2|||f||||f||||||||||2018-06-01 01:24:45.992831|2018-06-01 01:24:45.992831
NCT00822562|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2016-03-30|2009-01-13|2009-01-14|Estimate|||||||2016-03-30|2016-04-01|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|January 2009|Actual|2009-01-31||Interventional|||Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer|Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer|Completed||N/A|100|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:24:46.104391|2018-06-01 01:24:46.104391
NCT00822549|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-12-10|2009-01-13|2009-01-14|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2006||2006-09-30|January 2009|2009-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Pharmacokinetic, Pharmacodynamic and Pharmacogenetic of Morphine After Surgery|Assessment of the Pharmacokinetic, Pharmacodynamic, Pharmacogenetic Relationships of Morphine and Metabolites After Severe Postoperative Pain in Adults|Completed|||438|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-06-01 01:24:46.168679|2018-06-01 01:24:46.168679
NCT00822536|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2014-10-16|2009-01-13|2009-01-14|Estimate|||||||2014-10-16|2014-10-17|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|OPTIDUAL||Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation|Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation|Completed||Phase 4|1798|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:24:46.239082|2018-06-01 01:24:46.239082
NCT00822523|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2015-10-16||2016-08-05|2009-01-13|2009-01-14|Estimate|2016-08-05|2016-08-31|Estimate||||2016-08-05|2016-08-31|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|March 2009|Actual|2009-03-31||Interventional|||Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies|Strain Gauge Feasibility Assessment & Correlation With Compound Muscle Action Potential & Surface Electromyogram Parameters Before & After a Single Intramuscular Injection of Botulinum Toxin Type A Into Extensor Digitorum Brevis Muscle|Completed||N/A|13|Actual|Loma Linda University||3|||f||||f||||||||No||2018-06-01 01:24:46.372367|2018-06-01 01:24:46.372367
NCT00822510|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2015-11-30||2018-04-10|2009-01-13|2009-01-14|Estimate|2016-06-22|2016-06-23|Estimate||||2018-04-10|2018-05-10|Estimate|September 2006||2006-09-30|June 2016|2016-06-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Telephone Counseling: Men With Prostate Cancer & Partners|Telephone Counseling With Men With Prostate Cancer and Partners|Completed||Phase 1|79|Actual|University of Arizona||2|||f||||t||||||||No||2018-06-01 01:24:47.439183|2018-06-01 01:24:47.439183
NCT00822497|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2010-07-22|2009-01-13|2009-01-14|Estimate|||||||2010-07-22|2010-07-23|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MTS1||Efficacy of Music Therapy Protocols for Burn Debridement|The Efficacy of Music Therapy Protocols for Decreasing Pain, Anxiety, and Muscle Tension Levels During Burn Debridement: A Prospective Randomized Crossover Trial|Completed||Phase 1|50|Anticipated|MetroHealth Medical Center||3|||f||||f||||||||||2018-06-01 01:24:47.874154|2018-06-01 01:24:47.874154
NCT00822484|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2011-05-04|2009-01-13|2009-01-14|Estimate|||||||2011-05-04|2011-05-06|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study Evaluating Single Doses of ILV-095 in Healthy Japanese Male Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-095 Administered Subcutaneously to Healthy Japanese Male Subjects|Completed||Phase 1|48|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:24:48.066027|2018-06-01 01:24:48.066027
NCT00822471|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|January 2003||2003-01-31|January 2009|2009-01-31|July 2005|Actual|2005-07-31|January 2005|Actual|2005-01-31||Interventional|||"Feasibility and Impact of ABCs of Diabetes Self-Management Education Program at an Urban Public Library"|"Feasibility and Impact of of ABC's of Diabetes Self Management Education (DSME) Program for African Americans at an Urban Public Library on A1C, Lipid Lowering Agent Prescriptions and Emergency Department Visits"|Completed||N/A|360|Actual|Medstar Health Research Institute||1|||f||||f||||||||||2018-06-01 01:24:48.165296|2018-06-01 01:24:48.165296
NCT00822458|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2014-04-01|2009-01-13|2009-01-14|Estimate|||||||2014-04-01|2014-04-02|Estimate|January 2009||2009-01-31|June 2013|2013-06-30||||September 2013|Actual|2013-09-30||Interventional|||GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment|A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449|Completed||Phase 1|34|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:24:48.261201|2018-06-01 01:24:48.261201
NCT00822445|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-10-30|2009-01-13|2009-01-14|Estimate|||||||2012-10-30|2012-10-31|Estimate|June 2008||2008-06-30|February 2008|2008-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|S100||S100 Protein in Minor/Mild Traumatic Brain Injury|Diagnostic Value and Prognostic Value of the Blood Level Determination of S100 Protein in Minor or Mild Traumatic Brain Injury (GCS Glasgow Score 9 to 15).|Completed|||500|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 01:24:48.42071|2018-06-01 01:24:48.42071
NCT00822432|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-07-30|2009-01-13|2009-01-14|Estimate|||||||2012-07-30|2012-07-31|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|COMETH||Coproporphyrine Isomers and Methotrexate Elimination|Urinary Ratio of the Coproporphyrins Isomers I and III and Its Relationships With Methotrexate Elimination in Patients With a Lymphoid Malignancy|Completed|||85|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||Samples With DNA|"~     blood~   "|||2018-06-01 01:24:48.48528|2018-06-01 01:24:48.48528
NCT00822419|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Percutaneous Ketamine Versus Lidocaine for Mid-Sternotomy||Unknown status|Not yet recruiting|Phase 4|75|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-06-01 01:24:48.550966|2018-06-01 01:24:48.550966
NCT00822406|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-26|2009-01-13|2009-01-14|Estimate|||||||2009-01-26|2009-01-27|Estimate|July 2002||2002-07-31|January 2009|2009-01-31|December 2006|Actual|2006-12-31|||||Interventional|||Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis|Quantitative-Qualitative Clinical Trial to Evaluate the Effectiveness of Individualized Homeopathic Treatment in Perennial Allergic Rhinitis|Completed||Phase 4|41|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:24:48.641944|2018-06-01 01:24:48.641944
NCT00822393|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2018-03-26|2009-01-13|2009-01-14|Estimate|||||||2018-03-26|2018-03-27|Actual|November 2008||2008-11-30|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)|Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens|Completed||Phase 3|570|Actual|medac GmbH||2|||f||||t||||||||Undecided||2018-06-01 01:24:48.720259|2018-06-01 01:24:48.720259
NCT00822380|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|March 2003||2003-03-31|January 2009|2009-01-31|November 2004|Actual|2004-11-30|November 2003|Actual|2003-11-30||Interventional|||Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children|Evaluation of the Efficacy of Different Strategies to Treat Anemia in Mexican Children: A Randomized Clinical Trial|Completed||N/A|680|Actual|Universidad Autonoma de Queretaro||1|||f||||f||||||||||2018-06-01 01:24:48.862808|2018-06-01 01:24:48.862808
NCT00822367|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Blood Sugar Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes|Assessment of Glycemic Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes Mellitus|Completed||N/A|19|Actual|Walter Reed Army Medical Center||1|||f||||f||||||||||2018-06-01 01:24:48.932975|2018-06-01 01:24:48.932975
NCT00822354|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-31|2014-09-11||2014-12-02|2009-01-13|2009-01-14|Estimate|2014-12-02|2014-12-04|Estimate||||2014-12-02|2014-12-04|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Tadalafil for the Treatment of Raynaud's|Tadalafil for the Treatment of Secondary Raynaud's Phenomenon|Completed||N/A|10|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 01:24:49.009058|2018-06-01 01:24:49.009058
NCT00822341|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2014-03-25|2009-01-13|2009-01-14|Estimate|||||||2014-03-25|2014-03-27|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Single Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TG-0054 in Healthy Subjects|Completed||Phase 1|64|Actual|TaiGen Biotechnology Co., Ltd.|||||f||||||||||||||2018-06-01 01:24:49.383801|2018-06-01 01:24:49.383801
NCT00822328|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2009-03-23||2009-08-27|2009-01-13|2009-01-14|Estimate|2009-07-08|2009-08-19|Estimate||||2009-08-27|2009-09-02|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Fermented Milk Drink on Human Intestinal Microflora|Effects of a Fermented Milk Drink Containing Lactobacillus Casei Strain Shirota on the Human Intestinal Microflora|Completed||Phase 2|24|Actual|Cheng Hsin Rehabilitation Medical Center||2|||f||||f||||||||||2018-06-01 01:24:49.455276|2018-06-01 01:24:49.455276
NCT00822315|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-07-16|2009-01-13|2009-01-14|Estimate|||||||2013-07-16|2013-07-17|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis|Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis|Completed||Phase 2|155|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3|||f||||t||||||||||2018-06-01 01:24:49.753959|2018-06-01 01:24:49.753959
NCT00822302|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2015-06-05|2009-01-13|2009-01-14|Estimate|||||||2015-06-05|2015-06-09|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|REVEAL||Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia|Does recHDL Given i.v. Before CEA Prevent Cerebral Ischaemia? - the Reveal Study.|Completed||N/A|40|Actual|St George's, University of London||2|||f||||t||||||||||2018-06-01 01:24:49.844727|2018-06-01 01:24:49.844727
NCT00822289|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|February 2009||2009-02-28|January 2009|2009-01-31||||||||Observational|||The Effect of Radioactive Iodine Administration for Thyroid Diseases on H.Pylori Eradication|Effect of Radioactive Iodine on Eradication of Helicobacter Pylori in Patients Treated for Thyroid Diseases|Unknown status|Enrolling by invitation||120|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 01:24:49.910587|2018-06-01 01:24:49.910587
NCT00822276|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2014-04-03|2009-01-12|2009-01-14|Estimate|||||||2014-04-03|2014-04-04|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|MRSA||The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)|Pilot Study To Determine The Underlying Mechanisms For Infection And Colonization By Staphylococcus Aureus Of The Skin Of Atopic Dermatitis Subjects With And Without A History Of Eczema Herpeticum (ADVN MRSA 10)|Completed|||65|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||7||f||||t||||||Samples With DNA|"~     Nasal swabs, skin swabs, tape strippings, and blood draws.~   "|||2018-06-01 01:24:49.964231|2018-06-01 01:24:49.964231
NCT00822263|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2010-08-09|2009-01-13|2009-01-14|Estimate|||||||2010-08-09|2010-08-10|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||The Use of Anti-oxidants to Reduce Sequela of Mild Traumatic Brain Injury (mTBI) After Blast Exposure|The Use of Anti-oxidants to Reduce Sequela of Mild TBI (mTBI) After Blast Exposure|Completed||N/A|150|Anticipated|Brooke Army Medical Center||2|||f||||t||||||||||2018-06-01 01:24:50.038011|2018-06-01 01:24:50.038011
NCT00822250|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2010-10-20|2009-01-13|2009-01-14|Estimate|||||||2010-10-20|2010-10-21|Estimate|April 2008||2008-04-30|October 2010|2010-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis|Clinical and Biological Study of Sub-pigmentation During Infantile Cystinosis|Completed||N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:24:50.108968|2018-06-01 01:24:50.108968
NCT00822237|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2010-10-28||2017-03-14|2009-01-12|2009-01-14|Estimate|2011-04-19|2011-04-21|Estimate||||2017-03-14|2017-04-12|Actual|January 2009||2009-01-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)|Safety, Tolerability, and Immunogenicity of VARIVAX (2007 Commercial VZV Bulk Process) Administered Concomitantly With M-M-R II in Healthy Children 12-to-23 Months of Age|Completed||Phase 3|598|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:24:50.18025|2018-06-01 01:24:50.18025
NCT00822224|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2011-12-08|2009-01-13|2009-01-14|Estimate|||||||2011-12-08|2011-12-09|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Use of MEOPA (Equimolar Mixture of Nitrogen Protoxide and Oxygen) for Elderly With Dementia|Use of MEOPA for Elderly With Dementia.|Completed||N/A|50|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:24:50.369028|2018-06-01 01:24:50.369028
NCT00822211|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2016-11-16|2009-01-13|2009-01-14|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy|Completed||Phase 3|404|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:24:50.427876|2018-06-01 01:24:50.427876
NCT00822198|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||The Effect of Plantar Vibration on the Progression of Peripheral Neuropathy|The Effect of Plantar Vibration on the Progression of Peripheral Neuropathy|Completed||N/A|24|Actual|Binghamton University||1|||f||||f||||||||||2018-06-01 01:24:50.607862|2018-06-01 01:24:50.607862
NCT00822185|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2013-09-27||2014-12-12|2009-01-13|2009-01-14|Estimate|2014-09-22|2014-09-23|Estimate||||2014-12-12|2015-01-05|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers|A Single-centre, Randomised, Placebo-controlled, Double-blind, Single-dose, Dose-escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Doses of an Activated Recombinant FVII Analogue (NN1731) in Healthy Japanese Male Subjects|Completed||Phase 1|32|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 01:24:50.687062|2018-06-01 01:24:50.687062
NCT00822172|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2013-03-01||2013-04-11|2009-01-13|2009-01-14|Estimate|2013-04-11|2013-05-22|Estimate||||2013-04-11|2013-05-22|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|ECLECTIC||Evaluation of Cilostazol in Combination With L-Carnitine|Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication|Completed||Phase 4|164|Actual|Colorado Prevention Center||2|||f||||f||||||||||2018-06-01 01:24:51.296937|2018-06-01 01:24:51.296937
NCT00821990|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2012-01-18|2009-01-13|2009-01-14|Estimate|||||||2012-01-18|2012-01-20|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|||Second-line Therapy Versus Supportive Care for Pretreated Advanced Gastric Cancer|A Patient Preference Randomized Phase III Clinical Trial of Second-line Chemotherapy (SLC) in Advanced Gastric Cancer (AGC) Patients Pretreated With Both Fluoropyrimidines and Platinum|Completed||Phase 3|200|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 01:24:55.572176|2018-06-01 01:24:55.572176
NCT00822159|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2011-10-07|2009-01-13|2009-01-14|Estimate|||||||2011-10-07|2011-10-10|Estimate|November 2008||2008-11-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Densiprobe||Influence of Bone Strength Measured by DensiProbe on Bone Related Fixation Failure|Prospective Multicenter Cohort Study to Evaluate the Influence of Bone Strength Measured by DensiProbe Hip on Bone Related Fixation Failure in Patients With Hip Fractures Undergoing DHS Surgical Treatment.|Terminated||N/A|198|Anticipated|AO Clinical Investigation and Documentation||||Interim analysis showed statistically significant results|f||||f||||||||||2018-06-01 01:24:51.634086|2018-06-01 01:24:51.634086
NCT00822146|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2018-01-29|2009-01-13|2009-01-14|Estimate|||||||2018-01-29|2018-01-30|Actual|December 2008||2008-12-31|January 2018|2018-01-31|March 2013|Actual|2013-03-31|December 2011|Actual|2011-12-31||Interventional|||Cardiac Resynchronization Therapy (CRT) Efficacy Study||Completed||N/A|9|Actual|Medtronic Bakken Research Center||1|||f||||f||||||||||2018-06-01 01:24:51.71287|2018-06-01 01:24:51.71287
NCT00822133|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Percutaneous Ketamine Versus Lidocaine or Placebo, for Post-Surgery Analgesia, in Patients Undergoing Laparoscopic Partial Lung Resection||Unknown status|Not yet recruiting|Phase 4|75|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-06-01 01:24:51.7768|2018-06-01 01:24:51.7768
NCT00822120|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2017-10-03||2018-03-06|2009-01-13|2009-01-14|Estimate|2018-03-06|2018-04-04|Estimate||||2018-03-06|2018-04-04|Estimate|July 2009||2009-07-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2016|Actual|2016-04-30||Interventional||Only eligible and evaluable HIV-positive patients were included in the analysis.|S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma|A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging|Active, not recruiting||Phase 2|371|Actual|Southwest Oncology Group||4|||f||||f||||||||||2018-06-01 01:24:51.993349|2018-06-01 01:24:51.993349
NCT00822107|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2016-03-28|2009-01-13|2009-01-14|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||A Translational Approach to Gitelman Syndrome|A Translational Approach to Gitelman Syndrome|Completed||N/A|8|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:24:54.110534|2018-06-01 01:24:54.110534
NCT00822094|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2017-09-03|2013-02-20|2017-10-20|2009-01-13|2009-01-14|Estimate|2017-09-03|2017-09-29|Actual|2013-02-20|2013-02-22|Estimate|2017-10-20|2017-11-24|Actual|February 2009||2009-02-28|October 2017|2017-10-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional||"Safety Analysis Set~One subject in the Salvage Therapy arm was randomized and withdrew consent prior to treatment, and therefore was excluded from the analysis"|Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)|Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration|Completed||Phase 2|126|Actual|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:24:54.312722|2018-06-01 01:24:54.312722
NCT00822081|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 4|140|Actual|Bp Consulting, Inc||4|||f||||f||||||||||2018-06-01 01:24:54.972135|2018-06-01 01:24:54.972135
NCT00822068|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation|Improvement of Aphasia After Stroke by Intensive Training and Transcranial Direct Current Stimulation|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|University Hospital Muenster||3|||f||||f||||||||||2018-06-01 01:24:55.092794|2018-06-01 01:24:55.092794
NCT00822055|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|May 2005||2005-05-31|January 2009|2009-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 4|140|Actual|Allergan||4|||f||||f||||||||||2018-06-01 01:24:55.171786|2018-06-01 01:24:55.171786
NCT00822042|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2014-02-26|2009-01-13|2009-01-14|Estimate|||||||2014-02-26|2014-02-27|Estimate|August 2006||2006-08-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Observational|ADIPOKINES||Corticosteroid-induced Lipodystrophy and Adipokines|Study of Histological and Adipokines Expression Variations in Lipodystrophic Adipose Tissue During Corticosteroids-induced Lipodystrophy|Completed|||32|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Cytopunction (adipocytes), whole blood~   "|||2018-06-01 01:24:55.252606|2018-06-01 01:24:55.252606
NCT00822029|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-03-23|2009-01-13|2009-01-14|Estimate|||||||2012-03-23|2012-03-26|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy|Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy|Terminated||Phase 3|2|Actual|Centre Hospitalier Universitaire de Nice||2||only 2 patients inclued and Study Principal Investigator has left the hospital|f||||f||||||||||2018-06-01 01:24:55.33283|2018-06-01 01:24:55.33283
NCT00822016|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-06-27|2009-01-13|2009-01-14|Estimate|||||||2012-06-27|2012-06-29|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|||Observational Study of Best Supportive Care With or Without Surgery, Chemo or Radiotherapy in Pts With Carcinoma of Lung|INST 0701C: An Observational Outcomes Protocol of Standard Practice of Best Supportive Care With or Without Surgery, Chemotherapy or Radiotherapy in Patients With Carcinoma of the Lung|Terminated|||25|Actual|New Mexico Cancer Care Alliance||||PI left institution. Insufficient enrollment for analysis.|f||||t||||||||||2018-06-01 01:24:55.411605|2018-06-01 01:24:55.411605
NCT00822003|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2009-01-13|2009-01-13|2009-01-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects|Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile Following an Oral Glucose Tolerance Test in Healthy Male Subjects|Completed||Phase 1/Phase 2|16|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 01:24:55.470362|2018-06-01 01:24:55.470362
NCT00821964|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2017-04-14||2017-12-07|2009-01-13|2009-01-14|Estimate|2017-05-25|2017-06-28|Actual||||2017-12-07|2018-01-02|Actual|December 2008||2008-12-31|December 2017|2017-12-31|November 29, 2012|Actual|2012-11-29|November 2012|Actual|2012-11-30||Interventional|||Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer|Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases|Completed||Phase 2|15|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 01:24:56.112259|2018-06-01 01:24:56.112259
NCT00821951|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2012-12-07||2012-12-07|2009-01-12|2009-01-14|Estimate|2012-12-07|2013-01-17|Estimate||||2012-12-07|2013-01-17|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer|A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer|Completed||Phase 1|17|Actual|Yale University||1|||f||||f||||||||||2018-06-01 01:24:56.56277|2018-06-01 01:24:56.56277
NCT00821938|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2016-11-23|2009-01-13|2009-01-14|Estimate|||||||2016-11-23|2016-11-25|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2012|Actual|2012-07-31||Interventional|CRT-Narrow||Cardiac Resynchronization Therapy (CRT)-Narrow-dp/Dt-Study|CRT in Patients With Narrow QRS, Echodesynchronisation and LV dp/Dt-Response With Pressure Wire|Completed||Phase 4|30|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||||2018-06-01 01:24:56.715641|2018-06-01 01:24:56.715641
NCT00821925|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2011-12-07|2009-01-13|2009-01-14|Estimate|||||||2011-12-07|2011-12-08|Estimate|December 2006||2006-12-31|January 2009|2009-01-31||||||||Interventional|||Estimation of Osteoporosis' Prevalence in France: Pilot Study in the Department of the Alpes-Maritimes|Estimation of Osteoporosis' Prevalence in France: Pilot Study in the Department of the Alpes-Maritimes|Completed||N/A|800|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-06-01 01:24:56.777508|2018-06-01 01:24:56.777508
NCT00821912|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-02-27|2009-01-13|2009-01-14|Estimate|||||||2012-02-27|2012-02-28|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|TaxXel||TaxXel: Taxotere and Xeloda in Esophageal Cancer|A Phase I/II Study on the Treatment With Taxotere in Combination With Xeloda in Patients With Metastatic Oesophageal Cancer or Cancer in the Cardia Region|Unknown status|Active, not recruiting|Phase 1/Phase 2|93|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-06-01 01:24:56.825498|2018-06-01 01:24:56.825498
NCT00821899|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-03-19|2009-01-13|2009-01-14|Estimate|||||||2012-03-19|2012-03-20|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Bone Marrow Autotransplantation in Type 1 Diabetes|Regeneration of Insulin Production in Patients With Type 1 Diabetes by Autologous Bone Marrow Blood Infusion|Completed||N/A|3|Actual|Hospital Clinic of Barcelona|||||f||||f||||||||||2018-06-01 01:24:56.910055|2018-06-01 01:24:56.910055
NCT00821886|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2014-12-12||2014-12-12|2009-01-12|2009-01-14|Estimate|2014-12-12|2014-12-22|Estimate||||2014-12-12|2014-12-22|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|October 2014|Actual|2014-10-31|July 2011|Actual|2011-07-31||Interventional|||Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer|Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer|Completed||Phase 2|60|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 01:24:57.033923|2018-06-01 01:24:57.033923
NCT00821873|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2013-08-01||2013-11-06|2009-01-13|2009-01-14|Estimate|2013-10-14|2013-11-06|Estimate||||2013-11-06|2013-11-28|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CRB||Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.|Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR Plug) for Repair of Defects Created at the Harvest Site During the Osteochondral Autograft Transfer System(OATS)Procedure|Completed||Phase 3|9|Actual|RTI Surgical|"Enrollment was closed early due for 2 factors:~1) Slow enrollment and 2) A potential change in the regulatory pathway for allografts used in cartilage repair.~Of the 9 patients enrolled, 4 were lost to follow-up."|1|||f||||f||||||||||2018-06-01 01:24:57.335512|2018-06-01 01:24:57.335512
NCT00821860|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2013-06-27|2009-01-13|2009-01-14|Estimate|||||||2013-06-27|2013-06-28|Estimate|September 2003||2003-09-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|MesoVATS||Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma|Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma|Completed||Phase 3|196|Actual|Papworth Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 01:24:57.525921|2018-06-01 01:24:57.525921
NCT00821847|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2012-07-30|2009-01-13|2009-01-14|Estimate|||||||2012-07-30|2012-07-31|Estimate|June 2009||2009-06-30|June 2008|2008-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|HIVERS||Renal Function Assessment in HIV Patient|Markers of Glomerular Filtration Rate in the HIV Infected Patient - Role of Body Composition|Completed|||45|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||||||2018-06-01 01:24:57.625363|2018-06-01 01:24:57.625363
NCT00821834|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2011-07-25|2009-01-13|2009-01-14|Estimate|||||||2011-07-25|2011-07-26|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|CLEAN||Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned|A Randomized, Double Blind, Parallel Group Study to Investigate the Safety of 12 Weeks of Clopidogrel 75 mg Once Daily With a 300 mg Loading Dose Versus Ticlopidine 100 mg Twice Daily in Patients With Stable Angina or Old (Healed) Myocardial Infarction to Which Percutaneous Coronary Intervention is Being Planned - With Extended Treatment of Clopidogrel 75 mg Once Daily for 40 Weeks in a Patients' Subset|Completed||Phase 3|1003|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:24:57.704412|2018-06-01 01:24:57.704412
NCT00821821|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|2014-01-05||2014-04-07|2009-01-13|2009-01-14|Estimate|2014-04-07|2014-05-12|Estimate||||2014-04-07|2014-05-12|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke|A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke|Completed||Phase 2|36|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||t||||||||||2018-06-01 01:24:57.784361|2018-06-01 01:24:57.784361
NCT00821808|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-13|||2015-10-12|2009-01-13|2009-01-14|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Pressure Relted Study Comparing a Compression Device and Profore® on Healthy Volunteers|A Phase I, Randomized, Open-label, One-arm, Active Controlled Study to Evaluate the Pressure Interface Between Device and Skin of a Compression Device and Profore® on Healthy Volunteers|Completed||Phase 1|12|Actual|ConvaTec Inc.|||||f||||f||||||||||2018-06-01 01:24:58.132002|2018-06-01 01:24:58.132002
NCT00821795|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2013-10-23|2009-01-12|2009-01-13|Estimate|||||||2013-10-23|2013-10-24|Estimate|February 2009||2009-02-28|October 2013|2013-10-31||||June 2013|Actual|2013-06-30||Interventional|VIISTA||Veterans Inpatient Insulin Study and Transition to Outpatient Therapy|Veterans Inpatient Insulin Study and Transition Algorithm: Efficacy of Insulin Analogs for Inpatient Glycemic Control and Transition to Outpatient Therapy|Completed||Phase 4|120|Actual|Lexington VA Medical Center||2|||f||||f||||||||||2018-06-01 01:24:58.281962|2018-06-01 01:24:58.281962
NCT00821782|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2011-05-18|2009-01-09|2009-01-13|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2006||2006-06-30|April 2010|2010-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Evaluation of Bacteria in the Mouth and Throat of Healthy Adults Before and After the Administration of Either Levofloxacin or Azithromycin, Both Antibiotic Medications|A Randomized, Open-Label Study Comparing Levofloxacin Once-Daily 750 mg PO for 5 Days and Azithromycin Once-Daily 500 mg on Day One and Then 250 mg Days 2 Through 5 In a Microbiologic Evaluation for Emergence of Resistance in the Oropharyngeal Flora of Healthy Subjects|Completed||Phase 1|143|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|||||f||||||||||||||2018-06-01 01:24:58.355523|2018-06-01 01:24:58.355523
NCT00821769|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2010-07-16|2009-01-12|2009-01-13|Estimate|||||||2010-07-16|2010-07-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:24:58.407116|2018-06-01 01:24:58.407116
NCT00821756|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-12|2009-01-12|2009-01-13|Estimate|||||||2009-01-12|2009-01-13|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|August 2010|Anticipated|2010-08-31|August 2008|Actual|2008-08-31||Interventional|Amager||The Amager Project: Intervention After Suicide Attempt|The Amager Project. Intervention After Suicide Attempt: A Randomized Study.|Unknown status|Active, not recruiting|N/A|133|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:24:58.44258|2018-06-01 01:24:58.44258
NCT00821743|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2013-04-23|2009-01-12|2009-01-13|Estimate|||||||2013-04-23|2013-04-24|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Pedunculo-Pontin Nucleus (PPN) - Deep Brain Stimulation (DBS) in Gait and Balance Disturbance in Parkinson's Disease (PPN-GAB-PARK Study)|Study of Deep Brain Stimulation of the Pedunculo-pontin Nucleus (PPN) for the Treatment of Gait and Balance Disturbances in Patients With Parkinson's Disease (PPN-GAB-PARK Study)|Unknown status|Recruiting|Phase 1/Phase 2|5|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:24:58.510127|2018-06-01 01:24:58.510127
NCT00821730|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2011-01-06|2009-01-12|2009-01-13|Estimate|||||||2011-01-06|2011-01-07|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Perspectives of Family Members and Friends|Exploring the Learning Needs of Individuals With Inflammatory Arthritis From the Perspectives of Patients, Family Members and Friends, and Health Care Providers: Perspectives of Family Members and Friends|Completed|||15|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||None Retained|"~     This is a qualitative research study~   "|||2018-06-01 01:24:58.581775|2018-06-01 01:24:58.581775
NCT00821717|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2015-06-01|2009-01-12|2009-01-13|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|January 2011|Actual|2011-01-31|October 2009|Actual|2009-10-31||Interventional|EFFICACY-HF||EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure|A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency|Terminated||Phase 3|35|Actual|Vifor Inc.||2||"Positive FAIR-HF study data are available, this study is identical as EFFICACY-HF. Due to low~   recruitment in EFFICACY-HF the decision was made to terminate it."|f||||t||||||||||2018-06-01 01:24:58.667602|2018-06-01 01:24:58.667602
NCT00821691|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2014-04-18|2009-01-12|2009-01-13|Estimate|||||||2014-04-18|2014-04-21|Estimate|March 2009||2009-03-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CELIC-1||Action of Amantadine on Post-Stroke Aphasic Patients|Action of the Amantadine on Post Stroke Aphasic Patients' Language and Communication|Completed||Phase 2/Phase 3|50|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:24:58.864091|2018-06-01 01:24:58.864091
NCT00821678|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2015-02-19||2015-04-06|2009-01-09|2009-01-13|Estimate|2015-04-06|2015-04-23|Estimate||||2015-04-06|2015-04-23|Estimate|November 2009||2009-11-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|TOP||Telemedicine Outreach for Post Traumatic Stress in CBOCs|Telemedicine Outreach for Post Traumatic Stress in CBOCs|Completed||Phase 4|265|Actual|VA Office of Research and Development|High enrollment refusal rates may limit external validity.|2|||f||||t||||||||||2018-06-01 01:24:58.981821|2018-06-01 01:24:58.981821
NCT00821665|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-12|2009-01-12|2009-01-13|Estimate|||||||2009-01-12|2009-01-13|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose|Blood Glucose Homeostasis in Type 2 Diabetes: the Effects of Saccharose|Completed||N/A|39|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:24:59.349416|2018-06-01 01:24:59.349416
NCT00821652|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2015-01-06|2009-01-12|2009-01-13|Estimate|||||||2015-01-06|2015-01-08|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|January 2010|Actual|2010-01-31||Interventional|||Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination|Phase I Randomized, Double-blind, Placebo-controlled Study of Topical Resiquimod as an Adjuvant for NY-ESO1 Protein+Montanide Vaccination in Patients With Tumors That Often Express NY-ESO-1|Completed||Phase 1|26|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 01:24:59.442369|2018-06-01 01:24:59.442369
NCT00821639|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-11|||2009-10-04|2009-01-11|2009-01-13|Estimate|||||||2009-10-04|2009-10-06|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Reduction of Secondhand Smoke Exposure in Healthy Infants|Reduction of Secondhand Smoke Exposure in Healthy Infants|Completed||N/A|130|Actual|Tehran University of Medical Sciences|||||f||||t||||||||||2018-06-01 01:24:59.534572|2018-06-01 01:24:59.534572
NCT00821626|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2015-05-26|2009-01-12|2009-01-13|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Rapid Flu Tests in Travelers With Fever|Utility of Rapid Flu Tests in the Medical Management of Returning Travelers With Fever|Completed||Phase 4|200|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-06-01 01:24:59.598947|2018-06-01 01:24:59.598947
NCT00821262|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2015-10-13|2009-01-12|2009-01-13|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SEVO AIFA||Sevoflurane in Cardiac Surgery|Sevoflurane and Cardiac Protection in High Risk Patients Undergoing Cardiac Surgery. A Randomized Controlled Study.|Completed||Phase 4|200|Actual|Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-06-01 01:25:03.870855|2018-06-01 01:25:03.870855
NCT00821613|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2012-02-07|2009-01-12|2009-01-13|Estimate|||||||2012-02-07|2012-02-08|Estimate|September 2009||2009-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Data Collection Study of Raw Thermal Images for the Purpose of Developing a Device for Early Detection of Breast Cancer|Collection of Raw Data of Thermal Imaging for the Purpose of Developing a Device for Early Detection of Breast Cancer|Completed|||1827|Actual|Real Imaging Ltd.|||||f||||f||||||||||2018-06-01 01:24:59.677361|2018-06-01 01:24:59.677361
NCT00821600|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2014-05-20|2009-01-09|2009-01-13|Estimate|||||||2014-05-20|2014-05-21|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia|Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 01:24:59.735409|2018-06-01 01:24:59.735409
NCT00821587|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2011-08-04||2011-11-02|2009-01-09|2009-01-13|Estimate|2011-11-02|2011-12-08|Estimate||||2011-11-02|2011-12-08|Estimate|June 2004||2004-06-30|November 2011|2011-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation|Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation|Completed||Phase 4|39|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 01:24:59.841979|2018-06-01 01:24:59.841979
NCT00821574|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2017-02-28|2009-01-12|2009-01-13|Estimate|||||||2017-02-28|2017-03-01|Actual|July 2005||2005-07-31|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|LesScore||Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome|Project to Promote the Evaluation of the Cardiovascular Risk in the Clinical Practice and to Evaluate Its Evolution Following the Implementation of a Preventive Multifactorial Strategy Aimed to Reduce the Total Risk Level (SCORE Algorithm), in Subjects Suffering From Metabolic Syndrome and With a Risk Level ≥5%|Completed||Phase 4|144|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:25:00.119358|2018-06-01 01:25:00.119358
NCT00821561|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-10|||2010-02-24|2009-01-12|2009-01-13|Estimate|||||||2010-02-24|2010-02-26|Estimate|March 2009||2009-03-31|February 2010|2010-02-28|March 2010|Anticipated|2010-03-31|November 2009|Anticipated|2009-11-30||Interventional|||A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects|A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon® in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.|Withdrawn||Phase 2|90|Anticipated|CoDa Therapeutics Inc.||||Withdrawn prior to recruitment for business reasons.|f||||f||||||||||2018-06-01 01:25:00.184411|2018-06-01 01:25:00.184411
NCT00821548|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-12|2009-01-12|2009-01-13|Estimate|||||||2009-01-12|2009-01-13|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patients||Completed||N/A|9|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 01:25:00.224875|2018-06-01 01:25:00.224875
NCT00821535|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2010-11-15|2009-01-12|2009-01-13|Estimate|||||||2010-11-15|2010-11-16|Estimate|February 2009||2009-02-28|November 2010|2010-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers|An Open Label Single Dose Study To Investigate Safety And Pharmacokinetics Of Maraviroc Following A Single Oral Dose Of 300 Mg Maraviroc (Two 150 Mg Maraviroc Commercial Tablets) Under Fasting Conditions In Healthy Male Japanese Volunteers|Completed||Phase 1|12|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-06-01 01:25:00.28344|2018-06-01 01:25:00.28344
NCT00821522|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2010-07-21|2009-01-09|2009-01-13|Estimate|||||||2010-07-21|2010-07-22|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|May 2010|Anticipated|2010-05-31|March 2010|Anticipated|2010-03-31||Interventional|||The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery|The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery|Unknown status|Enrolling by invitation|Phase 1|120|Anticipated|Maine Medical Center Research Institute||2|||f||||f||||||||||2018-06-01 01:25:00.344752|2018-06-01 01:25:00.344752
NCT00821509|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2011-10-05||2012-02-06|2009-01-12|2009-01-13|Estimate|2012-02-06|2012-03-08|Estimate||||2012-02-06|2012-03-08|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31||Interventional|||STOPFLU: Is it Possible to Reduce the Number of Days Off in Office Work by Improved Hand-hygiene?|STOPFLU: Is it Possible to Reduce the Number of Days Off in Office Work by Improved Hand-hygiene?|Completed||N/A|683|Actual|National Institute for Health and Welfare, Finland|"In a pre-study interview, 90% stated when I have cold I usually come to work if I only can. Participants in the intervention arms, but not those of the control arm, were advised to stay home when sick: possible contribution to outcome measure 1."|3|||f||||f||||||||||2018-06-01 01:25:00.40913|2018-06-01 01:25:00.40913
NCT00821496|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-11-30|2009-01-09|2009-01-13|Estimate|||||||2009-11-30|2009-12-02|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Evaluate the Effect of VI-0521 on the Pharmacokinetics of Oral Contraceptive in Healthy Female Subjects|A Phase I, Open Label, Fixed Sequence, Single-Center Study to Evaluate the Effect of Multiple Dose Administration of VI-0521 on the Pharmacokinetics of a Single Dose of Oral Contraceptive in Healthy Female Subjects|Completed||Phase 1|20|Actual|VIVUS, Inc.||1|||f||||f||||||||||2018-06-01 01:25:00.790652|2018-06-01 01:25:00.790652
NCT00821483|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2013-04-16|2009-01-12|2009-01-13|Estimate|||||||2013-04-16|2013-04-18|Estimate|November 2006||2006-11-30|April 2013|2013-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine|Phase 3 Study to Assess the Efficacy and Safety of Frovatriptan|Completed||Phase 3|298|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||||2018-06-01 01:25:00.861978|2018-06-01 01:25:00.861978
NCT00821470|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-13|2009-01-12|2009-01-13|Estimate|||||||2009-01-13|2009-01-14|Estimate|January 1999||1999-01-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Osteonecrosis of the Femoral Head by Bone Marrow Transplantation|Treatment of Osteonecrosis of the Femoral Head With Implantation of Autologous Bone Marrow Cells, a Pilot Study|Completed||Phase 1|21|Actual|Erasme University Hospital||2|||f||||t||||||||||2018-06-01 01:25:00.918728|2018-06-01 01:25:00.918728
NCT00821457|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2010-03-08|2009-01-12|2009-01-13|Estimate|||||||2010-03-08|2010-03-09|Estimate|January 2009||2009-01-31|March 2010|2010-03-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Juvista in the Non-surgical Improvement of Existing Scars|A Within Patient, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy of Juvista in Improving the Appearance of Existing Scars That Are 2-6 Months Old|Withdrawn||N/A|40|Anticipated|Renovo||2|||f||||f||||||||||2018-06-01 01:25:00.986309|2018-06-01 01:25:00.986309
NCT00821444|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2011-04-11|2009-01-12|2009-01-13|Estimate|||||||2011-04-11|2011-04-13|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules|Phase 1 Study Of Ziprasidone Pharmacokinetics Of Reduced Food Effect Formulation B16 Under Fed And Fasting Conditions Compared To Commercial Geodon Capsules Under Fed Conditions In Healthy Subjects|Completed||Phase 1|11|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:25:01.053816|2018-06-01 01:25:01.053816
NCT00821431|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2014-09-03||2015-01-08|2009-01-12|2009-01-13|Estimate|2015-01-08|2015-01-09|Estimate||||2015-01-08|2015-01-09|Estimate|May 2006||2006-05-31|January 2015|2015-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Compression Device Versus 4-layer Compression System|A Phase II Study to Compare the Effect of a Compression Device to That of a 4-layer Compression System on Subjects With Venous Leg Ulcers.|Completed||Phase 2|90|Actual|ConvaTec Inc.||2|||f||||f||||||||||2018-06-01 01:25:01.142012|2018-06-01 01:25:01.142012
NCT00821418|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2010-05-08|2009-01-12|2009-01-13|Estimate|||||||2010-05-08|2010-05-11|Estimate|August 2009||2009-08-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Assessment of Treatment With PulseHaler on Patients With Chronic Obstructive Pulmonary Disease (COPD)|Assessment of the Safety and the Effect on Patients With COPD of Treatment With PulseHaler™ - a Novel Device for Pulsating Positive Expiratory Pressure Ventilation|Completed||N/A|30|Anticipated|Respinova LTD||2|||f||||||||||||||2018-06-01 01:25:01.444751|2018-06-01 01:25:01.444751
NCT00821405|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-12|2009-01-12|2009-01-13|Estimate|||||||2009-01-12|2009-01-13|Estimate|March 2009||2009-03-31|January 2009|2009-01-31|March 2010|Anticipated|2010-03-31|September 2009|Anticipated|2009-09-30||Observational|||Study of Peritoneal/Bowel Morphology and Splanchnic Hemodynamics by Sonography, Doppler Ultrasound and Computed Tomography in CAPD Patients||Unknown status|Not yet recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 01:25:01.541575|2018-06-01 01:25:01.541575
NCT00821392|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-12|2009-01-12|2009-01-13|Estimate|||||||2009-01-12|2009-01-13|Estimate|August 2006||2006-08-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Phase III Trial of Febuxostat in Korea Gout Patients|A Randomized, Multi-Center, Double Blinded, Allopurinol-Controlled, Placebo-Controlled Parallel Group, 5-Arm, Dose-Response,Bridging Study to Assess the Efficacy and Safety of Febuxostat in Subject With Gout|Completed||Phase 3|181|Actual|SK Chemicals Co.,Ltd.||5|||f||||||||||||||2018-06-01 01:25:01.606718|2018-06-01 01:25:01.606718
NCT00821379|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2012-12-19|2009-01-12|2009-01-13|Estimate|||||||2012-12-19|2012-12-20|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|September 2012|Actual|2012-09-30|January 2011|Actual|2011-01-31||Observational|CoPPer||CoPPer Study - Complications of Polycystic Ovary Syndrome (PCOS) Pregnancy: Evaluating Risk|Complications of PCOS Pregnancy: Evaluating Risk|Completed|||300|Actual|UMC Utrecht|||||f||||f||||||Samples With DNA|"~     Whole blood, serum and lithium heparine, urine and placenta tissue~   "|||2018-06-01 01:25:01.666903|2018-06-01 01:25:01.666903
NCT00821366|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-02-25|2009-01-12|2009-01-13|Estimate|||||||2009-02-25|2009-02-26|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|FEATS||Effective Aids Treatment and Support in the Free State (FEATS)|Effective Aids Treatment and Support in the Free State (FEATS): Adherence and Nutritional Support for Effective and Sustainable Antiretroviral Treatment in Resource Constrained Settings|Unknown status|Active, not recruiting|Phase 3|648|Actual|Centre for Health Systems Research & Development, University of the Free State||4|||f||||f||||||||||2018-06-01 01:25:01.727126|2018-06-01 01:25:01.727126
NCT00821353|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-11|||2013-02-04|2009-01-12|2009-01-13|Estimate|||||||2013-02-04|2013-02-05|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy|Sinus Rhythm Maintenance in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation - Randomized Comparison of Antiarrhythmic Therapy vs. Radiofrequency Catheter Ablation (SHAARC)|Completed||Phase 3|90|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-06-01 01:25:01.830357|2018-06-01 01:25:01.830357
NCT00821340|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2018-04-08|2009-01-12|2009-01-13|Estimate|||||||2018-04-08|2018-04-10|Actual|February 1, 2009|Actual|2009-02-01|February 2010|2010-02-28|January 1, 2017|Actual|2017-01-01|June 29, 2016|Actual|2016-06-29||Interventional|||Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations|Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations|Completed||Phase 1|3|Actual|Hadassah Medical Organization||1|||f||||f|f|f||||||No||2018-06-01 01:25:02.952899|2018-06-01 01:25:02.952899
NCT00821327|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2016-01-12||2016-09-15|2009-01-09|2009-01-13|Estimate|2016-02-02|2016-03-02|Estimate||||2016-09-15|2016-10-25|Estimate|August 2008||2008-08-31|September 2016|2016-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Gemzar, Cisp, Sunitinib Urothelial Ca|Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients With Advanced/Metastatic Urothelial Carcinoma|Completed||Phase 2|36|Actual|US Oncology Research||1|||f||||f||||||||||2018-06-01 01:25:03.067054|2018-06-01 01:25:03.067054
NCT00821314|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2010-06-15|2009-01-12|2009-01-13|Estimate|||||||2010-06-15|2010-06-16|Estimate|April 2009||2009-04-30|June 2010|2010-06-30||||December 2010|Anticipated|2010-12-31||Observational|||The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome|The Effect of Position (Sit/Stand up vs Supine Position) on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome|Unknown status|Recruiting||100|Anticipated|Maastricht University Medical Center|||||f||||t||||||||||2018-06-01 01:25:03.363794|2018-06-01 01:25:03.363794
NCT00821301|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-01-12|2009-01-12|2009-01-13|Estimate|||||||2009-01-12|2009-01-13|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|October 2010|Anticipated|2010-10-31|August 2010|Anticipated|2010-08-31||Interventional|||Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma|Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1|30|Anticipated|Immune Control|||||f||||t||||||||||2018-06-01 01:25:03.538413|2018-06-01 01:25:03.538413
NCT00821288|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2017-06-15|2009-01-12|2009-01-13|Estimate|||||||2017-06-15|2017-06-19|Actual|July 2007|Actual|2007-07-31|June 2017|2017-06-30|May 2013|Actual|2013-05-31|October 2011|Actual|2011-10-31||Interventional|||Post-treatment Care of Breast Cancer Survivors|Post-treatment Care of Breast Cancer Survivors|Completed||N/A|140|Actual|Columbia University||2|||f||||t|f|f||||||Undecided||2018-06-01 01:25:03.648671|2018-06-01 01:25:03.648671
NCT00821275|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-01-09|2009-01-09|2009-01-13|Estimate|||||||2009-01-09|2009-01-13|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma|Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma|Enrolling by invitation||Phase 2/Phase 3|900|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:25:03.744024|2018-06-01 01:25:03.744024
NCT00821236|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2011-03-24||2013-01-25|2009-01-12|2009-01-13|Estimate|2013-01-25|2013-03-01|Estimate||||2013-01-25|2013-03-01|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|WLCVLV-001||Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK|A Prospective, Multi Center Clinical Comparison of Fellow Eyes Undergoing Lasik Using the Wavelight Allegretto Wave™ Excimer Laser in One Eye and the Amo/Visx Customvue™ or the Ladarvision 4000 Excimer Laser System in the Contralateral Eye|Completed||Phase 4|40|Actual|Durrie Vision||3|||f||||f||||||||||2018-06-01 01:25:04.150021|2018-06-01 01:25:04.150021
NCT00821223|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2010-05-18|2009-01-12|2009-01-13|Estimate|||||||2010-05-18|2010-05-19|Estimate|February 2009||2009-02-28|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Outcome Following Phacoemulsification Versus Small Incision Cataract Surgery (SICS)|Comparison of Phacoemulsification Versus Manual Small Incision Cataract Surgery (SICS) : A Randomized Control Trial|Completed||N/A|420|Actual|Iladevi Cataract and IOL Research Center||2|||f||||t||||||||||2018-06-01 01:25:04.441439|2018-06-01 01:25:04.441439
NCT00821210|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2010-11-30|2009-01-12|2009-01-13|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|January 2010|Actual|2010-01-31||Interventional|||Obstructive Sleep Apnea and Acute Myocardial Infarction and the Role of Continuous Positive Airway Pressure (CPAP)Treatment|Obstructive Sleep Apnea and Acute Myocardial Infarction and the Role of CPAP Treatment: a Double -Blind, Randomized Control Trial|Completed||N/A|120|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:25:04.53556|2018-06-01 01:25:04.53556
NCT00821197|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2018-02-01|2009-01-12|2009-01-13|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2011||2011-02-28|February 2018|2018-02-28|May 2025|Anticipated|2025-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Long-limb or Distal Gastric Bypass for Superobesity - Randomized Study|Long -Limb Gastric or Distal Gastric Bypass in the Treatment of Super Obese Patients - a Prospective Randomized Study|Active, not recruiting||N/A|115|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:25:04.616554|2018-06-01 01:25:04.616554
NCT00821184|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2009-12-04||2018-03-08|2009-01-12|2009-01-13|Estimate|2010-07-29|2010-07-30|Estimate||||2018-03-08|2018-04-04|Actual|September 2006||2006-09-30|March 2018|2018-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder|A Prospective Randomized Trial of Behavioral Modification and Solifenacin (Vesicare)vs Solifenacin (Vesicare) Alone for the Treatment of Urge Incontinence in Patients With an Overactive Bladder|Terminated||Phase 3|12|Actual|Lahey Clinic||2||Insufficient subject availability/findings for data analysis|f||||f||||||||||2018-06-01 01:25:04.715688|2018-06-01 01:25:04.715688
NCT00821158|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|||2009-01-12|2009-01-12|2009-01-13|Estimate|||||||2009-01-12|2009-01-13|Estimate|February 2009||2009-02-28|January 2009|2009-01-31||||February 2011|Anticipated|2011-02-28||Interventional|||The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study|The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Maastricht University Medical Center||3|||f||||t||||||||||2018-06-01 01:25:04.926934|2018-06-01 01:25:04.926934
NCT00821145|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2012-07-11|2009-01-12|2009-01-13|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|LapAorta||Laparoscopic Versus Open Abdominal Aortic Aneurysm (AAA) Exclusion|Laparoscopic Aortic Resection Versus Open Surgery in Patients With AAA|Withdrawn||Phase 3|0|Actual|Augusta Hospital Duesseldorf||3||inability to recruit sufficient number of patients|f||||f||||||||||2018-06-01 01:25:05.10953|2018-06-01 01:25:05.10953
NCT00821132|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2018-03-27|2009-01-12|2009-01-13|Estimate|||||||2018-03-27|2018-03-29|Actual|January 1991||1991-01-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Observational|ALS||Genetics of Familial and Sporadic ALS|Identification of Genes Causing Familial ALS or Increasing Risk for Sporadic ALS and ALS With Frontotemporal Dementia and Understanding Disease Mechanism.|Recruiting|||15000|Anticipated|Northwestern University|||1||f||||t||||||Samples With DNA|"~     Whole blood and/or skin and CSF samples~      The investigators also collect brain and spinal cord tissue specimans.~   "|No||2018-06-01 01:25:05.204232|2018-06-01 01:25:05.204232
NCT00821119|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-12|2012-09-24||2013-03-03|2009-01-12|2009-01-13|Estimate|2011-06-24|2011-07-22|Estimate||||2013-03-03|2013-03-12|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Trial of Non Invasive Ventilation for Respiratoy Distress Syndrome|A Randomized Controlled Trial of Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Pressure as a Primary Mode for Respiratory Distress Syndrome in Preterm Infants|Completed||N/A|200|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||f||||||||||2018-06-01 01:25:05.34199|2018-06-01 01:25:05.34199
NCT00821106|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2010-03-18|2009-01-12|2009-01-13|Estimate|||||||2010-03-18|2010-03-19|Estimate|January 2009||2009-01-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|TALENT||Left Versus Right Transradial Approach for Percutaneous Coronary Procedures|Transradial Approach [LEft vs Right] aNd Procedural Times During Percutaneous Coronary Procedures: TALENT Study|Completed||N/A|1540|Actual|Policlinico Casilino ASL RMB||2|||f||||f||||||||||2018-06-01 01:25:05.641017|2018-06-01 01:25:05.641017
NCT00821093|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2011-07-22||2011-07-22|2009-01-12|2009-01-13|Estimate|2011-07-22|2011-08-18|Estimate||||2011-07-22|2011-08-18|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|INSIST||Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)|A 12 Week Treatment, Multi-center, Randomized, Parallel Group, Double Blind, Double Dummy Study to Assess the Superiority of Indacaterol (150 µg o.d.) Via a SDDPI in Patients With Moderate to Severe COPD, Using Salmeterol (50 µg b.i.d.) as an Active Comparator Delivered Via a DISKUS Inhaler|Completed||Phase 3|1123|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:25:05.778479|2018-06-01 01:25:05.778479
NCT00821080|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2015-04-30|2009-01-09|2009-01-13|Estimate|||||||2015-04-30|2015-05-01|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma|A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma|Completed||Phase 1|33|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 01:25:06.2825|2018-06-01 01:25:06.2825
NCT00821067|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-12-04|2009-01-12|2009-01-13|Estimate|||||||2009-12-04|2009-12-07|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||"The Effect of Oral D-Ribose in Baby Boomers With Fatigue. A Randomized, Double-Blind Study"|"The Effect of Oral D-Ribose in Baby Boomers With Fatigue. A Randomized, Double-Blind Study"|Completed||N/A|40|Anticipated|Bioenergy Life Science, Inc.||2|||f||||f||||||||||2018-06-01 01:25:06.354376|2018-06-01 01:25:06.354376
NCT00019539|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2013-06-19|2009-01-12|2009-01-13|Estimate|||||||2013-06-19|2013-06-20|Estimate|November 1998||1998-11-30|October 2004|2004-10-31|November 2004|Actual|2004-11-30|||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer|Phase II Randomized Study of Monoclonal Antibody VEGF in Patients With Unresectable Advanced Renal Cell Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:25:06.516157|2018-06-01 01:25:06.516157
NCT00821054|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2017-11-08|2009-01-08|2009-01-12|Estimate|||||||2017-11-08|2017-11-13|Actual|March 6, 2009|Actual|2009-03-06|November 2017|2017-11-30|March 22, 2011|Actual|2011-03-22|March 22, 2011|Actual|2011-03-22||Interventional|||A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients|An Open Label Study to Examine the Effects of Low-Fat and High-Fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients|Completed||Phase 1|24|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 01:25:06.579164|2018-06-01 01:25:06.579164
NCT00821041|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2011-05-05||2013-08-02|2009-01-09|2009-01-12|Estimate|2011-08-13|2011-09-16|Estimate||||2013-08-02|2013-08-08|Estimate|September 2006||2006-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|January 2012|Actual|2012-01-31||Interventional|||Internet-based Treatment for Chronic Insomnia|Evaluation of an Internet-based Treatment for Chronic Insomnia|Completed||Phase 2|118|Actual|University of Manitoba||2|||f||||f||||||||||2018-06-01 01:25:06.76982|2018-06-01 01:25:06.76982
NCT00821028|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2017-08-14|2009-01-09|2009-01-12|Estimate|||||||2017-08-14|2017-08-17|Actual|January 2009||2009-01-31|August 2017|2017-08-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|IRRITAX||Local Paclitaxel Delivery for SFA Disease|Treatment of Superficial Femoral Artery Atherosclerotic Disease With Local Delivery of Paclitaxel Using an Irrigating Catheter: a Single-center Pilot Study|Completed||N/A|27|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 01:25:06.984463|2018-06-01 01:25:06.984463
NCT00821015|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2017-12-04|2009-01-09|2009-01-12|Estimate|||||||2017-12-04|2017-12-06|Actual|June 2010||2010-06-30|December 2017|2017-12-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|CRYO-LA||Effect of Balloon Cryoablation on Left Atrial Function|Effect of Balloon Cryoablation on Left Atrial Function (CRYO-LA)|Completed||N/A|27|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|||||||No||2018-06-01 01:25:07.067249|2018-06-01 01:25:07.067249
NCT00821002|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08||2011-03-01|2013-09-16|2009-01-09|2009-01-12|Estimate||||2011-03-01|2011-03-16|Estimate|2013-09-16|2013-09-19|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug Delivery System (L-PPDS)|An Open-Label, Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)|Completed||Phase 2|32|Actual|Mati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 01:25:07.146915|2018-06-01 01:25:07.146915
NCT00820989|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2014-05-20|2009-01-09|2009-01-12|Estimate|||||||2014-05-20|2014-05-21|Estimate|February 2000||2000-02-29|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|Mono||Inflammation and the Host Response to Injury (In Healthy Volunteers)|Inflammation and the Host Response to Injury (In Healthy Volunteers)|Completed||Phase 1|116|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 01:25:07.227184|2018-06-01 01:25:07.227184
NCT00820976|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|March 1996||1996-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|March 2000|Actual|2000-03-31||Interventional|TLG-AML-95-002||Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML|A Phase III, Randomized Multicenter Study of Induction With or Without Granulocyte Colony-Stimulating Factor in AML|Completed||Phase 3|260|Actual|Turkish Leukemia Study Group||2|||f||||t||||||||||2018-06-01 01:25:07.306417|2018-06-01 01:25:07.306417
NCT00820963|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2011-05-11|2009-01-09|2009-01-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|July 2006||2006-07-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme|Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma|Completed||Phase 3|70|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 01:25:07.38978|2018-06-01 01:25:07.38978
NCT00820950|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08||2010-06-17|2018-01-15|2009-01-09|2009-01-12|Estimate||||2010-06-17|2010-06-22|Estimate|2018-01-15|2018-01-17|Actual|May 2007||2007-05-31|January 2018|2018-01-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis|A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis|Completed||Phase 2|29|Actual|Incyte Corporation||6|||f||||f||||||||||2018-06-01 01:25:07.470594|2018-06-01 01:25:07.470594
NCT00820937|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-27|||2009-08-26|2009-01-09|2009-01-12|Estimate|||||||2009-08-26|2009-08-27|Estimate|March 2006||2006-03-31|August 2009|2009-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|DatScan||Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI)|Interest of the Combination of the DaTSCAN Scintigraphy and MRI Scan in the Differential Diagnosis of Lewy Body Dementia From Alzheimer Disease in Patients With Hallucinations|Completed||N/A|20|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 01:25:07.585664|2018-06-01 01:25:07.585664
NCT00820924|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08||2012-03-22|2012-03-22|2009-01-08|2009-01-12|Estimate||||2012-03-22|2012-03-28|Estimate|2012-03-22|2012-03-28|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells|A Phase II Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Daily Dose of Lapatinib in Advanced Breast Cancer Patients With HER-2 Non-amplified Primary Tumours and HER-2 Positive Circulating Tumour Cells or EGFR Positive Circulating Tumor Cells|Terminated||Phase 2|23|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:25:07.651904|2018-06-01 01:25:07.651904
NCT00820911|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2017-02-22|2009-01-09|2009-01-12|Estimate|||||||2017-02-22|2017-02-24|Actual|September 2008||2008-09-30|February 2017|2017-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients|An Extension to a 12-month, Open-label, Randomised, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients|Completed||Phase 2|175|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:25:07.757799|2018-06-01 01:25:07.757799
NCT00820898|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2017-11-10||2017-12-05|2009-01-09|2009-01-12|Estimate|2017-11-10|2017-12-05|Actual||||2017-12-05|2017-12-29|Actual|February 2009||2009-02-28|May 2015|2015-05-31||||January 2011|Actual|2011-01-31||Interventional||Eligible and treated patients|Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|24|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 01:25:07.893308|2018-06-01 01:25:07.893308
NCT00820885|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2015-11-11|2009-01-09|2009-01-12|Estimate|||||||2015-11-11|2015-11-13|Estimate|July 2006||2006-07-31|January 2009|2009-01-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide|A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide|Completed||Phase 1|95|Actual|Shire||8|||f||||t||||||||||2018-06-01 01:25:08.344141|2018-06-01 01:25:08.344141
NCT00820872|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2017-02-01||2018-04-06|2009-01-09|2009-01-12|Estimate|2017-02-01|2017-03-22|Actual||||2018-04-06|2018-05-08|Actual|February 2009||2009-02-28|April 2018|2018-04-30||||December 2010|Actual|2010-12-31||Interventional|||Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer|Phase II Safety Study of Docetaxel and Carboplatin in Combination With Trastuzumab and Lapatinib in Early Breast Cancer|Active, not recruiting||Phase 2|30|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 01:25:08.450623|2018-06-01 01:25:08.450623
NCT00820859|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-07-01|2009-01-08|2009-01-12|Estimate|||||||2009-07-01|2009-07-03|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|TREA||Treatment Routes for Exploring Agitation|Treatment of Agitation in the Nursing Home|Unknown status|Recruiting|N/A|200|Anticipated|National Institute on Aging (NIA)||2|||f||||f||||||||||2018-06-01 01:25:08.948349|2018-06-01 01:25:08.948349
NCT00820846|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08||2015-05-28|2016-02-01|2009-01-08|2009-01-12|Estimate||||2015-07-02|2015-07-24|Estimate|2016-02-01|2016-02-15|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|August 2012|Actual|2012-08-31||Interventional|||Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults|A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants|Completed||Phase 2|299|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-06-01 01:25:09.060742|2018-06-01 01:25:09.060742
NCT00820833|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2015-03-25|2009-01-08|2009-01-12|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|June 2010|Actual|2010-06-30||Interventional|||Effect of Formula on Growth of Infants From Overweight or Obese Mothers|Effect of Protein Levels and Caloric Density on the Growth of Formula Fed Infants From Overweight or Obese Mothers|Completed||N/A|230|Actual|Nestlé||3|||f||||f||||||||||2018-06-01 01:25:09.181696|2018-06-01 01:25:09.181696
NCT00820820|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2012-10-08|2009-01-09|2009-01-12|Estimate|||||||2012-10-08|2012-10-10|Estimate|January 2009||2009-01-31|October 2012|2012-10-31||||July 2012|Actual|2012-07-31||Interventional|IDA-Adult||IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis|Immunotherapy of Atopic Dermatitis in Adult Patients by Anti-measles Vaccination IDA (Immunothérapie de la Dermatite Atopique)Protocol|Completed||N/A|20|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-06-01 01:25:09.265172|2018-06-01 01:25:09.265172
NCT00820807|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2011-06-16|2009-01-09|2009-01-12|Estimate|||||||2011-06-16|2011-06-17|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes|Novel Fiber Effects on Glucose Metabolism and Insulin Sensitivity for Individuals at High Risk for Diabetes: a Randomized, Placebo-controlled, Double-blind, Parallel Group Clinical Trial|Terminated||N/A|60|Anticipated|Cargill||3||Stopped due to a non-safety-related issue with the beverage (test vehicle).|f||||f||||||||||2018-06-01 01:25:09.352925|2018-06-01 01:25:09.352925
NCT00820794|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2015-03-04|2009-01-09|2009-01-12|Estimate|||||||2015-03-04|2015-03-05|Estimate|May 2009||2009-05-31|March 2015|2015-03-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects|A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects|Withdrawn||Phase 1|0|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:25:09.443202|2018-06-01 01:25:09.443202
NCT00820781|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|August 1977||1977-08-31|December 2008|2008-12-31|April 2003|Actual|2003-04-30|December 1977|Actual|1977-12-31||Interventional|||Endoscopic Sclerotherapy and/or Ligation Versus Portacaval Shunt for Bleeding Gastric Varices|Endoscopic Sclerotherapy and/or Ligation Versus Portacaval Shunt for Bleeding|Completed||N/A|518|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 01:25:09.528058|2018-06-01 01:25:09.528058
NCT00820768|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2018-04-09|2009-01-09|2009-01-12|Estimate|||||||2018-04-09|2018-04-11|Actual|April 1, 2012|Actual|2012-04-01|April 2018|2018-04-30|April 1, 2014|Anticipated|2014-04-01|April 1, 2013|Anticipated|2013-04-01||Interventional|||A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies|A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies|Withdrawn||Phase 1|0|Actual|Celgene||1|||f||||f||||||||||2018-06-01 01:25:09.611054|2018-06-01 01:25:09.611054
NCT00820755|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2013-07-01||2014-04-04|2009-01-09|2009-01-12|Estimate|2014-04-04|2014-05-05|Estimate||||2014-04-04|2014-05-05|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|December 2011|Actual|2011-12-31||Interventional|NEXT||Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)|Open, Randomized, Multinational Phase IIIb Trial Evaluating the Activity and Safety of Cetuximab as 250 mg/m^2 Weekly and 500 mg/m^2 Every Two Weeks Maintenance Therapy After Platinum-based Chemotherapy in Combination With Cetuximab as First-line Treatment for Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 3|583|Actual|Merck KGaA|Enrollment was stopped prematurely when cetuximab did not gain regulatory approval in this indication.|3|||f||||||||||||||2018-06-01 01:25:09.747336|2018-06-01 01:25:09.747336
NCT00820742|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2015-03-04|2009-01-09|2009-01-12|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2008||2008-02-29|March 2015|2015-03-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Observational|||Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.|The Efficacy, Safety, and Tolerability of Pegaptanib Sodium in Filipino Patients With Neovascular Age-related Macular Degeneration: A Post Marketing Surveillance Study.|Withdrawn|||0|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:25:10.790757|2018-06-01 01:25:10.790757
NCT00820729|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2012-09-17|2009-01-09|2009-01-12|Estimate|||||||2012-09-17|2012-09-18|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Biomarkers in Pulmonary Hypertension Associated to Interstitial Lung Disease|The Prevalence of Pulmonary Hypertension and the Significance of Different Biomarkers in Chronic Interstitial Lung Disease|Completed|||212|Actual|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 01:25:10.85354|2018-06-01 01:25:10.85354
NCT00820716|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2011-08-29|2009-01-09|2009-01-12|Estimate|||||||2011-08-29|2011-08-30|Estimate||||August 2011|2011-08-31||||||||Interventional|||Exercise Training in Asthma|Comparison of Two Types of Exercise Training for Asthmatic Subjects : Interests and Limits|Unknown status|Recruiting|N/A|45|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 01:25:10.908631|2018-06-01 01:25:10.908631
NCT00820703|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2010-08-29|2009-01-08|2009-01-12|Estimate|||||||2010-08-29|2010-08-31|Estimate|April 2009||2009-04-30|August 2010|2010-08-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers|A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-escalation, Single-center Study of the Safety and Clinical Effect of Nexagon® in the Treatment of Participants With Diabetic Foot Ulcers|Terminated||Phase 1/Phase 2|24|Anticipated|CoDa Therapeutics Inc.||||For business reasons|f||||f||||||||||2018-06-01 01:25:10.993225|2018-06-01 01:25:10.993225
NCT00820690|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2015-08-03|2009-01-09|2009-01-12|Estimate|||||||2015-08-03|2015-08-05|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|April 2012|Actual|2012-04-30||Observational|LABC||Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer|Gene Expression Signature and Immunohistochemical Markers Associated With Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer|Unknown status|Active, not recruiting||80|Actual|Barretos Cancer Hospital|||1||f||||f||||||Samples With DNA|"~     frozen tissue; parafin tissue~   "|||2018-06-01 01:25:11.143786|2018-06-01 01:25:11.143786
NCT00820677|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-12-11|2009-01-08|2009-01-12|Estimate|||||||2009-12-11|2009-12-14|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Newborn Health Information Study|Innovative Delivery of Newborn Anticipatory Guidance: The Incorporation of Media-Based Learning Into the Primary Care Office.|Completed||N/A|137|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 01:25:11.251781|2018-06-01 01:25:11.251781
NCT00820664|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2010-04-13||2016-01-21|2009-01-09|2009-01-12|Estimate|2010-04-13|2010-05-07|Estimate||||2016-01-21|2016-01-22|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women|A Randomized Clinical Trial to Evaluate the Effects of Estrogen on Uterine Endometrium in Healthy Postmenopausal Women|Completed||Phase 1|29|Actual|Merck Sharp & Dohme Corp.|"The registered secondary outcome: Mean gene expression intensity after 4 weeks of either 0.5 or 2 mg Estrace compared to placebo results are not available because of inadequate quantity and quality of tissue samples that were obtained."|3|||f||||f||||||||||2018-06-01 01:25:11.318564|2018-06-01 01:25:11.318564
NCT00820651|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2012-04-25|2009-01-09|2009-01-12|Estimate|||||||2012-04-25|2012-04-26|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis|Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study|Completed||Phase 3|158|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 01:25:11.676925|2018-06-01 01:25:11.676925
NCT00820638|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Myomo e100 NeuroRobotic System Home Safety Study|Myomo NeuroRobotic System Home Safety Study For Use by Stroke Survivors for Upper Extremity Rehabilitation in Their Homes|Unknown status|Recruiting|Phase 1|25|Anticipated|Myomo||1|||f||||f||||||||||2018-06-01 01:25:11.772656|2018-06-01 01:25:11.772656
NCT00820625|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2017-02-06|2009-01-09|2009-01-12|Estimate|||||||2017-02-06|2017-02-08|Estimate|May 2008||2008-05-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|Alster-Lost||Long-Standing Persistant Atrial Fibrillation-Pulmonary Vein Isolation With or Without Ablation|Ablation at St. Georg Hospital for Long-Standing Persistent Atrial Fibrillation - Pulmonary Vein Isolation With or Without Ablation of Complex Fragmented Atrial Potentials|Completed||N/A|124|Actual|Asklepios proresearch||2|||f||||f||||||||Undecided||2018-06-01 01:25:11.888692|2018-06-01 01:25:11.888692
NCT00820612|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2013-01-10||2013-02-21|2009-01-09|2009-01-12|Estimate|2013-01-10|2013-02-12|Estimate||||2013-02-21|2013-02-28|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients|A Prospective, Randomized, Controlled Trial of Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients.|Terminated||Phase 4|602|Actual|University of Michigan||2||"Stopped by DSMB for overwhelming benefit of indomethacin (unethical to withhold indomethacin~   from patients)"|f||||t||||||||||2018-06-01 01:25:11.969363|2018-06-01 01:25:11.969363
NCT00820599|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2017-02-07|2009-01-09|2009-01-12|Estimate|||||||2017-02-07|2017-02-09|Estimate|December 2008|Actual|2008-12-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|December 2010|Actual|2010-12-31||Interventional|PREVAIL-TF||Transfemoral Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)|Transfemoral Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (EUROPE)|Completed||N/A|213|Actual|Edwards Lifesciences||1|||f||||t|f|t|f|f||||Undecided||2018-06-01 01:25:12.196959|2018-06-01 01:25:12.196959
NCT00820586|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2012-02-01|2009-01-08|2009-01-12|Estimate|||||||2012-02-01|2012-02-02|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|December 2018|Anticipated|2018-12-31|January 2011|Actual|2011-01-31||Interventional|||Intramyocardial Delivery of Autologous Bone Marrow|Intramyocardial Delivery of Autologous Bone Marrow|Suspended||Phase 2|13|Actual|IRCCS San Raffaele||2||No more funding support for additional procedures|f||||f||||||||||2018-06-01 01:25:12.30036|2018-06-01 01:25:12.30036
NCT00820573|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2012-11-05||2013-12-11|2009-01-09|2009-01-12|Estimate|2013-12-11|2013-12-13|Estimate||||2013-12-11|2013-12-13|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM|Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|16|Actual|The University of Texas Health Science Center at San Antonio||4|||f||||f||||||||||2018-06-01 01:25:12.404187|2018-06-01 01:25:12.404187
NCT00820560|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2018-01-15|2009-01-08|2009-01-12|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2005||2005-01-31|January 2018|2018-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients With Solid Tumors|Completed||Phase 1|41|Actual|Incyte Corporation||2|||f||||f||||||||||2018-06-01 01:25:12.780404|2018-06-01 01:25:12.780404
NCT00820547|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2017-08-04|2009-01-09|2009-01-12|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2009||2009-01-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|April 2015|Actual|2015-04-30||Interventional|Beverly1||Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients|Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer|Active, not recruiting||Phase 2|100|Actual|UNICANCER||1|||f||||t||||||||||2018-06-01 01:25:12.858458|2018-06-01 01:25:12.858458
NCT00820534|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2010-11-12||2012-04-18|2009-01-09|2009-01-12|Estimate|2010-12-16|2011-01-19|Estimate||||2012-04-18|2012-04-20|Estimate|December 2008||2008-12-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers|A Randomised, Double-blind, Vehicle Controlled, Single Center, Parallel Group, Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers|Completed||Phase 4|126|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:25:12.971248|2018-06-01 01:25:12.971248
NCT00820521|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-01-30|2009-01-09|2009-01-12|Estimate|||||||2009-01-30|2009-02-02|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Study Evaluating Single Doses of GAP-134|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Orally to Healthy Subjects|Withdrawn||Phase 1|24|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:25:13.177657|2018-06-01 01:25:13.177657
NCT00820508|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2011-11-25|2009-01-09|2009-01-12|Estimate|||||||2011-11-25|2011-11-28|Estimate|December 2008||2008-12-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CHR-2845-001||Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies|A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies|Completed||Phase 1|18|Actual|Chroma Therapeutics||1|||f||||f||||||||||2018-06-01 01:25:13.232525|2018-06-01 01:25:13.232525
NCT00820495|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2013-08-02|2009-01-09|2009-01-12|Estimate|||||||2013-08-02|2013-08-05|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effectiveness of a Web-Assisted Quitline for Smokeless Tobacco Users|Effectiveness of a Web-Assisted Quitline for Smokeless Tobacco Users|Completed||Phase 2|1683|Actual|Oregon Research Institute||4|||f||||f||||||||||2018-06-01 01:25:13.303841|2018-06-01 01:25:13.303841
NCT00820482|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-09-17|2009-01-08|2009-01-12|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination.|A Prospective, Randomized, Controlled Trial Comparing Highly Purified hMG With Recombinant FSH + Recombinant LH in Women Undergoing Intrauterine Insemination: Ovarian Response and Clinical Outcomes.|Completed||Phase 4|80|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 01:25:13.38349|2018-06-01 01:25:13.38349
NCT00820469|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2017-05-10|2009-01-09|2009-01-12|Estimate|||||||2017-05-10|2017-05-12|Actual|September 2008||2008-09-30|May 2017|2017-05-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|PK-rituximab||Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab|Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders.|Completed||Phase 4|20|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 01:25:13.448188|2018-06-01 01:25:13.448188
NCT00820456|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2011-12-20|2009-01-09|2009-01-12|Estimate|||||||2011-12-20|2011-12-21|Estimate|April 2008||2008-04-30|March 2010|2010-03-31||||||||Observational|||Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI|Angle Interleaved Projection Reconstruction With K-Space Weighted Image Reconstruction for Dynamic Contrast MRI of Cancer Therapy Response|Unknown status|Active, not recruiting||60|Anticipated|American College of Radiology Imaging Network|||2||f||||t||||||||||2018-06-01 01:25:13.518575|2018-06-01 01:25:13.518575
NCT00820443|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2015-05-07||2015-08-28|2009-01-09|2009-01-12|Estimate|2015-08-28|2015-09-30|Estimate||||2015-08-28|2015-09-30|Estimate|June 2007||2007-06-30|August 2015|2015-08-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|COM||Ceramic on Metal Total Hip Replacement System Multi-Center,Investigational Device Exemption Clinical Trial|Ceramic on Metal Total Hip Replacement System IDE: A Non-Randomized, Multi-center, Historically Controlled Safety and Efficacy Study (Protocol Number:06-LJH-002)|Terminated||Phase 4|253|Actual|MicroPort Orthopedics Inc.||1||"not move forward with the commercialization of this product based on marketing needs and there~   is not a known safety issue or concern"|f||||f||||||||||2018-06-01 01:25:13.669942|2018-06-01 01:25:13.669942
NCT00820430|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|November 2006||2006-11-30|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||MRI Markers of Cartilage Damage in Knee With Osteoarthritis|A Multi-Center Trial on MR Image Markers of Knee Articular Cartilage Damage in Osteoarthritis|Completed|||53|Actual|American College of Radiology Imaging Network|||3||f||||t||||||||||2018-06-01 01:25:13.9113|2018-06-01 01:25:13.9113
NCT00820417|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|June 2004||2004-06-30|January 2009|2009-01-31|May 2008|Actual|2008-05-31|September 2007|Actual|2007-09-30||Interventional|||Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib|Phase 1 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of the Combination of Cetuximab (C-225), a Chimeric Monoclonal Antibody Against the Epidermal Growth Factor Receptor (EGFR), and Gefitinib (ZD1839), a Selective EGFR Tyrosine Kinase Inhibitor, in Patients With Advanced Cancer|Completed||Phase 1|63|Actual|Harrison Clinical Research||2|||f||||f||||||||||2018-06-01 01:25:14.052472|2018-06-01 01:25:14.052472
NCT00820404|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-07-16|2009-01-09|2009-01-12|Estimate|||||||2009-07-16|2009-07-17|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Evaluating Single Doses of BLI-489 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects|Completed||Phase 1|54|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:25:14.152386|2018-06-01 01:25:14.152386
NCT00820391|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|October 2005|Actual|2005-10-31|January 2005|Actual|2005-01-31||Interventional|||KIDNET Versus Meditation/Relaxation - a Dissemination RCTT for Children in Sri Lanka Traumatized by the War and the Tsunami|KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Treatment Trial for Children in Sri Lanka Traumatized by the War and the Tsunami|Completed||Phase 3|31|Actual|University of Konstanz||2|||f||||f||||||||||2018-06-01 01:25:14.227528|2018-06-01 01:25:14.227528
NCT00820378|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-12|2009-01-08|2009-01-12|Estimate|||||||2009-01-12|2009-01-14|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2015|Anticipated|2015-12-31|December 2010|Anticipated|2010-12-31||Observational|||The Epidemiology of Aortic Diameter in China|Epidemiology of Aortic Dimensions in Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors|Unknown status|Recruiting||2000|Anticipated|Zhejiang University|||1||f||||t||||||||||2018-06-01 01:25:14.301168|2018-06-01 01:25:14.301168
NCT00820365|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2011-05-17|2009-01-09|2009-01-12|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|ENTRANCE||SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease|Exploratory, Open-label Study to Demonstrate Efficacy, Safety and Tolerability of SC12267 (35 mg) in Patients With Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)|Completed||Phase 2|34|Actual|4SC AG|||||f||||t||||||||||2018-06-01 01:25:14.404798|2018-06-01 01:25:14.404798
NCT00820352|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2014-06-27|2009-01-09|2009-01-12|Estimate|||||||2014-06-27|2014-06-30|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|BADDHY||Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension|Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension|Completed||Phase 3|20|Actual|University Teaching Hospital Hall in Tirol||2|||f||||f||||||||||2018-06-01 01:25:14.518708|2018-06-01 01:25:14.518708
NCT00820339|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2016-03-30|2009-01-09|2009-01-12|Estimate|||||||2016-03-30|2016-04-01|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|November 2012|Actual|2012-11-30|December 2010|Actual|2010-12-31||Interventional|SHVE||Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy|Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy About Recurrence and Survival :A Prospective Randomized Trial|Completed||Phase 2/Phase 3|132|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:25:14.64104|2018-06-01 01:25:14.64104
NCT00820326|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-27|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|March 2004||2004-03-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|||||Interventional|Dolastron||Efficacy of Dolasetron in Patients With Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled, Study of Efficacy of DOLASETRON in Patients With Fibromyalgia|Completed||Phase 3|60|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-06-01 01:25:14.759608|2018-06-01 01:25:14.759608
NCT00820313|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|October 2006||2006-10-31|January 2009|2009-01-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers|Coronary Events, Risk Factors, and Quality of Life in Men and Women Enrolled in Intensive Lifestyle Interventions - A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers|Unknown status|Active, not recruiting|N/A|131|Actual|Preventive Medicine Research Institute||1|||f||||f||||||||||2018-06-01 01:25:14.861959|2018-06-01 01:25:14.861959
NCT00820300|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08||2011-03-01|2013-09-16|2009-01-09|2009-01-12|Estimate||||2011-03-01|2011-03-16|Estimate|2013-09-16|2013-09-19|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma|An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG)|Completed||Phase 2|113|Actual|Mati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 01:25:14.972898|2018-06-01 01:25:14.972898
NCT00820287|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2012-03-23|2009-01-09|2009-01-12|Estimate|||||||2012-03-23|2012-03-26|Estimate|September 2005||2005-09-30|January 2009|2009-01-31|June 2011|Actual|2011-06-30|January 2009|Actual|2009-01-31||Interventional|||Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk|Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk|Terminated||N/A|44|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-06-01 01:25:15.048297|2018-06-01 01:25:15.048297
NCT00820274|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2015-08-31|2009-01-09|2009-01-12|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|June 2016|Anticipated|2016-06-30|December 2013|Actual|2013-12-31||Interventional|MAUV||Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers|Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers|Terminated||Phase 2|10|Actual|University Hospital, Limoges||1||clinical trial have encountered difficulties enrolling a sufficient number of patients|f||||t||||||||||2018-06-01 01:25:15.112952|2018-06-01 01:25:15.112952
NCT00820261|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2012-09-06|2009-01-09|2009-01-12|Estimate|||||||2012-09-06|2012-09-07|Estimate|August 2009||2009-08-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|Rotavirus||Molecular Epidemiology of Rotavirus Diarrhea Among Infants and Young Children Attending Maua Methodist Hospital, Kenya|Molecular Epidemiology of Rotavirus Diarrhea Among Infants and Young Children Attending Maua Methodist Hospital, Kenya|Completed|||630|Actual|Institute of Primate Research|||1||f||||t||||||Samples With DNA|"~     The positive samples will be evaluated by sodium dodecyl polyacrylamide gel electrophoresis~     (SDS-PAGE) to determine the electropherotypes and genotyped using reverse transcriptase~     polymerase chain reaction (RT-PCR) on VP7 and VP4 gene and sequencing. Also, these positive~     samples will be retained for quality assurance and quality control.~   "|||2018-06-01 01:25:15.185722|2018-06-01 01:25:15.185722
NCT00820248|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|2017-01-26||2017-06-19|2009-01-09|2009-01-12|Estimate|2017-04-06|2017-06-20|Actual||||2017-06-19|2017-07-17|Actual|December 18, 2008|Actual|2008-12-18|June 2017|2017-06-30|February 17, 2017|Actual|2017-02-17|October 2014|Actual|2014-10-31||Interventional|||Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer|A Phase III Study of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab in Patients With Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|320|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 01:25:15.293866|2018-06-01 01:25:15.293866
NCT00820053|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2016-03-30|2009-01-08|2009-01-09|Estimate|||||||2016-03-30|2016-04-01|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection|Eastern Hepatobilliary Surgical Hospital|Completed||Phase 2|450|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:25:18.577243|2018-06-01 01:25:18.577243
NCT00820235|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2017-09-07|2009-01-09|2009-01-12|Estimate|||||||2017-09-07|2017-09-08|Actual|February 2009||2009-02-28|September 2017|2017-09-30||||June 2017|Actual|2017-06-30||Interventional|||Study Comparing Appearance and Function of Three Different Dental Implant Designs When Placed in Front Region of Upper Jaw|Prospective, Comparative Assessment of Single-tooth Replacement in Different Implant-abutment Settings|Active, not recruiting||N/A|144|Anticipated|Dentsply Sirona Implants||3|||f||||f||||||||||2018-06-01 01:25:15.830422|2018-06-01 01:25:15.830422
NCT00820222|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2013-01-17||2017-06-06|2009-01-08|2009-01-12|Estimate|2013-02-14|2013-03-15|Estimate||||2017-06-06|2017-07-07|Actual|April 14, 2009|Actual|2009-04-14|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|June 11, 2012|Actual|2012-06-11||Interventional|||Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer|A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic Breast Cancer|Active, not recruiting||Phase 3|546|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:25:15.952591|2018-06-01 01:25:15.952591
NCT00820196|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2012-09-16|2009-01-09|2009-01-12|Estimate|||||||2012-09-16|2012-09-18|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)|A Randomized, Double-Blind, Vehicle-controlled, Parallel Group, Dose-Ranging, Multi-center Study of the Efficacy and Safety of Nexagon® in the Treatment of Participants With Venous Leg Ulcers|Completed||Phase 2|98|Actual|CoDa Therapeutics Inc.|||||f||||t||||||||||2018-06-01 01:25:16.717982|2018-06-01 01:25:16.717982
NCT00820183|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-09|||2009-05-06|2009-01-09|2009-01-12|Estimate|||||||2009-05-06|2009-05-07|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|April 2008|Actual|2008-04-30|April 2007|Actual|2007-04-30||Interventional|INCOTECA||A Quality Improvement Plan for Hypertension Control|A Quality Improvement Plan for Hypertension Control: the INCOTECA Project|Completed||N/A|34327|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-06-01 01:25:17.702029|2018-06-01 01:25:17.702029
NCT00820170|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2018-01-19|2009-01-09|2009-01-12|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2009||2009-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194|A Phase I-II Study of Dasatinib in Combination With Weekly Paclitaxel for Patients With Metastatic Breast Carcinoma|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:25:17.773172|2018-06-01 01:25:17.773172
NCT00820157|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2013-08-10|2009-01-09|2009-01-12|Estimate|||||||2013-08-10|2013-08-13|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|November 2010|Actual|2010-11-30||Interventional|TACE||Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma|A Prospective Randomized Trial Comparing Cytoreductive Surgery Followed by Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Multinodular Hepatocellular Carcinoma (MNHCC)|Completed||N/A|120|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:25:17.85713|2018-06-01 01:25:17.85713
NCT00820144|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-09|2009-01-09|2009-01-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|February 2007|Actual|2007-02-28|April 2006|Actual|2006-04-30||Interventional|||Cholera Toxin B Subunit (CTB) Administered by Mucosal Way in Healthy Adult Volunteer|Functional Exploration of the Immune Response Using the B-Subunit of Cholera Toxin Administered by Mucosal Way in Healthy Adult Volunteer: Potential Role in Development of Vaccine Processes|Completed||Phase 1|40|Actual|Centre Hospitalier Universitaire de Nice||5|||f||||f||||||||||2018-06-01 01:25:17.948165|2018-06-01 01:25:17.948165
NCT00820131|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2014-12-08|2009-01-08|2009-01-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Interventional|GRIP-ME||Chronic Pain After Inguinal Hernia Repair|A Multicenter Prospective Randomized Trial on Chronic Pain After Inguinal Hernia Repair Using a Selfgrip-mesh|Completed||Phase 4|250|Anticipated|Medical University of Vienna||2|||f||||||||||||||2018-06-01 01:25:18.03521|2018-06-01 01:25:18.03521
NCT00820118|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2012-05-22|2009-01-08|2009-01-09|Estimate|||||||2012-05-22|2012-05-23|Estimate|May 2009||2009-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|TIPI||Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults|ARNS 141 TIPI : A Pilot Trial to Assess the Ability of an Intermittent Antiretroviral Therapy in Maintaining an Immunological Stability in Antiretroviral naïve HIV Infected Adults, With CD4 Count Above 500/mm3|Completed||Phase 2|45|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-06-01 01:25:18.111442|2018-06-01 01:25:18.111442
NCT00820105|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-12-23|2009-01-08|2009-01-09|Estimate|||||||2009-12-23|2009-12-24|Estimate|December 2008||2008-12-31|December 2009|2009-12-31||||January 2010|Anticipated|2010-01-31||Interventional|||ADX10059 Migraine Prevention Study|A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multicentre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 for the Prevention of Migraine|Terminated||Phase 2|350|Anticipated|Addex Pharma S.A.||4||Incidence of abnormalities of liver function tests is higher than expected in this population.|f||||f||||||||||2018-06-01 01:25:18.220443|2018-06-01 01:25:18.220443
NCT00820092|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-14|||2013-07-29|2009-01-07|2009-01-09|Estimate|||||||2013-07-29|2013-07-30|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers|A Phase 1,Dose Escalation Study to Compare the Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Profiles of the 24-hour Intravenous Administration of Xerecept in Healthy Japanese and Caucasian Adult Volunteers|Completed||Phase 1|38|Actual|Celtic Pharma Development Services||3|||f||||t||||||||||2018-06-01 01:25:18.409036|2018-06-01 01:25:18.409036
NCT00820079|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-12-23|2009-01-08|2009-01-09|Estimate|||||||2009-12-23|2009-12-24|Estimate|December 2008||2008-12-31|December 2009|2009-12-31||||October 2009|Actual|2009-10-31||Interventional|||ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)|A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 2|120|Anticipated|Addex Pharma S.A.||2|||f||||f||||||||||2018-06-01 01:25:18.490675|2018-06-01 01:25:18.490675
NCT00820027|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2015-05-26|2009-01-07|2009-01-09|Estimate|||||||2015-05-26|2015-05-27|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)|A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK0663/Etoricoxib and Ibuprofen in the Treatment of Postorthopedic Knee Replacement Surgery Pain|Completed||Phase 3|776|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:25:18.692208|2018-06-01 01:25:18.692208
NCT00820014|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2010-09-23|2009-01-08|2009-01-09|Estimate|||||||2010-09-23|2010-09-24|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Ocular Biodistribution Study for Topically Applied ESBA105|Evaluation of Tolerability, Safety and Ocular Pharmacokinetics of Topically Applied ESBA105 in Patients Undergoing Cataract Surgery or Combined Cataract Surgery and Vitrectomy|Completed||Phase 1/Phase 2|79|Actual|ESBATech AG||2|||f||||f||||||||||2018-06-01 01:25:18.776972|2018-06-01 01:25:18.776972
NCT00820001|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2013-02-15|2009-01-08|2009-01-09|Estimate|||||||2013-02-15|2013-02-18|Estimate|December 2003||2003-12-31|February 2013|2013-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|REACH||Resources to Enhance the Adjustment of Children (REACH)|Enhancing Long-Term Outcome in Child Behavior Disorders|Completed||N/A|254|Actual|University of Pittsburgh||4|||f||||f||||||||||2018-06-01 01:25:18.859148|2018-06-01 01:25:18.859148
NCT00819988|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2012-01-09|2009-01-08|2009-01-09|Estimate|||||||2012-01-09|2012-01-10|Estimate|May 2009||2009-05-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Pregabalin in the Prevention of Postoperative Delirium and Pain|A Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety and Efficacy of the Perioperative Administration of Pregabalin in Reducing the Incidence of Postoperative Delirium and Improving Acute Postoperative Pain Management|Completed||Phase 3|240|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 01:25:18.975784|2018-06-01 01:25:18.975784
NCT00819975|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-08|2009-01-08|2009-01-09|Estimate|||||||2009-01-08|2009-01-09|Estimate||||January 2009|2009-01-31|May 2008|Actual|2008-05-31|||||Interventional|||Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes|Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes|Completed||N/A|12|Actual|Aarhus University Hospital||4|||f||||f||||||||||2018-06-01 01:25:19.064473|2018-06-01 01:25:19.064473
NCT00819962|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2015-09-13|2009-01-08|2009-01-09|Estimate|||||||2015-09-13|2015-09-15|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Perioperative Analgesia Using Ultrasound (US) Guided Transversus Abdominis Plane (TAP) Block||Unknown status|Recruiting|Early Phase 1|42|Anticipated|King Saud University||1|||f||||t||||||||||2018-06-01 01:25:19.132016|2018-06-01 01:25:19.132016
NCT00819949|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2013-09-18|2009-01-08|2009-01-09|Estimate|||||||2013-09-18|2013-09-20|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Robot-assisted Gait Training on Freezing of Gait in Parkinson's Disease|Effect of Robot-assisted Gait Training on Freezing of Gait in Parkinson's Disease|Completed||Phase 1/Phase 2|20|Anticipated|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 01:25:19.196533|2018-06-01 01:25:19.196533
NCT00819936|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-08|2009-01-08|2009-01-09|Estimate|||||||2009-01-08|2009-01-09|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|December 2006||2006-12-31|December 2005|Actual|2005-12-31||Interventional|||A Controlled Trial of Effectiveness of a Backward Walking Program in Patients Recovering From Abdominal Aorta Surgery|A Controlled Trial of Effectiveness of a Backward Walking Program in Patients Recovering From an Abdominal Aorta Surgery|Completed||Phase 4|47|Actual|Medical University of Silesia||2|||f||||f||||||||||2018-06-01 01:25:19.261972|2018-06-01 01:25:19.261972
NCT00819923|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2011-05-04|2009-01-08|2009-01-09|Estimate|||||||2011-05-04|2011-05-05|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|December 2014|Anticipated|2014-12-31|May 2013|Anticipated|2013-05-31||Interventional|BASE-ACS||Comparison of Bio-Active-Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome|Comparison of Bio-Active-Stent to the Everolimus-Eluting Stent in Acute Coronary Syndrome (A Prospective, Randomized and a Multicenter Clinical Study)|Unknown status|Active, not recruiting|Phase 3|825|Actual|The Hospital District of Satakunta||2|||f||||t||||||||||2018-06-01 01:25:19.343739|2018-06-01 01:25:19.343739
NCT00819910|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2013-02-06||2014-04-08|2009-01-08|2009-01-09|Estimate|2014-01-24|2014-02-26|Estimate||||2014-04-08|2014-04-24|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|RAFAEL||Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)|Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)|Terminated||Phase 4|41|Actual|Brooke Army Medical Center|First, the study was terminated early per FDA recommendations restricting rosiglitazone use. Second, recruitment of patients was slow due to deployment restraints.|4||Slow recruitment and increase in deployment overseas limiting follow up|f||||t||||||||||2018-06-01 01:25:19.523263|2018-06-01 01:25:19.523263
NCT00819897|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2016-05-11|2009-01-08|2009-01-09|Estimate|||||||2016-05-11|2016-05-12|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|QUALICIS||Longitudinal Study in Clinically Isolated Syndrome (CIS) Patients Treated With Interferon Beta|Longitudinal Study in Clinical Isolated Syndrome Patients Treated With Interferon Beta. Correlation With Cognitive Disorders and Quality of Life.|Terminated|||37|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-06-01 01:25:20.095751|2018-06-01 01:25:20.095751
NCT00819884|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-05-06|2009-01-08|2009-01-09|Estimate|||||||2009-05-06|2009-05-07|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||To Evaluate 24-hr Glucose After OD vs BD AZD1656|A Randomised, Two Way Cross-Over, Single-Blind, Phase I Study to Evaluate 24-hr Glucose Profiles in Patients With T2DM When Dosed OD and BD on Top of Metformin for Four Days With AZD1656|Completed||Phase 1|36|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 01:25:20.177679|2018-06-01 01:25:20.177679
NCT00819871|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2013-05-02|2009-01-08|2009-01-09|Estimate|||||||2013-05-02|2013-05-03|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|||Nuclear Factor Kappa-B (NFKB1) Polymorphism and Organ Injury After Cardiac Surgery|Association of NFKB1 -94 Polymorphism With Lung and/or Kidney Injury After Cardiac Surgery With Cardiopulmonary Bypass|Completed|||105|Actual|Changhai Hospital|||4||f||||t||||||Samples With DNA|"~     3ml blood before surgery, after surgery and 24h after surgery respectively~   "|||2018-06-01 01:25:20.24746|2018-06-01 01:25:20.24746
NCT00819858|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2013-10-15|2009-01-08|2009-01-09|Estimate|||||||2013-10-15|2013-10-16|Estimate|January 2009||2009-01-31|October 2013|2013-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight|The Effectiveness of Ready to Use Therapeutic Food (RUTF) in Catch up Growth in Children After an Episode of P. Falciparum Malaria|Completed||N/A|180|Actual|Medecins Sans Frontieres, Netherlands||2|||f||||t||||||||||2018-06-01 01:25:20.304745|2018-06-01 01:25:20.304745
NCT00819845|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2016-01-27|2009-01-08|2009-01-09|Estimate|||||||2016-01-27|2016-01-28|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|December 2016|Anticipated|2016-12-31|June 2009|Actual|2009-06-30||Interventional|||Ramipril Versus Carvedilol in Duchenne and Becker Patients|Effects of Cardioprotective Therapy, Carvedilol vs Ramipril, in Patients Affected by Duchenne and Becker Muscular Dystrophy. Clinical Significance and Prognostic Value of Cardiac Magnetic Resonance Study.|Unknown status|Recruiting|Phase 4|194|Anticipated|Catholic University, Italy||2|||f||||f||||||||||2018-06-01 01:25:20.378004|2018-06-01 01:25:20.378004
NCT00819832|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2010-08-16||2013-11-27|2009-01-07|2009-01-09|Estimate|2010-12-14|2010-12-16|Estimate||||2013-11-27|2013-11-28|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Anderson Circulating Tumor Cell Burden (CTCB) Study|Assessment of Circulating Tumor Cell Burden After Radiofrequency-Based Plasma Ablation (COBLATION®) in Conjunction With Vertebroplasty or Kyphoplasty for Augmenting Painful Vertebral Compression Fractures Secondary to Malignancy|Terminated||Phase 4|3|Actual|M.D. Anderson Cancer Center||6||Terminated by sponsor.|f||||t||||||||||2018-06-01 01:25:20.473899|2018-06-01 01:25:20.473899
NCT00819819|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2017-03-21|2009-01-07|2009-01-09|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2008||2008-04-30|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Infant Nutrition and Risk of Celiac Disease|Infant Nutrition and Risk of Celiac Disease: Proposal for an Intervention, Prospective Multicenter Study|Terminated||N/A|80|Actual|Massachusetts General Hospital||2||A similar study was conducted and subsequently published in Italy.|f||||t||||||||||2018-06-01 01:25:20.700338|2018-06-01 01:25:20.700338
NCT00819806|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2017-07-26|2009-01-07|2009-01-09|Estimate|||||||2017-07-26|2017-07-31|Actual|January 2009||2009-01-31|July 2017|2017-07-31|January 2015|Actual|2015-01-31|May 2012|Actual|2012-05-31||Interventional|||CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors|Phase I Study of Vaccination With CpG 7909 and Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein in Patients With NY-ESO-1-expressing Tumors|Completed||Phase 1|21|Actual|University of Pittsburgh||6|||f||||t||||||||||2018-06-01 01:25:20.771165|2018-06-01 01:25:20.771165
NCT00819793|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08||2014-05-30|2016-04-08|2009-01-08|2009-01-09|Estimate||||2014-10-30|2014-11-06|Estimate|2016-04-08|2016-05-06|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|||CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass|Thoratec CentriMag VAS Failure-to-Wean From Cardiopulmonary Bypass Trial|Completed||N/A|32|Actual|St. Jude Medical||1|||f||||t||||||||||2018-06-01 01:25:20.853628|2018-06-01 01:25:20.853628
NCT00819780|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2014-07-10||2017-11-01|2009-01-08|2009-01-09|Estimate|2014-07-14|2014-08-06|Estimate||||2017-11-01|2017-11-06|Actual|April 2009||2009-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2012|Actual|2012-05-31||Interventional|||PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors|A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer|Completed||Phase 2|285|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:25:21.028975|2018-06-01 01:25:21.028975
NCT00819767|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2010-12-07||2011-06-02|2009-01-08|2009-01-09|Estimate|2011-06-02|2011-06-28|Estimate||||2011-06-02|2011-06-28|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise|An Eight-week, Randomized, Double-blind, Parallel-group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose|Completed||Phase 2|68|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:25:22.231681|2018-06-01 01:25:22.231681
NCT00819754|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2014-01-10|2009-01-08|2009-01-09|Estimate|||||||2014-01-10|2014-01-14|Estimate|November 2003||2003-11-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|IXO+A||A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer|A Phase I/II Clinical Trial of Combination of Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen With Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer|Terminated||Phase 1/Phase 2|23|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-06-01 01:25:22.485559|2018-06-01 01:25:22.485559
NCT00819741|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2010-11-05||2016-12-19|2009-01-08|2009-01-09|Estimate|2010-11-05|2010-12-08|Estimate||||2016-12-19|2017-02-10|Actual|February 2009||2009-02-28|December 2016|2016-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs|A 16-week, Open-label, Multicentre, Randomised, Parallel Study to Evaluate Efficacy and Safety of Repaglinide and Metformin Combination Therapy Compared to Repaglinide Monotherapy in Chinese OAD Naive Type 2 Diabetic Patients|Completed||Phase 4|433|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:25:22.581721|2018-06-01 01:25:22.581721
NCT00819728|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2011-01-10|2009-01-08|2009-01-09|Estimate|||||||2011-01-10|2011-01-11|Estimate|June 2000||2000-06-30|January 2011|2011-01-31|January 2003|Actual|2003-01-31|||||Interventional|||Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer|Multicenter Phase II Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|35|Actual|Sanofi||1|||||||||||||||||2018-06-01 01:25:23.186415|2018-06-01 01:25:23.186415
NCT00819715|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2010-10-10|2009-01-08|2009-01-09|Estimate|||||||2010-10-10|2010-10-13|Estimate|June 2008||2008-06-30|June 2009|2009-06-30||||January 2010|Actual|2010-01-31||Observational|||Electrogastrography in Small for Gestational Age Preterm Infants|Electrogastrography in Small for Gestational Age Preterm Infants Compared to Appropriate for Gestational Age Infants|Completed|||30|Anticipated|Meir Medical Center|||2||f||||t||||||||||2018-06-01 01:25:23.261352|2018-06-01 01:25:23.261352
NCT00819702|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2017-09-26|2009-01-07|2009-01-09|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2006||2006-05-31|September 2017|2017-09-30|May 2010|Actual|2010-05-31|March 2009|Actual|2009-03-31||Interventional|SEEK||A Safe Environment for Every Kid (SEEK): A Model for Primary Care|Preventing Child Maltreatment: A Role for Community Pediatricians|Completed||N/A|905|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 01:25:23.317634|2018-06-01 01:25:23.317634
NCT00819676|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-07-31|2009-01-08|2009-01-09|Estimate|||||||2009-07-31|2009-08-03|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Analysis of Exhaled Breath by Biosensors in Adults With Asthma|"Analysis of Exhaled Breath by Biosensors in Adults With Asthma: Observational Part of the Study Effects of add-on Therapy With Oral Montelukast on the Analysis of Exhale Breath by Biosensors in Adults With Asthma"|Completed|||47|Actual|Catholic University of the Sacred Heart|||2||f||||t||||||||||2018-06-01 01:25:23.4003|2018-06-01 01:25:23.4003
NCT00819663|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2011-08-17|2009-01-08|2009-01-09|Estimate|||||||2011-08-17|2011-08-19|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography|Intestinal Wall Remodeling After Initiation of Infliximab Therapy in Crohn's Disease Patients Undergoing Serial CT Enterography|Completed|||67|Actual|Mayo Clinic|||1||f||||t||||||||||2018-06-01 01:25:23.47995|2018-06-01 01:25:23.47995
NCT00819650|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-01|||2016-03-30|2009-01-08|2009-01-09|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection|Eastern Hepatobiliary Surgical Hospital|Completed||Phase 2|200|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:25:23.566404|2018-06-01 01:25:23.566404
NCT00819637|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2010-02-17||2015-03-17|2009-01-08|2009-01-09|Estimate|2010-05-25|2010-06-29|Estimate||||2015-03-17|2015-04-06|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients|A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Presenting to the Emergency Department and to Evaluate Its Side Effect and Safety Profile When Used in This Clinical Situation.|Terminated||Phase 4|2|Actual|Henry Ford Health System||3||Unable to enroll r/t study design & staffing issues. The trial terminated.|f||||f||||||||||2018-06-01 01:25:23.661808|2018-06-01 01:25:23.661808
NCT00819624|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2010-02-12|2009-01-08|2009-01-09|Estimate|||||||2010-02-12|2010-02-15|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Compare Two Ways of Completing Pain and Sleep Questions and to Evaluate a New Daily Questionaire for Assessing Fatigue in Fibromyalgia Patients|A Non-Drug Methodology Study To Explore The Psychometric Properties Of A Daily Diary Of Fatigue Symptoms And To Compare Two Modes Of Administration Of Pain And Sleep Interference Questions For Use With Fibromyalgia Patients|Completed||N/A|185|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:25:23.899061|2018-06-01 01:25:23.899061
NCT00819611|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2014-01-09|2009-01-08|2009-01-09|Estimate|||||||2014-01-09|2014-01-10|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Working Memory Training in Young ADHD Children|Working Memory Training: A Randomised Controlled Treatment Study in Young ADHD Children|Completed||Phase 4|51|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:25:24.060049|2018-06-01 01:25:24.060049
NCT00819598|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2009-11-10|2009-01-08|2009-01-09|Estimate|||||||2009-11-10|2009-11-13|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Pilot Study to Determine the Optimal Technique for Measurement of Ankle Blood Pressures|Pilot Study to Determine the Optimal Oscillometric-Based Technique for Measurement of Ankle Blood Pressures for the Ankle-brachial Index|Completed|||70|Anticipated|Summit Doppler Systems, Inc.|||1||f||||f||||||||||2018-06-01 01:25:24.145193|2018-06-01 01:25:24.145193
NCT00819585|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2011-02-28||2011-04-12|2009-01-08|2009-01-09|Estimate|2011-04-12|2011-05-06|Estimate||||2011-04-12|2011-05-06|Estimate|December 2008||2008-12-31|April 2011|2011-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy|A 24-week, Dose-ranging, Multi-center, Double-blind, Double-dummy, Active-controlled Study to Evaluate Canakinumab (ACZ885) for Prophylaxis of Signs and Symptoms of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy|Completed||Phase 2|432|Actual|Novartis||7|||f||||||||||||||2018-06-01 01:25:24.254539|2018-06-01 01:25:24.254539
NCT00819572|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2010-09-23|2009-01-08|2009-01-09|Estimate|||||||2010-09-23|2010-09-24|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee|A Double-blind, Randomised, Placebo-controlled Phase I/IIa Study to Investigate the Safety, Tolerability and Efficacy on Pain of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|27|Actual|ESBATech AG||3|||f||||t||||||||||2018-06-01 01:25:25.533464|2018-06-01 01:25:25.533464
NCT00819559|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2009-01-08|2009-01-07|2009-01-09|Estimate|||||||2009-01-08|2009-01-12|Estimate|March 2009||2009-03-31|January 2009|2009-01-31|December 2016|Anticipated|2016-12-31|February 2011|Anticipated|2011-02-28||Interventional|||Preoperative Chemoradiotheray for Rectal Cancer|Role of Preoperative Chemoradiotherapy in Clinically T3No Mid and Low Rectal Cancer : Multi-Institute Clinical Study|Unknown status|Not yet recruiting|N/A|1160|Anticipated|Korean Rectal Cancer Study Group||4|||f||||t||||||||||2018-06-01 01:25:25.61323|2018-06-01 01:25:25.61323
NCT00819546|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2017-07-07|2009-01-08|2009-01-09|Estimate|||||||2017-07-07|2017-07-11|Actual|January 2009||2009-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS|A Phase I Trial of Escalating Dose of RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS|Active, not recruiting||Phase 1|36|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||||2018-06-01 01:25:25.678479|2018-06-01 01:25:25.678479
NCT00819533|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-12-27|2009-01-08|2009-01-09|Estimate|||||||2009-12-27|2009-12-29|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety & Accuracy Study of the ActiSight Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Preliminary Safety and Accuracy of the ActiSight Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy|Completed||N/A|40|Actual|ActiViews Ltd.||1|||f||||f||||||||||2018-06-01 01:25:25.838127|2018-06-01 01:25:25.838127
NCT00819520|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2011-08-19|2009-01-08|2009-01-09|Estimate|||||||2011-08-19|2011-08-22|Estimate|February 2004||2004-02-29|August 2011|2011-08-31|October 2004|Actual|2004-10-31|September 2004|Actual|2004-09-30||Interventional|||Ivermectin in the Treatment of Head Lice|A Randomised, Double-Blind, Multicentre Study to Compare the Efficacy and Tolerability of Oral Ivermectin to Malathion 0.5% Lotion in the Treatment of Head Lice Infestation|Completed||Phase 3|812|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 01:25:25.905044|2018-06-01 01:25:25.905044
NCT00819507|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2017-05-17||2017-06-09|2009-01-08|2009-01-09|Estimate|2017-06-09|2017-07-11|Actual||||2017-06-09|2017-07-11|Actual|January 2009||2009-01-31|June 2017|2017-06-30|June 21, 2010|Actual|2010-06-21|January 2010|Actual|2010-01-31||Interventional|||VANOS Cream and Skin Barrier Function|Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis|Completed||Phase 4|25|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:25:26.021171|2018-06-01 01:25:26.021171
NCT00819494|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2010-11-17|2009-01-08|2009-01-09|Estimate|||||||2010-11-17|2010-11-18|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Role of Skin Tests for the Diagnosis of Immediate Hypersensitivity Reactions Due to Iodinated Contrast Media|Role of Skin Tests for the Diagnosis of Immediate Hypersensitivity Reactions Due to Iodinated Contrast Media|Completed||N/A|63|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-06-01 01:25:26.191207|2018-06-01 01:25:26.191207
NCT00819481|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2017-02-06|2009-01-08|2009-01-09|Estimate|||||||2017-02-06|2017-02-07|Estimate|February 2009||2009-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|January 2014|Actual|2014-01-31||Observational|||Post-Market Study of the 3DKnee™ System|Post-Market Study of the 3DKnee™ System Protocol No. PS -- 700|Active, not recruiting|||300|Anticipated|Encore Medical, L.P.|||1||f||||f||||||||||2018-06-01 01:25:26.261059|2018-06-01 01:25:26.261059
NCT00819468|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-08|2009-01-08|2009-01-09|Estimate|||||||2009-01-08|2009-01-09|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Pharmacokinetics of 20 mg Teduglutide in Subjects With Moderately Impaired Hepatic Function Compared to Healthy Subjects With Normal Hepatic Function|Pharmacokinetics of 20 mg Teduglutide in Subjects With Moderately Impaired Hepatic Function Compared to Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|NPS Pharma||2|||f||||f||||||||||2018-06-01 01:25:26.343126|2018-06-01 01:25:26.343126
NCT00819455|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2013-02-13|2009-01-08|2009-01-09|Estimate|||||||2013-02-13|2013-02-15|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Use of Information Technology in the Prevention of Diabetes|The Role of Information Technology in the Primary Prevention of Type 2 Diabetes|Completed||N/A|537|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals||2|||f||||t||||||||||2018-06-01 01:25:26.401772|2018-06-01 01:25:26.401772
NCT00819442|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-01-08|2009-01-08|2009-01-09|Estimate|||||||2009-01-08|2009-01-09|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Interventional|DESMIN||Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis|Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Ministry of Scientific Research and Information Technology, Poland||3|||f||||t||||||||||2018-06-01 01:25:26.497191|2018-06-01 01:25:26.497191
NCT00819429|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2015-05-13|2009-01-08|2009-01-09|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SASSI||Supplements and Social Skills Intervention Study|A Nutritional and Social Skills Intervention on Conduct Disorder and Hyperactivity|Completed||N/A|282|Actual|National Healthcare Group, Singapore||4|||f||||t||||||||||2018-06-01 01:25:26.565243|2018-06-01 01:25:26.565243
NCT00819416|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2010-04-13|2009-01-08|2009-01-09|Estimate|||||||2010-04-13|2010-04-14|Estimate|February 2009||2009-02-28|April 2010|2010-04-30|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|PRECISE||Fluid Resuscitation in Early Septic Shock|Five Percent Albumin Versus Normal Saline as Fluid Resuscitation Strategies for the Management of Early Suspected Septic Shock|Completed||Phase 2|47|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 01:25:26.647758|2018-06-01 01:25:26.647758
NCT00819403|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2013-02-27||2014-12-10|2009-01-08|2009-01-09|Estimate|2014-12-10|2014-12-18|Estimate||||2014-12-10|2014-12-18|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment|The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome|Completed||Phase 4|15|Actual|University of Maryland||2|||f||||f||||||||||2018-06-01 01:25:26.752298|2018-06-01 01:25:26.752298
NCT00819390|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|2014-08-26|2013-12-20|2014-10-03|2009-01-08|2009-01-09|Estimate|2014-08-26|2014-09-05|Estimate|2013-12-20|2014-01-28|Estimate|2014-10-03|2014-10-13|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional||Results are for all participants, off-ART and on-ART, who enrolled in the study.|Chloroquine for Reducing Immune Activation in HIV- Infected Individuals|A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation|Completed||Phase 2|70|Actual|AIDS Clinical Trials Group||4|||f||||t||||||||||2018-06-01 01:25:27.047344|2018-06-01 01:25:27.047344
NCT00819377|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2013-10-23|2009-01-08|2009-01-09|Estimate|||||||2013-10-23|2013-10-25|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Milrinone Inhaled in Cardiac Surgery|2- Inhaled Milrinone Prevents the Increase in Pulmonary Artery Pressure After CPB|Completed||Phase 2|124|Anticipated|Montreal Heart Institute||2|||f||||f||||||||||2018-06-01 01:25:28.281337|2018-06-01 01:25:28.281337
NCT00819364|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2009-08-10|2009-01-08|2009-01-09|Estimate|||||||2009-08-10|2009-08-11|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|August 2016|Anticipated|2016-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Early Intervention Program for Children With Autism (BCRI Model)|Early Intervention Program for Children With Autism (BCRI Model)|Unknown status|Enrolling by invitation|N/A|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:25:28.356748|2018-06-01 01:25:28.356748
NCT00819351|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2017-04-20|2009-01-08|2009-01-09|Estimate|||||||2017-04-20|2017-04-21|Actual|January 1, 2009|Actual|2009-01-01|April 2017|2017-04-30|March 2, 2016|Actual|2016-03-02|March 2, 2016|Actual|2016-03-02||Interventional|||ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase|NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion|Completed||Phase 3|650|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:25:28.412815|2018-06-01 01:25:28.412815
NCT00819338|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-08|||2012-07-03|2009-01-08|2009-01-09|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease|The Effect of n-3 Polyunsaturated Fatty Acid Supplementation in Patients With Non-alcoholic Fatty Liver Disease|Completed||Phase 2|58|Actual|University of Nottingham||2|||f||||f||||||||||2018-06-01 01:25:28.488531|2018-06-01 01:25:28.488531
NCT00819325|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-01-06|2009-01-06|2009-01-08|Estimate|||||||2009-01-06|2009-01-08|Estimate|August 2002||2002-08-31|January 2009|2009-01-31|March 2007|Actual|2007-03-31|November 2006|Actual|2006-11-30||Interventional|PPAR-G||Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients|Prevention of Neointimal Proliferation With Aggressive Reduction of Glucose Concentrations (Pioglitazone) Study -- PPAR-G -- An IVUS Pilot Feasibility Study in Type 2 Diabetic Patients.|Completed||Phase 4|50|Actual|Queen Elizabeth II Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:25:28.55185|2018-06-01 01:25:28.55185
NCT00819312|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2013-01-27|2009-01-07|2009-01-08|Estimate|||||||2013-01-27|2013-01-29|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||YAZ, Oral Contraceptive Registration in China|A Multicenter, Open-label, Single-arm Study to Investigate the Efficacy and Safety of the Oral Contraceptive YAZ (20 μg Ethinylestradiol, 3 mg Drospirenone) for 13 Cycles in 670 Healthy Chinese Female Volunteers.|Completed||Phase 3|675|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:25:28.621702|2018-06-01 01:25:28.621702
NCT00819299|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2018-01-31|2009-01-07|2009-01-08|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2008||2008-12-31|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ACI||Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes|A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay (ACI)™ ACI 7000PDT in Presbyopic Subjects|Completed||N/A|359|Actual|AcuFocus, Inc.||1|||f||||f||t|f|f|t|||Undecided||2018-06-01 01:25:28.698497|2018-06-01 01:25:28.698497
NCT00819286|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2011-12-27||2018-01-16|2009-01-07|2009-01-08|Estimate|2012-02-11|2012-03-15|Estimate||||2018-01-16|2018-02-13|Actual|November 2008||2008-11-30|January 2018|2018-01-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|RESTORE||Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain|A Prospective, Randomized-Controlled, Multicenter Study Evaluating Primary Plating in High-Risk Median Sternotomy Patients for Osteosynthesis and Pain|Completed||N/A|140|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:25:28.893019|2018-06-01 01:25:28.893019
NCT00819273|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2010-12-02|2009-01-07|2009-01-08|Estimate|||||||2010-12-02|2010-12-06|Estimate|March 2009||2009-03-31|December 2010|2010-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|CALLISTO||Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population|Investigation Into the CorrelAtion of pLasma Hs-CRP Concentrations and cardiovascuLar rISk in Korean populaTiOn|Completed|||1700|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:25:29.182872|2018-06-01 01:25:29.182872
NCT00819260|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2011-11-29||2013-05-17|2009-01-07|2009-01-08|Estimate|2013-05-17|2013-05-20|Estimate||||2013-05-17|2013-05-20|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Harmonic Scalpel Vs. Electrocautery in Breast Reduction Surgery|A Randomized Clinical Trial Comparing the Harmonic Scalpel to Electrocautery in Breast Reduction Surgery|Terminated||N/A|31|Actual|Dartmouth-Hitchcock Medical Center|We made a first analysis after 26 (intended enrollment 50) patients were enrolled and a result was strongly suggested. While the analysis was refined, 5 more patients enrolled. The study was then stopped after 31 patients enrolled.|2||Significant result achieved after enrollment of 31 of planned 50 subjects.|f||||f||||||||||2018-06-01 01:25:29.274357|2018-06-01 01:25:29.274357
NCT00819247|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2009-01-22||2011-05-18|2009-01-07|2009-01-08|Estimate|2009-03-30|2009-03-31|Estimate||||2011-05-18|2011-05-20|Estimate|March 2001||2001-03-31|May 2011|2011-05-31|August 2002|Actual|2002-08-31|May 2002|Actual|2002-05-31||Interventional|||The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer|A Six Month, Multi-centre, Open-labelled, 1:1:1 Randomised, Parallel Group Study Investigating the Efficacy and Safety of Three Dose Regimens of FE 200486 in Prostate Cancer Patients|Completed||Phase 2|129|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:25:29.508389|2018-06-01 01:25:29.508389
NCT00819234|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2013-08-12||2015-03-26|2009-01-07|2009-01-08|Estimate|2013-11-13|2013-12-05|Estimate||||2015-03-26|2015-04-15|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional||All participants who completed original study and chose to be enrolled into this extension study and were treated with study drug.|Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin|Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin in Obese and Overweight Subjects|Completed||Phase 2|274|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:25:30.480302|2018-06-01 01:25:30.480302
NCT00819221|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2018-03-28|2009-01-07|2009-01-08|Estimate|||||||2018-03-28|2018-03-29|Actual|January 5, 2009|Actual|2009-01-05|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2011|Actual|2011-11-30||Interventional|||AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours|A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx®) in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|44|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:25:32.562116|2018-06-01 01:25:32.562116
NCT00819208|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2018-05-14|2009-01-07|2009-01-08|Estimate|||||||2018-05-14|2018-05-15|Actual|December 3, 2008||2008-12-03|March 2017|2017-03-31|December 2030|Anticipated|2030-12-31|December 2029|Anticipated|2029-12-31||Interventional|||Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer|A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)|Recruiting||Phase 3|962|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 01:25:33.577404|2018-06-01 01:25:33.577404
NCT00819195|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2013-10-04|2009-01-07|2009-01-08|Estimate|||||||2013-10-04|2013-10-08|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis|Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis|Completed|||17|Actual|University of California, San Francisco|||2||f||||f||||||Samples Without DNA|"~     Peripheral blood mononuclear cells (PBMC) Serum RNA~   "|||2018-06-01 01:25:33.793468|2018-06-01 01:25:33.793468
NCT00819182|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2013-05-01||2016-02-24|2009-01-07|2009-01-08|Estimate|2014-01-14|2014-02-28|Estimate||||2016-02-24|2016-03-24|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|February 2013|Actual|2013-02-28|June 2011|Actual|2011-06-30||Interventional|||Breathe for Hot Flashes Randomized Controlled Trial|Breathe-intervention for Hot Flashes, Associated Outcomes, and Interference|Completed||N/A|218|Actual|Indiana University||3|||f||||t||||||||No|De-identified data available upon request.|2018-06-01 01:25:33.895399|2018-06-01 01:25:33.895399
NCT00819169|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06||2015-07-13|2016-11-02|2009-01-06|2009-01-08|Estimate||||2015-07-13|2015-08-03|Estimate|2016-11-02|2016-11-03|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors|A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors|Terminated||Phase 1/Phase 2|89|Actual|NantCell, Inc.||4||Sponsor decision - subjects rolled over to protocol 20101116|f||||||||||||||2018-06-01 01:25:34.560827|2018-06-01 01:25:34.560827
NCT00819156|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2009-01-22||2011-12-20|2009-01-07|2009-01-08|Estimate|2009-03-30|2009-03-31|Estimate||||2011-12-20|2011-12-28|Estimate|February 2004||2004-02-29|December 2011|2011-12-31|September 2005|Actual|2005-09-30|June 2005|Actual|2005-06-30||Interventional|||Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer|An Open-label, Randomised, Multi-centre, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Six Different Dosing Regimens in Patients With Prostate Cancer Treated for 12 Months|Completed||Phase 2|189|Actual|Ferring Pharmaceuticals||6|||f||||t||||||||||2018-06-01 01:25:34.737037|2018-06-01 01:25:34.737037
NCT00819143|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2017-06-30|2009-01-07|2009-01-08|Estimate|||||||2017-06-30|2017-07-02|Actual|December 29, 2008||2008-12-29|July 13, 2011|2011-07-13|July 13, 2011||2011-07-13|||||Observational|||Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease|Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease|Completed|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:25:36.893004|2018-06-01 01:25:36.893004
NCT00819130|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2017-11-29|2009-01-06|2009-01-08|Estimate|||||||2017-11-29|2017-12-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:25:36.948062|2018-06-01 01:25:36.948062
NCT00819117|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2010-01-06|2009-01-07|2009-01-08|Estimate|||||||2010-01-06|2010-01-07|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|INTREPID||Investigation of Transvenous Versus Epicardial Left Ventricular Stimulation Technique|INvestigation of TRansvenous Versus EPIcarDial Left Ventricular Stimulation Technique|Completed||N/A|20|Anticipated|St. Jude Medical||2|||f||||f||||||||||2018-06-01 01:25:36.987516|2018-06-01 01:25:36.987516
NCT00819104|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2009-09-07|2009-01-07|2009-01-08|Estimate|||||||2009-09-07|2009-09-09|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|||||Interventional|MARS||A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components|A Five-arm, Randomised, Open Label, Multi-centre, Prospective Study to Compare the Efficacy, Safety and Tolerability of Metoprolol XL Plus Amlodipine Combination (Selomax TM) With Metoprolol XL and Amlodipine as Individual Components in Management of Hypertension in Indian Patients.|Completed||Phase 4|402|Actual|AstraZeneca||5|||f||||f||||||||||2018-06-01 01:25:37.060713|2018-06-01 01:25:37.060713
NCT00819091|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2011-05-13||2014-06-17|2009-01-07|2009-01-08|Estimate|2011-07-01|2011-08-01|Estimate||||2014-06-17|2014-06-27|Estimate|December 2008||2008-12-31|December 2013|2013-12-31||||January 2010|Actual|2010-01-31||Interventional|||Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug|A Randomized, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 18 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control (HbA1c 7.0-10%) Despite Background Therapy With a Sulfonylurea Drug.|Completed||Phase 3|245|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:25:37.184212|2018-06-01 01:25:37.184212
NCT00819078|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2009-01-07|2009-01-07|2009-01-08|Estimate|||||||2009-01-07|2009-01-08|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|January 2014|Anticipated|2014-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Comparative Study of SR Bupropion for Adolescent Smoking Cessation|Randomized, Double-Blind, Placebo-Controlled Trial of SR Bupropion for Adolescent Smoking Cessation|Unknown status|Not yet recruiting|N/A|80|Anticipated|Geha Mental Health Center||2|||f||||f||||||||||2018-06-01 01:25:37.75288|2018-06-01 01:25:37.75288
NCT00819065|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2011-07-06|2009-01-07|2009-01-08|Estimate|||||||2011-07-06|2011-07-07|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity|Randomized Double-blind Clinical Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity|Completed||Phase 3|56|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:25:37.828849|2018-06-01 01:25:37.828849
NCT00819052|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2011-12-13||2014-11-07|2009-01-07|2009-01-08|Estimate|2012-01-23|2012-02-24|Estimate||||2014-11-07|2014-11-10|Estimate|December 2008||2008-12-31|November 2014|2014-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of treatment|Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients|An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program|Completed||Phase 3|445|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:25:37.949587|2018-06-01 01:25:37.949587
NCT00819039|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2013-12-23||2017-05-02|2009-01-07|2009-01-08|Estimate|2013-12-23|2014-02-14|Estimate||||2017-05-02|2017-06-02|Actual|January 26, 2009|Actual|2009-01-26|May 2017|2017-05-31|March 12, 2013|Actual|2013-03-12|March 12, 2013|Actual|2013-03-12||Interventional|||A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)|A Multi-center, 2-Part Study to Evaluate the Pharmacokinetics Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery|Completed||Phase 1|98|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:25:39.62481|2018-06-01 01:25:39.62481
NCT00819026|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2014-12-09|2009-01-07|2009-01-08|Estimate|||||||2014-12-09|2014-12-10|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors||Completed|||15|Actual|University of Wisconsin, Madison|||||f||||f||||||Samples Without DNA|"~     viral RNA~   "|||2018-06-01 01:25:40.104592|2018-06-01 01:25:40.104592
NCT00819013|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2011-11-01||2012-01-16|2009-01-06|2009-01-08|Estimate|2011-12-12|2012-01-16|Estimate||||2012-01-16|2012-01-19|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|FLU-A||Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Reactogenicity, and Immunogenicity of Recombinant M2e Influenza-A Vaccine Candidate ACAM FLU-A) in Healthy Adults|Completed||Phase 1|87|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 01:25:40.2026|2018-06-01 01:25:40.2026
NCT00819000|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2013-01-28|2009-01-07|2009-01-08|Estimate|||||||2013-01-28|2013-01-29|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|TOP MS||Therapy Optimization in Multiple Sclerosis (MS)|TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies|Completed|||2878|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-06-01 01:25:41.394857|2018-06-01 01:25:41.394857
NCT00818987|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2011-02-17|2009-01-06|2009-01-08|Estimate|||||||2011-02-17|2011-02-21|Estimate|November 2010||2010-11-30|February 2011|2011-02-28|October 2011|Anticipated|2011-10-31|May 2011|Anticipated|2011-05-31||Interventional|||Operative Versus Non Operative Treatment of Proximal Humerus (Shoulder Joint) Fractures|A Multicentre Prospective Randomized Control Trial on the Treatment of Three and Four Part Proximal Humerus Fractures in Patients 70 Years and Older: Comparing Open Reduction and Internal Fixation With Non Operative Treatment|Unknown status|Recruiting|Phase 1|120|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:25:41.470066|2018-06-01 01:25:41.470066
NCT00818961|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2013-03-22||2013-10-28|2009-01-07|2009-01-08|Estimate|2013-10-28|2013-12-18|Estimate||||2013-10-28|2013-12-18|Estimate|May 2005||2005-05-31|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer|Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies|Terminated||Phase 2|36|Actual|Northside Hospital, Inc.||1||terminated early due to meeting end point with fewer patients than anticipated|f||||f||||||||||2018-06-01 01:25:41.587704|2018-06-01 01:25:41.587704
NCT00818948|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-09-11|2009-01-06|2009-01-08|Estimate|||||||2014-09-11|2014-09-15|Estimate|March 2009||2009-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis|Completed||Phase 1|56|Actual|Amgen||2|||f||||f||||||||||2018-06-01 01:25:42.090904|2018-06-01 01:25:42.090904
NCT00818935|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-01-06|2009-01-06|2009-01-08|Estimate|||||||2009-01-06|2009-01-08|Estimate|June 2004||2004-06-30|January 2009|2009-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Low-Intermediate-Glycemic Index Caribbean Foods Versus High Glycemic Index Foods in Type 2 Diabetes|Glycemic Indices of Caribbean Foods and Application in Dietary Lifestyle Intervention for Management of Type 2 Diabetes Mellitus|Completed||N/A|65|Actual|University Hospital of the West Indies||2|||f||||t||||||||||2018-06-01 01:25:42.174054|2018-06-01 01:25:42.174054
NCT00818922|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2015-12-08|2009-01-06|2009-01-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:25:42.2376|2018-06-01 01:25:42.2376
NCT00818909|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2012-01-31|2009-01-07|2009-01-08|Estimate|||||||2012-01-31|2012-02-02|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Systane Clinical Experience Study|Study to Evaluate the Physical Effect of SYSTANE QID in People That Have Moderate to Severe Dry Feeling Eyes|Completed||Phase 4|941|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:25:42.268466|2018-06-01 01:25:42.268466
NCT00818896|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2012-09-18|2009-01-06|2009-01-08|Estimate|||||||2012-09-18|2012-09-19|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||Maternal Hypothyroidism in Pregnancy|A Model Statewide Trial to Detect and Treat Maternal Hypothyroidism in Pregnancy|Completed|||72|Actual|Women and Infants Hospital of Rhode Island|||||f||||t||||||Samples Without DNA|"~     Serum and urine samples from women who consent are to be stored in the freezer. Iodine~     measurements will be performed in urine samples and, possibly, serum samples. Consent is also~     asked for use of stored samples for other research purposes in the future.~   "|||2018-06-01 01:25:42.319104|2018-06-01 01:25:42.319104
NCT00818883|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2012-01-04||2012-01-04|2009-01-07|2009-01-08|Estimate|2012-01-04|2012-02-07|Estimate||||2012-01-04|2012-02-07|Estimate|February 2009||2009-02-28|January 2012|2012-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension|A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension|Completed||Phase 3|609|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:25:42.402326|2018-06-01 01:25:42.402326
NCT00818870|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2010-01-26|2009-01-06|2009-01-08|Estimate|||||||2010-01-26|2010-01-27|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH|A Randomized, Open-Label, Cross-Over, Dose-Ranging Study to Assess the Effect of Vecam 40/300 and Vecam 20/300 Administered at Bedtime Compared to Omeprazole 20 mg Administered Before Breakfast on Gastric pH|Completed||Phase 1|60|Anticipated|Vecta Ltd.||3|||f||||f||||||||||2018-06-01 01:25:43.188406|2018-06-01 01:25:43.188406
NCT00818857|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2016-06-16|2009-01-07|2009-01-08|Estimate|||||||2016-06-16|2016-06-20|Estimate|January 2009||2009-01-31|June 2016|2016-06-30|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|Get Screened||Primary Care Based Randomized Trial to Reduce Cancer Screening Disparities|Primary Care Based Randomized Trial to Reduce Cancer Screening Disparities|Completed||N/A|1072|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 01:25:43.265254|2018-06-01 01:25:43.265254
NCT00818844|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06||2015-07-27|2015-07-27|2009-01-07|2009-01-08|Estimate||||2015-07-27|2015-08-14|Estimate|2015-07-27|2015-08-14|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery||Completed||Phase 4|40|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:25:43.31681|2018-06-01 01:25:43.31681
NCT00818831|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2015-01-27|2009-01-07|2009-01-08|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2009||2009-01-31|January 2015|2015-01-31||||October 2015|Anticipated|2015-10-31||Interventional|||A Study of QBI-139 in Subjects With Advanced Solid Tumors|Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients With Refractory Malignancies|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Quintessence Biosciences, Inc.|||||f||||||||||||||2018-06-01 01:25:43.38211|2018-06-01 01:25:43.38211
NCT00818818|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2010-10-07|2009-01-06|2009-01-08|Estimate|||||||2010-10-07|2010-10-08|Estimate|August 2008||2008-08-31|October 2010|2010-10-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|Sbold||Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients|Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Infected With Leishmania (Viannia) Braziliensis in Bahia State, Brazil. An Open Uncontrolled Trial.|Completed||Phase 4|13|Actual|University of Brasilia||1|||f||||f||||||||||2018-06-01 01:25:43.443002|2018-06-01 01:25:43.443002
NCT00818805|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2009-12-03||2012-05-29|2009-01-07|2009-01-08|Estimate|2010-03-11|2010-03-15|Estimate||||2012-05-29|2012-06-04|Estimate|July 2008||2008-07-31|March 2010|2010-03-31||||July 2008|Actual|2008-07-31||Interventional|||Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)||Completed||Phase 4|50|Actual|Alcon Research|Technical problems with measurement leading to unreliable or uninterpretable data.|4|||f||||f||||||||||2018-06-01 01:25:43.650077|2018-06-01 01:25:43.650077
NCT00818792|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2013-01-14|2009-01-07|2009-01-08|Estimate|||||||2013-01-14|2013-01-15|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Interventional|RENAL-DES||Randomized Comparison of xiEnce and visioN Coronary Stents in the sAme muLtivessel Patient With Chronic kiDnEy diSease|A Multicenter, Randomized Trial to Compare Xience and Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease|Completed||Phase 2|215|Actual|European Hospital||2|||f||||t||||||||||2018-06-01 01:25:43.867485|2018-06-01 01:25:43.867485
NCT00818779|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2012-06-18||2017-10-31|2009-01-07|2009-01-08|Estimate|2012-10-18|2012-11-19|Estimate||||2017-10-31|2017-12-05|Actual|January 2008||2008-01-31|October 2017|2017-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Direct Renin Inhibition Effects on Atherosclerotic Biomarkers|Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With Stable Coronary Heart Disease and Type 2 Diabetes Mellitus|Completed||Phase 4|38|Actual|Texas Tech University Health Sciences Center|Small sample size led to large standard deviation in biomarkers assessed and limited power to detect a diffference|2|||f||||t||||||||||2018-06-01 01:25:43.955415|2018-06-01 01:25:43.955415
NCT00818766|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2016-11-23||2017-03-16|2009-01-07|2009-01-08|Estimate|2017-03-16|2017-04-26|Actual||||2017-03-16|2017-04-26|Actual|March 2008||2008-03-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||The Intent-to-Treat (ITT) Population included all participants who were randomized and received their allocated intervention. 1 participant in the antibiotic arm and 2 participants in the placebo arm were randomized twice but are only counted once (per their first randomization) in the ITT Population.|Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy|Extended Antibiotic Prophylaxis for the Prevention of Infectious Complications Associated With Tube Thoracostomy in Patients Undergoing Elective General Thoracic Surgery: A Double-Blind, Placebo-Controlled, Randomized Trial|Completed||N/A|251|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:25:44.29959|2018-06-01 01:25:44.29959
NCT00818753|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2011-08-05||2014-06-03|2009-01-07|2009-01-08|Estimate|2011-09-16|2011-10-25|Estimate||||2014-06-03|2014-06-09|Estimate|January 2009||2009-01-31|December 2013|2013-12-31||||August 2010|Actual|2010-08-31||Interventional|||Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention|The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization|Completed||Phase 2|53|Actual|Boehringer Ingelheim|Although a total of 50 patients are included in the FAS, 4 of these patients did not have data for the primary endpoint and are therefore not included in the odd ratio calculation|3|||f||||||||||||||2018-06-01 01:25:44.750115|2018-06-01 01:25:44.750115
NCT00818740|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-10-07|2009-01-07|2009-01-08|Estimate|||||||2009-10-07|2009-10-08|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Pharmacokinetic Study of ORM-12741 in Healthy Volunteers|Pharmacokinetics of ORM-12741 After Intravenous and Oral Administration and Effects of Food on ORM-12741 Pharmacokinetics; An Open, Randomised, Single Dose, Single Centre, Crossover Study in Healthy Male Subjects|Completed||Phase 1|12|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-06-01 01:25:45.207303|2018-06-01 01:25:45.207303
NCT00818727|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2009-01-07|2009-01-07|2009-01-08|Estimate|||||||2009-01-07|2009-01-08|Estimate|February 2009||2009-02-28|January 2009|2009-01-31||||January 2011|Anticipated|2011-01-31||Observational|||Bone Density of Newborn Infants to Mothers Treated With Selective Serotonin Reuptake Inhibitor (SSRI)||Unknown status|Not yet recruiting||40|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 01:25:45.287655|2018-06-01 01:25:45.287655
NCT00818714|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2015-11-30|2009-01-07|2009-01-08|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516|0516 GCC: Stereotactic Body Radiation Therapy As A Boost After Definitive Treatment With Concurrent Chemoradiation In Patients With Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|University of Maryland||1||There was no patient accrual nor study activity due to inability to fund PFTs.|f||||t||||||||||2018-06-01 01:25:45.342015|2018-06-01 01:25:45.342015
NCT00818701|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2010-09-23|2009-01-07|2009-01-08|Estimate|||||||2010-09-23|2010-09-24|Estimate|February 2009||2009-02-28|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|BNP+PDEVI||Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction|A Randomized, Double Blinded Placebo Controlled Cross-over Study of Low Dose B-type Natriuretic Peptide (Nesiritide) With or Without Concomitant Phosphodiesterase V (PDE V) Inhibition(Sildenafil) in Congestive Heart Failure Patients With Renal Dysfunction|Terminated||Phase 1|1|Actual|Mayo Clinic||2||started a NIH study that is competing for same subjects|f||||t||||||||||2018-06-01 01:25:45.419238|2018-06-01 01:25:45.419238
NCT00818688|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2009-01-12|2009-01-07|2009-01-08|Estimate|||||||2009-01-12|2009-01-13|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|January 2007|Actual|2007-01-31|October 2006|Actual|2006-10-31||Observational|POST||POST (Prospective Observational Superfial Thrombophlebitis)|Superficial Thrombophlebitis and Venous Thromboembolism: A Large Prospective Epidemiological Study|Completed|||844|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||||||2018-06-01 01:25:45.522045|2018-06-01 01:25:45.522045
NCT00818675|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|||2015-01-19|2009-01-07|2009-01-08|Estimate|||||||2015-01-19|2015-01-21|Estimate|March 2009||2009-03-31|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)|A Randomized Discontinuation Phase II Trial of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS Mutations|Terminated||Phase 2|80|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:25:45.602275|2018-06-01 01:25:45.602275
NCT00818662|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2014-06-27||2017-10-19|2009-01-07|2009-01-08|Estimate|2014-10-23|2014-10-28|Estimate||||2017-10-19|2017-11-24|Actual|December 2008||2008-12-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease|A Randomized, Double-Blind, Placebo-Controlled, Two Dose Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease|Completed||Phase 3|390|Actual|Shire||4|||f||||t||||||||||2018-06-01 01:25:45.766882|2018-06-01 01:25:45.766882
NCT00818649|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2013-01-17||2017-12-03|2009-01-07|2009-01-08|Estimate|2013-01-17|2013-02-25|Estimate||||2017-12-03|2017-12-28|Actual|January 2009||2009-01-31|December 2017|2017-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia|Phase II Trial of Velcade Plus Vorinostat in the Treatment of High Risk MDS and Relapsed/Refractory AML|Terminated||Phase 2|16|Actual|Masonic Cancer Center, University of Minnesota||1||Met protocol stop rule [i.e., extreme toxicity]|f||||t||||||||||2018-06-01 01:25:47.361931|2018-06-01 01:25:47.361931
NCT00818636|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2015-01-26|2009-01-06|2009-01-08|Estimate|||||||2015-01-26|2015-01-27|Estimate|August 2008||2008-08-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|March 2010|Actual|2010-03-31||Interventional|||Expressive Writing for Co-Occurring Depression and Alcohol Misuse|Expressive Writing for Co-Occurring Depression and Alcohol Misuse|Completed||N/A|89|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 01:25:47.557119|2018-06-01 01:25:47.557119
NCT00818623|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-07|2009-01-22||2011-05-18|2009-01-07|2009-01-08|Estimate|2009-03-30|2009-03-31|Estimate||||2011-05-18|2011-05-23|Estimate|November 2002||2002-11-30|May 2011|2011-05-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients|An Open-Label, Multi-Center, Parallel and Sequential, Ascending Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486 in Prostate Cancer Patients|Completed||Phase 2|172|Actual|Ferring Pharmaceuticals||8|||f||||f||||||||||2018-06-01 01:25:49.807532|2018-06-01 01:25:49.807532
NCT00818610|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2013-04-24|2009-01-06|2009-01-07|Estimate|||||||2013-04-24|2013-04-25|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|BICAP||Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia|Beta-lactam Monotherapy Versus Beta-lactam - Macrolide Association as Empiric Antibiotherapy Strategies in Non-severe Hospitalized Community-acquired Pneumonia: a Randomized, Non-inferiority, Open Trial.|Completed||Phase 4|601|Actual|Swiss National Fund for Scientific Research||2|||f||||t||||||||||2018-06-01 01:25:51.935579|2018-06-01 01:25:51.935579
NCT00818597|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2009-01-06|2009-01-06|2009-01-07|Estimate|||||||2009-01-06|2009-01-07|Estimate|December 2003||2003-12-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|April 2004|Actual|2004-04-30||Interventional|EISS-1||Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients|PhaseI/II Study of the Safety and Efficacy of the Use of Granulocyte-Concentrates Applied in Extracorporeal Circulation Devices-the EISS-1 Study|Completed||Phase 1/Phase 2|10|Actual|University of Rostock||1|||f||||f||||||||||2018-06-01 01:25:52.019659|2018-06-01 01:25:52.019659
NCT00818584|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2013-03-04|2009-01-06|2009-01-07|Estimate|||||||2013-03-04|2013-03-06|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates|A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates|Completed||Phase 1|13|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:25:52.087282|2018-06-01 01:25:52.087282
NCT00818571|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06||2015-05-20|2016-01-12|2009-01-06|2009-01-07|Estimate||||2016-01-12|2016-02-05|Estimate|2016-01-12|2016-02-05|Estimate|December 2008||2008-12-31|January 2016|2016-01-31||||May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients|An Open-label, Parallel Group Study to Determine the PK of 25 and 50 mg OD Single and Multiple Dose Over 14 Days, of Vildagliptin and Its Metabolites in Renal Impaired Patients Compared to Matching Healthy Volunteers|Completed||Phase 1/Phase 2|96|Actual|Novartis||4|||f||||||||||||||2018-06-01 01:25:52.172743|2018-06-01 01:25:52.172743
NCT00818558|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-12-07|2009-01-06|2009-01-07|Estimate|||||||2011-12-07|2011-12-08|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||The Method ISET (Insulation by Size of Epithelial Tumor Cells)|Evaluation of the Value Forecasts of the Identification of the Circulating Tumoral Cells (CTC) in the Broncho-lung Carcinomas Not in Small Cells of Stages I and II by the Method ISET (Insulation by Size of Epithelial Tumor Cells)|Unknown status|Recruiting|N/A|520|Anticipated|Centre Hospitalier Universitaire de Nice||6|||f||||||||||||||2018-06-01 01:25:52.245826|2018-06-01 01:25:52.245826
NCT00818545|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-01-06|2009-01-06|2009-01-07|Estimate|||||||2009-01-06|2009-01-07|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Transcriptomic Study of ER 4017 Topical Application in Elderly Subject|Transcriptomic Study of ER 4017 Topical Application in Elderly Subject|Completed||N/A|10|Actual|L'Oreal||2|||f||||t||||||||||2018-06-01 01:25:52.312817|2018-06-01 01:25:52.312817
NCT00818532|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2012-04-06|2009-01-06|2009-01-07|Estimate|||||||2012-04-06|2012-04-09|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Corneal Astigmatism Measurement Study||Completed|||50|Actual|Alcon Research|||1||f||||f||||||||||2018-06-01 01:25:52.404536|2018-06-01 01:25:52.404536
NCT00818519|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2011-04-06||2015-08-12|2009-01-06|2009-01-07|Estimate|2011-05-10|2011-06-09|Estimate||||2015-08-12|2015-08-25|Estimate|December 2008||2008-12-31|August 2015|2015-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||GA YAZ ACNE in China Phase III|A Multicenter, Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of an Oral Contraceptive Preparation YAZ (Drospirenone 3 mg / Ethinylestradiol 20 µg) for 6 Treatment Cycles in Women With Moderate Acne|Completed||Phase 3|179|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:25:52.5531|2018-06-01 01:25:52.5531
NCT00818506|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2012-11-20|2009-01-06|2009-01-07|Estimate|||||||2012-11-20|2012-11-21|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|||||Observational|||Associations Between Depression and Cardiovascular Disease - a Study of Patients With Late Onset Depression|Associations Between Depression and Cardiovascular Disease in Patients With Late Onset, Single Episode Major Depressive Disorder|Completed|||55|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 01:25:52.942976|2018-06-01 01:25:52.942976
NCT00818493|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06||2010-08-25|2012-05-15|2009-01-06|2009-01-07|Estimate||||2010-08-25|2010-08-30|Estimate|2012-05-15|2012-05-17|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty|An Open-Label Pilot Study of the Analgesic Efficacy and Safety Of Q8003 and of the Conversion From IV Morphine PCA Analgesia to Q8003 or to Percocet® in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty or Total Hip Arthroplasty|Completed||Phase 2|44|Actual|QRxPharma Inc.||3|||f||||f||||||||||2018-06-01 01:25:53.028103|2018-06-01 01:25:53.028103
NCT00818480|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06||2015-08-20|2015-08-20|2009-01-06|2009-01-07|Estimate||||2015-08-20|2015-09-04|Estimate|2015-08-20|2015-09-04|Estimate|February 2006||2006-02-28|August 2015|2015-08-31|August 2012|Actual|2012-08-31|March 2011|Actual|2011-03-31||Interventional|||An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155|Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155|Completed||Phase 2|10|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 01:25:53.101343|2018-06-01 01:25:53.101343
NCT00818467|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-11-27|2009-01-06|2009-01-07|Estimate|||||||2009-11-27|2009-12-01|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|Sunscreen||UVB Light and Sunscreen|3% Dihydroxyacetone (DHA or Sunless Tanning Agent) Inhibits Vitamin D Production in the Skin in Response to Ultraviolet Light|Completed||Phase 4|50|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 01:25:53.16976|2018-06-01 01:25:53.16976
NCT00818454|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2010-09-21||2014-01-21|2009-01-06|2009-01-07|Estimate|2010-10-26|2010-11-23|Estimate||||2014-01-21|2014-02-14|Estimate|December 2008||2008-12-31|January 2014|2014-01-31||||September 2009|Actual|2009-09-30||Interventional|||4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma|A Multicenter Randomized Study Starting With a 4 Week 2 Way Crossover Double Blind Treatment Phase Comparing the Efficacy and Safety of Combivent CFC MDI to Albuterol HFA MDI Followed by a 4 Week Open Label Combivent Respimat Treatment Phase When All Study Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma (GINA 2007 Treatment Steps 3-5)|Completed||Phase 2|226|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:25:53.259466|2018-06-01 01:25:53.259466
NCT00818441|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2016-04-25|2013-05-21|2016-04-25|2009-01-06|2009-01-07|Estimate|2016-04-25|2016-06-01|Estimate|2013-05-21|2013-05-29|Estimate|2016-04-25|2016-06-01|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2012|Actual|2012-04-30||Interventional|||Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung|A Phase 2, Open-Label Trial Of Dacomitinib (PF-00299804) In Selected Patients With Advanced Adenocarcinoma Of The Lung|Completed||Phase 2|119|Actual|Pfizer|Results have been included for Cohort B and updated for Cohort A since the Primary completion date.|2|||f||||f||||||||||2018-06-01 01:25:53.993998|2018-06-01 01:25:53.993998
NCT00818428|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2009-09-22|2009-01-05|2009-01-07|Estimate|||||||2009-09-22|2009-09-23|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|ECRIP||Randomized Clinical Trial of Phonological Interventions|The Contribution of a Speech Perception Intervention to the Prevention of Phonological Awareness Deficits in Children With Speech Sound Disorders|Unknown status|Recruiting|Phase 2/Phase 3|96|Anticipated|McGill University||4|||f||||f||||||||||2018-06-01 01:25:55.429216|2018-06-01 01:25:55.429216
NCT00818415|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2014-05-16|2009-01-06|2009-01-07|Estimate|||||||2014-05-16|2014-05-19|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Naproxen Sodium ER Pharmacokinetic Study|An Open Label, Randomised Two Way Crossover Trial to Determine the Pharmacokinetic Profile of an Extended Release Naproxen Sodium Tablet Relative to Aleve Tablets Following Single and Multiple Dose Administration Under Fed Conditions.|Completed||Phase 1|32|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:25:55.521362|2018-06-01 01:25:55.521362
NCT00818402|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-05-28|2009-01-06|2009-01-07|Estimate|||||||2015-05-28|2015-05-29|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|SILKE||Non-small Cell Lung Cancer and Quality of Life|Treatment of Non-small Cell Lung Cancer -Effects on Quality of Life and Symptom Control|Completed|||130|Actual|University of Turku|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:25:55.704575|2018-06-01 01:25:55.704575
NCT00818389|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2010-05-10||2011-03-18|2009-01-06|2009-01-07|Estimate|2011-03-18|2011-04-19|Estimate||||2011-03-18|2011-04-19|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|Terminated||Phase 2/Phase 3|84|Actual|Massachusetts General Hospital||2||"NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of~   84 subjects."|f||||t||||||||||2018-06-01 01:25:55.785133|2018-06-01 01:25:55.785133
NCT00818376|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-01-29|2009-01-06|2009-01-07|Estimate|||||||2009-01-29|2009-01-30|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|November 2006|Actual|2006-11-30||Interventional|||Staining and Calculus Formation After 0.12% Chlorhexidine Rinses|Staining And Calculus Formation After 0.12% Chlorhexidine Rinses In Plaque-Free And Plaque-Covered Surfaces. A Randomized Trial.|Completed||Phase 2|20|Actual|Lutheran University of Brazil|||||f||||t||||||||||2018-06-01 01:25:56.319405|2018-06-01 01:25:56.319405
NCT00818363|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05||2010-02-04|2014-08-20|2009-01-06|2009-01-07|Estimate||||2010-02-04|2010-02-08|Estimate|2014-08-20|2014-08-22|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Safety and Effectiveness Study of SABER™-Bupivacaine for Pain Following Shoulder Surgery|A Double-Blind, Multi-Center, Placebo-Controlled Trial of SABER™-Bupivacaine for Post-Operative Pain Control and Opioid Sparing/Opioid-Related Adverse Event Reduction Following Arthroscopic Shoulder Surgery|Completed||Phase 2|60|Actual|Durect||2|||f||||f||||||||||2018-06-01 01:25:56.403913|2018-06-01 01:25:56.403913
NCT00818350|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2009-01-06|2009-01-06|2009-01-07|Estimate|||||||2009-01-06|2009-01-07|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|January 2011|Anticipated|2011-01-31|August 2009|Anticipated|2009-08-31||Interventional|||Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer|Phase II Study of Sunitinib in Metastatic and Pretreated Urothelial Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|25|Actual|Campania Younger Oncologists Association||1|||f||||f||||||||||2018-06-01 01:25:56.497389|2018-06-01 01:25:56.497389
NCT00818337|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2011-08-08||2012-11-06|2009-01-06|2009-01-07|Estimate|2012-11-06|2012-12-04|Estimate||||2012-11-06|2012-12-04|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Aspirin Responsiveness in Women at Risk for Cardiac Events|Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study.|Completed||Phase 4|36|Actual|Creighton University||1|||f||||t||||||||||2018-06-01 01:25:56.568109|2018-06-01 01:25:56.568109
NCT00818324|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-04|2014-01-07||2014-01-07|2009-01-05|2009-01-07|Estimate|2014-01-07|2014-02-26|Estimate||||2014-01-07|2014-02-26|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Long Term Administration Study of OPC-12759 Ophthalmic Suspension|Long Term Administration Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients|Completed||Phase 3|154|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:25:56.736433|2018-06-01 01:25:56.736433
NCT00818311|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-01-06|2009-01-06|2009-01-07|Estimate|||||||2009-01-06|2009-01-07|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Skin Safety Profile of Different Exposure to the Light Emitting Diode (LED) in Healthy Subjects|Evaluation of the Effect of Photomodulation on Skin Safety Profile Following Different Schedules of Exposure to the Light Emitting Diode LED (Gentlewaves®) in Randomized Healthy Subjects|Completed||N/A|100|Actual|L'Oreal||1|||f||||t||||||||||2018-06-01 01:25:56.964069|2018-06-01 01:25:56.964069
NCT00818298|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2012-07-06|2009-01-06|2009-01-07|Estimate|||||||2012-07-06|2012-07-09|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study|24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study|Completed||N/A|12|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||||2018-06-01 01:25:57.034875|2018-06-01 01:25:57.034875
NCT00818285|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2017-03-21|2009-01-05|2009-01-07|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2008||2008-09-30|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Reducing Injuries From Medication-Related Falls Using Computerized Alerts for High Risk Patients|Reducing Injuries From Medication-Related Falls by Generating Targeted Computerized Alerts for High Risk Patients Within an Electronic Prescribing System|Recruiting||N/A|4800|Anticipated|McGill University||2|||f||||f||||||||Undecided||2018-06-01 01:25:57.114291|2018-06-01 01:25:57.114291
NCT00818272|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2011-12-22||2015-09-02|2009-01-06|2009-01-07|Estimate|2011-12-22|2012-02-01|Estimate||||2015-09-02|2015-09-03|Estimate|December 2002||2002-12-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)|Remicade Safety Line (Crohn's Disease)|Completed|||148|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:25:57.184076|2018-06-01 01:25:57.184076
NCT00818259|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2014-10-02||2017-05-02|2009-01-06|2009-01-07|Estimate|2014-11-14|2014-11-18|Estimate||||2017-05-02|2017-06-02|Actual|February 5, 2009|Actual|2009-02-05|May 2017|2017-05-31|January 20, 2014|Actual|2014-01-20|January 20, 2014|Actual|2014-01-20||Interventional||For analysis purposes, baseline (BL) data are presented by study part groups. The BL analysis population includes all unique enrolled participants in Parts I, II, III, IV and V. Part III participants who entered Parts IV and V are only counted in Part III; Part IV participants who entered Part V are only counted in Part IV.|A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)|A Multicenter, Open-Label, 5-Part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Aprepitant and Fosaprepitant Dimeglumine in Pediatric Patients Receiving Emetogenic Chemotherapy|Terminated||Phase 1|92|Actual|Merck Sharp & Dohme Corp.||7||"Study terminated early prior to completing targeted enrollment of participants <6 months of age~   due to recruitment challenges."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:25:57.366744|2018-06-01 01:25:57.366744
NCT00818246|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2009-01-07||2009-10-07|2009-01-06|2009-01-07|Estimate|2009-10-07|2009-11-16|Estimate||||2009-10-07|2009-11-16|Estimate||||October 2009|2009-10-31||||||||Interventional|||Light Emitting Diode (LED) for the Treatment of Wrinkles|Non-ablative Light Source for the Treatment of Rhytides (Wrinkles)|Completed||Phase 2/Phase 3|40|Actual|RoseLab Skin Optics Laboratory||2|||f||||f||||||||||2018-06-01 01:25:58.840837|2018-06-01 01:25:58.840837
NCT00818233|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2016-05-11|2009-01-06|2009-01-07|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2009||2009-01-31|May 2016|2016-05-31||||||||Observational|||Intra-observer and Inter-observer Variability With Dynamic Contour Tonometry.|Intra-observer and Inter-observer Variability With Dynamic Contour Tonometry.|Withdrawn|||0|Actual|Yale University|||1|Difficulty recruiting patients. PI left research facility.|f||||t||||||||||2018-06-01 01:25:59.011367|2018-06-01 01:25:59.011367
NCT00818220|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-05-26|2009-01-06|2009-01-07|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Protective Effects of Delayed Cord Clamping in Very Low Birth Weight (VLBW) Infants|Protective Effects of Delayed Cord Clamping in VLBW Infants|Completed||Phase 2|211|Actual|University of Rhode Island||2|||f||||t||||||||||2018-06-01 01:25:59.073964|2018-06-01 01:25:59.073964
NCT00818207|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2012-02-29||2012-02-29|2009-01-06|2009-01-07|Estimate|2012-02-29|2012-03-30|Estimate||||2012-02-29|2012-03-30|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|ACCESSATION||Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit|A Pragmatic, Randomized, Controlled Study Evaluating The Impact Of Access To Smoking Cessation Treatment Reimbursement On The Proportion Of Successful Quitters In A Canadian Population Of Smokers Motivated To Quit|Completed||Phase 4|1380|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:25:59.242926|2018-06-01 01:25:59.242926
NCT00818194|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2014-07-07|2009-01-06|2009-01-07|Estimate|||||||2014-07-07|2014-07-09|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers|A Comparison of Effects of Short-term Low Dose Exposure of Advagraf® and Neoral® Microemulsion Cyclosporine A on Renal Perfusion and Function in Healthy Volunteers|Completed||Phase 1|18|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:25:59.784201|2018-06-01 01:25:59.784201
NCT00818181|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2013-03-08|2009-01-06|2009-01-07|Estimate|||||||2013-03-08|2013-03-11|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|August 2010|Actual|2010-08-31|February 2009|Actual|2009-02-28||Interventional|||Open Label Safety Study of a Birch Pollen Allergen Extract|A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy|Completed||Phase 2|73|Actual|Allergopharma GmbH & Co. KG||1|||f||||||||||||||2018-06-01 01:25:59.866561|2018-06-01 01:25:59.866561
NCT00818168|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2011-12-22||2015-09-02|2009-01-06|2009-01-07|Estimate|2011-12-22|2012-02-01|Estimate||||2015-09-02|2015-09-03|Estimate|July 2003||2003-07-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)|Remicade Safety Line (Ankylosing Spondylitis)|Completed|||320|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:25:59.947964|2018-06-01 01:25:59.947964
NCT00818155|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2013-01-28|2009-01-06|2009-01-07|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Desvenlafaxine Succinate Sustained Release Administered Orally to Healthy Chinese Subjects.|Completed||Phase 1|36|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:26:00.132615|2018-06-01 01:26:00.132615
NCT00818142|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-11-30|2009-01-05|2009-01-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder|Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder|Completed|||16|Actual|HealthPartners Institute|||1||f||||f||||||||||2018-06-01 01:26:00.184977|2018-06-01 01:26:00.184977
NCT00818129|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2009-07-22|2009-01-06|2009-01-07|Estimate|||||||2009-07-22|2009-07-23|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|||||Interventional|||Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese|A Phase I, Randomized, Double-Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7295 Following Single and Multiple Ascending Oral Dose Administration in Healthy Male Japanese Subjects|Completed||Phase 1|62|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:26:00.244098|2018-06-01 01:26:00.244098
NCT00818116|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2010-06-30||2010-06-30|2009-01-06|2009-01-07|Estimate|2010-06-30|2010-07-30|Estimate||||2010-06-30|2010-07-30|Estimate|December 2008||2008-12-31|June 2010|2010-06-30||||July 2009|Actual|2009-07-31||Interventional|||Visual Function Evaluation of Bilateral AcrySof ReSTOR Aspheric IOL|Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric Intraocular Lens (IOL): Postmarket Evaluation|Completed||Phase 4|34|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:26:00.302045|2018-06-01 01:26:00.302045
NCT00818103|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2009-09-27|2009-01-05|2009-01-07|Estimate|||||||2009-09-27|2009-09-29|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Characteristic Study on Chinese Patients With Multiple Sclerosis|Characteristic Study on Chinese Patients With Multiple Sclerosis|Unknown status|Recruiting|N/A|600|Anticipated|Sun Yat-sen University||1|||t||||||||||||||2018-06-01 01:26:00.411792|2018-06-01 01:26:00.411792
NCT00818090|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2013-04-11|2009-01-06|2009-01-07|Estimate|||||||2013-04-11|2013-04-12|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Paclitaxel and Cisplatin for Thymic Neoplasm|A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma|Terminated||Phase 2|39|Actual|Korean Cancer Study Group||1||marginal statistical significance|f||||f||||||||||2018-06-01 01:26:00.480045|2018-06-01 01:26:00.480045
NCT00818077|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-11-30|2009-01-06|2009-01-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|September 2010|Actual|2010-09-30|July 2008|Actual|2008-07-31||Observational|||Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food|Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food|Completed|||15|Actual|HealthPartners Institute|||1||f||||f||||||||||2018-06-01 01:26:00.539199|2018-06-01 01:26:00.539199
NCT00818064|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2017-02-08|2009-01-06|2009-01-07|Estimate|||||||2017-02-08|2017-02-09|Estimate|December 2008||2008-12-31|February 2017|2017-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Single- Dose, Dose-escalation Trial of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis|Completed||Phase 1|32|Anticipated|Novo Nordisk A/S||8|||f||||f||||||||||2018-06-01 01:26:00.598989|2018-06-01 01:26:00.598989
NCT00818051|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2011-01-06|2009-01-06|2009-01-07|Estimate|||||||2011-01-06|2011-01-07|Estimate|August 2008||2008-08-31|January 2009|2009-01-31||||||||Interventional|||Radiation Therapy in Treating Women Who Have Undergone Breast Conservation Surgery and Systemic Therapy for Early Breast Cancer|Randomized Trial Testing Dose Escalated Intensity Modulated Radiotherapy for Women Treated by Breast Conservation Surgery and Appropriate Systemic Therapy for Early Breast Cancer|Unknown status|Recruiting|Phase 3|840|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 01:26:00.681807|2018-06-01 01:26:00.681807
NCT00818038|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2014-06-25|2009-01-06|2009-01-07|Estimate|||||||2014-06-25|2014-06-27|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|TRUST||A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function|Phase IV, Proof of Concept Study to Evaluate Tysabri Effectiveness in RRMS Patient Bladder Function|Completed|||30|Actual|Biogen|||1||f||||f||||||||||2018-06-01 01:26:00.744318|2018-06-01 01:26:00.744318
NCT00818025|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2016-09-29|2009-01-06|2009-01-07|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparing Methods for Tracking Health Information at Home After Lung Transplant|Phase III Trial of Pocket PATH: A Computerized Intervention to Promote Self-Care|Completed||N/A|211|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:26:00.962238|2018-06-01 01:26:00.962238
NCT00818012|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2014-08-11|2009-01-06|2009-01-07|Estimate|||||||2014-08-11|2014-08-12|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|APPRAISE||Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation|Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation In Patients Undergoing Successful Electrical Cardioversion to Sinus Rhythm|Completed|||129|Actual|Creighton University|||||f||||f||||||||||2018-06-01 01:26:01.030525|2018-06-01 01:26:01.030525
NCT00817999|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2011-08-08||2012-08-28|2009-01-06|2009-01-07|Estimate|2012-08-28|2012-10-01|Estimate||||2012-08-28|2012-10-01|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Impact of Grapefruit Juice on the Response to Clopidogrel|The Impact of Grapefruit Juice on the Response to a Loading Dose and Maintenance Dose of Clopidogrel in Healthy Volunteers|Completed||Phase 4|32|Actual|Creighton University||2|||f||||t||||||||||2018-06-01 01:26:01.101579|2018-06-01 01:26:01.101579
NCT00817986|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06||2010-09-08|2016-09-09|2009-01-06|2009-01-07|Estimate||||2010-09-10|2010-09-14|Estimate|2016-09-09|2016-09-23|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms|Completed||Phase 2|161|Actual|Indivior Inc.||4|||f||||f||||||||No||2018-06-01 01:26:01.30647|2018-06-01 01:26:01.30647
NCT00817973|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-01-08|2009-01-06|2009-01-07|Estimate|||||||2009-01-08|2009-01-09|Estimate||||January 2009|2009-01-31||||||||Interventional|||Differential Effects of Protein Quality on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes: Comparison of Whey, Casein, Gluten, and Cod Protein|Differential Effects of Protein Quality on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes: Comparison of Whey, Casein, Gluten, and Cod Protein|Completed||N/A|12|Actual|Aarhus University Hospital||4|||f||||f||||||||||2018-06-01 01:26:01.415338|2018-06-01 01:26:01.415338
NCT00817960|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2012-06-19|2009-01-06|2009-01-07|Estimate|||||||2012-06-19|2012-06-20|Estimate|July 2011||2011-07-31|December 2008|2008-12-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Effects of Ritalin on Postural Stability of Old Adults|Effects of Methylphenidate on Postural Stability of Old Adults Under Single and Dual Task Conditions.|Completed||N/A|30|Actual|Soroka University Medical Center||1|||f||||t||||||||||2018-06-01 01:26:01.486188|2018-06-01 01:26:01.486188
NCT00817947|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2009-01-06|2009-01-06|2009-01-07|Estimate|||||||2009-01-06|2009-01-07|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Airway Clearance Using High Frequency Chest Wall Oscillation|An Assessment of the Short-Term Effects of the Airway Clearance Technique of High Frequency Chest Wall Oscillation in People With Cystic Fibrosis|Completed||Phase 3|30|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:26:01.631427|2018-06-01 01:26:01.631427
NCT00817934|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2009-01-06|2009-01-06|2009-01-07|Estimate|||||||2009-01-06|2009-01-07|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|ABP||Safe, Effective, and More Tolerable 16 Tablets Colon Prep|Phase III of the AB Prep Safety and Efficacy in Colon Cleansing|Unknown status|Active, not recruiting||400|Anticipated|Long Neck Medical Enterprises|||1||f||||t||||||||||2018-06-01 01:26:01.70691|2018-06-01 01:26:01.70691
NCT00817921|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2014-02-04|2009-01-06|2009-01-07|Estimate|||||||2014-02-04|2014-02-05|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|SUIVIREIN||Effect of Prematurity on Renal Function in 5 Years Old Children|Effect of Prematurity on Renal Function in 5 Years Old Children Comparison of Former Premature Children Treated by Ibuprofen in the Neonatal Period to Controls|Completed|||168|Actual|Maternite Regionale Universitaire|||3||f||||f||||||Samples Without DNA|"~     Blood and urine samples~   "|||2018-06-01 01:26:01.78208|2018-06-01 01:26:01.78208
NCT00817908|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-04-20|2009-01-06|2009-01-07|Estimate|||||||2012-04-20|2012-04-23|Estimate|May 2008||2008-05-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Observational|||Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients|Quantiferon - CMV and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients|Completed|||131|Actual|University of Alberta|||1||f||||f||||||||||2018-06-01 01:26:01.858129|2018-06-01 01:26:01.858129
NCT00817895|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-04|||2016-03-29|2009-01-06|2009-01-07|Estimate|||||||2016-03-29|2016-03-31|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence|Clinical Randomized Control Trial of Intraoperative Implanting Chemotherapeutic Drugs Sustained Release Following Resection of Hepatocellular Carcinoma Against Postoperative Short-term Recurrence|Completed||N/A|150|Actual|Eastern Hepatobiliary Surgery Hospital||3|||f||||t||||||||||2018-06-01 01:26:01.925256|2018-06-01 01:26:01.925256
NCT00817882|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2010-11-22|2009-01-06|2009-01-07|Estimate|||||||2010-11-22|2010-11-23|Estimate|May 2009||2009-05-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Working Well With Back Pain (Feasibility RCT of Vocational Rehabilitation)|Changing Perceptions of Work Ability in People With Low Back Pain: Feasibility Randomised Controlled Trial and Economic Evaluation.|Completed||Phase 1/Phase 2|52|Actual|University of Nottingham||2|||f||||f||||||||||2018-06-01 01:26:02.008873|2018-06-01 01:26:02.008873
NCT00817869|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2014-11-28|2009-01-06|2009-01-07|Estimate|||||||2014-11-28|2014-12-02|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The HIP-HOP Flooring Study: Helping Injury Prevention in Hospitalised Older People|Pilot Cluster Randomised Controlled Trial of Flooring to Reduce Injuries From Falls in Elderly Care Units|Completed||N/A|571|Actual|University of Portsmouth||2|||f||||f||||||||||2018-06-01 01:26:02.096636|2018-06-01 01:26:02.096636
NCT00817843|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|2012-06-18||2013-01-04|2009-01-06|2009-01-07|Estimate|2013-01-04|2013-01-09|Estimate||||2013-01-04|2013-01-09|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PANACEA||The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study|Multicenter,Double Blind,Randomized, 2-period, Crossover Study to Compare Ezetimibe/Simvastatin (10mg/10 mg) Combination Tablet Versus Simvastatin 80mg Tablet on Postprandial Arterial Endothelial Function in Patients With Metabolic Syndrome|Completed||Phase 4|100|Actual|UMC Utrecht|One limitation is that the study was conducted in obese patients with the metabolic syndrome.|2|||f||||f||||||||||2018-06-01 01:26:02.213275|2018-06-01 01:26:02.213275
NCT00817830|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-07-15|2009-01-06|2009-01-07|Estimate|||||||2015-07-15|2015-07-16|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|October 2009||2009-10-31|May 2009||2009-05-31||Interventional|||Cardiovascular Safety Study of Lodenafil Carbonate in Patients With Coronaropathy During Physical Effort|Cardiovascular Safety Evaluation in Patients With Coronary Artery Disease During Physical Effort After Use Lodenafil Carbonate|Withdrawn||Phase 4|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||1||Difficulty in patient recruitment|f||||t||||||||||2018-06-01 01:26:02.463542|2018-06-01 01:26:02.463542
NCT00817817|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-06|||2017-03-27|2009-01-06|2009-01-07|Estimate|||||||2017-03-27|2017-03-28|Actual|October 1, 2002|Actual|2002-10-01|March 2017|2017-03-31|May 1, 2003|Actual|2003-05-01|May 1, 2003|Actual|2003-05-01||Interventional|||A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)|An Open-Label, Comparative, Randomized, Parallel, Multicenter Study to Determine the Efficacy and Safety of Two Dry Powder Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma|Completed||Phase 3|93|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:26:02.539495|2018-06-01 01:26:02.539495
NCT00817804|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-03|2009-05-05||2009-08-12|2009-01-05|2009-01-06|Estimate|2009-06-28|2009-08-12|Estimate||||2009-08-12|2009-08-19|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Cross-over Comparison of the V60 System to Other Bi-Level Noninvasive Ventilators|Cross-over Comparison of the V60 System to Other Bi-Level Noninvasive Ventilators for Pediatric Patients With Respiratory Failure or Respiratory Insufficiency|Completed||N/A|3|Actual|Respironics, California, Inc.|Terminated before 20 patients enrolled|2|||f||||f||||||||||2018-06-01 01:26:02.614249|2018-06-01 01:26:02.614249
NCT00817791|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-06-12|2009-01-05|2009-01-06|Estimate|||||||2009-06-12|2009-06-15|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|||Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery|Phase 1 Study of Protective Effect of Hyperbaric Oxygen Preconditioning on Brain and Myocardium Injury During CABG Surgery|Completed||N/A|49|Actual|Xijing Hospital||1|||f||||t||||||||||2018-06-01 01:26:02.813409|2018-06-01 01:26:02.813409
NCT00817778|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2012-07-24||2012-10-16|2009-01-05|2009-01-06|Estimate|2012-10-16|2012-11-16|Estimate||||2012-10-16|2012-11-16|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin|A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin|Completed||Phase 2|27|Actual|AstraZeneca|"The primary objective of the study was to assess safety and tolerability and hence the study was not sized based on statistical considerations. The most import outcome, no safety or tolerability concerns were identified, is not a numerical variable"|2|||f||||f||||||||||2018-06-01 01:26:02.885211|2018-06-01 01:26:02.885211
NCT00817765|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2009-11-27|2009-01-05|2009-01-06|Estimate|||||||2009-11-27|2009-12-01|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|EPOS||Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir|Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir|Completed||Phase 1|24|Anticipated|Radboud University||3|||f||||f||||||||||2018-06-01 01:26:03.277273|2018-06-01 01:26:03.277273
NCT00817752|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2010-03-17|2009-01-02|2009-01-06|Estimate|||||||2010-03-17|2010-03-18|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation|Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation|Completed||Phase 1|25|Actual|National University of Natural Medicine||1|||f||||t||||||||||2018-06-01 01:26:03.506792|2018-06-01 01:26:03.506792
NCT00817739|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-07-27|2009-01-05|2009-01-06|Estimate|||||||2015-07-27|2015-07-29|Estimate|December 1996||1996-12-31|July 2015|2015-07-31|December 2008|Actual|2008-12-31|September 2005|Actual|2005-09-30||Interventional|||Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c|Intermittent Hormonal Therapy With Leuprorelin (3.75 mg SR) and Flutamide in the Treatment of Stage D2 or Tx Nx M1 ≠ M1a Metastatic Cancer of the Prostate|Completed||Phase 2|341|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:26:03.593975|2018-06-01 01:26:03.593975
NCT00817726|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2018-05-01|2009-01-05|2009-01-06|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2009||2009-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|RBD6YR||RBD Longitudinal as Prognostic for PD|A Natural History Analysis of Rapid Eye Movement Sleep Behavior Disorder as Prognostic for Parkinson's Disease|Recruiting|||240|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f||||||Samples With DNA|"~     blood (serum)~   "|No||2018-06-01 01:26:03.671366|2018-06-01 01:26:03.671366
NCT00817713|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-02-15|2009-01-05|2009-01-06|Estimate|||||||2011-02-15|2011-02-16|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?|Can Anthelminthic Treatment Delay the Progression of HIV? Randomised Open-label Trial Testing Presumptive Anthelminthic Treatment on Progression of HIV in ART-naïve HIV-positive Patients in a Rural African Setting With Presumed High Prevalence of Helminth Infections.|Terminated||N/A|295|Actual|Swiss Tropical & Public Health Institute||2||"Terminated prematurely due to recruitment difficulties. Expansion to more study sites not~   planned."|f||||f||||||||||2018-06-01 01:26:03.749297|2018-06-01 01:26:03.749297
NCT00817700|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2017-01-09|2009-01-05|2009-01-06|Estimate|||||||2017-01-09|2017-01-11|Estimate|April 2005||2005-04-30|January 2017|2017-01-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional|PPG||Impact of a Sleep Debt in Middle-Aged and Older Adults|Alteration of Sleep and Circadian Timing in Aging- Impact of a Sleep Debt in Middle-Aged and Older Adults|Completed||N/A|72|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:26:03.837219|2018-06-01 01:26:03.837219
NCT00817687|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2012-07-05|2009-01-05|2009-01-06|Estimate|||||||2012-07-05|2012-07-09|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study of the Impact of an Early Biopsy in Patients Treated With CellCept (Mycophenolate Mofetil) After Kidney Transplantation|A Randomised, Multicenter, Open-label Study Evaluating the Impact on the Fibrosis at Week 52 of an Early Biopsy at (D10) Versus Standard Management in Patients Who Have Undergone de Novo Renal Transplantation and Received a Marginal Organ Transplant|Completed||Phase 4|66|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:26:03.901739|2018-06-01 01:26:03.901739
NCT00817674|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2013-09-04|2009-01-05|2009-01-06|Estimate|||||||2013-09-04|2013-09-05|Estimate|November 2007||2007-11-30|September 2013|2013-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|CRIC||Sleep Disturbances as a Non-traditional Risk Factor in CKD-Actigraphy|Sleep Disturbances as a Non-traditional Risk Factor in CKD-Wrist Actigraphy|Completed|||353|Actual|University of Chicago|||2||f||||f||||||||||2018-06-01 01:26:03.992361|2018-06-01 01:26:03.992361
NCT00817661|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-04|||2013-01-01|2009-01-05|2009-01-06|Estimate|||||||2013-01-01|2013-01-03|Estimate|February 2009||2009-02-28|January 2009|2009-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Vitamin A and Maternal-infant Flu Vaccine Response|Effect of Maternal Vitamin A Supplementation on Maternal Immune Response to Inactivated Influenza Vaccination, and on Passive Protection of Infants|Completed||N/A|66|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 01:26:04.04925|2018-06-01 01:26:04.04925
NCT00817648|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2010-06-11|2009-01-05|2009-01-06|Estimate|||||||2010-06-11|2010-06-15|Estimate|December 2008||2008-12-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia|A 6-Week, Multicenter, Rater-blind, Randomized, Risperidone-controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia|Completed||Phase 4|120|Actual|Shanghai Mental Health Center||2|||f||||f||||||||||2018-06-01 01:26:04.132082|2018-06-01 01:26:04.132082
NCT00817635|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05||2012-11-30|2012-11-30|2009-01-05|2009-01-06|Estimate||||2012-11-30|2012-12-04|Estimate|2012-11-30|2012-12-04|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic|A Phase II, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Multi-center, Dose Ranging Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Resistant Hypertension|Completed||Phase 2|155|Actual|Novartis||5|||f||||f||||||||||2018-06-01 01:26:04.229616|2018-06-01 01:26:04.229616
NCT00817622|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-03|||2009-11-17|2009-01-03|2009-01-06|Estimate|||||||2009-11-17|2009-11-18|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|EPA||Effects of EPA and Vitamin E on Leptin, Adiponectin and Enzymatic Antioxidants in Type 2 DM|Effects of EPA Alone and Combined With Vitamin E on Blood Leptin, Adiponectin and Enzymatic Antioxidants Levels in Type II Diabetic Patients; A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 4|129|Actual|Tehran University of Medical Sciences||4|||f||||t||||||||||2018-06-01 01:26:04.32475|2018-06-01 01:26:04.32475
NCT00817609|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2010-05-26|2009-01-05|2009-01-06|Estimate|||||||2010-05-26|2010-05-28|Estimate||||September 2009|2009-09-30||||||||Interventional|||Effectiveness and Safety of Angongniuhuang Pill on Restoring Consciousness for Patients Who Have Suffered From a Stroke||Unknown status|Not yet recruiting|Phase 2/Phase 3|60|Anticipated|Fudan University||2|||f||||||||||||||2018-06-01 01:26:04.387272|2018-06-01 01:26:04.387272
NCT00817596|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2012-03-02||2012-08-13|2009-01-05|2009-01-06|Estimate|2012-06-25|2012-07-31|Estimate||||2012-08-13|2012-08-17|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2008|Actual|2008-03-31||Interventional|PUMP||Prometra's Utilization in Mitigating Pain (PUMP)|Prometra's Utilization in Mitigating Pain (PUMP)|Completed||N/A|110|Actual|Flowonix Medical|||||f||||f||||||||||2018-06-01 01:26:05.411123|2018-06-01 01:26:05.411123
NCT00817583|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2009-01-26|2009-01-05|2009-01-06|Estimate|||||||2009-01-26|2009-01-27|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|July 2011|Anticipated|2011-07-31|July 2010|Anticipated|2010-07-31||Interventional|TPF for NPC||Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)|Phse II Study of Induction Chemotherapy With TPF Regimen Followed by Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Fudan University||1|||f||||t||||||||||2018-06-01 01:26:05.546535|2018-06-01 01:26:05.546535
NCT00817570|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-04|||2009-10-21|2009-01-05|2009-01-06|Estimate|||||||2009-10-21|2009-10-22|Estimate|April 2009||2009-04-30|October 2009|2009-10-31||||||||Observational|||Evaluation of Balance Reactions of Transfemoral Amputees Using the Virtual Analysis System|Evaluation of Balance Reactions of Transfemoral Amputees Using the Virtual|Suspended|||60|Anticipated|Sheba Medical Center|||3||f||||f||||||||||2018-06-01 01:26:05.62476|2018-06-01 01:26:05.62476
NCT00817557|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-05|2009-01-05|2009-01-06|Estimate|||||||2009-01-05|2009-01-06|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|||Use of Loteprednol for Contact Lens Intolerance and Dryness|Use of Loteprednol for Contact Lens Intolerance and Dryness|Unknown status|Enrolling by invitation|Phase 4|25|Anticipated|Hom, Milton M., OD, FAAO||2|||f||||t||||||||||2018-06-01 01:26:05.682412|2018-06-01 01:26:05.682412
NCT00817544|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2009-03-13|2009-01-05|2009-01-06|Estimate|||||||2009-03-13|2009-03-16|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|ALMAS||Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741|Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741; an Open, Non-Randomised, Single Centre Study in Healthy Male Subjects|Completed||Phase 1|6|Anticipated|Orion Corporation, Orion Pharma||1|||f||||f||||||||||2018-06-01 01:26:05.757142|2018-06-01 01:26:05.757142
NCT00817531|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2012-05-07||2012-08-27|2009-01-05|2009-01-06|Estimate|2012-06-12|2012-07-17|Estimate||||2012-08-27|2012-08-31|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients|A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3|Terminated||Phase 2|22|Actual|Baylor Breast Care Center|The study was terminated after internal analysis due to treatment futility. It does not meet the required number of responses to continue the study.|1||terminated due to futility after interim analysis|f||||t||||||||||2018-06-01 01:26:05.83185|2018-06-01 01:26:05.83185
NCT00817518|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2015-09-01|2009-01-05|2009-01-06|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors|An Open-label, Dose-escalation Study With Extension to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO4987655, a MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors|Completed||Phase 1|145|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:26:06.089275|2018-06-01 01:26:06.089275
NCT00817505|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2009-11-02|2009-01-05|2009-01-06|Estimate|||||||2009-11-02|2009-11-03|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||To Evaluate the Bioavailability of a Tablet of AZD1656|A Randomized, Open, Single-Dose, Single-Centre, Cross-over, Phase I Study in Type 1 Diabetes Mellitus Patients to Estimate the Extent and Rate of Absorption of AZD1656 After Administration of a Tablet Formulation in the Fasting State and Just Before Food in Comparison With an Oral Suspension of AZD1|Completed||Phase 1|11|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 01:26:06.178612|2018-06-01 01:26:06.178612
NCT00817492|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2013-09-04|2009-01-05|2009-01-06|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2006||2006-07-31|September 2013|2013-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|CRIC||Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease- University of Illinois|Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease|Completed|||89|Actual|University of Chicago|||2||f||||f||||||||||2018-06-01 01:26:06.253689|2018-06-01 01:26:06.253689
NCT00817479|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2016-06-02||2016-06-02|2009-01-05|2009-01-06|Estimate|2016-06-02|2016-07-13|Estimate||||2016-06-02|2016-07-13|Estimate|January 2003||2003-01-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Tumor Gene Expression in Women With Ovarian Cancer|Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer|Completed||Phase 4|20|Actual|University of Chicago||2|||f||||t||||||||No||2018-06-01 01:26:06.332188|2018-06-01 01:26:06.332188
NCT00817466|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2012-11-01|2009-01-05|2009-01-06|Estimate|||||||2012-11-01|2012-11-02|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|June 2011|Actual|2011-06-30||Interventional|||Bronchiolitis All-study, SE-Norway|Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis?|Unknown status|Active, not recruiting|Phase 4|500|Anticipated|Oslo University Hospital||4|||f||||t||||||||||2018-06-01 01:26:06.555857|2018-06-01 01:26:06.555857
NCT00817453|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-04-12|2009-01-05|2009-01-06|Estimate|||||||2011-04-12|2011-04-14|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|EPDX||Early Parkinson's Disease (PD) Cross-Sectional|Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD|Terminated|||150|Anticipated|The University of Texas Health Science Center, Houston|||3|All subjects transferred to long term study NCT00817726 RBD Longitudinal|f||||f||||||Samples With DNA|"~     CSF and serum~   "|||2018-06-01 01:26:06.647784|2018-06-01 01:26:06.647784
NCT00817440|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-01-10|2009-01-05|2009-01-06|Estimate|||||||2011-01-10|2011-01-11|Estimate|December 2008||2008-12-31|January 2011|2011-01-31||||May 2009|Actual|2009-05-31||Interventional|FEIGH||Effects of Fasting and Exercise on Insulin and GH Signaltransduction in Muscle and Fat|Effects of Fasting and Exercise on Insulin and GH Signaltransduction in Muscle and Fat|Completed||N/A|8|Actual|University of Aarhus||3|||f||||||||||||||2018-06-01 01:26:06.708093|2018-06-01 01:26:06.708093
NCT00817427|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2013-09-04|2009-01-05|2009-01-06|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|CRIC||Sleep Disturbances as a Risk Factor in Chronic Kidney Disease|Sleep Disturbance as a Non-Traditional Risk Factor in CKD|Completed||N/A|40|Actual|University of Chicago||3|||f||||f||||||||||2018-06-01 01:26:06.794832|2018-06-01 01:26:06.794832
NCT00817414|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05||2012-11-30|2012-11-30|2009-01-05|2009-01-06|Estimate||||2012-11-30|2012-12-04|Estimate|2012-11-30|2012-12-04|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension|A Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension|Completed||Phase 2|63|Actual|Novartis||6|||f||||f||||||||||2018-06-01 01:26:06.870333|2018-06-01 01:26:06.870333
NCT00817401|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-05|2009-01-05|2009-01-06|Estimate|||||||2009-01-05|2009-01-06|Estimate|July 2002||2002-07-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Systemic Hypothermia Improves Outcome of Hypoxic-Ischemic Encephalopathy|Effect of Systemic Hypothermia on Neonatal Hypoxic-Ischemic Encephalopathy|Completed||Phase 1/Phase 2|100|Actual|Zhengzhou University|||||f||||t||||||||||2018-06-01 01:26:06.95299|2018-06-01 01:26:06.95299
NCT00817388|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2010-06-04|2009-01-05|2009-01-06|Estimate|||||||2010-06-04|2010-06-07|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Correlating Ic/Pbs Symptoms With Urine Biomarkers|Correlating Ic/Pbs Symptoms With Urine Biomarkers|Completed|||26|Actual|William Beaumont Hospitals|||1||f||||f||||||Samples Without DNA|"~     Urine specimen.~   "|||2018-06-01 01:26:07.098103|2018-06-01 01:26:07.098103
NCT00817375|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-12-30|2009-01-05|2009-01-06|Estimate|||||||2015-12-30|2015-12-31|Estimate|February 2003||2003-02-28|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients|Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients|Recruiting||N/A|1000|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 01:26:07.176212|2018-06-01 01:26:07.176212
NCT00817362|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05||2012-12-06|2012-12-07|2009-01-05|2009-01-06|Estimate||||2012-12-06|2012-12-10|Estimate|2012-12-07|2012-12-11|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer|A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of IPI-504 in Combination With Trastuzumab in Patients With Pretreated, Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer|Terminated||Phase 2|29|Actual|Infinity Pharmaceuticals, Inc.||1||Limited efficacy response observed during interim analysis.|f||||f||||||||||2018-06-01 01:26:07.278169|2018-06-01 01:26:07.278169
NCT00817349|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2010-04-23|2009-01-05|2009-01-06|Estimate|||||||2010-04-23|2010-04-27|Estimate|July 2008||2008-07-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Angio-Seal Evolution Device Registry|Clinical Registry of the St. Jude Medical Angio-Seal(TM) Evolution(TM) Vascular Closure Device Following Diagnostic and/or Interventional Endovascular Procedures|Completed|||1004|Actual|St. Jude Medical|||||f||||f||||||||||2018-06-01 01:26:07.385363|2018-06-01 01:26:07.385363
NCT00817336|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2016-12-15||2017-07-07|2009-01-05|2009-01-06|Estimate|2017-07-07|2017-08-02|Actual||||2017-07-07|2017-08-02|Actual|June 2009||2009-06-30|July 2017|2017-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||There were no statistically significant differences by treatment order|Biomarkers in Schizophrenia|Effect of an NMDA-based Intervention on Biomarker Measures of Cognitive Dysfunction in Schizophrenia|Completed||Phase 2|16|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||t||||||||||2018-06-01 01:26:07.491814|2018-06-01 01:26:07.491814
NCT00817323|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2014-07-04|2009-01-05|2009-01-06|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression?|What is the Antidepressant Mechanism of Action of Quetiapine in Bipolar Depression? Evidence From Selective Neurotransmitter Depletion Studies|Withdrawn||Phase 3|0|Actual|University of British Columbia||1||"Recruitment did not take place for this research due to several delays and then one of the PIs~   moved out of the country and the project was closed"|f||||f||||||||||2018-06-01 01:26:07.785294|2018-06-01 01:26:07.785294
NCT00817310|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2013-12-16|2009-01-05|2009-01-06|Estimate|||||||2013-12-16|2013-12-17|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Neurophysiology and Anatomy of Severe Intraventricular Hemorrhage (IVH)|Influence of Altered Cerebral Spinal Fluid and Arterial Flows on Cerebral Processing Functions in Premature Infants With Severe Intraventricular Hemorrhage|Completed|||60|Actual|Vanderbilt University|||2||f||||t||||||||||2018-06-01 01:26:07.857998|2018-06-01 01:26:07.857998
NCT00817297|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-03|||2017-11-13|2009-01-05|2009-01-06|Estimate|||||||2017-11-13|2017-11-17|Actual|January 17, 2009|Actual|2009-01-17|April 2017|2017-04-30|April 7, 2009|Actual|2009-04-07|March 3, 2009|Actual|2009-03-03||Interventional|||Cross-over Comparison of the V60 System to Other Bi-Level Noninvasive Ventilators|Cross-over Comparison of the V60 System to Other Bi-Level Noninvasive Ventilators for Adult Patients With Respiratory Failure or Respiratory Insufficiency|Completed||N/A|16|Actual|Respironics, California, Inc.||2|||f||||f||f|||f|||No||2018-06-01 01:26:07.918943|2018-06-01 01:26:07.918943
NCT00817284|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-11-29|2009-01-05|2009-01-06|Estimate|||||||2011-11-29|2011-11-30|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)|A Randomized Phase II Trial With Bevacizumab, Irinotecan and Cerebral Radiotherapy Versus Bevacizumab, Temozolomide and Cerebral Radiotherapy as First Line Treatment for Patients With Glioblastoma Multiforme|Completed||Phase 2|60|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 01:26:07.993783|2018-06-01 01:26:07.993783
NCT00817271|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2009-05-06|2009-01-05|2009-01-06|Estimate|||||||2009-05-06|2009-05-07|Estimate|February 2009||2009-02-28|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||To Evaluate the Response to Glucagon During Hypoglycemia|A Randomised, Open, Two-Way Cross-Over, Phase I Study to Evaluate the Response to Glucagon Versus the Spontaneous Counter-Regulatory Response in T2DM Patients Treated With AZD1656 and Metformin During Hypoglycemia|Completed||Phase 1|8|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:26:08.082811|2018-06-01 01:26:08.082811
NCT00817258|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-05|2009-01-05|2009-01-06|Estimate|||||||2009-01-05|2009-01-06|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma|Phase Ⅱ Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|37|Anticipated|Fudan University||1|||f||||t||||||||||2018-06-01 01:26:08.156204|2018-06-01 01:26:08.156204
NCT00817245|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-01|||2009-01-05|2009-01-05|2009-01-06|Estimate|||||||2009-01-05|2009-01-06|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|ICSCR||Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)|Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR)|Completed||Phase 1/Phase 2|50|Actual|Tabriz University||2|||f||||t||||||||||2018-06-01 01:26:08.228963|2018-06-01 01:26:08.228963
NCT00817232|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2010-06-18|2009-01-05|2009-01-06|Estimate|||||||2010-06-18|2010-06-22|Estimate|December 2008||2008-12-31|August 2009|2009-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effectiveness of Microcurrent for Treatment of Tennis Elbow|Effectiveness of Microcurrent in the Treatment of Chronic Tennis Elbow - a Preliminary Trial|Completed||Phase 2/Phase 3|24|Anticipated|University of Hertfordshire||2|||f||||f||||||||||2018-06-01 01:26:08.330424|2018-06-01 01:26:08.330424
NCT00817219|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2012-12-04||2015-03-25|2009-01-05|2009-01-06|Estimate|2012-12-04|2013-01-07|Estimate||||2015-03-25|2015-04-14|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris|Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris|Completed||Phase 2|33|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 01:26:08.410745|2018-06-01 01:26:08.410745
NCT00817206|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2015-08-11||2015-08-11|2009-01-02|2009-01-06|Estimate|2015-08-11|2015-09-10|Estimate||||2015-08-11|2015-09-10|Estimate|December 2008||2008-12-31|August 2015|2015-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||Demographic information is given for all randomized subjects.|Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily|Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt.|Completed||Phase 3|326|Actual|Veloxis Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:26:08.621782|2018-06-01 01:26:08.621782
NCT00817193|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2010-05-27|2009-01-05|2009-01-06|Estimate|||||||2010-05-27|2010-05-28|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|STEP||Staying Healthy Through Education and Prevention Study|Early Screening and Exercise for Prevention of Disability in Persons Residing in Continuing Care Retirement Communities|Unknown status|Active, not recruiting|N/A|320|Anticipated|American Association of Homes and Services for the Aging||2|||f||||f||||||||||2018-06-01 01:26:09.217262|2018-06-01 01:26:09.217262
NCT00817180|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2014-03-14|2009-01-05|2009-01-06|Estimate|||||||2014-03-14|2014-03-17|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Long-term Study, Comparing Vest Therapy to Positive Expiratory Pressure (PEP) Therapy in the Treatment of Cystic Fibrosis|Multi-centre, Long-term Comparative Trial of High Frequency Chest Wall Oscillation Versus Positive Expiratory Pressure Mask in the Treatment of Cystic Fibrosis|Completed||Phase 2|107|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 01:26:09.314507|2018-06-01 01:26:09.314507
NCT00817167|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-01|||2014-11-17|2009-01-05|2009-01-06|Estimate|||||||2014-11-17|2014-11-19|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Added Value of inReach Software on Performance Characteristics of Standard Bronchoscopy|Open Label, Randomized, Comparative, Single Center, Pilot Study to Assess the Added Value of inReach Technology Software on Performance Characteristics of Standard Bronchoscopy.|Completed||N/A|30|Actual|superDimension Ltd.||2|||f||||f||||||||||2018-06-01 01:26:09.420492|2018-06-01 01:26:09.420492
NCT00817154|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2014-05-05|2009-01-05|2009-01-06|Estimate|||||||2014-05-05|2014-05-07|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI)|Individually Based Psychosocial Rehabilitation for Older People With SMI|Completed||Phase 1|38|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 01:26:09.505898|2018-06-01 01:26:09.505898
NCT00817141|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2017-03-23|2009-01-05|2009-01-06|Estimate|||||||2017-03-23|2017-03-27|Actual|March 2008||2008-03-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Urinary Catheter and Fast-track Surgery|Is Urinary Catheter Necessary After Fast-Track Colonic Surgery?|Completed|||60|Actual|Université Catholique de Louvain|||1||f||||f||||||||||2018-06-01 01:26:09.577777|2018-06-01 01:26:09.577777
NCT00817128|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2013-07-23|2009-01-05|2009-01-06|Estimate|||||||2013-07-23|2013-07-24|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|PEPTOC||Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1)|Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I|Completed||Phase 2/Phase 3|62|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:26:09.639721|2018-06-01 01:26:09.639721
NCT00817115|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2009-08-06|2009-01-05|2009-01-06|Estimate|||||||2009-08-06|2009-08-07|Estimate|February 2009||2009-02-28|January 2009|2009-01-31||||December 2009|Anticipated|2009-12-31||Interventional|||Evaluation of Exposure Reduction Using Region-of-Interest Fluoroscopy (X-ray Fovea Imaging) in Cardiac Interventions|Trial to Determine Non-inferiority of Exposure Dose Reduction and Diagnostic Performance of Region-of-Interest Fluoroscopy (X-ray Fovea Imaging) Compared to Standard Fluoroscopy in Patients Undergoing Cardiac Interventional Procedures|Unknown status|Active, not recruiting|Phase 1|75|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||||||||||||2018-06-01 01:26:09.721262|2018-06-01 01:26:09.721262
NCT00817102|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2014-04-14|2009-01-05|2009-01-06|Estimate|||||||2014-04-14|2014-04-15|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|November 2011|Actual|2011-11-30||Interventional|||Validation of Stenosis Assessment by Coronary Artery Computed Tomography Against Invasive Measurements of Fractional Flow Reserve in Patients With Significant Coronary Artery Stenoses||Completed||N/A|25|Actual|Piedmont Healthcare||1|||f||||f||||||||||2018-06-01 01:26:09.800362|2018-06-01 01:26:09.800362
NCT00817089|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-08-03|2009-01-05|2009-01-06|Estimate|||||||2011-08-03|2011-08-05|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|DEFINE II||Understanding Treatment Response With Naltrexone Among White Alcoholics|Defining an Endopheneotype for Alcohol Treatment With Naltrexone|Completed||Phase 4|40|Anticipated|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 01:26:09.86797|2018-06-01 01:26:09.86797
NCT00817076|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-04-20|2009-01-05|2009-01-06|Estimate|||||||2015-04-20|2015-04-21|Estimate|March 2003||2003-03-31|April 2015|2015-04-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)|Evaluation of the Efficacy and Safety of Desloratadine Syrup in Childhood Atopic Dermatitis|Completed||Phase 3|40|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:26:09.943578|2018-06-01 01:26:09.943578
NCT00817063|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|2017-07-17|2013-02-14|2017-10-09|2009-01-05|2009-01-06|Estimate|2017-10-09|2017-11-09|Actual|2013-02-14|2013-02-18|Estimate|2017-10-09|2017-11-09|Actual|January 8, 2009|Actual|2009-01-08|August 2017|2017-08-31|April 26, 2012|Actual|2012-04-26|April 26, 2012|Actual|2012-04-26||Interventional|HANDEL||Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema|Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy|Completed||Phase 3|599|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:26:10.09659|2018-06-01 01:26:10.09659
NCT00817050|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2017-03-22|2009-01-05|2009-01-06|Estimate|||||||2017-03-22|2017-03-24|Actual|December 1, 2004|Actual|2004-12-01|March 2017|2017-03-31|January 1, 2005|Actual|2005-01-01|January 1, 2005|Actual|2005-01-01||Interventional|||Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04207)|A Preference Evaluation of Nasonex® Nasal Spray (Unscented) vs. Flonase® Nasal Spray (Scented) in Subjects With Symptomatic Allergic Rhinitis (AR) - Single-Dose Cross-over|Completed||Phase 4|100|Actual|Merck Sharp & Dohme Corp.||2|||t||||f||||||||||2018-06-01 01:26:11.244249|2018-06-01 01:26:11.244249
NCT00817037|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2009-01-05|2009-01-05|2009-01-06|Estimate|||||||2009-01-05|2009-01-06|Estimate|May 2007||2007-05-31|January 2009|2009-01-31||||March 2009|Anticipated|2009-03-31||Interventional|||Sitaxsentan in Proteinuric Chronic Kidney Disease|The Effect of Sitaxsentan Once Daily Dosing on Proteinuria, 24-Hour Systemic Blood Pressure, and Arterial Stiffness in Subjects With Chronic Kidney Disease|Unknown status|Active, not recruiting|Phase 2|27|Actual|University of Edinburgh||3|||f||||t||||||||||2018-06-01 01:26:11.323477|2018-06-01 01:26:11.323477
NCT00817024|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-04|||2012-05-31|2009-01-05|2009-01-06|Estimate|||||||2012-05-31|2012-06-01|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)|Clinical Study of Herbal Formula in Post PCI Patients.|Completed||N/A|90|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||3|||f||||t||||||||||2018-06-01 01:26:11.423464|2018-06-01 01:26:11.423464
NCT00817011|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-12-30|2009-01-05|2009-01-06|Estimate|||||||2015-12-30|2015-12-31|Estimate|April 2006||2006-04-30|December 2015|2015-12-31|March 2018|Anticipated|2018-03-31|December 2016|Anticipated|2016-12-31||Interventional|PG||Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness|Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness|Unknown status|Recruiting|N/A|1000|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 01:26:11.49903|2018-06-01 01:26:11.49903
NCT00816998|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-04-06|2009-01-05|2009-01-06|Estimate|||||||2011-04-06|2011-04-08|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Range of Motion and Patients With Distal Radius Fractures|The Effect of Early vs. Delayed Range of Motion in the Outcome of Patients With Distal Radius Fractures|Completed||N/A|39|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:26:11.591391|2018-06-01 01:26:11.591391
NCT00816985|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2018-05-02|2009-01-05|2009-01-06|Estimate|||||||2018-05-02|2018-05-07|Actual|June 10, 2008|Actual|2008-06-10|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 27, 2011|Actual|2011-07-27||Interventional|||Liposuction for Arm Lymphedema Following Breast Cancer Surgery|Liposuction for Arm Lymphedema Following Breast Cancer Surgery|Active, not recruiting||N/A|7|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 01:26:11.667273|2018-06-01 01:26:11.667273
NCT00816972|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2015-07-21|2009-01-05|2009-01-06|Estimate|||||||2015-07-21|2015-07-23|Estimate|April 2005||2005-04-30|July 2015|2015-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)|Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip|Completed||Phase 2|540|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 01:26:11.736561|2018-06-01 01:26:11.736561
NCT00816959|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-05|||2011-07-19|2009-01-05|2009-01-06|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma|Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma|Unknown status|Not yet recruiting|Phase 3|1200|Anticipated|American Scitech International||2|||f||||f||||||||||2018-06-01 01:26:11.817103|2018-06-01 01:26:11.817103
NCT00816946|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2018-01-08|2009-01-02|2009-01-05|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2008||2008-07-31|January 2018|2018-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|NF Nutrition||District-based Mainstreaming Nutrition Project in Rural Pakistan|Scaling up Evidence-based Nutrition Interventions to Address Maternal and Child Health Outcomes in Pakistan: a District-based Demonstration Project in Rural Sindh|Completed||N/A|3000|Actual|Aga Khan University||2|||f||||f||||||||No||2018-06-01 01:26:11.891347|2018-06-01 01:26:11.891347
NCT00816933|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-05|2009-01-02|2009-01-05|Estimate|||||||2009-01-05|2009-01-06|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Trial on Postoperative Outcomes According to the Number of Trocar During Laparoscopic Appendectomy|Prospective Randomized Trial on the Assessment of Postoperative Outcomes According to the Number of Trocar During Laparoscopic Appendectomy|Unknown status|Recruiting|Phase 1|140|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-06-01 01:26:11.954729|2018-06-01 01:26:11.954729
NCT00816920|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-09-17|2009-01-02|2009-01-05|Estimate|||||||2009-09-17|2009-09-18|Estimate|September 2005||2005-09-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|CALTHRO||Natural History of Isolated Deep Vein Thrombosis of the Calf|"Diagnosis and Evolution of Isolated Deep Vein Thrombosis of the Calf in Symptomatic Outpatients. The Blind, Prospective CALTHRO Study."|Completed|||500|Anticipated|St. Orsola Hospital|||1||f||||t||||||||||2018-06-01 01:26:12.027838|2018-06-01 01:26:12.027838
NCT00816907|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|2013-01-03||2013-02-13|2009-01-02|2009-01-05|Estimate|2013-02-13|2013-03-27|Estimate||||2013-02-13|2013-03-27|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|METS||The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)|Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study|Completed||Phase 4|146|Actual|National Institute of Mental Health (NIMH)|Changes over periods of more than 16 weeks are unknown.|2|||f||||t||||||||||2018-06-01 01:26:12.109334|2018-06-01 01:26:12.109334
NCT00816894|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-01|||2013-12-09|2009-01-02|2009-01-05|Estimate|||||||2013-12-09|2013-12-10|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||D-serine Monotherapy for Schizophrenia|D-serine Antipsychotic Monotherapy for Treatment Refractory Schizophrenia|Completed||Phase 2|18|Actual|Herzog Hospital||2|||f||||t||||||||||2018-06-01 01:26:12.40627|2018-06-01 01:26:12.40627
NCT00816881|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2012-06-21|2009-01-02|2009-01-05|Estimate|||||||2012-06-21|2012-06-22|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Application and Generalization of Flutter Mucus Clearance Device|Application and Generalization of Flutter Mucus Clearance Device|Completed||N/A|356|Actual|Tongji University||2|||f||||t||||||||||2018-06-01 01:26:12.473688|2018-06-01 01:26:12.473688
NCT00816868|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2012-02-28|2009-01-02|2009-01-05|Estimate|||||||2012-02-28|2012-03-01|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|||A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung|A Phase II Study of Erlotinib in Combination With Capecitabine as First-line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|62|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-06-01 01:26:12.534488|2018-06-01 01:26:12.534488
NCT00816855|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-02|2009-01-02|2009-01-05|Estimate|||||||2009-01-02|2009-01-05|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma|Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|52|Anticipated|Fudan University||1|||f||||t||||||||||2018-06-01 01:26:12.617695|2018-06-01 01:26:12.617695
NCT00816842|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-02|2009-01-02|2009-01-05|Estimate|||||||2009-01-02|2009-01-05|Estimate|October 1998||1998-10-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Observational|||Plasma Citrulline Concentration in Tropical Enteropathy|Plasma Citrulline as Quantitative Biomarker of HIV Associate Villous Atrophy in a Tropical Enteropathy Population|Completed|||||Azienda Ospedaliero-Universitaria di Parma|||||f||||||||||||||2018-06-01 01:26:12.680592|2018-06-01 01:26:12.680592
NCT00816829|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|2009-01-08||2009-07-17|2009-01-02|2009-01-05|Estimate|2009-05-25|2009-07-07|Estimate||||2009-07-17|2009-07-22|Estimate|September 2005||2005-09-30|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of Fenofibrate on Sleep Apnea Syndrome|A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome|Terminated||Phase 2|34|Actual|Solvay Pharmaceuticals|Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and includes events started prior to the 1st administration but which worsened after the 1st intake.|2||The study was prematurely terminated because of slow recruitment|f||||f||||||||||2018-06-01 01:26:12.744707|2018-06-01 01:26:12.744707
NCT00816816|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2009-01-02|2009-01-02|2009-01-05|Estimate|||||||2009-01-02|2009-01-05|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma|Phase ⅡStudy of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|64|Anticipated|Fudan University||1|||f||||t||||||||||2018-06-01 01:26:13.143441|2018-06-01 01:26:13.143441
NCT00816803|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2009-01-02|2009-01-02|2009-01-05|Estimate|||||||2009-01-02|2009-01-05|Estimate|May 2005||2005-05-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cell Transplant in Spinal Cord Injury Patients|Autologous Bone Marrow Derived Cell Transplant in Spinal Cord Injury Patients|Completed||Phase 1/Phase 2|80|Actual|Cairo University||2|||f||||t||||||||||2018-06-01 01:26:13.211776|2018-06-01 01:26:13.211776
NCT00816790|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2015-09-10|2008-12-31|2009-01-05|Estimate|||||||2015-09-10|2015-09-14|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock|A Comparison of Standard Vs Renal Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock|Terminated||Phase 4|20|Anticipated|Fraser Health||2||Study stopped because of study personel movement to another institution.|f||||f||||||||||2018-06-01 01:26:13.275148|2018-06-01 01:26:13.275148
NCT00816777|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|2014-08-12||2018-02-15|2009-01-02|2009-01-05|Estimate|2015-08-17|2015-09-18|Estimate||||2018-02-15|2018-03-15|Actual|December 2008||2008-12-31|February 2018|2018-02-28|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|PARAGON||Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer|Feasibility and Prospective Randomized Study of Transarterial Chemoembolization Using Irinotecan Bead in Combination With Second Line Chemotherapy in the Treatment of Patients With Unresectable Metastatic Colorectal Cancer|Terminated||Phase 1/Phase 2|4|Actual|Generic Devices Consulting, Inc.||2||Lack of enrollment|f||||f|t|t|f|f||||No||2018-06-01 01:26:13.348163|2018-06-01 01:26:13.348163
NCT00816764|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-01|||2013-02-26|2009-01-02|2009-01-05|Estimate|||||||2013-02-26|2013-02-27|Estimate|October 2008||2008-10-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer|A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-8M4 Given as Monotherapy in Subjects With Advanced Ovarian Cancer|Completed||Phase 1|18|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 01:26:13.559591|2018-06-01 01:26:13.559591
NCT00816751|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2009-01-02|2009-01-02|2009-01-05|Estimate|||||||2009-01-02|2009-01-05|Estimate|December 2007||2007-12-31|January 2009|2009-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Paracervical Versus Intracervical Lidocaine|Paracervical Versus Intracervical Lidocaine for Suction Curettage: A Randomized Controlled Trial|Completed||N/A|132|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 01:26:13.637664|2018-06-01 01:26:13.637664
NCT00816738|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2009-01-02|2009-01-02|2009-01-05|Estimate|||||||2009-01-02|2009-01-05|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Observational|||Evaluation of the Treatment of Recurrent Corneal Erosions by Anterior Stromal Puncture With Nd: YAG Laser|Evaluation of the Treatment of Recurrent Corneal Erosions by Anterior Stromal Puncture With Nd: YAG Laser|Completed|||33|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:26:13.705234|2018-06-01 01:26:13.705234
NCT00816725|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2014-04-10|2009-01-02|2009-01-05|Estimate|||||||2014-04-10|2014-04-11|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effectiveness of a Web-based Prevention Program for Postpartum Depression|Using the Internet for English/Spanish Randomized Trials for Postpartum Depression|Completed||N/A|1000|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:26:13.768032|2018-06-01 01:26:13.768032
NCT00816712|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2015-02-12|2009-01-02|2009-01-05|Estimate|||||||2015-02-12|2015-02-13|Estimate|January 2008||2008-01-31|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)|A Randomized, Single-Blind, Placebo-Controlled, Single-dose, Parallel Design Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (FSR)|Completed||Phase 1|28|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 01:26:13.845432|2018-06-01 01:26:13.845432
NCT00816699|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-01|||2011-03-10|2009-01-02|2009-01-05|Estimate|||||||2011-03-10|2011-03-11|Estimate|December 2008||2008-12-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Effects of Providing Preprint Preoperative Anesthetic Risk Information|Effects of Providing Preprint Preoperative Anesthetic Risk Information|Completed||Phase 1/Phase 2|103|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 01:26:13.915268|2018-06-01 01:26:13.915268
NCT00816517|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2016-03-31|2008-12-31|2009-01-01|Estimate|||||||2016-03-31|2016-04-04|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Use of Botulinum Toxin to Treat Psoriasis|Pilot Study on the Safety and Efficacy of Botulinum Toxin Injections in the Treatment of Psoriasis Vulgaris.|Completed||Phase 1|8|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 01:26:15.648845|2018-06-01 01:26:15.648845
NCT00816686|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-01|||2013-02-26|2009-01-02|2009-01-05|Estimate|||||||2013-02-26|2013-02-27|Estimate|October 2008||2008-10-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer|A Phase 1, Open-Label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M18 Given as Monotherapy in Subjects With Advanced Renal Cell Carcinoma|Terminated||Phase 1|7|Actual|Astellas Pharma Inc||5||Trial was terminated due to the need to re-formulate the study drug.|f||||f||||||||||2018-06-01 01:26:13.987022|2018-06-01 01:26:13.987022
NCT00816673|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2009-01-04|2009-01-02|2009-01-05|Estimate|||||||2009-01-04|2009-01-06|Estimate|September 1996||1996-09-30|January 2009|2009-01-31|September 1997|Actual|1997-09-30|May 1997|Actual|1997-05-31||Interventional|Neu I||Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs|Phase II Study of Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs.|Completed||Phase 2|40|Actual|Neurim Pharmaceuticals Ltd.||2|||f||||||||||||||2018-06-01 01:26:14.069371|2018-06-01 01:26:14.069371
NCT00816660|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-02|||2017-10-19|2009-01-02|2009-01-05|Estimate|||||||2017-10-19|2017-10-23|Actual|December 2008||2008-12-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease|Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex (rVWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability in Type 3 Von Willebrand Disease (VWD)|Completed||Phase 1|32|Actual|Shire||2|||f||||t||||||||||2018-06-01 01:26:14.149358|2018-06-01 01:26:14.149358
NCT00816647|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2011-06-13|2008-12-31|2009-01-01|Estimate|||||||2011-06-13|2011-06-14|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||A Prospective Randomized Study of Medial Patellofemoral Ligament (MPFL) Reconstruction|A Prospective Randomized Study of Medial Patellofemoral Ligament Reconstruction Compared With Medial Reefing|Terminated||N/A|50|Anticipated|Finnish Defense Forces||2||"Stopped for benefit of the MPFL reconstruction arm and due to safety concerns of the medial~   reefing arm."|f||||f||||||||||2018-06-01 01:26:14.24367|2018-06-01 01:26:14.24367
NCT00816634|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2017-04-27|2008-12-30|2009-01-01|Estimate|||||||2017-04-27|2017-05-01|Actual|October 2008||2008-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|XP versus XT||Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma|A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Paclitaxel (XT) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|94|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 01:26:14.316652|2018-06-01 01:26:14.316652
NCT00816621|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2016-12-19|2008-12-30|2009-01-01|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of a Parent Training Program for Parents of Children Adopted Internationally|Early Intervention for Children Adopted Internationally|Active, not recruiting||N/A|220|Actual|University of Delaware||2|||f||||t||||||||||2018-06-01 01:26:14.394344|2018-06-01 01:26:14.394344
NCT00816608|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2013-10-24|2008-12-31|2009-01-01|Estimate|||||||2013-10-24|2013-10-25|Estimate|August 2006||2006-08-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Observational|MAXWEL||The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes|Study of MAXimum Weight in Lifetime on Glucose Homeostasis (MAXWEL)|Completed|||3000|Actual|Seoul National University Bundang Hospital|||1||f||||t||||||||||2018-06-01 01:26:14.46413|2018-06-01 01:26:14.46413
NCT00816595|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|2014-04-09||2017-05-23|2008-12-31|2009-01-01|Estimate|2014-04-09|2014-05-09|Estimate||||2017-05-23|2017-06-15|Actual|February 2009||2009-02-28|May 2017|2017-05-31|November 29, 2016|Actual|2016-11-29|July 2013|Actual|2013-07-31||Interventional|||Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|68|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 01:26:14.548179|2018-06-01 01:26:14.548179
NCT00816582|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2016-03-04|2008-12-31|2009-01-01|Estimate|||||||2016-03-04|2016-03-07|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer|A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer|Recruiting||Phase 2|100|Anticipated|British Columbia Cancer Agency||1|||f||||t||||||||||2018-06-01 01:26:14.982343|2018-06-01 01:26:14.982343
NCT00816569|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2008-12-31|2008-12-31|2009-01-01|Estimate|||||||2008-12-31|2009-01-01|Estimate|February 2009||2009-02-28|December 2008|2008-12-31|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Interventional|||Orthokeratology for Keratoconus|Orthokeratology Contact Lenses for Keratoconus|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:26:15.094036|2018-06-01 01:26:15.094036
NCT00816556|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|2014-02-12||2017-10-10|2008-12-30|2009-01-01|Estimate|2014-02-12|2014-03-28|Estimate||||2017-10-10|2017-11-13|Actual|October 2008||2008-10-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis|A Randomized Controlled Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis|Terminated||Phase 3|63|Actual|Mayo Clinic||3||Funding|f||||f||||||||||2018-06-01 01:26:15.179037|2018-06-01 01:26:15.179037
NCT00816543|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2012-12-17|2008-12-31|2009-01-01|Estimate|||||||2012-12-17|2012-12-18|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma|A Single Arm Phase II Feasibility Study of Neoadjuvant Docetaxel, Oxaliplatin and S-1 Chemotherapy in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma.|Completed||Phase 2|41|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:26:15.498145|2018-06-01 01:26:15.498145
NCT00816530|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2014-12-01|2008-12-31|2009-01-01|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|somo•InSIGHT||A Clinical Study to Evaluate Somo•v and Digital Mammography Together as a Breast Cancer Screening Method, Compared to Digital Mammography Alone, in Women With Dense Breasts.|A Prospective Multicenter Matched-pair Clinical Study to Evaluate the Sensitivity and Specificity of ABUS and Digital X-Ray Mammography (XRM) Together as a Breast Cancer Screening Method Compared to XRM Alone in Women With >50% Parenchymal Density.|Completed|||15679|Actual|U-Systems, Inc.|||1||f||||f||||||||||2018-06-01 01:26:15.560003|2018-06-01 01:26:15.560003
NCT00816504|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2015-09-03|2008-12-31|2009-01-01|Estimate|||||||2015-09-03|2015-09-07|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5|Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5|Withdrawn||Phase 1|0|Actual|Northwell Health||1||Under additional IRB Review|f||||f||||||||||2018-06-01 01:26:15.710488|2018-06-01 01:26:15.710488
NCT00816491|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2009-01-15|2008-12-31|2009-01-01|Estimate|||||||2009-01-15|2009-01-16|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Comparison Between Chromoendoscopy and Conventional Colonoscopy to Improve the Detection of Neoplasia in Patients With Ulcerative Colitis (UC)|Comparaison de la Chromo Endoscopie Virtuelle FICE (Fujinon Intelligent Chromoendoscopy) Avec la Coloscopie Conventionnelle Dans la détection de la Dysplasie Chez Patients Porteurs de Recto Colite ulcéro hémorragique (RCH).|Unknown status|Recruiting|N/A|80|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:26:15.857779|2018-06-01 01:26:15.857779
NCT00816478|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2015-09-08|2008-12-31|2009-01-01|Estimate|||||||2015-09-08|2015-09-10|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor|Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)|Terminated||Phase 1|15|Actual|Northwell Health||1||Study closed by Institutional Review Board|f||||t||||||||||2018-06-01 01:26:15.937831|2018-06-01 01:26:15.937831
NCT00816465|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2010-09-16|2008-12-31|2009-01-01|Estimate|||||||2010-09-16|2010-09-17|Estimate|May 2009||2009-05-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of Hoodia Gordonii for Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)||Completed||Phase 1|20|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 01:26:16.004429|2018-06-01 01:26:16.004429
NCT00816452|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2010-11-02|2008-12-31|2009-01-01|Estimate|||||||2010-11-02|2010-11-03|Estimate|January 2009||2009-01-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|InoPro||Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer|Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.|Completed|||180|Actual|Sanofi|||||f||||||||||||||2018-06-01 01:26:16.068161|2018-06-01 01:26:16.068161
NCT00816439|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2017-10-05|2008-12-31|2009-01-01|Estimate|||||||2017-10-05|2017-10-06|Actual|December 29, 2008||2008-12-29|August 28, 2014|2014-08-28|August 28, 2014||2014-08-28|||||Observational|||Imaging Cannabinoid CB1 Receptors in Alcohol Dependence|Imaging Cannabinoid CB1 Receptors in Alcohol Dependence|Completed|||101|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:26:16.131846|2018-06-01 01:26:16.131846
NCT00816426|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2018-05-23|2008-12-31|2009-01-01|Estimate|||||||2018-05-23|2018-05-24|Actual|December 29, 2008||2008-12-29|December 29, 2017|2017-12-29|December 29, 2017|Actual|2017-12-29|August 26, 2014|Actual|2014-08-26||Interventional|||Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis|Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery|Completed||Phase 1|19|Actual|National Institutes of Health Clinical Center (CC)||5|||f||||||||||||||2018-06-01 01:26:16.198916|2018-06-01 01:26:16.198916
NCT00816413|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2018-01-22|2008-12-31|2009-01-01|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2008||2008-09-30|January 2018|2018-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer|T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation|Withdrawn||Phase 1/Phase 2|0|Actual|University of Nebraska||||Screenings yielded inadequate eligible subjects to enroll.|f||||t||||||||||2018-06-01 01:26:16.322558|2018-06-01 01:26:16.322558
NCT00816400|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2016-12-21||2017-04-10|2008-12-30|2009-01-01|Estimate|2017-04-10|2017-04-11|Actual||||2017-04-10|2017-04-11|Actual|March 2009||2009-03-31|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|MEDI-575||A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.|A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-derived Growth Factor Receptor Alpha (PDGFRα), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists|Completed||Phase 1|49|Actual|MedImmune LLC||9|||f||||f||||||||||2018-06-01 01:26:16.506312|2018-06-01 01:26:16.506312
NCT00816387|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2010-12-02|2008-12-31|2009-01-01|Estimate|||||||2010-12-02|2010-12-03|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Fallopian Tube Sperm Perfusion (FSP) Versus Intra-uterine Insemination (IUI) in Natural Cycle|Fallopian Tube Sperm Perfusion (FSP) Versus Intra-uterine Insemination (IUI) in Natural Cycle: a Prospective Randomized Study|Completed||N/A|400|Anticipated|IRCCS Burlo Garofolo||2|||f||||t||||||||||2018-06-01 01:26:18.113383|2018-06-01 01:26:18.113383
NCT00816374|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2014-05-15|2008-12-31|2009-01-01|Estimate|||||||2014-05-15|2014-05-16|Estimate|August 2005||2005-08-31|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Tailored Intervention for Melanoma Patient's Families|Tailored Intervention for Melanoma Patient's Families|Completed||N/A|553|Actual|Fox Chase Cancer Center||2|||f||||f||||||||||2018-06-01 01:26:18.206275|2018-06-01 01:26:18.206275
NCT00816361|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2014-01-06|2008-12-30|2009-01-01|Estimate|||||||2014-01-06|2014-01-07|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists|Completed||Phase 1|43|Actual|MedImmune LLC||1|||f||||f||||||||||2018-06-01 01:26:18.302652|2018-06-01 01:26:18.302652
NCT00816348|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|2015-08-07||2017-01-30|2008-12-31|2009-01-01|Estimate|2016-01-11|2016-02-09|Estimate||||2017-01-30|2017-03-10|Actual|December 2008||2008-12-31|January 2017|2017-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Compassionate Use of Omegaven IV Fat Emulsion|Compassionate Use of Omegaven IV Fat Emulsion|Terminated||Phase 2|15|Actual|Northwell Health||1|||f||||f||||||||||2018-06-01 01:26:18.368507|2018-06-01 01:26:18.368507
NCT00815841|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2008-12-30|2008-12-30|2008-12-31|Estimate|||||||2008-12-30|2008-12-31|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Methylphenidate in Healthy Young Adults||Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Shaare Zedek Medical Center|||||f||||f||||||||||2018-06-01 01:26:25.237137|2018-06-01 01:26:25.237137
NCT00816335|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2016-03-31|2008-12-31|2009-01-01|Estimate|||||||2016-03-31|2016-04-04|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors|Pilot Study Evaluating a Combined and Integrated Technological Approach of F-18-FDG-Directed Perioperative PET/CT Imaging and Intraoperative Handheld Gamma Prove Detection of Known and Occult Disease in Patients Undergoing Surgery for Solid Malignancies|Completed||Early Phase 1|65|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:26:18.491434|2018-06-01 01:26:18.491434
NCT00816322|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2015-04-13|2008-12-31|2009-01-01|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2005||2005-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Fish Oil in Major Depressive Disorder|The Effect of Fish Oil in Major Depressive Disorder: a Double-blind Placebo-controlled Monotherapy Trail and a RCT for Recurrence Prevention|Completed||N/A|120|Actual|National Science Council, Taiwan||2|||f||||t||||||||||2018-06-01 01:26:18.56507|2018-06-01 01:26:18.56507
NCT00816309|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2011-03-31|2008-12-31|2009-01-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?|Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?|Completed||Phase 4|20|Actual|NHS Lothian||2|||f||||f||||||||||2018-06-01 01:26:18.620442|2018-06-01 01:26:18.620442
NCT00816296|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2015-08-21|2008-12-30|2009-01-01|Estimate|||||||2015-08-21|2015-08-24|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Observational|||Evaluation of Intestinal Microbiome in Obese Kids|Evaluation of the Intestinal Microbiome in Obese Children With and Without Non-Alcoholic Fatty Liver Disease|Withdrawn|||0|Actual|Medical College of Wisconsin|||2|PI has left institution|f||||f||||||Samples With DNA|"~     Participants will need to give a blood and stool samples on 3 separate occasions.~   "|||2018-06-01 01:26:18.689092|2018-06-01 01:26:18.689092
NCT00816283|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2012-07-16|2008-12-31|2009-01-01|Estimate|||||||2012-07-16|2012-07-17|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia|BMS CA180157: A Phase I Combination Study of Dasatinib Plus Vorinostat in Accelerated Phase, Chronic Phase Refractory to Second Line Therapy or Blast Crisis Chronic Myelogenous Leukemia (CML), and in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 1|5|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 01:26:19.706437|2018-06-01 01:26:19.706437
NCT00816270|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2008-12-31|2008-12-31|2009-01-01|Estimate|||||||2008-12-31|2009-01-01|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Liquid Bandage (2-Octyl-Cyanoacrylate) in Upper Lid Blepharoplasty|Comparison Between Liquid Bandage(2-Octyl-Cyanoacrylate)and Traditional Suture Closure in Upper Lid Blepharoplasty|Terminated||N/A|11|Actual|Federal University of São Paulo||1||Experimental results were unsatisfatory compared with control.|f||||t||||||||||2018-06-01 01:26:19.789219|2018-06-01 01:26:19.789219
NCT00816257|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2013-11-18|2008-12-31|2009-01-01|Estimate|||||||2013-11-18|2013-11-20|Estimate|November 2005||2005-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Lung Transplant Specimen Repository and Data Registry Protocol|Lung Transplant Specimen Repository and Data Registry Protocol|Completed|||64|Actual|Ohio State University|||||f||||f||||||Samples With DNA|"~     BAL specimen blood lung biopsy specimens~   "|||2018-06-01 01:26:19.854063|2018-06-01 01:26:19.854063
NCT00816244|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2012-04-12|2008-12-31|2009-01-01|Estimate|||||||2012-04-12|2012-04-13|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer|A Phase II Study of Neo-Adjuvant Statin Therapy in Postmenopausal Primary Breast Cancer: A Window-of-Opportunity Study|Completed||Phase 2|50|Actual|Lund University Hospital||1|||f||||f||||||||||2018-06-01 01:26:19.905345|2018-06-01 01:26:19.905345
NCT00816231|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2018-01-09|2008-12-31|2009-01-01|Estimate|||||||2018-01-09|2018-01-10|Actual|May 8, 2006|Actual|2006-05-08|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|March 2014|Actual|2014-03-31||Interventional|||Drug /Cue Interactions In Alcohol-Tobacco Comorbidity|Drug /Cue Interactions In Alcohol-Tobacco Comorbidity|Active, not recruiting||N/A|244|Actual|H. Lee Moffitt Cancer Center and Research Institute||4|||f||||f||||||||||2018-06-01 01:26:19.973804|2018-06-01 01:26:19.973804
NCT00816218|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2012-05-30|2008-12-31|2009-01-01|Estimate|||||||2012-05-30|2012-05-31|Estimate|March 2003||2003-03-31|May 2012|2012-05-31|November 2008|Actual|2008-11-30|July 2006|Actual|2006-07-31||Interventional|||Molecular Mechanisms of Type 2 Diabetes Mellitus|Molecular Mechanisms of Endothelial Dysfunction in Type 2 Diabetes Mellitus|Completed||Phase 4|39|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||||2018-06-01 01:26:20.05249|2018-06-01 01:26:20.05249
NCT00816205|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-31|||2009-04-06|2008-12-31|2009-01-01|Estimate|||||||2009-04-06|2009-04-07|Estimate||||April 2009|2009-04-30|April 2009|Actual|2009-04-30|||||Interventional|||An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects|An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects|Completed||Phase 1/Phase 2|||RDD Pharma Ltd||1|||f||||f||||||||||2018-06-01 01:26:20.121644|2018-06-01 01:26:20.121644
NCT00816192|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2012-07-26|2008-12-30|2008-12-31|Estimate|||||||2012-07-26|2012-07-27|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|CATAFABL||Comparison of Externally Versus Internally Cooled Tip Catheter Ablation in Paroxysmal Atrial Fibrillation|Comparison of Externally Versus Internally Cooled Tip Catheter in Achieving Long-term Electrical Isolation of Pulmonary Veins in Paroxysmal Atrial Fibrillation|Terminated||N/A|86|Actual|University Hospital, Bordeaux||2||The production of the device used in this study has been suspended.|f||||f||||||||||2018-06-01 01:26:20.179251|2018-06-01 01:26:20.179251
NCT00816179|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2014-10-30|2008-12-30|2008-12-31|Estimate|||||||2014-10-30|2014-11-03|Estimate|July 2008||2008-07-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Diagnostic Endoscopic Exploration for Pancreatic Head Mass|Human Clinical Trial of Diagnostic Transgastric Endoscopic Peritoneoscopy for Staging of Pancreatic Head Mass|Terminated||N/A|11|Actual|Ohio State University||||"Helical CT scans at our institution preclude the necessity for diagnostic laparoscopy in most~   cases at our institution."|f||||f||||||||||2018-06-01 01:26:20.341972|2018-06-01 01:26:20.341972
NCT00815828|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2008-12-30|2008-12-30|2008-12-31|Estimate|||||||2008-12-30|2008-12-31|Estimate|October 2006||2006-10-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||The Effects of Resistance Exercises in Glycemic Control of Women With Gestational Diabetes|The Effects of Resistance Exercises in Glycemic Control of Women With Gestational Diabetes - A Randomized Clinical Trial|Completed||N/A|64|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 01:26:25.284131|2018-06-01 01:26:25.284131
NCT00816166|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2014-04-18||2015-02-02|2008-12-30|2008-12-31|Estimate|2014-05-19|2014-06-16|Estimate||||2015-02-02|2015-02-20|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|April 2013|Actual|2013-04-30||Interventional|VISSIT|Analyses were based on an Intent-to-Treat (ITT) population, defined ad enrolled subjects who met the inclusion/exclusion criteria and who were randomized post angiogram. Stent and medical Therapy Group subjects were analyzed to their ITT randomized group regardless of treatment received.|VISSIT Intracranial Stent Study for Ischemic Therapy|Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease|Terminated||Phase 2/Phase 3|125|Actual|Codman & Shurtleff|Early termination of enrollment led to small numbers of subjects analyzed (less than 50% of the prospectively planned sample size). Various endpoints, subgroup and sensitivity analyses were not conducted because the study was not fully enrolled.|2|||f||||t||||||||||2018-06-01 01:26:20.465169|2018-06-01 01:26:20.465169
NCT00816153|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2008-12-30|2008-12-30|2008-12-31|Estimate|||||||2008-12-30|2008-12-31|Estimate|March 2008||2008-03-31|December 2008|2008-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Pleth Variability Index and Fluid Management During Surgery|Is Pleth Variability Index Able to Guide Fluid Management During Surgery?|Completed||N/A|97|Actual|Université Catholique de Louvain||2|||f||||f||||||||||2018-06-01 01:26:21.155347|2018-06-01 01:26:21.155347
NCT00816140|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2011-04-21|2008-12-30|2008-12-31|Estimate|||||||2011-04-21|2011-04-22|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication|Comparative Study of the Levofloxacin-Based and Clarithromycin-Based Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication and Change of Gut Flora and Drug Susceptibility Before and After Treatment|Completed||Phase 4|432|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:26:21.213925|2018-06-01 01:26:21.213925
NCT00816127|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2008-12-31|2008-12-30|2008-12-31|Estimate|||||||2008-12-31|2009-01-01|Estimate|October 2003||2003-10-31|December 2008|2008-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction|Intranasal DDAVP in Preventing Bleeding During Dental Extraction in Cirrhotic Patients|Completed||N/A|36|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 01:26:21.282775|2018-06-01 01:26:21.282775
NCT00816114|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2017-10-25|2008-12-30|2008-12-31|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2005|Actual|2005-06-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial|Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial|Recruiting|||3000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 01:26:21.355184|2018-06-01 01:26:21.355184
NCT00816101|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2010-12-13||2011-03-04|2008-12-30|2008-12-31|Estimate|2011-02-03|2011-03-01|Estimate||||2011-03-04|2011-03-09|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Efficacy Study of a New Antimicrobial Wound Dressing to Treat Wounds Caused by Curettage and Electrodesiccation|Efficacy of the PROCELLERA™ Wound Dressing in the Healing of Wounds After a Curettage and Electrodesiccation of Skin Lesions|Completed||Phase 2|26|Actual|Vomaris Innovations||3|||f||||f||||||||||2018-06-01 01:26:21.533461|2018-06-01 01:26:21.533461
NCT00816088|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2014-12-22|2008-12-30|2008-12-31|Estimate|||||||2014-12-22|2014-12-23|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Diagnostic and Management Strategies for Invasive Aspergillosis|Diagnostic and Management Strategies for Invasive Aspergillosis in Neutropenic Adult Haemato-Oncology Patients With a Proposal for Investigation of a Novel Potential Marker for Early Diagnosis: a Prospective Cohort Study|Completed|||203|Actual|King's College Hospital NHS Trust|||1||f||||f||||||Samples With DNA|"~     Seum, Whole blood, urine, broncho-alveolar lavage, tissue~   "|||2018-06-01 01:26:21.848915|2018-06-01 01:26:21.848915
NCT00816075|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2009-02-16|2008-12-30|2008-12-31|Estimate|||||||2009-02-16|2009-02-17|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Interventional|||Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection|The Efficacy of Distilled Water vs Mitomycin C as a Single Dose Immediate Instillation After Transurethral Resection of Intermediate Risk, Recurrent Superficial Bladder Cancer|Unknown status|Active, not recruiting|Phase 2/Phase 3|40|Anticipated|Bozyaka Training and Research Hospital||1|||f||||f||||||||||2018-06-01 01:26:21.920363|2018-06-01 01:26:21.920363
NCT00816062|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2016-08-01||2018-02-15|2008-12-30|2008-12-31|Estimate|2017-12-21|2018-01-23|Actual||||2018-02-15|2018-03-15|Actual|December 2008||2008-12-31|December 2017|2017-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|VITALITY||Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms|Endovascular Repair Using the Talent™ Abdominal Stent Graft System in Abdominal Aortic Aneurysms (VITALITY)|Completed||N/A|94|Actual|Medtronic Endovascular||1|||f||||f||||||||||2018-06-01 01:26:22.024598|2018-06-01 01:26:22.024598
NCT00816049|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2017-04-20|2008-12-30|2008-12-31|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2009|Actual|2009-01-31|April 2017|2017-04-30|March 2, 2016|Actual|2016-03-02|March 2, 2016|Actual|2016-03-02||Interventional|ALL2008con||ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy|Nordic Society of Paediatric Haematology and Oncology Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults (18-45 Years of Age) With ALL. Efficacy of Individualised 6MP Dosing During Consolidation Therapy|Completed||Phase 3|775|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:26:22.634638|2018-06-01 01:26:22.634638
NCT00816036|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2014-07-08||2015-04-06|2008-12-30|2008-12-31|Estimate|2014-08-05|2014-08-06|Estimate||||2015-04-06|2015-04-27|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Improving the Delivery of Smoking Cessation Guidelines in Hospitalized Veterans|Improving the Delivery of Smoking Cessation Guidelines in Hospitalized Veterans|Completed||N/A|898|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:26:22.732346|2018-06-01 01:26:22.732346
NCT00816023|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2010-12-14||2015-07-21|2008-12-30|2008-12-31|Estimate|2010-12-14|2011-01-12|Estimate||||2015-07-21|2015-08-11|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|CONSERV-1||A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume|CONSERV-1 (Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) A Phase 2 Randomized Placebo-controlled Dose-ranging Study in Subjects Exposed to Cardio-pulmonary Bypass During Primary Coronary Artery Bypass Graft Surgery|Completed||Phase 2|276|Actual|Cubist Pharmaceuticals LLC|Secondary efficacy variables were considered exploratory and, based on failure of the primary endpoint to meet statistical significance and early termination of the trial, are not presented.|4|||f||||t||||||||||2018-06-01 01:26:22.949104|2018-06-01 01:26:22.949104
NCT00816010|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2012-02-20|2008-12-30|2008-12-31|Estimate|||||||2012-02-20|2012-02-22|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Telephone Intervention in Patients With Acute Coronary Syndrome (ACS) and Diabetes|A Multicentre, Randomised Study to Examine the Effects of Telephone Intervention in Patients With Coronary Heart Disease and Diabetes|Terminated||N/A|137|Actual|Chinese University of Hong Kong||2||Due to lack of manpower at the various study sites|f||||f||||||||||2018-06-01 01:26:23.966736|2018-06-01 01:26:23.966736
NCT00815997|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2013-09-02|2008-12-30|2008-12-31|Estimate|||||||2013-09-02|2013-09-04|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|NAUSICA||Novel Angioplasty Using Coronary Accessor|Novel Angioplasty USIng Coronary Accessor|Completed||N/A|177|Actual|NAUSICA Investigators||2|||f||||t||||||||||2018-06-01 01:26:24.038037|2018-06-01 01:26:24.038037
NCT00815984|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2010-02-09|2008-12-30|2008-12-31|Estimate|||||||2010-02-09|2010-02-10|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Fractional Exhaled Nitric Oxide (FeNO) Result Prediction Factors in Children With Allergic Diseases|FeNO Result Prediction Factors in Children With Allergic Diseases|Completed|||800|Actual|Medical Universtity of Lodz|||1||f||||f||||||||||2018-06-01 01:26:24.133372|2018-06-01 01:26:24.133372
NCT00815971|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2008-12-30|2008-12-30|2008-12-31|Estimate|||||||2008-12-30|2008-12-31|Estimate|May 2008||2008-05-31|December 2008|2008-12-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Observational|||Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib|Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib|Unknown status|Recruiting||300|Anticipated|Aarhus University Hospital|||1||f||||t||||||Samples With DNA|"~     a fine neddle biopsi taken when the diagnosis non-small cell lung carcinoma was made +~     severals blood samples taken before and during treatment with erlotinib.~   "|||2018-06-01 01:26:24.200609|2018-06-01 01:26:24.200609
NCT00815958|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2017-01-20|2008-12-30|2008-12-31|Estimate|||||||2017-01-20|2017-01-24|Estimate|December 2007||2007-12-31|January 2017|2017-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Embolic Events Detected During Total Knee Arthroplasty With the Use of RIA (Reamer-Irrigator-Aspirator)|Embolic Events Detected During Total Knee Arthroplasty With and Without the Use of RIA (Reamer-Irrigator-Aspirator): A Blinded, Randomized, Controlled Clinical Study|Terminated||N/A|6|Actual|Ohio State University||2||administrative reasons|f||||f||||||||||2018-06-01 01:26:24.272552|2018-06-01 01:26:24.272552
NCT00815945|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2017-02-13|2008-12-30|2008-12-31|Estimate|||||||2017-02-13|2017-02-14|Actual|June 2008||2008-06-30|March 2014|2014-03-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors|Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors|Completed||Phase 2|41|Actual|AGO Study Group||1|||f||||f||||||||No||2018-06-01 01:26:24.344683|2018-06-01 01:26:24.344683
NCT00815932|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2017-10-03|2008-12-30|2008-12-31|Estimate|||||||2017-10-03|2017-10-05|Actual|September 2016||2016-09-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To CRPS or Diabetic Neuropathy|The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To Complex Regional Pain Syndrome (CRPS) or Diabetic Neuropathy-A PILOT, DOUBLE-BLIND, SHAM-CONTROLLED, CROSS-OVER STUDY|Withdrawn||N/A|0|Actual|Soroka University Medical Center||4||Due to unfixable problem in the research machine we had to withdrawn from the study|f||||||||||||||2018-06-01 01:26:24.451977|2018-06-01 01:26:24.451977
NCT00815919|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|2014-01-17||2015-06-29|2008-12-30|2008-12-31|Estimate|2014-01-17|2014-02-28|Estimate||||2015-06-29|2015-07-22|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|||Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease|A Phase II Trial of Bortezomib (Velcade) Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease|Completed||Phase 2|22|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:26:24.532529|2018-06-01 01:26:24.532529
NCT00815906|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2012-06-15|2008-12-30|2008-12-31|Estimate|||||||2012-06-15|2012-06-18|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis|An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Japanese Subjects With Rheumatoid Arthritis|Completed||Phase 1|20|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:26:24.745014|2018-06-01 01:26:24.745014
NCT00815893|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2009-07-27|2008-12-30|2008-12-31|Estimate|||||||2009-07-27|2009-07-28|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation|Interventional Study of Dexmedetomidine for Sedating Anticipated Difficult Airway Patients Undergoing Awake Fiberoptic Nasal Intubation|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t||||||||||2018-06-01 01:26:24.827834|2018-06-01 01:26:24.827834
NCT00815880|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2015-03-31|2008-12-30|2008-12-31|Estimate|||||||2015-03-31|2015-04-01|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||C-Pulse IDE Feasibility Study- A Heart Assist System|C-Pulse Implantable Counterpulsation Pump (ICP) Feasibility Study - A Heart Assist System|Completed||Phase 1|20|Actual|Sunshine Heart Inc.||1|||f||||t||||||||||2018-06-01 01:26:24.91169|2018-06-01 01:26:24.91169
NCT00815867|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-30|||2016-04-27|2008-12-30|2008-12-31|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|Neo-PDGF||Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant|Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant|Completed||Phase 3|108|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-06-01 01:26:24.987185|2018-06-01 01:26:24.987185
NCT00815854|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2018-05-01|2008-12-29|2008-12-31|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2008||2008-10-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects|Folate Pharmacogenomics and Risk of Atypical Antipsychotic Metabolic Side Effects|Active, not recruiting||N/A|150|Anticipated|University of Michigan||2|||f||||t||||||||||2018-06-01 01:26:25.16691|2018-06-01 01:26:25.16691
NCT00815815|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2013-08-08|2008-12-29|2008-12-31|Estimate|||||||2013-08-08|2013-08-12|Estimate|February 2004||2004-02-29|August 2013|2013-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effectiveness of High Intensity Inpatient Versus Stepped Intensity Treatment for Anorexia Nervosa|Anorexia Nervosa: The Importance of Treatment Intensity|Completed||N/A|41|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 01:26:25.347499|2018-06-01 01:26:25.347499
NCT00815802|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2008-12-29|2008-12-29|2008-12-30|Estimate|||||||2008-12-29|2008-12-30|Estimate|July 2007||2007-07-31|December 2008|2008-12-31||||||||Observational|FcrèchMV||Detection of Human Cytomegalovirus in the Saliva|Detection of Human Cytomegalovirus in the Saliva of 3 Month to 6 Year-Old Children in Day Care Centers : a Pilot Study.|Completed|||655|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 01:26:25.41211|2018-06-01 01:26:25.41211
NCT00815789|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2014-07-18|2008-12-29|2008-12-30|Estimate|||||||2014-07-18|2014-07-22|Estimate|December 2008||2008-12-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|CHANGE||Cholesterol, Hypertension and Glucose Education Study|Prevention of Cardiovascular Outcomes in African Americans With Diabetes|Completed||N/A|362|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:26:25.460935|2018-06-01 01:26:25.460935
NCT00815776|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2010-03-23||2010-08-16|2008-12-29|2008-12-30|Estimate|2010-07-09|2010-08-06|Estimate||||2010-08-16|2010-08-24|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Treatment Outcomes for Temporomandibular Disorders (TMD) Via the Clayton Intra-aural Device (CID) Clinical Trial|Treatment Outcome of Temporomandibular Disorders Via the Clayton Intra-aural Device (CID): A Randomized Clinical Trial|Completed||Phase 1/Phase 2|152|Actual|Ascentia Health, Inc.||3|||f||||f||||||||||2018-06-01 01:26:25.526516|2018-06-01 01:26:25.526516
NCT00815763|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2008-12-29|2008-12-29|2008-12-30|Estimate|||||||2008-12-29|2008-12-30|Estimate|September 2006||2006-09-30|December 2008|2008-12-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke|Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Multicenter Trial|Completed||Phase 3|390|Actual|Xijing Hospital||2|||f||||t||||||||||2018-06-01 01:26:25.802917|2018-06-01 01:26:25.802917
NCT00815750|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2014-07-30|2008-12-29|2008-12-30|Estimate|||||||2014-07-30|2014-07-31|Estimate|August 2008||2008-08-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients|Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients|Completed||N/A|147|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 01:26:25.863465|2018-06-01 01:26:25.863465
NCT00815737|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2010-05-26|2008-12-29|2008-12-30|Estimate|||||||2010-05-26|2010-05-28|Estimate|January 2009||2009-01-31|September 2009|2009-09-30||||||||Interventional|||Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage||Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Anticipated|Fudan University||2|||f||||||||||||||2018-06-01 01:26:26.114653|2018-06-01 01:26:26.114653
NCT00815724|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2013-03-07|2008-12-29|2008-12-30|Estimate|||||||2013-03-07|2013-03-11|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|DALI||Evaluating a Distance Learning Asthma Education Program for Pediatricians (The DALI Study)|Distributed Asthma Learning Initiative|Completed||N/A|24|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:26:26.191112|2018-06-01 01:26:26.191112
NCT00815711|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2014-08-21|2008-12-29|2008-12-30|Estimate|||||||2014-08-21|2014-08-22|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Idiopathic Pulmonary Fibrosis Registry for Future Studies|Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis|Unknown status|Recruiting||84|Anticipated|Ohio State University|||||f||||f||||||Samples With DNA|"~     blood serum BAL fluid lung biopsy~   "|||2018-06-01 01:26:26.263251|2018-06-01 01:26:26.263251
NCT00815698|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2015-03-18||2016-02-22|2008-12-29|2008-12-30|Estimate|2016-02-22|2016-03-23|Estimate||||2016-02-22|2016-03-23|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|Dangrip||Effect of Suture for Mesh Fixation in Lichtenstein Hernia Repair|Effect of Suture for Mesh Fixation in Lichtenstein Hernia Repair, a Prospective Controlled Randomized Trial|Completed||N/A|334|Actual|Herlev Hospital||2|||f||||f||||||||No||2018-06-01 01:26:26.33559|2018-06-01 01:26:26.33559
NCT00815685|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2011-04-27||2017-02-20|2008-12-29|2008-12-30|Estimate|2011-08-05|2011-09-08|Estimate||||2017-02-20|2017-03-23|Actual|July 2007||2007-07-31|December 2013|2013-12-31|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|||A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia|A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia|Completed||N/A|36|Actual|H. Lee Moffitt Cancer Center and Research Institute|This was a Pilot Supportive Care Intervention.|1|||f||||f||||||||||2018-06-01 01:26:26.531751|2018-06-01 01:26:26.531751
NCT00815672|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2017-12-13|2008-12-29|2008-12-30|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2007||2007-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|EXCAP||Exercise for Prostate Cancer Patients|The Influence of Home-based Aerobic and Resistance Exercise on Cancer-Related Fatigue, Strength, and Muscle Mass in Prostate Patients.|Active, not recruiting||N/A|122|Anticipated|University of Rochester||2|||f||||t||||||||||2018-06-01 01:26:26.83583|2018-06-01 01:26:26.83583
NCT00815659|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2011-03-24||2011-08-29|2008-12-29|2008-12-30|Estimate|2011-06-07|2011-07-04|Estimate||||2011-08-29|2011-08-31|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|EFFORT||Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome|Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT)|Completed||Phase 4|97|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:26:26.991816|2018-06-01 01:26:26.991816
NCT00815646|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2016-01-25|2008-12-29|2008-12-30|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Prevention and Treatment of Immersion Pulmonary Edema|Effects of the Dive Reflex on Pulmonary Arterial and Pulmonary Artery Wedge Pressures in Subjects Who Have Experienced Immersion Pulmonary Edema|Completed||Early Phase 1|10|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:26:27.500206|2018-06-01 01:26:27.500206
NCT00815633|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2018-04-11||2018-04-11|2008-12-29|2008-12-30|Estimate|2018-04-11|2018-05-11|Actual||||2018-04-11|2018-05-11|Actual|December 2008||2008-12-31|April 2018|2018-04-30|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris|A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris.|Terminated||Phase 4|1|Actual|Icahn School of Medicine at Mount Sinai||1||Failed to enroll patients. There is no data or results for this study.|f||||t||||||||||2018-06-01 01:26:27.57994|2018-06-01 01:26:27.57994
NCT00815607|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2013-07-17|2008-12-29|2008-12-30|Estimate|||||||2013-07-17|2013-07-18|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma|Phase 1b' Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12(INXN-3001) in Response to an Oral Activator Ligand in Patients With Unresectable Stage III C or IV Malignant Melanoma|Completed||Phase 1|12|Actual|Ziopharm|||||f||||||||||||||2018-06-01 01:26:27.802667|2018-06-01 01:26:27.802667
NCT00815594|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2008-12-29|2008-12-29|2008-12-30|Estimate|||||||2008-12-29|2008-12-30|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|May 2009|Anticipated|2009-05-31|March 2009|Anticipated|2009-03-31||Interventional|||Bleb Vascularity Change After Subconjunctival Injection Bevacizumab|Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Capital Medical University|||||f||||t||||||||||2018-06-01 01:26:27.869727|2018-06-01 01:26:27.869727
NCT00815581|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2010-04-07|2008-12-29|2008-12-30|Estimate|||||||2010-04-07|2010-04-08|Estimate|May 2008||2008-05-31|December 2008|2008-12-31||||||||Interventional|||Comparison of Photorefraction With Cycloautorefraction and Cycloretinoscopy at Emam Hosein Medical Centre in 2008-2009|Comparison of Photorefraction With Cycloautorefraction and Cycloretinoscopy at Emam Hosein Medical Centre in 2008-2009|Completed||Phase 1/Phase 2|||Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-06-01 01:26:27.928231|2018-06-01 01:26:27.928231
NCT00815568|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2008-12-29|2008-12-29|2008-12-30|Estimate|||||||2008-12-29|2008-12-30|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)|Prospective Phase II Clinical Trial of Myeloablative Conditioning Regimen With Fludarabine and Busulfan Plus 400 cGy Total Body Irradiation for Hematologic Malignancies|Unknown status|Recruiting|Phase 2|114|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 01:26:27.981879|2018-06-01 01:26:27.981879
NCT00815555|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-28|||2008-12-29|2008-12-29|2008-12-30|Estimate|||||||2008-12-29|2008-12-30|Estimate|December 2008||2008-12-31|December 2008|2008-12-31||||December 2011|Anticipated|2011-12-31||Observational|||CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients|CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients|Unknown status|Recruiting||500|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 01:26:28.063544|2018-06-01 01:26:28.063544
NCT00815542|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-25|||2012-03-22|2008-12-28|2008-12-30|Estimate|||||||2012-03-22|2012-03-23|Estimate|June 2012||2012-06-30|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Induction of Labor in Oligohydramnios|Induction of Labor in Oligohydramnios - A Comparison Between Two Modes of Cervical Ripening for Patients With Oligohydramnios at Term|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-06-01 01:26:28.248135|2018-06-01 01:26:28.248135
NCT00815529|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2008-12-29|2008-12-29|2008-12-30|Estimate|||||||2008-12-29|2008-12-30|Estimate||||December 2008|2008-12-31||||||||Expanded Access|||Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain|Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain|Available|||||Kyunghee University Medical Center|||||f||||||||||||||2018-06-01 01:26:28.325055|2018-06-01 01:26:28.325055
NCT00815516|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-27|2015-08-14||2015-10-12|2008-12-27|2008-12-30|Estimate|2015-08-14|2015-09-15|Estimate||||2015-10-12|2015-11-04|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MAGIC-2||Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis|A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis|Terminated||Phase 3|30|Actual|Astellas Pharma Inc||2||It was decided to discontinue the study due to insufficient recruitment.|f||||t||||||||||2018-06-01 01:26:28.433397|2018-06-01 01:26:28.433397
NCT00815503|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2011-03-15|2008-12-29|2008-12-30|Estimate|||||||2011-03-15|2011-03-16|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Postoperative Analgesia With Local Infiltration After Periacetabular Osteotomy|Postoperative Analgesia With Local Infiltration After Periacetabular Osteotomy For The Treatment Of Dysplasia|Completed||Phase 4|70|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 01:26:29.184921|2018-06-01 01:26:29.184921
NCT00815490|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|2012-11-19||2013-03-06|2008-12-29|2008-12-30|Estimate|2013-03-06|2013-04-16|Estimate||||2013-03-06|2013-04-16|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|April 2012|Actual|2012-04-30|November 2008|Actual|2008-11-30||Interventional|||Validation of Brain Oxygenation Monitor|Calibration and Validation of the Nonin Non-invasive Cerebral Oxygen Saturation Oximeter and Cerebral Sensor in Human Volunteers|Completed||N/A|18|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:26:29.263936|2018-06-01 01:26:29.263936
NCT00815477|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2012-02-17|2008-12-29|2008-12-30|Estimate|||||||2012-02-17|2012-02-20|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|I-START||Internet-Based Strategic Transdisciplinary Approach To Risk Reduction And Treatment|I-START: Internet-based Strategic Transdisciplinay Approach to Risk Reduction And Treatment|Completed||Phase 2/Phase 3|387|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:26:29.485969|2018-06-01 01:26:29.485969
NCT00815464|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2008-12-29|2008-12-29|2008-12-30|Estimate|||||||2008-12-29|2008-12-30|Estimate|March 2009||2009-03-31|December 2008|2008-12-31|March 2010|Anticipated|2010-03-31|September 2009|Anticipated|2009-09-30||Interventional|CHB||A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B|Efficacy Study of Liquid Acupuncture(Herb Acupoint Injection) Therapeutics in Chronic Hepatitis B(CHB) Based on Patients' Individual Condition|Unknown status|Not yet recruiting|N/A|30|Anticipated|Yu Medical Garden||1|||f||||t||||||||||2018-06-01 01:26:29.551934|2018-06-01 01:26:29.551934
NCT00815451|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2009-09-17|2008-12-29|2008-12-30|Estimate|||||||2009-09-17|2009-09-18|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Effect of Polyphenol-rich Dark Chocolate on Obesity|Effect of Polyphenols on Glucoregulatory Biomarkers, Blood Pressure and Lipid Profile in Overweight and Obese Subjects|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Queen Margaret University||2|||f||||t||||||||||2018-06-01 01:26:29.637346|2018-06-01 01:26:29.637346
NCT00815438|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2016-09-29|2008-12-29|2008-12-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Transvaginal Cholecystectomy Using Endoscopic Assistance|Laparoscopic Cholecystectomy Using Transvaginal Endoscopic Assistance|Withdrawn||Phase 1|0|Actual|University of Missouri-Columbia||1||Study personnel left institution|f||||f||||||||No||2018-06-01 01:26:29.720831|2018-06-01 01:26:29.720831
NCT00815425|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2014-12-01|2008-12-29|2008-12-30|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2000||2000-09-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Observational|CLEAR||Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (The CLEAR Registry)|Consortium for the Longitudinal Evaluation of African-Americans With Early Rheumatoid Arthritis (CLEAR) Registry|Completed|||1613|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||2||f||||t||||||Samples With DNA|"~     Blood, including DNA and serum, and urine~   "|||2018-06-01 01:26:29.797206|2018-06-01 01:26:29.797206
NCT00815412|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2015-11-25|2008-12-29|2008-12-30|Estimate|||||||2015-11-25|2015-11-26|Estimate|September 2004||2004-09-30|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|ACTIVATE||ACTIVATE: Standard Worksite Health Program vs. Activated Consumer|ACTIVATE: Standard Worksite Health Program vs. Activated Consumer|Completed||N/A|631|Actual|HealthPartners Institute||3|||f||||t||||||||||2018-06-01 01:26:29.864828|2018-06-01 01:26:29.864828
NCT00815399|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|||2015-11-17|2008-12-29|2008-12-30|Estimate|||||||2015-11-17|2015-11-18|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Pioglitazone Versus Metformin in Type 2 Diabetes|Effect of Pioglitazone Compared With Metformin on Endothelial Microparticles in Type 2 Diabetes. A Randomized Trial|Completed||Phase 4|150|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-06-01 01:26:29.91657|2018-06-01 01:26:29.91657
NCT00815386|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2011-02-10|2008-12-26|2008-12-30|Estimate|||||||2011-02-10|2011-02-14|Estimate|February 2009||2009-02-28|February 2011|2011-02-28|December 2015|Anticipated|2015-12-31|December 2010|Actual|2010-12-31||Interventional|PTOLEMY2Canada||Safety and Efficacy Study of the PTMA Device to Reduce Mitral Valve Regurgitation in Patients With Heart Failure|Safety and Efficacy of Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure|Suspended||Phase 2/Phase 3|20|Anticipated|Viacor||1||Company ended operations in January 2011|f||||t||||||||||2018-06-01 01:26:29.978675|2018-06-01 01:26:29.978675
NCT00815373|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2012-03-15|2008-12-29|2008-12-30|Estimate|||||||2012-03-15|2012-03-16|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|Xal-Cos||The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)|A Comparative Analysis of the Effects of Cosopt® Versus Xalacom® on Ocular Hemodynamics and Intraocular Pressure in Patients With Primary Open-angle Glaucoma|Withdrawn||N/A|0|Actual|Meir Medical Center||2||no participants recruded.|f||||t||||||||||2018-06-01 01:26:30.059326|2018-06-01 01:26:30.059326
NCT00815360|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|2013-05-23||2015-02-04|2008-12-29|2008-12-30|Estimate|2015-02-04|2015-03-05|Estimate||||2015-02-04|2015-03-05|Estimate|February 2008||2008-02-29|October 2014|2014-10-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|RaScaL||Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion|Ranibizumab (rhuFab V2) and Scatter Laser Photocoagulation in Treatment of Patients With Clinically-significant Diabetic Macular Edema With Peripheral Retinal Nonperfusion (RaScaL)|Completed||Phase 2|22|Actual|Retina Associates of Florida, P.A.|small study size|2|||f||||f||||||||||2018-06-01 01:26:30.136726|2018-06-01 01:26:30.136726
NCT00815347|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2012-06-16||2012-09-28|2008-12-29|2008-12-30|Estimate|2012-09-28|2012-10-01|Estimate||||2012-09-28|2012-10-01|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Bosentan for Poorly Controlled Asthma|The Effect of the ET-1 Receptor Antagonist, Bosentan on Patients With Poorly Controlled Asthma-A 17 Week, Double-blind, Placebo Controlled Crossover Trial|Terminated||Phase 2|11|Actual|UConn Health|Early termination leading to small numbers of subjects analyzed.|1||Difficulty in recruitment.|f||||t||||||||||2018-06-01 01:26:30.381815|2018-06-01 01:26:30.381815
NCT00815334|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-28|||2009-06-16|2008-12-28|2008-12-30|Estimate|||||||2009-06-16|2009-06-17|Estimate|October 2008||2008-10-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy of Endoscopic Subureteral Injection for Vesicoureteral Reflux in Adults With Decreased Bladder Compliance|Efficacy of Endoscopic Subureteral Injection for Vesicoureteral Reflux in Adults With Decreased Bladder Compliance|Completed||N/A|47|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 01:26:30.592585|2018-06-01 01:26:30.592585
NCT00815321|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-28|||2017-02-09|2008-12-29|2008-12-30|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2008||2008-12-31|February 2017|2017-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy|Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Chronic Myeloid Leukemia on Standard Drug Therapy|Completed||Phase 2|11|Actual|Singapore General Hospital|||||f||||t||||||||||2018-06-01 01:26:30.67494|2018-06-01 01:26:30.67494
NCT00815308|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-29|2010-10-15||2011-02-04|2008-12-29|2008-12-30|Estimate|2011-01-11|2011-02-03|Estimate||||2011-02-04|2011-02-08|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|EXCEL||Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma|An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)|Completed||Phase 2|55|Actual|Shandong Cancer Hospital and Institute||1|||f||||t||||||||||2018-06-01 01:26:30.737063|2018-06-01 01:26:30.737063
NCT00815295|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|2014-12-01||2014-12-05|2008-12-26|2008-12-30|Estimate|2014-12-05|2014-12-08|Estimate||||2014-12-05|2014-12-08|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study of Sorafenib/Cetuximab in Head and Neck Cancer|Sorafenib and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN):a Phase I B/II Trial|Completed||Phase 1/Phase 2|31|Actual|Duke University||1|||f||||t||||||||||2018-06-01 01:26:31.078637|2018-06-01 01:26:31.078637
NCT00815282|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2017-11-08|2008-12-26|2008-12-29|Estimate|||||||2017-11-08|2017-11-13|Actual|February 2009||2009-02-28|November 2017|2017-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HPV-kind||Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease|Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease|Completed||Phase 4|135|Actual|UMC Utrecht||1|||f||||f||||||||||2018-06-01 01:26:31.478547|2018-06-01 01:26:31.478547
NCT00815269|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2009-12-22|2008-12-26|2008-12-29|Estimate|||||||2009-12-22|2009-12-23|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|VEFIHA||Vasodilation Effect of Inhalational Anesthetics|Vasodilation Effect of Inhalational Anesthetics Including Halothane, Isoflurane, Sevoflurane, Desflurane and Enflurane|Completed||N/A|300|Actual|Nanjing Medical University||5|||f||||t||||||||||2018-06-01 01:26:31.560142|2018-06-01 01:26:31.560142
NCT00815256|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2008-12-26|2008-12-26|2008-12-29|Estimate|||||||2008-12-26|2008-12-29|Estimate|August 2008||2008-08-31|November 2008|2008-11-30||||August 2009|Anticipated|2009-08-31||Interventional|||Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus|The Safety and Effectiveness of Collagen Cross Linking With Riboflavin and Ultraviolet-A Light in Progressive Mild and Moderate Grades of Keratoconus.|Unknown status|Recruiting|Phase 3|15|Anticipated|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 01:26:31.633147|2018-06-01 01:26:31.633147
NCT00815243|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2008-12-26|2008-12-26|2008-12-29|Estimate|||||||2008-12-26|2008-12-29|Estimate|September 2007||2007-09-30|December 2008|2008-12-31|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|TeleTO||Telemedicine Consultation in Trauma and Orthopedic|Study of Clinical Workflow Changes, Anatomical and Functional Outcomes Due to Telemedicine Consultations in Trauma and Orthopedic|Completed||N/A|300|Actual|Donetsk National Medical University||3|||f||||f||||||||||2018-06-01 01:26:31.774535|2018-06-01 01:26:31.774535
NCT00815230|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-25|||2009-05-17|2008-12-25|2008-12-29|Estimate|||||||2009-05-17|2009-05-19|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|March 2009|Anticipated|2009-03-31|||||Observational|||Effect of Cardiac Computed Tomography Angiography on the Blood Reactive Oxygen Species Level|Effect of Cardiac Computed Tomography Angiography on the Blood Reactive Oxygen Species Level|Withdrawn|||20|Anticipated|National Taiwan University Hospital||||because of unexpected administrative barrier, it was very difficult to enroll case.|f||||f||||||None Retained|"~     only peripheral blood will be collected for measurement of reactive oxygen species.~   "|||2018-06-01 01:26:31.88348|2018-06-01 01:26:31.88348
NCT00815217|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2008-12-24|2008-12-24|2008-12-29|Estimate|||||||2008-12-24|2008-12-29|Estimate|February 2009||2009-02-28|December 2008|2008-12-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers|The Role of Lipoaspirate Injection in the Treatment of Diabetic Lower Extremity Wounds and Venous Stasis Ulcers|Unknown status|Not yet recruiting|N/A|250|Anticipated|Washington D.C. Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 01:26:31.969286|2018-06-01 01:26:31.969286
NCT00815204|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2015-02-02|2008-12-24|2008-12-29|Estimate|||||||2015-02-02|2015-02-04|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder|Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress Disorder|Completed|||39|Actual|Cedars-Sinai Medical Center|||3||f||||f||||||Samples Without DNA|"~     Will be collecting blood to check for hormone levels~   "|||2018-06-01 01:26:32.231539|2018-06-01 01:26:32.231539
NCT00815191|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2016-02-27||2016-06-07|2008-12-24|2008-12-29|Estimate|2016-06-07|2016-07-18|Estimate||||2016-06-07|2016-07-18|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||5 patients with missing data, including 3 in the warm-water sleeve group and 2 in the forced air group.|Comparison of Vital HEAT (vH2) Temperature Management System to Upper-body Forced-air Warming|A Comparison Study of the Vital HEAT (vH2) Temperature Management System to Upper-body Forced-air Warming in Patients Undergoing Open Abdominal Surgery Under General Anesthesia|Completed||N/A|73|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 01:26:32.459211|2018-06-01 01:26:32.459211
NCT00815178|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2008-12-26|2008-12-26|2008-12-29|Estimate|||||||2008-12-26|2008-12-29|Estimate|September 2006||2006-09-30|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness|Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness: A Randomized, Controlled Clinical Trial|Completed||N/A|25|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:26:32.861665|2018-06-01 01:26:32.861665
NCT00815165|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2013-09-05|2008-12-26|2008-12-29|Estimate|||||||2013-09-05|2013-09-09|Estimate|June 2006||2006-06-30|September 2013|2013-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Cytomegalovirus Cell-Mediated Immunity|Cell-Mediated Immune Responses to Cytomegalovirus gB/MF59 Vaccine|Completed|||165|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Blood.~   "|||2018-06-01 01:26:32.947692|2018-06-01 01:26:32.947692
NCT00815152|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2013-05-03|2008-12-26|2008-12-29|Estimate|||||||2013-05-03|2013-05-06|Estimate|December 2008||2008-12-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Coping With High Grade Glioma|Coping With High Grade Glioma|Terminated||N/A|14|Actual|Duke University||2||PI transferred to new institution.|f||||t||||||||||2018-06-01 01:26:33.01901|2018-06-01 01:26:33.01901
NCT00815139|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2008-12-26|2008-12-26|2008-12-29|Estimate|||||||2008-12-26|2008-12-29|Estimate|February 2008||2008-02-29|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Observational|ENDEAVOR OCT||Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography|Evaluation in 3 moNths Duration of nEointimAl coVerAge After zOtaRolimus-Eluting Stent Implantation by Optical Coherence Tomography (ENDEAVOR OCT)|Completed|||30|Actual|Yonsei University|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 01:26:33.098278|2018-06-01 01:26:33.098278
NCT00815126|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2010-11-17|2008-12-26|2008-12-29|Estimate|||||||2010-11-17|2010-11-18|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Nasal Provocation Test With Lysine-Acetylsalicylate (ASA) in Patients With Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Hypersensitivity|Association Between Nasal Provocation Test With Lysine-Acetylsalicylate(ASA) and Clinical Diagnosis in Patients With Aspirin/Nonsteroidal Anti-Inflammatory Drugs(NSAIDs) and/or Acetaminophen Immediate Sensitivity Reactions|Completed||N/A|34|Actual|Chulalongkorn University||3|||f||||f||||||||||2018-06-01 01:26:33.162382|2018-06-01 01:26:33.162382
NCT00815113|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-25|||2018-04-10|2008-12-26|2008-12-29|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2009|Actual|2009-10-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|Stomach||Screening for Gastric Cancer in High-risk Population|Screening for Gastric Cancer in High-risk Population|Completed|||80|Actual|Rabin Medical Center|||2||f||||t||||||Samples With DNA|"~     Gastric biopsies~   "|||2018-06-01 01:26:33.245857|2018-06-01 01:26:33.245857
NCT00815100|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-25|||2011-04-05|2008-12-26|2008-12-29|Estimate|||||||2011-04-05|2011-04-06|Estimate|April 2009||2009-04-30|April 2011|2011-04-30|April 2012|Anticipated|2012-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome|Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome|Unknown status|Recruiting|Phase 4|1270|Anticipated|Hospital Universitario de Canarias||2|||f||||t||||||||||2018-06-01 01:26:33.332106|2018-06-01 01:26:33.332106
NCT00815087|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-25|2013-11-13||2014-03-02|2008-12-26|2008-12-29|Estimate|2014-03-02|2014-03-26|Estimate||||2014-03-02|2014-03-26|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|February 2009|Actual|2009-02-28||Interventional||We decided to make the cut point when the numbers of 2 groups are equal.|Functional Electrical Stimulation in Irradiated Nasopharyngeal Carcinoma (NPC)|Efficacy of Functional Electrical Stimulation in Dysphagia of Nasopharyngeal Cancer Post Radiotherapy|Completed||Phase 2|20|Actual|National Taiwan University Hospital|Lack of information about muscle fibrosis, no control group. and the results from the small amount of subjects.|2|||f||||t||||||||||2018-06-01 01:26:33.620626|2018-06-01 01:26:33.620626
NCT00815074|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2008-12-24|2008-12-24|2008-12-29|Estimate|||||||2008-12-24|2008-12-29|Estimate||||December 2008|2008-12-31||||||||Observational|||Military Women's Health and Illness Behaviors in Deployed Settings||Unknown status|Not yet recruiting||||Wilford Hall Medical Center|||1||f||||f||||||||||2018-06-01 01:26:33.798661|2018-06-01 01:26:33.798661
NCT00815061|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2017-10-03|2008-12-26|2008-12-29|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2008||2008-07-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population|Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population|Withdrawn|||0|Actual|Rabin Medical Center|||||f||||f||||||||||2018-06-01 01:26:33.874412|2018-06-01 01:26:33.874412
NCT00815048|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2008-12-26|2008-12-26|2008-12-29|Estimate|||||||2008-12-26|2008-12-29|Estimate|January 2006||2006-01-31|December 2008|2008-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|RAIN||Remifentanil and Atropine for Intubation in Neonates|Remifentanil and Atropine for Intubation in Neonates; a Randomized Controlled Trial|Completed||Phase 4|30|Actual|King Saud University||2|||f||||t||||||||||2018-06-01 01:26:34.033337|2018-06-01 01:26:34.033337
NCT00815035|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|2017-03-27||2018-02-27|2008-12-26|2008-12-29|Estimate|2017-05-11|2017-05-15|Actual||||2018-02-27|2018-03-01|Actual|April 2009||2009-04-30|July 2017|2017-07-31|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|PnOIT3||Oral Immunotherapy (OIT) for Peanut Allergy|Oral Immunotherapy for Peanut Allergy- Peanut Oral Immunotherapy (PnOIT3)|Completed||Phase 2|16|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-06-01 01:26:34.108944|2018-06-01 01:26:34.108944
NCT00815022|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2014-01-11|2008-12-26|2008-12-29|Estimate|||||||2014-01-11|2014-01-14|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|ATOCEB||Influence of Anesthetic Temperature on Cephalad Sensory Blockade With Spinal Anesthesia|Influence of Anesthetic Temperature on Cephalad Sensory Blockade With Spinal Anesthesia for Cesarean Delivery|Completed||N/A|400|Actual|Nanjing Medical University||6|||f||||t||||||||||2018-06-01 01:26:34.702625|2018-06-01 01:26:34.702625
NCT00815009|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2012-07-13|2008-12-24|2008-12-29|Estimate|||||||2012-07-13|2012-07-16|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|NAFLD||Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease|Prospective Histopathologic Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease|Completed||N/A|56|Actual|San Antonio Military Medical Center||4|||f||||f||||||||||2018-06-01 01:26:34.831702|2018-06-01 01:26:34.831702
NCT00814996|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-25|||2008-12-26|2008-12-26|2008-12-29|Estimate|||||||2008-12-26|2008-12-29|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Social Functioning in Schizophrenia||Completed|||60|Anticipated|Far Eastern Memorial Hospital|||2||f||||||||||||||2018-06-01 01:26:34.982989|2018-06-01 01:26:34.982989
NCT00814983|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|2013-09-25||2013-09-25|2008-12-26|2008-12-29|Estimate|2013-09-25|2013-11-25|Estimate||||2013-09-25|2013-11-25|Estimate|July 2007||2007-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft|Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft|Terminated||Phase 1/Phase 2|15|Actual|Duke University||2||IND approval for naive T-cell depletion not obtained|f||||t||||||||||2018-06-01 01:26:35.105447|2018-06-01 01:26:35.105447
NCT00814970|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2014-04-22|2013-02-21|2016-03-14|2008-12-24|2008-12-25|Estimate|2014-04-22|2014-05-21|Estimate|2013-02-21|2013-02-25|Estimate|2016-03-14|2016-04-13|Estimate|November 2008||2008-11-30|February 2016|2016-02-29|December 2013|Actual|2013-12-31|September 2011|Actual|2011-09-30||Interventional|||The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions|The Complete® SE SFA Study: The Medtronic Complete Self-Expanding SFA Stent System for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and/or Proximal Popliteal Arteries|Completed||N/A|196|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 01:26:35.381336|2018-06-01 01:26:35.381336
NCT00814957|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2017-07-05|2008-12-23|2008-12-25|Estimate|||||||2017-07-05|2017-07-07|Actual|December 8, 2008|Actual|2008-12-08|July 2017|2017-07-31|June 11, 2009|Actual|2009-06-11|June 11, 2009|Actual|2009-06-11||Interventional|||An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK618334, Using 11C-PHNO as PET Ligand.|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:26:35.902415|2018-06-01 01:26:35.902415
NCT00814944|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2013-01-08|2008-12-24|2008-12-25|Estimate|||||||2013-01-08|2013-01-10|Estimate|April 2009||2009-04-30|July 2010|2010-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model|A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model|Completed||Phase 2|143|Actual|Santen Inc.||4|||f||||f||||||||||2018-06-01 01:26:36.001164|2018-06-01 01:26:36.001164
NCT00814931|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2009-01-09|2008-12-23|2008-12-25|Estimate|||||||2009-01-09|2009-01-13|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CXB722-100||Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males|A Phase 1, Multiple Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Examining the Effects of CXB722 in Mitigating Neuroendocrine Stress Response in Healthy Males|Completed||Phase 1|23|Actual|National Institute on Aging (NIA)||2|||f||||f||||||||||2018-06-01 01:26:37.065428|2018-06-01 01:26:37.065428
NCT00814918|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2014-12-02|2008-12-24|2008-12-25|Estimate|||||||2014-12-02|2014-12-04|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|February 2014|Anticipated|2014-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris|Topical 5-ALA-PDT With Blu-U Therapy Vs. Topical 5-ALA With Pulse Dye Laser In Treatine Recalcitrant Acne Vulgaris|Withdrawn||N/A|0|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:26:37.139712|2018-06-01 01:26:37.139712
NCT00814905|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2009-08-27|2008-12-23|2008-12-25|Estimate|||||||2009-08-27|2009-08-28|Estimate|June 2009||2009-06-30|August 2009|2009-08-31|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Interventional|||Treatment of Chorioamnionitis After Delivery|Treatment of Chorioamnionitis After Delivery|Unknown status|Recruiting|N/A|300|Anticipated|United States Naval Medical Center, Portsmouth||4|||f||||f||||||||||2018-06-01 01:26:37.206974|2018-06-01 01:26:37.206974
NCT00814892|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2013-05-16||2013-10-08|2008-12-24|2008-12-25|Estimate|2013-07-26|2013-08-29|Estimate||||2013-10-08|2013-11-05|Estimate|January 2009||2009-01-31|October 2013|2013-10-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional||Since only two participants were accrued, patient confidentiality prevents the reporting of these two participants.|Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer|A Phase II Trial to Determine the Safety, Tolerability and Efficacy of an Allogeneic Whole Cell Vaccine Administered With Autologous Myeloid Dendritic Cells to Patients With Non-Metastatic Androgen Independent Prostate Carcinoma|Terminated||Phase 2|2|Actual|Mayo Clinic||1||Study was terminated due to funding issues.|f||||t||||||||||2018-06-01 01:26:37.318076|2018-06-01 01:26:37.318076
NCT00814879|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2015-11-23||2016-01-04|2008-12-24|2008-12-25|Estimate|2016-01-04|2016-02-04|Estimate||||2016-01-04|2016-02-04|Estimate|May 2009||2009-05-31|January 2016|2016-01-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Pilot Study of a Raltegravir Based NRTI Sparing Regimen|A Pilot Randomized, Open-Label Study Comparing the Safety and Efficacy of a Raltegravir Based NRTI Sparing Regimen|Completed||N/A|60|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:26:37.534138|2018-06-01 01:26:37.534138
NCT00814866|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2016-10-26|2008-12-23|2008-12-25|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|BROCA||Bone Resorption, Osteoclastogenesis and Adalimumab|Bone Resorption, Osteoclastogenesis and Adalimumab|Completed||N/A|28|Actual|Université de Sherbrooke||1|||f||||t||||||||Undecided||2018-06-01 01:26:38.150615|2018-06-01 01:26:38.150615
NCT00814853|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2009-08-03|2008-12-24|2008-12-25|Estimate|||||||2009-08-03|2009-08-04|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Observational|NAVA||Electrical Activity of the Diaphragm During Extubation Readiness Testing|Electrical Activity of the Diaphragm During Extubation Readiness Testing|Unknown status|Recruiting||25|Anticipated|Boston Children’s Hospital|||1||f||||t||||||||||2018-06-01 01:26:38.275325|2018-06-01 01:26:38.275325
NCT00814840|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2016-04-12|2008-12-23|2008-12-25|Estimate|||||||2016-04-12|2016-04-13|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|January 2015|Actual|2015-01-31|July 2010|Actual|2010-07-31||Interventional|TRUST CRT||Efficiency Study of Triple-Site Cardiac Resynchronization in Patients With Heart Failure|Triple-Site Versus Standard Cardiac Resynchronization Therapy (TRUST CRT) Randomized Trial|Completed||Phase 2/Phase 3|100|Actual|Silesian Centre for Heart Diseases||2|||f||||t||||||||||2018-06-01 01:26:38.433808|2018-06-01 01:26:38.433808
NCT00814827|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2018-05-08|2008-12-24|2008-12-25|Estimate|||||||2018-05-08|2018-05-09|Actual|December 23, 2008||2008-12-23|April 26, 2018|2018-04-26||||||||Observational|||Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma|Mycobacterial and Opportunistic Infections in HIV-Negative Patients Associated With Autoantibodies to Interferon-gamma|Active, not recruiting|||224|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:26:38.540507|2018-06-01 01:26:38.540507
NCT00814814|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2017-04-27|2008-12-24|2008-12-25|Estimate|||||||2017-04-27|2017-04-28|Actual|August 2008||2008-08-31|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|March 2019|Anticipated|2019-03-31||Observational|||Protein S100 Beta as a Predictor of Resuscitation Outcome|Protein S100 Beta as a Predictor of the Outcome of Cardiopulmonary Resuscitation|Active, not recruiting|||313|Actual|Shaare Zedek Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood~   "|Yes||2018-06-01 01:26:38.61796|2018-06-01 01:26:38.61796
NCT00814801|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2012-03-13||2014-03-31|2008-12-24|2008-12-25|Estimate|2012-06-01|2012-07-04|Estimate||||2014-03-31|2014-04-17|Estimate|February 2007||2007-02-28|March 2014|2014-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease|Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia|Completed||Phase 3|580|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 01:26:38.72888|2018-06-01 01:26:38.72888
NCT00814788|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2017-03-06||2018-01-05|2008-12-24|2008-12-25|Estimate|2017-05-01|2017-06-01|Actual||||2018-01-05|2018-01-10|Actual|December 2008||2008-12-31|January 2018|2018-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|UCDCC#215||Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer|Phase II Trial of Bicalutamide and RAD001 in Patients With Hormone-Independent Prostatic Adenocarcinoma (HIPC) After the First-Line Androgen Deprivation Therapy|Completed||Phase 2|24|Actual|University of California, Davis||1|||f||||t|t|f||||||||2018-06-01 01:26:39.261452|2018-06-01 01:26:39.261452
NCT00814775|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2016-06-20||2016-08-22|2008-12-23|2008-12-25|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparison Between the Fastrach and CTrach Laryngeal Mask Airway|Comparison Between the Fastrach and CTrach Laryngeal Mask Airway for Intubation of Patients With a Mallampati Score 3 or 4|Terminated||N/A|43|Actual|The Cleveland Clinic||2||recruitment challenges, device no longer available|f||||f||||||||||2018-06-01 01:26:39.596943|2018-06-01 01:26:39.596943
NCT00814762|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2017-05-30|2008-12-23|2008-12-25|Estimate|||||||2017-05-30|2017-05-31|Actual|February 3, 2009|Actual|2009-02-03|May 2017|2017-05-31|August 18, 2010|Actual|2010-08-18|August 18, 2010|Actual|2010-08-18||Interventional|||Safety of the HIV Vaccine 732461 in HIV Infected Subjects Aged 18 to 55 Years Old|Study to Evaluate the Safety and Reactogenicity of the HIV Vaccine 732461 in HIV Infected Subjects Aged 18 to 55 Years Old|Completed||Phase 1|41|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:26:39.923519|2018-06-01 01:26:39.923519
NCT00814749|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2008-12-24|2008-12-24|2008-12-25|Estimate|||||||2008-12-24|2008-12-25|Estimate|November 2008||2008-11-30|December 2008|2008-12-31|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|VUSIS 2||Value of Urodynamics Prior to Stress Incontinence Surgery 2|a Multicentered Randomised Controlled Trial to Test the Cost Effectiveness of Urodynamics in Women With Symptoms of Stress Urinary Incontinence in Whom Surgical Treatment is Considered|Unknown status|Recruiting|N/A|600|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 01:26:40.073754|2018-06-01 01:26:40.073754
NCT00814736|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-12-22|2008-12-22|2008-12-25|Estimate|||||||2008-12-22|2008-12-25|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031|A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate The Safety And Toleration Of Single Dose Sildenafil In Subjects Receiving Chronic UK-369,003.|Completed||Phase 1|22|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:26:40.208964|2018-06-01 01:26:40.208964
NCT00814723|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2008-12-24|2008-12-24|2008-12-25|Estimate|||||||2008-12-24|2008-12-25|Estimate|September 2005||2005-09-30|December 2008|2008-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk|Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk|Completed||Phase 4|90|Actual|Medical University of Graz||2|||f||||t||||||||||2018-06-01 01:26:40.312486|2018-06-01 01:26:40.312486
NCT00814710|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2010-10-21||2016-10-06|2008-12-23|2008-12-25|Estimate|2010-10-21|2010-10-29|Estimate||||2016-10-06|2016-11-16|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age|Primary Vaccination Course in Healthy Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Tritanrix™-HepB/Hib at 6, 10 and 14 Weeks of Age|Completed||Phase 3|360|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:26:40.462733|2018-06-01 01:26:40.462733
NCT00814697|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2013-05-02||2014-01-08|2008-12-24|2008-12-25|Estimate|2014-01-08|2014-01-28|Estimate||||2014-01-08|2014-01-28|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease|Open-label, Exploratory Study of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Naming and Verbal Fluency in Patients With Alzheimer's Disease With Functional Imaging Correlates|Completed||Phase 2|12|Actual|The New York Memory Services||1|||f||||f||||||||||2018-06-01 01:26:41.193737|2018-06-01 01:26:41.193737
NCT00814671|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2016-08-03||2018-01-08|2008-12-24|2008-12-25|Estimate|2016-08-03|2016-09-28|Estimate||||2018-01-08|2018-02-06|Actual|April 2010||2010-04-30|January 2018|2018-01-31|September 2014|Actual|2014-09-30|June 2013|Actual|2013-06-30||Interventional|||Study of Daily Rifapentine for Pulmonary Tuberculosis|A Phase 2 Randomized, Open-label Trial of Daily Rifapentine 450mg or 600mg in Place of Rifampicin 600mg for Intensive Phase Treatment of Smear-positive Pulmonary Tuberculosis|Completed||Phase 2|153|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-06-01 01:26:41.356121|2018-06-01 01:26:41.356121
NCT00814658|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|2012-11-27||2013-08-22|2008-12-24|2008-12-25|Estimate|2013-08-22|2013-08-26|Estimate||||2013-08-22|2013-08-26|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life|The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life|Completed||Phase 4|22|Actual|Janssen-Cilag Farmaceutica Ltda.|The major limitation of this study was the small sample size. This was probably due to the short enrollment period and to the rigorous inclusion criteria that were adopted.|2|||f||||||||||||||2018-06-01 01:26:41.796772|2018-06-01 01:26:41.796772
NCT00814645|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2012-02-15|2008-12-24|2008-12-25|Estimate|||||||2012-02-15|2012-02-17|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|AIR001-CS02||Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers|A Placebo-Controlled, Phase 1b, Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution (AIR001 INHALATION SOLUTION) in Normal, Healthy Volunteers|Completed||Phase 1|25|Actual|Aires Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-06-01 01:26:42.562538|2018-06-01 01:26:42.562538
NCT00814632|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2013-12-24||2015-08-11|2008-12-23|2008-12-25|Estimate|2014-09-25|2014-09-29|Estimate||||2015-08-11|2015-08-13|Estimate|December 2008||2008-12-31|August 2015|2015-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||CC-10004 For The Treatment Of Vulvodynia|A Clinical Trial Of CC-10004 For The Treatment Of Vulvodynia|Completed||Phase 2|10|Actual|William Beaumont Hospitals|Small pilot study without placebo arm. Only 7 subjects completed treatment.|1|||f||||t||||||||||2018-06-01 01:26:42.680996|2018-06-01 01:26:42.680996
NCT00814619|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2014-04-29|2008-12-24|2008-12-25|Estimate|||||||2014-04-29|2014-04-30|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|May 2010|Actual|2010-05-31||Interventional|||Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer|Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial|Completed||Phase 2|68|Actual|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||||2018-06-01 01:26:42.839711|2018-06-01 01:26:42.839711
NCT00814606|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2013-06-28|2008-12-24|2008-12-25|Estimate|||||||2013-06-28|2013-07-01|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C|A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C|Withdrawn||Phase 2|0|Actual|University of Chicago||1||no one ever enrolled|f||||f||||||||||2018-06-01 01:26:42.972539|2018-06-01 01:26:42.972539
NCT00814593|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2014-06-30|2008-12-24|2008-12-25|Estimate|||||||2014-06-30|2014-07-02|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery|Randomized Phase II Trial of Intralesional Lymphokine Activated Killer Cells or Polifeprosan 20 With Carmustine Implant (Gliadel® Wafer) as Consolidation Therapy After Primary Treatment of Newly Diagnosed Resectable Glioblastoma|Terminated||Phase 2|80|Actual|Caladrius Biosciences, Inc.||2||Hoag Hospital ceased support.|f||||f||||||||||2018-06-01 01:26:43.147269|2018-06-01 01:26:43.147269
NCT00814580|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2011-03-10||2012-11-13|2008-12-23|2008-12-25|Estimate|2011-12-05|2012-01-10|Estimate||||2012-11-13|2012-11-20|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery|A Randomized, Double-Blind, Multi-Center, Parallel-Group Study of Tapentadol Immediate Release (IR) Versus Oxycodone IR for the Treatment of Subjects With Acute Post-Operative Pain Following Elective Arthroscopic Shoulder Surgery|Completed||Phase 3|382|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|No notable study limitations were identified by the Sponsor|2|||f||||f||||||||||2018-06-01 01:26:43.342083|2018-06-01 01:26:43.342083
NCT00814567|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2011-01-06|2008-12-24|2008-12-25|Estimate|||||||2011-01-06|2011-01-07|Estimate|October 2006||2006-10-31|December 2008|2008-12-31||||June 2010|Anticipated|2010-06-30||Interventional|||Radiation Therapy in Treating Women With Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery|Randomised Trial Testing Intensity Modulated and Partial Organ Radiotherapy After Breast Conservation Surgery for Early Breast Cancer|Unknown status|Recruiting|Phase 3|1935|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 01:26:45.888928|2018-06-01 01:26:45.888928
NCT00814554|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2010-06-29|2008-12-24|2008-12-25|Estimate|||||||2010-06-29|2010-06-30|Estimate|September 2006||2006-09-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|PRALIMAP||Effectiveness Evaluation of Three Strategies of Promotion of Healthy Dietary and Physical Activity Behaviours to Prevent Weight Excess Among Teenagers|PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial|Completed||N/A|5458|Actual|University of Nancy||8|||f||||t||||||||||2018-06-01 01:26:46.195915|2018-06-01 01:26:46.195915
NCT00814541|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2014-12-30|2008-12-24|2008-12-25|Estimate|||||||2014-12-30|2014-12-31|Estimate|December 2005||2005-12-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|June 2009|Actual|2009-06-30||Interventional|||PAD. ICORG 05-01, V11|Phase II Study to Assess the Safety, Efficacy, and Tolerability of Combination Therapy With Velcade (Bortezomib), Doxorubicin, and Dexamethasone (PAD) as Therapy for Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|53|Actual|Cancer Trials Ireland||3|||f||||||||||||||2018-06-01 01:26:46.283845|2018-06-01 01:26:46.283845
NCT00814528|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2014-03-24|2008-12-23|2008-12-25|Estimate|||||||2014-03-24|2014-03-26|Estimate|November 2007||2007-11-30|March 2014|2014-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses|Photodynamic Therapy Mediated by Topical Application of 5- ALA for the Treatment of Actinic Keratoses|Terminated||N/A|3|Actual|University of Chicago||2||Not enough subjects for study to be completed.|f||||f||||||||||2018-06-01 01:26:46.392801|2018-06-01 01:26:46.392801
NCT00814515|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2010-07-15|2008-12-24|2008-12-25|Estimate|||||||2010-07-15|2010-07-16|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome|A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome|Completed||Phase 3|482|Anticipated|Santen SAS||2|||f||||t||||||||||2018-06-01 01:26:46.497194|2018-06-01 01:26:46.497194
NCT00814502|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2017-02-02||2017-04-12|2008-12-24|2008-12-25|Estimate|2017-04-12|2017-05-22|Actual||||2017-04-12|2017-05-22|Actual|December 2008||2008-12-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Zolpidem CR and Hospitalized Patients With Dementia|Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study|Completed||N/A|20|Actual|Massachusetts General Hospital|Small sample size. We were unable to control for different treatments that our subjects received as inpatients.|2|||f||||t||||||||No||2018-06-01 01:26:46.568184|2018-06-01 01:26:46.568184
NCT00814489|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2012-12-19||2013-07-18|2008-12-23|2008-12-25|Estimate|2012-12-19|2013-01-25|Estimate||||2013-07-18|2013-07-26|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults|A Study to Evaluate GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Healthy Young Adults|Completed||Phase 1|40|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 01:26:46.958427|2018-06-01 01:26:46.958427
NCT00814476|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2013-07-09|2008-12-23|2008-12-24|Estimate|||||||2013-07-09|2013-07-10|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CareLink||The Effects of Regular Home Use Vs Diabetic Team- Supported Use of the Medtronic CareLink Therapy Management System.|The Efficacy, Short and Long Term Effects of Regular Home Use Vs Diabetic Team - Supported Use of the Medtronic CareLink Therapy Management System in Patients With Diabetes|Completed||Phase 4|70|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 01:26:48.051309|2018-06-01 01:26:48.051309
NCT00814463|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2013-01-23||2014-08-04|2008-12-23|2008-12-24|Estimate|2013-05-03|2013-05-07|Estimate||||2014-08-04|2014-08-06|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases|Phase II Single-arm Study of Post-operative Stereotactic Radiosurgery for Brain Metastases.|Terminated||Phase 2|1|Actual|Duke University||1||Early analysis indicated SRS not as beneficial post-op as pre-op|f||||f||||||||||2018-06-01 01:26:48.118162|2018-06-01 01:26:48.118162
NCT00814450|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2009-12-29|2008-12-23|2008-12-24|Estimate|||||||2009-12-29|2009-12-30|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ANGS-PCAB||Safety & Accuracy of the ActiSight Needle Guidance System in Percutaneous Chest Aspiration and Biopsy|A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating The Preliminary Safety And Accuracy Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Percutaneous Chest Aspiration And Biopsy|Completed||N/A|20|Actual|ActiViews Ltd.|||||f||||f||||||||||2018-06-01 01:26:48.301032|2018-06-01 01:26:48.301032
NCT00814437|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2016-01-15|2008-12-23|2008-12-24|Estimate|||||||2016-01-15|2016-01-18|Estimate|April 2009||2009-04-30|January 2016|2016-01-31||||December 2012|Anticipated|2012-12-31||Observational|001-KIS||Physiological Role of KiSS-1/GPR54 System in the Human Ovary|Physiological Role of KiSS-1/GPR54 System in the Human Ovary|Withdrawn|||0|Actual|IVI Sevilla|||1|Lack of funding|f||||f||||||Samples With DNA|"~     Human granulosa cells~   "|||2018-06-01 01:26:48.385797|2018-06-01 01:26:48.385797
NCT00814424|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2008-12-23|2008-12-23|2008-12-24|Estimate|||||||2008-12-23|2008-12-24|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|July 2009|Anticipated|2009-07-31|May 2009|Anticipated|2009-05-31||Interventional|||Quantitive And Qualitive Assessment Of The Oxygen Delivery And EtCO2 Sampling With The Smart Bite Block Mark III During An Upper Endoscopic Procedure Under Sedation|Quantitive And Qualitive Assessment Of The Oxygen Delivery And EtCO2 Sampling With The Smart Bite Block Mark III During An Upper Endoscopic Procedure Under Sedation|Unknown status|Not yet recruiting|N/A|70|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:26:48.439939|2018-06-01 01:26:48.439939
NCT00814411|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2008-12-23|2008-12-23|2008-12-24|Estimate|||||||2008-12-23|2008-12-24|Estimate|June 2008||2008-06-30|December 2008|2008-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|GCFP||A Trial of Group Versus Individual Family Planning Counseling in Ghana|A Randomized Trial of Group vs. Individual Family Planning Counseling in Ghana|Completed||Phase 3|648|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 01:26:48.546654|2018-06-01 01:26:48.546654
NCT00814398|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2016-01-15|2008-12-23|2008-12-24|Estimate|||||||2016-01-15|2016-01-18|Estimate|December 2008||2008-12-31|March 2011|2011-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Single Embryo Transfer Versus Double Embryo Transfer|Single Embryo Transfer Versus Double Embryo Transfer in Day 3 or Blastocyst Stage|Terminated||N/A|199|Actual|IVI Sevilla||4||Change in cryopreservation protocol|f||||f||||||||||2018-06-01 01:26:48.611525|2018-06-01 01:26:48.611525
NCT00814385|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2014-06-02|2008-12-23|2008-12-24|Estimate|||||||2014-06-02|2014-06-03|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04|A Randomized, Partially Observer-blind, Single-centre Study to Evaluate Safety and Immunogenicity of MF59-adjuvanted or Non-adjuvanted H5N1 Influenza Vaccines in Adults Primed With Adjuvanted Influenza A/Vietnam/1194/04 (H5N1) Vaccine|Completed||Phase 1/Phase 2|606|Actual|University Hospitals, Leicester||9|||f||||t||||||||||2018-06-01 01:26:48.70478|2018-06-01 01:26:48.70478
NCT00814372|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22||2015-02-16|2015-03-30|2008-12-23|2008-12-24|Estimate||||2015-03-09|2015-03-30|Estimate|2015-03-30|2015-04-17|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MBX-102/JNJ-39659100 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy|Terminated||Phase 2|242|Actual|CymaBay Therapeutics, Inc.||4||MBX-102 did not meet the target efficacy profile of HbA1c change.|f||||f||||||||||2018-06-01 01:26:48.904402|2018-06-01 01:26:48.904402
NCT00814359|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2011-01-19|2008-12-23|2008-12-24|Estimate|||||||2011-01-19|2011-01-20|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis|A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.|Completed||Phase 3|67|Actual|Juravinski Cancer Centre Foundation||2|||f||||f||||||||||2018-06-01 01:26:49.054046|2018-06-01 01:26:49.054046
NCT00814346|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2015-09-11||2016-02-26|2008-12-23|2008-12-24|Estimate|2016-02-26|2016-03-28|Estimate||||2016-02-26|2016-03-28|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions|Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study|Completed||Phase 2|49|Actual|Ipsen||2|||f||||f||||||||||2018-06-01 01:26:49.177503|2018-06-01 01:26:49.177503
NCT00814333|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2015-12-10||2015-12-10|2008-12-23|2008-12-24|Estimate|2015-12-10|2016-01-15|Estimate||||2015-12-10|2016-01-15|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis|A Randomized Controlled Trial Comparing Outcomes in Patients Treated With Merocel Packing or Thrombin-JMI for Anterior Epistaxis|Terminated||N/A|1|Actual|University of Kansas Medical Center||2||Product supplier change - bought out. Unable to enroll patients.|f||||f||||||||||2018-06-01 01:26:51.006562|2018-06-01 01:26:51.006562
NCT00814320|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2015-01-21|2011-11-30|2017-10-19|2008-12-23|2008-12-24|Estimate|2015-10-30|2015-12-03|Estimate|2011-11-30|2011-12-02|Estimate|2017-10-19|2017-11-24|Actual|December 2008||2008-12-31|October 2015|2015-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Gammagard Liquid and rHuPH20 in PID|Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases|Completed||Phase 3|89|Actual|Shire||2|||f||||f||||||||||2018-06-01 01:26:51.491566|2018-06-01 01:26:51.491566
NCT00814307|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2012-12-05|2010-11-18|2013-01-10|2008-12-22|2008-12-24|Estimate|2012-12-05|2013-01-11|Estimate|2010-11-18|2010-11-29|Estimate|2013-01-10|2013-01-18|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis|Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis|Completed||Phase 3|611|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 01:26:58.777779|2018-06-01 01:26:58.777779
NCT00814294|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2009-06-29|2008-12-23|2008-12-24|Estimate|||||||2009-06-29|2009-06-30|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|October 2009|Anticipated|2009-10-31|September 2009|Anticipated|2009-09-30||Interventional|||Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus|An 18-Week Randomized, Double-Blind, Multicenter, Comparator Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 2/Phase 3|230|Anticipated|Diasome Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:27:01.628171|2018-06-01 01:27:01.628171
NCT00814281|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-05-20|2008-12-23|2008-12-24|Estimate|||||||2009-05-20|2009-05-21|Estimate|May 2007||2007-05-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?|Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?|Completed||N/A|24|Anticipated|Marywood University||4|||f||||f||||||||||2018-06-01 01:27:01.829819|2018-06-01 01:27:01.829819
NCT00814268|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2014-02-27|2008-12-23|2008-12-24|Estimate|||||||2014-02-27|2014-02-28|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|COMPRESS||COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke|COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial|Completed||Phase 4|358|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:27:01.906295|2018-06-01 01:27:01.906295
NCT00814255|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2015-09-09||2016-07-01|2008-12-23|2008-12-24|Estimate|2016-07-01|2016-07-11|Estimate||||2016-07-01|2016-07-11|Estimate|December 2008||2008-12-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Interventional|FONTII||Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial|Novel Therapies for Resistant Focal Segmental Glomerulosclerosis|Completed||Phase 2|32|Actual|New York University School of Medicine|"Limited sample size~Extended enrollment period~Replacement of rosiglitazone with galactose after start of trial"|3|||f||||t||||||||Yes|will comply with NIDDK guidelines|2018-06-01 01:27:01.997735|2018-06-01 01:27:01.997735
NCT00814242|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2016-03-30|2008-12-23|2008-12-24|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|November 2011|Actual|2011-11-30|December 2009|Actual|2009-12-31||Interventional|||Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels|A Randomized Control Trial of Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels|Completed||Phase 2/Phase 3|120|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-06-01 01:27:02.449546|2018-06-01 01:27:02.449546
NCT00814229|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2009-07-20|2008-12-23|2008-12-24|Estimate|||||||2009-07-20|2009-07-21|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|||Safety and Immunogenicity of Influenza H9 Vaccine in Humans|Randomised Dose Ranging Observer Blind Single Centre Study to Evaluate Safety and Immunogenicity of Adjuvanted and Non-adjuvanted Influenza H9 Influenza Vaccine in Humans|Completed||Phase 1|353|Actual|University Hospitals, Leicester||14|||f||||t||||||||||2018-06-01 01:27:02.531025|2018-06-01 01:27:02.531025
NCT00814216|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2017-03-06|2008-12-23|2008-12-24|Estimate|||||||2017-03-06|2017-03-08|Actual|December 2008||2008-12-31|February 2017|2017-02-28||||October 2009|Actual|2009-10-31||Interventional|||Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients|Randomized, Double-blind, Two Way Cross-over, Proof of Concept Study to Compare Efficacy, Safety, Pharmacokinetics & Pharmacodynamics of QAV680 Versus Placebo, With an Extended Open-label Corticosteroid Period, in Steroid-free, Mild to Moderate Persistent Asthma Patients.|Completed||Phase 2|37|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:27:02.651959|2018-06-01 01:27:02.651959
NCT00814203|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|||2015-04-20|2008-12-23|2008-12-24|Estimate|||||||2015-04-20|2015-04-21|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||A Registry of COPD Patients to be Used for Future Studies|The Ohio State University COPD Registry|Unknown status|Recruiting||600|Anticipated|Ohio State University|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:27:02.7408|2018-06-01 01:27:02.7408
NCT00814190|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2010-01-05|2008-12-22|2008-12-24|Estimate|||||||2010-01-05|2010-01-07|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM)|Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus|Completed||N/A|50|Actual|Endocrine Research Society||2|||f||||f||||||||||2018-06-01 01:27:02.804904|2018-06-01 01:27:02.804904
NCT00814177|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2009-10-07||2012-07-24|2008-12-23|2008-12-24|Estimate|2009-10-07|2009-11-25|Estimate||||2012-07-24|2012-08-01|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|FORESPEAK-0||Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients|Management of Prothrombin Times Outside the Therapeutic Range in Patients on Warfarin and With Otherwise Stable Levels|Completed||Phase 2|160|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 01:27:02.881242|2018-06-01 01:27:02.881242
NCT00814164|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2016-05-18||2016-07-07|2008-12-23|2008-12-24|Estimate|2016-07-07|2016-08-17|Estimate||||2016-07-07|2016-08-17|Estimate|December 2008||2008-12-31|July 2016|2016-07-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional||All treated and eligible patients|Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study Evaluating Mechanisms of Resistance Following Treatment With Clofarabine and Daunorubicin in Newly Diagnosed Adult Acute Myeloid Leukemia Patients > or = to 60 Years Old|Terminated||Phase 2|21|Actual|Roswell Park Cancer Institute||1||Sponsor withdrew support|f||||t||||||||||2018-06-01 01:27:03.167211|2018-06-01 01:27:03.167211
NCT00814151|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2008-12-23|2008-12-23|2008-12-24|Estimate|||||||2008-12-23|2008-12-24|Estimate|July 2008||2008-07-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial|Primary Investigation Into the Performance of the MicroPhage S. Aureus / MSSA / MRSA Test Direct From Blood Culture.|Completed|||712|Actual|MicroPhage, Inc.|||2||f||||f||||||Samples Without DNA|"~     Retention of discrepant blood culture specimens only.~   "|||2018-06-01 01:27:03.570227|2018-06-01 01:27:03.570227
NCT00814138|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-23|2015-07-23||2016-04-26|2008-12-23|2008-12-24|Estimate|2015-11-18|2015-12-23|Estimate||||2016-04-26|2016-05-26|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Eligible participatns were aged at least 18 years; had a diagnosis of generalized Myasthenia Gravis Foundation of America class II, III or IV; positive acetylcholine receptor antibodies; stable dose of greater than or equal to 10 mg/day of prednisone.|Efficacy of Methotrexate in Myasthenia Gravis|Phase II Trial of Methotrexate in Myasthenia Gravis|Completed||Phase 2|50|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 01:27:03.883733|2018-06-01 01:27:03.883733
NCT00814125|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2009-04-30|2008-12-23|2008-12-24|Estimate|||||||2009-04-30|2009-05-01|Estimate|June 1997||1997-06-30|April 2009|2009-04-30|December 2005|Actual|2005-12-31|||||Interventional|||ATAC - Endometrial Sub-Protocol|A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women|Completed||Phase 3|285|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 01:27:04.296937|2018-06-01 01:27:04.296937
NCT00814112|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-10-07|2008-12-22|2008-12-23|Estimate|||||||2009-10-07|2009-10-08|Estimate|November 2008||2008-11-30|October 2009|2009-10-31||||November 2010|Anticipated|2010-11-30||Observational|GAGS||Glycosaminoglycans During Septic Shock - a Temporal Study|GAGS - Glykosaminoglykaner Vid Sepsis|Unknown status|Recruiting||20|Anticipated|Region Skane|||2||f||||f||||||Samples Without DNA|"~     Plasma and Urine.~   "|||2018-06-01 01:27:04.362144|2018-06-01 01:27:04.362144
NCT00814099|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-07-14|2008-12-19|2008-12-23|Estimate|||||||2015-07-14|2015-07-15|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|RESTORE||Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)|Sedation Management in Pediatric Patients With Acute Respiratory Failure|Completed||Phase 3|2449|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 01:27:04.437667|2018-06-01 01:27:04.437667
NCT00814086|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-20|||2014-12-29|2008-12-20|2008-12-23|Estimate|||||||2014-12-29|2014-12-31|Estimate|February 2009||2009-02-28|December 2014|2014-12-31||||July 2011|Actual|2011-07-31||Interventional|||Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma|Completed||Phase 1|23|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 01:27:04.642969|2018-06-01 01:27:04.642969
NCT00814073|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2012-09-25|2008-12-22|2008-12-23|Estimate|||||||2012-09-25|2012-09-26|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap|A 24-week With Possible Extension, Prospective, Multicentre, Randomized, Double Blind, Placebo-controlled, 2-parallel Group With a Randomization 1:1, Phase III Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap|Unknown status|Recruiting|Phase 3|200|Anticipated|AB Science||2|||f||||t||||||||||2018-06-01 01:27:04.768208|2018-06-01 01:27:04.768208
NCT00814060|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2012-05-10|2008-12-22|2008-12-23|Estimate|||||||2012-05-10|2012-05-14|Estimate|January 2009||2009-01-31|May 2012|2012-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)|A Single Dose Bioavailability Study of 2 New Tablet Formulations of Neratinib Compared With a Reference Capsule in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Puma Biotechnology, Inc.||3|||f||||f||||||||||2018-06-01 01:27:04.93546|2018-06-01 01:27:04.93546
NCT00814047|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate||||December 2008|2008-12-31||||||||Interventional|||The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery|The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery|Completed||Phase 4|18||Medical University of Vienna|||||f||||t||||||||||2018-06-01 01:27:05.019249|2018-06-01 01:27:05.019249
NCT00814034|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2015-09-04|2008-12-22|2008-12-23|Estimate|||||||2015-09-04|2015-09-07|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Observational|COPA||Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy|An Observational, Prospective Cohort Study, on Blood Coagulation Parameters in Postmenopausal Patients With Operable Breast Cancer Who Are Treated as Per Standard Practice With Adjuvant Hormonal Therapy for a Total of 5 Years|Completed|||306|Actual|Hellenic Breast Surgeons Society|||3||f||||t||||||||||2018-06-01 01:27:05.109727|2018-06-01 01:27:05.109727
NCT00814021|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-20|||2014-11-04|2008-12-20|2008-12-23|Estimate|||||||2014-11-04|2014-11-05|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain|Phase II Study, Multicenter, Open-label, Evaluating Efficacy of Treatment With Sutent® (Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer|Completed||Phase 2|21|Actual|Institut Claudius Regaud||1|||f||||||||||||||2018-06-01 01:27:05.182225|2018-06-01 01:27:05.182225
NCT00814008|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate|March 1999||1999-03-31|December 2008|2008-12-31|December 2003|Actual|2003-12-31|April 2000|Actual|2000-04-30||Interventional|||The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp|The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp|Completed||Phase 2|64|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-06-01 01:27:05.263358|2018-06-01 01:27:05.263358
NCT00813995|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2011-08-09||2017-04-07|2008-12-22|2008-12-23|Estimate|2011-08-09|2011-09-13|Estimate||||2017-04-07|2017-05-12|Actual|December 9, 2008|Actual|2008-12-09|April 2017|2017-04-30|August 9, 2010|Actual|2010-08-09|August 9, 2010|Actual|2010-08-09||Interventional|||A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)|A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|395|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:27:05.378554|2018-06-01 01:27:05.378554
NCT00813982|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2010-09-03||2012-06-26|2008-12-22|2008-12-23|Estimate|2010-10-06|2010-10-29|Estimate||||2012-06-26|2012-06-29|Estimate|November 2008||2008-11-30|January 2011|2011-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Daily Wear Comparison of Enhanced and Non-Enhanced Silicone Hydrogel Lenses|Daily Wear Comparison of Enhanced and Non-Enhanced Silicone Hydrogel Lenses|Completed||N/A|60|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 01:27:05.747844|2018-06-01 01:27:05.747844
NCT00813969|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2016-03-28|2008-12-22|2008-12-23|Estimate|||||||2016-03-28|2016-03-30|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS|A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis|Completed||Phase 1|24|Actual|The Cleveland Clinic||1|||f||||t||||||||||2018-06-01 01:27:05.896143|2018-06-01 01:27:05.896143
NCT00813956|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19||2016-02-17|2016-02-17|2008-12-19|2008-12-23|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer||Completed||Phase 2|80|Actual|Sanofi||1|||t||||f||||||||||2018-06-01 01:27:05.962078|2018-06-01 01:27:05.962078
NCT00813943|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2014-08-29||2017-01-12|2008-12-22|2008-12-23|Estimate|2014-12-04|2014-12-08|Estimate||||2017-01-12|2017-01-30|Estimate|March 2009||2009-03-31|January 2017|2017-01-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|CORE|Intent-to-treat (ITT) population included all the participants who were randomized to study treatment.|Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status|Cilengitide in Subjects With Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). [The CORE Study]|Completed||Phase 2|265|Actual|EMD Serono||3|||f||||||||||||||2018-06-01 01:27:06.049124|2018-06-01 01:27:06.049124
NCT00813930|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2010-03-22|2008-12-22|2008-12-23|Estimate|||||||2010-03-22|2010-03-23|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|LIFE-DM||Lifestyle Intervention For Effective Diabetes Management|Lifestyle Intervention For Effective Diabetes Management (LIFE-DM) Trial|Unknown status|Active, not recruiting|N/A|50|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 01:27:07.073038|2018-06-01 01:27:07.073038
NCT00813917|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2011-08-05||2012-07-10|2008-12-22|2008-12-23|Estimate|2011-09-08|2011-09-09|Estimate||||2012-07-10|2012-07-16|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|CHANCHEW||Varenicline for the Treatment of Smokeless Tobacco|Varenicline for the Treatment of Smokeless Tobacco Use|Completed||N/A|76|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:27:07.153845|2018-06-01 01:27:07.153845
NCT00813904|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2011-11-03||2011-11-03|2008-12-22|2008-12-23|Estimate|2011-11-03|2011-12-08|Estimate||||2011-11-03|2011-12-08|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis|A Phase 4, Open-Label, Single-Group Immunogenicity and Safety Study of Re-exposure to RECOTHROM� (rThrombin) in Surgical Hemostasis|Completed||Phase 4|31|Actual|ZymoGenetics||1|||f||||t||||||||||2018-06-01 01:27:07.496502|2018-06-01 01:27:07.496502
NCT00813891|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration|Efficacy of Ranibizumab (Lucentis) in Combination With Photodynamic Therapy for Neovascular Age-Related Macular Degeneration|Unknown status|Not yet recruiting|Phase 4|180|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-06-01 01:27:07.734961|2018-06-01 01:27:07.734961
NCT00813878|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-20|||2017-10-11|2008-12-20|2008-12-23|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2001||2001-07-31|October 2017|2017-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease|Optical Biosensor for the Early Detection of Breast Cancer|Terminated|||126|Actual|City of Hope Medical Center|||2|Closed due to low accrual|f||||t||||||||||2018-06-01 01:27:07.86834|2018-06-01 01:27:07.86834
NCT00813865|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22||2012-09-07|2012-09-07|2008-12-22|2008-12-23|Estimate||||2012-09-07|2012-09-11|Estimate|2012-09-07|2012-09-11|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Long-Term Extension Study of AT2101 in Type 1 Gaucher Patients|An Open-label, Multicenter, Long-term Extension Study to Assess the Safety, Efficacy, and Pharmacodynamics of AT2101 in Adult Patients With Type 1 Gaucher Disease|Completed||Phase 2|8|Actual|Amicus Therapeutics||2|||f||||f||||||||||2018-06-01 01:27:07.962649|2018-06-01 01:27:07.962649
NCT00813852|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-21|||2012-06-14|2008-12-21|2008-12-23|Estimate|||||||2012-06-14|2012-06-15|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2008|Actual|2008-07-31||Interventional|||The Study of Skeletal Muscle Function in Obstructive Sleep Apnea|The Study of Skeletal Muscle Function in Obstructive Sleep Apnea|Completed||N/A|129|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 01:27:08.050632|2018-06-01 01:27:08.050632
NCT00813839|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-05-06|2008-12-22|2008-12-23|Estimate|||||||2015-05-06|2015-05-08|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Automated Ventilator Controlled Weaning vs Daily Spontaneous Breathing Trial in Difficult to Wean ICU Patients|Comparison of Automated Ventilator Controlled Weaning to Daily Spontaneous Breathing Trial Weaning Protocol in ICU Patients Following Prolonged Mechanical Ventilation.|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||2||for inability to enroll subjects.|f||||f||||||||||2018-06-01 01:27:08.120854|2018-06-01 01:27:08.120854
NCT00813826|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-07-29|2008-12-22|2008-12-23|Estimate|||||||2009-07-29|2009-07-30|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|November 2009|Anticipated|2009-11-30|October 2009|Anticipated|2009-10-31||Interventional|||Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia|Unknown status|Active, not recruiting|Phase 2|204|Anticipated|Solace Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:27:08.187414|2018-06-01 01:27:08.187414
NCT00813813|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2015-12-18||2016-01-26|2008-12-22|2008-12-23|Estimate|2015-12-18|2016-01-27|Estimate||||2016-01-26|2016-02-26|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Intradiscal rhGDF-5 Phase I/II Clinical Trial|Phase I/II, Multicenter, Open-label, Single Administration, Dose Finding, Clinical Trial to Evaluate the Safety and Tolerability of Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration|Completed||Phase 1/Phase 2|32|Actual|DePuy Spine||1|||f||||t||||||||||2018-06-01 01:27:08.304199|2018-06-01 01:27:08.304199
NCT00813800|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2011-11-11||2011-12-23|2008-12-22|2008-12-23|Estimate|2011-12-23|2012-01-30|Estimate||||2011-12-23|2012-01-30|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|Varenicline||Varenicline in Bipolar Depressed Patients|Varenicline for Smoking Cessation in Bipolar Depressed Patients: An Open-Label 12-week Feasibility Trial|Completed||N/A|11|Actual|Mayo Clinic|Small sample size; limitations finding participants with stable state within their bipolar disorder.|1|||f||||f||||||||||2018-06-01 01:27:08.59878|2018-06-01 01:27:08.59878
NCT00813787|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2014-10-01|2008-12-22|2008-12-23|Estimate|||||||2014-10-01|2014-10-03|Estimate|February 2009||2009-02-28|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using Multi-exponential T2 Components|Investigation Into the Differentiation of Tumour and Healthy Brain Tissue Using a Specialized MRI Technique Called Multiexponential T2 Component Analysis|Unknown status|Recruiting||20|Anticipated|AHS Cancer Control Alberta|||2||f||||t||||||||||2018-06-01 01:27:08.777383|2018-06-01 01:27:08.777383
NCT00813774|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2013-09-06|2008-12-19|2008-12-23|Estimate|||||||2013-09-06|2013-09-09|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers|Open, Randomized, Parallel Group, Single Dose, Bioavailability Comparison of 3 Certolizumab Pegol Solution Formulations (Lyophilized, Liquid, Pre-filled Syringe Formulation) to Healthy Volunteers|Completed||Phase 1|149|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 01:27:08.836699|2018-06-01 01:27:08.836699
NCT00813761|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2011-10-24||2017-06-14|2008-12-22|2008-12-23|Estimate|2011-10-24|2011-11-24|Estimate||||2017-06-14|2017-07-11|Actual|September 1, 2008|Actual|2008-09-01|June 2017|2017-06-30|August 1, 2009|Actual|2009-08-01|August 1, 2009|Actual|2009-08-01||Interventional|||Clinical Evaluation of the Long‑Term Effects of Contact Lens Care Systems||Completed||N/A|473|Actual|Johnson & Johnson Vision Care, Inc.||8|||f||||f||||||||||2018-06-01 01:27:08.922023|2018-06-01 01:27:08.922023
NCT00813748|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2015-08-14||2017-06-08|2008-12-22|2008-12-23|Estimate|2015-08-14|2015-09-15|Estimate||||2017-06-08|2017-07-11|Actual|March 2009|Actual|2009-03-31|June 2017|2017-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|X-PAND|All enrolled participants.|Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing|Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair(R) Dosing|Completed|||118|Actual|Genentech, Inc.|Endpoint prioritization was not specified in study protocol; hence, all endpoints are reported as primary.||||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:27:09.697385|2018-06-01 01:27:09.697385
NCT00813735|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2012-10-02|2008-12-22|2008-12-23|Estimate|||||||2012-10-02|2012-10-03|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder|Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder|Completed||Phase 4|60|Actual|Lehigh Center for Clinical Research||2|||f||||t||||||||||2018-06-01 01:27:10.58387|2018-06-01 01:27:10.58387
NCT00813722|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2008-12-19|2008-12-19|2008-12-23|Estimate|||||||2008-12-19|2008-12-23|Estimate|March 1999||1999-03-31|December 2008|2008-12-31|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Interventional|||Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment|Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 4|400|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-06-01 01:27:10.690938|2018-06-01 01:27:10.690938
NCT00813709|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2012-11-27||2017-01-25|2008-12-22|2008-12-23|Estimate|2013-10-25|2013-10-28|Estimate||||2017-01-25|2017-03-08|Actual|December 2008||2008-12-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|August 2011|Actual|2011-08-31||Interventional|REFLEXION|Baseline data was presented for ITT population (402 participants) which included participants who had completed the REFLEX Study 27025 (NCT00404352) and were enrolled in this extension Study 28981 (REFLEXION).|Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)|Double-blind Extension of the Study 27025 (REFLEX) to Obtain Long-term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New Formulation (REFLEXION)|Completed||Phase 3|402|Actual|Merck KGaA||3|||f||||||||||||||2018-06-01 01:27:10.866264|2018-06-01 01:27:10.866264
NCT00813696|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate|April 2002||2002-04-30|December 2008|2008-12-31|September 2009|Anticipated|2009-09-30|March 2009|Anticipated|2009-03-31||Interventional|GIP-1||Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer|Gemcitabine vs Gemcitabine + Cisplatin in the Treatment of Advanced Pancreatic Cancer (Stage II III IV)|Unknown status|Active, not recruiting|Phase 3|400|Actual|Istituti Tumori Giovanni Paolo II||2|||f||||f||||||||||2018-06-01 01:27:12.263498|2018-06-01 01:27:12.263498
NCT00813683|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2015-10-19|2008-12-22|2008-12-23|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2008||2008-02-29|December 2008|2008-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Cephalic Version by Acupuncture for Breech Presentation|Study of Cephalic Version by Acupuncture for Breech Presentation.|Completed||N/A|259|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 01:27:12.383405|2018-06-01 01:27:12.383405
NCT00813670|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-09-10|2008-12-19|2008-12-23|Estimate|||||||2009-09-10|2009-09-14|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers|Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XPF-001 and to Investigate the Effect of Food on the Pharmacokinetics of a Single Dose of XPF-001 in Healthy Subjects|Completed||Phase 1|64|Anticipated|Xenon Pharmaceuticals Inc.||8|||f||||||||||||||2018-06-01 01:27:12.453698|2018-06-01 01:27:12.453698
NCT00813657|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate|January 2000||2000-01-31|December 2008|2008-12-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Resistance Exercise Training During Pregnancy: a Randomized Controlled Trial|Effects of Resistance Exercise Training Program Performed During the 2nd and 3rd Trimesters of Pregnancy on Maternal and Newborn Health|Completed||Phase 4|80|Actual|Universidad Politecnica de Madrid||1|||f||||t||||||||||2018-06-01 01:27:12.510102|2018-06-01 01:27:12.510102
NCT00813644|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-21|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate|December 2008||2008-12-31|December 2008|2008-12-31||||||||Observational|UROSIMULATOR08||A Study of Flexible Ureteroscopy Proficiency After Training on the Uromentor Simulator||Unknown status|Active, not recruiting||20|Anticipated|Rabin Medical Center|||2||f||||||||||||||2018-06-01 01:27:12.551749|2018-06-01 01:27:12.551749
NCT00813631|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-21|||2009-05-17|2008-12-21|2008-12-23|Estimate|||||||2009-05-17|2009-05-19|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|November 2009|Anticipated|2009-11-30|May 2009|Anticipated|2009-05-31||Interventional|MFW||The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound|The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound|Unknown status|Recruiting|Phase 4|70|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 01:27:12.594905|2018-06-01 01:27:12.594905
NCT00813618|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2008-12-19|2008-12-19|2008-12-23|Estimate|||||||2008-12-19|2008-12-23|Estimate|September 1999||1999-09-30|December 2008|2008-12-31|August 2004|Actual|2004-08-31|June 2004|Actual|2004-06-30||Interventional|Pediatric GvHD||Study of MEDI 507 in the Treatment of Pediatric Patients|Phase I Study of MEDI 507 in the Treatment of Pediatric Patients With at Least Grade II Acute Graft-Versus-Host Disease (GvHD)|Completed||Phase 1|10|Actual|MedImmune LLC||3|||f||||f||||||||||2018-06-01 01:27:12.676304|2018-06-01 01:27:12.676304
NCT00813605|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22||2016-03-07|2016-10-26|2008-12-22|2008-12-23|Estimate||||2016-03-07|2016-04-04|Estimate|2016-10-26|2016-10-27|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|January 2011|Actual|2011-01-31||Interventional|||QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma|A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma|Completed||Phase 2|155|Actual|NantCell, Inc.||3|||f||||f||||||||||2018-06-01 01:27:12.745552|2018-06-01 01:27:12.745552
NCT00813592|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2014-04-02||2014-06-04|2008-12-19|2008-12-23|Estimate|2014-04-02|2014-05-12|Estimate||||2014-06-04|2014-06-11|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma|A Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Who Have Previously Undergone or Are Not Candidates for Additional Surgery or Radiation|Terminated||Phase 2|2|Actual|University of Utah||1||Original PI left and company withdrew support.|f||||t||||||||||2018-06-01 01:27:14.062366|2018-06-01 01:27:14.062366
NCT00813579|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Observational|||Study of Prospective Assessment of Living Kidney Donors: Pre and Post Donation|Study of Prospective Assessment of Living Kidney Donors:Pre and Post Donation|Unknown status|Enrolling by invitation||80|Anticipated|Mansoura University|||||f||||t||||||||||2018-06-01 01:27:14.263709|2018-06-01 01:27:14.263709
NCT00813566|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2018-01-02|2008-12-19|2008-12-23|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2008||2008-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Multi-Tracer PET Assessment of Primary Brain Tumors|Multi-Tracer PET Assessment of Primary Brain Tumors|Recruiting|||20|Anticipated|University of Utah|||1||f||||t||||||||||2018-06-01 01:27:14.306986|2018-06-01 01:27:14.306986
NCT00813553|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2012-04-24|2008-12-22|2008-12-23|Estimate|||||||2012-04-24|2012-04-25|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|LitmusMagnet||Effect of β-alanine Supplementation on Muscle Carnosine|Effect of Two 8-week β-alanine Supplementation Protocols on Muscle Carnosine|Completed||N/A|30|Anticipated|Nestlé||3|||f||||f||||||||||2018-06-01 01:27:14.371945|2018-06-01 01:27:14.371945
NCT00813540|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2016-03-10|2008-12-22|2008-12-23|Estimate|||||||2016-03-10|2016-03-11|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors|The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|52|Actual|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-06-01 01:27:14.5239|2018-06-01 01:27:14.5239
NCT00813527|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2012-05-23|2008-12-19|2008-12-23|Estimate|||||||2012-05-23|2012-05-24|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels|A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia|Completed||Phase 2|213|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:27:14.613999|2018-06-01 01:27:14.613999
NCT00813514|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2014-11-20|2008-12-22|2008-12-23|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?|Does VEGF or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With CNV?|Withdrawn||N/A|0|Actual|Medical University of Vienna||1|||f||||||||||||||2018-06-01 01:27:14.773523|2018-06-01 01:27:14.773523
NCT00813501|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-20|||2011-03-03|2008-12-20|2008-12-23|Estimate|||||||2011-03-03|2011-03-07|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases|Evaluation of Clinical Utility of the Cylex ImmunKnow Assay in Hematopoietic Cell Transplantation|Terminated|||60|Actual|City of Hope Medical Center||||Terminated at the request of the study sponsor|f||||t||||||||||2018-06-01 01:27:14.860924|2018-06-01 01:27:14.860924
NCT00813488|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2010-08-31||2012-05-22|2008-12-22|2008-12-23|Estimate|2010-12-29|2010-12-31|Estimate||||2012-05-22|2012-05-28|Estimate|December 2008||2008-12-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain|A Double Blind, Active Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain|Completed||Phase 3|213|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 01:27:15.085367|2018-06-01 01:27:15.085367
NCT00813475|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-21|||2008-12-22|2008-12-22|2008-12-23|Estimate|||||||2008-12-22|2008-12-23|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study|Clinical Outcome of Tight Glucose Control of Diabetic Patients Hospitalized In General Internal Medicine Wards A National Israeli Study|Unknown status|Not yet recruiting|N/A|200|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 01:27:16.478315|2018-06-01 01:27:16.478315
NCT00813449|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-12-06|2008-12-22|2008-12-23|Estimate|||||||2009-12-06|2009-12-08|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|melanoma||Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma|Multicenter, Double-blinding, Randomized Controlled, Phase II Clinical Trial on Combined Chemotherapy of Endostar (Recombinant Human Endostatin) for Untreated Patients With Advanced Melanoma|Unknown status|Recruiting|Phase 2|140|Anticipated|Simcere Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-06-01 01:27:16.545628|2018-06-01 01:27:16.545628
NCT00813436|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-02-04|2008-12-22|2008-12-23|Estimate|||||||2009-02-04|2009-02-05|Estimate|May 2008||2008-05-31|December 2008|2008-12-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|20070766||The Effect of Intranasal Administration of Oxytocin on Empathic Abilities.|The Effect of Intranasal Administration of Oxytocin on Empathic Abilities of Healthy People and People Who Suffer From Schizophrenia.|Unknown status|Recruiting|Phase 2|100|Anticipated|Shalvata Mental Health Center||2|||f||||||||||||||2018-06-01 01:27:16.621806|2018-06-01 01:27:16.621806
NCT00813423|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-20|||2018-05-23|2008-12-20|2008-12-23|Estimate|||||||2018-05-23|2018-05-24|Actual|January 27, 2010|Actual|2010-01-27|May 2018|2018-05-31||||July 30, 2013|Actual|2013-07-30||Interventional|||Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy|Autophagic Modulation With Anti-angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine|Active, not recruiting||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:27:16.711259|2018-06-01 01:27:16.711259
NCT00813410|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-20|||2008-12-20|2008-12-20|2008-12-23|Estimate|||||||2008-12-20|2008-12-23|Estimate|February 2007||2007-02-28|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Adipose Tissue of Diabetic Patients|A Single Center, Open-Labeled Exploratory Study to Evaluate a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue of Type-1 Diabetic Patients|Completed||N/A|14|Actual|Medical University of Graz|||||f||||t||||||||||2018-06-01 01:27:16.783833|2018-06-01 01:27:16.783833
NCT00813397|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-05-21|2008-12-19|2008-12-23|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|C-MUST||Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.|Manageability and Safety Assessment of the SepraSpray Anti-adhesion Barrier in Abdominal Coelioscopic Surgery|Completed||N/A|210|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:27:16.838857|2018-06-01 01:27:16.838857
NCT00813384|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2014-12-12|2008-12-22|2008-12-23|Estimate|||||||2014-12-12|2014-12-16|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|February 2013|Actual|2013-02-28||Interventional|||A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors|A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 208 in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|54|Actual|Amgen||2|||f||||f||||||||||2018-06-01 01:27:16.923784|2018-06-01 01:27:16.923784
NCT00813371|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-08-24|2008-12-22|2008-12-23|Estimate|||||||2009-08-24|2009-08-25|Estimate|December 2008||2008-12-31|August 2009|2009-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Airway Pressure Release Ventilation as a Preventative Strategy|Airway Pressure Release Ventilation as a Preventative Strategy in Patients at Risk for Acute Respiratory Distress Syndrome|Withdrawn||N/A|0|Actual|Texas Tech University Health Sciences Center||2||Principal Investigator left the institution before subjects were enrolled|f||||f||||||||||2018-06-01 01:27:17.091254|2018-06-01 01:27:17.091254
NCT00813358|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2018-05-03|2008-12-22|2008-12-23|Estimate|||||||2018-05-03|2018-05-09|Actual|July 2009||2009-07-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|TX2 2PAS||Zenith TX2® Post-market Approval Study|Zenith TX2® TAA Endovascular Graft Post-approval Study|Active, not recruiting||N/A|115|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-06-01 01:27:17.169936|2018-06-01 01:27:17.169936
NCT00813345|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2009-04-24|2008-12-22|2008-12-23|Estimate|||||||2009-04-24|2009-04-27|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|LI-AMB||Ambulatory Anesthesia and Light Therapy|A Role for Light Therapy at Immediate Recovery From Short Duration Ambulatory Anesthesia to Prevent Dysregulation of Circadian Rest-Activity Rhythm in Patients Submitted to Colonoscopy.|Unknown status|Recruiting|N/A|360|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 01:27:17.276822|2018-06-01 01:27:17.276822
NCT00813332|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2010-01-22|2008-12-22|2008-12-23|Estimate|||||||2010-01-22|2010-01-25|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|October 2010|Anticipated|2010-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)|A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar（rh Recombined Endostatin）With Single Docetaxel In NSCLC Patients|Unknown status|Recruiting|Phase 4|300|Anticipated|Simcere Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-06-01 01:27:17.403358|2018-06-01 01:27:17.403358
NCT00813319|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2014-06-10||2014-08-11|2008-12-22|2008-12-23|Estimate|2014-08-11|2014-08-12|Estimate||||2014-08-11|2014-08-12|Estimate|October 2009||2009-10-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|November 2012|Actual|2012-11-30||Interventional|Girls OnGuard||Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females|Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents|Completed||Phase 3|216|Actual|Emory University|Limited sample size; Brevity of the computer-administered intervention; Substantial variability between and within clinics with respect to patient-provider interactions; Lack of a follow-up assessment.|2|||f||||t||||||||||2018-06-01 01:27:17.499112|2018-06-01 01:27:17.499112
NCT00813306|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2010-12-06|2008-12-22|2008-12-23|Estimate|||||||2010-12-06|2010-12-07|Estimate|December 2008||2008-12-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|||||Interventional|||14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations|A Double-blind, Randomized, Placebo-controlled, Single-centre Phase I Pharmacodynamic Cross-over Study to Assess the Effect of a Single Dose of AZD2066 Oral Solution in Comparison to Placebo on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in Healthy Subjects|Completed||Phase 1/Phase 2|40|Anticipated|AstraZeneca||5|||f||||f||||||||||2018-06-01 01:27:17.746179|2018-06-01 01:27:17.746179
NCT00813293|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2017-02-23|2008-12-22|2008-12-23|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2009|Actual|2009-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer|Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer|Active, not recruiting||Phase 2|20|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|f||||||Undecided||2018-06-01 01:27:17.821405|2018-06-01 01:27:17.821405
NCT00813280|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-11-25|2008-12-22|2008-12-23|Estimate|||||||2015-11-25|2015-11-26|Estimate|June 2008||2008-06-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|||Barriers to the Implementation of Complete Insulin Order Sets|Barriers to the Implementation of Complete Insulin Order Sets in the Management of Individuals With Hyperglycemia or Diabetes at Park Nicollet Methodist Hospital|Completed|||200|Actual|HealthPartners Institute|||1||f||||f||||||||||2018-06-01 01:27:17.906218|2018-06-01 01:27:17.906218
NCT00813267|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-21|||2012-10-06|2008-12-22|2008-12-23|Estimate|||||||2012-10-06|2012-10-10|Estimate|December 2009||2009-12-31|October 2012|2012-10-31|August 2015|Anticipated|2015-08-31|August 2011|Actual|2011-08-31||Interventional|||Mesenchymal Stem Cell for Osteonecrosis of the Femoral Head|Mesenchymal Stem Cell Transplantation in the Treatment of Osteonecrosis of the Femoral Head|Unknown status|Active, not recruiting|Early Phase 1|15|Actual|Fuzhou General Hospital||1|||f||||t||||||||||2018-06-01 01:27:17.984091|2018-06-01 01:27:17.984091
NCT00813254|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2012-04-18|2008-12-22|2008-12-23|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Cost Utility Analysis in Recurrent Ovarian Cancer|Quality of Life and Cost Utility Analysis in the Treatment of Recurrent, Platinum-Resistant Ovarian Cancer|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:27:18.066032|2018-06-01 01:27:18.066032
NCT00813241|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|||2010-03-01|2008-12-22|2008-12-23|Estimate|||||||2010-03-01|2010-03-02|Estimate|January 2009||2009-01-31|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers|A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Formulations Of Celecoxib In Healthy Volunteers|Completed||Phase 1|16|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:27:18.14646|2018-06-01 01:27:18.14646
NCT00813228|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2018-05-18|2008-12-19|2008-12-22|Estimate|||||||2018-05-18|2018-05-21|Actual|December 18, 2008||2008-12-18|January 19, 2018|2018-01-19|June 17, 2011|Actual|2011-06-17|||||Interventional|||Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals|Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals|Completed||Phase 1|76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:27:18.221677|2018-06-01 01:27:18.221677
NCT00813215|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2011-03-07|2008-12-19|2008-12-22|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|August 2011|Anticipated|2011-08-31|December 2010|Actual|2010-12-31||Interventional|PPDysMet||Postprandial Dysmetabolism|Postprandial Dysmetabolism - The Effects of Monounsaturated vs. Saturated Lipids on Lipid and Carbohydrate Metabolism and Inflammation in Healthy 1st Degree Relatives of Patients With Type 2 Diabetes.|Unknown status|Active, not recruiting|N/A|34|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-06-01 01:27:18.295637|2018-06-01 01:27:18.295637
NCT00813202|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-02-26|2008-12-18|2008-12-22|Estimate|||||||2014-02-26|2014-02-28|Estimate|October 2006||2006-10-31|February 2014|2014-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure|An Open-label, Single Arm, Multi-centered Clinical Trial on the Hemodynamics and Safety of Nesiritide in the Treatment of Patients With Acute Decompensate Heart Failure|Completed||Phase 3|41|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-06-01 01:27:18.363139|2018-06-01 01:27:18.363139
NCT00813189|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-05-04|2008-12-19|2008-12-22|Estimate|||||||2015-05-04|2015-05-05|Estimate|April 2005||2005-04-30|May 2015|2015-05-31|May 2012|Actual|2012-05-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy Study of Recombinant Growth Hormone on Muscle Function in Children Long-term Treated With Glucocorticoid|Effects of Growth Hormone on Corticoid Myopathy in Children With Chronic Disease: Effects on Muscle Mass and Strength|Completed||Phase 3|30|Actual|Association REMEDE||2|||f||||f||||||||||2018-06-01 01:27:18.443623|2018-06-01 01:27:18.443623
NCT00813176|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||One-Lung Ventilation in the Morbidly Obese Patient: A Comparison of a Left-Sided Broncho-Cath® Double Lumen Tube With the Arndt® Wire-Guided Blocker||Completed||N/A|50|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 01:27:18.514042|2018-06-01 01:27:18.514042
NCT00813163|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18||2014-06-28|2017-04-04|2008-12-19|2008-12-22|Estimate||||2014-06-28|2014-07-01|Estimate|2017-04-04|2017-04-06|Actual|January 2009||2009-01-31|January 2015|2015-01-31|July 2012|Actual|2012-07-31|December 2010|Actual|2010-12-31||Interventional|||Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer|A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|41|Actual|PharmaEngine||1|||f||||f||||||||||2018-06-01 01:27:18.599172|2018-06-01 01:27:18.599172
NCT00813150|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2014-03-28||2014-07-31|2008-12-18|2008-12-22|Estimate|2014-07-31|2014-08-15|Estimate||||2014-07-31|2014-08-15|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Number of Intent-to-treat (ITT) participants were included in Baseline analysis. Out of 93 randomized participants (Vd=46; Vcd=47), follow-up data on treatment response was not available for 3 participants, so, they were excluded from the Intent-to-treat (ITT) analysis data set and so, ITT included 90 participants (Vd=43; Vcd=47).|Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma|Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma|Completed||Phase 3|96|Actual|Janssen-Cilag G.m.b.H||2|||f||||f||||||||||2018-06-01 01:27:18.708008|2018-06-01 01:27:18.708008
NCT00813137|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-12-06|2008-12-19|2008-12-22|Estimate|||||||2009-12-06|2009-12-08|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer|A Multi-center Study of Folfox4 Combined With Recombinant Human Endostatin(Endostar)in Advanced Colorectal Cancer|Unknown status|Recruiting|Phase 2|120|Anticipated|Simcere Pharmaceutical Co., Ltd||1|||f||||t||||||||||2018-06-01 01:27:19.579322|2018-06-01 01:27:19.579322
NCT00813124|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-09-30|2008-12-18|2008-12-22|Estimate|||||||2014-09-30|2014-10-01|Estimate|December 2008||2008-12-31|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)|Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)|Completed||Phase 2|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:27:19.678294|2018-06-01 01:27:19.678294
NCT00813111|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2011-11-22|2010-08-25|2013-11-30|2008-12-18|2008-12-22|Estimate|2013-11-30|2014-01-16|Estimate|2010-08-27|2010-08-31|Estimate|2013-11-30|2014-01-16|Estimate|November 2008||2008-11-30|November 2013|2013-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation|A Phase 3, Multicenter, Randomized, Double-blind Parallel-group, Active-control Study to Evaluate the Safety and Efficacy of Local Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Bilateral, Cosmetic Sub-muscular Breast Augmentation|Terminated||Phase 3|136|Actual|Pacira Pharmaceuticals, Inc||2||Sponsor decision, unrelated to safety|f||||f||||||||||2018-06-01 01:27:19.794112|2018-06-01 01:27:19.794112
NCT00813098|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2010-10-05||2010-11-04|2008-12-19|2008-12-22|Estimate|2010-11-04|2010-12-02|Estimate||||2010-11-04|2010-12-02|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|July 2009|Actual|2009-07-31||Interventional|||Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome|Completed||Phase 2|155|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:27:20.086636|2018-06-01 01:27:20.086636
NCT00813085|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|April 2002||2002-04-30|December 2008|2008-12-31|December 2003|Actual|2003-12-31|September 2003|Actual|2003-09-30||Interventional|COMPETEII||A Randomized Trial of Electronic Integration of Care for Better Diabetes Outcomes; The COMPETE II Study|A Randomized Trial of Electronic Integration of Care for Better Diabetes Outcomes; The COMPETE II Study|Completed||N/A|511|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 01:27:20.527692|2018-06-01 01:27:20.527692
NCT00813072|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2012-03-01|2008-12-19|2008-12-22|Estimate|||||||2012-03-01|2012-03-02|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma|A Randomized Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Completed||Phase 2|135|Actual|PharmaEngine||3|||f||||t||||||||||2018-06-01 01:27:20.590395|2018-06-01 01:27:20.590395
NCT00813059|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2012-02-06|2008-12-19|2008-12-22|Estimate|||||||2012-02-06|2012-02-08|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy|Intravitreal Bevacizumab for Treatment of the Second Eye With Non-Arteritic Ischemic Optic Neuropathy|Unknown status|Recruiting|Phase 2|10|Anticipated|Mount Sinai Hospital, Canada||1|||f||||t||||||||||2018-06-01 01:27:20.689574|2018-06-01 01:27:20.689574
NCT00813046|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2014-05-23|2008-12-19|2008-12-22|Estimate|||||||2014-05-23|2014-05-26|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis|Preliminary Assessment of the Short Term Clinical Tolerability and Safety of Grass Pollen-derived Peptides for Oral Use in Antigen-specific Immunotherapy of Seasonal Allergic Rhinoconjunctivitis|Completed||Phase 1|8|Actual|BioTech Tools S.A.||1|||f||||t||||||||||2018-06-01 01:27:20.836931|2018-06-01 01:27:20.836931
NCT00813033|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2011-06-22|2008-12-19|2008-12-22|Estimate|||||||2011-06-22|2011-06-27|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Use of a Patient Decision Aid for Gastrologic Endoscopy in a Pediatric Setting|Creation and Pilot Evaluation of a Patient Decision Aid as an Adjunct to the Consenting Process for Gastrointestinal Endoscopy in a Pediatric Setting|Completed||N/A|80|Anticipated|Children's Mercy Hospital Kansas City||1|||f||||f||||||||||2018-06-01 01:27:20.893848|2018-06-01 01:27:20.893848
NCT00813020|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-02-20|2008-12-19|2008-12-22|Estimate|||||||2015-02-20|2015-02-23|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects|A Randomised, Single Centre, Double-blind, Incomplete Block Trial to Test for Equivalence Between Subcutaneous Injections of the GLP-1 Analogue NN9535 in 1 mg/ml, 3 mg/ml and 10 mg/ml Concentrations in Healthy Male Subject|Completed||Phase 1|44|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 01:27:20.951607|2018-06-01 01:27:20.951607
NCT00813007|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2017-10-18|2008-12-19|2008-12-22|Estimate|||||||2017-10-18|2017-10-20|Actual|December 16, 2008|Actual|2008-12-16|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Radical Trachelectomy for Women With Early Stage Cervical Cancer|Radical Trachelectomy for Women With Early Stage Cervical Cancer|Active, not recruiting|||50|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:27:21.019681|2018-06-01 01:27:21.019681
NCT00812994|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|January 2003||2003-01-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|December 2006|Actual|2006-12-31||Interventional|Lex/BDNF||Neurotrophic Factors and Depression|Blood Levels of Neurosteroids and Neurotrophic Factors in Normal Controls and in Patients With Major Depression|Completed||Phase 4|30|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:27:21.083304|2018-06-01 01:27:21.083304
NCT00812981|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2017-03-29|2009-09-09|2017-03-29|2008-12-18|2008-12-22|Estimate|2017-03-29|2017-06-16|Actual|2009-09-09|2009-09-10|Estimate|2017-03-29|2017-06-16|Actual|November 15, 2008|Actual|2008-11-15|March 2017|2017-03-31|June 7, 2009|Actual|2009-06-07|June 7, 2009|Actual|2009-06-07||Interventional|||A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.|Non-inferiority Study of GSK Biologicals' Pandemic Influenza Vaccine 1562902A.|Completed||Phase 3|320|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:27:21.193727|2018-06-01 01:27:21.193727
NCT00812968|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2013-09-30||2016-10-28|2008-12-19|2008-12-22|Estimate|2013-09-30|2013-12-17|Estimate||||2016-10-28|2016-12-12|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.|A Multicenter, Single-arm Study to Assess the Safety, Pharmacokinetics and Efficacy of Lenalidomide in Japanese Subjects With Low- or Intern=Mediate-1-risk Myelodysplastic Syndromes (MDS) Associated With a Deletion 5 (q31-33) Abnormality and Symptomatic Anemia|Completed||Phase 2|11|Actual|Celgene Corporation||1|||f||||t||||||||||2018-06-01 01:27:21.95322|2018-06-01 01:27:21.95322
NCT00812955|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2012-04-25|2010-08-27|2012-09-27|2008-12-19|2008-12-22|Estimate|2012-06-13|2012-08-01|Estimate|2010-09-03|2010-09-08|Estimate|2012-09-27|2012-10-03|Estimate|November 2008||2008-11-30|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||"Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (Bad Cholesterol) and Triglycerides"|An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects With Hypercholesterolemia|Completed||Phase 3|474|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:27:22.553439|2018-06-01 01:27:22.553439
NCT00812942|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|November 2003||2003-11-30|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2005|Actual|2005-11-30||Interventional|||Participation to Colorectal Cancer Screening With Fecal Occult Blood Test and Colonoscopy|Participation to Colorectal Cancer Screening With Faecal Occult Blood Test and Colonoscopy: an Italian, Multicenter, Randomized Population Study|Completed||N/A|9889|Actual|Istituto Superiore di Sanità||2|||f||||f||||||||||2018-06-01 01:27:23.242624|2018-06-01 01:27:23.242624
NCT00812929|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2017-07-10|2010-02-05|2017-08-21|2008-12-18|2008-12-22|Estimate|2017-08-21|2017-09-19|Actual|2010-02-05|2010-02-10|Estimate|2017-08-21|2017-09-19|Actual|December 1, 2008||2008-12-01|August 2017|2017-08-31|July 15, 2009|Actual|2009-07-15|June 1, 2009|Actual|2009-06-01||Interventional|||A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise|A Multi-centre, Randomized, Double-blind, Five-way Crossover Study Evaluating the Dose Response and Duration of Action of GSK2190915 Compared to Placebo in Subjects With Mild Asthma Who Experience Exercise Induced Bronchoconstriction.|Completed||Phase 2|47|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:27:23.393304|2018-06-01 01:27:23.393304
NCT00812916|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2015-11-12||2016-01-13|2008-12-19|2008-12-22|Estimate|2015-11-12|2015-12-16|Estimate||||2016-01-13|2016-02-08|Estimate|September 2008||2008-09-30|January 2016|2016-01-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|EXPRESSO|Enrolled patients|European Carto® XP REgistry for Validating Specialized CFAE SOftware|EXPRESSO - European Carto® XP REgistry for Validating Specialized CFAE SOftware|Completed|||206|Actual|Biosense Webster, Inc.|||1||f||||f||||||||||2018-06-01 01:27:25.148675|2018-06-01 01:27:25.148675
NCT00812903|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2015-12-01|2008-12-18|2008-12-22|Estimate|||||||2015-12-01|2015-12-03|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|||Neck Pain in Danish Military Pilots and Flight Crew|Neck Pain in Danish Military Pilots and Flight Crew - Environmental Factors With Influence on Performance (PH.D.-Project)|Completed||N/A|60|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-06-01 01:27:25.325602|2018-06-01 01:27:25.325602
NCT00812890|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2011-07-20|2008-12-18|2008-12-22|Estimate|||||||2011-07-20|2011-07-22|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Exploring Semi-Quantitative Pregnancy Tests and Their Impact on Reproductive Health Service Provision|Exploring Semi-Quantitative Pregnancy Tests and Their Impact on Reproductive Health Service Provision|Completed||Phase 1|400|Actual|Stanford University|||||f||||||||||||||2018-06-01 01:27:25.386098|2018-06-01 01:27:25.386098
NCT00812877|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2013-08-15||2015-05-03|2008-12-18|2008-12-22|Estimate|2015-05-03|2015-05-25|Estimate||||2015-05-03|2015-05-25|Estimate|May 2009||2009-05-31|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|MTA||Pulp Capping With Two Different Agents|Mineral Trioxide Aggregate (MTA) vs. Calcium Hydroxide (CaOH) in Direct Pulp Capping in NW PRECEDENT (Northwest Practice-based REsearch Collaborative in Evidence-based DENTistry Practices.|Completed||N/A|376|Actual|Oregon Health and Science University|"Randomization was by practice therefore, some dentists may have used a material with which they had little familiarity.~Lack of on-going monitoring of study procedures may have caused an inordinate number of failures in one practice."|2|||f||||t||||||||||2018-06-01 01:27:25.445206|2018-06-01 01:27:25.445206
NCT00812864|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2012-12-04|2008-12-19|2008-12-22|Estimate|||||||2012-12-04|2012-12-05|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional|capagec||Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)|Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥75 Years)|Completed||Phase 4|20|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 01:27:25.797209|2018-06-01 01:27:25.797209
NCT00812851|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2009-02-17|2008-12-19|2008-12-22|Estimate|||||||2009-02-17|2009-02-19|Estimate|April 2005||2005-04-30|November 2008|2008-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)|Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)|Completed||N/A|24|Actual|Cantonal Hospital of St. Gallen|||||f||||f||||||||||2018-06-01 01:27:25.864784|2018-06-01 01:27:25.864784
NCT00812838|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2016-11-07|2008-12-19|2008-12-22|Estimate|||||||2016-11-07|2016-11-09|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|||H-22411: BOTOX® for Peyronie's Disease|The Efficacy of Botulinum Toxin Type a in Treating Peyronie's Disease|Recruiting||Phase 2|20|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No|Data will be published in aggregate.|2018-06-01 01:27:25.941366|2018-06-01 01:27:25.941366
NCT00812825|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-08-11|2008-12-19|2008-12-22|Estimate|||||||2009-08-11|2009-08-12|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers|A Phase 1, Active and Placebo-Controlled, Multiple-Dose Escalation Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04171327 (Part 1), and a Single Dose Pharmacokinetic Assessment of a Tablet Formulation (Part 2) in Healthy Volunteers|Completed||Phase 1|78|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:27:26.061629|2018-06-01 01:27:26.061629
NCT00812812|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2011-09-08||2016-11-29|2008-12-18|2008-12-22|Estimate|2011-09-08|2011-10-13|Estimate||||2016-11-29|2017-01-13|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)|A Randomised, Double-blind, Placebo Controlled, Parallel Group , Flexible Dose Study to Evaluate the Efficacy and Safety of Paxil® Tablets in Children and Adolescents With Major Depressive Disorder<Post-marketing Clinical Study>|Terminated||Phase 4|56|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:27:26.15125|2018-06-01 01:27:26.15125
NCT00812799|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2010-04-29|2008-12-19|2008-12-22|Estimate|||||||2010-04-29|2010-04-30|Estimate|December 2008||2008-12-31|April 2010|2010-04-30|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|||A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis|A Randomised Double Blind Placebo-controlled, Long-term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis|Unknown status|Active, not recruiting|Phase 3|374|Actual|Artu Biologicals||2|||f||||f||||||||||2018-06-01 01:27:26.572057|2018-06-01 01:27:26.572057
NCT00812786|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2013-08-23|2008-12-19|2008-12-22|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2007||2007-07-31|December 2008|2008-12-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|PIGREC||Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients|Multicentre, Open Study for the Setting up of Population Pharmacokinetic Models and Bayesian Estimators for Individual Dose Adjustment of Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Everolimus) During the First Year Post-grafting in Adult Heart Transplant Recipients.|Completed||Phase 4|42|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 01:27:26.717925|2018-06-01 01:27:26.717925
NCT00812773|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2016-10-11|2008-12-18|2008-12-22|Estimate|||||||2016-10-11|2016-10-12|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study to Evaluate GSK2190915 in Subjects With Mild Asthma|A Randomised, Double-blind, Placebo-controlled, 3-period Cross-over Study to Evaluate the Effect of Two Doses of GSK2190915 on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma|Completed||Phase 2|17|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:27:26.793323|2018-06-01 01:27:26.793323
NCT00812760|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|October 2001||2001-10-31|December 2008|2008-12-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Effect of Levodopa on Human Multifocal Electroretinogram|Effect of Levodopa on Human Multifocal Electroretinogram|Completed||Phase 4|20|Actual|Medical University of Vienna||1|||f||||||||||||||2018-06-01 01:27:27.071297|2018-06-01 01:27:27.071297
NCT00812747|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|June 2007||2007-06-30|December 2008|2008-12-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Observational|||Surgical Wound Infections After Vascular Surgery: Prospective Multicenter Trial|Surgical Wound Infections After Vascular Surgery: Prospective Multicenter Trial|Completed|||||North Karelia Central Hospital|||1||f||||f||||||||||2018-06-01 01:27:27.149546|2018-06-01 01:27:27.149546
NCT00812734|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2013-04-02|2008-12-19|2008-12-22|Estimate|||||||2013-04-02|2013-04-04|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|September 2011|Actual|2011-09-30|March 2010|Actual|2010-03-31||Observational|EDONIS||Epidemiologic Multicentre Study of Neuropathic Post-surgical Pain|Etude épidémiologique Multicentrique Des Douleurs Neuropathiques Post-opératoires|Completed|||3322|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-06-01 01:27:27.213937|2018-06-01 01:27:27.213937
NCT00812721|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2017-03-30|2008-12-19|2008-12-22|Estimate|||||||2017-03-30|2017-04-04|Actual|January 2009||2009-01-31|March 2017|2017-03-31|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|||Tears Substitutions and Their Effects on Higher Order Aberrometery|Tears Substitutions and Their Effects on Higher Order Aberrometery|Withdrawn||N/A|0|Actual|University of Iowa||5||PI left institution|f||||t||||||||||2018-06-01 01:27:27.283056|2018-06-01 01:27:27.283056
NCT00812708|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2017-07-14|2008-12-19|2008-12-22|Estimate|||||||2017-07-14|2017-07-19|Actual|September 2002||2002-09-30|July 2017|2017-07-31|December 2030|Anticipated|2030-12-31|June 2014|Actual|2014-06-30||Interventional|||Morcher Artificial Iris Devices to Treat Light and Glare Sensitivity in Partial or Complete Aniridia|Compassionate Use Study of Morcher Artificial Iris Devices to Treat Light and Glare Sensitivity in Partial or Complete Aniridia|Active, not recruiting||N/A|72|Actual|University of California, Los Angeles||1|||f||||t||||||||No||2018-06-01 01:27:27.369743|2018-06-01 01:27:27.369743
NCT00812695|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2011-11-21|2008-12-19|2008-12-22|Estimate|||||||2011-11-21|2011-11-23|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Continuous Positive Airway Pressure (CPAP) in Patients With Resistant Hypertension and Obstructive Sleep Apnea (OSA)|Effects of Continuous Positive Airway Pressure in Patients With Resistant Hypertension and Obstructive Sleep Apnea|Completed||Phase 3|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:27:27.458843|2018-06-01 01:27:27.458843
NCT00812682|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2011-01-21|2008-12-19|2008-12-22|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2006||2006-09-30|January 2011|2011-01-31|August 2007|Actual|2007-08-31|||||Observational|REALITY||Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler|Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler|Completed|||217|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:27:27.522134|2018-06-01 01:27:27.522134
NCT00812669|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2017-11-21|2008-12-19|2008-12-22|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2008||2008-08-31|November 2017|2017-11-30|September 2022|Anticipated|2022-09-30|June 2021|Anticipated|2021-06-30||Interventional|||CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7|An Open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide and Rituximab in Patients With Chronic Lymphocytic Leukaemia Who Are Newly Diagnosed, Have Relapsed or Are Resistant to First-Line Treatment|Active, not recruiting||Phase 2|145|Anticipated|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 01:27:27.575308|2018-06-01 01:27:27.575308
NCT00812656|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-12-02|2008-12-19|2008-12-22|Estimate|||||||2009-12-02|2009-12-03|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|Stroke08||Serial Measurement of a Plasma Stroke Biomarker Panel in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Serial Measurement of a Plasma Stroke Biomarker Panel in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Completed|||50|Actual|Klinikum Ludwigshafen|||1||f||||f||||||||||2018-06-01 01:27:27.742665|2018-06-01 01:27:27.742665
NCT00812643|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-03-10|2008-12-19|2008-12-22|Estimate|||||||2009-03-10|2009-03-11|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|||||Interventional|||Excretion of Radiolabelled AZD0837|An Open, Single Centre Pharmacokinetic (Phase 1) Study of the Biliary Excretion of AZD0837 and Metabolites Following a Single Dose of [3H] AZD0837 Given in the Duodenum Via a Loc-I-Gut Catheter to Young Healthy Male Subjects|Completed||Phase 1|8|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:27:27.799121|2018-06-01 01:27:27.799121
NCT00812630|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2017-08-11|2008-12-19|2008-12-22|Estimate|||||||2017-08-11|2017-08-15|Actual|December 2008||2008-12-31|August 2017|2017-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study|A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 1|68|Actual|Population Council||1|||f||||f||||||||||2018-06-01 01:27:27.864172|2018-06-01 01:27:27.864172
NCT00812617|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-10-05|2008-12-19|2008-12-22|Estimate|||||||2009-10-05|2009-10-06|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|||||Interventional|||Effects of Mineral Water Consumption on Serum Lipid Parameters|Effects of Mineral Water Consumption on Serum Lipid Parameters: a Double-Blind, Randomized Controlled Trial|Completed||N/A|90|Anticipated|Hiroshima University||2|||f||||||||||||||2018-06-01 01:27:27.93809|2018-06-01 01:27:27.93809
NCT00812604|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2012-06-26||2014-05-21|2008-12-19|2008-12-22|Estimate|2014-05-21|2014-06-23|Estimate||||2014-05-21|2014-06-23|Estimate|April 2007||2007-04-30|May 2014|2014-05-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Analgesic Ointment on Temporomandibular Joint and Masticatory Muscle Pain|Effect of an Analgesic Ointment on the Relief of Temporomandibular Joint and Masticatory Muscle Pain: a Randomized, Double Blinded, Placebo-controlled Study.|Completed||N/A|55|Actual|The University of Hong Kong|In this study, the subjects were screened by clinical examinations and self-reported questionnaires. Ideally, the diagnosis should be made with a combination of radiographs, Magnetic Resonance Imaging or Computer Tomography.|2|||f||||f||||||||||2018-06-01 01:27:28.00929|2018-06-01 01:27:28.00929
NCT00812591|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2011-10-18|2008-12-19|2008-12-22|Estimate|||||||2011-10-18|2011-10-19|Estimate|May 2006||2006-05-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue for the Treatment of Type-1 Diabetic Patients|Evaluation of a Novel Method for Integrating Insulin Delivery and Glucose Sensing in Subcutaneous Tissue for the Treatment of Type-1 Diabetic Patients|Completed||N/A|20|Actual|Medical University of Graz|||||f||||t||||||||||2018-06-01 01:27:28.297899|2018-06-01 01:27:28.297899
NCT00812578|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2010-07-09|2008-12-19|2008-12-22|Estimate|||||||2010-07-09|2010-07-12|Estimate|December 2008||2008-12-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ProjectD||Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes|Metabolic Effects of Vitamin D in Patients With Type 2 Diabetes - a Randomized Controlled Trial|Completed||Phase 2|16|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 01:27:28.367157|2018-06-01 01:27:28.367157
NCT00812565|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2013-12-02||2014-04-02|2008-12-19|2008-12-22|Estimate|2014-04-02|2014-05-05|Estimate||||2014-04-02|2014-05-05|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||Full analysis set: All randomized patients who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment.|Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease|Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%)|Completed||Phase 2|58|Actual|Octapharma|Small numbers of patients per treatment group (between 5 and 8) and variable total Aβ levels over time.|8|||f||||t||||||||||2018-06-01 01:27:28.495646|2018-06-01 01:27:28.495646
NCT00812552|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-04-22|2008-12-18|2008-12-22|Estimate|||||||2013-04-22|2013-04-23|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|DESERT||Drug Eluting Stent Registry of Thrombosis|Drug Eluting Stent Registry of Thrombosis|Completed|||984|Actual|Medstar Health Research Institute|||2||f||||||||||||||2018-06-01 01:27:29.93299|2018-06-01 01:27:29.93299
NCT00812539|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-08-01|2008-12-18|2008-12-22|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Diabetes Connect: Patients and Providers Use of a Secure Website for Blood Glucose Monitoring in Type-2 Diabetes|A Randomized Clinical Trial of a Secure Website Shared Between Patients and Providers for Blood Glucose Monitoring in Type-2 Diabetes|Completed||N/A|20|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:27:30.115898|2018-06-01 01:27:30.115898
NCT00812526|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|September 2002||2002-09-30|December 2008|2008-12-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Regulation of Choroidal Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Regulation of Choroidal Blood Flow During Combined Changes in Intraocular Pressure and Arterial Blood Pressure|Completed||N/A|18|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 01:27:30.188748|2018-06-01 01:27:30.188748
NCT00812513|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2011-07-19|2008-12-19|2008-12-22|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns|Phase II Study of Efficacy of Recombinant Human Platelet-derived Growth Factor (R-Pdf/Gbb) in Healing Wounds Caused by Third Degree Thermal and Electrical Burns.|Unknown status|Not yet recruiting|Phase 2|120|Anticipated|American Scitech International|||||f||||f||||||||||2018-06-01 01:27:30.246941|2018-06-01 01:27:30.246941
NCT00812500|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-09-23|2008-12-19|2008-12-22|Estimate|||||||2013-09-23|2013-09-24|Estimate|May 2002||2002-05-31|December 2008|2008-12-31|January 2006|Actual|2006-01-31|May 2003|Actual|2003-05-31||Interventional|||Dietary Protein Requirement of Elderly Men and Women|Dietary Protein Requirement of Elderly Men and Women|Completed||N/A|48|Actual|Purdue University||4|||f||||||||||||||2018-06-01 01:27:30.318032|2018-06-01 01:27:30.318032
NCT00812487|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2013-09-06||2013-11-09|2008-12-19|2008-12-22|Estimate|2013-11-09|2013-12-31|Estimate||||2013-11-09|2013-12-31|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2012|Actual|2012-08-31||Interventional||"Patients were excluded from the analyses as described in Participant Flow"|Glycemic Control and Variability for Congestive Heart Failure Exacerbation|Glycemic Control and Variability for Congestive Heart Failure Exacerbation|Completed||Phase 1/Phase 2|75|Actual|Ohio State University|The study was limited by study drop-out. Sensor glucose values were reduced due to sensor failures, and cardiac assessments were limited due to a high number of patients with ectopy, arrhythmia or paced rhythms at baseline precluding analysis.|2|||f||||t||||||||||2018-06-01 01:27:30.400173|2018-06-01 01:27:30.400173
NCT00812474|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-11-16|2008-12-19|2008-12-22|Estimate|||||||2015-11-16|2015-11-18|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|June 2009|Actual|2009-06-30||Observational|||Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis|Regional Cortical Cerebral Quantitative MRI Perfusion Correlation Neurocognition in Multiple Sclerosis|Completed|||60|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 01:27:30.80038|2018-06-01 01:27:30.80038
NCT00812461|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2013-03-12||2013-07-17|2008-12-19|2008-12-22|Estimate|2013-07-05|2013-07-09|Estimate||||2013-07-17|2013-07-22|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|ESENSE2||Efficacy of Nalmefene in Patients With Alcohol Dependence|Nalmefene Efficacy Study II: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, as Needed Use, in Patients With Alcohol Dependence|Completed||Phase 3|678|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:27:30.873402|2018-06-01 01:27:30.873402
NCT00812448|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2009-11-24|2008-12-19|2008-12-22|Estimate|||||||2009-11-24|2009-11-26|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Catechin Containing Mask for the Prevention of Influenza Infection|The Effects of Tea Catechin Extracts Containing Mask on the Prevention of Influenza Infection|Completed||N/A|180|Actual|University of Shizuoka||1|||f||||f||||||||||2018-06-01 01:27:31.559659|2018-06-01 01:27:31.559659
NCT00812435|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-17|||2014-08-08|2008-12-19|2008-12-22|Estimate|||||||2014-08-08|2014-08-11|Estimate|August 2007||2007-08-31|August 2014|2014-08-31|March 2011|Actual|2011-03-31|July 2010|Actual|2010-07-31||Interventional|ESTEEM||Eptifibatide and ST Segment Resolution Following Primary PCI|Eptifibatide and ST Segment Resolution Following Primary PCI|Terminated||Phase 3|22|Actual|Medstar Health Research Institute||1|||f||||t||||||||||2018-06-01 01:27:31.637033|2018-06-01 01:27:31.637033
NCT00812422|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2010-01-15|2008-12-19|2008-12-22|Estimate|||||||2010-01-15|2010-01-18|Estimate|February 2008||2008-02-29|January 2010|2010-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Efficacy and Safety of Dexibuprofen Syrup|Multi-center, Randomized, Double Blinded (Double-dummy), Active-Controlled Parallel-group Comparative, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Dexibuprofen Syrup Compared to Ibuprofen Syrup in Patients With Fever of Common Cold (Acute Upper Respiratory Infection)|Completed||Phase 3|260|Actual|Inje University||3|||f||||t||||||||||2018-06-01 01:27:31.723454|2018-06-01 01:27:31.723454
NCT00812409|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-01-16|2008-12-19|2008-12-22|Estimate|||||||2013-01-16|2013-01-17|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|S-017||Resistance and Aerobic Exercise With Nutritional Supplementation in Men and Women|Resistance and Aerobic Exercise With Nutritional Supplementation in Men and Women|Completed||N/A|580|Actual|Purdue University||4|||f||||||||||||||2018-06-01 01:27:31.937495|2018-06-01 01:27:31.937495
NCT00812396|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2015-01-29|2008-12-19|2008-12-22|Estimate|||||||2015-01-29|2015-01-30|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Biomarkers of Muscle Anabolism (MK-0000-082)|A Randomized, Single-Blind, Placebo-Controlled, Fixed-Sequence, Single-Dose, Parallel Design Study to Utilize Comparative Proteomics to Identify Early Biomarkers of Muscle Anabolism|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:27:32.005514|2018-06-01 01:27:32.005514
NCT00812383|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-10-31|2008-12-19|2008-12-22|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2003||2003-08-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|COBRA||Carotid With Bivalirudin Angioplasty|Carotid With Bivalirudin Angioplasty|Completed||Phase 2/Phase 3|299|Actual|Medstar Health Research Institute||2|||f||||||||||||||2018-06-01 01:27:32.078728|2018-06-01 01:27:32.078728
NCT00812370|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2016-07-13|2008-12-18|2008-12-22|Estimate|||||||2016-07-13|2016-07-15|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|UNBLOCK||The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids|An Open-label, Dose-finding, Pharmacokinetic, Safety and Efficacy Study of Bivalirudin in Children Between 6 Months and 18 Years of Age|Completed||Phase 1|18|Actual|Children's Hospital Los Angeles||1|||f||||t||||||||||2018-06-01 01:27:32.149328|2018-06-01 01:27:32.149328
NCT00812357|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2011-12-27|2008-12-19|2008-12-22|Estimate|||||||2011-12-27|2011-12-29|Estimate|April 2009||2009-04-30|December 2011|2011-12-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Observational|SYMBIOSE||Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France|Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma|Completed|||579|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:27:32.268728|2018-06-01 01:27:32.268728
NCT00812344|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2010-12-02|2008-12-19|2008-12-22|Estimate|||||||2010-12-02|2010-12-03|Estimate|December 2008||2008-12-31|December 2010|2010-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Ketoconazole on Biliary Excretion of AZD0837|An Open, Randomised, Cross-over, Single Centre Pharmacokinetic (Phase I) Study of the Biliary Excretion Following Single Doses of AZD0837, Given in the Duodenum Via a Loc-I-Gut Catheter, Alone or in Combination With Ketoconazole (Once Daily for 4 Days), to Young Healthy Male Subjects|Completed||Phase 1|20|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:27:32.69756|2018-06-01 01:27:32.69756
NCT00812331|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2013-12-24|2013-03-28|2014-07-01|2008-12-18|2008-12-22|Estimate|2014-07-01|2014-07-28|Estimate|2013-03-28|2013-04-04|Estimate|2014-07-01|2014-07-28|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)|An Open-label Trial in Genotype 2, 3, 4, 5 and 6 Hepatitis C-infected Subjects to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 Following 7 Days Once Daily Dosing as Monotherapy.|Completed||Phase 2|37|Actual|Tibotec Pharmaceuticals, Ireland||5|||f||||f||||||||||2018-06-01 01:27:32.860027|2018-06-01 01:27:32.860027
NCT00812318|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2012-03-29|2008-12-18|2008-12-22|Estimate|||||||2012-03-29|2012-04-02|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.|A Single Dose, Randomized Study to Assess the Relative Bioavailability of Two Formulations and Food Effect on GSK1265744 in Healthy Male and Female Subjects|Completed||Phase 1|45|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-06-01 01:27:33.636397|2018-06-01 01:27:33.636397
NCT00812305|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09||2010-08-25|2010-09-03|2008-12-18|2008-12-22|Estimate||||2010-08-31|2010-09-06|Estimate|2010-09-03|2010-09-08|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects|A Randomized, Double-Blind, Phase 1 Study to Assess the Pharmacokinetics and Safety of SKY0402 in Subjects With Impaired Hepatic Function|Completed||Phase 1|16|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:27:33.719398|2018-06-01 01:27:33.719398
NCT00812292|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2011-06-08|2008-12-18|2008-12-22|Estimate|||||||2011-06-08|2011-06-09|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet Formulation|A Phase I, Open-label, Randomized, Crossover Trial in Healthy Adults to Compare the Oral Bioavailability of TMC278 From Three Concept Pediatric Formulations (Solution, Suspension, Granules) With That From the Adult Phase III Tablet Formulation.|Completed||Phase 1|36|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:27:33.785927|2018-06-01 01:27:33.785927
NCT00812279|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2009-03-05|2008-12-19|2008-12-22|Estimate|||||||2009-03-05|2009-03-06|Estimate|November 2008||2008-11-30|March 2009|2009-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article|A Controlled, Randomised, Open-Label, 3-Arm Parallel Single-Centre Confinement Study to Investigate Exposure to Selected Smoke Constituents in Smokers Switching From Conventional Cigarettes to SMAR Cigarettes for 5 Days|Completed||N/A|112|Actual|Philip Morris Products S.A.||3|||f||||f||||||||||2018-06-01 01:27:33.852706|2018-06-01 01:27:33.852706
NCT00812266|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2016-01-23|2008-12-19|2008-12-22|Estimate|||||||2016-01-23|2016-01-26|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|December 2013|Actual|2013-12-31||Interventional|||Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)|Randomized Phase III Trial of Topotecan and Cisplatin Versus Etoposide and Carboplatin in the Treatment of Patients With Previously Untreated Small Cell Lung Cancer and Extensive Disease|Terminated||Phase 3|281|Actual|Danish Oncological Lung Cancer Group||2||Slow accrual|f||||f||||||||||2018-06-01 01:27:33.935496|2018-06-01 01:27:33.935496
NCT00812253|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|2014-06-12||2017-12-03|2008-12-19|2008-12-22|Estimate|2014-07-14|2014-08-07|Estimate||||2017-12-03|2018-01-02|Actual|January 2009||2009-01-31|December 2017|2017-12-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional||Baseline population consists of patients with available study data.|Intensive Glycemic Control for Congestive Heart Failure Exacerbation|Intensive Glycemic Control for Congestive Heart Failure Exacerbation|Completed||Phase 2|74|Actual|Ohio State University|HRV and impedance data were limited due to medical devices, conditions that preclude measurement of HRV such as arrhythmias, or technical problems (N=2). The remainder of missing data were due to early hospital discharge.|2|||f||||t||||||||||2018-06-01 01:27:34.020724|2018-06-01 01:27:34.020724
NCT00812240|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2012-09-25|2008-12-19|2008-12-22|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment|A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumour in First Line Medical Treatment|Unknown status|Recruiting|Phase 3|222|Anticipated|AB Science||2|||f||||t||||||||||2018-06-01 01:27:34.318202|2018-06-01 01:27:34.318202
NCT00812227|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-05-09|2008-12-19|2008-12-22|Estimate|||||||2013-05-09|2013-05-13|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Neural Correlates of Psychodynamic Psychotherapy for Depression|Neural Correlates of Psychodynamic Psychotherapy for Depression|Completed||N/A|35|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:27:34.423565|2018-06-01 01:27:34.423565
NCT00812214|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate|April 2007||2007-04-30|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Insomnia in Migraineurs|Treatment of Insomnia in Migraineurs With Eszopiclone (Lunesta™) and Its Effect on Sleep Time, Headache Frequency, and Daytime Functioning: a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study|Completed||Phase 4|113|Actual|MedVadis Research Corporation||2|||f||||f||||||||||2018-06-01 01:27:34.483453|2018-06-01 01:27:34.483453
NCT00812201|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2012-10-02|2008-12-19|2008-12-22|Estimate|||||||2012-10-02|2012-10-03|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Observational|ELEVATE||Evaluation of Left Ventricular AutoThreshold|Evaluation of Left Ventricular AutoThreshold|Completed|||80|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-06-01 01:27:34.545519|2018-06-01 01:27:34.545519
NCT00812188|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-12-08|2008-12-19|2008-12-22|Estimate|||||||2014-12-08|2014-12-09|Estimate|November 2004||2004-11-30|December 2014|2014-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.|A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea|Completed||N/A|24|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 01:27:34.602284|2018-06-01 01:27:34.602284
NCT00812175|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2016-10-14|2008-12-19|2008-12-22|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|GIDEON||Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib|Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib|Completed|||3371|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:27:34.785422|2018-06-01 01:27:34.785422
NCT00812162|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-01-16|2008-12-18|2008-12-22|Estimate|||||||2013-01-16|2013-01-17|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|February 2009|Actual|2009-02-28||Interventional|||Effects of Dietary Pork and Egg on Appetite, Meal-patterning, and Weight Loss in Men|Effects of Dietary Pork and Egg on Appetite, Meal-patterning, and Weight Loss in Men|Completed||N/A|48|Actual|Purdue University||2|||f||||t||||||||||2018-06-01 01:27:34.954529|2018-06-01 01:27:34.954529
NCT00812149|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-19|||2017-10-05|2008-12-19|2008-12-22|Estimate|||||||2017-10-05|2017-10-06|Actual|December 17, 2008||2008-12-17|May 16, 2014|2014-05-16|May 16, 2014||2014-05-16|||||Observational|||Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3|Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers:The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3|Completed|||86|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:27:35.015947|2018-06-01 01:27:35.015947
NCT00812136|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-19|2008-12-19|2008-12-22|Estimate|||||||2008-12-19|2008-12-22|Estimate||||October 2008|2008-10-31||||||||Interventional|PMA||Parent Mentor Asthma Study|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|Completed||N/A|||University of Texas Southwestern Medical Center|||||f||||t||||||||||2018-06-01 01:27:35.079197|2018-06-01 01:27:35.079197
NCT00812123|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-18|2008-12-18|2008-12-19|Estimate|||||||2008-12-18|2008-12-19|Estimate|January 2001||2001-01-31|December 2008|2008-12-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Calcineurin Free Immunosuppression in Renal Transplant Recipients|Open, Single Center, Randomised, Parallel Group Pilot Study to Investigate a Calcineurin Free Immunosuppressive Treatment for de Novo Renal Transplant Recipients: A Comparison of a Rapamycin/MMF/Steroids Regime to a Cyclosporine A Neoral/MMF/Steroids Regimen in the Prevention of Acute Rejection Following Renal Transplantation|Completed||Phase 4|127|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 01:27:35.187575|2018-06-01 01:27:35.187575
NCT00812110|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2011-10-31||2012-12-13|2008-12-18|2008-12-19|Estimate|2012-12-13|2013-01-23|Estimate||||2012-12-13|2013-01-23|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home|Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home|Completed||Phase 4|336|Actual|Akron Children's Hospital|Exclusively urban,lower socioeconomic status population limits external generalizability. Study was uncontrolled; historical controls were referenced instead. Baseline vaccination rates were self-reported. Possible bias in at-risk determination.||||f||||f||||||||||2018-06-01 01:27:35.272297|2018-06-01 01:27:35.272297
NCT00812097|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2015-08-24||2016-03-07|2008-12-17|2008-12-19|Estimate|2016-03-07|2016-04-05|Estimate||||2016-03-07|2016-04-05|Estimate|February 2002||2002-02-28|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CPG|All enrolled subjects are included.|Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial|Study of the Safety and Effectiveness of Mentor Siltex® Contour Profile Gel Mammary Prostheses in Patients Who Are Undergoing Primary Breast Augmentation,Primary Breast Reconstruction or Revision|Completed||Phase 3|955|Actual|Mentor Worldwide, LLC||4|||f||||f||||||||||2018-06-01 01:27:35.435908|2018-06-01 01:27:35.435908
NCT00812084|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2015-06-11|2008-12-18|2008-12-19|Estimate|||||||2015-06-11|2015-06-12|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|CHO-CAP||Costs, Health Status and Outcomes of CAP (Community-Acquired Pneumonia)|Collecting Health Outcomes and Economic Data on Hospitalized Community-Acquired Pneumonia - a Prospective Cohort Study|Completed|||48634|Actual|UMC Utrecht|||2||f||||f||||||||||2018-06-01 01:27:36.026987|2018-06-01 01:27:36.026987
NCT00812071|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-08-19|2008-12-18|2008-12-19|Estimate|||||||2013-08-19|2013-08-20|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|FDA-OPD||Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin|Phase 1 Study of the Safety and Immunogenicity of RiVax With Alum in Healthy Adults|Completed||Phase 1|30|Actual|University of Texas Southwestern Medical Center|||||f||||t||||||||||2018-06-01 01:27:36.098198|2018-06-01 01:27:36.098198
NCT00812058|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2011-01-13|2008-12-18|2008-12-19|Estimate|||||||2011-01-13|2011-01-17|Estimate|November 2008||2008-11-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression|A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in the Treatment of Bipolar I Depression|Completed||Phase 2|180|Anticipated|Repligen Corporation||2|||f||||t||||||||||2018-06-01 01:27:36.171322|2018-06-01 01:27:36.171322
NCT00812045|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2009-05-05|2008-12-18|2008-12-19|Estimate|||||||2009-05-05|2009-05-06|Estimate|December 2009||2009-12-31|May 2009|2009-05-31|August 2010|Anticipated|2010-08-31|||||Interventional|CYBER||Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis|Withdrawn||Phase 2|44|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:27:36.299618|2018-06-01 01:27:36.299618
NCT00812032|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2010-07-30|2008-12-18|2008-12-19|Estimate|||||||2010-07-30|2010-08-02|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|DM-ASA 001||Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients|Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients|Completed||Phase 4|25|Actual|Karolinska Institutet|||||f||||f||||||||||2018-06-01 01:27:36.382765|2018-06-01 01:27:36.382765
NCT00809939|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-08-27|2008-12-16|2008-12-17|Estimate|||||||2011-08-27|2011-08-30|Estimate|December 2010||2010-12-31|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||17 Alfa Hydroxyprogesterone Caproate Versus Natural Progesterone for the Prevention of Preterm Labor||Unknown status|Active, not recruiting|Phase 3|800|Anticipated|Meir Medical Center||4|||f||||f||||||||||2018-06-01 01:28:35.294293|2018-06-01 01:28:35.294293
NCT00812019|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18||2017-10-23|2017-10-25|2008-12-18|2008-12-19|Estimate||||2017-10-23|2017-10-26|Actual|2017-10-25|2017-10-27|Actual|November 2008||2008-11-30|October 2017|2017-10-31|November 2010|Actual|2010-11-30|March 2009|Actual|2009-03-31||Interventional|||Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)|A Phase I/II, Randomized, Observer-blind, Multicenter, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine in Healthy Subjects 18 - 40 Years of Age.|Completed||Phase 1/Phase 2|753|Actual|Seqirus||12|||f||||t||||||||||2018-06-01 01:27:36.456979|2018-06-01 01:27:36.456979
NCT00812006|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2010-09-23||2017-05-11|2008-12-17|2008-12-19|Estimate|2011-01-26|2011-01-27|Estimate||||2017-05-11|2017-06-06|Actual|March 24, 2009|Actual|2009-03-24|May 2017|2017-05-31|October 22, 2009|Actual|2009-10-22|October 22, 2009|Actual|2009-10-22||Interventional|||A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis|Completed||Phase 3|108|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:27:36.577232|2018-06-01 01:27:36.577232
NCT00811993|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2016-11-01|2008-12-18|2008-12-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2009||2009-02-28|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors|Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies|Terminated||Phase 1|104|Actual|Hoffmann-La Roche||13|||f||||||||||||||2018-06-01 01:27:36.95819|2018-06-01 01:27:36.95819
NCT00811980|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2011-11-23|2008-12-18|2008-12-19|Estimate|||||||2011-11-23|2011-11-24|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents|The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents|Completed|||60|Actual|University of Utah|||1||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 01:27:37.078125|2018-06-01 01:27:37.078125
NCT00811967|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2017-03-08|2008-12-18|2008-12-19|Estimate|||||||2017-03-08|2017-03-13|Actual|February 2003||2003-02-28|March 2017|2017-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)|Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis|Terminated||Phase 3|50|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:27:37.140126|2018-06-01 01:27:37.140126
NCT00811954|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2014-06-23||2014-09-04|2008-12-18|2008-12-19|Estimate|2014-09-04|2014-09-05|Estimate||||2014-09-04|2014-09-05|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Intention to treat: All eligible participants were included in the baseline characteristics.|Comparative Study of Three NNRTI-Sparing HAART Regimens|The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment|Completed||Phase 3|1814|Actual|AIDS Clinical Trials Group||3|||f||||t||||||||||2018-06-01 01:27:37.255816|2018-06-01 01:27:37.255816
NCT00811941|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2013-03-12||2013-07-05|2008-12-18|2008-12-19|Estimate|2013-07-05|2013-08-07|Estimate||||2013-07-05|2013-08-07|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|SENSE||Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence|A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence|Completed||Phase 3|665|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:27:39.658331|2018-06-01 01:27:39.658331
NCT00811928|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2011-05-26|2011-04-27|2017-03-09|2008-12-18|2008-12-19|Estimate|2011-08-09|2011-09-13|Estimate|2011-04-27|2011-05-04|Estimate|2017-03-09|2017-04-07|Actual|November 2008||2008-11-30|March 2017|2017-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)|A Randomized, Open Label Parallel Controlled, Multicenter Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension Vs. Fluconazole (Capsule) in High-risk Leukopenic Patients for Prevention of Invasive Fungal Infection|Completed||Phase 3|252|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:27:41.130519|2018-06-01 01:27:41.130519
NCT00811915|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-06-18|2008-12-18|2008-12-19|Estimate|||||||2014-06-18|2014-06-19|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|EPARGNE||Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation|A Prospective, Comparative, Multicenter, Randomized Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation|Completed||Phase 3|65|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-06-01 01:27:42.253183|2018-06-01 01:27:42.253183
NCT00811902|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18||2016-01-28|2016-01-28|2008-12-18|2008-12-19|Estimate||||2016-01-28|2016-02-26|Estimate|2016-01-28|2016-02-26|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis|A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.|Completed||Phase 2|405|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 01:27:42.526146|2018-06-01 01:27:42.526146
NCT00811889|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18||2012-05-31|2012-06-12|2008-12-18|2008-12-19|Estimate||||2012-06-12|2012-06-14|Estimate|2012-06-12|2012-06-14|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease|A 52-Week, Multi-center, Double-blind, Randomized, Placebo-controlled Phase IIb Trial to Determine the Effects of Bardoxolone Methyl (RTA 402) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease With an eGFR of 20 - 45 mL/Min/1.73m2|Completed||Phase 2|227|Actual|Reata Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-06-01 01:27:42.793917|2018-06-01 01:27:42.793917
NCT00809406|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2008-12-15|2008-12-15|2008-12-17|Estimate|||||||2008-12-15|2008-12-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:28:43.833988|2018-06-01 01:28:43.833988
NCT00811876|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2010-01-21|2008-12-17|2008-12-19|Estimate|||||||2010-01-21|2010-01-22|Estimate|September 2008||2008-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|OCT||Retrospective, Non-interventional Study of Depo-Eligard®.|Monitoring Tolerance, Safety and Acceptance of Depo-Eligard® in an Open Label, Retrospective, Non-interventional Clinical Trial|Completed|||140|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-06-01 01:27:43.175709|2018-06-01 01:27:43.175709
NCT00811863|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2017-08-01|2008-12-18|2008-12-19|Estimate|||||||2017-08-01|2017-08-02|Actual|February 2009|Actual|2009-02-28|August 2017|2017-08-31|May 17, 2012|Actual|2012-05-17|May 17, 2012|Actual|2012-05-17||Observational|SHERLOC||Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection|A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging|Withdrawn|||0|Actual|Guerbet|||2|Study drug currently unavailable|f||||f||||||Samples Without DNA|"~     Serum; Plasma; Fixed tissue samples~   "|||2018-06-01 01:27:45.704528|2018-06-01 01:27:45.704528
NCT00811850|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2011-10-24||2012-07-25|2008-12-17|2008-12-19|Estimate|2012-07-25|2012-08-01|Estimate||||2012-07-25|2012-08-01|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow||Completed||Phase 4|15|Actual|Allergan||2|||f||||f||||||||||2018-06-01 01:27:46.001931|2018-06-01 01:27:46.001931
NCT00811837|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2009-11-17|2008-12-18|2008-12-19|Estimate|||||||2009-11-17|2009-11-18|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|September 2009|Anticipated|2009-09-30|July 2009|Anticipated|2009-07-31||Interventional|RemiSun 1||The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers|The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers|Unknown status|Recruiting|Phase 4|24|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:27:46.39898|2018-06-01 01:27:46.39898
NCT00811824|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-02-21|2008-12-18|2008-12-19|Estimate|||||||2013-02-21|2013-02-22|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|September 2009|Actual|2009-09-30||Interventional|||Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors|Effects of Physical Activity and Dietary Change in Minority Breast Cancer Survivors|Completed||Phase 2|42|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 01:27:46.493924|2018-06-01 01:27:46.493924
NCT00811811|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-18|2008-12-18|2008-12-19|Estimate|||||||2008-12-18|2008-12-19|Estimate|May 2005||2005-05-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|August 2006|Actual|2006-08-31||Interventional|||Behavioral Neurocardiac Training and Hypertension|Behavioral Neurocardiac Training With Biofeedback Augments Vagal-Heart Rate Modulation and Baroreflex Sensitivity Among Patients With Hypertension|Completed||N/A|65|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:27:46.566099|2018-06-01 01:27:46.566099
NCT00811798|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2011-09-08||2016-09-23|2008-12-18|2008-12-19|Estimate|2011-09-08|2011-10-13|Estimate||||2016-09-23|2016-10-20|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Subjects.|Completed||Phase 3|92|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:27:46.673043|2018-06-01 01:27:46.673043
NCT00811785|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2018-05-12|2008-12-18|2008-12-19|Estimate|||||||2018-05-12|2018-05-15|Actual|February 27, 2009||2009-02-27|May 11, 2018|2018-05-11|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency|Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency|Recruiting||Phase 3|100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:27:46.964175|2018-06-01 01:27:46.964175
NCT00811772|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2016-05-23|2008-12-18|2008-12-19|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|September 2020|Anticipated|2020-09-30|December 2014|Actual|2014-12-31||Interventional|NORSTENT||Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis|Comparison of the Long-term Effects on Mortality and Cardiovascular Morbidity of Percutaneous Coronary Intervention With Drug-eluting Stent Versus Bare-metal Stent. Randomized, Five-year Prospective, Multicenter Clinical Trial|Active, not recruiting||Phase 4|9000|Anticipated|University of Tromso||2|||f||||t||||||||Undecided||2018-06-01 01:27:47.053466|2018-06-01 01:27:47.053466
NCT00811759|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2010-10-06|2008-12-18|2008-12-19|Estimate|||||||2010-10-06|2010-10-07|Estimate|June 2007||2007-06-30|July 2009|2009-07-31||||May 2009|Anticipated|2009-05-31||Interventional|||Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma|Open-label, Single Center, Uncontrolled Phase I/II Study Evaluating the Safety and Maximum Tolerated Dose of Daily Sorafenib Administered in Combination With Prolonged Temozolomide in Patients With Metastatic Melanoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|58|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:27:47.144829|2018-06-01 01:27:47.144829
NCT00811746|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2013-05-28|2008-12-18|2008-12-19|Estimate|||||||2013-05-28|2013-05-30|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?|Hypnotics to Improve Polysomnography Yield: Eszopiclone vs Ramelteon?|Completed||N/A|90|Anticipated|Southern California Institute for Research and Education||3|||f||||f||||||||||2018-06-01 01:27:47.223971|2018-06-01 01:27:47.223971
NCT00811733|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2012-02-09||2017-04-28|2008-12-18|2008-12-19|Estimate|2012-04-03|2012-04-30|Estimate||||2017-04-28|2017-05-30|Actual|March 1, 2009||2009-03-01|March 2015|2015-03-31|February 1, 2014|Actual|2014-02-01|June 1, 2011|Actual|2011-06-01||Interventional|||A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia|A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia|Completed||Phase 2|37|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:27:47.418599|2018-06-01 01:27:47.418599
NCT00811720|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2013-03-12||2013-07-05|2008-12-18|2008-12-19|Estimate|2013-07-05|2013-07-09|Estimate||||2013-07-05|2013-07-09|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|ESENSE1||Efficacy of Nalmefene in Patients With Alcohol Dependence|Nalmefene Efficacy Study I: Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy Study of 20 mg Nalmefene, As-needed Use, in Patients With Alcohol Dependence|Completed||Phase 3|598|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:27:48.777123|2018-06-01 01:27:48.777123
NCT00811707|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-18|2008-12-18|2008-12-19|Estimate|||||||2008-12-18|2008-12-19|Estimate|June 2008||2008-06-30|August 2008|2008-08-31|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Observational|||Epidural Sonoanatomy Between Parturient and Non-Pregnant|To Compare Epidural Sonoanatomy Between Parturient and Non-Pregnant Young Female in Chinese Population|Unknown status|Recruiting||40|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||2||f||||f||||||||||2018-06-01 01:27:49.358028|2018-06-01 01:27:49.358028
NCT00811681|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-09-02|2008-12-18|2008-12-19|Estimate|||||||2013-09-02|2013-09-04|Estimate|December 2008||2008-12-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ACTFRIE||Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept|Effect of Pioglitazone Administered to Patients With Friedreich's ATAXIA:Proof of Concept|Completed||Phase 3|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:27:49.59877|2018-06-01 01:27:49.59877
NCT00811668|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2011-08-01|2008-12-18|2008-12-19|Estimate|||||||2011-08-01|2011-08-02|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|October 2009|Actual|2009-10-31|February 2009|Actual|2009-02-28||Interventional|VCR||Comparison of CPAP With SOMNOventCR in Patients With Underlying Heart Disease, Combined OSA and CSR|Crossover Comparison of Treatment With Continuous Positive Airway Pressure and Treatment With Adaptive Servo Ventilation (SOMNOventCR) in Patients With Underlying Heart Disease, Combined Obstructive Sleep Apnea and Cheyne-Stokes Respiration.|Completed||N/A|40|Actual|Wissenschaftliches Institut Bethanien e.V||2|||f||||f||||||||||2018-06-01 01:27:49.691291|2018-06-01 01:27:49.691291
NCT00811655|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2013-08-15||2013-10-30|2008-12-18|2008-12-19|Estimate|2013-10-30|2013-11-25|Estimate||||2013-10-30|2013-11-25|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Stereotactic Radiosurgery in Treating Patients With Brain Metastases|Phase II Single-arm Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases.|Terminated||Phase 2|6|Actual|Duke University|Early termination leading to small numbers of subjects analyzed.|1||Slow recruitment|f||||f||||||||||2018-06-01 01:27:49.77856|2018-06-01 01:27:49.77856
NCT00811642|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2011-03-31||2017-03-09|2008-12-18|2008-12-19|Estimate|2011-03-31|2011-04-29|Estimate||||2017-03-09|2017-04-07|Actual|November 2008||2008-11-30|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)|A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection|Completed||Phase 3|63|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:27:49.992323|2018-06-01 01:27:49.992323
NCT00811629|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-09-30|2008-12-18|2008-12-19|Estimate|||||||2013-09-30|2013-10-01|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Influence of Acute Respiratory Distress Syndrome (ARDS) and Severe Sepsis on sRAGE Levels in ICU Patients|Soluble Form of the Receptor for Advanced Glycation End Products (sRAGE) Levels in the Pulmonary Edema Fluid and Plasma From ICU Patients With ALI/ARDS and Severe Sepsis : an Observational Prospective Study.|Completed|||60|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-06-01 01:27:50.271786|2018-06-01 01:27:50.271786
NCT00811616|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2010-05-10|2008-12-18|2008-12-19|Estimate|||||||2010-05-10|2010-05-11|Estimate|July 2006||2006-07-31|May 2010|2010-05-31|March 2008|Actual|2008-03-31|||||Interventional|Maximus||A Safety and Efficacy of Supralimus™ Core™ Sirolimus Eluting Stent at MAX DDHV Institute|Safety And Efficacy Evaluation of Sirolimus Eluting Supralimus-Core™ Stent at MAX DDHV Institute in the Treatment of de Novo Native Coronary Artery Lesions|Completed||N/A|105|Actual|Sahajanand Medical Technologies Pvt. Ltd.|||||f||||t||||||||||2018-06-01 01:27:50.359471|2018-06-01 01:27:50.359471
NCT00811603|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2009-09-17|2008-12-18|2008-12-19|Estimate|||||||2009-09-17|2009-09-18|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery|Optimal Timing for Antibiotic Prophylaxis for Elective Cesarean Delivery in Term Gestations: A Randomized, Controlled Trial Comparing Cefazolin Administration Prior to Skin Incision Versus Following Cord Clamping|Completed||Phase 3|50|Actual|MemorialCare||2|||f||||t||||||||||2018-06-01 01:27:50.421514|2018-06-01 01:27:50.421514
NCT00811590|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2012-03-06||2013-07-19|2008-12-18|2008-12-19|Estimate|2012-06-04|2012-07-04|Estimate||||2013-07-19|2013-07-26|Estimate|November 2008||2008-11-30|July 2013|2013-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome|Pilot Study of mTOR Inhibitor Therapy for Treatment of Intestinal Polyps in Peutz-Jeghers Syndrome|Terminated||Phase 2|3|Actual|University of Utah|Early termination leading to small numbers of subjects analyzed|1||The study was ended early due to low enrollment.|f||||t||||||||||2018-06-01 01:27:50.495013|2018-06-01 01:27:50.495013
NCT00811577|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2012-05-16||2012-09-10|2008-12-18|2008-12-19|Estimate|2012-09-10|2012-10-11|Estimate||||2012-09-10|2012-10-11|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients|A Phase 2a Double Blind, Placebo Within-Patient Controlled, Multi-Center Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product in Trocar Sites of Arthroscopic Shoulder Surgery Patients|Completed||Phase 2|150|Actual|Capstone Therapeutics||2|||f||||f||||||||||2018-06-01 01:27:50.855819|2018-06-01 01:27:50.855819
NCT00811564|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2011-08-17||2011-08-17|2008-12-17|2008-12-19|Estimate|2011-08-17|2011-09-21|Estimate||||2011-08-17|2011-09-21|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects||Completed||Phase 4|148|Actual|Allergan||2|||f||||||||||||||2018-06-01 01:27:51.520744|2018-06-01 01:27:51.520744
NCT00811551|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2012-07-23|2008-12-18|2008-12-19|Estimate|||||||2012-07-23|2012-07-25|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|zWedge||Data Collection Study of Wedge Pressure Data in Patients With CRT-D Devices|zWedge Clinical Feasibility IDE Study|Completed|||22|Actual|St. Jude Medical|||||f||||f||||||||||2018-06-01 01:27:51.70276|2018-06-01 01:27:51.70276
NCT00811538|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2016-04-11|2008-12-18|2008-12-19|Estimate|||||||2016-04-11|2016-04-13|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Observational|SWISS||Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry|Swiss Intravenous and Intra-arterial Thrombolysis for Treatment of Acute Ischemic Stroke Registry (SWISS)|Completed|||1476|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 01:27:51.771317|2018-06-01 01:27:51.771317
NCT00811525|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2014-11-25|2008-12-17|2008-12-19|Estimate|||||||2014-11-25|2014-12-02|Estimate|August 2004||2004-08-31|November 2014|2014-11-30||||||||Expanded Access|CPG-CA||Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast Implant|Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast Implant|Approved for marketing|||||Mentor Worldwide, LLC|||||||||f||||||||||2018-06-01 01:27:51.84385|2018-06-01 01:27:51.84385
NCT00811512|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2008-12-18|2008-12-18|2008-12-19|Estimate|||||||2008-12-18|2008-12-19|Estimate|May 2007||2007-05-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Observational|||Fundus Changes in the Microphthalmy Eyes|Fundus Changes in the Microphthalmy Eyes|Completed|||3|Actual|Hospital de Olhos Sadalla Amin Ghanem|||||f||||t||||||||||2018-06-01 01:27:51.921021|2018-06-01 01:27:51.921021
NCT00811486|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2013-01-25|2008-12-18|2008-12-19|Estimate|||||||2013-01-25|2013-01-28|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure|Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure|Withdrawn||N/A|0|Actual|University of Colorado, Denver||2||Only 1 patient recruited, and he withdrew|f||||t||||||||||2018-06-01 01:27:52.089269|2018-06-01 01:27:52.089269
NCT00811473|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2011-10-27||2014-07-02|2008-12-18|2008-12-19|Estimate|2011-10-27|2011-12-01|Estimate||||2014-07-02|2014-07-15|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pediatric Bipolar Depression|An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression|Completed||Phase 3|193|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 01:27:52.180179|2018-06-01 01:27:52.180179
NCT00811460|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2016-11-01|2008-12-18|2008-12-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study of Taspoglutide in Type 2 Diabetic Patients|A Double-blind, Crossover, Randomized, Placebo-controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-phase Insulin Secretion in Type 2 Diabetic Patients|Completed||Phase 1|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:27:52.508467|2018-06-01 01:27:52.508467
NCT00811447|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2012-08-30|2008-12-18|2008-12-19|Estimate|||||||2012-08-30|2012-08-31|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Taxotere New Indication - Gastric Cancer Treatment Registration Trial|Open Label, Randomized Multicenter Study Docetaxel + 5-fluorouracil + Cisplatin Compared to Cisplatin + 5-fluorouracil in Patients With Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease|Completed||Phase 3|243|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:27:52.568942|2018-06-01 01:27:52.568942
NCT00811434|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2012-10-09||2014-02-07|2008-12-18|2008-12-19|Estimate|2014-02-07|2014-02-10|Estimate||||2014-02-07|2014-02-10|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|MHE||Study of Lactulose in Children With Chronic Liver Disease|Improvement of Cognitive Function and Healthcare -Related Quality of Life After Lactulose Treatment in Children With Chronic Liver Disease|Terminated||Phase 2|16|Actual|Indiana University||2||funding period ended|f||||t||||||||||2018-06-01 01:27:52.63056|2018-06-01 01:27:52.63056
NCT00811421|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-03-19|2008-12-18|2008-12-19|Estimate|||||||2014-03-19|2014-03-20|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|MiPPAD||Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy|Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy|Completed||N/A|5820|Actual|Hospital Clinic of Barcelona||5|||f||||t||||||||||2018-06-01 01:27:52.905726|2018-06-01 01:27:52.905726
NCT00811408|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2010-01-27|2008-12-18|2008-12-19|Estimate|||||||2010-01-27|2010-01-28|Estimate|April 2008||2008-04-30|July 2009|2009-07-31||||October 2009|Anticipated|2009-10-31||Interventional|||Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy|Modulating the Expression of Oncoproteins of Papillomavirus (HPV) to Increase Radiosensitivity: a Phase I Study of Antiviral Agent Cidofovir and Chemoradiotherapy Therapy in Cervical Cancers|Unknown status|Recruiting|Phase 1|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:27:53.001444|2018-06-01 01:27:53.001444
NCT00811395|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2012-10-03|2011-05-24|2012-12-18|2008-12-18|2008-12-19|Estimate|2012-12-18|2012-12-31|Estimate|2011-06-08|2011-06-09|Estimate|2012-12-18|2012-12-31|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis|Long-term Extension of the Multinational, Double-blind, Placebo Controlled Studies PDY6045 and PDY6046 to Document the Safety of Teriflunomide When Added to Treatment With Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis With Relapses|Completed||Phase 2|182|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 01:27:53.150405|2018-06-01 01:27:53.150405
NCT00811382|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|2016-12-05||2017-02-02|2008-12-18|2008-12-19|Estimate|2017-02-02|2017-03-23|Actual||||2017-02-02|2017-03-23|Actual|May 2008|Actual|2008-05-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|January 2014|Actual|2014-01-31||Interventional|effecT||Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)|Clinical effecT of Heart Failure Management Via Home Monitoring With a Focus on Atrial Fibrillation (effecT)|Terminated||N/A|163|Actual|Biotronik SE & Co. KG|Due to the disappointing enrollment speed, it has been decided to discontinue the study. Therefore, the study is not powered to test the planned hypothesis.|2||Criterion according study protocol to end study prematurely was fulfilled.|f||||t||||||||No||2018-06-01 01:27:55.007786|2018-06-01 01:27:55.007786
NCT00811369|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-11-15|2008-12-18|2008-12-19|Estimate|||||||2013-11-15|2013-11-18|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|ZAMBONEY||Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer|A Phase II, Multi-Centre, Randomized, Double-blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer|Completed||Phase 2|126|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 01:27:56.175061|2018-06-01 01:27:56.175061
NCT00811356|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2017-08-01|2008-12-18|2008-12-19|Estimate|||||||2017-08-01|2017-08-03|Actual|December 11, 2008|Actual|2008-12-11|August 2017|2017-08-31|March 30, 2009|Actual|2009-03-30|March 30, 2009|Actual|2009-03-30||Interventional|||A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria|A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects|Terminated||Phase 1|12|Actual|GlaxoSmithKline||1||safety issues (toxicity)|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:27:56.254701|2018-06-01 01:27:56.254701
NCT00811343|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-18|||2014-01-06|2008-12-18|2008-12-19|Estimate|||||||2014-01-06|2014-01-07|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|ETAT||Impact of New Immunological Diagnosis Tests of Latent Tuberculosis Before Anti TNF Therapy|Impact of New Immunological Diagnosis Tests of Latent Tuberculosis in Adults Patients Who Need Anti TNF Therapy.|Completed||N/A|430|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:27:56.344606|2018-06-01 01:27:56.344606
NCT00811330|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2015-06-18|2008-12-18|2008-12-19|Estimate|||||||2015-06-18|2015-06-19|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effects of High Dose Atorvastatin in Patients With Surgical Aortic Stenosis|Interest of Statin in Surgical Aortic Stenosis: From Myocardial Preconditioning to Ventricular Reverse Remodeling.|Unknown status|Recruiting|Phase 3|60|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 01:27:56.408131|2018-06-01 01:27:56.408131
NCT00811317|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2017-04-18||2017-10-24|2008-12-17|2008-12-18|Estimate|2017-10-24|2017-10-25|Actual||||2017-10-24|2017-10-25|Actual|May 2008||2008-05-31|October 2017|2017-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Closed-loop Glucose Control for Automated Management of Type 1 Diabetes|Closed-loop Glucose Control for Automated Management of Type 1 Diabetes|Completed||N/A|11|Actual|Boston University Charles River Campus||1|||f||||t||t|t|f||||Yes||2018-06-01 01:27:56.648452|2018-06-01 01:27:56.648452
NCT00811304|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2013-02-01|2008-12-17|2008-12-18|Estimate|||||||2013-02-01|2013-02-04|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|||Real-time Ultrasound Guided Labor Epidural Placement|Real-time Ultrasound Guided Labor Epidural Placement|Withdrawn|||0|Actual|University of Pittsburgh|||1|"We are unable to find a clip used to stabilize the epidural needle on the ultrasound probe to~   allow adequate epidural catheter placement."|f||||t||||||||||2018-06-01 01:27:57.012114|2018-06-01 01:27:57.012114
NCT00811291|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2012-07-03|2008-12-17|2008-12-18|Estimate|||||||2012-07-03|2012-07-04|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|August 2009|Actual|2009-08-31||Interventional|SIMBA||Influence of Vitamin-B-complex on Cognitive Ability of Kindergarten Kids|SIMBA-Study Investigating Mental Acuity Effects of B-vitamins in Children|Completed||N/A|250|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 01:27:57.071942|2018-06-01 01:27:57.071942
NCT00811278|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2011-10-07|2008-12-17|2008-12-18|Estimate|||||||2011-10-07|2011-10-12|Estimate|December 2008||2008-12-31|October 2011|2011-10-31||||June 2011|Actual|2011-06-30||Observational|||Approach to Predict Steroid Sensitivity in Patients With Asthma|A Non-Invasive Approach to Predict Steroid Sensitivity in Patients With Asthma|Completed|||30|Anticipated|Children's Mercy Hospital Kansas City|||3||f||||f||||||Samples With DNA|"~     Whole blood, DNA, RNA~   "|||2018-06-01 01:27:57.207769|2018-06-01 01:27:57.207769
NCT00811265|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2016-03-07|2008-12-17|2008-12-18|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety Evaluation of ExAblate MRgFUS for Prostate Cancer|Safety, Compatibility and Imaging Quality of ExAblate Prostate Applicator for Prostate Cancer|Completed||Phase 1|10|Anticipated|InSightec||1|||f||||f||||||||||2018-06-01 01:27:57.265333|2018-06-01 01:27:57.265333
NCT00811252|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2013-10-28||2013-12-23|2008-12-17|2008-12-18|Estimate|2013-10-28|2013-12-18|Estimate||||2013-12-23|2014-01-29|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional||Full-analysis set (FAS) – all patients in the all-patients-treated set (APTS) who had at least one valid post-baseline assessment of the primary efficacy variable|Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients|Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed Dose Study Comparing the Efficacy and Safety of [Vortioxetine] Lu AA21004 in Acute Treatment of Major Depressive Disorder in Elderly Patients|Completed||Phase 3|453|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-06-01 01:27:57.37829|2018-06-01 01:27:57.37829
NCT00811239|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|March 2004||2004-03-31|December 2008|2008-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Controlled Clinical Trial on The Use of a Specific Antivenom Against Envenoming by Bungarus Multicinctus|A Controlled Clinical Trial on The Use of a Specific Antivenom Against Envenoming by Bungarus Multicinctus|Completed||Phase 1/Phase 2|81|Actual|Hanoi Medical University||2|||f||||t||||||||||2018-06-01 01:27:58.276938|2018-06-01 01:27:58.276938
NCT00811226|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-12-16|2008-12-16|2008-12-18|Estimate|||||||2008-12-16|2008-12-18|Estimate|April 2007||2007-04-30|December 2008|2008-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)|Prospective, Multicentric, Open Clinic Essay to Evaluate the Use of OLMETEC® (Olmesartan Medoxomile) and OLMETEC PLUS® (Olmesartan Medoxomile Hydrochlorothiazide) in Stade I and II, According to JNC VII|Completed|||450|Anticipated|Schering-Plough|||1||f||||f||||||||||2018-06-01 01:27:58.578003|2018-06-01 01:27:58.578003
NCT00811213|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-07-10|2008-12-17|2008-12-18|Estimate|||||||2011-07-10|2011-07-12|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|SASQT||SensAwake™ Sleep Quality Trial|SASQT: SensAwake™ Sleep Quality Trial A Study to Test the Efficacy of the SensAwake™ Modification to Automatically Titrating Continuous Positive Airway Pressure to Reduce Wake After Sleep Onset in Patients With Moderate to Severe Obstructive Sleep Apnea.|Completed||Phase 4|45|Anticipated|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-06-01 01:27:58.889062|2018-06-01 01:27:58.889062
NCT00811200|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2009-06-30|2008-12-17|2008-12-18|Estimate|||||||2009-06-30|2009-07-02|Estimate|September 2009||2009-09-30|June 2009|2009-06-30||||January 2012|Anticipated|2012-01-31||Interventional|TORR||Treatment Of Radiation Retinopathy Trial|Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma.|Unknown status|Not yet recruiting|Phase 2/Phase 3|220|Anticipated|Leiden University Medical Center||3|||f||||t||||||||||2018-06-01 01:27:59.166139|2018-06-01 01:27:59.166139
NCT00811187|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||Paracervical Block During Office Hysteroscopy|Paracervical Block During Office Hysteroscopy: A Randomized Double Blind Placebo-Controlled Trial|Completed||N/A|80|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 01:27:59.45274|2018-06-01 01:27:59.45274
NCT00811174|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2013-07-25||2017-06-16|2008-12-17|2008-12-18|Estimate|2017-06-16|2017-07-14|Actual||||2017-06-16|2017-07-14|Actual|January 2009||2009-01-31|June 2017|2017-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||The study was terminated prematurely. Owing to the limited data available (only 5 patients enrolled, of whom 2 completed the study and 3 ended treatment prematurely), efficacy and PK analyses were not performed. The safety analysis did not yield any unexpected results suggestive of a change in the risk–benefit evaluation of Octagam 10%.|Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases|Clinical Study to Evaluate the Efficacy, Safety and Kinetics of Octagam 10% for Replacement Therapy in Primary Immunodeficiency Diseases|Terminated||Phase 3|5|Actual|Octapharma||1||Due to limited data available, efficacy, and PK analyses were not performed.|f||||f||||||||||2018-06-01 01:27:59.78393|2018-06-01 01:27:59.78393
NCT00811161|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2009-06-03|2008-12-17|2008-12-18|Estimate|||||||2009-06-03|2009-06-04|Estimate|May 2009||2009-05-31|June 2009|2009-06-30|April 2010|Anticipated|2010-04-30|February 2010|Anticipated|2010-02-28||Interventional|||An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin|An Open Label Study to Evaluate the Efficacy of Airgent in Treating Damaged and Wrinkled Skin|Unknown status|Recruiting|N/A|30|Anticipated|PerfAction Ltd.||1|||f||||f||||||||||2018-06-01 01:28:00.785238|2018-06-01 01:28:00.785238
NCT00811148|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2018-03-21|2008-12-17|2008-12-18|Estimate|||||||2018-03-21|2018-03-22|Actual|March 2006||2006-03-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|FCBTR||Florida Center for Brain Tumor Research|Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research|Recruiting|||4000|Anticipated|University of Florida|||1||f||||f|f|f||||Samples With DNA|"~     Tissue, medical information, cerebrospinal fluid, blood and answers to Quality of Life~     questionnaires will be stored and made available to researchers.~   "|No||2018-06-01 01:28:00.863214|2018-06-01 01:28:00.863214
NCT00811135|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2015-11-03||2016-08-23|2008-12-17|2008-12-18|Estimate|2015-11-03|2015-12-08|Estimate||||2016-08-23|2016-09-29|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||The Intention-To-Treat (ITT) population included all participants enrolled in the study who received at least one dose of any study medication.|A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer|A Single Arm Open-label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-line Treatment of Patients With HER2-positive Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 2|88|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:28:00.970853|2018-06-01 01:28:00.970853
NCT00811122|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2017-05-05|2008-12-17|2008-12-18|Estimate|||||||2017-05-05|2017-05-09|Actual|November 2009||2009-11-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|11C-PIB PET||Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly|Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly|Active, not recruiting||Early Phase 1|30|Anticipated|University of Utah|||||f||||t||||||||||2018-06-01 01:28:01.352712|2018-06-01 01:28:01.352712
NCT00811109|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2010-03-02|2008-12-17|2008-12-18|Estimate|||||||2010-03-02|2010-03-03|Estimate|December 2008||2008-12-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|HEMOTOL||HEMOTOL: Efficacy and Safety of Hemodialysis On-line Monitoring Devices on Hemodynamic Stability in Intensive Care Unit|HEMOTOL: Effects of New Dialysis On-line Monitoring Devices on Hemodynamic Stability During Intermittent Hemodialysis in Critically Ill Patients With Acute Kidney Injury : a Prospective Randomized Study.|Completed||Phase 2/Phase 3|600|Anticipated|University Hospital, Caen||3|||f||||t||||||||||2018-06-01 01:28:01.456597|2018-06-01 01:28:01.456597
NCT00811096|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2012-11-30|2008-12-17|2008-12-18|Estimate|||||||2012-11-30|2012-12-03|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax|Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax|Completed||Phase 2|20|Actual|Walter Reed Army Institute of Research (WRAIR)||2|||f||||t||||||||||2018-06-01 01:28:01.54693|2018-06-01 01:28:01.54693
NCT00811083|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|May 2005||2005-05-31|December 2008|2008-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Dimercaptosuccinic Acid (DMSA) Treatment of Children With Autism and Heavy Metal Toxicity|DMSA Treatment of Children With Autism and Heavy Metal Toxicity|Completed||Phase 1/Phase 2|80|Actual|Southwest College of Naturopathic Medicine||2|||f||||f||||||||||2018-06-01 01:28:01.649383|2018-06-01 01:28:01.649383
NCT00811070|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2014-03-03||2016-05-19|2008-12-17|2008-12-18|Estimate|2014-05-16|2014-06-04|Estimate||||2016-05-19|2016-06-28|Estimate|December 2007||2007-12-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|March 2013|Actual|2013-03-31||Interventional|||Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias|A Phase 1/2 Study Of SKI-606 Administered As A Single Agent In Japanese Subjects With Philadelphia Chromosome Positive Leukemias|Completed||Phase 2|63|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 01:28:01.811637|2018-06-01 01:28:01.811637
NCT00811057|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2013-02-25||2013-02-25|2008-12-17|2008-12-18|Estimate|2013-02-25|2013-04-04|Estimate||||2013-02-25|2013-04-04|Estimate|June 2004||2004-06-30|February 2013|2013-02-28|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Tocolysis for Preterm Labor|Tocolysis for Preterm Labor|Completed||N/A|301|Actual|University of Mississippi Medical Center||3|||f||||f||||||||||2018-06-01 01:28:03.044227|2018-06-01 01:28:03.044227
NCT00811044|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2010-10-01|2008-12-17|2008-12-18|Estimate|||||||2010-10-01|2010-10-04|Estimate|October 2000||2000-10-31|October 2010|2010-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|RHIE||Regulation of Hepatic Insulin Extraction|Regulation of Hepatic Insulin Extraction:Alterations of Insulin Secretion in Subjects With Genetic Variants That Determine Risk for Non-Insulin Dependant Diabetes Mellitus|Withdrawn|||1250|Anticipated|Washington University School of Medicine|||3|PI, Dr. K. Polonsky has moved to the University of Chicago.|f||||f||||||Samples With DNA|"~     Samples are collected for Glucose & various human peptide measurements and DNA. As peptide~     assay evolves, specimens may be re-tested.~   "|||2018-06-01 01:28:03.406035|2018-06-01 01:28:03.406035
NCT00811031|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2012-07-27|2008-12-17|2008-12-18|Estimate|||||||2012-07-27|2012-07-30|Estimate||||July 2012|2012-07-31||||||||Interventional|||Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)|A Phase II Study of Pre-operative Docetaxel for Progressive Localized Castration Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:28:03.471178|2018-06-01 01:28:03.471178
NCT00811018|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2012-03-29||2012-03-29|2008-12-16|2008-12-18|Estimate|2012-03-29|2012-04-24|Estimate||||2012-03-29|2012-04-24|Estimate|March 2003||2003-03-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|STRIDE-3||A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension|A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension|Terminated||Phase 3|1192|Actual|Pfizer|Mean and dispersion for clinical abnormalities were intended to be reported but due to early termination of study (09-Dec-2010) only number and percent of participants are available.|1||"This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically~   emerging evidence of hepatic injury."|f||||f||||||||||2018-06-01 01:28:03.580935|2018-06-01 01:28:03.580935
NCT00809393|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2016-09-22|2008-12-15|2008-12-17|Estimate|||||||2016-09-22|2016-09-23|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Exacylcardio||Dose-ranging Study of Two Doses of Tranexamic Acid During Cardiac Surgery|Comparison of Two Tranexamic Acid Dose Regimens on Transfusion Needs During Cardiac Surgery With Cardiopulmonary Bypass|Completed||Phase 4|600|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 01:28:43.877604|2018-06-01 01:28:43.877604
NCT00811005|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2009-09-17|2008-12-17|2008-12-18|Estimate|||||||2009-09-17|2009-09-18|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|October 2010|Anticipated|2010-10-31|October 2009|Anticipated|2009-10-31||Interventional|FVSA-PUVA||Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis|Comparison of Fumaric Acid Ester-PUVA (FAE-PUVA) Versus Acitretin-PUVA (Re-PUVA) in Pustular Palmoplantar Psoriasis,a Prospective, Randomized, Controlled, Single-blinded Study|Unknown status|Active, not recruiting|Phase 3|20|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:28:04.896092|2018-06-01 01:28:04.896092
NCT00810992|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2013-01-11|2008-12-17|2008-12-18|Estimate|||||||2013-01-11|2013-01-14|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|April 2011|Actual|2011-04-30|November 2010|Actual|2010-11-30||Interventional|TTM in CAD||Traditional Tibetan Medicine for Patients With Coronary Artery Disease|Behavioral and Nutritional Therapy in Patients With Coronary Artery Disease According to Traditional Tibetan Medicine Protocol|Completed||N/A|524|Actual|University Hospital Tuebingen||2|||f||||||||||||||2018-06-01 01:28:05.038444|2018-06-01 01:28:05.038444
NCT00810979|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17||2014-12-09|2015-01-16|2008-12-17|2008-12-18|Estimate||||2014-12-10|2014-12-31|Estimate|2015-01-16|2015-01-28|Estimate|January 2009||2009-01-31|January 2015|2015-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Different Doses of SLx-4090 in Combination With a Statin vs. Statin Mono-therapy in Patients With Hyperlipidemia|Completed||Phase 2|133|Actual|Kadmon Corporation, LLC||3|||f||||f||||||||||2018-06-01 01:28:05.123072|2018-06-01 01:28:05.123072
NCT00810953|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-06-27|2008-12-17|2008-12-18|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy|A Phase I/II Clinical Study Using Pentamidine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Undergoing Standard Therapy|Completed||Phase 1/Phase 2|10|Actual|Oncozyme Pharma Inc.||1|||f||||t||||||||||2018-06-01 01:28:05.222736|2018-06-01 01:28:05.222736
NCT00810940|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2010-12-06|2008-12-16|2008-12-18|Estimate|||||||2010-12-06|2010-12-08|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|ABELADRUG200||Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury|Phase 1/2 Multicenter, Randomized, Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Abela Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 01:28:05.283574|2018-06-01 01:28:05.283574
NCT00810927|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|September 2003||2003-09-30|December 2008|2008-12-31|August 2005|Actual|2005-08-31|February 2004|Actual|2004-02-29||Interventional|||Role of Nitrogen Oxide (NO) in the Control of Choroidal Blood Flow During a Decrease in Ocular Perfusion Pressure|Role of NO in the Control of Choroidal Blood Flow During a Decrease in Ocular Perfusion Pressure|Completed||Phase 2|22|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 01:28:05.384158|2018-06-01 01:28:05.384158
NCT00810914|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2009-09-17|2008-12-17|2008-12-18|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|Epidural||Patient Controlled Epidural Analgesia Versus Continuous Epidural Infusion: Obstetrical and Neonatal Outcomes|Patient Controlled Epidural Infusion Vs. Continuous Epidural Infusion: Obstetrical and Neonatal Outcomes|Unknown status|Recruiting|N/A|270|Anticipated|MemorialCare||3|||f||||f||||||||||2018-06-01 01:28:05.445666|2018-06-01 01:28:05.445666
NCT00810901|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2015-01-09||2015-06-23|2008-12-17|2008-12-18|Estimate|2015-06-23|2015-06-25|Estimate||||2015-06-23|2015-06-25|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Idecide||Intervention to Motivate Teens to be a Designated Organ Donor on Driver's License|Multimedia Intervention to Motivate Ethnic Teens to be Designated Donors|Completed||N/A|429|Actual|University of Hawaii||2|||f||||t||||||||||2018-06-01 01:28:05.574079|2018-06-01 01:28:05.574079
NCT00810888|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2017-09-22||2018-02-14|2008-12-17|2008-12-18|Estimate|2017-12-05|2018-01-08|Actual||||2018-02-14|2018-03-16|Actual|November 2010||2010-11-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|STOP-IT|"The baseline population consists of 19 subjects diagnosed as Spot Positive on CT and were eligible for randomization within the clinical trial portion of the protocol. In addition 73 subjects diagnosed as Spot Negative on CT were followed prospectively with no study intervention. All 92 subjects were followed to 90 days post stroke."|The Spot Sign for Predicting and Treating ICH Growth Study|The Spot Sign for Predicting and Treating Intracerebral Hemorrhage Growth Study|Completed||Phase 2|92|Actual|University of Cincinnati||3|||f||||t||||||||||2018-06-01 01:28:05.951746|2018-06-01 01:28:05.951746
NCT00810875|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2014-08-21|2008-12-17|2008-12-18|Estimate|||||||2014-08-21|2014-08-25|Estimate|April 2009||2009-04-30|August 2014|2014-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy|Analysis of the Maternal-fetal Interface During Maternal Hepatitis C Virus Infection and Influenza Virus Vaccination|Terminated|||6|Actual|University of California, San Francisco|||2|Terminated due to lack of enrollment|f||||f||||||Samples With DNA|"~     Plasma, peripheral and cord blood mononuclear cells, placental tissue~   "|||2018-06-01 01:28:07.152327|2018-06-01 01:28:07.152327
NCT00810862|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|November 2006||2006-11-30|December 2008|2008-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children|A 3-Week, Single-Blind, Placebo-Controlled, Within-Patient, Randomized Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children|Terminated||Phase 4|18|Actual|Children's Hospital of Michigan||2||Lack of subject enrollment over the past two years.|f||||f||||||||||2018-06-01 01:28:07.23437|2018-06-01 01:28:07.23437
NCT00810849|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2014-09-02|2008-12-17|2008-12-18|Estimate|||||||2014-09-02|2014-09-03|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|IMPI||A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis|A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis|Completed||Phase 3|1400|Actual|University of Cape Town||2|||f||||t||||||||||2018-06-01 01:28:07.316415|2018-06-01 01:28:07.316415
NCT00810836|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2013-09-12|2008-12-17|2008-12-18|Estimate|||||||2013-09-12|2013-09-16|Estimate|December 2008||2008-12-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis|A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of BG00012 When Given With Methotrexate to Subjects With Active RA Who Have Had an Inadequate Response to Conventional Disease-Modifying Anti-rheumatic Drug Therapy|Completed||Phase 2|153|Actual|Biogen||3|||f||||f||||||||||2018-06-01 01:28:07.402779|2018-06-01 01:28:07.402779
NCT00810823|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2011-07-05|2008-12-17|2008-12-18|Estimate|||||||2011-07-05|2011-07-06|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||The Effect of Gastric Bypass Surgery on the Glucose Metabolism Seen in Patients With Type 2 Diabetes|The Effect of Gastric Bypass Surgery on the Glucose Metabolism Seen in Patients With Type 2 Diabetes|Completed|||25|Actual|Hvidovre University Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 01:28:07.571073|2018-06-01 01:28:07.571073
NCT00810810|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2017-10-26||2017-11-28|2008-12-17|2008-12-18|Estimate|2017-10-26|2017-11-29|Actual||||2017-11-28|2017-12-26|Actual|July 2006||2006-07-31|November 2017|2017-11-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Immunomodulation Following Transfusion|Immunomodulation Following Transfusion|Completed||Phase 4|287|Actual|University of Washington||3|||f||||f||||||||||2018-06-01 01:28:07.670673|2018-06-01 01:28:07.670673
NCT00810797|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2018-01-26|2008-12-17|2008-12-18|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2, 2008|Actual|2008-12-02|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer|Intermittent Exemestane Therapy for Metastatic Breast Cancer|Active, not recruiting||Phase 2|36|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:28:08.243325|2018-06-01 01:28:08.243325
NCT00810784|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|March 2005||2005-03-31|December 2008|2008-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients|Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients|Completed|||121|Actual|University of Utah|||2||f||||t||||||||||2018-06-01 01:28:08.430613|2018-06-01 01:28:08.430613
NCT00810771|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2015-03-26||2015-06-01|2008-12-16|2008-12-18|Estimate|2015-06-01|2015-06-02|Estimate||||2015-06-01|2015-06-02|Estimate|February 2009||2009-02-28|June 2015|2015-06-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|EPIIC|"Baseline participants in Arm 1 and 2 reflect the number completing the survey. Not all participants enrolled to these arms completed the survey. Arm 3, usual care arm, was not a true 3rd arm and participants in this group did not complete the survey."|Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening|Evaluating a Preference-based Intervention for Increasing CRC Screening|Completed||N/A|466|Actual|VA Office of Research and Development|Usual care arm was not true 3rd arm. We identified pts meeting eligibility criteria & randomized ~ 10th pt to be followed, measuring CRC screening 6 mos later. No intervention or survey. Only 79.6% of those enrolled completed survey.|3|||f||||t||||||||||2018-06-01 01:28:08.632154|2018-06-01 01:28:08.632154
NCT00810758|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2009-11-30|2008-12-17|2008-12-18|Estimate|||||||2009-11-30|2009-12-01|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691|A Phase 1, Randomized, Placebo Controlled, Blinded (3rd Party Open), Sequential, Multiple-Dose Escalation Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 In Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:28:09.308668|2018-06-01 01:28:09.308668
NCT00810745|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2009-02-25|2008-12-17|2008-12-18|Estimate|||||||2009-02-25|2009-02-26|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||What Benefit With a New Stapler Device in the Surgical Treatment of Obstructed Defecation?|What Benefit With a New Stapler Device in the Surgical Treatment of Obstructed Defecation? Two-Year Outcomes From a Randomized Controlled Trial|Completed||Phase 4|80|Actual|University of Milan||1|||f||||f||||||||||2018-06-01 01:28:09.420918|2018-06-01 01:28:09.420918
NCT00810732|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17||2012-01-27|2012-08-08|2008-12-17|2008-12-18|Estimate||||2012-08-08|2012-08-16|Estimate|2012-08-08|2012-08-16|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|FCRD01||Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects|The Effects Of Sitaxsentan Once Daily Dosing On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Subjects With Chronic Kidney Disease.|Completed||Phase 2|27|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:28:09.512339|2018-06-01 01:28:09.512339
NCT00810719|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2017-01-13||2018-01-05|2008-12-17|2008-12-18|Estimate|2017-01-13|2017-03-07|Actual||||2018-01-05|2018-01-10|Actual|April 2009||2009-04-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer|Phase II Study of Gemcitabine and Intermittent Erlotinib in Advanced Pancreatic Cancer|Completed||Phase 2|30|Actual|University of California, Davis|Due to funding considerations, the study was closed after thirty participants were enrolled.|1|||f||||t||||||||||2018-06-01 01:28:09.666506|2018-06-01 01:28:09.666506
NCT00810706|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2008-12-16|2008-12-16|2008-12-18|Estimate|||||||2008-12-16|2008-12-18|Estimate|April 2001||2001-04-30|December 2008|2008-12-31|November 2005|Actual|2005-11-30|||||Interventional|ATENA||Adjuvant Post-Tamoxifen Exemestane Trial|A Phase III Randomized Parallel-Group Multicenter Trial, Designed to Compare 5 Years of Adjuvant Exemestane Versus 5 Years of Observation in Postmenopausal Women With Operable Breast Cancer Who Have Received 5-7 Years of Adjuvant Tamoxifen.|Terminated||Phase 3|448|Actual|Hellenic Breast Surgeons Society||2||Publication of MA17 results (similar trial in the extented adjuvant setting with letrozole)|f||||f||||||||||2018-06-01 01:28:09.96594|2018-06-01 01:28:09.96594
NCT00810693|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2013-11-05||2016-10-14|2008-12-17|2008-12-18|Estimate|2014-01-24|2014-02-26|Estimate||||2016-10-14|2016-11-28|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PATENT-1||A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)|Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)|Completed||Phase 3|445|Actual|Bayer||3|||f||||t||||||||||2018-06-01 01:28:10.124224|2018-06-01 01:28:10.124224
NCT00810680|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|September 2008||2008-09-30|December 2008|2008-12-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)|Use of Valproic Acid in Relapsed or Refractory Chronic Lymphocytic Leukemia|Unknown status|Recruiting|N/A|10|Anticipated|All India Institute of Medical Sciences, New Delhi||1|||f||||f||||||||||2018-06-01 01:28:11.661438|2018-06-01 01:28:11.661438
NCT00810667|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2016-11-07|2008-12-17|2008-12-18|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia|A Randomised, Double-blind, Parallel-Group, Fixed Dose Study Exploring the Efficacy and Safety of Lu AE58054 as Augmentation Therapy to Risperidone in Patients With Schizophrenia|Completed||Phase 2|124|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:28:12.836461|2018-06-01 01:28:12.836461
NCT00810654|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2011-01-18|2008-12-17|2008-12-18|Estimate|||||||2011-01-18|2011-01-19|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Aspergillus Niger Prolyl Endoprotease (AN-PEP) Enzyme on the Effects of Gluten Ingestion in Patients With Coeliac Disease|Study on The Effectiveness of Oral Administration of Prolyl Endoprotease for Gluten Detoxification as a Means to Treat Coeliac Disease|Completed||Phase 1/Phase 2|14|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-06-01 01:28:13.02851|2018-06-01 01:28:13.02851
NCT00810641|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2011-05-25||2011-05-31|2008-12-17|2008-12-18|Estimate|2011-05-31|2011-06-27|Estimate||||2011-05-31|2011-06-27|Estimate|January 2009||2009-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|BPPV-HC||Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo|Randomized Multicenter Study of Treatment of Horizontal Canal Benign Paroxysmal Positional Vertigo|Completed||Phase 3|157|Actual|Chonbuk National University|In this study, resolution of BPPV was determined using a telephone interview during the follow-ups after one week.|3|||f||||t||||||||||2018-06-01 01:28:13.178282|2018-06-01 01:28:13.178282
NCT00810628|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2014-10-23|2008-12-17|2008-12-18|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Cognitive Behavioral Therapy for Depression in Parkinson's Disease|Depression in Parkinson's Disease: A Pilot Project Using Cognitive Behavioral Therapy (CBT) to Improve Depression and Coping|Terminated||N/A|12|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:28:13.517222|2018-06-01 01:28:13.517222
NCT00810615|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2013-02-28|2008-12-17|2008-12-18|Estimate|||||||2013-02-28|2013-03-04|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Treatment of Traumatic Brain Injury With Hyperbaric Oxygen Therapy|Treatment of Moderate to Mild Cognitive Dysfunction Caused by Traumatic Brain Injury (TBI) With Hyperbaric Oxygen Therapy (HBOT)|Completed||Phase 1/Phase 2|50|Actual|San Antonio Military Medical Center||2|||f||||t||||||||||2018-06-01 01:28:13.596562|2018-06-01 01:28:13.596562
NCT00810602|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2013-11-27||2014-03-05|2008-12-17|2008-12-18|Estimate|2014-03-05|2014-04-11|Estimate||||2014-03-05|2014-04-11|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional||Only participants that completed 21 days of vorinostat were considered evaluable for both toxicity and the primary outcome, therfore only 50 of the 61 patients initially enrolled are represented in baseline characteristics.|Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant|Phase II Trial of Vorinostat Plus Tacrolimus & Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant|Completed||Phase 1/Phase 2|61|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 01:28:13.806065|2018-06-01 01:28:13.806065
NCT00810589|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|November 2008||2008-11-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ENM-HS-001||A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial|A Randomised, Single Centre, Double-Blind, Two-Period Crossover, Glucose Clamp Trial to Compare the Pharmacodynamic Effects of Single Doses of Insulin Detemir and Neutral Protamin Lispro (NPL) Insulin in Subjects With Type 1 Diabetes|Completed||Phase 1|30|Actual|Medical University of Graz||2|||f||||t||||||||||2018-06-01 01:28:14.197045|2018-06-01 01:28:14.197045
NCT00810576|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2010-06-11||2012-08-01|2008-12-16|2008-12-18|Estimate|2010-06-11|2010-07-09|Estimate||||2012-08-01|2012-08-07|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma|A Phase II Study To Determine The Safety and Efficacy Of The Combination of Vorinostat and Bortezomib In Patients With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||1||Terminated due to slow accrual.|f||||f||||||||||2018-06-01 01:28:14.306317|2018-06-01 01:28:14.306317
NCT00810563|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2009-08-27|2008-12-17|2008-12-18|Estimate|||||||2009-08-27|2009-08-28|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|August 2009|Anticipated|2009-08-31|March 2009|Anticipated|2009-03-31||Interventional|DOPOL||Does Bupivacaine in Laparoscopic Portals Reduce Post Surgery Pain in Tubal Ligation by Electrocoagulation?|Assessment of Postoperatory Pain After Laparoscopic Tubal Ligation by Electrocoagulation With Bupivacaine or Placebo|Unknown status|Recruiting|N/A|46|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 01:28:14.544293|2018-06-01 01:28:14.544293
NCT00810550|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2016-04-05|2008-12-17|2008-12-18|Estimate|||||||2016-04-05|2016-04-06|Estimate|October 2005||2005-10-31|April 2016|2016-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CUE-HF||Carotid Ultrasound in the Evaluation of Heart Failure|Carotid Ultrasound in the Evaluation of Heart Failure|Completed||N/A|150|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-06-01 01:28:14.772726|2018-06-01 01:28:14.772726
NCT00810524|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection|Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection.|Unknown status|Recruiting|Phase 4|600|Anticipated|Sun Yat-sen University||4|||f||||t||||||||||2018-06-01 01:28:14.885536|2018-06-01 01:28:14.885536
NCT00810511|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2010-07-23||2012-06-26|2008-12-17|2008-12-18|Estimate|2010-09-09|2010-10-01|Estimate||||2012-06-26|2012-06-29|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation of Two Silicone Hydrogel Lenses Over a One Month Period|Evaluation of Two Silicone Hydrogel Lenses Over a One Month Period|Completed||N/A|213|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 01:28:14.989659|2018-06-01 01:28:14.989659
NCT00810498|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2010-06-29|2008-12-17|2008-12-18|Estimate|||||||2010-06-29|2010-07-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:28:15.266225|2018-06-01 01:28:15.266225
NCT00810485|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2012-07-13|2008-12-17|2008-12-18|Estimate|||||||2012-07-13|2012-07-16|Estimate|December 2008||2008-12-31|July 2012|2012-07-31||||December 2009|Actual|2009-12-31||Interventional|||ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)|A Phase 2B, Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging, Multi-centre Study to Investigate the Efficacy, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 in Patients With Gastroesophageal Reflux Disease (GERD) Who Are Partial Responders to Proton Pump Inhibitor (PPI) Treatment|Completed||Phase 2|298|Actual|Addex Pharma S.A.||4|||f||||f||||||||||2018-06-01 01:28:15.314377|2018-06-01 01:28:15.314377
NCT00810472|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2016-10-24|2008-12-17|2008-12-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|FANCY||Functional Antigen Matching in Corneal Transplantation|Clinical Trial to Investigate Superiority of HLA Matching in Comparison to Random Graft Assignment With Respect to the Endpoint 'Time to First Endothelial Graft Rejection' in Penetrating Keratoplasty.|Completed||N/A|650|Anticipated|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 01:28:15.613615|2018-06-01 01:28:15.613615
NCT00810459|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2010-06-29|2008-12-17|2008-12-18|Estimate|||||||2010-06-29|2010-07-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:28:15.7252|2018-06-01 01:28:15.7252
NCT00810446|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2018-04-02|2008-12-17|2008-12-18|Estimate|||||||2018-04-02|2018-04-03|Actual|June 11, 2009|Actual|2009-06-11|April 2018|2018-04-30|July 17, 2018|Anticipated|2018-07-17|July 17, 2018|Anticipated|2018-07-17||Observational|||Safety And Efficacy Of Rifabutin In HIV Patients|Drug Use Investigation For Hiv Infection Patients Of Mycobutin (Regulatory Post Marketing Commitment Plan).|Active, not recruiting|||500|Anticipated|Pfizer|||1||f||||f||||||||||2018-06-01 01:28:15.854812|2018-06-01 01:28:15.854812
NCT00810433|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2014-02-06|2008-12-17|2008-12-18|Estimate|||||||2014-02-06|2014-02-07|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Clinical Study of the GO-LIF® Approach for Lumbar Spinal Fixation|A Clinical Safety and Feasibility Study of the GO-LIF® Approach|Completed||N/A|10|Actual|Mazor Robotics||1|||f||||f||||||||||2018-06-01 01:28:15.977415|2018-06-01 01:28:15.977415
NCT00810420|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|February 2007||2007-02-28|December 2008|2008-12-31|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Observational|||EEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes|EEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes|Completed|||||UNEEG Medical A/S|||||f||||f||||||||||2018-06-01 01:28:16.185416|2018-06-01 01:28:16.185416
NCT00810407|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2016-09-20|2008-12-17|2008-12-18|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2008||2008-11-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients|Special Investigation For Non-hiv Patients Of Mycobutin (Regulatory Post Marketing Commitment Plan).|Completed|||500|Anticipated|Pfizer|||1||f||||f||||||||||2018-06-01 01:28:16.278727|2018-06-01 01:28:16.278727
NCT00810394|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2017-01-19||2018-01-05|2008-12-17|2008-12-18|Estimate|2017-01-19|2017-03-10|Actual||||2018-01-05|2018-01-10|Actual|December 2008||2008-12-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional||With a sample size of 51 patients, this study has 90% power with an alpha of 0.05 to detect a dose re-escalation/escalation rate difference of 50% vs. 70%. If 31 or more patients are able to re-escalate successfully, the approach will be considered for further study.|Sorafenib in Treating Patients With Advanced Malignant Solid Tumors|Single Agent Sorafenib in Advanced Solid Tumors: Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375)|Completed||Phase 2|50|Actual|University of California, Davis||1|||f||||t|t|f||||||||2018-06-01 01:28:16.420142|2018-06-01 01:28:16.420142
NCT00810381|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2008-12-17|2008-12-17|2008-12-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|January 1999||1999-01-31|December 2008|2008-12-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects|Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects|Completed||N/A|14|Actual|Medical University of Vienna||4|||f||||t||||||||||2018-06-01 01:28:16.783158|2018-06-01 01:28:16.783158
NCT00810368|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2014-03-24||2018-04-09|2008-12-17|2008-12-18|Estimate|2016-07-08|2016-08-18|Estimate||||2018-04-09|2018-05-08|Actual|August 2008||2008-08-31|April 2018|2018-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Prior 2-back working memory scores in Gulf War Illness were an average of 17 out of 35 correct (5=95%CI). Sample size for a 50% increase in 2-back working memory scores was 13 per group. 10% per month drop out rate was predicted so our aim was to have 36 subjects enter the study.|Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)|Carnosine Versus Placebo Treatment Study in Gulf War Illness (GWI)|Completed||Phase 2|33|Actual|Georgetown University|"Small sample sizes. No measure of changes in brain carnosine/homocarnosine/GABA.~Subjective outcomes were insensitive to change. Stool consistency needed better scoring system."|2|||f||||f||||||||No||2018-06-01 01:28:16.909354|2018-06-01 01:28:16.909354
NCT00810355|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2016-07-22||2017-04-12|2008-12-16|2008-12-18|Estimate|2016-09-13|2016-10-31|Estimate||||2017-04-12|2017-05-23|Actual|October 1, 2009|Actual|2009-10-01|April 2017|2017-04-30|August 6, 2015|Actual|2015-08-06|August 6, 2015|Actual|2015-08-06||Interventional|||Cognitive Behavior Therapy and Work Outcome|Effects of CBT and Cognitive Remediation on Work in Schizophrenia|Completed||N/A|87|Actual|VA Office of Research and Development||3|||f||||f||||||||No||2018-06-01 01:28:17.380923|2018-06-01 01:28:17.380923
NCT00810342|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2015-01-09||2015-06-01|2008-12-17|2008-12-18|Estimate|2015-06-01|2015-06-04|Estimate||||2015-06-01|2015-06-04|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|"NaMikimiki"|Chi square test for differences in proportions; t test for differences in means|Physical Activity in Women With Infants|Physical Activity in Women With Infants|Completed||Phase 3|311|Actual|University of Hawaii||2|||f||||t||||||||||2018-06-01 01:28:17.807055|2018-06-01 01:28:17.807055
NCT00810329|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2014-02-24|2008-12-17|2008-12-18|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2007||2007-07-31|February 2014|2014-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome|Identify Unique Set of Proteins in Cerebrospinal Fluid, Which Are Believed to be Found in Chronic Fatigue Syndrome Participants, But Not in Healthy Controls.|Completed|||160|Actual|Georgetown University|||2||f||||t||||||Samples With DNA|"~     Cheek swabs, on the right and left inner cheek. Others:Cerebrospinal fluid samples,Blood~     samples Urine samples.~   "|||2018-06-01 01:28:18.321863|2018-06-01 01:28:18.321863
NCT00810316|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2009-09-30|2008-12-17|2008-12-18|Estimate|||||||2009-09-30|2009-10-01|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population|Evaluate The Pharmacokinetics Of Two Alprazolam Formulations (Immediate Release And Extended Release Tablets) And A Clonazepam Tablet In A Healthy Mexican Population|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:28:18.501036|2018-06-01 01:28:18.501036
NCT00810303|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|2010-06-21||2010-09-23|2008-12-17|2008-12-18|Estimate|2010-09-23|2010-10-11|Estimate||||2010-09-23|2010-10-11|Estimate|March 2009||2009-03-31|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2||Completed||Phase 1|12|Actual|University Medicine Greifswald||1|||f||||f||||||||||2018-06-01 01:28:18.640817|2018-06-01 01:28:18.640817
NCT00810277|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2016-03-01||2017-06-28|2008-12-17|2008-12-18|Estimate|2016-03-01|2016-03-31|Estimate||||2017-06-28|2017-08-03|Actual|November 30, 2008|Actual|2008-11-30|June 2017|2017-06-30|May 26, 2010|Actual|2010-05-26|May 26, 2010|Actual|2010-05-26||Interventional||Analysis population included all participants who entered the study.|A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs|An Open Label Study to Evaluate the Safety and Effect on Disease Activity of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARDs.|Completed||Phase 3|14|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:28:19.438218|2018-06-01 01:28:19.438218
NCT00810264|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2018-05-01|2008-12-17|2008-12-18|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2008||2008-12-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|CELESTIAL||Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar|CELESTIAL Post Approval Registry: Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry|Active, not recruiting|||2500|Anticipated|Biotronik, Inc.|||1||f||||f||||||||||2018-06-01 01:28:20.087756|2018-06-01 01:28:20.087756
NCT00810251|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-07-05|2008-12-16|2008-12-18|Estimate|||||||2011-07-05|2011-07-06|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Observational|MatrixRIB||MatrixRIB Implants for Surgical Stabilization of Flail Chest Injuries: A Registry|A Multi-Site Prospective, Non-Randomized Observational Study Utilizing MatrixRIB Implants for Surgical Stabilization of Flail Chest Injuries|Completed|||20|Actual|Legacy Biomechanics Laboratory|||1||f||||f||||||||||2018-06-01 01:28:20.288775|2018-06-01 01:28:20.288775
NCT00810238|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2012-09-03|2008-12-17|2008-12-18|Estimate|||||||2012-09-03|2012-09-05|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|July 2010|Actual|2010-07-31||Interventional|||C-Cure Clinical Trial|C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy|Completed||Phase 2/Phase 3|240|Anticipated|Celyad (formerly named Cardio3 BioSciences)||2|||f||||t||||||||||2018-06-01 01:28:20.64752|2018-06-01 01:28:20.64752
NCT00810225|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2014-02-24|2008-12-17|2008-12-18|Estimate|||||||2014-02-24|2014-02-25|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Study of Gulf War Illness (GWI) by Comparing GWI and Healthy Veterans|CNDP1 Polymorphisms in Gulf War Illness (GWI)|Completed|||516|Anticipated|Georgetown University|||2||f||||f||||||Samples With DNA|"~     Plasma, serum, urine, and buccal swab samples retained for testing as described in protocol.~   "|||2018-06-01 01:28:20.751797|2018-06-01 01:28:20.751797
NCT00810212|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-17|||2014-11-06|2008-12-17|2008-12-18|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Safety and Efficacy Study of NeoFuse in Subjects Requiring Posterolateral Lumbar Fusion|A Prospective, Multicenter, Randomized, Open-Label, Controlled Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With Mastergraft Granules in Subjects Undergoing Posterolateral Lumbar Fusion With Instrumentation|Withdrawn||Phase 1/Phase 2|0|Actual|Mesoblast, Ltd.||4||Sponsor preferred a better study design|f||||t||||||||||2018-06-01 01:28:20.832098|2018-06-01 01:28:20.832098
NCT00810199|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2014-05-01||2014-07-16|2008-12-16|2008-12-17|Estimate|2014-07-16|2014-07-18|Estimate||||2014-07-16|2014-07-18|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|August 2010|Actual|2010-08-31||Interventional||Baseline measures are based on the Safety Population and include all randomized participants who received at least one dose of study drug.|A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment|Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients...|Completed||Phase 3|556|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:28:21.122542|2018-06-01 01:28:21.122542
NCT00810186|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2016-03-21|2008-12-16|2008-12-17|Estimate|||||||2016-03-21|2016-03-22|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Continuous Monitoring of Lung Ventilation|Continuous Monitoring of Lungs Ventilation Dynamics by Small Surface Patches That Include Safe Mechanical Sensors. A Multicenter Study.|Completed|||77|Actual|Pneumedicare Ltd.|||1||f||||t||||||||||2018-06-01 01:28:23.233727|2018-06-01 01:28:23.233727
NCT00810173|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2008-12-16|2008-12-16|2008-12-17|Estimate|||||||2008-12-16|2008-12-17|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phone Call in Type 2 Diabetes Patient|Phone Call as an Intervention for Improving Walking Practice in Type 2 Diabetes: Influence of Personality Profile in This Response|Completed||N/A|48|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 01:28:23.306295|2018-06-01 01:28:23.306295
NCT00810160|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2017-07-11|2008-12-15|2008-12-17|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2009||2009-06-30|July 2017|2017-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants|Phase 1A Study of Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants|Completed||Phase 1|59|Actual|University of California, Davis||4|||f||||t||||||||||2018-06-01 01:28:23.474568|2018-06-01 01:28:23.474568
NCT00810147|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16||2012-03-24|2015-09-23|2008-12-16|2008-12-17|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|209|Actual|Bristol-Myers Squibb||5|||f||||t||||||||||2018-06-01 01:28:23.681014|2018-06-01 01:28:23.681014
NCT00810134|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-16|2008-12-16|2008-12-17|Estimate|||||||2008-12-16|2008-12-17|Estimate|January 2003||2003-01-31|December 2008|2008-12-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Bypass or Thurpass for Superficial Femoral Artery Occlusion? Scandinavian Thurpass Study|A Randomised Controlled Trial for the Treatment of 5 - 25 cm Superficial Femoral Artery oc-Clusions Comparing Femoropopliteal Bypass With 6 mm PTFE-Prosthesis and 6 - 7 mm Viabahn Endoprosthesis|Terminated||N/A|44|Actual|Helsinki University||2||Due to the results of interim analysis at the time 44 patients were recruited.|f||||f||||||||||2018-06-01 01:28:23.906688|2018-06-01 01:28:23.906688
NCT00810121|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2009-09-24|2008-12-16|2008-12-17|Estimate|||||||2009-09-24|2009-09-25|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of Non Inferiority Bi-Profenid® 200mg Versus Bi-Profenid® 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)|Non-inferiority Study of Bi-Profenid® 200 mg Versus Bi-Profenid® 300 mg in Patients Presenting With Pain Related to Closed, Benign, Acute Post-traumatic Conditions of the Motor System or Acute, Non-infectious Rheumatologic Conditions|Completed||Phase 3|409|Actual|Sanofi||2|||f||||||||||||||2018-06-01 01:28:24.027119|2018-06-01 01:28:24.027119
NCT00810108|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2012-04-25||2012-06-02|2008-12-16|2008-12-17|Estimate|2012-06-02|2012-07-06|Estimate||||2012-06-02|2012-07-06|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Lopinavir/Ritonavir (Kaletra) PK in Children|Pharmacokinetics of Lopinavir Crushed Versus Whole Tablets in Pediatric Patients|Completed||Phase 4|12|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The AUC of the crushed tablet administration were measured after a single dose only, rather than at steady-state; variable adherence may have impacted results.|2|||f||||f||||||||||2018-06-01 01:28:24.182666|2018-06-01 01:28:24.182666
NCT00810095|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2012-03-21||2012-06-19|2008-12-15|2008-12-17|Estimate|2012-06-19|2012-07-26|Estimate||||2012-06-19|2012-07-26|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PRIISM||Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study|A Feasibility Trial to Evaluate the MindFrame System in the Recanalization of Occluded Vessels in Patients Experiencing an Ischemic Stroke|Completed||Phase 2|40|Actual|MindFrame, Inc.||1|||f||||t||||||||||2018-06-01 01:28:24.777037|2018-06-01 01:28:24.777037
NCT00810082|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2011-10-24||2018-04-25|2008-12-16|2008-12-17|Estimate|2012-02-21|2012-03-26|Estimate||||2018-04-25|2018-05-23|Actual|December 2008||2008-12-31|April 2018|2018-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|RACE||Randomized ActiveStep Clinical Evaluation|Randomized ActiveStep Clinical Evaluation|Completed||N/A|65|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-06-01 01:28:25.258085|2018-06-01 01:28:25.258085
NCT00810069|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2011-02-04||2011-05-20|2008-12-16|2008-12-17|Estimate|2011-05-20|2011-06-21|Estimate||||2011-05-20|2011-06-21|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder|Comparison of Two Different Treatment Strategies in Patients With Major Depressive Disorder Not Exhibiting Improvement on Escitalopram Treatment: Early vs. Delayed Intervention Strategy|Completed||Phase 4|840|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:28:25.878042|2018-06-01 01:28:25.878042
NCT00810056|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2016-12-05|2008-12-16|2008-12-17|Estimate|||||||2016-12-05|2016-12-06|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Fostering Healthy Futures Efficacy Trial for Preadolescent Youth in Foster Care|Fostering Healthy Futures Efficacy Trial for Preadolescent Youth in Foster Care|Active, not recruiting||N/A|256|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:28:28.2104|2018-06-01 01:28:28.2104
NCT00810043|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2011-10-26||2017-12-06|2008-12-15|2008-12-17|Estimate|2011-10-26|2011-11-30|Estimate||||2017-12-06|2017-12-08|Actual|February 2009||2009-02-28|April 2014|2014-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|MDTSCORE||Medtronic SCORE Study - Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty|Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty|Completed||Phase 4|120|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-06-01 01:28:28.386859|2018-06-01 01:28:28.386859
NCT00810030|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2012-12-19|2008-12-16|2008-12-17|Estimate|||||||2012-12-19|2012-12-21|Estimate|October 2008||2008-10-31|December 2012|2012-12-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|FER-IBD-COR||FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR|Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease|Completed||Phase 3|484|Actual|Vifor Inc.||2|||f||||f||||||||||2018-06-01 01:28:29.307379|2018-06-01 01:28:29.307379
NCT00810017|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-11-04|2008-12-16|2008-12-17|Estimate|||||||2011-11-04|2011-11-07|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer|Phase II Clinical Study Combining Trastuzumab With Etoposide in Treatment of HER2-Positive Metastatic Breast Cancer.|Terminated||Phase 2|2|Actual|Washington Hospital Center||||Terminated due to difficulty in accruing patients|f||||t||||||||||2018-06-01 01:28:29.426566|2018-06-01 01:28:29.426566
NCT00810004|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2012-12-19|2008-12-16|2008-12-17|Estimate|||||||2012-12-19|2012-12-21|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|FER-IBD-MAIN||Maintenance Treatment of Iron Deficiency in IBD Patients|A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT®) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease|Completed||Phase 3|245|Actual|Vifor Inc.||2|||f||||f||||||||||2018-06-01 01:28:29.514674|2018-06-01 01:28:29.514674
NCT00809991|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2016-04-12|2008-12-16|2008-12-17|Estimate|||||||2016-04-12|2016-04-13|Estimate|November 2008||2008-11-30|April 2016|2016-04-30||||November 2016|Anticipated|2016-11-30||Interventional|||Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate|Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate|Unknown status|Recruiting|Phase 2|188|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 01:28:29.608442|2018-06-01 01:28:29.608442
NCT00809965|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2014-05-05|2012-10-11|2014-08-26|2008-12-16|2008-12-17|Estimate|2014-05-05|2014-06-02|Estimate|2012-10-11|2012-10-15|Estimate|2014-08-26|2014-09-17|Estimate|November 2008||2008-11-30|August 2014|2014-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome|Completed||Phase 3|15526|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||t||||||||||2018-06-01 01:28:29.941521|2018-06-01 01:28:29.941521
NCT00809952|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-17|Estimate|||||||2008-12-15|2008-12-17|Estimate||||December 2008|2008-12-31||||||||Observational|UGAI||Ultrasound Guided Artificial Insemination||Completed|||||Hospital de Cruces|||1||f||||||||||||||2018-06-01 01:28:35.245591|2018-06-01 01:28:35.245591
NCT00809926|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2010-12-10||2011-03-31|2008-12-16|2008-12-17|Estimate|2011-03-31|2011-05-02|Estimate||||2011-03-31|2011-05-02|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|VANTAGE||8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension|An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension|Completed||Phase 4|451|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:28:35.382211|2018-06-01 01:28:35.382211
NCT00809913|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2016-09-15|2008-12-16|2008-12-17|Estimate|||||||2016-09-15|2016-09-16|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|FUTIRST||Febrile Urinary Tract Infection Randomized Short Treatment Trial|Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days)|Completed||Phase 4|200|Actual|Leiden University Medical Center||2|||f||||t||||||||||2018-06-01 01:28:35.936783|2018-06-01 01:28:35.936783
NCT00809900|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2009-12-01|2008-12-16|2008-12-17|Estimate|||||||2009-12-01|2009-12-02|Estimate|June 2007||2007-06-30|December 2008|2008-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Bioavailability and Metabolism of Anthocyanins Following Acute Cranberry Consumption|Bioavailability and Metabolism of Anthocyanins Following Acute Cranberry (Vaccinium Macrocarpon)Consumption|Completed|||15|Actual|Tufts University|||1||f||||f||||||||||2018-06-01 01:28:36.030006|2018-06-01 01:28:36.030006
NCT00809887|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-17|Estimate|||||||2008-12-15|2008-12-17|Estimate|June 2006||2006-06-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|June 2008|Anticipated|2008-06-30||Interventional|||Micafungin Lock Therapy|Micafungin Lock Therapy to Clear Fungemia While Attempting to Preserve Central Venous Catheters|Terminated||Phase 1|20|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2||Inability to enroll subjects|f||||f||||||||||2018-06-01 01:28:36.09364|2018-06-01 01:28:36.09364
NCT00809874|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2009-11-09|2008-12-16|2008-12-17|Estimate|||||||2009-11-09|2009-11-10|Estimate|February 2008||2008-02-29|November 2009|2009-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects|Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects|Completed||N/A|11|Actual|Aarhus University Hospital||4|||f||||f||||||||||2018-06-01 01:28:36.162038|2018-06-01 01:28:36.162038
NCT00809861|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2014-05-28|2008-12-16|2008-12-17|Estimate|||||||2014-05-28|2014-05-29|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Volar Locking Plate Versus External Fixator/Cast Fixation for the Treatment of Distal Radius Fractures|Volar Locking Plate Versus External Fixator/Cast Fixation for the Treatment of Distal Radius Fractures. A Randomised Controlled Prospective Study|Completed||N/A|52|Actual|Mackay Base Hospital||2|||f||||t||||||||||2018-06-01 01:28:36.260613|2018-06-01 01:28:36.260613
NCT00809848|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2013-08-13|2011-03-31|2013-08-13|2008-12-16|2008-12-17|Estimate|2013-08-13|2013-10-18|Estimate|2011-03-31|2011-04-07|Estimate|2013-08-13|2013-10-18|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma||Completed||Phase 1/Phase 2|172|Actual|Allergan||5|||f||||f||||||||||2018-06-01 01:28:36.333855|2018-06-01 01:28:36.333855
NCT00809835|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2016-08-04||2017-05-11|2008-12-16|2008-12-17|Estimate|2017-05-11|2017-06-12|Actual||||2017-05-11|2017-06-12|Actual|December 2007||2007-12-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse|Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse With Methadone Maintained Individuals|Completed||Phase 2|120|Actual|Yale University||4|||f||||t||||||||Yes|De-identified data will be available to other researchers upon request. Please contact Dr. Carroll|2018-06-01 01:28:36.786672|2018-06-01 01:28:36.786672
NCT00809822|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2010-10-21|2008-12-16|2008-12-17|Estimate|||||||2010-10-21|2010-10-25|Estimate|November 2008||2008-11-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|NPB-01||Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(PhaseⅡ).|Completed||Phase 2|20|Anticipated|Nihon Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-06-01 01:28:37.222243|2018-06-01 01:28:37.222243
NCT00809809|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2012-03-21||2013-11-19|2008-12-16|2008-12-17|Estimate|2013-11-19|2014-01-08|Estimate||||2013-11-19|2014-01-08|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|December 2010|Actual|2010-12-31|September 2009|Actual|2009-09-30||Interventional|||Zinc for the Treatment of Herpes Simplex Labialis (HSL)|A Randomized, Double-blind, Placebo-controlled, Multi-Center Trial of Zinc for the Treatment of Herpes Simplex Labialis (HSL)|Completed||Phase 3|157|Actual|Integrative Medicine Institute|There may have been differences between the populations in the different study sites that influenced the outcome of this clinical trial.|2|||f||||t||||||||||2018-06-01 01:28:37.295651|2018-06-01 01:28:37.295651
NCT00809796|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2011-06-27|2008-12-16|2008-12-17|Estimate|||||||2011-06-27|2011-06-28|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment|A Phase I/II Clinical Study Using Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Folinic Acid, 5-Fluorouracil, or Capecitabine and Oxaliplatin Chemotherapy as Second-line and/or Third-line Treatment|Completed||Phase 1/Phase 2|15|Anticipated|Oncozyme Pharma Inc.||1|||f||||t||||||||||2018-06-01 01:28:37.51347|2018-06-01 01:28:37.51347
NCT00809783|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16||2011-11-02|2011-11-02|2008-12-16|2008-12-17|Estimate||||2011-11-02|2011-11-07|Estimate|2011-11-02|2011-11-07|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Interventional|||Extension Study Of Tanezumab In Osteoarthritis|A Phase 3, Multicenter, Randomized, Long Term Study Of The Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip|Terminated||Phase 3|2147|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:28:37.580179|2018-06-01 01:28:37.580179
NCT00809770|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2016-11-07|2008-12-16|2008-12-17|Estimate|||||||2016-11-07|2016-11-08|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|August 2013|Actual|2013-08-31|July 2012|Actual|2012-07-31||Interventional|||Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill|Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill|Completed||N/A|176|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 01:28:37.649952|2018-06-01 01:28:37.649952
NCT00809757|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2014-05-27||2014-07-01|2008-12-16|2008-12-17|Estimate|2014-07-01|2014-07-28|Estimate||||2014-07-01|2014-07-28|Estimate|December 2008||2008-12-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||One subject was randomized but not dosed in the Levalbuterol UDV arm.|A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma|A Safety, Efficacy, and Tolerability Study of Daily Dosing With Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months With Asthma|Completed||Phase 3|197|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 01:28:37.756993|2018-06-01 01:28:37.756993
NCT00809744|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-11-02|2008-12-16|2008-12-17|Estimate|||||||2011-11-02|2011-11-03|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|D-clamp||Vitamin D AND Glucose Handling Evaluated by Glucose Clamp|Vitamin D AND Cardiovascular Disease|Completed||Phase 2|160|Actual|University Hospital of North Norway|||||f||||f||||||||||2018-06-01 01:28:39.137596|2018-06-01 01:28:39.137596
NCT00809731|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2010-12-08|2008-12-16|2008-12-17|Estimate|||||||2010-12-08|2010-12-09|Estimate|December 2008||2008-12-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|QTP NIS||Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment|A Naturalistic Observational Study to Evaluate Efficacy of 2nd-generation Antipsychotics and Remission Status for Patients With Schizophrenia / Schizoaffective Disorder|Completed|||490|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:28:39.212722|2018-06-01 01:28:39.212722
NCT00809718|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2015-10-21|2008-12-16|2008-12-17|Estimate|||||||2015-10-21|2015-10-22|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||The Effect of Rifapentine on Raltegravir|The Effect of Rifapentine on Plasma Concentrations of Raltegravir|Completed||Phase 1|27|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-06-01 01:28:39.282907|2018-06-01 01:28:39.282907
NCT00809705|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2016-11-01|2008-12-16|2008-12-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of Taspoglutide on Gastric Emptying Measured by a Paracetamol Test After Single Dose and After Multiple Doses in Patients With Type 2 Diabetes|Completed||Phase 3|60|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:28:39.359903|2018-06-01 01:28:39.359903
NCT00809692|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-04-30|2008-12-16|2008-12-17|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2007||2007-09-30|April 2013|2013-04-30||||May 2015|Anticipated|2015-05-31||Interventional|||In Vivo Assessment of Histamine Pharmacodynamics|In Vivo Functional Assessment of Histamine Pharmacodynamics in Children|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 01:28:39.469453|2018-06-01 01:28:39.469453
NCT00809679|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15||2010-06-25|2012-06-06|2008-12-16|2008-12-17|Estimate||||2010-06-25|2010-06-30|Estimate|2012-06-06|2012-06-08|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia|A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled, Pilot Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia|Terminated||Phase 2|19|Actual|Pfizer||3||Some patients experienced asymptomatic, transient elevations in liver transaminases|f||||t||||||||||2018-06-01 01:28:39.558205|2018-06-01 01:28:39.558205
NCT00809666|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-17|Estimate|||||||2008-12-15|2008-12-17|Estimate|May 2000||2000-05-31|December 2008|2008-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|PRAM||Measuring Blood Pressure in Pregnancy Using Mercury and Automated Device|A Prospective Randomised Study of Automated Versus Mercury Blood Pressure Recordings in Pregnancy|Completed||N/A|220|Actual|St George Hospital, Australia||1|||f||||f||||||||||2018-06-01 01:28:39.649716|2018-06-01 01:28:39.649716
NCT00809653|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2010-03-30|2008-12-16|2008-12-17|Estimate|||||||2010-03-30|2010-03-31|Estimate|January 2009||2009-01-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Reducing the Pro-ischaemic Effects of Air Pollution Exposure Using a Simple Face Mask|Reducing the Pro-ischaemic Effects of Ambient Particulate Air Pollution in Patients With Coronary Heart Disease Using a Simple Face Mask Intervention|Completed||N/A|100|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:28:39.717928|2018-06-01 01:28:39.717928
NCT00809640|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2009-12-04|2008-12-16|2008-12-17|Estimate|||||||2009-12-04|2009-12-07|Estimate|February 2009||2009-02-28|December 2009|2009-12-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Active Management for Low Back Pain for 6 to 8 Year Old Schoolchildren|Active Management for Low Back Pain Taught to 6 to 8 Year Old Schoolchildren|Completed||N/A|700|Anticipated|Kovacs Foundation||2|||f||||t||||||||||2018-06-01 01:28:39.81612|2018-06-01 01:28:39.81612
NCT00809627|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2013-10-28|2008-12-16|2008-12-17|Estimate|||||||2013-10-28|2013-10-29|Estimate|January 2007||2007-01-31|October 2013|2013-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Caffeine Versus Placebo for Spinal Headaches|A Prospective Trial of IV Caffeine vs Placebo for Post-Dural-Puncture Headache in the Emergency Department|Completed||N/A|21|Actual|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-06-01 01:28:39.89197|2018-06-01 01:28:39.89197
NCT00809614|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2015-02-01||2015-10-14|2008-12-16|2008-12-17|Estimate|2015-10-14|2015-11-13|Estimate||||2015-10-14|2015-11-13|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||All patients who received at least one dose of study drug were included in the safety and tolerability evaluation.|Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis|Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis|Completed||Phase 2|42|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:28:40.314023|2018-06-01 01:28:40.314023
NCT00809601|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2013-03-21|2008-12-16|2008-12-17|Estimate|||||||2013-03-21|2013-03-22|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Study of Different Kinds of Ear Tubes|Randomized Controlled Study of Transmyringeal Tubes|Unknown status|Active, not recruiting|N/A|400|Anticipated|Danderyd Hospital||1|||f||||f||||||||||2018-06-01 01:28:40.951017|2018-06-01 01:28:40.951017
NCT00809588|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2018-01-30|2008-12-16|2008-12-17|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2003||2003-10-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|September 2016|Actual|2016-09-30||Interventional|||Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)|A Phase IB Study of Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor|Active, not recruiting||Phase 1|70|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:28:41.09836|2018-06-01 01:28:41.09836
NCT00809575|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2018-02-20|2008-12-16|2008-12-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2008||2008-11-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|PROMYS||Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes|Prognostic Significance and Longitudinal Assessment of Patient-reported Quality of Life and Symptoms in Myelodysplastic Syndromes. A Large-scale International, Observational Study: PROMYS Study|Recruiting|||1070|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 01:28:41.1924|2018-06-01 01:28:41.1924
NCT00809562|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16||2016-11-01|2016-11-01|2008-12-16|2008-12-17|Estimate||||2016-11-01|2016-11-02|Estimate|2016-11-01|2016-11-02|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of RO4917523 in Patients With Treatment Resistant Depression|An Exploratory Fixed Dose Randomized Double Blind Parallel-group Placebo-controlled Study of the Safety and of the Therapeutic Effects of Ro 4917523 in Patients With Treatment- Resistant Depression|Completed||Phase 2|46|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:28:41.412185|2018-06-01 01:28:41.412185
NCT00809549|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2012-07-11|2008-12-16|2008-12-17|Estimate|||||||2012-07-11|2012-07-13|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|GIST||Study to Determine The Effect of a Drug Called Neupogen on Stroke Recovery|Granulocyte-Colony Stimulating Factor In Ischemic Stroke (GIST): A Pilot Study|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 01:28:41.510075|2018-06-01 01:28:41.510075
NCT00809536|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2010-02-16|2008-12-15|2008-12-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time|A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Pharmacokinetics Of PD 0332334 And Metformin When Administered Concurrently In Healthy Subjects|Terminated||Phase 1|24|Actual|Pfizer||2||Please Detailed Description for termination reason.|f||||f||||||||||2018-06-01 01:28:41.592326|2018-06-01 01:28:41.592326
NCT00809523|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2012-09-07||2013-01-29|2008-12-16|2008-12-17|Estimate|2013-01-29|2013-03-06|Estimate||||2013-01-29|2013-03-06|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)|A Multicenter, Randomized Controlled Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)|Completed||Phase 2/Phase 3|106|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:28:41.709528|2018-06-01 01:28:41.709528
NCT00809510|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15||2011-09-01|2011-09-01|2008-12-16|2008-12-17|Estimate||||2011-09-01|2011-09-02|Estimate|2011-09-01|2011-09-02|Estimate|January 2009||2009-01-31|September 2011|2011-09-30||||June 2009|Actual|2009-06-30||Interventional|||A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study||Terminated||Phase 2|63|Actual|Abbott||1|||f||||||||||||||2018-06-01 01:28:42.029958|2018-06-01 01:28:42.029958
NCT00809497|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2012-03-28|2008-12-16|2008-12-17|Estimate|||||||2012-03-28|2012-03-29|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|January 2011|Actual|2011-01-31|September 2009|Actual|2009-09-30||Interventional|PLC||A Clinical Study on Efficacy & Safety Profile of Propionyl-L-carnitine Tablets for Peripheral Arterial Diseases|A Randomized, Multi-centre, Double-blind and Placebo Controlled Clinical Study of the Propionyl-L-carnitine Hydrochloride Tablets|Completed||Phase 3|239|Actual|Lee's Pharmaceutical Limited|||||f||||t||||||||||2018-06-01 01:28:42.120462|2018-06-01 01:28:42.120462
NCT00809484|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2009-01-03|2008-12-16|2008-12-17|Estimate|||||||2009-01-03|2009-01-06|Estimate|May 2004||2004-05-31|December 2008|2008-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|ARBI||Arimidex Bone Mass Index and Oral Bisphosphonates|A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.|Completed|||220|Actual|Hellenic Breast Surgeons Society|||3||f||||f||||||||||2018-06-01 01:28:42.175797|2018-06-01 01:28:42.175797
NCT00809471|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2012-05-25|2011-06-06|2012-08-10|2008-12-16|2008-12-17|Estimate|2012-05-25|2012-06-28|Estimate|2011-06-06|2011-06-21|Estimate|2012-08-10|2012-08-17|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|REVIVE-D||Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in the Treatment of Erectile Dysfunction in Diabetic Men|Completed||Phase 3|390|Actual|VIVUS, Inc.||3|||f||||f||||||||||2018-06-01 01:28:42.241491|2018-06-01 01:28:42.241491
NCT00809458|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2015-06-06||2015-06-22|2008-12-16|2008-12-17|Estimate|2015-06-06|2015-06-23|Estimate||||2015-06-22|2015-07-16|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|February 2013|Actual|2013-02-28|May 2010|Actual|2010-05-31||Interventional|||Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer|A Phase III Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Prior to Prostatectomy or Brachytherapy|Terminated||Phase 3|15|Actual|New Mexico Cancer Care Alliance||2||Low rate of accrual.|f||||t||||||||||2018-06-01 01:28:42.801344|2018-06-01 01:28:42.801344
NCT00809445|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2014-08-28||2015-10-13|2008-12-16|2008-12-17|Estimate|2014-09-09|2014-09-17|Estimate||||2015-10-13|2015-10-14|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional||Participants were recruited from 12 community-based drug treatment programs. The Baseline Analysis Population represents the 1281 participants who completed baseline and were subsequently randomized.|Rapid HIV Testing and Counseling in Drug Abuse Treatment|HIV Rapid Testing and Counseling in Drug Abuse Treatment Programs in the U.S.|Completed||Phase 3|1281|Actual|University of Miami||3|||f||||t||||||||||2018-06-01 01:28:43.096098|2018-06-01 01:28:43.096098
NCT00809432|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-17|Estimate|||||||2008-12-15|2008-12-17|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||The Cardiovascular Benefits of Reducing Personal Exposure to Air Pollution|Beneficial Cardiovascular Effects of Reducing Exposure to Particulate Air Pollution With a Simple Facemask|Completed||N/A|15|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:28:43.663964|2018-06-01 01:28:43.663964
NCT00809419|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2011-07-26|2008-12-15|2008-12-17|Estimate|||||||2011-07-26|2011-07-27|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|MERITAGE||A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy|A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration in Patients That Require Persistent Anti-VEGF Therapy|Unknown status|Active, not recruiting|Phase 1/Phase 2|32|Anticipated|NeoVista||1|||f||||f||||||||||2018-06-01 01:28:43.737263|2018-06-01 01:28:43.737263
NCT00809380|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-03-18|2008-12-16|2008-12-17|Estimate|||||||2013-03-18|2013-03-19|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|PP||Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial|Parental Presence During Fracture Reduction in Children at the Emergency Department; A Randomized Controlled Trial|Terminated||N/A|12|Actual|St. Justine's Hospital||2||Study ws terminated because of a too low recruitment rate.|f||||f||||||||||2018-06-01 01:28:43.948852|2018-06-01 01:28:43.948852
NCT00809367|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-02-06|2008-12-16|2008-12-17|Estimate|||||||2013-02-06|2013-02-07|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Collection and Banking of Leukemia Cells MDS/AML|Collection and Banking of Leukemia Cells for Vaccine Generation and Research in Patients With Advanced MDS or AML|Completed||N/A|90|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:28:44.029928|2018-06-01 01:28:44.029928
NCT00809354|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16||2011-11-02|2015-03-04|2008-12-16|2008-12-17|Estimate||||2011-11-02|2011-11-07|Estimate|2015-03-04|2015-03-24|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip|A Phase 3, Multi-Center, Randomized, Double-Blind, Controlled Study Of The Long-Term Analgesic Efficacy And Safety of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip|Terminated||Phase 3|2720|Actual|Pfizer||5||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:28:44.138129|2018-06-01 01:28:44.138129
NCT00809341|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2015-10-30|2008-12-16|2008-12-17|Estimate|||||||2015-10-30|2015-11-02|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Treatment Intensification With R-ICE and High-Dose Cyclophosphamide for Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning|Terminated||Phase 2|26|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||Low accrual|f||||t||||||||||2018-06-01 01:28:44.528162|2018-06-01 01:28:44.528162
NCT00809328|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2011-03-22||2011-05-16|2008-12-16|2008-12-17|Estimate|2011-03-22|2011-04-13|Estimate||||2011-05-16|2011-05-19|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)|A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Community Acquired Pneumonia (CAP) Requiring Initial Intravenous Therapy|Completed||Phase 3|102|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:28:44.614653|2018-06-01 01:28:44.614653
NCT00809315|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2016-12-05|2008-12-16|2008-12-17|Estimate|||||||2016-12-05|2016-12-06|Estimate|August 2002||2002-08-31|December 2016|2016-12-31||||December 2020|Anticipated|2020-12-31||Interventional|||Intervention Development and Pilot for Foster Care Youth|Intervention Development and Pilot for Foster Care Youth|Active, not recruiting||N/A|152|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:28:45.008676|2018-06-01 01:28:45.008676
NCT00809302|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2009-08-27|2008-12-15|2008-12-17|Estimate|||||||2009-08-27|2009-08-28|Estimate|December 2008||2008-12-31|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|August 2009|Anticipated|2009-08-31||Interventional|||Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1, 3, and 6 mg Twice Daily) in Patients With Early Parkinson Disease (APLIED)|Terminated||Phase 2|9|Actual|Neurogen Corporation||4||"Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns~   identified."|f||||t||||||||||2018-06-01 01:28:45.088736|2018-06-01 01:28:45.088736
NCT00809289|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2011-04-06|2008-12-16|2008-12-17|Estimate|||||||2011-04-06|2011-04-07|Estimate|December 2008||2008-12-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|TQT||Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers|A Randomized, Multiple Dose, Placebo and Active Controlled 3-way Crossover Study to Investigate the Effects of Esreboxetine on QTc Interval in Healthy Volunteers|Completed||Phase 1|40|Anticipated|Pfizer||3|||f||||f||||||||||2018-06-01 01:28:45.196547|2018-06-01 01:28:45.196547
NCT00809276|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2014-12-19||2015-01-29|2008-12-16|2008-12-17|Estimate|2015-01-13|2015-01-19|Estimate||||2015-01-29|2015-02-16|Estimate|May 2009||2009-05-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY|Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide|Completed||Phase 1/Phase 2|92|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||t||||||||||2018-06-01 01:28:45.285127|2018-06-01 01:28:45.285127
NCT00809263|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2014-02-12|2008-12-16|2008-12-17|Estimate|||||||2014-02-12|2014-02-13|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|December 2012|Anticipated|2012-12-31|January 2012|Anticipated|2012-01-31||Interventional|||Homeopathic Drug Provings|A Randomized, Double-blind, Placebo-controlled, Homeopathic Drug Proving Using a Crossover Design|Withdrawn||N/A|0|Actual|Integrative Medicine Institute|||||f||||t||||||||||2018-06-01 01:28:45.553394|2018-06-01 01:28:45.553394
NCT00809250|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2017-11-13|2008-12-16|2008-12-17|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2008||2008-11-30|November 2017|2017-11-30|December 2026|Anticipated|2026-12-31|May 2011|Actual|2011-05-31||Interventional|||Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation|Vaccination With Lethally Irradiated Autologous Myeloblasts With Granulocyte Macrophage-colony Stimulating Factor Secreting K562 Cells (GM-K562) in Patients With Advanced MDS or AML After Allogeneic Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 1|33|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:28:45.626672|2018-06-01 01:28:45.626672
NCT00809237|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2013-12-08|2008-12-16|2008-12-17|Estimate|||||||2013-12-08|2013-12-10|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Hydroxychloroquine and Gefitinib to Treat Lung Cancer|A Phase II With a Lead in Phase I Study to Examine the Tolerability, Safety Profile and Efficacy of Hydroxychloroquine and Gefitinib in Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 1/Phase 2|71|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-06-01 01:28:45.72783|2018-06-01 01:28:45.72783
NCT00809224|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2016-05-12|2008-12-16|2008-12-17|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2008||2008-05-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)|Tracking Brain Changes During Real and Imagined Movements in People With ALS (Lou Gehrig's Disease) and Healthy Volunteers.|Completed|||92|Actual|University of Michigan|||2||f||||f||||||||||2018-06-01 01:28:45.834525|2018-06-01 01:28:45.834525
NCT00809211|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2017-05-30|2008-12-16|2008-12-17|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2008||2008-10-31|May 2017|2017-05-31||||February 15, 2016|Actual|2016-02-15||Interventional|||Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|A Phase II Multi-center, Open-label, Study of Nilotinib at a Dose of 300mg Twice Daily in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Active, not recruiting||Phase 2|40|Anticipated|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 01:28:45.928737|2018-06-01 01:28:45.928737
NCT00809198|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2012-02-01|2008-12-16|2008-12-17|Estimate|||||||2012-02-01|2012-02-03|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Kynex Versus Refresh Plus Study in Subject With Dry Eye|The Effect of Kynex Versus Refresh Plus in Subjects With Mild to Moderate Dry Eye - A Parallel Group, Randomized, Masked Study|Completed||Phase 4|67|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:28:46.03649|2018-06-01 01:28:46.03649
NCT00809185|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2012-01-20||2015-09-29|2008-12-16|2008-12-17|Estimate|2012-04-10|2012-05-04|Estimate||||2015-09-29|2015-10-19|Estimate|November 2005||2005-11-30|September 2015|2015-09-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes|A Phase 2 Trial of RAD001(Everolimus) in Low and Intermediate-1 Risk Myelodysplastic Syndrome|Terminated||Phase 2|7|Actual|Case Comprehensive Cancer Center|The trial was stopped early due to slow accrual. 18-33 patients were needed to address objectives, however only 7 patients were enrolled. Insufficient patients responded to the treatment to allow laboratory correlates with response to be analyzed.|1||slow accrual|f||||t||||||||||2018-06-01 01:28:46.117138|2018-06-01 01:28:46.117138
NCT00809172|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2013-05-13|2008-12-16|2008-12-17|Estimate|||||||2013-05-13|2013-05-14|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|METHODA||Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients|Multicenter Randomised Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients|Completed||Phase 3|100|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 01:28:46.280988|2018-06-01 01:28:46.280988
NCT00809159|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2015-01-29||2015-12-07|2008-12-16|2008-12-17|Estimate|2015-08-17|2015-09-18|Estimate||||2015-12-07|2015-12-09|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis|Randomized, Placebo Controlled Double Blind, Multi-center Phase II Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Moderate to Severe Ankylosing Spondylitis|Completed||Phase 2|60|Actual|Novartis||5|||f||||||||||||||2018-06-01 01:28:46.411692|2018-06-01 01:28:46.411692
NCT00809146|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2012-03-18||2016-05-10|2008-12-16|2008-12-17|Estimate|2012-03-18|2012-04-13|Estimate||||2016-05-10|2016-06-17|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|RAMPART||Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications|A Double-blind Randomized Clinical Trial of the Efficacy of IM Midazolam Versus IV Lorazepam in the Pre-hospital Treatment of Status Epilepticus by Paramedics|Completed||Phase 3|1023|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:28:48.953029|2018-06-01 01:28:48.953029
NCT00809133|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|2016-02-16||2016-02-16|2008-12-16|2008-12-17|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Treated Set: Patients who received at least 1 dose of study treatment were included in the treated set.|Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours|A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours|Completed||Phase 1|83|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 01:28:50.720197|2018-06-01 01:28:50.720197
NCT00809120|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2010-06-09|2008-12-16|2008-12-17|Estimate|||||||2010-06-09|2010-06-10|Estimate|December 2008||2008-12-31|September 2008|2008-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|TOES||Tolerance to Electrostimulation in COPD Patients|Investigation of Clinical Tolerance, Cardio-respiratory Response and Muscle Fatigue During Electrostimulation|Completed||N/A|20|Actual|Laval University|||||f||||f||||||||||2018-06-01 01:28:56.816407|2018-06-01 01:28:56.816407
NCT00809107|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-16|||2009-02-18|2008-12-16|2008-12-17|Estimate|||||||2009-02-18|2009-02-19|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|FRET||Frozen Embryo Transfer (FET) in Natural Cycles or in Natural Cycles Controlled by Human Chorionic Gonadotropin (hCG) Administration|Cryopreserved-Thawed Embryo Transfer in Natural Cycle or in Natural Cycles Controlled by External Administration of hCG: a Prospective Randomized Study|Completed||N/A|150|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-06-01 01:28:56.883936|2018-06-01 01:28:56.883936
NCT00809094|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2013-02-14||2013-04-15|2008-12-15|2008-12-17|Estimate|2013-02-14|2013-03-15|Estimate||||2013-04-15|2013-04-22|Estimate|November 2008||2008-11-30|April 2013|2013-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients|A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients|Completed||Phase 2|70|Actual|Stanford University||2|||f||||||||||||||2018-06-01 01:28:56.961282|2018-06-01 01:28:56.961282
NCT00809081|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|July 2007||2007-07-31|December 2008|2008-12-31|January 2010|Anticipated|2010-01-31|June 2009|Anticipated|2009-06-30||Interventional|||Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy|A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy|Unknown status|Recruiting|Phase 3|38|Anticipated|Yonsei University||2|||f||||t||||||||||2018-06-01 01:28:57.422826|2018-06-01 01:28:57.422826
NCT00809068|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2010-01-31|2008-12-15|2008-12-16|Estimate|||||||2010-01-31|2010-02-02|Estimate|August 2005||2005-08-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|TibFen||High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone|Effects of Tibolone and PPARα-agonist on HDL Metabolism in Postmenopausal Women|Completed||Phase 4|20|Anticipated|Keogh Institute for Medical Research||2|||f||||t||||||||||2018-06-01 01:28:57.533501|2018-06-01 01:28:57.533501
NCT00808886|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|May 2009|Anticipated|2009-05-31|April 2009|Anticipated|2009-04-30||Observational|||Study of Comparison Between Pentacam and locs3|Comparison Between Pentacam Scheimpflug System and locs3 in Grading of Cataract|Unknown status|Not yet recruiting||||Soroka University Medical Center|||||f||||f||||||||||2018-06-01 01:28:59.534563|2018-06-01 01:28:59.534563
NCT00809055|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2015-12-17||2016-01-26|2008-12-15|2008-12-16|Estimate|2016-01-26|2016-02-24|Estimate||||2016-01-26|2016-02-24|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2010|Actual|2010-12-31||Interventional|||MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine|Magnetic Resonance Imaging and Neurodevelopmental Outcomes in Preterm Infants Following Administration of High-Dose Caffeine - A Pilot Study|Completed||Phase 4|74|Actual|Washington University School of Medicine||2|||f||||t||||||||No||2018-06-01 01:28:57.624127|2018-06-01 01:28:57.624127
NCT00809042|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|June 2007||2007-06-30|December 2008|2008-12-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia|The Effect of Combination Therapy of Hydroxyurea With L- Carnitine and Magnesium Chloride on he-Matologic Parameters and Cardiac Function of β-Thalassemia Intermedia Patients.|Completed||Phase 2|120|Anticipated|Shiraz University of Medical Sciences||4|||f||||t||||||||||2018-06-01 01:28:58.036101|2018-06-01 01:28:58.036101
NCT00809029|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2011-12-20|2008-12-15|2008-12-16|Estimate|||||||2011-12-20|2011-12-21|Estimate|April 2011||2011-04-30|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo Study|The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Hormone Sensitive Lipase, Lipoprotein Lipase And Adipokine Expression In Human Subcutaneous Adipose Tissue: An In Vivo Study|Unknown status|Recruiting|N/A|12|Anticipated|Aintree University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-06-01 01:28:58.107937|2018-06-01 01:28:58.107937
NCT00809016|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-13|||2011-05-12|2008-12-13|2008-12-16|Estimate|||||||2011-05-12|2011-05-13|Estimate|May 2007||2007-05-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||PET Scans in Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy|Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors|Completed||N/A|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:28:58.201096|2018-06-01 01:28:58.201096
NCT00809003|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|September 2007||2007-09-30|December 2008|2008-12-31|December 2007|Actual|2007-12-31|||||Observational|JADE||Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease|Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease|Completed|||60|Actual|University of Waterloo|||3||f||||f||||||||||2018-06-01 01:28:58.586244|2018-06-01 01:28:58.586244
NCT00808990|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2016-04-07|2008-12-15|2008-12-16|Estimate|||||||2016-04-07|2016-04-08|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||The Effect of Probiotics on Non Alcoholic Fatty Liver Disease|Probiotics and Non Alcoholic Steatohepatitis (NASH)|Terminated||Phase 1|38|Actual|Rabin Medical Center||2||"Time table was unfulfilled due to incompetent research coordinator. Inaccurate results and No~   conclusions can be withdrawn"|f||||f||||||||||2018-06-01 01:28:58.653275|2018-06-01 01:28:58.653275
NCT00808977|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2010-11-16|2008-12-15|2008-12-16|Estimate|||||||2010-11-16|2010-11-17|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis|A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis|Completed||Phase 2|80|Anticipated|Palau Pharma S.A.||3|||f||||f||||||||||2018-06-01 01:28:58.777505|2018-06-01 01:28:58.777505
NCT00808964|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2011-06-08|2008-12-15|2008-12-16|Estimate|||||||2011-06-08|2011-06-10|Estimate|January 2013||2013-01-31|June 2011|2011-06-30|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Interventional|SNAP-CABG-OFF||Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery|Phase 2 Study of NU172 Anticoagulation in Patients Undergoing Coronary Artery Bypass Graft Surgery OFF-Pump|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|ARCA Biopharma, Inc.|||||f||||t||||||||||2018-06-01 01:28:58.899409|2018-06-01 01:28:58.899409
NCT00808951|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-07-30|2008-12-15|2008-12-16|Estimate|||||||2015-07-30|2015-08-03|Estimate|December 2008||2008-12-31|July 2015|2015-07-31|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|||In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso|In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso|Completed||Phase 4|440|Actual|Centre Muraz||2|||f||||f||||||||||2018-06-01 01:28:58.958355|2018-06-01 01:28:58.958355
NCT00808938|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-02-11|2008-12-15|2008-12-16|Estimate|||||||2013-02-11|2013-02-13|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|MST||A Pilot Study of the Use of Magnetic Seizure Therapy for Depression|A Pilot Study of the Use of Magnetic Seizure Therapy for Treatment Resistant Depression|Completed||Phase 2|15|Actual|Bayside Health||1|||f||||f||||||||||2018-06-01 01:28:59.041003|2018-06-01 01:28:59.041003
NCT00808925|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-12-18|2008-12-15|2008-12-16|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||The Impact of Heat Acclimation on Pro- and Anti- Inflammatory Cytokine Response|The Impact of Heat Acclimation on Pro- and Anti- Inflammatory Cytokine Response|Terminated||N/A|10|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 01:28:59.157069|2018-06-01 01:28:59.157069
NCT00808912|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2010-06-22|2008-12-15|2008-12-16|Estimate|||||||2010-06-22|2010-06-23|Estimate|December 2008||2008-12-31|June 2010|2010-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Does Sildenafil Increase Exercise Performance in Air Pollution?|Decreased Pulmonary Artery Pressure by Oral Sildenafil Injection During Exercise in Air Pollution Increases Exercise Performance.|Completed||N/A|24|Anticipated|Marywood University||4|||f||||f||||||||||2018-06-01 01:28:59.234731|2018-06-01 01:28:59.234731
NCT00808899|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2010-04-19||2017-04-24|2008-12-15|2008-12-16|Estimate|2010-04-19|2010-05-20|Estimate||||2017-04-24|2017-05-30|Actual|December 2008||2008-12-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma|Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma|Terminated||Phase 2|4|Actual|St. Jude Children's Research Hospital|NB2008 was closed because of the publication of a new standard of care for treating high-risk neuroblastoma.At the time of closure, NB2008 had enrolled only 4 patients, which was an insufficient number of patients to answer the primary objective.|1||Voluntarily closed and terminated by the PI due to lack of feasibility|f||||f||||||||||2018-06-01 01:28:59.34588|2018-06-01 01:28:59.34588
NCT00808873|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|March 2011|Anticipated|2011-03-31|February 2011|Anticipated|2011-02-28||Interventional|||Socio-Educational Intervention for Rural Suicide Attempters|A Randomized Control Trial of a Socio-Educational Intervention for Rural Suicide Attempters in Tianjin Municipality and Shandong Province of China|Unknown status|Recruiting|N/A|450|Anticipated|Beijing HuiLongGuan Hospital||2|||f||||f||||||||||2018-06-01 01:28:59.645228|2018-06-01 01:28:59.645228
NCT00808860|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2010-12-03|2008-12-15|2008-12-16|Estimate|||||||2010-12-03|2010-12-06|Estimate|February 2008||2008-02-29|December 2008|2008-12-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients|Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients|Completed||Phase 1/Phase 2|25|Actual|Hanoi Medical University||2|||f||||t||||||||||2018-06-01 01:28:59.758774|2018-06-01 01:28:59.758774
NCT00808834|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2010-06-18||2012-06-26|2008-12-15|2008-12-16|Estimate|2010-09-16|2010-10-04|Estimate||||2012-06-26|2012-06-29|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Non-dispense Comfort Comparison of Two Silicone Hydrogel Lenses|Non-dispense Comfort Comparison of Two Silicone Hydrogel Lenses|Completed||N/A|196|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:28:59.854316|2018-06-01 01:28:59.854316
NCT00808821|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate||||October 2008|2008-10-31||||||||Observational|||Pharyngeal Carriage Rates and Genetic Typing of Group A Streptococcus and Streptococcus Pneumonia Among Israeli Military Basic Trainees|Pharyngeal Carriage Rates and Genetic Typing of Group A Streptococcus and Streptococcus Pneumonia Among Israeli Military Basic Trainees|Completed|||||Medical Corps, Israel Defense Force|||||f||||||||||||||2018-06-01 01:28:59.994529|2018-06-01 01:28:59.994529
NCT00808808|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2012-07-30||2013-10-28|2008-12-15|2008-12-16|Estimate|2012-08-10|2012-09-13|Estimate||||2013-10-28|2013-11-20|Estimate|September 2008||2008-09-30|October 2013|2013-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Observational|MA181||Assessing Choice in the Employer Setting (ACES) Study|Assessing Choice in the Employer Setting (ACES Study): An Observational Study to Assess the Impact of Offering Intranasal Vaccine on Influenza Vaccination Rates in the Employer Setting|Completed|||4411|Actual|MedImmune LLC|The study was conducted during a single season, data to evaluate effects of the intervention by race were unavailable, baseline vaccination data were available at the company level only, and vaccines received outside the workplace were not assessed.||3||f||||f||||||||||2018-06-01 01:29:00.093255|2018-06-01 01:29:00.093255
NCT00808795|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-13|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|April 2006||2006-04-30|December 2008|2008-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy of N-Acetylcysteine in Prevention of Post-Catheterization Contrast-Induced Nephropathy in Diabetic Patients With Chronic Kidney Disease|Efficacy of N-Acetylcysteine in Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization in Patients With Diabetes Mellitus and Chronic Kidney Disease: A Randomized Clinical Trial|Completed||Phase 3|90|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:29:00.483546|2018-06-01 01:29:00.483546
NCT00808782|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-14|||2013-02-06|2008-12-15|2008-12-16|Estimate|||||||2013-02-06|2013-02-07|Estimate|December 2008||2008-12-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Use of rTMS to Improve Theory of Mind Among Adults With Autism and Asperger's Disorder|The Use of rTMS to Improve Theory of Mind Among Adults With Autism and Asperger's Disorder|Completed||N/A|30|Actual|Bayside Health||2|||f||||f||||||||||2018-06-01 01:29:00.547991|2018-06-01 01:29:00.547991
NCT00808769|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2010-05-19||2015-05-07|2008-12-15|2008-12-16|Estimate|2011-03-29|2011-04-27|Estimate||||2015-05-07|2015-06-01|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression|Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression|Completed||Phase 4|30|Actual|Procter and Gamble|Results of this study were uninterpretable as noted in the Analysis Population Description.|2|||f||||f||||||||||2018-06-01 01:29:00.625348|2018-06-01 01:29:00.625348
NCT00808756|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2012-08-07|2008-12-15|2008-12-16|Estimate|||||||2012-08-07|2012-08-08|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|BAMBINOL||Study on Fermentable Carbohydrates in Healthy Infants|Study on Fermentable Carbohydrates in Healthy Infants|Completed||N/A|388|Actual|University Rovira i Virgili||3|||f||||t||||||||||2018-06-01 01:29:00.869186|2018-06-01 01:29:00.869186
NCT00808743|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-05-15|2008-12-15|2008-12-16|Estimate|||||||2013-05-15|2013-05-16|Estimate|May 2009||2009-05-31|August 2010|2010-08-31|January 2013|Actual|2013-01-31|July 2011|Actual|2011-07-31||Interventional|PreDuoFAP||Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis|Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP)|Completed||Phase 2/Phase 3|37|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:29:00.958606|2018-06-01 01:29:00.958606
NCT00808730|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2010-02-15|2008-12-15|2008-12-16|Estimate|||||||2010-02-15|2010-02-17|Estimate|February 2009||2009-02-28|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|MITASTHME||Role of Mitochondria in Non Severe Asthma|Role of Mitochondria in Human Bronchial Smooth Muscle Remodeling in Non Severe Asthma|Completed||N/A|32|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-06-01 01:29:01.046857|2018-06-01 01:29:01.046857
NCT00808717|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2009-07-14|2008-12-15|2008-12-16|Estimate|||||||2009-07-14|2009-07-15|Estimate|July 2007||2007-07-31|July 2009|2009-07-31||||December 2008|Actual|2008-12-31||Interventional|STATIN STEMI||Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI)|Efficacy of High Dose Atorvastatin Loading in ST Elevation Myocardial Infarction|Completed||Phase 4|170|Anticipated|Yonsei University||2|||f||||t||||||||||2018-06-01 01:29:01.121914|2018-06-01 01:29:01.121914
NCT00808704|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|August 2003||2003-08-31|December 2008|2008-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy|Effect of Erythropoietin on Neonatal Hypoxic Ischemic Encephalopathy|Completed||Phase 1/Phase 2|167|Actual|Zhengzhou University|||||f||||t||||||||||2018-06-01 01:29:01.206253|2018-06-01 01:29:01.206253
NCT00808691|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2015-01-05|2008-12-15|2008-12-16|Estimate|||||||2015-01-05|2015-01-06|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Observational|||Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit|Microcirculation and Oxidative Stress in Critically Ill Patients in Surgical Intensive Care Unit|Completed|||124|Actual|National Taiwan University Hospital|||6||f||||f||||||||||2018-06-01 01:29:01.27696|2018-06-01 01:29:01.27696
NCT00808678|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-09-27|2008-12-12|2008-12-16|Estimate|||||||2012-09-27|2012-09-28|Estimate|December 2008||2008-12-31|September 2012|2012-09-30||||January 2009|Actual|2009-01-31||Interventional|||Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium||Completed||Phase 1|90|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:29:01.345073|2018-06-01 01:29:01.345073
NCT00808665|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2017-06-20||2018-05-24|2008-12-15|2008-12-16|Estimate|2018-05-24|2018-05-25|Actual||||2018-05-24|2018-05-25|Actual|June 2009||2009-06-30|May 2018|2018-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|DEXREDLOS||Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion|Does Continuous Perioperative Dexmedetomidine Infusion Reduce Time to Discharge in Patients Undergoing Major Lumbar Fusion? A Double-Blind, Placebo-Controlled Study|Completed||Phase 4|68|Actual|Vanderbilt University Medical Center||2|||f||||t|t|f|||f|||Undecided||2018-06-01 01:29:01.491598|2018-06-01 01:29:01.491598
NCT00808652|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2016-05-05|2008-12-15|2008-12-16|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Prevalence and Outcome of Brachial Artery Endothelial Function in Morbidly Obese Patients Undergoing Bariatric Surgery|Prevalence and Outcome of Brachial Artery Endothelial Function in Morbidly Obese Patients Undergoing Bariatric Surgery|Terminated|||13|Actual|Sheba Medical Center||||not enough recruits|f||||f||||||||No||2018-06-01 01:29:01.796662|2018-06-01 01:29:01.796662
NCT00808639|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|2014-01-14||2016-09-09|2008-12-15|2008-12-16|Estimate|2014-04-15|2014-05-15|Estimate||||2016-09-09|2016-10-24|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|December 2013|Actual|2013-12-31||Interventional|||Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma|A Phase II Trial of Neoadjuvant Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma|Completed||Phase 2|39|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 01:29:01.881058|2018-06-01 01:29:01.881058
NCT00808626|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2015-05-01|2008-12-12|2008-12-16|Estimate|||||||2015-05-01|2015-05-04|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis|Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis|Withdrawn||Phase 1/Phase 2|0|Actual|Temple University||1||Lack of funding to complete trial. A lead member of research team retired.|f||||||||||||||2018-06-01 01:29:02.156745|2018-06-01 01:29:02.156745
NCT00808613|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2013-02-25|2008-12-15|2008-12-16|Estimate|||||||2013-02-25|2013-02-26|Estimate|December 2008||2008-12-31|February 2013|2013-02-28|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Optetrak Posterior Stabilized Versus Optetrak Hi-Flex|A Prospective, Single-center, Non-randomized, Consecutive Series Clinical Study Comparing the Functional Differences Between a Standard Posterior Stabilized Total Knee Replacement and a High-flexion Posterior Stabilized Total Knee Replacement|Withdrawn||Phase 4|0|Actual|Exactech||2||Study withdrawn prior to initiation|f||||f||||||||||2018-06-01 01:29:02.230596|2018-06-01 01:29:02.230596
NCT00808600|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2009-08-18|2008-12-15|2008-12-16|Estimate|||||||2009-08-18|2009-08-19|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|January 2014|Anticipated|2014-01-31|July 2013|Anticipated|2013-07-31||Interventional|||Empowerment of Lung and Heart-lung Transplant Patients|Empowerment of Lung and Heart-lung Transplant Patients by a Multimodal Resource-activating Behavioural Training Programme and Cardiopulmonary Exercise - a Randomised Controlled Study|Unknown status|Not yet recruiting|N/A|132|Anticipated|Hannover Medical School||4|||f||||f||||||||||2018-06-01 01:29:02.307125|2018-06-01 01:29:02.307125
NCT00808587|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2017-05-02|2008-12-15|2008-12-16|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2008||2008-10-31|May 2017|2017-05-31|March 2029|Anticipated|2029-03-31|September 2009|Actual|2009-09-30||Observational|||Scripps Genomics Health Initiative|Scripps Genomics Health Initiative|Active, not recruiting|||10000|Anticipated|Scripps Translational Science Institute|||1||f||||f||||||||||2018-06-01 01:29:02.42338|2018-06-01 01:29:02.42338
NCT00808574|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2008-12-12|2008-12-12|2008-12-16|Estimate|||||||2008-12-12|2008-12-16|Estimate|July 2008||2008-07-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Screening for Obstructive Sleep Apnea Among Members of an Internet Weight Loss Community|Effect of a Web-Based Presentation on Communication With Healthcare Providers|Completed||Early Phase 1|168|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 01:29:02.508634|2018-06-01 01:29:02.508634
NCT00808561|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2016-03-10|2008-12-15|2008-12-16|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|January 2011|Actual|2011-01-31||Interventional|||Randomized Fistula Study|Prospective Randomized Trial of Fistula vs. Forearm AV Graft in Patients With Poor Venous Access; Protocol #3, Version 1|Terminated||N/A|6|Actual|University of Pittsburgh||2||Slow enrollment due to multiple screen failures|f||||t||||||||||2018-06-01 01:29:02.591197|2018-06-01 01:29:02.591197
NCT00808548|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|February 2009|Anticipated|2009-02-28||Observational|||Exploring Stress and Coping Behaviors of the Major Carer Whose Children With Prader-Willi Syndrome||Unknown status|Not yet recruiting||8|Anticipated|Taichung Veterans General Hospital|||1||f||||t||||||||||2018-06-01 01:29:02.665907|2018-06-01 01:29:02.665907
NCT00808535|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-15|||2009-02-06|2008-12-15|2008-12-16|Estimate|||||||2009-02-06|2009-02-09|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Observational|||Cardiac Magnetic Resonance Imaging for Detecting Endothelial Dysfunction|A Pilot Study of Cardiac Magnetic Resonance Imaging For Detection of Myocardial Perfusion Abnormalities in Endothelial Dysfunction|Unknown status|Not yet recruiting||60|Anticipated|University of California, Los Angeles|||2||f||||f||||||||||2018-06-01 01:29:02.728648|2018-06-01 01:29:02.728648
NCT00808522|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-13|||2008-12-15|2008-12-15|2008-12-16|Estimate|||||||2008-12-15|2008-12-16|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women|Prevention of Breast Cancer: As Simple as hCG-A Randomized Clinical Trial in High Risk Women.|Unknown status|Recruiting|Phase 3|84|Anticipated|New York Presbyterian Hospital||2|||f||||f||||||||||2018-06-01 01:29:02.817116|2018-06-01 01:29:02.817116
NCT00808509|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2013-09-19||2013-11-21|2008-12-12|2008-12-16|Estimate|2013-09-19|2013-11-20|Estimate||||2013-11-21|2013-12-16|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ADMIRE||A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission|A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)|Completed||Phase 4|33|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 01:29:02.997443|2018-06-01 01:29:02.997443
NCT00808496|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2011-10-06|2008-12-12|2008-12-15|Estimate|||||||2011-10-06|2011-10-07|Estimate|June 2009||2009-06-30|October 2011|2011-10-31|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Interventional|MRx||The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis|A Double Blind Randomized Controlled Trial to Compare Biannual Peripheral Magnetic Resonance Imaging, Radiography, and Standard of Care on Pharmacotherapeutic Escalation in Inflammatory Arthritis|Unknown status|Active, not recruiting|Phase 4|186|Anticipated|McMaster University||3|||f||||t||||||||||2018-06-01 01:29:05.658002|2018-06-01 01:29:05.658002
NCT00808483|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2014-12-09||2015-01-08|2008-12-12|2008-12-15|Estimate|2015-01-08|2015-01-09|Estimate||||2015-01-08|2015-01-09|Estimate|October 2008||2008-10-31|January 2015|2015-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Walking Skill Training Program Effects in Patients With Total Hip Arthroplasty|Effect of a Walking Skill Training Program in Patients Who Have Undergone Total Hip Arthroplasty: Followup One Year After Surgery|Completed||N/A|68|Actual|University of Oslo||2|||f||||t||||||||||2018-06-01 01:29:05.853172|2018-06-01 01:29:05.853172
NCT00808470|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2015-05-08||2017-04-13|2008-12-12|2008-12-15|Estimate|2017-04-13|2017-05-19|Actual||||2017-04-13|2017-05-19|Actual|October 2008||2008-10-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||healthy young adults that meet audiometric enrollment criteria|Micronutrients to Prevent Noise-induced Hearing Loss|Micronutrient Intervention to Reduce Noise-Induced Hearing Loss: Prevention of Temporary Threshold Changes Induced by Use of a Digital Music Player|Completed||Phase 2|72|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:29:06.156174|2018-06-01 01:29:06.156174
NCT00808457|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2011-08-12|2008-12-12|2008-12-15|Estimate|||||||2011-08-12|2011-08-15|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Role of Chest Ultrasound in Diagnosing and Follow-up of Pneumonia|"Role of Chest Ultrasound in Diagnosing and Follow-up of Pneumonia. Prospective Comparison Between X-ray Chest Film in Two Planes and Low-dose Spiral Computed Tomography"|Completed|||397|Actual|University of Jena|||1||f||||f||||||||||2018-06-01 01:29:06.55031|2018-06-01 01:29:06.55031
NCT00808444|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2010-10-25||2016-10-06|2008-12-11|2008-12-15|Estimate|2010-10-25|2010-11-19|Estimate||||2016-10-06|2016-11-16|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age|Non-inferiority of a Commercial Lot of the Pneumococcal Vaccine GSK1024850A Compared to a Clinical Lot.|Completed||Phase 3|466|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:29:06.624096|2018-06-01 01:29:06.624096
NCT00808431|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2013-12-17|2008-12-12|2008-12-15|Estimate|||||||2013-12-17|2013-12-19|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||ST of TN-Salud Con La Familia: Prevent Onset of Ped Obesity|ST of TN-Salud Con La Familia: Prevent Onset of Ped Obesity|Completed||Phase 2/Phase 3|100|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 01:29:08.250277|2018-06-01 01:29:08.250277
NCT00808418|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2014-01-31|2008-12-12|2008-12-15|Estimate|||||||2014-01-31|2014-02-03|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer|A Phase 1 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC)|Completed||Phase 1|34|Actual|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-06-01 01:29:08.337932|2018-06-01 01:29:08.337932
NCT00808405|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2012-04-20|2011-03-31|2013-11-15|2008-12-12|2008-12-15|Estimate|2012-04-20|2012-05-18|Estimate|2011-03-31|2011-04-07|Estimate|2013-11-15|2013-12-11|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|PK/GUD||GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women|Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women|Completed||N/A|88|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 01:29:08.424482|2018-06-01 01:29:08.424482
NCT00808392|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2011-12-26|2008-12-12|2008-12-15|Estimate|||||||2011-12-26|2011-12-29|Estimate|November 2008||2008-11-30|December 2011|2011-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b|A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Investigate Immunogenicity and Safety of Haemophilus Influenzae Type b Vaccine in 2 - 4 Months Old Healthy Infants in China, According to the Recommended Regimen of 3 Intramuscular Doses Given One Month Apart|Completed||Phase 3|916|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:29:08.711657|2018-06-01 01:29:08.711657
NCT00808379|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2008-12-12|2008-12-12|2008-12-15|Estimate|||||||2008-12-12|2008-12-15|Estimate|May 2006||2006-05-31|December 2008|2008-12-31|July 2009|Anticipated|2009-07-31|February 2009|Anticipated|2009-02-28||Interventional|||Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers|Concurrent Chemo-Radiotherapy vs Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers. A Randomized Phase II Study|Unknown status|Active, not recruiting|Phase 2|90|Actual|Tata Memorial Hospital||2|||f||||t||||||||||2018-06-01 01:29:08.780013|2018-06-01 01:29:08.780013
NCT00808366|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2008-12-12|2008-12-12|2008-12-15|Estimate|||||||2008-12-12|2008-12-15|Estimate|October 2008||2008-10-31|December 2008|2008-12-31|October 2009|Anticipated|2009-10-31|June 2009|Anticipated|2009-06-30||Interventional|||Efficacy and Safety of RV4104A Ointment in Onychomycosis|A Randomized, Parallel-Group, Multicentre, Open-Labelled, Active-Controlled Study to Assess the Efficacy, Safety and Tolerability of RV4104A Ointment Versus Bifonazole-Urea Ointment for the Complete Removal of the Clinically Infected Nail Plate Area in Patients With Toenail Onychomycosis|Unknown status|Recruiting|N/A|228|Anticipated|Pierre Fabre Dermo Cosmetique||2|||f||||f||||||||||2018-06-01 01:29:08.870111|2018-06-01 01:29:08.870111
NCT00808353|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2008-12-12|2008-12-12|2008-12-15|Estimate|||||||2008-12-12|2008-12-15|Estimate|July 1985||1985-07-31|December 2008|2008-12-31||||||||Observational|||Genomic Approaches to Common Chronic Disease - Ancillary to ARIC|Genomic Approaches to Common Chronic Disease|Completed|||15792|Actual|University of Michigan|||||f||||t||||||Samples With DNA|"~     Blood and urine~   "|||2018-06-01 01:29:09.031761|2018-06-01 01:29:09.031761
NCT00808340|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2010-07-30||2017-08-31|2008-12-12|2008-12-15|Estimate|2010-07-30|2010-08-26|Estimate||||2017-08-31|2017-09-29|Actual|November 1, 2008|Actual|2008-11-01|August 2017|2017-08-31|December 1, 2008|Actual|2008-12-01|December 1, 2008|Actual|2008-12-01||Interventional|||Comparison of Three Soft Bifocal Contact Lenses||Completed||N/A|37|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||||||||||||2018-06-01 01:29:09.112441|2018-06-01 01:29:09.112441
NCT00808327|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2009-11-19|2008-12-11|2008-12-15|Estimate|||||||2009-11-19|2009-11-20|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Spinal Anesthesia for Cesarean Delivery: Bupivacaine With or Without Fentanyl|Spinal Anesthesia for Cesarean Delivery: Bupivacaine With or Without Fentanyl|Completed||N/A|140|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 01:29:09.433864|2018-06-01 01:29:09.433864
NCT00808314|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2012-08-01|2008-12-12|2008-12-15|Estimate|||||||2012-08-01|2012-08-02|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|September 2012|Anticipated|2012-09-30|December 2010|Actual|2010-12-31||Interventional|||Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress|Lexiscan(TM) Rb-82 Myocardial Perfusion Positron Emission Computed Tomography: A Comparison With Dipyridamole|Unknown status|Active, not recruiting|Phase 4|32|Anticipated|Cardiovascular Imaging Technologies||2|||f||||f||||||||||2018-06-01 01:29:09.526945|2018-06-01 01:29:09.526945
NCT00808301|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2015-03-17|2008-12-12|2008-12-15|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|July 2014|Actual|2014-07-31||Interventional|||Oat Products in the Treatment of Coeliac Disease in Children|Multicentre Clinical Trial on Oat Products in the Treatment of Coeliac Disease in Children|Unknown status|Active, not recruiting|N/A|300|Anticipated|Heinz Italia SpA||1|||f||||f||||||||||2018-06-01 01:29:09.62343|2018-06-01 01:29:09.62343
NCT00808288|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2011-10-06|2008-12-12|2008-12-15|Estimate|||||||2011-10-06|2011-10-10|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|A7881013||A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Phase 2b, Parallel Group, Placebo And Active Comparator Controlled Study To Investigate The Safety, Toleration And Efficacy Of 6-Week Once Daily Administration Of Inhaled PF-00610355 Dry Powder In Patients With Moderate Chronic Obstructive Pulmonary Disease.|Completed||Phase 2|405|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 01:29:09.733168|2018-06-01 01:29:09.733168
NCT00808275|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2011-12-02|2008-12-12|2008-12-15|Estimate|||||||2011-12-02|2011-12-06|Estimate|September 2004||2004-09-30|December 2011|2011-12-31|October 2007|Actual|2007-10-31|September 2006|Actual|2006-09-30||Interventional|||Caloric Restriction and Body Weight in Adults|Effect of Dietary Calcium on Body Weight Regulation in Adults|Completed||N/A|79|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 01:29:09.894225|2018-06-01 01:29:09.894225
NCT00808262|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2011-06-07|2008-12-12|2008-12-15|Estimate|||||||2011-06-07|2011-06-08|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease|"A Phase I/II, Open-label, Escalating Dose, Optimal Two-stage, Study of TNFα-Kinoid (TNF- K) Immunization in Crohn's Disease Patients"|Completed||Phase 1/Phase 2|21|Actual|Neovacs||3|||f||||t||||||||||2018-06-01 01:29:09.95469|2018-06-01 01:29:09.95469
NCT00808249|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2011-01-28||2011-06-15|2008-12-12|2008-12-15|Estimate|2011-04-20|2011-05-19|Estimate||||2011-06-15|2011-06-20|Estimate|December 2008||2008-12-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)|A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD)|Completed||Phase 2|725|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 01:29:10.162417|2018-06-01 01:29:10.162417
NCT00808236|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2010-05-21||2011-06-08|2008-12-11|2008-12-15|Estimate|2010-06-18|2010-07-16|Estimate||||2011-06-08|2011-06-10|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|PRINCE||Pre-ROSC Intra-Nasal Cooling Effectiveness|Trans-Nasal Cooling With the RhinoChill Device Following Cardiac Arrest: A Pilot Study|Completed||N/A|200|Actual|BeneChill, Inc||2|||f||||f||||||||||2018-06-01 01:29:10.703452|2018-06-01 01:29:10.703452
NCT00808223|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2013-12-10|2008-12-12|2008-12-15|Estimate|||||||2013-12-10|2013-12-12|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis|A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]|Completed||Phase 2|30|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 01:29:11.373331|2018-06-01 01:29:11.373331
NCT00808210|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11||2014-01-27|2016-11-01|2008-12-12|2008-12-15|Estimate||||2014-01-28|2014-02-28|Estimate|2016-11-01|2016-11-02|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab|A PHASE II RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE, COMPARED TO INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB|Terminated||Phase 2|28|Actual|Genentech, Inc.||2||"Based on analysis of results and consideration of available treatments, the overall benefit to~   risk profile of ocrelizumab was not favorable in RA."|f||||||||||||||2018-06-01 01:29:11.471284|2018-06-01 01:29:11.471284
NCT00808197|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2008-12-12|2008-12-12|2008-12-15|Estimate|||||||2008-12-12|2008-12-15|Estimate||||December 2008|2008-12-31||||||||Interventional|||Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation|Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation|Completed||N/A|41|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-06-01 01:29:11.794755|2018-06-01 01:29:11.794755
NCT00808184|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2012-10-31|2008-12-12|2008-12-15|Estimate|||||||2012-10-31|2012-11-01|Estimate|April 2010||2010-04-30|April 2010|2010-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype|Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype|Completed||Phase 4|25|Actual|National University Hospital, Singapore||1|||f||||f||||||||||2018-06-01 01:29:11.860556|2018-06-01 01:29:11.860556
NCT00808171|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2014-07-25|2008-12-12|2008-12-15|Estimate|||||||2014-07-25|2014-07-29|Estimate|February 2009||2009-02-28|July 2014|2014-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture|Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture|Completed||Phase 4|52|Actual|Federal University of Minas Gerais||3|||f||||t||||||||||2018-06-01 01:29:11.93381|2018-06-01 01:29:11.93381
NCT00808158|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2012-11-29|2008-12-12|2008-12-15|Estimate|||||||2012-11-29|2012-11-30|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|STRONG Kids||Examining the Relationship Between Tobacco Exposure, Abdominal Obesity, and Metabolic Syndrome in Adolescents (The STRONG Kids Study)|Metabolic Syndrome in Adolescents: Contribution of Tobacco and Central Fat|Completed|||117|Actual|University of Rochester|||1||f||||t||||||Samples With DNA|"~     Serum, whole blood, white blood cells, saliva, urine~   "|||2018-06-01 01:29:12.015282|2018-06-01 01:29:12.015282
NCT00808145|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2014-10-21|2008-12-12|2008-12-15|Estimate|||||||2014-10-21|2014-10-22|Estimate|February 2009||2009-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)|A Phase II Study of Sorafenib With Gemcitabine/Cisplatin in Advanced Hepatocellular Carcinoma|Withdrawn||Phase 2|0|Actual|Lahey Clinic||1||Lack of enrollment, many screen failures and non eligible study participants|f||||f||||||||||2018-06-01 01:29:12.074908|2018-06-01 01:29:12.074908
NCT00808132|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2013-10-30|2013-01-07|2014-03-10|2008-12-12|2008-12-15|Estimate|2013-10-30|2013-12-20|Estimate|2013-01-07|2013-01-14|Estimate|2014-03-10|2014-04-08|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||Safety population included all randomized participants who received at least one dose of study drug.|Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis|A Double-Blind, Randomized, Placebo And Active- Controlled Efficacy And Safety Study Of The Effects Of Bazedoxifene/Conjugated Estrogens Combinations On Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women|Completed||Phase 3|1886|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:29:12.269569|2018-06-01 01:29:12.269569
NCT00808119|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2009-07-17|2008-12-12|2008-12-15|Estimate|||||||2009-07-17|2009-07-21|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects|A Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 in Healthy, Male Subjects|Completed||Phase 1|30|Anticipated|RTI International|||||f||||t||||||||||2018-06-01 01:29:14.825674|2018-06-01 01:29:14.825674
NCT00808106|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2018-05-23|2008-12-12|2008-12-15|Estimate|||||||2018-05-23|2018-05-24|Actual|December 11, 2008||2008-12-11|January 12, 2018|2018-01-12||||||||Observational|||Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism|Clinical, Cellular, and Molecular Investigations Into Oculocutaneous Albinism|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:29:14.891372|2018-06-01 01:29:14.891372
NCT00808093|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2017-06-02|2008-12-11|2008-12-15|Estimate|||||||2017-06-02|2017-06-05|Actual|May 12, 2008|Actual|2008-05-12|June 2017|2017-06-30|August 27, 2008|Actual|2008-08-27|August 27, 2008|Actual|2008-08-27||Interventional|||Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects|Food Effect Study of GSK256073A in Healthy Subjects|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:29:15.016994|2018-06-01 01:29:15.016994
NCT00808080|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2015-11-30||2016-01-25|2008-12-12|2008-12-15|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|AMLCTL||A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)|A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia|Terminated||Phase 1/Phase 2|6|Actual|University of California, San Diego|Accrual trial was insufficient. No patient became eligible for CTL infusion. Cell culture information gleaned from a comparison of different culture methods will greatly facilitate future studies of autologous CTL-directed immunotherapy for AML.|1||lack of accrual|f||||t||||||||||2018-06-01 01:29:15.110486|2018-06-01 01:29:15.110486
NCT00808067|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2013-12-20||2014-06-03|2008-12-12|2008-12-15|Estimate|2014-03-03|2014-04-08|Estimate||||2014-06-03|2014-06-09|Estimate|November 2008||2008-11-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||SAF - Safety set; included all treated subjects, but excluded subjects from sites 1059 and 0246.|RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial|RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes|Completed||Phase 3|5897|Actual|Boehringer Ingelheim|Non-serious adverse events were not collected on subjects in this study.|2|||f||||||||||||||2018-06-01 01:29:15.442533|2018-06-01 01:29:15.442533
NCT00808054|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2014-07-24|2008-12-12|2008-12-15|Estimate|||||||2014-07-24|2014-07-25|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation of Analgesia With EMLA and Glucose Oral Solution|Evaluation of Analgesia With the Use of Eutectic Mixture of Local Anesthetics (Lidocaine and Prilocaine) and Oral Solution of Glucose to 25% in Preterm Neonates During Arterial Puncture and / or the Installation of Percutaneous Catheter|Completed||Phase 4|60|Actual|Federal University of Minas Gerais||3|||f||||t||||||||||2018-06-01 01:29:18.859352|2018-06-01 01:29:18.859352
NCT00808041|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2015-07-21|2008-12-12|2008-12-15|Estimate|||||||2015-07-21|2015-07-23|Estimate|July 2009||2009-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|September 2012|Actual|2012-09-30||Observational|||Chemotherapy Monitoring With Breast Computed Tomography (CT)|Breast Cancer Chemotherapy Monitoring With Dedicated Breast Computed Tomography|Completed|||3|Actual|Emory University|||1||f||||f||||||||||2018-06-01 01:29:18.953287|2018-06-01 01:29:18.953287
NCT00808028|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2015-03-27||2015-03-27|2008-12-12|2008-12-15|Estimate|2015-03-27|2015-04-14|Estimate||||2015-03-27|2015-04-14|Estimate|February 2009||2009-02-28|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||The stage 1 intent-to-treat (ITT) population included all randomized participants who received at least 1 vaccination and have at least 1 valid and determinate assay result from blood samples drawn during stage 1.|A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents|A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years|Completed||Phase 2|538|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:29:19.140958|2018-06-01 01:29:19.140958
NCT00808015|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2011-06-30||2015-04-21|2008-12-12|2008-12-15|Estimate|2011-06-30|2011-07-28|Estimate||||2015-04-21|2015-05-12|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|ASIA CHOICES||ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking|ASIA CHOICES CHampix Observational Investigation in the CEssation of Smoking|Completed|||1373|Actual|Pfizer|Outcome measures were not designated as primary or secondary measures as this study was a post-marketing, prospective, non-comparative and non-interventional study.||1||f||||f||||||||||2018-06-01 01:29:21.88218|2018-06-01 01:29:21.88218
NCT00808002|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|||2014-09-05|2008-12-12|2008-12-15|Estimate|||||||2014-09-05|2014-09-08|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine|Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine.|Completed||Phase 3|30|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 01:29:27.179895|2018-06-01 01:29:27.179895
NCT00807989|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|2014-01-20||2015-06-29|2008-12-12|2008-12-15|Estimate|2015-05-11|2015-05-29|Estimate||||2015-06-29|2015-07-27|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy|An Open Label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies (Phase Ⅳ)|Completed||Phase 4|207|Actual|Yonsei University||2|||f||||f||||||||||2018-06-01 01:29:27.302791|2018-06-01 01:29:27.302791
NCT00807976|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2010-10-07|2008-12-12|2008-12-15|Estimate|||||||2010-10-07|2010-10-08|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|ODET||Orthostatic Hypotension and Diabetes Mellitus|The Orthostatic Hypotension in the Diabetic Elderly Patients Trial (ODET)|Completed|||500|Anticipated|Medical Research Foundation, The Netherlands|||2||f||||f||||||||||2018-06-01 01:29:27.809708|2018-06-01 01:29:27.809708
NCT00807963|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2009-06-03|2008-12-11|2008-12-15|Estimate|||||||2009-06-03|2009-06-05|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|July 2009|Anticipated|2009-07-31||Interventional|||Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone|Phase I, Open-Label, Pharmacokinetic, Safety and Tolerability Study of Subcutaneously Administered Bisphosphonate With Recombinant Human Hyaluronidase (rHuPH20) vs Bisphosphonate|Unknown status|Active, not recruiting|Phase 1|72|Anticipated|Halozyme Therapeutics|||||f||||f||||||||||2018-06-01 01:29:27.919781|2018-06-01 01:29:27.919781
NCT00807950|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2014-01-21|2008-12-11|2008-12-15|Estimate|||||||2014-01-21|2014-01-22|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer|Phase II Study of Simvastatin in Primary Breast Cancer; Test of Its Potential Selectivity on Basal Subtype Breast Cancer|Unknown status|Active, not recruiting|Phase 2|100||National University Hospital, Singapore|||||f||||f||||||||||2018-06-01 01:29:28.031336|2018-06-01 01:29:28.031336
NCT00807937|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-12|2010-07-29||2010-09-16|2008-12-12|2008-12-15|Estimate|2010-09-16|2010-10-08|Estimate||||2010-09-16|2010-10-08|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325|A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, With a Lorazepam Arm, in Subjects With Generalized Anxiety Disorder (GAD)|Completed||Phase 2|369|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 01:29:28.137146|2018-06-01 01:29:28.137146
NCT00807924|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2017-03-30|2008-12-11|2008-12-12|Estimate|||||||2017-03-30|2017-03-31|Actual|December 2008||2008-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ABLATE||American Breast Laser Ablation Therapy Evaluation|American Breast Laser Ablation Therapy Evaluation (ABLATE): Monitoring the Long Term Safety and Efficacy of Novilase™ Breast Interstitial Laser Therapy in Real World Application|Recruiting|||200|Anticipated|Novian Health Inc.|||||f||||f||||||||||2018-06-01 01:29:28.70376|2018-06-01 01:29:28.70376
NCT00807911|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2018-01-09|2008-12-11|2008-12-12|Estimate|||||||2018-01-09|2018-01-11|Actual|November 2008||2008-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2014|Actual|2014-07-31||Interventional|||Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer|Randomized Phase II Study of Adjuvant Chemotherapy With 5-FU/Leucovorin vs. Oxaliplatin/5-FU/Leucovorin After Preoperative Chemoradiotherapy With Fluoropyrimidines Followed by Surgery in Patients With Locally Advanced Rectal Cancer|Active, not recruiting||Phase 2|320|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-06-01 01:29:28.807424|2018-06-01 01:29:28.807424
NCT00807898|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2017-05-02|2008-12-11|2008-12-12|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2009||2009-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making|Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making|Completed|||136|Actual|University of Louisville|||||f||||||||||||||2018-06-01 01:29:28.896393|2018-06-01 01:29:28.896393
NCT00807885|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2011-09-12||2011-10-21|2008-12-11|2008-12-12|Estimate|2011-09-12|2011-10-18|Estimate||||2011-10-21|2011-10-26|Estimate|December 2008||2008-12-31|October 2011|2011-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|INFUSE-AT||Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human Recombinant Hyaluronidase|INcreased Flow Utilizing Subcutaneously-Enabled Fluids Administration Technique Study (INFUSE-AT): A Randomized, Open-Label, Parallel Group, Phase IV, Study Evaluating the Techniques of Administration of Subcutaneous Fluids Enabled by Human Recombinant Hyaluronidase (Hylenex) in Healthy Adult Volunteers|Completed||Phase 4|100|Actual|Baxter Healthcare Corporation||9|||f||||f||||||||||2018-06-01 01:29:28.980407|2018-06-01 01:29:28.980407
NCT00807872|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2013-09-17|2008-12-11|2008-12-12|Estimate|||||||2013-09-17|2013-09-18|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|March 2012|Actual|2012-03-31||Interventional|||Radioimmunoimaging of AL Amyloidosis|Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4|Completed||Phase 1|40|Actual|University of Tennessee||1|||f||||f||||||||||2018-06-01 01:29:29.856011|2018-06-01 01:29:29.856011
NCT00807859|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2015-10-30|2008-12-11|2008-12-12|Estimate|||||||2015-10-30|2015-11-02|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|February 2014|Actual|2014-02-28||Interventional|||Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer|An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 1|65|Actual|Amgen||4|||f||||||||||||||2018-06-01 01:29:29.961896|2018-06-01 01:29:29.961896
NCT00807846|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2013-12-12||2015-10-07|2008-12-10|2008-12-12|Estimate|2015-10-07|2015-11-11|Estimate||||2015-10-07|2015-11-11|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects|A Phase 4, 6-week, Randomized Double Blind, Multicenter, Active-controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis.|Completed||Phase 4|201|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 01:29:30.137728|2018-06-01 01:29:30.137728
NCT00807833|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2015-08-17|2008-12-11|2008-12-12|Estimate|||||||2015-08-17|2015-08-18|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Observational|||Cerebral Blood Flow (CBF) Disturbances Following Traumatic Brain Injury (TBI) and Subarachnoid Hemorrhage (SAH)|Cerebral Blood Flow (CBF) Disturbances Following Traumatic Brain Injury (TBI) and Subarachnoid Hemorrhage (SAH)|Completed|||20|Actual|Azienda Ospedaliera San Gerardo di Monza|||1||f||||f||||||||||2018-06-01 01:29:30.99482|2018-06-01 01:29:30.99482
NCT00807820|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2014-01-23|2008-12-11|2008-12-12|Estimate|||||||2014-01-23|2014-01-24|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Observational|||Phase I Targeting Dominant Intraprostatic Lesion Using MR Spectroscopy and HDR Brachytherapy|Phase I Study of Targeting Dominant Intraprostatic Lesion Using Functional MR Spectroscopy and High Dose Rate Brachytherapy|Completed|||10|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:29:31.06325|2018-06-01 01:29:31.06325
NCT00807807|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-07-28|2008-12-11|2008-12-12|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 1996||1996-06-30|December 2008|2008-12-31|September 1996|Actual|1996-09-30|September 1996|Actual|1996-09-30||Interventional|FAST||Evaluating the Effects of Folic Acid Supplementation in Older Adults: The Folic Acid Supplementation Trial (The FAST Study)|Phase III Study of the Effects of Folic Acid Supplementation on Serum Folate and Plasma Homocysteine in Older Adults: A Dose-Response Trial|Completed||Phase 3|133|Actual|National Heart, Lung, and Blood Institute (NHLBI)||5|||f||||f||||||||||2018-06-01 01:29:31.162063|2018-06-01 01:29:31.162063
NCT00807794|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2008-12-10|2008-12-10|2008-12-12|Estimate|||||||2008-12-10|2008-12-12|Estimate|February 1997||1997-02-28|December 2008|2008-12-31|January 1998|Actual|1998-01-31|November 1997|Actual|1997-11-30||Interventional|||A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection|Phase I Evaluation of the Pharmacokinetics, Pharmacodynamics and Safety of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection|Completed||Phase 1|13|Actual|MedImmune LLC||5|||f||||||||||||||2018-06-01 01:29:31.270433|2018-06-01 01:29:31.270433
NCT00807781|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2015-01-02|2008-12-11|2008-12-12|Estimate|||||||2015-01-02|2015-01-05|Estimate|October 2009||2009-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Mammaglobin-A DNA Vaccine in Breast Cancer Patients With Metastatic Disease|Completed||Phase 1|15|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 01:29:31.463563|2018-06-01 01:29:31.463563
NCT00807768|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2018-03-27||2018-03-27|2008-12-11|2008-12-12|Estimate|2018-03-27|2018-04-27|Actual||||2018-03-27|2018-04-27|Actual|March 2009||2009-03-31|May 2017|2017-05-31||||December 2014|Actual|2014-12-31||Interventional||Enrolled patients|Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer|A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma|Active, not recruiting||Phase 3|601|Actual|Gynecologic Oncology Group||2|||f||||f||||||||||2018-06-01 01:29:31.667419|2018-06-01 01:29:31.667419
NCT00807755|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2018-01-05|2008-12-11|2008-12-12|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2009|Actual|2009-03-31|January 2018|2018-01-31|December 2011|Actual|2011-12-31|August 2010|Actual|2010-08-31||Interventional|||Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors|Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC)|Terminated||Phase 1|5|Actual|University of California, Davis||1||Number of known toxicities observed despite a treatment-naïve population|f||||t|t|f||||||||2018-06-01 01:29:33.551763|2018-06-01 01:29:33.551763
NCT00807742|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2011-06-23|2008-12-11|2008-12-12|Estimate|||||||2011-06-23|2011-06-27|Estimate|October 2008||2008-10-31|February 2009|2009-02-28|March 2013|Anticipated|2013-03-31|March 2012|Anticipated|2012-03-31||Interventional|SCMSUD||Contingency Management for Smoking in Substance Abusers|Contingent Vouchers for Smoking in Substance Abusers as Adjunct to Nicotine Patch|Unknown status|Recruiting|N/A|274|Anticipated|Brown University||2|||f||||f||||||||||2018-06-01 01:29:33.623103|2018-06-01 01:29:33.623103
NCT00807729|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2009-09-02|2008-12-11|2008-12-12|Estimate|||||||2009-09-02|2009-09-03|Estimate|January 1997||1997-01-31|September 2009|2009-09-30|November 2007|Actual|2007-11-30|July 2003|Actual|2003-07-31||Interventional|ERCP/CBDE||Randomized Trial of ERCP Then Laparoscopic Cholecystectomy vs. Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration in Patients With Likely Choledocholithiasis|Prospective Randomized Trial of Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration (LC + LCBDE) Versus Endoscopic Retrograde Cholangiopancreatography Sphincterotomy Plus Laparoscopic Cholecystectomy (ERCP/S + LC) for Common Bile Duct Stone Disease|Completed||N/A|122|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:29:33.833383|2018-06-01 01:29:33.833383
NCT00807716|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2014-12-04|2008-12-11|2008-12-12|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Physiotherapy After Total Knee Replacement|The Immediate and Long Term Effects of a Walking-skill Program Compared to Usual Physiotherapy Care in Patients Who Have Undergone Total Knee Arthroplasty (TKA): A Randomized Controlled Trial|Completed||N/A|57|Actual|University of Oslo||2|||f||||t||||||||||2018-06-01 01:29:33.908733|2018-06-01 01:29:33.908733
NCT00807703|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2009-12-16|2008-12-11|2008-12-12|Estimate|||||||2009-12-16|2009-12-17|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Select Stim||"Select Stim: Selective Stimulation of the Subthalamic Nucleus in Parkinson's Disease. A Feasibility Study"|"Select Stim: Selective Stimulation of the Subthalamic Nucleus in Parkinson's Disease. A Feasibility Study"|Completed||N/A|5|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 01:29:33.993262|2018-06-01 01:29:33.993262
NCT00807690|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2008-12-11|2008-12-11|2008-12-12|Estimate|||||||2008-12-11|2008-12-12|Estimate|November 2005||2005-11-30|December 2008|2008-12-31|January 2008|Actual|2008-01-31|||||Interventional|||Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo|Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study|Completed||Phase 3|||Oslo University Hospital|||||f||||||||||||||2018-06-01 01:29:34.062526|2018-06-01 01:29:34.062526
NCT00807677|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2013-07-01|2008-12-11|2008-12-12|Estimate|||||||2013-07-01|2013-07-02|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies|A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies|Completed||Phase 1|31|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:29:34.14783|2018-06-01 01:29:34.14783
NCT00807664|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2017-08-29||2018-01-11|2008-12-11|2008-12-12|Estimate|2017-11-02|2017-12-11|Actual||||2018-01-11|2018-01-16|Actual|December 2008||2008-12-31|January 2018|2018-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Biatain Ag vs Biatain in the Treament of Leg Ulcers|Clinical Assessment of Biatain Ag Dressings Compared to Biatain Dressings in the Treatment of Leg Ulcers|Completed||N/A|182|Actual|Coloplast A/S||2|||f||||f||||||||||2018-06-01 01:29:34.221835|2018-06-01 01:29:34.221835
NCT00807651|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2016-06-04|2008-12-11|2008-12-12|Estimate|||||||2016-06-04|2016-06-07|Estimate|February 2008||2008-02-29|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes|Safety and Efficacy Study of Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes-a Phase II Study|Active, not recruiting||Phase 2|40|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 01:29:34.589781|2018-06-01 01:29:34.589781
NCT00807625|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2012-07-12|2008-12-11|2008-12-12|Estimate|||||||2012-07-12|2012-07-13|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MSRC||Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia|Mucosal and Systemic Responses to Contraceptives in HIV-Infected Women in Zambia|Completed||Phase 2|66|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:29:34.682679|2018-06-01 01:29:34.682679
NCT00807612|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11||2014-09-19|2017-03-27|2008-12-11|2008-12-12|Estimate||||2014-09-19|2014-10-01|Estimate|2017-03-27|2017-03-29|Actual|January 2009||2009-01-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer|A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|49|Actual|NantCell, Inc.||3||Study was closed due to administrative decision|f||||||||||||||2018-06-01 01:29:34.79775|2018-06-01 01:29:34.79775
NCT00807599|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2018-02-15|2008-12-11|2008-12-12|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 10, 2008||2008-12-10|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L|A Phase II Clinical Trial for Untreated Patients With Multiple Myeloma Eligible for Stem Cell Transplant: Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L|Active, not recruiting||Phase 2|67|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-06-01 01:29:34.980376|2018-06-01 01:29:34.980376
NCT00807586|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2013-04-23|2008-12-11|2008-12-12|Estimate|||||||2013-04-23|2013-04-24|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2009|Actual|2009-12-31||Interventional|SAAB||Corticosteroid Pulse After Ablation|SAAB: Randomized, Double Blind STudy of Corticosteroid Pulse After Ablation|Unknown status|Active, not recruiting|Phase 4|120|Actual|Minneapolis Heart Institute Foundation||2|||f||||f||||||||||2018-06-01 01:29:35.117773|2018-06-01 01:29:35.117773
NCT00807573|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2015-10-19||2015-11-24|2008-12-11|2008-12-12|Estimate|2015-11-24|2015-12-30|Estimate||||2015-11-24|2015-12-30|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment|A Phase II Trial of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment|Completed||Phase 2|44|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:29:35.244437|2018-06-01 01:29:35.244437
NCT00807560|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2014-03-04||2015-12-02|2008-12-11|2008-12-12|Estimate|2015-12-02|2016-01-08|Estimate||||2015-12-02|2016-01-08|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PO||Parent-Based Treatment for Pediatric Overweight|Parent-Based Treatment for Pediatric Overweight|Completed||Phase 1/Phase 2|77|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 01:29:35.643657|2018-06-01 01:29:35.643657
NCT00807547|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-12-28|2008-12-11|2008-12-12|Estimate|||||||2015-12-28|2015-12-29|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||Intraseasonal Short-time Up-dosing With Alutard SQ Grasses|A Randomised, Parallel-group, Double-blind, Placebo-controlled, Multicentre Phase III Trial Assessing the Pharmacodynamic Efficacy and Safety of an Intra-seasonal Short-time Updosing Schedule for Alutard SQ|Completed||Phase 3|149|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-06-01 01:29:36.032292|2018-06-01 01:29:36.032292
NCT00807534|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2011-02-07|2008-12-11|2008-12-12|Estimate|||||||2011-02-07|2011-02-09|Estimate|October 2008||2008-10-31|May 2010|2010-05-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)|Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase 2: Sensitivity of the Step Test and Shuttle Walk to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD|Completed||N/A|44|Anticipated|Laval University||2|||f||||f||||||||||2018-06-01 01:29:36.131939|2018-06-01 01:29:36.131939
NCT00807521|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2014-12-16|2008-12-11|2008-12-12|Estimate|||||||2014-12-16|2014-12-17|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|STRESS||Steroid-induced Reduction of Surgical Stress Study|Reduction of the Cardiac Proapoptotic Stress Response by Dexamethasone in Patients Undergoing Coronary Artery Bypass Grafting Surgery|Withdrawn||N/A|0|Actual|VU University Medical Center||2||Research question was integrated in other study protocol|f||||f||||||||||2018-06-01 01:29:36.232957|2018-06-01 01:29:36.232957
NCT00807508|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2008-12-11|2008-12-11|2008-12-12|Estimate|||||||2008-12-11|2008-12-12|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Leucine Supplementation in Elderly Men|The Influence of Leucine Supplementation on Body Composition and Muscle Characteristics in Healthy Elderly|Completed||Phase 1/Phase 2|29|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:29:36.461761|2018-06-01 01:29:36.461761
NCT00807495|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2018-01-04|2012-06-19|2018-02-27|2008-12-11|2008-12-12|Estimate|2018-02-27|2018-03-27|Actual|2012-06-19|2012-06-29|Estimate|2018-02-27|2018-03-27|Actual|February 10, 2009|Actual|2009-02-10|February 2018|2018-02-28|February 13, 2013|Actual|2013-02-13|January 4, 2011|Actual|2011-01-04||Interventional||Safety population was defined as all participants who received any amount of alisertib.|Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma|A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|48|Actual|Takeda||1|||f||||f|t|f||||||||2018-06-01 01:29:36.608213|2018-06-01 01:29:36.608213
NCT00807482|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2017-09-12|2008-12-11|2008-12-12|Estimate|||||||2017-09-12|2017-09-14|Actual|January 2004||2004-01-31|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|||Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease|Diagnostic and Clinical Characterization of Patients With Unusual Genetic Disorders of the Airways|Recruiting|||1800|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     Blood samples, buckle scrape, semen, and scrape biopsy of nasal cells~   "|||2018-06-01 01:29:38.300064|2018-06-01 01:29:38.300064
NCT00807469|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2008-12-11|2008-12-11|2008-12-12|Estimate|||||||2008-12-11|2008-12-12|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|January 2015|Anticipated|2015-01-31|January 2013|Anticipated|2013-01-31||Observational|||Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD|Acute and Chronic Inflammatory Responses Induced by Smoking in Individuals Being Susceptible and Non-Susceptible for Development of COPD: From Specific Disease Phenotyping Towards Novel Made Therapy (Study 1)|Unknown status|Not yet recruiting||120|Anticipated|Top Institute Pharma|||5||f||||t||||||Samples With DNA|"~     Blood will be retained to investigate diffences in candidate genes (SNPs) for COPD between~     the 5 different groups.~   "|||2018-06-01 01:29:38.39025|2018-06-01 01:29:38.39025
NCT00807456|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|2016-03-16||2016-04-26|2008-12-11|2008-12-12|Estimate|2016-04-26|2016-05-30|Estimate||||2016-04-26|2016-05-30|Estimate|November 2008||2008-11-30|April 2016|2016-04-30||||June 2013|Actual|2013-06-30||Interventional|||Study to Evaluate an Implant With a Sloped Top in Patients With a Sloped Jaw Bone|A Prospective, Open, Single Arm, Multi-center Study to Evaluate Maintenance of Lingual Bone in Healed Ridges With the ASTRA TECH Implant System, OsseoSpeed™ Profile Implant. A 3-year Follow-up Study|Completed||N/A|65|Actual|Dentsply Sirona Implants||1|||f||||f||||||||||2018-06-01 01:29:38.498361|2018-06-01 01:29:38.498361
NCT00807443|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-11|||2013-01-31|2008-12-11|2008-12-12|Estimate|||||||2013-01-31|2013-02-01|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1|Pilot Study Of The Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 In Patients Taking Highly Active Antiretroviral Therapy|Completed||Phase 2|10|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||1|||f||||f||||||||||2018-06-01 01:29:38.682317|2018-06-01 01:29:38.682317
NCT00807430|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2009-10-20|2008-12-10|2008-12-11|Estimate|||||||2009-10-20|2009-10-21|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Treatment Period and Long-term Effect of Functional Electric Stimulation (FES) for Bruxism|A Single Centre, Randomised, Clinical Placebo Controlled Study of the Optimal Treatment and Long-term Effect of FES on Bruxism|Terminated||N/A|48|Anticipated|Medotech A/S||2|||f||||f||||||||||2018-06-01 01:29:38.745533|2018-06-01 01:29:38.745533
NCT00807404|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2010-05-26|2008-12-10|2008-12-11|Estimate|||||||2010-05-26|2010-05-27|Estimate|November 2006||2006-11-30|May 2010|2010-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Optical Coherence Tomography in Tissue Samples From Women Undergoing Mastectomy for the Treatment or Prevention of Breast Ductal Intraepithelial Neoplasia|Forward Image Guided Ductoscopy for Early Cancer Screening|Completed||N/A|50|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 01:29:38.834583|2018-06-01 01:29:38.834583
NCT00807391|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2011-06-22|2008-12-09|2008-12-11|Estimate|||||||2011-06-22|2011-06-23|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Transbronchial Catheter Aspiration and Transbronchial Needle Aspiration in the Diagnosis of Lung Cancer|Transbronchial Catheter Aspiration Compared to Transbronchial Needle Aspiration in the Diagnosis of Peripheral Nodules and Masses of the Lung|Completed||N/A|48|Actual|Helios Klinik Ambrock||1|||f||||f||||||||||2018-06-01 01:29:38.886482|2018-06-01 01:29:38.886482
NCT00807378|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2010-05-19|2008-12-09|2008-12-11|Estimate|||||||2010-05-19|2010-05-20|Estimate|July 2008||2008-07-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Observational|VIMPAC||Rijavithi Viral and Mycobacterium PCR Arrays in CNS Infection Study|Cerebrospinal Fluid Polymerase Chain Reaction Arrays for Central Nervous System Neurotropic Viral Infection and Mycobacterium Infection Study|Completed|||200|Anticipated|Rajavithi Hospital|||2||f||||t||||||Samples With DNA|"~     CSF DNA/RNA virus~   "|||2018-06-01 01:29:38.970749|2018-06-01 01:29:38.970749
NCT00807365|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2017-03-16||2017-03-16|2008-12-10|2008-12-11|Estimate|2017-03-16|2017-04-27|Actual||||2017-03-16|2017-04-27|Actual|December 17, 2007|Actual|2007-12-17|March 2017|2017-03-31|April 29, 2010|Actual|2010-04-29|April 29, 2010|Actual|2010-04-29||Interventional|PP2||Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly|Six Month Treatment of GHRH in the Elderly|Terminated||Phase 2|5|Actual|Johns Hopkins University||1||PI left JHU|f||||t||||||||||2018-06-01 01:29:39.159112|2018-06-01 01:29:39.159112
NCT00807352|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2011-08-04|2008-12-10|2008-12-11|Estimate|||||||2011-08-04|2011-08-05|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|PERC CTAS||The Canadian Triage and Acuity Scale for Children; A Prospective Multi-Center Evaluation.|The Canadian Triage and Acuity Scale for Children; A Prospective Multi-Center Evaluation.|Completed|||1464|Actual|St. Justine's Hospital|||4||f||||f||||||||||2018-06-01 01:29:39.350595|2018-06-01 01:29:39.350595
NCT00807339|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2017-03-20|2008-12-10|2008-12-11|Estimate|||||||2017-03-20|2017-03-21|Actual|March 2006|Actual|2006-03-31|March 2017|2017-03-31|August 20, 2014|Actual|2014-08-20|January 1, 2014|Actual|2014-01-01||Interventional|||CyberKnife for Unresectable Renal Tumors|CyberKnife Stereotactic Radiation for Unresectable Renal Tumors/PhaseI Study|Completed||N/A|17|Actual|Beth Israel Deaconess Medical Center||1|||f||||t|f|f||||||No||2018-06-01 01:29:39.431957|2018-06-01 01:29:39.431957
NCT00807326|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2012-07-06|2008-12-10|2008-12-11|Estimate|||||||2012-07-06|2012-07-10|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||A Comparison of Three Medications to Treat Diarrhea in Adults.|A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults|Completed||Phase 4|415|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-06-01 01:29:39.505409|2018-06-01 01:29:39.505409
NCT00807313|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2013-04-29|2008-12-10|2008-12-11|Estimate|||||||2013-04-29|2013-04-30|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|tomoligo||Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer|Non-interventional Observational Study of Helical Tomotherapy for Oligometastatic Colorectal Cancer|Completed|||53|Actual|Universitair Ziekenhuis Brussel|||2||f||||f||||||||||2018-06-01 01:29:39.60334|2018-06-01 01:29:39.60334
NCT00806000|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2012-10-09|2008-12-09|2008-12-10|Estimate|||||||2012-10-09|2012-10-10|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Prevalence of Exercise-Induced Asthma in Select Cohorts of College Athletes|Prevalence of Exercise-Induced Asthma in Select Cohorts of College Athletes|Completed|||150|Actual|Ohio State University|||1||f||||t||||||||||2018-06-01 01:30:06.467882|2018-06-01 01:30:06.467882
NCT00807300|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2015-12-02|2008-12-10|2008-12-11|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CEAL||Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma|Phase-III-Study to Evaluate the Efficacy of CT-guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma.|Completed||Phase 2|77|Actual|University of Magdeburg||2|||f||||f||||||||||2018-06-01 01:29:39.673466|2018-06-01 01:29:39.673466
NCT00807287|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|February 2005||2005-02-28|December 2008|2008-12-31|April 2006|Actual|2006-04-30|February 2006|Actual|2006-02-28||Interventional|||Evaluation of Two Methods of Jejunal Placement of Enteral Feeding Tubes in Critically Ill Patients|Evaluation of Two Methods of Jejunal Placement of Enteral Feeding Tubes in Critically Ill Patients: Endoscopic Versus Unguided, Frictional Method|Completed||N/A|42|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:29:39.822996|2018-06-01 01:29:39.822996
NCT00807274|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2009-09-24|2008-12-10|2008-12-11|Estimate|||||||2009-09-24|2009-09-25|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|||||Observational|||Renal Function in Adults With Congenital Heart Disease.|Prospective Evaluation of Renal Function in Adults With Congenital Heart Disease.|Withdrawn|||1200|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||||Alternative trial planned|f||||f||||||Samples Without DNA|"~     Plasma, serum and urine samples~   "|||2018-06-01 01:29:39.901365|2018-06-01 01:29:39.901365
NCT00807261|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2008-12-11|2008-12-10|2008-12-11|Estimate|||||||2008-12-11|2008-12-12|Estimate|September 2008||2008-09-30|December 2008|2008-12-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy|PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional|Unknown status|Enrolling by invitation|Phase 2|30|Anticipated|Asan Medical Center|||||f||||t||||||||||2018-06-01 01:29:39.961792|2018-06-01 01:29:39.961792
NCT00807248|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2011-06-15||2012-12-13|2008-12-10|2008-12-11|Estimate|2011-07-15|2011-08-11|Estimate||||2012-12-13|2012-12-17|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder|Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of Escitalopram in Combination With Two Fixed Doses of Gaboxadol Compared to Escitalopram in Major Depressive Disorder|Completed||Phase 2|490|Actual|H. Lundbeck A/S||4|||f||||f||||||||||2018-06-01 01:29:40.034922|2018-06-01 01:29:40.034922
NCT00807235|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2012-04-02||2012-05-11|2008-12-10|2008-12-11|Estimate|2012-05-11|2012-06-13|Estimate||||2012-05-11|2012-06-13|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Interventional|||Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants|An Open Label, Multicenter, Phase 2, Pilot Evaluation of SURFAXIN®(Lucinactant) Delivered as an Aerosol Via Nasal Continuous Positive Airway Pressure (nCPAP) in the Prevention of Respiratory Distress Syndrome in Premature Infants|Terminated||Phase 2|17|Actual|Windtree Therapeutics||2||Slow enrollment|f||||f||||||||||2018-06-01 01:29:41.039532|2018-06-01 01:29:41.039532
NCT00807222|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)|Study of the Effect of Vyvanse (Lisdexamfetamine Dimesylate) on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|24|Actual|Clinical Study Centers, LLC||2|||f||||f||||||||||2018-06-01 01:29:41.547405|2018-06-01 01:29:41.547405
NCT00807209|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2011-11-29|2010-08-25|2012-04-15|2008-12-09|2008-12-11|Estimate|2012-04-15|2012-05-15|Estimate|2010-08-27|2010-08-31|Estimate|2012-04-15|2012-05-15|Estimate|December 2008||2008-12-31|November 2011|2011-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Dose Finding Posterolateral Thoracotomy Study|A Phase 2 Open-Label, Parallel Group, Randomized, Dose-Finding Study to Assess the Efficacy and Safety of Intercostal SKY0402 in Subjects Undergoing Posterolateral Thoracotomy|Terminated||Phase 2|3|Actual|Pacira Pharmaceuticals, Inc|The study was terminated early due to Sponsor's decision, unrelated to safety. As there was only one patient in each group, no efficacy analyses were performed.|3||Sponsor decision unrelated to safety|f||||f||||||||||2018-06-01 01:29:41.648107|2018-06-01 01:29:41.648107
NCT00807196|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|September 2008||2008-09-30|December 2008|2008-12-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma|Phase I-II Non-Randomized Study of Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Indolent Non Hodgkin Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||t||||||||||2018-06-01 01:29:42.057462|2018-06-01 01:29:42.057462
NCT00807183|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2015-04-14|2008-12-10|2008-12-11|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|ARTIS||Indoor Woodsmoke PM and Asthma|Indoor Woodsmoke PM and Asthma: a Randomized Trial|Completed||Phase 3|122|Actual|National Institute of Environmental Health Sciences (NIEHS)||3|||f||||f||||||||||2018-06-01 01:29:42.161045|2018-06-01 01:29:42.161045
NCT00807170|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2016-08-26|2008-12-10|2008-12-11|Estimate|||||||2016-08-26|2016-08-29|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases|A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|5|Actual|Sanofi||1||Very slow recruitment|f||||t||||||||||2018-06-01 01:29:42.229329|2018-06-01 01:29:42.229329
NCT00807157|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2009-04-23|2008-12-10|2008-12-11|Estimate|||||||2009-04-23|2009-04-24|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|BIOSTRESS||Evaluation of a Probiotic On Anxiety and Stress in Healthy Adults Sensible to Daily Stress|Evaluation Des Effets Anti-Stress D'un Probiotique Nomme PROBIOSTICK® Sur Des Sujets Humains Volontaires Sains Sensibles Au Stress De La Vie Quotidienne|Completed||N/A|66|Anticipated|Institut Rosell Lallemand||2|||f||||t||||||||||2018-06-01 01:29:42.310982|2018-06-01 01:29:42.310982
NCT00805792|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2012-07-17||2012-10-04|2008-12-09|2008-12-10|Estimate|2012-10-04|2012-11-14|Estimate||||2012-10-04|2012-11-14|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|MASTER||Mayo Acute Stroke Trial for Enhancing Recovery|Mayo Acute Stroke Trial for Enhancing Recovery|Completed||Phase 2|33|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 01:30:10.599233|2018-06-01 01:30:10.599233
NCT00807144|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2011-06-27|2008-12-10|2008-12-11|Estimate|||||||2011-06-27|2011-06-28|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|TAESR||Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation|A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation|Unknown status|Recruiting|Phase 4|100|Anticipated|Hammersmith Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 01:29:42.406304|2018-06-01 01:29:42.406304
NCT00807131|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|September 2006||2006-09-30|December 2008|2008-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|EPHACA||Effectiveness of Pharmaceutical Care on Primary Care Patients With Uncontrolled Hypertension|Effectiveness of a Pharmaceutical Care Program on Primary Care Patients With Uncontrolled Hypertension- A Brazilian Multicenter RCT|Completed||N/A|301|Actual|Hospital de Clinicas de Porto Alegre||4|||f||||f||||||||||2018-06-01 01:29:42.50122|2018-06-01 01:29:42.50122
NCT00807118|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2010-03-23|2008-12-10|2008-12-11|Estimate|||||||2010-03-23|2010-03-24|Estimate|October 2008||2008-10-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect|A Phase 1, Open-Label, Randomized, Single-Dose, 2-Cohort, 3-Way Crossover Study To Determine Bioequivalence Of 4 Mg And 8 Mg Fesoterodine SR Tablet Of Commercial Formulation And 8 Mg Fesoterodine SR Tablet Between Formulation E(1) And Formulation F And Investigate Food Effect On Commercial Formulation In Healthy Subjects.|Completed||Phase 1|108|Anticipated|Pfizer||6|||f||||f||||||||||2018-06-01 01:29:42.588572|2018-06-01 01:29:42.588572
NCT00807105|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-01-04|2008-12-10|2008-12-11|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of the H-coil Transcranial Magnetic Stimulation TMS Device - Safety and Feasibility Study for Acute and Maintenance Treatment in Major Depressive Episode||Completed||Phase 2|29|Actual|Shalvata Mental Health Center||1|||f||||t||||||||||2018-06-01 01:29:42.660859|2018-06-01 01:29:42.660859
NCT00807092|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2010-11-12||2015-02-13|2008-12-10|2008-12-11|Estimate|2011-03-10|2011-04-11|Estimate||||2015-02-13|2015-03-04|Estimate|December 2008||2008-12-31|February 2015|2015-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes|Comparison of the Efficacy on Glycaemic Control and Safety Profile of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 Both in Combination With Metformin in Insulin-naïve Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Therapy|Completed||Phase 4|145|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:29:42.750007|2018-06-01 01:29:42.750007
NCT00807079|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2014-10-28|2008-12-10|2008-12-11|Estimate|||||||2014-10-28|2014-10-29|Estimate|September 2008||2008-09-30|October 2014|2014-10-31||||May 2011|Actual|2011-05-31||Interventional|||Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer|Phase I/II Study of Carboplatin in Association With Weekly Oral Topotecan in Patients With Metastatic or Recurrent Cervical Cancer|Completed||Phase 1/Phase 2|12|Actual|ARCAGY/ GINECO GROUP||1|||f||||t||||||||||2018-06-01 01:29:43.348445|2018-06-01 01:29:43.348445
NCT00807066|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2012-04-20|2008-12-10|2008-12-11|Estimate|||||||2012-04-20|2012-04-23|Estimate|November 2008||2008-11-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|November 2009|Actual|2009-11-30||Interventional|RANGE||Randomized Gefitinib Trial|Multicentric Randomized Phase III Study Comparing Gefitinib Versus Platinum-Based Chemotherapy In EGFR Fish Positive NSCLC Patients (Range)|Completed||Phase 3|1|Actual|Fondazione Humanitas per la Ricerca||2|||f||||f||||||||||2018-06-01 01:29:43.411563|2018-06-01 01:29:43.411563
NCT00807053|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-12-02|2008-12-10|2008-12-11|Estimate|||||||2016-12-02|2016-12-05|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)|A Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|480|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:29:43.476596|2018-06-01 01:29:43.476596
NCT00807040|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2017-05-26||2017-05-26|2008-12-10|2008-12-11|Estimate|2017-05-26|2017-07-31|Actual||||2017-05-26|2017-07-31|Actual|December 2008||2008-12-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|April 2013|Actual|2013-04-30||Interventional|||Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation|Evaluation of Outcomes Following Mitral Valve Repair/Replacement in Severe Chronic Ischemic Mitral Regurgitation|Completed||Phase 2|251|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 01:29:43.791976|2018-06-01 01:29:43.791976
NCT00807027|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2012-10-24|2008-12-10|2008-12-11|Estimate|||||||2012-10-24|2012-10-25|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea|Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea|Completed||Phase 3|180|Actual|Green Cross Cell Corporation||2|||f||||f||||||||||2018-06-01 01:29:44.394934|2018-06-01 01:29:44.394934
NCT00807014|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2011-11-23||2012-03-15|2008-12-10|2008-12-11|Estimate|2012-02-02|2012-03-06|Estimate||||2012-03-15|2012-03-20|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne|Single-blind, Multicenter, Parallel, Comparative, Randomized, Phase 4 Clinical Trial for the Evaluation of the Quality of Life, Efficacy and Tolerance of Duac® Gel Against Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris.|Completed||Phase 4|169|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:29:44.528622|2018-06-01 01:29:44.528622
NCT00807001|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2010-10-08||2016-08-18|2008-12-10|2008-12-11|Estimate|2010-10-08|2010-11-04|Estimate||||2016-08-18|2016-08-19|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects|A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected With Genotype 1 Chronic Hepatitis C|Completed||Phase 1/Phase 2|41|Actual|Merck Sharp & Dohme Corp.|Adverse events summarized the 3 days of IDX184 dosing and 14 days of treatment free follow up.|4|||f||||f||||||||||2018-06-01 01:29:45.357805|2018-06-01 01:29:45.357805
NCT00806988|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2017-04-11||2017-04-11|2008-12-10|2008-12-11|Estimate|2017-04-11|2017-06-26|Actual||||2017-04-11|2017-06-26|Actual|December 2008||2008-12-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation|Surgical Interventions for Moderate Ischemic Mitral Regurgitation|Completed||N/A|301|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 01:29:46.069976|2018-06-01 01:29:46.069976
NCT00806975|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Type 2 Diabetic Patients|Randomized，Open-Label，2-Period，Crossover Comparison of Randomized，Open-Label，2-Period，Crossover Comparison of Novo Rapid 30 Mix Injection FlexPen® and Humalog 25 Mix Injection KwikPen® in Adult Patients With Type 2 Diabetes Mellitus|Unknown status|Not yet recruiting|N/A|200|Anticipated|Nagaoka Red Cross Hospital||1|||f||||f||||||||||2018-06-01 01:29:46.652287|2018-06-01 01:29:46.652287
NCT00806962|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2015-05-05|2008-12-10|2008-12-11|Estimate|||||||2015-05-05|2015-05-06|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase 1 Norwalk Vaccine Study|Randomized Double-Blind Placebo-Controlled Phase 1, Safety and Immunogenicity Study of Two Dosages of Intranasal Norwalk Virus-like Particle Vaccine ( Norwalk VLP Antigen, MPL®, Chitosan, Mannitol, and Sucrose) Compared to Adjuvant/Excipients (MPL®, Chitosan, Mannitol, and Sucrose) and to Placebo (Empty Device|Completed||Phase 1|61|Actual|Takeda||4|||f||||t||||||||||2018-06-01 01:29:46.870312|2018-06-01 01:29:46.870312
NCT00806936|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-10-26|2008-12-10|2008-12-11|Estimate|||||||2016-10-26|2016-10-28|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects|A 16-week Multicentre, Open Label, Non-interventional, Observational Study to Investigate the Status of Human Insulin or Insulin Analogue Treatments With Focusing on Efficacy and Safety in Type 2 Diabetes Subjects Inadequately Controlled With Two or More Oral Antidiabetic Drugs in China|Completed|||4847|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 01:29:46.983468|2018-06-01 01:29:46.983468
NCT00806923|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-11-01|2008-12-10|2008-12-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2005||2005-02-28|November 2016|2016-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC|Completed||Phase 3|1044|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:29:47.105963|2018-06-01 01:29:47.105963
NCT00806910|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2011-06-22|2008-12-10|2008-12-11|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion|Evaluation of the Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion|Withdrawn||Phase 4|0|Actual|Albert Einstein Healthcare Network||2||Sponsor support withdrawn|f||||f||||||||||2018-06-01 01:29:47.51101|2018-06-01 01:29:47.51101
NCT00806897|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-11-22|2008-12-10|2008-12-11|Estimate|||||||2016-11-22|2016-11-23|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|LITHULEV1||Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®|Prospective, Multicentre, Open Label, Non-controlled, 24-week Observation in Type 2 Diabetics Using Once Daily Levemir® (Insulin Detemir) as Part of Their ITT Regimen|Completed|||74|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:29:47.619252|2018-06-01 01:29:47.619252
NCT00806884|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2015-06-04|2008-12-10|2008-12-11|Estimate|||||||2015-06-04|2015-06-08|Estimate|June 2008||2008-06-30|December 2008|2008-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Do Physiotherapy Techniques Improve Posture During Admission for a Chest Infection in Adults With Cystic Fibrosis?|Do Physiotherapy Joint and Muscle Movement (Musculoskeletal) Techniques Improve Posture, Pain, Sputum Clearance, Lung Function or Quality of Life During Admission for a Respiratory Exacerbation in Adults With Cystic Fibrosis?|Completed||N/A|50|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 01:29:47.714437|2018-06-01 01:29:47.714437
NCT00806871|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2012-04-03|2008-12-10|2008-12-11|Estimate|||||||2012-04-03|2012-04-04|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Steroid Injection Treatment of Carpal Tunnel Syndrome|Local Steroid Injection in the Treatment of Idiopathic Carpal Tunnel Syndrome: A Randomized Double-blind Placebo-controlled Trial Among Patients Planned for Surgical Treatment|Completed||Phase 2/Phase 3|112|Actual|Region Skane||3|||f||||t||||||||||2018-06-01 01:29:47.890131|2018-06-01 01:29:47.890131
NCT00806858|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-11-22|2008-12-10|2008-12-11|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus|NovoPen®4 Clinical Experience Programme: A Multicentre, Observational Study of NovoPen®4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus|Completed|||526|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:29:48.003974|2018-06-01 01:29:48.003974
NCT00806845|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2015-05-12|2008-12-10|2008-12-11|Estimate|||||||2015-05-12|2015-05-13|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|||Examination of B Cell Responses in Human Blood|Gewinnung Humaner antikörperproduzierender Zellen Aus Dem Blut|Completed|||50|Actual|Regenerative Medicine Network|||5||f||||t||||||Samples Without DNA|"~     peripheral blood~   "|||2018-06-01 01:29:48.095244|2018-06-01 01:29:48.095244
NCT00806832|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2015-07-06|2008-12-09|2008-12-11|Estimate|||||||2015-07-06|2015-07-07|Estimate|December 2008||2008-12-31|July 2015|2015-07-31|March 2010|Actual|2010-03-31|April 2009|Actual|2009-04-30||Observational|||The Effects of Medical Clowning on Blood Pressure and Pulse Rate of Patients Undergoing Cataract Surgery Under Local Anesthesia|The Effects of Medical Clowning on Blood Pressure and Pulse Rate of Patients Undergoing Cataract Surgery Under Local Anesthesia|Completed|||100|Anticipated|HaEmek Medical Center, Israel|||2||f||||f||||||||||2018-06-01 01:29:48.16761|2018-06-01 01:29:48.16761
NCT00806819|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2014-11-14||2016-12-08|2008-12-10|2008-12-11|Estimate|2014-11-14|2014-11-20|Estimate||||2016-12-08|2017-02-02|Estimate|December 2008||2008-12-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|June 2011|Actual|2011-06-30||Interventional||Randomised set uncut (RS): all patients who were randomised whether patients had received study treatment or not. Patients were allocated to the treatment groups as randomised, regardless of the actual medication taken.|Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC|Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy|Completed||Phase 3|718|Actual|Boehringer Ingelheim|Recruitment for the study was stopped early based on the results of a pre defined futility analysis.|5|||f||||||||||||||2018-06-01 01:29:48.308181|2018-06-01 01:29:48.308181
NCT00806806|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09||2010-08-25|2010-08-31|2008-12-09|2008-12-11|Estimate||||2010-08-31|2010-09-06|Estimate|2010-08-31|2010-09-06|Estimate|October 2008||2008-10-31|August 2010|2010-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|TTO||Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers|A Phase 1 Randomized, Single-blind, Sequential Cohort, Crossover Study to Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers|Completed||Phase 1|128|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:29:49.616158|2018-06-01 01:29:49.616158
NCT00806780|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|June 2003||2003-06-30|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Role of Routine on-Table Cholangiography in Laparoscopic Cholecystectomy|Is There a Role for Routine Intraoperative Cholangiography During Laparoscopic Cholecystectomy|Completed||N/A|200|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:29:49.684145|2018-06-01 01:29:49.684145
NCT00806767|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2011-05-14|2008-12-10|2008-12-11|Estimate|||||||2011-05-14|2011-05-17|Estimate|March 2007||2007-03-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer|Phase II Study of Allogeneic Transplant of Hematopoietic Stem Cells From a Compatible Family Donor in the Treatment of Patients Over 55 Years With Hematological Malignancies|Completed||Phase 2|82|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:29:49.742086|2018-06-01 01:29:49.742086
NCT00806754|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-11-22|2008-12-10|2008-12-11|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)|Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy|Completed||Phase 4|340|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:29:49.821529|2018-06-01 01:29:49.821529
NCT00806741|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2012-11-29|2008-12-10|2008-12-11|Estimate|||||||2012-11-29|2012-11-30|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|March 2010|Actual|2010-03-31||Interventional|||Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans|Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans|Completed||N/A|18|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 01:29:49.934737|2018-06-01 01:29:49.934737
NCT00806728|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|May 1998||1998-05-31|December 2008|2008-12-31|December 1998|Actual|1998-12-31|November 1998|Actual|1998-11-30||Interventional|||Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease|Phase I Study of MEDI-507 in the Treatment of Adult Patients With at Least Grade II Steroid-Resistant Acute Graft-Versus-Host Disease|Completed||Phase 1|17|Actual|MedImmune LLC||2|||f||||||||||||||2018-06-01 01:29:50.001304|2018-06-01 01:29:50.001304
NCT00806715|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2018-03-22|2008-12-10|2008-12-11|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 2007||2007-02-28|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Iron Overload in Stem Cell Transplant Recipients|Impact of Iron Overload in Pediatric Patients Undergoing Stem Cell Transplantation|Completed|||38|Actual|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     Peripheral blood specimens.~   "|||2018-06-01 01:29:50.07167|2018-06-01 01:29:50.07167
NCT00806689|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2010-07-01|2008-12-10|2008-12-11|Estimate|||||||2010-07-01|2010-07-02|Estimate|July 2007||2007-07-31|December 2008|2008-12-31|July 2011|Anticipated|2011-07-31|December 2008|Anticipated|2008-12-31||Observational|||Full Disclosure Observational Cardiac Rhythm Documentation Follow-up After Surgical Atrial Fibrillation Therapy||Unknown status|Recruiting||100|Anticipated|University of Luebeck|||1||f||||f||||||||||2018-06-01 01:29:51.187128|2018-06-01 01:29:51.187128
NCT00806676|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2017-04-18||2017-07-20|2008-12-09|2008-12-11|Estimate|2017-07-20|2017-07-24|Actual||||2017-07-20|2017-07-24|Actual|December 2008||2008-12-31|July 2017|2017-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease|Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease|Completed||N/A|67|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-06-01 01:29:51.293988|2018-06-01 01:29:51.293988
NCT00806663|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2012-09-07|2008-12-10|2008-12-11|Estimate|||||||2012-09-07|2012-09-10|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|||FOLFIRI and Sunitinib in Metastatic Colorectal Cancer|A Prospective Angiogenic Imaging Study With DCE-MRI and DCE-USI in Patients With Colorectal Cancer and Liver Metastases Receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy|Completed||Phase 2|22|Anticipated|Central European Society for Anticancer Drug Research|||||f||||f||||||||||2018-06-01 01:29:51.744495|2018-06-01 01:29:51.744495
NCT00806650|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2017-12-06|2008-12-10|2008-12-11|Estimate|||||||2017-12-06|2017-12-08|Actual|July 2008||2008-07-31|December 2017|2017-12-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Observational|||Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer|Development of a Blood Test of Anti-IMP3 Autoantibody and Serum MicroRNA Signature for the Detection of Renal Cell Carcinoma With Metastasis and Metastatic Potential|Completed|||155|Actual|City of Hope Medical Center|||1||f||||t||||||Samples With DNA|"~     Serum, plasma, and tissue~   "|||2018-06-01 01:29:51.827379|2018-06-01 01:29:51.827379
NCT00806637|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2008-12-10|2008-12-10|2008-12-11|Estimate|||||||2008-12-10|2008-12-11|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|September 2009|Anticipated|2009-09-30|May 2009|Anticipated|2009-05-31||Interventional|||Vessel Sealing System Uvulopalatoplasty Versus Uvulopalatal Flap|Vessel Sealing System Uvulopalatoplasty vs Uvulopalatal Flap: a Randomized, Control Study of Efficacy and Adverse Effects|Unknown status|Enrolling by invitation|N/A|30|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-06-01 01:29:51.915475|2018-06-01 01:29:51.915475
NCT00806624|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2015-01-15||2015-01-15|2008-12-10|2008-12-11|Estimate|2015-01-15|2015-01-26|Estimate||||2015-01-15|2015-01-26|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|November 2009|Actual|2009-11-30|October 2008|Actual|2008-10-31||Interventional|||DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation|A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects With Non-Valvular Atrial Fibrillation|Completed||Phase 2|234|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-06-01 01:29:52.849241|2018-06-01 01:29:52.849241
NCT00806611|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2016-10-19|2008-12-10|2008-12-11|Estimate|||||||2016-10-19|2016-10-21|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer|A Randomized, Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients With Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer|Completed||Phase 3|438|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 01:29:53.420438|2018-06-01 01:29:53.420438
NCT00806598|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2013-01-30||2013-03-08|2008-12-10|2008-12-11|Estimate|2013-01-30|2013-03-06|Estimate||||2013-03-08|2013-03-12|Estimate|May 2005||2005-05-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome|Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome|Completed||Phase 2|53|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:29:53.537865|2018-06-01 01:29:53.537865
NCT00806585|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2013-10-18||2015-09-18|2008-12-10|2008-12-11|Estimate|2013-10-18|2013-12-11|Estimate||||2015-09-18|2015-09-21|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)|A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy & Tolerability of MK0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) in Patients With T2DM and Hypertension|Terminated||Phase 2|620|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 01:29:53.87248|2018-06-01 01:29:53.87248
NCT00806572|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2017-02-06|2008-12-09|2008-12-11|Estimate|||||||2017-02-06|2017-02-08|Estimate|May 2002||2002-05-31|February 2017|2017-02-28|August 2007|Actual|2007-08-31|July 2004|Actual|2004-07-31||Interventional|||Treatment With hOKT3gamma1(Ala-Ala) in T1DM|Phase II Multiple Dose Treatment of Type 1 Diabetes Mellitus With hOKT3gamma1(Ala-Ala)|Terminated||Phase 2|10|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||Adverse events related to drug lot|f||||t||||||||Yes|Data access is provided to the public in Participant level data and additional relevant materials are available to the public in : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.|2018-06-01 01:29:54.779421|2018-06-01 01:29:54.779421
NCT00806559|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2011-12-13|2008-12-10|2008-12-11|Estimate|||||||2011-12-13|2011-12-14|Estimate|July 2007||2007-07-31|December 2011|2011-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|SIT||Space and Interaction Trial: Room Design and Patient-physician Interaction|SIT Trial: The Effect of Clinical Room Design on the Quality of the Clinical Encounter|Completed||N/A|60|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-06-01 01:29:54.872634|2018-06-01 01:29:54.872634
NCT00806546|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|2013-02-15|2012-11-07|2016-02-02|2008-12-10|2008-12-11|Estimate|2013-02-15|2013-03-20|Estimate|2013-02-06|2013-02-07|Estimate|2016-02-02|2016-02-04|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|NP101-009|Patients were asked to use study patches to treat migraine episodes with mild to severe headache pain for up to 12 months. The safety population included all subjects who applied at least one NP101 patch. Of the 514 subjects enrolled, 35 subjects did not treat for a total of 479 subjects in the safety population.|An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months|An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months|Completed||Phase 3|514|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 01:29:54.970428|2018-06-01 01:29:54.970428
NCT00806533|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-10|||2009-05-15|2008-12-10|2008-12-11|Estimate|||||||2009-05-15|2009-05-19|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Non-Interventional (Observational) Post-Authorization Safety Study of HES 130/0.42 in Paediatric Patients|Infusion of Venofundin 6% or Tetraspan 6% in Paediatric Patients Aged up to 12 Years|Completed|||1130|Actual|B. Braun Melsungen AG|||1||f||||f||||||||||2018-06-01 01:29:55.184554|2018-06-01 01:29:55.184554
NCT00806520|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2015-11-30|2008-12-09|2008-12-10|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control|Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)|Completed|||16|Actual|HealthPartners Institute|||||f||||f||||||||||2018-06-01 01:29:55.361491|2018-06-01 01:29:55.361491
NCT00806507|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-07-19|2008-12-09|2008-12-10|Estimate|||||||2012-07-19|2012-07-23|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients|Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients|Completed|||45|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:29:55.450004|2018-06-01 01:29:55.450004
NCT00806494|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2011-01-04||2011-01-04|2008-12-09|2008-12-10|Estimate|2011-01-04|2011-01-26|Estimate||||2011-01-04|2011-01-26|Estimate|February 2009||2009-02-28|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|SAFINA||UK Study Assessing Flexible Dose Fesoterodine in Adults|A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.|Completed||Phase 4|331|Actual|Pfizer|This was a single arm, non-comparative study. Hence no formal hypothesis testing was performed, and assessment of efficacy was based on changes from baseline in efficacy endpoints.|1|||f||||f||||||||||2018-06-01 01:29:55.595802|2018-06-01 01:29:55.595802
NCT00806481|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2011-11-22|2008-12-09|2008-12-10|Estimate|||||||2011-11-22|2011-11-23|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease|Does Phosphate Binding With Sevelamer Carbonate Improve Cardiovascular Structure and Function in Patients With Early Chronic Kidney Disease?|Completed||Phase 2|120|Actual|University Hospital Birmingham NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:29:56.139498|2018-06-01 01:29:56.139498
NCT00806468|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2010-12-17|2008-12-09|2008-12-10|Estimate|||||||2010-12-17|2010-12-20|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|DEPOPA||Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease|A Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease|Terminated||Phase 4|1|Actual|Johannes Gutenberg University Mainz||1||lack of recruitment|f||||f||||||||||2018-06-01 01:29:56.213548|2018-06-01 01:29:56.213548
NCT00806455|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2013-11-18|2008-12-09|2008-12-10|Estimate|||||||2013-11-18|2013-11-19|Estimate|July 2008||2008-07-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Exercise-Induced Bronchospasm in Cystic Fibrosis|Exercise-Induced Bronchospasm in Cystic Fibrosis|Completed|||14|Actual|Ohio State University|||||f||||f||||||Samples Without DNA|"~     blood, sputum~   "|||2018-06-01 01:29:56.276166|2018-06-01 01:29:56.276166
NCT00806442|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2014-07-16||2017-06-06|2008-12-09|2008-12-10|Estimate|2017-06-06|2017-07-03|Actual||||2017-06-06|2017-07-03|Actual|December 2008||2008-12-31|June 2017|2017-06-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Treatment of Bronchial Asthma With Borage and Echium Seed Oils|Treatment of Bronchial Asthma With Borage and Echium Seed Oils|Completed||Phase 1/Phase 2|43|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:29:56.352049|2018-06-01 01:29:56.352049
NCT00806429|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2017-10-13|2008-12-08|2008-12-10|Estimate|||||||2017-10-13|2017-10-17|Actual|August 2008||2008-08-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Transvaginal Appendectomy|Transvaginal Appendectomy|Completed||N/A|20|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:29:56.689687|2018-06-01 01:29:56.689687
NCT00806416|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2010-01-08||2015-10-01|2008-12-09|2008-12-10|Estimate|2010-01-08|2010-02-12|Estimate||||2015-10-01|2015-10-21|Estimate|May 2003||2003-05-31|October 2015|2015-10-31|January 2004|Actual|2004-01-31|August 2003|Actual|2003-08-31||Interventional|||A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D|A 2-Part, Open-Label, Randomized, Crossover Study to Evaluate the Bioequivalence of the 70 mg Alendronate/2800 IU Vitamin D3 Final Market Combination Tablet to a 70 mg Alendronate Marketed Tablet, and the Relative Bioavailability of Vitamin D3|Completed||Phase 1|244|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:29:56.812437|2018-06-01 01:29:56.812437
NCT00806403|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2008-11-07||2008-12-02|2008-12-02|2008-12-10|Estimate|2008-12-02|2008-12-10|Estimate||||2008-12-02|2008-12-10|Estimate|November 2001||2001-11-30|November 2008|2008-11-30|June 2004|Actual|2004-06-30|June 2003|Actual|2003-06-30||Interventional|SWEDES||Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction|Very Early Initiation of Treatment With Thrombolysis and Low Molecular Weight Heparin, Versus Abciximab and Low Molecular Weight Heparin Followed by Percutaneous Coronary Intervention, for Acute ST-Elevation Myocardial Infarction|Completed||Phase 4|205|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-06-01 01:29:57.251618|2018-06-01 01:29:57.251618
NCT00806390|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2014-05-19||2014-06-20|2008-12-09|2008-12-10|Estimate|2014-06-20|2014-07-22|Estimate||||2014-06-20|2014-07-22|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol|GCC0766: Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol|Terminated||Phase 4|15|Actual|University of Maryland||2||Poor enrollment|f||||t||||||||||2018-06-01 01:29:57.595827|2018-06-01 01:29:57.595827
NCT00806377|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2017-05-30|2008-12-09|2008-12-10|Estimate|||||||2017-05-30|2017-05-31|Actual|December 2008||2008-12-31|May 2017|2017-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|Dinosur||Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures|Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures|Completed|||100|Actual|Minneapolis Heart Institute Foundation|||||f||||f||||||||||2018-06-01 01:29:57.815378|2018-06-01 01:29:57.815378
NCT00806364|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2018-03-27|2008-12-09|2008-12-10|Estimate|||||||2018-03-27|2018-03-29|Actual|December 8, 2008||2008-12-08|November 2, 2017|2017-11-02||||||||Observational|||Normal Blood, Bone Marrow and Buccal Mucosa Protocol|Normal Blood, Bone Marrow and Buccal Mucosa Protocol|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:29:57.8828|2018-06-01 01:29:57.8828
NCT00806351|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2012-11-20|2012-10-11|2012-11-20|2008-12-09|2008-12-10|Estimate|2012-11-20|2012-12-20|Estimate|2012-10-11|2012-10-24|Estimate|2012-11-20|2012-12-20|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System|Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection|Terminated||Phase 3|21|Actual|Pfizer|Study prematurely terminated due to slow enrollment, not due to safety issues. Meaningful interpretation and comparison of treatment outcomes with caspofungin was difficult due to low number of participants (n=3) with confirmed Candida infection.|2||"The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not~   terminate due to any safety issues or concerns."|f||||t||||||||||2018-06-01 01:29:57.996126|2018-06-01 01:29:57.996126
NCT00806338|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2009-04-14|2008-12-09|2008-12-10|Estimate|||||||2009-04-14|2009-04-15|Estimate|November 2008||2008-11-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||An Ascending Multi-Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers|A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Multiple Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese or Overweight Type 2 Diabetic Volunteers|Completed||Phase 1|22|Actual|Genaera Corporation||4|||f||||f||||||||||2018-06-01 01:29:58.691845|2018-06-01 01:29:58.691845
NCT00806325|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2017-01-30|2008-12-09|2008-12-10|Estimate|||||||2017-01-30|2017-02-01|Estimate|November 2007||2007-11-30|January 2017|2017-01-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Observational|AML||Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia|Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia|Completed|||120|Actual|Ohio State University|||1||f||||f||||||Samples With DNA|"~     baseline blood sample drawn (2 tablespoons or 30 ml) at the beginning of the study. If~     subjects experience a fever another blood sample (10 ml up to 2 times) will be drawn at that~     time.~   "|No||2018-06-01 01:29:58.767349|2018-06-01 01:29:58.767349
NCT00806312|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2014-03-27|2008-12-09|2008-12-10|Estimate|||||||2014-03-27|2014-03-28|Estimate|July 2008||2008-07-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Expression and Significance of MiRNA|The Expression and Significance of miRNA Profile and Markers of Inflammation in Patients With Pulmonary Arterial Hypertension|Unknown status|Recruiting||200|Anticipated|Ohio State University|||2||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 01:29:58.827407|2018-06-01 01:29:58.827407
NCT00806299|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2011-10-04|2008-12-09|2008-12-10|Estimate|||||||2011-10-04|2011-10-06|Estimate|November 2008||2008-11-30|October 2011|2011-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Loperamide Grapefruit Juice Interaction PK Trial|An Open Label, Randomized, Single-dose, Fixed-Sequence Crossover Drug Interaction Study of Loperamide HCL With Grapefruit Juice|Completed||Phase 1|33|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-06-01 01:29:58.888937|2018-06-01 01:29:58.888937
NCT00806286|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09||2013-03-11|2013-03-15|2008-12-09|2008-12-10|Estimate||||2013-03-11|2013-03-18|Estimate|2013-03-15|2013-03-21|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer|Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Naïve Subjects With Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|111|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:29:58.967858|2018-06-01 01:29:58.967858
NCT00806273|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2009-10-07|2008-12-09|2008-12-10|Estimate|||||||2009-10-07|2009-10-08|Estimate|January 2009||2009-01-31|October 2009|2009-10-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||An in Vivo Comparison of the Debridement Efficiency of Needle Irrigation Versus Ultrasonic Irrigation|An in Vivo Comparison of the Debridement Efficacy of Needle Irrigation and Ultrasonic Root Canal Irrigation Techniques|Withdrawn||N/A|30|Anticipated|Oregon Health and Science University||2||Manufacturer changed device so no study will be done; ie it was never started|f||||f||||||||||2018-06-01 01:29:59.056427|2018-06-01 01:29:59.056427
NCT00806260|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2012-07-31|2009-11-20|2013-08-01|2008-12-09|2008-12-10|Estimate|2013-08-01|2013-09-13|Estimate|2009-11-20|2009-11-25|Estimate|2013-08-01|2013-09-13|Estimate|December 2008||2008-12-31|August 2013|2013-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.|A Phase 2, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Psychomotor Effect of VI-0521 in Healthy Overweight and Obese Subjects.|Completed||Phase 2|80|Actual|VIVUS, Inc.|Due to technical issues, an additional cohort of subjects were added to Period 1 only, which produced two additional treatment arms, alcohol only and alcohol placebo only. No change was made in the data analysis.|4|||f||||f||||||||||2018-06-01 01:29:59.122164|2018-06-01 01:29:59.122164
NCT00806247|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-05-17|2008-12-08|2008-12-10|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 2005||2005-01-31|April 2010|2010-04-30|August 2005|Actual|2005-08-31|||||Interventional|||A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of Tapentadol IR for Postoperative Pain Following Bunionectomy Surgery|A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of CG5503 (Tapentadol) IR for Postoperative Pain Following Bunionectomy Surgery|Completed||Phase 2|480|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:29:59.603811|2018-06-01 01:29:59.603811
NCT00806234|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2016-07-02||2017-04-21|2008-12-09|2008-12-10|Estimate|2017-04-21|2017-04-25|Actual||||2017-04-21|2017-04-25|Actual|January 2009||2009-01-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|IMPACT|127 subjects were randomized between 10/2009-10/2013 into three groups (CONTROL=47; MET=49; SWITCH=31). Safety analyses excluded 4 participants (CONTROL=1, MET=2, SWITCH=1) who discontinued at baseline. Primary efficacy analyses included 121 participants (CONTROL=44; MET=47; SWITCH=30) with ≥1 post-baseline vital sign measurement.|Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics|Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT)|Completed||Phase 4|127|Actual|Johns Hopkins University|27 subjects were randomized between 10/2009-10/2013 into three groups (CONTROL=47; MET=49; SWITCH=31). Safety analyses excluded 4 participants (CONTROL=1, MET=2, SWITCH=1) who discontinued at baseline.|3|||f||||t||||||||||2018-06-01 01:29:59.713637|2018-06-01 01:29:59.713637
NCT00806221|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2017-05-17||2017-06-09|2008-12-09|2008-12-10|Estimate|2017-06-09|2017-07-11|Actual||||2017-06-09|2017-07-11|Actual|November 2006||2006-11-30|June 2017|2017-06-30|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis|An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis|Completed||Phase 2|22|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:30:00.371923|2018-06-01 01:30:00.371923
NCT00806208|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2008-12-10|2008-12-09|2008-12-10|Estimate|||||||2008-12-10|2008-12-11|Estimate|January 1999||1999-01-31|December 2008|2008-12-31|March 2000|Actual|2000-03-31|January 2000|Actual|2000-01-31||Interventional|||Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)|Phase I Evaluation of Safety, Pharmacokinetics and Activity of Escalating Dose Levels of MEDI 507 in Patients Receiving Methylprednisolone for Initial Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)|Completed||Phase 1|34|Actual|MedImmune LLC||5|||f||||||||||||||2018-06-01 01:30:00.603022|2018-06-01 01:30:00.603022
NCT00806195|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2013-05-13|2011-05-30|2013-05-13|2008-12-09|2008-12-10|Estimate|2013-05-13|2013-07-09|Estimate|2011-05-30|2011-06-06|Estimate|2013-05-13|2013-07-09|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants|A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants|Completed||Phase 3|7744|Actual|Novartis||6|||f||||||||||||||2018-06-01 01:30:00.785587|2018-06-01 01:30:00.785587
NCT00806182|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2017-05-19|2008-12-09|2008-12-10|Estimate|||||||2017-05-19|2017-05-23|Actual|January 2008||2008-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|OMS||Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome|Cytokines as Biomarkers and Therapeutic Targets in Paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS)|Completed|||400|Actual|National Pediatric Neuroinflammation Organization, Inc.|||2||f||||f|f|f||||Samples Without DNA|"~     serum, plasma, cerebrospinal fluid~   "|No||2018-06-01 01:30:02.417923|2018-06-01 01:30:02.417923
NCT00806169|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-09-26|2008-12-09|2008-12-10|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2006||2006-04-30|September 2012|2012-09-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Combined Triple Therapy in Diabetic Retinopathy (DRP)|Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Diabetic Retinopathy|Completed||Phase 3|40|Actual|Johann Wolfgang Goethe University Hospital||3|||f||||f||||||||||2018-06-01 01:30:02.826121|2018-06-01 01:30:02.826121
NCT00806156|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04||2014-08-12|2014-08-12|2008-12-09|2008-12-10|Estimate||||2014-08-12|2014-08-15|Estimate|2014-08-12|2014-08-15|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer|A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer|Completed||Phase 2|178|Actual|Nektar Therapeutics||2|||f||||f||||||||||2018-06-01 01:30:02.992178|2018-06-01 01:30:02.992178
NCT00806143|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-02-23|2008-12-09|2008-12-10|Estimate|||||||2011-02-23|2011-02-24|Estimate|September 2008||2008-09-30|February 2011|2011-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression|Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression|Completed||Phase 4|16|Actual|Institute of Neuroscience, Florence, Italy||2|||f||||t||||||||||2018-06-01 01:30:03.153309|2018-06-01 01:30:03.153309
NCT00806130|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2017-11-07|2008-12-09|2008-12-10|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2008|Actual|2008-09-30|November 2017|2017-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients|Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients, a Cross-sectional Study|Completed|||40|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-06-01 01:30:03.308594|2018-06-01 01:30:03.308594
NCT00806117|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2018-03-24|2008-12-09|2008-12-10|Estimate|||||||2018-03-24|2018-03-27|Actual|February 25, 2008|Actual|2008-02-25|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Post-surgery Adjuvant Therapy for Cervical Carcinoma|Comparison of Different Adjuvant Treatments Following Radical Surgery in Early Stage Cervical Carcinoma|Active, not recruiting||Phase 3|1080|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-06-01 01:30:03.412757|2018-06-01 01:30:03.412757
NCT00806104|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2011-01-14|2008-12-09|2008-12-10|Estimate|||||||2011-01-14|2011-01-17|Estimate|March 2009||2009-03-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Fructo-oligosaccharides and Irritable Bowel Syndrome|Effect of Dietary Supplementation With Fructo-oligosaccharides on Visceral Sensitivity and on Taxonomic and Functional Composition of Intestinal Microbiota of IBS Patients|Completed||N/A|60|Anticipated|Beghin-Meiji||2|||f||||||||||||||2018-06-01 01:30:03.535681|2018-06-01 01:30:03.535681
NCT00806091|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2008-12-09|2008-12-09|2008-12-10|Estimate|||||||2008-12-09|2008-12-10|Estimate|July 2004||2004-07-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|||Functional Proteomics of Alveolar Macrophages|Functional Proteomics of Alveolar Macrophages|Completed|||72|Actual|Ohio State University|||1||f||||f||||||Samples With DNA|"~     blood BAL fluid breathe condensation saliva~   "|||2018-06-01 01:30:03.663551|2018-06-01 01:30:03.663551
NCT00806078|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2008-12-18||2012-08-22|2008-12-09|2008-12-10|Estimate|2009-07-07|2009-07-08|Estimate||||2012-08-22|2012-08-31|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Comparison Bioavailability Study of Quinine Sulfate in Chocolate Pudding|A Comparison of the Bioavailability of Quinine Sulfate Capsules Following a 648 mg Dose When Mixed in Chocolate Pudding Relative to That With Intact Capsules in Healthy Adults Under Fasting Conditions|Completed||Phase 1|18|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 01:30:03.724038|2018-06-01 01:30:03.724038
NCT00806065|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2012-01-19|2008-12-09|2008-12-10|Estimate|||||||2012-01-19|2012-01-20|Estimate|December 2008||2008-12-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Study of ENMD-2076 in Patients With Multiple Myeloma|A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|13|Actual|CASI Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:30:04.035337|2018-06-01 01:30:04.035337
NCT00806052|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2016-05-26|2008-12-09|2008-12-10|Estimate|||||||2016-05-26|2016-05-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:30:04.140643|2018-06-01 01:30:04.140643
NCT00806039|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2009-07-14|2008-12-09|2008-12-10|Estimate|||||||2009-07-14|2009-07-16|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|EARLI||Impact of Early Renal Involvement on the Development of Severe In-hospital Renal Failure|Impact of EArly Renal Involvement on the Developement of Severe In-hospital Renal Failure|Unknown status|Active, not recruiting|N/A|300|Anticipated|Saint Louis VA Medical Center||2|||f||||f||||||||||2018-06-01 01:30:04.245692|2018-06-01 01:30:04.245692
NCT00806026|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2012-05-07||2012-08-27|2008-12-09|2008-12-10|Estimate|2012-08-27|2012-09-27|Estimate||||2012-08-27|2012-09-27|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|RLS||Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients|Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome|Completed||Phase 3|731|Actual|Pfizer|Names of Daytime Function-Participant Reported Outcome (DF-PRO) and Limb Pain-Numerical Rating Scale (Limb Pain-NRS) were updated to RLS-NDI and Limb Pain-VAS respectively to reflect measurement appropriately.|6|||f||||t||||||||||2018-06-01 01:30:04.544943|2018-06-01 01:30:04.544943
NCT00806013|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2010-01-26|2008-12-09|2008-12-10|Estimate|||||||2010-01-26|2010-01-27|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|||||Observational|||Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide|Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject|Completed|||36|Actual|Chinese Academy of Sciences|||3||f||||f||||||Samples With DNA|"~     The whole blood samples of each person are stored at -80℃.~   "|||2018-06-01 01:30:06.397901|2018-06-01 01:30:06.397901
NCT00805974|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2009-01-13|2008-12-09|2008-12-10|Estimate|||||||2009-01-13|2009-01-14|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|DIAPASOM||Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I|Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I|Terminated||N/A|23|Actual|University Hospital, Grenoble||||difficulties for including diabetic patients|f||||f||||||||||2018-06-01 01:30:06.535863|2018-06-01 01:30:06.535863
NCT00805961|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2012-08-22||2013-07-01|2008-12-09|2008-12-10|Estimate|2012-08-22|2012-09-21|Estimate||||2013-07-01|2013-08-28|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|May 2013|Actual|2013-05-31|October 2009|Actual|2009-10-31||Interventional|||RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM|A Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in the First-line of Treatment of Patients With Glioblastoma Multiforme|Completed||Phase 2|68|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 01:30:06.61122|2018-06-01 01:30:06.61122
NCT00805948|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2017-02-06|2008-12-09|2008-12-10|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2009||2009-01-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|THRIVE||Post-Approval Clinical Study of the Talent Thoracic Stent Graft to Treat Thoracic Aortic Aneurysms (THRIVE)|Descending Thoracic Aortic Aneurysm Endovascular Repair Post-approval Study (THRIVE)|Active, not recruiting||N/A|256|Anticipated|Medtronic Endovascular||1|||f||||f||||||||||2018-06-01 01:30:07.023694|2018-06-01 01:30:07.023694
NCT00805935|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2011-11-28||2012-01-26|2008-12-09|2008-12-10|Estimate|2012-01-23|2012-01-25|Estimate||||2012-01-26|2012-01-27|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)|A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR® Versus FOLLISTIM® in Polycystic Ovarian Syndrome (PCOS) Patients|Completed||Phase 4|110|Actual|Ferring Pharmaceuticals||4|||f||||f||||||||||2018-06-01 01:30:07.208906|2018-06-01 01:30:07.208906
NCT00805922|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2016-11-21|2008-12-09|2008-12-10|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand|DiabCare Asia 2008. A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and To Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia|Completed|||2342|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Capillary or venous blood will be drawn for analysing HbA1c.~   "|||2018-06-01 01:30:09.612722|2018-06-01 01:30:09.612722
NCT00805909|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2009-06-08|2008-12-09|2008-12-10|Estimate|||||||2009-06-08|2009-06-09|Estimate|August 2007||2007-08-31|June 2009|2009-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||NI-0401 in Patients With Acute Renal Allograft Rejection|A Phase IIa, Open-Label, Dose-Titration, Multicenter Study to Assess the Safety and Preliminary Efficacy of NI-0401 in Patients With Acute Cellular Renal Allograft Rejection|Completed||Phase 1/Phase 2|12|Anticipated|NovImmune SA||1|||f||||t||||||||||2018-06-01 01:30:09.693513|2018-06-01 01:30:09.693513
NCT00805896|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2008-12-30|2008-12-09|2008-12-10|Estimate|||||||2008-12-30|2008-12-31|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Songyou Granule and Transarterial Chemoembolization for Hepatocellular Carcinoma|Effectiveness and Safety Study of TACE Plus Oral Songyou Granule for Unresectable HCC|Unknown status|Active, not recruiting|Phase 2|260|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 01:30:09.762651|2018-06-01 01:30:09.762651
NCT00805883|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-05-26|2008-12-09|2008-12-10|Estimate|||||||2011-05-26|2011-05-27|Estimate|February 2009||2009-02-28|December 2008|2008-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer Followed by Radical Prostatectomy|MRI Targeted Focal Laser Thermal Therapy of Prostate Cancer Followed by Radical Prostatectomy|Completed||Phase 1|10|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 01:30:09.841447|2018-06-01 01:30:09.841447
NCT00805870|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2011-08-11||2012-08-01|2008-12-09|2008-12-10|Estimate|2012-08-01|2012-09-05|Estimate||||2012-08-01|2012-09-05|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers|The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers|Completed||Phase 2|20|Actual|Western Michigan University||2|||f||||f||||||||||2018-06-01 01:30:09.92953|2018-06-01 01:30:09.92953
NCT00805857|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-12-09|2008-12-09|2008-12-10|Estimate|||||||2008-12-09|2008-12-10|Estimate|June 2008||2008-06-30|December 2008|2008-12-31||||December 2009|Anticipated|2009-12-31||Observational|||Surveillance Cohort Long-Term Toxicity Antiretrovirals in HIV-Infected Patients Enrolled in TPV Cohort|SCOLTA: SURVEILLANCE COHORT LONG-TERM TOXICITY ANTIRETROVIRALS|Withdrawn|||150|Anticipated|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:30:10.236285|2018-06-01 01:30:10.236285
NCT00805844|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2011-07-13|2008-12-09|2008-12-10|Estimate|||||||2011-07-13|2011-07-15|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Observational|||Motor Evoked Potentials and SedLine|Monitoring Depth of Anesthesia With the SedLine Facilitates Motor Evoked Potential (MEP) Monitoring During Corrective Spinal Surgery|Terminated|||70|Anticipated|University of California, San Francisco|||2|Sponsor terminated the study|f||||f||||||||||2018-06-01 01:30:10.292253|2018-06-01 01:30:10.292253
NCT00805831|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2010-07-04|2008-12-09|2008-12-10|Estimate|||||||2010-07-04|2010-07-07|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of Using HDH Device and Method - a Novel Sutureless Vascular Anastomosis|Safety and Efficacy of Using HDH Device and Method - a Novel Sutureless Vascular Anastomosis|Completed||N/A|10|Anticipated|HDH Medical Ltd||1|||f||||f||||||||||2018-06-01 01:30:10.346646|2018-06-01 01:30:10.346646
NCT00805818|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08||2018-01-31|2018-02-01|2008-12-08|2008-12-10|Estimate||||2018-01-31|2018-02-02|Estimate|2018-02-01|2018-02-05|Actual|April 2010||2010-04-30|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|INTREPID2566||Study of NNZ-2566 in Patients With Traumatic Brain Injury|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury|Completed||Phase 2|261|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||No||2018-06-01 01:30:10.421226|2018-06-01 01:30:10.421226
NCT00805805|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08||2017-05-19|2017-05-19|2008-12-08|2008-12-10|Estimate||||2017-05-19|2017-05-23|Actual|2017-05-19|2017-05-23|Actual|April 2006||2006-04-30|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis|Phase III Trial of Tetrathiomolybdate (TM) in Primary Biliary Cirrhosis|Completed||Phase 3|29|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:30:10.517802|2018-06-01 01:30:10.517802
NCT00805779|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-06-06|2008-12-08|2008-12-10|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder|Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder|Terminated||N/A|4|Actual|EMKinetics, Inc||||Major protocol changes needeed|f||||f||||||||||2018-06-01 01:30:10.873438|2018-06-01 01:30:10.873438
NCT00805766|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2012-09-02||2018-01-15|2008-12-09|2008-12-10|Estimate|2012-11-07|2012-12-05|Estimate||||2018-01-15|2018-02-09|Actual|December 2008||2008-12-31|January 2018|2018-01-31|July 2010|Actual|2010-07-31|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)|Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650 in Patients With Crohn's Disease (CD)|Completed||Phase 3|39|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 01:30:10.974144|2018-06-01 01:30:10.974144
NCT00805753|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|||2014-10-10|2008-12-09|2008-12-10|Estimate|||||||2014-10-10|2014-10-13|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|MN||Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy|A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN)|Completed||Phase 1|20|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 01:30:11.348665|2018-06-01 01:30:11.348665
NCT00805740|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2013-05-30||2013-05-30|2008-12-09|2008-12-10|Estimate|2013-05-30|2013-08-01|Estimate||||2013-05-30|2013-08-01|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida|Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection|Terminated||Phase 3|41|Actual|Pfizer|The study was prematurely terminated due to slow enrollment. The study was not terminated due to any safety issues or concerns.|2||"The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not~   terminated due to any safety issues or concerns."|f||||t||||||||||2018-06-01 01:30:12.476515|2018-06-01 01:30:12.476515
NCT00805714|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-03-28|2008-12-09|2008-12-10|Estimate|||||||2012-03-28|2012-03-30|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Observational|LAMIS||Livalo Acute Myocardial Infarction Study|A Prospective Clinical Observation Study to Evaluate the Influence of Long Term Treatment of Pitavastatin on the Therapeutic Prognosis and Safety in Acute Myocardial Infarction|Completed|||1128|Actual|JW Pharmaceutical|||1||f||||f||||||||||2018-06-01 01:30:13.22925|2018-06-01 01:30:13.22925
NCT00805701|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2014-05-12|2008-12-09|2008-12-10|Estimate|||||||2014-05-12|2014-05-14|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation|Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy|Completed||Phase 4|40|Actual|Bay State Clinical Trials, Inc.||2|||f||||f||||||||||2018-06-01 01:30:13.310447|2018-06-01 01:30:13.310447
NCT00805688|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2018-03-05|2008-12-09|2008-12-10|Estimate|||||||2018-03-05|2018-03-06|Actual|November 12, 2008|Actual|2008-11-12|March 2018|2018-03-31|February 27, 2018|Actual|2018-02-27|February 27, 2018|Actual|2018-02-27||Observational|||Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer|A Feasibility Study for Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer|Completed|||100|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood drawn (around 3½ tablespoons) before treatment starts to measure cytokines (biomarkers)~     and DNA.~   "|||2018-06-01 01:30:13.399815|2018-06-01 01:30:13.399815
NCT00805675|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-09|2011-12-12||2012-01-26|2008-12-09|2008-12-10|Estimate|2012-01-26|2012-02-28|Estimate||||2012-01-26|2012-02-28|Estimate|November 2008||2008-11-30|January 2012|2012-01-31||||December 2010|Actual|2010-12-31||Interventional|||Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB|A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB|Completed||Phase 3|83|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:30:13.5123|2018-06-01 01:30:13.5123
NCT00805662|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-08|2008-12-08|2008-12-09|Estimate|||||||2008-12-08|2008-12-09|Estimate|May 2003||2003-05-31|December 2008|2008-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|Oxy||Nasal Oxcytocin During IUI|Nasal Oxcytocin Fails to Increase Pregnancy Rate of IUI|Completed||N/A|86|Actual|Ludwig-Maximilians - University of Munich||1|||f||||t||||||||||2018-06-01 01:30:13.971566|2018-06-01 01:30:13.971566
NCT00805649|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-09-26|2008-12-08|2008-12-09|Estimate|||||||2012-09-26|2012-09-27|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Combined Therapy in Age-Related Macular Degeneration (ARMD)|Combined Therapy in ARMD - Retrospective Case Series|Completed||Phase 4|150|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-06-01 01:30:14.048906|2018-06-01 01:30:14.048906
NCT00805636|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-07|||2010-05-11|2008-12-08|2008-12-09|Estimate|||||||2010-05-11|2010-05-12|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.|Evaluation of Efficacy and Safety of 18FML10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Non-Hematological Solid Tumors to Radiation Therapy|Unknown status|Recruiting|Phase 2|30|Anticipated|Aposense Ltd.|||||f||||||||||||||2018-06-01 01:30:14.125494|2018-06-01 01:30:14.125494
NCT00805623|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-07|||2008-12-08|2008-12-08|2008-12-09|Estimate|||||||2008-12-08|2008-12-09|Estimate|March 2009||2009-03-31|December 2008|2008-12-31|October 2009|Anticipated|2009-10-31|August 2009|Anticipated|2009-08-31||Interventional|||Sucking and Sucrose as Pain Relief for Infants|Partial Blinded Controlled Study to Compare SucroseVs Water, With and Without Pacifier as Pain Reliever During Venous Puncture in Infants 3-12 Months Old|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Rabin Medical Center||4|||f||||f||||||||||2018-06-01 01:30:14.207001|2018-06-01 01:30:14.207001
NCT00800852|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|||2008-12-01|2008-12-01|2008-12-02|Estimate|||||||2008-12-01|2008-12-02|Estimate||||November 2008|2008-11-30||||||||Observational|||Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome|Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome|Completed|||||Samsung Medical Center|||||f||||t||||||||||2018-06-01 01:31:44.34733|2018-06-01 01:31:44.34733
NCT00805610|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2014-08-01|2008-12-08|2008-12-09|Estimate|||||||2014-08-01|2014-08-05|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Hepatocyte Transplantation in Liver Failure|The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure.|Withdrawn||Phase 1/Phase 2|0|Actual|Virginia Commonwealth University||1||Investigator taking position at another university-0 enrolled under this protocol.|f||||t||||||||||2018-06-01 01:30:14.288025|2018-06-01 01:30:14.288025
NCT00805597|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2016-08-04|2008-12-08|2008-12-09|Estimate|||||||2016-08-04|2016-08-08|Estimate|June 2008||2008-06-30|August 2016|2016-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes|A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes|Terminated||Phase 3|40|Actual|Chinese Academy of Medical Sciences||2||The recuiting was to slow to complete the study|f||||t||||||||||2018-06-01 01:30:14.34914|2018-06-01 01:30:14.34914
NCT00805584|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-04-20|2008-12-05|2008-12-09|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2003||2003-05-31|April 2015|2015-04-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)|A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius.|Completed||Phase 4|311|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:30:14.429652|2018-06-01 01:30:14.429652
NCT00805571|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2010-03-11|2008-12-05|2008-12-09|Estimate|||||||2010-03-11|2010-03-12|Estimate|October 2008||2008-10-31|March 2010|2010-03-31||||February 2010|Actual|2010-02-28||Observational|||Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients|Urinary Kidney Injury Molecule-1 As Diagnostic Biomarker of Proximal Tubular Injury in Adult and Pediatric Transplant Recipients|Completed|||120|Anticipated|Northwell Health|||2||f||||t||||||Samples With DNA|"~     Urine~   "|||2018-06-01 01:30:14.583315|2018-06-01 01:30:14.583315
NCT00805558|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2010-05-10|2008-12-08|2008-12-09|Estimate|||||||2010-05-10|2010-05-12|Estimate|February 2009||2009-02-28|October 2009|2009-10-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis|Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole as Adjunctive Therapy to Mechanical Treatment of Patients With Chronic Periodontitis|Completed||Phase 4|76|Actual|Facultad Nacional de Salud Publica||2|||f||||t||||||||||2018-06-01 01:30:14.658491|2018-06-01 01:30:14.658491
NCT00805545|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2012-02-03||2012-03-19|2008-12-05|2008-12-09|Estimate|2012-03-19|2012-04-16|Estimate||||2012-03-19|2012-04-16|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Timing of Antibiotic Prophylaxis for Cesarean Deliveries|The Timing of Antibiotic Prophylaxis for Cesarean Delivery|Completed||N/A|400|Actual|University of Florida|There were no limitations to the study. No technical problems occurred during the study.|2|||f||||f||||||||||2018-06-01 01:30:14.822592|2018-06-01 01:30:14.822592
NCT00805532|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-09-06|2008-12-08|2008-12-09|Estimate|||||||2013-09-06|2013-09-09|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Behavioral Activation for Posttraumatic Stress Disorder (PTSD)/ Depression Treatment in Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans|Behavioral Activation for PTSD, Depression Treatment in OIF/OEF Veterans|Completed||N/A|60|Anticipated|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:30:15.154663|2018-06-01 01:30:15.154663
NCT00805519|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2010-04-29|2008-12-08|2008-12-09|Estimate|||||||2010-04-29|2010-04-30|Estimate|February 2009||2009-02-28|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee|Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee Treated With Fixed Dose Combination of Glucosamine and Chondroitin Sulfate.|Completed||Phase 4|230|Actual|Ardabil University of Medical Sciences||4|||f||||t||||||||||2018-06-01 01:30:15.2858|2018-06-01 01:30:15.2858
NCT00805506|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-11-25|2008-12-08|2008-12-09|Estimate|||||||2015-11-25|2015-11-26|Estimate|February 2006||2006-02-28|December 2008|2008-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes|Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes|Completed|||16|Actual|HealthPartners Institute|||1||f||||f||||||||||2018-06-01 01:30:15.408763|2018-06-01 01:30:15.408763
NCT00805493|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-06|2013-06-17||2017-09-13|2008-12-06|2008-12-09|Estimate|2013-06-17|2013-08-23|Estimate||||2017-09-13|2017-09-15|Actual|November 2008||2008-11-30|September 2017|2017-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder|Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)|Limitations in enrollment led to early termination of the study.|3||Insufficient recruitment of participants|f||||f||||||||||2018-06-01 01:30:15.499609|2018-06-01 01:30:15.499609
NCT00805480|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2015-01-28|2012-05-31|2015-01-28|2008-12-08|2008-12-09|Estimate|2015-01-28|2015-02-10|Estimate|2012-05-31|2012-06-06|Estimate|2015-01-28|2015-02-10|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis|Phase II Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Multiple-loading Dose Regimen Study to Assess the Safety, Efficacy and Duration of Response of AIN457 in Patients With Chronic Plaque-type Psoriasis.|Completed||Phase 2|130|Actual|Novartis||4|||f||||f||||||||||2018-06-01 01:30:16.080497|2018-06-01 01:30:16.080497
NCT00805467|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2014-01-22||2014-05-23|2008-12-05|2008-12-09|Estimate|2014-05-23|2014-06-25|Estimate||||2014-05-23|2014-06-25|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies|An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study|Terminated||Phase 2|624|Actual|AstraZeneca||4||"AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to~   Rigel Pharmaceuticals."|f||||t||||||||||2018-06-01 01:30:17.40512|2018-06-01 01:30:17.40512
NCT00805454|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-05-06|2008-12-08|2008-12-09|Estimate|||||||2010-05-06|2010-05-07|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712|A Phase I, Open-Label,Positron Emission Tomography (PET) Study Healthy Subjects Following a Single Oral Dose of OPC-34712|Completed||Phase 1|15|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||||f||||t||||||||||2018-06-01 01:30:18.766742|2018-06-01 01:30:18.766742
NCT00805441|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2017-10-21|2010-05-27|2018-02-12|2008-12-05|2008-12-09|Estimate|2018-02-12|2018-02-13|Actual|2010-05-27|2010-06-02|Estimate|2018-02-12|2018-02-13|Actual|December 2008||2008-12-31|October 2017|2017-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Full Analysis Set: all randomized participants who received ≥1 dose study drug and contributed to post-baseline data.|A Study in the Treatment of Alcohol Dependence.|A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence|Completed||Phase 2|190|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 01:30:18.90214|2018-06-01 01:30:18.90214
NCT00805428|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2008-12-08|2008-12-08|2008-12-09|Estimate|||||||2008-12-08|2008-12-09|Estimate|September 2008||2008-09-30|December 2008|2008-12-31||||||||Observational|||Importance of CD4+CD25+ly in UC1. Investigation of Difference Between Blood Concentration IL 17, IL 33, Regulatory T ly in Patients With UC and Control Group||Unknown status|Recruiting||32|Anticipated|Clinical Hospital Center, Split|||2||f||||f||||||||||2018-06-01 01:30:19.726963|2018-06-01 01:30:19.726963
NCT00805415|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-07-14|2008-12-08|2008-12-09|Estimate|||||||2011-07-14|2011-07-15|Estimate|March 2003||2003-03-31|July 2011|2011-07-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens|Multicenter, Open-label, Randomized, Comparative Study to Evaluate Ovulation Inhibition With Two 4-phasic Oral Contraceptive Regimens Containing Estradiol Valerate and Dienogest Applied Daily for Three Cycles to 200 Healthy Female Volunteer|Completed||Phase 2|209|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:30:19.799355|2018-06-01 01:30:19.799355
NCT00805402|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2010-09-03|2008-12-08|2008-12-09|Estimate|||||||2010-09-03|2010-09-06|Estimate|July 2008||2008-07-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|Cytoven||Interest of Flow Cytometry for the Diagnosis, the Follow up and Specific Immunotherapy (SIT) Arrest of Hymenoptera Venom Allergy|Interest of Flow Cytometry for the Diagnosis, the Follow up and SIT Arrest of Hymenoptera Venom Allergy|Completed||N/A|75|Anticipated|University Hospital, Limoges||1|||f||||f||||||||||2018-06-01 01:30:19.89635|2018-06-01 01:30:19.89635
NCT00805389|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2012-12-19|2012-07-26|2017-11-07|2008-12-05|2008-12-09|Estimate|2012-12-19|2013-01-25|Estimate|2012-07-26|2012-08-03|Estimate|2017-11-07|2017-12-18|Actual|December 15, 2008|Actual|2008-12-15|November 2017|2017-11-30|July 14, 2011|Actual|2011-07-14|September 29, 2010|Actual|2010-09-29||Interventional|||Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine|Comparison of the Immunogenicity and Safety of Various Investigational and Licensed Formulations of Hepatitis B Surface Antigen (HBsAg) Vaccines.|Completed||Phase 2|713|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 01:30:20.213573|2018-06-01 01:30:20.213573
NCT00805376|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2018-01-30|2008-12-08|2008-12-09|Estimate|||||||2018-01-30|2018-01-31|Actual|February 2009||2009-02-28|January 2018|2018-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas|Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas|Completed||Phase 1|37|Actual|DNAtrix, Inc.||2|||f||||f||||||||||2018-06-01 01:30:25.795683|2018-06-01 01:30:25.795683
NCT00805350|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04||2016-02-05|2016-02-05|2008-12-08|2008-12-09|Estimate||||2016-02-05|2016-03-07|Estimate|2016-02-05|2016-03-07|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ECLIPSE||Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties|Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties: a 6-week, Randomized, Double-blind, Placebo-controlled, Polysomnography Study.|Completed||Phase 3|637|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:30:25.890223|2018-06-01 01:30:25.890223
NCT00805337|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-06|2008-12-06|2008-12-09|Estimate|||||||2008-12-06|2008-12-09|Estimate||||December 2008|2008-12-31||||||||Expanded Access|ADLG3||Low Levels of Electromagnetic Fields to Treat Advanced Cancer|Compassionate Treatment of Advanced Cancer With Amplitude-Modulated Electromagnetic Fields|No longer available|||||Pasche, Boris, M.D.|||||f||||||||||||||2018-06-01 01:30:26.010222|2018-06-01 01:30:26.010222
NCT00805324|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-04-20|2008-12-05|2008-12-09|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2003||2003-05-31|April 2015|2015-04-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)|Evaluation of the Efficacy and Safety of Desloratadine Syrup in Children Suffering From Seasonal Allergic Rhinitis With or Without Intermittent Asthma|Completed||Phase 3|54|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:30:26.074042|2018-06-01 01:30:26.074042
NCT00805311|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2015-10-07|2008-12-08|2008-12-09|Estimate|||||||2015-10-07|2015-10-12|Estimate|April 2009||2009-04-30|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|AMTEC||Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis|Carotid Endarterectomy Versus Optimal Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis|Terminated||Phase 4|400|Actual|Russian Cardiology Research and Production Center||2||Due to the clear advantage of carotid endarterectomy|f||||t||||||||||2018-06-01 01:30:26.179246|2018-06-01 01:30:26.179246
NCT00805298|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-10-23|2008-12-08|2008-12-09|Estimate|||||||2012-10-23|2012-10-24|Estimate|August 2008||2008-08-31|October 2012|2012-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Assessment of the Operative Course in Connection With Removal of Lower Third Molars|Assessment of the Operative Course in Connection With Removal of Lower Third Molars With Particular Consideration to the Occurence of Pain and Swelling|Completed||N/A|154|Actual|University of Aarhus||4|||f||||t||||||||||2018-06-01 01:30:26.279245|2018-06-01 01:30:26.279245
NCT00805285|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2013-01-24||2013-03-30|2008-12-08|2008-12-09|Estimate|2013-03-30|2013-05-13|Estimate||||2013-03-30|2013-05-13|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional||The only enrolled patient was withdrawn secondary to disease worsening.|The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis|Oral Budesonide and Rectal Hydrocortisone for the Treatment of Extensive Ulcerative Colitis: A Pilot Study|Terminated||Phase 2|2|Actual|University of Maryland|The study was terminated early by the University of Maryland HRPO secondary to limited recruitment of participants. This resulted in an inability to analyze the results.|1||Study terminated due to insufficient enrollment|f||||t||||||||||2018-06-01 01:30:26.406521|2018-06-01 01:30:26.406521
NCT00805272|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-03-16|2008-12-08|2008-12-09|Estimate|||||||2012-03-16|2012-03-19|Estimate|February 2009||2009-02-28|November 2008|2008-11-30|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|IGRAVIH||Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients|Medical and Economical Evaluation of New Diagnosis Tests of Mycobacterium Tuberculosis, Specific Immune Responses in HIV-infected Adults|Completed||N/A|536|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:30:26.625634|2018-06-01 01:30:26.625634
NCT00805259|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-12-18|2008-12-08|2008-12-09|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 2010||2010-08-31|December 2013|2013-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Promoting Mental Acuity in Elderly Populations Through Incentive for Technology Use|Promoting Mental Acuity in Elderly Populations Through Incentive for Technology Use|Completed||N/A|312|Actual|Carnegie Mellon University||4|||f||||f||||||||||2018-06-01 01:30:26.721642|2018-06-01 01:30:26.721642
NCT00805246|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2016-10-25|2008-12-05|2008-12-09|Estimate|||||||2016-10-25|2016-10-27|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|July 2017|Anticipated|2017-07-31|July 2013|Actual|2013-07-31||Observational|||Assessing the Prognosis of Pulmonary Embolism Using Clinical and Imaging Biomarkers (Retrospective & Prospective )|Identifying CT Imaging Biomarkers Associated With Prognosis of Pulmonary Embolism|Unknown status|Active, not recruiting||910|Actual|University of Pittsburgh|||1||f||||t||||||||||2018-06-01 01:30:26.811073|2018-06-01 01:30:26.811073
NCT00805233|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-07-20|2008-12-08|2008-12-09|Estimate|||||||2011-07-20|2011-07-22|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration|Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration|Completed||Phase 2|30|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 01:30:27.13929|2018-06-01 01:30:27.13929
NCT00805220|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2009-09-01|2008-12-08|2008-12-09|Estimate|||||||2009-09-01|2009-09-02|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Nordic Walking as Gait Training for Frail Elderly|Nordic Walking for Frail Elderly: a Randomized Pilot Trial|Completed||Phase 2|30|Anticipated|McGill University||2|||f||||t||||||||||2018-06-01 01:30:27.232558|2018-06-01 01:30:27.232558
NCT00805207|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-04-11|2008-12-08|2008-12-09|Estimate|||||||2013-04-11|2013-04-12|Estimate|September 2007||2007-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SCOR||Sex Steroids, Sleep, and Metabolic Dysfunction in Women|Sex Steroids, Sleep, and Metabolic Dysfunction in Women|Completed||N/A|61|Actual|Washington University School of Medicine||6|||f||||f||||||||||2018-06-01 01:30:27.312698|2018-06-01 01:30:27.312698
NCT00805194|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2014-11-14||2017-11-16|2008-12-08|2008-12-09|Estimate|2014-11-27|2014-12-01|Estimate||||2017-11-16|2017-12-13|Actual|December 3, 2008|Actual|2008-12-03|November 2017|2017-11-30|November 13, 2017|Actual|2017-11-13|November 2, 2010|Actual|2010-11-02||Interventional||Randomised Set (RS)- Includes all randomised patients, whether patients had received study treatment or not|LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer|Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy|Completed||Phase 3|1314|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:30:27.583475|2018-06-01 01:30:27.583475
NCT00805181|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2010-10-06|2008-12-08|2008-12-09|Estimate|||||||2010-10-06|2010-10-07|Estimate|December 2008||2008-12-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Kinetics of Biomarkers in Acute Pyelonephritis|Kinetics of Procalcitonin, C-reactive Protein and Pyuria in Uncomplicated Pyelonephritis in Women: A Pilot Study|Completed|||30|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-06-01 01:30:29.140878|2018-06-01 01:30:29.140878
NCT00805168|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2017-12-12|2008-12-08|2008-12-09|Estimate|||||||2017-12-12|2017-12-13|Actual|May 28, 2013|Actual|2013-05-28|December 2017|2017-12-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|INHALE 2||Inhaled Amikacin Solution (BAY 41-6551) as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia|Completed||Phase 3|461|Actual|Bayer||2|||f||||t|t|f||||||||2018-06-01 01:30:29.376828|2018-06-01 01:30:29.376828
NCT00805155|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-03-15|2008-12-08|2008-12-09|Estimate|||||||2012-03-15|2012-03-16|Estimate|February 2004||2004-02-29|March 2012|2012-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Observational|||Randomized Study to Compare the Bioavailability of Three Mometasone Furoate 0.1% Topical Lotions|Bioequivalence of Three Mometasone Furoate 0.1% Topical Lotions|Completed|||80|Actual|Perrigo Company|||3||f||||f||||||||||2018-06-01 01:30:29.844064|2018-06-01 01:30:29.844064
NCT00805142|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2013-03-22||2013-06-20|2008-12-08|2008-12-09|Estimate|2013-06-20|2013-07-29|Estimate||||2013-06-20|2013-07-29|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants|Phase II Study of JNS024PR in Cancer Pain Patients|Completed||Phase 2|78|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-06-01 01:30:29.961899|2018-06-01 01:30:29.961899
NCT00805129|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2018-01-02|2008-12-08|2008-12-09|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2008||2008-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium|Phase II Study of Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium|Active, not recruiting||Phase 2|46|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 01:30:30.481468|2018-06-01 01:30:30.481468
NCT00805116|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2016-05-06|2008-12-08|2008-12-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Marine Oils and Arthritis|Whale Oil Versus Cod Liver Oil in Rheumatoid Arthritis|Terminated||N/A|7|Actual|National Institute of Nutrition and Seafood Research, Norway||2||Recruitment to slow, most patients to well for treatment|f||||f||||||||||2018-06-01 01:30:30.574768|2018-06-01 01:30:30.574768
NCT00805103|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2016-12-28|2008-12-08|2008-12-09|Estimate|||||||2016-12-28|2016-12-29|Estimate|December 2008||2008-12-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|HF-SRT||Perfexion Brain Metastasis|Hypofractionated Stereotactic Radiotherapy (HF-SRT) for Large-Volume Brain Metastases|Terminated||Phase 1|9|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:30:30.64247|2018-06-01 01:30:30.64247
NCT00798486|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2009-12-03||2016-01-29|2008-11-25|2008-11-26|Estimate|2010-02-08|2010-03-09|Estimate||||2016-01-29|2016-02-29|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of the A1CNow+ Test Kit|In-Clinic Evaluation of the Redwood A1c Test Kit With Lay-Users and Professionals|Completed||N/A|110|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-06-01 01:32:23.480764|2018-06-01 01:32:23.480764
NCT00805090|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2009-04-29|2008-12-08|2008-12-09|Estimate|||||||2009-04-29|2009-04-30|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects|An Open-Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of DIC075V in Subjects With Mild or Moderate Chronic Renal Insufficiency and in Subjects With Mild Chronic Hepatic Impairment Compared to Healthy Adult Volunteers and a Randomized, Open-Label, Single-Dose, Two-Way, Crossover Study to Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Adult Volunteers.|Completed||Phase 1|37|Actual|Javelin Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:30:30.753796|2018-06-01 01:30:30.753796
NCT00805077|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2013-07-26|2008-12-08|2008-12-09|Estimate|||||||2013-07-26|2013-07-29|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|VPP||Pulmonary Surgery and Protective Mechanical Ventilation|Pulmonary Surgery and Protective Mechanical Ventilation|Completed||N/A|347|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:30:30.858203|2018-06-01 01:30:30.858203
NCT00805064|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-09-26|2008-12-08|2008-12-09|Estimate|||||||2012-09-26|2012-09-27|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|November 2008|Actual|2008-11-30|December 2007|Actual|2007-12-31||Interventional|||Combined Triple Procedure in Retinal Vein Occlusion (RVO)|Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Retinal Vein Occlusion|Completed||Phase 3|40|Actual|Johann Wolfgang Goethe University Hospital||3|||f||||f||||||||||2018-06-01 01:30:30.936289|2018-06-01 01:30:30.936289
NCT00805051|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-09-29|2008-12-08|2008-12-09|Estimate|||||||2011-09-29|2011-09-30|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Observational|||Acquired Von Willebrand Syndrome in Severe Aortic Stenosis|Does an Acquired Von Willebrand Syndrome Influence Perioperative Blood Loss in Patients With Severe Aortic Stenosis Undergoing Aortic Valve Replacement?|Completed|||60|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-06-01 01:30:31.003233|2018-06-01 01:30:31.003233
NCT00805038|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2011-05-24||2011-06-20|2008-12-08|2008-12-09|Estimate|2011-06-20|2011-07-15|Estimate||||2011-06-20|2011-07-15|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation|Transplant Navigator Intervention to Overcome Barriers to Kidney Transplantation|Completed||Phase 1/Phase 2|167|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-06-01 01:30:31.079511|2018-06-01 01:30:31.079511
NCT00805025|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2013-09-09|2011-08-04|2014-02-03|2008-12-08|2008-12-09|Estimate|2014-02-03|2014-03-20|Estimate|2011-08-04|2011-08-15|Estimate|2014-02-03|2014-03-20|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Enrolled and treated participants|Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis|An Open-Label, Multicenter Trial to Validate the Quality of Life Questionnaire-Bronchiectasis and to Evaluate Perception of Symptom Improvement Following One Course of Aztreonam for Inhalation Solution (AZLI) in Subjects With Bronchiectasis and Gram-negative Bacteria in the Airways|Completed||Phase 2|89|Actual|Gilead Sciences||1|||f||||f||||||||||2018-06-01 01:30:31.310107|2018-06-01 01:30:31.310107
NCT00805012|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-06|||2011-07-23|2008-12-08|2008-12-09|Estimate|||||||2011-07-23|2011-07-26|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)|A Randomized, Multicenter, Phase II Study of Docetaxel and TS-1 Combination as a First-line Treatment in Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)|Terminated||Phase 2|96|Anticipated|Seoul National University Hospital||2||slow accrual rate|f||||f||||||||||2018-06-01 01:30:31.68609|2018-06-01 01:30:31.68609
NCT00804999|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2017-03-31||2017-12-20|2008-12-08|2008-12-09|Estimate|2017-12-20|2018-01-23|Actual||||2017-12-20|2018-01-23|Actual|November 1, 2008|Actual|2008-11-01|December 2017|2017-12-31|March 1, 2009|Actual|2009-03-01|March 1, 2009|Actual|2009-03-01||Interventional|||Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure|Two Phase Clinical Study of the Impact of Contact Lenses and Solutions on Corneal Structure|Completed||N/A|51|Actual|University of Iowa||3|||f||||f||||||||No|There is no plan to share IPD.|2018-06-01 01:30:31.781945|2018-06-01 01:30:31.781945
NCT00804986|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2011-05-13|2010-10-25|2011-07-12|2008-12-08|2008-12-09|Estimate|2011-05-13|2011-06-15|Estimate|2010-10-25|2010-10-27|Estimate|2011-07-12|2011-07-14|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study for Patients With Type 2 Diabetes Mellitus|A 12-Week,Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|247|Actual|Eli Lilly and Company||6|||f||||||||||||||2018-06-01 01:30:32.202229|2018-06-01 01:30:32.202229
NCT00804973|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05||2010-04-16|2010-04-16|2008-12-05|2008-12-09|Estimate||||2010-04-16|2010-04-20|Estimate|2010-04-16|2010-04-20|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study in Subjects With Acute Migraines Headaches.|A Safety, Tolerability, and Efficacy Study of LY2590443 in the Treatment of Acute Migraine Headache|Terminated||Phase 2|120|Actual|Eli Lilly and Company||3||Due to efficacy results of interim analysis|f||||f||||||||||2018-06-01 01:30:34.78778|2018-06-01 01:30:34.78778
NCT00804960|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-06-24|2008-12-08|2008-12-09|Estimate|||||||2015-06-24|2015-06-25|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Interventional|Cost-Less||Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles?|Controlled Ovarian Stimulation With Letrozole Supplementation|Withdrawn||Phase 4|0|Actual|Center for Human Reproduction||2||lack of recruitment at this site|f||||f||||||||||2018-06-01 01:30:34.995992|2018-06-01 01:30:34.995992
NCT00804947|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-08|2008-12-08|2008-12-09|Estimate|||||||2008-12-08|2008-12-09|Estimate|September 2005||2005-09-30|December 2008|2008-12-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen|Ensayo Fase II de Trasplante autólogo de Sangre periférica en Pacientes Con Mieloma múltiple Tras Acondicionamiento Con Busulfan Intravenoso y Melfalan|Unknown status|Recruiting|Phase 2|50|Anticipated|Fundacion Para La Investigacion Hospital La Fe||1|||f||||f||||||||||2018-06-01 01:30:35.082064|2018-06-01 01:30:35.082064
NCT00804934|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-05-24|2008-12-08|2008-12-09|Estimate|||||||2012-05-24|2012-05-28|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|January 2009|Actual|2009-01-31|February 2008|Actual|2008-02-29||Observational|||Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis|Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months|Completed|||100|Actual|Retina Institute of Hawaii|||1||f||||t||||||||||2018-06-01 01:30:35.186621|2018-06-01 01:30:35.186621
NCT00804921|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2008-12-08|2008-12-08|2008-12-09|Estimate|||||||2008-12-08|2008-12-09|Estimate||||December 2008|2008-12-31||||||||Interventional|||Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab|Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results|Completed||Phase 2|||University of Sao Paulo|||||f||||t||||||||||2018-06-01 01:30:35.25919|2018-06-01 01:30:35.25919
NCT00804908|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2016-12-06||2017-03-01|2008-12-08|2008-12-09|Estimate|2017-03-01|2017-03-03|Actual||||2017-03-01|2017-03-03|Actual|February 2009||2009-02-28|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||ITT population defined as all randomized participants.|A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma|Completed||Phase 2|346|Actual|AbbVie||3|||f||||t||||||||||2018-06-01 01:30:35.354837|2018-06-01 01:30:35.354837
NCT00804895|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-11-23|2008-12-08|2008-12-09|Estimate|||||||2012-11-23|2012-11-27|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|CHCI||Cluster Headache Cortivazol Injection (CHCI)|A Double Blind Randomized Controlled Trial of Greater Occipital Nerve Infiltration in Cluster Headache|Completed||Phase 2/Phase 3|43|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:30:36.125983|2018-06-01 01:30:36.125983
NCT00804882|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2015-04-09|2008-12-08|2008-12-09|Estimate|||||||2015-04-09|2015-04-13|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|CHAMP-HF||Hispanics With Metabolic Syndrome and Non-ischemic Heart Failure|Correlation in Hispanics of Accelerated Metabolic Risk Profile and Non-ischemic Heart Failure (CHAMP-HF)|Withdrawn|||0|Actual|Texas Tech University Health Sciences Center|||4|Principal investigator is leaving the institution to obtain further training.|f||||f||||||Samples Without DNA|"~     Blood will be collected~   "|||2018-06-01 01:30:37.341612|2018-06-01 01:30:37.341612
NCT00804869|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-06|2008-12-06|2008-12-09|Estimate|||||||2008-12-06|2008-12-09|Estimate|October 2008||2008-10-31|December 2008|2008-12-31||||December 2008|Actual|2008-12-31||Observational|||A-Mode vs PalmScan Ultrasonography: Biometric Measurements.|Standard A-Mode Ultrasonography vs PalmScan Ultrasonography: Biometric Measurements.|Completed|||||Asociación para Evitar la Ceguera en México|||2||f||||t||||||||||2018-06-01 01:30:37.407486|2018-06-01 01:30:37.407486
NCT00804856|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-03-08|2008-12-08|2008-12-09|Estimate|||||||2018-03-08|2018-03-09|Actual|November 27, 2008|Actual|2008-11-27|March 2018|2018-03-31|July 11, 2018|Anticipated|2018-07-11|March 9, 2012|Actual|2012-03-09||Interventional|||Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia|An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia|Active, not recruiting||Phase 2|180|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 01:30:37.482551|2018-06-01 01:30:37.482551
NCT00804843|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2011-12-21|2011-10-20|2015-09-28|2008-12-08|2008-12-09|Estimate|2012-03-26|2012-04-19|Estimate|2011-10-20|2011-10-26|Estimate|2015-09-28|2015-09-30|Estimate|April 2009||2009-04-30|September 2015|2015-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|MCAT||Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)|A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA)|Completed||Phase 2|100|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:30:37.627338|2018-06-01 01:30:37.627338
NCT00804830|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-08-20|2008-12-08|2008-12-09|Estimate|||||||2012-08-20|2012-08-21|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer|Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Region Skane||1|||f||||t||||||||||2018-06-01 01:30:38.054126|2018-06-01 01:30:38.054126
NCT00804817|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2010-08-26|2008-12-08|2008-12-09|Estimate|||||||2010-08-26|2010-08-27|Estimate|December 2007||2007-12-31|December 2008|2008-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Somatic-psychosocial Care Concept for Oncologic Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|Somatic-psychosocial Multidisciplinary Care Concept for Oncologic Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): a Prospective Non-randomized Clinical Trial|Completed||N/A|84|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-06-01 01:30:38.162989|2018-06-01 01:30:38.162989
NCT00804804|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2011-03-04|2008-12-08|2008-12-09|Estimate|||||||2011-03-04|2011-03-07|Estimate|December 2008||2008-12-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SOMVIE||Aging, Sleep, Cognitive Process|Aging,Sleep and Cognitive Process|Completed||N/A|28|Anticipated|University Hospital, Bordeaux||4|||f||||f||||||||||2018-06-01 01:30:38.264121|2018-06-01 01:30:38.264121
NCT00804791|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-01-31|2008-12-08|2008-12-09|Estimate|||||||2012-01-31|2012-02-02|Estimate|November 2008||2008-11-30|January 2012|2012-01-31||||February 2009|Actual|2009-02-28||Interventional|||Residence Time Evaluation of Marketed OTC Ophthalmic Products||Completed||N/A|25|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:30:38.399103|2018-06-01 01:30:38.399103
NCT00804778|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-08|2008-12-08|2008-12-09|Estimate|||||||2008-12-08|2008-12-09|Estimate|March 2006||2006-03-31|December 2008|2008-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Comparison of USCOM Cardiac Output and Continuous Thermodilution Cardiac Output|Comparison of USCOM Cardiac Output and Continuous Thermodilution Cardiac Output in Patients With Coronary Artery Bypass Grafting|Completed|||18|Actual|Beijing Chao Yang Hospital|||2||f||||f||||||||||2018-06-01 01:30:38.472396|2018-06-01 01:30:38.472396
NCT00804765|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2014-08-25|2008-12-08|2008-12-09|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2008||2008-09-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|ETOIG||Impact of Education During Pregnancy in Overweight Pregnant Women|Impact of Pregnant Women Education in Case of Overweight or Obesity on Risk of Child Overweight and Pregnancy Outcome|Completed||N/A|275|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:30:38.558298|2018-06-01 01:30:38.558298
NCT00804752|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-07|||2008-12-08|2008-12-08|2008-12-09|Estimate|||||||2008-12-08|2008-12-09|Estimate||||December 2008|2008-12-31||||||||Interventional|||Vitamin D Treatment in Patients With Chronic Hepatitis C||Unknown status|Recruiting|N/A|||Hillel Yaffe Medical Center||1|||f||||||||||||||2018-06-01 01:30:38.661301|2018-06-01 01:30:38.661301
NCT00804739|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-02-23|2008-12-08|2008-12-09|Estimate|||||||2012-02-23|2012-02-27|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|MITT||Perinatal Depression Treatment in a Pediatric Setting- Pilot Phase|Adapting Collaborative Care Perinatal Depression Treatment to a Pediatric Setting - Pilot Phase|Completed||N/A|30|Actual|University of Rochester||1|||f||||t||||||||||2018-06-01 01:30:38.744533|2018-06-01 01:30:38.744533
NCT00804726|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2014-01-15|2008-12-08|2008-12-09|Estimate|||||||2014-01-15|2014-01-17|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of the Safety and Effectiveness of the Akreos MI Five-0 Intraocular Lens.|A Prospective, Open-label, Monocular Feasibility Clinical Evaluation of the Bausch & Lomb Akreos MI Five-O Accommodating Intraocular Lens.|Terminated||N/A|10|Actual|Bausch & Lomb Incorporated||1||Test lens did not meet near visual efficacy endpoints|f||||f||||||||||2018-06-01 01:30:38.82191|2018-06-01 01:30:38.82191
NCT00804713|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2014-05-19||2016-05-13|2008-12-08|2008-12-09|Estimate|2014-10-14|2014-10-15|Estimate||||2016-05-13|2016-06-17|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|June 2009|Actual|2009-06-30||Interventional|LTBI|recruits at Fort Jackson, SC in 2009 between April 1 and June 11|Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits|Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits|Unknown status|Active, not recruiting|N/A|2017|Actual|Uniformed Services University of the Health Sciences|A limitation of this study is the lack of a gold standard for determining the presence of M. tuberculosis infection, making it difficult to assess the true significance of discordance between TST and the interferon-gamma release assays (IGRAs).|1|||f||||f||||||||||2018-06-01 01:30:38.904602|2018-06-01 01:30:38.904602
NCT00804700|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2010-04-21|2008-12-08|2008-12-09|Estimate|||||||2010-04-21|2010-04-23|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Impact of Two Methods of Listening to Music During Exercise on Perceived Exertion and Overall Physical Activity|Impact of Two Methods of Listening to Music During Exercise on Perceived Exertion and Overall Physical Activity|Completed||N/A|46|Anticipated|Georgetown University||2|||f||||t||||||||||2018-06-01 01:30:39.088809|2018-06-01 01:30:39.088809
NCT00804687|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|2013-03-05||2013-09-27|2008-12-08|2008-12-09|Estimate|2013-07-23|2013-08-30|Estimate||||2013-09-27|2013-10-30|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis|A Randomized, Single-Dose, Single-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-Over Study to Compare the Relative Efficacy of JNJ-39220675, Pseudoephedrine and Placebo for the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model|Completed||Phase 2|53|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||6|||f||||f||||||||||2018-06-01 01:30:39.184104|2018-06-01 01:30:39.184104
NCT00804674|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2011-06-30|2008-12-08|2008-12-09|Estimate|||||||2011-06-30|2011-07-01|Estimate|August 2005||2005-08-31|June 2011|2011-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Pain Study Using Intermittent Bupivacain Injections After Breast Reconstruction With DIEP Flap|Improved Pain Relief Using Intermittent Bupivacain Injections at the Donor Site After Breast Reconstruction With Deep Inferior Epigastric Artery Perforator (DIEP) Flap|Completed||Phase 2|47|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:30:39.756356|2018-06-01 01:30:39.756356
NCT00804661|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2010-06-02|2008-12-08|2008-12-09|Estimate|||||||2010-06-02|2010-06-03|Estimate|July 2007||2007-07-31|May 2010|2010-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|Sommeil||Sleep in Patients With Cystic Fibrosis|Predictors of Nocturnal Hypoventilation in Patients With Cystic Fibrosis|Completed|||76|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-06-01 01:30:39.834836|2018-06-01 01:30:39.834836
NCT00804648|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2010-09-01||2015-02-18|2008-12-05|2008-12-09|Estimate|2010-10-01|2010-10-20|Estimate||||2015-02-18|2015-03-06|Estimate|November 2008||2008-11-30|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 4|30|Actual|Vistakon Pharmaceuticals||6|||f||||f||||||||||2018-06-01 01:30:39.943362|2018-06-01 01:30:39.943362
NCT00804622|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2012-07-10|2008-12-08|2008-12-09|Estimate|||||||2012-07-10|2012-07-11|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)|A Randomized, Open-label, Controlled, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine 600 mg and Tenofovir Disproxil Fumarate 300 mg in Combination or Telbivudine 600 mg or Tenofovir Disproxil Fumarate 300 mg Monotherapy Given Over 12 Weeks on the Kinetics of Hepatitis B Virus DNA in Adults With HBeAg Positive Compensated CHB|Completed||Phase 2|15|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-06-01 01:30:40.386317|2018-06-01 01:30:40.386317
NCT00804609|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2015-02-03||2017-09-11|2008-12-08|2008-12-09|Estimate|2016-02-07|2016-03-07|Estimate||||2017-09-11|2017-10-12|Actual|September 2008||2008-09-30|September 2017|2017-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Epidural Lidocaine on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® After Cesarean Delivery|A Study to Evaluate the Effects of Epidural Lidocaine Administration on the Pharmacokinetic and Pharmacodynamic Profiles of DepoDur® (Morphine Sulfate Extended-release Injection) in Patients Undergoing Cesarean Delivery|Completed||N/A|30|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 01:30:40.475568|2018-06-01 01:30:40.475568
NCT00804596|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2009-12-16||2016-01-29|2008-12-05|2008-12-09|Estimate|2010-02-08|2010-03-09|Estimate||||2016-01-29|2016-02-29|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System|Labeling Comprehension and Performance Evaluation of the Apollo Blood Glucose Monitoring System With Capillary Blood [Commercial Name is CONTOUR® USB]|Completed||N/A|74|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-06-01 01:30:40.716052|2018-06-01 01:30:40.716052
NCT00804583|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2018-01-24|2008-12-08|2008-12-09|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2004||2004-03-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease|Genetic Modifiers of CF Liver Disease|Active, not recruiting|||154|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     A one time blood draw of 35 mls~   "|||2018-06-01 01:30:40.877825|2018-06-01 01:30:40.877825
NCT00804401|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-03-15|2008-12-05|2008-12-08|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2004||2004-06-30|March 2012|2012-03-31||||July 2004|Actual|2004-07-31||Interventional|||Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Two Oral Formulations of Naproxen 500 mg Tablets Administered as 1 x 500 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|34|Actual|Perrigo Company||2|||f||||||||||||||2018-06-01 01:30:42.896073|2018-06-01 01:30:42.896073
NCT00804570|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2016-08-08|2010-12-09|2016-12-09|2008-12-05|2008-12-09|Estimate|2016-12-09|2017-02-03|Estimate|2010-12-09|2010-12-15|Estimate|2016-12-09|2017-02-03|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study for the Treatment of Alcohol Dependence|A Phase 2 Study of LY2196044 Compared With Placebo in the Treatment of Alcohol Dependence|Completed||Phase 2|375|Actual|Eli Lilly and Company|Based on exposure data from an Alcohol Interaction study, H9T-MC-NABL (unregistered Phase 1 trial), the maximum dose in this study was reduced from 250 mg to 125 mg of LY2196044 after about 2/3 into the conduct of the trial.|2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 01:30:40.999463|2018-06-01 01:30:40.999463
NCT00804557|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2011-05-05|2008-12-08|2008-12-09|Estimate|||||||2011-05-05|2011-05-06|Estimate|October 2008||2008-10-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization|Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization|Terminated|||25|Anticipated|Lahey Clinic|||2|pending design changes to the device|f||||f||||||||||2018-06-01 01:30:41.934064|2018-06-01 01:30:41.934064
NCT00804544|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-03-02|2008-12-08|2008-12-09|Estimate|||||||2012-03-02|2012-03-05|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||99mTc-MIBI SPECT/CT in Breast Malignancy|Tc-99m Sestamibi SPECT/CT for Prediction of the Response of Locally Advanced Breast Malignancy to Neoadjuvant Chemotherapy|Terminated||N/A|4|Actual|Lawson Health Research Institute||1||"4 patients have been enrolled into the pilot study. No complications reported. Another clinical~   trial has been designed."|f||||f||||||||||2018-06-01 01:30:42.020382|2018-06-01 01:30:42.020382
NCT00804531|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2017-08-11|2008-12-08|2008-12-09|Estimate|||||||2017-08-11|2017-08-14|Actual|April 2009||2009-04-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|PREDID||Intra-discal Steroid Injection for MODIC I Discopathy|Intra-discal Steroid Injection for MODIC I Discopathy: A Randomized Control Trial|Completed||Phase 4|137|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:30:42.110387|2018-06-01 01:30:42.110387
NCT00804518|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2016-07-15|2008-12-08|2008-12-09|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2008||2008-11-30|July 2016|2016-07-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Exercise on Heart Function in Healthy Elderly People|Aerobic Interval Training Reduces and Compensates Age Related Decline in Cardiac Function|Completed||N/A|45|Actual|Norwegian University of Science and Technology||1|||f||||t||||||||||2018-06-01 01:30:42.201579|2018-06-01 01:30:42.201579
NCT00804505|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-08|||2009-12-22|2008-12-08|2008-12-09|Estimate|||||||2009-12-22|2009-12-23|Estimate|June 2008||2008-06-30|December 2009|2009-12-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study|A 90 Day Multi-Center, Randomized, Parallel Group Daily Wear Investigation of a New Hybrid Lens SynergEyes SA Manufactured With a Rigid Gas Permeable Center (Petrafocon A) and a Silicone Hydrogel Skirt (Larafilcon A) Compared to SynergEyes A (Paflufocon D Hem-iberfilcon A)|Completed||N/A|98|Actual|SynergEyes, Inc.||2|||f||||f||||||||||2018-06-01 01:30:42.276054|2018-06-01 01:30:42.276054
NCT00804492|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-06-28|2008-12-05|2008-12-08|Estimate|||||||2010-06-28|2010-06-29|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Establishment of an Integrated Model for Prevention of Elderly Falls|Bureau of Health Promotion,Department of Health, R.O.C. (Taiwan)|Completed||N/A|900|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:30:42.358925|2018-06-01 01:30:42.358925
NCT00804479|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2016-01-20|2008-12-05|2008-12-08|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2002||2002-01-31|January 2016|2016-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Observational|CALM-PD Cohort||The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)|Unblinded, Multicenter, Prospective Follow-up of Long-term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.|Terminated|||222|Actual|University of Rochester|||1|Funding for the CALM-PD Cohort Study was terminated by sponsor.|f||||f||||||||||2018-06-01 01:30:42.436489|2018-06-01 01:30:42.436489
NCT00804466|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2018-04-04|2008-12-05|2008-12-08|Estimate|||||||2018-04-04|2018-04-05|Actual|December 4, 2008||2008-12-04|March 13, 2018|2018-03-13|December 20, 2022|Anticipated|2022-12-20|October 27, 2016|Actual|2016-10-27||Interventional|||Human Papillomavirus Epidemiology in Nigeria|Epidemiologic and Molecular Features of Cervical Cancer in Nigeria - Project Itoju (Care)|Active, not recruiting||Early Phase 1|1466|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 01:30:42.509568|2018-06-01 01:30:42.509568
NCT00804453|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2017-04-04|2008-12-05|2008-12-08|Estimate|||||||2017-04-04|2017-04-05|Actual|November 2008||2008-11-30|April 2017|2017-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line|Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line: A Pilot Monocentric Open Randomized and Cross-over Study.|Completed||N/A|16|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 01:30:42.58831|2018-06-01 01:30:42.58831
NCT00804440|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-03-15|2008-12-05|2008-12-08|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2004||2004-01-31|March 2012|2012-03-31||||January 2004|Actual|2004-01-31||Interventional|||Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Ibuprofen Tablet Formulations in Fasted Normal, Healthy Subjects|Completed||Phase 1|30|Actual|Perrigo Company||2|||f||||||||||||||2018-06-01 01:30:42.67577|2018-06-01 01:30:42.67577
NCT00804427|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2017-05-24|2008-12-04|2008-12-08|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2008||2008-12-31|May 2017|2017-05-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Effect of Fish Oil on Plasma Triglycerides in Adults|Effect of Fish Oil as an Ethyl Ester or Triglyceride Preparation on Plasma Triglycerides in Hypertriglyceridemic Adults|Completed||N/A|60|Actual|Stanford University||4|||f||||f|f|f||||||No||2018-06-01 01:30:42.736314|2018-06-01 01:30:42.736314
NCT00804414|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2010-01-25|2008-12-05|2008-12-08|Estimate|||||||2010-01-25|2010-01-26|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers|A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Soluble Beta-1,3/1,6-glucan (SBG) in Chronic Foot Ulcers in Patients With Diabetes|Completed||Phase 3|133|Actual|Biotec Pharmacon ASA||2|||f||||f||||||||||2018-06-01 01:30:42.82146|2018-06-01 01:30:42.82146
NCT00804388|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2011-01-06|2008-12-05|2008-12-08|Estimate|||||||2011-01-06|2011-01-07|Estimate|December 2008||2008-12-31|January 2011|2011-01-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Wear Measurements of E-Poly in an Uncemented THA With Either 32 or 36 mm Caput of Ceramics.|Comparing Polyethylene Wear Using 3. Generation Highly Crosslinked Polyethylene in an Uncemented Total Hip Prostheses With Either 32 mm or 36 mm Caput of Ceramics|Unknown status|Active, not recruiting|N/A|50|Anticipated|Lovisenberg Diakonale Hospital||2|||f||||f||||||||||2018-06-01 01:30:42.949413|2018-06-01 01:30:42.949413
NCT00804375|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2010-03-22|2008-12-05|2008-12-08|Estimate|||||||2010-03-22|2010-03-24|Estimate|December 2008||2008-12-31|March 2010|2010-03-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain|Study of the Efficacy, Safety and Tolerability of Topical 2PX (Strontium Chloride Hexahydrate) in Patients With Chronic, Moderate-to-severe Lower Limb Post-amputation Stump Pain.|Unknown status|Recruiting|Phase 2|150|Anticipated|Smerud Medical Research International AS||2|||f||||f||||||||||2018-06-01 01:30:43.037535|2018-06-01 01:30:43.037535
NCT00804362|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-07-29|2008-12-05|2008-12-08|Estimate|||||||2013-07-29|2013-07-30|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Validation of the Sickle Cell Disease Pain Burden Interview||Completed|||131|Actual|Connecticut Children's Medical Center|||||f||||||||||||||2018-06-01 01:30:43.215783|2018-06-01 01:30:43.215783
NCT00804349|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-02-13|2008-12-05|2008-12-08|Estimate|||||||2013-02-13|2013-02-15|Estimate|October 2008||2008-10-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ARIA-II||Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients|Apnea Rampant In Acute Decompensated Heart Failure II|Completed||Phase 4|6|Actual|Albert Einstein Healthcare Network||2|||f||||f||||||||||2018-06-01 01:30:43.282059|2018-06-01 01:30:43.282059
NCT00804336|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2016-10-18|2008-12-05|2008-12-08|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional|||Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors|Phase I Study of Pasireotide (SOM230) in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors|Completed||Phase 1|22|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:30:43.368135|2018-06-01 01:30:43.368135
NCT00804323|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-06|2008-12-05|2008-12-08|Estimate|||||||2008-12-06|2008-12-09|Estimate|December 2007||2007-12-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||PASCAL Trabeculoplasty|Semi-Automated Patterned Laser Trabeculoplasty|Unknown status|Recruiting|Phase 4|24|Anticipated|Asociación para Evitar la Ceguera en México||1|||f||||t||||||||||2018-06-01 01:30:43.468078|2018-06-01 01:30:43.468078
NCT00804310|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-03-27|2008-12-05|2008-12-08|Estimate|||||||2012-03-27|2012-03-28|Estimate|August 2009||2009-08-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|UCDCC#207||Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors|Phase I Study of Lapatinib (GW572016) in Combination With Weekly Ixabepilone (BMS 247550) in Advanced Solid Tumors|Terminated||Phase 1|5|Actual|University of California, Davis||1||Lack of funding|f||||t||||||||||2018-06-01 01:30:43.546394|2018-06-01 01:30:43.546394
NCT00804297|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|June 2005||2005-06-30|December 2008|2008-12-31|January 2007||2007-01-31|||||Interventional|||Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia|Comparison of Octreotide and Standard Therapy vs. Standard Therapy Alone for the Treatment of Hypoglycemia in Patients Taking Sulfonylureas or a Combination of Insulin and Sulfonylureas Presenting to the Emergency Department|Completed||Phase 3|40||Albert Einstein Healthcare Network|||||f||||||||||||||2018-06-01 01:30:43.631817|2018-06-01 01:30:43.631817
NCT00804284|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-08-17|2008-12-05|2008-12-08|Estimate|||||||2015-08-17|2015-08-19|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Observational|||Database Surveillance Safety Study of PENTACEL® Vaccine|Post-Licensure Safety Surveillance Study of Routine Use of PENTACEL® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine|Completed|||62538|Actual|Sanofi|||2||f||||f||||||||||2018-06-01 01:30:43.705002|2018-06-01 01:30:43.705002
NCT00804271|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-02-21|2008-12-05|2008-12-08|Estimate|||||||2013-02-21|2013-02-22|Estimate|December 2008||2008-12-31|February 2013|2013-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Memantine and Validation of a New Alzheimer's Disease Scale|Open Label, Single-Arm, Multi-Centre, Study to Validate a New Alzheimer's Disease Scale in Patients With DAT, Treated With Memantine|Completed||Phase 3|487|Actual|Merz Pharmaceuticals GmbH||1|||f||||f||||||||||2018-06-01 01:30:43.792865|2018-06-01 01:30:43.792865
NCT00804258|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-11-04|2008-12-05|2008-12-08|Estimate|||||||2015-11-04|2015-11-06|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer|Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer|Completed|||17|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 01:30:43.867523|2018-06-01 01:30:43.867523
NCT00804245|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2017-05-25|2008-12-05|2008-12-08|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2008||2008-08-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|June 2012|Actual|2012-06-30||Interventional|||C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer|A Pilot Study of Use of 11C-Choline PET-CT in the Metastatic Evaluation of Patients With Newly Diagnosed High Risk Adenocarcinoma of the Prostate|Completed||Phase 1|18|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-06-01 01:30:43.946473|2018-06-01 01:30:43.946473
NCT00804232|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|December 2015|Anticipated|2015-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Childhood Diabetes|Childhood Diabetes - Family Based Health Interventions for Child Health|Unknown status|Recruiting|N/A|210|Anticipated|Vardalinstitutet The Swedish Institute for Health Sciences||2|||f||||f||||||||||2018-06-01 01:30:44.056612|2018-06-01 01:30:44.056612
NCT00804219|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2011-07-20|2008-12-05|2008-12-08|Estimate|||||||2011-07-20|2011-07-22|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination|Characterization of Humoral and Cellular Immunity of Low and High-responders After TBE Vaccination|Completed||Phase 4|67|Actual|Medical University of Vienna||3|||f||||||||||||||2018-06-01 01:30:44.138823|2018-06-01 01:30:44.138823
NCT00804206|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|July 2008||2008-07-31|December 2008|2008-12-31||||July 2008|Anticipated|2008-07-31||Interventional|||Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation|Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation|Unknown status|Recruiting|Phase 4|15|Anticipated|Asociación para Evitar la Ceguera en México||2|||f||||||||||||||2018-06-01 01:30:44.228083|2018-06-01 01:30:44.228083
NCT00804193|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2012-09-10||2014-01-09|2008-12-05|2008-12-08|Estimate|2012-11-19|2012-12-17|Estimate||||2014-01-09|2014-01-13|Estimate|June 2004||2004-06-30|January 2014|2014-01-31|April 2005|Actual|2005-04-30|December 2004|Actual|2004-12-31||Interventional|||Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis|A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Topical Suspension to Reference Ciclopirox Topical Suspension 0.77% in the Treatment of Tinea Pedis|Completed||N/A|553|Actual|Perrigo Company||3|||f||||f||||||||||2018-06-01 01:30:44.342338|2018-06-01 01:30:44.342338
NCT00804180|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-06-19|2008-12-05|2008-12-08|Estimate|||||||2015-06-19|2015-06-23|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Group Therapy Intervention for Children and Adolescents With Injection-Related Anxiety and Their Caregivers|Evaluation of a Group Therapy Intervention for Children and Adolescents With Injection-Related Anxiety and Their Caregivers|Withdrawn||N/A|0|Actual|Medical College of Wisconsin||1||Lack of recruitment/participants|f||||f||||||||||2018-06-01 01:30:44.821123|2018-06-01 01:30:44.821123
NCT00804167|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2009-07-19|2008-12-05|2008-12-08|Estimate|||||||2009-07-19|2009-07-21|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|||||Observational|SERENITE||National Survey on Hypertension|Profile of Hypertensive Patients Aged of 75 Years and Older Seen in General Practitioner According to Their Renal Damage.|Completed|||4500|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:30:45.151701|2018-06-01 01:30:45.151701
NCT00804154|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2018-04-24|2008-12-05|2008-12-08|Estimate|||||||2018-04-24|2018-04-25|Actual|December 3, 2008||2008-12-03|April 18, 2018|2018-04-18|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer|A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer|Recruiting||Phase 1|45|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:30:48.621516|2018-06-01 01:30:48.621516
NCT00804141|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2014-08-29|2008-12-05|2008-12-08|Estimate|||||||2014-08-29|2014-09-01|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation|An Open-Label Study To Evaluate The Long-Term Safety Of Subcutaneous MOA-728 For Treatment Of Opioid-Induced Constipation In Subjects With Nonmalignant Pain|Completed||Phase 3|1040|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 01:30:48.747474|2018-06-01 01:30:48.747474
NCT00804128|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2014-12-15|2008-12-05|2008-12-08|Estimate|||||||2014-12-15|2014-12-17|Estimate|October 2008||2008-10-31|December 2014|2014-12-31||||December 2014|Anticipated|2014-12-31||Observational|||Contrast-Enhanced MRI in Women With Ductal Breast Carcinoma in Situ and in Healthy Volunteers|Contrast-enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)|Unknown status|Recruiting||90|Anticipated|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:30:49.099359|2018-06-01 01:30:49.099359
NCT00804115|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|August 2000||2000-08-31|December 2008|2008-12-31|December 2008|Anticipated|2008-12-31|September 2007|Actual|2007-09-30||Interventional|||The International Collaborative Exfoliation Syndrome Treatment Study|The International Collaborative Exfoliation Syndrome Treatment Study|Unknown status|Active, not recruiting|N/A|277|Actual|The New York Eye & Ear Infirmary||2|||f||||t||||||||||2018-06-01 01:30:49.170425|2018-06-01 01:30:49.170425
NCT00804102|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-05-03|2008-12-05|2008-12-08|Estimate|||||||2012-05-03|2012-05-04|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Transcorneal Electrical Stimulation Therapy for Retinal Disease|Transcorneal Electrical Stimulation Therapy for Retinal Disease - A Randomized, Single-blind Pilot Study|Completed||N/A|80|Actual|Okuvision GmbH||12|||f||||t||||||||||2018-06-01 01:30:49.263911|2018-06-01 01:30:49.263911
NCT00804089|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|December 2008||2008-12-31|December 2008|2008-12-31||||March 2009|Anticipated|2009-03-31||Interventional|||Traditional Acupuncture and Myofascial Trigger Point Dry Needling and Acupressure for Chronic Low Back Pain|Randomised Comparative Pragmatic Clinical Trial of Traditional Acupuncture and Superficial Dry Needling and Acupressure of Myofascial Trigger Points for the Treatment of Patients With Chronic Mechanical Low Back Pain|Unknown status|Recruiting|N/A|90|Anticipated|Hermano Miguel Foundation||3|||f||||t||||||||||2018-06-01 01:30:49.362796|2018-06-01 01:30:49.362796
NCT00804076|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2014-02-18|2008-12-05|2008-12-08|Estimate|||||||2014-02-18|2014-02-19|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|July 2013|Actual|2013-07-31|November 2010|Actual|2010-11-30||Interventional|||Gene Transfer for Cancer Pain|Gene Transfer for Intractable Pain: A Phase I Clinical Trial to Determine the Maximum Tolerable Dose of a Replication-Defective Herpes Simplex Virus Type I (HSV-1) Vector Expressing Human Preproenkephalin (NP2) in Patients With Malignancies|Completed||Phase 1|10|Actual|Diamyd Inc||1|||f||||t||||||||||2018-06-01 01:30:49.442583|2018-06-01 01:30:49.442583
NCT00804063|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-01-07|2008-12-05|2008-12-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Observational|||Serum Citrate in Diagnosis and Follow-up for Glaucoma|Serum Citrate in Diagnosis and Follow-up for Glaucoma|Completed|||20|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||Samples With DNA|"~     blood, urine, serum, aqueous~   "|||2018-06-01 01:30:49.528304|2018-06-01 01:30:49.528304
NCT00804050|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2011-06-27|2008-12-05|2008-12-08|Estimate|||||||2011-06-27|2011-06-28|Estimate|March 2007||2007-03-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Interventional|||Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts|Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts|Terminated||Phase 3|184|Anticipated|Fondazione Italiana Sindromi Mielodisplastiche Onlus||2||Difficulties of enrollment|f||||t||||||||||2018-06-01 01:30:49.708944|2018-06-01 01:30:49.708944
NCT00797615|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2010-10-06|2008-11-24|2008-11-25|Estimate|||||||2010-10-06|2010-10-07|Estimate|November 2008||2008-11-30|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|GEMAS||Project Diabetes: Weight Gain Prevention in Hispanic Girls (GEMAS Study)|Project Diabetes: Weight Gain Prevention in Hispanic Girls (GEMAS Study)|Completed||N/A|132|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:32:40.229715|2018-06-01 01:32:40.229715
NCT00804037|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|January 2007||2007-01-31|November 2008|2008-11-30||||December 2008|Actual|2008-12-31||Interventional|||Injection Snoreplasty: Comparison Between Ethanol and Ethanolamine Oleate|Injection Snoreplasty: Comparison Between Ethanol and Ethanolamine Oleate. A Randomized, Placebo-Controlled Study in Human Patients|Unknown status|Active, not recruiting|N/A|20|Actual|University of Sao Paulo||2|||f||||||||||||||2018-06-01 01:30:49.906206|2018-06-01 01:30:49.906206
NCT00804024|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-04-18|2008-12-05|2008-12-08|Estimate|||||||2013-04-18|2013-04-19|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31|1 Day|Observational [Patient Registry]|||ClearWay™ RX Registry Trial|Multi-center, Registry Trial of ClearWay™ RX Local Therapeutic Infusion Catheter for All Indications|Completed|||102|Actual|Atrium Medical Corporation|||1||f||||||||||||||2018-06-01 01:30:49.988628|2018-06-01 01:30:49.988628
NCT00804011|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|July 2004||2004-07-31|December 2008|2008-12-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|ATC||Automatic Tube Compensation (ATC) for Weaning Patients With Severe Neurotoxic Snake Envenoming|Automatic Tube Compensation Versus Pressure Support in Weaning Patients With Severe Neurotoxic Snake Envenoming|Completed||N/A|41|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-06-01 01:30:50.162416|2018-06-01 01:30:50.162416
NCT00803998|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2013-10-31|2008-12-05|2008-12-08|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 1994||1994-02-28|December 2008|2008-12-31|December 2006||2006-12-31|||||Observational|||Ocular Hypertension Treatment Study (OHTS)|Ocular Hypertension Treatment Study|Completed|||||The New York Eye & Ear Infirmary|||||f||||||||||||||2018-06-01 01:30:50.322912|2018-06-01 01:30:50.322912
NCT00803985|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2016-07-07|2008-12-05|2008-12-08|Estimate|||||||2016-07-07|2016-07-11|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2016|Actual|2016-01-31||Interventional|TEP-LICH||"Study Comparing Total Extraperitoneal Patch TEP Versus Lichtenstein According Chronic Pain"|Prospective Randomised Study Comparing TEP vs Lichtenstein in Primary Unilateral Inguinal Hernias According Chronic Pain|Enrolling by invitation||N/A|414|Actual|Skane University Hospital||2|||f||||f||||||||Undecided||2018-06-01 01:30:50.377908|2018-06-01 01:30:50.377908
NCT00803972|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-05-30|2008-12-05|2008-12-08|Estimate|||||||2012-05-30|2012-05-31|Estimate|November 2008||2008-11-30|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20|A Phase I, Randomized, Dose-Ranging, Pharmacokinetic, Glucodynamic, Safety, and Tolerability Study of SC Administered Humulin R and Humalog With or Without Recombinant Human Hyaluronidase (rHuPH20) in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Halozyme Therapeutics|||||f||||f||||||||||2018-06-01 01:30:50.508642|2018-06-01 01:30:50.508642
NCT00803959|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2013-05-07||2013-07-03|2008-12-05|2008-12-08|Estimate|2013-07-03|2013-08-06|Estimate||||2013-07-03|2013-08-06|Estimate|November 2008||2008-11-30|July 2013|2013-07-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|ValUE||Value of Urodynamic Evaluation|A Randomized Trial of Urodynamic Testing Before Stress-Incontinence Surgery|Completed||Phase 4|630|Actual|New England Research Institutes||2|||f||||f||||||||||2018-06-01 01:30:50.626386|2018-06-01 01:30:50.626386
NCT00803946|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-03-15|2008-12-05|2008-12-08|Estimate|||||||2012-03-15|2012-03-16|Estimate|November 2003||2003-11-30|March 2012|2012-03-31||||November 2003|Actual|2003-11-30||Interventional|||Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions|A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Ibuprofen Tablet Formulations in Normal, Healthy Men and Women Following Standard Meal|Completed||Phase 1|30|Actual|Perrigo Company||2|||f||||||||||||||2018-06-01 01:30:51.454111|2018-06-01 01:30:51.454111
NCT00803933|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2008-12-05|2008-12-05|2008-12-08|Estimate|||||||2008-12-05|2008-12-08|Estimate|February 2003||2003-02-28|December 2008|2008-12-31|June 2005|Actual|2005-06-30|February 2004|Actual|2004-02-29||Interventional|||Trial of DB289 for the Treatment of Stage I African Trypanosomiasis|Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis|Completed||Phase 2|111|Actual|Immtech Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:30:51.519472|2018-06-01 01:30:51.519472
NCT00803920|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2015-12-02|2008-12-05|2008-12-08|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide|CGM Substudy, Addendum 2, of the Following Exenatide LAR Protocol 2993LAR-105: A Randomized, Open-Label, Multicenter, Comparator Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications)|Completed|||8|Actual|HealthPartners Institute|||2||f||||f||||||||||2018-06-01 01:30:51.664211|2018-06-01 01:30:51.664211
NCT00803907|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2012-06-12|2008-12-05|2008-12-08|Estimate|||||||2012-06-12|2012-06-13|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|February 2013|Anticipated|2013-02-28|September 2012|Anticipated|2012-09-30||Interventional|Imiquimod||Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma|Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma|Unknown status|Recruiting|Phase 4|20|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-06-01 01:30:51.726572|2018-06-01 01:30:51.726572
NCT00803894|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2016-06-16|2008-12-05|2008-12-08|Estimate|||||||2016-06-16|2016-06-17|Estimate|December 2008||2008-12-31|June 2016|2016-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor|A Randomized Clinical Trial to Study the Effects of MK0752 Versus Placebo on Biomarkers in Healthy Young Adult Male Subjects|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:30:51.82484|2018-06-01 01:30:51.82484
NCT00803881|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2016-10-24|2008-12-05|2008-12-08|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Longitudinal Pathogen-colonization in Cystic Fibrosis Airways and Ability to Smell|Prevalence of Chronic Rhinosinusitis, Pathogen-colonization in the Upper and Lower Airways and Ability to Smell in Cystic Fibrosis|Recruiting|||180|Anticipated|University of Jena|||1||f||||f||||||||||2018-06-01 01:30:51.896392|2018-06-01 01:30:51.896392
NCT00803868|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-07-23|2008-12-05|2008-12-08|Estimate|||||||2012-07-23|2012-07-24|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia|Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia|Terminated||Phase 2/Phase 3|28|Actual|University of South Florida||2||"The DSMB recommended that the study be stopped as a result of concerns regarding safety and~   intolerability and insufficient evidence of efficacy."|f||||t||||||||||2018-06-01 01:30:51.997958|2018-06-01 01:30:51.997958
NCT00803855|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2009-05-14|2008-12-05|2008-12-08|Estimate|||||||2009-05-14|2009-05-15|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|SAD||Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 Including an Open Food Effect Panel in Healthy Male and Non-Fertile Female Volunteers|Completed||Phase 1|110|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:30:52.18157|2018-06-01 01:30:52.18157
NCT00803842|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-02-24|2008-12-05|2008-12-08|Estimate|||||||2015-02-24|2015-02-26|Estimate|October 2008||2008-10-31|February 2015|2015-02-28||||December 2009|Anticipated|2009-12-31||Interventional|||Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash|Evaluation of Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash|Withdrawn||N/A|0|Actual|Northwestern University||||Investigator left the institution and decided not to continue with the study.|f||||t||||||||||2018-06-01 01:30:52.250046|2018-06-01 01:30:52.250046
NCT00803829|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2011-07-05|2008-12-05|2008-12-08|Estimate|||||||2011-07-05|2011-07-06|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Synbiotic Treatment of Ulcerative Colitis Patients|Synbiotic Treatment of Ulcerative Colitis Patients|Completed||N/A|24|Actual|University of Dundee|||||f||||f||||||||||2018-06-01 01:30:52.335448|2018-06-01 01:30:52.335448
NCT00803816|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2015-05-22|2008-12-05|2008-12-08|Estimate|||||||2015-05-22|2015-05-27|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A|Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A|Completed||Phase 2|12|Actual|St. Franziskus Hospital||1|||f||||t||||||||||2018-06-01 01:30:52.46064|2018-06-01 01:30:52.46064
NCT00803803|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2016-11-20|2008-12-05|2008-12-08|Estimate|||||||2016-11-20|2016-11-22|Estimate|August 1978||1978-08-31|November 2016|2016-11-30|December 1979|Actual|1979-12-31|August 1979|Actual|1979-08-31||Interventional|||Dose, Effects and Characteristics of Pilocarpine|Dose, Effects and Characteristics of Pilocarpine|Completed||Phase 4|37|Actual|Wills Eye||2|||f||||f||||||||No||2018-06-01 01:30:52.624462|2018-06-01 01:30:52.624462
NCT00803790|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2011-01-27||2016-09-28|2008-12-05|2008-12-08|Estimate|2011-04-14|2011-05-09|Estimate||||2016-09-28|2016-11-16|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)|A 2-Part, Open-Label, Randomized, Crossover Study to Evaluate the Bioequivalence of the 70-mg Alendronate/5600 IU Vitamin D3 Final Market Combination Tablet to a 70-mg Alendronate Marketed Tablet, and the Relative Bioavailability of Vitamin D3|Completed||Phase 1|318|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 01:30:52.720941|2018-06-01 01:30:52.720941
NCT00803777|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2010-03-08||2016-01-29|2008-12-05|2008-12-08|Estimate|2010-05-14|2010-06-16|Estimate||||2016-01-29|2016-02-29|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||In-Clinic and Home-Use Study of a New Blood Glucose Monitoring System|In-Clinic and Home-Use Study of the AVATAR Blood Glucose Monitoring System in Children and Young Adults|Completed||N/A|147|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-06-01 01:30:53.123214|2018-06-01 01:30:53.123214
NCT00803764|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|||2012-03-15|2008-12-05|2008-12-08|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2004||2004-06-30|March 2012|2012-03-31||||July 2004|Actual|2004-07-31||Interventional|||Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Two Oral Formulations of Naproxen 500 mg Tablets Administered as 1 x 500 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|34|Actual|Perrigo Company||2|||f||||||||||||||2018-06-01 01:30:53.378275|2018-06-01 01:30:53.378275
NCT00803751|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2011-02-18||2017-05-03|2008-12-05|2008-12-08|Estimate|2017-05-03|2017-05-15|Actual||||2017-05-03|2017-05-15|Actual|May 2008||2008-05-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Truview||A Comparison of the Infant Truview EVO2 Video Laryngoscope and the Macintosh Laryngoscope in Pediatric Patients|A Comparison of the Infant Truview EVO2 Video Laryngoscope and the Macintosh Laryngoscope in Pediatric Patients|Completed||N/A|60|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 01:30:53.471173|2018-06-01 01:30:53.471173
NCT00803738|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-05|2012-05-11||2013-01-17|2008-12-05|2008-12-08|Estimate|2013-01-17|2013-02-20|Estimate||||2013-01-17|2013-02-20|Estimate|December 2002||2002-12-31|January 2013|2013-01-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis|A Multi-center, Randomized, Investigator-blinded, Parallel-group Study, Designed to Evaluate the Safety and Clinical Equivalence of Terconazole Vaginal Suppositories, 80 mg (Test Product) and Terconazole Vaginal Suppositories, 80 mg (Reference Product) in the Treatment of Vulvovaginal Candidiasis Caused by Candida Species|Completed||N/A|572|Actual|Perrigo Company||2|||f||||f||||||||||2018-06-01 01:30:53.90265|2018-06-01 01:30:53.90265
NCT00803725|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-01-22|2008-12-04|2008-12-05|Estimate|||||||2010-01-22|2010-01-26|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy|Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy Surgery|Completed||N/A|34|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:30:54.303927|2018-06-01 01:30:54.303927
NCT00803712|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2013-12-03||2016-06-27|2008-12-04|2008-12-05|Estimate|2014-02-10|2014-03-12|Estimate||||2016-06-27|2016-07-27|Estimate|February 2009||2009-02-28|June 2016|2016-06-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||20070360 Incident Dialysis|Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis|Completed||Phase 4|313|Actual|Amgen|This was an open-label study and neither investigators nor subjects were blinded to treatment modality. Cinacalcet was dosed by forced titration. Active vitamin D administration was at the discretion of the investigator in each treatment arm.|2|||f||||f||||||||||2018-06-01 01:30:54.514819|2018-06-01 01:30:54.514819
NCT00803699|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2018-05-24|2008-12-04|2008-12-05|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 2005||2005-11-30|May 2018|2018-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|LoDoSe||Predicting Dietary Selenium Needs to Achieve Target Blood Selenium Levels|Predicting Dietary Selenium Needs to Achieve Target Blood Selenium Levels|Completed||N/A|262|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 01:30:56.461307|2018-06-01 01:30:56.461307
NCT00803686|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2010-01-14||2014-06-05|2008-12-04|2008-12-05|Estimate|2014-06-05|2014-06-09|Estimate||||2014-06-05|2014-06-09|Estimate|December 2008||2008-12-31|June 2014|2014-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||Only 12 women entered Part 1, the two-period crossover portion of the study; hence the same 12 received both oral treatments and should not be counted twice. Only 9 of those 12 went on to Part 2, the open label, non-crossover portion of the study.|A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women|A Randomized, Open-Label, Placebo-Controlled, Two-Period Crossover Study of the Effect on CTx-1 Concentrations of a Single 200 μg Recombinant Salmon Calcitonin (rsCT) Dose Given at Night to Normal, Healthy, Postmenopausal Women|Completed||Phase 2|12|Actual|Tarsa Therapeutics, Inc.||4|||f||||f||||||||||2018-06-01 01:30:56.584932|2018-06-01 01:30:56.584932
NCT00803673|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2017-07-18|2008-12-04|2008-12-05|Estimate|||||||2017-07-18|2017-07-21|Actual|May 5, 2008|Actual|2008-05-05|July 2017|2017-07-31|October 16, 2008|Actual|2008-10-16|October 16, 2008|Actual|2008-10-16||Interventional|||A Healthy Volunteer Study With Inhaled GSK573719 and Placebo|A Single Centre, Randomized, Double-blind, Dose Ascending, Placebo-controlled Study, in Two Parts, to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Inhaled Doses of GSK573719 and Placebo Formulated With the Excipient Magnesium Stearate, in Healthy Subjects and in a Healthy Population of Cytochrome P450 Isoenzyme 2D6 Poor Metabolisers.|Completed||Phase 1|36|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:30:57.230758|2018-06-01 01:30:57.230758
NCT00803660|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2009-07-08|2008-12-04|2008-12-05|Estimate|||||||2009-07-08|2009-07-09|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|||||Observational|||Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes|In Practice Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes.|Completed|||1060|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:30:57.38208|2018-06-01 01:30:57.38208
NCT00803647|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2015-10-19||2018-04-06|2008-12-04|2008-12-05|Estimate|2016-07-26|2016-09-14|Estimate||||2018-04-06|2018-05-07|Actual|January 2010||2010-01-31|April 2018|2018-04-30|November 2014|Actual|2014-11-30|July 2013|Actual|2013-07-31||Interventional|||A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver|A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver|Completed||Phase 2|20|Actual|NSABP Foundation Inc||1|||f||||f||||||||||2018-06-01 01:30:57.556737|2018-06-01 01:30:57.556737
NCT00803634|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2014-06-03||2014-08-21|2008-12-04|2008-12-05|Estimate|2014-07-30|2014-08-19|Estimate||||2014-08-21|2014-08-29|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|PRONTO|Safety Population: Includes all patients dosed with clevidipine (for patients randomized to the clevidipine arm) of standard of care (SOC) (for patients randomized to the SOC arm) continuous IV antihypertensive therapy.|Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)|A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO)|Completed||Phase 3|117|Actual|The Medicines Company||2|||f||||t||||||||||2018-06-01 01:30:57.886091|2018-06-01 01:30:57.886091
NCT00803621|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2014-03-22|2008-12-04|2008-12-05|Estimate|||||||2014-03-22|2014-03-26|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|TOXODFA||Cerebral Toxoplasmosis and AIDS|Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii.|Completed|||46|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 01:30:58.774215|2018-06-01 01:30:58.774215
NCT00803608|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2014-08-12|2008-12-04|2008-12-05|Estimate|||||||2014-08-12|2014-08-13|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CareFULPrevent||The CareFUL Prevention Trial|Prospective, Randomized, Multiple Site Clinical Trial Comparing the Effectiveness of Novel Pressure Based Insoles to Current Care For Ulcer Prevention|Completed||Phase 2|130|Actual|DIApedia, LLC||2|||f||||t||||||||||2018-06-01 01:30:58.825505|2018-06-01 01:30:58.825505
NCT00803595|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2011-10-12||2011-11-29|2008-12-04|2008-12-05|Estimate|2011-10-12|2011-11-22|Estimate||||2011-11-29|2011-12-05|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|MARVEL||A Multinational Phase III Study of CS-8958 (MARVEL)|A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection|Completed||Phase 3|1002|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-06-01 01:30:58.920404|2018-06-01 01:30:58.920404
NCT00803582|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-01-20|2008-12-04|2008-12-05|Estimate|||||||2010-01-20|2010-01-22|Estimate|February 2007||2007-02-28|January 2010|2010-01-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Effectiveness of Acupuncture for Phonotraumatic Injuries|Effectiveness of Acupuncture for Phonotraumatic Injuries|Unknown status|Recruiting|Phase 2|135|Anticipated|The University of Hong Kong||3|||f||||t||||||||||2018-06-01 01:30:59.822851|2018-06-01 01:30:59.822851
NCT00803569|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2011-06-21|2008-12-04|2008-12-05|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen|Completed||Phase 1|6|Actual|Ludwig Institute for Cancer Research|||||f||||t||||||||||2018-06-01 01:30:59.968519|2018-06-01 01:30:59.968519
NCT00803556|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2011-06-23|2008-12-04|2008-12-05|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy|Phase 1 Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel|Completed||Phase 1|29|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 01:31:00.387056|2018-06-01 01:31:00.387056
NCT00803543|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2015-07-11||2017-06-14|2008-12-04|2008-12-05|Estimate|2017-06-14|2017-07-13|Actual||||2017-06-14|2017-07-13|Actual|January 2009||2009-01-31|June 2017|2017-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding|Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daiy Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding|Completed||N/A|103|Actual|University of Alabama at Birmingham|Small populations size. High level of patient withdrawal and loss to follow up.|2|||f||||f||||||||No||2018-06-01 01:31:00.540407|2018-06-01 01:31:00.540407
NCT00803530|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2011-06-27|2008-12-04|2008-12-05|Estimate|||||||2011-06-27|2011-06-28|Estimate|September 2005||2005-09-30|June 2011|2011-06-30|August 2010|Actual|2010-08-31|January 2007|Actual|2007-01-31||Interventional|||Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes|Phase II Multicenter Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes|Terminated||Phase 2|55|Anticipated|Fondazione Italiana Sindromi Mielodisplastiche Onlus||1||difficulties of enrollement|f||||f||||||||||2018-06-01 01:31:01.009531|2018-06-01 01:31:01.009531
NCT00803517|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2008-11-12||2009-03-11|2008-12-03|2008-12-05|Estimate|2008-12-03|2008-12-05|Estimate||||2009-03-11|2009-03-12|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy|Comparison of Multifocal Electroretinogram Assessment Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy|Completed|||24|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-06-01 01:31:01.095498|2018-06-01 01:31:01.095498
NCT00803504|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|November 2006||2006-11-30|December 2008|2008-12-31|August 2007|Actual|2007-08-31|||||Observational|||Correlation of Optic Disk Morphology and Ocular Perfusion Parameters in Patients With Primary Open Angle Glaucoma|Correlation of Optic Disk Morphology and Ocular Perfusion Parameters in Patients With Primary Open Angle Glaucoma|Completed|||103|Actual|Medical University of Vienna|||||f||||t||||||||||2018-06-01 01:31:01.412965|2018-06-01 01:31:01.412965
NCT00803491|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-08-17|2008-12-04|2008-12-05|Estimate|||||||2010-08-17|2010-08-18|Estimate|December 2008||2008-12-31|August 2010|2010-08-31|February 2013|Anticipated|2013-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Health Related Quality of Life After a Self-promoting Learning Program for People With Rheumatic Diseases|Health Related Quality of Life After a Self-promoting Problem-based Learning Program for People With Rheumatic Diseases: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|200|Anticipated|Spenshult Hospital||2|||f||||f||||||||||2018-06-01 01:31:01.480551|2018-06-01 01:31:01.480551
NCT00803478|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2016-02-01|2008-12-04|2008-12-05|Estimate|||||||2016-02-01|2016-02-03|Estimate|June 2004||2004-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2008|Actual|2008-09-30||Interventional|IDES||The Effect of Hinge Position and Hinge Width on Corneal Sensation and Dry Eye After IntraLase LASIK Procedure|The Effect of Hinge Position and Hinge Width on Corneal Sensation and Dry Eye After IntraLase LASIK Procedure|Withdrawn||N/A|0|Actual|University of Michigan||3|||f||||f||||||||||2018-06-01 01:31:01.573715|2018-06-01 01:31:01.573715
NCT00803465|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-03-15|2008-12-03|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|April 2003||2003-04-30|March 2012|2012-03-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Observational|||Randomized Study to Compare the Bioequivalence of Two Fluticasone Propionate 0.05% Topical Creams|Bioequivalence of Two Fluticasone Propionate 0.05% Topical Creams|Completed|||115|Actual|Perrigo Company|||5||f||||f||||||||||2018-06-01 01:31:01.692671|2018-06-01 01:31:01.692671
NCT00803452|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2017-04-07||2017-11-28|2008-12-03|2008-12-05|Estimate|2017-11-28|2017-12-22|Actual||||2017-11-28|2017-12-22|Actual|July 2008||2008-07-31|November 2017|2017-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Lipids of the Human Tear Film and Their Effect on Tear Stability|Lipids of the Human Tear Film and Their Effect on Tear Stability|Completed||Phase 4|31|Actual|University of Louisville||2|||f||||f||||||||||2018-06-01 01:31:01.822772|2018-06-01 01:31:01.822772
NCT00803439|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-03-15|2008-12-03|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Observational|||Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams|Bioequivalence of Two Clobetasol Propionate 0.05% Topical Foams|Completed|||80|Actual|Perrigo Company|||4||f||||f||||||||||2018-06-01 01:31:02.147194|2018-06-01 01:31:02.147194
NCT00803426|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2017-11-22|2008-12-04|2008-12-05|Estimate|||||||2017-11-22|2017-11-27|Actual|July 2008||2008-07-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Ultrasound Guided Popliteal Fossa Block. Does Blockade Distal to Sciatic Nerve Bifurcation Speed Onset Time? A Prospective, Randomized Trial|Ultrasound Guided Popliteal Fossa Block. Does Blockade Distal to Sciatic Nerve Bifurcation Speed Onset Time? A Prospective, Randomized Trial|Completed||N/A|55|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:31:02.251255|2018-06-01 01:31:02.251255
NCT00803413|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2008-11-07||2008-12-04|2008-12-04|2008-12-05|Estimate|2008-12-04|2008-12-05|Estimate||||2008-12-04|2008-12-05|Estimate|August 2002||2002-08-31|December 2008|2008-12-31|March 2004|Actual|2004-03-31|June 2003|Actual|2003-06-30||Interventional|||Effect of Back School and Supervised Walking in Sedentary Women With Chronic Low Back Pain|Effect of Back School and Supervised Walking in Sedentary Women With Chronic Low Back Pain: a Randomized Controlled Trial.|Completed||N/A|119|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-06-01 01:31:02.344235|2018-06-01 01:31:02.344235
NCT00803400|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2008-11-07||2009-04-21|2008-12-03|2008-12-05|Estimate|2008-12-03|2008-12-05|Estimate||||2009-04-21|2009-05-07|Estimate|July 2005||2005-07-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|AEIPDT||Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment|Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial|Completed||Phase 4|150|Actual|University of Buenos Aires|"Panic patients may sometimes be reluctant to use medication. This could lead to early drop outs.~Possible difficulties in following the exercise protocol."|2|||f||||f||||||||||2018-06-01 01:31:02.914088|2018-06-01 01:31:02.914088
NCT00803387|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative|Dry Eye and Irritation Comparison of Latanoprost 0.005% With the Preservative Benzalkonium Chloride (BAC) Vs Travoprost 0.004% Without BAC|Completed|||33|Actual|United States Air Force|||1||f||||||||||||||2018-06-01 01:31:03.302517|2018-06-01 01:31:03.302517
NCT00803374|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2011-11-18|2008-12-04|2008-12-05|Estimate|||||||2011-11-18|2011-11-21|Estimate|November 2010||2010-11-30|November 2011|2011-11-30|January 2013|Anticipated|2013-01-31|July 2012|Anticipated|2012-07-31||Interventional|||Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma|A Phase I, Multiple Ascending Dose Study of BMS-663513 (Anti CD137) in Combination With Ipilimumab (BMS-734016/Anti-CTLA-4) in Subjects With Unresectable Stage III or Stage IV Melanoma|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 01:31:03.388865|2018-06-01 01:31:03.388865
NCT00803361|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2010-11-19||2010-11-19|2008-12-03|2008-12-05|Estimate|2010-11-19|2010-12-17|Estimate||||2010-11-19|2010-12-17|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Duloxetine for the Treatment of Generalized Anxiety Disorder|Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China|Completed||Phase 3|210|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:31:03.647213|2018-06-01 01:31:03.647213
NCT00803348|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-04-25|2008-12-04|2008-12-05|Estimate|||||||2012-04-25|2012-04-26|Estimate|May 2009||2009-05-31|January 2010|2010-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Continuous Femoral Nerve Blockade and Readiness to Discharge Following Total Knee Arthroplasty|The Secret Recipe for Femoral Nerve Blockade After Total Knee Arthroplasty: A Randomized, Placebo-controlled, Double-blind Trial|Completed||N/A|99|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-06-01 01:31:04.304732|2018-06-01 01:31:04.304732
NCT00803335|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2015-05-25|2008-12-04|2008-12-05|Estimate|||||||2015-05-25|2015-05-27|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse|The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial|Completed||Phase 3|54|Actual|TriHealth Inc.||3|||f||||f||||||||||2018-06-01 01:31:04.433664|2018-06-01 01:31:04.433664
NCT00803322|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|September 2006||2006-09-30|December 2008|2008-12-31|April 2008|Actual|2008-04-30|September 2007|Actual|2007-09-30||Observational|community||Improving Community Based Tuberculosis Care in Ethiopia|Community Health Workers Improve Tuberculosis Case Notification and Treatment Success in Southern Ethiopia|Completed|||318|Actual|University of Bergen|||2||f||||f||||||||||2018-06-01 01:31:04.64018|2018-06-01 01:31:04.64018
NCT00803309|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2017-08-25|2008-12-04|2008-12-05|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2008||2008-11-30|August 2017|2017-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|OPTEX2/3||Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients|Optimization of Treatment for Patients With Chronic Hepatitis C Infected With HCV-genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response|Terminated||Phase 4|99|Actual|HepNet Study House, German Liverfoundation||2||"At the end of the planned recruitment period the expected number of subjects could not be~   included in the trial."|f||||t||||||||||2018-06-01 01:31:05.018189|2018-06-01 01:31:05.018189
NCT00803296|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-01-12|2008-12-04|2008-12-05|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2006||2006-01-31|December 2008|2008-12-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Observational|BMI-INK||Incretin Effect in Lean and Obese Subjects|The Impact of Obesity and Insulin Resistance on the Incretin Effect in Patients With Type 2 Diabetes and Healthy Subjects|Completed|||32|Actual|University Hospital, Gentofte, Copenhagen|||4||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 01:31:05.319034|2018-06-01 01:31:05.319034
NCT00803283|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2013-05-07||2013-08-08|2008-12-04|2008-12-05|Estimate|2013-08-08|2013-08-12|Estimate||||2013-08-08|2013-08-12|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain|A Randomized, Open-Labeled, Multi-Center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Comparing With Morphine SR in Cancer Pain Patients|Terminated||Phase 3|2|Actual|Johnson & Johnson Taiwan Ltd|This study had inadequate number of participants. 'The study was terminated early and the data for efficacy assessments were missing.|2|||f||||||||||||||2018-06-01 01:31:05.507874|2018-06-01 01:31:05.507874
NCT00803270|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2012-03-26||2013-05-08|2008-12-04|2008-12-05|Estimate|2012-04-12|2012-05-11|Estimate||||2013-05-08|2013-05-10|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|MIMOSA||Mixed Incontinence: Medical Or Surgical Approach?|Mixed Incontinence: Medical Or Surgical Approach?|Terminated||Phase 4|27|Actual|New England Research Institutes|Early termination leading to small numbers of participants for data analysis.|2||Feasibility Period ended.|f||||t||||||||||2018-06-01 01:31:05.859934|2018-06-01 01:31:05.859934
NCT00803257|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-06-12|2008-12-04|2008-12-05|Estimate|||||||2012-06-12|2012-06-13|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Lumbrical Stretching on Carpal Tunnel Syndrome|Effect of Lumbrical Stretching on Carpal Tunnel Syndrome|Completed||N/A|124|Actual|University of Pittsburgh||4|||f||||t||||||||||2018-06-01 01:31:06.292215|2018-06-01 01:31:06.292215
NCT00803244|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|2016-01-25||2016-04-18|2008-12-04|2008-12-05|Estimate|2016-04-18|2016-05-25|Estimate||||2016-04-18|2016-05-25|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional||"Safety Set: The Safety Set included all patients who received at least one dose of the investigational product.~The Full Analysis Set included all patients who received at least one dose of the investigational product and had at least one Adjusted Symptom Score during the pollen period while on treatment."|Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis|A Randomised, Double-blind, Placebo-controlled, Multi National, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablet, Starting 2 Months Before the Grass Pollen Season Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis|Completed||Phase 3|381|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-06-01 01:31:06.440731|2018-06-01 01:31:06.440731
NCT00803231|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-02-01|2008-12-04|2008-12-05|Estimate|||||||2010-02-01|2010-02-02|Estimate|November 2008||2008-11-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Follow-up Data of Patients Treated With XIGRIS® in France|Follow-up Data of Patients Treated With XIGRIS® DROTRECOGIN ALFA (ACTIVATED) in France|Completed|||1004|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-06-01 01:31:06.785315|2018-06-01 01:31:06.785315
NCT00803218|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-03-15|2008-12-03|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|November 2002||2002-11-30|March 2012|2012-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Observational|||Randomized Study to Compare the Bioavailability of Two Fluticasone Propionate 0.005% Topical Ointments|Bioequivalence of Two Fluticasone Propionate 0.005% Topical Ointments|Completed|||56|Actual|Perrigo Company|||2||f||||f||||||||||2018-06-01 01:31:06.865617|2018-06-01 01:31:06.865617
NCT00803205|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04||2013-06-27|2017-06-02|2008-12-04|2008-12-05|Estimate||||2013-06-27|2013-07-03|Estimate|2017-06-02|2017-06-06|Actual|July 2009|Actual|2009-07-31|May 2017|2017-05-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Interventional|||Study of Ataluren (PTC124™) in Cystic Fibrosis|A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis|Completed||Phase 3|238|Actual|PTC Therapeutics||2|||f||||t||||||||No||2018-06-01 01:31:06.939578|2018-06-01 01:31:06.939578
NCT00803192|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2012-03-15|2008-12-04|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2004||2004-06-30|March 2012|2012-03-31||||June 2004|Actual|2004-06-30||Interventional|||Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions|Completed||Phase 1|44|Actual|Perrigo Company||2|||f||||||||||||||2018-06-01 01:31:07.119649|2018-06-01 01:31:07.119649
NCT00803179|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2012-11-13||2012-12-10|2008-12-04|2008-12-05|Estimate|2012-12-10|2013-01-15|Estimate||||2012-12-10|2013-01-15|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Growth Hormone Therapy for Wasting in Cystic Fibrosis|Growth Hormone Therapy for Wasting in Cystic Fibrosis|Terminated||Phase 1|5|Actual|University of Massachusetts, Worcester||1||Poor enrollment, patients were lost to follow up|f||||f||||||||||2018-06-01 01:31:07.201463|2018-06-01 01:31:07.201463
NCT00803166|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-03-15|2008-12-04|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2004||2004-01-31|March 2012|2012-03-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Observational|||Randomized Study to Compare the Bioavailability of Three Halobetasol Propionate 0.05% Topical Creams|Bioequivalence of Three Halobetasol Propionate 0.05% Topical Creams|Completed|||60|Actual|Perrigo Company|||2||f||||f||||||||||2018-06-01 01:31:07.422275|2018-06-01 01:31:07.422275
NCT00803153|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate||||December 2008|2008-12-31||||||||Observational|||PASCAL: Safety and Complications, Experience After 1301 Consecutive Cases|Pattern Scan Laser Photocoagulation: Safety and Complications, Experience After 1301 Consecutive Cases.|Completed|||||Asociación para Evitar la Ceguera en México|||||f||||t||||||||||2018-06-01 01:31:07.690475|2018-06-01 01:31:07.690475
NCT00803140|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2015-05-27|2008-12-04|2008-12-05|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Cutaneous Scarring of Scalpel Versus Cautery|A Pilot Study Comparing Cutaneous Scarring When Scalpel Versus Cautery is Used to Make Skin Incisions|Terminated||N/A|4|Actual|Scott and White Hospital & Clinic||2||Slow accrual of subject enrollment.|f||||f||||||||||2018-06-01 01:31:07.766664|2018-06-01 01:31:07.766664
NCT00803127|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2009-08-10|2008-12-04|2008-12-05|Estimate|||||||2009-08-10|2009-08-11|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Observational|||VS-Sense Result Reading Clarity|VS-Sense Result Reading Clarity|Completed|||120|Anticipated|Carmel Medical Center|||1||f||||||||||Samples With DNA|"~     VAGINAL DISCHARGE~   "|||2018-06-01 01:31:07.868269|2018-06-01 01:31:07.868269
NCT00803114|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2008-11-07||2009-01-13|2008-12-04|2008-12-05|Estimate|2008-12-04|2008-12-05|Estimate||||2009-01-13|2009-01-14|Estimate|March 2002||2002-03-31|December 2008|2008-12-31|February 2005|Actual|2005-02-28|November 2004|Actual|2004-11-30||Interventional|||Epidural Morphine Following Vaginal Delivery|Epidural Morphine Following Vaginal Delivery: A Randomised, Double-Blind, Placebo-Controlled Trial|Completed||Phase 4|228|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-06-01 01:31:07.938151|2018-06-01 01:31:07.938151
NCT00803101|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2014-01-12|2013-11-07|2015-03-18|2008-12-04|2008-12-05|Estimate|2014-01-12|2014-02-25|Estimate|2013-11-07|2013-12-02|Estimate|2015-03-18|2015-04-06|Estimate|February 2009||2009-02-28|March 2014|2014-03-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|BE1116_3003|The Intention-to-Treat Efficacy (ITT-E) population included all randomized participants who had received any study product, underwent the intended surgical procedure, and had an INR > 1.3 prior to the infusion. Participants in the ITT-E population were analyzed 'as randomized'.|An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure|An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure|Completed||Phase 3|176|Actual|CSL Behring||2|||f||||||||||||||2018-06-01 01:31:08.407954|2018-06-01 01:31:08.407954
NCT00803088|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2015-06-17|2008-12-04|2008-12-05|Estimate|||||||2015-06-17|2015-06-18|Estimate|July 2010||2010-07-31|June 2015|2015-06-30||||December 2011|Anticipated|2011-12-31||Interventional|3to2||Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma|A Multicenter Clinical Trial Evaluating the Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma.|Withdrawn||N/A|0|Actual|Asthmatx, Inc.||1||Current treatment regimen of 3 procedures considered acceptable.|f||||t||||||||||2018-06-01 01:31:09.074652|2018-06-01 01:31:09.074652
NCT00803075|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2008-12-18|2008-12-04|2008-12-05|Estimate|||||||2008-12-18|2008-12-22|Estimate|February 2002||2002-02-28|December 2008|2008-12-31||||||||Interventional|||Endovascular Repair of Abdominal Aortic Aneurysms|TALENT Endoluminal Stent Graft System for the Treatment of Abdominal Aortic Aneurysms|Completed||Phase 4|200||Stanford University|||||||||||||||||||2018-06-01 01:31:09.155621|2018-06-01 01:31:09.155621
NCT00803062|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2015-12-15||2017-11-03|2008-12-04|2008-12-05|Estimate|2016-04-15|2016-05-24|Estimate||||2017-11-03|2017-12-07|Actual|April 2009||2009-04-30|November 2017|2017-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All enrolled patients.|Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer|A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix|Completed||Phase 3|452|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-06-01 01:31:09.324823|2018-06-01 01:31:09.324823
NCT00803049|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2016-12-05||2016-12-05|2008-12-04|2008-12-05|Estimate|2016-12-05|2017-01-30|Estimate||||2016-12-05|2017-01-30|Estimate|October 2006||2006-10-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis|Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses|Completed||Phase 3|742|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 01:31:13.62157|2018-06-01 01:31:13.62157
NCT00803036|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2018-01-30|2008-12-04|2008-12-05|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2009|Actual|2009-01-31|January 2018|2018-01-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Observational|COSBID-TBI||Observational Study of Cortical Spreading Depression in Human Brain Trauma|Spreading Depressions as Secondary Insults After Traumatic Injury to the Human Brain|Completed|||165|Actual|University of Cincinnati|||||f||||t||||||||||2018-06-01 01:31:15.263096|2018-06-01 01:31:15.263096
NCT00803023|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2011-07-21||2011-08-17|2008-12-03|2008-12-05|Estimate|2011-07-21|2011-08-16|Estimate||||2011-08-17|2011-08-19|Estimate|March 2010||2010-03-31|August 2011|2011-08-31||||July 2010|Actual|2010-07-31||Interventional|||Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia|Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia|Completed||Phase 3|129|Actual|Jazz Pharmaceuticals||4|||f||||f||||||||||2018-06-01 01:31:15.382523|2018-06-01 01:31:15.382523
NCT00803010|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2013-12-10||2015-07-10|2008-12-04|2008-12-05|Estimate|2014-04-03|2014-05-05|Estimate||||2015-07-10|2015-07-31|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Based on our preliminary data collected from patients receiving TAC/MTX, the acute GVHD (aGVHD) rate is estimated to be 80% at 100 days. A two-sided log-rank test will achieve 90% power at a 0.1 significance level. The result of this calculation serves as an approximation of power/sample size for the test we propose to use for the primary endpoint.|Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation|Phase II Trial of Tacrolimus and Rapamycin vs. Tacrolimus and Methotrexate as GVHD Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation|Completed||Phase 2|74|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 01:31:16.168278|2018-06-01 01:31:16.168278
NCT00802997|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2013-08-02||2013-11-08|2008-12-04|2008-12-05|Estimate|2013-11-08|2014-01-01|Estimate||||2013-11-08|2014-01-01|Estimate|June 2008||2008-06-30|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Trial Assessing Cooled Radiofrequency Denervation as a Treatment for Sacroiliac Joint Pain Using the Sinergy System|A Double Blind, Randomized, Controlled Trial Assessing Cooled Radiofrequency Denervation as a Treatment fr Sacroiliac Joint Pain Using the Sinergy System|Completed||N/A|51|Actual|Baylis Medical Company||2|||f||||f||||||||||2018-06-01 01:31:16.41474|2018-06-01 01:31:16.41474
NCT00802984|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2008-12-12|2008-12-04|2008-12-05|Estimate|||||||2008-12-12|2008-12-15|Estimate|January 2002||2002-01-31|December 2008|2008-12-31||||||||Interventional|||Endovascular Repair of Descending Thoracic Aortic Aneurysms|Endovascular Treatment of Thoracic Aortic Aneurysms Using the TALENT Stent Graft System|Completed||Phase 4|100||Stanford University|||||||||||||||||||2018-06-01 01:31:16.713723|2018-06-01 01:31:16.713723
NCT00802971|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2009-11-16|2008-12-03|2008-12-05|Estimate|||||||2009-11-16|2009-11-17|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Idiopathic Reactive Hypoglycaemia and Treatment With Fructo-Oligosaccharide|Prevalence of Idiopathic Reactive Hypoglycaemia and Impact of Fructo-Oligosaccharide Supplementation on Blood Glucose Variability|Completed||N/A|12|Actual|Asker & Baerum Hospital||2|||f||||f||||||||||2018-06-01 01:31:16.772194|2018-06-01 01:31:16.772194
NCT00802958|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-03-15|2008-12-04|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Observational|||Randomized Study to Compare the Bioavailability of Two Halobetasol Propionate 0.05% Topical Ointments|Bioequivalence of Two Halobetasol Propionate 0.05% Topical Ointments|Completed|||76|Actual|Perrigo Company|||3||f||||f||||||||||2018-06-01 01:31:16.837747|2018-06-01 01:31:16.837747
NCT00802945|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04||2014-08-12|2014-08-12|2008-12-04|2008-12-05|Estimate||||2014-08-12|2014-08-15|Estimate|2014-08-12|2014-08-15|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer|A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Breast Cancer Whose Disease Has Failed Prior Taxane-Based Treatment|Completed||Phase 2|70|Actual|Nektar Therapeutics||2|||f||||f||||||||||2018-06-01 01:31:16.899818|2018-06-01 01:31:16.899818
NCT00802932|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2013-01-29|2008-12-04|2008-12-05|Estimate|||||||2013-01-29|2013-01-30|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Tx|Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Treatment|Completed|||61|Actual|H. Lee Moffitt Cancer Center and Research Institute|||2||f||||f||||||||||2018-06-01 01:31:16.98922|2018-06-01 01:31:16.98922
NCT00802919|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2016-12-15||2017-10-24|2008-12-04|2008-12-05|Estimate|2017-10-24|2017-12-02|Actual||||2017-10-24|2017-12-02|Actual|September 2008||2008-09-30|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors|Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study|Completed||Phase 4|93|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-06-01 01:31:17.068107|2018-06-01 01:31:17.068107
NCT00802906|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-09-26|2008-12-04|2008-12-05|Estimate|||||||2012-09-26|2012-09-27|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)|Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy|Completed||N/A|12|Actual|Johann Wolfgang Goethe University Hospital||3|||f||||f||||||||||2018-06-01 01:31:17.396563|2018-06-01 01:31:17.396563
NCT00802893|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2017-07-20||2017-08-17|2008-12-04|2008-12-05|Estimate|2017-08-17|2017-08-21|Actual||||2017-08-17|2017-08-21|Actual|December 2008|Actual|2008-12-31|August 2017|2017-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel Study of Oral 6R-BH4 in Subjects With Isolated Systolic Hypertension and Endothelial Dysfunction|Terminated||Phase 2|3|Actual|Johns Hopkins University||2||"We were unable to recruit any subjects into this study so no subjects completed the protocol.~   Therefore, we are unable to provide any conclusions."|f||||t||||||||||2018-06-01 01:31:17.472041|2018-06-01 01:31:17.472041
NCT00802880|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2016-06-16||2016-12-20|2008-12-04|2008-12-05|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|March 2009||2009-03-31|December 2016|2016-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma|Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma|Completed||Phase 2|80|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 01:31:17.834851|2018-06-01 01:31:17.834851
NCT00802867|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2009-09-24||2016-04-12|2008-12-04|2008-12-05|Estimate|2009-12-08|2010-01-12|Estimate||||2016-04-12|2016-04-14|Estimate|February 2004||2004-02-29|April 2016|2016-04-30|September 2005|Actual|2005-09-30|June 2005|Actual|2005-06-30||Interventional|||Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™|Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T)|Completed||Phase 4|989|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 01:31:18.276192|2018-06-01 01:31:18.276192
NCT00802334|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2015-03-24|2008-12-03|2008-12-04|Estimate|||||||2015-03-24|2015-03-26|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||TDM of Generic Lopinavir/Ritonavir 200/50 mg|Therapeutic Drug Monitoring of the Generic Lopinavir/Ritonavir Tablets 200/50 mg in the Thai HIV-infected Patient|Completed||Phase 2|70|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-06-01 01:31:28.424097|2018-06-01 01:31:28.424097
NCT00802854|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2017-05-17||2017-07-05|2008-12-03|2008-12-05|Estimate|2017-07-05|2017-11-30|Actual||||2017-07-05|2017-11-30|Actual|March 2012||2012-03-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational||Safety analysis set included all participants who received at least 1 dose of Eraxis.|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV|Post Marketing Surveillance Study To Observe Safety And Effectiveness Of Eraxis (Registered) Iv.|Completed|||244|Actual|Pfizer|||||f||||f||||||||||2018-06-01 01:31:18.672779|2018-06-01 01:31:18.672779
NCT00802841|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2015-07-15||2015-10-15|2008-12-04|2008-12-05|Estimate|2015-10-15|2015-11-16|Estimate||||2015-10-15|2015-11-16|Estimate|May 2009||2009-05-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|LASOR||Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib|A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib|Completed||Phase 3|191|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:31:19.051756|2018-06-01 01:31:19.051756
NCT00802828|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2012-03-15|2008-12-04|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2004||2004-06-30|March 2012|2012-03-31||||June 2004|Actual|2004-06-30||Interventional|||Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|44|Actual|Perrigo Company||2|||f||||||||||||||2018-06-01 01:31:19.654989|2018-06-01 01:31:19.654989
NCT00802815|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2014-05-28|2008-12-04|2008-12-05|Estimate|||||||2014-05-28|2014-05-29|Estimate|April 2005||2005-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis|Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis|Completed||Early Phase 1|20|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 01:31:19.706941|2018-06-01 01:31:19.706941
NCT00802802|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2016-05-09|2008-12-04|2008-12-05|Estimate|||||||2016-05-09|2016-05-10|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children|Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-infected and HIV/TB Co-infected Infants and Children 3 Months to Less Than 36 Months of Age|Completed||Phase 1|155|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 01:31:19.770425|2018-06-01 01:31:19.770425
NCT00802789|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2016-04-07|2008-12-04|2008-12-05|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2007||2007-04-30|April 2016|2016-04-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Observational|||Montelukast in Chronic Asthma|Montelukast in Chronic Asthma: Non-interventional Study With Montelukast 10 mg|Completed|||2000|Actual|Merck Sharp & Dohme Corp.|||1||f||||||||||||||2018-06-01 01:31:19.993117|2018-06-01 01:31:19.993117
NCT00802776|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2017-03-13|2008-12-04|2008-12-05|Estimate|||||||2017-03-13|2017-03-15|Actual|October 2007||2007-10-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|December 2010|Actual|2010-12-31||Interventional|FLAK||Femtosecond Laser Assisted Keratoplasty|Comparison of Femtosecond Laser-Assisted and Traditional Keratoplasty for Keratoconus|Completed||N/A|24|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 01:31:20.054449|2018-06-01 01:31:20.054449
NCT00802763|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|February 2009||2009-02-28|December 2008|2008-12-31|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Observational|||Performance Proof of the New NORMA-SENSE|Performance Proof of the New NORMA-SENSE Panty Liner - in-Vivo STUD|Unknown status|Not yet recruiting||224|Anticipated|Carmel Medical Center|||1||f||||t||||||None Retained|"~     VAGINAL SECRETIONS~   "|||2018-06-01 01:31:20.137745|2018-06-01 01:31:20.137745
NCT00802750|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-09-27|2008-12-04|2008-12-05|Estimate|||||||2012-09-27|2012-09-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:31:20.233109|2018-06-01 01:31:20.233109
NCT00802737|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2012-05-17||2014-04-24|2008-12-04|2008-12-05|Estimate|2012-05-17|2012-06-26|Estimate||||2014-04-24|2014-05-14|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)|A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406|Completed||Phase 4|29|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:31:20.320355|2018-06-01 01:31:20.320355
NCT00802724|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-10-18|2008-12-04|2008-12-05|Estimate|||||||2012-10-18|2012-10-22|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|November 2010|Actual|2010-11-30|August 2009|Actual|2009-08-31||Interventional|||Classification-Directed Treatment of Low Back Pain|Classification-Directed Treatment of Low Back Pain|Completed||Phase 1|101|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 01:31:21.267192|2018-06-01 01:31:21.267192
NCT00802711|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2014-12-30|2008-12-04|2008-12-05|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer|Phase II Randomised Clinical Trial of Accelerated Partial Breast Irradiation (APBI) Comparing 3-Dimensional Conformal Radiation Therapy and Multi-Catheter Interstitial Brachytherapy.|Terminated||Phase 2|6|Actual|Cancer Trials Ireland||2||Slow accrual|f||||||||||||||2018-06-01 01:31:21.341653|2018-06-01 01:31:21.341653
NCT00802698|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|April 2008||2008-04-30|December 2008|2008-12-31||||April 2008|Anticipated|2008-04-30||Interventional|||The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform||Unknown status|Recruiting|Phase 1/Phase 2|5|Anticipated|Asociación para Evitar la Ceguera en México||1|||f||||||||||||||2018-06-01 01:31:21.408568|2018-06-01 01:31:21.408568
NCT00802685|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2013-06-17||2014-01-03|2008-12-04|2008-12-05|Estimate|2013-09-27|2013-11-28|Estimate||||2014-01-03|2014-02-05|Estimate|November 2007||2007-11-30|December 2013|2013-12-31|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Interventional|||Timing of PDA Closure and Respiratory Outcome in Premature Infants|Timing of PDA Closure and Respiratory Outcome in Premature Infants|Terminated||N/A|105|Actual|University of Miami||2||Lack of availability of IV ibuprofen as of 8/10 due to a manufacturer's recall|f||||t||||||||||2018-06-01 01:31:21.488426|2018-06-01 01:31:21.488426
NCT00802321|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2010-09-22|2008-12-02|2008-12-04|Estimate|||||||2010-09-22|2010-09-23|Estimate|April 2006||2006-04-30|September 2010|2010-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects|Pharmacokinetic Study of Single Dose Dutasteride in Healthy Subjects|Completed||N/A|40|Actual|UConn Health||1|||f||||f||||||||||2018-06-01 01:31:28.486786|2018-06-01 01:31:28.486786
NCT00802672|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2012-05-17||2013-01-17|2008-12-04|2008-12-05|Estimate|2012-05-17|2012-06-19|Estimate||||2013-01-17|2013-01-24|Estimate|December 2003||2003-12-31|January 2013|2013-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis|A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis|Completed||Phase 3|561|Actual|Perrigo Company||3|||f||||f||||||||||2018-06-01 01:31:21.703045|2018-06-01 01:31:21.703045
NCT00802659|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2014-11-10||2014-11-18|2008-12-04|2008-12-05|Estimate|2014-11-10|2014-11-18|Estimate||||2014-11-18|2014-12-05|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain|A Phase I/II Dose Escalation Study to Evaluate Pain Response Using Extracranial Stereotactic Radiosurgery to Treat Paraspinal Metastasis in Patients Who Have Received Prior Spinal Irradiation|Terminated||N/A|2|Actual|Washington University School of Medicine|The study was closed early due to slow accrual.|4||Terminated due to low accrual|f||||t||||||||||2018-06-01 01:31:22.012135|2018-06-01 01:31:22.012135
NCT00802646|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2009-07-02|2008-12-04|2008-12-05|Estimate|||||||2009-07-02|2009-07-03|Estimate|June 2009||2009-06-30|July 2009|2009-07-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|CSE||The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers|Randomized, Double-Blind, Placebo-Controlled Study of Effects of Combined Spinal Epidural Analgesia on Intrapartum Fever.|Withdrawn||N/A|168|Anticipated|Ochsner Health System||2||study moved to alternate site|f||||t||||||||||2018-06-01 01:31:22.32859|2018-06-01 01:31:22.32859
NCT00802633|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2013-12-21||2013-12-21|2008-12-04|2008-12-05|Estimate|2013-12-21|2014-02-11|Estimate||||2013-12-21|2014-02-11|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?|Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact Tissue-Sealing Device?|Terminated||N/A|80|Actual|Vanderbilt University|Study terminated after 80 subjects|2||Enrollment was stopped after eighty patients were enrolled.|f||||f||||||||||2018-06-01 01:31:22.400444|2018-06-01 01:31:22.400444
NCT00802620|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|June 2005||2005-06-30|December 2008|2008-12-31||||June 2005|Actual|2005-06-30||Interventional|||Amniotic Membrane Associated With Conjunctival Autograft Versus Conjunctival Autograft for Recurrent Pterygia||Unknown status|Enrolling by invitation|Phase 1|40|Actual|Federal University of São Paulo|||||f||||t||||||||||2018-06-01 01:31:22.699763|2018-06-01 01:31:22.699763
NCT00802607|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2017-06-30|2008-12-04|2008-12-05|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2, 2008||2008-12-02|October 4, 2010|2010-10-04|October 4, 2010||2010-10-04|||||Observational|||Collection of Tissue Specimens for Analysis and Establishment of Cell Cultures|Procurement of Normal and Abnormal Bone, Dermis and Adipose Tissue for Establishment of Cell Cultures and Tissue Analysis|Completed|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:31:22.75308|2018-06-01 01:31:22.75308
NCT00802594|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-04|2008-12-04|2008-12-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|August 2001||2001-08-31|December 2008|2008-12-31|November 2004|Actual|2004-11-30|August 2002|Actual|2002-08-31||Interventional|||A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis|Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis|Completed||Phase 2|30|Actual|Immtech Pharmaceuticals, Inc||1|||f||||f||||||||||2018-06-01 01:31:22.807367|2018-06-01 01:31:22.807367
NCT00802581|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2011-12-08|2008-12-04|2008-12-05|Estimate|||||||2011-12-08|2011-12-09|Estimate|May 2009||2009-05-31|May 2010|2010-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Circumferential Spread of Anesthetic and Success in Sciatic Nerve Blockade|Does Ensuring Circumferential Local Anesthetic Spread Improve the Success of Ultrasound Guided Sciatic Nerve Block at the Popliteal Fossa?|Completed||N/A|64|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:31:22.876579|2018-06-01 01:31:22.876579
NCT00802568|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2011-05-13|2008-12-04|2008-12-05|Estimate|||||||2011-05-13|2011-05-16|Estimate|April 2007||2007-04-30|December 2008|2008-12-31||||May 2011|Actual|2011-05-31||Interventional|||Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment|Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning in Treating Patients With Multiple Myeloma|Completed||Phase 2|48|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:31:22.943463|2018-06-01 01:31:22.943463
NCT00802555|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-07-11|2008-12-04|2008-12-05|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)|A Phase 1b Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)|Completed||Phase 1|21|Actual|ArQule||1|||f||||f||||||||||2018-06-01 01:31:23.008397|2018-06-01 01:31:23.008397
NCT00802542|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2010-12-02|2008-12-04|2008-12-05|Estimate|||||||2010-12-02|2010-12-03|Estimate|November 2008||2008-11-30|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||In-practice Evaluation of Atacand 16mg Antihypertensive Effect|In-practice Evaluation of Atacand 16mg Antihypertensive Effect|Completed|||400|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:31:23.086171|2018-06-01 01:31:23.086171
NCT00802529|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2016-05-09||2016-08-31|2008-12-04|2008-12-05|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease|Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial|Completed||Phase 2/Phase 3|60|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 01:31:23.220201|2018-06-01 01:31:23.220201
NCT00802516|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2017-10-11|2008-12-04|2008-12-05|Estimate|||||||2017-10-11|2017-10-12|Actual|June 2003||2003-06-30|December 2008|2008-12-31|June 2005|Actual|2005-06-30|January 2005|Actual|2005-01-31||Interventional|LTS||Long Term Effects of Plant Sterol and Stanol Esters|Effects of Long-term Daily Consumption of Plant Sterol or Stanol Esters in Statin-treated Patients|Completed||N/A|60|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 01:31:23.508304|2018-06-01 01:31:23.508304
NCT00802347|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02||2014-09-08|2014-09-08|2008-12-02|2008-12-04|Estimate||||2014-09-08|2014-09-18|Estimate|2014-09-08|2014-09-18|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation|Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation|Completed||Phase 1/Phase 2|374|Actual|Quark Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:31:28.301553|2018-06-01 01:31:28.301553
NCT00802503|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2013-01-07||2013-04-18|2008-12-04|2008-12-05|Estimate|2013-04-18|2013-04-19|Estimate||||2013-04-18|2013-04-19|Estimate|May 2008||2008-05-31|April 2013|2013-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients|Impact of Supplemental Parenteral Nutrition (SPN) on Infection Rate, Duration of Mechanical Ventilation and Rehabilitation in Intensive Care Unit Patients: A Quality Control Program for the Implementing of New Nutrition Guidelines|Completed||Phase 3|305|Actual|University Hospital, Geneva|The trial was limited by the fact that it was not double blinded by design. However, the risk of bias was reduced because the investigators worked independently from the physicians in charge of the patients.|2|||f||||f||||||||||2018-06-01 01:31:23.577602|2018-06-01 01:31:23.577602
NCT00802490|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2013-02-20|2008-12-04|2008-12-05|Estimate|||||||2013-02-20|2013-02-22|Estimate|May 2008||2008-05-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|EEG||Effectiveness of a Electroencephalogram (EEG) Biofeedback for the Treatment of ADHD|Pilot Trial of a Brain-computer Interface System Based Programme for the Treatment of ADHD|Completed||N/A|20|Anticipated|National Healthcare Group, Singapore||2|||f||||t||||||||||2018-06-01 01:31:23.865825|2018-06-01 01:31:23.865825
NCT00802477|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2011-07-29|2008-12-04|2008-12-05|Estimate|||||||2011-07-29|2011-08-01|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|||Application Of Autologous Blood Products During Modified Radical Mastectomy|Prospective Randomized Study Comparing Mastectomy Outcomes With Versus Without the Application of Autologous Blood Products to the Surgical Site|Unknown status|Recruiting|Phase 3|100|Anticipated|Marshall University||2|||f||||t||||||||||2018-06-01 01:31:23.965249|2018-06-01 01:31:23.965249
NCT00802464|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2017-08-10|2009-11-10|2017-11-10|2008-12-04|2008-12-05|Estimate|2017-11-10|2017-12-12|Actual|2009-11-12|2009-11-16|Estimate|2017-11-10|2017-12-12|Actual|January 12, 2009|Actual|2009-01-12|November 2017|2017-11-30|July 2, 2010|Actual|2010-07-02|July 2, 2010|Actual|2010-07-02||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years|Immunogenicity and Safety Study of Different Formulations of GSK Biologicals' Herpes Zoster Vaccine 1437173A When Administered Twice in Adults Aged 50 Years and Older|Completed||Phase 2|410|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:31:24.09142|2018-06-01 01:31:24.09142
NCT00802451|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|||2012-03-15|2008-12-04|2008-12-05|Estimate|||||||2012-03-15|2012-03-16|Estimate|February 2003||2003-02-28|March 2012|2012-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Bioavailability Study of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations|A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations|Completed||N/A|48|Actual|Perrigo Company||2|||f||||f||||||||||2018-06-01 01:31:26.326112|2018-06-01 01:31:26.326112
NCT00802438|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-04|2017-10-16||2017-11-13|2008-12-04|2008-12-05|Estimate|2017-11-13|2017-12-12|Actual||||2017-11-13|2017-12-12|Actual|June 2008||2008-06-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2013|Actual|2013-03-31||Interventional|||Eosinophilic Airway Inflammation and Mepolizumab|Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab|Active, not recruiting||N/A|38|Actual|University of Wisconsin, Madison|Our small sample size limits any meaningful consideration about the mechanisms of mepolizumab’s clinical action. The prolonged time commitment and inclusion of four bronchoscopies affected subject retention and limited the sample size.|1|||f||||t||||||||Undecided||2018-06-01 01:31:26.377719|2018-06-01 01:31:26.377719
NCT00802425|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03||2013-01-29|2014-06-24|2008-12-03|2008-12-04|Estimate||||2013-01-29|2013-01-31|Estimate|2014-06-24|2014-06-26|Estimate|December 2008||2008-12-31|June 2014|2014-06-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss|Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study|Completed||Phase 2|210|Actual|Auris Medical, Inc.||3|||f||||t||||||||||2018-06-01 01:31:26.619163|2018-06-01 01:31:26.619163
NCT00802412|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2016-09-27||2016-12-06|2008-12-03|2008-12-04|Estimate|2016-12-06|2017-01-31|Estimate||||2016-12-06|2017-01-31|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional|||Topiramate to Aid Smoking Cessation in Alcohol Dependent Men|Topiramate to Aid Smoking Cessation in Recovering Alcohol Dependent Men|Completed||Phase 2|132|Actual|VA Office of Research and Development|Dually-dependent male smokers with high rates of SUDs and psychiatric disorders, thus not generalizable to other populations; topiramate dose lower than the dose found to reduce smoking in active alcoholics; attrition may have impacted results.|2|||f||||t||||||||||2018-06-01 01:31:26.712369|2018-06-01 01:31:26.712369
NCT00802399|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2009-01-21|2008-12-03|2008-12-04|Estimate|||||||2009-01-21|2009-01-22|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|PLPO||Partial Lacrimal Punctual Occlusion|Partial Lacrimal Punctual Occlusion in the Management of Dry Eye|Completed||N/A|37|Actual|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-06-01 01:31:27.017234|2018-06-01 01:31:27.017234
NCT00802386|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2015-07-30|2008-12-03|2008-12-04|Estimate|||||||2015-07-30|2015-07-31|Estimate|January 2008||2008-01-31|July 2015|2015-07-31|May 2011|Actual|2011-05-31|March 2009|Actual|2009-03-31||Observational|||Bacterial Vaginosis Screening at IUD Insertion|Screening for Bacterial Vaginosis Screening at IUD Insertion: Is There a Role?|Completed|||70|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||Samples With DNA|"~     WHOLE BLOOD; VAGINAL SWAB~   "|||2018-06-01 01:31:27.095949|2018-06-01 01:31:27.095949
NCT00802373|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2014-09-17|2008-12-02|2008-12-04|Estimate|||||||2014-09-17|2014-09-18|Estimate|July 2003||2003-07-31|September 2014|2014-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|STAR||Solifenacin Succinate Versus Tolterodine 4mg Once Daily|Solifenacin in a Flexible Dose Regimen With Tolterodine as an Active Comparator in a Double-blind, Double-dummy, Randomised Overactive Bladder Symptom Trial|Completed||Phase 3|1355|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:31:27.194163|2018-06-01 01:31:27.194163
NCT00802360|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2011-05-03||2011-10-31|2008-12-03|2008-12-04|Estimate|2011-07-26|2011-08-30|Estimate||||2011-10-31|2011-11-02|Estimate|December 2008||2008-12-31|October 2011|2011-10-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||MENOPUR® Versus FOLLISTIM®|A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR® Versus FOLLISTIM® in GnRH Antagonist Cycles|Completed||Phase 4|173|Actual|Ferring Pharmaceuticals|This was an exploratory study that could be used as the basis for larger, adequately-powered studies. This limitation is the reason no statistical analyses are offered for study outcomes.|4|||f||||f||||||||||2018-06-01 01:31:27.521524|2018-06-01 01:31:27.521524
NCT00801749|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-05|2008-12-02|2008-12-03|Estimate|||||||2008-12-05|2008-12-08|Estimate|March 2005||2005-03-31|December 2008|2008-12-31|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Sleep and Daytime Activity in Healthy Subjects||Completed||N/A|||Nagoya University|||||f||||||||||||||2018-06-01 01:31:36.158859|2018-06-01 01:31:36.158859
NCT00802308|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-09-12|2008-12-03|2008-12-04|Estimate|||||||2016-09-12|2016-09-14|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effects of a Single Dose of Egalet® Morphine Combined With a Single Dose of Alcohol in Healthy Moderate Drinkers|A Randomized, Partially Blind, Four-way Crossover Study to Determine the Effects of a Single Dose of Egalet® Morphine Combined With a Single Dose of Alcohol in Healthy Male and Female Moderate Drinkers|Completed||Phase 1|24|Actual|Egalet Ltd||4|||f||||f||||||||||2018-06-01 01:31:28.548995|2018-06-01 01:31:28.548995
NCT00802295|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2009-09-17|2008-12-03|2008-12-04|Estimate|||||||2009-09-17|2009-09-18|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Aneuploidies and Different Stimulation Protocols|Influence of Ovarian Stimulation and Embryo Aneuploidy|Completed||N/A|30|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 01:31:28.608662|2018-06-01 01:31:28.608662
NCT00802282|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2016-02-23|2008-12-03|2008-12-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Psilocybin and Spiritual Practice|Effects of Psilocybin and Spiritual Practice on Persisting Changes in Attitudes and Behavior|Completed||Phase 1|75|Actual|Johns Hopkins University||5|||f||||t||||||||||2018-06-01 01:31:28.781591|2018-06-01 01:31:28.781591
NCT00802269|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate|March 2008||2008-03-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.|Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.|Completed||Phase 4|25|Actual|Asociación para Evitar la Ceguera en México||2|||f||||f||||||||||2018-06-01 01:31:28.862794|2018-06-01 01:31:28.862794
NCT00802256|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2009-04-09|2008-12-03|2008-12-04|Estimate|||||||2009-04-09|2009-04-10|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Comparative Evaluation of Pulpotomized Primary Molars With Mineral Trioxide Aggregate and New Endodonthic Cement|Comparative Evaluation of Pulpotomized Primary Molars With Mineralized Trioxide Aggregate & New Endodonthic Cement|Unknown status|Recruiting|Phase 3|80|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:31:28.935354|2018-06-01 01:31:28.935354
NCT00802243|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate|September 2007||2007-09-30|December 2008|2008-12-31||||||||Interventional|ARABUL||Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid|Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study|Unknown status|Recruiting|Phase 2|54|Anticipated|University Hospital, Limoges|||||f||||t||||||||||2018-06-01 01:31:29.033095|2018-06-01 01:31:29.033095
NCT00802230|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate|September 2002||2002-09-30|December 2008|2008-12-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|SELECT||Pharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure|Beta-Receptor SELECTivity of Carvedilol and Metoprolol Succinnate in Patients With Heart Failure: A Randomized Dose Ranging Trial (SELECT Trial)|Completed||Phase 4|25|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 01:31:29.112675|2018-06-01 01:31:29.112675
NCT00802217|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2011-06-08|2008-12-03|2008-12-04|Estimate|||||||2011-06-08|2011-06-10|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Oral Civamide Safety, Tolerability First in Human Study|A Phase 1 Open-Label, Single-Dose, Dose Escalation Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of Orally Administered Civamide (Zucapsaicin)|Terminated||Phase 1|12|Anticipated|Winston Laboratories||2||PK results demonstrated no systemic absorption|f||||t||||||||||2018-06-01 01:31:29.178222|2018-06-01 01:31:29.178222
NCT00802204|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2016-07-14||2017-03-29|2008-12-03|2008-12-04|Estimate|2017-03-29|2017-05-10|Actual||||2017-03-29|2017-05-10|Actual|December 2008||2008-12-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|April 2011|Actual|2011-04-30||Interventional|||Dopamine and Insulin Resistance|Dopamine Receptor Availability and Insulin Resistance|Completed||N/A|28|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 01:31:29.24957|2018-06-01 01:31:29.24957
NCT00802191|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2014-08-29|2008-12-02|2008-12-04|Estimate|||||||2014-08-29|2014-09-01|Estimate|August 2007||2007-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|May 2013|Actual|2013-05-31||Observational|||WiiMote Game Controller as a Device to Study Movement Disorders|WiiMote Game Controller as a Device to Study Movement Disorders|Terminated|||250|Actual|Vanderbilt University|||2|Lack of study participants, no data published.|f||||f||||||||||2018-06-01 01:31:29.618894|2018-06-01 01:31:29.618894
NCT00802178|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2009-09-30||2014-03-14|2008-12-03|2008-12-04|Estimate|2009-11-19|2009-11-20|Estimate||||2014-03-14|2014-04-11|Estimate|February 2006||2006-02-28|March 2014|2014-03-31||||September 2007|Actual|2007-09-30||Observational||Treated set (TS)|First Presentation of Parkinson Disease Patients to Neurologist|CEE PMSS (Central Eastern European Post-Marketing Surveillance Study) First Presentation of Mirapexin in Parkinson Patients|Completed|||2448|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:31:29.689901|2018-06-01 01:31:29.689901
NCT00802165|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Effect of Electroacupuncture on Pain Threshold|Effect of Electroacupuncture on Pain Threshold|Unknown status|Recruiting|Phase 1|40|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 01:31:31.788829|2018-06-01 01:31:31.788829
NCT00802152|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2017-06-13|2008-12-03|2008-12-04|Estimate|||||||2017-06-13|2017-06-15|Actual|May 2009||2009-05-31|June 2017|2017-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Using Health Information Technology (HIT) to Improve Ambulatory Chronic Disease Care: Smart Device Substudy|Using Health Information Technology (HIT) to Improve Ambulatory Chronic Disease Care: Smart Device Substudy|Completed||N/A|108|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 01:31:31.856311|2018-06-01 01:31:31.856311
NCT00802139|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2012-03-28|2008-12-03|2008-12-04|Estimate|||||||2012-03-28|2012-03-30|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|October 2010|Actual|2010-10-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy and Safety Study of Iron Sucrose and Oral Iron Acetyl-transferrin Hydroglycerin|A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia|Completed||Phase 4|58|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-06-01 01:31:32.024741|2018-06-01 01:31:32.024741
NCT00802126|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-02-05|2008-12-03|2008-12-04|Estimate|||||||2016-02-05|2016-02-08|Estimate|November 2007||2007-11-30|February 2016|2016-02-29|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy|Efficacy of Combining Intravitreal Bevacizumab With Photodynamic Therapy Using Reduced Light Fluence Rate in Choroidal Neovascularization Secondary to Pathologic Myopia.|Completed||Phase 1|16|Actual|"University of Campania Luigi Vanvitelli"||1|||f||||t||||||||||2018-06-01 01:31:32.115188|2018-06-01 01:31:32.115188
NCT00802113|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2015-04-22|2008-12-03|2008-12-04|Estimate|||||||2015-04-22|2015-04-23|Estimate|June 2003||2003-06-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Autologous and Allogeneic Transplant for Relapsed Lymphoma|Sequential Myeloablative Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease|Completed||Phase 1/Phase 2|31|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 01:31:32.185864|2018-06-01 01:31:32.185864
NCT00802100|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2012-11-19||2013-01-03|2008-12-03|2008-12-04|Estimate|2013-01-03|2013-02-08|Estimate||||2013-01-03|2013-02-08|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|COATS||Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia|Comparison of Optimal Antipsychotic Treatments for Schizophrenia Pilot Study|Completed||Phase 4|21|Actual|National Institute of Mental Health (NIMH)|It was determined in this pilot study that the existing procedures and eligibility criteria could not be adequately implemented and that a larger-scale study was not feasible.|3|||f||||t||||||||||2018-06-01 01:31:32.296137|2018-06-01 01:31:32.296137
NCT00802087|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-08-26|2008-12-03|2008-12-04|Estimate|||||||2016-08-26|2016-08-29|Estimate|November 2008||2008-11-30|August 2016|2016-08-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Single Dose Pharmacokinetics of Egalet® Hydrocodone|A Single-Centre, Single Dose, Randomized,Open Label, Exploratory, 5-way Crossover Study Evaluating the Pharmakokinetic Profiles of Various Egalet® Hydrocodone Formulations In Healthy Volunteers Under Fasting Conditions.|Completed||Phase 1|28|Actual|Egalet Ltd||5|||f||||f||||||||||2018-06-01 01:31:32.636353|2018-06-01 01:31:32.636353
NCT00802074|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2015-03-23||2016-01-27|2008-12-03|2008-12-04|Estimate|2016-01-27|2016-01-29|Estimate||||2016-01-27|2016-01-29|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects|A Randomized, Open-Label, Six-Period, Drug Interaction Study to Assess Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics Following Administration of RTG 400 mg BID for 14 Days Alone and in Combination With 14 Days of Either Fosamprenavir (FPV) 1400 mg BID, FPV 700 mg BID + RTV 100 mg BID or FPV 1400 mg + RTV 100 mg QD in Healthy Adult Subjects When Under Fasting Conditions|Completed||N/A|45|Actual|Garden State Infectious Disease Associates, PA|Data for Primary outcome measure assessments are not available per intervention. Values reported as means are of uncertain measure type (data are no longer available).|6|||f||||f||||||||||2018-06-01 01:31:32.731699|2018-06-01 01:31:32.731699
NCT00802061|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate||||December 2008|2008-12-31||||||||Interventional|||Sleep at 30 Degrees in Glaucoma||Completed||N/A|||University Health Network, Toronto|||||f||||t||||||||||2018-06-01 01:31:33.238559|2018-06-01 01:31:33.238559
NCT00802048|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2011-12-12|2008-12-03|2008-12-04|Estimate|||||||2011-12-12|2011-12-13|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|CARDIODOLAL||Local Anesthetic Infusion and Sternotomy|Study of Effectiveness of a Ropivacaïne Continuous Sternal Infusion to Reduce Postoperative Hyperalgesia Induced by Sternotomy After Cardiac Surgery|Terminated||Phase 3|21|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:31:33.290187|2018-06-01 01:31:33.290187
NCT00802035|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2011-08-22|2008-12-03|2008-12-04|Estimate|||||||2011-08-22|2011-08-23|Estimate|November 2008||2008-11-30|August 2011|2011-08-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||ALK29-002: A Study of Baclofen Formulations in Healthy Adults|A Phase 1, Single-Center, Open-Label Study of the Pharmacokinetics of Baclofen Formulations Administered to Healthy Adults|Completed||Phase 1|16|Actual|Alkermes, Inc.||4|||f||||f||||||||||2018-06-01 01:31:33.458353|2018-06-01 01:31:33.458353
NCT00802022|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2010-07-07|2008-12-03|2008-12-04|Estimate|||||||2010-07-07|2010-07-08|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SCS||Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy|Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy (PDP Study) A Pilot Study|Completed||N/A|15|Actual|Maastricht University Medical Center|||||f||||t||||||||||2018-06-01 01:31:33.536494|2018-06-01 01:31:33.536494
NCT00802009|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2010-01-22|2008-12-03|2008-12-04|Estimate|||||||2010-01-22|2010-01-26|Estimate|May 2009||2009-05-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade|Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade|Completed||N/A|44|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:31:33.609671|2018-06-01 01:31:33.609671
NCT00801996|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2016-05-11|2008-12-02|2008-12-04|Estimate|||||||2016-05-11|2016-05-13|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|September 2009|Anticipated|2009-09-30|September 2008|Anticipated|2008-09-30||Observational|ProstateCA||Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab Countries|Epidemiologic, Clinical and Genetic Profile of Prostate Cancer in Arab Countries|Withdrawn|||0|Actual|Weill Medical College of Cornell University|||2|Closed by Investigator|f||||f||||||Samples With DNA|"~     Blood and tissue will be collected from individuals with prostate cancer. Only blood will be~     collected from normal controls.~   "|Undecided||2018-06-01 01:31:33.686985|2018-06-01 01:31:33.686985
NCT00801983|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2014-05-19||2014-08-06|2008-12-03|2008-12-04|Estimate|2014-08-06|2014-08-22|Estimate||||2014-08-06|2014-08-22|Estimate|January 2009||2009-01-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|April 2011|Actual|2011-04-30||Interventional||GEE analyses allows a subjects inclusion even if they did not complete the full trial. Although we had a total of 15 subjects not complete the full trial we had sufficient data on 77 subjects to complete the GEE statistical analyses. With the crossover design we compared 77 subjects using the standard keyboard to 77 subjects using the alternative|The Effect of Alternative Keyboards on Discomfort and Typing Kinematics|The Effect of Alternative Keyboards on Discomfort and Typing Kinematics|Completed||N/A|85|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:31:33.763262|2018-06-01 01:31:33.763262
NCT00801970|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|January 2011|Anticipated|2011-01-31|June 2010|Anticipated|2010-06-30||Interventional|||Fear of Childbirth (Tokophobia) - Etiology, Essence and Clinical Implications|Fear of Childbirth (Tokophobia) - Etiology, Essence and Clinical Implications|Unknown status|Recruiting|N/A|150|Anticipated|Tel-Aviv Sourasky Medical Center||4|||f||||t||||||||||2018-06-01 01:31:34.129872|2018-06-01 01:31:34.129872
NCT00801957|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2014-09-17|2008-12-03|2008-12-04|Estimate|||||||2014-09-17|2014-09-18|Estimate|March 2003||2003-03-31|September 2014|2014-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis|A Double Blind, Multicentre, Randomised, Parallel Group Study to Demonstrate the Equivalence of the Response to Vaccination of a Tacrolimus Ointment Regimen to a Steroid Ointment Regimen in Children With Moderate to Severe Atopic Dermatitis|Completed||Phase 2|260|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 01:31:34.23602|2018-06-01 01:31:34.23602
NCT00801944|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2014-09-17|2008-12-02|2008-12-04|Estimate|||||||2014-09-17|2014-09-18|Estimate|April 2004||2004-04-30|September 2014|2014-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|SUNRISE||Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms|Solifenacin in the Treatment of Urgency Symptoms of Overactive Bladder in a Rising Dose, Randomized, Placebo-controlled, Double-blind Trial|Completed||Phase 3|973|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:31:34.371782|2018-06-01 01:31:34.371782
NCT00801931|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2013-07-17|2008-12-03|2008-12-04|Estimate|||||||2013-07-17|2013-07-19|Estimate|September 2007||2007-09-30|July 2013|2013-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Double Cord Blood Transplantation|Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders|Terminated||Phase 1/Phase 2|1|Actual|Columbia University||6||Poor accrual|f||||t||||||||||2018-06-01 01:31:34.57396|2018-06-01 01:31:34.57396
NCT00801918|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2013-05-14|2008-12-03|2008-12-04|Estimate|||||||2013-05-14|2013-05-15|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Denileukine Diftitox for Relapsed ALCL|A Phase II Pilot Multicenter Study of Denileukin Diftitox Alone and in Combination With ICE (ICED) Chemotherapy in Children, Adolescents and Young Adults (CAYA) With Relapsed or Refractory Anaplastic Large Cell Lymphoma|Withdrawn||Phase 2|0|Actual|Columbia University||2||Lack of funding|f||||t||||||||||2018-06-01 01:31:34.669659|2018-06-01 01:31:34.669659
NCT00801905|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|March 2009|Anticipated|2009-03-31|December 2008|Anticipated|2008-12-31||Interventional|NEPAF||Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation|Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation|Unknown status|Recruiting|Phase 2|50|Anticipated|Asociación para Evitar la Ceguera en México||2|||f||||f||||||||||2018-06-01 01:31:34.747904|2018-06-01 01:31:34.747904
NCT00801892|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|2014-02-11||2017-11-06|2008-12-03|2008-12-04|Estimate|2014-02-11|2014-03-27|Estimate||||2017-11-06|2017-11-08|Actual|April 2009||2009-04-30|November 2017|2017-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|OSA_DM|Sample primarily middle aged adults with type 2 diabetes|Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management|OSA, Sleepiness, and Activity in Diabetes Management|Completed||Phase 3|23|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:31:34.846564|2018-06-01 01:31:34.846564
NCT00801879|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2014-10-28|2008-12-03|2008-12-04|Estimate|||||||2014-10-28|2014-10-29|Estimate|September 2003||2003-09-30|October 2014|2014-10-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection|Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection|Completed||Phase 4|100|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 01:31:35.222759|2018-06-01 01:31:35.222759
NCT00801866|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate||||December 2008|2008-12-31||||||||Interventional|||Avastin for Post-Photocoagulation Macular Edema|Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab.|Completed||Phase 4|||Asociación para Evitar la Ceguera en México||2|||f||||t||||||||||2018-06-01 01:31:35.307999|2018-06-01 01:31:35.307999
NCT00801853|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2011-01-25|2008-12-03|2008-12-04|Estimate|||||||2011-01-25|2011-01-27|Estimate|March 2009||2009-03-31|November 2009|2009-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL|A Phase IIb Study to Investigate the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients Not Fully Controlled on Current Therapy|Completed||Phase 2|424|Anticipated|Aerovance, Inc.||4|||f||||f||||||||||2018-06-01 01:31:35.397236|2018-06-01 01:31:35.397236
NCT00801827|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2016-08-22||2017-01-27|2008-12-03|2008-12-04|Estimate|2017-01-27|2017-03-17|Actual||||2017-01-27|2017-03-17|Actual|January 2007||2007-01-31|January 2017|2017-01-31|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional|||PET Imaging and Bariatric Surgery|PET Imaging and Bariatric Surgery|Completed||Phase 1|7|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 01:31:35.564824|2018-06-01 01:31:35.564824
NCT00801814|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2008-12-03|2008-12-03|2008-12-04|Estimate|||||||2008-12-03|2008-12-04|Estimate|April 2006||2006-04-30|December 2008|2008-12-31|August 2006|Actual|2006-08-31|May 2006|Actual|2006-05-31||Interventional|||Effect of Escalating Doses of a Novel Viscous Polysaccharide on Postprandial Glycemia|Effect of Adding Escalating Doses of a Novel Highly Viscous Polysaccharide to Either a Liquid or a Solid Test Meal on Post Prandial Glycemia in Healthy Subjects: Determination of the Glycemic Reduction Index Potential (GRIP)|Completed||Phase 2/Phase 3|20|Actual|Glycemic Index Laboratories, Inc||6|||f||||f||||||||||2018-06-01 01:31:35.729785|2018-06-01 01:31:35.729785
NCT00801801|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2012-06-08||2017-04-07|2008-12-02|2008-12-04|Estimate|2013-06-14|2013-06-19|Estimate||||2017-04-07|2017-05-17|Actual|January 2008||2008-01-31|April 2017|2017-04-30|March 2011|Actual|2011-03-31|October 2009|Actual|2009-10-31||Interventional||Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.|Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC|Pilot Phase IIa Study of Metronomic Chemotherapy With Taxotere (Docetaxel) Plus Nexavar (Sorafenib) as First-Line Therapy in Performance Status-2 Patients With Advanced Non-Squamous Cell Non-Small Cell Lung Cancer|Terminated||Phase 2|5|Actual|University of Alabama at Birmingham|The study initially sought to accrue a maximum sample size of 43 subjects. However, due to subjects' measured response and levels of clinical benefit in addition to a cut in funding, the study was stopped early and terminated.|1||Sponsors withdrew funding; preliminary efficacy data was not encouraging.|f||||t||||||||||2018-06-01 01:31:35.809971|2018-06-01 01:31:35.809971
NCT00801788|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-08-26|2008-12-03|2008-12-04|Estimate|||||||2016-08-26|2016-08-29|Estimate|September 2008||2008-09-30|August 2016|2016-08-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||Single Dose Pharmacokinetics of Egalet® Oxycodone||Completed||Phase 1|16|Actual|Egalet Ltd||4|||f||||f||||||||||2018-06-01 01:31:35.975165|2018-06-01 01:31:35.975165
NCT00801775|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-03|||2011-06-10|2008-12-03|2008-12-04|Estimate|||||||2011-06-10|2011-06-13|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Improved Diagnosis of Peritoneal Dialysis Peritonitis by Calorimetry|Improved Diagnosis of Peritoneal Dialysis Peritonitis by Calorimetry|Terminated|||8|Actual|University Hospital, Basel, Switzerland||||The study was stopped march 2009 due to recruitment problems.|f||||f||||||||||2018-06-01 01:31:36.048897|2018-06-01 01:31:36.048897
NCT00801762|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|September 2008||2008-09-30|December 2008|2008-12-31|June 2009||2009-06-30|||||Observational|||Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology|Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology|Unknown status|Recruiting||30||Stanford University|||||f||||||||||||||2018-06-01 01:31:36.105011|2018-06-01 01:31:36.105011
NCT00801736|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2013-12-09|2008-12-02|2008-12-03|Estimate|||||||2013-12-09|2013-12-10|Estimate|October 2009||2009-10-31|December 2012|2012-12-31||||July 2013|Actual|2013-07-31||Interventional|ET||ERCC1 Targeted Trial|A Multicentre, Randomised, Phase III Trial of Platinum-based Chemotherapy Versus Non-platinum Chemotherapy, After ERCC1 Stratification, in Patients With Advanced/Metastatic Non-small Cell Lung Cancer|Terminated||Phase 3|648|Actual|University College, London||2||The antibody used did not appear prognostic/predictive based on interim results.|f||||t||||||||||2018-06-01 01:31:36.209748|2018-06-01 01:31:36.209748
NCT00801723|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02||2011-12-01|2014-04-08|2008-12-02|2008-12-03|Estimate||||2012-02-17|2012-02-23|Estimate|2014-04-08|2014-05-02|Estimate|December 2008||2008-12-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.|Randomised, Double-Blind, Multi-Centre, 12 Month Extension Study to Evaluate the Safety And Efficacy of Daily Budesonide MMX 6 mg Versus Placebo in the Maintenance of Remission in Subjects With Ulcerative Colitis.|Completed||Phase 3|123|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 01:31:36.307058|2018-06-01 01:31:36.307058
NCT00801710|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2009-12-02|2008-12-02|2008-12-03|Estimate|||||||2009-12-02|2009-12-04|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study|CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study|Completed||N/A|42|Actual|BridgePoint Medical||1|||f||||f||||||||||2018-06-01 01:31:36.448836|2018-06-01 01:31:36.448836
NCT00801697|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-06-20|2008-12-02|2008-12-03|Estimate|||||||2016-06-20|2016-06-21|Estimate|February 2009||2009-02-28|June 2016|2016-06-30|April 2015|Actual|2015-04-30|February 2011|Actual|2011-02-28||Interventional|||Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector|A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Subtype 35 (rAd35) and Subtype 5 (rAd5) HIV-1 Vaccines When Given as a Heterologous Prime-boost Regimen or as Boosts to a Recombinant DNA Vaccine in Healthy, Ad5-Naïve and Ad5-Exposed, Low Risk, HIV-1 Uninfected Adult Participants|Completed||Phase 1|192|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||||||||||||2018-06-01 01:31:36.510147|2018-06-01 01:31:36.510147
NCT00801684|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2011-03-18||2011-08-17|2008-12-02|2008-12-03|Estimate|2011-05-09|2011-05-10|Estimate||||2011-08-17|2011-08-19|Estimate|February 2009||2009-02-28|May 2011|2011-05-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD|Efficacy, Safety, Tolerability, and Pharmacokinetics of Trospium Inhalation Powder (TrIP) Administered to Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|24|Actual|Alkermes, Inc.||5|||f||||f||||||||||2018-06-01 01:31:36.691806|2018-06-01 01:31:36.691806
NCT00801671|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2011-06-15|2008-12-02|2008-12-03|Estimate|||||||2011-06-15|2011-06-17|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Russian Study of the Effect of Continuous Positive Airway Pressure (CPAP) in Hypertension|Study of Independent Role of Continuous Positive Airway Pressure Therapy on Systemic Arterial Pressure in Patients With Sleep Apnea Syndrome and Arterial Hypertension|Completed||Phase 3|50|Actual|Russian Cardiology Research and Production Center||2|||f||||f||||||||||2018-06-01 01:31:36.983545|2018-06-01 01:31:36.983545
NCT00801658|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-03|2008-12-02|2008-12-03|Estimate|||||||2008-12-03|2008-12-04|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|July 2009||2009-07-31|||||Interventional|||Efficacy of SLT in Patients With Insufficient IOP Control Under Maximum Tolerated Drug Therapy (Eye Drops)||Completed||Phase 4|30|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 01:31:37.062145|2018-06-01 01:31:37.062145
NCT00801645|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-01-04|2008-12-02|2008-12-03|Estimate|||||||2012-01-04|2012-01-05|Estimate|August 2004||2004-08-31|January 2012|2012-01-31|June 2010|Actual|2010-06-30|October 2008|Actual|2008-10-31||Interventional|||Effects of Exercise on Arterial Function and Insulin Resistance Syndrome in Pre-pubertal Obese Children|Effects of Aerobic Exercise Training on Arterial Function and Insulin Resistance Syndrome in Obese Children: A Randomized Controlled Trial|Completed||N/A|67|Actual|University Hospital, Geneva||4|||f||||f||||||||||2018-06-01 01:31:37.138256|2018-06-01 01:31:37.138256
NCT00801632|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2015-04-21||2015-11-06|2008-12-02|2008-12-03|Estimate|2015-04-21|2015-05-12|Estimate||||2015-11-06|2015-11-10|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional||Intent-to-treat|Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection|Renal Allograft Tolerance Through Mixed Chimerism|Completed||Phase 2|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 01:31:37.245525|2018-06-01 01:31:37.245525
NCT00801619|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-03-14|2008-12-02|2008-12-03|Estimate|||||||2016-03-14|2016-03-16|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Bilicurves: Using Information Technology to Improve the Management of Neonatal Hyperbilirubinemia|Bilicurves: Using Information Technology to Integrate Clinical Practice Guidelines Into the Management of Neonatal Hyperbilirubinemia|Completed|||273|Actual|Massachusetts General Hospital|||2||f||||t||||||||||2018-06-01 01:31:37.581809|2018-06-01 01:31:37.581809
NCT00801606|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-02-08|2008-12-02|2008-12-03|Estimate|||||||2016-02-08|2016-02-10|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|ICTBSG||Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis|Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients|Completed||Phase 3|403|Actual|All India Institute of Medical Sciences, New Delhi||4|||f||||t||||||||No||2018-06-01 01:31:37.642157|2018-06-01 01:31:37.642157
NCT00801593|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|May 2008||2008-05-31|December 2008|2008-12-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Observational|||Magnetic Resonance Imaging Follow-up on Temporomandibular Arthritis in Children With Juvenile Idiopathic Arthritis|Arthritis of the Temporomandibular Joints in Children With Juvenile Idiopathic Arthritis- Pilot Study on Diagnostic Value of Ultrasonography and Magnetic Resonance Imaging and Influence of Drug Treatment|Unknown status|Recruiting||50|Anticipated|University Hospital Tuebingen|||1||f||||f||||||||||2018-06-01 01:31:37.725331|2018-06-01 01:31:37.725331
NCT00801580|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2009-09-14|2008-12-02|2008-12-03|Estimate|||||||2009-09-14|2009-09-15|Estimate|March 2008||2008-03-31|September 2009|2009-09-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia|Open Label, Non-randomized, Phase II Study on Fractioned Cyclophosphamide, Vincristine, Liposomal Doxorubicin or Doxorubicin, and Dexamethasone (MY HYPER-CVAD) in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia|Unknown status|Recruiting|Phase 2|3|Anticipated|University of Bologna||1|||f||||||||||||||2018-06-01 01:31:37.796068|2018-06-01 01:31:37.796068
NCT00801567|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-03-09|2008-12-02|2008-12-03|Estimate|||||||2012-03-09|2012-03-12|Estimate|June 2010||2010-06-30|March 2012|2012-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation|A Magnetic Resonance Spectroscopy Study of Change in Brain Bioenergetics in Bipolar Disorder in Response to Photic Stimulation|Withdrawn||N/A|0|Actual|Mclean Hospital||1||Departure of essential Co-Investigator from McLean Hospital|f||||f||||||||||2018-06-01 01:31:37.891052|2018-06-01 01:31:37.891052
NCT00801554|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2013-10-21|2008-12-02|2008-12-03|Estimate|||||||2013-10-21|2013-10-22|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Autism Spectrum Disorders (ASD) Characterization Study|A Characterization Study of Individuals With Autism Spectrum Disorders|Completed|||26|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 01:31:37.950751|2018-06-01 01:31:37.950751
NCT00801541|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2015-03-18|2008-12-02|2008-12-03|Estimate|||||||2015-03-18|2015-03-19|Estimate|December 2005||2005-12-31|April 2014|2014-04-30|June 2014|Actual|2014-06-30|December 2008|Actual|2008-12-31||Observational|CNV-Markers||Characterization of Early Markers of Choroidal Neovascularization|Characterization of Early Markers of Choroidal Neovascularization in Fellow Eyes of Patients With AMD and CNV in One Eye. (CNV-Markers)|Completed|||60|Actual|Association for Innovation and Biomedical Research on Light and Image|||1||f||||t||||||||||2018-06-01 01:31:38.003714|2018-06-01 01:31:38.003714
NCT00801528|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2010-05-02|2008-12-02|2008-12-03|Estimate|||||||2010-05-02|2010-05-04|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Diclofenac vs. Ropivacaine for Cesarean Section|The Analgesic Efficacy of Continuous Wound Instillation With Diclofenac or Ropivacaine Following Cesarean Section: a Randomized, Double-blind, Placebo Controlled Study|Completed||Phase 4|75|Anticipated|Meir Medical Center||3|||f||||t||||||||||2018-06-01 01:31:38.071148|2018-06-01 01:31:38.071148
NCT00801515|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2011-07-21|2008-12-02|2008-12-03|Estimate|||||||2011-07-21|2011-07-25|Estimate|August 2009||2009-08-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Expanded Access|||A Compassionate Access Protocol For Those Patients Who Have Completed A4001029|A Compassionate Access Protocol For Those Patients Who Have Completed A4001029|No longer available|||||ViiV Healthcare|||||f||||f||||||||||2018-06-01 01:31:38.130731|2018-06-01 01:31:38.130731
NCT00801502|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2014-11-27|2008-12-02|2008-12-03|Estimate|||||||2014-11-27|2014-12-02|Estimate|May 2007||2007-05-31|December 2008|2008-12-31|March 2012|Actual|2012-03-31|August 2009|Actual|2009-08-31||Interventional|SiPS||Salmon in Pregnancy Study|The Effects of Oily Fish in Pregnancy on Markers and Manifestations of Allergic Diseases in Infants at Risk of Atopy|Completed||N/A|124|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 01:31:38.184686|2018-06-01 01:31:38.184686
NCT00801489|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2018-05-07|2008-12-02|2008-12-03|Estimate|||||||2018-05-07|2018-05-11|Actual|April 2007|Actual|2007-04-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias|A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia|Recruiting||Phase 2|200|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-06-01 01:31:38.291702|2018-06-01 01:31:38.291702
NCT00801476|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2009-11-17|2008-12-02|2008-12-03|Estimate|||||||2009-11-17|2009-11-18|Estimate|April 2008||2008-04-30|November 2009|2009-11-30|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Interventional|||Pre-operative Magnetic Resonance Imaging (MRI) in Young Breast Cancer Patients|A Prospective Cohort Study to Evaluate the Impact of Preoperative Breast Magnetic Resonance Imaging (MRI) on Surgical Decision-Making in Young Patients With Breast Cancer|Unknown status|Recruiting|N/A|44|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 01:31:38.376645|2018-06-01 01:31:38.376645
NCT00801463|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2011-05-17|2008-12-02|2008-12-03|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis|Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis|Completed||N/A|67|Actual|Nanjing University School of Medicine||2|||f||||t||||||||||2018-06-01 01:31:38.445796|2018-06-01 01:31:38.445796
NCT00801450|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2009-10-08|2008-12-02|2008-12-03|Estimate|||||||2009-10-08|2009-10-12|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|February 2009|Anticipated|2009-02-28|December 2008|Anticipated|2008-12-31||Interventional|||Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery||Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:31:38.512359|2018-06-01 01:31:38.512359
NCT00801437|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2011-06-28|2008-12-02|2008-12-03|Estimate|||||||2011-06-28|2011-06-29|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.|Non Interventional Study in Slovak Patients With Primary Open Angle Glaucoma and/or Ocular Hypertension Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy Due to Ineffectivity or Intolerance.|Completed|||457|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:31:38.581784|2018-06-01 01:31:38.581784
NCT00801424|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-10-01|2008-12-02|2008-12-03|Estimate|||||||2010-10-01|2010-10-04|Estimate|November 2008||2008-11-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|S2||Warmed Humidified Carbon Dioxide (CO2) for Open Surgery|Randomized Clinical Study for Core and Topical Warming of the Open Wound Cavity With Warmed Humidified CO2 Versus Control in Colon Surgery|Completed||N/A|80|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-06-01 01:31:38.672294|2018-06-01 01:31:38.672294
NCT00801411|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2009-06-16|2008-12-02|2008-12-03|Estimate|||||||2009-06-16|2009-06-17|Estimate|October 2008||2008-10-31|June 2009|2009-06-30||||||||Interventional|||Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery|A Randomised Phase 2 Study of Neoadjuvant Docetaxel and Cyclophosphamide Compared to Doxorubicin and Cyclophosphamide in Operable Node Negative Breast Cancer With Normal Topoisomerase IIα Expression|Unknown status|Recruiting|Phase 2|318|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:31:38.735245|2018-06-01 01:31:38.735245
NCT00801398|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2015-06-10|2008-12-02|2008-12-03|Estimate|||||||2015-06-10|2015-06-12|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.|An Open-Label, Ascending, Two-Part, Single- and Multiple-Dose Evaluation of the Safety, Pharmacokinetics, and Effectiveness of Oxymorphone for Acute Postoperatiave Pain in Pediatric Subjects|Completed||Phase 3|60|Actual|Endo Pharmaceuticals||1|||f||||t||||||||||2018-06-01 01:31:38.797327|2018-06-01 01:31:38.797327
NCT00801385|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2009-08-21|2008-12-02|2008-12-03|Estimate|||||||2009-08-21|2009-08-25|Estimate|September 2008||2008-09-30|August 2009|2009-08-31||||June 2009|Anticipated|2009-06-30||Interventional|||Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy|A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens|Unknown status|Recruiting|Phase 2|47|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:31:38.951912|2018-06-01 01:31:38.951912
NCT00801372|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2017-11-26|2008-12-02|2008-12-03|Estimate|||||||2017-11-26|2017-11-28|Actual|November 2008||2008-11-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells|Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells|Recruiting|||1|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 01:31:39.026714|2018-06-01 01:31:39.026714
NCT00801359|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-15|2008-12-02|2008-12-03|Estimate|||||||2008-12-15|2008-12-16|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||BSSPlus Versus Lactated Ringer's for Phacoemulsification|Comparison of Corneal Changes After Phacoemulsification Using BSSPlus Versus Lactated Ringer's Irrigating Solution|Completed||Phase 2|110|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:31:39.097123|2018-06-01 01:31:39.097123
NCT00801346|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2017-04-20|2008-12-02|2008-12-03|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2008||2008-11-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission|The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).|Completed|||224|Actual|Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 01:31:39.19044|2018-06-01 01:31:39.19044
NCT00801333|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2017-08-28|2008-12-02|2008-12-03|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2008||2008-11-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells|Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells|Recruiting|||25|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 01:31:39.27099|2018-06-01 01:31:39.27099
NCT00801320|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2018-05-10|2008-12-02|2008-12-03|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2008||2008-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2012|Actual|2012-08-31||Interventional|||Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Study of Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer (Ovarian Spore)|Active, not recruiting||N/A|100|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 01:31:39.345816|2018-06-01 01:31:39.345816
NCT00801307|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2014-08-08|2008-12-02|2008-12-03|Estimate|||||||2014-08-08|2014-08-11|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Interventional|||Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease|A Single Site,Exploratory,Phase I/II,Randomised Trial Comparing the Effect of He/O2 Mixtures(He/O2 78:22 and He/O2 65:35) to Medical Air on Pulmonary Function in Moderate/Severe Asthma and COPD Patients and Healthy Volunteers|Completed||Phase 1/Phase 2|30|Actual|Air Liquide SA||3|||f||||t||||||||||2018-06-01 01:31:39.429583|2018-06-01 01:31:39.429583
NCT00801294|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2017-12-28|2008-12-02|2008-12-03|Estimate|||||||2017-12-28|2017-12-29|Actual|July 1, 2006|Actual|2006-07-01|December 2017|2017-12-31||||November 1, 2007|Actual|2007-11-01||Interventional|||A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer|A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer|Completed||Phase 2|46|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:31:39.515297|2018-06-01 01:31:39.515297
NCT00801281|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2017-07-12|2008-12-02|2008-12-03|Estimate|||||||2017-07-12|2017-07-17|Actual|February 2007||2007-02-28|July 2017|2017-07-31|June 25, 2017|Actual|2017-06-25|June 25, 2017|Actual|2017-06-25||Interventional|PLRG4||First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.|First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG.|Completed||Phase 3|250|Actual|Polish Lymphoma Research Group||2|||f||||t||||||||No||2018-06-01 01:31:39.636902|2018-06-01 01:31:39.636902
NCT00801268|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2015-03-27|2008-12-02|2008-12-03|Estimate|||||||2015-03-27|2015-03-30|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease|Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Terminated||N/A|300|Actual|Nanjing University School of Medicine||2||high rate of drop-out|f||||t||||||||||2018-06-01 01:31:39.777306|2018-06-01 01:31:39.777306
NCT00801255|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2016-11-01|2008-12-02|2008-12-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients|A Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability and Antiviral Activity of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591) in Genotype 1 Chronic Hepatitis C Patients. INFORM 1|Completed||Phase 1|88|Actual|Hoffmann-La Roche||7|||f||||||||||||||2018-06-01 01:31:39.859548|2018-06-01 01:31:39.859548
NCT00801242|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2014-08-08|2013-06-19|2014-09-02|2008-12-02|2008-12-03|Estimate|2014-09-02|2014-09-03|Estimate|2013-06-19|2013-06-27|Estimate|2014-09-02|2014-09-03|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional||FAS, Cycle 1.|Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer|An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy|Completed||Phase 3|220|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:31:40.004085|2018-06-01 01:31:40.004085
NCT00801229|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2011-06-20||2014-02-05|2008-12-02|2008-12-03|Estimate|2011-07-27|2011-08-25|Estimate||||2014-02-05|2014-03-10|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Vyvanse on Driving in Young Adults With ADHD|The Effects of Vyvanse on the Driving Performance of Young Adults With ADHD: A Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 4|75|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:31:40.489504|2018-06-01 01:31:40.489504
NCT00801216|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|January 2012|Anticipated|2012-01-31|January 2010|Anticipated|2010-01-31||Interventional|SCNSL1||High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement|High-Dose Sequential Chemotherapy and Rituximab (R-HDS) in Patients With Systemic B-Cell Lymphoma With Central Nervous System Involvement at Diagnosis or Relapse|Unknown status|Recruiting|Phase 2|38|Anticipated|IRCCS San Raffaele||1|||t||||t||||||||||2018-06-01 01:31:40.720115|2018-06-01 01:31:40.720115
NCT00801203|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2012-05-08|2008-12-02|2008-12-03|Estimate|||||||2012-05-08|2012-05-09|Estimate|December 2008||2008-12-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence|A Phase II/III Controlled Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence|Completed||Phase 2/Phase 3|180|Actual|Pneumoflex Systems, LLC||2|||f||||f||||||||||2018-06-01 01:31:40.797353|2018-06-01 01:31:40.797353
NCT00801190|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|April 2011|Anticipated|2011-04-30|April 2010|Anticipated|2010-04-30||Interventional|||This Study Will Compare the Effect of Starch Containing to Non-Starch Containing Intravenous Fluid on Blood Loss During Coronary Artery Bypass Graft Surgery|"A Prospective Randomized Double-Blind Placebo-Controlled Trial of the Effects of Colloid (HES 130/0.4) Versus Crystalloid (Ringer's Lactate) on Bleeding in Patients Undergoing Cardiopulmonary Bypass for Primary CABG, Single Valve Repair/Replacement, or Combined Single Valve/CABG Surgery"|Unknown status|Not yet recruiting|N/A|500|Anticipated|St. Boniface General Hospital Research Centre||2|||f||||t||||||||||2018-06-01 01:31:40.863797|2018-06-01 01:31:40.863797
NCT00801177|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2010-10-11|2008-12-02|2008-12-03|Estimate|||||||2010-10-11|2010-10-13|Estimate|November 2004||2004-11-30|October 2010|2010-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy|Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy|Completed||Phase 1|60|Actual|ImClone LLC||2|||f||||f||||||||||2018-06-01 01:31:40.913308|2018-06-01 01:31:40.913308
NCT00801164|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-02-01|2008-12-02|2008-12-03|Estimate|||||||2012-02-01|2012-02-02|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|Diabetes||Exploratory Study of Iocide Oral Rinse in a Diabetic Population|Exploratory Study of Iocide Oral Rinse in a Diabetic Population|Completed||Phase 1|30|Actual|Biomedical Development Corporation||2|||f||||f||||||||||2018-06-01 01:31:40.996729|2018-06-01 01:31:40.996729
NCT00801151|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2010-05-19|2008-12-02|2008-12-03|Estimate|||||||2010-05-19|2010-05-20|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer|A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer.|Terminated||Phase 1|30|Anticipated|Institut Claudius Regaud||1|||f||||f||||||||||2018-06-01 01:31:41.926016|2018-06-01 01:31:41.926016
NCT00801138|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|2016-07-18||2017-03-21|2008-12-02|2008-12-03|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|November 2008||2008-11-30|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine|The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine|Terminated||N/A|218|Actual|The Cleveland Clinic||4||A strong primary outcome crosses the efficacy boundary at the interim analysis|f||||f||||||||No||2018-06-01 01:31:41.997996|2018-06-01 01:31:41.997996
NCT00801125|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2016-06-14|2008-12-02|2008-12-03|Estimate|||||||2016-06-14|2016-06-16|Estimate|December 2008||2008-12-31|January 2009|2009-01-31||||May 2010|Anticipated|2010-05-31||Interventional|||Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy|A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy|Withdrawn||Phase 4|0|Actual|Biogen||||Study sponsor decided to withdraw the current study prior to enrollment of first participant.|f||||||||||||||2018-06-01 01:31:42.250704|2018-06-01 01:31:42.250704
NCT00801112|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|January 2009||2009-01-31|December 2008|2008-12-31|January 2011|Anticipated|2011-01-31|||||Observational|||Bioimpedance as a Tool for Fluid Management in Peritoneal Dialysis (PD) Patients|Developing Bioimpedance (BIA) as a Tool for Fluid Management in Peritoneal Dialysis Patients: A Validation Study|Unknown status|Not yet recruiting||100|Anticipated|University Hospital of North Staffordshire|||4||f||||f||||||Samples Without DNA|"~     Whole blood, urine and peritoneal fluid.~   "|||2018-06-01 01:31:42.302881|2018-06-01 01:31:42.302881
NCT00801099|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2008-11-06||2015-07-16|2008-12-02|2008-12-03|Estimate|2008-12-02|2008-12-03|Estimate||||2015-07-16|2015-08-07|Estimate|December 2004||2004-12-31|July 2015|2015-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|SSI2||Benefit of a Single Preoperative Dose of Antibiotics for the Prevention of Surgical Site Infections|Benefit of a Single Preoperative Dose of Antibiotics in a Sub-Saharan District Hospital: Minimal Input, Massive Impact|Completed||N/A|276|Actual|Swiss Tropical & Public Health Institute||1|||f||||f||||||||||2018-06-01 01:31:42.368672|2018-06-01 01:31:42.368672
NCT00801086|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|November 2008||2008-11-30|December 2008|2008-12-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain|Phase II Double-Blind, Placebo-Controlled Study of the Safety and Preliminary Effectiveness of MTS-01 for the Prevention of Alopecia Induced by Whole Brain Radiotherapy|Unknown status|Recruiting|Phase 2|16|Anticipated|Mitos Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:31:42.495973|2018-06-01 01:31:42.495973
NCT00801073|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|February 2005||2005-02-28|December 2008|2008-12-31||||February 2005|Actual|2005-02-28||Interventional|||Comparison Amongst Scleral, Corneal and Amniotic Membrane Grafts to Restore Scleral Thinning||Unknown status|Enrolling by invitation|Phase 2/Phase 3|49|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-06-01 01:31:42.675504|2018-06-01 01:31:42.675504
NCT00801060|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02||2015-09-17|2015-09-17|2008-12-02|2008-12-03|Estimate||||2015-09-17|2015-10-02|Estimate|2015-09-17|2015-10-02|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination With Lumiliximab Versus FCR Alone in Subjects With Previously Untreated Chronic Lymphocytic Leukemia|Terminated||Phase 2|40|Actual|Biogen||2|||f||||f||||||||||2018-06-01 01:31:42.742299|2018-06-01 01:31:42.742299
NCT00801047|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2015-04-19|2008-12-02|2008-12-03|Estimate|||||||2015-04-19|2015-04-21|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Intravenous Remifentanil Patient-controlled Analgesia (PCA) and Epidural Patient Controlled Epidural Analgesia (PCEA) for Labor Analgesia|Comparison of the Efficacy Intravenous Remifentanil PCA and Epidural PCEA for Labor Analgesia|Completed||Phase 4|50|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:31:42.863487|2018-06-01 01:31:42.863487
NCT00801034|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2015-08-19|2008-12-02|2008-12-03|Estimate|||||||2015-08-19|2015-08-21|Estimate|November 2008||2008-11-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||The Effects of Potassium on Physiological and Cardiovascular Variables in Healthy Persons|The Effects of Potassium on Physiological Variables in the Kidney and Cardiovascular Variables in Healthy Persons in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study|Completed||Phase 1|25|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-06-01 01:31:42.936231|2018-06-01 01:31:42.936231
NCT00801021|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2010-03-04|2008-12-02|2008-12-03|Estimate|||||||2010-03-04|2010-03-08|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|UTI||Treatment and/or Prevention of Urinary Tract Infections|Treatment and/or Prevention of Urinary Tract Infections|Completed||Phase 1|3|Actual|Biomedical Development Corporation||1|||f||||f||||||||||2018-06-01 01:31:43.00838|2018-06-01 01:31:43.00838
NCT00801008|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2012-04-19|2008-12-02|2008-12-03|Estimate|||||||2012-04-19|2012-04-20|Estimate|July 2009||2009-07-31|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Exercise and Relaxation Intervention for Young Adult Cancer Survivors||Unknown status|Recruiting|N/A|60|Anticipated|The Miriam Hospital||2|||f||||f||||||||||2018-06-01 01:31:43.103525|2018-06-01 01:31:43.103525
NCT00800995|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|September 2005||2005-09-30|December 2008|2008-12-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)|SOD as Antioxidant Treatment OF ARMD|Completed||Phase 3|46|Actual|Centre de Recherche en Nutrition Humaine Rhone-Alpe||2|||f||||f||||||||||2018-06-01 01:31:43.184733|2018-06-01 01:31:43.184733
NCT00800982|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2013-02-19||2013-03-26|2008-12-02|2008-12-03|Estimate|2013-03-26|2013-05-07|Estimate||||2013-03-26|2013-05-07|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis|A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Tolerability of Narrow Band UVB Phototherapy in Enhancing Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque-Type Psoriasis|Completed||N/A|30|Actual|University of California, San Francisco|Of the 30 subjects enrolled, 3 were lost to follow-up, one moved out of state, and one voluntarily withdrew due to worsening of psoriasis.|2|||f||||t||||||||||2018-06-01 01:31:43.2728|2018-06-01 01:31:43.2728
NCT00800969|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2016-06-22|2008-12-02|2008-12-03|Estimate|||||||2016-06-22|2016-06-23|Estimate|October 2008||2008-10-31|June 2016|2016-06-30||||January 2015|Anticipated|2015-01-31||Interventional|||Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach||Withdrawn||Phase 2|0|Actual|University of Zurich||1|||f||||||||||||||2018-06-01 01:31:43.483197|2018-06-01 01:31:43.483197
NCT00800956|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2011-04-06|2008-12-02|2008-12-03|Estimate|||||||2011-04-06|2011-04-07|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|ADME||Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine|An Open Label, Single Oral Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Esreboxetine.|Completed||Phase 1|4|Anticipated|Pfizer||1|||f||||f||||||||||2018-06-01 01:31:43.548963|2018-06-01 01:31:43.548963
NCT00800943|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-02|2008-12-02|2008-12-03|Estimate|||||||2008-12-02|2008-12-03|Estimate|December 2003||2003-12-31|December 2008|2008-12-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|CRC005||Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy|A Clinical Research Consortium (CRC) Phase II Study of Subcutaneous Campath-1H in Patients With B-Cell Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy|Unknown status|Active, not recruiting|Phase 2|31|Actual|Chronic Lymphocytic Leukemia Research Consortium||1|||f||||t||||||||||2018-06-01 01:31:43.608146|2018-06-01 01:31:43.608146
NCT00800930|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-02|||2011-12-06|2008-12-02|2008-12-03|Estimate|||||||2011-12-06|2011-12-08|Estimate|January 2005||2005-01-31|December 2008|2008-12-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Therapeutic Induction of Endogenous Antibiotics|Therapeutic Induction of Endogenous Antibiotics for Improved Recovery in Shigellosis|Completed||Phase 2|80|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 01:31:43.681068|2018-06-01 01:31:43.681068
NCT00800917|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-06-01|2008-12-01|2008-12-02|Estimate|||||||2010-06-01|2010-06-02|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme|A Phase II Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme|Completed||Phase 2|12|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 01:31:43.846902|2018-06-01 01:31:43.846902
NCT00800904|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-12-02|2008-12-01|2008-12-02|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|||||Observational|||Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand|Asthma Control Among Patients Who Were Receiving Inhaled Corticosteroids in General Practice in Thailand|Completed|||1210|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:31:43.916576|2018-06-01 01:31:43.916576
NCT00800891|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|||2009-04-01|2008-11-30|2008-12-02|Estimate|||||||2009-04-01|2009-04-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:31:44.004966|2018-06-01 01:31:44.004966
NCT00800878|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-08|2008-12-01|2008-12-02|Estimate|||||||2008-12-08|2008-12-09|Estimate|February 2008||2008-02-29|November 2008|2008-11-30|April 2010|Anticipated|2010-04-30|December 2009|Anticipated|2009-12-31||Observational|CKD||Chronic Kidney Disease in Pakistani Population|Chronic Kidney Disease in the Pakistani Population|Unknown status|Recruiting||650|Anticipated|Aga Khan University|||||f||||||||||||||2018-06-01 01:31:44.03801|2018-06-01 01:31:44.03801
NCT00800865|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2011-01-12||2015-10-09|2008-12-01|2008-12-02|Estimate|2011-08-23|2011-10-04|Estimate||||2015-10-09|2015-11-03|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)|A 2-Stage, Open Label, Phase Ib Clinical Trial to Evaluate Biomarkers in Patients With Solid Tumor and Receiving a Single Dose of Cytotoxics|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:31:44.12719|2018-06-01 01:31:44.12719
NCT00800839|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2016-07-28||2016-07-28|2008-12-01|2008-12-02|Estimate|2016-07-28|2016-09-19|Estimate||||2016-07-28|2016-09-19|Estimate|September 2008||2008-09-30|July 2016|2016-07-31||||July 2015|Actual|2015-07-31||Interventional|||Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide|Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.|Completed||Phase 2|56|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:31:44.425612|2018-06-01 01:31:44.425612
NCT00800826|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-01|2008-12-01|2008-12-02|Estimate|||||||2008-12-01|2008-12-02|Estimate|November 2006||2006-11-30|December 2008|2008-12-31|April 2008|Actual|2008-04-30|||||Interventional|||The Combination Effect of Dexmedetomidine and Morphine in Postoperative Patient-Controlled Analgesia||Completed||Phase 4|150|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 01:31:44.780003|2018-06-01 01:31:44.780003
NCT00800813|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2014-07-10|2008-12-01|2008-12-02|Estimate|||||||2014-07-10|2014-07-14|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy|Assessing the Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy|Completed|||121|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:31:44.830455|2018-06-01 01:31:44.830455
NCT00800800|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2010-12-02|2008-12-01|2008-12-02|Estimate|||||||2010-12-02|2010-12-03|Estimate|November 2002||2002-11-30|December 2010|2010-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|ASTRONOMER||Effects of Rosuvastatin on Aortic Stenosis Progression|Effect of Cholesterol Lowering on the Progression of Aortic Stenosis in Patients With Mild to Moderate Aortic Stenosis (ASTRONOMER)Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin and The Sub-Study Protocol.|Completed||Phase 3|378|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:31:44.894122|2018-06-01 01:31:44.894122
NCT00800787|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2016-01-15|2008-12-01|2008-12-02|Estimate|||||||2016-01-15|2016-01-18|Estimate|April 2010||2010-04-30|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Interventional|Nabi-HB-SC||Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation|A Phase 3, Multicenter, Open Label Study to Assess the Safety and Efficacy of Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Associated Liver Disease Who Underwent Liver Transplantation|Withdrawn||Phase 3|0|Actual|Biotest Pharmaceuticals Corporation||1||New sponsor's existing product under evaluation for this indication|f||||t||||||||||2018-06-01 01:31:44.969093|2018-06-01 01:31:44.969093
NCT00800774|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2009-11-21|2008-12-01|2008-12-02|Estimate|||||||2009-11-21|2009-11-25|Estimate|January 1998||1998-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Ten-year Follow-up of Laser in Situ Keratomileusis in Patients 8 to 15 Years Old|Ten-year Follow-up of Laser in Situ Keratomileusis in Patients 8 to 15 Years Old|Completed||Phase 4|9|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-06-01 01:31:45.025916|2018-06-01 01:31:45.025916
NCT00800761|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-01|2008-12-01|2008-12-02|Estimate|||||||2008-12-01|2008-12-02|Estimate|December 2001||2001-12-31|December 2001|2001-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|DFODFPTM||Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major|Increased Survival and Reversion of Iron-Induced Cardiac Disease in Patients With Thalassemia Major Receiving Intensive Combined Chelation Therapy|Completed||Phase 4|||Ospedale Microcitemico||2|||f||||f||||||||||2018-06-01 01:31:45.085812|2018-06-01 01:31:45.085812
NCT00800748|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2017-05-19|2008-12-01|2008-12-02|Estimate|||||||2017-05-19|2017-05-22|Actual|February 1, 2006|Actual|2006-02-01|May 2017|2017-05-31|January 9, 2009|Actual|2009-01-09|January 9, 2009|Actual|2009-01-09||Interventional|||A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C|An Open, Phase IV, Multicentric Study, Evaluating Safety and Efficacy of Ribavirin (Copegus®) and Peginterferon Alfa-2a (Pegasys®) Combination in Specific Groups|Completed||Phase 4|372|Actual|Hoffmann-La Roche||3|||f|||||f|f||||||||2018-06-01 01:31:45.148141|2018-06-01 01:31:45.148141
NCT00800735|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2013-07-05||2013-09-30|2008-12-01|2008-12-02|Estimate|2013-07-05|2013-09-13|Estimate||||2013-09-30|2013-10-30|Estimate|April 2009||2009-04-30|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols|An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS®) as Monotherapy or in Combination With Ribavirin (COPEGUS®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols|Completed||Phase 3|30|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:31:45.352688|2018-06-01 01:31:45.352688
NCT00800722|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2017-02-08|2008-12-01|2008-12-02|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2008||2008-11-30|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.|Phase I Combined Use of Pulsed Dye Laser and Rapamycin|Completed||Phase 1|21|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 01:31:45.595619|2018-06-01 01:31:45.595619
NCT00800709|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2010-12-02|2008-12-01|2008-12-02|Estimate|||||||2010-12-02|2010-12-03|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease|Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study|Completed||Phase 4|26|Anticipated|Shanghai Mental Health Center||1|||f||||t||||||||||2018-06-01 01:31:45.670097|2018-06-01 01:31:45.670097
NCT00800696|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|||2011-04-20|2008-12-01|2008-12-02|Estimate|||||||2011-04-20|2011-04-21|Estimate|September 2010||2010-09-30|April 2011|2011-04-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Preventive Oral Care||Unknown status|Active, not recruiting|N/A|66|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-06-01 01:31:45.744066|2018-06-01 01:31:45.744066
NCT00800683|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2011-12-30||2014-05-15|2008-12-01|2008-12-02|Estimate|2011-12-30|2012-02-01|Estimate||||2014-05-15|2014-05-20|Estimate|December 2008||2008-12-31|May 2014|2014-05-31||||January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive|Safety in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 vs. Placebo, DB, Parallel Group, Randomized, Insulin Background Inclusive|Completed||Phase 3|133|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:31:45.869379|2018-06-01 01:31:45.869379
NCT00798499|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2009-07-01|2008-11-25|2008-11-26|Estimate|||||||2009-07-01|2009-07-02|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|||||Observational|||A Feasibility Study to Collect Data in Patients With Haemophilia|A Multi Centre Study With no Treatment, Designed to Gain Information About the Haemophilia Patient Population|Completed|||50|Anticipated|AstraZeneca|||1||f||||||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 01:32:23.401488|2018-06-01 01:32:23.401488
NCT00800670|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2017-09-05|2008-12-01|2008-12-02|Estimate|||||||2017-09-05|2017-09-08|Actual|June 2009||2009-06-30|September 2017|2017-09-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine|Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine|Terminated||Phase 1|24|Actual|McMaster University||2||Study was terminated after the low dose cohort had been enrolled|f||||f||||||||||2018-06-01 01:31:46.684607|2018-06-01 01:31:46.684607
NCT00800657|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2011-06-22|2008-12-01|2008-12-02|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|RCT and SCT||Stem Cells and Resynchronization Cardiac|Stem-Cells and Heart Failure in Several Ethiologies. Alternative Indication With Cardiac Resynchronization|Unknown status|Recruiting|Phase 1|30|Anticipated|Instituto de Molestias Cardiovasculares|||||f||||t||||||||||2018-06-01 01:31:46.743597|2018-06-01 01:31:46.743597
NCT00800644|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2018-01-08|2008-12-01|2008-12-02|Estimate|||||||2018-01-08|2018-01-10|Actual|November 2008|Actual|2008-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Pelvic Fractures and Radiation Therapy for Cervical Cancer|Evaluation of Bone Density and Pelvic Fractures in Women Undergoing Definitive Pelvic Radiation Therapy for Cervical, Endometrial or Vaginal Cancer|Active, not recruiting|||300|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 01:31:46.805192|2018-06-01 01:31:46.805192
NCT00800631|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-01|2008-12-01|2008-12-02|Estimate|||||||2008-12-01|2008-12-02|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|January 2009|Anticipated|2009-01-31||Observational|||The Biomarker and Cardiac Function in Sepsis|The Biomarker and Associated Cardiac Function in the Patients With Sepsis|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:31:46.86347|2018-06-01 01:31:46.86347
NCT00800618|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-02-09|2008-12-01|2008-12-02|Estimate|||||||2010-02-09|2010-02-10|Estimate|November 2008||2008-11-30|February 2010|2010-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women|A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalating, Parallel Group Study To Investigate The Safety, Toleration, Pharmacology And Pharmacokinetics, Of Multiple Doses Of PF-02413873 In Healthy Female Subjects.|Completed||Phase 1|42|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:31:46.913734|2018-06-01 01:31:46.913734
NCT00800605|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01||2009-10-28|2015-10-07|2008-12-01|2008-12-02|Estimate||||2009-10-28|2009-10-30|Estimate|2015-10-07|2015-10-29|Estimate|December 2008||2008-12-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection|Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection|Completed||Phase 3|7252|Actual|Ology Bioservices||2|||f||||t||||||||||2018-06-01 01:31:46.985952|2018-06-01 01:31:46.985952
NCT00800592|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2017-03-07|2008-12-01|2008-12-02|Estimate|||||||2017-03-07|2017-03-10|Actual|October 2008||2008-10-31|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Sildenafil IV Bolus Study|An Open Single Dose Study To Assess The Safety, Tolerability And Pharmacokinetics Of An Intravenous Bolus Dose (10 Mg) Of Sildenafil In Patients With Pulmonary Arterial Hypertension (PAH).|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:31:47.186572|2018-06-01 01:31:47.186572
NCT00800579|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2009-10-20|2008-12-01|2008-12-02|Estimate|||||||2009-10-20|2009-10-21|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers|Completed||Phase 1|12|Anticipated|Gilead Sciences||4|||f||||f||||||||||2018-06-01 01:31:47.255628|2018-06-01 01:31:47.255628
NCT00800566|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2012-07-31|2008-12-01|2008-12-02|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)|Phase I Study of Oral Clofarabine for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Sponsor terminated.|f||||t||||||||||2018-06-01 01:31:47.33013|2018-06-01 01:31:47.33013
NCT00800553|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2016-08-02|2008-12-01|2008-12-02|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2006||2006-11-30|August 2016|2016-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||fMRI-behavioral Study of Cholinergic Augmentation With Donepezil in Healthy Sleep Deprived Adults|The Neural and Behavioral Correlates of How Donepezil Modulates Memory and Inhibitory Efficiency in the Context of 24 Hours of Sleep Deprivation|Completed||Phase 4|43|Actual|Duke-NUS Graduate Medical School||2|||f||||t||||||||||2018-06-01 01:31:47.404422|2018-06-01 01:31:47.404422
NCT00800540|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2013-01-31||2013-03-20|2008-12-01|2008-12-02|Estimate|2013-03-20|2013-03-22|Estimate||||2013-03-20|2013-03-22|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||This reporting group includes all enrolled participants.|Circadian Ocular Perfusion Pressure and Ocular Blood Flow|Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma|Completed||Phase 4|35|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:31:47.504391|2018-06-01 01:31:47.504391
NCT00800527|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2008-12-01|2008-12-01|2008-12-02|Estimate|||||||2008-12-01|2008-12-02|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy|Phase 4 Study of Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy|Completed||Phase 4|110|Actual|Usak State Hospital||2|||f||||f||||||||||2018-06-01 01:31:47.983373|2018-06-01 01:31:47.983373
NCT00800514|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2011-07-18|2008-12-01|2008-12-02|Estimate|||||||2011-07-18|2011-07-19|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)|Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury|Terminated||N/A|16|Anticipated|Carolinas Healthcare System||1||Principal investigator took a position at another institution. No subjects enrolled.|f||||t||||||||||2018-06-01 01:31:48.102491|2018-06-01 01:31:48.102491
NCT00800332|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-11-11|2008-12-01|2008-12-02|Estimate|||||||2010-11-11|2010-11-15|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|||Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy|Double-blind, Placebo-controlled Dose-finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy|Completed||Phase 2|300|Anticipated|Cytos Biotechnology AG||3|||f||||f||||||||||2018-06-01 01:31:51.300531|2018-06-01 01:31:51.300531
NCT00800501|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-29|||2011-12-05|2008-12-01|2008-12-02|Estimate|||||||2011-12-05|2011-12-06|Estimate|December 2008||2008-12-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis|A Double-blind, Randomised, Parallel Group Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis, Using an Implanted Catheter and SynchroMed® II Pump|Completed||Phase 1/Phase 2|18|Actual|Newron Sweden AB||2|||f||||t||||||||||2018-06-01 01:31:48.168395|2018-06-01 01:31:48.168395
NCT00800488|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2014-07-25|2008-12-01|2008-12-02|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Observational|PRONOUR||Procalcitonin for Predicting Serious Bacterial Infection in Infants Less Than 3 Months|Usefulness of Serum Procalcitonin for Predicting Serious Bacterial Infection in Febrile Infants Less Than 3 Months|Completed|||2209|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 01:31:48.230412|2018-06-01 01:31:48.230412
NCT00800475|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-08-09|2008-12-01|2008-12-02|Estimate|||||||2013-08-09|2013-08-13|Estimate|July 2005||2005-07-31|August 2013|2013-08-31|September 2005|Actual|2005-09-30|July 2005|Actual|2005-07-31||Interventional|||Bioequivalence Study Between Two Oral Formulations of Gemfibrozil Tablets|A Relative Bioequivalence Study of 600 mg Gemfibrozil Tablets Under Fasting Conditions|Completed||Phase 1|40|Actual|Blu Caribe||2|||f||||f||||||||||2018-06-01 01:31:48.284688|2018-06-01 01:31:48.284688
NCT00800462|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2013-04-04|2008-12-01|2008-12-02|Estimate|||||||2013-04-04|2013-04-08|Estimate|March 2008||2008-03-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity|Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity|Completed||Phase 4|23|Actual|Toronto Rehabilitation Institute||3|||f||||f||||||||||2018-06-01 01:31:48.33345|2018-06-01 01:31:48.33345
NCT00800449|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|||2012-02-13|2008-12-01|2008-12-02|Estimate|||||||2012-02-13|2012-02-14|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Observational|||Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)|Prospective Assessment of the Distribution of Haptoglobin Phenotype in Septic and Non Septic Pre-term Neonates (PTSH)|Completed|||133|Actual|Carmel Medical Center|||||f||||t||||||Samples Without DNA|"~     Hp phenotype in blood test.~   "|||2018-06-01 01:31:48.402047|2018-06-01 01:31:48.402047
NCT00800436|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2016-10-24||2016-10-24|2008-12-01|2008-12-02|Estimate|2016-10-24|2016-12-16|Estimate||||2016-10-24|2016-12-16|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||"Safety Population: All participants who received at least one dose of study medication, whether prematurely withdrawn from the study or not. The Total column (n=70) includes 4 female participants who were counted twice as they were treated in both Cohort 2 and Cohort A."|A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females|An Open-Label, Two-Part, Multi-Centre, Trastuzumab Dose-Finding Study in Healthy Male Volunteers and HER2 Positive Female Patients|Completed||Phase 1|66|Actual|Hoffmann-La Roche||7|||f||||||||||||||2018-06-01 01:31:48.488199|2018-06-01 01:31:48.488199
NCT00800423|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|||2008-12-01|2008-12-01|2008-12-02|Estimate|||||||2008-12-01|2008-12-02|Estimate|January 2009||2009-01-31|November 2008|2008-11-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema|Phase 3 Study of Brimonidine Tartrate Drops Efficacy in Reducing Post Operative Corneal Edema After Cataract Surgery|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|Rabin Medical Center||3|||f||||f||||||||||2018-06-01 01:31:49.415726|2018-06-01 01:31:49.415726
NCT00800410|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2016-05-25|2008-12-01|2008-12-02|Estimate|||||||2016-05-25|2016-05-27|Estimate|September 2004||2004-09-30|May 2016|2016-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||REACH Detroit Partnership Family Intervention|A Pilot Randomized Diabetes Intervention Among Inner-city African American and Latino Adults|Completed||Phase 2|183|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 01:31:49.492547|2018-06-01 01:31:49.492547
NCT00800397|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2009-08-11|2008-12-01|2008-12-02|Estimate|||||||2009-08-11|2009-08-12|Estimate|December 2007||2007-12-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients|Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients|Completed|||80|Anticipated|WideMed LTD.|||||f||||t||||||||||2018-06-01 01:31:49.549576|2018-06-01 01:31:49.549576
NCT00800384|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|2015-10-13||2018-03-28|2008-12-01|2008-12-02|Estimate|2015-11-18|2015-12-22|Estimate||||2018-03-28|2018-03-30|Actual|January 2009||2009-01-31|March 2014|2014-03-31|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|SIMPLE||Shockless Implant Evaluation|Shockless Implant Evaluation|Completed||N/A|2500|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 01:31:49.62462|2018-06-01 01:31:49.62462
NCT00800371|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2008-12-01|2008-12-01|2008-12-02|Estimate|||||||2008-12-01|2008-12-02|Estimate|May 2008||2008-05-31|November 2008|2008-11-30|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Observational|||Magnetic Resonance Imaging (MRI) in Asymptomatic Patients With Juvenile Idiopathic Arthritis (JIA)|Diagnostic Value of MRI and Ultrasound in Patients With JIA|Unknown status|Recruiting||20|Anticipated|University Hospital Tuebingen|||1||f||||f||||||||||2018-06-01 01:31:50.803431|2018-06-01 01:31:50.803431
NCT00800358|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|||2012-12-04|2008-12-01|2008-12-02|Estimate|||||||2012-12-04|2012-12-06|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism|A Multi Centre, Open Label, Parallel Group, Randomized Controlled Trial to Compare the Safety and Efficacy of Oral Paricalcitol Versus Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Dialysis Patients|Completed||N/A|69|Actual|Penang Hospital, Malaysia||2|||f||||t||||||||||2018-06-01 01:31:50.884574|2018-06-01 01:31:50.884574
NCT00800345|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2016-12-28||2017-02-23|2008-12-01|2008-12-02|Estimate|2016-12-30|2017-02-23|Actual||||2017-02-23|2017-03-28|Actual|April 2009||2009-04-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors|A Phase I Trial of Oral Metronomic Topotecan in Combination With Oral Pazopanib Utilizing a Daily Dosing Schedule to Treat Recurrent or Persistent Gynecologic Tumors|Completed||Phase 1|33|Actual|Vector Oncology||1|||f||||f||||||||Undecided||2018-06-01 01:31:51.015866|2018-06-01 01:31:51.015866
NCT00800319|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2011-08-19|2008-12-01|2008-12-02|Estimate|||||||2011-08-19|2011-08-22|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||ALK33-001: A Study of RDC-0313 Administered to Healthy Adults|ALK33-001: A Phase 1 Study of the Pharmacokinetics of RDC-0313 Administered to Healthy Adults|Completed||Phase 1|16|Actual|Alkermes, Inc.||6|||f||||t||||||||||2018-06-01 01:31:51.383556|2018-06-01 01:31:51.383556
NCT00800306|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2009-10-14|2008-12-01|2008-12-02|Estimate|||||||2009-10-14|2009-10-15|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|February 2008|Actual|2008-02-29||Interventional|||Effects of Levosimendan on Microcirculation in Septic Shock|Levosimendan and Inhaled Nitric Oxide for Resuscitating the Microcirculation in Septic Shock. A Randomized Controlled Trial|Completed||Phase 2|40|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-06-01 01:31:51.478737|2018-06-01 01:31:51.478737
NCT00800293|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2012-03-15|2008-12-01|2008-12-02|Estimate|||||||2012-03-15|2012-03-16|Estimate|December 2002||2002-12-31|March 2012|2012-03-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Observational|||Randomized Study to Compare the Bioavailability of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams|Bioequivalence of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams|Completed|||116|Actual|Perrigo Company|||4||f||||f||||||||||2018-06-01 01:31:51.545871|2018-06-01 01:31:51.545871
NCT00800280|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-02-16|2008-12-01|2008-12-02|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body|A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of Steady-State Cimetidine On The Pharmacokinetics Of A Single Dose Of PD 0332334 In Healthy Subjects|Terminated||Phase 1|12|Actual|Pfizer||2||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 01:31:51.610453|2018-06-01 01:31:51.610453
NCT00800267|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2009-03-05|2008-12-01|2008-12-02|Estimate|||||||2009-03-05|2009-03-06|Estimate|July 1997||1997-07-31|March 2009|2009-03-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||A Study of Glaucoma or Ocular Hypertension in Patients Within the United States|A 6-Month, Randomized, Double-Masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-Month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Multicenter Study in the United States|Completed||Phase 3|418|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:31:51.690229|2018-06-01 01:31:51.690229
NCT00800254|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|2015-05-28||2015-07-14|2008-11-30|2008-12-02|Estimate|2015-07-14|2015-08-11|Estimate||||2015-07-14|2015-08-11|Estimate|October 2008||2008-10-31|July 2015|2015-07-31|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Interventional|||Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement|Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement|Completed||Phase 2|66|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:31:51.812545|2018-06-01 01:31:51.812545
NCT00800241|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2010-12-02|2008-12-01|2008-12-02|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2009||2009-05-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|||||Observational|||Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand|Budesonide/Formoterol for Maintenance and Reliever Therapy: A Medication Use Evaluation Among Persistent Asthma Patients in General Practice in Thailand|Completed|||1020|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:31:52.971451|2018-06-01 01:31:52.971451
NCT00800228|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-30|||2008-11-30|2008-11-30|2008-12-02|Estimate|||||||2008-11-30|2008-12-02|Estimate|March 2003||2003-03-31|November 2008|2008-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Salt Study: Inhibited Breathing Pattern and Sodium Inhibitors in Sodium Sensitivity of Blood Pressure|Inhibited Breathing Pattern and Sodium Inhibitors in Sodium Sensitivity of Blood Pressure|Completed|||96|Actual|National Institute on Aging (NIA)|||2||f||||f||||||||||2018-06-01 01:31:53.057994|2018-06-01 01:31:53.057994
NCT00800215|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|||2015-05-26|2008-12-01|2008-12-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2004||2004-03-31|May 2015|2015-05-31|November 2004|Actual|2004-11-30|August 2004|Actual|2004-08-31||Interventional|||A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927|A Multicenter, Double-blind, Double-dummy, Randomized Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization|Completed||Phase 2|60|Actual|UCB Pharma||4|||f||||t||||||||||2018-06-01 01:31:53.118708|2018-06-01 01:31:53.118708
NCT00800202|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01|2014-06-23||2014-11-10|2008-12-01|2008-12-02|Estimate|2014-11-10|2014-11-19|Estimate||||2014-11-10|2014-11-19|Estimate|April 2009||2009-04-30|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||The Intent-to-Treat (ITT) population: All participants enrolled in each arm who had at least one post-enrollment evaluation. Participants who were lost to follow-up immediately after enrollment were not included in the ITT population.|A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis|An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-carboplatin or Second Line Tarceva (Erlotinib) on Progression-free Survival in Non-squamous Non-small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis|Completed||Phase 2|91|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:31:53.225846|2018-06-01 01:31:53.225846
NCT00800189|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2012-03-07|2008-12-01|2008-12-02|Estimate|||||||2012-03-07|2012-03-09|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|Anterior EPI||Evaluation of the Informational Content of Setup Verification Images for Patients Receiving Breast Radiation Therapy (Anterior EPI)|A Prospective Evaluation of the Informational Content of Setup Verification Images for Patients Receiving Breast Radiation Therapy Tangentially With or Without Supraclavicular Treatment|Completed||N/A|200|Anticipated|British Columbia Cancer Agency|||||f||||t||||||||||2018-06-01 01:31:53.729917|2018-06-01 01:31:53.729917
NCT00800176|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-01||2016-07-26|2016-07-26|2008-12-01|2008-12-02|Estimate||||2016-07-26|2016-07-28|Estimate|2016-07-26|2016-07-28|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus|A Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled 12-week Study to Investigate Glycemic Parameters of Efficacy, Safety/ Tolerability and Pharmacokinetics of Five Dose Levels of RO4998452 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|405|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 01:31:53.801063|2018-06-01 01:31:53.801063
NCT00800163|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2010-07-22|2008-11-26|2008-12-01|Estimate|||||||2010-07-22|2010-07-23|Estimate|September 2005||2005-09-30|November 2008|2008-11-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|EHART||Improving Door-to-Balloon Time in STEMI|Emergency Department Physician Activation of the Catheterization Laboratory and Immediate Transfer to an Immediately Available Catheterization Lab Reduce Door-to-Balloon Time in ST-Elevation Myocardial Infarction|Unknown status|Recruiting|N/A|1000|Anticipated|St. Francis Hospitals & Health Centers||1|||f||||f||||||||||2018-06-01 01:31:53.976515|2018-06-01 01:31:53.976515
NCT00800150|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|||2015-06-03|2008-11-27|2008-12-01|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment|Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination With Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients With Advanced and Hematological Malignancies Who Are Not Eligible for Fully Myeloablative Regimen|Terminated||Phase 1|6|Actual|City of Hope Medical Center||||"Protocol objective could not be met. A new study with amended eligibility criteria will be~   developed."|f||||t||||||||||2018-06-01 01:31:54.14044|2018-06-01 01:31:54.14044
NCT00800137|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-04-08|2008-11-28|2008-12-01|Estimate|||||||2013-04-08|2013-04-10|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|BRUISECONTROL||Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial|Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL)|Terminated||Phase 4|984|Actual|Ottawa Heart Institute Research Corporation||2||At time of pre-specified 2nd interim analysis|f||||t||||||||||2018-06-01 01:31:54.259022|2018-06-01 01:31:54.259022
NCT00800124|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|||2014-11-21|2008-11-28|2008-12-01|Estimate|||||||2014-11-21|2014-11-24|Estimate|June 2005||2005-06-30|November 2008|2008-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CNC||Study on Cemented Versus Non-cemented Hemiarthroplasty in Elderly With Hip Fractures|A Prospective Randomized Multicenter Study on Cemented and Non-cemented Hemiprosthesis in Older Patients With Dislocated Hip Fracture.|Completed||N/A|334|Actual|Sykehuset Innlandet HF||2|||f||||f||||||||||2018-06-01 01:31:54.483486|2018-06-01 01:31:54.483486
NCT00800111|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2018-01-24|2008-11-28|2008-12-01|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2008||2008-02-29|January 2018|2018-01-31|February 2025|Anticipated|2025-02-28|February 2025|Anticipated|2025-02-28||Interventional|||Study of Endothelial Keratoplasty Outcomes|Open-enrollment, Prospective Study of Endothelial Keratoplasty Outcomes|Recruiting||N/A|5000|Anticipated|Cornea Research Foundation of America||1|||f||||t||||||||||2018-06-01 01:31:54.559046|2018-06-01 01:31:54.559046
NCT00800098|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-06-21|2008-11-28|2008-12-01|Estimate|||||||2013-06-21|2013-06-24|Estimate|December 2008||2008-12-31|June 2013|2013-06-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|||Effects of an Herbal Topical Cream on Osteoarthritis Symptoms, Biomarkers, and Disease Progression in the Knee|Effects of an Herbal Topical Cream on Osteoarthritis Symptoms, Biomarkers, and Disease Progression in the Knee|Completed||Early Phase 1|22|Actual|Stanford University||2|||f||||||||||||||2018-06-01 01:31:54.663842|2018-06-01 01:31:54.663842
NCT00800085|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2013-12-27|2008-11-28|2008-12-01|Estimate|||||||2013-12-27|2013-12-30|Estimate|October 2006||2006-10-31|December 2013|2013-12-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Beta Cell Function in (Pre) Type 1 Diabetes|Beta Cell Function in (Pre) Type 1 Diabetes|Unknown status|Enrolling by invitation|Phase 1/Phase 2|200|Anticipated|AZ-VUB||1|||f||||f||||||||||2018-06-01 01:31:54.764185|2018-06-01 01:31:54.764185
NCT00800072|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2014-02-26|2008-11-28|2008-12-01|Estimate|||||||2014-02-26|2014-02-27|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||NOWOX Oxygen Therapy Monitoring Device|Evaluation of NOWOX: a Medical Device Developed to Record Duration of Oxygen Use and Respiration Rate in Patients Requiring Oxygen Therapy|Completed||N/A|10|Actual|Air Liquide SA||1|||f||||f||||||||||2018-06-01 01:31:54.844026|2018-06-01 01:31:54.844026
NCT00800059|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|||2015-07-23|2008-11-28|2008-12-01|Estimate|||||||2015-07-23|2015-07-27|Estimate|November 2008||2008-11-30|July 2015|2015-07-31|November 2025|Anticipated|2025-11-30|November 2020|Anticipated|2020-11-30||Interventional|TMI-ASCT||Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma|A Dose Escalation Study of Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM)|Recruiting||Phase 1/Phase 2|27|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-06-01 01:31:54.907785|2018-06-01 01:31:54.907785
NCT00800046|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2017-11-16|2008-11-26|2008-12-01|Estimate|||||||2017-11-16|2017-11-20|Actual|November 2008||2008-11-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Percutaneous Treatment of Mitral Regurgitation Using the AccuCinch® System|A Study of Percutaneous Treatment of Mitral Regurgitation Using the AccuCinch® System|Recruiting||N/A|40|Anticipated|Ancora Heart, Inc.||1|||f||||f|f|t|t||t|||||2018-06-01 01:31:55.001554|2018-06-01 01:31:55.001554
NCT00800033|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2015-05-26|2008-11-28|2008-12-01|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effectiveness of Pulse-Based Foods Combined With Exercise for Improving Components of the Metabolic Syndrome|Effectiveness of Pulse-Based Foods Combined With Exercise for Improving Components of the Metabolic Syndrome|Completed||Phase 3|87|Actual|University of Saskatchewan||4|||f||||f||||||||||2018-06-01 01:31:55.13069|2018-06-01 01:31:55.13069
NCT00800007|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2009-02-19|2008-11-26|2008-12-01|Estimate|||||||2009-02-19|2009-02-20|Estimate|November 2008||2008-11-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus|A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Intravenous Doses of ANZ-521 in Hepatitis C Patients|Terminated||Phase 1/Phase 2|5|Actual|Anza Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 01:31:55.220499|2018-06-01 01:31:55.220499
NCT00799994|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2016-11-20|2008-11-28|2008-12-01|Estimate|||||||2016-11-20|2016-11-22|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Does Lowering Eye Pressure Affect the Results Obtained From Objective Visual Field Testing?|Effect of Acutely Lowering Intraocular Pressure on Multifocal Visual Evoked Potential Testing|Completed|||23|Actual|Wills Eye|||2||f||||f||||||||No||2018-06-01 01:31:55.29003|2018-06-01 01:31:55.29003
NCT00799981|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2012-09-27|2008-11-28|2008-12-01|Estimate|||||||2012-09-27|2012-09-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:31:55.347756|2018-06-01 01:31:55.347756
NCT00799968|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2008-11-28|2008-11-28|2008-12-01|Estimate|||||||2008-11-28|2008-12-01|Estimate|June 2002||2002-06-30|November 2008|2008-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|UKPTEC||12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China|Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China|Completed||Phase 4|129|Actual|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-06-01 01:31:55.394974|2018-06-01 01:31:55.394974
NCT00799955|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-01-22|2008-11-28|2008-12-01|Estimate|||||||2013-01-22|2013-01-23|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Comparing 2 Types of Pain Relief After Cesarean Delivery: Spinal Morphine and TAP Block|Comparison of Efficacy and Side Effects of Intrathecal Morphine and TAP Block for Post-cesarean Analgesia|Completed||N/A|70|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 01:31:55.575231|2018-06-01 01:31:55.575231
NCT00799942|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|||2010-06-30|2008-11-28|2008-12-01|Estimate|||||||2010-06-30|2010-07-01|Estimate|May 2009||2009-05-31|June 2010|2010-06-30||||||||Interventional|||Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus|Long-term Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus|Terminated||Phase 2|48|Anticipated|Merz Pharmaceuticals GmbH|||||f||||f||||||||||2018-06-01 01:31:55.699166|2018-06-01 01:31:55.699166
NCT00799929|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2015-12-22|2008-11-28|2008-12-01|Estimate|||||||2015-12-22|2015-12-24|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||IVF Clinical Trial of Two Different Treatment Protocols.|Efficiency and Patient Satisfaction of Two Different IVF Protocols.|Completed||N/A|564|Actual|New Hope Fertility Center||2|||f||||t||||||||||2018-06-01 01:31:55.745037|2018-06-01 01:31:55.745037
NCT00799916|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2009-09-14|2008-11-28|2008-12-01|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Saline Solution Versus Voluven®: A Controlled Study of Fluid Resuscitation in Severe Sepsis|Saline Solution Versus Voluven®: A Controlled Study of Fluid Resuscitation in Severe Sepsis|Completed||Phase 3|30|Anticipated|Universidad Nacional de La Plata||2|||f||||f||||||||||2018-06-01 01:31:55.804322|2018-06-01 01:31:55.804322
NCT00799903|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2017-07-12|2014-03-27|2017-07-12|2008-11-28|2008-12-01|Estimate|2017-07-12|2017-08-10|Actual|2014-03-27|2014-04-24|Estimate|2017-07-12|2017-08-10|Actual|December 1, 2008||2008-12-01|March 2017|2017-03-31|October 17, 2013|Actual|2013-10-17|October 1, 2013|Actual|2013-10-01||Interventional|STABILITY||The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial|LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)|Completed||Phase 3|15828|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:31:56.21761|2018-06-01 01:31:56.21761
NCT00799890|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2018-03-19|2008-11-28|2008-12-01|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2009||2009-05-31|December 2017|2017-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SUPREMES||Sunphenon in Progressive Forms of Multiple Sclerosis|Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis|Completed||Phase 2/Phase 3|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:32:02.114767|2018-06-01 01:32:02.114767
NCT00799877|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2018-05-08|2008-11-28|2008-12-01|Estimate|||||||2018-05-08|2018-05-14|Actual|September 26, 2008|Actual|2008-09-26|May 2018|2018-05-31|September 29, 2022|Anticipated|2022-09-29|September 29, 2022|Anticipated|2022-09-29||Observational|||Chronic Plaque Psoriasis (Ps) Registry|A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS)|Active, not recruiting|||6082|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-06-01 01:32:02.282323|2018-06-01 01:32:02.282323
NCT00799864|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2018-05-23|2008-11-28|2008-12-01|Estimate|||||||2018-05-23|2018-05-25|Actual|January 7, 2011|Actual|2011-01-07|May 2018|2018-05-31|September 28, 2027|Anticipated|2027-09-28|January 10, 2020|Anticipated|2020-01-10||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years|A Phase II, Open Label, Single Arm Trial to Evaluate the Pharmacokinetics,Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Antiretroviral Naive HIV-1 Infected Adolescents and Children Aged >= 6 to <18 Years|Recruiting||Phase 2|61|Anticipated|Janssen Sciences Ireland UC||1|||f||||t||f||||||||2018-06-01 01:32:02.924247|2018-06-01 01:32:02.924247
NCT00799851|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2008-11-28|2008-11-28|2008-12-01|Estimate|||||||2008-11-28|2008-12-01|Estimate|November 2004||2004-11-30|November 2008|2008-11-30|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices|Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection|Completed||Phase 4|38|Actual|Federal University of São Paulo||2|||||||t||||||||||2018-06-01 01:32:03.053323|2018-06-01 01:32:03.053323
NCT00799838|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2014-10-23|2008-11-28|2008-12-01|Estimate|||||||2014-10-23|2014-10-24|Estimate|November 2008||2008-11-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|DROPS||Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients|Local, Phase IV, Multicenter, Double-blind, Randomized, Parallel, With Two Treatment Arms, Placebo-controlled Study to Evaluate the Reduction of Inflammatory Symptoms in the Treatment of Bacterial Pharyngitis With Ketoprofen and Amoxicillin in Pediatric Patients.|Terminated||Phase 4|106|Actual|Sanofi||2||Recruitment challenges despite several attenpts to increase enrollment|f||||f||||||||||2018-06-01 01:32:03.118411|2018-06-01 01:32:03.118411
NCT00799825|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2013-07-18||2016-12-23|2008-11-26|2008-12-01|Estimate|2013-07-18|2013-09-20|Estimate||||2016-12-23|2017-02-13|Actual|January 2009||2009-01-31|December 2016|2016-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US|Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008|Completed||Phase 3|346|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:32:03.194726|2018-06-01 01:32:03.194726
NCT00799812|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2015-08-10|2008-11-26|2008-12-01|Estimate|||||||2015-08-10|2015-08-13|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Test for Preoperative Skin Preparations|ChloraPrep Triple Swabsticks, Hibiclens and Sterile Triple Swabsticks (Using Sterile Deionized Water)|Completed||Phase 1/Phase 2|111|Actual|CareFusion||5|||f||||f||||||||||2018-06-01 01:32:03.695114|2018-06-01 01:32:03.695114
NCT00799071|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2012-05-30|2008-11-26|2008-11-27|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|iPOD||Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)|Investigation of POsaconazole Prophylaxis in Children With Chronic Granulomatous Disease (CGD): Pharmacokinetics and Tolerability (iPOD)|Completed||Phase 2|12|Actual|Radboud University||1|||f||||f||||||||||2018-06-01 01:32:13.572803|2018-06-01 01:32:13.572803
NCT00799799|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2009-09-23|2008-11-28|2008-12-01|Estimate|||||||2009-09-23|2009-09-24|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells|Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells|Unknown status|Recruiting|Phase 1|15|Anticipated|University of Bologna||1|||f||||t||||||||||2018-06-01 01:32:03.779983|2018-06-01 01:32:03.779983
NCT00799786|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2010-08-12|2008-11-28|2008-12-01|Estimate|||||||2010-08-12|2010-08-13|Estimate|November 2008||2008-11-30|August 2010|2010-08-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Building Better Caregivers Online: An Online Workshop for Caregivers of Those With Traumatic Brain Injury, Post Traumatic Stress Disorder, or Alzheimer's or Other Dementia|Building Better Caregivers Online|Completed||Phase 1|120|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 01:32:03.846966|2018-06-01 01:32:03.846966
NCT00799773|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2013-05-07||2013-07-18|2008-11-26|2008-12-01|Estimate|2013-07-18|2013-07-22|Estimate||||2013-07-18|2013-07-22|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|STAR||Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)|STAR - Study of TTP and Rituximab, A Randomized Clinical Trial|Terminated||Phase 3|3|Actual|New England Research Institutes|One treatment arm had only one subject, so to protect patient confidentiality, results are not being entered.|2||Low enrollment rate|f||||t||||||||||2018-06-01 01:32:03.933734|2018-06-01 01:32:03.933734
NCT00799760|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2012-03-16|2008-11-28|2008-12-01|Estimate|||||||2012-03-16|2012-03-19|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|BIVIR||Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir|Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomises Double Blind Controlled Trial Study|Terminated||Phase 3|541|Actual|Assistance Publique - Hôpitaux de Paris||3||Just Terminated for the end of the pandemia|f||||t||||||||||2018-06-01 01:32:04.376318|2018-06-01 01:32:04.376318
NCT00799747|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2009-06-30|2008-11-28|2008-12-01|Estimate|||||||2009-06-30|2009-07-02|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|||||Interventional|||Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre Phase I Study in Healthy Japanese Male Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD4017 After Single Ascending Oral Doses|Completed||Phase 1|56|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:32:04.465391|2018-06-01 01:32:04.465391
NCT00799734|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2011-07-25|2008-11-28|2008-12-01|Estimate|||||||2011-07-25|2011-07-26|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Chinese Medicine Therapy on Menopausal Symptoms|A Double-blind Randomized Placebo-controlled Clinical Trial on the Effects of Chinese Medicine Formula (Erxian Decoction) on Menopausal Symptoms|Completed||N/A|108|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-06-01 01:32:04.535176|2018-06-01 01:32:04.535176
NCT00799721|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2008-11-28|2008-11-28|2008-12-01|Estimate|||||||2008-11-28|2008-12-01|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|February 2010|Anticipated|2010-02-28||Observational|||Urine VEGF Levels in Very Low Birth Weight (VLBW) Infants||Unknown status|Recruiting||160|Anticipated|Charite University, Berlin, Germany|||2||f||||||||||Samples Without DNA|"~     Urine samples that are centrifugated to get rid of any cells where stored at -80°C until~     ELISA is done.~   "|||2018-06-01 01:32:04.609099|2018-06-01 01:32:04.609099
NCT00799708|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2010-06-25||2016-02-18|2008-11-28|2008-12-01|Estimate|2010-06-25|2010-07-29|Estimate||||2016-02-18|2016-03-16|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Effects of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women|Completed||Phase 1|27|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 01:32:04.69679|2018-06-01 01:32:04.69679
NCT00799695|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2008-11-28|2008-11-28|2008-12-01|Estimate|||||||2008-11-28|2008-12-01|Estimate|January 2008||2008-01-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population|Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population|Completed||N/A|561|Actual|Henry Ford Health System|||||f||||f||||||||||2018-06-01 01:32:05.012597|2018-06-01 01:32:05.012597
NCT00799682|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2011-07-20|2008-11-28|2008-12-01|Estimate|||||||2011-07-20|2011-07-21|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®|An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z®|Completed||Phase 4|56|Actual|Ophthalmic Consultants of Long Island||2|||f||||||||||||||2018-06-01 01:32:05.075168|2018-06-01 01:32:05.075168
NCT00799669|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|||2018-03-13|2008-11-27|2008-12-01|Estimate|||||||2018-03-13|2018-03-15|Actual|February 2009|Actual|2009-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use|Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use|Active, not recruiting|||370|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 01:32:05.153696|2018-06-01 01:32:05.153696
NCT00799656|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-27|||2011-03-31|2008-11-28|2008-12-01|Estimate|||||||2011-03-31|2011-04-01|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|SERENEATI||Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain|Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-blind, Placebo-controlled, Cross-over Study|Completed||Phase 2|62|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:32:05.223083|2018-06-01 01:32:05.223083
NCT00799643|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2013-09-13||2017-11-08|2008-11-26|2008-12-01|Estimate|2013-09-13|2013-11-25|Estimate||||2017-11-08|2017-12-11|Actual|November 2008||2008-11-30|November 2017|2017-11-30||||September 2012|Actual|2012-09-30||Interventional|TINSALT2D-II||Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II|Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate|Completed||Phase 2/Phase 3|638|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-06-01 01:32:05.295923|2018-06-01 01:32:05.295923
NCT00799630|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2008-11-28|2008-11-28|2008-12-01|Estimate|||||||2008-11-28|2008-12-01|Estimate|November 2008||2008-11-30|November 2008|2008-11-30||||||||Interventional|||Effects of Nutraperf Consumption in Runners|Identification of the Effects of NUTRAPERF Consumption on Performance in Endurance-Type Exercise.|Completed||N/A|14|Actual|Lescuyer Laboratory|||||f||||f||||||||||2018-06-01 01:32:05.698487|2018-06-01 01:32:05.698487
NCT00799617|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2017-01-03|2015-06-09|2017-12-01|2008-11-26|2008-12-01|Estimate|2017-08-09|2017-08-28|Actual|2015-07-14|2015-08-05|Estimate|2017-12-01|2017-12-28|Actual|November 2009||2009-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2014|Actual|2014-07-31||Interventional||Two participants were randomized in error, one in each arm of the study.|The Testosterone Trials in Older Men|Randomized, Placebo-controlled, Double-blind Study of Seven Coordinated Testosterone Treatment Trials in Older Men|Active, not recruiting||Phase 3|790|Actual|University of Pennsylvania||2|||f||||t|t|f||||||||2018-06-01 01:32:05.84804|2018-06-01 01:32:05.84804
NCT00799604|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2012-07-30||2014-08-21|2008-11-28|2008-12-01|Estimate|2014-05-12|2014-06-04|Estimate||||2014-08-21|2014-08-29|Estimate|November 2008||2008-11-30|August 2014|2014-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|SPRINT|These analyses include the Safety population defined as all participants, irrespective of eligibility, who were enrolled in Treatment Period 1 (Bolus 1 - pre-anesthesia) and were dosed with clevidipine. The number of participants in the Safety population and Modified Intent-To-Treat (mITT) population are identical.|Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)|An Open-label Study in Patients Undergoing Cardiac Surgery to Evaluate the Effect of Bolus Clevidipine Administration (SPRINT)|Completed||Phase 2|30|Actual|The Medicines Company||1|||f||||f||||||||||2018-06-01 01:32:07.030454|2018-06-01 01:32:07.030454
NCT00799591|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2011-09-08||2011-11-15|2008-11-28|2008-12-01|Estimate|2011-11-15|2011-12-19|Estimate||||2011-11-15|2011-12-19|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||French Study In ICU Patients Treated With Tigecycline|French Prospective Observational Study In Intensive Care Unit (ICU) Patients Treated With Tigecycline|Completed|||156|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 01:32:07.49831|2018-06-01 01:32:07.49831
NCT00799578|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|2013-12-13||2013-12-13|2008-11-28|2008-12-01|Estimate|2013-12-13|2014-01-31|Estimate||||2013-12-13|2014-01-31|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)||Completed||Phase 1/Phase 2|13|Actual|University of California, San Diego||1|||f||||f||||||||||2018-06-01 01:32:07.9538|2018-06-01 01:32:07.9538
NCT00799565|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2011-07-13|2008-11-28|2008-12-01|Estimate|||||||2011-07-13|2011-07-14|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|MVP-France||Mitral Valve Prolapse (MVP) - France Study|Genetic Polymorphisms in Idiopathic Mitral Valve Prolapse :A French Prospective Study Using a Genome Wide Analysis|Completed||N/A|1179|Actual|French Cardiology Society||2|||f||||t||||||||||2018-06-01 01:32:08.109356|2018-06-01 01:32:08.109356
NCT00799552|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26||2010-09-07|2010-09-20|2008-11-28|2008-12-01|Estimate||||2010-09-07|2010-09-20|Estimate|2010-09-20|2010-09-24|Estimate|November 2008||2008-11-30|September 2010|2010-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye|A Phase II, Multi-Center, Double-Masked, Randomized, Placebo Controlled, Study on the Safety and Efficacy of RX-10045 on the Signs and Symptoms of Dry Eye in Every Day Environmental Conditions and During Provocation Using the Controlled Adverse Environment (CAE) Model|Completed||Phase 2|232|Actual|Resolvyx Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 01:32:08.201271|2018-06-01 01:32:08.201271
NCT00799539|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2015-11-30|2008-11-26|2008-12-01|Estimate|||||||2015-11-30|2015-12-02|Estimate||||November 2015|2015-11-30||||||||Expanded Access|||A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients|An International Single-Arm Study to Provide Further Safety and Efficacy Data on the Bortezomib(Velcade)/Melphalan/Prednisone Regimen in Previously Untreated Transplant Ineligible Multiple Myeloma Patients|No longer available|||||Janssen-Ortho Inc., Canada||||Company decision to cancel due to public funding|f||||f||||||||||2018-06-01 01:32:08.262164|2018-06-01 01:32:08.262164
NCT00799526|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2008-11-28|2008-11-28|2008-12-01|Estimate|||||||2008-11-28|2008-12-01|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|November 2010|Anticipated|2010-11-30|November 2008|Actual|2008-11-30||Interventional|||Transplant of Epithelium Conjunctival Human Autologous Cultivated ex Vivo in Amniotic Membrane for the Treatment of Symblepharon||Unknown status|Active, not recruiting|Phase 1|10|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 01:32:08.325767|2018-06-01 01:32:08.325767
NCT00799513|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-03-21|2008-11-28|2008-12-01|Estimate|||||||2012-03-21|2012-03-22|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma|A Phase II Trial to Evaluate the Safety and Activity of Single-agent Lenalidomide Given as Maintenance Therapy After Response to Second-line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-dose Chemotherapy and ASCT|Unknown status|Recruiting|Phase 2|47|Anticipated|IRCCS San Raffaele||1|||f||||t||||||||||2018-06-01 01:32:08.457427|2018-06-01 01:32:08.457427
NCT00799500|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-28|||2013-04-04|2008-11-28|2008-12-01|Estimate|||||||2013-04-04|2013-04-05|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Bacterial Vaginosis in Pregnancy: Detection by Weekly Vaginal pH Testing|Impact on Prematurity of a First-trimester Screening for Bacterial Vaginosis in Pregnancy Through Weekly Vaginal pH Determination. An Interventional, Community Study.|Completed||N/A|1049|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 01:32:08.543882|2018-06-01 01:32:08.543882
NCT00799487|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2010-06-25||2011-05-18|2008-11-26|2008-12-01|Estimate|2010-09-10|2010-10-01|Estimate||||2011-05-18|2011-05-24|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||CONCERTA Lab School Study|Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children With ADHD (The ABC Study)|Completed||Phase 4|89|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC||2|||f||||||||||||||2018-06-01 01:32:08.646028|2018-06-01 01:32:08.646028
NCT00799474|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2009-12-07||2016-02-25|2008-11-26|2008-11-27|Estimate|2009-12-07|2010-01-15|Estimate||||2016-02-25|2016-03-24|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination|Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination|Completed|||609|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 01:32:09.409341|2018-06-01 01:32:09.409341
NCT00799461|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2012-03-05|2008-11-26|2008-11-27|Estimate|||||||2012-03-05|2012-03-07|Estimate|August 2008||2008-08-31|March 2012|2012-03-31||||November 2011|Actual|2011-11-30||Interventional|||Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications|INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation|Completed||Phase 3|1337|Actual|Fred Hutchinson Cancer Research Center||3|||f||||f||||||||||2018-06-01 01:32:09.554358|2018-06-01 01:32:09.554358
NCT00799448|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2017-02-17|2008-11-26|2008-11-27|Estimate|||||||2017-02-17|2017-02-20|Actual|September 16, 2003|Actual|2003-09-16|February 2017|2017-02-28|September 20, 2004|Actual|2004-09-20|September 20, 2004|Actual|2004-09-20||Interventional|||Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes|Multi-centre, Open, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled With SU +/ Biguanide Therapy, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime Insulin vs. Insulin Alone|Terminated||Phase 4|40|Actual|Novo Nordisk A/S||||Low recruitment status|f||||f||||||||||2018-06-01 01:32:09.658707|2018-06-01 01:32:09.658707
NCT00799435|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2017-08-25||2017-08-25|2008-11-26|2008-11-27|Estimate|2017-08-25|2017-09-21|Actual||||2017-08-25|2017-09-21|Actual|July 2009||2009-07-31|August 2017|2017-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure|Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction|Terminated||Phase 4|2|Actual|Baylor College of Medicine|The study was stopped due to difficulties enrolling and fulfilling entry criteria|2||Inability to recruit adequate Sample Size who met the entry criteria|f||||f||||||||No||2018-06-01 01:32:09.723337|2018-06-01 01:32:09.723337
NCT00799422|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2012-10-16||2012-11-14|2008-11-25|2008-11-27|Estimate|2012-11-14|2012-11-16|Estimate||||2012-11-14|2012-11-16|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients|Evaluation of Lens Fit, Lens Parameters, and Circumlimbal Conjunctival Staining (CSS) in Normal Patients|Completed||N/A|26|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 01:32:09.975692|2018-06-01 01:32:09.975692
NCT00799409|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2010-06-14||2014-04-24|2008-11-26|2008-11-27|Estimate|2010-12-16|2011-01-20|Estimate||||2014-04-24|2014-05-09|Estimate|December 2008||2008-12-31|April 2014|2014-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Lab School Day Study for CONCERTA of Older Children With ADHD|The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD|Completed||Phase 4|78|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC||2|||f||||f||||||||||2018-06-01 01:32:10.208716|2018-06-01 01:32:10.208716
NCT00799396|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2016-02-18||2016-03-23|2008-11-26|2008-11-27|Estimate|2016-03-23|2016-03-28|Estimate||||2016-03-23|2016-03-28|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Participants were recruited from the Old Order Amish of Lancaster, Pennsylvania. They are well suited for genetic studies because they are a homogenous, closed, founder population.|Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)|Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)|Completed||Phase 4|682|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 01:32:10.99575|2018-06-01 01:32:10.99575
NCT00799383|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2017-10-31||2017-11-29|2008-11-26|2008-11-27|Estimate|2017-11-29|2017-12-26|Actual||||2017-11-29|2017-12-26|Actual|November 2008||2008-11-30|November 2017|2017-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia|Counteracting Risperidone-Induced Hyperprolactinemia in Youths|Completed||Phase 3|47|Actual|University of Iowa|Failure to enroll vitamin D deficient patients. The supplements dose were modest. The sample size was small. We may have included too broad a pubertal stage. We did not supplement other micronutrients. We did not include females.|2|||f||||f|t|f||||||||2018-06-01 01:32:11.173774|2018-06-01 01:32:11.173774
NCT00799370|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2014-06-25|2008-11-26|2008-11-27|Estimate|||||||2014-06-25|2014-06-26|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Randomized Control Trial on Postoperative Weight Bearing After High Tibial Osteotomy (HTO)|Prospective Study on Postoperative Weight Bearing After Opening Wedge High Tibial Osteotomy (HTO): Early Weight Bearing Versus Delayed. Open Labelled Randomized Clinical Study|Completed||N/A|50|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 01:32:11.574837|2018-06-01 01:32:11.574837
NCT00799357|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2010-01-11|2008-11-26|2008-11-27|Estimate|||||||2010-01-11|2010-01-12|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Utility of Bedside Ultrasound in the Prediction of Difficult Airway|Utility of Bedside Ultrasound in the Prediction of Difficult Airway|Completed|||162|Anticipated|University of Nebraska|||||f||||f||||||||||2018-06-01 01:32:11.738638|2018-06-01 01:32:11.738638
NCT00799344|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2014-01-15|2008-11-25|2008-11-27|Estimate|||||||2014-01-15|2014-01-16|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|REVEAL||REVEAL Study: Vessel Healing After Angioplasty|Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) Trial: Rationale, Objectives and Design|Completed|||34|Actual|CeloNova BioSciences, Inc.|||1||f||||f||||||||||2018-06-01 01:32:11.804669|2018-06-01 01:32:11.804669
NCT00799331|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2009-06-08|2008-11-26|2008-11-27|Estimate|||||||2009-06-08|2009-06-09|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Exploratory Study to Assess the Pharmacokinetics of AZD5985|An Exploratory Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Pharmacokinetics of Increasing Oral Doses of AZD5985 in Healthy Male Volunteers|Completed||Phase 1|32|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:32:11.880467|2018-06-01 01:32:11.880467
NCT00799305|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2008-11-26|2008-11-26|2008-11-27|Estimate|||||||2008-11-26|2008-11-27|Estimate|January 2009||2009-01-31|November 2008|2008-11-30||||||||Observational|||Correlation of Airflow Limitation and Other Respiratory Characteristics With Radiologic Changes of Lung Structure||Unknown status|Not yet recruiting||30|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-06-01 01:32:11.962935|2018-06-01 01:32:11.962935
NCT00799292|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2008-10-21||2008-11-26|2008-11-26|2008-11-27|Estimate|2008-11-26|2008-11-27|Estimate||||2008-11-26|2008-11-27|Estimate|January 2004||2004-01-31|November 2008|2008-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial|Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy|Completed||Phase 4|58|Actual|Ascher-Walsh, Charles, M.D.||2|||f||||f||||||||||2018-06-01 01:32:12.031124|2018-06-01 01:32:12.031124
NCT00799279|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2010-10-05|2008-11-26|2008-11-27|Estimate|||||||2010-10-05|2010-10-06|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Integrating Smoking Cessation Into Routine Primary Care Practice|Comparative Evaluation of the Efficacy and Cost-effectiveness of Two Interventions for Integrating Smoking Cessation Into Routine Primary Care Practice: A Cluster-randomized Trial|Completed||N/A|835|Actual|University of Waterloo||2|||f||||f||||||||||2018-06-01 01:32:12.232179|2018-06-01 01:32:12.232179
NCT00799266|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2018-01-24|2008-11-26|2008-11-27|Estimate|||||||2018-01-24|2018-01-26|Actual|December 4, 2008|Actual|2008-12-04|January 2018|2018-01-31|March 2, 2018|Anticipated|2018-03-02|March 2, 2018|Anticipated|2018-03-02||Interventional|||A Research Study of Zoledronic Acid in Children and Adolescents With Osteoporosis|A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous (i.v.) Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids|Active, not recruiting||Phase 3|34|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:32:12.307615|2018-06-01 01:32:12.307615
NCT00799240|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2014-11-05|2008-11-25|2008-11-27|Estimate|||||||2014-11-05|2014-11-07|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|July 2014|Actual|2014-07-31|February 2011|Actual|2011-02-28||Interventional|IMPACT||MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer|MK-0646 IMPACT Study: MK-0646, Insulin Growth Factor 1 Receptor Antibody in Stage IIIB or IV Metastatic Non-Squamous Lung Cancer, Combined With Pemetrexed (Alimta) and Cisplatin, a Randomized Phase II Trial.|Completed||Phase 2|27|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 01:32:12.419847|2018-06-01 01:32:12.419847
NCT00799227|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|2014-07-10|2010-09-24|2014-07-10|2008-11-26|2008-11-27|Estimate|2014-07-10|2014-08-04|Estimate|2010-09-24|2010-09-29|Estimate|2014-07-10|2014-08-04|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema||Completed||Phase 2|56|Actual|Allergan||1|||f||||f||||||||||2018-06-01 01:32:12.51523|2018-06-01 01:32:12.51523
NCT00799214|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2016-10-25|2008-11-25|2008-11-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study|Back to BASICS: Boric Acid, Alternate Solution for Intravaginal Colonization, Comparing Intravaginal Metronidazole to Boric Acid in Women Symptomatic for Bacterial Vaginosis|Completed||Phase 2/Phase 3|13|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 01:32:12.716517|2018-06-01 01:32:12.716517
NCT00799201|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2015-07-27|2008-11-26|2008-11-27|Estimate|||||||2015-07-27|2015-07-29|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients|A Prospective, Randomized Trial of Enteral Naloxone Versus a Traditional Bowel Regimen in Prevention of Constipation and Decreased Gastric Motility in Critically Ill Trauma Patients|Terminated||Phase 4|3|Actual|CAMC Health System||1||"Naloxone became unavailable due to manufacturing shortatges requiring the study to be~   terminated."|f||||t||||||||||2018-06-01 01:32:12.7895|2018-06-01 01:32:12.7895
NCT00799188|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-12-11|2008-11-26|2008-11-27|Estimate|||||||2013-12-11|2013-12-12|Estimate|October 2008||2008-10-31|December 2013|2013-12-31||||September 2014|Anticipated|2014-09-30||Interventional|CERTICOEUR||CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial|CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial|Unknown status|Active, not recruiting|Phase 3|175|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 01:32:12.866906|2018-06-01 01:32:12.866906
NCT00799175|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2008-11-26|2008-11-26|2008-11-27|Estimate|||||||2008-11-26|2008-11-27|Estimate|April 2007||2007-04-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|RAK-total||Local Infiltration Analgesia Following Total Knee Arthroplasty|Local Infiltration Analgesia With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Total Knee Arthroplasty|Completed||N/A|48|Actual|Region Örebro County||2|||f||||t||||||||||2018-06-01 01:32:12.941518|2018-06-01 01:32:12.941518
NCT00799162|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2011-09-23|2008-11-25|2008-11-27|Estimate|||||||2011-09-23|2011-09-26|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Observational|PPCSP||Prediction of Post-Cesarean Section Pain|Prediction of Post-Cesarean Section Pain|Unknown status|Recruiting||800|Anticipated|University of Washington|||1||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:32:13.009335|2018-06-01 01:32:13.009335
NCT00799149|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2008-11-26|2008-11-26|2008-11-27|Estimate|||||||2008-11-26|2008-11-27|Estimate|June 2006||2006-06-30|November 2008|2008-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Etoricoxib Versus Gabapentin for Knee Arthroscopy|Phase 4 Study Comparing the Efficacy of Etoricoxib Versus Gabapentin as Part of a Multimodal Analgesic Regimen for Ambulatory Knee Arthroscopy|Completed||Phase 4|75|Actual|Meir Medical Center||3|||f||||f||||||||||2018-06-01 01:32:13.089926|2018-06-01 01:32:13.089926
NCT00799136|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-09-11|2008-11-26|2008-11-27|Estimate|||||||2013-09-11|2013-09-12|Estimate|February 2008||2008-02-29|September 2013|2013-09-30|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|CATCH||A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL|Feasibility Study of CO-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of Acquired Immunodeficiency Syndrome (AIDS)-Related Lymphoma|Completed||Phase 2|6|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||t||||||||||2018-06-01 01:32:13.147221|2018-06-01 01:32:13.147221
NCT00799123|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2010-04-09|2008-11-26|2008-11-27|Estimate|||||||2010-04-09|2010-04-12|Estimate|August 2008||2008-08-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants||Completed|||100|Anticipated|Charite University, Berlin, Germany|||||f||||f|||||||"~     urine~   "|||2018-06-01 01:32:13.210817|2018-06-01 01:32:13.210817
NCT00799110|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2018-05-10|2008-11-26|2008-11-27|Estimate|||||||2018-05-10|2018-05-11|Actual|August 2008||2008-08-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod|Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With GM-CSF and Imiquimod|Active, not recruiting||Phase 2|23|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 01:32:13.258466|2018-06-01 01:32:13.258466
NCT00799097|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2010-05-19|2008-11-26|2008-11-27|Estimate|||||||2010-05-19|2010-05-20|Estimate|July 2004||2004-07-31|November 2008|2008-11-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|||Determinants of Surgical Outcomes in Chronic Sinusitis|Determinants of Surgical Outcomes in Chronic Sinusitis|Completed|||516|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-06-01 01:32:13.330819|2018-06-01 01:32:13.330819
NCT00799084|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2011-12-06|2008-11-26|2008-11-27|Estimate|||||||2011-12-06|2011-12-07|Estimate|April 2003||2003-04-30|December 2011|2011-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|ATSM||Automated Telephone Monitoring for Symptom Management|Automated Telephone Monitoring for Symptom Management|Completed||Phase 2|526|Actual|Michigan State University||2|||f||||f||||||||||2018-06-01 01:32:13.384322|2018-06-01 01:32:13.384322
NCT00799058|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26||2017-01-19|2017-09-07|2008-11-26|2008-11-27|Estimate||||2017-01-19|2017-01-23|Estimate|2017-09-07|2017-09-15|Actual|June 2009||2009-06-30|September 2017|2017-09-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring With Dapivirine for the Prevention of HIV-1 Infection in Women|Completed||Phase 3|180|Actual|International Partnership for Microbicides, Inc.||3|||f||||t||||||||No||2018-06-01 01:32:13.660998|2018-06-01 01:32:13.660998
NCT00799045|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2015-05-11|2008-11-26|2008-11-27|Estimate|||||||2015-05-11|2015-05-12|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|April 2015|Actual|2015-04-30||Interventional|CANOA||Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects|Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study)|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Laval University||2|||f||||f||||||||||2018-06-01 01:32:13.742498|2018-06-01 01:32:13.742498
NCT00799032|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2017-06-06|2008-11-26|2008-11-27|Estimate|||||||2017-06-06|2017-06-07|Actual|May 2007||2007-05-31|June 2017|2017-06-30|August 2008|Actual|2008-08-31|August 2007|Actual|2007-08-31||Interventional|ATLANTA||The ATLANTA First in Man Study of the Catania Stent|Assessment of The Latest Non-Thrombogenic Angioplasty Stent (ATLANTA): Prospective, First in Man, Non-Randomized, Single Center for Patients With Documented Myocardial Ischemia Undergoing PCI|Completed||Phase 1|55|Actual|CeloNova BioSciences, Inc.||1|||f||||t||||||||||2018-06-01 01:32:13.818039|2018-06-01 01:32:13.818039
NCT00799019|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2014-01-27|2008-11-26|2008-11-27|Estimate|||||||2014-01-27|2014-01-29|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|December 2013|Actual|2013-12-31||Observational|||A Prospective, Immunogenicity Surveillance Registry of Erythropoiesis Stimulating Agent (ESA) With Subcutaneous Exposure in Thailand|A Prospective, Immunogenicity Surveillance Registry of Erythropoiesis Stimulating Agent (ESA) With Subcutaneous Exposure in Thailand|Unknown status|Active, not recruiting||6500|Anticipated|Chulalongkorn University|||||f||||t||||||||||2018-06-01 01:32:13.883969|2018-06-01 01:32:13.883969
NCT00799006|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2009-07-17|2008-11-25|2008-11-27|Estimate|||||||2009-07-17|2009-07-20|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers|A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Subjects|Completed||Phase 1|27|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:32:13.945578|2018-06-01 01:32:13.945578
NCT00798993|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2013-06-06|2008-11-26|2008-11-27|Estimate|||||||2013-06-06|2013-06-10|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of 25-hydroxyvitamin D and a Structured Exercise Program on Dialysis Patients|The Effect of 25-hydroxyvitamin D Supplementation and a Structured Exercise Program on Exercise Capacity and Quality of Life in Dialysis Patients|Completed||Phase 4|19|Actual|Sir Charles Gairdner Hospital||3|||f||||f||||||||||2018-06-01 01:32:14.035481|2018-06-01 01:32:14.035481
NCT00798980|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-26|||2015-04-21|2008-11-26|2008-11-27|Estimate|||||||2015-04-21|2015-04-22|Estimate|February 2007||2007-02-28|April 2015|2015-04-30|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Observational|||Scandinavian Mirena Insertion Nulliparous Trial.|Scandinavian Mirena Insertion Nulliparous Trial of an Observational Study.|Completed|||224|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:32:14.123561|2018-06-01 01:32:14.123561
NCT00798967|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2011-12-23||2015-11-10|2008-11-26|2008-11-27|Estimate|2011-12-23|2012-02-01|Estimate||||2015-11-10|2015-12-08|Estimate|November 2008||2008-11-30|January 2015|2015-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|STEPS||Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects|A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome|Completed||Phase 3|86|Actual|Shire||2|||f||||t||||||||||2018-06-01 01:32:14.220337|2018-06-01 01:32:14.220337
NCT00798954|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2010-06-09|2008-11-26|2008-11-27|Estimate|||||||2010-06-09|2010-06-10|Estimate|June 2007||2007-06-30|June 2010|2010-06-30|March 2010|Actual|2010-03-31|December 2008|Actual|2008-12-31||Interventional|SINGLEKISS||Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial|A Multi-center Trial to Evaluate Paclitaxel- and Sirolimus-eluting Stents in Provisional T-stenting With Kissing Balloon Technique in the Treatment of Bifurcation Lesions|Completed||Phase 4|800|Anticipated|Vulnerable Plaque Society||2|||f||||t||||||||||2018-06-01 01:32:14.513427|2018-06-01 01:32:14.513427
NCT00798941|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2010-07-06|2008-11-26|2008-11-27|Estimate|||||||2010-07-06|2010-07-08|Estimate|February 2009||2009-02-28|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||ICU Patient and Family Comfort Study||Completed||N/A|120|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-06-01 01:32:15.607599|2018-06-01 01:32:15.607599
NCT00798915|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2018-04-30|2008-11-25|2008-11-26|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2008||2008-12-31|April 2018|2018-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus|Restoration of the GIP-mediated Incretin Effect in Persons With Type 2 Diabetes Mellitus|Completed||Phase 1|40|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 01:32:15.687579|2018-06-01 01:32:15.687579
NCT00798902|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-03-07|2008-11-25|2008-11-26|Estimate|||||||2012-03-07|2012-03-09|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|July 2012|Anticipated|2012-07-31||Interventional|||Pilot Study to Assess Safety/Preliminary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery|A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion|Unknown status|Active, not recruiting|Phase 1/Phase 2|22|Anticipated|BioSurface Engineering Technologies, Inc||2|||f||||t||||||||||2018-06-01 01:32:15.782039|2018-06-01 01:32:15.782039
NCT00798889|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2012-12-13||2012-12-13|2008-11-25|2008-11-26|Estimate|2012-12-13|2013-01-21|Estimate||||2012-12-13|2013-01-21|Estimate|March 2004||2004-03-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Rollover Protocol for Prior SU011248 Protocols|A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol|Completed||N/A|314|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:32:15.907234|2018-06-01 01:32:15.907234
NCT00798876|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2017-09-12|2008-11-25|2008-11-26|Estimate|||||||2017-09-12|2017-09-14|Actual|December 18, 2001|Actual|2001-12-18|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Low-Fat Fish Oil Diet for Prostate Cancer Prevention|Comparison Study of a Low-Fat Diet Supplemented With Fish Oil and a Standard Western Diet in Individuals With Prostate Cancer|Active, not recruiting||N/A|70|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 01:32:17.161604|2018-06-01 01:32:17.161604
NCT00798863|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2009-07-14|2008-11-25|2008-11-26|Estimate|||||||2009-07-14|2009-07-15|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|VANSsubmand||Study Of The Safety And Efficacy Video Assisted Submandibular Gland Resection Using A New Two Step Technique|Video Assisted Submandibular Resection, Two Step Technique|Completed||N/A|12|Actual|Faculty of Medicine, University of Alexandria||1|||f||||t||||||||||2018-06-01 01:32:17.272355|2018-06-01 01:32:17.272355
NCT00798850|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2015-04-07|2008-11-25|2008-11-26|Estimate|||||||2015-04-07|2015-04-09|Estimate|August 2002||2002-08-31|April 2015|2015-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease|Randomised Controlled Trial of Percutaneous Transluminal Angioplasty (PTA) Versus a Supervised Exercise Programme (SEP) in the Management of Intermittent Claudication (IC) Due to Femoro-popliteal Disease|Completed||N/A|178|Actual|University of Hull||3|||f||||f||||||||||2018-06-01 01:32:17.433245|2018-06-01 01:32:17.433245
NCT00798837|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2015-09-28|2008-11-25|2008-11-26|Estimate|||||||2015-09-28|2015-09-30|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Intraprostatic MAXimal Simultaneous Boost|A Dose-escalation Study Using a Maximal Simultaneous Intraprostatic Boost With RapidArc Intensity Modulated Radiotherapy in Intermediate Risk Prostate Cancer|Terminated||Phase 1|10|Actual|British Columbia Cancer Agency||1||Excess risk in rectal bleeding of first 10 patients|f||||t||||||||||2018-06-01 01:32:17.532257|2018-06-01 01:32:17.532257
NCT00798824|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2010-10-12|2008-11-25|2008-11-26|Estimate|||||||2010-10-12|2010-10-13|Estimate|August 2008||2008-08-31|October 2010|2010-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Impact of Nasogastric Indwelling Versus Oral Intermittent Tube Feeding Methods on Premature Infants|The Impact of Nasogastric Indwelling Versus Oral Intermittent Tube Feeding Methods on Premature Infants|Completed||N/A|24|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-06-01 01:32:17.608747|2018-06-01 01:32:17.608747
NCT00798811|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2016-10-17|2008-11-25|2008-11-26|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|October 2015|Actual|2015-10-31|October 2013|Actual|2013-10-31||Interventional|||High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors|Multicenter Clinical Trial to Evaluate Efficacy of High-dose Chemotherapy With Autologous Stem Cell Rescue for Children With High-risk Brain Tumors|Completed||Phase 2|100|Anticipated|Samsung Medical Center||3|||f||||t||||||||||2018-06-01 01:32:17.69531|2018-06-01 01:32:17.69531
NCT00798798|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2014-05-22|2008-11-24|2008-11-26|Estimate|||||||2014-05-22|2014-05-23|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Externally Implantable Tissue Expansion Device on Scar Length|Effect of Externally Implantable Tissue Expansion Device on Scar Length|Withdrawn||N/A|0|Actual|Northwestern University||1||Inability to recruit eligible subjects|f||||f||||||||||2018-06-01 01:32:17.772572|2018-06-01 01:32:17.772572
NCT00798785|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2013-12-27|2008-11-25|2008-11-26|Estimate|||||||2013-12-27|2013-12-30|Estimate|October 2006||2006-10-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients|Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|AZ-VUB||4|||f||||f||||||||||2018-06-01 01:32:17.838872|2018-06-01 01:32:17.838872
NCT00798772|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2018-04-13|2008-11-25|2008-11-26|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2009||2009-01-31|April 2018|2018-04-30|December 6, 2017|Actual|2017-12-06|May 2014|Actual|2014-05-31||Interventional|MAINTAIN||Micronutrients and Antioxidants in HIV Infection|A Randomized Control Clinical Trial Of Micronutrient & Antioxidant Supplementation in Persons With Untreated HIV Infection|Completed||N/A|171|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-06-01 01:32:17.947994|2018-06-01 01:32:17.947994
NCT00798759|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2012-03-30||2012-05-25|2008-11-25|2008-11-26|Estimate|2012-03-30|2012-04-23|Estimate||||2012-05-25|2012-06-01|Estimate|December 2008||2008-12-31|May 2012|2012-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN|Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and XALATAN®|Completed||Phase 4|236|Actual|Alcon Research|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)|2|||f||||f||||||||||2018-06-01 01:32:18.057638|2018-06-01 01:32:18.057638
NCT00798746|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2012-07-27|2008-11-25|2008-11-26|Estimate|||||||2012-07-27|2012-07-31|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Quality of Life After Esophagectomy for Cancer|Role of Pyloric Drainage in Reflux Symptoms After Esophagectomy for Cancer|Completed|||88|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 01:32:18.270754|2018-06-01 01:32:18.270754
NCT00798733|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2017-12-18|2008-11-25|2008-11-26|Estimate|||||||2017-12-18|2017-12-19|Actual|October 2008||2008-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||Study of Sacral Fractures Using Patient Based and Objective Outcomes|A Multicenter Prospective Cohort Study of Sacral Fractures Using Patient Based and Objective Outcomes|Active, not recruiting|||100|Actual|Boston Medical Center|||2||f||||t||||||||||2018-06-01 01:32:18.343532|2018-06-01 01:32:18.343532
NCT00798720|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2016-04-28||2016-09-29|2008-11-25|2008-11-26|Estimate|2016-09-29|2016-11-21|Estimate||||2016-09-29|2016-11-21|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer|Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|18|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 01:32:18.434394|2018-06-01 01:32:18.434394
NCT00798707|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2011-03-07||2011-06-08|2008-11-25|2008-11-26|Estimate|2011-05-12|2011-06-06|Estimate||||2011-06-08|2011-06-10|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (25 and 50 mg/Day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|709|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:32:18.948155|2018-06-01 01:32:18.948155
NCT00798694|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2012-12-20|2008-11-25|2008-11-26|Estimate|||||||2012-12-20|2012-12-21|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?|Ocular Surface Changes With Topical Prostaglandin Analog Therapy|Completed||Phase 4|58|Actual|Wills Eye||2|||f||||f||||||||||2018-06-01 01:32:20.631728|2018-06-01 01:32:20.631728
NCT00798681|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2010-08-09|2008-11-25|2008-11-26|Estimate|||||||2010-08-09|2010-08-10|Estimate|July 2008||2008-07-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|EPICOS||Evaluating the Influence of Ready-to-use (RTU) Parenteral Nutrition in the Clinical Outcome of Patients Study|EPICOS- Evaluating the Influence of RTU Parenteral Nutrition in the Clinical Outcome Patients Study|Completed||Phase 4|406|Actual|Fernandes Tavora Hospital||3|||f||||t||||||||||2018-06-01 01:32:20.746743|2018-06-01 01:32:20.746743
NCT00798668|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2013-09-23|2008-11-25|2008-11-26|Estimate|||||||2013-09-23|2013-09-24|Estimate|September 2006||2006-09-30|March 2010|2010-03-31|May 2008|Actual|2008-05-31|August 2007|Actual|2007-08-31||Interventional|||The Body's Response to Food Intake in Trained, Older Adults||Completed||N/A|50|Actual|Purdue University||4|||f||||||||||||||2018-06-01 01:32:20.86777|2018-06-01 01:32:20.86777
NCT00798655|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2016-06-28||2017-09-04|2008-11-25|2008-11-26|Estimate|2016-06-28|2016-08-09|Estimate||||2017-09-04|2017-10-03|Actual|November 2007|Actual|2007-11-30|September 2017|2017-09-30|November 9, 2016|Actual|2016-11-09|June 2015|Actual|2015-06-30||Interventional|||Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer|A Phase II Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer|Completed||Phase 2|46|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:32:20.95931|2018-06-01 01:32:20.95931
NCT00798642|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2014-04-01|2008-11-25|2008-11-26|Estimate|||||||2014-04-01|2014-04-02|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|UCRPT||Ulcerative Colitis Relapse Prevention Trial, Hypnosis|National Center for Complementary & Alternative Medicine, The Role of Gut-Directed Hypnotherapy in Relapse Prevention for Ulcerative Colitis|Completed||N/A|55|Actual|Northwestern University||3|||f||||t||||||||||2018-06-01 01:32:21.235944|2018-06-01 01:32:21.235944
NCT00798629|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2012-09-21|2008-11-25|2008-11-26|Estimate|||||||2012-09-21|2012-09-24|Estimate|November 2008||2008-11-30|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured|A Dose Ranging Trial of Adenovirus CCL-21 Transduced MART-1/gp100 Peptide-Pulsed Dendritic Cells Matured Using Cytokines for Patients With Chemotherapy-Resistant Metastatic Melanoma|Completed||Phase 1|13|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 01:32:21.319764|2018-06-01 01:32:21.319764
NCT00798616|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2014-12-05|2008-11-25|2008-11-26|Estimate|||||||2014-12-05|2014-12-09|Estimate||||October 2010|2010-10-31||||||||Interventional|SHARE||Steroids Helping Albuterol Responders Exclusively|"Are Steroids Efficacious in Hospitalized Patients With Bronchiolitis Who Show an Objective Clinical Improvement After Albuterol (Albuterol Responders)?"|Withdrawn||N/A|0|Actual|University Hospitals Cleveland Medical Center||4||We were unable to enroll a sufficient number of patients due to manpower.|f||||f||||||||||2018-06-01 01:32:21.397663|2018-06-01 01:32:21.397663
NCT00798603|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2016-12-01||2016-12-01|2008-11-25|2008-11-26|Estimate|2016-12-01|2017-01-25|Estimate||||2016-12-01|2017-01-25|Estimate|December 2008||2008-12-31|December 2016|2016-12-31|May 2013|Actual|2013-05-31|March 2011|Actual|2011-03-31||Interventional||All participants who received treatment.|Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2)|Completed||Phase 2|65|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 01:32:21.572345|2018-06-01 01:32:21.572345
NCT00798590|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2017-05-01||2017-06-01|2008-11-25|2008-11-26|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|December 2008||2008-12-31|June 2017|2017-06-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients|The Efficacy of GLP - 1 (7-36) Amide for Glycemic Control in Critically Ill Surgical Patients|Terminated||Phase 2|19|Actual|Johns Hopkins University||2||PI left JHU|f||||t||||||||||2018-06-01 01:32:22.425444|2018-06-01 01:32:22.425444
NCT00798577|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2010-03-02||2010-03-30|2008-11-25|2008-11-26|Estimate|2010-03-30|2010-03-31|Estimate||||2010-03-30|2010-03-31|Estimate|October 2008||2008-10-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment||Completed||Phase 4|24|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:32:22.693843|2018-06-01 01:32:22.693843
NCT00798564|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2011-08-02|2008-11-25|2008-11-26|Estimate|||||||2011-08-02|2011-08-04|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|December 2009|Actual|2009-12-31|||||Observational|||Exercise Induced Asthma and Airway Reactivity in Athletes|"Explorative Study Exercise Induced Asthma and Airway Reactivity in Athletes"|Completed|||300|Actual|Skane University Hospital|||||f||||f||||||||||2018-06-01 01:32:22.97931|2018-06-01 01:32:22.97931
NCT00798551|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2010-01-11|2008-11-25|2008-11-26|Estimate|||||||2010-01-11|2010-01-12|Estimate|November 2008||2008-11-30|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|April 2009|Anticipated|2009-04-30||Interventional|||Emergency Department Interventions to Improve Blood Pressure Follow-up|Emergency Department Interventions to Improve Blood Pressure Follow-up|Unknown status|Active, not recruiting|N/A|120|Anticipated|University of Nebraska||1|||f||||f||||||||||2018-06-01 01:32:23.047145|2018-06-01 01:32:23.047145
NCT00798538|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2015-07-23|2008-11-25|2008-11-26|Estimate|||||||2015-07-23|2015-07-24|Estimate|August 2005||2005-08-31|July 2015|2015-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|BELIEVE||Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)|Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)|Completed||Phase 4|60|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:32:23.129061|2018-06-01 01:32:23.129061
NCT00798525|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2012-06-20|2008-11-25|2008-11-26|Estimate|||||||2012-06-20|2012-06-21|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ALiCia||Argatroban Versus Lepirudin in Critically Ill Patients|Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial|Terminated||Phase 4|70|Actual|Heinrich-Heine University, Duesseldorf||2||Supply of Lepirudin ended on 01. April 2012, thus trial terminated on 31. March 2012|f||||t||||||||||2018-06-01 01:32:23.223442|2018-06-01 01:32:23.223442
NCT00798512|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2016-03-14|2008-11-25|2008-11-26|Estimate|||||||2016-03-14|2016-03-15|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|DESERVE||Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.|DESERVE: Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device. A Prospective, Multicenter Study.|Completed||N/A|127|Actual|Invatec S.p.A.||1|||f||||t||||||||||2018-06-01 01:32:23.318054|2018-06-01 01:32:23.318054
NCT00798473|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2008-11-25|2008-11-25|2008-11-26|Estimate|||||||2008-11-25|2008-11-26|Estimate|September 2004||2004-09-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|September 2007|Actual|2007-09-30||Interventional|||Zoledronate for Osteopenia in Pediatric Crohn's|A Randomized Controlled Trial of Zoledronate in the Treatment of Osteopenia in Children and Adolescents With Crohn's Disease|Completed||Phase 3|13|Actual|McGill University Health Center||2|||f||||t||||||||||2018-06-01 01:32:23.642982|2018-06-01 01:32:23.642982
NCT00798460|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2011-06-22|2008-11-25|2008-11-26|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients|A Multicenter, Randomized, Controlled Tial of Combination Therapy for Lamivudine-resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir|Terminated||Phase 4|30|Actual|Inje University||2||could not enroll patients|f||||t||||||||||2018-06-01 01:32:23.735405|2018-06-01 01:32:23.735405
NCT00798447|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2011-06-08|2008-11-25|2008-11-26|Estimate|||||||2011-06-08|2011-06-09|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery|A Prospective, Randomized, Double Blind Study to Compare the Efficacy and Safety of a n-3 Fatty Acid-containing Lipid Emulsion During Parenteral Nutrition in Patients Considered for Major Surgery for Gastric and Colorectal Cancer.|Completed||Phase 3|100|Anticipated|B. Braun Melsungen AG||2|||f||||f||||||||||2018-06-01 01:32:23.815168|2018-06-01 01:32:23.815168
NCT00798434|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2011-07-11||2011-11-08|2008-11-25|2008-11-26|Estimate|2011-11-08|2011-12-14|Estimate||||2011-11-08|2011-12-14|Estimate|June 2008||2008-06-30|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|SOFIA||A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.|A 24-Week, Multi-Centre Trial, Comprising A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase Followed By A 12-Week Open-Label Phase, To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Elderly Patients With Overactive Bladder.|Completed||Phase 4|794|Actual|Pfizer|The descriptive statistics and analyses of outcome measure 12 as defined in the protocol are not presented. Results are presented as defined in the statistical analysis plan.|2|||f||||f||||||||||2018-06-01 01:32:23.958989|2018-06-01 01:32:23.958989
NCT00798421|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2008-11-25|2008-11-25|2008-11-26|Estimate|||||||2008-11-25|2008-11-26|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|May 2009|Anticipated|2009-05-31|April 2009|Anticipated|2009-04-30||Observational|||Study to Evaluate Nosocomial Transmission of Influenza|Pilot Study to Develop a Model to Evaluate Nosocomial Transmission of Influenza|Unknown status|Not yet recruiting||50|Anticipated|University Hospitals, Leicester|||1||f||||f||||||Samples Without DNA|"~     Throat and nose swabs~   "|||2018-06-01 01:32:25.643442|2018-06-01 01:32:25.643442
NCT00798408|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2013-09-23|2008-11-25|2008-11-26|Estimate|||||||2013-09-23|2013-09-24|Estimate|February 2006||2006-02-28|December 2009|2009-12-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||The Body's Response to Food Intake in Older Adults||Completed||N/A|35|Actual|Purdue University||2|||f||||||||||||||2018-06-01 01:32:25.773275|2018-06-01 01:32:25.773275
NCT00798395|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2015-10-12|2008-11-25|2008-11-26|Estimate|||||||2015-10-12|2015-10-14|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)|A Randomized Double-blind, Placebo-controlled, 4-period Cross-over Study to Assess the Effect of Single and Multiple Doses of 1.5 mg and 4.5 mg Org 50081 and a Single Dose of 7.5 mg Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers.|Completed||Phase 1|32|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:32:25.897384|2018-06-01 01:32:25.897384
NCT00798382|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2012-06-12|2008-11-25|2008-11-26|Estimate|||||||2012-06-12|2012-06-14|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants|Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants|Completed||Phase 2/Phase 3|154|Actual|Abbott Nutrition||3|||f||||t||||||||||2018-06-01 01:32:25.976442|2018-06-01 01:32:25.976442
NCT00798369|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2011-01-20||2012-04-09|2008-11-25|2008-11-26|Estimate|2011-04-20|2011-05-16|Estimate||||2012-04-09|2012-04-10|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients|An Adaptive Dose-ranging, Multi-center, Single-blind, Double-dummy, Active-controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine|Completed||Phase 2|200|Actual|Novartis||6|||f||||||||||||||2018-06-01 01:32:26.139419|2018-06-01 01:32:26.139419
NCT00798356|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2012-06-13|2008-11-25|2008-11-26|Estimate|||||||2012-06-13|2012-06-14|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Yoga on Arrhythmia Burden and Quality of Life in Paroxysmal Atrial Fibrillation|The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Paroxysmal Atrial Fibrillation|Completed||N/A|84|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 01:32:27.083454|2018-06-01 01:32:27.083454
NCT00798343|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2014-06-02|2008-11-25|2008-11-26|Estimate|||||||2014-06-02|2014-06-03|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|March 2010|Actual|2010-03-31||Interventional|||Heterosubtypic Immune Responses to Influenza in Older People|Evaluation of Heterosubtypic Immune Responses in Older People Before and After Seasonal and Pandemic Influenza Vaccination|Completed||Phase 1|292|Actual|University Hospitals, Leicester||2|||f||||t||||||||||2018-06-01 01:32:27.197596|2018-06-01 01:32:27.197596
NCT00798330|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2013-11-19|2008-11-25|2008-11-26|Estimate|||||||2013-11-19|2013-11-21|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Dental Study in Cancer Patients With Central Venous Catheters|Pilot Study on Transient Bacteremia and Blood Stream Infections After Invasive Dental Procedures in Cancer Patients With Central Venous Catheters|Completed|||27|Actual|UConn Health|||||f||||t||||||||||2018-06-01 01:32:27.381851|2018-06-01 01:32:27.381851
NCT00798317|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2012-12-20||2014-12-02|2008-11-25|2008-11-26|Estimate|2012-12-20|2013-01-30|Estimate||||2014-12-02|2014-12-17|Estimate|December 2008||2008-12-31|April 2014|2014-04-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.|A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.|Completed||Phase 3|326|Actual|ThromboGenics||2|||f||||t||||||||||2018-06-01 01:32:28.44182|2018-06-01 01:32:28.44182
NCT00798304|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|2014-11-21||2014-11-21|2008-11-25|2008-11-26|Estimate|2014-11-21|2014-11-26|Estimate||||2014-11-21|2014-11-26|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants|An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants|Terminated||Phase 2|46|Actual|Pfizer|Immunogenicity results were not reported because the study was terminated due to the reactogenicity profile of the vaccine in infants prior to the first scheduled post-vaccination blood draw and no immunogenicity data were collected.|3||"Following program review within Pfizer, decision was made not to go ahead with this study. This~   study is cancelled"|f||||t||||||||||2018-06-01 01:32:28.85481|2018-06-01 01:32:28.85481
NCT00798291|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2010-03-19|2008-11-25|2008-11-26|Estimate|||||||2010-03-19|2010-03-22|Estimate|October 2008||2008-10-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation of AN777 in Elderly Subjects|Evaluation of AN777 in Elderly Subjects|Completed||Phase 2/Phase 3|108|Anticipated|Abbott Nutrition||4|||f||||t||||||||||2018-06-01 01:32:29.424272|2018-06-01 01:32:29.424272
NCT00798278|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2010-10-27|2008-11-25|2008-11-26|Estimate|||||||2010-10-27|2010-10-28|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood|Exploratory Multicentre Clinical Trial to Compare the Efficacy of Urokinase Versus Video-assisted Thoracoscopic for Treatment of Complicated Parapneumonic Empyema in Childhood|Completed||Phase 3|200|Anticipated|Spanish Society of Pediatric Surgery||2|||f||||f||||||||||2018-06-01 01:32:29.508342|2018-06-01 01:32:29.508342
NCT00798265|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2018-05-18|2008-11-25|2008-11-26|Estimate|||||||2018-05-18|2018-05-21|Actual|November 6, 2008||2008-11-06|October 10, 2017|2017-10-10|February 4, 2013|Actual|2013-02-04|September 22, 2012|Actual|2012-09-22||Interventional|||A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults|A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults|Completed||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 01:32:29.590364|2018-06-01 01:32:29.590364
NCT00798252|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2015-07-03|2008-11-25|2008-11-26|Estimate|||||||2015-07-03|2015-07-07|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers|A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors|Completed||Phase 1|111|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 01:32:29.742237|2018-06-01 01:32:29.742237
NCT00798239|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-03-07|2008-11-25|2008-11-26|Estimate|||||||2012-03-07|2012-03-09|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Pilot Study to Assess Safety/Prelimary Effectiveness of Prefix in Subjects With Degenerative Disc Disease (DDD) Undergoing Spine Fusion Surgery|A Multi-Center, Prospective, Parallel Group, Randomized, Pilot Study Evaluating Safety and Preliminary Effectiveness Of Prefix Compared To Iliac Crest Bone In Subjects With DDD Undergoing Transforaminal Lumbar Interbody Fusion|Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Anticipated|BioSurface Engineering Technologies, Inc||3|||f||||t||||||||||2018-06-01 01:32:29.890487|2018-06-01 01:32:29.890487
NCT00798226|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2017-03-08|2008-11-25|2008-11-26|Estimate|||||||2017-03-08|2017-03-09|Actual|November 2008||2008-11-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood|Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood: Interventional Trial in the COPSAC2010 (Copenhagen Studies on Asthma in Childhood) Birth Cohort|Active, not recruiting||Phase 3|800|Anticipated|Copenhagen Studies on Asthma in Childhood||2|||f||||f||||||||||2018-06-01 01:32:29.998765|2018-06-01 01:32:29.998765
NCT00798213|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2015-02-03|2008-11-25|2008-11-26|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)|A Phase 2 Study of SCH 727965 in Subjects With Relapsed and Refractory Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia|Terminated||Phase 2|29|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:32:30.108711|2018-06-01 01:32:30.108711
NCT00798200|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-25|||2016-03-02|2008-11-25|2008-11-26|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|CanWell||Community Based Exercise Program for Well Cancer Survivors|CanWell: YMCA Based Exercise Program for Well Cancer Survivors|Completed||Phase 1|200|Actual|McMaster University||1|||f||||f||||||||||2018-06-01 01:32:30.185236|2018-06-01 01:32:30.185236
NCT00798187|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2018-03-13|2008-11-25|2008-11-26|Estimate|||||||2018-03-13|2018-03-15|Actual|May 2009|Actual|2009-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis|Efficacy of Cancer Support Programs: A Social Comparison Theory Analysis|Active, not recruiting|||240|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||||||2018-06-01 01:32:30.262784|2018-06-01 01:32:30.262784
NCT00798174|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2009-12-04|2008-11-24|2008-11-26|Estimate|||||||2009-12-04|2009-12-07|Estimate|November 2008||2008-11-30|December 2009|2009-12-31||||January 2010|Anticipated|2010-01-31||Interventional|||The Effect of an Azygos Vein Coil on Defibrillation Threshold|The Effect of an Azygos Vein Coil on Defibrillation Threshold|Suspended||N/A|32|Anticipated|Washington University School of Medicine||2||"Failure of an inroducer sheath used in the technique specified by the study. posing a risk. No~   adverse outcome has occurred in a study patient."|f||||f||||||||||2018-06-01 01:32:30.354981|2018-06-01 01:32:30.354981
NCT00798161|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2011-05-20||2013-12-11|2008-11-24|2008-11-25|Estimate|2011-07-11|2011-08-04|Estimate||||2013-12-11|2014-01-28|Estimate|December 2008||2008-12-31|December 2013|2013-12-31||||May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design|A Phase III Randomised, Double-blind, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Free Combination of BI 1356 2.5 mg + Metformin 500 mg, or of BI 1356 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg Twice Daily), and BI 1356 (5.0 mg Once Daily) Over 24 Weeks in Drug Naive or Previously Treated (4 Weeks Wash-out and 2 Weeks Placebo run-in) Type 2 Diabetic Patients With Insufficient Glycaemic Control|Completed||Phase 3|857|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-06-01 01:32:30.675979|2018-06-01 01:32:30.675979
NCT00798148|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-23|||2012-05-31|2008-11-23|2008-11-25|Estimate|||||||2012-05-31|2012-06-04|Estimate|September 2008||2008-09-30|May 2012|2012-05-31||||July 2012|Anticipated|2012-07-31||Interventional|||131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma|Evaluation of Benefit and Side Effects of 131I-MIBG in Combination With Myeloablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Tehran University of Medical Sciences||1|||f||||||||||||||2018-06-01 01:32:32.7824|2018-06-01 01:32:32.7824
NCT00798135|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2014-08-25||2015-08-28|2008-11-24|2008-11-25|Estimate|2014-09-09|2014-09-10|Estimate||||2015-08-28|2015-09-11|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer|A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer|Completed||N/A|13|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 01:32:32.946348|2018-06-01 01:32:32.946348
NCT00798122|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2018-04-19|2008-11-24|2008-11-25|Estimate|||||||2018-04-19|2018-04-20|Actual|March 1, 2006|Actual|2006-03-01|April 2018|2018-04-30|June 1, 2022|Anticipated|2022-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|SWAN||Study of Women With Acute Coronary Syndromes and Nonobstructive Coronary Artery Disease|Study of Women With Acute Coronary Syndromes and Nonobstructive Coronary Artery Disease|Active, not recruiting||N/A|50|Anticipated|New York University School of Medicine||1|||f||||t|f|f||||||||2018-06-01 01:32:33.213761|2018-06-01 01:32:33.213761
NCT00798109|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2014-06-13|2008-11-24|2008-11-25|Estimate|||||||2014-06-13|2014-06-16|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|SCHIZOCAN||Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse|An Open Multicentric Randomized Clinical Trial Assessing the Impact of Motivational Interviewing on Cannabis Consumption in Patients With Psychiatric Disease|Completed||N/A|97|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:32:33.291674|2018-06-01 01:32:33.291674
NCT00798096|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2014-05-14||2016-08-09|2008-11-24|2008-11-25|Estimate|2014-05-14|2014-06-12|Estimate||||2016-08-09|2016-09-19|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma|Phase II, Multicenter, Simon Two-Stage Study of Fostamatinib Disodium in Patients With Relapsed or Refractory T-Cell Lymphoma|Completed||Phase 2|18|Actual|Rigel Pharmaceuticals|This is a small, non-randomized study.|1|||f||||t||||||||No||2018-06-01 01:32:33.390999|2018-06-01 01:32:33.390999
NCT00798083|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2011-06-21|2008-11-24|2008-11-25|Estimate|||||||2011-06-21|2011-06-22|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|NP||Neuropathic Pain Caused by Radiation Therapy|Topical Amitriptyline, Ketamine and Lidocaine in Neuropathic Pain Caused by Radiation Skin Reaction: a Pilot Study|Completed||Phase 3|22|Anticipated|British Columbia Cancer Agency|||||f||||t||||||||||2018-06-01 01:32:33.73059|2018-06-01 01:32:33.73059
NCT00798070|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2016-11-16|2008-11-24|2008-11-25|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|January 2022|Anticipated|2022-01-31|April 2016|Actual|2016-04-30||Interventional|PANTHER||Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients|PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients|Active, not recruiting||Phase 3|2017|Actual|Karolinska University Hospital||2|||f||||t||||||||Yes|Oral presentation at ASCO 4 June 2016 (completed). Study published in JAMA 8 Nov 2016.|2018-06-01 01:32:33.822206|2018-06-01 01:32:33.822206
NCT00798057|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2015-10-02|2008-11-24|2008-11-25|Estimate|||||||2015-10-02|2015-10-05|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|PI01||Proton Radiation Therapy for Pituitary Adenoma|Clinical Outcomes Study of Proton Radiation Therapy for Pituitary Adenoma|Terminated|||16|Actual|University of Florida|||1|Due to slow enrollment and feasibility issues.|f||||f||||||||||2018-06-01 01:32:34.008641|2018-06-01 01:32:34.008641
NCT00798044|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-01-18|2008-11-24|2008-11-25|Estimate|||||||2012-01-18|2012-01-20|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||Patient Feedback Effectiveness Study|Patient Feedback Effectiveness Study|Completed||N/A|118|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 01:32:34.0833|2018-06-01 01:32:34.0833
NCT00798031|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-05-25|2008-11-24|2008-11-25|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2008||2008-10-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Short implant||Case Series Evaluation of a Short Dental Implant|Case Series Evaluation of a Short Dental Implant Placed in the Posterior Maxilla in an Early Loading Protocol|Withdrawn||N/A|0|Actual|University of Iowa||1||As of 2017 study was terminated since investigators retired. No subjects recruited.|f||||t||||||||||2018-06-01 01:32:34.150864|2018-06-01 01:32:34.150864
NCT00798018|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2009-06-01||2009-12-17|2008-11-24|2008-11-25|Estimate|2009-12-17|2009-12-18|Estimate||||2009-12-17|2009-12-18|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence Phenomena|Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence Phenomena|Completed||N/A|100|Actual|Sichuan University||4|||f||||f||||||||||2018-06-01 01:32:34.231067|2018-06-01 01:32:34.231067
NCT00798005|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-06-07|2008-11-24|2008-11-25|Estimate|||||||2017-06-07|2017-06-08|Actual|June 2002||2002-06-30|June 2017|2017-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|TALISMAN202||Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Different Doses and Schedules of Administration of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.|Completed||Phase 2|71|Actual|Sanofi|||||f||||||||||||||2018-06-01 01:32:34.542877|2018-06-01 01:32:34.542877
NCT00797992|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|January 2007||2007-01-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Bevacizumab Intravitreal for Myopic Choroidal Neovascularization|Bevacizumab Intravitreal for Myopic Choroidal Neovascularization|Completed||Phase 4|5|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-06-01 01:32:34.60297|2018-06-01 01:32:34.60297
NCT00797979|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-11-23|2008-11-24|2008-11-25|Estimate|||||||2012-11-23|2012-11-27|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CRANIOSG||Implant System for Fixation of Cranial Bone Flaps After Craniotomy for Brain Surgery|Implant System for Fixation of Cranial Bone Flaps After Craniotomy for Brain Surgery|Completed||Phase 1|16|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:32:34.677083|2018-06-01 01:32:34.677083
NCT00797966|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2015-08-07|2012-05-10|2016-02-02|2008-11-24|2008-11-25|Estimate|2015-10-30|2015-12-03|Estimate|2012-05-10|2012-05-15|Estimate|2016-02-02|2016-02-29|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder|Completed||Phase 2|850|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-06-01 01:32:34.845497|2018-06-01 01:32:34.845497
NCT00797953|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-12-10|2008-11-24|2008-11-25|Estimate|||||||2012-12-10|2012-12-12|Estimate|February 2007||2007-02-28|December 2012|2012-12-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|T89 phase 2||Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina|A Phase II, Double Blind, Placebo-controlled, Randominzed, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of T89 in Patient With Chronic Stable Angina Pectoris|Completed||Phase 2|124|Actual|Tasly Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-06-01 01:32:36.125994|2018-06-01 01:32:36.125994
NCT00797940|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-11-30|2008-11-24|2008-11-25|Estimate|||||||2012-11-30|2012-12-03|Estimate|January 2009||2009-01-31|November 2012|2012-11-30||||December 2010|Anticipated|2010-12-31||Interventional|CLARITY-1||Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)|Phase II, Multi-center, Open-Label, Single-Arm Study of Intratumoral Infusion of PRX321 in Subjects With Glioblastoma Multiforme at First Recurrence or Progression|Withdrawn||Phase 2|0|Actual|Sophiris Bio Corp||1||No funding for study|f||||f||||||||||2018-06-01 01:32:36.224137|2018-06-01 01:32:36.224137
NCT00797927|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2009-04-27|2008-11-24|2008-11-25|Estimate|||||||2009-04-27|2009-04-29|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia|Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Patients With Schizophrenia|Completed||Phase 4|30|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:32:36.282686|2018-06-01 01:32:36.282686
NCT00797914|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-23|||2016-07-11|2008-11-24|2008-11-25|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2008||2008-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Evaluation of Handheld Colonoscopy Force Monitor by Expert Endoscopists in the Performance of Colonoscopy|Phase I Study for Evaluation of Handheld Colonoscopy Force Monitor by Expert Endoscopists in the Performance of Colonoscopy|Completed|||150|Actual|Artann Laboratories|||1||f||||f||||||||||2018-06-01 01:32:36.352988|2018-06-01 01:32:36.352988
NCT00797901|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2014-08-26|2008-11-24|2008-11-25|Estimate|||||||2014-08-26|2014-08-28|Estimate|August 2004||2004-08-31|August 2014|2014-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Depression Treatment in General Medical Settings|Depression Treatment in General Medical Settings|Completed||N/A|179|Actual|University of Puerto Rico||1|||f||||t||||||||||2018-06-01 01:32:36.419587|2018-06-01 01:32:36.419587
NCT00797888|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2018-04-24|2008-11-24|2008-11-25|Estimate|||||||2018-04-24|2018-04-25|Actual|September 2008||2008-09-30|April 2018|2018-04-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|Bronx A1c||Bronx A1c: Bring it Down for Health|Bronx A1c: Bring it Down for Health|Completed||N/A|941|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-06-01 01:32:36.493483|2018-06-01 01:32:36.493483
NCT00797875|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||PNF Stretching for TKA on ROM|The Effects of PNF Stretching on Knee Motion Following TKA|Unknown status|Not yet recruiting|N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:32:36.559009|2018-06-01 01:32:36.559009
NCT00797862|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2011-04-21||2011-10-07|2008-11-24|2008-11-25|Estimate|2011-04-21|2011-05-17|Estimate||||2011-10-07|2011-10-17|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ACCELERATE||Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension|A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With Essential Hypertension|Completed||Phase 3|1254|Actual|Novartis||3|||f||||f||||||||||2018-06-01 01:32:36.64621|2018-06-01 01:32:36.64621
NCT00797849|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-03-12|2008-11-24|2008-11-25|Estimate|||||||2012-03-12|2012-03-14|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Controlled Study of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees|A Randomized, Controlled Study to Evaluate the Effectiveness of Farabloc for Chronic Phantom Limb Pain Among Veteran Amputees|Completed||N/A|57|Actual|Southern California Institute for Research and Education||2|||f||||f||||||||||2018-06-01 01:32:37.19922|2018-06-01 01:32:37.19922
NCT00797836|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2012-01-09|2008-11-24|2008-11-25|Estimate|||||||2012-01-09|2012-01-10|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|QUANTIPS||Quantiferon for Detection of Latent Tuberculosis in Healthcare Workers|Cost-effectiveness of Quantiferon Gold in VITRO Test of T-lymphocytic Response for Detection of Latent Tuberculosis in At-risk Healthcare Workers|Completed||Phase 4|1024|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:32:37.284251|2018-06-01 01:32:37.284251
NCT00797823|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2011-06-24||2011-10-04|2008-11-24|2008-11-25|Estimate|2011-08-18|2011-09-26|Estimate||||2011-10-04|2011-10-07|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone|A Comparison of Two Sensor-Augmented Glycemic Control Systems in Persons With Type 1 Diabetes Mellitus: Subcutaneous (SC) Insulin and Glucagon Delivery vs. SC Insulin Only|Completed||Phase 2|14|Actual|Legacy Health System||3|||f||||f||||||||||2018-06-01 01:32:37.365041|2018-06-01 01:32:37.365041
NCT00797810|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2009-09-14|2008-11-24|2008-11-25|Estimate|||||||2009-09-14|2009-09-15|Estimate|December 2006||2006-12-31|September 2009|2009-09-30||||||||Interventional|||Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults|Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults|Unknown status|Recruiting|Phase 4|25|Anticipated|University of Bologna||1|||f||||t||||||||||2018-06-01 01:32:37.674343|2018-06-01 01:32:37.674343
NCT00797797|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2010-11-18||2011-01-20|2008-11-24|2008-11-25|Estimate|2011-01-20|2011-02-16|Estimate||||2011-01-20|2011-02-16|Estimate|November 2008||2008-11-30|January 2011|2011-01-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia|A Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran When Added to Pregabalin in the Treatment of Fibromyalgia|Completed||Phase 3|364|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 01:32:37.780483|2018-06-01 01:32:37.780483
NCT00797784|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2010-05-25|2008-11-24|2008-11-25|Estimate|||||||2010-05-25|2010-05-26|Estimate|October 2008||2008-10-31|November 2008|2008-11-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|DISCLUP2008||The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus|A Phase 2 Open Label Study to Assess the Efficacy and Safety of Etanercept (Enbrel®)for the Treatment of Discoid Lupus Erythematosus|Unknown status|Recruiting|Phase 2|20|Anticipated|Florida Academic Dermatology Centers|||||f||||t||||||||||2018-06-01 01:32:38.240347|2018-06-01 01:32:38.240347
NCT00797771|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-23|||2011-06-08|2008-11-24|2008-11-25|Estimate|||||||2011-06-08|2011-06-09|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||User Satisfaction Using the ADI Insulin Pump|Evaluation of User Satisfaction Using the ADI Insulin Pump|Completed||N/A|20|Anticipated|NiliMedix||1|||f||||f||||||||||2018-06-01 01:32:38.303363|2018-06-01 01:32:38.303363
NCT00797758|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2013-03-07|2008-11-24|2008-11-25|Estimate|||||||2013-03-07|2013-03-08|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|MINICORD||Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia|Assessment of Reduction of Cord Blood Transplantation Toxicity by Using Reduced Intensity Conditioning in Patients With Acute Myeloid Leukemia.|Completed||Phase 2|76|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:32:38.36442|2018-06-01 01:32:38.36442
NCT00797745|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2015-01-21|2008-11-24|2008-11-25|Estimate|||||||2015-01-21|2015-01-22|Estimate|November 2008||2008-11-30|January 2015|2015-01-31|September 2010|Actual|2010-09-30|July 2009|Actual|2009-07-31||Interventional|NEXT-1||A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)|A Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104)|Completed||Phase 2|111|Actual|Merck Sharp & Dohme Corp.||7|||f||||t||||||||||2018-06-01 01:32:38.447103|2018-06-01 01:32:38.447103
NCT00797732|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2017-10-03||2018-01-16|2008-11-21|2008-11-25|Estimate|2018-01-16|2018-02-13|Actual||||2018-01-16|2018-02-13|Actual|December 2008||2008-12-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|January 2013|Actual|2013-01-31||Interventional||The analysis population is comprised of all randomized participants.|A Pilot Study of Acupuncture Treatment for Dysphagia|Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer Patients: A Pilot Randomized Control Trial|Completed||N/A|42|Actual|Dana-Farber Cancer Institute||2|||f||||t|f|t|f|f||||No||2018-06-01 01:32:38.546176|2018-06-01 01:32:38.546176
NCT00797719|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2017-09-20|2008-11-24|2008-11-25|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2008||2008-10-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Short Neoadjuvant Hemithoracic IMRT for MPM|A Feasibility Study Evaluating Neoadjuvant Hemithoracic Intensity Modulated Radiation Therapy for Surgically Resectable Malignant Pleural Mesothelioma|Recruiting||Phase 1/Phase 2|100|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:32:38.861182|2018-06-01 01:32:38.861182
NCT00797706|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2010-02-04|2008-11-24|2008-11-25|Estimate|||||||2010-02-04|2010-02-05|Estimate|November 2008||2008-11-30|February 2010|2010-02-28|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers|A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers|Unknown status|Active, not recruiting|Phase 1/Phase 2|75|Anticipated|Kringle Pharma Europe AB||3|||f||||f||||||||||2018-06-01 01:32:38.932883|2018-06-01 01:32:38.932883
NCT00797693|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|January 2008||2008-01-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Misoprostol in Termination of First Trimester Missed Abortion|Oral Versus Vaginal Misoprostol as Cervical Ripening Agent Prior to Surgical Termination of First Trimester Missed Abortions in Hawler Maternity Teaching Hospital in Erbil/Iraq|Completed||N/A|100|Actual|Hawler Medical University||2|||f||||t||||||||||2018-06-01 01:32:39.0813|2018-06-01 01:32:39.0813
NCT00797680|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2016-01-15|2008-11-24|2008-11-25|Estimate|||||||2016-01-15|2016-01-18|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest|Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest|Completed||Phase 2|34|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:32:39.215574|2018-06-01 01:32:39.215574
NCT00797667|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2014-08-13||2017-05-26|2008-11-24|2008-11-25|Estimate|2014-09-04|2014-09-08|Estimate||||2017-05-26|2017-06-20|Actual|November 12, 2008|Actual|2008-11-12|May 2017|2017-05-31|May 20, 2009|Actual|2009-05-20|May 20, 2009|Actual|2009-05-20||Interventional||All enrolled participants who recieved at least one dose of study drug.|MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)|A Phase IIa, Multicenter, Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine|Terminated||Phase 2|660|Actual|Merck Sharp & Dohme Corp.|Based on a recommendation from the external Data Safety Monitoring Board (DSMB), a decision to terminate the trial was made on 26-Mar-2009.|3||"The study was terminated based on a recommendation of the DSMB following the identification of~   two patients with significant elevations in serum transaminases"|f||||t||||||||||2018-06-01 01:32:39.334334|2018-06-01 01:32:39.334334
NCT00797654|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2016-08-08|2008-11-24|2008-11-25|Estimate|||||||2016-08-08|2016-08-09|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|||HIV Prevention and Trauma Treatment in Men Who Have Sex With Men and Who Have a History of Sexual Abuse|Integrated HIV Prevention and Trauma Treatment in MSM With Sexual Abuse History (Project THRIVE)|Completed||N/A|46|Actual|Fenway Community Health||2|||f||||f||||||||||2018-06-01 01:32:39.780547|2018-06-01 01:32:39.780547
NCT00797641|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2009-12-03|2008-11-24|2008-11-25|Estimate|||||||2009-12-03|2009-12-04|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Observational|ENERGIB||European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)|European Survey of Non-Variceal Upper Gastro Intestinal Bleeding|Completed|||2500|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:32:39.866317|2018-06-01 01:32:39.866317
NCT00797628|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2013-08-27|2008-11-24|2008-11-25|Estimate|||||||2013-08-27|2013-08-28|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|QUIT-PRIMO||Web-delivered Provider Intervention for Tobacco Control|QUIT-PRIMO: Web-Delivered Clinical Microsystem Intervention for Tobacco Control|Completed||N/A|174|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 01:32:40.148652|2018-06-01 01:32:40.148652
NCT00797602|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-08-10|2008-11-24|2008-11-25|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2007||2007-01-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CH01||Proton Therapy for Chordomas and/or Chondrosarcomas|A Clinical Outcomes Protocol of Proton Beam Radiation Therapy for Chordomas and/or Chondrosarcomas of the Base of Skull and/or Spine|Completed|||189|Actual|University of Florida|||1||f||||f|f|f|||f|||Undecided||2018-06-01 01:32:40.315574|2018-06-01 01:32:40.315574
NCT00797589|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2015-08-24|2008-11-24|2008-11-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of Prime Solution on Fluid Balance After Open Heart Surgery|Effect of Prime Solution on Fluid Balance After Open Heart Surgery|Completed||Phase 4|35|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 01:32:40.424043|2018-06-01 01:32:40.424043
NCT00797576|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2010-06-21|2008-11-24|2008-11-25|Estimate|||||||2010-06-21|2010-06-22|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Observational|||Detection of Left Atrial Appendage (LAA) Thrombus: Comparison of Cardiac Magnetic Resonance Imaging and Transesophageal Echocardiogram|Detection of Left Atrial Appendage Thrombus in Patients Referred For Cardioversion: Comparative Analysis of Cardiac Magnetic Resonance Imaging and Transesophageal Echocardiogram|Unknown status|Recruiting||25|Anticipated|Gundersen Lutheran Medical Foundation|||2||f||||f||||||||||2018-06-01 01:32:40.640082|2018-06-01 01:32:40.640082
NCT00797563|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2009-11-17||2016-01-29|2008-11-24|2008-11-25|Estimate|2009-11-17|2009-12-22|Estimate||||2016-01-29|2016-02-29|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood|Clinical Evaluation of the Apollo Blood Glucose Monitoring System With Capillary and Venous Blood [Commercial Name is CONTOUR® USB]|Completed||N/A|102|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-06-01 01:32:40.735119|2018-06-01 01:32:40.735119
NCT00797550|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-03-07|2008-11-24|2008-11-25|Estimate|||||||2017-03-07|2017-03-10|Actual|April 2006||2006-04-30|March 2017|2017-03-31|October 2008|Actual|2008-10-31|August 2006|Actual|2006-08-31||Interventional|||Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion|Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion|Terminated||Phase 1/Phase 2|2|Actual|Vericel Corporation||2||Study was terminated early for business reasons (not safety reasons).|f||||f||||||||||2018-06-01 01:32:40.912282|2018-06-01 01:32:40.912282
NCT00797537|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2010-09-03|2008-11-24|2008-11-25|Estimate|||||||2010-09-03|2010-09-06|Estimate|May 2008||2008-05-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|chondro||Ultrasound and X-ray in Detecting Articular Cartilage Calcification|Concordance Entre l'échographie du Genou et la Radiographie Standard Dans la détection Des Calcifications Dans le Cadre de la Chondrocalcinose Articulaire|Completed||N/A|166|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 01:32:40.989446|2018-06-01 01:32:40.989446
NCT00797524|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2015-02-02|2008-11-24|2008-11-25|Estimate|||||||2015-02-02|2015-02-03|Estimate|November 2008||2008-11-30|February 2015|2015-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Function and Structure Imaging in Different Retinal Diseases: Retinal Leakage Analyzer Versus Optical Coherence Tomography|Function and Structure Imaging in Different Retinal Diseases. Retinal Leakage Analyzer vs. Optical Coherence Tomography.|Completed|||35|Actual|Association for Innovation and Biomedical Research on Light and Image|||3||f||||f||||||||||2018-06-01 01:32:41.057216|2018-06-01 01:32:41.057216
NCT00797511|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2012-10-24||2012-10-24|2008-11-24|2008-11-25|Estimate|2012-10-24|2012-11-26|Estimate||||2012-10-24|2012-11-26|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Immunogenicity and Safety of Adacel Polio Vaccine|Immunogenicity and Safety of ADACEL POLIO (TdcP-IPV Vaccine) Administered at 6 to 8 Years of Age as a Fifth Dose in Healthy Children in Taiwan|Completed||Phase 3|132|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:32:41.152519|2018-06-01 01:32:41.152519
NCT00797498|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-08-10|2008-11-24|2008-11-25|Estimate|||||||2017-08-10|2017-08-14|Actual|August 2006||2006-08-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|SI01||Photon/Proton Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Cancers of the Nasal Cavity and/or Paranasal Sinuses|Completed|||174|Actual|University of Florida|||1||f||||f||||||||Undecided||2018-06-01 01:32:41.393562|2018-06-01 01:32:41.393562
NCT00797485|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-22|||2013-08-23|2008-11-22|2008-11-25|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2008||2008-07-31|June 2009|2009-06-30||||July 2011|Anticipated|2011-07-31||Interventional|||Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Maintenance and Reinduction Chemotherapy With Avastin in Metastatic Colon Cancer: The MARTHA (SICOG 0803) Trial|Unknown status|Recruiting|Phase 3|672|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:32:41.467288|2018-06-01 01:32:41.467288
NCT00797472|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2011-07-19|2008-11-24|2008-11-25|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease|A Phase II Open Label, Multicenter, Randomized, Parallel Study Comparing the Efficacy of R-mabHD Alone and a Combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD)in Treating Patients With Hodgkin's Disease.|Unknown status|Not yet recruiting|Phase 2|120|Anticipated|American Scitech International||2|||f||||f||||||||||2018-06-01 01:32:41.556664|2018-06-01 01:32:41.556664
NCT00797459|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2010-08-11||2013-08-20|2008-11-24|2008-11-25|Estimate|2011-01-24|2011-02-21|Estimate||||2013-08-20|2013-09-06|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Safety & Tolerability Study That Compares Restylane to Restylane With Lidocaine While Correcting Wrinkles in the Nasolabial Folds|A Randomized, Double-Blind Study Comparing Safety and Tolerability of Restylane® With and Without Addition of 0.3% Lidocaine HCL During Correction of Nasolabial Folds|Completed||N/A|60|Actual|Medicis Global Service Corporation||1|||f||||f||||||||||2018-06-01 01:32:41.645122|2018-06-01 01:32:41.645122
NCT00797446|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-02-03|2008-11-24|2008-11-25|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2007||2007-09-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|OP01||Photon/Proton Radiation Therapy for Oropharyngeal Cancers|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Oropharyngeal Cancers|Terminated|||10|Actual|University of Florida|||1|Slow enrollment, feasibility issues|f||||f||||||||Undecided||2018-06-01 01:32:41.885367|2018-06-01 01:32:41.885367
NCT00797433|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2010-09-20|2008-11-24|2008-11-25|Estimate|||||||2010-09-20|2010-09-21|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Outcomes of Mechanically Ventilated Patients With Low Serum Testosterone|Outcomes of Mechanically Ventilated Patients With Low Serum Testosterone|Completed|||28|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-06-01 01:32:41.974064|2018-06-01 01:32:41.974064
NCT00797420|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-23|||2013-03-18|2008-11-24|2008-11-25|Estimate|||||||2013-03-18|2013-03-19|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|September 2011|Actual|2011-09-30|January 2010|Actual|2010-01-31||Interventional|||Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers|Pharmacokinetics of a Fluconazole Loading Dose in Infants and Toddlers|Completed||Phase 1|13|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:32:42.050781|2018-06-01 01:32:42.050781
NCT00797407|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|August 2006||2006-08-31|November 2008|2008-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs|Creatine Supplementation for the Prevention of Statin Myalgia|Completed||N/A|12|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-06-01 01:32:42.131926|2018-06-01 01:32:42.131926
NCT00797394|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2011-04-11|2008-11-24|2008-11-25|Estimate|||||||2011-04-11|2011-04-13|Estimate|November 2008||2008-11-30|April 2011|2011-04-30||||July 2010|Actual|2010-07-31||Interventional|||Efficacy of Natural Extract 2007RD01 Combined With Saw Palmetto in Benign Prostatic Hyperplasia Patients Compared to Saw Palmetto||Completed||Phase 2|110|Anticipated|innoVactiv Inc.||2|||f||||||||||||||2018-06-01 01:32:42.190677|2018-06-01 01:32:42.190677
NCT00797381|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|May 2009||2009-05-31|November 2008|2008-11-30|May 2011|Anticipated|2011-05-31|October 2010|Anticipated|2010-10-31||Observational|||Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety, Tolerability of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia|Unknown status|Not yet recruiting||100|Anticipated|Shanghai Public Health Clinical Center|||2||f||||f||||||Samples Without DNA|"~     3 ml plasm of each subject on week 4,8,12 and 24~   "|||2018-06-01 01:32:42.292947|2018-06-01 01:32:42.292947
NCT00797368|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2013-07-08|2008-11-24|2008-11-25|Estimate|||||||2013-07-08|2013-07-09|Estimate|November 2008||2008-11-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Manual Therapy and Exercise Versus Home Exercises in the Management of Patients Status Post Ankle Sprain|Manual Therapy and Exercise Versus Home Exercises in the Management of Patients Status Post Ankle Sprain: A Multi-Center Randomized Clinical Trial|Completed||N/A|74|Actual|Franklin Pierce University||2|||f||||f||||||||||2018-06-01 01:32:42.363566|2018-06-01 01:32:42.363566
NCT00797342|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2009-05-01|2008-11-24|2008-11-25|Estimate|||||||2009-05-01|2009-05-05|Estimate|December 2008||2008-12-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers|A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of PF-04629991 in Healthy Volunteers|Completed||Phase 1|27|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:32:42.42505|2018-06-01 01:32:42.42505
NCT00797329|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-23|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|July 2008||2008-07-31|November 2008|2008-11-30||||||||Observational|||Biological and Cognitive Markers of Violent Behavior in Forensic Patients With Polysubstance Use: Retrospective Evaluation||Unknown status|Active, not recruiting||200|Anticipated|BeerYaakov Mental Health Center|||1||f||||||||||||||2018-06-01 01:32:42.484648|2018-06-01 01:32:42.484648
NCT00797316|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2010-12-14||2011-03-08|2008-11-24|2008-11-25|Estimate|2010-12-14|2011-01-12|Estimate||||2011-03-08|2011-03-11|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|December 2009||2009-12-31|December 2009|Actual|2009-12-31||Interventional|AIMS||Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension|An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Forced-titration Study to Evaluate the Efficacy and Safety of Aliskiren Plus HCTZ Compared to Aliskiren Monotherapy in Metabolic Syndrome Patients With Stage 2 Hypertension|Completed||Phase 4|532|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:32:42.549954|2018-06-01 01:32:42.549954
NCT00797303|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-22|||2011-12-01|2008-11-22|2008-11-25|Estimate|||||||2011-12-01|2011-12-02|Estimate|January 2006||2006-01-31|November 2011|2011-11-30|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|BQ-1-08-ARVO||The Effect of Bevacizumab on Corneal Neovascularization|The Effect of Bevacizumab on Corneal Neovascularization|Completed||Phase 4|8|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-06-01 01:32:42.914583|2018-06-01 01:32:42.914583
NCT00797290|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-02-09|2008-11-24|2008-11-25|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2008||2008-06-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|NP01||Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Nasopharynx|Terminated|||9|Actual|University of Florida|||1|Slow enrollment, Feasibility issues|f||||f|f|f||||||No||2018-06-01 01:32:42.970428|2018-06-01 01:32:42.970428
NCT00797277|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2013-08-12||2014-09-11|2008-11-24|2008-11-25|Estimate|2014-09-11|2014-09-15|Estimate||||2014-09-11|2014-09-15|Estimate|July 2006||2006-07-31|September 2014|2014-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia|An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia|Completed||Phase 3|67|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:32:44.08522|2018-06-01 01:32:44.08522
NCT00797264|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2013-04-10|2008-11-24|2008-11-25|Estimate|||||||2013-04-10|2013-04-11|Estimate|November 2008||2008-11-30|April 2013|2013-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|KETAMINE||Ketamine Associated With Morphine PCA After Total Hip Arthroplasty|Impact of the Route of Administration of Ketamine Associated With Morphine PCA on Analgesia After Total Hip Arthroplasty|Completed||N/A|18|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-06-01 01:32:44.298837|2018-06-01 01:32:44.298837
NCT00797251|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|September 2007||2007-09-30|November 2008|2008-11-30|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Observational|||Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression|A Novel Simple Technique for Performing Anatomical Right Posterior Sectionectomy of the Liver: the Ultrasound-Guided Finger Compression|Unknown status|Active, not recruiting||10|Anticipated|University of Milan|||1||f||||t||||||||||2018-06-01 01:32:44.538197|2018-06-01 01:32:44.538197
NCT00797238|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2010-07-14|2008-11-24|2008-11-25|Estimate|||||||2010-07-14|2010-07-15|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|August 2010|Anticipated|2010-08-31|||||Observational|||DNA Repair Genes and Outcomes in Patients With Stage III NSCLC||Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     lung cancer tissue before and after treatment~   "|||2018-06-01 01:32:44.665166|2018-06-01 01:32:44.665166
NCT00797225|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21||2012-02-06|2013-01-02|2008-11-21|2008-11-25|Estimate||||2012-02-06|2012-02-08|Estimate|2013-01-02|2013-01-08|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety Study in Endometriosis With NBI-56418; Placebo and Active Controlled|A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis|Completed||Phase 2|174|Actual|AbbVie||4|||f||||f||||||||||2018-06-01 01:32:44.783973|2018-06-01 01:32:44.783973
NCT00797212|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2009-11-12||2016-09-29|2008-11-24|2008-11-25|Estimate|2009-11-12|2009-12-14|Estimate||||2016-09-29|2016-11-03|Estimate|November 2008||2008-11-30|September 2016|2016-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A New Glucose Meter With Alternative Site Testing|Clinical Evaluation of the Apollo Blood Glucose Monitoring System With Alternative Site Testing [Commercial Name is CONTOUR® USB]|Completed||N/A|50|Actual|Ascensia Diabetes Care||1|||f||||f||||||||Yes||2018-06-01 01:32:45.051105|2018-06-01 01:32:45.051105
NCT00797199|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2016-03-22|2008-11-24|2008-11-25|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|TiBS-HRT||Monitoring of Breast Tissue Change Due to Hormone Replacement Therapy in Post-menopausal Women Using OBS|Short-term Evaluations of Breast Tissue Change in Post-menopausal Women Using Optical Breast Spectroscopy (OBS)|Completed|||14|Actual|University Health Network, Toronto|||4||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:32:45.240074|2018-06-01 01:32:45.240074
NCT00797186|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2011-05-26|2008-11-24|2008-11-25|Estimate|||||||2011-05-26|2011-05-30|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus|Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus Using Regadenoson Stress Cardiac Magnetic Resonance Imaging|Unknown status|Recruiting|N/A|150|Anticipated|University of Virginia||1|||f||||t||||||||||2018-06-01 01:32:45.335008|2018-06-01 01:32:45.335008
NCT00797160|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Propofol Versus Midazolam as Premedication for Preterm Neonates With Respiratory Distress Syndrome (RDS)|Propofol and Remifentanil Versus Midazolam and Remifentanil as Premedication Allowing Very Early Extubation After Surfactant Treatment in Preterm Neonates With Respiratory Distress Syndrome|Unknown status|Recruiting|Phase 4|20|Anticipated|Federal University of Minas Gerais|||||f||||t||||||||||2018-06-01 01:32:45.426312|2018-06-01 01:32:45.426312
NCT00797134|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2015-02-02|2008-11-24|2008-11-25|Estimate|||||||2015-02-02|2015-02-03|Estimate|November 2008||2008-11-30|February 2015|2015-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Retinal Thickness Analysis Using Optical Coherence Tomography|Retinal Thickness Analysis Using Optical Coherence Tomography|Completed|||45|Actual|Association for Innovation and Biomedical Research on Light and Image|||1||f||||f||||||||||2018-06-01 01:32:45.557428|2018-06-01 01:32:45.557428
NCT00797121|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2008-11-24|2008-11-24|2008-11-25|Estimate|||||||2008-11-24|2008-11-25|Estimate|May 2008||2008-05-31|November 2008|2008-11-30|May 2013|Anticipated|2013-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma|Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor)|Unknown status|Recruiting|Phase 4|82|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:32:45.648895|2018-06-01 01:32:45.648895
NCT00797108|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|2015-07-08|2009-09-21|2016-02-11|2008-11-24|2008-11-25|Estimate|2016-02-11|2016-03-10|Estimate|2009-09-21|2009-09-28|Estimate|2016-02-11|2016-03-10|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Intent to treat (ITT) population included all randomized participants who received at least 1 dose of double blind study drug.|A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization|A Phase 2 Randomized, Double-blind, Double-dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin/Clavulanate Potassium (Augmentin) In Subjects With Community Acquired Pneumonia (Cap) Requiring Hospitalization|Completed||Phase 2|35|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:32:45.779819|2018-06-01 01:32:45.779819
NCT00797095|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-22|||2018-04-04|2008-11-22|2008-11-25|Estimate|||||||2018-04-04|2018-04-05|Actual|November 19, 2008||2008-11-19|October 20, 2014|2014-10-20|October 20, 2014||2014-10-20|||||Observational|||Health Behaviors in School-age Children: 2009-2010|Health Behaviors in School-Age Children: 2009/2010|Completed|||12651|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:32:46.375188|2018-06-01 01:32:46.375188
NCT00797082|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-07-29|2008-11-24|2008-11-25|Estimate|||||||2012-07-29|2012-07-31|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|March 2011|Actual|2011-03-31||Interventional|MRDiabetics||Magnetic Resonance Diabetic Cardiac Stress Imaging|Magnetic Resonance Diabetic Cardiac Stress Imaging : MRDIABETICS|Terminated||Phase 4|62|Actual|Assistance Publique - Hôpitaux de Paris||1||default of inclusion|f||||f||||||||||2018-06-01 01:32:46.523504|2018-06-01 01:32:46.523504
NCT00797069|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-23|||2010-07-29|2008-11-24|2008-11-25|Estimate|||||||2010-07-29|2010-07-30|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Comparison of Nutritional Products for People With Type 2 Diabetes|Comparison of Nutritional Products for People With Type 2 Diabetes|Completed||Phase 3|58|Actual|Abbott Nutrition||3|||f||||f||||||||||2018-06-01 01:32:46.603073|2018-06-01 01:32:46.603073
NCT00797056|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2015-03-30|2008-11-24|2008-11-25|Estimate|||||||2015-03-30|2015-04-01|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|STEMPAD||Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease|Pilot Study of Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease (STEMPAD Trial)|Completed||Early Phase 1|32|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:32:46.689856|2018-06-01 01:32:46.689856
NCT00797043|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-24|||2017-02-03|2008-11-24|2008-11-25|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2008||2008-09-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|SK01||Photon/Proton Radiation Therapy for Carcinoma of the Skin of the Head and Neck|A Clinical Outcomes Protocol of Photon/Proton Beam Radiation Therapy for Carcinoma of the Skin of the Head and Neck With Perineural Invasion|Terminated|||11|Actual|University of Florida|||1|Slow enrollment, feasibility issues|f||||f||||||||Undecided||2018-06-01 01:32:46.783812|2018-06-01 01:32:46.783812
NCT00796848|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2015-03-05|2008-11-21|2008-11-24|Estimate|||||||2015-03-05|2015-03-09|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring|Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring|Withdrawn||N/A|0|Actual|Stanford University|||||f||||||||||||||2018-06-01 01:32:51.150692|2018-06-01 01:32:51.150692
NCT00797030|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2008-11-21|2008-11-21|2008-11-24|Estimate|||||||2008-11-21|2008-11-24|Estimate|October 2006||2006-10-31|November 2008|2008-11-30|November 2008|Anticipated|2008-11-30|July 2008|Anticipated|2008-07-31||Interventional|||Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus|Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus|Unknown status|Active, not recruiting|Phase 4|20|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-06-01 01:32:46.875739|2018-06-01 01:32:46.875739
NCT00797017|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2014-04-24|2008-11-20|2008-11-24|Estimate|||||||2014-04-24|2014-04-28|Estimate|May 2008||2008-05-31|April 2014|2014-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Study on Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain|Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related Pain: Multicenter, Open Label, Prospective, Observational Study|Completed|||1576|Actual|Janssen Korea, Ltd., Korea|||7||f||||f||||||||||2018-06-01 01:32:46.961394|2018-06-01 01:32:46.961394
NCT00797004|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2012-06-27|2008-11-21|2008-11-24|Estimate|||||||2012-06-27|2012-06-29|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|ODOR||Olfactory Dysfunction of Rhinosinusitis|Olfactory Dysfunction of Rhinosinusitis|Completed|||23|Actual|University of Washington|||1||f||||f||||||||||2018-06-01 01:32:47.060731|2018-06-01 01:32:47.060731
NCT00796991|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2013-11-05||2013-12-31|2008-11-21|2008-11-24|Estimate|2013-12-31|2014-01-06|Estimate||||2013-12-31|2014-01-06|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|October 2012|Actual|2012-10-31|November 2009|Actual|2009-11-30||Interventional||All randomized and treated participants|Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine|A Randomized, Parallel, 3-arm Study to Characterize the Effect of Ipilimumab + Chemotherapy in Patients With Untreated Advanced Melanoma|Completed||Phase 1|72|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:32:47.515625|2018-06-01 01:32:47.515625
NCT00796978|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2015-07-15|2008-11-21|2008-11-24|Estimate|||||||2015-07-15|2015-07-16|Estimate|November 2008||2008-11-30|July 2015|2015-07-31||||November 2015|Anticipated|2015-11-30||Interventional|||Trastuzumab in Treating Older Women With Early-Stage Breast Cancer|Safety and Efficacy of Single Agent Adjuvant Trastuzumab in Older Women With Early Stage Breast Cancer: A Phase II Trial|Unknown status|Active, not recruiting|Phase 2|56|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:32:49.86662|2018-06-01 01:32:49.86662
NCT00796965|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-08-18|2008-11-21|2008-11-24|Estimate|||||||2009-08-18|2009-08-19|Estimate|December 2008||2008-12-31|August 2009|2009-08-31|March 2009|Actual|2009-03-31|||||Interventional|||Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects|A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7268 After Single Ascending Oral Doses in Healthy Subjects|Completed||Phase 1|48|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:32:49.954229|2018-06-01 01:32:49.954229
NCT00796952|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2011-09-16|2008-11-21|2008-11-24|Estimate|||||||2011-09-16|2011-09-20|Estimate|November 2001||2001-11-30|September 2011|2011-09-30|April 2005|Actual|2005-04-30|July 2004|Actual|2004-07-31||Interventional|Pharyngocise||Muscle Composition and Function for Swallowing in Head/Neck Cancer Patients|"Muscle Composition and Function for Swallowing in Head/Neck Cancer Patients Undergoing Radiotherapy: a Randomized Controlled Trial of Swallowing Therapy"|Completed||Phase 2|58|Actual|University of Florida||3|||f||||f||||||||||2018-06-01 01:32:50.016343|2018-06-01 01:32:50.016343
NCT00796939|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2015-04-09|2008-11-21|2008-11-24|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Effects of Light Treatment During Sleep on Young Men|Randomized, Placebo-Controlled Trial of Short Wavelength Light Administered Just Prior to Waking in Young Men|Completed||N/A|30|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 01:32:50.131523|2018-06-01 01:32:50.131523
NCT00796926|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2011-06-20||2011-10-04|2008-11-21|2008-11-24|Estimate|2011-07-19|2011-08-12|Estimate||||2011-10-04|2011-10-07|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes|Randomised Controlled Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes|Completed||Phase 3|30|Actual|Singapore National Eye Centre||2|||f||||f||||||||||2018-06-01 01:32:50.275232|2018-06-01 01:32:50.275232
NCT00796913|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2015-12-30|2008-11-21|2008-11-24|Estimate|||||||2015-12-30|2015-12-31|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Remission Induction and Sustenance in Graves' Disease 2|Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy|Unknown status|Active, not recruiting|N/A|250|Anticipated|Aalborg Universitetshospital||3|||f||||f||||||||No||2018-06-01 01:32:50.583691|2018-06-01 01:32:50.583691
NCT00796900|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-05-11|2008-11-21|2008-11-24|Estimate|||||||2011-05-11|2011-05-12|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|DTH1||Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)|Dantrolene as a Treatment for Hyperthermia in Patients After Subarachnoidal Hemorrhage|Terminated||Phase 2/Phase 3|34|Anticipated|Medical University of Vienna||2||organizationally not possible|f||||f||||||||||2018-06-01 01:32:50.692597|2018-06-01 01:32:50.692597
NCT00796887|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2012-09-12|2008-11-21|2008-11-24|Estimate|||||||2012-09-12|2012-09-14|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery|Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery|Completed||Phase 2|28|Actual|Henry Ford Health System||3|||f||||t||||||||||2018-06-01 01:32:50.764027|2018-06-01 01:32:50.764027
NCT00796874|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2013-07-24|2008-11-21|2008-11-24|Estimate|||||||2013-07-24|2013-07-25|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance|MR Imaging to Stratify Prostate Cancer Progression Risk in Patients on Active Surveillance|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||||PI decided to terminate study.|f||||t||||||||||2018-06-01 01:32:50.842129|2018-06-01 01:32:50.842129
NCT00796861|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2017-08-22||2017-12-19|2008-11-21|2008-11-24|Estimate|2017-12-19|2017-12-20|Actual||||2017-12-19|2017-12-20|Actual|May 2007||2007-05-31|December 2017|2017-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Trial of Sunitinib for Refractory Malignant Ascites|Phase II Pilot Efficacy Trial of Sunitinib for Refractory Malignant Ascites|Terminated||Phase 2|4|Actual|Milton S. Hershey Medical Center||1||Phycisican decided to terminate study due to slow patient accrual.|f||||t||||||||No|Not enough valuable data|2018-06-01 01:32:50.932278|2018-06-01 01:32:50.932278
NCT00796835|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-05-20|2008-11-20|2008-11-24|Estimate|||||||2011-05-20|2011-05-24|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|October 2004|Actual|2004-10-31|||||Interventional|||A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone|Dose-proportionality Study of the Five ER OROS Paliperidone To-be-marketed Tablet Strengths (3, 6, 9, 12, and 15 mg) in Healthy Male Subjects|Completed||Phase 1|50|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:32:51.209189|2018-06-01 01:32:51.209189
NCT00796822|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2013-03-13||2017-10-23|2008-11-21|2008-11-24|Estimate|2013-03-28|2013-05-17|Estimate||||2017-10-23|2017-11-28|Actual|January 2009||2009-01-31|October 2017|2017-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications|A Randomized, Placebo-Controlled Trial of Pentoxifylline to Improve Endothelial Function in HIV-Infected Patients Not Requiring Antiretroviral Therapy|Completed||Phase 2|26|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 01:32:51.275771|2018-06-01 01:32:51.275771
NCT00796809|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2015-12-11|2008-11-21|2008-11-24|Estimate|||||||2015-12-11|2015-12-14|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Observational|||Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis|Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis|Completed|||598|Actual|University of Arizona|||2||f||||t||||||||||2018-06-01 01:32:51.536226|2018-06-01 01:32:51.536226
NCT00796796|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2013-07-09|2008-11-21|2008-11-24|Estimate|||||||2013-07-09|2013-07-11|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Temsirolimus and Radiation for Non-Small Cell Lung Cancer|A Phase I Study of Temsirolimus and Thoracic Radiation in Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|10|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:32:51.598793|2018-06-01 01:32:51.598793
NCT00796783|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2014-06-19|2008-11-20|2008-11-24|Estimate|||||||2014-06-19|2014-06-20|Estimate|February 2009||2009-02-28|June 2014|2014-06-30||||June 2010|Actual|2010-06-30||Observational|||A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia|A Study to Confirm the Presence of Recurrent or Persistent Cushing's Syndrome in Patients With Clinical Signs or Symptoms of Hypercortisolemia Who Have Been Treated for Cushing's Disease|Terminated|||2|Actual|Corcept Therapeutics|||1||f||||f||||||||||2018-06-01 01:32:51.717121|2018-06-01 01:32:51.717121
NCT00796770|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2017-06-09|2008-11-21|2008-11-24|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2008||2008-11-30|June 2017|2017-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)|Vaccination of HIV-1 Infected Patients With Ex-vivo Generated Interferon-α Dendritic Cells Loaded With HIV-1 Lipopeptides and Activated With Lipopolysaccharide in Addition to Antiretroviral Treatment: Exploratory Phase I Study-(DALIA Trial)|Completed||Phase 1|19|Actual|Baylor Research Institute||1|||f||||t||||||||||2018-06-01 01:32:51.921847|2018-06-01 01:32:51.921847
NCT00796757|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2014-08-04||2015-05-22|2008-11-21|2008-11-24|Estimate|2015-05-22|2015-05-27|Estimate||||2015-05-22|2015-05-27|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Intent-to-treat (ITT) population: All participants who received at least 1 dose of either or both study drugs and had a valid baseline assessment and at least 1 postbaseline assessment.|A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).|An Open Label Study of the Effect of First Line Treatment With Avastin (Bevacizumab) in Combination With Low-dose Interferon on Progression-free Survival in Patients With Metastatic Clear Cell Renal Cell Carcinoma.|Completed||Phase 2|146|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:32:52.031741|2018-06-01 01:32:52.031741
NCT00796744|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2012-06-14|2012-04-09|2012-08-27|2008-11-21|2008-11-24|Estimate|2012-08-27|2012-09-27|Estimate|2012-04-09|2012-04-11|Estimate|2012-08-27|2012-09-27|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers|Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Evaluate the Safety and Effectiveness of DSC127 in Treating Subjects With Diabetic Ulcers|Completed||Phase 2|78|Actual|US Biotest, Inc.||3|||f||||f||||||||||2018-06-01 01:32:52.603495|2018-06-01 01:32:52.603495
NCT00796731|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2012-07-16|2008-11-21|2008-11-24|Estimate|||||||2012-07-16|2012-07-17|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma|A Dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Once Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 1|77|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:32:53.139174|2018-06-01 01:32:53.139174
NCT00796718|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2016-07-14||2016-07-14|2008-11-21|2008-11-24|Estimate|2016-07-14|2016-08-25|Estimate||||2016-07-14|2016-08-25|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||All enrolled participants.|A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer|An Open Label Study of the Effect of Xeloda and Radiotherapy on Pathological Response Rate in Patients With Locally Advanced Rectal Cancer|Completed||Phase 2|62|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:32:53.220942|2018-06-01 01:32:53.220942
NCT00796705|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2012-07-05||2012-09-28|2008-11-20|2008-11-24|Estimate|2012-07-05|2012-08-13|Estimate||||2012-09-28|2012-10-04|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)|Switching Anti-TNF-alpha Agents in Patients With RA With An Inadequate Response to TNF-alpha Inhibition|Terminated||Phase 4|13|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study terminated early due to recruitment feasibility issues. Thirteen subjects were enrolled and received treatment. No mechanistic analyses were performed.|2||Lack of Enrollment|f||||t||||||||||2018-06-01 01:32:53.425879|2018-06-01 01:32:53.425879
NCT00796692|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2008-11-21|2008-11-21|2008-11-24|Estimate|||||||2008-11-21|2008-11-24|Estimate|June 2002||2002-06-30|November 2008|2008-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|NATSPUTE||Nadroparin for the Initial Treatment of Pulmonary Thromboembolism|Efficacy and Safety of Body Weight Adjusted Nadroparin vs Standard Unfractionated Heparin for the Initial Treatment of Pulmonary Thromboembolism：a Multi-Centre, Randomised Controlled Trial in China|Completed||Phase 4|274|Actual|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-06-01 01:32:54.185945|2018-06-01 01:32:54.185945
NCT00796679|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2017-01-07|2008-11-21|2008-11-24|Estimate|||||||2017-01-07|2017-01-10|Estimate|October 2008||2008-10-31|January 2017|2017-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease|A Prospective, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Oral Paricalcitol in Retarding Cardiac Hypertrophy, Reducing Inflammation and Atherosclerosis in Stage 3 - 5 Chronic Kidney Disease|Completed||N/A|60|Actual|The University of Hong Kong||2|||f||||t||||||||No||2018-06-01 01:32:54.34464|2018-06-01 01:32:54.34464
NCT00796666|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2012-01-26||2015-03-04|2008-11-20|2008-11-24|Estimate|2012-01-26|2012-02-29|Estimate||||2015-03-04|2015-03-24|Estimate|May 2009||2009-05-31|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil|A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (NCT00795639)|Terminated||Phase 3|131|Actual|Pfizer|Study terminated early by sponsor, no Week 48 information collected.|2||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,~   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2018-06-01 01:32:54.476605|2018-06-01 01:32:54.476605
NCT00796653|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2014-03-28||2014-06-17|2008-11-21|2008-11-24|Estimate|2014-06-13|2014-06-16|Estimate||||2014-06-17|2014-06-27|Estimate|January 2009||2009-01-31|June 2014|2014-06-30||||December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|937|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 01:32:56.653172|2018-06-01 01:32:56.653172
NCT00796640|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2008-11-20|2008-11-24|Estimate|||||||2011-06-06|2011-06-08|Estimate|September 2003||2003-09-30|March 2010|2010-03-31|November 2003|Actual|2003-11-30|||||Interventional|||A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations|A Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics Under Fasting and Fed Conditions of 2 Paliperidone Extended-release Pellet Formulations With Paliperidone Oral Solution in Healthy Adults|Completed||Phase 1|35|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:33:00.165258|2018-06-01 01:33:00.165258
NCT00796627|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2017-05-03||2017-08-31|2008-11-21|2008-11-24|Estimate|2017-08-31|2017-09-29|Actual||||2017-08-31|2017-09-29|Actual|December 2006||2006-12-31|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Hypoxia-inducible Factor-1 (HIF-1) Regulated Circulating Angiogenic Cells (CACs) Recruitment in Burn Wound Healing|HIF-1 Regulated Circulating Angiogenic Cell Recruitment in Burn Wound Healing|Terminated||N/A|41|Actual|Johns Hopkins University||2||unable to recruit enough patients|f||||f||||||||No||2018-06-01 01:33:00.265327|2018-06-01 01:33:00.265327
NCT00796614|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2012-08-06||2015-09-29|2008-11-20|2008-11-24|Estimate|2012-08-06|2012-09-12|Estimate||||2015-09-29|2015-10-29|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||Treated Set (TS): Includes all patients who were documented to have taken at least one dose of randomised treatment.|Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder|A Phase IIb/III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Dose Ranging Study of Tamsulosin Hydrochloride (Low, Medium and High Dose) as Treatment in Children With Neuropathic Bladder for Three Months|Completed||Phase 2/Phase 3|231|Actual|Boehringer Ingelheim|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|4|||f||||f||||||||||2018-06-01 01:33:00.551446|2018-06-01 01:33:00.551446
NCT00796601|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-03-17|2008-11-21|2008-11-24|Estimate|||||||2009-03-17|2009-03-18|Estimate|May 2009||2009-05-31|March 2009|2009-03-31|November 2010|Anticipated|2010-11-30|May 2010|Anticipated|2010-05-31||Interventional|||Maintenance of Efficacy.|A 6-Month, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Maintenance Of Effect Study Of Esreboxetine (PNU-165442g) Administered Once Daily (QD) In Patients With Fibromyalgia.|Withdrawn||Phase 3|650|Anticipated|Pfizer||2||"This study has been cancelled as the esreboxetine development program is being discontinued.~   Safety and efficacy were not factors."|f||||t||||||||||2018-06-01 01:33:01.173516|2018-06-01 01:33:01.173516
NCT00796588|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2008-11-21|2008-11-21|2008-11-24|Estimate|||||||2008-11-21|2008-11-24|Estimate|April 2005||2005-04-30|November 2008|2008-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Effect of Remote Ischemic Preconditioning in Patients Undergoing Major Liver Surgery|The Effect of Remote Ischemic Preconditioning in Patients Undergoing Major Liver Surgery|Unknown status|Enrolling by invitation|N/A|48|Anticipated|Royal Free Hampstead NHS Trust||2|||f||||f||||||||||2018-06-01 01:33:01.234373|2018-06-01 01:33:01.234373
NCT00796575|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2015-04-02|2008-11-21|2008-11-24|Estimate|||||||2015-04-02|2015-04-03|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Multiple Doses of CS-8080 in Healthy Volunteers|A Randomized, Placebo-Controlled, Multiple Ascending Dose Study To Assess The Safety, Pharmacokinetics and Pharmacodynamics Of CS-8080 In Healthy Volunteers|Terminated||Phase 1|16|Actual|Daiichi Sankyo, Inc.||2||Safety concerns|f||||f||||||||||2018-06-01 01:33:01.295051|2018-06-01 01:33:01.295051
NCT00796562|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2016-12-13|2008-11-21|2008-11-24|Estimate|||||||2016-12-13|2016-12-14|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|mylehaplo||Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy|A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched Bone Marrow for Patients With Hematologic Malignancies|Completed||Phase 2|96|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||No||2018-06-01 01:33:01.419137|2018-06-01 01:33:01.419137
NCT00796549|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2013-08-08||2014-07-21|2008-11-21|2008-11-24|Estimate|2013-08-08|2013-10-17|Estimate||||2014-07-21|2014-07-22|Estimate|December 2008||2008-12-31|July 2014|2014-07-31||||May 2012|Actual|2012-05-31||Interventional|||BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients|A Phase II Single-arm Trial of BIBW 2992 in EGFR FISH Positive Non-small Cell Lung Cancer Patients|Completed||Phase 2|70|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 01:33:01.543836|2018-06-01 01:33:01.543836
NCT00796536|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2013-02-15|2008-11-21|2008-11-24|Estimate|||||||2013-02-15|2013-02-18|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|July 2011|Actual|2011-07-31|June 2010|Actual|2010-06-30||Interventional|||Using Functional MRI to Evaluate Cognitive Behavioral Therapy Treatment Response in Adults With Chronic Pain|Using fMRI to Evaluate CBT Treatment Response for Patients With Chronic Pain|Completed||Phase 1/Phase 2|40|Actual|University of Vermont||2|||f||||f||||||||||2018-06-01 01:33:01.967876|2018-06-01 01:33:01.967876
NCT00796523|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2008-10-16||2008-11-21|2008-11-21|2008-11-24|Estimate|2008-11-21|2008-11-24|Estimate||||2008-11-21|2008-11-24|Estimate|August 2005||2005-08-31|November 2008|2008-11-30|May 2006|Actual|2006-05-31|February 2006|Actual|2006-02-28||Interventional|||An Intervention to Decrease Infant Crying|A Randomized, Controlled Trial to Decrease Infant Crying|Completed||N/A|51|Actual|Riverside Methodist Hospital||2|||f||||t||||||||||2018-06-01 01:33:02.030634|2018-06-01 01:33:02.030634
NCT00796510|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2011-12-09||2012-01-20|2008-11-20|2008-11-24|Estimate|2012-01-20|2012-02-20|Estimate||||2012-01-20|2012-02-20|Estimate|July 2010||2010-07-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety|A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|3|Actual|Pfizer|Due to the premature termination only 3 participants were recruited into this study. No summarization or analysis was done.|2||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,~   specifically new emerging evidence of hepatic injury"|f||||f||||||||||2018-06-01 01:33:02.291795|2018-06-01 01:33:02.291795
NCT00796497|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-02-23|2008-11-21|2008-11-24|Estimate|||||||2011-02-23|2011-02-24|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)|Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study|Completed||Phase 4|14|Actual|Institute of Neuroscience, Florence, Italy||1|||f||||t||||||||||2018-06-01 01:33:02.540191|2018-06-01 01:33:02.540191
NCT00796484|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2015-08-19|2008-11-21|2008-11-24|Estimate|||||||2015-08-19|2015-08-21|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL888 in Subjects With Solid Tumors|Terminated||Phase 1|33|Actual|Exelixis||1||Sponsor decision|f||||||||||||||2018-06-01 01:33:02.630973|2018-06-01 01:33:02.630973
NCT00796471|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2008-11-20|2008-11-24|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 2003||2003-06-30|March 2010|2010-03-31|August 2003|Actual|2003-08-31|||||Interventional|||A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations|A Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics Under Fasting and Fed Conditions of 2 Paliperidone Extended-release Formulations With Paliperidone Oral Solution in Healthy Adults|Completed||Phase 1|35|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:33:02.702549|2018-06-01 01:33:02.702549
NCT00796458|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2013-08-09|2008-11-21|2008-11-24|Estimate|||||||2013-08-09|2013-08-12|Estimate|April 2005||2005-04-30|November 2008|2008-11-30||||October 2013|Anticipated|2013-10-31||Interventional|||Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer|Phase III Study of Chemo-hormonal Therapy Versus Hormonal Therapy Alone in Advanced Hormone-naives Prostate Cancer Patients.|Unknown status|Recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:33:02.793926|2018-06-01 01:33:02.793926
NCT00796445|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21||2012-11-16|2016-09-29|2008-11-21|2008-11-24|Estimate||||2012-11-16|2012-11-21|Estimate|2016-09-29|2016-09-30|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor|GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resected Melanoma|Terminated||Phase 3|1351|Actual|GlaxoSmithKline||2||"The study was terminated early following assessment of the two co-primary endpoints showing the~   lack of efficacy of the study product."|f||||||||||||||2018-06-01 01:33:02.945463|2018-06-01 01:33:02.945463
NCT00796432|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-08|2008-11-20|2008-11-24|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2003||2003-03-31|March 2010|2010-03-31|June 2003|Actual|2003-06-30|||||Interventional|||A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS Paliperidone|Open-label Positron Emission Tomography (PET) Study of Central D2-receptor Occupancy in Healthy Subjects Following a Single Oral Dose of OROS Paliperidone|Completed||Phase 1|4|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:33:03.580462|2018-06-01 01:33:03.580462
NCT00796419|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2017-03-17||2017-03-17|2008-11-21|2008-11-24|Estimate|2017-03-17|2017-04-28|Actual||||2017-03-17|2017-04-28|Actual|January 2009||2009-01-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|CEASE||Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)|Phase III Study Comparing Albumin and Hetastarch Therapy in Acute Lung Injury|Terminated||Phase 3|31|Actual|Emory University||2|||f||||t||||||||||2018-06-01 01:33:03.645464|2018-06-01 01:33:03.645464
NCT00796393|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2011-06-22|2008-11-21|2008-11-24|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study of the Effects of Probiotics Upon Infectious Episodes in Subject Aged More Than 60, During Winter.|Effects of Daily Consumption of a Probiotic on the Evolution of Infectious Episodes (ENT, Gastro-intestinal and Pulmonary), in Subject Aged 60 Years or Over, During Winter.|Completed||N/A|200|Actual|Institut Rosell Lallemand||4|||f||||f||||||||||2018-06-01 01:33:04.001077|2018-06-01 01:33:04.001077
NCT00796380|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2008-11-21|2008-11-21|2008-11-24|Estimate|||||||2008-11-21|2008-11-24|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|July 2010|Anticipated|2010-07-31|November 2009|Anticipated|2009-11-30||Interventional|||Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases|Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases|Unknown status|Not yet recruiting|Phase 4|1|Anticipated|Shenzhen Children's Hospital|||||f||||t||||||||||2018-06-01 01:33:04.109407|2018-06-01 01:33:04.109407
NCT00796367|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2012-07-31|2011-05-13|2012-09-05|2008-11-21|2008-11-24|Estimate|2012-07-31|2012-08-31|Estimate|2011-05-13|2011-05-18|Estimate|2012-09-05|2012-09-10|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)|A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.|Completed||Phase 3|676|Actual|VIVUS, Inc.||3|||f||||t||||||||||2018-06-01 01:33:04.188409|2018-06-01 01:33:04.188409
NCT00796354|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2010-02-15|2008-11-21|2008-11-24|Estimate|||||||2010-02-15|2010-02-17|Estimate|November 2008||2008-11-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Constipation Associated With Irritable Bowel Syndrome (IBS-C)|A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of Movicol® With Placebo in Patients With Constipation Associated With Irritable Bowel Syndrome (IBS)|Completed||Phase 3|210|Actual|Norgine||2|||f||||f||||||||||2018-06-01 01:33:04.742251|2018-06-01 01:33:04.742251
NCT00796341|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2008-12-01|2008-11-21|2008-11-24|Estimate|||||||2008-12-01|2008-12-02|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Endometrial Injury and IVF-ET Outcome|Does Endometrial Injury in the Non-Transfer Cycle Improve the IVF-ET Outcome in the Subsequent Cycle in Patients With Previous Failed IVF Cycles: A Randomized Control Trial|Completed||N/A|99|Actual|Bangalore Assisted Conception Centre||2|||f||||f||||||||||2018-06-01 01:33:04.857154|2018-06-01 01:33:04.857154
NCT00796328|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2014-03-14||2018-03-22|2008-11-21|2008-11-24|Estimate|2014-03-14|2014-04-21|Estimate||||2018-03-22|2018-04-23|Actual|November 2008||2008-11-30|March 2018|2018-03-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Up-Down Determination of the ED90 of Phenylephrine for Hypotension Prophylaxis in Cesarean Delivery|Up-down Determination of the ED90 of the Initial Rate of Infusion of Phenylephrine for the Prophylaxis of Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery|Terminated||Phase 4|45|Actual|IWK Health Centre||1||Results Invalid, study closed, analysis cannot proceed.|f||||t||||||||||2018-06-01 01:33:04.936095|2018-06-01 01:33:04.936095
NCT00796315|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2012-12-19||2013-01-29|2008-11-21|2008-11-24|Estimate|2012-12-19|2013-01-25|Estimate||||2013-01-29|2013-02-04|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children|A Single-dose, Open-label, Multi-center Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Ages 2 to < 18 Years|Completed||Phase 1|41|Actual|Procter and Gamble|Incidences of mild sedation are consistent with doxylamine's indication as an OTC sleep aid. Conclusive evaluation of sedation couldn't be undertaken in the absence of a control group. Also, children may nap in daytime confounding sedation assessment|1|||f||||f||||||||||2018-06-01 01:33:05.052094|2018-06-01 01:33:05.052094
NCT00796302|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|2016-02-18||2017-06-27|2008-11-21|2008-11-24|Estimate|2016-03-18|2016-04-20|Estimate||||2017-06-27|2017-07-26|Actual|August 2008||2008-08-31|June 2017|2017-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||ADHD & severe physical aggression|Treatment of Severe Childhood Aggression (The TOSCA Study)|Stimulant and Risperidone in Children With Severe Physical Aggression|Completed||Phase 4|168|Actual|Ohio State University|These results were obtained with children selected for severity of aggression and disruptive behavior, and the risk-benefit ratio may well be decreased for children with milder disruptive behavior or no physical aggression.|2|||f||||t||||||||||2018-06-01 01:33:05.340668|2018-06-01 01:33:05.340668
NCT00796289|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20||2010-12-16|2015-08-26|2008-11-21|2008-11-24|Estimate||||2010-12-16|2010-12-22|Estimate|2015-08-26|2015-09-09|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females|A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment With Clomiphene Citrate or Placebo in Anovulatory or Oligoovulatory Infertile Females|Completed||Phase 2|350|Actual|Ferring Pharmaceuticals||5|||f||||f||||||||||2018-06-01 01:33:05.621735|2018-06-01 01:33:05.621735
NCT00796276|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2008-11-20|2008-11-24|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2004||2004-05-31|March 2010|2010-03-31|August 2004|Actual|2004-08-31|||||Interventional|||A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release Paliperidone|Disposition of Paliperidone Enantiomers After Treatment With Different Formulations of the Racemate and the Separate Enantiomers and the Determination of the Absolute Bioavailability of IR and ER OROS Paliperidone|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:33:05.747868|2018-06-01 01:33:05.747868
NCT00796263|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2018-04-17|2008-11-21|2008-11-24|Estimate|||||||2018-04-17|2018-04-19|Actual|April 2009||2009-04-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|April 2021|Anticipated|2021-04-30||Interventional|AAHIV||Antiretroviral Therapy for Acute HIV Infection|Antiretroviral Therapy for Acute HIV Infection|Recruiting||Phase 3|536|Anticipated|South East Asia Research Collaboration with Hawaii||2|||f||||f||||||||Undecided||2018-06-01 01:33:05.802843|2018-06-01 01:33:05.802843
NCT00796250|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2017-03-21|2008-11-21|2008-11-24|Estimate|||||||2017-03-21|2017-03-23|Actual|November 1, 2003|Actual|2003-11-01|March 2017|2017-03-31|January 1, 2005|Actual|2005-01-01|January 1, 2005|Actual|2005-01-01||Interventional|||Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)|"Efficacy of Infliximab as Bridging Therapy in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With Azathioprine"|Terminated||Phase 3|9|Actual|Merck Sharp & Dohme Corp.||2||Due to poor patient recruitment, a decision was made to terminate this trial.|f||||f||||||||||2018-06-01 01:33:05.949146|2018-06-01 01:33:05.949146
NCT00796237|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2011-08-08|2008-11-21|2008-11-24|Estimate|||||||2011-08-08|2011-08-09|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Effects of Whole Body Vibration in Subacute Stroke Patients|Effects of Whole Body Vibration Training on Bone Health, Physical Fitness, and Neuromotor Performance in Individuals With Subacute Stroke: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-06-01 01:33:06.032821|2018-06-01 01:33:06.032821
NCT00796224|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2009-12-15||2010-02-01|2008-11-20|2008-11-24|Estimate|2009-12-16|2010-01-25|Estimate||||2010-02-01|2010-02-18|Estimate|December 2008||2008-12-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media|A Open Label, Randomized, Single Dose, Parallel Arm Study To Determine Pharmacokinetics Of Azithromycin Following Oral Administration Of Immediate-Release Or Extended-Release Formulation In Pediatric Subjects With Acute Otitis Media|Completed||Phase 2|38|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:33:06.126427|2018-06-01 01:33:06.126427
NCT00796211|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2009-01-14|2008-11-21|2008-11-24|Estimate|||||||2009-01-14|2009-01-15|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|197-002||A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis|A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis|Completed||Phase 2|20|Anticipated|Zalicus||5|||f||||f||||||||||2018-06-01 01:33:06.44725|2018-06-01 01:33:06.44725
NCT00796198|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2008-11-24|2008-11-21|2008-11-24|Estimate|||||||2008-11-24|2008-11-25|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|||Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure|A Pilot Study on the Effects of Cosopt on IOP Lowering and Ocular Diastolic Perfusion Pressure in Patients Not Controlled With Xalatan Monotherapy|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|University of Turin, Italy||2|||f||||f||||||||||2018-06-01 01:33:06.534555|2018-06-01 01:33:06.534555
NCT00796185|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2008-11-20|2008-11-24|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2003||2003-08-31|March 2010|2010-03-31|January 2004|Actual|2004-01-31|||||Interventional|||As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations|Comparison of Steady-state Pharmacokinetics of Paliperidone After Extended-release OROS� Paliperidone 15 mg and Immediate-release Oral Risperidone 8 mg b.i.d. in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|62|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:33:06.639043|2018-06-01 01:33:06.639043
NCT00796172|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2015-04-27|2008-11-21|2008-11-24|Estimate|||||||2015-04-27|2015-04-29|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Evaluating the Effectiveness of a Computerized Medication Adherence System at Reducing Cardiovascular Disease Risk Factors|Clinic-based Intervention to Improve Medication Adherence to Reduce Cardiovascular Disease Risks|Completed||Phase 2|308|Actual|PHCC LP||2|||f||||||||||||||2018-06-01 01:33:06.711327|2018-06-01 01:33:06.711327
NCT00796159|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-12-21|2008-11-21|2008-11-24|Estimate|||||||2009-12-21|2009-12-23|Estimate|July 2007||2007-07-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide|A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension|Completed|||1723|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:33:06.780854|2018-06-01 01:33:06.780854
NCT00796146|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2018-04-16|2008-11-21|2008-11-24|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2009||2009-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Observational|||Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population||Recruiting|||536|Anticipated|South East Asia Research Collaboration with Hawaii|||||f||||f||||||Samples With DNA|"~     serum, PBMC~   "|||2018-06-01 01:33:06.863692|2018-06-01 01:33:06.863692
NCT00796133|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2015-04-16|2008-11-21|2008-11-24|Estimate|||||||2015-04-16|2015-04-17|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women|A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women|Completed||Phase 2|18|Anticipated|Population Council||3|||f||||f||||||||||2018-06-01 01:33:06.94166|2018-06-01 01:33:06.94166
NCT00796120|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2014-03-25|2013-04-18|2015-12-09|2008-11-20|2008-11-24|Estimate|2014-09-15|2014-09-16|Estimate|2013-04-18|2013-04-26|Estimate|2015-12-09|2015-12-10|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Interventional|||An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)|A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)|Completed||Phase 3|121|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 01:33:07.019636|2018-06-01 01:33:07.019636
NCT00796107|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21||2016-07-07|2016-07-26|2008-11-21|2008-11-24|Estimate||||2016-07-07|2016-07-11|Estimate|2016-07-26|2016-07-28|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer|An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.|Completed||Phase 2|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:33:07.503144|2018-06-01 01:33:07.503144
NCT00796094|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2016-11-08|2008-11-21|2008-11-24|Estimate|||||||2016-11-08|2016-11-09|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Imaging of Soft Tissues|Elasticity Imaging of Soft Tissues|Completed|||30|Actual|University of Michigan|||1||f||||f||||||||Undecided||2018-06-01 01:33:07.575436|2018-06-01 01:33:07.575436
NCT00796081|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2008-11-20|2008-11-24|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 2006||2006-01-31|March 2010|2010-03-31|August 2006|Actual|2006-08-31|||||Interventional|||A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder|Open-label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-dose Extended-release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder|Completed||Phase 1|25|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:33:07.638927|2018-06-01 01:33:07.638927
NCT00796068|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2018-04-11|2008-11-21|2008-11-24|Estimate|||||||2018-04-11|2018-04-13|Actual|October 29, 2008|Actual|2008-10-29|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant|Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen|Recruiting||Phase 2|130|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f|t|f||||||||2018-06-01 01:33:07.700337|2018-06-01 01:33:07.700337
NCT00796055|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-11-16|2008-11-21|2008-11-24|Estimate|||||||2011-11-16|2011-11-17|Estimate|August 2009||2009-08-31|November 2011|2011-11-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|MEDI-547||Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors|A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression|Terminated||Phase 1|6|Actual|MedImmune LLC||1||MI-CP177 study closed per sponsor decision.|f||||f||||||||||2018-06-01 01:33:07.827476|2018-06-01 01:33:07.827476
NCT00796042|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-21|||2012-06-04|2008-11-21|2008-11-24|Estimate|||||||2012-06-04|2012-06-05|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|WOUND||Interdisciplinary Pressure Management & Mobility Program as an Alternative to Usual Care: A Pilot Study|Interdisciplinary Pressure Management & Mobility Program as an Alternative to Bed Rest: A Pilot Study|Completed||Phase 3|14|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-06-01 01:33:07.930732|2018-06-01 01:33:07.930732
NCT00796029|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-06|2008-11-20|2008-11-24|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 2003||2003-07-31|March 2010|2010-03-31|July 2003|Actual|2003-07-31|||||Interventional|||A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose|Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|5|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:33:08.093337|2018-06-01 01:33:08.093337
NCT00796003|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2013-05-31||2013-10-10|2008-11-21|2008-11-24|Estimate|2013-10-10|2013-12-09|Estimate||||2013-10-10|2013-12-09|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||For Baseline characteristics analysis, number of participants treated were analyzed (37) instead of number of participants enrolled (39). 2 enrolled participants were not treated.|A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome|A Phase I/II Clinical Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome|Completed||Phase 1|39|Actual|Janssen Pharmaceutical K.K.||3|||f||||t||||||||||2018-06-01 01:33:08.205232|2018-06-01 01:33:08.205232
NCT00795990|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2014-12-04|2008-11-21|2008-11-24|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants|Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants|Completed|||350|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:33:08.929774|2018-06-01 01:33:08.929774
NCT00795977|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2011-09-07|2008-11-20|2008-11-21|Estimate|||||||2011-09-07|2011-09-08|Estimate|November 2003||2003-11-30|September 2011|2011-09-30|November 2012|Anticipated|2012-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer|Phase I/II Study on Intratumor Dendritic Cell Injection Immunotherapy Using Immature Dendritic Cells With S Pyogenes Preparation (OK-432) for Patients With Resectable Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Fukushima Medical University||1|||f||||f||||||||||2018-06-01 01:33:08.989738|2018-06-01 01:33:08.989738
NCT00795964|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2010-09-23|2008-11-20|2008-11-21|Estimate|||||||2010-09-23|2010-09-24|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|tidalvolume||Influence of Tidal Volume on Postoperative Pulmonary Function|Influence of Tidal Volume on Postoperative Pulmonary Function|Completed||N/A|101|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-06-01 01:33:09.082134|2018-06-01 01:33:09.082134
NCT00795951|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2013-02-19||2013-12-19|2008-11-20|2008-11-21|Estimate|2013-12-19|2014-02-11|Estimate||||2013-12-19|2014-02-11|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents|Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents|Completed||Phase 4|102|Actual|Allerderm||1|||f||||f||||||||||2018-06-01 01:33:09.182018|2018-06-01 01:33:09.182018
NCT00795938|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2017-03-07|2008-11-19|2008-11-21|Estimate|||||||2017-03-07|2017-03-10|Actual|October 2008||2008-10-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.|An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of An Experimental Tablet Of Sildenafil With Or Without Water Relative To Viagra® Conventional Oral Tablet With Water.|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:33:09.716701|2018-06-01 01:33:09.716701
NCT00795925|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-20|2008-11-20|2008-11-21|Estimate|||||||2008-11-20|2008-11-21|Estimate|October 2004||2004-10-31|November 2008|2008-11-30|December 2005|Actual|2005-12-31|||||Interventional|||Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder|Dose-Escalating Study of Propiverine Hydrochloride (Mictonetten®) in Children Suffering From Frequency-Urgency-Syndrome and Urinary Incontinence Indicative of Detrusor Overactivity (Overactive Bladder)|Completed||Phase 2|30|Actual|APOGEPHA Arzneimittel GmbH||1|||f||||||||||||||2018-06-01 01:33:09.799199|2018-06-01 01:33:09.799199
NCT00795912|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-20|2008-11-20|2008-11-21|Estimate|||||||2008-11-20|2008-11-21|Estimate|May 2003||2003-05-31|November 2008|2008-11-30|January 2008|Actual|2008-01-31|November 2005|Actual|2005-11-30||Interventional|||A Study Of The Usage Of Statins In A Community Heart Failure Population|A Study Of The Usage Of Statins In A Community Heart Failure Population: The Impact of HMG Co-Enzyme A Reductase Inhibitors on Heart Structural Parameters, Brain Naturetic Peptide, Markers of Inflammation and Fibrosis|Completed||Phase 4|56|Actual|St Vincent's University Hospital, Ireland||2|||f||||t||||||||||2018-06-01 01:33:09.871642|2018-06-01 01:33:09.871642
NCT00795899|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-08-15|2008-11-20|2008-11-21|Estimate|||||||2011-08-15|2011-08-16|Estimate|January 2002||2002-01-31|August 2011|2011-08-31|September 2008|Actual|2008-09-30|December 2005|Actual|2005-12-31||Interventional|||Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)|Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer|Completed||Phase 2|230|Actual|German Breast Group||1|||f||||t||||||||||2018-06-01 01:33:09.970924|2018-06-01 01:33:09.970924
NCT00795886|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2011-03-01||2013-07-23|2008-11-19|2008-11-21|Estimate|2012-04-10|2012-05-07|Estimate||||2013-07-23|2013-07-31|Estimate|August 2005||2005-08-31|July 2013|2013-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)|CHP-753, Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2|63|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:33:10.059617|2018-06-01 01:33:10.059617
NCT00795873|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2013-09-16|2008-11-20|2008-11-21|Estimate|||||||2013-09-16|2013-09-18|Estimate|December 2008||2008-12-31|March 2012|2012-03-31||||||||Observational|||OVATIO CRT and SITUS OTW LV Lead Post Approval Study|OVATIO CRT and SITUS OTW LV Lead Post Approval Study|Completed|||2260|Anticipated|ELA Medical, Inc.|||||f||||f||||||||||2018-06-01 01:33:10.250773|2018-06-01 01:33:10.250773
NCT00795860|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2017-10-12|2008-11-20|2008-11-21|Estimate|||||||2017-10-12|2017-10-16|Actual|June 2003|Actual|2003-06-30|October 2017|2017-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise|Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise|Completed||N/A|36|Actual|University of Michigan||2|||f||||f|f|f||||||||2018-06-01 01:33:10.331306|2018-06-01 01:33:10.331306
NCT00795847|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-22|2008-11-20|2008-11-21|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Morning Hypertension and Preminent Therapy Study|The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension|Completed||Phase 4|216|Actual|Kurume University||2|||f||||t||||||||||2018-06-01 01:33:10.40354|2018-06-01 01:33:10.40354
NCT00795834|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-19|2008-11-19|2008-11-21|Estimate|||||||2008-11-19|2008-11-21|Estimate|June 2008||2008-06-30|November 2008|2008-11-30|March 2009|Anticipated|2009-03-31|January 2009|Anticipated|2009-01-31||Interventional|||Effects of a Beverage Rich in Fruit Extracts on Risk Factors Associated With Cardiovascular Disease|Pilot Study to Assess Effects of Novel Beverages on Established and Novel Risk Markers for Vascular Disease|Unknown status|Recruiting|N/A|40|Anticipated|University of Glasgow||2|||f||||f||||||||||2018-06-01 01:33:10.473024|2018-06-01 01:33:10.473024
NCT00795821|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2018-02-17|2011-01-28|2018-03-16|2008-11-19|2008-11-21|Estimate|2018-03-16|2018-03-20|Actual|2011-01-28|2011-02-07|Estimate|2018-03-16|2018-03-20|Actual|December 2008||2008-12-31|March 2018|2018-03-31|March 2011|Actual|2011-03-31|February 2010|Actual|2010-02-28||Interventional|||A Study in Adult Patients With Major Depressive Disorder|A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder|Completed||Phase 2/Phase 3|495|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 01:33:10.729214|2018-06-01 01:33:10.729214
NCT00795808|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2008-11-20|2008-11-20|2008-11-21|Estimate|||||||2008-11-20|2008-11-21|Estimate|August 2003||2003-08-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|PCOSMIC||PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene|Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome|Completed||Phase 4|171|Actual|University of Auckland, New Zealand||2|||f||||t||||||||||2018-06-01 01:33:13.856863|2018-06-01 01:33:13.856863
NCT00795795|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-03-30|2008-11-20|2008-11-21|Estimate|||||||2012-03-30|2012-04-02|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Preimplantation Genetic Screening in Women of Advanced Maternal Age|Randomized Controlled Trial (RCT) of Preimplantation Genetic Screening (PGS) in Women of Advanced Maternal Age (AMA)|Completed||N/A|640|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 01:33:13.941368|2018-06-01 01:33:13.941368
NCT00795782|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2016-04-13|2008-11-20|2008-11-21|Estimate|||||||2016-04-13|2016-04-15|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|||Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma|Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial|Completed||Phase 3|258|Actual|Samsung Medical Center||3|||f||||t||||||||Undecided||2018-06-01 01:33:14.008942|2018-06-01 01:33:14.008942
NCT00795769|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2017-03-06||2017-04-20|2008-11-20|2008-11-21|Estimate|2017-04-20|2017-05-23|Actual||||2017-04-20|2017-05-23|Actual|August 8, 2008|Actual|2008-08-08|April 2017|2017-04-30|June 10, 2009|Actual|2009-06-10|June 9, 2009|Actual|2009-06-09||Interventional|||Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant|Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells|Completed||Phase 2|49|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f|t|f||||||No||2018-06-01 01:33:14.096258|2018-06-01 01:33:14.096258
NCT00795756|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2014-10-21|2008-11-20|2008-11-21|Estimate|||||||2014-10-21|2014-10-22|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia|A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL|Completed||Phase 2/Phase 3|145|Actual|Northern Italy Leukemia Group||2|||f||||t||||||||||2018-06-01 01:33:15.110924|2018-06-01 01:33:15.110924
NCT00795743|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2014-05-05|2008-11-20|2008-11-21|Estimate|||||||2014-05-05|2014-05-06|Estimate|February 2008||2008-02-29|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Coagulation Changes in Trauma Patients|The Effect of Central Venous Catheters on Systemic Coagulation|Completed|||40|Actual|University of Miami|||||f||||f||||||||||2018-06-01 01:33:15.208012|2018-06-01 01:33:15.208012
NCT00795730|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-07-20|2008-11-20|2008-11-21|Estimate|||||||2009-07-20|2009-07-21|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease|Terminated||Phase 1|56|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:33:15.266788|2018-06-01 01:33:15.266788
NCT00795717|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2013-05-07||2014-12-02|2008-11-20|2008-11-21|Estimate|2014-12-02|2014-12-08|Estimate||||2014-12-02|2014-12-08|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|HALO||Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial|Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial|Completed||Phase 4|41|Actual|Tufts University|We had low numbers that may not represent the overall population. There was not an HIV negative control arm. The 4 week wash out was too short and therefore difficult to compare the post-treatment vs true post placebo effects.|2|||f||||t||||||||||2018-06-01 01:33:15.348095|2018-06-01 01:33:15.348095
NCT00795704|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2012-04-16||2012-06-29|2008-11-20|2008-11-21|Estimate|2012-06-29|2012-08-09|Estimate||||2012-06-29|2012-08-09|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|Mul-DM||Impact of Mulberry Leaf on Type 2 Diabetes|Effect of Mulberry Leaf Extract on Glycemic Durability in Non-insulin Dependent Diabetes Mellitus: a Double-blind, Randomized, Placebo-controlled Pilot Study (Mul-DM)|Completed||Phase 2/Phase 3|24|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-06-01 01:33:15.71719|2018-06-01 01:33:15.71719
NCT00795691|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2008-11-20|2008-11-20|2008-11-21|Estimate|||||||2008-11-20|2008-11-21|Estimate|May 2004||2004-05-31|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Diabetes Dietary Study- Low Carbohydrate and Low-Fat Diets in Type 2 Diabetes|High and Low Carbohydrate Weight Loss Approaches to Type 2 Diabetes Mellitus AKA The Diabetes Dietary Study (DDS)|Unknown status|Active, not recruiting|N/A|105|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-06-01 01:33:16.090954|2018-06-01 01:33:16.090954
NCT00795678|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2013-07-31|2008-11-20|2008-11-21|Estimate|||||||2013-07-31|2013-08-02|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Chemotherapeutic Agents in Brain/Breast|Clinical Study to Assess Entry of Chemotherapeutic Agents Into Brain Metastases in Women With Breast Cancer|Completed|||10|Actual|Case Comprehensive Cancer Center|||||f||||t||||||Samples With DNA|"~     Collection of blood before and after chemotherapy is administered and before and after~     resection of tumor in the operating room. Analysis of small portions of the brain tumor~     obtained at the time of craniotomy for drug collection.~   "|||2018-06-01 01:33:16.193546|2018-06-01 01:33:16.193546
NCT00795665|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2016-01-04|2008-11-20|2008-11-21|Estimate|||||||2016-01-04|2016-01-05|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|UCDCC#208||Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma|Phase II Study of Bevacizumab (Avastin) and BCNU for Treatment of Relapsed, High Grade Gliomas|Completed||Phase 2|7|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 01:33:16.285027|2018-06-01 01:33:16.285027
NCT00795652|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2016-09-01|2008-11-20|2008-11-21|Estimate|||||||2016-09-01|2016-09-02|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|MOM||Mom: Managing Our Mood, Part of The Family Help Program|Evidence-based, Distance Treatment for Postpartum Depression, Mom: Managing Our Mood, Part of The Family Help Program|Completed||Phase 2|62|Actual|IWK Health Centre||2|||f||||f||||||||No|Aggregate summary data would be made available but not individual data.|2018-06-01 01:33:16.379334|2018-06-01 01:33:16.379334
NCT00795639|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2012-01-30||2015-03-04|2008-11-20|2008-11-21|Estimate|2012-01-30|2012-03-01|Estimate||||2015-03-04|2015-03-24|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension|Terminated||Phase 3|183|Actual|Pfizer|Study terminated early.|2||"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns,~   specifically new emerging evidence of hepatic injury."|f||||t||||||||||2018-06-01 01:33:16.51844|2018-06-01 01:33:16.51844
NCT00795626|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2013-02-04|2008-11-20|2008-11-21|Estimate|||||||2013-02-04|2013-02-05|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|NERE-CR||Impact of Systematic Nursing Orientations in the Reduction of Predicted Cardiovascular Risk in Patients With Coronary Artery Disease.|Impact of Systematic Nursing Orientations in the Reduction of Predicted Cardiovascular Risk in Patients With Coronary Artery Disease.|Completed||N/A|74|Actual|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-06-01 01:33:17.069089|2018-06-01 01:33:17.069089
NCT00795613|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-10-16|2008-11-20|2008-11-21|Estimate|||||||2015-10-16|2015-10-19|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|October 2015|Anticipated|2015-10-31|November 2014|Actual|2014-11-30||Interventional|HD0607||Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)|Multicenter Clinical Study With Early Treatment Intensification In Patients With High- Risk Hodgkin Lymphoma, Identified As FDG-PET Scan Positive After 2 Conventional ABVD Courses|Unknown status|Active, not recruiting|Phase 2|450|Anticipated|Ospedale Santa Croce-Carle Cuneo||2|||f||||t||||||||||2018-06-01 01:33:17.20898|2018-06-01 01:33:17.20898
NCT00795600|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2011-08-09||2016-02-18|2008-11-20|2008-11-21|Estimate|2013-05-08|2013-06-17|Estimate||||2016-02-18|2016-03-16|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment|A Multi-centre, Open-labelled, Randomised, Two-group Parallel Trial Comparing the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After 26 Weeks of Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily, Both With Insulin Aspart at Mealtimes|Completed||Phase 4|60|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:33:17.383849|2018-06-01 01:33:17.383849
NCT00795587|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-11-07|2008-11-20|2008-11-21|Estimate|||||||2012-11-07|2012-11-08|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring|Compared Effects of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension|Terminated||Phase 4|3|Actual|University Hospital, Grenoble||2||evolution of patient's care allows no more recruitment|f||||t||||||||||2018-06-01 01:33:18.653406|2018-06-01 01:33:18.653406
NCT00795574|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2008-11-21|2008-11-20|2008-11-21|Estimate|||||||2008-11-21|2008-11-24|Estimate|June 2005||2005-06-30|November 2008|2008-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|HS2006||Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa|Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa|Completed||Phase 2|38|Actual|Florida Academic Dermatology Centers||2|||f||||t||||||||||2018-06-01 01:33:18.715852|2018-06-01 01:33:18.715852
NCT00795561|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2014-01-13|2008-11-20|2008-11-21|Estimate|||||||2014-01-13|2014-01-15|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|DIM||Management of Nausea and Vomiting of Pregnancy|Randomized Controlled Trial of Day Care Versus Inpatient Management of Nausea and Vomiting of Pregnancy|Completed||N/A|98|Actual|University College Cork||2|||f||||t||||||||||2018-06-01 01:33:18.773348|2018-06-01 01:33:18.773348
NCT00795548|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-01-20|2008-11-20|2008-11-21|Estimate|||||||2012-01-20|2012-01-23|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|October 2010|Actual|2010-10-31||Interventional|||Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation|Phase-II Trial to Assess the Efficacy and Toxicity of 5-Azacitidine in Addition to Standard DLI for the Treatment of Patients With AML or MDS Relapsing After Allogeneic Stem Cell Transplantation|Completed||Phase 2|30|Actual|Heinrich-Heine University, Duesseldorf||1|||f||||f||||||||||2018-06-01 01:33:18.901272|2018-06-01 01:33:18.901272
NCT00795535|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2014-12-12||2015-02-04|2008-11-19|2008-11-21|Estimate|2014-12-12|2014-12-22|Estimate||||2015-02-04|2015-02-09|Estimate|May 2007||2007-05-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|HRV|75 patients with complete HRV and trauma registry data|Heart Rate Variability in Trauma Patients|Heart Rate Variability in Trauma Patients|Completed|||95|Actual|University of Miami|||||f||||f||||||||||2018-06-01 01:33:19.056625|2018-06-01 01:33:19.056625
NCT00795522|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-04-20|2008-11-20|2008-11-21|Estimate|||||||2015-04-20|2015-04-21|Estimate|July 2003||2003-07-31|April 2015|2015-04-30|March 2005|Actual|2005-03-31|February 2005|Actual|2005-02-28||Interventional|||An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)|An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria|Completed||Phase 4|51|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:33:19.220665|2018-06-01 01:33:19.220665
NCT00795509|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2012-03-07||2012-06-05|2008-11-19|2008-11-21|Estimate|2012-06-05|2012-07-09|Estimate||||2012-06-05|2012-07-09|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).|Special Investigation For Long Term Use Of Detrusitol (Regulatory Post Marketing Commitment Plan).|Completed|||374|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:33:19.295105|2018-06-01 01:33:19.295105
NCT00795496|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-04-19|2008-11-20|2008-11-21|Estimate|||||||2011-04-19|2011-04-20|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Observational|||Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up|Bronchial Hyperreactivity in Atopic Dermatitis Patients - a 10 Year Follow-up|Completed|||50|Actual|Helsinki University|||1||f||||f||||||Samples Without DNA|"~     Serum is collected for measurement of IgE~   "|||2018-06-01 01:33:19.487991|2018-06-01 01:33:19.487991
NCT00795483|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-08-08|2008-11-20|2008-11-21|Estimate|||||||2012-08-08|2012-08-09|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort|Efficacy and Security of Annual and Biennial Zoledronic Acid for Osteoporosis Treatment in an HIV-infected Patients' Cohort|Completed||Phase 4|33|Actual|Germans Trias i Pujol Hospital||3|||f||||f||||||||||2018-06-01 01:33:19.587187|2018-06-01 01:33:19.587187
NCT00795470|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2015-12-01|2008-11-20|2008-11-21|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CAUTION||Factorial Trial of Antimicrobial Therapy and/or Catheter Change for Catheter Urinary Tract Infections.|A Pilot Concealed Randomized Double-blinded Placebo-controlled Factorial Trial of Antimicrobial Therapy and/or Catheter Change for Catheter-associated Urinary Tract Infections in the Critically Ill|Withdrawn||Phase 3|0|Actual|St. Michael's Hospital, Toronto||4||Not pursuing the study due to funding issues|f||||t||||||||||2018-06-01 01:33:19.668788|2018-06-01 01:33:19.668788
NCT00795457|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2017-07-04|2008-11-20|2008-11-21|Estimate|||||||2017-07-04|2017-07-06|Actual|January 2009||2009-01-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|February 2013|Actual|2013-02-28||Interventional|||Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas|A Bi-Institutional Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With WHO Grade II Low-Grade Gliomas|Completed||Early Phase 1|13|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:33:19.748996|2018-06-01 01:33:19.748996
NCT00795444|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2015-01-23|2008-11-20|2008-11-21|Estimate|||||||2015-01-23|2015-01-26|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1|Pilot Study Of The Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 In Patients Taking Highly Active Antiretroviral Therapy|Completed||Phase 2|10|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||1|||f||||f||||||||||2018-06-01 01:33:19.822859|2018-06-01 01:33:19.822859
NCT00795418|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10||2012-05-02|2012-05-02|2008-11-20|2008-11-21|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|October 2008||2008-10-31|May 2012|2012-05-31||||November 2010|Actual|2010-11-30||Interventional|||Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients|A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106|Completed||Phase 2|31|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:33:19.895438|2018-06-01 01:33:19.895438
NCT00795405|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-08-04|2008-11-20|2008-11-21|Estimate|||||||2009-08-04|2009-08-06|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Cardiovascular Effects of Sporting Events|Cardiovascular Effects of Major Sporting Events in Subjects With Coronary Heart Disease|Completed||Early Phase 1|38|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-06-01 01:33:19.978982|2018-06-01 01:33:19.978982
NCT00795392|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-09-17|2008-11-20|2008-11-21|Estimate|||||||2009-09-17|2009-09-18|Estimate|November 2008||2008-11-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|PEPO||Preoperative Psychological Evaluation as Predictor of Outcomes|Preoperative Psychological Evaluation as Predictor of Post-surgical Outcomes|Completed|||200|Actual|Nanjing Medical University|||2||f||||t||||||||||2018-06-01 01:33:20.055882|2018-06-01 01:33:20.055882
NCT00795379|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-20|2008-11-20|2008-11-21|Estimate|||||||2008-11-20|2008-11-21|Estimate|November 2008||2008-11-30|November 2008|2008-11-30||||November 2009|Anticipated|2009-11-30||Interventional|||Testing the Use of Interoceptive Exposure to Reduce Barriers to Psychotherapy|Testing the Use of Interoceptive Exposure to Reduce Barriers to Psychotherapy|Unknown status|Recruiting|N/A|40|Anticipated|G.V. (Sonny) Montgomery VA Medical Center||2|||f||||f||||||||||2018-06-01 01:33:20.124602|2018-06-01 01:33:20.124602
NCT00795366|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2014-12-01||2014-12-11|2008-11-20|2008-11-21|Estimate|2014-12-11|2014-12-12|Estimate||||2014-12-11|2014-12-12|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AVP||Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients|Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients|Completed||N/A|96|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 01:33:20.197028|2018-06-01 01:33:20.197028
NCT00795353|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2013-02-27|2008-11-20|2008-11-21|Estimate|||||||2013-02-27|2013-02-28|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|AWARE-2||Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Amevive Wisdom Acquired Through Real-world Evidence - 2 (A.W.A.R.E.-2) Program: Long-Term Study|Terminated|||64|Actual|Astellas Pharma Inc|||1|"The study was terminated early due to insufficient subject enrolment in order to meet the~   primary and secondary endpoints"|f||||f||||||Samples With DNA|"~     10mL blood sample - Biomarker Substudy only~   "|||2018-06-01 01:33:20.394162|2018-06-01 01:33:20.394162
NCT00795340|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2015-04-28||2015-11-18|2008-11-20|2008-11-21|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|January 2014|Actual|2014-01-31|June 2011|Actual|2011-06-30||Interventional||Intention to treat population|Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Double Blind Randomized Trial of Cediranib Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|306|Actual|Canadian Cancer Trials Group|Early termination at phase II part of the trial, leading to small numbers of subjects analyzed, and limited follow up time.|2|||f||||t||||||||||2018-06-01 01:33:20.524044|2018-06-01 01:33:20.524044
NCT00795327|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2010-10-01|2008-11-20|2008-11-21|Estimate|||||||2010-10-01|2010-10-04|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Injectable POLY-L-Lactic Acid for Treatment of Hill and Valley Acne Scarring|The Canadian Study of the Use of Injectable Poly-L-Lactic Acid Dermal Implant for the Treatment of Hill and Valley Acne Scarring|Completed||Phase 4|22|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:33:21.122194|2018-06-01 01:33:21.122194
NCT00795314|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-07-14|2008-11-20|2008-11-21|Estimate|||||||2009-07-14|2009-07-15|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|PABADUC||Propofol-butorphanol Anesthesia During Uterine Curettage|Propofol-butorphanol Combined Anesthesia During Uterine Curettage on Abortion|Completed||Phase 4|150|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 01:33:21.184841|2018-06-01 01:33:21.184841
NCT00795301|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2014-01-13|2008-11-20|2008-11-21|Estimate|||||||2014-01-13|2014-01-14|Estimate|July 2008||2008-07-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab|A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status.|Unknown status|Active, not recruiting|Phase 2|74||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 01:33:21.316065|2018-06-01 01:33:21.316065
NCT00795288|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2014-12-08||2016-02-23|2008-11-20|2008-11-21|Estimate|2015-01-07|2015-01-16|Estimate||||2016-02-23|2016-03-21|Estimate|August 2008||2008-08-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)|Effect of Statins on Cerebral Blood Flow After Subarachnoid Hemorrhage|Completed||Phase 1/Phase 2|42|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-06-01 01:33:21.39447|2018-06-01 01:33:21.39447
NCT00795275|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2012-12-27|2008-11-20|2008-11-21|Estimate|||||||2012-12-27|2012-12-31|Estimate|January 2008||2008-01-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|1651||Incretin Effect in People With Impaired Fasting Glucose|Exploring the Incretin Effect in People With IFG|Completed||N/A|23|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:33:21.701874|2018-06-01 01:33:21.701874
NCT00795262|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-05-04|2008-11-20|2008-11-21|Estimate|||||||2011-05-04|2011-05-05|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|QUALITY||Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension|A 22-week Randomized, Cross-over Study Comparing the Effects of Quinapril and Quinapril Plus Alpha-lipoic Acid (ALA) on Patients With Diabetes Mellitus and Hypertension|Completed||N/A|23|Actual|InVasc Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 01:33:21.781166|2018-06-01 01:33:21.781166
NCT00795249|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-06-22|2008-11-20|2008-11-21|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle|Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle|Completed||Early Phase 1|100|Actual|Kurume University||2|||f||||t||||||||||2018-06-01 01:33:21.859619|2018-06-01 01:33:21.859619
NCT00795236|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2011-07-15|2008-11-19|2008-11-21|Estimate|||||||2011-07-15|2011-07-18|Estimate|November 2009||2009-11-30|July 2011|2011-07-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Melatonin Studies of Totally Blind Children|Melatonin Studies in Young Blind Children and Adolescents|Unknown status|Recruiting|N/A|90|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 01:33:21.927344|2018-06-01 01:33:21.927344
NCT00795223|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2009-09-28|2008-11-20|2008-11-21|Estimate|||||||2009-09-28|2009-09-29|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparative Pain Control Between 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for FNB After TKA|Comparative Effect of 0.2 or 0.3 Spinal Morphine and 0.25 or 0.5 % Bupivacaine for Femoral Nerve Block After Total Knee Replacement|Completed||Phase 4|160|Actual|Mahidol University||4|||f||||f||||||||||2018-06-01 01:33:22.008084|2018-06-01 01:33:22.008084
NCT00795210|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2013-10-09||2013-12-06|2008-11-20|2008-11-21|Estimate|2013-12-06|2014-01-08|Estimate||||2013-12-06|2014-01-08|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Short-term Growth Hormone in HIV-infected Patients|Effects of Short-term Growth Hormone in HIV-infected Patients|Completed||N/A|25|Actual|Massachusetts General Hospital|The study was completed early due to the lack of availability of study drug for one of the arms.|3|||f||||f||||||||||2018-06-01 01:33:22.111633|2018-06-01 01:33:22.111633
NCT00795197|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-05-07|2008-11-19|2008-11-21|Estimate|||||||2015-05-07|2015-05-08|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A Screening Study Evaluating Disease Status of Gaucher Type I Patients|A Screening Protocol to Characterize the Disease Status of Gaucher Type 1 Patients for Potential Inclusion in a Subsequent Phase 3 Clinical Study|Withdrawn|||0|Actual|Sanofi|||1|No recruitment of patients|f||||f||||||Samples Without DNA|"~     Blood sample/Urine sample~   "|||2018-06-01 01:33:22.414917|2018-06-01 01:33:22.414917
NCT00795184|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2012-06-04||2016-05-02|2008-11-20|2008-11-21|Estimate|2016-05-02|2016-05-03|Estimate||||2016-05-02|2016-05-03|Estimate|November 2008||2008-11-30|May 2016|2016-05-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|DONTBIOPCE||Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy|Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy|Completed||N/A|122|Actual|Mauna Kea Technologies||2|||f||||f||||||||No||2018-06-01 01:33:22.490668|2018-06-01 01:33:22.490668
NCT00795171|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2010-08-17|2008-11-20|2008-11-21|Estimate|||||||2010-08-17|2010-08-18|Estimate|November 2008||2008-11-30|August 2010|2010-08-31|July 2011|Anticipated|2011-07-31|April 2011|Anticipated|2011-04-30||Interventional|||Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer|Randomized, Controlled Biomarker Study Evaluating the Anti-angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel|Unknown status|Recruiting|Phase 2|60|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:33:22.684042|2018-06-01 01:33:22.684042
NCT00795158|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2015-05-04|2008-11-20|2008-11-21|Estimate|||||||2015-05-04|2015-05-05|Estimate|November 2002||2002-11-30|May 2015|2015-05-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)|An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria|Completed||Phase 3|282|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:33:22.769191|2018-06-01 01:33:22.769191
NCT00795145|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2010-03-02||2010-05-17|2008-11-20|2008-11-21|Estimate|2010-05-17|2010-06-22|Estimate||||2010-05-17|2010-06-22|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study To Assess The Effect Of Linezolid On QTc Interval|Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects|Completed||Phase 1|49|Actual|Pfizer||7|||f||||f||||||||||2018-06-01 01:33:22.876437|2018-06-01 01:33:22.876437
NCT00795132|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2012-01-30||2013-07-23|2008-11-20|2008-11-21|Estimate|2012-07-11|2012-08-20|Estimate||||2013-07-23|2013-07-30|Estimate|April 2004||2004-04-30|July 2013|2013-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies|Reduced Intensity Conditioning Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation|Completed||Phase 2|47|Actual|University of Utah|Participants who experienced early relapse or death before engraftment were excluded from analysis.|3|||f||||t||||||||||2018-06-01 01:33:23.604684|2018-06-01 01:33:23.604684
NCT00795119|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2009-04-02|2008-11-19|2008-11-21|Estimate|||||||2009-04-02|2009-04-03|Estimate|September 2007||2007-09-30|November 2008|2008-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|NIRS||A Trial to Determine the Efficacy of Near Infrared Spectroscopy to Detect Intracranial Hemorrhage in Children|A Clinical Assessment of the Reliability of Near Infrared Spectroscopy for the Detection of Intracranial Hemorrhage in Young Children|Completed||N/A|73|Actual|IWK Health Centre||1|||f||||f||||||||||2018-06-01 01:33:23.808046|2018-06-01 01:33:23.808046
NCT00795106|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2016-12-05|2008-11-20|2008-11-21|Estimate|||||||2016-12-05|2016-12-06|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain|Double-blinded, Cross-over Randomized Controlled Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain|Withdrawn||Phase 2|0|Actual|Stamford Hospital||2||Difficulty finding a monitor|f||||t||||||||||2018-06-01 01:33:23.875906|2018-06-01 01:33:23.875906
NCT00795093|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2010-05-10|2008-11-20|2008-11-21|Estimate|||||||2010-05-10|2010-05-11|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|REMAIN||Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US|Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient|Completed|||552|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:33:24.027944|2018-06-01 01:33:24.027944
NCT00795080|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2018-02-09|2008-11-20|2008-11-21|Estimate|||||||2018-02-09|2018-02-13|Actual|July 15, 2012|Actual|2012-07-15|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Dynamic MRI and Quantitative MR CSF Flow Studies in Craniovertebral Junction Anomalies|Dynamic Magnetic Resonance Imaging (MRI) and Quantitative MR Cerebral Spinal Fluid (CSF) Flow Studies in Craniovertebral Junction Anomalies|Active, not recruiting|||43|Actual|University of Michigan|||3||f||||f|f|f||||||No||2018-06-01 01:33:24.224364|2018-06-01 01:33:24.224364
NCT00795067|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2015-03-30|2008-11-20|2008-11-21|Estimate|||||||2015-03-30|2015-03-31|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2010|Actual|2010-11-30||Observational|||Relation of Circulating Endothelium-derived Microparticle to Carotid Atherosclerosis|Relation of Circulating Endothelium-derived Microparticle to Carotid Atherosclerosis|Completed|||154|Actual|Kurume University|||1||f||||t||||||Samples Without DNA|"~     platelet-poor plasma whole blood urine~   "|||2018-06-01 01:33:24.286136|2018-06-01 01:33:24.286136
NCT00795054|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-10-05|2008-11-20|2008-11-21|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|September 2012|Actual|2012-09-30||Observational|||The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family|The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family: A Pilot Study|Completed|||30|Actual|Center for International Blood and Marrow Transplant Research|||1||f||||f||||||||||2018-06-01 01:33:24.337772|2018-06-01 01:33:24.337772
NCT00795041|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2010-10-15|2008-11-20|2008-11-21|Estimate|||||||2010-10-15|2010-10-18|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Observational|||Temporally Splitting Ovarian Stimulation and Embryo Transfer|Temporally Splitting Ovarian Stimulation and Embryo Transfer|Completed|||10|Actual|University of Luebeck|||1||f||||f||||||||||2018-06-01 01:33:24.40166|2018-06-01 01:33:24.40166
NCT00795028|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2017-05-13|2008-11-20|2008-11-21|Estimate|||||||2017-05-13|2017-05-16|Actual||||May 2017|2017-05-31||||March 2013|Actual|2013-03-31||Interventional|||Preventing Falls and Disability in Older Adults After Hip Fracture|Preventing Falls and Disability in Older Adults After Hip Fracture|Withdrawn||N/A|0|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:33:24.457696|2018-06-01 01:33:24.457696
NCT00795015|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2011-03-15|2008-11-20|2008-11-21|Estimate|||||||2011-03-15|2011-03-16|Estimate|April 2006||2006-04-30|March 2011|2011-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With IV Insulin|Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With an Intravenous Insulin Infusion|Completed||Phase 4|93|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 01:33:24.523004|2018-06-01 01:33:24.523004
NCT00795002|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|2013-01-08||2015-06-03|2008-11-20|2008-11-21|Estimate|2013-10-07|2013-12-05|Estimate||||2015-06-03|2015-06-30|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|September 2012|Actual|2012-09-30|November 2010|Actual|2010-11-30||Interventional|||Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, Previously Untreated, Poor Risk Acute Myelogenous Leukemias (AML)|Completed||Phase 2|78|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:33:24.606105|2018-06-01 01:33:24.606105
NCT00794989|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2016-06-01|2008-11-20|2008-11-21|Estimate|||||||2016-06-01|2016-06-03|Estimate|April 2008||2008-04-30|June 2016|2016-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer|A Study Evaluating the Effect of Flaxseed on Biomarkers of Breast Cancer Risk|Terminated||N/A|20|Actual|Roswell Park Cancer Institute||2||low accrual|f||||t||||||||||2018-06-01 01:33:24.88287|2018-06-01 01:33:24.88287
NCT00794976|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2015-05-11|2008-11-20|2008-11-21|Estimate|||||||2015-05-11|2015-05-13|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of a Dexamethasone Iontophoretic Transdermal Patch for the Treatment of Pain Associated With Lateral Epicondylitis|Completed||Phase 2|216|Actual|Travanti Pharma Inc.||4|||f||||f||||||||||2018-06-01 01:33:24.96777|2018-06-01 01:33:24.96777
NCT00794963|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2011-07-19||2015-04-14|2008-11-20|2008-11-21|Estimate|2011-11-17|2011-11-18|Estimate||||2015-04-14|2015-04-15|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|ATOMICS||Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia|Aggressive Treatment of Metabolic Syndrome in Patients Treated With Clozapine for Schizophrenia|Terminated||N/A|8|Actual|Northwell Health||2||Difficulty recruiting|f||||f||||||||||2018-06-01 01:33:25.081726|2018-06-01 01:33:25.081726
NCT00794950|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-20|||2018-01-30|2008-11-20|2008-11-21|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2009||2009-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Sutent||Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma|A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma|Active, not recruiting||Phase 2|36|Actual|University of Michigan||1|||f||||t|t|f|||f|||||2018-06-01 01:33:25.288895|2018-06-01 01:33:25.288895
NCT00794924|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2008-10-28||2008-11-19|2008-11-19|2008-11-20|Estimate|2008-11-19|2008-11-20|Estimate||||2008-11-19|2008-11-20|Estimate|February 2004||2004-02-29|November 2008|2008-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|PROAGE||Probiotics and Hospital Outcome in the Elderly|Effects of Commercially Available Probiotics on Hospital Outcome|Completed||N/A|345|Actual|Kaplan-Harzfeld Medical Center||2|||f||||t||||||||||2018-06-01 01:33:25.367225|2018-06-01 01:33:25.367225
NCT00794911|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2017-03-14|2008-11-19|2008-11-20|Estimate|||||||2017-03-14|2017-03-15|Actual|September 2007||2007-09-30|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation|Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation|Completed||N/A|75|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||t||||||||||2018-06-01 01:33:25.554733|2018-06-01 01:33:25.554733
NCT00794898|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2017-03-27|2008-11-19|2008-11-20|Estimate|||||||2017-03-27|2017-03-28|Actual|July 1, 2003|Actual|2003-07-01|March 2017|2017-03-31|April 1, 2004|Actual|2004-04-01|April 1, 2004|Actual|2004-04-01||Interventional|||Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)|Onset of Efficacy of Anti-TNF Chimeric Monoclonal Antibody (Remicade) in the Treatment of Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment|Completed||Phase 4|19|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:33:25.628535|2018-06-01 01:33:25.628535
NCT00794885|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2014-08-11|2008-11-19|2008-11-20|Estimate|||||||2014-08-11|2014-08-12|Estimate|May 2008||2008-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|CSPPT||China Stroke Primary Prevention Trial|Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.|Completed||Phase 4|20702|Actual|Shenzhen Ausa Pharmed Co.,Ltd||2|||f||||t||||||||||2018-06-01 01:33:25.704221|2018-06-01 01:33:25.704221
NCT00794872|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-19|2008-11-19|2008-11-20|Estimate|||||||2008-11-19|2008-11-20|Estimate|January 2007||2007-01-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Chemoreflex Sensitivity in Chronic Kidney Disease|Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease|Completed|||65|Actual|RWTH Aachen University|||3||f||||t||||||Samples Without DNA|"~     Measurement of the venous partial pressure of oxygen in blood samples~   "|||2018-06-01 01:33:25.782712|2018-06-01 01:33:25.782712
NCT00794859|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2009-08-03|2008-11-19|2008-11-20|Estimate|||||||2009-08-03|2009-08-04|Estimate|October 2008||2008-10-31|August 2009|2009-08-31||||December 2009|Anticipated|2009-12-31||Interventional|SMS||Sorafenib in Previously Treated Malignant Mesothelioma|Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy|Unknown status|Active, not recruiting|Phase 2|54|Anticipated|King's College London|||||f||||f||||||||||2018-06-01 01:33:25.880442|2018-06-01 01:33:25.880442
NCT00794846|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-04-01|2008-11-19|2008-11-20|Estimate|||||||2015-04-01|2015-04-03|Estimate|December 2002||2002-12-31|April 2015|2015-04-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)|Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis|Completed||Phase 4|124|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:33:25.952222|2018-06-01 01:33:25.952222
NCT00794820|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2016-07-13||2018-04-05|2008-11-18|2008-11-20|Estimate|2016-07-13|2016-08-23|Estimate||||2018-04-05|2018-05-08|Actual|December 2003||2003-12-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline|Fludarabine, Cyclophosphamide, and Multiple Dose Rituximab as Frontline Therapy in Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|66|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:33:26.022908|2018-06-01 01:33:26.022908
NCT00794807|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-19|2008-11-19|2008-11-20|Estimate|||||||2008-11-19|2008-11-20|Estimate|February 2004||2004-02-29|November 2008|2008-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Safety and Tolerability of Repeat Courses of IM Alefacept|A 12-Week Open-Label Followed by 4-Week Double-Blind Study to Determine the Safety and Efficacy of an Extended Course of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis|Completed||Phase 4|20|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 01:33:26.206657|2018-06-01 01:33:26.206657
NCT00794794|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-09-21|2008-11-19|2008-11-20|Estimate|||||||2015-09-21|2015-09-22|Estimate|November 2004||2004-11-30|September 2015|2015-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)|A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications|Completed||Phase 3|204|Actual|Merck Sharp & Dohme Corp.||1|||t||||f||||||||||2018-06-01 01:33:26.271402|2018-06-01 01:33:26.271402
NCT00794781|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2014-09-03|2008-11-19|2008-11-20|Estimate|||||||2014-09-03|2014-09-04|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|55|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 01:33:26.338359|2018-06-01 01:33:26.338359
NCT00794768|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-06-19|2008-11-19|2008-11-20|Estimate|||||||2015-06-19|2015-06-22|Estimate|November 2002||2002-11-30|June 2015|2015-06-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)|Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis|Completed||Phase 4|118|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:33:26.408698|2018-06-01 01:33:26.408698
NCT00794755|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2011-07-26|2008-11-19|2008-11-20|Estimate|||||||2011-07-26|2011-07-27|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|LOCK||Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy|A Phase III Pilot RCT (Randomized, Controlled Trial) to Assess the Effectiveness of Low Dose Vitamin K1 (200 Micrograms Per Day) on Improving Anticoagulation Control in Unstable Patients on Warfarin|Completed||Phase 3|100|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 01:33:26.468893|2018-06-01 01:33:26.468893
NCT00794742|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-04-09|2008-11-19|2008-11-20|Estimate|||||||2015-04-09|2015-04-13|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Antimicrobial Resistance of Bacteria in Burn Patients|Analyzing the Antimicrobial Resistance Profile of Bacterial Isolates Obtained From Severely Burned Patients|Completed|||32|Actual|Texas Tech University Health Sciences Center|||1||f||||f||||||Samples Without DNA|"~     Bacterial isolates of infected burn wounds~   "|||2018-06-01 01:33:26.539944|2018-06-01 01:33:26.539944
NCT00794729|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2017-06-30|2008-11-19|2008-11-20|Estimate|||||||2017-06-30|2017-07-02|Actual|October 16, 2008||2008-10-16|September 14, 2011|2011-09-14|September 14, 2011||2011-09-14|||||Observational|||Evaluating the Quality of Different Methods of Obtaining Informed Consent|"Sub-Study Evaluating the Quality of Different Methods of Obtaining Informed Consent"|Completed|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:33:26.651151|2018-06-01 01:33:26.651151
NCT00794716|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-06-09|2008-11-19|2008-11-20|Estimate|||||||2015-06-09|2015-06-10|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|November 2011|Actual|2011-11-30|March 2010|Actual|2010-03-31||Interventional|||Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)|Prospective Single-centre, Open-label Study to Assess the Pharmacokinetics of Cholyl-lysl-fluorescein (NRL972) in Patients With Clinical Evidence for Non-alcoholic Fatty Liver Disease (NAFLD): Supporting the Disease Staging Into Fatty Liver Disease Versus Non-alcoholic Steatohepatitis (NASH)|Completed||Phase 2|125|Actual|Norgine||1|||f||||f||||||||||2018-06-01 01:33:26.698933|2018-06-01 01:33:26.698933
NCT00794703|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2016-03-25|2008-11-19|2008-11-20|Estimate|||||||2016-03-25|2016-03-28|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections|A Multi-center, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of Mycamine® vs Itraconazole Oral Solution for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoietic Stem Cell Transplant|Completed||Phase 3|288|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 01:33:26.758741|2018-06-01 01:33:26.758741
NCT00794690|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2009-07-31|2008-11-19|2008-11-20|Estimate|||||||2009-07-31|2009-08-03|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|CR-LIVER||Safety Study of Black Cohosh Use by Postmenopausal Women on the Liver|Influence of Black Cohosh (Cimicifuga Racemosa) Use by Postmenopausal Women on Total Hepatic Perfusion and Liver Functions|Completed||N/A|100|Anticipated|Assiut University||1|||f||||f||||||||||2018-06-01 01:33:26.849254|2018-06-01 01:33:26.849254
NCT00794677|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2009-01-30||2009-07-31|2008-11-19|2008-11-20|Estimate|2009-07-31|2009-09-04|Estimate||||2009-07-31|2009-09-04|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|September 2008|Actual|2008-09-30|February 2008|Actual|2008-02-29||Interventional|||Effects of Ezetimibe on the Absorption of Oxidized Cholesterol|A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Plasma Appearance of 7-Ketocholesterol After an Oral Bolus in Patients With Primary Hypercholesterolemia|Completed||Phase 4|26|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||||2018-06-01 01:33:26.927561|2018-06-01 01:33:26.927561
NCT00794664|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2013-02-15|2010-10-02|2016-08-01|2008-11-19|2008-11-20|Estimate|2013-02-15|2013-03-21|Estimate|2010-10-02|2010-10-05|Estimate|2016-08-01|2016-09-09|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis|A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis|Completed||Phase 3|58|Actual|Kastle Therapeutics, LLC||2|||f||||t||||||||||2018-06-01 01:33:27.457537|2018-06-01 01:33:27.457537
NCT00794651|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-19|2008-11-19|2008-11-20|Estimate|||||||2008-11-19|2008-11-20|Estimate|January 2009||2009-01-31|November 2008|2008-11-30|June 2009|Anticipated|2009-06-30|May 2009|Anticipated|2009-05-31||Observational|||Osteoarthritis Bedside Testing Kit|Development of a Bedside Pain Assessment Kit for Evaluating Effectiveness of Drugs for Osteoarthritis|Unknown status|Not yet recruiting||25|Anticipated|Analgesic Solutions|||1||f||||f||||||||||2018-06-01 01:33:28.520868|2018-06-01 01:33:28.520868
NCT00794638|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2010-05-27|2008-11-19|2008-11-20|Estimate|||||||2010-05-27|2010-05-28|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma|A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma|Completed||Phase 1|12|Anticipated|SymBio Pharmaceuticals|||||f||||t||||||||||2018-06-01 01:33:28.589838|2018-06-01 01:33:28.589838
NCT00794625|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2012-07-13|2008-11-19|2008-11-20|Estimate|||||||2012-07-13|2012-07-16|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|November 2012|Anticipated|2012-11-30||Interventional|||Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)|Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD|Unknown status|Recruiting|Phase 4|270|Anticipated|National Institute of Mental Health (NIMH)||3|||f||||t||||||||||2018-06-01 01:33:28.679561|2018-06-01 01:33:28.679561
NCT00794612|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-12-18|2008-11-19|2008-11-20|Estimate|||||||2008-12-18|2008-12-19|Estimate|November 2008||2008-11-30|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Interventional|||Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.|Safety Dermatological Evaluation: Genital Mucous Irritation - Test in Use - Dermacyd Femina Pocket BR (Lactic Acid).|Completed||Phase 3|30|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:33:28.785849|2018-06-01 01:33:28.785849
NCT00794599|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-04-01|2008-11-19|2008-11-20|Estimate|||||||2015-04-01|2015-04-03|Estimate|December 2002||2002-12-31|April 2015|2015-04-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)|Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis|Completed||Phase 4|118|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:33:28.842604|2018-06-01 01:33:28.842604
NCT00794586|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18||2013-12-03|2013-12-03|2008-11-19|2008-11-20|Estimate||||2013-12-03|2013-12-27|Estimate|2013-12-03|2013-12-27|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection|A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa|Completed||Phase 2|120|Anticipated|Gilead Sciences||4|||f||||t||||||||||2018-06-01 01:33:28.965012|2018-06-01 01:33:28.965012
NCT00794573|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2016-03-14|2008-11-19|2008-11-20|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|EVITA||Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial|Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial|Completed||Phase 3|302|Actual|McGill University||2|||f||||t||||||||||2018-06-01 01:33:29.080955|2018-06-01 01:33:29.080955
NCT00794560|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2014-06-04||2014-11-05|2008-11-19|2008-11-20|Estimate|2014-07-23|2014-08-13|Estimate||||2014-11-05|2014-11-18|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Self-management of Low Molecular Weight Heparin Therapy|Self-management of Heparin Therapy - Drug Use Problems and Compliance With Self-injected Low Molecular Weight Heparin in Ambulatory Care|Completed||Phase 4|154|Actual|University Hospital, Basel, Switzerland||4|||f||||f||||||||||2018-06-01 01:33:29.164156|2018-06-01 01:33:29.164156
NCT00794547|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2014-03-31||2017-11-13|2008-11-19|2008-11-20|Estimate|2014-03-31|2014-05-05|Estimate||||2017-11-13|2017-12-12|Actual|December 2008||2008-12-31|November 2017|2017-11-30|August 2013|Actual|2013-08-31|October 2011|Actual|2011-10-31||Interventional||Thirty-four patients were enrolled (18 in phase I and 16 in phase II).|Phase I/II Calcitriol in Lung Cancer|A Phase I/II Clinical Trial of Intravenous (IV) Calcitriol With Fixed Dose of Cisplatin and Docetaxel in Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|34|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-06-01 01:33:29.428457|2018-06-01 01:33:29.428457
NCT00794534|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2016-07-26|2008-11-19|2008-11-20|Estimate|||||||2016-07-26|2016-07-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:33:29.678699|2018-06-01 01:33:29.678699
NCT00794508|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2016-03-09||2018-02-01|2008-11-19|2008-11-20|Estimate|2016-04-22|2016-05-30|Estimate||||2018-02-01|2018-03-01|Actual|November 2008||2008-11-30|February 2018|2018-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional||Pre-treatment|MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID|MND-ADA Transduction of CD34+ Cells From the Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID): Effect of Discontinuation of PEG-ADA and Marrow Cytoreduction With Busulfan|Completed||Phase 2|10|Actual|University of California, Los Angeles||1|||f||||t||||||||No||2018-06-01 01:33:29.714438|2018-06-01 01:33:29.714438
NCT00794495|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-04-01|2008-11-19|2008-11-20|Estimate|||||||2015-04-01|2015-04-03|Estimate|December 2002||2002-12-31|April 2015|2015-04-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)|Preference Evaluation of Clarinex Tablets vs. Zyrtec Tablets in Subjects With Symptomatic Allergic Rhinitis|Completed||Phase 4|122|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:33:30.837458|2018-06-01 01:33:30.837458
NCT00794482|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2009-10-07|2008-11-19|2008-11-20|Estimate|||||||2009-10-07|2009-10-08|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.|A Multi-centre, Multi-national Open Study in Patients With Hepatic Cirrhosis to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.|Completed||Phase 3|1200|Anticipated|Norgine|||||f||||t||||||||||2018-06-01 01:33:30.901355|2018-06-01 01:33:30.901355
NCT00794469|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2009-06-21||2013-08-01|2008-11-19|2008-11-20|Estimate|2009-10-22|2009-11-25|Estimate||||2013-08-01|2013-08-07|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Water Induced Thermogenesis in Obese Children|Water Induced Thermogenesis in Obese Children|Completed|||21|Actual|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 01:33:30.960158|2018-06-01 01:33:30.960158
NCT00794456|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2014-07-07|2008-11-19|2008-11-20|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety|Double Blind, Randomized Study, Controlled by Valeriana Officinalis, of Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Patients With Mild and Moderate Anxiety|Completed||Phase 3|150|Actual|Marjan Industria e Comercio ltda||2|||f||||t||||||||||2018-06-01 01:33:31.100457|2018-06-01 01:33:31.100457
NCT00794443|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2015-04-30|2008-11-18|2008-11-20|Estimate|||||||2015-04-30|2015-05-04|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients|A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.|Completed||Phase 2/Phase 3|692|Actual|Astellas Pharma Inc||3|||f||||||||||||||2018-06-01 01:33:31.175774|2018-06-01 01:33:31.175774
NCT00794430|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19||2015-01-09|2016-05-04|2008-11-19|2008-11-20|Estimate||||2015-01-09|2015-01-26|Estimate|2016-05-04|2016-06-03|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain|A Randomised, Double-blind, Placebo-controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for up to 13 Weeks in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)|Completed||Phase 2|161|Actual|Vernalis (R&D) Ltd||2|||f||||t||||||||||2018-06-01 01:33:31.261731|2018-06-01 01:33:31.261731
NCT00794417|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19||2011-04-17|2012-08-30|2008-11-19|2008-11-20|Estimate||||2011-04-17|2011-04-27|Estimate|2012-08-30|2012-09-05|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma|A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma|Completed||Phase 1/Phase 2|62|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:33:31.460442|2018-06-01 01:33:31.460442
NCT00793728|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2015-08-19|2008-11-18|2008-11-19|Estimate|||||||2015-08-19|2015-08-20|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Prospective Randomized Trial Comparing Two Techniques of Sleeve Gastrectomy|Prospective Randomized Trial Comparing Two Techniques of Sleeve Gastrectomy|Completed||N/A|52|Actual|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-06-01 01:33:42.25221|2018-06-01 01:33:42.25221
NCT00794404|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2016-10-28|2008-11-19|2008-11-20|Estimate|||||||2016-10-28|2016-10-31|Estimate|December 2004||2004-12-31|November 2008|2008-11-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Observational|EchoSpA||Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy|Evaluation of Power Doppler US Technique for the Diagnosis of Spondylarthropathy in Patients With Uncertain Diagnosis Consulting for Clinical Symptoms Suggestive of Spondylarthropathy|Completed|||489|Actual|Groupe Français d'Etude Génétique des Spondylarthropathies|||||f||||f||||||Samples With DNA|"~     whole blood~   "|No||2018-06-01 01:33:31.574321|2018-06-01 01:33:31.574321
NCT00794391|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2014-04-02|2008-11-19|2008-11-20|Estimate|||||||2014-04-02|2014-04-04|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)|Effects of a Brief Motivational Intervention on Risky Injection Practices Among Injecting Drug Users|Completed||N/A|219|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-06-01 01:33:31.64035|2018-06-01 01:33:31.64035
NCT00794378|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-07-03|2008-11-19|2008-11-20|Estimate|||||||2015-07-03|2015-07-07|Estimate|November 2004||2004-11-30|July 2015|2015-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED)|A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications|Completed||Phase 3|202|Actual|Merck Sharp & Dohme Corp.||1|||t||||f||||||||||2018-06-01 01:33:31.726837|2018-06-01 01:33:31.726837
NCT00794365|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2010-11-19||2010-11-19|2008-11-19|2008-11-20|Estimate|2010-11-19|2010-12-20|Estimate||||2010-11-19|2010-12-20|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients|Post-Marketing Surveillance Study To Observe The Safety And Effectiveness Of Varenicline (Champix) Tablets In Smoking Cessation Among Filipino Subjects|Completed|||330|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:33:31.817776|2018-06-01 01:33:31.817776
NCT00794352|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2018-03-27|2008-11-19|2008-11-20|Estimate|||||||2018-03-27|2018-03-29|Actual|November 18, 2008||2008-11-18|March 5, 2018|2018-03-05||||||||Observational|||Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System|Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the CNS|Recruiting|||1240|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:33:32.052992|2018-06-01 01:33:32.052992
NCT00794339|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2017-03-16|2008-11-19|2008-11-20|Estimate|||||||2017-03-16|2017-03-20|Actual|July 2009||2009-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|ACRIN6682||Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer|Copper Cu 64-ATSM and PET/CT Scan in Predicting Disease Progression in Patients With Newly-Diagnosed Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Undergoing Chemoradiotherapy Per NCCN Guidelines|Active, not recruiting||Phase 2|73|Actual|American College of Radiology Imaging Network||1|||f||||t||||||||Yes|See ACRIN data Sharing Policy https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx|2018-06-01 01:33:32.123039|2018-06-01 01:33:32.123039
NCT00794326|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2015-02-26|2008-11-19|2008-11-20|Estimate|||||||2015-02-26|2015-02-27|Estimate|October 2008||2008-10-31|September 2014|2014-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PDOne||Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD|Multicentric, Parallel, Controlled, Randomized, Single-blind Clinical Evaluation of New Low Sodium Peritoneal Dialysis Solution on Patients With Hypertension Treated With Continuous Ambulatory or Automated Peritoneal Dialysis|Completed||Phase 3|140|Anticipated|Fresenius Medical Care Deutschland GmbH||2|||f||||t||||||||||2018-06-01 01:33:32.205298|2018-06-01 01:33:32.205298
NCT00794313|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|2016-09-29||2018-01-08|2008-11-19|2008-11-20|Estimate|2017-04-03|2017-05-11|Actual||||2018-01-08|2018-02-01|Actual|September 2009||2009-09-30|January 2018|2018-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease|Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease|Terminated||N/A|3|Actual|Oregon Health and Science University||3||Funding Ended|f||||f||||||||No||2018-06-01 01:33:32.31627|2018-06-01 01:33:32.31627
NCT00794300|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-19|2008-11-19|2008-11-20|Estimate|||||||2008-11-19|2008-11-20|Estimate||||November 2008|2008-11-30||||||||Observational|||Reproducibility of Magnetic Resonance Myocardial Salvage Index|Reproducibility of Myocardial Salvage Index in Acute Myocardial Infarction by Cardiac Magnetic Resonance Imaging|Completed|||||University of Leipzig|||1||f||||f||||||||||2018-06-01 01:33:32.620635|2018-06-01 01:33:32.620635
NCT00794287|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-06-03|2008-11-19|2008-11-20|Estimate|||||||2015-06-03|2015-06-04|Estimate|January 2009||2009-01-31|June 2015|2015-06-30||||December 2010|Anticipated|2010-12-31||Observational|||Performance of CAST (Cellular Antigen Stimulation Test) in Patients With Wasp Venom Allergy: Evaluation of Neutralizing IgG Subclasses|Performance of CAST (Cellular Antigen Stiumulation Test)in Patients With Wasp Venom Allergy. Evaluation of Neutralizing IgG Subclasses|Withdrawn|||0|Actual|University of Zurich|||2||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 01:33:32.697564|2018-06-01 01:33:32.697564
NCT00794274|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2013-04-10|2008-11-19|2008-11-20|Estimate|||||||2013-04-10|2013-04-12|Estimate|November 2008||2008-11-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis|The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis|Completed||Phase 2/Phase 3|15|Actual|University of Cincinnati||1|||f||||t||||||||||2018-06-01 01:33:32.770142|2018-06-01 01:33:32.770142
NCT00794261|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2010-07-07|2008-11-19|2008-11-20|Estimate|||||||2010-07-07|2010-07-08|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|PALM||Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma|Assessment of the Efficacy and Tolerance, and Health Economic Study of a Single Administration of Pegfilgrastim in Lymphoma or Myeloma Patients Treated With Intensive Chemotherapy and Autologous Peripheral Stem Cell Transplantation|Completed||Phase 2|150|Anticipated|Centre Leon Berard||2|||f||||f||||||||||2018-06-01 01:33:32.861436|2018-06-01 01:33:32.861436
NCT00794248|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2015-04-01|2008-11-19|2008-11-20|Estimate|||||||2015-04-01|2015-04-03|Estimate|November 2002||2002-11-30|April 2015|2015-04-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)|Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis|Completed||Phase 4|122|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:33:32.970682|2018-06-01 01:33:32.970682
NCT00794235|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2010-01-07|2008-11-19|2008-11-20|Estimate|||||||2010-01-07|2010-01-08|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine|Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine|Completed||Phase 2|12|Anticipated|University of Zurich||1|||f||||f||||||||||2018-06-01 01:33:33.054497|2018-06-01 01:33:33.054497
NCT00794222|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-19|||2008-11-19|2008-11-19|2008-11-20|Estimate|||||||2008-11-19|2008-11-20|Estimate|February 2009||2009-02-28|November 2008|2008-11-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|mobiletype||A Mobile Phone Self-Monitoring Tool to Increase Emotional Self-Awareness and Reduce Depression in Young People|A Randomised Controlled Trial Investigating a Mobile Phone Self-Monitoring Tool (Mobiletype) to Increase Emotional Self-Awareness and Reduce Depressive Symptoms in Young People.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Murdoch Childrens Research Institute||2|||f||||t||||||||||2018-06-01 01:33:33.129017|2018-06-01 01:33:33.129017
NCT00794209|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-17|2008-11-17|2008-11-19|Estimate|||||||2008-11-17|2008-11-19|Estimate|March 2003||2003-03-31|November 2008|2008-11-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|LEF-07||Study Evaluating Inhaled AeroLEF Delivered in 4 Aerosol Delivery Devices in Healthy Volunteers|Phase lb, Five Period Crossover, Open-Label Study Evaluating a Single Dose Administration of 3mL or 5mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 Mcg/mL), Delivered by up to Four Aerosol Delivery Devices in Healthy Subjects|Completed||Phase 1|9|Actual|YM BioSciences||1|||f||||f||||||||||2018-06-01 01:33:33.219999|2018-06-01 01:33:33.219999
NCT00794196|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2016-04-13||2016-10-01|2008-11-17|2008-11-19|Estimate|2016-07-04|2016-08-15|Estimate||||2016-10-01|2016-11-22|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|PRODEFAR||Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care|Impact of the Pharmaceutical Care Program for Pharmacological Treatment of Depression in Primary Care on the Compliance to Antidepressants and Patient Wellbeing|Completed||N/A|179|Actual|Fundació Sant Joan de Déu||2|||f||||f||||||||||2018-06-01 01:33:33.292408|2018-06-01 01:33:33.292408
NCT00794183|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2012-06-22|2008-11-18|2008-11-19|Estimate|||||||2012-06-22|2012-06-26|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|BRAVO-CRT||A Pilot Study Comparing the Programmed Delay Between the Atrial and Ventricle Interval|A Pilot Study of theRelationship Between Atrio-Ventricular Delay and Changes in Biochemical Markers of Chronic Heart Failure During Cardiac Resynchronization Therapy (BRAVO-CRT)|Terminated||Early Phase 1|25|Actual|University of Minnesota - Clinical and Translational Science Institute||3||funding difficulty|f||||f||||||||||2018-06-01 01:33:33.53007|2018-06-01 01:33:33.53007
NCT00794170|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2012-08-15||2014-05-09|2008-11-18|2008-11-19|Estimate|2014-05-09|2014-06-09|Estimate||||2014-05-09|2014-06-09|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|I-SIGHT||Interactive Study to Increase Glaucoma Adherence to Treatment|I-SIGHT: Interactive Study to Increase Glaucoma adHerence to Treatment Phase 2: Participant Recruitment & Intervention Delivery and Evaluation|Completed||N/A|312|Actual|Emory University|There may have been a selection bias that contributed to a placebo effect in the control group. The “control” patients may have already been motivated to seek knowledge or involvement in management of glaucoma.|2|||f||||f||||||||||2018-06-01 01:33:33.607237|2018-06-01 01:33:33.607237
NCT00794157|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2011-07-22||2011-07-22|2008-11-18|2008-11-19|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|347|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:33:33.825319|2018-06-01 01:33:33.825319
NCT00794144|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2010-01-12||2010-02-23|2008-11-18|2008-11-19|Estimate|2010-01-12|2010-02-04|Estimate||||2010-02-23|2010-03-04|Estimate|October 2008||2008-10-31|February 2010|2010-02-28||||December 2008|Actual|2008-12-31||Interventional|||Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age||Completed||Phase 2|132|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:33:34.278987|2018-06-01 01:33:34.278987
NCT00794131|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2015-12-11|2008-11-18|2008-11-19|Estimate|||||||2015-12-11|2015-12-14|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors|Phase I Study of the Safety, Tolerability,and Tumor-Specific Replication of the Intravenous Administration of Green Fluorescent Protein Encoded Genetically Engineered Attenuated Vaccinia Virus, GL-ONC1, in Patients With Advanced Solid Organ Cancers.|Completed||Phase 1|43|Actual|Genelux Corporation|||||f||||t||||||||||2018-06-01 01:33:34.494435|2018-06-01 01:33:34.494435
NCT00794118|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2012-04-12||2012-04-12|2008-11-18|2008-11-19|Estimate|2012-04-12|2012-05-16|Estimate||||2012-04-12|2012-05-16|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|DOSE||Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study (Dose)|Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study|Completed|||299|Actual|Pfizer|Protocol did not indicate primary or secondary endpoints and all determination of primary or secondary endpoints were arbitrary.||1||f||||t||||||||||2018-06-01 01:33:34.619357|2018-06-01 01:33:34.619357
NCT00794105|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate|November 2008||2008-11-30|November 2008|2008-11-30||||||||Observational|||Observation of Gas Exchange in the Middle Ear||Unknown status|Not yet recruiting||||Shaare Zedek Medical Center|||2||f||||f||||||||||2018-06-01 01:33:35.336716|2018-06-01 01:33:35.336716
NCT00794092|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2010-04-07|2008-11-18|2008-11-19|Estimate|||||||2010-04-07|2010-04-08|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Magnetic Resonance Imaging of Aortic Aneurysm Instability|Magnetic Resonance Imaging of Aortic Aneurysm Instability|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|University of Edinburgh||1|||f||||f||||||||||2018-06-01 01:33:35.395413|2018-06-01 01:33:35.395413
NCT00794079|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2011-08-02|2008-11-18|2008-11-19|Estimate|||||||2011-08-02|2011-08-03|Estimate|June 2007||2007-06-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Omega-3 Fatty Acids and Muscle Protein Synthesis|Omega-3 Fatty Acids and Muscle Protein Synthesis|Completed||N/A|43|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:33:35.461771|2018-06-01 01:33:35.461771
NCT00794066|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2017-10-24|2008-11-18|2008-11-19|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2008||2008-08-31|October 2017|2017-10-31|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Observational|PARIS||Peripheral Arteriopathy Rate In Stroke|Prevalence of Peripheral Arterial Disease in Acute Ischemic and Hemorrhagic Stroke Patients|Completed|||1500|Actual|University of Erlangen-Nürnberg Medical School|||3||f||||f||||||||||2018-06-01 01:33:35.536555|2018-06-01 01:33:35.536555
NCT00792662|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2018-03-27|2008-11-17|2008-11-18|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2008|Actual|2008-11-30|March 2018|2018-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Improving Function, Quality of Life, Glycemia in Diabetics With Dementia|Improving Function, Quality of Life, Glycemia in Diabetics With Dementia|Withdrawn||Phase 4|0|Actual|University of Nebraska||2||No Subjects enrolled|f||||t||||||||||2018-06-01 01:34:02.386877|2018-06-01 01:34:02.386877
NCT00794053|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2009-07-14|2008-11-18|2008-11-19|Estimate|||||||2009-07-14|2009-07-15|Estimate|December 2002||2002-12-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer|The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer|Completed||Phase 3|45|Actual|Faculty of Medicine, University of Alexandria||1|||f||||t||||||||||2018-06-01 01:33:35.597922|2018-06-01 01:33:35.597922
NCT00794040|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2018-03-27|2008-11-18|2008-11-19|Estimate|||||||2018-03-27|2018-03-29|Actual|November 17, 2008||2008-11-17|February 1, 2018|2018-02-01|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation|A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation|Completed||Phase 2|103|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:33:35.673985|2018-06-01 01:33:35.673985
NCT00794027|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2013-07-31|2008-11-18|2008-11-19|Estimate|||||||2013-07-31|2013-08-02|Estimate|November 2008||2008-11-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|YOGA||The Effects of a Yoga Program in Heart Failure Patients|The Clinical Outcomes Associated With a Modified Yoga Program in Heart Failure|Completed||N/A|20|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:33:35.744854|2018-06-01 01:33:35.744854
NCT00794014|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2013-02-12|2008-11-17|2008-11-19|Estimate|||||||2013-02-12|2013-02-13|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion|Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion|Completed||N/A|258|Actual|Samsung Medical Center||2|||f||||||||||||||2018-06-01 01:33:35.816275|2018-06-01 01:33:35.816275
NCT00794001|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2016-12-09|2008-11-18|2008-11-19|Estimate|||||||2016-12-09|2016-12-12|Estimate|October 2007||2007-10-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|FITT-STEMI||Feedback Intervention and Treatment Times in ST- Elevation Myocardial Infarction|Feedback Intervention and Treatment Times in ST- Elevation Myocardial Infarction (FITT-STEMI): A Multicenter Trial Analyzing the Effects of Systematic Data Feedback on Treatment Quality and Survival Rates.|Recruiting||N/A|50000|Anticipated|St.Bernward Hospital||1|||f||||f||||||||Undecided||2018-06-01 01:33:35.88719|2018-06-01 01:33:35.88719
NCT00793988|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2009-04-02|2008-11-18|2008-11-19|Estimate|||||||2009-04-02|2009-04-03|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Vibration-Assisted Anaesthesia|Vibration-Assisted Anaesthesia: A Randomised Controlled Trial to Investigate Whether Vibration Reduces the Pain of Anaesthetic Injection in Eyelid Surgery|Completed||Phase 4|80|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:33:35.966997|2018-06-01 01:33:35.966997
NCT00793975|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-08-16|2008-11-17|2008-11-19|Estimate|||||||2013-08-16|2013-08-19|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy|Phase I Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded to Standard Therapy|Completed||Phase 1|37|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:33:36.036074|2018-06-01 01:33:36.036074
NCT00793962|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2017-07-20|2008-11-17|2008-11-19|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2008||2008-06-30|July 2017|2017-07-31|May 2021|Anticipated|2021-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer|A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Hypofractionation Radiotherapy in High-risk Breast Cancer|Active, not recruiting||Phase 3|810|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:33:36.113078|2018-06-01 01:33:36.113078
NCT00793936|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Observational|||Criteria for Choice of Right Double Lumen Tube (DLT)|Criteria for Choice of Right Double Lumen Tube for Lung Surgery|Unknown status|Not yet recruiting||40|Anticipated|Assaf-Harofeh Medical Center|||||f||||t||||||||||2018-06-01 01:33:36.272363|2018-06-01 01:33:36.272363
NCT00793923|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2012-12-18|2008-11-18|2008-11-19|Estimate|||||||2012-12-18|2012-12-19|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|Lucedex||A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD|A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet Age-related Macular Degeneration|Completed||Phase 1/Phase 2|40|Actual|Bay Area Retina Associates||2|||f||||f||||||||||2018-06-01 01:33:36.334506|2018-06-01 01:33:36.334506
NCT00793910|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2011-11-21||2014-07-10|2008-11-18|2008-11-19|Estimate|2012-01-04|2012-02-07|Estimate||||2014-07-10|2014-07-16|Estimate|July 2008||2008-07-31|July 2014|2014-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy|Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy: A Randomized, Double-masked, Single Center, Placebo-controlled Clinical Trial|Completed||N/A|106|Actual|Walter Reed Army Medical Center||2|||f||||||||||||||2018-06-01 01:33:36.427809|2018-06-01 01:33:36.427809
NCT00793897|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2012-07-12|2008-11-18|2008-11-19|Estimate|||||||2012-07-12|2012-07-13|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors|A Phase I Multiple Ascending Dose Study of BMS-754807 in Combination With Paclitaxel and Carboplatin in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|21|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:33:36.745165|2018-06-01 01:33:36.745165
NCT00793884|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2017-10-11|2008-11-18|2008-11-19|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2008||2008-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ELDEP||Emory Latino Diabetes Education Program|Emory Latino Diabetes Education Program|Recruiting|||800|Anticipated|Emory University|||1||f||||f||||||||||2018-06-01 01:33:36.826602|2018-06-01 01:33:36.826602
NCT00793715|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2010-07-22|2008-11-17|2008-11-19|Estimate|||||||2010-07-22|2010-07-26|Estimate|July 2010||2010-07-31|June 2010|2010-06-30|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|DECOMPRESS||Laparotomy Versus Percutaneous Puncture in Patients With Abdominal Compartment Syndrome During Acute Pancreatitis|Decompressive Laparotomy With Temporary Abdominal Closure Versus Percutaneous Puncture With Placement of Abdominal Catheter in Patients With Abdominal Compartment Syndrome During Acute Pancreatitis:Multicenter, Randomised, Controlled Study|Unknown status|Recruiting|N/A|100|Anticipated|University of Belgrade||2|||f||||f||||||||||2018-06-01 01:33:42.309037|2018-06-01 01:33:42.309037
NCT00793871|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2015-04-14||2015-10-16|2008-11-17|2008-11-19|Estimate|2015-04-14|2015-05-01|Estimate||||2015-10-16|2015-11-20|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|GIST|Safety analysis set included all participants who started study treatment.|Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor|A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate|Completed||Phase 4|60|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:33:36.930278|2018-06-01 01:33:36.930278
NCT00793858|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-06-06|2008-11-18|2008-11-19|Estimate|||||||2013-06-06|2013-06-07|Estimate|February 2009||2009-02-28|June 2013|2013-06-30||||September 2009|Anticipated|2009-09-30||Interventional|||A Pilot Investigation of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray|A Pilot Investigation of the Nasal Mucosal Absorption, Retention, and Metabolism of Ciclesonide When Administered as a Hypotonic Versus an Isotonic Formulation of Ciclesonide Nasal Spray When Each Formulation Is Administered to Currently Symptomatic Patients (18 Years or Older) With Documented Perennial Allergic Rhinitis (PAR).|Withdrawn||Phase 4|0|Actual|University of Chicago||6||Cost prohibitive and company withdrew support.|f||||f||||||||||2018-06-01 01:33:37.316752|2018-06-01 01:33:37.316752
NCT00793845|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2017-05-01|2008-11-18|2008-11-19|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2008||2008-08-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2015|Actual|2015-01-31||Interventional|||Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma|Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma|Active, not recruiting||Phase 2|40|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 01:33:37.40916|2018-06-01 01:33:37.40916
NCT00793832|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2013-06-27|2008-11-18|2008-11-19|Estimate|||||||2013-06-27|2013-07-01|Estimate|July 2007||2007-07-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of Supervised Exercise on Physical Fitness and Energy Expenditure in Post Bariatric Surgery Patients|The Effect of Supervised Cardiorespiratory Endurance Exercise Training on Physical Fitness and Energy Expenditure in Roun-en-Y Gastric Bypass and Gastric Banding Surgery Patients.|Completed||N/A|33|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 01:33:37.482751|2018-06-01 01:33:37.482751
NCT00793819|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2012-02-07||2012-02-07|2008-11-18|2008-11-19|Estimate|2012-02-07|2012-03-09|Estimate||||2012-02-07|2012-03-09|Estimate|January 2009||2009-01-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia|A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia|Completed||Phase 2|215|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:33:37.563219|2018-06-01 01:33:37.563219
NCT00793806|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2017-02-08|2008-11-18|2008-11-19|Estimate|||||||2017-02-08|2017-02-10|Actual|August 2008||2008-08-31|February 2017|2017-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease|Immunologic Abnormalities, Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease|Completed|||14|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 01:33:37.842922|2018-06-01 01:33:37.842922
NCT00793793|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2015-07-03||2015-08-18|2008-11-18|2008-11-19|Estimate|2015-08-18|2015-09-17|Estimate||||2015-08-18|2015-09-17|Estimate|September 2007||2007-09-30|August 2015|2015-08-31||||January 2011|Actual|2011-01-31||Interventional||Full Analysis Set (FAS): All randomized patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial medication.|Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced|Safety, Antiviral Activity, and Pharmacokinetics of Multiple Rising Oral Doses of BI 201335 NA in Treatment-naïve Patients With Chronic Hepatitis C Infection for 14 Days Monotherapy Followed by Combination With Pegylated Interferon and Ribavirin for an Additional 14 Days (Double-blind, Placebo Controlled), and in Treatment-experienced Patients With Chronic Hepatitis C Infection for 28 Days as Combination Therapy With Pegylated Interferon and Ribavirin (Open-label)|Completed||Phase 1|96|Actual|Boehringer Ingelheim|"Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information."|5|||f||||||||||||||2018-06-01 01:33:38.043192|2018-06-01 01:33:38.043192
NCT00793780|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2016-06-28|2012-01-25|2016-08-12|2008-11-18|2008-11-19|Estimate|2016-08-12|2016-10-06|Estimate|2012-01-25|2012-01-30|Estimate|2016-08-12|2016-10-06|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Overweight women between the ages of 18 and 70 years who met the DSM-IV criteria for schizophrenia or schizoaffective disorder, on the basis of Structured Clinical Interview for DSM-IV. An additional participant dropped out of the study after baseline data was collected.|Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia|Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia|Completed||N/A|24|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:33:41.720719|2018-06-01 01:33:41.720719
NCT00793767|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2009-05-28|2008-11-18|2008-11-19|Estimate|||||||2009-05-28|2009-05-29|Estimate|January 2009||2009-01-31|May 2009|2009-05-31||||April 2009|Actual|2009-04-30||Interventional|||Insulin Resistance and Substrate Metabolism After Acute Erythropoietin (EPO) Administration|Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men|Completed||N/A|10|Anticipated|Aarhus University Hospital||2|||f||||f||||||||||2018-06-01 01:33:42.051802|2018-06-01 01:33:42.051802
NCT00793754|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2011-10-25|2008-11-18|2008-11-19|Estimate|||||||2011-10-25|2011-10-26|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|RATIONAL||Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People|Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People|Completed||Phase 4|30|Actual|Fundacion GESICA||4|||f||||t||||||||||2018-06-01 01:33:42.119198|2018-06-01 01:33:42.119198
NCT00793741|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2018-01-16|2008-11-18|2008-11-19|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2007|Actual|2007-12-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness|Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness|Completed|||19|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||||||2018-06-01 01:33:42.184023|2018-06-01 01:33:42.184023
NCT00792649|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-11-17|2008-11-17|2008-11-18|Estimate|||||||2008-11-17|2008-11-18|Estimate|February 2008||2008-02-29|February 2008|2008-02-29||||||||Observational|||Comparison Between HD+ Endoscopy and Standard Videoendoscopy in Screening Colonoscopy||Unknown status|Enrolling by invitation||200|Anticipated|Johannes Gutenberg University Mainz|||2||f||||f||||||||||2018-06-01 01:34:02.484848|2018-06-01 01:34:02.484848
NCT00793702|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2013-01-18|2008-11-17|2008-11-19|Estimate|||||||2013-01-18|2013-01-21|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Risk of Sensitisation of the rdESAT-6 + rCFP-10 Skin Test Following Repeated Intradermal Administration|An Open Phase I Clinical Trial on the Safety and Risk of Sensitisation by Escalating Doses and Repeated Injections of the rdESAT-6 + rCFP-10 Skin Test Reagent Following Intradermal Administration to Healthy Adults|Completed||Phase 1|42|Actual|Statens Serum Institut||5|||f||||t||||||||||2018-06-01 01:33:42.386712|2018-06-01 01:33:42.386712
NCT00793689|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2009-10-15|2008-11-18|2008-11-19|Estimate|||||||2009-10-15|2009-10-16|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Observational|||Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy|Comparison of the Prognostic Value of Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test in the Evaluation of Parathyroid Function After Total Thyroidectomy|Completed|||127|Actual|Aristotle University Of Thessaloniki|||1||f||||||||||||||2018-06-01 01:33:42.448616|2018-06-01 01:33:42.448616
NCT00793676|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2017-09-07|2008-11-18|2008-11-19|Estimate|||||||2017-09-07|2017-09-11|Actual|September 2008||2008-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Asthma, Inflammation and G Protein-coupled Receptors (GPCR)|G Protein Coupled Receptor (GPCR)Signature as Biomarker of Chronic Pulmonary Inflammatory Diseases and of Therapeutic Follow-up|Completed||N/A|205|Actual|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-06-01 01:33:42.500649|2018-06-01 01:33:42.500649
NCT00793663|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2011-05-16|2008-11-18|2008-11-19|Estimate|||||||2011-05-16|2011-05-17|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|XABP||Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia|1) The Effect of Xenon and Sevoflurane on Hypnosis Monitors. 2) Prevention of Postoperative Nausea and Vomiting. 3) Rescue Treatment of Established Postoperative Nausea and Vomiting. Sevoflurane.|Completed||Phase 4|220|Anticipated|RWTH Aachen University||6|||f||||f||||||||||2018-06-01 01:33:43.544194|2018-06-01 01:33:43.544194
NCT00793650|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2012-03-14||2012-08-17|2008-11-18|2008-11-19|Estimate|2012-05-16|2012-06-18|Estimate||||2012-08-17|2012-08-30|Estimate|May 2005||2005-05-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|October 2009|Actual|2009-10-31||Interventional|||Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study|Combination High Dose Melphalan and Autologous PBSC Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study|Terminated||Phase 1/Phase 2|39|Actual|Emory University||2|||f||||t||||||||||2018-06-01 01:33:43.654624|2018-06-01 01:33:43.654624
NCT00793637|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2009-08-05|2008-11-17|2008-11-19|Estimate|||||||2009-08-05|2009-08-06|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|ASLS-Pre||Evaluation of Handling and Possible Complications Related to the Newly Developed Angular Stable Locking System (ASLS)|Prospective Multicenter Case Series to Evaluate Handling and Possible Complications Related to the Angular Stable Locking System in Patients With Proximal and Distal Tibial, Femoral and Humeral Fractures Treated With Intramedullary Nails|Completed|||30|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-06-01 01:33:43.93606|2018-06-01 01:33:43.93606
NCT00793624|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2014-03-28||2014-06-17|2008-11-18|2008-11-19|Estimate|2014-06-04|2014-06-05|Estimate||||2014-06-17|2014-06-27|Estimate|February 2009||2009-02-28|June 2014|2014-06-30||||December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 ug] and 10 ug [2 Actuations of 5 ug]) Delivered by the Respimat® Inhaler, and 48 Weeks of Twice Daily Foradil® (12 µg) Delivered by the Aerolizer® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|906|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 01:33:44.344563|2018-06-01 01:33:44.344563
NCT00793611|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2011-08-16||2017-09-08|2008-11-18|2008-11-19|Estimate|2011-09-20|2011-10-28|Estimate||||2017-09-08|2017-10-09|Actual|November 2008||2008-11-30|September 2017|2017-09-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Hypnotherapy for Treatment of Overactive Bladder|Hypnotherapy for Treatment of Overactive Bladder: A Feasibility Study|Completed||N/A|20|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 01:33:47.735561|2018-06-01 01:33:47.735561
NCT00793598|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2011-03-15|2008-11-18|2008-11-19|Estimate|||||||2011-03-15|2011-03-17|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||CMX001 in Post-transplant Patients With BK Virus Viruria|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of the Safety, Tolerability and Population Pharmacokinetics of CMX001 in Post-Transplant Subjects With BK Virus Viruria|Completed||Phase 1/Phase 2|60|Anticipated|Chimerix||2|||f||||t||||||||||2018-06-01 01:33:48.050928|2018-06-01 01:33:48.050928
NCT00793585|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2009-10-28||2016-04-25|2008-11-17|2008-11-19|Estimate|2011-06-06|2011-07-01|Estimate||||2016-04-25|2016-05-25|Estimate|July 2007||2007-07-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Controlled Study of Uric Acid on the Progression of IgA Nephropathy|A Prospective, Randomized Controlled Study of Uric Acid on the Progression of IgA Nephropathy|Completed||N/A|40|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:33:48.140671|2018-06-01 01:33:48.140671
NCT00793572|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|2017-04-11||2017-05-30|2008-11-18|2008-11-19|Estimate|2017-04-11|2017-05-18|Actual||||2017-05-30|2017-06-23|Actual|October 2008||2008-10-31|May 2017|2017-05-31||||October 2016|Actual|2016-10-31||Interventional|||Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma|Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma|Active, not recruiting||Phase 2|32|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 01:33:48.471883|2018-06-01 01:33:48.471883
NCT00793559|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Terlipressin Administration in Septic Shock Refractory to Catecholamines|Terlipressin Administration in Septic Shock Refractory to Catecholamines Bolus vs. Continuous Drip-Phase II|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 01:33:48.721323|2018-06-01 01:33:48.721323
NCT00792844|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-11-17|2008-11-17|2008-11-18|Estimate|||||||2008-11-17|2008-11-18|Estimate|February 2009||2009-02-28|November 2008|2008-11-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Comparison of Two Formulations of Bio-K|Comparison of Two Formulations of Lactobacillus Acidophilus and Lactobacillus Casei in the Prevention of Antibiotic-Associated Diarrhea: a Pilot Study|Unknown status|Not yet recruiting|N/A|90|Anticipated|McMaster University||3|||f||||||||||||||2018-06-01 01:33:59.031852|2018-06-01 01:33:59.031852
NCT00793546|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2012-10-04|2011-11-15|2012-10-04|2008-11-17|2008-11-19|Estimate|2012-10-04|2012-11-05|Estimate|2011-11-15|2011-11-21|Estimate|2012-10-04|2012-11-05|Estimate|February 2009||2009-02-28|October 2012|2012-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer|A Phase 2, Randomized, Open-Label Study Of Bosutinib Administered In Combination With Exemestane Versus Exemestane Alone As Second Line Therapy In Postmenopausal Women With Locally Advanced Or Metastatic ER+/PgR+/ErbB2- Breast Cancer|Terminated||Phase 2|42|Actual|Pfizer|Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:33:48.817621|2018-06-01 01:33:48.817621
NCT00793520|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2010-04-15||2010-06-01|2008-11-18|2008-11-19|Estimate|2010-06-01|2010-07-01|Estimate||||2010-06-01|2010-07-01|Estimate|November 2008||2008-11-30|June 2010|2010-06-30||||April 2009|Actual|2009-04-30||Interventional|||Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia||Terminated||Phase 3|2|Actual|Forest Laboratories|Early termination leading to small numbers of subjects enrolled. Technical problems with MRI equipment resulted in early study termination. No analysis was performed.|2|||f||||f||||||||||2018-06-01 01:33:49.30667|2018-06-01 01:33:49.30667
NCT00793507|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2013-02-04|2008-11-17|2008-11-19|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Oral Health Care Early Intervention Project|Oral Health Care Early Intervention Project|Completed||N/A|1178|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:33:49.548255|2018-06-01 01:33:49.548255
NCT00793494|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2016-04-12|2008-11-18|2008-11-19|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|POPSII||Efficacy of Probaclac in Irritable Bowel Syndrome in Children Aged 8 to 18 Years|Randomized Controlled Trial of Probaclac Versus Placebo in Children Aged 8 to 18 Years With Irritable Bowel Syndrome|Terminated||Phase 2|44|Actual|St. Justine's Hospital||2||Recruitment impossible|f||||t||||||||||2018-06-01 01:33:49.632947|2018-06-01 01:33:49.632947
NCT00793481|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2017-02-08|2008-11-14|2008-11-19|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2008||2008-11-30|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Vascular Reactivity in Metabolic Syndrome and Diabetic Patients Using Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Measure Microvascular Changes in Metabolic Syndrome and Diabetes Mellitus in Order to Assess Cardiovascular Disease Risk.|Completed|||50|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 01:33:49.706835|2018-06-01 01:33:49.706835
NCT00793468|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2016-02-11|2008-11-18|2008-11-19|Estimate|||||||2016-02-11|2016-02-15|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|December 2008|Anticipated|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Relapse Prevention Study in Newly Abstinent Smokers|A Study to Investigate the Effects of GSK598809 in Newly Abstinent Nicotine-dependent Subjects.|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||Study halted prior to enrollment of patients|f||||f||||||||||2018-06-01 01:33:49.773308|2018-06-01 01:33:49.773308
NCT00793455|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2011-09-01||2011-10-24|2008-11-18|2008-11-19|Estimate|2011-10-24|2011-12-01|Estimate||||2011-10-24|2011-12-01|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|UPQUAL||Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders|Using Precision Performance Measurement To Conduct Focused Quality Improvement. Sub-Study 1.|Completed||N/A|628|Actual|Northwestern University|This study does not identify the timing of the intervention that would have the most impact. Mailings occurred 3 months or more after the order was placed, contacting patients sooner may have been more effective.|2|||f||||f||||||||||2018-06-01 01:33:49.857522|2018-06-01 01:33:49.857522
NCT00793442|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2017-04-25|2008-11-18|2008-11-19|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2008|Actual|2008-03-31|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Endothelium in Severe Sepsis|Endothelial Cell Signaling and Microcirculatory Flow in Severe Sepsis|Completed|||910|Actual|Beth Israel Deaconess Medical Center|||2||f||||t|f|f||||||No||2018-06-01 01:33:50.182657|2018-06-01 01:33:50.182657
NCT00793429|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2008-11-20|2008-11-18|2008-11-19|Estimate|||||||2008-11-20|2008-11-21|Estimate||||November 2008|2008-11-30||||||||Interventional|||Safety Study of Prucalopride in Healthy Volunteers|A Double-Blind, Placebo-Controlled, Two-Way Cross-Over in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Prucalopride at Steady-State|Completed||Phase 1|||Movetis|||||f||||f||||||||||2018-06-01 01:33:50.281622|2018-06-01 01:33:50.281622
NCT00793416|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2013-10-28|2008-11-18|2008-11-19|Estimate|||||||2013-10-28|2013-10-29|Estimate|November 2008||2008-11-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||ShuntCheck Accuracy in Detecting Shunt Obstruction Normal Pressure Hydrocephalus (NPH) Patients|Accuracy of ShuntCheck and MRI in Detection of Shunt Obstruction in Patients Receiving Shunt Patency Test|Withdrawn||Phase 4|0|Actual|NeuroDx Development||1||Loss of study staffing|f||||f||||||||||2018-06-01 01:33:50.329368|2018-06-01 01:33:50.329368
NCT00793403|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2012-12-31||2012-12-31|2008-11-18|2008-11-19|Estimate|2012-12-31|2013-02-04|Estimate||||2012-12-31|2013-02-04|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|New Indices||Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study|"Current Adoption Of Composite Indices In Evaluating Rheumatoid Arthritis Patients: An Observational Study (NEW INDICES Study)"|Completed|||293|Actual|Pfizer|||1||f||||t||||||||||2018-06-01 01:33:50.439187|2018-06-01 01:33:50.439187
NCT00793390|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2018-04-13|2008-11-18|2008-11-19|Estimate|||||||2018-04-13|2018-04-17|Actual|November 17, 2008||2008-11-17|April 12, 2018|2018-04-12||||||||Observational|||Case-Control Study of Inflammatory Breast Cancer in North Africa|A Case-Control Study of Inflammatory Breast Cancer in North Africa|Completed|||773|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:33:50.931182|2018-06-01 01:33:50.931182
NCT00793377|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate||||November 2008|2008-11-30|September 2001|Actual|2001-09-30|||||Interventional|||Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer|A Randomized, Multicenter, Open Phase III Study Comparing a Dose-Intensified 8 Week Schedule of Adriamycin and Docetaxel (ADOC) With a Sequential 24 Week Schedule of Adriamycin/Cyclophosphamide Followed by Docetaxel (AC-DOC) Regimen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast (T2-3 N0-2 M0)|Completed||Phase 3|913|Actual|German Breast Group||2|||f||||||||||||||2018-06-01 01:33:50.997878|2018-06-01 01:33:50.997878
NCT00792675|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-11-17|2008-11-17|2008-11-18|Estimate|||||||2008-11-17|2008-11-18|Estimate|January 2003||2003-01-31|November 2008|2008-11-30|November 2007|Actual|2007-11-30|April 2006|Actual|2006-04-30||Interventional|RA&Ex||Effect of Exercise on the Disease Activity of Rheumatoid Arthritis||Completed||N/A|55|Actual|University of Nebraska||1|||f||||f||||||||||2018-06-01 01:34:02.309563|2018-06-01 01:34:02.309563
NCT00793364|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2009-05-27|2008-11-18|2008-11-19|Estimate|||||||2009-05-27|2009-05-28|Estimate|November 2008||2008-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet|Effect of Plant Stanol Ester-Containing Spread Based on Extra Virgin Olive Oil on Estimated Cardiovascular Risk, and Lipid-Inflammatory-Haemostatic Factors in Comparison to Mediterranean Diet: A Randomized, Placebo-Controlled Trial.|Completed||Phase 4|150|Actual|Hellenic Atherosclerosis Society||3|||f||||t||||||||||2018-06-01 01:33:51.120279|2018-06-01 01:33:51.120279
NCT00793351|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2016-10-17|2008-11-18|2008-11-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2013|Actual|2013-11-30||Interventional|||Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation With Reduced-intensity Conditioning in Children With Neuroblastoma Who Have Failed a Prior Autologous Transplantation|Completed||Phase 2|25|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-06-01 01:33:51.193816|2018-06-01 01:33:51.193816
NCT00793338|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|February 2011|Anticipated|2011-02-28|November 2010|Anticipated|2010-11-30||Interventional|||Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure|Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|University of New Mexico||1|||f||||t||||||||||2018-06-01 01:33:51.250089|2018-06-01 01:33:51.250089
NCT00793325|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2013-12-17||2013-12-17|2008-11-17|2008-11-19|Estimate|2013-12-17|2014-02-06|Estimate||||2013-12-17|2014-02-06|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Long Term Use of Somatropin in Patients Small for Gestational Age|Special Investigation Of Long Term Use Of Genotropin For SGA (Regulatory Post Marketing Commitment Plan)|Completed|||920|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:33:51.346374|2018-06-01 01:33:51.346374
NCT00793312|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2012-10-16|2008-11-17|2008-11-19|Estimate|||||||2012-10-16|2012-10-17|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Observational|||China Endeavor Registry: A Registry With The Endeavor Zotarolimus Eluting Coronary Stent in China|To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor™ Zotarolimus Eluting Coronary Stent System in Chinese Patients, A Prospective, Multicenter Registry|Completed|||2210|Actual|Medtronic Vascular|||||f||||f||||||||||2018-06-01 01:33:51.705173|2018-06-01 01:33:51.705173
NCT00793299|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2015-04-24|2008-11-18|2008-11-19|Estimate|||||||2015-04-24|2015-04-27|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Burden of Cancer in Children: A Pilot Study to Investigate the Impact and Content of Video Illness Narratives|Burden of Cancer in Children: A Pilot Study to Investigate the Impact and Content of Video Illness Narratives|Completed||N/A|11|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 01:33:51.756631|2018-06-01 01:33:51.756631
NCT00793286|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2008-11-21|2008-11-18|2008-11-19|Estimate|||||||2008-11-21|2008-11-24|Estimate|August 2004||2004-08-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Stapler Versus Glue for Laparoscopic Groin Hernia Repair|Stapler Versus Glue for Laparoscopic Groin Hernia Repair|Completed||N/A|80|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 01:33:51.814705|2018-06-01 01:33:51.814705
NCT00793273|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2014-08-13|2008-11-18|2008-11-19|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.|Evaluation of Glycaemic Control After Initiation of Levemir® in Patients With Type 2 Diabetes Mellitus and Time Period Between Diagnosis of Type 2 Diabetes Mellitus and Insulin Initiation.|Completed|||1074|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:33:51.883769|2018-06-01 01:33:51.883769
NCT00793260|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate|July 2006||2006-07-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|June 2007|Actual|2007-06-30||Interventional|||Deep Dive Randomized Control Trial|Deep Dive Randomized Control Trial|Completed||N/A|174120|Actual|Health Dialog||2|||f||||f||||||||||2018-06-01 01:33:51.943761|2018-06-01 01:33:51.943761
NCT00793247|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate||||November 2008|2008-11-30||||||||Interventional|||Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)|A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP).|Completed||Phase 2|||Movetis|||||f||||||||||||||2018-06-01 01:33:51.996299|2018-06-01 01:33:51.996299
NCT00793234|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2014-04-04|2008-11-18|2008-11-19|Estimate|||||||2014-04-04|2014-04-07|Estimate|December 2008||2008-12-31|April 2014|2014-04-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery|Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery: A Dose-Escalating, Multicenter, Randomised, Active- Controlled Open Label Study|Completed||Phase 2|316|Actual|ThromboGenics||4|||f||||t||||||||||2018-06-01 01:33:52.042175|2018-06-01 01:33:52.042175
NCT00793221|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2012-06-18|2008-11-17|2008-11-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|November 2008||2008-11-30|June 2012|2012-06-30||||July 2011|Actual|2011-07-31||Interventional|CIBELES||Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent|Randomized Comparison Between Sirolimus-eluting and Everolimus-eluting Coronary Stents in Chronic Coronary Occlusions|Completed||Phase 3|207|Actual|Spanish Society of Cardiology||2|||f||||t||||||||||2018-06-01 01:33:52.161075|2018-06-01 01:33:52.161075
NCT00793208|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2013-12-09|2008-11-17|2008-11-19|Estimate|||||||2013-12-09|2013-12-10|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|January 2025|Anticipated|2025-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Immunization of Patients With Non Small Cell Lung Cancer (NSCLC)|Active Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) Using Fibroblasts Transfected With DNA From Autologous Tumor (Phase IB Study)|Recruiting||Phase 1|22|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:33:52.23864|2018-06-01 01:33:52.23864
NCT00793195|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-18|||2011-11-02|2008-11-18|2008-11-19|Estimate|||||||2011-11-02|2011-11-03|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|January 2012|Anticipated|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?|Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants? A Pilot Double Blind Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 01:33:52.322373|2018-06-01 01:33:52.322373
NCT00793182|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2017-08-01||2017-09-04|2008-11-17|2008-11-19|Estimate|2017-09-04|2017-09-29|Actual||||2017-09-04|2017-09-29|Actual|January 2009||2009-01-31|September 2017|2017-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|CINOPSIS CT||Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography|A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Optiray 320 mgI/mL and Visipaque 320 mgI/mL on Renal Function in Subjects With Stable Reduced Renal Function Undergoing Contrast-enhanced Computed Tomography|Terminated||Phase 4|6|Actual|Guerbet|Due to the small number of subjects enrolled, no statistical analyses were performed.|2||Slow enrollment|f||||f||||||||||2018-06-01 01:33:52.419032|2018-06-01 01:33:52.419032
NCT00793169|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2010-09-30||2015-02-19|2008-11-18|2008-11-19|Estimate|2010-10-29|2010-11-30|Estimate||||2015-02-19|2015-03-06|Estimate|September 2007||2007-09-30|February 2015|2015-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery|Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery|Completed|||19|Actual|Northwestern University|Serum rather than plasma lidocaine levels were measured. For lidocaine levels, plasma and serum levels are similar, and serum levels are more routinely reported by reference laboratories. Hence our selection of serum levels for this study.||1||f||||f||||||||||2018-06-01 01:33:52.557646|2018-06-01 01:33:52.557646
NCT00793156|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2010-02-03|2008-11-17|2008-11-19|Estimate|||||||2010-02-03|2010-02-04|Estimate|December 2009||2009-12-31|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|AC120-8231||A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)|A Randomized-Withdrawal Phase 3 Study Evaluation the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)|Unknown status|Not yet recruiting|Phase 3|350|Anticipated|Acologix, Inc.||3|||f||||f||||||||||2018-06-01 01:33:52.672005|2018-06-01 01:33:52.672005
NCT00793143|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2017-08-22|2008-11-18|2008-11-19|Estimate|||||||2017-08-22|2017-08-24|Actual|April 2008||2008-04-30|August 2017|2017-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|SLEEVEPASS||Laparoscopic Gastric Bypass Versus Sleeve Gastrectomy to Treat Morbid Obesity|A Randomized Prospective Three-center Study: Laparoscopic Gastric Bypass vs. Laparoscopic Sleeve Gastrectomy in the Treatment of Morbid Obesity|Completed|||240|Actual|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     Tissue samples~   "|No||2018-06-01 01:33:52.805546|2018-06-01 01:33:52.805546
NCT00793130|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|||2008-11-18|2008-11-18|2008-11-19|Estimate|||||||2008-11-18|2008-11-19|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label|The Efficacy and Tolerability of Coltect as Add-on in Patients With Active Ulcerative Colitis - an Open Label|Unknown status|Recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||||2018-06-01 01:33:52.878653|2018-06-01 01:33:52.878653
NCT00793117|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-15|||2012-06-02|2008-11-18|2008-11-19|Estimate|||||||2012-06-02|2012-06-05|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||The Effect of Packing in Post Operative Management of FESS|The Evaluation of Effect of Pva Sponge in Prevention of Complications in Fess|Completed||Phase 4|66|Actual|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 01:33:52.957842|2018-06-01 01:33:52.957842
NCT00793104|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2013-07-12||2013-11-06|2008-11-18|2008-11-19|Estimate|2013-11-06|2013-12-25|Estimate||||2013-11-06|2013-12-25|Estimate|November 2008||2008-11-30|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.|Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Focal Cartilage Lesions in the Femoral Condyle|Terminated||Phase 3|10|Actual|RTI Surgical|"Enrollment was closed early due for 2 factors:~1) Slow enrollment and 2) A potential change in the regulatory pathway for allografts used in cartilage repair~1 patient was lost to follow up, with no data collected at the 24-month visit."|1||Slow enrolment & potential regulatory changes for allograft in cartilage repair|f||||f||||||||||2018-06-01 01:33:53.036995|2018-06-01 01:33:53.036995
NCT00793091|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-11-26|2008-11-18|2008-11-19|Estimate|||||||2008-11-26|2008-11-27|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|||Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract|A Phase 2, Randomized, Placebo-Controlled, Double-Masked, Multicenter Safety and Efficacy Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Acuity Due to Age-Related Cataract|Unknown status|Recruiting|Phase 2|80|Anticipated|Chakshu Research, Inc.||2|||f||||f||||||||||2018-06-01 01:33:53.205881|2018-06-01 01:33:53.205881
NCT00793078|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2011-02-28|2008-11-17|2008-11-19|Estimate|||||||2011-02-28|2011-03-01|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Arterial Blood Pressure-complexity in Septic Patients|Investigation of Arterial Blood Pressure-complexity and Its Relation to Outcome in Comparison Between Cardiac Surgery Versus Non-cardiac Surgery Septic Patients|Suspended|||72|Anticipated|University Hospital, Bonn||||Awaiting decision on financial support by Deutsche Forschungsgemeinschaft (DFG)|f||||f||||||||||2018-06-01 01:33:53.341801|2018-06-01 01:33:53.341801
NCT00793065|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2017-02-17|2008-11-18|2008-11-19|Estimate|||||||2017-02-17|2017-02-23|Actual|January 2008|Actual|2008-01-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Evaluating the Effects of EHRs, P4P and Medical Home Redesign in the Hudson Valley|Evaluating the Effects of EHRs, P4P and Medical Home Redesign in the Hudson Valley|Completed|||438|Actual|Weill Medical College of Cornell University|||3||f||||f||||||||||2018-06-01 01:33:53.409586|2018-06-01 01:33:53.409586
NCT00793052|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2008-11-16|2008-11-16|2008-11-19|Estimate|||||||2008-11-16|2008-11-19|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery|Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery: A Prospective, Double-Blind Study|Unknown status|Active, not recruiting|N/A|80|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-06-01 01:33:53.49312|2018-06-01 01:33:53.49312
NCT00793026|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2008-12-18|2008-11-17|2008-11-18|Estimate|||||||2008-12-18|2008-12-19|Estimate|November 2008||2008-11-30|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Interventional|||Dermacyd Breeze Pocket BR (Lactic Acid) - Acceptability|Safety Dermatological Evaluation: Genital Mucous Irritation - Test in Use - Dermacyd Breeze Pocket BR (Lactic Acid).|Completed||Phase 3|30|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:33:53.560559|2018-06-01 01:33:53.560559
NCT00793013|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2015-08-10|2008-11-17|2008-11-18|Estimate|||||||2015-08-10|2015-08-11|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PRESSURE||Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation|Primary Resuscitation Using Airway Pressure Release Ventilation Improves Recovery From Acute Lung Injury or Adult Respiratory Distress Syndrome and Reduces All Cause Mortality Compared to ARDS Net Low Tidal Volume-Cycled Ventilation.|Unknown status|Recruiting|Phase 2|368|Anticipated|University of Tennessee, Chattanooga||2|||f||||f||||||||||2018-06-01 01:33:53.662825|2018-06-01 01:33:53.662825
NCT00793000|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2011-05-03|2008-11-17|2008-11-18|Estimate|||||||2011-05-03|2011-05-04|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults|A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After First Time Administration Of Ascending Single Oral Doses To Healthy Adult Subjects|Completed||Phase 1|80|Actual|Pfizer||10|||f||||f||||||||||2018-06-01 01:33:53.76312|2018-06-01 01:33:53.76312
NCT00792974|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2009-02-04|2008-11-17|2008-11-18|Estimate|||||||2009-02-04|2009-02-05|Estimate|October 2008||2008-10-31|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||End-of-Life Fear in Patients With End-Stage Lung Disease (COPD)|End-of-Life Fear in Patients With End-Stage Lung Disease: Fears of Death and Dying, Wishes and Needs of Patients With Severe COPD|Unknown status|Recruiting||199|Anticipated|Philipps University Marburg Medical Center|||1||f||||t||||||||||2018-06-01 01:33:54.02544|2018-06-01 01:33:54.02544
NCT00792961|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|||2014-04-07|2008-11-16|2008-11-18|Estimate|||||||2014-04-07|2014-04-09|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery|In Vivo Confocal Endomicroscopy During da Vinci Robot Assisted Prostatectomy: Feasibility Study|Completed||N/A|10|Actual|Optiscan Pty Ltd||1|||f||||f||||||||||2018-06-01 01:33:54.221957|2018-06-01 01:33:54.221957
NCT00792948|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|2016-11-21||2018-04-20|2008-11-16|2008-11-18|Estimate|2017-03-16|2017-04-26|Actual||||2018-04-20|2018-04-24|Actual|September 1, 2009|Actual|2009-09-01|April 2018|2018-04-30|September 24, 2019|Anticipated|2019-09-24|June 1, 2016|Actual|2016-06-01||Interventional||Analysis includes eligible patients who received treatment.|Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia|Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)|Active, not recruiting||Phase 2|97|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 01:33:54.392792|2018-06-01 01:33:54.392792
NCT00792935|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2012-06-28||2015-12-16|2008-11-17|2008-11-18|Estimate|2012-08-31|2012-10-03|Estimate||||2015-12-16|2015-12-17|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)|A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy|Completed||Phase 2|143|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:33:55.7925|2018-06-01 01:33:55.7925
NCT00792922|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2017-04-13||2017-06-19|2008-11-17|2008-11-18|Estimate|2017-06-19|2017-07-18|Actual||||2017-06-19|2017-07-18|Actual|May 2008||2008-05-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|PRET|"For the final analysis the main effect of stop rule was not considered in Tanzania since no communities had prevalence < 5%.Only the main effect of coverage was analyzed there.~In Gambia and Niger stop rule was applied and analyzed along with the main effect of coverage."|Partnership for Rapid Elimination of Trachoma|Research to Programs for Trachoma Elimination: Antibiotic Trial|Completed||Phase 4|128|Actual|Johns Hopkins University||4|||f||||t||||||||No||2018-06-01 01:33:55.998875|2018-06-01 01:33:55.998875
NCT00792909|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2017-05-12|2009-09-09|2017-05-12|2008-11-17|2008-11-18|Estimate|2017-05-12|2017-12-14|Actual|2009-09-09|2009-09-10|Estimate|2017-05-12|2017-12-14|Actual|December 2, 2008|Actual|2008-12-02|May 2017|2017-05-31|July 2, 2009|Actual|2009-07-02|July 2, 2009|Actual|2009-07-02||Interventional|||Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A|Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children|Completed||Phase 3|172|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:33:56.386285|2018-06-01 01:33:56.386285
NCT00792896|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|||2008-11-17|2008-11-17|2008-11-18|Estimate|||||||2008-11-17|2008-11-18|Estimate|May 2008||2008-05-31|May 2008|2008-05-31||||December 2010|Anticipated|2010-12-31||Interventional|||Intervention Toward Truth-Telling and Advanced Directives in the Patient With Advanced or Metastatic Disease|A Longitudinal Study That Assessed the Effectiveness of Intervention Toward|Unknown status|Recruiting|N/A|150|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:33:58.729831|2018-06-01 01:33:58.729831
NCT00792883|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2015-10-26|2008-11-17|2008-11-18|Estimate|||||||2015-10-26|2015-10-28|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|PCL07||Clinical Protocol Validation to Identify Prognostic Markers for Critical Care Pediatric Patients|Clinical Protocol Validation to Identify Prognostic Markers for Critical Care Pediatric Patients|Completed|||1000|Actual|Oswaldo Cruz Foundation|||3||f||||t||||||Samples With DNA|"~     DNA extracts from blood or oral swab~   "|||2018-06-01 01:33:58.795962|2018-06-01 01:33:58.795962
NCT00792870|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2012-03-15|2008-11-14|2008-11-18|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of the Shape Up Rhode Island Campaign|Evaluation of the Shape Up Rhode Island Campaign: Study 4 Does Adding Behavioral Weight Control Information to Shape-Up Rhode Island Improve Outcomes?|Completed||N/A|179|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-06-01 01:33:58.872746|2018-06-01 01:33:58.872746
NCT00792857|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2014-09-26|2008-11-17|2008-11-18|Estimate|||||||2014-09-26|2014-09-29|Estimate|November 2008||2008-11-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)|Single-Dose, Two-Period, Open Label, Dose Determination, Randomized, Cross-Over Study of CTAP201 Injection and Doxercalciferol (Hectorol) Injection in Subjects With Stage 5 CKD and SHPT on Hemodialysis|Completed||Phase 1|24|Actual|OPKO Health, Inc.||4|||f||||f||||||||||2018-06-01 01:33:58.941266|2018-06-01 01:33:58.941266
NCT00792831|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-05-23|2008-11-17|2008-11-18|Estimate|||||||2013-05-23|2013-05-24|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia|Open Label, Uncontrolled, Pilot, Phase II Study of Histone-deacetylase Inhibitor ITF2357 Administered Orally to Subjects With Chronic Lymphocytic Leukemia (CLL) Refractory/Relapsed After Conventional Chemotherapy or Relapsed After Autologous Bone Marrow Transplantation|Terminated||Phase 2|3|Actual|Italfarmaco||1||"protocol needs complete restructuring in order to make it feasible and to complete the~   enrollment of 23 patients"|f||||t||||||||||2018-06-01 01:33:59.202261|2018-06-01 01:33:59.202261
NCT00792818|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|||2012-10-27|2008-11-16|2008-11-18|Estimate|||||||2012-10-27|2012-10-30|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen in Knee Osteoarthritis|The Efficacy and Safety of Curcuma Domestica Extracts and Ibuprofen for Therapy of Patients With Knee Osteoarthritis, the Randomized Double-blinded Controlled Trial, Multicenter Study|Completed||Phase 3|367|Actual|Mahidol University||2|||f||||t||||||||||2018-06-01 01:33:59.27551|2018-06-01 01:33:59.27551
NCT00792805|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2011-07-22||2011-07-22|2008-11-17|2008-11-18|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, 26-week Multicenter Randomized Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (150 and 300 µg Once Daily [od]) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|563|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:33:59.524143|2018-06-01 01:33:59.524143
NCT00792792|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2017-12-08|2008-11-14|2008-11-18|Estimate|||||||2017-12-08|2017-12-12|Actual|January 2007||2007-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Monitoring of Tissue Transfer Flaps by Modulated Imaging|Non-contact, Intra-operative & Post-operative Device, Evaluation of Tissue Transfer Flaps After Reconstructive Surgery.|Withdrawn|||0|Actual|University of California, Irvine|||1|Not a clinical trial study.|f||||f||||||||||2018-06-01 01:33:59.910876|2018-06-01 01:33:59.910876
NCT00792779|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2009-11-04|2008-11-17|2008-11-18|Estimate|||||||2009-11-04|2009-11-05|Estimate|November 2008||2008-11-30|November 2009|2009-11-30|June 2009|Anticipated|2009-06-30|May 2009|Anticipated|2009-05-31||Interventional|||Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty|Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty|Unknown status|Active, not recruiting|N/A|60|Anticipated|Centro Medico Campinas|||||f||||f||||||||||2018-06-01 01:34:00.017371|2018-06-01 01:34:00.017371
NCT00792766|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2013-09-17|2008-11-17|2008-11-18|Estimate|||||||2013-09-17|2013-09-18|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)|Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis|Completed||Phase 1/Phase 2|20|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 01:34:00.105143|2018-06-01 01:34:00.105143
NCT00792753|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2017-07-25|2008-11-17|2008-11-18|Estimate|||||||2017-07-25|2017-07-26|Actual|October 2008||2008-10-31|July 2017|2017-07-31|March 8, 2014|Actual|2014-03-08|November 2011|Actual|2011-11-30||Interventional|||"Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study EXCELLA II STUDY"|A Randomized, Single Blind, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Durable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions And A Randomized, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment Of Patients With De Novo Native Coronary Artery Lesions|Completed||N/A|360|Actual|Elixir Medical Corporation||3|||f||||t||||||||No||2018-06-01 01:34:00.181915|2018-06-01 01:34:00.181915
NCT00792740|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2012-02-01|2008-11-17|2008-11-18|Estimate|||||||2012-02-01|2012-02-02|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|Chron Disease||Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease|Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease|Terminated||Phase 1/Phase 2|51|Actual|Italfarmaco||2||"As no safety warnings were detected,Interim analysis from the first 40 patients reccomends to~   stop the trial for futility"|f||||t||||||||||2018-06-01 01:34:00.277782|2018-06-01 01:34:00.277782
NCT00792727|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14||2015-03-17|2015-05-12|2008-11-17|2008-11-18|Estimate||||2015-05-12|2015-06-04|Estimate|2015-05-12|2015-06-04|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee|Completed||Phase 3|380|Actual|Hisamitsu Pharmaceutical Co., Inc.||2|||f||||f||||||||||2018-06-01 01:34:00.384966|2018-06-01 01:34:00.384966
NCT00792714|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|||2010-01-31|2008-11-17|2008-11-18|Estimate|||||||2010-01-31|2010-02-02|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|DPM-PK-102||Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients|Determination of the Pharmacokinetics of Inhaled Mannitol After Single and Multiple Dosing in Cystic Fibrosis Patients|Completed||Phase 1|18|Anticipated|Pharmaxis|||||f||||f||||||||||2018-06-01 01:34:00.543023|2018-06-01 01:34:00.543023
NCT00792701|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|2016-10-26||2017-07-12|2008-11-16|2008-11-18|Estimate|2017-05-31|2017-07-02|Actual||||2017-07-12|2017-08-11|Actual|November 2008||2008-11-30|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer|Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|85|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 01:34:00.773451|2018-06-01 01:34:00.773451
NCT00792688|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2011-06-23||2011-07-22|2008-11-14|2008-11-18|Estimate|2011-06-23|2011-07-25|Estimate||||2011-07-22|2011-07-26|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation|Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.|Completed||Phase 2|26|Actual|Glycotex, Inc.||3|||f||||||||||||||2018-06-01 01:34:01.892632|2018-06-01 01:34:01.892632
NCT00792636|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2010-10-07|2010-08-12|2016-10-11|2008-11-17|2008-11-18|Estimate|2010-10-07|2010-11-04|Estimate|2010-08-12|2010-08-17|Estimate|2016-10-11|2016-11-23|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period|Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults|Completed||Phase 4|407|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:34:02.578927|2018-06-01 01:34:02.578927
NCT00792623|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2017-04-19||2017-04-19|2008-11-17|2008-11-18|Estimate|2017-04-19|2017-07-06|Actual||||2017-04-19|2017-07-06|Actual|September 8, 2003|Actual|2003-09-08|April 2017|2017-04-30|September 10, 2007|Actual|2007-09-10|September 10, 2007|Actual|2007-09-10||Interventional|||Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).|A Phase III, Open-label, Multi-centre Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM), Given as a Primary Vaccination at 4.5 Months and 6.5 Months Post-transplantation, in Autologous Stem Cell/ Bone Marrow Transplant Recipients Aged 18 Years and Older.|Completed||Phase 2|45|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:34:03.547313|2018-06-01 01:34:03.547313
NCT00792610|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-16|2009-08-16||2009-10-05|2008-11-17|2008-11-18|Estimate|2009-08-16|2009-09-24|Estimate||||2009-10-05|2009-10-06|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines|The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines|Completed||N/A|127|Actual|National Taiwan University Hospital|The possible presence of T cell memory among the seronegative patients for HBsAg(+), anti-HBc(+), and anti-HBs(+) could be a concern.|1|||f||||t||||||||||2018-06-01 01:34:04.036174|2018-06-01 01:34:04.036174
NCT00792597|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-03-06|2008-11-17|2008-11-18|Estimate|||||||2013-03-06|2013-03-07|Estimate|April 2009||2009-04-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Observational|||Comparison of Three Methods of Hemoglobin Monitoring|Comparison of Three Methods of Hemoglobin Monitoring in Patients Undergoing Spine Revision or Hip Revision Surgery.|Completed|||20|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-06-01 01:34:04.351062|2018-06-01 01:34:04.351062
NCT00792584|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2011-09-09|2008-11-17|2008-11-18|Estimate|||||||2011-09-09|2011-09-12|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|SWITCH-EE||Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz|Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz|Completed||N/A|50|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-06-01 01:34:04.416093|2018-06-01 01:34:04.416093
NCT00792571|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14||2014-02-11|2014-05-19|2008-11-17|2008-11-18|Estimate||||2014-02-11|2014-03-13|Estimate|2014-05-19|2014-05-29|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients|An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients.|Completed||Phase 2|18|Actual|Lung Biotechnology PBC||2|||f||||f||||||||||2018-06-01 01:34:04.490246|2018-06-01 01:34:04.490246
NCT00792558|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2015-08-31|2008-11-17|2008-11-18|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers|A Phase I Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced or Metastatic Solid Tumors|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 01:34:04.624251|2018-06-01 01:34:04.624251
NCT00792532|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2016-05-18|2008-11-17|2008-11-18|Estimate|||||||2016-05-18|2016-05-20|Estimate|July 2003||2003-07-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|iMRI||Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes|Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes|Recruiting||Phase 4|100|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:34:04.698082|2018-06-01 01:34:04.698082
NCT00792519|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2011-06-20|2008-11-17|2008-11-18|Estimate|||||||2011-06-20|2011-06-22|Estimate|February 2009||2009-02-28|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|KHBS||Cognitive Behavioral Treatment to Reduce Alcohol Use Among HIV-Infected Kenyans|Alcohol & HIV in Kenya: Stage 1 Trial of a Peer-Led Alcohol Behavior Intervention|Completed||Phase 1|75|Actual|Brown University||2|||f||||t||||||||||2018-06-01 01:34:04.776593|2018-06-01 01:34:04.776593
NCT00792506|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-05-23|2008-11-17|2008-11-18|Estimate|||||||2013-05-23|2013-05-24|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|||Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma|Phase II High Pulse Dose Clinical Trial of Orally Administered ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 2|1|Actual|Italfarmaco||1|||f||||||||||||||2018-06-01 01:34:04.879909|2018-06-01 01:34:04.879909
NCT00792493|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2009-09-23|2008-11-17|2008-11-18|Estimate|||||||2009-09-23|2009-09-24|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741|Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Multiple Ascending Doses of ORM-12741|Completed||Phase 1|51|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-06-01 01:34:04.991826|2018-06-01 01:34:04.991826
NCT00792480|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2008-11-17|2008-11-17|2008-11-18|Estimate|||||||2008-11-17|2008-11-18|Estimate|October 2005||2005-10-31|November 2008|2008-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|WIP||Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial|Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial|Terminated||N/A|100|Actual|Carolinas Medical Center||2||Resident research project limited by restrictions of residency program.|f||||t||||||||||2018-06-01 01:34:05.056536|2018-06-01 01:34:05.056536
NCT00792467|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2012-01-31|2008-11-17|2008-11-18|Estimate|||||||2012-01-31|2012-02-02|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients|Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients|Completed||Phase 1/Phase 2|24|Actual|Italfarmaco||1|||f||||t||||||||||2018-06-01 01:34:05.256389|2018-06-01 01:34:05.256389
NCT00792454|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2017-05-25|2008-11-17|2008-11-18|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2008||2008-10-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program||Completed||N/A|116|Actual|Maine Medical Center||2|||f||||f||||||||||2018-06-01 01:34:05.33427|2018-06-01 01:34:05.33427
NCT00792441|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2015-04-01|2008-11-17|2008-11-18|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2009|Actual|2009-12-31||Interventional|SIMT||Specific Inspiratory Muscle Training (SIMT)in the Patients With Ventilatory Dependence|Effect of Specific Inspiratory Inspiratory Training(SIMT)in the Patients With Ventilatory Dependence on Lung Function and Weaning Outcomes|Unknown status|Active, not recruiting|N/A|20|Anticipated|Khon Kaen University||1|||f||||t||||||||||2018-06-01 01:34:05.394261|2018-06-01 01:34:05.394261
NCT00792428|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|2017-04-14||2017-06-10|2008-11-17|2008-11-18|Estimate|2017-06-10|2017-07-11|Actual||||2017-06-10|2017-07-11|Actual|June 2006||2006-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|February 2013|Actual|2013-02-28||Interventional|TDCS+OT||Non-invasive Brain Stimulation and Occupational Therapy To Enhance Stroke Recovery|Facilitating Motor Recovery After Stroke Using tDCS|Active, not recruiting||N/A|20|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-06-01 01:34:05.483984|2018-06-01 01:34:05.483984
NCT00792415|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2010-04-23|2008-11-17|2008-11-18|Estimate|||||||2010-04-23|2010-04-26|Estimate|November 2009||2009-11-30|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|April 2010|Anticipated|2010-04-30||Observational|||Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool|Validation of a Pediatric Abstinence Syndrome Scoring Tool Utilizing a Standardized Hospital-Based Guideline for Iatrogenic Opioid Dependence|Unknown status|Recruiting||75|Anticipated|Banner Health|||2||f||||f||||||||||2018-06-01 01:34:05.77628|2018-06-01 01:34:05.77628
NCT00792402|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-17|||2011-11-22|2008-11-17|2008-11-18|Estimate|||||||2011-11-22|2011-11-23|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Computerized Guideline in Heart Failure: Implementation Process and Impact Evaluation|Implementation Process and Impact of the Heart Failure Electronic Clinical Guideline in the Catalan Health Institute Primary Care Health Board|Completed|||13008|Actual|Jordi Gol i Gurina Foundation|||2||f||||t||||||||||2018-06-01 01:34:05.849041|2018-06-01 01:34:05.849041
NCT00792389|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2008-11-14|2008-11-14|2008-11-17|Estimate|||||||2008-11-14|2008-11-17|Estimate|January 2009||2009-01-31|November 2008|2008-11-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Study of the Use of Humidified Warmed Gas and the Effect on Post-Operative Pain in Laparoscopic Cholecystectomies|Randomised Controlled Trail of Warmed Humidified Insufflation Versus Cold Non-Humidified Insufflation in Elective Laparoscopic Cholecystectomies: Does This Reduce Post-Operative Pain?|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Pennine Acute Hospitals NHS Trust||2|||f||||f||||||||||2018-06-01 01:34:05.938152|2018-06-01 01:34:05.938152
NCT00792376|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-08-02|2008-11-14|2008-11-17|Estimate|||||||2013-08-02|2013-08-06|Estimate|August 2009||2009-08-31|August 2013|2013-08-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"|"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"|Completed||Phase 4|56|Actual|Argentine Tennis Association||2|||f||||f||||||||||2018-06-01 01:34:06.029624|2018-06-01 01:34:06.029624
NCT00792363|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2012-06-12|2008-11-14|2008-11-17|Estimate|||||||2012-06-12|2012-06-13|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations|A Phase II Study of Irinotecan and Panitumumab as 3rd Line Treatment of Patients With Metastatic Colorectal Cancer Without KRAS Mutations|Completed||Phase 2|32|Actual|Vejle Hospital|||||f||||t||||||||||2018-06-01 01:34:06.177555|2018-06-01 01:34:06.177555
NCT00792350|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2014-05-13|2008-11-14|2008-11-17|Estimate|||||||2014-05-13|2014-05-14|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Observational|INSIGHT||INSIGHT - Post Marketing Surveillance|International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)|Completed|||791|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 01:34:06.252483|2018-06-01 01:34:06.252483
NCT00792337|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-09-10|2008-11-14|2008-11-17|Estimate|||||||2013-09-10|2013-09-11|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma|The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma|Completed||Phase 3|53|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 01:34:06.350297|2018-06-01 01:34:06.350297
NCT00792324|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2009-11-17|2008-11-14|2008-11-17|Estimate|||||||2009-11-17|2009-11-18|Estimate|June 2008||2008-06-30|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125|A Phase III, Double Blind, Mulit-centre, Randomised Placebo Controlled, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirez With Continuing Central Nervous System (CNS) Toxicity to TMC125.|Completed||Phase 3|24|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-06-01 01:34:06.557619|2018-06-01 01:34:06.557619
NCT00792311|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2010-03-25|2008-11-13|2008-11-17|Estimate|||||||2010-03-25|2010-03-26|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Tsui Test as a Predictor of Bupivacaine Consumption in Labour Epidurals|Tsui Test as a Predictor of Bupivacaine Consumption in Labour Epidurals|Completed||N/A|102|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||1|||f||||f||||||||||2018-06-01 01:34:06.644024|2018-06-01 01:34:06.644024
NCT00792298|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2014-08-19||2017-06-01|2008-11-14|2008-11-17|Estimate|2014-11-12|2014-11-14|Estimate||||2017-06-01|2017-07-02|Actual|November 5, 2008|Actual|2008-11-05|June 2017|2017-06-30|December 26, 2009|Actual|2009-12-26|December 26, 2009|Actual|2009-12-26||Interventional|||Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)|A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK-4305 in Patients With Primary Insomnia|Completed||Phase 2|254|Actual|Merck Sharp & Dohme Corp.||8|||f||||||||||||||2018-06-01 01:34:06.764992|2018-06-01 01:34:06.764992
NCT00792285|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-13|2008-11-13|2008-11-17|Estimate|||||||2008-11-13|2008-11-17|Estimate|March 2005||2005-03-31|November 2008|2008-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||RCT of Automated Telephone Outreach to Improve Colorectal Cancer Screening|Automated Telephone Outreach With Speech Recognition to Improve Colorectal Cancer Screening: A Randomized Controlled Trial|Completed||N/A|80000|Actual|Harvard Pilgrim Health Care||2|||f||||f||||||||||2018-06-01 01:34:07.835158|2018-06-01 01:34:07.835158
NCT00792272|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-07-19|2008-11-14|2008-11-17|Estimate|||||||2013-07-19|2013-07-22|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients|Prevalence of Aspirin Resistance in Hemodialysis Patients|Completed|||100|Actual|Northwell Health|||||f||||t||||||||||2018-06-01 01:34:08.145461|2018-06-01 01:34:08.145461
NCT00792259|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2013-12-12||2015-06-15|2008-11-14|2008-11-17|Estimate|2015-06-15|2015-06-17|Estimate||||2015-06-15|2015-06-17|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational||20 Normal Subjects 15 Retinal Disease subjects 13 Glaucoma Subjects|Topcon 3D OCT-1000 Optical Coherence Tomography System|Topcon 3D OCT-1000 Optical Coherence Tomography System for Measurements of Retinal and RNFL Thicknesses: Precision and Agreement Study|Completed|||48|Actual|Topcon Medical Systems, Inc.|||3||f||||f||||||||||2018-06-01 01:34:08.271692|2018-06-01 01:34:08.271692
NCT00792246|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2012-11-09|2008-11-13|2008-11-17|Estimate|||||||2012-11-09|2012-11-12|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease|Define the Pharmacokinetics of Oral Voriconazole in Children With Extensive Gastrointestinal Graft Versus Host Disease|Completed||Phase 1|5|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:34:08.735975|2018-06-01 01:34:08.735975
NCT00792233|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2016-04-13|2008-11-14|2008-11-17|Estimate|||||||2016-04-13|2016-04-15|Estimate|June 2009||2009-06-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2013|Actual|2013-10-31||Interventional|||Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA|Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA|Completed||Phase 4|137|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||Yes|deidentified subject information and results of testing have already been shared with multiple investigators requesting samples|2018-06-01 01:34:08.859198|2018-06-01 01:34:08.859198
NCT00792220|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2015-05-31|2008-11-14|2008-11-17|Estimate|||||||2015-05-31|2015-06-02|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|MSU||"Mobile Stroke-Unit for Reduction of the Response Time in Ischemic Stroke"|"Mobile Stroke-Unit for Reduction of the Response Time in Ischemic Stroke"|Completed||N/A|200|Anticipated|University Hospital, Saarland||2|||f||||t||||||||||2018-06-01 01:34:08.954778|2018-06-01 01:34:08.954778
NCT00792207|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2009-12-02|2008-11-14|2008-11-17|Estimate|||||||2009-12-02|2009-12-04|Estimate|June 2008||2008-06-30|December 2009|2009-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|StepUp||The Role of a Virtual Coach in Improving Adherence to an Activity Program for Overweight Adults|The Role of a Virtual Coach in Improving Adherence to an Activity Program for Overweight Adults|Completed||N/A|70|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:34:09.023182|2018-06-01 01:34:09.023182
NCT00792194|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2015-09-29|2008-11-14|2008-11-17|Estimate|||||||2015-09-29|2015-09-30|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Improvement of Aerobic Capacity in Cystic Fibrosis Patients With a One-year Home Training Period|Improvement of Aerobic Capacity in Cystic Fibrosis Patients With a One-year Home Training Period|Completed||N/A|50|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 01:34:09.097933|2018-06-01 01:34:09.097933
NCT00792181|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2008-11-14|2008-11-14|2008-11-17|Estimate|||||||2008-11-14|2008-11-17|Estimate|June 2008||2008-06-30|November 2008|2008-11-30||||November 2008|Actual|2008-11-30||Interventional|||To Relieve Pain and Anxiety - an Intervention Study in Ambulance Services|Intervention Study to Relieve Pain and Anxiety in Acute Myocardial Disease Focusing on Treatment With Benzodiazepines(Midazolam)and the Importance of a Caring Relation.|Completed||Phase 1|2800|Anticipated|Sahlgrenska University Hospital, Sweden||4|||f||||t||||||||||2018-06-01 01:34:09.163582|2018-06-01 01:34:09.163582
NCT00792168|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2008-11-14|2008-11-14|2008-11-17|Estimate|||||||2008-11-14|2008-11-17|Estimate|November 1996||1996-11-30|November 2008|2008-11-30|December 1998|Actual|1998-12-31|||||Interventional|||Physiologic Monitoring of Antidepressant Treatment Response|Physiologic Monitoring of Antidepressant Treatment Response|Completed||Phase 4|38|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:34:09.227066|2018-06-01 01:34:09.227066
NCT00792155|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2018-04-09|2008-11-14|2008-11-17|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2002||2002-11-30|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Polycystic Kidney Disease Data Repository|Autosomal Dominant Polycystic Kidney Disease Data Repository|Recruiting|||500|Anticipated|The Rogosin Institute|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:34:09.355921|2018-06-01 01:34:09.355921
NCT00792142|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2018-02-09|2008-11-14|2008-11-17|Estimate|||||||2018-02-09|2018-02-12|Actual|January 16, 2008||2008-01-16|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma|A Phase II Study of Maintenance Treatment With Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Multiple Myeloma|Active, not recruiting||Phase 2|45|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:34:09.464766|2018-06-01 01:34:09.464766
NCT00792129|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2012-02-14|2008-11-14|2008-11-17|Estimate|||||||2012-02-14|2012-02-16|Estimate|April 2004||2004-04-30|February 2012|2012-02-29|June 2009|Actual|2009-06-30|March 2006|Actual|2006-03-31||Observational|||MIS MiLIF Versus Open|A Multi-Center Study to Evaluate MiLIF(R) Versus Open Posterior Unilateral Lumbar Interbody Fusion (TLIF)|Completed|||113|Actual|Zimmer Biomet|||2||f||||f||||||||||2018-06-01 01:34:09.639018|2018-06-01 01:34:09.639018
NCT00792116|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2008-10-24||2008-11-18|2008-11-14|2008-11-17|Estimate|2008-11-14|2008-11-17|Estimate||||2008-11-18|2008-11-20|Estimate|February 2008||2008-02-29|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of Gum Chewing on Math Scores in Adolescents|The Effects of Gum Chewing on Standardized Math Scores in Adolescents|Completed||N/A|108|Actual|Baylor College of Medicine||2|||f||||||||||||||2018-06-01 01:34:09.86262|2018-06-01 01:34:09.86262
NCT00791947|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2011-09-07|2008-11-14|2008-11-17|Estimate|||||||2011-09-07|2011-09-08|Estimate|October 2001||2001-10-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2008|Actual|2008-08-31||Interventional|||A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT|A Nordic Phase II Study of Peripheral T-cell Lymphomas Based on Dose-intensive Induction and High-dose Consolidation With Autologous Stem Cell Rescue|Completed||Phase 2|166|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 01:34:13.321365|2018-06-01 01:34:13.321365
NCT00792103|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2013-02-15|2012-11-07|2016-02-02|2008-11-14|2008-11-17|Estimate|2013-03-26|2013-05-07|Estimate|2013-02-06|2013-02-07|Estimate|2016-02-02|2016-02-04|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|NP101-008|Per protocol, the intent-to-treat (ITT) population was defined as all subjects who applied and activated at least one NP101 study patch and had at least one post baseline assessment for each migraine symptom (pain, photophobia, phonophobia, and nausea). Of the 183 subjects who applied at least one study patch, 181 subjects met the ITT criteria.|An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months|An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months|Completed||Phase 3|198|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 01:34:10.153464|2018-06-01 01:34:10.153464
NCT00792090|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2008-11-14|2008-11-14|2008-11-17|Estimate|||||||2008-11-14|2008-11-17|Estimate|November 2003||2003-11-30|November 2008|2008-11-30|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Prevention of Cow's Milk Allergy in Children|Use of Fermented Milk in Prevention of Cow's Milk Allergy in New Born and Infant|Completed||N/A|142|Actual|Bledina||2|||f||||t||||||||||2018-06-01 01:34:10.520296|2018-06-01 01:34:10.520296
NCT00792077|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2017-09-12|2008-11-13|2008-11-17|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2008|Actual|2008-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue|A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue|Active, not recruiting||N/A|12|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:34:10.639784|2018-06-01 01:34:10.639784
NCT00792064|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2009-08-24|2008-11-14|2008-11-17|Estimate|||||||2009-08-24|2009-08-25|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Observational|||Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation|Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation- a Prospective Cohort Study|Unknown status|Recruiting||700|Anticipated|Hannover Medical School|||4||f||||t||||||||||2018-06-01 01:34:10.731034|2018-06-01 01:34:10.731034
NCT00792051|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2014-12-29|2008-11-13|2008-11-17|Estimate|||||||2014-12-29|2014-12-30|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children|A Randomised Controlled Trial of the Effectiveness of Vaccinating Children to Reduce Household Transmission of Influenza|Completed||N/A|2800|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-06-01 01:34:10.867856|2018-06-01 01:34:10.867856
NCT00792038|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2012-08-01|2008-11-14|2008-11-17|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Effect of Cognitive Behavioral Therapy in OCD Highlighted by Neuropsychological Tests and MRI: Pathophysiology and Treatment Outcome Predictors|Effect of Cognitive Behavioral Therapy in OCD Highlighted by Neuropsychological Tests and MRI: Pathophysiology and Treatment Outcome Predictors|Completed|||88|Actual|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Full blood~   "|||2018-06-01 01:34:10.96433|2018-06-01 01:34:10.96433
NCT00792025|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2011-05-14|2008-11-14|2008-11-17|Estimate|||||||2011-05-14|2011-05-17|Estimate|December 2008||2008-12-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer|A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent®) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease|Completed||Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:34:11.932652|2018-06-01 01:34:11.932652
NCT00792012|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2017-03-23|2008-11-14|2008-11-17|Estimate|||||||2017-03-23|2017-03-27|Actual|November 2005|Actual|2005-11-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma|A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)|Completed||Phase 1|37|Actual|University of Colorado, Denver||1|||f||||t||||||||No||2018-06-01 01:34:12.026441|2018-06-01 01:34:12.026441
NCT00791999|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2012-06-18||2012-08-09|2008-11-14|2008-11-17|Estimate|2012-06-27|2012-08-06|Estimate||||2012-08-09|2012-08-10|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX.|Completed||Phase 2/Phase 3|316|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 01:34:12.147081|2018-06-01 01:34:12.147081
NCT00791986|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2018-03-05|2008-11-14|2008-11-17|Estimate|||||||2018-03-05|2018-03-07|Actual|May 2006||2006-05-31|March 2018|2018-03-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Loaded Breathing Training in Essential Hypertension|Effects of Loaded Breathing Training on Blood Pressure in Essential Hypertensive Patients|Terminated||N/A|30|Actual|Khon Kaen University||3||End of study time and budget permission|f||||t||||||||||2018-06-01 01:34:12.61497|2018-06-01 01:34:12.61497
NCT00791973|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2014-06-06||2014-06-06|2008-11-14|2008-11-17|Estimate|2014-06-06|2014-07-08|Estimate||||2014-06-06|2014-07-08|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|May 2010|Actual|2010-05-31|April 2009|Actual|2009-04-30||Interventional|||Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen|Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen|Completed||Phase 4|15|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:34:12.697305|2018-06-01 01:34:12.697305
NCT00791960|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2010-03-25|2008-11-13|2008-11-17|Estimate|||||||2010-03-25|2010-03-29|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting|Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting: A Randomized, Double Blind, Placebo-Controlled Trial|Completed||N/A|149|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 01:34:13.203724|2018-06-01 01:34:13.203724
NCT00791934|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2014-05-06||2014-07-18|2008-11-13|2008-11-17|Estimate|2014-06-10|2014-07-14|Estimate||||2014-07-18|2014-07-25|Estimate|August 2008||2008-08-31|July 2014|2014-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|DELIVER||Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide|Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide (Kenalog-40)|Completed||Phase 3|63|Actual|Acclarent||1|||f||||f||||||||||2018-06-01 01:34:13.405439|2018-06-01 01:34:13.405439
NCT00791921|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2012-06-18||2012-08-05|2008-11-14|2008-11-17|Estimate|2012-06-27|2012-08-06|Estimate||||2012-08-05|2012-08-07|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated.|Completed||Phase 3|230|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:34:13.760575|2018-06-01 01:34:13.760575
NCT00791908|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2010-08-30||2015-02-18|2008-11-14|2008-11-17|Estimate|2010-11-23|2010-12-21|Estimate||||2015-02-18|2015-03-06|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata|Comparison of Electrodessication, Potassium Titanyl Phosphate (KTP) Laser and Pulsed Dye Laser for Treatment of Cherry Angiomata|Completed||N/A|15|Actual|Northwestern University|Absence of a cost analysis; all the participants were white; only one set of parameters (ie, for lasers, pulse duration and fluence; and for electrodesiccation, energy level) was used for treatment with each modality.|3|||f||||f||||||||||2018-06-01 01:34:14.281873|2018-06-01 01:34:14.281873
NCT00791895|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2017-02-22|2008-11-14|2008-11-17|Estimate|||||||2017-02-22|2017-02-24|Actual|June 26, 2003|Actual|2003-06-26|February 2017|2017-02-28|November 29, 2004|Actual|2004-11-29|October 31, 2004|Actual|2004-10-31||Interventional|||Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs|NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy|Completed||Phase 4|102|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 01:34:14.604895|2018-06-01 01:34:14.604895
NCT00791882|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2009-11-27|2008-11-14|2008-11-17|Estimate|||||||2009-11-27|2009-11-30|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|SST||Social Skills Training in Refractory Schizophrenia|Evaluation of Social Skills Training in Reducing Negative Symptoms in Patients With Refractory Schizophrenia|Unknown status|Recruiting|N/A|92|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:34:14.775381|2018-06-01 01:34:14.775381
NCT00791869|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-05-20|2008-11-14|2008-11-17|Estimate|||||||2013-05-20|2013-05-22|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Observational|||Pharmacogenetics of Bupropion Metabolism|Pharmacogenetics of Bupropion Metabolism|Completed|||43|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:34:15.045559|2018-06-01 01:34:15.045559
NCT00791856|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-04-15|2008-11-14|2008-11-17|Estimate|||||||2013-04-15|2013-04-17|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch|An Open-label, Multiple-dose, Randomized, Two-period Crossover Study to Assess Bioequivalence of the 300 Mcg/Day Testosterone Reduced-size Patch (14 cm2) Relative to the 300 Mcg/Day Testosterone Reference Patch (28 cm2)|Completed||Phase 1|110|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 01:34:15.141055|2018-06-01 01:34:15.141055
NCT00791843|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2013-12-09|2008-11-14|2008-11-17|Estimate|||||||2013-12-09|2013-12-10|Estimate|March 2004||2004-03-31|December 2013|2013-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|GHRH||The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure|The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure|Completed||Phase 2|3|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 01:34:15.257033|2018-06-01 01:34:15.257033
NCT00791830|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2013-01-07|2008-11-14|2008-11-17|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|SAFIR||Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan|Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study|Completed||Phase 3|82|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 01:34:15.336869|2018-06-01 01:34:15.336869
NCT00791817|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2011-08-04||2011-08-04|2008-11-14|2008-11-17|Estimate|2011-08-04|2011-09-07|Estimate||||2011-08-04|2011-09-07|Estimate|August 2005||2005-08-31|August 2011|2011-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study to Evaluate Potential Food Effects|An Open-label, Single Dose, Randomized, Crossover Study to Evaluate Potential Food Effects|Completed||Phase 1|10|Actual|Procter and Gamble||2|||f||||f||||||||||2018-06-01 01:34:15.526437|2018-06-01 01:34:15.526437
NCT00791804|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-14|2008-11-14|2008-11-17|Estimate|||||||2008-11-14|2008-11-17|Estimate|February 2004||2004-02-29|November 2008|2008-11-30|December 2004|Actual|2004-12-31|June 2004|Actual|2004-06-30||Interventional|Pain||Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery|A Phase II Study Evaluating Inhaled AeroLEF(Liposome-Encapsulated Fentanyl 500mcg/mL)for Post-Operative Pain in Adults After ACL Knee Surgery.|Completed||Phase 2|19|Actual|YM BioSciences||1|||f||||f||||||||||2018-06-01 01:34:15.942077|2018-06-01 01:34:15.942077
NCT00791791|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|||2012-06-14|2008-11-14|2008-11-17|Estimate|||||||2012-06-14|2012-06-15|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of Surgical Stress Index (SSI) During Sevoflurane/Remifentanil Anesthesia||Completed||N/A|24|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-06-01 01:34:16.074292|2018-06-01 01:34:16.074292
NCT00791778|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2012-11-01||2015-08-26|2008-11-14|2008-11-17|Estimate|2012-11-01|2012-11-30|Estimate||||2015-08-26|2015-09-28|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|||Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer|A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy|Completed||Phase 2|246|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:34:16.217057|2018-06-01 01:34:16.217057
NCT00791440|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2012-12-12|2008-11-13|2008-11-14|Estimate|||||||2012-12-12|2012-12-13|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Recovery From Psychosis in Schizophrenia - The Impact of Cognitive-Behavioral Therapy|Psychosis in Schizophrenia: Mechanisms of Recovery|Completed||N/A|34|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 01:34:26.047295|2018-06-01 01:34:26.047295
NCT00791765|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-14|2010-09-03||2014-07-14|2008-11-14|2008-11-17|Estimate|2013-09-04|2013-11-07|Estimate||||2014-07-14|2014-07-23|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Moderate to Severe Plaque Psoriasis With Scalp Involvement|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 4|124|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:34:17.615245|2018-06-01 01:34:17.615245
NCT00791752|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2009-06-15|2008-11-13|2008-11-14|Estimate|||||||2009-06-15|2009-06-16|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|March 2009|Actual|2009-03-31|||||Interventional|||Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017|A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase 1Study in Healthy Volunteers to Assess the Safety, Tolerability andPharmacokinetics of AZD4017 After Single Ascending Oral Doses|Completed||Phase 1|40|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 01:34:18.35474|2018-06-01 01:34:18.35474
NCT00791739|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2014-12-01|2008-11-13|2008-11-14|Estimate|||||||2014-12-01|2014-12-03|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Trazodone and Its Augmentation With Pregabalin in the Treatment of Fibromyalgia|Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)|Completed||Phase 4|66|Actual|Universidad de Granada||1|||f||||f||||||||||2018-06-01 01:34:18.468032|2018-06-01 01:34:18.468032
NCT00791726|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-07-19|2008-11-13|2008-11-14|Estimate|||||||2011-07-19|2011-07-21|Estimate|November 2008||2008-11-30|March 2011|2011-03-31||||||||Observational|||Microperimetry in Macular Edema|Place of Fundus-related Microperimetry in Uveitic Macular Edema|Completed|||30|Anticipated|St. Franziskus Hospital|||1||f||||f||||||||||2018-06-01 01:34:18.543848|2018-06-01 01:34:18.543848
NCT00791713|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-05-18|2008-11-13|2008-11-14|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|July 2006|Actual|2006-07-31|||||Interventional|||A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER|A Randomized, Open-label, Single-center, Crossover Study of the Potential Effects of Paroxetine on the Pharmacokinetics of a Single Dose of Paliperidone Extended-release in Healthy Men|Completed||Phase 1|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:18.601838|2018-06-01 01:34:18.601838
NCT00791700|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2015-10-06||2018-03-12|2008-11-12|2008-11-14|Estimate|2016-01-28|2016-02-25|Estimate||||2018-03-12|2018-03-14|Actual|April 22, 2009|Actual|2009-04-22|March 2018|2018-03-31|November 29, 2018|Anticipated|2018-11-29|April 14, 2015|Actual|2015-04-14||Interventional||The Full Analysis Set (FAS) consisted of all participants who received at least 1 dose of study drug (same as analysis population set [APS] 4).|An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children|An Open-label, Multicenter, Multiple-dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-experienced Ccr5-tropic Hiv-1 Infected Children 2 - <18 Years Of Age|Active, not recruiting||Phase 2|103|Actual|ViiV Healthcare|"Although the Participant Flow Table title indicates Overall Study, the data presented in that table is Subject Discontinuations Through Week 48. The study is ongoing."|1|||f||||t|t|f||||||||2018-06-01 01:34:18.793313|2018-06-01 01:34:18.793313
NCT00791687|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-13|2008-11-13|2008-11-14|Estimate|||||||2008-11-13|2008-11-14|Estimate|January 2003||2003-01-31|November 2008|2008-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Observational|RESOX||Prenatal Corticosteroids and Antioxidants in Preterm Infants|Prenatal Corticosteroids Enhance the Antioxidant Defense System in Extremely Low Gestational Age Neonates|Completed|||57|Actual|Fundacion Para La Investigacion Hospital La Fe|||2||f||||f||||||||||2018-06-01 01:34:20.380589|2018-06-01 01:34:20.380589
NCT00791674|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-13|2008-11-13|2008-11-14|Estimate|||||||2008-11-13|2008-11-14|Estimate|December 2007||2007-12-31|November 2008|2008-11-30||||||||Observational|||Opiate Sleep Disordered Breathing Study|Sleep Disordered Breathing in Patients With Chronic Pain and Long Term Opiate Therapy|Unknown status|Recruiting||50|Anticipated|Adelaide Institute for Sleep Health|||||f||||f||||||||||2018-06-01 01:34:20.43385|2018-06-01 01:34:20.43385
NCT00791661|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2012-09-07||2016-01-06|2008-11-13|2008-11-14|Estimate|2012-09-07|2012-10-10|Estimate||||2016-01-06|2016-01-07|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)|A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-1006 in Japanese Subject With Type 2 Diabetes|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:34:20.53699|2018-06-01 01:34:20.53699
NCT00791648|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2016-11-11||2017-10-18|2008-11-13|2008-11-14|Estimate|2017-01-11|2017-03-06|Actual||||2017-10-18|2017-11-21|Actual|July 2009||2009-07-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery|Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery|Completed||N/A|653|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||Undecided||2018-06-01 01:34:21.486279|2018-06-01 01:34:21.486279
NCT00791635|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2018-02-28|2008-11-13|2008-11-14|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2008|Actual|2008-09-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy|Longitudinal Evaluation of Women Undergoing Pelvic Exenteration for Treatment of Gynecologic Malignancy|Recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 01:34:21.909472|2018-06-01 01:34:21.909472
NCT00791622|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-05-17|2008-11-13|2008-11-14|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|June 2006|Actual|2006-06-30|||||Interventional|||A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating QT/QTc Intervals Following Administration of Extended-release Paliperidone and Quetiapine in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|110|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:22.017877|2018-06-01 01:34:22.017877
NCT00791609|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-13|2008-11-13|2008-11-14|Estimate|||||||2008-11-13|2008-11-14|Estimate|March 2008||2008-03-31|November 2008|2008-11-30||||||||Observational|||Evaluation the Feasibility of the FOSTI Device|Evaluation the Feasibility of the FOSTI Device Accurately and in a Real Time Way to Differentiate Malignant From Benign Tissue (Performed ex Vivo) in Cancer Surgery|Unknown status|Active, not recruiting||50|Actual|Optivasive Ltd.|||||f||||f||||||||||2018-06-01 01:34:22.074487|2018-06-01 01:34:22.074487
NCT00791596|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-13|2008-11-13|2008-11-14|Estimate|||||||2008-11-13|2008-11-14|Estimate|January 2005||2005-01-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|June 2005|Actual|2005-06-30||Interventional|||Effectiveness of Ergonomic Intervention|Effectiveness of an Ergonomic Intervention on Work-Related Posture and Low Back Pain in Video Display Terminal Operators: a 3 Year Cross-Over Trial|Completed||Phase 4|200|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 01:34:22.11884|2018-06-01 01:34:22.11884
NCT00791583|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2012-08-22|2008-11-13|2008-11-14|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|November 2008|Actual|2008-11-30||Observational|EM CVC MBP||ED Residents MBP During CVC Placement: Sim Lab Based Training|Emergency Medicine Residents Performance in Maximum Barrier Precautions During Central Venous Catheter Placement: Effect of Stimulation-based Training|Completed|||76|Actual|St. Luke's-Roosevelt Hospital Center|||||f||||f||||||||||2018-06-01 01:34:22.218679|2018-06-01 01:34:22.218679
NCT00791570|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2012-10-14|2008-11-13|2008-11-14|Estimate|||||||2012-10-14|2012-10-16|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy|Histocompatibility Leukocyte Antigen (HLA)-A*2402 and A*0201 Restricted Peptide Vaccine Therapy in Patients With Neovascular Maculopathy|Completed||Phase 1|17|Actual|Osaka University||1|||f||||t||||||||||2018-06-01 01:34:22.280195|2018-06-01 01:34:22.280195
NCT00791557|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2013-09-03||2016-09-27|2008-11-13|2008-11-14|Estimate|2013-09-03|2013-11-15|Estimate||||2016-09-27|2016-11-02|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease|An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum|Completed||N/A|2|Actual|University Hospitals Cleveland Medical Center|Due to timing of the study, only 2 subjects were enrolled.|1|||f||||f||||||||||2018-06-01 01:34:22.351347|2018-06-01 01:34:22.351347
NCT00791544|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2010-08-03|2008-11-13|2008-11-14|Estimate|||||||2010-08-03|2010-08-04|Estimate|November 2008||2008-11-30|August 2010|2010-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma|Dose-finding, Safety, Pharmacokinetic and Pharmacodynamic Study of AVE1642, an Anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination With Other Anti Cancer Therapies (Sorafenib or Erlotinib) in Patients With Advanced Liver Carcinoma|Terminated||Phase 1/Phase 2|13|Actual|Sanofi||8||"Company decision to discontinue the AVE1642 development program, not due to any safety or~   efficacy concerns"|f||||t||||||||||2018-06-01 01:34:22.513091|2018-06-01 01:34:22.513091
NCT00791531|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2012-04-23|2008-11-13|2008-11-14|Estimate|||||||2012-04-23|2012-04-24|Estimate|March 2009||2009-03-31|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers|Phase 1 Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers|Completed||Phase 1|25|Actual|KEMRI-Wellcome Trust Collaborative Research Program||1|||f||||f||||||||||2018-06-01 01:34:22.602|2018-06-01 01:34:22.602
NCT00791518|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2010-03-25||2014-07-24|2008-11-13|2008-11-14|Estimate|2010-03-25|2010-04-22|Estimate||||2014-07-24|2014-07-30|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|LABD||Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy|An Evaluation of Lung Function and Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy|Completed|||1084|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 01:34:22.780127|2018-06-01 01:34:22.780127
NCT00791505|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-13|2008-11-13|2008-11-14|Estimate|||||||2008-11-13|2008-11-14|Estimate|July 2002||2002-07-31|November 2008|2008-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Trimethoprim-Sulfamethoxazole Versus Ciprofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Requiring Mechanical Ventilation|Antibiotic Comparison Exacerbation COPD|Completed||Phase 3|170|Actual|University of Monastir||2|||f||||f||||||||||2018-06-01 01:34:23.338129|2018-06-01 01:34:23.338129
NCT00791492|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2012-11-16|2011-02-08|2012-11-16|2008-11-13|2008-11-14|Estimate|2012-11-16|2012-12-17|Estimate|2011-02-11|2011-02-15|Estimate|2012-11-16|2012-12-17|Estimate|July 2008||2008-07-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|August 2008|Actual|2008-08-31||Interventional|||An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy|An Open-Label Extension Of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy|Completed||Phase 2/Phase 3|86|Actual|Pfizer|Instead of intended endpoint 'heat pain and cooling threshold', results of 'summated 3 score for small nerve fiber function' were reported. Designation of outcomes as primary and secondary was based on study team input as study did not specify this.|1|||f||||f||||||||||2018-06-01 01:34:23.428185|2018-06-01 01:34:23.428185
NCT00791479|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2014-10-03|2010-10-25|2014-12-08|2008-11-12|2008-11-14|Estimate|2014-12-08|2014-12-10|Estimate|2010-10-25|2010-10-27|Estimate|2014-12-08|2014-12-10|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Participants who received at least one dose of study drug.|Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes|Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions|Completed||Phase 2|167|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 01:34:24.094001|2018-06-01 01:34:24.094001
NCT00791466|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2016-11-16|2008-11-13|2008-11-14|Estimate|||||||2016-11-16|2016-11-17|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2012|Actual|2012-05-31||Interventional|MITCH||Maternal Iodine Supplementation and Effects on Thyroid Function and Child Development|Iodine Supplementation in Pregnant Women Living in Mild-to-moderately Iodine Deficient Areas in India and Thailand: Effects on Pregnancy Outcome and Infant Development|Completed||N/A|829|Actual|Wageningen University||2|||f||||t||||||||||2018-06-01 01:34:25.839053|2018-06-01 01:34:25.839053
NCT00791453|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2009-05-11|2008-11-12|2008-11-14|Estimate|||||||2009-05-11|2009-05-12|Estimate|April 2008||2008-04-30|May 2009|2009-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|CHEC||Clarksdale Diabetes and Metabolism Clinic CHEC Study|Clarksdale Diabetes and Metabolism Clinic Consumer Health Education Center Study|Completed|||55|Actual|University of Mississippi Medical Center|||1||f||||t||||||Samples Without DNA|"~     No biospecimens are retained~   "|||2018-06-01 01:34:25.913026|2018-06-01 01:34:25.913026
NCT00791401|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-06-09|2008-11-13|2008-11-14|Estimate|||||||2011-06-09|2011-06-13|Estimate|April 2004||2004-04-30|March 2010|2010-03-31|February 2005|Actual|2005-02-28|||||Interventional|||A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function|The Pharmacokinetics of ER OROS Paliperidone in Subjects With Varying Degrees of Impaired Renal Function (Mild, Moderate, and Severe) as Compared to Subjects With Normal Renal Function|Completed||Phase 1|47|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:26.399989|2018-06-01 01:34:26.399989
NCT00791388|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2011-08-03||2011-09-27|2008-11-13|2008-11-14|Estimate|2011-09-27|2011-11-04|Estimate||||2011-09-27|2011-11-04|Estimate|August 2005||2005-08-31|September 2011|2011-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Multiple Rising Oral Dose Study of PG 760564 Administered Twice Daily to Healthy Male/Female Volunteers for 14 Days|Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of PG 760564 Administered Twice Daily to Healthy Male and Female Volunteers for 14 Days (27 Doses).|Completed||Phase 1|45|Actual|Procter and Gamble||5|||f||||f||||||||||2018-06-01 01:34:26.483407|2018-06-01 01:34:26.483407
NCT00791375|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2012-04-19|2008-11-13|2008-11-14|Estimate|||||||2012-04-19|2012-04-20|Estimate|May 2009||2009-05-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Web-based Physical Activity Intervention for Young Adult Cancer Survivors|Web-based Physical Activity Intervention for Young Adult Cancer Survivors|Completed||N/A|18|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-06-01 01:34:27.151914|2018-06-01 01:34:27.151914
NCT00791362|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2013-07-08|2008-11-13|2008-11-14|Estimate|||||||2013-07-08|2013-07-09|Estimate|December 2008||2008-12-31|May 2012|2012-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Evaluation Research of a National Accreditation and Improvement Programme for General Practice|Effects and Costs of a National Continuous Improvement Programme on Cardiovascular Diseases in Primary Care|Completed||N/A|1685|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:34:27.261377|2018-06-01 01:34:27.261377
NCT00791349|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-06-06|2008-11-13|2008-11-14|Estimate|||||||2011-06-06|2011-06-08|Estimate|February 2005||2005-02-28|March 2010|2010-03-31|May 2005|Actual|2005-05-31|||||Interventional|||A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone|A Placebo- and Positive-controlled, Randomized Study Evaluating QT and QTc Intervals Following Administration of Immediate-release Paliperidone in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|141|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:27.34058|2018-06-01 01:34:27.34058
NCT00791336|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2017-03-09||2017-06-29|2008-11-13|2008-11-14|Estimate|2017-06-29|2017-07-28|Actual||||2017-06-29|2017-07-28|Actual|August 2008||2008-08-31|June 2017|2017-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer|A Phase II Trial of the HIV Protease Inhibitor Nelfinavir and Concurrent Radiation and Chemotherapy in Patients With Stage III Non Small Cell Lung Cancer|Terminated||Phase 2|1|Actual|University of Iowa|There was only one treated participant. Conclusions cannot be drawn from these data due to limited sampling size.|1||Poor enrollment.|f||||t|t|f|||f|||No|Terminated due to poor enrollment; lack of data to share.|2018-06-01 01:34:27.419567|2018-06-01 01:34:27.419567
NCT00791323|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2011-08-17||2011-09-21|2008-11-12|2008-11-14|Estimate|2011-09-21|2011-09-23|Estimate||||2011-09-21|2011-09-23|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy of Ketorolac 0.4% in Prostaglandin Suppression||Completed||Phase 4|9|Actual|Allergan||2|||f||||f||||||||||2018-06-01 01:34:27.615645|2018-06-01 01:34:27.615645
NCT00791310|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2010-12-30|2008-11-13|2008-11-14|Estimate|||||||2010-12-30|2010-12-31|Estimate|November 2008||2008-11-30|December 2010|2010-12-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology|Phase 3b,Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology|Unknown status|Recruiting|Phase 3|30|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-06-01 01:34:27.833839|2018-06-01 01:34:27.833839
NCT00791297|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2017-08-11|2008-11-13|2008-11-14|Estimate|||||||2017-08-11|2017-08-15|Actual|October 2008||2008-10-31|August 2017|2017-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914|A Phase 2, Randomized Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914 on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women|Completed||Phase 2|55|Actual|Population Council||2|||f||||f||||||||||2018-06-01 01:34:27.932694|2018-06-01 01:34:27.932694
NCT00791284|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-06-06|2008-11-13|2008-11-14|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2004||2004-08-31|March 2010|2010-03-31|December 2004|Actual|2004-12-31|||||Interventional|||A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function|Pharmacokinetics of Paliperidone in Subjects With Moderate Hepatic Impairment as Compared to Subjects With Normal Hepatic Function.|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:28.037409|2018-06-01 01:34:28.037409
NCT00791271|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2015-11-12|2008-11-12|2008-11-14|Estimate|||||||2015-11-12|2015-11-16|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion|A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma|Completed||Phase 1|17|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 01:34:28.115376|2018-06-01 01:34:28.115376
NCT00791258|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2010-09-02||2010-09-30|2008-11-13|2008-11-14|Estimate|2010-09-02|2010-09-29|Estimate||||2010-09-30|2010-10-05|Estimate|November 2008||2008-11-30|September 2010|2010-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|BP CRUSH||A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure|A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy|Completed||Phase 4|999|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 01:34:28.413601|2018-06-01 01:34:28.413601
NCT00791245|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2014-08-07|2008-11-13|2008-11-14|Estimate|||||||2014-08-07|2014-08-11|Estimate|January 2006||2006-01-31|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Post Market Study of DeNovo NT, Natural Tissue Graft|A Post Market Study of Articular Cartilage Defects of the Knee Treated Wtih DeNovo NT, Natural Tissue Graft|Completed|||25|Actual|Zimmer Orthobiologics, Inc.|||1||f||||||||||||||2018-06-01 01:34:31.309753|2018-06-01 01:34:31.309753
NCT00791232|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-06-06|2008-11-13|2008-11-14|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2003||2003-03-31|March 2010|2010-03-31|June 2003|Actual|2003-06-30|||||Interventional|||A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Phase 1 Study to Compare the Tolerability of OROS Paliperidone (Extended Release) With Immediate-release (IR) Risperidone in Subjects With Schizophrenia|Completed||Phase 1|113|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:32.205606|2018-06-01 01:34:32.205606
NCT00791219|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12||2012-03-22|2012-03-22|2008-11-12|2008-11-14|Estimate||||2012-03-22|2012-03-29|Estimate|2012-03-22|2012-03-29|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis|A Randomized, Double Blind, Multiple-site, Placebo-Controlled Study, Comparing the Efficacy and Safety of SUBA™-Itraconazole Capsules Compared to SPORANOX® (Itraconazole) Capsules in the Treatment of Onychomycosis of the Toenail|Completed||Phase 2|175|Actual|Halcygen Pharmaceuticals Limited||3|||f||||f||||||||||2018-06-01 01:34:32.27438|2018-06-01 01:34:32.27438
NCT00791206|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2013-12-13|2008-11-13|2008-11-14|Estimate|||||||2013-12-13|2013-12-16|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Trial of the Effects of Remote Preconditioning on the Tissue Metabolism During Exercise and Ischemia|Single Blind Randomized Controlled Crossover Trial of the Effects of Remote Preconditioning on the Tissue Metabolism During Exercise and Ischemia|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 01:34:32.362653|2018-06-01 01:34:32.362653
NCT00791193|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-05-17|2008-11-13|2008-11-14|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2007||2007-03-31|April 2010|2010-04-30|May 2007|Actual|2007-05-31|||||Interventional|||A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR|Pharmacokinetic Evaluation of the Relative Bioavailability of Three Paliperidone Extended Release (ER) Formulations With Different in Vitro Release Profiles, and Comparison to Paliperidone Immediate Release (IR), in Healthy Male Subjects|Completed||Phase 1|80|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:32.427807|2018-06-01 01:34:32.427807
NCT00791180|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-09-28|2008-11-13|2008-11-14|Estimate|||||||2011-09-28|2011-09-29|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Posterior Lateral Fusion (PLF) With Dynesys|Clinical Outcomes Following Posterior Lateral Fusion With the Dynesys(R) Spinal System|Completed|||38|Actual|Zimmer Biomet|||||f||||f||||||||||2018-06-01 01:34:32.488742|2018-06-01 01:34:32.488742
NCT00791167|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-05-17|2008-11-13|2008-11-14|Estimate|||||||2011-05-17|2011-05-18|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|August 2006|Actual|2006-08-31|||||Interventional|||A Study of the Dose Proportionality of Extended Release Paliperidone|Evaluation of the Dose Proportionality of Two Dose Strengths (1.5 and 3 mg) of Extended-release Paliperidone After a Single Administration to Healthy Men|Completed||Phase 1|58|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:32.550524|2018-06-01 01:34:32.550524
NCT00791154|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23||2015-02-02|2016-10-26|2008-11-13|2008-11-14|Estimate||||2015-02-02|2015-02-19|Estimate|2016-10-26|2016-10-27|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|February 2013|Actual|2013-02-28|June 2012|Actual|2012-06-30||Interventional|||QUILT-2.013: A Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer|Amgen Protocol 20060534 - A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer|Completed||Phase 1/Phase 2|204|Actual|NantCell, Inc.||3|||f||||||||||||||2018-06-01 01:34:32.612489|2018-06-01 01:34:32.612489
NCT00791141|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2014-01-22|2008-11-13|2008-11-14|Estimate|||||||2014-01-22|2014-01-23|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|ACCRA-HN||Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer|Multicenter, Open-label Phase II Trial on Post-surgery Chemoradiation in Combination With Cetuximab in Squamous Cell Carcinoma of the Head and Neck With High Risk of Locoregional Recurrence.|Completed||Phase 2|80|Actual|Heinrich-Heine University, Duesseldorf||1|||f||||t||||||||||2018-06-01 01:34:32.806374|2018-06-01 01:34:32.806374
NCT00791128|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2016-11-01||2017-04-12|2008-11-13|2008-11-14|Estimate|2016-11-01|2016-12-28|Estimate||||2017-04-12|2017-06-01|Actual|October 2008||2008-10-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Study for Pre-Surgical Weight Loss in Type II Diabetes Patients|A Phase II Single-Center, Prospective, Open Label Study of Safety and Efficacy, of the GI Sleeve for Pre-Surgical Weight Loss, in Type II Diabetes Patients (Cohort 06-6B Only)|Completed||Phase 2|22|Actual|GI Dynamics||1|||f||||f||||||||Undecided||2018-06-01 01:34:32.933282|2018-06-01 01:34:32.933282
NCT00791115|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2017-09-21|2008-11-13|2008-11-14|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2008||2008-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Salvage Prostatectomy After Radiotherapy|Salvage Prostatectomy After Radiotherapy: Whole-Mount Histopathological Validation for Tumor-Targeted Salvage HDR Brachytherapy|Active, not recruiting||N/A|16|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:34:33.171767|2018-06-01 01:34:33.171767
NCT00791102|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2013-03-06||2013-07-08|2008-11-13|2008-11-14|Estimate|2013-07-08|2013-07-10|Estimate||||2013-07-08|2013-07-10|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC)|Completed||Phase 2/Phase 3|20|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:34:33.266932|2018-06-01 01:34:33.266932
NCT00791089|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2017-03-24||2017-08-10|2008-11-13|2008-11-14|Estimate|2017-03-24|2017-05-05|Actual||||2017-08-10|2017-09-12|Actual|November 2008||2008-11-30|August 2017|2017-08-31|October 2011|Actual|2011-10-31|December 2009|Actual|2009-12-31||Interventional||Baseline analysis is provided for all persons who actually began their assignment.|Effects of Fish Oil on Post Ablation Arrhythmias|Effect of Omega-3 Fatty Acids on Short and Long-Term Maintenance of Sinus Rhythm After Radiofrequency Catheter Ablation for Atrial Fibrillation|Terminated||Phase 4|12|Actual|University of Michigan|The Study was terminated before subject enrollment completion, due to financial concerns and loss of major support from the 21-day cardiac monitoring device. So small sample size means data should be interpreted with great caution.|2||unable to secure funding and long term follow up|f||||t||||||||||2018-06-01 01:34:33.514104|2018-06-01 01:34:33.514104
NCT00791076|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2017-05-01||2017-06-29|2008-11-13|2008-11-14|Estimate|2017-06-29|2017-07-12|Actual||||2017-06-29|2017-07-12|Actual|October 2007|Actual|2007-10-31|June 2017|2017-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||This study was terminated prematurely when the PI left the institution. Although 8 participants were enrolled in this study, their assignment to Arm/Group is unknown, since no data are available.|The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients|The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 (Auto-immune) and Post-pancreatectomy Diabetic Patients|Terminated||Phase 2|8|Actual|Johns Hopkins University||2||PI left JHU|f||||f||||||||||2018-06-01 01:34:33.745363|2018-06-01 01:34:33.745363
NCT00791063|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2013-02-12|2008-11-13|2008-11-14|Estimate|||||||2013-02-12|2013-02-13|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||18F ML-10 for Early Detection of Response of Brain Metastases to WBRT|An Open-Label Study to Evaluate 18F ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Whole Brain Radiation Therapy (WBRT)|Completed||Phase 2|10|Actual|Aposense Ltd.||1|||f||||t||||||||||2018-06-01 01:34:33.888546|2018-06-01 01:34:33.888546
NCT00791050|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2008-11-13|2008-11-13|2008-11-14|Estimate|||||||2008-11-13|2008-11-14|Estimate|January 2009||2009-01-31|October 2008|2008-10-31|March 2010|Anticipated|2010-03-31|January 2010|Anticipated|2010-01-31||Interventional|||Examine the Effects of Maintaining Body Core Temperature During CABGs|To Examine the Effects on Patients Outcomes of Maintaining Body Core Temperature During CABGs With Thermowrap|Unknown status|Not yet recruiting|N/A|300|Anticipated|Centro Cardiologico Monzino||2|||f||||f||||||||||2018-06-01 01:34:33.958454|2018-06-01 01:34:33.958454
NCT00791037|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2016-10-13||2017-04-17|2008-11-13|2008-11-14|Estimate|2017-04-17|2017-05-25|Actual||||2017-04-17|2017-05-25|Actual|October 2008||2008-10-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Breast Cancer|Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming With a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine in Patients With Advanced Stage HER2 Overexpressing Breast Cancer|Completed||Phase 1/Phase 2|23|Actual|University of Washington|All Other Adverse Events are reported regardless of attribution.|1|||f||||f||||||||No|We will report study data but will not call out individual participants.|2018-06-01 01:34:34.208111|2018-06-01 01:34:34.208111
NCT00791024|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2015-08-25|2008-11-13|2008-11-14|Estimate|||||||2015-08-25|2015-08-26|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Development of a New Method for Analgesia|Phase One Study and Two of a New Method for Local Analgesia|Completed||Phase 1/Phase 2|126|Actual|Hvidovre University Hospital||1|||f||||t||||||||||2018-06-01 01:34:34.521419|2018-06-01 01:34:34.521419
NCT00791011|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2014-03-03|2008-11-13|2008-11-14|Estimate|||||||2014-03-03|2014-03-05|Estimate|February 2008||2008-02-29|March 2014|2014-03-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|||Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat|A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma|Completed||Phase 1|33|Actual|Amgen||7|||f||||||||||||||2018-06-01 01:34:34.633178|2018-06-01 01:34:34.633178
NCT00790998|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2018-01-29|2008-11-13|2008-11-14|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2009||2009-04-30|November 2013|2013-11-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection|A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus|Completed||Phase 3|1497|Actual|Medicines Development Limited||2|||f||||t||||||||||2018-06-01 01:34:34.752729|2018-06-01 01:34:34.752729
NCT00790985|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2015-10-19|2008-11-13|2008-11-14|Estimate|||||||2015-10-19|2015-10-21|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy of Flavocoxid Compared With Naproxen in Subjects With Moderate-severe Osteoarthritis of the Knee|Phase 3. Efficacy of Flavocoxid Compared With Naproxen in Subjects With Moderate-severe Osteoarthritis of the Knee|Completed||N/A|220|Actual|Primus Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:34:34.923341|2018-06-01 01:34:34.923341
NCT00790972|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2016-05-19|2008-11-13|2008-11-14|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|June 2013|Anticipated|2013-06-30|June 2010|Anticipated|2010-06-30||Interventional|||The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity|The Efficacy of SinoFresh Nasal and Sinus Care Nasal Spray in Eliminating MRSA From the Nasal Cavity|Withdrawn||N/A|0|Actual|University of Chicago||2||Company went out of business.|f||||f||||||||||2018-06-01 01:34:35.051533|2018-06-01 01:34:35.051533
NCT00790959|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2012-02-21|2008-11-13|2008-11-14|Estimate|||||||2012-02-21|2012-02-22|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|SASA!||The SASA! Study: An Evaluation of a Community Intervention to Address Gender-based Violence and Reduce HIV/AIDS Risk in Uganda|The SASA! Study: a Cluster Randomised Controlled Trial of a Community Mobilisation Intervention to Prevention Violence Against Women and Reduce HIV/AIDS Risk in Kampala, Uganda|Unknown status|Recruiting|N/A|800|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-06-01 01:34:35.119236|2018-06-01 01:34:35.119236
NCT00790946|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2010-06-02|2008-11-13|2008-11-14|Estimate|||||||2010-06-02|2010-06-03|Estimate|June 2006||2006-06-30|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|KACT||Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)|Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension|Unknown status|Recruiting|Phase 4|250|Anticipated|Kagoshima University||2|||f||||t||||||||||2018-06-01 01:34:35.215462|2018-06-01 01:34:35.215462
NCT00790933|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2018-02-16|2008-11-13|2008-11-14|Estimate|||||||2018-02-16|2018-02-20|Actual|May 22, 2009|Actual|2009-05-22|February 2018|2018-02-28|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|GEMINI LTS||An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease|A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Subjects With Ulcerative Colitis and Crohn's Disease|Completed||Phase 3|2243|Actual|Takeda||1|||f||||t||||||||||2018-06-01 01:34:35.320807|2018-06-01 01:34:35.320807
NCT00790920|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2015-09-17|2008-11-13|2008-11-14|Estimate|||||||2015-09-17|2015-09-18|Estimate|December 2008||2008-12-31|September 2015|2015-09-30||||July 2014|Actual|2014-07-31||Interventional|DIAS-3||Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke|A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke|Completed||Phase 3|492|Actual|H. Lundbeck A/S||2|||f||||t||||||||||2018-06-01 01:34:35.511478|2018-06-01 01:34:35.511478
NCT00790907|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2011-05-10||2017-03-21|2008-11-13|2008-11-14|Estimate|2011-05-10|2011-06-07|Estimate||||2017-03-21|2017-03-23|Actual|February 2009||2009-02-28|March 2017|2017-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|FUTURA/OASIS 8||Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)|FondaparinUx Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS) (FUTURA). A Prospective Study Evaluating the Safety of Two Regimens of Adjunctive Intravenous UFH During PCI in High Risk Patients With Unstable Angina/Non ST Segment Elevation Myocardial Infarction (UA/NSTEMI) Initially Treated With Subcutaneous Fondaparinux and Referred for Early Coronary Angiography (OASIS 8)|Completed||Phase 4|3235|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:34:35.850728|2018-06-01 01:34:35.850728
NCT00790894|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-05-17|2008-11-13|2008-11-14|Estimate|||||||2011-05-17|2011-05-18|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|HIT||Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)|Phase II Randomized Trial of Ixabepilone Administered Weekly or Every Three Weeks in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Chemotherapy in the Neo-adjuvant or Adjuvant Setting|Terminated||Phase 2|64|Actual|Hellenic Cooperative Oncology Group||2||The low accrual rate of the study (25% of the expected accrual rate)|f||||f||||||||||2018-06-01 01:34:36.957409|2018-06-01 01:34:36.957409
NCT00790881|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2010-06-25|2008-11-13|2008-11-14|Estimate|||||||2010-06-25|2010-06-28|Estimate|October 2008||2008-10-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Artemether/Lumefantrine and Nevirapine Interaction Study in HIV-infected Adults|Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults|Completed||Phase 4|36|Anticipated|University of Cape Town||2|||f||||t||||||||||2018-06-01 01:34:37.033373|2018-06-01 01:34:37.033373
NCT00790868|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2017-05-02||2018-02-05|2008-11-13|2008-11-14|Estimate|2018-02-05|2018-03-07|Actual||||2018-02-05|2018-03-07|Actual|April 2008|Actual|2008-04-30|February 2018|2018-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|DCSPanic||Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder|Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder|Completed||Phase 2|180|Actual|Boston University Charles River Campus|"The investigators did not systematically collect fear estimates across exposure and are therefore unable to examine this factor as a moderator.~Unexpected site effects were observed for several of our outcome variables."|2|||f||||t|t|f|||t|||No||2018-06-01 01:34:37.149587|2018-06-01 01:34:37.149587
NCT00790855|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|2012-06-22||2012-12-03|2008-11-13|2008-11-14|Estimate|2012-09-18|2012-10-19|Estimate||||2012-12-03|2012-12-04|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Bendamustine in Acute Leukemia and MDS|Phase I-II Study of Bendamustine in Patients With Acute Leukemia and High-Risk Myelodysplastic Syndrome (MDS)|Terminated||Phase 1/Phase 2|27|Actual|M.D. Anderson Cancer Center||1||Lack of Response|f||||t||||||||||2018-06-01 01:34:37.716723|2018-06-01 01:34:37.716723
NCT00790842|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2018-05-21|2008-11-13|2008-11-14|Estimate|||||||2018-05-21|2018-05-23|Actual|January 21, 2009|Actual|2009-01-21|May 2018|2018-05-31|March 8, 2018|Actual|2018-03-08|September 30, 2017|Actual|2017-09-30||Interventional|PrE1003||Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction|A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function|Terminated||Phase 1/Phase 2|62|Actual|PrECOG, LLC.||3||Slow enrollment|f||||t|t|f||||||No|Data is proprietary.|2018-06-01 01:34:37.956573|2018-06-01 01:34:37.956573
NCT00790829|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-08-11|2008-11-13|2008-11-14|Estimate|||||||2011-08-11|2011-08-12|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Interventional|||Preemptive Use of the Nicotine Patch for Postoperative Pain Relief After Open Abdominal Surgery|Preemptive Use of Nicotine Patch for Postoperative Pain Relief in Open Abdominal Surgery|Unknown status|Recruiting|N/A|70|Anticipated|Stony Brook University||1|||f||||t||||||||||2018-06-01 01:34:38.142236|2018-06-01 01:34:38.142236
NCT00790816|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2018-02-26|2008-11-13|2008-11-14|Estimate|||||||2018-02-26|2018-02-28|Actual|October 2008||2008-10-31|February 2018|2018-02-28|August 19, 2016|Actual|2016-08-19|August 19, 2016|Actual|2016-08-19||Interventional|||Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents|An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors|Completed||Phase 1|500|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:34:38.278859|2018-06-01 01:34:38.278859
NCT00790803|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2012-12-20||2017-02-01|2008-11-13|2008-11-14|Estimate|2013-07-15|2013-09-26|Estimate||||2017-02-01|2017-03-13|Actual|March 2009||2009-03-31|February 2017|2017-02-28|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema|Vascular Endothelial Growth Factor (VEGF)Blockade With Intravitreal Pegaptnib in Non-Infectious Uveitic Cystoid Macular Edema (CME)|Completed||N/A|5|Actual|Wake Forest University Health Sciences|Implementing screening protocols to catch less progressed CME cases could improve outcomes.|1|||f||||f||||||||||2018-06-01 01:34:38.416119|2018-06-01 01:34:38.416119
NCT00790790|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2011-08-25|2010-10-25|2012-04-11|2008-11-12|2008-11-14|Estimate|2011-08-25|2011-10-05|Estimate|2010-10-25|2010-10-27|Estimate|2012-04-11|2012-04-17|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study in the Treatment of Osteoarthritis Knee Pain|A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain|Completed||Phase 2|147|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 01:34:38.685036|2018-06-01 01:34:38.685036
NCT00790777|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-13|||2011-05-17|2008-11-13|2008-11-14|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|May 2007|Actual|2007-05-31|||||Interventional|||A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville|A Single-dose, Open-label, Randomized, 2-way Crossover Pivotal Bioequivalence Study of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville Under Fasted Condition in Healthy Subjects|Completed||Phase 1|72|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:34:40.004796|2018-06-01 01:34:40.004796
NCT00790764|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2014-05-07|2008-11-12|2008-11-13|Estimate|||||||2014-05-07|2014-05-09|Estimate|November 2008||2008-11-30|April 2011|2011-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)|Phase II Study for the Transfer of Bone Marrow-Derived Mononuclear and Mesenchymal StemCells Into the Myocardium for the Treatment of Severe Coronary Ischemia|Suspended||Phase 2|60|Anticipated|TCA Cellular Therapy||2||Suspended due to lack of funding.|f||||t||||||||||2018-06-01 01:34:40.102067|2018-06-01 01:34:40.102067
NCT00790751|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2012-05-25|2011-06-06|2012-06-27|2008-11-10|2008-11-13|Estimate|2012-05-25|2012-06-28|Estimate|2011-06-06|2011-06-21|Estimate|2012-06-27|2012-07-11|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|REVIVE||Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in Subjects With Generalized Erectile Dysfunction|Completed||Phase 3|646|Actual|VIVUS, Inc.||4|||f||||f||||||||||2018-06-01 01:34:40.229623|2018-06-01 01:34:40.229623
NCT00790738|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2015-05-21||2015-06-05|2008-11-12|2008-11-13|Estimate|2015-06-05|2015-07-02|Estimate||||2015-06-05|2015-07-02|Estimate|July 2008||2008-07-31|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|T3||Liothyronine (T3) for Bipolar Depression|Randomized Double-Blind Trial of Liothyronine (T3) Augmentation to Treatment as Usual vs Placebo For The Treatment of Bipolar Depression|Completed||Phase 3|11|Actual|Northwell Health|Despite several changes made in order to enhance recruitment during the study period, the study was markedly underpowered. Therefore, no definitive conclusions could be drawn from the data.|2|||f||||t||||||||||2018-06-01 01:34:40.670469|2018-06-01 01:34:40.670469
NCT00790725|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2012-04-24|2008-11-11|2008-11-13|Estimate|||||||2012-04-24|2012-04-25|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Proportional Assist Ventilation vs Pressure Support Ventilation|Proportional Assist Ventilation vs. Pressure Support Ventilation in the Management of Patients Referred to a Respiratory Acute Care Unit|Terminated||N/A|12|Actual|Massachusetts General Hospital||2||"The patient population in RACU has changed significantly, we can not find potential subjects to~   recruit. The enrollment rate has reached zero."|f||||f||||||||||2018-06-01 01:34:40.909053|2018-06-01 01:34:40.909053
NCT00790699|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2011-11-16|2008-11-12|2008-11-13|Estimate|||||||2011-11-16|2011-11-17|Estimate|August 2009||2009-08-31|December 2009|2009-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port|A Randomized, Parallel, Single Center, Comparison, Pilot Study Evaluating the Safety and Efficacy of Using Symlin Alongside Insulin in a Multiple Injection Port (I-PORT)|Terminated||N/A|31|Actual|Texas Diabetes & Endocrinology, P.A.||2||Lack of patient population|f||||t||||||||||2018-06-01 01:34:40.986085|2018-06-01 01:34:40.986085
NCT00790686|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2014-08-20|2008-11-12|2008-11-13|Estimate|||||||2014-08-20|2014-08-21|Estimate|November 2008||2008-11-30|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TOTEME||Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter|Study of Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in the Treatment of Chronic Strictures of the Ureter|Completed||Phase 2|13|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-06-01 01:34:41.083461|2018-06-01 01:34:41.083461
NCT00790673|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2015-03-05||2015-03-31|2008-11-11|2008-11-13|Estimate|2015-03-31|2015-04-15|Estimate||||2015-03-31|2015-04-15|Estimate|July 2009||2009-07-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1|A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Safety, Tolerability, Biological Activity, and Pharmacokinetics of Orally Administered CF102 in Subjects With Chronic Hepatitis C Genotype 1|Completed||Phase 1/Phase 2|32|Actual|Can-Fite BioPharma||4|||f||||t||||||||||2018-06-01 01:34:41.187587|2018-06-01 01:34:41.187587
NCT00790660|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11||2010-02-26|2018-03-29|2008-11-11|2008-11-13|Estimate||||2010-02-26|2010-03-01|Estimate|2018-03-29|2018-04-02|Actual|October 23, 2008|Actual|2008-10-23|March 2018|2018-03-31|March 6, 2009|Actual|2009-03-06|March 6, 2009|Actual|2009-03-06||Interventional|||A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.|A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study to Assess the Safety and Tolerability of ASP1941 in Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|61|Actual|Astellas Pharma Inc||5|||f||||f||||||||No||2018-06-01 01:34:41.475349|2018-06-01 01:34:41.475349
NCT00790647|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2016-09-09||2016-12-13|2008-11-12|2008-11-13|Estimate|2016-12-13|2017-02-06|Estimate||||2016-12-13|2017-02-06|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|November 2014|Actual|2014-11-30|December 2012|Actual|2012-12-31||Interventional|||Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis|Phase II Trial of High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis|Completed||Phase 2|10|Actual|Boston Medical Center||1|||f||||t||||||||No||2018-06-01 01:34:41.579102|2018-06-01 01:34:41.579102
NCT00790634|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Mechanisms of Fronto-Subcortical Dysfunction: Comparing PD and OCD|Characterizing Mechanisms of Fronto-Subcortical Dysfunction: A Comparison Between Parkinson's Disease and Obsessive-Compulsive Disorder|Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||4||f||||f||||||||||2018-06-01 01:34:41.798097|2018-06-01 01:34:41.798097
NCT00790621|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:34:41.848145|2018-06-01 01:34:41.848145
NCT00790608|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2011-11-28|2008-11-12|2008-11-13|Estimate|||||||2011-11-28|2011-11-29|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|May 2009|Actual|2009-05-31||Interventional|||Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA)|A Phase II Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus in MRSA Positive Ulcers|Terminated||Phase 2|8|Actual|Nitric BioTherapeutics, Inc||||Limited recruitment|f||||f||||||||||2018-06-01 01:34:41.882318|2018-06-01 01:34:41.882318
NCT00790595|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2012-07-27|2008-11-12|2008-11-13|Estimate|||||||2012-07-27|2012-07-31|Estimate|June 2006||2006-06-30|July 2012|2012-07-31||||July 2009|Actual|2009-07-31||Interventional|||Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy|Phase I, Open Label, Single Center, Multiple Dose, Dose Escalation Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy|Completed||Phase 1|6|Actual|Jonsson Comprehensive Cancer Center||5|||f||||t||||||||||2018-06-01 01:34:41.939328|2018-06-01 01:34:41.939328
NCT00790582|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2009-03-11|2008-11-12|2008-11-13|Estimate|||||||2009-03-11|2009-03-12|Estimate|May 2008||2008-05-31|March 2009|2009-03-31|July 2010|Anticipated|2010-07-31|March 2010|Anticipated|2010-03-31||Interventional|Lithium||A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Forbes Norris MDA/ALS Research Center||1|||f||||t||||||||||2018-06-01 01:34:42.032458|2018-06-01 01:34:42.032458
NCT00790569|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2013-12-12||2017-09-19|2008-11-12|2008-11-13|Estimate|2013-12-12|2014-02-03|Estimate||||2017-09-19|2017-10-20|Actual|September 2008||2008-09-30|September 2017|2017-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||All eligible participants who completed enrollment and were randomized were included in baseline analyses.|Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking|Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers|Completed||N/A|315|Actual|Butler Hospital||3|||f||||t||||||||||2018-06-01 01:34:42.184965|2018-06-01 01:34:42.184965
NCT00790556|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2010-09-10||2016-02-11|2008-11-11|2008-11-13|Estimate|2010-12-17|2011-01-20|Estimate||||2016-02-11|2016-02-17|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245.|Completed||Phase 1|14|Actual|Merck Sharp & Dohme Corp.|Stat. analysis of HGP was not performed as insulin suppression lead to a near complete suppression of HGP in both placebo and MK-8245 treated subjects, making it impossible to determine if MK-8245 could lead to a greater insulin effect than placebo|2|||f||||||||||||||2018-06-01 01:34:42.865058|2018-06-01 01:34:42.865058
NCT00790543|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2018-01-08|2008-11-12|2008-11-13|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2008||2008-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|RS||Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease|Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children With Crohn's Disease|Active, not recruiting|||2000|Anticipated|Emory University|||1||f||||f||||||Samples With DNA|"~     At time of enrollment, whole blood for DNA and serum will be collected in all patients. Fresh~     fecal samples will also be requested. For gene expression analysis, biopsy specimens will be~     collected during regularly scheduled endoscopies.~   "|No||2018-06-01 01:34:43.173081|2018-06-01 01:34:43.173081
NCT00790530|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2008-11-11|2008-11-11|2008-11-13|Estimate|||||||2008-11-11|2008-11-13|Estimate|June 2006||2006-06-30|November 2008|2008-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|ATO-SR-DM||Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study|Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study|Completed||N/A|1200|Actual|Harvard Pilgrim Health Care||2|||f||||f||||||||||2018-06-01 01:34:43.344201|2018-06-01 01:34:43.344201
NCT00790517|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2015-03-12|2008-11-12|2008-11-13|Estimate|||||||2015-03-12|2015-03-17|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|STRIDE||Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)|Reducing Weight and Diabetes Risk in an Underserved Population|Completed||Phase 2|200|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 01:34:43.427201|2018-06-01 01:34:43.427201
NCT00790504|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2017-04-29|2008-11-12|2008-11-13|Estimate|||||||2017-04-29|2017-05-02|Actual|November 2008||2008-11-30|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Transperineal Ultrasound for the Female Pelvic Floor in Women With Multiple Gestation|Prospective Follow up of the Female Pelvic Floor in Multiple Gestation Using Transperineal Ultrasound|Withdrawn|||0|Actual|Sheba Medical Center|||2|Difficulty recruiting patient. Lack of research assistant.|f||||f||||||||||2018-06-01 01:34:43.526883|2018-06-01 01:34:43.526883
NCT00790491|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2013-11-06|2008-11-12|2008-11-13|Estimate|||||||2013-11-06|2013-11-07|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Automated Guidance Tool for Medical Encounters Addressing Therapeutic Lifestyle Changes (AuGMEnT).|Automated Guidance Tool for Medical Encounters Addressing Therapeutic Lifestyle Changes (AuGMEnT)|Completed||N/A|240|Actual|Griffin Hospital||1|||f||||f||||||||||2018-06-01 01:34:43.5986|2018-06-01 01:34:43.5986
NCT00790478|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2009-12-22|2008-11-12|2008-11-13|Estimate|||||||2009-12-22|2009-12-23|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|Melatonin & UC||Melatonin & Ulcerative Colitis|Melatonin and Ulcerative Colitis: A Pilot Clinical Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Emory University||2|||f||||t||||||||||2018-06-01 01:34:43.779471|2018-06-01 01:34:43.779471
NCT00790465|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|November 2010|Anticipated|2010-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Efficacy of Dark Chocolate in Achalasia Patients|Efficacy of Dark Chocolate in Achalasia Patients: Placebo-Controlled Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 01:34:43.923834|2018-06-01 01:34:43.923834
NCT00790452|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2011-11-04||2011-11-04|2008-11-11|2008-11-13|Estimate|2011-11-04|2011-12-08|Estimate||||2011-11-04|2011-12-08|Estimate|November 2008||2008-11-30|November 2011|2011-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma|A Randomized Phase II Trial of Aspirin for Primary Prophylaxis of Venous Thromboembolism in Glioblastoma|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center|Study terminated early due due to a drug supply issue.|2||Low accrual.|f||||t||||||||||2018-06-01 01:34:44.083341|2018-06-01 01:34:44.083341
NCT00790439|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2014-06-10|2008-11-10|2008-11-13|Estimate|||||||2014-06-10|2014-06-12|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant|Open Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran (LMW-SD) in Islet Transplantation After Kidney Transplantation (CIT-01B)|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||Due to funding limitations|f||||t||||||||||2018-06-01 01:34:44.474879|2018-06-01 01:34:44.474879
NCT00790426|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2016-04-28|2008-11-10|2008-11-13|Estimate|||||||2016-04-28|2016-05-02|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase II Study of TKI258 in Advanced Urothelial Carcinoma|A Phase II Multi-center, Non-randomized, Open Label Study of TKI258 in FGFR3 Mutated and FGFR3 Wild Type Advanced Urothelial Carcinoma|Completed||Phase 2|44|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:34:44.817927|2018-06-01 01:34:44.817927
NCT00790413|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2017-03-11|2008-11-12|2008-11-13|Estimate|||||||2017-03-11|2017-03-14|Actual|August 2005||2005-08-31|March 2017|2017-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Haploidentical Stem Cell Transplantation in Neuroblastoma|High-dose MIBG With Subsequent Transplantation of Haploidentical Stem Cells in Children With Therapy Resistant Neuroblastoma|Active, not recruiting||Early Phase 1|15|Anticipated|Lund University Hospital||1|||f||||||||||||||2018-06-01 01:34:45.052079|2018-06-01 01:34:45.052079
NCT00790400|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2012-05-23||2017-01-03|2008-11-12|2008-11-13|Estimate|2012-07-25|2012-08-28|Estimate||||2017-01-03|2017-02-17|Actual|April 2009||2009-04-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|June 2011|Actual|2011-06-30||Interventional|EXIST-2||Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)|A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)|Completed||Phase 3|118|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:34:45.299235|2018-06-01 01:34:45.299235
NCT00790387|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2010-03-23|2008-11-12|2008-11-13|Estimate|||||||2010-03-23|2010-03-24|Estimate|June 2004||2004-06-30|November 2008|2008-11-30|December 2006|Actual|2006-12-31|December 2005|Actual|2005-12-31||Interventional|||Tirofiban and Enoxaparin in High Risk Coronary Intervention|High Bolus Dose Tirofiban and Enoxaparin Provides Reduced Thrombin Generation and Inflammatory Markers in Patients With High Risk Undergoing Percutaneous Intervention|Completed||Phase 4|60|Actual|The Prince Charles Hospital||2|||f||||f||||||||||2018-06-01 01:34:46.648636|2018-06-01 01:34:46.648636
NCT00790374|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2011-02-28|2008-11-12|2008-11-13|Estimate|||||||2011-02-28|2011-03-01|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|STX64PC||BN83495 in Prostate Cancer|A Phase I Dose Escalating Study Evaluating the Pharmacodynamic Profile and Safety of BN83495 in Patients With Prostate Cancer With Evidence of Disease Progression While on Androgen Ablative Therapy|Completed||Phase 1|17|Actual|Ipsen||3|||f||||t||||||||||2018-06-01 01:34:46.735675|2018-06-01 01:34:46.735675
NCT00790361|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2017-08-25|2008-11-12|2008-11-13|Estimate|||||||2017-08-25|2017-08-28|Actual|June 18, 2009|Actual|2009-06-18|August 2017|2017-08-31|January 31, 2010|Actual|2010-01-31|January 31, 2010|Actual|2010-01-31||Observational|||The Natural History of Traumatic Spinal Cord Injury Using fMRI, MRS and DTI|Mapping the Natural History of Traumatic Spinal Cord Injury in the Sensorimotor Cortex Using Functional Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging|Completed|||20|Actual|Lawson Health Research Institute|||2||f||||f||||||||||2018-06-01 01:34:46.808978|2018-06-01 01:34:46.808978
NCT00790348|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|July 2008||2008-07-31|October 2008|2008-10-31||||July 2009|Anticipated|2009-07-31||Observational|||Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes|Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes|Unknown status|Recruiting||45|Anticipated|Wayne State University|||3||f||||f||||||Samples Without DNA|"~     Serum of patients will be kept for future studies~   "|||2018-06-01 01:34:46.952207|2018-06-01 01:34:46.952207
NCT00790335|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2017-12-18||2018-02-28|2008-11-12|2008-11-13|Estimate|2018-02-28|2018-03-29|Actual||||2018-02-28|2018-03-29|Actual|November 2009||2009-11-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ATTRACT|One patient was found not to meet the study inclusion criterion, and was excluded from all analyses by the adjudication committee.|Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis|Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial|Completed||Phase 3|692|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:34:47.120377|2018-06-01 01:34:47.120377
NCT00790322|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2010-02-18|2008-11-11|2008-11-13|Estimate|||||||2010-02-18|2010-02-19|Estimate|October 2008||2008-10-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Assess the Efficacy and Safety of SBG on Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Chemotherapy|Completed||Phase 3|130|Actual|Biotec Pharmacon ASA||2|||f||||f||||||||||2018-06-01 01:34:50.2422|2018-06-01 01:34:50.2422
NCT00790309|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2017-04-20|2008-11-11|2008-11-13|Estimate|||||||2017-04-20|2017-04-21|Actual|December 2008||2008-12-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Early Diabetes Resolution After Weight Loss Surgery|Hormonal and Inflammatory Parameters Affecting Early Diabetes Resolution Following Weight Loss Surgery|Completed|||75|Actual|Vanderbilt University Medical Center|||3||f||||f||||||Samples With DNA|"~     plasma and serum~   "|||2018-06-01 01:34:50.313674|2018-06-01 01:34:50.313674
NCT00790296|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2011-01-31||2017-12-04|2008-11-10|2008-11-13|Estimate|2011-04-05|2011-05-03|Estimate||||2017-12-04|2017-12-28|Actual|December 2006||2006-12-31|December 2017|2017-12-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue|A Pilot, Randomized Double-Blind Placebo-Controlled Crossover Study of Synthetic Thyrotropin Releasing Hormone (TRH) Administration for the Treatment of Fatigue in Patients With Cancer|Terminated||Phase 2|11|Actual|UConn Health|Limitation: small sample size|2||Interim analyses showed statistically and clinically significant results.|f||||t||||||||||2018-06-01 01:34:50.410049|2018-06-01 01:34:50.410049
NCT00790283|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2009-02-16|2008-11-12|2008-11-13|Estimate|||||||2009-02-16|2009-02-17|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|ANSWERS||Assessment of the Numen Stent With Evaluation in a Randomized Study|Assessment of the Numen Stent With Evaluation in a Randomized Study|Unknown status|Recruiting|Phase 2/Phase 3|500|Anticipated|International Biomedical Systems S.p.A.||2|||f||||f||||||||||2018-06-01 01:34:50.802632|2018-06-01 01:34:50.802632
NCT00790270|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2009-10-19||2012-10-22|2008-11-12|2008-11-13|Estimate|2012-10-22|2012-11-21|Estimate||||2012-10-22|2012-11-21|Estimate|January 2003||2003-01-31|October 2012|2012-10-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial|Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial|Completed||Phase 2|61|Actual|Stony Brook University||3|||f||||f||||||||||2018-06-01 01:34:50.954406|2018-06-01 01:34:50.954406
NCT00790257|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2018-03-13|2008-11-12|2008-11-13|Estimate|||||||2018-03-13|2018-03-15|Actual|November 2008||2008-11-30|March 2018|2018-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Efficacy Study of Encapsulated Human Islets Allotransplantation to Treat Type 1 Diabetes|A Monocentre Phase 1 Trial to Assess a Monolayer Cellular Device in the Treatment of Type 1 Diabetes|Withdrawn||Phase 1|0|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-06-01 01:34:51.384746|2018-06-01 01:34:51.384746
NCT00790244|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2011-07-03|2008-11-12|2008-11-13|Estimate|||||||2011-07-03|2011-07-06|Estimate|October 2007||2007-10-31|November 2008|2008-11-30|October 2022|Anticipated|2022-10-31|October 2012|Anticipated|2012-10-31||Interventional|SSGXX||A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall|A Scandinavian Sarcoma Group Treatment Protocol for Adult Patients With Non-metastatic High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall|Recruiting||Phase 2|188|Anticipated|Oslo University Hospital||4|||f||||t||||||||||2018-06-01 01:34:51.476095|2018-06-01 01:34:51.476095
NCT00790231|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2009-11-19|2008-11-12|2008-11-13|Estimate|||||||2009-11-19|2009-11-20|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Effects of Thoracic Epidural Anesthesia on Lower Urinary Tract Function|Effects of Thoracic Epidural Anesthesia on Lower Urinary Tract Function|Completed|||32|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 01:34:51.688423|2018-06-01 01:34:51.688423
NCT00790218|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2014-08-12||2015-02-26|2008-11-11|2008-11-13|Estimate|2015-02-26|2015-02-27|Estimate||||2015-02-26|2015-02-27|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma|A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|19|Actual|Can-Fite BioPharma||1|||f||||t||||||||||2018-06-01 01:34:51.803748|2018-06-01 01:34:51.803748
NCT00790205|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2016-03-15||2017-04-10|2008-11-11|2008-11-13|Estimate|2016-03-15|2016-04-15|Estimate||||2017-04-10|2017-05-15|Actual|December 10, 2008|Actual|2008-12-10|April 2017|2017-04-30|March 30, 2015|Actual|2015-03-30|March 30, 2015|Actual|2015-03-30||Interventional|TECOS||Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)|TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control|Completed||Phase 3|14671|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:34:52.341195|2018-06-01 01:34:52.341195
NCT00790192|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2011-09-01||2016-03-11|2008-11-12|2008-11-13|Estimate|2011-09-01|2011-10-06|Estimate||||2016-03-11|2016-03-17|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PEARL 3||Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.|A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)|Completed||Phase 3|488|Actual|Sunovion||4|||f||||t||||||||||2018-06-01 01:34:55.47237|2018-06-01 01:34:55.47237
NCT00790179|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|January 2003||2003-01-31|November 2008|2008-11-30|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty|Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty|Completed||N/A|225|Actual|Northwell Health||3|||f||||t||||||||||2018-06-01 01:34:56.137119|2018-06-01 01:34:56.137119
NCT00790166|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2018-04-25|2008-11-11|2008-11-13|Estimate|||||||2018-04-25|2018-04-27|Actual|October 2008||2008-10-31|June 2009|2009-06-30|June 24, 2009|Actual|2009-06-24|June 24, 2009|Actual|2009-06-24||Interventional|CIA-6||Effects of Humidity (During CPAP Treatment) on Mucociliary Clearance in Patients With Obstructive Sleep Apnea|Effects of nCPAP With and Without Humidification on: Inspiratory Temperature, Humidity, Saccharine Transit Time, Nasal Lavage and in Vitro Mucus Properties in Patients With Obstructive Sleep Apnea|Terminated||N/A|4|Actual|Fisher and Paykel Healthcare||3|||f||||||||||||||2018-06-01 01:34:56.206273|2018-06-01 01:34:56.206273
NCT00790153|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2009-04-09|2008-11-12|2008-11-13|Estimate|||||||2009-04-09|2009-04-10|Estimate|November 2008||2008-11-30|April 2009|2009-04-30|February 2009|Actual|2009-02-28|||||Interventional|||To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension|A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter Regulatory Response During Hypoglycaemia in Healthy Male Volunteers After a Single Oral Dose of AZD1656 Suspension in Comparison With Insulin Infusion|Completed||Phase 1|12|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 01:34:56.287057|2018-06-01 01:34:56.287057
NCT00790140|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|July 2005||2005-07-31|November 2008|2008-11-30|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery|Randomized Double Blinded Trial to Investigate Effects of an Enteral Nutritional Supplement Enriched With Eicosapentaenoic Acid on Body Composition,Complications,Stress Response,Immune Function & Quality of Life in After Esophagectomy|Unknown status|Recruiting|Phase 4|120|Anticipated|University of Dublin, Trinity College||2|||f||||t||||||||||2018-06-01 01:34:56.360294|2018-06-01 01:34:56.360294
NCT00790127|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11||2011-05-13|2011-05-18|2008-11-12|2008-11-13|Estimate||||2011-05-13|2011-05-18|Estimate|2011-05-18|2011-05-20|Estimate|March 2009||2009-03-31|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia|A Multi-National, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HQK-1001 in Subjects With Beta Thalassemia Intermedia, Including Hemoglobin E Beta Thalassemia|Completed||Phase 1/Phase 2|21|Actual|HemaQuest Pharmaceuticals Inc.||2|||f||||t||||||||||2018-06-01 01:34:56.454728|2018-06-01 01:34:56.454728
NCT00790114|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|CYP||Determine the Effect of Multiple Doses of AZD7325, CYP Study|A Phase I Open-Labeled, Fixed Sequence Study to Determine the Effect of Multiple Doses of AZD7325 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)|Completed||Phase 1|24|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:34:56.517225|2018-06-01 01:34:56.517225
NCT00790101|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2011-01-10|2008-11-12|2008-11-13|Estimate|||||||2011-01-10|2011-01-11|Estimate|June 2004||2004-06-30|January 2011|2011-01-31|October 2004|Actual|2004-10-31|||||Interventional|||Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation|An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis|Terminated||Phase 4|6|Actual|Sanofi||3|||f||||||||||||||2018-06-01 01:34:56.57846|2018-06-01 01:34:56.57846
NCT00790088|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2012-02-03|2008-11-12|2008-11-13|Estimate|||||||2012-02-03|2012-02-06|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy|International Report on Routine Practice of Sensor-enabled Pump Therapy|Unknown status|Active, not recruiting||300|Anticipated|Medtronic|||||f||||f||||||Samples With DNA|"~     capillary blood samples for HbA1c analysis~   "|||2018-06-01 01:34:56.679315|2018-06-01 01:34:56.679315
NCT00790075|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|January 2003||2003-01-31|November 2008|2008-11-30|December 2004|Actual|2004-12-31|June 2004|Actual|2004-06-30||Interventional|||Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children|Liquid Risperidone in the Treatment of Acute Agitation in Psychiatrically Hospitalized Children|Completed||Phase 4|24|Actual|Stony Brook University|||||f||||f||||||||||2018-06-01 01:34:56.917386|2018-06-01 01:34:56.917386
NCT00790062|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2012-05-30||2016-03-08|2008-11-12|2008-11-13|Estimate|2013-12-10|2014-01-30|Estimate||||2016-03-08|2016-04-08|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT|Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery|Completed||Phase 4|1798|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-06-01 01:34:57.012598|2018-06-01 01:34:57.012598
NCT00790049|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2012-04-23|2008-11-11|2008-11-13|Estimate|||||||2012-04-23|2012-04-24|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Safety Study of ARRY-371797 in Healthy Subjects||Completed||Phase 1|40|Actual|Array BioPharma||2|||f||||f||||||||||2018-06-01 01:34:57.474536|2018-06-01 01:34:57.474536
NCT00790036|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2017-06-14||2017-06-14|2008-11-12|2008-11-13|Estimate|2017-06-14|2017-07-12|Actual||||2017-06-14|2017-07-12|Actual|July 24, 2009|Actual|2009-07-24|June 2017|2017-06-30|June 15, 2016|Actual|2016-06-15|June 15, 2016|Actual|2016-06-15||Interventional|PILLAR2|Full Analysis Set (FAS) includes all randomized patients.|Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy|A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy|Completed||Phase 3|742|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:34:57.570643|2018-06-01 01:34:57.570643
NCT00790023|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2012-02-15|2009-08-07|2016-03-10|2008-11-11|2008-11-13|Estimate|2012-05-03|2012-06-08|Estimate|2009-08-07|2009-08-11|Estimate|2016-03-10|2016-04-08|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis|A Randomized, Multicenter, Double Blind, Placebo Controlled, Parallel Group, Phase III Clinical Trial to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol (160 μg Once Daily and 80 μg Once Daily) for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older.|Completed||Phase 3|707|Actual|Sunovion|This study was not designed or powered for a comparison of the 80mcg dose with the 160mcg dose therefore no statistical comparisons were planned between the two active groups. Publication references to 74 and 148mcg are equivalent to 80 and 160mcg|3|||f||||f||||||||||2018-06-01 01:34:59.238831|2018-06-01 01:34:59.238831
NCT00790010|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2018-01-30|2008-11-12|2008-11-13|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2009||2009-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma|A Phase I Trial of Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma|Active, not recruiting||Phase 1|46|Actual|Dana-Farber Cancer Institute||4|||f||||t||||||||||2018-06-01 01:35:01.350835|2018-06-01 01:35:01.350835
NCT00789997|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2013-06-04||2016-03-29|2008-11-12|2008-11-13|Estimate|2016-03-29|2016-04-11|Estimate||||2016-03-29|2016-04-11|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial|TNF-alpha Antagonists for Acute Exacerbations of COPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial|Completed||Phase 2/Phase 3|81|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 01:35:01.455758|2018-06-01 01:35:01.455758
NCT00789984|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate||||November 2008|2008-11-30||||||||Observational|||Corneal Specular Microscopy in Infectious and Noninfectious Uveitis||Completed|||||Federal University of São Paulo|||||f||||t||||||||||2018-06-01 01:35:01.774709|2018-06-01 01:35:01.774709
NCT00789971|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|March 2007||2007-03-31|November 2008|2008-11-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Triamcinolone Versus Topical Treatment in Post Operative Phacoemulsification|A Comparison of a Single Orbital Floor Injection of Triamcinolone Versus Conventional Steroid and Antibiotic Drops Used Post Operatively in Uneventful Phacoemulsification Surgery|Completed||N/A|150|Actual|Sligo General Hospital|||||f||||t||||||||||2018-06-01 01:35:01.825486|2018-06-01 01:35:01.825486
NCT00789958|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2016-08-02||2018-03-12|2008-11-12|2008-11-13|Estimate|2016-08-02|2016-09-22|Estimate||||2018-03-12|2018-04-09|Actual|December 2008||2008-12-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2014|Actual|2014-12-31||Interventional||All eligible and analyzable patients that received protocol treatment.|S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct|A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)|Completed||Phase 2|105|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 01:35:01.953707|2018-06-01 01:35:01.953707
NCT00789945|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2013-04-04|2008-11-12|2008-11-13|Estimate|||||||2013-04-04|2013-04-05|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TIME||Timing of Insulin Before Meals Everyday|The Importance of Insulin Timing in Type 1 Diabetes|Completed||N/A|40|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 01:35:03.001118|2018-06-01 01:35:03.001118
NCT00789932|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2013-02-01|2008-11-12|2008-11-13|Estimate|||||||2013-02-01|2013-02-05|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|BIACA-2||Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial|Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial|Completed||Phase 1/Phase 2|20|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-06-01 01:35:03.133986|2018-06-01 01:35:03.133986
NCT00789919|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2017-02-08|2008-11-12|2008-11-13|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2002||2002-03-31|November 2008|2008-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Mild Preeclampsia Near Term: Deliver or Deliberate?|Mild Preeclampsia Near Term: Deliver or Deliberate?|Completed||N/A|185|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-06-01 01:35:03.202498|2018-06-01 01:35:03.202498
NCT00789906|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|July 2008||2008-07-31|November 2008|2008-11-30||||||||Observational|||Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia|Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia|Unknown status|Recruiting||700|Anticipated|BeerYaakov Mental Health Center|||2||f||||||||||||||2018-06-01 01:35:03.282766|2018-06-01 01:35:03.282766
NCT00789893|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2015-06-10|2008-11-12|2008-11-13|Estimate|||||||2015-06-10|2015-06-11|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Study of Vaginal Dilator Use After Pelvic Radiotherapy|A Descriptive Study of Vaginal Dilator Use After Pelvic Radiotherapy|Completed|||115|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:35:03.421354|2018-06-01 01:35:03.421354
NCT00789880|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2012-12-07||2017-03-10|2008-11-11|2008-11-13|Estimate|2013-01-18|2013-01-22|Estimate||||2017-03-10|2017-04-12|Actual|December 2008||2008-12-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3|Analysis of the Response of Subjects With Atopic Dermatitis to Oral Vitamin D3 by Measurement of Antimicrobial Peptide Expression in Skin and Saliva|Completed||Phase 2|82|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 01:35:03.551366|2018-06-01 01:35:03.551366
NCT00789867|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2015-06-02|2008-11-11|2008-11-13|Estimate|||||||2015-06-02|2015-06-03|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|December 2010|Actual|2010-12-31|August 2009|Actual|2009-08-31||Interventional|||Single Dose of pGM169/GL67A in CF Patients|Evaluation of Safety and Gene Expression With a Single Dose of pGM169/GL67A Administered to the Nose and Lung of Individuals With Cystic Fibrosis|Completed||Phase 1/Phase 2|27|Actual|Imperial College London||1|||f||||t||||||||||2018-06-01 01:35:04.716242|2018-06-01 01:35:04.716242
NCT00789854|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2010-08-04||2012-04-23|2008-11-12|2008-11-13|Estimate|2012-04-23|2012-05-23|Estimate||||2012-04-23|2012-05-23|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|RUBY||Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients|A Randomised, 6-week, Multicentre, Open-label, Rater-blinded Parallel Group Study Comparing Quetiapine Extended Release Monotherapy and Augmentation With Lithium Augmentation in Patients With Treatment Resistant Depression|Completed||Phase 3|688|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:35:04.839104|2018-06-01 01:35:04.839104
NCT00789841|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2010-10-25|2008-11-12|2008-11-13|Estimate|||||||2010-10-25|2010-10-26|Estimate|September 2008||2008-09-30|October 2010|2010-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Gastrointestinal Motility in Patients With Neuroendocrine Tumors|Gastrointestinal Motility in Patients With Neuroendocrine Tumors-Effects of Sandostatin LAR|Completed|||13|Actual|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood samples wich are destroyed after analysis~   "|||2018-06-01 01:35:06.232646|2018-06-01 01:35:06.232646
NCT00789828|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|2012-03-01||2016-01-04|2008-11-12|2008-11-13|Estimate|2012-04-04|2012-05-01|Estimate||||2016-01-04|2016-02-03|Estimate|August 2009||2009-08-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|March 2011|Actual|2011-03-31||Interventional|EXIST-1||Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)|A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)|Completed||Phase 3|117|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:35:06.431105|2018-06-01 01:35:06.431105
NCT00789815|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2010-02-03||2017-08-03|2008-11-12|2008-11-13|Estimate|2010-04-01|2010-04-20|Estimate||||2017-08-03|2017-08-08|Actual|April 2008||2008-04-30|April 2010|2010-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Bispectral Index-guided Sedation for Flexible Bronchoscopy|Sedation for Flexible Bronchoscopy and Real Time Endobronchial Ultrasound -A Comparison Between Bispectral Index-guided Sedation and Conventional Sedation|Completed||Phase 4|500|Actual|Chang Gung Memorial Hospital|The bronchoscopists were not blinded to sedative procedures. It was difficult to accomplish totally blind conditions. The bronchoscopist would realize which protocol it was when only observing responses of the investigator.|2|||f||||f||||||||||2018-06-01 01:35:07.524916|2018-06-01 01:35:07.524916
NCT00789802|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2013-06-27||2018-03-19|2008-11-12|2008-11-13|Estimate|2014-12-08|2014-12-11|Estimate||||2018-03-19|2018-03-20|Actual|November 2008||2008-11-30|March 2018|2018-03-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC|A Randomized, Controlled Trial of Oral Naproxen and Transdermal Estradiol for Prevention of Unscheduled Bleeding in New Users of Levonorgestrel Intrauterine Contraception|Completed||N/A|129|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 01:35:07.994388|2018-06-01 01:35:07.994388
NCT00789789|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2017-05-31|2008-11-12|2008-11-13|Estimate|||||||2017-05-31|2017-06-01|Actual|December 2008||2008-12-31|May 2017|2017-05-31|September 30, 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials|Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials|Terminated|||488|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||1|stopped prematurely due to the absence of safety signal|f||||t||||||Samples With DNA|"~     Blood specimen collection (serum, plasma and whole blood)~   "|||2018-06-01 01:35:08.476365|2018-06-01 01:35:08.476365
NCT00789776|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2017-11-08|2008-11-12|2008-11-13|Estimate|||||||2017-11-08|2017-11-13|Actual|October 13, 2008||2008-10-13|November 2017|2017-11-30|May 18, 2021|Anticipated|2021-05-18|May 18, 2017|Actual|2017-05-18||Interventional|||Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer|A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation - A Multi Center Trial|Active, not recruiting||Phase 1/Phase 2|42|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 01:35:08.565125|2018-06-01 01:35:08.565125
NCT00789607|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2017-09-21|2008-11-12|2008-11-13|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2008||2008-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|FLIP||Fiducial Localization and Individualized Radiotherapy -Prostate Cancer|Fiducial Localization and Individualized Radiotherapy in Prostate Cancer (FLIP)|Active, not recruiting||Phase 2|60|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 01:35:13.904382|2018-06-01 01:35:13.904382
NCT00789763|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2012-11-28|2008-11-12|2008-11-13|Estimate|||||||2012-11-28|2012-11-29|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma|Open-label, Multicentric Phase I-II Trial to Evaluate the Efficacy and Safety of the Combination of Sorafenib (BAY 43-9006), Gemcitabine and Concurrent Radiotherapy, in Locally Advanced Pancreatic Carcinoma|Completed||Phase 1|12|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f||||||||||2018-06-01 01:35:08.699191|2018-06-01 01:35:08.699191
NCT00789750|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2017-05-24|2013-08-06|2017-06-23|2008-11-10|2008-11-13|Estimate|2017-06-23|2017-06-26|Actual|2013-08-06|2013-08-12|Estimate|2017-06-23|2017-06-26|Actual|April 2009||2009-04-30|June 2017|2017-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||All subjects randomized|Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 3|562|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:35:08.837331|2018-06-01 01:35:08.837331
NCT00789737|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2013-12-04|2012-12-03|2014-01-24|2008-11-10|2008-11-13|Estimate|2013-12-04|2014-01-22|Estimate|2012-12-03|2012-12-05|Estimate|2014-01-24|2014-02-27|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Welchol as Monotherapy for Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus|Completed||Phase 3|357|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:35:09.864129|2018-06-01 01:35:09.864129
NCT00789724|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2010-07-30||2017-10-24|2008-11-12|2008-11-13|Estimate|2010-07-30|2010-08-24|Estimate||||2017-10-24|2017-11-30|Actual|November 2008||2008-11-30|October 2017|2017-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|VCU-ART||Anakinra to Prevent Post-infarction Remodeling|Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART)|Completed||Phase 3|10|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-06-01 01:35:10.803431|2018-06-01 01:35:10.803431
NCT00789711|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2016-10-27|2008-11-12|2008-11-13|Estimate|||||||2016-10-27|2016-10-31|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|SAFE||An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes|A Multicentre, Open-label, Nonrandomised, Non-interventional, Observational Study to Compare Safety and Effectiveness of Biphasic Insulin Aspart 30 (NovoMix 30) and Insulin Detemir (Levemir) for the Treatment of Diabetes Mellitus|Completed|||3131|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 01:35:11.049081|2018-06-01 01:35:11.049081
NCT00789698|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2012-03-27||2015-05-19|2008-11-12|2008-11-13|Estimate|2012-07-13|2012-08-21|Estimate||||2015-05-19|2015-06-12|Estimate|December 2008||2008-12-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PEARL 3 Ext||Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia|A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study)|Completed||Phase 3|240|Actual|Sunovion||2|||f||||t||||||||||2018-06-01 01:35:11.169608|2018-06-01 01:35:11.169608
NCT00789685|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2015-05-11||2015-05-11|2008-11-12|2008-11-13|Estimate|2015-05-11|2015-05-27|Estimate||||2015-05-11|2015-05-27|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||The safety population was used for summaries of demographic and other baseline characteristics|Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II|A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.|Completed||Phase 1/Phase 2|37|Actual|Faron Pharmaceuticals Ltd||1|||f||||t||||||||||2018-06-01 01:35:11.945298|2018-06-01 01:35:11.945298
NCT00789672|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2010-09-14||2016-07-07|2008-11-10|2008-11-13|Estimate|2011-02-25|2011-03-23|Estimate||||2016-07-07|2016-07-13|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|ATS14||Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia|A Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia in 8 to 17 Year Olds|Completed||Phase 2|33|Actual|Jaeb Center for Health Research|Without a patching-only control group, no conclusions can be made regarding efficacy, safety, or side effects with this treatment. Placebo controlled trial is needed to see if levodopa can augment occlusion therapy in the treatment of amblyopia.|2|||f||||t||||||||||2018-06-01 01:35:12.410273|2018-06-01 01:35:12.410273
NCT00789659|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2017-02-08|2008-11-12|2008-11-13|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2010||2010-12-31|April 2012|2012-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Incisional Wound Vac in Obese Patients|Incisional Wound Vac in Obese Patients|Withdrawn||N/A|0|Actual|University of Mississippi Medical Center||1||PI did not want to go forward with study at this time|f||||f||||||||||2018-06-01 01:35:13.504634|2018-06-01 01:35:13.504634
NCT00789646|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2008-11-11|2008-11-11|2008-11-13|Estimate|||||||2008-11-11|2008-11-13|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|June 2009|Anticipated|2009-06-30|December 2008|Anticipated|2008-12-31||Interventional|||Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients|Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients.|Unknown status|Enrolling by invitation|N/A|32|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 01:35:13.584765|2018-06-01 01:35:13.584765
NCT00789633|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2012-09-25|2008-11-12|2008-11-13|Estimate|||||||2012-09-25|2012-09-26|Estimate|November 2008||2008-11-30|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer|A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 3|320|Anticipated|AB Science||2|||f||||t||||||||||2018-06-01 01:35:13.67196|2018-06-01 01:35:13.67196
NCT00789620|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2011-03-23|2008-11-12|2008-11-13|Estimate|||||||2011-03-23|2011-03-24|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery|Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery: A Prospective, Randomised, Placebo Controlled, Double-blind, Phase III Study|Completed||Phase 3|76|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 01:35:13.824747|2018-06-01 01:35:13.824747
NCT00789594|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2012-09-19|2008-11-12|2008-11-13|Estimate|||||||2012-09-19|2012-09-20|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|June 2012|Actual|2012-06-30||Interventional|LabMon||Improving Laboratory Monitoring in Community Practices: A Randomized Trial|Improving Laboratory Monitoring in Community Practices: A Randomized Trial|Unknown status|Active, not recruiting|N/A|50|Anticipated|VA Boston Healthcare System||4|||f||||f||||||||||2018-06-01 01:35:14.013079|2018-06-01 01:35:14.013079
NCT00789581|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2016-11-07||2017-06-13|2008-11-12|2008-11-13|Estimate|2017-03-01|2017-04-12|Actual||||2017-06-13|2017-07-02|Actual|December 2008||2008-12-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|TITAN|Analyses of baseline characteristics, demographics and efficacy includes all randomized patients.|A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer|Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer|Completed||Phase 3|614|Actual|SCRI Development Innovations, LLC||2|||f||||t||||||||||2018-06-01 01:35:14.14866|2018-06-01 01:35:14.14866
NCT00789568|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2014-08-11|2008-11-12|2008-11-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Interventional|||A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects|A Phase 1, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Effects of Sapropterin Dihydrochloride Oral Administration on QTc Intervals in Healthy Adult Subjects|Completed||Phase 1|56|Actual|BioMarin Pharmaceutical||4|||f||||f||||||||||2018-06-01 01:35:15.817854|2018-06-01 01:35:15.817854
NCT00789555|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2012-08-08||2018-01-12|2008-11-11|2008-11-13|Estimate|2012-08-08|2012-09-07|Estimate||||2018-01-12|2018-02-08|Actual|November 2008||2008-11-30|January 2018|2018-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis|Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis|Completed||Phase 4|1260|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 01:35:15.95464|2018-06-01 01:35:15.95464
NCT00789542|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|||2014-12-03|2008-11-11|2008-11-13|Estimate|||||||2014-12-03|2014-12-04|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|CLOTS-3||A RCT to Establish the Effectiveness of Intermittent Pneumatic Compression to Prevent Post Stroke DVT|A Randomised Trial to Establish the Effectiveness of Intermittent Pneumatic Compression to Prevent Post Stroke Deep Vein Thrombosis (DVT).|Completed||Phase 3|2876|Actual|University of Edinburgh||2|||f||||t||||||||||2018-06-01 01:35:16.605056|2018-06-01 01:35:16.605056
NCT00789529|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-11|2011-07-25||2013-04-22|2008-11-12|2008-11-13|Estimate|2013-04-22|2013-05-31|Estimate||||2013-04-22|2013-05-31|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Objective Testing of Tear Film Stability|Objective Testing of Tear Film Stability|Completed||N/A|32|Actual|Manhattan Vision Associates||2|||f||||f||||||||||2018-06-01 01:35:16.705999|2018-06-01 01:35:16.705999
NCT00789516|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2013-03-06|2008-11-11|2008-11-13|Estimate|||||||2013-03-06|2013-03-07|Estimate|June 2006||2006-06-30|March 2013|2013-03-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Observational|||The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation|The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation|Completed|||60|Actual|Mahidol University|||3||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 01:35:16.967498|2018-06-01 01:35:16.967498
NCT00789503|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|November 2004||2004-11-30|November 2008|2008-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Nursing-Home Residents Given Bread Fortified With Vitamin D3|Long-Term Effects of Giving Nursing-Home Residents Bread Fortified With 125 Micrograms (5000 IU) Vitamin D3 Per Daily Serving|Completed||Phase 1/Phase 2|45|Actual|University of Toronto||1|||f||||f||||||||||2018-06-01 01:35:17.033352|2018-06-01 01:35:17.033352
NCT00789490|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-12|||2008-11-12|2008-11-12|2008-11-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|October 2005||2005-10-31|November 2008|2008-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Relative Bioavailability of Iron and Folic Acid in New Test Supplement|Relative Bioavailability of Iron and Folic Acid From a New Powdered Supplement Compared to a Traditional Tablet in Pregnant Women|Completed||Phase 1|18|Actual|University of Toronto|||||f||||t||||||||||2018-06-01 01:35:17.124558|2018-06-01 01:35:17.124558
NCT00789477|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2014-08-28|2011-04-19|2014-08-28|2008-11-07|2008-11-11|Estimate|2014-08-28|2014-09-09|Estimate|2011-05-02|2011-05-05|Estimate|2014-08-28|2014-09-09|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|DA VINCI|Full analysis set (FAS): included all randomized patients who received any study drug, had baseline assessments, and had at least one (1) post-baseline assessment.|DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact|A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (DME)|Completed||Phase 2|221|Actual|Regeneron Pharmaceuticals||5|||f||||f||||||||||2018-06-01 01:35:17.25223|2018-06-01 01:35:17.25223
NCT00789464|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2015-09-11|2008-11-10|2008-11-11|Estimate|||||||2015-09-11|2015-09-15|Estimate||||September 2015|2015-09-30||||||||Interventional|||Probiotics for Girls With Recurring Urinary Tract Infections|H-23187: Probiotic Prophylaxis Against Recurrent Pediatric Urinary Tract Infection|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||2||Withdrawn by PI|f||||f||||||||||2018-06-01 01:35:18.657724|2018-06-01 01:35:18.657724
NCT00789451|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2010-10-22|2008-11-10|2008-11-11|Estimate|||||||2010-10-22|2010-10-25|Estimate|August 2008||2008-08-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of Ischaemic-reperfusion on the Endogenous Fibrinolysis in Man|The Effect of Ischaemic-reperfusion on the Endogenous Fibrinolysis in Man|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:35:18.729278|2018-06-01 01:35:18.729278
NCT00789438|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2009-10-27||2010-07-06|2008-11-10|2008-11-11|Estimate|2010-01-29|2010-02-19|Estimate||||2010-07-06|2010-07-13|Estimate|October 2008||2008-10-31|October 2009|2009-10-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Observational|||Evaluation of the Surgical Pleth Index During Spinal and General Anesthesia|The Effects of Sedation and Analgesia on the Surgical Pleth Index (SPI)|Completed|||69|Actual|University of Schleswig-Holstein|||3||f||||f||||||||||2018-06-01 01:35:18.809472|2018-06-01 01:35:18.809472
NCT00789425|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-07-12|2008-11-10|2008-11-11|Estimate|||||||2017-07-12|2017-07-13|Actual|September 2008||2008-09-30|July 2017|2017-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women|A Randomised, Double Blind, Parallel Group, 12-month Comparison of a Standardized Olive Extract With Placebo in Postmenopausal Women With Decreased Bone Mineral Density|Completed||Phase 2|64|Actual|BioActor||2|||f||||f||||||||||2018-06-01 01:35:19.035603|2018-06-01 01:35:19.035603
NCT00789412|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2009-10-27|2008-11-10|2008-11-11|Estimate|||||||2009-10-27|2009-10-28|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Observational|||Surgical Stress Index as a Tool for Monitoring Analgesia and/or Sedation in Critically Ill Patients|SSI for Monitoring of Analgesia and Sedation in Critically Ill Patients|Completed|||60|Anticipated|University of Schleswig-Holstein|||2||f||||f||||||||||2018-06-01 01:35:19.104004|2018-06-01 01:35:19.104004
NCT00789399|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2014-10-27|2008-11-10|2008-11-11|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis|A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis|Unknown status|Active, not recruiting|N/A|630|Anticipated|Prairie Education and Research Cooperative||2|||f||||t||||||||||2018-06-01 01:35:19.155404|2018-06-01 01:35:19.155404
NCT00789386|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2009-05-20|2008-11-10|2008-11-11|Estimate|||||||2009-05-20|2009-05-21|Estimate|November 2008||2008-11-30|May 2009|2009-05-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|RemiCaps2||The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers|The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers|Unknown status|Recruiting|Phase 4|24|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:35:19.305377|2018-06-01 01:35:19.305377
NCT00789373|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2011-06-20||2018-02-01|2008-11-10|2008-11-11|Estimate|2011-06-20|2011-07-18|Estimate||||2018-02-01|2018-03-01|Actual|November 2008||2008-11-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|June 2010|Actual|2010-06-30||Interventional|||A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer|A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung Cancer.|Completed||Phase 3|939|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:35:19.459553|2018-06-01 01:35:19.459553
NCT00789360|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2009-05-04|2008-11-10|2008-11-11|Estimate|||||||2009-05-04|2009-05-05|Estimate|November 2008||2008-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Staccato Loxapine Pulmonary Safety in Healthy Volunteers|Pulmonary Safety of Repeat Doses of Staccato® Loxapine for Inhalation in Healthy Volunteers|Completed||Phase 1|30|Anticipated|Alexza Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 01:35:20.976224|2018-06-01 01:35:20.976224
NCT00789347|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2010-04-01|2008-11-10|2008-11-11|Estimate|||||||2010-04-01|2010-04-02|Estimate|October 2008||2008-10-31|March 2010|2010-03-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Observational|||Analysis of Cortical Excitability in Neuropathic Pain|Analysis of Cortical Excitability in Neuropathic Pain: an Electrophysiology Study.|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||3||f||||f||||||Samples With DNA|"~     Genomic polymorphism of neurotrophic factors.~   "|||2018-06-01 01:35:21.056721|2018-06-01 01:35:21.056721
NCT00789334|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2009-08-21|2008-11-10|2008-11-11|Estimate|||||||2009-08-21|2009-08-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:35:21.186347|2018-06-01 01:35:21.186347
NCT00789321|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2010-04-30||2015-08-10|2008-11-10|2008-11-11|Estimate|2010-06-08|2010-07-08|Estimate||||2015-08-10|2015-08-11|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)|A Randomized Clinical Trial to Evaluate the Effects of Multiple Doses of Amlodipine 10 mg on Pedal Edema Measurements in Middle-Aged and Elderly Healthy Subjects and Patient With Hypertension|Completed||Phase 1|47|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:35:21.226549|2018-06-01 01:35:21.226549
NCT00789308|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2015-08-12|2008-11-10|2008-11-11|Estimate|||||||2015-08-12|2015-08-14|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation|Open Randomized Mult-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation (CIT-01A)|Completed||Phase 2|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:35:21.488746|2018-06-01 01:35:21.488746
NCT00789295|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|March 2004||2004-03-31|October 2008|2008-10-31||||||||Interventional|||Mediterranean Diet and Postprandial Lipemia|Mediterranean vs. Low-Carbohydrate Diet : Which is the Best Dietary Approach for Treating Postprandial Lipid Abnormalities and Improving Glucose Control in Type 2 Diabetic Patients?|Completed||N/A|||Federico II University||2|||f||||f||||||||||2018-06-01 01:35:21.60666|2018-06-01 01:35:21.60666
NCT00789282|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2017-05-17|2008-11-10|2008-11-11|Estimate|||||||2017-05-17|2017-05-19|Actual|February 2008||2008-02-29|April 2016|2016-04-30|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|||Improving the Care of Diabetic Patients: A Randomized Trial of a Family Physician Office-Based Chronic Disease Care Model for Patients With Type 2 Diabetes|Single-blinded, Two-arm, Randomized Clinical Trial of Patients With Type 2 Diabetes Mellitus That Will Compare'Usual Care' With an 'Enhanced Care' Model of Chronic Disease Management That is Based in the Practices of Family Physicians Participating in Primary Care Networks (PCN's).|Terminated||N/A|22|Actual|University of Alberta||2||Recruitment challenges.|f||||f||||||||||2018-06-01 01:35:21.681299|2018-06-01 01:35:21.681299
NCT00789269|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2010-05-26|2008-11-10|2008-11-11|Estimate|||||||2010-05-26|2010-05-28|Estimate|January 2009||2009-01-31|September 2009|2009-09-30||||||||Interventional|||Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From a Stroke||Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Fudan University||2|||f||||||||||||||2018-06-01 01:35:21.753553|2018-06-01 01:35:21.753553
NCT00789256|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2013-05-29||2018-03-20|2008-11-10|2008-11-11|Estimate|2013-05-29|2013-07-22|Estimate||||2018-03-20|2018-04-17|Actual|September 2004||2004-09-30|March 2018|2018-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Low Dose Melphalan and Bortezomib for AML and High-Risk MDS|A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes|Completed||N/A|26|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 01:35:21.849673|2018-06-01 01:35:21.849673
NCT00789243|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2010-10-22|2008-11-10|2008-11-11|Estimate|||||||2010-10-22|2010-10-25|Estimate|November 2008||2008-11-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of Ischaemic-Reperfusion and Ischaemic Preconditioning on the Endogenous Fibrinolysis in Man|The Effect of Ischaemic-Reperfusion and Ischaemic Preconditioning on the Endogenous Fibrinolysis in Man|Completed||N/A|12|Anticipated|University of Edinburgh||3|||f||||f||||||||||2018-06-01 01:35:22.139134|2018-06-01 01:35:22.139134
NCT00789230|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-09|||2018-02-22|2008-11-09|2008-11-11|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2006||2006-01-31|February 2018|2018-02-28|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|HUMP||Mesh Versus Suture Repair for Umbilical Hernias|Mesh Versus Suture Repair for Umbilical Hernias: a Double Blinded, Randomised Controlled Clinical Trial|Completed||N/A|300|Actual|Erasmus Medical Center||2|||f||||t|f|f||||||No||2018-06-01 01:35:22.219792|2018-06-01 01:35:22.219792
NCT00789217|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2010-11-26|2008-11-07|2008-11-11|Estimate|||||||2010-11-26|2010-11-29|Estimate|December 2008||2008-12-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|||Penicillin Skin Testing in Patients With History of Allergic Reactions to Betalactams|The Comparative Results of Penicillin Testing in Patients With History of Allergic Reactions to Betalactams Between Using In-house Penicillin Test Preparation and Commercial Available Penicillin Testing Kit|Completed||N/A|63|Actual|Chulalongkorn University||3|||f||||f||||||||||2018-06-01 01:35:22.327735|2018-06-01 01:35:22.327735
NCT00789204|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2009-09-21|2008-11-10|2008-11-11|Estimate|||||||2009-09-21|2009-09-22|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Postural Re-education in Low Back Pain|"Effectiveness of a Global Posture Reeducation Program for Patients With Low Back Pain"|Completed||Phase 1|100|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 01:35:22.397664|2018-06-01 01:35:22.397664
NCT00789191|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2010-11-18||2017-02-02|2008-11-10|2008-11-11|Estimate|2010-11-18|2010-12-10|Estimate||||2017-02-02|2017-03-14|Actual|November 2008||2008-11-30|February 2017|2017-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes|Effect of Detemir and Sitagliptin on Blood Glucose Control in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|222|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:35:22.495817|2018-06-01 01:35:22.495817
NCT00789178|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-09|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|April 2010|Anticipated|2010-04-30|October 2009|Anticipated|2009-10-31||Observational|||Cognitive and Memory Function in Patients With Fibromyalgia|Cognitive and Memory Function in Patients With Fibromyalgia and Their Influence on Disability|Unknown status|Not yet recruiting||80|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||||2018-06-01 01:35:23.344297|2018-06-01 01:35:23.344297
NCT00789165|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-08|||2017-01-08|2008-11-10|2008-11-11|Estimate|||||||2017-01-08|2017-01-10|Estimate|December 2009||2009-12-31|January 2017|2017-01-31||||December 2019|Anticipated|2019-12-31||Interventional|||Empiric Quinidine for Asymptomatic Brugada Syndrome|A Prospective Trial Of Empiric Quinidine Therapy For Asymptomatic Brugada Syndrome.|Recruiting||Phase 2/Phase 3|200|Anticipated|International Registry of Asymptomatic Brugada Syndrome||2|||f||||f||||||||||2018-06-01 01:35:23.467233|2018-06-01 01:35:23.467233
NCT00789152|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-03-22|2008-11-07|2008-11-11|Estimate|||||||2017-03-22|2017-03-24|Actual|December 1, 2003|Actual|2003-12-01|March 2017|2017-03-31|May 1, 2004|Actual|2004-05-01|May 1, 2004|Actual|2004-05-01||Interventional|||The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)|The Effects of Desloratadine and Levocetirizine on Nasal Obstruction in Subjects With Induced Allergic Rhinitis in the VCC Assessed Clinically and With Nasal Rhinomanometry and Nasal Flowmetry|Completed||Phase 3|81|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:35:23.597281|2018-06-01 01:35:23.597281
NCT00789139|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2015-06-18|2008-11-10|2008-11-11|Estimate|||||||2015-06-18|2015-06-19|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|RAPID XT||Recurrence of Arrhythmias After Pulmonary Veins Isolation Detected by ICM|Recurrence of Arrhythmias After Pulmonary Veins Isolation Detected by ICM|Completed||Phase 4|47|Actual|Hospital St. Joseph, Marseille, France||1|||f||||t||||||||||2018-06-01 01:35:23.69583|2018-06-01 01:35:23.69583
NCT00789126|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2009-02-18|2008-11-09|2008-11-11|Estimate|||||||2009-02-18|2009-02-19|Estimate|October 2008||2008-10-31|February 2009|2009-02-28||||||||Interventional|||Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Single-Dose Escalation Study and Multiple-Dose Escalation Study of VX-509 in Healthy Subjects|Completed||Phase 1|72|Anticipated|Vertex Pharmaceuticals Incorporated|||||||||||||||||||2018-06-01 01:35:23.7747|2018-06-01 01:35:23.7747
NCT00789113|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2015-01-29||2015-12-14|2008-11-07|2008-11-11|Estimate|2015-12-14|2016-01-20|Estimate||||2015-12-14|2016-01-20|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Determination of Absorption and Elimination of Lamotrigine-XR|Determination of Bioavailability and Clearance of Lamotrigine-XR by a Stable Isotope Technique|Completed||Phase 1/Phase 2|12|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 01:35:23.846757|2018-06-01 01:35:23.846757
NCT00789100|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2014-07-15|2008-11-10|2008-11-11|Estimate|||||||2014-07-15|2014-07-17|Estimate|February 2009||2009-02-28|July 2014|2014-07-31|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Observational|||Evaluation of Remote Patient Monitoring.|Evaluation of a Home-based Telemonitor Service|Withdrawn|||0|Actual|Brunel University|||2|Nottingham PCT withdrew for financial reasons|f||||t||||||||||2018-06-01 01:35:24.106712|2018-06-01 01:35:24.106712
NCT00789087|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|January 2005||2005-01-31|November 2008|2008-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion|Analysis of Clinical and Radiological Results of Two Methods of Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion|Completed||Phase 4|60|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:35:24.225304|2018-06-01 01:35:24.225304
NCT00789074|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2011-08-04||2013-11-18|2008-11-10|2008-11-11|Estimate|2012-05-21|2012-06-25|Estimate||||2013-11-18|2013-12-12|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Use of Varenicline for 4-weeks Prior to Quitting|Effects of an Extended Period of Varenicline Use Prior to Quitting Smoking on Post-quitting Urges to Smoke|Completed||Phase 3|101|Actual|Queen Mary University of London||2|||f||||f||||||||||2018-06-01 01:35:24.319893|2018-06-01 01:35:24.319893
NCT00789061|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|August 2006||2006-08-31|November 2008|2008-11-30|July 2009|Anticipated|2009-07-31|March 2008|Anticipated|2008-03-31||Interventional|||Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation|Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:35:24.807138|2018-06-01 01:35:24.807138
NCT00789048|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-09|||2011-04-27|2008-11-10|2008-11-11|Estimate|||||||2011-04-27|2011-04-28|Estimate|January 2009||2009-01-31|November 2008|2008-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||"The Influence of Operating Table Position Simulating Radiographs on Acetabular Cup Angle During Primary Total Hip Replacement"|"The Influence of Operating Table Position Simulating Radiographs on Acetabular Cup Angle During Primary Total Hip Replacement"|Completed||N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:35:24.933223|2018-06-01 01:35:24.933223
NCT00789035|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2014-05-16||2014-05-16|2008-11-10|2008-11-11|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|October 2008||2008-10-31|May 2014|2014-05-31||||October 2009|Actual|2009-10-31||Interventional||The treated set (TS) consisting of all randomised patients who were treated with at least 1 dose of study drug.|12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients|A Phase IIb, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (5 mg, 10 mg and 25 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo, as Monotherapy, With an Additional Open-label Metformin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control|Completed||Phase 2|408|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:35:25.028651|2018-06-01 01:35:25.028651
NCT00789022|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-09|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|January 2009||2009-01-31|November 2008|2008-11-30||||July 2010|Anticipated|2010-07-31||Observational|||Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment||Unknown status|Not yet recruiting||80|Anticipated|Shalvata Mental Health Center|||3||f||||f||||||||||2018-06-01 01:35:25.687316|2018-06-01 01:35:25.687316
NCT00789009|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-08|||2018-03-27|2008-11-08|2008-11-11|Estimate|||||||2018-03-27|2018-03-29|Actual|December 1, 2008||2008-12-01|December 15, 2017|2017-12-15||||||||Observational|||Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection|Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:35:25.755166|2018-06-01 01:35:25.755166
NCT00788996|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-09|||2008-11-12|2008-11-10|2008-11-11|Estimate|||||||2008-11-12|2008-11-13|Estimate|January 2009||2009-01-31|November 2008|2008-11-30|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|BIBE||Reduction of Environmental Tobacco Smoke (ETS) Exposure at Home: the BIBE Study|Effectiveness of a Brief Intervention Opportunistic Targeting Parents Who Smoke to Reduce Exposure to Secondhand Smoke in Babies: STUDY BIBE|Unknown status|Not yet recruiting|Phase 2|552|Anticipated|Jordi Gol i Gurina Foundation||1|||f||||t||||||||||2018-06-01 01:35:25.826408|2018-06-01 01:35:25.826408
NCT00788983|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2013-09-19|2008-11-10|2008-11-11|Estimate|||||||2013-09-19|2013-09-20|Estimate|November 2008||2008-11-30|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Induced Hypoxia Study for Validation of SpO2 Accuracy|Pulse Oximeter Responses to Multiple Levels of Stable Hypoxia|Completed|||12|Actual|Nonin Medical, Inc|||||f||||f||||||||||2018-06-01 01:35:26.025849|2018-06-01 01:35:26.025849
NCT00788970|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2009-01-12|2008-11-10|2008-11-11|Estimate|||||||2009-01-12|2009-01-13|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Shiatsu Adjuvant Therapy And Placebo For Schizophrenia|Shiatsu Adjuvant Therapy And Placebo For Schizophrenia:a Double Blind Study|Unknown status|Not yet recruiting|N/A|150|Anticipated|Herzog Hospital||3|||f||||t||||||||||2018-06-01 01:35:26.149563|2018-06-01 01:35:26.149563
NCT00788957|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2015-03-24|2014-03-26|2015-06-23|2008-11-10|2008-11-11|Estimate|2015-06-23|2015-07-20|Estimate|2014-03-26|2014-04-22|Estimate|2015-06-23|2015-07-20|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|October 2013|Actual|2013-10-31|February 2012|Actual|2012-02-29||Interventional||Safety analysis set, including participants who received at least one dose of respective investigational product in the corresponding parts of the study.|Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)|A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab Versus Panitumumab Alone in Subject With Wild-Type KRAS Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|153|Actual|Amgen||4|||f||||||||||||||2018-06-01 01:35:26.397018|2018-06-01 01:35:26.397018
NCT00788944|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2011-01-05|2008-11-10|2008-11-11|Estimate|||||||2011-01-05|2011-01-07|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Determine The Percentage Of Depressed Outpatients Who Do Not Effectively Metabolize Extended-release Venlafaxine HCl|An Open-Label Study To Evaluate The Prevalence Of Phenotypic Poor Metabolizers At CYP2D6 Among Venlafaxine-Treated Outpatients With Depression|Completed||Phase 4|971|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:35:28.354621|2018-06-01 01:35:28.354621
NCT00788931|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2012-11-26|2008-11-10|2008-11-11|Estimate|||||||2012-11-26|2012-11-27|Estimate|December 2008||2008-12-31|November 2012|2012-11-30||||August 2010|Actual|2010-08-31||Interventional|||A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer|A Phase Ib, Open-label, Two Arm Study of i.v. and Oral Panobinostat (LBH589) in Combination With i.v. Trastuzumab (Herceptin®) and i.v. Paclitaxel as Treatment for Adult Female Patients With HER2 Overexpressing Metastatic Breast Cancer (MBC)|Completed||Phase 1|15|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:35:28.467882|2018-06-01 01:35:28.467882
NCT00788918|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2013-01-10|2008-11-10|2008-11-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)|Study of Cerebral Function in Patients With Chronic Hepatitis C Infection Before and After Pegylated Interferon Alfa-2a and Ribavirin Therapy|Completed||N/A|100|Actual|University of Aarhus||4|||f||||t||||||||||2018-06-01 01:35:28.545931|2018-06-01 01:35:28.545931
NCT00788905|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2013-03-27|2008-11-10|2008-11-11|Estimate|||||||2013-03-27|2013-03-29|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|January 2014|Anticipated|2014-01-31|February 2011|Actual|2011-02-28||Interventional|||Comparison of Conventional Dialysis and the Allient System|Uremic Toxin Removal, Blood Cell Kinetics, and Inflammatory Response in Patients Treated With the Allient System|Unknown status|Active, not recruiting|N/A|40|Anticipated|Renal Research Institute||1|||f||||f||||||||||2018-06-01 01:35:28.727254|2018-06-01 01:35:28.727254
NCT00788892|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2017-09-03|2012-05-16|2017-12-15|2008-11-10|2008-11-11|Estimate|2017-12-15|2018-01-12|Actual|2012-05-16|2012-05-18|Estimate|2017-12-15|2018-01-12|Actual|October 2008||2008-10-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional||Safety population: All randomized participants who received at least one dose of study drug.|Trial of CPX-351 in Newly Diagnosed Elderly AML Patients|Phase IIB, Multicenter, Randomized, Open Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients With Untreated AML 60-75 Years of Age.|Completed||Phase 2|126|Actual|Jazz Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:35:28.902013|2018-06-01 01:35:28.902013
NCT00788879|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2013-05-07|2008-11-10|2008-11-11|Estimate|||||||2013-05-07|2013-05-09|Estimate|February 2003||2003-02-28|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TSSC||Tu Salud Si Cuenta Media Campaign|Evaluation of a Media Campaign: Tu Salud Si Cuenta|Completed||N/A|3100|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 01:35:29.540713|2018-06-01 01:35:29.540713
NCT00788866|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2014-10-16|2008-11-10|2008-11-11|Estimate|||||||2014-10-16|2014-10-17|Estimate|December 2008||2008-12-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|POM-1||Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)|Impact of Maternal Pomegranate Juice on Brain Injury in Infants With Intrauterine Growth Restriction (IUGR)|Completed||N/A|80|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:35:29.611938|2018-06-01 01:35:29.611938
NCT00788853|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2014-06-23|2008-11-10|2008-11-11|Estimate|||||||2014-06-23|2014-06-24|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|DiabCare Asia||A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia|DiabCare Asia 2008. A Cross-sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia and to Evaluate Perceptions and Practices of Physicians and Patients About Diabetes Management in Asia. DiabCare Asia 2008 - Indonesia|Completed|||1832|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 01:35:29.783391|2018-06-01 01:35:29.783391
NCT00788840|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|January 2008||2008-01-31|November 2008|2008-11-30||||August 2009|Anticipated|2009-08-31||Interventional|DEES||Detemir Energy Expenditure Study|A 24-Week, National, Single-Centre, Open-Labelled, Randomised, Parallel-Group Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as the Mealtime Insulin in Subjects With Type 2 Diabetes|Unknown status|Recruiting|Phase 4|30|Anticipated|University of Surrey||2|||f||||t||||||||||2018-06-01 01:35:29.879499|2018-06-01 01:35:29.879499
NCT00788827|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2015-01-21|2008-11-10|2008-11-11|Estimate|||||||2015-01-21|2015-01-22|Estimate|November 2008||2008-11-30|July 2011|2011-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant|A Phase I Safety and Tolerability Study Following the Infusion of Autologous Expanded Progeny of an Adult CD34+ Stem Cell Subset (InsulinCytes) to Patients With Type I Diabetes Mellitus and a Successful Renal Transplant|Completed||Phase 1|7|Actual|Imperial College London||1|||f||||t||||||||||2018-06-01 01:35:29.994745|2018-06-01 01:35:29.994745
NCT00788814|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2012-10-15|2008-11-10|2008-11-11|Estimate|||||||2012-10-15|2012-10-17|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of Pathways Curriculum for Use With WPD|Women Physical Disability and Depression: Communities Responding Now!|Completed||N/A|80|Actual|Oregon Health and Science University||1|||f||||t||||||||||2018-06-01 01:35:31.037505|2018-06-01 01:35:31.037505
NCT00788801|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2010-11-01|2008-11-07|2008-11-11|Estimate|||||||2010-11-01|2010-11-02|Estimate|December 2008||2008-12-31|September 2010|2010-09-30||||March 2009|Actual|2009-03-31||Interventional|||Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain||Completed||Phase 1|11|Actual|Abbott||3|||f||||||||||||||2018-06-01 01:35:31.10949|2018-06-01 01:35:31.10949
NCT00788788|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2008-11-20|2008-11-10|2008-11-11|Estimate|||||||2008-11-20|2008-11-21|Estimate|November 2007||2007-11-30|November 2008|2008-11-30||||December 2007|Actual|2007-12-31||Interventional|||Heliox in Experimental Upper Airway Obstruction|PoC Study of Heliox With Helium-Fractions Between 25 and 75% in Experimental Upper Airway Obstruction|Completed||Phase 1/Phase 2|44|Actual|University of Witten/Herdecke||3|||f||||t||||||||||2018-06-01 01:35:31.172706|2018-06-01 01:35:31.172706
NCT00788775|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2016-08-22||2018-04-20|2008-11-10|2008-11-11|Estimate|2016-10-16|2016-12-08|Estimate||||2018-04-20|2018-05-18|Actual|January 2009||2009-01-31|April 2018|2018-04-30|March 2014|Actual|2014-03-31|April 2011|Actual|2011-04-30||Interventional||The analysis dataset is comprised of treated patients.|Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma|A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma|Completed||Phase 2|20|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 01:35:31.287345|2018-06-01 01:35:31.287345
NCT00788762|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2014-05-09|2008-11-07|2008-11-11|Estimate|||||||2014-05-09|2014-05-12|Estimate|August 2007||2007-08-31|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|Taxiarchis||Myocilin Variations and Familial Glaucoma in Taxiarchis|Myocilin Variations and Familial Glaucoma in Taxiarchis, A Small Greek Village.|Unknown status|Recruiting||800|Anticipated|Aristotle University Of Thessaloniki|||1||f||||f||||||Samples With DNA|"~     Myocilin screening was performed from blood or saliva specimens taken from the village. The~     promoter region and exons 1-3 of myocilin were sequenced at the Portland Veterans~     Administration Medical center. Microsatellite marker analysis in the GLC1A region, including~     D1S452, D1S1619, D1S2790 and D1S242 was performed at deCODE (Reykjavik, Iceland).~   "|||2018-06-01 01:35:32.002275|2018-06-01 01:35:32.002275
NCT00788749|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|May 2004||2004-05-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|February 2008|Actual|2008-02-29||Interventional|||Medical Polypectomy and Predictors of Response|A Proof Of Concept Study to Investigate the Clinical, Histological And Molecular Predictors of Response to Oral and Intranasal Corticosteroid in Nasal Polyposis|Completed||Phase 4|60|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 01:35:32.099901|2018-06-01 01:35:32.099901
NCT00788736|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2016-10-25|2008-11-10|2008-11-11|Estimate|||||||2016-10-25|2016-10-27|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism|Development and Validation of Clinical Prediction Rules for Bleeding for Patients on Anticoagulant Therapy for Venous Thromboembolism|Completed|||2537|Actual|Ottawa Hospital Research Institute|||||f||||f||||||Samples With DNA|"~     Subjects may consent to optional DNA and plasma banking~   "|Undecided||2018-06-01 01:35:32.21168|2018-06-01 01:35:32.21168
NCT00788723|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2008-11-10|2008-11-10|2008-11-11|Estimate|||||||2008-11-10|2008-11-11|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|May 2009|Anticipated|2009-05-31|March 2009|Anticipated|2009-03-31||Interventional|||Cortical Excitability in Patients With Severe Brain Injury|Cortical Excitability in Patients With Severe Brain Injury|Unknown status|Recruiting|N/A|45|Anticipated|University of Aarhus||3|||f||||f||||||||||2018-06-01 01:35:32.353744|2018-06-01 01:35:32.353744
NCT00788554|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-09|||2011-08-18|2008-11-09|2008-11-11|Estimate|||||||2011-08-18|2011-08-19|Estimate|August 2000||2000-08-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2004|Actual|2004-03-31||Interventional|LEVEL||LEVEL Trial: Correction of Inguinal Hernia, Endoscopic Versus Lichtenstein|LEVEL Trial: Correction of Inguinal Hernia, Endoscopic Versus Lichtenstein. A Randomised Controlled Clinical Trial.|Completed||Phase 3|660|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-06-01 01:35:35.271908|2018-06-01 01:35:35.271908
NCT00788710|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2011-06-22||2015-11-30|2008-11-07|2008-11-11|Estimate|2011-06-22|2011-07-22|Estimate||||2015-11-30|2015-12-02|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Tolerability of MK0663/Etoricoxib in the Treatment of Pain After Abdominal Hysterectomy|Completed||Phase 3|430|Actual|Merck Sharp & Dohme Corp.|11 participants were screened & 10 participants were randomized at site 0028. An audit showed study medication dispensing logs were not kept. These 10 participants were invalidated and excluded from both efficacy & safety analyses.|3|||f||||f||||||||||2018-06-01 01:35:32.464959|2018-06-01 01:35:32.464959
NCT00788697|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2016-09-28|2014-08-18|2017-11-13|2008-11-10|2008-11-11|Estimate|2017-05-17|2017-06-14|Actual|2014-08-19|2014-08-21|Estimate|2017-11-13|2017-12-12|Actual|September 2009||2009-09-30|November 2017|2017-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization|Characterization of Focal Liver Lesions With SONOVUE®-Enhanced Ultrasound Imaging: A Phase III, Intrapatient Comparative Study Versus Un-enhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard|Completed||Phase 3|349|Actual|Bracco Diagnostics, Inc||1|||f||||f||||||||No||2018-06-01 01:35:32.988872|2018-06-01 01:35:32.988872
NCT00788684|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2018-04-23|2008-11-10|2008-11-11|Estimate|||||||2018-04-23|2018-04-25|Actual|August 19, 2009|Actual|2009-08-19|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers|A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Rituximab in Subjects With CD20-positive Lymphoid Malignancies|Active, not recruiting||Phase 1|29|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-06-01 01:35:33.758224|2018-06-01 01:35:33.758224
NCT00788671|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2017-09-12|2008-11-10|2008-11-11|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2008|Actual|2008-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC)|A Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma|Active, not recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:35:33.864542|2018-06-01 01:35:33.864542
NCT00788658|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2016-04-12|2008-11-10|2008-11-11|Estimate|||||||2016-04-12|2016-04-13|Estimate|December 2008||2008-12-31|April 2016|2016-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|EFI||Cognitive Behaviour Therapy for Patients With IBS|Cognitive Behavior Therapy (CBT) as Compared With Standard Therapy for Patients With IBS and Other Functional Gastrointestinal Disorders|Completed||N/A|100|Actual|Rabin Medical Center||2|||f||||t||||||||||2018-06-01 01:35:33.99774|2018-06-01 01:35:33.99774
NCT00788645|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2010-11-30|2008-11-10|2008-11-11|Estimate|||||||2010-11-30|2010-12-02|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||The Use of a Forecasting System for Predicting Exacerbations of COPD|The Use of a Forecasting System for Predicting Exacerbations of COPD: Effect on Symptoms and Hospitalisation and Relevance of Viral Infections|Completed||Early Phase 1|98|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:35:34.085879|2018-06-01 01:35:34.085879
NCT00788632|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2013-03-20|2008-11-10|2008-11-11|Estimate|||||||2013-03-20|2013-03-22|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|ICOMMIITT||Improving Care of Osteoporosis: Multi-Modal Intervention to Increase Testing and Treatment (ICOMMIITT)|Improving Care of Osteoporosis: Multi-Modal Intervention to Increase Testing and Treatment (ICOMMIITT)|Completed||N/A|12128|Actual|University of Alabama at Birmingham||3|||f||||f||||||||||2018-06-01 01:35:34.165192|2018-06-01 01:35:34.165192
NCT00788619|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2017-12-07|2008-11-10|2008-11-11|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2009|Actual|2009-01-31|December 2017|2017-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization (IVF)|Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization|Terminated||N/A|2|Actual|Johns Hopkins University||2||difficulty with recruitment|f||||f||||||||||2018-06-01 01:35:34.279388|2018-06-01 01:35:34.279388
NCT00788606|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2016-10-13|2008-11-10|2008-11-11|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma|Feasibility Study of R-CHOP Plus Bevacizumab in Patients With Diffuse Large B Cell Lymphoma (DLBCL)|Terminated||Phase 2|7|Actual|Royal Marsden NHS Foundation Trust||1||Toxicity and efficacy data from another trial|f||||t||||||||||2018-06-01 01:35:34.350379|2018-06-01 01:35:34.350379
NCT00788593|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|2014-01-27||2014-01-27|2008-11-10|2008-11-11|Estimate|2014-01-27|2014-03-12|Estimate||||2014-01-27|2014-03-12|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||Full analysis set (FAS) included all participants who received at least 1 dose of the study medication.|A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)|A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI)|Completed||Phase 3|82|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 01:35:34.489664|2018-06-01 01:35:34.489664
NCT00788580|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-08|||2015-03-05|2008-11-10|2008-11-11|Estimate|||||||2015-03-05|2015-03-06|Estimate||||March 2015|2015-03-31||||||||Interventional|||S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors|S0718: Phase I Study Evaluating The Combination of GW786034 (Pazopanib; NSC-737754; IND-XXXX) and CCI-779 (Temsirolimus; NSC-683864; IND-XXXX) in Patients With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|Southwest Oncology Group||||Study was discontinued.|f||||||||||||||2018-06-01 01:35:35.072626|2018-06-01 01:35:35.072626
NCT00788567|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2015-11-02|2008-11-10|2008-11-11|Estimate|||||||2015-11-02|2015-11-03|Estimate|June 2005||2005-06-30|November 2015|2015-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants|A Randomized, Open-label Study of the Achievement of a Mycophenolic Acid Therapeutic Window During Treatment With 2 Dosing Regimens of Oral CellCept Administered as a Component of Standard Immunosuppressive Therapy in Patients With Kidney Transplants|Completed||Phase 3|136|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:35:35.177945|2018-06-01 01:35:35.177945
NCT00788138|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2010-10-08|2008-11-07|2008-11-10|Estimate|||||||2010-10-08|2010-10-11|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Vitamin D Supplementation on Lung Function in an Acute Pulmonary Exacerbation of Cystic Fibrosis||Completed||N/A|30|Anticipated|Atlanta VA Medical Center||2|||f||||f||||||||||2018-06-01 01:35:39.090411|2018-06-01 01:35:39.090411
NCT00788541|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07||2012-11-28|2012-11-28|2008-11-10|2008-11-11|Estimate||||2012-11-28|2012-11-30|Estimate|2012-11-28|2012-11-30|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension|A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension|Terminated||Phase 2|197|Actual|Alcon Research||6||Project cancellation|f||||t||||||||||2018-06-01 01:35:35.345935|2018-06-01 01:35:35.345935
NCT00788528|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07||2018-04-26|2018-04-26|2008-11-10|2008-11-11|Estimate||||2018-04-26|2018-05-01|Actual|2018-04-26|2018-05-01|Actual|August 2008||2008-08-31|April 2018|2018-04-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|OLE||Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects|Open-Label Extension (OLE) Safety and Efficacy Study of Velneperit (S-2367) Following the Year-Long Controlled Clinical Trials of S-2367 in Obese Males and Females|Completed||Phase 2|766|Actual|Shionogi Inc.||1|||f||||f||||||||||2018-06-01 01:35:35.437395|2018-06-01 01:35:35.437395
NCT00788515|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2009-08-27|2008-11-10|2008-11-11|Estimate|||||||2009-08-27|2009-08-28|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|REST||Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties|Comparison of the Safety and Efficacy of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week,Randomized, Double-blind, Comparative, Parallel-group Study.|Terminated||Phase 3|33|Actual|Sanofi||2||"Sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary~   insomnia with predominant sleep maintenance problems"|f||||t||||||||||2018-06-01 01:35:35.669399|2018-06-01 01:35:35.669399
NCT00788502|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2010-05-21|2008-11-10|2008-11-11|Estimate|||||||2010-05-21|2010-05-24|Estimate|October 2008||2008-10-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Stress Reduction During In Vitro Fertilization|Stress Reduction During In Vitro Fertilization|Unknown status|Recruiting|N/A|45|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 01:35:35.746096|2018-06-01 01:35:35.746096
NCT00788489|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2011-10-03|2008-11-10|2008-11-11|Estimate|||||||2011-10-03|2011-10-04|Estimate|January 2006||2006-01-31|October 2011|2011-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|PETLAB||A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy|A Prospective Study to Evaluate the Role of 2-[18F]Fluoro-2-deoxy-D-glucose (FDG)-Positron Emission Tomography (PET), Breast Magnetic Resonance Imaging (MRI), and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|Completed|||49|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||f||||||||||2018-06-01 01:35:35.829324|2018-06-01 01:35:35.829324
NCT00788476|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2015-01-07|2008-11-07|2008-11-11|Estimate|||||||2015-01-07|2015-01-09|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Childhood Cancer Survivor Survey|Needs Assessment Survey in Childhood Cancer Survivors and Their Parents|Completed|||167|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 01:35:35.912344|2018-06-01 01:35:35.912344
NCT00788463|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2017-08-25|2008-11-07|2008-11-11|Estimate|||||||2017-08-25|2017-08-28|Actual|November 23, 2006|Actual|2006-11-23|August 2017|2017-08-31|November 30, 2011|Actual|2011-11-30|March 30, 2009|Actual|2009-03-30||Interventional|||A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps|A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps|Completed||Phase 2|30|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 01:35:36.015767|2018-06-01 01:35:36.015767
NCT00788450|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-09|||2014-01-14|2008-11-09|2008-11-11|Estimate|||||||2014-01-14|2014-01-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:35:36.13992|2018-06-01 01:35:36.13992
NCT00788437|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2009-12-15|2008-11-07|2008-11-11|Estimate|||||||2009-12-15|2009-12-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:35:36.183426|2018-06-01 01:35:36.183426
NCT00788424|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2015-07-22|2008-11-10|2008-11-11|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2008||2008-11-30|June 2008|2008-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Topical Application of AS101 for the Treatment of Psoriasis|Study of Topical Application of AS101 for the Treatment of Psoriasis|Withdrawn||Phase 2|0|Actual|BioMAS Ltd||2||Sponsor's considerations|f||||f||||||||||2018-06-01 01:35:36.227367|2018-06-01 01:35:36.227367
NCT00788398|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2016-02-10|2008-11-07|2008-11-10|Estimate|||||||2016-02-10|2016-02-11|Estimate|June 2009||2009-06-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|FLOW||Fluid Lavage of Open Wounds|Fluid Lavage of Open Wounds (FLOW): A Multi-center, Blinded, Factorial Trial Comparing Alternative Irrigating Solutions and Pressures in Patients With Open Fractures|Completed||N/A|2540|Actual|Greenville Health System||6|||f||||t||||||||||2018-06-01 01:35:36.312283|2018-06-01 01:35:36.312283
NCT00788385|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2015-04-13|2008-11-07|2008-11-10|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Multi-Center Study of ShuntCheck|Multi-Center Study of ShuntCheck|Withdrawn||Phase 4|0|Actual|NeuroDx Development||||Insufficient funding|f||||f||||||||||2018-06-01 01:35:36.471585|2018-06-01 01:35:36.471585
NCT00788372|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2013-03-21||2013-06-25|2008-11-06|2008-11-10|Estimate|2013-06-25|2013-06-26|Estimate||||2013-06-25|2013-06-26|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain|A Long-Term Study of JNS020QD in Patients With Chronic Pain|Completed||Phase 3|142|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-06-01 01:35:36.549816|2018-06-01 01:35:36.549816
NCT00788359|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2014-12-01|2008-11-06|2008-11-10|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2012|Actual|2012-07-31||Observational|||Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation|Multi-center Trial to Validate Protein Biomarkers of a Pulmonary Exacerbation in Cystic Fibrosis|Completed|||123|Actual|University of Colorado, Denver|||||f||||f||||||Samples Without DNA|"~     Blood (plasma)~   "|||2018-06-01 01:35:37.166818|2018-06-01 01:35:37.166818
NCT00788346|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2012-12-19|2008-11-07|2008-11-10|Estimate|||||||2012-12-19|2012-12-20|Estimate|March 2007||2007-03-31|November 2008|2008-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Reducing the Unnecessary Use of Heavily Marketed Medications: A Randomized Controlled Trial|Reducing Unnecessary Use of Heavily Marketed Medicines: A Randomized Controlled Trial of Computerized Prescribing Alerts and Clinician Education|Completed||N/A|257|Actual|VA Boston Healthcare System||3|||f||||f||||||||||2018-06-01 01:35:37.263517|2018-06-01 01:35:37.263517
NCT00788333|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2012-07-12|2008-11-07|2008-11-10|Estimate|||||||2012-07-12|2012-07-13|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer|A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin®) in Subjects With Advanced or Metastatic Her-2-positive Breast Cancer|Completed||Phase 1/Phase 2|40|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:35:37.336572|2018-06-01 01:35:37.336572
NCT00788320|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2012-01-18|2008-11-07|2008-11-10|Estimate|||||||2012-01-18|2012-01-20|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Vitamin D in Active Tuberculosis (TB) Study|Antimicrobial Peptide LL-37 (Cathelicidin) Production in Active Tuberculosis Disease: Role of Vitamin D Supplementation|Withdrawn||N/A|0|Actual|Atlanta VA Medical Center||2||Inadequate enrollment|f||||f||||||||||2018-06-01 01:35:37.455236|2018-06-01 01:35:37.455236
NCT00788307|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2018-02-07|2008-11-07|2008-11-10|Estimate|||||||2018-02-07|2018-02-09|Actual|July 2009|Actual|2009-07-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy|Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine|Active, not recruiting||Phase 1|24|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 01:35:37.5291|2018-06-01 01:35:37.5291
NCT00788294|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2009-07-14|2008-11-07|2008-11-10|Estimate|||||||2009-07-14|2009-07-15|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously|Pharmacokinetics And Safety Of A Single Dose Subcutaneous Or Intravenous Administration Of Tanezumab In Healthy Volunteers: An Open-Label, Non-Randomized Phase 1 Study|Completed||Phase 1|76|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:35:37.654711|2018-06-01 01:35:37.654711
NCT00788281|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2008-11-12|2008-11-07|2008-11-10|Estimate|||||||2008-11-12|2008-11-13|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|April 2016|Anticipated|2016-04-30|April 2011|Anticipated|2011-04-30||Interventional|||A Multi-Center Randomised Controlled Study to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer||Unknown status|Recruiting|Phase 2|200|Anticipated|Beijing Friendship Hospital||2|||f||||||||||||||2018-06-01 01:35:37.721417|2018-06-01 01:35:37.721417
NCT00788255|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2016-02-03||2016-10-17|2008-11-07|2008-11-10|Estimate|2016-08-22|2016-10-18|Estimate||||2016-10-17|2016-11-28|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational||All blood samples for this study were taken from a total cohort of 25 patients|In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.|In-vitro Study to Assess the Coagulation Effects of Exogenous Oxytocin Using Thromboelastography.|Completed|||25|Actual|Stanford University|||1||f||||t||||||None Retained|"~     Venous blood~   "|No||2018-06-01 01:35:37.799323|2018-06-01 01:35:37.799323
NCT00788242|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2016-11-22|2008-11-07|2008-11-10|Estimate|||||||2016-11-22|2016-11-23|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Glucose-Insulin-Potassium Infusion in Patients Undergoing Cardiac Surgery|The Effect of Glucose-Insulin-Potassium Infusion on Myocardial Injuries and Cardiac Function in Patients Undergoing Cardiac Surgery|Completed||N/A|200|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 01:35:38.260286|2018-06-01 01:35:38.260286
NCT00788229|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2010-04-01|2008-11-07|2008-11-10|Estimate|||||||2010-04-01|2010-04-02|Estimate|November 2008||2008-11-30|April 2010|2010-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome|A Phase II, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Safety of DHP-101, DHP-300, DHP-500 in Patients With Dry Eye Syndrome|Completed||Phase 2|72|Actual|Dhp Korea Co., Ltd.||4|||f||||t||||||||||2018-06-01 01:35:38.390881|2018-06-01 01:35:38.390881
NCT00788216|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2013-07-11|2008-11-07|2008-11-10|Estimate|||||||2013-07-11|2013-07-15|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|September 2009|Actual|2009-09-30||Observational|||Development & Validation of Utilities for Health States Relevant to Cervical Cancer Patients|Development and Validation of A Comprehensive Instrument to Determine Utilities for Health States Relevant to Cervical Gynecologic Cancer Patients|Completed|||60|Actual|Duke University|||2||f||||f||||||||||2018-06-01 01:35:38.48982|2018-06-01 01:35:38.48982
NCT00788203|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2011-07-21|2008-11-07|2008-11-10|Estimate|||||||2011-07-21|2011-07-25|Estimate|August 2008||2008-08-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Prevention of Childhood Obesity|The Development of an Early Intervention for the Prevention of Childhood Obesity|Completed|||130|Actual|Stanford University|||2||f||||||||||||||2018-06-01 01:35:38.606303|2018-06-01 01:35:38.606303
NCT00788190|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2011-04-07|2008-11-07|2008-11-10|Estimate|||||||2011-04-07|2011-04-11|Estimate|November 2008||2008-11-30|November 2008|2008-11-30||||||||Interventional|||Treatment of Distal Radius Fractures in Elderly Patients|Treatment of Distal Radius Fractures in Elderly Patients, a Randomized Controlled Trial|Withdrawn||N/A|65|Anticipated|Hand and Upper Limb Clinic, Canada||2||The inclusion/Exclusion criteria was too strict which restricted recruitment|f||||f||||||||||2018-06-01 01:35:38.685179|2018-06-01 01:35:38.685179
NCT00788177|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2011-09-26|2008-11-07|2008-11-10|Estimate|||||||2011-09-26|2011-09-27|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|December 2012|Anticipated|2012-12-31|March 2012|Anticipated|2012-03-31||Interventional|||Subretinal Macugen® for Neovascular Age-Related Macular Degeneration|Subretinal Macugen® for Neovascular Age-Related Macular Degeneration (SUMANA)|Unknown status|Recruiting|Phase 3|10|Anticipated|Klinikum Ludwigshafen|||||f||||f||||||||||2018-06-01 01:35:38.771707|2018-06-01 01:35:38.771707
NCT00788164|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2017-11-01|2008-11-07|2008-11-10|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2008||2008-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia|A Phase I Efficacy and Safety Study of HPV16-specific Therapeutic DNA-vaccinia Vaccination in Combination With Topical Imiquimod, in Patients With HPV16+ High Grade Cervical Dysplasia (CIN3)|Recruiting||Phase 1|48|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-06-01 01:35:38.857738|2018-06-01 01:35:38.857738
NCT00788151|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2014-09-18|2008-11-07|2008-11-10|Estimate|||||||2014-09-18|2014-09-19|Estimate|October 2008||2008-10-31|September 2014|2014-09-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years|Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru|Completed||Phase 2|300|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:35:38.958548|2018-06-01 01:35:38.958548
NCT00788125|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2018-02-09|2008-11-07|2008-11-10|Estimate|||||||2018-02-09|2018-02-12|Actual|September 3, 2008||2008-09-03|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors|Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial|Active, not recruiting||Phase 1/Phase 2|143|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:35:39.188667|2018-06-01 01:35:39.188667
NCT00788112|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2017-08-04|2008-11-07|2008-11-10|Estimate|||||||2017-08-04|2017-08-07|Actual|July 2009||2009-07-31|August 2017|2017-08-31|August 11, 2015|Actual|2015-08-11|November 3, 2011|Actual|2011-11-03||Interventional|||Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast|A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast|Completed||Phase 1|17|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:35:39.317085|2018-06-01 01:35:39.317085
NCT00788099|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2011-06-06|2008-11-07|2008-11-10|Estimate|||||||2011-06-06|2011-06-07|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas|Completed||Phase 1|45|Actual|PharmaMar||2|||f||||f||||||||||2018-06-01 01:35:39.396532|2018-06-01 01:35:39.396532
NCT00788073|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2013-02-07||2013-03-22|2008-11-07|2008-11-10|Estimate|2013-03-22|2013-05-06|Estimate||||2013-03-22|2013-05-06|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome|A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome|Completed||Phase 2|63|Actual|Seaside Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 01:35:39.482897|2018-06-01 01:35:39.482897
NCT00788060|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2015-02-12|2008-11-07|2008-11-10|Estimate|||||||2015-02-12|2015-02-16|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Rad/Sutent||A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma|A Single Arm, Phase Ib Study of RAD001 and Sunitinib in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 1|5|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:35:39.769786|2018-06-01 01:35:39.769786
NCT00788047|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2009-03-05|2008-11-07|2008-11-10|Estimate|||||||2009-03-05|2009-03-09|Estimate|November 2008||2008-11-30|March 2009|2009-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan|A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:35:39.875612|2018-06-01 01:35:39.875612
NCT00788034|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2015-06-22|2008-11-07|2008-11-10|Estimate|||||||2015-06-22|2015-06-23|Estimate|October 2008||2008-10-31|December 2012|2012-12-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder|A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Lu AA21004 in Patients With Generalized Anxiety Disorder|Completed||Phase 3|459|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:35:39.96753|2018-06-01 01:35:39.96753
NCT00788021|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2013-11-21|2008-11-07|2008-11-10|Estimate|||||||2013-11-21|2013-11-25|Estimate|September 2006||2006-09-30|November 2013|2013-11-30|October 2011|Actual|2011-10-31|January 2011|Actual|2011-01-31||Observational|PIP-01||Protective Immunity Project 01|Characterization of the Impact of Chronic Immunosuppressive Regimens on Protective Immunity Over Time in Renal Transplant Recipients|Completed|||124|Actual|Emory University|||3||f||||t||||||Samples Without DNA|"~     Whole blood, serum, PBMCs~   "|||2018-06-01 01:35:40.138979|2018-06-01 01:35:40.138979
NCT00788008|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2014-12-24||2015-03-23|2008-11-07|2008-11-10|Estimate|2015-03-23|2015-03-26|Estimate||||2015-03-23|2015-03-26|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly|Does Inhalational Anesthesia Accelerate Postoperative Cognitive Decline?|Completed||N/A|200|Actual|Duke University||2|||f||||t||||||||||2018-06-01 01:35:40.203038|2018-06-01 01:35:40.203038
NCT00787995|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2014-12-05|2008-11-06|2008-11-10|Estimate|||||||2014-12-05|2014-12-08|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)|A Multicenter, Multinational, Longitudinal Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)|Terminated|||353|Actual|BioMarin Pharmaceutical|||1||f||||f||||||||||2018-06-01 01:35:40.376964|2018-06-01 01:35:40.376964
NCT00787982|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2009-12-30|2008-11-07|2008-11-10|Estimate|||||||2009-12-30|2010-01-01|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|September 2010|Anticipated|2010-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors|Pilot Study Evaluating the Feasibility of Real-Time, Magnetic Resonance Thermal Imaging and Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Visualase, Inc.|||||f||||t||||||||||2018-06-01 01:35:40.443674|2018-06-01 01:35:40.443674
NCT00787969|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2018-01-08|2008-11-07|2008-11-10|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2009|Actual|2009-04-30|January 2018|2018-01-31|June 15, 2017|Actual|2017-06-15|April 2012|Actual|2012-04-30||Interventional|||Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)|Completed||Phase 1|74|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 01:35:40.528526|2018-06-01 01:35:40.528526
NCT00787956|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2013-04-09|2008-11-07|2008-11-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Internet Chronic Disease Self-Management Program for Australia|Evaluation of an Internet Chronic Disease Self-Management Program for Australia|Completed||Phase 3|300|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 01:35:40.940565|2018-06-01 01:35:40.940565
NCT00787943|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2010-09-24||2015-04-10|2008-11-07|2008-11-10|Estimate|2010-10-20|2010-11-17|Estimate||||2015-04-10|2015-05-01|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris|A Split-face, Paired-comparison, Pilot Study to Evaluate Safety and Efficacy of Two Topical Benzoyl Peroxide 10.0% Creams for Mild to Moderate Acne Vulgaris|Completed||N/A|10|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 01:35:41.034897|2018-06-01 01:35:41.034897
NCT00787930|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2012-12-31||2014-07-03|2008-11-07|2008-11-10|Estimate|2014-07-03|2014-07-31|Estimate||||2014-07-03|2014-07-31|Estimate|October 2005||2005-10-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Observational|BPD||Bipolar Disorder in Late Life|Bipolar Disorder in Late Life (Evaluation of MRI Hyperintensities and DTI in Bipolar Disorder)|Completed|||19|Actual|Duke University|Acute MRI hypothesis unable to be tested due to high subject response. Five subject scans could not be evaluated by DTI computer program.||2||f||||f||||||Samples With DNA|"~     DNA collected for genetic databank.~   "|||2018-06-01 01:35:41.456666|2018-06-01 01:35:41.456666
NCT00787917|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2011-07-11||2011-09-22|2008-11-07|2008-11-10|Estimate|2011-07-11|2011-08-04|Estimate||||2011-09-22|2011-09-26|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)|An Exploratory, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy of Multiple Doses of Omalizumab in Cystic Fibrosis Complicated by Allergic Bronchopulmonary Aspergillosis (ABPA)|Terminated||Phase 4|14|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:35:41.729729|2018-06-01 01:35:41.729729
NCT00787904|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2015-06-22||2016-10-21|2008-11-07|2008-11-10|Estimate|2016-10-21|2016-12-13|Estimate||||2016-10-21|2016-12-13|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|June 2011|Actual|2011-06-30||Observational|||Role of T-cells in Post-Menopausal Osteoporosis|The Role of T-cells in Women Undergoing Surgical Menopause|Completed|||19|Actual|Atlanta VA Medical Center|||3||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:35:42.219862|2018-06-01 01:35:42.219862
NCT00787891|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2012-07-27|2012-07-06|2013-01-22|2008-11-06|2008-11-10|Estimate|2012-09-10|2012-10-11|Estimate|2012-07-06|2012-07-18|Estimate|2013-01-22|2013-01-24|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients|A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endoscopically Proven GERD|Completed||Phase 3|127|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||t||||||||||2018-06-01 01:35:42.515645|2018-06-01 01:35:42.515645
NCT00787878|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2017-01-17|2008-11-07|2008-11-10|Estimate|||||||2017-01-17|2017-01-18|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects|Comparison of Safety in Small for Gestational Age (SGA) Subjects Treated With Norditropin® (Somatropin) 5 Years Ago With Untreated SGA Subjects and With Normal Average for Gestational Age (AGA) Subjects|Completed|||153|Actual|Novo Nordisk A/S|||3||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 01:35:43.196628|2018-06-01 01:35:43.196628
NCT00787865|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2018-02-05|2008-11-07|2008-11-10|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2008||2008-04-30|February 2018|2018-02-28|April 2026|Anticipated|2026-04-30|April 2021|Anticipated|2021-04-30||Observational|||Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease|Diffusion Tensor Imaging (DTI) as a Tool to Identify Infants With Krabbe Disease in Urgent Need of Treatment|Active, not recruiting|||100|Anticipated|University of Pittsburgh|||4||f||||f||||||||||2018-06-01 01:35:43.306129|2018-06-01 01:35:43.306129
NCT00787852|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2013-07-22||2014-07-24|2008-11-07|2008-11-10|Estimate|2013-07-22|2013-09-25|Estimate||||2014-07-24|2014-07-30|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional||11 were enrolled but 10 were treated|A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of Dasatinib With Concurrent Chemoradiation for Stage III NSCLC Principal Investigator: Howard Safran, MD.|Terminated||Phase 1|11|Actual|Brown University||2||for efficacy and safety reasons|f||||f||||||||||2018-06-01 01:35:43.366868|2018-06-01 01:35:43.366868
NCT00787839|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2014-12-05||2015-04-06|2008-11-07|2008-11-10|Estimate|2014-12-19|2014-12-23|Estimate||||2015-04-06|2015-04-27|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational||Individuals receiving care at the Atlanta VA Medical Center|Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care|Screening for Prediabetes and Early Diabetes in Primary Care|Completed|||1939|Actual|VA Office of Research and Development|Study in a single healthcare system, in a convenience sample of patients receiving care in a VA primary care clinic, in a population that was largely older, heavier, and predominantly male, and a single OGTT was used as the “gold standard”.||1||f||||f||||||None Retained|"~     blood samples~   "|||2018-06-01 01:35:44.619846|2018-06-01 01:35:44.619846
NCT00787826|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2017-10-12|2008-11-06|2008-11-10|Estimate|||||||2017-10-12|2017-10-13|Actual|August 28, 2009|Actual|2009-08-28|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine|A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4 in Healthy Adults At-Risk for Exposure to Francisella Tularensis|Enrolling by invitation||Phase 2|1000|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 01:35:44.85441|2018-06-01 01:35:44.85441
NCT00787813|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2008-11-19|2008-11-07|2008-11-10|Estimate|||||||2008-11-19|2008-11-20|Estimate|June 2008||2008-06-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|NAC-CC||N-Acetyl Cysteine After Cervical Cerclage|Effect of Oral N-Acetyl Cysteine on Pregnancy Outcome After Cervical Cerclage: a Randomized Controlled Trial|Completed||N/A|100|Anticipated|Assiut University||2|||f||||f||||||||||2018-06-01 01:35:44.921593|2018-06-01 01:35:44.921593
NCT00787800|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2013-05-21||2014-07-02|2008-11-06|2008-11-10|Estimate|2014-06-08|2014-06-11|Estimate||||2014-07-02|2014-07-24|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|RAPTURE||The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock|Reduction And Prevention of Tachyarrhythmias and Shocks Using Reduced Ventricular Pacing With Atrial Algorithms (The RAPTURE Study)|Completed||Phase 4|100|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:35:45.031492|2018-06-01 01:35:45.031492
NCT00787787|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2017-03-16||2017-04-27|2008-11-07|2008-11-10|Estimate|2017-04-27|2017-06-01|Actual||||2017-04-27|2017-06-01|Actual|September 2008||2008-09-30|April 2017|2017-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer|The CapSul Trial: A Phase II Study of Sunitinib and Capecitabine for the Treatment of Unresectable or Metastatic Hepatocellular Carcinoma (HCC)|Terminated||Phase 2|41|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 01:35:45.726266|2018-06-01 01:35:45.726266
NCT00787774|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|||2010-03-30|2008-11-07|2008-11-10|Estimate|||||||2010-03-30|2010-03-31|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|RAL-dyn||Integrase Resistance Analysis in HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression|Integrase Resistance Analysis in Treated Experienced HIV Patients Who Interrupted Raltegravir Due to Incomplete Viral Suppression|Unknown status|Recruiting|N/A|20|Anticipated|Hospital Clinic of Barcelona|||||f||||f||||||||||2018-06-01 01:35:46.06604|2018-06-01 01:35:46.06604
NCT00787761|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-07|2012-07-09||2012-08-29|2008-11-07|2008-11-10|Estimate|2012-08-29|2012-10-01|Estimate||||2012-08-29|2012-10-01|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|July 2010|Actual|2010-07-31||Interventional|||Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer|Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors|Completed||Phase 2|24|Actual|Northside Hospital, Inc.||1|||f||||f||||||||||2018-06-01 01:35:46.179239|2018-06-01 01:35:46.179239
NCT00787748|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2012-06-14|2008-11-06|2008-11-07|Estimate|||||||2012-06-14|2012-06-15|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|CORSAIB||COPD and Cardiovascular Risk in the Population|COPD and Cardiovascular Risk in the Population|Completed|||623|Actual|Cimera|||||f||||t||||||Samples Without DNA|"~     Samples of serum were frozen at -80 ºC~   "|||2018-06-01 01:35:46.599193|2018-06-01 01:35:46.599193
NCT00787735|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2017-03-02|2008-11-06|2008-11-07|Estimate|||||||2017-03-02|2017-03-06|Actual|January 2004||2004-01-31|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Improving Delivery of Mental Health Services for Patients With Drug Use and Other Behavioral and Emotional Problems|Services Research: Psychiatric Comorbidity in Drug Abuse|Completed||N/A|380|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:35:46.687351|2018-06-01 01:35:46.687351
NCT00787722|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2017-07-17|2008-11-06|2008-11-07|Estimate|||||||2017-07-17|2017-07-21|Actual|October 2008||2008-10-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Hematopoietic Stem Cell Transplant in Devic's Disease|Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease|Recruiting||Phase 1/Phase 2|40|Anticipated|Northwestern University||1|||f||||f||||||||No||2018-06-01 01:35:46.755349|2018-06-01 01:35:46.755349
NCT00787709|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2017-03-22|2008-11-06|2008-11-07|Estimate|||||||2017-03-22|2017-03-27|Actual|May 2007||2007-05-31|March 2017|2017-03-31|February 28, 2014|Actual|2014-02-28|April 2011|Actual|2011-04-30||Interventional|Pathways||Translational Obesity Research|Translational Research: Applying Drug Prevention to Obesity Prevention|Completed||N/A|1005|Actual|University of Southern California||2|||f||||t||||||||||2018-06-01 01:35:46.827496|2018-06-01 01:35:46.827496
NCT00787696|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2011-10-19|2008-11-06|2008-11-07|Estimate|||||||2011-10-19|2011-10-20|Estimate|September 2003||2003-09-30|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Healthy Teen Girls: HIV Risk Reduction|HIV Risk Reduction Among Young Incarcerated Females|Completed||Phase 1/Phase 2|333|Actual|Mississippi State University||2|||f||||f||||||||||2018-06-01 01:35:46.982779|2018-06-01 01:35:46.982779
NCT00787683|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2012-06-25|2008-11-06|2008-11-07|Estimate|||||||2012-06-25|2012-06-26|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|Monitor-ICD||Home-Monitoring in Implantable Cardioverter Defibrillator (ICD) Patients|Home-Monitoring in ICD Patients|Unknown status|Active, not recruiting|N/A|416|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:35:47.076341|2018-06-01 01:35:47.076341
NCT00787670|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2013-02-04|2008-11-06|2008-11-07|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Impact of GBS on CVD in Type 2 Diabetes Mellitus|Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus|Completed||N/A|84|Actual|Duke University||3|||f||||f||||||||||2018-06-01 01:35:47.171139|2018-06-01 01:35:47.171139
NCT00787657|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2015-10-15|2008-11-06|2008-11-07|Estimate|||||||2015-10-15|2015-10-16|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Observational|BEACON||Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment|Betaferon Prospective Study on Adherence, Coping and Nursing Support|Completed|||1723|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:35:47.270784|2018-06-01 01:35:47.270784
NCT00787644|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2015-01-08||2015-02-25|2008-11-06|2008-11-07|Estimate|2015-02-25|2015-02-26|Estimate||||2015-02-25|2015-02-26|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|GLITZ||Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)|A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics. (The GLITZ Asthma Study)|Terminated||Phase 2|28|Actual|University of Vermont|Early termination leading to small numbers of subjects analyzed|2||new safety concerns which emerged about pioglitazone during the trial|f||||t||||||||||2018-06-01 01:35:47.455496|2018-06-01 01:35:47.455496
NCT00787631|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-11-06|2008-11-06|2008-11-07|Estimate|||||||2008-11-06|2008-11-07|Estimate|December 2008||2008-12-31|October 2008|2008-10-31|December 2010|Anticipated|2010-12-31|January 2010|Anticipated|2010-01-31||Observational|||Analysis of Immunological Reactions to Foods in Birch Pollen-Allergic Patients|Analysis of Immunological Reactions to Pollen-Related Foods in Birch Pollen-Allergic Patients|Unknown status|Not yet recruiting||30|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-06-01 01:35:47.794026|2018-06-01 01:35:47.794026
NCT00787618|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2014-06-25||2014-08-08|2008-11-06|2008-11-07|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-08|2014-08-25|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional||Study prematurely terminated, no data available|Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females|A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX® (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers|Terminated||Phase 1/Phase 2|6|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Increased LFTs|f||||f||||||||||2018-06-01 01:35:47.855327|2018-06-01 01:35:47.855327
NCT00787605|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2010-12-20||2016-09-20|2008-11-06|2008-11-07|Estimate|2011-05-20|2011-05-23|Estimate||||2016-09-20|2016-10-27|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|ASTRIDE||Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus|An 8-week Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus|Completed||Phase 4|860|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:35:48.063198|2018-06-01 01:35:48.063198
NCT00787592|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2011-06-27|2008-11-06|2008-11-07|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||SSD vs Collagenase in Pediatric Burn Patients|A Prospective Comparison of Silver Sulfadiazine Cream and Collagenase Ointment for the Treatment of Burns in Children|Unknown status|Active, not recruiting||100|Actual|Children's Mercy Hospital Kansas City|||2||f||||t||||||||||2018-06-01 01:35:48.377019|2018-06-01 01:35:48.377019
NCT00787579|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2008-11-06|2008-11-06|2008-11-07|Estimate|||||||2008-11-06|2008-11-07|Estimate|April 2003||2003-04-30|November 2008|2008-11-30||||April 2008|Actual|2008-04-30||Interventional|||Assessment of Bifocal and Prismatic Bifocal Spectacles for Myopia Control in Children|Assessment of Bifocal and Prismatic Bifocal Spectacles for Myopia Control in Children|Completed||N/A|135|Actual|Essilor International||3|||f||||f||||||||||2018-06-01 01:35:48.456565|2018-06-01 01:35:48.456565
NCT00787566|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2011-05-24||2011-07-05|2008-11-06|2008-11-07|Estimate|2011-05-24|2011-06-21|Estimate||||2011-07-05|2011-07-12|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting|A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic Chemotherapy|Completed||Phase 2|68|Actual|Shin Nippon Biomedical Laboratories, Ltd.||3|||f||||||||||||||2018-06-01 01:35:48.549275|2018-06-01 01:35:48.549275
NCT00787553|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2008-11-06|2008-11-06|2008-11-07|Estimate|||||||2008-11-06|2008-11-07|Estimate|July 2006||2006-07-31|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy|Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy|Unknown status|Active, not recruiting|N/A|75|Actual|University of Campinas, Brazil||3|||f||||t||||||||||2018-06-01 01:35:48.878272|2018-06-01 01:35:48.878272
NCT00787540|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2008-11-06|2008-11-06|2008-11-07|Estimate|||||||2008-11-06|2008-11-07|Estimate|January 2009||2009-01-31|November 2008|2008-11-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Observational|||Chest Pain, Illness Perception Compliance and Psychosocial Outcome After Coronary Arteriography||Unknown status|Not yet recruiting||160|Anticipated|Hillel Yaffe Medical Center|||2||f||||||||||||||2018-06-01 01:35:48.949537|2018-06-01 01:35:48.949537
NCT00787527|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2014-09-02||2014-09-02|2008-11-06|2008-11-07|Estimate|2014-09-02|2014-09-09|Estimate||||2014-09-02|2014-09-09|Estimate|November 2008||2008-11-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma|A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|14|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:35:49.016314|2018-06-01 01:35:49.016314
NCT00787514|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2016-05-20|2008-11-06|2008-11-07|Estimate|||||||2016-05-20|2016-05-23|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||FR in Stored Plasma|Measurement of the Folate Receptor in Stored Plasma From Patients With Ovarian Cancer|Completed|||27|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 01:35:49.399859|2018-06-01 01:35:49.399859
NCT00787501|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2016-02-02|2008-11-06|2008-11-07|Estimate|||||||2016-02-02|2016-02-04|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|ssrifMRI||Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression|Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression|Completed||Phase 1|98|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:35:49.471304|2018-06-01 01:35:49.471304
NCT00787488|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2014-11-10|2008-11-06|2008-11-07|Estimate|||||||2014-11-10|2014-11-11|Estimate|April 2009||2009-04-30|November 2014|2014-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca|A Pilot Study of Intravenous and Intraperitoneal Chemotherapy Plus Abdominal Hyperthermia to Treat Optimally Debulked and Recurrent Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers|Withdrawn||N/A|0|Actual|Duke University||1||Study not funded|f||||f||||||||||2018-06-01 01:35:49.566264|2018-06-01 01:35:49.566264
NCT00787475|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2015-02-02|2008-11-06|2008-11-07|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|NOCHOP||Northern Manhattan Diabetes Community Outreach Project|Northern Manhattan Diabetes Community Outreach Project|Completed||N/A|360|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 01:35:49.654544|2018-06-01 01:35:49.654544
NCT00787462|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2017-08-24|2008-11-06|2008-11-07|Estimate|||||||2017-08-24|2017-08-28|Actual|February 2008||2008-02-29|September 2010|2010-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy|Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy|Terminated||N/A|3|Actual|University of Alberta||2||Restrictive inclusion criteria/limited pool of suitable subjects with SFN.|f||||f||||||||No|Data will not be shared due to insufficient recruitment.|2018-06-01 01:35:49.732167|2018-06-01 01:35:49.732167
NCT00787436|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2013-07-29|2008-11-06|2008-11-07|Estimate|||||||2013-07-29|2013-07-31|Estimate|May 2006||2006-05-31|July 2013|2013-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE|Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using Thalidomide|Withdrawn||Phase 3|0|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 01:35:49.819575|2018-06-01 01:35:49.819575
NCT00787423|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2018-03-20|2008-11-06|2008-11-07|Estimate|||||||2018-03-20|2018-03-21|Actual|November 5, 2008||2008-11-05|March 9, 2018|2018-03-09||||||||Observational|||Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment Population|Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment Population|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:35:49.904565|2018-06-01 01:35:49.904565
NCT00787410|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2012-06-05|2008-11-06|2008-11-07|Estimate|||||||2012-06-05|2012-06-06|Estimate|September 2003||2003-09-30|June 2012|2012-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma|An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma|Completed||Phase 2|23|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:35:49.985208|2018-06-01 01:35:49.985208
NCT00787397|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2016-01-06|2008-11-06|2008-11-07|Estimate|||||||2016-01-06|2016-01-08|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Sleep, Mood, and Behavior Study|Sleep, Mood, and Behavior Study:Transdisciplinary Studies of CBT for Anxiety in Youth|Completed||N/A|51|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:35:50.0535|2018-06-01 01:35:50.0535
NCT00787384|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2010-12-28|2008-11-06|2008-11-07|Estimate|||||||2010-12-28|2010-12-29|Estimate|October 2004||2004-10-31|December 2010|2010-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|NILG-HES1-03||Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes|Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes|Completed||Phase 2|25|Actual|Northern Italy Leukemia Group||1|||f||||f||||||||||2018-06-01 01:35:50.142724|2018-06-01 01:35:50.142724
NCT00787371|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2017-03-08|2008-11-06|2008-11-07|Estimate|||||||2017-03-08|2017-03-13|Actual|June 2005||2005-06-30|March 2017|2017-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)|Study to Confirm Dose Response With PegIntron (SCH 54031) Monotherapy in Patients With Chronic Hepatitis C|Completed||Phase 2|69|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:35:50.223535|2018-06-01 01:35:50.223535
NCT00787358|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2009-06-03|2008-11-06|2008-11-07|Estimate|||||||2009-06-03|2009-06-04|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|SHIFT||A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women|A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women With Intertrochanteric Fracture of the Hip|Withdrawn||Phase 2|50|Anticipated|Zelos Therapeutics||2||Change in company direction|f||||f||||||||||2018-06-01 01:35:50.302671|2018-06-01 01:35:50.302671
NCT00787345|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2010-09-20|2008-11-06|2008-11-07|Estimate|||||||2010-09-20|2010-09-22|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CVC||Simulation-based Training for Surgery Residents in Aseptic Techniques|General Surgery Residents Education in Maximum Barrier Precautions During Central Venous Catheter Placement: Effect of Simulation-Based Training|Completed||Phase 3|50|Anticipated|St. Luke's-Roosevelt Hospital Center||1|||f||||f||||||||||2018-06-01 01:35:50.409551|2018-06-01 01:35:50.409551
NCT00787332|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2012-11-29||2013-01-06|2008-11-06|2008-11-07|Estimate|2012-11-29|2012-12-31|Estimate||||2013-01-06|2013-01-10|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|HIT||A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome|A Comparative Clinical and Pharmacoeconomic Study Comparing Argatroban® IV vs Desirudin SC for Patients With Suspected Heparin-Induced Thrombocytopenia (HIT)With or Without Thrombosis Syndrome (HIT/TS)|Terminated||Phase 4|16|Actual|Canyon Pharmaceuticals, Inc.|Study stopped early due to poor enrollment.|2||Low enrollment|f||||f||||||||||2018-06-01 01:35:50.511192|2018-06-01 01:35:50.511192
NCT00787319|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2013-05-15||2013-10-08|2008-11-06|2008-11-07|Estimate|2013-05-15|2013-08-13|Estimate||||2013-10-08|2013-11-05|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice|Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice|Completed|||108|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:35:50.868388|2018-06-01 01:35:50.868388
NCT00787306|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2018-03-31|2008-11-06|2008-11-07|Estimate|||||||2018-03-31|2018-04-03|Actual|October 2008||2008-10-31|March 2018|2018-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Multi-CHARM||Cardiovascular Health And Risk Modification in Family Health Teams|Multidisciplinary Cardiovascular Health And Risk Modification in Family Health Teams|Completed||Phase 3|229|Actual|University of Toronto||2|||f||||f||||||||No||2018-06-01 01:35:51.229949|2018-06-01 01:35:51.229949
NCT00787293|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2011-02-10|2008-11-05|2008-11-07|Estimate|||||||2011-02-10|2011-02-14|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|November 2015|Anticipated|2015-11-30|November 2010|Actual|2010-11-30||Interventional|PTOLEMY-2||Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients|A Multi-center Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure|Suspended||Phase 2|30|Anticipated|Viacor||1||Company ended operations January 2011|f||||t||||||||||2018-06-01 01:35:51.309686|2018-06-01 01:35:51.309686
NCT00787280|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2013-02-18|2008-11-06|2008-11-07|Estimate|||||||2013-02-18|2013-02-20|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|DIET||Diet, Imaging and Energy Balance Trial (DIET)|Diet, Imaging and Energy Balance Trial|Completed||N/A|51|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:35:51.482263|2018-06-01 01:35:51.482263
NCT00787267|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2014-12-19||2016-05-31|2008-11-06|2008-11-07|Estimate|2014-12-19|2015-01-01|Estimate||||2016-05-31|2016-06-30|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TOP0801|All consented subjects included in baseline analysis.|Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC|Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|37|Actual|Duke University||1||Poor accrual|f||||t||||||||||2018-06-01 01:35:51.555732|2018-06-01 01:35:51.555732
NCT00787254|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2011-02-03||2012-02-01|2008-11-06|2008-11-07|Estimate|2011-04-11|2011-05-10|Estimate||||2012-02-01|2012-02-03|Estimate|April 2007||2007-04-30|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs|A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric and Duodenal Ulcers During Long-term Treatment With Nonsteroid Anti-inflammatory Drug|Completed||Phase 3|366|Actual|Takeda|This study was prematurely discontinued due to results available from a parallel study (AG-1749-CCT-351; NCT00762359) demonstrating a preventive effect on ulcer occurrence which impacted the risk/benefit profile.|2|||f||||t||||||||||2018-06-01 01:35:51.889312|2018-06-01 01:35:51.889312
NCT00787241|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2011-08-16||2014-03-17|2008-11-06|2008-11-07|Estimate|2012-01-16|2012-02-17|Estimate||||2014-03-17|2014-04-14|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Observational|||Platelet Count Trends in Pre-eclamptic Parturients|Platelet Count Trends in Pre-eclamptic Parturients: What is the Predictive Value of an Initial Platelet Count During Labor?|Completed|||445|Actual|Northwestern University|Retrospective trial and obtaining platelet counts was not done per protocol so cannot predict the greatest interval that is acceptable to demonstrate platelet counts greater than 150,000 during labor and delivery.||3||f||||f||||||||||2018-06-01 01:35:53.22827|2018-06-01 01:35:53.22827
NCT00786500|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2010-12-03|2008-11-05|2008-11-06|Estimate|||||||2010-12-03|2010-12-06|Estimate|February 2007||2007-02-28|November 2008|2008-11-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Anti-diabetic Effect of Gynostemma Pentaphyllum Tea in Type 2 Diabetic Patients|Anti-diabetic Effect of Gynostemma Pentaphyllum Tea in Type 2 Diabetic Patients|Completed||Phase 1/Phase 2|24|Actual|Hanoi Medical University||2|||f||||f||||||||||2018-06-01 01:36:04.545201|2018-06-01 01:36:04.545201
NCT00787215|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2015-08-21|2008-11-06|2008-11-07|Estimate|||||||2015-08-21|2015-08-24|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Survey on the Rate of Glucose Intolerance in Hong Kong Chinese|A Survey on the Rate of Glucose Intolerance in Hong Kong Chinese: Validation of the Chinese University Diabetes Screening Score|Active, not recruiting|||3000|Anticipated|Chinese University of Hong Kong|||1||f||||||||||||||2018-06-01 01:35:53.521787|2018-06-01 01:35:53.521787
NCT00787202|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2012-12-04||2013-03-06|2008-11-06|2008-11-07|Estimate|2013-03-06|2013-04-16|Estimate||||2013-03-06|2013-04-16|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.|A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study In Order To Investigate Safety And Efficacy Of CP- 690 550 In Subjects With Moderate To Severe Ulcerative Colitis.|Completed||Phase 2|195|Actual|Pfizer|Pharmacokinetic (PK) parameters and their correlation with clinical response and inflammatory biomarkers were not reported as data from future studies were to be pooled for analysis.|5|||f||||f||||||||||2018-06-01 01:35:53.661061|2018-06-01 01:35:53.661061
NCT00787189|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2009-06-23||2014-04-07|2008-11-06|2008-11-07|Estimate|2011-06-13|2011-07-11|Estimate||||2014-04-07|2014-04-24|Estimate|August 2007||2007-08-31|April 2014|2014-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals|The Effects of the Erchonia Hearing Laser on Word Recognition in Hearing Impaired Individuals Clinical Study Protocol|Completed||N/A|80|Actual|Erchonia Corporation||2|||f||||t||||||||||2018-06-01 01:35:55.154077|2018-06-01 01:35:55.154077
NCT00787176|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2015-10-29|2008-11-06|2008-11-07|Estimate|||||||2015-10-29|2015-11-02|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|July 2012|Actual|2012-07-31|February 2010|Actual|2010-02-28||Interventional|||The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes|The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes|Terminated||N/A|252|Actual|Northwestern University||4||Study concluded prematurely prior to meeting intended goal recruitment.|f||||f||||||||||2018-06-01 01:35:55.38506|2018-06-01 01:35:55.38506
NCT00787163|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2009-01-21|2008-11-06|2008-11-07|Estimate|||||||2009-01-21|2009-01-22|Estimate|September 2008||2008-09-30|November 2008|2008-11-30|December 2013|Anticipated|2013-12-31|September 2011|Anticipated|2011-09-30||Interventional|||Amnioinfusion Initiative|Open Randomized Trial Comparing Perinatal Outcome Following Expectant Management Versus Amnioinfusion in PPROM <25 Wks With Persistent Oligohydramnios|Unknown status|Recruiting|Phase 3|82|Anticipated|Università degli Studi di Brescia||2|||f||||t||||||||||2018-06-01 01:35:55.487106|2018-06-01 01:35:55.487106
NCT00787150|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2013-01-29||2013-04-23|2008-11-05|2008-11-07|Estimate|2013-01-29|2013-03-06|Estimate||||2013-04-23|2013-05-01|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation|A Phase 2b, Randomized, Partially Blind (Open Label Warfarin), Active-Controlled (Warfarin), Multicenter Study, To Evaluate The Safety And Efficacy In 2 Doses Of Apixaban In Comparison To Warfarin, Administered For 12 Weeks In Subjects With NVAF|Completed||Phase 2|222|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 01:35:55.615076|2018-06-01 01:35:55.615076
NCT00787137|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2010-08-12||2010-10-15|2008-11-06|2008-11-07|Estimate|2010-09-25|2010-10-15|Estimate||||2010-10-15|2010-10-26|Estimate|December 2008||2008-12-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Single Dose PG102 in Patients With Active Psoriatic Arthritis|A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis|Terminated||Phase 1|17|Actual|PanGenetics UK Limited|Termination prior to accrual of planned numbers of participants|3||poor recruitment|f||||t||||||||||2018-06-01 01:35:56.185587|2018-06-01 01:35:56.185587
NCT00787124|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2013-07-24||2013-12-13|2008-11-06|2008-11-07|Estimate|2013-12-13|2014-01-15|Estimate||||2013-12-13|2014-01-15|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Transfusions and Nitric Oxide Level in Preterm Infants|Transfusions and Nitric Oxide Level in Preterm Infants|Completed|||8|Actual|Duke University|no AE observed||2||f||||f||||||Samples Without DNA|"~     blood specimens for measurement of SNO-Hb. Samples will be discarded after measurement.~   "|||2018-06-01 01:35:56.561418|2018-06-01 01:35:56.561418
NCT00787111|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2010-02-22|2008-11-06|2008-11-07|Estimate|||||||2010-02-22|2010-02-23|Estimate|November 2008||2008-11-30|February 2010|2010-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|EMMA||Extended Management and Measurement of Autism|Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic Disorder|Terminated||Phase 3|128|Anticipated|Neuropharm||1|||f||||f||||||||||2018-06-01 01:35:56.753643|2018-06-01 01:35:56.753643
NCT00787098|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2009-07-02|2008-11-06|2008-11-07|Estimate|||||||2009-07-02|2009-07-03|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Investigating Modes of Progressive Mobility|Investigating Modes of Progressive Mobility|Completed||Phase 2|82|Anticipated|Hill-Rom||2|||f||||f||||||||||2018-06-01 01:35:56.827688|2018-06-01 01:35:56.827688
NCT00787085|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2008-11-06|2008-11-06|2008-11-07|Estimate|||||||2008-11-06|2008-11-07|Estimate|September 2001||2001-09-30|November 2008|2008-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|FACES||The Significance of Funguria in Hospitalized Patients|The Significance of Funguria in Hospitalized Patients (FACES)|Completed|||919|Actual|Los Angeles Biomedical Research Institute|||2||f||||t||||||Samples Without DNA|"~     Urine and blood cultures~   "|||2018-06-01 01:35:56.892023|2018-06-01 01:35:56.892023
NCT00787072|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2010-11-30|2008-11-06|2008-11-07|Estimate|||||||2010-11-30|2010-12-02|Estimate|October 2008||2008-10-31|November 2010|2010-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||AZD8075 Single Ascending Dose Study|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of AZD8075 in Healthy Male Volunteers|Terminated||Phase 1|72|Anticipated|AstraZeneca||2||"After reports of turbidity in urine in 4 of 8 volunteers in the 4th cohort, the study was~   halted temporarily."|f||||f||||||||||2018-06-01 01:35:56.951862|2018-06-01 01:35:56.951862
NCT00787059|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06||2016-02-18|2018-02-06|2008-11-06|2008-11-07|Estimate||||2016-04-26|2016-05-25|Estimate|2018-02-06|2018-02-09|Actual|July 2010||2010-07-31|August 2017|2017-08-31|November 16, 2017|Actual|2017-11-16|January 2015|Actual|2015-01-31||Interventional|||AC6 Gene Transfer for CHF|Phase I/II Study AC6 Gene Transfer for Congestive Heart Failure|Completed||Phase 1/Phase 2|56|Actual|Hammond, H. Kirk, M.D.||2|||f||||t||||||||Undecided|The trial remains blinded|2018-06-01 01:35:57.927754|2018-06-01 01:35:57.927754
NCT00787033|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2017-01-24|2008-11-05|2008-11-07|Estimate|||||||2017-01-24|2017-01-25|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|B0761001||A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies|A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies|Completed||Phase 1|46|Actual|Verastem, Inc.||1|||f||||f||||||||||2018-06-01 01:35:58.008163|2018-06-01 01:35:58.008163
NCT00787020|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|2010-10-06||2015-10-11|2008-11-06|2008-11-07|Estimate|2010-11-22|2010-12-17|Estimate||||2015-10-11|2015-11-03|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Observational|VISION||Ventriculostomies in SAH: ICP Open or Not?|Ventriculostomies in SAH: ICP Open or Not?|Completed|||37|Actual|Duke University|||2||f||||f||||||||||2018-06-01 01:35:58.104996|2018-06-01 01:35:58.104996
NCT00787007|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-06|||2012-01-19|2008-11-06|2008-11-07|Estimate|||||||2012-01-19|2012-01-20|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers|Randomized, Double-Blind, Single Rising Dose Study of S-equol in Normal Volunteers|Completed||Phase 1|60|Actual|Ausio Pharmaceuticals, LLC||7|||f||||t||||||||||2018-06-01 01:35:58.362297|2018-06-01 01:35:58.362297
NCT00786994|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2015-04-02||2015-08-30|2008-11-05|2008-11-06|Estimate|2015-07-20|2015-08-14|Estimate||||2015-08-30|2015-09-14|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||ITT|The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses|Randomized, Multicenter, Double Blind Study to Compare the Efficacy and Tolerability of Oleogel-S-10 for 3 Month Versus Placebo Only in Patients With Mild to Moderate Actinic Keratoses Located at the Face and Head Oleogel-S-10 in Actinic Keratoses Trial|Completed||Phase 2|165|Actual|Amryt Pharma||4|||f||||f||||||||||2018-06-01 01:35:58.455366|2018-06-01 01:35:58.455366
NCT00786981|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2018-02-06|2008-11-05|2008-11-06|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2009||2009-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Epidural Steroid Injection Versus Epidural Steroid Injection and Manual Physical Therapy and Exercise in the Management of Lumbar Spinal Stenosis|Epidural Steroid Injection Versus Epidural Steroid Injection and Manual Physical Therapy and Exercise in the Management of Lumbar Spinal Stenosis; a Randomized Clinical Trial|Active, not recruiting||N/A|80|Anticipated|Franklin Pierce University||2|||f||||f||||||||||2018-06-01 01:35:59.027527|2018-06-01 01:35:59.027527
NCT00786968|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2013-02-19|2008-11-04|2008-11-06|Estimate|||||||2013-02-19|2013-02-21|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I|An Extension Study of Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis I|Terminated||Phase 1|3|Actual|Dickson, Patricia I., M.D.||1||Due to slow enrolment.|f||||t||||||||||2018-06-01 01:35:59.120426|2018-06-01 01:35:59.120426
NCT00786942|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2010-05-21|2008-11-05|2008-11-06|Estimate|||||||2010-05-21|2010-05-24|Estimate|April 2006||2006-04-30|May 2010|2010-05-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Bone Graft Necessity in Opening-Wedge High Tibial Osteotomy|Bone Graft Necessity in Opening-Wedge High Tibial Osteotomy. A Randomized Clinical Trial|Completed||N/A|44|Anticipated|University of Campinas, Brazil||2|||f||||f||||||||||2018-06-01 01:35:59.220119|2018-06-01 01:35:59.220119
NCT00786929|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2009-02-03|2008-11-05|2008-11-06|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2003||2003-03-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|February 2007|Actual|2007-02-28||Interventional|||Acute Pancreatitis and Acute Fluid Collections|Randomized Controlled Trial on Sterile Fluid Collections Management in Acute Pancreatitis|Completed||Phase 4|63|Actual|University Medical Center, Tuzla||2|||f||||f||||||||||2018-06-01 01:35:59.346382|2018-06-01 01:35:59.346382
NCT00786916|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2013-01-23||2015-02-26|2008-11-05|2008-11-06|Estimate|2015-02-26|2015-02-27|Estimate||||2015-02-26|2015-02-27|Estimate|February 2008||2008-02-29|February 2015|2015-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of IV Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Sedation|Efficacy of Intravenous Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Procedural Sedation|Completed||Phase 4|109|Actual|Akron Children's Hospital|No complications or adverse reactions were associated with either study drug dose.|3|||f||||f||||||||||2018-06-01 01:35:59.434927|2018-06-01 01:35:59.434927
NCT00786903|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2015-04-02|2008-11-05|2008-11-06|Estimate|||||||2015-04-02|2015-04-03|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?|Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?|Completed|||202|Actual|Medical University of Graz|||||f||||t||||||Samples With DNA|"~     Respiratory secretions, blood, lung tissue~   "|||2018-06-01 01:35:59.717157|2018-06-01 01:35:59.717157
NCT00786890|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2015-08-21|2008-11-05|2008-11-06|Estimate|||||||2015-08-21|2015-08-24|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|JADE-HK2||A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong|A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong: The Joint Asia Diabetes Evaluation (JADE) Program Sub-study 2 (JADE-HK2)|Active, not recruiting|||3000|Anticipated|Chinese University of Hong Kong|||1||f||||||||||||||2018-06-01 01:35:59.777361|2018-06-01 01:35:59.777361
NCT00786877|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2015-01-15|2008-11-05|2008-11-06|Estimate|||||||2015-01-15|2015-01-16|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Cookstove Replacement for Prevention of ALRI and Low Birthweight in Nepal|Cookstove Replacement for Prevention of ALRI and Low Birthweight in Nepal|Completed||Phase 3|4678|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-06-01 01:35:59.859592|2018-06-01 01:35:59.859592
NCT00786864|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2008-10-14||2008-11-05|2008-11-05|2008-11-06|Estimate|2008-11-05|2008-11-06|Estimate||||2008-11-05|2008-11-06|Estimate|January 2007||2007-01-31|November 2008|2008-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|LBP||Exercise for Low Back Pain in Children|School-Based Specific Exercise Programme Reduces the Prevalence and Intensity of Low Back Pain in 12-13 Year Old Children: a Randomized Controlled Trial|Completed||N/A|72|Actual|University of Witwatersrand, South Africa|Only 2 schools, in a similar geographic and socioeconomic area were included, and therefore the results may not necessarily be generalized to a larger population|2|||f||||f||||||||||2018-06-01 01:35:59.945579|2018-06-01 01:35:59.945579
NCT00786851|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2016-08-16|2008-11-05|2008-11-06|Estimate|||||||2016-08-16|2016-08-17|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|||Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)|Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)|Completed||Phase 2|33|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-06-01 01:36:00.28299|2018-06-01 01:36:00.28299
NCT00786838|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2013-03-29||2014-03-13|2008-11-04|2008-11-06|Estimate|2013-12-05|2014-01-23|Estimate||||2014-03-13|2014-04-11|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram|A Single-Blind, Multicenter, Placebo-Controlled, Sequential Design Study Evaluating the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram|Completed||Phase 2|76|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 01:36:00.40932|2018-06-01 01:36:00.40932
NCT00786825|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2018-01-16|2008-11-05|2008-11-06|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2004|Actual|2004-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|Glycogen||Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla|Measurement of Glucose/Glycogen Metabolism in Humans Using Magnetic Resonance at 4 or 7 Tesla|Completed||N/A|57|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 01:36:00.8758|2018-06-01 01:36:00.8758
NCT00786812|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2017-02-21|2008-11-05|2008-11-06|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2008||2008-08-31|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|MACS0439||Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|Completed||Phase 4|89|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:36:00.96678|2018-06-01 01:36:00.96678
NCT00786799|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2011-09-14||2012-07-31|2008-11-05|2008-11-06|Estimate|2012-07-31|2012-08-31|Estimate||||2012-07-31|2012-08-31|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Omega-3 Fatty Acids for Autism Treatment|A Randomized, Double-Blind, Placebo-Controlled 12-week Study to Investigate the Effect of Omega-3 Fatty Acids on Hyperactivity in Childhood Autism|Completed||Phase 2|27|Actual|University of California, San Francisco|"Small sample size which results in a limited power to detect small to moderate treatment effects.~Relatively mild level of hyperactivity in both groups."|2|||f||||t||||||||||2018-06-01 01:36:01.100225|2018-06-01 01:36:01.100225
NCT00786786|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-11-02|2008-11-05|2008-11-06|Estimate|||||||2010-11-02|2010-11-04|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|||||Observational|||Perceived Barriers to Exercise in Individuals Living With Spinal Cord Injury|Perceived Barriers to Exercise in Individuals Living With Spinal Cord Injury.|Completed|||1000|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-06-01 01:36:01.426068|2018-06-01 01:36:01.426068
NCT00786773|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2010-12-06|2008-11-05|2008-11-06|Estimate|||||||2010-12-06|2010-12-07|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|June 2009|Actual|2009-06-30|||||Observational|||Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.|Epidemiological Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment|Completed|||2091|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:36:01.525244|2018-06-01 01:36:01.525244
NCT00786760|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2018-05-10|2008-11-05|2008-11-06|Estimate|||||||2018-05-10|2018-05-11|Actual|June 14, 2005|Actual|2005-06-14|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Natural History of HPV Infection in Men: The HIM Study|Natural History of HPV Infection in Men: The HIM Study|Active, not recruiting|||1431|Actual|H. Lee Moffitt Cancer Center and Research Institute|||2||f||||f||||||Samples With DNA|"~     This study will create a specimen repository with which to test future novel hypotheses~     related to HPV infection among men. To assess other genetic, infectious, or environmental~     factors that may influence acquisition and persistence of HPV infections in men, whole blood,~     serum, exfoliated penile cell samples, and oral cells will be stored in aliquots for future~     analyses as funding becomes available. Using banked specimens preserved for DNA, RNA, and~     protein analyses, we will be able to assess novel biomarkers such as methylation status of~     oncogenic HPV, polymorphisms in genes involved in innate immunity (e.g., TLR genes), and mRNA~     of the E6 and E7 HPV oncoproteins in the future.~   "|||2018-06-01 01:36:01.634813|2018-06-01 01:36:01.634813
NCT00786747|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2015-12-02|2008-11-05|2008-11-06|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional|||Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities|Randomized Controlled Trial of Tailored Interactive Multimedia to Reduce Colorectal Cancer Screening Disparities|Completed||N/A|1164|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 01:36:01.746595|2018-06-01 01:36:01.746595
NCT00786734|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2012-03-28|2008-11-05|2008-11-06|Estimate|||||||2012-03-28|2012-03-30|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|July 2010|Actual|2010-07-31|May 2009|Actual|2009-05-31||Interventional|||Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)|A Randomized, Open Label, Comparative Study to Evaluate Effect of Pitavastatin for Reduction of Myocardial Damage in Patient Are Scheduled Elective PCI for Stable Angina Pectoris|Withdrawn||Phase 4|0|Actual|JW Pharmaceutical||2|||f||||f||||||||||2018-06-01 01:36:01.834971|2018-06-01 01:36:01.834971
NCT00786721|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2017-02-08|2008-11-05|2008-11-06|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2006||2006-11-30|February 2017|2017-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort|Diffuse Optical Spectroscopy Measurement Technique is Helping Develop More Effective Diagnostic Tools and Therapeutic Regimes for Diabetes, Metabolic Syndrome and Other Mitochondrial Diseases Some Time in the Future|Completed|||9|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 01:36:01.909469|2018-06-01 01:36:01.909469
NCT00786708|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2014-02-07|2008-11-05|2008-11-06|Estimate|||||||2014-02-07|2014-02-10|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|December 2009|Actual|2009-12-31||Observational|||Sensitivity and Specificity of NGAL in an Emergency Room Population|Sensitivity and Specificity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in an Emergency Room Population|Completed|||2304|Actual|Columbia University|||1||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-06-01 01:36:01.994556|2018-06-01 01:36:01.994556
NCT00786695|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-03-02|2008-11-04|2008-11-06|Estimate|||||||2011-03-02|2011-03-04|Estimate|May 2006||2006-05-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ECP||Study Using Esomeprazole as a Diagnostic Test for GERD in Patients With NCCP|Esomeprazole as a Diagnostic Test for Gastroesophageal Reflux Disease in Patients With Noncardiac Chest Pain|Completed||N/A|60|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-06-01 01:36:02.16531|2018-06-01 01:36:02.16531
NCT00786682|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2013-09-23||2013-09-23|2008-11-05|2008-11-06|Estimate|2013-09-23|2013-11-25|Estimate||||2013-09-23|2013-11-25|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer|A Phase II Study of Docetaxel and Modulation of Autophagy With Hydroxychloroquine for Metastatic Hormone Refractory Prostate Cancer|Terminated||Phase 2|11|Actual|Rutgers, The State University of New Jersey||1||Lack of improved efficacy compared to historical controls, competing studies|f||||f||||||||||2018-06-01 01:36:02.270671|2018-06-01 01:36:02.270671
NCT00786669|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2015-02-24|2008-11-05|2008-11-06|Estimate|||||||2015-02-24|2015-02-25|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|VITAC||A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors|A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Relapsed/Refractory Pediatric Solid Tumors|Completed||Phase 1|13|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 01:36:02.528249|2018-06-01 01:36:02.528249
NCT00786656|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2018-05-17|2008-11-05|2008-11-06|Estimate|||||||2018-05-17|2018-05-18|Actual|November 3, 2008||2008-11-03|May 11, 2015|2015-05-11|May 11, 2015||2015-05-11|||||Observational|||Community Cancer Centers Pilot Patient Survey|NCI Community Cancer Center Pilot Program Patient Survey|Completed|||3955|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:36:02.630075|2018-06-01 01:36:02.630075
NCT00786643|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2011-11-17||2012-02-28|2008-11-05|2008-11-06|Estimate|2012-01-18|2012-02-22|Estimate||||2012-02-28|2012-03-01|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|GFL||Study of Gamma Interfereon in Metastatic Colorectal Carcinoma|Phase II Study of Gamma Interferon (IFN-γ) Added to Bolus + Infusional 5-Fluorouracil (5-FU) and Leucovorin (LV) +/- Bevacizumab (BV) in Metastatic Colorectal Carcinoma|Completed||Phase 2|48|Actual|Accelerated Community Oncology Research Network|Enrollment to stratum 1 was closed early due to difficulty accruing the required number of patients in this stratum.|2|||f||||t||||||||||2018-06-01 01:36:02.718433|2018-06-01 01:36:02.718433
NCT00786630|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2014-12-19|2008-11-05|2008-11-06|Estimate|||||||2014-12-19|2014-12-23|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Intervention to Reduce Injection Drug Use|Intervention to Reduce Injection Drug Use|Completed||N/A|726|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:36:03.302786|2018-06-01 01:36:03.302786
NCT00786617|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2015-03-18|2008-11-05|2008-11-06|Estimate|||||||2015-03-18|2015-03-20|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||The Efficacy of Nurse-driven, Protocol Guided Ventilator Weaning in a Medical-Surgical Intensive Care Unit (ICU)|The Efficacy of Nurse-driven, Protocol Guided Ventilator Weaning in a Medical-Surgical ICU|Completed|||202|Actual|St. Luke's-Roosevelt Hospital Center|||2||f||||t||||||||||2018-06-01 01:36:03.41381|2018-06-01 01:36:03.41381
NCT00786604|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-11-02|2008-11-05|2008-11-06|Estimate|||||||2010-11-02|2010-11-04|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|||||Observational|||Glucose Study, Spinal Cord Injury|Continuous Glucose Monitoring in Individuals With Spinal Cord Injury|Completed|||40|Anticipated|University of California, Irvine|||3||f||||f||||||||||2018-06-01 01:36:03.519368|2018-06-01 01:36:03.519368
NCT00786591|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2012-12-27|2008-11-04|2008-11-06|Estimate|||||||2012-12-27|2012-12-31|Estimate|June 2006||2006-06-30|December 2012|2012-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Study of New Biological Markers for Prediction of Severe Acute Pancreatitis|Clinical Evaluation of Novel Biological Markers for the Prediction of Severe Acute Pancreatitis|Completed|||75|Actual|National University Hospital, Singapore|||2||f||||f||||||Samples With DNA|"~     Whole blood; Serum~   "|||2018-06-01 01:36:03.591574|2018-06-01 01:36:03.591574
NCT00786578|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2014-10-23|2008-11-05|2008-11-06|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Evaluation of Skeletal Muscle Lipid Content by Magnetic Resonance Spectroscopy|Evaluation of Intramyocellular Lipid Content (IMCL) in Skeletal Muscle by Magnetic Resonance Spectroscopy|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||2|not funded|f||||f||||||Samples Without DNA|"~     blood will be sampled and retained for future metabolic testing as needed~   "|||2018-06-01 01:36:03.656487|2018-06-01 01:36:03.656487
NCT00786565|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2009-02-20||2011-12-07|2008-11-05|2008-11-06|Estimate|2010-12-09|2011-01-05|Estimate||||2011-12-07|2011-12-12|Estimate|January 2004||2004-01-31|December 2011|2011-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Clinical Evaluation of a New Aspheric Intraocular Lens.|Clinical Evaluation of a New Aspheric Intraocular Lens. A Prospective, Multi-Center, Comparative Study.|Completed||Phase 4|75|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 01:36:03.739938|2018-06-01 01:36:03.739938
NCT00786552|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2011-01-19|2008-11-05|2008-11-06|Estimate|||||||2011-01-19|2011-01-20|Estimate|November 2008||2008-11-30|January 2011|2011-01-31|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Interventional|Panthera||Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer|Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer|Unknown status|Recruiting|Phase 2|47|Anticipated|University of Schleswig-Holstein||1|||f||||||||||||||2018-06-01 01:36:04.105116|2018-06-01 01:36:04.105116
NCT00786539|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2017-02-08|2008-11-04|2008-11-06|Estimate|||||||2017-02-08|2017-02-10|Actual|October 2006||2006-10-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Mitochondria Inborn Errors of Metabolism and ANT Defects in Mitochondria Diseases|Investigation of the Nature and Prevalence of Mitochondria Disease|Completed|||18|Actual|University of California, Irvine|||||f||||f||||||||||2018-06-01 01:36:04.227379|2018-06-01 01:36:04.227379
NCT00786526|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2013-10-29|2008-11-05|2008-11-06|Estimate|||||||2013-10-29|2013-10-30|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Diaphragmatic Function in Ventilated Patients|Ventilator-Induced Diaphragmatic Dysfunction (VIDD) in Critically Ill Patients|Completed|||55|Actual|University Hospital, Montpellier|||||f||||f||||||||||2018-06-01 01:36:04.294533|2018-06-01 01:36:04.294533
NCT00786513|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2014-04-02|2008-11-05|2008-11-06|Estimate|||||||2014-04-02|2014-04-04|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy|Randomized Double Blind Controlled Trial of the Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy in Chronic Pseudomonas Aeruginosa Infected Cystic Fibrosis Patients|Completed||Phase 2|134|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 01:36:04.450436|2018-06-01 01:36:04.450436
NCT00786487|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2015-05-29||2015-07-22|2008-11-05|2008-11-06|Estimate|2015-07-22|2015-07-23|Estimate||||2015-07-22|2015-07-23|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Training Effects on Skeletal Muscle Fatty Acid Metabolism|Training Effects on Skeletal Muscle Fatty Acid Metabolism|Completed||N/A|33|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-06-01 01:36:04.700717|2018-06-01 01:36:04.700717
NCT00786474|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2016-01-06||2016-02-08|2008-11-05|2008-11-06|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)|Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery|Completed||Phase 3|1884|Actual|Duke University||2|||f||||t||||||||||2018-06-01 01:36:05.23462|2018-06-01 01:36:05.23462
NCT00786461|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2008-11-05|2008-11-05|2008-11-06|Estimate|||||||2008-11-05|2008-11-06|Estimate|March 2007||2007-03-31|November 2008|2008-11-30|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate|The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate|Unknown status|Recruiting|Phase 4|30|Anticipated|University of Aarhus|||||f||||t||||||||||2018-06-01 01:36:05.960489|2018-06-01 01:36:05.960489
NCT00786448|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2010-04-29|2008-11-05|2008-11-06|Estimate|||||||2010-04-29|2010-04-30|Estimate|January 2005||2005-01-31|April 2010|2010-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||Post Marketing Surveillance Study on Emselex After Launch in Germany|Post-Marketing Surveillance Study Emselex|Completed|||5821|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:36:06.064976|2018-06-01 01:36:06.064976
NCT00786435|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-11-02|2008-11-04|2008-11-06|Estimate|||||||2010-11-02|2010-11-04|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|||||Observational|||Carbohydrate Study, Chronic SCI|Carbohydrate Metabolism Impairments in Chronic Human Spinal Cord Injury|Completed|||70|Anticipated|University of California, Irvine|||3||f||||f||||||||||2018-06-01 01:36:06.143995|2018-06-01 01:36:06.143995
NCT00786422|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2013-12-20|2012-05-15|2015-10-20|2008-11-05|2008-11-06|Estimate|2014-05-14|2014-06-13|Estimate|2012-05-15|2012-05-16|Estimate|2015-10-20|2015-11-18|Estimate|May 2009||2009-05-31|October 2015|2015-10-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer|The EINSTEIN CYP Cohort Study Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-vein Thrombosis or Pulmonary Embolism Using a Strong CYP 3A4 Inducer|Completed||Phase 2|25|Actual|Bayer||1|||f||||t||||||||||2018-06-01 01:36:06.233728|2018-06-01 01:36:06.233728
NCT00786409|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|2016-11-08||2018-02-14|2008-11-05|2008-11-06|Estimate|2018-02-14|2018-02-15|Actual||||2018-02-14|2018-02-15|Actual|November 2008||2008-11-30|February 2018|2018-02-28|December 2011|Actual|2011-12-31|August 2010|Actual|2010-08-31||Interventional|||Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women|Immunogenicity and Safety of the Quadrivalent HPV Vaccine Gardasil in Female Systemic Lupus Erythematosus Patients Aged 9-26|Completed||N/A|27|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 01:36:06.577118|2018-06-01 01:36:06.577118
NCT00786396|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2014-08-18|2008-11-05|2008-11-06|Estimate|||||||2014-08-18|2014-08-20|Estimate|July 2004||2004-07-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Connect||Directly Observed Therapy for Community-Released HIV+ Prisoners|Directly Observed Therapy for Community-Released HIV+ Prisoners|Completed||N/A|151|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:36:06.834442|2018-06-01 01:36:06.834442
NCT00786383|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2013-08-16|2008-11-05|2008-11-06|Estimate|||||||2013-08-16|2013-08-19|Estimate|February 2006||2006-02-28|August 2013|2013-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy|Phase 1 Study of Every Other Week Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients With Advanced Solid Tumors Who Have Not Responded To Standard Therapy|Completed||Phase 1|25|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:36:06.93201|2018-06-01 01:36:06.93201
NCT00786370|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2012-02-09|2008-11-05|2008-11-06|Estimate|||||||2012-02-09|2012-02-10|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Dexmedetomidine vs. Propofol for Cataract Surgery|Dexmedetomidine vs. Propofol for Monitored Anesthesia Care During Cataract|Completed||Phase 4|24|Actual|The Cooper Health System||2|||f||||f||||||||||2018-06-01 01:36:07.003728|2018-06-01 01:36:07.003728
NCT00786357|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-06-22|2008-11-04|2008-11-06|Estimate|||||||2010-06-22|2010-06-23|Estimate|November 2008||2008-11-30|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|SETS-exp||Sleep Enhancement Training Study for Experienced Shiftworkers|Sleep Enhancement Training Study for Experienced Shiftworkers|Completed||Phase 1|32|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:36:07.11203|2018-06-01 01:36:07.11203
NCT00786344|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2008-11-04|2008-11-04|2008-11-06|Estimate|||||||2008-11-04|2008-11-06|Estimate|November 2004||2004-11-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||USC Well Elderly Study 2|Health Mediating Effects of the Well Elderly Program|Completed||N/A|460|Actual|University of Southern California||2|||f||||t||||||||||2018-06-01 01:36:07.16734|2018-06-01 01:36:07.16734
NCT00786331|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2009-07-31|2008-11-05|2008-11-06|Estimate|||||||2009-07-31|2009-08-03|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Interventional|||Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC|Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-small-cell Lung Cancer (NSCLC).|Unknown status|Recruiting|Phase 2|230|Anticipated|Gruppo Oncologico Italiano di Ricerca Clinica||2|||f||||t||||||||||2018-06-01 01:36:07.260157|2018-06-01 01:36:07.260157
NCT00786318|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2017-09-22|2008-11-05|2008-11-06|Estimate|||||||2017-09-22|2017-09-25|Actual|September 2008||2008-09-30|September 2017|2017-09-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Ziprasidone vs Standard Therapy for Agitated Patients in the ED|Prospective Double Blind Randomized Trial of Intramuscular Ziprasidone Compared With Standard Antipsychotic Therapy For The Treatment Of The Acutely Agitated Patient In The Emergency Department|Withdrawn||Phase 4|0|Actual|George Washington University||2||Sponsor terminated|f||||f||||||||||2018-06-01 01:36:07.49403|2018-06-01 01:36:07.49403
NCT00786305|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2008-11-05|2008-11-05|2008-11-06|Estimate|||||||2008-11-05|2008-11-06|Estimate|October 2004||2004-10-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia|Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa|Completed||Phase 2|40|Actual|Groupe Hospitalier Pitie-Salpetriere||2|||f||||f||||||||||2018-06-01 01:36:07.624264|2018-06-01 01:36:07.624264
NCT00786292|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2012-09-03|2008-11-05|2008-11-06|Estimate|||||||2012-09-03|2012-09-05|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|EVA||Evaluation of Variable Pressure Support Ventilation in the Therapy of Acute Lung Injury|Evaluation of Variable Pressure Support Ventilation in the Therapy of Acute Lung Injury (EVA-Trial)|Completed||N/A|||Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 01:36:07.730229|2018-06-01 01:36:07.730229
NCT00786279|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2016-01-11|2008-11-05|2008-11-06|Estimate|||||||2016-01-11|2016-01-12|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|April 2015|Actual|2015-04-30|March 2011|Actual|2011-03-31||Interventional|AAAPILOT||Alcohol and Atherosclerosis Pilot Study|Alcohol and Atherosclerosis Pilot Study|Completed||N/A|39|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-06-01 01:36:07.82615|2018-06-01 01:36:07.82615
NCT00786266|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-06-22|2008-11-04|2008-11-06|Estimate|||||||2010-06-22|2010-06-23|Estimate|November 2008||2008-11-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|SETS-novice||Sleep Enhancement Training Study for Novice Shiftworkers|Sleep Enhancement Training Study for Novice Shiftworkers|Completed||Phase 1|20|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:36:07.922726|2018-06-01 01:36:07.922726
NCT00786253|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2014-10-27|2008-11-05|2008-11-06|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2005||2005-10-31|October 2014|2014-10-31|January 2007|Actual|2007-01-31|||||Interventional|||Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction|A Randomized, Explorative, Double-blind, Double-dummy, Multi-center, Parallel Group Study to Assess Sustainable Efficacy of Once Daily Vardenafil (10 mg) for 12 and 24 Weeks Versus Vardenafil PRN in Men With Mild or Mild to Moderate ED|Completed||Phase 2|236|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:36:08.051202|2018-06-01 01:36:08.051202
NCT00786240|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2010-09-08|2008-11-05|2008-11-06|Estimate|||||||2010-09-08|2010-09-09|Estimate|January 2009||2009-01-31|September 2010|2010-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Phase1, Single Dose, Crossover Study to Determine Bioequivalence|A Phase 1, Open-Label, Randomized, Single-Dose, 2-Way Crossover Study To Determine Bioequivalence Of 4 Mg Fesoterodine SR Tablet Between Formulation D And Formulation E(1) In Healthy Subjects.|Completed||Phase 1|37|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:36:08.192136|2018-06-01 01:36:08.192136
NCT00786227|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2013-05-01|2008-11-05|2008-11-06|Estimate|||||||2013-05-01|2013-05-03|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Initial Validation of PROMIS Physical Function/Disability Scales in Rheumatoid Arthritis (RA)|Initial Validation of PROMIS Physical Function/Disability Scales in Rheumatoid Arthritis (RA)|Completed|||761|Actual|Stanford University|||1||f||||f||||||||||2018-06-01 01:36:08.277024|2018-06-01 01:36:08.277024
NCT00786214|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2013-06-20|2008-11-04|2008-11-06|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2007||2007-02-28|June 2013|2013-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Treatment of Functional Dyspepsia With Acupuncture|Treatment of Functional Dyspepsia With Acupuncture: A Randomized, Blinded, Sham Acupuncture Controlled Study|Completed||N/A|42|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-06-01 01:36:08.365953|2018-06-01 01:36:08.365953
NCT00786201|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04||2012-12-18|2015-11-24|2008-11-04|2008-11-06|Estimate||||2012-12-18|2012-12-20|Estimate|2015-11-24|2015-12-28|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|126|Actual|Centocor, Inc.||4|||f||||t||||||||||2018-06-01 01:36:08.456514|2018-06-01 01:36:08.456514
NCT00786188|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2013-07-16|2009-12-10|2015-10-14|2008-11-05|2008-11-06|Estimate|2014-01-28|2014-03-12|Estimate|2009-12-10|2009-12-14|Estimate|2015-10-14|2015-10-15|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause|A Phase 2, Exploratory, Eight-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 2|102|Actual|Noven Therapeutics||2|||f||||f||||||||||2018-06-01 01:36:08.610753|2018-06-01 01:36:08.610753
NCT00786175|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2015-08-21|2008-11-05|2008-11-06|Estimate|||||||2015-08-21|2015-08-24|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Survey to Evaluate the Rate of Abnormal Glucose Tolerance Among Hong Kong Chinese Subjects With Coronary Heart Disease|A Cross-sectional Observational Survey to Evaluate the Rate of Diabetes and Glucose Intolerance (Both Diagnosed and Undiagnosed) Among Hong Kong Chinese Subjects With Coronary Heart Disease|Withdrawn|||0|Actual|Chinese University of Hong Kong|||||f||||t||||||||||2018-06-01 01:36:09.160057|2018-06-01 01:36:09.160057
NCT00786162|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2012-03-14|2008-11-04|2008-11-06|Estimate|||||||2012-03-14|2012-03-15|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Blood Pressure Self Management for Hypertension & Prehypertension Using an Internet Enabled, Automated Self Management Program|Blood Pressure Self Management for Hypertension & Prehypertension Using an Internet Enabled, Automated Self Management Program|Completed||N/A|404|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:36:09.223096|2018-06-01 01:36:09.223096
NCT00786149|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2014-09-02|2008-11-05|2008-11-06|Estimate|||||||2014-09-02|2014-09-03|Estimate|September 2007||2007-09-30|September 2014|2014-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Improving Varenicline Adherence and Outcomes in Homeless Smokers|Improving Varenicline Adherence and Outcomes in Homeless Smokers|Completed||Phase 3|428|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 01:36:09.296815|2018-06-01 01:36:09.296815
NCT00786136|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2013-04-09|2008-11-05|2008-11-06|Estimate|||||||2013-04-09|2013-04-10|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|TRACK-D||Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes|Multicenter Randomized Controlled Study of Rosuvastatin for Prevention of Contrast Induced Acute Kidney Injury in Patients With Diabetes and Slight to Moderate Renal Insufficient|Completed||Phase 4|2998|Actual|Shenyang Northern Hospital||2|||f||||t||||||||||2018-06-01 01:36:09.386206|2018-06-01 01:36:09.386206
NCT00786123|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-03-02|2008-11-04|2008-11-06|Estimate|||||||2011-03-02|2011-03-04|Estimate|May 2006||2006-05-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome|Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome: a Randomized Double Blind Placebo Controlled Study|Completed||N/A|40|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-06-01 01:36:09.608305|2018-06-01 01:36:09.608305
NCT00786110|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-05|||2009-02-23|2008-11-05|2008-11-06|Estimate|||||||2009-02-23|2009-02-24|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|October 2010|Anticipated|2010-10-31|October 2009|Anticipated|2009-10-31||Interventional|PAXO||Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients|Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy|Unknown status|Recruiting|Phase 2|30|Anticipated|University of Turin, Italy||1|||f||||t||||||||||2018-06-01 01:36:09.705341|2018-06-01 01:36:09.705341
NCT00786097|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-08-21|2008-11-04|2008-11-05|Estimate|||||||2009-08-21|2009-08-25|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix|Completed||Phase 3|53|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:09.805371|2018-06-01 01:36:09.805371
NCT00786084|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-09-30|2008-11-04|2008-11-05|Estimate|||||||2009-09-30|2009-10-01|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Observational|PEH||Study of Paraesophageal Hernia Repair With Small Intestine Submucosa|Randomized Prospective Controlled Trial of Paraesophageal Hernia Repair With Small Intestine Submucosa (SIS)|Unknown status|Active, not recruiting||108|Anticipated|University of Washington|||2||f||||t||||||None Retained|"~     None retained.~   "|||2018-06-01 01:36:09.872999|2018-06-01 01:36:09.872999
NCT00786071|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-03-03|2008-11-04|2008-11-05|Estimate|||||||2010-03-03|2010-03-04|Estimate|May 2009||2009-05-31|March 2010|2010-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Metabolic Evaluation of Nutrition in Rett Syndrome|A Systematic Metabolic Approach to the Evaluation of Nutrition in Rett Syndrome According to the Cardiorespiratory Phenotype in Dutch Rett Girls|Completed|||13|Actual|Maastricht University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, dried blood spot, leukocytes, erythrocytes, urine.~   "|||2018-06-01 01:36:09.946303|2018-06-01 01:36:09.946303
NCT00786058|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-06-12|2008-11-04|2008-11-05|Estimate|||||||2009-06-12|2009-06-15|Estimate||||June 2009|2009-06-30||||||||Expanded Access|||A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003|A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)|Approved for marketing|||||CONKO-Studiengruppe|||||f||||||||||||||2018-06-01 01:36:10.002238|2018-06-01 01:36:10.002238
NCT00786045|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2013-04-26|2008-11-04|2008-11-05|Estimate|||||||2013-04-26|2013-04-29|Estimate|November 2002||2002-11-30|April 2013|2013-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|FITS||Fitness Intervention Trial for Stroke|Fitness Intervention Tiral for Stroke: Enhancing Walking Endurance Using Home Rehabilitation Programs|Completed||N/A|60|Actual|McGill University||2|||f||||f||||||||||2018-06-01 01:36:10.059689|2018-06-01 01:36:10.059689
NCT00786032|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2014-03-26||2015-01-06|2008-11-04|2008-11-05|Estimate|2015-01-06|2015-01-08|Estimate||||2015-01-06|2015-01-08|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Observational|ALS|Participant with ALS age more than 18, living at home within 100 miles of the pariticipating study site, visual acuity of al least 20/80, and communicate non-verbally with their significant other, caregiver and system operator, and with study personnel and demonstrate during the screening phase sufficient EEG interaction for the BCI to operate.|A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients|Cooperative Studies Program (CSP) #567 - A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients|Completed|||27|Actual|VA Office of Research and Development|Some limitations would be the Caregivers willingness and ability to support BCI user. In addition, the caregivers limited availability and the time commitment of the usage of the BCI system.||1||f||||t||||||||||2018-06-01 01:36:10.206972|2018-06-01 01:36:10.206972
NCT00786019|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2016-04-08|2008-11-04|2008-11-05|Estimate|||||||2016-04-08|2016-04-12|Estimate|May 2008||2008-05-31|April 2016|2016-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|InsITE||Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes|Influence Of Endothelial Function On Central and Peripheral Causes Of Exercise Impairment In Type 2 Diabetes|Completed||N/A|98|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-06-01 01:36:10.498304|2018-06-01 01:36:10.498304
NCT00786006|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-12-05|2008-11-04|2008-11-05|Estimate|||||||2011-12-05|2011-12-06|Estimate|March 2007||2007-03-31|December 2011|2011-12-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer|Randomized Phase II Trial of FOLFIRI3 vs. FOLFOX in Gemcitabine-refractory Advanced Pancreatic Cancer|Completed||Phase 2|61|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 01:36:10.621186|2018-06-01 01:36:10.621186
NCT00785993|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-10-01|2008-11-04|2008-11-05|Estimate|||||||2009-10-01|2009-10-02|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Egg-Banking and Ovo-donation|Impact of Egg-Banking in an Ovum-donation Program|Completed||Phase 4|320|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||||||||||||2018-06-01 01:36:10.720181|2018-06-01 01:36:10.720181
NCT00785980|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2009-09-10||2012-07-31|2008-11-04|2008-11-05|Estimate|2009-10-16|2009-10-21|Estimate||||2012-07-31|2012-08-07|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Drug - Drug Interaction Study of Quinine Sulfate and Ciprofloxacin|A One-Directional, Open-Label Drug Interaction Study to Investigate the Effects of Multiple-Dose Ciprofloxacin HCl on the Single-Dose Pharmacokinetics of Quinine in Healthy Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 01:36:10.818266|2018-06-01 01:36:10.818266
NCT00785967|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2015-04-13|2008-11-04|2008-11-05|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|RAG-1/2||Immune Responses in Patients Treated With Raltegravir|Immune Responses to Neo-Antigens in Patients Treated With Raltegravir: Insights on V(D)J Recombination and RAG-1/2 Recombinase Function|Withdrawn||Phase 3|0|Actual|McGill University Health Center||2||Unexpected and severe difficulties in recruitment.|f||||f||||||||||2018-06-01 01:36:11.12606|2018-06-01 01:36:11.12606
NCT00785954|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03||2011-08-30|2011-08-30|2008-11-03|2008-11-05|Estimate||||2011-08-30|2011-09-02|Estimate|2011-08-30|2011-09-02|Estimate|November 2008||2008-11-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|July 2010|Actual|2010-07-31||Interventional|PROTECTION AMI||Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack]|Inhibition of Delta-protein Kinase C for the Reduction of Infarct Size in Acute Myocardial Infarction|Completed||Phase 2|1180|Actual|KAI Pharmaceuticals||4|||f||||t||||||||||2018-06-01 01:36:11.24212|2018-06-01 01:36:11.24212
NCT00785941|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-10-12|2008-11-04|2008-11-05|Estimate|||||||2011-10-12|2011-10-13|Estimate|April 2006||2006-04-30|October 2011|2011-10-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available|Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 Administered Every Other Week in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available|Completed||Phase 1|16|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 01:36:11.543346|2018-06-01 01:36:11.543346
NCT00785928|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03||2010-10-25|2011-02-11|2008-11-03|2008-11-05|Estimate||||2010-10-25|2010-10-27|Estimate|2011-02-11|2011-02-15|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|||A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy|Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy|Completed||Phase 2|158|Actual|Eli Lilly and Company||7|||f||||f||||||||||2018-06-01 01:36:11.627555|2018-06-01 01:36:11.627555
NCT00785915|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2014-10-10|2008-11-04|2008-11-05|Estimate|||||||2014-10-10|2014-10-13|Estimate|November 2008||2008-11-30|October 2014|2014-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|JSAD/JMAD||AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects|A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects|Completed||Phase 1|40|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:36:11.763022|2018-06-01 01:36:11.763022
NCT00785902|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2011-02-18|2008-11-03|2008-11-05|Estimate|||||||2011-02-18|2011-02-21|Estimate||||February 2011|2011-02-28||||||||Interventional|A||AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial Fibrillation||Withdrawn||Phase 3|||AtriCure, Inc.|||||f||||t||||||||||2018-06-01 01:36:11.869469|2018-06-01 01:36:11.869469
NCT00785889|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-11-13|2008-11-04|2008-11-05|Estimate|||||||2008-11-13|2008-11-14|Estimate|March 2008||2008-03-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||RCT of Air Insufflation Versus Water Infusion Colonoscopy|A Randomized Controlled Comparison of Warm Water Infusion in Lieu of Air Insufflation vs. Air Insufflation for Aiding Colonoscopy Insertion in Sedated Patients Undergoing Colorectal Cancer (CRC) Screening and Surveillance.|Completed||N/A|56|Actual|East Bay Institute for Research and Education|||||f||||t||||||||||2018-06-01 01:36:11.919756|2018-06-01 01:36:11.919756
NCT00785876|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2017-10-06|2008-11-04|2008-11-05|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2008||2008-11-30|October 2017|2017-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Implementation of the Low Risk Ankle Rule|Controlled Radiography for Ankle Injury Cases in Kids in the Emergency Department: Implementation of the Low Risk Ankle Rule|Completed||N/A|3000|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 01:36:12.008709|2018-06-01 01:36:12.008709
NCT00785863|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-06-30|2008-11-04|2008-11-05|Estimate|||||||2011-06-30|2011-07-01|Estimate|December 2008||2008-12-31|November 2008|2008-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Modulation of Remifentanil-induced Postinfusion Hyperalgesia|Modulation of Remifentanil-induced Analgesia and Postinfusion Hyperalgesia by Parecoxib or Ketorolac in Humans|Completed||Phase 4|16|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-06-01 01:36:12.084478|2018-06-01 01:36:12.084478
NCT00785850|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-03-05|2008-11-04|2008-11-05|Estimate|||||||2009-03-05|2009-03-06|Estimate|August 2008||2008-08-31|March 2009|2009-03-31||||September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Safety.|Safety Dermatological Evaluation: Genital Mucous Irritation - Product Tested: Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower.|Completed||Phase 3|31|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:12.152776|2018-06-01 01:36:12.152776
NCT00785837|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|July 2005||2005-07-31|September 2008|2008-09-30|January 2009|Anticipated|2009-01-31|September 2008|Anticipated|2008-09-30||Interventional|hydrotherapy||Effects of Hydrotherapy in Pain and Quality of Sleep's Cycles in Preterm Newborn on Neonatal Intensive Care Units|Effects of Hydrotherapy in Pain and Quality of Sleep's Cycles in Preterm Newborn on Neonatal Intensive Care Units|Unknown status|Recruiting|N/A|8|Anticipated|Universidade Luterana do Brasil||2|||f||||t||||||||||2018-06-01 01:36:12.201719|2018-06-01 01:36:12.201719
NCT00785824|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2013-10-30|2008-11-04|2008-11-05|Estimate|||||||2013-10-30|2013-10-31|Estimate|January 2009||2009-01-31|October 2013|2013-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||African-American Bone Metabolism and Lactation Study|A Prospective Cohort Pilot Study of Bone Metabolism in Lactating and Non-lactating Postpartum African-American Women and Healthy Non-pregnant African-American Women|Completed|||58|Actual|University of Pittsburgh|||3||f||||t||||||Samples Without DNA|"~     archival blood serum and plasma~   "|||2018-06-01 01:36:12.268354|2018-06-01 01:36:12.268354
NCT00785811|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-03-15|2008-11-04|2008-11-05|Estimate|||||||2011-03-15|2011-03-16|Estimate|October 2008||2008-10-31|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Chronic Supplementation of L-arginine in the Muscular Performance|Randomized, Double Blind, Placebo Controlled Study of Parallel Groups to Evaluate the Effect of Chronic Supplementation of L-arginine in the Muscular Performance.|Terminated||Phase 4|36|Actual|Sanofi||2||Required by the investigator. The site could not recruit patients anymore.|f||||||||||||||2018-06-01 01:36:12.331506|2018-06-01 01:36:12.331506
NCT00785798|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2016-06-14||2016-06-14|2008-11-04|2008-11-05|Estimate|2016-06-14|2016-07-27|Estimate||||2016-06-14|2016-07-27|Estimate|January 2009||2009-01-31|June 2016|2016-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas|A Phase I/II Trial of Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas|Terminated||Phase 1/Phase 2|17|Actual|Yale University||1||sponsor requested|f||||f||||||||||2018-06-01 01:36:12.395548|2018-06-01 01:36:12.395548
NCT00785785|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2015-10-21||2016-05-10|2008-11-04|2008-11-05|Estimate|2016-03-09|2016-04-07|Estimate||||2016-05-10|2016-06-16|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ENESTg1||A Study of Nilotinib Versus Imatinib in GIST Patients|A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)|Completed||Phase 3|644|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:36:13.604817|2018-06-01 01:36:13.604817
NCT00785603|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-02-12|2008-11-04|2008-11-05|Estimate|||||||2009-02-12|2009-02-13|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|February 2009|Anticipated|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study|Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study|Unknown status|Active, not recruiting|Phase 4|12|Actual|University of Southern Denmark|||||f||||t||||||||||2018-06-01 01:36:17.170832|2018-06-01 01:36:17.170832
NCT00785772|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2011-03-29||2011-10-31|2008-11-03|2008-11-05|Estimate|2011-03-29|2011-04-27|Estimate||||2011-10-31|2011-11-16|Estimate|March 2010||2010-03-31|October 2011|2011-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment|A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment|Terminated||Phase 4|1|Actual|Pfizer|The study was completed with an enrollment of 1 subject because prolongation of the study period or a change in the inclusion criteria (the upper limit of age was deleted) did not lead to further enrollment of subjects.|3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:36:15.505831|2018-06-01 01:36:15.505831
NCT00785759|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-12-04|2008-11-04|2008-11-05|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|ALZ201||Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers|An Open-label Study to Assess Brain Uptake and Safety of AH110690 (18F) Injection in Subjects With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers|Completed||Phase 2|78|Actual|GE Healthcare|||||f||||t||||||||||2018-06-01 01:36:15.684464|2018-06-01 01:36:15.684464
NCT00785746|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2013-02-01|2008-11-04|2008-11-05|Estimate|||||||2013-02-01|2013-02-04|Estimate|August 2006||2006-08-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Improving Balance in Frail Elderly|Improving Balance in Frail Elderly: A Randomized Clinical Trial of Two Methods to Enhance Strength (Stretch and Strength Versus Core Strength)|Completed||Early Phase 1|60|Actual|McGill University||2|||f||||f||||||||||2018-06-01 01:36:15.753664|2018-06-01 01:36:15.753664
NCT00785733|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-11-30|2008-11-04|2008-11-05|Estimate|||||||2010-11-30|2010-12-02|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART|SMART Way of Treating Asthma. Non-interventional Study to Evaluate Clinical Efficacy of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Patients With Moderate and Severe Asthma|Completed|||1182|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:36:15.83888|2018-06-01 01:36:15.83888
NCT00785720|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-08-21|2008-11-04|2008-11-05|Estimate|||||||2009-08-21|2009-08-25|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Photo Avaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|Completed||Phase 3|26|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:15.960882|2018-06-01 01:36:15.960882
NCT00785707|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2017-02-17||2017-04-10|2008-11-04|2008-11-05|Estimate|2017-04-10|2017-06-26|Actual||||2017-04-10|2017-06-26|Actual|May 2008||2008-05-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|LittlEars||Littlears Auditory Questionnaire: Validation Study in CI Children|Littlears Auditory Questionnaire Validation Study in CI Children With LittlEARS My Diary: Language: North American English|Completed|||31|Actual|Med-El Corporation|||1||f||||f||||||||||2018-06-01 01:36:16.030909|2018-06-01 01:36:16.030909
NCT00785694|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2015-04-23|2008-11-04|2008-11-05|Estimate|||||||2015-04-23|2015-04-24|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Recurrence of Bladder Cancer After Transurethral Resection With Hexvix|Recurrence of Bladder Cancer After Transurethral Resection With Hexvix|Withdrawn||Phase 4|0|Actual|GE Healthcare||2||Rejected ethics approval in UK and Holland|f||||f||||||||||2018-06-01 01:36:16.177799|2018-06-01 01:36:16.177799
NCT00785681|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-08-21|2008-11-04|2008-11-05|Estimate|||||||2009-08-21|2009-08-25|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|Completed||Phase 3|53|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:16.246717|2018-06-01 01:36:16.246717
NCT00785668|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|February 2008|Actual|2008-02-29|||||Interventional|||A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects|A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects|Completed||Phase 1|10|Actual|Aerovance, Inc.|||||f||||f||||||||||2018-06-01 01:36:16.403617|2018-06-01 01:36:16.403617
NCT00785655|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-08-21|2008-11-04|2008-11-05|Estimate|||||||2009-08-21|2009-08-25|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower|Completed||Phase 3|53|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:16.468115|2018-06-01 01:36:16.468115
NCT00785642|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-03-05|2008-11-04|2008-11-05|Estimate|||||||2009-03-05|2009-03-06|Estimate|August 2008||2008-08-31|March 2009|2009-03-31||||September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.|Safety Dermatological Evaluation: Genital Mucous Irritation - Product Tested: Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid).|Completed||Phase 3|30|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:16.520843|2018-06-01 01:36:16.520843
NCT00785629|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2012-08-27||2012-09-28|2008-11-04|2008-11-05|Estimate|2012-09-28|2012-10-30|Estimate||||2012-09-28|2012-10-30|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD|A Double Blind Randomized Placebo Controlled Trial of Maintenance of Normal Serum Phosphorus in Chronic Kidney Disease (CKD)|Completed||N/A|148|Actual|Denver Nephrologists, P.C.|Single center study; Modest size of study; pilot study not powered to detect differences among subgroups of actively treated patients|4|||f||||t||||||||||2018-06-01 01:36:16.592354|2018-06-01 01:36:16.592354
NCT00785616|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2018-04-25|2008-11-04|2008-11-05|Estimate|||||||2018-04-25|2018-04-27|Actual|September 2008||2008-09-30|April 2018|2018-04-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence|A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence|Completed||Phase 4|55|Anticipated|Montefiore Medical Center|||||f||||f||||||||||2018-06-01 01:36:17.106953|2018-06-01 01:36:17.106953
NCT00785239|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2015-06-23|2008-11-04|2008-11-05|Estimate|||||||2015-06-23|2015-06-25|Estimate|April 2009||2009-04-30|June 2015|2015-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||CryoSpray Ablation(tm)Thoracic Patient Registry|CryoSpray Ablation(tm)Thoracic Patient Registry|Withdrawn|||0|Actual|CSA Medical, Inc.||||Business Reasons|f||||f||||||||||2018-06-01 01:36:26.85272|2018-06-01 01:36:26.85272
NCT00785590|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-08-21|2008-11-04|2008-11-05|Estimate|||||||2009-08-21|2009-08-25|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower - Photo Evaluation.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINLYN (Lactic Acid) Sweet Flower.|Completed||Phase 3|26|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:17.245656|2018-06-01 01:36:17.245656
NCT00785577|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2011-08-25|2011-02-25|2012-04-30|2008-11-03|2008-11-05|Estimate|2012-04-30|2012-05-31|Estimate|2011-02-25|2011-03-11|Estimate|2012-04-30|2012-05-31|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Study for Treatment of Pain in Patients With Diabetic Neuropathy.|A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Painful Diabetic Neuropathy.|Completed||Phase 2|273|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 01:36:17.557327|2018-06-01 01:36:17.557327
NCT00785564|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Observational|||Imaging Cardiac Electrical Remodeling With Electrocardiogram Imaging (ECGI)|Imaging Cardiac Electrical Remodeling With ECGI|Unknown status|Recruiting||10|Anticipated|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 01:36:20.371191|2018-06-01 01:36:20.371191
NCT00785551|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2012-07-31|2008-11-04|2008-11-05|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment|A Single-Dose, Open-Label Comparative Study of the Pharmacokinetics, Safety,and Tolerability of Oral Quinine Sulfate in Healthy Volunteers and Adults With Mild and Moderate Renal Impairment|Terminated||Phase 1|5|Actual|Mutual Pharmaceutical Company, Inc.||3||poor enrollment|f||||f||||||||||2018-06-01 01:36:20.429394|2018-06-01 01:36:20.429394
NCT00785538|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-06-14|2008-11-04|2008-11-05|Estimate|||||||2011-06-14|2011-06-15|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of IMC-A12 in Patients With Tumors Who No Longer Respond to Treatment or Who No Treatment if Available|Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available|Completed||Phase 1|24|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 01:36:20.645881|2018-06-01 01:36:20.645881
NCT00785525|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2017-06-13|2008-11-04|2008-11-05|Estimate|||||||2017-06-13|2017-06-14|Actual|February 1997||1997-02-28|October 2016|2016-10-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors|Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors|Recruiting||Phase 3|40000|Anticipated|Center for International Blood and Marrow Transplant Research|||||f||||t||||||||||2018-06-01 01:36:20.759321|2018-06-01 01:36:20.759321
NCT00785512|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2010-08-19||2010-08-19|2008-11-03|2008-11-05|Estimate|2010-08-19|2010-09-15|Estimate||||2010-08-19|2010-09-15|Estimate|November 2008||2008-11-30|August 2010|2010-08-31||||August 2009|Actual|2009-08-31||Interventional|||A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy|A Prospective, Randomized, Double-Blind, Placebo Controlled Study of the Long-Term Efficacy of Nebivolol in Hypertensive Patients After Withdrawal of Therapy|Completed||Phase 4|207|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 01:36:20.922745|2018-06-01 01:36:20.922745
NCT00785499|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2012-03-19|2008-11-04|2008-11-05|Estimate|||||||2012-03-19|2012-03-20|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|MoMS||Milk Components and Metabolic Syndrome|The Effect of Milk, Whey and Casein on Weight Loss and Risk Markers of Metabolic Syndrome in Overweight Children|Completed||N/A|193|Actual|University of Copenhagen||4|||f||||f||||||||||2018-06-01 01:36:21.265574|2018-06-01 01:36:21.265574
NCT00785486|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2009-03-11||2012-08-22|2008-11-04|2008-11-05|Estimate|2009-05-14|2009-07-08|Estimate||||2012-08-22|2012-08-31|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Drug-Drug Interaction Study of Qualaquin and Midazolam|A Pharmacokinetic Interaction Study Evaluating the Effect of Qualaquin (Quinine Sulfate) Capsules on Midazolam|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||3|||f||||f||||||||||2018-06-01 01:36:21.351259|2018-06-01 01:36:21.351259
NCT00785473|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-09-02|2008-11-04|2008-11-05|Estimate|||||||2011-09-02|2011-09-05|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis|Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study|Completed||Phase 4|80|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 01:36:21.577777|2018-06-01 01:36:21.577777
NCT00785460|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|January 2008||2008-01-31|November 2008|2008-11-30||||May 2008||2008-05-31||Interventional|||Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers|Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers|Completed||Phase 3|20|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-06-01 01:36:21.647396|2018-06-01 01:36:21.647396
NCT00785447|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-04-24|2008-11-03|2008-11-05|Estimate|||||||2012-04-24|2012-04-25|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing|Comparison of the Efficiency of Mouth-to-nose Breathing With Mouth-to-mouth Breathing in Non-paralyzed Adult Patients Under General Anesthesia|Completed||N/A|20|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:36:21.714395|2018-06-01 01:36:21.714395
NCT00785434|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-01-12|2008-11-04|2008-11-05|Estimate|||||||2010-01-12|2010-01-13|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD|Phase IV Pilot Study to Examine the Efficacy and Safety of Escitalopram in Doses up to 50 mg for the Treatment of Patients With Major Depressive Disorder (MDD).|Completed||Phase 4|60|Actual|Community Pharmacology Services Ltd||1|||f||||f||||||||||2018-06-01 01:36:21.783319|2018-06-01 01:36:21.783319
NCT00785421|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2015-01-07|2008-11-04|2008-11-05|Estimate|||||||2015-01-07|2015-01-08|Estimate|April 2004||2004-04-30|January 2015|2015-01-31|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|PROSPECT||Chemotherapy With or Without Enoxaparin in Pancreatic Cancer|A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT)|Completed||Phase 2/Phase 3|312|Actual|CONKO-Studiengruppe||2|||f||||t||||||||||2018-06-01 01:36:21.847191|2018-06-01 01:36:21.847191
NCT00785408|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2015-01-16|2008-11-04|2008-11-05|Estimate|||||||2015-01-16|2015-01-19|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects|Completed||Phase 2|273|Actual|AstraZeneca||6|||f||||f||||||||||2018-06-01 01:36:21.930027|2018-06-01 01:36:21.930027
NCT00785395|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2011-11-01|2008-11-04|2008-11-05|Estimate|||||||2011-11-01|2011-11-02|Estimate|June 2008||2008-06-30|November 2008|2008-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Up-Down Oxytocin Infusion|Up-down Determination of the ED90 of Oxytocin Infusions for the Prevention of Postpartum Uterine Atony in Parturients Undergoing Cesarean Delivery|Completed||Phase 4|40|Actual|IWK Health Centre||1|||f||||t||||||||||2018-06-01 01:36:22.260677|2018-06-01 01:36:22.260677
NCT00785382|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2012-10-30|2008-11-04|2008-11-05|Estimate|||||||2012-10-30|2012-10-31|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery|A Randomized, Placebo Controlled Trial of Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery|Completed||Phase 4|62|Actual|IWK Health Centre||2|||f||||t||||||||||2018-06-01 01:36:22.328813|2018-06-01 01:36:22.328813
NCT00785369|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2012-10-02|2008-11-04|2008-11-05|Estimate|||||||2012-10-02|2012-10-03|Estimate|August 2008||2008-08-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis|In Vivo Reflectance Confocal Microscopy for Pigmented Lesion Diagnosis: A Multi-center Study|Completed||N/A|441|Actual|Lucid, Inc.||1|||f||||f||||||||||2018-06-01 01:36:22.405769|2018-06-01 01:36:22.405769
NCT00785356|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2014-06-25||2014-08-05|2008-11-04|2008-11-05|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated|Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids|A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy|Terminated||Phase 3|8|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2018-06-01 01:36:22.50164|2018-06-01 01:36:22.50164
NCT00785343|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-12-23|2008-11-04|2008-11-05|Estimate|||||||2009-12-23|2009-12-24|Estimate|September 2008||2008-09-30|December 2009|2009-12-31||||||||Interventional|||Study of Robot-assisted Arm Therapy for Acute Stroke Patients|Effectiveness of Adding Robotic Therapy to Conventional Therapy for Acute Stroke Patients With Upper Extremity Paresis|Unknown status|Recruiting|Phase 1|40|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-06-01 01:36:22.655657|2018-06-01 01:36:22.655657
NCT00785330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-16|2008-11-04|2008-11-05|Estimate|||||||2009-04-16|2009-04-17|Estimate|April 2004||2004-04-30|November 2008|2008-11-30|April 2014|Anticipated|2014-04-30|March 2009|Anticipated|2009-03-31||Interventional|||Allo-hNHL (FluBuCy)|Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||t||||||||||2018-06-01 01:36:22.7422|2018-06-01 01:36:22.7422
NCT00785317|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|April 2010|Anticipated|2010-04-30|October 2009|Anticipated|2009-10-31||Interventional|BrAVA||Effects of Estradiol on Menopausal Breast|Effects of Oral 1 mg Oestradiol (E2)/ 2 mg of Drospirenone (DRSP) Compared to Oral 1 mg of Oestradiol (E2)/ 0.5 mg Noresthisterone Acetate (NETA)on the Postmenopausal Breast; a Double Blind Randomized Prospective Study|Unknown status|Recruiting|Phase 4|120|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 01:36:22.907207|2018-06-01 01:36:22.907207
NCT00785304|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2014-12-08|2008-11-04|2008-11-05|Estimate|||||||2014-12-08|2014-12-10|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|July 2011|Actual|2011-07-31||Observational|||Advanced MRI in Blast-related TBI|ADVANCED MRI IN BLAST-RELATED TBI|Unknown status|Enrolling by invitation||100|Anticipated|Washington University School of Medicine|||2||f||||t||||||||||2018-06-01 01:36:22.985984|2018-06-01 01:36:22.985984
NCT00785291|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2015-06-05||2016-11-14|2008-11-04|2008-11-05|Estimate|2015-06-05|2015-07-02|Estimate||||2016-11-14|2016-11-16|Estimate|October 2008||2008-10-31|November 2016|2016-11-30||||December 2013|Actual|2013-12-31||Interventional||All randomized participants are included in baseline characteristics.|Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer|A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-paclitaxel or Ixabepilone With or Without Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer|Active, not recruiting||Phase 3|799|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 01:36:23.412629|2018-06-01 01:36:23.412629
NCT00785278|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|July 2010|Anticipated|2010-07-31|October 2009|Anticipated|2009-10-31||Observational|||Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During Propulsion|Computationally Quantifying Wheelchair Set-Up to Minimize Peak Shoulder Joint Forces Throughout Manual Wheelchair Propulsion: A Pilot Study|Unknown status|Recruiting||9|Anticipated|Kessler Foundation|||2||f||||f||||||||||2018-06-01 01:36:26.654751|2018-06-01 01:36:26.654751
NCT00785265|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2017-09-08|2008-11-03|2008-11-05|Estimate|||||||2017-09-08|2017-09-12|Actual|August 2007||2007-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2015|Actual|2015-11-30||Interventional|||A Randomized Trial to Reduce the Disparity in Live Donor Kidney Transplantation|A Randomized Trial to Reduce the Disparity in Live Donor Kidney Transplantation|Active, not recruiting||N/A|180|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||f||||||||||2018-06-01 01:36:26.723946|2018-06-01 01:36:26.723946
NCT00785252|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2011-02-04|2008-11-03|2008-11-05|Estimate|||||||2011-02-04|2011-02-07|Estimate|September 2008||2008-09-30|February 2011|2011-02-28|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||EZIO Compared to Central Venous Lines for Emergency Vascular Access|Randomized Study of the EZIO Compared to Central Venous Lines Used for Emergency Vascular Access|Unknown status|Recruiting|Phase 4|50|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 01:36:26.792278|2018-06-01 01:36:26.792278
NCT00785226|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04||2015-09-24|2016-10-14|2008-11-04|2008-11-05|Estimate||||2015-09-24|2015-10-15|Estimate|2016-10-14|2016-10-17|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||RDEA119 and Sorafenib Combination Dose Escalation Study|A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer|Completed||Phase 1/Phase 2|62|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:36:27.073239|2018-06-01 01:36:27.073239
NCT00785213|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2009-10-20||2012-07-31|2008-11-03|2008-11-05|Estimate|2009-10-20|2009-11-26|Estimate||||2012-07-31|2012-08-07|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone|An Open-Label Drug-Drug Interaction Study to Investigate the Effects of Steady State Quinine on the Single-Dose Pharmacokinetics of Rosiglitazone Maleate in Healthy Volunteers|Completed||Phase 1|23|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 01:36:27.170403|2018-06-01 01:36:27.170403
NCT00785200|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2013-06-11|2008-11-04|2008-11-05|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||MRSA Colonization and Control in the Dallas County Jail|MRSA Colonization and Control in the Dallas County Jail|Completed||N/A|4194|Actual|University of Chicago||3|||f||||f||||||||||2018-06-01 01:36:27.443817|2018-06-01 01:36:27.443817
NCT00785187|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|December 2008||2008-12-31|November 2008|2008-11-30||||February 2009|Anticipated|2009-02-28||Interventional|||Affect of Dose Rate on UVR Induced Skin Erythema|Randomized Open Crossover Study Researching Affect of Dose Rate on UVR Induced Skin Erythema|Unknown status|Not yet recruiting|N/A|40|Anticipated|Goldenhersh, Michael, M.D.|||||f||||f||||||||||2018-06-01 01:36:27.514779|2018-06-01 01:36:27.514779
NCT00785174|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2008-11-04|2008-11-04|2008-11-05|Estimate|||||||2008-11-04|2008-11-05|Estimate|January 2005||2005-01-31|November 2008|2008-11-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Non-Invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema: a Multicentre Study||Completed||Phase 3|200|Actual|University of Monastir||2|||f||||f||||||||||2018-06-01 01:36:27.635742|2018-06-01 01:36:27.635742
NCT00785161|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2018-04-10|2008-11-04|2008-11-05|Estimate|||||||2018-04-10|2018-04-12|Actual|October 2008|Actual|2008-10-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|PICS||Penumbra Imaging Collaborative Study (PICS)|Penumbra Imaging Collaborative Study (PICS): A Multicenter Trial to Assess Outcome of Patients Revascularized by the Penumbra™ System|Completed|||289|Actual|Penumbra Inc.|||||f||||f||||||||||2018-06-01 01:36:27.713373|2018-06-01 01:36:27.713373
NCT00785148|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-03-05|2008-11-04|2008-11-05|Estimate|||||||2009-03-05|2009-03-06|Estimate|August 2008||2008-08-31|March 2009|2009-03-31||||September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety|Safety Dermatological Evaluation: Genital Mucous Irritation - Product Tested: Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid).|Completed||Phase 3|31|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:27.780026|2018-06-01 01:36:27.780026
NCT00785135|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2015-12-08|2008-11-03|2008-11-05|Estimate|||||||2015-12-08|2015-12-09|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria|Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study|Completed||Phase 3|13|Actual|Vision Specialists of Birmingham||2|||f||||f||||||||||2018-06-01 01:36:27.850245|2018-06-01 01:36:27.850245
NCT00785122|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2013-05-15|2008-11-04|2008-11-05|Estimate|||||||2013-05-15|2013-05-16|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|January 2011|Actual|2011-01-31||Interventional|IMA910-101||IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)|An Open Label, Multicenter Phase 1-2 Study to Investigate the Effectiveness, Safety and Immunogenicity of a Monotherapy With Intradermal IMA910 Plus GM-CSF Following Pre-treatment With Low-dose Cyclophosphamide in Advanced Colorectal Carcinoma Patients Who Have Successfully Completed a 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy.|Completed||Phase 1/Phase 2|92|Actual|immatics Biotechnologies GmbH|||||f||||t||||||||||2018-06-01 01:36:27.931257|2018-06-01 01:36:27.931257
NCT00785109|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2017-04-20|2008-11-04|2008-11-05|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2010||2010-01-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|08-002||Vitamin K Supplement for Inhibition of the Progress in Aortic Valve Calcification|Vitamin K Containing Nutritional Supplement for Activation of Matrix-GIa-proteins (MGP) and Inhibition of Aortic Valve Calcification Process|Completed||Phase 3|99|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-06-01 01:36:28.067711|2018-06-01 01:36:28.067711
NCT00785096|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2015-02-09|2008-11-04|2008-11-05|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||How do Patients, Nurses and Physicians Perceive Negative Postoperative Events?|Perception of Surgical Complications - Agreements Among Patients, Nurses and Physicians|Completed|||615|Actual|University of Zurich|||3||f||||t||||||||||2018-06-01 01:36:28.179427|2018-06-01 01:36:28.179427
NCT00785083|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2016-11-16|2008-11-04|2008-11-05|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2008||2008-09-30|November 2016|2016-11-30||||February 2009|Actual|2009-02-28||Interventional|||A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma|A Double-blind, Randomized, Placebo-controlled, Parallel, Time-lagged, Ascending, Multi-centre, Multiple-dose Study to Measure the Magnitude and Time Course of the Effect of FTY720 on FEV1 and Other Pulmonary Function Tests (FVC, FEF25-75%, and FEV1/FVC) in Patients With Moderate Asthma|Completed||Phase 2|36|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:36:28.237163|2018-06-01 01:36:28.237163
NCT00785070|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2009-02-05|2008-11-04|2008-11-05|Estimate|||||||2009-02-05|2009-02-09|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Observational|PROSPECT||Pre and Post Orthopedic Surgery Sleep and Cardiac Testing (PROSPECT)|Pre and Post Orthopedic Surgery Sleep and Cardiac Testing (PROSPECT)|Completed|||100|Anticipated|Memorial Health System|||1||f||||f||||||||||2018-06-01 01:36:28.309245|2018-06-01 01:36:28.309245
NCT00785057|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2010-12-02|2008-11-04|2008-11-05|Estimate|||||||2010-12-02|2010-12-03|Estimate|November 2008||2008-11-30|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|SAPIENCE||Retrospective Treatment Pattern Survey for the Patient With and Without History of Stroke|A Retrospective, Multi Centre, Non-interventional, Observational Study to Compare Treatment Pattern and Factors That Affect BP Control in Patients With and Without Stroke|Completed|||1000|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:36:28.363536|2018-06-01 01:36:28.363536
NCT00785044|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2015-04-08||2017-04-25|2008-11-04|2008-11-05|Estimate|2017-04-25|2017-04-26|Actual||||2017-04-25|2017-04-26|Actual|May 2008||2008-05-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Observational|||Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event|An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup|Completed|||471|Actual|GE Healthcare|Designed as a continuation of original phase 3, but objectives were built around analyses of integrated data from both studies. Distinct from endpoints used in MBG311 and MBG312. No intent to analyze current study on single original study basis.||1||f||||f||||||||||2018-06-01 01:36:28.607486|2018-06-01 01:36:28.607486
NCT00785031|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2012-06-13|2008-11-04|2008-11-05|Estimate|||||||2012-06-13|2012-06-14|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|IRIS||Internet Based Vascular Risk Factor Intervention and Self Management Study|Internet-based Vascular Risk Factor Management for Patients With Clinical Manifest Vascular Disease; a Randomized Controlled Trial|Completed||N/A|330|Actual|UMC Utrecht||2|||f||||f||||||||||2018-06-01 01:36:28.774194|2018-06-01 01:36:28.774194
NCT00785018|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2011-04-21|2008-11-04|2008-11-05|Estimate|||||||2011-04-21|2011-04-22|Estimate|November 2008||2008-11-30|May 2009|2009-05-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|VECTOR||In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia|In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia|Completed||N/A|20|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:36:28.85356|2018-06-01 01:36:28.85356
NCT00785005|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2012-04-17|2008-11-04|2008-11-05|Estimate|||||||2012-04-17|2012-04-19|Estimate|May 2008||2008-05-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|ExPRESS||What Makes Exercise Feel More Difficult to Women With and Without Type 2 Diabetes|Exercise-related Perceived Rate of Exertion at Steady-State Workloads (ExPRESS) in Type 2 Diabetes Mellitus|Completed|||99|Actual|University of Colorado, Denver|||2||f||||t||||||Samples Without DNA|"~     During the first visit, blood will be drawn for measurements of overall health (complete~     blood count and comprehensive metabolic panel), glucose and insulin levels, lipid levels,~     plasma FSH concentration, and HbA1C.~      On two separate visits, blood samples will be drawn from a warmed IV site to measure muscle~     metabolites which change with exercise (e.g., glucose, calcium, lactate, H+, K+, and HCO3-)~     and may be associated with muscle pain or fatigue.~   "|||2018-06-01 01:36:28.9262|2018-06-01 01:36:28.9262
NCT00784992|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2017-03-01|2008-11-04|2008-11-05|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2008||2008-11-30|March 2017|2017-03-31|June 2, 2016|Actual|2016-06-02|June 2, 2016|Actual|2016-06-02||Interventional|||A Comparison of Endonasal Dacryocystorhinostomy With and Without Silicone Tubes|A Randomised Controlled Trial to Compare Success and Complication Rates in Endonasal Dacryocystorhinostomy Surgery With and Without Silicone Tubes|Completed||Phase 4|200|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:36:28.985332|2018-06-01 01:36:28.985332
NCT00784979|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|2014-04-28||2015-06-22|2008-11-04|2008-11-05|Estimate|2015-06-22|2015-06-29|Estimate||||2015-06-22|2015-06-29|Estimate|January 2002||2002-01-31|June 2015|2015-06-30|April 2012|Actual|2012-04-30|December 2010|Actual|2010-12-31||Interventional|||Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation|Reduction of PRA (Panel Reactive Antibody) in Sensitized Patients Awaiting Live-Donor Renal Transplantation|Completed||Phase 4|26|Actual|Tampa General Hospital||1|||f||||f||||||||||2018-06-01 01:36:29.058918|2018-06-01 01:36:29.058918
NCT00784966|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-04|||2014-09-12|2008-11-04|2008-11-05|Estimate|||||||2014-09-12|2014-09-16|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|September 2017|Anticipated|2017-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Islet After Kidney Transplant for Type 1 Diabetes|Pancreatic Islet Transplantation in Patients With Type 1 Diabetes Mellitus|Withdrawn||Phase 1/Phase 2|0|Actual|Virginia Commonwealth University||2||University decision.|f||||t||||||||||2018-06-01 01:36:29.193716|2018-06-01 01:36:29.193716
NCT00784953|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2015-11-09|2008-11-03|2008-11-04|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Real Life Effectiveness in Patients With Not Optimally Controlled Asthma|Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA|Completed|||842|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:36:29.333677|2018-06-01 01:36:29.333677
NCT00784940|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2009-04-24|2008-11-03|2008-11-04|Estimate|||||||2009-04-24|2009-04-27|Estimate|June 1998||1998-06-30|April 2009|2009-04-30|April 2007|Actual|2007-04-30|March 2005|Actual|2005-03-31||Interventional|||ATAC - Bone Density Sub-Protocol|A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women|Completed||Phase 3|308|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 01:36:29.40943|2018-06-01 01:36:29.40943
NCT00784927|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-01|2015-03-23||2016-08-25|2008-11-01|2008-11-04|Estimate|2016-01-07|2016-02-08|Estimate||||2016-08-25|2016-10-07|Estimate|November 2008||2008-11-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|October 2013|Actual|2013-10-31||Interventional|||Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma|A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy|Completed||Phase 2|36|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 01:36:29.493191|2018-06-01 01:36:29.493191
NCT00784914|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-01|||2018-04-12|2008-11-01|2008-11-04|Estimate|||||||2018-04-12|2018-04-17|Actual|June 2008||2008-06-30|April 2018|2018-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors|A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors|Completed||Phase 1|12|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 01:36:29.784969|2018-06-01 01:36:29.784969
NCT00784901|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-02|||2008-11-10|2008-11-03|2008-11-04|Estimate|||||||2008-11-10|2008-11-11|Estimate|August 2008||2008-08-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmemtosa|Study of the Correlation Between Macular Thickness Analyzed by Optical Coherence Tomography and the Visual Functions in Retinitis Pigmemtosa|Completed|||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:36:29.876313|2018-06-01 01:36:29.876313
NCT00784888|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2012-03-14|2008-11-03|2008-11-04|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|TAMARA||Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy|A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients|Completed|||344|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:36:29.943222|2018-06-01 01:36:29.943222
NCT00784875|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2011-11-17|2010-12-09|2012-01-30|2008-10-31|2008-11-04|Estimate|2012-01-30|2012-02-29|Estimate|2010-12-09|2010-12-15|Estimate|2012-01-30|2012-02-29|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|SLUMBER||An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia|A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study of the Safety and Efficacy of LY2624803 in Outpatients With Insomnia|Completed||Phase 2|643|Actual|Eli Lilly and Company||4|||f||||t||||||||||2018-06-01 01:36:30.149937|2018-06-01 01:36:30.149937
NCT00784862|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2009-05-14|2008-11-03|2008-11-04|Estimate|||||||2009-05-14|2009-05-15|Estimate|June 1998||1998-06-30|May 2009|2009-05-31|March 1999|Actual|1999-03-31|||||Interventional|||ATAC - Pharmacokinetics (PK) Sub-Protocol|A Randomised, Double Blind Trial to Assess the Pharmacokinetics of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women|Completed||Phase 3|9358|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 01:36:32.748247|2018-06-01 01:36:32.748247
NCT00784849|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2012-04-18||2012-05-17|2008-11-03|2008-11-04|Estimate|2012-05-17|2012-06-20|Estimate||||2012-05-17|2012-06-20|Estimate|November 2004||2004-11-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)|Pilot Trial to Determine the Feasibility of a One Step Sentinel Lymph Node Biopsy Procedure Using Radiolabeled Methylene Blue (IND 70,627)|Completed||Phase 2|62|Actual|Louisiana State University Health Sciences Center in New Orleans||1|||f||||t||||||||||2018-06-01 01:36:32.81536|2018-06-01 01:36:32.81536
NCT00784836|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2010-02-17||2014-04-07|2008-11-03|2008-11-04|Estimate|2014-04-07|2014-05-07|Estimate||||2014-04-07|2014-05-07|Estimate|October 2008||2008-10-31|April 2014|2014-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients|A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis|Terminated||Phase 3|3|Actual|Biogen|Early termination with partial data from 3 subjects, therefore, no statistical analysis performed.|1||Terminated early by Sponsor for business reasons unrelated to safety.|f||||f||||||||||2018-06-01 01:36:32.963964|2018-06-01 01:36:32.963964
NCT00784823|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2014-02-01|2008-11-03|2008-11-04|Estimate|||||||2014-02-01|2014-02-04|Estimate|January 2007||2007-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Mel-Vel||Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma|A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction With High Dose Melphalan as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|32|Actual|Hackensack University Medical Center||1|||f||||t||||||||||2018-06-01 01:36:33.104267|2018-06-01 01:36:33.104267
NCT00784810|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2011-07-14||2011-09-22|2008-11-03|2008-11-04|Estimate|2011-09-22|2011-11-02|Estimate||||2011-09-22|2011-11-02|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|||A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis|A Double-blind, Double-dummy, Parallel Group, Randomised Study to Compare the Efficacy & Tolerability of Oxycodone/Naloxone Prolonged Release (OXN PR) & Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis|Completed||Phase 4|247|Actual|Napp Pharmaceuticals Limited||2|||f||||f||||||||||2018-06-01 01:36:33.166065|2018-06-01 01:36:33.166065
NCT00784797|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-02|||2013-11-20|2008-11-03|2008-11-04|Estimate|||||||2013-11-20|2013-11-21|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Misopristol Versus Pitocin for Second Trimester Abortion|Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion|Completed||Phase 4|145|Actual|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 01:36:33.561712|2018-06-01 01:36:33.561712
NCT00784784|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2011-05-13||2014-11-07|2008-11-03|2008-11-04|Estimate|2011-08-02|2011-09-02|Estimate||||2014-11-07|2014-11-21|Estimate|November 2008||2008-11-30|November 2014|2014-11-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|Stop-Flu-2||Zanamivir Versus Trivalent Split Virus Influenza Vaccine|A Pilot Study for a Randomized Controlled Trial to Compare Trivalent Split Virus Influenza Vaccine to Seasonal Antiviral Prophylaxis in Healthcare and Other Healthy Adults: Assessment of Zanamivir Versus Vaccine (Stop-Flu-2)|Completed||Phase 3|64|Actual|Mount Sinai Hospital, Canada|Pilot study: Limited number of participants|2|||f||||f||||||||||2018-06-01 01:36:33.63857|2018-06-01 01:36:33.63857
NCT00784771|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2015-11-19|2008-11-03|2008-11-04|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2005||2005-01-31|November 2008|2008-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Hypnotherapeutic Olfactory Conditioning for Posttraumatic Stress Disorder (PTSD)|Hypnotherapeutic Olfactory Conditioning for Chronic Combat-Related Posttraumatic Stress Disorder|Completed||N/A|36|Actual|Herzog Hospital|||||f||||f||||||||||2018-06-01 01:36:33.873394|2018-06-01 01:36:33.873394
NCT00784758|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2011-03-08|2008-11-03|2008-11-04|Estimate|||||||2011-03-08|2011-03-09|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|July 2011|Anticipated|2011-07-31|April 2011|Anticipated|2011-04-30||Interventional|FAMOUS||Fenzian Asthma Multicenter Outcomes Study|Effect of Fenzian™ Treatment on Symptoms, Pulmonary Function and Albuterol/Salbutamol Use in Patients With Mild to Moderate Persistent Asthma: A Multicenter, Sham-Controlled Clinical Trial|Unknown status|Active, not recruiting|N/A|125|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:36:33.934456|2018-06-01 01:36:33.934456
NCT00784745|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2014-05-19|2008-11-03|2008-11-04|Estimate|||||||2014-05-19|2014-05-21|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect|Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect|Completed||N/A|21|Actual|University Hospital, Gentofte, Copenhagen||1|||f||||f||||||||||2018-06-01 01:36:34.086062|2018-06-01 01:36:34.086062
NCT00784732|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2016-11-16|2008-11-03|2008-11-04|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber|A Randomized, Partially-blinded, Placebo-controlled, Two-way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model|Completed||Phase 2|44|Actual|Novartis||3|||f||||f||||||||||2018-06-01 01:36:34.155166|2018-06-01 01:36:34.155166
NCT00784719|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2012-11-29|2011-03-24|2013-02-27|2008-11-03|2008-11-04|Estimate|2013-02-27|2013-04-09|Estimate|2011-03-24|2011-04-01|Estimate|2013-02-27|2013-04-09|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.|A Phase I/II Prospective, Randomized, Double Masked, Vehicle And Comparator Controlled, Dose Ranging Study Of CP-690,550 In Subjects With Dry Eye Disease.|Completed||Phase 1/Phase 2|327|Actual|Pfizer|In this study, a variance was made in the planned analysis. At the time of data analysis, results from Stage 1 and 2 were combined for efficacy and safety analyses. Hence, results are presented together for both stages.|6|||f||||f||||||||||2018-06-01 01:36:34.326553|2018-06-01 01:36:34.326553
NCT00784706|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-08-26|2008-11-03|2008-11-04|Estimate|||||||2012-08-26|2012-08-28|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Combined Therapy on Neglect Syndrome in Stroke Patients|Effect of Combined Therapy on Neglect Syndrome in Stroke Patients|Completed||N/A|30|Actual|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-06-01 01:36:37.370493|2018-06-01 01:36:37.370493
NCT00784693|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03||2011-03-14|2011-04-22|2008-11-03|2008-11-04|Estimate||||2011-03-14|2011-03-25|Estimate|2011-04-22|2011-04-29|Estimate|December 2008||2008-12-31|April 2011|2011-04-30|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis|A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Pain Associated With Endometriosis|Terminated||Phase 2|48|Actual|Pfizer||2||"Further recruitment into the study was ceased on 10th December 2009, not attributed to safety.~   All patients recruited in the study completed all study visits."|f||||f||||||||||2018-06-01 01:36:37.456273|2018-06-01 01:36:37.456273
NCT00784680|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2009-04-30|2008-11-03|2008-11-04|Estimate|||||||2009-04-30|2009-05-01|Estimate|April 1998||1998-04-30|April 2009|2009-04-30|April 2004|Actual|2004-04-30|||||Interventional|||ATAC - Quality of Life Sub-Protocol|A Randomised, Double-Blind, Parallel Group Trial to Assess Quality of Life With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women|Completed||Phase 3|308|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 01:36:37.544572|2018-06-01 01:36:37.544572
NCT00784667|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2010-11-29|2008-11-03|2008-11-04|Estimate|||||||2010-11-29|2010-11-30|Estimate|October 2008||2008-10-31|November 2008|2008-11-30|February 2011|Anticipated|2011-02-28|January 2010|Actual|2010-01-31||Interventional|Dux||Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib|Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab (Erbitux) and Erlotinib (Tarceva) in Patients With Chemotherapy-refractory Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Austin Health|||||f||||t||||||||||2018-06-01 01:36:37.598648|2018-06-01 01:36:37.598648
NCT00784654|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2012-07-16||2015-05-12|2008-11-03|2008-11-04|Estimate|2012-08-30|2012-10-02|Estimate||||2015-05-12|2015-06-08|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17|A Phase III, Double-blind, Placebo-controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention- Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|276|Actual|Shire||2|||f||||||||||||||2018-06-01 01:36:37.863295|2018-06-01 01:36:37.863295
NCT00784641|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2013-02-13|2008-10-31|2008-11-04|Estimate|||||||2013-02-13|2013-02-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:36:38.580142|2018-06-01 01:36:38.580142
NCT00784615|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-11-18|2008-11-03|2008-11-04|Estimate|||||||2008-11-18|2008-11-19|Estimate|December 2007||2007-12-31|October 2008|2008-10-31||||||||Observational|||Evaluation of Endocrine and Metabolic Parameters in the New Diagnostic Phenotypes of Polycystic Ovary Syndrome|Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome|Unknown status|Recruiting||80|Anticipated|Universidad Nacional de Córdoba|||5||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 01:36:38.629858|2018-06-01 01:36:38.629858
NCT00784602|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2017-12-30|2008-11-03|2008-11-04|Estimate|||||||2017-12-30|2018-01-03|Actual|October 29, 2008|Actual|2008-10-29|December 2017|2017-12-31|August 29, 2016|Actual|2016-08-29|August 29, 2016|Actual|2016-08-29||Observational|||Observing Pelvic Organ Prolapse Symptoms And Treatment Outcomes|Observing Pelvic Organ Prolapse Symptoms And Treatment Outcomes|Terminated|||301|Actual|William Beaumont Hospitals||||Shift in department's research interests|f||||f||||||||No||2018-06-01 01:36:38.734322|2018-06-01 01:36:38.734322
NCT00784589|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2017-06-13|2008-11-03|2008-11-04|Estimate|||||||2017-06-13|2017-06-14|Actual|July 2009||2009-07-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2013|Actual|2013-12-31||Interventional|Rituximab 3||Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus|Comparison Between Monoclonal Antibody CD20 Treatment (Rituximab (mabthéra))and General Corticotherapy Treatment in Patients With Pemphigus|Completed||Phase 3|90|Anticipated|University Hospital, Rouen||2|||f||||t||||||||||2018-06-01 01:36:38.796464|2018-06-01 01:36:38.796464
NCT00784576|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-12-02|2008-11-03|2008-11-04|Estimate|||||||2008-12-02|2008-12-03|Estimate|November 2004||2004-11-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|April 2007|Actual|2007-04-30||Observational|IPDACS||Incidence and Predictors of Delirium After Cardiac Surgery|Incidence and Predictors of Delirium After Cardiac Surgery: A Prospective Observational Cohort Study|Completed|||563|Actual|Medical Universtity of Lodz|||1||f||||f||||||||||2018-06-01 01:36:38.872423|2018-06-01 01:36:38.872423
NCT00784563|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2015-01-16||2015-08-25|2008-11-03|2008-11-04|Estimate|2015-08-25|2015-09-15|Estimate||||2015-08-25|2015-09-15|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Baseline characteristics of subjects.|Effects of Aerobic Exercise in Parkinson's Disease|Effects of Aerobic Exercise in Parkinson's Disease|Completed||N/A|104|Actual|VA Office of Research and Development|We adapted our design in response to recruitment challenges and preliminary results over the course of the study. This uncontrolled study cannot prove efficacy, but provides guidance for a future Phase III study on aerobic exercise in PD.|2|||f||||t||||||||||2018-06-01 01:36:38.957719|2018-06-01 01:36:38.957719
NCT00784550|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2010-11-18|2010-08-12|2016-10-11|2008-11-03|2008-11-04|Estimate|2010-11-18|2010-12-10|Estimate|2010-08-12|2010-08-17|Estimate|2016-10-11|2016-11-23|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ADC111114||A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).|A Randomized, Double-Blind, Parallel-Group, 24-Week Study to Evaluate the Efficacy and Safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Inhalation Powder) BID Plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD Versus Spiriva QD Plus Placebo DISKUS BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|342|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:36:39.608278|2018-06-01 01:36:39.608278
NCT00784537|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2018-02-07|2008-11-03|2008-11-04|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2008||2008-09-30|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|HD0801||High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients|Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients|Completed||Phase 2/Phase 3|520|Actual|Fondazione Italiana Linfomi ONLUS||2|||f||||f||||||||||2018-06-01 01:36:40.08831|2018-06-01 01:36:40.08831
NCT00784524|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-01|||2015-04-10|2008-11-01|2008-11-04|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca|A Phase II Study of Allogeneic Large Multivalent Immunogen (LMI) Vaccine and IL-2 for the Treatment of Stable Metastatic Breast Cancer|Terminated||Phase 2|14|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||t||||||||||2018-06-01 01:36:40.276793|2018-06-01 01:36:40.276793
NCT00784511|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2014-11-13|2008-11-03|2008-11-04|Estimate|||||||2014-11-13|2014-11-14|Estimate|July 2008||2008-07-31|November 2014|2014-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans|Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans|Completed||Phase 2|100|Actual|Tufts University||2|||f||||f||||||||||2018-06-01 01:36:40.351768|2018-06-01 01:36:40.351768
NCT00784498|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-02|||2010-07-31|2008-11-03|2008-11-04|Estimate|||||||2010-07-31|2010-08-03|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department|Procedural Sedation for Painful Orthopedic Manipulations With Propofol vs. Midazolam/Ketamine in the Adult Emergency Department|Completed||Phase 4|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-06-01 01:36:40.423095|2018-06-01 01:36:40.423095
NCT00784485|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2011-03-08|2008-11-03|2008-11-04|Estimate|||||||2011-03-08|2011-03-09|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Non-invasive Measures of Effects of Xolair in Asthma|Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Treatment With Omalizumab|Terminated||Phase 4|13|Anticipated|University of California, Los Angeles||1||Terminated due to poor enrollment.|f||||f||||||||||2018-06-01 01:36:40.486838|2018-06-01 01:36:40.486838
NCT00784472|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-07-05|2008-11-03|2008-11-04|Estimate|||||||2012-07-05|2012-07-09|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Visceral Pain From the Upper Urinary Tract - a Trial on the Effect of Morphine and Oxycodone in Patients Undergoing PCNL|Visceral Pain Originating From the Upper Urinary Tract - a Randomized Controlled Trial on the Effect of Morphine and Oxycodone in Patients Undergoing Percutaneous Nephrolithotomy (PCNL)|Completed||Phase 3|55|Actual|Fredericia Hosptial||2|||f||||t||||||||||2018-06-01 01:36:40.565031|2018-06-01 01:36:40.565031
NCT00784459|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|2013-06-11||2013-12-16|2008-11-03|2008-11-04|Estimate|2013-12-16|2014-02-05|Estimate||||2013-12-16|2014-02-05|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|CIA||The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics|Costimulation Inhibition in Asthma|Completed||Phase 2|24|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:36:40.639139|2018-06-01 01:36:40.639139
NCT00784446|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2013-01-04|2008-11-03|2008-11-04|Estimate|||||||2013-01-04|2013-01-07|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2010|Actual|2010-08-31||Interventional|||First-line Therapy of Stage IV Colorectal Cancer|A Phase I/II Study of Capecitabine/Oxaliplatin (XELOX) in Combination With Bevacizumab and Imatinib as First-line Treatment of Patients With Stage IV Colorectal Cancer|Completed||Phase 1/Phase 2|51|Actual|University of Cologne||1|||f||||t||||||||||2018-06-01 01:36:40.99117|2018-06-01 01:36:40.99117
NCT00784433|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2012-02-08|2008-11-03|2008-11-04|Estimate|||||||2012-02-08|2012-02-09|Estimate|May 2010||2010-05-31|August 2009|2009-08-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|CASCADE||The CArdiovasCulAr Diabetes & Ethanol (CASCADE) Trial|Cardiovascular and Metabolic Effects of Moderate Alcohol Consumption in Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Ben-Gurion University of the Negev||3|||f||||t||||||||||2018-06-01 01:36:41.118578|2018-06-01 01:36:41.118578
NCT00784420|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-11-17|2008-11-03|2008-11-04|Estimate|||||||2008-11-17|2008-11-18|Estimate|September 2008||2008-09-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Drug Interaction Study Between Raltegravir And UK-453,061|Open-Label, Randomized, 3-Way Crossover Study To Estimate The Interaction Between Multiple Dose Raltegravir And UK-453,061 In Healthy Subjects|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:36:41.188087|2018-06-01 01:36:41.188087
NCT00784407|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-03|||2008-11-03|2008-11-03|2008-11-04|Estimate|||||||2008-11-03|2008-11-04|Estimate|February 2008||2008-02-29|October 2008|2008-10-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Thyroid Surgery With the New Harmonic Scalpel: a Prospective Randomized Study|Thyroid Surgery With the New Harmonic Scalpel: a Prospective Randomized Study|Completed||N/A|90|Actual|Hippocration General Hospital||2|||f||||t||||||||||2018-06-01 01:36:41.255279|2018-06-01 01:36:41.255279
NCT00784394|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-01|||2016-12-28|2008-11-01|2008-11-04|Estimate|||||||2016-12-28|2016-12-29|Estimate|April 2004||2004-04-30|December 2016|2016-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Diindolylmethane in Preventing Cancer in Healthy Volunteers|Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-indolylmethane (DIM)|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 01:36:41.323906|2018-06-01 01:36:41.323906
NCT00784381|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-11-16|2008-10-31|2008-11-03|Estimate|||||||2012-11-16|2012-11-19|Estimate|May 2007||2007-05-31|October 2008|2008-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|Ordoclic-IR||Computer Prescribing System and Impaired Renal Function|Impact of a Counselling System Coupled With a Computer Prescribing System to Optimize the Use of the Drugs for Old Subjects Having Renal Function Impairment|Completed|||12|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||||||2018-06-01 01:36:41.403311|2018-06-01 01:36:41.403311
NCT00784368|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2013-03-21||2013-06-19|2008-10-31|2008-11-03|Estimate|2013-06-19|2013-07-25|Estimate||||2013-06-19|2013-07-25|Estimate|January 2008||2008-01-31|June 2013|2013-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection|A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection.|Completed||Phase 3|55|Actual|Janssen Pharmaceutical K.K.||3|||f||||t||||||||||2018-06-01 01:36:41.507566|2018-06-01 01:36:41.507566
NCT00784355|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2017-03-07|2008-10-31|2008-11-03|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2009||2009-01-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Laparoscopic Cholecystectomy in Idiopathic Pancreatitis|Does Laparoscopic Cholecystectomy Prevent Recurrence in Idiopathic Pancreatitis? A Prospective Multicentre Randomized Study|Recruiting||N/A|200|Anticipated|Kuopio University Hospital||2|||f||||f||||||||Undecided||2018-06-01 01:36:42.297572|2018-06-01 01:36:42.297572
NCT00784342|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-12-12|2008-10-30|2008-11-03|Estimate|||||||2012-12-12|2012-12-13|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Validation of PROMIS Banks With COPD Exacerbations|Validation of PROMIS Banks With COPD Exacerbations|Completed|||188|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-06-01 01:36:42.38633|2018-06-01 01:36:42.38633
NCT00784329|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2017-08-22|2008-10-31|2008-11-03|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2008|Actual|2008-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease|Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease|Active, not recruiting||N/A|15|Anticipated|Lahey Clinic||1|||f||||f||||||||||2018-06-01 01:36:42.453415|2018-06-01 01:36:42.453415
NCT00784316|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2011-11-23|2008-10-31|2008-11-03|Estimate|||||||2011-11-23|2011-11-24|Estimate|August 2007||2007-08-31|November 2011|2011-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery|Intravenous Metoprolol Versus Intravenous Amiodarone in the Prevention of Atrial Fibrillation After Cardiac Surgery|Completed||Phase 4|316|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 01:36:42.565669|2018-06-01 01:36:42.565669
NCT00784303|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2014-08-06|2008-10-31|2008-11-03|Estimate|||||||2014-08-06|2014-08-08|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology|Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology|Completed||Phase 2|116|Actual|Eisai Inc.||1|||f||||f||||||||||2018-06-01 01:36:42.636548|2018-06-01 01:36:42.636548
NCT00784290|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-03-22|2008-10-30|2008-11-03|Estimate|||||||2012-03-22|2012-03-26|Estimate|September 2003||2003-09-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|October 2010|Actual|2010-10-31||Interventional|||Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma|Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|35|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:36:42.901062|2018-06-01 01:36:42.901062
NCT00784277|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2010-07-22||2012-01-09|2008-10-31|2008-11-03|Estimate|2012-01-09|2012-02-13|Estimate||||2012-01-09|2012-02-13|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Arm, Multicenter Study in Subjects With End-Stage Joint Disease to Compare the Frequency of Constipation Symptoms in SubjectsTreated With Tapentadol IR and Oxycodone IR Using a Bowel Function Patient Diary|Completed||Phase 3|597|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||7|||f||||f||||||||||2018-06-01 01:36:43.000761|2018-06-01 01:36:43.000761
NCT00784264|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2010-01-11|2008-10-31|2008-11-03|Estimate|||||||2010-01-11|2010-01-12|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|||||Observational|IMT||A Study on Intima Media Thickness (IMT) in Middle-aged Subjects|A Study on Intima Media Thickness (IMT) in Middle-aged Subjects|Completed|||200|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:36:43.619048|2018-06-01 01:36:43.619048
NCT00784251|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2013-12-10|2008-10-30|2008-11-03|Estimate|||||||2013-12-10|2013-12-11|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Validating PROMIS Instruments in Back and Leg Pain|Validating PROMIS Instruments in Back and Leg Pain|Completed|||226|Actual|University of Washington|||||f||||f||||||||||2018-06-01 01:36:43.675688|2018-06-01 01:36:43.675688
NCT00784238|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2014-02-07||2014-02-07|2008-10-31|2008-11-03|Estimate|2014-02-07|2014-03-27|Estimate||||2014-02-07|2014-03-27|Estimate|April 2008||2008-04-30|February 2014|2014-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|Power||Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants|An Open-label, Prospective, Non-Comparative Study to Evaluate Subjective Well-Being and Responses in Patients With Schizophrenia Who Had Switched to Paliperidone Extended-Release Tablets|Completed||Phase 4|289|Actual|Janssen Korea, Ltd., Korea|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.|1|||f||||f||||||||||2018-06-01 01:36:43.773612|2018-06-01 01:36:43.773612
NCT00784225|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2018-01-31|2008-10-31|2008-11-03|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2004||2004-07-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|November 2017|Actual|2017-11-30||Interventional|SEE||S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000|S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE)|Active, not recruiting||Phase 3|2774|Actual|Southwest Oncology Group||4|||f||||t||||||||||2018-06-01 01:36:44.449747|2018-06-01 01:36:44.449747
NCT00784212|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2016-09-21|2008-10-31|2008-11-03|Estimate|||||||2016-09-21|2016-09-23|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy|A Multicenter, Single-blind, Within-subject, Placebo-controlled Proof of Concept Study to Assess the Effect of Single Oral Doses of BGG492 on the Photoparoxysmal EEG Response in Patients With Photosensitive Epilepsy|Completed||Phase 2|13|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:36:44.535508|2018-06-01 01:36:44.535508
NCT00784199|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2013-05-13|2008-10-30|2008-11-03|Estimate|||||||2013-05-13|2013-05-14|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Validating PROMIS Instruments in Depression|Validating PROMIS Instruments in Depression|Completed|||115|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 01:36:44.603445|2018-06-01 01:36:44.603445
NCT00784186|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2014-02-18|2008-10-31|2008-11-03|Estimate|||||||2014-02-18|2014-02-20|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial|Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial|Completed||N/A|120|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 01:36:44.663447|2018-06-01 01:36:44.663447
NCT00784173|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2008-10-31|2008-10-31|2008-11-03|Estimate|||||||2008-10-31|2008-11-03|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Observational|||Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome|Middle and Inner Ear Malformation in Children With Velocardiofacial Syndrome|Completed|||2|Actual|Pontificia Universidade Catolica de Sao Paulo|||||f||||f||||||||||2018-06-01 01:36:44.729158|2018-06-01 01:36:44.729158
NCT00784160|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2009-08-21|2008-10-31|2008-11-03|Estimate|||||||2009-08-21|2009-08-25|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid)- Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd PH_DETINBACK Tangerine Mix.|Completed||Phase 3|53|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:44.779687|2018-06-01 01:36:44.779687
NCT00784147|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2014-03-11||2014-04-17|2008-10-30|2008-11-03|Estimate|2014-03-11|2014-04-17|Estimate||||2014-04-17|2014-05-05|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|TMB-202|Baseline measures were assessed using the Intent-to-Treat (ITT) population, defined as all randomized patients regardless of whether a dose of study medication was received.|Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1|A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1(Amended to 24-Weeks)|Completed||Phase 2|113|Actual|TaiMed Biologics Inc.|ACTG Adherence Questionnaire data were incomplete due to insufficient data collection methods. No clinically meaningful information was gained upon review of these results.|2|||f||||t||||||||||2018-06-01 01:36:44.876558|2018-06-01 01:36:44.876558
NCT00784134|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2017-03-30||2017-06-01|2008-10-31|2008-11-03|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|July 2009||2009-07-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|CLEAR III||Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III|Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III|Completed||Phase 3|500|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-06-01 01:36:45.413386|2018-06-01 01:36:45.413386
NCT00784121|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2008-12-18|2008-10-31|2008-11-03|Estimate|||||||2008-12-18|2008-12-19|Estimate|October 2008||2008-10-31|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Interventional|||Dermacyd Breeze (Lactic Acid) Pocket BR - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Breeze Pocket BR.|Completed||Phase 3|54|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:48.213165|2018-06-01 01:36:48.213165
NCT00784108|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-02-08|2008-10-30|2008-11-03|Estimate|||||||2017-02-08|2017-02-10|Actual|October 2008||2008-10-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.|Non-contact Imaging Device (Camera) Can Help Improve Treatment for Patients With Basal Cell Carcinoma.|Completed||Phase 1|11|Actual|University of California, Irvine||2|||f||||t||||||||||2018-06-01 01:36:48.284345|2018-06-01 01:36:48.284345
NCT00784095|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2014-10-03||2016-03-11|2008-10-30|2008-11-03|Estimate|2016-03-11|2016-03-22|Estimate||||2016-03-11|2016-03-22|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Outlook Quality of Life Intervention|Outlook: An Intervention to Improve Quality of Life in Serious Illness|Completed||N/A|36|Actual|VA Office of Research and Development|Therefore, due to the small sample size, finding are met with caution. Subjects were not randomized by any condition. As a result, those in the Control arm were more functionally able than the other two arms at baseline.|3|||f||||f||||||||No||2018-06-01 01:36:48.473281|2018-06-01 01:36:48.473281
NCT00784082|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2013-01-30|2008-10-31|2008-11-03|Estimate|||||||2013-01-30|2013-01-31|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|||Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease|Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease|Completed|||62|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Sample with DNA~   "|||2018-06-01 01:36:49.050019|2018-06-01 01:36:49.050019
NCT00784069|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2008-12-18|2008-10-31|2008-11-03|Estimate|||||||2008-12-18|2008-12-19|Estimate|October 2008||2008-10-31|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Interventional|||Dermacyd Breeze (Lactic Acid) Pocket BR - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Breeze Pocket BR.|Completed||Phase 3|27|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:49.282898|2018-06-01 01:36:49.282898
NCT00784056|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2009-08-21|2008-10-31|2008-11-03|Estimate|||||||2009-08-21|2009-08-25|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|Completed||Phase 3|26|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:49.430234|2018-06-01 01:36:49.430234
NCT00783848|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2013-04-26|2008-10-30|2008-11-03|Estimate|||||||2013-04-26|2013-04-29|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Validating PROMIS Instruments in Congestive Heart Failure Patients Receiving a Heart Transplant|Validating PROMIS Instruments in Congestive Heart Failure Patients Receiving a Heart Transplant|Completed|||58|Actual|Duke University|||||f||||f||||||||||2018-06-01 01:36:51.411975|2018-06-01 01:36:51.411975
NCT00784043|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2018-02-20||2018-04-26|2008-10-31|2008-11-03|Estimate|2018-04-26|2018-05-25|Actual||||2018-04-26|2018-05-25|Actual|March 2004||2004-03-31|April 2018|2018-04-30|February 2017|Actual|2017-02-28|September 2009|Actual|2009-09-30||Interventional|||Bilateral Cochlear Implantation in Children With the MED-EL Cochlear Implant|Longitudinal Efficacy in Young Children Implanted Bilaterally With MED-EL COMBI 40+ / PULSARCI100/SONATATI100 Cochlear Implant Systems.|Terminated||N/A|37|Actual|Med-El Corporation|Protocol was terminated due to inability to find unilateral matches.|2|||f||||f||||||||||2018-06-01 01:36:49.503794|2018-06-01 01:36:49.503794
NCT00784030|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2012-04-25||2016-03-07|2008-10-31|2008-11-03|Estimate|2016-03-07|2016-04-06|Estimate||||2016-03-07|2016-04-06|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||High Water Intake to Slow Progression of Polycystic Kidney Disease|The Effect of Water Loading on Urinary Biomarkers|Completed||N/A|23|Actual|New York University School of Medicine|This was a very small study, so larger numbers are needed. Urine cAMP measurement as a surrogate of response to water treatment needs further validation.|2|||f||||f||||||||||2018-06-01 01:36:49.821414|2018-06-01 01:36:49.821414
NCT00784017|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2013-02-26|2008-10-31|2008-11-03|Estimate|||||||2013-02-26|2013-02-27|Estimate|October 2008||2008-10-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia|Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia|Completed||Phase 3|199|Actual|medac GmbH||2|||f||||t||||||||||2018-06-01 01:36:50.010868|2018-06-01 01:36:50.010868
NCT00784004|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2014-12-01|2008-10-31|2008-11-03|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Investigation of Efficiency of Breathing With Different Breathing Patterns|Investigation of Efficiency of Breathing With Different Breathing Patterns in Healthy Volunteers and Patients With Respiratory Failure|Completed||N/A|26|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:36:50.095702|2018-06-01 01:36:50.095702
NCT00783991|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2013-06-05|2008-10-30|2008-11-03|Estimate|||||||2013-06-05|2013-06-06|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Investigating the Impact of Mode of Administration on Item Response|Investigating the Impact of Mode of Administration on Item Response|Completed|||800|Actual|Stony Brook University|||4||f||||f||||||||||2018-06-01 01:36:50.173284|2018-06-01 01:36:50.173284
NCT00783978|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2012-11-16|2008-10-31|2008-11-03|Estimate|||||||2012-11-16|2012-11-19|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|APSE||Surfactant Disorders and Chronic Lung Disease|Surfactant Disorders Associated With Chronic Lung Disease in Children.|Completed|||58|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma, DNA~   "|||2018-06-01 01:36:50.265542|2018-06-01 01:36:50.265542
NCT00783965|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2013-07-31||2016-01-13|2008-10-31|2008-11-03|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|July 2004||2004-07-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|June 2012|Actual|2012-06-30||Interventional|||Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back|A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome|Completed||Phase 2|34|Actual|Children's Hospital & Research Center Oakland|Non-compliance and large drop-out rates leading to small numbers of data analyzed.|2|||f||||t||||||||||2018-06-01 01:36:50.39809|2018-06-01 01:36:50.39809
NCT00783952|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2016-10-28||2017-03-08|2008-10-31|2008-11-03|Estimate|2017-03-08|2017-04-20|Actual||||2017-03-08|2017-04-20|Actual|November 2008||2008-11-30|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Validation of Mixed Venous Blood Oxygen Saturation Obtained With a Novel Mathematical Equation|Validation of Mixed Venous Blood Oxygen Saturation Obtained With a Novel Mathematical Equation Using Arterial Oxygen Saturation and Various Local Tissue Oxygen Saturations.|Terminated||N/A|8|Actual|Massachusetts General Hospital||1||Inability to recruit subjects|f||||f||||||||||2018-06-01 01:36:50.788651|2018-06-01 01:36:50.788651
NCT00783939|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2009-03-05|2008-10-31|2008-11-03|Estimate|||||||2009-03-05|2009-03-06|Estimate|September 2008||2008-09-30|March 2009|2009-03-31||||September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Safety.|Safety Dermatological Evaluation: Vaginal Mucous Irritation - Product Tested: Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid).|Completed||Phase 3|31|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:50.935172|2018-06-01 01:36:50.935172
NCT00783926|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2015-10-07|2008-10-31|2008-11-03|Estimate|||||||2015-10-07|2015-10-09|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)|Double Blind, Multi-Center, Phase 1 Study of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Subjects Aged 18 to 45 Years|Completed||Phase 1|422|Actual|Ology Bioservices||2|||f||||t||||||||||2018-06-01 01:36:50.997822|2018-06-01 01:36:50.997822
NCT00783913|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2017-06-30|2008-10-31|2008-11-03|Estimate|||||||2017-06-30|2017-07-02|Actual|October 29, 2008||2008-10-29|October 24, 2011|2011-10-24|October 24, 2011|Actual|2011-10-24|October 24, 2011|Actual|2011-10-24||Interventional|||Using Transcranial Direct Current Stimulation (tDCS) to Enhance the Benefit of Movement Training in Stoke Patients|Enhancing the Beneficial Effects of Upper Extremity Visuomotor Training With tDCS|Completed||N/A|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:36:51.076362|2018-06-01 01:36:51.076362
NCT00783900|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2017-03-01|2008-10-31|2008-11-03|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2007||2007-01-31|November 2011|2011-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Intravenous Administration of Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery|Intravenous Metoprolol Versus Biatrial Pacing in the Prevention of Atrial Fibrillation After Cardiac Surgery|Completed||Phase 4|316|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 01:36:51.159588|2018-06-01 01:36:51.159588
NCT00783887|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2013-08-06|2008-10-31|2008-11-03|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|DCP||Diagnosis of Primary Ciliary Dyskinesia|Molecular Diagnosis of Primary Ciliary Dyskinesia|Completed|||125|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     DNA, Serum, White blood cells~   "|||2018-06-01 01:36:51.237701|2018-06-01 01:36:51.237701
NCT00783861|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2008-12-18|2008-10-31|2008-11-03|Estimate|||||||2008-12-18|2008-12-19|Estimate|October 2008||2008-10-31|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Interventional|||Dermacyd Femina (Lactic Acid) Pocket BR - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Femina Pocket BR.|Completed||Phase 3|54|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:51.329194|2018-06-01 01:36:51.329194
NCT00783835|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2013-03-22||2013-07-19|2008-10-31|2008-11-03|Estimate|2013-07-19|2013-07-23|Estimate||||2013-07-19|2013-07-23|Estimate|February 2008||2008-02-29|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Evaluate the Efficacy and Quality of Life of Long-Acting Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Multicenter Open Trial to Evaluate the Effectiveness and Quality of Life in Adults With Attention Deficit /Hyperactivity Disorder (ADHD) Treated With Long Acting Methylphenidate (CONCERTA)|Completed||Phase 4|60|Actual|Janssen-Cilag Farmaceutica Ltda.||1|||f||||f||||||||||2018-06-01 01:36:51.496702|2018-06-01 01:36:51.496702
NCT00783822|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2012-11-08|2008-10-31|2008-11-03|Estimate|||||||2012-11-08|2012-11-09|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|January 2011|Actual|2011-01-31||Interventional|TIME||Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients|Behavioral and Psychosocial Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients: a Multicenter Study|Completed||N/A|265|Actual|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-06-01 01:36:51.837899|2018-06-01 01:36:51.837899
NCT00783809|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2012-04-26|2008-10-31|2008-11-03|Estimate|||||||2012-04-26|2012-04-27|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|MOONSTRIP||Measurement of Optic Nerve Sheath in Traumatic Raised Intracranial Pressure|Measurement of Optic Nerve Sheath in Traumatic Raised Intracranial Pressure|Unknown status|Active, not recruiting||560|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 01:36:51.916907|2018-06-01 01:36:51.916907
NCT00783796|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2011-11-29||2014-10-31|2008-10-30|2008-11-03|Estimate|2011-11-29|2012-01-05|Estimate||||2014-10-31|2014-11-04|Estimate|October 2008||2008-10-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|SPIRIT SV||SPIRIT Small Vessel Registry|Spirit Small Vessel Registry (SPIRIT SV)|Completed||Phase 3|150|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 01:36:52.069118|2018-06-01 01:36:52.069118
NCT00783783|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2012-12-10|2008-10-31|2008-11-03|Estimate|||||||2012-12-10|2012-12-11|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||CYP2D6 Pharmacogenetics in Risperidone-Treated Children|CYP2D6 PHARMACOGENETICS IN RISPERIDONE-TREATED CHILDREN AND ADOLESCENTS WITH PSYCHIATRIC OR NEURODEVELOPMENTAL DISORDERS|Completed|||47|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples With DNA|"~     DNA from blood, buccal swab, or saliva~   "|||2018-06-01 01:36:53.482022|2018-06-01 01:36:53.482022
NCT00783770|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2011-05-16|2008-10-31|2008-11-03|Estimate|||||||2011-05-16|2011-05-18|Estimate|July 2005||2005-07-31|May 2011|2011-05-31||||March 2007|Actual|2007-03-31||Observational|||Maternal and Infant Cord Blood Monosaccharide Content|Comparison of Monosaccharide Content of Maternal and Umbilical Venous Cord Blood in Term and Preterm Pregnancies|Completed|||48|Actual|Arkansas Children's Hospital Research Institute|||3||f||||f||||||Samples Without DNA|"~     plasma will be stored~   "|||2018-06-01 01:36:53.590727|2018-06-01 01:36:53.590727
NCT00783757|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-07-25|2008-10-30|2008-11-03|Estimate|||||||2017-07-25|2017-07-27|Actual|August 2008||2008-08-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2014|Actual|2014-12-31||Interventional|||TOBI to Monitor Response to Neoadjuvant Therapy in Breast Cancer|Functional Metabolic Near-infrared Tomographic Optical Breast Imaging (TOBI) to Monitor Response to Neoadjuvant Therapy in Breast Cancer|Completed||N/A|30|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 01:36:53.647087|2018-06-01 01:36:53.647087
NCT00783744|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2009-09-25|2008-10-31|2008-11-03|Estimate|||||||2009-09-25|2009-09-28|Estimate|December 2001||2001-12-31|September 2009|2009-09-30||||August 2003|Actual|2003-08-31||Interventional|LAPTOP||Insulin Glargine Combination Therapies in Type II Diabetics|28-week, Open, Randomized, Multinational, Multicenter Clinical Trial to Compare Efficacy and Safety of Combination Therapy of Glimepiride Plus Metformin Plus HOE901 Insulin Analogue Versus a Two-injection Conventional Therapy With Premixed Insulin NPH 30/70 Bid in Type 2 Diabetes Mellitus Patients Poorly Controlled With Oral Antidiabetic Drug Treatment.|Completed||Phase 3|375|Actual|Sanofi||2|||f||||||||||||||2018-06-01 01:36:53.734201|2018-06-01 01:36:53.734201
NCT00783731|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2011-07-25|2008-10-31|2008-11-03|Estimate|||||||2011-07-25|2011-07-26|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Low Dose of Midazolam is Superior to Conventional Dose for Rapid Sequence Intubation in Emergency Department (ED)||Completed||N/A|||Seoul National University Hospital||1|||f||||||||||||||2018-06-01 01:36:53.831779|2018-06-01 01:36:53.831779
NCT00783718|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2014-06-19|2013-01-14|2014-06-19|2008-10-31|2008-11-03|Estimate|2014-06-19|2014-07-18|Estimate|2013-01-14|2013-01-23|Estimate|2014-06-19|2014-07-18|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|GEMINI I|Baseline characteristics are provided for the Induction Phase Safety Population, defined as all participants, in both Cohort 1 and Cohort 2, who received any amount of study drug in the Induction Phase (Weeks 0-6), according to the actual study drug received.|Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis|A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients With Moderate to Severe Ulcerative Colitis|Completed||Phase 3|895|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 01:36:54.126842|2018-06-01 01:36:54.126842
NCT00783705|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2015-04-29||2017-10-30|2008-10-31|2008-11-03|Estimate|2015-07-28|2015-08-25|Estimate||||2017-10-30|2017-12-05|Actual|November 2008||2008-11-30|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia|Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol Versus Placebo in Smokers With Bronchial Dysplasia|Completed||Phase 2|85|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:36:56.1747|2018-06-01 01:36:56.1747
NCT00783692|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2014-06-19|2013-04-08|2014-06-19|2008-10-31|2008-11-03|Estimate|2014-06-19|2014-07-21|Estimate|2013-04-08|2013-04-15|Estimate|2014-06-19|2014-07-21|Estimate|December 2008||2008-12-31|June 2014|2014-06-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|GEMINI II|The Induction Phase Safety Population, defined as all participants, in both Cohort 1 and Cohort 2, who received any amount of study drug in the Induction Phase (Weeks 0 to 6), according to the actual study drug received.|Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease|A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease|Completed||Phase 3|1116|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 01:36:57.171953|2018-06-01 01:36:57.171953
NCT00782665|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-31|Estimate|||||||2008-10-28|2008-10-31|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|||Myometrial Biopsy for the Detection of Infection|Myometrial Biopsy for the Detection of Infection|Unknown status|Recruiting|N/A|1000|Anticipated|The Woman's Hospital of Texas||2|||f||||f||||||||||2018-06-01 01:37:13.44054|2018-06-01 01:37:13.44054
NCT00783679|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-04-24|2008-10-31|2008-11-03|Estimate|||||||2012-04-24|2012-04-25|Estimate|November 2009||2009-11-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation|Determining the Feasibility and Accuracy of Exhaled CO2 to Measure Cardiac Output in Ventilated Patients Without Tracheal Intubation|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||Understaffing and inadequate funding|f||||f||||||||||2018-06-01 01:36:59.674159|2018-06-01 01:36:59.674159
NCT00783666|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2009-08-21|2008-10-31|2008-11-03|Estimate|||||||2009-08-21|2009-08-25|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINBACK Tangerine Mix|Completed||Phase 3|26|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:59.737562|2018-06-01 01:36:59.737562
NCT00783653|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2013-09-20|2008-10-31|2008-11-03|Estimate|||||||2013-09-20|2013-09-23|Estimate|August 2008||2008-08-31|September 2013|2013-09-30||||July 2013|Actual|2013-07-31||Interventional|||Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years|Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age|Completed||Phase 1/Phase 2|22|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-06-01 01:36:59.807646|2018-06-01 01:36:59.807646
NCT00783640|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|||2008-12-18|2008-10-31|2008-11-03|Estimate|||||||2008-12-18|2008-12-19|Estimate|October 2008||2008-10-31|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Interventional|||Dermacyd Femina (Lactic Acid) Pocket BR - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Femina Pocket BR.|Completed||Phase 3|27|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:36:59.87771|2018-06-01 01:36:59.87771
NCT00783627|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2011-02-22|2008-10-31|2008-11-03|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Observational|DREPANOPEC||Sickle Cell Disease and Endothelial Progenitor Cells (EPCs)|Evaluation of Angiogenic Potential in Sickle Cell Disease. CARACTERIZATION of Endothelial Progenitor Cells|Completed|||66|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:36:59.94342|2018-06-01 01:36:59.94342
NCT00783614|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-31|2012-01-16||2017-10-19|2008-10-31|2008-11-03|Estimate|2012-03-23|2012-04-17|Estimate||||2017-10-19|2017-11-21|Actual|October 2008||2008-10-31|October 2017|2017-10-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Aspirin and Antiretroviral Therapy in HIV Infected Patients|The Effect of Aspirin and Antiretroviral Therapy on Cardiovascular Risk in HIV Infected Patients: A Pilot Study|Terminated||Phase 2|22|Actual|Minneapolis Medical Research Foundation|Early termination leading to small number of subjects analyzed. Study recruitment difficulty due to inclusion of ART deferral component.|4||Lack of funding|f||||f||||||||||2018-06-01 01:37:00.062568|2018-06-01 01:37:00.062568
NCT00783601|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2015-10-15|2008-10-30|2008-10-31|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2004||2004-10-31|October 2015|2015-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||MK0524 Asthma POC Study (0524-008)(COMPLETED)|A Multicenter, Randomized, Double Blind, Crossover Study Comparing the Effect of MK0524 With Placebo and Concomitant Administration of MK0524 Plus Montelukast in Adult Patients With Chronic Asthma|Completed||Phase 2|130|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:37:00.449781|2018-06-01 01:37:00.449781
NCT00783588|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2008-10-30|2008-10-30|2008-10-31|Estimate|||||||2008-10-30|2008-10-31|Estimate|May 2007||2007-05-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase I Extension Trial of Repeated Infusions of ISF35|A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914|Completed||Phase 1|4|Actual|Memgen, LLC|||||f||||t||||||||||2018-06-01 01:37:00.523638|2018-06-01 01:37:00.523638
NCT00783575|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2015-08-21|2008-10-29|2008-10-31|Estimate|||||||2015-08-21|2015-08-24|Estimate|October 2002||2002-10-31|August 2015|2015-08-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease|Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease|Withdrawn|||0|Actual|Medical College of Wisconsin|||1|PI has left institution|f||||t||||||Samples With DNA|"~     DNA extraction, serology~   "|||2018-06-01 01:37:00.613825|2018-06-01 01:37:00.613825
NCT00783562|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2008-10-30|2008-10-30|2008-10-31|Estimate|||||||2008-10-30|2008-10-31|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Preventive Intervention in Nursery School Teachers|Effectiveness of an Extension-Oriented Exercise Program in Preventing Neck and Low Back Complaints in Nursery School Teachers|Completed||Phase 1|71|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 01:37:00.688881|2018-06-01 01:37:00.688881
NCT00783549|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2017-07-05|2008-10-30|2008-10-31|Estimate|||||||2017-07-05|2017-07-07|Actual|September 4, 2008|Actual|2008-09-04|July 2017|2017-07-31|March 31, 2009|Actual|2009-03-31|March 31, 2009|Actual|2009-03-31||Interventional|||A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.|A Study in Healthy Volunteers of Single Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Compound Alone and When Co-administered With Sitagliptin|Completed||Phase 1|76|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:37:00.760664|2018-06-01 01:37:00.760664
NCT00783536|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2009-06-01|2008-10-30|2008-10-31|Estimate|||||||2009-06-01|2009-06-02|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|DOTAR||A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis|An Randomized, Open Label, Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate With DMARD Therapy in Subjects With Active Early Rheumatoid Arthritis|Withdrawn||Phase 4|402|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:37:01.82394|2018-06-01 01:37:01.82394
NCT00783523|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2013-08-06|2008-10-30|2008-10-31|Estimate|||||||2013-08-06|2013-08-09|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Influence of MMP on Brain AVM Hemorrhage|Influence of Matrix Metalloproteinase on Brain Arteriovenous Malformation Hemorrhage|Completed||Phase 1|33|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:37:01.913585|2018-06-01 01:37:01.913585
NCT00783510|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2018-03-13|2008-10-30|2008-10-31|Estimate|||||||2018-03-13|2018-03-15|Actual|July 11, 2008|Actual|2008-07-11|March 2018|2018-03-31|January 8, 2024|Anticipated|2024-01-08|January 8, 2024|Anticipated|2024-01-08||Observational|STRIVE||Juvenile Idiopathic Arthritis (JIA) Registry|A Long-term, Multi-center, Longitudinal Post-marketing, Observational Study to Assess Long Term Safety and Effectiveness of HUMIRA® (Adalimumab) in Children With Moderately to Severely Active Polyarticular or Polyarticular-course Juvenile Idiopathic Arthritis (JIA) - STRIVE|Active, not recruiting|||833|Actual|AbbVie|||2||f||||f||f|||f|||Undecided||2018-06-01 01:37:02.015391|2018-06-01 01:37:02.015391
NCT00783497|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2015-12-16|2008-10-30|2008-10-31|Estimate|||||||2015-12-16|2015-12-17|Estimate|October 2005||2005-10-31|December 2015|2015-12-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Evaluating the Relationship Between Stress, Ethnicity, and Blood Pressure|Stress, Blood Pressure, & Ethnicity|Completed|||203|Actual|University of California, San Diego|||2||f||||t||||||Samples With DNA|"~     Serum, urine~   "|||2018-06-01 01:37:02.305111|2018-06-01 01:37:02.305111
NCT00783484|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2009-05-28|2008-10-30|2008-10-31|Estimate|||||||2009-05-28|2009-06-02|Estimate|October 2008||2008-10-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects|A Double-Blind (3rd Party Open), Placebo-Controlled, Crossover, Dose Escalating Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539, To Assess The Potential Of PF-03716539 To Inhibit CYP3A4 (In Vivo) And To Evaluate The Drug Interaction Potential Between PF-03716539 And Darunavir Or Maraviroc In Healthy Adult Subjects|Completed||Phase 1|37|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 01:37:02.3778|2018-06-01 01:37:02.3778
NCT00783471|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2010-06-15|2008-10-30|2008-10-31|Estimate|||||||2010-06-15|2010-06-16|Estimate|November 2008||2008-11-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|DOPERLO||Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)|Docetaxel Combined With Pulsatile Erlotinib (Tarceva®) In Patients With Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)|Terminated||Phase 2|51|Actual|Hellenic Cooperative Oncology Group||2||"The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both~   treatment arms."|f||||f||||||||||2018-06-01 01:37:02.512801|2018-06-01 01:37:02.512801
NCT00783458|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-03-22|2008-10-30|2008-10-31|Estimate|||||||2017-03-22|2017-03-24|Actual|December 1, 2004|Actual|2004-12-01|March 2017|2017-03-31|January 1, 2005|Actual|2005-01-01|January 1, 2005|Actual|2005-01-01||Interventional|||Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)|A Preference Evaluation of Nasonex® Nasal Spray (Unscented) vs. Flonase® Nasal Spray (Scented) in Subjects With Symptomatic Allergic Rhinitis (AR) - Single-Dose Cross-over|Completed||Phase 4|100|Actual|Merck Sharp & Dohme Corp.||2|||t||||f||||||||||2018-06-01 01:37:02.616939|2018-06-01 01:37:02.616939
NCT00783445|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2014-03-10|2008-10-30|2008-10-31|Estimate|||||||2014-03-10|2014-03-11|Estimate|December 2008||2008-12-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluating the Effectiveness of a Community Exercise Program to Reduce the Risk of Metabolic Syndrome Among Black Americans|Community Exercise and Metabolic Syndrome in Black Families|Completed||Phase 3|204|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 01:37:02.706735|2018-06-01 01:37:02.706735
NCT00783432|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2008-12-29||2009-10-01|2008-10-30|2008-10-31|Estimate|2009-08-27|2009-10-02|Estimate||||2009-10-01|2009-10-06|Estimate|July 2006||2006-07-31|October 2009|2009-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis|Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis|Completed||Phase 3|862|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:37:02.866871|2018-06-01 01:37:02.866871
NCT00783419|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2016-04-22|2008-10-30|2008-10-31|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2007||2007-03-31|April 2016|2016-04-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Observational|||Rate of Pelvic Inflammatory Disease at St. Michael's Hospital|Rate of Pelvic Inflammatory Disease and Tubo-ovarian Abscess at SMH|Completed|||55|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-06-01 01:37:03.748802|2018-06-01 01:37:03.748802
NCT00783406|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30||2009-03-24|2010-10-27|2008-10-30|2008-10-31|Estimate||||2010-10-27|2010-11-01|Estimate|2010-10-27|2010-11-01|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|A7881010||Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.|A Phase 2A, Double Blind (3rd Party Open), 4 Way Cross-Over, Placebo Controlled Study To Investigate The Pharmacokinetics, Safety, Toleration And Efficacy Of Single Inhaled Doses Of PF-00610355 In Moderate COPD Patients.|Completed||Phase 2|20|Anticipated|Pfizer||4|||f||||f||||||||||2018-06-01 01:37:03.804345|2018-06-01 01:37:03.804345
NCT00783393|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-05-12|2008-10-30|2008-10-31|Estimate|||||||2017-05-12|2017-05-15|Actual|May 27, 2003|Actual|2003-05-27|May 2017|2017-05-31|June 17, 2005|Actual|2005-06-17|June 17, 2005|Actual|2005-06-17||Interventional|||SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)|SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma|Completed||Phase 2|32|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-06-01 01:37:03.90803|2018-06-01 01:37:03.90803
NCT00783380|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2008-10-31|2008-10-30|2008-10-31|Estimate|||||||2008-10-31|2008-11-03|Estimate|October 2005||2005-10-31|October 2008|2008-10-31|March 2008|Actual|2008-03-31|July 2006|Actual|2006-07-31||Interventional|||Influenza Vaccination in Immunocompromized Patients|Double Blind Randomized Comparison of a Subunit- and a Virosomal Influenza Vaccine in Immunocom-Promized Patients|Completed||Phase 4|304|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 01:37:03.992564|2018-06-01 01:37:03.992564
NCT00783367|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-01-24|2008-10-30|2008-10-31|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2008||2008-07-31|January 2017|2017-01-31||||December 2013|Actual|2013-12-31||Interventional|||Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas|Phase 2 Trial of Lenalidomide (Revlimid)-Dexamethasone + Rituximab in Recurrent Small B-Cell Non-Hodgkin Lymphomas (NHL) Resistant to Rituximab|Active, not recruiting||Phase 2|25|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 01:37:04.126912|2018-06-01 01:37:04.126912
NCT00783354|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-03-28|2008-10-30|2008-10-31|Estimate|||||||2017-03-28|2017-03-29|Actual|April 1, 2003|Actual|2003-04-01|March 2017|2017-03-31|April 1, 2004|Actual|2004-04-01|February 1, 2004|Actual|2004-02-01||Interventional|ATTITUD||A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)|"A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® Continuous Treatment Versus Aerius® PRN Regimen on Chronic Idiopathic Urticaria Patient Quality of Life"|Completed||Phase 4|129|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:37:04.240915|2018-06-01 01:37:04.240915
NCT00783341|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2009-07-16|2008-10-30|2008-10-31|Estimate|||||||2009-07-16|2009-07-17|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously|An Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as 6-Day Continuous Infusions to Healthy Subjects|Completed||Phase 1|25|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:37:04.321923|2018-06-01 01:37:04.321923
NCT00783328|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2011-06-22|2008-10-30|2008-10-31|Estimate|||||||2011-06-22|2011-06-27|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors|A Clinical Phase 1 Safety And Pharmacokinetic/Pharmacodynamic Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors|Completed||Phase 1|13|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 01:37:04.385729|2018-06-01 01:37:04.385729
NCT00783315|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2009-05-11|2008-10-30|2008-10-31|Estimate|||||||2009-05-11|2009-05-12|Estimate|January 2008||2008-01-31|April 2009|2009-04-30||||February 2011|Anticipated|2011-02-28||Interventional|POWER||Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)|Practice-Based Opportunities for Weight Reduction Trial at Johns Hopkins|Unknown status|Active, not recruiting|Phase 3|390|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||t||||||||||2018-06-01 01:37:04.459714|2018-06-01 01:37:04.459714
NCT00783302|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2014-11-04||2014-12-09|2008-10-30|2008-10-31|Estimate|2014-12-09|2014-12-11|Estimate||||2014-12-09|2014-12-11|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Observational|||Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care|A Prospective, Multi-Center Registry Study for Clinical Outcome in Subjects Undergoing Coronary Computed Tomography Angiography (CCTA) Examination (VISIPAQUE Registry Study)|Completed|||885|Actual|GE Healthcare|||||f||||f||||||||||2018-06-01 01:37:04.558167|2018-06-01 01:37:04.558167
NCT00783289|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30||2012-06-28|2012-08-20|2008-10-30|2008-10-31|Estimate||||2012-08-20|2012-08-29|Estimate|2012-08-20|2012-08-29|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|MEDI-563||A Phase 2a Study to Evaluate the Safety and Tolerability of MEDI-563 in Adults With Asthma|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple-dose Subcutaneous Administration of MEDI-563, a Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, in Adults With Asthma|Completed||Phase 2|25|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 01:37:04.802959|2018-06-01 01:37:04.802959
NCT00783276|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2016-07-13|2008-10-30|2008-10-31|Estimate|||||||2016-07-13|2016-07-14|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||An fMRI Study of SYN115 in Cocaine Dependent Subjects|An fMRI Study of SYN115 in Cocaine Dependent Subjects|Completed||Early Phase 1|26|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 01:37:04.892383|2018-06-01 01:37:04.892383
NCT00783263|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2011-08-10|2011-05-10|2017-03-09|2008-10-30|2008-10-31|Estimate|2011-08-10|2011-09-14|Estimate|2011-05-10|2011-05-17|Estimate|2017-03-09|2017-04-06|Actual|November 2008||2008-11-30|March 2017|2017-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)|A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease|Completed||Phase 3|440|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:37:04.984483|2018-06-01 01:37:04.984483
NCT00783250|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-07-16|2008-10-30|2008-10-31|Estimate|||||||2012-07-16|2012-07-17|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Interventional|||Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effect of Bronchodilators on Respiratory Mechanics in COPD Patients With Poor Reversibility|Terminated||Phase 4|20|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2||Problems with data collection|f||||t||||||||||2018-06-01 01:37:05.552039|2018-06-01 01:37:05.552039
NCT00783237|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-03-21|2008-10-30|2008-10-31|Estimate|||||||2017-03-21|2017-03-23|Actual|December 1, 2003|Actual|2003-12-01|March 2017|2017-03-31|February 21, 2004|Actual|2004-02-21|February 21, 2004|Actual|2004-02-21||Interventional|||Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)|Onset of Action of Mometasone Furoate Nasal Spray vs. Placebo in Induced Allergic Rhinitis|Completed||Phase 4|340|Actual|Merck Sharp & Dohme Corp.||2|||t||||f||||||||||2018-06-01 01:37:05.634742|2018-06-01 01:37:05.634742
NCT00783224|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2010-04-15||2015-05-04|2008-10-30|2008-10-31|Estimate|2010-06-09|2010-07-12|Estimate||||2015-05-04|2015-05-20|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|December 2005|Actual|2005-12-31|November 2005|Actual|2005-11-30||Interventional|||A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)|Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis|Completed||Phase 3|351|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:37:05.732358|2018-06-01 01:37:05.732358
NCT00783211|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-05-10|2008-10-30|2008-10-31|Estimate|||||||2017-05-10|2017-05-11|Actual|August 1, 2004|Actual|2004-08-01|May 2017|2017-05-31|October 1, 2004|Actual|2004-10-01|October 1, 2004|Actual|2004-10-01||Interventional|||Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)|A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)|Completed||Phase 4|722|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:37:06.077099|2018-06-01 01:37:06.077099
NCT00783198|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2014-04-25||2017-01-18|2008-10-30|2008-10-31|Estimate|2014-06-09|2014-07-14|Estimate||||2017-01-18|2017-03-03|Actual|September 2009||2009-09-30|January 2017|2017-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma|Completed||Phase 2/Phase 3|565|Actual|ALK-Abelló A/S||3|||f||||t||||||||||2018-06-01 01:37:06.212513|2018-06-01 01:37:06.212513
NCT00783185|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2010-01-11|2008-10-30|2008-10-31|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2006||2006-01-31|October 2008|2008-10-31|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment|Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis|Completed||Phase 1|50|Anticipated|University of Konstanz||2|||f||||f||||||||||2018-06-01 01:37:06.681159|2018-06-01 01:37:06.681159
NCT00783172|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2013-02-11|2008-10-30|2008-10-31|Estimate|||||||2013-02-11|2013-02-13|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|August 2010|Actual|2010-08-31||Interventional|||Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer|OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study|Terminated||Phase 1|4|Actual|Penn State University||1||Problems with IRB|f||||t||||||||||2018-06-01 01:37:06.758009|2018-06-01 01:37:06.758009
NCT00783159|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2011-01-11|2008-10-30|2008-10-31|Estimate|||||||2011-01-11|2011-01-12|Estimate|June 2008||2008-06-30|January 2011|2011-01-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|FiAT||Fit in the Aged by Professional Training|The Effect of Different Training Modalities and Vitamin D Supplementation on Functionality in Prefrail Elderly Persons|Completed||N/A|69|Actual|University of Erlangen-Nürnberg Medical School||3|||f||||f||||||||||2018-06-01 01:37:06.845145|2018-06-01 01:37:06.845145
NCT00783146|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-05-10|2008-10-30|2008-10-31|Estimate|||||||2017-05-10|2017-05-11|Actual|August 1, 2004|Actual|2004-08-01|May 2017|2017-05-31|October 1, 2004|Actual|2004-10-01|October 1, 2004|Actual|2004-10-01||Interventional|||Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)|A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)|Completed||Phase 4|728|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:37:06.930789|2018-06-01 01:37:06.930789
NCT00783133|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-03-21|2008-10-30|2008-10-31|Estimate|||||||2017-03-21|2017-03-23|Actual|November 1, 2002|Actual|2002-11-01|March 2017|2017-03-31|June 1, 2003|Actual|2003-06-01|June 1, 2003|Actual|2003-06-01||Interventional|||Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)|Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis|Completed||Phase 4|131|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:37:07.00857|2018-06-01 01:37:07.00857
NCT00783120|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2013-11-01|2008-10-30|2008-10-31|Estimate|||||||2013-11-01|2013-11-04|Estimate|January 2008||2008-01-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|RESIS||Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia - a Multicenter Study|Completed||N/A|197|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||t||||||||||2018-06-01 01:37:07.077231|2018-06-01 01:37:07.077231
NCT00783107|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-12-10|2008-10-30|2008-10-31|Estimate|||||||2012-12-10|2012-12-11|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)|Clinical Investigation of Aerosol Immunotherapy in COPD: A Phase I Placebo-Controlled Dose Escalation/Deescalation Trial of Aerosol Cyclosporine (CyIS) in Patients With Gold Stage III Chronic Obstructive Pulmonary Disease|Completed||Phase 1|8|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:37:07.144413|2018-06-01 01:37:07.144413
NCT00783094|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|2010-06-25||2011-03-18|2008-10-30|2008-10-31|Estimate|2010-06-25|2010-07-28|Estimate||||2011-03-18|2011-03-29|Estimate|November 2008||2008-11-30|March 2011|2011-03-31|April 2010|Actual|2010-04-30|June 2009|Actual|2009-06-30||Interventional|||Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Efficacy and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks Followed by an Open-Label Extension to Evaluate the Long-Term Safety and Efficacy of Tadalafil in Japanese Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 2|422|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 01:37:07.276685|2018-06-01 01:37:07.276685
NCT00783081|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-03-21|2008-10-30|2008-10-31|Estimate|||||||2012-03-21|2012-03-22|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication||Completed||Phase 2|387|Actual|Kowa Research Institute, Inc.||5|||f||||t||||||||||2018-06-01 01:37:09.141033|2018-06-01 01:37:09.141033
NCT00783068|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2010-11-04|2008-10-30|2008-10-31|Estimate|||||||2010-11-04|2010-11-05|Estimate|August 2008||2008-08-31|October 2008|2008-10-31|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional|||Anti-inflammatory Effects of GTS-21 After LPS|The Effect of the Alpha-7 Nicotinic AChR Agonist GTS-21 on Inflammation and End-organ Dysfunction During Human Endotoxemia|Completed||N/A|12|Actual|Radboud University||2|||f||||t||||||||||2018-06-01 01:37:09.298068|2018-06-01 01:37:09.298068
NCT00783055|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2008-10-30|2008-10-30|2008-10-31|Estimate|||||||2008-10-30|2008-10-31|Estimate|March 2005||2005-03-31|August 2008|2008-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Autonomy Among Physically Frail Older People in Nursing Homes|Autonomy Among Physically Frail Older People in Nursing Homes: a Study Protocol for an Intervention Study|Completed||N/A|66|Actual|University of Southern Denmark||1|||f||||f||||||||||2018-06-01 01:37:09.413849|2018-06-01 01:37:09.413849
NCT00783042|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2009-06-29|2008-10-30|2008-10-31|Estimate|||||||2009-06-29|2009-06-30|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|||||Interventional|||Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements|A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Transthoracic Doppler Echocardiography Method as a Non-Invasive Method for Coronary Function Measurements; Ability to Detect Short-Term Statin Effects in Patients With Increased Cardiovascular Risk|Completed||Early Phase 1|80|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:37:09.482325|2018-06-01 01:37:09.482325
NCT00783029|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2012-02-06|2008-10-30|2008-10-31|Estimate|||||||2012-02-06|2012-02-07|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Measurement of the Eye's Blood Vessels Using the Dynamic Vessel Analyzer (DVA)|Reproducibility of Dynamic Vessel Analyzer Measurements and Establishment of Standards|Completed|||87|Actual|Penn State University|||1||f||||f||||||||||2018-06-01 01:37:09.57158|2018-06-01 01:37:09.57158
NCT00783016|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2011-07-25|2008-10-30|2008-10-31|Estimate|||||||2011-07-25|2011-07-26|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Effect of Pain Control on the Diagnosis of Acute Appendicitis on the Diagnostic Accuracy of General Surgeon||Completed||Phase 4|234|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-06-01 01:37:09.633158|2018-06-01 01:37:09.633158
NCT00783003|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2017-07-13|2008-10-30|2008-10-31|Estimate|||||||2017-07-13|2017-07-18|Actual|November 10, 2008|Actual|2008-11-10|July 2017|2017-07-31|February 6, 2009|Actual|2009-02-06|February 6, 2009|Actual|2009-02-06||Interventional|||A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects|A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705 and GW642444 as Monotherapies and in Combination in Healthy Japanese Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:37:09.790966|2018-06-01 01:37:09.790966
NCT00782990|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2008-11-04|2008-10-30|2008-10-31|Estimate|||||||2008-11-04|2008-11-05|Estimate|January 2001||2001-01-31|November 2008|2008-11-30|June 2007|Actual|2007-06-30|October 2004|Actual|2004-10-31||Interventional|||A 3 Year Follow-up Prospective Open Randomized Trial of TVT Versus Colposuspension for Primary Stress Incontinence|A Three Year Follow-up Prospective Open Randomized Trial of Tension-Free Vaginal Tape and Colposuspension for Primary Urodynamic Stress Incontinence|Completed||Phase 4|50|Actual|Hospital Severo Ochoa||2|||f||||||||||||||2018-06-01 01:37:09.8934|2018-06-01 01:37:09.8934
NCT00782977|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2012-12-19|2008-10-30|2008-10-31|Estimate|||||||2012-12-19|2012-12-20|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Apneic Oxygenation Via Nasal Cannulae Prevents Arterial Hypoxemia|Oxygenation Via Nasal Cannulae Prevents Arterial Hypoxemia During the Apneic Period in Paralyzed Patients|Completed||N/A|90|Anticipated|University of Manitoba||3|||f||||f||||||||||2018-06-01 01:37:09.972575|2018-06-01 01:37:09.972575
NCT00782964|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2009-12-23|2008-10-30|2008-10-31|Estimate|||||||2009-12-23|2009-12-24|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|||||Observational|DRIA||Antidepressant Incomplete Response Depression|Assessment of Therapeutic Strategies in Unipolar Depression With Incomplete Response to a Antidepressant Treatment in Regular Clinical Practicing.|Completed|||364|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:37:10.054367|2018-06-01 01:37:10.054367
NCT00782951|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2015-09-11|2008-10-30|2008-10-31|Estimate|||||||2015-09-11|2015-09-14|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800)|A Randomized, Double-blind, Active and Placebo Controlled Trial to Compare the Relative Analgesic Efficacy and Safety of a Single Intravenous Dose of ORG 28611 3 mcg/kg, Morphine Sulfate 0.12 mg/kg, and Placebo in Patients Experiencing Moderate to Severe Pain After Dental Impaction Surgery.|Terminated||Phase 2|11|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:37:10.173983|2018-06-01 01:37:10.173983
NCT00782938|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2010-01-13|2008-10-30|2008-10-31|Estimate|||||||2010-01-13|2010-01-14|Estimate|May 2008||2008-05-31|October 2008|2008-10-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Observational|||The Role of Serum Anticholinergic Activity in ACVB Patients|Serum Anticholinergic Activity (SAA) and BIS-EEG as Potential Markers for Cognitive Ability and/or the Anticholinergic Medication in ACVB Patients|Completed|||100|Anticipated|Heidelberg University|||2||f||||f||||||||||2018-06-01 01:37:10.232879|2018-06-01 01:37:10.232879
NCT00782925|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2014-12-01|2008-10-30|2008-10-31|Estimate|||||||2014-12-01|2014-12-02|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PRESLO||An Educational and Exercise Program as Secondary Prevention of Recurrent Lower Back Pain in Healthcare Workers|An Educational and Exercise Program as Secondary Prevention of Recurrent Lower Back Pain in Healthcare Workers: A Randomized, Controlled, 2-year Follow-up Study.|Completed||N/A|351|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 01:37:10.294461|2018-06-01 01:37:10.294461
NCT00782912|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2015-04-20|2008-10-30|2008-10-31|Estimate|||||||2015-04-20|2015-04-22|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|PPADS||Postpartum Anemia and Postpartum Depression|Is Postpartum Anemia an Independent Risk Factor for Development of Postpartum Depression?|Completed|||103|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 01:37:10.362167|2018-06-01 01:37:10.362167
NCT00782899|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2010-12-08|2008-10-30|2008-10-31|Estimate|||||||2010-12-08|2010-12-10|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|4D||Four Dimensions in Schizophrenia|Prospective Observational Study About Progress of Subjective Well-being Sensation in Schizophrenic Patients|Completed|||320|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:37:10.434234|2018-06-01 01:37:10.434234
NCT00782886|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2011-01-25|2008-10-29|2008-10-31|Estimate|||||||2011-01-25|2011-01-27|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer|Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer|Completed|||75|Anticipated|Pathfinder Therapeutics|||||f||||t||||||||||2018-06-01 01:37:10.724703|2018-06-01 01:37:10.724703
NCT00782873|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2008-10-29|2008-10-29|2008-10-31|Estimate|||||||2008-10-29|2008-10-31|Estimate|March 2008||2008-03-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Observational|||Balanced Propofol Sedation During Upper Endoscopy in Morbidly Obese Patients|Balanced Propofol Sedation During Upper Endoscopy in Morbidly Obese Patients: Assessment of Cardiopulmonary Parameters|Completed|||65|Actual|Research Associates of New York, LLP|||1||f||||f||||||||||2018-06-01 01:37:10.793434|2018-06-01 01:37:10.793434
NCT00782860|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2009-03-30|2008-10-29|2008-10-31|Estimate|||||||2009-03-30|2009-03-31|Estimate||||March 2009|2009-03-31||||||||Observational|||Early Pregnancy Failure: Factors Affecting Successful Medical Termination Treatment||Completed|||||Western Galilee Hospital-Nahariya|||2||f||||||||||||||2018-06-01 01:37:10.861043|2018-06-01 01:37:10.861043
NCT00782847|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2008-10-30|2008-10-30|2008-10-31|Estimate|||||||2008-10-30|2008-10-31|Estimate|July 2004||2004-07-31|October 2008|2008-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|DiaNe||Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy|A Prospective Controlled Randomized Multicenter Trial to Evaluate the Effect of a Structurized Multifactorial Behavior Modifying Consultation and Support Programme DiaNe for People With Diabetic Nephropathy|Completed||Phase 3|125|Actual|DiaNe HCM GmbH||2|||f||||f||||||||||2018-06-01 01:37:10.917127|2018-06-01 01:37:10.917127
NCT00782652|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2016-09-08|2008-10-29|2008-10-31|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2006||2006-03-31|September 2016|2016-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients|The Effects of Nitric Oxide for Inhalation on Survival or the Need for Dialysis or a Right Ventricular Assistance Device (RVAD) in Right Ventricular Infarction Patients|Terminated||Phase 2|3|Actual|Mallinckrodt||2||Slow enrollment|f||||t||||||||||2018-06-01 01:37:13.514302|2018-06-01 01:37:13.514302
NCT00782834|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2010-12-17||2013-04-15|2008-10-29|2008-10-31|Estimate|2011-08-26|2011-08-29|Estimate||||2013-04-15|2013-04-22|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|October 2009|Actual|2009-10-31|July 2008|Actual|2008-07-31||Interventional|07060|"Screened:~Started: 15 patients Completed: 14 patients Comments: 1 patient deemed ineligible due to arrhythmia.~Treatment Phase:~Started: 14 patients Completed: 13 patients Comments: 1 patient on extensive pathology review was found to have a solitary fibrous tumor, not GIST."|Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)|Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib|Terminated||Phase 2|13|Actual|Fox Chase Cancer Center|The study failed to meet its accrual goals. Study terminated prior to accruing 17 subjects due to futility of meeting endpoint.|||Stopped early for futility, unable to meet accrual goals|f||||f||||||||||2018-06-01 01:37:11.011158|2018-06-01 01:37:11.011158
NCT00782821|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2015-10-20||2015-12-14|2008-10-29|2008-10-31|Estimate|2015-12-14|2016-01-20|Estimate||||2015-12-14|2016-01-20|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients|Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B-Cell Depleting Therapy in Combination With Anti-Thymocyte Globulin [Rabbit] (Thymoglobulin®, Genzyme), Tacrolimus (Prograf®, Astellas), Mycophenolate Mofetil (CellCept®, Roche) and Corticosteroid Minimization|Completed||Phase 4|40|Actual|University of Cincinnati||4|||f||||f||||||||||2018-06-01 01:37:11.313567|2018-06-01 01:37:11.313567
NCT00782808|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2014-09-25|2008-10-29|2008-10-31|Estimate|||||||2014-09-25|2014-09-26|Estimate|March 2009||2009-03-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Observational|||Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV||Completed|||60|Actual|South East Asia Research Collaboration with Hawaii|||2||f||||f||||||||||2018-06-01 01:37:11.818799|2018-06-01 01:37:11.818799
NCT00782795|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2017-09-19||2017-12-11|2008-10-29|2008-10-31|Estimate|2017-11-07|2017-12-11|Actual||||2017-12-11|2018-01-11|Actual|November 2008||2008-11-30|December 2017|2017-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality|Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality|Completed||Phase 2|64|Actual|University of Michigan||2|||f||||t||||||||No||2018-06-01 01:37:11.9349|2018-06-01 01:37:11.9349
NCT00782782|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-26|||2008-10-28|2008-10-28|2008-10-31|Estimate|||||||2008-10-28|2008-10-31|Estimate|August 2008||2008-08-31|October 2008|2008-10-31|December 2011|Anticipated|2011-12-31|December 2009|Anticipated|2009-12-31||Observational|||Vascular Sensitivity to Adrenergic Agonists in Patients With CHF and in Healthy Subjects|Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects|Unknown status|Active, not recruiting||80|Anticipated|Hadassah Medical Organization|||||f||||f||||||Samples Without DNA|"~     samples for norepinephrine and PRA will be retained~   "|||2018-06-01 01:37:12.370462|2018-06-01 01:37:12.370462
NCT00782769|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29||2011-08-16|2016-07-20|2008-10-29|2008-10-31|Estimate||||2011-08-16|2011-08-23|Estimate|2016-07-20|2016-07-22|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Safety Extension Study of DR-OXY-301|A Multicenter, Parallel-Group Extension Study to Evaluate the Safety of Two Doses of DR-3001 in Women With Overactive Bladder|Completed||Phase 3|240|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 01:37:12.433739|2018-06-01 01:37:12.433739
NCT00782756|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2017-12-13||2018-01-10|2008-10-29|2008-10-31|Estimate|2018-01-10|2018-02-06|Actual||||2018-01-10|2018-02-06|Actual|October 28, 2008|Actual|2008-10-28|March 2017|2017-03-31|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma|A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma|Completed||Phase 2|40|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||t|||||||||2018-06-01 01:37:12.533294|2018-06-01 01:37:12.533294
NCT00782743|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2015-09-22|2008-10-29|2008-10-31|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Comparison of Phenprocoumon and Acetylsalicylic Acid (ASA)|Prospective Comparison of Phenprocoumon (Marcumar) and Acetylsalicylic Acid (ASA)With Regard to the Progress of Valvular and Coronary Calcification|Completed|||157|Actual|RWTH Aachen University|||2||f||||f||||||Samples Without DNA|"~     Biomarkers for inflammation, measuring of inhibitors of calcification~   "|||2018-06-01 01:37:12.879851|2018-06-01 01:37:12.879851
NCT00782730|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2013-06-11|2008-10-29|2008-10-31|Estimate|||||||2013-06-11|2013-06-13|Estimate|October 2008||2008-10-31|June 2013|2013-06-30||||December 2009|Actual|2009-12-31||Observational|||Assessment of Third Trimester Post-void Residual and Validation of Bladder Scanner in Pregnancy and Post-partum|Assessment of Third Trimester Post-void Residual Along With Determining Validity of the Bladder Scanner in the Third Trimester of Pregnancy and Postpartum|Completed|||35|Actual|West Virginia University|||1||f||||f||||||||||2018-06-01 01:37:12.943446|2018-06-01 01:37:12.943446
NCT00782717|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2011-08-17||2012-10-22|2008-10-29|2008-10-31|Estimate|2011-08-17|2011-09-21|Estimate||||2012-10-22|2012-10-26|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients|A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients|Completed||Phase 2|263|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:37:13.01113|2018-06-01 01:37:13.01113
NCT00782704|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2015-02-09|2008-10-29|2008-10-31|Estimate|||||||2015-02-09|2015-02-10|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Development and Validation of a Morbidity Index for Complications in Minor and Major Abdominal Surgery|Development and Validation of a Morbidity Index for Complications in Minor and Major Abdominal Surgery|Completed|||219|Actual|University of Zurich|||3||f||||t||||||||||2018-06-01 01:37:13.261508|2018-06-01 01:37:13.261508
NCT00782691|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2008-10-29|2008-10-29|2008-10-31|Estimate|||||||2008-10-29|2008-10-31|Estimate|July 2008||2008-07-31|October 2008|2008-10-31||||December 2009|Anticipated|2009-12-31||Observational|||Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.|Validation of FDG-PET Segmentation Tools for Tumor Delineation by Correlation of CT- and FDG-PET Volume Measurements With Histopathology of Nodal Metastases of Head and Neck Carcinomas.|Unknown status|Recruiting||15|Anticipated|Radboud University|||1||f||||||||||Samples With DNA|"~     Head-and-neck cancer patients will undergo a therapeutic lymph node dissection of the~     cervical nodes. This treatment is given whether the patient is enrolled in the study or not.~     Histological specimens of cancer patients are always stored for possible future refference in~     the routine clinical practice.~   "|||2018-06-01 01:37:13.31602|2018-06-01 01:37:13.31602
NCT00782639|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2011-06-29||2012-01-24|2008-10-28|2008-10-31|Estimate|2011-08-01|2011-09-01|Estimate||||2012-01-24|2012-01-26|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|RECARE||Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients|RECARE (REnal Safety Following the Intra-Arterial Administration of Iopamidol vs. Iodixanol During Coronary AngiogRaphy in DiabEtic Patients)|Terminated||Phase 4|23|Actual|Bracco Diagnostics, Inc|This study was terminated early due to low enrollment. Only 1 patient in the Iopamiro-370 group had CIN (per all 3 definitions [first 3 secondary outcome measures] of CIN); therefore, no formal analyses were performed.|2||This study was terminated early due to slow enrollment.|f||||f||||||||||2018-06-01 01:37:13.599827|2018-06-01 01:37:13.599827
NCT00782626|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2015-12-30||2015-12-30|2008-10-29|2008-10-31|Estimate|2015-12-30|2016-02-02|Estimate||||2015-12-30|2016-02-02|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas|A Phase II Study of Everolimus (RAD001) for Children With Chemotherapy and/or Radiation-Refractory Progressive or Recurrent Low-Grade Gliomas|Completed||Phase 2|23|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:37:13.869848|2018-06-01 01:37:13.869848
NCT00782613|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2009-01-29|2008-10-29|2008-10-31|Estimate|||||||2009-01-29|2009-01-30|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis|Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Wafety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic|Terminated||Phase 2|30|Anticipated|Synvista Therapeutics, Inc||2||Study has been termination early due to financial contraints.|f||||f||||||||||2018-06-01 01:37:14.112818|2018-06-01 01:37:14.112818
NCT00782600|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2009-06-05|2008-10-29|2008-10-31|Estimate|||||||2009-06-05|2009-06-09|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers|A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers|Completed||Phase 1|16|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:37:14.182766|2018-06-01 01:37:14.182766
NCT00782587|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2010-02-05|2008-10-29|2008-10-31|Estimate|||||||2010-02-05|2010-02-08|Estimate|October 2008||2008-10-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|IPOP||Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer|Phase I Safety and Tolerability Study of Immediate Post-Operative Intravesical Instillation of Chemophase® (Recombinant Human Hyaluronidase in Combination With Mitomycin) in Patients With Non-Muscle-Invasive Bladder Cancer|Completed||Phase 1|14|Actual|Halozyme Therapeutics||1|||f||||f||||||||||2018-06-01 01:37:14.255272|2018-06-01 01:37:14.255272
NCT00782574|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2018-02-27|2008-10-30|2008-10-31|Estimate|||||||2018-02-27|2018-02-28|Actual|November 12, 2008|Actual|2008-11-12|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|February 1, 2012|Actual|2012-02-01||Interventional|||Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients|A Phase I Open Label, Multi Centre Study of AZD2281 Administered Orally in Combination With Cisplatin, to Assess the Safety and Tolerability in Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|56|Actual|AstraZeneca||1|||t||||t||||||||||2018-06-01 01:37:14.334951|2018-06-01 01:37:14.334951
NCT00782561|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2009-07-14|2008-10-28|2008-10-31|Estimate|||||||2009-07-14|2009-07-16|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|March 2011|Anticipated|2011-03-31|June 2010|Anticipated|2010-06-30||Interventional|||Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)|A Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental Glomerulosclerosis|Terminated||Phase 1|12|Anticipated|FibroGen||1|||f||||f||||||||||2018-06-01 01:37:14.406186|2018-06-01 01:37:14.406186
NCT00782548|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2008-10-29|2008-10-29|2008-10-31|Estimate|||||||2008-10-29|2008-10-31|Estimate|May 2004||2004-05-31|October 2008|2008-10-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults|A Phase IV, Comparative, Randomized, Double Blind, Single-Dose, 2-Way Crossover Study to Evaluate the Pharmacokinetics and Safety of Alpharma Branded Products Division (KADIAN)and Ligand Pharmaceuticals Inc. (Avinza) 30 mg Morphine Sulfate Sustained-Release Capsules in Healthy Adult Volunteers Under Fed Conditions|Completed||Phase 4|40|Actual|Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.||2|||f||||||||||||||2018-06-01 01:37:14.484732|2018-06-01 01:37:14.484732
NCT00782535|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29||2010-08-18|2011-11-17|2008-10-29|2008-10-31|Estimate||||2010-08-18|2010-08-20|Estimate|2011-11-17|2011-11-21|Estimate|December 2008||2008-12-31|November 2011|2011-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)|EVALUATION OF THE SAFETY AND EFFICACY OF TREATMENT WITH SINGLE DOSES OF CHF 4226 pMDI IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE A Multicenter, Randomized, Double-Blind,Placebo-Controlled, 5-Way Crossover Study|Completed||Phase 2|20|Actual|Chiesi USA||5|||f||||f||||||||||2018-06-01 01:37:14.568084|2018-06-01 01:37:14.568084
NCT00782522|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2012-03-26|2008-10-29|2008-10-31|Estimate|||||||2012-03-26|2012-03-27|Estimate|April 2009||2009-04-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effect Study of an Eccentric Training Program and Stretching for Patients With Chronical Rotator Cuff Tendinopathy|Effect Study of an Eccentric Training Program and Stretching for Patients With Chronical Rotator Cuff Tendinopathy|Completed||N/A|69|Actual|University Ghent||2|||f||||f||||||||||2018-06-01 01:37:14.64413|2018-06-01 01:37:14.64413
NCT00782509|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2014-03-28||2014-06-17|2008-10-29|2008-10-31|Estimate|2014-06-13|2014-06-17|Estimate||||2014-06-17|2014-06-27|Estimate|February 2009||2009-02-28|June 2014|2014-06-30||||September 2010|Actual|2010-09-30||Interventional|||12 / 48 wk Pivotal PFT vs PBO in COPD II|Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD|Completed||Phase 3|644|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 01:37:14.80877|2018-06-01 01:37:14.80877
NCT00782496|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2010-09-27||2016-01-29|2008-10-28|2008-10-31|Estimate|2010-11-01|2010-11-30|Estimate||||2016-01-29|2016-02-29|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Glucose Meter Study|A New Contour Blood Glucose Monitoring System With High Frequency Testing Patients|Completed||N/A|211|Actual|Ascensia Diabetes Care||2|||f||||f||||||||||2018-06-01 01:37:17.215666|2018-06-01 01:37:17.215666
NCT00782483|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2014-01-06||2014-06-19|2008-10-29|2008-10-31|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Personalized Interactive Laser Therapy of Port Wine Stain|Personalized Interactive Laser Therapy of Port Wine Stain - Study 2|Terminated||N/A|6|Actual|University of Arkansas|PI relocated and protocol was terminated, and no subject returned for treatment under protocol.|||PI moved out of state.|f||||t||||||||||2018-06-01 01:37:17.541862|2018-06-01 01:37:17.541862
NCT00782470|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2014-10-31|2008-10-29|2008-10-31|Estimate|||||||2014-10-31|2014-11-03|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A|A Prospective, Non-interventional, Multi-center, Open-label Study to Evaluate the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Subjects With Severe Hemophilia A Receiving Prophylaxis and On-demand Treatment Regimen|Completed|||38|Actual|Bayer|||3||f||||f||||||||||2018-06-01 01:37:17.673031|2018-06-01 01:37:17.673031
NCT00782457|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2015-03-17|2008-10-29|2008-10-31|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2002||2002-01-31|October 2008|2008-10-31|December 2010||2010-12-31|February 2007|Actual|2007-02-28||Interventional|||Prospective Randomised Study Comparing Laparoscopic Versus Open Surgery in Patients With Rectal Cancer||Completed||Phase 3|200|Anticipated|Hospital Universitario Virgen de la Arrixaca||2|||f||||||||||||||2018-06-01 01:37:17.75415|2018-06-01 01:37:17.75415
NCT00782444|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2018-03-12|2008-10-30|2008-10-31|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2009||2009-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CAOS||Computer Navigation vs Conventional Technique in Knee Arthroplasty|Computer Navigation vs Conventional Technique in Knee Arthroplasty. A Prospective, Randomised, Clinical and Radiostereometric Trial|Active, not recruiting||N/A|200|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-06-01 01:37:17.812421|2018-06-01 01:37:17.812421
NCT00782431|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30||2009-10-29|2015-10-07|2008-10-30|2008-10-31|Estimate||||2009-10-29|2009-11-02|Estimate|2015-10-07|2015-10-29|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older|Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal Influenza Vaccine in Adults Aged 50 Years and Older|Completed||Phase 3|3195|Anticipated|Ology Bioservices||2|||f||||t||||||||||2018-06-01 01:37:17.893187|2018-06-01 01:37:17.893187
NCT00782418|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2010-03-19||2016-11-03|2008-10-29|2008-10-31|Estimate|2010-03-19|2010-04-06|Estimate||||2016-11-03|2016-12-21|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)|A Randomized Clinical Trial to Study Glucose Dependent Insulin Secretion Methodologies in Healthy Lean Male Subjects|Completed||Phase 1|27|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 01:37:17.996273|2018-06-01 01:37:17.996273
NCT00782405|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2011-04-18|2008-10-29|2008-10-31|Estimate|||||||2011-04-18|2011-04-19|Estimate|October 2008||2008-10-31|April 2011|2011-04-30||||April 2011|Actual|2011-04-30||Interventional|||Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine|Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine|Completed||Phase 3|40|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 01:37:18.373966|2018-06-01 01:37:18.373966
NCT00782392|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2011-05-16|2008-10-29|2008-10-31|Estimate|||||||2011-05-16|2011-05-18|Estimate|January 2007||2007-01-31|May 2011|2011-05-31||||June 2007|Actual|2007-06-30||Observational|||Bioavailability and Dosing of a Monosaccharide Supplement in Adults|Bioavailability and Dosing of an Oral Monosaccharide Supplement in Adults and Effects on Resting Brain Activity|Completed|||15|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:37:18.448037|2018-06-01 01:37:18.448037
NCT00782379|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2013-03-18||2013-10-28|2008-10-29|2008-10-31|Estimate|2013-03-18|2013-05-03|Estimate||||2013-10-28|2013-11-21|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer|A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies|Completed||Phase 2|20|Actual|Northside Hospital, Inc.||1|||f||||f||||||||||2018-06-01 01:37:18.503737|2018-06-01 01:37:18.503737
NCT00782366|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2011-04-25|2008-10-29|2008-10-31|Estimate|||||||2011-04-25|2011-04-27|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|PGT||Predictive Genetic Risk Assessment Trial|Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment|Completed|||26|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 01:37:19.904824|2018-06-01 01:37:19.904824
NCT00782353|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2012-11-12|2008-10-29|2008-10-31|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection|A Phase 1, Randomized, Double-Blind, Ascending Multiple-Dose Study of the Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Chronic Hepatitis C Infection|Completed||Phase 1|35|Actual|Hoffmann-La Roche||3|||f||||f||||||||||2018-06-01 01:37:19.988104|2018-06-01 01:37:19.988104
NCT00782340|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2014-03-18|2012-01-25|2014-04-22|2008-10-29|2008-10-31|Estimate|2014-04-22|2014-05-16|Estimate|2012-01-25|2012-01-30|Estimate|2014-04-22|2014-05-16|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|NOH301||A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa|Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH|Completed||Phase 3|263|Actual|Chelsea Therapeutics||2|||f||||f||||||||||2018-06-01 01:37:20.192619|2018-06-01 01:37:20.192619
NCT00782327|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2015-06-02|2008-10-29|2008-10-31|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers|Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers|Unknown status|Recruiting|Phase 3|174|Anticipated|University Hospital, Ghent||2|||f||||t||||||||||2018-06-01 01:37:20.879306|2018-06-01 01:37:20.879306
NCT00782314|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2009-07-23|2008-10-29|2008-10-31|Estimate|||||||2009-07-23|2009-07-24|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|April 2009|Actual|2009-04-30|||||Observational|||Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice|Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice|Completed|||400|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:37:20.965312|2018-06-01 01:37:20.965312
NCT00782301|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2012-01-18|2008-10-29|2008-10-31|Estimate|||||||2012-01-18|2012-01-19|Estimate|March 2009||2009-03-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients|A Multicenter, Randomized, Open, Comparative Trial Of Maraviroc Versus Etravirine Each In Combination With Darunavir/Ritonavir And Raltegravir For The Treatment Of Antiretroviral-Experienced HIV-1 Subjects Co-Infected With Hepatitis C And/Or Hepatitis B|Withdrawn||Phase 4|0|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-06-01 01:37:21.05864|2018-06-01 01:37:21.05864
NCT00782288|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2015-10-14||2017-09-12|2008-10-29|2008-10-31|Estimate|2016-01-21|2016-01-22|Estimate||||2017-09-12|2017-09-14|Actual|August 2010||2010-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase II Study of Digitoxin to Treat Cystic Fibrosis|Phase II Study of Digitoxin to Treat Cystic Fibrosis|Completed||Phase 2|24|Actual|National Jewish Health|Steady states of digitoxin were not achieved in subjects until relatively late the in 28 day treatment period. This would suggest that it may require a much longer treatment course to meaningfully effect inflammation in the airways.|3|||f||||t||||||||||2018-06-01 01:37:21.201458|2018-06-01 01:37:21.201458
NCT00782275|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2017-02-01||2018-01-01|2008-10-29|2008-10-31|Estimate|2017-11-22|2017-12-20|Actual||||2018-01-01|2018-01-24|Actual|April 2009|Actual|2009-04-30|January 2018|2018-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The analysis dataset is comprised of all treated patients as opposed to enrolled patients.|Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma|A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|41|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:37:22.155638|2018-06-01 01:37:22.155638
NCT00782262|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-29|2008-10-29|2008-10-31|Estimate|||||||2008-10-29|2008-10-31|Estimate|April 2005||2005-04-30|October 2008|2008-10-31||||January 2009|Anticipated|2009-01-31||Interventional|||Weight Loss Effects on Heart and Blood Vessel Function in Obesity|Effects of Obesity and Diet Induced Weight Loss on Cardiovascular Risk Factors, Vascular and Ventricular Structure and Function in Obese Men|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|University of Adelaide||3|||f||||t||||||||||2018-06-01 01:37:22.557321|2018-06-01 01:37:22.557321
NCT00782249|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2014-12-04|2008-10-29|2008-10-31|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2005||2005-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy|Prospective Randomized Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy|Unknown status|Recruiting|N/A|45|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 01:37:22.630574|2018-06-01 01:37:22.630574
NCT00782236|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2016-03-03|2008-10-28|2008-10-31|Estimate|||||||2016-03-03|2016-03-04|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|October 2009|Actual|2009-10-31|November 2007|Actual|2007-11-30||Interventional|||Comparison of Straumann BoneCeramic vs. Allograft Bone in Extraction Sockets|Comparison of an Alloplast (Straumann Bone Ceramic) to an Allograft of Freeze Dried Bone (FDBA) for Preservation of the Alveolar Ridge Following Tooth Extraction: a Prospective, Randomized, Controlled Clinical Study|Terminated||Phase 4|13|Actual|Institut Straumann AG||2||Lack of enrollment|f||||f||||||||No||2018-06-01 01:37:22.722424|2018-06-01 01:37:22.722424
NCT00782223|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2008-10-29|2008-10-29|2008-10-31|Estimate|||||||2008-10-29|2008-10-31|Estimate|July 2008||2008-07-31|October 2008|2008-10-31||||December 2008|Anticipated|2008-12-31||Observational|||Assessment of Digital Radiograph Measurements of Hip,Spine and Lower Limbs|Assessment of Hip, Spine and Lower Limbs Digital Radiograph Measurements in Pediatric Population: Using PACS Integrated Computer Software (TraumaCad From OrthoCrat)|Unknown status|Active, not recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||5||f||||f||||||||||2018-06-01 01:37:22.783714|2018-06-01 01:37:22.783714
NCT00782210|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2014-03-28||2014-06-03|2008-10-29|2008-10-31|Estimate|2014-03-28|2014-04-30|Estimate||||2014-06-03|2014-06-09|Estimate|November 2008||2008-11-30|March 2014|2014-03-31||||September 2010|Actual|2010-09-30||Interventional|||12 / 48 Week Pivotal PFT vs PBO in COPD I|Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 mcg [2 Actuations of 2.5 mcg] and 10 mcg [2 Actuations of 5 mcg]) Delivered by the Respimat® Inhaler, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|625|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 01:37:22.944386|2018-06-01 01:37:22.944386
NCT00782197|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-30|||2010-10-01|2008-10-30|2008-10-31|Estimate|||||||2010-10-01|2010-10-04|Estimate|January 2008||2008-01-31|October 2010|2010-10-31||||||||Interventional|||Autologous Plasma Rich in Growth Factors (PRGF) Treating the Symptomatic Knee OA|Efficacy and Safety of the Infiltration of Autologous Plasma Rich in Growth Factors (PRGF) in the Symptomatic Treatment of Knee Osteoarthritis|Completed||Phase 4|240|Anticipated|Biotechnology Institute IMASD||2|||f||||f||||||||||2018-06-01 01:37:25.276419|2018-06-01 01:37:25.276419
NCT00782184|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|2011-09-22||2017-03-17|2008-10-29|2008-10-31|Estimate|2011-09-22|2011-10-31|Estimate||||2017-03-17|2017-04-14|Actual|November 2008||2008-11-30|March 2017|2017-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)|A Randomized, Double-Blind, Active-Controlled Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk and Not Adequately Controlled With Atorvastatin: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin Versus Doubling the Baseline Dose of Atorvastatin|Completed||Phase 3|250|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:37:25.386522|2018-06-01 01:37:25.386522
NCT00782171|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2016-03-03||2017-04-06|2008-10-28|2008-10-31|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|July 2004||2004-07-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|October 2006|Actual|2006-10-31||Interventional||missing at least one tooth in the posterior maxilla or mandible|Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface|Immediate and Delayed Loading of 4.1 mm and 4.8 mm Implants in the Posterior Mandible & Maxilla: A Controlled Randomized Study of Single or 2-4 Unit Restorations Loaded Immediately After Surgery or Four Weeks After Surgery|Completed||Phase 4|266|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-06-01 01:37:25.885832|2018-06-01 01:37:25.885832
NCT00782145|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2011-07-11|2008-10-29|2008-10-31|Estimate|||||||2011-07-11|2011-07-13|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families|HSCT-CHESS to Enhance Hematopoietic Transplant Recovery|Completed||Phase 3|198|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-06-01 01:37:26.455459|2018-06-01 01:37:26.455459
NCT00782132|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2016-04-22|2008-10-29|2008-10-31|Estimate|||||||2016-04-22|2016-04-25|Estimate|November 2006||2006-11-30|April 2016|2016-04-30|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Observational|||Access to Infertility Services: Clinic Perspective|Access to Infertility Services in Ontario for Couples in Which One or Both Partners is HIV-Positive|Completed|||23|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-06-01 01:37:26.555733|2018-06-01 01:37:26.555733
NCT00782119|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-29|2008-10-29|2008-10-31|Estimate|||||||2008-10-29|2008-10-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:37:26.606315|2018-06-01 01:37:26.606315
NCT00782106|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2018-01-23|2008-10-29|2008-10-31|Estimate|||||||2018-01-23|2018-01-25|Actual|December 4, 2006|Actual|2006-12-04|January 2018|2018-01-31|November 1, 2007|Actual|2007-11-01|November 1, 2007|Actual|2007-11-01||Interventional|||Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously|Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)|Completed||Phase 1/Phase 2|11|Actual|Shire||2|||f||||f||||||||||2018-06-01 01:37:26.638143|2018-06-01 01:37:26.638143
NCT00782093|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2012-10-11|2008-10-29|2008-10-31|Estimate|||||||2012-10-11|2012-10-12|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration||Completed||Phase 1|63|Actual|Ophthotech Corporation|||||f||||f||||||||||2018-06-01 01:37:26.708231|2018-06-01 01:37:26.708231
NCT00782080|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-29|||2014-03-12|2008-10-29|2008-10-31|Estimate|||||||2014-03-12|2014-03-13|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD|Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) Versus Placebo in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|155|Actual|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-06-01 01:37:26.765055|2018-06-01 01:37:26.765055
NCT00782067|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2017-05-03||2017-05-03|2008-10-28|2008-10-29|Estimate|2017-05-03|2017-06-06|Actual||||2017-05-03|2017-06-06|Actual|October 15, 2008|Actual|2008-10-15|May 2017|2017-05-31|July 12, 2017|Anticipated|2017-07-12|December 1, 2014|Actual|2014-12-01||Interventional|||Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia|A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease|Active, not recruiting||Phase 2|116|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:37:26.855939|2018-06-01 01:37:26.855939
NCT00782054|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2008-10-27|2008-10-27|2008-10-29|Estimate|||||||2008-10-27|2008-10-29|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of Post Burn Rehabilitation Population for Itch Control|Evaluation of Provase in the Post Burn Rehabilitation Population for Itch Control and Moisturization Properties|Completed||Phase 4|23|Actual|Swiss-American Products, Inc||2|||f||||t||||||||||2018-06-01 01:37:27.456929|2018-06-01 01:37:27.456929
NCT00782041|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2009-09-14|2008-10-28|2008-10-29|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 2003||2003-01-31|September 2009|2009-09-30||||August 2003|Actual|2003-08-31||Interventional|||Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer|Phase II Study of Oxaliplatin in Combination With 5-fluorouracil (5-FU) and Folinic Acid (FA) in Patients Who Have Failed First-line Treatment for Locally Advanced or Metastatic Cervical Cancer.|Terminated||Phase 2|11|Actual|Sanofi||1||protocol violation|f||||f||||||||||2018-06-01 01:37:27.548211|2018-06-01 01:37:27.548211
NCT00782028|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Integrating Well-Woman and Well-Baby Care to Improve Parenting and Family Wellness|Integrating Well-Woman and Well-Baby Care to Improve Parenting and Family Wellness|Unknown status|Not yet recruiting|N/A|170|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-06-01 01:37:27.631437|2018-06-01 01:37:27.631437
NCT00782015|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2017-04-26|2008-10-28|2008-10-29|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2008||2008-10-31|April 2017|2017-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effects of Almonds on Vascular Reactivity in Patients With Coronary Artery Disease|Effects of Almonds on Vascular Reactivity and Biomarkers of Inflammation, Oxidative Stress and Endothelial Function in Patients With Coronary Artery Disease|Completed||N/A|45|Actual|Tufts University||2|||f||||f||||||||||2018-06-01 01:37:27.702815|2018-06-01 01:37:27.702815
NCT00782002|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2010-09-29|2008-10-28|2008-10-29|Estimate|||||||2010-09-29|2010-09-30|Estimate|July 2006||2006-07-31|September 2010|2010-09-30|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy|Phase 1 Study of Weekly Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) Monoclonal Antibody IMC-18F1 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or For Whom No Standard Therapy is Available|Completed||Phase 1|27|Actual|ImClone LLC||1|||f||||t||||||||||2018-06-01 01:37:27.787441|2018-06-01 01:37:27.787441
NCT00781989|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2011-09-29|2008-10-28|2008-10-29|Estimate|||||||2011-09-29|2011-09-30|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Ultrasonography as a Biomarker in Early Rheumatoid Arthritis|Qualification of Ultrasonography as a Biomarker of Prognosis and Response to Treatment in Early Rheumatoid Arthritis|Completed|||101|Actual|Imperial College London|||1||f||||f||||||Samples With DNA|"~     whole blood / serum~   "|||2018-06-01 01:37:27.864621|2018-06-01 01:37:27.864621
NCT00781976|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2010-03-30|2008-10-28|2008-10-29|Estimate|||||||2010-03-30|2010-03-31|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Antiviral Activity of AZD7295 in HCV Carriers|A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease|Completed||Phase 1|31|Actual|Arrow Therapeutics||2|||f||||t||||||||||2018-06-01 01:37:27.921297|2018-06-01 01:37:27.921297
NCT00781963|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2014-09-17||2015-04-06|2008-10-28|2008-10-29|Estimate|2014-09-30|2014-10-02|Estimate||||2015-04-06|2015-04-27|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||Implementing Sleep Interventions for Older Veterans|Implementing Sleep Interventions for Older Veterans|Completed||N/A|519|Actual|VA Office of Research and Development|The study sample was predominantly older male veterans, so results may not be generalizable to older women.|3|||f||||f||||||||||2018-06-01 01:37:27.998672|2018-06-01 01:37:27.998672
NCT00781950|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2014-12-04||2016-10-27|2008-10-28|2008-10-29|Estimate|2014-12-04|2014-12-12|Estimate||||2016-10-27|2016-12-12|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|March 2011|Actual|2011-03-31||Interventional|FLAXPAD||Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease|A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease|Completed||Phase 2/Phase 3|110|Actual|St. Boniface General Hospital Research Centre||2|||f||||t||||||||||2018-06-01 01:37:28.251637|2018-06-01 01:37:28.251637
NCT00781937|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2011-09-01||2017-09-29|2008-10-28|2008-10-29|Estimate|2011-10-20|2011-11-28|Estimate||||2017-09-29|2017-11-01|Actual|October 30, 2008|Actual|2008-10-30|September 2017|2017-09-30|September 1, 2010|Actual|2010-09-01|September 1, 2010|Actual|2010-09-01||Interventional|||Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance|Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period|Completed||Phase 3|422|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:37:28.526097|2018-06-01 01:37:28.526097
NCT00781924|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2011-08-04|2008-10-28|2008-10-29|Estimate|||||||2011-08-04|2011-08-08|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Observational|||Interventional Sonography Guided by Image Fusion|Interventional Sonography Guided by Image Fusion|Completed|||60|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-06-01 01:37:29.457968|2018-06-01 01:37:29.457968
NCT00781911|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2018-03-17|2010-09-01|2018-03-17|2008-10-27|2008-10-29|Estimate|2018-03-17|2018-04-18|Actual|2010-09-01|2010-09-06|Estimate|2018-03-17|2018-04-18|Actual|February 2009||2009-02-28|March 2018|2018-03-31|May 2016|Actual|2016-05-31|July 2011|Actual|2011-07-31||Interventional|||A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer|A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma|Completed||Phase 2|43|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|Lilly provides access to the individual participant data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-06-01 01:37:29.527001|2018-06-01 01:37:29.527001
NCT00781898|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2017-04-17||2017-09-21|2008-10-28|2008-10-29|Estimate|2017-09-21|2017-10-23|Actual||||2017-09-21|2017-10-23|Actual|June 2008||2008-06-30|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Participants in this arm were randomized to Depot Nalttrexone (Extended Release Naltrexone)|Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site|Prevention of Relapse to Opioid Addiction Using Depot Naltrexone|Completed||Phase 2/Phase 3|308|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 01:37:30.308509|2018-06-01 01:37:30.308509
NCT00781885|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27||2012-04-13|2012-04-13|2008-10-28|2008-10-29|Estimate||||2012-04-13|2012-04-18|Estimate|2012-04-13|2012-04-18|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients|A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients|Completed||Phase 2|19|Actual|Lung Biotechnology PBC|||||f||||f||||||||||2018-06-01 01:37:30.649927|2018-06-01 01:37:30.649927
NCT00781872|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|October 2006||2006-10-31|October 2008|2008-10-31||||December 2009|Anticipated|2009-12-31||Interventional|||Mesenchymal Stem Cells for the Treatment of MS|Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS)|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:37:30.734096|2018-06-01 01:37:30.734096
NCT00781859|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2012-12-20||2014-12-02|2008-10-28|2008-10-29|Estimate|2012-12-20|2013-01-28|Estimate||||2014-12-02|2014-12-17|Estimate|December 2008||2008-12-31|April 2014|2014-04-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.|A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion|Completed||Phase 3|326|Actual|ThromboGenics||2|||f||||t||||||||||2018-06-01 01:37:30.849852|2018-06-01 01:37:30.849852
NCT00781846|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2015-02-12|2008-10-28|2008-10-29|Estimate|||||||2015-02-12|2015-02-13|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)|A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers|Completed||Phase 1|17|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:37:31.257525|2018-06-01 01:37:31.257525
NCT00781833|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-01-19|2008-10-27|2008-10-29|Estimate|||||||2012-01-19|2012-01-23|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Use of Implanted Microstimulators for Decreasing Spasticity and Improving Motion Following Spinal Cord Injury|Case Study Testing the Use of Implanted Microstimulators for Decreasing Spasticity and Improving Motion Following Spinal Cord Injury|Terminated||N/A|1|Actual|The Alfred E. Mann Foundation for Scientific Research||1||Participation of single subject enrolled was terminated.|f||||f||||||||||2018-06-01 01:37:31.338168|2018-06-01 01:37:31.338168
NCT00781820|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2013-06-09|2008-10-28|2008-10-29|Estimate|||||||2013-06-09|2013-06-11|Estimate|October 2008||2008-10-31|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste|A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste|Completed||Phase 3|693|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:37:31.439693|2018-06-01 01:37:31.439693
NCT00781807|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2009-08-24|2008-10-28|2008-10-29|Estimate|||||||2009-08-24|2009-08-25|Estimate|November 2008||2008-11-30|August 2009|2009-08-31|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|||Rehabilitation and Outcome for Patients on LVAD Support|Multi-module Rehabilitation for Patients on LVAD Support - Impact on Long-term Outcomes|Unknown status|Recruiting|N/A|80|Anticipated|Hannover Medical School||1|||f||||t||||||||||2018-06-01 01:37:31.594082|2018-06-01 01:37:31.594082
NCT00781794|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2009-07-21|2008-10-28|2008-10-29|Estimate|||||||2009-07-21|2009-07-22|Estimate|January 2009||2009-01-31|July 2009|2009-07-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia|Terminated||Phase 1|30|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 01:37:31.685226|2018-06-01 01:37:31.685226
NCT00781781|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2015-02-03|2008-10-28|2008-10-29|Estimate|||||||2015-02-03|2015-02-04|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|December 2011|Actual|2011-12-31|August 2008|Actual|2008-08-31||Interventional|||Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning|Multicenter, Openlabel, Phase II Intergroups (GELTAMO/GETH) Trial, on the Use of Alemtuzumab for Unrelated Donor Reduced Intensity Conditioning Allogenic Transplant in Hematological Malignancies Patients|Terminated||Phase 2|34|Actual|CABYC||2||Inability to recruit the number of patients established in the study protocol (34 of 40)|f||||f||||||||||2018-06-01 01:37:31.752439|2018-06-01 01:37:31.752439
NCT00781768|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2011-09-13|2008-10-28|2008-10-29|Estimate|||||||2011-09-13|2011-09-14|Estimate|August 2003||2003-08-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|October 2008|Actual|2008-10-31||Interventional|||Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea|A Prospective, Randomized Phase III Trial of Oral Ondansetron and Dexamethasone Versus Oral Ondansetron, Dexamethasone and Apreptant (MK-869)for the Prevention of N/V Associated With Highly Emetogenic Preparative Regimens Prior to Stem Cell Transplantation.|Completed||Phase 4|180|Actual|Loyola University||2|||f||||f||||||||||2018-06-01 01:37:31.836508|2018-06-01 01:37:31.836508
NCT00781755|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2015-06-03|2008-10-28|2008-10-29|Estimate|||||||2015-06-03|2015-06-04|Estimate||||December 2008|2008-12-31||||||||Interventional|||Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal|Phase 4 Study of Treating Schizophrenic Smokers Using Varenicline and Behavioral Intervention: Effects on Craving, Cues and Withdrawal|Withdrawn||Phase 4|0|Actual|VA Boston Healthcare System||2||"Study design was altered such that a treatment component was removed through the VA IRB. We did~   not and will not begin this clinical trial."|f||||f||||||||||2018-06-01 01:37:31.910059|2018-06-01 01:37:31.910059
NCT00781742|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27||2012-02-21|2012-07-16|2008-10-28|2008-10-29|Estimate||||2012-02-21|2012-02-23|Estimate|2012-07-16|2012-07-25|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||AZD6765 Severe Major Depressive Disorder (MDD) IV|A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants|Completed||Phase 2|152|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 01:37:32.024055|2018-06-01 01:37:32.024055
NCT00781729|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|September 2004||2004-09-30|August 2008|2008-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Yoga for Kyphosis Trial|Phase 2 Study of Yoga for Excess Thoracic Curvature.|Completed||Phase 2|118|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 01:37:32.195432|2018-06-01 01:37:32.195432
NCT00781716|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|CREST-MI||Safety and Efficacy Study of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction (STEMI) and Analysis of Current Status of Emergency PCI Green Channel for STEMI Patients in China|Comparison of Safety and Efficacy of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction and Analysis of Current Status of Emergency PCI Green Channel for Patients With ST Elevation Myocardial Infarction in China|Unknown status|Not yet recruiting|N/A|1020|Anticipated|Beijing Chao Yang Hospital||2|||f||||f||||||||||2018-06-01 01:37:32.263442|2018-06-01 01:37:32.263442
NCT00781703|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2014-07-14|2008-10-28|2008-10-29|Estimate|||||||2014-07-14|2014-07-15|Estimate|February 2008||2008-02-29|July 2014|2014-07-31|February 2014|Actual|2014-02-28|June 2012|Actual|2012-06-30||Interventional|DIAMOND||Evaluation of a Natural Experiment to Improve Statewide Depression Care in Minnesota (MN)|DIAMOND Study: Evaluation of a Natural Experiment to Improve Statewide Depression Care in MN|Completed||N/A|2631|Actual|HealthPartners Institute||1|||f||||f||||||||||2018-06-01 01:37:32.333326|2018-06-01 01:37:32.333326
NCT00781690|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2017-05-05|2008-10-28|2008-10-29|Estimate|||||||2017-05-05|2017-05-08|Actual|September 2008||2008-09-30|May 2017|2017-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|RHODES||Reduction of Heparin Dose in Dialysis With Evodial System|Pilot, Prospective, Multicenter, Open and Non-randomised Study: Definition of an Index of Anti Xa Value at the End of Hemodialysis Treatment.|Completed||N/A|53|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-06-01 01:37:32.404242|2018-06-01 01:37:32.404242
NCT00781677|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2010-01-11|2008-10-27|2008-10-29|Estimate|||||||2010-01-11|2010-01-12|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||Using Neuroimaging to Investigate Major Depressive Disorder|Using Neuroimaging to Investigate Neurobiological Correlates of Treatment Resistance Associated With Co-morbid Anxiety in Major Depressive Disorder|Unknown status|Recruiting||50|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||||2018-06-01 01:37:32.475715|2018-06-01 01:37:32.475715
NCT00781664|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-11-19|2008-10-28|2008-10-29|Estimate|||||||2008-11-19|2008-11-21|Estimate|October 2008||2008-10-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Cumulative Irritation Test|21-Day Cumulative Irritation Test|Completed||Phase 1|44|Actual|Pfizer||9|||f||||f||||||||||2018-06-01 01:37:32.543898|2018-06-01 01:37:32.543898
NCT00781638|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2012-04-02|2008-10-28|2008-10-29|Estimate|||||||2012-04-02|2012-04-03|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||ADAPT Adacolumn Pediatric Trial in Ulcerative Colitis|Open Uncontrolled Investigation to Assess the Efficacy and Safety of Adacolumn® Granulocytes, Monocytes / Macrophage Apheresis Device in Children and Adolescents With Active Ulcerative Colitis|Completed||N/A|24|Actual|Otsuka Frankfurt Research Institute GmbH|||||f||||f||||||||||2018-06-01 01:37:32.648846|2018-06-01 01:37:32.648846
NCT00781625|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-29|2008-10-28|2008-10-29|Estimate|||||||2008-10-29|2008-10-31|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Probiotics as a Prophylactic Aid in Women With Recurrent Urinary Tract Infections (UTI's)|Probiotics/Lactobacillus as a Prophylactic Aid in Recurrent Bacterial Cystitis in Women. A Randomized, Prospective, Double-Blinded, Placebo Controlled, Multi-Center Study.|Unknown status|Recruiting|N/A|120|Anticipated|University Hospital, Akershus||3|||f||||t||||||||||2018-06-01 01:37:32.721228|2018-06-01 01:37:32.721228
NCT00781612|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2018-05-30|2008-10-27|2008-10-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 16, 2008|Actual|2008-10-16|May 2018|2018-05-31|September 21, 2022|Anticipated|2022-09-21|September 21, 2022|Anticipated|2022-09-21||Interventional|||A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies|An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study|Recruiting||Phase 2|720|Anticipated|Genentech, Inc.||1|||f||||f||||||||||2018-06-01 01:37:32.830381|2018-06-01 01:37:32.830381
NCT00781599|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2012-04-19||2012-06-27|2008-10-28|2008-10-29|Estimate|2012-05-24|2012-06-27|Estimate||||2012-06-27|2012-07-11|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers|Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers|Completed||N/A|72|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 01:37:34.397509|2018-06-01 01:37:34.397509
NCT00781586|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2013-11-20|2008-10-28|2008-10-29|Estimate|||||||2013-11-20|2013-11-21|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.|A Randomized, Single Center, Double-blind, Three-way Crossover Trial to Evaluate the Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.|Completed||Phase 4|22|Actual|Bayer||3|||f||||f||||||||||2018-06-01 01:37:34.66113|2018-06-01 01:37:34.66113
NCT00781573|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2013-11-01|2008-10-28|2008-10-29|Estimate|||||||2013-11-01|2013-11-04|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|March 2013|Actual|2013-03-31||Interventional|SCORE||Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)|Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)|Unknown status|Active, not recruiting|N/A|280|Anticipated|North Texas Veterans Healthcare System||2|||f||||t||||||||||2018-06-01 01:37:34.737172|2018-06-01 01:37:34.737172
NCT00781560|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2009-08-06|2008-10-28|2008-10-29|Estimate|||||||2009-08-06|2009-08-07|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|||||Observational|CRE NIS||Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal|A Cross-sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks|Completed|||2575|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:37:34.814769|2018-06-01 01:37:34.814769
NCT00781547|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|January 1999||1999-01-31|October 2008|2008-10-31|May 2005|Actual|2005-05-31|September 2003|Actual|2003-09-30||Interventional|GHDM||Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus||Completed||Phase 3|40|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 01:37:34.88978|2018-06-01 01:37:34.88978
NCT00781534|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2010-02-18|2008-10-27|2008-10-29|Estimate|||||||2010-02-18|2010-02-19|Estimate|September 2003||2003-09-30|February 2010|2010-02-28|September 2008|Actual|2008-09-30|December 2004|Actual|2004-12-31||Interventional|||A Clinical Trial of Ginseng in Diabetes|A Clinical Trial of Ginseng for Glucose Intolerance|Completed||Early Phase 1|19|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 01:37:34.955804|2018-06-01 01:37:34.955804
NCT00781521|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|November 2002||2002-11-30|October 2008|2008-10-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children|A Pilot, Multicenter, Open Label, Non Comparative Study of the Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media Twice Daily for Seven Days in Children With Tympanostomy Tubes|Completed||Phase 3|96|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 01:37:35.116034|2018-06-01 01:37:35.116034
NCT00781508|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2013-04-22||2014-06-23|2008-10-28|2008-10-29|Estimate|2014-05-20|2014-06-23|Estimate||||2014-06-23|2014-07-02|Estimate|December 2006||2006-12-31|June 2014|2014-06-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Effects of Viagra on Heart Function in Patients With Heart Failure|Single Dose Sildenafil in Heart Failure Patients Improves 6-minute Walk Test by a Reduction in Left Ventricular Filling Pressure|Completed||Phase 4|10|Actual|MetroHealth Medical Center|The study was limited by the small number of participants. Additionally, the inclusion criterion of a systolic pulmonary artery pressure of > 40 mmHg was no longer present in the majority of patients at the time they presented for study.|2|||f||||f||||||||||2018-06-01 01:37:35.21516|2018-06-01 01:37:35.21516
NCT00781495|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2011-07-11|2008-10-28|2008-10-29|Estimate|||||||2011-07-11|2011-07-12|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Determinants of Insulin-induced Weight Gain in Type 2 Diabetes Mellitus|Determinants of Insulin-induced Weight Gain in Type 2 Diabetes Mellitus|Unknown status|Recruiting||75|Anticipated|Radboud University|||1||f||||f||||||||||2018-06-01 01:37:35.472819|2018-06-01 01:37:35.472819
NCT00781482|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2016-02-25|2008-10-28|2008-10-29|Estimate|||||||2016-02-25|2016-02-26|Estimate||||February 2016|2016-02-29||||||||Interventional|||Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem|Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem|Withdrawn||Phase 4|0|Actual|Kettering Health Network||1||Sponsor elected not to conduct study at this time.|f||||f||||||||||2018-06-01 01:37:35.573278|2018-06-01 01:37:35.573278
NCT00781469|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2015-05-27|2008-10-28|2008-10-29|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood|A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood|Completed|||29|Actual|Imperial College London|||3||f||||f||||||Samples With DNA|"~     Blood and synovium~   "|||2018-06-01 01:37:35.65705|2018-06-01 01:37:35.65705
NCT00781456|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2014-08-19|2013-04-10|2016-12-12|2008-10-28|2008-10-29|Estimate|2014-08-19|2014-08-29|Estimate|2013-04-10|2013-04-16|Estimate|2016-12-12|2017-02-06|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Intent-to-treat population includes all randomly assigned and treated participants who had at least 1 week of postbaseline migraine data.|A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches|A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo For the Management of Menstrually-Related Migraine Headaches.|Completed||Phase 2|109|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 01:37:35.774619|2018-06-01 01:37:35.774619
NCT00781443|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27||2010-05-04|2010-05-04|2008-10-27|2008-10-29|Estimate||||2010-05-04|2010-05-06|Estimate|2010-05-04|2010-05-06|Estimate|December 2008||2008-12-31|May 2010|2010-05-31||||November 2009|Actual|2009-11-30||Interventional|||A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|Completed||Phase 2|29|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 01:37:36.282079|2018-06-01 01:37:36.282079
NCT00781430|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2012-05-10|2008-10-28|2008-10-29|Estimate|||||||2012-05-10|2012-05-14|Estimate|April 2009||2009-04-30|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease|An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Neratinib In Subjects With Chronic Hepatic Impairment And In Matched Healthy Adults|Completed||Phase 1|27|Actual|Puma Biotechnology, Inc.||1|||f||||f||||||||||2018-06-01 01:37:36.377612|2018-06-01 01:37:36.377612
NCT00781417|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2012-02-04|2008-10-28|2008-10-29|Estimate|||||||2012-02-04|2012-02-07|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|POSH-D||Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease|Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease|Completed||N/A|48|Actual|Atlanta VA Medical Center||2|||f||||f||||||||||2018-06-01 01:37:36.451494|2018-06-01 01:37:36.451494
NCT00781404|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|||2013-02-15|2008-10-28|2008-10-29|Estimate|||||||2013-02-15|2013-02-18|Estimate|October 2008||2008-10-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|PROMISE||Myocardial Protection With Adenosine During Primary Percutaneous Coronary Intervention in Pts With STEMI|Myocardial Protection During reperfusión in Patients With Acute Coronary Syndrome With ST Segment Elevation Submitted to Primary Angioplasty: Effect of Intracoronary Adenosine on Infarct Size and Ventricular Remodeling.|Completed||Phase 3|201|Actual|Hospital Universitari Vall d'Hebron Research Institute|||||f||||f||||||||||2018-06-01 01:37:36.522862|2018-06-01 01:37:36.522862
NCT00781391|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2015-02-05||2015-03-12|2008-10-28|2008-10-29|Estimate|2015-03-12|2015-03-25|Estimate||||2015-03-12|2015-03-25|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|EngageAFTIMI48||Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation|A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of Edoxaban (DU-176b) Versus Warfarin In Subjects With Atrial Fibrillation - Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48)|Completed||Phase 3|21105|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-06-01 01:37:37.086508|2018-06-01 01:37:37.086508
NCT00781378|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2008-10-28|2008-10-28|2008-10-29|Estimate|||||||2008-10-28|2008-10-29|Estimate|June 2002||2002-06-30|October 2008|2008-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China|Efficacy and Safety Evaluation of Low Dosage of Recombinant Tissue Plasminogen Activator (rt-PA) in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China|Completed||Phase 4|118|Actual|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-06-01 01:37:47.904283|2018-06-01 01:37:47.904283
NCT00781365|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28|2014-02-27||2017-03-15|2008-10-28|2008-10-29|Estimate|2014-06-12|2014-07-14|Estimate||||2017-03-15|2017-04-13|Actual|March 2009||2009-03-31|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Hyperlink||Home Blood Pressure Telemonitoring and Case Management to Control Hypertension|Home Blood Pressure Telemonitoring and Case Management to Control Hypertension|Completed||N/A|450|Actual|HealthPartners Institute|1) Response rate: 1 in 7 patients solicited by mail responded;of those screened, 1 in 4 eligible. 2) Participants were well-educated, had high income levels, 3) 1 integrated health care system, 4) study was not blinded.|2|||f||||t||||||||No||2018-06-01 01:37:48.084739|2018-06-01 01:37:48.084739
NCT00781352|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2016-06-28|2008-10-28|2008-10-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|November 1998||1998-11-30|June 2016|2016-06-30|March 2007|Actual|2007-03-31|November 2003|Actual|2003-11-30||Interventional|||Nitrous Oxide and Risk of Cancer Recurrence After Colorectal Surgery: A Randomized, Blinded Study|Nitrous Oxide Does Not Increase the Risk of Cancer Recurrence After Colorectal Surgery: A Randomized, Blinded Study|Completed||Phase 3|408|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 01:37:48.831532|2018-06-01 01:37:48.831532
NCT00781339|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-28||2011-09-06|2011-09-06|2008-10-28|2008-10-29|Estimate||||2011-09-06|2011-09-12|Estimate|2011-09-06|2011-09-12|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients|A Phase IIa Open Label Study to Evaluate the Safety and Antimicrobial Effects of NVC-422 on Bacteriuria in Chronically Catheterized Subjects|Completed||Phase 2|20|Actual|NovaBay Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:37:48.952772|2018-06-01 01:37:48.952772
NCT00781326|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2016-03-22||2016-08-05|2008-10-27|2008-10-29|Estimate|2016-08-05|2016-09-29|Estimate||||2016-08-05|2016-09-29|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression|Treatment of Depression Occurring in the Setting of Cerebrovascular Risk -- A Pilot Study|Terminated||Phase 4|9|Actual|University of Pittsburgh|Study was terminated for administrative reasons at the end of Phase I (open label antidepressant treatment). No subjects entered Phase II (Nimodipine vs Placebo).|1||Final cost of study medication was significantly greater than initial estimate,|f||||f||||||||||2018-06-01 01:37:49.111927|2018-06-01 01:37:49.111927
NCT00781313|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2016-07-19|2008-10-28|2008-10-29|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Observational|||Disaster Preparedness Among Families Caring for Children With Diabetes|Pre-hurricane Disaster Preparedness: A Survey in Pediatric Type 1 Diabetes|Completed|||142|Actual|Baylor College of Medicine|||||f||||f||||||||No||2018-06-01 01:37:49.520494|2018-06-01 01:37:49.520494
NCT00781300|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2008-10-27|2008-10-27|2008-10-28|Estimate|||||||2008-10-27|2008-10-28|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|February 2007|Actual|2007-02-28|November 2006|Actual|2006-11-30||Interventional|||Intraocular Pressure With Loteprednol and Dexamethasone|A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery|Completed||Phase 4|35|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 01:37:49.582643|2018-06-01 01:37:49.582643
NCT00781287|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2013-08-08|2008-10-27|2008-10-28|Estimate|||||||2013-08-08|2013-08-12|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|February 2012|Actual|2012-02-29||Interventional|UW PIC 330||Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1|Impact of Raltegravir (Isentress/MK-0518) - Containing Regimens on HIV-1 Infected CD4+ T-Cells During Acute and Early HIV-1 Infection: A Randomized, Controlled Study Comparing Standard Antiretroviral Therapy to Standard Therapy Plus Raltegravir|Terminated||Phase 4|10|Actual|University of Washington||2||Enrollment too slow.|f||||f||||||||||2018-06-01 01:37:49.689785|2018-06-01 01:37:49.689785
NCT00781274|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2012-06-05||2014-04-16|2008-10-26|2008-10-28|Estimate|2012-07-16|2012-08-20|Estimate||||2014-04-16|2014-05-02|Estimate|December 2008||2008-12-31|April 2014|2014-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment|Completed||Phase 3|32|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 01:37:49.845192|2018-06-01 01:37:49.845192
NCT00781261|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2013-01-11|2008-10-27|2008-10-28|Estimate|||||||2013-01-11|2013-01-14|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|BONES||Osteonecrosis of the Hip and Bisphosphonate Treatment|A Randomised Controlled Trial of Bisphosphonate Therapy in Osteonecrosis of the Hip|Unknown status|Recruiting|Phase 2|120|Anticipated|University of Sydney||2|||f||||f||||||||||2018-06-01 01:37:50.127574|2018-06-01 01:37:50.127574
NCT00781248|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-26|||2009-03-24|2008-10-27|2008-10-28|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy Study of the NG Shield, a Device Intended to Reduce Pain and Discomfort Level Related to Nasogasstric Tube Usage|Evaluation of Safety and Efficacy of the NasoGastric Shield (NG Shield) in Healthy Subjects With Indwelling Nasogastric Tube|Completed||Phase 2|24|Anticipated|Nanovibronix||2|||f||||t||||||||||2018-06-01 01:37:50.494863|2018-06-01 01:37:50.494863
NCT00781222|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2008-10-27|2008-10-27|2008-10-28|Estimate|||||||2008-10-27|2008-10-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:37:50.606185|2018-06-01 01:37:50.606185
NCT00781209|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-26|||2008-10-27|2008-10-27|2008-10-28|Estimate|||||||2008-10-27|2008-10-28|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2010|Anticipated|2010-12-31|October 2009|Anticipated|2009-10-31||Interventional|||The Role of Posterior Fossa Irradiation (PFI) Plus Stereotactic Radiosurgery (SRS) for Cerebellar Metastases|A Phase II Trial Evaluating the Role of Posterior Fossa Irradiation (PFI) Plus Stereotactic Radiosurgery (SRS) for Cerebellar Metastases|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-06-01 01:37:50.709247|2018-06-01 01:37:50.709247
NCT00781196|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2009-08-03|2008-10-27|2008-10-28|Estimate|||||||2009-08-03|2009-08-04|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|PIGO||Folic Acid Supplementation in Phenytoin Induced Gingival Overgrowth|Effect of Low Dose Oral Folic Acid Supplementation on Phenytoin Induced Gingival Overgrowth: A Randomized Double Blind Controlled Trial.|Completed||Phase 3|120|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 01:37:50.810744|2018-06-01 01:37:50.810744
NCT00781183|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-12-20|2008-10-27|2008-10-28|Estimate|||||||2012-12-20|2012-12-21|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Does Pulmonary Rehabilitation Change Self-Selected And Maximum Sustainable Walking Speed In Patients With Lung Disease?|Does Pulmonary Rehabilitation Change The Self-Selected And Maximum Sustainable Walking Speed In Patients With Symptomatic Lung Disease?|Completed||N/A|64|Actual|West Park Healthcare Centre||1|||f||||f||||||||||2018-06-01 01:37:50.885315|2018-06-01 01:37:50.885315
NCT00781170|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2009-05-27|2008-10-27|2008-10-28|Estimate|||||||2009-05-27|2009-05-28|Estimate|May 2000||2000-05-31|May 2009|2009-05-31||||||||Interventional|||Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma|Dose-Reduced Allogeneic Stem Cell Transplantation as Induction of a Graft-Versus-Myeloma-Effect After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma Stage II/III|Completed||Phase 2|20|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-06-01 01:37:51.012024|2018-06-01 01:37:51.012024
NCT00781157|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2013-05-22|2008-10-27|2008-10-28|Estimate|||||||2013-05-22|2013-05-23|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Phenylephrine for Spinal Induced Hypotension|Up-down Determination of the ED90 of Phenylephrine for Spinal Induced Hypotension in Parturients Undergoing Cesarean Delivery|Completed||Phase 4|66|Actual|IWK Health Centre||1|||f||||t||||||||||2018-06-01 01:37:51.132792|2018-06-01 01:37:51.132792
NCT00781144|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2008-10-27|2008-10-27|2008-10-28|Estimate|||||||2008-10-27|2008-10-28|Estimate|August 2007||2007-08-31|October 2008|2008-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Determination of Forces Used in Palpatory Diagnosis|The Effect of Experience and Gender on the Palpatory Forces Exerted by Novice and Experienced Osteopaths in Australia|Completed|||82|Actual|Nova Southeastern University|||3||f||||f||||||||||2018-06-01 01:37:51.287289|2018-06-01 01:37:51.287289
NCT00781131|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2013-05-22|2008-10-27|2008-10-28|Estimate|||||||2013-05-22|2013-05-23|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Trial of Pregabalin for Post-operative Pain in Women Undergoing Abdominal Hysterectomy|A Randomized, Placebo Controlled Trial of Pregabalin for Post-operative Pain in Women Undergoing Abdominal Hysterectomy|Completed||Phase 4|101|Actual|IWK Health Centre||3|||f||||t||||||||||2018-06-01 01:37:51.411647|2018-06-01 01:37:51.411647
NCT00781118|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24||2015-06-22|2018-03-09|2008-10-27|2008-10-28|Estimate||||2016-09-26|2016-09-28|Estimate|2018-03-09|2018-03-14|Actual|December 2008|Actual|2008-12-31|March 2018|2018-03-31|May 17, 2017|Actual|2017-05-17|May 1, 2014|Actual|2014-05-01||Interventional|ALERTS||AngelMed for Early Recognition and Treatment of STEMI|AngelMed for Early Recognition and Treatment of STEMI|Completed||Phase 3|1020|Actual|Angel Medical Systems||2|||f||||t||||||||Yes|When we have completed review with the FDA, the IPD will will be made available.|2018-06-01 01:37:51.512393|2018-06-01 01:37:51.512393
NCT00781105|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2017-02-20|2008-10-27|2008-10-28|Estimate|||||||2017-02-20|2017-02-23|Actual|August 1, 2008|Actual|2008-08-01|February 2017|2017-02-28|September 16, 2010|Actual|2010-09-16|September 16, 2010|Actual|2010-09-16||Interventional|Chinese PAC||Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B|An Open-label, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B|Completed||Phase 4|2200|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:37:51.743061|2018-06-01 01:37:51.743061
NCT00781092|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-09-19|2008-10-27|2008-10-28|Estimate|||||||2012-09-19|2012-09-20|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes|A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes|Completed||Phase 4|30|Actual|Durrie Vision||2|||f||||f||||||||||2018-06-01 01:37:51.834576|2018-06-01 01:37:51.834576
NCT00781079|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2014-09-18||2015-04-06|2008-10-27|2008-10-28|Estimate|2014-10-03|2014-10-06|Estimate||||2015-04-06|2015-04-27|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|PEER|Veteran patients of MHICM teams|Do Consumer Providers Enhance Recovery?|Promoting Recovery Using Mental Health Consumer Providers|Completed||N/A|285|Actual|VA Office of Research and Development|1. cluster randomized trial - teams may have exerted influence on the findings. 2. analyses were intent-to-treat, but about half the veterans in the PS group did not receive any PS services. 3. the study involved a small number of peers (n=6)|2|||f||||t||||||||||2018-06-01 01:37:51.937113|2018-06-01 01:37:51.937113
NCT00781066|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2008-10-27|2008-10-27|2008-10-28|Estimate|||||||2008-10-27|2008-10-28|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|CCT||Controlled Cord Traction During Third Stage of Labor|Controlled Cord Traction During Third Stage of Labor: Pilot Trial|Completed||Phase 3|200|Actual|Universidad de la Republica||2|||f||||t||||||||||2018-06-01 01:37:52.371211|2018-06-01 01:37:52.371211
NCT00781053|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2013-02-08|2008-10-27|2008-10-28|Estimate|||||||2013-02-08|2013-02-11|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study|Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study With P144 Topical Adminsitration for Skin Fibrosis in Patients With Systemic Sclerosis|Completed||Phase 2|38|Actual|ISDIN||1|||f||||f||||||||||2018-06-01 01:37:52.534263|2018-06-01 01:37:52.534263
NCT00781040|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2016-04-19|2008-10-27|2008-10-28|Estimate|||||||2016-04-19|2016-04-20|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients|Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients|Unknown status|Recruiting||270|Anticipated|Kuopio University Hospital|||1||f||||f||||||||No||2018-06-01 01:37:52.641553|2018-06-01 01:37:52.641553
NCT00781027|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2010-05-19|2008-10-27|2008-10-28|Estimate|||||||2010-05-19|2010-05-20|Estimate|December 2008||2008-12-31|May 2010|2010-05-31||||May 2010|Actual|2010-05-31||Interventional|||Fuchs' Torsional Phaco Study|Fuchs' Endothelial Dystrophy and Cataract Surgery: Can Torsional Phacoemulsification Decrease the Risk for Corneal Decompensation|Completed||Phase 4|50|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:37:52.726312|2018-06-01 01:37:52.726312
NCT00781001|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2013-07-29|2008-10-24|2008-10-28|Estimate|||||||2013-07-29|2013-07-30|Estimate|July 2008||2008-07-31|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy|Efficacy of Inhaled Cannabis in Diabetic Painful Peripheral Neuropathy|Completed||Phase 1/Phase 2|17|Actual|Center for Medicinal Cannabis Research||4|||f||||t||||||||||2018-06-01 01:37:52.934455|2018-06-01 01:37:52.934455
NCT00780988|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2012-01-21|2008-10-27|2008-10-28|Estimate|||||||2012-01-21|2012-01-24|Estimate||||January 2012|2012-01-31||||||||Interventional|||Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer|A Pilot Study to Assess the Safety and Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination Prior to Autologous Hematopoietic and Immune Cell Rescue in Metastatic Colorectal Cancer|Withdrawn||Phase 1|0|Actual|Stanford University|||||f||||||||||||||2018-06-01 01:37:53.017504|2018-06-01 01:37:53.017504
NCT00780975|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2017-01-03|2008-10-27|2008-10-28|Estimate|||||||2017-01-03|2017-01-04|Estimate|February 2005||2005-02-28|January 2017|2017-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer|A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..|Terminated||Phase 2|8|Actual|PharmaMar||1||Poor recruitment|f||||f||||||||||2018-06-01 01:37:53.102063|2018-06-01 01:37:53.102063
NCT00780962|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2017-04-25||2018-01-04|2008-10-27|2008-10-28|Estimate|2018-01-04|2018-01-31|Actual||||2018-01-04|2018-01-31|Actual|October 16, 2007|Actual|2007-10-16|October 2017|2017-10-31|August 9, 2010|Actual|2010-08-09|August 9, 2010|Actual|2010-08-09||Interventional||399 subjects were consented to participate in the study, of whom 357 (89.4%) completed a second blood draw to determine outcome and were included in the study.|N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients|N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients|Completed||Phase 2|399|Actual|Beth Israel Deaconess Medical Center|Our results were obtained in patients considered to be at relatively low risk for contrast-induced nephropathy and should not be extended to patients who might be at higher risk for it.|2|||f||||t|t|f||||||No||2018-06-01 01:37:53.214901|2018-06-01 01:37:53.214901
NCT00780949|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-08-02|2008-10-27|2008-10-28|Estimate|||||||2012-08-02|2012-08-03|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PLAC||Immunological Consequences of CARD15/NOD2 Mutations in Crohn's Disease|Immunological Consequences of CARD15/NOD2 Mutations in Crohn's Disease|Completed||N/A|110|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:37:53.647402|2018-06-01 01:37:53.647402
NCT00780936|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2008-11-21|2008-10-27|2008-10-28|Estimate|||||||2008-11-21|2008-11-24|Estimate|October 2007||2007-10-31|November 2008|2008-11-30|July 2008||2008-07-31|||||Interventional|||Effects of a Peripheral Nerve Block on Biomarkers of Pain and Inflammation|Effect of Peripheral Nerve Block on Inflammatory and Nociceptive Biomarkers in a UV-B Burn Model in Humans|Completed||N/A|15||Stanford University|||||f||||||||||||||2018-06-01 01:37:53.745161|2018-06-01 01:37:53.745161
NCT00780923|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2013-03-25|2008-10-27|2008-10-28|Estimate|||||||2013-03-25|2013-03-27|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Continuous Positive Airway Pressure Treatment on Inflammation in Patients With Obstructive Sleep Apnea|A Longitudinal Study of Short-Term Effects of CPAP Treatment on Airway and Systemic Inflammation in Patients With Obstructive Sleep Apnea|Completed||N/A|43|Actual|Kyoto University, Graduate School of Medicine||1|||f||||t||||||||||2018-06-01 01:37:54.009156|2018-06-01 01:37:54.009156
NCT00780910|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2012-06-05||2014-04-16|2008-10-26|2008-10-28|Estimate|2012-07-16|2012-08-20|Estimate||||2014-04-16|2014-05-02|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment|Completed||Phase 3|109|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 01:37:54.235134|2018-06-01 01:37:54.235134
NCT00780897|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2008-10-27|2008-10-27|2008-10-28|Estimate|||||||2008-10-27|2008-10-28|Estimate|March 2005||2005-03-31|October 2008|2008-10-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Observational|GéNIOP||Premature Ovarian Failure (Genetic and Physiopathologic Analysis)|Premature Ovarian Failure : Genetic and Physiopathologic Analysis|Unknown status|Recruiting||87|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     One ovarian biopsy during the protocol to evaluate ovocytes number and transcriptome~     analysis.~   "|||2018-06-01 01:37:54.57044|2018-06-01 01:37:54.57044
NCT00780884|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-26|||2015-06-21|2008-10-26|2008-10-28|Estimate|||||||2015-06-21|2015-06-23|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients|Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients|Completed||N/A|21|Actual|HaEmek Medical Center, Israel||1|||f||||t||||||||||2018-06-01 01:37:54.660697|2018-06-01 01:37:54.660697
NCT00780858|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-25|||2015-05-05|2008-10-27|2008-10-28|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|LP||Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI|GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI|Completed|||662|Actual|IVI Madrid|||2||f||||f||||||||||2018-06-01 01:37:54.783037|2018-06-01 01:37:54.783037
NCT00780845|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2008-11-03|2008-10-27|2008-10-28|Estimate|||||||2008-11-03|2008-11-04|Estimate|January 2003||2003-01-31|October 2008|2008-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||AKIN Criteria: Acute Kidney Injury After On-Pump Coronary Artery Bypass Graft (CABG)|AKIN (Acute Kidney Injury Network): Acute Kidney Injury After On-Pump Coronary Artery Bypass Graft Surgery|Completed|||817|Actual|Hospital de Base|||2||f||||f||||||||||2018-06-01 01:37:54.891514|2018-06-01 01:37:54.891514
NCT00780832|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2016-02-23|2008-10-27|2008-10-28|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder|Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder|Terminated||N/A|8|Actual|IWK Health Centre||2||Insufficient elligible patients available in a reasonable time frame.|f||||f||||||||||2018-06-01 01:37:54.976808|2018-06-01 01:37:54.976808
NCT00780819|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2013-05-13|2008-10-27|2008-10-28|Estimate|||||||2013-05-13|2013-05-14|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|July 2009|Actual|2009-07-31||Interventional|BZS||Borderzone Sampling|Does Borderzone Contrast Enhancement on Intraoperative MRI During High Grade Glioma Resection Correlate With Residual Tumor?|Completed||N/A|10|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-06-01 01:37:55.079067|2018-06-01 01:37:55.079067
NCT00780806|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2011-08-22|2008-10-24|2008-10-28|Estimate|||||||2011-08-22|2011-08-23|Estimate|October 2008||2008-10-31|August 2011|2011-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults|An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development|Completed||Phase 1/Phase 2|60|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||t||||||||||2018-06-01 01:37:55.193576|2018-06-01 01:37:55.193576
NCT00780793|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-02-01|2008-10-27|2008-10-28|Estimate|||||||2012-02-01|2012-02-02|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|STRASS||Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study|Effect of TNF-blocker Injections Spacing on Rheumatoid Arthritis Inflammatory Activity in Patients in Clinical Remission or Low Disease Activity|Completed||Phase 4|250|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:37:55.290728|2018-06-01 01:37:55.290728
NCT00780780|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2018-03-19|2008-10-27|2008-10-28|Estimate|||||||2018-03-19|2018-03-20|Actual|July 2007|Actual|2007-07-31|August 2012|2012-08-31|October 2012|Actual|2012-10-31|August 2008|Actual|2008-08-31||Interventional|NEVANAC||Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema|A Randomized Parallel, Masked to Evaluate the Efficacy of Triamcinolone Associated With Nepafenac (Nevanac) Compared With Intravitreal Injection of Triamcinolone for Treatment of Clinically Significant Diabetic Macular Edema|Completed||Phase 3|40|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 01:37:55.36001|2018-06-01 01:37:55.36001
NCT00780767|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2012-08-15|2008-10-27|2008-10-28|Estimate|||||||2012-08-15|2012-08-16|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ART-MPE||Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism|Angiojet Rheolytic Thrombectomy In Case of Massive Pulmonary Embolism A Prospective Single Center Feasibility and Safety Pilot Trial|Completed||Phase 2|10|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-06-01 01:37:55.46218|2018-06-01 01:37:55.46218
NCT00780754|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-26|||2018-03-04|2008-10-27|2008-10-28|Estimate|||||||2018-03-04|2018-03-06|Actual|April 2007|Actual|2007-04-30|October 2008|2008-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia|Effect of 5α Reductase Inhibitor Dutasteride on the Prevention of the Prostate Cancer in Men With High Grade Intraepithelial Neoplasia of the Prostate|Completed||Phase 3|200|Anticipated|Kaunas University of Medicine||2|||f||||f||||||||||2018-06-01 01:37:55.537329|2018-06-01 01:37:55.537329
NCT00780559|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2018-03-15|2008-10-24|2008-10-27|Estimate|||||||2018-03-15|2018-03-16|Actual|November 1, 2009|Actual|2009-11-01|March 2018|2018-03-31|February 8, 2018|Actual|2018-02-08|December 31, 2017|Actual|2017-12-31||Interventional|INMED||Improving Neuropathy and Mobility in People With Early Diabetes|Improving Neuropathy and Mobility in Subjects With Early Diabetes|Completed||Phase 2|72|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-06-01 01:37:59.100116|2018-06-01 01:37:59.100116
NCT00780741|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2012-08-23||2016-05-19|2008-10-27|2008-10-28|Estimate|2012-10-11|2012-11-12|Estimate||||2016-05-19|2016-06-24|Estimate|October 2008||2008-10-31|May 2016|2016-05-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|NLD3||Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old|A Randomized Trial Comparing Immediate Probing in an Office Setting With Deferred Probing in a Facility Setting for Treatment of Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old|Completed||Phase 3|220|Actual|Jaeb Center for Health Research|"Conclusions not definitive--would need larger sample size.~Participants with bilateral NLDO excluded, so results not generalizable to bilateral cases.~Actual costs may vary by region and payer.~Did not include costs of follow up visits."|2|||f||||t||||||||||2018-06-01 01:37:55.86159|2018-06-01 01:37:55.86159
NCT00780728|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2009-11-12|2008-10-27|2008-10-28|Estimate|||||||2009-11-12|2009-11-13|Estimate||||November 2009|2009-11-30||||||||Interventional|||Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension|Addition of Sildenafil to Bosentan Monotherapy in Patients With Pulmonary Arterial Hypertension (PAH)|Withdrawn||Phase 3|||University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 01:37:56.422943|2018-06-01 01:37:56.422943
NCT00780715|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|2017-05-24||2017-10-25|2008-10-27|2008-10-28|Estimate|2017-10-25|2017-10-26|Actual||||2017-10-25|2017-10-26|Actual|December 2008||2008-12-31|October 2017|2017-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|ROAD||Response To Oral Agents in Diabetes (ROAD)- Pilot Study|Response To Oral Agents in Diabetes (ROAD)- Pilot Study|Completed||Phase 4|29|Actual|University of Dundee|Note that this study was a pilot study and was not designed or powered to show significance of differences in outcomes between groups. Primary aim was to demonstrate efficacy of novel route of recruitment from primary care.|4|||f||||f||||||||||2018-06-01 01:37:56.48862|2018-06-01 01:37:56.48862
NCT00780702|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2018-05-19|2008-10-27|2008-10-28|Estimate|||||||2018-05-19|2018-05-22|Actual|May 8, 2008||2008-05-08|February 27, 2014|2014-02-27|April 16, 2013|Actual|2013-04-16|April 16, 2013|Actual|2013-04-16||Interventional|||Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients|Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients|Completed||Phase 1|41|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 01:37:56.744237|2018-06-01 01:37:56.744237
NCT00780676|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2015-06-10||2015-07-16|2008-10-27|2008-10-28|Estimate|2015-07-16|2015-07-20|Estimate||||2015-07-16|2015-07-20|Estimate|June 2009||2009-06-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Individuals who were positive for more than one predictor were assigned to the marker arm for which they had the highest percentile positivity.|Personalized Treatment Selection for Metastatic Breast Cancer|Personalized Treatment Selection for Metastatic Breast Cancer|Terminated||Phase 2|97|Actual|M.D. Anderson Cancer Center|Study terminated according to early stopping rules.|4||Closed early for futility.|f||||f||||||||||2018-06-01 01:37:56.866079|2018-06-01 01:37:56.866079
NCT00780663|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-27|||2011-06-13|2008-10-27|2008-10-28|Estimate|||||||2011-06-13|2011-06-15|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma|A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma|Completed||Phase 2|25|Anticipated|Cylene Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:37:57.139199|2018-06-01 01:37:57.139199
NCT00780650|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2018-05-04|2008-10-24|2008-10-27|Estimate|||||||2018-05-04|2018-05-07|Actual|May 2009||2009-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q4-Atomoxetine|Active, not recruiting||Early Phase 1|56|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 01:37:57.240208|2018-06-01 01:37:57.240208
NCT00780637|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2016-07-14|2008-10-24|2008-10-27|Estimate|||||||2016-07-14|2016-07-15|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|P1A3C||Brachial Artery t-PA Release in Heart Transplant Recipients|Characterization of Brachial Arterial t-PA Release, Vasodilator Function, and Vascular Compliance and Correlation With Fibrinolytic Balance, Oxidative Stress, and Inflammation Measures in Heart Transplant Recipients (SCCOR Project 1, Aim 3C)|Withdrawn||N/A|0|Actual|Vanderbilt University||1||Bradykinin Shortage, SCCOR expired prior to BK availability, lack of enrollment.|t||||t||||||||||2018-06-01 01:37:57.321567|2018-06-01 01:37:57.321567
NCT00780624|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2016-04-20|2008-10-24|2008-10-27|Estimate|||||||2016-04-20|2016-04-21|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Nasal Intermittent Positive Pressure Ventilation In Newborn Infants With Respiratory Distress Syndrome|Nasal Intermittent Positive Pressure Ventilation In Newborn Infants With Respiratory Distress Syndrome|Completed||N/A|100|Actual|Third Military Medical University||2|||f||||t||||||||Undecided||2018-06-01 01:37:57.386362|2018-06-01 01:37:57.386362
NCT00780611|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2015-03-16|2008-10-24|2008-10-27|Estimate|||||||2015-03-16|2015-03-17|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|GCC0832||Investigating the Improvement in 4D CT Images Using AV Biofeedback|Investigating the Improvement in 4D CT Images Using Audiovisual Biofeedback: An Intra-fraction and an Inter-fraction Evaluation.|Completed|||25|Actual|University of Maryland|||||f||||t||||||||||2018-06-01 01:37:57.449605|2018-06-01 01:37:57.449605
NCT00780598|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2012-06-27|2008-10-24|2008-10-27|Estimate|||||||2012-06-27|2012-06-28|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|OPAL||Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML|The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia|Completed||Phase 2|76|Actual|Chroma Therapeutics||1|||f||||t||||||||||2018-06-01 01:37:58.723147|2018-06-01 01:37:58.723147
NCT00780585|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2014-12-18|2008-10-24|2008-10-27|Estimate|||||||2014-12-18|2014-12-19|Estimate|April 2007||2007-04-30|December 2014|2014-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)|A Multi-center Cardiac Safety Study of Subjects Who Participated in Organon Sponsored Phase 1 and Phase 2 Completed and Discontinued Trials With Org 24448|Completed|||95|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:37:58.834727|2018-06-01 01:37:58.834727
NCT00780572|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2015-10-15||2015-11-18|2008-10-24|2008-10-27|Estimate|2015-10-15|2015-11-18|Estimate||||2015-11-18|2015-12-21|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|VA ADE||Implementation of Real-time ADE Surveillance and Decision Support|Implementation of Real-Time ADE Surveillance and Decision Support|Completed||N/A|595|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:37:58.911791|2018-06-01 01:37:58.911791
NCT00780546|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|July 2009|Anticipated|2009-07-31|May 2009|Anticipated|2009-05-31||Observational|||Spatial Epidemiology of Tuberculosis (TB) Infection|Spatial Epidemiology of Tuberculosis Infection|Unknown status|Not yet recruiting||1000|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:37:59.173728|2018-06-01 01:37:59.173728
NCT00780533|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|August 2008||2008-08-31|October 2008|2008-10-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Changes in and Determinants of Movement Performance, Functional Status, and Health-Related Quality of Life After Stroke Rehabilitation|Changes in and Determinants of Movement Performance, Functional Status, and Health-Related Quality of Life After Stroke Rehabilitation|Unknown status|Active, not recruiting||70|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 01:37:59.23588|2018-06-01 01:37:59.23588
NCT00780520|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Effect of Glutamine on Systemic Inflammation During Human Experimental Endotoxemia|The Effect of Glutamine Infusion on the Inflammatory Response and HSP-70 in BMNCs During Human Experimental|Completed||N/A|8|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:38:00.03333|2018-06-01 01:38:00.03333
NCT00780507|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2013-05-29|2008-10-24|2008-10-27|Estimate|||||||2013-05-29|2013-05-31|Estimate|August 2007||2007-08-31|May 2013|2013-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Fecal Biomarker Study for Patients With Ulcerative Colitis|Fecal Biomarker Study for Patients From a Once Daily Study for Efficacy in a Ulcerative Colitis Maintenance Study|Completed|||89|Actual|Warner Chilcott|||2||f||||f||||||None Retained|"~     Human feces protein biomarkers Enrollment is number of specimens rather than number of~     subjects~   "|||2018-06-01 01:38:00.154626|2018-06-01 01:38:00.154626
NCT00780494|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2012-09-03|2008-10-24|2008-10-27|Estimate|||||||2012-09-03|2012-09-05|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma|A Phase II Study of Capecitabine, Carboplatin, and Bevacizumab for Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma|Unknown status|Recruiting|Phase 2|35|Anticipated|Stanford University||1|||f||||t||||||||||2018-06-01 01:38:00.299908|2018-06-01 01:38:00.299908
NCT00780481|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2017-03-16||2017-07-13|2008-10-24|2008-10-27|Estimate|2017-07-13|2017-07-14|Actual||||2017-07-13|2017-07-14|Actual|January 2007|Actual|2007-01-31|July 2017|2017-07-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|P1A3B|Data was lost, we do not have sex/gender|Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation|Characterization of Brachial Arterial t-PA Release, Vasodilator Function, and Vascular Compliance and Correlation With Fibrinolytic Balance, Oxidative Stress, and Inflammation Measures (SCCOR Project 1 Aim 3B)|Terminated||N/A|13|Actual|Vanderbilt University Medical Center||1||Lack of enrollment due to strict inclusion/exclusion criteria. Bradykinin shortage|f||||t||||||||||2018-06-01 01:38:00.406546|2018-06-01 01:38:00.406546
NCT00780468|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2014-03-26|2008-10-23|2008-10-27|Estimate|||||||2014-03-26|2014-03-27|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Pilot Study to Evaluate a Revised Method of Assessing Food in a Commercial Weight Management Program Format|A Pilot Study to Evaluate a Revised Method of Assessing Food in a Commercial Weight Management Program Format|Completed||N/A|134|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:38:00.64783|2018-06-01 01:38:00.64783
NCT00780455|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2013-01-22||2015-05-08|2008-10-24|2008-10-27|Estimate|2013-01-22|2013-02-26|Estimate||||2015-05-08|2015-05-29|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Rehabilitation Study in MS Patients|Multicenter, Open Label, Randomized and Parallel Group Phase IV Pilot Study Evaluating the Effectiveness of Functional Rehabilitation Protocol in RRMS Patients Treated With Betaferon®|Terminated||Phase 4|4|Actual|Bayer|Due to the very low number of patients enrolled in the study, no statistical report was done. Study was early terminated.|2|||f||||f||||||||||2018-06-01 01:38:00.747743|2018-06-01 01:38:00.747743
NCT00780442|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals|D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals|Completed||Phase 2|28|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 01:38:01.122366|2018-06-01 01:38:01.122366
NCT00780429|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|June 2006||2006-06-30|October 2008|2008-10-31||||||||Observational|||Pharmacokinetics and Pharmacodynamics of MPA in Stable Renal Transplant Patients|Evaluation of Pharmacokinetic and Pharmacodynamic Parameters in Renal Transplant Patients Receiving Mycophenolic Acid and Stable for at Least 3 Months|Unknown status|Active, not recruiting||54|Actual|IRCCS Policlinico S. Matteo|||3||f||||f||||||||||2018-06-01 01:38:01.217628|2018-06-01 01:38:01.217628
NCT00780416|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2012-06-05||2014-04-16|2008-10-24|2008-10-27|Estimate|2012-07-16|2012-08-20|Estimate||||2014-04-16|2014-05-02|Estimate|November 2008||2008-11-30|April 2014|2014-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C|A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naïve Subjects With Genotype 1 Hepatitis C|Completed||Phase 3|189|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 01:38:01.303589|2018-06-01 01:38:01.303589
NCT00780403|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2010-02-17||2015-09-21|2008-10-23|2008-10-27|Estimate|2010-07-02|2010-07-30|Estimate||||2015-09-21|2015-09-22|Estimate|August 2005||2005-08-31|September 2015|2015-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)|A Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications|Completed||Phase 4|220|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:38:01.653707|2018-06-01 01:38:01.653707
NCT00780390|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2018-02-26|2008-10-24|2008-10-27|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2008||2008-01-31|February 2018|2018-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CRPS||Autonomic Dysfunction and Spinal Cord Stimulation in Complex Regional Pain Syndrome|Autonomic Dysfunction and Spinal Cord Stimulator in Complex Regional Pain Syndrome|Terminated||N/A|10|Actual|Vanderbilt University Medical Center||2||Lack of enrollment and discontinued funding|f||||f|f|f||||||||2018-06-01 01:38:01.883394|2018-06-01 01:38:01.883394
NCT00780377|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2017-03-16|2008-10-24|2008-10-27|Estimate|||||||2017-03-16|2017-03-20|Actual|October 2008|Actual|2008-10-31|March 2017|2017-03-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|P1A4D||Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients|The Effects of Cardiac Innervation on Intra-coronary t-PA Release|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||1||Unable to perform study due to unavailable drug, then unable to partner with cath lab|f||||t||||||||||2018-06-01 01:38:01.965594|2018-06-01 01:38:01.965594
NCT00780364|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2015-05-29|2008-10-24|2008-10-27|Estimate|||||||2015-05-29|2015-06-01|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|||Sour Taste and Cold Temperature in Dysphagia|Sour Taste and Cold Temperature Effects on Pharyngeal Transit Time After Ischemic Stroke:Anatomic and Functional Bases.|Terminated|||30|Actual|UPECLIN HC FM Botucatu Unesp|||||f||||f||||||||||2018-06-01 01:38:02.052781|2018-06-01 01:38:02.052781
NCT00780351|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2009-10-21|2008-10-24|2008-10-27|Estimate|||||||2009-10-21|2009-10-23|Estimate|October 2008||2008-10-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|||||Observational|||Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)|Pharmacokinetics and Dosing of Vancomycin in Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)|Completed|||15|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     serum~   "|||2018-06-01 01:38:02.123537|2018-06-01 01:38:02.123537
NCT00780338|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2014-11-04||2015-05-08|2008-10-24|2008-10-27|Estimate|2015-05-05|2015-05-07|Estimate||||2015-05-08|2015-06-01|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|January 2013|Actual|2013-01-31||Interventional|AGTO||Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes|Enhancing Prevention Capacity With Developmental Assets and Getting to Outcomes|Completed||Phase 2|376|Actual|RAND||2|||f||||f||||||||||2018-06-01 01:38:02.239517|2018-06-01 01:38:02.239517
NCT00780325|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2014-02-05|2008-10-24|2008-10-27|Estimate|||||||2014-02-05|2014-02-06|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition|A Single Center, Double-blind, Placebo-controlled Phase I Single-dose Cross-over Study in Healthy Subjects to Investigate the Inhibitory Effect of CG100649, Celecoxib, Naproxen, and Acetazolamide on the Activity of Cyclooxygenases (COX-1, COX-2) and Carbonic Anhydrases (CA-I, CA-II)|Terminated||Phase 1|26|Actual|University of Pennsylvania||6||"A total of three parts were planned for this study. The sponsor funded only Part 1, so that~   neither Part 2 nor Part 3 of this study has been conducted."|f||||f||||||||||2018-06-01 01:38:02.756167|2018-06-01 01:38:02.756167
NCT00780312|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2013-07-01|2008-10-24|2008-10-27|Estimate|||||||2013-07-01|2013-07-02|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|HOHF||Physiotherapy Treatment for Patients Suffering From Head and Neck Cancer|Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment|Completed||Phase 2|97|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:38:02.853055|2018-06-01 01:38:02.853055
NCT00780299|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2016-06-23|2008-10-24|2008-10-27|Estimate|||||||2016-06-23|2016-06-24|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|June 2016|Actual|2016-06-30||Interventional|Hyperdia||Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability in Post-resuscitation Shock|Hemodynamic Efficiency of an Hemodialysis Treatment With High Permeability (HDHP) During the Early Period of Post-resuscitation Shock|Active, not recruiting||Phase 3|38|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:38:02.976506|2018-06-01 01:38:02.976506
NCT00780286|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2015-04-14|2008-10-24|2008-10-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:38:03.066938|2018-06-01 01:38:03.066938
NCT00780273|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|2014-03-17||2014-08-18|2008-10-24|2008-10-27|Estimate|2014-08-18|2014-08-19|Estimate||||2014-08-18|2014-08-19|Estimate|September 2008||2008-09-30|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Success Rate of Immediately Loaded Implants With Platform Switched Design Placed in Anterior Part of Mandible and Restored With Fixed Prostheses|Success Rate of Immediately Loaded Implants With Platform Switched Design Placed in the Anterior Part of the Mandible and Restored With Fixed Prostheses: a Randomized, Split-mouth, Masked, Prospective, Open, Comparison, Monocenter Trial|Completed||Phase 4|19|Actual|Dentsply International||2|||f||||f||||||||||2018-06-01 01:38:03.11395|2018-06-01 01:38:03.11395
NCT00780260|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2013-12-10|2008-10-24|2008-10-27|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Case Management Alternatives for African American Women at High Risk for HIV|Case Management Alternatives for African American Women at High Risk for HIV|Completed||Phase 3|562|Actual|Nova Southeastern University||2|||f||||f||||||||||2018-06-01 01:38:03.341811|2018-06-01 01:38:03.341811
NCT00780247|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|Alaska/Hawaii||Environmental Influences on Vitamin D Status|Environmental Influences on Vitamin D Status|Completed|||50|Actual|Creighton University|||2||f||||f||||||||||2018-06-01 01:38:03.435475|2018-06-01 01:38:03.435475
NCT00780234|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2016-09-30|2008-10-24|2008-10-27|Estimate|||||||2016-09-30|2016-10-03|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|June 2016|Actual|2016-06-30||Interventional|||Pioglitazone for Lung Cancer Chemoprevention|Pioglitazone for Lung Cancer Chemoprevention|Active, not recruiting||Phase 2|391|Anticipated|VA Office of Research and Development||2|||f||||t||||||||No||2018-06-01 01:38:03.5251|2018-06-01 01:38:03.5251
NCT00780221|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Observational|CRP-Han||C-Reactive Protein (CRP) Gene Variants and Coronary Artery Disease in a Chinese Han Population|CRP Gene Variants and Coronary Artery Disease in a Chinese Han Population|Unknown status|Recruiting||1000|Anticipated|Fudan University|||2||f||||t||||||Samples With DNA|"~     Blood sample will be examined and DNA variants be analyzed.~   "|||2018-06-01 01:38:03.622322|2018-06-01 01:38:03.622322
NCT00780208|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2009-08-14|2008-10-24|2008-10-27|Estimate|||||||2009-08-14|2009-08-17|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||Evaluating the Methylphenidate Patch to Treat Former Stimulant Users With ADHD|The Evaluation of the Safety and Efficacy of the Methylphenidate Patch in Former Stimulant Users With ADHD|Completed||N/A|20|Anticipated|Medical University of South Carolina||1|||f||||f||||||||||2018-06-01 01:38:03.689558|2018-06-01 01:38:03.689558
NCT00780195|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2014-12-10|2008-10-24|2008-10-27|Estimate|||||||2014-12-10|2014-12-11|Estimate|July 1998||1998-07-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|November 2000|Actual|2000-11-30||Interventional|||Metabolic Adaptations to Diabetes in African Americans|Metabolic Adaptations to Diabetes|Completed||N/A|16|Actual|Vanderbilt University||4|||f||||f||||||||||2018-06-01 01:38:03.86651|2018-06-01 01:38:03.86651
NCT00780182|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2010-02-01|2008-10-24|2008-10-27|Estimate|||||||2010-02-01|2010-02-02|Estimate|October 2008||2008-10-31|February 2010|2010-02-28|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers|An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability|Completed||Phase 1|24|Anticipated|Chimerix||1|||f||||t||||||||||2018-06-01 01:38:03.944413|2018-06-01 01:38:03.944413
NCT00780169|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2013-05-09|2008-10-23|2008-10-27|Estimate|||||||2013-05-09|2013-05-13|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Interventional|||Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer|A Phase I Study of Sorafenib (Nexavar®) in Combination With FOLFIRI as First Line Therapy for Metastatic Colorectal Cancer|Completed||Phase 1|16|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-06-01 01:38:04.014677|2018-06-01 01:38:04.014677
NCT00780156|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2013-09-27|2008-10-24|2008-10-27|Estimate|||||||2013-09-27|2013-09-30|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|ITALIC||The ITALIC Study: Is There A LIfe for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel|The ITALIC Study Is There A LIfe for DES After Discontinuation of Clopidogrel : The ITALIC Study|Terminated|||1235|Actual|French Cardiology Society||||"No more information will be given. No consequences on security and treatment of patients:~   standard therapy is already performed for all patients."|f||||t||||||||||2018-06-01 01:38:04.100607|2018-06-01 01:38:04.100607
NCT00780143|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2014-10-27|2008-10-24|2008-10-27|Estimate|||||||2014-10-27|2014-10-28|Estimate|November 2007||2007-11-30|November 2013|2013-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia|Phase I/II Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia|Terminated||Phase 1/Phase 2|35|Anticipated|PharmaMar||1||Poor recruitment|f||||f||||||||||2018-06-01 01:38:04.159775|2018-06-01 01:38:04.159775
NCT00780130|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-27|2008-10-23|2008-10-27|Estimate|||||||2008-10-27|2008-10-28|Estimate|May 2008||2008-05-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||SPARQ and Core Proprioception|The Relationship of Core Stability to Core Proprioception|Completed|||20|Actual|Logan College of Chiropractic|||1||f||||f||||||||||2018-06-01 01:38:04.233126|2018-06-01 01:38:04.233126
NCT00780117|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2012-07-25|2008-10-24|2008-10-27|Estimate|||||||2012-07-25|2012-07-26|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Observational|Currarino||Characterization of At-risk Population for Pre-sacral Tumor in CURRARINO Syndrome|Characterization of At-risk Population and Prognosis Factors for SACRO-coccygeal Teratoma in CURRARINO Syndrome. A Clinical, Molecular and Pathological Study.|Completed|||57|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Pathological tumoral tissue analysis after surgical removal · Annual serum alpha-foeto~     protein level monitoring~   "|||2018-06-01 01:38:04.295398|2018-06-01 01:38:04.295398
NCT00780104|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2016-06-07|2008-10-24|2008-10-27|Estimate|||||||2016-06-07|2016-06-08|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|UPCC 02407||Sirolimus in Combination With MEC in High Risk Myeloid Leukemias|A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias|Completed||Phase 1|15|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 01:38:04.360149|2018-06-01 01:38:04.360149
NCT00780091|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2010-08-11|2008-10-24|2008-10-27|Estimate|||||||2010-08-11|2010-08-12|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|OPTIMON||Optimisation of Monitoring for Clinical Research Studies|Evaluation of Efficacy and Cost of Two Monitoring Strategies for Public Clinical Research - OPTIMON: Optimisation of Monitoring for Clinical Research Studies|Completed|||1800|Anticipated|University Hospital, Bordeaux|||2||f||||t||||||||||2018-06-01 01:38:04.433201|2018-06-01 01:38:04.433201
NCT00780078|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2017-01-03|2008-10-24|2008-10-27|Estimate|||||||2017-01-03|2017-01-04|Estimate|October 2008||2008-10-31|December 2016|2016-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|EVAKIN||Clinical Evaluation of Swallowing Disorders as a Predictor of Extubation Failure|Clinical Evaluation by Physical Therapist of Swallowing Disorders as a Predictor of Extubation Failure in Patients Intubated Orotracheally for Over 6 Days|Completed|||160|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||||||2018-06-01 01:38:04.511611|2018-06-01 01:38:04.511611
NCT00780065|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-24|2008-10-24|2008-10-27|Estimate|||||||2008-10-24|2008-10-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:38:04.581916|2018-06-01 01:38:04.581916
NCT00780052|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-24|||2016-09-23|2008-10-24|2008-10-27|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2002||2002-09-30|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|UPCC 04701||Infusional C-myb ASODN in Advanced Hematologic Malignancies|Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies|Completed||Phase 1|13|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 01:38:04.629248|2018-06-01 01:38:04.629248
NCT00780039|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2017-05-12|2008-10-23|2008-10-24|Estimate|||||||2017-05-12|2017-05-15|Actual|October 1, 2003|Actual|2003-10-01|May 2017|2017-05-31|September 6, 2007|Actual|2007-09-06|September 6, 2007|Actual|2007-09-06||Interventional|||A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)|Phase II, Open-Label, Study of CAELYX and Carboplatin Intermediate Platinum-Sensitive (6-12 Months Treatment-free Interval) Relapsed Epithelial Ovarian Cancer.|Completed||Phase 2|58|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:38:04.697847|2018-06-01 01:38:04.697847
NCT00780026|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2017-11-03||2017-11-03|2008-10-22|2008-10-24|Estimate|2017-11-03|2017-12-06|Actual||||2017-11-03|2017-12-06|Actual|July 2008||2008-07-31|November 2017|2017-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Intraoperative Glucose Control in Liver Transplant|Effect Of Intraoperative Strict Glycemic Control During Liver Transplantation On Postoperative Morbidity And Mortality|Completed||Phase 4|100|Actual|University of Michigan||2|||f||||f|t|||||||||2018-06-01 01:38:04.773429|2018-06-01 01:38:04.773429
NCT00780013|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|May 2002||2002-05-31|October 2008|2008-10-31|June 2002|Actual|2002-06-30|May 2002|Actual|2002-05-31||Interventional|||Bioequivalence Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fed Conditions|Crossover Bioavailability Study on Metformin Formulations Comparing Metformin Hydrochloride Liquid 500 mg/5mL of Ranbaxy Laboratories With GlucophageA® 1000 mg Tablets of Bristol-Myers Squibb in Healthy, Adult, Male and Female Volunteers Under Fed Conditions, Following a 1000 mg Dose|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:05.289248|2018-06-01 01:38:05.289248
NCT00780000|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23||2010-09-10|2015-10-12|2008-10-23|2008-10-24|Estimate||||2010-09-10|2010-09-14|Estimate|2015-10-12|2015-11-04|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer|Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer|Terminated||Phase 2|4|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:38:05.370596|2018-06-01 01:38:05.370596
NCT00779987|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-12-02|2008-10-22|2008-10-24|Estimate|||||||2008-12-02|2008-12-03|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Autologous Serum Efficacy Study in Patients With Severe Dry Eye|Autologous Serum Efficacy Study in Patients With Severe Dry Eye|Completed||Phase 2|12|Actual|University of Chile||2|||f||||t||||||||||2018-06-01 01:38:05.44688|2018-06-01 01:38:05.44688
NCT00779974|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-02-25|2008-10-22|2008-10-24|Estimate|||||||2015-02-25|2015-02-27|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Electromyography Evaluation of Subscapularis Function After Total Shoulder Arthroplasty|Electromyography Evaluation of Subscapularis Function After Total Shoulder|Completed|||32|Actual|Milton S. Hershey Medical Center|||1||f||||f||||||||||2018-06-01 01:38:05.517649|2018-06-01 01:38:05.517649
NCT00779961|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|April 2008||2008-04-30|October 2008|2008-10-31|April 2013|Anticipated|2013-04-30|April 2011|Anticipated|2011-04-30||Interventional|||An Investigation for the Optimal Timing of a Cleft Palate Repair|An Investigation for the Optimal Timing of a Cleft Palate Repair|Unknown status|Recruiting|Early Phase 1|320|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 01:38:05.584071|2018-06-01 01:38:05.584071
NCT00779948|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2013-08-05|2008-10-23|2008-10-24|Estimate|||||||2013-08-05|2013-08-07|Estimate|December 2008||2008-12-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|January 2012|Actual|2012-01-31||Observational|DIFINE||Dynamic Internal Fixation of Femoral Neck Fractures|Dynamic Internal Fixation of Femoral Neck Fractures|Completed|||171|Actual|Aesculap AG|||2||f||||f||||||||||2018-06-01 01:38:05.659981|2018-06-01 01:38:05.659981
NCT00779935|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2017-05-10|2008-10-23|2008-10-24|Estimate|||||||2017-05-10|2017-05-11|Actual|October 1, 2004|Actual|2004-10-01|May 2017|2017-05-31|February 1, 2007|Actual|2007-02-01|October 1, 2005|Actual|2005-10-01||Interventional|||Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)|Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study|Completed||Phase 4|44|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:38:05.724295|2018-06-01 01:38:05.724295
NCT00779922|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2016-10-10|2008-10-23|2008-10-24|Estimate|||||||2016-10-10|2016-10-11|Estimate|November 2008||2008-11-30|October 2016|2016-10-31||||September 2012|Actual|2012-09-30||Interventional|||Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function||Completed||Phase 2|39|Actual|Poitiers University Hospital||1|||f||||f||||||||||2018-06-01 01:38:05.776911|2018-06-01 01:38:05.776911
NCT00779909|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2017-05-26||2017-08-30|2008-10-22|2008-10-24|Estimate|2017-08-30|2017-10-02|Actual||||2017-08-30|2017-10-02|Actual|December 2008||2008-12-31|August 2017|2017-08-31|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Interventional|||Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model|Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model|Completed||Early Phase 1|35|Actual|Boston University|There were recruitment delays due to the potential seasonal impact on vitamin D levels from the sun and the research center was relocated. Both resulted in lower enrollment during the funded time frame than originally projected.|4|||f||||f|t|f||||||No||2018-06-01 01:38:05.847861|2018-06-01 01:38:05.847861
NCT00779896|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-24|Estimate|||||||2008-10-22|2008-10-24|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study|Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|McGill University|||||f||||f||||||||||2018-06-01 01:38:06.54218|2018-06-01 01:38:06.54218
NCT00779883|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)|A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)|Completed||Phase 1|9|Actual|Memgen, LLC|||||f||||t||||||||||2018-06-01 01:38:06.626143|2018-06-01 01:38:06.626143
NCT00779870|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-03-25|2008-10-23|2008-10-24|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Airway Smooth Muscle and Asthma Severity|Evaluating the Role of Oxidant/Anti-oxidant Balance and the Relationship of Asthma Severity on Airway Smooth Muscle Proliferation, Migration and Cytokine Release.|Completed|||52|Actual|Imperial College London|||4||f||||f||||||Samples With DNA|"~     endobronchial biopsies and cultured airway smooth muscle cells~   "|||2018-06-01 01:38:06.737522|2018-06-01 01:38:06.737522
NCT00779857|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2013-02-11||2013-05-31|2008-10-23|2008-10-24|Estimate|2013-05-31|2013-06-04|Estimate||||2013-05-31|2013-06-04|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2009|Actual|2009-10-31||Interventional|EXCLUDE|70 patients treated with AtriClip LAA Exclusion System|AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery|Exclusion of the Left Atrial Appendage With the AtriClip LAA Exclusion Device in Patients Undergoing Concomitant Cardiac Surgery|Completed||Phase 2|70|Actual|AtriCure, Inc.||1|||f||||t||||||||||2018-06-01 01:38:06.839843|2018-06-01 01:38:06.839843
NCT00779844|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2016-09-22|2008-10-23|2008-10-24|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|LoopObese||Anesthesic Propofol and Remifentanil Requirements in Obese Patients|Intravenous Anesthesia in Obese Patients: Propofol and Remifentanil Requirements|Terminated||Phase 4|63|Actual|Hopital Foch||2||difficulty in recruiting|f||||f||||||||||2018-06-01 01:38:07.093623|2018-06-01 01:38:07.093623
NCT00779831|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|June 2004||2004-06-30|October 2008|2008-10-31|December 2004|Actual|2004-12-31|June 2004|Actual|2004-06-30||Interventional|||Bioequivalence Study on Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions|Comparative, Randomized, Single Dose, 2 Way Crossover Bioavailability Study of Ranbaxy and Warner - Lambert (Sudafed ® 12 Hour) 120 mg Pseudoephedrine Hydrochloride Extended - Release Tablets in Healthy Adult Volunteers Under Fasting Conditions.|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:07.185539|2018-06-01 01:38:07.185539
NCT00779818|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Electrical Acupuncture and Laser Therapy for Low Back Pain|Electrical Acupuncture and Laser Therapy for Low Back Pain|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 01:38:07.264464|2018-06-01 01:38:07.264464
NCT00779805|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|June 2004||2004-06-30|October 2008|2008-10-31|October 2004|Actual|2004-10-31|June 2004|Actual|2004-06-30||Interventional|||Bioequivalence Study of Pseudoephedrine HCl 120 mg ER Tablets Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Pseudoephedrine Hydrochloride Formulations Comparing Pseudoephedrine Hydrochloride 120 mg ER Tablets of Ranbaxy Laboratories With Sudafed 120 mg ER Tablets of Pfizer Consumer Health Care in Healthy, Adult, Human Subjects Under Fed Conditions.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:07.335926|2018-06-01 01:38:07.335926
NCT00779792|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|WA+TR_1||Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation|Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation|Unknown status|Active, not recruiting|Phase 4|36|Actual|Odense University Hospital|||||f||||t||||||||||2018-06-01 01:38:07.407813|2018-06-01 01:38:07.407813
NCT00779779|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2010-06-29||2010-11-24|2008-10-23|2008-10-24|Estimate|2010-06-29|2010-07-30|Estimate||||2010-11-24|2010-12-15|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants|Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.|Completed||Phase 4|522|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:38:07.505042|2018-06-01 01:38:07.505042
NCT00779766|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2012-04-12||2016-09-08|2008-10-23|2008-10-24|Estimate|2012-04-12|2012-05-10|Estimate||||2016-09-08|2016-10-25|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|September 2011|Actual|2011-09-30||Interventional|||Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects|Efficacy, Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects|Completed||Phase 3|6081|Actual|GlaxoSmithKline|At the time of the event-triggered analysis at Month 24, some safety results remain blinded and are not presented here since the study is still ongoing. These results will be updated once they become available.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:38:07.799411|2018-06-01 01:38:07.799411
NCT00779753|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2013-08-01|2008-10-23|2008-10-24|Estimate|||||||2013-08-01|2013-08-05|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Determination of Lysine Requirement in the Parenterally Fed Neonate|Determination of Lysine Requirement in the Parenterally Fed Neonate|Completed||N/A|6|Actual|The Hospital for Sick Children||1|||f||||t||||||||||2018-06-01 01:38:10.767828|2018-06-01 01:38:10.767828
NCT00779740|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2017-03-24|2008-10-23|2008-10-24|Estimate|||||||2017-03-24|2017-03-28|Actual|February 1, 2005|Actual|2005-02-01|March 2017|2017-03-31|April 1, 2005|Actual|2005-04-01|April 1, 2005|Actual|2005-04-01||Interventional|||Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)|Clinical Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray|Completed||Phase 3|102|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:38:10.916472|2018-06-01 01:38:10.916472
NCT00779727|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|October 1999||1999-10-31|September 2008|2008-09-30|June 2004||2004-06-30|||||Interventional|||Post-Cesarean Wound Drainage is Not Necessary in Women at Increased Risk of Hemorrhage||Terminated||Phase 4|||University of Zurich|||||f||||||||||||||2018-06-01 01:38:10.988801|2018-06-01 01:38:10.988801
NCT00779714|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-24|Estimate|||||||2008-10-22|2008-10-24|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Interventional|ChemoSensMM||Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC|Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma|Unknown status|Recruiting|Phase 3|360|Anticipated|University of Wuerzburg||2|||f||||t||||||||||2018-06-01 01:38:11.045268|2018-06-01 01:38:11.045268
NCT00779701|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2015-05-22||2017-02-08|2008-10-23|2008-10-24|Estimate|2015-05-22|2015-06-09|Estimate||||2017-02-08|2017-03-16|Actual|March 2007||2007-03-31|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation|Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation|Completed||Phase 4|27|Actual|Temple University||1|||f||||f||||||||No||2018-06-01 01:38:11.196971|2018-06-01 01:38:11.196971
NCT00779688|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2011-02-09|2008-10-23|2008-10-24|Estimate|||||||2011-02-09|2011-02-10|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|October 2010|Actual|2010-10-31|September 2009|Actual|2009-09-30||Observational|||A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers|Endoscopic Retrograde CholangioPancreatography Endomicroscopy Registry Outcomes Database|Completed|||130|Actual|Mauna Kea Technologies|||||f||||f||||||||||2018-06-01 01:38:11.331245|2018-06-01 01:38:11.331245
NCT00779675|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2012-09-27||2015-10-30|2008-10-23|2008-10-24|Estimate|2012-09-27|2012-10-29|Estimate||||2015-10-30|2015-11-02|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Observational|REALITY||Assessment of Long-Term Infliximab for Psoriasis (P05319)|Real-World Assessment of Long-Term Infliximab Therapy for Psoriasis|Completed|||660|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:38:11.42026|2018-06-01 01:38:11.42026
NCT00779662|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|February 2008||2008-02-29|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||The Prevalence of Rheumatic Heart Disease in School Children in Fiji|The Prevalence of Rheumatic Heart Disease in School Children in Fiji|Unknown status|Active, not recruiting||2000|Anticipated|Queensland Institute of Medical Research|||||f||||||||||||||2018-06-01 01:38:11.838491|2018-06-01 01:38:11.838491
NCT00779649|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2009-10-29|2008-10-23|2008-10-24|Estimate|||||||2009-10-29|2009-11-02|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|LUSTER||MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial|MoviPrep® Versus HalfLytely® for Colon Cleansing: An Investigator-blinded, Randomized Trial.|Completed||Phase 4|220|Anticipated|Research Associates of New York, LLP||2|||f||||f||||||||||2018-06-01 01:38:11.887256|2018-06-01 01:38:11.887256
NCT00779636|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2017-03-21|2008-10-23|2008-10-24|Estimate|||||||2017-03-21|2017-03-23|Actual|July 1, 2003|Actual|2003-07-01|March 2017|2017-03-31|November 1, 2004|Actual|2004-11-01|November 1, 2004|Actual|2004-11-01||Interventional|||Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)|Efficacy and Safety of Desloratadine 10 mg Daily vs. Placebo in Subjects With Allergic Airway Disease During the Pollen Season|Completed||Phase 4|506|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:38:11.95596|2018-06-01 01:38:11.95596
NCT00779623|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:38:12.025902|2018-06-01 01:38:12.025902
NCT00779610|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||The Effects of Passive and Active Vibration Therapy on Grip Strength and Myoelectric Activity|The Effects of Passive and Active Vibration Therapy on Grip Strength and Myoelectric Activity|Unknown status|Recruiting|Phase 1|40|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 01:38:12.077515|2018-06-01 01:38:12.077515
NCT00779597|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2010-08-26|2008-10-23|2008-10-24|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Improvement of Self Management for Oncologic Patients With Pain|Improvement of Self Management Skills for Oncologic Patients With Pain Through a Trans Institutional Nursing Intervention: a Cluster Randomized Multi Center Study|Completed||N/A|208|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-06-01 01:38:12.144387|2018-06-01 01:38:12.144387
NCT00779584|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2017-02-02||2017-04-05|2008-10-22|2008-10-24|Estimate|2017-04-05|2017-06-20|Actual||||2017-04-05|2017-06-20|Actual|October 2008||2008-10-31|April 2017|2017-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)|A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|45|Actual|Merck Sharp & Dohme Corp.||9|||f||||f||||||||||2018-06-01 01:38:12.260119|2018-06-01 01:38:12.260119
NCT00779571|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2014-10-09|2008-10-22|2008-10-24|Estimate|||||||2014-10-09|2014-10-10|Estimate|October 2008||2008-10-31|October 2014|2014-10-31|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|FEMIN||The Female Health Dietary Intervention Study|Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study|Completed||N/A|61|Actual|The Hospital of Vestfold||2|||f||||f||||||||||2018-06-01 01:38:14.232499|2018-06-01 01:38:14.232499
NCT00779558|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2015-05-28||2015-06-10|2008-10-23|2008-10-24|Estimate|2015-06-10|2015-06-12|Estimate||||2015-06-10|2015-06-12|Estimate|November 2005||2005-11-30|June 2015|2015-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Heparin and the Reduction of Thrombosis (HART) Trial|Heparin and Catheter-related Thrombosis in Neonates and Infants Following Cardiac Surgery|Completed||N/A|90|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 01:38:14.29785|2018-06-01 01:38:14.29785
NCT00779545|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2017-05-10|2008-10-23|2008-10-24|Estimate|||||||2017-05-10|2017-05-11|Actual|April 8, 2004|Actual|2004-04-08|May 2017|2017-05-31|August 6, 2004|Actual|2004-08-06|August 6, 2004|Actual|2004-08-06||Interventional|||A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)|Dose Finding and Dose Regimen Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis|Completed||Phase 2|455|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:38:14.705067|2018-06-01 01:38:14.705067
NCT00779532|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2015-09-23|2008-10-23|2008-10-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)|A Randomized, Double-blind, Placebo and Positive Controlled, Parallel Group Trial to Investigate the Effect of Multiple Doses of NOMAC-E2 on QT/QTc Interval in Healthy Women|Completed||Phase 1|189|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:38:14.807406|2018-06-01 01:38:14.807406
NCT00779519|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23||2010-07-15|2011-06-08|2008-10-23|2008-10-24|Estimate||||2010-07-20|2010-07-22|Estimate|2011-06-08|2011-06-27|Estimate|February 2009||2009-02-28|June 2011|2011-06-30||||December 2009|Actual|2009-12-31||Interventional|||Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss|A Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study to Assess Safety and Tolerability of TTP435 in Obese (Class 1-2) Subjects Over 8 Weeks of Treatment|Completed||Phase 2|100|Actual|vTv Therapeutics||2|||f||||f||||||||||2018-06-01 01:38:14.889514|2018-06-01 01:38:14.889514
NCT00779506|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2010-05-20||2011-10-19|2008-10-23|2008-10-24|Estimate|2011-10-19|2011-11-23|Estimate||||2011-10-19|2011-11-23|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|QUENCH||Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)|A 8-week, Multi-Centre, Open-label, Non-comparative, Phase IV Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) With Daily Dose 400mg-800mg in the Treatment of Acute Schizophrenic Patients|Completed||Phase 4|96|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:38:15.009109|2018-06-01 01:38:15.009109
NCT00779493|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-03-10|2008-10-23|2008-10-24|Estimate|||||||2015-03-10|2015-03-11|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|CuTIBS||Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial|Study Title: Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial|Completed||Phase 4|17|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 01:38:15.307618|2018-06-01 01:38:15.307618
NCT00779480|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2016-06-14|2008-10-22|2008-10-24|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)|Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia|Terminated||Phase 1|14|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1||Failure to demonstrate a tolerable dose that had potential for efficacy.|f||||t||||||||||2018-06-01 01:38:15.388308|2018-06-01 01:38:15.388308
NCT00779467|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2016-10-27||2017-11-06|2008-10-22|2008-10-24|Estimate|2017-02-23|2017-04-10|Actual||||2017-11-06|2017-11-08|Actual|October 2008||2008-10-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Epidural Neostigmine for Labor Pain|Epidural Neostigmine Dose Response for the Treatment of Labor Pain|Completed||N/A|200|Actual|Wake Forest University Health Sciences||4|||f||||t||||||||||2018-06-01 01:38:15.487267|2018-06-01 01:38:15.487267
NCT00779454|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2017-03-09|2008-10-22|2008-10-24|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2008||2008-09-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma|Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma|Completed||Phase 2|72|Actual|Vejle Hospital||2|||f||||t||||||||||2018-06-01 01:38:15.896725|2018-06-01 01:38:15.896725
NCT00779441|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|August 2005||2005-08-31|October 2008|2008-10-31|November 2005|Actual|2005-11-30|September 2005|Actual|2005-09-30||Interventional|||Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions|An Open Label, Relative Bioavailability Study of 10 mg Zolpidem Tablet Under Non-Fasting Conditions|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:15.978979|2018-06-01 01:38:15.978979
NCT00779428|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23||2015-09-23|2015-09-23|2008-10-23|2008-10-24|Estimate||||2010-02-27|2010-03-02|Estimate|2015-09-23|2015-10-12|Estimate|July 2006||2006-07-31|September 2015|2015-09-30|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin|Phase 2 Clinical Trial of Tanespimycin in Patients With Advanced Malignancies After Failure of Previous Anti-cancer Therapy Regimens Who Have Participated on a Prior Protocol Investigating Tanespimycin|Completed||Phase 2|6|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:38:16.053859|2018-06-01 01:38:16.053859
NCT00779415|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-02-26|2008-10-22|2008-10-24|Estimate|||||||2015-02-26|2015-02-27|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Long Term Prognosis of MRI Diagnosed Partial Thickness Tears of the Rotator Cuff|Long Term Prognosis of MRI Diagnosed Partial Thickness Tears of the Rotator Cuff|Completed|||10|Actual|Milton S. Hershey Medical Center|||1||f||||f||||||||||2018-06-01 01:38:16.144774|2018-06-01 01:38:16.144774
NCT00779402|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2017-04-10||2017-06-29|2008-10-23|2008-10-24|Estimate|2017-06-29|2018-01-29|Actual||||2017-06-29|2018-01-29|Actual|October 2001||2001-10-31|June 2017|2017-06-30|May 2015|Actual|2015-05-31|August 2006|Actual|2006-08-31||Interventional|PROTECT||PROvenge Treatment and Early Cancer Treatment|Autologous PAP-loaded Dendritic Cell Vaccine (Sipuleucel-T, APC8015, Provenge®) in Patients With Non-metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: a Randomized, Controlled, Double-blind Trial|Completed||Phase 3|176|Actual|Dendreon||2|||f||||f|t|f||||||Undecided||2018-06-01 01:38:16.257065|2018-06-01 01:38:16.257065
NCT00779389|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2016-01-12|2008-10-23|2008-10-24|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family|Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers|Completed||Phase 1|58|Actual|University of Pittsburgh||4|||f||||f||||||||||2018-06-01 01:38:17.0104|2018-06-01 01:38:17.0104
NCT00779376|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|February 2005||2005-02-28|October 2008|2008-10-31|April 2005|Actual|2005-04-30|March 2005|Actual|2005-03-31||Interventional|||Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and GlaxoSmithKline (Retrovir ® ) 300 mg Zidovudine Tablets in Healthy Adult Volunteers Under Fed Conditions|Completed||N/A|68|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:17.097039|2018-06-01 01:38:17.097039
NCT00779363|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2016-09-21|2008-10-23|2008-10-24|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2004||2004-06-30|April 2013|2013-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients|A Prospective Clinical Trial of the TANTALUS System In Treatment of Obese to Morbidly Obese Patients|Completed||N/A|14|Actual|MetaCure (USA), Inc.||1|||f||||t||||||||||2018-06-01 01:38:17.150652|2018-06-01 01:38:17.150652
NCT00779350|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|August 2005||2005-08-31|October 2008|2008-10-31|October 2005|Actual|2005-10-31|August 2005|Actual|2005-08-31||Interventional|||Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Pfizer Formulations of Sertraline 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions.|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:17.216532|2018-06-01 01:38:17.216532
NCT00779337|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2012-05-21|2008-10-22|2008-10-24|Estimate|||||||2012-05-21|2012-05-22|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|EPL||Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas|Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas|Completed||Phase 1|8|Actual|Queensland Institute of Medical Research||1|||f||||f||||||||||2018-06-01 01:38:17.274057|2018-06-01 01:38:17.274057
NCT00779324|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23||2014-07-27|2014-08-11|2008-10-23|2008-10-24|Estimate||||2014-08-11|2014-09-12|Estimate|2014-08-11|2014-09-12|Estimate|August 2009||2009-08-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study|A Multi-Center, Parallel-Group, Randomized, Double-Blind, Placebo-Controlled Trial of Amantadine Hydrochloride in the Treatment of Chronic Traumatic Brain Injury Irritability and Aggression: A Replication Study|Completed||N/A|168|Actual|Carolinas Healthcare System||2|||f||||t||||||||||2018-06-01 01:38:17.336628|2018-06-01 01:38:17.336628
NCT00778986|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2010-09-29|2008-10-23|2008-10-24|Estimate|||||||2010-09-29|2010-09-30|Estimate|March 2009||2009-03-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effects of Remote Patient Monitoring on Heart Failure Management|Effects of Remote Patient Monitoring on Heart Failure Management: A Randomized Controlled Trial|Completed||N/A|100|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:38:22.349309|2018-06-01 01:38:22.349309
NCT00779311|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2011-09-09||2011-10-31|2008-10-23|2008-10-24|Estimate|2011-09-13|2011-10-26|Estimate||||2011-10-31|2011-11-02|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer|A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer|Terminated||Phase 1|8|Actual|Accelerated Community Oncology Research Network|Early termination due to the MTD determined to be Dose Level 1, leading to a small number of subjects analyzed.|1||Dose limiting toxicity at the lowest planned dose level.|f||||f||||||||||2018-06-01 01:38:17.445329|2018-06-01 01:38:17.445329
NCT00779298|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate||||October 2008|2008-10-31||||||||Observational|||Effect of Commercial Rye Whole-Meal Bread on Postprandial Blood Glucose and Gastric Emptying in Healthy Subjects|Effect of Commercial Rye Whole-Meal Bread on Postprandial Blood Glucose and Gastric Emptying in Healthy Subjects|Completed|||||Lund University Hospital|||1||f||||t||||||||||2018-06-01 01:38:19.043263|2018-06-01 01:38:19.043263
NCT00779285|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2010-02-11||2015-06-18|2008-10-23|2008-10-24|Estimate|2010-02-11|2010-03-10|Estimate||||2015-06-18|2015-07-14|Estimate|February 2006||2006-02-28|June 2015|2015-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)|Cardiac Safety Profile of Caelyx Therapy in Anthracyclin Pretreated Metastatic Breast Cancer Patients.|Terminated||Phase 4|1|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:38:19.098997|2018-06-01 01:38:19.098997
NCT00779272|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases|Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases|Completed|||184|Anticipated|University of Zurich|||2||f||||f||||||||||2018-06-01 01:38:19.22813|2018-06-01 01:38:19.22813
NCT00779259|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2009-05-27||2009-10-20|2008-10-23|2008-10-24|Estimate|2009-05-27|2009-07-17|Estimate||||2009-10-20|2009-10-28|Estimate|August 2007||2007-08-31|October 2009|2009-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline|A Pharmacokinetic Drug-Drug Interaction Study to Evaluate the Effect of Steady-State Quinine Sulfate on the Pharmacokinetics of Single-Dose Theophylline in Healthy Adult Males|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||3|||f||||f||||||||||2018-06-01 01:38:19.314115|2018-06-01 01:38:19.314115
NCT00779246|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2011-08-01||2018-04-16|2008-10-23|2008-10-24|Estimate|2012-02-16|2012-03-21|Estimate||||2018-04-16|2018-05-15|Actual|June 2008||2008-06-30|April 2018|2018-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Cost-Effectiveness Study Comparing Chlorhexidine Bathing With Active Surveillance Cultures to Prevent Methicillin-resistant Staphylococcus Aureus & Other Hospital Infections|Cost-Effectiveness of Chlorhexidine Bathing vs. Active Surveillance Cultures to Prevent Acquisition of Methicillin-resistant Staphylococcus Aureus and Other Hospital-Acquired Infections: A Pilot Study|Completed||N/A|1518|Actual|Christiana Care Health Services|"Single-center, single-unit study limits generalizability~MRSA acquisition rates lower during both intervention groups than expected, resulting in under-powering of study~Baseline rate of acquisition of colonization unknown"|2|||f||||f||||||||||2018-06-01 01:38:19.763987|2018-06-01 01:38:19.763987
NCT00779233|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|October 2004|Actual|2004-10-31|September 2004|Actual|2004-09-30||Interventional|||Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and GlaxoSmithKline Formulation of Zidovudine Tablets 300 mg in Healthy Adult Volunteers Under Fasting Conditions.|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:20.025222|2018-06-01 01:38:20.025222
NCT00779220|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2015-03-24|2008-10-23|2008-10-24|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2010|Actual|2010-02-28||Interventional|||A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy|Terminated||Phase 2|152|Actual|Chugai Pharmaceutical||4|||f||||f||||||||||2018-06-01 01:38:20.116933|2018-06-01 01:38:20.116933
NCT00779207|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|November 2006||2006-11-30|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Weight Loss and Exercise on Liver and Muscle Fat in Obese Elderly|Effect of Weight Loss and Exercise on Intrahepatic and Intramyocellular Fat in Obese Older Adults|Completed||Phase 3|20|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:38:20.229217|2018-06-01 01:38:20.229217
NCT00779194|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2016-10-12|2008-10-23|2008-10-24|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2008||2008-10-31|October 2016|2016-10-31||||December 2015|Actual|2015-12-31||Interventional|Rapamune||Prospective Study of Rapamycin for the Treatment of SLE|Prospective Study of Rapamycin for the Treatment of SLE|Completed||Phase 2|40|Actual|State University of New York - Upstate Medical University||4|||f||||t||||||||||2018-06-01 01:38:20.317712|2018-06-01 01:38:20.317712
NCT00779181|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-12-16|2008-10-23|2008-10-24|Estimate|||||||2008-12-16|2008-12-17|Estimate|October 2008||2008-10-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension|A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension|Completed||Phase 2|80|Actual|Addrenex Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 01:38:20.395996|2018-06-01 01:38:20.395996
NCT00779168|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2018-05-07|2008-10-23|2008-10-24|Estimate|||||||2018-05-07|2018-05-09|Actual|September 26, 2008||2008-09-26|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy|A Phase Ib Trial of Mushroom Powder in Biochemically Recurrent Prostate Cancer|Active, not recruiting||Phase 1|36|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:38:20.472754|2018-06-01 01:38:20.472754
NCT00779155|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2011-05-13||2011-07-07|2008-10-23|2008-10-24|Estimate|2011-06-09|2011-07-08|Estimate||||2011-07-07|2011-07-12|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of Magnetic Fields for Treatment of Parkinson's Disease|A Double-blind, Sham-stimulation Controlled Study of the Application of Magnetic Fields Using the Jacobson Resonator for the Treatment of Parkinson's Disease.|Completed||Phase 2|12|Actual|pico-tesla Magnetic Therapies, LLC||2|||f||||t||||||||||2018-06-01 01:38:20.555458|2018-06-01 01:38:20.555458
NCT00779142|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2014-05-27||2017-12-26|2008-10-22|2008-10-24|Estimate|2014-05-27|2014-06-30|Estimate||||2017-12-26|2018-01-23|Actual|September 2011||2011-09-30|November 2017|2017-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Patients with Recalcitrant Diabetic Macular Edema|Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies|Evaluation of the Utility of Intravitreal Methotrexate in Patients With Recalcitrant Diabetic Macular Edema in an Open Label, Nonrandomized, Uncontrolled, Interventional Pilot Trial|Terminated||N/A|2|Actual|Wake Forest University Health Sciences||1||recent research indicates Lucentis to be an effictive treatment|f||||f||||||||||2018-06-01 01:38:20.732257|2018-06-01 01:38:20.732257
NCT00779129|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2015-09-29|2008-10-23|2008-10-24|Estimate|||||||2015-09-29|2015-09-30|Estimate|March 2003||2003-03-31|September 2015|2015-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)|Phase II Trial of Caelyx and Cyclophosphamide in Metastatic Breast Cancer|Completed||Phase 2|70|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:38:20.892177|2018-06-01 01:38:20.892177
NCT00779116|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2010-02-17||2015-04-06|2008-10-23|2008-10-24|Estimate|2010-06-03|2010-07-05|Estimate||||2015-04-06|2015-04-28|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)|A Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications|Completed||Phase 4|217|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:38:21.061997|2018-06-01 01:38:21.061997
NCT00779103|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-06-08|2008-10-23|2008-10-24|Estimate|||||||2015-06-08|2015-06-10|Estimate|September 2004||2004-09-30|June 2015|2015-06-30|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Interventional|||Histrelin Subcutaneous Implant in Children With Central Precocious Puberty|Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty|Completed||Phase 3|36|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:38:21.226423|2018-06-01 01:38:21.226423
NCT00779090|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-24|Estimate|||||||2008-10-22|2008-10-24|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||Functional Residual Capacity (FRC) Guided Alveolar Recruitment Strategy|The Influence of a Functional Residual Capacity Guided Alveolar Recruitment Strategy After Open Endotracheal Suctioning on Oxygenation and Regional Ventilation|Completed||Phase 4|59|Actual|University of Luebeck||4|||f||||f||||||||||2018-06-01 01:38:21.289026|2018-06-01 01:38:21.289026
NCT00779077|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2009-04-22|2008-10-23|2008-10-24|Estimate|||||||2009-04-22|2009-04-24|Estimate|January 2009||2009-01-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Cystic Fibrosis (CF) Flow Rates Study|An Open, Observational, Non-Interventional Study of Inspiratory Flow Rates and Volumes in Subjects With Cystic Fibrosis Inhaling Via a Spirometer With the High Resistance RS01 Dry Powder Inhaler Device in Series|Completed|||25|Actual|Pharmaxis|||1||f||||f||||||||||2018-06-01 01:38:21.352718|2018-06-01 01:38:21.352718
NCT00779064|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2014-12-23|2008-10-23|2008-10-24|Estimate|||||||2014-12-23|2014-12-25|Estimate|July 2004||2004-07-31|December 2014|2014-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status|BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status|Completed||Phase 2|36|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:38:21.405614|2018-06-01 01:38:21.405614
NCT00779051|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|August 2005||2005-08-31|October 2008|2008-10-31|October 2005|Actual|2005-10-31|September 2005|Actual|2005-09-30||Interventional|||Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions|An Open Label, Relative Bioavailability Study of 10 mg Zolpidem Tablet Under Fasting Conditions|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:21.48531|2018-06-01 01:38:21.48531
NCT00779038|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2013-01-10||2014-04-22|2008-10-23|2008-10-24|Estimate|2013-01-10|2013-02-13|Estimate||||2014-04-22|2014-05-05|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy Study of Fentanyl Iontophoretic Transdermal System (ITS) for Management of Moderate to Severe Acute Pain in Participants Who Have Undergone Elective Spine or Orthopedic Surgery|Clinical Outcome Study in Postoperative Pain Management to Demonstrate the Efficacy and Safety of IONSYS (Fentanyl ITS Iontophoretic Transdermal System) in Daily Clinical Practice and to Assess Its Convenience (IPAC)|Terminated||Phase 4|13|Actual|Janssen Cilag N.V./S.A.|No efficacy results were reported because the study was prematurely terminated, following the worldwide voluntary withdrawal of Fentanyl Iontophoretic Transdermal System (IONSYS) by Janssen-Cilag.|1||Stopped prematurely in 2008 due to IONSYS withdrawal off the market globally|f||||f||||||||||2018-06-01 01:38:21.566304|2018-06-01 01:38:21.566304
NCT00779025|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2011-03-30||2011-10-04|2008-10-23|2008-10-24|Estimate|2011-05-02|2011-05-05|Estimate||||2011-10-04|2011-10-07|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use Conditions|A Safety Evaluation of Personal Lubricant Product When Used by Couples in Home-use Conditions|Completed||N/A|82|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 01:38:21.779682|2018-06-01 01:38:21.779682
NCT00779012|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2017-05-10|2008-10-23|2008-10-24|Estimate|||||||2017-05-10|2017-05-11|Actual|October 1, 2004|Actual|2004-10-01|May 2017|2017-05-31|June 1, 2007|Actual|2007-06-01|June 1, 2007|Actual|2007-06-01||Interventional|||A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)|Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis|Completed||Phase 4|42|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:38:22.002708|2018-06-01 01:38:22.002708
NCT00778999|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2009-06-23||2017-04-06|2008-10-23|2008-10-24|Estimate|2009-06-23|2009-08-12|Estimate||||2017-04-06|2017-05-12|Actual|October 1, 2006|Actual|2006-10-01|April 2017|2017-04-30|July 24, 2008|Actual|2008-07-24|July 24, 2008|Actual|2008-07-24||Interventional|Xpect||Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)|A Randomized, Open-Label Clinical Trial to Identify Predictive Factors for Controlled Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH in GnRH Antagonist Regimen With or Without Oral Contraceptive Scheduling|Completed||Phase 4|442|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:38:22.094635|2018-06-01 01:38:22.094635
NCT00778973|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2008-10-23|2008-10-23|2008-10-24|Estimate|||||||2008-10-23|2008-10-24|Estimate|August 2005||2005-08-31|October 2008|2008-10-31|October 2005|Actual|2005-10-31|September 2005|Actual|2005-09-30||Interventional|||Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Pfizer Formulation of Sertraline 100 mg Tablets in Healthy Adult Volunteers Under Fed Conditions.|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:22.42903|2018-06-01 01:38:22.42903
NCT00778960|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-07-09|2008-10-22|2008-10-24|Estimate|||||||2015-07-09|2015-07-13|Estimate|January 2009||2009-01-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.|Mechanistic Pathways of Mindfulness Meditation in Post-traumatic Stress Disorder.|Completed||N/A|102|Actual|Oregon Health and Science University||4|||f||||f||||||||||2018-06-01 01:38:22.503933|2018-06-01 01:38:22.503933
NCT00778947|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2016-05-16|2008-10-22|2008-10-24|Estimate|||||||2016-05-16|2016-05-17|Estimate|November 2008||2008-11-30|October 2008|2008-10-31||||September 2009|Anticipated|2009-09-30||Interventional|HARMONIC001||Single Centre Study to Compare Harmonic Scalpel to Conventional Diathermy in Free Tissue Transfer Breast Reconstruction|Comparison of Harmonic Scalpel to Conventional Diathermy in Free Tissue Transfer for Breast Reconstruction|Withdrawn||N/A|0|Actual|St Andrew's Centre for Plastic Surgery||2||Study abandoned and was never started|f||||||||||||||2018-06-01 01:38:22.571687|2018-06-01 01:38:22.571687
NCT00778934|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|||2011-10-04|2008-10-23|2008-10-24|Estimate|||||||2011-10-04|2011-10-06|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||In-Home Use Study to Evaluate Use of an Intimate Health Product in Females|A Single-blind, Multi-center, In-home Use Study to Evaluate Sexual Enhancement Effects of Product PD-F-5394 in Females|Completed||N/A|79|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 01:38:22.646343|2018-06-01 01:38:22.646343
NCT00778921|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2010-12-13||2016-09-20|2008-10-23|2008-10-24|Estimate|2011-02-25|2011-03-23|Estimate||||2016-09-20|2016-10-27|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone|A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy|Completed||Phase 3|847|Actual|Novartis||3|||f||||f||||||||||2018-06-01 01:38:22.713138|2018-06-01 01:38:22.713138
NCT00778908|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2012-08-17|2008-10-22|2008-10-24|Estimate|||||||2012-08-17|2012-08-21|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma|Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial|Completed||Phase 2/Phase 3|120|Actual|Guangxi Medical University||2|||f||||t||||||||||2018-06-01 01:38:23.070014|2018-06-01 01:38:23.070014
NCT00778895|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2012-12-19|2011-11-16|2016-10-07|2008-10-23|2008-10-24|Estimate|2013-07-03|2013-07-09|Estimate|2011-11-16|2011-11-21|Estimate|2016-10-07|2016-11-21|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control|Clinical Study in Children, 6 Months to 3 Years of Age, to Assess the Immunogenicity and Safety of Two Dose Levels of Thimerosal-free Fluviral® Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control|Completed||Phase 2|390|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:38:23.172285|2018-06-01 01:38:23.172285
NCT00778882|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2016-02-10|2008-10-23|2008-10-24|Estimate|||||||2016-02-10|2016-02-11|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|October 2022|Anticipated|2022-10-31|October 2008|Actual|2008-10-31||Interventional|||Gene Therapy for Chronic Granulomatous Disease in Korea|An Open-label, Uncontrolled, Single Center, Phase I/II Trial to Assess the Safety and Efficacy of Autologous Hematopoietic Stem Cells Transduced With MT-gp91 Retroviral Vector in gp91 Defective Chronic Granulomatous Disease Patients|Active, not recruiting||Phase 1/Phase 2|2|Actual|ViroMed Co., Ltd.||1|||f||||f||||||||||2018-06-01 01:38:23.850079|2018-06-01 01:38:23.850079
NCT00778869|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-23|2010-02-17||2015-06-08|2008-10-23|2008-10-24|Estimate|2010-03-26|2010-04-09|Estimate||||2015-06-08|2015-07-03|Estimate|August 2005||2005-08-31|June 2015|2015-06-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)|Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls|Completed||Phase 4|10|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:38:23.959989|2018-06-01 01:38:23.959989
NCT00778856|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2015-03-26|2008-10-23|2008-10-24|Estimate|||||||2015-03-26|2015-03-27|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|VCA-01||Hand Transplantation for the Reconstruction of Below the Elbow Amputations|Hand Transplantation for the Reconstruction of Below the Elbow Amputations|Terminated||N/A|19|Actual|Emory University||1||Principal Investigator relocated to another institution|f||||t||||||||||2018-06-01 01:38:24.0877|2018-06-01 01:38:24.0877
NCT00778843|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2012-05-02|2008-10-22|2008-10-23|Estimate|||||||2012-05-02|2012-05-04|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C|Efficacy and Safety of Viusid as Antioxidant and Immunomodulator Nutritional Supplement in Patients With Chronic Hepatitis C and Non-responders to Standard Antiviral Therapy. A Randomized and Double Blind Controlled Trial|Completed||Phase 3|60|Actual|Catalysis SL||2|||f||||f||||||||||2018-06-01 01:38:24.156905|2018-06-01 01:38:24.156905
NCT00778830|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2015-04-28||2015-04-28|2008-10-22|2008-10-23|Estimate|2015-04-28|2015-05-14|Estimate||||2015-04-28|2015-05-14|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|APEC|Intention-to-treat (ITT) population consisted of all the enrolled subjects who received at least one dose of study treatment.|Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)|An Asia Pacific Non-randomized, Open-label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)|Completed||Phase 1/Phase 2|289|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 01:38:24.26823|2018-06-01 01:38:24.26823
NCT00778817|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2013-08-30||2014-03-28|2008-10-22|2008-10-23|Estimate|2013-08-30|2013-11-06|Estimate||||2014-03-28|2014-04-29|Estimate|December 2008||2008-12-31|December 2013|2013-12-31|March 2014|Actual|2014-03-31|May 2012|Actual|2012-05-31||Interventional|||IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery|Multi-Institutional Phase II Study of IMC-A12, a Recombinant Human IgG1 Monoclonal Antibody Directed at the Type I Insulin-Like Growth Factor Receptor IGF1R, in Adrenocortical Carcinoma: IMC-A12 With Mitotane vs Mitotane Alone|Terminated||Phase 2|20|Actual|National Cancer Institute (NCI)|After the treatment of 20 subjects, a protocol defined interim analysis was completed for safety and futility. The trial was permanently halted based on futility concerns.|1||The trial was permanently halted due to futility concerns.|f||||t||||||||||2018-06-01 01:38:24.832736|2018-06-01 01:38:24.832736
NCT00778804|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|July 2004||2004-07-31|October 2008|2008-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Preventing Heart Disease in Underserved Patients|Preventing Heart Disease in Underserved Patients|Completed||N/A|465|Actual|Temple University||2|||f||||t||||||||||2018-06-01 01:38:25.102654|2018-06-01 01:38:25.102654
NCT00778791|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|April 2004||2004-04-30|October 2008|2008-10-31|July 2004|Actual|2004-07-31|April 2004|Actual|2004-04-30||Interventional|||Bioequivalence Study of Metformin HCl 750 mg XR Under Fasting Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Metformin HC1 750 mg Extended-Release Tablets (Ranbaxy) With That of Glucophage® XR 750 mg Tablets (Bristol Myers Squibb) in Healthy, Adult, Subjects Under Fasting Conditions.|Completed||N/A|60|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:25.268342|2018-06-01 01:38:25.268342
NCT00778778|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|May 2005||2005-05-31|October 2008|2008-10-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions|Blinded, Comparative, Randomized, Single-Dose, Three Way Crossover Bioavailability Study of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg Cefprozil Tablets in Healthy Adult Volunteers Under Fasting Conditions.|Completed||N/A|27|Actual|Ranbaxy Inc.||3|||f||||t||||||||||2018-06-01 01:38:25.355948|2018-06-01 01:38:25.355948
NCT00778765|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|September 2002||2002-09-30|October 2008|2008-10-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Bioequivalence Study of Gabapentin 400 mg Capsules Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Parke-Davis (Neurontin®) 400 mg Gabapentin Capsules in Healthy Adult Volunteers Under Fed Conditions|Completed||N/A|24|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:25.443734|2018-06-01 01:38:25.443734
NCT00778752|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-05-12|2008-10-22|2008-10-23|Estimate|||||||2015-05-12|2015-05-13|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma|Dose-finding Study of Lenalidomide as Maintenance Therapy in Multiple Myeloma After Allogeneic Stem Cell Transplantation|Completed||Phase 1/Phase 2|24|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-06-01 01:38:25.531004|2018-06-01 01:38:25.531004
NCT00778739|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|June 2005||2005-06-30|October 2008|2008-10-31|July 2005|Actual|2005-07-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fed Conditions|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Cefprozil 250 mg/5 mL Oral Suspension Versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) in Normal Healthy Non-Smoking Male and Female Subjects|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:25.609601|2018-06-01 01:38:25.609601
NCT00778726|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|December 2004|Actual|2004-12-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets in Healthy Volunteers|Completed||N/A|42|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:25.682199|2018-06-01 01:38:25.682199
NCT00778713|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|March 2003||2003-03-31|October 2008|2008-10-31|April 2003|Actual|2003-04-30|March 2003|Actual|2003-03-31||Interventional|||Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions|A Bioequivalence Study of Test and Reference Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Non-Fasting Conditions|Completed||N/A|33|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:25.748149|2018-06-01 01:38:25.748149
NCT00778700|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21||2010-06-17|2018-01-15|2008-10-21|2008-10-23|Estimate||||2010-06-17|2010-06-22|Estimate|2018-01-15|2018-01-17|Actual|October 2008||2008-10-31|January 2018|2018-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis|A Double-Blind, Randomized, Vehicle-Controlled Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis|Completed||Phase 2|199|Actual|Incyte Corporation||4|||f||||f||||||||||2018-06-01 01:38:25.819008|2018-06-01 01:38:25.819008
NCT00778687|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2013-12-22|2008-10-22|2008-10-23|Estimate|||||||2013-12-22|2013-12-24|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Heart Rate Variability Change After Liver Transplantation|Effects of Liver Transplantation on the Heart Rate Variability in Patients With End-Stage Liver Disease|Completed|||30|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:38:25.937695|2018-06-01 01:38:25.937695
NCT00778674|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2004||2004-10-31|October 2008|2008-10-31|December 2004|Actual|2004-12-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets in Healthy Volunteers|Completed||N/A|30|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:25.987827|2018-06-01 01:38:25.987827
NCT00778661|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg Amoxicillin (as the Trihydrate)/57 mg Clavulanic Acid (as the Potassium Salt) Chewable Tablets in Healthy Adult Volunteers Following Administration of a Two Tablet Dose Under Fasting Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:26.058994|2018-06-01 01:38:26.058994
NCT00778648|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2010-09-09||2010-09-09|2008-10-21|2008-10-23|Estimate|2010-09-09|2010-10-05|Estimate||||2010-09-09|2010-10-05|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms|Effectiveness of an Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms|Completed||N/A|543|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:38:26.125731|2018-06-01 01:38:26.125731
NCT00778622|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2013-06-14||2013-08-19|2008-10-22|2008-10-23|Estimate|2013-06-14|2013-08-20|Estimate||||2013-08-19|2013-08-23|Estimate|November 2009||2009-11-30|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||Baseline population consisted of: all participants enrolled into one of three body weight arms, normal, overweight or obese, based on body mass index at screening; and who were assigned to treatment with Glucophage XR. This population was used for analysis of demographics.|Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients|The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes|Completed||Phase 4|371|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:38:26.381811|2018-06-01 01:38:26.381811
NCT00778609|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2016-01-13|2008-10-22|2008-10-23|Estimate|||||||2016-01-13|2016-01-14|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Microgynon on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment|Completed||Phase 3|449|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:38:27.292422|2018-06-01 01:38:27.292422
NCT00778596|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2012-05-24|2008-10-22|2008-10-23|Estimate|||||||2012-05-24|2012-05-25|Estimate|February 2009||2009-02-28|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Prednisolone Priming Study in Patients With Chronic Hepatitis B|A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B|Unknown status|Recruiting|Phase 4|160|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-06-01 01:38:27.448607|2018-06-01 01:38:27.448607
NCT00778583|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|September 2003||2003-09-30|October 2008|2008-10-31|December 2003|Actual|2003-12-31|October 2003|Actual|2003-10-31||Interventional|||Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions|An Open Label, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Nitrofurantoin Formulations Comparing Nitrofurantoin 100 mg Capsules of Ranbaxy Laboratories With Macrobid 100 mg Capsules in Healthy, Adult, Human Subjects Under Fed Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:27.532573|2018-06-01 01:38:27.532573
NCT00778570|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2014-11-28|2008-10-21|2008-10-23|Estimate|||||||2014-11-28|2014-12-02|Estimate|February 2007||2007-02-28|November 2014|2014-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Advanced Surface Ablation (ASA) vs Laser-Assisted In Situ Keratomileusis (LASIK)|A Combined Retrospective and Prospective Chart Review Analysis of Visual Outcomes Following Excimer Laser Vision Correction|Recruiting|||4000|Anticipated|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-06-01 01:38:27.605007|2018-06-01 01:38:27.605007
NCT00778557|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|June 2005||2005-06-30|October 2008|2008-10-31|July 2005|Actual|2005-07-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions|A Three-Way Crossover, Blinded, Single-Dose, Fasting, Bioequivalence Study of One Test Formulation of Cefprozil 250 mg/5 mL Oral Suspension Versus Two Reference Formulation of Cefzil TM Powder for Oral Suspension (250 mg/5 mL) in Normal Healthy Non-Smoking Male and Female Subjects|Completed||N/A|35|Actual|Ranbaxy Inc.||3|||f||||t||||||||||2018-06-01 01:38:27.673801|2018-06-01 01:38:27.673801
NCT00778544|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg-42.9 mg/ 5 mL Oral Suspension Under Fed Conditions|Randomized, Open-Label, 2 - Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg- 42.9 mg/ 5 mL Oral Suspension and Augmentin ES-600 (Reference) Following a 600 mg- 42.9 mg Dose in Healthy Subjects Under Fed Conditions.|Completed||N/A|48|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:27.752931|2018-06-01 01:38:27.752931
NCT00778531|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2014-11-18|2008-10-22|2008-10-23|Estimate|||||||2014-11-18|2014-11-19|Estimate|September 2007||2007-09-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Protocol for the Post-approval Study of ArteFill® for Correction of Nasolabial Folds|Protocol for the Post-approval Study of ArteFill® for Correction of Nasolabial Folds|Completed||Phase 4|1008|Actual|Suneva Medical, Inc.||1|||f||||f||||||||||2018-06-01 01:38:27.820217|2018-06-01 01:38:27.820217
NCT00778518|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2009-10-09|2008-10-22|2008-10-23|Estimate|||||||2009-10-09|2009-10-12|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).|Phase IIb Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).|Completed||Phase 2|36|Anticipated|Ambrx, Inc.||3|||f||||f||||||||||2018-06-01 01:38:27.97558|2018-06-01 01:38:27.97558
NCT00778505|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2016-09-22|2008-10-22|2008-10-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|LoopPed||Use of Closed-loop Anesthesia in Pediatric Patients|Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison in Pediatric Patients Between Manual Perfusion and Automated Perfusion|Terminated||Phase 4|45|Actual|Hopital Foch||2||difficulty in recruiting|f||||f||||||||||2018-06-01 01:38:28.114422|2018-06-01 01:38:28.114422
NCT00778492|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|May 2008||2008-05-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|October 2008|Anticipated|2008-10-31||Observational|||Thrombelastogram in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery|Thrombelastogram and Predicting Microvascular Bleeding in Patients Receiving Antiplatelet Medication Undergoing Cardiac Surgery|Unknown status|Recruiting||60|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 01:38:28.218487|2018-06-01 01:38:28.218487
NCT00778479|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2015-03-19|2008-10-22|2008-10-23|Estimate|||||||2015-03-19|2015-03-24|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Evaluation of the Safety of Sepraspray in Open Abdominal Surgery|Evaluation of the Safety of Sepraspray in Open Abdominal Surgery|Terminated||N/A|155|Actual|Sanofi||2||Terminated by Sponsor: see details below|f||||t||||||||||2018-06-01 01:38:28.326913|2018-06-01 01:38:28.326913
NCT00778466|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|February 2006||2006-02-28|October 2008|2008-10-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Bristol Myers Squibb Formulations of Metformin 1000 mg Tablets in Healthy Adult Volunteers Under Fed Conditions|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:28.447356|2018-06-01 01:38:28.447356
NCT00778453|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-05|||2012-07-31|2008-10-21|2008-10-23|Estimate|||||||2012-07-31|2012-08-02|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Relative Effects and Predictive Models of Contemporary Upper Limb Training Programs in Stroke Patients|Relative Effects and Predictive Models of Contemporary Upper Limb Training Programs in Stroke Patients Delivered in Hospital-based and Home-based Settings|Completed||N/A|150|Actual|Chang Gung Memorial Hospital||6|||f||||f||||||||||2018-06-01 01:38:28.6034|2018-06-01 01:38:28.6034
NCT00778440|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2009-08-06|2008-10-22|2008-10-23|Estimate|||||||2009-08-06|2009-08-07|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Observational|LESIONAT||Risk Level of Suffering From Traffic Injury in Primary Health Care: LESIONAT Project|Risk Level of Suffering From Traffic Injury in Primary Health Care: LESIONAT Project|Unknown status|Enrolling by invitation||1540|Anticipated|Jordi Gol i Gurina Foundation|||||f||||t||||||||||2018-06-01 01:38:28.730826|2018-06-01 01:38:28.730826
NCT00778427|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|February 2006||2006-02-28|October 2008|2008-10-31|April 2006|Actual|2006-04-30|February 2006|Actual|2006-02-28||Interventional|||Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Bristol Myers Squibb Formulations of Metformin 1000 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:28.84546|2018-06-01 01:38:28.84546
NCT00778414|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions|Randomized, Open - Label, 2 - Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 600mg - 42.9 mg/ 5 mL Oral Suspension and Augmentin ES - 600 (Reference) Following a 600 mg - 42.9 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||N/A|48|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:28.942696|2018-06-01 01:38:28.942696
NCT00778401|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Fasting Condition|Completed||N/A|28|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:29.06535|2018-06-01 01:38:29.06535
NCT00778388|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2012-10-18|2008-10-22|2008-10-23|Estimate|||||||2012-10-18|2012-10-19|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers|Against Pseudomonas Aeruginosa in Healthy Volunteers|Completed||Phase 1|157|Actual|Valneva Austria GmbH||5|||f||||t||||||||||2018-06-01 01:38:29.162779|2018-06-01 01:38:29.162779
NCT00778375|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2016-01-28||2016-06-15|2008-10-21|2008-10-23|Estimate|2016-01-28|2016-02-26|Estimate||||2016-06-15|2016-07-14|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 2|122|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 01:38:29.329442|2018-06-01 01:38:29.329442
NCT00778362|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|January 2006||2006-01-31|October 2008|2008-10-31|December 2012|Anticipated|2012-12-31|October 2008|Anticipated|2008-10-31||Observational|||Splenic Function After Spleen-Preserving Distal Pancreatectomy With Excision of Splenic Artery and Vein|Splenic Function After Spleen-Preserving Distal Pancreatectomy With Excision of Splenic Artery and Vein|Unknown status|Active, not recruiting||40|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 01:38:29.639978|2018-06-01 01:38:29.639978
NCT00778349|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|April 2002||2002-04-30|October 2008|2008-10-31|July 2002|Actual|2002-07-31|May 2002|Actual|2002-05-31||Interventional|||A Comparitive Bioavailability Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fasting Conditions and After Low and High Fat Meal|A Randomized, Three-Treatment, Three-Period, Six-Sequence, Single-Dose, Crossover Pharmacokinetic Study on Metformin Hydrochloride Solution 100 mg/mL of Ranbaxy Laboratories Comparing the Pharmacokinetic Profile of Metformin Under Fasting Condition, After a Low Fat Meal and After a High Fat Meal in Healthy, Adult, Human Male Subjects.|Completed||N/A|34|Actual|Ranbaxy Inc.||3|||f||||t||||||||||2018-06-01 01:38:29.727632|2018-06-01 01:38:29.727632
NCT00778336|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2011-02-22||2014-10-08|2008-10-22|2008-10-23|Estimate|2011-03-28|2011-04-26|Estimate||||2014-10-08|2014-10-17|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Observational|||A Prospective Observational Registry of Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters|Peripheral Use of AngioJet Rheolytic Thrombectomy With Mid-Length Catheters|Completed|||452|Actual|Boston Scientific Corporation|Non randomized observational registry||4||f||||f||||||||||2018-06-01 01:38:29.831622|2018-06-01 01:38:29.831622
NCT00778323|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-09|||2011-02-24|2008-10-21|2008-10-23|Estimate|||||||2011-02-24|2011-02-25|Estimate|September 2007||2007-09-30|November 2008|2008-11-30|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional|||Clinical Trial of Remote Preconditioning in Patients Undergoing Cervical Decompression Surgery|Effects of Remote Ischemic Preconditioning on Biochemical Markers and Neurological Outcomes in Patients Undergoing Elective Cervical Decompression Surgery|Completed||Phase 1/Phase 2|51|Actual|Xijing Hospital||1|||f||||t||||||||||2018-06-01 01:38:30.223711|2018-06-01 01:38:30.223711
NCT00778310|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2012-04-26||2012-06-08|2008-10-22|2008-10-23|Estimate|2012-06-08|2012-07-13|Estimate||||2012-06-08|2012-07-13|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Neuroimaging of the Effects of Concerta in the Treatment of ADHD|Functional Neuroimaging of Acute Concerta Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Differences Across Development|Completed||Phase 4|76|Actual|The University of Texas Health Science Center at San Antonio|No typically developing control group compared to either the adult or child group.|2|||f||||f||||||||||2018-06-01 01:38:30.300778|2018-06-01 01:38:30.300778
NCT00778297|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2012-05-18|2008-10-22|2008-10-23|Estimate|||||||2012-05-18|2012-05-21|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine|Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine With 6 Mcg HA/Strain/Dos Antigen Content|Completed||N/A|234|Actual|Fluart Innovative Vaccine Ltd, Hungary||2|||f||||t||||||||||2018-06-01 01:38:30.525852|2018-06-01 01:38:30.525852
NCT00778284|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg Amoxicillin (as the Trihydrate)/57 mg Clavulanic Acid (as the Potassium Salt) Chewable Tablets in Healthy Adult Volunteers Following Administration of a Two Tablet Dose Under Fed Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:30.586578|2018-06-01 01:38:30.586578
NCT00778271|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|September 2002||2002-09-30|October 2008|2008-10-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Bioequivalence Study of Gabapentin 400 mg Capsules Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Park:-Davis (Neurontin®) 400 mg Gabapentin Capsules in Healthy Adult Volunteers Under Fasting Conditions|Completed||N/A|26|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:30.653104|2018-06-01 01:38:30.653104
NCT00778258|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2015-12-17||2016-03-29|2008-10-21|2008-10-23|Estimate|2016-03-29|2016-03-30|Estimate||||2016-03-29|2016-03-30|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All Enrolled|Study of Milk Allergy and Tolerance in Children|Dietary Intervention in Milk Allergy and Tolerance Development|Completed||Phase 2|170|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-06-01 01:38:30.786831|2018-06-01 01:38:30.786831
NCT00778245|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|May 2005||2005-05-31|October 2008|2008-10-31|October 2005|Actual|2005-10-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions|An Open - Label, Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg Cefprozil Tablets in Healthy Adult Volunteers Under Fed Conditions.|Completed||N/A|26|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:33.272819|2018-06-01 01:38:33.272819
NCT00778232|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions|A Relative Bioavailability Study of 800 mg Gabapentin Tablets Under Non-Fasting Conditions|Completed||N/A|22|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:33.35698|2018-06-01 01:38:33.35698
NCT00778219|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2009-12-14|2008-10-22|2008-10-23|Estimate|||||||2009-12-14|2009-12-15|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Comparison of Heart Rate Variability Among Tracheal Intubation Methods|Comparison of Autonomic Stimulation Among Different Tracheal Intubation Methods -- Using Non-invasive Heart Rate Variability Spectral Power as an Indicator|Completed|||60|Anticipated|National Taiwan University Hospital|||3||f||||t||||||||||2018-06-01 01:38:33.430964|2018-06-01 01:38:33.430964
NCT00778206|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2017-06-06|2008-10-22|2008-10-23|Estimate|||||||2017-06-06|2017-06-08|Actual|September 2008||2008-09-30|June 2017|2017-06-30|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Observational|PKUDOS||PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry|PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry|Recruiting|||3500|Anticipated|BioMarin Pharmaceutical|||2||f||||f||||||||||2018-06-01 01:38:33.518286|2018-06-01 01:38:33.518286
NCT00778193|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Lesions2||Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers|A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing|Completed||Phase 4|125|Actual|Research Associates of New York, LLP||5|||f||||f||||||||||2018-06-01 01:38:33.811936|2018-06-01 01:38:33.811936
NCT00778180|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2005||2005-10-31|October 2008|2008-10-31|November 2005|Actual|2005-11-30|October 2005|Actual|2005-10-31||Interventional|||Bioequivalence Study of Furosemide 80mg Tablets Under Fasting Conditions|A Study to Compare the Relative Bioavailability of Ranbaxy and Aventis Formulations of Furosemide 80 mg Tablets in Healthy Adult Volunteers Under Fasted Condition.|Completed||N/A|44|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:33.91161|2018-06-01 01:38:33.91161
NCT00778167|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2013-01-15||2014-05-06|2008-10-22|2008-10-23|Estimate|2013-03-11|2013-04-23|Estimate||||2014-05-06|2014-05-21|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase I/Randomized Phase II Study of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|18|Actual|National Cancer Institute (NCI)|Phase I of the study was completed but because of concerns about the achievable dose intensity at the maximum tolerated dose (MTD), the expansion into a randomized phase II study comparing full-dose erlotinib with the combination was cancelled.|2|||f||||||||||||||2018-06-01 01:38:34.025936|2018-06-01 01:38:34.025936
NCT00778154|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2013-06-03|2008-10-22|2008-10-23|Estimate|||||||2013-06-03|2013-06-05|Estimate|January 2004||2004-01-31|June 2013|2013-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate|A Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Long-Term Alendronate or Risedronate|Completed|||105|Actual|Warner Chilcott|||4||f||||f||||||Samples Without DNA|"~     bone biopsies~   "|||2018-06-01 01:38:34.395017|2018-06-01 01:38:34.395017
NCT00778141|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|April 2004||2004-04-30|October 2008|2008-10-31|June 2004|Actual|2004-06-30|April 2004|Actual|2004-04-30||Interventional|||Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions|A Relative Bioavailability Study of Metformin HCl 750 mg XR Tablets Under Non-Fasting Conditions.|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:34.466734|2018-06-01 01:38:34.466734
NCT00778128|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2010-09-03|2008-10-22|2008-10-23|Estimate|||||||2010-09-03|2010-09-06|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour|A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour|Completed||Phase 1|26|Actual|Clavis Pharma||2|||f||||f||||||||||2018-06-01 01:38:34.554366|2018-06-01 01:38:34.554366
NCT00778115|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|November 2004||2004-11-30|October 2008|2008-10-31|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions|A Relative Bioavailability Study of Loperamide HCl 2 mg and Simethicone 125 mg Tablets to Imodium® Advanced Caplets Under Fasting Condition|Completed||N/A|26|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:34.754147|2018-06-01 01:38:34.754147
NCT00778102|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|2015-07-10||2016-11-01|2008-10-22|2008-10-23|Estimate|2015-07-10|2015-08-07|Estimate||||2016-11-01|2016-11-02|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Intent-to-Treat (ITT) Population: All randomized participants. Participants were analyzed according to which treatment group they were randomized, regardless of the treatment actually received.|A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.|A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus Bevacizumab (OLIVIA)|Completed||Phase 2|80|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:38:34.899061|2018-06-01 01:38:34.899061
NCT00778089|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2010-03-19|2008-10-22|2008-10-23|Estimate|||||||2010-03-19|2010-03-23|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|September 2008|Anticipated|2008-09-30||Interventional|||Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing|Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing|Terminated||Phase 1|498|Actual|Suneva Medical, Inc.||||Closed incomplete due to Artes Medical Closing|f||||f||||||||||2018-06-01 01:38:35.905152|2018-06-01 01:38:35.905152
NCT00778076|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2009-03-31|2008-10-22|2008-10-23|Estimate|||||||2009-03-31|2009-04-01|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics|The Biomechanical Impact of Intra-Articular Hyaluronic Acid in Knee Osteoarthritis Patients: A Randomized, Double Blind, Placebo Controlled Study|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|University of Western Ontario, Canada||2|||f||||f||||||||||2018-06-01 01:38:35.967617|2018-06-01 01:38:35.967617
NCT00778063|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2013-03-14|2008-10-21|2008-10-23|Estimate|||||||2013-03-14|2013-03-15|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|PED-DEX||Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients|Intranasal Dexmedetomidine Decreases Emergence Delirium in Pediatric Patients After Sevoflurane Based General Anesthesia|Unknown status|Recruiting|N/A|80|Anticipated|Ochsner Health System||2|||f||||t||||||||||2018-06-01 01:38:36.059476|2018-06-01 01:38:36.059476
NCT00778050|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of 600 mg Amoxicillin Dispersible Tablets vs 400 mg/ 5 mL Amoxil ® for Oral Suspension Under Fasting Conditions.|Completed||N/A|26|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:36.149062|2018-06-01 01:38:36.149062
NCT00778037|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence Study of Cyclobenzaprine Hydrochloride 10 mg Tablets, USP Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study Comparing Cyclobenzaprine Hydrochloride 10 mg Tablet of Ohm Labs Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc USA.) With Flexeril® 10 mg Tablet (Containing Cyclobenzaprine Hydrochloride 10 mg) Manufactured by Merck & Co Inc., USA and Distributed by McNeil Consumer & Speciality Pharmaceuticals, in Healthy, Adult, Male, Human Subjects Under Fasting Condition.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:36.220449|2018-06-01 01:38:36.220449
NCT00778024|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2009-12-11|2008-10-22|2008-10-23|Estimate|||||||2009-12-11|2009-12-15|Estimate|August 2003||2003-08-31|December 2009|2009-12-31|December 2003|Actual|2003-12-31|October 2003|Actual|2003-10-31||Interventional|||Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions|The Objective of This Randomized, Single-dose, Two-way Evaluation is to Compare the Bioequivalence of a Test Fluoxetine HCL Formulation (Ranbaxy Laboratories Limited, Lot No. 6320101) to an Equivalent Oral Dose of the Commercially Available Fluoxetine HCL (Prozac®, Dista Products Company, Lot No 6RK57M) in a Test Population of 36 Adult Subjects Under Fasting Conditions.|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:36.300621|2018-06-01 01:38:36.300621
NCT00778011|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2012-06-27|2008-10-22|2008-10-23|Estimate|||||||2012-06-27|2012-06-28|Estimate|November 2005||2005-11-30|June 2012|2012-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Uncomplicated Nausea and Vomiting in the Emergency Department|Ondansetron 4 mg vs. 2 mg vs. Metoclopramide 10 mg for Nausea and Vomiting in the Emergency Department: A Randomized, Double-Blind Clinical Trial|Completed||Phase 4|137|Actual|WellSpan Health||3|||f||||f||||||||||2018-06-01 01:38:36.361014|2018-06-01 01:38:36.361014
NCT00777998|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2018-05-03|2008-10-22|2008-10-23|Estimate|||||||2018-05-03|2018-05-04|Actual|October 14, 2008|Actual|2008-10-14|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|April 17, 2018|Actual|2018-04-17||Interventional|||Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma|Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy With Thalidomide/ DLI for Patients With Multiple Myeloma (MM) and Age < _60 Years: A Phase II-study|Active, not recruiting||Phase 2|221|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-06-01 01:38:36.561468|2018-06-01 01:38:36.561468
NCT00777985|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2014-05-20|2008-10-22|2008-10-23|Estimate|||||||2014-05-20|2014-05-21|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|BOSAS||Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea|Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan|Completed||Phase 2|19|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 01:38:36.670678|2018-06-01 01:38:36.670678
NCT00777972|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-22|||2008-10-22|2008-10-22|2008-10-23|Estimate|||||||2008-10-22|2008-10-23|Estimate|March 2003||2003-03-31|October 2008|2008-10-31|April 2003|Actual|2003-04-30|March 2003|Actual|2003-03-31||Interventional|||Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions|A Bioequivalence Study of Test and Reference Fosinopril Sodium/ Hydrochlorothiazide 20/12.5 mg Tablets Under Fasting Conditions|Completed||N/A|34|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:36.767479|2018-06-01 01:38:36.767479
NCT00777959|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2015-08-18|2008-10-21|2008-10-22|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)|A Phase II Randomized, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus (Ridaforolimus) in Men With Asymptomatic, Metastatic Castrate-resistant Prostate Cancer|Completed||Phase 2|22|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 01:38:36.847295|2018-06-01 01:38:36.847295
NCT00777946|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2010-12-13||2011-06-30|2008-10-21|2008-10-22|Estimate|2011-05-13|2011-06-15|Estimate||||2011-06-30|2011-07-12|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone|A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy|Completed||Phase 3|818|Actual|Novartis||3|||f||||f||||||||||2018-06-01 01:38:37.008294|2018-06-01 01:38:37.008294
NCT00777933|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2011-04-21|2008-10-21|2008-10-22|Estimate|||||||2011-04-21|2011-04-22|Estimate|July 2000||2000-07-31|April 2011|2011-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation|Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation|Completed||N/A|131|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 01:38:37.417102|2018-06-01 01:38:37.417102
NCT00777920|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2018-05-03|2008-10-21|2008-10-22|Estimate|||||||2018-05-03|2018-05-07|Actual|November 2008|Actual|2008-11-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|ABS-LT||Study of Ambrisentan in Subjects With Pulmonary Hypertension|ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension|Active, not recruiting||Phase 3|300|Anticipated|Gilead Sciences||1|||f||||t||||||||||2018-06-01 01:38:37.49491|2018-06-01 01:38:37.49491
NCT00777907|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-08-05|2008-10-21|2008-10-22|Estimate|||||||2015-08-05|2015-08-07|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|COCOA||Complete Occlusion of Coilable Aneurysms|Complete Occlusion of Coilable Aneurysms|Completed||Phase 3|13|Actual|Chestnut Medical Technologies||2|||f||||f||||||||||2018-06-01 01:38:37.619545|2018-06-01 01:38:37.619545
NCT00777894|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2016-04-14|2008-10-21|2008-10-22|Estimate|||||||2016-04-14|2016-04-15|Estimate|November 2008||2008-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|External Beam Radiotherapy for Unresectable Hepatocellular Carcinoma. A Multicenter Phase I/II Trial.|Completed||Phase 1/Phase 2|18|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-06-01 01:38:37.710701|2018-06-01 01:38:37.710701
NCT00777868|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2012-06-20|2008-10-20|2008-10-22|Estimate|||||||2012-06-20|2012-06-22|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis||Completed||Phase 2|135|Actual|Dow Pharmaceutical Sciences||4|||f||||||||||||||2018-06-01 01:38:37.827857|2018-06-01 01:38:37.827857
NCT00777855|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2013-01-14||2013-05-08|2008-10-21|2008-10-22|Estimate|2013-05-08|2013-07-17|Estimate||||2013-05-08|2013-07-17|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.|The Effects of Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers.|Completed||N/A|10|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:38:37.939738|2018-06-01 01:38:37.939738
NCT00777842|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-12-29|2008-10-21|2008-10-22|Estimate|||||||2015-12-29|2015-12-31|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery|Silencing the c-Myc Gene Using Third Generation Antisense Restenosis Therapy|Terminated||N/A|19|Actual|Cook Group Incorporated||1||In this feasibility study device did not perform as well as expected.|f||||||||||||||2018-06-01 01:38:38.199539|2018-06-01 01:38:38.199539
NCT00777829|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-12-08|2008-10-20|2008-10-22|Estimate|||||||2015-12-08|2015-12-10|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Memory Consolidation in Pharmacologically Enhanced Naps|Understanding Memory Consolidation by Studying Pharmacologically Enhanced Naps.|Completed||N/A|30|Actual|University of California, San Diego||5|||f||||t||||||||||2018-06-01 01:38:38.278143|2018-06-01 01:38:38.278143
NCT00777816|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2015-12-28|2008-10-20|2008-10-22|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 2009||2009-02-28|December 2015|2015-12-31||||October 2014|Actual|2014-10-31||Interventional|||Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis|A Blinded, Placebo-controlled, Study of the Safety and Pharmacokinetics of XOMA 052 Administered to Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis|Suspended||Phase 2|18|Anticipated|XOMA (US) LLC||2|||f||||f||||||||||2018-06-01 01:38:38.380411|2018-06-01 01:38:38.380411
NCT00777803|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2012-01-23||2012-03-07|2008-10-21|2008-10-22|Estimate|2012-01-23|2012-02-10|Estimate||||2012-03-07|2012-03-08|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|Head2Head||NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines|A Prospective, Multicenter, Randomized, Rater- and Subject-Blind, Parallel Group Trial to Investigate the Non-Inferiority of NT 201, Free of Complexing Proteins, in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines|Completed||Phase 3|381|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 01:38:38.470746|2018-06-01 01:38:38.470746
NCT00777790|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2008-12-02||2014-01-21|2008-10-21|2008-10-22|Estimate|2009-02-18|2009-03-19|Estimate||||2014-01-21|2014-02-14|Estimate|February 2004||2004-02-29|January 2014|2014-01-31|April 2005|Actual|2005-04-30|April 2004|Actual|2004-04-30||Interventional|||Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents|Antibody Responses to a Booster Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, Menactra® in Adolescents Who Previously Received Menomune® or Menactra®|Completed||Phase 2|241|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 01:38:39.025307|2018-06-01 01:38:39.025307
NCT00777777|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-21|2008-10-21|2008-10-22|Estimate|||||||2008-10-21|2008-10-22|Estimate|August 2008||2008-08-31|October 2008|2008-10-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|eSVS||The eSVS (TM) Mesh External Saphenous Vein Support Trial|The eSVS(TM)Mesh External Saphenous Vein Support Trial|Unknown status|Recruiting|Phase 2|120|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-06-01 01:38:39.441742|2018-06-01 01:38:39.441742
NCT00777764|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2010-08-19||2017-05-16|2008-10-21|2008-10-22|Estimate|2011-01-18|2011-02-14|Estimate||||2017-05-16|2017-06-14|Actual|August 2008|Actual|2008-08-31|May 2017|2017-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)|The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)|Completed||Phase 4|60|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 01:38:39.543602|2018-06-01 01:38:39.543602
NCT00777751|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2018-01-08|2008-10-21|2008-10-22|Estimate|||||||2018-01-08|2018-01-10|Actual|October 6, 2008|Actual|2008-10-06|January 2018|2018-01-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Observational|||Radiation Therapy and Cardiac Enzymes|Radiation Therapy and Cardiac Biomarkers|Completed|||30|Actual|M.D. Anderson Cancer Center|||||f||||f|f|f||||||||2018-06-01 01:38:39.780206|2018-06-01 01:38:39.780206
NCT00777738|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2013-01-17|2008-10-21|2008-10-22|Estimate|||||||2013-01-17|2013-01-18|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|WM2||Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia|A Phase IIA Trial Testing the Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia|Completed||Phase 2|34|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:38:39.84217|2018-06-01 01:38:39.84217
NCT00777725|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2011-07-20|2008-10-21|2008-10-22|Estimate|||||||2011-07-20|2011-07-21|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Observational|||Non-invasive Assessment of Liver Stiffness/Fibrosis by Transient Elastography (Fibroscan) in Patients With Left and/or Right Sided Heart Failure|Non-invasive Assessment of Liver Stiffness/Fibrosis by Transient Elastography (Fibroscan) in Patients With Left and/or Right Sided Heart Failure|Completed|||125|Actual|Monash University|||4||f||||f||||||Samples Without DNA|"~     Blood samples for fibrotic biomarkers.~   "|||2018-06-01 01:38:39.91824|2018-06-01 01:38:39.91824
NCT00777712|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2018-03-16|2008-10-21|2008-10-22|Estimate|||||||2018-03-16|2018-03-20|Actual|September 2008||2008-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Observational|WoundVac||Mechanisms Underlying Impaired Diabetic Wound Healing|Mechanisms Underlying Impaired Diabetic Wound Healing|Recruiting|||300|Anticipated|Ohio State University|||6||f||||f||||||Samples With DNA|"~     Blood, Wound Vac Sponge.~   "|||2018-06-01 01:38:39.997989|2018-06-01 01:38:39.997989
NCT00777699|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2012-02-02|2008-10-20|2008-10-22|Estimate|||||||2012-02-02|2012-02-03|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of XL765 in Combination With Erlotinib in Subjects With Solid Tumors|Completed||Phase 1|80|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:38:40.118279|2018-06-01 01:38:40.118279
NCT00777686|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2012-03-29|2008-10-21|2008-10-22|Estimate|||||||2012-03-29|2012-03-30|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Measuring Non-Enhancing Glioblastoma Progression|Quantifying Progression of Non-Enhancing Tumor in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Agents|Completed|||7|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:38:40.196784|2018-06-01 01:38:40.196784
NCT00777673|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2013-01-03|2008-10-21|2008-10-22|Estimate|||||||2013-01-03|2013-01-04|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|October 2013|Anticipated|2013-10-31|January 2013|Anticipated|2013-01-31||Interventional|||Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.|Neoadjuvant Weekly Nab-paclitaxel (Abraxane®) Plus Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently To Chemotherapy For Palpable And Operable Triple Negative Invasive Breast Cancer|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|University of Tennessee Cancer Institute|||||f||||t||||||||||2018-06-01 01:38:40.277717|2018-06-01 01:38:40.277717
NCT00777647|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2017-03-28|2008-10-21|2008-10-22|Estimate|||||||2017-03-28|2017-03-29|Actual|May 2008||2008-05-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Carbonated Soft Drinks on the Body Weight|Effect of Carbonated Soft Drinks on Body Weight, Fat Distribution and Metabolic Risk Factors|Completed||N/A|60|Actual|Aarhus University Hospital||4|||f||||f||||||||||2018-06-01 01:38:40.356678|2018-06-01 01:38:40.356678
NCT00777634|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2012-03-09||2012-04-23|2008-10-20|2008-10-22|Estimate|2012-04-23|2012-05-29|Estimate||||2012-04-23|2012-05-29|Estimate|June 2005||2005-06-30|April 2012|2012-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Follow-Up Extension to the Family Study of Binge Eating Disorder|Follow-Up Extension to the Family Study of Binge Eating Disorder|Completed|||268|Actual|Mclean Hospital|||2||f||||f||||||||||2018-06-01 01:38:40.460403|2018-06-01 01:38:40.460403
NCT00777621|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2016-02-11|2008-10-21|2008-10-22|Estimate|||||||2016-02-11|2016-02-12|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CREG||Caloric Restriction, Exercise, and Glucoregulation in Humans|Caloric Restriction, Exercise, and Glucoregulation in Humans|Completed||N/A|69|Actual|St. Louis University||3|||f||||f||||||||||2018-06-01 01:38:40.754981|2018-06-01 01:38:40.754981
NCT00777608|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2011-01-27||2015-08-11|2008-10-21|2008-10-22|Estimate|2011-01-27|2011-02-24|Estimate||||2015-08-11|2015-08-25|Estimate|December 2008||2008-12-31|August 2015|2015-08-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, With Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the CogState Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients|Completed||Phase 1|106|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:38:40.836451|2018-06-01 01:38:40.836451
NCT00777595|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2009-03-26|2008-10-20|2008-10-22|Estimate|||||||2009-03-26|2009-03-27|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CT14||Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers|A Randomized, Double Blind, Single Dose, Positive and Placebo Controlled, Crossover Study of the Effects of Inhaled Carmoterol, at the Proposed Therapeutic and Supratherapeutic Doses, on the QTc Intervals in Healthy Subjects|Completed||Phase 1|47|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-06-01 01:38:41.121107|2018-06-01 01:38:41.121107
NCT00777582|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2018-03-05|2008-10-21|2008-10-22|Estimate|||||||2018-03-05|2018-03-06|Actual|October 27, 2008|Actual|2008-10-27|March 2018|2018-03-31|December 28, 2018|Anticipated|2018-12-28|February 6, 2009|Actual|2009-02-06||Interventional|||Phase I Comparative Bioavailability Study|A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|197|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:38:41.202487|2018-06-01 01:38:41.202487
NCT00777569|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2017-01-13|2008-10-21|2008-10-22|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2005||2005-03-31|December 2008|2008-12-31|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Interventional|||Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine|Study 2: Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine|Completed||Phase 2|66|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 01:38:41.300175|2018-06-01 01:38:41.300175
NCT00777556|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2012-09-14||2012-09-14|2008-10-21|2008-10-22|Estimate|2012-09-14|2012-10-18|Estimate||||2012-09-14|2012-10-18|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Emergency Contraception Actual Use Study|Plan B® 1.5 Emergency Contraception Actual Use Study in Adolescents|Completed||Phase 3|343|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 01:38:41.405245|2018-06-01 01:38:41.405245
NCT00777543|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-11-12|2008-10-21|2008-10-22|Estimate|||||||2009-11-12|2009-11-13|Estimate|November 2008||2008-11-30|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Increasing Ferulic Acid Bioavailability in Bran|The Effect of Pre-treatment of Bran on the Bioavailability of Ferulic Acid and Other Bioactive Compounds From Wholegrain Breads Enriched in Bran|Unknown status|Active, not recruiting|N/A|8|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:38:41.679742|2018-06-01 01:38:41.679742
NCT00777530|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-22|2008-10-21|2008-10-22|Estimate|||||||2008-10-22|2008-10-23|Estimate|April 2008||2008-04-30|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects|Ascending Single-Dose Of The Safety, Tolerability, And Pharmacokinetics Of Bosutinib Administered Orally With Multiple Doses Of Ketoconazole To Healthy Adult Subjects.|Completed||Phase 1|48|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:38:41.848201|2018-06-01 01:38:41.848201
NCT00777517|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2009-08-26|2008-10-20|2008-10-22|Estimate|||||||2009-08-26|2009-08-27|Estimate|November 2008||2008-11-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Bioequivalence Study On Pediatric Appropriate Formulation|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A Pediatric Appropriate Formulation To A 10 Mg Commercial Atorvastatin Calcium Tablet Formulation In Healthy Subjects|Completed||Phase 1|76|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:38:41.920826|2018-06-01 01:38:41.920826
NCT00777504|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2011-09-15|2008-10-21|2008-10-22|Estimate|||||||2011-09-15|2011-09-16|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|April 2012|Anticipated|2012-04-30|January 2012|Anticipated|2012-01-31||Interventional|||Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors|Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors|Unknown status|Recruiting|Phase 4|30|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 01:38:42.008853|2018-06-01 01:38:42.008853
NCT00777491|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2018-04-19|2008-10-21|2008-10-22|Estimate|||||||2018-04-19|2018-04-20|Actual|December 2008||2008-12-31|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|July 10, 2017|Actual|2017-07-10||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery|A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant Chemotherapy|Active, not recruiting||Phase 2|64|Anticipated|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 01:38:42.112122|2018-06-01 01:38:42.112122
NCT00777478|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2012-02-02|2008-10-21|2008-10-22|Estimate|||||||2012-02-02|2012-02-03|Estimate|December 2008||2008-12-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|May 2012|Anticipated|2012-05-31||Interventional|sutent-capiri||Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer|A Phase I Dose Escalation Study With Sunitinib (SutentR) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer|Unknown status|Recruiting|Phase 1|32|Anticipated|Radboud University|||||f||||t||||||||||2018-06-01 01:38:42.274596|2018-06-01 01:38:42.274596
NCT00777465|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2014-05-19|2008-10-21|2008-10-22|Estimate|||||||2014-05-19|2014-05-21|Estimate|January 2003||2003-01-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Acute Kidney Injury After Cardiac Surgery Based on KDIGO Criteria|Prognostic Value of Acute Kidney Injury After Cardiac Surgery According to Kidney Disease: Improving Global Outcomes Definition and Staging (KDIGO) Criteria|Completed|||2804|Actual|Hospital de Base|||4||f||||f||||||||||2018-06-01 01:38:42.358759|2018-06-01 01:38:42.358759
NCT00777452|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2008-10-21|2008-10-21|2008-10-22|Estimate|||||||2008-10-21|2008-10-22|Estimate|March 2005||2005-03-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||A Prospective Longitudinal Study of Health-Related Quality of Life in Men With Clinically Localized Prostate Cancer|A Prospective Quality of Life Study in Men With Clinically Localized Prostate Carcinoma Treated With Different Treatment Modalities|Completed|||93|Actual|Samsung Medical Center|||4||f||||t||||||||||2018-06-01 01:38:42.433305|2018-06-01 01:38:42.433305
NCT00777439|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2016-08-17|2008-10-21|2008-10-22|Estimate|||||||2016-08-17|2016-08-18|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Domperidone for Refractory Gastrointestinal Disorders|An Investigational New Drug Program for the Use of Domperidone in the Treatment of Refractory Gastroesophageal Reflux Disease and Other Gastrointestinal Motility Disorders|Recruiting||N/A|75|Anticipated|Arnold, George, M.D.||1|||f||||t||||||||||2018-06-01 01:38:42.518263|2018-06-01 01:38:42.518263
NCT00777426|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2014-09-25|2008-10-21|2008-10-22|Estimate|||||||2014-09-25|2014-09-26|Estimate|September 2008||2008-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Observational|||HIV-1 Specific Immune Responses in Thai Individuals With HIV Dementia||Completed|||60|Actual|South East Asia Research Collaboration with Hawaii|||3||f||||t||||||Samples Without DNA|"~     PBMC, Plasma, Urine~   "|||2018-06-01 01:38:42.677111|2018-06-01 01:38:42.677111
NCT00777413|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-22|Estimate|||||||2008-10-20|2008-10-22|Estimate|November 2002||2002-11-30|October 2008|2008-10-31|January 2003|Actual|2003-01-31|November 2002|Actual|2002-11-30||Interventional|||Bioequivalecne Study of Minocycline 100mg Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Minocycline 100 mg Capsules in Healthy Volunteers|Completed||N/A|24|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:38:42.760314|2018-06-01 01:38:42.760314
NCT00777400|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2013-05-13|2008-10-21|2008-10-22|Estimate|||||||2013-05-13|2013-05-14|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells|A Pilot Trial to Assess the Effect of CNI Conversion to Efalizumab in T Regulatory Cells in Renal Transplantation|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, San Francisco||1||"New safety information reported in the post-marketing setting with efalizumab for treatment of~   chronic plaque psoriasis and trial conduct feasibility issues."|f||||t||||||||||2018-06-01 01:38:42.836726|2018-06-01 01:38:42.836726
NCT00777387|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2014-01-06|2008-10-20|2008-10-22|Estimate|||||||2014-01-06|2014-01-07|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Randomized Controlled Trial Comparing Slow-freezing to Vitrification of Oocytes|Cryopreservation of Oocytes: A Randomized Controlled Trial Comparing Slow-freezing to Vitrification|Terminated||N/A|14|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||Studies emerged that demonstrated the superiority of vitrification|f||||f||||||||||2018-06-01 01:38:42.970196|2018-06-01 01:38:42.970196
NCT00777374|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2011-01-31|2008-10-21|2008-10-22|Estimate|||||||2011-01-31|2011-02-01|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|ZU-SkinSIT-003||Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration|Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind Preseasonal Study to Assess Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration|Completed||Phase 2|97|Actual|University of Zurich||2|||f||||t||||||||||2018-06-01 01:38:43.087674|2018-06-01 01:38:43.087674
NCT00777361|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2010-11-17|2008-10-21|2008-10-22|Estimate|||||||2010-11-17|2010-11-18|Estimate|October 2008||2008-10-31|November 2010|2010-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|MB||Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers|An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers With Different CYP2D6 Genotype|Terminated||Phase 1|9|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:38:43.161946|2018-06-01 01:38:43.161946
NCT00777348|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2009-04-07|2008-10-21|2008-10-22|Estimate|||||||2009-04-07|2009-04-08|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|AERIA||To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol|Clinical Trial to Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol in Comparison to the Single Components and Placebo in Adults With Exercise Induced Asthma Randomised, Placebo-Controlled, Double-Blind, Crossover, Multicentre Study|Completed||Phase 2|62|Actual|MEDA Pharma GmbH & Co. KG||4|||f||||t||||||||||2018-06-01 01:38:43.240688|2018-06-01 01:38:43.240688
NCT00777335|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2012-01-06||2015-10-27|2008-10-21|2008-10-22|Estimate|2012-03-15|2012-04-10|Estimate||||2015-10-27|2015-11-24|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer|A Randomized Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2 Positive Locally Recurrent or Metastatic Breast Cancer|Terminated||Phase 2|4|Actual|Translational Research in Oncology|The recruitment rate has shown to be very low worldwide. In total, 4 patients only were recruited, instead of the 132 initially targeted. Due to the very small number of subjects randomized in this study, only descriptive analyses have been made.|2||Very low recruitement rate.|f||||f||||||||||2018-06-01 01:38:43.366347|2018-06-01 01:38:43.366347
NCT00777322|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2011-07-20|2008-10-21|2008-10-22|Estimate|||||||2011-07-20|2011-07-21|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|T-Cat||T-Cat Laser & Cross-linking for Keratoconus|Pilot Study of Excimer Laser Topography-Computer Assisted Treatment (T-Cat) Combined With Corneal Collagen Cross-linking With Riboflavin and UV Light|Completed||N/A|15|Actual|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||t||||||||||2018-06-01 01:38:43.762084|2018-06-01 01:38:43.762084
NCT00777309|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21||2013-02-06|2013-02-22|2008-10-21|2008-10-22|Estimate||||2013-02-06|2013-02-08|Estimate|2013-02-22|2013-02-28|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase 2 Study of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|167|Actual|ArQule||2|||f||||f||||||||||2018-06-01 01:38:43.859532|2018-06-01 01:38:43.859532
NCT00777296|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15||2016-11-17|2016-11-17|2008-10-21|2008-10-22|Estimate||||2016-11-17|2016-11-18|Estimate|2016-11-17|2016-11-18|Estimate|February 2007||2007-02-28|September 2015|2015-09-30|February 2010|Actual|2010-02-28|February 2008|Actual|2008-02-29||Interventional|||Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™)|Phase 1b/2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.|Completed||Phase 1/Phase 2|||Insmed Incorporated||4|||f||||t||||||||||2018-06-01 01:38:44.009735|2018-06-01 01:38:44.009735
NCT00777283|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2015-03-06|2008-10-20|2008-10-22|Estimate|||||||2015-03-06|2015-03-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:38:44.105657|2018-06-01 01:38:44.105657
NCT00777270|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2008-10-21|2008-10-21|2008-10-22|Estimate|||||||2008-10-21|2008-10-22|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|October 2007|Actual|2007-10-31|July 2007|Actual|2007-07-31||Interventional|||Continuous Versus Interrupted Sutures for Repair of Episiotomy or Second Degree Tears: a Randomised Controlled Trial|Continuous Versus Interrupted Sutures for Repair of Episiotomy or Second Degree Tears: a Randomised Controlled Trial|Completed||N/A|445|Actual|Hospital Universitario Principe de Asturias||2|||f||||t||||||||||2018-06-01 01:38:44.141562|2018-06-01 01:38:44.141562
NCT00777257|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2009-09-24||2014-01-21|2008-10-21|2008-10-22|Estimate|2009-12-01|2009-12-31|Estimate||||2014-01-21|2014-02-14|Estimate|April 2005||2005-04-30|January 2014|2014-01-31|September 2007|Actual|2007-09-30|March 2007|Actual|2007-03-31||Interventional|||Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine|Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine)|Completed||Phase 4|1345|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 01:38:44.367549|2018-06-01 01:38:44.367549
NCT00777244|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2017-05-04|2008-10-21|2008-10-22|Estimate|||||||2017-05-04|2017-05-08|Actual|April 2008||2008-04-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ADIUVO||Efficacy of Adjuvant Mitotane Treatment (ADIUVO)|Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence|Recruiting||Phase 3|200|Anticipated|University of Turin, Italy||2|||f||||t||||||||No||2018-06-01 01:38:45.008566|2018-06-01 01:38:45.008566
NCT00777231|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20||2012-10-31|2018-04-19|2008-10-20|2008-10-22|Estimate||||2013-02-22|2013-02-28|Estimate|2018-04-19|2018-04-24|Actual|January 2005||2005-01-31|April 2018|2018-04-30|August 2013|Actual|2013-08-31|August 2010|Actual|2010-08-31||Interventional|||Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies|Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies|Completed||Phase 1/Phase 2|9|Actual|University of Louisville||4|||f||||t|t|f||||||Undecided||2018-06-01 01:38:45.158412|2018-06-01 01:38:45.158412
NCT00777218|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2010-06-23|2008-10-21|2008-10-22|Estimate|||||||2010-06-23|2010-06-24|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|July 2011|Anticipated|2011-07-31|December 2010|Anticipated|2010-12-31||Interventional|||Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine|Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine|Unknown status|Recruiting|N/A|90|Anticipated|University of South Alabama||3|||f||||f||||||||||2018-06-01 01:38:45.254713|2018-06-01 01:38:45.254713
NCT00777205|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2014-12-30||2015-04-06|2008-10-21|2008-10-22|Estimate|2015-03-04|2015-03-18|Estimate||||2015-04-06|2015-04-27|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|DIAL-UP|Fifty-six of the patients randomized to the telephone-based peer support intervention were excluded from main study analyses because of an unforeseen disruption in their 6-month intervention that was unrelated to patient characteristics.|Improving Depression Management Through Peer Support|Improving Depression Management Through Peer Support|Completed||N/A|443|Actual|VA Office of Research and Development|56 of the patients randomized to the telephone-based peer support intervention were excluded from main study analyses because of an unforeseen disruption in their 6-month intervention that was unrelated to patient characteristics.|2|||f||||t||||||||||2018-06-01 01:38:45.333239|2018-06-01 01:38:45.333239
NCT00777192|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2018-02-20|2008-10-20|2008-10-22|Estimate|||||||2018-02-20|2018-02-22|Actual|August 2008|Actual|2008-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Longitudinal Study of Symptoms in Colorectal Cancer|Prospective Study of Symptoms Related to Oxaliplatin-based Regimens in the Treatment of Colorectal Cancer|Active, not recruiting|||500|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Serum and cell samples will also be collected during chemotherapy for analysis of cytokines~     and their relationship to symptom production.~   "|||2018-06-01 01:38:46.68396|2018-06-01 01:38:46.68396
NCT00777179|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2011-04-27||2016-08-29|2008-10-21|2008-10-22|Estimate|2011-06-13|2011-07-08|Estimate||||2016-08-29|2016-10-10|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|||Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy|Randomized, Double-blinded, Placebo-controlled Phase II Study of Vandetanib (ZactimaTM) Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy|Completed||Phase 2|117|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:38:46.78964|2018-06-01 01:38:46.78964
NCT00777166|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2014-03-13|2008-10-21|2008-10-22|Estimate|||||||2014-03-13|2014-03-14|Estimate|December 2005||2005-12-31|March 2014|2014-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Cardiac Effects of Oxytocin Administrated During Cesarean Section, Signs of Myocardial Ischemia|Phase 4 Study of Oxytocin Used During Cesarean Section|Completed||Phase 4|103|Actual|Uppsala University||2|||f||||f||||||||||2018-06-01 01:38:47.824271|2018-06-01 01:38:47.824271
NCT00777153|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2012-04-03|2011-04-06|2016-11-07|2008-10-21|2008-10-22|Estimate|2012-11-21|2012-12-21|Estimate|2011-04-06|2011-04-12|Estimate|2016-11-07|2016-12-28|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|April 2010|Actual|2010-04-30||Interventional|REGAL||Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma|A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone|Completed||Phase 3|423|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 01:38:47.995583|2018-06-01 01:38:47.995583
NCT00777140|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2012-07-04|2008-10-21|2008-10-22|Estimate|||||||2012-07-04|2012-07-06|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TANDEM-1||Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion|Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator|Completed||Phase 2|62|Actual|Germans Trias i Pujol Hospital||2|||f||||t||||||||||2018-06-01 01:38:48.91931|2018-06-01 01:38:48.91931
NCT00777127|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2013-01-31|2008-10-21|2008-10-22|Estimate|||||||2013-01-31|2013-02-01|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|LEIDA||Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses|Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)|Completed||Phase 4|258|Actual|MEDA Pharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 01:38:49.001163|2018-06-01 01:38:49.001163
NCT00775918|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|June 2005||2005-06-30|October 2008|2008-10-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivaelnce Study of Doxycycline Monohydrate 100mg Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Doxycycline Monohydrate 100 mg Tablets in Healthy Volunteers|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:09.963913|2018-06-01 01:39:09.963913
NCT00777114|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2011-03-08|2008-10-21|2008-10-22|Estimate|||||||2011-03-08|2011-03-10|Estimate|October 2008||2008-10-31|March 2011|2011-03-31||||November 2011|Anticipated|2011-11-30||Interventional|||Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy|Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy|Unknown status|Recruiting|Phase 1|25|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-06-01 01:38:49.197864|2018-06-01 01:38:49.197864
NCT00777101|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2017-08-10|2012-04-17|2018-04-03|2008-10-21|2008-10-22|Estimate|2017-10-06|2017-11-09|Actual|2012-04-17|2012-04-19|Estimate|2018-04-03|2018-05-01|Actual|February 2009||2009-02-28|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|March 2011|Actual|2011-03-31||Interventional||Randomized Population|Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer|A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer|Active, not recruiting||Phase 2|233|Actual|Puma Biotechnology, Inc.|Pharmacokinetic Analyses not included here; they are part of a population PK analysis.|2|||f||||t|t|f||||||||2018-06-01 01:38:49.327088|2018-06-01 01:38:49.327088
NCT00777088|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2016-11-17|2008-10-21|2008-10-22|Estimate|||||||2016-11-17|2016-11-18|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PUFS||Pipeline for Uncoilable or Failed Aneurysms|Pipeline for Uncoilable or Failed Aneurysms|Completed||N/A|135|Actual|Medtronic Neurovascular Clinical Affairs||1|||f||||f||||||||||2018-06-01 01:38:50.231201|2018-06-01 01:38:50.231201
NCT00777075|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2008-10-21|2008-10-21|2008-10-22|Estimate|||||||2008-10-21|2008-10-22|Estimate|July 2003||2003-07-31|October 2008|2008-10-31|November 2005||2005-11-30|||||Interventional|||L-Arginine and Erectile Dysfunction|Oral Administration of L-Arginine in Patients With Erectile Dysfunction|Completed||Phase 4|57||Hannover Medical School||2|||f||||f||||||||||2018-06-01 01:38:50.35331|2018-06-01 01:38:50.35331
NCT00777062|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2013-12-12||2018-01-24|2008-10-21|2008-10-22|Estimate|2013-12-12|2014-01-29|Estimate||||2018-01-24|2018-01-26|Actual|July 2009||2009-07-31|January 2018|2018-01-31|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Interventional|||VIVITROL as a Treatment for Cocaine and Alcohol Dependence|A Phase II, Randomized, Double-Blind Pilot Trial of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) for the Treatment of Cocaine and Alcohol Dependence|Completed||Phase 2|80|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 01:38:50.46645|2018-06-01 01:38:50.46645
NCT00777049|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2016-05-26||2016-07-14|2008-10-21|2008-10-22|Estimate|2016-07-14|2016-07-15|Estimate||||2016-07-14|2016-07-15|Estimate|February 2009||2009-02-28|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer|A Phase II, Open-label Multicenter Trial of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 2|54|Actual|Translational Research in Oncology|In Arm II, low recruitment resulted in insufficient data (and enrollment was stopped). In Arm I, the required number of tumor responses was not reached. Unable to determine efficacy (small sample); secondary objectives also removed from the protocol.|2|||f||||f||||||||No||2018-06-01 01:38:50.780939|2018-06-01 01:38:50.780939
NCT00777036|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2017-12-06|2017-08-23|2018-01-04|2008-10-21|2008-10-22|Estimate|2017-12-06|2018-01-05|Actual|2017-08-23|2017-08-24|Actual|2018-01-04|2018-01-29|Actual|February 19, 2009|Actual|2009-02-19|January 2018|2018-01-31|September 23, 2021|Anticipated|2021-09-23|September 1, 2016|Actual|2016-09-01||Interventional|||A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib|A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib|Active, not recruiting||Phase 2|145|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 01:38:51.509208|2018-06-01 01:38:51.509208
NCT00777023|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2012-01-16||2012-02-21|2008-10-21|2008-10-22|Estimate|2012-01-16|2012-02-17|Estimate||||2012-02-21|2012-02-22|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 3|565|Actual|Depomed||3|||f||||f||||||||||2018-06-01 01:38:53.823708|2018-06-01 01:38:53.823708
NCT00777010|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2017-03-23|2008-10-21|2008-10-22|Estimate|||||||2017-03-23|2017-03-24|Actual|September 1, 2008||2008-09-01|March 2017|2017-03-31|March 15, 2017|Actual|2017-03-15|December 31, 2016|Actual|2016-12-31||Interventional|||Energy Metabolism and Cognitive Aging|Energy Metabolism and Cognitive Aging|Completed||N/A|62|Actual|University of Cincinnati||2|||f||||f||||||||No||2018-06-01 01:38:54.851898|2018-06-01 01:38:54.851898
NCT00776997|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2012-04-25||2018-04-03|2008-10-20|2008-10-22|Estimate|2013-09-09|2013-11-13|Estimate||||2018-04-03|2018-05-04|Actual|November 2008||2008-11-30|March 2018|2018-03-31|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|||LINX Reflux Management System Clinical Study Protocol|LINX Reflux Management System Clinical Study Protocol|Completed||N/A|100|Actual|Torax Medical Incorporated||1|||f||||f||||||||||2018-06-01 01:38:54.957455|2018-06-01 01:38:54.957455
NCT00776984|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2012-07-20||2014-09-09|2008-10-21|2008-10-22|Estimate|2012-09-21|2012-09-27|Estimate||||2014-09-09|2014-09-10|Estimate|October 2008||2008-10-31|September 2014|2014-09-30||||July 2011|Actual|2011-07-31||Interventional|||Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma|Completed||Phase 3|453|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:38:55.280752|2018-06-01 01:38:55.280752
NCT00776971|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2008-10-21|2008-10-21|2008-10-22|Estimate|||||||2008-10-21|2008-10-22|Estimate|November 2007||2007-11-30|August 2008|2008-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effect of Carbonated Soft Drinks on Appetite-Regulation|Carbonated Soft Drinks May Alter Appetite Sensation and Appetite-Regulating Hormone Level and Lead to Increased Energy Intake.|Completed||N/A|24|Actual|Aarhus University Hospital||4|||f||||f||||||||||2018-06-01 01:38:56.484832|2018-06-01 01:38:56.484832
NCT00776958|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2014-07-30|2008-10-20|2008-10-22|Estimate|||||||2014-07-30|2014-07-31|Estimate|July 2008||2008-07-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Observational|||Lynne Cohen Consortium Project: Multi-Center Database/Registry|Multi - Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer - A Lynne Cohen Consortium Project|Completed|||176|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:38:56.557574|2018-06-01 01:38:56.557574
NCT00776945|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-06-05|2008-10-21|2008-10-22|Estimate|||||||2015-06-05|2015-06-08|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|fPAM||Feasibility and Functionality of fPAM Imaging in Melanoma|Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Characterization and Early Diagnosis of Melanoma|Terminated|||2|Actual|Washington University School of Medicine||||no funding|f||||f||||||Samples Without DNA|"~     Tissue biopsies may be performed if locoregional recurrence validated by clinical~     examination.~   "|||2018-06-01 01:38:56.658751|2018-06-01 01:38:56.658751
NCT00776932|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|||2015-05-26|2008-10-21|2008-10-22|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2007||2007-06-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|August 2011|Actual|2011-08-31||Observational|JRPIT||Chronic Knee Pain Study|Disparity in Joint Replacement: Pathway to Intervention|Completed|||852|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-06-01 01:38:56.729072|2018-06-01 01:38:56.729072
NCT00776919|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-21|2011-12-21||2016-10-11|2008-10-21|2008-10-22|Estimate|2011-12-21|2012-01-30|Estimate||||2016-10-11|2016-11-23|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne|A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of A Clindamycin / Benzoyl Peroxide Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel In Subjects With Acne Vulgaris|Completed||Phase 3|1315|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:38:56.846791|2018-06-01 01:38:56.846791
NCT00776906|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-01-19|2008-10-21|2008-10-22|Estimate|||||||2015-01-19|2015-01-21|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Advance® 18PTX® Balloon Catheter Study|Advance® 18PTX® Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery With a Paclitaxel-coated Balloon|Completed||N/A|150|Actual|Cook Group Incorporated||2|||f||||||||||||||2018-06-01 01:38:58.528667|2018-06-01 01:38:58.528667
NCT00776893|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:38:58.598965|2018-06-01 01:38:58.598965
NCT00776880|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2009-12-22|2008-10-20|2008-10-21|Estimate|||||||2009-12-22|2009-12-23|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|ASAINPA||Does American Society of Anesthesiologists (ASA) Physical Status Scale Enough in Patients Assessment|Reevaluating the American Society of Anesthesiologists (ASA) Physical Status System in Patients Assessment and Compared With a New Scale of Physical-psycho-social Gauge Raised by Our Institution|Completed|||1500|Actual|Nanjing Medical University|||2||f||||t||||||||||2018-06-01 01:38:58.633774|2018-06-01 01:38:58.633774
NCT00776867|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2017-07-31|2008-10-20|2008-10-21|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2008||2008-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors|Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors|Completed||Phase 1|38|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:38:58.713098|2018-06-01 01:38:58.713098
NCT00776854|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|November 2009|Anticipated|2009-11-30|July 2009|Anticipated|2009-07-31||Interventional|||Bioburden Reduction of Diabetic Foot Ulcer|Noveon Laser Treatment to Effect Bioburden Reduction or Elimination in Diabetic Foot Ulcer: A Davice Performance Clinical Study|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Nomir Medical Technologies|||||f||||||||||||||2018-06-01 01:38:58.814698|2018-06-01 01:38:58.814698
NCT00776841|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-19|||2010-11-02|2008-10-20|2008-10-21|Estimate|||||||2010-11-02|2010-11-03|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers|Completed||Phase 1|41|Actual|Galmed Medical Reserch||7|||f||||t||||||||||2018-06-01 01:38:58.875194|2018-06-01 01:38:58.875194
NCT00776828|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2013-12-15|2008-10-20|2008-10-21|Estimate|||||||2013-12-15|2013-12-17|Estimate|November 2006||2006-11-30|December 2013|2013-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CILON-T||The Efficacy of CILostazol ON Ischemic Complications After DES Implantation|Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation|Completed||Phase 4|960|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 01:38:59.046205|2018-06-01 01:38:59.046205
NCT00776815|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:38:59.138202|2018-06-01 01:38:59.138202
NCT00776802|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-19|||2013-06-21|2008-10-20|2008-10-21|Estimate|||||||2013-06-21|2013-06-25|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|GCS-100LE||GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Phase 1/2 Study of GCS-100 in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B Cell Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|La Jolla Pharmaceutical Company||1||Lack of funding|f||||f||||||||||2018-06-01 01:38:59.173389|2018-06-01 01:38:59.173389
NCT00776789|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2010-06-01||2014-01-10|2008-10-20|2008-10-21|Estimate|2014-01-10|2014-02-27|Estimate||||2014-01-10|2014-02-27|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Early Skin to Skin Contact on Breast Feeding Behaviour in Term Newborns: A Randomized Controlled Trial|Effect of Early Skin to Skin Contact on Breast Feeding Behaviour in Term Newborns: A Randomized Controlled Trial|Completed||N/A|41|Actual|All India Institute of Medical Sciences, New Delhi|This study evaluated breast feeding behaviour of term neonates with only one video, which may not have been an accurate marker of feeding behavior.There could a possibility of inadvertent bias at the time of intervention.|2|||f||||f||||||||||2018-06-01 01:38:59.255069|2018-06-01 01:38:59.255069
NCT00776776|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-21|2008-10-20|2008-10-21|Estimate|||||||2008-10-21|2008-10-22|Estimate|April 2005||2005-04-30|August 2008|2008-08-31|April 2010|Anticipated|2010-04-30|April 2007|Actual|2007-04-30||Observational|FABS||Follow-up of Adolescent Bariatric Surgery|Follow-up of Adolescent Bariatric Surgery|Unknown status|Enrolling by invitation||180|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 01:38:59.491304|2018-06-01 01:38:59.491304
NCT00776763|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2011-07-20|2008-10-17|2008-10-21|Estimate|||||||2011-07-20|2011-07-22|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|KIA-ProRet||Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab|The Profile of the Growth Factors and Other Mediators of Angiogenesis in the Ocular Fluids in Proliferative Retinopathies (AMD and PDR) Before and After the Intravitreal Administration of Bevacizumab (Avastin) as an Anti-VEGF Blocker|Completed||Phase 2|150|Anticipated|Ophthalmological Association Edelweiss||1|||f||||||||||||||2018-06-01 01:38:59.566459|2018-06-01 01:38:59.566459
NCT00776750|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|September 2003||2003-09-30|October 2008|2008-10-31|May 2004||2004-05-31|May 2004||2004-05-31||Interventional|||Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients|Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients|Completed||Phase 4|407|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-06-01 01:38:59.639036|2018-06-01 01:38:59.639036
NCT00776737|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2017-06-30|2008-10-18|2008-10-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 16, 2008||2008-10-16|January 14, 2011|2011-01-14|January 14, 2011||2011-01-14|||||Observational|||Studies of Measures of Attention|Studies of Measures of Attention|Completed|||36|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:38:59.722875|2018-06-01 01:38:59.722875
NCT00776724|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-19|||2012-11-15|2008-10-20|2008-10-21|Estimate|||||||2012-11-15|2012-11-16|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|TaiNAC||Tailored Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm|A Randomized Phase III Study of Docetaxel/ Epirubicin Versus Tailored Regimens as Neoadjuvant Chemotherapy for Stage II/III Breast Cancer With Tumor Size More Than 2 cm|Unknown status|Recruiting|Phase 3|272|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:38:59.800193|2018-06-01 01:38:59.800193
NCT00776711|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2017-06-30|2008-10-18|2008-10-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 16, 2008||2008-10-16|January 14, 2011|2011-01-14|January 14, 2011|Actual|2011-01-14|January 14, 2011|Actual|2011-01-14||Interventional|||Vaccine for Prevention of Bird Flu|An Open-Label, Randomized Phase I Study in Healthy Adults of 4 Prime-Boost Schedules With Monovalent Influenza Subunit Virion (H5N1) Vaccine (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant DNA Plasmid (H5) Vaccine (VRC, NIAID)|Completed||Phase 1|60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:38:59.871969|2018-06-01 01:38:59.871969
NCT00776698|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2016-11-01|2008-10-20|2008-10-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.|An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-squamous Non-small Cell Lung Cancer.|Completed||Phase 1|1|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:38:59.929718|2018-06-01 01:38:59.929718
NCT00776685|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2011-06-24|2008-10-20|2008-10-21|Estimate|||||||2011-06-24|2011-06-27|Estimate|May 2007||2007-05-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|Adventure||Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse|Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals|Completed||Phase 2/Phase 3|3190|Actual|King's College London||4|||f||||t||||||||||2018-06-01 01:39:00.045763|2018-06-01 01:39:00.045763
NCT00776672|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Bioequivalence Study of Fosinopril 40mg Tablets Under Fed Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Fosinopril Sodium 40 mg Tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) With That of Monopril® in Healthy Adult Subjects Under Non-Fasting Conditions|Completed||N/A|24|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:00.134023|2018-06-01 01:39:00.134023
NCT00776659|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2013-09-12||2013-09-12|2008-10-20|2008-10-21|Estimate|2013-09-12|2013-11-19|Estimate||||2013-09-12|2013-11-19|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin|An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin|Terminated|||39|Actual|Pfizer|Study was terminated due to slow enrollment and observational nature of the study. Low number of participants enrolled was not sufficient to conduct the planned analysis. Study was not terminated due to safety concerns.||1|See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:39:01.222879|2018-06-01 01:39:01.222879
NCT00776646|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|May 2006||2006-05-31|October 2008|2008-10-31|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|||Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two- Sequence, Single-Dose, Crossover Bioavailability Study Comparing Hydrochlorothiazide 50 mg Tablet of Ohm Laboratories (A Subsidiary of Ranbaxy Pharmaceuticals USA) With Hydrochlorothiazide 50 mg Tablet of IVAX Pharmaceuticals in Healthy, Adult, Human, Male Subjects Under Fasting Condition|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:01.46554|2018-06-01 01:39:01.46554
NCT00776633|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2016-08-29|2008-10-20|2008-10-21|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2008||2008-09-30|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|December 2013|Actual|2013-12-31||Interventional|ISAR-TRIPLE||Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation|Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting|Unknown status|Active, not recruiting|Phase 4|614|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 01:39:01.546771|2018-06-01 01:39:01.546771
NCT00776620|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|July 2003||2003-07-31|October 2008|2008-10-31|September 2003|Actual|2003-09-30|August 2003|Actual|2003-08-31||Interventional|||Bioequivalence Study of Glimepiride 1mg Tablets Under Fed Conditions|A Relative Bioavailability Study of Glimepiride 1 MG Tablets Under Fed Conditions|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:01.685721|2018-06-01 01:39:01.685721
NCT00775723|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-30|2008-10-17|2008-10-20|Estimate|||||||2008-10-30|2008-11-03|Estimate|January 2008||2008-01-31|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Melatonin Production Delay in Preterm Infants|Term-Born Infants at 9 and 12 Months of Age: A Randomized Controlled Trial|Completed|||46|Actual|Tel Aviv University|||||f||||f||||||||||2018-06-01 01:39:11.528228|2018-06-01 01:39:11.528228
NCT00776607|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|LIT||Randomized Controlled Trial of Insulin Versus Tablets for Latent Autoimmune Diabetes in Adults (LADA)|Randomized, Controlled, Parallel-Group Prospective Study to Investigate the Clinical Effectiveness of Early Insulin Treatment in Patients With Latent Autoimmune Diabetes in Adults|Unknown status|Recruiting|N/A|200|Anticipated|Abertawe Bro Morgannwg University NHS Trust||2|||f||||t||||||||||2018-06-01 01:39:01.76563|2018-06-01 01:39:01.76563
NCT00776594|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2015-07-29||2016-09-12|2008-10-20|2008-10-21|Estimate|2016-07-13|2016-08-23|Estimate||||2016-09-12|2016-10-21|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|December 2014|Actual|2014-12-31||Interventional|||Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy|Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy|Completed||Phase 2|102|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 01:39:02.023873|2018-06-01 01:39:02.023873
NCT00776581|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2009-09-17|2008-10-20|2008-10-21|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|POPIC||Ten-year Practice of Labor Pain Control in China|A Ten-year Practice of Labor Pain Control in China|Completed|||40000|Actual|Nanjing Medical University|||4||f||||t||||||||||2018-06-01 01:39:02.642555|2018-06-01 01:39:02.642555
NCT00776568|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|February 2008||2008-02-29|October 2008|2008-10-31||||August 2009|Anticipated|2009-08-31||Interventional|||Treatment of Refractory Angina Pectoris by Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Refractory Angina Pectoris|Unknown status|Active, not recruiting|Phase 3|60|Actual|Universal Research Group||2|||f||||t||||||||||2018-06-01 01:39:02.744734|2018-06-01 01:39:02.744734
NCT00776555|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2010-05-05||2015-03-03|2008-10-20|2008-10-21|Estimate|2010-06-04|2010-07-07|Estimate||||2015-03-03|2015-03-23|Estimate|November 2008||2008-11-30|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution|A Single-Blind, Randomized Study of the Comparative Drug Likeability and Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as a Solution|Terminated||Phase 1|3|Actual|Shire|Shire decided to cancel this study on march 31, 2009 due to changes in business priorities. The study termination was not related to any data or safety concerns.|2||The study was stopped by the sponsor based on a non-safety related business priority decision.|f||||f||||||||||2018-06-01 01:39:02.866665|2018-06-01 01:39:02.866665
NCT00776542|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|January 2003|Actual|2003-01-31|November 2002|Actual|2002-11-30||Interventional|||Bioequivalence Study of Minocycline 100mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Minocycline 100 mg Capsules in Healthy Volunteers|Completed||N/A|28|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:03.13082|2018-06-01 01:39:03.13082
NCT00776529|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2009-01-28|2008-10-20|2008-10-21|Estimate|||||||2009-01-28|2009-01-29|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Combination of Strength and Sensorimotor Training|Randomized Controlled Trial of Two Combinations of Strength and Sensorimotor Training: Effects on Strength, Power and Balance|Completed||Phase 1|30|Actual|University of Applied Sciences of Western Switzerland||2|||f||||f||||||||||2018-06-01 01:39:03.251365|2018-06-01 01:39:03.251365
NCT00776516|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2013-07-01|2008-10-20|2008-10-21|Estimate|||||||2013-07-01|2013-07-03|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers|A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178)|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:39:03.376091|2018-06-01 01:39:03.376091
NCT00776503|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2014-03-19|2008-10-20|2008-10-21|Estimate|||||||2014-03-19|2014-03-20|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|GFMVOR2007||Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia|A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes|Completed||Phase 1/Phase 2|52|Actual|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||||2018-06-01 01:39:03.608462|2018-06-01 01:39:03.608462
NCT00776490|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|July 2003||2003-07-31|October 2008|2008-10-31|September 2003|Actual|2003-09-30|August 2003|Actual|2003-08-31||Interventional|||Bioequivalence Study of Glimepiride 1mg Tablets Under Fasting Conditions|A Relative Bioavailability Study of Glimepiride 1 MG Tablets Under Fasting Conditions|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:03.719698|2018-06-01 01:39:03.719698
NCT00776477|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-19|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|December 2007||2007-12-31|October 2008|2008-10-31||||December 2008|Anticipated|2008-12-31||Interventional|||The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease||Unknown status|Recruiting|Phase 3|300|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||||||||||||2018-06-01 01:39:03.805123|2018-06-01 01:39:03.805123
NCT00776464|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|January 2010|Anticipated|2010-01-31|November 2009|Anticipated|2009-11-30||Interventional|||Treating Onychomychosis||Unknown status|Not yet recruiting|Phase 2/Phase 3|60|Anticipated|Nomir Medical Technologies|||||f||||||||||||||2018-06-01 01:39:03.905969|2018-06-01 01:39:03.905969
NCT00776451|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2009-06-02|2008-10-20|2008-10-21|Estimate|||||||2009-06-02|2009-06-03|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Observational|||Usability of the PreView PHP for Home Use in Intermediate AMD Patients|Usability of the PreView PHP for Home Use in Intermediate Age Related Macular Degeneration Patients|Completed|||66|Anticipated|Notal Vision Ltd|||1||f||||t||||||||||2018-06-01 01:39:03.999896|2018-06-01 01:39:03.999896
NCT00776438|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2015-06-16|2008-10-17|2008-10-21|Estimate|||||||2015-06-16|2015-06-17|Estimate|September 2007||2007-09-30|June 2015|2015-06-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines|Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route|Completed||Phase 2|160|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 01:39:04.145878|2018-06-01 01:39:04.145878
NCT00776425|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2017-06-28|2008-10-20|2008-10-21|Estimate|||||||2017-06-28|2017-07-02|Actual|January 2007||2007-01-31|June 2017|2017-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies|Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders|Completed||Phase 4|117|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:39:04.301332|2018-06-01 01:39:04.301332
NCT00776412|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2018-03-27|2008-10-18|2008-10-21|Estimate|||||||2018-03-27|2018-03-29|Actual|October 17, 2008||2008-10-17|January 25, 2018|2018-01-25||||||||Observational|||Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults|Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults|Recruiting|||375|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:39:04.471338|2018-06-01 01:39:04.471338
NCT00776399|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2018-03-20|2008-10-20|2008-10-21|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2008||2008-10-31|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|December 1, 2017|Actual|2017-12-01||Interventional|||Radiofrequency Ablation in Resectable Colorectal Lung Metastasis|Radiofrequency Ablation in Resectable Colorectal Lung Metastasis: A Phase-II Clinical Trial|Active, not recruiting||Phase 2|70|Anticipated|Mie University||1|||f||||t||||||||||2018-06-01 01:39:04.559016|2018-06-01 01:39:04.559016
NCT00776386|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-19|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Observational|||Determinants and Practical Significance of Change in Motor Ability, Functional Performance, and HRQOL After Stroke|Determinants and Practical Significance of Change in Motor Ability, Functional Performance, and HRQOL After Distributed Constraint-Induced Therapy in Stroke|Unknown status|Active, not recruiting||70|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 01:39:04.691356|2018-06-01 01:39:04.691356
NCT00776373|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-19|||2016-06-07|2008-10-20|2008-10-21|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2007||2007-01-31|June 2016|2016-06-30||||December 2009|Actual|2009-12-31||Interventional|UPCC 25406||Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies|A Phase I/II, Open-label Single Institution Study Evaluating Rapamycin in Combination With High-dose Etoposide and Cytarabine in Relapsed or Refractory Aggressive Lymphoid Malignancies|Terminated||Phase 1/Phase 2|4|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 01:39:04.752618|2018-06-01 01:39:04.752618
NCT00776360|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2015-04-06|2008-10-20|2008-10-21|Estimate|||||||2015-04-06|2015-04-07|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effect of Oxytocin on the Gastric Emptying|The Effect of Oxytocin on Gastric Emptying in Patients With Gastro Paresis|Completed||Early Phase 1|12|Actual|Skane University Hospital||2|||f||||t||||||||||2018-06-01 01:39:04.833794|2018-06-01 01:39:04.833794
NCT00776347|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-10-14|2008-10-20|2008-10-21|Estimate|||||||2015-10-14|2015-10-15|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)|Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)|Completed||N/A|24|Actual|Osaka University||1|||f||||f||||||||||2018-06-01 01:39:04.939654|2018-06-01 01:39:04.939654
NCT00776334|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|December 2002|Actual|2002-12-31|November 2002|Actual|2002-11-30||Interventional|||Bioequivalence Study of Fosinopril 40mg Tablets Under Fasting Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Fosinopril Sodium 40 mg Tablets (Ranbaxy Laboratories Limited, Lot No. 1238312) With That of Monopril® (Bristol-Myers Squibb, Lot No. 1D47960), in Healthy Adult Subjects Under Fasting Conditions.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:05.023531|2018-06-01 01:39:05.023531
NCT00776321|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia|A Placebo Controlled, Double Blind, Randomised, 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia|Completed||Phase 2|142|Actual|Karo Bio AB||3|||f||||t||||||||||2018-06-01 01:39:05.105221|2018-06-01 01:39:05.105221
NCT00776308|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2012-01-23|2008-10-20|2008-10-21|Estimate|||||||2012-01-23|2012-01-25|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|MBI||Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery|Molecular Breast Imaging in the Preoperative Evaluation of Women With Biopsy Proven Breast Cancer|Completed|||98|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 01:39:05.189225|2018-06-01 01:39:05.189225
NCT00776295|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2011-10-04||2013-01-16|2008-10-20|2008-10-21|Estimate|2012-05-18|2012-06-21|Estimate||||2013-01-16|2013-01-24|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer|Phase II Trial of Autologous Peripheral Blood Hematopoietic Cell Transplantation (PBHCT) Followed by Dendritic Cell p53 Vaccination and Adoptive T Cell Transfer in Patients With Limited Stage Small Cell Lung Cancer|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|Early termination of trial due to small number of subjects thus leading to unreliabe data|1||Low accrual|f||||t||||||||||2018-06-01 01:39:05.352126|2018-06-01 01:39:05.352126
NCT00776282|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|July 2006||2006-07-31|October 2008|2008-10-31|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||Bioequivalence Study of Loratadine Orally Disintegrating Tablets 10 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study on Loratadine Formulations Comparing Loratadine 10 mg Orally Disintegrating Tablets of Ohm Laboratories, Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With Claritin® Reditabs® 10 mg Tablet (Containing Loratadine 10 mg) of Schering- Plough Healthcare Product Inc, in Healthy, Adult, Male, Human Subjects Under Fed Condition|Completed||N/A|80|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:05.55287|2018-06-01 01:39:05.55287
NCT00776269|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|October 2008||2008-10-31|September 2008|2008-09-30||||||||Interventional|||Comparison of Argon Laser and Radiofrequency in Trichiasis Treatment|Comparison the Result of Argon Laser and Radiofrequency in Trichiasis Treatment of Patients Referred to Labbafinejad Oculoplastic Clinic|Unknown status|Recruiting|N/A|||Shahid Beheshti University of Medical Sciences||1|||f||||f||||||||||2018-06-01 01:39:05.630268|2018-06-01 01:39:05.630268
NCT00776256|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|February 2007||2007-02-28|October 2008|2008-10-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Effects of Oligofructose and Barley on Satiety and Energy Intake|The Effect of Meal Replacement Bars Containing Different Types of Fibres (Oligofructose and/or Barley) on Satiety and Energy Intake|Completed||N/A|24|Actual|Unilever R&D||4|||f||||f||||||||||2018-06-01 01:39:05.713427|2018-06-01 01:39:05.713427
NCT00776243|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2010-05-10|2008-10-20|2008-10-21|Estimate|||||||2010-05-10|2010-05-12|Estimate|October 2008||2008-10-31|October 2009|2009-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Short-term Effect of Intensive Insulin Therapy on Incretin Secretion|Short-term Effect of Intensive Insulin Therapy on Incretin Secretion|Completed|||30|Anticipated|The Catholic University of Korea|||2||f||||f||||||Samples Without DNA|"~     plasma serum~   "|||2018-06-01 01:39:05.825715|2018-06-01 01:39:05.825715
NCT00776230|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|2013-12-05||2016-03-29|2008-10-20|2008-10-21|Estimate|2013-12-05|2014-01-23|Estimate||||2016-03-29|2016-05-04|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling|Immunogenicity of a Commercial Batch of the Japanese Encephalitis Vaccine IC51 up to Twenty-four Months Post Filling. An Open-label, Multicenter, Phase 3 Study|Completed||Phase 3|304|Actual|Valneva Austria GmbH||3|||f||||f||||||||||2018-06-01 01:39:05.926387|2018-06-01 01:39:05.926387
NCT00776217|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study on Loratadine Formulations Comparing Loratadine 10 mg Orally Disintegrating Tablets of Ohm Laboratories, Inc. (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With Claritin® Reditabs 10 mg Tablet (Containing Loratadine 10 mg) of Schering- Plough Healthcare Product Inc, in Healthy, Adult, Male, Human Subjects Under Fasting Condition|Completed||N/A|80|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:06.396203|2018-06-01 01:39:06.396203
NCT00776204|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2017-02-28|2008-10-20|2008-10-21|Estimate|||||||2017-02-28|2017-03-01|Actual|May 2008||2008-05-31|February 2017|2017-02-28|February 2011|Actual|2011-02-28|July 2009|Actual|2009-07-31||Interventional|OCTDESI||The Optical Coherence Tomography Drug Eluting Stent Investigation|The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)|Completed||N/A|60|Actual|Boston Scientific Corporation||3|||f||||t||||||||No||2018-06-01 01:39:06.4755|2018-06-01 01:39:06.4755
NCT00776191|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2015-06-03|2008-10-20|2008-10-21|Estimate|||||||2015-06-03|2015-06-04|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|NephropaedPD01||Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism|Randomized, Multicenter Cross-over Study in Investigating the Effect of Bicarbonate-based Solutions (Physioneal 35 vs. 40) on Protein Metabolism in Children and Adolescents on Chronic Peritoneal Dialysis|Terminated||Phase 4|5|Actual|University of Erlangen-Nürnberg Medical School||2||al study sites stoped on 15/05/2012 because of insufficient recrutement.|f||||f||||||||||2018-06-01 01:39:06.590304|2018-06-01 01:39:06.590304
NCT00776178|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-18|||2018-05-17|2008-10-18|2008-10-21|Estimate|||||||2018-05-17|2018-05-18|Actual|October 17, 2008||2008-10-17|March 6, 2018|2018-03-06||||||||Observational|||Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health|Feasibility Study: Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health|Completed|||68|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:39:06.690524|2018-06-01 01:39:06.690524
NCT00776165|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2010-02-01|2008-10-20|2008-10-21|Estimate|||||||2010-02-01|2010-02-03|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)|A Phase 3 Randomized Controlled Open Label Comparative Multicentric Trial To Compare The Safety And Efficacy of Indigenous Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) With Neupogen In Patients on Myelosuppressive Therapy for Non Myeloid Malignancies.|Completed||Phase 3|126|Anticipated|Shantha Biotechnics Limited||2|||f||||f||||||||||2018-06-01 01:39:06.764332|2018-06-01 01:39:06.764332
NCT00776152|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-20|||2008-10-20|2008-10-20|2008-10-21|Estimate|||||||2008-10-20|2008-10-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:39:06.852189|2018-06-01 01:39:06.852189
NCT00776139|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|October 2004||2004-10-31|October 2008|2008-10-31|December 2004|Actual|2004-12-31|October 2004|Actual|2004-10-31||Interventional|||Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions|An Open Label, Randomized, Single-Center, Single-Dose, Two-Treatment, Two-Period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec® Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fasting Condition|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:06.892306|2018-06-01 01:39:06.892306
NCT00776126|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2017-03-03|2008-10-17|2008-10-20|Estimate|||||||2017-03-03|2017-03-06|Actual|October 2008||2008-10-31|March 2017|2017-03-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|NRR||Digital Breast Tomosynthesis Preference Study|Radiologists' Preference Study - Digital Breast Tomosynthesis|Completed|||51|Actual|UNC Lineberger Comprehensive Cancer Center|||1||f||||f||||||||||2018-06-01 01:39:06.970767|2018-06-01 01:39:06.970767
NCT00776113|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|August 2003||2003-08-31|October 2008|2008-10-31|December 2003|Actual|2003-12-31|September 2003|Actual|2003-09-30||Interventional|||Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:07.054135|2018-06-01 01:39:07.054135
NCT00776100|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2016-11-16||2017-01-13|2008-10-17|2008-10-20|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|October 2008||2008-10-31|January 2017|2017-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||All participants who met the eligibility criteria and started the study.|Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of Oligometastatic Stage IV Non-Small Cell Lung Cancer (NSCLC) Treated With Systemic Therapy Plus Either Radiotherapy to All Sites of Gross Residual Disease or No Radiotherapy|Terminated||Phase 2|3|Actual|Alliance for Clinical Trials in Oncology||2||Study was terminated prematurely due to slow accrual.|f||||f||||||||||2018-06-01 01:39:07.158606|2018-06-01 01:39:07.158606
NCT00776087|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2017-06-29|2008-10-17|2008-10-20|Estimate|||||||2017-06-29|2017-07-02|Actual|October 17, 2008|Actual|2008-10-17|June 2017|2017-06-30|October 27, 2016|Actual|2016-10-27|July 21, 2016|Actual|2016-07-21||Interventional|EuroEco||European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)|European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)|Terminated||N/A|409|Actual|Biotronik SE & Co. KG||2||"it is unethical to continue a study with deactivation of HM in the control arm although a~   reduced risk of all-cause death has been shown in previous trials"|f||||f||||||||No||2018-06-01 01:39:07.779865|2018-06-01 01:39:07.779865
NCT00776074|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2010-06-17|2008-10-16|2008-10-20|Estimate|||||||2010-06-17|2010-06-22|Estimate|June 2006||2006-06-30|June 2010|2010-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids.|3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients With Uterine Fibroids|Completed||Phase 2|80|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:39:07.89819|2018-06-01 01:39:07.89819
NCT00776048|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2010-06-23|2008-10-17|2008-10-20|Estimate|||||||2010-06-23|2010-06-24|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Validation of an Obstacle Course Used in Patients With Muscle Tightness|The Validation of a New Method to Evaluate the Effects of Chemoneurolytic Intervention on Balance and Community Ambulation in Spastic Hemiplegic Patients|Unknown status|Enrolling by invitation||40|Anticipated|Kessler Foundation|||2||f||||f||||||||||2018-06-01 01:39:07.98732|2018-06-01 01:39:07.98732
NCT00776035|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2017-03-28|2008-10-17|2008-10-20|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2008||2008-01-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Sex and Obesity: Effects on Heart Failure Study|Sex and Obesity Effects on Myocardial Blood Flow and Metabolism|Active, not recruiting|||10|Anticipated|Washington University School of Medicine|||1||f||||f||||||Samples With DNA|"~     Non diagnostic genetic samples~   "|||2018-06-01 01:39:08.075228|2018-06-01 01:39:08.075228
NCT00776022|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2010-03-01|2008-10-17|2008-10-20|Estimate|||||||2010-03-01|2010-03-02|Estimate|April 2005||2005-04-30|March 2010|2010-03-31|June 2005|Actual|2005-06-30|April 2005|Actual|2005-04-30||Interventional|||Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions|An Open Label, Randomized, Single-center, Single-dose, Two-treatment, Two-period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec® Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fed Condition|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:08.203707|2018-06-01 01:39:08.203707
NCT00776009|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2010-12-13||2011-06-06|2008-10-16|2008-10-20|Estimate|2011-02-22|2011-03-16|Estimate||||2011-06-06|2011-06-08|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.|A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.|Completed||Phase 4|165|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:39:08.285859|2018-06-01 01:39:08.285859
NCT00775996|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|August 2003||2003-08-31|October 2008|2008-10-31|November 2003|Actual|2003-11-30|September 2003|Actual|2003-09-30||Interventional|||Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions|The Objective of This Study Was to Compare the Single-Dose Relative Bioavailability of Ranbaxy and Abbott (Tranxene® T-Tab®) 15 mg Clorazepate Dipotassium Tablets Under Fasting Conditions.|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:08.801631|2018-06-01 01:39:08.801631
NCT00775983|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2013-05-07||2013-10-18|2008-10-16|2008-10-20|Estimate|2013-05-07|2013-07-17|Estimate||||2013-10-18|2013-11-14|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|DvL|Of 72 eligible and enrolled participants, 3 were excluded from analysis because they did not receive an abortion (2 in the Same-day Dilapan-S group, and 1 in the Overnight laminaria group).|Dilapan Versus Laminaria|Same-day Dilapan Versus Overnight Laminaria for Cervical Preparation for Early Second-trimester Surgical Abortion|Completed||N/A|72|Actual|University of California, San Francisco|-inadequate power to compare complications directly between study groups. Procedure time was chosen as a proxy for procedural difficulty and thus potential complications|2|||f||||t||||||||||2018-06-01 01:39:08.893145|2018-06-01 01:39:08.893145
NCT00775970|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|May 2008||2008-05-31|October 2008|2008-10-31||||||||Interventional|||Walking, Spontaneous Physical Activity and Lipid Oxidation After Dietary Treatment of Obesity|Influence of Walking on Spontaneous Physical Activity and on Lipid Oxidation Following Dietary Treatment of Obesity|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Tours|||||f||||f||||||||||2018-06-01 01:39:09.16652|2018-06-01 01:39:09.16652
NCT00775957|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2010-09-27|2008-10-17|2008-10-20|Estimate|||||||2010-09-27|2010-09-28|Estimate|October 2008||2008-10-31|September 2010|2010-09-30||||||||Observational|||Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma|Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgknin's Lymphoma|Terminated|||35|Anticipated|University of Oklahoma|||2|Terminated by institutional review board|f||||t||||||||||2018-06-01 01:39:09.307591|2018-06-01 01:39:09.307591
NCT00775944|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2012-07-25||2012-09-26|2008-10-17|2008-10-20|Estimate|2012-09-26|2012-10-26|Estimate||||2012-09-26|2012-10-26|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Interventional|PORTSSS||Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS/Stop Together Trial)|Trial Comparing Different Methods of Support With Stopping Smoking Offered Through The National Health Service (NHS) Smoking Helpline|Completed||Phase 4|2591|Actual|University of Nottingham||4|||f||||f||||||||||2018-06-01 01:39:09.413585|2018-06-01 01:39:09.413585
NCT00775931|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2015-04-22|2008-10-16|2008-10-20|Estimate|||||||2015-04-22|2015-04-24|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Allogeneic Transplantation For Severe Osteopetrosis|Allogeneic Hematopoietic Stem Cell Transplantation For Severe Osteopetrosis|Unknown status|Active, not recruiting|Phase 2/Phase 3|23|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 01:39:09.861556|2018-06-01 01:39:09.861556
NCT00775905|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-20|Estimate|||||||2008-10-16|2008-10-20|Estimate|July 2005||2005-07-31|October 2008|2008-10-31|October 2005|Actual|2005-10-31|August 2005|Actual|2005-08-31||Interventional|||Bioequivalence Study of Amlodipine Tablets Under Fasting Conditions|The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fasted Subjects.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:10.032327|2018-06-01 01:39:10.032327
NCT00775892|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2011-08-07|2008-10-16|2008-10-20|Estimate|||||||2011-08-07|2011-08-09|Estimate|September 2008||2008-09-30|August 2011|2011-08-31||||May 2010|Actual|2010-05-31||Interventional|||SeriACL™ Device (Gen IB) Trial for Anterior Cruciate Ligament (ACL) Repair|A Multi-Center Open Label Study to Evaluate the SeriACL™ Device (Gen IB) for Primary Anterior Cruciate Ligament Repair|Completed||Phase 1/Phase 2|30|Anticipated|Serica Technologies, Inc.|||||f||||t||||||||||2018-06-01 01:39:10.100908|2018-06-01 01:39:10.100908
NCT00775879|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2013-05-17|2008-10-17|2008-10-20|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|SIZE||Interest of the Induction With Target-controlled Inhalation of Sevoflurane on Spikes Wave Occurrence|Interest of the Induction With Target-controlled Inhalation of Sevoflurane on Spikes Wave Occurrence|Completed||N/A|34|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:39:10.252491|2018-06-01 01:39:10.252491
NCT00775866|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2017-11-27|2008-10-16|2008-10-20|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2006||2006-10-31|November 2017|2017-11-30|September 15, 2017|Actual|2017-09-15|May 2015|Actual|2015-05-31||Interventional|||MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy|MRI - Guided Biopsy for Suspicion of Locally Recurrent Prostate Cancer After External Beam Radiotherapy|Completed||N/A|82|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:39:10.341937|2018-06-01 01:39:10.341937
NCT00775853|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2018-03-30|2008-10-17|2008-10-20|Estimate|||||||2018-03-30|2018-04-02|Actual|October 16, 2008||2008-10-16|February 7, 2018|2018-02-07||||||||Observational|||Biomarkers of Risk of Parkinson Disease|Biomarkers of Risk of Parkinson Disease|Active, not recruiting|||88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:39:10.429163|2018-06-01 01:39:10.429163
NCT00775840|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2010-06-17|2008-10-16|2008-10-20|Estimate|||||||2010-06-17|2010-06-22|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.|"Candesartan Added Therapy for Treatment Optimization of Symptomatic Heart Failure With Diastolic Dysfunction in Diabetic and Hypertensive Patients A Randomized, Placebo-controlled, Double-blind, Parallel-group and Multicenter Clinical Phase III Study Investigating the Effects on NT-proBNP Over 6 Months"|Completed||Phase 3|22|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:39:10.516014|2018-06-01 01:39:10.516014
NCT00775827|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|November 2002||2002-11-30|October 2008|2008-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Bioequivalency Study of Fenofibrate 160mg Tablets Under Fasting Conditions|A Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Fenofibrate Formulations Comparing Fenofibrate 160 mg Tablets of Ranbaxy Laboratories With Tricor 160 mg Tablets of in Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:10.683571|2018-06-01 01:39:10.683571
NCT00775814|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-08-06|2008-10-17|2008-10-20|Estimate|||||||2012-08-06|2012-08-08|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.|Double-blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous ß-blocker or Calcium Channel Blocker|Completed||Phase 4|188|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:39:10.779727|2018-06-01 01:39:10.779727
NCT00775801|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2018-01-18|2008-10-17|2008-10-20|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2008||2008-09-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FLD||Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease|An IDE Study of the Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease|Active, not recruiting||N/A|300|Anticipated|AxioMed Spine Corporation||2|||f||||t||||||||||2018-06-01 01:39:10.914692|2018-06-01 01:39:10.914692
NCT00775788|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-11-17|2008-10-17|2008-10-20|Estimate|||||||2008-11-17|2008-11-18|Estimate|June 2008||2008-06-30|October 2008|2008-10-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Autologous Fat Grafting to the Breast|Autologous Fat Grafting to the Breast|Unknown status|Recruiting|N/A|50|Anticipated|Louisiana State University Health Sciences Center in New Orleans||6|||f||||f||||||||||2018-06-01 01:39:11.026228|2018-06-01 01:39:11.026228
NCT00775775|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-10-02|2008-10-17|2008-10-20|Estimate|||||||2009-10-02|2009-10-06|Estimate|May 2003||2003-05-31|October 2009|2009-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Fatigue, Sleep Disorders and Endocrine Abnormalities in TBI Patients|The Relationship Between Fatigue, Sleep Disorders and Endocrine Abnormalities Following Traumatic Brain Injury|Unknown status|Recruiting||50|Anticipated|Kessler Foundation|||1||f||||f||||||||||2018-06-01 01:39:11.128373|2018-06-01 01:39:11.128373
NCT00775762|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|December 2010|Anticipated|2010-12-31|January 2009|Anticipated|2009-01-31||Interventional|||Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events||Unknown status|Not yet recruiting|Phase 3|213|Anticipated|Catholic University of the Sacred Heart||3|||f||||t||||||||||2018-06-01 01:39:11.221133|2018-06-01 01:39:11.221133
NCT00775749|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2011-10-25|2008-10-17|2008-10-20|Estimate|||||||2011-10-25|2011-10-26|Estimate|April 2009||2009-04-30|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Transdermal Nicotine in Female Patients at High Risk for Post Operative Nausea and/or Vomiting (PONV)|Transdermal Nicotine in Female Patients at High Risk for PONV|Withdrawn||N/A|560|Anticipated|Ochsner Health System||2||The study is not feasible with the number of subjects needed to complete it.|f||||t||||||||||2018-06-01 01:39:11.345975|2018-06-01 01:39:11.345975
NCT00775736|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2017-01-10|2008-10-17|2008-10-20|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2008||2008-10-31|January 2017|2017-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|Mix2Mix||Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin|Observational Study Evaluating Safety in Patients With Type 2 Diabetes Treated With NovoMix® 30 or NovoMix® 50 or NovoMix®70 (Biphasic Insulin Aspart)|Completed|||611|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:39:11.437161|2018-06-01 01:39:11.437161
NCT00775710|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2011-06-21|2008-10-17|2008-10-20|Estimate|||||||2011-06-21|2011-06-22|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Clinical Trial Assessing Two Protocols to Withdraw Non-invasive Ventilation in Hypercapnic Respiratory Failure|A Randomized Controlled Trial Comparing Two Protocols to Withdraw Non-invasive Ventilation (NIV) After an Episode of Hypercapnic Respiratory Failure|Completed||Phase 4|128|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 01:39:11.602461|2018-06-01 01:39:11.602461
NCT00775697|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2013-06-18|2008-10-17|2008-10-20|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Montelukast in Children With Wheezing|Montelukast Effects on Pulmonary Function in Children With Wheezing Aged Less Than 2 Years|Unknown status|Enrolling by invitation|Phase 4|40|Anticipated|Universita di Verona||1|||f||||t||||||||||2018-06-01 01:39:11.69271|2018-06-01 01:39:11.69271
NCT00775684|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2016-09-22||2017-12-08|2008-10-17|2008-10-20|Estimate|2017-10-31|2017-12-06|Actual||||2017-12-08|2018-01-04|Actual|October 2008||2008-10-31|December 2017|2017-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass|A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes|Completed||N/A|47|Actual|University of Pennsylvania||3|||f||||f||||||||Undecided||2018-06-01 01:39:11.80059|2018-06-01 01:39:11.80059
NCT00775671|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2012-09-23||2012-09-23|2008-10-17|2008-10-20|Estimate|2012-09-23|2012-10-23|Estimate||||2012-09-23|2012-10-23|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome|Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome|Completed||Phase 4|46|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:39:12.263937|2018-06-01 01:39:12.263937
NCT00775658|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2017-02-21||2017-06-12|2008-10-17|2008-10-20|Estimate|2017-06-12|2017-07-12|Actual||||2017-06-12|2017-07-12|Actual|January 2008||2008-01-31|June 2017|2017-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Olopatadine Eye Drops and Allergy Skin Testing|Effect of Olopatadine Hydrochloride 0.2% Ophthalmic Solution on Epicutaneous Skin Prick Testing With Histamine and Saline|Completed||N/A|24|Actual|Vanderbilt University Medical Center|Small sample size and majority female patients.|2|||f||||f||||||||No||2018-06-01 01:39:12.48926|2018-06-01 01:39:12.48926
NCT00775645|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2016-11-14||2017-06-29|2008-10-17|2008-10-20|Estimate|2017-02-23|2017-04-10|Actual||||2017-06-29|2017-08-14|Actual|September 2009||2009-09-30|June 2017|2017-06-30|June 2013|Actual|2013-06-30|January 2012|Actual|2012-01-31||Interventional||437 patients registered, 27 ineligible, 1 withdrew consent, 409 evaluable patients at baseline.|S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo|S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III|Completed||Phase 3|437|Actual|Southwest Oncology Group||2|||f||||t|f|f||||||No||2018-06-01 01:39:12.710095|2018-06-01 01:39:12.710095
NCT00775632|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2016-06-21|2008-10-17|2008-10-20|Estimate|||||||2016-06-21|2016-06-23|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants|A Phase II Randomized Study Comparing Low Dose Alemtuzumab and Cyclosporine With Standard of Care for the Prevention of Chronic Extensive GVHD for Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Hematological Malignancies|Completed||Phase 2|78|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 01:39:13.841865|2018-06-01 01:39:13.841865
NCT00775619|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|September 2003||2003-09-30|October 2008|2008-10-31|December 2003|Actual|2003-12-31|September 2003|Actual|2003-09-30||Interventional|||Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Carvedilol Formulations Comparing Carvedilol 12.5 mg Tablets of Ranbaxy Laboratories With Coreg® 12.5 mg Tablets of Glaxosmithkline in Healthy, Adult, Human Subjects Under Fed Conditions|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:13.946582|2018-06-01 01:39:13.946582
NCT00775606|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2013-06-28||2014-05-30|2008-10-17|2008-10-20|Estimate|2014-04-29|2014-05-29|Estimate||||2014-05-30|2014-06-09|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease|A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART (Highly Active Antiretroviral Therapy) Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease|Terminated||Phase 4|15|Actual|Rush University Medical Center|Study was terminated due to the slow recruitment and the small number of subjects.|2||Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.|f||||f||||||||||2018-06-01 01:39:14.048383|2018-06-01 01:39:14.048383
NCT00775593|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2014-06-10||2017-10-10|2008-10-17|2008-10-20|Estimate|2015-03-15|2015-03-23|Estimate||||2017-10-10|2017-11-09|Actual|December 2008||2008-12-31|October 2017|2017-10-31|October 23, 2013|Actual|2013-10-23|June 2012|Actual|2012-06-30||Interventional|AML1107||Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Completed||Phase 2|60|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 01:39:14.394225|2018-06-01 01:39:14.394225
NCT00775580|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|May 2005||2005-05-31|October 2008|2008-10-31|July 2005|Actual|2005-07-31|May 2005|Actual|2005-05-31||Interventional|||Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Atenolol 100 mg Capsules in Healthy Volunteers|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:14.672559|2018-06-01 01:39:14.672559
NCT00775567|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2011-08-09|2008-10-17|2008-10-20|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MEF||Effect of Fructose on Colonic Microflora|Colonic Microbial and Clinical Adaptation to Large Doses of Fructose|Completed||N/A|45|Actual|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||t||||||||||2018-06-01 01:39:14.742491|2018-06-01 01:39:14.742491
NCT00775554|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2015-10-13|2008-10-17|2008-10-20|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2008||2008-09-30|October 2008|2008-10-31||||August 2009|Anticipated|2009-08-31||Interventional|||Comparison Study of Using Ultrasound Guidance for Hematoma Blocks vs. Traditional Approach|"Are Ultrasound-guided Hematoma Blocks for Distal Forearm Fractures Superior to the Landmark-guided Method for Hematoma Blocks?"|Withdrawn||N/A|0|Actual|St. Luke's-Roosevelt Hospital Center||2||no participants enrolled|f||||t||||||||||2018-06-01 01:39:14.838223|2018-06-01 01:39:14.838223
NCT00775541|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2012-06-15|2008-10-17|2008-10-20|Estimate|||||||2012-06-15|2012-06-18|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Hyperglycemia and Oxidative Stress in the Human Brain With Diabetes|Hyperglycemia and Oxidative Stress in the Human Brain With Diabetes|Terminated||N/A|5|Actual|University of Kansas Medical Center||1||Insufficient dose for MRI scanning|f||||t||||||||||2018-06-01 01:39:14.922951|2018-06-01 01:39:14.922951
NCT00775528|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2010-09-09||2010-10-25|2008-10-17|2008-10-20|Estimate|2010-09-09|2010-10-01|Estimate||||2010-10-25|2010-11-08|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|An Open Label, Multi-center, Study to Assess the Safety and Tolerability of Pancrelipase Delayed Release Capsules in Infants and Children Less Than 7 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Completed||Phase 3|19|Actual|Solvay Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:39:15.043188|2018-06-01 01:39:15.043188
NCT00775515|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2011-04-29|2008-10-17|2008-10-20|Estimate|||||||2011-04-29|2011-05-02|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Laparoscopic Prostatectomy for Chronic Prostatitis|Laparoscopic Prostatectomy for Chronic Prostatitis|Unknown status|Recruiting|Phase 2|100|Anticipated|The Krongrad Institute||1|||f||||f||||||||||2018-06-01 01:39:15.277969|2018-06-01 01:39:15.277969
NCT00775502|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2016-06-14|2008-10-17|2008-10-20|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma|Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma|Terminated||Phase 1|23|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1||lack of efficacy in Multiple myeloma|f||||f||||||||||2018-06-01 01:39:15.385718|2018-06-01 01:39:15.385718
NCT00775489|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2011-01-04|2008-10-17|2008-10-20|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2010||2010-01-31|October 2008|2008-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Nasal Steroids in Controlled Glaucoma|The Effect of Beclomethasone Nasal Spray on Intraocular Pressure in Ocular Hypertension or Controlled Glaucoma|Completed||N/A|19|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:39:15.49716|2018-06-01 01:39:15.49716
NCT00775476|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2013-12-12|2008-10-17|2008-10-20|Estimate|||||||2013-12-12|2013-12-13|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|June 2019|Anticipated|2019-06-30|October 2017|Anticipated|2017-10-31||Interventional|NAC||Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine|Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine|Suspended||Phase 1/Phase 2|478|Anticipated|State University of New York - Upstate Medical University||3||"Funds from original NIH grant, AT4332, have been exhausted. While new funding is thought with~   revised study design, no new patients will be recruited."|f||||t||||||||||2018-06-01 01:39:15.609699|2018-06-01 01:39:15.609699
NCT00775463|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2014-01-31|2013-02-26|2014-01-31|2008-10-17|2008-10-20|Estimate|2014-01-31|2014-03-17|Estimate|2013-02-26|2013-03-04|Estimate|2014-01-31|2014-03-17|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|DISTOL-1|Baseline demographics and characteristics were summarized for subjects who received at least one dose of study drug. One subject in the treprostinil diethanolamine treatment group was randomized, withdrew consent and exited the study prior to taking any study medication and is not included in the summary.|Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine|DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study|Completed||Phase 2|148|Actual|United Therapeutics||2|||f||||f||||||||||2018-06-01 01:39:15.750458|2018-06-01 01:39:15.750458
NCT00775450|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2011-07-14|2010-03-31|2013-12-05|2008-10-16|2008-10-20|Estimate|2011-07-14|2011-08-11|Estimate|2010-03-31|2010-04-02|Estimate|2013-12-05|2013-12-31|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Influenza Vaccine Revaccination in Ambulatory Elderly Subjects|Safety and Immunogenicity of Revaccination With Influenza Vaccine in Ambulatory Elderly Subjects Previously Vaccinated With Fluzone ID, Fluzone HD, and Fluzone® IM|Completed||Phase 2|807|Actual|Sanofi||5|||f||||f||||||||||2018-06-01 01:39:17.738233|2018-06-01 01:39:17.738233
NCT00775437|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2015-12-17||2015-12-17|2008-10-17|2008-10-20|Estimate|2015-12-17|2016-01-26|Estimate||||2015-12-17|2016-01-26|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use|Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA)|Completed||Phase 3|32|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 01:39:19.028346|2018-06-01 01:39:19.028346
NCT00775424|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2016-08-24|2008-10-17|2008-10-20|Estimate|||||||2016-08-24|2016-08-25|Estimate|September 2008||2008-09-30|August 2016|2016-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection|A PHASE Ib PARTIALLY RANDOMIZED PILOT STUDY INTENDED TO EVALUATE THE SAFETY AND IMMUNOLOGICAL EFFECTS OF HIV-1 DNA IMMUNIZATION (PENNVAX-B) WITH OR WITHOUT CO-ADMINISTRATION OF CONSTRUCTS CONTAINING DNA ENCODING FOR THE EXPRESSION OF EITHER IL-12 OR IL-15 IN HIV INFECTED INDIVIDUALS|Completed||Phase 1|38|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 01:39:20.687684|2018-06-01 01:39:20.687684
NCT00775411|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2012-08-01|2010-09-24|2012-08-01|2008-10-16|2008-10-20|Estimate|2012-08-01|2012-09-03|Estimate|2010-09-24|2010-09-29|Estimate|2012-08-01|2012-09-03|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)||Completed||Phase 2|44|Actual|Allergan||1|||f||||f||||||||||2018-06-01 01:39:20.831645|2018-06-01 01:39:20.831645
NCT00775398|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-06-06|2008-10-16|2008-10-20|Estimate|||||||2012-06-06|2012-06-07|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Observational|MOSAIC||Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters.|A Phase 4, Multicenter, Open-Label, Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® (Thrombin, Topical U.S.P [Bovine Origin]) on Coagulation Parameters|Completed|||553|Actual|Pfizer|||4||f||||f||||||None Retained|"~     Whole blood~   "|||2018-06-01 01:39:21.022942|2018-06-01 01:39:21.022942
NCT00775385|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2017-03-01|2008-10-17|2008-10-20|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2009||2009-04-30|March 2017|2017-03-31|January 21, 2016|Actual|2016-01-21|April 2013|Actual|2013-04-30||Interventional|TASTE||TAilored Post-Surgical Therapy in Early Stage NSCLC|Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-squamous Non Small Cell Lung Cancer (NSCLC).|Completed||Phase 2/Phase 3|152|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||||2018-06-01 01:39:21.245707|2018-06-01 01:39:21.245707
NCT00775372|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|December 2005|Actual|2005-12-31|October 2005|Actual|2005-10-31||Interventional|||Bioequivaelnce Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fed Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Four-Period, Two- Sequence, Single-Dose, Crossover Fully Replicated, Bioavailability Study on Clarithromycin Formulations Comparing Clarithromycin 250 mg/5 mL Powder for Oral Suspension of Ranbaxy Laboratories With Biaxin® Granules 250 mg/5 mL Oral Suspension in Healthy, Adult,Human, Male Subjects Under Fed Conditions.|Completed||N/A|40||Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:21.381974|2018-06-01 01:39:21.381974
NCT00775359|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|August 2002||2002-08-31|October 2008|2008-10-31|October 2002|Actual|2002-10-31|September 2002|Actual|2002-09-30||Interventional|||Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Relative Bioavailability Study of Ranbaxy and Abbott (TriCor®) 160 mg Fenofibrate Tablets in Healthy Adult Volunteers Under Fed Conditions|Completed||N/A|24|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:21.460976|2018-06-01 01:39:21.460976
NCT00775346|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2010-03-15||2014-08-05|2008-10-17|2008-10-20|Estimate|2010-05-20|2010-06-16|Estimate||||2014-08-05|2014-08-07|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||A Multi-Center Study to Assess the Performance of Saturation Patterns.|A Multi-Center Study to Assess the Performance of the Saturation Pattern Detection (SPD) Software Algorithm.|Completed|||92|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-06-01 01:39:21.539808|2018-06-01 01:39:21.539808
NCT00775333|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|December 2003||2003-12-31|October 2008|2008-10-31|April 2008|Actual|2008-04-30|||||Observational|||Nerve Entrapment in Diabetic Patients|Clinical Outcomes of Surgical Release Among Diabetic Patients With Carpal Tunnel Syndrome. A Prospective Study With Matched Controls|Completed|||67|Actual|Skane University Hospital|||2||f||||f||||||||||2018-06-01 01:39:21.682756|2018-06-01 01:39:21.682756
NCT00775320|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2016-05-12|2008-10-17|2008-10-20|Estimate|||||||2016-05-12|2016-05-16|Estimate|October 2008||2008-10-31|May 2016|2016-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-flourothymidine PET|Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-fluorothymidine Positron Emission Tomography|Terminated|||13|Actual|University of Oklahoma|||1|Study closed by institutional review board|f||||t||||||Samples Without DNA|"~     Tissue from brain tumor~   "|||2018-06-01 01:39:21.768318|2018-06-01 01:39:21.768318
NCT00775307|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2017-03-01|2008-10-17|2008-10-20|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2008||2008-11-30|March 2017|2017-03-31|April 18, 2016|Actual|2016-04-18|December 2015|Actual|2015-12-31||Interventional|||Adjuvant Pazopanib in Stage I NSCLC|A Randomized, Double-blind, Placebo-controlled Phase II-III Multi-centre Study to Evaluate the Effect of Adjuvant Pazopanib (GW786034) Versus Placebo on Post-surgical Disease-free Survival in Patients With Stage I Non Small Cell Lung Cancer and Tumor Size Equal or Inferior to 5 cm.|Completed||Phase 2/Phase 3|142|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||||2018-06-01 01:39:21.844982|2018-06-01 01:39:21.844982
NCT00775294|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2011-05-11|2008-10-17|2008-10-20|Estimate|||||||2011-05-11|2011-05-13|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|May 2009|Actual|2009-05-31||Interventional|||Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue|A Phase IV, Open Label Study in Healthy Male Subjects to Investigate the Extent of Maraviroc Exposure in Blood, Saliva, Seminal Fluid, and Rectal Mucosal Tissue Following Single and Multiple Dosing of Maraviroc|Completed||Phase 1|14|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 01:39:21.976183|2018-06-01 01:39:21.976183
NCT00775281|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2010-04-25|2008-10-17|2008-10-20|Estimate|||||||2010-04-25|2010-04-27|Estimate|October 2006||2006-10-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.|Mediators of Neurogenic Inflammation in the Urinary Tract as Key Factors in the Painful Bladder Syndrome / Interstitial Cystitis and Bladder Dysfunction|Completed|||45|Anticipated|University Hospital Inselspital, Berne|||3||f||||f||||||Samples With DNA|"~     cold cut bladder biopsies~   "|||2018-06-01 01:39:22.040171|2018-06-01 01:39:22.040171
NCT00775268|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2018-05-18|2008-10-17|2008-10-20|Estimate|||||||2018-05-18|2018-05-21|Actual|September 29, 2008||2008-09-29|October 23, 2014|2014-10-23|October 23, 2014|Actual|2014-10-23|||||Interventional|||18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma|A Pilot Study of 18F Fluorothymidine (FLT) PET/CT in Lymphoma|Terminated||Phase 1/Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 01:39:22.143922|2018-06-01 01:39:22.143922
NCT00775255|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-20|Estimate|||||||2008-10-16|2008-10-20|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|December 2005|Actual|2005-12-31|September 2005|Actual|2005-09-30||Interventional|||Bioequivalence Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioavailability Study on Clarithromycin Formulations Comparing Clarithromycin 250 mg/5 mL Powder for Oral Suspension of Ranbaxy Laboratories With Biaxin® Granules 250 mg/5 mL Oral Suspension in Healthy, Adult, Human, Male Subjects Under Fasting Conditions.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:22.258623|2018-06-01 01:39:22.258623
NCT00775242|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-08-21|2008-10-16|2008-10-20|Estimate|||||||2009-08-21|2009-08-25|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.|Comparative Efficacy and Safety Study of Three Different Doses of a Formulation Composed of Crystalline Estradiol and Progesterone Microspheres, Indicated for Monthly IM Injection for the Treatment ot Climacteric Symptoms.|Completed||Phase 2/Phase 3|103|Actual|Centro A.F. de Estudios Tecnologicos, S.A.||1|||f||||f||||||||||2018-06-01 01:39:22.327367|2018-06-01 01:39:22.327367
NCT00775229|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2013-10-09||2014-01-31|2008-10-17|2008-10-20|Estimate|2014-01-31|2014-03-17|Estimate||||2014-01-31|2014-03-17|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Naltrexone in the Treatment of Trichotillomania|A Double-blind, Placebo-controlled Study of Naltrexone in Trichotillomania|Completed||Phase 2|51|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 01:39:22.414982|2018-06-01 01:39:22.414982
NCT00775216|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2015-05-21|2008-10-17|2008-10-20|Estimate|||||||2015-05-21|2015-05-25|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Project Diabetes: Prescription for Healthy Living|Project Diabetes: Prescription for Healthy Living|Terminated||N/A|13|Actual|Vanderbilt University||2||grant funding ended and lack of sufficient participants to complete trial|f||||f||||||||||2018-06-01 01:39:22.673506|2018-06-01 01:39:22.673506
NCT00775203|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2010-02-25|2009-03-16|2012-04-24|2008-10-17|2008-10-20|Estimate|2010-03-24|2010-04-07|Estimate|2009-10-02|2009-10-07|Estimate|2012-04-24|2012-04-27|Estimate|June 2007||2007-06-30|April 2012|2012-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.|A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.|Completed||Phase 3|412|Actual|Labopharm Inc.||2|||f||||||||||||||2018-06-01 01:39:22.855302|2018-06-01 01:39:22.855302
NCT00775190|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|2017-03-03||2017-03-03|2008-10-17|2008-10-20|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|October 2008||2008-10-31|March 2017|2017-03-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives|Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives|Terminated||N/A|12|Actual|William Beaumont Hospitals|Early Study termination. No data analysis.|2||unale to recruit , progress report not filed by PI|f||||f||||||||No||2018-06-01 01:39:23.626813|2018-06-01 01:39:23.626813
NCT00775177|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-17|||2008-10-17|2008-10-17|2008-10-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|June 2005||2005-06-30|October 2008|2008-10-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Doxycycline Monohydrate 100mg Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Doxycycline Monohydrate 100 mg Tablets in Healthy Volunteers|Completed||N/A|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:24.061543|2018-06-01 01:39:24.061543
NCT00775164|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-08-30|2008-10-17|2008-10-20|Estimate|||||||2012-08-30|2012-08-31|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|February 2011|Anticipated|2011-02-28|December 2010|Anticipated|2010-12-31||Interventional|||Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study|Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study|Withdrawn||Phase 4|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Inadequate enrollment|f||||t||||||||||2018-06-01 01:39:24.149619|2018-06-01 01:39:24.149619
NCT00775151|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-20|Estimate|||||||2008-10-16|2008-10-20|Estimate|July 2005||2005-07-31|October 2008|2008-10-31|November 2005|Actual|2005-11-30|August 2005|Actual|2005-08-31||Interventional|||Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions|The Objective of This Study Was to Compare the Rate and Extent of Absorption of Ranbaxy Amlodipine 10 mg Tablet to That of Norvasc® 10 mg Tablet After a Single, One Tablet Dose in Fed State Subjects.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:24.236674|2018-06-01 01:39:24.236674
NCT00775138|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15||2016-09-29|2016-09-29|2008-10-16|2008-10-17|Estimate||||2016-09-29|2016-10-03|Estimate|2016-09-29|2016-10-03|Estimate|June 2008||2008-06-30|September 2016|2016-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis.|A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace™) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa|Completed||Phase 1/Phase 2|64|Actual|Insmed Incorporated||3|||f||||t||||||||||2018-06-01 01:39:24.323073|2018-06-01 01:39:24.323073
NCT00775125|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2010-12-16|2008-10-16|2008-10-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.|A Phase I, Open-label, Randomized, 2-way Crossover Trial in 40 Healthy Subjects to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.|Completed||Phase 1|40|Actual|Tibotec BVBA|||||f||||||||||||||2018-06-01 01:39:24.437995|2018-06-01 01:39:24.437995
NCT00775112|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|July 2004||2004-07-31|October 2008|2008-10-31||||September 2006||2006-09-30||Interventional|||Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology|Randomized Evaluation of a Positioning Pillow for Lumbar Puncture in Paediatric Hematology-Oncology|Completed||N/A|124|Actual|Centre Leon Berard||2|||f||||f||||||||||2018-06-01 01:39:24.510676|2018-06-01 01:39:24.510676
NCT00775099|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Combustion Derived Air Pollution and Vascular Function|The Effects of Combustion-Derived Air Pollution on Vascular Vasomotor and Fibrinolytic Function in Healthy Volunteers (Diesel Exposure)|Completed||N/A|16|Actual|University of Edinburgh||4|||f||||f||||||||||2018-06-01 01:39:24.584067|2018-06-01 01:39:24.584067
NCT00775086|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2011-06-06|2008-10-16|2008-10-17|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|August 2004|Actual|2004-08-31|||||Interventional|||Bioequivalence Study of Patches With Different Equilibration Profiles|A Definitive Bioequivalence Study of ORTHO EVRA Exhibiting Faster Equilibration Profile and Currently Marketed ORTHO EVRA in Healthy Female Volunteers|Completed||Phase 1|42|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:39:24.668041|2018-06-01 01:39:24.668041
NCT00775073|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-04-27|2008-10-16|2008-10-17|Estimate|||||||2012-04-27|2012-04-30|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|January 2011|Actual|2011-01-31||Interventional|||Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001|Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001|Completed||Phase 2|33|Actual|Treiber, Gerhard||1|||f||||t||||||||||2018-06-01 01:39:24.739659|2018-06-01 01:39:24.739659
NCT00775060|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2016-04-06|2008-10-16|2008-10-17|Estimate|||||||2016-04-06|2016-04-07|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Observational|||Maastricht IBS Cohort|Maastricht IBS Cohort: Phenotypical and Genotypical Characterization of Patients With Irritable Bowel Syndrome.|Recruiting|||600|Anticipated|Maastricht University Medical Center|||||f||||f||||||||No||2018-06-01 01:39:24.830506|2018-06-01 01:39:24.830506
NCT00775047|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|August 2006||2006-08-31|October 2008|2008-10-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|PAD||Pharmacist-Administered Injections for Contraception|Pharmacist-Administered Injections of Depo-Medroxyprogesterone Acetate for Contraception: A Pilot Randomized Controlled Trial|Completed||N/A|50|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 01:39:24.914067|2018-06-01 01:39:24.914067
NCT00775034|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2014-12-04|2008-10-16|2008-10-17|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|DREAM||Drainage Versus Sealant in Double Blinded Monocentric Open Incisional Hernia Repair|Drainage Versus Sealant in Double Blinded Monocentric Open Incisional Hernia Repair|Unknown status|Recruiting|Phase 4|100|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:39:25.00924|2018-06-01 01:39:25.00924
NCT00775021|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2011-02-07||2015-05-05|2008-10-15|2008-10-17|Estimate|2011-02-07|2011-03-03|Estimate||||2015-05-05|2015-05-21|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Clinical Comparison of Two Daily Disposable Contact Lenses.||Completed||N/A|123|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 01:39:25.105224|2018-06-01 01:39:25.105224
NCT00775008|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2009-03-02|2008-10-15|2008-10-17|Estimate|||||||2009-03-02|2009-03-03|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Media Effects Study on Health-Related Content||Completed||Early Phase 1|40|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 01:39:25.316557|2018-06-01 01:39:25.316557
NCT00774995|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2011-05-26||2016-09-27|2008-10-16|2008-10-17|Estimate|2011-05-26|2011-06-27|Estimate||||2016-09-27|2016-11-02|Estimate|November 2008||2008-11-30|September 2016|2016-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.|Study to Evaluate the Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With GSK Biologicals' Engerix™-B Vaccine, Approximately 20 Years Ago.|Completed||Phase 4|49|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL).The table shows updated results following complete retesting and reanalysis|4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:39:25.381829|2018-06-01 01:39:25.381829
NCT00774982|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-07-16|2008-10-16|2008-10-17|Estimate|||||||2009-07-16|2009-07-17|Estimate|December 2008||2008-12-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients|Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease|Completed||Phase 1|12|Actual|Teva GTC||2|||f||||f||||||||||2018-06-01 01:39:25.908174|2018-06-01 01:39:25.908174
NCT00774969|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease|Phase 1 Study to Evaluate the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri-Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease|Completed||Phase 1|19|Actual|S.L.A. Pharma AG||1|||f||||t||||||||||2018-06-01 01:39:25.98292|2018-06-01 01:39:25.98292
NCT00774956|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2012-03-19|2008-10-16|2008-10-17|Estimate|||||||2012-03-19|2012-03-20|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Shoulder Training: Muscle Recruitment Patterns and the Effect of an Exercise Program|Shoulder Training: Muscle Recruitment Patterns and the Effect of an Exercise Program|Completed||N/A|77|Actual|University Ghent||2|||f||||f||||||||||2018-06-01 01:39:26.042155|2018-06-01 01:39:26.042155
NCT00774943|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2013-04-05|2008-10-16|2008-10-17|Estimate|||||||2013-04-05|2013-04-09|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of AMG 557 in Adults With Systemic Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|58|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:39:26.172839|2018-06-01 01:39:26.172839
NCT00774930|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2015-08-05||2016-12-28|2008-10-16|2008-10-17|Estimate|2016-01-07|2016-02-09|Estimate||||2016-12-28|2017-02-14|Actual|May 2009||2009-05-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|May 2013|Actual|2013-05-31||Interventional|ELECT|Intent-to-treat (ITT) population: All randomised subjects (regardless of whether the subjects received or adhered to the allocated treatment group). Subjects from the ITT population were analysed under the randomised treatment group.|An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome|A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome|Completed||Phase 3|115|Actual|Ipsen|None specified.|2|||f||||t||||||||||2018-06-01 01:39:26.299845|2018-06-01 01:39:26.299845
NCT00774917|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-06-22|2008-10-16|2008-10-17|Estimate|||||||2009-06-22|2009-06-23|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|March 2010|Anticipated|2010-03-31|September 2009|Anticipated|2009-09-30||Interventional|NAUTIC||Numen Stent Assessment Using OCT Technique in a Single Center Study|Numen Stent Assessment Using OCT Technique in a Single Center Study|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|International Biomedical Systems S.p.A.||1|||f||||f||||||||||2018-06-01 01:39:27.252163|2018-06-01 01:39:27.252163
NCT00774904|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-17|2008-10-16|2008-10-17|Estimate|||||||2008-10-17|2008-10-20|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Adiponectin and Insulin Resistance in Diabetic Nephropathy|Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan|Completed||N/A|80|Actual|Health Science Center of Xi’an Jiaotong University|||||f||||||||||||||2018-06-01 01:39:27.347147|2018-06-01 01:39:27.347147
NCT00774891|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-02-16|2008-10-16|2008-10-17|Estimate|||||||2012-02-16|2012-02-17|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Comparison Of Left Ventricular Volume And Wall Stress With Dobutamine And Exercise Echocardiography|Comparison Of Left Ventricular Volume And Wall Stress With Dobutamine And Exercise Echocardiography|Withdrawn|||0|Actual|Lahey Clinic||||difficulty enrolling patients into this study|f||||f||||||||||2018-06-01 01:39:27.416583|2018-06-01 01:39:27.416583
NCT00774722|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2013-06-04|2008-10-16|2008-10-17|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2006||2006-09-30|June 2013|2013-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Randomised Controlled Trial of the Use of Topical Metronidazole (10%) to Reduce Pain After Haemorrhoidectomy|Phase 2 Study Evaluation of Topical 10% Metronidazole Ointment for the Reduction of Pain After Haemorrhoidectomy|Completed||Phase 2/Phase 3|59|Actual|S.L.A. Pharma AG||2|||f||||f||||||||||2018-06-01 01:39:30.433222|2018-06-01 01:39:30.433222
NCT00774878|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2011-03-02|2008-10-16|2008-10-17|Estimate|||||||2011-03-02|2011-03-03|Estimate|October 2008||2008-10-31|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer|Multicenter, Randomized, Open Label Study Evaluating an Anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) Monoclonal Antibody, AVE1642, Administered Every 4 Weeks in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer|Terminated||Phase 2|18|Actual|Sanofi||2||"Company decision to discontinue the AVE1642 development program, not due to any safety or~   efficacy concerns"|f||||f||||||||||2018-06-01 01:39:27.49402|2018-06-01 01:39:27.49402
NCT00774865|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2013-10-07|2008-10-15|2008-10-17|Estimate|||||||2013-10-07|2013-10-08|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|June 2012|Actual|2012-06-30||Observational|ZEUSFUPCTA||Long Term Follow-up of Robotic Assisted Surgical Revascularization|Long Term Follow-up of Robotic Assisted Surgical Revascularization With CT Angiography|Unknown status|Enrolling by invitation||150|Anticipated|Lawson Health Research Institute|||1||f||||f||||||||||2018-06-01 01:39:27.570804|2018-06-01 01:39:27.570804
NCT00774852|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2014-08-18||2016-01-15|2008-10-16|2008-10-17|Estimate|2014-10-07|2014-10-09|Estimate||||2016-01-15|2016-02-08|Estimate|November 2008||2008-11-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|December 2012|Actual|2012-12-31||Interventional|ACCESS|Intent-to-treat sample|Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis|A Randomized, Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs Cyclophosphamide Alone in the Treatment of Lupus Nephritis|Completed||Phase 2|137|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:39:27.691992|2018-06-01 01:39:27.691992
NCT00774839|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2016-08-09|2008-10-16|2008-10-17|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients|A Study of Economic Circumstances, Service Utilization, and Service Needs Among Older Colon Cancer Patients|Completed|||62|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:39:28.701747|2018-06-01 01:39:28.701747
NCT00774826|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2011-02-14|2008-10-16|2008-10-17|Estimate|||||||2011-02-14|2011-02-15|Estimate|December 2005||2005-12-31|February 2011|2011-02-28|March 2014|Anticipated|2014-03-31|September 2010|Actual|2010-09-30||Interventional|||Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma|Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma|Unknown status|Active, not recruiting|Phase 3|534|Actual|Fondazione Italiana Linfomi ONLUS||3|||f||||f||||||||||2018-06-01 01:39:28.802975|2018-06-01 01:39:28.802975
NCT00774813|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Nexalin Therapy for the Treatment of Depressive Symptoms|Phase II Study Using Nexalin Therapy for the Treatment of Depressive Symptoms Associated With Mild to Moderate Depression Episodes|Completed||Phase 2|120|Actual|Kalaco Scientific, Inc.||3|||f||||f||||||||||2018-06-01 01:39:29.063939|2018-06-01 01:39:29.063939
NCT00774800|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2010-04-27||2014-08-25|2008-10-15|2008-10-17|Estimate|2014-08-25|2014-09-05|Estimate||||2014-08-25|2014-09-05|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||All participants who received at least 1 dose of Humalog, Humulin-R, or recombinant human hyaluronidase PH20 (rHuPH20).|Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus|Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humulin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients|Completed||Phase 2|22|Actual|Halozyme Therapeutics||1|||f||||f||||||||||2018-06-01 01:39:29.178299|2018-06-01 01:39:29.178299
NCT00774787|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2010-09-30||2016-10-03|2008-10-16|2008-10-17|Estimate|2010-09-30|2010-10-27|Estimate||||2016-10-03|2016-11-07|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses|A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses|Completed||Phase 4|27|Actual|Rigel Dermatology|Open label; small patient number; planned secondary endpoint of change in only lesions treated with cryotherapy (baseline) not determinable as only all lesions (baseline + new) consistently captured.|2|||f||||f||||||||||2018-06-01 01:39:29.610692|2018-06-01 01:39:29.610692
NCT00774774|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2011-04-22|2008-10-16|2008-10-17|Estimate|||||||2011-04-22|2011-04-26|Estimate|January 2009||2009-01-31|September 2008|2008-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|GRIPMASK||Face Masks for Preventing Influenza Transmission|a Randomized Controlled Trial Evaluating the Effectiveness and the Safety of Surgical Masks Wared by the Index Patient for Preventing Secondary Transmission of Influenza A in Households|Completed||Phase 4|372|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:39:29.930158|2018-06-01 01:39:29.930158
NCT00774761|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16||2013-05-10|2013-05-10|2008-10-16|2008-10-17|Estimate||||2013-05-10|2013-05-20|Estimate|2013-05-10|2013-05-20|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Multiple-Dose,Double-Blind,Crossover Trial to Assess the Systemic Exposure of Fluticasone Propionate (FP)/Formoterol Fumarate (FF) Fixed-Dose Combination in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|97|Actual|Dey||5|||f||||f||||||||||2018-06-01 01:39:30.018332|2018-06-01 01:39:30.018332
NCT00774748|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2011-04-08||2017-04-12|2008-10-16|2008-10-17|Estimate|2011-06-13|2011-07-12|Estimate||||2017-04-12|2017-05-23|Actual|August 2008||2008-08-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Once Weekly Subcutaneous Ports for the Administration of Anticoagulants|Once Weekly Subcutaneous Ports for the Administration of Anticoagulants - A Prospective Pharmacokinetic and Clinical Utilization Study|Completed||N/A|21|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 01:39:30.124291|2018-06-01 01:39:30.124291
NCT00774735|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2010-09-09|2008-10-16|2008-10-17|Estimate|||||||2010-09-09|2010-09-13|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||GSK1349572 Drug Interaction Study With Protease Inhibitors|A Phase I, Open Label, Randomized, Two Period, One-way Two Sequence Crossover Study to Evaluate the Effect of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING111405).|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:39:30.33763|2018-06-01 01:39:30.33763
NCT00774709|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2013-09-27|2008-10-16|2008-10-17|Estimate|||||||2013-09-27|2013-09-30|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|KaRen||Karolinska-Rennes (KaRen) Prospective Study of Exercise Stress Echocardiography in Heart Failure With Preserved Ejection Fraction|Ancillary Study of the Registry Karolinska-Rennes (KaRen) : Prospective Study of Dyssynchrony in Heart Failure With Preserved Ejection Fraction|Completed|||90|Actual|French Cardiology Society|||1||f||||t||||||||||2018-06-01 01:39:30.505569|2018-06-01 01:39:30.505569
NCT00774696|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|December 2002||2002-12-31|October 2008|2008-10-31|February 2003|Actual|2003-02-28|December 2002|Actual|2002-12-31||Interventional|||Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions|The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Under Non-Fasting Conditions.|Completed||N/A|24||Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:30.563068|2018-06-01 01:39:30.563068
NCT00774683|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2011-10-21|2008-10-16|2008-10-17|Estimate|||||||2011-10-21|2011-10-25|Estimate|August 2008||2008-08-31|October 2011|2011-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women|A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women|Completed|||1|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     blood specimens and cervicovaginal fluids~   "|||2018-06-01 01:39:30.634232|2018-06-01 01:39:30.634232
NCT00774657|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-02-16|2008-10-16|2008-10-17|Estimate|||||||2012-02-16|2012-02-17|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography|Patterns Of Left Ventricular Remodeling In Patients With Aortic Stenosis Assessed By Two-Dimensional And Three-Dimensional Echocardiography|Withdrawn|||0|Actual|Lahey Clinic||||Unable to identify and recruit suitable study subjects|f||||f||||||||||2018-06-01 01:39:30.773253|2018-06-01 01:39:30.773253
NCT00774644|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-11-17|2008-10-16|2008-10-17|Estimate|||||||2008-11-17|2008-11-18|Estimate|December 2002||2002-12-31|October 2008|2008-10-31|February 2003|Actual|2003-02-28|January 2003|Actual|2003-01-31||Interventional|||Bioequivalence Study of Clarithromycin 500mg Tablets Under Fasting Conditions.|The Objective of This Study is to Compare the Relative Bioavailability of Clarithromycin 500 mg Tablets (Ranbaxy Laboratories Limited) With That of BIAXIN® 500 mg Tablets in Healthy, Adult Subjects Under Fasting Conditions.|Completed||N/A|33|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:30.829295|2018-06-01 01:39:30.829295
NCT00774631|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-09-14|2008-10-16|2008-10-17|Estimate|||||||2012-09-14|2012-09-17|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|IHPOTOTAM||IHPOTOTAM : Induced HyPOthermia TO Treat Adult Meningitis|Mild Induced Hypothermia to Treat Severe Community Acquired Meningitis in Adults Admitted to Intensive Care Unit|Terminated||Phase 4|98|Actual|Assistance Publique - Hôpitaux de Paris||2||The sponsor stoppes the study for the security problem.|f||||f||||||||||2018-06-01 01:39:30.886636|2018-06-01 01:39:30.886636
NCT00774618|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2013-03-20|2008-10-16|2008-10-17|Estimate|||||||2013-03-20|2013-03-22|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of Surgical Treatment on Pain and Disability for Chronic, Non-healing Rib Fracture|Prospective Trial of Operative Management of Rib Fracture Non-Union|Completed||Phase 4|34|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 01:39:30.95978|2018-06-01 01:39:30.95978
NCT00774605|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-01-22|2008-10-16|2008-10-17|Estimate|||||||2009-01-22|2009-01-26|Estimate|December 2008||2008-12-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin|A Phase 1, Open-Label, Nonrandomized, Single Dose Study To Characterize The Pharmacokinetics Of A Varenicline (CP-526,555) Transdermal Solution And A Varenicline Transdermal Delivery System Applied To The Skin Of Adult Smokers|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:39:31.095676|2018-06-01 01:39:31.095676
NCT00774592|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2017-11-01|2008-10-16|2008-10-17|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2004||2004-09-30|November 2017|2017-11-30|May 2016|Actual|2016-05-31|December 2008|Actual|2008-12-31||Interventional|||HIV Risk Reduction in Youth in the Bahamas|Adolescent Risk Reduction in the Bahamas-Peers and Parents|Completed||N/A|1360|Actual|Wayne State University||7|||f||||f||||||||||2018-06-01 01:39:31.167097|2018-06-01 01:39:31.167097
NCT00774579|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2015-06-03|2008-10-16|2008-10-17|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Observational|||The Effect of Growth Hormone Replacement on Liver Fat|Growth Hormone Replacement in Adults With Growth Hormone Deficiency (GHD) - The Effect on Liver Fat.|Completed|||30|Actual|Imperial College London|||2||f||||f||||||Samples Without DNA|"~     plasma, serum, leucocytes, 24-hour urine~   "|||2018-06-01 01:39:31.269933|2018-06-01 01:39:31.269933
NCT00774566|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2014-12-07|2008-10-16|2008-10-17|Estimate|||||||2014-12-07|2014-12-09|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|FreezeAF||PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF)|A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial|Completed||Phase 4|322|Actual|Staedtisches Klinikum Karlsruhe||2|||f||||f||||||||||2018-06-01 01:39:31.351536|2018-06-01 01:39:31.351536
NCT00774553|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2010-01-14|2008-10-16|2008-10-17|Estimate|||||||2010-01-14|2010-01-15|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|||||Interventional|||To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin|A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Subjects With T2DM Treated With Metformin|Completed||Phase 1|70|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 01:39:31.44047|2018-06-01 01:39:31.44047
NCT00774540|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2015-04-22|2008-10-16|2008-10-17|Estimate|||||||2015-04-22|2015-04-23|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|Knemikro01||Acute Pain and Inflammation After Surgery|Acute Pain and Role of Ketolorac in Inflammatory Mediators After Knee Arthroscopy Evaluated by Microdialysis|Completed||Phase 4|40|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 01:39:31.513375|2018-06-01 01:39:31.513375
NCT00774527|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-12|||2011-02-16|2008-10-16|2008-10-17|Estimate|||||||2011-02-16|2011-02-17|Estimate|March 2003||2003-03-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|CyFluCyATG||Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT|Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome|Completed||Phase 3|82|Actual|Cooperative Study Group A for Hematology||1|||f||||f||||||||||2018-06-01 01:39:31.59483|2018-06-01 01:39:31.59483
NCT00774514|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-04-08|2008-10-16|2008-10-17|Estimate|||||||2009-04-08|2009-04-09|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Cardiovascular Effects of Nitrogen Dioxide Exposure|The Cardiovascular Effects of Nitrogen Dioxide Exposure|Completed||N/A|12|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:39:31.663612|2018-06-01 01:39:31.663612
NCT00774501|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2016-02-17|2008-10-16|2008-10-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy|A Pilot Study to Assess the Feasibility of Using Anesthesia and Suspended Ventilation to Immobilize Liver Tumors During Radiotherapy|Completed||N/A|10|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:39:31.731675|2018-06-01 01:39:31.731675
NCT00774488|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2006||2006-01-31|October 2008|2008-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Acute Effects of Glucose Dependent Insulinotropic Polypeptide (GIP) on Subcutaneous Adipose Tissue||Completed||N/A|17|Actual|German Institute of Human Nutrition|||||f||||t||||||||||2018-06-01 01:39:31.794657|2018-06-01 01:39:31.794657
NCT00774475|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-23|2008-10-16|2008-10-17|Estimate|||||||2008-10-23|2008-10-24|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|January 2011|Anticipated|2011-01-31|November 2010|Anticipated|2010-11-30||Interventional|DANTE||Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition|Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation|Unknown status|Not yet recruiting|Phase 3|442|Anticipated|University of Florence||2|||f||||f||||||||||2018-06-01 01:39:31.849249|2018-06-01 01:39:31.849249
NCT00774462|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-12-10|2008-10-16|2008-10-17|Estimate|||||||2012-12-10|2012-12-11|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|FORCE||Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis|FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis|Completed||Phase 2|30|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:39:31.931607|2018-06-01 01:39:31.931607
NCT00774449|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2011-07-19|2008-10-16|2008-10-17|Estimate|||||||2011-07-19|2011-07-21|Estimate|July 2009||2009-07-31|July 2009|2009-07-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation|Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation|Unknown status|Recruiting||261|Anticipated|Hannover Medical School|||1||f||||t||||||Samples Without DNA|"~     bronchoalveolar lavage, transbronchial biopsies, blood samples~   "|||2018-06-01 01:39:33.09674|2018-06-01 01:39:33.09674
NCT00774436|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-10-03|2008-10-15|2008-10-17|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2008||2008-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of Focal Cryoablation in Low-Risk Prostate Cancer|A Phase II Study of Focal Cryoablation in Low-Risk Prostate Cancer|Active, not recruiting||Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:39:33.177427|2018-06-01 01:39:33.177427
NCT00774423|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2013-02-13|2008-10-16|2008-10-17|Estimate|||||||2013-02-13|2013-02-15|Estimate|January 2006||2006-01-31|September 2011|2011-09-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|ASIRI||Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)|Multicentric, Randomized, Double-blind Study Versus Placebo, With Two Parallel Groups Treated to Evaluate the Efficacy and the Tolerance of Riluzole in Children and Young Adults (6 to 20 Years of Age) With SMA. (Type II and Type III)|Completed||Phase 2/Phase 3|141|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:39:33.253199|2018-06-01 01:39:33.253199
NCT00774397|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2015-07-03|2014-07-10|2015-10-14|2008-10-16|2008-10-17|Estimate|2015-10-14|2015-11-16|Estimate|2014-07-10|2014-07-11|Estimate|2015-10-14|2015-11-16|Estimate|October 2008||2008-10-31|October 2015|2015-10-31||||November 2011|Actual|2011-11-30||Interventional||Treated set: The treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, whether randomised or not|Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)|Antiviral Effect, Safety and Pharmacokinetics of BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naïve and Treatment-experienced Patients for 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Double-blinded, Randomised, Placebo-controlled, Phase II)|Completed||Phase 2|719|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-06-01 01:39:33.46872|2018-06-01 01:39:33.46872
NCT00774384|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2016-11-14|2008-10-16|2008-10-17|Estimate|||||||2016-11-14|2016-11-15|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Regulation of Mucosal Immune Response to Systemic MenB Vaccine|A Phase II, Open Label, Randomised, Single Centre Study To Evaluate The Importance Of Naturally Induced Immune Regulation On The Mucosal Immune Response To Meningococcal Serogroup B Outer Membrane Vesicle (Omv) Vaccine When Administered Intramuscularly To Adults & Adolescents|Completed||Phase 2|9|Actual|University Hospitals Bristol NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:39:36.499738|2018-06-01 01:39:36.499738
NCT00774371|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2011-09-16|2008-10-16|2008-10-17|Estimate|||||||2011-09-16|2011-09-20|Estimate|January 2005||2005-01-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|SHAPE||Weight Reduction Intervention for Breast Cancer Survivors|The Survivors' Health And Physical Exercise Study|Completed||N/A|253|Actual|University of California, San Diego||1|||f||||f||||||||||2018-06-01 01:39:36.574677|2018-06-01 01:39:36.574677
NCT00774358|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2017-08-14|2008-10-16|2008-10-17|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2008||2008-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|WAS||Interleukin-2 Treatment for Wiskott-Aldrich Syndrome|Reinstituting Natural Killer Cell Cytotoxicity and Cytoskeletal Dynamics in Wiskott-Aldrich Syndrome With IL-2 Therapy|Completed||Phase 1|9|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-06-01 01:39:36.643769|2018-06-01 01:39:36.643769
NCT00774345|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2018-04-16|2008-10-16|2008-10-17|Estimate|||||||2018-04-16|2018-04-18|Actual|January 27, 2009|Actual|2009-01-27|April 2018|2018-04-30|October 27, 2020|Anticipated|2020-10-27|October 27, 2020|Anticipated|2020-10-27||Interventional|||A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)|Active, not recruiting||Phase 3|317|Actual|Celgene||2|||f||||t||||||||||2018-06-01 01:39:36.786257|2018-06-01 01:39:36.786257
NCT00774332|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-15|2008-10-15|2008-10-17|Estimate|||||||2008-10-15|2008-10-17|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|June 2006|Actual|2006-06-30||Interventional|||A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL|A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL|Unknown status|Recruiting|Phase 2|37|Anticipated|Cooperative Study Group A for Hematology|||||f||||f||||||||||2018-06-01 01:39:37.253976|2018-06-01 01:39:37.253976
NCT00774319|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-04-10|2008-10-16|2008-10-17|Estimate|||||||2012-04-10|2012-04-11|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|Condor||TPF Induction With Concomitant Chemoradiation to Treat Patients With Head and Neck Cancer|A Randomised Study of TPF as Neoadjuvant Chemotherapy Followed by Concomitant Chemoradiotherapy (CRT) With Conventional Radiotherapy (RT) Versus Concomitant CRT With Accelerated RT in Patients With Locally Advanced Head and Neck Squamous Cell Cancer (HNSCC) in Good Condition. The Condor Study. A Study of the Dutch Head and Neck Cancer Group (DHNCG).|Unknown status|Recruiting|Phase 2|70|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 01:39:37.522739|2018-06-01 01:39:37.522739
NCT00774306|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2014-11-19||2017-12-14|2008-10-16|2008-10-17|Estimate|2014-11-19|2014-11-25|Estimate||||2017-12-14|2017-12-18|Actual|April 2009||2009-04-30|December 2017|2017-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Antiepileptic Drugs and Vascular Risk Markers|The Effects of Antiepileptic Drugs on Serum Lipids and Inflammation in Patients With Subarachnoid Hemorrhage|Terminated||N/A|52|Actual|Thomas Jefferson University|"Study terminated due to 1) change in clinical practice; 2) inadequate recruitment and follow-up.~Number of pts providing full data was <15% of goal. Because of this, any analysis of data was considered futile, and no analyses were performed."|4||study no longer consistent with current clinical practice|f||||f||||||||||2018-06-01 01:39:37.628881|2018-06-01 01:39:37.628881
NCT00774293|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|OMEO||Homoeopathic Association in Aortic Valve Surgery|Preliminary Study of a Homoeopathic Association in Patients Undergoing Aortic Valve Surgery.|Completed||Phase 4|92|Actual|BOIRON||2|||f||||f||||||||||2018-06-01 01:39:37.967067|2018-06-01 01:39:37.967067
NCT00774280|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2011-02-10|2008-10-15|2008-10-17|Estimate|||||||2011-02-10|2011-02-14|Estimate|May 2002||2002-05-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|BuCyvsBUFlu||Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen|Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome|Completed||Phase 3|130|Actual|Cooperative Study Group A for Hematology||2|||f||||t||||||||||2018-06-01 01:39:38.064716|2018-06-01 01:39:38.064716
NCT00774267|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|2013-10-30||2014-03-10|2008-10-16|2008-10-17|Estimate|2013-10-30|2013-12-20|Estimate||||2014-03-10|2014-04-08|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Study Evaluating Changes In Mammographic Breast Density|Evaluation Of Changes In Mammographic Breast Density Associated With Bazedoxifene Acetate/Conjugated Estrogens, Raloxifene And Placebo In Postmenopausal Women: An Ancillary Study Of Protocol 3115A1-303-WW|Completed|||507|Actual|Pfizer|||4||f||||f||||||||||2018-06-01 01:39:38.151083|2018-06-01 01:39:38.151083
NCT00774254|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2018-04-03|2008-10-16|2008-10-17|Estimate|||||||2018-04-03|2018-04-04|Actual|October 15, 2008||2008-10-15|March 19, 2018|2018-03-19||||||||Observational|||Reactions to Disease Risk Information|Participant Reactions to Disease Risk Information|Completed|||132|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:39:38.576105|2018-06-01 01:39:38.576105
NCT00774241|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2016-11-01|2008-10-16|2008-10-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer|An Open Label Study of the Effect of First Line Combination Treatment With Avastin and Docetaxel on Disease Response in Patients With Metastatic Breast Cancer|Withdrawn||Phase 4|0|Actual|Hoffmann-La Roche||1||Study was put on hold then out of Medical Plan therefore cancelled|f||||||||||||||2018-06-01 01:39:38.640981|2018-06-01 01:39:38.640981
NCT00774228|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-08-07|2008-10-16|2008-10-17|Estimate|||||||2009-08-07|2009-08-10|Estimate|November 2008||2008-11-30|August 2009|2009-08-31||||||||Interventional|||I-ZIP Ocular Bandage Pivotal Study|Clinical Evaluation of the I-ZIP® Ocular Bandage as a Protective Ocular Bandage in Subjects Undergoing Clear Corneal Cataract Surgery With IOL Implantation: A Pivotal Study|Completed||N/A|||Ocular Therapeutix, Inc.||2|||f||||||||||||||2018-06-01 01:39:38.750709|2018-06-01 01:39:38.750709
NCT00774215|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2010-01-25|2008-10-16|2008-10-17|Estimate|||||||2010-01-25|2010-01-26|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Evaluation of the Avaulta Procedure for the Correction of Pelvic Organ Prolapse - Results at 1 Year|Retrospective Cohort of the Avaulta Vaginal Mesh Procedure as a Treatment of Pelvic Organ Prolapse|Completed|||103|Anticipated|Atlantic Health System|||||f||||f||||||||||2018-06-01 01:39:38.848742|2018-06-01 01:39:38.848742
NCT00774202|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-01-31|2008-10-16|2008-10-17|Estimate|||||||2017-01-31|2017-02-02|Estimate|November 2003||2003-11-30|January 2017|2017-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP|A Rand. Trial Comp Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment|Completed||Phase 2/Phase 3|17|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 01:39:38.934378|2018-06-01 01:39:38.934378
NCT00774007|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome|Effect of Mesalazine on Low Grade Mucosal Inflammation in Irritable Bowel Syndrome. A Pilot Double Blind Placebo Controlled Study.|Completed||Phase 2/Phase 3|20|Actual|SOFAR S.p.A.||2|||f||||t||||||||||2018-06-01 01:39:43.114586|2018-06-01 01:39:43.114586
NCT00774189|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-16|2008-10-16|2008-10-17|Estimate|||||||2008-10-16|2008-10-17|Estimate|July 2003||2003-07-31|October 2008|2008-10-31|November 2003|Actual|2003-11-30|August 2003|Actual|2003-08-31||Interventional|||Bioequivalence Study of Clarithromycin 250mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomised, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover Bioavailability Study on Clarithromycin Formulations, Comparing Clarithromycin 250 mg Tablets of Ranbaxy Laboratories With Biaxin 250 mg Tablets of Abbott Laboratories in Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|32|Actual|Ranbaxy Inc.||2|||f||||t||||||||||2018-06-01 01:39:39.043857|2018-06-01 01:39:39.043857
NCT00774176|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-06-28|2008-10-16|2008-10-17|Estimate|||||||2017-06-28|2017-06-29|Actual|June 2004||2004-06-30|June 2017|2017-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|PA-SCOPE||Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations|Pennsylvania Study of Chronic Obstructive Pulmonary Exacerbations (PA-SCOPE)|Completed|||1066|Actual|Temple University|||3||f||||t|f|f||||Samples With DNA|"~     Ancillary studies collect blood specimens for gene expression and genetic factors.~   "|No||2018-06-01 01:39:39.122572|2018-06-01 01:39:39.122572
NCT00774163|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2012-06-13||2016-12-15|2008-10-16|2008-10-17|Estimate|2013-06-05|2013-07-12|Estimate||||2016-12-15|2016-12-19|Estimate|February 2010||2010-02-28|December 2016|2016-12-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Safety of Lactobacillus Reuteri in Healthy Volunteers|Phase 1: Safety of Lactobacillus Reuteri in Healthy Volunteers|Completed||Phase 1|45|Actual|Tulane University||2|||f||||f||||||||||2018-06-01 01:39:39.246044|2018-06-01 01:39:39.246044
NCT00774150|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2014-07-17|2008-10-16|2008-10-17|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CATS||Transdisciplinary Studies of CBT for Anxiety in Youth: Child Anxiety Treatment Study|Transdisciplinary Studies of CBT for Anxiety in Youth|Completed||N/A|194|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:39:39.660242|2018-06-01 01:39:39.660242
NCT00774137|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2015-02-02|2008-10-16|2008-10-17|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2007||2007-04-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Observational|||Examining New Diagnostic Tests for Acute Kidney Injury After Heart Surgery|Phase IV Multi Center Validation Study of Novel Biomarkers of Acute Kidney Injury After Cardiac Surgery|Completed|||1550|Actual|Yale University|||||f||||f||||||Samples With DNA|"~     Urine, plasma, buffy coat (optional)~   "|||2018-06-01 01:39:39.914862|2018-06-01 01:39:39.914862
NCT00774124|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2017-10-18|2008-10-16|2008-10-17|Estimate|||||||2017-10-18|2017-10-20|Actual|August 2007||2007-08-31|October 2017|2017-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Improving Outcomes in Underserved Women With GDM|Improving Outcomes in Underserved Women With GDM|Completed||N/A|57|Actual|Temple University||2|||f||||f||||||||||2018-06-01 01:39:40.004295|2018-06-01 01:39:40.004295
NCT00774111|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2009-06-04|2008-10-16|2008-10-17|Estimate|||||||2009-06-04|2009-06-05|Estimate|October 2008||2008-10-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||GSK1349572 Drug Interaction Study With Etravirine|A Phase I, Open Label, Two Period, Single Fixed-Sequence Crossover Study to Evaluate the Effect of Etravirine on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING111603)|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:39:40.094407|2018-06-01 01:39:40.094407
NCT00774098|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2010-03-31|2008-10-16|2008-10-17|Estimate|||||||2010-03-31|2010-04-01|Estimate|January 2007||2007-01-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections|Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections|Completed||N/A|60|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-06-01 01:39:40.389654|2018-06-01 01:39:40.389654
NCT00774085|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2012-04-26|2008-10-16|2008-10-17|Estimate|||||||2012-04-26|2012-04-27|Estimate|November 2004||2004-11-30|April 2012|2012-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|e-STAR||An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone|Electronic Schizophrenia Treatment Adherence Registry|Completed|||408|Actual|Janssen Cilag N.V./S.A.|||1||f||||f||||||||||2018-06-01 01:39:40.643016|2018-06-01 01:39:40.643016
NCT00774072|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-16|||2014-12-03|2008-10-16|2008-10-17|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization|Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways|Completed||Phase 2|9|Actual|University of Jena||2|||f||||t||||||||||2018-06-01 01:39:40.935762|2018-06-01 01:39:40.935762
NCT00774059|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-10-11|2008-10-15|2008-10-16|Estimate|||||||2017-10-11|2017-10-12|Actual||||October 2017|2017-10-31||||||||Interventional|||Evaluation of Safety and Performance of the Orbix Breast Lift System|Phase 1 Study to Evaluate the Safety and Performance of the Orbix Breast Lift System|Withdrawn||N/A|0|Actual|Maastricht University Medical Center||||No EC approval obtained|f||||t||||||||||2018-06-01 01:39:41.248033|2018-06-01 01:39:41.248033
NCT00774046|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2012-12-17||2014-01-16|2008-10-15|2008-10-16|Estimate|2013-06-20|2013-06-24|Estimate||||2014-01-16|2014-02-11|Estimate|December 2002||2002-12-31|January 2014|2014-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML|High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia|Completed||Phase 2|32|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 01:39:41.675452|2018-06-01 01:39:41.675452
NCT00774033|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-07-25|2008-10-15|2008-10-16|Estimate|||||||2012-07-25|2012-07-26|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|ENSEM||Epidermal Cells Delivery and Acute Burns|A Randomized Trial Comparing Recell® Autologous Epidermal Cells Harvesting Kits Versus Classic Skin Grafts for the Treatment of Acute Burn in Adults and Children|Terminated||Phase 3|51|Actual|Assistance Publique - Hôpitaux de Paris||2||Not enough patients included|f||||f||||||||||2018-06-01 01:39:42.483657|2018-06-01 01:39:42.483657
NCT00774020|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-02-21|2008-10-15|2008-10-16|Estimate|||||||2017-02-21|2017-02-23|Actual|October 30, 2008|Actual|2008-10-30|February 2017|2017-02-28|January 14, 2011|Actual|2011-01-14|January 14, 2011|Actual|2011-01-14||Interventional|||Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)|A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China|Completed||Phase 4|9|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:39:42.802567|2018-06-01 01:39:42.802567
NCT00773994|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-10-17|2008-10-15|2008-10-16|Estimate|||||||2017-10-17|2017-10-18|Actual|May 2008||2008-05-31|October 2017|2017-10-31|July 15, 2015|Actual|2015-07-15|July 2015|Actual|2015-07-31||Interventional|||Pilot Study Evaluating Characteristic Closure Patterns of the Normal Velopharyngeal Portal|Pilot Study Evaluating Characteristic Closure Patterns of the Normal Velopharyngeal Portal|Completed||N/A|4|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-06-01 01:39:43.472009|2018-06-01 01:39:43.472009
NCT00773981|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-11-03|2008-10-15|2008-10-16|Estimate|||||||2008-11-03|2008-11-04|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Transrectal Vacuum Assisted Drainage: A New Method of Treating Anastomotic Leakage After Rectal Resection|"Transrectal Vacuum Assisted Drainage: A NEW METHOD OF TREATING ANASTOMOTIC LEAKAGE AFTER RECTAL RESECTION. A Prospective Randomized Multicenter Study in Cooperation With The Danish Colorectal Cancer Group"|Unknown status|Recruiting|Phase 3|60|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 01:39:43.798908|2018-06-01 01:39:43.798908
NCT00773968|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2016-03-04||2016-03-04|2008-10-15|2008-10-16|Estimate|2016-03-04|2016-04-04|Estimate||||2016-03-04|2016-04-04|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|ORION|Safety population included all participants who entered the study and received at least one dose of methoxy polyethylene glycol-epoetin beta.|A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of Subcutaneous C.E.R.A. for the Maintenance of Haemoglobin Levels in Pre-Dialysis Patients With Chronic Renal Anaemia|Completed||Phase 3|140|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:39:44.142015|2018-06-01 01:39:44.142015
NCT00773955|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2013-02-13||2014-04-23|2008-10-15|2008-10-16|Estimate|2013-02-13|2013-03-21|Estimate||||2014-04-23|2014-05-12|Estimate|November 2008||2008-11-30|October 2011|2011-10-31|August 2010|Actual|2010-08-31|October 2009|Actual|2009-10-31||Interventional|||R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer|A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:39:44.875107|2018-06-01 01:39:44.875107
NCT00773942|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2009-10-30|2008-10-15|2008-10-16|Estimate|||||||2009-10-30|2009-11-02|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries|Design & Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries|Completed||N/A|637|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-06-01 01:39:45.622342|2018-06-01 01:39:45.622342
NCT00773929|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2010-04-23|2008-10-15|2008-10-16|Estimate|||||||2010-04-23|2010-04-27|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer|A Multicenter Phase I Clinical and Pharmacokinetic Study of Oral TAK-593 in Subjects With Nonhematologic Advanced Cancer|Completed||Phase 1|60|Anticipated|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:39:45.933966|2018-06-01 01:39:45.933966
NCT00773916|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2009-08-14|2008-10-15|2008-10-16|Estimate|||||||2009-08-14|2009-08-17|Estimate|March 2006||2006-03-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder||Completed||Phase 4|130|Anticipated|Federal University of Rio Grande do Sul|||||f||||t||||||||||2018-06-01 01:39:46.155706|2018-06-01 01:39:46.155706
NCT00773903|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2008-11-24|2008-10-15|2008-10-16|Estimate|||||||2008-11-24|2008-11-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:39:46.417988|2018-06-01 01:39:46.417988
NCT00773890|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-05-07|2008-10-14|2008-10-16|Estimate|||||||2009-05-07|2009-05-11|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||TRF-1101 Assessment in Sickle Cell Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Activity of TRF-1101 on Microvascular Blood Flow, Vascular Endothelial Injury, and Vasoocclusive Pain in Patients With Sickle Cell Disease|Terminated||Phase 1/Phase 2|80|Anticipated|TRF Pharma, Inc||2||"Study was stopped due to perceived futility because the baseline pain score in first 40~   patients was too low to be able demonstrate an improvement"|f||||t||||||||||2018-06-01 01:39:46.462797|2018-06-01 01:39:46.462797
NCT00773877|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients|Comparison of RNFL Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients|Unknown status|Recruiting||400|Anticipated|Yonsei University|||2||f||||t||||||||||2018-06-01 01:39:46.697497|2018-06-01 01:39:46.697497
NCT00773864|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|January 2014|Anticipated|2014-01-31|October 2009|Anticipated|2009-10-31||Observational|MOSAR||Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community-Healthcare Workers|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community- the Role of Healthcare Workers|Unknown status|Not yet recruiting||150|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 01:39:46.772071|2018-06-01 01:39:46.772071
NCT00773851|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2016-04-21|2008-10-15|2008-10-16|Estimate|||||||2016-04-21|2016-04-25|Estimate|April 2005||2005-04-30|April 2016|2016-04-30|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Interventional|||Transfacial Sutures Versus Stapler for Mesh Fixation in Laparoscopic Ventral Hernia Repair|Mesh Shrinkage Following Transfacial Suturing Versus Stapler for Mesh Fixation in Laparoscopic Ventral Hernia Repair: a Prospective, Randomised Blinded Study|Completed||N/A|36|Actual|Medtronic - MITG||2|||f||||f||||||||||2018-06-01 01:39:46.84317|2018-06-01 01:39:46.84317
NCT00773838|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2016-04-22|2008-10-15|2008-10-16|Estimate|||||||2016-04-22|2016-04-25|Estimate|December 2008||2008-12-31|April 2016|2016-04-30|April 2012|Actual|2012-04-30|May 2011|Actual|2011-05-31||Interventional|||Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ)|An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|143|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-06-01 01:39:46.922643|2018-06-01 01:39:46.922643
NCT00773825|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2015-06-17|2008-10-15|2008-10-16|Estimate|||||||2015-06-17|2015-06-18|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|EPIGEN||Genomic Imprinting and Assisted Reproductive Technologies|Assessment of the Risk of Imprinting Defects in Children Born Following Assisted Reproductive Technologies (ART)|Completed|||542|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||Samples With DNA|"~     whole blood (serum, ADN) and placenta samples~   "|||2018-06-01 01:39:47.006226|2018-06-01 01:39:47.006226
NCT00773812|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-01-11|2008-10-15|2008-10-16|Estimate|||||||2017-01-11|2017-01-13|Estimate|July 2007||2007-07-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Placebo-Controlled Pilot Trial of Mecamylamine for Treatment of Autism Spectrum Disorders|Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine|Completed||Phase 1|20|Actual|Ohio State University||2|||f||||f||||||||||2018-06-01 01:39:47.075829|2018-06-01 01:39:47.075829
NCT00773799|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|January 2014|Anticipated|2014-01-31|October 2009|Anticipated|2009-10-31||Observational|MOSAR||Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community|Unknown status|Not yet recruiting||1200|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-06-01 01:39:47.162794|2018-06-01 01:39:47.162794
NCT00773786|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2013-05-29||2015-05-19|2008-10-15|2008-10-16|Estimate|2015-05-19|2015-06-03|Estimate||||2015-05-19|2015-06-03|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)|A Double-Blind, Crossover Study to Assess the Effects of Nebulized Brovana Added to Tiotropium on FEV1, Hyperinflation, and Exercise Endurance Capacity in COPD|Completed||Phase 4|20|Actual|Saint Francis Care||2|||f||||f||||||||||2018-06-01 01:39:47.310509|2018-06-01 01:39:47.310509
NCT00773773|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-11-01|2008-10-15|2008-10-16|Estimate|||||||2017-11-01|2017-11-06|Actual|October 14, 2008|Actual|2008-10-14|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer|A Study to Assess if a Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can be Used to Predict Which Patients Undergoing Prostatic Biopsy Will be Diagnosed With Cancer|Active, not recruiting||N/A|500|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:39:47.531876|2018-06-01 01:39:47.531876
NCT00773760|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2009-08-04|2008-10-15|2008-10-16|Estimate|||||||2009-08-04|2009-08-06|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Observational|||MOR and COMT SNP Polymorphism and Pain|Does mu Opioid Receptor (MOR) and Catechol-O-methyltransferase (COMT) Genes Polymorphism Correlate of Clinical Postoperative Pain and Response to Analgesics|Unknown status|Recruiting||100|Anticipated|East Tallinn Central Hospital|||1||f||||t||||||Samples With DNA|"~     blood~   "|||2018-06-01 01:39:47.606206|2018-06-01 01:39:47.606206
NCT00773747|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2015-08-20|2008-10-15|2008-10-16|Estimate|||||||2015-08-20|2015-08-21|Estimate|December 2008||2008-12-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|September 2011|Actual|2011-09-30||Interventional|||Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)|An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma|Completed||Phase 3|637|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 01:39:47.692898|2018-06-01 01:39:47.692898
NCT00773734|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2014-10-22|2013-07-26|2016-10-27|2008-10-15|2008-10-16|Estimate|2014-11-06|2014-11-13|Estimate|2013-07-26|2013-08-02|Estimate|2016-10-27|2016-12-12|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|August 2009|Actual|2009-08-31||Interventional||The intent-to-treat (ITT) population consisted of all randomized participants.|Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)|A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)|Completed||Phase 2|352|Actual|Celgene Corporation||6|||f||||t||||||||||2018-06-01 01:39:47.904308|2018-06-01 01:39:47.904308
NCT00773721|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2014-09-26|2008-10-15|2008-10-16|Estimate|||||||2014-09-26|2014-09-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:39:52.831962|2018-06-01 01:39:52.831962
NCT00773708|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2015-03-10|2008-10-14|2008-10-16|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2009||2009-03-31|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product|Pilot Study to Assess the Role of Immune Activation and Apoptosis as a Marker for Treatment Intensification With Raltegravir in Hiv-infected Patients on Antiretroviral Therapy With Long-term Viral Suppression and Unfavourable Immunologic Response (Discordant Patients: v+i-)|Completed||Phase 4|57|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 01:39:52.866278|2018-06-01 01:39:52.866278
NCT00773695|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2018-05-22|2008-10-15|2008-10-16|Estimate|||||||2018-05-22|2018-05-23|Actual|November 7, 2008|Actual|2008-11-07|May 2018|2018-05-31|January 16, 2023|Anticipated|2023-01-16|January 16, 2023|Anticipated|2023-01-16||Interventional|||A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer|A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadjuvant Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Reference to the Obtained Responses in Patients With Large Primary HER2 Negative Breast Cancers|Active, not recruiting||Phase 2|150|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 01:39:52.943571|2018-06-01 01:39:52.943571
NCT00773682|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2011-11-16|2008-10-15|2008-10-16|Estimate|||||||2011-11-16|2011-11-17|Estimate|June 2008||2008-06-30|September 2008|2008-09-30|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|mdph||Efficacy and Tolerability of Mud Packs Therapy in Osteoarthritis of the Hand|Efficacy and Tolerability of Mud Packs Therapy in Osteoarthritis of the Hands: a One Year Follow-up|Completed||Phase 4|60|Actual|University of Siena|||||f||||f||||||||||2018-06-01 01:39:53.161055|2018-06-01 01:39:53.161055
NCT00773669|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2013-05-30|2008-10-15|2008-10-16|Estimate|||||||2013-05-30|2013-05-31|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Observational|||Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007|Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007|Completed|||24|Actual|Summa Health System|||||f||||f||||||||||2018-06-01 01:39:53.225364|2018-06-01 01:39:53.225364
NCT00773656|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2014-02-26|2008-10-15|2008-10-16|Estimate|||||||2014-02-26|2014-02-27|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|EPOPA||Patients Overexposed for a Prostate Adenocarcinoma|Surveillance of the Cohort of Patients Overexposed in a Course of Conformational Radiotherapy for a Prostate Adenocarcinoma in Jean MONNET Hospital, Epinal, France. Epinal: Patients Overexposed for a Prostate Adenocarcinoma|Completed|||249|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||Samples With DNA|"~     White cells, serum and DNA~   "|||2018-06-01 01:39:53.288446|2018-06-01 01:39:53.288446
NCT00773643|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2017-10-17|2008-10-15|2008-10-16|Estimate|||||||2017-10-17|2017-10-18|Actual|April 2008||2008-04-30|October 2017|2017-10-31||||April 2020|Anticipated|2020-04-30||Interventional|||Osteogenic Profiling of Tissue From Children With Craniosynostosis|Osteogenic Profiling of Tissue From Children With Craniosynostosis|Active, not recruiting||N/A|50|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-06-01 01:39:53.359788|2018-06-01 01:39:53.359788
NCT00773630|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2011-09-08|2008-10-15|2008-10-16|Estimate|||||||2011-09-08|2011-09-09|Estimate|December 2008||2008-12-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions||Completed||Phase 1|44|Actual|Otsuka Frankfurt Research Institute GmbH||4|||f||||f||||||||||2018-06-01 01:39:53.444503|2018-06-01 01:39:53.444503
NCT00773617|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2018-03-27|2008-10-15|2008-10-16|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2009||2009-03-31|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Testing an Alternative Therapy for Bulimia Nervosa|Integrative Cognitive Affective Therapy for Bulimia Nervosa (ICAT)|Completed||N/A|80|Actual|Neuropsychiatric Research Institute, Fargo, North Dakota||2|||f||||t||||||||||2018-06-01 01:39:53.514851|2018-06-01 01:39:53.514851
NCT00773604|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2015-08-05|2008-10-14|2008-10-16|Estimate|||||||2015-08-05|2015-08-07|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|STN DBS||Deep Brain Stimulation in Patients With Dystonia|Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) in Patients With Dystonia|Completed||Phase 1/Phase 2|22|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:39:53.596186|2018-06-01 01:39:53.596186
NCT00773591|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2015-03-27|2008-10-15|2008-10-16|Estimate|||||||2015-03-27|2015-03-30|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|Snoring||Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders|Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders (Snoring Study)|Withdrawn||Phase 2|0|Actual|Merz Pharmaceuticals GmbH||2||"The BfArM (CA)approved the trial in Nov 2008. However, the responsible EC refused approval in~   March 2009."|f||||f||||||||||2018-06-01 01:39:53.661122|2018-06-01 01:39:53.661122
NCT00773578|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2009-02-12|2008-10-15|2008-10-16|Estimate|||||||2009-02-12|2009-02-13|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Observational|NOLN||Exhaled Nitric Oxide and Nasal Lavage Fluid|Impact of Environmental Tobacco Smoke on Exhaled Nitric Oxide and on Biomarkers of Nasal Inflammation in Atopic Asthmatic Children|Completed|||49|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 01:39:53.727501|2018-06-01 01:39:53.727501
NCT00773565|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-08-22|2008-10-15|2008-10-16|Estimate|||||||2012-08-22|2012-08-23|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Identification of Novel Targets for Regulation of Adipose Tissue Mass|Identification of Novel Targets for Regulation of Adipose Tissue Mass|Completed||N/A|62|Actual|Heidelberg University||1|||f||||f||||||||||2018-06-01 01:39:53.803059|2018-06-01 01:39:53.803059
NCT00773552|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2016-12-05|2008-10-15|2008-10-16|Estimate|||||||2016-12-05|2016-12-06|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder|Randomized Double Blinded Placebo-controlled Trial of the Once Daily 5mg Dose of Solifenacin Succinate vs. Placebo in Inner City Women Ages 20-45 With Overactive Bladder|Withdrawn||Phase 4|0|Actual|Stamford Hospital||2||Investigator Left Institution|f||||f||||||||||2018-06-01 01:39:53.859193|2018-06-01 01:39:53.859193
NCT00773539|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2008-10-14|2008-10-14|2008-10-16|Estimate|||||||2008-10-14|2008-10-16|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|August 2009|Anticipated|2009-08-31|February 2009|Anticipated|2009-02-28||Interventional|CRYO-RF||A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy|Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy|Unknown status|Recruiting|Phase 4|78|Anticipated|Herz-Zentrums Bad Krozingen||3|||f||||t||||||||||2018-06-01 01:39:53.949426|2018-06-01 01:39:53.949426
NCT00773526|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2016-11-01|2008-10-15|2008-10-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.|An Open Label Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO5126766, a Dual Raf and MEK Inhibitor, Administered Orally as Monotherapy in Patients With Advanced Tumors|Completed||Phase 1|52|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:39:54.021796|2018-06-01 01:39:54.021796
NCT00773513|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2018-01-15|2008-10-15|2008-10-16|Estimate|||||||2018-01-15|2018-01-17|Actual|December 12, 2008|Actual|2008-12-12|January 2018|2018-01-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)|A Randomized, Controlled, Open-Label, Multi-Centre, Parallel-Group Study To Assess All-Cause Mortality And Cardiovascular Morbidity In Patients With Chronic Kidney Disease On Dialysis And Those Not On Renal Replacement Therapy Under Treatment With MIRCERA® Or Reference ESAs.|Completed||Phase 4|2828|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-06-01 01:39:54.097633|2018-06-01 01:39:54.097633
NCT00773500|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2012-02-27|2008-10-15|2008-10-16|Estimate|||||||2012-02-27|2012-02-28|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Observational|BWHCERT5E||Impact of Vendor Systems on Ambulatory Medication Safety|Impact of Vendor Systems on Ambulatory Medication Safety|Completed|||20|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-06-01 01:39:55.797803|2018-06-01 01:39:55.797803
NCT00773487|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-07-24|2008-10-15|2008-10-16|Estimate|||||||2009-07-24|2009-07-28|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Influence of Diesel Exhaust Particles (DEP) With and Without Organic Compounds on the Allergic Inflammation in Asthmatic Subjects|Influence of Diesel Exhaust Particles (DEP) With and Without Organic Compounds on the Allergic Inflammation in Asthmatic Subjects|Completed||N/A|15|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||||||||||||2018-06-01 01:39:55.886824|2018-06-01 01:39:55.886824
NCT00773474|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2015-12-15||2016-01-21|2008-10-14|2008-10-16|Estimate|2016-01-21|2016-02-18|Estimate||||2016-01-21|2016-02-18|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Lonafarnib in Metastatic Breast Cancer|A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer|Terminated||Phase 2|29|Actual|Hoosier Cancer Research Network||1||funding terminated|f||||t||||||||||2018-06-01 01:39:55.982457|2018-06-01 01:39:55.982457
NCT00773461|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2015-12-29||2017-06-27|2008-10-15|2008-10-16|Estimate|2016-06-09|2016-07-21|Estimate||||2017-06-27|2017-08-01|Actual|October 31, 2008|Actual|2008-10-31|June 2017|2017-06-30|July 22, 2010|Actual|2010-07-22|July 22, 2010|Actual|2010-07-22||Interventional||Intent-to-Treat (ITT) Population: The ITT population included all randomized participants who received at least one infusion of study treatment; Per Protocol (PP) Population: The PP population included all participants in the ITT population who adhered to the protocol.|A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.|A Randomized, Double Blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With DMARD Therapy, in Patients With Active Rheumatoid Arthritis and Inadequate Response to Current DMARD Therapy|Completed||Phase 3|209|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:39:56.386446|2018-06-01 01:39:56.386446
NCT00773448|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2015-07-02|2008-10-15|2008-10-16|Estimate|||||||2015-07-02|2015-07-07|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SOME||Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism|Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism: an Open Randomized Controlled Trial Using a Comprehensive Abdomen/Pelvis Computed Tomography|Completed||N/A|862|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 01:39:57.219689|2018-06-01 01:39:57.219689
NCT00773435|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2015-11-30|2008-10-14|2008-10-16|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2008||2008-11-30|December 2008|2008-12-31|August 2009|Anticipated|2009-08-31|May 2009|Anticipated|2009-05-31||Interventional|||Effects of Echinacea in Children|Assessing the in Vivo Effect of Echinacea Purpurea on Markers of Immune Activities in Children|Withdrawn||N/A|0|Actual|University of Washington||2||Decided to conduct study in adults first|f||||t||||||||||2018-06-01 01:39:57.304665|2018-06-01 01:39:57.304665
NCT00773422|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2018-02-21||2018-03-22|2008-10-15|2008-10-16|Estimate|2018-03-22|2018-04-23|Actual||||2018-03-22|2018-04-23|Actual|January 2008||2008-01-31|March 2018|2018-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse|The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse|Completed||Phase 2|30|Actual|Yale University||3|||f||||t||||||||||2018-06-01 01:39:57.381779|2018-06-01 01:39:57.381779
NCT00773409|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-09-14|2008-10-15|2008-10-16|Estimate|||||||2012-09-14|2012-09-18|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)|A Prospective Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 4 to 5 Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents Within the Past 10 Years|Completed|||405|Actual|Bracco Diagnostics, Inc|||||f||||f||||||Samples Without DNA|"~     fixed tissue samples and tissue sample for testing of GBCA.~   "|||2018-06-01 01:39:57.62377|2018-06-01 01:39:57.62377
NCT00773383|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2011-03-31||2013-06-19|2008-10-15|2008-10-16|Estimate|2011-08-12|2011-09-16|Estimate||||2013-06-19|2013-06-24|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.|An Open-label Study to Determine the Effect of R1507 Plus Tarceva (Erlotinib) on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) With Progressive Disease After Clinical Benefit to Second or Third Line Tarceva Monotherapy.|Terminated||Phase 2|35|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:39:57.704204|2018-06-01 01:39:57.704204
NCT00773370|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2016-02-26||2016-08-11|2008-10-15|2008-10-16|Estimate|2016-08-11|2016-08-15|Estimate||||2016-08-11|2016-08-15|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|APA-Stroke||Adaptive Physical Activity for Chronic Stroke|Adaptive Physical Activity for Chronic Stroke|Completed||Phase 1|76|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-06-01 01:39:58.189317|2018-06-01 01:39:58.189317
NCT00773357|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2018-01-12|2008-10-15|2008-10-16|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2008||2008-10-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Modeling Stress-precipitated Smoking Behavior for Medication Development|Modeling Stress-precipitated Smoking Behavior for Medication Development|Active, not recruiting||Phase 2|240|Anticipated|Yale University||3|||f||||t||||||||||2018-06-01 01:39:58.633187|2018-06-01 01:39:58.633187
NCT00773344|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15||2010-09-10|2015-10-12|2008-10-15|2008-10-16|Estimate||||2010-09-10|2010-09-13|Estimate|2015-10-12|2015-11-04|Estimate|December 2005||2005-12-31|October 2015|2015-10-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin|Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin|Completed||Phase 1/Phase 2|25|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:39:58.716236|2018-06-01 01:39:58.716236
NCT00773331|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2016-11-01|2008-10-15|2008-10-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.|An Open Label Randomized Controlled Study to Compare the Efficacy and Safety of Once Every 4 Weeks Administration of Mircera Versus Short-acting Epoetin for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia.|Completed||Phase 3|281|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:39:58.807412|2018-06-01 01:39:58.807412
NCT00773318|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2012-03-02|2008-10-15|2008-10-16|Estimate|||||||2012-03-02|2012-03-05|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||SPECT-CT Guided Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) in Prostate Cancer|SPECT-CT Guided Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) in Prostate Cancer|Terminated||N/A|30|Actual|Lawson Health Research Institute||1||"1 patient has been enrolled. No complications reported. The research team decided to terminate~   the clinical trial due to insufficient patients' accrual."|f||||f||||||||||2018-06-01 01:39:58.89829|2018-06-01 01:39:58.89829
NCT00773305|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-12-26|2008-10-15|2008-10-16|Estimate|||||||2012-12-26|2012-12-28|Estimate|October 2008||2008-10-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|November 2010|Actual|2010-11-30||Observational|||Efficacy of Prostate Seed Implantation for Local Control of Early Stage Prostate Cancer|Chart Review of the Efficacy of Prostate Seed Implantation for Local Control of Early Stage Prostate Cancer|Completed|||200|Actual|Summa Health System|||||f||||f||||||||||2018-06-01 01:39:58.979167|2018-06-01 01:39:58.979167
NCT00773292|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2013-04-12|2008-10-15|2008-10-16|Estimate|||||||2013-04-12|2013-04-15|Estimate|August 2006||2006-08-31|April 2013|2013-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|HAM05||Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)|The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP|Completed||Phase 2/Phase 3|7|Actual|Imperial College London||1|||f||||t||||||||||2018-06-01 01:39:59.031572|2018-06-01 01:39:59.031572
NCT00773279|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2015-10-12||2017-02-06|2008-10-15|2008-10-16|Estimate|2017-02-06|2017-03-27|Actual||||2017-02-06|2017-03-27|Actual|September 2008||2008-09-30|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics|A Multi-centre, Randomised, Open-label, Cross-over Study to Explore Effectiveness, Safety, and Preference of a New Disposable Pen PDS290 Versus FlexPen® in Subjects With Type 1 or Type 2 Diabetes|Completed||Phase 3|242|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 01:39:59.13455|2018-06-01 01:39:59.13455
NCT00773266|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-09-26|2008-10-15|2008-10-16|Estimate|||||||2012-09-26|2012-09-27|Estimate|September 2006||2006-09-30|September 2012|2012-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Intraocular Position of Secondary Iris-Fixated IOLs in Aphakic Eyes|Intraocular Architecture of Secondary Implanted Anterior Chamber Iris-Fixated Lenses in Aphakic Eyes Evaluated With Anterior Segment Optical Coherence Tomography|Completed|||16|Actual|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-06-01 01:39:59.522672|2018-06-01 01:39:59.522672
NCT00773253|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2011-02-15||2011-09-09|2008-10-15|2008-10-16|Estimate|2011-09-09|2011-10-13|Estimate||||2011-09-09|2011-10-13|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Botox for Cervical Dystonia Following EMG Mapping|Pre-injection, Multi-channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia.|Completed||Phase 4|10|Actual|University of California, San Francisco|One patient received single channel injection, but did not get multi-channel injection because the frontalis test showed immunity to botulinum toxin indicating no possibility of clinical benefit. This is an exclusion criterion.|2|||f||||f||||||||||2018-06-01 01:39:59.577716|2018-06-01 01:39:59.577716
NCT00773240|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2011-08-27|2008-10-15|2008-10-16|Estimate|||||||2011-08-27|2011-08-30|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment|A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis|Completed||Phase 3|276|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-06-01 01:39:59.904289|2018-06-01 01:39:59.904289
NCT00773227|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2015-11-19|2008-10-15|2008-10-16|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2004||2004-04-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|OPMD||Treatment of Dysphagia in Oculopharyngeal Muscular Dystrophy by Autologous Transplantation of Myoblasts|Treatment of Dysphagia in Oculopharyngeal Muscular Dystrophy by Autologous Transplantation of Myoblasts|Completed||Phase 2|30|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:39:59.972266|2018-06-01 01:39:59.972266
NCT00773214|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2015-02-05|2008-10-15|2008-10-16|Estimate|||||||2015-02-05|2015-02-06|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|||Inter Individual Variation in Weight Loss Response to Exercise|Identification and Characterization of Individual Variability in Exercise-induced Weight Loss: Biological and Behavioral Markers of Success.|Completed||N/A|22|Actual|Norwegian University of Science and Technology||1|||f||||t||||||||||2018-06-01 01:40:00.070449|2018-06-01 01:40:00.070449
NCT00773201|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-07-25|2008-10-15|2008-10-16|Estimate|||||||2012-07-25|2012-07-26|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Generepol||Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation|Identification of the Genetic Sources of Variability of the Adaptation of the Ventricular Repolarisation at a Pharmacological and Physiological Stimulus in an Apparently Normal Population|Completed||Phase 1|997|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:40:00.177376|2018-06-01 01:40:00.177376
NCT00773188|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2016-11-01|2008-10-15|2008-10-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.|A Single-arm, Open-label, Multicenter Feasibility Trial of Bevacizumab Given in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Locally Advanced Unresectable Non-squamous, Non-small Cell Lung Cancer|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:40:00.243175|2018-06-01 01:40:00.243175
NCT00773175|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2011-12-02|2008-10-15|2008-10-16|Estimate|||||||2011-12-02|2011-12-05|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|PEDs-II||Subcutaneous Rehydration Compared to Intravenous Rehydration|Subcutaneous Rehydration With Hylenex Compared to Intravenous Rehydration in Infants and Young Children With Mild to Moderate Dehydration|Completed||Phase 4|186|Anticipated|Halozyme Therapeutics||2|||f||||f||||||||||2018-06-01 01:40:00.320564|2018-06-01 01:40:00.320564
NCT00773162|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2014-02-24|2008-10-15|2008-10-16|Estimate|||||||2014-02-24|2014-02-25|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Flushing in Social Anxiety Disorder on Seroquel|A Single-center, Randomized, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Extended Release Tablets) to Placebo in Social Phobia Patients and Changes in Their Vasodilatory Response to Methyl-Nicotinate|Completed||Phase 3|21|Actual|START Clinic for Mood and Anxiety Disorders||2|||f||||f||||||||||2018-06-01 01:40:00.492057|2018-06-01 01:40:00.492057
NCT00773149|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2012-07-25|2008-10-15|2008-10-16|Estimate|||||||2012-07-25|2012-07-26|Estimate|October 2006||2006-10-31|February 2011|2011-02-28|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|Campath||Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia|Phase I/II Study of Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia (ALL) or ALL in Relapse.|Completed||Phase 1/Phase 2|12|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:40:00.597004|2018-06-01 01:40:00.597004
NCT00773136|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2013-06-22||2014-03-20|2008-10-15|2008-10-16|Estimate|2014-03-20|2014-04-16|Estimate||||2014-03-20|2014-04-16|Estimate|February 2008||2008-02-29|March 2014|2014-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes|Effect of Bimatoprost (Lumigan) in Gel Suspension Applied to the Eyelashes on Eyelash Growth|Completed||N/A|21|Actual|University of Miami|A larger and longer term study would help assess the incidence of ocular side effects related to the Bimatoprost. This randomized controlled study evaluated patients after only 6 weeks of application of the drug.|1|||f||||f||||||||||2018-06-01 01:40:00.697186|2018-06-01 01:40:00.697186
NCT00773123|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.||Unknown status|Recruiting||300|Anticipated|Yonsei University|||2||f||||t||||||||||2018-06-01 01:40:00.911502|2018-06-01 01:40:00.911502
NCT00773110|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2014-05-27|2008-10-15|2008-10-16|Estimate|||||||2014-05-27|2014-05-28|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Albumin to Reduce Inflammation Following Surgery|Scavenging Free Haemoglobin Attenuates the Systemic Inflammatory Response Following Surgery|Terminated||Phase 2|232|Actual|Imperial College London||2||Recruitment under target, Finding|f||||t||||||||||2018-06-01 01:40:00.985724|2018-06-01 01:40:00.985724
NCT00773097|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|2013-07-17||2018-01-18|2008-10-15|2008-10-16|Estimate|2013-12-13|2014-02-03|Estimate||||2018-01-18|2018-02-16|Estimate|October 2008||2008-10-31|January 2018|2018-01-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional||A total of 39 subjects completed the 52 weeks of the study.|Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma|Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma|Completed||Phase 2|46|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:40:01.098231|2018-06-01 01:40:01.098231
NCT00773084|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2015-05-11|2008-10-15|2008-10-16|Estimate|||||||2015-05-11|2015-05-12|Estimate|September 2008||2008-09-30|March 2011|2011-03-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|ARID-HF||Aliskiren and Renin Inhibition in Diastolic Heart Failure|Aliskiren and Renin Inhibition in Diastolic Heart Failure in Mexican Americans|Withdrawn||N/A|0|Actual|Texas Tech University Health Sciences Center||1||Difficulty in recruiting patients and then the PI left the institution|f||||f||||||||||2018-06-01 01:40:01.46649|2018-06-01 01:40:01.46649
NCT00773071|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2012-06-07|2008-10-15|2008-10-16|Estimate|||||||2012-06-07|2012-06-08|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers|Added-value of SPECT/CT in Patients Undergoing Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) for Gynecological Cancers|Completed||N/A|15|Actual|Lawson Health Research Institute||1|||f||||t||||||||||2018-06-01 01:40:01.55219|2018-06-01 01:40:01.55219
NCT00773058|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-02-17|2008-10-15|2008-10-16|Estimate|||||||2009-02-17|2009-02-18|Estimate|December 2008||2008-12-31|January 2009|2009-01-31||||April 2009|Anticipated|2009-04-30||Interventional|||Effect of Treatment With Stress-Doses Glucocorticoid in Patients With Acute Respiratory Distress Syndrome (ARDS)|Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Southeast University, China||4|||f||||f||||||||||2018-06-01 01:40:01.707368|2018-06-01 01:40:01.707368
NCT00773045|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|April 2006||2006-04-30|October 2008|2008-10-31|October 2007|Actual|2007-10-31|August 2006|Actual|2006-08-31||Observational|PIJNICU2||Pain Measurement and Pain Management in the Intensive Care Unit(ICU)|Pain Measurement and Pain Management in the ICU|Completed|||190|Actual|St. Antonius Hospital|||1||f||||f||||||||||2018-06-01 01:40:01.910143|2018-06-01 01:40:01.910143
NCT00773032|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2008||2008-10-31|October 2008|2008-10-31||||June 2009|Anticipated|2009-06-30||Interventional|||Age-Dependent Memory Benefits From Pharmacologically Enhanced Naps?||Unknown status|Recruiting|N/A|||University of California, San Diego||3|||f||||||||||||||2018-06-01 01:40:02.077732|2018-06-01 01:40:02.077732
NCT00773019|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2009-06-09|2008-10-14|2008-10-16|Estimate|||||||2009-06-09|2009-06-10|Estimate|November 2004||2004-11-30|June 2009|2009-06-30|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Observational|||SynchroMed II Post-Approval Study|SynchroMed II Programmable Drug Infusion System Post-Approval Study|Completed|||84|Actual|MedtronicNeuro|||||f||||f||||||||||2018-06-01 01:40:02.170474|2018-06-01 01:40:02.170474
NCT00773006|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2011-10-03|2008-10-15|2008-10-16|Estimate|||||||2011-10-03|2011-10-05|Estimate|February 2008||2008-02-29|October 2011|2011-10-31|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Observational|CAPCIR||Canadian Anticoagulant Percutaneous Coronary Intervention Registry|Canadian Prospective, Observational Study on the Use of LMWH in the Setting of Percutaneous Coronary Intervention|Completed|||747|Actual|University of Alberta|||3||f||||f||||||||||2018-06-01 01:40:02.252065|2018-06-01 01:40:02.252065
NCT00772993|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-15|||2008-10-15|2008-10-15|2008-10-16|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma|Efficacy of RNFL / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma|Unknown status|Recruiting||400|Anticipated|Yonsei University|||4||f||||t||||||||||2018-06-01 01:40:02.371183|2018-06-01 01:40:02.371183
NCT00772980|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2010-06-30|2008-10-14|2008-10-15|Estimate|||||||2010-06-30|2010-07-01|Estimate|November 2008||2008-11-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus|A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus|Completed||Phase 3|400|Anticipated|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 01:40:02.474228|2018-06-01 01:40:02.474228
NCT00772967|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2009-11-19||2015-10-16|2008-10-13|2008-10-15|Estimate|2012-11-06|2012-12-05|Estimate||||2015-10-16|2015-11-20|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)|A Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Analgesic Effects of Naproxen and Ultracet in a Walking Model of Osteoarthritis Knee Pain|Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:40:02.613383|2018-06-01 01:40:02.613383
NCT00772954|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2012-03-13||2012-04-19|2008-10-10|2008-10-15|Estimate|2012-04-19|2012-05-21|Estimate||||2012-04-19|2012-05-21|Estimate|March 2006||2006-03-31|April 2012|2012-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity|A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of Two Doses of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18 - 55 Years)|Terminated||Phase 1|36|Actual|Sanofi|This study was terminated early in light of issues with CTM stability. All other study procedures and visits were performed per protocol.|3||Issues with CTM stability.|f||||f||||||||||2018-06-01 01:40:03.216542|2018-06-01 01:40:03.216542
NCT00772941|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2013-12-09||2014-01-28|2008-10-13|2008-10-15|Estimate|2013-12-09|2014-01-24|Estimate||||2014-01-28|2014-02-28|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Champix (Regulatory Post Marketing Commitment Plan)|Completed|||3939|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:40:04.257979|2018-06-01 01:40:04.257979
NCT00772928|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2009-09-23||2012-01-30|2008-10-14|2008-10-15|Estimate|2010-01-21|2010-02-12|Estimate||||2012-01-30|2012-02-01|Estimate|October 2003||2003-10-31|January 2012|2012-01-31|November 2006|Actual|2006-11-30|May 2006|Actual|2006-05-31||Interventional|||Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™|Immunogenicity Assessment of Pentacel™ (Hybrid CP20/20/5/3DT-mIPV//PRP-T) When Given at Different Times From or Concurrently With a Pneumococcal Conjugate Vaccine|Completed||Phase 3|1167|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:40:05.278706|2018-06-01 01:40:05.278706
NCT00772915|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-12|2012-06-26||2017-08-28|2008-10-12|2008-10-15|Estimate|2012-06-26|2012-08-08|Estimate||||2017-08-28|2017-09-26|Actual|December 2008||2008-12-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|March 2011|Actual|2011-03-31||Interventional|||Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|"A Phase II Trial of Revlimid® and On Demand Dexamethasone Dosing in Patients With Newly Diagnosed Symptomatic Multiple Myeloma"|Active, not recruiting||Phase 2|39|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 01:40:06.239714|2018-06-01 01:40:06.239714
NCT00772902|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2011-11-18|2008-10-14|2008-10-15|Estimate|||||||2011-11-18|2011-11-21|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|ROCKET II||ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial|A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol|Completed||Phase 4|85|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 01:40:06.700193|2018-06-01 01:40:06.700193
NCT00772889|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2012-03-29|2010-07-02|2017-04-20|2008-10-14|2008-10-15|Estimate|2012-03-29|2012-04-24|Estimate|2010-07-02|2010-07-07|Estimate|2017-04-20|2017-05-17|Actual|October 9, 2008||2008-10-09|April 2017|2017-04-30|December 15, 2009|Actual|2009-12-15|December 15, 2009|Actual|2009-12-15||Interventional|||Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly|Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly|Completed||Phase 3|971|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:40:06.883157|2018-06-01 01:40:06.883157
NCT00772876|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2012-11-21|2008-10-13|2008-10-15|Estimate|||||||2012-11-21|2012-11-22|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies|An Open Label, Multicenter Phase I Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies|Completed||Phase 1|39|Actual|Piramal Enterprises Limited||1|||f||||f||||||||||2018-06-01 01:40:08.426408|2018-06-01 01:40:08.426408
NCT00772863|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2009-10-28|2008-10-14|2008-10-15|Estimate|||||||2009-10-28|2009-10-29|Estimate|September 2003||2003-09-30|October 2009|2009-10-31||||June 2008|Actual|2008-06-30||Interventional|Tax-Over||Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer|The Evaluation of Efficacy and Safety of Subsequent Cisplatin and Docetaxel Regimen In The First Line Treatment of Advanced Epithelial Ovarian Cancer|Completed||Phase 2|37|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:40:08.509824|2018-06-01 01:40:08.509824
NCT00772850|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2010-07-14|2008-10-14|2008-10-15|Estimate|||||||2010-07-14|2010-07-15|Estimate|October 2008||2008-10-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|SRC||Rotator Cuff Injury in Antegrade Locked Nailing for Humeral Fractures|Sonographic Evaluation of Rotator Cuff Injury in Antegrade Locked Nailing for Humeral Fractures|Completed|||50|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 01:40:08.568367|2018-06-01 01:40:08.568367
NCT00772837|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-11-09|2008-10-14|2008-10-15|Estimate|||||||2009-11-09|2009-11-10|Estimate|August 2006||2006-08-31|November 2009|2009-11-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|EEHPDS||Effect of Eradication of Helicobacter Pylori on the Dyspeptic Symptoms|Effect of Eradication of Helicobacter Pylori on the Dyspeptic Symptoms.|Completed||N/A|370|Actual|Aga Khan University||2|||f||||f||||||||||2018-06-01 01:40:08.637346|2018-06-01 01:40:08.637346
NCT00772824|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-08-10|2008-10-14|2008-10-15|Estimate|||||||2009-08-10|2009-08-11|Estimate|December 2007||2007-12-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients|Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial|Unknown status|Recruiting|Phase 4|30|Anticipated|Banaras Hindu University||3|||f||||f||||||||||2018-06-01 01:40:08.737982|2018-06-01 01:40:08.737982
NCT00772811|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-05|||2011-02-16|2008-10-12|2008-10-15|Estimate|||||||2011-02-16|2011-02-17|Estimate|July 2001||2001-07-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|Flu-Mel||Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma|Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma|Completed||Phase 2|38|Actual|Cooperative Study Group A for Hematology||1|||f||||t||||||||||2018-06-01 01:40:08.830812|2018-06-01 01:40:08.830812
NCT00772798|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2008-10-14|2008-10-14|2008-10-15|Estimate|||||||2008-10-14|2008-10-15|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer|A Phase I/II Non-Comparative Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat in Patient With Advanced, Recurrent, Epithelial Ovarian Cancer|Unknown status|Recruiting|Phase 2|70|Anticipated|Herlev Hospital|||||f||||t||||||||||2018-06-01 01:40:08.921416|2018-06-01 01:40:08.921416
NCT00772785|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09||2011-01-05|2017-06-12|2008-10-10|2008-10-15|Estimate||||2012-10-23|2012-10-30|Estimate|2017-06-12|2017-06-14|Actual|September 2008||2008-09-30|June 2017|2017-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|PRO-809||Study of Probuphine in Patients With Opioid Dependence|An Open-label, Multi-center Extension Study of Probuphine in Patients With Opioid Dependence|Terminated||Phase 3|16|Actual|Braeburn Pharmaceuticals||1||This study was terminated for reasons not related to efficacy or safety|f||||t||||||||||2018-06-01 01:40:09.017794|2018-06-01 01:40:09.017794
NCT00772772|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2011-03-10||2015-01-06|2008-10-13|2008-10-15|Estimate|2011-05-11|2011-06-13|Estimate||||2015-01-06|2015-01-15|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Vitamin D Repletion in Chronic Kidney Disease|The Effect of Vitamin D3 Repletion in Chronic Kidney Disease Stage 3|Completed||Early Phase 1|12|Actual|Rockefeller University||1|||f||||f||||||||||2018-06-01 01:40:09.107202|2018-06-01 01:40:09.107202
NCT00772759|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-05-04|2008-10-14|2008-10-15|Estimate|||||||2009-05-04|2009-05-05|Estimate|October 2008||2008-10-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|||||Interventional|||Assess Safety, Tolerability and PK of AZD3199 in Japanese|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Japanese Healthy Men|Completed||Phase 1|27|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 01:40:09.365915|2018-06-01 01:40:09.365915
NCT00772746|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2008-10-14|2008-10-14|2008-10-15|Estimate|||||||2008-10-14|2008-10-15|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|CBT||Cognitive Behavioral Therapy in Panic Disorder|Effectiveness of Specific Model of Cognitive-Behavioral Therapy in Panic Disorder Patients With Agoraphobia|Completed|||50|Actual|Universidade Federal do Rio de Janeiro|||1||f||||t||||||None Retained|"~     None retained~   "|||2018-06-01 01:40:09.562247|2018-06-01 01:40:09.562247
NCT00772733|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2011-02-21|2008-10-14|2008-10-15|Estimate|||||||2011-02-21|2011-02-23|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|KOSMOS||A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment|A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment|Completed|||936|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:40:09.780935|2018-06-01 01:40:09.780935
NCT00772720|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2010-03-30|2008-10-14|2008-10-15|Estimate|||||||2010-03-30|2010-03-31|Estimate|March 2010||2010-03-31|March 2010|2010-03-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|RALMET-VOLHCB||Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers|Study on the Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers|Unknown status|Recruiting|Phase 1|14|Anticipated|Hospital Clinic of Barcelona|||||f||||f||||||||||2018-06-01 01:40:09.86362|2018-06-01 01:40:09.86362
NCT00772707|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2012-08-01||2012-08-31|2008-10-13|2008-10-15|Estimate|2012-08-01|2012-09-03|Estimate||||2012-08-31|2012-09-07|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Multi‐Center Investigation of Patient Acceptability of OPTI‐FREE RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)|A 30 Day, Multi‐Centered, Open Label Study To Determine Comfort and Overall Contact Lens Wearing Experience Using OPTI‐FREE RepleniSH® MPDS as Compared to COMPLETE®MPS Easy Rub™ or ReNu MultiPlus® in Daily Wear Soft Contact Lens Patients|Completed||N/A|114|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:40:09.933339|2018-06-01 01:40:09.933339
NCT00772694|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2008-10-23|2008-10-14|2008-10-15|Estimate|||||||2008-10-23|2008-10-24|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|GCT||Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy|Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy|Unknown status|Recruiting|Phase 2|20|Anticipated|Fondation Wygrajmy Zdrowie||1|||f||||t||||||||||2018-06-01 01:40:10.099416|2018-06-01 01:40:10.099416
NCT00772681|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2009-12-04|2008-10-14|2008-10-15|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2004||2004-10-31|December 2009|2009-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Tax-Nazo||Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma|Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx|Completed||Phase 4|57|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:40:10.200363|2018-06-01 01:40:10.200363
NCT00772668|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-12|2013-01-18||2017-11-06|2008-10-12|2008-10-15|Estimate|2013-01-18|2013-02-21|Estimate||||2017-11-06|2017-12-11|Actual|September 25, 2009|Actual|2009-09-25|November 2017|2017-11-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL|Pilot Study of RCVELP as First Line Therapy for Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)|Terminated||N/A|3|Actual|University of Miami|This study was terminated early due to lack of funding. All patients were removed from the study.|1||Funding|f||||t||||||||||2018-06-01 01:40:10.365762|2018-06-01 01:40:10.365762
NCT00772655|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2012-07-31|2008-10-14|2008-10-15|Estimate|||||||2012-07-31|2012-08-02|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|June 2015|Anticipated|2015-06-30|June 2010|Actual|2010-06-30||Interventional|||Zevalin® First Line in Follicular Lymphoma|Multicenter European Pilot Study of 90Yttrium-Ibritumomab Tiuxetan as First Line Therapy for Stage III - IV Follicular Lymphoma (and Selected Patients With Extended Stage II) Followed by Consolidation Rituximab for Patients in Complete Remission But With Persistent Molecular Disease|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-06-01 01:40:10.607769|2018-06-01 01:40:10.607769
NCT00772642|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-11|||2017-06-30|2008-10-11|2008-10-15|Estimate|||||||2017-06-30|2017-07-02|Actual|October 8, 2008||2008-10-08|September 10, 2010|2010-09-10|September 10, 2010||2010-09-10|||||Observational|||Immune Parameters in the Cord Blood of Newborns Exposed to Malaria in the Womb|Profiling Immunological Parameters in the Cord Blood of Neonates Exposed to Plasmodium Falciparum in Utero|Completed|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:40:10.736029|2018-06-01 01:40:10.736029
NCT00772629|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2009-03-16||2014-01-21|2008-10-13|2008-10-15|Estimate|2009-03-16|2009-04-27|Estimate||||2014-01-21|2014-02-14|Estimate|January 2004||2004-01-31|January 2014|2014-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults|Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults Who Were Either Previously Vaccinated With Unconjugated Meningococcal Polysaccharide (Serogroups A, C or Serogroups A, C, Y, and W-135) Vaccine or Not Vaccinated With Meningococcal Vaccine|Terminated||Phase 2|18|Actual|Sanofi|Enrollment was terminated before the planned sample size was achieved because the principal investigator and the Sponsor decided that sufficient sera had been obtained to meet the secondary objective of the study.|2||See detailed description for termination reason|f||||f||||||||||2018-06-01 01:40:10.814585|2018-06-01 01:40:10.814585
NCT00772616|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-11|||2016-09-22|2008-10-11|2008-10-15|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2008||2008-09-30|September 2016|2016-09-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||Influence of Intraoperative Analgesia on the Postoperative Morphine Consumption|Influence of Intraoperative Analgesia (Sufentanil Administered According to the Usual Criteria or Remifentanil Administered by a Closed-loop System Using Bispectral Index as the Controller) on the Postoperative Morphine Consumption|Completed||Phase 4|60|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 01:40:11.137806|2018-06-01 01:40:11.137806
NCT00772603|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2013-04-09||2013-12-23|2008-10-10|2008-10-15|Estimate|2013-12-23|2014-02-11|Estimate||||2013-12-23|2014-02-11|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|PROSPER1||Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures|Phase III Study to Evaluate the Efficacy and Safety of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Completed||Phase 3|366|Actual|Supernus Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 01:40:11.239508|2018-06-01 01:40:11.239508
NCT00772590|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2012-05-06||2012-07-23|2008-10-14|2008-10-15|Estimate|2012-07-23|2012-08-24|Estimate||||2012-07-23|2012-08-24|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|CORAL||Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response|Randomised Double-blind Placebo Controlled Study to Measure the Effect of Antiretroviral Therapy (ART) Intensification With Raltegravir and/or Hyper-immune Bovine Colostrum on CD4+ T Cell Count in ART Treated, HIV-1 Infected Individuals With Suboptimal CD4+ T Cell Responses|Completed||Phase 4|75|Actual|Kirby Institute|Effect of interventions only measured in peripheral blood|4|||f||||f||||||||||2018-06-01 01:40:12.095874|2018-06-01 01:40:12.095874
NCT00772577|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2010-12-07||2011-03-08|2008-10-14|2008-10-15|Estimate|2011-02-07|2011-03-02|Estimate||||2011-03-08|2011-03-11|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|ATTAIN||Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension|An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension|Completed||Phase 4|386|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:40:12.642983|2018-06-01 01:40:12.642983
NCT00772564|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-11|||2012-05-25|2008-10-14|2008-10-15|Estimate|||||||2012-05-25|2012-05-28|Estimate|August 2008||2008-08-31|May 2012|2012-05-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||The Use of Statins for Myocardial Death Prevention|The Use of Statins for Myocardial Death Prevention: From Cell to Bedside|Completed||Phase 4|25|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-06-01 01:40:13.012328|2018-06-01 01:40:13.012328
NCT00772551|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2010-08-13|2008-10-14|2008-10-15|Estimate|||||||2010-08-13|2010-08-16|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Raltegravir and Ezetimibe PK Study|Evaluation of the Pharmacokinetics and Safety of Raltegravir and Ezetimibe When Co-administered to Male and Female Healthy Volunteers|Completed||Phase 1|26|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-06-01 01:40:13.12698|2018-06-01 01:40:13.12698
NCT00772538|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2012-07-25||2014-07-30|2008-10-13|2008-10-15|Estimate|2012-09-25|2012-09-27|Estimate||||2014-07-30|2014-08-18|Estimate|October 2008||2008-10-31|July 2014|2014-07-31||||July 2011|Actual|2011-07-31||Interventional|||Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)|A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma|Completed||Phase 3|459|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:40:13.277996|2018-06-01 01:40:13.277996
NCT00772525|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13||2016-01-28|2016-01-28|2008-10-13|2008-10-15|Estimate||||2016-01-28|2016-02-26|Estimate|2016-01-28|2016-02-26|Estimate|September 2008||2008-09-30|January 2016|2016-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis|A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis|Completed||Phase 2|31|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 01:40:14.465118|2018-06-01 01:40:14.465118
NCT00772512|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2010-03-17|2008-10-13|2008-10-15|Estimate|||||||2010-03-17|2010-03-19|Estimate|November 2008||2008-11-30|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study Of The Effect Of PF-04802540 On Sleep Measures|Subject- And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 3-Way Crossover Study To Study Effects Of PF-04802540 On Polysomnography Endpoints In Healthy Volunteers|Completed||Phase 1|13|Actual|Taisho Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-06-01 01:40:14.571872|2018-06-01 01:40:14.571872
NCT00772499|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2008-10-14|2008-10-14|2008-10-15|Estimate|||||||2008-10-14|2008-10-15|Estimate|November 2002||2002-11-30|October 2008|2008-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|VIOS||Vascular Improvement With Olmesartan Medoxomil Study|Vascular Improvement With Olmesartan Medoxomil Study|Completed||Phase 4|100|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:40:14.681732|2018-06-01 01:40:14.681732
NCT00772486|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2010-11-18|2008-10-14|2008-10-15|Estimate|||||||2010-11-18|2010-11-19|Estimate|September 2008||2008-09-30|November 2010|2010-11-30||||April 2011|Anticipated|2011-04-30||Interventional|||A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL|A Phase 1b Study of Repeated Doses of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Combination With Fludarabine, Cyclophosphamide and Rituximab (FCR) in Subjects With Chronic Lymphocytic Leukemia (CLL)|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|Memgen, LLC|||||f||||t||||||||||2018-06-01 01:40:14.789038|2018-06-01 01:40:14.789038
NCT00772473|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2009-05-22|2008-10-14|2008-10-15|Estimate|||||||2009-05-22|2009-05-25|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine|Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine|Completed|||34|Actual|Clinvest|||1||f||||f||||||None Retained|"~     saliva~   "|||2018-06-01 01:40:14.916611|2018-06-01 01:40:14.916611
NCT00772460|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-09-18|2008-10-14|2008-10-15|Estimate|||||||2009-09-18|2009-09-21|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|HDV||Comparison of a New Patient Warming System Using Polymer Conductive Warming With Forced Air Warming During Surgery|Comparison of a New Patient Warming System Using Polymer Conductive Warming With Forced Air Warming During Surgery|Completed||Phase 3|80|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:40:15.006798|2018-06-01 01:40:15.006798
NCT00772447|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2011-09-09||2015-02-23|2008-10-14|2008-10-15|Estimate|2015-02-23|2015-03-09|Estimate||||2015-02-23|2015-03-09|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||One patient was randomized but did not receive any study drug, so the patient was not included in FAS(full analysis set) population analysis.|China Registration Study in Patients With Skin Infections|A Phase 3, Multicentre, Randomised, Investigator-blinded, Parallel-groupStudy of the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects With cSSSI|Completed||Phase 3|265|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:40:15.135899|2018-06-01 01:40:15.135899
NCT00772434|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2011-11-17|2008-10-14|2008-10-15|Estimate|||||||2011-11-17|2011-11-18|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Assessment of Bleeding Symptoms in Normal Individuals Using a Comprehensive History Phenotyping Instrument|Assessment of Bleeding Symptoms in Normal Individuals Using a Comprehensive History Phenotyping Instrument|Completed|||412|Actual|Rockefeller University|||||f||||f||||||||||2018-06-01 01:40:15.806076|2018-06-01 01:40:15.806076
NCT00772421|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2012-01-27|2008-10-14|2008-10-15|Estimate|||||||2012-01-27|2012-01-31|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|SANTE RR||Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Rhythm|Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy - Recruitment Rhythm (SANTE RR)|Completed|||29|Actual|MedtronicNeuro|||2||f||||t||||||||||2018-06-01 01:40:15.865824|2018-06-01 01:40:15.865824
NCT00772408|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2013-02-27|2008-10-13|2008-10-15|Estimate|||||||2013-02-27|2013-02-28|Estimate|August 2006||2006-08-31|October 2008|2008-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis|Relationship Between TLR2 Polymorphism and Pulmonary Tuberculosis|Completed|||300|Actual|Chang Gung Memorial Hospital|||2||f||||t||||||Samples With DNA|"~     peripheral blood leukocyte DNA and plasma~   "|||2018-06-01 01:40:15.935435|2018-06-01 01:40:15.935435
NCT00772395|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2014-09-18|2008-10-14|2008-10-15|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2006||2006-04-30|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PREVENT||Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty|Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study|Completed||Phase 4|78|Actual|Danderyd Hospital||2|||f||||f||||||||||2018-06-01 01:40:16.006956|2018-06-01 01:40:16.006956
NCT00772382|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2014-04-10|2011-12-04|2014-09-05|2008-10-13|2008-10-15|Estimate|2014-04-10|2014-05-12|Estimate|2011-12-04|2011-12-08|Estimate|2014-09-05|2014-09-15|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia|A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia|Completed||Phase 3|116|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 01:40:16.139453|2018-06-01 01:40:16.139453
NCT00772369|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2010-03-15||2014-01-20|2008-10-13|2008-10-15|Estimate|2010-03-15|2010-04-02|Estimate||||2014-01-20|2014-02-14|Estimate|September 2003||2003-09-30|January 2014|2014-01-31|April 2005|Actual|2005-04-30|April 2004|Actual|2004-04-30||Observational|||Retrospective Survey of Safety of Fourth Dose Pentacel® in Children|Retrospective Safety Survey of Selected Events in the 6 Months Following the 4th Dose of the Pentacel® Vaccination Series in Children|Completed|||3214|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:40:16.770401|2018-06-01 01:40:16.770401
NCT00772356|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2016-03-01|2008-10-14|2008-10-15|Estimate|||||||2016-03-01|2016-03-03|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes|A Monocenter, Open-Label Glucose Clamp Study Examining the Metabolic Effect of Insulin Infusion Intervals for Basal Insulin Infusion in Patients With Type I Diabetes|Completed||N/A|14|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:40:18.08255|2018-06-01 01:40:18.08255
NCT00772343|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10||2012-06-28|2013-09-06|2008-10-14|2008-10-15|Estimate||||2012-06-28|2012-07-02|Estimate|2013-09-06|2013-09-17|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|June 2012|Actual|2012-06-30|July 2011|Actual|2011-07-31||Interventional|||Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection|A Phase II Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of A Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection (CDI)|Completed||Phase 2|116|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 01:40:18.156206|2018-06-01 01:40:18.156206
NCT00772330|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2017-04-03|2008-10-14|2008-10-15|Estimate|||||||2017-04-03|2017-04-04|Actual|October 2007||2007-10-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Clinical Study of the Safety and Performance of the Miami InnFocus Drainage Implant to Relieve Glaucoma Symptoms|Clinical Study of the Safety and Performance of the Miami InnFocus Drainage Implant to Relieve Glaucoma Symptoms|Completed||Phase 1|23|Actual|InnFocus Inc.||1|||f||||f|f|f||||||||2018-06-01 01:40:18.289534|2018-06-01 01:40:18.289534
NCT00772317|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2016-01-11|2008-10-14|2008-10-15|Estimate|||||||2016-01-11|2016-01-12|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Interventional|STAR||A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)|A Multicenter Clinical Study of the Sonablate® 450 (Sonablate) for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)|Active, not recruiting||N/A|117|Actual|SonaCare Medical||1|||f||||t||||||||||2018-06-01 01:40:18.367088|2018-06-01 01:40:18.367088
NCT00772304|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2009-12-03||2010-02-23|2008-10-13|2008-10-15|Estimate|2010-01-11|2010-02-02|Estimate||||2010-02-23|2010-03-02|Estimate|October 2008||2008-10-31|February 2010|2010-02-28||||November 2008|Actual|2008-11-30||Interventional|||Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis||Completed||Phase 4|102|Actual|Alcon Research|Small sample size. The severity of symptoms experienced by patients may have masked their ability to detect taste and smell.|1|||f||||f||||||||||2018-06-01 01:40:18.458654|2018-06-01 01:40:18.458654
NCT00772291|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2011-08-18|2008-10-14|2008-10-15|Estimate|||||||2011-08-18|2011-08-19|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|pregabalin||Chronic Pain Management After Herniorraphy|Chronic Pain Management After Herniorraphy:Pregabalin vs Placebo. A Double-blinded Randomised Controlled Clinical Trial.|Completed||Phase 3|140|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-06-01 01:40:18.704346|2018-06-01 01:40:18.704346
NCT00772278|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2017-07-24|2008-10-14|2008-10-15|Estimate|||||||2017-07-24|2017-07-25|Actual|January 2009||2009-01-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparing Carotid Stenting With Endarterectomy in Severe Asymptomatic Carotid Stenosis|A Randomized Evaluation of Short Term and Long Term Outcome After Endovascular Repair by Stenting of Carotid Artery Stenosis in Patients With Severe (70% and Higher) Asymptomatic Carotid Stenosis|Completed||Phase 4|137|Actual|Carmel Medical Center||2|||f||||t||||||||||2018-06-01 01:40:18.78934|2018-06-01 01:40:18.78934
NCT00772265|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2012-12-26|2008-10-14|2008-10-15|Estimate|||||||2012-12-26|2012-12-27|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Comparative Glucose Clamp Study of Wockhardt's Human Isophane Insulin With Novolin N,in Healthy Subjects|A Randomized Single Center Double Blind 2 Period Crossover Glucose Clamp Study to Test for Bioequivalence Between 2 Recombinant Human Isophane Insulins Wockhardt's Human Isophane Insulin Injection100IU/ml With Novolin N in Healthy Subjects|Completed||Phase 1|56|Actual|Wockhardt||2|||f||||f||||||||||2018-06-01 01:40:18.881882|2018-06-01 01:40:18.881882
NCT00772252|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2010-06-28|2008-10-14|2008-10-15|Estimate|||||||2010-06-28|2010-06-29|Estimate|August 2008||2008-08-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Observational|||Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment|Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 01:40:18.972588|2018-06-01 01:40:18.972588
NCT00772239|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2011-04-23|2008-10-13|2008-10-15|Estimate|||||||2011-04-23|2011-04-26|Estimate|October 2008||2008-10-31|April 2011|2011-04-30||||August 2010|Actual|2010-08-31||Interventional|ROTEM||Perioperative Coagulation Management in Cardiac Surgery.|Perioperative Coagulation Management in Cardiac Surgery. Rotem Versus Standard Pratctice. A Randomized Trial.|Terminated||N/A|100|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-06-01 01:40:19.058074|2018-06-01 01:40:19.058074
NCT00772226|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2012-09-09|2008-10-14|2008-10-15|Estimate|||||||2012-09-09|2012-09-11|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Use of Music as Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy in a Day Care Unit|The Use of Music as Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy in a Day Care Unit|Completed||Phase 3|204|Actual|Randers Regional Hospital||2|||f||||f||||||||||2018-06-01 01:40:19.145278|2018-06-01 01:40:19.145278
NCT00772213|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2013-10-29|2008-10-14|2008-10-15|Estimate|||||||2013-10-29|2013-10-30|Estimate|February 2003||2003-02-28|October 2013|2013-10-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|MIGTS||The Multifunctional Image Guided Therapy Suite (MIGTS) in Emergency Multiple Trauma Care|The Impact of a Multifunctional Image Guided Therapy Suite (MIGTS) on Emergency Multiple Trauma Care - a Controlled Clinical Pilot Study|Completed||N/A|168|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 01:40:19.234324|2018-06-01 01:40:19.234324
NCT00772200|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2017-10-19|2008-10-14|2008-10-15|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2008||2008-09-30|October 2017|2017-10-31||||January 2100|Anticipated|2100-01-31||Observational|||Neuropsychological and Behavioral Testing in Younger Patients With Cancer|Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer|Recruiting|||755|Anticipated|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 01:40:19.388233|2018-06-01 01:40:19.388233
NCT00772187|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2010-09-21|2008-10-14|2008-10-15|Estimate|||||||2010-09-21|2010-09-22|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Intraoperative and Postoperative Analgesia for Laparoscopic Surgery.|Intraoperative and Postoperative Analgesia for Laparoscopic Surgery.|Completed||Phase 4|40|Anticipated|Rambam Health Care Campus||2|||f||||||||||||||2018-06-01 01:40:20.137779|2018-06-01 01:40:20.137779
NCT00772174|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2010-07-01|2008-10-13|2008-10-15|Estimate|||||||2010-07-01|2010-07-05|Estimate|January 2007||2007-01-31|July 2010|2010-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|PRISMA||Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes|Double-blind, Randomized, Multicenter, Parallel-Group Study to Evaluate the Effects of Pioglitazone on Metabolic Syndrome in Patients With Type 2 Diabetes Treated With Metformin|Completed||Phase 3|418|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:40:20.231263|2018-06-01 01:40:20.231263
NCT00772161|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-01-20|2008-10-14|2008-10-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2008||2008-10-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MPH-Kinetics||Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Single-Center, Single-Blind, Randomized, Oral Dose Cross-Over Study in Prepuberal Boys With ADHD to Investigate Efficacy and Bioequivalence of 20 mg Ritalin LA Compared to 20 mg Medikinet Retard After Treatment With o.d. Doses Over 7 Days Each.|Completed||Phase 1/Phase 2|24|Actual|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 01:40:20.349736|2018-06-01 01:40:20.349736
NCT00772148|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2015-05-12||2015-06-02|2008-10-14|2008-10-15|Estimate|2015-06-02|2015-06-25|Estimate||||2015-06-02|2015-06-25|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients|A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-Tacro™ Tablets Once Daily and Prograf® Capsules Twice Daily in Adult De Novo Liver Transplant Patients|Completed||Phase 2|58|Actual|Veloxis Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:40:20.501496|2018-06-01 01:40:20.501496
NCT00772135|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2008-10-14|2008-10-14|2008-10-15|Estimate|||||||2008-10-14|2008-10-15|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|April 2009|Anticipated|2009-04-30|February 2009|Anticipated|2009-02-28||Interventional|||Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients|Pulmonary Hypertension in Adolescents and Adults With Congenital Heart Disease|Unknown status|Recruiting|N/A|15|Anticipated|Oslo University Hospital|||||f||||f||||||||||2018-06-01 01:40:21.131686|2018-06-01 01:40:21.131686
NCT00772122|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2008-10-14|2008-10-14|2008-10-15|Estimate|||||||2008-10-14|2008-10-15|Estimate|January 2000||2000-01-31|October 2008|2008-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Use of G-CSF for the Treatment of Unexplained Recurrent Miscarriage|Controlled Trial in Women With Recurrent Miscarriage of G-CSF Versus Placebo|Completed||Phase 4|68|Actual|University of Florence||2|||f||||t||||||||||2018-06-01 01:40:21.205902|2018-06-01 01:40:21.205902
NCT00772109|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2011-07-16|2010-03-31|2016-04-12|2008-10-13|2008-10-15|Estimate|2011-07-16|2011-08-10|Estimate|2010-03-31|2010-04-02|Estimate|2016-04-12|2016-04-14|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults|Lot Consistency, Immunogenicity, and Safety Study of Three Lots of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years|Completed||Phase 3|4292|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 01:40:21.409204|2018-06-01 01:40:21.409204
NCT00772096|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2015-03-09|2008-10-14|2008-10-15|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Septic Encephalopathy and Late Cognitive Dysfunction|Septic Encephalopathy and Late Cognitive Dysfunction in Patients With Sepsis - the Role of Inflammation|Completed||Phase 4|50|Actual|University Hospital, Basel, Switzerland||2|||f||||||||||||||2018-06-01 01:40:22.564296|2018-06-01 01:40:22.564296
NCT00772083|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2010-08-10|2008-10-14|2008-10-15|Estimate|||||||2010-08-10|2010-08-11|Estimate|November 2008||2008-11-30|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors|Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors|Completed||N/A|400|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-06-01 01:40:22.643405|2018-06-01 01:40:22.643405
NCT00772070|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2009-03-26||2014-01-21|2008-10-14|2008-10-15|Estimate|2009-03-26|2009-05-14|Estimate||||2014-01-21|2014-02-14|Estimate|March 2003||2003-03-31|January 2014|2014-01-31|May 2004|Actual|2004-05-31|August 2003|Actual|2003-08-31||Interventional|||Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine|Antibody Responses to a Reduced Dose of Menomune® in Children Who Previously Received an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, TetraMenD|Completed||Phase 2|173|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:40:22.755403|2018-06-01 01:40:22.755403
NCT00772057|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-12-18|2008-10-14|2008-10-15|Estimate|||||||2009-12-18|2009-12-21|Estimate|October 2004||2004-10-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)|Early Primary Prophylaxis With Beta-Blockers In Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: A Randomized Controlled Trial|Completed||N/A|164|Actual|Govind Ballabh Pant Hospital||2|||f||||f||||||||||2018-06-01 01:40:23.146475|2018-06-01 01:40:23.146475
NCT00772044|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2010-03-31|2008-10-14|2008-10-15|Estimate|||||||2010-03-31|2010-04-01|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|AERO||Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea|Randomized, Double-blind Study to Compare Safety and Effectiveness of the ProventTM Professional Sleep Apnea Therapy Device to Sham for the Non-invasive Treatment of OSAH|Completed||Phase 4|250|Anticipated|Ventus Medical, Inc.||2|||f||||f||||||||||2018-06-01 01:40:23.215158|2018-06-01 01:40:23.215158
NCT00772031|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2011-10-18||2012-01-20|2008-10-14|2008-10-15|Estimate|2011-12-14|2012-01-19|Estimate||||2012-01-20|2012-01-24|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|CMTT||NINDS CRC Chronic Migraine Treatment Trial|NINDS Clinical Research Collaboration Chronic Migraine Treatment Trial|Completed||Phase 3|191|Actual|The EMMES Corporation||2|||f||||t||||||||||2018-06-01 01:40:23.322057|2018-06-01 01:40:23.322057
NCT00772018|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-12|||2012-02-01|2008-10-12|2008-10-15|Estimate|||||||2012-02-01|2012-02-02|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Quality of Life and Symptom Management in Patients With Bladder Cancer|A Qualitative Study of Patients With Non-Invasive Bladder Cancer|Completed|||28|Actual|Baylor College of Medicine|||||f||||f||||||||||2018-06-01 01:40:23.950419|2018-06-01 01:40:23.950419
NCT00772005|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2011-03-31||2012-06-21|2008-10-10|2008-10-15|Estimate|2012-06-21|2012-07-27|Estimate||||2012-06-21|2012-07-27|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia|A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia|Completed||Phase 2|287|Actual|Teva Pharmaceutical Industries||4|||f||||t||||||||||2018-06-01 01:40:24.198659|2018-06-01 01:40:24.198659
NCT00771992|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2010-08-03|2008-10-14|2008-10-15|Estimate|||||||2010-08-03|2010-08-04|Estimate|October 2008||2008-10-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Interventional|||Ex Vivo Effect of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma|Ex Vivo Effect of Surfactant Protein D on Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge in Patients With Asthma|Completed||N/A|15|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||||||||||||2018-06-01 01:40:29.996611|2018-06-01 01:40:29.996611
NCT00771979|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2009-06-17|2008-10-14|2008-10-15|Estimate|||||||2009-06-17|2009-06-18|Estimate|November 2008||2008-11-30|June 2009|2009-06-30|March 2009|Actual|2009-03-31|||||Interventional|||Relative Bioavailability of Phase II and Phase III Formulations of AZD0530|A Phase I, Randomised, Open-Label, Cross-Over, Single Centre Study in Healthy Volunteers to Determine the Relative Bioavailability of the Phase III Tablet Formulation to the Phase II Tablet Formulation of AZD0530|Completed||Phase 1|18|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:40:30.057077|2018-06-01 01:40:30.057077
NCT00771966|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2012-10-19|2008-10-14|2008-10-15|Estimate|||||||2012-10-19|2012-10-22|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Radical Prostatectomy and Perioperative Fluid Therapy|Radical Prostatectomy and Perioperative Fluid Therapy|Completed||Phase 4|44|Actual|Rigshospitalet, Denmark||2|||f||||||||||||||2018-06-01 01:40:30.114833|2018-06-01 01:40:30.114833
NCT00771797|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2015-09-22|2008-10-10|2008-10-13|Estimate|||||||2015-09-22|2015-09-23|Estimate|October 2008||2008-10-31|September 2015|2015-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Peripheral Artery Occlusive Diseases (PAOD) Study - Clinical Assessment|Clinical Study to Assess the Clinical Efficacy of Flavanol-rich Cocoa on Vascular Function in Diabetic Patients With PAOD|Withdrawn||Phase 2|0|Actual|RWTH Aachen University||2||investigator took study to university hospital duesseldorf|f||||f||||||||||2018-06-01 01:40:35.72487|2018-06-01 01:40:35.72487
NCT00771953|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2013-05-28||2017-04-11|2008-10-14|2008-10-15|Estimate|2013-05-28|2013-07-22|Estimate||||2017-04-11|2017-05-17|Actual|November 2008||2008-11-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|May 2012|Actual|2012-05-31||Interventional|||0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer|0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients|Completed||Phase 2|109|Actual|University of Maryland|This study is limited by the relatively low numbers and the hetereogeneity between concurrent treatments (docetaxel vs. pemetrexed). However, in analyses stratified by docetaxel and pemetrexed, results for an affect of apricoxib were still null.|2|||f||||t||||||||||2018-06-01 01:40:30.189688|2018-06-01 01:40:30.189688
NCT00771940|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-02-02|2008-10-13|2008-10-15|Estimate|||||||2009-02-02|2009-02-03|Estimate|October 2008||2008-10-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Peripheral Metabolic Effects of Ghrelin|Peripheral Metabolic Effects of Intra Arterial Ghrelin Infusion in Healthy Controls|Completed||Phase 1|8|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-06-01 01:40:30.450353|2018-06-01 01:40:30.450353
NCT00771927|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2013-03-08||2014-10-17|2008-10-14|2008-10-15|Estimate|2013-03-08|2013-04-22|Estimate||||2014-10-17|2014-10-27|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|PASS|Baseline characteristics refer to the Safety Set (SS). Safety Set includes all patients who have signed a data consent form, provided Baseline characteristic data, and received treatment at least once.|Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures|Post-Authorization Safety Study to Evaluate the Long-Term Safety and Tolerability of Vimpat® (Lacosamide) as Add-On Therapy in Epilepsy Patients With Partial-Onset Seizures Who Are Uncontrolled on Current Therapy|Completed|||1005|Actual|UCB Pharma|||2||f||||f||||||||||2018-06-01 01:40:30.543193|2018-06-01 01:40:30.543193
NCT00771914|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2011-10-10||2012-10-31|2008-10-14|2008-10-15|Estimate|2012-05-25|2012-06-29|Estimate||||2012-10-31|2012-11-06|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Effects of Omega-3 Fatty Acids on Aspirin Resistance|The Effects of Omega-3 Fatty Acids on Aspirin Resistance|Completed||Phase 1/Phase 2|27|Actual|University of Rochester||4|||f||||t||||||||||2018-06-01 01:40:32.895318|2018-06-01 01:40:32.895318
NCT00771901|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2017-09-15||2018-04-25|2008-10-14|2008-10-15|Estimate|2018-04-25|2018-05-28|Estimate||||2018-04-25|2018-05-28|Estimate|February 2008|Actual|2008-02-29|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TUDCA/PBA||Effect of Endoplasmic Reticulum Stress on Metabolic Function|Effect of Endoplasmic Reticulum Stress on Metabolic Function|Completed||N/A|101|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 01:40:33.242377|2018-06-01 01:40:33.242377
NCT00771888|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|||2008-11-12|2008-10-14|2008-10-15|Estimate|||||||2008-11-12|2008-11-13|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|August 2009|Anticipated|2009-08-31|October 2008|Actual|2008-10-31||Interventional|LOCKCYST-ext||Open-Label Extension of LOCKCYST Trial|Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers|Unknown status|Active, not recruiting|Phase 2/Phase 3|54|Anticipated|Radboud University||1|||f||||f||||||||||2018-06-01 01:40:33.547184|2018-06-01 01:40:33.547184
NCT00771875|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|2015-10-27||2015-12-17|2008-10-14|2008-10-15|Estimate|2015-12-17|2016-01-27|Estimate||||2015-12-17|2016-01-27|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Randomized Trial for Mixed Acute Rejection|B-Cell Targeted Therapy for Acute Renal Allograft Rejection With an Antibody Mediated Component: A Prospective, Randomized, Open-Label Study|Completed||Phase 2|30|Actual|University of Cincinnati||3|||f||||t||||||||||2018-06-01 01:40:33.650824|2018-06-01 01:40:33.650824
NCT00771862|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-14|||2018-03-15|2008-10-14|2008-10-15|Estimate|||||||2018-03-15|2018-03-19|Actual|October 2008||2008-10-31|March 2018|2018-03-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study|Prevention of Phantom Limb and Stump Pain Using Ambulatory Continuous Peripheral Nerve Blocks: A Pilot Study|Terminated||Phase 4|16|Actual|University of California, San Diego||2||Could not secure funding to complete the study.|f||||f||||||||||2018-06-01 01:40:34.217345|2018-06-01 01:40:34.217345
NCT00771849|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-13|2009-03-16||2016-04-12|2008-10-13|2008-10-15|Estimate|2009-03-16|2009-04-24|Estimate||||2016-04-12|2016-04-14|Estimate|August 2003||2003-08-31|April 2016|2016-04-30|May 2004|Actual|2004-05-31|March 2004|Actual|2004-03-31||Interventional|||Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children|Antibody Responses for Serogroup C After One Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine Versus a Non-meningococcal Control Vaccine in Children Who Have Previously Received a Monovalent Meningococcal C Conjugate Vaccine|Completed||Phase 2|103|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:40:34.302696|2018-06-01 01:40:34.302696
NCT00771836|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-10-14|2008-10-14|2008-10-15|Estimate|||||||2008-10-14|2008-10-15|Estimate|July 2004||2004-07-31|October 2008|2008-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|AHR||Airway Reactivity in Children Before and After BMT Bone Marrow Transplantation|Airway Reactivity in Children Before and After Bone Marrow Transplantation|Completed|||39|Actual|Rambam Health Care Campus|||||f||||f||||||None Retained|"~     Not retained~   "|||2018-06-01 01:40:34.539545|2018-06-01 01:40:34.539545
NCT00771823|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2010-08-13|2008-10-14|2008-10-15|Estimate|||||||2010-08-13|2010-08-16|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers|A Placebo Controlled Study of the Impact on Insulin Sensitivity and Lipid Profile of Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers|Completed||Phase 1|16|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-06-01 01:40:34.592341|2018-06-01 01:40:34.592341
NCT00771810|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2013-02-25||2017-10-10|2008-10-09|2008-10-13|Estimate|2013-04-30|2013-06-07|Estimate||||2017-10-10|2017-11-13|Actual|October 2008||2008-10-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer|Ph IIb Study Evaluating the Safety & Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Combination Gemcitabine and Platinum Therapy for Ovarian, Fallopian Tube, or Peritoneal Carcinoma|Completed||Phase 2|34|Actual|Tarix Pharmaceuticals|Feasibility considerations (e.g., slow patient enrollment and lower incidence of Grade 3-4 thrombocytopenia than planned) necessitated early termination of the study after 34 patients had been enrolled.|3|||f||||f||||||||||2018-06-01 01:40:34.703174|2018-06-01 01:40:34.703174
NCT00771784|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2012-08-21|2008-10-10|2008-10-13|Estimate|||||||2012-08-21|2012-08-22|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Effects of Tracheal Intubation on Ventilation With a Laryngeal Mask During Percutaneous Dilatation Tracheostomy|Effects of Short- and of Long-term Tracheal Intubation on Ventilation With a Laryngeal Mask During Percutaneous Dilatation Tracheostomy.|Completed|||60|Actual|University of Padova|||2||f||||t||||||||||2018-06-01 01:40:35.78548|2018-06-01 01:40:35.78548
NCT00771771|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2014-02-24|2008-10-10|2008-10-13|Estimate|||||||2014-02-24|2014-02-25|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||Early Supported Discharge After Stroke in Bergen|Early Supported Discharge After Stroke in Bergen. An RCT Looking at the Collaboration Between Hospital Service and Primary Health Care.|Completed||N/A|306|Actual|Haukeland University Hospital||3|||f||||f||||||||||2018-06-01 01:40:35.843046|2018-06-01 01:40:35.843046
NCT00771758|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2010-12-08||2014-04-24|2008-10-10|2008-10-13|Estimate|2011-03-10|2011-04-07|Estimate||||2014-04-24|2014-05-09|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis|A Randomized, Double-Blind, Placebo- and Oxycodone Immediate Release (IR)-Controlled Study of Tapentadol IR for the Treatment of Acute Pain Caused by Vertebral Compression Fractures Associated With Osteoporosis|Completed||Phase 3|108|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|Insufficient number of participants enrolled to meet proposed sample size, so that statistical inferences could not be made.|3|||f||||f||||||||||2018-06-01 01:40:36.097004|2018-06-01 01:40:36.097004
NCT00771745|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2013-01-18||2015-12-15|2008-10-10|2008-10-13|Estimate|2015-10-20|2015-11-23|Estimate||||2015-12-15|2016-01-18|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients|Prospective, Single Center, Pilot Study of Pretransplant Thymoglobulin Administration and Early Corticosteroid Withdrawal in Living Donor Renal Transplant Recipients Under Mycophenolate Mofetil (MMF) and Tacrolimus Immunosuppression|Completed||Phase 4|11|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 01:40:37.356881|2018-06-01 01:40:37.356881
NCT00771732|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-10-10|2008-10-10|2008-10-13|Estimate|||||||2008-10-10|2008-10-13|Estimate|May 2008||2008-05-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Using Light Therapy to Treat Toe Nail Fungus|Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Nomir Medical Technologies||2|||f||||t||||||||||2018-06-01 01:40:37.594142|2018-06-01 01:40:37.594142
NCT00771719|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-07-27|2008-10-09|2008-10-13|Estimate|||||||2012-07-27|2012-07-30|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia|Open-Label Exploratory, Multiple-Dose Study of Ceftobiprole to Evaluate the Pharmacokinetics and Broncho-Alveolar Penetration in Adults With Ventilator-Associated Pneumonia|Terminated||Phase 1|1|Actual|Basilea Pharmaceutica||1||Study closed due to lack of enrollment; challenging patient population.|f||||f||||||||||2018-06-01 01:40:37.682851|2018-06-01 01:40:37.682851
NCT00771706|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2012-04-19|2008-10-10|2008-10-13|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux|Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux|Withdrawn||Phase 3|0|Actual|Massachusetts Eye and Ear Infirmary||2||This study was not activated, no data was collected.|f||||f||||||||||2018-06-01 01:40:37.741067|2018-06-01 01:40:37.741067
NCT00771693|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2010-11-04|2008-10-10|2008-10-13|Estimate|||||||2010-11-04|2010-11-05|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)|Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With NIDDM: a Placebo-controlled Dose-response Study With Insulin Aspart (Novorapid®)|Completed||Phase 4|18|Actual|Karolinska Institutet|||||f||||f||||||||||2018-06-01 01:40:37.800585|2018-06-01 01:40:37.800585
NCT00771680|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2016-10-26|2008-10-10|2008-10-13|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes|Evaluation of Effectiveness and Safety of Levemir® (Insulin Detemir), NovoMix® (Biphasic Insulin Aspart) and/or NovoRapid® (Insulin Aspart) in Insulin naïve Subjects With Type 2 Diabetes.|Completed|||10408|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:40:37.858789|2018-06-01 01:40:37.858789
NCT00771667|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2011-10-10|2011-04-26|2013-03-26|2008-10-10|2008-10-13|Estimate|2012-06-21|2012-07-27|Estimate|2011-04-26|2011-05-03|Estimate|2013-03-26|2013-04-01|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy|A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy|Completed||Phase 2|526|Actual|Centocor, Inc.||10|||f||||t||||||||||2018-06-01 01:40:38.005572|2018-06-01 01:40:38.005572
NCT00771654|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2012-08-30|2008-10-10|2008-10-13|Estimate|||||||2012-08-30|2012-08-31|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Phentermine/Gastric Band Weight Loss Study|Does the Addition of Phentermine Increase Weight Loss in the Obese After Gastric Band Operation?|Withdrawn||N/A|0|Actual|Carolinas Healthcare System||2||Low enrollment|f||||t||||||||||2018-06-01 01:40:39.934612|2018-06-01 01:40:39.934612
NCT00771641|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2014-01-23|2008-10-10|2008-10-13|Estimate|||||||2014-01-23|2014-01-24|Estimate||||January 2014|2014-01-31|November 2013|Actual|2013-11-30|August 2002|Actual|2002-08-31||Interventional|||Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck|Phase III Randomized Comparison of Radiotherapy Fractionation in Advanced Squamous Cell Carcinoma of the Head and Neck: Twice-Daily Hyperfractionation vs Split-Course Accelerated Hyperfractionation vs Accelerated Fractionation With Concomitant Boost vs Standard Fractionation|Completed||Phase 3|1113|Actual|Radiation Therapy Oncology Group||4|||f||||t||||||||||2018-06-01 01:40:40.005052|2018-06-01 01:40:40.005052
NCT00771628|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2009-07-10|2008-10-10|2008-10-13|Estimate|||||||2009-07-10|2009-07-14|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Flex-It Stylet to Malleable Stylet for GlideScope Intubation: A Randomized Controlled Trial|Comparison of Flex-It Stylet to Malleable Stylet for GlideScope Intubation: A Randomized Controlled Trial|Completed||N/A|80|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 01:40:40.090053|2018-06-01 01:40:40.090053
NCT00771615|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2013-12-19|2010-07-02|2016-10-06|2008-10-10|2008-10-13|Estimate|2014-08-21|2014-09-04|Estimate|2010-07-02|2010-07-07|Estimate|2016-10-06|2016-11-16|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years|A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age|Completed||Phase 2|469|Actual|GlaxoSmithKline||9|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:40:40.218565|2018-06-01 01:40:40.218565
NCT00771602|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2011-04-04||2015-05-27|2008-10-10|2008-10-13|Estimate|2011-04-04|2011-04-29|Estimate||||2015-05-27|2015-06-23|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Alemtuzumab + Rituximab Consolidation in CLL|A Randomized Trial of Rituximab vs Alemtuzumab vs Alemtuzumab + Rituximab as Consolidation Therapy for Patients With Chronic Lymphocytic Leukemia (CLL) With Evidence of Residual Disease Following Prior Chemo(Immuno)Therapy|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||3||Lack of accrual.|f||||f||||||||||2018-06-01 01:40:42.349926|2018-06-01 01:40:42.349926
NCT00771589|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2008-10-10|2008-10-10|2008-10-13|Estimate|||||||2008-10-10|2008-10-13|Estimate|May 2008||2008-05-31|October 2008|2008-10-31|April 2009|Anticipated|2009-04-30|January 2009|Anticipated|2009-01-31||Interventional|||Active Knee Prosthesis Study for Improvement of Locomotion for Above Knee Amputees|The Active Knee Prosthesis Will be Tested to Evaluate How Well it Improves the Gait Symmetry and Reduces the Metabolic Cost of an Amputee During Walking. The Prosthesis Will be Attached to the Socket of the Amputee.|Unknown status|Recruiting|N/A|10|Anticipated|Providence VA Medical Center||1|||f||||t||||||||||2018-06-01 01:40:42.540866|2018-06-01 01:40:42.540866
NCT00771576|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2017-07-14|2008-10-10|2008-10-13|Estimate|||||||2017-07-14|2017-07-18|Actual|September 2006||2006-09-30|July 2017|2017-07-31|June 13, 2012|Actual|2012-06-13|September 2008|Actual|2008-09-30||Observational|||PET Scan Imaging of Beta Cell Mass|PET Scan Imaging of Pancreatic Beta Cell Mass With DTBZ|Completed|||30|Actual|Columbia University|||3||f||||t||||||None Retained|"~     Blood~   "|||2018-06-01 01:40:42.611242|2018-06-01 01:40:42.611242
NCT00771563|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2013-06-27|2008-10-10|2008-10-13|Estimate|||||||2013-06-27|2013-06-28|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|SYRINGES||Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)|Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cisplatin Based First Line Chemotherapy: the SYRINGES Trial|Completed||Phase 3|104|Actual|University Hospital, Antwerp||2|||f||||f||||||||||2018-06-01 01:40:42.680954|2018-06-01 01:40:42.680954
NCT00771537|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2013-04-07||2013-06-28|2008-10-10|2008-10-13|Estimate|2013-06-28|2013-07-09|Estimate||||2013-06-28|2013-07-09|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||HIV Testing & Womens Attitudes on HIV Vaccine Trials|HIV Testing & Womens Attitudes on HIV Vaccine Trials|Completed||Phase 3|2031|Actual|Indiana University||16|||f||||t||||||||||2018-06-01 01:40:42.77634|2018-06-01 01:40:42.77634
NCT00771524|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2012-07-27|2008-10-10|2008-10-13|Estimate|||||||2012-07-27|2012-07-30|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone|Open-Label, Pharmacokinetic Study of the Penetration of Ceftobiprole Into Bone|Completed||Phase 1|22|Actual|Basilea Pharmaceutica||2|||f||||f||||||||||2018-06-01 01:40:43.515405|2018-06-01 01:40:43.515405
NCT00771511|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2013-02-06|2008-10-10|2008-10-13|Estimate|||||||2013-02-06|2013-02-07|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Cervical Capsaicin for Labor Induction and Pain Relief|Cervical Capsaicin for Labor Induction and Pain Relief|Withdrawn||Phase 4|0|Actual|Columbia University||2||PI left the institution.|f||||t||||||||||2018-06-01 01:40:43.573216|2018-06-01 01:40:43.573216
NCT00771498|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2015-05-15|2008-10-10|2008-10-13|Estimate|||||||2015-05-15|2015-05-19|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|A06-295||An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin|An Evaluation of the Pharmacological Interaction of Lopinavir 800mg - Ritonavir 200mg Combination and Rifampin in Subjects Presenting Tuberculosis, With Contraindication for Antiretroviral Regimens Including Efavirenz|Completed||Phase 4|30|Actual|Oswaldo Cruz Foundation||1|||f||||f||||||||||2018-06-01 01:40:43.630607|2018-06-01 01:40:43.630607
NCT00771485|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-02-08|2008-10-10|2008-10-13|Estimate|||||||2012-02-08|2012-02-10|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Efficacy of Bowel Preparation Before Colonoscopy|Study of Efficacy of Bowel Preparation Before Colonoscopy|Completed||Phase 2|148|Actual|C.B. Fleet Company, Inc.||2|||f||||f||||||||||2018-06-01 01:40:43.70782|2018-06-01 01:40:43.70782
NCT00771472|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2012-05-30||2015-04-02|2008-10-09|2008-10-13|Estimate|2012-05-30|2012-07-04|Estimate||||2015-04-02|2015-04-21|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)|Phase I Clinical Study of MK-0683 in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)|Completed||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:40:43.898721|2018-06-01 01:40:43.898721
NCT00771459|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2011-06-22|2008-10-10|2008-10-13|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Local Infiltration Analgesia in Major Spine Surgery With Ropivacaine Versus Placebo|Lokal Infiltrations Analgesi Med Ropivakain 0,5 % Versus Placebo Ved Rygkirurgi for Spinalstenose: et Prospektivt Randomiseret, Dobbeltblindet, Placebo-kontrolleret Studie|Completed||Phase 4|48|Anticipated|Hvidovre University Hospital||2|||f||||||||||||||2018-06-01 01:40:44.146374|2018-06-01 01:40:44.146374
NCT00771095|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2008-10-09|2008-10-09|2008-10-10|Estimate|||||||2008-10-09|2008-10-10|Estimate|January 2008||2008-01-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|POD||Pounds Off Digitally Study: A Podcasting Weight Loss Intervention|Pounds Off Digitally Study: A Podcasting Weight Loss Intervention|Completed||Phase 1|94|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 01:40:47.927027|2018-06-01 01:40:47.927027
NCT00771446|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09||2012-07-24|2013-04-05|2008-10-10|2008-10-13|Estimate||||2012-07-24|2012-08-01|Estimate|2013-04-05|2013-04-12|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ELAD||Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency|Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) in Patients With Acute on Chronic Hepatitis (AOCH)|Completed||Phase 1/Phase 2|18|Actual|Vital Therapies, Inc.||2|||f||||t||||||||||2018-06-01 01:40:44.213623|2018-06-01 01:40:44.213623
NCT00771433|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2011-05-12|2008-10-10|2008-10-13|Estimate|||||||2011-05-12|2011-05-13|Estimate|October 2007||2007-10-31|December 2008|2008-12-31||||May 2011|Actual|2011-05-31||Interventional|||G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer|Evaluation of the Efficacy of Adding Daily G-CSF (Granulocyte Colony Stimulating Factor) for Prevention of Hematologic Toxicity Due to Neoadjuvant or Adjvuant Chemotherapy in Breast Cancer|Completed||Phase 2|120|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:40:44.304824|2018-06-01 01:40:44.304824
NCT00771420|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2012-07-19|2008-10-10|2008-10-13|Estimate|||||||2012-07-19|2012-07-20|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis|A Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CAM-3001 in Patients With Rheumatoid Arthritis.|Completed||Phase 1|38|Actual|MedImmune LLC||7|||f||||t||||||||||2018-06-01 01:40:44.372235|2018-06-01 01:40:44.372235
NCT00771407|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2013-08-20||2015-08-25|2008-10-10|2008-10-13|Estimate|2015-08-25|2015-09-28|Estimate||||2015-08-25|2015-09-28|Estimate|December 2008||2008-12-31|August 2015|2015-08-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|PriSm|The Baseline Analysis population is the 113 subjects in the Intent To Treat population.|Parastomal Reinforcement With Strattice|A Prospective, Multicenter, Randomized, Controlled, Third-party Blinded Study of Strattice Fascial Inlay for Parastomal Reinforcement in Patients Undergoing Surgery for Permanent Abdominal Wall Ostomies|Completed||Phase 4|120|Actual|LifeCell||2|||f||||f||||||||||2018-06-01 01:40:44.472942|2018-06-01 01:40:44.472942
NCT00771394|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2013-02-13|2008-10-09|2008-10-13|Estimate|||||||2013-02-13|2013-02-15|Estimate|October 2008||2008-10-31|February 2013|2013-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride|Completed||Phase 4|638|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 01:40:45.267845|2018-06-01 01:40:45.267845
NCT00771381|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2014-10-01|2008-10-10|2008-10-13|Estimate|||||||2014-10-01|2014-10-03|Estimate|November 2008||2008-11-30|March 2012|2012-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer|A Phase II Pre-Treatment Hypoxia PET Imaging Study Using 18F-FAZA in Patients With Invasive Duct Carcinoma of the Breast|Unknown status|Recruiting|Phase 2|30|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||||2018-06-01 01:40:45.359197|2018-06-01 01:40:45.359197
NCT00771368|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2012-01-18|2008-10-10|2008-10-13|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Reduction of Bacteria in MRSA Positive Ulcers|A Clinical Trial on the Reduction of Bacteria (Including MRSA) in MRSA Positive Ulcers and Lesions|Terminated||Phase 1/Phase 2|20|Anticipated|Nitric BioTherapeutics, Inc||1||limited recruitment|f||||f||||||||||2018-06-01 01:40:45.434097|2018-06-01 01:40:45.434097
NCT00771355|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2011-03-28|2008-10-09|2008-10-13|Estimate|||||||2011-03-28|2011-03-30|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy|In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy|Terminated|||40|Anticipated|Massachusetts General Hospital|||4|Lack of study staff.|f||||f||||||||||2018-06-01 01:40:45.506374|2018-06-01 01:40:45.506374
NCT00771342|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2010-02-02|2008-10-10|2008-10-13|Estimate|||||||2010-02-02|2010-02-03|Estimate|December 2008||2008-12-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)|A Blinded Placebo Controlled Single Cross-over Clinical Trial to Evaluate Fungicidal Activity With Topical Application of 1% Gaseous Nitric Oxide in Subjects With Moderate to Severe Tinea Pedis (Athlete's Foot)|Completed||Phase 2|50|Anticipated|Nitric BioTherapeutics, Inc||2|||f||||f||||||||||2018-06-01 01:40:45.563667|2018-06-01 01:40:45.563667
NCT00771329|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2013-09-12|2008-10-10|2008-10-13|Estimate|||||||2013-09-12|2013-09-16|Estimate|October 2008||2008-10-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.|Completed||Phase 1|53|Actual|Biogen||2|||f||||t||||||||||2018-06-01 01:40:45.629878|2018-06-01 01:40:45.629878
NCT00771316|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2010-04-22||2017-02-14|2008-10-09|2008-10-13|Estimate|2010-06-14|2010-07-09|Estimate||||2017-02-14|2017-03-21|Actual|December 2008||2008-12-31|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)|A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated Urinary Tract Infection|Terminated||Phase 3|6|Actual|Merck Sharp & Dohme Corp.|The reason for early termination: Study was terminated early due to feasibility issues including slow enrollment.|2||feasibility and low enrollment|f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:40:45.768401|2018-06-01 01:40:45.768401
NCT00771303|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2018-05-03|2008-10-10|2008-10-13|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2008|Actual|2008-09-30|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study|Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study|Completed|||402|Actual|University Hospital, Geneva|||1||f||||t||||||Samples Without DNA|"~     Nt-pro BNP measurement~   "|||2018-06-01 01:40:45.971646|2018-06-01 01:40:45.971646
NCT00771290|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2012-11-13|2008-10-10|2008-10-13|Estimate|||||||2012-11-13|2012-11-15|Estimate|March 2008||2008-03-31|November 2012|2012-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Comparision of Air Versus CO2 for Distention During Sigmoidoscopy|Prospective,Randomized Trial Comparing Colonic Distension After Intra-operative Sigmoidoscopy Using Ambient Air or Carbon Dioxide|Terminated||N/A|54|Actual|Columbia University|||||f||||f||||||||||2018-06-01 01:40:46.060184|2018-06-01 01:40:46.060184
NCT00771277|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2014-09-05||2015-04-06|2008-10-10|2008-10-13|Estimate|2014-09-11|2014-09-18|Estimate||||2015-04-06|2015-04-28|Estimate|September 2008||2008-09-30|August 2014|2014-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||All families were National Guard families. The veterans were divided between mild and moderate TBI with co-morbid PTSD and 1 to 5 years post-injury. Patients were all male except for one wife. All were Caucasian. Ages of patients ranged from mid 20s to mid 40s.|Team Based Initiative Support|Team Based Initiative Support|Completed||N/A|6|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:40:46.126264|2018-06-01 01:40:46.126264
NCT00771264|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2010-08-26||2012-04-13|2008-10-10|2008-10-13|Estimate|2010-08-26|2010-09-21|Estimate||||2012-04-13|2012-04-18|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SUmiT||Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms||Completed||Phase 4|220|Actual|Uroplasty, Inc||2|||f||||||||||||||2018-06-01 01:40:46.29682|2018-06-01 01:40:46.29682
NCT00771251|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2015-11-02|2008-10-10|2008-10-13|Estimate|||||||2015-11-02|2015-11-03|Estimate|May 2008||2008-05-31|November 2015|2015-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)|A Study of Golimumab (CNTO148) Monotherapy in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|311|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 01:40:46.53397|2018-06-01 01:40:46.53397
NCT00771238|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|2015-03-23||2017-07-07|2008-10-10|2008-10-13|Estimate|2015-08-25|2015-09-28|Estimate||||2017-07-07|2017-08-07|Actual|November 2008||2008-11-30|August 2015|2015-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||ICU patients in a high acuity Medical / Surgical ICU.|Pilot Study of Incidence and Change in Existing Pressure Ulcers: TC500 Bed Compared With Standard Beds|A Pilot Study of Pressure Ulcer Incidence and Change in Existing Pressure Ulcers Comparing Subjects Placed on the TC500 Bed With Standard Beds in the 850-SICU Unit|Completed||N/A|52|Actual|Hill-Rom||2|||f||||f||||||||||2018-06-01 01:40:46.764734|2018-06-01 01:40:46.764734
NCT00771225|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2010-02-02|2008-10-10|2008-10-13|Estimate|||||||2010-02-02|2010-02-03|Estimate|November 2008||2008-11-30|October 2008|2008-10-31|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Interventional|||National,Multicentric Randomised Study of the Correction of Genital Prolapse With Fascial Repair or Mesh-Prolift|A National Multicentric Randomised Study of the Correction of Genital Prolapse With Fascial Repair or Mesh (Prolift)|Unknown status|Active, not recruiting|Phase 4|180|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:40:46.971535|2018-06-01 01:40:46.971535
NCT00771212|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2014-05-22|2008-10-10|2008-10-13|Estimate|||||||2014-05-22|2014-05-23|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Observational Study on the Patients With Pain Medications|Observational Study on the Patients With Pain Medications|Completed|||2636|Actual|Johnson & Johnson Taiwan Ltd|||1||f||||||||||||||2018-06-01 01:40:47.054514|2018-06-01 01:40:47.054514
NCT00771199|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2014-09-16|2008-10-10|2008-10-13|Estimate|||||||2014-09-16|2014-09-17|Estimate|October 2008||2008-10-31|September 2014|2014-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain|An Open-label, Multicenter Study to Evaluate the Safety/Tolerability and Clinical Utility of Low-dose TTS-Fentanyl D-TRANS in Taiwan Patients With Cancer Pain|Completed||Phase 4|14|Actual|Janssen-Cilag Ltd.||1|||f||||f||||||||||2018-06-01 01:40:47.105548|2018-06-01 01:40:47.105548
NCT00771186|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2010-06-16|2008-10-10|2008-10-13|Estimate|||||||2010-06-16|2010-06-22|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Intraoperative Laryngeal Electromyography (LEMG) in Children With Vocal Fold Immobility: a Longitudinal Study|Intraoperative Laryngeal Electromyography (LEMG) in Children With Vocal Fold Immobility: a Longitudinal Study|Completed|||40|Anticipated|Massachusetts Eye and Ear Infirmary|||1||f||||f||||||||||2018-06-01 01:40:47.160983|2018-06-01 01:40:47.160983
NCT00771173|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2015-04-20||2016-08-22|2008-10-10|2008-10-13|Estimate|2015-05-27|2015-06-11|Estimate||||2016-08-22|2016-09-29|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CATH||CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial|THE CAT(H) STUDY CATHETER ANALGESIA TRIAL Phenazopyrdine vs. Placebo: a Randomized Controlled Trial A CREST 2010 Project|Completed||Phase 4|258|Actual|Loyola University|One limitation of our study was inconsistent collection of our primary outcome data. Nursing staff and house staff failed to collect VAS scores consistently.|2|||f||||f||||||||Undecided||2018-06-01 01:40:47.213123|2018-06-01 01:40:47.213123
NCT00771160|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2017-03-17|2008-10-10|2008-10-13|Estimate|||||||2017-03-17|2017-03-21|Actual|September 2004||2004-09-30|March 2017|2017-03-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)|MK0476 Phase III Long-term Study -Perennial Allergic Rhinitis-|Completed||Phase 3|120|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:40:47.567461|2018-06-01 01:40:47.567461
NCT00771147|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-06-14|2008-10-10|2008-10-13|Estimate|||||||2012-06-14|2012-06-15|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|||||Observational|PONDIAC||A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®|Prospective Open-label Non-interventional, Non-controlled Multi Observational and Pharmaco-economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar® Treatment Under Daily-life Treatment Conditions|Completed|||71|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 01:40:47.636038|2018-06-01 01:40:47.636038
NCT00771134|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10||2014-05-14|2014-05-14|2008-10-10|2008-10-13|Estimate||||2014-05-14|2014-05-28|Estimate|2014-05-14|2014-05-28|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression|Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of Lu AA39959 in the Treatment of Depression in Patients With Bipolar I or II Disorder|Terminated||Phase 2|105|Actual|H. Lundbeck A/S||3||Study was previously suspended and is now terminated|f||||f||||||||||2018-06-01 01:40:47.705975|2018-06-01 01:40:47.705975
NCT00771121|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-10|||2008-10-10|2008-10-10|2008-10-13|Estimate|||||||2008-10-10|2008-10-13|Estimate||||October 2008|2008-10-31||||||||Interventional|||Effect of Moisturizing Creams on Skin Barrier Function||Unknown status|Recruiting|Phase 4|||ACO Hud Nordic AB||2|||f||||f||||||||||2018-06-01 01:40:47.781334|2018-06-01 01:40:47.781334
NCT00771108|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2011-09-02|2008-10-10|2008-10-13|Estimate|||||||2011-09-02|2011-09-07|Estimate|May 2006||2006-05-31|September 2011|2011-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ED||Exercise Dose and Nonalcoholic Fatty Liver Disease|Exercise Dose and Nonalcoholic Fatty Liver Disease|Completed||N/A|33|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:40:47.846239|2018-06-01 01:40:47.846239
NCT00771082|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-06-05|2008-10-09|2008-10-10|Estimate|||||||2012-06-05|2012-06-06|Estimate|January 2003||2003-01-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Osteoarthritis and Body Composition: Evaluation of Systematic Mediators|Osteoarthritis and Body Composition: Evaluation of Systematic Mediators|Terminated|||1033|Actual|National Institute on Aging (NIA)|||||f||||f||||||Samples Without DNA|"~     Banked serum and urine samples~   "|||2018-06-01 01:40:47.988775|2018-06-01 01:40:47.988775
NCT00771069|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-12-02|2008-10-09|2008-10-10|Estimate|||||||2010-12-02|2010-12-03|Estimate|November 2008||2008-11-30|December 2010|2010-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|CRYSTAL-CO||Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension|A Retrospective, Multi Centre, Non-interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Type II Diabetes Mellitus Patients With DM Related Complication and Hypertension.|Completed|||2000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:40:48.161492|2018-06-01 01:40:48.161492
NCT00771056|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2015-12-17||2016-08-18|2008-10-09|2008-10-10|Estimate|2016-06-15|2016-07-26|Estimate||||2016-08-18|2016-08-22|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Hydroxychloroquine in Untreated B-CLL Patients|Phase II Study to Evaluate the Tolerability and Efficacy of Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients With Hydroxychloroquine.|Terminated||Phase 2|23|Actual|Northwell Health||1||study suspended while data is reviewed for safety and efficacy.|f||||f||||||||No|There is no plan to contact each individual patient (participant in the trial) and inform hem/her of results of this trial as it affects each one of them.|2018-06-01 01:40:48.244584|2018-06-01 01:40:48.244584
NCT00771043|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2009-07-29|2008-10-09|2008-10-10|Estimate|||||||2009-07-29|2009-07-30|Estimate|November 2008||2008-11-30|July 2009|2009-07-31|June 2010|Anticipated|2010-06-30|August 2009|Anticipated|2009-08-31||Interventional|PRTOECT||A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a|Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a|Withdrawn||Phase 4|50|Anticipated|Biogen||2||Sponsor decision to withdraw study at this time.|f||||f||||||||||2018-06-01 01:40:48.421474|2018-06-01 01:40:48.421474
NCT00771030|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09||2015-12-14|2016-10-31|2008-10-09|2008-10-10|Estimate||||2016-10-03|2016-10-05|Estimate|2016-10-31|2016-11-01|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|||Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis|Completed||Phase 1/Phase 2|40|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:40:48.482714|2018-06-01 01:40:48.482714
NCT00771017|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2013-08-16|2008-10-09|2008-10-10|Estimate|||||||2013-08-16|2013-08-20|Estimate|July 2008||2008-07-31|August 2013|2013-08-31||||April 2010|Anticipated|2010-04-30||Interventional|||Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer|A Randomized, Phase II Trial of Brief Androgen-Ablation Combined With Cell-based CG1940/CG8711 Immunotherapy For Prostate Cancer in Patients With Non-Metastatic, Biochemically Relapsed Prostate Cancer|Withdrawn||Phase 2|0|Actual|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-06-01 01:40:48.550001|2018-06-01 01:40:48.550001
NCT00771004|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-07-01|2008-10-09|2008-10-10|Estimate|||||||2010-07-01|2010-07-05|Estimate|August 2006||2006-08-31|July 2010|2010-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.|Pilot Trial Studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients With Type II Diabetes and Insulin Resistance Undergoing Elective PTCA. A Randomized Double-blinded Phase II Study.|Completed||Phase 2|63|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:40:48.620693|2018-06-01 01:40:48.620693
NCT00770991|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2016-02-11||2016-02-11|2008-10-09|2008-10-10|Estimate|2016-02-11|2016-02-15|Estimate||||2016-02-11|2016-02-15|Estimate|December 2005||2005-12-31|February 2016|2016-02-29|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)|A Pilot Study To Investigate the Biological Modulation of Familial Adenomatous Polyposis (FAP) by Lyophilized Black Raspberries|Completed||Phase 1|34|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 01:40:48.733201|2018-06-01 01:40:48.733201
NCT00770978|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-07-27|2008-10-09|2008-10-10|Estimate|||||||2012-07-27|2012-07-30|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU|Open-Label, Parallel Group, Multiple-dose Study of Ceftobiprole to Evaluate the Plasma Pharmacokinetics in Adults in Intensive Care Units|Completed||Phase 1|33|Actual|Basilea Pharmaceutica||2|||f||||f||||||||||2018-06-01 01:40:49.015583|2018-06-01 01:40:49.015583
NCT00770965|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2015-02-02|2012-05-31|2018-02-12|2008-10-09|2008-10-10|Estimate|2015-02-02|2015-02-18|Estimate|2012-05-31|2012-06-06|Estimate|2018-02-12|2018-03-12|Actual|September 10, 2008|Actual|2008-09-10|February 2018|2018-02-28|September 17, 2009|Actual|2009-09-17|September 17, 2009|Actual|2009-09-17||Interventional|||Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis|Phase II Single Dose, Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Study to Assess the Efficacy of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis|Completed||Phase 2|80|Actual|Novartis||4|||f||||f||||||||||2018-06-01 01:40:49.114021|2018-06-01 01:40:49.114021
NCT00770952|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-07-01|2008-10-09|2008-10-10|Estimate|||||||2010-07-01|2010-07-05|Estimate|December 2006||2006-12-31|July 2010|2010-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.|Effects of Pioglitazone in Combination With Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|91|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:40:49.473953|2018-06-01 01:40:49.473953
NCT00770939|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2011-10-07|2008-10-09|2008-10-10|Estimate|||||||2011-10-07|2011-10-12|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of the Effect of Vivostat Platelet Rich Fibrin(PRF) in the Treatment of Diabetic Foot Ulcers|A Cohort Study to Evaluate the Effect of Vivostat Platelet Rich Fibrin on Diabetic Foot Ulcers.|Completed||Phase 4|60|Anticipated|Vivostat|||||f||||f||||||||||2018-06-01 01:40:49.571562|2018-06-01 01:40:49.571562
NCT00770926|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2013-05-19|2008-10-08|2008-10-10|Estimate|||||||2013-05-19|2013-05-21|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|August 2009|Actual|2009-08-31||Interventional|LWBW||Reducing Disparities in Diabetes Risk Through Lifestyle Changes in Community Settings|Physical Activity and Diet to to Reduce Disparities in Diabetes Risk|Completed||N/A|230|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:40:49.655597|2018-06-01 01:40:49.655597
NCT00770913|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2011-09-13||2012-04-16|2008-10-09|2008-10-10|Estimate|2012-03-12|2012-04-13|Estimate||||2012-04-16|2012-04-18|Estimate|October 2008||2008-10-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis|Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis|Completed||Phase 2/Phase 3|337|Actual|Eisai Inc.|"In the Participant flow section, there is only one Reason for Not Completed per participant reported, even if there were multiple reasons."|3|||f||||||||||||||2018-06-01 01:40:49.749497|2018-06-01 01:40:49.749497
NCT00770900|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-12-17|2008-10-09|2008-10-10|Estimate|||||||2010-12-17|2010-12-20|Estimate|September 2008||2008-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate the Inflammatory Cells Activity in Patients With Persistent Asthma Treated With Montelukast (0476-403)(COMPLETED)|Prospective, Randomized, Double-blind, Study to Evaluate the Eosinophils Activation Parameters and Phagocyte Function in Patients With Persistent Asthma Treated With Montelukast|Completed||Phase 4|83|Actual|University of Brasilia||2|||f||||||||||||||2018-06-01 01:40:50.210748|2018-06-01 01:40:50.210748
NCT00770887|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2011-08-09|2008-10-09|2008-10-10|Estimate|||||||2011-08-09|2011-08-11|Estimate|May 2010||2010-05-31|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|SAD||Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate|Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate: A Pilot Observational Study of Feasibility and Acceptability|Completed|||50|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-06-01 01:40:50.280509|2018-06-01 01:40:50.280509
NCT00770874|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2017-02-03|2008-10-09|2008-10-10|Estimate|||||||2017-02-03|2017-02-06|Estimate|September 2008||2008-09-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer|Phase III Study of S-1 + Cisplatin Compared With Single-agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix|Completed||Phase 3|375|Actual|Taiho Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:40:50.358413|2018-06-01 01:40:50.358413
NCT00770861|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2010-11-09||2010-12-21|2008-10-09|2008-10-10|Estimate|2010-12-21|2011-01-26|Estimate||||2010-12-21|2011-01-26|Estimate|September 2008||2008-09-30|December 2010|2010-12-31||||November 2009|Actual|2009-11-30||Interventional|||A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients|A Multicenter, Prospective, Randomized, Double-blind, Placebo-Controlled, Dose-Titration Study of Nebivolol Monotherapy in Hispanic Patients With Stage 1 or Stage 2 Hypertension|Completed||Phase 4|277|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 01:40:50.459146|2018-06-01 01:40:50.459146
NCT00770848|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09||2013-04-15|2014-02-06|2008-10-09|2008-10-10|Estimate||||2013-04-15|2013-04-23|Estimate|2014-02-06|2014-03-10|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|January 2011|Actual|2011-01-31||Interventional|||AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer|A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer|Completed||Phase 1/Phase 2|162|Actual|Amgen||4|||f||||||||||||||2018-06-01 01:40:50.802631|2018-06-01 01:40:50.802631
NCT00770835|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2011-07-11|2008-10-08|2008-10-10|Estimate|||||||2011-07-11|2011-07-12|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|SPLENDOR||Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.|Effects of Pioglitazone on Endothelial Progenitor Cells in Type 2 Diabetic Patients With Vascular Complications - The SPLENDOR Study.|Completed||Phase 4|39|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:40:50.918542|2018-06-01 01:40:50.918542
NCT00770822|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2016-01-11|2008-10-09|2008-10-10|Estimate|||||||2016-01-11|2016-01-12|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|December 2017|Anticipated|2017-12-31|July 2013|Actual|2013-07-31||Interventional|SetPace||Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer|A Multicenter Clinical Study of the Sonablate® 500 (SB-500) for the Treatment of Localized (T1c/T2a) Prostate Cancer With HIFU|Unknown status|Active, not recruiting|N/A|466|Anticipated|SonaCare Medical||2|||f||||t||||||||||2018-06-01 01:40:51.025699|2018-06-01 01:40:51.025699
NCT00770809|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2015-05-07||2016-11-01|2008-10-09|2008-10-10|Estimate|2015-05-07|2015-05-27|Estimate||||2016-11-01|2016-11-03|Estimate|December 2008||2008-12-31|November 2016|2016-11-30||||January 2014|Actual|2014-01-31||Interventional|||Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery|Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer|Active, not recruiting||Phase 3|305|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 01:40:51.255509|2018-06-01 01:40:51.255509
NCT00770796|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2015-10-15|2008-10-09|2008-10-10|Estimate|||||||2015-10-15|2015-10-16|Estimate|April 2006||2006-04-30|October 2015|2015-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Statins for Prevention of Contrast Induced Nephropathy|Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With Chronic Renal Disease|Completed||Phase 4|304|Actual|Ospedale Misericordia e Dolce||2|||f||||t||||||||||2018-06-01 01:40:52.670784|2018-06-01 01:40:52.670784
NCT00770783|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2013-10-28|2008-10-09|2008-10-10|Estimate|||||||2013-10-28|2013-10-29|Estimate|February 2005||2005-02-28|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|September 2013|Actual|2013-09-30||Interventional|||Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression|Efficacy of Magnetic Seizure Therapy (MST) in Refractory Major Depression|Unknown status|Active, not recruiting|Phase 3|30|Anticipated|University Hospital, Bonn||2|||f||||f||||||||||2018-06-01 01:40:52.736439|2018-06-01 01:40:52.736439
NCT00770770|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2015-04-17||2015-05-08|2008-10-09|2008-10-10|Estimate|2015-05-08|2015-05-28|Estimate||||2015-05-08|2015-05-28|Estimate|May 2009||2009-05-31|May 2015|2015-05-31||||October 2013|Actual|2013-10-31||Interventional|FAVOR||Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina|A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien™ (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Edema Secondary to Retinal Vein Occlusion|Terminated||Phase 2|20|Actual|Alimera Sciences||2|||f||||f||||||||||2018-06-01 01:40:52.829518|2018-06-01 01:40:52.829518
NCT00770757|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2015-12-17||2016-01-28|2008-10-08|2008-10-10|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||CC-4047 (Pomalidomide) for Graft vs. Host Disease|A Phase 2, Open-Label, Single-Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients With Advanced Chronic Graft-Versus-Host Disease Developing After Allogeneic Hematological Stem Cell Transplantation|Completed||Phase 2|13|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 01:40:53.236572|2018-06-01 01:40:53.236572
NCT00770744|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2016-11-07|2008-10-09|2008-10-10|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Efficacy of Lu 31-130 in Patients With Schizophrenia|A Randomised, Double-blind, Parallel-group, Active-controlled, Flexible Dose Study Exploring the Efficacy and Safety of 12 Weeks Treatment With Lu 31-130 in Patients With Schizophrenia|Completed||Phase 2|93|Actual|H. Lundbeck A/S||2|||f||||t||||||||||2018-06-01 01:40:53.525352|2018-06-01 01:40:53.525352
NCT00770731|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2013-02-12|2008-10-09|2008-10-10|Estimate|||||||2013-02-12|2013-02-13|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of Temsirolimus, Topotecan, and Bortezomib|A Phase I Study of Temsirolimus, Topotecan, and Bortezomib in Patients With Advanced Malignancy|Completed||Phase 1|80|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 01:40:53.613137|2018-06-01 01:40:53.613137
NCT00770718|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2011-11-22|2008-10-09|2008-10-10|Estimate|||||||2011-11-22|2011-11-24|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage|A Comparison of Recombinant Activated Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma for Anticoagulation Reversal in Warfarin-Associated Acute Intracranial Hemorrhage: A Dose Ranging Pilot Study|Terminated||Phase 1|2|Actual|University of Utah||3||poor enrollment|f||||t||||||||||2018-06-01 01:40:53.685856|2018-06-01 01:40:53.685856
NCT00770705|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2017-04-27|2008-10-09|2008-10-10|Estimate|||||||2017-04-27|2017-05-01|Actual|October 2008|Actual|2008-10-31|April 2017|2017-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery|Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery|Withdrawn||Phase 2|0|Actual|Vanderbilt University Medical Center||2||poor enrollment|f||||t||||||||||2018-06-01 01:40:55.011634|2018-06-01 01:40:55.011634
NCT00770692|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2012-10-24||2012-10-24|2008-10-09|2008-10-10|Estimate|2012-10-24|2012-11-22|Estimate||||2012-10-24|2012-11-22|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)|A Phase III Study of SEP-190 (Eszopiclone) in Patients With Insomnia|Completed||Phase 3|369|Actual|Eisai Inc.||4|||f||||||||||||||2018-06-01 01:40:55.119725|2018-06-01 01:40:55.119725
NCT00770679|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2017-07-17||2017-08-14|2008-10-09|2008-10-10|Estimate|2017-08-14|2017-09-13|Actual||||2017-08-14|2017-09-13|Actual|June 2008|Actual|2008-06-30|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging|Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging|Terminated||N/A|16|Actual|Johns Hopkins University||1||Delayed recruitment, funding exhausted|f||||f||||||||||2018-06-01 01:40:56.434595|2018-06-01 01:40:56.434595
NCT00770666|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2008-10-09|2008-10-09|2008-10-10|Estimate|||||||2008-10-09|2008-10-10|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Combination Medications vs. Patch Alone for Medically-Ill Smokers|Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness|Completed||Phase 4|127|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 01:40:56.575393|2018-06-01 01:40:56.575393
NCT00770653|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2010-09-13||2010-09-13|2008-10-09|2008-10-10|Estimate|2010-09-13|2010-10-06|Estimate||||2010-09-13|2010-10-06|Estimate|April 2007||2007-04-30|September 2010|2010-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.|Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic Dyslipidemia|Completed||Phase 3|305|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:40:56.719455|2018-06-01 01:40:56.719455
NCT00770640|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-08-31|2008-10-09|2008-10-10|Estimate|||||||2010-08-31|2010-09-01|Estimate|August 2008||2008-08-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PIOren||Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.|Comparison of the Effects of Pioglitazone vs. Placebo When Given in Addition to Standard Insulin Treatment in Patients With Type 2 Diabetes Mellitus and Renal Failure|Completed||Phase 2|40|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:40:57.73286|2018-06-01 01:40:57.73286
NCT00770627|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-04-12|2008-10-09|2008-10-10|Estimate|||||||2010-04-12|2010-04-13|Estimate|October 2008||2008-10-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children|A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children|Unknown status|Enrolling by invitation|Phase 4|160|Anticipated|Laboratoires URGO||2|||f||||f||||||||||2018-06-01 01:40:57.819996|2018-06-01 01:40:57.819996
NCT00770614|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-05-06|2008-10-09|2008-10-10|Estimate|||||||2012-05-06|2012-05-08|Estimate|March 2004||2004-03-31|May 2012|2012-05-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Hydration and Contrast-Induced Nephropathy in Primary Angioplasty|Hydration and Contrast-Induced Nephropathy in Primary Angioplasty. A Randomized, Placebo Controlled, Trial.|Completed||Phase 4|450|Actual|Ospedale Misericordia e Dolce||3|||f||||t||||||||||2018-06-01 01:40:57.892995|2018-06-01 01:40:57.892995
NCT00770601|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-05-03|2008-10-09|2008-10-10|Estimate|||||||2012-05-03|2012-05-04|Estimate|January 2009||2009-01-31|May 2012|2012-05-31||||February 2011|Actual|2011-02-28||Interventional|||Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease|A Multi-Center, Open Label, 24-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics of Canakinumab (Anti-IL-1 Beta Antibody) in Patients With NOMID / CINCA Syndrome|Terminated||Phase 3|6|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:40:58.064944|2018-06-01 01:40:58.064944
NCT00770406|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2009-08-03|2008-10-09|2008-10-10|Estimate|||||||2009-08-03|2009-08-04|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Intravesical Instillation of Botulinum Toxin Type A to Patients With Urge Urinary Incontinence|Intravesikal Instillation af Botulinum Toxin Type A Til Patienter Med Urge Urininkontinens|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Glostrup University Hospital, Copenhagen|||||f||||f||||||||||2018-06-01 01:41:00.897477|2018-06-01 01:41:00.897477
NCT00770588|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2012-01-17||2016-01-15|2008-10-09|2008-10-10|Estimate|2012-07-11|2012-08-20|Estimate||||2016-01-15|2016-02-08|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|INFORM||Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)|A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy|Completed||Phase 4|296|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:40:58.156841|2018-06-01 01:40:58.156841
NCT00770575|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-07-01|2008-10-09|2008-10-10|Estimate|||||||2010-07-01|2010-07-05|Estimate|June 2005||2005-06-30|July 2010|2010-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease|Double Blinded Study of the Effects of Pioglitazone in Combination With Atorvastatin in Comparison to Atorvastatin Treatment Alone on Intima-Media Thickness in Patients at Risk for Vascular Complications|Completed||Phase 2|148|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:40:58.540158|2018-06-01 01:40:58.540158
NCT00770562|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2014-06-26||2014-10-21|2008-10-09|2008-10-10|Estimate|2014-10-21|2014-10-22|Estimate||||2014-10-21|2014-10-22|Estimate|July 2005||2005-07-31|October 2014|2014-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic Purpura|Completed||Phase 3|103|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:40:58.652272|2018-06-01 01:40:58.652272
NCT00770536|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2015-09-25|2008-10-09|2008-10-10|Estimate|||||||2015-09-25|2015-09-29|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|January 2012|Actual|2012-01-31||Interventional|||AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR|A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer|Completed||Phase 1|103|Actual|Amgen||2|||f||||f||||||||||2018-06-01 01:40:59.385056|2018-06-01 01:40:59.385056
NCT00770523|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-05|||2011-06-08|2008-10-09|2008-10-10|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 2003||2003-12-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Observational|||Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells|Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies|Completed|||52|Actual|Cooperative Study Group A for Hematology|||||f||||f||||||||||2018-06-01 01:40:59.576331|2018-06-01 01:40:59.576331
NCT00770510|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2012-12-28||2012-12-28|2008-10-09|2008-10-10|Estimate|2012-12-28|2013-02-04|Estimate||||2012-12-28|2013-02-04|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)|A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia|Completed||Phase 2/Phase 3|192|Actual|Eisai Inc.||5|||f||||f||||||||||2018-06-01 01:40:59.658332|2018-06-01 01:40:59.658332
NCT00770497|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-07-01|2008-10-09|2008-10-10|Estimate|||||||2010-07-01|2010-07-05|Estimate|March 2007||2007-03-31|July 2010|2010-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.|Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-blinded Phase II Study.|Completed||Phase 2|172|Actual|Takeda||3|||f||||f||||||||||2018-06-01 01:41:00.035157|2018-06-01 01:41:00.035157
NCT00770484|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2015-05-29||2016-07-06|2008-10-09|2008-10-10|Estimate|2015-06-16|2015-07-09|Estimate||||2016-07-06|2016-08-05|Estimate|November 2008||2008-11-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Exercise in OI|Effects of Exercise in Orthostatic Intolerance|Completed||N/A|12|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:41:00.160109|2018-06-01 01:41:00.160109
NCT00770471|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2012-05-01|2008-10-09|2008-10-10|Estimate|||||||2012-05-01|2012-05-03|Estimate|June 2009||2009-06-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Temozolomide and ABT-888 in Subjects With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 1/Phase 2|24|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 01:41:00.372248|2018-06-01 01:41:00.372248
NCT00770458|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2010-01-04|2008-10-09|2008-10-10|Estimate|||||||2010-01-04|2010-01-06|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker|Completed|||1000|Anticipated|Sequenom, Inc.|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:41:00.458376|2018-06-01 01:41:00.458376
NCT00770445|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2010-08-17|2008-10-09|2008-10-10|Estimate|||||||2010-08-17|2010-08-18|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PIOcomb||Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.|Impact of Pioglitazone, Metformin and the Combination of Both on Cardiovascular Risk in Insulin-treated Patients With Type 2 Diabetes - The PIOcomb Study|Completed||Phase 4|121|Actual|Takeda||3|||f||||f||||||||||2018-06-01 01:41:00.534148|2018-06-01 01:41:00.534148
NCT00770432|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2009-06-24||2015-02-20|2008-10-09|2008-10-10|Estimate|2009-06-24|2009-08-12|Estimate||||2015-02-20|2015-03-11|Estimate|November 2007||2007-11-30|February 2015|2015-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)|A Randomized, Placebo-Controlled, Double-Blind, Trial of Polyethylene Glycol 3350 Laxative for the Treatment of Occasional Constipation.|Completed||Phase 4|203|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:41:00.654409|2018-06-01 01:41:00.654409
NCT00770419|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2015-05-27|2008-10-09|2008-10-10|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Observational|||Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers|Perception of Caregiver Burden|Withdrawn|||0|Actual|Rutgers, The State University of New Jersey||||Slow accrual|f||||t||||||||||2018-06-01 01:41:00.826178|2018-06-01 01:41:00.826178
NCT00770393|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2008-10-09|2008-10-09|2008-10-10|Estimate|||||||2008-10-09|2008-10-10|Estimate|February 2002||2002-02-28|October 2008|2008-10-31|June 2007|Actual|2007-06-30|June 2005|Actual|2005-06-30||Interventional|||Laryngeal Preservation in Pyriform Sinus Carcinoma|Randomized Phase III Trial Comparing Induction Chemotherapy Followed by Radiotherapy to Concomitant Chemoradiotherapy for Laryngeal Preservation in T3MO Pyriform Sinus Carcinoma|Completed||Phase 2/Phase 3|71|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-06-01 01:41:00.950925|2018-06-01 01:41:00.950925
NCT00770380|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2017-10-28|2008-10-09|2008-10-10|Estimate|||||||2017-10-28|2017-10-31|Actual|June 2007||2007-06-30|October 2017|2017-10-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|HypnoRelapse||Hypnosis for Smoking Relapse Prevention|Hypnosis for Smoking Relapse Prevention|Completed||N/A|139|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:41:01.121738|2018-06-01 01:41:01.121738
NCT00770367|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2010-07-08||2011-12-02|2008-10-09|2008-10-10|Estimate|2010-10-21|2010-11-18|Estimate||||2011-12-02|2011-12-06|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes|Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes|Completed||Phase 4|36|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:41:01.202444|2018-06-01 01:41:01.202444
NCT00770354|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|||2009-08-07|2008-10-09|2008-10-10|Estimate|||||||2009-08-07|2009-08-10|Estimate|September 2008||2008-09-30|August 2009|2009-08-31|August 2011|Anticipated|2011-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer|A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|Terminated||Phase 2|110|Anticipated|Antisoma Research||2|||f||||t||||||||||2018-06-01 01:41:01.438508|2018-06-01 01:41:01.438508
NCT00770341|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2011-05-17|2011-02-16|2017-02-21|2008-10-09|2008-10-10|Estimate|2011-05-17|2011-06-15|Estimate|2011-02-16|2011-03-08|Estimate|2017-02-21|2017-03-24|Actual|September 2008||2008-09-30|February 2017|2017-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)|A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA|Completed||Phase 3|122|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:41:01.536648|2018-06-01 01:41:01.536648
NCT00770328|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2017-03-16||2017-10-24|2008-10-09|2008-10-10|Estimate|2017-10-24|2017-11-30|Actual||||2017-10-24|2017-11-30|Actual|May 2003||2003-05-31|October 2017|2017-10-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||The Effects of Pentoxifylline on PAI-1 in an Obese Population|The Effects of Pentoxifylline on PAI-1 in an Obese Population|Completed||Phase 4|37|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 01:41:02.117698|2018-06-01 01:41:02.117698
NCT00770315|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-09|2014-04-25||2017-01-18|2008-10-09|2008-10-10|Estimate|2014-06-02|2014-07-03|Estimate||||2017-01-18|2017-03-03|Actual|September 2009||2009-09-30|January 2017|2017-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma|Completed||Phase 2/Phase 3|784|Actual|ALK-Abelló A/S||4|||f||||t||||||||||2018-06-01 01:41:02.371913|2018-06-01 01:41:02.371913
NCT00770302|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-07-08|2008-10-08|2008-10-09|Estimate|||||||2009-07-08|2009-07-09|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin|An Open Label, Pharmacokinetic Study of Single and Multiple Doses of 5 mg Saxagliptin in Healthy Chinese Subjects Living in China|Completed||Phase 1|34|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:41:02.881484|2018-06-01 01:41:02.881484
NCT00770289|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2012-06-06||2012-08-01|2008-10-08|2008-10-09|Estimate|2012-08-01|2012-08-31|Estimate||||2012-08-01|2012-08-31|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|B2411003||Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)|Open Label, Observational, Non-interventional Study for the Evaluation of Remission Rates in Patients With MDD Under Treatment With Various Anti-depressives|Completed|||851|Actual|Pfizer|Protocol did not indicate primary or secondary endpoints and designation of endpoints as primary or secondary endpoints was arbitrary.||1||f||||f||||||||||2018-06-01 01:41:02.988764|2018-06-01 01:41:02.988764
NCT00770276|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2018-01-02|2008-10-08|2008-10-09|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2005||2005-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|February 2018|Anticipated|2018-02-28||Observational|MOS||Mannheim Obesity Study|Mannheim Obesity Pilot Study: Evaluation of Metabolic Und Cardiovascular Risk in Obesity|Active, not recruiting|||120|Anticipated|Universitätsmedizin Mannheim|||2||f||||f||||||||||2018-06-01 01:41:03.188386|2018-06-01 01:41:03.188386
NCT00770263|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2015-06-02|2008-10-08|2008-10-09|Estimate|||||||2015-06-02|2015-06-03|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Erlotinib and Temsirolimus for Solid Tumors|Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies|Completed||Phase 1|46|Actual|Washington University School of Medicine||5|||f||||f||||||||||2018-06-01 01:41:03.255654|2018-06-01 01:41:03.255654
NCT00770250|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2010-11-30|2008-10-08|2008-10-09|Estimate|||||||2010-11-30|2010-12-02|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|March 2009|Actual|2009-03-31|||||Observational|SYMPTOMES||National Survey on Asthma|A Mirror Assessment of the Words Used By Patients and Physicians to Express Asthma Symptoms, According To the Patient's Level of Asthma Control In General Medicine|Completed|||1704|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:41:03.63688|2018-06-01 01:41:03.63688
NCT00770237|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2011-09-12|2008-10-08|2008-10-09|Estimate|||||||2011-09-12|2011-09-13|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia|Effects of Smoking Cues on Tobacco Craving Responses and the Reinforcing Efficacy of Cigarettes in Smokers With and Without Schizophrenia|Completed||N/A|44|Anticipated|University of Maryland||1|||f||||f||||||||||2018-06-01 01:41:05.132919|2018-06-01 01:41:05.132919
NCT00770224|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2018-01-31|2008-10-08|2008-10-09|Estimate|||||||2018-01-31|2018-02-01|Actual|April 2009||2009-04-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2017|Actual|2017-04-30||Interventional|||S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma|A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 2|87|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 01:41:05.212136|2018-06-01 01:41:05.212136
NCT00770211|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2011-08-09|2010-03-25|2011-10-05|2008-10-08|2008-10-09|Estimate|2011-08-09|2011-09-13|Estimate|2010-03-25|2010-03-29|Estimate|2011-10-05|2011-10-07|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines.|Completed||Phase 3|271|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 01:41:05.593439|2018-06-01 01:41:05.593439
NCT00770198|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2008-10-08|2008-10-08|2008-10-09|Estimate|||||||2008-10-08|2008-10-09|Estimate|January 2005||2005-01-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|January 2007|Actual|2007-01-31||Observational|||sgp130 in Chronic Human Liver Disease|Study of IL-6 Transsignaling in Chronic Human Liver Disease|Completed|||129|Actual|Erasme University Hospital|||2||f||||f||||||Samples Without DNA|"~     plasma, liver biopsies, and peripheral blood mononuclear cell culture medium.~   "|||2018-06-01 01:41:05.841567|2018-06-01 01:41:05.841567
NCT00770185|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-11-25|2008-10-08|2008-10-09|Estimate|||||||2016-11-25|2016-11-28|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|March 2012|Actual|2012-03-31||Interventional|||Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer|A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer|Completed||Phase 2|35|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-06-01 01:41:06.058739|2018-06-01 01:41:06.058739
NCT00770172|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2011-05-12|2008-10-08|2008-10-09|Estimate|||||||2011-05-12|2011-05-13|Estimate|October 2007||2007-10-31|December 2008|2008-12-31||||May 2011|Actual|2011-05-31||Interventional|||G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy|Moderate Persistent Neutropenia: Comparison of Administration of G-CSF (Granulocyte Colony Stimulating Factor) 1 Day Out of 2 Versus Traditional Schedules to Maintain Dose Intensity. Phase III Multicenter Study in Patients With Solid Tumors Receiving Chemotherapy|Completed||Phase 3|140|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:41:06.160751|2018-06-01 01:41:06.160751
NCT00770159|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-02-04|2008-10-08|2008-10-09|Estimate|||||||2016-02-04|2016-02-05|Estimate|November 2004||2004-11-30|January 2016|2016-01-31|November 2005|Actual|2005-11-30|June 2005|Actual|2005-06-30||Interventional|||A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)|A Double-Blind, Placebo-Controlled, Once-Weekly, Multiple-Dose Study to Investigate the Safety, Tolerability, Plasma Concentration Profile and Effects on Biochemical Markers of Bone Resorption of MK0822 in Healthy Postmenopausal Female Subjects|Completed||Phase 1|78|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:41:06.262168|2018-06-01 01:41:06.262168
NCT00770146|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2013-02-15|2010-09-30|2016-08-01|2008-10-08|2008-10-09|Estimate|2013-02-15|2013-03-20|Estimate|2010-09-30|2010-10-05|Estimate|2016-08-01|2016-09-09|Estimate|November 2008||2008-11-30|August 2016|2016-08-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) as Add-on Therapy in High Risk Hypercholesterolemic Patients|Completed||Phase 3|158|Actual|Kastle Therapeutics, LLC||2|||f||||t||||||||||2018-06-01 01:41:06.536027|2018-06-01 01:41:06.536027
NCT00770133|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08||2011-04-26|2013-11-22|2008-10-08|2008-10-09|Estimate||||2011-04-26|2011-05-03|Estimate|2013-11-22|2013-12-17|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.|A Multi-center, Double-masked, Randomized, Placebo-controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis.|Completed||Phase 3|133|Actual|Bausch & Lomb Incorporated||4|||f||||f||||||||||2018-06-01 01:41:07.725359|2018-06-01 01:41:07.725359
NCT00770120|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2016-10-26||2017-01-10|2008-10-08|2008-10-09|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|December 2008||2008-12-31|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Number of patients who were eligible and received treatment and thus analyzable.|S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery|Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)|Completed||Phase 2|61|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 01:41:08.817728|2018-06-01 01:41:08.817728
NCT00770107|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-06-22|2008-10-08|2008-10-09|Estimate|||||||2011-06-22|2011-06-27|Estimate|June 2004||2004-06-30|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Thiamine Supplementation to Improve Cardiac Function in Patients With Congestive Heart Failure|Thiamine Supplementation to Improve Cardiac Function in Patients With Congestive Heart Failure on Long-term Treatment With Diuretic Drugs|Completed||N/A|12|Anticipated|Luzerner Kantonsspital||2|||f||||||||||||||2018-06-01 01:41:09.486704|2018-06-01 01:41:09.486704
NCT00770094|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-08-04|2008-10-08|2008-10-09|Estimate|||||||2009-08-04|2009-08-06|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|VBLWL-001||Multi Laser Platform Comparison Study for LASIK|A Prospective, Randomized, Multi Center Clinical Comparison Of Fellow Eyes Undergoing Lasik Using The Amo/Visx Customvue™ , The Bausch And Lomb Zyoptix And Planoscan And The Wavelight Allegretto Wave™ Wavefront Guided And Wavefront Optimized Excimer Laser Systems|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|Durrie Vision||3|||f||||f||||||||||2018-06-01 01:41:09.553168|2018-06-01 01:41:09.553168
NCT00770081|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08||2013-01-02|2013-01-02|2008-10-08|2008-10-09|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-02|2013-01-04|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)|A 28-week Extension to a 24-week Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Sitagliptin (25 mg qd) in Patients With Type 2 Diabetes and Severe Renal Insufficiency|Completed||Phase 3|75|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:41:09.697981|2018-06-01 01:41:09.697981
NCT00770068|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2017-04-10|2008-10-08|2008-10-09|Estimate|||||||2017-04-10|2017-04-12|Actual|July 15, 2006||2006-07-15|April 2017|2017-04-30|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Observational|||Examining the Link Between Depression and Seasonal Allergies|Seasonality of Depression and Airborne Allergens|Completed|||100|Actual|University of Maryland|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:41:09.967588|2018-06-01 01:41:09.967588
NCT00770055|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2011-01-27|2008-10-08|2008-10-09|Estimate|||||||2011-01-27|2011-01-31|Estimate|November 2001||2001-11-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|||Internet Use Among Women With Recurrent Metastatic Breast Cancer|Internet Use Among Women With Recurrent Breast Cancer|Completed||N/A|70|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 01:41:10.040142|2018-06-01 01:41:10.040142
NCT00770042|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-11-30|2008-10-08|2008-10-09|Estimate|||||||2009-11-30|2009-12-02|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil|A Phase I, Single-Centre, Open-Label, Randomized, One-sequence Crossover, Three-Group Study to Evaluate the Effect of Ketoconazole, Ritonavir and Erythromicin on the Safety and Pharmacokinetics of Avanafil (TA-1790) in Healthy Male Subjects|Completed||Phase 1|44|Actual|VIVUS, Inc.||3|||f||||f||||||||||2018-06-01 01:41:10.111415|2018-06-01 01:41:10.111415
NCT00770029|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2011-08-09|2010-03-25|2013-02-21|2008-10-08|2008-10-09|Estimate|2011-08-09|2011-09-13|Estimate|2010-03-25|2010-03-29|Estimate|2013-02-21|2013-02-27|Estimate|October 2008||2008-10-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines. No. 2|Completed||Phase 3|276|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 01:41:10.206637|2018-06-01 01:41:10.206637
NCT00770016|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2010-10-25|2008-10-08|2008-10-09|Estimate|||||||2010-10-25|2010-10-26|Estimate|January 2010||2010-01-31|October 2010|2010-10-31|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism|Insulin Sensitivity and Metabolism Before and After Treatment in Patients With Hypothyroidism|Terminated||N/A|0|Actual|University of Aarhus||1||no longer interested in doing the study|f||||t||||||||||2018-06-01 01:41:10.489724|2018-06-01 01:41:10.489724
NCT00770003|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2015-08-13|2008-10-08|2008-10-09|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|February 2010|Actual|2010-02-28|March 2009|Actual|2009-03-31||Interventional|||Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848|A Double-blind, Placebo Controlled, Randomized, Parallel Group Study to Investigate the Tolerability, Safety, Pharmacodynamics and Pharmacokinetics of Repeated Weekly Doses of AZD8848 Administered Intranasally to Seasonal Allergic Rhinitis Patients|Completed||Phase 1|103|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:41:10.570844|2018-06-01 01:41:10.570844
NCT00769990|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2017-12-11|2008-10-08|2008-10-09|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2008||2008-09-30|July 2011|2011-07-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases|Phase I-II Trial of Genistein in Subjects Receiving Palliative External Beam Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life|Withdrawn||Phase 1/Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||1||No patient accrual.|f||||t||||||||||2018-06-01 01:41:10.654876|2018-06-01 01:41:10.654876
NCT00769964|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-06-24|2008-10-08|2008-10-09|Estimate|||||||2009-06-24|2009-06-25|Estimate|September 2008||2008-09-30|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||VA111913 TS: First in Human Study|A First in Human Study Consisting of a Two-Part, Double-Blind, Placebo-Controlled, Escalating Single and Multiple Dose Study of VA111913 TS in Adult Non-Pregnant Women Volunteers With a Single Dose, Open, Fed vs. Fasting Crossover Phase|Completed||Phase 1|98|Actual|Vantia Ltd|||||f||||||||||||||2018-06-01 01:41:10.74043|2018-06-01 01:41:10.74043
NCT00769951|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2015-10-01|2008-10-08|2008-10-09|Estimate|||||||2015-10-01|2015-10-02|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Study of Physical and Mental Health of Older Patients With Newly Diagnosed Cancer|The Geriatric-Oncology Database: A Resource for Advancing Research in Older Cancer Patients|Completed|||46|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 01:41:10.800777|2018-06-01 01:41:10.800777
NCT00769938|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2013-01-12|2008-10-08|2008-10-09|Estimate|||||||2013-01-12|2013-01-15|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|WOEST||WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)|What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing|Completed||Phase 4|573|Actual|R&D Cardiologie||2|||f||||t||||||||||2018-06-01 01:41:10.871447|2018-06-01 01:41:10.871447
NCT00769925|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2012-01-06|2008-10-08|2008-10-09|Estimate|||||||2012-01-06|2012-01-10|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|February 2012|Anticipated|2012-02-29|January 2012|Anticipated|2012-01-31||Interventional|||Assessing Different Methods of Anxiety Care in Pediatric Settings|Improving Care for Anxiety in Pediatric Settings|Unknown status|Active, not recruiting|N/A|52|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-06-01 01:41:10.955458|2018-06-01 01:41:10.955458
NCT00769912|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2014-08-28|2008-10-08|2008-10-09|Estimate|||||||2014-08-28|2014-08-29|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Evaluation of of a Prefixed 50% N2O- 50%O2 Mixture in Legal Abortion Under Local Analgesia|Evaluation of of a Prefixed 50% N2O- 50%O2 Mixture in Legal Abortion Under Local Analgesia|Completed||Phase 3|71|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 01:41:11.022908|2018-06-01 01:41:11.022908
NCT00769899|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-03-17|2008-10-08|2008-10-09|Estimate|||||||2009-03-17|2009-03-18|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|JSAD||AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects|A Phase I,Single-Center,Randomised,Double-Blind,Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7325 in Healthy Male Japanese Subjects|Completed||Phase 1|48|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 01:41:11.08043|2018-06-01 01:41:11.08043
NCT00769691|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2017-08-17|2008-10-07|2008-10-09|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2008||2008-04-30|August 2017|2017-08-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Observational|||Monitoring of Cerebral Blood Flow Autoregulation Using Near Infrared Spectroscopy|Cerebral Autoregulation Monitoring in Adults Undergoing Cardiac Surgery: Comparison of Near Infrared Spectroscopy With Transcranial Doppler|Completed|||225|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-06-01 01:41:13.539483|2018-06-01 01:41:13.539483
NCT00769886|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08||2009-12-17|2013-11-22|2008-10-08|2008-10-09|Estimate||||2009-12-17|2009-12-21|Estimate|2013-11-22|2013-12-17|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.|A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis|Completed||Phase 3|144|Actual|Bausch & Lomb Incorporated||4|||f||||f||||||||||2018-06-01 01:41:11.139807|2018-06-01 01:41:11.139807
NCT00769873|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-06-23|2008-10-08|2008-10-09|Estimate|||||||2009-06-23|2009-06-24|Estimate|October 2006||2006-10-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Anticoagulation Post Laparoscopic Splenectomy|Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698|Terminated||Phase 2|35|Actual|University of Alberta||2||"Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered~   trial."|f||||f||||||||||2018-06-01 01:41:11.202928|2018-06-01 01:41:11.202928
NCT00769860|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2016-11-22||2016-11-22|2008-10-08|2008-10-09|Estimate|2016-11-22|2017-01-19|Estimate||||2016-11-22|2017-01-19|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Arimoclomol in Sporadic Inclusion Body Myositis|Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis|Completed||Phase 2/Phase 3|24|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 01:41:11.392259|2018-06-01 01:41:11.392259
NCT00769847|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2015-05-29|2008-10-07|2008-10-09|Estimate|||||||2015-05-29|2015-06-02|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|September 2013|Anticipated|2013-09-30|July 2009|Actual|2009-07-31||Observational|||Endoscopic Treatment for Isolated, Single Suture Craniosynostosis|Endoscopic Treatment for Isolated, Single Suture Craniosynostosis|Withdrawn|||0|Actual|University of Utah|||1|Study was withdrawn due to lack of resources.|f||||f||||||||||2018-06-01 01:41:11.856337|2018-06-01 01:41:11.856337
NCT00769834|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2018-02-26|2008-10-08|2008-10-09|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2010||2010-01-31|February 2018|2018-02-28|April 2011|Anticipated|2011-04-30|December 2010|Anticipated|2010-12-31||Observational|||Disc Edema in Patients With Chronic Kidney Disease|Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease|Withdrawn|||0|Actual|University of Mississippi Medical Center|||1|All investigators have moved to different oranizations|f||||f||||||||||2018-06-01 01:41:11.92717|2018-06-01 01:41:11.92717
NCT00769821|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2012-12-11|2008-10-08|2008-10-09|Estimate|||||||2012-12-11|2012-12-12|Estimate|February 2007||2007-02-28|December 2012|2012-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||The Impact of Lymphedema on Breast Cancer Survivors|The Impact of Lymphedema on Local and Overall Functioning|Completed|||145|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:41:12.009031|2018-06-01 01:41:12.009031
NCT00769808|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2013-05-30|2008-10-08|2008-10-09|Estimate|||||||2013-05-30|2013-06-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:41:12.090178|2018-06-01 01:41:12.090178
NCT00769795|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07||2017-03-27|2017-03-28|2008-10-08|2008-10-09|Estimate||||2017-03-28|2017-03-29|Actual|2017-03-28|2017-03-29|Actual|October 2008||2008-10-31|March 2017|2017-03-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer|Phase II Study of Neoadjuvant IMC-A12 Combined With Androgen Deprivation Prior to Prostatectomy|Completed||Phase 2|29|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 01:41:12.128434|2018-06-01 01:41:12.128434
NCT00769782|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-09-27|2008-10-08|2008-10-09|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|GISTs||Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor|Phase II Multicenter Clinical Trial on Surgery for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)|Completed||Phase 2|6|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||||2018-06-01 01:41:12.220677|2018-06-01 01:41:12.220677
NCT00769769|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2013-08-22|2008-10-08|2008-10-09|Estimate|||||||2013-08-22|2013-08-23|Estimate|October 2008||2008-10-31|August 2013|2013-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparing Delivery Methods of Cognitive Behavioral Therapy for Depressed African-American Dementia Caregivers|Telephone CBT for Depressed African-American Dementia Caregivers|Completed||Phase 3|106|Actual|Florida State University||2|||f||||t||||||||||2018-06-01 01:41:12.330924|2018-06-01 01:41:12.330924
NCT00769756|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2008-10-08|2008-10-08|2008-10-09|Estimate|||||||2008-10-08|2008-10-09|Estimate|April 2006||2006-04-30|October 2008|2008-10-31|December 2007|Actual|2007-12-31|April 2007|Actual|2007-04-30||Observational|||Evaluation of Three New Strategies to Fight Obesity in Families|Evaluation of Three New Strategies to Fight Obesity in Families|Completed|||261|Actual|University of Magdeburg|||3||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-06-01 01:41:12.399566|2018-06-01 01:41:12.399566
NCT00769730|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2009-08-02|2008-10-07|2008-10-09|Estimate|||||||2009-08-02|2009-08-04|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication|Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication|Completed|||25|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||f||||||Samples With DNA|"~     serum~   "|||2018-06-01 01:41:12.456391|2018-06-01 01:41:12.456391
NCT00769717|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-08-26|2008-10-08|2008-10-09|Estimate|||||||2009-08-26|2009-08-27|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Evaluation of a Health at Every Size vs a Behavioral Weight Loss Approach for Obese Women|Comparative Health Improvements and Rate of Relapse in Weight-Centered vs. Wellness-Centered Interventions for Obese Women|Unknown status|Active, not recruiting|Phase 2/Phase 3|80|Anticipated|The Reading Hospital and Medical Center||2|||f||||f||||||||||2018-06-01 01:41:12.514462|2018-06-01 01:41:12.514462
NCT00769704|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2015-09-22||2016-06-14|2008-10-08|2008-10-09|Estimate|2015-11-12|2015-12-17|Estimate||||2016-06-14|2016-07-13|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|September 2014|Actual|2014-09-30|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma|A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease|Completed||Phase 3|437|Actual|BioVex Limited||2|||f||||t||||||||||2018-06-01 01:41:12.634529|2018-06-01 01:41:12.634529
NCT00769678|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2013-04-16|2008-10-08|2008-10-09|Estimate|||||||2013-04-16|2013-04-17|Estimate|October 2008||2008-10-31|April 2013|2013-04-30||||May 2012|Actual|2012-05-31||Interventional|||Stimulation of the Diaphragm in Patients With Severe Heart Failure Following Heart Surgery|Biventricular Pacing and Stimulation of the Diaphragm in Patients With Severe Heart Failure Following Heart Surgery (Epiphrenic II Pilot Trial)|Completed||N/A|33|Actual|Luzerner Kantonsspital||1|||f||||||||||||||2018-06-01 01:41:13.598344|2018-06-01 01:41:13.598344
NCT00769665|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2012-01-31|2008-10-08|2008-10-09|Estimate|||||||2012-01-31|2012-02-02|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||A 2-week Clinical Comparison of SYSTANE® Ultra to Sensitive Eyes Rewetting Drops in Contact Lens Wearing Patients.||Completed|||47|Actual|Alcon Research|||2||f||||f||||||||||2018-06-01 01:41:13.663428|2018-06-01 01:41:13.663428
NCT00769652|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2013-11-15||2013-11-15|2008-10-08|2008-10-09|Estimate|2013-11-15|2014-01-07|Estimate||||2013-11-15|2014-01-07|Estimate|October 2006||2006-10-31|November 2013|2013-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer|The Influence of Changes in Body Composition on Quality of Life in Cancer Patients and The Impact of Medical Nutrition Therapy by a Registered Dietitian on Outcome|Terminated||N/A|8|Actual|Rutgers, The State University of New Jersey||2||slow accrual|f||||f||||||||||2018-06-01 01:41:13.751545|2018-06-01 01:41:13.751545
NCT00769626|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2011-07-15|2008-10-08|2008-10-09|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|May 2010|Actual|2010-05-31|September 2009|Actual|2009-09-30||Interventional|||Standardizing Management of Patients With Low Back Pain in Primary Care and Physical Therapy|Standardizing Management of Patients With Low Back Pain in Primary Care and Physical Therapy: A Randomized Clinical Trial|Terminated||Phase 3|15|Actual|Intermountain Health Care, Inc.||2||Unable to recruit patients|f||||f||||||||||2018-06-01 01:41:13.965732|2018-06-01 01:41:13.965732
NCT00769613|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2013-12-17|2008-10-08|2008-10-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2008||2008-08-31|August 2010|2010-08-31||||August 2014|Anticipated|2014-08-31||Interventional|||Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections|Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 01:41:14.045902|2018-06-01 01:41:14.045902
NCT00769600|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-10-12|2008-10-08|2008-10-09|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|Itraconazole||A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer|A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer|Terminated||Phase 2|23|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||Low accrual.|f||||t||||||||||2018-06-01 01:41:14.132774|2018-06-01 01:41:14.132774
NCT00769587|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-04-25|2008-10-08|2008-10-09|Estimate|||||||2016-04-25|2016-04-26|Estimate|June 2007||2007-06-30|April 2016|2016-04-30|October 2012|Actual|2012-10-31|May 2011|Actual|2011-05-31||Interventional|||Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis|Phase II Study of Thalidomide in Mastocytosis|Completed||Phase 2|20|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||t||||||||||2018-06-01 01:41:14.222651|2018-06-01 01:41:14.222651
NCT00769574|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2014-08-28|2008-10-08|2008-10-09|Estimate|||||||2014-08-28|2014-08-29|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Assessment of New Biomarkers in the Management and Triage of Patients With Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome.|Assessment of New Biomarkers in the Management and Triage of Patients With Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome.|Completed||N/A|143|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 01:41:14.288135|2018-06-01 01:41:14.288135
NCT00769561|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2013-05-24||2013-12-04|2008-10-08|2008-10-09|Estimate|2013-12-04|2013-12-30|Estimate||||2013-12-04|2013-12-30|Estimate|August 2008||2008-08-31|December 2013|2013-12-31|April 2011|Actual|2011-04-30|July 2010|Actual|2010-07-31||Interventional|||Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders|Comparison of a Biofeedback-Based Cognitive Behavioral Treatment and Occlusal Splint Therapy for Temporomandibular Disorders. A Randomized Clinical Trial.|Completed||Phase 2/Phase 3|58|Actual|Philipps University Marburg Medical Center||2|||f||||t||||||||||2018-06-01 01:41:14.369521|2018-06-01 01:41:14.369521
NCT00769548|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-12-30|2008-10-08|2008-10-09|Estimate|||||||2016-12-30|2017-01-04|Estimate|April 1995||1995-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|April 2001|Actual|2001-04-30||Interventional|||Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer|A PHASE III TRIAL COMPARING WHOLE PELVIC IRRADIATION FOLLOWED BY A CONEDOWN BOOST TO BOOST IRRADIATION ONLY AND COMPARING NEOADJUVANT TO ADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS)|Completed||Phase 3|1322|Actual|Radiation Therapy Oncology Group||4|||f||||t||||||||||2018-06-01 01:41:14.683617|2018-06-01 01:41:14.683617
NCT00769535|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2013-04-26|2008-10-07|2008-10-09|Estimate|||||||2013-04-26|2013-04-30|Estimate|January 2006||2006-01-31|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|HSP70||Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma|Relationship Between Polymorphism of Heat Shock Protein 70 Gene and Hepatocellular Carcinoma|Completed||N/A|600|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||||2018-06-01 01:41:14.759654|2018-06-01 01:41:14.759654
NCT00769522|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2018-05-09|2008-10-08|2008-10-09|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2, 2008|Actual|2008-10-02|May 2018|2018-05-31|January 2018|Actual|2018-01-31|July 2011|Actual|2011-07-31||Interventional|||FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia|Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia|Completed||Phase 3|564|Actual|German CLL Study Group||2|||f||||t||||||||No||2018-06-01 01:41:14.821177|2018-06-01 01:41:14.821177
NCT00769509|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2015-07-20|2008-10-08|2008-10-09|Estimate|||||||2015-07-20|2015-07-22|Estimate|March 2009||2009-03-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Energy Expenditure Assessment of Premature Infants|Energy Expenditure Assessment of Preterm Infant With Very Low Birth Weight Fed With Human Milk or Preterm Formula|Completed||Phase 4|25|Actual|Oswaldo Cruz Foundation||2|||f||||t||||||||||2018-06-01 01:41:14.905616|2018-06-01 01:41:14.905616
NCT00769496|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2013-01-21|2008-10-08|2008-10-09|Estimate|||||||2013-01-21|2013-01-23|Estimate|January 2005||2005-01-31|January 2013|2013-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||BAY 77-1931 Long-term Extension From Phase II Study|A Long-term, Open Label Extension, Non-controlled Study to Assess the Efficacy and Safety of BAY 77-1931 (Lanthanum Carbonate) for Hyperphosphatemia in Patients Undergoing Hemodialysis|Completed||Phase 2|145|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:41:14.96568|2018-06-01 01:41:14.96568
NCT00769483|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-11-22|2008-10-08|2008-10-09|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2008||2008-11-30|November 2016|2016-11-30||||November 2018|Anticipated|2018-11-30||Interventional|||MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer|A Phase I/ Randomized Phase II Study of Gemcitabine Plus Erlotinib Plus MK-0646; Gemcitabine Plus MK-0646 and Gemcitabine Plus Erlotinib for Patients With Advanced Pancreatic Cancer (IISP#33337)|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|M.D. Anderson Cancer Center||5|||f||||t||||||||||2018-06-01 01:41:15.032448|2018-06-01 01:41:15.032448
NCT00769470|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-01-20|2008-10-08|2008-10-09|Estimate|||||||2016-01-20|2016-01-22|Estimate|April 2009||2009-04-30|January 2016|2016-01-31||||November 2013|Actual|2013-11-30||Interventional|||Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery|A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment With Single-Agent Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) With Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients With HER2/Neu-Amplified Operable Breast Cancer|Completed||Phase 2|18|Actual|Translational Oncology Research International||3|||f||||t||||||||||2018-06-01 01:41:15.218462|2018-06-01 01:41:15.218462
NCT00769457|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-05-25|2008-10-08|2008-10-09|Estimate|||||||2016-05-25|2016-05-27|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|OptiLink-HF||OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network|OptiLink HF Study (Optimization of Heart Failure Management Using Medtronic OptiVol® Fluid Status Monitoring and Medtronic CareLink® Network)|Completed||Phase 4|1002|Actual|Medtronic Bakken Research Center||2|||f||||t||||||||No||2018-06-01 01:41:15.309351|2018-06-01 01:41:15.309351
NCT00769431|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2013-07-24|2008-10-08|2008-10-09|Estimate|||||||2013-07-24|2013-07-26|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Evaluating Symptom Management Educational Materials for Patients With Prostate Cancer|FOCUS GROUP EVALUATION OF PROSTATE CANCER SYMPTOM MANAGEMENT EDUCATION MATERIALS|Completed||N/A|7|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 01:41:15.382006|2018-06-01 01:41:15.382006
NCT00769418|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2015-08-18|2008-10-08|2008-10-09|Estimate|||||||2015-08-18|2015-08-19|Estimate|September 2004||2004-09-30|August 2015|2015-08-31|September 2006|Actual|2006-09-30|December 2004|Actual|2004-12-31||Interventional|||Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)|A Double-Blind, Randomized, Placebo-Controlled, Multi-Panel, Multiple Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0822 in Healthy Male and Postmenopausal Female Subjects|Completed||Phase 1|62|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:41:15.449376|2018-06-01 01:41:15.449376
NCT00769405|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2016-08-29|2008-10-08|2008-10-09|Estimate|||||||2016-08-29|2016-08-30|Estimate|February 2008||2008-02-29|August 2016|2016-08-31||||December 2015|Actual|2015-12-31||Interventional|||Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer|Phase III Study Evaluating the Use of Systemic Chemotherapy and Chemohyperthemia Intraperitoneal Preoperatively (CHIP) and After Maximum Resection of Peritoneal Carcinomatosis Originating With Colorectal Cancer|Completed||Phase 3|264|Actual|UNICANCER||2|||f||||||||||||||2018-06-01 01:41:15.515359|2018-06-01 01:41:15.515359
NCT00769392|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2012-05-09|2008-10-08|2008-10-09|Estimate|||||||2012-05-09|2012-05-10|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|October 2012|Anticipated|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection|Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection|Unknown status|Active, not recruiting|N/A|100|Anticipated|Lahey Clinic||4|||f||||f||||||||||2018-06-01 01:41:15.621458|2018-06-01 01:41:15.621458
NCT00769379|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2018-05-24|2008-10-08|2008-10-09|Estimate|||||||2018-05-24|2018-05-25|Actual|November 10, 2008|Actual|2008-11-10|April 2018|2018-04-30||||March 31, 2019|Anticipated|2019-03-31||Interventional|||Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy|A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy|Active, not recruiting||Phase 3|2000|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 01:41:15.826786|2018-06-01 01:41:15.826786
NCT00769366|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2017-04-28|2008-10-07|2008-10-09|Estimate|||||||2017-04-28|2017-05-02|Actual|June 2, 2005||2005-06-02|April 2017|2017-04-30|November 1, 2016|Actual|2016-11-01|November 1, 2011|Actual|2011-11-01||Interventional|STEP-IN-AMI||Randomized, Controlled Study on Short-term Psychotherapy After Acute Myocardial Infarction|Randomized, Controlled Study on Short-term Psychotherapy After Acute Myocardial Infarction: The Step-in-AMI Trial (Short TErm Psychotherapy IN Acute Myocardial Infarction)|Completed||N/A|101|Actual|San Filippo Neri General Hospital||2|||f||||f||||||||||2018-06-01 01:41:17.827091|2018-06-01 01:41:17.827091
NCT00769353|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2014-05-20|2008-10-07|2008-10-09|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness|Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness|Completed||N/A|90|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:41:17.89103|2018-06-01 01:41:17.89103
NCT00769340|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2008-10-08|2008-10-08|2008-10-09|Estimate|||||||2008-10-08|2008-10-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:41:17.971035|2018-06-01 01:41:17.971035
NCT00769327|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2015-01-27|2008-10-08|2008-10-09|Estimate|||||||2015-01-27|2015-01-28|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CML0408||Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia|Front-line Treatment of Philadelphia Positive (Ph Pos), BCRABL Positive, Chronic Myeloid Leukemia (CML) With Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imotinib) A Phase II Exploratory Multicentric Centre.|Completed||Phase 2|129|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 01:41:18.015995|2018-06-01 01:41:18.015995
NCT00769314|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|2011-10-26||2012-11-21|2008-10-08|2008-10-09|Estimate|2012-11-21|2012-12-21|Estimate||||2012-11-21|2012-12-21|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|August 2009|Actual|2009-08-31|November 2008|Actual|2008-11-30||Interventional|LIP||Phase 3 Clinical Study for the Treatment of Cold Sore|A Randomised, Double-Blind, Single Dose, One-Day Early Administration, Multicentre Study Comparing the Efficacy and Safety of Acyclovir Lauriad® 50 mg Muco-adhesive Buccal Tablet to Matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients.|Completed||Phase 3|1727|Actual|Onxeo||2|||f||||f||||||||||2018-06-01 01:41:18.223347|2018-06-01 01:41:18.223347
NCT00769301|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2011-06-29|2008-10-08|2008-10-09|Estimate|||||||2011-06-29|2011-06-30|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|December 2014|Anticipated|2014-12-31|December 2011|Anticipated|2011-12-31||Observational|||Symptom Clusters in Cancer Patients and Their Caregivers- a Longitudinal Study|Advancing the Science of Symptom Management and Support for Cancer Patients and Their Caregivers|Unknown status|Active, not recruiting||500|Anticipated|Oslo University Hospital|||2||f||||t||||||Samples With DNA|"~     DNA analyses for genotyping subgroups of patients based on their experience with pain,~     fatigue, sleep disturbance and depression will test the hypothesis that gene polymorphisms~     within the selected candidate genes will exhibit significant differences in frequency~     distribution among the different patient subgroups that are identified through cluster~     analysis.~   "|||2018-06-01 01:41:18.830304|2018-06-01 01:41:18.830304
NCT00769288|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2014-01-06|2008-10-08|2008-10-09|Estimate|||||||2014-01-06|2014-01-07|Estimate|July 2009||2009-07-31|January 2014|2014-01-31||||December 2013|Actual|2013-12-31||Interventional|||FAU in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-B-D-arabinofuranosyl) Uracil, NSC#678515) in Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:41:18.89591|2018-06-01 01:41:18.89591
NCT00769275|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2008-10-08|2008-10-08|2008-10-09|Estimate|||||||2008-10-08|2008-10-09|Estimate|August 2000||2000-08-31|October 2008|2008-10-31|January 2008|Actual|2008-01-31|September 2007|Actual|2007-09-30||Observational|DIAD||Detection of Ischemia in Asymptomatic Diabetics|Detection of Ischemia in Asymptomatic Diabetics|Completed|||1123|Actual|Yale University|||2||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-06-01 01:41:18.983755|2018-06-01 01:41:18.983755
NCT00769262|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2017-05-30|2008-10-08|2008-10-09|Estimate|||||||2017-05-30|2017-06-01|Actual|October 22, 2008|Actual|2008-10-22|May 2017|2017-05-31|January 26, 2011|Actual|2011-01-26|January 26, 2011|Actual|2011-01-26||Interventional|||Weaning Thermoregulatory Support in Preterm Neonates|Effect of Conservative Weaning of Thermoregulatory Support on Weight Gain and Length of Stay in Preterm Neonates|Terminated||N/A|8|Actual|University of Missouri-Columbia||2||insufficient resources to conduct study|f||||f||||||||No||2018-06-01 01:41:19.045062|2018-06-01 01:41:19.045062
NCT00769249|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2015-03-17|2008-10-08|2008-10-09|Estimate|||||||2015-03-17|2015-03-19|Estimate|February 2008||2008-02-29|March 2015|2015-03-31||||December 2010|Anticipated|2010-12-31||Observational|||Positive Changes in Quality of Life of Older Cancer Patients and Their Caregivers|Correlates of Post-Traumatic Growth in Cancer Patients and Their Partners|Withdrawn|||0|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 01:41:19.110933|2018-06-01 01:41:19.110933
NCT00769236|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2014-08-27|2008-10-08|2008-10-09|Estimate|||||||2014-08-27|2014-08-28|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease|Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease|Completed||N/A|160|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 01:41:19.166001|2018-06-01 01:41:19.166001
NCT00769223|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2018-04-30|2008-10-08|2008-10-09|Estimate|||||||2018-04-30|2018-05-02|Actual|February 1993||1993-02-28|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|||Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer|Pre-Operative Gleason Score and PSA and Clinical Stage in Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer|Recruiting|||3500|Anticipated|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:41:19.22643|2018-06-01 01:41:19.22643
NCT00769210|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2016-03-29|2008-10-08|2008-10-09|Estimate|||||||2016-03-29|2016-03-31|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure|The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure|Completed||Early Phase 1|12|Actual|University of Utah||1|||f||||f||||||||||2018-06-01 01:41:19.436285|2018-06-01 01:41:19.436285
NCT00769197|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-08|||2009-04-28|2008-10-08|2008-10-09|Estimate|||||||2009-04-28|2009-04-29|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Optic Discs in Children With Cerebral Palsy|Optic Nerve Head Morphology in Children With Perinatal Onset Static Encephalopathy|Completed|||61|Actual|University of Mississippi Medical Center|||2||f||||f||||||||||2018-06-01 01:41:19.501612|2018-06-01 01:41:19.501612
NCT00769184|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2014-11-14||2015-07-22|2008-10-08|2008-10-09|Estimate|2015-07-22|2015-08-19|Estimate||||2015-07-22|2015-08-19|Estimate|October 2008||2008-10-31|July 2015|2015-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Fifteen patients with localized chronic plaque psoriasis (less than or equal to 6% BSA and PGA score greater than or equal to 3) were enrolled. Eleven patients completed the study. Three patients were removed due to an adverse event, and 1 patient was lost to follow-up after week 2.|Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis|A Steroid-Sparing Effect of Supplemental LCD Treatment in Patients With Moderate-to-Severe Localized Psoriasis Lesions: a Pilot Study.|Completed||N/A|15|Actual|NeoStrata Company, Inc.|This was a bilateral study in which 15 subjects total were recruited and randomized to receive both interventions simultaneously by dividing treatment arms to each side of the body.|2|||f||||t||||||||||2018-06-01 01:41:19.577816|2018-06-01 01:41:19.577816
NCT00769171|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2014-12-17|2008-10-07|2008-10-08|Estimate|||||||2014-12-17|2014-12-18|Estimate|October 2005||2005-10-31|December 2014|2014-12-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|DRAGON||Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)|A Prospective, Randomized, Double-blinded, Multi-center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidazole 500mg Every 12h for the Treatment of Patients With Complicated Intra-abdominal Infections|Completed||Phase 3|364|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:41:19.78541|2018-06-01 01:41:19.78541
NCT00769158|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2012-02-03|2008-10-06|2008-10-08|Estimate|||||||2012-02-03|2012-02-07|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study|Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study|Completed||Phase 1|4|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 01:41:19.875143|2018-06-01 01:41:19.875143
NCT00769145|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2017-07-07|2008-10-07|2008-10-08|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2008||2008-10-31|July 2017|2017-07-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery|Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery|Completed||Phase 1|5|Actual|University of Miami||1|||f||||f||||||||||2018-06-01 01:41:19.937895|2018-06-01 01:41:19.937895
NCT00769132|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2008-10-30||2015-09-03|2008-10-07|2008-10-08|Estimate|2008-11-26|2008-11-27|Estimate||||2015-09-03|2015-09-18|Estimate|August 2007||2007-08-31|September 2015|2015-09-30|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia|Completed||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 01:41:20.011459|2018-06-01 01:41:20.011459
NCT00769119|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2012-01-24||2012-08-14|2008-10-07|2008-10-08|Estimate|2012-06-19|2012-07-25|Estimate||||2012-08-14|2012-08-20|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|NEPAL||A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis|A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Bronchiectasis|Completed||Phase 2|38|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:41:20.310143|2018-06-01 01:41:20.310143
NCT00769106|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2016-04-13|2008-10-07|2008-10-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|HCC-CIK||Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer|A Randomized Controlled Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients With Hepatocellular Carcinoma Who Underwent Radical Resection.|Completed||Phase 3|200|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:41:21.608177|2018-06-01 01:41:21.608177
NCT00769093|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2017-04-19|2008-10-07|2008-10-08|Estimate|||||||2017-04-19|2017-04-21|Actual|October 2008||2008-10-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy|Pilot Study to Compare Dynamic MR Imaging Changes in Patients With Recurrent High Grade Glioma, Receiving an Antiangiogenic Drug, Bevacizumab, Versus Dexamethasone. Dual Agent MR Imaging Study, Using Gadolinium and Ferumoxytol (Code 7228)|Terminated||Phase 1|6|Actual|OHSU Knight Cancer Institute||2||Inadequate enrollment|f||||t||||||||||2018-06-01 01:41:21.671327|2018-06-01 01:41:21.671327
NCT00769080|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2011-11-28|2008-10-07|2008-10-08|Estimate|||||||2011-11-28|2011-11-29|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|October 2010|Actual|2010-10-31|||||Observational|ARI NIS||The Performance of Patient Support Program in Early Stage Breast Cancer|A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence With Adjuvant Aromatase Inhibitors (AI) Medication for Postmenopausal, Early Stage Breast Cancer|Completed|||524|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 01:41:21.747565|2018-06-01 01:41:21.747565
NCT00769067|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2015-07-27|2011-11-15|2015-09-22|2008-10-07|2008-10-08|Estimate|2015-07-27|2015-08-21|Estimate|2011-11-15|2011-11-21|Estimate|2015-09-22|2015-10-07|Estimate|November 2008||2008-11-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|October 2010|Actual|2010-10-31||Interventional||Intent-to-treat (ITT) population included all randomized participants with study drug assignment designated according to initial randomization, regardless of treatment received.|A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen|A Randomized Phase 2 Trial Of Pf-00299804 Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen|Completed||Phase 2|188|Actual|Pfizer||2|||f||||||||||||||2018-06-01 01:41:21.983645|2018-06-01 01:41:21.983645
NCT00769054|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2010-07-08|2008-10-07|2008-10-08|Estimate|||||||2010-07-08|2010-07-09|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Local Infiltration Analgesia With Ropivacaine in Posterior Vaginal Wall Prolapse:a Randomized, Double-Blind Study|Lokal Infiltrations Analgesi Med Ropivakain 1 % Versus Placebo VED Vaginale Descensusoperationer: ET Prospektivt Randomiseret, Dobbeltblindet, Placebo- Kontrolleret Studie|Completed||Phase 4|48|Anticipated|Hvidovre University Hospital||2|||f||||||||||||||2018-06-01 01:41:22.947233|2018-06-01 01:41:22.947233
NCT00769041|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2011-01-05|2008-10-06|2008-10-08|Estimate|||||||2011-01-05|2011-01-07|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Thorough EKG Safety Study of TA-1790 (Avanafil)|A Blinded, Randomized Crossover Trial to Define the ECG Effects of TA-1790 (Avanafil) Using a Single Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin in Healthy Men: A Thorough ECG Trial|Completed||Phase 1|57|Actual|VIVUS, Inc.||4|||f||||f||||||||||2018-06-01 01:41:23.124779|2018-06-01 01:41:23.124779
NCT00769028|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2011-08-16|2008-10-07|2008-10-08|Estimate|||||||2011-08-16|2011-08-18|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|September 2011|Anticipated|2011-09-30|February 2011|Actual|2011-02-28||Interventional|||AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis|A Double-Blind Placebo-Controlled Pilot Study of Safety and Tolerability of AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Daval International Limited||2|||f||||t||||||||||2018-06-01 01:41:23.207234|2018-06-01 01:41:23.207234
NCT00769015|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2014-10-09||2014-11-13|2008-10-07|2008-10-08|Estimate|2014-11-13|2014-11-20|Estimate||||2014-11-13|2014-11-20|Estimate|June 2009||2009-06-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|VITAL||Low Vision Depression Prevention Trial for Age Related Macular Degeneration|Low Vision Depression Prevention Trial for Age Related Macular Degeneration|Completed||Phase 3|188|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 01:41:23.329372|2018-06-01 01:41:23.329372
NCT00769002|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2013-08-26|2008-10-07|2008-10-08|Estimate|||||||2013-08-26|2013-08-27|Estimate|September 2008||2008-09-30|August 2013|2013-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Pro00000226||PET-CT Scans in Healthy Volunteers After Flu Vaccination|Impact of Bilateral Priming on Response to Unilateral Flu Vaccination|Completed||N/A|16|Actual|Hackensack University Medical Center||2|||f||||t||||||||||2018-06-01 01:41:23.841897|2018-06-01 01:41:23.841897
NCT00768989|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2011-10-19||2012-02-22|2008-10-07|2008-10-08|Estimate|2011-12-09|2012-01-16|Estimate||||2012-02-22|2012-02-24|Estimate|November 2008||2008-11-30|February 2012|2012-02-29|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|SPARTAN||Phase IIB Pilot of Atazanavir + Raltegravir|A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Combination With Tenofovir/Emtricitabine QD in Treatment Naive HIV-Infected Subjects|Terminated||Phase 2|167|Actual|Bristol-Myers Squibb||2||"Efficacy endpoint met, but overall experimental dosing regimen not considered optimal to~   support further clinical development in this population."|f||||f||||||||||2018-06-01 01:41:24.037787|2018-06-01 01:41:24.037787
NCT00768950|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2013-08-13|2008-10-07|2008-10-08|Estimate|||||||2013-08-13|2013-08-14|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|SPONDILENDO||The Characterization of Small Bowel and Colonic Involvement in Patients With Seronegative Spondyloarthritides|The Characterization of Small Bowel and Colonic Involvement in Patients With Seronegative Spondyloarthritides|Completed|||65|Actual|Carol Davila University of Medicine and Pharmacy|||1||f||||t||||||||||2018-06-01 01:41:25.308966|2018-06-01 01:41:25.308966
NCT00768937|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2010-11-08|2008-10-07|2008-10-08|Estimate|||||||2010-11-08|2010-11-09|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma|Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response|Completed||Phase 1/Phase 2|22|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-06-01 01:41:25.472195|2018-06-01 01:41:25.472195
NCT00768924|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-09-28|2008-10-06|2008-10-08|Estimate|||||||2011-09-28|2011-09-30|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Observational|||CopiOs(TM) Bone Void Filler in the Post-Harvest Iliac Crest|CopiOs(TM) Bone Void Filler in the Post-Harvest Iliac Crest|Completed|||35|Actual|Zimmer Biomet|||1||f||||||||||||||2018-06-01 01:41:25.561944|2018-06-01 01:41:25.561944
NCT00768911|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2010-10-26|2008-10-07|2008-10-08|Estimate|||||||2010-10-26|2010-10-27|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|June 2011|Anticipated|2011-06-30|October 2010|Anticipated|2010-10-31||Interventional|||CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme|Phase 1, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of CT-322 Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Adnexus, A Bristol-Myers Squibb R&D Company||1|||f||||f||||||||||2018-06-01 01:41:25.633023|2018-06-01 01:41:25.633023
NCT00768898|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2009-09-21||2012-03-19|2008-10-06|2008-10-08|Estimate|2012-03-19|2012-04-13|Estimate||||2012-03-19|2012-04-13|Estimate|August 2008||2008-08-31|March 2012|2012-03-31||||September 2008|Actual|2008-09-30||Observational|||Defining the Conjunctival Staining Method: Instillation Volume and Time Course to Assess Staining With Lissamine Green||Completed|||30|Actual|Alcon Research|||3||f||||f||||||||||2018-06-01 01:41:25.748776|2018-06-01 01:41:25.748776
NCT00768885|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2013-03-15|2008-10-06|2008-10-08|Estimate|||||||2013-03-15|2013-03-18|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs.|Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs|Completed||N/A|64|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 01:41:26.00215|2018-06-01 01:41:26.00215
NCT00768872|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2016-10-13|2008-10-07|2008-10-08|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|ADR-SCS||Spinal Cord Stimulation Research Study|Neuro Ambulatory Data Recorder (ADR) Spinal Cord Stimulation (SCS) Study|Completed|||66|Actual|MedtronicNeuro|||||f||||f||||||||||2018-06-01 01:41:26.078365|2018-06-01 01:41:26.078365
NCT00768859|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2012-05-10|2008-10-07|2008-10-08|Estimate|||||||2012-05-10|2012-05-11|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|TRAIN||Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study|Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study|Completed||Phase 2|111|Actual|The Netherlands Cancer Institute||1|||f||||t||||||||||2018-06-01 01:41:26.170986|2018-06-01 01:41:26.170986
NCT00768846|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2008-10-11|2008-10-06|2008-10-08|Estimate|||||||2008-10-11|2008-10-15|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|June 2011|Anticipated|2011-06-30|May 2010|Anticipated|2010-05-31||Interventional|ZEPPELIN||Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World|Randomized Comparison of Zotarolimus- and Everolimus-Eluting Stents for Coronary Treatment|Unknown status|Recruiting|Phase 4|2600|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 01:41:26.266115|2018-06-01 01:41:26.266115
NCT00768833|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2014-08-20|2008-10-07|2008-10-08|Estimate|||||||2014-08-20|2014-08-21|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|Carriage||Study Evaluating the Nasopharyngeal Carriage in Healthy Children|Nasopharyngeal Carriage in Children After Introduction of General Pneumococcal Immunization in Germany|Completed|||242|Actual|Pfizer|||||f||||f||||||||||2018-06-01 01:41:26.382149|2018-06-01 01:41:26.382149
NCT00768820|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2017-07-20|2008-10-07|2008-10-08|Estimate|||||||2017-07-20|2017-07-21|Actual|May 2001||2001-05-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|VCFS||The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome|The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors|Recruiting||Phase 4|400|Anticipated|The Chaim Sheba Medical Center||1|||f||||t||||||||||2018-06-01 01:41:26.442637|2018-06-01 01:41:26.442637
NCT00768807|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2012-05-04|2008-10-07|2008-10-08|Estimate|||||||2012-05-04|2012-05-08|Estimate|October 2009||2009-10-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|October 2009|Actual|2009-10-31||Interventional|||Structural and Functional Left Ventricular Remodelling in Patients With Obstructive Sleep Apnea|Structural and Functional Left Ventricular Remodelling in Patients With Obstructive Sleep Apnea|Completed||N/A|450|Actual|Associação Fundo de Incentivo à Pesquisa||2|||f||||f||||||||||2018-06-01 01:41:26.562759|2018-06-01 01:41:26.562759
NCT00768794|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2013-05-30|2008-10-07|2008-10-08|Estimate|||||||2013-05-30|2013-05-31|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy|A Trial Using Acidophilus for the Treatment and Prevention of Oral Candidiasis in Head and Neck Cancer Patients Undergoing Radiation Therapy|Completed||N/A|5|Actual|Summa Health System||1|||f||||f||||||||||2018-06-01 01:41:26.63279|2018-06-01 01:41:26.63279
NCT00768781|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2013-05-28|2008-10-07|2008-10-08|Estimate|||||||2013-05-28|2013-05-30|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|||Mindfulness-Based Approaches to Insomnia|Augmenting Behavior Therapy for Insomnia With Mindfulness Meditation|Completed||Phase 2|54|Actual|Rush University Medical Center||3|||f||||f||||||||||2018-06-01 01:41:26.700734|2018-06-01 01:41:26.700734
NCT00768768|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-03-10|2008-10-06|2008-10-08|Estimate|||||||2009-03-10|2009-03-12|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Iontophoretic Application of Terbinafine Gel to the Large Toe Nail|A Study of Skin/Nail Sensation and the Pharmacokinetics of the Uptake of Terbinafine in the Great Toe Nail and Systemically Following Treatment With the Electrokinetic Transungual System (ETS)-Terbinafine Gel in Healthy Normal Voluneteers|Completed||Phase 1|40|Anticipated|Transport Pharmaceuticals||5|||f||||f||||||||||2018-06-01 01:41:26.77781|2018-06-01 01:41:26.77781
NCT00768755|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2012-03-01||2015-10-06|2008-10-07|2008-10-08|Estimate|2012-03-01|2012-03-30|Estimate||||2015-10-06|2015-10-28|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer|Randomized Phase 2 Study Of Cisplatin/Pemetrexed With Or Without Axitinib (AG-013736) As First-Line Treatment For Patients With Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|180|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:41:26.912376|2018-06-01 01:41:26.912376
NCT00768742|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2013-11-22|2008-10-06|2008-10-08|Estimate|||||||2013-11-22|2013-11-25|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|FAST||Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study|Clinical Study to Assess the Safety and Effectiveness of VizAblate(tm) Intrauterine Ultrasound-guided RF Ablation (IUUSgRFA) of Submucosal and Intramural Uterine Fibroids on the Reduction of Pictorial Blood Loss Assessment Scores|Withdrawn||N/A|0|Actual|Gynesonics||||study revised and reinitiated under another protocol|f||||f||||||||||2018-06-01 01:41:28.306487|2018-06-01 01:41:28.306487
NCT00768729|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2013-02-14|2008-10-06|2008-10-08|Estimate|||||||2013-02-14|2013-02-15|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation|Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation|Completed||Phase 1|7|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 01:41:28.390923|2018-06-01 01:41:28.390923
NCT00768716|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2018-02-05|2008-10-07|2008-10-08|Estimate|||||||2018-02-05|2018-02-06|Actual|December 2008|Actual|2008-12-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics|Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics|Completed||Phase 4|148|Actual|Tufts University||2|||f||||f||||||||||2018-06-01 01:41:28.541141|2018-06-01 01:41:28.541141
NCT00768703|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2016-11-01|2008-10-06|2008-10-08|Estimate|||||||2016-11-01|2016-11-03|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Percutaneous Endoscopic Tracheal Plug/Unplug for CDH|Percutaneous Endoscopic Tracheal Plug/Unplug for Congenital Diaphragmatic Hernia|Active, not recruiting||Phase 1/Phase 2|10|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:41:28.640198|2018-06-01 01:41:28.640198
NCT00768690|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2010-10-11|2008-10-07|2008-10-08|Estimate|||||||2010-10-11|2010-10-13|Estimate|October 2008||2008-10-31|September 2010|2010-09-30||||February 2009|Actual|2009-02-28||Interventional|||A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333||Completed||Phase 1|45|Actual|Abbott||5|||f||||||||||||||2018-06-01 01:41:28.731369|2018-06-01 01:41:28.731369
NCT00768677|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2008-10-07|2008-10-07|2008-10-08|Estimate|||||||2008-10-07|2008-10-08|Estimate|July 2003||2003-07-31|September 2008|2008-09-30||||||||Interventional|||Topiramate for Binge Eating Disorder Among Adolescents|Open-Label Study of Topiramate for Binge Eating Disorder and Bulimia Nervosa Among Adolescents|Completed||N/A|||The Zucker Hillside Hospital|||||f||||f||||||||||2018-06-01 01:41:28.854973|2018-06-01 01:41:28.854973
NCT00768664|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07||2011-06-03|2012-06-01|2008-10-07|2008-10-08|Estimate||||2011-06-03|2011-06-16|Estimate|2012-06-01|2012-06-07|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|May 2010|Actual|2010-05-31||Interventional|||Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer|Clinical Phase 2 Multicenter Trial Of PF-00299804 In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck|Completed||Phase 2|69|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:41:28.926166|2018-06-01 01:41:28.926166
NCT00768651|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2015-05-10||2015-05-29|2008-10-07|2008-10-08|Estimate|2015-05-29|2015-06-18|Estimate||||2015-05-29|2015-06-18|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional||Patients with evidence of early graft insufficiency following a period of insulin independence after one or more islet infusions for c-peptide negative type 1 diabetes participated in the study.|Incretin Effect and Use After Clinical Islet Transplantation|Pilot Study of Safety and Efficacy of Combined Use of Dipeptidyl-peptidase Inhibitor (Sitagliptin) and Proton Pump Inhibitor (Pantoprazole) to Prevent Beta-cell Apoptosis and Promote Islet Regeneration in Islet Transplant Recipients With Early Graft Dysfunction|Completed||Phase 2|8|Actual|University of Alberta|The major weaknesses of the study are the small sample size and the lack of a control group.|1|||f||||f||||||||||2018-06-01 01:41:29.080445|2018-06-01 01:41:29.080445
NCT00768638|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2015-04-28|2008-10-07|2008-10-08|Estimate|||||||2015-04-28|2015-04-29|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|SARP||Study of Atorvastatin Dose Dependent Reduction of Proteinuria|The Renal Protective Effects of Low-dose and High-dose Atorvastatin in Patients With Glomerular Disease and Proteinuria: a Randomized Controlled Double Blinded Study|Completed||Phase 4|23|Actual|Laval University||2|||f||||f||||||||||2018-06-01 01:41:29.40824|2018-06-01 01:41:29.40824
NCT00768625|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2008-10-07|2008-10-07|2008-10-08|Estimate|||||||2008-10-07|2008-10-08|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|December 2012|Anticipated|2012-12-31|March 2011|Anticipated|2011-03-31||Observational|ERA||Cardiovascular Risk Stratification in Patients With Obstructive Sleep Apnea|Cardiovascular Risk Stratification in Patients With Obstructive Sleep Apnea|Unknown status|Recruiting||2000|Anticipated|Associacao Fundo de Incentivo a Psicofarmcologia|||||f||||f||||||||||2018-06-01 01:41:29.492236|2018-06-01 01:41:29.492236
NCT00768612|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2013-01-28|2008-10-07|2008-10-08|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia|A Randomized, Double-Blind, Risperidone-Reference, Parallel-Group, Safety, and Tolerability Study of Vabicaserin (SCA-136) in Japanese Subjects With Acute Exacerbation of Schizophrenia|Withdrawn||Phase 2|0|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||t||||||||||2018-06-01 01:41:29.602979|2018-06-01 01:41:29.602979
NCT00768599|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2012-12-05||2012-12-05|2008-10-07|2008-10-08|Estimate|2012-12-05|2013-01-09|Estimate||||2012-12-05|2013-01-09|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||A Study of Econazole Foam 1% in Athlete's Foot|A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis|Completed||Phase 2|135|Actual|AmDerma||3|||f||||f||||||||||2018-06-01 01:41:29.688269|2018-06-01 01:41:29.688269
NCT00768586|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2008-10-14|2008-10-07|2008-10-08|Estimate|||||||2008-10-14|2008-10-15|Estimate|February 2008||2008-02-29|September 2008|2008-09-30||||||||Observational|fVEP||Analysis of the Early Development of the Visual Function in Extreme Premature Infants Under 28th Weeks of Gestation|Analysis of the Early Development of the Visual Function in Extreme Premature Infants Under 28th Weeks of Gestation. - A Prospective Study to Identify Normal Values of Flash Visual Evoked Potentials in This Population|Unknown status|Recruiting||40|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-06-01 01:41:30.134107|2018-06-01 01:41:30.134107
NCT00768573|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2015-04-27|2008-10-07|2008-10-08|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Taste Test of a New Formulation of Sildenafil (Revatio)|A Single-Blind Study In Healthy Adult Volunteers To Investigate The Palatability Of Different Oral Suspension Formulations Of Revatio®|Completed|||4|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:41:30.187954|2018-06-01 01:41:30.187954
NCT00768560|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2009-09-28||2015-05-13|2008-10-07|2008-10-08|Estimate|2010-01-07|2010-02-02|Estimate||||2015-05-13|2015-06-08|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study|Evaluation of the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of BAY A1040 CR Tablet on High Dose Administration in Patients With Essential Hypertension.|Completed||Phase 2|35|Actual|Bayer||3|||f||||f||||||||||2018-06-01 01:41:30.270266|2018-06-01 01:41:30.270266
NCT00768547|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2011-07-21|2008-10-07|2008-10-08|Estimate|||||||2011-07-21|2011-07-22|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Risk Stratification in Acutely Admitted Medical Patients|Risk Stratification in Acutely Admitted Medical Patients|Completed|||5900|Actual|Ribe County Hospital|||2||f||||f||||||||||2018-06-01 01:41:30.82406|2018-06-01 01:41:30.82406
NCT00768534|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2016-10-05|2008-10-07|2008-10-08|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media|Microbiological Analysis Of Spontaneous Draining Acute Otitis Media Including Serotype Distribution Of Pneumococcal Isolates|Completed|||2138|Actual|Pfizer|||||f||||f||||||Samples Without DNA|"~     Middle ear fluid and anasopharyngeal swab~   "|||2018-06-01 01:41:30.894322|2018-06-01 01:41:30.894322
NCT00768521|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2014-08-01||2018-01-24|2008-10-07|2008-10-08|Estimate|2014-08-01|2014-08-19|Estimate||||2018-01-24|2018-02-21|Estimate|September 3, 2008|Actual|2008-09-03|January 2018|2018-01-31|January 19, 2009|Actual|2009-01-19|January 19, 2009|Actual|2009-01-19||Interventional|||A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)|A Randomized, Placebo Controlled, Crossover Study to Evaluate the Effects of Tolterodine Tartrate on Urodynamic Parameters in Patients With Overactive Bladder|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.|The analysis presented includes all patients. An analysis excluding patients who were misdosed yielded different results with a similar conclusion and are not presented.|4|||f||||||||||||||2018-06-01 01:41:31.042282|2018-06-01 01:41:31.042282
NCT00768508|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2013-03-14|2008-10-06|2008-10-08|Estimate|||||||2013-03-14|2013-03-15|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Combined Pharmacotherapies for Alcoholism|Combined Pharmacotherapies for Alcoholism|Completed||Phase 3|300|Actual|University of Virginia||4|||f||||t||||||||||2018-06-01 01:41:31.234298|2018-06-01 01:41:31.234298
NCT00768495|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-06-02|2008-10-07|2008-10-08|Estimate|||||||2009-06-02|2009-06-04|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|CLI-Pre/Post||Hyperspectral Imaging Pre and Post Endovascular Intervention|Evaluation of the Success of Endovascular Peripheral Revascularization for the Treatment of Chronic Limb Ischemia by Measuring OxyHb and DeoxyHb Using a New Hyperspectral Imaging Device (OxyVu).|Unknown status|Recruiting||60|Anticipated|HyperMed|||1||f||||f||||||||||2018-06-01 01:41:31.323161|2018-06-01 01:41:31.323161
NCT00768482|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07||2011-01-05|2017-06-12|2008-10-07|2008-10-08|Estimate||||2012-10-23|2012-10-30|Estimate|2017-06-12|2017-06-14|Actual|September 2008||2008-09-30|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PRO-810||A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence|A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence|Terminated||Phase 3|9|Actual|Braeburn Pharmaceuticals||1||This study was terminated for reasons not related to efficacy or safety|f||||t||||||||||2018-06-01 01:41:31.452391|2018-06-01 01:41:31.452391
NCT00768469|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2012-05-10|2008-10-07|2008-10-08|Estimate|||||||2012-05-10|2012-05-14|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Evaluating Safety And Tolerability, Solid Tumor|A Phase 1 Study Of Neratinib (HKI-272) In Combination With Paclitaxel In Subjects With Solid Tumors|Completed||Phase 1|10|Actual|Puma Biotechnology, Inc.||1|||f||||t||||||||||2018-06-01 01:41:31.520421|2018-06-01 01:41:31.520421
NCT00768456|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2011-06-22|2008-10-07|2008-10-08|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2008||2008-10-31|July 2008|2008-07-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||Local Infiltration Analgesia With Ropivacaine Versus Placebo in Vaginal Hysterectomy: a Randomized, Double-Blind Study|Lokal Infiltrations Analgesi Med Ropivakain 0,5 % Versus Placebo VED Vaginal Hysterektomi: ET Prospektivt Randomiseret, Dobbeltblind ET, Placebo-kontrolleret Studie|Completed||Phase 4|48|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 01:41:31.595501|2018-06-01 01:41:31.595501
NCT00768443|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2010-12-06|2008-10-07|2008-10-08|Estimate|||||||2010-12-06|2010-12-07|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|February 2009|Actual|2009-02-28|||||Observational|PHENIX||Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)|Epidemiological Study to Assess the Symptom Patterns and Management Strategies in Patients Consulting With Persistent GERD Symptoms in Primary Care|Completed|||2674|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:41:31.700412|2018-06-01 01:41:31.700412
NCT00768430|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2013-09-05||2013-12-27|2008-10-07|2008-10-08|Estimate|2013-12-27|2014-01-31|Estimate||||2013-12-27|2014-01-31|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Optimization of IV Ketamine for Treatment Resistant Depression|Optimization of Intravenous Ketamine for Treatment-Resistant Depression: A Randomized, Placebo-Controlled, Triple-masked, Clinical Trial|Completed||Phase 2|73|Actual|Baylor College of Medicine|Limitations of our trial include stringent enrollment criteria due to concerns about ketamine’s psychoactive effects and abuse liability. A proportion of screened patients (17.2%) refused or were unable to tolerate psychotropic washout.|2|||f||||t||||||||||2018-06-01 01:41:31.820074|2018-06-01 01:41:31.820074
NCT00768417|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2013-11-15|2008-10-07|2008-10-08|Estimate|||||||2013-11-15|2013-11-18|Estimate|April 2006||2006-04-30|November 2013|2013-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Availability of Lipids in Almonds in Healthy Individuals|Mastication of Almonds: Effects of Lipid Bioaccessibility, Appetite, and Hormone Response|Completed|||20|Actual|Purdue University|||1||f||||t||||||Samples With DNA|"~     Plasma, feces~   "|||2018-06-01 01:41:32.047954|2018-06-01 01:41:32.047954
NCT00768404|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2009-11-30|2008-10-07|2008-10-08|Estimate|||||||2009-11-30|2009-12-01|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment|A Phase I, Open-Label, Parallel-Group, Single Dose, Non-Randomized Study To Compare The Pharmacokinetics Of Each Individual Component (Topiramate And Phentermine) Of The Combination Product VI-0521 In Subjects With Mild, Moderate And Severe Renal Impairment To Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|VIVUS, Inc.||1|||f||||f||||||||||2018-06-01 01:41:32.131442|2018-06-01 01:41:32.131442
NCT00768391|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2011-06-27|2008-10-07|2008-10-08|Estimate|||||||2011-06-27|2011-06-28|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|January 2010|Actual|2010-01-31|March 2009|Actual|2009-03-31||Interventional|||Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available|Phase I Study of Anti-Platelet Derived Growth Factor Receptor Alpha (PDGFRa) Monoclonal Antibody IMC-3G3 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom no Standard Therapy is Available|Completed||Phase 1|20|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 01:41:32.227369|2018-06-01 01:41:32.227369
NCT00768378|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2012-06-27|2008-10-06|2008-10-08|Estimate|||||||2012-06-27|2012-06-28|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy Study of BrainPort® Balance Device in Peripheral Vestibular Dysfunction.|A Controlled Clinical Study to Evaluate the Safety and Efficacy of the BrainPort® Balance Device When Used to Improve Balance in Subjects With Peripheral Vestibular Dysfunction|Completed||N/A|147|Actual|Wicab||2|||f||||f||||||||||2018-06-01 01:41:32.305153|2018-06-01 01:41:32.305153
NCT00768365|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2008-10-07|2008-10-07|2008-10-08|Estimate|||||||2008-10-07|2008-10-08|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|adrenal||Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma|Cardiovascular Risk in Patients With Non-Functional Adrenal Incidentaloma: Myth or Reality?|Completed|||105|Actual|Istanbul University|||3||f||||f||||||||||2018-06-01 01:41:32.422386|2018-06-01 01:41:32.422386
NCT00768352|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2008-10-07|2008-10-07|2008-10-08|Estimate|||||||2008-10-07|2008-10-08|Estimate|February 2008||2008-02-29|October 2008|2008-10-31|June 2009|Anticipated|2009-06-30|February 2009|Anticipated|2009-02-28||Interventional|||Educational Intervention for Optimizing Adolescent Mental Health Screening and Treatment in Pediatric Residency|An Educational Intervention for Optimizing Adolescent Mental Health Screening Skills and Treatment in Pediatric Residency|Unknown status|Recruiting|N/A|50|Anticipated|Brooke Army Medical Center||1|||f||||||||||||||2018-06-01 01:41:32.501102|2018-06-01 01:41:32.501102
NCT00768339|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2011-07-12|2008-10-06|2008-10-08|Estimate|||||||2011-07-12|2011-07-13|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|September 2011|Anticipated|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas|AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas|Terminated||Phase 1/Phase 2|25|Actual|Aegera Therapeutics||1||Slow recruitment|f||||f||||||||||2018-06-01 01:41:32.571348|2018-06-01 01:41:32.571348
NCT00768326|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2016-11-07|2008-10-07|2008-10-08|Estimate|||||||2016-11-07|2016-11-08|Estimate|March 2007||2007-03-31|November 2016|2016-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Efficacy of Lu 31-130 in Patients With Schizophrenia|A Double-blind, Randomised, Parallel-group, Placebo-controlled Study of the Safety, Tolerability and Efficacy Following Sequential Dose Regimens of Lu 31-130 to Patients With Schizophrenia|Completed||Phase 2|280|Actual|H. Lundbeck A/S||6|||f||||t||||||||||2018-06-01 01:41:32.66303|2018-06-01 01:41:32.66303
NCT00768313|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2010-05-14|2008-10-07|2008-10-08|Estimate|||||||2010-05-14|2010-05-17|Estimate|September 2008||2008-09-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Phase IV Comparing Rods of Yield Strengths to Correct Adolescent Idiopathic Scoliosis.|A Multi-Centre Randomized Phase IV Clinical Trial Comparing Rods of Varying Yield Strengths and Their Ability to Hold Correction of Adolescent Idiopathic Scoliosis.|Terminated||Phase 4|0|Actual|Queen's University||2||lack of enrollment|f||||f||||||||||2018-06-01 01:41:32.771241|2018-06-01 01:41:32.771241
NCT00768300|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2013-07-15||2014-02-27|2008-10-07|2008-10-08|Estimate|2014-02-27|2014-04-08|Estimate||||2014-02-27|2014-04-08|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|ARTEMIS-IPF|Full Analysis Set: participants who were randomized and treated|(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF|ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)|Terminated||Phase 3|494|Actual|Gilead Sciences||2||Lack of efficacy|f||||t||||||||||2018-06-01 01:41:32.924818|2018-06-01 01:41:32.924818
NCT00768287|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2017-06-26|2008-10-07|2008-10-08|Estimate|||||||2017-06-26|2017-06-28|Actual|January 2009|Actual|2009-01-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|November 2011|Actual|2011-11-30||Interventional|||Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B|Phase I/II/III Pharmacokinetic and Outcome Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B|Completed||Phase 2/Phase 3|77|Actual|Aptevo Therapeutics||1|||f||||t||||||||||2018-06-01 01:41:34.535523|2018-06-01 01:41:34.535523
NCT00768274|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07||2013-10-28|2016-07-21|2008-10-07|2008-10-08|Estimate||||2013-10-28|2013-11-20|Estimate|2016-07-21|2016-07-25|Estimate|September 2008||2008-09-30|July 2016|2016-07-31||||August 2009|Actual|2009-08-31||Interventional|||Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol|A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of 28-Day Oral Dosing of RVX000222 in Healthy Subjects and Subjects With Low High Density Lipoprotein (HDL)|Completed||Phase 1/Phase 2|72|Actual|Resverlogix Corp||3|||f||||||||||||||2018-06-01 01:41:34.669474|2018-06-01 01:41:34.669474
NCT00768261|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2012-07-19|2008-10-07|2008-10-08|Estimate|||||||2012-07-19|2012-07-20|Estimate|November 2004||2004-11-30|July 2012|2012-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Corticolimbic Degeneration and Treatment of Dementia|Corticolimbic Degeneration and Treatment of Dementia|Completed||Phase 4|39|Actual|Washington University School of Medicine||4|||f||||f||||||||||2018-06-01 01:41:34.769945|2018-06-01 01:41:34.769945
NCT00768248|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2011-09-13|2008-10-07|2008-10-08|Estimate|||||||2011-09-13|2011-09-14|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Naval Medical Center San Diego (NMCSD) - Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain|Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain|Terminated||N/A|2|Actual|University of California, San Diego||2||No longer enrolling patients, not enough enrollment|f||||f||||||||||2018-06-01 01:41:34.892718|2018-06-01 01:41:34.892718
NCT00768235|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|||2008-10-07|2008-10-07|2008-10-08|Estimate|||||||2008-10-07|2008-10-08|Estimate|March 2007||2007-03-31|October 2008|2008-10-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Yoga Program in Respiratory Function|Influence of Yoga Program in Respiratory Function of Older Women|Completed||Phase 1/Phase 2|36|Actual|Catholic University of Brasília||2|||f||||t||||||||||2018-06-01 01:41:34.966498|2018-06-01 01:41:34.966498
NCT00768222|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-07|2011-06-27||2011-08-29|2008-10-07|2008-10-08|Estimate|2011-07-27|2011-08-25|Estimate||||2011-08-29|2011-08-31|Estimate|October 2008||2008-10-31|August 2011|2011-08-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery|Pilot Evaluation of Cosmetic Outcome and Surgical Site Infection Rates of Coated VICRYL* Plus Antibacterial (Polyglactin 910) Suture Compared to Chinese Silk in Scheduled Breast Cancer Surgery|Completed||Phase 4|101|Actual|Ethicon, Inc.||2|||f||||f||||||||||2018-06-01 01:41:35.099926|2018-06-01 01:41:35.099926
NCT00768209|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-11-30|2008-10-07|2008-10-08|Estimate|||||||2009-11-30|2009-12-01|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment|A Phase I, Open Label, Single-Dose Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment and In Healthy Control Subjects|Completed||Phase 1|18|Actual|VIVUS, Inc.||1|||f||||f||||||||||2018-06-01 01:41:35.395322|2018-06-01 01:41:35.395322
NCT00768196|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2010-12-06|2008-10-06|2008-10-07|Estimate|||||||2010-12-06|2010-12-07|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|February 2009|Actual|2009-02-28|||||Observational|Preedom||Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients|Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients|Completed|||2000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:41:35.459072|2018-06-01 01:41:35.459072
NCT00768183|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-07|Estimate|||||||2008-10-03|2008-10-07|Estimate|May 2006||2006-05-31|October 2008|2008-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water|A Phase 1, Single-Center, Open-Label, Drug Interaction Study to Evaluate the Effect of Alcohol Ingestion on the Pharmacokinetics of Alpharma Branded Products Division Inc. (KADIAN) Morphine Sulfate Extended-Release Capsules in Healthy Adult Volunteers Under Fasting and Fed Conditions and Relative Bioavailability Assessment of an Immediate Release Morphine Solution|Completed||Phase 1|32|Actual|Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.||4|||f||||||||||||||2018-06-01 01:41:35.51333|2018-06-01 01:41:35.51333
NCT00768170|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2015-07-02|2008-10-06|2008-10-07|Estimate|||||||2015-07-02|2015-07-03|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028)|A Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK0633 in Japanese Asthmatic Children Aged 12 to Less Than 16 Years|Completed||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:41:35.653517|2018-06-01 01:41:35.653517
NCT00768157|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-02-06|2008-10-06|2008-10-07|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma|Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:41:35.718532|2018-06-01 01:41:35.718532
NCT00768144|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2014-06-05||2017-05-04|2008-10-06|2008-10-07|Estimate|2014-11-24|2014-12-02|Estimate||||2017-05-04|2017-06-05|Actual|September 2008||2008-09-30|May 2017|2017-05-31|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Interventional||The analysis dataset is comprised of all enrolled patients.|Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma|A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma|Completed||Phase 2|36|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 01:41:35.900258|2018-06-01 01:41:35.900258
NCT00768131|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2015-10-26|2008-10-06|2008-10-07|Estimate|||||||2015-10-26|2015-10-28|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel|A Randomized Phase II Trial to Assess the Predictive Value of Increased EGFR Copy Number by FISH in Patients With Advanced / Metastatic NSCLC Treated With Cetuximab and Carboplatin / Paclitaxel|Withdrawn||Phase 2|0|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:41:36.142599|2018-06-01 01:41:36.142599
NCT00768118|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|2014-04-10||2014-06-10|2008-10-04|2008-10-07|Estimate|2014-04-10|2014-05-12|Estimate||||2014-06-10|2014-06-23|Estimate|April 2008||2008-04-30|June 2014|2014-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants|A Pilot Study of Biomarker Alterations By Nutritional Agents|Completed||N/A|11|Actual|Barbara Ann Karmanos Cancer Institute|The study has small numbers, it was a proof-of-concept study only to demonstrate that agents taken orally can alter biomarkers, similar to the results obtained from in vitro studies, it was to open doors for future studies.|1|||f||||t||||||||||2018-06-01 01:41:36.265277|2018-06-01 01:41:36.265277
NCT00768105|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2010-12-02|2008-10-06|2008-10-07|Estimate|||||||2010-12-02|2010-12-03|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin|A Randomized, Single-Blind, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Subjects With T2DM Treated With Insulin|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 01:41:36.543807|2018-06-01 01:41:36.543807
NCT00766064|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2016-08-22|2008-10-02|2008-10-03|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2008||2008-09-30|August 2016|2016-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)|Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)|Withdrawn||Phase 4|0|Actual|Yale University||1|||f||||f||||||||||2018-06-01 01:42:03.638043|2018-06-01 01:42:03.638043
NCT00768079|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03||2016-07-14|2016-07-14|2008-10-03|2008-10-07|Estimate||||2016-07-14|2016-07-18|Estimate|2016-07-14|2016-07-18|Estimate|February 2009||2009-02-28|July 2016|2016-07-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|MEDI-563||A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563|A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Safety and Efficacy of Intravenously Administered MEDI-563, A Humanized Anti-interleukin-5 Receptor Alpha Monoclonal Antibody, on Asthma Control Following Acute Exacerbations in Adults|Completed||Phase 2|110|Actual|MedImmune LLC||3|||f||||f||||||||||2018-06-01 01:41:36.632664|2018-06-01 01:41:36.632664
NCT00768066|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2014-01-17||2015-11-09|2008-10-03|2008-10-07|Estimate|2015-11-09|2015-12-14|Estimate||||2015-11-09|2015-12-14|Estimate|August 2008||2008-08-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|August 2012|Actual|2012-08-31||Interventional|TAC-HFT|This is the number of patients who were randomized and received the study product injection.|The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)|A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.|Completed||Phase 1/Phase 2|65|Actual|University of Miami||3|||f||||t||||||||||2018-06-01 01:41:36.739615|2018-06-01 01:41:36.739615
NCT00768053|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2011-03-24||2011-07-28|2008-10-06|2008-10-07|Estimate|2011-03-24|2011-04-21|Estimate||||2011-07-28|2011-07-29|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|Rainbow||Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients|Open-Label Study To Evaluate The EULAR-RAID Score, Rheumatoid Arthritis Impact Of Disease Score, In Rheumatoid Arthritis Patients Eligible To Etanercept And Who Will Receive Etanercept|Completed||Phase 4|108|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:41:38.684298|2018-06-01 01:41:38.684298
NCT00768040|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2012-02-02||2012-02-02|2008-10-06|2008-10-07|Estimate|2012-02-02|2012-03-06|Estimate||||2012-02-02|2012-03-06|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema|A Randomized, Double-masked, Placebo-controlled, add-on Study to Assess the Efficacy of Oral Aliskiren 300 mg Once Daily for Diabetic Macular Edema|Terminated||Phase 2|39|Actual|Novartis|This study was terminated early due to low recruitment of patients. The study lacked power against the original objective of statistically significance for changes in central retinal thickness due to the much reduced sample size.|2||Inadequate enrollment|f||||f||||||||||2018-06-01 01:41:39.32336|2018-06-01 01:41:39.32336
NCT00768027|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-06-02|2008-10-06|2008-10-07|Estimate|||||||2009-06-02|2009-06-04|Estimate|August 2008||2008-08-31|June 2009|2009-06-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Observational|HBOT||Outcome Assessment in Patients Treated With Hyperbaric Oxygen Using OxyVu Tissue Oxygenation Monitoring System|Outcome Assessment in Patients Treated With Hyperbaric Oxygen Using OxyVu Tissue Oxygenation Monitoring System|Suspended|||60|Anticipated|HyperMed||||Seeking additional funds|f||||f||||||||||2018-06-01 01:41:39.74739|2018-06-01 01:41:39.74739
NCT00768014|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-05|||2008-10-06|2008-10-06|2008-10-07|Estimate|||||||2008-10-06|2008-10-07|Estimate|March 2008||2008-03-31|October 2008|2008-10-31|December 2010|Anticipated|2010-12-31|July 2008|Anticipated|2008-07-31||Observational|TENS||fMRI Measurements on Pain Relief Methods in First Stage Labor Pain|fMRI Measurements on the Effect of Transcutaneous Electrical Nerve Stimulation (TENS) on Acupuncture Points Verses Spontaneous Normal Vaginal Delivery to Relief of Labor Pain|Unknown status|Recruiting||60|Anticipated|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-06-01 01:41:39.827103|2018-06-01 01:41:39.827103
NCT00768001|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2012-01-30|2008-10-06|2008-10-07|Estimate|||||||2012-01-30|2012-02-01|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Genetic Analysis of Liver Cancer|Genetic Analysis of Liver Cancer|Terminated|||41|Actual|Stanford University||||low accrual|f||||||||||Samples With DNA|"~     tumor sample~   "|||2018-06-01 01:41:39.897161|2018-06-01 01:41:39.897161
NCT00767988|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2015-09-11|2008-10-06|2008-10-07|Estimate|||||||2015-09-11|2015-09-15|Estimate||||September 2015|2015-09-30||||||||Interventional|||Probiotics in Girls With Spina Bifida|Probiotics Improvement of Gastrointestinal and Genitourinary Health in Girls With Spina Bifida (H-23245)|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||2||Withdrawn by PI|f||||f||||||||||2018-06-01 01:41:39.944608|2018-06-01 01:41:39.944608
NCT00767975|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2010-11-25|2008-10-06|2008-10-07|Estimate|||||||2010-11-25|2010-11-29|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|LTBI_prison||Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison|Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison|Completed||Phase 3|2384|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:41:40.034396|2018-06-01 01:41:40.034396
NCT00767962|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2015-08-21|2008-10-06|2008-10-07|Estimate|||||||2015-08-21|2015-08-24|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Prospective Randomised Study of Efficacy, Safety and Costs of Talc Pleurodesis Under Medical Thoracoscopy and Pleurodesis Under Video-assisted Thoracoscopy Surgery for Recurrent Primary Spontaneous Pneumothorax|A Prospective Randomised Study of Efficacy, Safety and Costs of Talc Pleurodesis Under Medical Thoracoscopy and Pleurodesis Under Video-assisted Thoracoscopy Surgery for Recurrent Primary Spontaneous Pneumothorax|Completed||N/A|62|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 01:41:40.102393|2018-06-01 01:41:40.102393
NCT00767949|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2012-04-13|2008-10-06|2008-10-07|Estimate|||||||2012-04-13|2012-04-16|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|August 2012|Anticipated|2012-08-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration|A Phase 1, Dose-Escalating, Multi-Center, Study of iSONEP (Sonepcizumab [LT1009]) Administered as an Intravitreal Injection to Subjects With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|Unknown status|Active, not recruiting|Phase 1|15|Actual|Lpath, Inc.||1|||f||||f||||||||||2018-06-01 01:41:40.16609|2018-06-01 01:41:40.16609
NCT00767936|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2016-06-28|2008-10-06|2008-10-07|Estimate|||||||2016-06-28|2016-06-29|Estimate|March 2008||2008-03-31|June 2016|2016-06-30|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Observational|||Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma|Viral and Host Factors Associated With Development of Hepatitis B Virus-related Hepatocellular Carcinoma|Terminated|||135|Actual|Stanford University|||||f||||||||||Samples Without DNA|"~     blood~   "|||2018-06-01 01:41:40.329249|2018-06-01 01:41:40.329249
NCT00767546|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-05|||2008-10-06|2008-10-06|2008-10-07|Estimate|||||||2008-10-06|2008-10-07|Estimate|May 2009||2009-05-31|October 2008|2008-10-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients|Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 01:41:44.689387|2018-06-01 01:41:44.689387
NCT00767923|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-06-02|2008-10-06|2008-10-07|Estimate|||||||2009-06-02|2009-06-04|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|February 2010|Anticipated|2010-02-28|February 2009|Actual|2009-02-28||Observational|LOA||Validation of OxyVu for Assessing Level of Amputation With Comparison to Other Modalities|Clinical Validation of HyperMed OxyVu Tissue Oximeter for Assessing Level of Amputation With Comparison to Other Modalities|Unknown status|Active, not recruiting||20|Actual|HyperMed|||||f||||f||||||||||2018-06-01 01:41:40.462687|2018-06-01 01:41:40.462687
NCT00767910|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2016-01-04|2008-10-03|2008-10-07|Estimate|||||||2016-01-04|2016-01-05|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:41:40.546763|2018-06-01 01:41:40.546763
NCT00767897|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2017-09-08|2008-10-06|2008-10-07|Estimate|||||||2017-09-08|2017-09-11|Actual|November 2011||2011-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients|The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients|Active, not recruiting|||72|Actual|Indiana University|||4||f||||t||||||||||2018-06-01 01:41:40.580965|2018-06-01 01:41:40.580965
NCT00767884|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2014-02-18|2008-10-06|2008-10-07|Estimate|||||||2014-02-18|2014-02-19|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PRP||Effect of Panretinal Photocoagulation on Optic Nerve Head Topography|Effect of Panretinal Photocoagulation on Optic Nerve Head Topography and Nerve Fiber Layer Parameters|Terminated|||9|Actual|University of Nebraska||||Low subject recruitment|f||||f||||||||||2018-06-01 01:41:40.646276|2018-06-01 01:41:40.646276
NCT00767871|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2011-07-21|2008-10-06|2008-10-07|Estimate|||||||2011-07-21|2011-07-25|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|August 2007|Actual|2007-08-31||Interventional|||Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder|Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder|Completed||Phase 4|46|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 01:41:40.707724|2018-06-01 01:41:40.707724
NCT00767858|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2018-04-04|2008-10-06|2008-10-07|Estimate|||||||2018-04-04|2018-04-05|Actual|September 24, 2008||2008-09-24|February 24, 2016|2016-02-24|February 24, 2016||2016-02-24|||||Observational|||Cultural Congruence in International Genetics Research|Cultural Congruence in International Genetics Research: Perceptions of Opportunities and Challenges Among Researchers|Terminated|||9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:41:40.783834|2018-06-01 01:41:40.783834
NCT00767845|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|||2016-11-07|2008-10-04|2008-10-07|Estimate|||||||2016-11-07|2016-11-09|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Symptom Management in African-American Men With Localized Prostate Cancer|PROSTATE CANCER SYMPTOM MANAGEMENT FOR LOW LITERACY MEN|Withdrawn|||0|Actual|Baylor College of Medicine||||No subjects were enrolled here or at UCSF.|f||||f||||||||||2018-06-01 01:41:40.842904|2018-06-01 01:41:40.842904
NCT00767832|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2009-11-06|2008-10-06|2008-10-07|Estimate|||||||2009-11-06|2009-11-09|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Thromboelastography to Assess Hemostatic Changes in Patients Undergoing Elective Cesarean Delivery.|Thromboelastography to Assess Hemostatic Changes in Patients Undergoing Elective Cesarean Delivery.|Completed|||60|Anticipated|Stanford University|||||f||||||||||None Retained|"~     Venous blood~   "|||2018-06-01 01:41:40.906156|2018-06-01 01:41:40.906156
NCT00767819|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2018-05-01|2008-10-06|2008-10-07|Estimate|||||||2018-05-01|2018-05-03|Actual|March 31, 2008|Actual|2008-03-31|May 2018|2018-05-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Treatment of Patients With RAD001 With Progressive Sarcoma|Multicenter, Triple-arm, Single-stage, Phase II Trial to Determine the Preliminary Efficacy and Safety of RAD001 in Patients With Histological Evidence of Progressive or Metastatic Bone or Soft Tissue Sarcomas|Completed||Phase 2|71|Actual|Novartis||3|||f|||||f|f||||||Undecided||2018-06-01 01:41:40.969374|2018-06-01 01:41:40.969374
NCT00767806|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2010-06-24||2010-09-30|2008-10-06|2008-10-07|Estimate|2010-09-30|2010-10-18|Estimate||||2010-09-30|2010-10-18|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study for Patient With Chronic Low Back Pain|Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain|Completed||Phase 3|401|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:41:41.128279|2018-06-01 01:41:41.128279
NCT00767793|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2015-10-01|2008-10-06|2008-10-07|Estimate|||||||2015-10-01|2015-10-02|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Ascending Dose Study of INS117548 Ophthalmic Solution in Subjects With Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma|Completed||Phase 1|84|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 01:41:42.579526|2018-06-01 01:41:42.579526
NCT00767780|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-05|2008-10-05|2008-10-07|Estimate|||||||2008-10-05|2008-10-07|Estimate|October 2006||2006-10-31|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||The Effect of a New Biomechanical Device||Completed|||200|Anticipated|Assaf-Harofeh Medical Center|||5||f||||f||||||||||2018-06-01 01:41:42.654906|2018-06-01 01:41:42.654906
NCT00767767|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2017-02-24||2018-04-30|2008-10-06|2008-10-07|Estimate|2017-02-24|2017-04-10|Actual||||2018-04-30|2018-05-30|Actual|October 2008|Actual|2008-10-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2011|Actual|2011-05-31||Interventional|||The Effect of Intravenous Anesthetics on Fear Learning and Memory|The Effect of Intravenous Anesthetics on Fear Learning and Memory|Active, not recruiting||N/A|67|Actual|Weill Medical College of Cornell University||5|||f||||f||||||||No||2018-06-01 01:41:42.737389|2018-06-01 01:41:42.737389
NCT00767754|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2011-07-21|2008-10-06|2008-10-07|Estimate|||||||2011-07-21|2011-07-25|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Interventional|||Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder|Phase 4 Study of Panic Disorder That Expresses to Change of Cerebral Glucose Metabolism After 12 Week of Paroxetine Treatment|Completed||Phase 4|37|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 01:41:43.042153|2018-06-01 01:41:43.042153
NCT00767741|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|||2013-04-03|2008-10-06|2008-10-07|Estimate|||||||2013-04-03|2013-04-04|Estimate|November 2010||2010-11-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Evaluation of the Effects of Heating or Massaging or Vibrating at the Vicinity of the Insulin Delivery Site|Evaluation of the Effects of Heating or Massaging or Vibrating at the Vicinity of the Insulin Delivery Site|Completed||N/A|100|Actual|Insuline Medical Ltd.||1|||f||||f||||||||||2018-06-01 01:41:43.113025|2018-06-01 01:41:43.113025
NCT00767728|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2009-12-21|2008-10-06|2008-10-07|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2004||2004-12-31|December 2009|2009-12-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis|Completed||Phase 3|256|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 01:41:43.178139|2018-06-01 01:41:43.178139
NCT00767715|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-07|Estimate|||||||2008-10-03|2008-10-07|Estimate|October 2004||2004-10-31|October 2008|2008-10-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Study in the Treatment of Acute Mania|A Randomized Open Label Study on the Efficacy, Tolerability, and Total Costs of Olanzapine Versus Conventional Antipsychotics in the Treatment of Acute Mania in Sweden|Terminated||Phase 4|11|Actual|Eli Lilly and Company||2||Trial discontinued due to low enrollment|f||||f||||||||||2018-06-01 01:41:43.256567|2018-06-01 01:41:43.256567
NCT00767702|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2018-05-23|2008-10-06|2008-10-07|Estimate|||||||2018-05-23|2018-05-24|Actual|September 18, 2008||2008-09-18|August 8, 2012|2012-08-08|August 8, 2012||2012-08-08|||||Observational|||Use of Population Descriptors in Human Genetic Research|Exploring the Use of Population Descriptors in Human Genetic Research|Completed|||18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:41:43.342308|2018-06-01 01:41:43.342308
NCT00767689|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-08-03|2008-10-06|2008-10-07|Estimate|||||||2009-08-03|2009-08-06|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||A Randomized Trial to Determine if Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Treated With Capecitabine Chemotherapy||Unknown status|Recruiting|N/A|96|Anticipated|John H. Stroger Hospital||2|||f||||f||||||||||2018-06-01 01:41:43.395525|2018-06-01 01:41:43.395525
NCT00767676|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|2013-10-09||2014-06-26|2008-10-06|2008-10-07|Estimate|2014-06-26|2014-06-27|Estimate||||2014-06-26|2014-06-27|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Contact Sensitization Potential of 828 Ointment|Evaluation of the Contact Sensitization Potential of 828 Ointment in Normal Healthy Adults|Completed||Phase 1|259|Actual|Healthpoint||1|||f||||f||||||||||2018-06-01 01:41:43.462852|2018-06-01 01:41:43.462852
NCT00767663|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2015-10-29|2008-10-06|2008-10-07|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|P3||Persantin Preceding Elective PCI|Does Pretreatment With Persantin Reduce Periprocedural Troponin-I Release in Patients Undergoing Elective Single Vessel PCI|Completed||Phase 4|30|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:41:43.599028|2018-06-01 01:41:43.599028
NCT00767650|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2017-06-30|2008-10-06|2008-10-07|Estimate|||||||2017-06-30|2017-07-02|Actual|September 23, 2008||2008-09-23|June 28, 2011|2011-06-28|June 28, 2011||2011-06-28|||||Observational|||Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia|Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia|Completed|||7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:41:43.673028|2018-06-01 01:41:43.673028
NCT00767637|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2014-06-19|2008-10-06|2008-10-07|Estimate|||||||2014-06-19|2014-06-20|Estimate|June 2005||2005-06-30|June 2014|2014-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone|Open Label, Non-controlled Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone in Patients With Hyperphosphatemia Receiving Dialysis|Completed||Phase 2|14|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:41:43.722002|2018-06-01 01:41:43.722002
NCT00767624|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2016-08-05||2016-10-10|2008-10-06|2008-10-07|Estimate|2016-10-10|2016-12-05|Estimate||||2016-10-10|2016-12-05|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Intent to treat|TRIAD - Treatment of Insomnia and Depression|Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants|Completed||Phase 2/Phase 3|150|Actual|Stanford University|Our results do not inform clinical guidelines for any single antidepressant medication.|2|||f||||t||||||||No||2018-06-01 01:41:43.790188|2018-06-01 01:41:43.790188
NCT00767611|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|||2012-05-09|2008-10-04|2008-10-07|Estimate|||||||2012-05-09|2012-05-10|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|||||Observational|||Molecular Markers of Human Sperm Function|Molecular Markers of Human Sperm Function|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:41:44.136482|2018-06-01 01:41:44.136482
NCT00767598|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2008-10-06|2008-10-06|2008-10-07|Estimate|||||||2008-10-06|2008-10-07|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|CYP3APDE5I||The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects|The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors(PDE5I) in Male Subjects|Completed||Phase 1|21|Actual|Inje University||3|||f||||t||||||||||2018-06-01 01:41:44.202692|2018-06-01 01:41:44.202692
NCT00767585|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-07-02|2008-10-06|2008-10-07|Estimate|||||||2009-07-02|2009-07-03|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|||||Observational|||An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice|An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice|Completed|||560|Anticipated|AstraZeneca|||8||f||||f||||||||||2018-06-01 01:41:44.280778|2018-06-01 01:41:44.280778
NCT00767572|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2012-11-09||2013-10-11|2008-10-06|2008-10-07|Estimate|2013-10-11|2013-10-14|Estimate||||2013-10-11|2013-10-14|Estimate|August 2008||2008-08-31|October 2013|2013-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Statins and Endothelial Function in Patients With Coarctation of the Aorta|Effects of Statins on Endothelial Function in Patients With Coarctation of the Aorta|Terminated||Phase 4|12|Actual|University of California, San Francisco|All patients were enrolled and completed the study interventions and assessments. Technical problems with measurements may have led to some unreliable data.|2||low enrollment|f||||t||||||||||2018-06-01 01:41:44.364188|2018-06-01 01:41:44.364188
NCT00767559|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-09-23|2008-10-06|2008-10-07|Estimate|||||||2011-09-23|2011-09-26|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|October 2012|Anticipated|2012-10-31|October 2011|Anticipated|2011-10-31||Interventional|DVT||Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery|Prophylaxis Against Thromboembolic Disease Following Orthopaedic Surgeries on Extremities|Unknown status|Active, not recruiting|N/A|330|Anticipated|The New England Baptist Hospital||3|||f||||t||||||||||2018-06-01 01:41:44.593665|2018-06-01 01:41:44.593665
NCT00767520|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2012-05-08||2013-02-22|2008-10-06|2008-10-07|Estimate|2012-05-08|2012-06-11|Estimate||||2013-02-22|2013-02-28|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer|A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (AromasinÂ®) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI)|Completed||Phase 2|155|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:41:44.878401|2018-06-01 01:41:44.878401
NCT00767507|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2013-04-23||2014-02-21|2008-10-06|2008-10-07|Estimate|2014-02-21|2014-04-04|Estimate||||2014-02-21|2014-04-04|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|Bridge|This is the Safety Population: Includs both Stage I and Stage II patients who received any study drug and were classified according to the actual treatment received. Stage I (open-label) patients were analyzed based on the dose they received; Stage II (randomized) patients were analyzed based on the actual treatment, cangrelor or placebo, received.|Maintenance of Platelet Inhibition With Cangrelor|BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry|Completed||Phase 2|221|Actual|The Medicines Company||2|||f||||t||||||||||2018-06-01 01:41:45.925651|2018-06-01 01:41:45.925651
NCT00767494|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2012-09-18|2008-10-06|2008-10-07|Estimate|||||||2012-09-18|2012-09-19|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT||Terminated||Phase 3|17|Actual|Alcon Research||4||Project Cancelled|f||||f||||||||||2018-06-01 01:41:46.506462|2018-06-01 01:41:46.506462
NCT00767481|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2012-07-18|2008-10-06|2008-10-07|Estimate|||||||2012-07-18|2012-07-19|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT||Terminated||Phase 3|6|Actual|Alcon Research||3||Project Cancelled|f||||f||||||||||2018-06-01 01:41:46.579056|2018-06-01 01:41:46.579056
NCT00767468|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|||2012-05-22|2008-10-04|2008-10-07|Estimate|||||||2012-05-22|2012-05-23|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|November 2010|Actual|2010-11-30|February 2010|Actual|2010-02-28||Interventional|||Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis|A Phase IB Study of Sorafenib for Patient With Locally Advanced or Metastatic Hepatocellular Carcinoma and Child's B Cirrhosis|Terminated||Phase 1|6|Actual|UNC Lineberger Comprehensive Cancer Center||2||Funding unavailable|f||||t||||||||||2018-06-01 01:41:46.648571|2018-06-01 01:41:46.648571
NCT00767455|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|2013-10-09||2014-01-29|2008-10-04|2008-10-07|Estimate|2014-01-29|2014-03-14|Estimate||||2014-01-29|2014-03-14|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Cumulative Irritation Potential of 828 Ointment|Evaluation of the Cumulative Irritation Potential of 828 Ointment in a Population of Normal Healthy Subjects|Completed||Phase 1|59|Actual|Healthpoint||1|||f||||f||||||||||2018-06-01 01:41:46.729647|2018-06-01 01:41:46.729647
NCT00767442|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-12-14|2008-10-06|2008-10-07|Estimate|||||||2009-12-14|2009-12-15|Estimate|December 2008||2008-12-31|December 2009|2009-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Least Invasive Nonlinear Light Microscopy|Least Invasive Nonlinear Light Microscopy|Unknown status|Recruiting||10|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 01:41:46.875348|2018-06-01 01:41:46.875348
NCT00767429|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2010-07-26|2008-10-06|2008-10-07|Estimate|||||||2010-07-26|2010-07-27|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|field||Development of an Acceleration Based Fall Risk Detector|Development of an Acceleration Based Fall Risk Detector|Unknown status|Recruiting|N/A|100|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||||2018-06-01 01:41:47.008431|2018-06-01 01:41:47.008431
NCT00767416|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03||2016-07-18|2016-07-18|2008-10-03|2008-10-07|Estimate||||2016-07-18|2016-07-20|Estimate|2016-07-18|2016-07-20|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|MEDI-559||A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children|A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-559, a Live Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus in Healthy 1 to <24 Month-Old Children|Completed||Phase 1/Phase 2|116|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 01:41:47.116182|2018-06-01 01:41:47.116182
NCT00767403|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2012-04-02|2008-10-03|2008-10-07|Estimate|||||||2012-04-02|2012-04-03|Estimate|January 2010||2010-01-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Internet Intervention for Childhood Encopresis|An Internet Intervention for Childhood Constipation and Encopresis|Completed||N/A|290|Actual|University of Virginia||3|||f||||||||||||||2018-06-01 01:41:47.295825|2018-06-01 01:41:47.295825
NCT00767390|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2015-10-12|2008-10-03|2008-10-07|Estimate|||||||2015-10-12|2015-10-14|Estimate|October 2008||2008-10-31|October 2015|2015-10-31||||||||Observational|Human Patch||CARTO 3 Human Patch Study|CARTO 3 ACL Patches Effectiveness Over Prolonged Clinical Case|Withdrawn|||0|Actual|Biosense Webster, Inc.|||1|The required results were obtained through alternate methodology|f||||f||||||||||2018-06-01 01:41:47.367983|2018-06-01 01:41:47.367983
NCT00767377|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2013-10-12|2008-10-06|2008-10-07|Estimate|||||||2013-10-12|2013-10-16|Estimate|May 2007||2007-05-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|||Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC|Phase II Trial of Epirubicin, Oxaliplatin and 5-day 5-fluorouracil in Patients With Advanced and Metastatic Gastric Cancer|Completed||Phase 2|163|Actual|Fudan University||1|||f||||f||||||||||2018-06-01 01:41:47.458072|2018-06-01 01:41:47.458072
NCT00767364|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2014-03-18||2014-06-11|2008-10-06|2008-10-07|Estimate|2014-06-11|2014-06-13|Estimate||||2014-06-11|2014-06-13|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|October 2012|Actual|2012-10-31||Interventional|||Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome|Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome: A Pilot Study|Completed||Phase 1|8|Actual|Children's Hospital of Michigan|The small sample size makes generalization of the study data difficult.|2|||f||||t||||||||||2018-06-01 01:41:47.546366|2018-06-01 01:41:47.546366
NCT00767351|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2010-07-22|2008-10-06|2008-10-07|Estimate|||||||2010-07-22|2010-07-23|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||Variation in Serum Levels of Metformin in Patients With Reduced Renal Function|Intraindividual Variation of Serum Metformin in a Cohort of Patients With Type 2 DM and Moderately Reduced Renal Function|Completed|||30|Anticipated|Skane University Hospital|||||f||||f||||||||||2018-06-01 01:41:47.860764|2018-06-01 01:41:47.860764
NCT00767338|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2012-12-12||2013-06-24|2008-10-06|2008-10-07|Estimate|2013-03-29|2013-05-08|Estimate||||2013-06-24|2013-07-02|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|VIA||Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis|A Prospective, Randomized, Study of Microsurgical Varicocelectomy Versus Observation in the Treatment of Male Partners With a Palpable Varicocele and an Abnormal Semen Analysis|Terminated||Phase 3|3|Actual|Yale University||4||"The DSMB recommended stopping the study because of concerns about the dismal recruitment, the~   drain on network resources, and the need for a study redesign."|f||||t||||||||||2018-06-01 01:41:47.921975|2018-06-01 01:41:47.921975
NCT00767325|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|2013-03-13||2013-06-24|2008-10-06|2008-10-07|Estimate|2013-06-20|2013-06-21|Estimate||||2013-06-24|2013-07-02|Estimate|December 2008||2008-12-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography|Multi-Center, Open Label Study to Assess Early Response to Abatacept With Background Methotrexate Using Power Doppler Ultrasonography in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|Completed||Phase 3|104|Actual|Bristol-Myers Squibb|Power Doppler ultrasonography values from 1 site (8 participants were excluded due to technical and quality issues with PDUS scoring and compliance issues.)|1|||f||||f||||||||||2018-06-01 01:41:48.259401|2018-06-01 01:41:48.259401
NCT00767312|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2018-03-27|2008-10-06|2008-10-07|Estimate|||||||2018-03-27|2018-03-29|Actual|October 1, 2008||2008-10-01|December 19, 2017|2017-12-19||||||||Observational|||Analysis of HIV-1 Replication During Antiretroviral Therapy|Analysis of HIV-1 Replication During Antiretroviral Therapy|Enrolling by invitation|||43|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:41:48.604421|2018-06-01 01:41:48.604421
NCT00767299|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03||2015-04-08|2015-04-08|2008-10-06|2008-10-07|Estimate||||2015-04-08|2015-04-30|Estimate|2015-04-08|2015-04-30|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of Arzoxifene to Treat Korean Women With Osteoporosis|Effects of Arzoxifene on Bone Mineral Density in Korean Postmenopausal Women With Osteoporosis|Completed||Phase 2|91|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:41:48.678828|2018-06-01 01:41:48.678828
NCT00767286|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-04|||2014-01-27|2008-10-04|2008-10-07|Estimate|||||||2014-01-27|2014-01-28|Estimate||||July 2011|2011-07-31|November 2003|Actual|2003-11-30|||||Interventional|||Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer|A PHASE III TRIAL OF THE USE OF LONG TERM TOTAL ANDROGEN SUPPRESSION FOLLOWING NEOADJUVANT HORMONAL CYTOREDUCTION AND RADIOTHERAPY IN LOCALLY ADVANCED CARCINOMA OF THE PROSTATE|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:41:48.753101|2018-06-01 01:41:48.753101
NCT00767273|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2012-06-07|2008-10-06|2008-10-07|Estimate|||||||2012-06-07|2012-06-11|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx|Pilot Study to Investigate the Role of Metabolic Imaging in Predicting Tumor Response and Outcome After Therapy for Pancreatic Cancer|Completed||N/A|30|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 01:41:48.826908|2018-06-01 01:41:48.826908
NCT00767260|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2017-09-20|2008-10-06|2008-10-07|Estimate|||||||2017-09-20|2017-09-21|Actual|March 2008||2008-03-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2012|Actual|2012-03-31||Interventional|||Bone Marrow Mononuclear Cell and Hyperbaric Oxygen Therapy in Diabetes Mellitus|Autologous Bone Marrow Mononuclear Cell Infusion With Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|82|Actual|Fuzhou General Hospital||4|||f||||t||||||||||2018-06-01 01:41:48.886583|2018-06-01 01:41:48.886583
NCT00767247|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2010-12-02|2008-10-06|2008-10-07|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|ATACA||Analysis of Antihypertensive Treatment Efficacy|Analysis of Antihypertensive Treatment Efficacy|Terminated|||2000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:41:49.036828|2018-06-01 01:41:49.036828
NCT00767234|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2016-07-06|2008-10-06|2008-10-07|Estimate|||||||2016-07-06|2016-07-11|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Permission to Collect Blood Over Time for Research|Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers|Terminated|||104|Actual|Stanford University||||Accrual issues - Low Accrual|f||||t||||||Samples Without DNA|"~     blood~   "|||2018-06-01 01:41:49.113945|2018-06-01 01:41:49.113945
NCT00767221|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-05|||2009-04-20|2008-10-05|2008-10-07|Estimate|||||||2009-04-20|2009-04-21|Estimate|October 2005||2005-10-31|April 2009|2009-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study|Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study|Completed||Phase 2|20|Anticipated|Calliditas Therapeutics AB||1|||f||||f||||||||||2018-06-01 01:41:49.173061|2018-06-01 01:41:49.173061
NCT00767208|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-06|||2009-05-19|2008-10-06|2008-10-07|Estimate|||||||2009-05-19|2009-05-20|Estimate|January 2005||2005-01-31|May 2009|2009-05-31|May 2008|Actual|2008-05-31|May 2006|Actual|2006-05-31||Interventional|||Diabetes and Metabolic Postprandial Responses|Comparison of Postprandial Metabolic Responses Between Type 2 Diabetic and Healthy Overweight Subjects|Completed||N/A|24||Centre de Recherche en Nutrition Humaine Rhone-Alpe||2|||f||||f||||||||||2018-06-01 01:41:49.237867|2018-06-01 01:41:49.237867
NCT00767195|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2010-06-06|2008-10-03|2008-10-06|Estimate|||||||2010-06-06|2010-06-08|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Power Spectral Analysis of Breath Sound in Pulmonary Edema|Power Spectral Analysis of Lung Sounds Detected at Bilateral Lung Bases in Patients With Cardiogenic and Non-cardiogenic Pulmonary Edema|Unknown status|Recruiting||60|Anticipated|Taipei Veterans General Hospital, Taiwan|||3||f||||t||||||||||2018-06-01 01:41:49.294287|2018-06-01 01:41:49.294287
NCT00767182|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2016-03-22|2008-10-03|2008-10-06|Estimate|||||||2016-03-22|2016-03-23|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|VOLUPLA||Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers|Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers - Monocentric Prospective Cohort|Completed|||40|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     plasma and serum samples~   "|No||2018-06-01 01:41:49.364377|2018-06-01 01:41:49.364377
NCT00767169|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2013-12-09|2008-10-03|2008-10-06|Estimate|||||||2013-12-09|2013-12-10|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Bisphosphonate-coated Dental Implants||Completed||Phase 2|16|Actual|University Hospital, Linkoeping||1|||f||||f||||||||||2018-06-01 01:41:49.442514|2018-06-01 01:41:49.442514
NCT00767156|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|November 2008|Anticipated|2008-11-30||Interventional|SBanti-aging||Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging|Subjective and Instrumental Evaluation of the Effects of Treatments With Two Sea Buckthorn Oil Products on Cutaneous Aging|Unknown status|Not yet recruiting|N/A|60|Anticipated|Institute of Skin and Product Evaluation, Italy||4|||f||||f||||||||||2018-06-01 01:41:49.58749|2018-06-01 01:41:49.58749
NCT00767130|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|SIM||DNA Diagnostic System for Statin Safety and Efficacy|DNA Diagnostic System for Statin Safety and Efficacy|Unknown status|Recruiting||750|Anticipated|Genomas, Inc|||3||f||||f||||||Samples With DNA|"~     DNA extracted from blood samples~   "|||2018-06-01 01:41:49.697045|2018-06-01 01:41:49.697045
NCT00767117|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-06-08|2008-10-03|2008-10-06|Estimate|||||||2011-06-08|2011-06-09|Estimate|September 2008||2008-09-30|May 2010|2010-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.|A Phase I, Open-label, Randomized Cross-over, 2-period, 2-way Interaction Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Subjects.|Completed||Phase 1|16|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:41:49.802132|2018-06-01 01:41:49.802132
NCT00767104|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2010-11-12||2017-04-05|2008-10-03|2008-10-06|Estimate|2017-04-05|2017-04-10|Actual||||2017-04-05|2017-04-10|Actual|October 2008||2008-10-31|April 2017|2017-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy of Silk - Like Bedding Fabric Pillow Case in the Treatment of Acne Vulgaris|A Study to Evaluate the Efficacy of Silk - Like Bedding Fabric, as Used in a Standard Pillow Case, in the Treatment of Acne Vulgaris|Completed||N/A|40|Actual|Wake Forest University Health Sciences|Results limited by low number of participants.|2|||f||||f||||||||No||2018-06-01 01:41:49.895449|2018-06-01 01:41:49.895449
NCT00767091|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2012-04-23|2008-10-03|2008-10-06|Estimate|||||||2012-04-23|2012-04-24|Estimate|March 2009||2009-03-31|March 2009|2009-03-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|CHoPA-I||Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentric Trial|Completed||Phase 3|40|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-06-01 01:41:50.250803|2018-06-01 01:41:50.250803
NCT00767065|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|January 2009||2009-01-31|September 2008|2008-09-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|EXACCT||Early Cardiac Computed Tomography (CT) In Patients Admitted With Acute Chest Pain|The Role of Early X-Ray Cardiac Computed Tomography in Patients Admitted With Acute Chest Pain|Unknown status|Not yet recruiting|N/A|250|Anticipated|Chelsea and Westminster NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:41:50.349528|2018-06-01 01:41:50.349528
NCT00767052|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2009-06-29|2008-10-03|2008-10-06|Estimate|||||||2009-06-29|2009-06-30|Estimate|September 2008||2008-09-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|||||Interventional|||Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236|A Randomised Single Centre Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral Multiple Ascending Daily Doses of AZD1236 Tablet by a Single-Blind, Placebo-Controlled, and Single Dose Relative Bioavailability of the Oral Suspension and Oral Tablet Formulations by an Open Cross-Over in Healthy Japanese Men|Completed||Phase 1|48|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:41:50.448378|2018-06-01 01:41:50.448378
NCT00767039|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2011-04-27||2011-09-28|2008-10-03|2008-10-06|Estimate|2011-08-15|2011-09-20|Estimate||||2011-09-28|2011-10-03|Estimate|January 2005||2005-01-31|October 2008|2008-10-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|CAST||Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants|Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome.|Terminated||Phase 4|52|Actual|Boston Medical Center|The primary limitations are the small number of patients, the high rate of chronic lung disease in the beractant group and the open-label design of the study.|2||Slow recruitment,changes in protocols, larger than anticipated differences|f||||f||||||||||2018-06-01 01:41:50.585779|2018-06-01 01:41:50.585779
NCT00767026|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-06-21|2008-10-03|2008-10-06|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||COPE Intervention for Parents of Children With Epilepsy|COPE Intervention for Parents of Children With Epilepsy|Completed||Phase 1|88|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 01:41:51.08345|2018-06-01 01:41:51.08345
NCT00767013|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2013-04-16|2008-10-03|2008-10-06|Estimate|||||||2013-04-16|2013-04-17|Estimate|May 2007||2007-05-31|April 2013|2013-04-30||||December 2013|Anticipated|2013-12-31||Interventional|||Preoperative Assessment of Aortic Valve Stenosis and Coronary Artery Disease|Preoperative Assessment of Aortic Valve Stenosis and Coronary Artery Disease: Dual-source Computed Tomography Compared With Invasive Coronary Angiography and Transthoracic Echocardiography|Unknown status|Recruiting|N/A|65|Anticipated|Luzerner Kantonsspital||1|||f||||t||||||||||2018-06-01 01:41:51.17537|2018-06-01 01:41:51.17537
NCT00767000|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2012-06-19||2015-02-02|2008-10-03|2008-10-06|Estimate|2012-07-31|2012-09-03|Estimate||||2015-02-02|2015-02-19|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin|Terminated||Phase 2|813|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-06-01 01:41:51.293805|2018-06-01 01:41:51.293805
NCT00766987|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2018-05-28|2008-10-02|2008-10-06|Estimate|||||||2018-05-28|2018-05-30|Actual|April 2007||2007-04-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Observational|CADRE||Cardiac FDG PET Viability Registry|Ontario Provincial Registry Project for Cardiac Viability Assessment Using FDG PET|Recruiting|||2000|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||f||||||||No||2018-06-01 01:41:52.276978|2018-06-01 01:41:52.276978
NCT00766974|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Compression Aided Management of Edema in Patients With C3 Venous Disease|Compression Versus Anti-Embolism Stockings in Patients With Leg Edema: Objective Investigation of Interface Compression and Edema Measurements, Clinical Outcomes, and Quality of Life.|Unknown status|Recruiting|Phase 4|40|Anticipated|BSN Medical Inc||2|||f||||f||||||||||2018-06-01 01:41:52.409764|2018-06-01 01:41:52.409764
NCT00766961|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2018-01-23|2008-10-03|2008-10-06|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2007||2007-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||TAE and Surgery in Patients With Peptic Ulcer Bleeding Uncontrolled by Endoscopic Therapy|Randomized Comparison of Trans-catheter Arterial Embolization (TAE) and Surgery in Patients With Major Peptic Ulcer Bleeding Uncontrolled by Endoscopic Therapy|Suspended||N/A|184|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:41:52.522702|2018-06-01 01:41:52.522702
NCT00766948|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2018-03-08|2008-10-02|2008-10-06|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2008||2008-08-31|March 2018|2018-03-31|August 2030|Anticipated|2030-08-31|August 2030|Anticipated|2030-08-31||Observational|||The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry|The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry|Active, not recruiting|||100|Anticipated|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Blood or Saliva~   "|||2018-06-01 01:41:52.591166|2018-06-01 01:41:52.591166
NCT00766935|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-02|2008-10-02|2008-10-06|Estimate|||||||2008-10-02|2008-10-06|Estimate|November 2007||2007-11-30|October 2008|2008-10-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Observational|||The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device|The Equivalency of the Imp SFB7+ (L-Dex U400) With the Imp XCA Device|Completed|||30|Actual|ImpediMed Limited|||2||f||||f||||||||||2018-06-01 01:41:52.64903|2018-06-01 01:41:52.64903
NCT00766909|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-11-07|2008-10-03|2008-10-06|Estimate|||||||2011-11-07|2011-11-08|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|June 2010|Actual|2010-06-30||Interventional|CSATAC||Diabetogenicity of Cyclosporine and Tacrolimus|Diabetogenicity of Cyclosporine and Tacrolimus|Completed||Phase 4|18|Actual|University of Aarhus||3|||f||||t||||||||||2018-06-01 01:41:52.707951|2018-06-01 01:41:52.707951
NCT00766896|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2013-06-20|2008-10-03|2008-10-06|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 2009||2009-07-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PLARAS||Platelet Hyperreactivity to Aspirin and Stroke|Platelet Hyperreactivity to Aspirin and Stroke: A Prospective Study With Clinical Outcomes|Completed||Phase 4|203|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 01:41:52.792516|2018-06-01 01:41:52.792516
NCT00766883|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2018-05-24|2008-10-03|2008-10-06|Estimate|||||||2018-05-24|2018-05-25|Actual|September 29, 2008||2008-09-29|September 28, 2017|2017-09-28|December 15, 2010|Actual|2010-12-15|December 15, 2010|Actual|2010-12-15||Interventional|||Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant|A Phase II Clinical Trial to Determine the Effectiveness of Problem Solving Education in Caregivers and Patients During Allogeneic HSCT|Completed||Phase 2|195|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:41:52.868549|2018-06-01 01:41:52.868549
NCT00766870|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2010-09-28|2008-10-03|2008-10-06|Estimate|||||||2010-09-28|2010-09-29|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder|A Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active-referenced Study Evaluating the Efficacy and Safety of Three Fixed Dose Regimens of Lu AA34893 in the Treatment of Major Depressive Disorder|Terminated||Phase 2|35|Actual|H. Lundbeck A/S||5||Study was previously paused and is now terminated|f||||f||||||||||2018-06-01 01:41:52.926869|2018-06-01 01:41:52.926869
NCT00766857|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2015-12-08|2008-10-03|2008-10-06|Estimate|||||||2015-12-08|2015-12-09|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure|The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial|Completed||Phase 4|27|Actual|VU University Medical Center||2|||f||||f||||||||||2018-06-01 01:41:52.992434|2018-06-01 01:41:52.992434
NCT00766844|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2013-01-21|2008-10-03|2008-10-06|Estimate|||||||2013-01-21|2013-01-23|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||Cervical Spinal Cord Stimulation for the Prevention of Cerebral Vasospasm|Cervical Spinal Cord Stimulation for the Prevention of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Using MTS Trial System 3510|Completed||Phase 1|12|Actual|University of Illinois at Chicago||1|||f||||t||||||||||2018-06-01 01:41:53.077424|2018-06-01 01:41:53.077424
NCT00766831|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2013-06-19||2013-09-13|2008-10-03|2008-10-06|Estimate|2013-06-19|2013-08-26|Estimate||||2013-09-13|2013-10-23|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain|Hydromorphone OROS in Korean Cancer Patients: Evaluation of Its Clinical Usefulness in Improvement of Sleep Disturbance|Completed||Phase 4|190|Actual|Janssen Korea, Ltd., Korea||1|||f||||t||||||||||2018-06-01 01:41:54.101354|2018-06-01 01:41:54.101354
NCT00766818|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-05-11|2008-10-03|2008-10-06|Estimate|||||||2011-05-11|2011-05-13|Estimate|January 2007||2007-01-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet|The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet: A Longitudinal Investigation in the Second and Third Trimesters Including Empiric Dosage Adjustment|Completed||Phase 1|12|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 01:41:54.600694|2018-06-01 01:41:54.600694
NCT00766805|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|Secondary||Endoscopic Variceal Ligation (EVL)+ Drugs Versus Endoscopic Variceal Ligation (EVL) Alone For Secondary Prophylaxis|Endoscopic Variceal Ligation Plus Propranolol And Isosorbide Mononitrate Versus Endoscopic Variceal Ligation Alone For Secondary Prophylaxis Of Variceal Bleeding: A Randomized Controlled Trial|Completed||N/A|177|Actual|Govind Ballabh Pant Hospital||2|||f||||f||||||||||2018-06-01 01:41:54.665667|2018-06-01 01:41:54.665667
NCT00766792|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-30|2008-10-03|2008-10-06|Estimate|||||||2008-10-30|2008-10-31|Estimate|December 2005||2005-12-31|October 2008|2008-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis|Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis|Completed||N/A|15|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:41:54.858507|2018-06-01 01:41:54.858507
NCT00766779|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2017-08-30|2008-10-03|2008-10-06|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2010||2010-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||HCT Versus CT in Elderly AML|Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission|Terminated||Phase 3|126|Actual|European Group for Blood and Marrow Transplantation||2||Recommendation of DMC|f||||t||||||||||2018-06-01 01:41:54.950554|2018-06-01 01:41:54.950554
NCT00766766|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2013-09-05|2008-10-03|2008-10-06|Estimate|||||||2013-09-05|2013-09-06|Estimate|September 2002||2002-09-30|September 2013|2013-09-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Reduction of Environmental Tobacco Smoke (ETS) Exposure In Pediatric Cancer Patients|Reduction of Environmental Tobacco Smoke (ETS) Exposure In Pediatric Cancer Patients|Completed||N/A|166|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 01:41:55.11104|2018-06-01 01:41:55.11104
NCT00766753|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2017-03-31||2018-01-10|2008-10-03|2008-10-06|Estimate|2017-03-31|2017-05-11|Actual||||2018-01-10|2018-02-07|Actual|December 2006|Actual|2006-12-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|September 2009|Actual|2009-09-30||Interventional||Patients with recurrent malignant glioma treated with novel vaccination with type 1 polarized dendritic cells ( DC1) loaded with synthetic peptides for (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and arboxymethylcellulose (poly-ICLC) who received at least one vaccine up to 4 vaccines|Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas|A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas|Completed||Phase 1/Phase 2|22|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:41:55.206565|2018-06-01 01:41:55.206565
NCT00766740|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|ATTEMPT||Long Term Clinical Efficacy of Thrombectomy Devices in Acute ST Elevation Myocardial Infarction|Individual-Patient-Data Pooled-Analysis Comparing Long Term Clinical Outcome in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention With or Without Prior Thrombectomy|Completed||Phase 4|2686|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 01:41:55.49167|2018-06-01 01:41:55.49167
NCT00766727|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2011-07-01|2008-10-03|2008-10-06|Estimate|||||||2011-07-01|2011-07-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:41:55.570586|2018-06-01 01:41:55.570586
NCT00766714|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|January 2000||2000-01-31|October 2008|2008-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Efficacy Study of the Embryo Transfer Catheter|The Efficacy of the Embryo Transfer Catheter in IVF and ICSI is Operator-Dependent: a Randomized Clinical Trial|Completed||N/A|1446|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:41:55.60091|2018-06-01 01:41:55.60091
NCT00766701|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|January 2003||2003-01-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Spectroscopic Evaluation of Cervical Neoplasia|Pivotal Study for Assessment of Cervical Neoplasia Using Fluorescence and Reflectance Spectroscopy|Completed|||1599|Actual|Guided Therapeutics|||||f||||t||||||Samples With DNA|"~     histology slides~   "|||2018-06-01 01:41:55.666217|2018-06-01 01:41:55.666217
NCT00766688|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03||2016-04-15|2016-04-15|2008-10-03|2008-10-06|Estimate||||2016-04-15|2016-05-16|Estimate|2016-04-15|2016-05-16|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia|A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AVE5530 When Added to Ongoing Stable Statin Therapy at High Doses in Patients With Severe Primary Hypercholesterolemia|Terminated||Phase 3|643|Actual|Sanofi||3||AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|f||||f||||||||||2018-06-01 01:41:55.738199|2018-06-01 01:41:55.738199
NCT00766675|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2013-02-18||2013-05-29|2008-10-03|2008-10-06|Estimate|2013-05-29|2013-07-03|Estimate||||2013-05-29|2013-07-03|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||An Efficacy Study of Combination of Tramadol and Acetaminophen Tablets in the Treatment of Participants With Fibromyalgia Pain|Ultracet (Tramadol HCL [37.5 mg]/Acetaminophen [325 mg]) Combination Tablets in the Treatment of the Pain of Fibromyalgia|Completed||Phase 4|80|Actual|Johnson & Johnson Taiwan Ltd||1|||f||||f||||||||||2018-06-01 01:41:55.889381|2018-06-01 01:41:55.889381
NCT00766662|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|October 2006||2006-10-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Intermittent Preventive Treatment in Infant in Mali||Completed||N/A|||University of Bamako|||||f||||f||||||||||2018-06-01 01:41:56.453917|2018-06-01 01:41:56.453917
NCT00766649|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2013-04-15||2014-04-07|2008-10-03|2008-10-06|Estimate|2013-06-27|2013-07-01|Estimate||||2014-04-07|2014-05-01|Estimate|October 2008||2008-10-31|April 2014|2014-04-30|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|SIRGA||Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD|Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration|Completed||Phase 1/Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 01:41:56.556032|2018-06-01 01:41:56.556032
NCT00766636|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2015-08-19||2016-04-18|2008-10-03|2008-10-06|Estimate|2015-08-19|2015-09-18|Estimate||||2016-04-18|2016-05-19|Estimate|September 2008||2008-09-30|August 2015|2015-08-31||||November 2012|Actual|2012-11-30||Interventional||One participant in Gemcitabine + Erlotinib with Radiation did not receive any treatment.|Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy|A Randomized Phase II Study of Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy for Patients With Resectable Adenocarcinoma of the Pancreas|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||t||||||||||2018-06-01 01:41:56.838677|2018-06-01 01:41:56.838677
NCT00766623|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2009-09-28|2008-10-03|2008-10-06|Estimate|||||||2009-09-28|2009-09-29|Estimate|October 2008||2008-10-31|September 2009|2009-09-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|EMPEF||Elucidation and Monitoring Postprandial Endothelial Function|Elucidation and Monitoring Postprandial Endothelial Function|Completed||N/A|20|Anticipated|Wageningen University||6|||f||||f||||||||||2018-06-01 01:41:57.038145|2018-06-01 01:41:57.038145
NCT00766415|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2010-11-30||2014-01-27|2008-10-03|2008-10-06|Estimate|2014-01-27|2014-02-28|Estimate||||2014-01-27|2014-02-28|Estimate|November 2008||2008-11-30|January 2014|2014-01-31|June 2009|Actual|2009-06-30|||||Interventional|Biopsy|One patient randomised to the placebo group voluntarily discontinued from the study after randomisation before receiving any investigational product. This patient is excluded from the analysis.|14729-D9831C00002- 1 Month Biopsy Study|A Double-blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|52|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 01:41:59.666541|2018-06-01 01:41:59.666541
NCT00766597|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2015-11-12||2015-12-28|2008-10-03|2008-10-06|Estimate|2015-12-28|2016-02-01|Estimate||||2015-12-28|2016-02-01|Estimate|August 2009||2009-08-31|December 2015|2015-12-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional||The HIV-1 infected antiretroviral therapy experienced participants With CCR5-tropic virus who started treatment in Step II|Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents|Phase I/II Open-Label Study to Evaluate the PK, Safety, Tolerability and Antiviral Activity of Vicriviroc, a Novel CCR5 Antagonist in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents|Completed||Phase 1/Phase 2|9|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Study was terminated early with Merck's announcement on July 15, 2010 on the discontinuation of the development of Vicriviroc, with 4 participants given study drug and only 1 participant reached Week 24.|1|||f||||||||||||||2018-06-01 01:41:57.123119|2018-06-01 01:41:57.123119
NCT00766584|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2018-03-08|2008-10-03|2008-10-06|Estimate|||||||2018-03-08|2018-03-09|Actual|January 15, 2003|Actual|2003-01-15|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|SYNAPSE||Autonomic Nervous System Activity, Aging and Sleep Apnea/Hypopnea|Autonomic Nervous System Activity, Aging and Sleep Apnea/Hypopnea in a Prospective Cohort of Subjects Aged 67 Years|Active, not recruiting|||852|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-06-01 01:41:57.343745|2018-06-01 01:41:57.343745
NCT00766571|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2018-05-24|2008-10-03|2008-10-06|Estimate|||||||2018-05-24|2018-05-25|Actual|September 29, 2008||2008-09-29|June 29, 2017|2017-06-29|June 29, 2017||2017-06-29|||||Observational|||Clinical and Genetic Studies of VACTERL Association|Clinical and Genetic Studies of VACTERL Association|Completed|||304|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:41:57.508751|2018-06-01 01:41:57.508751
NCT00766558|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2017-06-16|2008-10-03|2008-10-06|Estimate|||||||2017-06-16|2017-06-20|Actual|June 2009||2009-06-30|June 2017|2017-06-30|July 2013|Actual|2013-07-31|June 2010|Actual|2010-06-30||Observational|||The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population|Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology|Completed|||29|Actual|Milton S. Hershey Medical Center|||2||f||||t||||||||||2018-06-01 01:41:57.573626|2018-06-01 01:41:57.573626
NCT00766545|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2009-01-08|2008-10-03|2008-10-06|Estimate|||||||2009-01-08|2009-01-12|Estimate|April 1992||1992-04-30|January 2009|2009-01-31|March 1997|Actual|1997-03-31|March 1997|Actual|1997-03-31||Interventional|CSPS||Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.|Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.|Completed||Phase 3|1095|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-06-01 01:41:57.647494|2018-06-01 01:41:57.647494
NCT00766532|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2012-07-06||2012-09-13|2008-10-02|2008-10-06|Estimate|2012-09-13|2012-09-14|Estimate||||2012-09-13|2012-09-14|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?|Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?|Completed||Phase 4|12|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 01:41:57.719593|2018-06-01 01:41:57.719593
NCT00766519|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2013-11-18|2008-10-03|2008-10-06|Estimate|||||||2013-11-18|2013-11-19|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|EVOLUTION||Effect of Intraoperative Volume Optimization on Outcome After Intrabdominal Surgery|Effect of Intraoperative Volume Optimization on Outcome After Intrabdominal Surgery: a Multicenter, Randomized, Double-blind, Comparative Study|Completed||Phase 4|104|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-06-01 01:41:57.852533|2018-06-01 01:41:57.852533
NCT00766506|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2013-01-21||2013-03-14|2008-10-03|2008-10-06|Estimate|2013-03-14|2013-04-25|Estimate||||2013-03-14|2013-04-25|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery|Comparison of Ionsys and Routine Care With Morphine IV (Intravenous) PCA in the Management of Early Post-operative Mobilisation, Ability to Mobilise and in Time to Fitness For Discharge|Terminated||Phase 4|108|Actual|Janssen-Cilag Ltd.|Study was temporarily stopped due to an issue with a batch of drug outside the study and later permanently stopped.|2||Product class one recall|f||||f||||||||||2018-06-01 01:41:57.963431|2018-06-01 01:41:57.963431
NCT00766493|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|2012-06-28||2016-08-22|2008-10-03|2008-10-06|Estimate|2012-06-28|2012-08-07|Estimate||||2016-08-22|2016-09-29|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|EMBOLDEN||GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN)|GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (GORE EMBOLDEN)|Completed||Phase 3|250|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-06-01 01:41:58.525136|2018-06-01 01:41:58.525136
NCT00766480|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2013-08-23|2008-10-03|2008-10-06|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2007||2007-01-31|July 2009|2009-07-31||||March 2010|Anticipated|2010-03-31||Interventional|||Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus|An Investigational Study of Chemoradiosensitivity Prediction With Genetic Profiling of Esophageal Biopsy for Squamous Cell Carcinoma of the Esophagus|Unknown status|Recruiting|N/A|160|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:41:58.832767|2018-06-01 01:41:58.832767
NCT00766467|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2016-03-04||2016-06-17|2008-10-02|2008-10-06|Estimate|2016-06-17|2016-07-28|Estimate||||2016-06-17|2016-07-28|Estimate|September 2008||2008-09-30|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas|A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment|Completed||Phase 2|81|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 01:41:58.960644|2018-06-01 01:41:58.960644
NCT00766454|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2017-07-27|2008-10-03|2008-10-06|Estimate|||||||2017-07-27|2017-08-01|Actual|November 1998||1998-11-30|October 2015|2015-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer|Metabolic Genotypes and Oncogenic Damage in Breast Cancer|Completed|||1104|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 01:41:59.362492|2018-06-01 01:41:59.362492
NCT00766441|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2010-01-11|2008-10-03|2008-10-06|Estimate|||||||2010-01-11|2010-01-12|Estimate|August 2008||2008-08-31|October 2008|2008-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan|Sitagliptin Versus Sulphonylurea Based Treatments in Muslim Patients With Type 2 Diabetes During Ramadan|Terminated||Phase 4|22|Actual|University of Manchester||2||inadequate recruitment|f||||t||||||||||2018-06-01 01:41:59.446629|2018-06-01 01:41:59.446629
NCT00766402|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2014-10-14|2008-10-03|2008-10-06|Estimate|||||||2014-10-14|2014-10-15|Estimate|October 2008||2008-10-31|October 2014|2014-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)|A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet®) vs. Diclofenac (Voltaren®) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)|Terminated||Phase 4|8|Actual|Johnson & Johnson Taiwan Ltd||2|||f||||f||||||||||2018-06-01 01:42:00.135993|2018-06-01 01:42:00.135993
NCT00766389|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-03|||2008-10-03|2008-10-03|2008-10-06|Estimate|||||||2008-10-03|2008-10-06|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|February 2009|Anticipated|2009-02-28|December 2008|Anticipated|2008-12-31||Observational|||Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus Optical Coherence Tomography (OCT)|Retinal Nerve Fiber Layer Thickness Analysis With Cirrus HD OCT Versus Stratus OCT|Unknown status|Recruiting||200|Anticipated|Yonsei University|||2||f||||f||||||||||2018-06-01 01:42:00.211431|2018-06-01 01:42:00.211431
NCT00766376|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2010-01-06||2010-01-06|2008-10-01|2008-10-03|Estimate|2010-01-06|2010-01-29|Estimate||||2010-01-06|2010-01-29|Estimate|July 2007||2007-07-31|January 2010|2010-01-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Safety and Efficacy Evaluation of Erbium Treatment|Safety and Efficacy Evaluation of Fractional Erbium Treatment|Unknown status|Active, not recruiting|N/A|151|Actual|Palomar Medical Technologies, Inc.|||||f||||f||||||||||2018-06-01 01:42:00.294652|2018-06-01 01:42:00.294652
NCT00766363|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2011-06-16||2012-04-18|2008-10-02|2008-10-03|Estimate|2011-06-16|2011-07-14|Estimate||||2012-04-18|2012-04-20|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease|Completed||Phase 1|49|Actual|FORUM Pharmaceuticals Inc||4|||f||||f||||||||||2018-06-01 01:42:00.4573|2018-06-01 01:42:00.4573
NCT00766350|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2014-12-01|2008-10-02|2008-10-03|Estimate|||||||2014-12-01|2014-12-03|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|||Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia|A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia|Completed||Phase 4|90|Actual|Universidad de Granada||2|||f||||f||||||||||2018-06-01 01:42:00.976853|2018-06-01 01:42:00.976853
NCT00766337|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2013-01-08|2008-10-01|2008-10-03|Estimate|||||||2013-01-08|2013-01-10|Estimate|December 2008||2008-12-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|EMERALD||Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration|A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|Terminated||Phase 2|62|Actual|Santen Inc.||3|||f||||f||||||||||2018-06-01 01:42:01.062067|2018-06-01 01:42:01.062067
NCT00766324|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02||2014-05-13|2014-05-13|2008-10-02|2008-10-03|Estimate||||2014-05-13|2014-05-28|Estimate|2014-05-13|2014-05-28|Estimate|September 2007||2007-09-30|May 2014|2014-05-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||PHA-739358 for Treatment of Hormone Refractory Prostate Cancer|A Phase II Study of PHA-739358 in Patients With Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|118|Actual|Nerviano Medical Sciences||2|||f||||f||||||||||2018-06-01 01:42:01.145975|2018-06-01 01:42:01.145975
NCT00766311|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2012-01-05|2008-10-02|2008-10-03|Estimate|||||||2012-01-05|2012-01-09|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|XRCISL||Aerobic and Strengthening Exercise for Acute Leukemia|Aerobic and Strengthening Exercise for Acute Leukemia|Completed||N/A|20|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 01:42:01.208836|2018-06-01 01:42:01.208836
NCT00766298|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2017-07-26|2008-10-02|2008-10-03|Estimate|||||||2017-07-26|2017-07-31|Actual|June 2004||2004-06-30|July 2017|2017-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SHELL||Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss|Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss|Completed||N/A|102|Actual|University of Pittsburgh||3|||f||||t||||||||No||2018-06-01 01:42:01.281038|2018-06-01 01:42:01.281038
NCT00766285|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2015-07-30|2008-10-02|2008-10-03|Estimate|||||||2015-07-30|2015-08-03|Estimate||||December 2009|2009-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||High Dose Influenza in Immunosuppressed Subjects|Safety and Immunogenicity of High Dose Baculovirus-Expressed Recombinant Trivalent HA Influenza Vaccine in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: Phase II Double-Blind Trial|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 01:42:01.353165|2018-06-01 01:42:01.353165
NCT00766272|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2013-09-19|2008-10-02|2008-10-03|Estimate|||||||2013-09-19|2013-09-23|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Lokomat Training Effects on MS Gait Abnormalities|Gait Rehabilitation for Multiple Sclerosis Using Robot-assisted Body-weight-supported Treadmill Training (Lokomat)|Terminated||Phase 1/Phase 2|20|Actual|VA Office of Research and Development||1||Study re-designed|f||||f||||||||||2018-06-01 01:42:01.42971|2018-06-01 01:42:01.42971
NCT00766259|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-02|2008-10-02|2008-10-03|Estimate|||||||2008-10-02|2008-10-03|Estimate|July 2009||2009-07-31|October 2008|2008-10-31|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Observational|||Relationship of Staphylococcal Colonization to Infection|Relationship of Staphylococcal Colonization to Infection|Unknown status|Not yet recruiting||4400|Anticipated|Veterans BioMedical Research Institute|||6||f||||f||||||None Retained|"~     only bacterial strains collected~   "|||2018-06-01 01:42:01.486242|2018-06-01 01:42:01.486242
NCT00766246|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2016-04-18|2008-10-02|2008-10-03|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase II Avastin Trial for Stage IIIB/IV NSCLC|A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer|Terminated||Phase 2|125|Actual|Pharmatech||2||Withdrawal of funding support|f||||t||||||||Yes||2018-06-01 01:42:01.539831|2018-06-01 01:42:01.539831
NCT00766233|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2016-01-15|2008-10-02|2008-10-03|Estimate|||||||2016-01-15|2016-01-18|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Optimal Application Dose of Superficial Hyperthermia|Phase III Study for Analysis of the Optimal Application Dose of Superficial Hyperthermia|Unknown status|Active, not recruiting|Phase 3|17|Actual|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-06-01 01:42:01.646822|2018-06-01 01:42:01.646822
NCT00766220|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2012-12-28|2008-10-02|2008-10-03|Estimate|||||||2012-12-28|2013-01-03|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver|Phase II Randomized Study of SIR-Spheres, Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Metastases to the Liver|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2||Slow Accrual and withdrawn/exclusion of 2 participants.|f||||t||||||||||2018-06-01 01:42:01.708701|2018-06-01 01:42:01.708701
NCT00766207|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2011-05-11|2008-10-02|2008-10-03|Estimate|||||||2011-05-11|2011-05-12|Estimate|October 2008||2008-10-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|April 2010|Actual|2010-04-30||Interventional|PREVENT||Electronic Notification of Teratogenic Risks|Preconception Risk Evaluation Via Electronic Medical Record Notification of Teratogenic Risks|Completed||N/A|2593|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:42:01.781945|2018-06-01 01:42:01.781945
NCT00766194|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2013-09-10|2008-10-02|2008-10-03|Estimate|||||||2013-09-10|2013-09-12|Estimate|May 2007||2007-05-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Nasopharyngeal Pressure Measurement During Neonatal Nasal Respiratory Support|Nasopharyngeal Pressure Measurement During Neonatal Nasal Respiratory Support|Terminated|||20|Actual|University of Utah||||slow enrollment|f||||f||||||||||2018-06-01 01:42:01.863449|2018-06-01 01:42:01.863449
NCT00766181|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2010-05-24|2008-10-02|2008-10-03|Estimate|||||||2010-05-24|2010-05-25|Estimate|October 2008||2008-10-31|November 2008|2008-11-30|April 2009|Anticipated|2009-04-30|February 2009|Anticipated|2009-02-28||Observational|||Satisfaction With Pediatric Intravenous Catheter Placement in the Emergency Department|An Evaluation of Parent and Nurse Satisfaction Associated With Pediatric Peripheral Intravenous Catheter Placement Using Standard of Care vs. ZingoTM in the Emergency Department|Terminated|||200|Anticipated|Anesiva, Inc.|||2|Product withdrawn from distribution|f||||f||||||||||2018-06-01 01:42:01.919132|2018-06-01 01:42:01.919132
NCT00766168|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2012-06-12|2008-10-02|2008-10-03|Estimate|||||||2012-06-12|2012-06-14|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|PVS-07-07||High Refractive Index Material 510(k)|Prospective Study of Substantial Equivalence of Rigid Gas Permeable HDS HI 1.54™ Daily Wear Lenses for Correction of Naturally Occurring Myopia and Hyperopia From +20 to - 20 D Sphere (Spectacle Plane) With and Without Astigmatism.|Completed||N/A|76|Actual|Paragon Vision Sciences||2|||f||||f||||||||||2018-06-01 01:42:01.998775|2018-06-01 01:42:01.998775
NCT00766155|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2016-10-11|2008-10-02|2008-10-03|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2008||2008-08-31|October 2016|2016-10-31||||September 2011|Actual|2011-09-30||Interventional|PETACC-6||Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer|Preoperative Chemoradiotherapy and Postoperative Chemotherapy With Capecitabine and Oxaplatin vs.Capecitabine Alone in Locally Advanced Rectal Cancer (PETACC-6)|Completed||Phase 3|1094|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 01:42:02.106798|2018-06-01 01:42:02.106798
NCT00766142|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2009-07-07|2008-10-02|2008-10-03|Estimate|||||||2009-07-07|2009-07-08|Estimate|May 2007||2007-05-31|July 2009|2009-07-31||||December 2009|Anticipated|2009-12-31||Interventional|||Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer|Clinical Phase II Study Evaluating Systemic Chemotherapy in Combination With Cetuximab as Adjuvant Treatment in Patients With Completely Surgically Resected Peritoneal Carcinomatosis of Colorectal Origin|Unknown status|Recruiting|Phase 2|46|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:42:02.310235|2018-06-01 01:42:02.310235
NCT00766129|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2011-07-04|2008-10-02|2008-10-03|Estimate|||||||2011-07-04|2011-07-06|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Comparison of Safety and Efficacy of Two Different Drug Eluting Stents Implanted Into Saphenous Vein Grafts|Comparison of Safety and Efficacy of Drug Eluting Stents : TAXUS (Boston Scientific) vs. LUC-Chopin (Balton, Poland) Implanted Into Saphenous Vein Grafts. Study With Serial Intravascular Ultrasounds.|Unknown status|Active, not recruiting|Phase 3|50|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-06-01 01:42:02.402278|2018-06-01 01:42:02.402278
NCT00766116|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2017-08-11|2008-10-02|2008-10-03|Estimate|||||||2017-08-11|2017-08-15|Actual|July 2005||2005-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|June 2015|Actual|2015-06-30||Interventional|||Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)|A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML|Active, not recruiting||Phase 1/Phase 2|50|Actual|University of California, San Diego||1|||f||||t||||||||||2018-06-01 01:42:02.493596|2018-06-01 01:42:02.493596
NCT00766103|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2016-10-19|2008-10-02|2008-10-03|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of PaCO2 Levels on Cerebral Metabolism and Perfusion During Induced Hypothermia.|The Effects of PaCO2 Levels on Cerebral Metabolism and Perfusion During Induced Hypothermia.|Completed||N/A|8|Actual|Tampere University Hospital||1|||f||||||||||||||2018-06-01 01:42:02.619793|2018-06-01 01:42:02.619793
NCT00766090|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2013-06-06|2010-02-05|2016-10-26|2008-10-02|2008-10-03|Estimate|2013-06-06|2013-08-07|Estimate|2010-02-05|2010-02-10|Estimate|2016-10-26|2016-12-08|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma|A Multi-Centre, Randomized, Double Blind Cross-over Study to Assess the Non-inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma|Completed||Phase 2|190|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:42:02.748134|2018-06-01 01:42:02.748134
NCT00766077|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2010-04-12|2008-10-02|2008-10-03|Estimate|||||||2010-04-12|2010-04-14|Estimate|September 2008||2008-09-30|April 2010|2010-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Bone Geometry, Strength, and Biomechanical Changes in Runners With a History of Stress Fractures|Bone Geometry, Strength, and Biomechanical Changes in Runners With a History of Stress Fractures|Completed|||32|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:42:03.586314|2018-06-01 01:42:03.586314
NCT00766051|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2011-04-04||2016-11-14|2008-10-02|2008-10-03|Estimate|2012-09-09|2012-09-11|Estimate||||2016-11-14|2017-01-02|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|March 2010|Actual|2010-03-31|June 2008|Actual|2008-06-30||Interventional|NBOTI||A Study of Neurophysiologically Based Occupational Therapy Intervention (NBOTI) for Feeding in the NCCU.|The Efficacy of Neurophysiologically Based Occupational Therapy Intervention in the Neonatal Intensive Care Unit: An Exploratory Study|Completed||N/A|10|Actual|University of Utah|The limitation of this study is that the effectiveness of the neurophysiologically based occupational therapy intervention applies to the diagnostic groups of the infants that participated in this study.|2|||f||||f||||||||||2018-06-01 01:42:03.718529|2018-06-01 01:42:03.718529
NCT00766038|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-12-31|2008-09-30|2008-10-03|Estimate|||||||2015-12-31|2016-01-01|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|Growth-TBI||Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.|A Phase II, Randomized Controlled Trial of Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.|Completed||Phase 2|63|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 01:42:03.957634|2018-06-01 01:42:03.957634
NCT00766025|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2009-02-27|2008-10-02|2008-10-03|Estimate|||||||2009-02-27|2009-03-02|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|||||Interventional|||Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin|A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium|Completed||Phase 1|50|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:42:04.027145|2018-06-01 01:42:04.027145
NCT00766012|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2009-08-24|2008-10-02|2008-10-03|Estimate|||||||2009-08-24|2009-08-25|Estimate|September 2008||2008-09-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|||||Interventional|||Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects|A Phase I, Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Oral Doses of AZD2066 in Japanese Healthy Male Subjects|Completed||Phase 1|132|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:42:04.094525|2018-06-01 01:42:04.094525
NCT00765999|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2013-01-11|2008-10-02|2008-10-03|Estimate|||||||2013-01-11|2013-01-15|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation|An Open-Label, Long-Term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation|Completed||Phase 3|1557|Actual|Forest Laboratories||1|||f||||f||||||||||2018-06-01 01:42:04.183076|2018-06-01 01:42:04.183076
NCT00765986|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2014-10-02|2008-10-02|2008-10-03|Estimate|||||||2014-10-02|2014-10-03|Estimate|October 2008||2008-10-31|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Observational|||Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy|A Study to See if a New Type of Imaging Can Help Our Understanding of the Course of Non-small Cell Lung Cancer in Patients Undergoing Treatment With Radiotherapy or Chemoradiotherapy|Unknown status|Recruiting||30|Anticipated|AHS Cancer Control Alberta|||1||f||||f||||||||||2018-06-01 01:42:04.389829|2018-06-01 01:42:04.389829
NCT00765973|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2017-10-16|2008-10-02|2008-10-03|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2008||2008-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors|A Phase 1 Study of Topotecan Liposomes Injection (TLI) in Subjects With Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors|Active, not recruiting||Phase 1|50|Anticipated|Spectrum Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:42:04.457483|2018-06-01 01:42:04.457483
NCT00765960|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2011-08-11|2008-10-02|2008-10-03|Estimate|||||||2011-08-11|2011-08-12|Estimate|September 2008||2008-09-30|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Observational|iLASIK||Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure|Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure|Terminated|||0|Actual|Medical University of South Carolina||||Prinicipal Investigator separating employment from University.|f||||f||||||||||2018-06-01 01:42:05.409414|2018-06-01 01:42:05.409414
NCT00765947|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2010-12-13||2011-03-08|2008-10-02|2008-10-03|Estimate|2010-12-13|2011-01-11|Estimate||||2011-03-08|2011-03-11|Estimate|September 2008||2008-09-30|March 2011|2011-03-31|August 2009||2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension|A Twenty-four Week, Open-label, Non-comparative, Multi-center Study to Assess the Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension.|Completed||Phase 4|256|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:42:05.473181|2018-06-01 01:42:05.473181
NCT00765934|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2010-05-17|2008-10-02|2008-10-03|Estimate|||||||2010-05-17|2010-05-18|Estimate|November 2009||2009-11-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Influence of Rapydan on Clinical Chemistry and Hematology Measurements|Does Rapydan Influence Routine Clinical Chemistry and Hematology Measurements?|Completed||N/A|25|Anticipated|LabNoord||1|||f||||t||||||||||2018-06-01 01:42:05.654001|2018-06-01 01:42:05.654001
NCT00765921|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2016-12-01|2008-10-02|2008-10-03|Estimate|||||||2016-12-01|2016-12-02|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma|A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma|Completed||Phase 1|40|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||f||||||||No||2018-06-01 01:42:05.724218|2018-06-01 01:42:05.724218
NCT00765908|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2008-10-02|2008-10-02|2008-10-03|Estimate|||||||2008-10-02|2008-10-03|Estimate|October 2008||2008-10-31|August 2008|2008-08-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Ischaemic Pre-Conditioning in Elective Percutaneous Coronary Intervention (PCI) Patients|Ischaemic Pre-Conditioning in Elective PCI Patients - Attenuation of Subsequent Ischaemia in a Validated Animal Model|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:42:05.795427|2018-06-01 01:42:05.795427
NCT00765895|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2014-04-09||2015-04-15|2008-10-02|2008-10-03|Estimate|2015-04-15|2015-04-16|Estimate||||2015-04-15|2015-04-16|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|NORIG||Nortriptyline for Idiopathic Gastroparesis|Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)|Completed||Phase 3|130|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 01:42:05.880284|2018-06-01 01:42:05.880284
NCT00765882|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2012-09-28|2011-09-30|2012-12-19|2008-10-02|2008-10-03|Estimate|2012-12-19|2013-01-30|Estimate|2011-09-30|2011-10-05|Estimate|2012-12-19|2013-01-30|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks in Patients With Chronic Constipation|Completed||Phase 3|633|Actual|Forest Laboratories||3|||f||||||||||||||2018-06-01 01:42:06.675925|2018-06-01 01:42:06.675925
NCT00765869|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2008-10-02|2008-10-02|2008-10-03|Estimate|||||||2008-10-02|2008-10-03|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|February 2009|Anticipated|2009-02-28|December 2008|Anticipated|2008-12-31||Interventional|||Randomised Controlled Trial of a Literacy Sensitive Decision Aid for Bowel Cancer Screening|A Randomised Controlled Trial of a Bowel Cancer Screening Decision Aid for Adults With Low Education and Literacy|Unknown status|Recruiting|N/A|555|Anticipated|University of Sydney||3|||f||||f||||||||||2018-06-01 01:42:07.348922|2018-06-01 01:42:07.348922
NCT00765856|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2015-06-10|2008-10-02|2008-10-03|Estimate|||||||2015-06-10|2015-06-12|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects|An Open-Label Safety and Tolerability Study of Immediate-Release and Extended-Release Oxymorphone in Opioid-Tolerant Pediatric Subjects With Chronic Pain.|Terminated||Phase 3|27|Actual|Endo Pharmaceuticals||1||Terminated new protocol developed which incorporated Pharmacokinetics|f||||f||||||||||2018-06-01 01:42:07.444995|2018-06-01 01:42:07.444995
NCT00765843|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2014-04-28||2014-06-19|2008-10-02|2008-10-03|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Trial of Custom Foot Orthoses for the Treatment of Plantar Heel Pain|A Randomized Controlled Trial of Custom Foot Orthoses for the Treatment of Plantar Heel Pain|Completed||N/A|77|Actual|Rosalind Franklin University of Medicine and Science||3|||f||||f||||||||||2018-06-01 01:42:07.545645|2018-06-01 01:42:07.545645
NCT00765830|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02||2013-01-02|2013-01-02|2008-10-02|2008-10-03|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-02|2013-01-04|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)|A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency|Completed||Phase 3|349|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:42:07.847809|2018-06-01 01:42:07.847809
NCT00765817|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2011-01-04||2016-10-21|2008-10-01|2008-10-03|Estimate|2011-01-04|2011-01-26|Estimate||||2016-10-21|2016-10-24|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||One subject per group withdrew from the study prior to the first dose of study medication and therefore are not part of the baseline or subsequent analysis.|Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus|A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications|Completed||Phase 3|261|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:42:08.11437|2018-06-01 01:42:08.11437
NCT00765804|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02||2010-08-20|2010-08-27|2008-10-02|2008-10-03|Estimate||||2010-08-20|2010-08-25|Estimate|2010-08-27|2010-08-31|Estimate|October 2008||2008-10-31|August 2010|2010-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye|Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for Treatment of Dry Eye in the Controlled Adverse Environment Model|Completed||Phase 2|89|Actual|Eyegate Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 01:42:08.848768|2018-06-01 01:42:08.848768
NCT00765791|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2013-12-17|2008-10-02|2008-10-03|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 2008||2008-12-31|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|2B/Not 2B||Shoulder Function After Level IIB Neck Dissection: A Randomized Controlled Study|Shoulder Function After Level IIB Neck Dissection: A Randomized Controlled|Unknown status|Enrolling by invitation|Early Phase 1|32|Anticipated|University of Alberta||2|||f||||t||||||||||2018-06-01 01:42:08.931283|2018-06-01 01:42:08.931283
NCT00765778|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-15|2008-10-02|2008-10-03|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|January 2014|Anticipated|2014-01-31|October 2009|Anticipated|2009-10-31||Observational|||Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community|Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community:the Role of Family Members and Caregivers in Dissemination of MDR in Rehabilitation Centers|Unknown status|Not yet recruiting||400|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 01:42:09.012543|2018-06-01 01:42:09.012543
NCT00765765|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2013-11-06||2013-11-06|2008-10-02|2008-10-03|Estimate|2013-11-06|2013-12-25|Estimate||||2013-11-06|2013-12-25|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer|Phase I/II Study of Ixabepilone in Combination With the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients With Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|6|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||f||||||||||2018-06-01 01:42:09.099225|2018-06-01 01:42:09.099225
NCT00765752|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2013-01-18|2008-10-02|2008-10-03|Estimate|||||||2013-01-18|2013-01-21|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Cortical GABA Concentrations in Insomnia|The Association of Cortical GABA Concentrations in Subjects With Primary Insomnia and Depression in Partial Remission With Residual Insomnia|Completed|||23|Actual|Yale University|||2||f||||f||||||||||2018-06-01 01:42:09.320623|2018-06-01 01:42:09.320623
NCT00765739|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2013-01-23|2008-10-02|2008-10-03|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|NMES||The Effect of Neuromuscular Electrical Stimulation (NMES)|The Effect of Neuromuscular Electrical Stimulation (NMES) in Inducing Muscle Hypertrophy and Improvement in Muscle Torque Output Within the Quadriceps Muscle of Elderly People|Completed||Phase 2|23|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 01:42:09.392031|2018-06-01 01:42:09.392031
NCT00765726|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2011-12-16||2011-12-16|2008-10-02|2008-10-03|Estimate|2011-12-16|2012-01-20|Estimate||||2011-12-16|2012-01-20|Estimate|February 2009||2009-02-28|December 2011|2011-12-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Study Evaluating The Safety Of Xyntha In Usual Care Settings|A Postauthorization Safety Surveillance Study Of Xyntha In Usual Care Settings|Terminated||Phase 4|12|Actual|Pfizer|The study was discontinued because the sponsor had ongoing studies collecting similar safety data.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:42:09.484251|2018-06-01 01:42:09.484251
NCT00765713|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2013-04-01|2008-10-02|2008-10-03|Estimate|||||||2013-04-01|2013-04-02|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|SAHS-ICD||Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias|Sleep Apnea-hypopnea Syndrome and Ventricular Arrhythmias in Patients With Systolic Ventricular Dysfunction and Implantable Cardioverter-defibrillator. Incidence and Effect of CPAP Treatment|Completed||Phase 4|224|Actual|Hospital Universitario La Paz||2|||f||||f||||||||||2018-06-01 01:42:09.683879|2018-06-01 01:42:09.683879
NCT00765700|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01||2013-09-17|2013-09-20|2008-10-02|2008-10-03|Estimate||||2013-09-20|2013-09-27|Estimate|2013-09-20|2013-09-27|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel™ (Ketoprofen Topical Cream 10%) in the Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury.|Completed||Phase 3|364|Actual|Imprimis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 01:42:09.751447|2018-06-01 01:42:09.751447
NCT00765687|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2013-12-08|2008-10-02|2008-10-03|Estimate|||||||2013-12-08|2013-12-10|Estimate|August 2008||2008-08-31|December 2011|2011-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|BLEST||Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates|A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates|Completed||Phase 4|432|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-06-01 01:42:09.822826|2018-06-01 01:42:09.822826
NCT00765674|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2011-01-12||2011-04-15|2008-10-02|2008-10-03|Estimate|2011-04-15|2011-05-09|Estimate||||2011-04-15|2011-05-09|Estimate|September 2008||2008-09-30|April 2011|2011-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension|An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension|Completed||Phase 3|1191|Actual|Novartis||4|||f||||f||||||||||2018-06-01 01:42:09.892865|2018-06-01 01:42:09.892865
NCT00765661|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2014-07-09||2015-05-18|2008-10-02|2008-10-03|Estimate|2015-05-18|2015-05-19|Estimate||||2015-05-18|2015-05-19|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients|A Phase 2, Open-Label, Multi-Center, Randomized Trial To Demonstrate The Pharmacokinetics Of LCP-Tacro™ Tablets Once Daily and Prograf® Capsules Twice Daily In Adult De Novo Kidney Transplant Patients|Completed||Phase 2|63|Actual|Veloxis Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:42:10.258349|2018-06-01 01:42:10.258349
NCT00765648|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2011-07-18||2014-12-11|2008-10-02|2008-10-03|Estimate|2014-12-04|2014-12-11|Estimate||||2014-12-11|2015-01-06|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CLUE||Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department|A Phase IV, Randomized Trial to Determine the Efficacy and Safety of Cardene Intravenous (I.V.) Versus Labetalol for Management of Hypertensive Emergencies in the Emergency Department Setting|Completed||Phase 4|226|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 01:42:10.887916|2018-06-01 01:42:10.887916
NCT00765635|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-02|2008-10-02|2008-10-03|Estimate|||||||2008-10-02|2008-10-03|Estimate|September 2008||2008-09-30|October 2008|2008-10-31||||October 2008|Actual|2008-10-31||Interventional|||Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal|Randomized, Placebo-Controlled Evaluation of Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal|Completed||Phase 4|90|Actual|Hospital Clinic of Barcelona||3|||f||||t||||||||||2018-06-01 01:42:11.212021|2018-06-01 01:42:11.212021
NCT00765622|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-02|2008-10-02|2008-10-03|Estimate|||||||2008-10-02|2008-10-03|Estimate|April 2007||2007-04-30|August 2008|2008-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Assessment of Pelvic Floor Function in Elderly|Assessment of Pelvic Floor Function in Women With Urinary Incontinence|Completed|||153|Actual|Catholic University of Brasília|||2||f||||t||||||Samples Without DNA|"~     Women~   "|||2018-06-01 01:42:11.291918|2018-06-01 01:42:11.291918
NCT00765609|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-02|2008-10-02|2008-10-03|Estimate|||||||2008-10-02|2008-10-03|Estimate|December 2008||2008-12-31|September 2008|2008-09-30|March 2009|Anticipated|2009-03-31|February 2009|Anticipated|2009-02-28||Observational|||To Evaluate the Paediatric Analgesia Slide|To Evaluate the Paediatric Analgesia Slide, a New Device Developed to Assist Parents in Administering Paracetamol to Children at Home|Unknown status|Not yet recruiting||140|Anticipated|County Durham and Darlington NHS Foundation Trust|||2||f||||f||||||||||2018-06-01 01:42:11.409558|2018-06-01 01:42:11.409558
NCT00765596|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2011-11-15|2008-10-02|2008-10-03|Estimate|||||||2011-11-15|2011-11-17|Estimate|January 2005||2005-01-31|November 2011|2011-11-30||||December 2006|Actual|2006-12-31||Observational|||Ghrelin Changes After Roux-en-Y Gastric Bypass|Ghrelin Changes After Roux-en-Y Gastric Bypass: Does Gastric Pouch vs. Gastric Remnant Feeding Affect Secretion?|Completed|||14|Actual|Vanderbilt University|||2||f||||f||||||Samples With DNA|"~     plasma, tissues~   "|||2018-06-01 01:42:11.475797|2018-06-01 01:42:11.475797
NCT00765583|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2011-09-20|2008-10-02|2008-10-03|Estimate|||||||2011-09-20|2011-09-22|Estimate|November 2005||2005-11-30|September 2011|2011-09-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||A Study to Determine How Long Restylane® Will Last After Initial Treatment With 2 Different Re-treatment Schedules.|A Randomized, Evaluator-Blind, Multi-Center, Comparison of the Efficacy and Persistence of Correction of Nasolabial Folds With Restylane® Using Two Different Re-Treatment Schedules|Completed||Phase 4|75|Actual|Medicis Aesthetics, Inc.||1|||f||||f||||||||||2018-06-01 01:42:11.541229|2018-06-01 01:42:11.541229
NCT00765570|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|2015-02-16||2015-04-29|2008-10-02|2008-10-03|Estimate|2015-02-16|2015-03-02|Estimate||||2015-04-29|2015-05-18|Estimate|February 2003||2003-02-28|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy|Treatment of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy A Phase II Randomized Trial|Terminated||Phase 2|12|Actual|Summa Health System||2||Accrual too slow - would not enroll enough subjects to determine outcome|f||||f||||||||||2018-06-01 01:42:11.62825|2018-06-01 01:42:11.62825
NCT00765557|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-10-02|2008-10-02|2008-10-03|Estimate|||||||2008-10-02|2008-10-03|Estimate||||October 2008|2008-10-31||||||||Expanded Access|||Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome|Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome|Available|||||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 01:42:11.847938|2018-06-01 01:42:11.847938
NCT00765544|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2013-09-19|2008-10-02|2008-10-03|Estimate|||||||2013-09-19|2013-09-23|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Targeted Lower Extremity Joint Training|Robot-assisted Ankle Rehabilitation for Multiple Sclerosis (Anklebot)|Terminated||Phase 1/Phase 2|10|Actual|VA Office of Research and Development||3||Study re-design|f||||t||||||||||2018-06-01 01:42:11.896364|2018-06-01 01:42:11.896364
NCT00765531|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-10-30|2008-10-02|2008-10-03|Estimate|||||||2008-10-30|2008-10-31|Estimate||||October 2008|2008-10-31||||||||Expanded Access|||Hypercalciuria and Calcium Stone Disease in Caucasian Patients|Hypercalciuria and Calcium Stone Disease in Caucasian Patients|Available|||||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 01:42:11.954602|2018-06-01 01:42:11.954602
NCT00765518|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02||2016-06-23|2016-06-29|2008-10-02|2008-10-03|Estimate||||2016-06-28|2016-06-30|Estimate|2016-06-29|2016-07-01|Estimate|September 2008||2008-09-30|June 2016|2016-06-30|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)|Intramyocardial Delivery of Autologous Bone Marrow Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy|Completed||Phase 2|40|Actual|Vericel Corporation||2|||f||||t||||||||||2018-06-01 01:42:12.002548|2018-06-01 01:42:12.002548
NCT00765505|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2018-02-03|2008-10-02|2008-10-03|Estimate|||||||2018-02-03|2018-02-06|Actual|July 2004||2004-07-31|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|MIRA||Muscle Lipid and Insulin Resistance in the Elderly|Muscle Lipid and Insulin Resistance in the Elderly|Completed||N/A|92|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:42:12.076678|2018-06-01 01:42:12.076678
NCT00765492|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2009-06-25|2008-10-02|2008-10-03|Estimate|||||||2009-06-25|2009-06-26|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|||||Interventional|||AZD8529 Multiple Ascending Dose Study in Healthy Subjects|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8529 When Given as Single and Multiple Ascending Oral Doses in Healthy Subjects|Completed||Phase 1|47|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:42:12.143326|2018-06-01 01:42:12.143326
NCT00765479|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2013-09-19|2008-10-02|2008-10-03|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 2006||2006-12-31|August 2009|2009-08-31|July 2013|Actual|2013-07-31|September 2011|Actual|2011-09-30||Interventional|||Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer|Randomized Placebo-Controlled Adjuvant Study of Prevention of Prostate Cancer Recurrence After Radical Prostatectomy by Soy Protein Isolate|Completed||Phase 2/Phase 3|284|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:42:12.195806|2018-06-01 01:42:12.195806
NCT00765466|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2008-10-21|2008-10-02|2008-10-03|Estimate|||||||2008-10-21|2008-10-22|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies|A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies|Unknown status|Recruiting|Phase 2|30|Anticipated|McGill University|||||f||||t||||||||||2018-06-01 01:42:12.262665|2018-06-01 01:42:12.262665
NCT00765453|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2015-08-06|2008-10-02|2008-10-03|Estimate|||||||2015-08-06|2015-08-07|Estimate|March 2008||2008-03-31|August 2015|2015-08-31|March 2018|Anticipated|2018-03-31|March 2014|Actual|2014-03-31||Interventional|REGEN-AMI||Bone Marrow Derived Adult Stem Cells for Acute Anterior Myocardial Infarction|Randomised Controlled Clinical Trial of the Use of Autologous Bone Marrow Derived Progenitor Cells to Salvage Myocardium in Patients With Acute Anterior Myocardial Infarction|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Barts & The London NHS Trust||2|||f||||t||||||||||2018-06-01 01:42:12.32803|2018-06-01 01:42:12.32803
NCT00765440|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2015-02-08|2008-10-02|2008-10-03|Estimate|||||||2015-02-08|2015-02-10|Estimate|July 2007||2007-07-31|February 2015|2015-02-28|April 2011|Actual|2011-04-30|July 2009|Actual|2009-07-31||Interventional|||Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract|Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract|Completed||Phase 3|311|Actual|Centre Antoine Lacassagne||3|||f||||f||||||||||2018-06-01 01:42:12.393006|2018-06-01 01:42:12.393006
NCT00765427|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2009-03-27|2008-10-01|2008-10-03|Estimate|||||||2009-03-27|2009-03-30|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers|A Phase 1a, Repeat-Dose Escalation Study to Investigate the Safety and Tolerability of a 7-Day Repeated Dose of Retinoid QLT091001 in Healthy Volunteers|Completed||Phase 1|18|Anticipated|QLT Inc.|||||f||||t||||||||||2018-06-01 01:42:12.458931|2018-06-01 01:42:12.458931
NCT00765414|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-02|||2014-02-04|2008-10-02|2008-10-03|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2003||2003-04-30|February 2014|2014-02-28|August 2006|Actual|2006-08-31|April 2006|Actual|2006-04-30||Interventional|||Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.|An Open-Label Extension Study of the Long-Term Safety and Efficacy of Recombinant Human Acid α-Glucosidase (rhGAA) Given as Enyzme Replacement Therapy to a Single Patient With Pompe Disease (Glycogen Storage Disease Type II) Who Were Previously Enrolled in Genzyme-Sponsored Enzyme Replacement Therapy Studies|Completed||Phase 2|1|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 01:42:12.595835|2018-06-01 01:42:12.595835
NCT00765401|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-11-21|2008-09-30|2008-10-02|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2008|Actual|2008-11-30|November 2017|2017-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients|An Investigation of the Association Between Helicobacter Pylori Infection and Abdominal Pain in Cystic Fibrosis Patients|Withdrawn|||0|Actual|Penn State University|||2|No participants enrolled|f||||f||||||||||2018-06-01 01:42:12.664997|2018-06-01 01:42:12.664997
NCT00765388|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2011-09-19||2014-01-27|2008-10-01|2008-10-02|Estimate|2014-01-27|2014-03-11|Estimate||||2014-01-27|2014-03-11|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|DK188OS||A Randomised Cross-over Study With Two 1-piece Urostomy Bags.|A Comparative, Randomised, Crossover Study With 2 Urostomy Bags Among 30 Urostomy-operated Persons in UK|Completed||Phase 4|27|Actual|Coloplast A/S||2|||f||||f||||||||||2018-06-01 01:42:12.743462|2018-06-01 01:42:12.743462
NCT00765375|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2012-08-29||2015-04-28|2008-10-01|2008-10-02|Estimate|2015-04-28|2015-04-30|Estimate||||2015-04-28|2015-04-30|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of the Use of Botox on Acne|Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A Injections for Subjects With Mild to Moderate Acne Vulgaris|Terminated||Phase 2|5|Actual|DeNova Research|Study terminated after 5 subjects|1||Investigator decision|f||||t||||||||||2018-06-01 01:42:13.168495|2018-06-01 01:42:13.168495
NCT00765349|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2015-10-07|2008-10-01|2008-10-02|Estimate|||||||2015-10-07|2015-10-12|Estimate|May 2008||2008-05-31|October 2015|2015-10-31||||||||Observational|||Clinical Observational Study Investigating the Role of Diastolic Dysfunction in Determining Abnormal Cardiorespiratory Exercise Testing Parameters in Patients Undergoing Major Surgery||Unknown status|Recruiting||30|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||||||2018-06-01 01:42:13.504046|2018-06-01 01:42:13.504046
NCT00765336|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2011-09-28||2011-11-02|2008-09-30|2008-10-02|Estimate|2011-11-02|2011-12-07|Estimate||||2011-11-02|2011-12-07|Estimate|November 2006||2006-11-30|November 2011|2011-11-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Minocycline Extended-Release Tablets on Spermatogenesis in Human Males|Completed||Phase 4|180|Actual|Medicis Pharmaceutical Corporation||2|||f||||t||||||||||2018-06-01 01:42:13.568606|2018-06-01 01:42:13.568606
NCT00765323|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30||2012-03-05|2013-09-20|2008-10-01|2008-10-02|Estimate||||2013-09-17|2013-09-20|Estimate|2013-09-20|2013-09-27|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly|Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly|Terminated||Phase 3|169|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:42:13.83162|2018-06-01 01:42:13.83162
NCT00765310|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2018-05-10|2008-10-01|2008-10-02|Estimate|||||||2018-05-10|2018-05-11|Actual|April 2009||2009-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2011|Actual|2011-11-30||Interventional|||Lipoic Acid and Prevention of Heart Disease|The Role of R-alpha Lipoic Acid in Prevention of Atherosclerotic Vascular Disease|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|Oregon State University||2|||f||||t||||||||||2018-06-01 01:42:13.956389|2018-06-01 01:42:13.956389
NCT00765297|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2010-07-26|2008-10-01|2008-10-02|Estimate|||||||2010-07-26|2010-07-27|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|stumble||Identify Subjects at Risk for Falling Using Acceleration Based Gait Analysis System|Identify Subjects at Risk for Falling Using Acceleration Based Gait Analysis System|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 01:42:14.029776|2018-06-01 01:42:14.029776
NCT00765284|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2011-06-29|2008-10-01|2008-10-02|Estimate|||||||2011-06-29|2011-06-30|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Effect of Niaspan on Cholesterol in Men|Effect of Niaspan on Parameters of Reverse Cholesterol Transport and HDL-C Subclasses in Male Subjects With Low HDL-C Levels|Completed|||15|Anticipated|KineMed|||2||f||||f||||||Samples With DNA|"~     Stool, urine, and blood samples will be taken and analyzed as part of the study.~   "|||2018-06-01 01:42:14.105421|2018-06-01 01:42:14.105421
NCT00765271|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2009-11-17|2008-10-01|2008-10-02|Estimate|||||||2009-11-17|2009-11-18|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects|A Study Investigating Plasma Abacavir and Its Intracellular Anabolite Carbovir-triphosphate Pharmacokinetics in the Absence and in the Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects.|Completed||Phase 1|29|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-06-01 01:42:14.163906|2018-06-01 01:42:14.163906
NCT00765258|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2013-08-19|2008-10-01|2008-10-02|Estimate|||||||2013-08-19|2013-08-21|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|May 2012|Actual|2012-05-31||Observational|||Utility of CT Fluoroscopy Guidance During Percutaneous Sacroplasty With Quality of Life Assessment|Utility of CT Fluoroscopy Guidance During Percutaneous Sacroplasty With Quality of Life Assessment|Completed|||14|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 01:42:14.231341|2018-06-01 01:42:14.231341
NCT00765245|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2015-02-27||2016-03-10|2008-10-01|2008-10-02|Estimate|2016-03-10|2016-04-11|Estimate||||2016-03-10|2016-04-11|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma|A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma|Completed||Phase 2|44|Actual|Vanderbilt-Ingram Cancer Center|"Pre-specified Outcomes Measures data were not collected as anticipated in original protocol, thus results will not be reported."|2|||f||||t||||||||||2018-06-01 01:42:14.302164|2018-06-01 01:42:14.302164
NCT00765232|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2011-11-18||2011-12-21|2008-10-01|2008-10-02|Estimate|2011-12-21|2012-01-27|Estimate||||2011-12-21|2012-01-27|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy|The Efficacy of Continuous Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy: a Double Blinded Randomized Placebo Controlled Trial.|Completed||Phase 4|111|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:42:14.788822|2018-06-01 01:42:14.788822
NCT00765219|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2015-07-21|2008-10-01|2008-10-02|Estimate|||||||2015-07-21|2015-07-23|Estimate|May 2008||2008-05-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|December 2013|Actual|2013-12-31||Interventional|||Cognitive Behavior Treatment of Older Adults With Generalized Anxiety Disorder in Primary Care|Treating Late-life GAD in Primary Care: Enhancing Outcomes and Translational Value|Completed||N/A|222|Anticipated|Baylor College of Medicine||3|||f||||f||||||||||2018-06-01 01:42:14.967524|2018-06-01 01:42:14.967524
NCT00765206|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2009-08-28||2015-02-20|2008-09-30|2008-10-02|Estimate|2010-04-08|2010-04-30|Estimate||||2015-02-20|2015-03-11|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)|Randomized, Crossover Pharmacodynamic Study Comparing the Effects of Zegerid® (20 mg Omeprazole/Sodium Bicarbonate) and Prilosec OTC® Tablets (20 Mg-equivalent Omeprazole)|Completed||Phase 3|60|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:42:15.032093|2018-06-01 01:42:15.032093
NCT00765193|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2009-06-27||2010-04-14|2008-10-01|2008-10-02|Estimate|2010-04-14|2010-04-15|Estimate||||2010-04-14|2010-04-15|Estimate|May 2008||2008-05-31|April 2010|2010-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|TBSE||The Impact of Total Body Skin Examination on Skin Cancer Detection|The Impact of Total Body Skin Examination on Skin Cancer Detection|Completed||N/A|14381|Actual|Medical University of Graz||1|||f||||f||||||||||2018-06-01 01:42:15.168715|2018-06-01 01:42:15.168715
NCT00765180|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2015-11-17|2008-10-01|2008-10-02|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Transparent Retractable Extension Device and Narrow Band Imaging on Colorectal Adenoma Detection||Completed||N/A|200|Actual|Showa Inan General Hospital||2|||f||||f||||||||||2018-06-01 01:42:15.449712|2018-06-01 01:42:15.449712
NCT00765154|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2010-10-29|2008-10-01|2008-10-02|Estimate|||||||2010-10-29|2010-11-01|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||NNRTI/PI Toxicity Switch to Darunavir Study|Phase IV, Two-arm, Open-label, Single-centre Randomised Pilot Study to Assess the Feasibility of Immediate or Deferred Switching of HIV-infected Individuals Intolerant of Efavirenz, Ritonavir-boosted Lopinavir or Ritonavir-boosted Darunavir|Terminated||Phase 4|12|Actual|St Stephens Aids Trust||2||Difficulties in recruitment due to a change in the nature of practice.|f||||f||||||||||2018-06-01 01:42:15.604077|2018-06-01 01:42:15.604077
NCT00765141|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-11-24|2008-10-01|2008-10-02|Estimate|||||||2015-11-24|2015-11-26|Estimate|June 2008||2008-06-30|November 2015|2015-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study|A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host Microbe Scientific Study|Withdrawn|||0|Actual|Southwest Regional Wound Care Center|||1|No participants enrolled per PI discretion|f||||t||||||Samples With DNA|"~     The samples can include material such as wound debridement, removed orthopedic implants,~     removed catheters or shunts, excised tonsils, amputated tissue, sputum, stool, or other~     excretions.~   "|||2018-06-01 01:42:15.683613|2018-06-01 01:42:15.683613
NCT00765128|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2011-11-18||2011-12-21|2008-10-01|2008-10-02|Estimate|2011-12-21|2012-01-27|Estimate||||2011-12-21|2012-01-27|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy|The Efficacy of Continuous Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy: a Double Blinded Randomized Placebo Controlled Trial|Completed||Phase 4|17|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:42:15.759004|2018-06-01 01:42:15.759004
NCT00765115|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-09-30|2008-09-30|2008-10-02|Estimate|||||||2008-09-30|2008-10-02|Estimate|July 2006||2006-07-31|September 2008|2008-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.|Assessment of LY450139-Mediated Inhibition of Amyloid Beta Formation Determined by 13C6-Leucine In Healthy Subjects|Completed||Phase 1|27|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 01:42:15.998094|2018-06-01 01:42:15.998094
NCT00765102|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2012-09-26||2016-03-30|2008-10-01|2008-10-02|Estimate|2012-11-21|2012-12-20|Estimate||||2016-03-30|2016-05-04|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Trial of Romidepsin and Bortezomib for Multiple Myeloma|A Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients With Relapsed or Refractory Disease|Terminated||Phase 2|32|Actual|Celgene Corporation||1||There was a change in the Sponsor's research strategy; safety concerns were not a factor.|f||||f||||||||||2018-06-01 01:42:16.119953|2018-06-01 01:42:16.119953
NCT00765089|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2016-02-11|2008-09-30|2008-10-02|Estimate|||||||2016-02-11|2016-02-12|Estimate|December 2005||2005-12-31|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation|Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation|Completed||Phase 4|35|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:42:16.514842|2018-06-01 01:42:16.514842
NCT00765076|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2012-03-08|2010-07-02|2016-10-06|2008-10-01|2008-10-02|Estimate|2012-03-08|2012-04-05|Estimate|2010-07-02|2010-07-07|Estimate|2016-10-06|2016-11-16|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older|Observer-blind Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects|Completed||Phase 3|192|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:42:16.644975|2018-06-01 01:42:16.644975
NCT00765063|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2011-08-11||2011-12-01|2008-09-30|2008-10-02|Estimate|2011-12-01|2012-01-13|Estimate||||2011-12-01|2012-01-13|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)|A 6 Month, Prospective, Open-Label Multiple Center Extension Trial To Evaluate The Long Term Safety And Sustained Efficacy Of Fragmin In The Treatment Of Chronic Foot Ulcers In Diabetic Patients With Peripheral Arterial Occlusive Disease|Completed||Phase 2/Phase 3|62|Actual|Pfizer|Study enrollment was terminated before planned number of participants was obtained. Although randomized participants were allowed to complete entire course of therapy according to protocol and study status was therefore designated as completed.|1|||f||||f||||||||||2018-06-01 01:42:17.693678|2018-06-01 01:42:17.693678
NCT00765050|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2014-04-04|2008-10-01|2008-10-02|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF|A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF|Terminated||Phase 1/Phase 2|13|Actual|PETHEMA Foundation||1|||f||||t||||||||||2018-06-01 01:42:19.008591|2018-06-01 01:42:19.008591
NCT00765037|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2009-06-08||2010-08-03|2008-10-01|2008-10-02|Estimate|2010-08-03|2010-08-25|Estimate||||2010-08-03|2010-08-25|Estimate|August 2008||2008-08-31|August 2010|2010-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Retrospective Encore Reverse Shoulder Prosthesis Study|Post Market Study on the Efficacy of the Encore Reverse Shoulder Prosthesis in a Small Group of Subjects|Completed|||19|Actual|Encore Medical, L.P.|||1||f||||f||||||||||2018-06-01 01:42:19.104215|2018-06-01 01:42:19.104215
NCT00765024|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-09-03|2008-09-30|2008-10-02|Estimate|||||||2017-09-03|2017-09-07|Actual|July 2008|Actual|2008-07-31|September 2017|2017-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Ivermectin Versus Albendazole for Chronic Strongyloidiasis|Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis|Completed||Phase 3|90|Actual|Mahidol University||3|||f||||f||||||||||2018-06-01 01:42:19.252406|2018-06-01 01:42:19.252406
NCT00765011|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2011-02-12|2008-10-01|2008-10-02|Estimate|||||||2011-02-12|2011-02-15|Estimate|October 2008||2008-10-31|February 2011|2011-02-28|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|||TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer|A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF|Unknown status|Recruiting|Phase 2|92|Anticipated|Grupo Español de Tratamiento de Tumores de Cabeza y Cuello||2|||f||||f||||||||||2018-06-01 01:42:19.335097|2018-06-01 01:42:19.335097
NCT00764998|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2017-04-26|2008-10-01|2008-10-02|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2008||2008-10-31|April 2017|2017-04-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Influenza Vaccine in HIV|A Controlled Trial to Assess the Immunogenicity and Efficacy of Three Vaccine Dosing Strategies in HIV Infected Adults|Completed||Phase 3|285|Actual|Ottawa Hospital Research Institute||2|||f||||||||||||||2018-06-01 01:42:19.462071|2018-06-01 01:42:19.462071
NCT00764985|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2010-07-01|2008-10-01|2008-10-02|Estimate|||||||2010-07-01|2010-07-02|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Observational|E-STOP||Evaluation of Syncope,Its Diagnosis, Treatment, Outcome and Prognosis|E-STOP Registry: A Registry for the Evaluation of Syncope,Its Diagnosis, Treatment, Outcome and Prognosis Using Our SELF-Pathway|Completed|||540|Anticipated|St. Luke's-Roosevelt Hospital Center|||1||f||||f||||||||||2018-06-01 01:42:19.640132|2018-06-01 01:42:19.640132
NCT00764972|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-10-17|2008-10-01|2008-10-02|Estimate|||||||2008-10-17|2008-10-21|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer|A Phase IB/II Trial of Combination of Vinorelbine With Sorafenib (BAY 43-9006) as First-Line Treatment in Patients With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|36|Anticipated|McGill University||1|||f||||t||||||||||2018-06-01 01:42:19.700249|2018-06-01 01:42:19.700249
NCT00764959|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2011-02-08|2008-10-01|2008-10-02|Estimate|||||||2011-02-08|2011-02-09|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Retrospective Study of the Linear™ Hip|Post-Market Study of the Linear™ Hip System|Terminated|||200|Anticipated|Encore Medical, L.P.|||1|Enrollment and data collection insufficient to continue study.|f||||f||||||||||2018-06-01 01:42:19.785741|2018-06-01 01:42:19.785741
NCT00764946|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2012-02-13||2017-02-14|2008-10-01|2008-10-02|Estimate|2012-03-16|2012-04-12|Estimate||||2017-02-14|2017-03-21|Actual|October 2008||2008-10-31|February 2017|2017-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)|A Phase III Open-Label Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of MK0518/Raltegravir in a Diverse Cohort of HIV-Infected Patients|Completed||Phase 3|209|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:42:19.881213|2018-06-01 01:42:19.881213
NCT00764933|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2010-06-01|2008-10-01|2008-10-02|Estimate|||||||2010-06-01|2010-06-03|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Structured Information During the Intensive Care Unit Stay|A Randomized Controlled Multi Center Study to Evaluate the Efficacy of a Structured Information Program During ICU Stay|Completed||N/A|211|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-06-01 01:42:20.374352|2018-06-01 01:42:20.374352
NCT00764920|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-08-23|2008-10-01|2008-10-02|Estimate|||||||2017-08-23|2017-08-25|Actual|October 2008||2008-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Skin Imaging With Technologies in Development|Non-invasive Imaging Modalities for Assessment of Normal and Lesional Skin|Withdrawn|||0|Actual|University of California, Irvine|||1|Not a clinical trial|f||||f||||||||||2018-06-01 01:42:20.437448|2018-06-01 01:42:20.437448
NCT00764907|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2009-07-07|2008-10-01|2008-10-02|Estimate|||||||2009-07-07|2009-07-08|Estimate|November 2002||2002-11-30|July 2009|2009-07-31||||October 2007|Anticipated|2007-10-31||Interventional|||Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia|A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 3|4000|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 01:42:20.507992|2018-06-01 01:42:20.507992
NCT00764894|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2011-02-08|2008-10-01|2008-10-02|Estimate|||||||2011-02-08|2011-02-09|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Foundation Knee Study - Retrospective|Post-Market Study of the Foundation Knee System|Terminated|||200|Anticipated|Encore Medical, L.P.|||1|Enrollment and data collection insufficient to continue study.|f||||f||||||||||2018-06-01 01:42:20.620407|2018-06-01 01:42:20.620407
NCT00764881|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2011-07-28||2014-12-08|2008-10-01|2008-10-02|Estimate|2012-03-06|2012-04-03|Estimate||||2014-12-08|2014-12-30|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of SH T00658ID on Libido|Multi-center, Double-blind, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive Containing Estradiol Valerate and Dienogest (SH T00658ID) Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon) Over 6 Treatment Cycles on Alleviating Complaints of Reduced Libido in Women With Acquired Female Sexual Dysfunction (FSD) Associated With Oral Contraceptive Use|Completed||Phase 3|217|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:42:20.893404|2018-06-01 01:42:20.893404
NCT00764868|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2011-01-31||2014-01-10|2008-09-30|2008-10-02|Estimate|2011-03-01|2011-03-28|Estimate||||2014-01-10|2014-02-07|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study|A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|269|Actual|Shire||1|||f||||f||||||||||2018-06-01 01:42:22.691681|2018-06-01 01:42:22.691681
NCT00764855|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2012-05-04|2008-10-01|2008-10-02|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Validation of the Effect of Propofol and Opiates Closed-loop Administration Device During Anesthesia and Sedation|Validation of the Effect of Propofol and Opiates Closed-loop Administration Device During Anesthesia and Sedation|Completed|||180|Actual|University Hospital, Ghent|||1||f||||f||||||||||2018-06-01 01:42:22.972012|2018-06-01 01:42:22.972012
NCT00764842|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2011-02-08|2008-10-01|2008-10-02|Estimate|||||||2011-02-08|2011-02-09|Estimate|January 2008||2008-01-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Efficacy of the CLP® Hip - Retrospective|Post-Market Study: The Efficacy of the CLP® Hip|Terminated|||61|Actual|Encore Medical, L.P.|||1|Enrollment and data collection insufficient to continue study.|f||||f||||||||||2018-06-01 01:42:23.049067|2018-06-01 01:42:23.049067
NCT00764829|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2012-02-13|2008-09-30|2008-10-02|Estimate|||||||2012-02-13|2012-02-15|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Blood Samples to Evaluate Biomarkers of Donor Chimerism|Blood Samples to Evaluate Biomarkers of Donor Chimerism|Completed|||80|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||f||||||Samples With DNA|"~     plasma,DNA~   "|||2018-06-01 01:42:23.110552|2018-06-01 01:42:23.110552
NCT00764816|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2011-06-22|2008-10-01|2008-10-02|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4|Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4|Completed||N/A|9|Actual|Indiana University||2|||f||||f||||||||||2018-06-01 01:42:23.167252|2018-06-01 01:42:23.167252
NCT00764803|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2010-03-09|2008-09-30|2008-10-02|Estimate|||||||2010-03-09|2010-03-11|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||3DKnee™ System vs. the MJS Knee System|Post-Market Study: The Efficacy of the 3DKnee™ System vs. the MJS Knee System|Terminated|||27|Actual|Encore Medical, L.P.|||2|Corporate decision to discontinue distribution of MJS Knee.|f||||f||||||||||2018-06-01 01:42:23.239923|2018-06-01 01:42:23.239923
NCT00764790|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2010-02-25||2016-10-11|2008-10-01|2008-10-02|Estimate|2010-06-29|2010-07-27|Estimate||||2016-10-11|2016-11-23|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children|Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children|Completed||Phase 3|3317|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:42:23.336501|2018-06-01 01:42:23.336501
NCT00764777|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2013-01-24|2008-10-01|2008-10-02|Estimate|||||||2013-01-24|2013-01-25|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|September 2010|Actual|2010-09-30||Interventional|BRAVISSIMO||Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions|Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions|Completed||Phase 4|325|Actual|Flanders Medical Research Program||1|||f||||f||||||||||2018-06-01 01:42:24.063683|2018-06-01 01:42:24.063683
NCT00764764|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2016-10-03|2008-10-01|2008-10-02|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2008||2008-05-31|July 2009|2009-07-31||||May 2008|Actual|2008-05-31||Interventional|||Study of the Effect of Neck Treatment on Shoulder Impingement|Shoulder Impingement: A By-Product of Cervical Spine Dysfunction?|Terminated||Phase 1|30|Anticipated|CAMC Health System||2||PI left institution|f||||t||||||||||2018-06-01 01:42:24.132664|2018-06-01 01:42:24.132664
NCT00764751|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2013-10-18|2008-10-01|2008-10-02|Estimate|||||||2013-10-18|2013-10-21|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris|LEO 19123 Cream in the Treatment of Psoriasis Vulgaris|Completed||Phase 2|51|Actual|LEO Pharma||3|||f||||f||||||||||2018-06-01 01:42:24.200317|2018-06-01 01:42:24.200317
NCT00764738|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2013-03-18|2008-09-30|2008-10-02|Estimate|||||||2013-03-18|2013-03-19|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration|Study Investigating High Resolution OCT, Multifocal ERG and Microperimetry Outcomes of Monthly vs As Needed Ranibizumab in Neovascular Age-Related Macular Degeneration|Completed||Phase 2/Phase 3|45|Actual|Retina Macula Institute||2|||f||||t||||||||||2018-06-01 01:42:24.269058|2018-06-01 01:42:24.269058
NCT00764725|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2008-12-22|2008-10-01|2008-10-02|Estimate|||||||2008-12-22|2008-12-23|Estimate|December 2002||2002-12-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|April 2007|Actual|2007-04-30||Interventional|SWEFOT||Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)|A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX|Completed||Phase 4|487|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 01:42:24.331211|2018-06-01 01:42:24.331211
NCT00764712|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2012-03-09|2008-10-01|2008-10-02|Estimate|||||||2012-03-09|2012-03-12|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients|Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients|Completed||N/A|120|Actual|Charles University, Czech Republic||3|||f||||f||||||||||2018-06-01 01:42:24.481788|2018-06-01 01:42:24.481788
NCT00764699|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2015-05-15||2018-02-23|2008-10-01|2008-10-02|Estimate|2018-02-23|2018-03-02|Actual||||2018-02-23|2018-03-02|Actual|October 2008||2008-10-31|February 2018|2018-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Increlex® on Children With Crohn Disease|Effect of Increlex® on Children With Crohn Disease|Terminated||Phase 2/Phase 3|3|Actual|Nationwide Children's Hospital||1||PI left institution|f||||f||||||||||2018-06-01 01:42:24.556605|2018-06-01 01:42:24.556605
NCT00764686|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2009-09-28|2008-10-01|2008-10-02|Estimate|||||||2009-09-28|2009-09-29|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||A Study Investigating an Exercise and Education Programme for Individuals With Ankylosing Spondylitis|A Study Investigating an Exercise and Education Programme for Individuals With Ankylosing Spondylitis.|Completed||Phase 3|18|Anticipated|University College Dublin||2|||f||||t||||||||||2018-06-01 01:42:24.700814|2018-06-01 01:42:24.700814
NCT00764673|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2010-11-19||2011-02-08|2008-10-01|2008-10-02|Estimate|2011-02-08|2011-03-02|Estimate||||2011-02-08|2011-03-02|Estimate|October 2006||2006-10-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The 3DKnee™ System: A Post-Market Study|The 3DKnee™ System: A Post-Market Study|Completed||Phase 4|71|Actual|Encore Medical, L.P.||1|||f||||f||||||||||2018-06-01 01:42:24.788377|2018-06-01 01:42:24.788377
NCT00764660|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2016-06-07||2016-07-20|2008-10-01|2008-10-02|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|February 2009||2009-02-28|July 2016|2016-07-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|OD-H||Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)|A Prospective, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Subjects With Alcohol Dependence.|Terminated||Phase 2|141|Actual|Merck Sharp & Dohme Corp.||2||"Based on the outcome of a planned interim analysis, the study was stopped early due to~   futility."|f||||f||||||||||2018-06-01 01:42:25.032814|2018-06-01 01:42:25.032814
NCT00764647|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2017-07-05|2008-10-01|2008-10-02|Estimate|||||||2017-07-05|2017-07-07|Actual|March 2006|Actual|2006-03-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|September 2011|Actual|2011-09-30||Interventional|||Education Program for Family Caregivers|Evaluation of Education Program for Family Caregivers of Frail Elders|Completed||N/A|42|Actual|CAMC Health System||1|||f||||f||||||||No||2018-06-01 01:42:25.5228|2018-06-01 01:42:25.5228
NCT00764634|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30||2011-06-29|2011-11-28|2008-09-30|2008-10-02|Estimate||||2011-06-29|2011-07-01|Estimate|2011-11-28|2011-12-02|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B|A Phase 2, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Dosing Schedule and Antibody Kinetics of Recombinant Botulinum Vaccine A/B, rBV A/B-40, in Healthy Adults|Completed||Phase 2|440|Actual|DynPort Vaccine Company LLC, A CSC Company||4|||f||||t||||||||||2018-06-01 01:42:25.591431|2018-06-01 01:42:25.591431
NCT00764621|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2014-11-03|2008-10-01|2008-10-02|Estimate|||||||2014-11-03|2014-11-04|Estimate|October 2008||2008-10-31|November 2014|2014-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Health Economic Evaluation of Primovist-enhanced Liver MRI|Multi-center, Randomized Comparison Study to eVALUatE Outcomes and Resource Needs of Imaging and Treatment Following Primovist-enhanced MRI of the Liver in Comparison to Extracellular Contrast Media (ECCM)-Enhanced MRI and Contrast-enhanced Computed Tomography (CT) in Patients With a History of Colorectal Cancer and Known or Suspected Metachronous Liver Metastases.|Completed||Phase 4|360|Actual|Bayer||3|||f||||f||||||||||2018-06-01 01:42:25.686179|2018-06-01 01:42:25.686179
NCT00764608|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-11-24|2008-10-01|2008-10-02|Estimate|||||||2015-11-24|2015-11-26|Estimate|June 2008||2008-06-30|November 2015|2015-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Study of the Human Skin Microbiome|Study of the Human Skin Microbiome|Withdrawn|||0|Actual|Southwest Regional Wound Care Center|||1|No Participants enrolled, per PI discretion|f||||t||||||Samples With DNA|"~     The subjects' samples will be analyzed using DNA methods in order to identify the types of~     microbes present on the swabs. Other substances such as proteins, RNA, and other metabolites~     may also be analyzed. DNA or other molecular components of the sample will be extracted.~     Alternately, microbes in the sample can be cultured directly. The samples will be explored~     using molecular analyses. The backbone of the analyses will be shotgun metagenomic sequencing~     and 16S rDNA amplicon sequencing. The results of these analyses will be used to identify and~     describe the microbiome of the skin.~   "|||2018-06-01 01:42:25.804002|2018-06-01 01:42:25.804002
NCT00764595|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2016-09-27|2008-10-01|2008-10-02|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|GISTs||Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor|Phase II Multicenter Clinical Trial on Imatinib Treatment for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)|Completed||Phase 2|5|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||||2018-06-01 01:42:25.862754|2018-06-01 01:42:25.862754
NCT00764582|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2009-08-24|2008-10-01|2008-10-02|Estimate|||||||2009-08-24|2009-08-26|Estimate|September 2008||2008-09-30|August 2009|2009-08-31||||March 2009|Anticipated|2009-03-31||Interventional|||Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery|A Randomized, Observer-masked, Parallel-group, Multicenter Trial Evaluating the Ocular Penetration of 1.5% Levofloxacin Ophthalmic Solution and 0.5% Moxifloxacin Ophthalmic Solution in Subjects Undergoing Corneal Transplant Surgery|Terminated||Phase 4|60|Anticipated|Santen Inc.||2||Study terminated due to lack of enrollment.|f||||f||||||||||2018-06-01 01:42:25.965373|2018-06-01 01:42:25.965373
NCT00764569|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2017-02-08|2008-10-01|2008-10-02|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2008||2008-11-30|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||The Investigation of a Fluorescence/Elastic Scattering Spectroscopy (F-ESS) Device for Oral Tissue Characterization|a Non-invasive Device for the Detection, Diagnosis and Screening of Oral Pathology|Completed|||77|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 01:42:26.036934|2018-06-01 01:42:26.036934
NCT00764556|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2009-10-13|2008-10-01|2008-10-02|Estimate|||||||2009-10-13|2009-10-14|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|IPS2008||Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards|Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards|Completed||Phase 2|20|Actual|St George's, University of London||1|||f||||t||||||||||2018-06-01 01:42:26.110852|2018-06-01 01:42:26.110852
NCT00764543|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-10-01|2008-10-01|2008-10-02|Estimate|||||||2008-10-01|2008-10-02|Estimate||||October 2008|2008-10-31||||||||Expanded Access|||Ambulatory Blood Pressure Measurement in Children With Congenital Urine Flow Obstruction|Ambulatory Blood Pressure Measurement in Children With Congenital Urine Flow Obstruction|Available|||||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 01:42:26.250243|2018-06-01 01:42:26.250243
NCT00764530|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-07-26|2008-10-01|2008-10-02|Estimate|||||||2017-07-26|2017-07-28|Actual|November 2003||2003-11-30|July 2017|2017-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Cementless Alumina-Alumina Total Hip and Hybrid|Keramos Ceramic/Ceramic Total Hip System|Completed||N/A|342|Actual|Encore Medical, L.P.||2|||f||||f||||||||||2018-06-01 01:42:26.293449|2018-06-01 01:42:26.293449
NCT00764517|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2017-08-31|2016-11-28|2017-11-09|2008-10-01|2008-10-02|Estimate|2017-10-11|2017-11-13|Actual|2016-11-28|2016-12-29|Estimate|2017-11-09|2017-12-11|Actual|August 2008||2008-08-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|January 2015|Actual|2015-01-31||Interventional|||Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma|Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma|Completed||Phase 2|57|Actual|OHSU Knight Cancer Institute|Secondary objectives and outcomes not evaluated due to technical challenges collecting the data, and lack of budget and personnel to complete the analysis.|2|||f||||t||||||||||2018-06-01 01:42:26.367189|2018-06-01 01:42:26.367189
NCT00764504|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2010-11-19||2011-03-21|2008-09-30|2008-10-02|Estimate|2011-03-21|2011-04-19|Estimate||||2011-03-21|2011-04-19|Estimate|October 2002||2002-10-31|March 2011|2011-03-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|RSP||Reverse Shoulder Prosthesis Study|Encore Reverse Shoulder Prosthesis|Completed||Phase 3|516|Actual|Encore Medical, L.P.||3|||f||||f||||||||||2018-06-01 01:42:26.904795|2018-06-01 01:42:26.904795
NCT00764491|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2013-09-19|2008-10-01|2008-10-02|Estimate|||||||2013-09-19|2013-09-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:42:27.411473|2018-06-01 01:42:27.411473
NCT00764309|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2012-01-30||2012-01-30|2008-10-01|2008-10-02|Estimate|2012-01-30|2012-02-29|Estimate||||2012-01-30|2012-02-29|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional|||Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis|An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis|Completed||Phase 1/Phase 2|47|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:42:32.210688|2018-06-01 01:42:32.210688
NCT00764478|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2015-03-26||2017-08-31|2008-10-01|2008-10-02|Estimate|2015-04-08|2015-04-24|Estimate||||2017-08-31|2017-09-29|Actual|April 6, 2012|Actual|2012-04-06|August 2017|2017-08-31|May 28, 2014|Actual|2014-05-28|April 30, 2014|Actual|2014-04-30||Interventional||Randomized participants who received at least one dose of trial medication|Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)|A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects With Bipolar 1 Disorder Experiencing an Acute Manic or Mixed Episode (Protocol P05691 [Formerly 041044])|Completed||Phase 3|367|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:42:27.547388|2018-06-01 01:42:27.547388
NCT00764465|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2015-03-24||2016-01-27|2008-10-01|2008-10-02|Estimate|2016-01-27|2016-01-29|Estimate||||2016-01-27|2016-01-29|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||An Interaction Study to Assess Drug Levels in Healthy Adult Subjects|Steady State Pharmacokinetics (PK) of Fosamprenavir (FPV) Alone or in Combination With Low Dose Ritonavir (/r) (1400mg BID, 1400mg/100mg QD or 700/100mg BID) and the Chemokine Receptor 5 (CCR5) Entry Inhibitor Maraviroc (MVC) 300mg BID in Healthy Volunteers|Completed||Phase 2|45|Actual|Garden State Infectious Disease Associates, PA|Data for primary outcomes are not available per intervention . Values reported as means are uncertain measure type (data no longer available).|6|||f||||f||||||||||2018-06-01 01:42:28.947498|2018-06-01 01:42:28.947498
NCT00764452|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2012-05-03|2008-10-01|2008-10-02|Estimate|||||||2012-05-03|2012-05-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:42:30.343793|2018-06-01 01:42:30.343793
NCT00764439|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2012-07-06|2008-10-01|2008-10-02|Estimate|||||||2012-07-06|2012-07-10|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pilot Study of a New Nicotine Replacement Therapy|Pilot Study on Usage Patterns of a Novel Nicotine Replacement Therapy - A Multi-Center, Open, 3-Week Randomized Low Intervention Study of Two Different Directions for Use in Smokers Motivated to Quit|Completed||Phase 2|258|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 01:42:30.380421|2018-06-01 01:42:30.380421
NCT00764426|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-10-01|2008-10-01|2008-10-02|Estimate|||||||2008-10-01|2008-10-02|Estimate|June 2004||2004-06-30|October 2008|2008-10-31||||||||Interventional|||Alcohol, Inflammation and Atherosclerosis|Clinical Study of the Effect of Different Alcoholic and Non-Alcoholic Beverages on Markers of Inflammation|Completed||N/A|72|Actual|European Research Advisory Board||2|||f||||f||||||||||2018-06-01 01:42:30.47053|2018-06-01 01:42:30.47053
NCT00764413|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2014-11-21|2008-10-01|2008-10-02|Estimate|||||||2014-11-21|2014-11-24|Estimate|April 2009||2009-04-30|February 2014|2014-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Chronotherapy in Acute Multiple Sclerosis (MS) Attack|Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment?|Terminated||N/A|57|Actual|Sykehuset Innlandet HF||2||Low inclusion frequency and not enough human resources for completing study|f||||f||||||||||2018-06-01 01:42:30.552753|2018-06-01 01:42:30.552753
NCT00764400|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2018-04-04|2008-09-30|2008-10-02|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2008||2008-08-31|April 2018|2018-04-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Treatment for Word Retrieval Impairments in Aphasia|Communication Outcomes for Naming Treatments in Aphasia|Completed||N/A|24|Actual|Old Dominion University||2|||f||||f||||||||||2018-06-01 01:42:30.648471|2018-06-01 01:42:30.648471
NCT00764387|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2014-12-04|2008-10-01|2008-10-02|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.|Contrast-enhanced MRI Examination of Cerebral Neoplastic Enhancing Lesions: Comparison of Diagnostic Efficacy of Gd-DOTA 0.5M and Gadobutrol 1.0 M at 0.1 mmol/kg Body Weight: Intraindividual Comparison Clinical Study.|Completed||Phase 4|166|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:42:30.738661|2018-06-01 01:42:30.738661
NCT00764374|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2014-10-28|2008-10-01|2008-10-02|Estimate|||||||2014-10-28|2014-10-29|Estimate|August 2008||2008-08-31|October 2014|2014-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia|A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia|Completed||Phase 3|412|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 01:42:30.941499|2018-06-01 01:42:30.941499
NCT00764361|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2012-02-24||2017-03-09|2008-10-01|2008-10-02|Estimate|2012-03-08|2012-04-05|Estimate||||2017-03-09|2017-04-07|Actual|January 2009||2009-01-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers|A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of NanoDOX™ Hydrogel(1.0% Doxycycline Monohydrate)in Diabetic Adult Subjects With Lower Extremity Ulcers Compared to Placebo Hydrogel.|Completed||Phase 2|15|Actual|NanoSHIFT LLC|enrollment stopped before reaching the initial 40 subjects anticipated due to slow enrollment of subjects|2|||f||||t||||||||||2018-06-01 01:42:31.102985|2018-06-01 01:42:31.102985
NCT00764348|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2011-09-06|2008-10-01|2008-10-02|Estimate|||||||2011-09-06|2011-09-07|Estimate||||September 2011|2011-09-30||||||||Observational|||Evaluation of Wound Biofilm in Acute and Chronic Wounds|Evaluation of Wound Biofilm in Acute and Chronic Wounds|Withdrawn|||0|Actual|Southwest Regional Wound Care Center|||1|withdrawn as MSU approval obained|f||||f||||||Samples With DNA|"~     traumatic, diabetic foot ulcer, decubitus ulcer, venous leg ulcer~   "|||2018-06-01 01:42:31.360772|2018-06-01 01:42:31.360772
NCT00764335|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2018-03-16|2008-10-01|2008-10-02|Estimate|||||||2018-03-16|2018-03-20|Actual|January 2007|Actual|2007-01-31|March 2018|2018-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Unilateral vs Bilateral Total Hip Arthroplasty|Unilateral vs Bilateral Total Hip Arthroplasty - the Influence of Medial Femoral Head Offset and Effects on Strength and Aerobic Endurance Capacity|Completed|||40|Actual|Norwegian University of Science and Technology|||4||f||||f||||||||||2018-06-01 01:42:31.429476|2018-06-01 01:42:31.429476
NCT00764322|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|2017-03-31||2017-07-03|2008-10-01|2008-10-02|Estimate|2017-06-05|2017-07-02|Actual||||2017-07-03|2017-08-01|Actual|June 18, 2008||2008-06-18|July 2017|2017-07-31|July 1, 2011|Actual|2011-07-01|September 28, 2010|Actual|2010-09-28||Interventional|NRR||Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen|Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population|Completed||Phase 2|501|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||No||2018-06-01 01:42:31.539557|2018-06-01 01:42:31.539557
NCT00764296|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2011-09-06|2008-10-01|2008-10-02|Estimate|||||||2011-09-06|2011-09-07|Estimate|December 2006||2006-12-31|September 2011|2011-09-30||||||||Observational|||Collection of Samples for the Evaluation of Wound Biofilm in Acute and Chronic Wounds|Collection of Samples for the Evaluation of Wound Biofilm in Acute and Chronic Wounds|Completed|||34|Actual|Southwest Regional Wound Care Center|||1||f||||t||||||Samples With DNA|"~     The debridement sample will be processed to extract DNA for 16s rDNA evaluation in order to~     determine the microbial population of the sample using a more sensitive means than standard~     culture.~   "|||2018-06-01 01:42:32.649472|2018-06-01 01:42:32.649472
NCT00764283|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2009-04-14|2008-10-01|2008-10-02|Estimate|||||||2009-04-14|2009-04-15|Estimate|November 2008||2008-11-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||The Prevention of Postoperative Epidural Catheter Migration: a Comparison of Three Types of Dressing|The Prevention of Postoperative Epidural Catheter Migration: a Comparison of Three Types of Dressing|Completed||N/A|200|Anticipated|University Ghent||3|||f||||f||||||||||2018-06-01 01:42:32.715011|2018-06-01 01:42:32.715011
NCT00764270|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2017-09-21|2008-10-01|2008-10-02|Estimate|||||||2017-09-21|2017-09-25|Actual|August 2011||2011-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2011|Actual|2011-11-30||Interventional|||The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease|The Role of R-alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease|Active, not recruiting||Phase 2/Phase 3|50|Anticipated|Oregon State University||2|||f||||t||||||||||2018-06-01 01:42:32.789477|2018-06-01 01:42:32.789477
NCT00764257|ClinicalTrials.gov processed this data on May 31, 2018|2008-10-01|||2011-12-19|2008-10-01|2008-10-02|Estimate|||||||2011-12-19|2011-12-20|Estimate|October 2004||2004-10-31|December 2011|2011-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||PREVELLE Shape (CX002) Dermal Filler Protocol|A Multicenter, Evaluator-Masked Study to Assess the Efficacy and Safety of Mentor's CX002 Dermal Filler Medical Device, When Applied as an Intradermal Implant for the Correction of Facial Wrinkles and Lip Augmentation (CX002 Dermal Filler Protocol)|Completed||Phase 3|||Mentor Worldwide, LLC||2|||f||||t||||||||||2018-06-01 01:42:32.87842|2018-06-01 01:42:32.87842
NCT00764244|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-03-23|2008-09-30|2008-10-01|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2005||2005-01-31|November 2014|2014-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|VITRILASE||Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema|VITRILASE Study: Prospective Randomized Trial Comparing the Effect of Laser, Vitrectomy and Intravitreal Triamcinolone Injection for Diabetic Macular Edema|Completed||Phase 3|72|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-06-01 01:42:32.942563|2018-06-01 01:42:32.942563
NCT00764231|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2012-02-07|2008-09-30|2008-10-01|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2008||2008-10-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML)|A Pilot Study of a Home-based Exercise Intervention for Patients With AML|Completed||Phase 2|40|Actual|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-06-01 01:42:33.050653|2018-06-01 01:42:33.050653
NCT00764218|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-09-30|2008-09-30|2008-10-01|Estimate|||||||2008-09-30|2008-10-01|Estimate|March 2001||2001-03-31|January 2001|2001-01-31|December 2008|Anticipated|2008-12-31|December 2003|Anticipated|2003-12-31||Interventional|SAS-HTA||Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome|Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome : Role of Hypertension|Unknown status|Recruiting|Early Phase 1|300|Anticipated|University Hospital, Grenoble||4|||f||||t||||||||||2018-06-01 01:42:33.155291|2018-06-01 01:42:33.155291
NCT00764205|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-09-30|2008-09-30|2008-10-01|Estimate|||||||2008-09-30|2008-10-01|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|November 2010|Anticipated|2010-11-30|November 2009|Anticipated|2009-11-30||Observational|||Randomized Trial of Prehospital Tropin Levels in Acute Coronary Syndrome (ACS)|Randomized Trial of Prehospital Troponin Assessment Using the i-STAT Blood Analyzer|Unknown status|Active, not recruiting||1200|Anticipated|Redmond Fire Department Medic One|||2||f||||f||||||||||2018-06-01 01:42:33.270569|2018-06-01 01:42:33.270569
NCT00764192|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2009-01-12|2008-09-29|2008-10-01|Estimate|||||||2009-01-12|2009-01-13|Estimate|October 2006||2006-10-31|January 2009|2009-01-31|October 2007|Actual|2007-10-31|February 2007|Actual|2007-02-28||Interventional|||Influence of Hemodialysis on Endothel-Depending Dilatation of Peripheral Arteries|Angiologic Study of the Influence of Hemodialysis on Endothelial Function|Completed||N/A|14|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-06-01 01:42:33.331787|2018-06-01 01:42:33.331787
NCT00764179|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2016-10-04|2008-09-30|2008-10-01|Estimate|||||||2016-10-04|2016-10-05|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Proneonat||"Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study (Proneonat)"|"Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study (Proneonat)"|Terminated||N/A|93|Actual|Nantes University Hospital||2||difficulties of recruitment, high number of patients lost to follow-up|f||||f||||||||||2018-06-01 01:42:33.426157|2018-06-01 01:42:33.426157
NCT00764166|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-09-30|2008-09-30|2008-10-01|Estimate|||||||2008-09-30|2008-10-01|Estimate|June 2003||2003-06-30|September 2008|2008-09-30|November 2010|Anticipated|2010-11-30|November 2009|Anticipated|2009-11-30||Interventional|RisingPSA||A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel|Non-Metastatic High-Risk Prostate Cancer Patients With Biochemical Relapse Only After Local Treatment. A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel|Unknown status|Active, not recruiting|Phase 3|254|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:42:33.50819|2018-06-01 01:42:33.50819
NCT00764153|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2014-10-22|2008-09-29|2008-10-01|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2002||2002-10-31|October 2014|2014-10-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Hemiarthroplasty or Internal Fixation for Displaced Femoral Neck Fractures - 5 Years Follow up|Hemiarthroplasty or Internal Fixation for Displaced Femoral Neck Fractures - 5 Years Follow up|Completed||N/A|222|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:42:33.578307|2018-06-01 01:42:33.578307
NCT00764140|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2013-04-17|2008-09-29|2008-10-01|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Tumor Growth Factors in Hepatocellular Carcinoma|Insulin-like Growth Factors (IGF) Axis (IGFs, Its Binding Proteins,Receptors), Transforming Growth Factor Alpha and Beta 1 and Epidermal Growth Factor in the Urine and Serum of Patients With Hepatocellular Carcinoma.|Completed|||400|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood and/or urine~   "|||2018-06-01 01:42:33.64756|2018-06-01 01:42:33.64756
NCT00764127|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2013-01-30|2008-09-30|2008-10-01|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||The Development of an Eating Laboratory for Overweight Adolescents|The Development of an Eating Laboratory for Overweight Adolescents|Completed|||36|Actual|New York State Psychiatric Institute|||3||f||||t||||||Samples Without DNA|"~     10 cc (2 teaspoons) of blood will be drawn during the screening assessment to screen for~     medical illness.~      60 cc (12 teaspoons) of blood will be drawn from an indwelling IV catheter during the~     single-item meal to assay for meal-related hormones (ghrelin, leptin,cholecystokinin,~     insulin, peptideY). Bariatric surgery participants may have an additional 20 cc of blood~     taken to measure glucose responses to the meal.~   "|||2018-06-01 01:42:33.717343|2018-06-01 01:42:33.717343
NCT00764114|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2013-05-03|2008-09-30|2008-10-01|Estimate|||||||2013-05-03|2013-05-06|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional|DTS||Comparison of Two Antimicrobial Therapy Duration for Spondylodiscitis|Comparison of Two Antimicrobial Therapy Duration (6 Weeks Versus 12 Weeks)for Spondylodiscitis|Completed||Phase 4|351|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:42:33.782772|2018-06-01 01:42:33.782772
NCT00764101|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2011-07-07|2008-09-29|2008-10-01|Estimate|||||||2011-07-07|2011-07-08|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Attentional Bias Modification in Patients With Posttraumatic Stress Disorder|Effects of Attentional Bias Modification on Attentional Bias and Symptoms of Posttraumatic Stress Disorder|Completed||Phase 2|80|Anticipated|PsyQ||2|||f||||f||||||||||2018-06-01 01:42:33.85564|2018-06-01 01:42:33.85564
NCT00764088|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2015-11-24|2008-09-30|2008-10-01|Estimate|||||||2015-11-24|2015-11-26|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||A Retrospective Analysis of Patients With Full Thickness Wounds on a Case by Case Basis|A Retrospective Analysis of Patients With Full Thickness Wounds on a Case by Case Basis|Completed|||4|Actual|Southwest Regional Wound Care Center|||1||f||||t||||||||||2018-06-01 01:42:33.949517|2018-06-01 01:42:33.949517
NCT00764075|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-07-06|2008-09-29|2008-10-01|Estimate|||||||2011-07-06|2011-07-07|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|EK138/08||Guided Placement of CRT-Leads|CT and 3D-Echocardiography Placement of CRT-Leads|Completed||N/A|132|Anticipated|RWTH Aachen University||3|||f||||f||||||||||2018-06-01 01:42:34.02752|2018-06-01 01:42:34.02752
NCT00764062|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-09-30|2008-09-30|2008-10-01|Estimate|||||||2008-09-30|2008-10-01|Estimate|September 2005||2005-09-30|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|ODAMOX||Amoxicillin Susceptibility of Oral Streptococci After a 3-Day or a 7-Day Amoxicillin Therapy|Randomized Controlled Trial Short Antibiotic Therapy (3-Day) Versus Long Antibiotic Therapy (7-Day) in Odontology-Stomatology: Impact on the Resistance of Oral Streptococci|Terminated||Phase 4|81|Actual|Assistance Publique - Hôpitaux de Paris||2||The trial was stopped earlier than planned because of the slow accrual rate.|f||||f||||||||||2018-06-01 01:42:34.189832|2018-06-01 01:42:34.189832
NCT00764049|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-02-24|2008-09-30|2008-10-01|Estimate|||||||2015-02-24|2015-02-25|Estimate|June 2009||2009-06-30|February 2015|2015-02-28|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|DACAR||Single Pass Albumin Dialysis in Patients With Cirrhosis|Prospective Pilot Study Assessing Safety and Efficacy of Single Pass Albumin Dialysis in Patients With Acute on Chronic Liver Failure|Completed||Phase 1/Phase 2|11|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:42:34.288324|2018-06-01 01:42:34.288324
NCT00764036|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-07-28|2008-09-30|2008-10-01|Estimate|||||||2017-07-28|2017-08-01|Actual|October 2008|Actual|2008-10-31|July 2017|2017-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ARTIC-M33/2||Study of Artesunate in Metastatic Breast Cancer|Prospective Open Uncontrolled Phase I Study of Compatibility, Safety&Pharmacokinetics of Artesunate, a Semisynthetic Derivative of Artemisinin From the Chinese Herb Artemisia Annua in Patients With Metastatic/Locally Advanced Breast Cancer|Completed||Phase 1|23|Actual|Heidelberg University||1|||f||||t|f|f||||||No||2018-06-01 01:42:34.357157|2018-06-01 01:42:34.357157
NCT00764023|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-11-24|2008-09-30|2008-10-01|Estimate|||||||2015-11-24|2015-11-26|Estimate|March 2008||2008-03-31|November 2015|2015-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune, or Host-Microbe Scientific Study|A Multi-Center Protocol for Obtaining and Storing Human Samples for Immediate or Future Microbial, Immune,or Host-Microbe Scientific Study|Completed|||97|Actual|Southwest Regional Wound Care Center|||2||f||||t||||||Samples With DNA|"~     The intent of this protocol is to salvage human-related material that is normally destined~     for destruction, so it can be used in infection-related scientific studies~   "|||2018-06-01 01:42:34.452119|2018-06-01 01:42:34.452119
NCT00764010|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-06-30|2008-09-30|2008-10-01|Estimate|||||||2011-06-30|2011-07-01|Estimate|May 1997||1997-05-31|September 2008|2008-09-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|DOIT||Diet and Omega-3 Intervention Trial on Atherosclerosis|Diet and Omega-3 Intervention Trial on Atherosclerosis|Completed||Phase 3|563|Actual|Oslo University Hospital||4|||f||||t||||||||||2018-06-01 01:42:34.531553|2018-06-01 01:42:34.531553
NCT00763997|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2008-09-29|2008-09-29|2008-10-01|Estimate|||||||2008-09-29|2008-10-01|Estimate|February 2004||2004-02-29|September 2008|2008-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages|Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation|Completed||N/A|80|Actual|Ruhr University of Bochum||4|||f||||f||||||||||2018-06-01 01:42:34.609841|2018-06-01 01:42:34.609841
NCT00763984|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-01-14|2008-09-30|2008-10-01|Estimate|||||||2015-01-14|2015-01-15|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Self-Care to Prevent Birth-Related Urinary Incontinence in Diverse Women|PERL 4: Promoting Effective Recovery From Labor|Completed||Phase 3|432|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:42:34.698333|2018-06-01 01:42:34.698333
NCT00763971|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2012-02-27||2014-06-06|2008-09-30|2008-10-01|Estimate|2012-02-27|2012-03-22|Estimate||||2014-06-06|2014-06-12|Estimate|October 2008||2008-10-31|August 2013|2013-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17|A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|336|Actual|Shire||3|||f||||||||||||||2018-06-01 01:42:34.834219|2018-06-01 01:42:34.834219
NCT00763958|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2011-02-04||2012-05-01|2008-09-29|2008-10-01|Estimate|2012-05-01|2012-06-04|Estimate||||2012-05-01|2012-06-04|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Relapse Prevention to Reduce HIV Among Women Prisoners|Relapse Prevention to Reduce HIV Among Women Prisoners|Completed||Phase 4|44|Actual|University of Alabama at Birmingham|Slow recruitment with poor retention. Transient population that was difficult to effectively track.|2|||f||||t||||||||||2018-06-01 01:42:35.978533|2018-06-01 01:42:35.978533
NCT00763945|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2009-09-17|2008-09-29|2008-10-01|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|ADMIRE||Infarction Register|Aachen Digital Myocardial Infarction Register|Completed|||5000|Anticipated|RWTH Aachen University|||1||f||||f||||||||||2018-06-01 01:42:36.378093|2018-06-01 01:42:36.378093
NCT00763932|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2014-02-04|2008-09-30|2008-10-01|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2003||2003-04-30|February 2014|2014-02-28|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Extension Study of Long-term Safety and Efficacy of Myozyme in Patients With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored Enzyme Replacement Therapy (ERT) Studies|A Multicenter, Open-Label Extension Study of the Long-Term Safety and Efficacy of Recombinant Human Acid α-Glucosidase (rhGAA) in Patients With Pompe Disease (Glycogen Storage Disease Type II) Who Were Previously Enrolled in Genzyme-Sponsored Enzyme Replacement Therapy Studies|Completed||Phase 2|7|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 01:42:36.510959|2018-06-01 01:42:36.510959
NCT00763919|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2011-10-24||2014-10-09|2008-09-29|2008-10-01|Estimate|2011-11-16|2011-12-21|Estimate||||2014-10-09|2014-10-20|Estimate|July 2008||2008-07-31|October 2014|2014-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Customized Medication Adherence Enhancement for Treating Adults With Bipolar Disorder|Customized Adherence Enhancement in Bipolar Disorder (CAE in BD)|Completed||N/A|43|Actual|Case Western Reserve University||1|||f||||t||||||||||2018-06-01 01:42:36.60333|2018-06-01 01:42:36.60333
NCT00763906|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-09-30|2008-09-30|2008-10-01|Estimate|||||||2008-09-30|2008-10-01|Estimate|November 2004||2004-11-30|September 2008|2008-09-30|January 2007|Actual|2007-01-31|November 2006|Actual|2006-11-30||Interventional|CATECHOFLOU||Norepinephrine Weaning in Septic Patients|Continuous Administration of Norepinephrine Assisted by Fuzzy Logic Assisted Control in Septic Shock Patients|Completed||Phase 4|40|Actual|Association pour le Développement de la Recherche et de l'Enseignement en Médecine d'Urgence||2|||f||||t||||||||||2018-06-01 01:42:37.241124|2018-06-01 01:42:37.241124
NCT00763893|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-11-03|2008-09-30|2008-10-01|Estimate|||||||2015-11-03|2015-11-04|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|MARFANSARTAN||Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome|Multicenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome|Terminated||Phase 3|303|Actual|Assistance Publique - Hôpitaux de Paris||2||"A similar publication has been released, suggesting a beneficial effect of sartans, and only 15~   patients remained to be seen for their visit at 36 months."|f||||t||||||||||2018-06-01 01:42:37.401647|2018-06-01 01:42:37.401647
NCT00763880|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2013-11-18|2008-09-26|2008-10-01|Estimate|||||||2013-11-18|2013-11-19|Estimate|November 2005||2005-11-30|November 2013|2013-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction|Hematoma Blocks in Forearm Fractures: An Effective Adjunct to Procedural Sedation?|Terminated||Phase 4|89|Actual|Rhode Island Hospital||2||Recruitment was taking longer than originally anticipated.|f||||t||||||||||2018-06-01 01:42:37.552133|2018-06-01 01:42:37.552133
NCT00763867|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2013-04-04||2014-07-14|2008-09-30|2008-10-01|Estimate|2013-07-02|2013-07-03|Estimate||||2014-07-14|2014-07-23|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|RELAX||Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)|Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)|Completed||Phase 3|216|Actual|Duke University||2|||f||||t||||||||||2018-06-01 01:42:37.787658|2018-06-01 01:42:37.787658
NCT00763841|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2010-01-19|2008-09-30|2008-10-01|Estimate|||||||2010-01-19|2010-01-20|Estimate|September 1999||1999-09-30|November 2009|2009-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Transcranial Magnetic Stimulation (TMS) for Treatment of Auditory Hallucinations|A Pilot Study Using Transcranial Magnetic Stimulation (TMS) to Investigate the Role of the Temporal Cortex in Schizophrenic Patients With Auditory Hallucinations|Completed||Phase 1|18|Anticipated|The University of New South Wales||2|||f||||f||||||||||2018-06-01 01:42:39.14718|2018-06-01 01:42:39.14718
NCT00763828|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-08-23|2008-09-30|2008-10-01|Estimate|||||||2017-08-23|2017-08-25|Actual|February 2018|Anticipated|2018-02-28|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|CHIPAHA||Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack?|Can Hypothermia be Incorporated Into Primary Angioplasty for Heart Attack?|Not yet recruiting||N/A|20|Anticipated|Life Recovery Systems||1|||f||||t|f|t|f|||||||2018-06-01 01:42:39.216092|2018-06-01 01:42:39.216092
NCT00763815|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2016-08-18|2012-05-07|2016-10-14|2008-09-30|2008-10-01|Estimate|2016-08-18|2016-10-11|Estimate|2012-05-07|2012-05-10|Estimate|2016-10-14|2016-11-28|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|GETGOAL-P|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone|Completed||Phase 3|484|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:42:39.371519|2018-06-01 01:42:39.371519
NCT00763802|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2014-04-04|2008-09-30|2008-10-01|Estimate|||||||2014-04-04|2014-04-07|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Observational|CPM||Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2|Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2|Completed|||400|Actual|Association for Innovation and Biomedical Research on Light and Image|||1||f||||||||||||||2018-06-01 01:42:40.344914|2018-06-01 01:42:40.344914
NCT00763633|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2008-12-30|2008-09-29|2008-10-01|Estimate|||||||2008-12-30|2008-12-31|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||B6 Treatment for Nausea and Vomiting in Pregnancy|Vitamin B6 Concentration and Treatment in Nausea and Vomiting of Pregnancy|Unknown status|Recruiting|Phase 4|150|Anticipated|Showa University||2|||f||||t||||||||||2018-06-01 01:42:41.841689|2018-06-01 01:42:41.841689
NCT00763789|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2010-01-05|2008-09-30|2008-10-01|Estimate|||||||2010-01-05|2010-01-06|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|September 2010|Anticipated|2010-09-30|||||Interventional|||Local Anaesthesia and Remifentanil Sedation Versus Total Intravenous Anaesthesia for Hysteroscopic Surgery in an Ambulatory Surgery Department.|Local Anaesthesia and Remifentanil Sedation Versus Total Intravenous Anaesthesia for Hysteroscopic Surgery in an Ambulatory Surgery Department. A Randomized Clinical Trial.|Unknown status|Recruiting|N/A|96|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||||||||||||2018-06-01 01:42:40.42643|2018-06-01 01:42:40.42643
NCT00763776|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2014-02-26|2008-09-30|2008-10-01|Estimate|||||||2014-02-26|2014-02-27|Estimate|July 2008||2008-07-31|January 2011|2011-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|SECCI||Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector|Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the Ultrasonic Dissector : Randomized Comparative Study.|Terminated||N/A|27|Actual|Assistance Publique - Hôpitaux de Paris||2||difficulty for the patient recruiting|f||||f||||||||||2018-06-01 01:42:40.512669|2018-06-01 01:42:40.512669
NCT00763763|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2011-10-04|2008-09-30|2008-10-01|Estimate|||||||2011-10-04|2011-10-05|Estimate|December 2004||2004-12-31|October 2011|2011-10-31|January 2010|Actual|2010-01-31|October 2007|Actual|2007-10-31||Interventional|AFR07||Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive|Study to Evaluate Efficacy and Safety of Glivec® in Combination With Vincristine and Dexamethasone in Patients With Lymphoid Blast Crisis CML or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Relapse or Refractory|Completed||Phase 2|55|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:42:40.594646|2018-06-01 01:42:40.594646
NCT00763750|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2013-05-09||2014-06-18|2008-09-30|2008-10-01|Estimate|2013-10-25|2013-12-16|Estimate||||2014-06-18|2014-06-27|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional|||BrUOG-Brain-223:A Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103)|BrUOG-Brain-223-A Phase II Study of PPX (CT-2103), Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors (CTI # CT2103) Principal Investigator: Howard Safran, M.D.|Completed||Phase 2|25|Actual|Brown University||1|||f||||t||||||||||2018-06-01 01:42:40.713009|2018-06-01 01:42:40.713009
NCT00763737|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2018-05-25|2008-09-30|2008-10-01|Estimate|||||||2018-05-25|2018-05-30|Actual|August 2010||2010-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|TOTAL moderate||Randomized Controlled Trial of Fetoscopic Endoluminal Tracheal Occlusion With a Balloon Versus Expectant Management During Pregnancy in Fetuses With Left Sided Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia.|Randomized Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) Versus Expectant Management During Pregnancy in Fetuses With Left Sided and Isolated Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia.|Recruiting||N/A|196|Anticipated|University Hospital, Gasthuisberg||2|||f||||t||||||||||2018-06-01 01:42:40.910926|2018-06-01 01:42:40.910926
NCT00763724|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2010-03-09|2008-09-30|2008-10-01|Estimate|||||||2010-03-09|2010-03-10|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults|A Propensity-Matched Retrospective Cohort Study of Antidepressant Drug Exposure and Risk of Suicide Attempt in Adults From a Large U.S. Managed Care Population|Completed|||254432|Actual|Eli Lilly and Company|||7||f||||f||||||||||2018-06-01 01:42:41.067556|2018-06-01 01:42:41.067556
NCT00763711|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2012-01-09|2008-09-30|2008-10-01|Estimate|||||||2012-01-09|2012-01-10|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|NG||Injectable Bulking Agent Needle Guide|Injectable Bulking Agent Needle Guide|Terminated||Phase 1|17|Actual|Carbon Medical Technologies||1|||f||||f||||||||||2018-06-01 01:42:41.138585|2018-06-01 01:42:41.138585
NCT00763698|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2011-07-26||2011-09-28|2008-09-29|2008-10-01|Estimate|2011-09-28|2011-11-04|Estimate||||2011-09-28|2011-11-04|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|May 2010|Actual|2010-05-31|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy Study of the QuickFlex Micro Model 1258T Left Heart Pacing Lead|QuickFlex Micro Model 1258T Left Heart Pacing Lead|Completed||N/A|86|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 01:42:41.292429|2018-06-01 01:42:41.292429
NCT00763685|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2012-01-29|2008-09-30|2008-10-01|Estimate|||||||2012-01-29|2012-01-31|Estimate|June 2010||2010-06-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery|Double-Blind, Randomized, Placebo -Controlled Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery|Terminated||Phase 4|40|Actual|East Tallinn Central Hospital||3||"The gynecological laparoscopic surgery transition to day surgery made following the study~   protocol not possible."|f||||f||||||||||2018-06-01 01:42:41.526461|2018-06-01 01:42:41.526461
NCT00763672|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2013-03-26|2008-09-30|2008-10-01|Estimate|||||||2013-03-26|2013-03-28|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|MOMA||MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study|Impact of a Single Second-trimester Plasma sFlt-1 and/or Urinary PlGF Assay on Maternofetal Morbidity/Mortality|Completed||N/A|1040|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:42:41.607541|2018-06-01 01:42:41.607541
NCT00763659|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2012-07-19|2008-09-30|2008-10-01|Estimate|||||||2012-07-19|2012-07-20|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|LUTEGA||Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)|Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)|Completed||N/A|172|Actual|University of Jena||3|||f||||f||||||||||2018-06-01 01:42:41.6836|2018-06-01 01:42:41.6836
NCT00763646|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2008-10-20|2008-09-30|2008-10-01|Estimate|||||||2008-10-20|2008-10-21|Estimate|April 2007||2007-04-30|September 2008|2008-09-30||||December 2010|Anticipated|2010-12-31||Interventional|||Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma|Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|McGill University|||||f||||t||||||||||2018-06-01 01:42:41.744831|2018-06-01 01:42:41.744831
NCT00763620|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2011-09-22|2008-09-30|2008-10-01|Estimate|||||||2011-09-22|2011-09-23|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Mini-LBA||Assessment of the Diagnostic Capacity of the Mini-broncho Alveolar Lavage Performed Through a Suction Catheter|Assessment of the Diagnostic Capacity of a New Sampling Technique for Lower Respiratory Tract Culture for Patients With Acute Infectious Pneumonia Admitted in Intensive Care Unit and Non Intubated.|Completed||N/A|36|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:42:41.942329|2018-06-01 01:42:41.942329
NCT00763607|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2010-09-01|2008-09-30|2008-10-01|Estimate|||||||2010-09-01|2010-09-02|Estimate|November 2007||2007-11-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|February 2008|Actual|2008-02-29||Observational|||Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)|Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer|Completed|||454|Anticipated|Istituto Clinico Humanitas|||1||f||||f||||||Samples With DNA|"~     Paraffine embedded tumor sections~   "|||2018-06-01 01:42:42.052007|2018-06-01 01:42:42.052007
NCT00763594|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2015-08-31|2008-09-30|2008-10-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|May 2016|Anticipated|2016-05-31||Interventional|LURIPP||Linköping University Relational and Interpersonal Psychotherapy Project|Randomized Controlled Trial of Interpersonal and Brief Relational Psychotherapy for Major Depressive Disorder.|Unknown status|Recruiting|Phase 2|120|Anticipated|Linkoeping University||2|||f||||f||||||||||2018-06-01 01:42:42.116393|2018-06-01 01:42:42.116393
NCT00763581|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2017-01-31|2008-09-29|2008-10-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2008||2008-04-30|January 2017|2017-01-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Observational|||Personal Adherence Evaluation of Medication Use for Adult Bipolar Disorder Patients|Personal Adherence Evaluation of Individuals Receiving Treatment for Bipolar Disorder (PAE in BD)|Completed|||20|Actual|Case Western Reserve University|||||f||||t||||||||||2018-06-01 01:42:42.285956|2018-06-01 01:42:42.285956
NCT00763568|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2008-09-26|2008-09-26|2008-10-01|Estimate|||||||2008-09-26|2008-10-01|Estimate|August 2006||2006-08-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C|Study of a 4-Week Lead-In With Nitazoxanide Followed By 36 Weeks of Nitazoxanide Plus Peginterferon Alfa-2a in the Treatment of Chronic Hepatitis C|Completed||Phase 2|40|Actual|Romark Laboratories L.C.||1|||f||||f||||||||||2018-06-01 01:42:42.33859|2018-06-01 01:42:42.33859
NCT00763555|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30||2010-10-16|2012-01-06|2008-09-30|2008-10-01|Estimate||||2010-12-02|2010-12-06|Estimate|2012-01-06|2012-01-11|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis|A Multicenter, Randomized, Vehicle-controlled, Efficacy and Safety Study of CD2027 3µg/g Oily Spray Applied Twice Daily for 8 Weeks in Subjects With Plaque-type Psoriasis|Completed||Phase 2|88|Actual|Galderma||2|||f||||||||||||||2018-06-01 01:42:42.402008|2018-06-01 01:42:42.402008
NCT00763542|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2013-11-03|2008-09-30|2008-10-01|Estimate|||||||2013-11-03|2013-11-05|Estimate|July 2008||2008-07-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|July 2011|Actual|2011-07-31||Interventional|||Combined Treatment for Patients With Comorbid Substance Use Disorders and Post-traumatic Stress Disorder (PTSD): an Integration of Cognitive-behavioral Treatment (CBT) and Trauma-focused Structured Writing Therapy|A Randomized Controlled Trial Comparing (1) a Combined Treatment of CBT for Substance Use Disorders (SUD) and Trauma-focused Structured Writing Therapy With (2) CBT for SUD Alone in Patients With Comorbid SUD and PTSD|Completed||Phase 2|130|Actual|VU University of Amsterdam||2|||f||||f||||||||||2018-06-01 01:42:42.466369|2018-06-01 01:42:42.466369
NCT00763529|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2017-09-21|2008-09-29|2008-10-01|Estimate|||||||2017-09-21|2017-09-25|Actual|January 1, 2003|Actual|2003-01-01|September 2017|2017-09-30|January 1, 2005|Actual|2005-01-01|January 1, 2005|Actual|2005-01-01||Interventional|||Elocon vs Fluticasone in Localized Psoriasis (P03197)|Elocon vs Fluticasone in Localized Psoriasis|Completed||Phase 4|245|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:42:42.535865|2018-06-01 01:42:42.535865
NCT00763516|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2017-09-01|2008-09-30|2008-10-01|Estimate|||||||2017-09-01|2017-09-06|Actual|February 2009||2009-02-28|September 2017|2017-09-30|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Interventional|PC02||Proton Radiation for Resectable Carcinoma of the Pancreas|A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas|Completed||N/A|8|Actual|University of Florida||1|||f||||t|f|f||||||Undecided||2018-06-01 01:42:42.621929|2018-06-01 01:42:42.621929
NCT00763503|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29||2010-10-13|2012-01-06|2008-09-30|2008-10-01|Estimate||||2010-10-13|2010-10-19|Estimate|2012-01-06|2012-01-11|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis|Pharmacokinetic and Pharmacodynamic Study of CD 2027 3µg/g Oily Spray Applied Twice Daily for 3 Weeks Under Conditions of Maximized Use in Adults With Plaque-type Psoriasis|Completed||Phase 2|26|Actual|Galderma||1|||f||||||||||||||2018-06-01 01:42:42.728849|2018-06-01 01:42:42.728849
NCT00763490|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2015-01-05||2016-11-03|2008-09-30|2008-10-01|Estimate|2015-01-05|2015-01-12|Estimate||||2016-11-03|2016-12-23|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|March 2013|Actual|2013-03-31||Interventional|||Trial Of Double Umbilical Cord Blood Transplantation|Trial Of Double Umbilical Cord Blood Transplantation|Completed||Phase 2|20|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 01:42:42.865085|2018-06-01 01:42:42.865085
NCT00763477|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2010-07-26|2008-09-30|2008-10-01|Estimate|||||||2010-07-26|2010-07-27|Estimate|April 2010||2010-04-30|July 2010|2010-07-31|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Interventional|ghrelin||Ghrelin in Cystic Fibrosis|The Effect of Ghrelin on Appetite and Immune Function in Patients With Cystic Fibrosis|Unknown status|Recruiting|N/A|20|Anticipated|Papworth Hospital||1|||f||||t||||||||||2018-06-01 01:42:43.102418|2018-06-01 01:42:43.102418
NCT00763464|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2011-07-06|2008-09-29|2008-10-01|Estimate|||||||2011-07-06|2011-07-07|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|FEMCAD||Coronary Artery Disease (CAD) in Postmenopausal Women|Coronary Artery Disease in Postmenopausal Women. Comparison of Myocardial Szintigraphy With Sress-Echocardiography and Stress-MRI.|Completed||N/A|100|Anticipated|RWTH Aachen University|||||f||||f||||||||||2018-06-01 01:42:43.212811|2018-06-01 01:42:43.212811
NCT00763113|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2017-06-15|2008-09-26|2008-09-30|Estimate|||||||2017-06-15|2017-06-16|Actual|June 2007||2007-06-30|June 2017|2017-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Prospective Randomized Study on Vanguard Cruciate Retaining Versus Vanguard High Flex Posterior Stabilized Total Knee System in the Early Range of Motion|A Prospective Randomized Study on Vanguard Cruciate Retaining Versus Vanguard High Flex Posterior Stabilized Total Knee System in the Early Range of Motion|Completed||N/A|173|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:42:50.513079|2018-06-01 01:42:50.513079
NCT00763451|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|2016-08-18|2012-02-21|2016-10-21|2008-09-30|2008-10-01|Estimate|2016-10-21|2016-12-14|Estimate|2012-02-21|2012-02-23|Estimate|2016-10-21|2016-12-14|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|GETGOAL-F1|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin|Completed||Phase 3|484|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 01:42:43.366632|2018-06-01 01:42:43.366632
NCT00763438|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-30|||2016-11-07|2008-09-30|2008-10-01|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia|A Prospective, Open-label, Single-arm, Multinational, Multi-centre, Flexible-dose, Extension Study of the SCoP 99824 With Sertindole for Patients Suffering From Schizophrenia|Completed||Phase 4|18|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-06-01 01:42:44.720249|2018-06-01 01:42:44.720249
NCT00763425|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2015-11-17|2008-09-30|2008-10-01|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|COLD||Prospective Randomized Comparison of Cold Snare Polypectomy and Conventional Polypectomy||Completed||N/A|200|Actual|Showa Inan General Hospital||2|||f||||f||||||||||2018-06-01 01:42:44.798169|2018-06-01 01:42:44.798169
NCT00763412|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2016-07-11||2017-05-03|2008-09-30|2008-10-01|Estimate|2017-05-03|2017-06-05|Actual||||2017-05-03|2017-06-05|Actual|November 2006||2006-11-30|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Patients attended the Washington University CF Clinics between 2006 and 2008.|Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis|Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis|Completed||N/A|31|Actual|Arbelaez, Ana Maria|A limitation of the study was the very small sample size.|2|||f||||t|t|f||||||Undecided|The outcome was inconclusive for this hypothesis, but the data may be valuable in future research. We are not currently sharing data from this project.|2018-06-01 01:42:44.871564|2018-06-01 01:42:44.871564
NCT00763399|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2012-07-16|2008-09-29|2008-10-01|Estimate|||||||2012-07-16|2012-07-17|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Probiotics on Intestinal Bacterial Population and Immune Modulation|Phase 4 Study of Probiotics on Intestinal Bacterial Population and Immune Modulation|Completed||Phase 4|300|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 01:42:45.389768|2018-06-01 01:42:45.389768
NCT00763386|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2011-12-13||2012-05-25|2008-09-29|2008-09-30|Estimate|2012-05-24|2012-05-25|Estimate||||2012-05-25|2012-06-04|Estimate|June 2001||2001-06-30|May 2012|2012-05-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Compare the NexGen LPS and LPS-Flex Knee Implants|Prospective Randomized Multicenter Study of NexGen LPS-Flex Knee|Completed||N/A|331|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:42:45.456689|2018-06-01 01:42:45.456689
NCT00763373|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2008-09-29|2008-09-29|2008-09-30|Estimate|||||||2008-09-29|2008-09-30|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Observational|||Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch|Unnecessary IV Antibiotic Days Using General Criteria for Antibiotic Switch|Completed|||187|Actual|Sorlandet Hospital HF|||2||f||||f||||||||||2018-06-01 01:42:45.775302|2018-06-01 01:42:45.775302
NCT00763360|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2011-12-20||2011-12-20|2008-09-29|2008-09-30|Estimate|2011-12-20|2012-01-24|Estimate||||2011-12-20|2012-01-24|Estimate|May 2008||2008-05-31|December 2011|2011-12-31||||September 2010|Actual|2010-09-30||Interventional|||To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.|To Compare the Ability of DiscoVisc® Ophthalmic Viscosurgical Device (OVD) to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.|Completed||Phase 4|184|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 01:42:45.860998|2018-06-01 01:42:45.860998
NCT00763347|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-05-18|2008-09-29|2008-09-30|Estimate|||||||2012-05-18|2012-05-21|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate Treatment With SYR-619 in Subjects With Type 2 Diabetes|Terminated||Phase 2|82|Actual|Takeda||6||Voluntarily terminated based on preliminary non-clinical findings.|f||||f||||||||||2018-06-01 01:42:46.148653|2018-06-01 01:42:46.148653
NCT00763321|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2013-11-01|2011-11-22|2014-01-08|2008-09-29|2008-09-30|Estimate|2013-11-01|2013-12-23|Estimate|2011-11-22|2011-11-24|Estimate|2014-01-08|2014-02-06|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)|A Phase 3, Open-Label Period Followed by a Randomized, Double-blind Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain|Completed||Phase 3|287|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 01:42:46.238724|2018-06-01 01:42:46.238724
NCT00763308|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-26|2008-09-26|2008-09-30|Estimate|||||||2008-09-26|2008-09-30|Estimate|April 2009||2009-04-30|September 2008|2008-09-30|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||A Web-Based Cardiovascular Intervention for the Workplace|Fast Track Program to Create a Web-Based Cardiovascular Intervention for the Workplace|Unknown status|Not yet recruiting|Phase 1|300|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||f||||||||||2018-06-01 01:42:47.522971|2018-06-01 01:42:47.522971
NCT00763295|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-28|||2012-10-25|2008-09-28|2008-09-30|Estimate|||||||2012-10-25|2012-10-26|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?|Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?|Completed|||53|Actual|Northwell Health|||1||f||||f||||||||||2018-06-01 01:42:47.611904|2018-06-01 01:42:47.611904
NCT00763100|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-01-05|2008-09-26|2008-09-30|Estimate|||||||2011-01-05|2011-01-06|Estimate|May 2008||2008-05-31|January 2011|2011-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|BIRADS||Efficacy of Tomosynthesis in the BIRADS 3 Population|The Efficacy of Tomosynthesis in the BIRADS 3 Population Including Surveillance of Patients in the Treatment or Post-Treatment for Breast Cancer|Completed|||690|Anticipated|WellSpan Health|||1||f||||t||||||||||2018-06-01 01:42:50.581767|2018-06-01 01:42:50.581767
NCT00763282|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-11-24||2015-04-06|2008-09-29|2008-09-30|Estimate|2015-01-07|2015-01-08|Estimate||||2015-04-06|2015-04-27|Estimate|November 2008||2008-11-30|October 2014|2014-10-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional||For the SM+MI arm there was 1 death (post-randomization, pre-data collection) which accounts for the discrepency between starting participants (72) and baseline participants (71) for that group.|Self-Management to Prevent Ulcers in Veterans With SCI (Spinal Cord Injury)|Self-Management to Prevent Ulcers in Veterans With Spinal Cord Injury|Completed||N/A|144|Actual|VA Office of Research and Development|The study was underpowered because of difficulties encountered with recruitment and retention. Delivering an adequate “dose” of the treatments and site coordinator fidelity to the MI intervention were also limitations.|2|||f||||t||||||||||2018-06-01 01:42:47.703316|2018-06-01 01:42:47.703316
NCT00763269|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-08-24||2012-03-05|2008-09-26|2008-09-30|Estimate|2010-08-24|2010-09-17|Estimate||||2012-03-05|2012-03-07|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Efficacy of a Toothpaste to Reduce Sensitivity|The Efficacy of a Toothpaste to Reduce Sensitivity|Completed||Phase 3|626|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:42:48.60351|2018-06-01 01:42:48.60351
NCT00763256|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2012-03-05||2015-07-10|2008-09-29|2008-09-30|Estimate|2012-03-05|2012-04-02|Estimate||||2015-07-10|2015-07-28|Estimate|May 2006||2006-05-31|July 2015|2015-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics|The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics|Completed||Phase 3|33|Actual|Colgate Palmolive||2|||f||||t||||||||||2018-06-01 01:42:48.896141|2018-06-01 01:42:48.896141
NCT00763243|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2013-11-05||2017-04-13|2008-09-29|2008-09-30|Estimate|2017-04-13|2017-07-11|Actual||||2017-04-13|2017-07-11|Actual|August 2008||2008-08-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Pilot Study of the Feasibility and Efficacy of Working Memory Training in Children With Cochlear Implants|Pilot Study of the Feasibility and Efficacy of Working Memory Training in Children With Cochlear Implants|Completed||N/A|9|Actual|Indiana University||1|||f||||t||||||||No||2018-06-01 01:42:49.227218|2018-06-01 01:42:49.227218
NCT00763230|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-04-29|2008-09-26|2008-09-30|Estimate|||||||2011-04-29|2011-05-02|Estimate|April 2008||2008-04-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of Transcranial Direct Current Stimulation (tDCS) to Treat Depression|A Sham-controlled Study of Transcranial Direct Current Stimulation (tDCS) as a Treatment for Depression|Completed||Phase 2/Phase 3|68|Anticipated|The University of New South Wales||2|||f||||f||||||||||2018-06-01 01:42:49.500112|2018-06-01 01:42:49.500112
NCT00763217|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2015-05-12|2008-09-29|2008-09-30|Estimate|||||||2015-05-12|2015-05-13|Estimate|June 2005||2005-06-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2009|Actual|2009-06-30||Observational|biostroke||Clinical Biological and Pharmacological Factors Influencing Stroke Outcome|Characterization of Clinical, Biological and Pharmacological Markers of Stroke Outcome|Completed|||550|Actual|University Hospital, Lille|||1||f||||f||||||Samples Without DNA|"~     whole blood and serum~   "|||2018-06-01 01:42:49.582881|2018-06-01 01:42:49.582881
NCT00763204|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2018-02-28|2008-09-26|2008-09-30|Estimate|||||||2018-02-28|2018-03-02|Actual|February 29, 2008|Actual|2008-02-29|February 2018|2018-02-28|March 31, 2008|Actual|2008-03-31|March 31, 2008|Actual|2008-03-31||Interventional|||A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test|A Phase I, Randomized, Observer-blind, Single-center, Vehicle- And Comparator-controlled, Initial Dose-ranging Study To Assess The Antipsoriatic Efficacy Of Different Concentrations Of An2728 Cream In A Psoriasis Plaque Test|Completed||Phase 1|12|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:42:49.66103|2018-06-01 01:42:49.66103
NCT00763191|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2012-12-07|2008-09-29|2008-09-30|Estimate|||||||2012-12-07|2012-12-10|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Analysis of Oculo-motor Deficiencies Associated With FMR1 Gene Expression (Genetic Abnormality Predisposing to a Neurodegenerative Disease)|Analysis of Oculo-motor Deficiencies Associated With FMR1 Gene Expression (Genetic Abnormality Predisposing to a Neurodegenerative Disease)|Terminated||N/A|27|Actual|Nantes University Hospital||||departure of the principal investigator and nobody else was able to continue this study.|f||||f||||||||||2018-06-01 01:42:49.831074|2018-06-01 01:42:49.831074
NCT00763178|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2015-04-21|2008-09-29|2008-09-30|Estimate|||||||2015-04-21|2015-04-23|Estimate|February 2007||2007-02-28|April 2015|2015-04-30|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||Effects of Duloxetine on Fear Conditioning in Posttraumatic Stress Disorder (PTSD)|Effects of Duloxetine on Fear Conditioning in PTSD|Completed||Early Phase 1|26|Actual|Yale University||1|||f||||f||||||||||2018-06-01 01:42:49.892857|2018-06-01 01:42:49.892857
NCT00763165|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2008-09-30|2008-09-26|2008-09-30|Estimate|||||||2008-09-30|2008-10-02|Estimate|November 2000||2000-11-30|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Periodontal Disease and Cardiovascular Disease|Periodontal Disease and Cardiovascular Disease|Unknown status|Active, not recruiting|Phase 3|438|Actual|Colgate Palmolive||2|||f||||t||||||||||2018-06-01 01:42:49.978914|2018-06-01 01:42:49.978914
NCT00763152|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2015-10-13|2008-09-26|2008-09-30|Estimate|||||||2015-10-13|2015-10-15|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||CMT-07-08: The PROstate Bed Evaluation Study|The Probe Study - The PROstate Bed Evaluation - A Study to Record the Implant Experience, Transponder Stability and Tracking Data of the Calypso 4D Localization Study in the Prostate Bed|Completed|||12|Actual|Varian Medical|||1||f||||f||||||||||2018-06-01 01:42:50.065624|2018-06-01 01:42:50.065624
NCT00763139|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-05-21||2014-11-12|2008-09-29|2008-09-30|Estimate|2014-11-12|2014-11-13|Estimate||||2014-11-12|2014-11-13|Estimate|April 2009||2009-04-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional|||Inflammation and Insulin Resistance in Rheumatoid Arthritis|Inflammation and Insulin Resistance in Rheumatoid Arthritis|Completed||N/A|34|Actual|Vanderbilt University|Study relatively small, but efficiently designed. Crossover design has the advantage of comparing changes in the same patient and the disadvantage that subtle, undetected carryover effects may occur. 8 week drug exposure shorter than most trials.|2|||f||||t||||||||||2018-06-01 01:42:50.177002|2018-06-01 01:42:50.177002
NCT00763126|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-28|||2008-09-29|2008-09-29|2008-09-30|Estimate|||||||2008-09-29|2008-09-30|Estimate|October 2008||2008-10-31|September 2008|2008-09-30||||October 2009|Anticipated|2009-10-31||Interventional|||Does Having a Spouse Present During Epidural Analgesia Affect Stress Levels in the Parturient and Her Spouse?|The Effect of the Presence of a Spouse on the Parturient's and Her Spouse's Stress Level During Epidural Analgesia During Labor as Measured by Salivary Amylase|Unknown status|Not yet recruiting|N/A|200|Anticipated|Rabin Medical Center||2|||f||||||||||||||2018-06-01 01:42:50.442329|2018-06-01 01:42:50.442329
NCT00763087|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2017-11-03|2008-09-26|2008-09-30|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2008||2008-09-30|November 2017|2017-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet|Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet|Completed||N/A|43|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 01:42:50.634985|2018-06-01 01:42:50.634985
NCT00763074|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2008-12-11|2008-09-29|2008-09-30|Estimate|||||||2008-12-11|2008-12-12|Estimate|April 2006||2006-04-30|September 2008|2008-09-30|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Exercise and Diet in Type 2 Diabetic Women|Clinical Trial of Exercise and Diet in Type 2 Diabetic Women|Completed||N/A|70|Actual|Eulji University Hospital||4|||f||||t||||||||||2018-06-01 01:42:50.717651|2018-06-01 01:42:50.717651
NCT00763061|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2009-04-28||2010-02-23|2008-09-29|2008-09-30|Estimate|2009-12-21|2010-01-26|Estimate||||2010-02-23|2010-03-02|Estimate|May 2006||2006-05-31|February 2010|2010-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension|A Twelve-Week, Double Masked, Parallel Group, Study of Travoprost 0.004% Compared to Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 4|111|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:42:50.802798|2018-06-01 01:42:50.802798
NCT00763048|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-08-19||2011-06-10|2008-09-26|2008-09-30|Estimate|2011-02-02|2011-03-01|Estimate||||2011-06-10|2011-06-14|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Collection of Gingival Crevicular Fluid From Periodontitis Patients|Collection of Gingival Crevicular Fluid From Periodontitis Patients|Completed||Phase 3|39|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:42:51.04472|2018-06-01 01:42:51.04472
NCT00763035|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-07-28|2008-09-29|2008-09-30|Estimate|||||||2011-07-28|2011-07-29|Estimate|January 2009||2009-01-31|April 2010|2010-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)|Comparison of Dobutamine and Regadenoson Stress CMR|Terminated||Phase 4|40|Anticipated|Wake Forest University Health Sciences||2||Potential participants with COPD/asthma unwilling to participate.|f||||f||||||||||2018-06-01 01:42:51.38844|2018-06-01 01:42:51.38844
NCT00763022|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-11-08|2008-09-29|2008-09-30|Estimate|||||||2012-11-08|2012-11-12|Estimate|November 2003||2003-11-30|November 2012|2012-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|302|Actual|Takeda||3|||f||||f||||||||||2018-06-01 01:42:51.458386|2018-06-01 01:42:51.458386
NCT00763009|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2016-05-10||2018-03-14|2008-09-26|2008-09-30|Estimate|2017-04-24|2017-05-24|Actual||||2018-03-14|2018-04-13|Actual|September 2002|Actual|2002-09-30|March 2018|2018-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Persantine: Variation in Response Trial|Persantine: Variation in Response Trial|Terminated||Phase 4|8|Actual|UConn Health|Trial terminated early due to poor patient enrollment. All patients responded hemodynamically. Therefore, analysis of responders vs non-responders could not be performed. Adenosine transporter was not analyzed since there was no comparator group.|1||Limited numbers of patients qualified for trial|f||||t|t|f||||||||2018-06-01 01:42:51.525499|2018-06-01 01:42:51.525499
NCT00762996|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-10-24||2015-05-05|2008-09-29|2008-09-30|Estimate|2009-05-01|2009-06-23|Estimate||||2015-05-05|2015-05-21|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Clinical Evaluation of Two Daily Disposable Contact Lenses||Completed||N/A|65|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||f||||||||||2018-06-01 01:42:51.738831|2018-06-01 01:42:51.738831
NCT00762983|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2015-02-12|2008-09-29|2008-09-30|Estimate|||||||2015-02-12|2015-02-13|Estimate|March 2008||2008-03-31|February 2015|2015-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)|Claritin® Tablet 10 mg, Claritin® RediTabs® 10 mg, Claritin® Dry Syrup 1% Drug Use Investigation (Pediatrics)|Completed|||1003|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:42:51.960791|2018-06-01 01:42:51.960791
NCT00762970|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2015-07-01||2016-05-04|2008-09-29|2008-09-30|Estimate|2015-07-01|2015-07-29|Estimate||||2016-05-04|2016-06-06|Estimate|April 2007||2007-04-30|May 2016|2016-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||Baseline summary was conducted on all subjects who randomized in the study.|Controlling Myopia Progression With Soft Contact Lenses||Completed||N/A|150|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f||||||||||2018-06-01 01:42:52.045058|2018-06-01 01:42:52.045058
NCT00762957|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-02-24|2008-09-26|2008-09-30|Estimate|||||||2012-02-24|2012-02-28|Estimate|November 2004||2004-11-30|February 2012|2012-02-29|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of a Combination of TAK-559 and Metformin Compared to Placebo and Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|15|Actual|Takeda||3||Hepatic Safety Signal Identified.|f||||f||||||||||2018-06-01 01:42:52.353857|2018-06-01 01:42:52.353857
NCT00762944|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-10-17|2008-09-29|2008-09-30|Estimate|||||||2011-10-17|2011-10-19|Estimate|September 2005||2005-09-30|October 2011|2011-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Total Temporomandibular Joint Replacement System Post Approval Study|Total Temporomandibular Joint Replacement System Post Approval Study|Completed|||92|Actual|Zimmer Biomet|||||f||||f||||||||||2018-06-01 01:42:52.46413|2018-06-01 01:42:52.46413
NCT00762931|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2018-03-16|2016-02-23|2018-04-16|2008-09-29|2008-09-30|Estimate|2018-04-16|2018-05-15|Actual|2018-03-08|2018-03-09|Actual|2018-04-16|2018-05-15|Actual|September 2008||2008-09-30|April 2018|2018-04-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional||Safety population|Neurostimulation for the Relief of Acute Bronchoconstriction|Neurostimulation for the Relief of Acute Bronchoconstriction|Completed||N/A|25|Actual|ElectroCore LLC||1|||f||||f||||||||No||2018-06-01 01:42:52.54721|2018-06-01 01:42:52.54721
NCT00762918|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2010-02-19|2008-09-26|2008-09-30|Estimate|||||||2010-02-19|2010-02-22|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|September 2008|Anticipated|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Vitamin D3 for the Treatment of Low Vitamin D in Cystic Fibrosis|Vitamin D and Its Non-Classic Roles in Cystic Fibrosis|Withdrawn||Phase 3|0|Actual|Children's Hospital of Philadelphia||||Recruitment|f||||t||||||||||2018-06-01 01:42:52.756138|2018-06-01 01:42:52.756138
NCT00762905|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2010-01-11|2008-09-29|2008-09-30|Estimate|||||||2010-01-11|2010-01-12|Estimate|April 2006||2006-04-30|January 2010|2010-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Clinical Trial of MedLogic LiquiBand Laparoscopic Versus Dermabond in the Closure of Surgical Incisions|A Prospective, Randomised, Controlled, Double-masked, Multi-center Clinical Trial of MedLogic LiquiBand Laparoscopic Versus Dermabond in the Closure of Surgical Incisions|Completed||N/A|460|Anticipated|MedLogic Global Limited||2|||f||||f||||||||||2018-06-01 01:42:52.824109|2018-06-01 01:42:52.824109
NCT00762892|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-12-19||2014-12-19|2008-09-29|2008-09-30|Estimate|2014-12-19|2015-01-05|Estimate||||2014-12-19|2015-01-05|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|RAN||Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients|A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients|Completed||Phase 4|33|Actual|The University of Texas Health Science Center, Houston|Limitations are the relatively small sample size and loss to follow-up. Medical records of patients that were lost to follow up was reviewed to ensure that no SAE occurred. We also attempted multiple times to contact patients.|2|||f||||f||||||||||2018-06-01 01:42:52.923028|2018-06-01 01:42:52.923028
NCT00762879|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2017-09-29|2008-09-26|2008-09-30|Estimate|||||||2017-09-29|2017-10-03|Actual|April 2008||2008-04-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|January 2014|Actual|2014-01-31||Observational|Spine QCT||Spine Quantitative Computed Tomography (QCT)|Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children|Completed|||127|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||Samples Without DNA|"~     urine~   "|||2018-06-01 01:42:53.269321|2018-06-01 01:42:53.269321
NCT00762866|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2018-02-27|2008-09-29|2008-09-30|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2008||2008-09-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31|2 Weeks|Observational [Patient Registry]|PGPP||Psychiatric Genotype/Phenotype Project Repository|Psychiatric Genotype/Phenotype Project|Enrolling by invitation|||300|Anticipated|Vanderbilt University Medical Center|||3||f||||f||||||Samples With DNA|"~     Blood, urine, saliva~   "|||2018-06-01 01:42:53.331803|2018-06-01 01:42:53.331803
NCT00762853|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-08-19||2012-02-16|2008-09-26|2008-09-30|Estimate|2010-08-19|2010-09-14|Estimate||||2012-02-16|2012-02-17|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Development of Clinical Method to Triclosan Retention in Plaque Following Brushing|Development of Clinical Method to Triclosan Retention in Plaque Following Brushing|Completed||Phase 3|20|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:42:53.396104|2018-06-01 01:42:53.396104
NCT00762840|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2009-06-04|2008-09-29|2008-09-30|Estimate|||||||2009-06-04|2009-06-05|Estimate|October 2006||2006-10-31|June 2009|2009-06-30||||April 2010|Anticipated|2010-04-30||Interventional|||Safety and Efficacy of the Apexum Ablator|Clinical Study to Evaluate the Safety and Efficacy of the Apexum Ablator in Subjects With Periapical Lesions Associated With Root Canal Infection|Unknown status|Recruiting|N/A|100|Anticipated|Apexum Ltd.||2|||f||||f||||||||||2018-06-01 01:42:53.601879|2018-06-01 01:42:53.601879
NCT00762814|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2018-05-04|2008-09-26|2008-09-30|Estimate|||||||2018-05-04|2018-05-11|Actual|May 2008||2008-05-31|May 2018|2018-05-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease|The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease|Terminated||Early Phase 1|4|Actual|Washington University School of Medicine||1||There was no funding for the device to be used in the study.|f||||t||||||||||2018-06-01 01:42:53.665296|2018-06-01 01:42:53.665296
NCT00762801|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2016-10-24|2008-09-29|2008-09-30|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects|Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects|Withdrawn|||0|Actual|University of North Texas Health Science Center||||Principal Investigator left institution.|f||||t||||||||No||2018-06-01 01:42:53.724457|2018-06-01 01:42:53.724457
NCT00762788|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-09-11||2015-06-01|2008-09-26|2008-09-30|Estimate|2015-05-14|2015-05-15|Estimate||||2015-06-01|2015-06-29|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Clinical Trial of Several Contact Lenses in Extended Wear||Completed||N/A|350|Actual|Johnson & Johnson Vision Care, Inc.|Cautions for results: low completed enrollment numbers and number of non-neophytes lower than required per protocol. Arms not gender matched; Proportion of neophytes/non-neophytes not balanced; High rate of drop-out among subjects enrolled.|6|||f||||||||||||||2018-06-01 01:42:53.790612|2018-06-01 01:42:53.790612
NCT00762775|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2014-12-10|2008-09-29|2008-09-30|Estimate|||||||2014-12-10|2014-12-11|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PTH Modified||The Interaction Between Calcium and Vitamin D Intake|The Interaction Between Calcium and Vitamin D Intake|Completed||N/A|78|Actual|Winthrop University Hospital||4|||f||||f||||||||||2018-06-01 01:42:54.275792|2018-06-01 01:42:54.275792
NCT00762762|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2012-04-02||2012-04-02|2008-09-26|2008-09-30|Estimate|2012-04-02|2012-04-26|Estimate||||2012-04-02|2012-04-26|Estimate|March 2006||2006-03-31|April 2012|2012-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Investigate Plaque and Gingival Index|Investigate Plaque and Gingival Index|Completed||Phase 3|46|Actual|Colgate Palmolive||2|||f||||t||||||||||2018-06-01 01:42:54.339762|2018-06-01 01:42:54.339762
NCT00762749|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-10-04|2008-09-26|2008-09-30|Estimate|||||||2011-10-04|2011-10-06|Estimate|September 2008||2008-09-30|October 2011|2011-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study to Evaluate Diphenhydramine in Children and Adolescents|An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Diphenhydramine in Children and Adolescents|Completed||Phase 1|36|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 01:42:54.858812|2018-06-01 01:42:54.858812
NCT00762736|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-02-27|2008-09-29|2008-09-30|Estimate|||||||2012-02-27|2012-02-28|Estimate|July 2004||2004-07-31|February 2012|2012-02-29|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS™) in Combination With TAK-536 in Subjects With Type II Diabetes|Completed||Phase 2|704|Actual|Takeda||6|||f||||f||||||||||2018-06-01 01:42:55.059439|2018-06-01 01:42:55.059439
NCT00762723|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-02-10||2014-03-26|2008-09-29|2008-09-30|Estimate|2014-02-10|2014-03-26|Estimate||||2014-03-26|2014-04-17|Estimate|February 2008||2008-02-29|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Clinical Outcomes of the Trinica(R) Anterior Lumbar Plate: Fixed Screws vs. Variable Screws|A Comparison of Clinical Outcomes Comparing Fixed-angle, Variable-angle, and Hybrid Screw Configuration for the Trinica(R) Anterior Lumbar Plate System|Terminated||N/A|19|Actual|Zimmer Biomet||3||Study was stopped due to slow enrollment|f||||f||||||||||2018-06-01 01:42:55.302699|2018-06-01 01:42:55.302699
NCT00762710|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2013-08-05|2008-09-26|2008-09-30|Estimate|||||||2013-08-05|2013-08-07|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Study of the Medication Prazosin for Alcohol Dependence|Clinical Trial of the Adrenergic Alpha-1 Antagonist Prazosin for Alcohol Dependence|Unknown status|Recruiting|Phase 2|150|Anticipated|Seattle Institute for Biomedical and Clinical Research||2|||f||||t||||||||||2018-06-01 01:42:55.569536|2018-06-01 01:42:55.569536
NCT00762697|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2015-11-24|2008-09-29|2008-09-30|Estimate|||||||2015-11-24|2015-11-26|Estimate|June 2007||2007-06-30|November 2015|2015-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Obtaining and Storing Blood Samples and Debridement Samples for Wound Related Research|Obtaining and Storing Blood Samples and Debridement Samples for Wound Related Research|Completed|||20|Actual|Southwest Regional Wound Care Center|||||f||||t||||||Samples With DNA|"~     Analytical methods used to examine the blood or debridement can investigate morphological,~     molecular, immunological, cellular, viral, biochemical, chemical, genetic, and/or~     transcriptional components of the samples~   "|||2018-06-01 01:42:55.659999|2018-06-01 01:42:55.659999
NCT00762684|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-11-08|2008-09-29|2008-09-30|Estimate|||||||2012-11-08|2012-11-12|Estimate|November 2004||2004-11-30|November 2012|2012-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of TAK-559 Compared to Placebo in the Treatment of Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|8|Actual|Takeda||2||Hepatic safety signal identified.|f||||f||||||||||2018-06-01 01:42:55.719764|2018-06-01 01:42:55.719764
NCT00762671|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2008-09-29|2008-09-29|2008-09-30|Estimate|||||||2008-09-29|2008-09-30|Estimate|May 1999||1999-05-31|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus|Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus|Completed||Phase 2/Phase 3|60|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 01:42:55.791902|2018-06-01 01:42:55.791902
NCT00762658|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2018-03-27|2008-09-29|2008-09-30|Estimate|||||||2018-03-27|2018-03-29|Actual|November 30, 2007|Actual|2007-11-30|March 2018|2018-03-31|December 31, 2007|Actual|2007-12-31|December 31, 2007|Actual|2007-12-31||Interventional|||A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test|A Phase I, Randomized, Observer-blind, Single-center, Vehicle- And Comparator-controlled, Initial Dose-ranging Study To Assess The Antipsoriatic Efficacy Of Different Concentrations Of An2728 Ointment In A Psoriasis Plaque Test|Completed||Phase 1|12|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 01:42:55.858403|2018-06-01 01:42:55.858403
NCT00762645|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2010-01-07||2010-03-12|2008-09-29|2008-09-30|Estimate|2010-03-03|2010-03-15|Estimate||||2010-03-12|2010-03-16|Estimate|February 2007||2007-02-28|March 2010|2010-03-31||||May 2008|Actual|2008-05-31||Interventional|||Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)|A Twelve-Week, Double Masked, Parallel Group, Primary-Therapy Pilot Study of the Safety and Efficacy of Travoprost 0.004% Compared to Pilocarpine 1% in Patients With Chronic Angle-Closure Glaucoma|Completed||Phase 4|30|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:42:55.943048|2018-06-01 01:42:55.943048
NCT00762632|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2012-08-07|2008-09-29|2008-09-30|Estimate|||||||2012-08-07|2012-08-08|Estimate|December 2007||2007-12-31|August 2012|2012-08-31||||June 2012|Actual|2012-06-30||Interventional|||Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia|An Open-label Phase I/II (Proof of Concept) Trial of an Combination of Nilotinib (AMN 107) and RAD001 in Patients With Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|40|Anticipated|Technische Universität München|||||f||||t||||||||||2018-06-01 01:42:56.151701|2018-06-01 01:42:56.151701
NCT00762619|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-08-24||2011-01-04|2008-09-29|2008-09-30|Estimate|2011-01-04|2011-01-25|Estimate||||2011-01-04|2011-01-25|Estimate|April 2007||2007-04-30|January 2011|2011-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Clinical Study to Examine Brushing on Dental Implants|Clinical Study to Examine Brushing on Dental Implants|Completed||Phase 3|105|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:42:56.275617|2018-06-01 01:42:56.275617
NCT00762606|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2011-06-07||2012-10-26|2008-09-29|2008-09-30|Estimate|2011-06-07|2011-07-08|Estimate||||2012-10-26|2012-10-31|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phaco Versus Small Incision Cataract Surgery (SICS) Health Economic Study|A Twelve-Months, Single-Masked, Parallel Group, Health Economic Study of Phacoemulsification Versus Small Incision Cataract Surgery (SICS) in Chinese Patients With Senile Cataract.|Completed||N/A|106|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:42:57.619153|2018-06-01 01:42:57.619153
NCT00762593|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2008-10-16|2008-09-29|2008-09-30|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2006||2006-01-31|October 2008|2008-10-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|KEAT F1||Trial Evaluating Transvaginal Electrical Stimulation With a Home Use Programmable Device for Urinary Stress Incontinence|A Multicenter Double Blind Randomized Placebo Controlled Trial Evaluating Transvaginal Electrical Stimulation With a Home Use Programmable Device for Urinary Stress Incontinence|Unknown status|Active, not recruiting|Phase 2|150|Actual|Akontis||2|||f||||t||||||||||2018-06-01 01:42:57.849149|2018-06-01 01:42:57.849149
NCT00762580|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2018-01-24|2008-09-26|2008-09-30|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2006||2006-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|MOON||Features to Predict Success With Nonoperative Treatment of Patients With Rotator Cuff Tears|Features to Predict Success With Nonoperative Treatment of Patients With Rotator Cuff Tears|Active, not recruiting|||452|Actual|Vanderbilt University Medical Center|||1||f||||t||||||||Yes|De Identified data from this cohort is only available to members of the MOON Shoulder Consortium. The member must provide a description of the use of the data to the research coordinator. The data request is then presented to the MOON consortium. A unanimous agreement of the plan by the consortium must be received prior to receiving the data.|2018-06-01 01:42:57.944097|2018-06-01 01:42:57.944097
NCT00762567|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-10-04|2008-09-26|2008-09-30|Estimate|||||||2011-10-04|2011-10-06|Estimate|September 2008||2008-09-30|October 2011|2011-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Phenylephrine Pediatric Pharmacokinetic Study|An Open-Label, Single-Dose Study Evaluating the Pharmacokinetics of Phenylephrine in Children and Adolescents|Completed||Phase 1|36|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 01:42:58.07265|2018-06-01 01:42:58.07265
NCT00762554|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2008-09-29|2008-09-29|2008-09-30|Estimate|||||||2008-09-29|2008-09-30|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Depodur vs Fentanyl Infusion for Post-C/S Analgesia|A Comparison of Single Dose Depodur With Fentanyl Infusion for Post-Cesarean Section Analgesia|Unknown status|Not yet recruiting|N/A|300|Anticipated|Goodman, Evan, M.D.||3|||f||||t||||||||||2018-06-01 01:42:58.209269|2018-06-01 01:42:58.209269
NCT00762541|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26||2013-08-07|2013-08-22|2008-09-26|2008-09-30|Estimate||||2013-08-22|2013-08-30|Estimate|2013-08-22|2013-08-30|Estimate|October 2006||2006-10-31|August 2013|2013-08-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia|A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of > -7.00 D to -12.00 D Of Myopia With Up To -6.00 D Of Astigmatism, and Maximum MRSE of ≤ -12.00 D|Completed||N/A|129|Actual|Carl Zeiss Meditec, Inc.|||||f||||t||||||||||2018-06-01 01:42:58.295092|2018-06-01 01:42:58.295092
NCT00762515|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-08-19||2010-12-14|2008-09-26|2008-09-30|Estimate|2010-11-15|2010-12-14|Estimate||||2010-12-14|2010-12-28|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes|Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes|Completed||Phase 3|44|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:42:58.760068|2018-06-01 01:42:58.760068
NCT00762502|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-03-28||2015-05-06|2008-09-26|2008-09-30|Estimate|2014-11-18|2014-11-25|Estimate||||2015-05-06|2015-05-22|Estimate|June 2007||2007-06-30|May 2015|2015-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Comparison of Senofilcon A Toric Lenses to Balafilcon A Toric Lenses Over Extended Wear Period|Comparison of Senofilcon A Toric Lenses to Balafilcon A Toric Lenses Over Extended Wear Period|Completed||N/A|112|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f||||||||||2018-06-01 01:42:59.020459|2018-06-01 01:42:59.020459
NCT00762489|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2011-04-28|2008-09-29|2008-09-30|Estimate|||||||2011-04-28|2011-04-29|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Comparison of Three Methods of Taking Temperatures in the Well Baby Nursery|Comparison of Temporal Artery, Axillary, and Rectal Temperatures in Newborn Patients in the Well Baby Nursery.|Completed||N/A|104|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-06-01 01:42:59.260506|2018-06-01 01:42:59.260506
NCT00762476|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2012-02-08||2012-03-21|2008-09-26|2008-09-30|Estimate|2012-03-21|2012-04-16|Estimate||||2012-03-21|2012-04-16|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses|A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II EFFICACY TRIAL OF AV LOTION (FORMULA NO. 3804-250A) FOR THE PREVENTION OF COLD ILLNESS IN HUMAN SUBJECTS|Completed||Phase 2|411|Actual|The Dial Corporation||2|||f||||f||||||||||2018-06-01 01:42:59.352709|2018-06-01 01:42:59.352709
NCT00762463|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2011-06-17||2011-07-26|2008-09-29|2008-09-30|Estimate|2011-07-26|2011-08-23|Estimate||||2011-07-26|2011-08-23|Estimate|July 2009||2009-07-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis|A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy|Completed||Phase 3|240|Actual|Pfizer|The protocol does not specify time points for secondary endpoints; these are described in the statistical analysis plan.|2|||f||||f||||||||||2018-06-01 01:42:59.644654|2018-06-01 01:42:59.644654
NCT00762450|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-12-14||2012-03-05|2008-09-29|2008-09-30|Estimate|2011-01-19|2011-02-15|Estimate||||2012-03-05|2012-03-07|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect on Bacterial Glycolytic Acid Formation on Plaque|Effect on Bacterial Glycolytic Acid Formation on Plaque|Completed||Phase 3|6|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 01:43:03.418143|2018-06-01 01:43:03.418143
NCT00762437|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-27|||2011-06-16|2008-09-29|2008-09-30|Estimate|||||||2011-06-16|2011-06-20|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Non-Invasive Cooling of Fat Cells||Completed||N/A|240|Anticipated|Zeltiq Aesthetics||1|||f||||f||||||||||2018-06-01 01:43:04.750531|2018-06-01 01:43:04.750531
NCT00762424|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2013-12-16||2014-12-16|2008-09-29|2008-09-30|Estimate|2014-12-16|2014-12-17|Estimate||||2014-12-16|2014-12-17|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Flowmax|results not available|Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis|Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis|Completed||N/A|53|Actual|WellSpan Health||2|||f||||f||||||||||2018-06-01 01:43:04.936654|2018-06-01 01:43:04.936654
NCT00762411|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2013-11-06|2011-08-22|2015-01-28|2008-09-26|2008-09-30|Estimate|2014-09-22|2014-09-25|Estimate|2011-08-22|2011-08-23|Estimate|2015-01-28|2015-02-16|Estimate|September 2008||2008-09-30|January 2015|2015-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|IDENTITY-2||Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo|Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo|Completed||Phase 3|1111|Actual|Eli Lilly and Company|All dosing for 4-week post-study drug cessation timeframe outcome measures stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants. No assessments made during 32-week follow up.|2|||f||||t||||||||||2018-06-01 01:43:05.241932|2018-06-01 01:43:05.241932
NCT00762398|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2008-09-29|2008-09-29|2008-09-30|Estimate|||||||2008-09-29|2008-09-30|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|July 2009|Anticipated|2009-07-31|December 2008|Anticipated|2008-12-31||Observational|||Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients|Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients|Unknown status|Enrolling by invitation||100|Anticipated|University of California, Irvine|||1||f||||f||||||Samples With DNA|"~     Blood sample for the measurement of Hct, and ABG~   "|||2018-06-01 01:43:07.550654|2018-06-01 01:43:07.550654
NCT00762385|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2008-12-05||2015-05-05|2008-09-29|2008-09-30|Estimate|2010-01-22|2010-02-10|Estimate||||2015-05-05|2015-05-21|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Clinical Comparison of Two Silicone-Hydrogel Contact Lenses||Completed||N/A|97|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 01:43:07.626319|2018-06-01 01:43:07.626319
NCT00762372|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-08-16|2008-09-26|2008-09-30|Estimate|||||||2011-08-16|2011-08-18|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)|Phase 2/3 Clinical Study With BLM-240 in Adult Surgery Patients That Need General Anesthesia|Completed||Phase 2/Phase 3|216|Actual|Baxter Healthcare Corporation||3|||f||||f||||||||||2018-06-01 01:43:07.852546|2018-06-01 01:43:07.852546
NCT00762359|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2011-02-03||2012-02-01|2008-09-29|2008-09-30|Estimate|2011-04-11|2011-05-10|Estimate||||2012-02-01|2012-02-03|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers|A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.|Terminated||Phase 3|461|Actual|Takeda|On September 2008, the Efficacy and Safety Evaluation Committee recommended that this study be discontinued based on the interim analysis.|2||AG-1749 superior to Gefarnate in ulcer prevention|f||||t||||||||||2018-06-01 01:43:08.144922|2018-06-01 01:43:08.144922
NCT00762138|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2014-02-25|2008-09-29|2008-09-30|Estimate|||||||2014-02-25|2014-02-26|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|TAPS||The AutoloGel™ Post-Market Surveillance (TAPS) Program|The AutoloGel™ Post-Market Surveillance (TAPS) Program|Terminated||N/A|131|Actual|Cytomedix||1||Discontinued due to favorable results|f||||t||||||||||2018-06-01 01:43:12.235985|2018-06-01 01:43:12.235985
NCT00762346|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2013-12-08|2008-09-29|2008-09-30|Estimate|||||||2013-12-08|2013-12-10|Estimate|September 2008||2008-09-30|December 2011|2011-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis|Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis|Completed||Phase 4|156|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-06-01 01:43:09.478412|2018-06-01 01:43:09.478412
NCT00762333|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2018-02-06|2008-09-26|2008-09-30|Estimate|||||||2018-02-06|2018-02-08|Actual|June 2007||2007-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Circulating Markers for Ischemic Heart Disease|Circulating Markers for Ischemic Heart Disease|Recruiting|||550|Anticipated|UConn Health|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 01:43:09.624446|2018-06-01 01:43:09.624446
NCT00762320|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2013-11-14||2014-02-05|2008-09-29|2008-09-30|Estimate|2014-02-05|2014-03-24|Estimate||||2014-02-05|2014-03-24|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparison of Liquid Kaletra and Low Dose Kaletra Tablets|Comparison of Liquid Kaletra and Low Dose Kaletra Tablets in HIV-Positive Children|Completed||N/A|8|Actual|Phoenix Children's Hospital|Early termination leading to small number of subjects analyzed.|1|||f||||f||||||||||2018-06-01 01:43:09.736356|2018-06-01 01:43:09.736356
NCT00762307|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-27|||2012-01-04|2008-09-27|2008-09-30|Estimate|||||||2012-01-04|2012-01-06|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Non-invasive Cooling of Subcutaneous Fat||Completed||N/A|192|Actual|Zeltiq Aesthetics||1|||f||||f||||||||||2018-06-01 01:43:10.027749|2018-06-01 01:43:10.027749
NCT00762294|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2011-12-14|2008-09-29|2008-09-30|Estimate|||||||2011-12-14|2011-12-15|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Anastrozole and Letrozole|Effect Of Anastrozole And Letrozole On Bone Turnover Markers And Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer: A Pilot Study|Completed|||25|Actual|UConn Health|||1||f||||f||||||||||2018-06-01 01:43:10.093321|2018-06-01 01:43:10.093321
NCT00762281|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-08-09|2008-09-26|2008-09-30|Estimate|||||||2012-08-09|2012-08-13|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|October 2008|Actual|2008-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Effectiveness Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Hyperopia|A Prospective, Randomized, Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of ≤ +6.0 D Of Hyperopia With Or Without Astigmatism Of +0.50 D To +3.50 D And MRSE ≤ +6.50 D|Completed||N/A|189|Actual|Carl Zeiss Meditec, Inc.||1|||f||||t||||||||||2018-06-01 01:43:10.155816|2018-06-01 01:43:10.155816
NCT00762268|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-06-17||2014-08-25|2008-09-29|2008-09-30|Estimate|2014-08-25|2014-08-26|Estimate||||2014-08-25|2014-08-26|Estimate|September 2008||2008-09-30|August 2014|2014-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Individuals entering the treatment phase of the study.|A Trial of SAMe for Treatment-Resistant Bipolar Depression|Intermittent-Dose Oral SAMe (S-adenosyl-L-methionine) in Persistent and Treatment-Refractory Bipolar Depression: A Double-Blind Pilot Trial With an Optional Open-label Follow-up|Completed||N/A|17|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 01:43:10.238238|2018-06-01 01:43:10.238238
NCT00762255|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2013-07-24|2008-09-29|2008-09-30|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma|A Phase I Trial of Vorinostat in Combination With Bevacizumab and Irinotecan in Recurrent Glioblastoma|Completed||Phase 1|19|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-06-01 01:43:10.456169|2018-06-01 01:43:10.456169
NCT00762242|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2016-12-08|2008-09-29|2008-09-30|Estimate|||||||2016-12-08|2016-12-12|Estimate|May 2007||2007-05-31|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Metabolomic Profiling of Novel Mediators of Vascular Function|Metabolomic Profiling of Novel Mediators of Vascular Function|Terminated|||48|Actual|Brigham and Women's Hospital|||1|Study enrollment was no adequate.|f||||t||||||Samples Without DNA|"~     plasma samples for assays of novel biomarkers~   "|||2018-06-01 01:43:10.539807|2018-06-01 01:43:10.539807
NCT00762229|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2013-04-17||2013-06-12|2008-09-29|2008-09-30|Estimate|2013-06-12|2013-06-14|Estimate||||2013-06-12|2013-06-14|Estimate|July 2007||2007-07-31|June 2013|2013-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)|Prospective Evaluation of LDL Levels in Patients Converted From Zetia (Ezetimibe)10 mg to 5 mg|Completed||N/A|39|Actual|Bronx VA Medical Center||2|||f||||t||||||||||2018-06-01 01:43:10.60596|2018-06-01 01:43:10.60596
NCT00762216|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-04-14||2012-10-26|2008-09-29|2008-09-30|Estimate|2010-04-14|2010-05-10|Estimate||||2012-10-26|2012-10-31|Estimate|May 2008||2008-05-31|May 2010|2010-05-31||||June 2009|Actual|2009-06-30||Interventional|||Rotational Stability of the AcrySof® Toric|Rotational Stability of the AcrySof® Toric|Completed||N/A|71|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:43:10.810141|2018-06-01 01:43:10.810141
NCT00762190|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-11-08|2008-09-29|2008-09-30|Estimate|||||||2012-11-08|2012-11-12|Estimate|November 2003||2003-11-30|November 2012|2012-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of TAK-559 in the Treatment of Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|348|Actual|Takeda||2||Hepatic safety signal identified.|f||||f||||||||||2018-06-01 01:43:10.924375|2018-06-01 01:43:10.924375
NCT00762177|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-12-14||2011-02-22|2008-09-26|2008-09-30|Estimate|2011-01-18|2011-02-14|Estimate||||2011-02-22|2011-03-23|Estimate|May 2008||2008-05-31|February 2011|2011-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Investigate Oral Bacteria in Adult Population|Investigate Oral Bacteria in Adult Population|Completed||Phase 3|24|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 01:43:11.145593|2018-06-01 01:43:11.145593
NCT00762164|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2013-04-16||2013-04-19|2008-09-29|2008-09-30|Estimate|2013-04-19|2013-07-03|Estimate||||2013-04-19|2013-07-03|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol|Comparative Efficacy of a Vytorin 10/80 Tablet Split Into 4 (Estimated Dose Ezetimibe 2.5 + Simvastatin 20) Versus Simvastatin 20 Milligrams on LDL Cholesterol|Completed||Phase 4|34|Actual|Bronx VA Medical Center||2|||f||||f||||||||||2018-06-01 01:43:11.920094|2018-06-01 01:43:11.920094
NCT00762151|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-06-22|2008-09-29|2008-09-30|Estimate|||||||2015-06-22|2015-06-24|Estimate|November 2007||2007-11-30|September 2008|2008-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study to Investigate the Anti-Plaque Effect of AN0128 Toothpaste|Clinical Research Study to Investigate the Anti-Plaque Effect of a Prototype Toothpaste Containing an Anacor Material Via the MGMPI Method|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:43:12.168073|2018-06-01 01:43:12.168073
NCT00762125|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2014-12-01|2008-09-29|2008-09-30|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment|Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment|Completed||Phase 2|266|Actual|University of Washington||4|||f||||||||||||||2018-06-01 01:43:12.318661|2018-06-01 01:43:12.318661
NCT00762112|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-11-08|2008-09-29|2008-09-30|Estimate|||||||2012-11-08|2012-11-12|Estimate|November 2003||2003-11-30|November 2012|2012-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus|A Long-Term, Open-Label, Phase 3a Safety Study of Oral TAK-559 (32 mg QD) in the Treatment of Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|316|Actual|Takeda||1||Hepatic safety signal identified.|f||||f||||||||||2018-06-01 01:43:12.402437|2018-06-01 01:43:12.402437
NCT00762099|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2011-04-07|2008-09-29|2008-09-30|Estimate|||||||2011-04-07|2011-04-08|Estimate|May 2009||2009-05-31|April 2011|2011-04-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|RCT||Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery|The Short and Long Term Effects of Perioperative Pregabalin Use on Functional Rehabilitation, Pain Outcomes and Anxiety Following Total Hip Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial.|Unknown status|Recruiting|Phase 4|184|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:43:12.481138|2018-06-01 01:43:12.481138
NCT00762086|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-28|2012-07-23||2012-08-27|2008-09-28|2008-09-30|Estimate|2012-07-23|2012-08-27|Estimate||||2012-08-27|2012-08-31|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II|A Prospective, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of a New Intermittent Pneumatic Compression Device on Initial Claudication Distance in Patients With Peripheral Arterial Disease Stage II.|Completed||N/A|67|Actual|Mego Afek Ltd.||2|||f||||f||||||||||2018-06-01 01:43:12.56751|2018-06-01 01:43:12.56751
NCT00762073|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2015-08-03||2015-09-02|2008-09-29|2008-09-30|Estimate|2015-09-02|2015-10-05|Estimate||||2015-09-02|2015-10-05|Estimate|November 2008||2008-11-30|March 2014|2014-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||The Safety Analysis Set, defined as all randomized participants who received at least one dose of double-blind study drug. Treatment group assignment was the treatment actually received. One participant in the medium dose group was enrolled and randomized then withdrew consent and did not receive study drug.|Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis|Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents|Completed||Phase 2|82|Actual|Shire||4|||f||||f||||||||||2018-06-01 01:43:12.83608|2018-06-01 01:43:12.83608
NCT00762060|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2015-03-17|2008-09-29|2008-09-30|Estimate|||||||2015-03-17|2015-03-19|Estimate|November 2006||2006-11-30|December 2014|2014-12-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Observational|MISS||Multicenter Infection Surveillance Study Following Colorectal Procedures|Phase IV Multicenter Infection Surveillance Study Following Colorectal Procedures|Completed|||289|Actual|Halyard Health|||2||f||||f||||||||||2018-06-01 01:43:13.687038|2018-06-01 01:43:13.687038
NCT00762047|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2013-07-29|2008-09-29|2008-09-30|Estimate|||||||2013-07-29|2013-07-30|Estimate|June 2004||2004-06-30|January 2012|2012-01-31|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||A Prospective, Multi-center, Randomized, Blinded Study to Evaluate Durasphere FI for the Treatment of Fecal Incontinence|Phase 2 IDE Study of Durasphere FI in the Treatment of Fecal Incontinence|Terminated||Phase 2|90|Actual|Carbon Medical Technologies||2|||f||||f||||||||||2018-06-01 01:43:13.757784|2018-06-01 01:43:13.757784
NCT00762034|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2013-03-28||2015-11-16|2008-09-26|2008-09-30|Estimate|2013-09-26|2013-11-28|Estimate||||2015-11-16|2015-12-21|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|April 2012|Actual|2012-04-30||Interventional||All randomized participants.|A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer|Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer|Completed||Phase 3|939|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 01:43:13.857483|2018-06-01 01:43:13.857483
NCT00762021|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-09-30||2010-11-24|2008-09-29|2008-09-30|Estimate|2010-11-24|2010-12-22|Estimate||||2010-11-24|2010-12-22|Estimate|December 2006||2006-12-31|November 2010|2010-11-30||||August 2009|Actual|2009-08-31||Interventional|||Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens||Completed||N/A|104|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:43:15.761114|2018-06-01 01:43:15.761114
NCT00762008|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2018-02-06|2008-09-29|2008-09-30|Estimate|||||||2018-02-06|2018-02-08|Actual|December 2005||2005-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure|Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure|Recruiting|||500|Anticipated|UConn Health|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 01:43:16.274777|2018-06-01 01:43:16.274777
NCT00761995|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-07-17|2008-09-29|2008-09-30|Estimate|||||||2012-07-17|2012-07-18|Estimate|February 2009||2009-02-28|January 2012|2012-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension||Completed||Phase 4|200|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:43:16.413063|2018-06-01 01:43:16.413063
NCT00761982|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-28|||2011-11-27|2008-09-28|2008-09-30|Estimate|||||||2011-11-27|2011-11-29|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.|Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment|Completed||Phase 1/Phase 2|20|Anticipated|Hospital Universitario Central de Asturias||1|||f||||f||||||||||2018-06-01 01:43:16.485173|2018-06-01 01:43:16.485173
NCT00761969|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-28|2015-09-29||2015-11-12|2008-09-29|2008-09-30|Estimate|2015-11-12|2015-11-17|Estimate||||2015-11-12|2015-11-17|Estimate|December 2004||2004-12-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PID-PAB||Prevention of Ischemic Events in Patients With Peripheral Arterial Disease|Prevention of Ischemic Events in Patients With Peripheral Arterial Disease by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice|Completed|||1455|Actual|KRKA|||2||f||||t||||||Samples With DNA|"~     blood (16 ml) for analysis of inflammatory markers (from serum) and genotyping, to be~     correlated with clinical outcomes.~      Anonymity of patients is proveded by coding the samples and the patients clinical records.~   "|||2018-06-01 01:43:16.758163|2018-06-01 01:43:16.758163
NCT00761956|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2012-04-02||2012-06-12|2008-09-29|2008-09-30|Estimate|2012-06-12|2012-07-16|Estimate||||2012-06-12|2012-07-16|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Compare the NexGen CR and CR-Flex Knee Implants|Prospective Randomized Multicenter Study of NexGen CR-Flex Knee|Completed||N/A|189|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:43:17.475645|2018-06-01 01:43:17.475645
NCT00761943|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2017-04-19|2008-09-29|2008-09-30|Estimate|||||||2017-04-19|2017-04-20|Actual|December 2006||2006-12-31|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|||Correlating Clinical Disease State With Color Doppler Ultrasound|"Adhesive Capsulitis-Correlating Clinical Disease State With Color Doppler Ultrasound"|Completed|||30|Actual|Vanderbilt University Medical Center|||||f||||t||||||||||2018-06-01 01:43:17.916966|2018-06-01 01:43:17.916966
NCT00761930|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-08-19||2013-08-08|2008-09-26|2008-09-30|Estimate|2010-10-02|2010-10-20|Estimate||||2013-08-08|2013-08-15|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Compare the Clinical Efficacy of Prototype Toothpastes.|Compare the Clinical Efficacy of Prototype Toothpastes.|Completed||Phase 3|103|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 01:43:18.036585|2018-06-01 01:43:18.036585
NCT00761917|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2015-03-30|2008-09-26|2008-09-30|Estimate|||||||2015-03-30|2015-03-31|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Observational|||Diagnostic Evaluation of the Tear Film|Analysis of the Tear Film Lipid Layer|Completed|||229|Actual|TearScience, Inc.|||2||f||||f||||||||||2018-06-01 01:43:18.660795|2018-06-01 01:43:18.660795
NCT00761904|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2010-05-03|2008-09-29|2008-09-30|Estimate|||||||2010-05-03|2010-05-05|Estimate|December 2010||2010-12-31|May 2010|2010-05-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|SAMPLES||The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians|A Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples|Unknown status|Not yet recruiting|N/A|660|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:43:18.727034|2018-06-01 01:43:18.727034
NCT00761891|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2015-12-04|2008-09-29|2008-09-30|Estimate|||||||2015-12-04|2015-12-07|Estimate|May 2007||2007-05-31|December 2015|2015-12-31|January 2010|Actual|2010-01-31|May 2008|Actual|2008-05-31||Interventional|||Validation of an Assay to Measure Cyclooxygenase-1 Activity|Validation of an Ex Vivo Cyclooxygenase-1 Catalytic Assay in Humans|Completed||N/A|60|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:43:18.797096|2018-06-01 01:43:18.797096
NCT00761878|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2009-07-03|2008-09-26|2008-09-30|Estimate|||||||2009-07-03|2009-07-07|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluation of the PlasmaJet Neutral Argon Plasma System to Treat Skin Ageing|Evaluation of the PlasmaJet Neutral Argon Plasma System for Skin Regeneration and Comparison With the Rhytec Portrait PSR Plasma System|Completed||N/A|35|Actual|Plasma Surgical Inc||1|||f||||f||||||||||2018-06-01 01:43:18.860138|2018-06-01 01:43:18.860138
NCT00761865|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|2013-12-03||2015-08-03|2008-09-29|2008-09-30|Estimate|2015-08-03|2015-08-07|Estimate||||2015-08-03|2015-08-07|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Lateral Ankle Sprain Study|Lateral Ankle Sprain Study|Terminated||N/A|34|Actual|University of Rochester||2||low enrollment|f||||f||||||||||2018-06-01 01:43:18.915765|2018-06-01 01:43:18.915765
NCT00761852|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2008-09-29|2008-09-29|2008-09-30|Estimate|||||||2008-09-29|2008-09-30|Estimate|May 1999||1999-05-31|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Signaling Mechanisms and Vascular Function in Diabetes Mellitus|Signaling Mechanisms and Vascular Function in Diabetes Mellitus|Completed||Phase 2/Phase 3|30|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 01:43:20.045549|2018-06-01 01:43:20.045549
NCT00761839|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2015-05-05|2008-09-29|2008-09-30|Estimate|||||||2015-05-05|2015-05-06|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Does Use of a Wound After-care Summary Improve Patient Satisfaction and Time to Wound Healing?|Does Use of a Wound After-care Summary Improve Patient Satisfaction and Time to Wound Healing?|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||"Study was withdrawn because of a problem with the software used for generating the aftercare~   summary."|f||||f||||||||||2018-06-01 01:43:20.11543|2018-06-01 01:43:20.11543
NCT00761826|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26||2013-08-07|2013-08-22|2008-09-26|2008-09-30|Estimate||||2013-08-22|2013-08-30|Estimate|2013-08-22|2013-08-30|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism|A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D|Completed||N/A|126|Actual|Carl Zeiss Meditec, Inc.|||||f||||t||||||||||2018-06-01 01:43:20.181741|2018-06-01 01:43:20.181741
NCT00761813|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2017-11-02||2018-01-03|2008-09-26|2008-09-30|Estimate|2018-01-03|2018-01-05|Actual||||2018-01-03|2018-01-05|Actual|March 2009||2009-03-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)|Fixation Using Alternative Implants for the Treatment of Hip Fractures: A Multi-Centre Randomized Trial Comparing Sliding Hip Screws and Cancellous Screws on Revision Surgery Rates and Quality of Life in the Treatment of Femoral Neck Fractures|Completed||N/A|1108|Actual|University of Minnesota - Clinical and Translational Science Institute|Surgeons and patients were not blinded.|2|||f||||t||||||||||2018-06-01 01:43:20.285037|2018-06-01 01:43:20.285037
NCT00761800|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-29|||2009-05-28|2008-09-29|2008-09-30|Estimate|||||||2009-05-28|2009-05-29|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Dermacyd Teen Care Tangerina Mix - Compatibility|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermal Irritability, Dermal Sensitivity) of Dermacyd Teen Care Tangerina Mix .|Completed||Phase 3|51|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:43:20.781731|2018-06-01 01:43:20.781731
NCT00761787|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2009-03-05|2008-09-29|2008-09-30|Estimate|||||||2009-03-05|2009-03-09|Estimate|May 2005||2005-05-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|CARGOII||Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY|Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY|Completed|||800|Anticipated|XDx|||1||f||||f||||||Samples Without DNA|"~     venous blood whole blood white blood cells~   "|||2018-06-01 01:43:20.849729|2018-06-01 01:43:20.849729
NCT00761449|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2012-04-26|2008-09-26|2008-09-29|Estimate|||||||2012-04-26|2012-04-27|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5|A Multicentre Phase II Study of the Efficacy and Safety of Lenalidomide in High-risk Myeloid Disease (High-risk MDS and AML) With a Karyotype Including Del(5q) or Monosomy 5|Completed||Phase 2|28|Actual|Nordic MDS Group||1|||f||||t||||||||||2018-06-01 01:43:28.25151|2018-06-01 01:43:28.25151
NCT00761774|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2018-03-20||2018-03-20|2008-09-29|2008-09-30|Estimate|2018-03-20|2018-04-23|Actual||||2018-03-20|2018-04-23|Actual|November 2008||2008-11-30|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional||Baseline Characteristics refer to the Safety Set which consisted of all subjects who received at least 1 dose of study medication.|An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam|An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy.|Completed||Phase 3|108|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 01:43:20.985128|2018-06-01 01:43:20.985128
NCT00761761|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2015-02-19||2016-03-14|2008-09-26|2008-09-29|Estimate|2016-03-14|2016-04-14|Estimate||||2016-03-14|2016-04-14|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Sensoril(Ashwaganhda)for Bipolar Disorder|Sensoril® (Ashwagandha) - A Standardized Extract From a Medicinal Plant - (Withania Somnifera) for Cognitive Enhancement in Persons With Bipolar Disorder: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study|Completed||Phase 3|60|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:43:21.37435|2018-06-01 01:43:21.37435
NCT00761748|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2010-03-08||2012-11-29|2008-09-26|2008-09-29|Estimate|2012-11-29|2013-01-01|Estimate||||2012-11-29|2013-01-01|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Comparison of Two Urostomy Bags (2-piece).|A Comparative, Randomised, Crossover Study With SenSura Uro 2-piece Versus ConvaTec 2-piece Among 30 Urostomy-operated Persons in Germany|Completed||Phase 3|30|Actual|Coloplast A/S||2|||f||||f||||||||||2018-06-01 01:43:21.624297|2018-06-01 01:43:21.624297
NCT00761735|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2013-10-28||2017-03-07|2008-09-26|2008-09-29|Estimate|2013-10-28|2013-12-17|Estimate||||2017-03-07|2017-04-04|Actual|July 2007||2007-07-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)|Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C|Completed||Phase 3|94|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:43:21.85944|2018-06-01 01:43:21.85944
NCT00761722|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2016-12-14|2008-09-26|2008-09-29|Estimate|||||||2016-12-14|2016-12-15|Estimate|August 2008||2008-08-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|RACE||Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma|A Phase I, Dose-Ranging Study to Evaluate the Pharmacokinetics and Safety of Azacitidine Administered Subcutaneously (SC) and as Different Oral Formulations in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML), Lymphoma, and Multiple Myeloma|Completed||Phase 1|31|Actual|Celgene Corporation||2|||f||||f||||||||||2018-06-01 01:43:22.132284|2018-06-01 01:43:22.132284
NCT00761709|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25||2014-07-10|2014-07-11|2008-09-26|2008-09-29|Estimate||||2014-07-10|2014-07-14|Estimate|2014-07-11|2014-07-15|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 2|104|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 01:43:22.236353|2018-06-01 01:43:22.236353
NCT00761696|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2012-06-19|2008-09-25|2008-09-29|Estimate|||||||2012-06-19|2012-06-21|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies|A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies|Completed||Phase 1|94|Actual|Infinity Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:43:22.30901|2018-06-01 01:43:22.30901
NCT00761683|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2009-09-08|2008-09-26|2008-09-29|Estimate|||||||2009-09-08|2009-09-10|Estimate|October 2008||2008-10-31|September 2009|2009-09-30||||||||Observational|ESIS||Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS|Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS|Terminated|||105|Anticipated|AstraZeneca|||1|"Anticipated number of patients not achieved. All Patients recruited in the study completed all~   study visits."|f||||f||||||||||2018-06-01 01:43:22.389707|2018-06-01 01:43:22.389707
NCT00761670|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2010-12-08|2008-09-26|2008-09-29|Estimate|||||||2010-12-08|2010-12-09|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|AMIMIND||Efficacy Study on Cognitive Functions in Schizophrenic Patients|Comparative Efficacy of Amisulpride vs Risperidone on Cognitive Functions in Patients With Chronic Schizophrenia|Completed||Phase 4|37|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:43:22.45678|2018-06-01 01:43:22.45678
NCT00761657|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-01-28|2008-09-25|2008-09-29|Estimate|||||||2013-01-28|2013-01-30|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phase 2 Study of FG-4592 in Subjects With Anemia and Chronic Kidney Disease Not Requiring Dialysis|A Randomized, Single-blind, Placebo-controlled, 4-Week Treatment Study of the Safety and Biologic Activity of Escalating Multiple Oral Doses of FG-4592 in Subjects With Chronic Kidney Disease Not Requiring Dialysis|Completed||Phase 2|117|Actual|FibroGen||7|||f||||t||||||||||2018-06-01 01:43:22.543033|2018-06-01 01:43:22.543033
NCT00761644|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2018-05-29|2008-09-26|2008-09-29|Estimate|||||||2018-05-29|2018-05-30|Actual|August 21, 2008|Actual|2008-08-21|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Doxil, Bevacizumab and Temsirolimus Trial|A Phase I Trial of Doxil, Bevacizumab and Temsirolimus|Active, not recruiting||Phase 1|200|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:43:22.679825|2018-06-01 01:43:22.679825
NCT00761631|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2011-07-15||2013-05-30|2008-09-26|2008-09-29|Estimate|2011-07-15|2011-08-10|Estimate||||2013-05-30|2013-07-31|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years|A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States|Completed||Phase 3|1200|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:43:22.8563|2018-06-01 01:43:22.8563
NCT00761618|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2018-01-08|2008-09-26|2008-09-29|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2009|Actual|2009-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Intrapleural Catheter Daily Versus Three Times a Week Drainage|Effectiveness of Daily Versus Three Times a Week Drainage After Placement of Intrapleural Catheters for the Palliative Management of Pleural Effusions Associated With Malignancies|Active, not recruiting||Phase 3|280|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-06-01 01:43:25.21628|2018-06-01 01:43:25.21628
NCT00761605|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2014-01-24||2014-09-03|2008-09-26|2008-09-29|Estimate|2014-01-24|2014-03-06|Estimate||||2014-09-03|2014-09-10|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|PASS||Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants|An Open-label Prospective, Non-comparative Study to Evaluate the Subjective Experiences Upon Transition to Paliperidone Extended Release(ER) in Subjects With Schizophrenia|Completed||Phase 4|387|Actual|Janssen Korea, Ltd., Korea|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.|1|||f||||f||||||||||2018-06-01 01:43:25.375556|2018-06-01 01:43:25.375556
NCT00761592|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2009-01-30||2013-10-25|2008-09-25|2008-09-29|Estimate|2009-05-18|2009-07-09|Estimate||||2013-10-25|2013-11-19|Estimate|July 2006||2006-07-31|October 2013|2013-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm||Completed||Phase 4|65|Actual|Allergan|This was a pilot study.|2|||f||||f||||||||||2018-06-01 01:43:25.758971|2018-06-01 01:43:25.758971
NCT00761579|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2014-01-16||2014-05-01|2008-09-26|2008-09-29|Estimate|2014-05-01|2014-06-03|Estimate||||2014-05-01|2014-06-03|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|PERFECT||Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission|An Open-Label Prospective, Non-Comparative Study To Explore The Tolerability, Safety and Effectiveness Upon Transition to Paliperidone Slow-Release Tablet in Schizophrenic Patients|Completed||Phase 4|190|Actual|Janssen Korea, Ltd., Korea|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.|1|||f||||f||||||||||2018-06-01 01:43:26.060854|2018-06-01 01:43:26.060854
NCT00761566|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2013-08-14|2008-09-26|2008-09-29|Estimate|||||||2013-08-14|2013-08-15|Estimate|October 2008||2008-10-31|August 2013|2013-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effect of Remote Preconditioning on the Exercise Performance of the Elite Swimmers|Double Blind Randomized Controlled Trial of the Effect of Remote Preconditioning on the Exercise Performance of the Elite Swimmers|Completed||Phase 2|24|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 01:43:26.63527|2018-06-01 01:43:26.63527
NCT00761553|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-01-16|2008-09-26|2008-09-29|Estimate|||||||2013-01-16|2013-01-17|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||Dietary Supplements and Exercise in Aging Adults||Completed||N/A|49|Actual|Purdue University||4|||f||||||||||||||2018-06-01 01:43:26.710464|2018-06-01 01:43:26.710464
NCT00761540|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2017-01-25|2008-09-26|2008-09-29|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2008||2008-10-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo|A Dose Escalation Study to Investigate the Pharmacokinetics, Tolerability and Safety of Liraglutide After Multiple s.c. Doses in Healthy Chinese Male Subjects|Completed||Phase 1|37|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-06-01 01:43:26.775126|2018-06-01 01:43:26.775126
NCT00761527|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2011-11-04||2015-07-15|2008-09-26|2008-09-29|Estimate|2012-01-27|2012-03-01|Estimate||||2015-07-15|2015-07-28|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)|Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients|Completed|||2980|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:43:26.894945|2018-06-01 01:43:26.894945
NCT00761514|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2009-08-26||2009-10-23|2008-09-25|2008-09-29|Estimate|2009-10-23|2009-11-19|Estimate||||2009-10-23|2009-11-19|Estimate|November 2006||2006-11-30|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|VIVIR||Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira|Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira as Their First Anti-TNF Monoclonal Antibody (VIVIR)|Terminated||Phase 4|14|Actual|Abbott|This study was terminated early due to lack of enrollment. Only 7 subjects completed 24 weeks of treatment. That number is too small to provide reliable data on the effectiveness of the treatment.|1||The study was terminated due to low enrollment.|f||||f||||||||||2018-06-01 01:43:27.085384|2018-06-01 01:43:27.085384
NCT00761501|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2010-12-07|2008-09-26|2008-09-29|Estimate|||||||2010-12-07|2010-12-09|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E|Phase I, Open-label, Randomized, 3-way Crossover Study to Assess Relative Bioavailability of Single Oral Dose of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E in Healthy Volunteers|Completed||Phase 1|38|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:43:27.333177|2018-06-01 01:43:27.333177
NCT00761488|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2015-05-08|2008-09-26|2008-09-29|Estimate|||||||2015-05-08|2015-05-12|Estimate||||January 2010|2010-01-31||||||||Interventional|||Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric||Withdrawn||Phase 4|0|Actual|Alcon Research||1||Primary Investigator resigned from hospital|f||||||||||||||2018-06-01 01:43:27.405252|2018-06-01 01:43:27.405252
NCT00761475|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2016-10-27|2008-09-26|2008-09-29|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|April 2015|Actual|2015-04-30|December 2012|Actual|2012-12-31||Interventional|PRIMA||Primary Mesh Closure of Abdominal Midline Wounds|Primary Mesh Closure of Abdominal Midline Wounds; a Prospective Randomized Multicenter Trial|Completed||Phase 3|480|Actual|Erasmus Medical Center||3|||f||||t||||||||||2018-06-01 01:43:27.469683|2018-06-01 01:43:27.469683
NCT00761462|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2008-12-19||2015-07-13|2008-09-26|2008-09-29|Estimate|2009-03-11|2009-04-14|Estimate||||2015-07-13|2015-07-31|Estimate|October 1999||1999-10-31|July 2015|2015-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||BAY 0 9867 Cipro Pediatric Use Study (QUIP)|A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses|Completed||Phase 3|1029|Actual|Bayer|The study was not randomized or blinded; the demographic and baseline infection characteristics were not comparable for the treatment groups; the long term followup times were different for the two groups (5 year versus 2 years).|2|||f||||t||||||||||2018-06-01 01:43:27.568334|2018-06-01 01:43:27.568334
NCT00761436|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2014-11-27|2008-09-26|2008-09-29|Estimate|||||||2014-11-27|2014-12-02|Estimate|February 2000||2000-02-29|November 2014|2014-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pilot Study of Safety and Efficacy of Spheramine|Stereotactic Intrastriatal Implantation of Spheramine in Advanced Parkinson's Disease Patients: A Pilot Study of Tolerability and Efficacy.|Terminated||Phase 2|6|Actual|Bayer||1||Study was completed, only life long extended follow-up phase was discontinued after 12 years|f||||f||||||||||2018-06-01 01:43:28.331726|2018-06-01 01:43:28.331726
NCT00761423|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-05-17|2008-09-26|2008-09-29|Estimate|||||||2017-05-17|2017-05-18|Actual|August 2008||2008-08-31|May 2017|2017-05-31|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|PRICT||The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial|The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial|Completed||Phase 4|81|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:43:28.38432|2018-06-01 01:43:28.38432
NCT00761410|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2016-06-17|2008-09-26|2008-09-29|Estimate|||||||2016-06-17|2016-06-20|Estimate|October 2004||2004-10-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|February 2010|Actual|2010-02-28||Interventional|||A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee System|A Prospective, Non-Comparative Multi Centre Study to Evaluate the Clinical Performance of the DePuy Press Fit Condylar (P.F.C.) Sigma Rotating Platform High Flexion Knee.|Terminated||Phase 4|170|Actual|DePuy International||1||Study was terminated early due to prolonged recruitment period.|f||||f||||||||||2018-06-01 01:43:28.454117|2018-06-01 01:43:28.454117
NCT00761397|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-06-16|2008-09-26|2008-09-29|Estimate|||||||2017-06-16|2017-06-19|Actual|September 2008|Actual|2008-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Adherence to Swallowing Exercises in Head and Neck Cancer|Adherence to Swallowing Exercises in Head and Neck Cancer|Active, not recruiting|||350|Anticipated|M.D. Anderson Cancer Center|||2||f||||t||||||||||2018-06-01 01:43:28.519681|2018-06-01 01:43:28.519681
NCT00761384|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2016-02-18|2008-09-26|2008-09-29|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|HITT||High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma|A Prospective Study With Individually Adjusted High Dose 90Y-Ibritumomab Tiuxetan Treatment With Peripheral Blood Stem Cells Support to Improve Outcome for Patients With Refractory/Recurrent B-cell Lymphoma, Stage II-IV|Completed||Phase 1/Phase 2|7|Actual|Lund University Hospital||1|||f||||f||||||||||2018-06-01 01:43:28.600582|2018-06-01 01:43:28.600582
NCT00761371|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2015-04-09|2008-09-26|2008-09-29|Estimate|||||||2015-04-09|2015-04-10|Estimate|August 2002||2002-08-31|April 2015|2015-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients|Exploratory Evaluation of Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients Treated With HAART (CD4+ ≥ 200 Cells mm3): An Open Labeled, Non-comparative Study|Completed||Phase 4|52|Actual|MEDA Pharma GmbH & Co. KG||1|||f||||||||||||||2018-06-01 01:43:28.784874|2018-06-01 01:43:28.784874
NCT00761358|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2010-11-21|2008-09-25|2008-09-29|Estimate|||||||2010-11-21|2010-11-23|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia|To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms|Completed||Phase 3|820|Anticipated|Zeria Pharmaceutical||2|||f||||f||||||||||2018-06-01 01:43:28.877129|2018-06-01 01:43:28.877129
NCT00761345|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2015-01-22||2017-01-24|2008-09-26|2008-09-29|Estimate|2016-03-01|2016-03-31|Estimate||||2017-01-24|2017-03-07|Actual|September 2008||2008-09-30|January 2017|2017-01-31|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Interventional||Patients with locally advanced or metastatic pancreatic cancer confined to the abdomen and an ECOG performance status (PS) of 0-1 who had received 0-1 prior regimens (without Gemcitabine or Erlotinib) and no prior radiotherapy were eligible|Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer|Phase I Study of Low-Dose Fractionated Radiotherapy as a Chemosensitizer for Gemcitabine and Erlotinib in Patients With Locally Advanced or Limited Metastatic Pancreatic Cancer|Completed||Phase 1|27|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-06-01 01:43:28.974513|2018-06-01 01:43:28.974513
NCT00761332|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2011-06-20|2008-09-26|2008-09-29|Estimate|||||||2011-06-20|2011-06-21|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Back Pain in Patients With Severe Osteoporosis|An Observational Study to Assess Back Pain in Patients With Severe Osteoporosis Treated With Teriparatide Versus Antiresorptives|Completed|||650|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-06-01 01:43:29.185133|2018-06-01 01:43:29.185133
NCT00761319|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2012-03-30||2012-04-20|2008-09-25|2008-09-29|Estimate|2012-03-30|2012-04-23|Estimate||||2012-04-20|2012-04-26|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health|An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution|Completed||Phase 3|705|Actual|Alcon Research|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)|2|||f||||f||||||||||2018-06-01 01:43:29.337375|2018-06-01 01:43:29.337375
NCT00761306|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2013-10-28||2013-12-23|2008-09-26|2008-09-29|Estimate|2013-10-28|2013-12-17|Estimate||||2013-12-23|2014-01-29|Estimate|June 2007||2007-06-30|December 2013|2013-12-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional||Age and Sex: all-patients-treated set (APTS) - all patients who took at least one dose of Vortioxetine in Study NCT00761306 / 11492C; MADRS and HAM-D-24: full-analysis set (FAS) = 74 - all patients in the APTS who had at least one valid Baseline and one valid post-Baseline assessment of the MADRS total score in Study NCT00761306 / 11492C.|Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults|A Long-term, Open-label Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder|Completed||Phase 2|74|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-06-01 01:43:29.576814|2018-06-01 01:43:29.576814
NCT00761137|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2011-08-05||2015-09-22|2008-09-26|2008-09-29|Estimate|2015-09-22|2015-10-12|Estimate||||2015-09-22|2015-10-12|Estimate|March 2008||2008-03-31|April 2013|2013-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|NH004-2||Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients|A Two-Phase, Double Blind, Placebo-Controlled, Randomized, Crossover Study of the Safety and Efficacy of Intra-Oral NH004 Films for the Short-Term Relief of Sialorrhea Symptoms in Parkinson's Disease Patients|Completed||Phase 2|19|Actual|NeuroHealing Pharmaceuticals Inc.||4|||f||||t||||||||||2018-06-01 01:43:33.29315|2018-06-01 01:43:33.29315
NCT00761280|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|2014-08-07|2013-01-18|2014-11-04|2008-09-26|2008-09-29|Estimate|2014-08-07|2014-08-22|Estimate|2013-01-18|2013-01-28|Estimate|2014-11-04|2014-11-14|Estimate|December 2008||2008-12-31|November 2014|2014-11-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|SAPPHIRE|The Intent-to-treat population includes all participants randomized.|Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma|Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.|Terminated||Phase 3|27|Actual|Isarna Therapeutics GmbH|Early termination of the study leading to recruitment of 27 of 180 planned subjects and incomplete collection of data. Survival results are based on post-study collection of additional survival data under a protocol amendment.|2||Unable to recruit the projected patient number. All analyses are descriptive, only.|f||||t||||||||||2018-06-01 01:43:29.832095|2018-06-01 01:43:29.832095
NCT00761267|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2018-05-24|2008-09-26|2008-09-29|Estimate|||||||2018-05-24|2018-05-25|Actual|February 27, 2009|Actual|2009-02-27|May 2018|2018-05-31|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis|A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia|Completed||Phase 3|69|Actual|Pfizer||1|||f||||t|t|f||||||No||2018-06-01 01:43:30.870582|2018-06-01 01:43:30.870582
NCT00761254|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2012-09-11|2008-09-26|2008-09-29|Estimate|||||||2012-09-11|2012-09-13|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Domperidone for Relief of Gastrointestinal Disorders|Oral Domperidone for Relief of Gastrointestinal Disorders in Patients Who Failed Standard Therapy|Terminated||N/A|42|Actual|Carle Physician Group||||PI withdrew due to increased responsibilities in clinical department.|f||||f||||||||||2018-06-01 01:43:30.984027|2018-06-01 01:43:30.984027
NCT00761241|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2010-05-25|2008-09-26|2008-09-29|Estimate|||||||2010-05-25|2010-05-26|Estimate|September 2008||2008-09-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT|A Phase II Protocol in Borderline Resectable Pancreatic Cancer Using Gemcitabine/Docetaxel Chemotherapy and An Oxaliplatin-Based Chemoradiation.|Completed||Phase 2|40|Anticipated|Benaroya Research Institute|||||f||||f||||||||||2018-06-01 01:43:31.04733|2018-06-01 01:43:31.04733
NCT00761228|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2017-03-29|2008-09-26|2008-09-29|Estimate|||||||2017-03-29|2017-03-31|Actual|July 2010||2010-07-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NH001-2||Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury|A Double-blind, Placebo-controlled, Randomized Study of the Safety and Efficacy of NH001 in Improving the Functional Outcome of Patients in a Vegetative State or Minimally Conscious State Following a Severe Traumatic Brain Injury|Suspended||Phase 2|76|Anticipated|NeuroHealing Pharmaceuticals Inc.||2|||f||||t||||||||||2018-06-01 01:43:31.236481|2018-06-01 01:43:31.236481
NCT00761215|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2014-07-15|2014-04-02|2017-08-30|2008-09-26|2008-09-29|Estimate|2014-07-15|2014-08-07|Estimate|2014-04-02|2014-04-30|Estimate|2017-08-30|2017-09-27|Actual|September 17, 2008|Actual|2008-09-17|August 2017|2017-08-31|February 24, 2009|Actual|2009-02-24|February 24, 2009|Actual|2009-02-24||Interventional||All randomized participants who received study drug.|Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections|A Phase 2 Multi-Center, Randomized, Double-Blind, Non-Controlled Study Comparing the Safety, Tolerance, and Efficacy of TR-701 in Patients With Complicated Skin and Skin Structure Infections|Completed||Phase 2|192|Actual|Trius Therapeutics LLC||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:43:31.328403|2018-06-01 01:43:31.328403
NCT00761202|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2010-01-12||2013-10-25|2008-09-26|2008-09-29|Estimate|2010-01-12|2010-02-04|Estimate||||2013-10-25|2013-11-19|Estimate|August 2007||2007-08-31|October 2013|2013-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms||Completed||Phase 4|50|Actual|Allergan||2|||f||||f||||||||||2018-06-01 01:43:31.702803|2018-06-01 01:43:31.702803
NCT00761189|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2014-01-22||2014-01-22|2008-09-25|2008-09-29|Estimate|2014-01-22|2014-03-05|Estimate||||2014-01-22|2014-03-05|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|PANDORA||PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia|An Open Label, Prospective, Non-comparative Study to Evaluate Flexible Dose of Paliperidone Extended-Release and Clinical Response in the Treatment of Subjects With Schizophrenia|Completed||Phase 4|491|Actual|Janssen Korea, Ltd., Korea|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.|1|||f||||f||||||||||2018-06-01 01:43:32.180412|2018-06-01 01:43:32.180412
NCT00761176|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2015-10-26||2015-11-30|2008-09-26|2008-09-29|Estimate|2015-11-30|2016-01-05|Estimate||||2015-11-30|2016-01-05|Estimate|July 2008||2008-07-31|November 2015|2015-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers|A Controlled Study Comparing Basic Wound Care to the Provant® Therapy System as an Adjunct to Basic Wound Care for Wound Surface Area Reduction in Diabetic Plantar Foot Wounds|Terminated||N/A|8|Actual|Regenesis Biomedical, Inc.||2||Protocol Violations noted for 6 of 8 patients|f||||f||||||||||2018-06-01 01:43:32.600899|2018-06-01 01:43:32.600899
NCT00761163|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-01-16|2008-09-26|2008-09-29|Estimate|||||||2013-01-16|2013-01-17|Estimate|February 2007||2007-02-28|January 2013|2013-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||The Body's Response to Aerobic Versus Resistance Exercise||Completed||N/A|25|Actual|Purdue University||3|||f||||||||||||||2018-06-01 01:43:32.846834|2018-06-01 01:43:32.846834
NCT00761150|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2013-11-01|2012-10-08|2014-01-09|2008-09-26|2008-09-29|Estimate|2013-11-01|2013-12-23|Estimate|2012-10-08|2012-10-11|Estimate|2014-01-09|2014-02-07|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)|A Phase 3, Open-Label Period Followed by a Randomized, Double-blind, Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain|Completed||Phase 3|308|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 01:43:32.937125|2018-06-01 01:43:32.937125
NCT00757796|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2008-09-21|2008-09-21|2008-09-23|Estimate|||||||2008-09-21|2008-09-23|Estimate|October 2008||2008-10-31|September 2008|2008-09-30||||||||Observational|||Obstructive Sleep Apnea Syndrome and Attention Executive Function Disturbances|Obstructive Sleep Apnea Syndrome and Attention Executive Function Disturbances|Unknown status|Not yet recruiting||80|Anticipated|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 01:44:25.053257|2018-06-01 01:44:25.053257
NCT00761124|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-26|||2017-08-24|2008-09-26|2008-09-29|Estimate|||||||2017-08-24|2017-08-28|Actual|April 2003|Actual|2003-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|PSA||Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men|Informed Decision-Making Regarding PSA Screening|Active, not recruiting||N/A|1006|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-06-01 01:43:33.459434|2018-06-01 01:43:33.459434
NCT00761111|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2008-10-07|2008-09-26|2008-09-29|Estimate|||||||2008-10-07|2008-10-08|Estimate|June 2007||2007-06-30|October 2008|2008-10-31||||May 2008|Anticipated|2008-05-31||Interventional|||Could a Simple Information Booklet Modify Low Back Pain Patients Beliefs After Lumbar Discectomy?|Could a Simple Information Booklet Modify Low Back Pain Patients Beliefs After Lumbar Discectomy?|Unknown status|Active, not recruiting|Phase 3|140|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:43:33.52318|2018-06-01 01:43:33.52318
NCT00761098|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2011-01-03|2008-09-26|2008-09-29|Estimate|||||||2011-01-03|2011-01-04|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|August 2010|Anticipated|2010-08-31|May 2010|Anticipated|2010-05-31||Interventional|||Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)|A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis|Unknown status|Recruiting|Phase 4|80|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 01:43:33.589395|2018-06-01 01:43:33.589395
NCT00761085|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2016-07-18|2008-09-24|2008-09-26|Estimate|||||||2016-07-18|2016-07-20|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MSCD||Methadone in Pediatric and Adult Sickle Cell Patients|Methadone in Pediatric and Adult Sickle Cell Patients|Recruiting||N/A|54|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:43:33.676899|2018-06-01 01:43:33.676899
NCT00761072|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-03-05|2008-09-25|2008-09-26|Estimate|||||||2013-03-05|2013-03-07|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Remifentanil Propofol Infusion in Pediatric Spinal Surgery|An Evaluation of RemifentanilPropofol Infusion in Pediatric Spinal Surgery|Completed|||12|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-06-01 01:43:33.739637|2018-06-01 01:43:33.739637
NCT00761059|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2009-02-24|2008-09-25|2008-09-26|Estimate|||||||2009-02-24|2009-02-25|Estimate|October 2008||2008-10-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|Glucose FG||Analgesic Efficacy of Oral Glucose in Preterm Neonates During Suctioning|Prospective, Placebo-Controlled Blinded Clinical Trial to Study the Efficacy of Orally Administered Glucose 20% for Relieving Pain During Nasopharyngeal Suctioning in Preterm Infants > 1500g Under CPAP-Therapy|Unknown status|Recruiting|N/A|40|Anticipated|University of Cologne||2|||f||||f||||||||||2018-06-01 01:43:33.91498|2018-06-01 01:43:33.91498
NCT00761046|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-07-06|2008-09-25|2008-09-26|Estimate|||||||2017-07-06|2017-07-07|Actual|October 2008||2008-10-31|July 2017|2017-07-31||||||||Observational|||Retrospective Study on Cenos Stem With BoneMaster HA|Retrospective Study on Cenos Stem With BoneMaster HA|Withdrawn|||0|Actual|Zimmer Biomet||||No data have been obtained at all in this time.|f||||f||||||||||2018-06-01 01:43:33.992124|2018-06-01 01:43:33.992124
NCT00761033|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2016-12-06|2008-09-25|2008-09-26|Estimate|||||||2016-12-06|2016-12-08|Estimate|October 2008||2008-10-31|December 2016|2016-12-31||||||||Interventional|||Music to Reduce Pain and Anxiety in the Pediatric Emergency Department|Music to Reduce Pain and Anxiety in the Pediatric Emergency Department: a Randomized Controlled Trial of Children 3-6 Years Undergoing Intravenous Placement|Completed||N/A|42|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 01:43:34.038766|2018-06-01 01:43:34.038766
NCT00761020|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2010-06-02|2008-09-25|2008-09-26|Estimate|||||||2010-06-02|2010-06-03|Estimate|September 2008||2008-09-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection|Analysis of Anti-Plasmodium Falciparum Merozoite Surface Protein 1 Antigen Specific Antibodies in a Human Malaria Challenge Using Mefloquine Prophylaxis to Confirm Assay Sensitivity and Establish Key Antibody Kinetic Parameters|Completed||Phase 1|31|Anticipated|Walter Reed Army Institute of Research (WRAIR)||2|||f||||t||||||||||2018-06-01 01:43:34.101263|2018-06-01 01:43:34.101263
NCT00761007|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2010-09-08||2012-03-20|2008-09-25|2008-09-26|Estimate|2010-09-08|2010-10-01|Estimate||||2012-03-20|2012-03-21|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|IRIS||Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)|Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Effect of a 4-week Treatment With Oral Doses of Ibodutant (Code: MEN15596) in Irritable Bowel Syndrome (IBS).|Completed||Phase 2|554|Actual|Menarini Group||4|||f||||f||||||||||2018-06-01 01:43:34.191238|2018-06-01 01:43:34.191238
NCT00760994|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-01-14|2008-09-25|2008-09-26|Estimate|||||||2013-01-14|2013-01-15|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|COPE||Reducing Alcohol Use & Post-traumatic Stress Disorder (PTSD) With Cognitive Restructuring & Experiential Acceptance|Reducing Alcohol Use & PTSD w/ Cognitive Restructuring & Experiential Acceptance|Completed||N/A|133|Actual|Seattle Institute for Biomedical and Clinical Research||3|||f||||t||||||||||2018-06-01 01:43:34.57253|2018-06-01 01:43:34.57253
NCT00760981|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2010-02-17|2008-09-25|2008-09-26|Estimate|||||||2010-02-17|2010-02-19|Estimate|September 2008||2008-09-30|February 2010|2010-02-28|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease|A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 01:43:34.687769|2018-06-01 01:43:34.687769
NCT00760968|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-06-09|2008-09-25|2008-09-26|Estimate|||||||2010-06-09|2010-06-11|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms in Subjects With Rheumatoid Arthritis|Completed||Phase 2|224|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:43:34.755278|2018-06-01 01:43:34.755278
NCT00760955|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24||2016-06-20|2016-06-20|2008-09-25|2008-09-26|Estimate||||2016-06-20|2016-06-22|Estimate|2016-06-20|2016-06-22|Estimate|September 2006||2006-09-30|June 2016|2016-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy|Completed||Phase 2|338|Actual|Takeda||4|||f||||t||||||||||2018-06-01 01:43:34.870752|2018-06-01 01:43:34.870752
NCT00760942|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2013-12-09|2008-09-25|2008-09-26|Estimate|||||||2013-12-09|2013-12-10|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Liquid Preterm Formula Versus Powdered Human Milk Fortifier in VLBW Infants|Randomized Study of a Liquid High-Calorie Preterm Formula Versus Powdered Human Milk Fortifier in Very-Low Birthweight Infants|Completed||N/A|84|Actual|University of Oklahoma||2|||f||||t||||||||||2018-06-01 01:43:35.987457|2018-06-01 01:43:35.987457
NCT00760929|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25||2016-07-26|2016-11-01|2008-09-25|2008-09-26|Estimate||||2016-07-26|2016-07-28|Estimate|2016-11-01|2016-11-02|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).|A Randomized, Placebo Controlled Study to Determine the Effect of Two Dose Schedules of R1507 or Placebo, Both in Combination With Erlotinib (Tarceva®), on Progression-free Survival in Patients With Advanced Non-small Cell Lung Cancer With Disease Progression After First or Second Line Chemotherapy|Completed||Phase 2|167|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 01:43:36.069723|2018-06-01 01:43:36.069723
NCT00760916|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-01-29|2008-09-25|2008-09-26|Estimate|||||||2013-01-29|2013-01-30|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)|FREEDOM DR: An International, Multi-Center, 12-Week, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study Followed by a 12-Week Open-Label Extension Study to Assess the Efficacy, Safety, and Dose Response of UT-15C SR in Subjects With Pulmonary Hypertension|Withdrawn||Phase 3|0|Actual|United Therapeutics||4||Study stopped prior to subject enrollment.|f||||f||||||||||2018-06-01 01:43:36.241473|2018-06-01 01:43:36.241473
NCT00760903|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-01-04|2008-09-25|2008-09-26|Estimate|||||||2017-01-04|2017-01-06|Estimate|June 2003||2003-06-30|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Observational|||Magnetic Resonance (MR) Spectroscopy and Diffusion Tensor Imaging in Determining Brain Injury and Subsequent Clinical Outcome in Patients of Moderate Brain Trauma||Withdrawn|||0|Actual|University of Michigan|||5|Study was not started due to PI concentrating on other studies|f||||f||||||||No||2018-06-01 01:43:36.483435|2018-06-01 01:43:36.483435
NCT00760890|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-25|2008-09-25|2008-09-26|Estimate|||||||2008-09-25|2008-09-26|Estimate|June 2001||2001-06-30|September 2008|2008-09-30|October 2005|Actual|2005-10-31|June 2005|Actual|2005-06-30||Interventional|BFe01B1||Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation|Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation|Completed||N/A|171|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||3|||f||||||||||||||2018-06-01 01:43:36.574042|2018-06-01 01:43:36.574042
NCT00760877|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2016-07-01||2016-10-04|2008-09-25|2008-09-26|Estimate|2016-07-01|2016-08-16|Estimate||||2016-10-04|2016-11-08|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)|An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.|Completed||Phase 3|207|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:43:36.701799|2018-06-01 01:43:36.701799
NCT00760864|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-06-09|2008-09-24|2008-09-26|Estimate|||||||2010-06-09|2010-06-11|Estimate|August 2004||2004-08-31|June 2010|2010-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis|Completed||Phase 2|432|Actual|Takeda||4|||f||||f||||||||||2018-06-01 01:43:37.373363|2018-06-01 01:43:37.373363
NCT00760851|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2011-03-17|2008-09-25|2008-09-26|Estimate|||||||2011-03-17|2011-03-18|Estimate|September 2008||2008-09-30|February 2011|2011-02-28|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|SIPPY II||Yogurt Study in Children 2-4 Years Old Attending Daycare|Study to Investigate the Potential of Probiotics II|Completed||Phase 3|190|Anticipated|Georgetown University||2|||f||||t||||||||||2018-06-01 01:43:37.480216|2018-06-01 01:43:37.480216
NCT00760838|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2013-10-22||2014-06-25|2008-09-25|2008-09-26|Estimate|2014-06-25|2014-06-26|Estimate||||2014-06-25|2014-06-26|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Interventional|AZISAST||AZISAST Study: AZIthromycin in Severe ASThma Study|The AZIthromycin in Severe ASThma (AZISAST) Study: a Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy, Safety and Cost-effectiveness of Azithromycin as add-on Therapy in Adult Subjects With Severe Persistent Asthma, Who Remain Inadequately Controlled Despite GINA (2006) Step 4 or 5 Therapy|Completed||Phase 4|109|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:43:37.673111|2018-06-01 01:43:37.673111
NCT00760825|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2014-06-16|2008-09-25|2008-09-26|Estimate|||||||2014-06-16|2014-06-17|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children|An Open Label Post Licensure Trial to Evaluate the Safety and Immunogenicity of Indigenously Manufactured Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine(Shanchol™)|Completed||Phase 4|200|Actual|International Vaccine Institute||1|||f||||t||||||||||2018-06-01 01:43:38.141311|2018-06-01 01:43:38.141311
NCT00760812|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2014-02-19|2008-09-25|2008-09-26|Estimate|||||||2014-02-19|2014-02-20|Estimate|April 2007||2007-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|May 2013|Actual|2013-05-31||Interventional|||Comparing Parent-Implemented Interventions for Toddlers With Autism Spectrum Disorders|Effects of Parent-Implemented Intervention for Toddlers With Autism Spectrum (The ESI Study)|Completed||N/A|82|Actual|Florida State University||2|||f||||t||||||||||2018-06-01 01:43:38.255035|2018-06-01 01:43:38.255035
NCT00760799|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2012-05-01|2008-09-25|2008-09-26|Estimate|||||||2012-05-01|2012-05-02|Estimate|March 2007||2007-03-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Randomized Study of Anular Repair With the Xclose Tissue Repair System|Randomized Study of Anular Repair With the Xclose Tissue Repair System|Completed||Phase 4|750|Actual|Anulex Technologies, Inc.||2|||f||||f||||||||||2018-06-01 01:43:38.371516|2018-06-01 01:43:38.371516
NCT00760305|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2011-05-23|2008-09-25|2008-09-26|Estimate|||||||2011-05-23|2011-05-24|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|Pro-self||Pro-self Pain Management in Norway|Pro-self - a Nursing Intervention to Support and Educate Cancer Patients and Their Caregivers so That the Patient Can Stay Home|Completed||N/A|167|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:43:46.077311|2018-06-01 01:43:46.077311
NCT00760786|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-25|2008-09-25|2008-09-26|Estimate|||||||2008-09-25|2008-09-26|Estimate|July 2008||2008-07-31|September 2008|2008-09-30||||February 2010|Anticipated|2010-02-28||Interventional|||Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque|Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque: Serial Virtual Histology Intravascular Ultrasound Analysis|Unknown status|Recruiting|N/A|60|Anticipated|Samsung Medical Center||4|||f||||t||||||||||2018-06-01 01:43:38.495744|2018-06-01 01:43:38.495744
NCT00760773|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2018-04-16|2008-09-25|2008-09-26|Estimate|||||||2018-04-16|2018-04-17|Actual|April 2009||2009-04-30|April 2018|2018-04-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Impact of Emergency Department Probiotic Treatment of Diarrheal Illness on Daycare Attendance|Impact of Emergency Department Probiotic Treatment of Diarrheal Illness on Daycare Attendance: Randomized Controlled Trial and Economic Analysis|Terminated||Phase 2|132|Actual|The Hospital for Sick Children||3||Funding ended and fewer than required number of patients enrolled.|f||||t||||||||||2018-06-01 01:43:38.577546|2018-06-01 01:43:38.577546
NCT00760760|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2016-03-14|2008-09-25|2008-09-26|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|September 2014|Actual|2014-09-30||Interventional|PUFA-ATI||n-3 Polyunsaturated Fatty Acids in Obesity|Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients|Completed||Phase 2|55|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:43:38.667996|2018-06-01 01:43:38.667996
NCT00760747|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2011-08-02||2011-08-02|2008-09-25|2008-09-26|Estimate|2011-08-02|2011-09-01|Estimate||||2011-08-02|2011-09-01|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|ADHD SWITCH||Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)|A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning Compared With Fast Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|112|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:43:38.770734|2018-06-01 01:43:38.770734
NCT00760734|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-04-16|2008-09-25|2008-09-26|Estimate|||||||2017-04-16|2017-04-18|Actual|September 2008||2008-09-30|April 2017|2017-04-30|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|||Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)|HBOT in Chronic Traumatic Brain Injury/Post Concussion Syndrome and TBI/PTSD Pilot Trial|Completed||Phase 1|30|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||t||||||||||2018-06-01 01:43:39.266519|2018-06-01 01:43:39.266519
NCT00760721|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2016-11-23|2008-09-25|2008-09-26|Estimate|||||||2016-11-23|2016-11-28|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Increasing Hepatitis B Screening Among Korean Church Attendees|Increasing Hepatitis B Screening Among Korean Church Attendees (Component Project) Program Project Title: Liver Cancer Control Interventions for Asian Americans|Completed||Phase 3|1123|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:43:39.337285|2018-06-01 01:43:39.337285
NCT00760708|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2013-01-16|2008-09-25|2008-09-26|Estimate|||||||2013-01-16|2013-01-17|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Circulating Adenosine Levels Before and After Intravenous (IV) Persantine|Circulating Adenosine Levels Before and After Intravenous (IV) Persantine|Terminated|||221|Actual|UConn Health|||1|Persantine is no longer being used at UCHC for pharmacological stress testing|f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:43:39.40559|2018-06-01 01:43:39.40559
NCT00760695|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-05-08|2008-09-25|2008-09-26|Estimate|||||||2013-05-08|2013-05-10|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa|Cannabinoid CB1 Receptor Agonist Treatment in Severe Chronic Anorexia Nervosa|Completed||Phase 3|24|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 01:43:39.461488|2018-06-01 01:43:39.461488
NCT00760682|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2012-05-23|2008-09-25|2008-09-26|Estimate|||||||2012-05-23|2012-05-25|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study|Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study|Unknown status|Recruiting|Phase 2|114|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:43:39.619733|2018-06-01 01:43:39.619733
NCT00760669|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2013-06-06||2013-09-25|2008-09-25|2008-09-26|Estimate|2013-06-06|2013-08-12|Estimate||||2013-09-25|2013-10-29|Estimate|May 2007||2007-05-31|September 2013|2013-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational||Baseline characteristics were performed on safety analysis set. Data presented only for 1055 participants as they were part of safety analysis set. Safety analysis set included all participants who received at least 1 dose of study medication.|An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants|Post Marketing Surveillance of Remicade in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Patients|Completed|||1061|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-06-01 01:43:39.818172|2018-06-01 01:43:39.818172
NCT00760656|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-06-09|2008-09-25|2008-09-26|Estimate|||||||2017-06-09|2017-06-12|Actual|September 13, 2007|Actual|2007-09-13|June 2017|2017-06-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|SJLIFE||Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer|Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer|Recruiting|||8000|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Control Participants - Storage of Biological Specimens~      Blood, serum and urine:~      A peripheral blood order will be placed in MILLI by a member of the clinical staff and the~     control participant will have 23cc of peripheral blood (6cc each in 3 NaHeparin tube, 5cc in~     red top) collected for the study. The collected peripheral blood sample will be stored in the~     institutional tissue bank. The sample will be tagged accordingly and will be only released to~     fulfill future objectives of the SJLIFE protocol.~   "|||2018-06-01 01:43:40.149907|2018-06-01 01:43:40.149907
NCT00760643|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-07-06|2008-09-25|2008-09-26|Estimate|||||||2017-07-06|2017-07-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:43:40.246053|2018-06-01 01:43:40.246053
NCT00759590|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-10-19|2008-09-24|2008-09-25|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2008||2008-09-30|October 2015|2015-10-31||||March 2015|Actual|2015-03-31||Observational|||Comparison of Two Methods to Estimate the Lung Recruitment|Comparisons of Two Methods to Estimate the Lung Recruitment|Unknown status|Recruiting||30|Anticipated|Policlinico Hospital|||1||f||||f||||||||||2018-06-01 01:43:56.130268|2018-06-01 01:43:56.130268
NCT00760630|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-09-03|2008-09-24|2008-09-26|Estimate|||||||2010-09-03|2010-09-06|Estimate|December 2009||2009-12-31|September 2010|2010-09-30|April 2012|Anticipated|2012-04-30|October 2011|Anticipated|2011-10-31||Interventional|MASES||Measurements to Assess Severity of Epicardial Stenoses|Simultaneous Measurements Of Pressure Gradient, Blood Flow and Percentage Area Stenosis Of Coronary Epicardial Lesions To Assess Severity Of Epicardial Stenosis And Myocardial Infarction|Suspended||Early Phase 1|76|Anticipated|University of Cincinnati||1||IRB Approval on study expired May 28, 2009|f||||f||||||||||2018-06-01 01:43:40.290075|2018-06-01 01:43:40.290075
NCT00760617|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2012-03-29|2009-05-20|2016-10-11|2008-09-25|2008-09-26|Estimate|2012-03-29|2012-04-23|Estimate|2009-09-28|2009-09-30|Estimate|2016-10-11|2016-11-23|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older|Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects.|Completed||Phase 3|526|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:43:40.437913|2018-06-01 01:43:40.437913
NCT00760604|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2012-08-10|2008-09-25|2008-09-26|Estimate|||||||2012-08-10|2012-08-13|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer|A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Patients With Locally Advanced Esophageal Cancer|Terminated||Phase 3|4|Actual|Weill Medical College of Cornell University||2||Closed due to slow patient accrual.|f||||f||||||||||2018-06-01 01:43:41.615678|2018-06-01 01:43:41.615678
NCT00760591|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-25|2008-09-25|2008-09-26|Estimate|||||||2008-09-25|2008-09-26|Estimate|September 2008||2008-09-30|September 2008|2008-09-30||||||||Observational|||Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)|Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)|Unknown status|Recruiting||30|Anticipated|Soon Chun Hyang University|||||f||||f||||||None Retained|"~     Serum, Urine~   "|||2018-06-01 01:43:41.683209|2018-06-01 01:43:41.683209
NCT00760578|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2013-03-19||2013-03-19|2008-09-25|2008-09-26|Estimate|2013-03-19|2013-05-03|Estimate||||2013-03-19|2013-05-03|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator|A Phase 2A, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of Mitoglitazone™ in Type 2 Diabetic Patients|Completed||Phase 2|86|Actual|Metabolic Solutions Development Company||4|||f||||f||||||||||2018-06-01 01:43:41.748682|2018-06-01 01:43:41.748682
NCT00760565|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2016-11-01|2008-09-25|2008-09-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).|A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4905417 Following Intravenous Infusion in Healthy Volunteers and Patients With Peripheral Arterial Disease|Completed||Phase 1|72|Actual|Hoffmann-La Roche||12|||f||||||||||||||2018-06-01 01:43:42.33916|2018-06-01 01:43:42.33916
NCT00760552|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2014-12-03||2015-04-06|2008-09-24|2008-09-26|Estimate|2014-12-15|2014-12-17|Estimate||||2015-04-06|2015-04-27|Estimate|November 2009||2009-11-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Trial of Low and High Intensity Strategies to Maintain BP Control|Trial of Low And High Intensity Strategies to Maintain Blood Pressure Control|Completed||N/A|249|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:43:42.440775|2018-06-01 01:43:42.440775
NCT00760539|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24||2014-07-10|2014-07-14|2008-09-25|2008-09-26|Estimate||||2014-07-10|2014-07-14|Estimate|2014-07-14|2014-07-16|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Travoprost/Timolol BAC-free|A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|87|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:43:42.845812|2018-06-01 01:43:42.845812
NCT00760526|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2012-10-26||2016-09-02|2008-09-25|2008-09-26|Estimate|2013-09-26|2013-12-04|Estimate||||2016-09-02|2016-10-19|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM|A Randomized Clinical Trial to Assess the Efficacy and Safety of Real-Time Continuous Glucose Monitoring in the Management of Type 1 Diabetes in Young Children (4 to <10 Year Olds)|Completed||Phase 3|146|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 01:43:42.964186|2018-06-01 01:43:42.964186
NCT00760513|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2018-04-17|2008-09-25|2008-09-26|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2009||2009-11-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids|The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease|Active, not recruiting||Phase 2|100|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:43:43.370584|2018-06-01 01:43:43.370584
NCT00760500|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2015-02-16|2008-09-25|2008-09-26|Estimate|||||||2015-02-16|2015-02-18|Estimate|January 2004||2004-01-31|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China|Surveillance of Influenza Virus Among Children With Febrile Respiratory Complaints Attending the Pediatric Clinic of the First Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong, Mainland China|Completed|||13201|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples Without DNA|"~     Nasopharyngeal specimen taken by swab~   "|||2018-06-01 01:43:43.447033|2018-06-01 01:43:43.447033
NCT00760487|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2009-09-22||2012-01-12|2008-09-25|2008-09-26|Estimate|2010-03-25|2010-04-07|Estimate||||2012-01-12|2012-01-16|Estimate|October 2006||2006-10-31|January 2012|2012-01-31||||June 2008|Actual|2008-06-30||Interventional|||Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens||Completed||Phase 4|120|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:43:43.536658|2018-06-01 01:43:43.536658
NCT00760474|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2012-03-07||2012-06-22|2008-09-25|2008-09-26|Estimate|2012-03-07|2012-04-04|Estimate||||2012-06-22|2012-07-11|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An fMRI Study Of Brain Response In Patients With Fibromyalgia|A Double-Blind, Placebo-Controlled Cross-Over Study In Fibromyalgia Subjects To Examine Effects Of Pregabalin On Brain Response To Mechanical Pain As Assessed By Functional Magnetic Resonance Imaging, Proton Magnetic Resonance Spectroscopy And Subjective Ratings|Completed||Phase 1|27|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:43:43.772167|2018-06-01 01:43:43.772167
NCT00760461|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2016-09-15||2017-08-17|2008-09-24|2008-09-26|Estimate|2017-08-17|2017-08-18|Actual||||2017-08-17|2017-08-18|Actual|October 2008||2008-10-31|February 2017|2017-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Domperidone in Refractory Gastroparesis|Domperidone in Refractory Gastroparesis|Terminated||Phase 2|44|Actual|Yale University||1||Enrolled subjects were unable to receive drug from dispensing pharmacy.|f||||f||||||||||2018-06-01 01:43:44.523367|2018-06-01 01:43:44.523367
NCT00760448|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-01-26|2008-09-25|2008-09-26|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2004||2004-04-30|January 2017|2017-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia|Trial Investigating the Hypoglycaemic Response to Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes|Completed||Phase 1|25|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 01:43:44.627321|2018-06-01 01:43:44.627321
NCT00760435|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2014-05-19||2014-11-12|2008-09-25|2008-09-26|Estimate|2014-10-30|2014-11-13|Estimate||||2014-11-12|2014-11-24|Estimate|March 2009||2009-03-31|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease|Infliximab (Remicade®) Plus Intravenous Immunoglobulin (IVIG) for the Primary Treatment of Patients With Acute Kawasaki Disease|Completed||Phase 3|196|Actual|University of California, San Diego|The major limitation of our study was the low rate of treatment-resistance in the placebo arm (11%, compared to historical IVIG resistance rates of 20%), which decreased our power to detect a difference in the primary outcome measure.|2|||f||||t||||||||||2018-06-01 01:43:44.699345|2018-06-01 01:43:44.699345
NCT00760422|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2012-04-19|2008-09-25|2008-09-26|Estimate|||||||2012-04-19|2012-04-20|Estimate|December 2008||2008-12-31|August 2008|2008-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|NIR||Clinical Evaluation of NIR (Non-Invasive Infrared) Thermometer Performance||Completed|||500|Anticipated|Medisim Ltd|||2||f||||t||||||||||2018-06-01 01:43:45.117225|2018-06-01 01:43:45.117225
NCT00760409|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-12-20|2008-09-24|2008-09-26|Estimate|||||||2017-12-20|2017-12-22|Actual|September 2008||2008-09-30|December 2017|2017-12-31|June 1, 2015|Actual|2015-06-01|June 1, 2015|Actual|2015-06-01||Observational|||Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI|Prospective Study Differentiating Recurrent Brain Tumor Versus Radiation Injury Using Magnetic Resonance (MR) Spectroscopy, Diffusion Tensor Imaging and Diffusion Weighted Imaging on 3T(Tesla) MR Scanner|Completed|||28|Actual|University of Michigan|||2||f||||t||||||||No||2018-06-01 01:43:45.18102|2018-06-01 01:43:45.18102
NCT00760396|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2009-04-06|2008-09-25|2008-09-26|Estimate|||||||2009-04-06|2009-04-07|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||Multiple-Dose Study of VGX-1027 in Healthy Subjects|A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety and Pharmacokinetics of VGX-1027 in Healthy Subjects|Completed||Phase 1|40|Actual|VGX Pharmaceuticals, LLC||4|||f||||f||||||||||2018-06-01 01:43:45.239721|2018-06-01 01:43:45.239721
NCT00760383|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2014-04-17||2014-12-01|2008-09-25|2008-09-26|Estimate|2014-12-01|2014-12-04|Estimate||||2014-12-01|2014-12-04|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation|Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation|Completed||N/A|60|Actual|University of Oregon||2|||f||||t||||||||||2018-06-01 01:43:45.304577|2018-06-01 01:43:45.304577
NCT00760370|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2011-12-06|2008-09-25|2008-09-26|Estimate|||||||2011-12-06|2011-12-07|Estimate|December 2008||2008-12-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer|Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone|Completed||Phase 2|60|Actual|Vejle Hospital|||||f||||t||||||||||2018-06-01 01:43:45.568111|2018-06-01 01:43:45.568111
NCT00760357|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-11-24|2008-09-25|2008-09-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|April 2007||2007-04-30|November 2015|2015-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||A Retrospective Analysis of Patients With Full Thickness Wounds in Limbs With Critical Ischemia|A Retrospective Analysis of Patients With Full Thickness Wounds in Limbs With Critical Ischemia|Completed|||190|Actual|Southwest Regional Wound Care Center|||1||f||||t||||||Samples With DNA|"~     Once the patients are identified that have a full thickness wound on a limb clearly~     identified as having critical limb ischemia, these patients will be evaluated. The data that~     will be extracted from each chart will include patient's age, patient's gender, number of~     office visits, presence of diabetes, presence of osteomyelitis, type and amount of antibiotic~     administered, number of hyperbaric oxygen treatments, and if the wound healed.~   "|||2018-06-01 01:43:45.649332|2018-06-01 01:43:45.649332
NCT00760344|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24||2016-06-20|2016-06-20|2008-09-25|2008-09-26|Estimate||||2016-06-20|2016-06-22|Estimate|2016-06-20|2016-06-22|Estimate|March 2007||2007-03-31|June 2016|2016-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Treatment With SYR-472 in Subjects With Type 2 Diabetes|Completed||Phase 2|386|Actual|Takeda||6|||f||||f||||||||||2018-06-01 01:43:45.733912|2018-06-01 01:43:45.733912
NCT00760331|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-25|2008-09-25|2008-09-26|Estimate|||||||2008-09-25|2008-09-26|Estimate|June 2008||2008-06-30|September 2008|2008-09-30|July 2028|Anticipated|2028-07-31|||||Observational|TCF2||Long Term Follow up of a Cohort of Children With TCF2 Mutation:Evolution of Endocrine and Renal Function|A Long Term Follow up of a Cohort of Children With TCF2 Mutation:Evolution of Endocrine and Renal Function|Recruiting|||100|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 01:43:45.947848|2018-06-01 01:43:45.947848
NCT00760318|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2008-09-25|2008-09-25|2008-09-26|Estimate|||||||2008-09-25|2008-09-26|Estimate|November 2005||2005-11-30|September 2008|2008-09-30|December 2008|Anticipated|2008-12-31|October 2007|Actual|2007-10-31||Interventional|Keppra||Keppra for Cervical Dystonia|Prospective Double Blind Evaluation of Levetiracetam (Keppra) for the Treatment of Cervical Dystonia|Suspended||Phase 2|17|Actual|University of South Florida||||Sponsor decided to stop enrollment to review data.|f||||f||||||||||2018-06-01 01:43:46.011522|2018-06-01 01:43:46.011522
NCT00760292|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-25|2008-09-25|2008-09-26|Estimate|||||||2008-09-25|2008-09-26|Estimate|May 2008||2008-05-31|June 2008|2008-06-30|April 2011|Anticipated|2011-04-30|December 2009|Anticipated|2009-12-31||Observational|GenVarT2DM||Genetic Variants and Phenotypic Characteristics of Patients With T2DM|Genetic Variants and Phenotypic Characteristics of Patients With T2DM|Unknown status|Active, not recruiting||2000|Anticipated|Odense University Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:43:46.144361|2018-06-01 01:43:46.144361
NCT00760279|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-25|2008-09-25|2008-09-26|Estimate|||||||2008-09-25|2008-09-26|Estimate|September 2005||2005-09-30|September 2008|2008-09-30||||||||Interventional|||An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates|An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates Pediatric Pharmacology Research Unit, Children's Hospital of Michigan|Completed||Phase 1|16|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||||||2018-06-01 01:43:46.192811|2018-06-01 01:43:46.192811
NCT00760266|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|2010-12-22||2011-03-31|2008-09-25|2008-09-26|Estimate|2010-12-22|2011-01-21|Estimate||||2011-03-31|2011-04-04|Estimate|September 2008||2008-09-30|March 2011|2011-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ACTION||Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population|An 8-week Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to HCTZ (25 mg) in Older Patients With Stage 2 Systolic Hypertension|Completed||Phase 4|451|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:43:46.263191|2018-06-01 01:43:46.263191
NCT00760253|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2009-12-14|2008-09-25|2008-09-26|Estimate|||||||2009-12-14|2009-12-15|Estimate|September 2008||2008-09-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|||Compare the Side Effects and Difference Awake Level of Three TCI Propofol Formula in TVOR Patients|Compare the Side Effects and Differences Awake Level of Propofol by Using Three TCI Formula of Anesthesia in TVOR Patients|Completed|||118|Actual|National Taiwan University Hospital|||3||f||||f||||||||||2018-06-01 01:43:46.491418|2018-06-01 01:43:46.491418
NCT00760240|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2010-04-23|2008-09-25|2008-09-26|Estimate|||||||2010-04-23|2010-04-26|Estimate|September 2008||2008-09-30|April 2010|2010-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Ability of Patients With Low Vision to Properly Instill Eye Drops|Objective Evaluation of the Ability of Patients With Decreased Vision or Restricted Visual Fields to Properly Instill Eye Drops|Completed|||200|Anticipated|Mid-Atlantic Glaucoma Experts|||2||f||||f||||||||||2018-06-01 01:43:46.556825|2018-06-01 01:43:46.556825
NCT00760227|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2011-09-27|2008-09-25|2008-09-26|Estimate|||||||2011-09-27|2011-09-29|Estimate|January 2003||2003-01-31|September 2011|2011-09-30||||December 2007|Actual|2007-12-31||Interventional|||Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation|Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation|Completed||N/A|189|Actual|St. Jude Children's Research Hospital||3|||f||||f||||||||||2018-06-01 01:43:46.663921|2018-06-01 01:43:46.663921
NCT00760214|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2011-03-24||2012-11-08|2008-09-25|2008-09-26|Estimate|2011-03-24|2011-04-19|Estimate||||2012-11-08|2012-11-15|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension|A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension|Completed||Phase 3|885|Actual|Takeda||3|||f||||f||||||||||2018-06-01 01:43:46.811999|2018-06-01 01:43:46.811999
NCT00760201|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2011-04-18|2008-09-25|2008-09-26|Estimate|||||||2011-04-18|2011-04-19|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Observational|HospExe||Qualitative Analysis of Hospital Executives, Physician Administrators, and Hospital Legal Counsels' Perceptions of End-of-Life Care|Analysis of Hospital Executives, Physician Administrators, and Hospital Legal Counsels� Perceptions of End-of-Life Care|Completed|||14|Anticipated|VA Office of Research and Development|||1||f||||f|||||||"~     Qualitative Analysis~   "|||2018-06-01 01:43:47.548859|2018-06-01 01:43:47.548859
NCT00760188|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2017-08-31|2008-09-25|2008-09-26|Estimate|||||||2017-08-31|2017-09-05|Actual|December 2011|Actual|2011-12-31|July 2017|2017-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Prospective Data Collection on Cementless Oxford Partial Knee|Prospective Clinical Evaluation of the Cementless Oxford Partial Knee|Withdrawn|||0|Actual|Zimmer Biomet||||No patients recruited into study.|f||||f||||||||No|There is no plan to share Individual Patient Data.|2018-06-01 01:43:47.612165|2018-06-01 01:43:47.612165
NCT00760175|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2015-05-26|2008-09-25|2008-09-26|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients|A Randomized, Controlled Trial Comparing Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients|Completed||N/A|85|Actual|University of Alberta||2|||f||||t||||||||||2018-06-01 01:43:47.69877|2018-06-01 01:43:47.69877
NCT00760162|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2011-08-02|2008-09-25|2008-09-26|Estimate|||||||2011-08-02|2011-08-03|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|Probiotics||Pilot-Scale Clinical Trials of Kibow Biotics® in Chronic Kidney Failure|Pilot-Scale Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Chronic Kidney Failure|Completed|||180|Actual|Kibow Biotech Inc.|||6||f||||t||||||||||2018-06-01 01:43:47.787441|2018-06-01 01:43:47.787441
NCT00760149|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2013-09-06|2008-09-25|2008-09-26|Estimate|||||||2013-09-06|2013-09-09|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|High RIF||Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis|Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.|Completed||Phase 2|150|Actual|Radboud University||3|||f||||t||||||||||2018-06-01 01:43:47.871919|2018-06-01 01:43:47.871919
NCT00760136|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2008-10-23|2008-09-25|2008-09-26|Estimate|||||||2008-10-23|2008-10-24|Estimate|August 2006||2006-08-31|September 2008|2008-09-30|July 2009|Anticipated|2009-07-31|||||Observational|||The Role of Quadriceps Contraction in Patellar Repositioning - a Computed Tomography Study|The Role of Quadriceps Contraction in Patellar Repositioning-a Computed Tomography Study|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:43:47.990364|2018-06-01 01:43:47.990364
NCT00760123|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2014-08-22|2008-09-25|2008-09-26|Estimate|||||||2014-08-22|2014-08-25|Estimate|May 2005||2005-05-31|August 2014|2014-08-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Lymphedema Prevention in Breast Cancer|Lymphedema Prevention in Breast Cancer: a Simple Blind, Randomized, Prospective Clinical Trial of the Efficacy of Physical Therapy|Completed||N/A|120|Actual|University of Alcala||2|||f||||t||||||||||2018-06-01 01:43:48.083109|2018-06-01 01:43:48.083109
NCT00760110|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-25|||2008-09-30|2008-09-25|2008-09-26|Estimate|||||||2008-09-30|2008-10-01|Estimate|November 1997||1997-11-30|September 2008|2008-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||A Cohort Study of Morning Home Blood Pressure Measurement in Type 2 Diabetic Patients|Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients: Long-Term Results of a Prospective Longitudinal Study|Completed|||400|Actual|Nagaoka Red Cross Hospital|||2||f||||f||||||||||2018-06-01 01:43:48.157948|2018-06-01 01:43:48.157948
NCT00760097|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2013-02-04|2008-09-24|2008-09-25|Estimate|||||||2013-02-04|2013-02-06|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|aTDCS||Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression|Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression|Completed||Phase 4|18|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-06-01 01:43:48.241202|2018-06-01 01:43:48.241202
NCT00760084|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2009-08-05||2011-08-03|2008-09-24|2008-09-25|Estimate|2011-07-06|2011-08-02|Estimate||||2011-08-03|2011-08-08|Estimate|July 2005||2005-07-31|August 2011|2011-08-31|February 2008|Actual|2008-02-29|September 2005|Actual|2005-09-30||Interventional|||Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|An Expanded Access Protocol to Administer Decitabine to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Completed||Phase 2|10|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 01:43:48.336768|2018-06-01 01:43:48.336768
NCT00760071|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-04-14|2008-09-24|2008-09-25|Estimate|||||||2010-04-14|2010-04-15|Estimate|July 2006||2006-07-31|April 2010|2010-04-30|September 2009|Actual|2009-09-30|October 2008|Actual|2008-10-31||Observational|||Magnetic Resonance Imaging (MRI) for Early Diagnosis of Cystic Fibrosis (CF)|Evaluation of Morphological and Functional Magnetic Resonance Imaging (MRI) for Early Diagnosis of Lung Changes in Children (0-6 Years) With Cystic Fibrosis (CF)|Completed|||30|Anticipated|German Cancer Research Center|||2||f||||t||||||||||2018-06-01 01:43:48.587556|2018-06-01 01:43:48.587556
NCT00760058|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-05-08|2008-09-24|2008-09-25|Estimate|||||||2015-05-08|2015-05-12|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL|Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL|Withdrawn||Phase 4|0|Actual|Alcon Research||3||Enrollment not initiated for study.|f||||f||||||||||2018-06-01 01:43:48.651045|2018-06-01 01:43:48.651045
NCT00760045|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-01-05|2008-09-24|2008-09-25|Estimate|||||||2010-01-05|2010-01-06|Estimate|August 2008||2008-08-31|January 2010|2010-01-31||||October 2008|Actual|2008-10-31||Interventional|||Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time||Completed||Phase 2|40|Anticipated|Alcon Research||4|||f||||f||||||||||2018-06-01 01:43:48.717674|2018-06-01 01:43:48.717674
NCT00760032|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2012-12-04|2008-09-24|2008-09-25|Estimate|||||||2012-12-04|2012-12-05|Estimate||||December 2012|2012-12-31||||||||Interventional|||Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients|Association of Serum Levels of Lipopolysaccharide Binding Protein (LBP) With the Evolution of Pro- and Anti-inflammatory Cytokines, and the Development of Severe Infectious Events in Cirrhotic Patients|Withdrawn||Phase 4|0|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2||was not possible to measure LBP levels because we cannot found the kit|f||||t||||||||||2018-06-01 01:43:48.779859|2018-06-01 01:43:48.779859
NCT00760019|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2016-12-08||2017-04-17|2008-09-24|2008-09-25|Estimate|2017-02-22|2017-04-06|Actual||||2017-04-17|2017-05-16|Actual|August 2005||2005-08-31|April 2017|2017-04-30|February 2011|Actual|2011-02-28|October 2009|Actual|2009-10-31||Interventional|||Inflammation and Vascular Function in Atherosclerosis|Inflammation and Vascular Function in Atherosclerosis|Completed||Phase 2/Phase 3|58|Actual|Brigham and Women's Hospital||2|||f||||t||||||||No||2018-06-01 01:43:48.857314|2018-06-01 01:43:48.857314
NCT00760006|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2017-10-19||2018-01-04|2008-09-24|2008-09-25|Estimate|2018-01-04|2018-02-01|Actual||||2018-01-04|2018-02-01|Actual|May 2008||2008-05-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Preventing Complications in Cleft Palate Repair With Antibiotics|Efficacy of Preoperative Prophylactic Antibiotics in Preventing Complications in the Primary Repair of Cleft Palates|Completed||Phase 2|224|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:43:49.047237|2018-06-01 01:43:49.047237
NCT00759993|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2012-09-06|2008-09-24|2008-09-25|Estimate|||||||2012-09-06|2012-09-07|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|June 2012|Actual|2012-06-30||Interventional|||Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.|A 6 Week, Blinded, Randomized, Controlled Pilot Study to Evaluate the Safety and Efficacy of Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.|Terminated||Phase 2|60|Anticipated|State University of New York - Upstate Medical University||2||inability to recruit and retain|f||||f||||||||||2018-06-01 01:43:49.254932|2018-06-01 01:43:49.254932
NCT00759980|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2011-03-22|2008-09-24|2008-09-25|Estimate|||||||2011-03-22|2011-03-23|Estimate|October 2008||2008-10-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Transfusing Neonates Based on Platelet Mass|Transfusing Neonates Based on Platelet Mass in the Neonatal Intensive Care Unit: A Randomized Pilot Study|Completed|||50|Anticipated|Christiana Care Health Services|||2||f||||f||||||||||2018-06-01 01:43:49.315624|2018-06-01 01:43:49.315624
NCT00759967|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2013-07-31||2017-04-26|2008-09-24|2008-09-25|Estimate|2017-04-26|2017-08-04|Actual||||2017-04-26|2017-08-04|Actual|September 2007||2007-09-30|January 2017|2017-01-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional||3 patients withdrew prior to randomization, analysis based on the 19 patients randomized|Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control|Randomized Cross-over Study of Short Daily Hemodialysis Compared to Conventional Hemodialysis to Determine the Mechanisms of Hypertension Control|Completed||N/A|22|Actual|Ottawa Hospital Research Institute|Although 2 patients stopped doing short daily HD they were included in the intention to treat analysis with their short daily HD BPs carried forward|2|||f||||t||||||||||2018-06-01 01:43:49.465311|2018-06-01 01:43:49.465311
NCT00759954|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2008-12-01||2010-08-13|2008-09-24|2008-09-25|Estimate|2009-07-21|2009-09-01|Estimate||||2010-08-13|2010-08-17|Estimate|September 2004||2004-09-30|August 2010|2010-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study Comparing the Bioavailability of a Morphine Sulfate Sustained Release Capsule 1 x 200mg to KADIAN 2 x 100mg Capsules Administered Orally as a Sprinkle on Applesauce|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||f||||||||||2018-06-01 01:43:49.705458|2018-06-01 01:43:49.705458
NCT00759941|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2012-07-12||2013-12-11|2008-09-24|2008-09-25|Estimate|2012-07-12|2012-08-16|Estimate||||2013-12-11|2014-01-13|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin|A Comparison of Brinzolamide Ophthalmic Suspension, 1% (Azopt) TID vs. Placebo TID Added to Latanoprost Ophthalmic Solution, 0.005% (Xalatan) in Patients With Elevated IOP on a Prostaglandin|Completed||Phase 4|86|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:43:49.96846|2018-06-01 01:43:49.96846
NCT00759928|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2014-07-01|2008-09-24|2008-09-25|Estimate|||||||2014-07-01|2014-07-02|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|||PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors|Pharmacokinetic Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors|Completed||Phase 1|48|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 01:43:50.160927|2018-06-01 01:43:50.160927
NCT00759915|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2008-12-05||2010-08-13|2008-09-24|2008-09-25|Estimate|2009-07-21|2009-09-01|Estimate||||2010-08-13|2010-08-17|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions|A Randomized Two-way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Formulation of KADIAN (2 x 10mg) Capsules Compared to a KADIAN 20 mg Capsule in Healthy Adult Subjects Under Fed Conditions|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||||||||||||2018-06-01 01:43:50.241754|2018-06-01 01:43:50.241754
NCT00759902|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2008-12-05||2010-08-13|2008-09-24|2008-09-25|Estimate|2009-07-21|2009-09-01|Estimate||||2010-08-13|2010-08-17|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions|A Randomized Two-way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Formulation of KADIAN (2 x 10mg) Capsules Compared to a KADIAN 20 mg Capsule in Healthy Adult Subjects Under Fasted Conditions|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||||||||||||2018-06-01 01:43:50.544257|2018-06-01 01:43:50.544257
NCT00759889|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-12-28|2008-09-24|2008-09-25|Estimate|||||||2017-12-28|2018-01-02|Actual|March 2007||2007-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Obtaining and Storing Standard of Care Wound Biopsies for Immediate or Future Wound-Related Scientific Study|Obtaining and Storing Standard of Care Wound Biopsies for Immediate or Future Wound Related Scientific Study|Recruiting|||5|Anticipated|Southwest Regional Wound Care Center|||1||f||||t||||||Samples With DNA|"~     Wound edge biopsies that are obtained through standard of care protocols will be subjected to~     additional microscopic and molecular analyses following the completion of standard medical~     assessment.~   "|||2018-06-01 01:43:51.809712|2018-06-01 01:43:51.809712
NCT00759876|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-05-30|2008-09-23|2008-09-25|Estimate|||||||2017-05-30|2017-06-01|Actual|July 2008||2008-07-31|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)|A Phase 2a Extension Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy|Terminated||Phase 2|36|Actual|PTC Therapeutics||1|||f||||f||||||||No||2018-06-01 01:43:51.875658|2018-06-01 01:43:51.875658
NCT00759863|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2009-06-22||2010-02-22|2008-09-24|2008-09-25|Estimate|2010-02-04|2010-02-23|Estimate||||2010-02-22|2010-03-02|Estimate|August 2006||2006-08-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|Lifezig||LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia|LifeZig System for Individuals With Alzheimer's Disease|Completed||Phase 2|242|Actual|Photozig, Inc.||2|||f||||||||||||||2018-06-01 01:43:51.972332|2018-06-01 01:43:51.972332
NCT00759850|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2008-09-24|2008-09-24|2008-09-25|Estimate|||||||2008-09-24|2008-09-25|Estimate|October 2003||2003-10-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|October 2005|Actual|2005-10-31||Interventional|PASEO||Drug Eluting Stent (DES) in Primary Angioplasty|PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial|Completed||Phase 2/Phase 3|270|Actual|San Giuseppe Moscati Hospital||3|||f||||f||||||||||2018-06-01 01:43:52.249596|2018-06-01 01:43:52.249596
NCT00759837|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2009-07-15|2008-09-24|2008-09-25|Estimate|||||||2009-07-15|2009-07-16|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects|An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Bosutinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults|Completed||Phase 1|27|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:43:52.367458|2018-06-01 01:43:52.367458
NCT00759824|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-02-11|2008-09-24|2008-09-25|Estimate|||||||2015-02-11|2015-02-12|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide|A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide|Completed||Phase 2|64|Actual|European Lung Cancer Working Party||1|||f||||t||||||||||2018-06-01 01:43:52.536189|2018-06-01 01:43:52.536189
NCT00759811|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2009-09-04||2013-03-29|2008-09-24|2008-09-25|Estimate|2013-03-29|2013-05-08|Estimate||||2013-03-29|2013-05-08|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|METIS||METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial)|METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure: Randomized Double-blind, Placebo-controlled Trial (METIS Trial)|Completed||Phase 2/Phase 3|50|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t||||||||||2018-06-01 01:43:52.702484|2018-06-01 01:43:52.702484
NCT00759798|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-10-04|2008-09-24|2008-09-25|Estimate|||||||2017-10-04|2017-10-06|Actual|August 2008|Actual|2008-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)|Prospective Identification of Significant Prognostic Factors in Patients Treated With Fludarabine, Cyclophosphamide, and Rituximab (FCR) as Initial Therapy for Chronic Lymphocytic Leukemia.|Active, not recruiting||Phase 2|300|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:43:53.038585|2018-06-01 01:43:53.038585
NCT00759785|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2016-11-21||2017-03-03|2008-09-24|2008-09-25|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|September 2008||2008-09-30|January 2017|2017-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)|A Study to Establish Proof-of-Biology for MK-0646 in Breast Cancer|Completed||Phase 1|48|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:43:53.145422|2018-06-01 01:43:53.145422
NCT00759772|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2017-02-08||2017-04-05|2008-09-24|2008-09-25|Estimate|2017-02-08|2017-03-28|Actual||||2017-04-05|2017-05-11|Actual|September 2008||2008-09-30|April 2017|2017-04-30|February 22, 2016|Actual|2016-02-22|February 22, 2016|Actual|2016-02-22||Interventional|||The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa|The Role of PTH in Low Bone Mass in Anorexia Nervosa|Completed||Phase 2|23|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:43:53.395865|2018-06-01 01:43:53.395865
NCT00759759|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2008-12-05||2010-08-13|2008-09-24|2008-09-25|Estimate|2009-07-21|2009-09-01|Estimate||||2010-08-13|2010-08-17|Estimate|September 2004||2004-09-30|August 2010|2010-08-31|October 2004|Actual|2004-10-31|September 2004|Actual|2004-09-30||Interventional|||Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study Comparing the Bioavailability of a Morphine Sulfate Sustained Release Capsule 1 x 200mg to KADIAN 2 x 100mg Capsules Under Fasting Conditions|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||||||||||||2018-06-01 01:43:53.651231|2018-06-01 01:43:53.651231
NCT00759746|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-02-20|2008-09-24|2008-09-25|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2009||2009-10-31|February 2017|2017-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|COMPASS||Childhood Obesity Treatment: A Maintenance Approach|Childhood Obesity Treatment: A Maintenance Approach|Completed||N/A|482|Actual|Washington University School of Medicine||3|||f||||t|f|f||||||||2018-06-01 01:43:53.962902|2018-06-01 01:43:53.962902
NCT00759733|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-08-04|2008-09-24|2008-09-25|Estimate|||||||2010-08-04|2010-08-05|Estimate|July 2008||2008-07-31|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Observational|||Evaluation Cardiac Function With Echo and BNP in Obstetrical Patients With/Without Cardiac Disease|Prospective Cohort Evaluation of Cardiac Function With Echocardiography and Serum B-type Natriuretic Peptide (BNP) in Obstetrical Patients With and Without a History of Cardiac Disease|Unknown status|Not yet recruiting||40|Anticipated|State University of New York - Upstate Medical University|||2||f||||f||||||||||2018-06-01 01:43:54.035603|2018-06-01 01:43:54.035603
NCT00759720|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2012-02-01|2008-09-24|2008-09-25|Estimate|||||||2012-02-01|2012-02-02|Estimate|November 2003||2003-11-30|February 2012|2012-02-29|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|ORIGAMI||Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of a Combination of TAK-559 and Glyburide Compared to Placebo and Glyburide in the Treatment of Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|447|Actual|Takeda||3||Potential hepatic safety signal|f||||f||||||||||2018-06-01 01:43:54.318775|2018-06-01 01:43:54.318775
NCT00759707|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2016-12-08||2017-04-17|2008-09-24|2008-09-25|Estimate|2017-02-22|2017-04-06|Actual||||2017-04-17|2017-05-16|Actual|April 2006||2006-04-30|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Endothelial Function in Lower Extremity Bypass Grafts|Endothelial Function in Lower Extremity Bypass Grafts|Completed||N/A|19|Actual|Brigham and Women's Hospital||1|||f||||t||||||||No||2018-06-01 01:43:54.494186|2018-06-01 01:43:54.494186
NCT00759694|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2014-10-16|2008-09-24|2008-09-25|Estimate|||||||2014-10-16|2014-10-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:43:54.674261|2018-06-01 01:43:54.674261
NCT00759681|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2012-10-31||2012-12-20|2008-09-23|2008-09-25|Estimate|2012-12-20|2013-01-31|Estimate||||2012-12-20|2013-01-31|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|StEPS||ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial|A Prospective, Multi-center, Randomized Study to Evaluate the Safety and Efficacy of ArterX Vascular Sealant.|Completed||Phase 3|217|Actual|Tenaxis Medical, Inc.|There were no significant trial limitations.|2|||f||||t||||||||||2018-06-01 01:43:54.719407|2018-06-01 01:43:54.719407
NCT00759668|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2010-10-12||2011-01-05|2008-09-24|2008-09-25|Estimate|2011-01-05|2011-01-26|Estimate||||2011-01-05|2011-01-26|Estimate|May 2007||2007-05-31|January 2011|2011-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Visual Function and Patient Satisfaction After Bilateral Implantation of AcrySof Natural ReSTOR (Model SN60D3) or AcrySof Natural Monofocal (Model SN60AT)||Completed||N/A|35|Actual|Alcon Research|Visual acuity data were collected in different units (i.e. c, twentieth, decimal, Jaeger) and were converted to LogMAR after inclusion in the database. This led to inevitable approximations of the data.|2|||f||||f||||||||||2018-06-01 01:43:55.014346|2018-06-01 01:43:55.014346
NCT00759655|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2010-12-14||2011-02-03|2008-09-23|2008-09-25|Estimate|2010-12-14|2011-01-04|Estimate||||2011-02-03|2011-02-07|Estimate|June 2009||2009-06-30|February 2011|2011-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age|An Open-Label Study To Evaluate The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age In Usual Care Settings|Terminated||Phase 3|1|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:43:55.309597|2018-06-01 01:43:55.309597
NCT00759642|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2017-04-17||2017-04-17|2008-09-24|2008-09-25|Estimate|2017-04-17|2017-05-23|Actual||||2017-04-17|2017-05-23|Actual|March 2009||2009-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2015|Actual|2015-11-30||Interventional|||Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy|Phase II Trial of Lapatinib in Women With Hormone Receptor Positive (Estrogen Receptor [ER] and/or Progesterone Receptor [PR] +) Human Epidermal Growth Factor Receptor 2 (HER-2) Negative Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy|Active, not recruiting||Phase 2|33|Actual|University of Kansas Medical Center||1|||f||||t||||||||No||2018-06-01 01:43:55.524182|2018-06-01 01:43:55.524182
NCT00759629|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2008-09-24|2008-09-24|2008-09-25|Estimate|||||||2008-09-24|2008-09-25|Estimate|May 2001||2001-05-31|September 2008|2008-09-30|August 2005|Actual|2005-08-31|January 2005|Actual|2005-01-31||Interventional|Brave-2||Beyond 12 Hours Reperfusion AlternatiVe Evaluation Trial|An International, Multicenter, Randomized Trial Assessing the Value of Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting > 12 Hours From Onset of Symptoms|Completed||Phase 4|365|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 01:43:55.781381|2018-06-01 01:43:55.781381
NCT00759616|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-06-15|2008-09-24|2008-09-25|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2003||2003-04-30|June 2017|2017-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Outcome Analysis of the Oxford Partial Knee Arthroplasty|Outcome Analysis of the Oxford Partial Knee Arthroplasty|Completed||N/A|156|Actual|Zimmer Biomet||1|||f||||f||||||||||2018-06-01 01:43:55.859732|2018-06-01 01:43:55.859732
NCT00759603|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2015-07-27||2015-07-27|2008-09-24|2008-09-25|Estimate|2015-07-27|2015-08-27|Estimate||||2015-07-27|2015-08-27|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia|Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 01:43:55.928547|2018-06-01 01:43:55.928547
NCT00759577|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2011-11-18||2015-10-05|2008-09-24|2008-09-25|Estimate|2012-04-26|2012-05-30|Estimate||||2015-10-05|2015-10-26|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||"Feasibility of At-home Titration of Solifenacin"|"Feasibility of At-home Titration of Solifenacin 5 and 10mg and Effect on Symptoms and Quality of Life in a Typical OAB Population"|Terminated||Phase 4|36|Actual|New York University School of Medicine|Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.|1||difficulty with enrollment|f||||t||||||||||2018-06-01 01:43:56.296903|2018-06-01 01:43:56.296903
NCT00759564|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2015-12-11||2016-02-10|2008-09-24|2008-09-25|Estimate|2015-12-11|2016-01-18|Estimate||||2016-02-10|2016-03-11|Estimate|November 2008||2008-11-30|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function|An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function|Completed||Phase 1|29|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:43:56.456429|2018-06-01 01:43:56.456429
NCT00759551|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-06-17|2008-09-24|2008-09-25|Estimate|||||||2010-06-17|2010-06-22|Estimate|August 2004||2004-08-31|June 2010|2010-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients With Mild to Moderate Uncomplicated Essential Hypertension|Completed||Phase 2|555|Actual|Takeda||7|||f||||f||||||||||2018-06-01 01:43:57.896436|2018-06-01 01:43:57.896436
NCT00759538|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2012-07-30|2008-09-24|2008-09-25|Estimate|||||||2012-07-30|2012-07-31|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|December 2008|Actual|2008-12-31|July 2007|Actual|2007-07-31||Observational|||Effect of Early Pulmonary Rehabilitation After Lung Transplantation|Effect of Early Pulmonary Rehabilitation After Lung Transplantation in Patients With a Prolonged Length of Stay on the Waiting List and Hospitalization After Transplantation|Completed|||120|Actual|Hannover Medical School|||1||f||||f||||||||||2018-06-01 01:43:57.986164|2018-06-01 01:43:57.986164
NCT00759525|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2013-08-15||2016-09-14|2008-09-24|2008-09-25|Estimate|2015-05-26|2015-05-28|Estimate||||2016-09-14|2016-10-26|Estimate|February 2002||2002-02-28|September 2016|2016-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||Cross Over study|The Role of Mineralocorticoid Receptors in Vascular Function|The Role of Mineralocorticoid Receptors in Vascular Function|Completed||Phase 2/Phase 3|15|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:43:58.065826|2018-06-01 01:43:58.065826
NCT00759512|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2009-02-02|2008-09-24|2008-09-25|Estimate|||||||2009-02-02|2009-02-04|Estimate|August 2003||2003-08-31|February 2009|2009-02-28||||August 2005|Actual|2005-08-31||Interventional|||Effects of Therapeutic Touch on Osteoarthritis of the Knee||Completed||N/A|60|Actual|University of Toledo Health Science Campus||2|||f||||f||||||||||2018-06-01 01:43:58.274917|2018-06-01 01:43:58.274917
NCT00759499|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-12-28|2008-09-24|2008-09-25|Estimate|||||||2017-12-28|2018-01-02|Actual|January 2007||2007-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Obtaining and Storing Wound Debridment Samples For Immediate or Future Wound-Related Scientific Study|Obtaining and Storing Wound Debridment Samples for Immediate or Future Wound-Related Scientific Study|Enrolling by invitation|||829|Anticipated|Southwest Regional Wound Care Center|||1||f||||f||||||Samples With DNA|"~     The intent of this protocol is to salvage wound material that is normally destined for~     destruction, so it can be used in wound-related scientific studies~   "|No||2018-06-01 01:43:58.330808|2018-06-01 01:43:58.330808
NCT00759486|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-10-17|2008-09-24|2008-09-25|Estimate|||||||2017-10-17|2017-10-18|Actual|October 2005||2005-10-31|October 2017|2017-10-31||||October 2020|Anticipated|2020-10-31||Observational|||Pediatric Facial Fracture Study|Pediatric Facial Fracture Growth and Development Study|Recruiting|||1000|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 01:43:58.382451|2018-06-01 01:43:58.382451
NCT00759473|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2013-05-21||2016-03-14|2008-09-24|2008-09-25|Estimate|2013-05-21|2013-07-10|Estimate||||2016-03-14|2016-04-13|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||D-Cycloserine Facilitation of Cocaine - Cue Extinction|D-Cycloserine Facilitation of Cocaine - Cue Extinction|Completed||Phase 2|79|Actual|Medical University of South Carolina||5|||f||||t||||||||||2018-06-01 01:43:58.535308|2018-06-01 01:43:58.535308
NCT00759460|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2013-09-19|2008-09-24|2008-09-25|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia|An Exploratory Study Conducted as an add-on to Clinical Trial 11286, to Evaluate the Metabolic Effect of up to 12 Weeks Treatment With Sertindole and Olanzapine in Patients With Schizophrenia|Completed||Phase 3|250|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:43:59.006585|2018-06-01 01:43:59.006585
NCT00759447|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2008-09-24|2008-09-24|2008-09-25|Estimate|||||||2008-09-24|2008-09-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:43:59.096096|2018-06-01 01:43:59.096096
NCT00759434|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2014-12-02|2008-09-24|2008-09-25|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2004||2004-03-31|December 2014|2014-12-31||||August 2009|Actual|2009-08-31||Interventional|||A New Method of Surgically Treating Varicose Veins and Venous Ulcers - a Study to Assess Clinical and Economic Value|A Dual Centre, Randomised Controlled Trial of the Clinical and Cost Effectiveness of Endovenous Laser Therapy (EVLT) in the Treatment of Varicose Veins and Venous Ulcers|Unknown status|Active, not recruiting|N/A|260|Anticipated|University of Hull||2|||f||||f||||||||||2018-06-01 01:43:59.132405|2018-06-01 01:43:59.132405
NCT00759421|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2013-09-13|2008-09-24|2008-09-25|Estimate|||||||2013-09-13|2013-09-16|Estimate|October 2006||2006-10-31|September 2013|2013-09-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Exploratory Cognition Study of Sertindole in Patients With Schizophrenia|An Exploratory Cognition Study Conducted as an add-on to Clinical Trial 11286, to Evaluate the Neurocognitive Effects of 12 Weeks Treatment With Sertindole and Olanzapine in Patients With Schizophrenia|Completed||Phase 3|96|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 01:43:59.206627|2018-06-01 01:43:59.206627
NCT00759408|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-05-03|2008-09-24|2008-09-25|Estimate|||||||2010-05-03|2010-05-05|Estimate|February 1999||1999-02-28|April 2010|2010-04-30|June 2011|Anticipated|2011-06-30|October 2010|Anticipated|2010-10-31||Interventional|||The Role of Endothelin in Pulmonary Hypertension|The Role of Endothelin in Pulmonary Hypertension|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-06-01 01:43:59.281763|2018-06-01 01:43:59.281763
NCT00759395|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2012-10-10||2012-10-10|2008-09-24|2008-09-25|Estimate|2012-10-10|2012-11-08|Estimate||||2012-10-10|2012-11-08|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)|An Investigation of the Antidepressant Efficacy of a Selective, High, Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder|Completed||Phase 2|22|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 01:43:59.38279|2018-06-01 01:43:59.38279
NCT00759382|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2018-01-30|2008-09-24|2008-09-25|Estimate|||||||2018-01-30|2018-01-31|Actual|July 2008||2008-07-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Observational|||Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.|Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.|Active, not recruiting|||340|Anticipated|European Lung Cancer Working Party|||1||f||||t||||||||Undecided||2018-06-01 01:43:59.737464|2018-06-01 01:43:59.737464
NCT00759369|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2012-02-24|2008-09-24|2008-09-25|Estimate|||||||2012-02-24|2012-02-27|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Water as Therapy in Autosomal Dominant Polycystic Kidney Disease|Completed||N/A|11|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 01:43:59.827032|2018-06-01 01:43:59.827032
NCT00759356|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2008-12-05||2010-08-13|2008-09-24|2008-09-25|Estimate|2009-07-21|2009-09-01|Estimate||||2010-08-13|2010-08-17|Estimate|August 2004||2004-08-31|August 2010|2010-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study Comparing the Bioavailability of a Morphine Sulfate Sustained Release Capsule 1 x 200mg to KADIAN 2 x 100mg Capsules Under Fed Conditions|Completed||Phase 1|36|Actual|Actavis Inc.||2|||f||||||||||||||2018-06-01 01:43:59.900786|2018-06-01 01:43:59.900786
NCT00759343|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2016-03-14|2008-09-24|2008-09-25|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Stone Centre Urine and Serum Bank|Stone Centre Urine and Serum Bank|Active, not recruiting|||500|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     Urine and serum of stone-forming individuals and non-stone forming controls will be banked~     for analysis of protein biomarkers and predisposing factors. Ureteral stents removed from~     patients that would otherwise be discarded will be processed and stored to assess for~     bacterial and biofilm adherence.~      Serum and Urine specimens will be collected, de-identified, and banked/retained.~   "|||2018-06-01 01:44:00.223189|2018-06-01 01:44:00.223189
NCT00759330|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2016-05-13||2016-08-12|2008-09-24|2008-09-25|Estimate|2016-08-12|2016-10-06|Estimate||||2016-08-12|2016-10-06|Estimate|October 2007||2007-10-31|June 2016|2016-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|LBP||Flurbiprofen Tape for Treatment of Chronic Low Back Pain|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Flurbiprofen Tape for Treatment of Chronic Low Back Pain|Completed||Phase 2|127|Actual|Teikoku Pharma USA, Inc.||4|||f||||f||||||||||2018-06-01 01:44:00.314721|2018-06-01 01:44:00.314721
NCT00759317|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2014-07-01|2008-09-24|2008-09-25|Estimate|||||||2014-07-01|2014-07-03|Estimate|June 2001||2001-06-30|July 2014|2014-07-31|September 2002|Actual|2002-09-30|August 2002|Actual|2002-08-31||Interventional|Ven Nls I||Physiologic Monitoring of Antidepressant Treatment Response|Physiologic Monitoring of Antidepressant Medication Effects in Normal Controls Subjects I|Completed||Phase 4|37|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:44:00.976796|2018-06-01 01:44:00.976796
NCT00759304|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2017-09-13|2008-09-24|2008-09-25|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2, 2000|Actual|2000-01-02|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|PROOF||Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events|Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events on a Prospective Cohort of Subjects Aged 65 Years|Active, not recruiting|||1011|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples With DNA|"~     Serum, DNA~   "|No||2018-06-01 01:44:01.035765|2018-06-01 01:44:01.035765
NCT00759291|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2018-01-16|2008-09-24|2008-09-25|Estimate|||||||2018-01-16|2018-01-18|Actual|April 1, 2006|Actual|2006-04-01|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 1, 2017|Actual|2017-12-01||Interventional|||The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome|The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome|Completed||Phase 2/Phase 3|40|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 01:44:01.09442|2018-06-01 01:44:01.09442
NCT00759278|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2008-09-24|2008-09-24|2008-09-25|Estimate|||||||2008-09-24|2008-09-25|Estimate|August 2008||2008-08-31|September 2008|2008-09-30|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Observational|||Comparison Fetal Hemodynamic Measurements Antihypertensive Versus Control|A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-Hypertensive Medication and Controls|Unknown status|Not yet recruiting||60|Anticipated|State University of New York - Upstate Medical University|||2||f||||f||||||||||2018-06-01 01:44:01.218703|2018-06-01 01:44:01.218703
NCT00759265|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-10-06|2008-09-24|2008-09-25|Estimate|||||||2015-10-06|2015-10-07|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|||Improving Mobility in Diabetic Patients Through Resistance Training|Improving Mobility in Diabetic Patients Through Resistance Training|Completed||N/A|160|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:44:01.30244|2018-06-01 01:44:01.30244
NCT00759252|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-08-27|2008-09-24|2008-09-25|Estimate|||||||2015-08-27|2015-08-28|Estimate|February 2008||2008-02-29|August 2015|2015-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|PRISM-PC||Perceptions Regarding Investigational Screening for Memory Problems in Primary Care|Perceptions Regarding Investigational Screening for Memory Problems in Primary Care: The PRISM-PC Study|Completed|||954|Actual|Indiana University|||||f||||f||||||||||2018-06-01 01:44:01.360146|2018-06-01 01:44:01.360146
NCT00759239|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2016-11-18|2008-09-24|2008-09-25|Estimate|||||||2016-11-18|2016-11-22|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension||Completed||Phase 4|36|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:44:01.414643|2018-06-01 01:44:01.414643
NCT00759226|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2008-09-25|2008-09-24|2008-09-25|Estimate|||||||2008-09-25|2008-09-26|Estimate|July 2002||2002-07-31|September 2008|2008-09-30|August 2007|Actual|2007-08-31|July 2005|Actual|2005-07-31||Interventional|CONKO-101||Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer|An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer|Completed||Phase 2|92|Actual|CONKO-Studiengruppe|||||f||||t||||||||||2018-06-01 01:44:01.479722|2018-06-01 01:44:01.479722
NCT00759213|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2012-02-16|2008-09-24|2008-09-25|Estimate|||||||2012-02-16|2012-02-17|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|November 2008|Actual|2008-11-30||Observational|||Discharge Planning Assessment of Family Needs|Discharge Planning Assessment of Family Needs and Concerns at the Time of Infant's Discharge in the NICU|Completed|||250|Actual|Christiana Care Health Services|||1||f||||f||||||||||2018-06-01 01:44:01.551556|2018-06-01 01:44:01.551556
NCT00759200|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2016-11-15|2008-09-23|2008-09-25|Estimate|||||||2016-11-15|2016-11-16|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients|An Open-label, Randomized, Multicenter, Active-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of Albinterferon Alfa 2b Administered Every 4 Weeks Plus Ribavirin in Interferon Alfa-naïve Patients With Genotype 2/3 Chronic Hepatitis C|Completed||Phase 2|525|Anticipated|Novartis||5|||f||||||||||||||2018-06-01 01:44:01.616214|2018-06-01 01:44:01.616214
NCT00759187|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2008-10-16||2010-02-24|2008-09-23|2008-09-25|Estimate|2008-11-11|2008-11-18|Estimate||||2010-02-24|2010-03-04|Estimate|January 2008||2008-01-31|November 2008|2008-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluate Clinical Research From Commerical Oral Care Products|Evaluate Clinical Research From Commerical Oral Care Products|Completed||Phase 3|25|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-06-01 01:44:01.831319|2018-06-01 01:44:01.831319
NCT00759174|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2013-08-08||2013-08-08|2008-09-22|2008-09-25|Estimate|2013-08-08|2013-10-17|Estimate||||2013-08-08|2013-10-17|Estimate|November 2008||2008-11-30|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION|"Case Crossover Study of PDE5 Inhibitor Exposure as a Potential Trigger Factor for Acute NAION"|Completed|||673|Actual|Pfizer|Potential for bias from inaccuracies in recall of exposure and exposure-based enrollment were evaluated. Although these sources of bias cannot be excluded, they were unlikely to have substantially affected the primary results.||1||f||||f||||||||||2018-06-01 01:44:02.1802|2018-06-01 01:44:02.1802
NCT00759161|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2017-01-12|2011-02-09|2017-01-12|2008-09-23|2008-09-25|Estimate|2017-01-12|2017-03-06|Actual|2011-02-09|2011-02-14|Estimate|2017-01-12|2017-03-06|Actual|November 2007||2007-11-30|January 2017|2017-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||ITT population included all randomized participants who received at least 1 dose of study drug.|Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis|A Double-Blind, Randomized Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis|Completed||Phase 2|35|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:44:02.56014|2018-06-01 01:44:02.56014
NCT00759148|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2011-02-23||2017-12-05|2008-09-23|2008-09-25|Estimate|2011-02-23|2011-03-22|Estimate||||2017-12-05|2018-01-02|Actual|October 2008|Actual|2008-10-31|December 2017|2017-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||This population analysis includes all subjects who received study drug (Safety Analysis Set).|Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis||Completed||Phase 3|1179|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:44:03.07193|2018-06-01 01:44:03.07193
NCT00759135|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23||2010-08-30|2012-06-12|2008-09-24|2008-09-25|Estimate||||2010-08-30|2010-09-03|Estimate|2012-06-12|2012-06-14|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)|Phase 2 Multicenter Randomized Two Dose Level and Non-Inferiority Clinical Evaluation of Transrectal Administration of NX-1207 for the Treatment of BPH|Completed||Phase 2|85|Actual|Nymox Corporation||3|||f||||f||||||||||2018-06-01 01:44:03.871782|2018-06-01 01:44:03.871782
NCT00759122|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2008-09-23|2008-09-23|2008-09-25|Estimate|||||||2008-09-23|2008-09-25|Estimate|November 2002||2002-11-30|September 2008|2008-09-30|December 2005|Actual|2005-12-31|November 2005|Actual|2005-11-30||Interventional|||Electroencephalography (EEG) Biomarkers of Response in Depression|EEG Biomarkers of Response in Depression|Completed||Phase 4|44|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:44:03.993927|2018-06-01 01:44:03.993927
NCT00759109|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2011-03-24||2017-03-09|2008-09-23|2008-09-25|Estimate|2011-03-24|2011-04-18|Estimate||||2017-03-09|2017-04-07|Actual|March 2002||2002-03-31|March 2017|2017-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)|Long-term Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation: a Multicenter Study of Hepatocellular Carcinoma Prevention in Patients Non-responders to Combined Therapy With Alpha Interferon + Ribavirin or Peginterferon Alpha + Ribavirin or to Interferon Monotherapy|Completed||Phase 3|150|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:44:04.080553|2018-06-01 01:44:04.080553
NCT00759096|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2009-09-11||2010-01-25|2008-09-23|2008-09-25|Estimate|2010-01-25|2010-02-10|Estimate||||2010-01-25|2010-02-10|Estimate|May 2007||2007-05-31|January 2010|2010-01-31||||July 2008|Actual|2008-07-31||Interventional|||Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL|Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL|Completed||Phase 4|30|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:44:04.700735|2018-06-01 01:44:04.700735
NCT00759083|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2011-11-08|2008-09-23|2008-09-25|Estimate|||||||2011-11-08|2011-11-10|Estimate|September 2008||2008-09-30|November 2011|2011-11-30||||September 2009|Actual|2009-09-30||Interventional|||Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients|Bivalirudin PCI Registry in HIT/HITTS Patients|Completed||Phase 4|150|Actual|The Medicines Company||1|||f||||f||||||||||2018-06-01 01:44:04.841324|2018-06-01 01:44:04.841324
NCT00759070|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2013-02-21|2008-09-23|2008-09-25|Estimate|||||||2013-02-21|2013-02-22|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|LIPOTAR-07||Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism|Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-naive HIV-infected Subjects|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 01:44:04.936842|2018-06-01 01:44:04.936842
NCT00759057|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2012-06-26|2008-09-23|2008-09-25|Estimate|||||||2012-06-26|2012-06-28|Estimate|March 2003||2003-03-31|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||A Clinical Study of the Dynesys(R) Spinal System|A Clinical Study of the Dynesys(R) Spinal System As a Non-fusion Device for Spinal Stabilization|Terminated||Phase 3|399|Actual|Zimmer Biomet||2||PMA not approved. FDA granted permission to close the study.|f||||f||||||||||2018-06-01 01:44:05.037621|2018-06-01 01:44:05.037621
NCT00759044|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-10-13|2008-09-24|2008-09-25|Estimate|||||||2015-10-13|2015-10-15|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function|Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function|Completed|||90|Actual|Association for Innovation and Biomedical Research on Light and Image|||2||f||||||||||||||2018-06-01 01:44:05.188562|2018-06-01 01:44:05.188562
NCT00759031|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2008-10-16||2012-04-11|2008-09-23|2008-09-25|Estimate|2008-11-20|2008-11-25|Estimate||||2012-04-11|2012-04-13|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Investigation of Dental Plaque and Gingival Index|Investigation of Dental Plaque and Gingival Index|Completed||Phase 3|19|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:44:05.35041|2018-06-01 01:44:05.35041
NCT00759018|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2015-10-20|2008-09-23|2008-09-25|Estimate|||||||2015-10-20|2015-10-22|Estimate||||October 2015|2015-10-31||||||||Expanded Access|||Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD|Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD|No longer available|||||Mesoblast, Ltd.|||||||||||||||||||2018-06-01 01:44:05.713582|2018-06-01 01:44:05.713582
NCT00759005|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2008-09-23|2008-09-23|2008-09-25|Estimate|||||||2008-09-23|2008-09-25|Estimate|March 2007||2007-03-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Stress on Heroin-Related Memory Retrieval||Completed||N/A|||National Institute on Drug Dependence, China||1|||f||||||||||||||2018-06-01 01:44:05.804722|2018-06-01 01:44:05.804722
NCT00758992|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2016-03-11|2008-09-23|2008-09-25|Estimate|||||||2016-03-11|2016-03-14|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages|Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages|Completed|||14|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 01:44:05.869719|2018-06-01 01:44:05.869719
NCT00758979|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-06-16|2008-09-23|2008-09-25|Estimate|||||||2017-06-16|2017-06-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:44:05.926708|2018-06-01 01:44:05.926708
NCT00758966|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22||2012-11-27|2012-11-27|2008-09-23|2008-09-25|Estimate||||2012-11-27|2012-11-29|Estimate|2012-11-27|2012-11-29|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder|A Proof-of-Concept, Multicenter, Randomized, Double-Blind, Parallel Study of Naltrexone Sustained-Release (SR) and/or Fluoxetine Therapy in the Treatment of Subjects With Obsessive-Compulsive Disorder (OCD)|Terminated||Phase 2|8|Actual|Orexigen Therapeutics, Inc||3||Sponsor Decision- Financial Considerations|f||||f||||||||||2018-06-01 01:44:05.959863|2018-06-01 01:44:05.959863
NCT00758953|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23||2010-01-11|2012-03-02|2008-09-24|2008-09-25|Estimate||||2010-01-11|2010-01-13|Estimate|2012-03-02|2012-03-06|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pain Associated With Endometriosis||Completed||Phase 2|66|Actual|Lumara Health, Inc.||4|||f||||f||||||||||2018-06-01 01:44:06.069794|2018-06-01 01:44:06.069794
NCT00758940|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2015-05-08|2008-09-24|2008-09-25|Estimate|||||||2015-05-08|2015-05-12|Estimate||||January 2010|2010-01-31||||||||Interventional|||Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL|A Six-months, Open-labelled Clinical Assessment of Visual Function After Bilateral Implantation of Arcysof ReSTOR Multifocal Intra-ocular Lens|Withdrawn||Phase 4|0|Actual|Alcon Research||1||Primary Investigator resigned from Hospital|f||||f||||||||||2018-06-01 01:44:06.285822|2018-06-01 01:44:06.285822
NCT00758927|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2009-08-03|2008-09-23|2008-09-25|Estimate|||||||2009-08-03|2009-08-06|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|April 2010|Anticipated|2010-04-30||Interventional|||The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients|The Effects of OMACOR on the LDL Sub-fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia|Unknown status|Recruiting|Phase 4|70|Anticipated|Inje University||2|||f||||t||||||||||2018-06-01 01:44:06.352789|2018-06-01 01:44:06.352789
NCT00758914|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2008-09-23|2008-09-23|2008-09-25|Estimate|||||||2008-09-23|2008-09-25|Estimate|May 1997||1997-05-31|September 2008|2008-09-30||||August 2001|Actual|2001-08-31||Interventional|||Vitamin E and Infection in the Elderly|Vitamin E and Infection in the Elderly|Completed||N/A|||Tufts University|||||f||||t||||||||||2018-06-01 01:44:06.434955|2018-06-01 01:44:06.434955
NCT00758901|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-03-09|2008-09-23|2008-09-25|Estimate|||||||2017-03-09|2017-03-10|Actual|November 2003||2003-11-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||ROCC Knee Data Collection|A Prospective, Multicentre Study Evaluating the Clinical Performance of the ROCC Knee Prosthesis|Terminated|||200|Actual|Zimmer Biomet|||1|Site Decision|f||||f||||||||||2018-06-01 01:44:06.48516|2018-06-01 01:44:06.48516
NCT00758888|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2009-07-23|2008-09-23|2008-09-25|Estimate|||||||2009-07-23|2009-07-24|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Effect of Orthopedic Blocking on Cervical Spine Flexion and Extension Strength|Effect of Orthopedic Blocking on Cervical Spine Flexion and Extension Strength|Unknown status|Recruiting|N/A|30|Anticipated|Logan College of Chiropractic||3|||f||||f||||||||||2018-06-01 01:44:06.548861|2018-06-01 01:44:06.548861
NCT00758875|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2012-02-11|2008-09-23|2008-09-25|Estimate|||||||2012-02-11|2012-02-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:44:06.612378|2018-06-01 01:44:06.612378
NCT00758862|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2013-12-19|2008-09-23|2008-09-25|Estimate|||||||2013-12-19|2013-12-20|Estimate|December 2008||2008-12-31|August 2009|2009-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo|The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo|Completed||Phase 2|20|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 01:44:06.643422|2018-06-01 01:44:06.643422
NCT00758849|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2008-09-30|2008-09-24|2008-09-25|Estimate|||||||2008-09-30|2008-10-01|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|Foehn||Fipamezole in Neurogenic Orthostatic Hypotension|A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|Juvantia Pharma Ltd||2|||f||||f||||||||||2018-06-01 01:44:06.705972|2018-06-01 01:44:06.705972
NCT00758836|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2014-07-18||2017-05-25|2008-09-23|2008-09-25|Estimate|2014-07-18|2014-08-11|Estimate||||2017-05-25|2017-06-20|Actual|December 3, 2008|Actual|2008-12-03|May 2017|2017-05-31|August 24, 2009|Actual|2009-08-24|August 24, 2009|Actual|2009-08-24||Interventional|||A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)|A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK0974 Co-administered With Ibuprofen or Acetaminophen in Patients With Migraine With or Without Aura|Completed||Phase 2|683|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:44:06.797562|2018-06-01 01:44:06.797562
NCT00758823|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2009-10-23|2008-09-24|2008-09-25|Estimate|||||||2009-10-23|2009-10-27|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Randomized Controlled Trial Comparing Efficacy and Tolerance of Four Pediculicides|Randomized Controlled Trial Comparing Efficacy and Tolerance of Four Pediculicides Acting Mechanically With Reference Product Acting Chemically (Prioderm)|Completed||N/A|750|Anticipated|Omega Pharma|||||f||||t||||||||||2018-06-01 01:44:07.235364|2018-06-01 01:44:07.235364
NCT00758810|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2009-06-16|2008-09-24|2008-09-25|Estimate|||||||2009-06-16|2009-06-17|Estimate|October 2006||2006-10-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|OLIMPIC||Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors|Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors, Daily Physical Activity, Dietary Habits and Blood Glucose and Fatty Acids in Coronary Syndromes Patients|Completed|||354|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||||||2018-06-01 01:44:08.256621|2018-06-01 01:44:08.256621
NCT00758797|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2014-05-22|2008-09-24|2008-09-25|Estimate|||||||2014-05-22|2014-05-23|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Novel Treatment for Metastatic Melanoma|In Situ Photoimmunotherapy: A Tumor Directed Treatment for Advanced Melanoma With Cutaneous Metastases|Terminated||Phase 1|7|Actual|Northwestern University||1||Study was not renewed during annual Northwestern Cancer Center review.|f||||t||||||||||2018-06-01 01:44:08.349102|2018-06-01 01:44:08.349102
NCT00758784|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19||2011-09-02|2013-01-03|2008-09-22|2008-09-25|Estimate||||2011-09-02|2011-09-12|Estimate|2013-01-03|2013-01-08|Estimate|August 2008||2008-08-31|January 2013|2013-01-31||||June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease||Completed||Phase 2|38|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 01:44:08.418026|2018-06-01 01:44:08.418026
NCT00758771|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2014-01-22||2014-01-22|2008-09-23|2008-09-25|Estimate|2014-01-22|2014-03-05|Estimate||||2014-01-22|2014-03-05|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|GIST||Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents|Using State-of-the-art Rheological Methods to Characterize CF Sputum and the Effects of Mucoactive Agents: A Pilot Study|Completed|||38|Actual|University of California, San Francisco|||2||f||||f||||||Samples Without DNA|"~     Sputum~   "|||2018-06-01 01:44:08.486553|2018-06-01 01:44:08.486553
NCT00758758|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2013-05-09||2013-08-09|2008-09-23|2008-09-25|Estimate|2013-07-11|2013-08-12|Estimate||||2013-08-09|2013-08-23|Estimate|December 2001||2001-12-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||Performance of the Hedrocel(R) Cervical Fusion Device|Performance of the Hedrocel(R) Cervical Fusion Device|Completed||Phase 3|231|Actual|Zimmer Biomet||8|||f||||f||||||||||2018-06-01 01:44:08.688667|2018-06-01 01:44:08.688667
NCT00758745|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2011-07-01||2014-08-15|2008-09-24|2008-09-25|Estimate|2011-07-01|2011-07-28|Estimate||||2014-08-15|2014-08-19|Estimate|January 2006||2006-01-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Randomized Contralateral Clinical Trial With Single-piece (SN60WF) vs. Three Piece (MA60AC) AcrySof Intraocular Lenses (IOLs) on Development of Posterior Chamber Opacification (PCO).||Completed||N/A|81|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:44:09.450012|2018-06-01 01:44:09.450012
NCT00758732|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2015-09-25|2008-09-24|2008-09-25|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2005||2005-10-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma|A Multicenter Randomized Phase II Study of Docetaxel/Carboplatin Versus Docetaxel/Pegylated Liposomal Doxorubicin as Second Line Treatment in Patients With Platinum Sensitive Disease|Terminated||Phase 2|34|Actual|Hellenic Oncology Research Group||2||Poor accrual|f||||||||||||||2018-06-01 01:44:09.654599|2018-06-01 01:44:09.654599
NCT00758719|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2016-02-26|2008-09-23|2008-09-25|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Evaluate Effectiveness of the Biomet Lumbar Spinal Fusion System|A Prospective Multicenter Lumbar Spine Fusion Study to Evaluate the Effectiveness of the Biomet Lumbar Spinal Fusion System|Completed|||53|Actual|Zimmer Biomet|||||f||||f||||||||Undecided||2018-06-01 01:44:09.759248|2018-06-01 01:44:09.759248
NCT00758706|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2011-07-25||2015-04-14|2008-09-23|2008-09-25|Estimate|2015-04-14|2015-04-16|Estimate||||2015-04-14|2015-04-16|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|BICO||A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Double-blind, Randomised, Placebo-controlled, Parallel Group Multi-centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Bood and Uine of AZD1236 Administered as Oral Tablet in Moderate to Severe COPD Patients During a 6 Week Period.|Completed||Phase 2|55|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:44:09.872151|2018-06-01 01:44:09.872151
NCT00758693|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2012-01-10|2008-09-22|2008-09-25|Estimate|||||||2012-01-10|2012-01-11|Estimate|October 2008||2008-10-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)|Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia: A Phase II Study|Withdrawn||Phase 2|0|Actual|University of Kentucky||1||Funding was withdrawn due to insufficient accrual|f||||f||||||||||2018-06-01 01:44:10.266081|2018-06-01 01:44:10.266081
NCT00758680|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2012-07-24||2016-02-04|2008-09-23|2008-09-25|Estimate|2012-07-24|2012-08-28|Estimate||||2016-02-04|2016-02-05|Estimate|August 2008||2008-08-31|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1006.|Terminated||Phase 1|112|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-06-01 01:44:10.466853|2018-06-01 01:44:10.466853
NCT00758667|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2013-12-23||2014-12-08|2008-09-23|2008-09-25|Estimate|2014-12-08|2014-12-10|Estimate||||2014-12-08|2014-12-10|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional||Participants with capsular contracture after breast implants that elected to have capsule removed and implant exchanged; followup for recurrence of capsulsar contracture|Chemically Assisted Capsulectomy-A New Clinical Approach|Chemically Assisted Capsulectomy-A New Clinical Approach|Terminated||N/A|20|Actual|Vanderbilt University||2||preliminary analysis showed no difference|f||||f||||||||||2018-06-01 01:44:11.481154|2018-06-01 01:44:11.481154
NCT00758654|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2012-03-28|2008-09-23|2008-09-25|Estimate|||||||2012-03-28|2012-03-30|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Strain-Encoded Cardiac Magnetic Resonance Imaging for Dobutamine Stress Testing|Strain-Encoded Cardiac Magnetic Resonance Imaging as an Adjunct for Dobutamine Stress Testing.|Completed|||320|Actual|Heidelberg University|||2||f||||f||||||||||2018-06-01 01:44:11.704026|2018-06-01 01:44:11.704026
NCT00758641|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2017-03-13|2008-09-22|2008-09-25|Estimate|||||||2017-03-13|2017-03-14|Actual|September 2009||2009-09-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Platelet Rich Plasma to Treat Plantar Fasciitis|Use of PRP to Treat Plantar Fasciitis, Blinded and Randomized as a Multi Center Study|Completed||Phase 4|115|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:44:11.794799|2018-06-01 01:44:11.794799
NCT00758628|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2009-09-03|2008-09-23|2008-09-25|Estimate|||||||2009-09-03|2009-09-04|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.|Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.|Completed||Phase 4|50|Anticipated|Bp Consulting, Inc||2|||f||||f||||||||||2018-06-01 01:44:11.87287|2018-06-01 01:44:11.87287
NCT00758615|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-12-04|2008-09-23|2008-09-25|Estimate|||||||2013-12-04|2013-12-06|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Pilot Evaluation of a Walking School Bus Program|Pilot and Feasibility Evaluation of a Walking School Bus Program Intervention for Elementary School Students|Completed||N/A|149|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-06-01 01:44:11.936468|2018-06-01 01:44:11.936468
NCT00758602|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|2014-07-08||2014-07-08|2008-09-24|2008-09-25|Estimate|2014-07-08|2014-08-04|Estimate||||2014-07-08|2014-08-04|Estimate|September 2008||2008-09-30|July 2014|2014-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||Intent-to-Treat (ITT) population: all randomized patients who received at least one dose ofthe treatment-group specific medication.|A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.|A Randomized, Open Label Study Comparing the Effect of CellCept Combined With Low Dose Versus Standard Dose Tacrolimus, and Corticosteroids, on Kidney Function in Renal Transplantation Patients|Completed||Phase 4|210|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:44:12.016287|2018-06-01 01:44:12.016287
NCT00758589|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2013-07-01||2014-01-24|2008-09-24|2008-09-25|Estimate|2013-10-24|2013-12-13|Estimate||||2014-01-24|2014-02-26|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|July 2009|Actual|2009-07-31|||||Interventional|OLIVE||One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids|A Double-blind, Randomised, Parallel Group, Multicentre Phase IIb, Placebo-Controlled, 1 Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids|Completed||Phase 2|368|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:44:12.572046|2018-06-01 01:44:12.572046
NCT00758576|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2010-10-08||2010-12-06|2008-09-24|2008-09-25|Estimate|2010-11-03|2010-12-02|Estimate||||2010-12-06|2010-12-21|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||ReSTOR Natural +3.0D Study In Japan|ReSTOR Natural +3.0D (Diopter) Study In Japan|Completed||N/A|64|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:44:13.259522|2018-06-01 01:44:13.259522
NCT00758563|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2008-10-16||2008-11-20|2008-09-23|2008-09-25|Estimate|2008-11-18|2008-11-20|Estimate||||2008-11-20|2008-11-25|Estimate|March 2008||2008-03-31|November 2008|2008-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Train New Examiners Via Modified Gingival Margin Plaque|Train New Examiners Via Modified Gingival Margin Plaque|Completed||Phase 3|15|Actual|Colgate Palmolive||2|||f||||t||||||||||2018-06-01 01:44:13.442124|2018-06-01 01:44:13.442124
NCT00758550|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2009-08-13||2010-03-04|2008-09-24|2008-09-25|Estimate|2010-03-04|2010-03-16|Estimate||||2010-03-04|2010-03-16|Estimate|April 2007||2007-04-30|March 2010|2010-03-31||||June 2008|Actual|2008-06-30||Interventional|||Visual Function After Bilateral Implantation of AcrySof® Toric|Visual Function After Bilateral Implantation of AcrySof® Toric|Completed||Phase 4|60|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:44:13.783878|2018-06-01 01:44:13.783878
NCT00758537|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2009-07-13|2008-09-23|2008-09-25|Estimate|||||||2009-07-13|2009-07-14|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|October 2008||2008-10-31|||||Observational|||Tryptophan Metabolism in Kidney Disease||Completed|||80|Anticipated|Charite University, Berlin, Germany|||4||f||||||||||||||2018-06-01 01:44:14.012272|2018-06-01 01:44:14.012272
NCT00758524|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23||2012-05-31|2012-05-31|2008-09-23|2008-09-25|Estimate||||2012-05-31|2012-06-06|Estimate|2012-05-31|2012-06-06|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension|Completed||Phase 2|526|Actual|Novartis||6|||f||||f||||||||||2018-06-01 01:44:14.088961|2018-06-01 01:44:14.088961
NCT00758511|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2013-11-13|2008-09-23|2008-09-25|Estimate|||||||2013-11-13|2013-11-15|Estimate|January 2009||2009-01-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|PAMINA||Pain Reactivity to Non-Pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit|Pain Reactivity to Non-pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit|Completed||Early Phase 1|71|Actual|University of Basel||3|||f||||f||||||||||2018-06-01 01:44:14.170303|2018-06-01 01:44:14.170303
NCT00758498|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2010-04-30||2013-07-12|2008-09-24|2008-09-25|Estimate|2010-06-11|2010-07-08|Estimate||||2013-07-12|2013-07-19|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder|A 3-Day, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Armodafinil Treatment (50 and 150 mg/Day) in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder|Completed||Phase 3|427|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 01:44:14.274029|2018-06-01 01:44:14.274029
NCT00758485|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2013-03-11||2015-08-04|2008-09-23|2008-09-25|Estimate|2013-03-11|2013-04-22|Estimate||||2015-08-04|2015-08-21|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)|A Randomized, Safety-assessor Blinded Trial Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in Adult Subjects Scheduled for Surgery Requiring Profound Neuromuscular Blockade|Completed||Phase 3|140|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:44:15.134959|2018-06-01 01:44:15.134959
NCT00758472|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-06-16|2008-09-23|2008-09-25|Estimate|||||||2017-06-16|2017-06-19|Actual|March 2005||2005-03-31|June 2017|2017-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||ReCap Total Hip Resurfacing Prospective Data Collection|ReCap Total Hip Resurfacing Prospective Data Collection|Terminated|||82|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 01:44:15.409557|2018-06-01 01:44:15.409557
NCT00758459|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2011-07-25||2011-07-25|2008-09-23|2008-09-25|Estimate|2011-07-25|2011-08-19|Estimate||||2011-07-25|2011-08-19|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|March 2009|Actual|2009-03-31|||||Interventional|CERA||Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236as an Oral Tablet in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|74|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:44:15.571382|2018-06-01 01:44:15.571382
NCT00758446|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-03-12|2008-09-23|2008-09-25|Estimate|||||||2013-03-12|2013-03-13|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis|A Double-blind, Randomized, Placebo-controlled, Cross-over, Allergen Challenge Study to Evaluate the Efficacy, Safety and Tolerability of BLX-028914 in Subjects With Allergic Rhinitis|Completed||Phase 2|36|Actual|Dart NeuroScience, LLC||3|||f||||f||||||||||2018-06-01 01:44:16.072372|2018-06-01 01:44:16.072372
NCT00758433|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2011-06-08|2008-09-23|2008-09-25|Estimate|||||||2011-06-08|2011-06-10|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Civamide Patch Safety, Tolerability and PK Study|Randomized, Double-Blind, Placebo-Controlled Evaluation of the Tolerability of Two Civamide (Zucapsaicin) Patch Strengths Compared to Placebo Patch in Healthy Volunteers|Completed||Phase 1|39|Actual|Winston Laboratories||3|||f||||f||||||||||2018-06-01 01:44:16.135575|2018-06-01 01:44:16.135575
NCT00758420|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2014-01-06|2011-09-14|2015-02-19|2008-09-22|2008-09-25|Estimate|2014-02-25|2014-03-24|Estimate|2011-09-14|2011-09-21|Estimate|2015-02-19|2015-03-09|Estimate|October 2008||2008-10-31|February 2015|2015-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|Pilot|Treated patients with a week 8 study assessment.|Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence|A Randomized, Single Blind, Placebo Controlled, Multicenter Study to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for the Treatment of Symptomatic, Visible Varicose Veins With Saphenofemoral Junction (SFJ) Incompetence.|Completed||Phase 2/Phase 3|77|Actual|BTG International Inc.||2|||f||||f||||||||||2018-06-01 01:44:16.212355|2018-06-01 01:44:16.212355
NCT00758407|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-24|||2010-01-12|2008-09-24|2008-09-25|Estimate|||||||2010-01-12|2010-01-13|Estimate|August 2006||2006-08-31|January 2010|2010-01-31||||January 2010|Actual|2010-01-31||Interventional|EMF||Methylphenidate Treatment of Cancer-Related Fatigue|Placebo Controlled Double Blind Study With Methylphenidate in Treatment of Adults With Cancer-Related Fatigue|Completed||Phase 2/Phase 3|66|Anticipated|Medice Arzneimittel Pütter GmbH & Co KG||2|||f||||f||||||||||2018-06-01 01:44:16.56183|2018-06-01 01:44:16.56183
NCT00758394|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2008-10-16||2013-08-08|2008-09-23|2008-09-25|Estimate|2008-11-18|2008-11-19|Estimate||||2013-08-08|2013-08-15|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Clinical Study to Compare Dental Plaque Control|Clinical Study to Compare Dental Plaque Control|Completed||Phase 3|29|Actual|Colgate Palmolive||4|||f||||f||||||||||2018-06-01 01:44:16.666746|2018-06-01 01:44:16.666746
NCT00758381|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2008-10-09|2008-09-23|2008-09-25|Estimate|||||||2008-10-09|2008-10-10|Estimate|August 2007||2007-08-31|October 2008|2008-10-31|August 2009|Anticipated|2009-08-31|August 2008|Anticipated|2008-08-31||Interventional|MAPS||Metastatic Advanced Pancreas Sorafenib|A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial|Unknown status|Recruiting|Phase 2|114|Anticipated|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||2|||f||||f||||||||||2018-06-01 01:44:17.078325|2018-06-01 01:44:17.078325
NCT00758368|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2011-07-21|2008-09-23|2008-09-25|Estimate|||||||2011-07-21|2011-07-22|Estimate|March 2009||2009-03-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease|Comparison of Continuous and Pulsatile Apomorphine Administration in Parkinson's Disease Complicated by Levodopa-induced Dyskinesia|Withdrawn||Phase 2|24|Anticipated|Oregon Health and Science University||2||Inadequate support to conduct the study|f||||f||||||||||2018-06-01 01:44:17.17529|2018-06-01 01:44:17.17529
NCT00758355|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-02-21|2008-09-23|2008-09-25|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2008||2008-03-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|December 2013|Actual|2013-12-31||Observational|||Data Collection on ReCap/Magnum in Total Hip Replacement and Resurfacing|A Prospective, Multicentre Study Evaluating the Clinical Performance of the ReCap/Magnum in Total Hip Replacement and Resurfacing|Completed|||150|Actual|Zimmer Biomet|||2||f||||f||||||||||2018-06-01 01:44:17.242286|2018-06-01 01:44:17.242286
NCT00758342|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2009-09-10||2010-02-23|2008-09-24|2008-09-25|Estimate|2010-01-15|2010-02-05|Estimate||||2010-02-23|2010-03-02|Estimate|May 2006||2006-05-31|February 2010|2010-02-28||||March 2008|Actual|2008-03-31||Interventional|||Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)|A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma|Terminated||Phase 4|37|Actual|Alcon Research||2||difficulty of enrolling patients|f||||f||||||||||2018-06-01 01:44:17.370685|2018-06-01 01:44:17.370685
NCT00758316|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2017-02-09|2008-09-23|2008-09-25|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2008||2008-09-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions|A Prospective, Randomized Controlled Trial for a Rapid Pleurodesis Protocol for the Management of Pleural Effusions|Completed||Phase 3|120|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-06-01 01:44:17.687698|2018-06-01 01:44:17.687698
NCT00758303|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23||2013-08-22|2013-08-29|2008-09-23|2008-09-25|Estimate||||2013-08-29|2013-09-13|Estimate|2013-08-29|2013-09-13|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Evaluate the Lipid Regulating Effects of TRIA-662|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of TRIA-662|Completed||Phase 2/Phase 3|211|Actual|Cortria Corporation||3|||f||||t||||||||||2018-06-01 01:44:17.787281|2018-06-01 01:44:17.787281
NCT00758290|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2008-10-16||2008-11-20|2008-09-23|2008-09-25|Estimate|2008-11-20|2008-11-25|Estimate||||2008-11-20|2008-11-25|Estimate|May 2008||2008-05-31|November 2008|2008-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Clinical Study to Evaluate Dental Plaque|Clinical Study to Evaluate Dental Plaque|Completed||Phase 3|23|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-06-01 01:44:17.85434|2018-06-01 01:44:17.85434
NCT00758277|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2011-06-22|2008-09-23|2008-09-25|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|Keppra-2||Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients|Efficacy and Safety of Levetiracetam in Prevention of Alcohol Relapse in Recently Detoxified Alcohol Dependent Patients|Completed||Phase 3|201|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 01:44:18.126403|2018-06-01 01:44:18.126403
NCT00758264|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|2017-04-06|2009-09-09|2018-05-08|2008-09-23|2008-09-25|Estimate|2018-05-08|2018-05-09|Actual|2009-09-09|2009-09-10|Estimate|2018-05-08|2018-05-09|Actual|October 30, 2008||2008-10-30|April 2017|2017-04-30|November 2, 2009|Actual|2009-11-02|June 2, 2009|Actual|2009-06-02||Interventional|||Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration|Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-administered With GSK Biologicals' Pneumococcal Vaccine GSK1024850A in Healthy 12-23-month-old Children Previously Primed With GSK1024850A|Completed||Phase 3|363|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:44:18.279672|2018-06-01 01:44:18.279672
NCT00758251|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2010-12-08|2008-09-23|2008-09-25|Estimate|||||||2010-12-08|2010-12-10|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment|Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment|Completed|||80|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:44:19.447405|2018-06-01 01:44:19.447405
NCT00758238|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2008-09-23|2008-09-23|2008-09-25|Estimate|||||||2008-09-23|2008-09-25|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|myBP||Development and Pilot-Testing of a Patient Self Management Approach for Hypertension Using Personal Electronic Health Records|Evidence-Based Development and Initial Evaluation of a Facilitated Patient Self Management e Health Strategy Intervention for Hypertension|Unknown status|Not yet recruiting|N/A|120|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 01:44:19.509525|2018-06-01 01:44:19.509525
NCT00758225|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2011-05-30|2008-09-23|2008-09-25|Estimate|||||||2011-05-30|2011-06-01|Estimate|September 2008||2008-09-30|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)|A Phase II Open-label Extension Study to Obtain Long-term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001|Completed||Phase 2|21|Anticipated|Santhera Pharmaceuticals||1|||f||||t||||||||||2018-06-01 01:44:19.574035|2018-06-01 01:44:19.574035
NCT00758212|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2008-10-08|2008-09-23|2008-09-25|Estimate|||||||2008-10-08|2008-10-09|Estimate|November 2008||2008-11-30|September 2008|2008-09-30|April 2009|Anticipated|2009-04-30|January 2009|Anticipated|2009-01-31||Interventional|||Influenza Vaccination at a Reduced Dose Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem|Influenza Vaccination at a Reduced Dose of 1:10 Using Mesotherapy in HIV/AIDS Patients at the Hadassah AIDS Center, Jerusalem|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:44:19.678074|2018-06-01 01:44:19.678074
NCT00758199|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2012-03-14|2008-09-24|2008-09-25|Estimate|||||||2012-03-14|2012-03-15|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery|Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery|Completed||Phase 4|49|Actual|Bp Consulting, Inc||3|||f||||f||||||||||2018-06-01 01:44:19.864912|2018-06-01 01:44:19.864912
NCT00758186|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-23|||2018-04-16|2008-09-23|2008-09-25|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2004||2004-10-31|April 2018|2018-04-30|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Randomized Trial of Colonic Stents as a Bridge to Surgery|Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial.|Completed||Phase 3|40|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-06-01 01:44:19.934003|2018-06-01 01:44:19.934003
NCT00758173|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-08-23|2008-09-22|2008-09-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|September 2008|2008-09-30||||||||Observational|||Study of Genes and the Environment in Patients With Prostate Cancer Residing in the East Anglia, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Prostate Cancer in East Anglia, Trent and West Midlands|Unknown status|Recruiting||2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:44:20.005069|2018-06-01 01:44:20.005069
NCT00758160|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2013-09-05||2014-03-10|2008-09-22|2008-09-23|Estimate|2014-03-10|2014-04-08|Estimate||||2014-03-10|2014-04-08|Estimate|March 2008||2008-03-31|March 2014|2014-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Impact of Osmotic Release Oral Delivery System Methylphenidate (OROS MPH) Upon Family of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD|Completed||Phase 4|296|Actual|Johnson & Johnson Taiwan Ltd||1|||f||||f||||||||||2018-06-01 01:44:20.121077|2018-06-01 01:44:20.121077
NCT00758147|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2008-09-22|2008-09-22|2008-09-23|Estimate|||||||2008-09-22|2008-09-23|Estimate|November 2008||2008-11-30|September 2008|2008-09-30|June 2010|Anticipated|2010-06-30|November 2009|Anticipated|2009-11-30||Interventional|||Force Feedback Joystick in Upper Limb Rehabilitation Following Stroke|Assessment of Force Feedback Joystick in Upper Limb Rehabilitation Following Stroke|Unknown status|Not yet recruiting|N/A|30|Anticipated|Rabin Medical Center|||||f||||t||||||||||2018-06-01 01:44:20.5358|2018-06-01 01:44:20.5358
NCT00758134|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-05-27|2008-09-22|2008-09-23|Estimate|||||||2013-05-27|2013-05-29|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients|Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509)|Terminated||Phase 2|9|Actual|Istituto Clinico Humanitas||1||Insufficient accrual|f||||f||||||||||2018-06-01 01:44:20.633871|2018-06-01 01:44:20.633871
NCT00758121|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2009-11-04|2008-09-19|2008-09-23|Estimate|||||||2009-11-04|2009-11-06|Estimate|November 2008||2008-11-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|CORRELATE-HF||Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients|CORRELATE-HF: Correlation Of Respiratory Rate Level And Trend Evaluation in Heart Failure Patients|Terminated|||56|Actual|Boston Scientific Corporation|||1|"Inappropriate therapy associated with certain right ventricular (RV) lead complications may~   occur more frequently if the Respiratory Sensor is programmed On"|f||||f||||||||||2018-06-01 01:44:20.719644|2018-06-01 01:44:20.719644
NCT00758108|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-20|||2018-04-26|2008-09-20|2008-09-23|Estimate|||||||2018-04-26|2018-04-27|Actual|September 11, 2008||2008-09-11|April 29, 2015|2015-04-29|April 29, 2015||2015-04-29|||||Observational|||Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions|WAGR Syndrome and Other 11p Contiguous Gene Deletions: Clinical Characterization and Correlation With Genotype|Completed|||197|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:44:20.788955|2018-06-01 01:44:20.788955
NCT00758095|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-11-20|2008-09-22|2008-09-23|Estimate|||||||2013-11-20|2013-11-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:44:20.861821|2018-06-01 01:44:20.861821
NCT00758082|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2010-03-10|2008-09-22|2008-09-23|Estimate|||||||2010-03-10|2010-03-11|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|TELFIT||Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients|Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study|Completed||Phase 3|62|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-06-01 01:44:20.903193|2018-06-01 01:44:20.903193
NCT00758069|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2009-08-17||2017-03-31|2008-09-22|2008-09-23|Estimate|2009-09-24|2009-09-25|Estimate||||2017-03-31|2017-05-05|Actual|July 3, 2005|Actual|2005-07-03|March 2017|2017-03-31|February 13, 2006|Actual|2006-02-13|February 13, 2006|Actual|2006-02-13||Interventional|||Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)|Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects|Completed||Phase 2|80|Actual|Merck Sharp & Dohme Corp.|Reported overdoses, regardless of association with reported adverse events, were considered as serious adverse events in this study. The patients for whom the event of overdose was reported had no concomitant AEs with the overdose.|3|||f||||f||||||||||2018-06-01 01:44:20.994224|2018-06-01 01:44:20.994224
NCT00758056|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-08-23|2008-09-22|2008-09-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|September 2008|2008-09-30||||||||Observational|||Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Endometrial Cancer in East Anglia, Oxford Trent and West Midlands|Unknown status|Recruiting||2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:44:21.293152|2018-06-01 01:44:21.293152
NCT00758043|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2011-06-22||2013-09-30|2008-09-19|2008-09-23|Estimate|2011-06-22|2011-07-21|Estimate||||2013-09-30|2013-10-30|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response|A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®)|Completed||Phase 3|540|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-06-01 01:44:21.419818|2018-06-01 01:44:21.419818
NCT00758030|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2011-06-06|2008-09-22|2008-09-23|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2004||2004-03-31|March 2010|2010-03-31|July 2004|Actual|2004-07-31|||||Interventional|||Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Evaluate and Compare the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Subjects.|Completed||Phase 1|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 01:44:22.259325|2018-06-01 01:44:22.259325
NCT00758017|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2011-06-21|2008-09-22|2008-09-23|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Efficacy of Different Acupuncture Methods for Chronic Low Back Pain|Efficacy of Different Acupuncture Methods for Chronic Low Back Pain|Completed||N/A|150|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:44:22.308392|2018-06-01 01:44:22.308392
NCT00758004|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2009-11-16|2008-09-22|2008-09-23|Estimate|||||||2009-11-16|2009-11-18|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Bioequivalence Study Of Pediatric Appropriate Formulation|An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing A New 80 Mg (2x40 mg) Pediatric Appropriate Formulation To A 80 Mg Commercial Atorvastatin Calcium Tablet Formulation In Healthy Subjects|Completed||Phase 1|76|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:44:22.366933|2018-06-01 01:44:22.366933
NCT00757991|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-08-23|2008-09-22|2008-09-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|September 2008|2008-09-30||||||||Observational|||Blood Samples From Healthy Volunteers for Genetic Studies in the East Anglia Region of the United Kingdom|A Population Based Control Collection for Genetic Studies in East Anglia|Unknown status|Recruiting||4000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:44:22.428865|2018-06-01 01:44:22.428865
NCT00757978|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2008-12-17|2008-09-22|2008-09-23|Estimate|||||||2008-12-17|2008-12-18|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms|Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study|Completed||Phase 4|22|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 01:44:22.57028|2018-06-01 01:44:22.57028
NCT00757965|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-08-23|2008-09-22|2008-09-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|September 2008|2008-09-30||||||||Observational|||Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Colorectal Cancer in East Anglia|Unknown status|Recruiting||2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:44:22.643159|2018-06-01 01:44:22.643159
NCT00757952|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2016-03-28|2008-09-22|2008-09-23|Estimate|||||||2016-03-28|2016-03-30|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction|Early Detection of Epithelial Ovarian Cancer Using Exhaled Breath Markers: GC/FT-ICR Mass Spectrometry and Canine Olfaction.|Completed|||109|Actual|Pine Street Foundation|||||f||||f||||||||||2018-06-01 01:44:22.703298|2018-06-01 01:44:22.703298
NCT00757939|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2015-08-10|2008-09-19|2008-09-23|Estimate|||||||2015-08-10|2015-08-11|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)|A Two-Part Cross-Sectional and Longitudinal Study to Assess Regional Cerebral Blood Flow by Dynamic Arterial Spin Labeling as an Alzheimer's Disease Biomarker as Compared to FDG-PET in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:44:22.771908|2018-06-01 01:44:22.771908
NCT00757926|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2010-02-02|2008-09-22|2008-09-23|Estimate|||||||2010-02-02|2010-02-03|Estimate|September 2009||2009-09-30|February 2010|2010-02-28|September 2010|Anticipated|2010-09-30|August 2010|Anticipated|2010-08-31||Interventional|||Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants|Phase I/II, Randomized, Double-blind, Placebo-controlled, Staged Dosage Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Series of Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Infants Concurrently With Other Standard EPI Vaccines|Withdrawn||Phase 1/Phase 2|240|Anticipated|Shantha Biotechnics Limited||2||Replaced with an alternate study|f||||t||||||||||2018-06-01 01:44:22.832352|2018-06-01 01:44:22.832352
NCT00757913|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2010-02-23|2008-09-22|2008-09-23|Estimate|||||||2010-02-23|2010-02-24|Estimate|September 2008||2008-09-30|February 2010|2010-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||n-3 Enriched Nutrition Therapy and Postoperative Cognitive Dysfunction After Cardiac Surgery|The Effect of n-3 Enriched Nutrition Therapy on Postoperative Cognitive Dysfunction and Delirium After Elective Cardiac Surgery|Terminated||Phase 4|400|Anticipated|University Hospital, Basel, Switzerland||2||Insufficient recruitment rate|f||||||||||||||2018-06-01 01:44:22.893848|2018-06-01 01:44:22.893848
NCT00757900|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2008-10-08|2008-09-19|2008-09-23|Estimate|||||||2008-10-08|2008-10-09|Estimate|April 2008||2008-04-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy of Influenza Vaccine in HIV Infected Adults|Efficacy of Influenza Vaccine in HIV Infected Adults|Completed||Phase 4|507|Actual|University of Witwatersrand, South Africa||2|||f||||f||||||||||2018-06-01 01:44:22.945642|2018-06-01 01:44:22.945642
NCT00757887|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2010-11-08|2008-09-22|2008-09-23|Estimate|||||||2010-11-08|2010-11-09|Estimate|October 2009||2009-10-31|October 2009|2009-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites|Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites|Completed||N/A|15|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 01:44:23.011671|2018-06-01 01:44:23.011671
NCT00757874|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2015-09-05|2008-09-22|2008-09-23|Estimate|||||||2015-09-05|2015-09-09|Estimate|April 2006||2006-04-30|September 2015|2015-09-30|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus|A Double Blind Phase II Study Comparing Safety and Efficacy of Tacrolimus Versus Topical Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus.|Completed||Phase 2|56|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-06-01 01:44:23.085276|2018-06-01 01:44:23.085276
NCT00757848|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2012-01-24||2012-08-14|2008-09-22|2008-09-23|Estimate|2012-06-19|2012-07-25|Estimate||||2012-08-14|2012-08-20|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|INCA||A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis|A Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients With Cystic Fibrosis|Completed||Phase 2|56|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:44:23.16628|2018-06-01 01:44:23.16628
NCT00757835|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2014-05-09|2008-09-22|2008-09-23|Estimate|||||||2014-05-09|2014-05-12|Estimate|May 2008||2008-05-31|May 2014|2014-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG|24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma|Completed||Phase 4|40|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 01:44:24.473709|2018-06-01 01:44:24.473709
NCT00757822|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2015-09-28||2016-04-07|2008-09-19|2008-09-23|Estimate|2016-04-07|2016-05-13|Estimate||||2016-04-07|2016-05-13|Estimate|December 2009||2009-12-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|December 2013|Actual|2013-12-31||Interventional|PONV||Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients|Prevention of Postoperative Nausea and Vomiting in Surgical Patients|Completed||N/A|216|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:44:24.569516|2018-06-01 01:44:24.569516
NCT00757809|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2012-05-10|2008-09-22|2008-09-23|Estimate|||||||2012-05-10|2012-05-14|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Evaluating The Tolerability Of Multiple Doses Of HKI-272|A Blinded, Randomized, Multiple-Dose, Parallel Group Study to Characterize the Occurrence of Mild to Moderate Diarrhea After Administration of Neratinib Either 240-mg Once Daily or 120-mg Twice Daily for 14 Days to Healthy Subjects|Completed||Phase 1|50|Actual|Puma Biotechnology, Inc.||2|||f||||f||||||||||2018-06-01 01:44:24.992337|2018-06-01 01:44:24.992337
NCT00757783|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2010-08-12||2015-11-30|2008-09-22|2008-09-23|Estimate|2010-08-12|2010-09-10|Estimate||||2015-11-30|2015-12-30|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|July 2012|Actual|2012-07-31|August 2009|Actual|2009-08-31||Interventional|||Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment|A Multicenter, Open-label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-daily Darunavir Versus Atazanavir in HIV-infected Treatment-naive Adult Patients|Completed||Phase 4|68|Actual|Tibotec, Inc|65 subjects were enrolled/treated in the main study. 3 subjects were enrolled, randomized, not treated and excluded from analyses (n=68). An additional 18 subjects were enrolled in a substudy extension and excluded from the main analyses.|2|||f||||||||||||||2018-06-01 01:44:25.890844|2018-06-01 01:44:25.890844
NCT00757770|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2016-09-06|2008-09-22|2008-09-23|Estimate|||||||2016-09-06|2016-09-07|Estimate|August 2003||2003-08-31|September 2016|2016-09-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine|Study to Assess the Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine in Terms of Immunogenicity and Safety When Given to Healthy Infants at 2 and 4 Months of Age|Completed||Phase 3|854|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:44:26.503751|2018-06-01 01:44:26.503751
NCT00757757|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21||2013-02-09|2013-02-09|2008-09-22|2008-09-23|Estimate||||2013-02-09|2013-02-12|Estimate|2013-02-09|2013-02-12|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases|A Phase I/II Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases|Terminated||Phase 1/Phase 2|3|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:44:26.604096|2018-06-01 01:44:26.604096
NCT00757744|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2011-05-16|2008-09-22|2008-09-23|Estimate|||||||2011-05-16|2011-05-18|Estimate|September 2007||2007-09-30|May 2011|2011-05-31|September 2010|Actual|2010-09-30|January 2010|Actual|2010-01-31||Interventional|||Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China|Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China|Completed||Phase 3|45|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:44:26.678824|2018-06-01 01:44:26.678824
NCT00757731|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-07-10|2008-09-22|2008-09-23|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||FMS European Long-Term Study|A European Phase III, Multicentre, Double-blind, Randomised, Monotherapy, 12-month Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome|Completed||Phase 3|490|Actual|Pierre Fabre Medicament||3|||f||||||||||||||2018-06-01 01:44:26.762644|2018-06-01 01:44:26.762644
NCT00757718|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2009-09-04|2008-09-22|2008-09-23|Estimate|||||||2009-09-04|2009-09-09|Estimate|December 2008||2008-12-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Sleep Disordered Breathing and Gestational Hypertension|Sleep Disordered Breathing and Gestational Hypertension|Completed||N/A|26|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 01:44:26.844661|2018-06-01 01:44:26.844661
NCT00757705|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2014-02-05||2014-02-05|2008-09-19|2008-09-23|Estimate|2014-02-05|2014-03-19|Estimate||||2014-02-05|2014-03-19|Estimate|March 2008||2008-03-31|February 2014|2014-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia|An Open-label Prospective Trial to Evaluate the Tolerability, Safety and Maintained Efficacy of a Transition to Paliperidone ER in Subjects With Schizophrenia Previously Unsuccessfully Treated With Other Oral Antipsychotics|Completed||Phase 4|299|Actual|Johnson & Johnson Taiwan Ltd|Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.|1|||f||||f||||||||||2018-06-01 01:44:26.948079|2018-06-01 01:44:26.948079
NCT00757692|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2013-02-19|2008-09-22|2008-09-23|Estimate|||||||2013-02-19|2013-02-20|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.|A Phase II Randomised Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.|Completed||Phase 2|74|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-06-01 01:44:27.213463|2018-06-01 01:44:27.213463
NCT00757679|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-07-10|2008-09-22|2008-09-23|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran|Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran. An Exploratory Placebo-controlled Clinical Trial in Fibromyalgia Out-patients|Completed||Phase 2|153|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-06-01 01:44:27.291315|2018-06-01 01:44:27.291315
NCT00757666|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2012-01-24||2017-05-17|2008-09-22|2008-09-23|Estimate|2017-05-17|2017-06-14|Actual||||2017-05-17|2017-06-14|Actual|December 2008|Actual|2008-12-31|May 2017|2017-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|APPROPRIATE||APPROPRIATE - Rate Adaptive Pacing Sensor|Assessment of Proper Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation or Accelerometer|Terminated||N/A|566|Actual|Boston Scientific Corporation|Early termination leading to small numbers of subjects analyzed. As the study was stopped early, the primary objective is underpowered.|2||Difficulty enrollment; higher than planned patient attrition and data attrition|f||||f||||||||No||2018-06-01 01:44:27.376747|2018-06-01 01:44:27.376747
NCT00757653|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2017-06-16|2008-09-22|2008-09-23|Estimate|||||||2017-06-16|2017-06-20|Actual|October 2003||2003-10-31|June 2017|2017-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Retrieval Study and Histological Examination Of A Hip Femoral Components With Hydroxyapatite Coatings|Retrieval Study and Histological Examination Of A Hip Femoral Components With Hydroxyapatite Coatings|Terminated||N/A|57|Actual|Zimmer Biomet||3||slow enrollment|f||||f|f|f||||||||2018-06-01 01:44:27.69141|2018-06-01 01:44:27.69141
NCT00757640|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-20|||2008-09-20|2008-09-20|2008-09-23|Estimate|||||||2008-09-20|2008-09-23|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|September 2015|Anticipated|2015-09-30|September 2010|Anticipated|2010-09-30||Interventional|CHOLEGAS||Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery|The CHOLEGAS Study: Multicentric Randomized, Double-Blinded, Controlled Trial of Gastrectomy Plus Prophylactic Cholecystectomy Versus Gastrectomy Only, in Adults Submitted to Gastric Cancer Surgery With Curative Intent.|Unknown status|Recruiting|Phase 4|150|Anticipated|Italian Research Group for Gastric Cancer||2|||f||||f||||||||||2018-06-01 01:44:27.763657|2018-06-01 01:44:27.763657
NCT00757627|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2010-01-04||2015-08-13|2008-09-22|2008-09-23|Estimate|2010-04-20|2010-05-11|Estimate||||2015-08-13|2015-08-14|Estimate|December 2007||2007-12-31|August 2015|2015-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)|Patient-reported Outcomes With Etoricoxib in Real Life|Completed||Phase 4|500|Actual|Merck Sharp & Dohme Corp.|Open-labeled, non-controlled|1|||f||||||||||||||2018-06-01 01:44:27.896578|2018-06-01 01:44:27.896578
NCT00757614|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-08-23|2008-09-22|2008-09-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|April 2010|2010-04-30||||||||Observational|||Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Cancer in East Anglia, Trent and West Midlands|Unknown status|Recruiting||14000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:44:28.336858|2018-06-01 01:44:28.336858
NCT00757601|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2012-07-31||2016-02-04|2008-09-22|2008-09-23|Estimate|2012-08-08|2012-09-07|Estimate||||2016-02-04|2016-02-05|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)|A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK1006.|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||12|||f||||f||||||||||2018-06-01 01:44:28.483898|2018-06-01 01:44:28.483898
NCT00757588|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2011-08-10||2015-05-08|2008-09-22|2008-09-23|Estimate|2011-11-10|2011-12-13|Estimate||||2015-05-08|2015-06-01|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin|A Multicenter, Randomized, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin|Completed||Phase 3|455|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 01:44:29.553487|2018-06-01 01:44:29.553487
NCT00757575|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2012-03-26|2008-09-22|2008-09-23|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan|Epidemiological Surveillance Network Study To Assess the Disease of Pneumonia in Infants and Children in Japan|Completed|||28511|Actual|Pfizer|||1||f||||t||||||||||2018-06-01 01:44:30.75715|2018-06-01 01:44:30.75715
NCT00757562|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2017-03-21|2008-09-22|2008-09-23|Estimate|||||||2017-03-21|2017-03-23|Actual|November 1, 2002|Actual|2002-11-01|March 2017|2017-03-31|October 1, 2003|Actual|2003-10-01|October 1, 2003|Actual|2003-10-01||Interventional|||Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)|Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages >=2 to <12 Years, Who Are Poor Metabolizers of Desloratadine|Completed||Phase 3|97|Actual|Merck Sharp & Dohme Corp.||2|||t||||f||||||||||2018-06-01 01:44:30.81163|2018-06-01 01:44:30.81163
NCT00757549|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2017-10-27|2008-09-22|2008-09-23|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2008||2008-09-30|March 2017|2017-03-31|October 25, 2017|Actual|2017-10-25|August 2011|Actual|2011-08-31||Interventional|||3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx|Comparison of FLT and FDG PET in the Evaluation of Response to Cetuximab, Cisplatin and Radiation Therapy in Advanced Head and Neck Malignancies or Response to Standard Chemo-radiotherapy in Esophageal Malignancies|Completed||Early Phase 1|30|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 01:44:30.87186|2018-06-01 01:44:30.87186
NCT00757536|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2016-01-24|2008-09-22|2008-09-23|Estimate|||||||2016-01-24|2016-01-26|Estimate|May 2006||2006-05-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment|Primary Vitrectomy Combined With 360° Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment (V.E.E. Study)|Completed||N/A|60|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||No||2018-06-01 01:44:30.957159|2018-06-01 01:44:30.957159
NCT00757523|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2017-08-15|2008-09-21|2008-09-23|Estimate|||||||2017-08-15|2017-08-17|Actual|September 10, 2008|Actual|2008-09-10|August 2017|2017-08-31|June 24, 2009|Actual|2009-06-24|April 24, 2009|Actual|2009-04-24||Interventional|||Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris|A Multi-center, Randomized, Evaluator-blind, Parallel-group Evaluation of the Efficacy, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Topical Treatment of Facial Acne Vulgaris|Completed||Phase 4|382|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:44:31.055918|2018-06-01 01:44:31.055918
NCT00757510|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2014-12-08|2008-09-22|2008-09-23|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|CHDRR||Congenital Heart Disease Research Registry|Congenital Heart Disease Research Registry|Terminated|||861|Actual|Emory University|||1|Insufficient funding|f||||f||||||Samples With DNA|"~     Blood and serum collected from Registry subjects will be cryopreserved for potential future~     genetic and/or protein-based studies.~   "|||2018-06-01 01:44:31.177024|2018-06-01 01:44:31.177024
NCT00757497|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-20|||2018-05-16|2008-09-20|2008-09-23|Estimate|||||||2018-05-16|2018-05-17|Actual|September 17, 2008||2008-09-17|August 18, 2015|2015-08-18|August 18, 2015|Actual|2015-08-18|||||Interventional|||Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia|Safety of Transcranial Direct Current Brain Stimulation (TDCS) for Improvement of Psychotic Symptoms and Cognitive Functioning in Childhood Onset Schizophrenia (COS)|Terminated||Phase 1|20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:44:31.237905|2018-06-01 01:44:31.237905
NCT00757484|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2015-05-27||2015-12-15|2008-09-22|2008-09-23|Estimate|2015-12-15|2015-12-17|Estimate||||2015-12-15|2015-12-17|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational||This was a chart review study. 37 participants were not analyzed because the data in their chart was not available.|Evaluation of Postoperative Blood Pressure Changes After Benign Gynecologic Surgery|Evaluation of Postoperative Blood Pressure Changes After Benign Gynecologic Surgery|Completed|||528|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 01:44:31.311878|2018-06-01 01:44:31.311878
NCT00757471|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2016-01-24|2008-09-22|2008-09-23|Estimate|||||||2016-01-24|2016-01-26|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Brillant Blue Versus Indocyanine Green for Macular Hole Surgery|Membranepeeling With Brillant Blue Versus Membranepeeling With Indocyanine Green for Patients With Idiopathic Macular Holes.|Completed||N/A|60|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||||2018-06-01 01:44:31.571708|2018-06-01 01:44:31.571708
NCT00757458|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2008-09-22|2008-09-22|2008-09-23|Estimate|||||||2008-09-22|2008-09-23|Estimate|December 2008||2008-12-31|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Evaluation of Bacterial and Fungal Contamination During Propofol Continuous Infusion|Evaluation of Bacterial and Fungal Contamination During Propofol Continuous Infusion in Patients Undergoing General Anesthesia|Unknown status|Not yet recruiting|N/A|652|Anticipated|University of Sao Paulo||4|||f||||t||||||||||2018-06-01 01:44:31.651695|2018-06-01 01:44:31.651695
NCT00757445|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2008-09-22|2008-09-22|2008-09-23|Estimate|||||||2008-09-22|2008-09-23|Estimate|January 1997||1997-01-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Treatment Results on Patients With Debridement and Prosthesis Retention in the Hip|Treatment Results on Patients With Debridement and Prosthesis Retention in the Hip 1997-2007|Completed|||105|Actual|Sorlandet Hospital HF|||||f||||f||||||||||2018-06-01 01:44:31.725446|2018-06-01 01:44:31.725446
NCT00757432|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2011-04-08|2008-09-22|2008-09-23|Estimate|||||||2011-04-08|2011-04-11|Estimate|September 2007||2007-09-30|April 2011|2011-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Recovery After Robotic Urogynecological Surgery: The Patient's Perspective|Recovery After Robotic Urogynecological Surgery: The Patient's Perspective|Completed|||22|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 01:44:31.832061|2018-06-01 01:44:31.832061
NCT00757419|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2010-12-06|2008-09-22|2008-09-23|Estimate|||||||2010-12-06|2010-12-07|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||AZD3355 Dose-escalation Study in Healthy Males|A Phase 1 Single Centre Single-blind Randomised Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD3355 After Administration of Single Ascending Doses and Multiple Repeated Doses in Healthy Male Volunteers|Completed||Phase 1|54|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:44:31.889744|2018-06-01 01:44:31.889744
NCT00757406|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2009-04-14|2008-09-21|2008-09-23|Estimate|||||||2009-04-14|2009-04-16|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Assessment of Unilateral Lymphoedema of the Leg|Assessment of Unilateral Lymphoedema of the Leg|Completed|||45|Anticipated|ImpediMed Limited|||2||f||||t||||||||||2018-06-01 01:44:31.961993|2018-06-01 01:44:31.961993
NCT00757393|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-09-05|2008-09-22|2008-09-23|Estimate|||||||2013-09-05|2013-09-09|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis|Growth Hormone Therapy and Bone Quality in Pediatric Osteoporosis|Unknown status|Recruiting|Phase 3|28|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 01:44:32.032077|2018-06-01 01:44:32.032077
NCT00757380|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2016-01-24|2008-09-22|2008-09-23|Estimate|||||||2016-01-24|2016-01-26|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Trypan Blue Versus Brillant Blue for Epiretinal Membranes|Membranepeeling With Trypan Blue Versus Membranpeeling With Brillant Blue for Patients With Idiopathic Epiretinal Membranes|Completed||N/A|60|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||||2018-06-01 01:44:32.134986|2018-06-01 01:44:32.134986
NCT00757367|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-12-13|2008-09-22|2008-09-23|Estimate|||||||2013-12-13|2013-12-17|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)|A Phase 1, Open-Label, Controlled Clinical Trial to Determine the Pulmonary Residence Time of Insulin and Fumaryl Diketopiperazine, Utilizing Bronchoalveolar Lavage, After Administration of Technosphere® Insulin Inhalation Powder in Healthy Subjects|Completed||Phase 1|13|Actual|Mannkind Corporation||1|||f||||||||||||||2018-06-01 01:44:32.2045|2018-06-01 01:44:32.2045
NCT00757354|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2017-06-16|2008-09-22|2008-09-23|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2012||2012-06-30|June 2017|2017-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty|A Clinical Evaluation of Metal Ion Release From Metal-on-Metal Cementless Total Hip Arthroplasty|Completed||N/A|77|Actual|Zimmer Biomet||1|||f||||t||||||||||2018-06-01 01:44:32.273488|2018-06-01 01:44:32.273488
NCT00757341|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2009-04-24|2008-09-22|2008-09-23|Estimate|||||||2009-04-24|2009-04-27|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606|An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled Bosutinib in Healthy Male Subjects|Completed||Phase 1|6|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:44:32.344264|2018-06-01 01:44:32.344264
NCT00757328|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2009-02-16|2008-09-22|2008-09-23|Estimate|||||||2009-02-16|2009-02-18|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|||||Observational|EPIDEP||Treatment Clinical Practice in Bipolar Depression in Spain|EPIDEP. Epidemiologic Study in Bipolar Depression: Evaluation of the Usual Clinical Practice of Psychiatrists in Spain|Completed|||378|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:44:32.722455|2018-06-01 01:44:32.722455
NCT00757315|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-03-27|2008-09-22|2008-09-23|Estimate|||||||2013-03-27|2013-03-29|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|September 2009|Actual|2009-09-30||Interventional|||NdYag Laser for Acne Keloidalis Nuchae|Prospective, Controlled Study of the Efficacy of NdYag for Acne Keloidalis Nuchae|Unknown status|Active, not recruiting|N/A|20|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-06-01 01:44:32.817407|2018-06-01 01:44:32.817407
NCT00757302|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2015-09-29|2008-09-22|2008-09-23|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2008||2008-09-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Intraoperative Gamma Camera for Breast Cancer Surgery|Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer|Completed||Phase 3|110|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 01:44:32.894835|2018-06-01 01:44:32.894835
NCT00757289|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2017-05-17|2008-09-22|2008-09-23|Estimate|||||||2017-05-17|2017-05-19|Actual|August 2007||2007-08-31|May 2017|2017-05-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Platelet-rich-plasma Treating Tennis Elbow|Use of Platelet-rich-plasma to Treat Tennis Elbow, A Blinded and Randomized Single Center Study|Completed||N/A|106|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-06-01 01:44:32.973021|2018-06-01 01:44:32.973021
NCT00757276|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2014-12-12|2008-09-22|2008-09-23|Estimate|||||||2014-12-12|2014-12-15|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study|Copeptin in the Diagnosis and Differential Diagnosis of Diabetes Insipidus. The CoSIP-Study|Completed|||50|Actual|University Hospital, Basel, Switzerland|||1||f||||||||||Samples Without DNA|"~     bood sampling~   "|||2018-06-01 01:44:33.056075|2018-06-01 01:44:33.056075
NCT00757263|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-08-23|2008-09-22|2008-09-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|September 2008|2008-09-30||||||||Observational|||Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Ovarian Cancer in East Anglia, Oxford, Trent and West Midlands|Unknown status|Recruiting||2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:44:33.115103|2018-06-01 01:44:33.115103
NCT00757250|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2012-02-27|2008-09-21|2008-09-23|Estimate|||||||2012-02-27|2012-02-29|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy|A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART|Terminated||Phase 1|13|Actual|US Biotest, Inc.||5||Difficulty recruiting subjects to dosing cohort 5.|f||||t||||||||||2018-06-01 01:44:33.242513|2018-06-01 01:44:33.242513
NCT00757237|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2011-04-08||2011-06-07|2008-09-22|2008-09-23|Estimate|2011-06-07|2011-07-04|Estimate||||2011-06-07|2011-07-04|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa|An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam for Inhalation Solution (AZLI) Versus Tobramycin Inhalation Solution (TIS) in an Intermittent Aerosolized Antibiotic Regimen in Subjects With Cystic Fibrosis Followed by an Open-Label, Single Arm Extension (European Union [EU] Only)|Completed||Phase 3|274|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 01:44:33.419826|2018-06-01 01:44:33.419826
NCT00757224|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-21|||2008-09-22|2008-09-22|2008-09-23|Estimate|||||||2008-09-22|2008-09-23|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|October 2009|Anticipated|2009-10-31|November 2008|Anticipated|2008-11-30||Interventional|||Parental Education on Passive Smoke Exposure and Respiratory Diseases in Infants||Unknown status|Not yet recruiting|N/A|150|Anticipated|Assaf-Harofeh Medical Center||3|||f||||||||||||||2018-06-01 01:44:34.397341|2018-06-01 01:44:34.397341
NCT00757211|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-08-23|2008-09-22|2008-09-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|September 2008|2008-09-30||||||||Observational|||Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom|A Population Based Study of Genetic Predisposition and Gene-Environment Interactions in Breast Cancer in East Anglia|Unknown status|Recruiting||6000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:44:34.463212|2018-06-01 01:44:34.463212
NCT00757198|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2013-09-11|2008-09-22|2008-09-23|Estimate|||||||2013-09-11|2013-09-12|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|REMISYD||Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.|Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.|Completed||Phase 4|90|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 01:44:34.52557|2018-06-01 01:44:34.52557
NCT00757185|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2016-07-01|2008-09-22|2008-09-23|Estimate|||||||2016-07-01|2016-07-04|Estimate|February 2008||2008-02-29|July 2016|2016-07-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Compromised Microcirculation in Women With Polycystic Ovary Syndrome|Compromised Microcirculation in Women With Polycystic Ovary Syndrome|Completed||Early Phase 1|28|Actual|Yale University||2|||f||||||||||||||2018-06-01 01:44:34.595641|2018-06-01 01:44:34.595641
NCT00757172|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|2014-07-25||2016-02-10|2008-09-22|2008-09-23|Estimate|2014-08-14|2014-08-19|Estimate||||2016-02-10|2016-03-11|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|November 2011|Actual|2011-11-30||Interventional||All registered participants who have met the eligibility criteria.|Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction|A Phase II Study of Neoadjuvant Therapy With Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of the Distal Esophagus|Completed||Phase 2|70|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 01:44:34.715395|2018-06-01 01:44:34.715395
NCT00757159|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-22|||2012-01-16|2008-09-22|2008-09-23|Estimate|||||||2012-01-16|2012-01-18|Estimate|August 2008||2008-08-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study on Regenerative Treatment of Intra-bony Defects|Randomised, Clinical Controlled Study on Treatment of Intra-bony Defects With Enamel Matrix Protein (Emdogain®) vs. Nanocrystalline Hydroxyapatite (Ostim®)|Completed||Phase 4|56|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 01:44:35.389481|2018-06-01 01:44:35.389481
NCT00757146|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2010-06-22|2008-09-22|2008-09-23|Estimate|||||||2010-06-22|2010-06-24|Estimate|March 2006||2006-03-31|June 2010|2010-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Neonatal Intensive Care (NICU) Course and Hospital Outcome of Infants With BPD Treated Using Inhaled Nitric Oxide|NICU Course and Hospital Outcome of Infants With Bronchopulmonary Dysplasia Treated Using Inhaled Nitric Oxide|Completed|||18|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:44:35.468752|2018-06-01 01:44:35.468752
NCT00757133|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2014-12-04|2008-09-18|2008-09-22|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PRIMAAT||Prevention of Incisional Hernia by Mesh Augmentation After Midline Laparotomy for Aortic Aneurysm Treatment|Prevention of Incisional Hernia by Mesh Augmentation After Midline Laparotomy for Aortic Aneurysm Treatment.|Completed||N/A|120|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:44:35.548902|2018-06-01 01:44:35.548902
NCT00757120|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2018-05-02|2008-09-19|2008-09-22|Estimate|||||||2018-05-02|2018-05-04|Actual|October 2007||2007-10-31|May 2018|2018-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Biomarkers and Genetic Factors Related to Emphysema|SCCOR: Alveolar and Airway Mechanisms for COPD Project 3: Membrane-Type 1 Matrix Metalloproteinase and Extracellular Matrix Metalloproteinase Inducer in Cigarette Smoke-Induced Lung Inflammation and Emphysema Pathogenesis|Completed|||145|Actual|Washington University School of Medicine|||2||f||||t||||||Samples With DNA|"~     Blood cells, serum, extracted RNA and DNA, lung fluid~   "|||2018-06-01 01:44:35.686731|2018-06-01 01:44:35.686731
NCT00757107|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2016-03-11|2008-09-19|2008-09-22|Estimate|||||||2016-03-11|2016-03-14|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|||Taperloc Versus Taplerloc Microplasty|Clinical Evaluation of Taperloc Total Hip System With Two Different Stem Lengths|Completed||N/A|60|Actual|University Hospital, Linkoeping||2|||f||||t||||||||Yes||2018-06-01 01:44:35.743772|2018-06-01 01:44:35.743772
NCT00757081|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2013-02-06|2008-09-19|2008-09-22|Estimate|||||||2013-02-06|2013-02-07|Estimate|June 2008||2008-06-30|May 2009|2009-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate the Effect of Injection Lypolysis (Lipodissolve) Treatments to Reduce Body Fat|Metabolic And Structural Effects Of Phosphatidylcholine And Deoxycholate Injections On Subcutaneous Fat|Completed||N/A|20|Actual|BodyAesthetic Research Center||1|||f||||f||||||||||2018-06-01 01:44:35.873915|2018-06-01 01:44:35.873915
NCT00757068|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2015-05-26|2008-09-19|2008-09-22|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|STARTS||Strategies to Avoid Returning to Smoking|Addressing Postpartum Mood and Weight Concerns to Sustain Smoking Cessation|Completed||N/A|300|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:44:35.936226|2018-06-01 01:44:35.936226
NCT00757055|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2014-11-24|2008-09-19|2008-09-22|Estimate|||||||2014-11-24|2014-11-25|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|January 2014|Anticipated|2014-01-31|November 2013|Anticipated|2013-11-30||Interventional|||If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure|If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure|Withdrawn||Phase 2|0|Actual|St Vincent's University Hospital, Ireland||2||Difficulty recruit pts with PSHF HR > 70 & high BNP.|f||||f||||||||||2018-06-01 01:44:36.008404|2018-06-01 01:44:36.008404
NCT00757042|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2011-05-19|2008-09-19|2008-09-22|Estimate|||||||2011-05-19|2011-05-20|Estimate|October 2008||2008-10-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis|Completed||Phase 1|78|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:44:36.088022|2018-06-01 01:44:36.088022
NCT00757029|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2011-10-04|2008-09-19|2008-09-22|Estimate|||||||2011-10-04|2011-10-05|Estimate|October 2005||2005-10-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2008|Actual|2008-08-31||Interventional|NETADHD||Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)|Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate|Completed||Phase 4|150|Anticipated|Hallym University Medical Center||1|||f||||f||||||||||2018-06-01 01:44:36.154246|2018-06-01 01:44:36.154246
NCT00757016|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2008-09-19|2008-09-19|2008-09-22|Estimate|||||||2008-09-19|2008-09-22|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Injection Treatment of Corticosteroid to Pelvic Ligament Insertions on Women With Longlasting Backpain After Pregnancy|Injection Treatment of Slow-Release Corticosteroid to the Sacrospinous Ligament Insertions on Women With Long-Lasting Low Back Pain Starting in Pregnancy.|Completed||N/A|38|Actual|Sundsvall Hospital||2|||f||||t||||||||||2018-06-01 01:44:36.221678|2018-06-01 01:44:36.221678
NCT00757003|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2017-01-10||2017-01-10|2008-09-19|2008-09-22|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|October 2001||2001-10-31|January 2017|2017-01-31|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease|A Clinical Study of the TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Diseases for Non-Surgical Candidates Under the Physician Sponsored IDE.|Completed||Phase 3|100|Actual|Stanford University||1|||f||||f||||||||Yes|Data is made available upon request to colleagues conducting similar studies throughout the US.|2018-06-01 01:44:36.289281|2018-06-01 01:44:36.289281
NCT00756990|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2015-09-30|2008-09-19|2008-09-22|Estimate|||||||2015-09-30|2015-10-02|Estimate|November 2005||2005-11-30|September 2015|2015-09-30|August 2011|Actual|2011-08-31|March 2009|Actual|2009-03-31||Interventional|||Depot Naltrexone Treatment of Opioid Dependent Parolees|Depot Naltrexone Treatment of Opioid Dependent Parolees|Completed||N/A|61|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 01:44:36.548132|2018-06-01 01:44:36.548132
NCT00756977|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2013-02-19|2009-11-16|2013-08-09|2008-09-19|2008-09-22|Estimate|2013-07-08|2013-08-09|Estimate|2009-11-16|2009-11-18|Estimate|2013-08-09|2013-08-15|Estimate|August 2008||2008-08-31|August 2013|2013-08-31||||November 2008|Actual|2008-11-30||Interventional||Intent to Treat population|BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|Completed||Phase 3|394|Actual|Braintree Laboratories||2|||f||||f||||||||||2018-06-01 01:44:36.633099|2018-06-01 01:44:36.633099
NCT00756964|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2011-11-23||2012-08-01|2008-09-19|2008-09-22|Estimate|2012-08-01|2012-09-03|Estimate||||2012-08-01|2012-09-03|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|RasbAKI||Lowering Serum Uric Acid to Prevent Acute Kidney Injury|Effect of Rasburicase on Acute Kidney Injury, Kidney Function, the Incidence of Renal Replacement Therapy and All-cause Mortality Following Cardiac Surgery.|Completed||Phase 2|26|Actual|University of Florida|The limitation of the pilot study is that it was not powered to provide definite answers, an inherent limitation attributed to the absence of similar studies.|2|||f||||t||||||||||2018-06-01 01:44:37.065656|2018-06-01 01:44:37.065656
NCT00756951|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2009-11-20|2008-09-18|2008-09-22|Estimate|||||||2009-11-20|2009-11-23|Estimate|September 2008||2008-09-30|December 2008|2008-12-31||||||||Interventional|SCV-07 OM||Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Safety and Efficacy of SC-07 for the Delay to Onset of Severe Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck.|Completed||Phase 2|59||SciClone Pharmaceuticals||3|||f||||t||||||||||2018-06-01 01:44:37.300807|2018-06-01 01:44:37.300807
NCT00756938|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2014-01-16|2013-08-01|2017-03-30|2008-09-19|2008-09-22|Estimate|2014-01-16|2014-03-03|Estimate|2013-08-01|2013-08-08|Estimate|2017-03-30|2017-05-03|Actual|March 1, 2009|Actual|2009-03-01|March 2017|2017-03-31|August 14, 2012|Actual|2012-08-14|August 14, 2012|Actual|2012-08-14||Interventional|||Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)|A Phase III, Randomized, Open-Label, Parallel-Group, Dose-Ranging Clinical Trial to Study the Safety and Efficacy of MK954/Losartan Potassium in Pediatric Patients With Hypertension|Completed||Phase 3|101|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:44:37.446292|2018-06-01 01:44:37.446292
NCT00756925|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-05-02|2008-09-18|2008-09-22|Estimate|||||||2018-05-02|2018-05-07|Actual|February 2009||2009-02-28|May 2018|2018-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Gender and Neural Substrates of Stress and Craving|Exploring Gender Differences in the Neural Substrates of Stress Induced Drug Craving|Completed|||19|Actual|Medical University of South Carolina|||2||f||||t||||||||||2018-06-01 01:44:38.282042|2018-06-01 01:44:38.282042
NCT00756912|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2014-07-10|2008-09-19|2008-09-22|Estimate|||||||2014-07-10|2014-07-11|Estimate|September 2008||2008-09-30|July 2014|2014-07-31||||November 2008|Actual|2008-11-30||Interventional|||A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors|A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors|Terminated||Phase 1|30|Actual|Eisai Inc.||1||"This study was terminated in November 2008 due to a business decision (resources)."|f||||f||||||||||2018-06-01 01:44:38.345719|2018-06-01 01:44:38.345719
NCT00756899|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2012-10-25|2008-09-19|2008-09-22|Estimate|||||||2012-10-25|2012-10-26|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|VDS||Vitamin D Deficiency and Low Bone Mineral Content in Children|The Relationship Between Vitamin D Deficiency and Low Bone Mineral Content in Children|Completed|||45|Actual|University of Massachusetts, Worcester|||2||f||||f||||||||||2018-06-01 01:44:38.411805|2018-06-01 01:44:38.411805
NCT00756886|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2012-05-31||2013-02-26|2008-09-19|2008-09-22|Estimate|2013-02-26|2013-04-02|Estimate||||2013-02-26|2013-04-02|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study|Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study|Completed||N/A|73|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:44:38.474131|2018-06-01 01:44:38.474131
NCT00756873|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2008-09-19|2008-09-19|2008-09-22|Estimate|||||||2008-09-19|2008-09-22|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Etoricoxib in Ear Nose Throat Surgery|Analgesic Efficacy and Safety of Etoricoxib in Ear Nose Throat Surgery|Unknown status|Not yet recruiting|Phase 3|90|Anticipated|University of Regensburg||3|||f||||f||||||||||2018-06-01 01:44:38.815493|2018-06-01 01:44:38.815493
NCT00756860|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2012-05-31|2008-09-18|2008-09-22|Estimate|||||||2012-05-31|2012-06-04|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|September 2009|Actual|2009-09-30|August 2008|Actual|2008-08-31||Interventional|||A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)|A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®) on Phosphate Binding in Healthy Volunteers|Completed||Phase 1|66|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:44:38.900705|2018-06-01 01:44:38.900705
NCT00756847|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2013-04-09|2008-09-18|2008-09-22|Estimate|||||||2013-04-09|2013-04-10|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors|Completed||Phase 1|52|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:44:38.962854|2018-06-01 01:44:38.962854
NCT00756834|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-19|2008-09-19|2008-09-22|Estimate|||||||2008-09-19|2008-09-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:44:39.035743|2018-06-01 01:44:39.035743
NCT00756821|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2012-10-23|2008-09-18|2008-09-22|Estimate|||||||2012-10-23|2012-10-24|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|BforSMA||A Pilot Study of Biomarkers for Spinal Muscular Atrophy|A Pilot Study of Biomarkers for Spinal Muscular Atrophy|Completed|||130|Actual|New England Research Institutes|||2||f||||f||||||Samples With DNA|"~     Whole blood, plasma, PBMCs, and urine~   "|||2018-06-01 01:44:39.075055|2018-06-01 01:44:39.075055
NCT00756808|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2014-02-06|2008-09-19|2008-09-22|Estimate|||||||2014-02-06|2014-02-07|Estimate|October 2007||2007-10-31|February 2014|2014-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?|Is Tuberculin Skin Testing Effective in Screening for Latent TB in Elderly Residents of Nursing Homes? Comparison With a New IFN-y Based Assay|Completed|||135|Actual|Northwell Health|||||f||||f||||||||||2018-06-01 01:44:39.161546|2018-06-01 01:44:39.161546
NCT00756795|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-04-09|2008-09-19|2008-09-22|Estimate|||||||2018-04-09|2018-04-11|Actual|April 2008|Actual|2008-04-30|April 2018|2018-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|I-PAP||Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study)|Increasing Physical Activity of Patients With Head and Neck Cancer (I-PAP Study)|Withdrawn||Early Phase 1|0|Actual|University of Nebraska||1||PI chose not to continue with this unfunded study|f||||f||||||||||2018-06-01 01:44:39.210961|2018-06-01 01:44:39.210961
NCT00756782|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2012-03-01|2008-09-19|2008-09-22|Estimate|||||||2012-03-01|2012-03-05|Estimate|October 2008||2008-10-31|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma|Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma|Withdrawn||Phase 2|0|Actual|Taiho Oncology, Inc.||2||Terminated due to safety concerns.|f||||f||||||||||2018-06-01 01:44:39.274618|2018-06-01 01:44:39.274618
NCT00756769|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-02-04|2008-09-18|2008-09-22|Estimate|||||||2018-02-04|2018-02-06|Actual|April 2003||2003-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|SLEIGH||Systemic Lupus Erythematosus in Gullah Health|Systemic Lupus Erythematosus in Gullah Health|Recruiting|||750|Anticipated|Medical University of South Carolina|||3||f||||f||||||||||2018-06-01 01:44:39.33469|2018-06-01 01:44:39.33469
NCT00756756|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2008-09-19|2008-09-19|2008-09-22|Estimate|||||||2008-09-19|2008-09-22|Estimate|June 2007||2007-06-30|September 2008|2008-09-30|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||The Effect of Granulocyte Colony Stimulating Factor (G-CSF) on Myocardial Function After Acute Anterior Myocardial Infarction, a Prospective Double Blind Randomized Placebo Controlled Study|The Effect of Granulocyte Colony Stimulating Factor (G-CSF) on Myocardial Function After Acute Anterior Myocardial Infarction, a Prospective Double Blind Randomized Placebo Controlled Study|Completed||N/A|20|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:44:39.39132|2018-06-01 01:44:39.39132
NCT00756743|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2010-03-17|2008-09-19|2008-09-22|Estimate|||||||2010-03-17|2010-03-19|Estimate|September 2008||2008-09-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers|A Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04802540 After Multiple Oral Dose Administration To Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Taisho Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:44:39.451428|2018-06-01 01:44:39.451428
NCT00756730|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2012-02-21||2017-07-18|2008-09-19|2008-09-22|Estimate|2012-06-08|2012-07-13|Estimate||||2017-07-18|2017-08-21|Actual|September 2008||2008-09-30|July 2017|2017-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|LARD||Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r|Randomized, Open-label Study of Switch From Lopinavir/Ritonavir (LPV/r) or Fosamprenavir/Ritonavir (FPV/r) to Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r) (Plus Background Nucleoside Reverse Transcriptase Inhibitors) in Patients Experiencing Triglyceride Elevations While Receiving LPV/r or FPV/r.|Completed||Phase 4|49|Actual|Community Research Initiative of New England||2|||f||||||||||||||2018-06-01 01:44:39.520586|2018-06-01 01:44:39.520586
NCT00756717|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2015-04-01|2008-09-19|2008-09-22|Estimate|||||||2015-04-01|2015-04-03|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|May 2018|Anticipated|2018-05-31|May 2015|Anticipated|2015-05-31||Interventional|MK-0752||Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer|A Pilot Study of MK-0752 in Combination With Tamoxifen or Letrozole in Patients With Early Stage Breast Cancer Prior to Surgery|Unknown status|Active, not recruiting|N/A|22|Actual|Loyola University||1|||f||||t||||||||||2018-06-01 01:44:40.940315|2018-06-01 01:44:40.940315
NCT00756704|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2011-11-02|2008-09-19|2008-09-22|Estimate|||||||2011-11-02|2011-11-04|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effectiveness of Smoking Cessation Guidelines in the Emergency Department|The Effectiveness of Smoking Cessation Guidelines in the Emergency Department|Completed||N/A|789|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 01:44:41.011037|2018-06-01 01:44:41.011037
NCT00756691|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2017-11-10|2008-09-19|2008-09-22|Estimate|||||||2017-11-10|2017-11-14|Actual||||November 2017|2017-11-30||||||||Observational|||A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA|A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA|Withdrawn|||0|Actual|AHS Cancer Control Alberta|||2|Limited scanner availability|f||||f||||||||||2018-06-01 01:44:41.074342|2018-06-01 01:44:41.074342
NCT00756678|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2011-09-22||2011-09-22|2008-09-19|2008-09-22|Estimate|2011-09-22|2011-10-31|Estimate||||2011-09-22|2011-10-31|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Acceptability of Two Lubricant Eye Drops||Completed||Phase 4|51|Actual|Allergan||2|||f||||f||||||||||2018-06-01 01:44:41.164193|2018-06-01 01:44:41.164193
NCT00756665|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2017-11-07|2008-09-18|2008-09-22|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2008||2008-07-31|November 2017|2017-11-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|PASS||Prostate Active Surveillance Study|Canary Prostate Active Surveillance Study|Recruiting|||2300|Anticipated|University of Washington|||||f||||t||||||Samples With DNA|"~     serum, plasma, white cells, DNA, urine, prostate tissue~   "|||2018-06-01 01:44:41.488053|2018-06-01 01:44:41.488053
NCT00756652|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-02-06|2008-09-19|2008-09-22|Estimate|||||||2018-02-06|2018-02-07|Actual|November 1, 2006|Actual|2006-11-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|MGPAS||Mentor MemoryGel Post-Approval Study|MemoryGel Silicone Gel-Filled Breast Implant Post-Approval Study|Active, not recruiting|||43046|Actual|Mentor Worldwide, LLC|||2||f||||f||||||||||2018-06-01 01:44:41.607184|2018-06-01 01:44:41.607184
NCT00756639|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-04-18|2008-09-19|2008-09-22|Estimate|||||||2018-04-18|2018-04-19|Actual|July 21, 2008|Actual|2008-07-21|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium|Prophylactic Cranial Irradiation (PCI) for Patients With Small Cell Carcinoma of the Urothelium|Active, not recruiting||Phase 2|31|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:44:41.680807|2018-06-01 01:44:41.680807
NCT00756626|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2010-10-01|2008-09-19|2008-09-22|Estimate|||||||2010-10-01|2010-10-04|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|FYCS||Feeding Young Children Study: Bottle Weaning Intervention|Feeding Young Children Study (FYCS)- a Randomized Control Trial of a Bottle Weaning Intervention Aimed at Reducing the Risk of Overweight in Low Income Multi-ethnic Toddlers.|Unknown status|Active, not recruiting|Phase 3|464|Anticipated|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 01:44:41.760116|2018-06-01 01:44:41.760116
NCT00756613|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2017-10-02|2008-09-19|2008-09-22|Estimate|||||||2017-10-02|2017-10-03|Actual|February 1, 2008|Actual|2008-02-01|September 2017|2017-09-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|VADT-F||The VA Diabetes Trial Follow-up Study (VADT-FS)|CSP #465FS - VA Diabetes Trial Long Term Follow-up Study|Completed|||1044|Actual|VA Office of Research and Development|||1||f||||t|f|f|||f|||Undecided||2018-06-01 01:44:41.8351|2018-06-01 01:44:41.8351
NCT00756600|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-01-24|2008-09-19|2008-09-22|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2006||2006-10-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|GAS||A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants|A Multi-site Randomised Controlled Trial Comparing Regional and General Anaesthesia for Effects on Neurodevelopmental Outcome and Apnoea in Infants|Active, not recruiting||Phase 4|720|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 01:44:41.92445|2018-06-01 01:44:41.92445
NCT00756587|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2008-10-30|2008-09-19|2008-09-22|Estimate|||||||2008-10-30|2008-10-31|Estimate|December 2003||2003-12-31|September 2008|2008-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Cup Versus Bottle Feeding for Late Preterm Infants|Cup Versus Bottle Feeding for Hospitalized Late Preterm Infants in Egypt|Completed||N/A|60|Actual|Cairo University||2|||f||||f||||||||||2018-06-01 01:44:42.057214|2018-06-01 01:44:42.057214
NCT00756574|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2009-07-15||2009-07-15|2008-09-19|2008-09-22|Estimate|2009-07-15|2009-08-21|Estimate||||2009-07-15|2009-08-21|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Randomized Control Trial to Study the Efficacy of the Surgical Mask Versus the N95 Respirator to Prevent Influenza|A Randomized Control Trial of Surgical Masks vs N95 Respirators to Prevent Influenza in Health Care Workers|Completed||N/A|447|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 01:44:42.143192|2018-06-01 01:44:42.143192
NCT00756561|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2010-11-08||2016-05-10|2008-09-19|2008-09-22|Estimate|2013-05-01|2013-07-19|Estimate||||2016-05-10|2016-06-13|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Observational|HOP-2A||HOP-2A - Intratesticular Hormone Levels|Intratesticular Hormone Levels in Healthy Young Men|Completed|||10|Actual|University of Washington|Early termination of study leading to data analysis of the first ten of eleven men receiving aspirations.||||f||||f||||||Samples Without DNA|"~     serum blood, testicular tissue~   "|||2018-06-01 01:44:42.410473|2018-06-01 01:44:42.410473
NCT00755807|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2011-06-13||2011-11-04|2008-09-17|2008-09-19|Estimate|2011-11-04|2011-12-09|Estimate||||2011-11-04|2011-12-09|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||Duloxetine for Multiple Sclerosis Pain|Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.|Completed||Phase 3|239|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:44:53.59056|2018-06-01 01:44:53.59056
NCT00756548|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2013-02-19|2009-11-16|2013-12-03|2008-09-19|2008-09-22|Estimate|2013-12-03|2013-12-27|Estimate|2009-11-16|2009-11-18|Estimate|2013-12-03|2013-12-27|Estimate|August 2008||2008-08-31|December 2013|2013-12-31||||November 2008|Actual|2008-11-30||Interventional||Intent-to-treat population|BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|Completed||Phase 3|386|Actual|Braintree Laboratories||2|||f||||f||||||||||2018-06-01 01:44:42.584269|2018-06-01 01:44:42.584269
NCT00756535|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2008-09-19|2008-09-19|2008-09-22|Estimate|||||||2008-09-19|2008-09-22|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Exercise Training in a Geriatric Hospital Ward||Unknown status|Not yet recruiting|N/A|160|Anticipated|Health Center of the City of Joensuu||2|||f||||f||||||||||2018-06-01 01:44:43.130571|2018-06-01 01:44:43.130571
NCT00756522|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2012-09-14|2008-09-19|2008-09-22|Estimate|||||||2012-09-14|2012-09-17|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Analyzing Lung Tissue in People With and Without Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation|Specialized Center of Clinically Oriented Research: Alveolar and Airway Mechanisms for COPD. Detection: Lung Imaging and Profiling (Project 1)|Unknown status|Enrolling by invitation||63|Actual|Washington University School of Medicine|||||f||||t||||||Samples With DNA|"~     Plasma, serum, isolated RNA and DNA, and lung tissue~   "|||2018-06-01 01:44:43.21673|2018-06-01 01:44:43.21673
NCT00756509|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2018-04-17|2008-09-19|2008-09-22|Estimate|||||||2018-04-17|2018-04-19|Actual|August 29, 2008|Actual|2008-08-29|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib|An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy of Nilotinib in Adult Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line Treatment|Active, not recruiting||Phase 4|44|Actual|Novartis||1|||f||||f|f|f||||||Undecided||2018-06-01 01:44:43.288883|2018-06-01 01:44:43.288883
NCT00756496|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2009-06-29|2008-09-19|2008-09-22|Estimate|||||||2009-06-29|2009-06-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:44:43.374787|2018-06-01 01:44:43.374787
NCT00756483|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-19|2008-09-19|2008-09-22|Estimate|||||||2008-09-19|2008-09-22|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|October 2009|Anticipated|2009-10-31|March 2009|Anticipated|2009-03-31||Observational|||Stability Plus - Outcomes From Extended Continuum of Care|Study the Effects of Pre- and Post-Operative Resistive Exercise in Total Arthroplasty Patients Using the Stability Plus Exercise System|Unknown status|Not yet recruiting||200|Anticipated|Stability Plus, LLC|||4||f||||t||||||||||2018-06-01 01:44:43.41695|2018-06-01 01:44:43.41695
NCT00756470|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2014-10-30||2014-11-04|2008-09-19|2008-09-22|Estimate|2014-11-03|2014-11-05|Estimate||||2014-11-04|2014-11-17|Estimate|October 2008||2008-10-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Phase II Neoadjuvant in Inflammatory Breast Cancer|A Phase II Study of Neoadjuvant Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With Inflammatory Breast Cancer Whose Tumors Overexpress ErbB2 (Her2/Neu)|Terminated||Phase 2|15|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 01:44:43.526084|2018-06-01 01:44:43.526084
NCT00756457|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2013-02-14||2014-06-30|2008-09-19|2008-09-22|Estimate|2014-06-30|2014-07-02|Estimate||||2014-06-30|2014-07-02|Estimate|July 2007||2007-07-31|June 2014|2014-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Bracing and Strengthening for Posterior Tibial Tendon Dysfunction|The Effect of Bracing and Strengthening Exercises on Posterior Tibial Tendon Dysfunction|Completed||Phase 2|39|Actual|Ithaca College||2|||f||||f||||||||||2018-06-01 01:44:43.774049|2018-06-01 01:44:43.774049
NCT00756444|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2013-10-23||2014-03-28|2008-09-19|2008-09-22|Estimate|2013-10-23|2013-12-13|Estimate||||2014-03-28|2014-04-17|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck|A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (Amended Version 20-March-2009)|Completed||Phase 2|67|Actual|Amgen||2|||f||||t||||||||||2018-06-01 01:44:44.194357|2018-06-01 01:44:44.194357
NCT00756431|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2017-06-16|2008-09-19|2008-09-22|Estimate|||||||2017-06-16|2017-06-19|Actual|January 2004||2004-01-31|June 2017|2017-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Clinical Evaluation on HA Coated Dynamic Hip Screws for Trochanteric Femoral Fractures|Prospective Randomized Double Blinded Clinical Evaluation on HA Coated Dynamic Hip Screws for Trochanteric Femoral Fractures|Withdrawn||N/A|0|Actual|Zimmer Biomet||2||No data so far|f||||f||||||||||2018-06-01 01:44:44.546102|2018-06-01 01:44:44.546102
NCT00756418|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2017-09-15|2008-09-19|2008-09-22|Estimate|||||||2017-09-15|2017-09-18|Actual|June 1, 2003|Actual|2003-06-01|September 2017|2017-09-30|August 28, 2004|Actual|2004-08-28|August 28, 2004|Actual|2004-08-28||Interventional|||Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)|A Randomized Open-Label Comparative Study of Montelukast Versus Theophylline Added to Inhaled Corticosteroid in Pediatric Patients With Bronchial Asthma|Completed||Phase 4|84|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:44:44.691898|2018-06-01 01:44:44.691898
NCT00756405|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2017-05-24|2008-09-19|2008-09-22|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2007||2007-03-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Dietary Antioxidants on Cardiovascular Risk Factors|Potential Health Benefits of Dietary Antioxidants From Supplements v. Foods|Completed||N/A|88|Actual|Stanford University||3|||f||||f|f|f||||||No||2018-06-01 01:44:44.770256|2018-06-01 01:44:44.770256
NCT00756392|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2016-07-14|2008-09-19|2008-09-22|Estimate|||||||2016-07-14|2016-07-18|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Magnetic Resonance (MR) Spectroscopy in Localized Prostate Cancer|MR Spectroscopy in Localized Prostate Cancer|Completed||N/A|10|Actual|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-06-01 01:44:44.84855|2018-06-01 01:44:44.84855
NCT00756379|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-05-09|2008-09-19|2008-09-22|Estimate|||||||2018-05-09|2018-05-15|Actual|March 11, 2009|Actual|2009-03-11|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|Century||Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease|Randomized Trial of Comprehensive Lifestyle Modifications, Optimal Pharmacological Treatment and PET Imaging for Detection and Management of Stable Coronary Artery Disease|Active, not recruiting||Phase 3|1085|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-06-01 01:44:44.918789|2018-06-01 01:44:44.918789
NCT00756366|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2018-05-28|2008-09-19|2008-09-22|Estimate|||||||2018-05-28|2018-05-30|Actual|July 2005||2005-07-31|May 2018|2018-05-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|PET-OSA||CPAP Therapy in Patients With Heart Failure and Obstructive Sleep Apnea.|Effects of Continuous Positive Airway Pressure Therapy on Myocardial Energetics and Sympathetic Nerve Function in Patients With Heart Failure and Obstructive Sleep Apnea.|Completed||Phase 1|67|Actual|Ottawa Heart Institute Research Corporation||3|||f||||f||||||||||2018-06-01 01:44:45.00081|2018-06-01 01:44:45.00081
NCT00756353|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2011-04-14|2008-09-19|2008-09-22|Estimate|||||||2011-04-14|2011-04-15|Estimate|June 2006||2006-06-30|September 2008|2008-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||"Survey of Buprenorphine Use Among Out of Care Population in France (P04933)(COMPLETED)"|Out of Care Patient Survey|Completed|||600|Actual|Indivior Inc.|||2||f||||f||||||||||2018-06-01 01:44:45.094658|2018-06-01 01:44:45.094658
NCT00756340|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2015-10-13|2008-09-18|2008-09-22|Estimate|||||||2015-10-13|2015-10-14|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors|A Phase I Trial of RAD001 (Everolimus) and Avastin(R) (Bevacizumab) in Children With Recurrent Solid Tumors|Completed||Phase 1|16|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 01:44:45.16661|2018-06-01 01:44:45.16661
NCT00756327|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2009-08-14|2008-09-19|2008-09-22|Estimate|||||||2009-08-14|2009-08-17|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||AquaLase Capsule Wash for Pediatric Eyes|AquaLase Capsule Wash for Pediatric Eyes|Completed|||20|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-06-01 01:44:45.2507|2018-06-01 01:44:45.2507
NCT00756314|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2010-09-09||2010-10-06|2008-09-19|2008-09-22|Estimate|2010-09-09|2010-09-30|Estimate||||2010-10-06|2010-10-13|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|APA||Contraceptive Counseling Following an Abortion|Effectiveness of Contraceptive Counseling of Women Following an Abortion in Recife, Brasil: a Randomized Controlled Intervention Study.|Completed||N/A|246|Actual|Instituto Materno Infantil Prof. Fernando Figueira|"The time of the follow up of six months after the abortion, not having the possibility to evaluate the effectiveness of the measurement in longer term.~However, this decision may have contributed to overestimate the intervention effect."|2|||f||||t||||||||||2018-06-01 01:44:45.324865|2018-06-01 01:44:45.324865
NCT00756301|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2012-06-05|2008-09-19|2008-09-22|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Cutaneous Administration of Local Anesthetic for Spine Injection Procedures|Cutaneous Administration of Local Anesthetic for Spine Injection Procedures: A Prospective Randomized Controlled Trial of Patient Preferred Method|Completed||N/A|55|Actual|Stanford University||3|||f||||||||||||||2018-06-01 01:44:45.616041|2018-06-01 01:44:45.616041
NCT00756288|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2016-08-29|2008-09-19|2008-09-22|Estimate|||||||2016-08-29|2016-08-30|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Photo-therapy With a Topical Retinoid Versus Photo-therapy Alone for Actinic Keratoses|A Randomized Controlled Paired Comparison of Photo-therapy With a Topical Retinoid Cream Pretreatment Versus PDT Alone for Actinic Keratoses|Withdrawn||N/A|0|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 01:44:45.701776|2018-06-01 01:44:45.701776
NCT00756275|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2017-08-25||2018-04-06|2008-09-19|2008-09-22|Estimate|2018-04-06|2018-05-08|Actual||||2018-04-06|2018-05-08|Actual|January 2009||2009-01-31|April 2018|2018-04-30|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|VARSUD||Varenicline and Motivational Advice for Smokers With Substance Use Disorders|Varenicline and Motivational Advice for Smokers With SUD|Completed||N/A|158|Actual|Brown University||2|||f||||t||||||||||2018-06-01 01:44:45.822358|2018-06-01 01:44:45.822358
NCT00756262|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2014-09-24|2008-09-19|2008-09-22|Estimate|||||||2014-09-24|2014-09-26|Estimate|March 2003||2003-03-31|September 2014|2014-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|VRE||Probiotic Lactobacillus GG to Eliminate VRE Colonization|Probiotic Lactobacillus GG to Eliminate VRE Colonization|Terminated||Phase 1|11|Actual|Tufts Medical Center||2||Insufficient recruitment, no additional funding available|f||||t||||||||||2018-06-01 01:44:46.229967|2018-06-01 01:44:46.229967
NCT00756249|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2010-09-24|2008-09-19|2008-09-22|Estimate|||||||2010-09-24|2010-09-27|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke|Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke|Completed||Phase 1|16|Actual|H. Lundbeck A/S||6|||f||||t||||||||||2018-06-01 01:44:46.301667|2018-06-01 01:44:46.301667
NCT00756236|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|2017-04-07||2017-06-29|2008-09-19|2008-09-22|Estimate|2017-05-26|2017-06-28|Actual||||2017-06-29|2017-07-31|Actual|October 2008||2008-10-31|June 2017|2017-06-30|September 2, 2015|Actual|2015-09-02|September 2, 2015|Actual|2015-09-02||Interventional|||A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement|A Comparison of the Effect of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement|Completed||N/A|60|Actual|University of Oklahoma|"Surgical stimulus was not standardized.~ß-blockade in Group M was not as uniform as that of Group E.~There was considerable variation in achieving the target BIS level."|3|||f||||t||||||||No||2018-06-01 01:44:46.383459|2018-06-01 01:44:46.383459
NCT00756223|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2013-11-20|2008-09-19|2008-09-22|Estimate|||||||2013-11-20|2013-11-21|Estimate|November 2008||2008-11-30|November 2013|2013-11-30||||October 2010|Actual|2010-10-31||Interventional|||Phase I Study of BI 831266 in Patients With Advanced Solid Tumours|An Open-label Phase I Single Dose Escalation Trial of Two Dosing Schedules of BI 831266 Administered Intravenously Over 24 h Continuously in Patients With Advanced Solid Tumours|Completed||Phase 1|25|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:44:46.634906|2018-06-01 01:44:46.634906
NCT00756210|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-22|Estimate|||||||2008-09-18|2008-09-22|Estimate||||September 2008|2008-09-30||||||||Interventional|||Lifestyle and Obesity||Completed||N/A|||University College of Antwerp|||||f||||||||||||||2018-06-01 01:44:46.703863|2018-06-01 01:44:46.703863
NCT00756197|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2015-08-06|2008-09-18|2008-09-22|Estimate|||||||2015-08-06|2015-08-07|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|September 2009|Anticipated|2009-09-30|March 2009|Anticipated|2009-03-31||Interventional|CSALGI2||CryoSpray Ablation(TM)to Determine Safety and Feasibility in Radiation Induced Proctitis|A Single Center Pilot Study of CryoSpray Ablation(TM) to Determine Safety and Feasibility in Radiation Induced Proctitis (CSA LGI-2)|Withdrawn||Phase 4|0|Actual|CSA Medical, Inc.||2||Considering more robust design.|f||||f||||||||||2018-06-01 01:44:46.751714|2018-06-01 01:44:46.751714
NCT00756184|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-19|||2011-09-27|2008-09-19|2008-09-22|Estimate|||||||2011-09-27|2011-09-28|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Value of an Intervention to Enhance Adherence in Glaucoma Patients|1-year Randomized Control Trial Investigating the Value of an Intervention to Enhance Adherence in Glaucoma Patients Receiving Prostaglandin Monotherapy and in Patients Who Are Candidates for Adjunctive Therapy|Completed||Phase 4|107|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 01:44:46.823299|2018-06-01 01:44:46.823299
NCT00756171|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2012-12-17|2008-09-18|2008-09-19|Estimate|||||||2012-12-17|2012-12-18|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|COPE||Colesevelam Versus Placebo in Cholestatic Pruritus|Colesevelam Versus Placebo in Cholestatic Pruritus. A Double-blind, Placebo-controlled Study|Completed||Phase 2/Phase 3|38|Actual|Foundation for Liver Research||2|||f||||t||||||||||2018-06-01 01:44:46.884233|2018-06-01 01:44:46.884233
NCT00756158|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2010-07-14|2008-09-18|2008-09-19|Estimate|||||||2010-07-14|2010-07-15|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|||||Observational|||Molecular Studies on the Candidate Genes of Dopaminergic and Noradrenergic Systems in ADHD|Molecular Studies on the Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention-deficit Hyperactivity Disorder|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments~   "|||2018-06-01 01:44:46.945517|2018-06-01 01:44:46.945517
NCT00756145|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2015-05-13|2008-09-18|2008-09-19|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Use of Low Molecular Weight Heparin in Hemodiafiltration|The Use of Low Molecular Weight Heparin in Hemodiafiltration|Completed||Phase 4|15|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 01:44:47.086453|2018-06-01 01:44:47.086453
NCT00756132|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2018-02-26|2008-09-17|2008-09-19|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2008||2008-08-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2012|Actual|2012-09-30||Observational|Cyto-Cog||Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca|Role of Inflammatory Markers in Predicting Disease Recurrency and Cognitive Performance in Women With High Risk and Locally Advanced Breast Cancer|Completed|||120|Actual|University Health Network, Toronto|||4||f||||f||||||||||2018-06-01 01:44:47.171213|2018-06-01 01:44:47.171213
NCT00756119|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2012-05-30|2008-09-18|2008-09-19|Estimate|||||||2012-05-30|2012-05-31|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Measurement of Cardiac Output and Blood Volumes Using Transonic Ultrasound Dilution Technology|Measurement of Cardiac Output and Blood Volumes Using Transonic Ultrasound Dilution Technology - Clinical Evaluation and Validation|Completed|||26|Actual|Transonic Systems Inc.|||||f||||f||||||||||2018-06-01 01:44:47.243542|2018-06-01 01:44:47.243542
NCT00756106|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2014-02-06|2008-09-18|2008-09-19|Estimate|||||||2014-02-06|2014-02-07|Estimate|July 2008||2008-07-31|February 2014|2014-02-28||||September 2011|Actual|2011-09-30||Observational|||MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma|Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques|Terminated|||16|Actual|Massachusetts General Hospital||||Funding ended|f||||t||||||||||2018-06-01 01:44:47.295738|2018-06-01 01:44:47.295738
NCT00756093|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2009-09-25||2012-01-31|2008-09-17|2008-09-19|Estimate|2010-02-23|2010-03-11|Estimate||||2012-01-31|2012-02-02|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Acute Comfort and Blurring Profile Evaluation of Marketed Lubricant Eye Drops||Completed||N/A|20|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 01:44:47.372308|2018-06-01 01:44:47.372308
NCT00756080|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2010-03-08|2008-09-18|2008-09-19|Estimate|||||||2010-03-08|2010-03-09|Estimate|September 2008||2008-09-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||"Effects of Oral Citrulline on Protein Metabolism in Healthy Humans: a Prospective, Randomized, Double-blind , Cross-over Study (Citrugrêle)"|"Effects of Oral Citrulline on Protein Metabolism in Healthy Humans: a Prospective, Randomized, Double-blind , Cross-over Study"|Completed||Phase 1|12|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 01:44:47.5617|2018-06-01 01:44:47.5617
NCT00756067|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2017-05-09|2008-09-18|2008-09-19|Estimate|||||||2017-05-09|2017-05-10|Actual|September 19, 2008|Actual|2008-09-19|May 2017|2017-05-31|May 28, 2009|Actual|2009-05-28|May 28, 2009|Actual|2009-05-28||Interventional|||Evaluation of Pneumococcal Vaccine Formulations in Elderly|A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189241A) in Elderly Subjects.|Completed||Phase 1|168|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:44:47.636349|2018-06-01 01:44:47.636349
NCT00756041|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2012-02-27|2008-09-17|2008-09-19|Estimate|||||||2012-02-27|2012-02-28|Estimate|September 2005||2005-09-30|February 2012|2012-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy|An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy|Terminated||Phase 2|221|Actual|Takeda||1||Lack of Efficacy.|f||||f||||||||||2018-06-01 01:44:47.763468|2018-06-01 01:44:47.763468
NCT00756028|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2016-01-12|2008-09-18|2008-09-19|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|KvL||Short Versus Long Protocol for IVF and IVF+ICSI|Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study|Completed||Phase 4|1099|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 01:44:47.828835|2018-06-01 01:44:47.828835
NCT00756015|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2013-10-11|2008-09-18|2008-09-19|Estimate|||||||2013-10-11|2013-10-16|Estimate|November 2007||2007-11-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Post-op Rehabilitation's Influence on Tendon Healing & Clinical Outcomes Following Arthroscopic Rotator Cuff Repair|Healing After Arthroscopic Rotator Cuff Repair: A Prospective, Randomized Trial of Early Range of Motion Versus Immobilization|Completed||N/A|150|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 01:44:47.899847|2018-06-01 01:44:47.899847
NCT00756002|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2009-04-03||2010-05-31|2008-09-18|2008-09-19|Estimate|2009-10-21|2009-11-05|Estimate||||2010-05-31|2010-06-02|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia|A Randomized, Double-Blind, Placebo-Controlled, Polysomnography Plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults With Chronic Insomnia|Completed||Phase 3|259|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:44:48.016215|2018-06-01 01:44:48.016215
NCT00755989|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|December 2008||2008-12-31|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds|A Phase 3, Single-Centered, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Trial of Morphine Sulfate Gel 0.1% in Patients With Stage 2-3 Wounds|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Banner Health||2|||f||||t||||||||||2018-06-01 01:44:49.172728|2018-06-01 01:44:49.172728
NCT00755976|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-13|||2014-12-30|2008-09-18|2008-09-19|Estimate|||||||2014-12-30|2014-12-31|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma|Phase II Trial of the Multi-Drug Resistance Protein Modulating Agent Sulindac in Combination With Epirubicin in Patients With Advanced Melanoma|Completed||Phase 2|32|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 01:44:49.489031|2018-06-01 01:44:49.489031
NCT00755963|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2011-07-20|2008-09-18|2008-09-19|Estimate|||||||2011-07-20|2011-07-22|Estimate|May 2009||2009-05-31|July 2010|2010-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women|The Influence of Hormone Replacement Therapy on the Cerebral Serotonin-1A Receptor Distribution and Mood in Postmenopausal Women|Completed||Phase 4|30|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 01:44:49.848476|2018-06-01 01:44:49.848476
NCT00755950|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2016-06-07|2008-09-18|2008-09-19|Estimate|||||||2016-06-07|2016-06-09|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|November 2011|Actual|2011-11-30||Interventional|||Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis|A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period|Terminated||Phase 2/Phase 3|70|Actual|University of Maryland||3||Low enrollment|f||||t||||||||||2018-06-01 01:44:50.1397|2018-06-01 01:44:50.1397
NCT00755937|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2008-09-29||2015-05-26|2008-09-17|2008-09-19|Estimate|2009-04-24|2009-06-11|Estimate||||2015-05-26|2015-06-22|Estimate|February 2002||2002-02-28|May 2015|2015-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|RemiTRAC®||Remicade® Crohn's Disease Registry Across Canada (Study P02793)|Remicade® Treatment Registry Across Canada in Crohn's Disease|Terminated|||556|Actual|Merck Sharp & Dohme Corp.|This was an observational study. There were no imposed interventions from the Sponsor including imposing specific duration of treatment or data collection beyond the standard of care.||1|Satisfied a post-marketing commitment to Canadian Health Authorities.|f||||f||||||||||2018-06-01 01:44:50.487708|2018-06-01 01:44:50.487708
NCT00755924|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-11-25|2008-09-17|2008-09-19|Estimate|||||||2015-11-25|2015-11-26|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|August 2009|Actual|2009-08-31||Interventional|||Prospective Randomized Clinical Trial Evaluating the Impact of Vinegar on High Density Lipoprotein||Completed||Phase 1|114|Actual|HealthPartners Institute|||||f||||f||||||||||2018-06-01 01:44:51.177466|2018-06-01 01:44:51.177466
NCT00755911|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2013-01-07||2015-05-28|2008-09-18|2008-09-19|Estimate|2014-03-04|2014-04-15|Estimate||||2015-05-28|2015-07-03|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy|Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy|Completed||Phase 1/Phase 2|24|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:44:51.263061|2018-06-01 01:44:51.263061
NCT00755898|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|December 2003||2003-12-31|September 2008|2008-09-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Urinary Excretion of Acetylamantadine by Cancer Patients|Urinary Excretion of Acetylamantadine by Cancer Patients|Completed||Phase 2|150|Actual|University of Manitoba||2|||f||||f||||||||||2018-06-01 01:44:51.71136|2018-06-01 01:44:51.71136
NCT00755885|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2017-01-25|2008-09-18|2008-09-19|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2008||2008-10-31|January 2017|2017-01-31|June 4, 2016|Actual|2016-06-04|June 4, 2016|Actual|2016-06-04||Interventional|||Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer|A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients With Oestrogen (ER) or Androgen Receptor (AR) Positive Advanced or Metastatic Breast Carcinoma|Completed||Phase 1/Phase 2|77|Actual|Cancer Research UK|||||f||||||||||||||2018-06-01 01:44:51.808564|2018-06-01 01:44:51.808564
NCT00755872|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2011-10-07|2008-09-18|2008-09-19|Estimate|||||||2011-10-07|2011-10-12|Estimate|November 2007||2007-11-30|October 2011|2011-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate|Influence of a High-fat Meal on the Bioavailability of a Two Different Formulations of Risedronate|Completed||Phase 1|76|Actual|Warner Chilcott||4|||f||||t||||||||||2018-06-01 01:44:51.891255|2018-06-01 01:44:51.891255
NCT00755859|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|May 1998||1998-05-31|August 2008|2008-08-31|September 2007|Actual|2007-09-30|December 2004|Actual|2004-12-31||Interventional|||"Steroids and Azathioprine Versus Steroids Alone in IgAN"|Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial.|Completed||Phase 4|206|Actual|A. Manzoni Hospital||2|||f||||t||||||||||2018-06-01 01:44:51.987637|2018-06-01 01:44:51.987637
NCT00755846|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2011-06-08||2012-02-01|2008-09-17|2008-09-19|Estimate|2011-07-28|2011-08-29|Estimate||||2012-02-01|2012-02-03|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison Study to Determine the Efficacy and Safety of SYR110322 in Patients With Type 2 Diabetes, Who Are Either Receiving No Current Treatment or Currently Treated With Diet and Exercise, Sulfonylurea, Metformin or a Combination of Sulfonylurea and Metformin|Completed||Phase 2|265|Actual|Takeda||6|||f||||f||||||||||2018-06-01 01:44:52.207195|2018-06-01 01:44:52.207195
NCT00755833|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2016-10-27|2008-09-18|2008-09-19|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months|A Prospective, Multicentre, Open Label, Un-controlled , Observational, 12-month Study in Subjects Using: NovoMix® 50 (Biphasic Insulin Aspart 50) for Treatment of Type 2 Diabetes Mellitus in Slovenia|Completed|||270|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:44:53.397272|2018-06-01 01:44:53.397272
NCT00755794|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2017-03-10|2008-09-18|2008-09-19|Estimate|||||||2017-03-10|2017-03-13|Actual|June 2006||2006-06-30|March 2017|2017-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|SAS||The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)|An 8 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Adding Montelukast Sodium 10 mg Per Day to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma|Completed||Phase 3|800|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:44:56.289191|2018-06-01 01:44:56.289191
NCT00755781|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2012-09-13|2008-09-18|2008-09-19|Estimate|||||||2012-09-13|2012-09-17|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|CIS001||Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation|A Multi-Center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation|Completed||Phase 3|284|Actual|APT Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 01:44:56.373296|2018-06-01 01:44:56.373296
NCT00755768|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|September 2006|Actual|2006-09-30|||||Interventional|||More Time Better Outcome - a Randomised Trial to Investigate the Effect of More Dietetic Time in Dialysis Patients|More Time Better Outcome - a Randomised Trial to Investigate the Effect of More Dietetic Time on Phosphate Levels in End Stage Renal Failure Patients|Completed||N/A|75||Royal Free Hampstead NHS Trust|||||f||||f||||||||||2018-06-01 01:44:56.568149|2018-06-01 01:44:56.568149
NCT00755755|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2012-07-26||2012-12-11|2008-09-18|2008-09-19|Estimate|2012-10-16|2012-11-16|Estimate||||2012-12-11|2012-12-13|Estimate|October 2008||2008-10-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|PEARLI||PGL4001 Versus Placebo in Uterine Myomas|A Phase III, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of PGL4001 (Ulipristal) Versus Placebo for Pre-Operative Treatment of Symptomatic Uterine Myomas|Completed||Phase 3|241|Actual|PregLem SA||3|||f||||t||||||||||2018-06-01 01:44:56.650785|2018-06-01 01:44:56.650785
NCT00755742|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2011-09-21|2008-09-17|2008-09-19|Estimate|||||||2011-09-21|2011-09-22|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C|Evaluation of the Impact of a Combined Program of Diet, Exercise and Behavior Modification on the Insulin Resistance and Adipokine Profile in Obese Patients With Current and Cured Chronic Hepatitis C.|Completed||N/A|24|Actual|University Health Network, Toronto||4|||f||||t||||||||||2018-06-01 01:44:57.21316|2018-06-01 01:44:57.21316
NCT00755729|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway|The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway|Completed||Phase 4|32|Actual|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-06-01 01:44:57.30129|2018-06-01 01:44:57.30129
NCT00755716|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|2016-11-10|2012-06-20|2017-08-15|2008-09-18|2008-09-19|Estimate|2017-08-15|2017-08-16|Actual|2012-08-24|2012-08-31|Estimate|2017-08-15|2017-08-16|Actual|April 2006||2006-04-30|August 2017|2017-08-31|August 2013|Actual|2013-08-31|December 2008|Actual|2008-12-31||Interventional|||Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study|Topiramate Alone and in Combination With the Nicotine Patch for Smoking Cessation: A Pilot Study|Completed||Phase 3|57|Actual|UConn Health||3|||f||||f||||||||No||2018-06-01 01:44:57.383407|2018-06-01 01:44:57.383407
NCT00755703|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-12-31|2008-09-18|2008-09-19|Estimate|||||||2015-12-31|2016-01-01|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|September 2009|Actual|2009-09-30||Interventional|||Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.|A Phase I, Dose-Ranging Safety and Immunogenicity Study of an Adenovirus-vectored Intranasal, Pandemic (Hemagglutinin H5) Influenza Vaccine, ADhVN1203/04.H5, in Healthy Adults|Completed||Phase 1|48|Actual|Altimmune, Inc.||4|||f||||t||||||||||2018-06-01 01:44:57.698095|2018-06-01 01:44:57.698095
NCT00755690|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2014-02-17|2008-09-18|2008-09-19|Estimate|||||||2014-02-17|2014-02-19|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease|Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease|Completed||N/A|32|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 01:44:57.764663|2018-06-01 01:44:57.764663
NCT00755677|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2012-03-20|2008-09-18|2008-09-19|Estimate|||||||2012-03-20|2012-03-21|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease|Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease|Completed||Early Phase 1|26|Actual|St. Boniface General Hospital Research Centre||1|||f||||f||||||||||2018-06-01 01:44:57.845557|2018-06-01 01:44:57.845557
NCT00755664|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2015-06-04|2008-09-18|2008-09-19|Estimate|||||||2015-06-04|2015-06-08|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Low-dose Complex B-vitamins on Homocysteine and Framingham Risk Score Among Chinese Elderly|Effects of Low-dose B-vitamins Supplementation on Plasma Homocysteine and Framingham Risk Score: Double Blind Randomized Controlled Trial in Healthy Chinese Elderly|Completed||Phase 3|390|Actual|Peking University||2|||f||||t||||||||||2018-06-01 01:44:57.948047|2018-06-01 01:44:57.948047
NCT00755651|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Studies on the H Pipelle, a New Device for Endometrial Sampling at Hysteroscopy|Studies on the H Pipelle, a New Device for Endometrial Sampling at Hysteroscopy|Completed||N/A|180|Actual|Royal Free Hampstead NHS Trust||2|||f||||f||||||||||2018-06-01 01:44:58.036806|2018-06-01 01:44:58.036806
NCT00755638|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2009-07-10|2008-09-17|2008-09-19|Estimate|||||||2009-07-10|2009-07-14|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ACE-031 (ActRIIB-IgG1) in Healthy, Postmenopausal Volunteers|Completed||Phase 1|48|Actual|Acceleron Pharma, Inc.||1|||f||||f||||||||||2018-06-01 01:44:58.11433|2018-06-01 01:44:58.11433
NCT00755599|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|EASE||Eisenhower's Alternative Speculum Examination|The EASE Trial: Eisenhower's Alternative Speculum Examination|Unknown status|Active, not recruiting|N/A|1200|Anticipated|Eisenhower Army Medical Center||2|||f||||f||||||||||2018-06-01 01:44:58.247078|2018-06-01 01:44:58.247078
NCT00755586|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2009-08-17|2008-09-18|2008-09-19|Estimate|||||||2009-08-17|2009-08-18|Estimate|January 2009||2009-01-31|August 2009|2009-08-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Stem Cell Therapy to Improve the Muscle Function of Patients With Partly Denervated Muscles of the Arm|Autologous Bone Marrow Transplantation for Muscle Improvement in Traumatic Brachial Plexus Injuries|Unknown status|Recruiting|Phase 1/Phase 2|18|Anticipated|Leiden University Medical Center||3|||f||||f||||||||||2018-06-01 01:44:58.340716|2018-06-01 01:44:58.340716
NCT00755573|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2010-08-19|2008-09-18|2008-09-19|Estimate|||||||2010-08-19|2010-08-20|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|CPP||Pain and Chronic Pancreatitis - Clinical End Experimental Studies|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical and Experimental Pilot Study of Pregabalin in Patients With Chronic Pancreatitis|Completed||Phase 2/Phase 3|64|Actual|Aalborg Universitetshospital||2|||f||||t||||||||||2018-06-01 01:44:58.44358|2018-06-01 01:44:58.44358
NCT00755560|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2016-02-18|2008-09-18|2008-09-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|July 2015|Actual|2015-07-31||Interventional|||Treatment of Asymptomatic Toxocariasis With Albendazole in Children|Treatment of Asymptomatic Toxocariasis With Albendazole in Children. A Prospective, Randomized, Placebo-controlled Clinical Trial|Unknown status|Active, not recruiting|Phase 3|50|Anticipated|Hospital de Niños R. Gutierrez de Buenos Aires||2|||f||||t||||||||Undecided||2018-06-01 01:44:58.519918|2018-06-01 01:44:58.519918
NCT00755547|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2013-03-27|2008-09-18|2008-09-19|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2008||2008-04-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|POWER||A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth|Physical Activity for Overweight Youth at Risk for Type 2 Diabetes Mellitus (POWER) Trial|Completed||Phase 4|120|Actual|University of Manitoba||3|||f||||||||||||||2018-06-01 01:44:58.610076|2018-06-01 01:44:58.610076
NCT00755534|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2013-02-12|2008-09-18|2008-09-19|Estimate|||||||2013-02-12|2013-02-13|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC|A Parallel Phase II Study With Irinotecan/Cetuximab (Until PD) Followed by XELOX/Cetuximab (Until PD) vs the Reverse Sequence in Metastatic CRC With Previous Benefit on Irinotecan/Bevacizumab Based Therapy|Terminated||Phase 2|68|Actual|Hellenic Oncology Research Group||2||Due to poor accrual|f||||f||||||||||2018-06-01 01:44:58.694804|2018-06-01 01:44:58.694804
NCT00755521|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2012-08-09|2008-09-18|2008-09-19|Estimate|||||||2012-08-09|2012-08-10|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|October 2010|Actual|2010-10-31||Interventional|||Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia|Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures|Unknown status|Recruiting|Phase 4|80|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-06-01 01:44:58.803521|2018-06-01 01:44:58.803521
NCT00755508|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2012-02-27|2008-09-17|2008-09-19|Estimate|||||||2012-02-27|2012-02-28|Estimate|November 2005||2005-11-30|February 2012|2012-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study to Evaluate the Safety and Efficacy of ROZEREM™ Taken in Combination With Gabapentin for the Treatment of Subjects With Chronic Insomnia|Completed||Phase 2|378|Actual|Takeda||5|||f||||f||||||||||2018-06-01 01:44:58.890584|2018-06-01 01:44:58.890584
NCT00755495|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2012-02-27|2008-09-17|2008-09-19|Estimate|||||||2012-02-27|2012-02-28|Estimate|July 2006||2006-07-31|February 2012|2012-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Proof-of-Concept Study to Evaluate the Safety and Efficacy of Ramelteon Taken in Combination With Doxepin for the Treatment of Subjects With Chronic Insomnia|Completed||Phase 2|472|Actual|Takeda||4|||f||||f||||||||||2018-06-01 01:44:58.974784|2018-06-01 01:44:58.974784
NCT00755482|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee|Randomised, Placebo Controlled Trial to Examine the Effect of Aquamin F on NSAID Dose Reduction in Subjects With Osteoarthritis of the Knee.|Completed||Phase 1/Phase 2|29|Actual|Marigot Ltd.||2|||f||||f||||||||||2018-06-01 01:44:59.058565|2018-06-01 01:44:59.058565
NCT00755469|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2013-12-03|2008-09-18|2008-09-19|Estimate|||||||2013-12-03|2013-12-05|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Post-conditioning to Reduce Infarct Size|"Modification of Reperfusion by Post-Conditioning Reduces Infarct Size in Acute Myocardial Infarction"|Completed||N/A|43|Actual|Minneapolis Heart Institute Foundation||1|||f||||f||||||||||2018-06-01 01:44:59.142811|2018-06-01 01:44:59.142811
NCT00755456|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2013-03-25|2008-09-18|2008-09-19|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)|Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis|Unknown status|Recruiting|Phase 2|80|Anticipated|Iperboreal Pharma Srl||2|||f||||f||||||||||2018-06-01 01:44:59.261854|2018-06-01 01:44:59.261854
NCT00755443|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|February 2003||2003-02-28|September 2008|2008-09-30|December 2005|Actual|2005-12-31|September 2004|Actual|2004-09-30||Interventional|DIABETES||Sirolimus-Eluting Stent Versus Standard Stent in Diabetic|A Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients|Completed||Phase 4|160|Actual|Hospital San Carlos, Madrid||2|||f||||t||||||||||2018-06-01 01:44:59.36093|2018-06-01 01:44:59.36093
NCT00755092|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2009-02-10|2008-09-17|2008-09-18|Estimate|||||||2009-02-10|2009-02-11|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|DINAM||Effect of Doula in Nulliparas and Multiparas|Analgesic Efficacy of Doula in Nulliparous and Multiparous Women|Completed||N/A|150|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 01:45:06.050625|2018-06-01 01:45:06.050625
NCT00755430|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2008-09-18|2008-09-18|2008-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|January 2009||2009-01-31|September 2008|2008-09-30|December 2012|Anticipated|2012-12-31|||||Observational|||Structural and Functional Connectivity in Autism Spectrum Disorders|Structural and Functional Connectivity in Autism Spectrum Disorders by Using Diffusion Spectrum Imaging and Functional Magnetic Resonance Imaging Studies|Unknown status|Not yet recruiting||150|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-06-01 01:44:59.436064|2018-06-01 01:44:59.436064
NCT00755417|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2011-12-21||2012-02-03|2008-09-18|2008-09-19|Estimate|2012-02-03|2012-03-07|Estimate||||2012-02-03|2012-03-07|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 3|541|Actual|Depomed||3|||f||||f||||||||||2018-06-01 01:44:59.513724|2018-06-01 01:44:59.513724
NCT00755404|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2013-03-25|2008-09-18|2008-09-19|Estimate|||||||2013-03-25|2013-03-26|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)|Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-Carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis|Unknown status|Recruiting|Phase 2|20|Anticipated|Iperboreal Pharma Srl||2|||f||||f||||||||||2018-06-01 01:45:00.007814|2018-06-01 01:45:00.007814
NCT00755391|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2012-10-25|2008-09-18|2008-09-19|Estimate|||||||2012-10-25|2012-10-26|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Cognitive Behavioral Therapy for Adolescents With Bulimia|Cognitive Behavioral Therapy for Adolescents With Bulimia|Completed||N/A|8|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 01:45:00.136385|2018-06-01 01:45:00.136385
NCT00755378|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-18|||2009-03-25|2008-09-18|2008-09-19|Estimate|||||||2009-03-25|2009-03-26|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|||||Interventional|SAD||AZD8529 Single Ascending Dose Study|Phase I, Single-Center, Randomized, Double-Blind, Placebo Controlled Single-Ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and PK of AZD8529 in Healthy Subjects Part B: A Randomized, Open Label Study to Assess the Effect of Food on AZD 8529|Completed||Phase 1|58|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:45:00.265926|2018-06-01 01:45:00.265926
NCT00755365|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2008-09-17|2008-09-17|2008-09-18|Estimate|||||||2008-09-17|2008-09-18|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|September 2008|Anticipated|2008-09-30|December 2007|Actual|2007-12-31||Observational|||Intraoperative Angioembolization in the Management of Pelvic Fracture-Related Hemodynamic Instability|Intraoperative Angioembolization in the Management of Pelvic Fracture-Related Hemodynamic Instability|Unknown status|Active, not recruiting||15|Anticipated|Penn State University|||||f||||f||||||||||2018-06-01 01:45:00.352489|2018-06-01 01:45:00.352489
NCT00755352|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2015-04-02|2008-09-16|2008-09-18|Estimate|||||||2015-04-02|2015-04-03|Estimate|November 2002||2002-11-30|April 2015|2015-04-30|April 2005|Actual|2005-04-30|June 2003|Actual|2003-06-30||Interventional|||A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.|Efficacy of WelChol as an Add-on to Pravastatin Therapy|Completed||Phase 4|67|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:45:00.553245|2018-06-01 01:45:00.553245
NCT00755339|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2018-04-26|2008-09-17|2008-09-18|Estimate|||||||2018-04-26|2018-04-27|Actual|September 15, 2008||2008-09-15|October 25, 2016|2016-10-25|October 25, 2016||2016-10-25|||||Observational|||Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome|Understanding the Anatomy and Physiology of the Sensory Experience and Its Role in Generating Tics in Tourette Syndrome|Completed|||54|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:45:00.650973|2018-06-01 01:45:00.650973
NCT00755326|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2013-02-19|2008-09-17|2008-09-18|Estimate|||||||2013-02-19|2013-02-20|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|TCM-OAK||Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee|Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee|Completed||Phase 2|120|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 01:45:00.715403|2018-06-01 01:45:00.715403
NCT00755313|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2017-11-21|2008-09-17|2008-09-18|Estimate|||||||2017-11-21|2017-11-24|Actual|May 2007||2007-05-31|November 2017|2017-11-30|June 6, 2014|Actual|2014-06-06|September 2012|Actual|2012-09-30||Observational|||Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer|Effects of Chemotherapy on Brain Structure and Function|Completed|||81|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 01:45:00.797709|2018-06-01 01:45:00.797709
NCT00755300|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2011-08-11|2008-09-17|2008-09-18|Estimate|||||||2011-08-11|2011-08-15|Estimate|June 2006||2006-06-30|August 2011|2011-08-31|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Observational|||Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques|Total Knee Arthroplasty And Thromboembolism: A Comparison Between Two Surgical Techniques|Completed|||15|Actual|University of California, Davis|||2||f||||f||||||||||2018-06-01 01:45:00.884874|2018-06-01 01:45:00.884874
NCT00755287|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17||2016-07-26|2016-07-27|2008-09-17|2008-09-18|Estimate||||2016-07-26|2016-07-28|Estimate|2016-07-27|2016-07-29|Estimate|November 2008||2008-11-30|July 2016|2016-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.|A Multicenter, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naïve Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy|Completed||Phase 3|1072|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:45:00.995824|2018-06-01 01:45:00.995824
NCT00755274|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2010-02-01||2016-04-12|2008-09-16|2008-09-18|Estimate|2010-03-10|2010-04-01|Estimate||||2016-04-12|2016-04-14|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2008-2009 Formulation)|Completed||Phase 4|32|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:45:01.52301|2018-06-01 01:45:01.52301
NCT00755261|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2015-04-15||2015-05-07|2008-09-17|2008-09-18|Estimate|2015-05-07|2015-05-08|Estimate||||2015-05-07|2015-05-08|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Phase II Study of Doxorubicin and Avastin® in Sarcoma.|Phase II Study of Doxorubicin and Avastin® for Patients With Advanced Soft-tissue Sarcomas.|Terminated||Phase 2|4|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||The study has been terminated due to low accrual.|f||||t||||||||||2018-06-01 01:45:02.721959|2018-06-01 01:45:02.721959
NCT00755248|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2008-09-16|2008-09-16|2008-09-18|Estimate|||||||2008-09-16|2008-09-18|Estimate|January 2007||2007-01-31|September 2008|2008-09-30|January 2011|Anticipated|2011-01-31|||||Observational|||Coronary Artery Bypass Grafting: Factors Related to Late Events and Saphenous Graft Patency|Coronary Artery Bypass Grafting: Factors Related to Late Events and Saphenous Graft Patency|Unknown status|Recruiting||300|Anticipated|Centro Cardiologico Monzino|||1||f||||f||||||Samples With DNA|"~     Plasma,serum, whole blood~   "|||2018-06-01 01:45:03.048741|2018-06-01 01:45:03.048741
NCT00755235|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2011-07-22||2017-10-11|2008-09-17|2008-09-18|Estimate|2012-05-31|2012-06-01|Estimate||||2017-10-11|2017-11-13|Actual|April 2009||2009-04-30|October 2017|2017-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Feasibility of Depression Care Management by E-mail|Pilot Trial of Depression Care Management by Electronic Secure Messaging|Completed||N/A|208|Actual|Kaiser Permanente|Findings apply only to patients who choose to communicate by online messaging.|2|||f||||f||||||||||2018-06-01 01:45:03.180998|2018-06-01 01:45:03.180998
NCT00755222|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2011-01-18||2017-09-07|2008-09-17|2008-09-18|Estimate|2011-03-28|2011-04-26|Estimate||||2017-09-07|2017-10-05|Actual|August 2008||2008-08-31|September 2017|2017-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease|A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Two Times a Week for Up to Three Treatment Cycles (2 x 3) in Subjects With Peyronie's Disease|Completed||Phase 2|147|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:45:03.512431|2018-06-01 01:45:03.512431
NCT00755209|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2013-11-20|2008-09-16|2008-09-18|Estimate|||||||2013-11-20|2013-11-25|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Traumatic Brain Injury|Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Adults With Traumatic Brain Injury; a Randomised, Double-blinded, Placebo-controlled Trial|Completed||Phase 3|238|Actual|Khon Kaen University||1|||f||||f||||||||||2018-06-01 01:45:04.006385|2018-06-01 01:45:04.006385
NCT00755196|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2017-01-12|2011-02-09|2017-01-12|2008-09-17|2008-09-18|Estimate|2017-01-12|2017-03-06|Actual|2011-02-09|2011-02-14|Estimate|2017-01-12|2017-03-06|Actual|September 2008||2008-09-30|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||Intent-to-treat (ITT) population included all randomized participants who received the study medication.|Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis|A Double-Blind, Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis|Completed||Phase 2|30|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:45:04.176506|2018-06-01 01:45:04.176506
NCT00755183|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17||2012-03-15|2012-03-15|2008-09-17|2008-09-18|Estimate||||2012-03-15|2012-03-19|Estimate|2012-03-15|2012-03-19|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction|A Single-Center, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Testosterone 0.03% Ophthalmic Solution Compared to Vehicle for the Treatment of Meibomian Gland Dysfunction|Completed||Phase 2|60|Actual|ORA, Inc.||2|||f||||f||||||||||2018-06-01 01:45:04.579778|2018-06-01 01:45:04.579778
NCT00755170|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2016-10-03|2008-09-17|2008-09-18|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer|A Phase II Study of the Combination of Metronomic Vinorelbine and Bevacizumab as 2nd Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|48|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 01:45:04.691179|2018-06-01 01:45:04.691179
NCT00755157|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-10-06|2008-09-17|2008-09-18|Estimate|||||||2015-10-06|2015-10-07|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer|A Phase II Study of the Combination of Metronomic Docetaxel and Bevacizumab as 2nd Line Treatment in Patients With Small Cell Lung Cancer (SCLC)|Withdrawn||Phase 2|0|Actual|University Hospital of Crete||1|||f||||f||||||||||2018-06-01 01:45:04.830401|2018-06-01 01:45:04.830401
NCT00755144|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2017-06-16|2008-09-17|2008-09-18|Estimate|||||||2017-06-16|2017-06-20|Actual|April 2007||2007-04-30|June 2017|2017-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Randomized Control Trial to Assess Early Clinical and Functional Outcome of the ROCC and LCS Total Knee Implant Designs|A Prospective Randomized Study on Early Clinical and Functional Outcome of the ROCC and LCS Total Knee Arthroplasty Implant Designs|Completed||N/A|200|Actual|Zimmer Biomet||2|||f||||f|f|f||||||||2018-06-01 01:45:05.003112|2018-06-01 01:45:05.003112
NCT00755131|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2009-11-05||2010-01-25|2008-09-17|2008-09-18|Estimate|2009-12-18|2010-01-25|Estimate||||2010-01-25|2010-02-02|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction|Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction|Completed||N/A|75|Actual|Federico II University||2|||f||||f||||||||||2018-06-01 01:45:05.135733|2018-06-01 01:45:05.135733
NCT00755118|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-10-06|2008-09-17|2008-09-18|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc|Phase II Study Of Weekly Administration Oxaliplatin Plus 5-Fu/Lv (Aio Regimen) Plus Bevacizumab, Alternative With Irinotecan Plus 5-Fu/Lv(Aio Regimen) Plus Cetuximab, As Salvage Treatment In Pretreated Patients With Mcrc|Terminated||Phase 2|24|Actual|University Hospital of Crete||1||Due to poor Accrual|f||||f||||||||||2018-06-01 01:45:05.540212|2018-06-01 01:45:05.540212
NCT00755105|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2008-12-30||2011-08-04|2008-09-17|2008-09-18|Estimate|2009-04-08|2009-04-09|Estimate||||2011-08-04|2011-08-10|Estimate|September 1998||1998-09-30|August 2011|2011-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Measurements of Body Iron Excretion of Healthy Adults|Body Iron Excretion of Healthy Adults as Measured by Isotope Dilution|Completed|||77|Actual|USDA Grand Forks Human Nutrition Research Center|||||f||||f||||||||||2018-06-01 01:45:05.723128|2018-06-01 01:45:05.723128
NCT00755079|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2014-06-16||2015-02-24|2008-09-16|2008-09-18|Estimate|2014-06-16|2014-07-16|Estimate||||2015-02-24|2015-03-17|Estimate|April 2007||2007-04-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|August 2012|Actual|2012-08-31||Interventional|||Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury|A Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Determine the Effect of an Oral Beta-2 Agonist on Respiratory Muscle Strength in Spinal Cord Injury|Completed||Phase 2/Phase 3|40|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:45:06.141221|2018-06-01 01:45:06.141221
NCT00755066|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2008-09-25|2008-09-17|2008-09-18|Estimate|||||||2008-09-25|2008-09-26|Estimate||||September 2008|2008-09-30||||||||Interventional|||Effect of Intranasal Corticosteroids on Systemic Allergen Specific IgE|The Effect of Intranasal Corticosteroid on the Immune Response Following Nasal Allergen Challenge in Patients Suffering From Seasonal Allergic Rhinitis|Completed||N/A|48|Actual|Medical University of Vienna||2|||f||||||||||||||2018-06-01 01:45:06.382805|2018-06-01 01:45:06.382805
NCT00755053|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-08-04|2008-09-17|2008-09-18|Estimate|||||||2015-08-04|2015-08-06|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparative Efficacy of Ovule vs Tablet|An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis|Completed||Phase 3|466|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:45:06.493781|2018-06-01 01:45:06.493781
NCT00755040|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2016-10-14||2017-01-24|2008-09-17|2008-09-18|Estimate|2016-10-14|2016-12-08|Estimate||||2017-01-24|2017-03-07|Actual|October 2008||2008-10-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional|||Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder|Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation|Completed||Phase 3|164|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-06-01 01:45:06.625128|2018-06-01 01:45:06.625128
NCT00755027|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-08-07|2008-09-17|2008-09-18|Estimate|||||||2015-08-07|2015-08-10|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Rasagiline and Apathy in Parkinson's Disease|A Randomised Placebo-controlled Trial of Rasagiline in Parkinson Disease Patients With Symptoms of Apathy|Completed||Phase 4|40|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t||||||||||2018-06-01 01:45:06.958667|2018-06-01 01:45:06.958667
NCT00755014|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2008-09-17|2008-09-17|2008-09-18|Estimate|||||||2008-09-17|2008-09-18|Estimate|September 2007||2007-09-30|September 2008|2008-09-30|July 2008|Actual|2008-07-31|March 2008|Actual|2008-03-31||Interventional|||Study Effect of Red Wine Consumption on Endothelial Progenitor Cells and Endothelial Function|Taipei Veterans General Hospital|Completed||Phase 1|40|Actual|Taipei Veterans General Hospital, Taiwan||1|||f||||f||||||||||2018-06-01 01:45:07.054461|2018-06-01 01:45:07.054461
NCT00755001|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2017-07-06|2008-09-17|2008-09-18|Estimate|||||||2017-07-06|2017-07-07|Actual|May 2007||2007-05-31|July 2017|2017-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Clinical Study on BiHapro Total Hip System With Different Surface Coatings|Clinical Study on BiHapro Total Hip System With Different Surface Coatings|Terminated|||40|Actual|Zimmer Biomet|||2|The site decided to stop the study|f||||f||||||||||2018-06-01 01:45:07.129943|2018-06-01 01:45:07.129943
NCT00754988|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17||2016-11-01|2016-11-03|2008-09-17|2008-09-18|Estimate||||2016-11-01|2016-11-02|Estimate|2016-11-03|2016-11-04|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.|A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.|Completed||Phase 3|666|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 01:45:07.24895|2018-06-01 01:45:07.24895
NCT00754975|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2017-02-28|2008-09-16|2008-09-18|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2008||2008-01-31|February 2017|2017-02-28|July 2010|Actual|2010-07-31|May 2009|Actual|2009-05-31||Interventional|||JACTAX LD Drug Eluting Stent Trial|A Clinical Trial Comparing the Performance of the JACTAX LD DES With the TAXUS™ Libertè™ DES|Completed||N/A|130|Actual|Boston Scientific Corporation||2|||f||||t||||||||No||2018-06-01 01:45:07.517488|2018-06-01 01:45:07.517488
NCT00754962|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2018-01-19|2008-09-17|2008-09-18|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2006||2006-12-31|January 2018|2018-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-way Crossover Bioequivalency Study of Protriptyline Tablets 10 mg Under Fasted Conditions|Completed||N/A|38|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 01:45:08.565072|2018-06-01 01:45:08.565072
NCT00754949|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2014-03-03|2008-09-17|2008-09-18|Estimate|||||||2014-03-03|2014-03-04|Estimate||||March 2014|2014-03-31||||||||Interventional|||Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis|A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical and Anti-Microbial Efficacy and Safety of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone in the Treatment of Subjects With Blepharoconjunctivitis|Withdrawn||Phase 3|0|Actual|InSite Vision||3|||f||||f||||||||||2018-06-01 01:45:08.642768|2018-06-01 01:45:08.642768
NCT00754936|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2018-02-13|2008-09-17|2008-09-18|Estimate|||||||2018-02-13|2018-02-14|Actual|May 2007|Actual|2007-05-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ERP||Treatment Response of Geriatric Depression|ERPs, Cognitive Dysfunction and Treatment Response of Geriatric Depression|Recruiting||N/A|120|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||Undecided||2018-06-01 01:45:08.712386|2018-06-01 01:45:08.712386
NCT00754923|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2014-04-15||2018-02-12|2008-09-17|2008-09-18|Estimate|2014-05-14|2014-06-04|Estimate||||2018-02-12|2018-02-14|Actual|October 2008|Actual|2008-10-31|February 2018|2018-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Single Agent Sorafenib in Non-small Cell Lung Cancer Patients Who Never Smoked or Were Former Light Smokers.|Terminated||Phase 2|11|Actual|Ohio State University Comprehensive Cancer Center|The study was discontinued, after withdrawal from the sponsor due to slow accrual. The discovery of EGFR mutations changed the scope of the trial.|1|||f||||t||||||||||2018-06-01 01:45:08.804363|2018-06-01 01:45:08.804363
NCT00754910|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2010-02-02|2008-09-17|2008-09-18|Estimate|||||||2010-02-02|2010-02-03|Estimate|December 2008||2008-12-31|June 2009|2009-06-30||||October 2010|Anticipated|2010-10-31||Interventional|||Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease|Immunobiology of Photodynamic Therapy in Lung Cancer Patients|Unknown status|Recruiting|N/A|236|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:45:08.992814|2018-06-01 01:45:08.992814
NCT00754884|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2015-12-03|2008-09-16|2008-09-18|Estimate|||||||2015-12-03|2015-12-04|Estimate|October 2008||2008-10-31|December 2015|2015-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|CALFI||Calcitonin in the Treatment of Fibromyalgia|Phase IV Study of Nasal Salmon Calcitonin in the Treatment of Symptoms and Signs of Fibromyalgia|Withdrawn||Phase 4|0|Actual|Unidad de Investigacion en Enfermedades Cronico-Degenerativas||2||Study drug was not longer available in our country.|f||||f||||||||||2018-06-01 01:45:09.217144|2018-06-01 01:45:09.217144
NCT00754871|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-01-26|2008-09-17|2008-09-18|Estimate|||||||2015-01-26|2015-01-27|Estimate|September 2008||2008-09-30|January 2015|2015-01-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Pharmacodynamic Characterization of Dienogest|A Double-blind, Randomized, Dose-controlled Study to Evaluate Pharmacodynamic Properties of Four Oral Doses of Dienogest (DNG) in 100 Healthy Young Female Volunteers Over a Period of Two Cycles up to a Maximum of 72 Days|Completed||Phase 1|102|Actual|Bayer||4|||f||||f||||||||||2018-06-01 01:45:09.421646|2018-06-01 01:45:09.421646
NCT00754858|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2014-11-26|2008-09-17|2008-09-18|Estimate|||||||2014-11-26|2014-12-02|Estimate|October 2008||2008-10-31|November 2014|2014-11-30|June 2012|Actual|2012-06-30|May 2010|Actual|2010-05-31||Interventional|||Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer|Phase II Study of Camtobell Inj.(Belotecan) in Combination With Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer|Completed||Phase 2|42|Actual|Yonsei University||1|||f||||f||||||||||2018-06-01 01:45:09.545357|2018-06-01 01:45:09.545357
NCT00754845|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2017-01-10|2008-09-17|2008-09-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2004||2004-10-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|July 2015|Actual|2015-07-31||Interventional|||Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy|A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)|Unknown status|Active, not recruiting|Phase 3|1918|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 01:45:09.660211|2018-06-01 01:45:09.660211
NCT00754832|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2011-09-09||2012-01-20|2008-09-17|2008-09-18|Estimate|2012-01-20|2012-01-24|Estimate||||2012-01-20|2012-01-24|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|September 2008|Actual|2008-09-30||Interventional|||American Ginseng Treatment for Multiple Sclerosis Related Fatigue|A Double-blinded, Placebo-controlled Crossover Pilot Study of American Ginseng Treatment for Multiple Sclerosis Related Fatigue|Completed||Phase 2|56|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 01:45:09.858405|2018-06-01 01:45:09.858405
NCT00754819|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2009-10-07|2008-09-16|2008-09-18|Estimate|||||||2009-10-07|2009-10-08|Estimate|April 2008||2008-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|COOL||Targeting Inflammation in Acute Coronary Syndrome Using Colchicine|Colchicine Compared With Placebo to Reduce Hs-CRP in Patients With Acute Coronary Syndromes- Targeting Inflammation in Atherosclerosis Trial|Completed||Phase 2/Phase 3|80|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 01:45:10.081617|2018-06-01 01:45:10.081617
NCT00754806|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2008-09-17|2008-09-17|2008-09-18|Estimate|||||||2008-09-17|2008-09-18|Estimate|February 2007||2007-02-28|September 2008|2008-09-30|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Observational|||Prospective Randomized Comparison of Clinical Results of Hand Assisted Laparoscopic Splenectomies and Open Splenectomies|Prospective Randomized Study Between Open and Hand Assisted Splenectomies|Completed|||27|Actual|Istanbul University|||||f||||t||||||||||2018-06-01 01:45:10.152362|2018-06-01 01:45:10.152362
NCT00754793|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2012-06-13||2013-12-16|2008-09-17|2008-09-18|Estimate|2012-06-27|2012-08-03|Estimate||||2013-12-16|2014-01-17|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|August 2010|Actual|2010-08-31||Interventional|SFPAT||Sinusitis and Facial Pain Disorders Anti-Depression Trial|Sinusitis and Facial Pain Disorders Anti-Depression Trial|Terminated||Phase 4|3|Actual|University of Washington||2||poor recruitment|f||||f||||||||||2018-06-01 01:45:10.216346|2018-06-01 01:45:10.216346
NCT00754780|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2012-03-15|2008-09-17|2008-09-18|Estimate|||||||2012-03-15|2012-03-19|Estimate|September 2000||2000-09-30|March 2012|2012-03-31||||August 2004|Actual|2004-08-31||Interventional|||Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1|Phase II Clinical Trial of Pirfenidone for the Treatment of Patients With Neurofibromatosis Type I|Completed||Phase 2|24|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 01:45:10.467754|2018-06-01 01:45:10.467754
NCT00754767|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2017-03-01||2017-08-10|2008-09-17|2008-09-18|Estimate|2017-03-01|2017-04-13|Actual||||2017-08-10|2017-09-11|Actual|January 2, 2007|Actual|2007-01-02|October 2015|2015-10-31|May 2, 2008|Actual|2008-05-02|April 2, 2008|Actual|2008-04-02||Interventional|||L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer|Pilot Study of L-Carnitine Supplementation in the Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Metastatic Breast Cancer|Terminated||Phase 4|2|Actual|HealthPartners Institute||2||unable to accrue study participants|f||||f|t|f||||||||2018-06-01 01:45:10.532339|2018-06-01 01:45:10.532339
NCT00754754|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2017-09-14|2008-09-17|2008-09-18|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2008||2008-09-30|September 2017|2017-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Brain Retraction Monitoring Sensor Study|Brain Retraction Monitoring Sensor|Completed||N/A|2|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 01:45:10.74417|2018-06-01 01:45:10.74417
NCT00754741|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2015-03-23||2015-04-21|2008-09-16|2008-09-18|Estimate|2015-04-17|2015-04-22|Estimate||||2015-04-21|2015-05-08|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|April 2010|Actual|2010-04-30||Interventional|MIDAS||Multi-arm Intervention Diabetes Adherence Study|Phase III Clinical Trial of the Effectiveness of Adherence Data and Motivational Interviewing to Improve Medication Adherence and Both Glycated Hemoglobin and Cholesterol Control|Completed||Phase 3|1692|Actual|Henry Ford Health System||3|||f||||t||||||||||2018-06-01 01:45:10.949979|2018-06-01 01:45:10.949979
NCT00754728|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2017-02-28|2008-09-16|2008-09-18|Estimate|||||||2017-02-28|2017-03-01|Actual|July 2007||2007-07-31|February 2017|2017-02-28|January 2010|Actual|2010-01-31|November 2008|Actual|2008-11-30||Interventional|||"JACTAX Trial Drug Eluting Stent Trial"|"JACTAX Trial Drug Eluting Stent Trial"|Completed||N/A|103|Actual|Boston Scientific Corporation||1|||f||||t||||||||No||2018-06-01 01:45:12.126489|2018-06-01 01:45:12.126489
NCT00754715|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2008-12-12|2008-09-17|2008-09-18|Estimate|||||||2008-12-12|2008-12-15|Estimate|September 2008||2008-09-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers|A Phase I, Single-Centre, Randomised, Double-Blind, Placebo-Controlled Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 in Young and Elderly Healthy Volunteers After Oral Single Ascending Doses|Completed||Phase 1|72|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:45:12.210543|2018-06-01 01:45:12.210543
NCT00754702|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-09-25|2008-09-17|2008-09-18|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2008||2008-10-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer|Vinorelbine Metronomic Plus Lapatinib as Salvage Therapy for Patients With Overexpressing HER-2 Metastatic Breast Cancer. A Multicenter Phase II Study|Terminated||Phase 2|16|Actual|University Hospital of Crete||1||Poor accrual|f||||f||||||||||2018-06-01 01:45:12.303365|2018-06-01 01:45:12.303365
NCT00754689|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2016-05-13|2008-09-17|2008-09-18|Estimate|||||||2016-05-13|2016-05-17|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes|A Multicenter, Double Blind, Placebo Controlled Randomized Study of the Efficacy and Safety of Two Rimonabant/Metformin Combinations for Reducing A1C in the Treatment of Patients With Type 2 Diabetes Mellitus Who Are Not on Current Drug Therapy.|Withdrawn||Phase 3|0|Actual|Sanofi||5||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 01:45:12.377266|2018-06-01 01:45:12.377266
NCT00754676|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2011-12-05|2008-09-17|2008-09-18|Estimate|||||||2011-12-05|2011-12-06|Estimate|October 2004||2004-10-31|December 2011|2011-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Endoscopic Stenting for Chronic Abdominal Pain|Randomized Single Blind Trial of Endoscopic Stenting for Chronic Pancreatitis-Associated Abdominal Pain|Completed|||2|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 01:45:12.467895|2018-06-01 01:45:12.467895
NCT00754663|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2008-09-17|2008-09-17|2008-09-18|Estimate|||||||2008-09-17|2008-09-18|Estimate|May 2008||2008-05-31|September 2008|2008-09-30|November 2009|Anticipated|2009-11-30|September 2009|Anticipated|2009-09-30||Interventional|BETA||Exercise Training in Patients With Cardioverter-Defibrillators|BETA: Beneficial Effects of Exercise Training in Patients With Implantable Cardioverter-Defibrillators|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 01:45:12.515388|2018-06-01 01:45:12.515388
NCT00754650|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2014-05-27||2014-05-27|2008-09-17|2008-09-18|Estimate|2014-05-27|2014-06-26|Estimate||||2014-05-27|2014-06-26|Estimate|September 2008||2008-09-30|May 2014|2014-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||Intent-to-treat population: All participants who received at least 1 administration of the study drug.|A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia|ML21206 - Bevacizumab in Chronic Lymphocytic Leukemia: A Proof of Concept Study|Completed||Phase 2|2|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:45:12.622455|2018-06-01 01:45:12.622455
NCT00754637|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2017-06-19|2008-09-17|2008-09-18|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2009||2009-12-31|June 2017|2017-06-30|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Observational|MTT||Microplasty Tibial Tray Data Collection|Microplasty Tibial Tray Multi-Center Data Collection|Withdrawn|||0|Actual|Zimmer Biomet|||1|The study was withdrawn because it no longer fit the business need.|f||||f||||||||||2018-06-01 01:45:12.811092|2018-06-01 01:45:12.811092
NCT00754624|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2014-07-22|2009-06-09|2014-10-09|2008-09-17|2008-09-18|Estimate|2014-10-09|2014-10-16|Estimate|2009-10-01|2009-10-05|Estimate|2014-10-09|2014-10-16|Estimate|May 2004||2004-05-31|October 2014|2014-10-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial|"A Four-year, Safety and Tolerability, Open-Label, Follow on Trial Evaluating Technosphere® Insulin in Subjects With Type 2 Diabetes Mellitus."|Completed||Phase 2|229|Actual|Mannkind Corporation||1|||f||||||||||||||2018-06-01 01:45:13.073531|2018-06-01 01:45:13.073531
NCT00754611|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2010-02-03|2008-09-16|2008-09-18|Estimate|||||||2010-02-03|2010-02-04|Estimate|December 2008||2008-12-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||The Evolution and Management of Migraine Recurrence Beyond 24 Hours|The Evolution and Management of Migraine Recurrence Beyond 24 Hours: A Prospective Study of Tertiary Care Center Patients|Unknown status|Active, not recruiting||100|Anticipated|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 01:45:13.408645|2018-06-01 01:45:13.408645
NCT00754598|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-17|2008-09-17|2008-09-18|Estimate|||||||2008-09-17|2008-09-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:45:13.469707|2018-06-01 01:45:13.469707
NCT00754585|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2010-11-16|2008-09-17|2008-09-18|Estimate|||||||2010-11-16|2010-11-17|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||The Effectiveness of the Logic Back™Support.|The Effectiveness of the Logic Back™Support in Promoting a Comfortable Neutral Low Back Position, Reduced Muscular Effort, Improved Performance, and Decreased Postural Shifts in Seating.|Completed|||24|Anticipated|Canadian Memorial Chiropractic College|||1||f||||f||||||||||2018-06-01 01:45:13.511265|2018-06-01 01:45:13.511265
NCT00754572|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2014-06-23||2015-05-13|2008-09-17|2008-09-18|Estimate|2015-05-13|2015-05-15|Estimate||||2015-05-13|2015-05-15|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Intention to treat (ITT) population: All participants who received at least one dose of study drug and who had at least one effectiveness measurement performed after baseline.|A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis|Completed||Phase 3|418|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:45:13.621412|2018-06-01 01:45:13.621412
NCT00754559|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2014-04-07||2016-01-14|2008-09-17|2008-09-18|Estimate|2014-05-12|2014-06-10|Estimate||||2016-01-14|2016-02-08|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||All treated participants were included in the safety population as well as the intent to-treat (ITT) population.|A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.|"Effectiveness After Four and Twentyfour Weeks and Safety of Tocilizumab in Patients With Active RA"|Completed||Phase 3|286|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-06-01 01:45:14.337694|2018-06-01 01:45:14.337694
NCT00754221|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2011-05-31|2008-09-16|2008-09-17|Estimate|||||||2011-05-31|2011-06-01|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia|A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia|Terminated||Phase 3|390|Actual|Pfizer||1||"This study has been terminated early as the esreboxetine development program is being~   discontinued. There are no safety or efficacy concerns."|f||||t||||||||||2018-06-01 01:45:19.816617|2018-06-01 01:45:19.816617
NCT00754546|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2009-08-03||2013-05-28|2008-09-17|2008-09-18|Estimate|2013-05-28|2013-05-29|Estimate||||2013-05-28|2013-05-29|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|ARFEET||Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD|Effects of Arformoterol on Exercise Endurance Time and Breathlessness in COPD: Cycle Ergometer vs. Treadmill|Completed||Phase 4|20|Actual|Dartmouth-Hitchcock Medical Center|Study completed with no reported adverse effects. One limitation of the study is frequent exercise tests involving 7 visits for each participant|2|||f||||t||||||||||2018-06-01 01:45:15.346847|2018-06-01 01:45:15.346847
NCT00754533|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2011-09-07|2008-09-17|2008-09-18|Estimate|||||||2011-09-07|2011-09-08|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|FRAXIO||Continuous Versus Interval Training in Patients With Coronary Artery Disease: FRAXIO Study|Influence of Different Exercise Training Programs in Patients With Coronary Artery Disease on Cardiac and Respiratory Parameters|Completed||N/A|64|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-06-01 01:45:15.576405|2018-06-01 01:45:15.576405
NCT00754520|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2017-03-06|2008-09-16|2008-09-18|Estimate|||||||2017-03-06|2017-03-08|Actual|May 2009||2009-05-31|April 2016|2016-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study Comparing Ceramic-on-metal Articulation to Metal-on-metal Articulation in Cementless Primary Hip Arthroplasty|A Multi-center Prospective Randomized Control Trial to Compare Two Articulating Bearing Surfaces, Ceramic-on-metal and Metal-on-metal as Used in Cementless Primary Hip Arthroplasty|Active, not recruiting||N/A|212|Actual|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-06-01 01:45:15.640666|2018-06-01 01:45:15.640666
NCT00754507|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2015-04-02|2008-09-16|2008-09-18|Estimate|||||||2015-04-02|2015-04-03|Estimate|November 2002||2002-11-30|April 2015|2015-04-30|April 2005|Actual|2005-04-30|June 2003|Actual|2003-06-30||Interventional|||A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Atorvastatin for at Least 4 Weeks.|Efficacy of WelChol as an Add-on to Atorvastatin Therapy|Completed||Phase 4|65|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:45:15.728416|2018-06-01 01:45:15.728416
NCT00754494|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2014-04-23||2014-12-22|2008-09-17|2008-09-18|Estimate|2014-12-22|2015-01-06|Estimate||||2014-12-22|2015-01-06|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|October 2012|Actual|2012-10-31||Interventional|||Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma|A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 01:45:15.828674|2018-06-01 01:45:15.828674
NCT00754481|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2015-07-29|2008-09-17|2008-09-18|Estimate|||||||2015-07-29|2015-07-31|Estimate|January 2005||2005-01-31|July 2015|2015-07-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Hypothermia for Cardiac Arrest in Paediatrics|Hypothermia for Cardiac Arrest in Paediatrics (HypCAP) - Pilot Study|Completed||Phase 2|38|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 01:45:16.550088|2018-06-01 01:45:16.550088
NCT00754468|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2014-06-09||2015-10-06|2008-09-16|2008-09-18|Estimate|2015-10-06|2015-11-04|Estimate||||2015-10-06|2015-11-04|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ESODOI||Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.|A STUDY OF CRYOSPRAY ABLATIONTM USING SURGICAL RESECTION SPECIMENS TO DETERMINE TREATMENT EFFECT, DEPTH OF INJURY, AND SIDE EFFECTS IN THE ESOPHAGUS (CSA Depth 3)|Completed||Phase 4|7|Actual|CSA Medical, Inc.|single center, small number of subjects|2|||f||||t||||||||||2018-06-01 01:45:16.695831|2018-06-01 01:45:16.695831
NCT00754455|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16||2013-07-16|2013-07-16|2008-09-16|2008-09-18|Estimate||||2013-07-16|2013-07-18|Estimate|2013-07-16|2013-07-18|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults|A Phase 2a Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Healthy Adults|Completed||Phase 2|317|Actual|Novavax||4|||f||||t||||||||||2018-06-01 01:45:17.029004|2018-06-01 01:45:17.029004
NCT00754442|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2013-01-17||2017-04-13|2008-09-17|2008-09-18|Estimate|2014-05-13|2014-05-14|Estimate||||2017-04-13|2017-05-17|Actual|February 2007||2007-02-28|April 2017|2017-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|1hydroxylase||Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism|Clinical and Molecular Characterization of Suspected Partial 25-hydroxyvitamin D-1-alpha-hydroxylase Deficiency|Completed||N/A|20|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 01:45:17.130432|2018-06-01 01:45:17.130432
NCT00754429|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2013-10-22|2008-09-17|2008-09-18|Estimate|||||||2013-10-22|2013-10-23|Estimate|June 2004||2004-06-30|October 2013|2013-10-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)|The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients|Completed||Phase 4|40|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||||||||||||2018-06-01 01:45:17.409029|2018-06-01 01:45:17.409029
NCT00754416|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2017-03-06|2008-09-17|2008-09-18|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2003||2003-03-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||S.E.S Shoulder Arthroplasty Data Collection|A Prospective, Multicentre Study Evaluating the Clinical Performance of the S.E.S Shoulder Prosthesis|Terminated|||100|Actual|Zimmer Biomet|||1|Product no more sold|f||||f||||||||||2018-06-01 01:45:17.483831|2018-06-01 01:45:17.483831
NCT00754403|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2010-07-01|2008-09-17|2008-09-18|Estimate|||||||2010-07-01|2010-07-05|Estimate|July 2005||2005-07-31|July 2010|2010-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects on Glycemic Control With Concomitantly Administered Pioglitazone HCl and Metformin HCl Extended Release (Fortamet®) in Subjects With Type 2 Diabetes|Completed||Phase 4|312|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:45:17.562825|2018-06-01 01:45:17.562825
NCT00754390|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2008-12-17||2011-05-31|2008-09-17|2008-09-18|Estimate|2009-04-15|2009-06-08|Estimate||||2011-05-31|2011-06-02|Estimate|November 2005||2005-11-30|May 2011|2011-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effects of Calcium and Phytate on Zinc Absorption|Effects of Calcium and Phytate on Zinc Absorption|Completed||N/A|17|Actual|USDA Grand Forks Human Nutrition Research Center||1|||f||||f||||||||||2018-06-01 01:45:17.657504|2018-06-01 01:45:17.657504
NCT00753857|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2008-09-16|2008-09-16|2008-09-17|Estimate|||||||2008-09-16|2008-09-17|Estimate|October 2006||2006-10-31|September 2008|2008-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Drug Facts Box: Helping Consumers Understand Drugs for Risk Reduction|The Drug Facts Box: Helping Consumers Understand Drugs for Risk Reduction|Completed||Phase 3|260|Actual|White River Junction Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 01:45:28.901497|2018-06-01 01:45:28.901497
NCT00754377|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2014-08-29||2015-04-27|2008-09-17|2008-09-18|Estimate|2014-11-05|2014-11-14|Estimate||||2015-04-27|2015-05-12|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|July 2008|Actual|2008-07-31||Observational||No descriptive information was collected from subjects.|Developing a Practice-Based Learning and Improvement Quality Improvement (QI) Systems Impact Assessment Questionnaire|Developing a PBLI QI Systems Impact Assessment Questionnaire|Completed|||92|Actual|VA Office of Research and Development|While necessary limitations for initial assessment tool development, concerns will be addressed in the multi-site trial of the curriculum, including assessment of the training manual and codebooks that were developed during this project.||2||f||||f||||||||||2018-06-01 01:45:17.851048|2018-06-01 01:45:17.851048
NCT00754364|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2014-01-28|2008-09-17|2008-09-18|Estimate|||||||2014-01-28|2014-01-29|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|May 2014|Anticipated|2014-05-31||Interventional|||Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients|A Randomized Phase II Study of Progression Free Survival Comparing Gemcitabine (1000 mg/m2 Infusion) Versus Carboplatin (AUC5 Infusion) Plus Alimta (500 mg/m2 Infusion) as First-line Chemotherapy in Elderly Patients With Locally Advanced (Stage IIIb) or Metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|108|Anticipated|Istituto Clinico Humanitas||2||low enrollment rate|f||||f||||||||||2018-06-01 01:45:18.052235|2018-06-01 01:45:18.052235
NCT00754351|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|||2012-06-26|2008-09-17|2008-09-18|Estimate|||||||2012-06-26|2012-06-28|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer|Docetaxel, Gemcitabine and Bevacizumab as Salvage Therapy for Metastatic Breast Cancer|Completed||Phase 2|48|Actual|University Hospital of Crete||1|||f||||f||||||||||2018-06-01 01:45:18.119386|2018-06-01 01:45:18.119386
NCT00754338|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-17|2010-03-26||2010-09-28|2008-09-17|2008-09-18|Estimate|2010-08-23|2010-09-20|Estimate||||2010-09-28|2010-10-05|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens|Evaluation of Disinfecting Solutions and Protein Remover With a Silicone Hydrogel Lens|Completed||N/A|76|Actual|University of Waterloo||4|||f||||f||||||||||2018-06-01 01:45:18.218224|2018-06-01 01:45:18.218224
NCT00754325|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2016-05-16||2016-05-25|2008-09-16|2008-09-17|Estimate|2016-05-24|2016-05-25|Estimate||||2016-05-25|2016-05-26|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|January 2014|Actual|2014-01-31|November 2011|Actual|2011-11-30||Interventional||Intent To Treat (ITT) Population; all randomized participants|Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor|Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor|Completed||Phase 2|100|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:45:18.620069|2018-06-01 01:45:18.620069
NCT00754312|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2010-02-02|2008-09-15|2008-09-17|Estimate|||||||2010-02-02|2010-02-03|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer|A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer|Withdrawn||Phase 1|30|Anticipated|Syndax Pharmaceuticals||3||This study has been transfered from a sponsored trial to an investigator initiated trial.|f||||f||||||||||2018-06-01 01:45:19.182214|2018-06-01 01:45:19.182214
NCT00754299|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2011-08-05|2008-09-15|2008-09-17|Estimate|||||||2011-08-05|2011-08-08|Estimate|October 2010||2010-10-31|September 2008|2008-09-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Observational|nicotine||Smoking Cessation in Nonunion, Malunion, Osseous Infection|Outcome of a Prospective Protocol for Smoking Cessation in Nonunion, Malunion, Osseous Infection, and Infected Nonunion Patients|Withdrawn|||60|Anticipated|Penn State University||||Study could not get funding; research never initiated.|f||||f||||||||||2018-06-01 01:45:19.249905|2018-06-01 01:45:19.249905
NCT00754286|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2010-03-04|2008-09-16|2008-09-17|Estimate|||||||2010-03-04|2010-03-05|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer|A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer|Unknown status|Recruiting|N/A|132|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-06-01 01:45:19.312287|2018-06-01 01:45:19.312287
NCT00754273|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2011-03-22|2008-09-16|2008-09-17|Estimate|||||||2011-03-22|2011-03-23|Estimate|September 2008||2008-09-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|MRSA||An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS|Prospective Evaluation Of Protected Alveolar Lavage (PAL) Staphylococcus Aurues Resistance Patterns|Completed|||1250|Anticipated|University of Kentucky|||1||f||||f||||||||||2018-06-01 01:45:19.39227|2018-06-01 01:45:19.39227
NCT00754260|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2015-12-10|2008-09-15|2008-09-17|Estimate|||||||2015-12-10|2015-12-14|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Caffeine Reduction and Overactive Bladder Symptoms|Caffeine Reduction Education And Overactive Bladder Symptoms|Unknown status|Active, not recruiting|N/A|110|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-06-01 01:45:19.453113|2018-06-01 01:45:19.453113
NCT00754247|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2010-10-18|2008-09-15|2008-09-17|Estimate|||||||2010-10-18|2010-10-19|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars|A Prospective, Randomized, Investigator-blinded, Placebo-controlled, Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars|Completed||Phase 4|30|Actual|University of Miami||3|||f||||f||||||||||2018-06-01 01:45:19.518099|2018-06-01 01:45:19.518099
NCT00754234|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2008-12-30||2011-06-01|2008-09-16|2008-09-17|Estimate|2009-04-09|2009-06-02|Estimate||||2011-06-01|2011-06-14|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Iron Bioavailability From MyPyramid Menus|Iron Bioavailability From MyPyramid Menus|Completed||N/A|16|Actual|USDA Grand Forks Human Nutrition Research Center||1|||f||||f||||||||||2018-06-01 01:45:19.669013|2018-06-01 01:45:19.669013
NCT00754208|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2017-12-19||2018-02-20|2008-09-16|2008-09-17|Estimate|2018-02-20|2018-02-21|Estimate||||2018-02-20|2018-02-21|Estimate|October 2008||2008-10-31|February 2018|2018-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children|Long Acting Stimulant Treatment of ADHD in Young Children|Completed||Phase 4|7|Actual|University of Nebraska|This study is limited by a small sample size and open-label design.|1|||f||||f||||||||||2018-06-01 01:45:20.131773|2018-06-01 01:45:20.131773
NCT00754195|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2015-02-19|2008-09-16|2008-09-17|Estimate|||||||2015-02-19|2015-02-23|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Insertion Distance of Thoracic Epidural Catheters in the Context of Thoracotomy Procedures.|Influence of Catheter Insertion Distance on the Quality of Thoracic Epidural Analgesia in the Context of Thoracotomy Procedures.|Completed||N/A|120|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||f||||||||||2018-06-01 01:45:20.467138|2018-06-01 01:45:20.467138
NCT00754182|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2010-05-03|2008-09-16|2008-09-17|Estimate|||||||2010-05-03|2010-05-05|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|SCSvsSG||Subcuticular Suture Versus Synthetic Glue in Thyroidectomy Incision|Comparison of Esthetic Results Between Subcuticular Suture and Synthetic Glue in Thyroidectomy Incision: a RCT|Completed||N/A|100|Actual|Azienda Ospedaliero-Universitaria di Modena||2|||f||||f||||||||||2018-06-01 01:45:20.542914|2018-06-01 01:45:20.542914
NCT00754169|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2017-10-05|2008-09-16|2008-09-17|Estimate|||||||2017-10-05|2017-10-06|Actual|September 5, 2008||2008-09-05|January 9, 2013|2013-01-09|January 9, 2013||2013-01-09|||||Observational|||Warfighter Head Injury Study|Warfighter Head Injury Study a Comprehensive, Multidisciplinary Research Evaluation|Terminated|||314|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:45:20.622265|2018-06-01 01:45:20.622265
NCT00754156|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2013-07-15||2017-01-18|2008-09-16|2008-09-17|Estimate|2014-02-15|2014-03-18|Estimate||||2017-01-18|2017-03-03|Actual|September 2008||2008-09-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ABRA||ABRA Abdominal Closure System in Open Abdomen Management|A Prospective, Controlled Evaluation of ABRA Abdominal Wall Closure System in Combination With V.A.C. Therapy Compared to V.A.C. Alone in the Management of Open Abdomen|Completed||Phase 4|14|Actual|University of Kentucky|"Limited by small sample size, and lack of closely matched patient groups.~Limited by product change from the original VAC to the ABThera system mid study.~Limited by a significant learning curve in application and use of the ABRA device."|2|||f||||f||||||||||2018-06-01 01:45:20.701155|2018-06-01 01:45:20.701155
NCT00754143|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2017-08-09|2008-09-15|2008-09-17|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2008||2008-03-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy|A Randomized, Double-blind, Placebo-Controlled, Phase 1 Study of Safety, Pharmacokinetics and Pharmacodynamics of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy on Background ACEi and/or ARB Therapy|Completed||Phase 1|38|Actual|FibroGen||3|||f||||t||||||||||2018-06-01 01:45:21.027696|2018-06-01 01:45:21.027696
NCT00754130|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2012-08-31||2015-02-23|2008-09-16|2008-09-17|Estimate|2012-08-31|2012-10-03|Estimate||||2015-02-23|2015-03-12|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).|A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 in Japanese Patients With Type 2 Diabetes|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:45:21.124308|2018-06-01 01:45:21.124308
NCT00754117|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2018-05-25|2008-09-16|2008-09-17|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2008|Actual|2008-05-31|May 2018|2018-05-31|December 8, 2012|Actual|2012-12-08|December 2010|Actual|2010-12-31||Observational|||Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)|Early Response Assessment in Patients With Diffuse Large B-cell Lymphoma Using 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)|Completed|||8|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 01:45:21.616909|2018-06-01 01:45:21.616909
NCT00754104|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2011-01-17|2008-09-15|2008-09-17|Estimate|||||||2011-01-17|2011-01-19|Estimate|September 2008||2008-09-30|January 2009|2009-01-31||||December 2008|Actual|2008-12-31||Interventional|||Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors|A Phase 1, Open Label Study of ABT-869 in Combination With Tarceva in Subjects With Advanced Non-hematologic Malignancy|Withdrawn||Phase 1|0|Actual|Abbott||1|||f||||||||||||||2018-06-01 01:45:21.787773|2018-06-01 01:45:21.787773
NCT00754091|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2015-04-14|2008-09-15|2008-09-17|Estimate|||||||2015-04-14|2015-04-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:45:21.841291|2018-06-01 01:45:21.841291
NCT00754078|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2016-07-04|2008-09-15|2008-09-17|Estimate|||||||2016-07-04|2016-07-06|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy|A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy|Active, not recruiting||Phase 2|58|Actual|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-06-01 01:45:21.875318|2018-06-01 01:45:21.875318
NCT00754065|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|2012-05-10||2013-07-15|2008-09-16|2008-09-17|Estimate|2012-07-25|2012-08-28|Estimate||||2013-07-15|2013-07-19|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Ortho Tri-Cyclen Lo on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment.|Completed||Phase 3|409|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:45:22.126733|2018-06-01 01:45:22.126733
NCT00754052|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2018-03-23||2018-03-23|2008-09-16|2008-09-17|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|September 2008||2008-09-30|March 2018|2018-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17|A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17|Terminated||Phase 3|8|Actual|Eisai Inc.|This was a 10-week double blind placebo-controlled trial that was terminated early due to the results of a similarly-designed study showing it would be futile to continue this study.|3||Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.|f||||f||||||||||2018-06-01 01:45:26.148257|2018-06-01 01:45:26.148257
NCT00754039|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2015-04-02|2008-09-16|2008-09-17|Estimate|||||||2015-04-02|2015-04-03|Estimate|February 2003||2003-02-28|April 2015|2015-04-30|March 2004|Actual|2004-03-31|September 2003|Actual|2003-09-30||Interventional|||Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol|The Effects of the Combination of Welchol and Tricor Compared to TriCor Alone in Patients With Mixed Hyperlipidemia|Completed||Phase 4|129|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:45:26.483426|2018-06-01 01:45:26.483426
NCT00754026|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2010-05-27|2008-09-16|2008-09-17|Estimate|||||||2010-05-27|2010-05-28|Estimate|September 2008||2008-09-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Insertion Distance of Interscalene Perineural Catheters in the Context of Shoulder Surgery.|Influence of the Insertion Distance on Loss of Sensation Produced by Interscalene Perineural Catheters in the Context of Shoulder Surgery.|Completed||N/A|60|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 01:45:26.575449|2018-06-01 01:45:26.575449
NCT00754013|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2011-07-21||2017-02-14|2008-09-16|2008-09-17|Estimate|2013-01-11|2013-02-13|Estimate||||2017-02-14|2017-03-21|Actual|September 2008||2008-09-30|February 2017|2017-02-28|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10|A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10|Terminated||Phase 3|9|Actual|Eisai Inc.|Due to the study terminating early,only 9 subjects were enrolled and these subjects receive only limited exposure to study medications with no subject reaching his/her maximum targeted dose. Therefore,the planned efficacy criteria were not analyzed.|2||Sufficient evidence of efficacy not met.|f||||t||||||||||2018-06-01 01:45:26.653718|2018-06-01 01:45:26.653718
NCT00754000|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2012-04-27|2008-09-15|2008-09-17|Estimate|||||||2012-04-27|2012-04-30|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|September 2009|Actual|2009-09-30|||||Observational|AIM||The AIM Study: Assessing the Impact of Margin Reduction|The AIM Study: Assessing the Impact of Margin Reduction|Completed|||82|Actual|Varian Medical|||1||f||||f||||||||||2018-06-01 01:45:26.872832|2018-06-01 01:45:26.872832
NCT00753987|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2013-08-30|2008-09-15|2008-09-17|Estimate|||||||2013-08-30|2013-09-02|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|January 2007|Actual|2007-01-31|July 2006|Actual|2006-07-31||Interventional|||Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis|Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis|Completed||Phase 1|13|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 01:45:26.96237|2018-06-01 01:45:26.96237
NCT00753974|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2018-01-30|2008-09-16|2008-09-17|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2008||2008-06-30|January 2018|2018-01-31|June 2025|Anticipated|2025-06-30|June 2025|Anticipated|2025-06-30||Observational|||Cardiovascular Biorepository|Cardiovascular Biorepository|Enrolling by invitation|||1000|Anticipated|University of Kentucky|||1||f||||f||||||Samples With DNA|"~     During this study, tissues samples will be used to help identify trends in genetic~     information for patients with heart failure. No clinically important information that could~     be used by the subject will be identified. Therefore, the results of these studies will not~     be shared with the subjects.~   "|||2018-06-01 01:45:27.031054|2018-06-01 01:45:27.031054
NCT00753961|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2017-01-25|2008-09-16|2008-09-17|Estimate|||||||2017-01-25|2017-01-27|Estimate|September 2008||2008-09-30|January 2017|2017-01-31|April 2010|Actual|2010-04-30|March 2009|Actual|2009-03-31||Interventional|||Effect Of The Consumption Of Fermented Dairy Drink On Common Infections In Shift-Workers|EFFECT OF THE CONSUMPTION OF FERMENTED DAIRY DRINK ON COMMON INFECTIONS IN SHIFT-WORKERS|Completed||N/A|1340|Actual|Danone Research||2|||f||||t||||||||||2018-06-01 01:45:27.089074|2018-06-01 01:45:27.089074
NCT00753948|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2013-09-27||2014-07-02|2008-09-15|2008-09-17|Estimate|2014-07-02|2014-07-04|Estimate||||2014-07-02|2014-07-04|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Exhaled Levels of Nitric Oxide|The Effect of Nitric Oxide on Pulmonary Resistances and Blood Pressure in Persons With Tetraplegia|Completed||Phase 2/Phase 3|23|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 01:45:27.164637|2018-06-01 01:45:27.164637
NCT00753935|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2017-04-07||2018-03-19|2008-09-15|2008-09-17|Estimate|2018-03-19|2018-04-19|Actual||||2018-03-19|2018-04-19|Actual|June 2006||2006-06-30|March 2018|2018-03-31|March 2014|Actual|2014-03-31|August 2011|Actual|2011-08-31||Interventional|||Aspirin Resistance in Coronary Artery Disease|Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease|Completed||Early Phase 1|92|Actual|Vanderbilt University Medical Center|There are no limitations or caveats.|2|||f||||f||||||||||2018-06-01 01:45:27.445136|2018-06-01 01:45:27.445136
NCT00753922|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2013-06-12||2014-03-21|2008-09-15|2008-09-17|Estimate|2013-06-12|2013-08-23|Estimate||||2014-03-21|2014-04-16|Estimate|September 2000||2000-09-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||All enrolled subjects are included|Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses|Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision|Completed||Phase 3|1008|Actual|Mentor Worldwide, LLC|Adverse events were not coded according to the MedDRA dictionary, rather they were collected as Complications in alignment with the 2006 FDA Guidance for Industry and FDA Staff – Saline, Silicone Gel, and Alternative Breast Implants.|4|||t||||f||||||||||2018-06-01 01:45:27.80386|2018-06-01 01:45:27.80386
NCT00753909|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2016-10-03|2008-09-16|2008-09-17|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer|Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer|Completed||Phase 2|50|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 01:45:28.304102|2018-06-01 01:45:28.304102
NCT00753896|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2012-02-14|2010-08-13|2015-04-20|2008-09-15|2008-09-17|Estimate|2012-02-14|2012-03-20|Estimate|2010-08-13|2010-08-18|Estimate|2015-04-20|2015-04-21|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin|Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin|Completed||Phase 3|134|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:45:28.423723|2018-06-01 01:45:28.423723
NCT00753883|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2008-09-16|2008-09-16|2008-09-17|Estimate|||||||2008-09-16|2008-09-17|Estimate|July 2006||2006-07-31|September 2008|2008-09-30||||May 2008|Actual|2008-05-31||Interventional|||Ezetrol Post-Marketing Study|A Randomized, Open-Labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety of Ezetimibe Alone Versus Statin in the Treatment of Hypercholesterolemia|Completed||Phase 4|40|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:45:28.754898|2018-06-01 01:45:28.754898
NCT00753870|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2011-04-14|2008-09-16|2008-09-17|Estimate|||||||2011-04-14|2011-04-18|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers|Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers|Terminated||Phase 1|2|Actual|University of North Carolina, Chapel Hill||1||Lack of funding|f||||f||||||||||2018-06-01 01:45:28.828429|2018-06-01 01:45:28.828429
NCT00753844|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2012-04-04|2008-09-16|2008-09-17|Estimate|||||||2012-04-04|2012-04-06|Estimate|November 2006||2006-11-30|April 2012|2012-04-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer|Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10|Completed||Phase 1|7|Actual|Kinki University|||||f||||||||||||||2018-06-01 01:45:28.962095|2018-06-01 01:45:28.962095
NCT00753831|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2012-07-11|2008-09-16|2008-09-17|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy of Aurosling in Frontalis Sling Suspension Surgery|Randomized, Double Blind, Active Controlled Study of the Efficacy, Surgical Outcome and Complications of Silicone Rod Sling in Frontalis Sling Suspension Surgery|Completed||Phase 4|16|Actual|Aurolab||1|||f||||t||||||||||2018-06-01 01:45:29.014923|2018-06-01 01:45:29.014923
NCT00753818|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2008-09-16|2008-09-16|2008-09-17|Estimate|||||||2008-09-16|2008-09-17|Estimate||||September 2008|2008-09-30||||||||Interventional|||Developmental Effects of Infant Formula Supplemented With LCPUFA||Completed||N/A|||Mead Johnson Nutrition||4|||f||||||||||||||2018-06-01 01:45:29.08517|2018-06-01 01:45:29.08517
NCT00753805|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2008-09-15|2008-09-15|2008-09-17|Estimate|||||||2008-09-15|2008-09-17|Estimate|August 2004||2004-08-31|June 2008|2008-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Dietetic Effects of Mare's Milk in Patients With Atopic Dermatitis|Dietetic Effects of Oral Intervention With Mare's Milk on the SCORAD, Faecal Microbiota and Immunological Parameters in Patients With Atopic Dermatitis|Completed||N/A|23|Actual|University of Jena|||||f||||t||||||||||2018-06-01 01:45:29.151236|2018-06-01 01:45:29.151236
NCT00753792|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2011-06-01|2008-09-16|2008-09-17|Estimate|||||||2011-06-01|2011-06-02|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse|Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse|Completed||Phase 4|49|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 01:45:29.220179|2018-06-01 01:45:29.220179
NCT00753779|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-16|||2015-04-02|2008-09-16|2008-09-17|Estimate|||||||2015-04-02|2015-04-03|Estimate|November 2002||2002-11-30|April 2015|2015-04-30|April 2005|Actual|2005-04-30|June 2003|Actual|2003-06-30||Interventional|||A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.|Efficacy of WelChol® as an Add-on to Simvastatin Therapy|Completed||Phase 4|72|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:45:29.309873|2018-06-01 01:45:29.309873
NCT00753766|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2014-09-19||2014-10-20|2008-09-16|2008-09-17|Estimate|2014-09-19|2014-09-26|Estimate||||2014-10-20|2014-10-29|Estimate|October 2005||2005-10-31|October 2014|2014-10-31|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Interventional|||Multifactorial Pre-operative Intervention in Diabetes Mellitus|Multifactorial Pre-Operative Intervention in Diabetes Mellitus|Completed||N/A|1|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:45:29.482749|2018-06-01 01:45:29.482749
NCT00753753|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2015-06-24|2008-09-15|2008-09-16|Estimate|||||||2015-06-24|2015-06-25|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|November 2009|Actual|2009-11-30|October 2008|Actual|2008-10-31||Observational|VERIFRENCHY||VerifyNow French Registry|Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)|Completed|||1001|Actual|Association Pour le Développement des Soins Cardiologiques de la ville de Chartres|||||f||||t||||||||||2018-06-01 01:45:29.750186|2018-06-01 01:45:29.750186
NCT00753740|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12||2012-02-24|2017-04-18|2008-09-12|2008-09-16|Estimate||||2012-02-27|2012-02-29|Estimate|2017-04-18|2017-04-19|Actual|September 2008||2008-09-30|April 2017|2017-04-30|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.|A Phase II Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of Maintenance IT-101 in Platinum Sensitive Ovarian Cancer Patients Who Received 4-6 Cycles of a 2nd Line Platinum-Based Regimen Without Disease Progression.|Withdrawn||Phase 2|0|Actual|NewLink Genetics Corporation||3||Poor trial recruitment|f||||t||||||||||2018-06-01 01:45:29.813308|2018-06-01 01:45:29.813308
NCT00753727|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-14|||2011-06-21|2008-09-15|2008-09-16|Estimate|||||||2011-06-21|2011-06-23|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|March 2016|Anticipated|2016-03-31|March 2012|Anticipated|2012-03-31||Interventional|SUNXRT||Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma|A Phase IB/II Study of Sunitinib in Combination With Neoadjuvant Radiation in Patients With Resectable Soft-tissue Sarcoma|Unknown status|Recruiting|Phase 1/Phase 2|26|Anticipated|Australasian Sarcoma Study Group|||||f||||t||||||||||2018-06-01 01:45:29.89664|2018-06-01 01:45:29.89664
NCT00753714|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2012-08-29||2016-08-30|2008-09-15|2008-09-16|Estimate|2012-08-29|2012-09-28|Estimate||||2016-08-30|2016-10-17|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|ZELIG||Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine|Phase II, Randomised, Double-blind, Two-arm, Parallel Study of Vandetanib (ZACTIMA™ , ZD6474) Plus Gemcitabine (Gemzar® ) or Gemcitabine Plus Placebo as First Line Treatment of Advanced (Stage IIIB or IV) Non Small Cell Lung Cancer (NSCLC) Elderly Patients.|Completed||Phase 2|124|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:45:29.979642|2018-06-01 01:45:29.979642
NCT00753688|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2011-11-17||2013-08-15|2008-09-15|2008-09-16|Estimate|2011-11-17|2011-12-21|Estimate||||2013-08-15|2013-08-22|Estimate|October 2008||2008-10-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|November 2010|Actual|2010-11-30||Interventional|PALETTE||Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy|A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy|Completed||Phase 3|369|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 01:45:30.525301|2018-06-01 01:45:30.525301
NCT00753675|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2013-09-27|2011-03-28|2016-08-29|2008-09-15|2008-09-16|Estimate|2013-09-27|2013-11-28|Estimate|2011-03-28|2011-04-06|Estimate|2016-08-29|2016-10-10|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|VANGOGH|Patient screened 180 Patient Randomized 174 (1 never treated) Sceening failures 6 Patient Treated 173 (ITT=165 ; 8 excluded from ITT due to missing postbaseline assesment)|Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer|A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)|Completed||Phase 2|174|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:45:31.851668|2018-06-01 01:45:31.851668
NCT00753662|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-14|||2011-09-12|2008-09-15|2008-09-16|Estimate|||||||2011-09-12|2011-09-13|Estimate|November 2008||2008-11-30|September 2011|2011-09-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|TMS in AD||Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease|Phase 2 (Feasibility) Study of Transcranial Magnetic Stimulation as Additional Therapy to Drug Treatment in Patients With Alzheimer's Disease|Unknown status|Recruiting|Phase 2|45|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||t||||||||||2018-06-01 01:45:32.925431|2018-06-01 01:45:32.925431
NCT00753649|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2016-10-06|2013-04-11|2016-10-06|2008-09-15|2008-09-16|Estimate|2016-10-06|2016-11-30|Estimate|2013-04-11|2013-04-18|Estimate|2016-10-06|2016-11-30|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants|Completed||Phase 4|224|Actual|GlaxoSmithKline|None reported.|2|||f||||||||||||||2018-06-01 01:45:33.020399|2018-06-01 01:45:33.020399
NCT00753636|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-13|2011-01-13||2013-04-29|2008-09-15|2008-09-16|Estimate|2011-06-08|2011-07-01|Estimate||||2013-04-29|2013-05-06|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|February 2010|Actual|2010-02-28|June 2009|Actual|2009-06-30||Interventional|||Parkinson's Disease Isradipine Safety Study|Phase II Safety and Tolerability of Isradipine (A Potential Neuroprotective Agent) in Patients With Parkinson's Disease- Stage II|Completed||Phase 2|31|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 01:45:33.314552|2018-06-01 01:45:33.314552
NCT00753623|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2013-11-01||2017-04-03|2008-09-15|2008-09-16|Estimate|2014-06-19|2014-07-18|Estimate||||2017-04-03|2017-05-15|Actual|September 2008||2008-09-30|April 2017|2017-04-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Management of Neuropathic Pain With Ramelteon|Clinical Management of Neuropathic Pain With Ramelteon|Terminated||N/A|23|Actual|Massachusetts General Hospital|Problems with recruitment and termination of the study consequently resulted in uninterpretable data.|2||Recruitment did not accrue as expected.|f||||f||||||||No||2018-06-01 01:45:33.526557|2018-06-01 01:45:33.526557
NCT00753610|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2017-03-21|2008-09-15|2008-09-16|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2007||2007-01-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|EPC||Endothelial Progenitor Cells in Cervical Cancer Patients Receiving Chemoradiation|Effect of Concurrent Chemoradiation on Circulating Endothelial Progenitor Cells in Cervical Cancer|Recruiting|||30|Anticipated|Mackay Memorial Hospital|||||f||||t||||||||||2018-06-01 01:45:33.736425|2018-06-01 01:45:33.736425
NCT00753597|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2013-02-05|2008-09-12|2008-09-16|Estimate|||||||2013-02-05|2013-02-06|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|RADS||Rescue of Steroidogenic Capacity in Adrenocortical Failure Study (RADS)|Immunotherapeutic Rescue of Steroidogenic Function in Autoimmune Adrenocortical Failure: Pilot Study|Completed||Phase 4|6|Actual|Newcastle University||1|||f||||t||||||||||2018-06-01 01:45:33.892899|2018-06-01 01:45:33.892899
NCT00753571|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2009-12-29|2008-09-15|2008-09-16|Estimate|||||||2009-12-29|2009-12-30|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|October 2010|Anticipated|2010-10-31|December 2008|Anticipated|2008-12-31||Interventional|||Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response|Cistanche Total Glycosides Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response|Unknown status|Recruiting|Phase 2|40|Anticipated|Peking University||2|||f||||f||||||||||2018-06-01 01:45:33.95851|2018-06-01 01:45:33.95851
NCT00753558|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2010-09-19|2008-09-14|2008-09-16|Estimate|||||||2010-09-19|2010-09-21|Estimate|November 2008||2008-11-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Selective Digestive Decontamination in Carriers of Carbapenem-resistant Klebsiella Pneumoniae|A Randomized,Double-Blind,Placebo-Controled Trial of Selective Digestive Decontamination Using Oral Gentamicin and Oral Polymyxin E for Eradication of Carbapenem-Resistant Klebsiella Pneumoniae Carriage|Completed||N/A|||Soroka University Medical Center||2|||f||||t||||||||||2018-06-01 01:45:34.038015|2018-06-01 01:45:34.038015
NCT00753545|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2012-12-07||2018-03-20|2008-09-15|2008-09-16|Estimate|2011-08-24|2011-09-29|Estimate||||2018-03-20|2018-04-18|Actual|August 28, 2008|Actual|2008-08-28|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|June 30, 2010|Actual|2010-06-30||Interventional|||Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer|Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens|Active, not recruiting||Phase 2|265|Actual|AstraZeneca|For OM DoR: The subset of patients evaluable for response who responded to study treatment.Values in results table may be under-estimates as some patients had not progressed at final analysis,so true duration is likely to be greater than in database.|2|||t||||f||||||||||2018-06-01 01:45:34.125252|2018-06-01 01:45:34.125252
NCT00753532|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2014-12-05|2008-09-15|2008-09-16|Estimate|||||||2014-12-05|2014-12-09|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Neuroprotective and Cardioprotective Effects Of Palm Vitamin E Tocotrienols|A Double Blind Placebo Controlled Study On The Neuroprotective And Anti-Atherogenic Effects Of Palm TocotrienolRich Fraction(Palm Vitamin E)|Completed||Phase 2|241|Actual|University of Science Malaysia||2|||f||||t||||||||||2018-06-01 01:45:34.87641|2018-06-01 01:45:34.87641
NCT00753519|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-13|2012-08-31||2012-10-14|2008-09-13|2008-09-16|Estimate|2012-10-14|2012-11-15|Estimate||||2012-10-14|2012-11-15|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Transcranial Magnetic Stimulation to Treat Parkinson's Disease|Intermittent Theta-Burst Transcranial Magnetic Stimulation (TBS) for the Treatment of Parkinson Disease|Completed||Phase 1/Phase 2|28|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 01:45:34.967318|2018-06-01 01:45:34.967318
NCT00753506|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2011-08-22||2012-02-27|2008-09-15|2008-09-16|Estimate|2012-01-17|2012-02-20|Estimate||||2012-02-27|2012-02-28|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Artemisinin to Reduce The Symptoms of Schizophrenia|Double-Blind Trial of Artemisinin to Reduce The Symptoms of Schizophrenia|Completed||N/A|66|Actual|Sheppard Pratt Health System||2|||f||||t||||||||||2018-06-01 01:45:35.4792|2018-06-01 01:45:35.4792
NCT00753493|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2012-07-12|2008-09-12|2008-09-16|Estimate|||||||2012-07-12|2012-07-13|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients|Phase I Pharmacokinetic and Safety Study of Intravenous Topiramate in Adult Patients|Completed||Phase 1|20|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 01:45:35.779323|2018-06-01 01:45:35.779323
NCT00753480|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2008-11-06|2008-09-12|2008-09-16|Estimate|||||||2008-11-06|2008-11-07|Estimate|September 2008||2008-09-30|November 2008|2008-11-30||||||||Interventional|||A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of D4064A Administered Intravenously to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer After a Platinum-Containing Regimen|Suspended||Phase 1|56|Anticipated|Genentech, Inc.|||||f||||||||||||||2018-06-01 01:45:35.842717|2018-06-01 01:45:35.842717
NCT00753467|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2010-10-20|2008-09-15|2008-09-16|Estimate|||||||2010-10-20|2010-10-21|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B|Protocol Title: A Phase II Open-labeled Study to Determine the Safety and Preliminary Efficacy of Interferon-gamma 1b (IFN-γ 1b) in Patients With Chronic Hepatitis B Who Are HBV DNA Positive|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Huntington Medical Research Institutes||3|||f||||t||||||||||2018-06-01 01:45:35.903967|2018-06-01 01:45:35.903967
NCT00753454|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2012-05-10||2014-08-26|2008-09-15|2008-09-16|Estimate|2012-05-10|2012-06-14|Estimate||||2014-08-26|2014-09-05|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|Dose Flex II||Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)|A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.|Completed||Phase 3|168|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 01:45:36.016225|2018-06-01 01:45:36.016225
NCT00753441|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2017-10-26|2008-09-15|2008-09-16|Estimate|||||||2017-10-26|2017-10-27|Actual|February 1, 2009|Actual|2009-02-01|October 2017|2017-10-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|STENTBY||Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic Head|Endoscopic Biliary Stenting on Demand Versus Surgical Biliary Bypass for Palliation of Patients With Advanced Cancer of the Pancreatic Head: STENTBY - A Randomized Controlled Trial|Terminated||N/A|24|Actual|Heidelberg University||2||Low patient accrual|f||||t||||||||||2018-06-01 01:45:36.566361|2018-06-01 01:45:36.566361
NCT00753428|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2018-04-17|2008-09-15|2008-09-16|Estimate|||||||2018-04-17|2018-04-19|Actual|November 2008|Actual|2008-11-30|April 2018|2018-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Community-based Evaluation of a Pilot PMTCT Project in Kafue District|CIDRZ 1236 - Community-based Evaluation of a Pilot PMTCT Project in Kafue District: Impact of HAART to Prevent Pediatric AIDS in Rural Zambia.|Completed|||4129|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     Finger/Heel pricks will be performed for Dried Blood Spot Cards.~   "|||2018-06-01 01:45:36.683754|2018-06-01 01:45:36.683754
NCT00753415|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2014-03-19||2015-02-26|2008-09-15|2008-09-16|Estimate|2014-05-07|2014-06-03|Estimate||||2015-02-26|2015-03-17|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)|A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors|Completed||Phase 1|37|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-06-01 01:45:36.805753|2018-06-01 01:45:36.805753
NCT00753402|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2015-05-26|2008-09-15|2008-09-16|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Epi||The Effects of Epinephrine in Endotoxemia in Normal Volunteers|The Effects of Epinephrine in Endotoxemia in Normal Volunteers|Completed||Phase 1|37|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 01:45:38.23308|2018-06-01 01:45:38.23308
NCT00753389|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2008-09-15|2008-09-15|2008-09-16|Estimate|||||||2008-09-15|2008-09-16|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|March 2009|Anticipated|2009-03-31|||||Observational|PORC||Muscle Relaxants and Post-Anesthesia Complications|Epidemiologic Study on Short and Long-Term Effects of Anesthesia With Muscle Relaxants (Epidemiologische Untersuchung Kurz- Und längerfristiger Auswirkungen Der Anästhesie Mit Muskelrelaxanzien)|Unknown status|Recruiting||20000|Anticipated|Technische Universität München|||1||f||||||||||||||2018-06-01 01:45:38.31306|2018-06-01 01:45:38.31306
NCT00753363|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2014-10-15||2017-10-27|2008-09-12|2008-09-16|Estimate|2014-12-16|2014-12-22|Estimate||||2017-10-27|2017-12-04|Actual|April 1, 2007|Actual|2007-04-01|October 2017|2017-10-31|November 29, 2018|Anticipated|2018-11-29|November 29, 2012|Actual|2012-11-29||Interventional|IRIS||Exercise and Inflammation in the Elderly|Exercise, Inflammation and Pro-thrombotic Modulators in the Elderly|Active, not recruiting||N/A|119|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-06-01 01:45:38.393573|2018-06-01 01:45:38.393573
NCT00753350|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2013-03-01|2008-09-15|2008-09-16|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SENSATE||METHOD (Minimally Invasive, Endoscopically-delivered, Tolerable by Human Individuals, Non-morbid Obesity Device) Study|An Open-label, Single-center, Feasibility Study Designed to Evaluate the Safety and Tolerability of Sensate™ Anchored Gastric Device in Subjects With Non-morbid Obesity|Completed||Phase 1|15|Actual|Sensate LLC||1|||f||||f||||||||||2018-06-01 01:45:38.69311|2018-06-01 01:45:38.69311
NCT00753337|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2012-02-10||2016-03-07|2008-09-15|2008-09-16|Estimate|2013-11-07|2013-12-30|Estimate||||2016-03-07|2016-04-04|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|September 2013|Actual|2013-09-30|February 2011|Actual|2011-02-28||Interventional|ACTIVE||The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study|The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study Using the Medtronic Assurant Cobalt Iliac Balloon-Expandable Stent System|Completed||N/A|123|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 01:45:38.77668|2018-06-01 01:45:38.77668
NCT00753324|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2016-03-25|2008-09-15|2008-09-16|Estimate|||||||2016-03-25|2016-03-29|Estimate|May 2009||2009-05-31|March 2016|2016-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia|Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia).|Completed||Phase 4|284|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 01:45:39.043129|2018-06-01 01:45:39.043129
NCT00753142|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2014-07-07||2014-07-07|2008-09-15|2008-09-16|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|March 2004||2004-03-31|July 2014|2014-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises|Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises|Completed||N/A|28|Actual|Emory University||3|||f||||t||||||||||2018-06-01 01:45:43.207509|2018-06-01 01:45:43.207509
NCT00753311|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2011-10-07|2008-09-15|2008-09-16|Estimate|||||||2011-10-07|2011-10-12|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Interventional|||Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.|A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms.|Completed||Phase 4|80|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-06-01 01:45:39.111491|2018-06-01 01:45:39.111491
NCT00753298|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2009-04-06||2012-09-27|2008-09-15|2008-09-16|Estimate|2009-04-06|2009-06-02|Estimate||||2012-09-27|2012-10-04|Estimate|January 2007||2007-01-31|September 2012|2012-09-30||||March 2008|Actual|2008-03-31||Interventional|||A Randomized, Fully-blinded Parallel Groups Study of Catheter Materials Used for Clean Intermittent Catheterisation|A Multi-centre, Double-blind, Randomized, Parallel Groups Study Comparing PVC and Polyolefin-based Elastomer (POBE) as Catheter Materials, Outcomes Will be Measured by Subject Perception.|Completed||N/A|195|Actual|Wellspect HealthCare||2|||f||||f||||||||||2018-06-01 01:45:39.183429|2018-06-01 01:45:39.183429
NCT00753285|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12||2014-09-15|2014-11-03|2008-09-15|2008-09-16|Estimate||||2014-09-15|2014-09-29|Estimate|2014-11-03|2014-11-10|Estimate|September 2008||2008-09-30|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Renal Denervation in Patients With Refractory Hypertension|Renal Denervation in Patients With Refractory Hypertension|Completed||N/A|35|Actual|Medtronic Vascular||1|||f||||f||||||||||2018-06-01 01:45:39.589408|2018-06-01 01:45:39.589408
NCT00753272|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2012-04-26|2010-07-02|2017-08-23|2008-09-12|2008-09-16|Estimate|2012-05-17|2012-06-19|Estimate|2010-07-02|2010-07-07|Estimate|2017-08-23|2017-09-21|Actual|September 15, 2008|Actual|2008-09-15|August 2017|2017-08-31|January 5, 2011|Actual|2011-01-05|June 18, 2010|Actual|2010-06-18||Interventional|||Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older|Observer-blind Superior Efficacy Trial With GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects|Completed||Phase 3|43695|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:45:39.730953|2018-06-01 01:45:39.730953
NCT00753259|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2010-04-19|2008-09-15|2008-09-16|Estimate|||||||2010-04-19|2010-04-20|Estimate|June 2006||2006-06-30|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|AFClinic||Atrial Fibrillation (AF) Clinic to Improve the Treatment of Patients With Atrial Fibrillation.|The Effect of a Nurse-driven ICT-supported Disease Management Program to Improve the Treatment of Patients With Atrial Fibrillation.|Completed||N/A|712|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:45:42.287824|2018-06-01 01:45:42.287824
NCT00753246|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2012-11-30|2008-09-15|2008-09-16|Estimate|||||||2012-11-30|2012-12-03|Estimate|August 2007||2007-08-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|||||Interventional|||Nimotuzumab in Adults With Glioblastoma Multiforma|Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV|Completed||Phase 3|150|Anticipated|Oncoscience AG||2|||f||||t||||||||||2018-06-01 01:45:42.380443|2018-06-01 01:45:42.380443
NCT00753233|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2017-06-30|2008-09-15|2008-09-16|Estimate|||||||2017-06-30|2017-07-02|Actual|September 5, 2008||2008-09-05|January 25, 2012|2012-01-25|January 25, 2012||2012-01-25|||||Observational|||Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy|Long Term Follow Up of Children and Adolescents Diagnosed With Hypertrophic Cardiomyopathy: Identification of Risk Factors That Predict Arrhythmia Events|Completed|||145|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:45:42.478993|2018-06-01 01:45:42.478993
NCT00753220|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2013-07-25||2014-11-03|2008-09-15|2008-09-16|Estimate|2014-11-03|2014-11-04|Estimate||||2014-11-03|2014-11-04|Estimate|August 2009||2009-08-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|CRITICAL||Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer|A Phase I/IIa Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy With Autologous Immature Dendritic Cells (VDC2008) in Chemo-naïve Men With Prostatic Adenocarcinoma and Limited Metastases to Lymph Nodes and/or Bone|Terminated||Phase 1/Phase 2|7|Actual|Bostwick Laboratories||1||Withdrew the IND with the FDA.|f||||f||||||||||2018-06-01 01:45:42.565636|2018-06-01 01:45:42.565636
NCT00753207|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-13|||2016-02-12|2008-09-13|2008-09-16|Estimate|||||||2016-02-12|2016-02-15|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|November 2008|Actual|2008-11-30||Interventional|||Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30|An Open-Label Phase I Study of Fixed Dose Lapatinib in Combination With an Escalating Dose of Epirubicin in Metastatic Breast Cancer|Completed||Phase 1|10|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 01:45:42.741067|2018-06-01 01:45:42.741067
NCT00753194|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2008-09-15|2008-09-15|2008-09-16|Estimate|||||||2008-09-15|2008-09-16|Estimate|March 2005||2005-03-31|September 2008|2008-09-30|January 2007|Actual|2007-01-31|March 2006|Actual|2006-03-31||Observational|NHS||False Positive Results in Newborn Hearing Screening|False-Positive Results in Newborn Hearing Screening: Possible Causes|Completed|||1110|Actual|Federal University of São Paulo|||2||f||||f||||||||||2018-06-01 01:45:42.915312|2018-06-01 01:45:42.915312
NCT00753181|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2009-04-24|2008-09-12|2008-09-16|Estimate|||||||2009-04-24|2009-04-27|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes|Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes|Completed||Phase 3|60|Actual|Abbott Nutrition||3|||f||||f||||||||||2018-06-01 01:45:42.982307|2018-06-01 01:45:42.982307
NCT00753168|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2009-01-06|2008-09-15|2008-09-16|Estimate|||||||2009-01-06|2009-01-07|Estimate|September 2008||2008-09-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma|A Randomized, Parallel-Group, Multi-Center, Investigator-Masked, Active-and Placebo-Controlled, Phase 1-2 Evaluation of the Safety and Efficacy of OT-730 Ophthalmic Solution in Reducing the Intraocular Pressure in Subjects With Ocular Hypertension or Open-Angle Glaucoma|Completed||Phase 1/Phase 2|48|Anticipated|Othera Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:45:43.069295|2018-06-01 01:45:43.069295
NCT00753155|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2008-09-15|2008-09-15|2008-09-16|Estimate|||||||2008-09-15|2008-09-16|Estimate|January 2002||2002-01-31|September 2008|2008-09-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|Ergo-LTx||Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Lung Transplantation (Ergo-LTx)|Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Lnug Transplantation|Unknown status|Active, not recruiting|N/A|89|Actual|Hannover Medical School|||||f||||t||||||||||2018-06-01 01:45:43.154591|2018-06-01 01:45:43.154591
NCT00753129|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2010-05-03|2008-09-15|2008-09-16|Estimate|||||||2010-05-03|2010-05-04|Estimate|October 2008||2008-10-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Head Elevation in Prone Position|Influence of Head Elevation in Prone Position on Gas Exchange and Lung Mechanics in Patients With ALI/ARDS|Completed||Phase 2|20|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:45:43.484604|2018-06-01 01:45:43.484604
NCT00753116|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2012-11-02|2008-09-15|2008-09-16|Estimate|||||||2012-11-02|2012-11-06|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension|Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension|Completed||Phase 1|20|Anticipated|Medtronic Vascular|||||f||||t||||||||||2018-06-01 01:45:43.542912|2018-06-01 01:45:43.542912
NCT00753103|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2008-09-15|2008-09-15|2008-09-16|Estimate|||||||2008-09-15|2008-09-16|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|ACTIVE||Anti-Cytokine Therapy for Vasculitis|Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis|Completed||Phase 2|37|Actual|University Hospital Birmingham NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:45:43.595374|2018-06-01 01:45:43.595374
NCT00753090|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2017-03-06|2008-09-15|2008-09-16|Estimate|||||||2017-03-06|2017-03-09|Actual|June 2009||2009-06-30|March 2017|2017-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Vanguard™ Deep Dish Rotating Platform Knee Clinical Evaluation|Vanguard™ Deep Dish Rotating Platform Knee Clinical Evaluation|Active, not recruiting||N/A|329|Actual|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-06-01 01:45:43.691662|2018-06-01 01:45:43.691662
NCT00753077|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-14|||2011-09-02|2008-09-15|2008-09-16|Estimate|||||||2011-09-02|2011-09-05|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||Three Dimensional Morphology of Upper Respiratory Tract and Mandibular Position on Obstructive Sleep Apnea||Completed|||20|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:45:43.778599|2018-06-01 01:45:43.778599
NCT00753064|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-14|||2008-09-15|2008-09-15|2008-09-16|Estimate|||||||2008-09-15|2008-09-16|Estimate|September 2006||2006-09-30|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||AScVS and/ or Prazosin for Scorpion Envenomation|Comparative Study of Efficacy of Antiscorpion Venom Serum(AScVS)vs Prazosin in the Management of Severe Scorpion(Mesobuthus Tamulus Concanesis Pocock)Envenomation and Evaluation of Effects of the Combination of AScVS + Prazosin Therapy.|Completed||Phase 3|81|Actual|Haffkine Bio-Pharmaceutical Corporation Ltd.||3|||f||||f||||||||||2018-06-01 01:45:43.826759|2018-06-01 01:45:43.826759
NCT00753051|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2012-05-04|2008-09-15|2008-09-16|Estimate|||||||2012-05-04|2012-05-07|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|TCRS||Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)|Treatment of Clozapine-resistant Schizophrenia : Comparison Between Augmentation With Haloperidol and Electroconvulsive Therapy|Completed||N/A|18|Actual|Khon Kaen University||2|||f||||f||||||||||2018-06-01 01:45:43.911349|2018-06-01 01:45:43.911349
NCT00753038|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2014-11-03|2008-09-12|2008-09-16|Estimate|||||||2014-11-03|2014-11-04|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|May 2013|Actual|2013-05-31|July 2011|Actual|2011-07-31||Interventional|||Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma|Phase 2 Study of Intravenous Administration of a Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck.|Completed||Phase 2|14|Actual|Oncolytics Biotech|||||f||||f||||||||||2018-06-01 01:45:44.146202|2018-06-01 01:45:44.146202
NCT00753025|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2008-09-15|2008-09-15|2008-09-16|Estimate|||||||2008-09-15|2008-09-16|Estimate|October 2006||2006-10-31|September 2008|2008-09-30|February 2008|Actual|2008-02-29|June 2007|Actual|2007-06-30||Interventional|||Autologous Bone Marrow For Lower Extremity Ischemia Treating|Randomized Double Blind Placebo-Controlled Research Of Treatment Efficiency For Patients With Lower Extremity Arteriosclerosis Obliterans By Autologous Transplantation Of Bone Marrow Progenitor Cells|Completed||Phase 2|42|Actual|Clinical Center of Cellular Technologies, Russia||3|||f||||t||||||||||2018-06-01 01:45:44.238551|2018-06-01 01:45:44.238551
NCT00753012|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2012-05-02||2012-08-22|2008-09-15|2008-09-16|Estimate|2012-08-22|2012-09-24|Estimate||||2012-08-22|2012-09-24|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults|An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 4|24|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:45:44.327992|2018-06-01 01:45:44.327992
NCT00752999|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2012-04-26|2008-09-15|2008-09-16|Estimate|||||||2012-04-26|2012-04-30|Estimate|November 2008||2008-11-30|April 2012|2012-04-30|March 2010|Anticipated|2010-03-31|November 2009|Anticipated|2009-11-30||Interventional|SOLEIL||Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus Patients With Active Disease|Withdrawn||Phase 2|0|Actual|Rigel Pharmaceuticals||2||Study was withdrawn for business reasons before study start.|f||||t||||||||||2018-06-01 01:45:44.691093|2018-06-01 01:45:44.691093
NCT00752986|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2014-09-15|2011-03-28|2016-10-11|2008-09-15|2008-09-16|Estimate|2014-10-02|2014-10-06|Estimate|2011-04-20|2011-04-28|Estimate|2016-10-11|2016-12-05|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ZACFAST|No data were analyzed due to the premature study interruption and sample of patients was too low.|ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial|A Randomized,Double-blind,Parallel-group,Multicentre,Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/Daily or Placebo)With Fulvestrant (Loading Dose)in Postmenopausal Advanced BC Patients|Terminated||Phase 2|39|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:45:44.802958|2018-06-01 01:45:44.802958
NCT00752973|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|2014-02-19||2014-07-14|2008-09-15|2008-09-16|Estimate|2014-02-19|2014-04-03|Estimate||||2014-07-14|2014-08-07|Estimate|September 2008||2008-09-30|July 2014|2014-07-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice|Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis|Completed||Phase 2/Phase 3|12|Actual|Taro Pharmaceuticals USA||1|||f||||f||||||||||2018-06-01 01:45:45.362219|2018-06-01 01:45:45.362219
NCT00752960|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2008-09-12|2008-09-12|2008-09-16|Estimate|||||||2008-09-12|2008-09-16|Estimate|January 2007||2007-01-31|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|DIMS||DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics|DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics|Unknown status|Recruiting||1000|Anticipated|Genomas, Inc|||5||f||||f||||||Samples With DNA|"~     DNA extracted from whole blood~   "|||2018-06-01 01:45:45.576802|2018-06-01 01:45:45.576802
NCT00752947|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2009-03-10|2008-09-15|2008-09-16|Estimate|||||||2009-03-10|2009-03-11|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|May 2010|Anticipated|2010-05-31|March 2010|Anticipated|2010-03-31||Interventional|||Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors|Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors|Unknown status|Recruiting|Phase 4|186|Anticipated|Beijing Hospital||2|||f||||t||||||||||2018-06-01 01:45:45.669644|2018-06-01 01:45:45.669644
NCT00752934|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2011-04-17|2008-09-15|2008-09-16|Estimate|||||||2011-04-17|2011-04-19|Estimate|October 2010||2010-10-31|September 2008|2008-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes?||Unknown status|Recruiting|Phase 4|20|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-06-01 01:45:45.765974|2018-06-01 01:45:45.765974
NCT00752921|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2008-09-15|2008-09-15|2008-09-16|Estimate|||||||2008-09-15|2008-09-16|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache|Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 01:45:45.851125|2018-06-01 01:45:45.851125
NCT00752908|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2012-04-10|2008-09-15|2008-09-16|Estimate|||||||2012-04-10|2012-04-11|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Tissue Penetration of Antibiotics in Obesity|Tissue Penetration of Antibiotics in Obesity|Completed|||30|Actual|Washington University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     plasma, interstitial fluid~   "|||2018-06-01 01:45:45.954443|2018-06-01 01:45:45.954443
NCT00752895|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-13|2015-09-28||2017-06-21|2008-09-13|2008-09-16|Estimate|2015-09-28|2015-11-02|Estimate||||2017-06-21|2017-08-04|Actual|September 2008||2008-09-30|June 2017|2017-06-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional||All randomized participants|American Ginseng Extract in Preventing Respiratory Infection and in Reducing Antibiotic Use in Patients With CLL|A Randomized, Double-Blind, Placebo Controlled Trial of North American Ginseng Extract (CVT-E002; COLD-fX®) to Prevent Respiratory Infection and Reduce Antibiotic Use in Patients With Chronic Lymphocytic Leukemia|Completed||N/A|293|Actual|Wake Forest University Health Sciences||2|||f||||t|f|f||||||No||2018-06-01 01:45:46.052313|2018-06-01 01:45:46.052313
NCT00752882|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2011-01-18|2008-09-15|2008-09-16|Estimate|||||||2011-01-18|2011-01-19|Estimate||||January 2011|2011-01-31|June 2009|Anticipated|2009-06-30|||||Interventional|||Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration|Comparison of Ceftazidime Pharmacokinetic in Cerebrospinal Fluid Between Continuous and Intermittent Administration|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:45:46.723354|2018-06-01 01:45:46.723354
NCT00752869|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-15|||2013-02-25|2008-09-15|2008-09-16|Estimate|||||||2013-02-25|2013-02-26|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DUT/T||Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement|"Dutasteride in Men Receiving Testosterone Therapy: Impact on Serum PSA, Testosterone, DHT Levels and Prostate Volume: Implications for Prostate Safety"|Completed||Phase 4|24|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-06-01 01:45:46.798813|2018-06-01 01:45:46.798813
NCT00752856|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-13|||2014-03-31|2008-09-15|2008-09-16|Estimate|||||||2014-03-31|2014-04-02|Estimate|September 2008||2008-09-30|March 2014|2014-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients|Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients|Completed||Phase 2|50|Actual|California Collaborative Treatment Group||2|||f||||t||||||||||2018-06-01 01:45:46.904518|2018-06-01 01:45:46.904518
NCT00752843|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2012-02-15|2008-09-15|2008-09-16|Estimate|||||||2012-02-15|2012-02-17|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers|A Phase I, Open-Label, Fixed-Sequence Study to Determine the Effect of Single and Multiple Oral Doses of CORLUX (TM) (Mifepristone) on the Pharmacokinetics of a Single Oral Dose of Fluvastatin (a CYP2C9 Probe) in Healthy Volunteers|Completed||Phase 1|20|Actual|Corcept Therapeutics||1|||f||||t||||||||||2018-06-01 01:45:47.011199|2018-06-01 01:45:47.011199
NCT00752830|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2008-10-28|2008-09-12|2008-09-15|Estimate|||||||2008-10-28|2008-10-29|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328|A Phase I, Open, Randomized, Single-Dose, Two-Treatment (Fed Versus Fasting), Two-Period Cross-Over Single-Centre Study to Evaluate the Effect of Food on the Pharmacokinetics of AZD0328 Following Oral Administration (Capsule) in Healthy Male Subjects|Completed||Phase 1|14|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:45:47.102003|2018-06-01 01:45:47.102003
NCT00752817|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2008-10-06|2008-09-12|2008-09-15|Estimate|||||||2008-10-06|2008-10-07|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|LAC||Creating a Proficiency-Based Virtual Reality Simulation Training Programme for Laparoscopic Assisted Colectomy|Creating and Implementing a Proficiency-Based Progression Virtual Reality Training Programme for Higher Surgical Trainees for Laparoscopic Assisted Sigmoid Colectomy.|Unknown status|Recruiting|N/A|16|Anticipated|Royal College of Surgeons, Ireland||2|||f||||t||||||||||2018-06-01 01:45:47.237441|2018-06-01 01:45:47.237441
NCT00752804|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2015-06-02|2008-09-12|2008-09-15|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Uremic Toxins in the ICU: Patients After Cardiac Surgery|Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients After Cardiac Surgery|Unknown status|Recruiting|N/A|12|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 01:45:47.403183|2018-06-01 01:45:47.403183
NCT00752791|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2012-04-16||2012-08-13|2008-09-12|2008-09-15|Estimate|2012-08-13|2012-08-15|Estimate||||2012-08-13|2012-08-15|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.|A Phase 2 Study of the Safety and Efficacy of Hematide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin|Completed||Phase 2|59|Actual|Takeda||1|||f||||f||||||||||2018-06-01 01:45:47.513837|2018-06-01 01:45:47.513837
NCT00752778|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2012-11-09|2008-09-12|2008-09-15|Estimate|||||||2012-11-09|2012-11-12|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri|MRI Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri|Terminated||Phase 4|8|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 01:45:47.875345|2018-06-01 01:45:47.875345
NCT00752765|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2015-06-02|2008-09-12|2008-09-15|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2008||2008-09-30|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee|The Effects of Bariatric Surgery Weight Loss on Knee Pain in Patients With Osteoarthritis of the Knee|Completed|||30|Anticipated|Penn State University|||||f||||t||||||||||2018-06-01 01:45:47.962043|2018-06-01 01:45:47.962043
NCT00752752|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2012-04-02|2008-09-12|2008-09-15|Estimate|||||||2012-04-02|2012-04-03|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|MARATHON-MRI||The Acute Cardiovascular Effects of Marathon Running Using Magnetic Resonance Imaging|The Acute Cardiovascular Effects of Marathon Running Using Magnetic Resonance Imaging|Completed|||25|Actual|William Beaumont Hospitals|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:45:48.043608|2018-06-01 01:45:48.043608
NCT00752739|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2012-08-13|2008-09-12|2008-09-15|Estimate|||||||2012-08-13|2012-08-15|Estimate|August 2002||2002-08-31|August 2012|2012-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Selenium in Treating Patients With Prostate Cancer|Phase II Chemoprevention Trial of Selenium and Prostate Cancer (Watchful Waiting With Selenium Trial)|Completed||Phase 2|220|Anticipated|University of Arizona||3|||f||||||||||||||2018-06-01 01:45:48.109648|2018-06-01 01:45:48.109648
NCT00752726|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2010-07-21||2013-02-28|2008-09-12|2008-09-15|Estimate|2013-01-04|2013-02-07|Estimate||||2013-02-28|2013-03-08|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Orlistat in Body Composition|The Effects of Weight Reduction With Orlistat vs. Placebo on Changes in Body Composition|Completed||Phase 4|131|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:45:48.217767|2018-06-01 01:45:48.217767
NCT00752713|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2008-09-15|2008-09-12|2008-09-15|Estimate|||||||2008-09-15|2008-09-16|Estimate|January 2007||2007-01-31|September 2008|2008-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|137-2005||Strain-Encoded Magnetic Resonance Imaging in Acute Myocardial Infarction|Strain-Encoded Magnetic Resonance Imaging for Evaluation of Left Ventricular Function and Acute Myocardial Infarction|Completed|||48|Actual|RWTH Aachen University|||2||f||||f||||||||||2018-06-01 01:45:48.657722|2018-06-01 01:45:48.657722
NCT00752700|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2014-12-04|2008-09-12|2008-09-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|REINFORCE||Resistance Exercise Training For Radically Treated Respiratory Cancer|Resistance Training in Radically Treated Respiratory Cancer Patients: a Prospective Randomized Multicenter Study|Completed||N/A|113|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 01:45:48.724019|2018-06-01 01:45:48.724019
NCT00752687|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2010-10-19|2008-09-12|2008-09-15|Estimate|||||||2010-10-19|2010-10-21|Estimate|September 2008||2008-09-30|September 2010|2010-09-30||||May 2009|Actual|2009-05-31||Interventional|||A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults||Completed||Phase 1|100|Actual|Abbott||2|||f||||||||||||||2018-06-01 01:45:48.795705|2018-06-01 01:45:48.795705
NCT00752674|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2008-09-11|2008-09-11|2008-09-15|Estimate|||||||2008-09-11|2008-09-15|Estimate|August 2006||2006-08-31|September 2008|2008-09-30|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||Neuromuscular Balance in Low Back Pain|The Effectiveness of Neuromuscular Balance in Low Back Pain|Completed||Phase 4|12|Actual|Fortaleza University||1|||f||||t||||||||||2018-06-01 01:45:48.849943|2018-06-01 01:45:48.849943
NCT00752661|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-05-16|2008-09-12|2008-09-15|Estimate|||||||2011-05-16|2011-05-17|Estimate|June 2007||2007-06-30|August 2010|2010-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain|An Exploratory Study of an Active Ingredient of JNS013-tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back Pain|Completed||Phase 2|119|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 01:45:48.909084|2018-06-01 01:45:48.909084
NCT00752648|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2010-04-26|2008-09-12|2008-09-15|Estimate|||||||2010-04-26|2010-04-28|Estimate|July 2008||2008-07-31|April 2010|2010-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule|A Phase I, Open-label, 3-way Crossover Trial in Healthy Subjects to Compare the Bioavailability of a Single Oral Dose of TMC435350 Formulated as 2 Different Solid Formulations to That of a Single Oral Dose of TMC435350 Formulated as a Powder Blend Capsule.|Completed||Phase 1|24|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:45:48.958295|2018-06-01 01:45:48.958295
NCT00752635|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-05-18|2008-09-12|2008-09-15|Estimate|||||||2011-05-18|2011-05-19|Estimate|September 2004||2004-09-30|April 2010|2010-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris|Comparison of Efficacy and Safety of Tricilest (Norgestimate-ethinyl Estradiol) and Diane-35 (Cyproterone Acetate-ethinyl Estradiol) in the Treatment of Acne Vulgaris|Completed||Phase 4|48|Actual|Johnson & Johnson Taiwan Ltd|||||f||||||||||||||2018-06-01 01:45:49.005759|2018-06-01 01:45:49.005759
NCT00752622|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2011-06-23||2017-03-16|2008-09-12|2008-09-15|Estimate|2011-06-23|2011-07-22|Estimate||||2017-03-16|2017-04-13|Actual|November 2008||2008-11-30|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|OPTIMIST||Treatment With Infliximab in a Medical Setting (Study P05587)|Optimization of Treatment With Infliximab in a Medical Setting|Terminated||Phase 4|100|Actual|Merck Sharp & Dohme Corp.|Due to early study termination, no statistical analysis was performed for the interventional part of this study, therefore, endpoints dedicated to this phase of the study have not been analyzed.|2||"Factors that led to termination: recruitment challenges and a lower incidence of flares than~   estimated, causing a high risk of the study being underpowered."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:45:49.074463|2018-06-01 01:45:49.074463
NCT00752609|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2012-04-16||2012-06-26|2008-09-12|2008-09-15|Estimate|2012-06-26|2012-07-27|Estimate||||2012-06-26|2012-07-27|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.|A Phase 2 Study of the Safety and Efficacy of Hematide Injection for the Maintenance Treatment of Anemia in Subjects With Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa|Completed||Phase 2|102|Actual|Takeda||1|||f||||f||||||||||2018-06-01 01:45:49.505918|2018-06-01 01:45:49.505918
NCT00752596|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2017-01-31|2008-09-12|2008-09-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2005||2005-09-30|January 2017|2017-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Compassionate Use Study of 125 mg Per Day of Azimilide Dihydrochloride in One Patient|Compassionate Use Study to Assess the Long Term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in One Patient Following Termination of the SHIELD Open-label Study 2001060|Completed||Phase 2|1|Actual|Forest Laboratories||1|||f||||f||||||||||2018-06-01 01:45:50.725462|2018-06-01 01:45:50.725462
NCT00752583|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2014-12-04|2008-09-12|2008-09-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Peritoneal Dialysis Versus Haemodialysis|Clinical Study in Order to Quantify Solute Removal in Peritoneal Dialysis Versus Haemodialysis|Unknown status|Recruiting|N/A|75|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:45:51.037523|2018-06-01 01:45:51.037523
NCT00752570|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11||2015-07-13|2015-08-14|2008-09-12|2008-09-15|Estimate||||2015-07-13|2015-08-03|Estimate|2015-08-14|2015-09-02|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|June 2012|Actual|2012-06-30|September 2010|Actual|2010-09-30||Interventional|||A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma|A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma|Completed||Phase 2|144|Actual|Amgen||2|||f||||||||||||||2018-06-01 01:45:51.346584|2018-06-01 01:45:51.346584
NCT00752557|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2015-06-15|2008-09-12|2008-09-15|Estimate|||||||2015-06-15|2015-06-16|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD|A Phase 2, Multicenter, Randomized, Active-controlled, Parallel-group, Dose-finding And Safety Study Of Recombinant Human Bone Morphogenetic Protein-2 (Rhbmp-2)/Calcium Phosphate Matrix (Cpm) In Subjects With Decreased Bone Mineral Density|Completed||Phase 2|50|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 01:45:51.619592|2018-06-01 01:45:51.619592
NCT00752544|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2010-04-26|2008-09-12|2008-09-15|Estimate|||||||2010-04-26|2010-04-28|Estimate|August 2008||2008-08-31|April 2010|2010-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male Volunteers|Phase I, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Ascending Oral Doses of TMC435350 After Single and Repeated Dosing in Healthy Japanese Male Subjects|Completed||Phase 1|30|Actual|Tibotec Pharmaceuticals, Ireland|||||||||||||||||||2018-06-01 01:45:51.806719|2018-06-01 01:45:51.806719
NCT00752531|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2013-03-21|2008-09-11|2008-09-15|Estimate|||||||2013-03-21|2013-03-25|Estimate|December 2003||2003-12-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Home Automated Telemanagement in Chronic Obstructive Pulmonary Disorder|Evaluation of Home Automated Telemanagement in COPD|Completed||N/A|280|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:45:51.877026|2018-06-01 01:45:51.877026
NCT00752518|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-05-16|2008-09-12|2008-09-15|Estimate|||||||2011-05-16|2011-05-17|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|January 2006|Actual|2006-01-31|||||Interventional|||A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients|A Phase I/II Study of JNJ-26866138 (Bortezomib) in Japanese Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|35|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 01:45:51.95842|2018-06-01 01:45:51.95842
NCT00752505|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12||2011-06-07|2011-06-07|2008-09-12|2008-09-15|Estimate||||2011-06-07|2011-06-21|Estimate|2011-06-07|2011-06-21|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia.|A Phase 2 Randomized Double-Blind Placebo-Controlled Crossover Study Assessing The Ability Of Esreboxetine (PNU-165442g) To Improve Cognitive Function In Fibromyalgia Patients.|Completed||Phase 2|89|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:45:52.018151|2018-06-01 01:45:52.018151
NCT00752492|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2011-04-19|2008-09-12|2008-09-15|Estimate|||||||2011-04-19|2011-04-20|Estimate|September 2008||2008-09-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional|||Acceleration of Recovery From General Anesthesia - Efficacy of Isocapnic Hyperpnoea in Obese Patients Undergoing Isoflurane Anesthesia|Acceleration of Recovery From General Anesthesia - Efficacy of Isocapnic Hyperpnoea in Obese Patients Undergoing Isoflurane Anesthesia|Completed||N/A|44|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 01:45:52.119018|2018-06-01 01:45:52.119018
NCT00752479|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2015-04-08|2008-09-12|2008-09-15|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance|Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance|Terminated||Phase 1/Phase 2|4|Actual|Mario Negri Institute for Pharmacological Research||2||Necessity of major revision of the protocol|f||||f||||||||||2018-06-01 01:45:52.190501|2018-06-01 01:45:52.190501
NCT00752466|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-05-17|2008-09-12|2008-09-15|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2003||2003-03-31|April 2010|2010-04-30|March 2004|Actual|2004-03-31|||||Interventional|||A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately|A Drug Interaction Study of the Pharmacokinetics of Flunarizine and Topiramate (RWJ-17021-000) During Mono- and Concomitant Therapy|Completed||Phase 1|75|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:45:52.275366|2018-06-01 01:45:52.275366
NCT00752453|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2015-06-02|2008-09-12|2008-09-15|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Uremic Toxins in the Intensive Care Units (ICU): Patients With Lactate Acidosis|Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Lactate Acidosis|Unknown status|Recruiting|N/A|12|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 01:45:52.331587|2018-06-01 01:45:52.331587
NCT00752440|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2008-09-15|2008-09-12|2008-09-15|Estimate|||||||2008-09-15|2008-09-16|Estimate|August 2006||2006-08-31|September 2008|2008-09-30|July 2009|Anticipated|2009-07-31|November 2008|Anticipated|2008-11-30||Interventional|||Inspiratory Muscle Training in Patients With Autonomic Neuropathic|Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial|Unknown status|Recruiting|Phase 4|24|Anticipated|Instituto de Cardiologia do Rio Grande do Sul|||||f||||t||||||||||2018-06-01 01:45:52.395545|2018-06-01 01:45:52.395545
NCT00752427|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-06-06|2008-09-11|2008-09-15|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 2004||2004-06-30|April 2010|2010-04-30|November 2005|Actual|2005-11-30|||||Interventional|||24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia|R076477-SCH-702: a 24 Week Open-Label Extension to R076477-SCH-302|Completed||Phase 3|86|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:45:52.455143|2018-06-01 01:45:52.455143
NCT00752414|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2018-01-17|2008-09-12|2008-09-15|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2008||2008-07-31|January 2018|2018-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients|Phase 1b, Randomized, Single-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Administered for 5 Days to Chronic Bronchitis Patients|Completed||Phase 1|21|Actual|Horizon Pharma USA, Inc.||2|||f||||f||||||||||2018-06-01 01:45:52.503597|2018-06-01 01:45:52.503597
NCT00752401|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2014-01-20|2008-09-11|2008-09-15|Estimate|||||||2014-01-20|2014-01-22|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|VITA-D||Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients|VITA-D: Cholecalciferol Substitution in Vitamin D Deficient Kidney Transplant Recipients: A Randomized, Placebo-controlled Study to Evaluate the Posttransplant Outcome|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:45:52.570264|2018-06-01 01:45:52.570264
NCT00752388|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2013-11-18|2008-09-12|2008-09-15|Estimate|||||||2013-11-18|2013-11-19|Estimate|November 2008||2008-11-30|November 2013|2013-11-30||||November 2008|Actual|2008-11-30||Observational|||Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease|Application of the WHO-5 Well-being Index (WHO-5) as a Screening Instrument for Depression in Parkinson's Disease|Completed|||1588|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:45:52.67165|2018-06-01 01:45:52.67165
NCT00752375|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2015-01-14|2008-09-12|2008-09-15|Estimate|||||||2015-01-14|2015-01-16|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Antibiotic Prophylaxis in Children With Pyelonephritis|A Randomized Controlled Trial of Antibiotic Prophylaxis in Children With Pyelonephritis in the Abscence of Vesicoureteral Reflux|Withdrawn||Phase 3|0|Actual|University of Alberta||2||No participants|f||||f||||||||||2018-06-01 01:45:53.185398|2018-06-01 01:45:53.185398
NCT00752362|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2015-11-19|2008-09-12|2008-09-15|Estimate|||||||2015-11-19|2015-11-20|Estimate|March 2006||2006-03-31|November 2015|2015-11-30||||May 2008|Actual|2008-05-31||Interventional|||Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT)|PercutAneous INTervention With Biodegradable- Polymer Based Paclitaxel-eluting, Sirolimus-eluting, or Bare Stents for the Treatment of de Novo Coronary Lesions.|Completed||Phase 4|280|Actual|Sahajanand Medical Technologies Pvt. Ltd.||3|||f||||t||||||||||2018-06-01 01:45:53.266711|2018-06-01 01:45:53.266711
NCT00752349|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-12|2008-09-12|2008-09-15|Estimate|||||||2008-09-12|2008-09-15|Estimate||||September 2008|2008-09-30||||||||Expanded Access|||To Evaluate Oral Phase Swallowing Function Using Submental Ultrasound|To Evaluate Oral Phase Swallowing Function Using Submental Ultrasound|Available|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 01:45:54.388155|2018-06-01 01:45:54.388155
NCT00752336|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2008-09-12|2008-09-12|2008-09-15|Estimate|||||||2008-09-12|2008-09-15|Estimate|January 2002||2002-01-31|September 2008|2008-09-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|Ergo-HTx||Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation|Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation|Unknown status|Active, not recruiting|N/A|87|Actual|Hannover Medical School|||||f||||t||||||||||2018-06-01 01:45:54.567219|2018-06-01 01:45:54.567219
NCT00752323|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2018-03-02|2008-09-12|2008-09-15|Estimate|||||||2018-03-02|2018-03-06|Actual|August 18, 2008|Actual|2008-08-18|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma|Fluorescence-Guided Detection of Malignant Gliomas: A Dose Ranging Study Using 5-Aminolevulinic Acid (ALA) Induced Protoporphyrin (PpIX) in a Multicenter Phase II Clinical Trial|Recruiting||Phase 2|120|Anticipated|Case Comprehensive Cancer Center||4|||f||||t|t|f|||f|||||2018-06-01 01:45:54.700992|2018-06-01 01:45:54.700992
NCT00752310|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-06-08|2008-09-12|2008-09-15|Estimate|||||||2011-06-08|2011-06-09|Estimate|April 2008||2008-04-30|April 2010|2010-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet|A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects Receiving DRV Combined With RTV Low Dose to Compare the Oral Bioavailability of DRV Suspension to That of DRV 300 mg Tablet Under Fasted and Fed Conditions, and to Assess Multiple Dose Pharmacokinetics of the DRV Suspension|Completed||Phase 1|23|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:45:54.799269|2018-06-01 01:45:54.799269
NCT00752297|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10||2011-05-03|2011-09-01|2008-09-12|2008-09-15|Estimate||||2011-05-04|2011-05-06|Estimate|2011-09-01|2011-09-12|Estimate|June 2007||2007-06-30|September 2011|2011-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|PT-03a||Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows|"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Dose Pivotal Trial to Demonstrate the Safety and Efficacy of PurTox® for the Treatment of Glabellar Rhytides (Frown Lines)"|Completed||Phase 3|402|Actual|Mentor Worldwide, LLC||2|||f||||f||||||||||2018-06-01 01:45:54.857785|2018-06-01 01:45:54.857785
NCT00752284|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2008-12-05|2008-09-12|2008-09-15|Estimate|||||||2008-12-05|2008-12-08|Estimate|June 2006||2006-06-30|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|coronrct||Safety of Coronectomy vs Excision of Wisdom Teeth|Randomized Controlled Trial of Safety of Coronectomy Versus Excision of Wisdom Teeth|Completed||N/A|349|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:45:54.940576|2018-06-01 01:45:54.940576
NCT00752271|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2009-12-17|2008-09-11|2008-09-15|Estimate|||||||2009-12-17|2009-12-18|Estimate|May 2008||2008-05-31|December 2009|2009-12-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||AMS Study: Inflammatory and Biomechanical Contributors to Arthritis Development Following Arthroscopic Meniscectomy|Inflammatory and Biomechanical Contributors to Arthritis Development Following Arthroscopic Meniscectomy|Terminated|||32|Anticipated|National Institute on Aging (NIA)|||2||f||||f||||||||||2018-06-01 01:45:55.017212|2018-06-01 01:45:55.017212
NCT00752258|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11||2011-09-01|2011-09-01|2008-09-12|2008-09-15|Estimate||||2011-09-01|2011-09-12|Estimate|2011-09-01|2011-09-12|Estimate|February 2008||2008-02-29|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PT-03c||A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows|"A Phase III, Multi-Center, Long-Term, Repeat-Treatment, Open-Label, Single-Arm Trial to Demonstrate the Safety of Repeat Treatment With PurTox® for the Treatment of Glabellar Rhytides (Frown Lines)"|Completed||Phase 3|576|Actual|Mentor Worldwide, LLC||1|||f||||f||||||||||2018-06-01 01:45:55.121019|2018-06-01 01:45:55.121019
NCT00752245|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2015-06-02|2008-09-12|2008-09-15|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Uremic Toxins in the Intensive Care Unit (ICU): Patients With Sepsis|Study of the Kinetics of Uremic Toxins in the ICU Patients With Acute Renal Failure, in Order to Optimize the Dialysis Dose: Patients With Sepsis/Multi-organ Failure|Unknown status|Recruiting|N/A|12|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 01:45:55.230371|2018-06-01 01:45:55.230371
NCT00752232|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2014-05-09||2015-11-30|2008-09-12|2008-09-15|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease|A Phaseiia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease.|Completed||Phase 2|40|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 01:45:55.462172|2018-06-01 01:45:55.462172
NCT00752219|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2009-12-01|2008-09-11|2008-09-15|Estimate|||||||2009-12-01|2009-12-02|Estimate|March 2009||2009-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections|A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults|Completed||Phase 2|200|Anticipated|Novexel Inc||2|||f||||f||||||||||2018-06-01 01:45:58.71799|2018-06-01 01:45:58.71799
NCT00752206|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2018-05-09|2008-09-12|2008-09-15|Estimate|||||||2018-05-09|2018-05-11|Actual|March 2009|Actual|2009-03-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|||A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung|A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung|Completed||Phase 2|46|Actual|Sarcoma Alliance for Research through Collaboration||2|||f||||t||||||||||2018-06-01 01:45:59.132436|2018-06-01 01:45:59.132436
NCT00752193|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2015-06-03|2008-09-12|2008-09-15|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System.|Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System|Unknown status|Recruiting|N/A|206|Anticipated|University Ghent||2|||f||||f||||||||||2018-06-01 01:45:59.452699|2018-06-01 01:45:59.452699
NCT00752180|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2012-12-26|2008-09-12|2008-09-15|Estimate|||||||2012-12-26|2012-12-27|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics|A Single Dose,Single Centre,Double Blind,Crossover Study Comparing the Pharmacokinetic Profiles of Wockhardt's Insulin Human Injection, Soluble (Recombinant DNA Origin) for Injection and Actrapid in Type 1 Diabetics|Completed||Phase 1|28|Actual|Wockhardt||2|||f||||f||||||||||2018-06-01 01:45:59.755665|2018-06-01 01:45:59.755665
NCT00752167|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2016-05-10|2008-09-12|2008-09-15|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2007||2007-02-28|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes|Diagnosis of EIB and Asthma in NCAA Division I Athletes|Completed|||74|Actual|University of Arizona|||2||f||||f||||||||No||2018-06-01 01:46:00.020951|2018-06-01 01:46:00.020951
NCT00752154|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2010-07-01|2008-09-12|2008-09-15|Estimate|||||||2010-07-01|2010-07-02|Estimate|January 2010||2010-01-31|September 2008|2008-09-30|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|||Curcumin in Rheumatoid Arthritis|Curcumin in Rheumatoid Arthritis - ACross-Over Pilot Study|Unknown status|Recruiting|Early Phase 1|40|Anticipated|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 01:46:00.297604|2018-06-01 01:46:00.297604
NCT00752141|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-09-22|2008-09-11|2008-09-15|Estimate|||||||2011-09-22|2011-09-23|Estimate|September 2008||2008-09-30|September 2011|2011-09-30||||October 2008|Actual|2008-10-31||Interventional|||Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers|Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers|Completed||Phase 1|153|Actual|Watson Pharmaceuticals||3|||f||||||||||||||2018-06-01 01:46:00.591809|2018-06-01 01:46:00.591809
NCT00752128|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|2011-10-31||2013-04-18|2008-09-12|2008-09-15|Estimate|2011-10-31|2011-12-06|Estimate||||2013-04-18|2013-04-25|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|October 2010|Actual|2010-10-31||Observational|R-Int||RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population|RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population|Completed|||2349|Actual|Medtronic Vascular|The data collection in this registry was limited to the collection of MACE (death, myocardial infarction (Q- and non-Q-wave), emergent cardiac bypass surgery and TLR) and stent thrombosis events.||||f||||t||||||||||2018-06-01 01:46:00.817209|2018-06-01 01:46:00.817209
NCT00752115|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2011-09-05|2008-09-12|2008-09-15|Estimate|||||||2011-09-05|2011-09-07|Estimate|February 2007||2007-02-28|April 2009|2009-04-30|December 2010|Actual|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer|Randomized Phase II Study of Combination Chemotherapy With Sildenafil Plus Carboplatin and Weekly Paclitaxel in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer|Completed||Phase 2/Phase 3|120|Anticipated|Hamamatsu University||2|||f||||t||||||||||2018-06-01 01:46:01.089132|2018-06-01 01:46:01.089132
NCT00752102|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2017-08-24||2017-12-07|2008-09-12|2008-09-15|Estimate|2017-12-07|2017-12-08|Actual||||2017-12-07|2017-12-08|Actual|September 2008||2008-09-30|December 2017|2017-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|VCOR||Vitamin D and Coronary Calcification Study|A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4|Completed||Phase 4|44|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-06-01 01:46:01.194807|2018-06-01 01:46:01.194807
NCT00752089|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2011-09-07|2011-09-07|2016-10-17|2008-09-12|2008-09-15|Estimate|2016-10-17|2016-12-08|Estimate|2016-10-17|2016-12-08|Estimate|2016-10-17|2016-12-08|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Experimental Dentifrice Remineralization/Fluoride Uptake in an in Situ Model|Exploratory Evaluation of an Experimental Fluoride Dentifrice Formulation Using an in Situ Remineralization/Fluoride Uptake Model|Completed||Phase 2|20|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 01:46:01.769781|2018-06-01 01:46:01.769781
NCT00752076|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2009-11-25|2008-09-12|2008-09-15|Estimate|||||||2009-11-25|2009-12-01|Estimate|April 2008||2008-04-30|November 2009|2009-11-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|EGFR||Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment|Detection of Epithelial Growth Factor Receptor (EGFR) Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 01:46:02.063495|2018-06-01 01:46:02.063495
NCT00752063|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2008-09-12|2008-09-12|2008-09-15|Estimate|||||||2008-09-12|2008-09-15|Estimate|September 2007||2007-09-30|September 2008|2008-09-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|SECOX||Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma|A Phase IIa Trial of Sorafenib With Capecitabine and Oxaliplatin in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|52|Anticipated|The University of Hong Kong||1|||f||||t||||||||||2018-06-01 01:46:02.155855|2018-06-01 01:46:02.155855
NCT00752050|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11||2011-05-03|2011-09-01|2008-09-11|2008-09-15|Estimate||||2011-05-04|2011-05-06|Estimate|2011-09-01|2011-09-12|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|PT-03b||Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows|"A Phase 3, Multi-Center Trial to Demonstrate the Safety and Efficacy of Repeat Treatment With PurTox® for the Treatment of Glabellar Rhytides (Frown Lines)"|Completed||Phase 3|699|Actual|Mentor Worldwide, LLC||2|||f||||f||||||||||2018-06-01 01:46:02.254996|2018-06-01 01:46:02.254996
NCT00752037|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-12|||2011-07-19|2008-09-12|2008-09-15|Estimate|||||||2011-07-19|2011-07-20|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients|Safety and Efficacy of Lopinavir/Ritonavir in Combination With Raltegravir in HIV-infected Patients|Completed||Phase 4|30|Actual|Saint Michael's Medical Center||1|||f||||f||||||||||2018-06-01 01:46:02.346469|2018-06-01 01:46:02.346469
NCT00752024|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-09-12|2008-09-12|2008-09-15|Estimate|||||||2008-09-12|2008-09-15|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|SATIH||Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study|Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study（SATIH）|Unknown status|Not yet recruiting|N/A|60|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-06-01 01:46:02.443386|2018-06-01 01:46:02.443386
NCT00752011|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2012-10-16|2008-09-11|2008-09-12|Estimate|||||||2012-10-16|2012-10-18|Estimate|June 2008||2008-06-30|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|||Phase I Study of TAS-106 in Combo With Carboplatin|Phase I Dose Escalating Study Of Tas-106 In Combination With Carboplatin In Patients With Solid Tumors|Completed||Phase 1|45|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:46:02.523966|2018-06-01 01:46:02.523966
NCT00751998|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2011-03-16||2013-02-04|2008-09-11|2008-09-12|Estimate|2011-03-16|2011-04-12|Estimate||||2013-02-04|2013-02-11|Estimate|November 2006||2006-11-30|February 2013|2013-02-28|October 2009|Actual|2009-10-31|April 2008|Actual|2008-04-30||Interventional|||Spy II Clinical Registry|A Clinical Registry to Assess Performance and Clinical Utility of the SpyGlass Direct Visualization System|Completed||Phase 4|297|Actual|Boston Scientific Corporation||1|||f||||||||||||||2018-06-01 01:46:02.609155|2018-06-01 01:46:02.609155
NCT00751985|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-04-13|2008-09-11|2008-09-12|Estimate|||||||2011-04-13|2011-04-14|Estimate|September 2008||2008-09-30|May 2009|2009-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Web-based Ultra-brief Intervention for Heavy Drinkers Trial|Web-based Ultra-brief Intervention for Heavy Drinkers - a Randomized Controlled Trial Comparing Personalized Normative Feedback With Self-help Material|Completed||Phase 3|1380|Actual|University of Southern Denmark||3|||f||||t||||||||||2018-06-01 01:46:02.884761|2018-06-01 01:46:02.884761
NCT00751972|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2013-03-15||2018-05-24|2008-09-11|2008-09-12|Estimate|2014-04-02|2014-05-02|Estimate||||2018-05-24|2018-05-30|Actual|August 2008||2008-08-31|May 2018|2018-05-31|August 2013|Actual|2013-08-31|August 2010|Actual|2010-08-31||Interventional|ADVANCE||Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure|Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure|Completed||N/A|140|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||t||||||||||2018-06-01 01:46:03.094567|2018-06-01 01:46:03.094567
NCT00751959|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2012-07-18|2008-09-11|2008-09-12|Estimate|||||||2012-07-18|2012-07-19|Estimate|April 2009||2009-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|NINSAPP||Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks|Surfactant Application During Spontaneous Breathing With CPAP or During Mechanical Ventilation in the Therapy of IRDS in Premature Infants < 27 Weeks|Completed||N/A|213|Actual|University of Cologne||2|||f||||t||||||||||2018-06-01 01:46:03.518748|2018-06-01 01:46:03.518748
NCT00751946|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2010-09-24|2008-09-11|2008-09-12|Estimate|||||||2010-09-24|2010-09-27|Estimate|March 2006||2006-03-31|September 2010|2010-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|GIRLS||Girls In Recovery From Life Stress (GIRLS) Study|Girls In Recovery From Life Stress (GIRLS) Study|Completed||Phase 2|70|Actual|UConn Health||2|||f||||t||||||||||2018-06-01 01:46:03.610139|2018-06-01 01:46:03.610139
NCT00751933|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2015-04-10||2015-04-10|2008-09-11|2008-09-12|Estimate|2015-04-10|2015-04-28|Estimate||||2015-04-10|2015-04-28|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Interventional|||Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis|A Controlled Study of Salmonella Ty21a and Cholera/ ETEC-vaccine and the Role of Oats in Daily Diet as a New Treatment in Patients With Mild or Moderate Ulcerative Colitis.|Terminated||Phase 2|3|Actual|Haukeland University Hospital||4||Lack of patients compatible with the protocol´s criteria|f||||f||||||||||2018-06-01 01:46:03.695218|2018-06-01 01:46:03.695218
NCT00751920|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2016-01-04|2008-09-10|2008-09-12|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules|Comparative Evaluation of MRI and MDCT for the Detection of Metastic Pulmonary Nodules|Terminated||Phase 3|1|Actual|The Hospital for Sick Children||1||"The sponsor-investigator relocated to a different institution and was not able to continue the~   study."|f||||f||||||||||2018-06-01 01:46:03.866352|2018-06-01 01:46:03.866352
NCT00751907|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2010-09-27|2008-09-10|2008-09-12|Estimate|||||||2010-09-27|2010-09-28|Estimate|June 2006||2006-06-30|September 2010|2010-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|CAPP||Cerebral and Peripheral Perfusion Pilot Study|Impact of Atorvastatin on Cerebral Perfusion and Endothelial Function|Completed||Phase 2|16|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 01:46:03.947071|2018-06-01 01:46:03.947071
NCT00751894|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2011-01-18|2008-09-11|2008-09-12|Estimate|||||||2011-01-18|2011-01-19|Estimate||||January 2011|2011-01-31||||||||Interventional|MEG-5||Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)|Haematopoietic Progenitor Cell Mobilization in Children With Malignancies: Evaluation of Pegfilgrastim at 200µg/kg After Chemotherapy|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:46:04.025417|2018-06-01 01:46:04.025417
NCT00751881|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2013-04-16||2016-05-27|2008-09-11|2008-09-12|Estimate|2013-06-24|2013-06-26|Estimate||||2016-05-27|2016-07-07|Estimate|August 2008||2008-08-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|April 2012|Actual|2012-04-30||Interventional|TOWER||An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis|A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis|Completed||Phase 3|1169|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 01:46:04.190748|2018-06-01 01:46:04.190748
NCT00751868|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2014-12-16|2008-09-11|2008-09-12|Estimate|||||||2014-12-16|2014-12-17|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|GIM9||FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC|NEO-ADIXERN (NEO-ADjuvant IXabepilone in Breast Cancer). A Feasibility Study of Dose-dense FEC With G-CSF Support Followed by Dose-dense Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in Breast Cancer|Completed||Phase 2|47|Actual|Consorzio Oncotech||1|||f||||t||||||||||2018-06-01 01:46:06.759029|2018-06-01 01:46:06.759029
NCT00751855|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2012-07-26|2008-09-11|2008-09-12|Estimate|||||||2012-07-26|2012-07-27|Estimate|July 2008||2008-07-31|October 2010|2010-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Cortisol Augmentation of Prolonged Exposure Therapy|Cortisol Augmentation of Prolonged Exposure Therapy|Completed||N/A|11|Actual|Bronx VA Medical Center||2|||f||||f||||||||||2018-06-01 01:46:06.853785|2018-06-01 01:46:06.853785
NCT00751842|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2012-10-09|2008-09-11|2008-09-12|Estimate|||||||2012-10-09|2012-10-10|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT|A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (USA)|Terminated||Phase 3|331|Actual|Diamyd Therapeutics AB||3||"Based on other clinical trial results it was unlikely the study would meet the efficacy~   endpoints"|f||||t||||||||||2018-06-01 01:46:06.951028|2018-06-01 01:46:06.951028
NCT00751829|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2008-09-11|2008-09-11|2008-09-12|Estimate|||||||2008-09-11|2008-09-12|Estimate|July 2003||2003-07-31|September 2008|2008-09-30|February 2005|Actual|2005-02-28|October 2004|Actual|2004-10-31||Interventional|||Isolated Systolic Hypertension in the Elderly and Very Elderly|Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension|Completed||Phase 3|417|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:46:07.081521|2018-06-01 01:46:07.081521
NCT00751816|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2015-12-08|2008-09-11|2008-09-12|Estimate|||||||2015-12-08|2015-12-10|Estimate|June 2008||2008-06-30|December 2015|2015-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Head & Neck Cancer Survivorship: Physical and Functional Status|Head & Neck Cancer Survivorship: Physical and Functional Status|Completed|||23|Actual|Vanderbilt University|||1||f||||f||||||||||2018-06-01 01:46:07.148811|2018-06-01 01:46:07.148811
NCT00751803|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25||2014-04-30|2014-11-12|2008-09-11|2008-09-12|Estimate||||2014-04-30|2014-05-16|Estimate|2014-11-12|2014-11-24|Estimate|August 2008||2008-08-31|November 2014|2014-11-30||||May 2009|Actual|2009-05-31||Interventional|||BI 44370 TA in Acute Migraine Attack|A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity|Completed||Phase 2|416|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-06-01 01:46:07.249314|2018-06-01 01:46:07.249314
NCT00751790|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2009-12-21||2014-07-17|2008-09-11|2008-09-12|Estimate|2012-06-12|2012-06-13|Estimate||||2014-07-17|2014-07-25|Estimate|July 2006||2006-07-31|August 2012|2012-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer|A Multicenter, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics and Safety of Two Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer.|Completed||Phase 3|120|Actual|Debiopharm International SA||1|||f||||f||||||||||2018-06-01 01:46:07.497387|2018-06-01 01:46:07.497387
NCT00751777|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2014-01-30||2014-03-17|2008-09-11|2008-09-12|Estimate|2014-03-17|2014-04-21|Estimate||||2014-03-17|2014-04-21|Estimate|September 2008||2008-09-30|March 2014|2014-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||Intent-to-Treat (ITT) Population: all study subjects who were consented, randomized, and had a baseline serology|Traveler's Diarrhea (TD) Automated Process|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults|Completed||Phase 2|120|Actual|Intercell USA, Inc.||2|||f||||f||||||||||2018-06-01 01:46:07.77475|2018-06-01 01:46:07.77475
NCT00751764|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2010-09-15|2008-09-11|2008-09-12|Estimate|||||||2010-09-15|2010-09-16|Estimate|November 2008||2008-11-30|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women|An Open-Label, Single-Dose Study to Evaluate the Excretion of Moxidectin Into the Breast Milk of Lactating, Non-breastfeeding Women.|Completed||Phase 1|12|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:46:08.060101|2018-06-01 01:46:08.060101
NCT00751751|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2008-09-11|2008-09-11|2008-09-12|Estimate|||||||2008-09-11|2008-09-12|Estimate|June 2003||2003-06-30|September 2008|2008-09-30|June 2005|Actual|2005-06-30|April 2005|Actual|2005-04-30||Interventional|||Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly|Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension.|Completed||Phase 3|441|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:46:08.123514|2018-06-01 01:46:08.123514
NCT00751738|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2017-01-31|2008-09-11|2008-09-12|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2002||2002-10-31|January 2017|2017-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)|A Multi-center, Open-label, Follow-up Study to Assess the Long-term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in Patients With an Implantable Cardioverter Defibrillator|Completed||Phase 3|330|Actual|Forest Laboratories||1|||f||||f||||||||||2018-06-01 01:46:08.207929|2018-06-01 01:46:08.207929
NCT00751712|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2016-03-28|2008-09-11|2008-09-12|Estimate|||||||2016-03-28|2016-03-29|Estimate|May 2006||2006-05-31|March 2016|2016-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|CerebralOx||Cerebral Oximetric Monitoring of the Posterior Circulation|Cerebral Oximetric Monitoring of the Posterior Circulation in Neonates and Infants During Complex Aortic Arch Reconstruction.|Completed|||13|Actual|Children's Hospitals and Clinics of Minnesota|||1||f||||f||||||||No||2018-06-01 01:46:08.610123|2018-06-01 01:46:08.610123
NCT00751699|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2013-04-15|2008-09-11|2008-09-12|Estimate|||||||2013-04-15|2013-04-17|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers|A Randomized, Open-label, Multiple Dose, Parallel Group Study to Evaluate 5 ASA and N Ac 5 ASA Pharmacokinetics Following Administration of Oral Doses of Asacol 2.4 g/Day and Lialda 2.4 g/Day for 7 Days in Healthy Volunteers|Completed||Phase 1|37|Actual|Warner Chilcott||3|||f||||f||||||||||2018-06-01 01:46:08.678234|2018-06-01 01:46:08.678234
NCT00751686|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2013-02-14|2008-09-11|2008-09-12|Estimate|||||||2013-02-14|2013-02-18|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Estimation of the Burden of Rotavirus Gastroenteritis (RV GE) in Children Less Than 5 Years in Greece|To Estimate the Burden of Rotavirus Gastroenteritis (RV GE) in Children < 5 Years of Age in Greece|Completed|||128|Actual|GlaxoSmithKline|||1||f||||||||||Samples Without DNA|"~     Stool sample~   "|||2018-06-01 01:46:08.754046|2018-06-01 01:46:08.754046
NCT00751673|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2017-03-09|2008-09-11|2008-09-12|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2006||2006-01-31|July 2016|2016-07-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||TESS Shoulder Arthroplasty Data Collection|A Prospective, Multicentre Study Evaluating the Clinical Performance of the T.E.S.S Anatomic and Reverse Shoulder Prostheses|Active, not recruiting|||600|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 01:46:08.835023|2018-06-01 01:46:08.835023
NCT00751660|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2012-03-07|2008-09-11|2008-09-12|Estimate|||||||2012-03-07|2012-03-09|Estimate|September 2008||2008-09-30|March 2012|2012-03-31||||March 2013|Anticipated|2013-03-31||Interventional|Pan Can||Screening Methods in Finding Lung Cancer Early in Current or Former Smokers|Early Detection of Lung Cancer - A Pan Canadian Study|Unknown status|Active, not recruiting|N/A|2504|Actual|British Columbia Cancer Agency|||||f||||f||||||||||2018-06-01 01:46:08.910373|2018-06-01 01:46:08.910373
NCT00751647|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2014-02-13|2008-09-11|2008-09-12|Estimate|||||||2014-02-13|2014-02-14|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional|CSREP||Cystic Fibrosis Core Strengthening and Respiratory Exercise Program|Cystic Fibrosis Core Strengthening and Respiratory Exercise Program (CSREP)|Completed||Phase 2|6|Actual|Children's Hospitals and Clinics of Minnesota||1|||f||||f||||||||||2018-06-01 01:46:08.99536|2018-06-01 01:46:08.99536
NCT00751634|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2012-01-09||2013-04-30|2008-09-10|2008-09-12|Estimate|2012-03-13|2012-04-09|Estimate||||2013-04-30|2013-05-06|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Temperature Control in Central Fever in the Neuro-ICU|Temperature Control in Central Fever in the Neuro-ICU|Completed||Phase 4|20|Actual|Northwestern University||1|||f||||f||||||||||2018-06-01 01:46:09.142356|2018-06-01 01:46:09.142356
NCT00751621|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2012-12-19||2014-03-05|2008-09-11|2008-09-12|Estimate|2012-12-19|2013-01-25|Estimate||||2014-03-05|2014-04-02|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)|A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)|Completed||Phase 3|40|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 01:46:09.344614|2018-06-01 01:46:09.344614
NCT00751608|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2016-09-22|2008-09-11|2008-09-12|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2006||2006-09-30|September 2016|2016-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients|A Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Evaluate the Effect of APL180 on Endothelial Function in Patients With Familial Hypercholesterolemia|Withdrawn||Phase 2|0|Actual|Novartis||3|||f||||f||||||||||2018-06-01 01:46:09.790271|2018-06-01 01:46:09.790271
NCT00751595|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2016-03-03|2008-09-11|2008-09-12|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|ISS T-002||Immunogenicity and Safety Trial of the HIV-1 Tat Vaccine|A Phase II Randomized, Open Label, Immunogenicity and Safety Trial of the Vaccine Based on the Recombinant Biologically Active HIV-1 Tat Protein in Anti-Tat Negative HIV-1 Infected HAART-treated Adult Subjects.|Completed||Phase 2|168|Actual|Istituto Superiore di Sanità||2|||f||||t||||||||||2018-06-01 01:46:09.864896|2018-06-01 01:46:09.864896
NCT00751582|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-17|||2016-03-20|2008-09-11|2008-09-12|Estimate|||||||2016-03-20|2016-03-22|Estimate|July 1998||1998-07-31|September 2008|2008-09-30|November 1998|Actual|1998-11-30|November 1998|Actual|1998-11-30||Interventional|||Effective Means to Address Moderately Malnourished Children|Effective Means to Address Moderately Malnourished Children Within BINP Communities|Completed||N/A|300|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 01:46:09.963235|2018-06-01 01:46:09.963235
NCT00751569|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-11|2008-09-11|2008-09-12|Estimate|||||||2008-09-11|2008-09-12|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|September 2009|Anticipated|2009-09-30|||||Observational|||microRNA Profile in Umbilical Cord Blood NK Cells|microRNA Profile in Umbilical Cord Blood NK Cells|Unknown status|Recruiting||5|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     Umbilical cord blood~   "|||2018-06-01 01:46:10.028384|2018-06-01 01:46:10.028384
NCT00751556|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2014-04-18|2008-09-11|2008-09-12|Estimate|||||||2014-04-18|2014-04-21|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Single/Multiple Dose Bioavailability Trial|An Open Label, Randomized, Two-Way Crossover Trial to Determine the Pharmacokinetic Profile of an Extended Release Naproxen Sodium Tablet Relative to Aleve Tablets Following Single and Multiple Dose Administration in Healthy Adult Subjects|Completed||Phase 1|32|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:46:10.100333|2018-06-01 01:46:10.100333
NCT00751543|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2010-06-28|2008-09-11|2008-09-12|Estimate|||||||2010-06-28|2010-06-29|Estimate|January 2008||2008-01-31|June 2010|2010-06-30||||December 2010|Anticipated|2010-12-31||Interventional|||The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy|The Character of Perfusion Parameters Derived From MDCT Between Adenocarcinoma and Squamous Cell Carcinoma of Lung in the Treatment Course of Radiation Therapy|Unknown status|Recruiting|N/A|20|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:46:10.159498|2018-06-01 01:46:10.159498
NCT00751530|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2010-07-22||2017-06-13|2008-09-11|2008-09-12|Estimate|2011-05-18|2011-06-17|Estimate||||2017-06-13|2017-07-02|Actual|March 1, 2008|Actual|2008-03-01|July 2012|2012-07-31|June 15, 2009|Actual|2009-06-15|June 15, 2009|Actual|2009-06-15||Observational|BRAVO||BRAVO: Background Regimen of Raltegravir on Virologic Outcome|Outcomes of Early Raltegravir Experience: Comparison of Virologic Response in Regimens Not Containing a Protease Inhibitor in the Antiretroviral Background Regimen Versus a Protease Inhibitor in the Background Regimen|Completed|||442|Actual|Community Research Initiative of New England|||2||f||||f||||||||||2018-06-01 01:46:10.218319|2018-06-01 01:46:10.218319
NCT00751517|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2008-09-11|2008-09-11|2008-09-12|Estimate|||||||2008-09-11|2008-09-12|Estimate||||September 2008|2008-09-30||||||||Interventional|||Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides|Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.|Unknown status|Active, not recruiting|Phase 2|||University of Parma||2|||f||||f||||||||||2018-06-01 01:46:10.58249|2018-06-01 01:46:10.58249
NCT00751504|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2013-01-23|2008-09-11|2008-09-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Quetiapine in the Treatment of Psychotic Depression - a Pilot Study|Quetiapine in the Treatment of Psychotic Depression - a Pilot Study|Completed||Phase 3|16|Actual|Ruhr University of Bochum|||||f||||t||||||||||2018-06-01 01:46:10.655308|2018-06-01 01:46:10.655308
NCT00751491|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2009-05-05|2008-09-11|2008-09-12|Estimate|||||||2009-05-05|2009-05-06|Estimate|September 2008||2008-09-30|May 2009|2009-05-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|RACE||Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)|Randomized Comparison of Adenosin Intracoronary Infusion and Clopidogrel Pretreatment on Myonecrosis Occurence in Elective PCI|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Roma La Sapienza||3|||f||||f||||||||||2018-06-01 01:46:10.724716|2018-06-01 01:46:10.724716
NCT00751478|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2013-09-13|2008-09-11|2008-09-12|Estimate|||||||2013-09-13|2013-09-16|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)|A Randomized, Double-Blind, Triple-Dummy, Single-Dose, Four-Way Crossover Study to Determine the Relative Bioavailability, Pharmacodynamic Effects, and Safety of Equivalent Doses of Whole and Crushed ALO-01 Versus Morphine IR in Opioid Experienced, Non-Dependent Subjects|Completed||Phase 1/Phase 2|32|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:46:10.829264|2018-06-01 01:46:10.829264
NCT00751465|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2015-09-10|2008-09-11|2008-09-12|Estimate|||||||2015-09-10|2015-09-11|Estimate|November 2008||2008-11-30|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability|Clinical Specificity of Dysfunctional Habitual Attention Processes in Fear of Blushing and Their Changeability|Completed||N/A|82|Actual|Technische Universität Dresden||3|||f||||t||||||||||2018-06-01 01:46:10.913108|2018-06-01 01:46:10.913108
NCT00751452|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2011-01-18|2008-09-11|2008-09-12|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Observational|||Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children|Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children|Unknown status|Recruiting||30|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-06-01 01:46:10.984792|2018-06-01 01:46:10.984792
NCT00751439|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2010-06-10|2008-09-11|2008-09-12|Estimate|||||||2010-06-10|2010-06-11|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Observational|||Verification of Pulse Oximetry in Neonatal Population|Verification of Pulse Oximetry in Neonatal Population|Completed|||25|Anticipated|Children's Hospitals and Clinics of Minnesota|||||f||||f||||||||||2018-06-01 01:46:11.0483|2018-06-01 01:46:11.0483
NCT00751426|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2008-09-11|2008-09-11|2008-09-12|Estimate|||||||2008-09-11|2008-09-12|Estimate|August 1999||1999-08-31|August 2008|2008-08-31|May 2002|Actual|2002-05-31|February 2002|Actual|2002-02-28||Observational|||Treatment of Hepatitis C in Psychiatric Patients|Treatment of Chronic Hepatitis c With Interferon-Alpha 2a and Ribavirin: a Comparison of Patients With Psychiatric Disorders and Controls|Completed|||81|Actual|Charite University, Berlin, Germany|||||f||||t||||||||||2018-06-01 01:46:11.161541|2018-06-01 01:46:11.161541
NCT00751413|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2015-05-29|2008-09-11|2008-09-12|Estimate|||||||2015-05-29|2015-06-01|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)|A Multicenter, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 6 to Less Than 12 Years|Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 01:46:11.227632|2018-06-01 01:46:11.227632
NCT00751400|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|2011-01-03|2009-12-09|2015-08-12|2008-09-11|2008-09-12|Estimate|2011-04-19|2011-05-17|Estimate|2009-12-09|2009-12-10|Estimate|2015-08-12|2015-08-25|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Naproxen Sodium Extended-Release Actual Use Study|An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting|Completed||Phase 3|497|Actual|Bayer|No control group, detailed data collected for up to 10 days during 1 month followup, data recall by subjects may vary|1|||f||||f||||||||||2018-06-01 01:46:11.313502|2018-06-01 01:46:11.313502
NCT00750776|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2013-04-14|2008-09-10|2008-09-11|Estimate|||||||2013-04-14|2013-04-16|Estimate|August 2003||2003-08-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|||||Observational|KvaliMed||KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment|KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment|Terminated|||212|Anticipated|Psychiatric Centre Rigshospitalet||||Due to lack of financial support|f||||f||||||||||2018-06-01 01:46:21.398539|2018-06-01 01:46:21.398539
NCT00751387|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-11|||2010-11-27|2008-09-11|2008-09-12|Estimate|||||||2010-11-27|2010-11-30|Estimate|November 2008||2008-11-30|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia|Australian Descriptive Epidemiology Study of Severity of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Exposure to Biological Disease Modifying Anti-rheumatic Drugs (bDMARDs)|Completed|||559|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 01:46:11.715522|2018-06-01 01:46:11.715522
NCT00751374|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-10|2008-09-10|2008-09-11|Estimate|||||||2008-09-10|2008-09-11|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis|Prospective, Randomized, Open-Label Study of Topical Antibiotic Prophylaxis at the Catheter Exit Site: Continuous Daily Gentamicin Cream Versus Cyclical Gentamicin Cream and Mupirocin 2% Cream Alternating at Monthly Basis.|Unknown status|Not yet recruiting|Phase 4|500|Anticipated|Kwong Wah Hospital||2|||f||||t||||||||||2018-06-01 01:46:11.785238|2018-06-01 01:46:11.785238
NCT00751361|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-10|2008-09-10|2008-09-11|Estimate|||||||2008-09-10|2008-09-11|Estimate|November 1998||1998-11-30|September 2008|2008-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|ART||Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial|Prospective, Randomized, Controlled Clinical Study Evaluating the Efficacy of Rheopheresis for Dry Age-Related Macular Degeneration Dry AMD Treatment With Rheopheresis Trial - ART|Completed||Phase 4|52|Actual|Apheresis Research Institute||2|||f||||t||||||||||2018-06-01 01:46:11.885208|2018-06-01 01:46:11.885208
NCT00751348|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2017-03-13|2010-07-02|2017-05-04|2008-09-10|2008-09-11|Estimate|2017-03-13|2017-04-24|Actual|2010-07-02|2010-07-07|Estimate|2017-05-04|2017-06-05|Actual|October 1, 2008||2008-10-01|March 2017|2017-03-31|May 27, 2010|Actual|2010-05-27|May 27, 2010|Actual|2010-05-27||Interventional|||Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136|Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136|Completed||Phase 3|475|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:46:11.984375|2018-06-01 01:46:11.984375
NCT00751335|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2009-06-22|2008-09-10|2008-09-11|Estimate|||||||2009-06-22|2009-06-23|Estimate|August 2006||2006-08-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||ThermoSmart® Versus Conventional Humidification in Continuous Positive Airway Pressure (CPAP)|Prospective, Randomized, Double-Blind Cross-Over Study Comparing ThermoSmart® to Conventional Heated Humidity in Patients Suing Continuous Positive Airway Pressure|Completed||N/A|79|Actual|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-06-01 01:46:12.452776|2018-06-01 01:46:12.452776
NCT00751322|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2012-01-27|2008-09-10|2008-09-11|Estimate|||||||2012-01-27|2012-01-31|Estimate|August 2008||2008-08-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31||Interventional|TRALI2||Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients|Project 2 (Mayo): Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients|Completed||N/A|100|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:46:12.517423|2018-06-01 01:46:12.517423
NCT00751309|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-12-17|2008-09-10|2008-09-11|Estimate|||||||2008-12-17|2008-12-18|Estimate|April 2004||2004-04-30|December 2008|2008-12-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Observational|LARGO||Lung Allograft Rejection Gene Expression Observational (LARGO) Study|Lung Allograft Rejection Gene Expression Observational (LARGO) Study|Terminated|||2044|Actual|XDx|||1|Restructuring and refocus of company.|f||||f||||||Samples Without DNA|"~     venous blood plasma~   "|||2018-06-01 01:46:12.584152|2018-06-01 01:46:12.584152
NCT00751296|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2015-12-29||2016-05-12|2008-09-10|2008-09-11|Estimate|2016-04-06|2016-05-12|Estimate||||2016-05-12|2016-06-16|Estimate|August 2006||2006-08-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Rev-CLL||Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)|A Phase 2 Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 2|27|Actual|University Health Network, Toronto|Original study protocol used a starting lenalidomide dose of 10mg OD for 21days of a 28-day cycle, escalating weekly by 5mg to a target of 25mg daily. Toxicities reported with the first two enrolled patients lead to the current protocol amendment.|1||Seven years of follow-up & final analysis done in Dec 2012.|f||||t||||||||||2018-06-01 01:46:12.673638|2018-06-01 01:46:12.673638
NCT00751283|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2013-08-12|2008-09-09|2008-09-11|Estimate|||||||2013-08-12|2013-08-14|Estimate|August 2007||2007-08-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities|Minnow Medical GRST Peripheral Catheter System First-in-Man Study Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities|Withdrawn||Phase 2/Phase 3|0|Actual|Vessix Vascular, Inc||1||Data was inconclusive|f||||t||||||||||2018-06-01 01:46:13.022932|2018-06-01 01:46:13.022932
NCT00751270|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2016-03-02|2008-09-10|2008-09-11|Estimate|||||||2016-03-02|2016-03-04|Estimate|November 2005||2005-11-30|March 2016|2016-03-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|BrTK01||Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas|A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas|Completed||Phase 1|15|Actual|Advantagene, Inc.||2|||f||||t||||||||||2018-06-01 01:46:13.11782|2018-06-01 01:46:13.11782
NCT00751257|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-03-22|2008-09-10|2008-09-11|Estimate|||||||2017-03-22|2017-03-23|Actual|December 2006||2006-12-31|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||N-Acetylcysteine and Smoking Reduction|A Randomized Controlled Trial of Oral N-acetylcysteine for Smoking Reduction: a Pilot Study|Completed||Phase 2|33|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:46:13.205651|2018-06-01 01:46:13.205651
NCT00751244|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2010-09-24|2008-09-10|2008-09-11|Estimate|||||||2010-09-24|2010-09-27|Estimate|January 2005||2005-01-31|September 2010|2010-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|MOMS||Mothers Overcoming and Managing Stress|Breaking the Cycle for Women With Behavioral Problems and Crime|Completed||Phase 2|147|Actual|UConn Health||3|||f||||f||||||||||2018-06-01 01:46:13.281632|2018-06-01 01:46:13.281632
NCT00751231|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10||2017-09-20|2017-09-20|2008-09-10|2008-09-11|Estimate||||2017-09-20|2017-09-28|Actual|2017-09-20|2017-09-28|Actual|December 2008||2008-12-31|June 2012|2012-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|INNOVATE-PCI||A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI|A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI|Completed||Phase 2|652|Actual|Portola Pharmaceuticals||4|||f||||t||||||||||2018-06-01 01:46:13.392992|2018-06-01 01:46:13.392992
NCT00751218|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-10-12|2008-09-10|2008-09-11|Estimate|||||||2017-10-12|2017-10-13|Actual|May 6, 2004|Actual|2004-05-06|October 2017|2017-10-31|May 24, 2005|Actual|2005-05-24|May 24, 2005|Actual|2005-05-24||Interventional|||A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)|A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)|Completed||Phase 4|174|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:46:13.617975|2018-06-01 01:46:13.617975
NCT00751205|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2014-10-27|2008-09-10|2008-09-11|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2008||2008-08-31|October 2014|2014-10-31|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional|||Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)|(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.|Completed||Phase 2|150|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:46:13.715929|2018-06-01 01:46:13.715929
NCT00751192|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-10-08|2008-09-10|2008-09-11|Estimate|||||||2008-10-08|2008-10-09|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Effect of an Online Video-Based Intervention to Increase HIV Testing in Men Who Have Sex With Men in Peru||Completed||N/A|||NGO Via Libre||2|||f||||f||||||||||2018-06-01 01:46:13.85668|2018-06-01 01:46:13.85668
NCT00751179|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2012-02-23||2015-06-03|2008-09-10|2008-09-11|Estimate|2012-02-23|2012-03-20|Estimate||||2015-06-03|2015-06-30|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)|A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety Assessor Blinded Trial in Adult Subjects Comparing Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Subjects Undergoing Short Surgical Procedures in Out-patient Surgicenters|Completed||Phase 3|161|Actual|Merck Sharp & Dohme Corp.|The potassium change from baseline interval included most/all of the intubation/surgical period for the sug but not the suc or roc analysis. AE reporting interval included the entire intubation/surgery period for the suc but not the roc-sug group.|2|||f||||f||||||||||2018-06-01 01:46:13.968467|2018-06-01 01:46:13.968467
NCT00751166|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-03-22|2008-09-10|2008-09-11|Estimate|||||||2017-03-22|2017-03-24|Actual|March 1, 2004|Actual|2004-03-01|March 2017|2017-03-31|May 1, 2005|Actual|2005-05-01|May 1, 2005|Actual|2005-05-01||Interventional|||A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)|A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)|Terminated||Phase 4|149|Actual|Merck Sharp & Dohme Corp.||3||Study could not be re-supplied with study medication in a timely manner.|f||||f||||||||||2018-06-01 01:46:14.320775|2018-06-01 01:46:14.320775
NCT00751153|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-10-08|2008-09-10|2008-09-11|Estimate|||||||2008-10-08|2008-10-09|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment|Open Label Phase 4, 48 Week Pilot Study of the Antiviral Efficacy and Tolerability of the Combination of Isentress™ and ReyatazTM When Substituted for Current Antiviral Regimen in Patients With Viral Suppression But Who Are Experiencing Adverse Events Related to Their Current Antiviral Regimen.|Unknown status|Recruiting|Phase 4|40|Anticipated|Peter J. Ruane, M.D., Inc.|||||f||||f||||||||||2018-06-01 01:46:14.39749|2018-06-01 01:46:14.39749
NCT00751140|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2012-12-04||2017-04-26|2008-09-10|2008-09-11|Estimate|2012-12-04|2013-01-08|Estimate||||2017-04-26|2017-05-30|Actual|September 2008||2008-09-30|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection|Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract|Completed||N/A|20|Actual|H. Lee Moffitt Cancer Center and Research Institute|The sample size was small because it was a single institution study. It was thus underpowered to achieve a cancer-specific endpoint pertaining to the oncological merit of performing a modified RPLND in the context of UUT-UC.|1|||f||||t||||||||||2018-06-01 01:46:14.475825|2018-06-01 01:46:14.475825
NCT00751127|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2011-03-24|2008-09-10|2008-09-11|Estimate|||||||2011-03-24|2011-03-25|Estimate|January 1993||1993-01-31|September 2008|2008-09-30|February 1994|Actual|1994-02-28|February 1994|Actual|1994-02-28||Interventional|||A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension|A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United States.|Completed||Phase 3|268|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:46:14.649874|2018-06-01 01:46:14.649874
NCT00751114|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2012-07-06||2012-09-03|2008-09-10|2008-09-11|Estimate|2012-08-14|2012-08-15|Estimate||||2012-09-03|2012-09-10|Estimate|November 2008||2008-11-30|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|EASIE||Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients|Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled|Completed||Phase 4|515|Actual|Sanofi||2|||f||||||||||||||2018-06-01 01:46:14.768406|2018-06-01 01:46:14.768406
NCT00751101|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2018-02-27|2008-09-10|2008-09-11|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2007||2007-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 3, 2015|Actual|2015-06-03||Interventional|||Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer|Pilot Study of Nicotine Patches to Reduce Hand-Foot Syndrome Associated With Capecitabine Chemotherapy in Patients With Metastatic Breast Cancer|Active, not recruiting||N/A|24|Actual|University of California, San Francisco||2|||f||||t|t|f|||f|||||2018-06-01 01:46:15.440418|2018-06-01 01:46:15.440418
NCT00751088|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2013-02-26|2008-09-10|2008-09-11|Estimate|||||||2013-02-26|2013-02-27|Estimate|September 2008||2008-09-30|July 2009|2009-07-31||||||||Interventional|||A Randomized Controlled Study Comparing Three Single-incision Devices for Female Urinary Stress Incontinence|A Comparison Among Three Single-incision Devices for the Treatment of Female Urinary Genuine Stress Incontinence: a Randomized Controlled Study.|Completed||Phase 4|||University Magna Graecia||4|||f||||||||||||||2018-06-01 01:46:15.523642|2018-06-01 01:46:15.523642
NCT00750009|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2013-08-20|2008-09-09|2008-09-10|Estimate|||||||2013-08-20|2013-08-21|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial|Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT)|Completed||Phase 3|583|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 01:46:31.054742|2018-06-01 01:46:31.054742
NCT00751075|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-03-21|2008-09-10|2008-09-11|Estimate|||||||2017-03-21|2017-03-23|Actual|December 1, 2003|Actual|2003-12-01|March 2017|2017-03-31|June 22, 2004|Actual|2004-06-22|May 6, 2004|Actual|2004-05-06||Interventional|||Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)|Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis|Completed||Phase 3|981|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:46:15.660898|2018-06-01 01:46:15.660898
NCT00751062|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-10|2008-09-10|2008-09-11|Estimate|||||||2008-09-10|2008-09-11|Estimate|November 1992||1992-11-30|September 2008|2008-09-30|December 1993|Actual|1993-12-31|December 1993|Actual|1993-12-31||Interventional|||A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia|A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in Scandinavia|Completed||Phase 3|267|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:46:15.747511|2018-06-01 01:46:15.747511
NCT00751049|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-10|2008-09-10|2008-09-11|Estimate|||||||2008-09-10|2008-09-11|Estimate|December 1992||1992-12-31|September 2008|2008-09-30|December 1993|Actual|1993-12-31|December 1993|Actual|1993-12-31||Interventional|||A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom|A 6-Month, Randomized, Double-Masked Comparison of PhXA41 With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-Centre Study in the United Kingdom|Completed||Phase 3|294|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:46:15.854388|2018-06-01 01:46:15.854388
NCT00751036|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2013-10-29||2014-02-25|2008-09-10|2008-09-11|Estimate|2014-02-25|2014-03-26|Estimate||||2014-02-25|2014-03-26|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|MACS0375||Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg|Randomized Phase III Trial Comparing Nilotinib 800mg to Imatinib 800 mg for the Treatment of Patients With Advanced and/or Metastatic Gastrointestinal Stromal Tumors Refractory to Imatinib 400 mg|Terminated||Phase 3|94|Actual|Novartis|Patients were limited (planned 300, Actual 94). Early termination of study; not sufficient power to test the original primary hypothesis with respect to PFS. Only descriptive analyses were carried out for this study.|2|||f||||f||||||||||2018-06-01 01:46:15.979125|2018-06-01 01:46:15.979125
NCT00751023|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2011-08-04|2008-09-10|2008-09-11|Estimate|||||||2011-08-04|2011-08-05|Estimate|February 2009||2009-02-28|November 2009|2009-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Modafinil in Methamphetamine Dependence|Effects of Modafinil in Methamphetamine Dependence|Completed||Phase 4|60|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:46:16.413819|2018-06-01 01:46:16.413819
NCT00751010|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-10-10|2008-09-10|2008-09-11|Estimate|||||||2008-10-10|2008-10-15|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Relationship: Interstitial Cystitis & Vulvodynia-Part 2|Relationship: Interstitial Cystitis & Vulvodynia-Part 2|Completed|||127|Anticipated|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 01:46:16.473936|2018-06-01 01:46:16.473936
NCT00750997|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-04-27|2008-09-10|2008-09-11|Estimate|||||||2017-04-27|2017-05-01|Actual|November 2007||2007-11-30|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Hypertonic Modulation of Inflammation Following Injury|Hypertonic Modulation of Inflammation Following Injury|Terminated|||119|Actual|University of Washington|||2|Enrollment in the clinical trial was stopped for futility|f||||t||||||Samples Without DNA|"~     plasma~   "|No|Data from the primary RCT will be made available through the Resuscitation Outcomes consortium. This was an ancillary study|2018-06-01 01:46:16.526633|2018-06-01 01:46:16.526633
NCT00750984|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2018-01-09|2008-09-10|2008-09-11|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2008||2008-09-30|September 2016|2016-09-30|February 2017|Actual|2017-02-28|July 2013|Actual|2013-07-31||Interventional|||A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing|A Comparison of Two Different Surgical Techniques for Total Hip Resurfacing|Completed||N/A|49|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 01:46:17.579043|2018-06-01 01:46:17.579043
NCT00750971|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-03-17|2008-09-10|2008-09-11|Estimate|||||||2017-03-17|2017-03-20|Actual|August 2008||2008-08-31|March 2017|2017-03-31|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Interventional|ASSIST||Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)|An Open-Label, Phase II Multicenter Cohort Study of Immunoablation With Cyclophosphamide and Antithymocyte-Globulin and Transplantation of Autologous Cd34-Enriched Hemapoietic Stem Cells Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Refractory Systemic Lupus Erythematosus|Recruiting||Phase 2|30|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 01:46:17.663862|2018-06-01 01:46:17.663862
NCT00750958|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-10|2008-09-10|2008-09-11|Estimate|||||||2008-09-10|2008-09-11|Estimate|June 2008||2008-06-30|September 2008|2008-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PREVENT||PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard|PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard|Completed||N/A|287|Actual|Datascope Patient Monitoring||1|||f||||t||||||||||2018-06-01 01:46:17.785437|2018-06-01 01:46:17.785437
NCT00750945|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2009-09-25|2008-09-10|2008-09-11|Estimate|||||||2009-09-25|2009-09-28|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Treadmill and Music Cueing for Gait Training in Mild to Moderate Parkinson's Disease|Treadmill and Music Cueing for Gait Training in Mild to Moderate Parkinson's Disease: a Preliminary Study|Completed||N/A|30|Actual|Chulalongkorn University||3|||f||||t||||||||||2018-06-01 01:46:17.846782|2018-06-01 01:46:17.846782
NCT00750932|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-02-23|2008-09-10|2008-09-11|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2008||2008-01-31|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|Pro-Muco||Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis|Study of the Biodistribution of PMN Serine Proteases in Sputum of Patients Affected by Cystic Fibrosis: Towards New Anti-inflammatory Therapies|Completed|||52|Actual|University Hospital, Tours|||3||f||||t||||||Samples With DNA|"~     Whole blood Sputum~   "|||2018-06-01 01:46:17.918365|2018-06-01 01:46:17.918365
NCT00750763|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2009-08-24|2008-09-10|2008-09-11|Estimate|||||||2009-08-24|2009-08-25|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Tolerability, Efficacy and Mucosal Inflammation Associated With Orally Administered Colon Cleansing for Colonoscopy|A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy|Completed||Phase 4|676|Actual|Fremantle Hospital and Health Service||3|||f||||f||||||||||2018-06-01 01:46:21.467817|2018-06-01 01:46:21.467817
NCT00750919|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2014-05-22||2015-07-02|2008-09-10|2008-09-11|Estimate|2014-05-22|2014-06-24|Estimate||||2015-07-02|2015-07-24|Estimate|October 2008||2008-10-31|July 2015|2015-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)|A Twenty-six Weeks, Open-label Extension Trial to Evaluate Safety and Efficacy of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 21106|Terminated||Phase 3|184|Actual|Merck Sharp & Dohme Corp.|This study was terminated due to the Sponsor's decision not to continue development of esmertazapine for this indication.|1||"This trial was stopped prematurely due to the Sponsor's decision not to continue the~   development of esmertazapine for this indication."|f||||f||||||||||2018-06-01 01:46:17.988111|2018-06-01 01:46:17.988111
NCT00750906|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2013-03-06|2008-09-09|2008-09-11|Estimate|||||||2013-03-06|2013-03-07|Estimate|October 2008||2008-10-31|March 2013|2013-03-31||||||||Observational|||ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes|The Muscle Biochemical, Serum Potassium and Cardiovascular Changes After Succinylcholine in Patients Undergoing Electroconvulsive Therapy.|Suspended|||20|Anticipated|University of California, San Francisco||||Study on hold since 2009. Awaiting FDA approval of Sugammdex to complete second arm of study.|f||||f||||||||||2018-06-01 01:46:18.257628|2018-06-01 01:46:18.257628
NCT00750893|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2011-01-28||2014-10-23|2008-09-10|2008-09-11|Estimate|2011-01-28|2011-02-25|Estimate||||2014-10-23|2014-11-03|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants|Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ or Rotarix™ Liquid Formulation (Oral Suspension or Prefilled Syringe) When Administered According to the Prescribing Information in Korea|Completed|||3111|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 01:46:18.338785|2018-06-01 01:46:18.338785
NCT00750880|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2014-07-15||2015-06-29|2008-09-10|2008-09-11|Estimate|2014-07-15|2014-08-07|Estimate||||2015-06-29|2015-07-22|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Inten-to-Treat (ITT) population: all participants included in the study who received at least 1 dose of study medication.|An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.|International Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy.|Completed||Phase 3|1681|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:46:18.868267|2018-06-01 01:46:18.868267
NCT00750867|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2013-12-26||2017-01-05|2008-09-09|2008-09-11|Estimate|2015-09-28|2015-10-26|Estimate||||2017-01-05|2017-02-23|Actual|June 2008||2008-06-30|September 2015|2015-09-30|December 2012|Actual|2012-12-31|September 2009|Actual|2009-09-30||Interventional|||Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins|Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins|Completed||Phase 2|9|Actual|University of Massachusetts, Worcester|The main study limitation is its small size and open label character.|1|||f||||f||||||||||2018-06-01 01:46:20.187775|2018-06-01 01:46:20.187775
NCT00750854|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2016-02-11|2008-09-10|2008-09-11|Estimate|||||||2016-02-11|2016-02-15|Estimate|November 2003||2003-11-30|February 2016|2016-02-29|April 2004|Actual|2004-04-30|February 2004|Actual|2004-02-29||Interventional|||Efficacy & Safety Study of Natural Eggshell Membrane (NEM) for the Treatment of Joint & Connective Tissue Disorders|A Double Arm Study to Evaluate the Effectiveness of NEM Compositions for the Treatment of Joint and Connective Tissue Pain|Completed||N/A|28|Actual|ESM Technologies, LLC||2|||f||||f||||||||No||2018-06-01 01:46:20.382211|2018-06-01 01:46:20.382211
NCT00750841|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2018-05-18|2008-09-10|2008-09-11|Estimate|||||||2018-05-18|2018-05-21|Actual|September 9, 2008|Actual|2008-09-09|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|July 30, 2009|Actual|2009-07-30||Interventional|||Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours|A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|65|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:46:20.467002|2018-06-01 01:46:20.467002
NCT00750828|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2008-09-10|2008-09-10|2008-09-11|Estimate|||||||2008-09-10|2008-09-11|Estimate|January 2004||2004-01-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Observational|||Gingival Wetness and Gingival Crevicular Fluid Volume in Patients With Dry Mouth|Gingival Wetness and Gingival Crevicular Fluid Volume in Patients With Dry Mouth|Completed|||28|Actual|Hacettepe University|||||f||||t||||||||||2018-06-01 01:46:20.541019|2018-06-01 01:46:20.541019
NCT00750815|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2013-09-23||2013-12-03|2008-09-10|2008-09-11|Estimate|2013-12-03|2014-01-20|Estimate||||2013-12-03|2014-01-20|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional||Overall Survival by disease risk stratification: 54 participants with cytogenetics and fluorescence in situ hybridisation (FISH) results available for risk stratification. All other measures: 58 Participants.|Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)|An Open Label Phase I/II Study of the Safety and Efficacy of Cyclophosphamide, Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL), and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|58|Actual|H. Lee Moffitt Cancer Center and Research Institute|Trial closed early after 58 patients were enrolled due to slow accrual and shortage of pegylated liposomal doxorubicin. Only 54 participants had cytogenetics and fluorescence in situ hybridisation (FISH) results available for risk stratification.|2|||f||||t||||||||||2018-06-01 01:46:20.619809|2018-06-01 01:46:20.619809
NCT00750802|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2009-06-25|2008-09-10|2008-09-11|Estimate|||||||2009-06-25|2009-06-26|Estimate|September 2008||2008-09-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|||||Interventional|||A Sedation/Cognition/EEG Study Using AZD6280 and Comparator|A Phase 1, Single Centre, Single Dose, Double-Blind, Double-Dummy, Four-Way Crossover, Placebo-Controlled, Randomized Study to Investigate the Effects of AZD6280 on Sedation, Cognition and EEG in Comparison With Lorazepam in Healthy Male Volunteers|Completed||Phase 1|17|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:46:21.211344|2018-06-01 01:46:21.211344
NCT00750789|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2008-09-10|2008-09-10|2008-09-11|Estimate|||||||2008-09-10|2008-09-11|Estimate|September 2008||2008-09-30|September 2008|2008-09-30||||November 2008|Anticipated|2008-11-30||Interventional|||The Effect of Dates on Plasma Lipids, Oxidative Stress and the Atherogenicity of Serum in Healthy Adults||Unknown status|Not yet recruiting|Phase 4|10|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 01:46:21.336401|2018-06-01 01:46:21.336401
NCT00750750|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|||2017-03-20|2008-09-10|2008-09-11|Estimate|||||||2017-03-20|2017-03-22|Actual|January 1, 2003|Actual|2003-01-01|March 2017|2017-03-31|September 1, 2003|Actual|2003-09-01|September 1, 2003|Actual|2003-09-01||Interventional|||Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)|Efficacy and Safety of 200 mcg QD or 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Amoxicillin vs Placebo as Primary Treatment of Subjects With Acute Rhinosinusitis|Completed||Phase 2|981|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 01:46:21.536999|2018-06-01 01:46:21.536999
NCT00750737|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-10|2015-12-01||2016-08-22|2008-09-10|2008-09-11|Estimate|2015-12-01|2016-01-06|Estimate||||2016-08-22|2016-09-29|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)|Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant|Completed||Phase 3|46|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 01:46:21.616662|2018-06-01 01:46:21.616662
NCT00750724|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2010-05-25|2008-09-09|2008-09-10|Estimate|||||||2010-05-25|2010-05-26|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|GoOn MRI||"Efficacy Study of Go On in Magnetic Resonance Imaging (MRI) Improvement in Osteoarthritis (OA) Knee"|Phase 3 Study GoON and MRI Improvement in OA Knee|Completed||Phase 3|60|Actual|Khon Kaen University||2|||f||||t||||||||||2018-06-01 01:46:21.873835|2018-06-01 01:46:21.873835
NCT00750711|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2008-09-15|2008-09-09|2008-09-10|Estimate|||||||2008-09-15|2008-09-16|Estimate|March 2008||2008-03-31|September 2008|2008-09-30||||January 2010|Anticipated|2010-01-31||Interventional|||Typical Flutter Ablation:A Comparison of 4 mm Versus 2 mm Irrigated cathéters|Typical Flutter Ablation:A Comparison of 4 mm Versus 2 mm Irrigated cathéters|Unknown status|Recruiting|N/A|200|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-06-01 01:46:21.933296|2018-06-01 01:46:21.933296
NCT00750698|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2011-03-17|2008-09-08|2008-09-10|Estimate|||||||2011-03-17|2011-03-18|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib|A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib|Completed||Phase 2|70|Anticipated|Syndax Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:46:22.081488|2018-06-01 01:46:22.081488
NCT00750685|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09||2014-12-17|2018-05-07|2008-09-09|2008-09-10|Estimate||||2014-12-17|2015-01-07|Estimate|2018-05-07|2018-05-08|Actual|March 1, 2007|Actual|2007-03-01|May 2018|2018-05-31|March 4, 2014|Actual|2014-03-04|March 4, 2014|Actual|2014-03-04||Interventional|||Study of the Mentor Becker Expander/Breast Implant in Subjects Who Are Undergoing Primary Breast Reconstruction|Study of the Safety and Effectiveness of the Mentor Becker Expander/Breast Implant in Subjects Who Are Undergoing Primary Breast Reconstruction|Terminated||Phase 3|315|Actual|Mentor Worldwide, LLC||1||Sponsor Terminated|t||||f||||||||||2018-06-01 01:46:22.227825|2018-06-01 01:46:22.227825
NCT00750672|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2012-07-11|2008-09-09|2008-09-10|Estimate|||||||2012-07-11|2012-07-13|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Observational|||Follow-up Care After Treatment for Endometrial Cancer|Follow-up After Primary Therapy for Endometrial Cancer; Implementation of a Cancer Care Ontario Guideline: A Pilot Evaluation Study.|Completed|||20|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 01:46:22.308155|2018-06-01 01:46:22.308155
NCT00750659|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2016-04-19|2008-09-09|2008-09-10|Estimate|||||||2016-04-19|2016-04-20|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Nilotinib Pre and Post Allogeneic Stem Cell Transplantation|Open-label Trial of Nilotinib in Patients With Advanced (>CP1) Chronic Myeloid Leukemia or Ph+ Acute Lymphatic Leukemia Pre- and Post- Allogeneic Stem Cell Transplantation.|Completed||Phase 2|24|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 01:46:22.384699|2018-06-01 01:46:22.384699
NCT00750646|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2008-09-09|2008-09-09|2008-09-10|Estimate|||||||2008-09-09|2008-09-10|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|August 2009|Anticipated|2009-08-31|March 2009|Anticipated|2009-03-31||Observational|||Observational Study of How Patients Take Eye Drops|The Relationship Between Glaucoma Medication Self-Efficacy, Outcome Expectations, Eye Drop Tech., Adherence and IOP.|Unknown status|Recruiting||220|Anticipated|Robin, Alan L., M.D.|||1||f||||t||||||||||2018-06-01 01:46:22.479204|2018-06-01 01:46:22.479204
NCT00750633|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08||2012-11-28|2012-11-29|2008-09-09|2008-09-10|Estimate||||2012-11-28|2012-11-30|Estimate|2012-11-29|2012-12-03|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Phase III Study of an Otic Formulation in Acute Otitis Externa||Completed||Phase 3|990|Actual|Alcon Research||3|||f||||t||||||||||2018-06-01 01:46:22.569922|2018-06-01 01:46:22.569922
NCT00750620|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2013-09-04|2008-09-09|2008-09-10|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment|A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Effect of Mild, Moderate and Severe Renal Impairment on the Pharmacokinetics of YM178|Completed||Phase 1|33|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 01:46:22.655279|2018-06-01 01:46:22.655279
NCT00750594|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2017-12-21|2008-09-09|2008-09-10|Estimate|||||||2017-12-21|2017-12-26|Actual|April 2008||2008-04-30|December 2017|2017-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Patent Foramen Ovale in Children With Migraine Headaches|Patent Foramen Ovale in Children With Migraine Headaches|Completed|||109|Actual|University of Utah|||2||f||||f||||||||||2018-06-01 01:46:22.761115|2018-06-01 01:46:22.761115
NCT00750581|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2016-08-17|2008-09-08|2008-09-10|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants|An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants- A Randomized Pilot Study|Terminated||Phase 2/Phase 3|9|Actual|University of Calgary||2||Study medication was no longer available for study|f||||t||||||||||2018-06-01 01:46:22.857837|2018-06-01 01:46:22.857837
NCT00750568|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2008-09-09|2008-09-09|2008-09-10|Estimate|||||||2008-09-09|2008-09-10|Estimate|October 2007||2007-10-31|August 2008|2008-08-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Observational|||Intravenous Terbutaline in Severe Status Asthmaticus|Pharmacokinetics and Pharmacodynamics of Terbutaline Given as a Continuous Intravenous Infusion in Severe Status Asthmaticus|Unknown status|Enrolling by invitation||36|Anticipated|Wayne State University|||3||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:46:22.93534|2018-06-01 01:46:22.93534
NCT00750555|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2012-10-10|2008-09-09|2008-09-10|Estimate|||||||2012-10-10|2012-10-11|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer|Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer|Terminated||Phase 2|4|Actual|Geisinger Clinic||1||Dr. Amy Law left Geisinger Health System. 4 patients enrolled|f||||f||||||||||2018-06-01 01:46:23.00042|2018-06-01 01:46:23.00042
NCT00750529|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2014-07-04|2008-09-09|2008-09-10|Estimate|||||||2014-07-04|2014-07-08|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Alzheimer and Sleep|Effects of Galantamine and Donépézil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease.|Completed||Phase 1|15|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-06-01 01:46:23.147307|2018-06-01 01:46:23.147307
NCT00750516|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2009-06-24|2008-09-09|2008-09-10|Estimate|||||||2009-06-24|2009-06-25|Estimate|September 2008||2008-09-30|June 2009|2009-06-30||||||||Observational|||Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet|Lactic Acid Levels In Hypotensive Patients Without(Standard) and With Tourniquet|Suspended|||100|Anticipated|State University of New York - Upstate Medical University|||1|Insufficient patient enrolled|f||||f||||||||||2018-06-01 01:46:23.258499|2018-06-01 01:46:23.258499
NCT00750503|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2008-09-09|2008-09-09|2008-09-10|Estimate|||||||2008-09-09|2008-09-10|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Workplace Tobacco Cessation And Oral Cancer Screening Study|Workplace Tobacco Cessation And Oral Cancer Screening Study|Completed||Phase 3|104|Actual|Tata Memorial Hospital|||||f||||t||||||||||2018-06-01 01:46:23.34082|2018-06-01 01:46:23.34082
NCT00750477|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2016-02-11|2008-09-08|2008-09-10|Estimate|||||||2016-02-11|2016-02-15|Estimate|December 2004||2004-12-31|February 2016|2016-02-29|May 2006|Actual|2006-05-31|January 2006|Actual|2006-01-31||Interventional|OPTION||Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis|A Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of Natural Eggshell Membrane (NEM) in the Treatment of Pain & Stiffness Associated With Moderate Osteoarthritis of the Knee|Completed||N/A|67|Actual|ESM Technologies, LLC||2|||f||||f||||||||No||2018-06-01 01:46:23.446359|2018-06-01 01:46:23.446359
NCT00750464|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2009-10-12|2008-09-09|2008-09-10|Estimate|||||||2009-10-12|2009-10-14|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|August 2009|Actual|2009-08-31|||||Observational|||Collection of Raw Data of Thermal Imaging for the Purpose of Developing a Device for Early Detection of Breast Cancer|Collection of Raw Data of Thermal Imaging for the Purpose of Developing a Device for Early Detection of Breast Cancer|Completed|||575|Actual|Real Imaging Ltd.|||||f||||f||||||||||2018-06-01 01:46:23.607842|2018-06-01 01:46:23.607842
NCT00750451|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2009-03-19|2008-09-09|2008-09-10|Estimate|||||||2009-03-19|2009-03-20|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Low Molecular Weight Heparin in Recurrent Implantation Failure|Empirical Low Molecular Weight Heparin Administration in the Luteal Phase in Patients With Recurrent Implantation Failures: a Randomized Open Labeled Trial|Completed||N/A|||V.K.V. American Hospital, Istanbul||2|||f||||||||||||||2018-06-01 01:46:23.67235|2018-06-01 01:46:23.67235
NCT00750438|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2016-11-18|2008-09-09|2008-09-10|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Fibre Products on Appetite and Weight|Increased Short Chain Fatty Acids in the Colon Are Associated With Improved Energy Homeostasis and Insulin Sensitivity.|Completed||N/A|58|Actual|Imperial College London||3|||f||||t||||||||||2018-06-01 01:46:23.850071|2018-06-01 01:46:23.850071
NCT00750425|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2011-03-09|2008-09-09|2008-09-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|April 2009|Actual|2009-04-30||Interventional|||Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours|A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours|Completed||Phase 1|46|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:46:24.152371|2018-06-01 01:46:24.152371
NCT00750412|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2011-10-17|2008-09-09|2008-09-10|Estimate|||||||2011-10-17|2011-10-18|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Assessment of Voluntary Adolescent Mental Health Screening and Referral in a Children's Hospital Emergency Department|An Assessment of Voluntary Adolescent Mental Health Screening and Referral in a Children's Hospital Emergency Department|Completed||N/A|112|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-06-01 01:46:24.360706|2018-06-01 01:46:24.360706
NCT00750399|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2012-04-25|2008-09-09|2008-09-10|Estimate|||||||2012-04-25|2012-04-26|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma|An Open Label Study to Evaluate the Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma|Completed||Phase 1|10|Actual|The New York Eye Cancer Center||1|||f||||f||||||||||2018-06-01 01:46:24.738278|2018-06-01 01:46:24.738278
NCT00750386|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2011-05-20|2008-09-09|2008-09-10|Estimate|||||||2011-05-20|2011-05-23|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas|Dose Dense Administration of Paclitaxel and Carboplatin Combination as 1st Line Treatment in Patients With Ovarian Carcinoma|Completed||Phase 1/Phase 2|50|Anticipated|Hellenic Oncology Research Group||1|||f||||||||||||||2018-06-01 01:46:24.85877|2018-06-01 01:46:24.85877
NCT00750373|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2012-06-29||2015-04-06|2008-09-09|2008-09-10|Estimate|2012-08-08|2012-09-07|Estimate||||2015-04-06|2015-04-23|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|EASE||Early Surgery Versus Conventional Treatment in Infective Endocarditis|A Randomized Comparison of Early Surgery Versus Conventional Treatment Strategy in Patients With High Embolic Risk of Infective Endocarditis|Completed||Phase 4|76|Actual|Asan Medical Center|The EASE trial was a limited study in scope, in that it included patients with severe valvular disease and large vegetations, and excluded those with major stroke, prosthetic valve endocarditis or aortic abscess.|2|||f||||f||||||||||2018-06-01 01:46:25.02191|2018-06-01 01:46:25.02191
NCT00750191|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2013-09-13||2013-11-20|2008-09-09|2008-09-10|Estimate|2013-11-20|2014-01-08|Estimate||||2013-11-20|2014-01-08|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty|A Randomized, Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty for Treatment of Discogenic Lower Back Pain|Completed||Phase 1|64|Actual|Baylis Medical Company||2|||f||||t||||||||||2018-06-01 01:46:28.962092|2018-06-01 01:46:28.962092
NCT00750360|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2008-12-23||2016-11-03|2008-09-09|2008-09-10|Estimate|2009-04-08|2009-06-02|Estimate||||2016-11-03|2016-12-22|Estimate|October 2003||2003-10-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.|Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Influenza Split Vaccine FLUARIX™ Administered According to the Prescribing Information in Korean Subjects Aged More Than 6 Months of Age at the Time of Vaccination|Completed||Phase 4|883|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:46:25.351971|2018-06-01 01:46:25.351971
NCT00750347|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2011-01-18|2008-09-09|2008-09-10|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Antagonistic Interaction CB1-paracetamol|Evaluation of the Interaction of Rimonabant (Antagonist of CB1 Receptor) on the Analgesic Effect of Paracetamol in Intravenous Administration|Completed||Phase 1|24|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:46:25.937459|2018-06-01 01:46:25.937459
NCT00750334|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2015-05-19|2008-09-09|2008-09-10|Estimate|||||||2015-05-19|2015-05-21|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)|A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)|Terminated||Phase 1|2|Actual|Sanofi||2||Terminated to focus on comparable trial, CLOMDS02507|f||||f||||||||||2018-06-01 01:46:26.008485|2018-06-01 01:46:26.008485
NCT00750308|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2010-01-06||2014-12-08|2008-09-09|2008-09-10|Estimate|2010-03-25|2010-04-12|Estimate||||2014-12-08|2014-12-18|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional||We provide baseline data for those 18 subjects who completed all four treatment arms and whose data are analyzed in this crossover study.|Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i|Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi|Completed||N/A|27|Actual|Vanderbilt University||12|||f||||f||||||||||2018-06-01 01:46:26.136359|2018-06-01 01:46:26.136359
NCT00750295|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2013-10-16|2008-09-09|2008-09-10|Estimate|||||||2013-10-16|2013-10-18|Estimate|February 2007||2007-02-28|August 2011|2011-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis|An Open Label, Multiple Dose, Time-lagged, Switch Study to Evaluate the Safety, Tolerability and Activity of Escalating SBR759 Doses in Patients With Chronic Kidney Disease on Hemodialysis|Completed||Phase 1/Phase 2|60|Actual|Novartis||7|||f||||f||||||||||2018-06-01 01:46:26.56409|2018-06-01 01:46:26.56409
NCT00750282|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2014-06-16|2013-05-10|2014-07-15|2008-09-09|2008-09-10|Estimate|2014-06-16|2014-07-16|Estimate|2013-05-10|2013-05-20|Estimate|2014-07-15|2014-07-24|Estimate|August 2008||2008-08-31|July 2014|2014-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||"dropout in Part A occurred due to pre-treatment AEs.~dropouts in Part B occurred due to withdrawal of consent."|Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers|An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection/Exclusion of Cerebral Amyloid Beta in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers|Completed||Phase 2|422|Actual|Piramal Imaging SA||1|||f||||f||||||||||2018-06-01 01:46:26.721927|2018-06-01 01:46:26.721927
NCT00750269|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2016-06-30||2018-03-22|2008-09-09|2008-09-10|Estimate|2017-03-30|2017-05-10|Actual||||2018-03-22|2018-04-23|Actual|February 2009||2009-02-28|March 2018|2018-03-31||||September 2014|Actual|2014-09-30||Interventional||All eligible patients receiving protocol treatment|Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer|Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients|Active, not recruiting||Phase 1/Phase 2|120|Actual|Radiation Therapy Oncology Group||9|||f||||t||||||||||2018-06-01 01:46:27.386265|2018-06-01 01:46:27.386265
NCT00750256|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2017-07-19|2008-09-09|2008-09-10|Estimate|||||||2017-07-19|2017-07-21|Actual|July 7, 2008|Actual|2008-07-07|July 2017|2017-07-31|December 12, 2008|Actual|2008-12-12|December 12, 2008|Actual|2008-12-12||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects|A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:46:28.375222|2018-06-01 01:46:28.375222
NCT00750243|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08||2010-09-17|2010-10-04|2008-09-08|2008-09-10|Estimate||||2010-10-04|2010-10-06|Estimate|2010-10-04|2010-10-06|Estimate|September 2008||2008-09-30|October 2010|2010-10-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Comparator Study of LT-NS001 in Healthy Subjects With Endoscopic Evaluation|A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation|Completed||Phase 1|120|Actual|Logical Therapeutics||2|||f||||f||||||||||2018-06-01 01:46:28.444109|2018-06-01 01:46:28.444109
NCT00750230|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2016-02-11|2008-09-09|2008-09-10|Estimate|||||||2016-02-11|2016-02-15|Estimate|October 2003||2003-10-31|February 2016|2016-02-29|January 2004|Actual|2004-01-31|December 2003|Actual|2003-12-31||Interventional|||Pilot Study of the Efficacy & Safety of Natural Eggshell Membrane (NEM) for Joint & Connective Tissue Disorders|A Single Arm Pilot Study to Evaluate the Effectiveness of Eggshell Membrane Compositions for the Treatment of Pain Associated With Connective Tissue and Joints|Completed||N/A|11|Actual|ESM Technologies, LLC||1|||f||||f||||||||No||2018-06-01 01:46:28.511524|2018-06-01 01:46:28.511524
NCT00750217|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2008-09-09|2008-09-09|2008-09-10|Estimate|||||||2008-09-09|2008-09-10|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|May 2009|Anticipated|2009-05-31|February 2009|Anticipated|2009-02-28||Interventional|||Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches|Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone.|Unknown status|Recruiting|Phase 4|10|Anticipated|Psychiatric University Hospital, Zurich|||||f||||t||||||||||2018-06-01 01:46:28.592299|2018-06-01 01:46:28.592299
NCT00750204|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2017-04-06||2017-04-06|2008-09-09|2008-09-10|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|July 2008|Actual|2008-07-31|April 2017|2017-04-30|October 15, 2008|Actual|2008-10-15|October 15, 2008|Actual|2008-10-15||Interventional|||Airway Pressure Release Ventilation in Acute Lung Injury|Airway Pressure Release Ventilation in Acute Lung Injury|Terminated||N/A|2|Actual|Johns Hopkins University||2||slow recruitment|f||||f||||||||||2018-06-01 01:46:28.704434|2018-06-01 01:46:28.704434
NCT00750178|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2017-04-05|2008-09-09|2008-09-10|Estimate|||||||2017-04-05|2017-04-07|Actual|November 1, 2004|Actual|2004-11-01|April 2017|2017-04-30|November 1, 2005|Actual|2005-11-01|August 1, 2005|Actual|2005-08-01||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)|A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 01:46:29.191263|2018-06-01 01:46:29.191263
NCT00750165|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2017-06-16|2008-09-09|2008-09-10|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2007||2007-05-31|June 2017|2017-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Auto Continuous Positive Airway Pressure (CPAP) Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Auto CPAP Based Energy Spectrum Analysis of Flow for Treatment of Obstructive Sleep Apnea Hypopnea Syndrome.|Completed||N/A|30|Actual|Fisher and Paykel Healthcare||1|||f||||t||||||||||2018-06-01 01:46:29.304824|2018-06-01 01:46:29.304824
NCT00750152|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2012-02-08|2011-06-14|2013-04-15|2008-09-09|2008-09-10|Estimate|2012-02-08|2012-03-13|Estimate|2011-07-11|2011-07-14|Estimate|2013-04-15|2013-04-22|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris|A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris|Completed||Phase 3|334|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-06-01 01:46:29.385045|2018-06-01 01:46:29.385045
NCT00750139|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2012-02-13|2011-06-14|2013-04-19|2008-09-09|2008-09-10|Estimate|2012-12-18|2013-01-29|Estimate|2011-07-11|2011-07-14|Estimate|2013-04-19|2013-04-26|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis|A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis|Completed||Phase 3|707|Actual|Merz North America, Inc.||4|||f||||f||||||||||2018-06-01 01:46:29.667185|2018-06-01 01:46:29.667185
NCT00750126|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2011-01-18|2008-09-09|2008-09-10|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2007||2007-04-30|January 2011|2011-01-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|RICE||Allogeneic Hematopoietic Stem Cell Transplantation|Feasibility Study on Allogeneic Hematopoietic Stem Cell Transplantation Following Fludarabine-Busulfan-ALS-based Reduced-intensity Conditioning in Children With Hematological Malignancy or Solid Tumor Not Responding to Standard Therapy or for Which the Indication for Allograft is Maintained But Cannot be Carried Out Due to the Toxicity Involved in Myeloablative Conditioning.|Unknown status|Recruiting|Phase 2|30|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:46:30.004359|2018-06-01 01:46:30.004359
NCT00750113|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2014-12-04|2008-09-09|2008-09-10|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.|A Multicenter Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control and Beyond: Comparison of Two Treatment Strategies.|Completed||Phase 4|405|Actual|Bayer||3|||f||||f||||||||||2018-06-01 01:46:30.076745|2018-06-01 01:46:30.076745
NCT00750100|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2010-10-08|2008-09-09|2008-09-10|Estimate|||||||2010-10-08|2010-10-11|Estimate|September 2007||2007-09-30|September 2008|2008-09-30|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|||Low Dose hCG in the Late Follicular Phase|Among ICSI Patients Undergoing Antagonist Protocols With Recombinant FSH, Does Replacement of Recombinant FSH by 200 IU of hCG in the Late Follicular Phase Compared With Continuing Recombinant FSH, Result in a Similar Number of Oocytes?|Completed||Phase 4|70|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-06-01 01:46:30.281051|2018-06-01 01:46:30.281051
NCT00750087|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2010-02-04|2008-09-09|2008-09-10|Estimate|||||||2010-02-04|2010-02-05|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR|Non-interventional Study to Observe Treatment Efficacy in Maintaining Symptoms Control in Patients With Schizophrenia, Treated With Seroquel XR|Completed|||578|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:46:30.355402|2018-06-01 01:46:30.355402
NCT00750074|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2017-02-24|2008-09-09|2008-09-10|Estimate|||||||2017-02-24|2017-02-28|Actual|November 2007||2007-11-30|February 2017|2017-02-28|October 2010|Actual|2010-10-31|September 2009|Actual|2009-09-30||Observational|||Slope of the Pressure-Time Waveform Predicts Resistance and Compliance in Mechanically Ventilated Subjects|Slope of the Pressure-Time Waveform Predicts Respiratory System Resistance and Elastance in Mechanically Ventilated Subjects|Completed|||12|Actual|University of Iowa|||1||f||||f||||||||||2018-06-01 01:46:30.439339|2018-06-01 01:46:30.439339
NCT00750061|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-30|2015-01-06||2015-04-28|2008-09-09|2008-09-10|Estimate|2015-04-28|2015-05-04|Estimate||||2015-04-28|2015-05-04|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries|Efficacy and Safety pf Lithium Carbonate in the Treatment of Chronic Spinal Cord Injuries: a Double-Blind, Randomized, Placebo-Controlled Clinical Trial|Completed||Phase 2|40|Actual|China Spinal Cord Injury Network||2|||f||||t||||||||||2018-06-01 01:46:30.565169|2018-06-01 01:46:30.565169
NCT00750048|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2012-01-26|2008-09-09|2008-09-10|Estimate|||||||2012-01-26|2012-01-30|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Impact of Naloxone on the Analgesic Effect of Paracetamol in Healthy Volunteers|Impact of Naloxone on the Analgesic Effect of Paracetamol in Healthy Volunteers|Completed||Phase 1|12|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 01:46:30.866665|2018-06-01 01:46:30.866665
NCT00750035|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2008-10-23|2008-09-09|2008-09-10|Estimate|||||||2008-10-23|2008-10-24|Estimate|January 1996||1996-01-31|September 2008|2008-09-30|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||Total Versus Subtotal Hysterectomy:a Randomised, Prospective Multicentre Study of the Effect on Urinary, Sexual and Bowel Function||Completed||N/A|279|Actual|St George's Healthcare NHS Trust||2|||f||||t||||||||||2018-06-01 01:46:30.916417|2018-06-01 01:46:30.916417
NCT00750022|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2009-09-18|2008-09-09|2008-09-10|Estimate|||||||2009-09-18|2009-09-21|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Feasibility of Integrating Indirect Calorimetry (IC) Technology in Primary Care|Feasibility Study of Integrating IC Technology With the WatchWT Comprehensive Weight Reduction Program.|Completed||N/A|75|Actual|Colorado Center for Chronic Care Innovations, Inc.||2|||f||||f||||||||||2018-06-01 01:46:30.970354|2018-06-01 01:46:30.970354
NCT00749996|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2014-04-24||2016-01-26|2008-09-09|2008-09-10|Estimate|2014-04-24|2014-05-23|Estimate||||2016-01-26|2016-01-28|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease|Herniectomy vs. Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease|Completed||Phase 4|165|Actual|Medtronic Spinal and Biologics|The current study was limited by not reaching the target enrollment. Because of the low patient recruitment rate, despite major efforts by the investigators and sponsor, enrollment was stopped prematurely.|2|||f||||f||||||||||2018-06-01 01:46:31.204373|2018-06-01 01:46:31.204373
NCT00749983|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2012-10-01|2008-09-09|2008-09-10|Estimate|||||||2012-10-01|2012-10-02|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Creatine Supplementation in Women With Knee Osteoarthritis and Fibromyalgia||Completed||N/A|60|Actual|University of Sao Paulo||2|||f||||||||||||||2018-06-01 01:46:31.563414|2018-06-01 01:46:31.563414
NCT00749970|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|||2010-12-08|2008-09-09|2008-09-10|Estimate|||||||2010-12-08|2010-12-10|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|SWN-K||Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia|Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia|Completed|||100|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:46:31.627291|2018-06-01 01:46:31.627291
NCT00749957|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2015-11-30||2017-12-01|2008-09-08|2008-09-10|Estimate|2016-04-07|2016-04-08|Estimate||||2017-12-01|2017-12-28|Actual|June 17, 2009|Actual|2009-06-17|October 2017|2017-10-31|September 22, 2017|Actual|2017-09-22|September 23, 2014|Actual|2014-09-23||Interventional|||Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis|A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2|Completed||Phase 1/Phase 2|12|Actual|Applied Genetic Technologies Corp||2|||f||||t||||||||||2018-06-01 01:46:31.712769|2018-06-01 01:46:31.712769
NCT00749944|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-09|2010-07-07||2010-08-24|2008-09-09|2008-09-10|Estimate|2010-07-07|2010-08-09|Estimate||||2010-08-24|2010-08-31|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo|An Experimental Medicine, Randomized, Double-Blind Study Assessing Neuropsychiatric Symptoms In Quitting Smokers Treated With Varenicline Tartrate Or Placebo|Completed||Phase 4|110|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:46:32.130125|2018-06-01 01:46:32.130125
NCT00749931|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-07|2014-05-26||2014-05-26|2008-09-07|2008-09-09|Estimate|2014-05-26|2014-06-27|Estimate||||2014-05-26|2014-06-27|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|Pivotal||MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery|MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery|Completed||N/A|664|Actual|Dune Medical Devices||2|||f||||f||||||||||2018-06-01 01:46:33.964882|2018-06-01 01:46:33.964882
NCT00749918|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2008-10-16|2008-09-08|2008-09-09|Estimate|||||||2008-10-16|2008-10-20|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Vitamin D Deficiency and Vitamin D Supplementation on Glucose Metabolism|Improved Insulin Sensitivity With Therapeutic Vitamin D Replacement in Pre-Diabetic Vitamin D Deficient Individuals|Completed||N/A|12|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 01:46:34.208599|2018-06-01 01:46:34.208599
NCT00749905|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-07-21|2008-09-08|2008-09-09|Estimate|||||||2010-07-21|2010-07-22|Estimate|January 2009||2009-01-31|July 2010|2010-07-31||||July 2009|Anticipated|2009-07-31||Interventional|||Low Fiber Diet for Bowel Preparation for Colon Capsule Examination|A Prospective Randomized Controlled Investigator-blinded Study of Low Fiber Diet for Bowel Preparation for Colon Capsule Examination|Terminated||Phase 2|75|Anticipated|Sheba Medical Center||2||was not able to recruit enough patients|f||||f||||||||||2018-06-01 01:46:34.27924|2018-06-01 01:46:34.27924
NCT00749892|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2018-01-08|2008-09-05|2008-09-09|Estimate|||||||2018-01-08|2018-01-10|Actual|June 2008|Actual|2008-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma|A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy|Active, not recruiting||Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:46:34.330711|2018-06-01 01:46:34.330711
NCT00749879|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2010-02-10|2008-09-05|2008-09-09|Estimate|||||||2010-02-10|2010-02-11|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Crossover Study of the Safety and PK Properties of Proellex®|A Phase I, Open-Label, Randomized, Single-Center, Unblinded, Single-Dose, Five-Way Crossover Study of the Safety and PK Properties of Proellex®|Completed||Phase 1|17|Actual|Repros Therapeutics Inc.||5|||f||||f||||||||||2018-06-01 01:46:34.476808|2018-06-01 01:46:34.476808
NCT00749866|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-08-09|2008-09-08|2008-09-09|Estimate|||||||2010-08-09|2010-08-10|Estimate|May 2007||2007-05-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Long Term Nebulised Gentamicin in Patients With Bronchiectasis|Can Long Term Nebulised Gentamicin Reduce The Bacterial Burden, Break the Vicious Cycle of Inflammation and Improve Quality of Life in Patients With Bronchiectasis|Completed||Phase 4|60|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:46:34.568482|2018-06-01 01:46:34.568482
NCT00749853|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2015-05-03|2008-09-08|2008-09-09|Estimate|||||||2015-05-03|2015-05-05|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Efficacy of Ovarian Stimulation Based on FSHR Genotype Status|Prospective, Randomized Open Trial to Evaluate the Efficacy of an Ovarian Stimulation Protocol Based on FSH Receptor Genotype|Suspended||Phase 3|165|Anticipated|Medical University of Vienna||2||PI left the institution|f||||f||||||||||2018-06-01 01:46:34.654282|2018-06-01 01:46:34.654282
NCT00749840|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2013-02-12|2008-09-08|2008-09-09|Estimate|||||||2013-02-12|2013-02-13|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Attitudes and Beliefs and the Steps of HIV Care|Attitudes and Beliefs and the Steps of HIV Care|Completed|||200|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:46:34.720057|2018-06-01 01:46:34.720057
NCT00749827|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2016-04-19|2008-09-08|2008-09-09|Estimate|||||||2016-04-19|2016-04-20|Estimate||||April 2016|2016-04-30||||||||Interventional|CIN||Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy (CIN)|Exploring the Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy|Withdrawn||Phase 4|0|Actual|Memorial University of Newfoundland||2||No funding received|f||||f||||||||Undecided||2018-06-01 01:46:34.784508|2018-06-01 01:46:34.784508
NCT00749801|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2008-09-08|2008-09-08|2008-09-09|Estimate|||||||2008-09-08|2008-09-09|Estimate|May 2007||2007-05-31|September 2008|2008-09-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Geneferm Nattokinase|A Randomized, Double-Blind, Placebo-Controlled, Parallel Comparison Study to Evaluate the Efficacy and Safety of Oral Administration of Nattokinase (From GeneFerm Biotechnology Co., Ltd.) Taken by Dyslipidemia Patients|Completed||N/A|47|Actual|Chi Mei Medical Hospital||3|||f||||f||||||||||2018-06-01 01:46:34.916575|2018-06-01 01:46:34.916575
NCT00749788|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05||2013-01-31|2013-01-31|2008-09-05|2008-09-09|Estimate||||2013-01-31|2013-02-04|Estimate|2013-01-31|2013-02-04|Estimate|December 2006||2006-12-31|January 2013|2013-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-302 Administered Daily for Four Weeks in Subjects With Low HDL-C Levels|Completed||Phase 2|150|Actual|Akros Pharma Inc.||3|||f||||f||||||||||2018-06-01 01:46:34.993209|2018-06-01 01:46:34.993209
NCT00749775|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2013-11-20||2013-11-20|2008-09-05|2008-09-09|Estimate|2013-11-20|2014-01-08|Estimate||||2013-11-20|2014-01-08|Estimate|June 2008||2008-06-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|ESSENCE||Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness|Completed|||3338|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:46:35.054987|2018-06-01 01:46:35.054987
NCT00749762|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2015-05-01|2008-09-08|2008-09-09|Estimate|||||||2015-05-01|2015-05-05|Estimate|October 2002||2002-10-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Pulmonary Function During Prone and Supine Positioning in NICU Infants Requiring Assisted Ventilation|Pulmonary Function During Prone and Supine Positioning in Neonatal Intensive Care Unit (NICU) Infants Requiring Assisted Ventilation|Withdrawn|||0|Actual|University of Utah||||Computers/hardware for data collection/storage are outdated and unserviceable.|f||||f||||||||||2018-06-01 01:46:35.267074|2018-06-01 01:46:35.267074
NCT00749749|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2018-05-23|2008-09-08|2008-09-09|Estimate|||||||2018-05-23|2018-05-25|Actual|September 2008||2008-09-30|May 2018|2018-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy|A Phase II, Randomized, Single-dose, Unblinded Study to Compare the Efficacy and Safety of the CollaRx Bupivacaine Implant With the ON-Q PainBuster Post-op Pain Relief System in Women Following Abdominal Hysterectomy|Completed||Phase 2|27|Actual|Innocoll||2|||f||||f||||||||No||2018-06-01 01:46:35.32537|2018-06-01 01:46:35.32537
NCT00749736|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2013-03-28|2008-09-08|2008-09-09|Estimate|||||||2013-03-28|2013-03-29|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.|The Role of Vitamin D in Immune Function in Patients With CKD Stages 3 and 4.|Completed||Phase 4|100|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 01:46:35.395634|2018-06-01 01:46:35.395634
NCT00749723|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2015-07-07|2008-09-05|2008-09-09|Estimate|||||||2015-07-07|2015-07-08|Estimate|February 2006||2006-02-28|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|January 2013|Actual|2013-01-31||Interventional|HIT-REZ-2005||Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children|Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents|Unknown status|Active, not recruiting|Phase 2/Phase 3|160|Anticipated|University Hospital, Bonn||4|||f||||t||||||||||2018-06-01 01:46:36.422744|2018-06-01 01:46:36.422744
NCT00749710|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2008-09-08|2008-09-08|2008-09-09|Estimate|||||||2008-09-08|2008-09-09|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel|Blood Loss and Complications of Internal Fixation of Femoral Neck Fractures in Patients Treated With Clopidogrel|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 01:46:36.570957|2018-06-01 01:46:36.570957
NCT00749697|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2008-09-08|2008-09-08|2008-09-09|Estimate|||||||2008-09-08|2008-09-09|Estimate|May 2008||2008-05-31|September 2008|2008-09-30|July 2010|Anticipated|2010-07-31|January 2010|Anticipated|2010-01-31||Interventional|||Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases|Investigating Absorbed Radiation Dose Delivered to Differentiated Thyroid Cancer Metastases Following Administration of Fixed Activity of Radioactive Iodine|Unknown status|Recruiting|N/A|10|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 01:46:36.64049|2018-06-01 01:46:36.64049
NCT00749684|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2010-10-22||2015-10-16|2008-09-08|2008-09-09|Estimate|2011-02-25|2011-03-24|Estimate||||2015-10-16|2015-10-19|Estimate|December 1996||1996-12-31|October 2015|2015-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)|Efficacy and Safety of High-dose Treatment With the Immunomodulator Interferon-α-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma.|Completed|||138|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:46:36.733447|2018-06-01 01:46:36.733447
NCT00749671|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2015-09-20||2016-08-26|2008-09-08|2008-09-09|Estimate|2016-08-26|2016-10-19|Estimate||||2016-08-26|2016-10-19|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Bispectral Index Monitoring During Testing in the Electrophysiology Lab|To Assess the Utility of BIS Monitoring in the Administration of Moderate Sedation in Patients Undergoing Implantable Cardioverter -Defibrillator (ICD) Implantation With Defibrillatory Threshold (DFT) Testing|Terminated||N/A|20|Actual|Baystate Medical Center||2||Lack of enrollment|f||||f||||||||No||2018-06-01 01:46:37.029265|2018-06-01 01:46:37.029265
NCT00749658|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2016-06-23|2008-09-05|2008-09-09|Estimate|||||||2016-06-23|2016-06-24|Estimate|November 2008||2008-11-30|June 2016|2016-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|ChanBan||Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence|Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence|Completed||Phase 2/Phase 3|10|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-06-01 01:46:37.254652|2018-06-01 01:46:37.254652
NCT00749645|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-07|||2016-06-21|2008-09-08|2008-09-09|Estimate|||||||2016-06-21|2016-06-23|Estimate|October 2006||2006-10-31|October 2014|2014-10-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|FANG30-RA||Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients|Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients|Completed||Phase 2|60|Actual|Universidad Austral de Chile||2|||f||||t||||||||Yes|All these data has been accepted for publication in Clinical Rheumatology|2018-06-01 01:46:37.388632|2018-06-01 01:46:37.388632
NCT00749632|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05||2009-10-13|2009-10-13|2008-09-08|2008-09-09|Estimate||||2009-10-13|2009-10-15|Estimate|2009-10-13|2009-10-15|Estimate|July 2007||2007-07-31|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|FP1097-002||A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence|An Open-Label, Dose Escalating Study to Evaluate the Safety of Intravaginal Oxybutynin in Subjects With Urge Urinary Incontinence|Completed||Phase 2|45|Actual|FemmePharma Global Healthcare, Inc.||3|||f||||f||||||||||2018-06-01 01:46:37.486687|2018-06-01 01:46:37.486687
NCT00749619|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-07|||2008-09-08|2008-09-08|2008-09-09|Estimate|||||||2008-09-08|2008-09-09|Estimate|May 2007||2007-05-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?||Completed||Phase 3|||Western Galilee Hospital-Nahariya||3|||f||||f||||||||||2018-06-01 01:46:37.553674|2018-06-01 01:46:37.553674
NCT00749606|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2015-06-01||2018-02-06|2008-09-05|2008-09-09|Estimate|2017-10-31|2017-12-05|Actual||||2018-02-06|2018-02-12|Actual|June 2009||2009-06-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|October 2012|Actual|2012-10-31||Interventional|||Study to Promote Weight Loss in Primary Care Practices|Weight Loss in Primary Care: a Translation of the Diabetes Prevention Program|Completed||N/A|257|Actual|State University of New York - Upstate Medical University||2|||f||||t|f|f||||||||2018-06-01 01:46:37.649396|2018-06-01 01:46:37.649396
NCT00749593|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2012-06-08|2008-09-08|2008-09-09|Estimate|||||||2012-06-08|2012-06-11|Estimate|August 2004||2004-08-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|June 2007|Actual|2007-06-30||Observational|CaHASE||Study of UK Adults With Congenital Adrenal Hyperplasia.|Cross-Sectional Multi-Centre Study of UK Adults With Congenital Adrenal Hyperplasia.|Completed|||25|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||t||||||||||2018-06-01 01:46:38.149193|2018-06-01 01:46:38.149193
NCT00749580|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2014-03-27||2014-12-02|2008-09-08|2008-09-09|Estimate|2014-06-24|2014-07-22|Estimate||||2014-12-02|2014-12-17|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen|A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir Versus NRTIs as a Backbone in HIV-Infected Patients Switched From a Stable Boosted PI Regimen|Completed||N/A|46|Actual|University of South Florida|This is a pilot study and has a small sample size.|2|||f||||f||||||||||2018-06-01 01:46:38.317738|2018-06-01 01:46:38.317738
NCT00749567|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2015-09-25|2008-09-08|2008-09-09|Estimate|||||||2015-09-25|2015-09-28|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer|Combination of Erlotinib (Tarceva®) and Bevacizumab (Avastin®) as Second-line Treatment in Locally Advanced / Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC) Patients: A Phase II Study|Terminated||Phase 2|13|Actual|Hellenic Oncology Research Group||1||Poor accrual|f||||f||||||||||2018-06-01 01:46:38.620416|2018-06-01 01:46:38.620416
NCT00749554|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-06-04|2008-09-08|2008-09-09|Estimate|||||||2010-06-04|2010-06-07|Estimate|April 2008||2008-04-30|June 2010|2010-06-30||||August 2010|Anticipated|2010-08-31||Interventional|TD-RCT-002||Trial of Disc Biacuplasty to Treat Chronic Discogenic Low Back Pain|Blinded Randomised Placebo-Controlled Trial of TransDiscal Biacuplasty for Patients With Mechanical Low Back Pain of Disc Origin|Terminated||Phase 4|40|Anticipated|Baylis Medical Company||2||Primary Investigator Retired.|f||||f||||||||||2018-06-01 01:46:38.723692|2018-06-01 01:46:38.723692
NCT00749541|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-07|||2010-12-15|2008-09-08|2008-09-09|Estimate|||||||2010-12-15|2010-12-16|Estimate|November 2008||2008-11-30|September 2008|2008-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Vitamin d Levels and Coronary Catheterization|25 Hydroxy Vitamin d Levels in Patients Undergoing an Elective Coronary Catheterization|Completed|||100|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-06-01 01:46:38.80568|2018-06-01 01:46:38.80568
NCT00749528|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2012-03-14|2008-09-08|2008-09-09|Estimate|||||||2012-03-14|2012-03-15|Estimate|September 2007||2007-09-30|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing|Sectional Prospective Randomised Study of Evaluation Toxic Metals, Trace Elements Status and Total Antioxidant Activity in Children With Recurrent Wheezing.|Completed|||95|Actual|Kecioren Education and Training Hospital|||2||f||||f||||||Samples Without DNA|"~     Group 1: Children with recurrent wheezing. Plasma and Hair specimen are retined Group 2:~     Healthy children. Plasma and Hair specimen are retined~   "|||2018-06-01 01:46:38.867838|2018-06-01 01:46:38.867838
NCT00749515|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-12-01|2008-09-08|2008-09-09|Estimate|||||||2010-12-01|2010-12-03|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Pilot Study for Patients With Poor Response to Deferasirox|Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)|Completed||Phase 4|15|Actual|Boston Children’s Hospital|||||f||||f||||||||||2018-06-01 01:46:38.946223|2018-06-01 01:46:38.946223
NCT00749502|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2013-07-23|2008-09-08|2008-09-09|Estimate|||||||2013-07-23|2013-07-25|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|September 2011|Actual|2011-09-30||Interventional|||A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)|A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies|Completed||Phase 1|113|Actual|Tesaro, Inc.||4|||f||||f||||||||||2018-06-01 01:46:39.03014|2018-06-01 01:46:39.03014
NCT00749489|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2014-06-24|2008-09-08|2008-09-09|Estimate|||||||2014-06-24|2014-06-25|Estimate|November 2008||2008-11-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Improving Pain and Function in Hip Fracture|Improving Pain and Function in Hip Fracture|Completed||Phase 3|164|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 01:46:39.097896|2018-06-01 01:46:39.097896
NCT00749476|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2010-01-29||2011-06-06|2008-09-08|2008-09-09|Estimate|2010-05-26|2010-06-29|Estimate||||2011-06-06|2011-06-08|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX|Reformulated BeneFIX Efficacy and Safety After Conversion From a pdFIX|Completed||Phase 4|1|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:46:39.17843|2018-06-01 01:46:39.17843
NCT00749463|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2010-04-23||2012-07-06|2008-09-08|2008-09-09|Estimate|2010-09-14|2010-10-01|Estimate||||2012-07-06|2012-07-13|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment|Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment|Completed||Phase 4|300|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-06-01 01:46:39.361429|2018-06-01 01:46:39.361429
NCT00749450|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-06|||2012-04-23|2008-09-06|2008-09-09|Estimate|||||||2012-04-23|2012-04-24|Estimate|March 2008||2008-03-31|April 2012|2012-04-30||||March 2013|Anticipated|2013-03-31||Interventional|||Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer|Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer|Unknown status|Recruiting|Phase 3|9500|Anticipated|Cancer Research UK, Glasgow||2|||f||||t||||||||||2018-06-01 01:46:39.88495|2018-06-01 01:46:39.88495
NCT00749437|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-06|||2012-06-13|2008-09-06|2008-09-09|Estimate|||||||2012-06-13|2012-06-14|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer|Feasibility of 3-D Conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage, Node Negative Breast Cancer Patients Using Acculoc Fiducial Markers: A Phase I Trial|Completed||Phase 1|34|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 01:46:39.950678|2018-06-01 01:46:39.950678
NCT00749424|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-02-03|2008-09-08|2008-09-09|Estimate|||||||2010-02-03|2010-02-04|Estimate|January 2004||2004-01-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|May 2005|Actual|2005-05-31||Interventional|CACTUS||The Study of the Crushing Technique Application Using SES in Coronary Bifurcations.|"CORONARY BIFURCATIONS: APPLICATION OF THE CRUSHING TECHNIQUE USING SIROLIMUS-ELUTING STENTS - The CACTUS Trial"|Completed||Phase 4|350|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 01:46:40.107319|2018-06-01 01:46:40.107319
NCT00749411|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08||2010-02-05|2017-01-13|2008-09-08|2008-09-09|Estimate||||2010-02-05|2010-02-10|Estimate|2017-01-13|2017-01-16|Estimate|November 2008||2008-11-30|January 2017|2017-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD|Completed||Phase 2|61|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:46:40.177923|2018-06-01 01:46:40.177923
NCT00749398|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2011-08-31||2015-07-15|2008-09-05|2008-09-09|Estimate|2011-08-31|2011-10-04|Estimate||||2015-07-15|2015-07-28|Estimate|September 2007||2007-09-30|July 2015|2015-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|PHODYPSO||Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047)|Atlas of the Evolution of Psoriasis Lesions Under Remicade® : A Dynamic Standardized Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab|Completed|||133|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:46:40.326792|2018-06-01 01:46:40.326792
NCT00749385|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2008-12-19|2008-09-08|2008-09-09|Estimate|||||||2008-12-19|2008-12-23|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels|A Randomized, Open-Label, 4-Way Crossover Study to Evaluate Naproxen and Esomeprazole Plasma Levels in Healthy Subjects Following Oral Administration of PN 400, Enteric-Coated Naproxen 500mg Plus Enteric-Coated Esomeprazole 20mg, Enteric-Coated Naproxen 500mg Alone, and Enteric-Coated Esomeprazole 20mg Alone.|Completed||Phase 1|40|Actual|POZEN||4|||f||||f||||||||||2018-06-01 01:46:40.656006|2018-06-01 01:46:40.656006
NCT00749372|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-11-04|2008-09-08|2008-09-09|Estimate|||||||2010-11-04|2010-11-05|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Interventional|T2*MRI||MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions|T2* Cardiac MRI Screening of Highly Transfused Patients With Myelodysplastic Syndrome|Unknown status|Recruiting|N/A|50|Anticipated|Weill Medical College of Cornell University||1|||f||||||||||||||2018-06-01 01:46:40.732315|2018-06-01 01:46:40.732315
NCT00749359|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2017-08-02|2008-09-05|2008-09-09|Estimate|||||||2017-08-02|2017-08-04|Actual|July 7, 2008|Actual|2008-07-07|August 2017|2017-08-31|September 16, 2008|Actual|2008-09-16|September 16, 2008|Actual|2008-09-16||Interventional|||PAXIL CR Bioequivalence Study|An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga|Completed||Phase 1|166|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:46:40.808048|2018-06-01 01:46:40.808048
NCT00749346|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2011-09-26|2008-09-08|2008-09-09|Estimate|||||||2011-09-26|2011-09-27|Estimate|May 2008||2008-05-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer|An Open Label Pilot Study of NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer|Completed||Phase 1/Phase 2|42|Anticipated|NovoCure Ltd.||1|||f||||f||||||||||2018-06-01 01:46:40.904608|2018-06-01 01:46:40.904608
NCT00749333|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2009-04-29|2008-09-08|2008-09-09|Estimate|||||||2009-04-29|2009-04-30|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.|A Phase I, Randomised, Double Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Oral Doses of AZD8566 in Healthy Volunteers|Completed||Phase 1|108|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:46:40.994043|2018-06-01 01:46:40.994043
NCT00749320|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2017-12-07|2008-09-08|2008-09-09|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2008||2008-09-30|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma|Active, not recruiting||N/A|40|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||No|No plan to share IPD|2018-06-01 01:46:41.075967|2018-06-01 01:46:41.075967
NCT00749307|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2009-11-24|2008-09-08|2008-09-09|Estimate|||||||2009-11-24|2009-11-25|Estimate|June 2008||2008-06-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Effects of Docosahexaenoic Acid (DHA) on Heart Rate Variability in Elderly Patients|Effects of Supplementation With Algal Triacylglycerols Versus Placebo on Heart Rate Variability in Elderly Patients|Completed||Phase 2/Phase 3|50|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||||2018-06-01 01:46:41.151552|2018-06-01 01:46:41.151552
NCT00749294|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-08-06|2008-09-08|2008-09-09|Estimate|||||||2010-08-06|2010-08-09|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Anogenital Wart Burden and Cost of Illnesses|Measurement of Anogenital Wart Burden, and Cost of Illnesses in Bangkok|Completed|||150|Anticipated|Mahidol University|||1||f||||f||||||||||2018-06-01 01:46:41.232304|2018-06-01 01:46:41.232304
NCT00749281|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-07-07|2008-09-08|2008-09-09|Estimate|||||||2010-07-07|2010-07-08|Estimate|September 2008||2008-09-30|August 2009|2009-08-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Observational|||Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease|Neutrophil Gelatinase-associated Disease: a Potential Biomarker of the Severity of Coronary Artery Disease|Completed|||73|Actual|Cardiovascular Research Society, Greece|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:46:41.306367|2018-06-01 01:46:41.306367
NCT00749268|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2013-10-14||2015-09-09|2008-09-08|2008-09-09|Estimate|2015-09-09|2015-10-05|Estimate||||2015-09-09|2015-10-05|Estimate|October 2008||2008-10-31|September 2015|2015-09-30|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional||"1 inguinal pt assigned to receive AbsorbaTack was treated with ProTack and one patient assigned to receive ProTack received AbsorbaTack. These patients are included in the intent to treat population above, but were omitted from the safety population."|AbsorbaTack Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair|Evaluation of Postoperative Pain Following Laparoscopic Hernia Repair: A Prospective, Randomized Comparison to Evaluate the Incidence of Post-operative Pain Associated With Absorbable Fixation (AbsorbaTack) vs Conventional Fixation (ProTack) Following Laparoscopic Hernia Repair|Completed||Phase 4|216|Actual|Medtronic - MITG||2|||f||||f||||||||||2018-06-01 01:46:41.39796|2018-06-01 01:46:41.39796
NCT00749255|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2011-01-17|2008-09-08|2008-09-09|Estimate|||||||2011-01-17|2011-01-19|Estimate|May 2008||2008-05-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|||||Observational|||Collect Breast Cancer Patients' Digital Mammography Images With Corresponding Reports for the Development of Software|R2 Case Collection|Terminated|||200|Anticipated|WellSpan Health|||1|not enough personnel to conduct study at site|f||||f||||||||||2018-06-01 01:46:41.887631|2018-06-01 01:46:41.887631
NCT00749242|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2014-12-13|2008-09-08|2008-09-09|Estimate|||||||2014-12-13|2014-12-16|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|TRAUMAA1-2-3||Comparative Study of Balloon Kyphoplasty and Conservative Treatment|Prospective Randomized Study Comparing Balloon Kyphoplasty and Conservative Treatment in Acute Traumatic Vertebral Fractures, Types A1, A2, AND A3.1 According to the Magerl Classification (STIC 3)|Completed||Phase 4|41|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:46:41.941158|2018-06-01 01:46:41.941158
NCT00749229|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2017-01-03|2008-09-08|2008-09-09|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|TRAUMAA3B1C1||Feasibility Study of Balloon Kyphoplasty in Traumatic Vertebral Fractures Needing Surgical Fixation|Prospective Cohort Study on the Feasibility and Reliability of 'Open' Balloon Kyphoplasty in Types A3.2, A3.3, B1 and C1 MAGERL Classification Vertebral Fractures(STIC 4)|Terminated||Phase 4|17|Actual|Assistance Publique - Hôpitaux de Paris||1||the number of patients recruited at present is sufficient for analysis.|f||||f||||||||||2018-06-01 01:46:42.011279|2018-06-01 01:46:42.011279
NCT00749216|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05||2010-05-27|2010-05-27|2008-09-05|2008-09-09|Estimate||||2010-05-27|2010-06-02|Estimate|2010-05-27|2010-06-02|Estimate|September 2008||2008-09-30|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease|Multiple-Dose Safety in Japanese Subjects With Mild-to-Moderate Alzheimer's Disease|Completed||Phase 2|33|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 01:46:42.070495|2018-06-01 01:46:42.070495
NCT00749203|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2017-04-12||2018-02-13|2008-09-08|2008-09-09|Estimate|2018-02-13|2018-02-14|Actual||||2018-02-13|2018-02-14|Actual|January 2009||2009-01-31|February 2018|2018-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|KetPTSD||Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)|Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder|Completed||Phase 2|41|Actual|Icahn School of Medicine at Mount Sinai|Several patients did not receive a second infusion per protocol because of sustained reduction in PTSD symptom levels . The study also does not address the safety or efficacy of ketamine in combination with other psychotropic medications in PTSD.|2|||f||||t||||||||||2018-06-01 01:46:42.231419|2018-06-01 01:46:42.231419
NCT00749190|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2014-05-16||2014-05-16|2008-09-08|2008-09-09|Estimate|2014-05-16|2014-06-13|Estimate||||2014-05-16|2014-06-13|Estimate|August 2008||2008-08-31|May 2014|2014-05-31||||October 2009|Actual|2009-10-31||Interventional||Treated Set (TS) consisting of all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|BI 10773 add-on to Metformin in Patients With Type 2 Diabetes|A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy|Completed||Phase 2|495|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:46:42.844803|2018-06-01 01:46:42.844803
NCT00749177|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2015-03-04|2008-09-05|2008-09-09|Estimate|||||||2015-03-04|2015-03-06|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|B2W||Blending Two Worlds: Traditional Aboriginal Healing Strategies for Depression and Anxiety|Blending Two Worlds: Traditional Aboriginal Healing Strategies for Depression and Anxiety. Possible Options for Children, Youth and Families|Terminated||N/A|4|Actual|Fraser Health||3||Primary investigator left program: unable to recruit a replacement|f||||f||||||||||2018-06-01 01:46:43.788935|2018-06-01 01:46:43.788935
NCT00749164|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2009-08-10|2008-09-08|2008-09-09|Estimate|||||||2009-08-10|2009-08-11|Estimate|September 2009||2009-09-30|August 2009|2009-08-31|August 2012|Anticipated|2012-08-31|February 2012|Anticipated|2012-02-29||Interventional|MSCGVHD||Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment|Allogeneic Mesenchymal Stem Cell Infusion for Treatment Of Steroid Resistant GVHD|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 01:46:43.865186|2018-06-01 01:46:43.865186
NCT00749151|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2010-11-17|2008-09-05|2008-09-09|Estimate|||||||2010-11-17|2010-11-18|Estimate|December 2002||2002-12-31|November 2010|2010-11-30|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|QUITLINE||Effectiveness of the American Lung Association Reactive Anti-Smoking Telephone Help Line in Illinois|A Randomized Controlled Trial on the Effectiveness of the American Lung Association Reactive Anti-Smoking Telephone Help Line in Illinois|Completed||N/A|990|Actual|Southern Illinois University||2|||f||||t||||||||||2018-06-01 01:46:43.936313|2018-06-01 01:46:43.936313
NCT00749138|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2010-03-07|2008-09-05|2008-09-09|Estimate|||||||2010-03-07|2010-03-09|Estimate|November 2008||2008-11-30|March 2010|2010-03-31|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy|Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy|Completed||Phase 1|18|Anticipated|Bader, Ted, M.D.||1|||f||||f||||||||||2018-06-01 01:46:44.010578|2018-06-01 01:46:44.010578
NCT00749125|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2013-03-18|2008-09-08|2008-09-09|Estimate|||||||2013-03-18|2013-03-19|Estimate|July 2001||2001-07-31|March 2013|2013-03-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||fMRI Studies of Emotional Brain Circuitry in People With Major Depression|fMRI Studies of Emotional Circuitry in Major Depression|Completed||N/A|100|Actual|National Institute of Mental Health (NIMH)||2|||f||||f||||||||||2018-06-01 01:46:44.080484|2018-06-01 01:46:44.080484
NCT00749112|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2010-08-27|2008-09-08|2008-09-09|Estimate|||||||2010-08-27|2010-08-30|Estimate|August 2008||2008-08-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias|Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias|Completed||Phase 2/Phase 3|19|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||f||||||||||2018-06-01 01:46:44.15397|2018-06-01 01:46:44.15397
NCT00749099|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-07|||2013-02-20|2008-09-08|2008-09-09|Estimate|||||||2013-02-20|2013-02-22|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)|092206: Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum) From PANCRECARB® (Pancrelipase), Delayed Release Capsules, Buffered and Enteric-Coated Microspheres|Terminated||N/A|11|Actual|Digestive Care, Inc.||2||No longer required study by FDA for NDA approval.|f||||t||||||||||2018-06-01 01:46:44.220361|2018-06-01 01:46:44.220361
NCT00749086|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2014-12-13|2008-09-08|2008-09-09|Estimate|||||||2014-12-13|2014-12-16|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|OSTEO+6||Comparison of Balloon Kyphoplasty and Vertebroplasty in Subacute Osteoporotic Vertebral Fractures|Prospective Randomized Study of Balloon Kyphoplasty and Vertebroplasty in Subacute (Older Than 6 Weeks) Osteoporotic Vertebral Fractures (STIC2)|Completed||Phase 4|97|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:46:44.270547|2018-06-01 01:46:44.270547
NCT00749073|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2013-01-18||2013-04-02|2008-09-08|2008-09-09|Estimate|2013-02-21|2013-04-04|Estimate||||2013-04-02|2013-04-10|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Vertos MILD™ Preliminary Patient Evaluation Study|A Single-center, Prospective, Clinical Study to Assess the Clinical Application and Outcomes of Minimally Invasive Lumbar Decompression With the MILD™ Devices in Patients With Symptomatic Central Foraminal Lumbar Spinal Stenosis.|Completed||N/A|10|Actual|Vertos Medical, Inc.|Small pilot series with short follow-up. Procedure experience of investigator limited. Minimal information available regarding appropriate patient selection, thus patient pool confined to complex cases wait-listed for more aggressive laminectomy.|1|||f||||f||||||||||2018-06-01 01:46:44.33552|2018-06-01 01:46:44.33552
NCT00749060|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2014-12-13|2008-09-08|2008-09-09|Estimate|||||||2014-12-13|2014-12-16|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|OSTEO-6||Comparison of Balloon Kyphoplasty, Vertebroplasty and Conservative Management in Acute Osteoporotic Vertebral Fractures|Prospective Randomized Comparative Study of Balloon Kyphoplasty,Vertebroplasty and Conservative Management in Acute Osteoporotic Vertebral Fractures of Less Than 6 Weeks|Completed||N/A|48|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-06-01 01:46:44.470386|2018-06-01 01:46:44.470386
NCT00749047|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2009-09-15|2008-09-08|2008-09-09|Estimate|||||||2009-09-15|2009-09-16|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine?|A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes.|Unknown status|Active, not recruiting|Phase 4|12|Anticipated|Christchurch Hospital||1|||f||||f||||||||||2018-06-01 01:46:44.538171|2018-06-01 01:46:44.538171
NCT00749034|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2010-05-19|2008-09-08|2008-09-09|Estimate|||||||2010-05-19|2010-05-20|Estimate|September 2008||2008-09-30|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers|Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination|Completed||Phase 1|80|Actual|Vakzine Projekt Management GmbH||2|||f||||f||||||||||2018-06-01 01:46:44.690241|2018-06-01 01:46:44.690241
NCT00749021|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2012-10-03|2008-09-08|2008-09-09|Estimate|||||||2012-10-03|2012-10-05|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments|A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.|Completed||Phase 1|40|Actual|Southern California Desert Retina Consultants, MC||4|||f||||f||||||||||2018-06-01 01:46:44.769181|2018-06-01 01:46:44.769181
NCT00749008|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2014-02-24|2008-09-08|2008-09-09|Estimate|||||||2014-02-24|2014-02-25|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Study of Generalized Movements for Early Prediction of Cerebral Palsy|Early Prediction of Cerebral Palsy in Preterm Infants and Term Infants Using Detection of Generalized Movements|Completed|||63|Actual|Hawaii Pacific Health|||2||f||||t||||||||||2018-06-01 01:46:44.856974|2018-06-01 01:46:44.856974
NCT00748995|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2018-01-29|2008-09-08|2008-09-09|Estimate|||||||2018-01-29|2018-01-31|Actual|August 31, 2010|Actual|2010-08-31|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|July 10, 2014|Actual|2014-07-10||Observational|||Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study|CSP #566 - Neuropsychological and Mental Outcomes of Operation Iraqi Freedom (OIF): A Longitudinal Cohort Study|Active, not recruiting|||817|Anticipated|VA Office of Research and Development|||1||f||||t|f|f|||f|None Retained|"~     No Biospecimens were collected~   "|No||2018-06-01 01:46:44.911049|2018-06-01 01:46:44.911049
NCT00748982|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2011-01-25||2011-06-22|2008-09-05|2008-09-09|Estimate|2011-05-12|2011-06-13|Estimate||||2011-06-22|2011-06-27|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction|A Single-centre, Single-blind, Randomised, Placebo-controlled Phase IIa Study to Investigate the Effect of AZD1305 Given as an Intravenous (iv) Infusion on Left Ventricular Performance in Patients With Left Ventricular Dysfunction|Completed||Phase 2|16|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:46:44.981747|2018-06-01 01:46:44.981747
NCT00748449|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2011-09-09|2008-09-05|2008-09-08|Estimate|||||||2011-09-09|2011-09-12|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|COLO-TDM||Colonography Versus Colonoscopy in High Risk Patient|Acceptability and Effectiveness of Colonography Compared to Colonoscopy for the Detection of Advanced Adenomas in Patients at High Risk for Colorectal Cancer|Terminated||N/A|39|Actual|Assistance Publique - Hôpitaux de Paris||2||No more inclusions|f||||f||||||||||2018-06-01 01:46:50.983988|2018-06-01 01:46:50.983988
NCT00748969|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2014-10-30||2017-10-17|2008-09-08|2008-09-09|Estimate|2014-11-19|2014-11-24|Estimate||||2017-10-17|2017-11-20|Actual|November 2008||2008-11-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Clinical Trial of Growth Hormone in MPS I, II, and VI|Phase II/III, Randomized, Clinical Trial of the Effects of Nutropin AQ® on Growth and Bone Metabolism in Children With MPS I, II, and VI and Short Stature|Terminated||Phase 2/Phase 3|2|Actual|Los Angeles Biomedical Research Institute||2||Insufficient recruitment.|f||||f||||||||||2018-06-01 01:46:45.200658|2018-06-01 01:46:45.200658
NCT00748956|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2017-04-12||2017-07-03|2008-09-08|2008-09-09|Estimate|2017-04-12|2017-05-17|Actual||||2017-07-03|2017-08-01|Actual|January 2010||2010-01-31|July 2017|2017-07-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|NPY||Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers|Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers|Completed||Phase 2|10|Actual|Icahn School of Medicine at Mount Sinai|Small sample size|3|||f||||t||||||||||2018-06-01 01:46:45.437679|2018-06-01 01:46:45.437679
NCT00748943|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2008-09-11|2008-09-08|2008-09-09|Estimate|||||||2008-09-11|2008-09-12|Estimate|March 2007||2007-03-31|September 2008|2008-09-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Clinical and Microbiological Effects of a Mouthwash Containing Chlorine Dioxide|The Clinical Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor and Salivary Periodontal and Malodorous Bacteria Using for 7days|Completed||Phase 1|15|Actual|Tokyo Medical and Dental University|||||f||||f||||||||||2018-06-01 01:46:45.733424|2018-06-01 01:46:45.733424
NCT00748930|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2015-02-12|2008-09-05|2008-09-09|Estimate|||||||2015-02-12|2015-02-13|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Observational|||The Canadian Follow-up Program for the ATTRACT Study (P04868)(TERMINATED)|The Canadian ATTRACT Follow-up Program|Terminated|||13|Actual|Merck Sharp & Dohme Corp.|||1|Challenging data collection|f||||f||||||||||2018-06-01 01:46:45.793478|2018-06-01 01:46:45.793478
NCT00748917|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2017-08-01|2008-09-08|2008-09-09|Estimate|||||||2017-08-01|2017-08-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:46:45.852903|2018-06-01 01:46:45.852903
NCT00748904|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2011-01-03|2008-09-08|2008-09-09|Estimate|||||||2011-01-03|2011-01-04|Estimate|June 2008||2008-06-30|January 2011|2011-01-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Rifaximin Versus Lactulose in Renal Failure|A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure|Unknown status|Recruiting|Phase 4|70|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 01:46:45.885814|2018-06-01 01:46:45.885814
NCT00748891|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2011-06-30|2008-09-08|2008-09-09|Estimate|||||||2011-06-30|2011-07-01|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|February 2010|Actual|2010-02-28||Interventional|||DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)|Exploratory Open-Label, Non-randomised, Single Centre Methodology Study Comparing DCE-CT and DCE-MRI as Markers of Changes in Vascular Activity Mediated by a Positive Control Agent [Cediranib (Recentin™; AZD2171), a Potent Inhibitor of VEGF-driven Angiogenesis] in Patients With Advanced Solid Tumour|Completed||Phase 1|35|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:46:45.957428|2018-06-01 01:46:45.957428
NCT00748878|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2013-10-11|2008-09-08|2008-09-09|Estimate|||||||2013-10-11|2013-10-16|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|||Platelet Function During ECMO (Extra Corporeal Membrane Oxygenation)|Platelet Function During ECMO|Completed|||5|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:46:46.020285|2018-06-01 01:46:46.020285
NCT00748865|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2009-09-25||2012-01-31|2008-09-05|2008-09-09|Estimate|2010-02-23|2010-03-11|Estimate||||2012-01-31|2012-02-02|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Acute Comfort and Blur of Systane Ultra and Systane||Completed||N/A|20|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:46:46.07564|2018-06-01 01:46:46.07564
NCT00748852|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05||2013-01-31|2013-01-31|2008-09-08|2008-09-09|Estimate||||2013-01-31|2013-02-04|Estimate|2013-01-31|2013-02-04|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety Study of JTT-302 in Subjects With Low HDL-C Levels|An Eight Week, Open-label Extension Study Evaluating the Safety of JTT-302 Administered Once Daily in Subjects With Low HDL-C Levels Who Have Completed the Treatment Phase of Study AT302-U-06-003|Completed||Phase 2|103|Actual|Akros Pharma Inc.||1|||f||||f||||||||||2018-06-01 01:46:46.200997|2018-06-01 01:46:46.200997
NCT00748839|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2012-11-22|2008-09-05|2008-09-09|Estimate|||||||2012-11-22|2012-11-27|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|Score-TIH||Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical|Heparin-Induced Thrombocytopenia : Development and Validation of a Predictive Clinical Score: a Prospective Multicenter Study Under the Auspices of the French Haemostasis and Thrombosis Study Group (GEHT)in Cooperation With the French Association of Regional PharmacoVigilance Center (AFCRPV)|Completed|||2700|Actual|Centre Hospitalier Universitaire de Saint Etienne|||||f||||f||||||Samples Without DNA|"~     blood sample~   "|||2018-06-01 01:46:46.252766|2018-06-01 01:46:46.252766
NCT00748826|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2011-12-22||2015-09-02|2008-09-05|2008-09-09|Estimate|2011-12-22|2012-02-01|Estimate||||2015-09-02|2015-09-03|Estimate|August 2002||2002-08-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Remicade Safety Line (Study P03236)(COMPLETED)|Remicade Safety Line|Completed|||576|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:46:46.442756|2018-06-01 01:46:46.442756
NCT00748813|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2016-11-30|2008-09-08|2008-09-09|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2008||2008-06-30|December 2011|2011-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2008/2009|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Sub|Completed||Phase 2|133|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:46:46.583835|2018-06-01 01:46:46.583835
NCT00748800|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2009-02-05|2008-09-08|2008-09-09|Estimate|||||||2009-02-05|2009-02-06|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|October 2007|Actual|2007-10-31|May 2007|Actual|2007-05-31||Interventional|||An Affect Management Intervention for Juvenile Offenders|An Affect Management Intervention for Juvenile Offenders|Completed||Phase 1|95|Actual|Rhode Island Hospital||2|||f||||f||||||||||2018-06-01 01:46:46.650645|2018-06-01 01:46:46.650645
NCT00748436|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2009-05-06|2008-09-05|2008-09-08|Estimate|||||||2009-05-06|2009-05-07|Estimate|September 2008||2008-09-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy Study of Betahistine on Body Weight in Obese Female Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects|Completed||Phase 2|187|Actual|OBEcure Ltd.||3|||f||||t||||||||||2018-06-01 01:46:51.242585|2018-06-01 01:46:51.242585
NCT00748787|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2011-06-07|2008-09-08|2008-09-09|Estimate|||||||2011-06-07|2011-06-08|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Trial to Evaluate the Effect of Plantago Ovata Husk in the Remission of Metabolic Syndrome in Children and Adolescents|Multicenter, Double Blind, Randomized, Controlled With Placebo, to Evaluate the Effect of the Treatment With Plantago Ovata Husk in the Incidence of the Remission of Metabolic Syndrome in Children and Adolescents Between 10 to 16 Years Old.|Terminated||Phase 2|19|Actual|Rottapharm Spain||2||"It was very difficult to fulfill the inclusion criteria, therefore the expected time of~   inclusion was delayed so much time."|f||||f||||||||||2018-06-01 01:46:46.710668|2018-06-01 01:46:46.710668
NCT00748774|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2016-01-05|2008-09-08|2008-09-09|Estimate|||||||2016-01-05|2016-01-07|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Brain Tumor Patient-Caregiver Congruence, MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)|Primary Brain Tumor Patient and Caregiver Congruence in Symptom Report Using the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)|Completed|||115|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 01:46:46.777959|2018-06-01 01:46:46.777959
NCT00748761|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2014-12-16|2008-09-08|2008-09-09|Estimate|||||||2014-12-16|2014-12-18|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Cognitive Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|Cognitive-Behavioral Therapy & Glutamatergic Neurometabolites in Pediatric OCD|Unknown status|Active, not recruiting|N/A|108|Anticipated|University of California, Los Angeles||3|||f||||f||||||||||2018-06-01 01:46:46.838179|2018-06-01 01:46:46.838179
NCT00748748|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|||2012-07-03|2008-09-08|2008-09-09|Estimate|||||||2012-07-03|2012-07-04|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Lactobacillus Probiotic on Healthy Adults|Effect of Lactobacillus Probiotic on Healthy Adults|Completed||Phase 1|20|Actual|Fargo VA Medical Center||1|||f||||f||||||||||2018-06-01 01:46:46.902831|2018-06-01 01:46:46.902831
NCT00748735|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-07|||2008-09-08|2008-09-08|2008-09-09|Estimate|||||||2008-09-08|2008-09-09|Estimate||||January 2008|2008-01-31||||||||Observational|||Left Ventricular Lead Position in Cardiac Resynchronization Therapy|Optimal Definition of Left Ventricular Lead Position in Cardiac Resynchronization Therapy by Myocardial Deformation Imaging|Completed|||55|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-06-01 01:46:47.013293|2018-06-01 01:46:47.013293
NCT00748722|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2008-09-07|2008-09-07|2008-09-09|Estimate|||||||2008-09-07|2008-09-09|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Observational|DIEP||Pre-Operative Imaging of Abdominal Wall Perforators Using CT Angiography|Pre-Operative Imaging of Abdominal Wall Perforators Using CT Angiography for DIEP Breast Reconstruction|Unknown status|Active, not recruiting||20|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||||||2018-06-01 01:46:47.083321|2018-06-01 01:46:47.083321
NCT00748709|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-08|2013-08-08||2013-11-05|2008-09-08|2008-09-09|Estimate|2013-08-08|2013-10-14|Estimate||||2013-11-05|2013-11-28|Estimate|October 2008||2008-10-31|November 2013|2013-11-30||||November 2010|Actual|2010-11-30||Interventional|||Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.|An Open Label Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.|Terminated||Phase 2|20|Actual|Boehringer Ingelheim|Due to early study termination, only data on the primary efficacy endpoint were summarized, no CIs were produced and efficacy and safety results were presented for the overall population rather than by tumor category.|1|||f||||||||||||||2018-06-01 01:46:47.15696|2018-06-01 01:46:47.15696
NCT00748696|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2012-02-20|2008-09-04|2008-09-08|Estimate|||||||2012-02-20|2012-02-22|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Combined Effects of Resistance Training and Nutritional Supplements in the Treatment of Sarcopenia|Combined Effects of Resistance Training and Nutritional Supplements in the Treatment of Sarcopenia|Terminated||Phase 3|2|Actual|Centre Hospitalier Universitaire de Nice||4|||f||||f||||||||||2018-06-01 01:46:47.411042|2018-06-01 01:46:47.411042
NCT00748683|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2009-12-14|2008-09-05|2008-09-08|Estimate|||||||2009-12-14|2009-12-15|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|||Development of an Integrated Health Care Environment for Elderly With RFID Technology|Development of an Integrated Health Care Environment for Elderly With RFID Technology|Completed||Early Phase 1|15|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:46:47.487509|2018-06-01 01:46:47.487509
NCT00748670|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2008-09-05|2008-09-05|2008-09-08|Estimate|||||||2008-09-05|2008-09-08|Estimate|September 1999||1999-09-30|September 2008|2008-09-30||||October 2006|Actual|2006-10-31||Interventional|||Treatment With Fixture Microthread™ in Patients With Poor Bone Quality and no Teeth in the Upper Jaw, When Using Two-Stage Surgery|An Open, Prospective, Multicenter Study to Evaluate Treatment of Edentulous Upper Jaws With an Implant-Supported Prosthesis Retained by Astra Tech Dental Implants, Fixture Micro-Macro in Patients With Poor Bone Quality|Terminated||N/A|23|Actual|Dentsply Sirona Implants||1||"Decision to modify the product under study as a result of feedback regarding subjective feeling~   during installation procedure. For more info, see brief summary."|f||||f||||||||||2018-06-01 01:46:47.538898|2018-06-01 01:46:47.538898
NCT00748657|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2015-05-27||2018-03-20|2008-09-05|2008-09-08|Estimate|2015-05-27|2015-06-10|Estimate||||2018-03-20|2018-04-18|Actual|September 22, 2008|Actual|2008-09-22|March 2018|2018-03-31|January 31, 2013|Actual|2013-01-31|January 31, 2013|Actual|2013-01-31||Interventional||Eligibile and treatmed patients|Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary|A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary|Completed||Phase 2|36|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 01:46:47.617082|2018-06-01 01:46:47.617082
NCT00748644|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2018-03-01|2008-09-05|2008-09-08|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2008||2008-10-31|January 2012|2012-01-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|MAINRITSAN||Efficacy Study of Two Treatments in the Remission of Vasculitis|MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis|Completed||Phase 3|117|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:46:48.044356|2018-06-01 01:46:48.044356
NCT00748631|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2015-03-23|2008-09-05|2008-09-08|Estimate|||||||2015-03-23|2015-03-24|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|KYPHOK||Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.|"Assessment of Percutaneous Balloon Kyphoplasty in the Treatment of Malignant Vertebral Fractures (Multiple Myeloma and Osteolytic Metastases) : Observational Study"|Terminated||N/A|60|Actual|Assistance Publique - Hôpitaux de Paris||1||the data collected are enough to obtain a qualitative analysis.|f||||f||||||||||2018-06-01 01:46:48.158519|2018-06-01 01:46:48.158519
NCT00748605|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05||2018-04-26|2018-05-09|2008-09-05|2008-09-08|Estimate||||2018-04-26|2018-05-01|Actual|2018-05-09|2018-05-11|Actual|June 2007||2007-06-30|May 2018|2018-05-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet|A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0 or 1600 mg/Day of S-2367 Administered Orally Once Daily With an Initial 6-Week Low Calorie Diet in Obese Males and Females|Completed||Phase 2|842|Actual|Shionogi Inc.||3|||f||||f||||||||||2018-06-01 01:46:48.370869|2018-06-01 01:46:48.370869
NCT00748592|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2009-02-11|2008-09-05|2008-09-08|Estimate|||||||2009-02-11|2009-02-12|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia|PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover, Multicenter Polysomnography Trial Of PD 0200390 In Elderly Subjects With Primary Insomnia|Withdrawn||Phase 2|0|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:46:48.53811|2018-06-01 01:46:48.53811
NCT00748579|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2010-07-30||2015-10-07|2008-09-04|2008-09-08|Estimate|2010-07-30|2010-08-23|Estimate||||2015-10-07|2015-10-29|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|July 2009|Actual|2009-07-31|November 2008|Actual|2008-11-30||Interventional|||Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency|A Phase II Open-Label Study to Investigate the Effects of CK-1827452 Injection on Ventricular Performance, Myocardial Oxygen Consumption, and Myocardial Efficiency in Patients With Heart Failure and Left Ventricular Systolic Dysfunction|Terminated||Phase 2|2|Actual|Cytokinetics|Inadequate enrollment led to early termination of study and insufficient number of patients for analysis.|2||"Decision to discontinue due to challenges of trial design and constraints on enrolling eligible~   and consenting patients."|f||||t||||||||||2018-06-01 01:46:48.639206|2018-06-01 01:46:48.639206
NCT00748566|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2013-04-29||2013-04-29|2008-09-05|2008-09-08|Estimate|2013-04-29|2013-06-19|Estimate||||2013-04-29|2013-06-19|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome|A One-Year, Phase IV, Open-Label, Non-Comparative Trial Of The Effect Of Ziprasidone HCL On Metabolic Syndrome Risk Factors In Patients With Psychotic Disorders|Terminated||Phase 4|172|Actual|Pfizer|The study was prematurely terminated by sponsor due to changes in organizational strategy and resources, not due to safety concerns.|1||See Detailed Description|f||||f||||||||||2018-06-01 01:46:48.84523|2018-06-01 01:46:48.84523
NCT00748553|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2017-03-14||2017-06-27|2008-09-05|2008-09-08|Estimate|2017-06-27|2017-07-26|Actual||||2017-06-27|2017-07-26|Actual|September 2008||2008-09-30|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|VA|In the Phase I cohort, two patients stopped during Cycle I due to disease progression, and one was removed in cycle 4 due to noncompliance. In the Phase II cohort, one patient opted out after 1 cycle because of toxicity.|A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer|A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer|Completed||Phase 1/Phase 2|30|Actual|University of Utah||1|||f||||f||||||||||2018-06-01 01:46:49.573429|2018-06-01 01:46:49.573429
NCT00748540|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05||2016-03-09|2016-03-09|2008-09-05|2008-09-08|Estimate||||2016-03-09|2016-04-07|Estimate|2016-03-09|2016-04-07|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|VSBRW||Safety and Efficacy of the Vibrant Soundbridge (VSB) for Mixed and Conductive Hearing Losses|Clinical Trial of the Vibrant Soundbridge as a Treatment for Conductive and Mixed Hearing Losses, Using Direct Round Window Cochlear Stimulation.|Completed||N/A|50|Actual|Med-El Corporation||1|||f||||f||||||||||2018-06-01 01:46:50.088592|2018-06-01 01:46:50.088592
NCT00748527|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2013-07-09|2008-09-05|2008-09-08|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 2007||2007-07-31|September 2008|2008-09-30|November 2010|Actual|2010-11-30|December 2009|Actual|2009-12-31||Interventional|||Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Cancer Research UK Randomised, Multicentre, Phase II Trial of the DNAhypomethylating Agent, 5-Aza-2'-Deoxycytidine (Decitabine) Given Intravenously in Combination With Carboplatin, Versus Carboplatin Alone Given 4 Weekly in Patients With Progressive, Advanced Ovarian Cancer|Terminated||Phase 2|134|Anticipated|National Cancer Institute (NCI)||2||"The study was withdrawn due to certain adverse events [hypersensitivity]."|f||||||||||||||2018-06-01 01:46:50.301615|2018-06-01 01:46:50.301615
NCT00748514|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2008-10-06|2008-09-05|2008-09-08|Estimate|||||||2008-10-06|2008-10-07|Estimate|June 1995||1995-06-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||A Capsular Incision and Biochemical Recurrence After Radical Perineal Prostatectomy|Impact of a Capsular Incision on Biochemical Recurrence After Radical Perineal Prostatectomy|Completed|||266|Actual|Samsung Medical Center|||||f||||t||||||Samples Without DNA|"~     prostate gland~   "|||2018-06-01 01:46:50.424103|2018-06-01 01:46:50.424103
NCT00748501|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04||2012-10-30|2012-10-30|2008-09-05|2008-09-08|Estimate||||2012-10-30|2012-11-01|Estimate|2012-10-30|2012-11-01|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ALS||Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Phase 2 Repeat-Dosing Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis|Completed||Phase 2|45|Actual|Sangamo Therapeutics||2|||f||||f||||||||||2018-06-01 01:46:50.505582|2018-06-01 01:46:50.505582
NCT00748488|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2012-01-27|2008-09-05|2008-09-08|Estimate|||||||2012-01-27|2012-01-31|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ParkFit||Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease|The ParkFit Study; Effectiveness of an Active Lifestyle Promotion Program for Patients With Parkinson's Disease|Completed||Phase 3|700|Actual|Radboud University||2|||f||||t||||||||||2018-06-01 01:46:50.626144|2018-06-01 01:46:50.626144
NCT00748475|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2013-02-19|2008-09-05|2008-09-08|Estimate|||||||2013-02-19|2013-02-20|Estimate|September 2008||2008-09-30|February 2013|2013-02-28||||May 2010|Actual|2010-05-31||Interventional|||Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus|Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus|Completed||N/A|12|Actual|University of Konstanz||1|||f||||f||||||||||2018-06-01 01:46:50.792605|2018-06-01 01:46:50.792605
NCT00748462|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2014-01-24|2008-09-05|2008-09-08|Estimate|||||||2014-01-24|2014-01-28|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CO2||Fractional CO2 Treatment of Acne Scars in Asians|Clinical Quality Assurance Study: Fractional CO2 Treatment of Acne Scars in Asians|Completed||Phase 4|12|Actual|Mahidol University||1|||f||||t||||||||||2018-06-01 01:46:50.87631|2018-06-01 01:46:50.87631
NCT00748423|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2013-08-01|2008-09-05|2008-09-08|Estimate|||||||2013-08-01|2013-08-02|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|INOSTA||Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)|Bicentric Study of the Effect of Inhaled Nitric Oxide Compared to Placebo in Acute Chest Syndrome of Adult Sickle Cell Patients|Completed||Phase 2/Phase 3|100|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:46:51.34831|2018-06-01 01:46:51.34831
NCT00748410|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2017-08-18||2017-08-20|2008-09-05|2008-09-08|Estimate|2017-08-20|2018-03-14|Actual||||2017-08-20|2018-03-14|Actual|January 22, 2009|Actual|2009-01-22|August 2017|2017-08-31|December 12, 2009|Actual|2009-12-12|December 12, 2009|Actual|2009-12-12||Interventional|||Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis|An Open Label, 7-day Repeat Dose Study to Evaluate the Pharmacodynamics of SB-656933-AAA in Patients With Ulcerative Colitis.|Terminated||Phase 2|3|Actual|GlaxoSmithKline|This study was early terminated on 17 February 2010 because investigational drug and further that the duration of treatment (7 days) was unlikely to provide any clinical benefit to participants.|1||SB-656933 is no longer being developed for ulcerative colitis.|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:46:51.469323|2018-06-01 01:46:51.469323
NCT00748397|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2008-09-05|2008-09-05|2008-09-08|Estimate|||||||2008-09-05|2008-09-08|Estimate|January 1999||1999-01-31|September 2008|2008-09-30||||December 2007|Actual|2007-12-31||Interventional|||Evaluation of Treatment With Fixture Microthread™ in Patients Missing All Teeth in the Upper Jaw, When Using One-Stage Surgery|An Open, Prospective, Multicenter Study to Evaluate Treatment of Edentulous Upper Jaws With Fixed Detachable Bridges Retained by Astra Tech Dental Implants, Fixture Micro-Macro|Terminated||N/A|54|Actual|Dentsply Sirona Implants||1||"Decision to modify the product under study as a result of feedback regarding subjective feeling~   during installation procedure. For more info, see brief summary."|f||||f||||||||||2018-06-01 01:46:52.080673|2018-06-01 01:46:52.080673
NCT00748384|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-05-14|2008-09-05|2008-09-08|Estimate|||||||2013-05-14|2013-05-15|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|UU2||Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients|Usability of the Foresee Home in Intermediate Age Related Macular Degeneration Patients|Completed|||30|Actual|Notal Vision Ltd|||2||f||||f||||||||||2018-06-01 01:46:52.246988|2018-06-01 01:46:52.246988
NCT00748371|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2017-04-10|2008-09-05|2008-09-08|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2004||2004-06-30|April 2017|2017-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration|Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration|Terminated||Phase 4|51|Actual|Vanderbilt University Medical Center||3||Funding issue|f||||f|f|f||||||No||2018-06-01 01:46:52.314066|2018-06-01 01:46:52.314066
NCT00748358|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2013-09-17|2008-09-05|2008-09-08|Estimate|||||||2013-09-17|2013-09-18|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PROSUT||An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer|An Open Label Phase II Study of Oral Treatment With Sunitinib (SUTENT) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen|Completed||Phase 2|50|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:46:52.391373|2018-06-01 01:46:52.391373
NCT00748345|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2011-12-15|2008-09-05|2008-09-08|Estimate|||||||2011-12-15|2011-12-16|Estimate|February 2009||2009-02-28|July 2011|2011-07-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|Caspo-brûlés||Pharmacokinetics of Caspofungin in Burn Patients|Pharmacokinetics of Caspofungin in Burn Patients|Completed||Phase 2/Phase 3|2|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:46:52.472289|2018-06-01 01:46:52.472289
NCT00748332|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2012-08-21|2008-09-04|2008-09-08|Estimate|||||||2012-08-21|2012-08-22|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|August 2012|Actual|2012-08-31|June 2011|Actual|2011-06-30||Interventional|||Protein-energy Oral Supplementation Enriched With Omega-3 Fatty Acids in Cardiac Cachexia|Effects of a Protein-energy Oral Supplement Enriched With Omega-3 Fatty Acids Compared to a Standard Protein-energy Supplement in Cardiac Cachexia|Terminated||Phase 3|6|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:46:52.557876|2018-06-01 01:46:52.557876
NCT00748319|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2012-08-21|2008-09-05|2008-09-08|Estimate|||||||2012-08-21|2012-08-22|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|KIR||Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma|Analysis of Killer Immunoglobulin-like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T-cell Lymphomas (Mycosis Fungoid and Sézary Syndrome) in Patients With Erythroderma or Erythematous Patches/Plaques.|Completed||N/A|495|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:46:52.634082|2018-06-01 01:46:52.634082
NCT00748306|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2016-10-11|2008-09-05|2008-09-08|Estimate|||||||2016-10-11|2016-10-12|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study in Mild Asthmatic Patients|A Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With GSK2190915 on the Allergen-induced Asthmatic Response in Subjects With Mild Asthma|Completed||Phase 2|19|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:46:52.698244|2018-06-01 01:46:52.698244
NCT00748293|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2008-09-05|2008-09-05|2008-09-08|Estimate|||||||2008-09-05|2008-09-08|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet|Achievement of Better Examinee Compliance on Colon Cleansing Before Colonoscopy Without Sacrificing Cleansing Effect - A Multi-Center Endoscopist-Blinded Randomized Trial Using Commercialized Low-Residue Diet|Unknown status|Recruiting|N/A|224|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:46:52.796111|2018-06-01 01:46:52.796111
NCT00748280|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2017-04-26|2008-09-04|2008-09-08|Estimate|||||||2017-04-26|2017-04-28|Actual|April 2008||2008-04-30|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2008|Actual|2008-09-30||Interventional|VPT||Vital Pulp Therapy to Treat Irreversible Pulpitis|Pulpotomy Versus Root Canal Therapy to Treat Irreversible Pulpitis in Human Permanent Molars: A Multicenter Randomized Non-inferiority Trial.|Completed||N/A|615|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:46:52.870128|2018-06-01 01:46:52.870128
NCT00748267|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2011-03-03|2008-09-05|2008-09-08|Estimate|||||||2011-03-03|2011-03-07|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer|Use of Pre-Operative Hypnosis to Reduce Post-Operative Pain and Anesthesia Related Side-Effects|Completed||N/A|20|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 01:46:52.949107|2018-06-01 01:46:52.949107
NCT00748254|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2018-01-30|2008-09-04|2008-09-08|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2008||2008-02-29|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis|Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis|Enrolling by invitation|||120|Anticipated|University of Michigan|||2||f||||f||||||||No||2018-06-01 01:46:53.031237|2018-06-01 01:46:53.031237
NCT00748241|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2011-08-23||2012-01-12|2008-09-05|2008-09-08|Estimate|2012-01-12|2012-02-15|Estimate||||2012-01-12|2012-02-15|Estimate|September 2000||2000-09-30|January 2012|2012-01-31||||August 2008|Actual|2008-08-31||Interventional|||Study to Evaluate Implant Survival Rate of Astra Tech Fixture ST in the Posterior Maxilla With One-stage Surgery and Early Loading|An Open Prospective Study to Evaluate the Survival Rate and Marginal Bone Response of Astra Tech Dental Implants, Fixture ST, in Patients With Tooth Loss in the Posterior Maxilla.|Completed||N/A|19|Actual|Dentsply Sirona Implants||1|||f||||f||||||||||2018-06-01 01:46:53.098238|2018-06-01 01:46:53.098238
NCT00748228|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2015-06-11|2008-09-05|2008-09-08|Estimate|||||||2015-06-11|2015-06-15|Estimate|November 2004||2004-11-30|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Dopamine in Orthostatic Tolerance|Dopamine in Orthostatic Tolerance|Terminated||N/A|22|Actual|Vanderbilt University||3||This study is being replaced by another protocol.|f||||f||||||||||2018-06-01 01:46:53.245662|2018-06-01 01:46:53.245662
NCT00748215|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2014-08-14|2008-09-05|2008-09-08|Estimate|||||||2014-08-14|2014-08-15|Estimate|February 2009||2009-02-28|August 2014|2014-08-31||||August 2014|Actual|2014-08-31||Interventional|||Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan|Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|100|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 01:46:54.447597|2018-06-01 01:46:54.447597
NCT00748202|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2011-01-18|2008-09-04|2008-09-08|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|PASSION||Berinert P Study of Subcutaneous Versus Intravenous Administration|Pharmacokinetics Berinert P Study of Subcutaneous Versus Intravenous Administration in Subjects With Moderate Hereditary Angioedema - The Passion Study|Completed||Phase 3|24|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-06-01 01:46:54.526706|2018-06-01 01:46:54.526706
NCT00748189|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2013-11-14||2018-03-28|2008-09-05|2008-09-08|Estimate|2014-02-27|2014-03-26|Estimate||||2018-03-28|2018-04-25|Actual|December 22, 2008|Actual|2008-12-22|March 2018|2018-03-31|June 16, 2022|Anticipated|2022-06-16|March 20, 2013|Actual|2013-03-20||Interventional|COMPLEMENT 1||Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia|A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 3|447|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:46:54.711807|2018-06-01 01:46:54.711807
NCT00748176|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2009-12-14|2008-09-05|2008-09-08|Estimate|||||||2009-12-14|2009-12-15|Estimate|July 2008||2008-07-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||The Relationship of Abdominal Circumference and Trunk Length With the Level of Spinal Anesthesia in Obstetric Patients|The Relationship of Abdominal Circumference and Trunk Length With the Level of Spinal Anesthesia in Obstetric Patients|Completed|||30|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 01:46:56.358283|2018-06-01 01:46:56.358283
NCT00748163|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2011-08-31|2008-09-05|2008-09-08|Estimate|||||||2011-08-31|2011-09-02|Estimate|August 2008||2008-08-31|August 2011|2011-08-31||||||||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer|Phase II Study of ABI-007 Plus Sunitinib as First Line Treatment for Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||1||Study has been abandoned for lack of available funding.|||||t||||||||||2018-06-01 01:46:56.426987|2018-06-01 01:46:56.426987
NCT00748150|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2012-01-04|2008-09-05|2008-09-08|Estimate|||||||2012-01-04|2012-01-05|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects|A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects|Completed||Phase 2|143|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:46:56.517839|2018-06-01 01:46:56.517839
NCT00748137|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2010-02-05|2008-09-05|2008-09-08|Estimate|||||||2010-02-05|2010-02-08|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|January 2011|Anticipated|2011-01-31|October 2010|Anticipated|2010-10-31||Interventional|||Bolus Insulin Card Calculator Randomised Controlled Study|Bolus Insulin Card Calculator Randomised Controlled Study|Unknown status|Recruiting|N/A|150|Anticipated|John Hunter Children's Hospital||2|||f||||f||||||||||2018-06-01 01:46:56.59717|2018-06-01 01:46:56.59717
NCT00748124|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04||2013-02-22|2014-09-04|2008-09-05|2008-09-08|Estimate||||2013-02-22|2013-02-28|Estimate|2014-09-04|2014-09-11|Estimate|August 2008||2008-08-31|September 2014|2014-09-30|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||PleuraSeal Pivotal Study (US)|A Prospective Multicenter Randomized Clinical Study to Evaluate the PleuraSeal Sealant System as an Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy|Terminated||Phase 3|230|Actual|Integra LifeSciences Corporation||2||Interim analysis results were not supportive of primary endpoint|f||||f||||||||||2018-06-01 01:46:56.697581|2018-06-01 01:46:56.697581
NCT00748111|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2015-12-15|2008-09-05|2008-09-08|Estimate|||||||2015-12-15|2015-12-16|Estimate|August 2008||2008-08-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|TIDE||Thrombus and Inflammation Study in Sudden Cardiac DEath|Thrombus and Inflammation in Sudden Cardiac DEath|Completed||N/A|380|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-06-01 01:46:56.759898|2018-06-01 01:46:56.759898
NCT00747227|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2011-03-04||2011-10-06|2008-09-04|2008-09-05|Estimate|2011-10-06|2011-11-11|Estimate||||2011-10-06|2011-11-11|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)|Clinical Evaluation of a Modified Light Transmission IOL|Completed||Phase 3|250|Actual|Abbott Medical Optics||2|||f||||f||||||||||2018-06-01 01:47:06.184772|2018-06-01 01:47:06.184772
NCT00748098|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2011-04-21|2010-08-12|2013-07-15|2008-09-05|2008-09-08|Estimate|2011-04-21|2011-05-18|Estimate|2010-08-12|2010-08-18|Estimate|2013-07-15|2013-07-22|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance|Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance|Completed||Phase 3|136|Actual|XenoPort, Inc.||2|||f||||f||||||||||2018-06-01 01:46:56.871152|2018-06-01 01:46:56.871152
NCT00748085|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2014-06-16||2015-06-30|2008-09-04|2008-09-08|Estimate|2014-06-16|2014-07-16|Estimate||||2015-06-30|2015-07-23|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|ICEtheMAD||CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)|A Multi-Center Study of CryoSpray Ablation(tm)in Malignant Airway Disease to Determine, Safety, and Tissue Effect in the Lung (ICE the MAD)|Terminated||N/A|5|Actual|CSA Medical, Inc.||1||Business Reasons|f||||t||||||||||2018-06-01 01:46:57.451163|2018-06-01 01:46:57.451163
NCT00748072|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|2014-12-30||2014-12-30|2008-09-05|2008-09-08|Estimate|2014-12-30|2015-01-13|Estimate||||2014-12-30|2015-01-13|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy|1-deamino 8-d-arginine Vasopressin in Percutaneous Ultrasound-guided Renal Biopsy: a Randomized Controlled Trial|Completed||Phase 4|162|Actual|University of Bari|A possible limitation of the study is the single-center design of the study, which could reduce the generalizability of our results and their external validity.|2|||f||||f||||||||||2018-06-01 01:46:57.72706|2018-06-01 01:46:57.72706
NCT00748059|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2018-03-26|2008-09-05|2008-09-08|Estimate|||||||2018-03-26|2018-03-27|Actual|December 1996||1996-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Pathophysiology of Orthostatic Hypotension|The Pathophysiology of Orthostatic Hypotension|Active, not recruiting||Phase 1|25|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 01:46:57.887327|2018-06-01 01:46:57.887327
NCT00748046|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2014-06-24|2008-09-05|2008-09-08|Estimate|||||||2014-06-24|2014-06-25|Estimate|August 2008||2008-08-31|June 2014|2014-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton|Phase 1, Open-label, Single Ascending-dose Study to Assess Safety, Pharmacokinetics, Biodistribution and Radiation Dosimetry of Intravenous Doses of Alpharadin™ Injection (Radium-223 Chloride) in Patients With HRPC and Skeletal Metastases|Completed||Phase 1|10|Actual|Bayer||1|||f||||f||||||||||2018-06-01 01:46:57.965221|2018-06-01 01:46:57.965221
NCT00748033|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2012-09-27|2008-09-05|2008-09-08|Estimate|||||||2012-09-27|2012-09-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:46:58.050982|2018-06-01 01:46:58.050982
NCT00748020|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2008-09-05|2008-09-05|2008-09-08|Estimate|||||||2008-09-05|2008-09-08|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|January 2007|Actual|2007-01-31|May 2006|Actual|2006-05-31||Interventional|||Narrow-Band UVB-Therapy in Psoriasis|Narrow-Band UVB-Therapy in Psoriasis: Randomised Double-Blind Comparison of Erythematogenic and Suberythematogenic Irradiation Regimens|Completed||Phase 4|109|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 01:46:58.086027|2018-06-01 01:46:58.086027
NCT00748007|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2012-11-27|2008-09-05|2008-09-08|Estimate|||||||2012-11-27|2012-11-28|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of Rivastigmine in Patients With Down Syndrome|Efficacy of Rivastigmine in Patients With Down Syndrome|Completed||N/A|14|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:46:58.154625|2018-06-01 01:46:58.154625
NCT00747994|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2010-07-12|2008-09-05|2008-09-08|Estimate|||||||2010-07-12|2010-07-13|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|PAGET||Genetic Study of Families Affected by Paget's Disease of Bone|Genetic Study of Families Affected by Paget's Disease of Bone|Completed|||83|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     collection of extracted DNA, RNA and serum samples and urinary samples~   "|||2018-06-01 01:46:58.231136|2018-06-01 01:46:58.231136
NCT00747981|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2011-12-14|2008-09-05|2008-09-08|Estimate|||||||2011-12-14|2011-12-15|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|October 2011|Actual|2011-10-31|April 2010|Actual|2010-04-30||Interventional|SICE||Thoracic Computed Tomography Scan for Diagnosis of Aspirated Foreign Bodies.|Management and Assessment of Thoracic CT Scan for Diagnosis of Aspirated Foreign Bodies in Children|Completed||N/A|311|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:46:58.300137|2018-06-01 01:46:58.300137
NCT00747968|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2011-06-29|2008-09-05|2008-09-08|Estimate|||||||2011-06-29|2011-06-30|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|||The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET|The Effect of the GLP-1 Analogue Exenatide on Glucose Metabolism in the CNS and Heart During Hyperglycemia in Type-2 Diabetic Patients Assessed by PET|Completed||Phase 2/Phase 3|8|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 01:46:58.37191|2018-06-01 01:46:58.37191
NCT00747955|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2018-05-19|2008-09-05|2008-09-08|Estimate|||||||2018-05-19|2018-05-22|Actual|August 28, 2008||2008-08-28|April 7, 2017|2017-04-07|April 7, 2017||2017-04-07|||||Observational|||Evaluation of Assessments of Motor Performance, Physical Impairments and Functional Abilities|Evaluation of Assessments of Motor Performance, Physical Impairments and Functional Abilities|Terminated|||29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:46:58.466217|2018-06-01 01:46:58.466217
NCT00747942|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-09-05|2008-09-05|2008-09-08|Estimate|||||||2008-09-05|2008-09-08|Estimate|October 2006||2006-10-31|September 2008|2008-09-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|STAM||Support for Increased Physical Activity (Stöd Till Aktivare Motion)|Intervention Program for Physically Inactive and Overweight Immigrant Women From the Middle East and Latin America Living in Sweden|Unknown status|Active, not recruiting|N/A|234|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 01:46:58.518689|2018-06-01 01:46:58.518689
NCT00747929|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05||2018-04-25|2018-05-08|2008-09-05|2008-09-08|Estimate||||2018-04-25|2018-04-27|Actual|2018-05-08|2018-05-10|Estimate|June 2007||2007-06-30|May 2018|2018-05-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet|A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800, or 1600 mg/Day of S-2367 Administered Orally Once Daily With a Reduced Calorie Diet in Obese Males and Females|Completed||Phase 2|724|Actual|Shionogi Inc.||3|||f||||f||||||||||2018-06-01 01:46:58.597087|2018-06-01 01:46:58.597087
NCT00747916|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2014-07-02||2015-06-23|2008-09-04|2008-09-08|Estimate|2015-06-04|2015-06-08|Estimate||||2015-06-23|2015-07-16|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||"Safety, Efficacy, and Side Effects Study of Interventional Cryotherapy in the Pleural Space(ICE PLS)"|"A Pilot Study of the Safety, Efficacy, and Side Effects of Interventional Cryotherapy for the Eradication of Disease in the Pleural Space (ICE PLS)"|Terminated||Phase 4|3|Actual|CSA Medical, Inc.||1||Business Reasons|f||||f||||||||||2018-06-01 01:46:58.723323|2018-06-01 01:46:58.723323
NCT00747903|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-05|||2014-01-09|2008-09-05|2008-09-08|Estimate|||||||2014-01-09|2014-01-10|Estimate|February 2008||2008-02-29|July 2009|2009-07-31||||December 2010|Anticipated|2010-12-31||Interventional|||Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer|Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma|Unknown status|Recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:46:58.906149|2018-06-01 01:46:58.906149
NCT00747890|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2011-10-31|2008-09-04|2008-09-05|Estimate|||||||2011-10-31|2011-11-01|Estimate|September 2008||2008-09-30|October 2011|2011-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Surgical Treatment of Mild Obstructive Sleep Apnea|The Effects of Surgical Treatment on Mild Obstructive Sleep Apnea and Its Co-morbidities|Unknown status|Recruiting|N/A|100|Anticipated|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 01:46:58.970041|2018-06-01 01:46:58.970041
NCT00747877|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-08-09|2008-09-04|2008-09-05|Estimate|||||||2013-08-09|2013-08-12|Estimate|April 2008||2008-04-30|June 2009|2009-06-30||||April 2012|Anticipated|2012-04-30||Interventional|||High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy|Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue.|Unknown status|Recruiting|Phase 3|460|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:46:59.052826|2018-06-01 01:46:59.052826
NCT00747864|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2010-07-21|2008-09-04|2008-09-05|Estimate|||||||2010-07-21|2010-07-23|Estimate|April 2006||2006-04-30|July 2010|2010-07-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Observational|||Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life|Relationship of Gestational Age and Urine Concentration of S100B in Preterm and Term Infants in the First Week of Life|Completed|||106|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:46:59.237261|2018-06-01 01:46:59.237261
NCT00747851|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2017-10-25|2008-09-04|2008-09-05|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2003||2003-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Necrotizing Enterocolitis (NEC) & Platelet-Activating Factor (PAF)-Stimulated Protein Translation in Premature Infants|Necrotizing Enterocolitis (NEC) & Platelet-Activating Factor (PAF)-Stimulated Protein Translation in Premature Infants|Recruiting|||388|Anticipated|University of Utah|||||f||||f||||||||||2018-06-01 01:46:59.287728|2018-06-01 01:46:59.287728
NCT00747838|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-05-24|2008-09-04|2008-09-05|Estimate|||||||2013-05-24|2013-05-27|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|STAR||A Multicenter Data Registry for Outcomes From Surgical Treatment of Atrial Arrhythmias|Surgical Treatment for Atrial Arrhythmia Registry (STAR Outcomes)|Terminated|||106|Actual|Virginia Commonwealth University||||Low enrollment.|f||||f||||||||||2018-06-01 01:46:59.448346|2018-06-01 01:46:59.448346
NCT00747825|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2011-10-07|2008-09-04|2008-09-05|Estimate|||||||2011-10-07|2011-10-12|Estimate|December 2009||2009-12-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma|A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, and Determination of Radiation Dosimetry for 131-I-MIP-1145|Terminated||Phase 1|12|Anticipated|Molecular Insight Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 01:46:59.506215|2018-06-01 01:46:59.506215
NCT00747812|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2012-06-28||2012-06-28|2008-09-04|2008-09-05|Estimate|2012-06-28|2012-08-03|Estimate||||2012-06-28|2012-08-03|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|November 2008|Actual|2008-11-30||Interventional|PRISM UK||Study of Occipital Nerve Stimulation for Drug Refractory Migraine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Occipital Nerve Stimulation for Drug Refractory Migraine|Terminated||Phase 2|11|Actual|Boston Scientific Corporation|Insufficient data collected from limited number of implanted subjects.|2||Sponsor closed enrollment early based on interim data from the PRISM US Pivotal Study.|f||||f||||||||||2018-06-01 01:46:59.601645|2018-06-01 01:46:59.601645
NCT00747799|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-12-08|2008-09-04|2008-09-05|Estimate|||||||2013-12-08|2013-12-10|Estimate|January 2009||2009-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Interventional|||Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)|Phase II Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Are Failure of Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)|Completed||Phase 2|54|Actual|Sun Yat-sen University||1|||f||||||||||||||2018-06-01 01:46:59.910518|2018-06-01 01:46:59.910518
NCT00747786|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-10-07|2008-09-04|2008-09-05|Estimate|||||||2013-10-07|2013-10-08|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Observational|||Non Interventional Post Marketing Programme in Neuroendocrine Tumours|"An Observational, Multicentre, Open Label, Non Interventional Programme to Assess the Long-Term Safety and Efficacy of Somatuline Autogel in the Treatment of Neuroendocrine Tumours When Administered by Patients or Their Partners (Home Injection Group) or Administered by Healthcare Professionals"|Completed|||40|Actual|Ipsen|||||f||||f||||||||||2018-06-01 01:46:59.977535|2018-06-01 01:46:59.977535
NCT00747773|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2014-01-08|2008-09-04|2008-09-05|Estimate|||||||2014-01-08|2014-01-09|Estimate|November 2007||2007-11-30|January 2014|2014-01-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|CSAir 1||Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung|A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung|Completed||Phase 4|21|Actual|CSA Medical, Inc.|||||f||||t||||||||||2018-06-01 01:47:00.043153|2018-06-01 01:47:00.043153
NCT00747760|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-09-10|2008-09-04|2008-09-05|Estimate|||||||2008-09-10|2008-09-11|Estimate|December 2005||2005-12-31|September 2008|2008-09-30|December 2006|Actual|2006-12-31|July 2006|Actual|2006-07-31||Observational|TSHR||TSH Receptor Mutations Among a Consanguineous Community|The Prevalence of TSH Receptor Mutation Among the Arab Population of Israel|Completed|||209|Actual|HaEmek Medical Center, Israel|||2||f||||f||||||Samples With DNA|"~     Blood samples were taken with EDTA and Genomic DNA was extracted from peripheral mononuclear~     cells using the Blood Amp Kit (QIAGEN Inc., Valencia, CA)~   "|||2018-06-01 01:47:00.135484|2018-06-01 01:47:00.135484
NCT00747747|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2011-12-05||2012-03-12|2008-09-04|2008-09-05|Estimate|2012-03-12|2012-03-14|Estimate||||2012-03-12|2012-03-14|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|February 2010|Actual|2010-02-28|January 2009|Actual|2009-01-31||Interventional|SToSS||Sinuclean's Treatment Of Sinusitis' Symptoms|Safety and Efficacy (for Symptoms Remission) of the Treatment of the Acute Episode of Sinusitis With Ecballium Elaterium (SINUclean DM® Nasal Spray) as Co-adjuvant of the Antibiotic Therapy: Comparative, Prospective, Randomized, Open Study.|Completed||Phase 4|49|Actual|Galsor S.r.l.|Clinical diagnosis could not be confirmed before treatment start due to logistics problems to make cranial MRI in due time.|3|||f||||f||||||||||2018-06-01 01:47:00.220035|2018-06-01 01:47:00.220035
NCT00747734|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2011-04-18|2008-09-04|2008-09-05|Estimate|||||||2011-04-18|2011-04-20|Estimate|September 2008||2008-09-30|April 2011|2011-04-30||||||||Interventional|||A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|35|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 01:47:00.61515|2018-06-01 01:47:00.61515
NCT00747721|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2009-04-20|2008-09-04|2008-09-05|Estimate|||||||2009-04-20|2009-04-21|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|DEX PK||Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU|Pharmacokinetics of Intravenous Dexmedetomidine for Prolonged Infusion in Critically Ill, Ventilated Patients in Intensive Care Unit; an Open, Non-Randomised, Single Centre Study|Completed||Phase 1|13|Actual|Orion Corporation, Orion Pharma||1|||f||||f||||||||||2018-06-01 01:47:00.667862|2018-06-01 01:47:00.667862
NCT00747708|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-10-08|2008-09-04|2008-09-05|Estimate|||||||2013-10-08|2013-10-09|Estimate|August 2005||2005-08-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|REGEN-IHD||Bone Marrow Derived Adult Stem Cells for Chronic Heart Failure|Randomised Control Trial to Compare the Effects of G-CSF and Autologous Bone Marrow Progenitor Cells Infusion on the Quality of Life and Left Ventricular Function in Patients With Heart Failure Secondary to Ischaemic Heart Disease|Completed||Phase 2/Phase 3|148|Actual|Barts & The London NHS Trust||3|||f||||t||||||||||2018-06-01 01:47:00.728482|2018-06-01 01:47:00.728482
NCT00747695|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2011-01-07|2008-09-04|2008-09-05|Estimate|||||||2011-01-07|2011-01-10|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|September 2009|Actual|2009-09-30|||||Interventional|||A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive|A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With GERD 1 to 11 Years Old, Inclusive|Completed||Phase 1|31|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:47:00.80346|2018-06-01 01:47:00.80346
NCT00747682|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2010-06-22|2008-09-04|2008-09-05|Estimate|||||||2010-06-22|2010-06-24|Estimate|July 2006||2006-07-31|June 2010|2010-06-30|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Observational|||Cerebral Perfusion, Oxygenation, Electrical Activity|Alterations in Cerebral Perfusion, Oxygenation, Electrical Activity, and Markers of Cerebral Damage Associated With Cerebro-spinal Fluid Reservior Aspiration in Neonates With Post Hemorrhagic Hydrocephalus|Completed|||30|Anticipated|University of Utah|||||f||||f||||||||||2018-06-01 01:47:00.85968|2018-06-01 01:47:00.85968
NCT00747669|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2012-03-22|2008-09-03|2008-09-05|Estimate|||||||2012-03-22|2012-03-23|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Pharmacokinetic Study of Synera™ in Neonates and Infants|A Pharmacokinetic Study of Synera™ (Lidocaine 70 mg and Tetracaine 70 mg Topical Patch) to Evaluate the Systemic Exposure to Lidocaine and Tetracaine in Neonates and Infants|Suspended||Phase 4|11|Anticipated|ZARS Pharma Inc.||||Difficulty with enrollment|f||||f||||||||||2018-06-01 01:47:00.919075|2018-06-01 01:47:00.919075
NCT00747656|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2018-02-08|2008-09-04|2008-09-05|Estimate|||||||2018-02-08|2018-02-12|Actual|February 2009||2009-02-28|February 2018|2018-02-28|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|PREDICT||Prehospital Evaluation and Economic Analysis of Different Coronary Syndrome Treatment Strategies - PREDICT|The Impact of Prehospital 12 Lead ECG With Advanced Emergency Department Notification on Time to In-hospital Reperfusion Strategy in Patients With Acute ST Segment Elevation Myocardial Infarction - A Prospective Study|Completed|||446|Actual|St. Joseph's Healthcare Hamilton|||4||f||||f||||||||||2018-06-01 01:47:00.973529|2018-06-01 01:47:00.973529
NCT00747643|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2011-07-27||2013-11-21|2008-09-04|2008-09-05|Estimate|2011-10-21|2011-11-29|Estimate||||2013-11-21|2013-12-16|Estimate|September 2008||2008-09-30|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement|Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement|Completed||N/A|163|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-06-01 01:47:01.055534|2018-06-01 01:47:01.055534
NCT00747630|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2012-12-14|2008-09-04|2008-09-05|Estimate|||||||2012-12-14|2012-12-17|Estimate|May 2006||2006-05-31|December 2012|2012-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome (FAS)|Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome|Terminated||Early Phase 1|99|Actual|Texas Tech University Health Sciences Center||1||This project was not a clinical trial requiring registration|f||||f||||||||||2018-06-01 01:47:01.428103|2018-06-01 01:47:01.428103
NCT00747617|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2011-08-04||2016-02-09|2008-09-04|2008-09-05|Estimate|2013-01-28|2013-01-29|Estimate||||2016-02-09|2016-03-10|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)|Theca Cell Function in Women With Polycystic Ovary Syndrome|Completed||Phase 3|25|Actual|University of California, San Diego||2|||f||||t||||||||No||2018-06-01 01:47:01.493085|2018-06-01 01:47:01.493085
NCT00747604|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2015-04-02|2008-09-04|2008-09-05|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2006||2006-06-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex|Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex|Terminated|||1378|Actual|Ipsen|||1|Shortage of Increlex supply|f||||t||||||||||2018-06-01 01:47:01.882655|2018-06-01 01:47:01.882655
NCT00747591|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2010-07-21|2008-09-04|2008-09-05|Estimate|||||||2010-07-21|2010-07-23|Estimate|November 2002||2002-11-30|July 2010|2010-07-31|April 2005|Actual|2005-04-30|February 2005|Actual|2005-02-28||Observational|||Urine Concentration of S100B in Extremely Premature Infants|Correlation of Urine Concentration of S100B in Extremely Premature Infants With Gestational Age and Severity of Intraventricular Hemorrhage|Completed|||68|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:47:01.981628|2018-06-01 01:47:01.981628
NCT00747578|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-09-05|2008-09-04|2008-09-05|Estimate|||||||2008-09-05|2008-09-08|Estimate|September 2008||2008-09-30|September 2008|2008-09-30||||||||Observational|||Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan|Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan|Unknown status|Recruiting||300|Anticipated|Taichung Veterans General Hospital|||3||f||||||||||||||2018-06-01 01:47:02.065006|2018-06-01 01:47:02.065006
NCT00747565|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2009-08-14||2013-02-27|2008-09-03|2008-09-05|Estimate|2010-11-30|2010-12-02|Estimate||||2013-02-27|2013-03-04|Estimate|November 2004||2004-11-30|February 2013|2013-02-28|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|||Safety and Effectiveness of a Multifocal Intraocular Lens (IOL)|Clinical Evaluation of the Tecnis Multifocal Intraocular Lens (IOL), Model ZM900, Original Study (DIOL-101-TCNS); Clinical Evaluation of the Tecnis Multifocal Intraocular Lens, Model ZM900, Expansion Study (DIOL-104-TCNS)|Completed||N/A|470|Actual|Abbott Medical Optics|Results from the original study (DIOL-101-TCNS) and the expansion study (DIOL-104-TCNS) were analyzed together. The original study enrolled both multifocal and monofocal control subjects; the expansion study enrolled additional multifocal subjects.|2|||f||||f||||||||||2018-06-01 01:47:02.132469|2018-06-01 01:47:02.132469
NCT00747552|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2009-07-21||2010-01-22|2008-09-04|2008-09-05|Estimate|2009-12-11|2010-01-18|Estimate||||2010-01-22|2010-01-26|Estimate|January 2006||2006-01-31|January 2010|2010-01-31|May 2009|Actual|2009-05-31|April 2008|Actual|2008-04-30||Observational|||Intra-Abdominal Hypertension in Neonatal Intensive Care Patients|Intra-Abdominal Hypertension in Neonatal Intensive Care Patients|Completed|||30|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:47:02.595066|2018-06-01 01:47:02.595066
NCT00747539|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2016-05-11|2008-09-04|2008-09-05|Estimate|||||||2016-05-11|2016-05-13|Estimate|July 2008||2008-07-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy|Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy|Completed|||330|Actual|University of California, Los Angeles|||2||f||||t||||||Samples Without DNA|"~     Urine samples will be collected.~   "|||2018-06-01 01:47:02.754414|2018-06-01 01:47:02.754414
NCT00747526|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-07-05|2008-09-04|2008-09-05|Estimate|||||||2013-07-05|2013-07-08|Estimate|December 2007||2007-12-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive|A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects With GERD 1 to 11 Months Old, Inclusive|Completed||Phase 1|51|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-06-01 01:47:02.86006|2018-06-01 01:47:02.86006
NCT00747513|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2012-05-31|2008-09-04|2008-09-05|Estimate|||||||2012-05-31|2012-06-01|Estimate|September 2009||2009-09-30|May 2012|2012-05-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||A Multi-component Program to Reduce Obesity in Children|A Multi-component Program to Improve Lifestyle Habits and Reduce Obesity in Children|Completed||N/A|3600|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 01:47:03.002488|2018-06-01 01:47:03.002488
NCT00747500|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-04-22|2008-09-04|2008-09-05|Estimate|||||||2013-04-22|2013-04-23|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Observational|||Non Interventional Post Marketing Programme in Acromegaly|"An Observational, Multicentre, Open Label, Non Interventional Programme to Assess the Long-term Safety and Efficacy of Somatuline® Autogel® in the Treatment of Acromegaly When Administered by Patients or Their Partners (Home Injection Group) or Administered by Healthcare Professionals."|Completed|||42|Actual|Ipsen|||||f||||f||||||||||2018-06-01 01:47:03.194441|2018-06-01 01:47:03.194441
NCT00747487|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2013-05-24|2008-09-04|2008-09-05|Estimate|||||||2013-05-24|2013-05-27|Estimate|November 2007||2007-11-30|May 2013|2013-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|RHODOS||Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy|A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy|Completed||Phase 2|85|Actual|Santhera Pharmaceuticals||2|||f||||t||||||||||2018-06-01 01:47:03.272164|2018-06-01 01:47:03.272164
NCT00747474|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2012-01-05||2012-02-13|2008-09-04|2008-09-05|Estimate|2012-01-05|2012-02-09|Estimate||||2012-02-13|2012-02-16|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors|A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) When Administered to Patients With Advanced Solid Tumors|Completed||Phase 1|54|Actual|Taiwan Liposome Company|||||f||||t||||||||||2018-06-01 01:47:03.435246|2018-06-01 01:47:03.435246
NCT00747461|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2015-06-04||2015-08-11|2008-09-04|2008-09-05|Estimate|2015-06-04|2015-06-26|Estimate||||2015-08-11|2015-08-18|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|ICEtheBAD||"Interventional Cryotherapy for the Eradication of Benign Airway Disease (ICE the BAD)"|"Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease(ICE THE BAD)"|Terminated||Phase 4|5|Actual|CSA Medical, Inc.||1||Business Reasons|f||||f||||||||||2018-06-01 01:47:04.145772|2018-06-01 01:47:04.145772
NCT00747448|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2016-02-01|2008-09-04|2008-09-05|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||CryoSpray Ablation (TM) GI Patient Registry|CryoSpray Ablation (TM) GI Patient Registry|Completed|||199|Actual|CSA Medical, Inc.|||||f||||f||||||||No||2018-06-01 01:47:04.29667|2018-06-01 01:47:04.29667
NCT00747435|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2017-02-13||2017-04-10|2008-09-04|2008-09-05|Estimate|2017-04-10|2017-05-17|Actual||||2017-04-10|2017-05-17|Actual|February 2007||2007-02-28|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|EAS|6 participants withdrew before study completion, outcome measures are reported 67 participants|Safety and Effectiveness of the MED-EL Electric-Acoustic System|The MED-EL EAS (Electric-Acoustic System) Using the PULSARCI100 FLEXeas / SONATATI100 FLEXeas and the DUET Speech Processor|Completed||N/A|73|Actual|Med-El Corporation||2|||f||||f|f|t|f|f||||||2018-06-01 01:47:04.38398|2018-06-01 01:47:04.38398
NCT00747422|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2017-11-22|2008-09-04|2008-09-05|Estimate|||||||2017-11-22|2017-11-24|Actual|July 2008||2008-07-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of the Effectiveness and Safety of the Ulthera™ System for the Treatment of Wrinkles Around the Eyes|Evaluation of the Effectiveness and Safety of the Ulthera™ System for the Treatment of Periorbital Wrinkles|Completed||N/A|100|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-06-01 01:47:04.617018|2018-06-01 01:47:04.617018
NCT00747409|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-09-04|2008-09-04|2008-09-05|Estimate|||||||2008-09-04|2008-09-05|Estimate|July 2004||2004-07-31|September 2008|2008-09-30|June 2009|Anticipated|2009-06-30|March 2009|Anticipated|2009-03-31||Interventional|||Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes|Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes.|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Munich Municipal Hospital||2|||f||||t||||||||||2018-06-01 01:47:04.686391|2018-06-01 01:47:04.686391
NCT00747396|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2017-12-07|2008-09-04|2008-09-05|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2000||2000-09-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|BEIP||The Bucharest Early Intervention Project|The Bucharest Early Intervention Project: Effects of Early Psychosocial Deprivation on Mental Health in Adolescence|Active, not recruiting||N/A|136|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 01:47:04.766717|2018-06-01 01:47:04.766717
NCT00747383|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2012-12-04|2008-09-04|2008-09-05|Estimate|||||||2012-12-04|2012-12-05|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|MSD-GLP1||How Improvement in Control of Diabetes Influences the Production of a Hormone Produced in the Gut Which Improves the Release and Action of Insulin.|Influence of Improving Glycaemic Control on Glucagon-Like-Peptide-1 Response to an Oral Glucose Load. Comparison of Sulphonylurea With DPP-4 Inhibition.|Completed||N/A|74|Actual|The Royal Bournemouth Hospital||2|||f||||t||||||||||2018-06-01 01:47:04.837307|2018-06-01 01:47:04.837307
NCT00747370|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2008-09-04|2008-09-04|2008-09-05|Estimate|||||||2008-09-04|2008-09-05|Estimate|January 2002||2002-01-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Dynamic MRI of the Behaviour of Female Pelvic Floor|The Suitability of Dynamic MRI for Pelvic Floor, Bladder Neck and Midurethra|Completed||Early Phase 1|74|Actual|Kuopio University Hospital||3|||f||||f||||||||||2018-06-01 01:47:04.899932|2018-06-01 01:47:04.899932
NCT00747357|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2016-02-18|2008-09-04|2008-09-05|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|September 2012|Actual|2012-09-30||Interventional|INDICOR||INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent|The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent to Treat Coronary Artery Disease in a Real World Scenario|Completed||Phase 3|97|Actual|Heart Centre Rotenburg||2|||f||||t||||||||||2018-06-01 01:47:04.966176|2018-06-01 01:47:04.966176
NCT00747344|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|2012-09-05||2013-03-22|2008-09-04|2008-09-05|Estimate|2012-09-05|2012-10-05|Estimate||||2013-03-22|2013-03-29|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis|Completed||Phase 3|121|Actual|Centocor, Inc.||4|||f||||t||||||||||2018-06-01 01:47:05.036031|2018-06-01 01:47:05.036031
NCT00747331|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2009-04-10|2008-09-04|2008-09-05|Estimate|||||||2009-04-10|2009-04-13|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass|Fenoldopam Prophylaxis of Splanchnic Organs Underperfusion During Cardiopulmonary Bypass: a Randomized, Controlled Trial.|Completed||Phase 4|80|Anticipated|IRCCS Policlinico S. Donato||2|||f||||f||||||||||2018-06-01 01:47:05.463051|2018-06-01 01:47:05.463051
NCT00747318|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04||2011-06-08|2011-06-08|2008-09-04|2008-09-05|Estimate||||2011-06-08|2011-06-23|Estimate|2011-06-08|2011-06-23|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005|A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005, Incorporating Amendment 1 and 2|Completed||Phase 3|280|Actual|SkyePharma AG||1|||f||||f||||||||||2018-06-01 01:47:05.569537|2018-06-01 01:47:05.569537
NCT00747305|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2015-10-21|2008-09-04|2008-09-05|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery|Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma|Terminated||Phase 1|17|Actual|Medical University of South Carolina||1||Study terminated early due to low accrual.|f||||t||||||||||2018-06-01 01:47:05.723059|2018-06-01 01:47:05.723059
NCT00747292|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-09-04|2008-09-04|2008-09-05|Estimate|||||||2008-09-04|2008-09-05|Estimate|December 2007||2007-12-31|September 2008|2008-09-30|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Peri-Operative Management of Patients Undergoing Laparoscopic Colorectal Surgery|Randomised Controlled Trial Comparing the Effects of Epidural, Spinal and PCA in Patients Undergoing Laparoscopic Colectomy.|Unknown status|Recruiting|Phase 1/Phase 2|99|Anticipated|Minimal Access Therapy Training Unit||3|||f||||f||||||||||2018-06-01 01:47:05.812376|2018-06-01 01:47:05.812376
NCT00747279|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-09-08|2008-09-04|2008-09-05|Estimate|||||||2008-09-08|2008-09-09|Estimate|June 2007||2007-06-30|September 2008|2008-09-30||||||||Interventional|||Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke|Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke|Unknown status|Recruiting|Phase 4|70|Anticipated|Hospital Sao Domingos||2|||f||||f||||||||||2018-06-01 01:47:05.904845|2018-06-01 01:47:05.904845
NCT00747266|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2008-09-04|2008-09-04|2008-09-05|Estimate|||||||2008-09-04|2008-09-05|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:47:05.987432|2018-06-01 01:47:05.987432
NCT00747253|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2016-10-05|2008-09-04|2008-09-05|Estimate|||||||2016-10-05|2016-10-06|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors|AutoLITT™ FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors|Completed||Phase 1|10|Actual|Monteris Medical||1|||f||||t||||||||||2018-06-01 01:47:06.034288|2018-06-01 01:47:06.034288
NCT00747240|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2015-05-11|2008-09-04|2008-09-05|Estimate|||||||2015-05-11|2015-05-12|Estimate|February 2002||2002-02-28|July 2014|2014-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression|Platelet-activating Factor Acetylhydrolase (Paf-ah) Gene Expression And The Incidence Of Chronic Lung Disease (Cld) In Very Low Birth Weight Infants|Completed|||139|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:47:06.10376|2018-06-01 01:47:06.10376
NCT00747214|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2014-01-16||2014-04-22|2008-09-04|2008-09-05|Estimate|2014-04-22|2014-05-20|Estimate||||2014-04-22|2014-05-20|Estimate|November 2004||2004-11-30|April 2014|2014-04-30|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Interventional||Baseline analysis population is equal to the per protocol population defined as the subset of intent to treat population with no major protocol deviations including entry criteria and use of restricted medications and with study drug compliance of at least 75% during Days 1 to 42.|A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA|A Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to That of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects With RA|Completed||Phase 2|59|Actual|Zalicus||2|||f||||f||||||||||2018-06-01 01:47:06.512404|2018-06-01 01:47:06.512404
NCT00747201|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-04|||2014-05-21|2008-09-04|2008-09-05|Estimate|||||||2014-05-21|2014-05-22|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Adapting the Bipolar Care Model for Chronic Care Management in Community-based Health Care Sites|Implementing Chronic Care Management for Bipolar Disorder|Completed||N/A|384|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 01:47:06.73237|2018-06-01 01:47:06.73237
NCT00747188|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2008-09-03|2008-09-03|2008-09-04|Estimate|||||||2008-09-03|2008-09-04|Estimate|February 2006||2006-02-28|September 2008|2008-09-30|January 2008|Actual|2008-01-31|July 2007|Actual|2007-07-31||Interventional|PBL||The Impact of Problem-Based Learning (PBL) and Lecturing|The Impact of Problem-Based Learning (PBL) and Lecturing on the Behavior and Attitudes of Iranian Nursing Students: a Randomised Controlled Trial (RCT)|Completed||N/A|||University of Tasmania||2|||f||||t||||||||||2018-06-01 01:47:06.795252|2018-06-01 01:47:06.795252
NCT00747175|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2010-12-02|2008-09-03|2008-09-04|Estimate|||||||2010-12-02|2010-12-03|Estimate|August 2008||2008-08-31|December 2010|2010-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|MAD||A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes|A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in T2DM Subjects|Completed||Phase 1|52|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 01:47:06.842911|2018-06-01 01:47:06.842911
NCT00747162|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2013-11-26|2008-09-03|2008-09-04|Estimate|||||||2013-11-26|2013-11-27|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Muscle Oxygenation and Skin Pigmentation|Correlation Between Muscle Oxygenation and Skin Pigmentation|Withdrawn||Phase 4|0|Actual|Emory University||1||incorporated into other study|f||||f||||||||||2018-06-01 01:47:06.933989|2018-06-01 01:47:06.933989
NCT00747149|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2010-08-06||2011-08-29|2008-09-03|2008-09-04|Estimate|2011-06-07|2011-07-04|Estimate||||2011-08-29|2011-08-31|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|ADAPT||A Diabetes Study to Treat A Population Previously Not at Target|12-week, Open-label, Multi-center, Prospective Study Evaluating the Effect of Individualizing Starting Doses of Rosuvastatin According to Baseline LDL (Low Density Lipoprotein)-Cholesterol Levels on Achieving Cholesterol Targets in Type 2 Diabetic Patients|Completed||Phase 4|598|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 01:47:07.015103|2018-06-01 01:47:07.015103
NCT00747136|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2016-04-12|2008-09-03|2008-09-04|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Observational|||WavSTAT® Optical Biopsy System to Target Esophageal Biopsies|A Prospective Evaluation of the WavSTAT® Optical Biopsy System to Target Esophageal Biopsies: An Adjunctive Tool to Assist the Endoscopist to Identify Dysplasia or Cancer|Terminated|||47|Actual|SpectraScience||||Study has been terminated for inadequate results|f||||t||||||Samples Without DNA|"~     esophageal biopsies will be collected.~   "|||2018-06-01 01:47:07.431482|2018-06-01 01:47:07.431482
NCT00747123|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03||2012-09-11|2016-10-25|2008-09-03|2008-09-04|Estimate||||2012-09-11|2012-09-13|Estimate|2016-10-25|2016-10-27|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma|A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma|Completed||Phase 2|30|Actual|Celgene Corporation||4|||f||||t||||||||||2018-06-01 01:47:07.479111|2018-06-01 01:47:07.479111
NCT00747110|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2012-06-25|2008-09-03|2008-09-04|Estimate|||||||2012-06-25|2012-06-26|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2008|Actual|2008-08-31||Interventional|||Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)|Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With 9 mg Budesonide or 3 g Mesalazine in Patients With Active Ulcerative Colitis|Completed||Phase 3|343|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-06-01 01:47:07.549234|2018-06-01 01:47:07.549234
NCT00747097|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2011-02-09|2008-09-03|2008-09-04|Estimate|||||||2011-02-09|2011-02-10|Estimate|September 2008||2008-09-30|February 2011|2011-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|ECHO||Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study|Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study|Completed||Phase 2|43|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-06-01 01:47:07.625463|2018-06-01 01:47:07.625463
NCT00747084|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2017-04-19|2008-09-03|2008-09-04|Estimate|||||||2017-04-19|2017-04-21|Actual|December 2007|Actual|2007-12-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Can Simple and Inexpensive Techniques Enhance Patient Comfort|Can Simple and Inexpensive Techniques Enhance Patient Comfort in Sedation Risk-free Screening and Surveillance Colonoscopy?|Terminated||Phase 1/Phase 2|82|Actual|VA Office of Research and Development||2||"Instruments necessary to continue project have been removed via medical center staff.~   Therefore, the project cannot continue until they have been replaced."|f||||f||||||||||2018-06-01 01:47:08.660265|2018-06-01 01:47:08.660265
NCT00747071|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2012-08-27|2008-09-03|2008-09-04|Estimate|||||||2012-08-27|2012-08-28|Estimate|September 2011||2011-09-30|June 2011|2011-06-30|November 2013|Anticipated|2013-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies|Safety and Validation of Efficacy of Oral Administration of the Food Additive Colostrum Derived Anti Clostridium Difficile Antibodies|Withdrawn||Phase 2/Phase 3|0|Actual|Hadassah Medical Organization||2||Sponsors decision|f||||t||||||||||2018-06-01 01:47:08.753183|2018-06-01 01:47:08.753183
NCT00747058|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2010-01-07|2008-09-03|2008-09-04|Estimate|||||||2010-01-07|2010-01-08|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects|Completed||Phase 1|28|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:47:08.825044|2018-06-01 01:47:08.825044
NCT00747045|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2014-12-02|2008-09-03|2008-09-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients|A Prospective Single Blind Controlled Study to Assess the Efficacy of a Lung Protective Ventilation Strategy in the Prevention of Reperfusion Lung Injury Following PTE|Completed||N/A|128|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 01:47:08.906954|2018-06-01 01:47:08.906954
NCT00747032|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2012-05-04|2008-09-03|2008-09-04|Estimate|||||||2012-05-04|2012-05-07|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|April 2011|Anticipated|2011-04-30|February 2011|Anticipated|2011-02-28||Interventional|||To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis|Multi-Center, Double-Blind, Randomized, Vehicle-controlled, Parallel-Group Study Comparing NYC-0462 Ointment To a Vehicle Control|Withdrawn||Phase 3|0|Actual|Nycomed||2||Study withdrawn due to business decisions. No subjects were treated.|f||||f||||||||||2018-06-01 01:47:08.985687|2018-06-01 01:47:08.985687
NCT00747019|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2009-06-30|2008-09-03|2008-09-04|Estimate|||||||2009-06-30|2009-07-02|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Prosocial Behavior and Exercise Among Older Adults|Prosocial Behavior and Exercise Among Older Adults|Unknown status|Recruiting|N/A|80|Anticipated|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 01:47:09.059957|2018-06-01 01:47:09.059957
NCT00747006|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2014-07-22|2009-06-09|2014-10-21|2008-09-03|2008-09-04|Estimate|2014-10-20|2014-10-21|Estimate|2009-10-23|2009-10-27|Estimate|2014-10-21|2014-10-30|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional||Randomized Subjects. Patients were randomly assigned to various carbohydrate loads (0%, 50%, 100%, 150% or 200%). The 100% carbohydrate load was determined based upon their standard insulin dose for their normal meal.|Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake|A Phase 2, Single-Center, Open-Label, Pharmacodynamic Clinical Trial to Evaluate the Effect of Technosphere® Insulin Inhalation Powder Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Postprandial Glucose Levels in Subjects With Type 1 and Type 2 Diabetes Mellitus Ingesting Meals With Varied Carbohydrate Content|Terminated||Phase 2|18|Actual|Mannkind Corporation|- Early termination of trial leading to small numbers of subjects analyzed.|2||Business reasons|f||||||||||||||2018-06-01 01:47:09.18573|2018-06-01 01:47:09.18573
NCT00746993|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2012-12-11|2008-09-02|2008-09-04|Estimate|||||||2012-12-11|2012-12-12|Estimate|October 2008||2008-10-31|December 2012|2012-12-31|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Randomized Controlled Trial of Structured Contraceptive Counseling in Adult Women|Structured Contraceptive Counseling--A Randomized Controlled Trial|Completed||N/A|250|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 01:47:09.987763|2018-06-01 01:47:09.987763
NCT00746980|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2016-06-13|2008-09-03|2008-09-04|Estimate|||||||2016-06-13|2016-06-14|Estimate|August 2008||2008-08-31|June 2016|2016-06-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Efalizumab in the Treatment of Alopecia, Phase II|Efalizumab in the Treatment of Alopecia Totalis/Universalis in Young Adults, Phase II|Withdrawn||Phase 2|0|Actual|Northwestern University||1||Newly identified safety concerns have changed the risk and benefit considerations|f||||t||||||||||2018-06-01 01:47:10.103986|2018-06-01 01:47:10.103986
NCT00746967|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-09-03|2008-09-03|2008-09-04|Estimate|||||||2008-09-03|2008-09-04|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|February 2004|Actual|2004-02-29|||||Interventional|||An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder|An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder|Completed||Phase 2|267|Actual|Pfizer||1|||f||||||||||||||2018-06-01 01:47:10.210122|2018-06-01 01:47:10.210122
NCT00746954|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2013-11-05||2016-02-16|2008-09-03|2008-09-04|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|CSA treatment||Buspirone as a Potential Treatment for Recurrent Central Apnea|Buspirone as a Potential Treatment for Recurrent Central Apneas|Terminated||Phase 3|8|Actual|VA Office of Research and Development|"VA population turned out to have a high number of heart failure patients who had psychiatric co-morbidity or were empirically treated with antidepressants, precluding participation.~There were not enrolled enough participants."|3||Patient recruitment and Funding inadequate to finish trial|f||||t||||||||||2018-06-01 01:47:10.391422|2018-06-01 01:47:10.391422
NCT00746941|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2013-01-03||2014-07-02|2008-09-03|2008-09-04|Estimate|2014-07-02|2014-07-31|Estimate||||2014-07-02|2014-07-31|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)|A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)|Terminated||Phase 1/Phase 2|37|Actual|Biogen|From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early.|2||Primary endpoint not achieved|f||||f||||||||||2018-06-01 01:47:10.739375|2018-06-01 01:47:10.739375
NCT00746928|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2008-09-03|2008-09-03|2008-09-04|Estimate|||||||2008-09-03|2008-09-04|Estimate|September 2005||2005-09-30|September 2008|2008-09-30|October 2008|Anticipated|2008-10-31|July 2007|Actual|2007-07-31||Interventional|||Cardiovascular Consequences of Intermittent Hypoxia in Healthy Subjects|Cardiovascular Consequences of Intermittent Hypoxia in Healthy Subjects|Unknown status|Active, not recruiting|N/A|12|Actual|University Hospital, Grenoble|||||f||||f||||||||||2018-06-01 01:47:12.136566|2018-06-01 01:47:12.136566
NCT00746564|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2015-04-13|2012-08-24|2015-11-01|2008-09-03|2008-09-04|Estimate|2015-04-13|2015-04-30|Estimate|2012-08-24|2012-08-31|Estimate|2015-11-01|2015-12-01|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|February 2011|Actual|2011-02-28||Interventional||All patients implanted with the Confirm Device.|Study of New Implantable Loop Recorder|Confirm Implantable Cardiac Monitor Study|Completed||N/A|75|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 01:47:17.038241|2018-06-01 01:47:17.038241
NCT00746915|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2009-06-03|2008-09-03|2008-09-04|Estimate|||||||2009-06-03|2009-06-05|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Phase I Study Evaluating The Safety And Efficacy of a Device for Collection of Electrical Bioimpedance Data|A Prospective, Single-Center, Phase I Study Evaluating the Safety and Initial Efficacy of the Epidetect Device for Collection of Bioimpedance Data of Human Tissues in Patients Undergoing Elective Pain Relief Treatment of Lumbar Epidural Steroid Injection Under Fluoroscopy|Unknown status|Recruiting|Phase 1|20|Anticipated|ImpediGuide Ltd|||||f||||t||||||||||2018-06-01 01:47:12.202031|2018-06-01 01:47:12.202031
NCT00746902|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2014-11-06|2008-09-03|2008-09-04|Estimate|||||||2014-11-06|2014-11-07|Estimate|June 2008||2008-06-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|RHOOSAS||Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome|Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome|Completed||Phase 3|62|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-06-01 01:47:12.275212|2018-06-01 01:47:12.275212
NCT00746889|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2010-04-05||2010-07-29|2008-09-03|2008-09-04|Estimate|2010-07-29|2010-08-25|Estimate||||2010-07-29|2010-08-25|Estimate|March 2004||2004-03-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis|Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis: A Randomized Placebo-Controlled Clinical Trial|Completed||N/A|79|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 01:47:12.44227|2018-06-01 01:47:12.44227
NCT00746876|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2016-04-18|2008-09-03|2008-09-04|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2012|Actual|2012-12-31||Interventional|HEMIUNIBIPOL||Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures.|Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures. A Randomized Trial of RSA Measurements of Acetabular Wear.|Completed||N/A|28|Actual|Sykehuset Asker og Baerum||2|||f||||f||||||||||2018-06-01 01:47:12.688802|2018-06-01 01:47:12.688802
NCT00746863|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2010-03-19||2010-06-15|2008-09-03|2008-09-04|Estimate|2010-05-18|2010-06-09|Estimate||||2010-06-15|2010-06-22|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Randomized Control Trial to Assess Postoperative Pain After Sling Placement|Injection of 0.125% Marcaine During Mid-Urethral Sling Placement for Pain Relief: A Randomized Control Trial|Completed||N/A|42|Actual|University of North Carolina, Chapel Hill|Our exclusion criteria were strict, and as such, results presented here may have limited generalizability. Other limitations include that we can only address operations performed under general anesthesia.|2|||f||||f||||||||||2018-06-01 01:47:12.784964|2018-06-01 01:47:12.784964
NCT00746850|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2011-10-12|2008-09-03|2008-09-04|Estimate|||||||2011-10-12|2011-10-13|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|HAC||Harmonic in Laparoscopic Cholecystectomy for Acute Cholecystitis|Randomized, Double-blind, Controlled Trial of Harmonic(H) Versus Monopolar Diathermy (M) for Laparoscopic Cholecystectomy (LC) for Acute Cholecystitis (AC) in Adults.|Completed||N/A|42|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 01:47:13.139359|2018-06-01 01:47:13.139359
NCT00746837|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2010-11-30|2008-09-03|2008-09-04|Estimate|||||||2010-11-30|2010-12-02|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||AZD5672 Absolute Bioavailability Study|A Phase I Study to Assess Absolute Bioavailability of AZD5672 at Steady-state in Healthy Volunteers|Completed||Phase 1|26|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:47:13.218563|2018-06-01 01:47:13.218563
NCT00746824|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2012-08-31|2008-09-03|2008-09-04|Estimate|||||||2012-08-31|2012-09-03|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.|TM30339: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Repeated Subcutaneous Dose-range Study Designed to Determine the Weight Loss in Obese Subjects.|Terminated||Phase 2|192|Actual|7TM Pharma A/S||6||The IND was withdrawn.|f||||f||||||||||2018-06-01 01:47:13.29424|2018-06-01 01:47:13.29424
NCT00746811|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2010-01-26|2008-09-03|2008-09-04|Estimate|||||||2010-01-26|2010-01-28|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|October 2010|Anticipated|2010-10-31|July 2010|Anticipated|2010-07-31||Interventional|||Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia|A Double-blind, Randomized, Placebo-controlled, Two-period Crossover Trial to Assess the Effects of 4 g/d P-OM3 on LDL-C and Other Aspects of the Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia|Unknown status|Recruiting|Phase 4|32|Anticipated|Provident Clinical Research||2|||f||||f||||||||||2018-06-01 01:47:13.367821|2018-06-01 01:47:13.367821
NCT00746798|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2011-09-27||2015-03-17|2008-09-03|2008-09-04|Estimate|2011-09-27|2011-11-02|Estimate||||2015-03-17|2015-04-03|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|WinVax004||Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults|Randomized, Modified, Double-blind, Placebo-controlled, Phase II, Dose-ranging Study of the Safety and Immunogenicity of Single Dose ChimeriVax-WN02 Vaccine in Healthy Adults.|Completed||Phase 2|479|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 01:47:13.476042|2018-06-01 01:47:13.476042
NCT00746785|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2013-11-15||2014-01-30|2008-09-03|2008-09-04|Estimate|2014-01-30|2014-03-20|Estimate||||2014-01-30|2014-03-20|Estimate|September 2002||2002-09-30|January 2014|2014-01-31|September 2011|Actual|2011-09-30|May 2010|Actual|2010-05-31||Interventional|||A New Pharmacotherapy for Alcohol Dependence: Olanzapine|A New Pharmacotherapy for Alcohol Dependence: Olanzapine|Completed||Phase 3|304|Actual|The Mind Research Network||3|||f||||f||||||||||2018-06-01 01:47:14.079612|2018-06-01 01:47:14.079612
NCT00746772|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2010-09-07|2008-09-03|2008-09-04|Estimate|||||||2010-09-07|2010-09-08|Estimate|April 2006||2006-04-30|September 2010|2010-09-30|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy of Purslane in Treatment of Oral Lichen Planus|Treatment of Oral Lichen Planus Lesions|Completed||Phase 2|37|Actual|Qazvin University Of Medical Sciences||2|||f||||f||||||||||2018-06-01 01:47:14.358383|2018-06-01 01:47:14.358383
NCT00746759|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2015-06-02|2008-09-03|2008-09-04|Estimate|||||||2015-06-02|2015-06-04|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|AEGIS IDE||Airway Epithelium Gene Expression: AEGIS IDE|Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS IDE|Completed|||1331|Actual|Allegro Diagnostics, Corp.|||1||f||||f||||||Samples With DNA|"~     Cells, Blood~   "|||2018-06-01 01:47:14.440053|2018-06-01 01:47:14.440053
NCT00746200|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2010-05-10|2008-08-31|2008-09-03|Estimate|||||||2010-05-10|2010-05-12|Estimate|October 2008||2008-10-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Acupuncture for Chronic Constipation|Randomised Controlled Trial of Acupuncture for Patients With Chronic Constipation|Completed||Phase 3|80|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:47:21.464998|2018-06-01 01:47:21.464998
NCT00746746|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2011-01-12|2008-09-03|2008-09-04|Estimate|||||||2011-01-12|2011-01-13|Estimate|June 2008||2008-06-30|September 2008|2008-09-30|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Interventional|||A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma|A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b (PEG-Intron)and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Ochsner Health System|||||f||||t||||||||||2018-06-01 01:47:14.535524|2018-06-01 01:47:14.535524
NCT00746733|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2009-10-14||2009-11-18|2008-09-03|2008-09-04|Estimate|2009-10-14|2009-11-17|Estimate||||2009-11-18|2009-11-20|Estimate|September 2008||2008-09-30|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC|A Phase I, Open-Label, Randomized, Four Period Crossover Drug Interaction Study to Evaluate the Pharmacokinetic Profiles of VYVANSE™ and ADDERALL XR When Each is Administered Alone and in Combination With the Proton Pump Inhibitor Prilosec OTC™ in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Shire||2|||f||||||||||||||2018-06-01 01:47:14.713745|2018-06-01 01:47:14.713745
NCT00746720|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2012-05-02|2008-09-03|2008-09-04|Estimate|||||||2012-05-02|2012-05-03|Estimate|May 2006||2006-05-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Interventional|||Modulation of the Surgical Inflammatory Response by Etoricoxib|Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral Versus Central|Terminated||Phase 2|23|Actual|University of Erlangen-Nürnberg Medical School||4||Patient recruitment difficulties|f||||t||||||||||2018-06-01 01:47:15.462843|2018-06-01 01:47:15.462843
NCT00746707|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2011-12-17|2008-09-03|2008-09-04|Estimate|||||||2011-12-17|2011-12-20|Estimate|September 2008||2008-09-30|December 2011|2011-12-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Biologic Glue for First Degree Perineal Tears|Randomized Control Trial for the Comparison of Biologic Glue Versus Suturing for First Degree Perineal Tears|Completed||N/A|102|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:47:15.556999|2018-06-01 01:47:15.556999
NCT00746694|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2010-12-21||2015-08-26|2008-09-03|2008-09-04|Estimate|2010-12-21|2011-01-17|Estimate||||2015-08-26|2015-08-27|Estimate|October 2007||2007-10-31|August 2015|2015-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)|Epidemiological Study to Assess the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Pegylated Liposomal Doxorubicin|Completed|||154|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:47:15.670227|2018-06-01 01:47:15.670227
NCT00746681|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-12-18|2008-09-03|2008-09-04|Estimate|||||||2009-12-18|2009-12-21|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder|A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder|Completed||Phase 2|188|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:47:15.862417|2018-06-01 01:47:15.862417
NCT00746668|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2014-12-22||2015-02-24|2008-09-03|2008-09-04|Estimate|2015-02-24|2015-02-27|Estimate||||2015-02-24|2015-02-27|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Multi-Center Study of Reading Rehabilitation in Macular Disease|A Multi-Center Study of Reading Rehabilitation in Macular Disease|Completed||N/A|36|Actual|VA Office of Research and Development||7|||f||||f||||||||||2018-06-01 01:47:15.999284|2018-06-01 01:47:15.999284
NCT00746655|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2015-12-23|2008-09-03|2008-09-04|Estimate|||||||2015-12-23|2015-12-24|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||SBRT + TACE for Primary Hepatocellular Carcinoma|A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)|Withdrawn||N/A|0|Actual|University of Pittsburgh||1||Unable to recruit|f||||t||||||||||2018-06-01 01:47:16.240524|2018-06-01 01:47:16.240524
NCT00746642|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2009-06-02|2008-09-03|2008-09-04|Estimate|||||||2009-06-02|2009-06-04|Estimate|October 2009||2009-10-31|June 2009|2009-06-30|October 2010|Anticipated|2010-10-31|May 2010|Anticipated|2010-05-31||Interventional|||Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study|Use of Mellitor Sensor for Continuous Glucose Monitoring - An Ex-Vivo Study|Unknown status|Not yet recruiting|N/A|20|Anticipated|Mellitor||2|||f||||f||||||||||2018-06-01 01:47:16.351666|2018-06-01 01:47:16.351666
NCT00746629|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2015-05-19|2008-09-03|2008-09-04|Estimate|||||||2015-05-19|2015-05-21|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FOCUS||Familial Overweight: Comparing Use of Strategies|Behavioral Skill Adherence in Pediatric Obesity Treatment|Completed||N/A|72|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-06-01 01:47:16.430645|2018-06-01 01:47:16.430645
NCT00746616|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02||2013-03-21|2013-04-02|2008-09-03|2008-09-04|Estimate||||2013-03-21|2013-04-01|Estimate|2013-04-02|2013-04-10|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Durom(R) Hip Resurfacing System Multicenter Trial|Durom(R) Hip Resurfacing System Multicenter Trial|Completed||Phase 3|40|Actual|Zimmer Biomet||1|||f||||f||||||||||2018-06-01 01:47:16.493306|2018-06-01 01:47:16.493306
NCT00746603|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2013-07-17|2008-09-02|2008-09-04|Estimate|||||||2013-07-17|2013-07-19|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors|A Feasibility Study to Evaluate the Safety of Simvastatin in Young Adults Treated for Hodgkin's Disease|Terminated||N/A|18|Actual|Columbia University||1||Poor enrollment|f||||t||||||||||2018-06-01 01:47:16.618078|2018-06-01 01:47:16.618078
NCT00746590|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2016-05-03||2016-05-03|2008-09-03|2008-09-04|Estimate|2016-05-03|2016-06-09|Estimate||||2016-05-03|2016-06-09|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma|A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC)|Terminated||Phase 2|1|Actual|BTG International Inc.||1||Study terminated prematurely by sponsor for business reason. One patient was enrolled.|f||||f||||||||Yes||2018-06-01 01:47:16.715165|2018-06-01 01:47:16.715165
NCT00746577|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2012-02-21|2008-09-03|2008-09-04|Estimate|||||||2012-02-21|2012-02-22|Estimate|August 2008||2008-08-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Organizational Factors Influencing Practice Improvement in Community Based Care|Organizational Factors Influencing Practice Improvement in Community Based|Completed||N/A|910|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 01:47:16.908746|2018-06-01 01:47:16.908746
NCT00746551|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2015-01-15||2015-02-11|2008-09-03|2008-09-04|Estimate|2015-02-11|2015-02-16|Estimate||||2015-02-11|2015-02-16|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|EIVF||Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment|Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial|Completed||Phase 4|80|Actual|Mahidol University||2|||f||||t||||||||||2018-06-01 01:47:17.330615|2018-06-01 01:47:17.330615
NCT00746538|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2008-09-03|2008-09-03|2008-09-04|Estimate|||||||2008-09-03|2008-09-04|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|July 2009|Anticipated|2009-07-31|March 2009|Anticipated|2009-03-31||Interventional|||Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent|Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial|Unknown status|Recruiting|Phase 4|80|Anticipated|Khon Kaen University||2|||f||||f||||||||||2018-06-01 01:47:17.579445|2018-06-01 01:47:17.579445
NCT00746525|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2017-01-19|2008-09-03|2008-09-04|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2008||2008-09-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke|Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke|Completed||N/A|8|Actual|Louis Stokes VA Medical Center||1|||f||||f||||||||||2018-06-01 01:47:17.715616|2018-06-01 01:47:17.715616
NCT00746512|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2010-12-17||2015-05-07|2008-09-03|2008-09-04|Estimate|2011-03-10|2011-04-08|Estimate||||2015-05-07|2015-05-29|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)|A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Access the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler Ultrasound Signal of Synovium in Patients With Rheumatoid Arthritis|Completed||Phase 1|45|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 01:47:17.802313|2018-06-01 01:47:17.802313
NCT00746499|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2012-10-12|2008-09-03|2008-09-04|Estimate|||||||2012-10-12|2012-10-15|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.|A Phase 1, Open-Label Study, Investigating First-Dose and Steady-State Pharmacokinetics of Raltegravir in the Genital Tract of HIV Uninfected Women|Completed||Phase 1|7|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 01:47:18.19357|2018-06-01 01:47:18.19357
NCT00746486|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2017-02-07|2008-09-03|2008-09-04|Estimate|||||||2017-02-07|2017-02-08|Estimate|February 2009||2009-02-28|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)|Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study Comparing the Combination of Ursodeoxycholic Acid Capsules Plus Budesonide Capsules to Ursodeoxycholic Acid Capsules Plus Placebo in the Treatment of Primary Biliary Cirrhosis|Terminated||Phase 3|62|Actual|Dr. Falk Pharma GmbH||2||Study stopped based on the recommendation of the IDMC after a planned Interim Analysis|f||||f||||||||||2018-06-01 01:47:18.282282|2018-06-01 01:47:18.282282
NCT00746473|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-03|2008-09-03|2008-09-04|Estimate|||||||2008-09-03|2008-09-04|Estimate|August 2004||2004-08-31|September 2008|2008-09-30|October 2005|Actual|2005-10-31|||||Observational|||Assessment of Cytokine Values in Serum and by RT-PCR in HIV-1 Individuals With and Without HAART|Assessment of Cytokine Values in Serum and by Specific cDNA Amplification and Detection Using RT-PCR in HIV-1 Infected Individuals With and Without Highly Active Anti-Retroviral Therapy (HAART)|Completed|||73|Actual|UPECLIN HC FM Botucatu Unesp|||4||f||||t||||||||||2018-06-01 01:47:18.365739|2018-06-01 01:47:18.365739
NCT00746460|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2014-01-10|2008-09-03|2008-09-04|Estimate|||||||2014-01-10|2014-01-14|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||The Healthy Options Feasibility Study|"The Effectiveness of CVD Risk Profiles When Used by Allied Health Care Providers (HCP) Within a Groupe de Médecine de Famille: The Healthy Options Feasibility Study."|Completed||N/A|50|Actual|McGill University||1|||f||||f||||||||||2018-06-01 01:47:18.428835|2018-06-01 01:47:18.428835
NCT00746447|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2012-06-25|2008-09-03|2008-09-04|Estimate|||||||2012-06-25|2012-06-26|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|March 2008|Actual|2008-03-31|April 2007|Actual|2007-04-30||Interventional|||Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)|Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Maintenance of Remission in Patients With Ulcerative Colitis|Completed||Phase 3|648|Actual|Dr. Falk Pharma GmbH||3|||f||||f||||||||||2018-06-01 01:47:18.502725|2018-06-01 01:47:18.502725
NCT00746434|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2016-12-02|2008-09-03|2008-09-04|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|||A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis|A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis|Withdrawn||Phase 2|0|Actual|AstraZeneca||2||Study withdrawn due to business decisions. No subjects were treated.|f||||t||||||||||2018-06-01 01:47:18.585176|2018-06-01 01:47:18.585176
NCT00746421|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2013-09-13||2014-03-31|2008-09-03|2008-09-04|Estimate|2014-02-12|2014-03-28|Estimate||||2014-03-31|2014-04-17|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder|Phase IV Study of Quetiapine XR Aimed at Disability and Cognitive Impairments.|Terminated||Phase 4|32|Actual|Emory University|We were unable to perform the pre-planned primary and secondary statistical analyses between group comparisons as the groups sizes were too small to compare meaningfully.|2||Sponsor withdrew funding|f||||t||||||||||2018-06-01 01:47:18.65561|2018-06-01 01:47:18.65561
NCT00746408|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2009-06-15|2008-09-03|2008-09-04|Estimate|||||||2009-06-15|2009-06-16|Estimate|January 2009||2009-01-31|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Observational|||Tailored Internet Information Supply for Patients|Study of the Quality of Self-Diagnosis by Headache Patients Getting Tailored Internet Information|Unknown status|Recruiting||500|Anticipated|Health & Life Sciences University, Tryol|||4||f||||t||||||||||2018-06-01 01:47:18.873585|2018-06-01 01:47:18.873585
NCT00746395|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2013-08-15||2016-11-07|2008-09-03|2008-09-04|Estimate|2016-11-07|2017-01-04|Estimate||||2016-11-07|2017-01-04|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy|Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy|Completed||Phase 4|45|Actual|University of South Alabama|Study participant enrollment met per protocol requirement.|2|||f||||f||||||||||2018-06-01 01:47:18.972476|2018-06-01 01:47:18.972476
NCT00746382|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2016-11-30|2008-09-03|2008-09-04|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2008||2008-11-30|October 2016|2016-10-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|||A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)|A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis|Withdrawn||Phase 2|0|Actual|AstraZeneca||2||Study withdrawn due to business decisions. No subjects were treated.|f||||f||||||||||2018-06-01 01:47:19.177236|2018-06-01 01:47:19.177236
NCT00746369|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2013-11-18|2008-09-03|2008-09-04|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|IMARA||IMARA, Adapting SiHLE for Detained African American Adolescent Females|IMARA, Adapting SiHLE for Detained African American Adolescent Females|Completed||N/A|188|Actual|Emory University||2|||f||||f||||||||||2018-06-01 01:47:19.227935|2018-06-01 01:47:19.227935
NCT00746356|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2011-07-24||2013-02-20|2008-09-03|2008-09-04|Estimate|2013-02-20|2013-03-01|Estimate||||2013-02-20|2013-03-01|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|January 2010|Actual|2010-01-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds|A Clinical Evaluation of the Current™ Radio Frequency (RF) Implantable Cardioverter Defibrillator (ICD) Models 2215/1215 and Promote™ RF Cardiac Resynchronization Therapy Defibrillator (CRT-D) Model 3215 Pulse Generators|Completed||N/A|128|Actual|St. Jude Medical||2|||f||||f||||||||||2018-06-01 01:47:19.295145|2018-06-01 01:47:19.295145
NCT00746343|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|||2013-12-11|2008-09-03|2008-09-04|Estimate|||||||2013-12-11|2013-12-12|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MedRisk||Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study|Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study|Completed||N/A|122|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 01:47:19.491096|2018-06-01 01:47:19.491096
NCT00746330|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-03|2010-11-21||2011-06-03|2008-09-03|2008-09-04|Estimate|2011-03-08|2011-04-14|Estimate||||2011-06-03|2011-06-07|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Multi-centre, 4-way Cross-over Study to Compare the Single Dose Bronchodilatory Effect of Formoterol Fumarate in Combination With Mometasone Furoate Delivered Via Pressurized Metered Dose Inhaler (pMDI) to Placebo Delivered Via pMDI in Children Aged 5-11 Years Old With Persistent Asthma|Completed||Phase 2|32|Actual|Novartis||4|||f||||||||||||||2018-06-01 01:47:19.633775|2018-06-01 01:47:19.633775
NCT00746317|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2012-10-15|2008-09-02|2008-09-03|Estimate|||||||2012-10-15|2012-10-17|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2010|Actual|2010-10-31||Interventional|||A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)|A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 Administered Weekly in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC)|Completed||Phase 1|27|Actual|Chugai Pharmaceutical||1|||f||||f||||||||||2018-06-01 01:47:20.42472|2018-06-01 01:47:20.42472
NCT00746304|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2008-08-31|2008-08-31|2008-09-03|Estimate|||||||2008-08-31|2008-09-03|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Observational|||Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin|Long-Term Outcomes in the Treatment of Infantile and Acquired Esotropia With Botulinum Toxin|Completed|||164|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-06-01 01:47:20.509664|2018-06-01 01:47:20.509664
NCT00746291|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2012-07-09|2008-09-02|2008-09-03|Estimate|||||||2012-07-09|2012-07-10|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Heart Rate Variability (HRV) Among Children With Brain Damage|Assessment of Autonomic Nervous System With Analysis of Heart Rate Variability in Children With Brain Damage.|Terminated||N/A|80|Actual|Alyn Pediatric & Adolecent Rehabilitation Center||3|||f||||f||||||||||2018-06-01 01:47:20.575938|2018-06-01 01:47:20.575938
NCT00746278|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2010-02-25|2008-08-29|2008-09-03|Estimate|||||||2010-02-25|2010-02-26|Estimate|September 2008||2008-09-30|May 2008|2008-05-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|||A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian Reserve|A Random Clinical Trial of the Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst|Completed||Phase 4|180|Actual|Shandong Provincial Hospital||3|||f||||t||||||||||2018-06-01 01:47:20.724549|2018-06-01 01:47:20.724549
NCT00746265|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2013-08-05|2008-09-02|2008-09-03|Estimate|||||||2013-08-05|2013-08-07|Estimate|September 2008||2008-09-30|August 2013|2013-08-31|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|MYH||Behavioral Treatment for Weight Loss|Acceptance-based Behavior Treatment: An Innovative Weight Control|Completed||N/A|128|Actual|Drexel University||2|||f||||t||||||||||2018-06-01 01:47:20.816818|2018-06-01 01:47:20.816818
NCT00746252|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2016-10-11||2018-02-22|2008-09-02|2008-09-03|Estimate|2018-02-22|2018-03-21|Actual||||2018-02-22|2018-03-21|Actual|June 2008||2008-06-30|February 2018|2018-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|PAMS||Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder|Investigating Metabolic Side Effects of Antipsychotic Medications in Children|Terminated||N/A|5|Actual|University of Maryland|The study funding stopped before a sufficient number of participants could be enrolled and therefore the study was terminated. Additionally the stopping criteria of 5% weight gain limited the length of time participants were in the study.|2||Due low rate of participation and lack of funding|f||||t||||||||No||2018-06-01 01:47:20.903738|2018-06-01 01:47:20.903738
NCT00746239|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2015-06-18||2018-04-30|2008-09-02|2008-09-03|Estimate|2015-09-14|2015-10-15|Estimate||||2018-04-30|2018-05-30|Actual|August 2008||2008-08-31|April 2018|2018-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety|Ramelteon for Sleep Initiation Insomnia in Panic Disorder Who Are Also on Escitalopram for Anxiety: A Double Blind, Randomized Clinical Trial|Terminated||N/A|11|Actual|Milton S. Hershey Medical Center||2||Funding for continuation was not received.|f||||||||||||||2018-06-01 01:47:21.193212|2018-06-01 01:47:21.193212
NCT00746226|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|February 2007|Actual|2007-02-28|June 2006|Actual|2006-06-30||Interventional|||Probiotics for Birch Pollen Allergy|Probiotic Intervention for Children With Birch Pollen Allergy|Completed||Phase 1/Phase 2|47|Actual|Danisco||2|||f||||f||||||||||2018-06-01 01:47:21.341228|2018-06-01 01:47:21.341228
NCT00746213|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2009-06-03|2008-09-02|2008-09-03|Estimate|||||||2009-06-03|2009-06-04|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Chronic Pain After Thoracotomy, an Incidence Study|Chronic Pain After Thoracotomy, an Incidence Study|Completed|||1340|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 01:47:21.409711|2018-06-01 01:47:21.409711
NCT00746187|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2014-03-12||2016-03-14|2008-09-02|2008-09-03|Estimate|2014-03-12|2014-04-16|Estimate||||2016-03-14|2016-04-13|Estimate|December 2002||2002-12-31|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Compare Marginal Bone Loss Around Implants From Two Dental Implant Systems.|An Open, Randomized Study to Compare Two Dental Implant Systems With Regard to Changes in Marginal Bone Level.|Completed||N/A|36|Actual|Dentsply Sirona Implants||2|||f||||f||||||||||2018-06-01 01:47:21.542807|2018-06-01 01:47:21.542807
NCT00746174|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|February 2004||2004-02-29|September 2008|2008-09-30|February 2008|Actual|2008-02-29|March 2007|Actual|2007-03-31||Interventional|||Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone|Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone|Completed||Phase 4|24|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 01:47:21.736902|2018-06-01 01:47:21.736902
NCT00746161|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-03|2008-09-02|2008-09-03|Estimate|||||||2008-09-03|2008-09-04|Estimate|April 2002||2002-04-30|September 2008|2008-09-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Evaluation of Double Tract Reconstruction After Total Gastrectomy in Patients With Gastric Cancer|A Prospective Randomized Controlled Trial Comparing Double Tract Method With Roux-en-Y Method After Total Gastrectomy in Patients With Gastric Cancer|Completed||Phase 3|44|Actual|Wakayama Medical University||2|||f||||t||||||||||2018-06-01 01:47:21.837175|2018-06-01 01:47:21.837175
NCT00746148|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2012-12-03|2008-09-02|2008-09-03|Estimate|||||||2012-12-03|2012-12-04|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|REPOS||Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study|Reflexology's Effect on Polycystic Ovary Syndrome (REPOS): A Pilot Study|Unknown status|Not yet recruiting|Phase 3|140|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-06-01 01:47:21.899025|2018-06-01 01:47:21.899025
NCT00746135|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2016-10-21|2008-09-02|2008-09-03|Estimate|||||||2016-10-21|2016-10-24|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|December 2012|Actual|2012-12-31|October 2010|Actual|2010-10-31||Interventional|TRI-V||TRI-V Heart Failure (HF) Implanted Cardioverter Defibrillator (ICD) Study|TRI-V Resynchronization in Paced Heart Failure Patients With ICD Indication.|Completed||N/A|40|Actual|St. Jude Medical||3|||f||||f||||||||||2018-06-01 01:47:21.961187|2018-06-01 01:47:21.961187
NCT00746122|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2018-04-06|2008-09-02|2008-09-03|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2009|Actual|2009-09-30|August 2017|2017-08-31|July 21, 2016|Actual|2016-07-21|August 21, 2013|Actual|2013-08-21||Interventional|IMPROVE||Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair|Can Emergency Endovascular Aneurysm Repair (eEVAR) Improve the Survival From Ruptured Abdominal Aortic Aneurysm?|Completed||N/A|613|Actual|Imperial College London||2|||f||||t||||||||Yes|The datasets generated during and/or analysed during the current study are/will be available upon request from mjs212@medschl.cam.ac.uk after approval by the Trial Management Committee.|2018-06-01 01:47:22.027235|2018-06-01 01:47:22.027235
NCT00746109|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2011-01-03|2008-09-02|2008-09-03|Estimate|||||||2011-01-03|2011-01-04|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Study of Wound Packing After Superficial Skin Abscess Drainage|Randomized Clinical Trial of Wound Packing Following Incision and Drainage of Superficial Skin Abscesses in the Pediatric Emergency Department|Completed||Phase 4|60|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 01:47:22.194924|2018-06-01 01:47:22.194924
NCT00746096|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2014-04-08||2014-06-12|2008-09-01|2008-09-03|Estimate|2014-05-15|2014-06-13|Estimate||||2014-06-12|2014-06-26|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||58 and 57 pts were assigned to IKH-01 or placebo group, and 57 and 56 pts started study drug adminitstration. Five pts in the IKH-01 group were excluded from FAS due to no available data of efficacy but include safety set and 1 pts placebo group was exculded from FAS and safety analysis population because of no visti after the drug administration.|Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea|Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Primary Dysmenorrhea.|Completed||Phase 3|115|Actual|Nobelpharma||2|||f||||t||||||||||2018-06-01 01:47:22.267755|2018-06-01 01:47:22.267755
NCT00746083|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|April 2001||2001-04-30|September 2008|2008-09-30|January 2007|Actual|2007-01-31|July 2005|Actual|2005-07-31||Interventional|||Challenge!, a Health Promotion/ Obesity Prevention Program for Teens|Randomized Controlled Trial for Health Promotion/ Obesity Prevention Targeting Low-Income, Urban, African-American Adolescents|Completed||N/A|235|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 01:47:22.483917|2018-06-01 01:47:22.483917
NCT00746070|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2010-05-03|2008-09-01|2008-09-03|Estimate|||||||2010-05-03|2010-05-04|Estimate|January 2007||2007-01-31|April 2010|2010-04-30|January 2013|Anticipated|2013-01-31|December 2009|Anticipated|2009-12-31||Observational|TAIPAI||Postoperative Cardiovascular Index Change of Primary Aldosteronism|Postoperative Cardiovascular Index Change of Primary Aldosteronism|Unknown status|Enrolling by invitation||300|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 01:47:22.557308|2018-06-01 01:47:22.557308
NCT00746057|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2013-09-27|2008-09-02|2008-09-03|Estimate|||||||2013-09-27|2013-09-30|Estimate|May 2006||2006-05-31|September 2013|2013-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft (Protocol DPRC Array)|Evaluation of an Early Screening Test of Chronic Rejection and of Operational Tolerance by MicroArray in Renal Graft.|Terminated||N/A|134|Actual|Nantes University Hospital||1||The number of included patients is sufficient.|f||||f||||||||||2018-06-01 01:47:22.642056|2018-06-01 01:47:22.642056
NCT00746044|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2009-05-14|2008-09-01|2008-09-03|Estimate|||||||2009-05-14|2009-05-15|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Observational|COVOL||Measurement of MRP2 Function Using Urinary Coproporphyrins|Evaluation of the Ratio of Urinary Coproporphyrins I and III as a Potential Biomarker of MRP2 Function in Man|Completed|||40|Actual|University Hospital, Tours|||1||f||||f||||||Samples With DNA|"~     24h urine DNA~   "|||2018-06-01 01:47:22.739652|2018-06-01 01:47:22.739652
NCT00746031|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2010-10-22|2008-09-02|2008-09-03|Estimate|||||||2010-10-22|2010-10-25|Estimate|December 2008||2008-12-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids|Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids.|Completed||Phase 4|30|Actual|University of Edinburgh||3|||f||||f||||||||||2018-06-01 01:47:22.785631|2018-06-01 01:47:22.785631
NCT00746018|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2018-01-04||2018-03-15|2008-09-02|2008-09-03|Estimate|2018-01-04|2018-01-30|Actual||||2018-03-15|2018-04-11|Actual|August 2008||2008-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy|Evaluation of Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy|Completed||N/A|39|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:47:22.855007|2018-06-01 01:47:22.855007
NCT00746005|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-30|||2011-01-11|2008-09-02|2008-09-03|Estimate|||||||2011-01-11|2011-01-12|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Fish Oil Supplementation on Cognition in MCI Patients and the Influence of the APOE4 Allele|Challenge Study: The Efficacy of Fish Oil Supplementation on Cognitive Performance in MCI Patients and the Influence of the APOE-epsilon4 Allele|Completed||N/A|40|Anticipated|Wageningen University||2|||f||||f||||||||||2018-06-01 01:47:24.02917|2018-06-01 01:47:24.02917
NCT00745992|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients|Voriconazole Therapeutic Drug Monitoring and CYP2C19 Genetic Polymorphisms in Taiwanese Patients|Unknown status|Not yet recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     plasma~   "|||2018-06-01 01:47:24.095508|2018-06-01 01:47:24.095508
NCT00745966|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-10-03|2008-09-02|2008-09-03|Estimate|||||||2008-10-03|2008-10-06|Estimate|July 2008||2008-07-31|September 2008|2008-09-30||||September 2008|Actual|2008-09-30||Observational|POLE||Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder|A 8-Week, Multicenter, Open-Label, Observational Study of Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder|Completed|||1000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:47:24.193235|2018-06-01 01:47:24.193235
NCT00745953|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2009-08-17|2008-09-02|2008-09-03|Estimate|||||||2009-08-17|2009-08-19|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Regression of Fatty Heart by Valsartan Therapy|Regression of Fatty Heart by Valsartan Therapy|Unknown status|Recruiting|Phase 4|28|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 01:47:24.27055|2018-06-01 01:47:24.27055
NCT00745940|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2013-06-28||2014-02-27|2008-09-02|2008-09-03|Estimate|2014-01-03|2014-02-17|Estimate||||2014-02-27|2014-03-28|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||We initially had 57 MBCT Intervention group participants and 48 Control group participants. 29 participants (28%) did not complete the study – 17 prior to their respective arm starting and 8 during the intervention. Thus, for our analysis we had 38 in each arm.|Mindfulness-Based Cognitive Therapy Intervention to Treat Depression in Individuals With a Traumatic Brain Injury|A Multi-site, Randomized, Controlled Trial of a Mindfulness-based Cognitive Therapy Intervention for Treating Depression in a Traumatic Brain Injury Population.|Completed||N/A|105|Actual|Lakehead University|It is not possible to generalize our findings to the general population of people with a traumatic brain injury. Participants self-selected. Some did not complete the intervention. The control group was a “wait-list” control group.|2|||f||||f||||||||||2018-06-01 01:47:24.370555|2018-06-01 01:47:24.370555
NCT00745927|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2012-08-13|2008-09-02|2008-09-03|Estimate|||||||2012-08-13|2012-08-14|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Application of CO2 Insufflations in Colonoscopy Randomized Trial|Application of CO2 Insufflations in Colonoscopy Examination-A Single-blinded Randomized Trial|Unknown status|Recruiting|N/A|400|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:47:24.732917|2018-06-01 01:47:24.732917
NCT00745914|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2017-01-07|2008-09-02|2008-09-03|Estimate|||||||2017-01-07|2017-01-10|Estimate|September 2008||2008-09-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients|A Randomized Placebo-Controlled Study to Evaluate the Efficacy of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Inducing Carotid Atherosclerotic Plaque Regression in Diabetic End-Stage Renal Disease Patients|Completed||N/A|22|Actual|The University of Hong Kong||2|||f||||t||||||||No||2018-06-01 01:47:24.825122|2018-06-01 01:47:24.825122
NCT00745901|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2010-04-22||2011-06-08|2008-09-02|2008-09-03|Estimate|2010-04-22|2010-05-25|Estimate||||2011-06-08|2011-06-10|Estimate|May 2008||2008-05-31|April 2010|2010-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females|An Open Label Study to Evaluate Cycle Control With Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) and Yaz (Drospirenone/Ethinyl Estradiol) in Healthy Sexually Active Females|Completed||Phase 4|355|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|||||f||||||||||||||2018-06-01 01:47:24.983944|2018-06-01 01:47:24.983944
NCT00745888|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2009-09-04|2008-09-02|2008-09-03|Estimate|||||||2009-09-04|2009-09-09|Estimate|May 2007||2007-05-31|August 2009|2009-08-31||||||||Observational|||Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit|Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     blood sample~   "|||2018-06-01 01:47:25.741334|2018-06-01 01:47:25.741334
NCT00745875|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2012-04-26||2012-04-26|2008-09-02|2008-09-03|Estimate|2012-04-26|2012-06-06|Estimate||||2012-04-26|2012-06-06|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study|A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Platinum-based Chemotherapy Regimen|Completed||Phase 2|66|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 01:47:25.89737|2018-06-01 01:47:25.89737
NCT00745862|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2013-07-23|2008-09-02|2008-09-03|Estimate|||||||2013-07-23|2013-07-25|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma|Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma|Completed|||118|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:47:26.394416|2018-06-01 01:47:26.394416
NCT00745849|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2008-08-29|2008-08-29|2008-09-03|Estimate|||||||2008-08-29|2008-09-03|Estimate|June 2005||2005-06-30|August 2008|2008-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial|Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-Blind, Placebo Controlled Trial|Completed||N/A|43|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 01:47:26.576848|2018-06-01 01:47:26.576848
NCT00745823|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2012-03-06|2011-09-29|2017-02-14|2008-09-02|2008-09-03|Estimate|2012-03-30|2012-04-25|Estimate|2011-09-29|2011-10-05|Estimate|2017-02-14|2017-03-21|Actual|September 2008||2008-09-30|February 2017|2017-02-28|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|||A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)|A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients|Terminated||Phase 3|775|Actual|Merck Sharp & Dohme Corp.|The study was terminated before the 96-week efficacy analysis. Adverse event data were collected for the entire treatment period up to a maximum of Week 108, which defines the Overall Study period.|2||"Primary efficacy analysis at Week 48 did not demonstrate non-inferiority of raltegravir 800 mg~   once daily versus raltegravir 400 mg twice daily"|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:47:26.82577|2018-06-01 01:47:26.82577
NCT00745810|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2011-10-13|2008-08-31|2008-09-03|Estimate|||||||2011-10-13|2011-10-17|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Observational|||Anesthetic Management and Remote Reperfusion Injuries|The Effects of Anesthetic Management on Oxidative Injuries After Cardiopulmonary Bypass|Completed|||40|Actual|National Taiwan University Hospital|||1||f||||f||||||None Retained|"~     whole blood and plasma~   "|||2018-06-01 01:47:27.632146|2018-06-01 01:47:27.632146
NCT00745797|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2017-03-02|2008-09-02|2008-09-03|Estimate|||||||2017-03-02|2017-03-06|Actual|April 2008||2008-04-30|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PCI||Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy|Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy：A Multi-center Randomized Phase ⅢTrial|Terminated||Phase 3|5|Actual|Chinese Society of Lung Cancer||2||this trial enroll extremely slow and No funding support|f||||t||||||||||2018-06-01 01:47:27.72876|2018-06-01 01:47:27.72876
NCT00745784|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2011-08-17|2008-09-02|2008-09-03|Estimate|||||||2011-08-17|2011-08-18|Estimate|January 2009||2009-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Prolonged Grief in Young Bereaved Spouses and Partners|Lost to Cancer: Prolonged Grief in Young Bereaved Spouses and Partners|Completed|||60|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:47:27.871808|2018-06-01 01:47:27.871808
NCT00745771|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2009-03-19|2008-09-02|2008-09-03|Estimate|||||||2009-03-19|2009-03-20|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|November 2008|Actual|2008-11-30|February 2008|Actual|2008-02-29||Interventional|||Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness|Multiple Dose, Double-Blind, Double-Dummy, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness From Exercise|Completed||Phase 2|168|Actual|IDEA AG||2|||f||||f||||||||||2018-06-01 01:47:28.034646|2018-06-01 01:47:28.034646
NCT00745758|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|May 2008||2008-05-31|September 2008|2008-09-30|September 2008|Anticipated|2008-09-30|||||Observational|||The Factors Cause Vasospasm After Aneurysmal Subarachnoid Hemorrhage|The Factors Cause Vasospasm After Aneurysmal Subarachnoid Hemorrhage|Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     CSF~   "|||2018-06-01 01:47:28.140233|2018-06-01 01:47:28.140233
NCT00745745|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2013-07-26|2008-09-02|2008-09-03|Estimate|||||||2013-07-26|2013-07-29|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|June 2011|Actual|2011-06-30||Interventional|SPICE||Septal Positioning of Ventricular Implanted Cardioverter Defibrillator (ICD) Leads|Septal Positioning of Ventricular ICD Leads|Completed||N/A|299|Actual|St. Jude Medical||2|||f||||f||||||||||2018-06-01 01:47:28.223424|2018-06-01 01:47:28.223424
NCT00745732|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2014-03-12|2008-09-02|2008-09-03|Estimate|||||||2014-03-12|2014-03-13|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)|A Phase I Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer|Terminated||Phase 1|3|Actual|M.D. Anderson Cancer Center||1||Sponsor withdrew support.|f||||f||||||||||2018-06-01 01:47:28.316322|2018-06-01 01:47:28.316322
NCT00745719|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2017-01-14|2008-09-01|2008-09-03|Estimate|||||||2017-01-14|2017-01-18|Estimate|March 2007||2007-03-31|January 2017|2017-01-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Parathyroidectomy in Endstage Renal Disease|A Pilot Study to Evaluate the Efficacy of Total Parathyroidectomy in Retarding Cardiovascular Calcification in End-stage Renal Disease Patients|Completed||Phase 4|62|Actual|The University of Hong Kong||1|||f||||t||||||||No||2018-06-01 01:47:28.400369|2018-06-01 01:47:28.400369
NCT00745706|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2015-03-10|2008-09-02|2008-09-03|Estimate|||||||2015-03-10|2015-03-11|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|DISCERN-AF||Discerning Symptomatic and Asymptomatic Episodes Pre and Post Radiofrequency Ablation of Atrial Fibrillation|Discerning Symptomatic and Asymptomatic Episodes Pre and Post Radiofrequency Ablation of Atrial Fibrillation|Completed||N/A|50|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-06-01 01:47:28.484842|2018-06-01 01:47:28.484842
NCT00745693|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-04|2008-09-02|2008-09-03|Estimate|||||||2008-09-04|2008-09-05|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin|The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin|Completed||N/A|15|Actual|University of Edinburgh||4|||f||||f||||||||||2018-06-01 01:47:28.724604|2018-06-01 01:47:28.724604
NCT00745680|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2011-01-20|2008-09-02|2008-09-03|Estimate|||||||2011-01-20|2011-01-24|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|October 2011|Anticipated|2011-10-31|||||Observational|||Speckle Tracking Imaging and Realtime 3 Dimensional Echocardiograhy to Study LV Function and Remodeling After Acute Myocardial Infarction (AMI)|Morphodynamic Study of Left Ventricular Remodeling With Possible Mechanisms for Pharmacologic Therapy: Assessment by Real-time 3-dimensional Echocardiography and 2-dimensional Speck Tracking Imaging.|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 01:47:28.830577|2018-06-01 01:47:28.830577
NCT00745667|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|July 1999||1999-07-31|September 2008|2008-09-30|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|LAMA||The LAMA Trial: Laparoscopic Correction of Perforated Peptic Ulcer Versus Open Correction|The LAMA Trial: Laparoscopic Correction of Perforated Peptic Ulcer Versus Open Correction by Upper Laparotomy|Completed||N/A|109|Actual|Erasme University Hospital||2|||f||||f||||||||||2018-06-01 01:47:28.914171|2018-06-01 01:47:28.914171
NCT00745641|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2009-08-05|2008-09-01|2008-09-03|Estimate|||||||2009-08-05|2009-08-07|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Abdominal Computed Tomography and the Blood Reactive Oxygen Species Level|Effect of Abdominal X-ray Computed Tomography Examination on the Blood Reactive Oxygen Species Level|Withdrawn|||60|Anticipated|National Taiwan University Hospital|||1|"because of the presence of unexpected administrative barrier to interfere the collection of~   case"|f||||f||||||None Retained|"~     only peripheral blood will be collected for measurement of reactive oxygen species.~   "|||2018-06-01 01:47:29.157792|2018-06-01 01:47:29.157792
NCT00745628|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|CCS-CHD||Chinese Cohort Study of Coronary Heart Disease|Cross-Sectional Investigation of Secondary Prevention on Coronary Heart Disease and Generalization of Standardized Secondary Prevention in Chinese Coronary Heart Disease Patients|Unknown status|Recruiting||10000|Anticipated|Ministry of Science and Technology of the People´s Republic of China|||||f||||t||||||||||2018-06-01 01:47:29.242653|2018-06-01 01:47:29.242653
NCT00745615|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2017-10-09|2008-09-02|2008-09-03|Estimate|||||||2017-10-09|2017-10-11|Actual|December 31, 2006|Actual|2006-12-31|October 2017|2017-10-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease|An Active Extension of LAQ/5062 Study. a Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group Study, to Evaluate the Safety, Tolerability and Efficacy of Two Doses (0.3 mg and 0.6 mg) of Laquinimod, Orally Administered in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects (Study LAQ/5063 Active Double-Blind Phase) Followed by an Open Label Phase of Laquinimod 0.6 mg Daily (LAQ/5063 OL)|Terminated||Phase 2|209|Actual|Teva Pharmaceutical Industries||2||"Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the~   study drug in the relevant dose."|f||||t|t|f||||||||2018-06-01 01:47:29.331812|2018-06-01 01:47:29.331812
NCT00745602|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2010-02-17|2008-09-02|2008-09-03|Estimate|||||||2010-02-17|2010-02-18|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||The Effect of Atrial Fibrillation Hemodynamics on Regulation of Cerebral Blood Flow|The Effect of Atrial Fibrillation Hemodynamics on Regulation of Cerebral Blood Flow|Unknown status|Recruiting|N/A|10|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-06-01 01:47:29.496089|2018-06-01 01:47:29.496089
NCT00745589|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2017-01-07|2008-09-02|2008-09-03|Estimate|||||||2017-01-07|2017-01-10|Estimate|July 2008||2008-07-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Sevelamer Hydrochloride in Peritoneal Dialysis Patients|Use of Sevelamer Hydrochloride to Control Hyperphosphatemia and Reduce Calcification Burden in the Poor Peritoneal Dialysis Patients|Completed||N/A|60|Actual|The University of Hong Kong||2|||f||||t||||||||No||2018-06-01 01:47:29.588964|2018-06-01 01:47:29.588964
NCT00745576|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2010-02-05|2008-09-02|2008-09-03|Estimate|||||||2010-02-05|2010-02-08|Estimate|October 2008||2008-10-31|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered|An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Verapamil Immediate Release (IR) and a Single Dose of SAM-531 When Co-administered Orally to Healthy Young Adult Subjects|Completed||Phase 1|14|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:47:29.705771|2018-06-01 01:47:29.705771
NCT00745563|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-30|||2011-06-08|2008-08-30|2008-09-03|Estimate|||||||2011-06-08|2011-06-09|Estimate|October 2008||2008-10-31|December 2008|2008-12-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Effects of Intra-uterine Slow-Release Insemination on Pregnancy Rate in Women Designated for Artificial Insemination|Testing the Effect of Intra-uterine Slow-Release Insemination (SRI) on the Pregnancy Rate in Women Designated for Artificial Insemination|Completed||N/A|100|Anticipated|Fertiligent||1|||f||||t||||||||||2018-06-01 01:47:29.853368|2018-06-01 01:47:29.853368
NCT00745550|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2012-04-19|2008-09-02|2008-09-03|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis|A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis|Completed||Phase 1/Phase 2|55|Actual|S*BIO|||||f||||f||||||||||2018-06-01 01:47:29.919761|2018-06-01 01:47:29.919761
NCT00745537|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2015-05-27|2008-09-02|2008-09-03|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|T-BOOM||T- BOOM Teens--Building Options and Opportunities for Moms|Teens--Building Options and Opportunities for Moms|Completed||N/A|23|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-06-01 01:47:30.006498|2018-06-01 01:47:30.006498
NCT00745524|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2012-05-16|2008-09-02|2008-09-03|Estimate|||||||2012-05-16|2012-05-17|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|December 2009|Actual|2009-12-31|||||Observational|||Screening for Attention-deficit/Hyperactivity Disorder (ADHD) in Adolescent and Adult High Risk Populations|Screening for Attention-deficit/Hyperactivity Disorder (ADHD) in Adolescent and Adult High Risk Populations|Completed|||1910|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:47:30.121536|2018-06-01 01:47:30.121536
NCT00745511|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2009-06-07|2008-09-02|2008-09-03|Estimate|||||||2009-06-07|2009-06-09|Estimate|March 2009||2009-03-31|June 2009|2009-06-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)|A Randomized, Multi-Center, Double Blind, 3 Arm, Phase I/II Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)|Unknown status|Recruiting|Phase 1/Phase 2|96|Anticipated|Ora Bio Ltd.||3|||f||||t||||||||||2018-06-01 01:47:30.421699|2018-06-01 01:47:30.421699
NCT00745498|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2012-06-06||2015-11-17|2008-09-02|2008-09-03|Estimate|2015-11-17|2015-12-21|Estimate||||2015-11-17|2015-12-21|Estimate|June 2008||2008-06-30|November 2015|2015-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|IBDV||Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy|Efficacy Study of Pre- and Intra-operative Intravitreal Bevacizumab Injection on Postoperative Vitreous Hemorrhage After Diabetic Vitrectomy|Completed||N/A|126|Actual|Seoul National University Bundang Hospital||3|||f||||t||||||||||2018-06-01 01:47:30.555807|2018-06-01 01:47:30.555807
NCT00745485|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2017-02-23|2008-09-02|2008-09-03|Estimate|||||||2017-02-23|2017-02-27|Actual|August 2008||2008-08-31|February 2017|2017-02-28||||July 2010|Actual|2010-07-31||Interventional|LISA||Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid|A Phase IV Study of the Safety and Feasibility of Rooms-based Infusion of Zoledronic Acid for Women With Post-menopausal Osteoporosis|Completed||Phase 4|186|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:47:30.899979|2018-06-01 01:47:30.899979
NCT00745472|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Observational|||Auditory Evoked Potentials and Experimental Pain|The Amplitude of Auditory Evoked Potentials and the Intensity of Experimental Pain Stimulation in Healthy Volunteers|Completed|||20|Actual|Odense University Hospital|||2||f||||f||||||||||2018-06-01 01:47:30.985708|2018-06-01 01:47:30.985708
NCT00745459|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2010-11-08|2008-09-02|2008-09-03|Estimate|||||||2010-11-08|2010-11-09|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy|Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Open-label Study)|Completed||Phase 3|100|Anticipated|Nihon Pharmaceutical Co., Ltd||1|||f||||t||||||||||2018-06-01 01:47:31.041148|2018-06-01 01:47:31.041148
NCT00745446|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-04|2008-09-02|2008-09-03|Estimate|||||||2008-09-04|2008-09-05|Estimate|September 2007||2007-09-30|September 2008|2008-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation|The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation|Completed||N/A|18|Actual|University of Edinburgh||3|||f||||f||||||||||2018-06-01 01:47:31.111878|2018-06-01 01:47:31.111878
NCT00745433|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2016-03-02|2008-09-02|2008-09-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|REPAMET 2||Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide|REPAMET 2: Observational Study of the Switch From Metformin Monotherapy to Bitherapy With Metformin and Repaglinide|Completed|||906|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:47:31.196637|2018-06-01 01:47:31.196637
NCT00745420|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2017-08-23||2018-04-11|2008-08-29|2008-09-03|Estimate|2017-11-28|2017-12-26|Actual||||2018-04-11|2018-05-10|Estimate|August 2008||2008-08-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|SCURT||Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)|Unrelated Donor Reduced Intensity Bone Marrow Transplant for Children With Severe Sickle Cell Disease (BMT CTN #0601)|Completed||Phase 2|30|Actual|Medical College of Wisconsin||1|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-06-01 01:47:31.294417|2018-06-01 01:47:31.294417
NCT00745407|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|||||Interventional|||Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients||Completed||Phase 4|||Gachon University Gil Medical Center||1|||f||||t||||||||||2018-06-01 01:47:31.835663|2018-06-01 01:47:31.835663
NCT00745394|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|April 2008||2008-04-30|September 2008|2008-09-30|December 2008|Anticipated|2008-12-31|August 2008|Anticipated|2008-08-31||Observational|NIRS||Validation of Near Infrared Spectroscopy (NIRS) During Heart-Lung Bypass in Children|Validation of Somatic and Cerebral Near Infrared Spectroscopy (NIRS) During Cardiopulmonary Bypass In Pediatric Patients: A Prospective Clinical Study|Unknown status|Recruiting||10|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 01:47:31.94122|2018-06-01 01:47:31.94122
NCT00745381|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2017-08-02|2008-09-02|2008-09-03|Estimate|||||||2017-08-02|2017-08-03|Actual|August 2008||2008-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors|Gastroenteropancreatic and Unknown Primary Neuroendocrine Registry A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors|Recruiting|||500|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     All participants will be invited to provide a DNA (blood sample) and tissue sample for the~     purposes of developing a tissue repository. Blood samples will be collected. Expected accrual~     is 150 patients per year. Patients who donate blood and/or tissue samples are considered~     evaluable for protocol; however, it is preferred that both are obtained.~   "|||2018-06-01 01:47:32.018743|2018-06-01 01:47:32.018743
NCT00745368|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|2012-07-25||2012-09-07|2008-09-02|2008-09-03|Estimate|2012-09-07|2012-10-10|Estimate||||2012-09-07|2012-10-10|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women|Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women|Completed||N/A|28|Actual|University of Rochester|Due to limited sample size and large intersubject variability, more study comparing male and female GT concentrations is needed.|1|||f||||f||||||||||2018-06-01 01:47:32.182115|2018-06-01 01:47:32.182115
NCT00745355|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2017-09-05|2008-09-02|2008-09-03|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2008||2008-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Quality of Life in Patients With Bladder Cancer|A Prospective Study of Quality of Life in Patients With Bladder Cancer|Active, not recruiting|||550|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:47:32.465381|2018-06-01 01:47:32.465381
NCT00745342|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2018-04-20|2008-09-02|2008-09-03|Estimate|||||||2018-04-20|2018-04-23|Actual|March 1999||1999-03-31|April 2018|2018-04-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Optimizing Adherence and Glycemia in Youth With New Insulin-dependent Diabetes Mellitus (IDDM)|Optimizing Adherence and Glycemia in Youth With New IDDM|Completed||N/A|105|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-06-01 01:47:32.566725|2018-06-01 01:47:32.566725
NCT00745329|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2008-09-02|2008-09-02|2008-09-03|Estimate|||||||2008-09-02|2008-09-03|Estimate|October 2008||2008-10-31|September 2008|2008-09-30||||||||Observational|||The Effect of Infliximab on Sperm Quality|The Effect of Infliximab,Adalimumab, Azathioprines and 5-Aminosalicylate on Semen Quality in Men With Inflammatory Bowel Disease|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-06-01 01:47:32.711725|2018-06-01 01:47:32.711725
NCT00744991|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29||2010-10-25|2010-10-25|2008-08-29|2008-09-01|Estimate||||2010-10-25|2010-10-27|Estimate|2010-10-25|2010-10-27|Estimate|September 2008||2008-09-30|October 2010|2010-10-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma|A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma|Completed||Phase 2|25|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:47:37.363749|2018-06-01 01:47:37.363749
NCT00745316|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02||2015-11-19|2016-01-07|2008-09-02|2008-09-03|Estimate||||2016-01-07|2016-02-05|Estimate|2016-01-07|2016-02-05|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|POSEIDON||Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients With Heart Failure and Renal Insufficiency|Terminated||Phase 2|34|Actual|Biogen||6||Company Decision|f||||t||||||||||2018-06-01 01:47:32.926357|2018-06-01 01:47:32.926357
NCT00745303|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2008-09-01|2008-09-01|2008-09-03|Estimate|||||||2008-09-01|2008-09-03|Estimate|May 2002||2002-05-31|September 2008|2008-09-30|March 2004|Actual|2004-03-31|May 2003|Actual|2003-05-31||Observational|||Effect of Tai Chi Chuan on Autonomic Nervous Modulation in Aged Subjects|Effect of Tai Chi Chuan on Autonomic Nervous Modulation, Blood Lipid and Cytokines Production in Aged Subjects|Completed|||50|Actual|Taipei Veterans General Hospital, Taiwan|||2||f||||f||||||Samples Without DNA|"~     Blood sample obtained from each subject was withdrawn for the quantitative measurements of~     total cholesterol (TC), high-density lipoprotein--cholesterol (HDL-C), high-density~     lipoprotein--cholesterol (LDL-C), triglyceride (TG), fasting blood sugar (FBS), and uric acid~     (UA). The immunoenzymometric assays for the quantitative measurement of tumor necrosis~     factor-α (TNF-α) and interferon-γ (IFN-γ) in the serum were also performed on the blood~     sample from each subject.~   "|||2018-06-01 01:47:33.059851|2018-06-01 01:47:33.059851
NCT00745290|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2011-11-23|2010-08-25|2013-07-03|2008-08-29|2008-09-03|Estimate|2013-07-03|2013-08-06|Estimate|2010-08-27|2010-08-31|Estimate|2013-07-03|2013-08-06|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|TKA||A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Active Control Study to Evaluate the Safety and Efficacy of a Single Intraoperative Administration of SKY0402 For Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty|Completed||Phase 3|245|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:47:33.193928|2018-06-01 01:47:33.193928
NCT00745277|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2012-11-28|2008-09-02|2008-09-03|Estimate|||||||2012-11-28|2012-11-30|Estimate|August 2008||2008-08-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||High and Low Dose Treatment of Carbidopa in Parkinson's Disease|A Randomized Controlled Trial of Four Week Outpatient Treatment of Parkinson's Disease Comparing High and Low Dose Carbidopa.|Completed||Phase 2|12|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 01:47:33.520958|2018-06-01 01:47:33.520958
NCT00745264|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2009-03-19|2008-09-02|2008-09-03|Estimate|||||||2009-03-19|2009-03-20|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise|Multi-Centre, Open-Label, Two Segment, Parallel Group Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise|Completed||Phase 1|80|Actual|IDEA AG||4|||f||||||||||||||2018-06-01 01:47:33.618161|2018-06-01 01:47:33.618161
NCT00745251|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|2012-07-31|2011-05-13|2012-09-05|2008-08-31|2008-09-03|Estimate|2012-09-05|2012-10-05|Estimate|2011-05-13|2011-05-18|Estimate|2012-09-05|2012-10-05|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults|Completed||Phase 1/Phase 2|45|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-06-01 01:47:33.696391|2018-06-01 01:47:33.696391
NCT00745238|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2012-08-10|2008-09-02|2008-09-03|Estimate|||||||2012-08-10|2012-08-13|Estimate|June 2008||2008-06-30|September 2008|2008-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Cardiovascular Consequences of NIV Withdrawal in Patients With Myotonic Dystrophy|Four Weeks Withdrawal of Non-invasive Ventilation (NIV) in Patients With Myotonic Dystrophy: Cardiovascular, Metabolic and Daytime Vigilance Induced Changes|Unknown status|Recruiting|N/A|35|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-06-01 01:47:34.100398|2018-06-01 01:47:34.100398
NCT00745225|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2017-01-07|2008-09-02|2008-09-03|Estimate|||||||2017-01-07|2017-01-10|Estimate|February 2006||2006-02-28|January 2017|2017-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|PPAR||Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients|Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?|Completed||Phase 4|160|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-06-01 01:47:34.277025|2018-06-01 01:47:34.277025
NCT00745212|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2017-11-07|2008-09-02|2008-09-03|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2008||2008-06-30|November 2017|2017-11-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|STRATHEGE||Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women|Prospective Multicentric Evaluation of an Antithrombotic Therapeutic Strategy in Pregnant Women With a Risk of Thromboembolism and/or a Risk of Placental Vascular Complication, Strategy Determined With a Risk Score.|Completed|||2280|Actual|Centre Hospitalier Universitaire de Saint Etienne|||||f||||t||||||||||2018-06-01 01:47:34.536911|2018-06-01 01:47:34.536911
NCT00745199|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2009-08-17|2008-09-02|2008-09-03|Estimate|||||||2009-08-17|2009-08-18|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus|Phase II Study of the Effect of Oral Cromolyn Sodium on Uremic Pruritus and Serum Tryptase Levels of Hemodialysed Patients|Completed||Phase 2|62|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-06-01 01:47:34.605276|2018-06-01 01:47:34.605276
NCT00745186|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2017-03-16|2008-09-02|2008-09-03|Estimate|||||||2017-03-16|2017-03-20|Actual|August 2007||2007-08-31|June 2015|2015-06-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers|A Randomized, Open Label, Four Way Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety After Intramuscular (IM) Administration of Mayne Glucagon for Injection With Glucagen® (Novo Nordisk) in Healthy Volunteers.|Completed||Phase 1|28|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:47:34.789661|2018-06-01 01:47:34.789661
NCT00745173|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2009-02-11|2008-09-02|2008-09-03|Estimate|||||||2009-02-11|2009-02-12|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Evaluating Premarin and Bazedoxifene Potential Interaction|An Open-Label, Single/Multiple Dose Non-Randomized, 3-Period, Crossover Study To Determine The Potential Drug Interaction Of Conjugated Estrogens (CE) On Bazedoxifene In Healthy Postmenopausal Women.|Completed||Phase 1|30|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:47:34.891965|2018-06-01 01:47:34.891965
NCT00745160|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2011-03-29|2008-09-02|2008-09-03|Estimate|||||||2011-03-29|2011-03-30|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes|Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes|Completed|||115|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     blood sample for DNA analysis~   "|||2018-06-01 01:47:34.992805|2018-06-01 01:47:34.992805
NCT00745147|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-31|||2010-05-03|2008-08-31|2008-09-03|Estimate|||||||2010-05-03|2010-05-04|Estimate|July 2008||2008-07-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Comparison of TCM and Laxatives for Adults With Chronic Constipation|Comparison of Chinese Herbal Formula and Lactulose for Adults With Chronic Constipation-a Randomized ,Double-Blind, Controlled Trial|Completed||Phase 3|93|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:47:35.246394|2018-06-01 01:47:35.246394
NCT00745134|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2018-01-05|2008-09-02|2008-09-03|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2008|Actual|2008-08-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer|A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer|Active, not recruiting||Phase 2|45|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 01:47:35.507478|2018-06-01 01:47:35.507478
NCT00745121|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2018-01-30|2008-09-02|2008-09-03|Estimate|||||||2018-01-30|2018-02-01|Actual|July 16, 2008||2008-07-16|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 1, 2017|Actual|2017-11-01||Interventional|||Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis|An Open, Prospective, Non-randomized, Controlled, Multicenter Study to Evaluate Clinical Outcome of the ASTRA TECH Implant System, OsseoSpeed™ Implant in Women Over 60 Years of Age With Osteoporosis/Osteopenia|Completed||N/A|103|Actual|Dentsply Sirona Implants||2|||f||||f||||||||||2018-06-01 01:47:35.719748|2018-06-01 01:47:35.719748
NCT00745108|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|||2017-04-06|2008-09-02|2008-09-03|Estimate|||||||2017-04-06|2017-04-07|Actual|October 1, 2001|Actual|2001-10-01|April 2017|2017-04-30|July 21, 2005|Actual|2005-07-21|July 21, 2005|Actual|2005-07-21||Interventional|THEBES||Tibolone Endometrium Study (Study 32972)(P06470)|A Multinational, Multicenter, Randomized, Double-blind, Parallel Group, Active Controlled, Comparative Trial, to Assess the Endometrial Histological Profile Following Treatment With Tibolone (Org OD14) Versus Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA) in Postmenopausal Women|Completed||Phase 3|32|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 01:47:35.854656|2018-06-01 01:47:35.854656
NCT00745095|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-02|2014-04-18||2014-07-02|2008-09-02|2008-09-03|Estimate|2014-05-28|2014-06-30|Estimate||||2014-07-02|2014-07-16|Estimate|March 2009||2009-03-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage|Efficacy and Safety of Bowel Preparations for Colonoscopy in SCI|Completed||Phase 4|360|Actual|VA Office of Research and Development||6|||f||||f||||||||||2018-06-01 01:47:35.960519|2018-06-01 01:47:35.960519
NCT00745069|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2011-05-17|2008-08-29|2008-09-01|Estimate|||||||2011-05-17|2011-05-18|Estimate|July 2004||2004-07-31|April 2010|2010-04-30|August 2005|Actual|2005-08-31|||||Interventional|||Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis|4-Week Randomized Multicenter DB, Placebo- and Active-controlled, Parallel-group, Forced-titration Phase 2B Study of Efficacy and Safety With CG5503 Prolonged Release (PR) to 233 mg BID and Oxycodone PR to 20 mg BID vs Placebo in Subjects With Moderate to Severe Chronic Pain of Knee Osteoarthritis|Completed||Phase 2|670|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:47:36.408463|2018-06-01 01:47:36.408463
NCT00745056|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2017-11-02|2008-08-29|2008-09-01|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2008||2008-08-31|March 2017|2017-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|WHIMS-ECHO||Examining the Relationship Between Hormone Therapy (HT) and Cognitive Function (The WHIMS-ECHO Study)|Women's Health Initiative Memory Study--Epidemiology of Cognitive Health Outcomes|Active, not recruiting|||2922|Actual|Wake Forest University Health Sciences|||||f||||t||||||||Yes|WHIMS-ECHO will follow guidelines, methods and processes as set forth in the WHI 2015-2020 Data Sharing Plan. Limited data sets will be archived on the WHIMS-ECHO website. Accompanying the limited data sets, substantial electronic documentation will be provided in a standard format that is readable on a variety of platforms. Documentation will include data collection forms, a description of study protocol and procedures, description of all variable re-coding and a list of major study publications. These data will be available to users only under a data-sharing agreement that provides for: a commitment to using the data only for research purposes and not to identify any individual participant; a commitment to securing the data using appropriate computer technology; and a commitment to destroying or returning the data after analyses are completed. Data will be made available for timely release no later than the acceptance for publication of the main findings from the final dataset.|2018-06-01 01:47:36.49364|2018-06-01 01:47:36.49364
NCT00745043|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2008-08-29|2008-08-29|2008-09-01|Estimate|||||||2008-08-29|2008-09-01|Estimate|May 2005||2005-05-31|August 2008|2008-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|BOLD||Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study|Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD?|Completed||N/A|11|Actual|Waikato Hospital||4|||f||||f||||||||||2018-06-01 01:47:36.67972|2018-06-01 01:47:36.67972
NCT00745030|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2010-10-12||2011-04-18|2008-08-29|2008-09-01|Estimate|2010-10-12|2010-11-10|Estimate||||2011-04-18|2011-04-21|Estimate|June 2008||2008-06-30|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism|Efficacy and Tolerability of Ramelteon in Patients With REM Behavior Disorder and Parkinsonism: A Placebo Controlled, Double Blind, Randomized, Prospective Pilot Study|Terminated||N/A|3|Actual|Northwestern University||2||Low subject recruitment and enrollment.|f||||t||||||||||2018-06-01 01:47:36.809737|2018-06-01 01:47:36.809737
NCT00745017|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-08-29|2008-08-29|2008-09-01|Estimate|||||||2008-08-29|2008-09-01|Estimate|July 2001||2001-07-31|August 2008|2008-08-31||||July 2006|Actual|2006-07-31||Interventional|||Stress Generation and Recurrent Depression: The Role of Differential Treatment Response|Stress Generation and Recurrent Depression: The Role of Differential Treatment Response|Completed||Phase 1|72|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 01:47:37.219032|2018-06-01 01:47:37.219032
NCT00745004|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2012-01-23|2008-08-29|2008-09-01|Estimate|||||||2012-01-23|2012-01-24|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D)|"Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D): Identifying the Responder"|Completed||Phase 4|150|Actual|University of Nottingham||2|||f||||f||||||||||2018-06-01 01:47:37.295746|2018-06-01 01:47:37.295746
NCT00744978|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2011-10-12||2011-10-12|2008-08-29|2008-09-01|Estimate|2011-10-12|2011-11-22|Estimate||||2011-10-12|2011-11-22|Estimate|July 2009||2009-07-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease|A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Crossover Trial of Varenicline Tartrate (CP-526,555) in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|66|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 01:47:37.551318|2018-06-01 01:47:37.551318
NCT00744965|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2017-01-25|2008-08-29|2008-09-01|Estimate|||||||2017-01-25|2017-01-26|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2013|Actual|2013-01-31||Interventional|||Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo|A Randomized Controlled Clinical Trial of Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo|Completed||Phase 4|395|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 01:47:38.491042|2018-06-01 01:47:38.491042
NCT00744952|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2017-05-01|2008-08-29|2008-09-01|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2008|Actual|2008-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Use of MRI and PET for Assessing Disease Activity in Takayasu's Arteritis|VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-vessel Vasculitis (Takayasu's Arteritis):Development as Clinical Trial Outcome Measures|Recruiting|||36|Anticipated|University of Pennsylvania|||||f||||t||||||||||2018-06-01 01:47:38.557079|2018-06-01 01:47:38.557079
NCT00744939|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2014-07-29||2014-09-17|2008-08-29|2008-09-01|Estimate|2014-09-17|2014-09-22|Estimate||||2014-09-17|2014-09-22|Estimate|November 2008||2008-11-30|September 2014|2014-09-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Observational|||Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist|Prospective Non-randomized Observational (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Magnevist® Injection in Patients With Moderate Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information.|Completed|||168|Actual|Bayer|Bayer HealthCare was informed about the release from the postmarketing surveillance (PMS) for Magnevist with a letter dated 02 JUN 2011. As a consequence Bayer HealthCare stopped enrollment for this study on 01 AUG 2011.||1||f||||f||||||Samples Without DNA|"~     Serum creatinine must be obtained within 6 weeks of the administration of Magnevist, or as~     currently recommended by the American College of Radiology. At the Baseline within 48 hrs.~     pre-injection a chemistry panel will be obtained in all patients after intravenous access has~     been obtained.~   "|||2018-06-01 01:47:38.673073|2018-06-01 01:47:38.673073
NCT00744926|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29||2016-07-26|2016-07-26|2008-08-29|2008-09-01|Estimate||||2016-07-26|2016-07-28|Estimate|2016-07-26|2016-07-28|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise|Completed||Phase 3|373|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:47:40.828381|2018-06-01 01:47:40.828381
NCT00744913|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2013-08-14|2008-08-29|2008-09-01|Estimate|||||||2013-08-14|2013-08-15|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|||Study of Nicotine Replacement Therapy in Pregnancy|Randomized, Controlled Open-Label Study of Nicotine Replacement Therapy in Pregnancy|Withdrawn||Phase 3|0|Actual|The Hospital for Sick Children||2||Discontinued due to difficulty in recruitment|f||||t||||||||||2018-06-01 01:47:41.095882|2018-06-01 01:47:41.095882
NCT00744900|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2009-07-24|2008-08-29|2008-09-01|Estimate|||||||2009-07-24|2009-07-28|Estimate|September 2008||2008-09-30|July 2009|2009-07-31||||||||Interventional|GFPC 07-01||Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)|A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL).|Completed||Phase 2|45|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-06-01 01:47:41.193543|2018-06-01 01:47:41.193543
NCT00744887|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2011-06-08|2008-08-29|2008-09-01|Estimate|||||||2011-06-08|2011-06-09|Estimate|August 2008||2008-08-31|April 2010|2010-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.|Phase I, Open-label, Randomized, 3-way Crossover Trial to Assess the Pharmacokinetics of Darunavir (DRV) Given Once-daily With Different Doses of Ritonavir in Healthy Subjects.|Completed||Phase 1|21|Actual|Tibotec Pharmaceuticals, Ireland|||||||||||||||||||2018-06-01 01:47:41.327168|2018-06-01 01:47:41.327168
NCT00744874|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2012-07-25||2012-12-11|2008-08-29|2008-09-01|Estimate|2012-12-11|2013-01-18|Estimate||||2012-12-11|2013-01-18|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|September 2009|Actual|2009-09-30||Interventional|MAP-PAF||Ablation of the Pulmonary Veins for Paroxysmal Afib|Multi-Array Ablation of the Pulmonary Veins for Paroxysmal Atrial Fibrillation|Completed||Phase 4|55|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||f||||||||||2018-06-01 01:47:41.414277|2018-06-01 01:47:41.414277
NCT00744861|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2013-07-23|2008-08-29|2008-09-01|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|EXO-SPINE||Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar Surgery|EXO-SPINE: A Prospective, Multi-center, Double-blind, Randomized, Placebo Controlled Pivotal Study of Ultrasound as Adjunctive Therapy for Increasing Posterolateral Fusion Success Following Single Level Posterior Instrumented Lumbar Surgery|Terminated||N/A|310|Actual|Bioventus LLC||2||Terminated following interim analysis|f||||f||||||||||2018-06-01 01:47:41.740316|2018-06-01 01:47:41.740316
NCT00744848|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2011-11-23|2010-08-25|2013-07-03|2008-08-28|2008-09-01|Estimate|2013-07-03|2013-08-06|Estimate|2010-08-27|2010-08-31|Estimate|2013-07-03|2013-08-06|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy|Phase 3, Multicenter, Randomized, Double-Blind, Parallel-group, Active-control Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy|Completed||Phase 3|204|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:47:41.931144|2018-06-01 01:47:41.931144
NCT00744835|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2012-06-04|2008-08-29|2008-09-01|Estimate|||||||2012-06-04|2012-06-05|Estimate|August 2006||2006-08-31|June 2012|2012-06-30|July 2008|Actual|2008-07-31|August 2007|Actual|2007-08-31||Interventional|||Atrial Fibrillation Ablation Pilot Study|Atrial Fibrillation Ablation Pilot Study- Study Number AFI-20|Completed||Phase 1|53|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||t||||||||||2018-06-01 01:47:42.269829|2018-06-01 01:47:42.269829
NCT00744809|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2011-06-08|2008-08-29|2008-09-01|Estimate|||||||2011-06-08|2011-06-09|Estimate|August 2008||2008-08-31|March 2010|2010-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.|A Phase I, Double-blind, Double-dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-state and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-state on the QT/QTc Interval, in 2 Randomized Panels of Healthy Volunteers|Completed||Phase 1|120|Actual|Tibotec Pharmaceuticals, Ireland|||||||||||||||||||2018-06-01 01:47:42.44971|2018-06-01 01:47:42.44971
NCT00744796|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2008-08-29|2008-08-29|2008-09-01|Estimate|||||||2008-08-29|2008-09-01|Estimate|December 2006||2006-12-31|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|DSAEK||Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty|Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) in Patients With Corneal Endothelial Cell Dysfunction: Clinical Outcomes and Diagnostic Imaging Analysis|Unknown status|Recruiting|N/A|200|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-06-01 01:47:42.512252|2018-06-01 01:47:42.512252
NCT00744770|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2010-04-26|2008-08-29|2008-09-01|Estimate|||||||2010-04-26|2010-04-28|Estimate|October 2008||2008-10-31|April 2010|2010-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.|A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial in Subjects on Stable Methadone Maintenance Therapy, to Investigate the Potential Interaction Between TMC278 25 mg q.d. and Methadone, at Steady-state.|Completed||Phase 1|13|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:47:42.618077|2018-06-01 01:47:42.618077
NCT00744757|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2013-03-19||2013-08-26|2008-08-29|2008-09-01|Estimate|2013-07-16|2013-08-15|Estimate||||2013-08-26|2013-09-09|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|September 2010|Actual|2010-09-30||Interventional|||An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)|A Phase II Multi-center Study of 5-AZA-2'-Deoxycytidine (Decitabine) Single Agent in Taiwanese Patients With Myelodysplastic Syndrome (MDS)|Completed||Phase 2|37|Actual|Johnson & Johnson Taiwan Ltd||1|||f||||f||||||||||2018-06-01 01:47:42.732618|2018-06-01 01:47:42.732618
NCT00744744|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2012-02-01|2008-08-29|2008-09-01|Estimate|||||||2012-02-01|2012-02-02|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Health-Related Quality of Life in Patients With Bladder Cancer|A CROSS-SECTIONAL STUDY OF PATIENT-REPORTED OUTCOMES FOR BLADDER CANCER PATIENTS WITH NON-INVASIVE DISEASE|Completed|||138|Actual|Baylor College of Medicine|||1||f||||f||||||||||2018-06-01 01:47:43.31633|2018-06-01 01:47:43.31633
NCT00744731|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29||2013-01-15|2013-06-10|2008-08-29|2008-09-01|Estimate||||2013-06-10|2013-06-18|Estimate|2013-06-10|2013-06-18|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures|The Open Label Extension Portion of the Study Entitled A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.|Completed||Phase 3|403|Actual|SK Life Science||2|||f||||||||||||||2018-06-01 01:47:43.382093|2018-06-01 01:47:43.382093
NCT00744718|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2016-11-15|2008-08-29|2008-09-01|Estimate|||||||2016-11-15|2016-11-16|Estimate|August 2008||2008-08-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Bevacizumab and Carboplatin for Patients With Ovarian Cancer|Bevacizumab and Carboplatin for Patients With Platin Resistant Epithelial Ovarian Cancer. A Phase II Study.|Completed||Phase 2|73|Actual|Vejle Hospital|||||f||||t||||||||||2018-06-01 01:47:43.448315|2018-06-01 01:47:43.448315
NCT00744705|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2008-08-29|2008-08-29|2008-09-01|Estimate|||||||2008-08-29|2008-09-01|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|November 2008|Anticipated|2008-11-30||Observational|||Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians|Normative Database of the Retinal Nerve Fiber Layer Thickness Measured by the Cirrus HD OCT in Asians|Unknown status|Not yet recruiting||200|Anticipated|Yonsei University|||1||f||||t||||||||||2018-06-01 01:47:43.500614|2018-06-01 01:47:43.500614
NCT00744692|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2014-07-23||2014-07-23|2008-08-29|2008-09-01|Estimate|2014-07-23|2014-08-13|Estimate||||2014-07-23|2014-08-13|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|December 2012|Actual|2012-12-31||Interventional||22 subjects undergoing umbilical cord blood transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders|A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation|Completed||Phase 1|22|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:47:43.5816|2018-06-01 01:47:43.5816
NCT00744679|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2015-02-06|2008-08-29|2008-09-01|Estimate|||||||2015-02-06|2015-02-10|Estimate|November 2008||2008-11-30|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State|An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions|Completed||Phase 4|20|Actual|Biogen||1|||f||||f||||||||||2018-06-01 01:47:43.913798|2018-06-01 01:47:43.913798
NCT00744666|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2009-08-04|2008-08-29|2008-09-01|Estimate|||||||2009-08-04|2009-08-06|Estimate|September 2008||2008-09-30|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Interventional|IVTA:PRE-TREAT||IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids|IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids|Unknown status|Recruiting|Phase 4|70|Anticipated|Hotel Dieu Hospital||2|||f||||f||||||||||2018-06-01 01:47:43.980223|2018-06-01 01:47:43.980223
NCT00744653|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2011-03-22||2014-06-18|2008-08-29|2008-09-01|Estimate|2014-06-18|2014-07-18|Estimate||||2014-06-18|2014-07-18|Estimate|October 2008||2008-10-31|June 2014|2014-06-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.|Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.|Terminated||Phase 2|17|Actual|Copenhagen University Hospital at Herlev|Early termination due to too few objective respondes using the primary endpoint.|1||Primary endpoint measure not suitable for evaluation|f||||t||||||||||2018-06-01 01:47:44.091563|2018-06-01 01:47:44.091563
NCT00742898|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2009-09-14|2008-08-26|2008-08-28|Estimate|||||||2009-09-14|2009-09-15|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Evaluation of Opt-Out Rapid HIV Testing in the Emergency Department|Non-targeted Opt-out Rapid HIV Screening in the Emergency Department: a Controlled Clinical Trial|Completed||N/A|120000|Anticipated|Denver Health and Hospital Authority||2|||f||||f||||||||||2018-06-01 01:48:17.304804|2018-06-01 01:48:17.304804
NCT00744640|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2010-01-11|2008-08-29|2008-09-01|Estimate|||||||2010-01-11|2010-01-12|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|GEMOXEL||Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma|Gemcitabine, Oxaliplatin and Capecitabine (GEMOXEL) for Patients With Advanced Pancreatic Adenocarcinoma (APC): A Phase I/II Study|Completed||Phase 1/Phase 2|46|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 01:47:44.265412|2018-06-01 01:47:44.265412
NCT00744627|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2013-10-25||2014-01-28|2008-08-29|2008-09-01|Estimate|2014-01-28|2014-03-03|Estimate||||2014-01-28|2014-03-03|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder|Completed||Phase 3|301|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:47:44.431051|2018-06-01 01:47:44.431051
NCT00744614|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2010-10-19|2008-08-29|2008-09-01|Estimate|||||||2010-10-19|2010-10-21|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Use Of Capnography As Surrogate Measure Of PC02 In Medical Intensive Care Unit (ICU) Patients|Use Of Capnography As Surrogate Measure Of PC02 In Medical ICU Patients|Terminated|||70|Anticipated|Lahey Clinic|||1|"Principal Investigator (central contact) has left the organization and requests the study be~   terminated"|f||||f||||||||||2018-06-01 01:47:45.495883|2018-06-01 01:47:45.495883
NCT00744601|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2012-12-31|2008-08-29|2008-09-01|Estimate|||||||2012-12-31|2013-01-03|Estimate|April 2007||2007-04-30|December 2012|2012-12-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Observational|||Impulsivity, Neural Deficits and Cocaine Addiction|Impulsivity, Neural Deficits, and Relapse in Cocaine Addiction|Completed|||90|Actual|University of Texas Southwestern Medical Center|||2||f||||f||||||Samples With DNA|"~     urine, blood, plasma, and erythrocytes~   "|||2018-06-01 01:47:45.562821|2018-06-01 01:47:45.562821
NCT00744588|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2013-01-02|2008-08-29|2008-09-01|Estimate|||||||2013-01-02|2013-01-03|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Observational|||Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism|Stress, HPA Dysfunction, and Relapse in Alcoholism|Completed|||75|Actual|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples With DNA|"~     serum plasma whole blood urine~   "|||2018-06-01 01:47:45.619046|2018-06-01 01:47:45.619046
NCT00744575|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2010-10-08|2008-08-29|2008-09-01|Estimate|||||||2010-10-08|2010-10-11|Estimate|August 2008||2008-08-31|January 2009|2009-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Assessment of a Specific Neurophysiological Brain Pattern in Patients Suffering From Chronic Back Pain|Assessment of a Specific Neurophysiological Brain Pattern in Patients Suffering From Chronic Back Pain|Completed|||72|Anticipated|University Hospital Freiburg|||2||f||||f||||||||||2018-06-01 01:47:45.67363|2018-06-01 01:47:45.67363
NCT00744562|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2016-09-16|2008-08-29|2008-09-01|Estimate|||||||2016-09-16|2016-09-20|Estimate|August 2008||2008-08-31|September 2016|2016-09-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors|Completed||Phase 1|42|Actual|OncoMed Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 01:47:45.734026|2018-06-01 01:47:45.734026
NCT00744549|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2018-02-13|2008-08-29|2008-09-01|Estimate|||||||2018-02-13|2018-02-14|Actual|May 2008||2008-05-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance|The Impact of Antioxidants on MRI Markers of Cell Proliferation and Hypoxia Among Men on Active Surveillance With Early Stage Prostate Cancer|Completed||Phase 2|16|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 01:47:45.785329|2018-06-01 01:47:45.785329
NCT00744536|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2017-06-08|2008-08-29|2008-09-01|Estimate|||||||2017-06-08|2017-06-09|Actual|January 2008||2008-01-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|REMMYDYS||Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS|"Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study"|Completed||Phase 2|20|Actual|Sunnybrook Health Sciences Centre||1|||f||||t|f|f|||f|||No||2018-06-01 01:47:45.905944|2018-06-01 01:47:45.905944
NCT00744523|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2010-03-10||2016-01-28|2008-08-29|2008-09-01|Estimate|2010-04-14|2010-05-05|Estimate||||2016-01-28|2016-02-26|Estimate|September 2007||2007-09-30|January 2016|2016-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|ARMOUR||Proximal Protection With The Mo.Ma Device During Carotid Stenting|ARMOUR: Proximal Protection With The Mo.Ma Device During Carotid Stenting|Completed||N/A|262|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 01:47:46.016249|2018-06-01 01:47:46.016249
NCT00744510|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2012-12-03|2008-08-29|2008-09-01|Estimate|||||||2012-12-03|2012-12-04|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|REPOS||Reflexology's Effect on Polycystic Ovary Syndrome (PCOS)|Reflexology's Effect on Polycystic Ovary Syndrome (REPOS): A Pilot Study|Unknown status|Not yet recruiting|Phase 3|140|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-06-01 01:47:46.866576|2018-06-01 01:47:46.866576
NCT00744497|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|2013-11-15||2016-08-23|2008-08-29|2008-09-01|Estimate|2014-01-07|2014-02-06|Estimate||||2016-08-23|2016-10-17|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|August 2012|Actual|2012-08-31||Interventional|READY|All participants who were randomized to receive any treatment|Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer|A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer|Completed||Phase 3|1930|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 01:47:47.074321|2018-06-01 01:47:47.074321
NCT00744484|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2017-03-31|2008-08-29|2008-09-01|Estimate|||||||2017-03-31|2017-04-04|Actual|February 2008|Actual|2008-02-29|March 2017|2017-03-31|September 2010|Actual|2010-09-30|May 2009|Actual|2009-05-31||Interventional|||A 12 Week Physical Training Programme for Patients With Chronic Obstructive Pulmonary Disease|A 12 Week Physical Training Programme for Patients With Chronic Obstructive Pulmonary Disease (COPD)-a Comparison of Water Based and Land Based Group Training|Completed||N/A|22|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||No||2018-06-01 01:47:49.063048|2018-06-01 01:47:49.063048
NCT00744471|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29||2011-04-14|2011-04-25|2008-08-29|2008-09-01|Estimate||||2011-04-14|2011-04-26|Estimate|2011-04-25|2011-04-29|Estimate|November 2008||2008-11-30|April 2011|2011-04-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Tanezumab in Osteoarthritis Of The Hip|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Hip|Completed||Phase 3|627|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 01:47:49.16556|2018-06-01 01:47:49.16556
NCT00744458|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2010-05-26|2008-08-29|2008-09-01|Estimate|||||||2010-05-26|2010-05-27|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|TAHADIRA||Treat Arterial Hypertension and Diabetes in Rural Africa|A Prospective Randomised Trial Comparing Three Interventions to Improve Treatment Adherence Among Patients With Arterial Hypertension or Diabetes in Rural Cameroon (TAHADIRA-trial 1)|Completed||N/A|223|Actual|Cooperation Afrique||3|||f||||t||||||||||2018-06-01 01:47:49.3718|2018-06-01 01:47:49.3718
NCT00744445|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2008-08-29|2008-08-29|2008-09-01|Estimate|||||||2008-08-29|2008-09-01|Estimate|October 1993||1993-10-31|August 2008|2008-08-31|August 1998|Actual|1998-08-31|August 1998|Actual|1998-08-31||Interventional|||Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity|Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity|Completed||Phase 2|46|Actual|Sunnybrook Health Sciences Centre||3|||f||||f||||||||||2018-06-01 01:47:49.451001|2018-06-01 01:47:49.451001
NCT00744419|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2015-12-01|2008-08-29|2008-09-01|Estimate|||||||2015-12-01|2015-12-03|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants|A Multicenter, Open-label, Single and Multiple Dose Pharmacokinetic Study of IV Pantoprazole in Preterm Infants and Infants 0-11 Months With a Clinical Diagnosis of Gastroesophageal Reflux Disease (GERD) or the Need for Acid Suppression|Completed||Phase 1|24|Actual|University of Louisville||1|||f||||t||||||||||2018-06-01 01:47:49.513165|2018-06-01 01:47:49.513165
NCT00744406|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-08-29|2008-08-29|2008-09-01|Estimate|||||||2008-08-29|2008-09-01|Estimate|July 2003||2003-07-31|August 2008|2008-08-31||||September 2006|Actual|2006-09-30||Interventional|||Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression|Patient Dimensions as Predictors of Response, Relapse and Recurrence Following Cognitive-Behavioral Therapy, Interpersonal Psychotherapy and Pharmacotherapy Treatment of Patients With Major Depression.|Completed||Phase 2|72|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 01:47:49.585702|2018-06-01 01:47:49.585702
NCT00744393|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2018-02-21|2008-08-29|2008-09-01|Estimate|||||||2018-02-21|2018-02-23|Actual|October 2008||2008-10-31|February 2018|2018-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||The Effect of Sodium Oxybate on Sleep Architecture|The Effect of Sodium Oxybate on Sleep Architecture in Critically Ill Patients: A Double-Blind, Crossover Pilot Study|Withdrawn||Phase 2|0|Actual|Tufts Medical Center||2||Sponsor pulled funding secondary to economy issues|f||||f||||||||||2018-06-01 01:47:49.671249|2018-06-01 01:47:49.671249
NCT00744380|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2016-03-09||2016-08-04|2008-08-29|2008-09-01|Estimate|2016-08-04|2016-09-28|Estimate||||2016-08-04|2016-09-28|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Dexmedetomidine Versus Midazolam for Facilitating Extubation|Dexmedetomidine vs. Midazolam for Facilitating Extubation in Medical and Surgical ICU Patients: A Randomized, Double-Blind Study|Completed||N/A|23|Actual|University of Colorado, Denver||2|||f||||f||||||||Yes|Publication|2018-06-01 01:47:49.749118|2018-06-01 01:47:49.749118
NCT00744367|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29||2016-07-26|2016-08-03|2008-08-29|2008-09-01|Estimate||||2016-07-26|2016-07-28|Estimate|2016-08-03|2016-08-05|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone|Completed||Phase 3|326|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:47:50.17004|2018-06-01 01:47:50.17004
NCT00744354|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-29|||2018-01-16|2008-08-29|2008-09-01|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2008||2008-10-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|December 2011|Actual|2011-12-31||Interventional|||Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma|Terminated||Phase 1|32|Actual|UNC Lineberger Comprehensive Cancer Center||1||Drugs unavailable- study terminated 1/2/18|f||||t||||||||||2018-06-01 01:47:50.433352|2018-06-01 01:47:50.433352
NCT00744341|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2010-09-16|2008-08-28|2008-08-29|Estimate|||||||2010-09-16|2010-09-17|Estimate|February 2009||2009-02-28|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure|A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subjects Hospitalized With Acute Decompensated Heart Failure and Renal Dysfunction (Reno-Defend 1)|Terminated||Phase 2|46|Actual|Solvay Pharmaceuticals||5||This study was stopped 29OCT2009 due to strategic drug development considerations|f||||t||||||||||2018-06-01 01:47:50.553952|2018-06-01 01:47:50.553952
NCT00744328|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2014-10-13||2014-10-20|2008-08-28|2008-08-29|Estimate|2014-10-20|2014-10-23|Estimate||||2014-10-20|2014-10-23|Estimate|August 2008||2008-08-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|E2SERT||Postpartum Depression: Transdermal Estradiol Versus Sertraline|Postpartum Depression: Transdermal Estradiol Versus Sertraline|Terminated||Phase 4|85|Actual|Northwestern University||3||Recruitment Issues|f||||t||||||||||2018-06-01 01:47:50.857176|2018-06-01 01:47:50.857176
NCT00744315|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2008-10-14|2008-08-27|2008-08-29|Estimate|||||||2008-10-14|2008-10-15|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|May 2009|Anticipated|2009-05-31|July 2008|Actual|2008-07-31||Interventional|THEANGIOGEN||Induced Angiogenesis by Genic Therapy in Advanced Ischemic Cardiomyopathy|Induced Angiogenesis by Genic Therapy With VEGF165 in Advanced Ischemic Cardiomyopathy - Historical Controlled Trial|Unknown status|Recruiting|Phase 2|20|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||1|||f||||t||||||||||2018-06-01 01:47:51.321749|2018-06-01 01:47:51.321749
NCT00744302|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2015-05-20|2008-08-28|2008-08-29|Estimate|||||||2015-05-20|2015-05-22|Estimate|April 2006||2006-04-30|May 2015|2015-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.|Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.|Completed||Phase 2|180|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:47:51.428088|2018-06-01 01:47:51.428088
NCT00744289|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-06-14|2008-08-28|2008-08-29|Estimate|||||||2011-06-14|2011-06-16|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|HAVIT||Hepatitis B Acceptability and Vaccination Incentive Trial|A Randomised Controlled Trial to Evaluate the Effectiveness of a Small Financial Incentive After the Second and Third Dose of a Hepatitis B Vaccine, on Vaccine Completion in People Who Inject Drugs|Completed||N/A|204|Actual|Kirby Institute||2|||f||||f||||||||||2018-06-01 01:47:51.52714|2018-06-01 01:47:51.52714
NCT00744276|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28||2010-05-25|2010-05-25|2008-08-28|2008-08-29|Estimate||||2010-05-25|2010-05-27|Estimate|2010-05-25|2010-05-27|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|FP1198-001||A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Evaluation of the Use of Topically Administered Danazol Versus Placebo in Subjects With Pain Associated With Fibrocystic Breast Disease|Completed||Phase 2|60|Anticipated|FemmePharma Global Healthcare, Inc.||6|||f||||f||||||||||2018-06-01 01:47:51.633104|2018-06-01 01:47:51.633104
NCT00744263|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2014-10-01||2014-10-01|2008-08-28|2008-08-29|Estimate|2014-10-01|2014-10-06|Estimate||||2014-10-01|2014-10-06|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CAPITA|Safety population included all participants who received study vaccine and who had any safety data.|Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults|A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease|Completed||Phase 4|84496|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 01:47:51.877973|2018-06-01 01:47:51.877973
NCT00744250|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2013-02-20|2008-08-28|2008-08-29|Estimate|||||||2013-02-20|2013-02-22|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control|Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control in Patients With Pancreatic Insufficiency|Terminated||Phase 4|3|Actual|Digestive Care, Inc.||1||No longer required study by FDA for NDA approval.|f||||f||||||||||2018-06-01 01:47:55.637614|2018-06-01 01:47:55.637614
NCT00744237|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2011-06-30||2011-06-30|2008-08-28|2008-08-29|Estimate|2011-06-30|2011-07-29|Estimate||||2011-06-30|2011-07-29|Estimate|August 2008||2008-08-31|June 2011|2011-06-30||||July 2010|Actual|2010-07-31||Interventional|||Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients|Glycemic Effects of Nebivolol Compared With Metoprolol Extended Release and Compared With Hydrochlorothiazide In Hypertensive Patients With Type 2 Diabetes Mellitus: A Pilot Study|Completed||Phase 4|231|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 01:47:55.791948|2018-06-01 01:47:55.791948
NCT00744224|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2010-01-12|2008-08-28|2008-08-29|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|PREDEX||PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide|Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers|Completed||N/A|8|Anticipated|VU University Medical Center||3|||f||||f||||||||||2018-06-01 01:47:57.04998|2018-06-01 01:47:57.04998
NCT00744211|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2014-11-07||2017-11-07|2008-08-28|2008-08-29|Estimate|2017-11-07|2017-11-09|Actual||||2017-11-07|2017-11-09|Actual|July 2008||2008-07-31|November 2017|2017-11-30|April 2013|Actual|2013-04-30|June 2011|Actual|2011-06-30||Interventional|||Proteolytic Enzyme Induction Within the Human Myocardial Interstitium|Proteolytic Enzyme Induction Within the Human Myocardial Interstitium|Completed||N/A|29|Actual|VA Office of Research and Development|Small sample size, which in turn can result in a disproportionate number of patients with greater pre-operative risk profiles randomized to one treatment group.|3|||f||||t||||||||No||2018-06-01 01:47:57.143603|2018-06-01 01:47:57.143603
NCT00744198|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2013-04-05|2008-08-28|2008-08-29|Estimate|||||||2013-04-05|2013-04-08|Estimate|August 2012||2012-08-31|April 2013|2013-04-30||||August 2014|Anticipated|2014-08-31||Interventional|||Autologous Versus Synthetic Versus Biological Sling for Trans-obturator Correction of Urinary Stress Incontinence|A Comparison in Terms of Efficacy and Safety Among Three Different Materials for Trans-obturator Correction of Urinary Stress Incontinence: Autologous, Synthetic and Biological Sling|Unknown status|Recruiting|Phase 4|8|Anticipated|University Magna Graecia||3|||f||||||||||||||2018-06-01 01:47:57.812451|2018-06-01 01:47:57.812451
NCT00744185|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2012-07-18|2008-08-28|2008-08-29|Estimate|||||||2012-07-18|2012-07-19|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|HEMANGIOMA||Propranolol in Capillary Hemangiomas|Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas|Terminated||Phase 2/Phase 3|14|Actual|University Hospital, Bordeaux||2||Study halted prematurely due to some difficulties in recruitment of patients|f||||t||||||||||2018-06-01 01:47:57.922255|2018-06-01 01:47:57.922255
NCT00744172|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2014-11-17|2008-08-28|2008-08-29|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2006|Actual|2006-12-31||Interventional|Finhyst 2006||Finhyst 2006: Study on Morbidity of Hysterectomies in Finland|Finhyst 2006: Incidence, Methods, Complications and Effect on Quality of Life of Hysterectomies in Finland in 2006|Completed||N/A|5279|Actual|Society for Gynecological Surgery in Finland||3|||f||||t||||||||||2018-06-01 01:47:58.006987|2018-06-01 01:47:58.006987
NCT00744159|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2008-08-28|2008-08-28|2008-08-29|Estimate|||||||2008-08-28|2008-08-29|Estimate|January 2006||2006-01-31|August 2008|2008-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Prospective Comparison of Immunological Benefit of Laparoscopic Colectomy|Prospective Comparative Study of Immunological Benefit Between Laparoscopic Colectomy and Open Colectomy|Completed|||84|Actual|Samsung Medical Center|||2||f||||f||||||||||2018-06-01 01:47:58.098789|2018-06-01 01:47:58.098789
NCT00744146|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2010-09-16|2008-08-28|2008-08-29|Estimate|||||||2010-09-16|2010-09-17|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||First Time in Human Study of Protexia|Phase I, Randomized, Controlled, Third-party Double-blind, Dose Escalating Study of Protexia Administered Intramuscularly at One or Two Time Points in Healthy Human Volunteers|Completed||Phase 1|33|Actual|PharmAthene, Inc.||5|||f||||t||||||||||2018-06-01 01:47:58.271636|2018-06-01 01:47:58.271636
NCT00744133|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2014-08-07|2008-08-28|2008-08-29|Estimate|||||||2014-08-07|2014-08-08|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Interventional|||Malaria Challenge With NF54 Strain|An Interventional Plasmodium Falciparum Malaria Challenge Model Utilizing the NF54 Strain of Parasite Transmitted by Aseptic A. Stephensi Mosquitoes to Healthy Malaria-Naïve Adult Volunteers|Completed||Phase 1|37|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 01:47:58.714492|2018-06-01 01:47:58.714492
NCT00744120|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2013-12-19|2008-08-28|2008-08-29|Estimate|||||||2013-12-19|2013-12-20|Estimate|October 2003||2003-10-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Lymphoma Follow-up|Lymphoma Follow-up Protocol|Completed|||51|Actual|National Institutes of Health Clinical Center (CC)|||||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-06-01 01:47:58.820317|2018-06-01 01:47:58.820317
NCT00744107|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2009-08-04|2008-08-28|2008-08-29|Estimate|||||||2009-08-04|2009-08-06|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|September 2010|Anticipated|2010-09-30|July 2010|Anticipated|2010-07-31||Interventional|||Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease|The Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease|Unknown status|Active, not recruiting|Phase 2|258|Anticipated|Medlogics Device Corporation|||||f||||t||||||||||2018-06-01 01:47:58.899432|2018-06-01 01:47:58.899432
NCT00744094|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2015-09-22|2008-08-28|2008-08-29|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Resistance Training in Elderly|The Influence of Resistance Training on Body Composition and Muscle Characteristics in Healthy Elderly|Completed||Phase 1/Phase 2|26|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:47:58.994821|2018-06-01 01:47:58.994821
NCT00744081|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-08-28|2008-08-28|2008-08-29|Estimate|||||||2008-08-28|2008-08-29|Estimate|July 2004||2004-07-31|August 2008|2008-08-31||||December 2007|Anticipated|2007-12-31||Interventional|||Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)|Open-Label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)|Unknown status|Recruiting|Phase 2|130|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 01:47:59.161582|2018-06-01 01:47:59.161582
NCT00744068|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2016-11-23|2008-08-28|2008-08-29|Estimate|||||||2016-11-23|2016-11-28|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||Four Models of Telephone Support for Stimulant Recovery|Four Models of Telephone Support for Stimulant Recovery|Completed||N/A|302|Actual|University of California, Los Angeles||5|||f||||t||||||||||2018-06-01 01:47:59.26566|2018-06-01 01:47:59.26566
NCT00744055|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2015-10-27||2016-03-18|2008-08-28|2008-08-29|Estimate|2015-12-11|2016-01-18|Estimate||||2016-03-18|2016-04-18|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Veterans|Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).|The Use of Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).|Completed||Phase 3|96|Actual|Yale University||2|||f||||t||||||||||2018-06-01 01:47:59.404369|2018-06-01 01:47:59.404369
NCT00744042|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2011-05-15||2016-01-25|2008-08-28|2008-08-29|Estimate|2011-08-24|2011-09-30|Estimate||||2016-01-25|2016-02-22|Estimate|September 2008||2008-09-30|January 2016|2016-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)|A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of Asfotase Alfa in up to 10 Severely Affected Patients With for the Treatment of Severely Affected Patients With Infantile Hypophosphatasia (HPP)|Completed||Phase 1/Phase 2|11|Actual|Alexion Pharma GmbH||1|||f||||t||||||||||2018-06-01 01:47:59.756749|2018-06-01 01:47:59.756749
NCT00744029|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-08-29|2008-08-28|2008-08-29|Estimate|||||||2008-08-29|2008-09-01|Estimate|February 2004||2004-02-29|August 2008|2008-08-31|June 2007|Actual|2007-06-30|December 2005|Actual|2005-12-31||Interventional|BASS||Reduction of Prehospital Delays in Stroke and Transient Ischaemic Attack (TIA)|Population-Based Intervention to Reduce Prehospital Delays in Patients With Stroke and Transient Ischaemic Attack|Completed||N/A|1388|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:48:00.2247|2018-06-01 01:48:00.2247
NCT00744016|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2009-12-21|2008-08-28|2008-08-29|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2004||2004-12-31|December 2009|2009-12-31|October 2007|Actual|2007-10-31|May 2007|Actual|2007-05-31||Interventional|||Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis|Completed||Phase 3|305|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 01:48:00.361473|2018-06-01 01:48:00.361473
NCT00744003|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2013-11-15|2008-08-28|2008-08-29|Estimate|||||||2013-11-15|2013-11-18|Estimate|July 2008||2008-07-31|November 2013|2013-11-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||An Observational Study of Early Coagulopathy, or Clotting Disorder, in Injured Patients|Early Trauma Induced Coagulopathy (ETIC): A Pilot Study to Determine Its Definition and Risk Factors|Withdrawn|||0|Actual|Emory University||||PI no longer at Emory; no participants enrolled, study not conducted|f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:48:00.569919|2018-06-01 01:48:00.569919
NCT00743990|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2017-11-21|2008-08-28|2008-08-29|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2008||2008-10-31|November 2017|2017-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Effect of a Medicated Topical Therapy , Petrolatum, and No Treatment on Nocturnal Cough|Effect of a Medicated Topical Therapy, Petrolatum, and No Treatment on Nocturnal Cough and Congestion for Children With Upper Respiratory Infections|Completed||N/A|143|Actual|Penn State University||3|||f||||t||||||||||2018-06-01 01:48:00.651347|2018-06-01 01:48:00.651347
NCT00743977|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-08-28|2008-08-28|2008-08-29|Estimate|||||||2008-08-28|2008-08-29|Estimate|August 2008||2008-08-31|August 2008|2008-08-31||||November 2008|Anticipated|2008-11-30||Interventional|||Bioequivalence of Phenazopyridine HCl in Healthy Volunteers|2 Treatment, 2 Period, Randomized, Single Blinded, Crossover Bioequivalence of Phenazopyridine HCl in 24 Healthy Volunteers|Unknown status|Active, not recruiting|N/A|24|Actual|Universal Enterprises||2|||f||||t||||||||||2018-06-01 01:48:00.729133|2018-06-01 01:48:00.729133
NCT00743964|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2010-01-13|2008-08-28|2008-08-29|Estimate|||||||2010-01-13|2010-01-15|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)|A Randomized Phase II Study of Combination Chemotherapy With Epirubicin , Cisplatin and Capecitabine (ECX) or Cisplatin and Capecitabine (CX) in Advanced Gastric Cancer|Completed||Phase 2|91|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 01:48:00.812995|2018-06-01 01:48:00.812995
NCT00743951|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2016-03-29|2008-08-28|2008-08-29|Estimate|||||||2016-03-29|2016-03-31|Estimate|January 2007||2007-01-31|March 2016|2016-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Feasibility Study: Effect of Patient Decision Aids for Total Joint Replacement on Surgical Referrals|Feasibility Study: Does Screening Plus Patient Decision Aids Reduce Unnecessary Surgical Referrals for Total Joint Arthroplasty in Practices With Long Waiting Lists for Surgical Consults?|Completed||Phase 3|142|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-06-01 01:48:00.962525|2018-06-01 01:48:00.962525
NCT00742534|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2011-12-27|2008-08-26|2008-08-27|Estimate|||||||2011-12-27|2011-12-30|Estimate|August 2008||2008-08-31|December 2011|2011-12-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Phase 1 Intravenous Citrulline for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants|Phase 1 Intravenous Citrulline for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants|Withdrawn||Phase 1|0|Actual|Vanderbilt University||||Study never began|f||||t||||||||||2018-06-01 01:48:24.371391|2018-06-01 01:48:24.371391
NCT00743938|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27||2015-09-23|2015-09-23|2008-08-28|2008-08-29|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|June 2012|Actual|2012-06-30|August 2010|Actual|2010-08-31||Interventional|||A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC|A Double-Blind, Randomized, Parallel Two-Arm Phase II Trial of BMS-690514 Versus Erlotinib in Previously Treated NSCLC Patients|Completed||Phase 2|141|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 01:48:01.06216|2018-06-01 01:48:01.06216
NCT00743925|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27||2012-01-31|2014-01-30|2008-08-28|2008-08-29|Estimate||||2012-01-31|2012-02-02|Estimate|2014-01-30|2014-03-04|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|FRANCIS-ACS||FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes|FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes|Completed||Phase 2|625|Actual|Anthera Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:48:01.210079|2018-06-01 01:48:01.210079
NCT00743912|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2009-12-21|2008-08-28|2008-08-29|Estimate|||||||2009-12-21|2009-12-22|Estimate|September 2008||2008-09-30|December 2009|2009-12-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Open-Label Study to Evaluate the Effect of Rifaximin on Midazolam in Normal Healthy Volunteers|A Phase 1, Single Arm, Open-Label Study to Evaluate the Effect of Rifaximin 550 MG Tablets TID on the Pharmacokinetics of Orally Administered Midazolam in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 01:48:01.370248|2018-06-01 01:48:01.370248
NCT00743899|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2013-12-08|2008-08-28|2008-08-29|Estimate|||||||2013-12-08|2013-12-10|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|June 2016|Anticipated|2016-06-30|June 2013|Actual|2013-06-30||Interventional|SMART-CASE||Conservative Versus Aggressive Revascularization in Patients With Intermediate Lesions Undergoing Percutaneous Coronary Intervention With Angiography Guidance Alone|Conservative Versus Aggressive Revascularization in Patients With Intermediate Lesions Undergoing Percutaneous Coronary Intervention With Angiography Guidance Alone (SMART-CASE)|Unknown status|Active, not recruiting|N/A|899|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 01:48:01.437348|2018-06-01 01:48:01.437348
NCT00743886|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2011-07-10|2008-08-28|2008-08-29|Estimate|||||||2011-07-10|2011-07-12|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Influence of Plasma Rich in Growth Factors (PRGF) on Healing of Medial Collateral Ligament (MCL) Tear|Influence of PRGF on Healing of MCL Tear - Randomized-Double-Blind-Placebo Control Trail|Withdrawn||Phase 2/Phase 3|50|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-06-01 01:48:01.520755|2018-06-01 01:48:01.520755
NCT00743873|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2011-07-10|2008-08-28|2008-08-29|Estimate|||||||2011-07-10|2011-07-12|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Platelet-rich Plasma (PRP) Treatment for Medial Retinaculum Tear Post Medial Patellar Dislocation|PRP Treatment for Medial Retinaculum Tear - Randomized-Double-Blind-Placebo Control Trail|Completed||Phase 2/Phase 3|50|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-06-01 01:48:01.595582|2018-06-01 01:48:01.595582
NCT00743860|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2016-11-15|2008-08-28|2008-08-29|Estimate|||||||2016-11-15|2016-11-16|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848|A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and Its Metabolites in Healthy Volunteers.|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:48:01.714305|2018-06-01 01:48:01.714305
NCT00743847|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2009-02-20|2008-08-27|2008-08-29|Estimate|||||||2009-02-20|2009-02-24|Estimate|March 2009||2009-03-31|February 2009|2009-02-28|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia|A Phase 2 6-Week, Double-Blind, Placebo-Controlled, Multicenter Trial Of Varenicline Tartrate (CP-526,555) For Cognitive Impairment In Subjects With Schizophrenia|Withdrawn||Phase 2|0|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 01:48:01.835433|2018-06-01 01:48:01.835433
NCT00743834|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-09-03|2008-08-28|2008-08-29|Estimate|||||||2008-09-03|2008-09-04|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)|Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Rogers Center for Research & Training, Inc.||1|||f||||f||||||||||2018-06-01 01:48:01.942968|2018-06-01 01:48:01.942968
NCT00743821|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2014-05-05|2008-08-28|2008-08-29|Estimate|||||||2014-05-05|2014-05-07|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|Eye-TRAC||Eye-Tracking Rapid Attention Computation|Eye-Tracking Rapid Attention Computation|Completed|||426|Actual|Brain Trauma Foundation|||2||f||||f||||||||||2018-06-01 01:48:02.059173|2018-06-01 01:48:02.059173
NCT00743808|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2015-11-30|2008-08-28|2008-08-29|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|September 2010|Actual|2010-09-30|May 2008|Actual|2008-05-31||Observational|||Hypertension and Diabetes Initiative - Improving Hypertension Control in Individuals With Diabetes|Improving Hypertension Control in Individuals With Diabetes|Completed|||11510|Actual|HealthPartners Institute|||||f||||f||||||||||2018-06-01 01:48:02.143495|2018-06-01 01:48:02.143495
NCT00743795|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27||2012-06-06|2013-10-11|2008-08-28|2008-08-29|Estimate||||2012-06-06|2012-06-08|Estimate|2013-10-11|2013-11-05|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS 9190, in Combination With Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection (GS-US-196-0103)|Completed||Phase 2|252|Actual|Gilead Sciences||3|||f||||t||||||||||2018-06-01 01:48:02.232375|2018-06-01 01:48:02.232375
NCT00743782|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2018-05-17|2008-08-28|2008-08-29|Estimate|||||||2018-05-17|2018-05-18|Actual|August 22, 2008||2008-08-22|April 7, 2014|2014-04-07|April 7, 2014|Actual|2014-04-07|April 7, 2014|Actual|2014-04-07||Interventional|||Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism|Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism|Completed||Early Phase 1|24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:48:02.485391|2018-06-01 01:48:02.485391
NCT00743769|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2017-04-13|2008-08-28|2008-08-29|Estimate|||||||2017-04-13|2017-04-17|Actual|April 2008||2008-04-30|April 2017|2017-04-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Phase 1 Study of the Safety and Tolerability of the Intravenous Administration of Thymosin Beta 4 and Its Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers|Withdrawn||Phase 1|0|Actual|RegeneRx Biopharmaceuticals, Inc.||2||Study never initiated due to contract manufacturing issues|f||||f||||||||||2018-06-01 01:48:02.557645|2018-06-01 01:48:02.557645
NCT00743756|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2014-06-07|2008-08-28|2008-08-29|Estimate|||||||2014-06-07|2014-06-10|Estimate|April 2006||2006-04-30|June 2014|2014-06-30|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|||Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With Type 2 Diabetes Mellitus (DM)|Study of a Home Delivered Meal Program on Obese Elderly African American Subjects With T2Dm|Terminated||N/A|38|Actual|Emory University||3||slow patient enrollment|f||||f||||||||||2018-06-01 01:48:02.656124|2018-06-01 01:48:02.656124
NCT00743743|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2015-08-21|2008-08-28|2008-08-29|Estimate|||||||2015-08-21|2015-08-24|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease|Randomized, Placebo-controlled Clinical Trial of Resveratrol Supplement Effects on Cognition, Function and Behavior in Patients With Mild-to-moderate Alzheimer's Disease|Withdrawn||Phase 3|0|Actual|Medical College of Wisconsin||2||PI has left institution|f||||t||||||||||2018-06-01 01:48:02.813125|2018-06-01 01:48:02.813125
NCT00743730|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2015-11-04||2017-10-24|2008-08-28|2008-08-29|Estimate|2016-09-26|2016-11-15|Estimate||||2017-10-24|2017-11-28|Actual|June 2005||2005-06-30|January 2017|2017-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|PNCA||Parent Nurse Controlled Analgesic in Pediatric Patients With Developmental Delay|Outcomes And Parent Satisfaction Associated With Parent/Nurse Controlled Analgesia In Pediatric Patients With Developmental Delay|Completed||N/A|94|Actual|Medical College of Wisconsin||3|||f||||f||||||||||2018-06-01 01:48:02.912937|2018-06-01 01:48:02.912937
NCT00743717|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2013-02-27||2013-05-21|2008-08-27|2008-08-29|Estimate|2013-05-20|2013-05-22|Estimate||||2013-05-21|2013-05-27|Estimate|February 2004||2004-02-29|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of the Safety and Effectiveness of the Kinamed Gem Ceramic Femoral Component for Total Knee Replacement|Clinical Trial on the Zirconia Femoral Component for the Gem Total Knee System|Completed||Phase 2|4|Actual|Kinamed Incorporated||2|||f||||f||||||||||2018-06-01 01:48:03.303149|2018-06-01 01:48:03.303149
NCT00743704|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2009-04-18|2008-08-28|2008-08-29|Estimate|||||||2009-04-18|2009-04-21|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model|Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model|Completed||N/A|15|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||||||||||||2018-06-01 01:48:03.615967|2018-06-01 01:48:03.615967
NCT00743691|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2009-02-05|2008-08-28|2008-08-29|Estimate|||||||2009-02-05|2009-02-06|Estimate|April 2009||2009-04-30|February 2009|2009-02-28|October 2010|Anticipated|2010-10-31|April 2010|Anticipated|2010-04-30||Interventional|||Impact Study of Community Based Treatment of Neonatal Infection by Health Extension Workers on Neonatal Mortality|Impact of Strengthened Health Extension Program and Community Based Treatment of Neonatal Infections on Neonatal Mortality in Oromia and South Nation and Nationalities & People Region(SNNPR), Ethiopia|Unknown status|Not yet recruiting|N/A|660000|Anticipated|Save the Children||2|||f||||t||||||||||2018-06-01 01:48:03.697243|2018-06-01 01:48:03.697243
NCT00743678|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2013-06-13|2008-08-28|2008-08-29|Estimate|||||||2013-06-13|2013-06-14|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis|A Phase II Study of Neoadjuvant FOLFOX6 Plus Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis|Completed||Phase 2|73|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 01:48:03.82426|2018-06-01 01:48:03.82426
NCT00743665|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2018-03-22|2008-08-28|2008-08-29|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2007||2007-06-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Quality of Life And Psychological Symptoms In Children With Cyclic Vomiting Syndrome (CVS)|Quality of Life And Psychological Symptoms In Children With Cyclic Vomiting Syndrome|Completed|||41|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 01:48:03.929174|2018-06-01 01:48:03.929174
NCT00743652|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2011-09-09||2012-03-13|2008-08-28|2008-08-29|Estimate|2012-01-05|2012-02-10|Estimate||||2012-03-13|2012-03-15|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.|A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.|Completed||Phase 3|373|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 01:48:04.105351|2018-06-01 01:48:04.105351
NCT00743639|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-08-28|2008-08-28|2008-08-29|Estimate|||||||2008-08-28|2008-08-29|Estimate|July 2005||2005-07-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2006|Actual|2006-06-30||Interventional|SDILCM||Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy|Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy: Randomized Clinical Trial|Completed||Phase 2/Phase 3|30|Actual|Instituto de Cardiologia do Rio Grande do Sul||1|||f||||t||||||||||2018-06-01 01:48:06.263283|2018-06-01 01:48:06.263283
NCT00743626|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2018-02-20|2008-08-28|2008-08-29|Estimate|||||||2018-02-20|2018-02-22|Actual|December 2006|Actual|2006-12-31|February 2018|2018-02-28|January 2011|Actual|2011-01-31|August 2008|Actual|2008-08-31||Interventional|||Pap Smear Research Study|Evaluation of the Role of Human Papillomavirus Testing and p16 Expression in the Management of Patients Undergoing Cervical Cancer Screening|Completed||N/A|1712|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 01:48:06.349612|2018-06-01 01:48:06.349612
NCT00743613|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2008-09-02|2008-08-28|2008-08-29|Estimate|||||||2008-09-02|2008-09-03|Estimate|February 2005||2005-02-28|September 2008|2008-09-30|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Observational|PREPARED||Predicting Peripheral Arterial Disease in Men With Erectile Dysfunction|Predicting Peripheral Arterial Disease in Men With Erectile Dysfunction|Completed|||175|Actual|Bruton Avenue Family Practice|||||f||||f||||||||||2018-06-01 01:48:06.438046|2018-06-01 01:48:06.438046
NCT00743600|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2016-11-08|2008-08-27|2008-08-29|Estimate|||||||2016-11-08|2016-11-09|Estimate|September 2005||2005-09-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Ultrasound Evaluation of the Rotator Cable and Associated Structures.|Ultrasound Evaluation of the Rotator Cable and Associated Structures.|Completed||N/A|123|Actual|University of Michigan||2|||f||||f||||||||Yes||2018-06-01 01:48:06.56801|2018-06-01 01:48:06.56801
NCT00743587|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2010-03-10|2008-08-28|2008-08-29|Estimate|||||||2010-03-10|2010-03-11|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb|A Randomized, Double-Blind, Placebo And Active Controlled Methodology Study Investigating The Effects Of Tramadol And Naproxen On The Pain Thresholds Of Patients With Severe Pain Due To Osteoarthritis Of The Thumb|Completed||Phase 1|36|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:48:06.673679|2018-06-01 01:48:06.673679
NCT00743574|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|2013-02-15||2013-06-20|2008-08-28|2008-08-29|Estimate|2013-06-20|2013-07-29|Estimate||||2013-06-20|2013-07-29|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||the number of participants for analysis was determined by the number who completed the study.|Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)|Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)|Completed||N/A|36|Actual|Yale University|No limitations|1|||f||||t||||||||||2018-06-01 01:48:06.779429|2018-06-01 01:48:06.779429
NCT00743561|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2012-04-27|2008-08-28|2008-08-29|Estimate|||||||2012-04-27|2012-04-30|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Assessment of Ambulatory Polygraphy in the Detection of Sleep Apnea in Multiple System Atrophy (SAMSA)|Study of the Performance of Ambulatory Nocturnal Polygraphy in the Diagnosis of Sleep Apnea in Multiple System Atrophy|Completed||N/A|30|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-06-01 01:48:07.013278|2018-06-01 01:48:07.013278
NCT00743548|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2010-11-12|2008-08-28|2008-08-29|Estimate|||||||2010-11-12|2010-11-16|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparing the Inter-dental Brush to Dental Floss|Comparison of Inter-dental Brush to Dental Floss for Reduction of Plaque and Bleeding in Areas With Intact Papilla: A Clinical Trial|Completed||Phase 3|32|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 01:48:07.099036|2018-06-01 01:48:07.099036
NCT00743535|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2013-04-05|2008-08-28|2008-08-29|Estimate|||||||2013-04-05|2013-04-08|Estimate|February 2008||2008-02-29|April 2013|2013-04-30||||February 2013|Actual|2013-02-28||Interventional|||Anterior Defect Correction With Mesh Plus Treatment of Stress Incontinence With Transobturator or Transvaginal Approach|A Comparison in Terms of Efficacy and Safety Between Transobturator and Transvaginal Tape Performed at the Same Time of Anterior Defect Correction With Mesh|Terminated||Phase 4|15|Actual|University Magna Graecia||2||Low recruitment rate.|f||||||||||||||2018-06-01 01:48:07.176264|2018-06-01 01:48:07.176264
NCT00743522|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-28|||2015-06-04|2008-08-28|2008-08-29|Estimate|||||||2015-06-04|2015-06-08|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|PROVIDE||Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication|Programming Implantable Cardioverter Defibrillators (ICDs) in Patients With Primary Prevention Indication to Prolong Time to First Shock|Completed|||1670|Actual|St. Jude Medical|||2||f||||t||||||||||2018-06-01 01:48:07.341109|2018-06-01 01:48:07.341109
NCT00743509|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2013-04-04||2015-08-31|2008-08-28|2008-08-29|Estimate|2013-04-04|2013-05-22|Estimate||||2015-08-31|2015-09-28|Estimate|August 2008||2008-08-31|August 2015|2015-08-31|September 2012|Actual|2012-09-30|April 2010|Actual|2010-04-30||Interventional|OCR||A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma|A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma|Completed||Phase 2|49|Actual|University of Michigan Cancer Center||1|||f||||||||||||||2018-06-01 01:48:07.436705|2018-06-01 01:48:07.436705
NCT00743496|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2017-08-14|2008-08-27|2008-08-28|Estimate|||||||2017-08-14|2017-08-17|Actual|October 8, 2008|Actual|2008-10-08|August 2017|2017-08-31|April 18, 2014|Actual|2014-04-18|April 1, 2014|Actual|2014-04-01||Interventional|||A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma|A Phase I Trial Of The Humanized Anti-GD2 Antibody (HU14.18K322A) In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma|Completed||Phase 1|50|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-06-01 01:48:07.665366|2018-06-01 01:48:07.665366
NCT00743483|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2014-11-05||2014-11-17|2008-08-27|2008-08-28|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-17|2014-11-18|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency|An Open Label, Exploratory Study on the Effect of rhBSSL on the Fat Absorption in Patients With Cystic Fibrosis and Pancreatic Insufficiency|Completed||Phase 2|15|Actual|Swedish Orphan Biovitrum||1|||f||||f||||||||||2018-06-01 01:48:07.747711|2018-06-01 01:48:07.747711
NCT00743470|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2010-10-29|2008-08-27|2008-08-28|Estimate|||||||2010-10-29|2010-11-02|Estimate|August 2008||2008-08-31|September 2010|2010-09-30||||October 2008|Actual|2008-10-31||Interventional|||A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects|A Comparison of the Bioavailability of Rifabutin With and Without Lopinavir/Ritonavir in Healthy Adult Subjects|Terminated||Phase 1|15|Actual|Abbott||2|||f||||||||||||||2018-06-01 01:48:07.933117|2018-06-01 01:48:07.933117
NCT00743457|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2012-10-12|2008-08-27|2008-08-28|Estimate|||||||2012-10-12|2012-10-15|Estimate|August 2008||2008-08-31|October 2012|2012-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Observational|||Study of Ultrasound of the Eye for Children With Suspected Shunt Failure|Pediatric Ocular Ultrasound for VPS Failure|Completed|||36|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-06-01 01:48:08.0285|2018-06-01 01:48:08.0285
NCT00743444|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2011-03-16||2013-07-17|2008-08-26|2008-08-28|Estimate|2011-05-10|2011-06-10|Estimate||||2013-07-17|2013-07-22|Estimate|February 2007||2007-02-28|July 2013|2013-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||TLESR-impedance Study in Patients|A Double-blind, Placebo Controlled, Randomized, Two Centre Phase IIA Pharmacodynamic Cross-over Study to Assess the Effect of AZD3355, 65 mg Bid, on Transient Lower Esophageal Sphincter Relaxations (TLESRs) in GERD Patients With an Incomplete Response to PPI Treatment|Completed||Phase 2|27|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:48:08.121859|2018-06-01 01:48:08.121859
NCT00743431|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2010-05-21||2015-03-26|2008-08-27|2008-08-28|Estimate|2010-05-21|2010-06-22|Estimate||||2015-03-26|2015-04-15|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)|Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE).|Completed|||224|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:48:09.465662|2018-06-01 01:48:09.465662
NCT00742521|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2015-06-09|2008-08-26|2008-08-27|Estimate|||||||2015-06-09|2015-06-10|Estimate|March 2001||2001-03-31|June 2015|2015-06-30|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Question 3|Completed||N/A|22|Actual|Vanderbilt University||4|||f||||f||||||||||2018-06-01 01:48:24.42883|2018-06-01 01:48:24.42883
NCT00743418|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2008-08-27|2008-08-27|2008-08-28|Estimate|||||||2008-08-27|2008-08-28|Estimate|June 2007||2007-06-30|August 2008|2008-08-31||||December 2012|Anticipated|2012-12-31||Interventional|SenTra||Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease|The Use of Advanced Tracking Technologies for the Analysis of Mobility in Alzheimer's Disease and Related Cognitive Disorders|Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||||||||||||2018-06-01 01:48:09.657014|2018-06-01 01:48:09.657014
NCT00743405|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2017-07-18|2008-08-27|2008-08-28|Estimate|||||||2017-07-18|2017-07-21|Actual|May 2, 2008|Actual|2008-05-02|July 2017|2017-07-31|December 15, 2008|Actual|2008-12-15|December 15, 2008|Actual|2008-12-15||Interventional|||Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects|Single-blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:48:09.756691|2018-06-01 01:48:09.756691
NCT00743392|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2013-11-15|2008-08-26|2008-08-28|Estimate|||||||2013-11-15|2013-11-19|Estimate|July 2008||2008-07-31|November 2013|2013-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||HPV Infections in Older Women|HPV Infections in Older Women|Completed|||503|Actual|University of Washington|||||f||||f||||||Samples With DNA|"~     Vaginal swab samples for HPV DNA testing~   "|||2018-06-01 01:48:09.844722|2018-06-01 01:48:09.844722
NCT00743379|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2015-05-05|2008-08-26|2008-08-28|Estimate|||||||2015-05-05|2015-05-07|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors|A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed in Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|71|Actual|Threshold Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:48:09.937282|2018-06-01 01:48:09.937282
NCT00743366|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2016-10-20||2017-07-17|2008-08-26|2008-08-28|Estimate|2017-06-12|2017-07-12|Actual||||2017-07-17|2017-08-18|Actual|August 2008||2008-08-31|July 2017|2017-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Quetiapine on Marijuana Withdrawal and Relapse|Effect of Quetiapine on Marijuana Withdrawal and Relapse|Completed||Phase 2|20|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 01:48:10.098895|2018-06-01 01:48:10.098895
NCT00743353|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2009-01-29|2008-08-27|2008-08-28|Estimate|||||||2009-01-29|2009-02-02|Estimate|August 2008||2008-08-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|K5||Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5|An Exploratory, Multi-Center, Open Label, Non-Randomized Study of F-18 RGD-K5|Completed||Early Phase 1|16|Anticipated|Siemens Molecular Imaging||1|||f||||f||||||||||2018-06-01 01:48:10.455722|2018-06-01 01:48:10.455722
NCT00743340|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2018-02-12||2018-03-28|2008-08-27|2008-08-28|Estimate|2018-03-28|2018-04-26|Actual||||2018-03-28|2018-04-26|Actual|November 22, 2005|Actual|2005-11-22|March 2018|2018-03-31|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional||Safety Analysis Set: all enrolled participants who have received at least 1 dose of study drug|Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine|A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa With Continued Access to Emtricitabine|Completed||Phase 2|50|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-06-01 01:48:10.549596|2018-06-01 01:48:10.549596
NCT00743327|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2012-08-03|2008-08-26|2008-08-28|Estimate|||||||2012-08-03|2012-08-06|Estimate|October 2008||2008-10-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|ADT||Androgen Deprivation Therapy Study|Metabolic and Cardiovascular Complications in Men With Prostate Cancer Undergoing Long-term Androgen Deprivation Therapy|Terminated|||1|Actual|National Institutes of Health Clinical Center (CC)|||3|No Participants completed study|f||||f||||||Samples Without DNA|"~     Serum, Muscle biopsy specimens~   "|||2018-06-01 01:48:10.972537|2018-06-01 01:48:10.972537
NCT00743314|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2016-10-12|2008-08-27|2008-08-28|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer|Integration of SPECT/CT Lymphoscintigraphy Into Breast Cancer Radiation for LymphaticSparing|Completed||N/A|30|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 01:48:11.102522|2018-06-01 01:48:11.102522
NCT00743301|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2008-08-27|2008-08-27|2008-08-28|Estimate|||||||2008-08-27|2008-08-28|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|February 2009|Anticipated|2009-02-28||Interventional|A305||The Effect of Palm Olein, Olive Oil and Lard and on Risk Markers of Cardiovascular Disease|Effects of Palm Olein Versus Olive Oil on Blood Lipids, Lipoproteins and Novel Risk Markers of Cardiovascular Disease|Unknown status|Recruiting|N/A|45|Anticipated|University of Copenhagen||3|||f||||f||||||||||2018-06-01 01:48:11.219464|2018-06-01 01:48:11.219464
NCT00743288|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2014-01-21||2014-04-24|2008-08-27|2008-08-28|Estimate|2014-03-24|2014-04-25|Estimate||||2014-04-24|2014-05-08|Estimate|July 2008||2008-07-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma|A Phase I/II Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM)|Completed||Phase 1/Phase 2|40|Actual|Oncotherapeutics||1|||f||||f||||||||||2018-06-01 01:48:11.365857|2018-06-01 01:48:11.365857
NCT00743275|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2010-02-01||2016-04-12|2008-08-27|2008-08-28|Estimate|2010-02-01|2010-02-23|Estimate||||2016-04-12|2016-05-16|Estimate|August 2008||2008-08-31|April 2016|2016-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination|Immunogenicity and Safety Among Adults of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)|Completed||Phase 4|120|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:48:11.781957|2018-06-01 01:48:11.781957
NCT00743262|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2010-08-02||2016-08-25|2008-08-27|2008-08-28|Estimate|2010-10-13|2010-11-03|Estimate||||2016-08-25|2016-10-06|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|April 2009|Actual|2009-04-30|August 2008|Actual|2008-08-31||Interventional|||Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis|Second Amendment on Phase I Trial NO7VEG 'Assessment of a Next Generation Indwelling Provox Voice Rehabilitation System (Vega)': Vega Siri Addendum.|Completed||Phase 1/Phase 2|15|Actual|Atos Medical AB|Provox ActiValve users have short device life with normal indwelling prostheses (and hence use the Provox ActiValve). Therefore, the device life measured in this patient group is very short and not representative of the normal Provox Vega user.||||f||||f||||||||||2018-06-01 01:48:12.29814|2018-06-01 01:48:12.29814
NCT00742352|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2008-09-08|2008-08-26|2008-08-27|Estimate|||||||2008-09-08|2008-09-09|Estimate|September 2008||2008-09-30|August 2008|2008-08-31||||||||Observational|||PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy||Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||t||||||||||2018-06-01 01:48:28.008197|2018-06-01 01:48:28.008197
NCT00743249|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2013-02-22||2013-04-03|2008-08-27|2008-08-28|Estimate|2013-04-03|2013-04-04|Estimate||||2013-04-03|2013-04-04|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||This reporting group includes all randomized participants for whom stent insertion was successfully completed (57).|Punctal Plug Study to Determine the Safety and Retention Times of Various Lengths of Canalicular Stents in Volunteers|A Three-Month Safety Study to Determine the Retention Times of Side-Arm Canalicular Stents|Completed||N/A|60|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:48:12.517308|2018-06-01 01:48:12.517308
NCT00743236|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2017-04-04|2008-08-27|2008-08-28|Estimate|||||||2017-04-04|2017-04-06|Actual|August 2008||2008-08-31|April 2017|2017-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer|A Phase III Multi-Institutional Randomized Clinical Trial: Effect of Type of Ischemia - Warm vs Cold During Partial Nephrectomy - on Renal Function|Completed||N/A|1|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-06-01 01:48:12.818211|2018-06-01 01:48:12.818211
NCT00743223|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-08-27|2008-08-27|2008-08-28|Estimate|||||||2008-08-27|2008-08-28|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|||||Observational|||The Frequency Forward Head Posture in Subjects With Temporomandibular Disorder|The Frequency Forward Head Posture in Subjects With Temporomandibular Disorder|Completed|||100|Actual|Federal University of Mato Grosso do Sul|||2||f||||f||||||||||2018-06-01 01:48:13.049291|2018-06-01 01:48:13.049291
NCT00743210|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2014-07-14|2008-08-26|2008-08-28|Estimate|||||||2014-07-14|2014-07-16|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Oral L-Citrulline and ADMA in Pregnancy|Phase 1 Study of Oral L-citrulline on ADMA/L-arginine and Endothelial-dependent Vascular Function in Pregnancy.|Completed||Phase 1|41|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:48:13.168474|2018-06-01 01:48:13.168474
NCT00743197|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2011-09-13||2011-11-30|2008-08-26|2008-08-28|Estimate|2011-10-19|2011-11-23|Estimate||||2011-11-30|2011-12-05|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Women With Chest Pain and Normal Coronary Arteries Study|Women With Chest Pain and Normal Coronary Arteries Study: A Randomized Study of Medical Treatment and Therapeutic Lifestyle Changes|Terminated||N/A|3|Actual|Northwestern University|Study terminated due to departure of PI; all work including analyses ceased upon departure.In addition,study end points were based on changes b/w groups treatment vs. usual care) at 12 mo follow up- none of the subjects completed the Mo 12 visit.|2||Terminated due to departure of PI from institution.|f||||f||||||||||2018-06-01 01:48:13.297656|2018-06-01 01:48:13.297656
NCT00743184|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2013-12-02|2008-08-27|2008-08-28|Estimate|||||||2013-12-02|2013-12-04|Estimate|September 2008||2008-09-30|August 2013|2013-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Trial of the Safety and Efficacy of Ozarelix in Patients With Benign Prostatic Hyperplasia (BPH)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|Terminated||Phase 2|860|Anticipated|Spectrum Pharmaceuticals, Inc||3|||f||||f||||||||||2018-06-01 01:48:13.675477|2018-06-01 01:48:13.675477
NCT00743171|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-08-27|2008-08-26|2008-08-28|Estimate|||||||2008-08-27|2008-08-29|Estimate|January 2000||2000-01-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Long-Term Study On Home Spirometry After Lung Transplantation|Long-Term Study On Home Spirometry After Lung Transplantation|Completed|||152|Actual|Hannover Medical School|||3||f||||f||||||||||2018-06-01 01:48:13.795597|2018-06-01 01:48:13.795597
NCT00743158|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2017-07-31|2008-08-27|2008-08-28|Estimate|||||||2017-07-31|2017-08-02|Actual|August 2008||2008-08-31|July 2017|2017-07-31||||||||Observational|Ztr||Transfer Impedance in Cystic Fibrosis|Transfer Impedance in Cystic Fibrosis (Ztr)|Recruiting|||40|Anticipated|Boston Children’s Hospital|||||f||||||||||||||2018-06-01 01:48:13.921588|2018-06-01 01:48:13.921588
NCT00743145|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2016-10-25|2008-08-26|2008-08-28|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana|Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana|Completed||Phase 2|49|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 01:48:14.005923|2018-06-01 01:48:14.005923
NCT00743132|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2010-01-22|2008-08-27|2008-08-28|Estimate|||||||2010-01-22|2010-01-25|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|StV 11-2008||Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection|Novel Prediction Score for Postoperative Acute Renal Failure (ARF) Following Liver Resection|Completed|||569|Actual|University of Zurich|||2||f||||f||||||||||2018-06-01 01:48:14.168738|2018-06-01 01:48:14.168738
NCT00743119|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2016-10-20||2017-11-07|2008-08-26|2008-08-28|Estimate|2017-11-07|2017-12-11|Actual||||2017-11-07|2017-12-11|Actual|June 2008||2008-06-30|November 2017|2017-11-30|May 2013|Actual|2013-05-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers|Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers|Completed||Phase 2|34|Actual|New York State Psychiatric Institute||5|||f||||f|t|f||||||No||2018-06-01 01:48:14.236792|2018-06-01 01:48:14.236792
NCT00743106|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2016-06-20||2018-05-02|2008-08-27|2008-08-28|Estimate|2016-09-13|2016-10-31|Estimate||||2018-05-02|2018-05-30|Actual|September 2002||2002-09-30|May 2018|2018-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery|The Effect of Fenoldopam on Renal Function in Solitary Partial Nephrectomy Surgery|Terminated||N/A|90|Actual|The Cleveland Clinic||2||Executive committee determined to close study after interim analysis.|f||||f||||||||||2018-06-01 01:48:14.607043|2018-06-01 01:48:14.607043
NCT00743093|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2013-03-18||2013-09-06|2008-08-27|2008-08-28|Estimate|2013-06-19|2013-07-25|Estimate||||2013-09-06|2013-09-18|Estimate|August 2008||2008-08-31|September 2013|2013-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Baseline characteristics were collected on all subjects at screening and included: race, ethnicity, gender, age, weight, and height. The number of participants included in the analysis (276) is based on the safety population, which includes any subject that took at least one dose of study medication.|Aminotransferase Trends During Prolonged Acetaminophen Dosing|Aminotransferase Trends During Prolonged Therapeutic Acetaminophen Dosing|Completed||Phase 4|398|Actual|Denver Health and Hospital Authority|This study was limited to healthy volunteers. The ingestion of each dose of study drug and use of other medications was self-reported.|2|||f||||t||||||||||2018-06-01 01:48:14.944525|2018-06-01 01:48:14.944525
NCT00743080|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2010-11-02|2008-08-27|2008-08-28|Estimate|||||||2010-11-02|2010-11-03|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|January 2010||2010-01-31|||||Interventional|||Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators|GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study|Completed||Phase 4|||University Magna Graecia||2|||f||||||||||||||2018-06-01 01:48:15.268867|2018-06-01 01:48:15.268867
NCT00743067|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2017-07-24|2008-08-27|2008-08-28|Estimate|||||||2017-07-24|2017-07-26|Actual|August 9, 2006|Actual|2006-08-09|July 2017|2017-07-31|November 9, 2009|Actual|2009-11-09|May 2, 2009|Actual|2009-05-02||Interventional|||A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors|Completed||Phase 1|37|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:48:15.345962|2018-06-01 01:48:15.345962
NCT00743054|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2015-05-19|2008-08-27|2008-08-28|Estimate|||||||2015-05-19|2015-05-21|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|August 2011|Actual|2011-08-31|August 2009|Actual|2009-08-31||Observational|||microRNA Expression in Renal Cell Carcinoma|microRNA Expression in Renal Cell Carcinoma|Completed|||50|Actual|Sun Yat-sen University|||||f||||t||||||Samples With DNA|"~     The tumor tissues and tumor adjacent tissues will be collected when patients receive renal~     cell carcinoma resection.~      The blood and urine will be collected before patients receive operation. And the blood and~     urine of some healthy volunteers will be collected as the control group.~   "|||2018-06-01 01:48:15.44991|2018-06-01 01:48:15.44991
NCT00743041|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2018-04-23|2008-08-27|2008-08-28|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2008||2008-12-31|April 2018|2018-04-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||The Effect of EFT on Psychological States in a Veterans Population|The Effect of EFT (Emotional Freedom Techniques) on Psychological States in a Veterans Population: A Randomized Controlled Trial|Completed||Early Phase 1|100|Anticipated|Soul Medicine Institute||2|||f||||f||||||||||2018-06-01 01:48:15.504638|2018-06-01 01:48:15.504638
NCT00743028|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2010-10-06|2008-08-27|2008-08-28|Estimate|||||||2010-10-06|2010-10-07|Estimate|August 2008||2008-08-31|September 2010|2010-09-30||||August 2010|Actual|2010-08-31||Interventional|||Assess the Oral Bioavailability of New ABT-263 Formulations|A Single Dose Study Evaluating the Oral Bioavailability and Pharmacokinetics of the Capsule Formulation of ABT-263 in Subjects With Cancer|Completed||Phase 1|36|Actual|Abbott||6|||f||||||||||||||2018-06-01 01:48:15.574881|2018-06-01 01:48:15.574881
NCT00743015|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2013-10-31|2008-08-27|2008-08-28|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2008||2008-09-30|October 2013|2013-10-31||||March 2009|Actual|2009-03-31||Interventional|||Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks|Relative Bioavailability Following Single Oral Administration of 200 mg of BI 44370 During and Between Migraine Attacks in Male and Female Migraine Patients. An Open-label, Fixed-sequence, Two-period Study With Intraindividual Comparison|Completed||Phase 1|19|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:48:15.660264|2018-06-01 01:48:15.660264
NCT00743002|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26||2013-06-04|2013-06-13|2008-08-26|2008-08-28|Estimate||||2013-06-13|2013-06-21|Estimate|2013-06-13|2013-06-21|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione|A Multi-center, Double-blind, Randomized, Placebo-controlled Study of TT223 in Patients With Type 2 Diabetes Treated With Metformin and/or TZD|Completed||Phase 2|87|Actual|Transition Therapeutics||2|||f||||f||||||||||2018-06-01 01:48:15.746581|2018-06-01 01:48:15.746581
NCT00742989|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-08-27|2008-08-27|2008-08-28|Estimate|||||||2008-08-27|2008-08-28|Estimate|May 2005||2005-05-31|August 2008|2008-08-31|July 2006|Actual|2006-07-31|July 2005|Actual|2005-07-31||Interventional|||Effect of Osteopathic Lymphatic Treatment on Plasma Volume, Protein Concentration and Albumin Concentration.|The Short-Term Effect of Osteopathic Lymphatic Treatment on Blood Cell Count, Plasma Protein, and Blood Pressure: A Pilot Study in a Cross-Over Design|Completed||N/A|15|Actual|Kansas City University of Medicine and Biosciences||2|||f||||f||||||||||2018-06-01 01:48:15.8469|2018-06-01 01:48:15.8469
NCT00742976|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2010-01-19|2008-08-27|2008-08-28|Estimate|||||||2010-01-19|2010-01-20|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Le-Na||Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention, and Weight in Type 2 Diabetic Patients|Effects of Insulin Detemir and NPH Insulin on Renal Handling of Sodium, Fluid Retention and Weight in Type 2 Diabetic Patients|Completed||Phase 4|24|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:48:15.916675|2018-06-01 01:48:15.916675
NCT00742963|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2017-07-14||2017-09-25|2008-08-26|2008-08-28|Estimate|2017-08-23|2017-09-25|Actual||||2017-09-25|2017-10-26|Actual|August 2008||2008-08-31|September 2017|2017-09-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional||107 enrolled, 101 dosed.|Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma|A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma|Completed||Phase 1/Phase 2|107|Actual|Threshold Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:48:16.00008|2018-06-01 01:48:16.00008
NCT00742950|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-06-24|2008-08-27|2008-08-28|Estimate|||||||2011-06-24|2011-06-27|Estimate|August 2008||2008-08-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|CINPHA||Refractive Change Induced by 2.8-mm Corneal Incision|Study of Refractive Change Induced by 2.8-mm Corneal Incisions for Cataract Surgery|Completed||N/A|108|Anticipated|Hospital Universitario Ramon y Cajal||3|||f||||t||||||||||2018-06-01 01:48:16.295026|2018-06-01 01:48:16.295026
NCT00742937|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2009-07-28|2008-08-27|2008-08-28|Estimate|||||||2009-07-28|2009-07-29|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Impact of Maternal Supplementation With Dual Megadose of Vitamin A|Impact of Supplementation With Dual Megadose of Vitamin A in the Post-partum About Vitamin A Levels in Breast Milk, Serum Levels of Vitamin A and Iron in the Binomial Mother-son and Growth and Morbidity of Children Under 6 Months|Completed||Phase 2/Phase 3|239|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-06-01 01:48:16.389353|2018-06-01 01:48:16.389353
NCT00742924|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2014-06-04||2014-06-04|2008-08-27|2008-08-28|Estimate|2014-06-04|2014-07-04|Estimate||||2014-06-04|2014-07-04|Estimate|August 2008||2008-08-31|June 2014|2014-06-30||||April 2012|Actual|2012-04-30||Interventional|||Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma|Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma|Completed||Phase 1|24|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 01:48:16.505201|2018-06-01 01:48:16.505201
NCT00742911|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2014-10-29|2008-08-26|2008-08-28|Estimate|||||||2014-10-29|2014-10-31|Estimate|July 2008||2008-07-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver|Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver|Completed||Phase 1|21|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:48:17.185616|2018-06-01 01:48:17.185616
NCT00742885|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2013-12-20|2009-05-20|2016-10-11|2008-08-27|2008-08-28|Estimate|2014-01-09|2014-02-24|Estimate|2009-09-28|2009-09-30|Estimate|2016-10-11|2016-11-23|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine|Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1557484A.|Completed||Phase 2|100|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:48:17.414513|2018-06-01 01:48:17.414513
NCT00742872|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2013-02-27||2013-02-27|2008-08-27|2008-08-28|Estimate|2013-02-27|2013-04-09|Estimate||||2013-02-27|2013-04-09|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome|A Prospective Double-Blind Placebo-Controlled Trial of Mosapride in Patients With Constipation-Predominant Irritable Bowel Syndrome|Terminated||Phase 3|41|Actual|American University of Beirut Medical Center|High placebo response rate, high dropout rate.|2||Poor recruitment, high drop out rate|f||||f||||||||||2018-06-01 01:48:18.632391|2018-06-01 01:48:18.632391
NCT00742859|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2017-07-20|2016-11-30|2017-09-25|2008-08-26|2008-08-28|Estimate|2017-08-25|2017-09-26|Actual|2016-11-30|2016-12-02|Estimate|2017-09-25|2017-10-26|Actual|October 2008||2008-10-31|July 2017|2017-07-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|EXPLORE-Xa|All randomized patients who took at least 1 dose of study medication after randomization.|Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin|A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation (EXPLORE Xa)|Completed||Phase 2|508|Actual|Portola Pharmaceuticals||4|||f||||t||||||||||2018-06-01 01:48:18.849548|2018-06-01 01:48:18.849548
NCT00742846|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2015-02-25|2008-08-27|2008-08-28|Estimate|||||||2015-02-25|2015-02-27|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis|Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||4||No enrollment|f||||f||||||||||2018-06-01 01:48:19.466896|2018-06-01 01:48:19.466896
NCT00742833|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-09-02|2008-08-27|2008-08-28|Estimate|||||||2009-09-02|2009-09-04|Estimate||||September 2009|2009-09-30||||||||Interventional|||A Phase II Study of KUC-7483 in Patients With Overactive Bladder|A Randomized, Double Blind, Placebo Controlled, Phase II Study of KUC-7483 in Patients With Overactive Bladder|Completed||Phase 2|400|Anticipated|Kissei Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:48:19.551809|2018-06-01 01:48:19.551809
NCT00742820|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2009-02-06|2008-08-27|2008-08-28|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers|Randomized, Controlled, 3-Arm, Open Label, Cross-Over Bioequivalence Study Comparing Liquid PhosLo vs. PhosLo Gelcaps Using Calcium Citrate as a Positive Control in Healthy Volunteers|Completed||Phase 1|46|Actual|Fresenius Medical Care North America||3|||f||||f||||||||||2018-06-01 01:48:19.616968|2018-06-01 01:48:19.616968
NCT00742807|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2014-12-04|2008-08-27|2008-08-28|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols|Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols|Unknown status|Recruiting|Phase 4|300|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:48:19.707677|2018-06-01 01:48:19.707677
NCT00742794|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2010-08-18|2008-08-27|2008-08-28|Estimate|||||||2010-08-18|2010-08-19|Estimate|August 2008||2008-08-31|September 2008|2008-09-30|August 2010|Actual|2010-08-31|||||Observational|ZU-HVA-001||Frequency of Hymenoptera-stings in Patients Under Allergen-Specific Immunotherapy (SIT)|Frequency of Hymenoptera-stings in Patients Under and After Allergen-specific Immunotherapy: a Retrospective Data-analysis Considering Socio-economic Aspects|Completed|||200|Anticipated|University of Zurich|||1||f||||t||||||||||2018-06-01 01:48:19.772264|2018-06-01 01:48:19.772264
NCT00742781|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2013-01-23||2013-07-08|2008-08-27|2008-08-28|Estimate|2013-05-28|2013-07-01|Estimate||||2013-07-08|2013-07-26|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|CTSA||Vitamin D Supplementation in Crohn's Patients|"Vitamin D and Crohn's Disease From the Bench to the Clinic"|Completed||Phase 1|21|Actual|Penn State University|The main limitation of the study was the lack of placebo control and the small size of the study.|1|||f||||f||||||||||2018-06-01 01:48:19.837508|2018-06-01 01:48:19.837508
NCT00742768|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2018-04-25|2008-08-27|2008-08-28|Estimate|||||||2018-04-25|2018-04-26|Actual|June 2008||2008-06-30|March 2009|2009-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Absorption of Vitamin K2|Comparison of Absorption of Vitamin K2 Human Study Gelpell|Completed||N/A|16|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:48:20.099231|2018-06-01 01:48:20.099231
NCT00742755|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2016-08-17|2008-08-27|2008-08-28|Estimate|||||||2016-08-17|2016-08-19|Estimate|September 2003||2003-09-30|February 2016|2016-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women|Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women|Completed||N/A|160|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 01:48:20.187371|2018-06-01 01:48:20.187371
NCT00742742|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2015-02-04|2008-08-27|2008-08-28|Estimate|||||||2015-02-04|2015-02-05|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|WIMS||Walnut Intervention on Metabolic Syndrome (WIMS)|The Effects of Walnut Supplement on Cardio-Metabolic Risk Factors in Patients With Metabolic Syndrome|Completed||Phase 2/Phase 3|189|Actual|Chinese Academy of Sciences||2|||f||||f||||||||||2018-06-01 01:48:20.279147|2018-06-01 01:48:20.279147
NCT00742729|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2016-07-28|2008-08-27|2008-08-28|Estimate|||||||2016-07-28|2016-08-01|Estimate|September 2004||2004-09-30|November 2010|2010-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Increasing Colorectal Cancer Screening Among Filipino Americans|Increasing Colorectal Cancer Screening Among Filipino Americans|Completed||N/A|906|Actual|Jonsson Comprehensive Cancer Center||3|||f||||f||||||||||2018-06-01 01:48:20.362094|2018-06-01 01:48:20.362094
NCT00740285|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-08-21|2008-08-21|2008-08-22|Estimate|||||||2008-08-21|2008-08-22|Estimate|April 2004||2004-04-30|August 2008|2008-08-31|April 2007|Actual|2007-04-30|April 2006|Actual|2006-04-30||Interventional|||Effectiveness and Safety of Lidocaine for Scleroderma|Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial|Completed||Phase 2/Phase 3|26|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:48:58.569554|2018-06-01 01:48:58.569554
NCT00742716|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26||2014-10-30|2014-10-30|2008-08-26|2008-08-28|Estimate||||2014-10-30|2014-11-06|Estimate|2014-10-30|2014-11-06|Estimate|October 2008||2008-10-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease|An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis|Completed||Phase 2|41|Actual|OPKO Health, Inc.||4|||f||||f||||||||||2018-06-01 01:48:20.466261|2018-06-01 01:48:20.466261
NCT00742703|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2009-03-06|2008-08-27|2008-08-28|Estimate|||||||2009-03-06|2009-03-09|Estimate|August 2008||2008-08-31|March 2009|2009-03-31||||||||Interventional|||Study of the Effects of a Mineralized Water Ingestion Upon Lipidic Absorption Mechanisms|Study of the Effects of a Mineralized Water Ingestion Upon Lipidic Absorption Mechanisms|Completed||N/A|12|Anticipated|Multimed||2|||f||||f||||||||||2018-06-01 01:48:20.568142|2018-06-01 01:48:20.568142
NCT00742690|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2014-10-11|2008-08-27|2008-08-28|Estimate|||||||2014-10-11|2014-10-15|Estimate|May 2005||2005-05-31|October 2014|2014-10-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome|Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study.|Unknown status|Recruiting|Phase 2/Phase 3|70|Anticipated|University of Padova||2|||f||||f||||||||||2018-06-01 01:48:20.627636|2018-06-01 01:48:20.627636
NCT00742677|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|||2013-09-19|2008-08-27|2008-08-28|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2007||2007-01-31|July 2009|2009-07-31||||March 2008|Anticipated|2008-03-31||Interventional|||Feeding Schedules After Surgery in Patients With Gynecologic Cancer|Early Oral Feeding After a Gynaecologic Oncologic Laparotomy: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|180|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:48:20.730403|2018-06-01 01:48:20.730403
NCT00742664|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-08-04|2008-08-27|2008-08-28|Estimate|||||||2011-08-04|2011-08-08|Estimate|September 2008||2008-09-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project|Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project|Completed||Phase 1/Phase 2|24|Anticipated|University of South Florida||2|||f||||f||||||||||2018-06-01 01:48:20.80361|2018-06-01 01:48:20.80361
NCT00742638|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2008-08-26|2008-08-26|2008-08-28|Estimate|||||||2008-08-26|2008-08-28|Estimate|March 2008||2008-03-31|August 2008|2008-08-31|August 2010|Anticipated|2010-08-31|May 2010|Anticipated|2010-05-31||Interventional|||To Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.|An Open Label, Randomised, Valproate-Controlled Study to Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.|Unknown status|Recruiting|N/A|70|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 01:48:20.873606|2018-06-01 01:48:20.873606
NCT00742625|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-27|2013-01-02||2014-09-04|2008-08-27|2008-08-28|Estimate|2013-01-02|2013-02-05|Estimate||||2014-09-04|2014-09-12|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|December 2012|Actual|2012-12-31|July 2010|Actual|2010-07-31||Interventional|||Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|Dose Escalation and Phase II Study of Bortezomib (IND #58443) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years|Completed||Phase 1/Phase 2|95|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:48:20.995331|2018-06-01 01:48:20.995331
NCT00742612|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-02-09|2008-08-26|2008-08-27|Estimate|||||||2010-02-09|2010-02-10|Estimate|February 2009||2009-02-28|July 2009|2009-07-31|April 2010|Anticipated|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy|A Study of the Effect of ARC1779 Injection on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy|Terminated||Phase 2|100|Anticipated|Archemix Corp.||2||Enrollment slower than expected|f||||t||||||||||2018-06-01 01:48:21.695966|2018-06-01 01:48:21.695966
NCT00742599|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-11-08|2008-08-26|2008-08-27|Estimate|||||||2010-11-08|2010-11-09|Estimate|September 2008||2008-09-30|November 2010|2010-11-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy|Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Randomized, Double-blind, Parallel-assignment , Placebo-controlled Study)|Completed||Phase 3|80|Anticipated|Nihon Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-06-01 01:48:21.775338|2018-06-01 01:48:21.775338
NCT00742586|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2016-10-14|2008-08-26|2008-08-27|Estimate|||||||2016-10-14|2016-10-18|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Autonomic Failure Patients for RNA Blood Sampling|Identification of Autonomic Failure Patients, Controls and Blood Sampling for Pilot Study|Completed|||30|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 01:48:21.838048|2018-06-01 01:48:21.838048
NCT00742573|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2017-06-12|2008-08-25|2008-08-27|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2008||2008-08-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics|Improving the Effectiveness of Treatment for Depression in Hispanics|Active, not recruiting||Phase 2|170|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 01:48:21.89126|2018-06-01 01:48:21.89126
NCT00742560|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2017-10-11||2018-01-08|2008-08-26|2008-08-27|Estimate|2018-01-08|2018-01-10|Actual||||2018-01-08|2018-01-10|Actual|August 2008||2008-08-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||Safety population: all randomized participants who received at least 1 dose of study drug|A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma|A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma|Completed||Phase 2|101|Actual|AbbVie||5|||f||||t||||||||||2018-06-01 01:48:22.14859|2018-06-01 01:48:22.14859
NCT00742547|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2013-12-10|2008-08-26|2008-08-27|Estimate|||||||2013-12-10|2013-12-11|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|DIANA||Type 2 Diabetes Mellitus: New Approaches to Optimize Medical Care in General Practice|DIANA - Diabetes Mellitus: Neue Wege Der Optimierung Der allgemeinärztlichen Betreuung|Completed||N/A|204|Actual|German Cancer Research Center||2|||f||||f||||||||||2018-06-01 01:48:24.251897|2018-06-01 01:48:24.251897
NCT00742508|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2010-05-17||2017-06-27|2008-08-26|2008-08-27|Estimate|2010-07-23|2010-08-19|Estimate||||2017-06-27|2017-08-02|Actual|August 28, 2008|Actual|2008-08-28|June 2017|2017-06-30|August 21, 2009|Actual|2009-08-21|August 21, 2009|Actual|2009-08-21||Interventional|||A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure|A Study to Evaluate the Safety and Tolerability of SK&F-105517-D in Patients With Chronic Heart Failure- An Open-label Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SK&F-105517-D in Patients With Chronic Heart Failure (Phase I/II Study)|Completed||Phase 1|41|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:48:24.575522|2018-06-01 01:48:24.575522
NCT00742495|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2012-10-23|2008-08-26|2008-08-27|Estimate|||||||2012-10-23|2012-10-24|Estimate|March 2009||2009-03-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|BCX1777-108||Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.|A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma.|Terminated||Phase 1/Phase 2|2|Actual|Mundipharma Research Limited||||Slow Recruitment|f||||t||||||||||2018-06-01 01:48:26.031437|2018-06-01 01:48:26.031437
NCT00742482|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2009-02-16|2008-08-26|2008-08-27|Estimate|||||||2009-02-16|2009-02-17|Estimate|January 2003||2003-01-31|February 2009|2009-02-28|June 2005|Actual|2005-06-30|January 2005|Actual|2005-01-31||Interventional|||Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy|A Phase III Study With Freeze Dried HL10, Three Dosages of 200 mg/kg Ideal Body Weight Versus Standard Therapy in ALI/ARDS Patients|Terminated||Phase 3|418|Actual|LEO Pharma||||"A 300 patient safety analysis by the Data Monitoring Committee showed a trend towards higher~   mortality in the treatment group."|f||||t||||||||||2018-06-01 01:48:26.189346|2018-06-01 01:48:26.189346
NCT00742469|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-24|||2017-04-26|2008-08-26|2008-08-27|Estimate|||||||2017-04-26|2017-04-27|Actual|June 2005||2005-06-30|April 2017|2017-04-30|April 2007|Actual|2007-04-30|September 2005|Actual|2005-09-30||Interventional|||Rifaximin for Prevention of Travellers' Diarrhea|A Randomized,Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Rifaximin for the Prevention of Travellers' Diarrhea|Completed||Phase 3|210|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 01:48:26.297868|2018-06-01 01:48:26.297868
NCT00742456|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-02-22|2008-08-26|2008-08-27|Estimate|||||||2011-02-22|2011-02-23|Estimate|January 2009||2009-01-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Microvascular Dilatation After Endogenous Induced Hyperinsulinemia|Insulin-induced Microvascular Dilatation During a Physiological Stimulus - Studies in Hypertension and Obesity.|Completed||N/A|48|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:48:26.38979|2018-06-01 01:48:26.38979
NCT00742443|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-03-02|2008-08-26|2008-08-27|Estimate|||||||2011-03-02|2011-03-03|Estimate|December 2008||2008-12-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|Revise||Juvista in Scar Revision Surgery of Disfiguring Scars|A Double Blind, Within Patient, Placebo Controlled Trial to Assess the Efficacy of Juvista (Avotermin) in Conjunction With Scar Revision Surgery for the Improvement of Disfiguring Scars.|Completed||Phase 3|350|Anticipated|Renovo||3|||f||||f||||||||||2018-06-01 01:48:26.597248|2018-06-01 01:48:26.597248
NCT00742430|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2012-02-11|2008-08-26|2008-08-27|Estimate|||||||2012-02-11|2012-02-14|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|August 2011|Actual|2011-08-31|||||Observational|||Resistance on Antithrombotic Drugs in Ischemic Heart Disease|Assessment of Aspirin and Clopidogrel Resistance in Ischemic Heart Disease Using Multiplate Function Analyser and it's Correlation With Major Adverse Cardiac Events|Completed|||141|Actual|University of Zagreb|||2||f||||f||||||||||2018-06-01 01:48:26.719691|2018-06-01 01:48:26.719691
NCT00742417|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2015-12-03||2016-05-05|2008-08-25|2008-08-27|Estimate|2016-05-05|2016-06-14|Estimate||||2016-05-05|2016-06-14|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional||The baseline analysis population included all randomized subjects who received at least one plasma exchange session or one sham procedure.|Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid|Phase II Study to Evaluate the Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid, and Its Effects in Patients With Mild-moderate Alzheimer's Disease.|Completed||Phase 2|42|Actual|Grifols Biologicals Inc.||2|||f||||f||||||||||2018-06-01 01:48:26.842721|2018-06-01 01:48:26.842721
NCT00742404|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2013-12-17|2008-08-26|2008-08-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 2008||2008-07-31|June 2010|2010-06-30||||July 2010|Anticipated|2010-07-31||Interventional|||Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM)|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:48:27.50446|2018-06-01 01:48:27.50446
NCT00742391|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2012-02-21|2010-07-13|2015-02-18|2008-08-26|2008-08-27|Estimate|2012-02-21|2012-03-21|Estimate|2010-07-13|2010-07-15|Estimate|2015-02-18|2015-03-06|Estimate|September 2008||2008-09-30|March 2012|2012-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations|A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05% In Patients With Actinic Keratoses ON Non-head Locations (REGION-I)|Completed||Phase 3|255|Actual|Peplin||2|||f||||f||||||||||2018-06-01 01:48:27.610015|2018-06-01 01:48:27.610015
NCT00742378|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-09-22|2008-08-26|2008-08-27|Estimate|||||||2008-09-22|2008-09-23|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|December 2008|Anticipated|2008-12-31|October 2008|Anticipated|2008-10-31||Observational|||Discriminating Ability of the Cirrus High Definition (HD) Optical Coherence Tomography (OCT) for Glaucoma|Discriminating Ability of the Cirrus HD OCT for Glaucoma|Unknown status|Recruiting||200|Anticipated|Yonsei University|||2||f||||t||||||||||2018-06-01 01:48:27.870805|2018-06-01 01:48:27.870805
NCT00742365|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2018-02-15|2008-08-25|2008-08-27|Estimate|||||||2018-02-15|2018-02-19|Actual|November 2007||2007-11-30|February 2018|2018-02-28|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Observational|||Predicting Effectiveness of Light Treatment for Winter Seasonal Affective Disorder|Predicting Light Treatment's Effectiveness on Reducing Depression and Cardiovascular Risk in Seasonal Affective Disorder|Completed|||41|Actual|University of Maryland|||2||f||||t||||||||||2018-06-01 01:48:27.940738|2018-06-01 01:48:27.940738
NCT00742339|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2014-10-11|2008-08-26|2008-08-27|Estimate|||||||2014-10-11|2014-10-15|Estimate|May 2005||2005-05-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome|Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome (HRS): An Open Multicentric Randomized Study|Terminated||Phase 2/Phase 3|49|Actual|University of Padova||2||"Decision of independent monitoring committee: Risk of non-response to treatment significantly~   higher in midodrine group than in terlipressin group."|f||||f||||||||||2018-06-01 01:48:28.069674|2018-06-01 01:48:28.069674
NCT00742326|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2014-04-10||2016-10-26|2008-08-26|2008-08-27|Estimate|2014-05-15|2014-06-16|Estimate||||2016-10-26|2016-12-09|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections|Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection|Terminated||Phase 4|13|Actual|National Institutes of Health Clinical Center (CC)|The study failed to enroll to the originally established sample size due to slow enrollment.|2||Enrollment stopped prior to complete enrollment due to slow accrual|f||||t||||||||No|Decision will be made at the time of request|2018-06-01 01:48:28.145324|2018-06-01 01:48:28.145324
NCT00742313|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2013-11-08||2014-02-17|2008-08-26|2008-08-27|Estimate|2014-02-17|2014-03-05|Estimate||||2014-02-17|2014-03-05|Estimate|June 2009||2009-06-30|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)|Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)|Terminated||Phase 4|50|Actual|Duke University|This study was terminated early|2||No statistical differences on study endpoints between groups.|f||||f||||||||||2018-06-01 01:48:28.444955|2018-06-01 01:48:28.444955
NCT00742300|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-11-21|2008-08-26|2008-08-27|Estimate|||||||2008-11-21|2008-11-24|Estimate|January 1998||1998-01-31|November 2008|2008-11-30||||||||Interventional|ASTRAD||Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases|Phase I/II Open-Label Monocentric Clinical Trial for Induction of Tolerance With CD34-Enriched Autologous Hematopoietic Stem Cell Transplantation After High-Dose Chemotherapy With Cyclophosphamide and Rabbit-Antithymocyte Globulin for Refractory Autoimmune Diseases|Unknown status|Active, not recruiting|Phase 1/Phase 2|||Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 01:48:28.617939|2018-06-01 01:48:28.617939
NCT00742287|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-10-28|2008-08-26|2008-08-27|Estimate|||||||2011-10-28|2011-11-01|Estimate|February 2009||2009-02-28|October 2011|2011-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|INC001||Cardiovascular Effects of Oligomeric Procyanidins (OPCs) in Smokers|The Effects of Oligomeric Procyanidins (OPCs) on Vascular Function, Biomarkers of Oxidative Stress and Inflammation in Smokers: a Pilot Study|Completed||N/A|28|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:48:28.694592|2018-06-01 01:48:28.694592
NCT00742274|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2013-03-14||2013-11-08|2008-08-26|2008-08-27|Estimate|2013-03-15|2013-05-09|Estimate||||2013-11-08|2013-12-04|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|February 2012|Actual|2012-02-29||Interventional|ADSORB||A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection|A Randomized European Study Comparing Endoluminal Stent Grafting and Best Medical Therapy (BMT) to BMT Alone in the Treatment of Acute Uncomplicated Type B Aortic Dissection|Completed||N/A|61|Actual|W.L.Gore & Associates||2|||f||||t||||||||||2018-06-01 01:48:28.76935|2018-06-01 01:48:28.76935
NCT00742261|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2017-07-05|2008-08-26|2008-08-27|Estimate|||||||2017-07-05|2017-07-07|Actual|August 11, 2008|Actual|2008-08-11|July 2017|2017-07-31|June 24, 2009|Actual|2009-06-24|June 24, 2009|Actual|2009-06-24||Interventional|||A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors|An Open-label, Randomized, Two-way Balanced Crossover Study to Investigate the Bioavailability of Two Forms ofGSK1363089 in Subjects With Solid Tumors|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:48:29.230097|2018-06-01 01:48:29.230097
NCT00742248|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-08-26|2008-08-26|2008-08-27|Estimate|||||||2008-08-26|2008-08-27|Estimate|September 2004||2004-09-30|August 2008|2008-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)|Double Blind, Double Dummy, Multicentre, Randomised, Placebo- Controlled, Crossover Design Clinical Trial of 12 μg (Single Dose and Repeated Doses) Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant or DPI (Aerolizertm Inhaler) in Patients With Partially Reversible COPD|Completed||Phase 2|54|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-06-01 01:48:29.328411|2018-06-01 01:48:29.328411
NCT00742235|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2013-06-05||2016-03-15|2008-08-25|2008-08-27|Estimate|2013-09-09|2013-11-11|Estimate||||2016-03-15|2016-04-14|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects|hCAP18 Levels and Vitamin D Deficiency in Healthy Subjects|Completed||N/A|99|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:48:29.417559|2018-06-01 01:48:29.417559
NCT00742222|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2016-05-16|2008-08-26|2008-08-27|Estimate|||||||2016-05-16|2016-05-17|Estimate|May 2008||2008-05-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|EXIBT||Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer|Electronic Xoft Intersociety Brachytherapy Trial|Completed||Phase 4|63|Actual|Xoft, Inc.||1|||f||||t||||||||||2018-06-01 01:48:29.614548|2018-06-01 01:48:29.614548
NCT00742209|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|2011-07-25||2013-07-15|2008-08-26|2008-08-27|Estimate|2011-10-26|2011-12-05|Estimate||||2013-07-15|2013-07-22|Estimate|August 2008||2008-08-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Intent to Treat population|Prevention Study in Adult Patients Suffering From Migraine Headaches|Study MPX111381: A Dose-ranging Study Evaluating the Efficacy, Safety and Tolerability of GSK1838262 (XP13512) in the Prophylactic Treatment of Migraine Headache|Completed||Phase 2|526|Actual|XenoPort, Inc.||5|||f||||f||||||||||2018-06-01 01:48:29.812779|2018-06-01 01:48:29.812779
NCT00742196|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-08-26|2008-08-26|2008-08-27|Estimate|||||||2008-08-26|2008-08-27|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|March 2009|Anticipated|2009-03-31|December 2008|Anticipated|2008-12-31||Observational|||Retinal Nerve Fiber Layer Thickness Measurement on Parapapillary Atrophy With the Cirrus High-Definition (HD) Optical Coherence Tomography (OCT)|Retinal Nerve Fiber Layer Thickness Measurement on Parapapillary Atrophy With|Unknown status|Not yet recruiting||30|Anticipated|Yonsei University|||2||f||||t||||||||||2018-06-01 01:48:31.125136|2018-06-01 01:48:31.125136
NCT00740272|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2011-10-17|2008-08-21|2008-08-22|Estimate|||||||2011-10-17|2011-10-18|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Alternative||Af Ablation In Brady-Tachy Syndrome|Af Ablation In Brady-Tachy Syndrome|Terminated||N/A|38|Actual|St. Jude Medical||2||Slow recruitment|f||||f||||||||||2018-06-01 01:48:58.658232|2018-06-01 01:48:58.658232
NCT00742183|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2010-06-03||2017-11-06|2008-08-26|2008-08-27|Estimate|2010-10-11|2010-11-19|Estimate||||2017-11-06|2017-12-08|Actual|August 2008||2008-08-31|November 2017|2017-11-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®|An Open, Parallel, Randomized, Comparative, Multi-centre Investigation in US Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene® in the Treatment of Partial Thickness Burns.|Completed||N/A|100|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-06-01 01:48:31.220771|2018-06-01 01:48:31.220771
NCT00742170|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2014-10-15||2014-10-15|2008-08-25|2008-08-27|Estimate|2014-10-15|2014-10-21|Estimate||||2014-10-15|2014-10-21|Estimate|August 2007||2007-08-31|October 2014|2014-10-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Transdermal Electroacupuncture for Opioid Detoxification|Transdermal Electroacupuncture for Opioid Detoxification|Completed||Phase 1/Phase 2|48|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 01:48:31.462796|2018-06-01 01:48:31.462796
NCT00742157|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-08-15|2008-08-26|2008-08-27|Estimate|||||||2011-08-15|2011-08-16|Estimate|March 2003||2003-03-31|August 2011|2011-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)|An Open-label Evaluation of the Long-term Efficacy and Safety of a Standardized Regimen of Growth Hormone, Glutamine and a Modified Diet in the Treatment of Patients With Short Bowel Syndrome|Terminated||Phase 4|30|Anticipated|University of Nebraska||1||Lack of Enrollment|f||||f||||||||||2018-06-01 01:48:31.732015|2018-06-01 01:48:31.732015
NCT00742144|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2017-11-13|2008-08-26|2008-08-27|Estimate|||||||2017-11-13|2017-11-17|Actual|September 19, 2008|Actual|2008-09-19|November 2017|2017-11-30|November 18, 2009|Actual|2009-11-18|November 18, 2009|Actual|2009-11-18||Interventional|||Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia|An Open-label Phase I Study of Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:48:31.805378|2018-06-01 01:48:31.805378
NCT00742131|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2017-07-27|2008-08-26|2008-08-27|Estimate|||||||2017-07-27|2017-07-31|Actual|March 17, 2005|Actual|2005-03-17|July 2017|2017-07-31|August 29, 2011|Actual|2011-08-29|May 13, 2008|Actual|2008-05-13||Interventional|||A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors|Completed||Phase 1|40|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:48:31.868752|2018-06-01 01:48:31.868752
NCT00742118|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2015-09-29|2008-08-26|2008-08-27|Estimate|||||||2015-09-29|2015-09-30|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|February 2016|Anticipated|2016-02-29||Interventional|||Effects of the Soluble Mediators of Mastocytes on the Intestinal Epithelial Barrier and of the Enteric Nervous System During the Syndrome of the Irritable Bowel|Effects of the Soluble Mediators of Mastocytes on the Intestinal Epithelial Barrier and of the entérique Nervous System During the Syndrome of the Irritable Bowel|Unknown status|Recruiting|N/A|200|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-06-01 01:48:31.995997|2018-06-01 01:48:31.995997
NCT00742105|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2016-06-20|2008-08-26|2008-08-27|Estimate|||||||2016-06-20|2016-06-21|Estimate|November 2008||2008-11-30|June 2016|2016-06-30||||March 2010|Actual|2010-03-31||Interventional|||Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan|A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan|Completed||Phase 1|21|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:48:32.114697|2018-06-01 01:48:32.114697
NCT00742092|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2014-03-05|2008-08-26|2008-08-27|Estimate|||||||2014-03-05|2014-03-07|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Miglustat in Cystic Fibrosis|Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation|Completed||Phase 2|11|Actual|Actelion||2|||f||||f||||||||||2018-06-01 01:48:32.198523|2018-06-01 01:48:32.198523
NCT00742079|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2014-08-11||2017-11-20|2008-08-25|2008-08-27|Estimate|2014-09-03|2014-09-05|Estimate||||2017-11-20|2017-12-19|Actual|September 2006||2006-09-30|September 2014|2014-09-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia|Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia|Completed||Phase 4|21|Actual|Massachusetts General Hospital|The cross-over design of this study produced results that are difficult to interpret due to a significant order effect. Larger and longer trials are needed to assess whether this treatment may benefit patients with medication resistant delusions.|2|||f||||f||||||||||2018-06-01 01:48:32.40534|2018-06-01 01:48:32.40534
NCT00742066|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2011-03-16|2008-08-26|2008-08-27|Estimate|||||||2011-03-16|2011-03-17|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Role of AT1-receptor Blockers in Insulin-induced Vasodilation.|Insulin-induced Microvascular Activity in Patients With Essential Hypertension: a Possible Role for Angiotensin II AT1-receptor Blockers.|Unknown status|Active, not recruiting|N/A|32|Anticipated|Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 01:48:32.728723|2018-06-01 01:48:32.728723
NCT00742053|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2012-04-25||2017-07-12|2008-08-26|2008-08-27|Estimate|2012-07-27|2012-08-31|Estimate||||2017-07-12|2017-08-10|Actual|June 2008||2008-06-30|July 2017|2017-07-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Electrocardiogram (ECG) Guided Peripherally Inserted Central Catheter (PICC) Placement|A Study of Electrocardiogram (ECG) Guidance for Placement of Peripherally Inserted Central Catheters (PICC)|Terminated||N/A|7|Actual|C. R. Bard|The study was terminated early due to poor enrollment.|1||Enrollment rate was too slow.|f||||f||||||||No||2018-06-01 01:48:32.809473|2018-06-01 01:48:32.809473
NCT00742040|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-26|||2008-08-26|2008-08-26|2008-08-27|Estimate|||||||2008-08-26|2008-08-27|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Rapid Versus Prolonged Inpatient Up-Titration of Captopril|Rapid Versus Prolonged Inpatient Up-Titration of Captopril: A Randomized Clinical Trial|Unknown status|Recruiting|Phase 2|50|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 01:48:32.941542|2018-06-01 01:48:32.941542
NCT00742027|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2016-01-16|2008-08-26|2008-08-27|Estimate|||||||2016-01-16|2016-01-20|Estimate|September 2008||2008-09-30|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma|A Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma After High-dose Chemotherapy With Autologous Stem Cell.|Completed||Phase 2|129|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:48:33.045775|2018-06-01 01:48:33.045775
NCT00742014|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2013-12-13|2008-08-26|2008-08-27|Estimate|||||||2013-12-13|2013-12-16|Estimate|August 2008||2008-08-31|December 2013|2013-12-31||||June 2014|Anticipated|2014-06-30||Interventional|||The Assessment of Right Ventricular Contractility in Response to Sildenafil|The Assessment of Right Ventricular Contractility in Response to Sildenafil in Pediatric Patients With Pulmonary Arterial Hypertension|Suspended||Phase 3|10|Anticipated|The Hospital for Sick Children||1||absorption of oral sildenafil not consistent|f||||f||||||||||2018-06-01 01:48:33.255165|2018-06-01 01:48:33.255165
NCT00742001|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-03-15|2008-08-26|2008-08-27|Estimate|||||||2010-03-15|2010-03-16|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|IMPROVE||Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival|IMPROVE: Inactivation of Whole Blood With Mirasol (R): Performance in Red Blood Cells, Platelets and Plasma Investigation|Terminated||Phase 1|12|Actual|Terumo BCTbio||3||"An endpoint difference between 3 energies was not observed. Correlations between recovery and~   ATP were established, and will be used for a Whole Blood system."|f||||f||||||||||2018-06-01 01:48:33.338647|2018-06-01 01:48:33.338647
NCT00741988|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2013-01-23||2013-03-29|2008-08-26|2008-08-27|Estimate|2013-01-23|2013-02-27|Estimate||||2013-03-29|2013-04-09|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2010|Actual|2010-09-30||Interventional|||Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer|Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer|Completed||Phase 2|82|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 01:48:33.439877|2018-06-01 01:48:33.439877
NCT00741975|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2012-04-12|2008-08-25|2008-08-27|Estimate|||||||2012-04-12|2012-04-13|Estimate|April 2007||2007-04-30|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|Project TRAC||Affect Management Intervention for Early Adolescents Wtih Mental Health Problems|Affect Management Intervention for Early Adolescents With Mental Health Problems|Completed||Phase 1|138|Actual|Rhode Island Hospital||2|||f||||f||||||||||2018-06-01 01:48:33.97434|2018-06-01 01:48:33.97434
NCT00741962|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2009-05-11|2008-08-25|2008-08-26|Estimate|||||||2009-05-11|2009-05-12|Estimate|August 2008||2008-08-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study on the Effects of VR-3 Herbal Blend Intake on Acute and Chronic Stress in Healthy Adults|A Pilot Double-Blind Crossover Study on the Effects of VR-3 Herbal Blend Intake on Acute and Chronic Stress and Their Biomarkers in Healthy Adults|Completed||N/A|20|Anticipated|NEMA Research, Inc.||2|||f||||||||||||||2018-06-01 01:48:34.05526|2018-06-01 01:48:34.05526
NCT00741949|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2011-08-25|2008-08-25|2008-08-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SEDA-FIBRO||Broncho-alveolar Lavage Under Noninvasive Ventilation With Propofol TCI in Patient With AHRF|Fiberoptic Bronchoscopy With Broncho-alveolar Lavage Under Noninvasive Ventilation With Propofol Target Controled Infusion in Patient With Acute Hypoxemic Respiratory Failure. A Randomized Controlled Study : SEDA-FIBRO.|Completed||Phase 3|46|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 01:48:34.129205|2018-06-01 01:48:34.129205
NCT00741936|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2011-08-02||2016-05-23|2008-08-25|2008-08-26|Estimate|2011-11-14|2011-12-16|Estimate||||2016-05-23|2016-06-24|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation|Chinese Herbal Medicine for Functional Constipation: A Randomized, Double-blind, Placebo Controlled Trial|Completed||Phase 2|120|Actual|Hong Kong Baptist University||2|||f||||t||||||||||2018-06-01 01:48:34.263716|2018-06-01 01:48:34.263716
NCT00741923|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2012-06-14|2008-08-25|2008-08-26|Estimate|||||||2012-06-14|2012-06-15|Estimate|November 2007||2007-11-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Effect of Consuming Beans for One Month on Blood Lipids, Satiety, Intake Regulation and Body Weight|Beans and Potatoes in the Regulation of Food Intake and Risk Factors for Chronic Diseases. Effect of Consuming Beans for One Month on Blood Lipids, Satiety, Intake Regulation and Body Weight|Completed||N/A|14|Actual|University of Toronto||1|||f||||f||||||||||2018-06-01 01:48:34.820078|2018-06-01 01:48:34.820078
NCT00741910|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2012-08-22|2008-08-22|2008-08-26|Estimate|||||||2012-08-22|2012-08-23|Estimate|July 2003||2003-07-31|August 2012|2012-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|CD06||Extension Study of Semapimod 60 mg IV x 3 Days|Extension Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease|Completed||Phase 2|15|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:48:34.888268|2018-06-01 01:48:34.888268
NCT00741897|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2009-09-14|2008-08-25|2008-08-26|Estimate|||||||2009-09-14|2009-09-15|Estimate|March 2002||2002-03-31|September 2009|2009-09-30||||December 2003|Actual|2003-12-31||Interventional|||Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis|A Monitored Release Study On The Efficacy And Safety of Fexofenadine (Telfast®) 30mg Pediatric Tablets On Filipino Children Aged 6 To 11 for The Relief of Perennial And Intermittent Allergic Rhinitis.|Completed||Phase 4|264|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:48:34.985576|2018-06-01 01:48:34.985576
NCT00741884|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2015-04-21|2008-08-25|2008-08-26|Estimate|||||||2015-04-21|2015-04-22|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Three Doses of a Controlled Release Formulation of Varenicline for Smoking Cessation|A Phase 2, Seven Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group Study To Evaluate The Safety And Efficacy Of Three Doses Of A Controlled Release Formulation Of Varenicline For Smoking Cessation|Withdrawn||Phase 2|0|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 01:48:35.09218|2018-06-01 01:48:35.09218
NCT00741871|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2012-04-19|2008-08-22|2008-08-26|Estimate|||||||2012-04-19|2012-04-20|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies|A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies|Completed||Phase 1|35|Actual|S*BIO|||||f||||f||||||||||2018-06-01 01:48:35.259841|2018-06-01 01:48:35.259841
NCT00741858|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2015-06-15||2015-07-08|2008-08-25|2008-08-26|Estimate|2015-07-08|2015-07-13|Estimate||||2015-07-08|2015-07-13|Estimate|April 2003||2003-04-30|July 2015|2015-07-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Duragen Versus Duraguard in Chiari Surgery|Prospective Randomized Study of Duragen vs. Duraguard in Chiari Surgery|Completed||Phase 3|34|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 01:48:35.336825|2018-06-01 01:48:35.336825
NCT00741845|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2012-03-05|2008-08-25|2008-08-26|Estimate|||||||2012-03-05|2012-03-06|Estimate|June 2008||2008-06-30|March 2012|2012-03-31||||June 2009|Actual|2009-06-30||Interventional|||Prevention of Persistence of Bacterial Vaginosis|Prevention of Persistence of Bacterial Vaginosis: The Effects of High Dose Intravaginal Metronidazole|Terminated||Phase 3|117|Actual|Embil Pharmaceutical Co. Ltd||3||"Terminated for site documentation and monitoring issues - not safety, study drug, or adverse~   event issues."|f||||||||||||||2018-06-01 01:48:35.605027|2018-06-01 01:48:35.605027
NCT00741832|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2008-11-13|2008-08-22|2008-08-26|Estimate|||||||2008-11-13|2008-11-14|Estimate|March 2008||2008-03-31|November 2008|2008-11-30|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||The Effects of a Positive Expiratory Pressure (PEP) on Dyspnea and Dynamic Hyperinflation During Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effects of a Positive Expiratory Pressure (PEP) on Dyspnea and Dynamic Hyperinflation During Exercise in COPD Patients|Unknown status|Recruiting|N/A|11|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-06-01 01:48:35.674167|2018-06-01 01:48:35.674167
NCT00741819|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-23|2012-05-17||2013-01-16|2008-08-25|2008-08-26|Estimate|2013-01-16|2013-02-20|Estimate||||2013-01-16|2013-02-20|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects|An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension.|Completed||Phase 4|73|Actual|United Therapeutics|Small, open-label study without comparison arm.|1|||f||||f||||||||||2018-06-01 01:48:35.798556|2018-06-01 01:48:35.798556
NCT00741806|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-03-01|2008-08-25|2008-08-26|Estimate|||||||2010-03-01|2010-03-02|Estimate|August 2008||2008-08-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|GHB-CS03||Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults|Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults|Completed||Phase 1|32|Actual|AVIR Green Hills Biotechnology AG||2|||f||||t||||||||||2018-06-01 01:48:36.100935|2018-06-01 01:48:36.100935
NCT00741793|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2018-03-23|2008-08-22|2008-08-26|Estimate|||||||2018-03-23|2018-03-27|Actual|February 12, 2002|Actual|2002-02-12|March 2018|2018-03-31|September 17, 2018|Anticipated|2018-09-17|September 17, 2018|Anticipated|2018-09-17||Observational|BioTRAC||Biologic Treatment Registry Across Canada|BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA)|Active, not recruiting|||3000|Anticipated|Janssen Inc.|||||f||||f||f||||||||2018-06-01 01:48:36.158903|2018-06-01 01:48:36.158903
NCT00741780|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2015-03-19|2008-08-25|2008-08-26|Estimate|||||||2015-03-19|2015-03-24|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).|Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240µg/kg) Plus G-CSF (10µg/kg) Versus G-CSF (10µg/kg) Plus Placebo to Mobilize and Collect ≥ 6X 10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation|Completed|||164|Actual|Sanofi|||2||f||||f||||||||||2018-06-01 01:48:36.215845|2018-06-01 01:48:36.215845
NCT00741767|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2015-10-05|2008-08-25|2008-08-26|Estimate|||||||2015-10-05|2015-10-06|Estimate|August 2008||2008-08-31|October 2015|2015-10-31|February 2012|Actual|2012-02-29|September 2010|Anticipated|2010-09-30||Interventional|AQuOS-COPD||The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD|The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (Advair and Quality of Sleep in COPD)|Withdrawn||N/A|0|Actual|Northwestern University||2||Study subject enrollment difficulties|f||||f||||||||||2018-06-01 01:48:36.27806|2018-06-01 01:48:36.27806
NCT00741754|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2009-03-30|2008-08-25|2008-08-26|Estimate|||||||2009-03-30|2009-04-01|Estimate|June 2005||2005-06-30|August 2008|2008-08-31|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|EUWSFDAR||Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use HcT20|Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use of Lauryl-Diethylene-Glycol-Ether Sodium Sulfate Associated With Calcium Hydroxide (hCt20).|Completed||Phase 2|31|Actual|UPECLIN HC FM Botucatu Unesp||1|||f||||t||||||||||2018-06-01 01:48:36.353627|2018-06-01 01:48:36.353627
NCT00741741|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2010-10-22|2008-08-22|2008-08-26|Estimate|||||||2010-10-22|2010-10-26|Estimate|July 2008||2008-07-31|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.|Phase I, Double Blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Multiple (Monthly) Intramuscular and Subcutaneous Doses of TMC278LA.|Terminated||Phase 1|20|Actual|Tibotec Pharmaceuticals, Ireland||||Strategic decision|f||||f||||||||||2018-06-01 01:48:37.398282|2018-06-01 01:48:37.398282
NCT00741728|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2011-12-08|2008-08-25|2008-08-26|Estimate|||||||2011-12-08|2011-12-09|Estimate|June 2008||2008-06-30|December 2011|2011-12-31|December 2019|Anticipated|2019-12-31|June 2012|Anticipated|2012-06-30||Observational|PPSIII||Heart Rate, Baroreflex Sensitivity and Cardiovascular Morbidity and Mortality in the Population|Heart Rate, Baroreflex Sensitivity and Cardiovascular Morbidity and Mortality in the Population. The Paris Prospective Study III|Recruiting|||10000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||t||||||Samples With DNA|"~     Blood samples and DNA taken from fresh blood~   "|||2018-06-01 01:48:37.457944|2018-06-01 01:48:37.457944
NCT00741715|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25||2016-04-15|2016-04-15|2008-08-25|2008-08-26|Estimate||||2016-04-15|2016-05-16|Estimate|2016-04-15|2016-05-16|Estimate|August 2008||2008-08-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia|"A Multicenter, Randomized, Placebo-controlled, Factorial Design, 12-month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day Co-administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia"|Terminated||Phase 3|1736|Actual|Sanofi||15||AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|f||||f||||||||||2018-06-01 01:48:37.551017|2018-06-01 01:48:37.551017
NCT00741702|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2012-05-15|2008-08-25|2008-08-26|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 2001||2001-09-30|May 2012|2012-05-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|DREAM3||Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples|Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples|Completed||N/A|95|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:48:37.639563|2018-06-01 01:48:37.639563
NCT00741689|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-12-02|2008-08-25|2008-08-26|Estimate|||||||2010-12-02|2010-12-03|Estimate|August 2008||2008-08-31|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers|A Randomised, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Oral Doses of AZD1656 in Japanese Healthy Male Volunteers|Completed||Phase 1|36|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 01:48:37.713992|2018-06-01 01:48:37.713992
NCT00741676|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2008-12-30|2008-08-25|2008-08-26|Estimate|||||||2008-12-30|2008-12-31|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Comparison of the Laparoscopy-Assisted Distal Gastrectomy and Open Distal Gastrectomy for Advanced Gastric Cancer|Comparison of the Laparoscopy-Assisted Distal Gastrectomy(LADG) and Open Distal Gastrectomy (ODG) for Advanced Gastric Cancer (Stage Ib and II).|Unknown status|Recruiting|Phase 1|124|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-06-01 01:48:37.781005|2018-06-01 01:48:37.781005
NCT00741663|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2008-09-24|2008-08-25|2008-08-26|Estimate|||||||2008-09-24|2008-09-25|Estimate|April 2005||2005-04-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|SVSSF||Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)|Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis|Completed||Phase 4|100|Anticipated|University of Padova||2|||f||||f||||||||||2018-06-01 01:48:37.876176|2018-06-01 01:48:37.876176
NCT00741650|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2015-02-25|2008-08-25|2008-08-26|Estimate|||||||2015-02-25|2015-02-26|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|Ibedrift||Ibedrift- A Trial Comparing a New Approach to Musculoskeletal Pain Consisting of Education and Peer Involvement to Treatment as Usual|Ibedrift- Health Related Coping. A Randomized Controlled Trial Comparing a Worksite Educational Intervention With or Without Referral to Treatment as Usual.|Completed||Phase 2/Phase 3|2097|Actual|Uni Research||3|||f||||f||||||||||2018-06-01 01:48:38.752995|2018-06-01 01:48:38.752995
NCT00741637|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2012-03-29|2008-08-25|2008-08-26|Estimate|||||||2012-03-29|2012-03-30|Estimate|July 2010||2010-07-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults|A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Single Dose Regimen of Live Attenuated Oral Cholera Vaccine (Choleragarde®) in HIV-Seropositive Adults in Thailand|Completed||Phase 2|32|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-06-01 01:48:38.828468|2018-06-01 01:48:38.828468
NCT00741624|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2009-06-02|2008-08-25|2008-08-26|Estimate|||||||2009-06-02|2009-06-03|Estimate|September 2008||2008-09-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Pain Reduce Following Refractive Surgery|Mitigating Pain Following Refractive Surgery|Completed||Phase 2|2|Actual|FORSIGHT Vision3||1|||f||||t||||||||||2018-06-01 01:48:38.900639|2018-06-01 01:48:38.900639
NCT00741611|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2012-08-27||2012-09-26|2008-08-25|2008-08-26|Estimate|2012-09-26|2012-10-26|Estimate||||2012-09-26|2012-10-26|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|MAGELLAN||Study of HD Mesh Ablation System for Treatment of Paroxysmal Atrial Fibrillation|A Randomized Controlled Trial of Radiofrequency Ablation for the Treatment of Paroxysmal Atrial Fibrillation Using the Bard High Density Mesh Ablation System (MAGELLAN)|Terminated||Phase 3|44|Actual|C. R. Bard|Due to the study’s early termination and enrollment of only 7 randomized patients, predefined study endpoints were not evaluable. Treated patients were followed through 12 months postprocedure and data were summarized where possible.|2||Business reasons|f||||t||||||||||2018-06-01 01:48:38.983377|2018-06-01 01:48:38.983377
NCT00741598|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2016-09-29||2017-03-21|2008-08-25|2008-08-26|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|September 2008||2008-09-30|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder|The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder|Completed||Phase 4|72|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 01:48:39.45604|2018-06-01 01:48:39.45604
NCT00741585|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2017-12-04|2008-08-25|2008-08-26|Estimate|||||||2017-12-04|2017-12-06|Actual|September 1, 2008|Actual|2008-09-01|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|HYGIA||Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment|Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment|Recruiting||Phase 4|18000|Anticipated|University of Vigo||2|||f||||t||||||||||2018-06-01 01:48:39.790759|2018-06-01 01:48:39.790759
NCT00741572|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2017-02-22|2008-08-25|2008-08-26|Estimate|||||||2017-02-22|2017-02-24|Actual|August 2008||2008-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Observational|||Individual Sensitivity for Interstitial Lung Diseases|Individual Sensitivity for Interstitial Lung Diseases|Completed|||100|Anticipated|Maastricht University Medical Center|||2||f||||f||||||Samples With DNA|"~     The patients will be asked to donate 5L exhaled air and 20 ml blood.~   "|||2018-06-01 01:48:39.992968|2018-06-01 01:48:39.992968
NCT00741559|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2014-05-12|2008-08-25|2008-08-26|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2008||2008-03-31|May 2014|2014-05-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Combined Role of Position Emission Tomography (PET) and Magnetoencephalography (MEG) in Nonlesional Epilepsy|Combined Role of PET and MEG in Nonlesional Epilepsy in Pediatric Population|Completed||Phase 3|59|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 01:48:40.067902|2018-06-01 01:48:40.067902
NCT00741546|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2008-08-25|2008-08-25|2008-08-26|Estimate|||||||2008-08-25|2008-08-26|Estimate|March 2007||2007-03-31|August 2008|2008-08-31||||September 2010|Anticipated|2010-09-30||Observational|||Association of Low Vitamin D Levels With Mortality in Patients With Reduced Left Ventricular Function Referred to Cardiac Surgery|Association of Low Vitamin D Levels With Mortality in Patients With Reduced Left Ventricular Function Referred to Cardiac Surgery|Unknown status|Enrolling by invitation||160|Anticipated|Johann Wolfgang Goethe University Hospital|||1||f||||t||||||||||2018-06-01 01:48:40.164316|2018-06-01 01:48:40.164316
NCT00741533|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-11-17|2008-08-25|2008-08-26|Estimate|||||||2010-11-17|2010-11-18|Estimate|February 2008||2008-02-29|November 2010|2010-11-30|July 2009|Actual|2009-07-31|November 2008|Actual|2008-11-30||Observational|||Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital|Quality of Life in Thai Women Diagnosed Cervical Cancer at King Chulalongkorn Memorial Hospital|Completed|||172|Actual|Chulalongkorn University|||||f||||f||||||||||2018-06-01 01:48:40.229154|2018-06-01 01:48:40.229154
NCT00741520|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-10-27|2008-08-25|2008-08-26|Estimate|||||||2010-10-27|2010-10-28|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|OSA-NORMO||Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients|Cardiovascular Impact of Obstructive Sleep Apnea in Normotensive Patients and the Effects of Continuous Positive Airway Pressure|Completed||Phase 4|36|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 01:48:40.303721|2018-06-01 01:48:40.303721
NCT00741507|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2009-07-14|2008-08-25|2008-08-26|Estimate|||||||2009-07-14|2009-07-15|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|UNADAREW||Unhealthy Alcohol Drinking and Anesthetic Requirement in Women|Unhealthy Alcohol Drinking and Anesthetic Requirement in General Anesthesia in Women|Completed||N/A|200|Actual|Nanjing Medical University||5|||f||||t||||||||||2018-06-01 01:48:40.399875|2018-06-01 01:48:40.399875
NCT00741494|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-12-26|2008-08-25|2008-08-26|Estimate|||||||2010-12-26|2010-12-28|Estimate|August 2008||2008-08-31|December 2010|2010-12-31||||December 2010|Actual|2010-12-31||Interventional|||Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI)|Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI) for Patients Having a Low Versus High Proportion of Hyaluronan Binding Sperm (HBA)|Completed||N/A|801|Actual|Biocoat||5|||f||||f||||||||||2018-06-01 01:48:40.622256|2018-06-01 01:48:40.622256
NCT00741481|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2011-02-23|2008-08-25|2008-08-26|Estimate|||||||2011-02-23|2011-02-24|Estimate|June 2006||2006-06-30|February 2011|2011-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|earlyPETmCRC||PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.|Evaluation of Prognostic and Predictive Value of PETSCAn in ColoRectal Cancer (CRC)|Completed|||40|Anticipated|Jules Bordet Institute|||1||f||||f||||||||||2018-06-01 01:48:40.786389|2018-06-01 01:48:40.786389
NCT00741468|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2014-07-03||2014-08-20|2008-08-25|2008-08-26|Estimate|2014-08-20|2014-08-22|Estimate||||2014-08-20|2014-08-22|Estimate|July 2008||2008-07-31|August 2014|2014-08-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional||All subjects enrolled|Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects|An Open-Label, Multiple-Dose, Non-Randomized Study to Assess the Drug-Drug Interactions of Proellex® (CDB-4124) With Cytochrome P450 Isoenzymes CYP1A2, 2C9, 2C19, 2D6, and 3A4 in Healthy Female Subjects|Completed||Phase 1|18|Actual|Repros Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 01:48:40.933686|2018-06-01 01:48:40.933686
NCT00741455|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2018-03-22|2008-08-25|2008-08-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 2004||2004-06-30|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|January 2023|Anticipated|2023-01-31||Interventional|||Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies|Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies|Active, not recruiting||N/A|22|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 01:48:41.263183|2018-06-01 01:48:41.263183
NCT00741442|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25||2014-01-07|2014-01-07|2008-08-25|2008-08-26|Estimate||||2014-01-07|2014-02-06|Estimate|2014-01-07|2014-02-06|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout|Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout|Completed||Phase 2|3|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-06-01 01:48:41.42123|2018-06-01 01:48:41.42123
NCT00741429|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2014-12-01|2008-08-25|2008-08-26|Estimate|||||||2014-12-01|2014-12-03|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||A 2-Month Safety Follow-Up Trial|A 2-Month Safety Follow-up Trial of Subjects From MannKind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030|Completed|||649|Actual|Mannkind Corporation|||2||f||||||||||||||2018-06-01 01:48:41.535735|2018-06-01 01:48:41.535735
NCT00741416|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2011-06-30|2008-08-25|2008-08-26|Estimate|||||||2011-06-30|2011-07-01|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|IHS||Biorepository: Indiana Health Study|Collection and Storage of Human Biological Materials (Blood Sample) and Linked Phenotypic Information (Health History) for Research Purposes|Unknown status|Recruiting||1400|Anticipated|Fairbanks Institute|||2||f||||t||||||Samples With DNA|"~     70ml of whole blood: 3-10 ml EDTA tubes for collection of whole blood 3-10 ml SST tubes (red~     tops) for collection of serum 2-3ml PAXgene tubes for collection of RNA A minimum of 1 EDTA~     and 1 SST tube is required for enrollment into the study.~   "|||2018-06-01 01:48:41.809764|2018-06-01 01:48:41.809764
NCT00741403|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2016-12-28|2008-08-25|2008-08-26|Estimate|||||||2016-12-28|2016-12-29|Estimate|August 2008||2008-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies|An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients|Completed||Phase 1|39|Actual|Rafael Pharmaceuticals Inc.||1|||f||||f||||||||||2018-06-01 01:48:41.92663|2018-06-01 01:48:41.92663
NCT00741390|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2009-09-02||2010-03-05|2008-08-25|2008-08-26|Estimate|2010-03-05|2010-03-10|Estimate||||2010-03-05|2010-03-10|Estimate|August 2008||2008-08-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose|Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose When Using Different Currently Marketed Lancing Devices and Lancets|Completed||N/A|250|Actual|Becton, Dickinson and Company||4|||f||||f||||||||||2018-06-01 01:48:42.017719|2018-06-01 01:48:42.017719
NCT00741377|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2013-02-15|2008-08-25|2008-08-26|Estimate|||||||2013-02-15|2013-02-18|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients|A Phase Ib/II Multicenter Dose-determination Study, With an Adaptive, Randomized, Placebo-controlled, Double-blind Phase II, Using Various Repeated IV Doses of BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients With Prior Skeletal-related Event|Completed||Phase 1|28|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:48:42.454493|2018-06-01 01:48:42.454493
NCT00741364|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2011-09-29|2008-08-25|2008-08-26|Estimate|||||||2011-09-29|2011-09-30|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|July 2012|Anticipated|2012-07-31|February 2012|Anticipated|2012-02-29||Interventional|DProstate||Vitamin D Effects on Prostate Pathology|Randomized Trial of the Effects of Vitamin D on Prostate Cancer-associated Lesions and on Vitamin D Metabolites in Prostate|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|University of Toronto||3|||f||||f||||||||||2018-06-01 01:48:42.545374|2018-06-01 01:48:42.545374
NCT00741351|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2011-09-07|2008-08-25|2008-08-26|Estimate|||||||2011-09-07|2011-09-08|Estimate|December 2007||2007-12-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|Neuromorfeo||Anesthesiological Strategies in Elective Craniotomy|Anesthesiological Strategies in Elective Craniotomy: Randomized, Equivalence, Open Trial|Completed||Phase 3|411|Actual|Azienda Ospedaliera San Gerardo di Monza||3|||f||||t||||||||||2018-06-01 01:48:42.646284|2018-06-01 01:48:42.646284
NCT00741169|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2013-04-17|2008-08-22|2008-08-26|Estimate|||||||2013-04-17|2013-04-18|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.|Phase I, Open-label, 3-way Crossover Trial in Healthy Volunteers to Determine the Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.|Completed||Phase 1|21|Actual|Tibotec Pharmaceuticals, Ireland||6|||f||||f||||||||||2018-06-01 01:48:46.558924|2018-06-01 01:48:46.558924
NCT00741338|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2014-06-02||2014-06-02|2008-08-25|2008-08-26|Estimate|2014-06-02|2014-07-02|Estimate||||2014-06-02|2014-07-02|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Analysis population included all enrolled participants, including 1 participant who was screen failure.|Immune Tolerance Study With Aldurazyme® (Laronidase)|A Trial of Antigen-specific Immune Tolerance Induction in Mucopolysaccharidosis I (MPS I) Patients Initiating Enzyme Replacement Therapy With Aldurazyme® (Laronidase)|Completed||Phase 1/Phase 2|7|Actual|Sanofi|Study was discontinued on September 10,2013 due to changing standards of care for this population, practical infeasibility of routinely monitoring plasma CsA in clinical setting, inconclusive results of interim analysis and not due to safety concern.|2|||f||||t||||||||||2018-06-01 01:48:42.798586|2018-06-01 01:48:42.798586
NCT00741325|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2014-02-10|2008-08-25|2008-08-26|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).|Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240µg/kg) Plus G-CSF (10µg/kg) Versus G-CSF (10µg/kg) Plus Placebo to Mobilize and Collect ≥ 5X 10^6 CD34+ Cells/kg in Non-Hodgkin's Lymphoma Patients for Autologous Transplantation|Completed|||178|Actual|Sanofi|||2||f||||f||||||||||2018-06-01 01:48:43.24817|2018-06-01 01:48:43.24817
NCT00741312|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2011-01-20|2008-08-22|2008-08-26|Estimate|||||||2011-01-20|2011-01-21|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Influence of Physical Exercise on Endothelial Function in Pregnant Women|Influence of Physical Exercise on Endothelial Function in Pregnant Women: Randomized Clinical Trial|Completed||Phase 1/Phase 2|64|Anticipated|Universidad del Valle, Colombia||2|||f||||f||||||||||2018-06-01 01:48:43.321089|2018-06-01 01:48:43.321089
NCT00741299|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2012-07-25|2008-08-25|2008-08-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Observational|||A Study of the Association Between Tobacco Smoking and Bipolar Affective Disorder|Association Between Tobacco Smoking and Bipolar Affective Disorder.Clinico-epidemiological, Cross-sectional, Retrospective Study.|Completed|||100|Actual|Tirat Carmel Mental Health Center|||||f||||f||||||||||2018-06-01 01:48:43.394852|2018-06-01 01:48:43.394852
NCT00741286|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2010-08-03||2011-08-04|2008-08-25|2008-08-26|Estimate|2011-08-04|2011-09-05|Estimate||||2011-08-04|2011-09-05|Estimate|November 2006||2006-11-30|August 2010|2010-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ECLIPse||Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler|Study for the Multi-Center Placebo-Controlled Double-Blind Clinical Trial for the Evaluation of the Effect of Cilostazol on Pulsatility Index of Transcranial Doppler in the Acute Lacunar Infarction Patients|Completed||Phase 4|203|Actual|Inje University||2|||f||||f||||||||||2018-06-01 01:48:43.471575|2018-06-01 01:48:43.471575
NCT00741273|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2014-06-27||2014-08-08|2008-08-25|2008-08-26|Estimate|2014-08-08|2014-08-28|Estimate||||2014-08-08|2014-08-28|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional||ITT and Safety populations were the same|Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults|An Open-label, Two-stage, Dose-escalation, Parallel Group Study to Evaluate the Safety and Pharmacokinetics Profile of Proellex® (CDB-4124) in Female Patients With Impaired Hepatic Function and Healthy Adult Volunteers|Completed||Phase 1|16|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-06-01 01:48:43.735203|2018-06-01 01:48:43.735203
NCT00741260|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2017-08-10|2013-01-28|2017-10-06|2008-08-22|2008-08-26|Estimate|2017-10-06|2017-11-09|Actual|2013-01-28|2013-01-30|Estimate|2017-10-06|2017-11-09|Actual|December 2008||2008-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|November 2010|Actual|2010-11-30||Interventional||Safety population|Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer|A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer|Active, not recruiting||Phase 1/Phase 2|105|Actual|Puma Biotechnology, Inc.||7|||f||||f|t|f||||||||2018-06-01 01:48:44.016485|2018-06-01 01:48:44.016485
NCT00741247|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2009-06-23|2008-08-25|2008-08-26|Estimate|||||||2009-06-23|2009-06-24|Estimate|August 2008||2008-08-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Mediastinal Staging of Lung Cancer With EBUS-TBNA and EUS-B-FNA|Minimally Invasive Mediastinal Staging of Potentially Operable Lung Cancer With Endobronchial Ultrasound Guided Transbronchial Needle Aspiration(EBUS-TBNA) and Transesophageal Aspiration Using Ultrasonic Bronchoscope (EUS-B-FNA)|Completed||N/A|150|Actual|National Cancer Center, Korea|||||f||||t||||||||||2018-06-01 01:48:45.996042|2018-06-01 01:48:45.996042
NCT00741234|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2012-04-19|2008-08-22|2008-08-26|Estimate|||||||2012-04-19|2012-04-23|Estimate|April 2007||2007-04-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine|A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies|Completed||Phase 1|85|Actual|S*BIO||3|||f||||f||||||||||2018-06-01 01:48:46.059802|2018-06-01 01:48:46.059802
NCT00741221|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2016-10-03|2008-08-25|2008-08-26|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer|Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|50|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 01:48:46.158519|2018-06-01 01:48:46.158519
NCT00741208|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2011-06-03|2008-08-25|2008-08-26|Estimate|||||||2011-06-03|2011-06-08|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Modification of Asthma With Soy Isoflavone|Modification of Asthma With Soy Isoflavone|Completed||N/A|20|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 01:48:46.248941|2018-06-01 01:48:46.248941
NCT00741195|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2016-10-03|2008-08-25|2008-08-26|Estimate|||||||2016-10-03|2016-10-04|Estimate|April 2008||2008-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer|Docetaxel Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC|Completed||Phase 2|50|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 01:48:46.318261|2018-06-01 01:48:46.318261
NCT00741182|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2015-03-17|2008-08-25|2008-08-26|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Effect of PTH(1-34) Treatment on Fracture Healing in Vivo|Effect of PTH(1-34) Treatment on Fracture Healing in Vivo|Withdrawn||Phase 2|0|Actual|Glostrup University Hospital, Copenhagen||4|||f||||t||||||||||2018-06-01 01:48:46.40088|2018-06-01 01:48:46.40088
NCT00741156|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2013-07-26||2015-11-16|2008-08-25|2008-08-26|Estimate|2015-11-16|2015-12-18|Estimate||||2015-11-16|2015-12-18|Estimate|July 2008||2008-07-31|November 2015|2015-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution|The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection|Completed||Phase 3|12|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 01:48:46.650446|2018-06-01 01:48:46.650446
NCT00741143|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-23|||2008-08-25|2008-08-25|2008-08-26|Estimate|||||||2008-08-25|2008-08-26|Estimate|August 2007||2007-08-31|August 2008|2008-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Iron Fortified Wheat Flour on Cognition and Iron Status in Indian School Children|Effect of Iron Fortified Wheat Flour on Cognition and Iron Status in Indian School Children|Completed||N/A|194|Actual|St. John's Research Institute||2|||f||||f||||||||||2018-06-01 01:48:46.839066|2018-06-01 01:48:46.839066
NCT00741130|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2008-08-25|2008-08-25|2008-08-26|Estimate|||||||2008-08-25|2008-08-26|Estimate|July 2008||2008-07-31|August 2008|2008-08-31|January 2009|Anticipated|2009-01-31|October 2008|Anticipated|2008-10-31||Observational|||Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT|Corrected Measurement of the Retinal Nerve Fiber Layer Thickness by Optic Disc Configuration With the Cirrus HD OCT|Unknown status|Recruiting||50|Anticipated|Yonsei University|||2||f||||t||||||||||2018-06-01 01:48:46.904423|2018-06-01 01:48:46.904423
NCT00741117|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2013-03-05|2008-08-25|2008-08-26|Estimate|||||||2013-03-05|2013-03-06|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Conjugated Hyperbilirubinemia and Pulse Oximetry|The Influence of Conjugated Hyperbilirubinemia on Pulse Oximetric Accuracy in Liver Disease|Terminated||N/A|4|Actual|Emory University||3||Study stopped due to insufficient personnel required to conduct trial.|f||||f||||||||||2018-06-01 01:48:46.967677|2018-06-01 01:48:46.967677
NCT00741104|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-06-11||2017-01-02|2008-08-22|2008-08-26|Estimate|2009-07-09|2009-08-21|Estimate||||2017-01-02|2017-01-04|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|REQUEST||A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)|A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients|Completed|||363|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:48:47.060774|2018-06-01 01:48:47.060774
NCT00741091|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|2011-06-02||2011-08-22|2008-08-25|2008-08-26|Estimate|2011-07-25|2011-08-19|Estimate||||2011-08-22|2011-08-24|Estimate|December 2008||2008-12-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CABANA||A Carotid Stenting Boston Scientific Surveillance Program|A Carotid Stenting Boston Scientific Surveillance Program Carotid WALLSTENT Monorail Endoprosthesis FilterWire EZ™ Embolic Protection System|Completed||Phase 4|1097|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 01:48:47.276062|2018-06-01 01:48:47.276062
NCT00741078|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-28|2008-08-25|2008-08-26|Estimate|||||||2008-08-28|2008-08-29|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|||||Interventional|||Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension|Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension|Completed||Phase 4|||Gachon University Gil Medical Center||1|||f||||t||||||||||2018-06-01 01:48:48.071957|2018-06-01 01:48:48.071957
NCT00741065|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-25|||2010-02-10|2008-08-25|2008-08-26|Estimate|||||||2010-02-10|2010-02-11|Estimate|September 2008||2008-09-30|February 2010|2010-02-28|February 2010|Anticipated|2010-02-28|June 2009|Anticipated|2009-06-30||Interventional|DESWT||DESWT-Pilot Study on the Safety of Myocardial Regeneration by Direct Epicardial Shock Wave Therapy in Combination With Coronary Artery Bypass Grafting|DESWT-Pilot Study on the Safety of Myocardial Regeneration by Direct Epicardial Shock Wave Therapy in Combination With Coronary Artery Bypass Grafting|Unknown status|Active, not recruiting|N/A|10|Anticipated|Cardiac Regeneration Technologies, LLC|||||f||||f||||||||||2018-06-01 01:48:48.14046|2018-06-01 01:48:48.14046
NCT00741052|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2011-07-11|2008-08-25|2008-08-26|Estimate|||||||2011-07-11|2011-07-12|Estimate|July 2007||2007-07-31|August 2008|2008-08-31|June 2010|Actual|2010-06-30|October 2008|Actual|2008-10-31||Interventional|||Ciprofloxacin Multiple Dose for Adult Cholera|Randomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy of Multiple-dose Ciprofloxacin With Single Dose Azithromycin Therapy for Adults With Cholera Due to Multiply Resistant Strains of V. Cholerae O1 or O139|Completed||Phase 3|218|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||||2018-06-01 01:48:48.20286|2018-06-01 01:48:48.20286
NCT00741039|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2015-10-19||2015-10-19|2008-08-22|2008-08-26|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|August 2008||2008-08-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older|Phase II Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older|Completed||Phase 2|126|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 01:48:48.286213|2018-06-01 01:48:48.286213
NCT00741026|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2012-11-29||2014-07-11|2008-08-22|2008-08-25|Estimate|2014-07-11|2014-07-14|Estimate||||2014-07-11|2014-07-14|Estimate|August 2008||2008-08-31|July 2014|2014-07-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers|A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers|Completed||N/A|15|Actual|Milton S. Hershey Medical Center|One episode of orthostatic hypotension requiring unblinding. One individual with emesis after glucose challenge and that individual's glucose tolerance data were unavailable analysis.|2|||f||||t||||||||||2018-06-01 01:48:48.503315|2018-06-01 01:48:48.503315
NCT00741013|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2009-08-04||2014-04-22|2008-08-22|2008-08-25|Estimate|2014-04-22|2014-05-26|Estimate||||2014-04-22|2014-05-26|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Quantifying Airway Inflammation With Radiologic Tests|Imaging Biomarkers of Pulmonary Inflammation|Completed||Early Phase 1|22|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 01:48:48.881671|2018-06-01 01:48:48.881671
NCT00741000|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2008-08-22|2008-08-22|2008-08-25|Estimate|||||||2008-08-22|2008-08-25|Estimate|July 2008||2008-07-31|August 2008|2008-08-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|CSEROM||Cervical Stairstep and Effects on Range of Motion (ROM)|The Effects of Cervical Stairstep on Cervical Range of Motion|Unknown status|Recruiting|Phase 1|50|Anticipated|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 01:48:49.157295|2018-06-01 01:48:49.157295
NCT00740818|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2008-08-22|2008-08-22|2008-08-25|Estimate|||||||2008-08-22|2008-08-25|Estimate|July 2008||2008-07-31|August 2008|2008-08-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Logan Basic and Dysmenorrhea|A Pilot Study: Logan Basic Technique and Auxiliary Abdominal Contacts for Reducing Symptomatology of Primary Dysmenorrhea|Unknown status|Recruiting|Phase 2|30|Anticipated|Logan College of Chiropractic||3|||f||||f||||||||||2018-06-01 01:48:51.539901|2018-06-01 01:48:51.539901
NCT00740987|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2015-02-10|2008-08-22|2008-08-25|Estimate|||||||2015-02-10|2015-02-11|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CIREA2||Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)|Evaluation of Intermittent Pneumatic Compression Associated With Elastic Stockings and Anticoagulant Prophylaxis Versus Anticoagulant Prophylaxis Alone on Venous Thromboembolism Incidence in ICU Patients Without High Risk of Bleeding|Completed||Phase 3|621|Actual|University Hospital, Brest||2|||f||||||||||||||2018-06-01 01:48:49.211109|2018-06-01 01:48:49.211109
NCT00740974|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2008-08-22|2008-08-22|2008-08-25|Estimate|||||||2008-08-22|2008-08-25|Estimate||||August 2008|2008-08-31||||||||Observational|||Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula||Completed|||||Mead Johnson Nutrition|||||f||||||||||||||2018-06-01 01:48:49.288097|2018-06-01 01:48:49.288097
NCT00740961|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2015-10-01|2008-08-22|2008-08-25|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer|The Vulnerable Elders Survey Study of Older Cancer Patients|Terminated|||63|Actual|Case Comprehensive Cancer Center|||2|low accrual|f||||t||||||Samples Without DNA|"~     Approximately 13mls of blood will be drawn at each of the three time-points for testing for~     biologic correlates of frailty (pre study, mid-study and post-study).~   "|||2018-06-01 01:48:49.334463|2018-06-01 01:48:49.334463
NCT00740948|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2015-03-04|2008-08-22|2008-08-25|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|TEARS||Tolerance and Efficacy of Rituximab in Sjogren's Disease|Tolerance and Efficacy of Rituximab in Sjogren's Disease|Completed||Phase 2/Phase 3|122|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-06-01 01:48:49.532976|2018-06-01 01:48:49.532976
NCT00740935|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2013-10-18|2008-08-22|2008-08-25|Estimate|||||||2013-10-18|2013-10-22|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|IVANHOE||Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.|Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.|Completed||Phase 4|7204|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-06-01 01:48:49.622863|2018-06-01 01:48:49.622863
NCT00740922|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2011-06-06|2008-08-22|2008-08-25|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 1999||1999-07-31|April 2010|2010-04-30|April 2001|Actual|2001-04-30|||||Observational|||Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers|A Multicenter Clinical Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers|Completed|||563|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||||||||||||||||2018-06-01 01:48:49.687502|2018-06-01 01:48:49.687502
NCT00740909|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2012-06-19|2008-08-22|2008-08-25|Estimate|||||||2012-06-19|2012-06-20|Estimate|November 2008||2008-11-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|CBT for TTM||Cognitive Behavioral Therapy for Trichotillomania|Cognitive Behavioral Therapy for Trichotillomania|Completed||Phase 1/Phase 2|38|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 01:48:49.748168|2018-06-01 01:48:49.748168
NCT00740896|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2009-04-07|2008-08-22|2008-08-25|Estimate|||||||2009-04-07|2009-04-08|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Acute Effects of Smoking on Airway Dendritic Cells|Acute Effects of Smoking on Airway Dendritic Cells|Completed||N/A|16|Actual|University of Rostock||2|||f||||f||||||||||2018-06-01 01:48:49.809927|2018-06-01 01:48:49.809927
NCT00740883|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2017-01-11|2008-08-22|2008-08-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2007||2007-07-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|PADIS EP||"Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. PADIS-PE Study."|"Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Pulmonary Embolism: a Multicentre Double-blind Randomized Controlled Trial. PADIS-PE Study."|Completed||Phase 3|374|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-06-01 01:48:49.872117|2018-06-01 01:48:49.872117
NCT00740870|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2017-04-07||2018-04-24|2008-08-22|2008-08-25|Estimate|2017-05-31|2017-07-02|Actual||||2018-04-24|2018-04-26|Actual|January 2007|Actual|2007-01-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|May 2015|Actual|2015-05-31||Interventional||All stubjects enrolled|Melody Transcatheter Pulmonary Valve (TPV) Study: Post Approval Study of the Original Investigational Device Exemption (IDE) Cohort|Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients With Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Feasibility Study|Active, not recruiting||N/A|171|Actual|Medtronic Cardiovascular||1|||f||||f||||||||||2018-06-01 01:48:50.008571|2018-06-01 01:48:50.008571
NCT00740857|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2009-10-30||2011-06-01|2008-08-22|2008-08-25|Estimate|2010-07-15|2010-08-12|Estimate||||2011-06-01|2011-06-06|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study Comparing the Efficacy of Two Ibuprofen Formulations|A Study Comparing the Efficacy of Two Ibuprofen Formulations|Completed||Phase 4|211|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 01:48:50.370753|2018-06-01 01:48:50.370753
NCT00740844|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2012-02-13|2008-08-22|2008-08-25|Estimate|||||||2012-02-13|2012-02-14|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|CIREA1||Efficacy of Intermittent Pneumatic Compression (IPC) on Venous Thromboembolism Incidence in Intensive Care Unit (ICU) Patients With High Bleeding Risk|Evaluation of Intermittent Pneumatic Compression (IPC) of the Lower Limbs Associated With Elastic Stockings (ES) Compared to ES Alone on Venous Thromboembolism Incidence in Patients With High Bleeding Risk Hospitalized in Intensive Medical Care Units|Completed||Phase 3|408|Actual|University Hospital, Brest||2|||f||||||||||||||2018-06-01 01:48:50.867506|2018-06-01 01:48:50.867506
NCT00740831|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2012-07-26||2012-12-13|2008-08-22|2008-08-25|Estimate|2012-10-16|2012-11-16|Estimate||||2012-12-13|2012-12-17|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|PEARLII||PGL4001 Versus GnRH-agonist in Uterine Myomas|A Phase III, Randomised, Parallel Group, Double-blind, Double-dummy, Active Comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of PGL4001 vs GnRH-agonist for Pre-operative Ttt of Symptomatic Uterine Myomas|Completed||Phase 3|301|Actual|PregLem SA||3|||f||||t||||||||||2018-06-01 01:48:50.985644|2018-06-01 01:48:50.985644
NCT00740298|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2013-10-08|2008-08-21|2008-08-22|Estimate|||||||2013-10-08|2013-10-09|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Thermal Analgesia in Newborns|Thermal Analgesia in Newborns|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Chicago||2|||f||||f||||||||||2018-06-01 01:48:58.491417|2018-06-01 01:48:58.491417
NCT00740805|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2018-05-15|2008-08-22|2008-08-25|Estimate|||||||2018-05-15|2018-05-16|Actual|August 18, 2008|Actual|2008-08-18|May 2018|2018-05-31||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma|A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|90|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 01:48:51.594855|2018-06-01 01:48:51.594855
NCT00740792|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2012-05-15|2011-06-23|2012-08-07|2008-08-22|2008-08-25|Estimate|2012-08-07|2012-09-07|Estimate|2011-07-12|2011-07-14|Estimate|2012-08-07|2012-09-07|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.|Completed||Phase 3|776|Actual|Meda Pharmaceuticals||4|||f||||f||||||||||2018-06-01 01:48:51.684109|2018-06-01 01:48:51.684109
NCT00740779|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2012-01-23||2012-01-23|2008-08-22|2008-08-25|Estimate|2012-01-23|2012-02-24|Estimate||||2012-01-23|2012-02-24|Estimate|September 2008||2008-09-30|January 2012|2012-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.|A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome|Completed||Phase 2|153|Actual|Watson Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:48:52.191526|2018-06-01 01:48:52.191526
NCT00740766|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2009-06-04|2008-08-22|2008-08-25|Estimate|||||||2009-06-04|2009-06-08|Estimate|June 1998||1998-06-30|June 2009|2009-06-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Perinatal Outcomes in Nutritionally Monitored Obese Pregnant Women|Perinatal Outcomes in Nutritionally Monitored Obese Pregnant Women|Completed||N/A|257|Actual|Jamaica Hospital Medical Center||2|||f||||f||||||||||2018-06-01 01:48:52.495136|2018-06-01 01:48:52.495136
NCT00740753|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2017-11-07|2008-08-22|2008-08-25|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2004||2004-08-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|Y-90HDE||Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option|A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma|Enrolling by invitation||N/A|400|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:48:52.556898|2018-06-01 01:48:52.556898
NCT00740740|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2008-08-22|2008-08-22|2008-08-25|Estimate|||||||2008-08-22|2008-08-25|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|||Biomarkers of Aneurysm Wall Strength|Biological and Biochemical Markers of Aneurysm Wall Degradation; Towards Non-Invasive Wall Strength Analysis.|Unknown status|Recruiting||50|Anticipated|Radboud University|||3||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells, urine, tissue~   "|||2018-06-01 01:48:52.609422|2018-06-01 01:48:52.609422
NCT00740727|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2009-03-03||2009-09-10|2008-08-22|2008-08-25|Estimate|2009-09-10|2009-09-11|Estimate||||2009-09-10|2009-09-11|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||EASI Access II --- Follow-up Study to the EASI Access Trial|Enzymatically Augmented Subcutaneous Infusion (EASI) Access II Trial|Completed||Phase 1|18|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 01:48:52.756524|2018-06-01 01:48:52.756524
NCT00740714|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2012-07-24||2012-12-24|2008-08-22|2008-08-25|Estimate|2012-12-24|2013-01-31|Estimate||||2012-12-24|2013-01-31|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|QE3||Effects of Coenzyme Q10 (CoQ) in Parkinson Disease|Effects of Coenzyme Q10 in Parkinson Disease - Phase III|Terminated||Phase 3|600|Actual|Weill Medical College of Cornell University|The planned interim analysis for futility based on the first 300 subjects has reached the pre-specified termination criterion.|3||"The investigational drug is unlikely to demonstrate efficacy over placebo for this indication.~   However, no safety issues were discovered."|f||||t||||||||||2018-06-01 01:48:52.997487|2018-06-01 01:48:52.997487
NCT00740701|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2018-01-31|2008-08-22|2008-08-25|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2000||2000-04-30|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Effects of Transcranial Magnetic Stimulation to the Cerebellum on Cognition|fMRI and TMS Analysis of Cerebellar Cognitive Function|Enrolling by invitation||N/A|188|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:48:54.0418|2018-06-01 01:48:54.0418
NCT00740688|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2008-08-21|2008-08-21|2008-08-25|Estimate|||||||2008-08-21|2008-08-25|Estimate|June 2008||2008-06-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Basic and Balance: Logan Basic Technique on Bilateral Weight Balance|The Effects of Logan Basic Technique on Bilateral Weight Balance|Completed||Phase 2|75|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 01:48:54.190239|2018-06-01 01:48:54.190239
NCT00740675|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2011-01-05|2008-08-22|2008-08-25|Estimate|||||||2011-01-05|2011-01-06|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|February 2011|Anticipated|2011-02-28|August 2009|Actual|2009-08-31||Interventional|||Ambulatory Medication Reconciliation Following Hospital Discharge|"Ambulatory Medication Reconciliation Following Hospital Discharge: Project 4 From Center for Education and Research on Therapeutics (CERT) on Health Information Technology"|Unknown status|Active, not recruiting|N/A|912|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 01:48:54.240605|2018-06-01 01:48:54.240605
NCT00740662|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2012-12-19|2008-08-22|2008-08-25|Estimate|||||||2012-12-19|2012-12-20|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Intraoperative Measuring of Small Bowel Length Compared to Measuring by Magnetic Resonance Imaging (MRI) in Morbid Obese Patients|Prospective Study for the Quantification of a Compensatory Increase in Small Bowel Length After Roux-en-Y Gastric Bypass in Morbid Obese Patients by Pre- and Postoperative Length-Measuring With MRI Compared to Intraoperative Length-Measuring|Terminated|||7|Actual|University Hospital Inselspital, Berne|||1|Recruiting problems|f||||f||||||||||2018-06-01 01:48:54.307844|2018-06-01 01:48:54.307844
NCT00740649|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2009-03-30|2008-08-22|2008-08-25|Estimate|||||||2009-03-30|2009-03-31|Estimate|October 2008||2008-10-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of HSD-016|Single Ascending Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of HSD-016 Administered Orally To Healthy Japanese Male Subjects|Completed||Phase 1|74|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:48:54.394197|2018-06-01 01:48:54.394197
NCT00740636|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2015-10-20||2016-07-01|2008-08-22|2008-08-25|Estimate|2015-12-29|2016-02-01|Estimate||||2016-07-01|2016-08-01|Estimate|August 2008||2008-08-31|June 2016|2016-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer|Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer|Completed||Phase 2|92|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 01:48:54.581587|2018-06-01 01:48:54.581587
NCT00740623|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21||2013-01-15|2013-01-15|2008-08-21|2008-08-25|Estimate||||2013-01-15|2013-01-24|Estimate|2013-01-15|2013-01-24|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures.|Completed||Phase 3|547|Actual|SK Life Science||3|||f||||||||||||||2018-06-01 01:48:54.911288|2018-06-01 01:48:54.911288
NCT00740610|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21||2014-01-03|2014-01-03|2008-08-22|2008-08-25|Estimate||||2014-01-03|2014-02-04|Estimate|2014-01-03|2014-02-04|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)|A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)|Completed||Phase 2|124|Actual|Gilead Sciences||5|||f||||t||||||||||2018-06-01 01:48:54.997036|2018-06-01 01:48:54.997036
NCT00740597|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|2014-06-12||2014-06-12|2008-08-22|2008-08-25|Estimate|2014-06-12|2014-07-11|Estimate||||2014-06-12|2014-07-11|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma|Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas|Terminated||Phase 2|1|Actual|City of Hope Medical Center|Study closed 05/12/2010 (opened 7/25/2008): No patients were accrued and treated per protocol in nearly two years (2 patients were screened). The study was terminated by the IRB when the PI decided not to continue. Protocol objectives were not met.|1||No patients were enrolled on the study|f||||t||||||||||2018-06-01 01:48:55.09698|2018-06-01 01:48:55.09698
NCT00740584|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2012-04-03||2012-07-05|2008-08-21|2008-08-25|Estimate|2012-07-05|2012-08-14|Estimate||||2012-07-05|2012-08-14|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.|Assessment of Local Retention and Duration of Activity of SPL7013 Following Vaginal Application of 3% SPL7013 Gel (VivaGel) in Healthy Volunteers|Completed||Phase 1/Phase 2|12|Actual|Starpharma Pty Ltd||1|||f||||f||||||||||2018-06-01 01:48:55.225479|2018-06-01 01:48:55.225479
NCT00740571|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2009-02-04|2008-08-22|2008-08-25|Estimate|||||||2009-02-04|2009-02-05|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|Off-label||Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer|A Randomised Controlled Trial in the Palliative Setting Regarding Off-Label Medication: Investigating the Efficiency of Amitriptyline Versus Pregabalin From a Societal Perspective|Unknown status|Recruiting|Phase 3|130|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 01:48:55.340863|2018-06-01 01:48:55.340863
NCT00740558|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2008-08-26|2008-08-22|2008-08-25|Estimate|||||||2008-08-26|2008-08-27|Estimate|July 2004||2004-07-31|August 2008|2008-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Heart Rate Variability Modulation Following a Manipulation in Pain Free Patients Versus Patients in Pain|Heart Rate Variability Modulation Following a Manipulation in Pain Free Patients Versus Patients in Pain|Completed||N/A|53|Actual|Universite du Quebec a Montreal||2|||f||||t||||||||||2018-06-01 01:48:55.421094|2018-06-01 01:48:55.421094
NCT00740545|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2015-03-04|2008-08-22|2008-08-25|Estimate|||||||2015-03-04|2015-03-05|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|PREFIX||Prevention of Unexplained Recurrent Abortion by Enoxaparine|Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées|Terminated||Phase 3|258|Actual|University Hospital, Brest||2||Stopped for futility|f||||t||||||||||2018-06-01 01:48:55.486234|2018-06-01 01:48:55.486234
NCT00740532|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2010-09-01|2008-08-22|2008-08-25|Estimate|||||||2010-09-01|2010-09-02|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|March 2008|Actual|2008-03-31||Observational|||Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients|Observational Study Assessing Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients|Completed|||11|Actual|Istituto Clinico Humanitas|||1||f||||f||||||Samples With DNA|"~     Paraffine embedded tumor sections~   "|||2018-06-01 01:48:55.549603|2018-06-01 01:48:55.549603
NCT00740519|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-02-02|2008-08-22|2008-08-25|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2008||2008-09-30|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|SOLVE™||Observational Study on Safety of Self-titration of Once Daily Levemir®|Evaluation on Safety of Self-titration in Insulin naïve People With Type 2 Diabetes Treated With Levemir® (Insulin Detemir) and Oral Antidiabetic Agents|Completed|||882|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:48:56.494192|2018-06-01 01:48:56.494192
NCT00740506|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2017-06-30|2008-08-22|2008-08-25|Estimate|||||||2017-06-30|2017-07-02|Actual|August 20, 2008||2008-08-20|July 13, 2009|2009-07-13|July 13, 2009|Actual|2009-07-13|July 13, 2009|Actual|2009-07-13||Interventional|||Behavioral and Environmetal Factors and Time to Delivery|Behavioral and Environmental Factors and Time to Delivery|Completed||Phase 4|510||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:48:56.615511|2018-06-01 01:48:56.615511
NCT00740493|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2017-01-11|2008-08-22|2008-08-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2007||2007-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|PADIS TVP||Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)|"Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Proximal Deep Vein Thrombosis: a Multicentre Double-Blind Randomized Controlled Trial. PADIS-TVP Study."|Completed||Phase 3|104|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-06-01 01:48:56.680276|2018-06-01 01:48:56.680276
NCT00740480|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2009-07-15||2009-08-20|2008-08-22|2008-08-25|Estimate|2009-07-15|2009-08-21|Estimate||||2009-08-20|2009-08-25|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Study of the ENTact Septal Staple System for Tissue Approximation During Septoplasty|A Prospective, Non-Randomized, Limited-Use Evaluation of the ENTact Septal Staple System for Tissue Approximation During Septoplasties|Completed|||25|Actual|ENTrigue Surgical, Inc.|||1||f||||f||||||||||2018-06-01 01:48:56.785297|2018-06-01 01:48:56.785297
NCT00740467|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2010-01-27|2008-08-22|2008-08-25|Estimate|||||||2010-01-27|2010-01-28|Estimate|January 2008||2008-01-31|July 2009|2009-07-31||||January 2010|Anticipated|2010-01-31||Interventional|||Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders|Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation|Unknown status|Recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:48:56.930372|2018-06-01 01:48:56.930372
NCT00740454|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2010-12-27|2008-08-22|2008-08-25|Estimate|||||||2010-12-27|2010-12-28|Estimate|January 2006||2006-01-31|December 2010|2010-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|EDVIGE||Single Complete Compression Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy and Postpartum|Diagnostic Exclusion Value of a Negative Single Distal and Proximal Lower Limb Veins Compression Ultrasonography in Pregnant and Post-partum Women With a Clinically Suspected Deep Vein Thrombosis|Completed|||200|Anticipated|University Hospital, Brest|||1||f||||f||||||||||2018-06-01 01:48:57.024859|2018-06-01 01:48:57.024859
NCT00740441|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2009-09-24|2008-08-22|2008-08-25|Estimate|||||||2009-09-24|2009-09-25|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|September 2009|Anticipated|2009-09-30||Interventional|||A Phase II Study of AS1411 in Renal Cell Carcinoma|A Phase II, Open Label, Single Arm Study of AS1411 in Patients With Metastatic Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Antisoma Research||1|||||||f||||||||||2018-06-01 01:48:57.202552|2018-06-01 01:48:57.202552
NCT00740428|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2009-12-04|2008-08-22|2008-08-25|Estimate|||||||2009-12-04|2009-12-07|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction|The Effectiveness of Pelvic Floor Exercises During Gestation in the Prevention of Urinary Incontinence and Pelvic Floor Muscle Dysfunction.|Completed||Phase 2/Phase 3|48|Anticipated|UPECLIN HC FM Botucatu Unesp||1|||f||||f||||||||||2018-06-01 01:48:57.292455|2018-06-01 01:48:57.292455
NCT00740415|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2016-03-15|2008-08-22|2008-08-25|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|May 2011|Actual|2011-05-31||Interventional|ManteauRiBVD||Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma|First-line Treatment of Mantle Cell Lymphoma of Old Patients . Evaluate the Efficacy, Toxicity, and Molecular Prognostic Factors of Velcade®) in Association With Chemotherapy and Immunotherapy With Rituximab|Completed||Phase 2|39|Actual|French Innovative Leukemia Organisation||1|||f||||t||||||||No||2018-06-01 01:48:57.569946|2018-06-01 01:48:57.569946
NCT00740402|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-22|||2010-04-15|2008-08-22|2008-08-25|Estimate|||||||2010-04-15|2010-04-16|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Observational|||Motor Learning of a Planning Task in Stroke Patients: the Maze Paradigm Measured Through Time and Error as Variables|Motor Learning of a Planning Task in Stroke Patients|Completed|||20|Actual|Faculdades Metropolitanas Unidas|||||f||||t||||||None Retained|"~     no biospecimens are to be retained~   "|||2018-06-01 01:48:57.733304|2018-06-01 01:48:57.733304
NCT00740389|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2011-06-08|2008-08-22|2008-08-25|Estimate|||||||2011-06-08|2011-06-09|Estimate|September 2008||2008-09-30|April 2010|2010-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.|A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.|Completed||Phase 1|18|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:48:57.859349|2018-06-01 01:48:57.859349
NCT00740376|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2017-01-06|2008-08-21|2008-08-25|Estimate|||||||2017-01-06|2017-01-09|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MBK||Uniglide™ Mobile Bearing Unicondylar Knee System vs the Uniglide™ Fixed Bearing Unicondylar Knee System|A Prospective, Comparative, Randomized, Double Blind, Multi-center Study of the Uniglide™ Mobile Bearing Unicondylar Knee System vs. Uniglide™ Fixed Bearing Unicondylar Knee System|Terminated||Phase 3|47|Actual|Corin||2||enrollment closed|f||||t||||||||||2018-06-01 01:48:57.952015|2018-06-01 01:48:57.952015
NCT00740363|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2012-09-21|2008-08-22|2008-08-25|Estimate|||||||2012-09-21|2012-09-25|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Sitagliptin in Renal Transplant Recipients|The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08|Completed||Phase 4|25|Actual|University of Oslo School of Pharmacy||2|||f||||f||||||||||2018-06-01 01:48:58.062|2018-06-01 01:48:58.062
NCT00740350|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2008-08-22|2008-08-22|2008-08-25|Estimate|||||||2008-08-22|2008-08-25|Estimate|March 2007||2007-03-31|August 2008|2008-08-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Logan Basic During Pregnancy on Labor and Childbirth|Does the Logan Basic Protocol for Chiropractic Care During Pregnancy Reduce Labor Time and Increase the Ease of Labor and Childbirth?|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 01:48:58.174789|2018-06-01 01:48:58.174789
NCT00740337|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2012-09-14|2008-08-20|2008-08-22|Estimate|||||||2012-09-14|2012-09-17|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Factors That Affect the Development of COPD Symptoms|Specialized Center of Clinically Oriented Research: Alveolar and Airway Mechanisms of COPD. Airway Determinants: Innate Immune Signaling (Project 4)|Unknown status|Enrolling by invitation||82|Actual|Washington University School of Medicine|||2||f||||t||||||Samples With DNA|"~     Plasma, serum, isolated RNA and DNA, lung tissue~   "|||2018-06-01 01:48:58.28117|2018-06-01 01:48:58.28117
NCT00740324|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2010-11-08|2008-08-21|2008-08-22|Estimate|||||||2010-11-08|2010-11-09|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men|Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men During Endoscopy|Completed||Phase 3|30|Anticipated|Nihon Pharmaceutical Co., Ltd||3|||f||||t||||||||||2018-06-01 01:48:58.354029|2018-06-01 01:48:58.354029
NCT00740311|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2010-06-01|2008-08-21|2008-08-22|Estimate|||||||2010-06-01|2010-06-02|Estimate|November 2007||2007-11-30|June 2010|2010-06-30|May 2011|Anticipated|2011-05-31|November 2010|Anticipated|2010-11-30||Interventional|||Filling of Tooth Sockets With MBCP Gel TM Versus Technical Without Filling|Comparative Clinical Study of the Prevention of the Reduction of Alveolar Crest by Alveoli Filling With an Injectable Calcium Phosphate After Extraction of Mandibular Molar or Pre Molar|Unknown status|Recruiting|N/A|||Nantes University Hospital||2|||f||||||||||||||2018-06-01 01:48:58.419136|2018-06-01 01:48:58.419136
NCT00740259|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-20|2008-08-20|2008-08-22|Estimate|||||||2008-08-20|2008-08-22|Estimate|September 2004||2004-09-30|August 2008|2008-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol|Is Flunarizine a Cheap, Well-Tolerated and Long-Acting Atypical Antipsychotic? A Randomized Double-Blind Flexible-Dose Clinical Trial Versus Haloperidol for the Treatment of Schizophrenia|Completed||Phase 4|70|Actual|Ambulatório de Bipolaridade|||||f||||f||||||||||2018-06-01 01:48:58.755968|2018-06-01 01:48:58.755968
NCT00740246|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2008-08-21|2008-08-21|2008-08-22|Estimate|||||||2008-08-21|2008-08-22|Estimate|June 2005||2005-06-30|August 2008|2008-08-31||||||||Interventional|||Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia|A Multi-Center, Randomized, Blinded, Placebo Controlled, Cross-Over Study to Investigate the Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia|Completed||Phase 3|||Luitpold Pharmaceuticals|||||||||f||||||||||2018-06-01 01:48:58.867522|2018-06-01 01:48:58.867522
NCT00740233|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2014-03-26|2008-08-20|2008-08-22|Estimate|||||||2014-03-26|2014-03-27|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|PROCAIM||Web-Based Survey of Pain, Stress and Complementary and Alternative Medicine||Completed|||2300|Actual|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 01:48:59.013097|2018-06-01 01:48:59.013097
NCT00740220|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2009-02-13||2017-11-06|2008-08-20|2008-08-22|Estimate|2009-03-13|2009-04-20|Estimate||||2017-11-06|2017-12-15|Actual|September 2006||2006-09-30|April 2016|2016-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|6MWT||Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation|Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation|Completed|||97|Actual|Wake Forest University Health Sciences|Study was conducted in a Pulmonary Rehabilitation Population and may not be generalizable.||1||f||||f||||||||Undecided|Data could only be shared if requestor had IRB approval and funding to re-contact all participants for permission.|2018-06-01 01:48:59.099529|2018-06-01 01:48:59.099529
NCT00740207|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2010-09-13||2011-05-05|2008-08-21|2008-08-22|Estimate|2011-03-15|2011-04-18|Estimate||||2011-05-05|2011-05-09|Estimate|September 2008||2008-09-30|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA|A Phase IV Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral Digital Subtraction Angiography (DSA)|Completed||Phase 4|33|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-06-01 01:48:59.294073|2018-06-01 01:48:59.294073
NCT00740194|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2011-08-29|2008-08-21|2008-08-22|Estimate|||||||2011-08-29|2011-08-30|Estimate|August 2008||2008-08-31|August 2011|2011-08-31|August 2010|Actual|2010-08-31|December 2008|Actual|2008-12-31||Interventional|||Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men|Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men.|Completed||Phase 1/Phase 2|20|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:48:59.777698|2018-06-01 01:48:59.777698
NCT00740181|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2013-05-14||2014-07-27|2008-08-21|2008-08-22|Estimate|2013-05-14|2013-07-02|Estimate||||2014-07-27|2014-08-01|Estimate|August 2008||2008-08-31|July 2014|2014-07-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Decitabine, Cytarabine, GCSF for Refractory AML/MDS|A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-morbidities.|Terminated||Phase 2|9|Actual|Brown University||1||Lack of efficacy|f||||t||||||||||2018-06-01 01:48:59.892009|2018-06-01 01:48:59.892009
NCT00740168|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2016-01-20|2008-08-20|2008-08-22|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2007||2007-05-31|January 2016|2016-01-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Observational|BevaRet||Bevacizumab Treatment and Retinal Vessel Monitoring|Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy|Completed|||20|Actual|Technische Universität Dresden|||1||f||||f||||||||||2018-06-01 01:49:00.13934|2018-06-01 01:49:00.13934
NCT00740155|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2015-03-02|2008-08-21|2008-08-22|Estimate|||||||2015-03-02|2015-03-03|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults|Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years|Completed||Phase 2|154|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 01:49:00.320002|2018-06-01 01:49:00.320002
NCT00740142|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2009-06-25|2008-08-21|2008-08-22|Estimate|||||||2009-06-25|2009-06-26|Estimate|September 2008||2008-09-30|December 2008|2008-12-31|August 2010|Anticipated|2010-08-31|May 2010|Anticipated|2010-05-31||Interventional|||Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy|Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy|Unknown status|Recruiting|Phase 4|34|Anticipated|Mahidol University||2|||f||||t||||||||||2018-06-01 01:49:00.40643|2018-06-01 01:49:00.40643
NCT00740129|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2016-11-15|2008-08-21|2008-08-22|Estimate|||||||2016-11-15|2016-11-16|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Re-treatment of Patients With Paget's Disease Using Zoledronic Acid|An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies|Completed||Phase 4|6|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:49:00.531319|2018-06-01 01:49:00.531319
NCT00740116|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2012-06-26|2008-08-21|2008-08-22|Estimate|||||||2012-06-26|2012-06-28|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Tranexamic Acid in Surgery of Advanced Ovarian Cancer|Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study|Completed||Phase 4|100|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-06-01 01:49:00.64705|2018-06-01 01:49:00.64705
NCT00740103|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2012-08-22|2008-08-21|2008-08-22|Estimate|||||||2012-08-22|2012-08-23|Estimate|December 2002||2002-12-31|August 2012|2012-08-31|September 2004|Actual|2004-09-30|July 2004|Actual|2004-07-31||Interventional|CD05||Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease|Long-term Study of Semapimod (CNI-1493) for Treatment of Moderate to Severe Crohn's Disease With Reference to Study CNI-1493-CD-04, 1 or 3 Days' Treatment vs. Placebo|Completed||Phase 2|119|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:49:00.753641|2018-06-01 01:49:00.753641
NCT00740090|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2017-06-30|2008-08-21|2008-08-22|Estimate|||||||2017-06-30|2017-07-02|Actual|August 11, 2008||2008-08-11|June 9, 2009|2009-06-09||||June 9, 2009|Actual|2009-06-09||Interventional|||Malaria Vaccine for Children in Mali|Phase 1, Randomized, Double-Blind, Dose-Escalating Study of the Safety, Reactogenicity, and Immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Children in Mali|Completed||Phase 1|200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:49:00.867426|2018-06-01 01:49:00.867426
NCT00740077|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2009-02-06|2008-08-20|2008-08-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2008||2008-08-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Bioavailability of Flavonoids and Phenolic Acids From Cranberry Juice Cocktail in Healthy Older Adults|Bioavailability of Flavonoids and Phenolic Acids From Cranberry Juice Cocktail in Healthy Older Adults|Completed||N/A|10|Actual|Tufts University|||||f||||t||||||||||2018-06-01 01:49:01.049412|2018-06-01 01:49:01.049412
NCT00740064|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2009-01-27|2008-08-21|2008-08-22|Estimate|||||||2009-01-27|2009-01-28|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|November 2009|Anticipated|2009-11-30|August 2009|Anticipated|2009-08-31||Interventional|SHIELD||Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects|A Pilot Study of Highly Active Antiretroviral Therapy Using Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Antiretroviral Naive HIV-Infected Subjects|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Denver Infectious Disease Consultants, PLLC|||||f||||t||||||||||2018-06-01 01:49:01.290778|2018-06-01 01:49:01.290778
NCT00740051|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2011-08-03||2014-06-17|2008-08-21|2008-08-22|Estimate|2011-09-19|2011-10-26|Estimate||||2014-06-17|2014-06-27|Estimate|August 2008||2008-08-31|December 2013|2013-12-31||||August 2010|Actual|2010-08-31||Interventional||Number of participants and other baseline values taken from interim analysis.|A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate|A Randomised, db, Placebo-controlled, Parallel Group Efficacy and Safety Study of BI 1356 (5mg), Administered Orally Once Daily for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients With Insufficient Glycaemic Control for Whom Metformin Therapy is Inappropriate (Intolerability or Contraindication)|Completed||Phase 3|227|Actual|Boehringer Ingelheim|Primary analysis (at interim) was rerun using final study database|3|||f||||||||||||||2018-06-01 01:49:01.426205|2018-06-01 01:49:01.426205
NCT00740038|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2017-02-20|2008-08-21|2008-08-22|Estimate|||||||2017-02-20|2017-02-23|Actual|August 2006||2006-08-31|August 2011|2011-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Support for People Undergoing Chemotherapy|Study of Stress Management and Exercise Intervention During Cancer Chemotherapy|Completed||N/A|471|Actual|H. Lee Moffitt Cancer Center and Research Institute||4|||f||||f||||||||||2018-06-01 01:49:02.261765|2018-06-01 01:49:02.261765
NCT00740025|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2010-10-12|2008-08-21|2008-08-22|Estimate|||||||2010-10-12|2010-10-14|Estimate|January 2006||2006-01-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|QD vs BID||Once Daily vs Twice Daily Administration of Gonadotropins in Assisted Reproductive Technologies (ART)|A Prospective Randomized Study of QD vs BID Dosing in ART|Completed|||200|Anticipated|Virginia Center for Reproductive Medicine|||2||f||||f||||||||||2018-06-01 01:49:02.388003|2018-06-01 01:49:02.388003
NCT00740012|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-09-25|2008-08-21|2008-08-22|Estimate|||||||2008-09-25|2008-09-29|Estimate|March 2007||2007-03-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)|Blutzucker-Nachtprofile Mit Wecker Und Selbstmessungen gegenüber Fremdmessungen Durch Spezialisiertes Pflegepersonal: Eine Analyse Mittels Kontinuierlichem Glukose-Monitoring (Glucoday®)|Completed||N/A|32|Anticipated|Diabeteszentrum Bad Lauterberg im Harz||4|||f||||f||||||||||2018-06-01 01:49:02.475189|2018-06-01 01:49:02.475189
NCT00739999|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2010-03-15||2010-08-19|2008-08-21|2008-08-22|Estimate|2010-08-19|2010-08-20|Estimate||||2010-08-19|2010-08-20|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia|A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia|Completed||Phase 1|39|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:49:02.683003|2018-06-01 01:49:02.683003
NCT00739986|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2012-08-22|2008-08-21|2008-08-22|Estimate|||||||2012-08-22|2012-08-23|Estimate|October 2002||2002-10-31|August 2012|2012-08-31|August 2004|Actual|2004-08-31|June 2004|Actual|2004-06-30||Interventional|CD04||Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo|A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment vs. Placebo|Completed||Phase 2|152|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:49:03.761101|2018-06-01 01:49:03.761101
NCT00739973|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2011-01-13||2011-06-02|2008-08-21|2008-08-22|Estimate|2011-03-31|2011-05-03|Estimate||||2011-06-02|2011-06-06|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension|An 8-week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Amlodipine in Patients With Essential Hypertension|Completed||Phase 3|2694|Actual|Novartis||9|||f||||f||||||||||2018-06-01 01:49:03.928072|2018-06-01 01:49:03.928072
NCT00739960|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2013-06-10|2008-08-20|2008-08-22|Estimate|||||||2013-06-10|2013-06-11|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|STAR||Safety Study of Abatacept to Treat Refractory Sarcoidosis|Sarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive Sarcoidosis|Terminated||Phase 2|1|Actual|University of Chicago||1||Funding has been pulled|f||||t||||||||||2018-06-01 01:49:05.441126|2018-06-01 01:49:05.441126
NCT00739947|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2014-07-25|2008-08-21|2008-08-22|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Arthroscopic Surgical Outcome Study In Subjects With Rotator Cuff Tears|A Prospective Study To Evaluate Surgical Outcomes In Subjects With Full-Thickness Rotator Cuff Tears Treated By Means Of A Double-Row Arthroscopic Repair|Completed|||162|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:49:05.535021|2018-06-01 01:49:05.535021
NCT00739934|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2010-09-17||2011-01-26|2008-08-21|2008-08-22|Estimate|2011-01-06|2011-01-25|Estimate||||2011-01-26|2011-01-28|Estimate|December 2008||2008-12-31|January 2011|2011-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection|An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Children Aged 2 To <12 Years Who Are At High Risk For Systemic Fungal Infection|Completed||Phase 2|40|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:49:05.701278|2018-06-01 01:49:05.701278
NCT00739921|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2014-06-30|2008-08-20|2008-08-22|Estimate|||||||2014-06-30|2014-07-01|Estimate|June 2006||2006-06-30|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA|PCR Analysis of Nasal Polyps for Fungal DNA|Unknown status|Recruiting|N/A|260|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:49:06.447162|2018-06-01 01:49:06.447162
NCT00739908|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2012-02-14||2012-06-26|2008-08-21|2008-08-22|Estimate|2012-06-26|2012-06-27|Estimate||||2012-06-26|2012-06-27|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|CX157-200||A Study of CX157 (TriRima) for the Treatment of Depression|A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder|Completed||Phase 2|285|Actual|CeNeRx BioPharma Inc.|Subjects were asked to take 6 capsules 3 times a day for 6 weeks. Non-adherence with the study medication was high based on the population PK data. This likely contributed to the results in CX157 treatment group.|2|||f||||t||||||||||2018-06-01 01:49:06.532087|2018-06-01 01:49:06.532087
NCT00739895|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2011-10-02|2008-08-21|2008-08-22|Estimate|||||||2011-10-02|2011-10-04|Estimate|June 2007||2007-06-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Assessment of Cardiac Involvement of Common Cold in High Performing Athletes by Cardiac Magnetic Resonance Imaging (MRI)|Left Ventricular Dilatation in Athletes With Common Colds; a Cardio-vascular MRI Study|Terminated|||100|Anticipated|University of Calgary|||1||f||||t||||||||||2018-06-01 01:49:07.144007|2018-06-01 01:49:07.144007
NCT00739882|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2010-06-28||2014-01-26|2008-08-21|2008-08-22|Estimate|2010-08-04|2010-08-30|Estimate||||2014-01-26|2014-02-27|Estimate|April 2008||2008-04-30|January 2014|2014-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TRUST||TRUST Study: Raptiva ® in Hand & Foot Psoriasis|A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva ® in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Involving Hands and/or Feet, With or Without Pustules.|Terminated||Phase 4|76|Actual|Merck KGaA|Following the recommendation of the European Medicines Agency (EMEA) to suspend the marketing authorization of Raptiva® and the subsequent premature termination of this trial analysis of efficacy-related endpoints was not performed|2||"The study was terminated after the European Medicines Agency recommended to suspend the~   marketing authorisation of Raptiva in the European Union"|f||||||||||||||2018-06-01 01:49:07.241839|2018-06-01 01:49:07.241839
NCT00739869|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2015-10-16|2008-08-20|2008-08-22|Estimate|||||||2015-10-16|2015-10-19|Estimate|May 2004||2004-05-31|October 2015|2015-10-31|March 2007|Actual|2007-03-31|April 2006|Actual|2006-04-30||Observational|WHIMS-MRI||Evaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study)|Effects of Hormone Therapy on Subclinical Neurological Pathology-The WHIMS-MRI Collaborative Study|Completed|||1426|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||1||f||||t||||||||||2018-06-01 01:49:08.059036|2018-06-01 01:49:08.059036
NCT00739856|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-21|2008-08-21|2008-08-22|Estimate|||||||2008-08-21|2008-08-22|Estimate|January 2005||2005-01-31|August 2008|2008-08-31||||December 2005|Actual|2005-12-31||Interventional|||Use of Electroconvulsive Therapy (ECT) in Chronic, Severe, Treatment Resistant Posttraumatic Stress Disorder|Efficacy of ECT in Chronic, Severe, Antidepressant- And CBT-Refractory Posttraumatic Stress Disorder: An Open, Prospective Study|Completed||N/A|20|Actual|Government Medical College Srinagar|||||f||||f||||||||||2018-06-01 01:49:08.356153|2018-06-01 01:49:08.356153
NCT00739843|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2016-10-31|2008-08-21|2008-08-22|Estimate|||||||2016-10-31|2016-11-01|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients|Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients|Terminated|||55|Actual|University of Chicago|||||f||||t||||||||||2018-06-01 01:49:08.443905|2018-06-01 01:49:08.443905
NCT00739830|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2015-06-30|2008-08-20|2008-08-22|Estimate|||||||2015-06-30|2015-07-01|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|July 2012|Actual|2012-07-31|February 2011|Actual|2011-02-28||Interventional|||Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)|A Randomized Phase II Trial of Ridaforolimus (AP23573; MK-8669) Compared to Progestin or Chemotherapy in Female Adult Patients With Advanced Endometrial Carcinoma|Completed||Phase 2|130|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:49:08.569484|2018-06-01 01:49:08.569484
NCT00739817|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2009-08-15|2008-08-21|2008-08-22|Estimate|||||||2009-08-15|2009-08-18|Estimate|July 2010||2010-07-31|August 2009|2009-08-31||||||||Observational|||Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide|Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide|Unknown status|Not yet recruiting||6000|Anticipated|Ziv Hospital|||||f||||||||||||||2018-06-01 01:49:08.693704|2018-06-01 01:49:08.693704
NCT00739791|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2012-09-12|2008-08-21|2008-08-22|Estimate|||||||2012-09-12|2012-09-14|Estimate|September 2003||2003-09-30|September 2012|2012-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer|Pilot Trial of Gene Expression Modulation by Intervention With Nutrition and Lifestyle|Completed||N/A|34|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 01:49:08.776486|2018-06-01 01:49:08.776486
NCT00739778|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-12-16|2008-08-21|2008-08-22|Estimate|||||||2008-12-16|2008-12-18|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of a Novel Sweetener on the pH of Dental Plaque.|Effect of a Novel Sweetener on the pH of Dental Plaque.|Completed||Phase 2|24|Anticipated|Cargill|||||f||||f||||||||||2018-06-01 01:49:08.860729|2018-06-01 01:49:08.860729
NCT00739765|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2015-09-08||2017-07-13|2008-08-20|2008-08-22|Estimate|2015-10-13|2015-11-16|Estimate||||2017-07-13|2017-08-21|Actual|April 2008||2008-04-30|July 2017|2017-07-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|||Effectiveness of Three Different Psychotherapies for Chronic Post-Traumatic Stress Disorder|Psychotherapies for Chronic Post-Traumatic Stress Disorder|Completed||Phase 3|110|Actual|New York State Psychiatric Institute|Limited generalizability of unmedicated sample; incomplete therapist fidelity rating; limited sample size.|3|||f||||t||||||||No||2018-06-01 01:49:09.031515|2018-06-01 01:49:09.031515
NCT00739752|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2017-04-06||2017-09-15|2008-08-21|2008-08-22|Estimate|2017-09-15|2017-10-16|Actual||||2017-09-15|2017-10-16|Actual|June 2003||2003-06-30|September 2017|2017-09-30|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics|Interventions to Increase HBV Vaccinations in STD Clinics|Completed||N/A|1747|Actual|Indiana University||6|||f||||t|f|f||||||No||2018-06-01 01:49:09.700149|2018-06-01 01:49:09.700149
NCT00736671|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2016-03-02|2008-08-15|2008-08-18|Estimate|||||||2016-03-02|2016-03-04|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Observational|||Striatal and Extra-striatal Mechanisms of Falling in Parkinson's Disease|Striatal and Extra-striatal Mechanisms of Falling in Parkinson's Disease|Completed|||88|Actual|University of Michigan|||2||f||||f||||||||No||2018-06-01 01:49:58.437988|2018-06-01 01:49:58.437988
NCT00739739|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20||2011-03-16|2011-03-16|2008-08-20|2008-08-22|Estimate||||2011-03-16|2011-03-28|Estimate|2011-03-16|2011-03-28|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis|A Phase 2, 12 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Proof Of Concept Study Evaluating The Efficacy And Safety Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis/Painful Bladder Syndrome.|Completed||Phase 2|161|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:49:10.518308|2018-06-01 01:49:10.518308
NCT00739713|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2018-03-19|2008-08-21|2008-08-22|Estimate|||||||2018-03-19|2018-03-20|Actual|September 2008|Actual|2008-09-30|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|DESB||Effects of Sea Buckthorn Oil on Dry Eye|Effects of Sea Buckthorn Oil on Dry Eye|Completed||N/A|100|Actual|University of Turku||2|||f||||f||||||||||2018-06-01 01:49:10.692184|2018-06-01 01:49:10.692184
NCT00739700|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2017-11-06|2008-08-20|2008-08-22|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2007|Actual|2007-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2009|Actual|2009-12-31||Observational|NIBP vs IABP||Non-invasive Blood Pressure (BP) Monitoring Compared to A-Line BP Monitoring|Accuracy and Precision of Oscillometric Blood Pressure Monitoring in the Arm, Calf and Thighs of Medical ICU Patients When Compared to Invasive Arterial Blood Pressure Monitoring|Completed|||116|Actual|Wake Forest University Health Sciences|||1||f||||f||||||||Yes|A requestor must have local IRB approval and funding to support a request of this data. It will be provided de-identified and shared authorship is required.|2018-06-01 01:49:10.815683|2018-06-01 01:49:10.815683
NCT00739687|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2009-01-29|2008-08-21|2008-08-22|Estimate|||||||2009-01-29|2009-01-30|Estimate|August 2008||2008-08-31|January 2009|2009-01-31|October 2009|Anticipated|2009-10-31|August 2009|Anticipated|2009-08-31||Interventional|BENEFICIAL||Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure|A Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure|Terminated||Phase 2|100|Anticipated|Synvista Therapeutics, Inc||2||Study has been termination early due to financial constraints.|f||||f||||||||||2018-06-01 01:49:10.874663|2018-06-01 01:49:10.874663
NCT00739674|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2010-07-14||2017-03-31|2008-08-21|2008-08-22|Estimate|2010-07-14|2010-08-11|Estimate||||2017-03-31|2017-05-05|Actual|February 1, 2008|Actual|2008-02-01|March 2017|2017-03-31|January 1, 2010|Actual|2010-01-01|July 1, 2009|Actual|2009-07-01||Interventional|||SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)|Randomized Open-label Trial to Evaluate the Effectiveness of Diet Management With a Losartan Titration Regimen Versus Losartan Titration Regimen Alone on Blood Pressure Reduction in Hypertensives.|Completed||Phase 3|992|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:49:10.971673|2018-06-01 01:49:10.971673
NCT00739661|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2012-02-10||2017-05-15|2008-08-21|2008-08-22|Estimate|2012-04-02|2012-04-26|Estimate||||2017-05-15|2017-06-08|Actual|December 2008|Actual|2008-12-31|May 2017|2017-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission|Completed||Phase 2|104|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 01:49:12.224332|2018-06-01 01:49:12.224332
NCT00739648|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2011-09-04||2018-01-17|2008-08-21|2008-08-22|Estimate|2012-01-31|2012-03-02|Estimate||||2018-01-17|2018-01-19|Actual|October 2008||2008-10-31|January 2018|2018-01-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients|Completed||Phase 2|322|Actual|Horizon Pharma USA, Inc.||2|||f||||t||||||||||2018-06-01 01:49:12.893471|2018-06-01 01:49:12.893471
NCT00739635|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|||2016-02-03|2008-08-21|2008-08-22|Estimate|||||||2016-02-03|2016-02-04|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|EASE||Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus|A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus|Completed||Phase 3|411|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 01:49:13.494542|2018-06-01 01:49:13.494542
NCT00739622|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2010-04-26|2008-08-21|2008-08-22|Estimate|||||||2010-04-26|2010-04-28|Estimate|July 2008||2008-07-31|April 2010|2010-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.|A Phase I, Open-label Drug-drug Interaction Trial to Investigate the Effect of TMC278 25 mg q.d. on the Steady State Pharmacokinetics of Ethinylestradiol and Norethindrone, in Healthy Women|Completed||Phase 1|18|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:49:13.623443|2018-06-01 01:49:13.623443
NCT00739609|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2015-05-29|2008-08-21|2008-08-22|Estimate|||||||2015-05-29|2015-06-01|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|D-1MT||IDO Inhibitor Study for Relapsed or Refractory Solid Tumors|A Phase I Study of Indoximod [1-methyl-D-tryptophan (D-1MT)] in Patients With Relapsed or Refractory Solid Tumors|Terminated||Phase 1|17|Actual|NewLink Genetics Corporation||1||Lack of enrollment.|f||||t||||||||||2018-06-01 01:49:13.67443|2018-06-01 01:49:13.67443
NCT00739596|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-21|2010-12-14||2016-09-20|2008-08-21|2008-08-22|Estimate|2010-12-14|2011-01-12|Estimate||||2016-09-20|2016-10-27|Estimate|July 2008||2008-07-31|February 2011|2011-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|ATLAAST||Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans|An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension|Completed||Phase 4|332|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:49:13.752208|2018-06-01 01:49:13.752208
NCT00739583|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2010-03-09||2013-06-05|2008-08-20|2008-08-21|Estimate|2013-06-05|2013-07-10|Estimate||||2013-06-05|2013-07-10|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|site marking||Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions|Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions|Completed||Phase 4|20|Actual|Johns Hopkins University|"Non-standardization of the amount of ink used to mark each site.~The use of only one type of marking pen.~No measurement of the amount of pressure use to apply the skin cleaning solutions.~Potential subjectivity of surgeons viewing initials"|2|||f||||f||||||||||2018-06-01 01:49:14.049481|2018-06-01 01:49:14.049481
NCT00739570|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-22|2008-08-20|2008-08-21|Estimate|||||||2008-08-22|2008-08-25|Estimate|June 2008||2008-06-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||The Effect of Manipulations of the Lumbar Spine on Six Different Outcome Measures|The Effect of Manipulations of the Lumbar Spine on Six Different Outcome Measures.|Completed||N/A|20|Actual|Universite du Quebec a Montreal||2|||f||||f||||||||||2018-06-01 01:49:14.323603|2018-06-01 01:49:14.323603
NCT00739557|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2015-12-03|2008-08-20|2008-08-21|Estimate|||||||2015-12-03|2015-12-07|Estimate|August 2008||2008-08-31|December 2015|2015-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||A Pilot Study to Evaluate the Systemic Inflammatory Response of Thoracoabdominal Aortic Aneurysm Repair.|A Pilot Study to Evaluate the Systemic Inflammatory Response of Thoracoabdominal Aortic Aneurysm Repair.|Withdrawn|||0|Actual|The University of Texas Health Science Center, Houston||||Investigator left the institution, another PI has not been named.|f||||f||||||Samples Without DNA|"~     Blood and saliva samples will be obtained for the purposes of this study and will be~     maintained until complete analysis of the samples for all patients is complete.~   "|||2018-06-01 01:49:14.381424|2018-06-01 01:49:14.381424
NCT00739544|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-20|2008-08-20|2008-08-21|Estimate|||||||2008-08-20|2008-08-21|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Chronic Pain After Operation for Breast Cancer|Examination of Healthy Female Subjects in the Project: Disposing Factors for Chronic Pain After Operation for Breast Cancer|Unknown status|Enrolling by invitation|Early Phase 1|20|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-06-01 01:49:14.429332|2018-06-01 01:49:14.429332
NCT00739531|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-08-20|2008-08-20|2008-08-21|Estimate|||||||2008-08-20|2008-08-21|Estimate|October 2007||2007-10-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Measuring Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System|Measuring the Fractional Concentration of Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System|Completed|||150|Anticipated|Apieron|||1||f||||f||||||||||2018-06-01 01:49:14.489947|2018-06-01 01:49:14.489947
NCT00739518|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2018-05-02|2008-08-20|2008-08-21|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2004||2004-10-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams|Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies|Enrolling by invitation||N/A|500|Anticipated|University of Michigan||1|||f||||f||||||||No||2018-06-01 01:49:14.559557|2018-06-01 01:49:14.559557
NCT00739505|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2014-05-27|2008-08-20|2008-08-21|Estimate|||||||2014-05-27|2014-05-29|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)|A Multicenter, Open-Label, Dose Escalating Study of the Safety, Tolerability and Pharmacology of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)|Completed||Phase 1|6|Actual|Alexion Pharma GmbH||2|||f||||t||||||||||2018-06-01 01:49:14.642513|2018-06-01 01:49:14.642513
NCT00739492|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2016-12-05|2008-08-20|2008-08-21|Estimate|||||||2016-12-05|2016-12-06|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||Testing Strategies for Weight Loss, II||Completed||Phase 1/Phase 2|66|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 01:49:14.735218|2018-06-01 01:49:14.735218
NCT00739479|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2012-10-25|2008-08-19|2008-08-21|Estimate|||||||2012-10-25|2012-10-29|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||CCRC: Effects of Partially Hydrolyzed Whey Peptides (PHWP) On Weight Loss In Individuals With The Metabolic Syndrome (METS)|CCRC: Effects of Partially Hydrolyzed Whey Peptides (PHWP) On Weight Loss In Individuals With The Metabolic Syndrome (METS)|Completed||N/A|35|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 01:49:15.720078|2018-06-01 01:49:15.720078
NCT00739466|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2016-01-17|2008-08-20|2008-08-21|Estimate|||||||2016-01-17|2016-01-20|Estimate|September 2008||2008-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|BLAST||Biorest Liposomal Alendronate With Stenting sTudy (BLAST)|Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation|Completed||Phase 2|226|Actual|BIOrest Ltd.||3|||f||||f||||||||||2018-06-01 01:49:15.79273|2018-06-01 01:49:15.79273
NCT00739453|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2011-12-21|2008-08-19|2008-08-21|Estimate|||||||2011-12-21|2011-12-22|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)|A Phase I Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) in Patients With Advanced Solid Tumors|Completed||Phase 1|95|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 01:49:15.892664|2018-06-01 01:49:15.892664
NCT00739440|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2013-08-06|2008-08-20|2008-08-21|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Randomized Controlled Trial to Compare Two Anti-scorpion Serums|Randomized Controlled Trial to Evaluate Efficiency and Safety of the Polyvalent Antiscorpion Serum of Birmex Versus Other Commercial Serum|Completed||Phase 4|120|Actual|Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.||2|||f||||f||||||||||2018-06-01 01:49:16.000746|2018-06-01 01:49:16.000746
NCT00739414|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2014-04-16|2008-08-20|2008-08-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|July 2008||2008-07-31|March 2010|2010-03-31||||November 2009|Actual|2009-11-30||Interventional|||Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors|A Phase IA, Dose-escalating Study of LBH589 Administered Intravenously in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|14|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:49:16.080505|2018-06-01 01:49:16.080505
NCT00739401|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19||2011-09-17|2011-09-29|2008-08-19|2008-08-21|Estimate||||2011-09-29|2011-10-05|Estimate|2011-09-29|2011-10-05|Estimate|May 2006||2006-05-31|September 2011|2011-09-30|July 2013|Anticipated|2013-07-31|July 2008|Actual|2008-07-31||Interventional|||Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm|Endologix Powerlink® Suprarenal Proximal Cuff|Unknown status|Active, not recruiting|Phase 2|44|Actual|Endologix||1|||f||||t||||||||||2018-06-01 01:49:16.148133|2018-06-01 01:49:16.148133
NCT00739388|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2013-04-09|2008-08-20|2008-08-21|Estimate|||||||2013-04-09|2013-04-10|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|January 2010|Actual|2010-01-31||Interventional|||Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy|5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial.|Completed||Phase 2|47|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-06-01 01:49:16.323798|2018-06-01 01:49:16.323798
NCT00739375|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2013-12-12|2008-08-20|2008-08-21|Estimate|||||||2013-12-12|2013-12-13|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.|The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.|Completed||Phase 1|50|Actual|Shaare Zedek Medical Center|||||f||||f||||||||||2018-06-01 01:49:16.468841|2018-06-01 01:49:16.468841
NCT00739362|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2018-05-24|2008-08-20|2008-08-21|Estimate|||||||2018-05-24|2018-05-25|Actual|August 4, 2008||2008-08-04|May 15, 2018|2018-05-15|January 30, 2021|Anticipated|2021-01-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment|The Effects of Transcranial Direct Current Stimulation (TDCS) on Food Intake and Weight Loss|Recruiting||Phase 2|148|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 01:49:16.536249|2018-06-01 01:49:16.536249
NCT00739349|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20||2015-04-29|2016-05-26|2008-08-20|2008-08-21|Estimate||||2015-04-29|2015-05-18|Estimate|2016-05-26|2016-06-06|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye|A Phase II, Multi-Center, Double-Masked, Randomized Study of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions Compared to Vehicle for the Treatment of the Signs and Symptoms of Dry Eye|Completed||Phase 2|132|Actual|Santen SAS||3|||f||||t||||||||||2018-06-01 01:49:16.631215|2018-06-01 01:49:16.631215
NCT00739336|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2015-06-01||2016-08-11|2008-08-20|2008-08-21|Estimate|2016-08-11|2016-10-05|Estimate||||2016-08-11|2016-10-05|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Diabetes Prevention and Control in the Workplace: A Pilot Study|Diabetes Prevention and Control in the Workplace: A Pilot Study|Completed||N/A|45|Actual|State University of New York - Upstate Medical University||2|||f||||f||||||||||2018-06-01 01:49:16.723643|2018-06-01 01:49:16.723643
NCT00739323|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-02-27|2008-08-19|2008-08-21|Estimate|||||||2017-02-27|2017-03-01|Actual|December 2006||2006-12-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|EPC||Impaired Wound Healing in Diabetic Foot Ulceration|Impaired Wound Healing in Diabetic Foot Ulceration|Completed|||137|Actual|Beth Israel Deaconess Medical Center|||||f||||t||||||||||2018-06-01 01:49:16.979168|2018-06-01 01:49:16.979168
NCT00739310|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2015-04-20||2017-07-07|2008-08-20|2008-08-21|Estimate|2015-08-24|2015-09-24|Estimate||||2017-07-07|2017-08-07|Actual|August 2008||2008-08-31|July 2017|2017-07-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional||Patients who completed 12 months of prospective therapy|Study Assessing High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations|A Pilot Study to Assess the Efficacy and Effectiveness of High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations in Children With Muscle Weakness and Restrictive Lung Disease CR-0088|Completed||N/A|29|Actual|Hill-Rom|Study design was sub-optimal due to lack of control group and lack of randomization|1|||f||||f||||||||||2018-06-01 01:49:17.049273|2018-06-01 01:49:17.049273
NCT00739297|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2010-01-14||2017-03-10|2008-08-19|2008-08-21|Estimate|2010-03-25|2010-04-09|Estimate||||2017-03-10|2017-04-10|Actual|July 2008||2008-07-31|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)|A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK0476 in Patients With Chronic Asthma|Completed||Phase 1|68|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:49:17.241222|2018-06-01 01:49:17.241222
NCT00739284|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-20|2008-08-20|2008-08-21|Estimate|||||||2008-08-20|2008-08-21|Estimate|August 2008||2008-08-31|August 2008|2008-08-31||||August 2008|Anticipated|2008-08-31||Interventional|JJVsPCN08||A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney||Unknown status|Recruiting|N/A|60|Anticipated|Rabin Medical Center|||||f||||t||||||||||2018-06-01 01:49:17.759815|2018-06-01 01:49:17.759815
NCT00739271|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-21|2008-08-20|2008-08-21|Estimate|||||||2008-08-21|2008-08-22|Estimate|October 2005||2005-10-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|March 2007|Actual|2007-03-31||Interventional|||Early Enteral Feeding After Intestinal Anastomosis|Early Enteral Feeding After Intestinal Anastomosis|Completed||N/A|82|Actual|Christian Medical College and Hospital, Ludhiana, India||2|||f||||f||||||||||2018-06-01 01:49:17.889477|2018-06-01 01:49:17.889477
NCT00739258|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2012-01-20|2008-08-20|2008-08-21|Estimate|||||||2012-01-20|2012-01-23|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison|Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison and Set up the Notional Halfway Home in Union Area of Medical Facility|Completed|||700|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||3||f||||f||||||||||2018-06-01 01:49:17.969805|2018-06-01 01:49:17.969805
NCT00739245|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-08-20|2008-08-20|2008-08-21|Estimate|||||||2008-08-20|2008-08-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:49:18.067335|2018-06-01 01:49:18.067335
NCT00739232|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2009-07-31|2008-08-20|2008-08-21|Estimate|||||||2009-07-31|2009-08-03|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016|Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HSD-016 Administered Orally to Healthy Subjects|Completed||Phase 1|74|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:49:18.122785|2018-06-01 01:49:18.122785
NCT00739219|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2009-01-19|2008-08-20|2008-08-21|Estimate|||||||2009-01-19|2009-01-21|Estimate|December 2006||2006-12-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|Outcomes||Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO)|Management of Asthma Patients Guided by Exhaled Nitric Oxide (eNO) Using the Apieron NO Analyzer|Terminated||Phase 4|260|Actual|Apieron||2||Study terminated due to lack of care guidelines in the protocol.|f||||f||||||||||2018-06-01 01:49:18.259309|2018-06-01 01:49:18.259309
NCT00739206|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2010-06-15|2008-08-20|2008-08-21|Estimate|||||||2010-06-15|2010-06-16|Estimate|August 2008||2008-08-31|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.|A Multicenter, Open Label, Efficacy and Safety Study of Parenteral SAR97276A in the Treatment of Symptomatic Uncomplicated and Severe Malaria in Adults and Children|Terminated||Phase 2|113|Actual|Sanofi||3||"In accordance with protocol's predefined criteria and Data Monitoring Committee recommendation~   due to insufficient level of efficacy"|f||||t||||||||||2018-06-01 01:49:18.343521|2018-06-01 01:49:18.343521
NCT00739193|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2017-09-07|2008-08-20|2008-08-21|Estimate|||||||2017-09-07|2017-09-11|Actual|August 2008||2008-08-31|September 2017|2017-09-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure|A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure|Withdrawn||Phase 2|0|Actual|Baxter Healthcare Corporation||3|||f||||f||||||||||2018-06-01 01:49:18.438181|2018-06-01 01:49:18.438181
NCT00739180|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2012-11-02|2008-08-20|2008-08-21|Estimate|||||||2012-11-02|2012-11-06|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes|Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes|Completed||N/A|45|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 01:49:18.524346|2018-06-01 01:49:18.524346
NCT00739167|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2015-10-14|2008-08-20|2008-08-21|Estimate|||||||2015-10-14|2015-10-16|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer|A Quality of Life Study for Patients With Primary or Metastatic Liver Cancer Who Are Treated With Radioembolization (Y90 Microspheres) or Transcatheter Arterial Embolization (TACE)|Completed|||74|Actual|Northwestern University|||3||f||||t||||||||||2018-06-01 01:49:18.598577|2018-06-01 01:49:18.598577
NCT00739154|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-08-20|2008-08-20|2008-08-21|Estimate|||||||2008-08-20|2008-08-21|Estimate|November 2008||2008-11-30|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Observational|||Protective Effect of Phenytoin on Glaucoma|Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma|Unknown status|Not yet recruiting||200|Anticipated|Rabin Medical Center|||3||f||||f||||||||||2018-06-01 01:49:18.677948|2018-06-01 01:49:18.677948
NCT00739141|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-09-06|2008-08-19|2008-08-21|Estimate|||||||2017-09-06|2017-09-07|Actual|August 2008||2008-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.|A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.|Recruiting||Phase 2|80|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:49:18.758537|2018-06-01 01:49:18.758537
NCT00739128|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2011-04-14|2008-08-20|2008-08-21|Estimate|||||||2011-04-14|2011-04-15|Estimate|February 2009||2009-02-28|April 2011|2011-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Response to Hepatitis B Vaccine in Celiac Disease Patients|Intradermal Immunization Against Hepatitis B Virus in Celiac Disease- a Randomized Controlled Trial|Terminated||N/A|210|Anticipated|Shaare Zedek Medical Center||2||"Believed that a better study was to compare the response to engerix B vs Sci-B-Vac vaccine in~   this patient group."|f||||f||||||||||2018-06-01 01:49:18.851636|2018-06-01 01:49:18.851636
NCT00739115|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2015-08-25|2008-08-20|2008-08-21|Estimate|||||||2015-08-25|2015-08-26|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study|The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study|Completed||N/A|13|Actual|Hawaii Pacific Health||2|||f||||t||||||||||2018-06-01 01:49:19.009678|2018-06-01 01:49:19.009678
NCT00739102|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2013-07-08|2009-11-11|2014-03-28|2008-08-20|2008-08-21|Estimate|2013-09-17|2013-09-18|Estimate|2009-11-11|2009-11-16|Estimate|2014-03-28|2014-04-17|Estimate|August 2008||2008-08-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|May 2011|Actual|2011-05-31||Interventional|STROLL|Modified Intent-To-Treat (ITT) Population|S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease|S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease (STROLL)|Completed||N/A|250|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 01:49:19.100281|2018-06-01 01:49:19.100281
NCT00739089|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2017-11-06|2008-08-20|2008-08-21|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2008||2008-08-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Presep and Vascath Interaction Study|A Pilot Study to Compare the Interaction Between Central Venous Mixed Venous Oxygen Saturation Catheters and Central Venous Hemodialysis Catheters|Withdrawn|||0|Actual|Wake Forest University Health Sciences||||Study stopped due to a lack of enrollment.|f||||f||||||||Yes|de-identified data would have been shared with any other investigator with a local IRB approved protocol to evaluate de-identified patient data|2018-06-01 01:49:19.487104|2018-06-01 01:49:19.487104
NCT00739076|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2015-04-01|2008-08-20|2008-08-21|Estimate|||||||2015-04-01|2015-04-03|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|VRHTrauma||Pain Control After Trauma|Pain Control After Trauma|Completed||N/A|184|Actual|University of Washington||3|||f||||f||||||||||2018-06-01 01:49:19.64887|2018-06-01 01:49:19.64887
NCT00739063|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2011-12-21||2012-02-10|2008-08-19|2008-08-21|Estimate|2012-02-10|2012-03-15|Estimate||||2012-02-10|2012-03-15|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer|Study of Erlotinib, Small Molecule Targeting Epidermal Growth Factor Receptor (EGFR) in Treatment of Patients w/EGFR-overexpressing 'Triple Receptor-negative' Metastatic Carcinoma of Breast That Progressed on Anthracyclines and Taxanes|Terminated||Phase 2|11|Actual|M.D. Anderson Cancer Center||1||Poor Accrual|f||||f||||||||||2018-06-01 01:49:19.753423|2018-06-01 01:49:19.753423
NCT00739050|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2010-08-26||2017-03-31|2008-08-19|2008-08-21|Estimate|2010-11-16|2010-12-16|Estimate||||2017-03-31|2017-05-05|Actual|September 19, 2007|Actual|2007-09-19|March 2017|2017-03-31|February 1, 2008|Actual|2008-02-01|February 1, 2008|Actual|2008-02-01||Interventional|||Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)|Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus|Terminated||Phase 4|4|Actual|Merck Sharp & Dohme Corp.|The Investigator was not able to recruit the required patients and was not able to get the necessary equipment. The protocol was terminated for Administrative Reasons.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:49:19.992057|2018-06-01 01:49:19.992057
NCT00734708|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2012-06-14|2008-08-13|2008-08-14|Estimate|||||||2012-06-14|2012-06-15|Estimate|August 2008||2008-08-31|June 2012|2012-06-30||||March 2010|Actual|2010-03-31||Interventional|||Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)||Completed||Phase 3|328|Actual|Kaken Pharmaceutical||2|||f||||f||||||||||2018-06-01 01:50:33.915321|2018-06-01 01:50:33.915321
NCT00739037|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2009-08-03|2008-08-19|2008-08-21|Estimate|||||||2009-08-03|2009-08-04|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease|A Randomized, Single Dose, Placebo-Controlled, 2 Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAZ 417 in Cerebrospinal Fluid, When Administered Orally to Subjects With Alzheimer's Disease|Terminated||Phase 1|10|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:49:20.241121|2018-06-01 01:49:20.241121
NCT00739024|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2011-07-22||2012-08-22|2008-08-20|2008-08-21|Estimate|2012-08-22|2012-08-23|Estimate||||2012-08-22|2012-08-23|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|September 2010|Actual|2010-09-30|April 2009|Actual|2009-04-30||Interventional|||A Study of a Melatonin Receptor Agonist to Prevent Migraine|A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine|Terminated||Phase 2|18|Actual|Swedish Medical Center|Early termination leading to small numbers of subjects analyzed|2||Recruitment slow and administrative reasons|f||||f||||||||||2018-06-01 01:49:20.341453|2018-06-01 01:49:20.341453
NCT00739011|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-12-07|2008-08-19|2008-08-21|Estimate|||||||2008-12-07|2008-12-09|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Validation of HC250 and HC240 Series.|Validation of Customer Requirements for the HC244/HC254|Completed||N/A|40|Anticipated|Fisher and Paykel Healthcare||1|||f||||f||||||||||2018-06-01 01:49:20.6162|2018-06-01 01:49:20.6162
NCT00738998|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2018-02-05|2008-08-19|2008-08-21|Estimate|||||||2018-02-05|2018-02-07|Actual|June 2008|Actual|2008-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors|Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors|Active, not recruiting||N/A|102|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-06-01 01:49:20.686183|2018-06-01 01:49:20.686183
NCT00738985|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2015-03-23|2008-08-20|2008-08-21|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors|Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Patients With Mixed Hyperlipidemia and Two or More Risk Factors to Cardiovascular Disease.|Withdrawn||Phase 4|0|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2||The study was cancelled due to budget limitations|f||||f||||||||||2018-06-01 01:49:20.766483|2018-06-01 01:49:20.766483
NCT00738972|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2013-07-20|2011-08-16|2013-08-17|2008-08-19|2008-08-21|Estimate|2013-07-20|2013-08-13|Estimate|2011-08-16|2011-08-23|Estimate|2013-08-17|2013-08-26|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)|Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.|Terminated||Phase 3|12|Actual|Fundación Lindavista del Corazón AC|This study was terminated early and due to sample size it was not possible to perform further statistical analyses.|4||"Study terminated early due to sample size, not possible to perform further statistical~   analysis."|f||||||||||||||2018-06-01 01:49:20.8461|2018-06-01 01:49:20.8461
NCT00738959|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2008-10-28|2008-08-20|2008-08-21|Estimate|||||||2008-10-28|2008-10-29|Estimate|June 2008||2008-06-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety, Tolerability & PK of AZD0328 in Caucasian & Japanese|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0328 in Healthy Young Japanese and Caucasian Male Volunteers After Oral Single and Multiple Ascending Doses|Completed||Phase 1|64|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:49:21.079794|2018-06-01 01:49:21.079794
NCT00738946|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2010-06-03|2008-08-20|2008-08-21|Estimate|||||||2010-06-03|2010-06-04|Estimate|August 2008||2008-08-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|IPTc/ITNs||A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children|A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children|Completed||N/A|6000|Anticipated|London School of Hygiene and Tropical Medicine||1|||f||||t||||||||||2018-06-01 01:49:21.142028|2018-06-01 01:49:21.142028
NCT00738933|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2011-02-11|2008-08-20|2008-08-21|Estimate|||||||2011-02-11|2011-02-14|Estimate|April 2008||2008-04-30|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Dietary Phytosterols and Human Aortic Valve|Effects of Dietary Plant Sterols and Stanols on Sterol Composition and Structure of the Human Aortic Valve|Unknown status|Recruiting|N/A|60|Anticipated|Helsinki University||3|||f||||f||||||||||2018-06-01 01:49:21.222852|2018-06-01 01:49:21.222852
NCT00738920|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-10-03|2008-08-19|2008-08-21|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2010||2010-08-31|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Interventional|||Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome|Self Administered CBT for IBS: A Multisite Trial|Completed||Phase 2/Phase 3|462|Actual|State University of New York at Buffalo||3|||f||||t||||||||Undecided||2018-06-01 01:49:21.343834|2018-06-01 01:49:21.343834
NCT00738907|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2014-09-23|2008-08-19|2008-08-21|Estimate|||||||2014-09-23|2014-09-25|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Observational|||Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes.|Assessment of Beta Cell Mass by PET Scans With [11C] DTBZ in Longstanding Type 1 Diabetes|Completed|||18|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 01:49:21.445645|2018-06-01 01:49:21.445645
NCT00738894|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-08-15|2008-08-20|2008-08-21|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2008||2008-08-31|August 2017|2017-08-31|February 2020|Anticipated|2020-02-29|April 24, 2017|Actual|2017-04-24||Interventional|HLX 06-03||GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study|GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients With Patent Foramen Ovale (PFO)|Active, not recruiting||N/A|664|Anticipated|W.L.Gore & Associates||2|||f||||t||||||||||2018-06-01 01:49:21.517081|2018-06-01 01:49:21.517081
NCT00738543|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2009-07-17||2013-06-18|2008-08-19|2008-08-20|Estimate|2010-07-21|2010-08-17|Estimate||||2013-06-18|2013-06-24|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Povidone-iodine Against Sodium Hypochlorite as Skin Antiseptics|Comparative Study of 10% Povidone-iodine Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers.|Completed||Phase 3|48|Actual|Universidad de Guanajuato||1|||f||||f||||||||||2018-06-01 01:49:26.023863|2018-06-01 01:49:26.023863
NCT00738881|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|2013-11-27||2015-10-06|2008-08-20|2008-08-21|Estimate|2014-09-26|2014-10-02|Estimate||||2015-10-06|2015-10-29|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31||Interventional|MARVEL||Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer|MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib|Terminated||Phase 3|23|Actual|National Cancer Institute (NCI)||2||Slow accrual|f||||||||||||||2018-06-01 01:49:21.644685|2018-06-01 01:49:21.644685
NCT00738868|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2011-05-12|2008-08-20|2008-08-21|Estimate|||||||2011-05-12|2011-05-13|Estimate|October 2007||2007-10-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery|Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck|Completed||Phase 2|45|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:49:22.38901|2018-06-01 01:49:22.38901
NCT00738855|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-11-25|2008-08-20|2008-08-21|Estimate|||||||2008-11-25|2008-11-26|Estimate|February 2006||2006-02-28|August 2008|2008-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO)|Clinical Impacts of Oral Gastrografin Follow Through in Adhesive Small Bowel Obstruction (SBO).|Completed||N/A|100|Actual|Mansoura University||2|||f||||t||||||||||2018-06-01 01:49:22.458187|2018-06-01 01:49:22.458187
NCT00738842|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2010-12-02|2008-08-20|2008-08-21|Estimate|||||||2010-12-02|2010-12-03|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Uric Acid Study in Healthy Male Volunteers|A Randomised, Double-Blind, Two-Period Crossover Study to Assess the Effect of AZD6140 on Uric Acid Levels in Healthy Male Volunteers|Completed||Phase 1|24|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:49:22.558096|2018-06-01 01:49:22.558096
NCT00738829|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2013-08-29|2008-08-20|2008-08-21|Estimate|||||||2013-08-29|2013-08-30|Estimate|October 2008||2008-10-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL|Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Concomitant Evaluation of Safety and Efficacy.|Completed||Phase 1/Phase 2|45|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||t||||||||||2018-06-01 01:49:22.633239|2018-06-01 01:49:22.633239
NCT00738816|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-20|||2010-12-13|2008-08-20|2008-08-21|Estimate|||||||2010-12-13|2010-12-14|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Effect of Systematic Medication Review in Elderly Patients Admitted to an Orthopedic Department|The Effect of Systematic Medication Review in Elderly Patients Admitted to an Orthopedic Department.|Completed||N/A|108|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 01:49:22.72861|2018-06-01 01:49:22.72861
NCT00738803|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2009-02-05|2008-08-19|2008-08-20|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|April 2010|Anticipated|2010-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Restoration of Leg Length, Offset, and Center of Rotation in Total Hip Replacement|Restoration of Leg Length, Offset, and Center of Rotation in Total Hip Replacement|Unknown status|Recruiting|N/A|100|Anticipated|Tennessee Orthopedic Alliance||1|||f||||f||||||||||2018-06-01 01:49:22.802003|2018-06-01 01:49:22.802003
NCT00738790|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2010-04-14|2008-08-19|2008-08-20|Estimate|||||||2010-04-14|2010-04-15|Estimate|November 2003||2003-11-30|April 2010|2010-04-30|November 2013|Anticipated|2013-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Preoperative Radiotherapy and Local Excision in Rectal Cancer|The Randomised Study of Preoperative Radiotherapy and Local Excision for Radiosensitive Rectal Cancer|Unknown status|Recruiting|Phase 3|102|Anticipated|Polish Colorectal Cancer Study Group||2|||f||||t||||||||||2018-06-01 01:49:22.89198|2018-06-01 01:49:22.89198
NCT00738777|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-09-13|2008-08-19|2008-08-20|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2008|Actual|2008-07-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer|A Randomized, Prospective Trial of 2-6 Weeks Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-study).|Recruiting||Phase 2|250|Anticipated|The Netherlands Cancer Institute||4|||f||||f||||||||||2018-06-01 01:49:22.979568|2018-06-01 01:49:22.979568
NCT00738764|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-01-05|2008-08-19|2008-08-20|Estimate|||||||2012-01-05|2012-01-06|Estimate|July 2008||2008-07-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Trial of PDL192 in Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors|Completed||Phase 1|30|Actual|Abbott||6|||f||||f||||||||||2018-06-01 01:49:23.099854|2018-06-01 01:49:23.099854
NCT00738751|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2015-02-03|2008-08-18|2008-08-20|Estimate|||||||2015-02-03|2015-02-04|Estimate|November 2008||2008-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|August 2013|Actual|2013-08-31||Interventional|||Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers|Phase I Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)|Completed||Phase 1|44|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 01:49:23.17008|2018-06-01 01:49:23.17008
NCT00738738|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2012-11-30|2008-08-18|2008-08-20|Estimate|||||||2012-11-30|2012-12-03|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)|A Phase 3, 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder|Withdrawn||Phase 3|0|Actual|Pfizer||||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 01:49:23.248321|2018-06-01 01:49:23.248321
NCT00738725|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2015-01-26|2008-08-19|2008-08-20|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population|A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population Combining Targeted and Unsupervised Biological Measurements With Non-Invasive Imaging Modalities to Identify Biomarkers That Predict Near Term (1-3-years) Outcomes|Completed|||7687|Actual|BG Medicine, Inc|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, RNA and DNA~   "|||2018-06-01 01:49:23.31334|2018-06-01 01:49:23.31334
NCT00737022|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2008-08-14|2008-08-14|2008-08-18|Estimate|||||||2008-08-14|2008-08-18|Estimate|May 2005||2005-05-31|July 2006|2006-07-31|December 2006|Actual|2006-12-31|July 2006|Actual|2006-07-31||Observational|||Macular Appearance After Diabetic Vitrectomy|Macular Appearance After Diabetic Vitrectomy for Fibrovascular Proliferation -An Optical Coherence Tomography Study|Completed|||108|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:49:51.252338|2018-06-01 01:49:51.252338
NCT00738712|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-12-19|2008-08-19|2008-08-20|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2, 2011|Actual|2011-05-02|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies for Vascular, Abdominal, and Pelvic Exams|Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies for Vascular, Abdominal, and Pelvic Exams|Active, not recruiting||N/A|20|Anticipated|University of Michigan||1|||f||||t|f|f||||||No||2018-06-01 01:49:23.382169|2018-06-01 01:49:23.382169
NCT00738699|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2016-12-13|2013-11-18|2017-02-10|2008-08-18|2008-08-20|Estimate|2017-02-10|2017-03-30|Actual|2013-11-18|2013-12-12|Estimate|2017-02-10|2017-03-30|Actual|September 2008||2008-09-30|February 2017|2017-02-28|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|FAR-122|Intent-to-Treat population included, the primary population for the evaluation of efficacy, was defined as all participant who were randomly assigned to test article, analyzed by the treatment assigned.|An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer|A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety oF MORAb-003(Farletuzumab) in Combination With Paclitaxel Therapy in Subjects With Platinum-Resistant or Refractory Relapsed Ovarian Cancer|Terminated||Phase 2|415|Actual|Morphotek|This study was prematurely terminated by the sponsor following results of the preplanned futility analysis showing the study was unlikely to meet its statistically-defined coprimary endpoints.|2||study did not meet pre-specified criteria for continuation following interim futility analysis|f||||t||||||||||2018-06-01 01:49:23.483538|2018-06-01 01:49:23.483538
NCT00738686|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-08-20|2008-08-19|2008-08-20|Estimate|||||||2008-08-20|2008-08-21|Estimate|June 2004||2004-06-30|August 2008|2008-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|AUTAX||Austrian Multivessel Taxus-Stent Registry|Austrian Multivessel Taxus-Stent Registry|Completed||Phase 4|441|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 01:49:24.451653|2018-06-01 01:49:24.451653
NCT00738673|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2012-12-12||2012-12-12|2008-08-19|2008-08-20|Estimate|2012-12-12|2013-01-18|Estimate||||2012-12-12|2013-01-18|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer|An Open-Label, Multi-Centre, Uncontrolled, Exploratory Trial Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment After PSA-Failure in GnRH Agonist Treated Patients With Prostate Cancer|Completed||Phase 2|37|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:49:24.595545|2018-06-01 01:49:24.595545
NCT00738660|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2008-08-19|2008-08-19|2008-08-20|Estimate|||||||2008-08-19|2008-08-20|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|START1DM||Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy|Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy|Completed||Phase 3|30|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||f||||||||||2018-06-01 01:49:25.241519|2018-06-01 01:49:25.241519
NCT00738647|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2011-11-04|2008-08-19|2008-08-20|Estimate|||||||2011-11-04|2011-11-07|Estimate|May 2007||2007-05-31|November 2011|2011-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Assessment of a New Resin-based Composite Filling Material|Assessment of a New Resin-based Composite Restorative Material|Active, not recruiting||N/A|72|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 01:49:25.308365|2018-06-01 01:49:25.308365
NCT00738634|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-07-18|2008-08-18|2008-08-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|IN2SHAPE||IN2SHAPE: A Study of Physical Activity and Depressive Symptoms in Adolescence|IN2SHAPE Intervention to Stay Healthy and Physical Everyday: A Randomised Controlled Trial for the Feasibility and Effectiveness of a Self-motivated Physical Activity Intervention on the Mental Health of Adolescents.|Completed||N/A|26|Actual|Australian National University||3|||f||||||||||||||2018-06-01 01:49:25.363943|2018-06-01 01:49:25.363943
NCT00738621|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2013-12-18|2008-08-19|2008-08-20|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2008||2008-07-31|August 2008|2008-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients|A Comparison of Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients|Completed||Phase 4|100|Actual|Scott and White Hospital & Clinic||2|||f||||t||||||||||2018-06-01 01:49:25.4472|2018-06-01 01:49:25.4472
NCT00738608|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2009-09-17|2008-08-18|2008-08-20|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Observational|||Etoricoxib as a Pre-emptive Analgesic in Therapeutic Arthroscopy|Etoricoxib as a Pre-emptive Analgesic in Therapeutic Arthroscopy|Completed|||66|Anticipated|Marienkrankenhaus Soest|||2||f||||f||||||||||2018-06-01 01:49:25.541655|2018-06-01 01:49:25.541655
NCT00738595|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2009-05-28|2008-08-19|2008-08-20|Estimate|||||||2009-05-28|2009-05-29|Estimate|August 2008||2008-08-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.|Phase II Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation, Effect on it Own and in Combination With Open Label Nicotine Replacement Therapy.|Completed||Phase 2|400|Anticipated|Evotec Neurosciences GmbH||4|||f||||f||||||||||2018-06-01 01:49:25.644321|2018-06-01 01:49:25.644321
NCT00738582|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19||2013-11-18|2015-11-13|2008-08-19|2008-08-20|Estimate||||2013-11-18|2013-12-12|Estimate|2015-11-13|2015-12-11|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|June 2011|Actual|2011-06-30||Interventional|Amatuximab||An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma|An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma|Completed||Phase 2|89|Actual|Morphotek||1|||f||||t||||||||||2018-06-01 01:49:25.796395|2018-06-01 01:49:25.796395
NCT00738569|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-03-27|2008-08-19|2008-08-20|Estimate|||||||2017-03-27|2017-03-29|Actual|July 2008|Actual|2008-07-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen|A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen|Completed||N/A|30|Actual|National Jewish Health||1|||f||||f||||||||Undecided||2018-06-01 01:49:25.89044|2018-06-01 01:49:25.89044
NCT00738556|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2009-01-28|2008-08-19|2008-08-20|Estimate|||||||2009-01-28|2009-01-29|Estimate|January 2003||2003-01-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Spot Drug-Eluting Stenting for Long Coronary Stenoses|Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study|Completed||N/A|179|Actual|Cardiovascular Research Society, Greece||2|||f||||t||||||||||2018-06-01 01:49:25.95024|2018-06-01 01:49:25.95024
NCT00738530|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2016-03-22||2016-05-16|2008-08-19|2008-08-20|Estimate|2016-05-16|2016-06-23|Estimate||||2016-05-16|2016-06-23|Estimate|June 2004||2004-06-30|May 2016|2016-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Intent-to-treat population (ITT) included all participants randomized into the study.|A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy|A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma|Completed||Phase 3|649|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:49:27.148388|2018-06-01 01:49:27.148388
NCT00738517|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2016-05-10|2008-08-18|2008-08-20|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||Immunoadsorption and Immunoglobulin Substitution for Heart Failure After Myocardial Infarction|Immunoadsorption With Subsequent Immunoglobulin Substitution for Patients With Heart Failure After Myocardial Infarction|Withdrawn||Phase 1/Phase 2|0|Actual|University Medicine Greifswald||2||PI left center|f||||f||||||||||2018-06-01 01:49:28.131424|2018-06-01 01:49:28.131424
NCT00738504|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2008-08-19|2008-08-19|2008-08-20|Estimate|||||||2008-08-19|2008-08-20|Estimate|June 2008||2008-06-30|August 2008|2008-08-31||||||||Observational|||Intensive Insulin Therapy and Acute Kidney Injury. Analysis Using RIFLE Criteria.|INTENSIVE INSULIN THERAPY REALLY REDUCES THE INCIDENCE OF ACUTE KIDNEY INJURY IN CRITICALLY ILL PATIENTS? An Analysis Using the RIFLE Criteria for Definition of Acute Kidney Injury.|Completed|||337||Hospital Sao Domingos|||4||f||||t||||||||||2018-06-01 01:49:28.214876|2018-06-01 01:49:28.214876
NCT00738491|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2014-12-01|2008-08-19|2008-08-20|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Effects of Ambient Air Pollution Exposure in Patients With Stable Angina Pectoris During Normal Daily Activities|Effects of Ambient Air Pollution Exposure in Patients With Stable Angina Pectoris During Normal Daily Activities|Terminated|||1|Actual|University of Edinburgh|||2|Study performed in alternative location (Beijing China)|f||||f||||||Samples Without DNA|"~     Plasma samples Serum samples~   "|||2018-06-01 01:49:28.274768|2018-06-01 01:49:28.274768
NCT00738478|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2009-02-17|2008-08-19|2008-08-20|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Quality of Life After Routine Nasogastric Decompression After Distal Gastrectomy for Gastric Cancer Patients|Phase III Study for the Significance of Nasogastric Decompression Tube After Curative Distal Gastrectomy for Gastric Cancer Patients|Completed||Phase 3|180|Actual|Wakayama Medical University||2|||f||||t||||||||||2018-06-01 01:49:28.343099|2018-06-01 01:49:28.343099
NCT00738452|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2018-02-09|2008-08-19|2008-08-20|Estimate|||||||2018-02-09|2018-02-13|Actual|August 6, 2008||2008-08-06|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy|A Phase I Trial of Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66) After Completion of Radiation Therapy Alone, or Radiation Therapy Plus Systemic Therapy in Unresectable or Medically Inoperable, Non-metastatic CEA-Producing Stage I-IIIB Non-Small Cell Lung Cancer|Completed||Phase 1|10|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:49:28.405512|2018-06-01 01:49:28.405512
NCT00738439|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2017-10-10|2008-08-19|2008-08-20|Estimate|||||||2017-10-10|2017-10-11|Actual|October 2008||2008-10-31|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|PON||Prospective, Multi-Center Adult Spinal Deformity Outcomes Database Registry|Prospective, Multi-Center Adult Spinal Deformity Outcomes Database Registry|Enrolling by invitation|||936|Anticipated|International Spine Study Group Foundation|||2||f||||f||||||||||2018-06-01 01:49:28.573821|2018-06-01 01:49:28.573821
NCT00738426|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2014-02-25||2014-04-01|2008-08-19|2008-08-20|Estimate|2014-04-01|2014-05-02|Estimate||||2014-04-01|2014-05-02|Estimate|October 2007||2007-10-31|April 2014|2014-04-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Study of Low Level Laser Therapy for Body Contouring|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Body Contouring of the Waist, Hips and Thighs Clinical Study Protocol|Completed||N/A|72|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-06-01 01:49:28.657862|2018-06-01 01:49:28.657862
NCT00738413|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2010-11-04|2008-08-19|2008-08-20|Estimate|||||||2010-11-04|2010-11-05|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both|An Iron Balance Study Comparing Deferasirox, Deferoxamine and the Combination of Both Drugs|Unknown status|Recruiting|Phase 1/Phase 2|6|Anticipated|Weill Medical College of Cornell University||3|||f||||t||||||||||2018-06-01 01:49:28.886244|2018-06-01 01:49:28.886244
NCT00738400|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2010-11-26||2015-11-12|2008-08-19|2008-08-20|Estimate|2011-04-29|2011-06-01|Estimate||||2015-11-12|2015-11-16|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome|Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC)|Completed||Phase 4|150|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:49:28.995798|2018-06-01 01:49:28.995798
NCT00738387|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19||2012-05-01|2015-12-29|2008-08-19|2008-08-20|Estimate||||2012-05-01|2012-05-03|Estimate|2015-12-29|2016-02-02|Estimate|December 2008||2008-12-31|May 2012|2012-05-31||||December 2010|Actual|2010-12-31||Interventional|ATTRACT-2||A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer|A Phase III, Randomized, Double-blind, Placebo-controlled Multi-center Study of ASA404 in Combination With Docetaxel in Second-line Treatment of Patients With Locally Advanced or Metastatic (Stage IIIb/IV) Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|900|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:49:29.352787|2018-06-01 01:49:29.352787
NCT00738374|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2014-12-19||2017-07-06|2008-08-19|2008-08-20|Estimate|2015-02-12|2015-02-16|Estimate||||2017-07-06|2017-08-15|Actual|November 3, 2008|Actual|2008-11-03|June 2017|2017-06-30|January 14, 2013|Actual|2013-01-14|January 14, 2013|Actual|2013-01-14||Interventional||All enrolled participants.|A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.|A Study of Chlorambucil Plus MabThera as Induction Therapy Followed in Responders by Maintenance Therapy Versus Observation on Response Rate in Patients >=60 Years With Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 2|97|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:49:29.757219|2018-06-01 01:49:29.757219
NCT00738361|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2015-10-28||2016-01-14|2008-08-19|2008-08-20|Estimate|2016-01-14|2016-02-12|Estimate||||2016-01-14|2016-02-12|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|April 2013|Actual|2013-04-30|July 2012|Actual|2012-07-31||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery|A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma|Completed||Phase 2|4|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:49:30.63276|2018-06-01 01:49:30.63276
NCT00738348|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-06-06|2008-08-19|2008-08-20|Estimate|||||||2012-06-06|2012-06-08|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|KMS||Effect of Perioperative Sivelstat Administration for Liver Resection|Effect of Perioperative Sivelstat Administration for Liver Resection|Completed||N/A|50|Actual|Kochi University||2|||f||||t||||||||||2018-06-01 01:49:30.834778|2018-06-01 01:49:30.834778
NCT00738335|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2012-10-02|2008-08-19|2008-08-20|Estimate|||||||2012-10-02|2012-10-04|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases|A Phase I Open-Label, Dose-Finding Study to Evaluate the Safety and Efficacy of Concurrent Radiosurgery and Erlotinib Administration in Non-Small Cell Lung Cancer Patients With Brain Metastases|Withdrawn||Phase 1|0|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 01:49:30.89997|2018-06-01 01:49:30.89997
NCT00738322|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2009-06-29|2008-08-18|2008-08-20|Estimate|||||||2009-06-29|2009-06-30|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|||||Interventional|||To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects|A Single-Centre, Single-Blind, Randomised, Placebo-Controlled, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD1305 in Healthy Male Japanese Subjects|Completed||Phase 1|36|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:49:30.966214|2018-06-01 01:49:30.966214
NCT00738309|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2016-04-18|2008-08-19|2008-08-20|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2006||2006-05-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PSK||Prospective Study of Scheuermann's Kyphosis|Prospective Study of Scheuermann's Kyphosis|Completed|||147|Actual|Setting Scoliosis Straight Foundation|||2||f||||f||||||||||2018-06-01 01:49:31.021256|2018-06-01 01:49:31.021256
NCT00738296|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2015-06-23|2008-08-18|2008-08-20|Estimate|||||||2015-06-23|2015-06-24|Estimate|April 2005||2005-04-30|August 2008|2008-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|VYCTOR||Vytorin on Carotid Intima-media Thickness and Overall Rigidity|Vytorin on Carotid Intima-media Thickness and Overall Rigidity|Completed||Phase 4|90|Actual|Hospital Regional 1o de Octubre||3|||f||||||||||||||2018-06-01 01:49:31.081992|2018-06-01 01:49:31.081992
NCT00738283|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2012-09-24||2017-03-13|2008-08-18|2008-08-20|Estimate|2015-07-23|2015-08-21|Estimate||||2017-03-13|2017-04-11|Actual|September 2008||2008-09-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Zinc and Copper Absorption in Neonates With Bilious Losses|Zinc and Copper Absorption in Neonates With Bilious Losses|Completed|||17|Actual|Baylor College of Medicine|Only 10 infants achieved a majority of enteral feeds with the ostomy in place, of which only 7 were fully enterally fed at the time of the study. This is a mixed group, but nonetheless representative of infants with small intestinal ostomies.||||f||||f||||||Samples Without DNA|"~     Blood, stool, gastric residuals, and urine~   "|||2018-06-01 01:49:31.230751|2018-06-01 01:49:31.230751
NCT00738257|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2010-05-14|2008-08-19|2008-08-20|Estimate|||||||2010-05-14|2010-05-17|Estimate|June 2000||2000-06-30|May 2010|2010-05-31||||December 2004|Actual|2004-12-31||Interventional|SMART||A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.|A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid Based Immunosuppressive Regimen.|Completed||Phase 4|126|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:49:31.364085|2018-06-01 01:49:31.364085
NCT00738244|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2011-09-23|2008-08-18|2008-08-20|Estimate|||||||2011-09-23|2011-09-26|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Effectiveness of Hearing-aid Based Wind-noise Algorithm|Methods of Wind Noise Suppression in Hearing Aids|Completed|||60|Anticipated|University of Iowa|||2||f||||f||||||||||2018-06-01 01:49:31.421785|2018-06-01 01:49:31.421785
NCT00738231|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2009-06-18|2008-08-19|2008-08-20|Estimate|||||||2009-06-18|2009-06-19|Estimate|September 2007||2007-09-30|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|May 2008|Actual|2008-05-31||Interventional|||Training Methods for a Doctrine Of Life With Healthy Heart|Two Distinct Training Methods for Healthy Heart in Low Social and Economical Society|Unknown status|Enrolling by invitation|N/A|498|Actual|Eskisehir Osmangazi University||2|||f||||f||||||||||2018-06-01 01:49:31.479713|2018-06-01 01:49:31.479713
NCT00738218|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-08-19|2008-08-19|2008-08-20|Estimate|||||||2008-08-19|2008-08-20|Estimate|October 2005||2005-10-31|August 2008|2008-08-31||||February 2007|Actual|2007-02-28||Interventional|CORE-64||Diagnostic Accuracy of Multi-Detector Spiral Computed Tomography Angiography Using 64 Detectors|"Coronary Evaluation Using Multi-Detector Spiral Computed Tomography Angiography Using 64 Detectors: CORE-64 Study"|Completed||N/A|405|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 01:49:31.579241|2018-06-01 01:49:31.579241
NCT00738205|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2014-03-10|2008-08-19|2008-08-20|Estimate|||||||2014-03-10|2014-03-11|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Observational|||Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector|Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector When Administering Saizen® Growth Hormone to Children With Growth Disorders|Completed|||834|Actual|Merck KGaA|||2||f||||||||||||||2018-06-01 01:49:31.694966|2018-06-01 01:49:31.694966
NCT00738192|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2009-03-10|2008-08-18|2008-08-20|Estimate|||||||2009-03-10|2009-03-11|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|CARAN||Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia|Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia in Gynecological Laparoscopic Surgeries|Completed||Phase 4|150|Actual|Nanjing Medical University||3|||f||||t||||||||||2018-06-01 01:49:31.779116|2018-06-01 01:49:31.779116
NCT00738010|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-09-16|2008-08-19|2008-08-20|Estimate|||||||2008-09-16|2008-09-17|Estimate|April 2005||2005-04-30|September 2008|2008-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|NMES||Effectiveness of Kneehab in Strengthening Quadriceps in Rehabilitation Post Anterior Cruciate Ligament (ACL) Reconstruction|The Effectiveness of Kneehab in Strengthening the Quadriceps of Patients in Rehabilitation After Anterior Cruciate Ligament Reconstruction|Completed||Phase 3|131|Actual|Bio-Medical Research, Ltd.||3|||f||||f||||||||||2018-06-01 01:49:34.275705|2018-06-01 01:49:34.275705
NCT00738179|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2015-02-04|2008-08-19|2008-08-20|Estimate|||||||2015-02-04|2015-02-06|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SAVE||Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease|Sleep Apnea cardioVascular Endpoints Study - Investigating the Effectiveness of Treatment With CPAP vs Standard Care in Reducing CV Morbidity and Mortality in Patients With Co-existing CV Disease and Moderate-severe Obstructive Sleep Apnea.|Unknown status|Active, not recruiting|Phase 3|2500|Anticipated|Adelaide Institute for Sleep Health||2|||f||||t||||||||||2018-06-01 01:49:31.876051|2018-06-01 01:49:31.876051
NCT00738166|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2016-07-27|2008-08-19|2008-08-20|Estimate|||||||2016-07-27|2016-07-29|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|OrgTrace||Content, Bioavailability and Health Effects of Trace Elements and Bioactive Components in Organic Agricultural Systems||Completed||N/A|18|Actual|University of Copenhagen||3|||f||||||||||||||2018-06-01 01:49:31.953144|2018-06-01 01:49:31.953144
NCT00738153|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2014-08-13|2008-08-19|2008-08-20|Estimate|||||||2014-08-13|2014-08-15|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes|Efficacy and Safety Study of Levemir® (Insulin Detemir) to Treat Type 1 and 2 Diabetes Mellitus|Completed|||798|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:49:32.016|2018-06-01 01:49:32.016
NCT00738140|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2013-07-09|2008-08-19|2008-08-20|Estimate|||||||2013-07-09|2013-07-11|Estimate|September 2007||2007-09-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors|Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors|Completed||Phase 2|15|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 01:49:32.083065|2018-06-01 01:49:32.083065
NCT00738127|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2008-08-19|2008-08-19|2008-08-20|Estimate|||||||2008-08-19|2008-08-20|Estimate|October 1992||1992-10-31|August 2008|2008-08-31|October 2004|Actual|2004-10-31|June 2004|Actual|2004-06-30||Interventional|ADTPD||Safety Study of Surgical Technique to Treat Acute Dorsal Trans-Scaphoid Perilunate Dislocations|Surgical Techniques for Acute Dorsal Trans-Scaphoid Perilunate Dislocations|Completed||N/A|801|Actual|The Second Hospital of Qinhuangdao||2|||f||||t||||||||||2018-06-01 01:49:32.155084|2018-06-01 01:49:32.155084
NCT00738114|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2013-11-20|2008-08-19|2008-08-20|Estimate|||||||2013-11-20|2013-11-21|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Diabetes in the Perioperative Period|Type 2 Diabetes in the Perioperative Period: Prevalence and Clinical Outcome|Completed|||3184|Actual|Emory University|||2||f||||f||||||||||2018-06-01 01:49:32.227587|2018-06-01 01:49:32.227587
NCT00738101|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2018-02-12|2008-08-19|2008-08-20|Estimate|||||||2018-02-12|2018-02-14|Actual|September 2008||2008-09-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants|Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants|Recruiting||N/A|15|Anticipated|Baylor College of Medicine||1|||f||||t||||||||Yes|Please see the IPD sharing section below.|2018-06-01 01:49:32.292317|2018-06-01 01:49:32.292317
NCT00738088|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2018-05-01|2008-08-18|2008-08-20|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2007|Actual|2007-06-30|May 2018|2018-05-31|March 3, 2011|Actual|2011-03-03|March 3, 2011|Actual|2011-03-03||Interventional|||Variation in Sulphonylurea Response in Type 2 Diabetes|The Use of Glycaemic Response to Sulphonylureas as a Tool to Investigate Type 2 Diabetes Pathophysiology|Terminated||Phase 4|14|Actual|NHS Tayside||1||Following Regulator inspection in 2009, study terminated as inadequate approvals were in place|f||||f||||||||||2018-06-01 01:49:32.480863|2018-06-01 01:49:32.480863
NCT00738075|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2008-08-19|2008-08-19|2008-08-20|Estimate|||||||2008-08-19|2008-08-20|Estimate|October 2008||2008-10-31|August 2008|2008-08-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Observational|||Automatic Recognition of Freezing of Gait Episodes|Online Automatic Recognition of Freezing of Gait Episodes|Unknown status|Not yet recruiting||30|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-06-01 01:49:32.559517|2018-06-01 01:49:32.559517
NCT00738062|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2014-03-18|2012-01-25|2014-04-22|2008-08-19|2008-08-20|Estimate|2014-04-22|2014-05-16|Estimate|2012-01-25|2012-01-30|Estimate|2014-04-22|2014-05-16|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|NOH303|Omits 1 patient who randomized into the study in error and did not receive study drug.|Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)|An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension|Completed||Phase 3|103|Actual|Chelsea Therapeutics||2|||f||||f||||||||||2018-06-01 01:49:32.684643|2018-06-01 01:49:32.684643
NCT00738049|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2013-01-25||2014-07-25|2008-08-19|2008-08-20|Estimate|2014-07-25|2014-08-15|Estimate||||2014-07-25|2014-08-15|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Darusentan||Darusentan Effect on PET Uptake Heterogeneity|A Phase 2, Investigator-Initiated, Feasibility Study to Evaluate the Mechanisms of Coronary Endothelial Dysfunction Imaged As Resting Myocardial Perfusion Heterogeneity After Endothelin Receptor Blockade With Darusentan|Completed||Phase 2|40|Actual|The University of Texas Health Science Center, Houston|The trial was stopped after 20 enrollments as the manufacturer of darusentan halted further development of the drug after a negative phase 3 trial in resistant hypertension.|2|||f||||f||||||||||2018-06-01 01:49:33.749599|2018-06-01 01:49:33.749599
NCT00738036|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-05-10|2008-08-19|2008-08-20|Estimate|||||||2017-05-10|2017-05-12|Actual|April 2008||2008-04-30|May 2017|2017-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Acute Pain Episodes in Patients Under Opioid Maintenance Therapy : Clinical Management and Long Term Effects|Acute Pain Episodes in Patients Under Opioid Maintenance Therapy : Clinical Management and Long Term Effects|Completed|||151|Actual|University Hospital, Toulouse|||2||f||||f||||||||||2018-06-01 01:49:33.991231|2018-06-01 01:49:33.991231
NCT00738023|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|2014-12-18||2014-12-18|2008-08-19|2008-08-20|Estimate|2014-12-18|2014-12-30|Estimate||||2014-12-18|2014-12-30|Estimate|March 2004||2004-03-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes|Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes|Completed||Phase 4|36|Actual|Emory University||2|||f||||t||||||||||2018-06-01 01:49:34.075491|2018-06-01 01:49:34.075491
NCT00737997|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2014-11-18|2008-08-19|2008-08-20|Estimate|||||||2014-11-18|2014-11-19|Estimate|December 2006||2006-12-31|November 2014|2014-11-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Effect of Early Morphine Administration on the Development of Acute Opioid Tolerance During Pediatric Scoliosis Surgery|Effect of Early Administration of Morphine on the Development of Acute Opioid Tolerance During Infusion of Remifentanil for Pediatric Scoliosis Surgery|Completed||Phase 3|40|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 01:49:34.35496|2018-06-01 01:49:34.35496
NCT00737984|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-04-19|2008-08-19|2008-08-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Improving the Pregnancy Rate With Endometrial Sampling Before Intrauterine Insemination|Improving the Pregnancy Rate With Endometrial Sampling Before Intrauterine Insemination|Terminated||N/A|9|Actual|McGill University Health Center||2||Because very low number of patients were enrolled|f||||f||||||||||2018-06-01 01:49:34.414542|2018-06-01 01:49:34.414542
NCT00737971|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2016-04-29|2008-08-19|2008-08-20|Estimate|||||||2016-04-29|2016-05-03|Estimate|August 2008||2008-08-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|ATEMD||Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema|A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema|Completed||Phase 4|142|Actual|Federal University of São Paulo||3|||f||||f||||||||Yes|data presented in several congresses: ARVO 2010-- poster ARVO 2011, WOC BERLIN 2010, WOC ABU DABHI 2012 (partial data) CBO 2014 (final data)|2018-06-01 01:49:34.478527|2018-06-01 01:49:34.478527
NCT00737958|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2010-03-30|2008-08-19|2008-08-20|Estimate|||||||2010-03-30|2010-03-31|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||The Effects of Diesel Exhaust Inhalation On Exercise Capacity In Patients With Stable Angina Pectoris|The Effects of Diesel Exhaust Inhalation On Exercise Capacity In Patients With Stable Angina Pectoris|Completed|||19|Actual|University of Edinburgh|||1||f||||f||||||Samples Without DNA|"~     Plasma samples Serum samples~   "|||2018-06-01 01:49:34.541707|2018-06-01 01:49:34.541707
NCT00737945|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2017-08-23|2008-08-19|2008-08-20|Estimate|||||||2017-08-23|2017-08-24|Actual|August 2006||2006-08-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Prognostic Value of Endothelial Dysfunction and Coronary Complexity|Incremental Significance of Endothelial Function Assessed by Reactive Hyperemia Peripheral Arterial Tonometry to Improve Risk Stratification in High Risk Patients for Cardiovascular Events|Completed|||1000|Actual|Kumamoto University|||1||f||||f||||||||||2018-06-01 01:49:34.601054|2018-06-01 01:49:34.601054
NCT00737932|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2015-03-19|2008-08-19|2008-08-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Laquinimod Phase IIa Study in Active Crohn's Disease|A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn's Disease.|Completed||Phase 2|180|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 01:49:34.755953|2018-06-01 01:49:34.755953
NCT00737919|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2011-02-09|2008-08-19|2008-08-20|Estimate|||||||2011-02-09|2011-02-10|Estimate|May 2006||2006-05-31|August 2008|2008-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Influence of Dietary Plant Sterols and Plant Stanols on Cholesterol and Plant Sterol Levels in Atheromatous Plaques|The Influence of Dietary Plant Sterols and Plant Stanols on Cholesterol and Plant Sterol Levels in Atheromatous Plaques|Completed||N/A|30|Anticipated|Helsinki University||2|||f||||f||||||||||2018-06-01 01:49:34.861872|2018-06-01 01:49:34.861872
NCT00737906|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2015-08-25|2008-08-19|2008-08-20|Estimate|||||||2015-08-25|2015-08-26|Estimate|October 2007||2007-10-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Surgical Reduction of the Inferior Turbinates for Nasal Obstruction|Surgical Reduction of the Inferior Turbinate Using a Coblation® Device for Treatment of Nasal Obstruction: A Prospective, Multi-center Clinical Study|Terminated||Phase 4|30|Actual|ArthroCare Corporation||1|||f||||f||||||||||2018-06-01 01:49:34.928182|2018-06-01 01:49:34.928182
NCT00737893|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2017-07-24|2008-08-19|2008-08-20|Estimate|||||||2017-07-24|2017-07-26|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ERECT||Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy|Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: a Prospective Randomized Controlled Trial (ERECT)|Recruiting||Phase 2|50|Anticipated|Johns Hopkins University||2|||f||||f|t|f||||||Undecided||2018-06-01 01:49:35.010247|2018-06-01 01:49:35.010247
NCT00737880|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-08-19|2008-08-19|2008-08-20|Estimate|||||||2008-08-19|2008-08-20|Estimate|July 2001||2001-07-31|August 2008|2008-08-31|December 2005|Actual|2005-12-31|January 2004|Actual|2004-01-31||Interventional|||Histidine-Tryptophane-Ketoglutarate (HTK) vs University of Wisconsin (UW) Perfusion in Clinical Pancreas Transplantation|A Prospective Randomized Multicenter Trial Comparing Histidine-Tryptophane-Ketoglutarate (HTK) Versus University of Wisconsin (UW) Perfusion Solution in Clinical Pancreas Transplantation|Completed||Phase 4|68|Actual|Medical University Innsbruck||2|||f||||f||||||||||2018-06-01 01:49:35.102244|2018-06-01 01:49:35.102244
NCT00737867|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2011-04-01|2008-08-19|2008-08-20|Estimate|||||||2011-04-01|2011-04-04|Estimate|September 2007||2007-09-30|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer|Vinorelbine Plus Gemcitabine (VG) Versus Vinorelbine Plus Carboplatin (VC) in Advanced Non-small Cell Lung Cancer. An Open Randomized Multicenter Phase III Trial From Norwegian Lung Cancer Study Group (NLCG)|Completed||Phase 3|444|Anticipated|The Norwegian Lung Cancer Study Group||2|||f||||f||||||||||2018-06-01 01:49:35.240052|2018-06-01 01:49:35.240052
NCT00737854|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2008-12-09|2008-08-19|2008-08-20|Estimate|||||||2008-12-09|2008-12-11|Estimate|May 2008||2008-05-31|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|May 2010|Anticipated|2010-05-31||Interventional|TOLP||Free Soft Tissue Graft in Treatment of Oral Lichen Planus|Free Soft Tissue Graft in Treatment of Oral Lichen Planus|Unknown status|Recruiting|Phase 1|20|Anticipated|Qazvin University Of Medical Sciences||1|||f||||t||||||||||2018-06-01 01:49:35.319221|2018-06-01 01:49:35.319221
NCT00737841|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2008-08-19|2008-08-19|2008-08-20|Estimate|||||||2008-08-19|2008-08-20|Estimate|January 2006||2006-01-31|August 2008|2008-08-31|September 2008|Anticipated|2008-09-30|August 2008|Anticipated|2008-08-31||Interventional|PBIBS||Effect of Bifidobacterium on Irritable Bowel Syndrome|Effect of Bifidobacterium on Irritable Bowel Syndrome|Unknown status|Recruiting|N/A|50|Anticipated|Tohoku University||2|||f||||f||||||||||2018-06-01 01:49:35.388648|2018-06-01 01:49:35.388648
NCT00737828|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2014-05-20|2008-08-19|2008-08-20|Estimate|||||||2014-05-20|2014-05-21|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Cardiopulmonary Exercise Testing and Preoperative Risk Stratification|A Randomised Controlled Trial of the Utility of Cardiopulmonary Exercise (CPX) Testing for Preoperative Risk Stratification to Guide Perioperative Care and Thereby Reduce Postoperative Morbidity|Completed||N/A|228|Actual|University College London Hospitals||2|||f||||f||||||||||2018-06-01 01:49:35.470763|2018-06-01 01:49:35.470763
NCT00737815|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-06-18|2008-08-19|2008-08-20|Estimate|||||||2012-06-18|2012-06-19|Estimate|June 2007||2007-06-30|June 2012|2012-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Randomized Crossover Study of Magnesium Supplementation|Magnesium Supplements, Plasma Inflammatory Markers, and Gene Expression in Overweight Individuals With Metabolic Syndrome: a Randomized , Controlled Crossover Trial|Completed||N/A|14|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:49:35.550086|2018-06-01 01:49:35.550086
NCT00737802|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2017-09-19|2008-08-19|2008-08-20|Estimate|||||||2017-09-19|2017-09-21|Actual|February 2008||2008-02-29|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter|In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter|Recruiting|||100|Anticipated|Northwell Health|||3||f||||f||||||||No||2018-06-01 01:49:35.620315|2018-06-01 01:49:35.620315
NCT00737789|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2015-03-03|2008-08-19|2008-08-20|Estimate|||||||2015-03-03|2015-03-04|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.|Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.|Completed||Phase 3|206|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:49:35.700695|2018-06-01 01:49:35.700695
NCT00737776|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2016-10-27|2008-08-19|2008-08-20|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|UPGRADE||Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes|NovoMix® 30 UPGRADE (NovoMix® 30 Use for Progressed Glycemic Control in Realistic Administration to DiabEtes Mellitus): A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Efficacy and Safety Study in Patients Using Biphasic Insulin Aspart 30 (NovoMix® 30) for the Treatment of Diabetes Mellitus|Completed|||1068|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:49:36.057603|2018-06-01 01:49:36.057603
NCT00737763|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2014-05-09|2008-08-19|2008-08-20|Estimate|||||||2014-05-09|2014-05-12|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|BRiTE||Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab|Beta Cell Rescue in New Onset Type 1 Diabetes Mellitus With the LFA-1 Antibody Efalizumab|Withdrawn||Phase 2|0|Actual|Emory University||2||drug withdrawn from market|f||||t||||||||||2018-06-01 01:49:36.151154|2018-06-01 01:49:36.151154
NCT00737750|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2008-08-27|2008-08-19|2008-08-20|Estimate|||||||2008-08-27|2008-08-28|Estimate|April 2005||2005-04-30|August 2008|2008-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|NMES||Effectiveness of Kneehab in Strengthening the Quadriceps of Patients Post Anterior Cruciate Ligament (ACL) Reconstruction|Phase III Study in Patients Undergoing Rehabilitation Post-Surgical Reconstruction of the Anterior Cruciate Ligament (ACL)|Completed||Phase 3|131|Actual|Bio-Medical Research, Ltd.||3|||f||||f||||||||||2018-06-01 01:49:36.228776|2018-06-01 01:49:36.228776
NCT00737737|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-16|2015-04-09||2015-04-09|2008-08-19|2008-08-20|Estimate|2015-04-09|2015-04-29|Estimate||||2015-04-09|2015-04-29|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|||Hormone Function in Men Treated for Pain With Opioids or Placebo|Effects of Chronic Musculoskeletal Pain and Opioidergic Versus Placebo Interventions on Neuroendocrine Function in Men|Completed||Phase 4|8|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 01:49:36.338448|2018-06-01 01:49:36.338448
NCT00737724|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-19|||2015-03-24|2008-08-19|2008-08-20|Estimate|||||||2015-03-24|2015-03-26|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment|Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial.|Terminated||N/A|63|Actual|Instituto Nacional de Enfermedades Respiratorias||2||Other published trials showed definitive expected superiority of Group 1|f||||t||||||||||2018-06-01 01:49:36.635479|2018-06-01 01:49:36.635479
NCT00737711|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2016-03-08||2016-04-26|2008-08-18|2008-08-19|Estimate|2016-04-26|2016-06-02|Estimate||||2016-04-26|2016-06-02|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Safety population included all participants who receive at least one dose of study medication.|A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Two Weekly Administration of Intravenous Methoxy Polyethylene Glycol-epoetin Beta (MIRCERA) for the Treatment of Chronic Renal Anemia in Dialysis Patients Not Currently Treated With Erythropoietin-stimulating Agent (ESA).|Completed||Phase 4|189|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:49:36.838296|2018-06-01 01:49:36.838296
NCT00737698|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2016-02-17|2008-08-18|2008-08-19|Estimate|||||||2016-02-17|2016-02-19|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|October 2010|Actual|2010-10-31|October 2008|Actual|2008-10-31||Interventional|||Comparison of Repetitive Magnetic Stimulation (rMS) and Exercise Versus no Active Treatment on Quadriceps Function in Chronic Obstructive Pulmonary Disease (COPD)|Is the Anaerobic Quadriceps Muscle Phenotype in Chronic Obstructive Pulmonary Disease Mediated by Reduced Muscle Concentrations of Peroxisome Proliferator-Activated Receptors Alpha and Delta?|Completed||N/A|71|Actual|Imperial College London||3|||f||||f||||||||||2018-06-01 01:49:37.399093|2018-06-01 01:49:37.399093
NCT00737685|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-03-23|2008-08-18|2008-08-19|Estimate|||||||2012-03-23|2012-03-26|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|||Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)|Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Bone Marrow (or Mobilized Peripheral Blood) Transplantation in Severe Aplastic Anemia|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|The Korean Society of Pediatric Hematology Oncology||1|||f||||f||||||||||2018-06-01 01:49:37.457356|2018-06-01 01:49:37.457356
NCT00737672|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2014-02-06|2013-05-14|2014-10-14|2008-08-18|2008-08-19|Estimate|2014-10-14|2014-10-21|Estimate|2013-05-14|2013-05-22|Estimate|2014-10-14|2014-10-21|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|May 2011|Actual|2011-05-31||Interventional|REVISE||GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis|GORE VIABAHN® Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients|Completed||Phase 3|293|Actual|W.L.Gore & Associates||2|||f||||t||||||||||2018-06-01 01:49:37.572514|2018-06-01 01:49:37.572514
NCT00737659|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2010-03-25|2008-08-18|2008-08-19|Estimate|||||||2010-03-25|2010-03-26|Estimate|August 2008||2008-08-31|December 2008|2008-12-31|August 2013|Anticipated|2013-08-31|August 2011|Anticipated|2011-08-31||Interventional|MMF||CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients|Phase IV, Open-Label, Multicenter, Randomized Study Comparing Mycophenolate Mofetil (MMF) Dose Adjustment Based on Blood MPA Concentration to Standard Care Treatment With MMF in Renal Transplant Recipients Receiving Tacrolimus|Unknown status|Recruiting|Phase 4|138|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 01:49:38.835558|2018-06-01 01:49:38.835558
NCT00737646|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2012-12-14|2008-08-18|2008-08-19|Estimate|||||||2012-12-14|2012-12-17|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional|||Evaluation of an Intervention to Increase Colorectal Cancer Screening in Primary Care Clinics|Evaluation of an Intervention to Increase Colorectal Cancer Screening in Primary Care Clinics|Completed||N/A|5066|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-06-01 01:49:38.920457|2018-06-01 01:49:38.920457
NCT00737633|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|2012-07-31|2009-11-30|2012-09-05|2008-08-18|2008-08-19|Estimate|2012-07-31|2012-09-03|Estimate|2009-11-30|2009-12-02|Estimate|2012-09-05|2012-09-10|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults|An Open-Label, Non-Randomized Multicenter Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults|Terminated||Phase 2|101|Actual|VIVUS, Inc.||2||Limited regulatory value to uncontrolled trials. No safety/efficacy concerns.|f||||f||||||||||2018-06-01 01:49:39.024508|2018-06-01 01:49:39.024508
NCT00737620|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2012-10-29|2008-08-18|2008-08-19|Estimate|||||||2012-10-29|2012-10-30|Estimate|March 2008||2008-03-31|December 2011|2011-12-31||||November 2011|Actual|2011-11-30||Interventional|||Evaluation of Heparin Bonded Vascular Graft Versus Standard Graft in Prosthetic Arteriovenous Access for Hemodialysis|Evaluation of Heparin Bonded Vascular Graft Versus Standard Graft in Prosthetic Arteriovenous Access for Hemodialysis|Completed||Phase 4|160|Actual|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 01:49:39.327033|2018-06-01 01:49:39.327033
NCT00737607|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2008-08-18|2008-08-18|2008-08-19|Estimate|||||||2008-08-18|2008-08-19|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|MEDLLSS||Clinical Outcome Study of Minimally Invasive Decompression for Lumbar Spinal Stenosis|Clinical Study of Microendoscopic Decompressive Laminotomy for Treatment of Lumbar Spinal Stenosis|Unknown status|Recruiting||60|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 01:49:39.395865|2018-06-01 01:49:39.395865
NCT00737594|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2016-02-16||2016-02-16|2008-08-15|2008-08-19|Estimate|2016-02-16|2016-03-16|Estimate||||2016-02-16|2016-03-16|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional||Study was terminated early, data was not analyzed.|Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension|A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension|Terminated||Phase 2|9|Actual|Sucampo Pharma Americas, LLC||3||Failure to enroll a suitable number of qualified subjects.|f||||t||||||||||2018-06-01 01:49:39.461989|2018-06-01 01:49:39.461989
NCT00737581|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2017-01-30|2008-08-18|2008-08-19|Estimate|||||||2017-01-30|2017-02-01|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Spinal Cord Stimulation Research Study|Posture Responsive Spinal Cord Stimulation Research Study|Completed|||20|Actual|MedtronicNeuro|||||f||||f||||||||||2018-06-01 01:49:39.609225|2018-06-01 01:49:39.609225
NCT00737568|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2012-11-15||2016-02-09|2008-08-15|2008-08-19|Estimate|2013-03-01|2013-04-11|Estimate||||2016-02-09|2016-03-11|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|February 2015|Actual|2015-02-28|November 2011|Actual|2011-11-30||Interventional|||Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine|A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects With Chronic Hepatitis B Who Are Resistant to Lamivudine|Completed||Phase 3|280|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t||||||||||2018-06-01 01:49:39.704251|2018-06-01 01:49:39.704251
NCT00737555|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-02-14|2008-08-18|2008-08-19|Estimate|||||||2012-02-14|2012-02-15|Estimate|August 2006||2006-08-31|February 2012|2012-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours|A Phase 1b Dose-escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours|Completed||Phase 1|23|Actual|Chroma Therapeutics||1|||f||||t||||||||||2018-06-01 01:49:40.769683|2018-06-01 01:49:40.769683
NCT00737542|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2009-11-25|2008-08-18|2008-08-19|Estimate|||||||2009-11-25|2009-11-26|Estimate||||August 2008|2008-08-31||||||||Interventional|||Local Lidocaine Infiltration for Pain Management Post Cesarean Delivery.|A Prospective Randomized Double-blind, Placebo-controlled Study of the Effect of Preoperative Analgesia With Local Lidocaine Infiltration for Pain Management Post Cesarean Delivery.|Unknown status|Not yet recruiting|N/A|||Soroka University Medical Center||2|||f||||||||||||||2018-06-01 01:49:40.839649|2018-06-01 01:49:40.839649
NCT00737529|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2013-06-28||2017-11-30|2008-08-18|2008-08-19|Estimate|2013-06-28|2013-09-09|Estimate||||2017-11-30|2017-12-05|Actual|December 22, 2008|Actual|2008-12-22|November 2017|2017-11-30|November 8, 2017|Actual|2017-11-08|October 15, 2012|Actual|2012-10-15||Interventional|EMERGE|The baseline characteristics are from the participants assesed within the Intent to Treat Population (ITT). The ITT population was defined as all enrolled participants who received at least one dose of study drug. The ITT population was the primary analysis population used for all efficacy analyses.|"A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The EMERGE Trial"|A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantel Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Refractory To Bortezomib|Completed||Phase 2|134|Actual|Celgene||1|||f||||t||||||||||2018-06-01 01:49:40.971121|2018-06-01 01:49:40.971121
NCT00737516|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15||2013-06-04|2013-06-12|2008-08-18|2008-08-19|Estimate||||2013-06-12|2013-06-21|Estimate|2013-06-12|2013-06-21|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation|A Centralized Cord Blood Registry to Facilitate Allogeneic, Unrelated Donor Umbilical Cord Blood Transplantation|Completed||Phase 2|3621|Actual|National Marrow Donor Program||1|||f||||t||||||||||2018-06-01 01:49:41.732575|2018-06-01 01:49:41.732575
NCT00737503|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-16|||2011-06-25|2008-08-18|2008-08-19|Estimate|||||||2011-06-25|2011-06-28|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab|Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab|Completed||Phase 4|4550|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-06-01 01:49:41.841404|2018-06-01 01:49:41.841404
NCT00737490|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2014-07-31|2008-08-18|2008-08-19|Estimate|||||||2014-07-31|2014-08-01|Estimate|June 2005||2005-06-30|April 2013|2013-04-30|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|Devise-CRT||Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)|Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)|Completed||N/A|40|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:49:41.914995|2018-06-01 01:49:41.914995
NCT00737477|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2016-06-17||2017-05-30|2008-08-18|2008-08-19|Estimate|2016-06-17|2016-07-28|Estimate||||2017-05-30|2017-06-23|Actual|September 30, 2008|Actual|2008-09-30|May 2017|2017-05-31|July 31, 2011|Actual|2011-07-31|July 31, 2011|Actual|2011-07-31||Interventional|MISTRAL|Intent-to-Treat (ITT) Population: All participants who received at least one dose of Mircera and provided at least one Hb evaluation between Weeks 0 to 24, and for whom any follow-up information was available.|A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis|A Single Arm, Open-Label, Multicentre Study to Assess the Maintenance of Haemoglobin Levels With Once Monthly Subcutaneous Administration of C.E.R.A (Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease on Peritoneal Dialysis|Completed||Phase 3|96|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:49:42.016129|2018-06-01 01:49:42.016129
NCT00737464|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2016-02-25||2017-11-02|2008-08-18|2008-08-19|Estimate|2016-03-30|2016-04-29|Estimate||||2017-11-02|2017-12-07|Actual|August 26, 2008|Actual|2008-08-26|November 2017|2017-11-30|September 12, 2009|Actual|2009-09-12|September 12, 2009|Actual|2009-09-12||Interventional||Safety population included all enrolled participants who received at least one dose of study medication.|A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous MIRCERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia|Completed||Phase 4|132|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-06-01 01:49:42.513153|2018-06-01 01:49:42.513153
NCT00737451|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2012-03-26|2008-08-18|2008-08-19|Estimate|||||||2012-03-26|2012-03-27|Estimate|March 2008||2008-03-31|September 2009|2009-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Association of Thyroid Autoimmunity and Chronic Urticaria|Association of Thyroid Autoimmunity and Chronic Urticaria in Taiwan|Completed|||155|Actual|Far Eastern Memorial Hospital|||1||f||||t||||||||||2018-06-01 01:49:42.949224|2018-06-01 01:49:42.949224
NCT00737438|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2016-01-04||2016-01-04|2008-08-18|2008-08-19|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma|A Phase II Study of Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma|Completed||Phase 2|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:49:43.014419|2018-06-01 01:49:43.014419
NCT00737425|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2008-10-27|2008-08-18|2008-08-19|Estimate|||||||2008-10-27|2008-10-28|Estimate|September 2008||2008-09-30|October 2008|2008-10-31||||||||Interventional|||Safety and Efficacy Study of Pain Shield Device to Treat Subjects Following Laparoscopic-Assisted Abdominal Surgery|Evaluation of Safety and Efficacy of the PainShield Device for the Treatment of Subjects Who Underwent Laparoscopic-Assisted Abdominal Surgery|Unknown status|Recruiting|Phase 4|80|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-06-01 01:49:43.365637|2018-06-01 01:49:43.365637
NCT00737412|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2010-01-19|2008-08-18|2008-08-19|Estimate|||||||2010-01-19|2010-01-21|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults|A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults.|Completed||Phase 3|277|Actual|Bio-K Plus International Inc.||2|||f||||t||||||||||2018-06-01 01:49:43.454054|2018-06-01 01:49:43.454054
NCT00737399|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2018-04-23|2008-08-18|2008-08-19|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2008||2008-09-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Interventional|||Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)|Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)|Recruiting||Early Phase 1|14|Anticipated|Soul Medicine Institute||1|||f||||f||||||||||2018-06-01 01:49:43.537317|2018-06-01 01:49:43.537317
NCT00737386|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2011-08-15|2008-08-18|2008-08-19|Estimate|||||||2011-08-15|2011-08-16|Estimate|September 2009||2009-09-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank||Unknown status|Enrolling by invitation||600|Anticipated|Hadassah Medical Organization|||||f||||f||||||None Retained|"~     Blood samples~   "|||2018-06-01 01:49:43.622519|2018-06-01 01:49:43.622519
NCT00737373|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|||2012-09-18|2008-08-18|2008-08-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|August 2007||2007-08-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|December 2009|Actual|2009-12-31||Interventional|||Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer|A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile|Completed||Phase 2|143|Actual|Krankenhaus Nordwest||2|||f||||f||||||||||2018-06-01 01:49:43.672671|2018-06-01 01:49:43.672671
NCT00737360|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-18|2012-04-20||2012-08-02|2008-08-18|2008-08-19|Estimate|2012-08-02|2012-09-05|Estimate||||2012-08-02|2012-09-05|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|||Phase II Study of TAS-106 to Treat Head and Neck Cancer|Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy|Terminated||Phase 2|27|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-06-01 01:49:43.827095|2018-06-01 01:49:43.827095
NCT00737347|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2008-08-18|2008-08-18|2008-08-19|Estimate|||||||2008-08-18|2008-08-19|Estimate|September 2003||2003-09-30|August 2008|2008-08-31|April 2008|Actual|2008-04-30|March 2007|Actual|2007-03-31||Interventional|||Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone|Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone|Completed||Phase 3|39|Actual|Northwestern University||3|||f||||f||||||||||2018-06-01 01:49:44.105815|2018-06-01 01:49:44.105815
NCT00737334|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2009-11-09|2008-08-15|2008-08-19|Estimate|||||||2009-11-09|2009-11-11|Estimate|September 2008||2008-09-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||EEG, Cerebral Oximetry, and Arterial to Jugular Venous Lactate to Assess Cerebral Ischemia During Carotid Endarterectomy|A Comparison of the EEGo Monitor, BIS Monitor, and FORE-SIGHT Cerebral Oximeter With Arterial to Jugular Venous Lactate Difference to Assess Cerebral Ischemia During Carotid Endarterectomy|Completed||N/A|40|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-06-01 01:49:44.213134|2018-06-01 01:49:44.213134
NCT00737321|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2017-07-20|2008-08-18|2008-08-19|Estimate|||||||2017-07-20|2017-07-24|Actual|August 2008||2008-08-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Mechanisms Regulating Wound Vascularization|Mechanisms Regulating Wound Vascularization|Active, not recruiting|||80|Anticipated|Ohio State University|||2||f||||f||||||Samples With DNA|"~     All participnts with wounds will have 3 mm punch biopsy performed twice or three times in the~     whole study period.Obtained tissue sample will be processed immidiately and frozen in liquid~     nitrogen.The tissue sample will transport to research lab for genomic analysis.~   "|||2018-06-01 01:49:44.293313|2018-06-01 01:49:44.293313
NCT00737308|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-17|||2015-05-14|2008-08-17|2008-08-19|Estimate|||||||2015-05-14|2015-05-15|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Properties and Clinical Performance of Zirconia-based Dental Ceramics|Properties and Clinical Performance of Zirconia-based Dental Ceramics|Completed||N/A|20|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 01:49:44.374492|2018-06-01 01:49:44.374492
NCT00737295|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2010-11-15|2008-08-15|2008-08-18|Estimate|||||||2010-11-15|2010-11-16|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Ultrasound for Diagnosis of Biliary Dyskinesia|Study to Investigate the Role of Ultrasound for Diagnosis of Biliary Dyskinesia|Terminated||N/A|25|Actual|Texas Tech University Health Sciences Center||1||PI left institution, study interest wained-so stopped.|f||||f||||||||||2018-06-01 01:49:44.446317|2018-06-01 01:49:44.446317
NCT00737282|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2014-06-25||2014-08-05|2008-08-15|2008-08-18|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated|Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids|A Phase III, Open-Label, Parallel, Randomized, Multicenter Study Evaluating the Safety of 25 And 50 mg Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids|Terminated||Phase 3|175|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|2||Repros stopped study for safety and FDA put study on hold.|f||||t||||||||||2018-06-01 01:49:44.522699|2018-06-01 01:49:44.522699
NCT00737269|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2013-03-01|2008-08-14|2008-08-18|Estimate|||||||2013-03-01|2013-03-04|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||A Complicated Skin and Soft-tissue Infection Patient Registry|A Prospective, Multi-center, Observational Registry Involving Patients Hospitalized With Complicated Skin and Soft Tissue Infections (cSSTI) for IV Antibiotic Therapy|Completed|||1081|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|||||f||||||||||||||2018-06-01 01:49:44.726283|2018-06-01 01:49:44.726283
NCT00737256|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2012-09-06|2008-08-14|2008-08-18|Estimate|||||||2012-09-06|2012-09-07|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|May 2014|Anticipated|2014-05-31|May 2013|Anticipated|2013-05-31||Interventional|||A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence|A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence|Unknown status|Recruiting|Phase 2|44|Anticipated|Denver Research Institute||2|||f||||t||||||||||2018-06-01 01:49:44.855855|2018-06-01 01:49:44.855855
NCT00737243|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2015-10-07||2016-07-07|2008-08-15|2008-08-18|Estimate|2016-07-07|2016-08-17|Estimate||||2016-07-07|2016-08-17|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional||252 patients who had successful assays.|Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site|A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site|Completed||Phase 2|289|Actual|SCRI Development Innovations, LLC|The focus of this study was to evaluate the ability of the 92-gene assay to successfully predict tumor tissue of origin, not to assess one particular treatment|2|||f||||f||||||||||2018-06-01 01:49:44.945538|2018-06-01 01:49:44.945538
NCT00737230|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2013-08-23|2008-08-15|2008-08-18|Estimate|||||||2013-08-23|2013-08-26|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|July 2012|Actual|2012-07-31|September 2010|Actual|2010-09-30||Interventional|||Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis|Effective Management of Radiation-induced Bowel Injury: A Randomized Controlled Trial|Completed||N/A|250|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:49:45.278825|2018-06-01 01:49:45.278825
NCT00737217|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2013-06-24|2008-08-15|2008-08-18|Estimate|||||||2013-06-24|2013-06-26|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease|Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease|Completed|||74|Actual|University of Michigan|||2||f||||f||||||||||2018-06-01 01:49:45.393526|2018-06-01 01:49:45.393526
NCT00737204|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-03-13||2014-06-11|2008-08-14|2008-08-18|Estimate|2014-06-11|2014-06-12|Estimate||||2014-06-11|2014-06-12|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS|Armodafinil Treatment for Fatigue in HIV+ Patients|Completed||Phase 4|70|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 01:49:45.45913|2018-06-01 01:49:45.45913
NCT00737191|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2012-03-07|2008-08-15|2008-08-18|Estimate|||||||2012-03-07|2012-03-09|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain|Analgesic Effect of Olanzapine in Cancer Pain: A Double-Blind Randomized Placebo-Controlled Parallel Group Pilot Study|Withdrawn||N/A|0|Actual|Mayo Clinic||3||No accrual; No patients enrolled|f||||t||||||||||2018-06-01 01:49:45.740811|2018-06-01 01:49:45.740811
NCT00737178|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2012-12-31||2014-09-18|2008-08-15|2008-08-18|Estimate|2014-09-18|2014-09-19|Estimate||||2014-09-18|2014-09-19|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|October 2009|Actual|2009-10-31||Interventional|||Immediate Versus Delayed Insertion of the Copper Intrauterine Device (IUD) After Medication Abortion|A Randomized Trial of Immediate Versus Delayed Insertion of the Copper T380A Following Medication Abortion|Completed||Phase 4|156|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 01:49:45.927642|2018-06-01 01:49:45.927642
NCT00737165|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2013-10-30|2008-08-15|2008-08-18|Estimate|||||||2013-10-30|2013-10-31|Estimate|July 2006||2006-07-31|October 2013|2013-10-31|March 2011|Actual|2011-03-31|December 2009|Actual|2009-12-31||Interventional|NOCOMIT-J||A Community Intervention Trial of Multimodal Suicide Prevention Program in Japan (NOCOMIT-J)|A Community Intervention Trial of Multimodal Suicide Prevention Program in Japan (NOCOMIT-J)|Completed||N/A|1951060|Actual|Japan Foundation for Neuroscience and Mental Health||2|||f||||t||||||||||2018-06-01 01:49:46.171256|2018-06-01 01:49:46.171256
NCT00737152|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-07-19|2008-08-14|2008-08-18|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|ASI-DMII||Evaluate the Side Effects and Benefits of RAS 130 With or Without Diet and Exercise in Type II Diabetes Mellitus|Phase II, Open-Label Study to Assess the Cardiovascular Side Effects and Efficacy for Reducing Blood Glucose Level in Type II Diabetes Mellitus Patients Being Treated With RAS 130 With or Without Diet and Exercise|Unknown status|Not yet recruiting|Phase 2|460|Anticipated|American Scitech International||1|||f||||f||||||||||2018-06-01 01:49:46.254923|2018-06-01 01:49:46.254923
NCT00737139|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2012-08-29|2008-08-15|2008-08-18|Estimate|||||||2012-08-29|2012-08-31|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine|A Prospective, Randomized, Double-Blind Controlled Clinical Trial to Evaluate the Post-Operative Blood Loss and Transfusion Rate Following Total Joint Arthroplasty With Intra-articular Injection of Bupivacaine and Epinephrine|Terminated||N/A|33|Actual|Rush University Medical Center||2||"Prohibitively expensive and efficacy of tranexamic acid rendered topic clinically less~   relevant."|f||||f||||||||||2018-06-01 01:49:46.351094|2018-06-01 01:49:46.351094
NCT00737126|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2008-08-18|2008-08-15|2008-08-18|Estimate|||||||2008-08-18|2008-08-19|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||The Effect of Folic Acid Administration in the Progression of Microalbuminuria|Folic Acid Administration Reduces the Progression of Microalbuminuria|Completed||N/A|40|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||f||||||||||2018-06-01 01:49:46.433392|2018-06-01 01:49:46.433392
NCT00737113|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2014-03-18|2008-08-15|2008-08-18|Estimate|||||||2014-03-18|2014-03-20|Estimate|September 2008||2008-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|May 2012|Actual|2012-05-31||Interventional|||Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant|Recombinant Human Growth Hormone(RH-GH) For Accelerating Immune Reconstitution In Pediatric and Adult Patients Undergoing Allogeneic Stem Cell Transplantation|Terminated||Phase 1|14|Actual|Duke University||||Study was terminated early due to low accrual.|f||||f||||||||||2018-06-01 01:49:46.497017|2018-06-01 01:49:46.497017
NCT00737100|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2011-03-21||2014-05-07|2008-08-15|2008-08-18|Estimate|2011-03-21|2011-04-13|Estimate||||2014-05-07|2014-05-16|Estimate|September 2008||2008-09-30|January 2014|2014-01-31||||April 2010|Actual|2010-04-30||Interventional|||Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis|A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 mcg and 5 mcg) Administered Once Daily Via the Respimat Device for 12 Weeks in Patients With Cystic Fibrosis.|Completed||Phase 2|510|Actual|Boehringer Ingelheim||3|||t||||||||||||||2018-06-01 01:49:46.587287|2018-06-01 01:49:46.587287
NCT00737087|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2016-04-20|2008-08-15|2008-08-18|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|October 2013|Actual|2013-10-31||Interventional|||Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder|A Multi-centred, Non-comparative, Non-randomised, Open, Post Marketing Investigation to Look at the Long-term Clinical Efficacy of the Delta Xtend Reverse Total Shoulder Used in the Treatment of Shoulders With Rotator Cuff Deficiencies.|Terminated||N/A|144|Actual|DePuy International||1||Study was stopped due to low follow-up compliance at study sites.|f||||f||||||||||2018-06-01 01:49:49.490785|2018-06-01 01:49:49.490785
NCT00737074|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2008-08-15|2008-08-15|2008-08-18|Estimate|||||||2008-08-15|2008-08-18|Estimate|January 2002||2002-01-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Observational|||Macular Hole in Diabetic Retinopathy|Macular Hole in Proliferative Diabetic Retinopathy With Fibrovascular Proliferation|Completed|||23|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:49:49.560685|2018-06-01 01:49:49.560685
NCT00737061|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2009-08-26||2017-08-08|2008-08-15|2008-08-18|Estimate|2012-12-14|2013-01-25|Estimate||||2017-08-08|2017-09-08|Actual|November 2002||2002-11-30|August 2017|2017-08-31|February 4, 2013|Actual|2013-02-04|December 2005|Actual|2005-12-31||Interventional|EASE||Safety & Efficacy Study of the Adiana System for Women Who Desire Permanent Birth Control (Sterilization)|A Multi-Center, Prospective Evaluation of the Adiana System for Transcervical Sterilization Using Electrothermal Energy in Women Aged 18-45 - The EASE Trial|Terminated||N/A|770|Actual|Hologic, Inc.|At the time of analysis, 481 completed 3 years. Due to the cumulative nature of the analysis, subjects may be lost to follow-up at one time and return to follow-up at a subsequent point. All subjects who have not withdrawn consent will be followed.|1||Product Pre-Market Approval withdrawn|f||||t||||||||||2018-06-01 01:49:49.663794|2018-06-01 01:49:49.663794
NCT00737048|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-03-25||2016-03-29|2008-08-15|2008-08-18|Estimate|2013-06-26|2013-08-01|Estimate||||2016-03-29|2016-03-31|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain|A Double-Blind Comparative Study of JNS013 in Patients With Post-Tooth-Extraction Pain|Completed||Phase 3|328|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 01:49:50.205744|2018-06-01 01:49:50.205744
NCT00737035|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-08-05|2008-08-14|2008-08-18|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Effectiveness of a Web-based Intervention for Guardians of Children Whose One Parent Has Murdered the Other|Testing an IHCA for Guardians of Survivors of Intraparental Homicide|Withdrawn||N/A|0|Actual|University of Virginia||2||Recruitment difficulties|f||||t||||||||||2018-06-01 01:49:51.171283|2018-06-01 01:49:51.171283
NCT00737009|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2011-06-21|2008-08-15|2008-08-18|Estimate|||||||2011-06-21|2011-06-22|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment|An Observational Study of Adherence to Adjuvant Anastrozole Therapy in Postmenopausal Patients With Early Breast Cancer Over One Year Follow-up.|Completed|||259|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 01:49:51.30649|2018-06-01 01:49:51.30649
NCT00736996|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2015-11-06||2015-12-10|2008-08-14|2008-08-18|Estimate|2015-12-10|2016-01-15|Estimate||||2015-12-10|2016-01-15|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|POEM||Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)|Pioglitazone and Exercise Effects on Older Adults With MCI and Metabolic Syndrome|Completed||Phase 2|78|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-06-01 01:49:51.438231|2018-06-01 01:49:51.438231
NCT00736983|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2012-04-16|2008-08-15|2008-08-18|Estimate|||||||2012-04-16|2012-04-17|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|Adafi||Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's|Adalimumab for the Treatment of Perianal Fistulas in Crohn's Disease More Effective Alone or Combined to Ciprofloxacin|Completed||Phase 3|76|Actual|Foundation for Liver Research||2|||f||||f||||||||||2018-06-01 01:49:52.045548|2018-06-01 01:49:52.045548
NCT00736970|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-08-26|2008-08-14|2008-08-18|Estimate|||||||2015-08-26|2015-08-27|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)|A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer|Completed||Phase 2|34|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:49:52.144476|2018-06-01 01:49:52.144476
NCT00736957|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-03-25||2014-06-23|2008-08-15|2008-08-18|Estimate|2013-06-14|2013-06-20|Estimate||||2014-06-23|2014-07-02|Estimate|May 2008||2008-05-31|June 2014|2014-06-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||A Long-term Efficacy and Safety Study of Tramadol Hydrochloride Plus Acetaminophen (JNS013) in Japanese Participants With Chronic Pain|A Study of a Long-term Administration of JNS013 in Patients With Chronic Pain|Completed||Phase 3|219|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-06-01 01:49:52.267535|2018-06-01 01:49:52.267535
NCT00736944|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2013-11-18||2018-01-31|2008-08-15|2008-08-18|Estimate|2013-11-18|2014-01-07|Estimate||||2018-01-31|2018-03-02|Actual|December 19, 2008||2008-12-19|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2010|Actual|2010-08-31||Interventional|||Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer|Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy|Active, not recruiting||Phase 2|30|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-06-01 01:49:52.816368|2018-06-01 01:49:52.816368
NCT00736931|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2012-05-25|2008-08-15|2008-08-18|Estimate|||||||2012-05-25|2012-05-28|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam|Randomized, Comparative, Double-blind, Placebo-controlled, Triple-dummy, Four-way Cross-over Study to Investigate Neurocognitive Effects of Brivaracetam in Healthy Subjects|Completed||Phase 1|20|Actual|UCB Pharma||4|||f||||f||||||||||2018-06-01 01:49:53.462409|2018-06-01 01:49:53.462409
NCT00736918|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2014-01-14|2008-08-15|2008-08-18|Estimate|||||||2014-01-14|2014-01-16|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|June 2011|Actual|2011-06-30||Interventional|ACTION-J||RCT of Post-Suicide Attempt Case Management (ACTION-J)|A Randomized Controlled Multicenter Trial of Post-Suicide Attempt Case Management for the Prevention of Further Attempts in Japan (ACTION-J)|Completed||Phase 3|914|Actual|Japan Foundation for Neuroscience and Mental Health||2|||f||||t||||||||||2018-06-01 01:49:53.549153|2018-06-01 01:49:53.549153
NCT00736905|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2010-04-26|2008-08-14|2008-08-18|Estimate|||||||2010-04-26|2010-04-28|Estimate|June 2008||2008-06-30|April 2010|2010-04-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.|Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function|Completed||Phase 1|32|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 01:49:53.660317|2018-06-01 01:49:53.660317
NCT00736892|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2012-09-13|2008-08-15|2008-08-18|Estimate|||||||2012-09-13|2012-09-14|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|ALIEN||Incidence of Acute Lung Injury: The Alien Study|Acute Lung Injury: Epidemiology and Natural History. The ALIEN Study|Completed|||282|Actual|Villar, Jesus, M.D.|||1||f||||f||||||||||2018-06-01 01:49:53.733547|2018-06-01 01:49:53.733547
NCT00736879|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2014-02-05||2017-04-18|2008-08-15|2008-08-18|Estimate|2014-04-01|2014-05-02|Estimate||||2017-04-18|2017-04-20|Actual|September 22, 2008|Actual|2008-09-22|April 2017|2017-04-30|December 29, 2009|Actual|2009-12-29|December 29, 2009|Actual|2009-12-29||Interventional||All randomized participants who took at least one dose of double-blind study medication were included in the analysis.|Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 3|497|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:49:53.861857|2018-06-01 01:49:53.861857
NCT00736866|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2010-07-08|2008-08-14|2008-08-18|Estimate|||||||2010-07-08|2010-07-12|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ACT||The Acetylcysteine for Contrast-Induced Nephropathy Trial|A Pragmatic Randomized Clinical Trial Evaluating the Effect of Acetylcysteine for Contrast-induced Nephropathy|Completed||Phase 3|2300|Anticipated|Hospital do Coracao||2|||f||||f||||||||||2018-06-01 01:49:55.234282|2018-06-01 01:49:55.234282
NCT00736853|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-04-12||2013-07-22|2008-08-15|2008-08-18|Estimate|2013-07-22|2013-09-26|Estimate||||2013-07-22|2013-09-26|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||An Efficacy and Safety Study of Acetaminophen Plus Tramadol Hydrochloride (JNS013) in Participants With Chronic Pain|A Phase 3 Study of JNS013 in Patients With Chronic Pain|Completed||Phase 3|321|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 01:49:55.344043|2018-06-01 01:49:55.344043
NCT00736840|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2011-06-16||2012-02-15|2008-08-15|2008-08-18|Estimate|2012-02-15|2012-03-16|Estimate||||2012-02-15|2012-03-16|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MBT||BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis|Pivotal Study to Evaluate the Efficacy and Safety of the BreathID® System for Detection of Cirrhosis Using the ¹³C-methacetin Breath Test(MBT)|Completed||Phase 3|414|Actual|Exalenz Bioscience LTD.|Technical problems caused the termination of 2 subjects who did not complete breath test. Liver biopsy, 1 patient refused and others had signs of HCC thus disqualified.|1|||f||||t||||||||||2018-06-01 01:49:56.519741|2018-06-01 01:49:56.519741
NCT00736827|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2015-12-02|2008-08-15|2008-08-18|Estimate|||||||2015-12-02|2015-12-04|Estimate|August 2008||2008-08-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Observational|BICUK||BK Virus and Renal Dysfunction in Postoperative/Posttraumatic Critically Ill Patients|BK Virus and Renal Dysfunction in Postoperative/Posttraumatic Critically Ill Patients|Completed|||51|Actual|University of Ulm|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, white blood cells; urine~   "|||2018-06-01 01:49:56.713268|2018-06-01 01:49:56.713268
NCT00736814|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2011-02-23|2008-08-15|2008-08-18|Estimate|||||||2011-02-23|2011-02-24|Estimate|June 2008||2008-06-30|August 2009|2009-08-31||||||||Interventional|||First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Genotype-driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy|Unknown status|Recruiting|Phase 2|117|Anticipated|National Cancer Institute (NCI)||5|||f||||||||||||||2018-06-01 01:49:56.796501|2018-06-01 01:49:56.796501
NCT00736801|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2008-08-20|2008-08-15|2008-08-18|Estimate|||||||2008-08-20|2008-08-21|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|||Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma|Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma|Completed||N/A|35|Actual|University of Rostock||1|||f||||f||||||||||2018-06-01 01:49:56.886426|2018-06-01 01:49:56.886426
NCT00736788|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2010-12-08|2008-08-15|2008-08-18|Estimate|||||||2010-12-08|2010-12-10|Estimate|August 2008||2008-08-31|December 2010|2010-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers|A Phase 1, Single-Centre, Randomised, Double-Blind (Within Panels), Placebo-Controlled Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1704 After Administration of Oral Single Ascending Doses in Healthy Japanese Male and Non-Fertile Female Volunteers|Terminated||Phase 1|16|Actual|AstraZeneca||2||"AZD1704 has essentially similar PK profile in Japanese subjects as in Caucasians. One of the~   main purposes of the study has thereby been achieved."|f||||t||||||||||2018-06-01 01:49:56.957757|2018-06-01 01:49:56.957757
NCT00736775|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2010-10-26|2008-08-15|2008-08-18|Estimate|||||||2010-10-26|2010-10-27|Estimate|August 2008||2008-08-31|October 2010|2010-10-31||||May 2010|Actual|2010-05-31||Interventional|||A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease|A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|56|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 01:49:57.024497|2018-06-01 01:49:57.024497
NCT00736762|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2008-08-15|2008-08-15|2008-08-18|Estimate|||||||2008-08-15|2008-08-18|Estimate|February 2008||2008-02-29|August 2008|2008-08-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Effects of Global Postural re-Education Program|Effects of Global Postural re-Education Program on the Biomechanical Characteristics of the Elderly Balance.|Completed||N/A|30|Actual|University of the State of Santa Catarina||1|||f||||f||||||||||2018-06-01 01:49:57.083401|2018-06-01 01:49:57.083401
NCT00736749|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2017-10-19|2008-08-15|2008-08-18|Estimate|||||||2017-10-19|2017-10-23|Actual|May 2008||2008-05-31|October 2017|2017-10-31||||January 2100|Anticipated|2100-01-31||Observational|||Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies|Umbrella Long-Term Follow-Up Protocol|Recruiting|||4485|Anticipated|Children's Oncology Group|||1||f||||||||||||||2018-06-01 01:49:57.191231|2018-06-01 01:49:57.191231
NCT00736736|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2008-08-14|2008-08-14|2008-08-18|Estimate|||||||2008-08-14|2008-08-18|Estimate|March 2008||2008-03-31|June 2008|2008-06-30||||July 2008|Actual|2008-07-31||Interventional|||Effects of Hip Abductor and External Rotator Strength Training in Patients With Patellofemoral Pain Syndrome||Completed||N/A|85|Actual|National Taiwan University Hospital||3|||f||||||||||||||2018-06-01 01:49:57.77019|2018-06-01 01:49:57.77019
NCT00736723|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2015-12-02||2016-11-24|2008-08-15|2008-08-18|Estimate|2016-11-24|2017-01-20|Estimate||||2016-11-24|2017-01-20|Estimate|August 2008||2008-08-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Observational|NICUPS|surveyed daily for sepsis, organ dysfunctions and shock|NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock|NT-proBNP in Postoperative/Posttraumatic Critically Ill Patients With Severe SIRS/Sepsis and Shock|Completed|||51|Actual|University of Ulm|Myocardial depression has not been verified in our patients by a low cardiac index or by echocardiography||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, white blood cells~   "|Yes||2018-06-01 01:49:57.916474|2018-06-01 01:49:57.916474
NCT00736710|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2012-12-04|2008-08-15|2008-08-18|Estimate|||||||2012-12-04|2012-12-05|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||rTMS Effects on Smoking Cessation and Cognition in Schizophrenia|Effects of rTMS on Smoking Cessation and Cognitive Outcomes in Outpatients With Schizophrenia Treated With Transdermal Nicotine Patch|Completed||N/A|15|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 01:49:58.210137|2018-06-01 01:49:58.210137
NCT00736697|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2011-02-14|2008-08-15|2008-08-18|Estimate|||||||2011-02-14|2011-02-15|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin|An Open-Label, Randomized, Single-Dose, Parallel-Group Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Moxidectin Administered Orally to Healthy Subjects|Completed||Phase 1|54|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:49:58.285623|2018-06-01 01:49:58.285623
NCT00736684|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2011-02-10|2008-08-15|2008-08-18|Estimate|||||||2011-02-10|2011-02-11|Estimate|November 2007||2007-11-30|February 2011|2011-02-28|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|PROGAINT-ES||Proximal Femoral Nail Antirotation™ (PFNA) Versus Gamma Nail 3™ (Gamma3) for Intramedullary Nailing of Unstable Trochanteric Fractures|Proximal Femoral Nail Antirotation™ (PFNA) Versus Gamma Nail 3™ (Gamma3) for Intramedullary Nailing of Unstable Trochanteric Fractures - a Multicenter Randomized Controlled Trial|Completed||Phase 4|440|Anticipated|AO Clinical Investigation and Documentation||2|||f||||t||||||||||2018-06-01 01:49:58.364827|2018-06-01 01:49:58.364827
NCT00736658|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2009-09-29|2008-08-15|2008-08-18|Estimate|||||||2009-09-29|2009-09-30|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|September 2008|Actual|2008-09-30|||||Interventional|JMAD||AZD1386 Japanese Multiple Ascending Dosing Study|A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Japanese Young and Elderly Subjects After Oral Multiple Doses.|Completed||Phase 1|32|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:49:58.515042|2018-06-01 01:49:58.515042
NCT00736645|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2017-10-23||2017-10-23|2008-08-15|2008-08-18|Estimate|2017-10-23|2017-11-28|Actual||||2017-10-23|2017-11-28|Actual|August 2008||2008-08-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All treated and eligible patients|Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer|A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy|Completed||Phase 2|55|Actual|Roswell Park Cancer Institute||4|||f||||t||||||||||2018-06-01 01:49:58.591643|2018-06-01 01:49:58.591643
NCT00736632|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2018-02-05|2008-08-15|2008-08-18|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2006||2006-05-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|January 2016|Actual|2016-01-31||Interventional|||Vitamin D, Insulin Resistance, and Cardiovascular Disease|Vitamin D, Insulin Resistance, and Cardiovascular Disease|Active, not recruiting||N/A|90|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:49:59.117388|2018-06-01 01:49:59.117388
NCT00736619|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2016-08-09|2008-08-15|2008-08-18|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)|Completed||Phase 1|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:49:59.216443|2018-06-01 01:49:59.216443
NCT00736606|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2010-11-30|2008-08-15|2008-08-18|Estimate|||||||2010-11-30|2010-12-02|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Assess Co-Administered AZD9056 (Steady State) and Simvastatin (Single Dose) in Healthy Volunteers|A Phase I, Single Centre, Open-Label Study to Assess the Pharmacokinetics of Both AZD9056 (Steady State) and Simvastatin (Single Dose) When Co-Administered in Healthy Volunteers|Completed||Phase 1|12|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:49:59.300902|2018-06-01 01:49:59.300902
NCT00736593|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2009-04-23|2008-08-15|2008-08-18|Estimate|||||||2009-04-23|2009-04-27|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||A Study Evaluating Nexagon™ in the Treatment of Skin Wounds.|A Phase 1 Randomized, Prospective, Within-Subject, Double-Blind, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Full-Thickness Punch Wounds|Completed||Phase 1|43|Anticipated|CoDa Therapeutics Inc.||1|||f||||t||||||||||2018-06-01 01:49:59.383063|2018-06-01 01:49:59.383063
NCT00736580|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2012-12-18||2012-12-18|2008-08-14|2008-08-18|Estimate|2012-12-18|2013-01-24|Estimate||||2012-12-18|2013-01-24|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Glove Perforation When Using Blunt Verses Sharp Needles in Cesarean Delivery|Glove Perforation When Using Blunt vs. Sharp Needles in Cesarean Delivery|Completed||N/A|240|Actual|West Virginia University||2|||f||||f||||||||||2018-06-01 01:49:59.470659|2018-06-01 01:49:59.470659
NCT00736567|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2014-10-27|2008-08-14|2008-08-18|Estimate|||||||2014-10-27|2014-10-28|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|||||Observational|||Evaluation of a Diagnostic Enteric Card for Management of Diarrhea|Evaluation of a Diagnostic Enteric Card for Management of Diarrhea in a Clinical Site in Fortaleza, Brazil|Completed|||436|Actual|PATH|||||f||||f||||||Samples Without DNA|"~     Stool samples are retained for future research.~   "|||2018-06-01 01:49:59.7368|2018-06-01 01:49:59.7368
NCT00736554|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-01-04|2008-08-15|2008-08-18|Estimate|||||||2011-01-04|2011-01-05|Estimate|July 2008||2008-07-31|January 2011|2011-01-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Observational|CA-MRSA||What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center?|Prevalence of MRSA in Skin and Soft Tissue Infections in Two Ontario Emergency Departments.|Completed|||152|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 01:49:59.790653|2018-06-01 01:49:59.790653
NCT00736541|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2017-07-25|2008-08-15|2008-08-18|Estimate|||||||2017-07-25|2017-07-27|Actual|July 2004||2004-07-31|July 2017|2017-07-31|January 2008|Actual|2008-01-31|April 2007|Actual|2007-04-30||Interventional|NAC||N-acetylcysteine in Liver Transplantation|Investigation of the Efficacy of N-acetylcysteine (NAC) to Protect Against Hepato-renal Ischemia-reperfusion Injury in Patients Undergoing Orthotopic Liver Transplantation|Completed||N/A|100|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:49:59.847241|2018-06-01 01:49:59.847241
NCT00736528|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2009-02-23|2008-08-15|2008-08-18|Estimate|||||||2009-02-23|2009-02-25|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers|An Investigator And Subject-Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 In Healthy Elderly Subjects|Terminated||Phase 1|10|Actual|Pfizer||4||See Detailed Description for termination reason.|f||||f||||||||||2018-06-01 01:49:59.913278|2018-06-01 01:49:59.913278
NCT00736515|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|||2017-08-02|2008-08-15|2008-08-18|Estimate|||||||2017-08-02|2017-08-03|Actual|October 2008||2008-10-31|August 2017|2017-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|CODMS||Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes|Phase 4 Study of Comparison of Combination Therapy of Gliclazide MR and Basal Insulin With Pre-mix Insulin Monotherapy for the Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|160|Actual|Servier (Tianjin) Pharmaceutical Co. LTD.||2|||f||||t|f|f|||f|||Undecided||2018-06-01 01:50:00.006667|2018-06-01 01:50:00.006667
NCT00736502|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2012-07-30||2014-02-03|2008-08-15|2008-08-18|Estimate|2012-07-30|2012-08-31|Estimate||||2014-02-03|2014-03-07|Estimate|September 2008||2008-09-30|February 2014|2014-02-28||||July 2011|Actual|2011-07-31||Observational||Treated set|PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.|Longterm Efficacy and Safety of NVP-based HAART in HIV-1 Positive Patients in the Daily Clinical Practice.|Completed|||280|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 01:50:00.096879|2018-06-01 01:50:00.096879
NCT00736489|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-15|2010-11-30||2014-05-08|2008-08-15|2008-08-18|Estimate|2014-02-21|2014-04-03|Estimate||||2014-05-08|2014-05-19|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199|A Phase II, Double-blind, Placebo-controlled, Randomised, 6-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a β2-agonist) Compared to Formoterol in Asthmatic Patients|Completed||Phase 2|37|Actual|AstraZeneca||6|||f||||f||||||||||2018-06-01 01:50:00.362512|2018-06-01 01:50:00.362512
NCT00736476|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2016-09-30||2017-01-09|2008-08-13|2008-08-15|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|October 2008||2008-10-31|September 2016|2016-09-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults|Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity, and Efficacy of an Novartis' Investigational H. Pylori Vaccine in H. Pylori-Negative Adults|Completed||Phase 1|63|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:50:01.776131|2018-06-01 01:50:01.776131
NCT00736463|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-07-20|2008-08-14|2008-08-15|Estimate|||||||2011-07-20|2011-07-22|Estimate|January 2005||2005-01-31|August 2008|2008-08-31||||January 2012|Anticipated|2012-01-31||Interventional|||Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)|Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein|Unknown status|Recruiting|Phase 4|80|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 01:50:02.416992|2018-06-01 01:50:02.416992
NCT00736450|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2012-10-11|2008-08-14|2008-08-15|Estimate|||||||2012-10-11|2012-10-15|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R|Terminated||N/A|37|Actual|University of Nebraska||1||Manufacturer is no longer making the drug.|f||||t||||||||||2018-06-01 01:50:02.494201|2018-06-01 01:50:02.494201
NCT00736437|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2008-08-14|2008-08-14|2008-08-15|Estimate|||||||2008-08-14|2008-08-15|Estimate|August 1999||1999-08-31|August 2008|2008-08-31|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis|Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis|Completed||Phase 2|417|Actual|Medivir||2|||f||||f||||||||||2018-06-01 01:50:02.616472|2018-06-01 01:50:02.616472
NCT00736424|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2014-01-10|2008-08-13|2008-08-15|Estimate|||||||2014-01-10|2014-01-14|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|SUDEP||Brain Stimulation for Epilepsy Long Term Follow-up|Brain Stimulation for Epilepsy Long Term Follow-up|Completed|||9|Actual|MedtronicNeuro|||1||f||||t||||||||||2018-06-01 01:50:02.700599|2018-06-01 01:50:02.700599
NCT00736411|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2015-10-27|2008-08-14|2008-08-15|Estimate|||||||2015-10-27|2015-10-29|Estimate|August 2008||2008-08-31|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||In Vitro Fertilization (IVF) and Acupuncture for Infertility|IVF and Acupuncture for Infertility: A Randomized Controlled Trail|Terminated||N/A|320|Actual|Pacific Fertility Center||2||"Adjustments to ensure clear outcomes and scientific merit integrated. Study closed at 14~   subjects. New protocol submitted to IRB."|f||||t||||||||||2018-06-01 01:50:02.818193|2018-06-01 01:50:02.818193
NCT00736398|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2013-04-01|2008-08-14|2008-08-15|Estimate|||||||2013-04-01|2013-04-04|Estimate|August 2008||2008-08-31|April 2013|2013-04-30||||||||Observational|FACT||Fusion Assessment Clinical Trial|Fusion Assessment Clinical Trial (FACT)|Completed|||50|Anticipated|Flexuspine, Inc.|||1||f||||f||||||||||2018-06-01 01:50:02.923574|2018-06-01 01:50:02.923574
NCT00736385|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2015-03-17||2016-12-05|2008-08-14|2008-08-15|Estimate|2015-03-17|2015-03-26|Estimate||||2016-12-05|2016-12-07|Estimate|April 2009||2009-04-30|December 2016|2016-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|NAFLD||Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)|Hyperinsulinemia and Insulin Resistance in Nonalcoholic Fatty Liver Disease. Metformin for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial|Terminated||Phase 4|11|Actual|Duke University|Study was terminated early due to difficulties with enrollment.|2|||f||||f||||||||||2018-06-01 01:50:02.989658|2018-06-01 01:50:02.989658
NCT00736372|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2018-05-14|2008-08-14|2008-08-15|Estimate|||||||2018-05-14|2018-05-17|Actual|June 2008||2008-06-30|March 2013|2013-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer|A Phase Ib Trial of PX-12 Administered as a 72-Hour Infusion Every 21 Days in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer That is Refractory to Standard Treatment|Completed||Phase 1|14|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 01:50:03.322077|2018-06-01 01:50:03.322077
NCT00736346|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2008-08-14|2008-08-14|2008-08-15|Estimate|||||||2008-08-14|2008-08-15|Estimate|October 2005||2005-10-31|August 2008|2008-08-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|MADONA||Treatment of Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain|Efficacy of Three Treatment Modalities for Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain|Unknown status|Recruiting|N/A|204|Anticipated|Universite du Quebec a Montreal||4|||f||||f||||||||||2018-06-01 01:50:03.402247|2018-06-01 01:50:03.402247
NCT00736333|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-06-13||2014-10-31|2008-08-14|2008-08-15|Estimate|2011-06-13|2011-07-07|Estimate||||2014-10-31|2014-11-05|Estimate|November 2006||2006-11-30|October 2014|2014-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)|Observational Program of Caelyx in MBC - Prevention and Treatment of PPE and Infusion Reactions|Completed|||167|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:50:03.512661|2018-06-01 01:50:03.512661
NCT00736320|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2017-05-02|2008-08-14|2008-08-15|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2009||2009-11-30|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|HD16||HD16 for Early Stage Hodgkin Lymphoma|HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET|Active, not recruiting||Phase 3|1150|Actual|University of Cologne||2|||f||||t||||||||||2018-06-01 01:50:03.681727|2018-06-01 01:50:03.681727
NCT00736307|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-07-14|2008-08-14|2008-08-15|Estimate|||||||2011-07-14|2011-07-15|Estimate|October 2007||2007-10-31|April 2010|2010-04-30|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients|Transplantation of Ex-Vivo Expanded Human Limbal Epithelial Stem Cells (LSC) on Amniotic Membrane (AM) for Limbal Stem Cell Deficiency (LSCD)|Completed||Phase 1/Phase 2|10|Actual|Royan Institute||1|||f||||t||||||||||2018-06-01 01:50:04.78334|2018-06-01 01:50:04.78334
NCT00736294|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-07-27|2008-08-14|2008-08-15|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2008||2008-07-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PREFACE||Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter|Prevention of Atrial Fibrillation by the Prescription of Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter|Terminated||Phase 3|198|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||Difficulty to include patients|f||||t||||||||||2018-06-01 01:50:04.891147|2018-06-01 01:50:04.891147
NCT00736281|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2016-06-16|2008-08-14|2008-08-15|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2008||2008-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Sublingual Immunotherapy for Food Allergy|Sublingual Immunotherapy for Food Allergy|Terminated||N/A|31|Actual|University of Missouri-Columbia||2||Due to recently published research, this is no longer a novel study.|f||||t||||||||||2018-06-01 01:50:04.996087|2018-06-01 01:50:04.996087
NCT00736268|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2014-08-06|2008-08-14|2008-08-15|Estimate|||||||2014-08-06|2014-08-07|Estimate|August 2008||2008-08-31|August 2014|2014-08-31||||May 2013|Actual|2013-05-31||Interventional|||Coping Skills for Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Caregivers|Telephone-based Intervention for Patients With COPD and Their Caregivers|Completed||N/A|746|Actual|Duke University||2|||f||||t||||||||||2018-06-01 01:50:05.079852|2018-06-01 01:50:05.079852
NCT00736255|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-08-17||2016-07-22|2008-08-14|2008-08-15|Estimate|2012-08-07|2012-09-07|Estimate||||2016-07-22|2016-09-02|Estimate|December 2007||2007-12-31|July 2016|2016-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study|Lis-dexamphetamine (LDX/SPD489)as a Treatment for Smoking Cessation in Nicotine Dependent Individuals With ADHD|Completed||N/A|32|Actual|Duke University|Limitations of the study: 1. Our sample size was quite small and this can realistically only be considered a pilot trial. 2.We did not collect systematic follow-up data on our sample after the end of treatment.3.the duration of our trial was short.|2|||f||||f||||||||||2018-06-01 01:50:05.19568|2018-06-01 01:50:05.19568
NCT00736242|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2012-12-21||2015-02-02|2008-08-14|2008-08-15|Estimate|2013-02-27|2013-04-08|Estimate||||2015-02-02|2015-02-19|Estimate|December 2005||2005-12-31|February 2015|2015-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)|Treatment of Chronic Hepatitis C in HIV-infected Patients With PegIntron Pen and Rebetol According to German Law (§ 67 Abs 6 AMG)|Completed|||232|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:50:05.686339|2018-06-01 01:50:05.686339
NCT00736229|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-06-04||2014-11-19|2008-08-14|2008-08-15|Estimate|2014-11-19|2014-11-20|Estimate||||2014-11-19|2014-11-20|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|August 2012|Actual|2012-08-31|June 2011|Actual|2011-06-30||Interventional|||Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients|Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit|Completed||Phase 4|40|Actual|Saint Luke's Health System|Modest number of patients enrolled, not powered to examine the effects of exenatide on hard clinical outcomes, no randomization, differences in baseline glucose levels and duration of therapy.|1|||f||||t||||||||||2018-06-01 01:50:06.085839|2018-06-01 01:50:06.085839
NCT00736216|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-03-17|2008-08-14|2008-08-15|Estimate|||||||2015-03-17|2015-03-19|Estimate|July 2008||2008-07-31|March 2015|2015-03-31||||July 2009|Actual|2009-07-31||Observational|||Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults|Knowledge and Perceptions About Human Papillomavirus and Cervical Cancer Risk Among Young Adults|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||PI left the institution|f||||t||||||||||2018-06-01 01:50:06.418302|2018-06-01 01:50:06.418302
NCT00736203|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2013-02-06|2008-08-14|2008-08-15|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|MPVS||Memory and Picture Viewing Study|Memory and Picture Viewing Study|Completed|||116|Actual|Duke University|||1||f||||f||||||Samples With DNA|"~     saliva, blood~   "|||2018-06-01 01:50:06.49308|2018-06-01 01:50:06.49308
NCT00736190|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-07-07||2011-11-30|2008-08-14|2008-08-15|Estimate|2011-07-07|2011-08-03|Estimate||||2011-11-30|2011-12-05|Estimate|August 2008||2008-08-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection|A Phase IV Study to Evaluate the Efficacy, Safety and Tolerability of Tenofovir DF in Asian-American Adults With Chronic Hepatitis B Infection|Completed||Phase 4|90|Actual|Gilead Sciences||1|||f||||f||||||||||2018-06-01 01:50:06.598806|2018-06-01 01:50:06.598806
NCT00736177|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2014-04-08|2008-08-13|2008-08-15|Estimate|||||||2014-04-08|2014-04-09|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Comparison of Transfers of Fresh and Thawed Embryos in Patients With Prior Failed Embryo Transfer Cycles|Comparison of Transfers of Fresh and Thawed Embryos in Patients With Prior Failed Embryo Transfer Cycles|Withdrawn||N/A|0|Actual|Fertility Center of Las Vegas||2||No recruitment|f||||f||||||||||2018-06-01 01:50:07.088666|2018-06-01 01:50:07.088666
NCT00736164|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2012-02-03|2008-08-14|2008-08-15|Estimate|||||||2012-02-03|2012-02-06|Estimate|August 2008||2008-08-31|February 2012|2012-02-29||||June 2012|Anticipated|2012-06-30||Interventional|||Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer|A Randomized, Double Blind, Placebo Controlled Clinical Trial of Supplementation of L-Selenomethionine in Patients With Prostate Cancer Prior to Prostatectomy or Brachytherapy (Se Pre-Prostatectomy/Pre-Brachytherapy Trial)|Withdrawn||Phase 2|0|Actual|Roswell Park Cancer Institute||2||No accrual|f||||||||||||||2018-06-01 01:50:07.190796|2018-06-01 01:50:07.190796
NCT00736151|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2009-08-06|2008-08-14|2008-08-15|Estimate|||||||2009-08-06|2009-08-07|Estimate|May 2004||2004-05-31|August 2009|2009-08-31||||April 2007|Actual|2007-04-30||Interventional|||Phase II Dose Titration Study in Patients With Neuropathic Pain|A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain|Completed||Phase 2|272|Actual|Newron Pharmaceuticals SPA||2|||f||||||||||||||2018-06-01 01:50:07.275083|2018-06-01 01:50:07.275083
NCT00736138|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-12-10|2008-08-14|2008-08-15|Estimate|||||||2015-12-10|2015-12-11|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Hyperpronation and Foot Pain|Effect of Training and Pellots in Treatment of Foot Pain Caused by Hyperpronation|Completed||N/A|50|Actual|Northern Orthopaedic Division, Denmark||2|||f||||||||||||||2018-06-01 01:50:07.42262|2018-06-01 01:50:07.42262
NCT00727168|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2008-08-01|2008-07-30|2008-08-01|Estimate|||||||2008-08-01|2008-08-04|Estimate|November 2007||2007-11-30|August 2008|2008-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Screening for Glaucoma in Namil Area, South Korea|Epidemiologic Study for the Prevalence of Glaucoma in Namil Area, Geumsan City, South Korea|Completed|||1532|Actual|Korean Glaucoma Society|||||f||||t||||||||||2018-06-01 01:53:12.87041|2018-06-01 01:53:12.87041
NCT00736125|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-03-05||2013-04-17|2008-08-14|2008-08-15|Estimate|2013-04-16|2013-04-18|Estimate||||2013-04-17|2013-04-19|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|September 2009|Actual|2009-09-30||Interventional|||A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events|A Comparison of Intraoperative Embolic Events During Total Knee Arthroplasty Performed With CarboJet Assisted Versus Standard Orthopedic Techniques: A Pilot Study|Completed||Phase 2|20|Actual|Kinamed Incorporated||2|||f||||f||||||||||2018-06-01 01:50:07.517693|2018-06-01 01:50:07.517693
NCT00736112|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2016-09-29|2008-08-14|2008-08-15|Estimate|||||||2016-09-29|2016-09-30|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|FATA||Food Allergy - Tubes - Adenoids (FATA) Trial|A New Approach to Otitis Media With Effusion (OME)|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||3||The investigator left the institution|f||||t||||||||No||2018-06-01 01:50:07.805|2018-06-01 01:50:07.805
NCT00736099|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2011-12-21||2014-06-18|2008-08-14|2008-08-15|Estimate|2012-02-06|2012-03-08|Estimate||||2014-06-18|2014-06-27|Estimate|August 2008||2008-08-31|December 2013|2013-12-31||||December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM|A 78 Week Open Label Extension to Trials Assessing the Safety and Efficacy of BI 1356 (5 mg) as Monotherapy or in Combination With Other Antidiabetic Medications in Type 2 Diabetic Patients.|Completed||Phase 3|2122|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:50:08.00122|2018-06-01 01:50:08.00122
NCT00736086|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2008-08-14|2008-08-14|2008-08-15|Estimate|||||||2008-08-14|2008-08-15|Estimate|March 2006||2006-03-31|August 2008|2008-08-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Observational|||RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System|A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization|Completed|||165|Actual|Abbott Vascular|||1||f||||t||||||||||2018-06-01 01:50:09.888017|2018-06-01 01:50:09.888017
NCT00736073|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2012-11-15||2015-06-18|2008-08-14|2008-08-15|Estimate|2013-03-11|2013-04-19|Estimate||||2015-06-18|2015-06-22|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|August 2010|Actual|2010-08-31||Interventional|||A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|A Randomized, Double-Blind, Prospective Trial of Oral Administration of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Completed||N/A|73|Actual|Duke University|Unable to control for pre-procedure dosing|2|||f||||f||||||||||2018-06-01 01:50:10.007636|2018-06-01 01:50:10.007636
NCT00736060|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-08-25|2008-08-14|2008-08-15|Estimate|||||||2011-08-25|2011-08-26|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|November 2008|Actual|2008-11-30|||||Observational|||Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever|Study the Clinical and Laboratory Characteristics and the Outcome of Sickle Cell Anemia Patients Admitted to the Pediatric Ward Because of Fever as the Presenting Symptom|Completed|||60|Anticipated|HaEmek Medical Center, Israel|||2||f||||f||||||||||2018-06-01 01:50:10.331313|2018-06-01 01:50:10.331313
NCT00736047|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2017-03-17|2008-08-14|2008-08-15|Estimate|||||||2017-03-17|2017-03-21|Actual|August 2008|Actual|2008-08-31|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.|A Double Blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.|Completed||Phase 2|200|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:50:10.42868|2018-06-01 01:50:10.42868
NCT00736034|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2010-03-04||2010-03-26|2008-08-14|2008-08-15|Estimate|2010-03-04|2010-03-24|Estimate||||2010-03-26|2010-03-30|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment|A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment|Completed||Phase 4|18|Actual|Enzymotec|||||f||||||||||||||2018-06-01 01:50:10.531023|2018-06-01 01:50:10.531023
NCT00736021|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2010-03-21|2008-08-14|2008-08-15|Estimate|||||||2010-03-21|2010-03-23|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Treatment of Post-traumatic Stress Disorder With High Doses of Escitalopram|Post-marketing, Twelve Weeks, Open Label Study of up to 40 mg. Escitalopram in Chronic PTSD|Completed||N/A|38|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:50:10.660734|2018-06-01 01:50:10.660734
NCT00736008|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-08-25|2008-08-14|2008-08-15|Estimate|||||||2011-08-25|2011-08-26|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Thrombophilic Risk Factors in Pediatric Patients Diagnosed at the Ha'Emek Medical Center|The Study Will Summarize the Clinical and Laboratory Data of All the Pediatric Patients Diagnosed With Thrombotic Events at the Pediatric Hematology Unit|Completed|||100|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-06-01 01:50:10.765951|2018-06-01 01:50:10.765951
NCT00735995|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2014-04-11|2008-08-13|2008-08-15|Estimate|||||||2014-04-11|2014-04-14|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Effectiveness of Cognitive Behavioral Therapy (CBT) for Child Anxiety Disorders in Community Clinics in Norway|Effectiveness of Group and Individual Treatment of Childhood Anxiety Disorders in Community Clinics. A Randomized Controlled Trial.|Completed||Phase 2|165|Actual|Regionsenter for barn og unges psykiske helse||3|||f||||f||||||||||2018-06-01 01:50:10.839127|2018-06-01 01:50:10.839127
NCT00735969|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2014-06-16||2014-10-10|2008-08-14|2008-08-15|Estimate|2014-09-08|2014-09-16|Estimate||||2014-10-10|2014-10-20|Estimate|August 2008||2008-08-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Patients 18 years of age and older with chronic hepatitis C genotype 1 who have not been successfully treated with a standard course of Peginterferon and ribavirin.|High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1|High Dose Ribavirin in Combination With Peginterferon for Patients With Chronic Hepatitis C Genotype 1 Infection Who Have Failed to Respond or Relapsed After Standard Therapy|Completed||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||f||||||||||2018-06-01 01:50:10.97633|2018-06-01 01:50:10.97633
NCT00735956|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2010-08-19|2008-08-14|2008-08-15|Estimate|||||||2010-08-19|2010-08-23|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|PARTNER||PARTNER Recruitment and Brief Intervention Pilot Study|PARTNER: The Underage Drinking: Building Health Care System Research|Completed||Phase 1/Phase 2|300|Anticipated|Duke University|||||f||||f||||||||||2018-06-01 01:50:11.176072|2018-06-01 01:50:11.176072
NCT00735943|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2011-07-21||2011-08-26|2008-08-14|2008-08-15|Estimate|2011-07-21|2011-08-16|Estimate||||2011-08-26|2011-08-29|Estimate|November 2008||2008-11-30|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Macugen Observational Study|Macugen Observational Study|Terminated|||22|Actual|Pfizer|Outcome measures were not designated as primary or secondary measures as this study was an observational non-interventional study.|||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:50:11.274822|2018-06-01 01:50:11.274822
NCT00735930|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-04-01|2008-08-14|2008-08-15|Estimate|||||||2015-04-01|2015-04-02|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|March 2013|Actual|2013-03-31||Interventional|||Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase 1 Trial of Flavopiridol in Combination With Lenalidomide in Patients With Relapsed or Refractory B-Cell CLL/SLL|Completed||Phase 1|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:50:11.53551|2018-06-01 01:50:11.53551
NCT00735917|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-10-07||2014-04-25|2008-08-14|2008-08-15|Estimate|2013-10-07|2013-12-05|Estimate||||2014-04-25|2014-05-14|Estimate|October 2008||2008-10-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional|||Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer|A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:50:11.634309|2018-06-01 01:50:11.634309
NCT00735904|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2012-11-30|2011-12-16|2012-11-30|2008-08-13|2008-08-15|Estimate|2012-11-30|2013-01-03|Estimate|2011-12-16|2011-12-22|Estimate|2012-11-30|2013-01-03|Estimate|December 2008||2008-12-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer|Phase 2 Trial Of AG-013736 As First-Line Treatment For Patients With Squamous Non-Small Cell Lung Cancer Receiving Treatment With Cisplatin And Gemcitabine|Completed||Phase 2|38|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:50:12.03766|2018-06-01 01:50:12.03766
NCT00735878|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2009-04-29|2008-08-14|2008-08-15|Estimate|||||||2009-04-29|2009-04-30|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|January 2009|Actual|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|||Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer|A Phase I/II Pharmacokinetic and Pharmacodynamic Study of ABT-751 in Combination With Carboplatin in Patients With Advanced Lung Cancer|Terminated||Phase 1/Phase 2|33|Anticipated|Dartmouth-Hitchcock Medical Center||||"It was decided to close the study to further enrollment based on data from a similar study~   using ABT-751 and Pemetrexed that did not show efficacy."|f||||t||||||||||2018-06-01 01:50:12.282929|2018-06-01 01:50:12.282929
NCT00735865|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2009-05-22|2008-08-13|2008-08-15|Estimate|||||||2009-05-22|2009-05-25|Estimate|July 2003||2003-07-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion|Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion|Completed||N/A|55|Actual|Lahey Clinic||4|||f||||f||||||||||2018-06-01 01:50:12.402027|2018-06-01 01:50:12.402027
NCT00735852|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2016-10-12|2008-08-14|2008-08-15|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2008||2008-12-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women|A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women|Completed||Phase 4|31|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||t||||||||||2018-06-01 01:50:12.483202|2018-06-01 01:50:12.483202
NCT00735839|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2012-05-23||2015-12-18|2008-08-13|2008-08-15|Estimate|2012-05-23|2012-06-26|Estimate||||2015-12-18|2015-12-21|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck S. Aureus Vaccine (V710) in Healthy Male Japanese Subjects|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:50:12.634318|2018-06-01 01:50:12.634318
NCT00735826|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2011-12-02|2008-08-14|2008-08-15|Estimate|||||||2011-12-02|2011-12-05|Estimate|March 2009||2009-03-31|December 2011|2011-12-31||||December 2012|Anticipated|2012-12-31||Interventional|||A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer|A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|N/A|10|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 01:50:12.868763|2018-06-01 01:50:12.868763
NCT00735813|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2012-09-04|2008-08-14|2008-08-15|Estimate|||||||2012-09-04|2012-09-05|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia|A Randomised Study of Taurolock for the Locking of Tunneled Central Venous Catheters in Children With Malignant Diseases.|Completed||Phase 3|129|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-06-01 01:50:12.974281|2018-06-01 01:50:12.974281
NCT00735800|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-05-04|2008-08-14|2008-08-15|Estimate|||||||2015-05-04|2015-05-05|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Telephone Support for Dementia Caregivers|Psychosocial Telephone Intervention for Dementia Caregivers|Completed||Phase 2|250|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-06-01 01:50:13.10478|2018-06-01 01:50:13.10478
NCT00735787|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2010-09-01||2010-10-11|2008-08-14|2008-08-15|Estimate|2010-10-11|2010-11-01|Estimate||||2010-10-11|2010-11-01|Estimate|August 2008||2008-08-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet|Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet|Completed||Phase 4|81|Actual|Abbott|Based on one investigator's non-compliance with the protocol at one site, ITT analyses were conducted in a smaller number of subjects that excluded all 9 subjects from this one site.|2|||f||||f||||||||||2018-06-01 01:50:13.239942|2018-06-01 01:50:13.239942
NCT00735774|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2009-11-23|2008-08-13|2008-08-15|Estimate|||||||2009-11-23|2009-11-25|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Suitability of 11C-ORM-13070 as a PET Tracer|Suitability of 11C-ORM-13070 as a Positron Emission Tomography Tracer; an Open Study in Healthy Males|Completed||Phase 1|18|Actual|Orion Corporation, Orion Pharma||1|||f||||f||||||||||2018-06-01 01:50:14.097549|2018-06-01 01:50:14.097549
NCT00731640|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2009-09-09||2010-03-19|2008-08-08|2008-08-11|Estimate|2010-03-04|2010-03-16|Estimate||||2010-03-19|2010-03-23|Estimate|June 2007||2007-06-30|March 2010|2010-03-31||||May 2008|Actual|2008-05-31||Interventional|||Contralateral ReSTOR / Monofocal or Phakic Eye|Clinical Outcomes With AcrySof ReSTOR Aspheric Apodized Diffractive Intraocular Lens (IOL) in One Eye and a Contralateral Monofocal IOL or Phakic Eye|Completed||Phase 4|52|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 01:51:48.999878|2018-06-01 01:51:48.999878
NCT00735761|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2008-08-14|2008-08-14|2008-08-15|Estimate|||||||2008-08-14|2008-08-15|Estimate|December 2006||2006-12-31|August 2008|2008-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients|A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients|Completed||Phase 3|201|Actual|Medivir||2|||f||||f||||||||||2018-06-01 01:50:14.158389|2018-06-01 01:50:14.158389
NCT00735748|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2014-12-04|2008-08-14|2008-08-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Comparison of Tramadol Orally Versus an Optimized Dose of Intravenous Tramadol for Postoperative Pain Relief in Ambulatory Surgery|Comparison of the Therapeutic Efficacy and Side Effects of Tramadol Per os (Tradonal Odis® Orodispersible Tablets) Versus an Optimised Dosis of Intravenous Tramadol for Postoperative Pain Relief in Ambulatory Surgery.|Unknown status|Recruiting|Phase 4|200|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 01:50:14.21645|2018-06-01 01:50:14.21645
NCT00735735|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2014-03-11|2008-08-14|2008-08-15|Estimate|||||||2014-03-11|2014-03-13|Estimate|February 2009||2009-02-28|March 2014|2014-03-31||||January 2012|Actual|2012-01-31||Interventional|||Measurement of Substance P in Saliva of Low Back Pain Patients|Study of the Measurement of Substance P in the Saliva of Patients With Low Back Pain|Suspended||N/A|40|Anticipated|Kovacs Foundation|||||f||||t||||||||||2018-06-01 01:50:14.297143|2018-06-01 01:50:14.297143
NCT00735722|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2016-03-31|2008-08-14|2008-08-15|Estimate|||||||2016-03-31|2016-04-04|Estimate|July 2009||2009-07-31|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|AFMAZE-CABG||A(f)MAZE-CABG Study|A Prospective Randomized Trial Comparing Freedom From Atrial Fibrillation at One Year Post CABG in Patients Undergoing Concomitant Left Atrial Ablation Using HIFU Versus CABG in Patients With Persistent or Long Standing Persistent AF|Terminated||N/A|188|Actual|St. Jude Medical||2||Insufficient recruitment|f||||t||||||||||2018-06-01 01:50:14.374607|2018-06-01 01:50:14.374607
NCT00735709|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-10-25||2013-10-25|2008-08-14|2008-08-15|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|August 2008||2008-08-31|October 2013|2013-10-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder|Completed||Phase 3|560|Actual|Takeda||4|||f||||f||||||||||2018-06-01 01:50:14.594822|2018-06-01 01:50:14.594822
NCT00735696|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2014-12-17|2010-07-26|2014-12-17|2008-08-14|2008-08-15|Estimate|2014-12-17|2014-12-29|Estimate|2010-07-26|2010-07-29|Estimate|2014-12-17|2014-12-29|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional||Modified intent to treat population (mITT): All participants who received any quantity of study drug.|A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer|A Phase 2, Open-label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-line Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer|Completed||Phase 2|41|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 01:50:16.857065|2018-06-01 01:50:16.857065
NCT00735683|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2015-05-29|2008-08-14|2008-08-15|Estimate|||||||2015-05-29|2015-06-02|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety|Double-Blind, Randomized, Placebo-Controlled, 12-Week Study of the Safety and Efficacy of ATHX-105 Phosphate for the Treatment of Obesity|Withdrawn||Phase 2|0|Actual|Athersys, Inc||6|||f||||f||||||||||2018-06-01 01:50:17.293014|2018-06-01 01:50:17.293014
NCT00735670|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2013-04-03||2016-10-07|2008-08-14|2008-08-15|Estimate|2016-10-07|2016-10-13|Estimate||||2016-10-07|2016-10-13|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional||Participants meeting eligibility criteria for the final protocol version.|Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury|Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury|Completed||N/A|34|Actual|University of Michigan|Difficulties with recruitment and high rate of withdrawal (57%) resulted in a very small sample. As such, results must be taken with caution given low power in this study.|2|||f||||t||||||||||2018-06-01 01:50:17.370236|2018-06-01 01:50:17.370236
NCT00735657|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-02-24|2008-08-14|2008-08-15|Estimate|||||||2010-02-24|2010-02-25|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Anesthesia for Pars Plana Vitrectomy (PPV) With Insulin Needle|Anesthesia for PPV Using Insulin Needle|Unknown status|Recruiting|N/A|120|Anticipated|King Khaled Eye Specialist Hospital||2|||f||||t||||||||||2018-06-01 01:50:17.687568|2018-06-01 01:50:17.687568
NCT00735644|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2014-06-25||2015-04-01|2008-08-14|2008-08-15|Estimate|2014-07-25|2014-08-15|Estimate||||2015-04-01|2015-04-21|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional||The baseline analysis population represents the participants who have received the trial vaccine or control vaccine (safety analysis set). Data on participants were analyzed and presented according to the vaccine they actually received.|Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines|Lot-to-lot Consistency, Bridging, and Safety Trial of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines|Completed||Phase 3|1200|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 01:50:17.785294|2018-06-01 01:50:17.785294
NCT00735631|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-12-06|2008-08-14|2008-08-15|Estimate|||||||2011-12-06|2011-12-07|Estimate|June 2008||2008-06-30|December 2011|2011-12-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Evaluation of the Accuracy, Safety and Robustness of a Single-input-single-output (SISO) Model-based Predictive Closed-loop System to Guide Patient-individualized ICU Sedation|Evaluation of the Accuracy, Safety and Robustness of a Single-input-single-output (SISO) Model-based Predictive Closed-loop System to Guide Patient-individualized ICU Sedation.|Completed||Phase 4|36|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 01:50:18.620651|2018-06-01 01:50:18.620651
NCT00735618|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2009-03-03||2011-11-15|2008-08-13|2008-08-15|Estimate|2011-11-15|2011-12-19|Estimate||||2011-11-15|2011-12-19|Estimate|June 2008||2008-06-30|November 2011|2011-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Relaxation and Heart Rate Variability|Pilot Study on the Effects of a Brief Relaxation Program on Heart Rate Variability in Cancer Patients|Completed||N/A|20|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:50:18.70273|2018-06-01 01:50:18.70273
NCT00735605|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2010-01-12|2008-08-14|2008-08-15|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2006||2006-09-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparative Study Between Surgical and Non Surgical Treatment of Anismus in Patients|Comparative Study Between Surgical and Non Surgical Treatment of Anismus in Patients With Symptoms of Obstructed Defecation|Completed||N/A|60|Actual|Mansoura University||3|||f||||t||||||||||2018-06-01 01:50:18.826018|2018-06-01 01:50:18.826018
NCT00735592|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2011-08-25|2008-08-14|2008-08-15|Estimate|||||||2011-08-25|2011-08-26|Estimate|March 2008||2008-03-31|August 2011|2011-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Value of Radiological Follow up in Children Hospitalized With Lobar Pneumonia|The Study Intend to Evaluate the Usefulness of Performing a Follow up X Rays in Children Admitted With Lobar Pneumonia.|Completed|||200|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-06-01 01:50:18.895676|2018-06-01 01:50:18.895676
NCT00735579|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2017-04-21|2008-08-14|2008-08-15|Estimate|||||||2017-04-21|2017-04-24|Actual|July 2008||2008-07-31|April 2017|2017-04-30|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Observational|INWOUND||Wound Healing Abnormalities in Major Abdominal Surgery|Incidence of Wound-healing-abnormalities in Major Abdominal Surgery - Association With Factors of Coagulation|Completed|||260|Actual|Klinikum St. Georg gGmbH|||1||f||||f||||||Samples Without DNA|"~     1) serum samples for measurement of coagulation factors~   "|||2018-06-01 01:50:19.015749|2018-06-01 01:50:19.015749
NCT00735566|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2012-10-16|2008-08-14|2008-08-15|Estimate|||||||2012-10-16|2012-10-18|Estimate|April 2006||2006-04-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|July 2008|Actual|2008-07-31||Observational|||Antiangiogenic Factors in Gastric Cancer|The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression|Completed|||240|Actual|National Cancer Center, Korea|||||f||||f||||||Samples Without DNA|"~     Serum for protein assay using ELISA~   "|||2018-06-01 01:50:19.121615|2018-06-01 01:50:19.121615
NCT00735553|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2014-06-25||2014-08-05|2008-08-13|2008-08-15|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated|Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids|A Phase III, Three-arm, Parallel Design, Placebo-controlled, Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids|Terminated||Phase 3|77|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2018-06-01 01:50:19.229583|2018-06-01 01:50:19.229583
NCT00735540|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-08-30|2008-08-14|2008-08-15|Estimate|||||||2015-08-30|2015-09-01|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Clinical Diagnosis of Teenagers Admitted to Pediatric Departments|The Purpose of This Study is to Analyze the Clinical Characteristics of Teenagers Admitted to Pediatric Departments|Completed|||1389|Actual|HaEmek Medical Center, Israel|||3||f||||t||||||||||2018-06-01 01:50:19.42752|2018-06-01 01:50:19.42752
NCT00735527|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2009-05-04|2008-08-14|2008-08-15|Estimate|||||||2009-05-04|2009-05-05|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|INLOR||Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children|Intra-Nasal vs. Intra-Venous Lorazepam for Control of Acute Seizures in Children: Prospective Open Labeled Randomized Equivalence Trial|Completed||Phase 3|140|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 01:50:19.514154|2018-06-01 01:50:19.514154
NCT00735514|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-10-01|2008-08-14|2008-08-15|Estimate|||||||2015-10-01|2015-10-02|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|||Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer|Adherence to Vaginal Dilation Following Pelvic Radiotherapy for Gynecological Cancers|Completed|||83|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 01:50:19.605212|2018-06-01 01:50:19.605212
NCT00735501|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2014-10-28|2008-08-13|2008-08-15|Estimate|||||||2014-10-28|2014-10-29|Estimate|March 2008||2008-03-31|October 2014|2014-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes|Safety of Levemir® (Insulin Detemir) Treatment in Patients With Type 2 Diabetes|Completed|||314|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:50:19.686859|2018-06-01 01:50:19.686859
NCT00735488|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2015-08-30|2008-08-14|2008-08-15|Estimate|||||||2015-08-30|2015-09-01|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Sickle Cell Anemia Screening and Prevention in Northern Israel|Summary of the Data From the Prevention Programme for Hemoglobinopathies in Northern Israel|Completed|||69|Actual|HaEmek Medical Center, Israel|||2||f||||t||||||||||2018-06-01 01:50:19.809191|2018-06-01 01:50:19.809191
NCT00735475|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-07-03||2018-04-25|2008-08-14|2008-08-15|Estimate|2011-08-02|2011-09-01|Estimate||||2018-04-25|2018-05-23|Actual|October 2008||2008-10-31|April 2018|2018-04-30|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine|A Phase IV, Randomized, Observer-Blind, Multi-Center, Non Inferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Inactivated Split-Virion Influenza Vaccine in Adults Aged Greater Than or Equal to 65 Years|Completed||Phase 4|1268|Actual|Seqirus||2|||f||||||||||||||2018-06-01 01:50:19.930684|2018-06-01 01:50:19.930684
NCT00735462|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|2011-04-24||2011-06-21|2008-08-14|2008-08-15|Estimate|2011-06-21|2011-07-20|Estimate||||2011-06-21|2011-07-20|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts|A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts|Completed||Phase 3|511|Actual|Graceway Pharmaceuticals, LLC|There was a high percentage of lost to follow up in this study. Since the disease studied in this study can be wait and watch, typically a high lost to follow up rate were seen in these kind of trials.|3|||f||||f||||||||||2018-06-01 01:50:20.573978|2018-06-01 01:50:20.573978
NCT00735449|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-10-17||2012-11-13|2008-08-14|2008-08-15|Estimate|2011-10-17|2011-11-24|Estimate||||2012-11-13|2012-11-19|Estimate|July 2008||2008-07-31|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects|Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects|Completed||Phase 4|204|Actual|Allergan||2|||f||||||||||||||2018-06-01 01:50:20.938322|2018-06-01 01:50:20.938322
NCT00735436|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2012-12-31||2013-02-04|2008-08-14|2008-08-15|Estimate|2012-12-31|2013-02-04|Estimate||||2013-02-04|2013-02-11|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|July 2011|Actual|2011-07-31||Interventional|||A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)|Phase II Trial for Patients With Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Avastin Plus Irinotecan|Terminated||Phase 2|18|Actual|Duke University||1||Study enrollment was halted due to slow accrual.|f||||f||||||||||2018-06-01 01:50:21.235277|2018-06-01 01:50:21.235277
NCT00735423|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-14|||2018-02-06|2008-08-14|2008-08-15|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2008|Actual|2008-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Infant Diet Effects on Brain Function and Language Processing (fMRI)|Effects of Neonatal Diet on Language, Neurocognitive Functions at Eight Years Old: fMRI, ERP and Standardized Behavioral Measures|Active, not recruiting|||100|Anticipated|Arkansas Children's Hospital Research Institute|||1||f||||f||||||||||2018-06-01 01:50:21.454819|2018-06-01 01:50:21.454819
NCT00735410|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2016-11-30|2008-08-13|2008-08-15|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2008||2008-06-30|November 2011|2011-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2008/2009 When Administered to Adult and Elderly Subjects|Completed||Phase 3|134|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:50:21.576394|2018-06-01 01:50:21.576394
NCT00735397|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2015-09-16||2016-02-11|2008-08-13|2008-08-14|Estimate|2015-12-17|2016-01-26|Estimate||||2016-02-11|2016-03-14|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Completed||Phase 3|1218|Actual|Eisai Inc.||1|||f||||t||||||||||2018-06-01 01:50:21.709555|2018-06-01 01:50:21.709555
NCT00735384|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2018-01-12|2008-08-13|2008-08-14|Estimate|||||||2018-01-12|2018-01-16|Actual|September 2006||2006-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Muscle Force Assessment in the Intensive Care Unit and in Primary Myopathies|Application of Methodology of Non-invasive Stimulated Muscle Force Assessment to ICU Patients and Patients With Primary Myopathies to Characterize Their Muscle Weakness - Extension of the Study Protocol: 2008 to 2018|Recruiting|||80|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-06-01 01:50:24.742099|2018-06-01 01:50:24.742099
NCT00735371|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2010-02-01||2017-02-10|2008-08-13|2008-08-14|Estimate|2010-02-01|2010-02-23|Estimate||||2017-02-10|2017-03-20|Actual|October 2008||2008-10-31|February 2017|2017-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|314|Actual|Shire||4|||f||||f||||||||||2018-06-01 01:50:24.896042|2018-06-01 01:50:24.896042
NCT00735358|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-10-04|2008-08-13|2008-08-14|Estimate|||||||2010-10-04|2010-10-06|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Comparison of Endoscopic Injection of Conventional and Double Doses Cyanoacrylate for Gastric Variceal Hemorrhage||Completed||Phase 4|105|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-06-01 01:50:25.581471|2018-06-01 01:50:25.581471
NCT00735345|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2015-03-06|2008-08-13|2008-08-14|Estimate|||||||2015-03-06|2015-03-09|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma|Chemotherapy Induction and Chemoradiotherapy Combined With Cetuximab Respectively in Patients With Non-Metastatic Esophageal Carcinoma: A Multicentric Phase II Study|Terminated||Phase 2|50|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1||because of safety concerns the study was terminated prematurely|f||||f||||||||||2018-06-01 01:50:25.742945|2018-06-01 01:50:25.742945
NCT00735332|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2010-08-04|2008-08-13|2008-08-14|Estimate|||||||2010-08-04|2010-08-05|Estimate|August 2008||2008-08-31|August 2010|2010-08-31|October 2010|Anticipated|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma|A Phase IIa Study of TLN-232 as Second-line Therapy for Patients With Metastatic Melanoma|Terminated||Phase 2|49|Anticipated|Thallion Pharmaceuticals||1||License termination.|f||||f||||||||||2018-06-01 01:50:25.886235|2018-06-01 01:50:25.886235
NCT00735319|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-01-11|2008-08-13|2008-08-14|Estimate|||||||2010-01-11|2010-01-12|Estimate|September 2008||2008-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|TcB RCT||Transcutaneous Bilirubinometers in the Community|Transcutaneous Bilirubinometers in the Community and the Reduction of Morbidity Associated to Jaundice: A Clustered Randomized Controlled Trial.|Completed||N/A|10000|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 01:50:26.025186|2018-06-01 01:50:26.025186
NCT00735306|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-10-14||2015-05-22|2008-08-13|2008-08-14|Estimate|2011-10-14|2011-11-24|Estimate||||2015-05-22|2015-06-18|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|TART||Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma|A Phase I/II Trial of Radiation, Avastin and Tarceva for Resectable or Locally Advanced Pancreatic Adenocarcinoma|Completed||Phase 1|12|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:50:26.144251|2018-06-01 01:50:26.144251
NCT00735293|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-09-17|2008-08-13|2008-08-14|Estimate|||||||2008-09-17|2008-09-19|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|VASER AxHH||VASER Treatment of Axillary Hyperhidrosis/Bromidrosis|The Use of the VASER System in the Treatment of Axillary Hyperhidrosis and/or Axillary Bromidrosis|Completed||Phase 4|13|Actual|Commons Aesthetic Plastic Surgery||1|||f||||f||||||||||2018-06-01 01:50:26.488042|2018-06-01 01:50:26.488042
NCT00735280|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2012-01-03|2008-08-13|2008-08-14|Estimate|||||||2012-01-03|2012-01-05|Estimate|August 2008||2008-08-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|ISAR-REACT-3A||Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI|Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions|Completed||Phase 4|2505|Actual|Deutsches Herzzentrum Muenchen||1|||f||||f||||||||||2018-06-01 01:50:26.593567|2018-06-01 01:50:26.593567
NCT00735267|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12||2010-08-25|2012-11-09|2008-08-13|2008-08-14|Estimate||||2010-08-25|2010-08-30|Estimate|2012-11-09|2012-11-16|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)|A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder|Terminated||Phase 3|468|Actual|Pfizer||||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 01:50:26.725243|2018-06-01 01:50:26.725243
NCT00735254|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2017-04-24||2018-02-07|2008-08-13|2008-08-14|Estimate|2018-02-07|2018-02-08|Actual||||2018-02-07|2018-02-08|Actual|July 2008||2008-07-31|February 2018|2018-02-28|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional||PI left institution, no data available.|Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars|Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars|Terminated||N/A|3|Actual|The Cleveland Clinic|protocol was not followed and data was not collected. reported to IRB, closed study. PI left institution|4||PI decision|f||||f||||||||No||2018-06-01 01:50:27.076811|2018-06-01 01:50:27.076811
NCT00735241|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2015-05-21|2008-08-13|2008-08-14|Estimate|||||||2015-05-21|2015-05-22|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|FAST||FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma|Pilot Study of FOLFOX6 Plus Sir-Spheres® Microspheres (Chemo-radiotherapy) in Combination With Bevacizumab (Avastin) as a First Line Treatment in Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma|Withdrawn||Phase 2/Phase 3|0|Actual|Sirtex Medical||||Withdrawn by the study sponsor.|f||||t||||||||||2018-06-01 01:50:27.42179|2018-06-01 01:50:27.42179
NCT00735228|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-08-15|2008-08-13|2008-08-14|Estimate|||||||2008-08-15|2008-08-18|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|KMS||Tight Glycemic Control by Artificial Pancreas|Benefit of Tight Glycemic Control in Surgical Patients: Prospective Randomized Clinical Trial|Unknown status|Recruiting|N/A|400|Anticipated|Kochi University||2|||f||||t||||||||||2018-06-01 01:50:27.516845|2018-06-01 01:50:27.516845
NCT00735215|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2009-12-21|2008-08-13|2008-08-14|Estimate|||||||2009-12-21|2009-12-23|Estimate|October 2008||2008-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Observational|||Faslodex Registry: Fulvestrant in Current Clinical Practice|Faslodex Registry: a Belgian Observational Study to Evaluate the Use of Fulvestrant in Current Clinical Practice|Completed|||200|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:50:27.622066|2018-06-01 01:50:27.622066
NCT00735189|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-06-23|2008-08-12|2008-08-14|Estimate|||||||2010-06-23|2010-06-24|Estimate|November 2007||2007-11-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Does Anticoagulant Control Change Following Referral Back to the Primary Care Physician?|Does Anticoagulant Control Change Following Referral Back to the Primary Care Physician? A Prospective Randomized Trial|Completed||Phase 4|96|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 01:50:27.732702|2018-06-01 01:50:27.732702
NCT00735176|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2017-12-07|2008-08-13|2008-08-14|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2008|Actual|2008-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|NORCAT||The Norwegian Cervical Arthroplasty Trial|Treatment of Cervical Radiculopathy With Arthroplasty Compared With Discectomy With Fusion and Cage (ACDF. Clinical, Radiological and Biomechanical Aspects. A Randomized Multicenter Study.|Active, not recruiting||N/A|136|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-06-01 01:50:27.857553|2018-06-01 01:50:27.857553
NCT00735163|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2009-04-15|2008-08-13|2008-08-14|Estimate|||||||2009-04-15|2009-04-16|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|Aldea _01||Blood Glucose Control With A Software-Algorithm In Intensive Care Unit (ICU) Patients|Mono-Centric, Open, Non-Controlled Study To Investigate The Feasibility Of Blood Glucose Control With The Software-Algorithm eMPC (Enhanced Model Predictive Control) In ICU Patients|Completed||N/A|20|Actual|B. Braun Melsungen AG||1|||f||||f||||||||||2018-06-01 01:50:27.959942|2018-06-01 01:50:27.959942
NCT00735150|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-10-08|2008-08-12|2008-08-14|Estimate|||||||2010-10-08|2010-10-11|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk|Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk|Completed|||34|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 01:50:28.058177|2018-06-01 01:50:28.058177
NCT00735137|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2009-11-02|2008-08-13|2008-08-14|Estimate|||||||2009-11-02|2009-11-03|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|February 2012|Anticipated|2012-02-29|October 2011|Anticipated|2011-10-31||Interventional|||Randomized Study of Pessary Versus Standard Management in Women With Increased Chance of Premature Birth|Randomized Study of Pessary vs Standard Management in Women With Increased Chance of Premature Birth|Unknown status|Recruiting|Phase 3|2780|Anticipated|King's College Hospital NHS Trust||4|||f||||t||||||||||2018-06-01 01:50:28.150254|2018-06-01 01:50:28.150254
NCT00735124|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2017-04-26|2008-08-13|2008-08-14|Estimate|||||||2017-04-26|2017-04-28|Actual|November 6, 2008|Actual|2008-11-06|April 2017|2017-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Post-Operative Pain Scores and Analgesic Requirements After Elective Inguinal Herniorrhaphy|An Investigation of Post-Operative Pain Scores and Analgesic Requirements After Ambulatory Inguinal Herniorrhaphy With Pre-Operative Gabapentin Therapy|Terminated||Phase 2/Phase 3|5|Actual|University of Oklahoma||2||Changes to surgical practices led to the loss of eligible patients|f||||t||||||||No||2018-06-01 01:50:28.341592|2018-06-01 01:50:28.341592
NCT00735111|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2013-01-15|2008-08-13|2008-08-14|Estimate|||||||2013-01-15|2013-01-17|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Do Self-Rated Performance Status Scores Correlate With Health-Care-Provider-Scores?|Do Self-Rated Karnofsky Performance Status (KPS) Scores Correlate With Health-Care-Provider-Rated Scores?|Completed||N/A|200|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 01:50:28.426003|2018-06-01 01:50:28.426003
NCT00735098|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2013-02-04|2008-08-13|2008-08-14|Estimate|||||||2013-02-04|2013-02-06|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of Home-Based Rehabilitation Treatments Among Persons With Symptomatic Knee Osteoarthritis|The Effects of Home-Based Rehabilitation Treatments Among Persons With Symptomatic Knee Osteoarthritis.|Completed||N/A|44|Actual|University of Zululand||4|||f||||||||||||||2018-06-01 01:50:28.539925|2018-06-01 01:50:28.539925
NCT00735085|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30||2011-09-09|2011-09-09|2008-08-13|2008-08-14|Estimate||||2011-09-09|2011-09-21|Estimate|2011-09-09|2011-09-21|Estimate|April 2009||2009-04-30|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.|A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics After Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients With Moderate and Severe Traumatic Brain Injury|Terminated||Phase 2|57|Actual|Abbott||2||This study was stopped 20 May 2010 due to strategic considerations|f||||t||||||||||2018-06-01 01:50:28.65872|2018-06-01 01:50:28.65872
NCT00735072|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2011-06-05||2012-06-13|2008-08-13|2008-08-14|Estimate|2012-06-13|2012-07-18|Estimate||||2012-06-13|2012-07-18|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure|Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure|Completed||Phase 4|45|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:50:28.779254|2018-06-01 01:50:28.779254
NCT00735059|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2009-08-20|2008-08-13|2008-08-14|Estimate|||||||2009-08-20|2009-08-21|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Test of the Nipro ELISIO H Dialyzer in Different Dialysis Treatment Procedures|Test of the Nipro ELISIO H Dialyzer in Different Dialysis Treatment Procedures|Completed||N/A|14|Anticipated|EXcorLab GmbH||2|||f||||f||||||||||2018-06-01 01:50:29.15231|2018-06-01 01:50:29.15231
NCT00735046|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2011-01-13|2008-08-13|2008-08-14|Estimate|||||||2011-01-13|2011-01-14|Estimate|April 2008||2008-04-30|July 2008|2008-07-31|April 2010|Actual|2010-04-30|||||Observational|KORDIAL||Cognitive Behavioural Therapy of Early Dementia|Cognitive Behavioural Resource-based Therapy of Early Dementia in the Everyday Setting|Completed|||200|Anticipated|Technische Universität München|||2||f||||t||||||None Retained|"~     not required~   "|||2018-06-01 01:50:29.232286|2018-06-01 01:50:29.232286
NCT00735033|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-08-18|2008-08-13|2008-08-14|Estimate|||||||2008-08-18|2008-08-19|Estimate||||May 2008|2008-05-31||||||||Interventional|||The Effects of the Swiss Ball on Cerebral Vascular Accident|The Effects of the Swiss Ball on Patients With Hemiplegia Due to Cerebral Vascular Accident|Completed||N/A|||Fortaleza University|||||f||||t||||||||||2018-06-01 01:50:29.374208|2018-06-01 01:50:29.374208
NCT00735020|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2014-01-23|2008-08-13|2008-08-14|Estimate|||||||2014-01-23|2014-01-24|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines|A Phase I, Observer-Blind, Randomized, Single-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines in Healthy Adults Aged 18 to 39 Years.|Completed||Phase 1|72|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:50:29.441847|2018-06-01 01:50:29.441847
NCT00735007|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2010-07-14||2013-10-21|2008-08-13|2008-08-14|Estimate|2010-07-14|2010-08-11|Estimate||||2013-10-21|2013-11-14|Estimate|July 2008||2008-07-31|October 2013|2013-10-31||||January 2009|Actual|2009-01-31||Interventional|||12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.|International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS)|Completed||Phase 3|106|Actual|EMD Serono||1|||f||||f||||||||||2018-06-01 01:50:29.592007|2018-06-01 01:50:29.592007
NCT00734994|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|2011-08-01||2015-06-01|2008-08-13|2008-08-14|Estimate|2011-08-01|2011-08-30|Estimate||||2015-06-01|2015-06-29|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer|Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy|Completed||Early Phase 1|15|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:50:30.194453|2018-06-01 01:50:30.194453
NCT00734981|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2011-06-22|2008-08-13|2008-08-14|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2012||2012-01-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Observational|||Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System|Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System|Unknown status|Not yet recruiting||60|Anticipated|Lotus Bio Inc.|||||f||||t||||||None Retained|"~     Semen~   "|||2018-06-01 01:50:30.477326|2018-06-01 01:50:30.477326
NCT00734968|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2016-05-20||2016-08-17|2008-08-13|2008-08-14|Estimate|2016-08-17|2016-10-11|Estimate||||2016-08-17|2016-10-11|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence|Does Prophylaxis With Macrobid Reduce the Incidence of Urinary Tract Infection in Patients Who Receive a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence: Randomized, Double Blinded Placebo Controlled Clinical Trial|Completed||Phase 4|161|Actual|University of Missouri-Columbia||2|||f||||t||||||||Undecided||2018-06-01 01:50:30.62269|2018-06-01 01:50:30.62269
NCT00734955|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2017-12-15|2008-08-13|2008-08-14|Estimate|||||||2017-12-15|2017-12-18|Actual|May 2006||2006-05-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients|An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients|Recruiting||N/A|530|Anticipated|Duke University||3|||f||||t||||||||||2018-06-01 01:50:30.893978|2018-06-01 01:50:30.893978
NCT00734942|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-12-22|2008-08-12|2008-08-14|Estimate|||||||2008-12-22|2008-12-23|Estimate|January 2009||2009-01-31|August 2008|2008-08-31|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||Development and Implementation of Evidence-Based Family-Oriented Support for Young Carers and Their Families in Germany|Improved Health-Related Quality of Life for Young Carers and Their Families in Germany on the Basis of Evidence-Based Family-Oriented Support|Unknown status|Not yet recruiting|N/A|150|Anticipated|University of Witten/Herdecke||2|||f||||f||||||||||2018-06-01 01:50:30.983893|2018-06-01 01:50:30.983893
NCT00734929|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-04-07||2017-01-31|2008-08-13|2008-08-14|Estimate|2011-05-05|2011-06-03|Estimate||||2017-01-31|2017-03-13|Actual|September 2007||2007-09-30|January 2017|2017-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy|A Comparison of the Combination of Aprepitant and Dexamethasone Versus the Combination of Ondansetron and Dexamethasone for the Prevention of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Craniotomy|Completed||Phase 4|115|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:50:31.074502|2018-06-01 01:50:31.074502
NCT00734916|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2010-02-03|2008-08-13|2008-08-14|Estimate|||||||2010-02-03|2010-02-04|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Immune Modulation by Parenteral Lipids|Immune Modulation by Omega-3 Versus Omega-6 Based Parenteral Lipids in Healthy Volunteers|Completed||N/A|8|Anticipated|Radboud University||3|||f||||f||||||||||2018-06-01 01:50:31.423858|2018-06-01 01:50:31.423858
NCT00734903|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2016-12-15|2008-08-12|2008-08-14|Estimate|||||||2016-12-15|2016-12-16|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|March 2015|Actual|2015-03-31||Interventional|WPR||A Randomized Controlled Trial on Women's Substance Abuse Treatment|A Randomized Controlled Trial on Women's Substance Abuse Treatment|Active, not recruiting||Phase 2|66|Anticipated|VA Office of Research and Development||2|||f||||t||||||||No||2018-06-01 01:50:31.610337|2018-06-01 01:50:31.610337
NCT00734890|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2012-03-14|2008-08-13|2008-08-14|Estimate|||||||2012-03-14|2012-03-16|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma|Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas|Completed||Phase 1|18|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 01:50:31.707327|2018-06-01 01:50:31.707327
NCT00734877|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2017-10-09|2008-08-13|2008-08-14|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2008|Actual|2008-07-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|TT4B||UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma|UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)|Recruiting||Phase 3|400|Anticipated|University of Arkansas||2|||f||||t||||||||||2018-06-01 01:50:31.832544|2018-06-01 01:50:31.832544
NCT00734864|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2012-11-20|2008-08-13|2008-08-14|Estimate|||||||2012-11-20|2012-11-21|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|June 2012|Anticipated|2012-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma|Phase I Study of Dasatinib Plus Protracted Temozolomide in Recurrent Malignant Glioma|Withdrawn||Phase 1|0|Actual|Duke University||2||Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB.|f||||f||||||||||2018-06-01 01:50:31.9865|2018-06-01 01:50:31.9865
NCT00734851|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2015-09-21||2015-11-18|2008-08-13|2008-08-14|Estimate|2015-11-18|2015-12-23|Estimate||||2015-11-18|2015-12-23|Estimate|December 2008||2008-12-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Multimodality Phase II Study in Prostate Cancer|Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study|Terminated||Phase 2|36|Actual|Duke University||1||Dose Limiting Toxicities|f||||t||||||||||2018-06-01 01:50:32.115699|2018-06-01 01:50:32.115699
NCT00734838|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2017-06-15|2008-08-13|2008-08-14|Estimate|||||||2017-06-15|2017-06-16|Actual|January 2006||2006-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy|Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy|Recruiting||N/A|162|Anticipated|Duke University||2|||f||||t||||||||||2018-06-01 01:50:32.488752|2018-06-01 01:50:32.488752
NCT00734825|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2012-06-27|2008-08-13|2008-08-14|Estimate|||||||2012-06-27|2012-06-28|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|September 2010|Actual|2010-09-30|November 2008|Actual|2008-11-30||Interventional|||Emergency Department CT Scanning for Appendicitis|Emergency Department CT Scanning for Appendicitis: IV Contrast vs. IV and Oral Contrast|Completed||N/A|244|Actual|WellSpan Health||2|||f||||f||||||||||2018-06-01 01:50:32.557251|2018-06-01 01:50:32.557251
NCT00734812|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2013-01-23|2008-08-13|2008-08-14|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Laparoscopic Supracervical Hysterectomy Versus Total Laparoscopic Hysterectomy|LSH vs. TLH, A Randomized Single Blind Trial|Withdrawn||Phase 3|0|Actual|Brigham and Women's Hospital||2||Study was withdrawn prior to any enrollment.|f||||f||||||||||2018-06-01 01:50:32.631096|2018-06-01 01:50:32.631096
NCT00734799|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2014-02-03||2015-08-11|2008-08-13|2008-08-14|Estimate|2015-08-11|2015-09-07|Estimate||||2015-08-11|2015-09-07|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Treating Co-Morbid Sleep Difficulties in Veterans With Posttraumatic Stress Disorder (PTSD): A Pilot Study|Treating Co-Morbid Sleep Difficulties in Veterans With PTSD: A Pilot Study|Completed||N/A|22|Actual|Durham VA Medical Center||2|||f||||f||||||||||2018-06-01 01:50:32.708406|2018-06-01 01:50:32.708406
NCT00734786|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-22|2008-08-13|2008-08-14|Estimate|||||||2008-08-22|2008-08-25|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles|Efficacy and Safety of a Cutaneous Formulation of Gonyautoxin 2/3 (GTX 2/3) for the Treatment of Facial Wrinkles. Study # CLN 08-003.|Withdrawn||Phase 1/Phase 2|15|Anticipated|Phytotox SA||1||Study cancelled.|f||||f||||||||||2018-06-01 01:50:33.08994|2018-06-01 01:50:33.08994
NCT00734773|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2012-05-16|2008-08-13|2008-08-14|Estimate|||||||2012-05-16|2012-05-18|Estimate|November 2008||2008-11-30|May 2012|2012-05-31||||||||Interventional|||Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL|A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-dose Methotrexate (MTX)-Based Chemo-immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma|Withdrawn||Early Phase 1|0|Actual|Northwestern University||||Lack of funding|f||||t||||||||||2018-06-01 01:50:33.234939|2018-06-01 01:50:33.234939
NCT00734760|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-08-12|2008-08-12|2008-08-14|Estimate|||||||2008-08-12|2008-08-14|Estimate|February 2001||2001-02-28|August 2008|2008-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|PROMOTION||An Intervention to Reduce Prehospital Delay to Treatment in Acute Coronary Syndrome|Reducing Prehospital Delay in Acute Myocardial Infarction|Completed||N/A|3522|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:50:33.31517|2018-06-01 01:50:33.31517
NCT00734747|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2015-05-15||2015-12-30|2008-08-13|2008-08-14|Estimate|2015-07-15|2015-08-14|Estimate||||2015-12-30|2016-02-02|Estimate|May 2008||2008-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|May 2011|Actual|2011-05-31||Interventional||All subjects consented for enrollment|Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)|Evaluation of the Medigus SRS Endoscopic Stapling System for the Treatment of Gastro-Esophageal Reflux Disease (GERD)|Completed||Phase 3|72|Actual|Medigus Ltd||1|||f||||f||||||||||2018-06-01 01:50:33.413867|2018-06-01 01:50:33.413867
NCT00734734|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2015-12-21||2015-12-21|2008-08-13|2008-08-14|Estimate|2015-12-21|2016-01-28|Estimate||||2015-12-21|2016-01-28|Estimate|June 2008||2008-06-30|December 2015|2015-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Baseline analysis population was defined as all participants who were enrolled.|Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009, When Administered to Elderly Subjects|Completed||Phase 2|64|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:50:33.659332|2018-06-01 01:50:33.659332
NCT00734721|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2017-12-22|2008-08-13|2008-08-14|Estimate|||||||2017-12-22|2017-12-26|Actual|December 1, 2007|Actual|2007-12-01|August 2008|2008-08-31|June 1, 2012|Actual|2012-06-01|May 1, 2010|Actual|2010-05-01||Interventional|FIVA||Assessment of Psychological Strain and Perioperative Fear in Intravitreal Injections|Fear of Intravitreal Injection - Assessment of Psychological Strain and Potential Contributing Factors|Completed||Phase 2|40|Actual|University Hospital Tuebingen||4|||f||||f||||||||||2018-06-01 01:50:33.850073|2018-06-01 01:50:33.850073
NCT00734695|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2010-02-28|2008-08-13|2008-08-14|Estimate|||||||2010-02-28|2010-03-02|Estimate|July 2009||2009-07-31|February 2010|2010-02-28|February 2010|Anticipated|2010-02-28|November 2009|Anticipated|2009-11-30||Interventional|||Comparing the Use of Vitamin c (Ascorbic Acid) in Eye Burn in Subconjunctival Injection to Topical or Oral Treatment.|The Effect of Subconjunctival Vitamin c on Recovery Rate and End Result From Eye Burn.|Withdrawn||Phase 1|20|Anticipated|The Baruch Padeh Medical Center, Poriya||3||couldn't recruit patients|f||||f||||||||||2018-06-01 01:50:34.005164|2018-06-01 01:50:34.005164
NCT00734682|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2015-01-05|2008-08-13|2008-08-14|Estimate|||||||2015-01-05|2015-01-07|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas|A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas|Completed||Phase 1|34|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:50:34.10255|2018-06-01 01:50:34.10255
NCT00734669|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2016-10-24|2008-08-13|2008-08-14|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|January 2016|Actual|2016-01-31||Observational|||Risk of Hypoglycemia in Type 2 Diabetes|Risk of Hypoglycemia in Type 2 Diabetes - Effects of Glibenclamide and Exercise on Cardiovascular, Hormonal, and Metabolic Parameters|Completed|||12|Actual|University of Giessen|||1||f||||f||||||||No||2018-06-01 01:50:34.172245|2018-06-01 01:50:34.172245
NCT00734656|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2011-10-27||2012-03-26|2008-08-13|2008-08-14|Estimate|2012-02-21|2012-03-27|Estimate||||2012-03-26|2012-03-28|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Pharmacogenetics of Alcohol: Treatment Implications|Subjective and Physiological Effects of Alcohol: Role of Genetic Variation and Adrenal Hormones|Completed||N/A|94|Actual|UConn Health||4|||f||||f||||||||||2018-06-01 01:50:34.230661|2018-06-01 01:50:34.230661
NCT00734643|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2018-02-27|2008-08-13|2008-08-14|Estimate|||||||2018-02-27|2018-03-01|Actual|June 2006||2006-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Family Adaptation Study Following the Diagnosis of Hypoplastic Left Heart Syndrome in a Newborn|Family Stress, Coping and Outcomes Following the Diagnosis of Hypoplastic Left Heart Syndrome in a Newborn|Active, not recruiting|||213|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 01:50:34.689162|2018-06-01 01:50:34.689162
NCT00734630|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-03-31||2011-03-31|2008-08-13|2008-08-14|Estimate|2011-03-31|2011-04-26|Estimate||||2011-03-31|2011-04-26|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Nebivolol Added To Antihypertensive Treatment With Lisinopril or Losartan in Patients With Hypertension.|Completed||Phase 4|491|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 01:50:34.793058|2018-06-01 01:50:34.793058
NCT00734617|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-02-03||2014-07-02|2008-08-13|2008-08-14|Estimate|2011-02-03|2011-03-01|Estimate||||2014-07-02|2014-07-15|Estimate|August 2007||2007-08-31|February 2011|2011-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|CON NIC II||Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II|Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II|Completed||Phase 3|479|Actual|Duke University||2|||f||||t||||||||||2018-06-01 01:50:35.240296|2018-06-01 01:50:35.240296
NCT00734604|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2010-09-20||2010-10-21|2008-08-12|2008-08-14|Estimate|2010-10-21|2010-11-18|Estimate||||2010-10-21|2010-11-18|Estimate|August 2008||2008-08-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.|A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.|Completed||Phase 3|378|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-06-01 01:50:35.575284|2018-06-01 01:50:35.575284
NCT00734591|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2012-09-24||2012-09-24|2008-08-12|2008-08-14|Estimate|2012-09-24|2012-10-23|Estimate||||2012-09-24|2012-10-23|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|FUSE||Follow-Up Study for Exubera|An Observational Follow-Up Study Of Patients Previously Enrolled In Exubera Controlled Clinical Trials|Completed|||7439|Actual|Pfizer|Detection and/or reporting bias possible in continuous analysis (presented here) of lung cancer mortality and lung cancer incidence endpoints. Study had insufficient power to draw clear statistical conclusions due to small number of events.||2||f||||f||||||||||2018-06-01 01:50:37.14645|2018-06-01 01:50:37.14645
NCT00734578|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2010-10-22||2012-02-10|2008-08-13|2008-08-14|Estimate|2010-10-22|2010-11-23|Estimate||||2012-02-10|2012-02-14|Estimate|September 2008||2008-09-30|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of SPD503 in Combination With Psychostimulants|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 Years With a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|461|Actual|Shire||3|||f||||f||||||||||2018-06-01 01:50:38.818834|2018-06-01 01:50:38.818834
NCT00734565|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2012-02-06|2008-08-12|2008-08-14|Estimate|||||||2012-02-06|2012-02-08|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b|A Phase I, Single-arm, Single-center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months|Completed||Phase 1|40|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:50:39.579549|2018-06-01 01:50:39.579549
NCT00734552|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2015-05-20|2008-08-13|2008-08-14|Estimate|||||||2015-05-20|2015-05-22|Estimate|October 2007||2007-10-31|May 2015|2015-05-31|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Interventional|||Study to Evaluate the Protective Effect of α-Keto Acid With Low-protein Diet on Renal Function in PD Patients|Randomized, Open-Label, Prospective Study to Evaluate the Protective Effect of α-Keto Acid With Low-protein Diet on Residual Renal Function (RRF) in Peritoneal Dialysis Patients|Completed||N/A|100|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:50:39.650314|2018-06-01 01:50:39.650314
NCT00734539|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2014-06-17|2013-03-25|2014-07-27|2008-08-13|2008-08-14|Estimate|2014-06-17|2014-07-17|Estimate|2013-03-25|2013-04-01|Estimate|2014-07-27|2014-08-01|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|December 2011|Actual|2011-12-31||Interventional||Infants who received at least 1 dose of study drug (Modified Intent-to-Treat population)|Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight|Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants < 750 Grams Birth|Completed||Phase 3|362|Actual|Duke University||2|||f||||t||||||||||2018-06-01 01:50:39.791906|2018-06-01 01:50:39.791906
NCT00734526|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2015-11-04|2008-08-13|2008-08-14|Estimate|||||||2015-11-04|2015-11-05|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma|A Phase I Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma|Completed||Phase 1|18|Actual|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-06-01 01:50:40.506152|2018-06-01 01:50:40.506152
NCT00734513|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2016-11-23|2008-08-13|2008-08-14|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2003||2003-01-31|August 2008|2008-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Partner-Assisted Emotional Disclosure for GI Cancer|Partner Assisted Emotional Disclosure for GI Cancer|Completed||N/A|300|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:50:40.599861|2018-06-01 01:50:40.599861
NCT00734500|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2011-08-31||2012-11-16|2008-08-13|2008-08-14|Estimate|2011-11-09|2011-12-14|Estimate||||2012-11-16|2012-11-21|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Anidulafungin PK in Infants and Toddlers|Anidulafungin PK in Infants and Toddlers|Completed||Phase 1|15|Actual|Duke University||1|||f||||||||||||||2018-06-01 01:50:40.695676|2018-06-01 01:50:40.695676
NCT00734487|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2018-05-14|2008-08-13|2008-08-14|Estimate|||||||2018-05-14|2018-05-17|Actual|June 2008||2008-06-30|May 2018|2018-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|A2ASDOCT||AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study|Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study|Completed|||470|Actual|Duke University|||2||f||||f||||||||Yes|"All findings resulting from the A2A SDOCT study will be prepared for publication in peer-reviewed journals and posted on PubMed Central once accepted.~We are supportive of efforts by publishers and professional societies to develop technologies for on-line publishing of entire experimental datasets. We will archive experimental results and findings from the proposed project for at least the duration of the project, and make the underlying datasets available to other researchers upon request."|2018-06-01 01:50:40.9118|2018-06-01 01:50:40.9118
NCT00734474|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2014-10-03|2011-09-20|2015-03-31|2008-08-12|2008-08-14|Estimate|2015-01-26|2015-01-28|Estimate|2011-09-20|2011-09-26|Estimate|2015-03-31|2015-04-20|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional||All randomized participants.|A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin|A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin|Completed||Phase 2/Phase 3|1202|Actual|Eli Lilly and Company||9|||f||||t||||||||||2018-06-01 01:50:41.170725|2018-06-01 01:50:41.170725
NCT00734461|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12||2016-03-30|2016-03-30|2008-08-13|2008-08-14|Estimate||||2016-03-30|2016-05-02|Estimate|2016-03-30|2016-05-02|Estimate|August 2007||2007-08-31|March 2016|2016-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse|A Single-Center, Randomized, Double-Blind, Active- and Placebo-Controlled Crossover Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse|Completed||Phase 2|14|Actual|Pain Therapeutics||7|||f||||f||||||||||2018-06-01 01:50:45.941392|2018-06-01 01:50:45.941392
NCT00734448|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2014-06-12|2008-08-13|2008-08-14|Estimate|||||||2014-06-12|2014-06-13|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Myo-inositol Administration in Gestational Diabetes|Effect of Myo-inositol Administration on Insulin Sensitivity in Gestational Diabetes Patients by Continuous Glucose Monitoring System (CGMS)|Unknown status|Recruiting|N/A|30|Anticipated|University of Messina||1|||f||||f||||||||||2018-06-01 01:50:46.115152|2018-06-01 01:50:46.115152
NCT00734435|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12||2012-11-27|2012-11-27|2008-08-13|2008-08-14|Estimate||||2012-11-27|2012-11-29|Estimate|2012-11-27|2012-11-29|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects|A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis|Terminated||Phase 2|26|Actual|Orexigen Therapeutics, Inc||2||Sponsor Decision- Financial Considerations|f||||f||||||||||2018-06-01 01:50:46.287384|2018-06-01 01:50:46.287384
NCT00734422|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2011-08-03|2008-08-12|2008-08-14|Estimate|||||||2011-08-03|2011-08-04|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Interventional|||Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants|Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants|Completed||Phase 2/Phase 3|67|Actual|VU University of Amsterdam||2|||f||||f||||||||||2018-06-01 01:50:46.39318|2018-06-01 01:50:46.39318
NCT00734409|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2012-08-10||2013-03-21|2008-08-13|2008-08-14|Estimate|2012-08-10|2012-09-11|Estimate||||2013-03-21|2013-03-29|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|COST_2||Combining Objective and Subjective Sedation Assessment Tools|Combining Objective and Subjective Sedation Assessment Tools - Second Study|Completed||N/A|300|Actual|Duke University||2|||f||||f||||||||||2018-06-01 01:50:46.482288|2018-06-01 01:50:46.482288
NCT00734396|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2013-01-04|2008-08-13|2008-08-14|Estimate|||||||2013-01-04|2013-01-07|Estimate|February 2009||2009-02-28|January 2013|2013-01-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|Measure||Mesenchymal Stem Cells and Subclinical Rejection|Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Allograft Rejection After Renal Transplantation|Completed||Phase 1/Phase 2|15|Actual|Leiden University Medical Center|||||f||||f||||||||||2018-06-01 01:50:46.732844|2018-06-01 01:50:46.732844
NCT00734383|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2012-07-11|2008-08-13|2008-08-14|Estimate|||||||2012-07-11|2012-07-13|Estimate|April 2005||2005-04-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Propofol Cardioprotection for Type II Diabetics|PRO-TECT II: Propofol Cardioprotection for Type II Diabetics|Completed||Phase 2/Phase 3|137|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 01:50:46.81711|2018-06-01 01:50:46.81711
NCT00734370|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2013-03-20|2008-08-13|2008-08-14|Estimate|||||||2013-03-20|2013-03-21|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||Virtual Reality Exposure Therapy in Agoraphobic Participants|Virtual Reality Exposure Therapy in Agoraphobic Participants|Completed||Phase 2/Phase 3|55|Actual|VU University of Amsterdam||3|||f||||f||||||||||2018-06-01 01:50:46.902412|2018-06-01 01:50:46.902412
NCT00734357|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2014-06-12|2008-08-13|2008-08-14|Estimate|||||||2014-06-12|2014-06-13|Estimate|October 2009||2009-10-31|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients|Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients|Completed||N/A|413|Actual|University of Michigan||2|||f||||||||||||||2018-06-01 01:50:46.972496|2018-06-01 01:50:46.972496
NCT00734344|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2016-01-05||2016-04-25|2008-08-13|2008-08-14|Estimate|2016-04-25|2016-05-30|Estimate||||2016-04-25|2016-05-30|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection|Pilot Study of Raltegravir/Tenofovir/Emtricitabine Versus Efavirenz/Tenofovir/Emtricitabine for Adults With Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis|Completed||N/A|18|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:50:47.06065|2018-06-01 01:50:47.06065
NCT00734331|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-08-13|2008-08-13|2008-08-14|Estimate|||||||2008-08-13|2008-08-14|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Observational|||Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease||Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||Samples With DNA|"~     serum, colonic tissue, whole blood~   "|||2018-06-01 01:50:47.756918|2018-06-01 01:50:47.756918
NCT00734318|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2012-08-09|2008-08-13|2008-08-14|Estimate|||||||2012-08-09|2012-08-10|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma|A Double Blind, Double Dummy, Randomised, Multicentre, Four Arm Parallel Group Study to Assess the Efficacy and Safety of FlutiForm® pMDI 250/10µg (2 Puffs Bid) vs Fluticasone pMDI 250µg (2 Puffs Bid) Plus Formoterol pMDI 12µg (2 Puffs Bid) Administered Concurrently in Adult Subjects With Severe Persistent, Reversible Asthma.|Completed||Phase 3|1667|Actual|Mundipharma Research Limited||4|||f||||f||||||||||2018-06-01 01:50:48.036183|2018-06-01 01:50:48.036183
NCT00734305|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2016-07-12||2016-08-30|2008-08-12|2008-08-14|Estimate|2016-08-30|2016-09-01|Estimate||||2016-08-30|2016-09-01|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|May 2010|Actual|2010-05-31||Interventional|||Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment|A Phase I and Pharmocologic Study of MM-121 in Patients With Refractory Advanced Solid Tumors|Completed||Phase 1|44|Actual|Merrimack Pharmaceuticals||1|||f||||t||||||||No||2018-06-01 01:50:48.139964|2018-06-01 01:50:48.139964
NCT00734292|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04||2010-08-24|2010-08-24|2008-08-13|2008-08-14|Estimate||||2010-08-24|2010-08-27|Estimate|2010-08-24|2010-08-27|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma|A Randomized, Placebo-controlled, Double-blind, Crossover, Single-dose Exposure Study to Evaluate the Early Bronchodilating Effect of FlutiForm 100/10 µg HFA pMDI and FlutiForm 250/10 µg HFA pMDI, Compared to Placebo in Adult Subjects With Mild to Moderate Asthma|Completed||Phase 2|39|Anticipated|SkyePharma AG||3|||f||||f||||||||||2018-06-01 01:50:48.652101|2018-06-01 01:50:48.652101
NCT00734279|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-12-21|2008-08-13|2008-08-14|Estimate|||||||2017-12-21|2017-12-26|Actual|March 2006||2006-03-31|December 2017|2017-12-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Follicle-Stimulating Hormone (FSH) and the Onset of Puberty|Follicle-Stimulating Hormone (FSH) and the Onset of Puberty|Completed||Early Phase 1|11|Actual|University of Utah||4|||f||||f||||||||||2018-06-01 01:50:48.797709|2018-06-01 01:50:48.797709
NCT00734266|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2013-03-05|2008-08-13|2008-08-14|Estimate|||||||2013-03-05|2013-03-06|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Changes in Leukotrienes During Cardiac Surgery in Patients With Chronic Obstructive Pulmonary Disease|Changes in Leukotrienes During Cardiac Surgery in Patients With Chronic Obstructive Pulmonary Disease|Completed|||20|Actual|Massachusetts General Hospital|||2||f||||t||||||||||2018-06-01 01:50:48.89804|2018-06-01 01:50:48.89804
NCT00734253|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12||2014-05-02|2015-10-06|2008-08-12|2008-08-14|Estimate||||2014-05-02|2014-05-20|Estimate|2015-10-06|2015-10-28|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2b Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Nephropathy Due to Type 2 Diabetes|Completed||Phase 2|317|Actual|NephroGenex, Inc.||3|||f||||t||||||||||2018-06-01 01:50:48.957955|2018-06-01 01:50:48.957955
NCT00734240|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-07-28|2008-08-12|2008-08-14|Estimate|||||||2010-07-28|2010-07-29|Estimate|July 2008||2008-07-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers|Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers|Completed||Phase 1|103|Actual|Ionis Pharmaceuticals, Inc.||16|||f||||f||||||||||2018-06-01 01:50:49.051259|2018-06-01 01:50:49.051259
NCT00734227|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|||2008-08-13|2008-08-13|2008-08-14|Estimate|||||||2008-08-13|2008-08-14|Estimate|July 1996||1996-07-31|July 2008|2008-07-31|July 2006|Actual|2006-07-31|October 2003|Actual|2003-10-31||Interventional|||TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis|TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis|Completed||N/A|153|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 01:50:49.175731|2018-06-01 01:50:49.175731
NCT00734214|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2012-05-11||2015-04-07|2008-08-13|2008-08-14|Estimate|2012-05-11|2012-06-13|Estimate||||2015-04-07|2015-04-29|Estimate|March 2008||2008-03-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial|Hypotonic Versus Isotonic Parenteral Fluids in Children - a Randomized Controlled Trial|Completed||Phase 3|258|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 01:50:49.271395|2018-06-01 01:50:49.271395
NCT00734201|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2011-07-21|2008-08-13|2008-08-14|Estimate|||||||2011-07-21|2011-07-25|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of Low Doses of V24343 in Obese Subjects|A Double-blind, Placebo-controlled, Parallel Group Study of the Effect of V24343 on Blood Pressure and Weight in Obese Subjects|Completed||Phase 1|32|Actual|Vernalis (R&D) Ltd||1|||f||||f||||||||||2018-06-01 01:50:49.546568|2018-06-01 01:50:49.546568
NCT00734188|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2011-07-12|2008-08-13|2008-08-14|Estimate|||||||2011-07-12|2011-07-14|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma|A Multi-Center, Open-Label, Phase I, Dose-Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma|Completed||Phase 1|21|Anticipated|Pain Therapeutics|||||f||||f||||||||||2018-06-01 01:50:49.620691|2018-06-01 01:50:49.620691
NCT00726817|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2017-02-22|2008-07-31|2008-08-01|Estimate|||||||2017-02-22|2017-02-24|Actual|December 2007||2007-12-31|July 2008|2008-07-31||||February 2008|Actual|2008-02-29||Interventional|||The Effects of Butyrate Enemas on Visceral Perception|The Effects of Butyrate Enemas on Visceral Perception|Completed||N/A|11|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 01:53:17.529921|2018-06-01 01:53:17.529921
NCT00734175|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2009-08-05|2008-08-12|2008-08-14|Estimate|||||||2009-08-05|2009-08-07|Estimate|September 2008||2008-09-30|September 2008|2008-09-30||||December 2008|Actual|2008-12-31||Interventional|||Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine|Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H6N1 (6-2) AA ca Recombinant (A/Teal/Hong Kong/W312/1997 (H6N1) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H6N1 Infection in the Event of a Pandemic|Completed||Phase 1|22|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-06-01 01:50:49.681537|2018-06-01 01:50:49.681537
NCT00734162|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-13|2012-10-08|2012-04-16|2016-07-20|2008-08-13|2008-08-14|Estimate|2012-10-08|2012-11-07|Estimate|2012-04-16|2012-04-18|Estimate|2016-07-20|2016-09-01|Estimate|December 2008||2008-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|March 2011|Actual|2011-03-31||Interventional|||Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection|A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents With Chronic Hepatitis B Infection|Completed||Phase 3|106|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 01:50:49.821322|2018-06-01 01:50:49.821322
NCT00734149|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2013-02-11||2016-03-21|2008-08-13|2008-08-14|Estimate|2013-05-30|2013-05-31|Estimate||||2016-03-21|2016-04-19|Estimate|July 2004||2004-07-31|March 2016|2016-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|MVP||Bortezomib With Melphalan and Prednisone for Multiple Myeloma|A Prospective Study of Bortezomib in Combination With Melphalan and Prednisone for Patients With Previously Untreated Multiple Myeloma|Completed||Phase 2|45|Actual|Duke University||1|||f||||f||||||||||2018-06-01 01:50:52.155913|2018-06-01 01:50:52.155913
NCT00734136|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2009-02-17|2008-08-13|2008-08-14|Estimate|||||||2009-02-17|2009-02-18|Estimate|May 2005||2005-05-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|July 2005|Actual|2005-07-31||Interventional|||Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome|Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome|Terminated||N/A|100|Actual|Lahey Clinic||2||Insufficient findings for data analysis|f||||f||||||||||2018-06-01 01:50:52.454011|2018-06-01 01:50:52.454011
NCT00734123|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-08-13|2008-08-13|2008-08-14|Estimate|||||||2008-08-13|2008-08-14|Estimate|April 2008||2008-04-30|August 2008|2008-08-31|May 2013|Anticipated|2013-05-31|April 2009|Anticipated|2009-04-30||Interventional|PRIMARIA||Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.|Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases.|Unknown status|Recruiting|Phase 4|2948|Anticipated|Hospital Arnau de Vilanova||2|||f||||t||||||||||2018-06-01 01:50:52.545991|2018-06-01 01:50:52.545991
NCT00734110|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-06-05|2008-08-12|2008-08-13|Estimate|||||||2015-06-05|2015-06-09|Estimate|July 2000||2000-07-31|June 2015|2015-06-30|June 2010|Actual|2010-06-30|April 2009|Actual|2009-04-30||Interventional|||Long-term Study of The Press Fit Condylar (P.F.C.) Sigma Total Knee Replacement System|Multi-Centre Clinical Study of the P.F.C.® Sigma Total Knee System|Terminated||Phase 4|723|Actual|DePuy International||1||"The study achieved the stated objective to record pre & post operative outcomes at a minimum 5~   years."|f||||f||||||||||2018-06-01 01:50:52.679837|2018-06-01 01:50:52.679837
NCT00734097|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2009-09-25||2012-09-10|2008-08-12|2008-08-13|Estimate|2012-09-10|2012-10-10|Estimate||||2012-09-10|2012-10-10|Estimate|November 2007||2007-11-30|August 2012|2012-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|NEON||A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)|An Open Label, Multicentre Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)|Completed||Phase 4|314|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:50:52.789084|2018-06-01 01:50:52.789084
NCT00734084|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-06-05|2008-08-12|2008-08-13|Estimate|||||||2015-06-05|2015-06-09|Estimate|June 2001||2001-06-30|June 2015|2015-06-30|April 2008|Actual|2008-04-30|December 2004|Actual|2004-12-31||Interventional|||A Study to Evaluate the DePuy Minimally Invasive Unicompartmental Knee|A Prospective, Non-Comparative Multi-centre Study to Evaluate the Safety and Performance of the DePuy Minimally Invasive (Preservation) Unicompartmental Knee and Instrumentation.|Terminated||Phase 4|247|Actual|DePuy International||1||"After a review of status, request of investigators & since similar data was available from~   other sources"|f||||f||||||||||2018-06-01 01:50:53.15523|2018-06-01 01:50:53.15523
NCT00734071|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2013-10-25||2013-10-25|2008-08-11|2008-08-13|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder|Completed||Phase 3|304|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:50:53.291188|2018-06-01 01:50:53.291188
NCT00734058|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-08-12|2008-08-12|2008-08-13|Estimate|||||||2008-08-12|2008-08-13|Estimate|December 2008||2008-12-31|August 2008|2008-08-31|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|SAAF-T||SOLAR & ATRILAZE Atrial Fibrillation Trial|Atrial Fibrillation Treatment Using Laser Ablation of Cardiac Tissue During Concomitant Cardiac Surgery|Unknown status|Not yet recruiting|Phase 3|90|Anticipated|EndoPhotonix, Inc.||1|||f||||f||||||||||2018-06-01 01:50:54.299359|2018-06-01 01:50:54.299359
NCT00734045|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-12-08|2008-08-12|2008-08-13|Estimate|||||||2008-12-08|2008-12-10|Estimate|February 2008||2008-02-29|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|WB-13||Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples|Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples|Completed|||450|Anticipated|Nanogen, Inc.|||2||f||||f||||||||||2018-06-01 01:50:54.369754|2018-06-01 01:50:54.369754
NCT00734032|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2017-07-18|2010-02-05|2018-01-10|2008-08-12|2008-08-13|Estimate|2018-01-10|2018-01-12|Actual|2010-02-05|2010-02-10|Estimate|2018-01-10|2018-01-12|Actual|August 26, 2008|Actual|2008-08-26|January 2018|2018-01-31|January 16, 2009|Actual|2009-01-16|January 16, 2009|Actual|2009-01-16||Interventional|||A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients|A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A Multicenter, Randomized, Double-blind, Placebo-controlled Study of SB-480848 to Evaluate the Efficacy and Safety -|Completed||Phase 2|107|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:50:54.562411|2018-06-01 01:50:54.562411
NCT00717691|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2012-04-27|2008-07-16|2008-07-17|Estimate|||||||2012-04-27|2012-04-30|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Hallux Limitus Treated With Dynamic Splinting: A Randomized, Controlled Trial|Hallux Limitus Treated With Dynamic Splinting: A Randomized, Controlled Trial|Completed||N/A|50|Actual|Dynasplint Systems, Inc.||2|||f||||t||||||||||2018-06-01 01:56:06.634866|2018-06-01 01:56:06.634866
NCT00734019|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2018-01-15|2008-08-12|2008-08-13|Estimate|||||||2018-01-15|2018-01-17|Actual|October 1, 2005|Actual|2005-10-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Survivorship of the Press Fit Condylar (P.F.C.) Sigma Fixed Bearing Knee With a Cobalt Chrome Tibial Tray|A Prospective, Non-comparative, Multicentre, Multinational Study to Determine the Survivorship of the P.F.C. Fixed Bearing Knee System Using a Moderately Cross-linked Polyethylene Insert and a Cobalt Chrome Tibial Tray.|Active, not recruiting||Phase 4|650|Actual|DePuy International||1|||f||||f||||||||||2018-06-01 01:50:55.169257|2018-06-01 01:50:55.169257
NCT00734006|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-05-06|2008-08-12|2008-08-13|Estimate|||||||2015-05-06|2015-05-07|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Cortico-cortical Connectivity During Midazolam Sedation in Humans; a TMS/EEG Study|Cortico-cortical Connectivity During Midazolam Sedation in Humans; a TMS/EEG Study|Completed|||20|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 01:50:55.245624|2018-06-01 01:50:55.245624
NCT00733993|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2016-07-14||2017-02-01|2008-08-12|2008-08-13|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|April 2008||2008-04-30|February 2017|2017-02-28|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Caffeine and Cocaine|Experiment 1: Adenosine Receptor A2A Antagonists and Cocaine Dependence|Completed||Phase 1/Phase 2|23|Actual|Virginia Commonwealth University||4|||f||||t||||||||||2018-06-01 01:50:55.343709|2018-06-01 01:50:55.343709
NCT00733980|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2017-08-29|2011-03-17|2017-10-15|2008-08-12|2008-08-13|Estimate|2017-10-15|2017-11-17|Actual|2011-03-17|2011-03-28|Estimate|2017-10-15|2017-11-17|Actual|October 2, 2008|Actual|2008-10-02|August 2017|2017-08-31|June 18, 2010|Actual|2010-06-18|June 18, 2010|Actual|2010-06-18||Interventional|||A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder|A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder|Completed||Phase 2|150|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:50:55.879106|2018-06-01 01:50:55.879106
NCT00733967|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2012-07-25|2008-08-11|2008-08-13|Estimate|||||||2012-07-25|2012-07-27|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Varenicline-Methamphetamine Interaction Study (2008)|A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline In Methamphetamine-Dependent Volunteers Receiving Methamphetamine|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||2||No longer active|f||||t||||||||||2018-06-01 01:51:03.625971|2018-06-01 01:51:03.625971
NCT00733954|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2009-04-30||2014-04-28|2008-08-11|2008-08-13|Estimate|2009-07-13|2009-08-20|Estimate||||2014-04-28|2014-05-15|Estimate|August 2007||2007-08-31|April 2014|2014-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis|A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate Ointment With Regard to Efficacy, Safety, Subject Satisfaction and Duration of Response in Moderate to Severe Plaque Psoriasis|Completed||Phase 4|250|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 01:51:03.98087|2018-06-01 01:51:03.98087
NCT00733941|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2015-05-26|2008-08-12|2008-08-13|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Interval Training in Young Healthy Individuals|Interval Training: Training, Detraining and Retraining; an Interventional Study|Completed||N/A|24|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 01:51:05.647792|2018-06-01 01:51:05.647792
NCT00733928|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2016-05-27|2008-08-12|2008-08-13|Estimate|||||||2016-05-27|2016-06-01|Estimate|October 1999||1999-10-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|May 2005|Actual|2005-05-31||Interventional|||The Press Fit Condylar (P.F.C.) Sigma Metal-backed Versus All-poly|Randomised Prospective Comparison of P.F.C All-polyethylene Versus Metal-backed Tibial Component. A Clinical, Radiological and Roentgen Stereophotogrammetric Analysis (RSA) Study.|Completed||Phase 4|67|Actual|DePuy International||2|||f||||f||||||||||2018-06-01 01:51:05.974163|2018-06-01 01:51:05.974163
NCT00733915|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2016-08-01|2008-08-12|2008-08-13|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2002||2002-03-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|September 2007|Actual|2007-09-30||Interventional|||Long-term Study of the DePuy Low Contact Stress (LCS) Complete Total Knee System|A Prospective, Non-Comparative Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS) Complete Mobile-bearing Total Knee System.|Completed||Phase 4|241|Actual|DePuy International||1|||f||||f||||||||||2018-06-01 01:51:06.223027|2018-06-01 01:51:06.223027
NCT00733902|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11||2010-12-21|2011-01-04|2008-08-12|2008-08-13|Estimate||||2011-01-04|2011-01-07|Estimate|2011-01-04|2011-01-07|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Tanezumab in Osteoarthritis of the Knee|A Phase 3 Randomized, Double Blind, Placebo-Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee|Completed||Phase 3|697|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 01:51:06.318079|2018-06-01 01:51:06.318079
NCT00733889|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2013-02-19|2008-08-12|2008-08-13|Estimate|||||||2013-02-19|2013-02-20|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma|Phase II, Multicentre, Uncontrolled Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Chemotherapy (Docetaxel, Cisplatin, 5-fluorouracil) as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy (Cisplatin) Plus Cetuximab in Patients With a Locoregional Esophageal Carcinoma|Completed||Phase 2|50|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-06-01 01:51:06.487117|2018-06-01 01:51:06.487117
NCT00733876|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2014-08-05|2008-08-11|2008-08-13|Estimate|||||||2014-08-05|2014-08-06|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|May 2010|Actual|2010-05-31||Interventional|||Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery|Phase I Clinical Trial, Dose-escalating Intra-aortic Infusion of Allogeneic , Bone Marrow-derived Multipotent Stromal Cells to Prevent and Treat Post-operative Acute Kidney Injury in Patients Who Require On-pump Cardiac Surgery|Completed||Phase 1|15|Anticipated|AlloCure Inc.||1|||f||||t||||||||||2018-06-01 01:51:06.5556|2018-06-01 01:51:06.5556
NCT00733863|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2010-05-10|2008-08-11|2008-08-13|Estimate|||||||2010-05-10|2010-05-12|Estimate|July 2008||2008-07-31|May 2010|2010-05-31||||February 2010|Actual|2010-02-28||Interventional|||Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.|A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106|Completed||Phase 2|27|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:51:06.802028|2018-06-01 01:51:06.802028
NCT00733850|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-06-17|2008-08-11|2008-08-13|Estimate|||||||2015-06-17|2015-06-19|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer|A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection Plus Gemcitabine (G+K) Versus Gemcitabine in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|85|Actual|KangLaiTe USA||2|||f||||t||||||||||2018-06-01 01:51:07.117534|2018-06-01 01:51:07.117534
NCT00733837|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-12-17|2008-08-12|2008-08-13|Estimate|||||||2008-12-17|2008-12-18|Estimate|July 2008||2008-07-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Cervical Multifidus Muscle Function||Completed||Phase 1|30|Anticipated|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 01:51:07.491725|2018-06-01 01:51:07.491725
NCT00733824|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2016-07-18||2017-01-26|2008-08-11|2008-08-13|Estimate|2016-09-09|2016-10-28|Estimate||||2017-01-26|2017-03-09|Actual|November 2008||2008-11-30|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma|A Phase I/II Study of Intravenous AMD3100 Added to a Mobilization Regimen of G-CSF to Increase the Number of Autologous Peripheral Blood Stem Cells Collected From Patients With Lymphoma|Completed||Phase 1/Phase 2|61|Actual|Washington University School of Medicine||5|||f||||t|t|f||||||No||2018-06-01 01:51:07.85774|2018-06-01 01:51:07.85774
NCT00733811|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-08-12|2008-08-12|2008-08-13|Estimate|||||||2008-08-12|2008-08-13|Estimate|September 2000||2000-09-30|July 2008|2008-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|SEQDFPDFO||Efficacy Study of the Use of Sequential DFP-DFO Versus DFP|Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients|Completed||Phase 4|213|Actual|Azienda Ospedaliera V. Cervello||2|||f||||t||||||||||2018-06-01 01:51:09.202114|2018-06-01 01:51:09.202114
NCT00733798|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2009-05-08|2008-08-11|2008-08-13|Estimate|||||||2009-05-08|2009-05-11|Estimate||||May 2009|2009-05-31||||||||Interventional|||A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma|A Phase 1/2, Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Melanoma|Terminated||Phase 1/Phase 2|58|Anticipated|TransMolecular||1||For Strategic Reasons|f||||f||||||||||2018-06-01 01:51:09.508711|2018-06-01 01:51:09.508711
NCT00733785|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2017-07-18|2008-08-12|2008-08-13|Estimate|||||||2017-07-18|2017-07-21|Actual|August 13, 2008|Actual|2008-08-13|July 2017|2017-07-31|November 28, 2008|Actual|2008-11-28|November 28, 2008|Actual|2008-11-28||Interventional|Rosi XR||PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers|An Open-Label, Randomized, Crossover Study to the Dose Proportionality of RSG XR in Healthy Volunteers in Fasting Conditions|Completed||Phase 1|60|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-06-01 01:51:09.812949|2018-06-01 01:51:09.812949
NCT00733772|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-02-04|2008-08-12|2008-08-13|Estimate|||||||2015-02-04|2015-02-05|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|FIMS||Flaxseed Intervention on Metabolic Syndrome|The Effects of Flaxseed Supplement on Cardio-metabolic Risk Factors in Patients With Metabolic Syndrome|Completed||Phase 2/Phase 3|189|Actual|Chinese Academy of Sciences||2|||f||||f||||||||||2018-06-01 01:51:09.896628|2018-06-01 01:51:09.896628
NCT00733759|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-08-12|2008-08-12|2008-08-13|Estimate|||||||2008-08-12|2008-08-13|Estimate||||August 2008|2008-08-31||||||||Observational|||Contrast Echocardiography in Patients With Pulmonary Arteriovenous Malformations (PAVMs)|The Evaluation of Intra-Cardiac Shunts in Patients With Pulmonary Arteriovenous Malformations|Unknown status|Active, not recruiting||45|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 01:51:09.952156|2018-06-01 01:51:09.952156
NCT00733746|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2017-03-28||2017-05-23|2008-08-12|2008-08-13|Estimate|2017-03-28|2017-05-08|Actual||||2017-05-23|2017-06-16|Actual|April 2009||2009-04-30|May 2017|2017-05-31||||November 2015|Actual|2015-11-30||Interventional||All patients that started protocol treatment were included in this analysis.|Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|123|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 01:51:10.090412|2018-06-01 01:51:10.090412
NCT00733733|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-08-12|2008-08-12|2008-08-13|Estimate|||||||2008-08-12|2008-08-13|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|June 2010|Anticipated|2010-06-30|January 2010|Anticipated|2010-01-31||Interventional|ATG||Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor|A Prospective, Randomized, Open, Multicenter Study to Evaluate the Efficacy and Tolerability of Induction Therapy With a Single High-Dose Anti-T-Lymphocyte Globulin (ATG) in Renal Transplant Patients With a Kidney From a Non-Heart-Beating Donor and Tacrolimus, Mycophenolate Mofetil, and Steroids as Basic Immunosuppression.|Unknown status|Recruiting|Phase 3|180|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 01:51:10.548295|2018-06-01 01:51:10.548295
NCT00733720|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2017-01-11|2008-08-11|2008-08-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2008||2008-08-31|October 2009|2009-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Buprenorphine Naltrexone-P1 A-Cocaine|Attenuation of Opioid Effects of Three Different Doses of Sublingual Buprenorphine / Naloxone by Oral Naltrexone in Healthy Volunteers|Completed||Phase 1|8|Anticipated|National Institute on Drug Abuse (NIDA)||1|||f||||||||||||||2018-06-01 01:51:10.636855|2018-06-01 01:51:10.636855
NCT00733707|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2016-03-16|2008-08-12|2008-08-13|Estimate|||||||2016-03-16|2016-03-18|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Improving Adherence With Oral Contraceptives Using Daily Text Messaging Reminders|Improving Adherence With Oral Contraceptives Using Daily Text Messaging Reminders|Completed||N/A|82|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-06-01 01:51:10.708157|2018-06-01 01:51:10.708157
NCT00733694|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-12-17|2008-08-12|2008-08-13|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2000||2000-04-30|December 2015|2015-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|DRAGON||Outcome Study of Total Knee Arthroplasty in Asian Patients|Clinical Evaluation of the Low Contact Stress (LCS) Classic and Universal Mobile-bearing Total Knee System. The Asian LCS User Group - 'The Dragon Knee Study'|Completed||Phase 4|607|Actual|DePuy International||1|||f||||f||||||||||2018-06-01 01:51:10.768515|2018-06-01 01:51:10.768515
NCT00733681|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-01-21|2008-08-12|2008-08-13|Estimate|||||||2015-01-21|2015-01-22|Estimate|March 2004||2004-03-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|TC3||The Press Fit Condylar (P.F.C.) Sigma Rotating Platform (RP) TC3 Revision Knee in Revision Knee Arthroplasty|A Prospective, Non-comparative Study to Evaluate the Performance of the DePuy P.F.C. Sigma Rotating Platform TC3 Knee Prosthesis in Revision Knee Arthroplasty.|Terminated||Phase 4|181|Actual|DePuy International||1||Subjects were no longer able to remain compliant with follow-up intervals|f||||f||||||||||2018-06-01 01:51:10.833231|2018-06-01 01:51:10.833231
NCT00733668|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2009-03-24|2008-08-12|2008-08-13|Estimate|||||||2009-03-24|2009-03-25|Estimate|March 2006||2006-03-31|March 2009|2009-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|UNIQUE||Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder|An Open-Label, Non-Comparative, Multi-Centre, Phase II Prospective Trial to Assess the Efficacy of Quetiapine Fumarate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) in SSRI-Resistant Major Depressive Disorder.|Completed||Phase 2|||AstraZeneca|||||f||||f||||||||||2018-06-01 01:51:10.952346|2018-06-01 01:51:10.952346
NCT00733655|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2015-05-28|2008-08-12|2008-08-13|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia||Active, not recruiting|||50|Anticipated|Imperial College London|||||f||||||||||Samples Without DNA|"~     Histological samples~   "|||2018-06-01 01:51:11.013291|2018-06-01 01:51:11.013291
NCT00733642|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2009-07-24|2008-08-11|2008-08-13|Estimate|||||||2009-07-24|2009-07-28|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease|An Open Label, Single Dose Escalation Study Of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease|Completed||Phase 1|15|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:51:11.061081|2018-06-01 01:51:11.061081
NCT00733629|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2008-08-12|2008-08-12|2008-08-13|Estimate|||||||2008-08-12|2008-08-13|Estimate||||August 2008|2008-08-31||||||||Observational|||Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia|In Vitro Studies pf Endothelial Cells Derived From HHT Patients|Unknown status|Active, not recruiting||100|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 01:51:11.185205|2018-06-01 01:51:11.185205
NCT00733616|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2013-02-19|2008-08-12|2008-08-13|Estimate|||||||2013-02-19|2013-02-20|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status|Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.|Completed||Phase 2|44|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-06-01 01:51:11.230118|2018-06-01 01:51:11.230118
NCT00733603|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-01-12|2008-08-12|2008-08-13|Estimate|||||||2010-01-12|2010-01-14|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|May 2009|Anticipated|2009-05-31|February 2009|Anticipated|2009-02-28||Interventional|IC03||Physical Therapy in Women With Interstitial Cystitis|A Single-Blinded Randomized Multi-Center Trial to Evaluate the Efficacy and Durability of Myofascial Tissue Manipulation in Women With Interstitial Cystitis/Painful Bladder Syndrome|Unknown status|Active, not recruiting|N/A|88|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 01:51:11.317642|2018-06-01 01:51:11.317642
NCT00733590|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2017-08-10|2008-08-12|2008-08-13|Estimate|||||||2017-08-10|2017-08-14|Actual|June 2003|Actual|2003-06-30|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|PROSe-ICD||Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention|Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention (PROSe-ICD)|Recruiting|||1500|Anticipated|Johns Hopkins University|||||f||||f||||||Samples With DNA|"~     Whole blood drawn at 6-12 month intervals~   "|||2018-06-01 01:51:11.568759|2018-06-01 01:51:11.568759
NCT00733577|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2017-07-10|2008-08-12|2008-08-13|Estimate|||||||2017-07-10|2017-07-13|Actual|August 11, 2008|Actual|2008-08-11|July 2017|2017-07-31|March 3, 2009|Actual|2009-03-03|March 3, 2009|Actual|2009-03-03||Interventional|||A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.|A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral SB756050 Administered for 6 Days to Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|48|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:51:11.647747|2018-06-01 01:51:11.647747
NCT00733564|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2009-03-30|2008-08-12|2008-08-13|Estimate|||||||2009-03-30|2009-03-31|Estimate|August 2008||2008-08-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|EDAUC||Evaluation of Different Anesthesia for Uterine Curettage|Evaluation of the Anesthetic Efficacy of Propofol,Sevoflurane and Paracervical Block for Uterine Curettage|Completed||N/A|150|Anticipated|Nanjing Medical University||3|||f||||t||||||||||2018-06-01 01:51:11.751731|2018-06-01 01:51:11.751731
NCT00733551|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2017-07-13|2008-08-12|2008-08-13|Estimate|||||||2017-07-13|2017-07-18|Actual|September 23, 2008|Actual|2008-09-23|July 2017|2017-07-31|July 20, 2009|Actual|2009-07-20|July 20, 2009|Actual|2009-07-20||Interventional|||Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.|A Randomized, Double-blind, Ascending Dose Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Repeat Doses of Motilin Receptor Agonist GSK962040 in Male and Female Healthy Volunteers|Completed||Phase 1|31|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:51:11.823535|2018-06-01 01:51:11.823535
NCT00733538|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2012-03-23|2008-08-12|2008-08-13|Estimate|||||||2012-03-23|2012-03-26|Estimate|December 2004||2004-12-31|February 2009|2009-02-28|November 2012|Anticipated|2012-11-30|November 2009|Actual|2009-11-30||Interventional|IFM-01-04||Stage I Multiple Myeloma Treatment|Stage I Multiple Myeloma Treatment|Unknown status|Active, not recruiting|Phase 4|350|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 01:51:11.921592|2018-06-01 01:51:11.921592
NCT00733525|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2014-05-23|2008-08-12|2008-08-13|Estimate|||||||2014-05-23|2014-05-26|Estimate|September 2000||2000-09-30|May 2014|2014-05-31|August 2005|Actual|2005-08-31|April 2005|Actual|2005-04-30||Interventional|||Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa|Stepped Care vs Best Available Care for Bulimia Nervosa|Completed||N/A|293|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 01:51:11.992653|2018-06-01 01:51:11.992653
NCT00733512|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2010-03-24||2017-02-23|2008-08-11|2008-08-13|Estimate|2010-03-24|2010-04-15|Estimate||||2017-02-23|2017-03-27|Actual|June 2007||2007-06-30|April 2010|2010-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Surgeon Experience ReSTOR A +4 Intraocular Lens (IOL)|Surgeon Experience ReSTOR Aspheric +4 Intraocular Lens (IOL)|Completed|||146|Actual|Alcon Research|||1||f||||||||||||||2018-06-01 01:51:12.140944|2018-06-01 01:51:12.140944
NCT00716313|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-15|2008-07-15|2008-07-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:56:30.088613|2018-06-01 01:56:30.088613
NCT00733499|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2014-03-22||2018-02-28|2008-08-12|2008-08-13|Estimate|2014-07-31|2014-08-04|Estimate||||2018-02-28|2018-03-02|Actual|September 2006||2006-09-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|October 2009|Actual|2009-10-31||Interventional||The number of participants in the intent to treat population (All eligible subjects, admitted to the study that receive the allocated treatment, and have at least one usable post-treatment assessment).|A Study to Determine the Difference in Low Contact Stress (LCS) Duofix Versus Low Contact Stress (LCS) Porocoat Knee Systems|A Prospective, Randomised, Single Blinded Study Comparing the Pain, Biological Fixation and Outcomes of Patients With LCS Complete Duofix or LCS Porocoat Knee Systems|Active, not recruiting||Phase 4|206|Actual|DePuy International||2|||f||||f||||||||||2018-06-01 01:51:12.31067|2018-06-01 01:51:12.31067
NCT00733486|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-06-08|2008-08-12|2008-08-13|Estimate|||||||2015-06-08|2015-06-09|Estimate|August 2005||2005-08-31|June 2015|2015-06-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS®) Complete Anterior-Posterior Glide (APG) Mobile Bearing Knee|A Prospective, Non-Comparative Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS®) Complete Anterior-Posterior Glide (AP Glide) Mobile Bearing Knee System in Primary Knee Arthroplasty|Terminated||Phase 4|233|Actual|DePuy International||1||"The study was terminated at 2 years as investigators were unable to continue participation in~   the study."|f||||f||||||||||2018-06-01 01:51:12.602451|2018-06-01 01:51:12.602451
NCT00733473|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2011-12-17|2008-08-12|2008-08-13|Estimate|||||||2011-12-17|2011-12-20|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing|Phase 4 Study of Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing|Completed||Phase 4|100|Actual|Kecioren Education and Training Hospital||2|||f||||f||||||||||2018-06-01 01:51:12.69381|2018-06-01 01:51:12.69381
NCT00733460|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2013-06-06|2008-08-12|2008-08-13|Estimate|||||||2013-06-06|2013-06-10|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET|A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of BFPET as a Potential Myocardial Perfusion Imaging (MPI) Agent for PET|Completed||Phase 1|12|Actual|Fluoropharma, Inc.||1|||f||||f||||||||||2018-06-01 01:51:12.778764|2018-06-01 01:51:12.778764
NCT00733447|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2015-07-28|2008-08-12|2008-08-13|Estimate|||||||2015-07-28|2015-07-30|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|May 2014|Anticipated|2014-05-31|August 2013|Actual|2013-08-31||Expanded Access|||SynCardia Freedom Driver System Study|SynCardia Freedom Driver System Study|Approved for marketing|||||SynCardia Systems. LLC|||||||||t||||||||||2018-06-01 01:51:12.84009|2018-06-01 01:51:12.84009
NCT00733434|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2009-10-26|2008-08-12|2008-08-13|Estimate|||||||2009-10-26|2009-10-27|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|July 2010|Anticipated|2010-07-31|July 2009|Anticipated|2009-07-31||Interventional|PGE1HNM||The Use of Prostaglandin E1 in Head and Neck Microsurgery|Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery|Unknown status|Recruiting|Phase 4|242|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:51:12.900388|2018-06-01 01:51:12.900388
NCT00733421|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2009-12-07||2010-01-15|2008-08-12|2008-08-13|Estimate|2009-12-09|2010-01-13|Estimate||||2010-01-15|2010-01-20|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery|The Effect of Anti-inflammatory Analgesics on Bone Repair, Pain and Gastro-intestinal Side Effects After Hallux Valgus Surgery; a Prospective Randomised Double-blind Placebo Controlled Study.|Completed||Phase 4|100|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 01:51:12.998133|2018-06-01 01:51:12.998133
NCT00733408|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2017-11-20|2008-08-12|2008-08-13|Estimate|||||||2017-11-20|2017-11-22|Actual|April 23, 2008|Actual|2008-04-23|November 2017|2017-11-30|March 2, 2018|Anticipated|2018-03-02|July 20, 2017|Actual|2017-07-20||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer|Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib|Active, not recruiting||Phase 2|63|Anticipated|University of Washington||1|||f||||f||||||||||2018-06-01 01:51:13.314507|2018-06-01 01:51:13.314507
NCT00733395|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-08-11|2008-08-11|2008-08-13|Estimate|||||||2008-08-11|2008-08-13|Estimate|August 2008||2008-08-31|August 2008|2008-08-31||||August 2008|Anticipated|2008-08-31||Interventional|||Hood to Coast Injury Study|Comparison of Two Juice Drinks in Preventing the Symptoms of Muscle Pain Among Runners|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 01:51:13.41601|2018-06-01 01:51:13.41601
NCT00733382|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-08-11|2008-08-11|2008-08-13|Estimate|||||||2008-08-11|2008-08-13|Estimate|February 2008||2008-02-29|August 2008|2008-08-31|August 2009|Anticipated|2009-08-31|December 2008|Anticipated|2008-12-31||Interventional|||Effect of Dexamethasone on Migraine Headache|The Effect of Dexamethasone in the Attack of Migraine Headache and to Prevent of Its Relapse After Discharge From Emergency Department: a Randomized, Double-Blind, Controlled Trial.|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-06-01 01:51:13.468684|2018-06-01 01:51:13.468684
NCT00733369|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2014-03-22||2016-08-01|2008-08-12|2008-08-13|Estimate|2014-08-12|2014-08-26|Estimate||||2016-08-01|2016-09-13|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2010|Actual|2010-08-31||Interventional||Study protocol was designed and executed on using ‘knees’ as study units. Out of 106 enrolled knees, 11 knees were removed from analysis for following reasons: 8 protocol violations [bilaterals accrued at site bilaterals not allowed; used 1st knee operated upon] (4 inv, 4 control); 2 ltfu (1 inv, 1 control); 1 missing outcome (1 inv, 0 control).|A Study to Compare the Press Fit Condylar (P.F.C.) Sigma Rotating-platform High-flexion (RP-F) Versus the Press Fit Condylar (P.F.C.) Sigma Rotating-platform (RP) Knee Implants|A Prospective, Single Blinded, Multi-centre Randomised Controlled Trial Comparing the Post Operative Range of Motion of the P.F.C. Sigma RP-F Knee With the P.F.C. Sigma RP Knee in Primary Total Knee Arthroplasty.|Terminated||Phase 4|106|Actual|DePuy International||2||"This study was closed for the reason of slow recruitment with only 16% of the target subjects~   recruited over a 29 month period."|f||||f||||||||||2018-06-01 01:51:13.719756|2018-06-01 01:51:13.719756
NCT00733187|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2017-11-17|2008-08-08|2008-08-12|Estimate|||||||2017-11-17|2017-11-21|Actual|February 2009||2009-02-28|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869|A Pharmacokinetic Study to Evaluate the Effect of Food on the Oral Bioavailability and Effect of Diurnal Variation on the Pharmacokinetics of ABT-869|Completed||Phase 1|34|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 01:51:18.944757|2018-06-01 01:51:18.944757
NCT00733356|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2013-06-21||2018-01-16|2008-08-12|2008-08-13|Estimate|2018-01-16|2018-02-14|Actual||||2018-01-16|2018-02-14|Actual|July 2008||2008-07-31|January 2018|2018-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|VBHR|Subjects who met study criteria for ADHD as a primary diagnosis and no other major psychiatric diagnosis and had an IQ score at 80 or above and continued to be willing to participate in Vyvanse treatment phase. All subjects received their first reading tests at baseline visit.|The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading|The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading|Completed||Phase 4|42|Actual|University of California, Irvine|"This is a small sample of well characterized children with ADHD who were only treated for 1 month.~In addition, we did not select for children with reading disability."|1|||f||||t||||||||No||2018-06-01 01:51:14.679554|2018-06-01 01:51:14.679554
NCT00733343|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2016-10-26|2008-08-11|2008-08-13|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|Serve-HF||Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure|Treatment of Sleep-Disordered Breathing With Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients With Heart Failure|Completed||Phase 4|1325|Actual|ResMed||2|||f||||t||||||||||2018-06-01 01:51:14.941333|2018-06-01 01:51:14.941333
NCT00733330|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2014-03-24||2014-07-29|2008-08-12|2008-08-13|Estimate|2014-07-29|2014-08-15|Estimate||||2014-07-29|2014-08-15|Estimate|January 2005||2005-01-31|July 2014|2014-07-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional||86 subjects were enrolled, but 2 were intraoperatively excluded and did not receive surgery. Gender data is unavailable on one MiTKR subject.|Minimally Invasive Total Knee Replacement - Navigated Versus Non-navigated Study|Computer Assisted Navigation in Minimally Invasive Total Knee Arthroplasty: Comparing the Alignment Achieved Using the DePuy Ci Minimally Invasive (Mi) Versus the DePuy Non Navigated Conventional Total Knee Arthroplasty.|Terminated||Phase 4|86|Actual|DePuy International||2||"A sample size recalculation indicated an increase from 154 to 1500 subjects was required so the~   study stopped as new target was considered unfeasible."|f||||f||||||||||2018-06-01 01:51:15.343968|2018-06-01 01:51:15.343968
NCT00733317|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2011-12-17|2008-08-12|2008-08-13|Estimate|||||||2011-12-17|2011-12-20|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Budesonide for Emergency Treatment of Acute Wheezing in Children|Phase 4 Study of Budesonide for Emergency Treatment of Acute Wheezing in Children|Completed||Phase 4|100|Actual|Kecioren Education and Training Hospital||2|||f||||f||||||||||2018-06-01 01:51:16.125039|2018-06-01 01:51:16.125039
NCT00733304|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|2017-09-17|2012-03-01|2017-10-31|2008-08-12|2008-08-13|Estimate|2017-10-31|2017-12-05|Actual|2012-03-01|2012-03-05|Estimate|2017-10-31|2017-12-05|Actual|June 25, 2008|Actual|2008-06-25|October 2017|2017-10-31|September 9, 2009|Actual|2009-09-09|September 9, 2009|Actual|2009-09-09||Interventional|||An Extension to Study MD7108240|An Extension Study to Protocol MD7108240: Pazopanib Eye Drops in Subjects With Neovascular Age-related Macular Degeneration|Completed||Phase 2|42|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 01:51:16.269824|2018-06-01 01:51:16.269824
NCT00733291|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2009-04-10||2011-12-21|2008-08-11|2008-08-13|Estimate|2011-11-16|2011-12-21|Estimate||||2011-12-21|2011-12-28|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Daily Disposable Lenses With Multi-Purpose Solution (MPS)||Completed||N/A|64|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 01:51:17.725306|2018-06-01 01:51:17.725306
NCT00733278|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2013-10-08||2014-07-16|2008-08-12|2008-08-13|Estimate|2014-07-16|2014-08-11|Estimate||||2014-07-16|2014-08-11|Estimate|November 2007||2007-11-30|July 2014|2014-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section|Acceptability and Technical Feasibility of Insertion of a Copper IUD at Time of Elective C-section: A Pilot Study|Completed||Phase 4|7|Actual|Los Angeles Biomedical Research Institute|Pilot study involving only seven subjects, which limits generalizability of findings.|1|||f||||f||||||||||2018-06-01 01:51:18.13799|2018-06-01 01:51:18.13799
NCT00733265|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2010-12-02|2008-08-12|2008-08-13|Estimate|||||||2010-12-02|2010-12-03|Estimate|February 2007||2007-02-28|December 2010|2010-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers|Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers|Completed||Phase 1|24|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:51:18.295344|2018-06-01 01:51:18.295344
NCT00733252|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-12|||2015-10-01|2008-08-12|2008-08-13|Estimate|||||||2015-10-01|2015-10-02|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|||Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease|Optical Coherence Tomography of Human Airways|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||Low interest|f||||t||||||Samples Without DNA|"~     Fresh Bronchi from 10 subjects undergoing pneumonectomy or lobectomy for malignant and benign~     processes will be obtained from the UHCMC Pathology Department as discarded tissue from fresh~     specimens~   "|||2018-06-01 01:51:18.378079|2018-06-01 01:51:18.378079
NCT00733239|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2012-04-16|2008-08-11|2008-08-13|Estimate|||||||2012-04-16|2012-04-18|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|OMDD2||Drug Discrimination in Methadone-Maintained Humans Study 2|Drug Discrimination in Methadone-Maintained Humans Study 2|Completed||Phase 1|15|Actual|University of Arkansas||1|||f||||t||||||||||2018-06-01 01:51:18.445258|2018-06-01 01:51:18.445258
NCT00733226|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2009-12-16||2014-07-04|2008-08-12|2008-08-13|Estimate|2010-07-21|2010-08-16|Estimate||||2014-07-04|2014-07-16|Estimate|August 2007||2007-08-31|July 2014|2014-07-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing|Phase IV Study of Effect of OM-85 BV (Broncho-Vaxom) on Wheezing Related Morbidity in Children With Recurrent Wheezing|Completed||Phase 4|80|Actual|Kecioren Education and Training Hospital|Main shortcoming of our study is the small sample size. This might have hampered the appearance of some statistically meaningful differences such as wheezing attacks that require steroid treatment, rate and duration of hospitalizations.|2|||f||||f||||||||||2018-06-01 01:51:18.542966|2018-06-01 01:51:18.542966
NCT00733213|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2009-10-13|2008-08-11|2008-08-12|Estimate|||||||2009-10-13|2009-10-14|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|||||Observational|||Depiction of Prostate Cancer Treatment Alternatives in Greece|Depiction of Prostate Cancer Treatment Alternatives in Greece|Completed|||310|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:51:18.827913|2018-06-01 01:51:18.827913
NCT00733200|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2009-12-10|2008-08-11|2008-08-12|Estimate|||||||2009-12-10|2009-12-11|Estimate||||August 2008|2008-08-31||||||||Interventional|||Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?|Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?|Completed||N/A|||Huazhong University of Science and Technology||1|||f||||t||||||||||2018-06-01 01:51:18.884942|2018-06-01 01:51:18.884942
NCT00733174|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2008-08-11|2008-08-11|2008-08-12|Estimate|||||||2008-08-11|2008-08-12|Estimate|March 2004||2004-03-31|August 2008|2008-08-31||||January 2009|Anticipated|2009-01-31||Interventional|||Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance|Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance|Unknown status|Recruiting|Phase 4|60|Anticipated|Denver Research Institute||2|||f||||t||||||||||2018-06-01 01:51:18.998124|2018-06-01 01:51:18.998124
NCT00733161|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2010-07-06|2008-08-11|2008-08-12|Estimate|||||||2010-07-06|2010-07-07|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Passive Exercise on Systemic Endothelial Function in Elderly Patients With Chronic Heart Failure|Effect of Passive Exercise on Systemic Endothelial Function in Elderly Patients With Chronic Heart Failure|Completed||Phase 4|30|Actual|Kyoto University||2|||f||||||||||||||2018-06-01 01:51:19.065292|2018-06-01 01:51:19.065292
NCT00733148|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-07|2008-08-07|2008-08-12|Estimate|||||||2008-08-07|2008-08-12|Estimate|July 2004||2004-07-31|August 2008|2008-08-31|April 2005|Actual|2005-04-30|January 2005|Actual|2005-01-31||Observational|||Correlation Between the Interstitial and Arterial Glucose in Post Surgery Patients|Randomised Trial to Investigate the Correlation Between the Interstitial and Arterial Blood Concentrations of Glucose During Subcutaneous Microdialysis Glucose Monitoring in Post Surgery Patients at the Intensive Care Unit.|Completed|||40|Actual|Medical University of Graz|||2||f||||t||||||||||2018-06-01 01:51:19.148659|2018-06-01 01:51:19.148659
NCT00733135|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2014-06-05||2015-08-14|2008-08-11|2008-08-12|Estimate|2014-06-05|2014-07-04|Estimate||||2015-08-14|2015-08-26|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of the SilverHawk™ /TurboHawk™ Plaque Excision Systems Used With SpiderFX to Treat Calcified Peripheral Arterial Disease (DEFINITIVE Ca++)|Determination of Safety and Effectiveness of the SilverHawk™ Peripheral Plaque Excision System for Calcium (SilverHawk LS-C) and the SpiderFX™ Embolic Protection Device for the Treatment of Calcified Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries (DEFINITIVE Ca++)|Completed||Phase 2/Phase 3|133|Actual|Medtronic Endovascular||1|||f||||f||||||||||2018-06-01 01:51:19.217382|2018-06-01 01:51:19.217382
NCT00733122|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2011-01-13|2008-08-11|2008-08-12|Estimate|||||||2011-01-13|2011-01-14|Estimate|October 2009||2009-10-31|January 2011|2011-01-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)|Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.|Suspended||Phase 3|600|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 01:51:20.422758|2018-06-01 01:51:20.422758
NCT00733109|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2010-01-08|2008-08-11|2008-08-12|Estimate|||||||2010-01-08|2010-01-11|Estimate|March 2003||2003-03-31|August 2008|2008-08-31|July 2007|Actual|2007-07-31|July 2006|Actual|2006-07-31||Interventional|CIN2||Management of Cervical Intraepithelial Neoplasia Grade 2|Management of Cervical Intraepithelial Neoplasia Grade 2|Completed||Phase 4|90|Actual|Universidade Cidade de Sao Paulo||2|||f||||t||||||||||2018-06-01 01:51:20.486136|2018-06-01 01:51:20.486136
NCT00733096|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2012-08-24||2012-10-05|2008-08-11|2008-08-12|Estimate|2012-10-05|2012-10-08|Estimate||||2012-10-05|2012-10-08|Estimate|August 2008||2008-08-31|September 2010|2010-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy||Completed||Phase 2/Phase 3|84|Actual|Johns Hopkins University|Subjects who failed to obtain benefit were unblinded after 1-month, which limits conclusions regarding long-term efficacy.|3|||f||||f||||||||||2018-06-01 01:51:20.58869|2018-06-01 01:51:20.58869
NCT00733083|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2008-08-08|2008-08-08|2008-08-12|Estimate|||||||2008-08-08|2008-08-12|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|DOM||A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients|A Comparative Study With Pre-Emptive Parenteral Oxycodone, Morphine and Dexamethasone in the Treatment of Postoperative Pain in Paediatric Patients 4 to 12 Years of Age|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Turku||4|||f||||f||||||||||2018-06-01 01:51:20.926522|2018-06-01 01:51:20.926522
NCT00733070|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-10|||2013-07-06|2008-08-10|2008-08-12|Estimate|||||||2013-07-06|2013-07-09|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries|A Multicenter Multinational Study to Evaluate the Safety and Efficacy of the CiTop™ ExPander™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries|Terminated||N/A|30|Anticipated|Ovalum||||no interest to develop the product|f||||f||||||||||2018-06-01 01:51:21.120065|2018-06-01 01:51:21.120065
NCT00733057|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-08-11|2008-08-11|2008-08-12|Estimate|||||||2008-08-11|2008-08-12|Estimate|August 2003||2003-08-31|August 2008|2008-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Minocycline for the Treatment of Early-Phase Schizophrenia|A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia|Completed||Phase 3|70|Actual|Shalvata Mental Health Center||2|||f||||f||||||||||2018-06-01 01:51:21.205845|2018-06-01 01:51:21.205845
NCT00733044|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2013-05-06|2008-08-07|2008-08-12|Estimate|||||||2013-05-06|2013-05-07|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|||Cost-effectiveness of Multidisciplinary Management of Tinnitus|Cost-effectiveness of Multidisciplinary Management of Tinnitus at a Specialised Tinnitus Centre|Completed||N/A|492|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 01:51:21.31334|2018-06-01 01:51:21.31334
NCT00733031|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2010-12-09|2008-08-11|2008-08-12|Estimate|||||||2010-12-09|2010-12-10|Estimate|August 2008||2008-08-31|December 2010|2010-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients With Refractory Solid Malignancies|Terminated||Phase 1|75|Anticipated|AstraZeneca||3||"PK results demonstrate low and variable plasma concentrations so that achieving therapeutic~   concentrations is unlikely."|f||||f||||||||||2018-06-01 01:51:21.395463|2018-06-01 01:51:21.395463
NCT00733018|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2017-01-27|2008-08-11|2008-08-12|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2007||2007-12-31|January 2017|2017-01-31|July 2009|Actual|2009-07-31|June 2008|Actual|2008-06-30||Interventional|Foodgene||Nutrigenomics Diet Intervention Study Comparing Effects of Western and Balanced Diet in Healthy Subjects|Health Risk Assessment of Dietary Carbohydrates in Chronic Disease Development|Completed||N/A|40|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-06-01 01:51:21.52505|2018-06-01 01:51:21.52505
NCT00733005|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2009-10-13||2017-03-15|2008-08-08|2008-08-12|Estimate|2009-10-13|2009-11-19|Estimate||||2017-03-15|2017-04-12|Actual|July 2008||2008-07-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 3|324|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:51:21.641841|2018-06-01 01:51:21.641841
NCT00732992|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2010-10-27||2011-03-15|2008-08-11|2008-08-12|Estimate|2010-10-27|2010-11-25|Estimate||||2011-03-15|2011-03-17|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies|Phase 1 Study Of Sunitinib (SU011248) In Combination With Pemetrexed In Patients With Advanced Solid Malignancies In Japan|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:51:21.981273|2018-06-01 01:51:21.981273
NCT00732979|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2013-05-16|2008-08-11|2008-08-12|Estimate|||||||2013-05-16|2013-05-17|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|IVC CLAMP||Infrahepatic Inferior Vena Cava Clamping During Hepatectomy|IVC CLAMP: Infrahepatic Inferior Vena Cava Clamping During Hepatectomy - A Randomized Controlled Trial|Completed||N/A|152|Actual|Heidelberg University||2|||f||||t||||||||||2018-06-01 01:51:22.573299|2018-06-01 01:51:22.573299
NCT00732966|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-10|||2008-08-11|2008-08-11|2008-08-12|Estimate|||||||2008-08-11|2008-08-12|Estimate|September 2008||2008-09-30|August 2008|2008-08-31||||September 2009|Anticipated|2009-09-30||Interventional|||Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?|Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?|Unknown status|Not yet recruiting|N/A|30|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 01:51:22.660788|2018-06-01 01:51:22.660788
NCT00732953|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2014-06-07|2008-08-08|2008-08-12|Estimate|||||||2014-06-07|2014-06-10|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|February 2014|Actual|2014-02-28|January 2010|Actual|2010-01-31||Interventional|||Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries|Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries - a Randomized Clinical Trial.|Completed||Phase 2/Phase 3|120|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 01:51:22.822377|2018-06-01 01:51:22.822377
NCT00732940|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2011-04-07||2013-08-01|2008-08-11|2008-08-12|Estimate|2011-04-07|2011-05-05|Estimate||||2013-08-01|2013-08-07|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|March 2012|Actual|2012-03-31|October 2009|Actual|2009-10-31||Interventional|||Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 2, Multi-Center, Randomized, Open Label, Trial to Evaluate the Safety, Tolerability, and Biological Activity of 2 Dosing Schedules of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)|Terminated||Phase 2|56|Actual|Human Genome Sciences Inc.||2||Sponsor terminated study for business reasons.|f||||t||||||||||2018-06-01 01:51:22.989354|2018-06-01 01:51:22.989354
NCT00732927|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-07|2008-08-07|2008-08-12|Estimate|||||||2008-08-07|2008-08-12|Estimate|July 2002||2002-07-31|August 2008|2008-08-31|September 2007|Actual|2007-09-30|July 2006|Actual|2006-07-31||Interventional|PARVO||Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion|Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study|Terminated||Phase 3|67|Actual|Università degli Studi dell'Insubria||2||slow recruitment rate|f||||f||||||||||2018-06-01 01:51:23.771781|2018-06-01 01:51:23.771781
NCT00732914|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2014-04-22|2008-08-11|2008-08-12|Estimate|||||||2014-04-22|2014-04-23|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Sequential Study to Treat Renal Cell Carcinoma|A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma|Completed||Phase 3|272|Actual|Sponsor GmbH||2|||f||||f||||||||||2018-06-01 01:51:23.870269|2018-06-01 01:51:23.870269
NCT00732901|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2016-07-20||2017-06-09|2008-08-08|2008-08-12|Estimate|2017-02-10|2017-03-30|Actual||||2017-06-09|2017-06-14|Actual|June 2008||2008-06-30|June 2017|2017-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Clinical Neurobiology of Serotonin and Addiction|Project 1: Clinical Neurobiology of Serotonin and Addiction|Completed||Phase 2/Phase 3|160|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 01:51:24.02403|2018-06-01 01:51:24.02403
NCT00732888|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2013-12-17|2008-08-11|2008-08-12|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers|Effect of Calcium Supplements on Nilotinib Hydrochloride Pharmacokinetics in Healthy Volunteers (CAMN107DUS10T) (UPCI 08-077)|Completed||Phase 1|14|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:51:24.277404|2018-06-01 01:51:24.277404
NCT00732875|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2009-06-02||2017-03-16|2008-08-08|2008-08-12|Estimate|2009-06-02|2009-07-21|Estimate||||2017-03-16|2017-04-13|Actual|August 2006||2006-08-31|March 2017|2017-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)|A Placebo-controlled, Double-blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment (Open-label Extension Part)|Completed||Phase 3|92|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:51:24.359573|2018-06-01 01:51:24.359573
NCT00732862|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2014-12-10|2008-08-11|2008-08-12|Estimate|||||||2014-12-10|2014-12-11|Estimate|February 1998||1998-02-28|December 2014|2014-12-31|December 2008|Actual|2008-12-31|March 2000|Actual|2000-03-31||Interventional|||Metabolic Adaptation to Diabetes|Metabolic Adaptation to Diabetes|Completed||N/A|15|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 01:51:24.562647|2018-06-01 01:51:24.562647
NCT00732849|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-08|2008-08-08|2008-08-12|Estimate|||||||2008-08-08|2008-08-12|Estimate|June 2002||2002-06-30|July 2008|2008-07-31|November 2007|Actual|2007-11-30|September 2002|Actual|2002-09-30||Interventional|||The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery|The Impact of the Type and Route of Nutritional Support on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.|Completed||Phase 4|600|Actual|Jagiellonian University||4|||f||||f||||||||||2018-06-01 01:51:24.625706|2018-06-01 01:51:24.625706
NCT00732836|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2016-02-04|2008-08-11|2008-08-12|Estimate|||||||2016-02-04|2016-02-05|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Hepatic Arterial Infusion (HAI) of Abraxane|Phase I Trial of Hepatic Arterial Infusion of Abraxane With a Pharmacokinetic Study in Advanced Solid Cancer Patients With Predominant Hepatic Metastases|Completed||Phase 1|64|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 01:51:24.746497|2018-06-01 01:51:24.746497
NCT00732823|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-10-29|2008-08-11|2008-08-12|Estimate|||||||2008-10-29|2008-10-31|Estimate|July 2005||2005-07-31|August 2008|2008-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Compression Device Safety Study|A Phase II Randomized Study to Evaluate the Safety of the Compression Test Device Using Intermittent Pneumatic Compression Mode in Subjects With Venous Insufficiency and Oedema|Completed||Phase 2|16|Actual|ConvaTec Inc.||4|||f||||f||||||||||2018-06-01 01:51:24.937819|2018-06-01 01:51:24.937819
NCT00732810|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2015-08-04|2008-08-08|2008-08-12|Estimate|||||||2015-08-04|2015-08-05|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)|A Randomized Phase 2 Study of SCH 727965 in Subjects With Advanced Breast and Non Small Cell Lung (NSCLC) Cancers|Completed||Phase 2|97|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 01:51:25.026957|2018-06-01 01:51:25.026957
NCT00732797|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2011-08-11|2008-08-07|2008-08-12|Estimate|||||||2011-08-11|2011-08-12|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||A Trial of Booklet Based Self Management of Dizziness|Evaluation of the Cost-effectiveness of Booklet-based Self-management of Dizziness in Primary Care, With and Without Expert Telephone Support|Completed||Phase 2|337|Actual|University of Southampton||3|||f||||f||||||||||2018-06-01 01:51:25.105153|2018-06-01 01:51:25.105153
NCT00732784|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2013-12-17|2008-08-11|2008-08-12|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers|Effect of Calcium Supplements on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS 280) (UPCI 08-072)|Completed||Phase 1|11|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:51:25.194508|2018-06-01 01:51:25.194508
NCT00732771|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-08-25|2008-08-08|2008-08-12|Estimate|||||||2009-08-25|2009-08-26|Estimate|June 2008||2008-06-30|August 2009|2009-08-31||||May 2009|Actual|2009-05-31||Interventional|||Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism|A Pilot, Single-blind, Forced-titration Study to Assess the Hemodynamic and Hormonal Effects, Safety and Tolerability of the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism|Completed||Phase 2|12|Anticipated|Novartis||1|||f||||||||||||||2018-06-01 01:51:25.272676|2018-06-01 01:51:25.272676
NCT00732758|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2015-09-22||2015-11-30|2008-08-11|2008-08-12|Estimate|2015-09-22|2015-10-22|Estimate||||2015-11-30|2015-12-29|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|Vitamin D RCT||Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3|Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3|Completed||Phase 1|157|Actual|University of Pittsburgh|No limitations.|2|||f||||f||||||||||2018-06-01 01:51:25.349275|2018-06-01 01:51:25.349275
NCT00732745|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-09|||2011-08-19|2008-08-09|2008-08-12|Estimate|||||||2011-08-19|2011-08-22|Estimate|October 2008||2008-10-31|August 2011|2011-08-31||||June 2010|Actual|2010-06-30||Interventional|||Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction|Phase I/II Study of the Combination of Oxaliplatin / Docetaxel and ZACTIMA for the Treatment of Advanced Cancers of the Esophagus and Gastroesophageal Junction|Terminated||Phase 1|9|Actual|Case Comprehensive Cancer Center||2||Lost funding for Phase II portion of study|f||||t||||||||||2018-06-01 01:51:25.795718|2018-06-01 01:51:25.795718
NCT00732732|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2011-08-05|2008-08-11|2008-08-12|Estimate|||||||2011-08-05|2011-08-08|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Controlled Trial of Plantain Powder in Infantile Diarrhea|A Controlled Trail of Plantain Powder (Green Banana) in Infantile Diarrhea.|Terminated||N/A|200|Anticipated|Augusta University||2||"Closed by US IRB due to lack of an adequate system for continuing review by the Indian IRB. No~   subjects enrolled in US."|f||||f||||||||||2018-06-01 01:51:25.891363|2018-06-01 01:51:25.891363
NCT00732719|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-10-29|2008-08-11|2008-08-12|Estimate|||||||2008-10-29|2008-10-31|Estimate|October 2004||2004-10-31|August 2008|2008-08-31|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Compression Device Safety Study on Edema|A Phase II Non-Comparative Study Evaluating the Effects of the Compression Test Device on Oedema|Completed||Phase 2|12|Actual|ConvaTec Inc.||7|||f||||f||||||||||2018-06-01 01:51:25.969652|2018-06-01 01:51:25.969652
NCT00732706|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2008-08-11|2008-08-11|2008-08-12|Estimate|||||||2008-08-11|2008-08-12|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|FNB||Femoral Nerve Block: Anatomical Insertion Point - A Prospective Randomised Double-Blind Controlled Trial|Femoral Nerve Block: Anatomical Insertion Point - A Prospective Randomised Double-Blind Controlled Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:51:26.07257|2018-06-01 01:51:26.07257
NCT00732693|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2008-08-11|2008-08-11|2008-08-12|Estimate|||||||2008-08-11|2008-08-12|Estimate|February 2002||2002-02-28|August 2008|2008-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure|Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters|Completed||Phase 4|42|Actual|University of Edinburgh||2|||f||||f||||||||||2018-06-01 01:51:26.247362|2018-06-01 01:51:26.247362
NCT00732680|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2013-11-13||2016-03-18|2008-08-11|2008-08-12|Estimate|2013-12-30|2014-02-13|Estimate||||2016-03-18|2016-04-18|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome Syndrome|Prospective Case Series Evaluating Short and Long Term Benefits of the Use of Botox in the Treatment of Empty Nose Syndrome|Terminated||Phase 1/Phase 2|9|Actual|Mayo Clinic|No study data was collected in the study. The Lead investigator moved to a new medical center; the study was stopped when he left.|1||Lead investigator moved to a new medical center; study was stopped when he left.|f||||f||||||||||2018-06-01 01:51:26.358242|2018-06-01 01:51:26.358242
NCT00732329|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2015-02-10|2008-08-08|2008-08-12|Estimate|||||||2015-02-10|2015-02-11|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|ERGODEM||Effectiveness of Home Based Occupational Therapy for Dementia.|Effectiveness of an Optimized Home Based Occupational Therapy for Patients With Dementia.|Completed||N/A|160|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 01:51:32.462485|2018-06-01 01:51:32.462485
NCT00732654|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2016-03-28||2017-04-06|2008-08-11|2008-08-12|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|August 2008||2008-08-31|April 2017|2017-04-30|June 2012|Actual|2012-06-30|June 2010|Actual|2010-06-30||Interventional|||The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy|The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy|Completed||Phase 1/Phase 2|30|Actual|Johns Hopkins University|Please refer to the links section, it contains a link to the publication of this research study in the Journal of Allergy and Clinical Immunology|3|||f||||t||||||||||2018-06-01 01:51:26.526989|2018-06-01 01:51:26.526989
NCT00732641|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2011-10-27||2017-03-07|2008-08-08|2008-08-12|Estimate|2011-10-27|2011-12-02|Estimate||||2017-03-07|2017-04-04|Actual|December 2000||2000-12-31|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)|Phase III Randomized, Prospective Multi-center Trial of PEG-Interferon α-2b as a Maintenance Therapy, Compared to Observation, in Patients With Multiple Myeloma Who Responded to Induction Therapy (Protocol No P01972)|Completed||Phase 3|244|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:51:26.977715|2018-06-01 01:51:26.977715
NCT00732628|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2009-02-20|2008-08-07|2008-08-12|Estimate|||||||2009-02-20|2009-02-24|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|||||Observational|||Evaluating Outcomes in the Placement of Boomerang Percutaneous Device|Technical and Clinical Outcomes Following Placement of Boomerang Percutaneous Closure Device After Cerebral Angiography or Neurointerventional Procedures|Terminated|||200|Anticipated|University of Michigan|||1|Physician is no longer associated with the Univ. of Michigan Medical Center|f||||f||||||||||2018-06-01 01:51:27.463611|2018-06-01 01:51:27.463611
NCT00732615|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2015-02-20|2012-10-09|2015-11-10|2008-08-11|2008-08-12|Estimate|2015-02-20|2015-03-06|Estimate|2012-10-09|2012-10-11|Estimate|2015-11-10|2015-12-08|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|REPLACE||Use of NPSP558 in the Treatment of Hypoparathyroidism|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism|Completed||Phase 3|124|Actual|Shire||2|||f||||t||||||||||2018-06-01 01:51:27.535516|2018-06-01 01:51:27.535516
NCT00732602|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2009-02-12|2008-08-11|2008-08-12|Estimate|||||||2009-02-12|2009-02-13|Estimate|January 2008||2008-01-31|February 2009|2009-02-28||||August 2008|Actual|2008-08-31||Interventional|||The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes|The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes|Completed||N/A|8|Actual|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-06-01 01:51:28.235731|2018-06-01 01:51:28.235731
NCT00732589|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2009-11-17|2008-08-08|2008-08-12|Estimate|||||||2009-11-17|2009-11-18|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|SSNB||SSNB in Hemiplegic Shoulder Pain|Suprascapular Nerve Block in Hemiplegic Shoulder Pain.|Completed||Phase 2|0|Anticipated|Chulalongkorn University||2|||f||||f||||||||||2018-06-01 01:51:28.381421|2018-06-01 01:51:28.381421
NCT00732576|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2017-02-22|2008-08-07|2008-08-12|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2008||2008-01-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Omega-3 Fatty Acids and Menaquinone-7 on Thrombotic Tendency|Effects of Omega-3 Fatty Acids and Menaquinone-7 on Thrombotic Tendency|Completed||N/A|57|Actual|Maastricht University Medical Center||8|||f||||f||||||||||2018-06-01 01:51:28.518055|2018-06-01 01:51:28.518055
NCT00732563|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-09|||2017-10-16|2008-08-09|2008-08-12|Estimate|||||||2017-10-16|2017-10-18|Actual|July 16, 2008|Actual|2008-07-16|October 2017|2017-10-31|July 26, 2017|Actual|2017-07-26|June 29, 2012|Actual|2012-06-29||Interventional|||Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery|Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer|Completed||N/A|100|Actual|Roswell Park Cancer Institute|||||f||||t|f|f||||||||2018-06-01 01:51:28.60051|2018-06-01 01:51:28.60051
NCT00732550|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-03|||2016-04-13|2008-08-11|2008-08-12|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Single Trocar Cholecystectomy to Standard Laparoscopic Cholecystectomy|Comparison of Single Trocar Cholecystectomy to Standard Laparoscopic Cholecystectomy|Active, not recruiting||N/A|20|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 01:51:28.685958|2018-06-01 01:51:28.685958
NCT00732537|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2008-08-08|2008-08-08|2008-08-12|Estimate|||||||2008-08-08|2008-08-12|Estimate|March 1999||1999-03-31|August 2008|2008-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Inhaled Nitric Oxide by Oxygen Hood in Neonates|Inhaled Nitric Oxide in Neonates With Elevated A-aDO2 Gradients Not Requiring Mechanical Ventilation|Completed||Phase 4|8|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 01:51:28.785264|2018-06-01 01:51:28.785264
NCT00732524|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2008-08-11|2008-08-11|2008-08-12|Estimate|||||||2008-08-11|2008-08-12|Estimate|September 2004||2004-09-30|August 2008|2008-08-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA|Combination of Sulfonylureas and Insulin Glargine as Safety Net Outpatient Therapy for Unstable Diabetes and Impending Diabetic Ketoacidosis (DKA)|Completed||Phase 4|80|Actual|John H. Stroger Hospital||2|||f||||t||||||||||2018-06-01 01:51:28.877032|2018-06-01 01:51:28.877032
NCT00732511|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2011-02-09|2008-08-11|2008-08-12|Estimate|||||||2011-02-09|2011-02-10|Estimate|April 2008||2008-04-30|February 2011|2011-02-28|April 2009|Anticipated|2009-04-30|December 2008|Anticipated|2008-12-31||Interventional|||Coreg CR, Blood Vessel Stiffness and Blood Vessel Function|Effect of Coreg CR on BP, Endothelial Function, Exhaled Nitric Oxide, and Nitric Oxide Production and Oxidation|Unknown status|Recruiting|Phase 4|40|Anticipated|State University of New York - Downstate Medical Center||2|||f||||f||||||||||2018-06-01 01:51:28.978513|2018-06-01 01:51:28.978513
NCT00732498|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-09|||2018-04-12|2008-08-09|2008-08-12|Estimate|||||||2018-04-12|2018-04-13|Actual|May 15, 2006|Actual|2006-05-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ESHAP||Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL|Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 2|52|Anticipated|University of Arizona||1|||f||||t||||||||||2018-06-01 01:51:29.089994|2018-06-01 01:51:29.089994
NCT00732485|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2012-12-10|2008-08-11|2008-08-12|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate|The Role of Mitochondrial Oxidation on Insulin Resistance in Burn Patients Treated With Fenofibrate|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||2||Principal Investigator Changed|f||||t||||||||||2018-06-01 01:51:29.197165|2018-06-01 01:51:29.197165
NCT00732472|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|2014-01-02||2016-10-11|2008-08-11|2008-08-12|Estimate|2014-01-02|2014-02-17|Estimate||||2016-10-11|2016-11-23|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days|A Randomised, Double-blind, Placebo-controlled, Dose Ascending, 2-cohort, Parallel Group Study to Examine the Safety, Tolerability and Pharmacokinetics of Once-daily Inhaled Doses of GSK573719 Formulated With the Excipient Magnesium Stearatein COPD Subjects for 7 Days|Completed||Phase 2|37|Actual|GlaxoSmithKline|Subject 303 and Subject 317 correspond to the same participant who was randomized and dosed on two separate occasions. This participant has been counted as two separate participants on all the outputs.|1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:51:29.384089|2018-06-01 01:51:29.384089
NCT00732459|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-09|||2008-08-15|2008-08-11|2008-08-12|Estimate|||||||2008-08-15|2008-08-18|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|July 2008|Actual|2008-07-31||Observational|||Clinical Trial of Electro-Acupuncture Preconditioning in Patients Underwent Heart Valve Replacement Surgery|Clinical Trial of The Myocardial Protective Effects of Repeated Electroacupuncture Preconditioning in Heart Valve Replacement Surgery|Unknown status|Enrolling by invitation||60|Anticipated|Xijing Hospital|||2||f||||t||||||||||2018-06-01 01:51:31.146369|2018-06-01 01:51:31.146369
NCT00732446|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2011-06-21|2008-08-11|2008-08-12|Estimate|||||||2011-06-21|2011-06-22|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|BRA-07-02||Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis|An Evaluation of the Safety and Efficacy of the Administration of a Fixed Combination of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops Compared With the Individual Administration of Moxifloxacin 0.5% and Dexamethasone 0.1% in the Treatment of Bacterial Ocular Inflammation and Infection (Blepharitis and/or Keratitis and/or Conjunctivitis)|Completed||Phase 3|100|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:51:31.226747|2018-06-01 01:51:31.226747
NCT00732433|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2017-09-06|2008-08-07|2008-08-12|Estimate|||||||2017-09-06|2017-09-07|Actual|June 2000||2000-06-30|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Digital Mammography: Computer-Aided Breast Cancer Diagnosis|Digital Mammography: Computer-Aided Breast Cancer Diagnosis|Active, not recruiting||N/A|500|Anticipated|University of Michigan||1|||f||||t||||||||||2018-06-01 01:51:31.395144|2018-06-01 01:51:31.395144
NCT00732420|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-11|||2017-11-08|2008-08-11|2008-08-12|Estimate|||||||2017-11-08|2017-11-13|Actual|September 24, 2008|Actual|2008-09-24|November 2017|2017-11-30|June 12, 2013|Actual|2013-06-12|June 12, 2013|Actual|2013-06-12||Interventional|||Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors|A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in Combination With Pazopanib in Subjects With Advanced Solid Tumors|Completed||Phase 1|68|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 01:51:31.496832|2018-06-01 01:51:31.496832
NCT00732407|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-10|||2008-08-11|2008-08-11|2008-08-12|Estimate|||||||2008-08-11|2008-08-12|Estimate|September 2008||2008-09-30|August 2008|2008-08-31||||September 2009|Anticipated|2009-09-30||Interventional|||Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)|Effect of Aliskiren on Arterial Stiffness and Platelet Function in Patients With Type 2 Diabetes Mellitus, a Comparison With Losartan|Unknown status|Not yet recruiting|N/A|40|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 01:51:31.616614|2018-06-01 01:51:31.616614
NCT00732394|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2008-08-08|2008-08-08|2008-08-12|Estimate|||||||2008-08-08|2008-08-12|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|January 2010|Anticipated|2010-01-31|August 2009|Anticipated|2009-08-31||Interventional|||A Comparative Study: Non-Surgical Spinal Decompression and Spinal Manipulative Therapy- Utilizing a Quantifiable Musculoskeletal Functional Assessment Risk Analysis Tool (MSDR®) in Patients With Chronic Low Back Pain|This is a Study is for the Purpose of Quantifying Function of the Back and Lower Extremities, and to Assess the Inter-Regional Biomechanical Relationships of the Neck, Upper Extremities, Back, and Lower Extremities in Patients Suffering From Chronic Low Back Pain.|Unknown status|Recruiting|N/A|200|Anticipated|MedAppraise, Inc.|||||f||||t||||||||||2018-06-01 01:51:31.719104|2018-06-01 01:51:31.719104
NCT00732381|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2009-10-07||2017-03-16|2008-08-08|2008-08-12|Estimate|2009-10-07|2009-11-13|Estimate||||2017-03-16|2017-04-13|Actual|August 2008||2008-08-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 3|351|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:51:31.824088|2018-06-01 01:51:31.824088
NCT00732368|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2017-03-22|2008-08-08|2008-08-12|Estimate|||||||2017-03-22|2017-03-24|Actual|May 1, 2005|Actual|2005-05-01|March 2017|2017-03-31|January 1, 2006|Actual|2006-01-01|January 1, 2006|Actual|2006-01-01||Interventional|||A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)|A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis|Completed||Phase 3|98|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:51:32.134952|2018-06-01 01:51:32.134952
NCT00732355|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2016-02-29|2008-08-11|2008-08-12|Estimate|||||||2016-02-29|2016-03-02|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Observational|SyphPoc||Syph-Check Syphilis Antibody Point of Care (POC) Test|One-Step Syphilis Point of Care Test for Rapid Immunoassay Screening of Antibodies to Treponema Pallidum|Terminated|||400|Actual|Healthcare Providers Direct, Inc.|||2|insufficient patient populations|f||||f||||||||No||2018-06-01 01:51:32.218248|2018-06-01 01:51:32.218248
NCT00732342|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2015-08-17|2008-08-07|2008-08-12|Estimate|||||||2015-08-17|2015-08-18|Estimate|February 2008||2008-02-29|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Duration||Contingency Management Treatment Duration|Contingency Management Treatment Duration|Completed||Phase 2|310|Actual|UConn Health||4|||f||||f||||||||||2018-06-01 01:51:32.342529|2018-06-01 01:51:32.342529
NCT00732316|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2012-07-16|2008-08-08|2008-08-11|Estimate|||||||2012-07-16|2012-07-17|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|May 2011|Actual|2011-05-31|December 2009|Actual|2009-12-31||Interventional|||Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome|HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND MYELODYSPLASTIC SYNDROME - A PHASE 2 STUDY|Completed||Phase 2|54|Actual|Asan Medical Center|||||f||||f||||||||||2018-06-01 01:51:32.56933|2018-06-01 01:51:32.56933
NCT00732303|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2016-02-24||2016-03-23|2008-08-07|2008-08-11|Estimate|2016-03-23|2016-04-27|Estimate||||2016-03-23|2016-04-27|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer|A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129|Terminated||Phase 2|8|Actual|Hoosier Cancer Research Network||1||Study terminated due to withdrawal of pharmaceutical funding|f||||t||||||||||2018-06-01 01:51:32.690996|2018-06-01 01:51:32.690996
NCT00732290|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2013-03-22|2008-08-08|2008-08-11|Estimate|||||||2013-03-22|2013-03-25|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PLATINE||Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine|Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine|Completed||Phase 1|10|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-06-01 01:51:33.044693|2018-06-01 01:51:33.044693
NCT00732277|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2016-05-05|2008-08-08|2008-08-11|Estimate|||||||2016-05-05|2016-05-06|Estimate|April 2008||2008-04-30|May 2016|2016-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|StePS||Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study|Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis (Steroids in Paediatric Sepsis, StePS) - a Randomised Pilot Study|Completed||Phase 2|21|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||No||2018-06-01 01:51:33.131002|2018-06-01 01:51:33.131002
NCT00732264|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-10-17|2008-08-08|2008-08-11|Estimate|||||||2008-10-17|2008-10-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:51:33.256994|2018-06-01 01:51:33.256994
NCT00732251|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2018-01-25||2018-01-25|2008-08-08|2008-08-11|Estimate|2018-01-25|2018-02-21|Estimate||||2018-01-25|2018-02-21|Estimate|August 2008||2008-08-31|January 2018|2018-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Allopurinol Maintenance Study for Bipolar Disorder|An Open Label, Naturalistic Study With Allopurinol Augmentation for Prevention of Mania in Bipolar Disorder|Terminated||Phase 4|15|Actual|Cedars-Sinai Medical Center||1||The outpatient area of the department of psychiatry at CSMC closed.|f||||f||||||||||2018-06-01 01:51:33.307665|2018-06-01 01:51:33.307665
NCT00732238|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2014-10-28||2015-01-21|2008-08-08|2008-08-11|Estimate|2014-10-28|2014-11-03|Estimate||||2015-01-21|2015-02-16|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Multifaceted Treatment of Catheter-related Urinary Tract Infection|Multifaceted Treatment of Catheter-related Urinary Tract Infection|Completed||Phase 2|61|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:51:33.5077|2018-06-01 01:51:33.5077
NCT00732225|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2010-03-31||2010-06-30|2008-08-08|2008-08-11|Estimate|2010-06-30|2010-07-30|Estimate||||2010-06-30|2010-07-30|Estimate|May 2007||2007-05-31|June 2010|2010-06-30||||February 2008|Actual|2008-02-29||Interventional|||DisCoVisc Comparative Evaluation|A Prospective, Non-randomized Comparison of DisCoVisc to Dispersive and Cohesive Ophthalmic Viscosurgical Devices (OVDs) in Non-eventful Cataract Surgery|Completed||Phase 3|173|Actual|Alcon Research|At the time of surgery, patients were assigned to a study group based on the availability of study Ophthalmic Viscosurgical Devices (OVDs).|5|||f||||f||||||||||2018-06-01 01:51:33.780741|2018-06-01 01:51:33.780741
NCT00732212|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2017-02-24||2017-06-16|2008-08-06|2008-08-11|Estimate|2017-02-24|2017-04-11|Actual||||2017-06-16|2017-07-13|Actual|February 18, 2009|Actual|2009-02-18|June 2017|2017-06-30|January 7, 2016|Actual|2016-01-07|January 7, 2016|Actual|2016-01-07||Interventional|||Doppler Ultrasound Probe for Blood Flow Detection in Severe Upper Gastrointestinal Hemorrhage|Doppler Ultrasound Probe for Blood Flow Detection in Severe UGI Bleed|Completed||N/A|235|Actual|VA Office of Research and Development|Potential limitations of this study are expense of equipment, learning curve as new technology, and no other randomized controlled studies have been reported to confirm the results.|2|||f||||t|f|t|f|f|t|||No||2018-06-01 01:51:34.309149|2018-06-01 01:51:34.309149
NCT00732199|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2016-12-14||2017-04-10|2008-08-08|2008-08-11|Estimate|2017-04-10|2017-06-28|Actual||||2017-04-10|2017-06-28|Actual|October 2008||2008-10-31|April 2017|2017-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||We studied normal subjects. Subjects were assigned to two age categories, ‘young’ between 18 and 50 years, and ‘elderly' >55-60 years respectively. Participants with data available were included in the analysis Normal participants (controls) will have apnea hypopnea index, AHI<5/hour, respiratory events /hour of sleep|Determinants of Age Related Breathing Instability During Non-Rapid-Eye-Movement (NREM) Sleep|Determinants of Age-specific Breathing Instability During Sleep|Completed||N/A|92|Actual|VA Office of Research and Development|Participants who could not maintain stable sleep could not be included in the analyses. Participants also dropped out after the initial diagnostic sleep study as they did not want to continue the experimental arms.|2|||f||||t||||||||No||2018-06-01 01:51:34.816499|2018-06-01 01:51:34.816499
NCT00732186|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2016-02-16|2008-08-07|2008-08-11|Estimate|||||||2016-02-16|2016-02-17|Estimate|August 2009||2009-08-31|November 2009|2009-11-30|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia|Phase Ib Study Evaluating the Safety and Exploring the Molecular and Cytogenetic Response of Combination Therapy With Dasatinib and Ipilimumab in Patients With Chronic or Accelerated Phase Chronic Myeloid Leukemia|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 01:51:35.274096|2018-06-01 01:51:35.274096
NCT00732173|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2013-02-07|2008-08-08|2008-08-11|Estimate|||||||2013-02-07|2013-02-08|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer|Survivors of Uterine Cancer Empowered By Exercise and Healthy Diet (SUCCEED)|Completed||N/A|74|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 01:51:35.347718|2018-06-01 01:51:35.347718
NCT00732160|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2015-05-08||2017-02-21|2008-08-05|2008-08-11|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|September 2008||2008-09-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional||Healthy volunteers|Aldosterone and Glucose Homeostasis|Aldosterone and Glucose Homeostasis|Completed||N/A|34|Actual|Vanderbilt University Medical Center||4|||f||||t||||||||||2018-06-01 01:51:35.430289|2018-06-01 01:51:35.430289
NCT00732147|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2012-06-02|2008-08-08|2008-08-11|Estimate|||||||2012-06-02|2012-06-05|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM|Effects of Pramlintide on Endogenous Production of VLDL-Triglyceride and Glucose in the Post Prandial State in Type 2 Diabetes Mellitus|Withdrawn||N/A|0|Actual|University of Maryland||2||Sponsor could not fund.|f||||f||||||||||2018-06-01 01:51:36.857766|2018-06-01 01:51:36.857766
NCT00732134|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-08|2008-08-08|2008-08-11|Estimate|||||||2008-08-08|2008-08-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:51:36.946785|2018-06-01 01:51:36.946785
NCT00732121|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2010-06-25|2008-08-07|2008-08-11|Estimate|||||||2010-06-25|2010-06-28|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|June 2010|Anticipated|2010-06-30||Interventional|||Bone Turnover in Type 2 Diabetes Patients|Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|University of Vermont||2|||f||||f||||||||||2018-06-01 01:51:36.999724|2018-06-01 01:51:36.999724
NCT00732108|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2015-03-04|2008-08-08|2008-08-11|Estimate|||||||2015-03-04|2015-03-06|Estimate|November 2008||2008-11-30|March 2015|2015-03-31||||August 2011|Anticipated|2011-08-31||Interventional|||Is Topiramate Effective in Treating Dizziness in Patient's With Migraine-Associated Dizziness|Efficacy of Topiramate in Patients Wih Migraine-Associated Dizziness|Withdrawn||N/A|0|Actual|University of California, San Francisco||2||No subjects enrolled|f||||t||||||||||2018-06-01 01:51:37.091734|2018-06-01 01:51:37.091734
NCT00732095|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2010-12-13|2008-08-08|2008-08-11|Estimate|||||||2010-12-13|2010-12-14|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|PSC3||Promoting Self-Change From Alcohol Problems: Mechanisms of Change in a Community-Based Intervention|Promoting Self-Change From Alcohol Problems: Mechanisms of Change in a Community-Based Intervention|Completed||Phase 3|283|Actual|Nova Southeastern University||1|||f||||f||||||||||2018-06-01 01:51:37.193678|2018-06-01 01:51:37.193678
NCT00732082|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2013-06-11|2008-08-08|2008-08-11|Estimate|||||||2013-06-11|2013-06-12|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|September 2012|Actual|2012-09-30|February 2010|Actual|2010-02-28||Interventional|||Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer|Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer|Terminated||Phase 1|18|Actual|Washington University School of Medicine||5||Company manufacturing study drug was unable to continue production.|f||||f||||||||||2018-06-01 01:51:37.293621|2018-06-01 01:51:37.293621
NCT00732069|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2012-07-18||2013-06-22|2008-08-06|2008-08-11|Estimate|2013-05-10|2013-06-20|Estimate||||2013-06-22|2013-07-02|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis|Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 2|Completed||Phase 2|19|Actual|Vanderbilt University||6|||f||||t||||||||||2018-06-01 01:51:37.440287|2018-06-01 01:51:37.440287
NCT00732056|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2015-12-22|2008-08-08|2008-08-11|Estimate|||||||2015-12-22|2015-12-24|Estimate|July 2008||2008-07-31|December 2015|2015-12-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer|A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 1|24|Actual|Geron Corporation||1|||f||||f||||||||||2018-06-01 01:51:38.683439|2018-06-01 01:51:38.683439
NCT00732043|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2012-03-15|2008-08-08|2008-08-11|Estimate|||||||2012-03-15|2012-03-16|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer|A 48-Month Extension to the Randomized, Double-blind, Placebo-Controlled Study of the Effects of Pomegranate Extract on Rising Prostate-Specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|Roll International Corporation||3|||f||||t||||||||||2018-06-01 01:51:38.773179|2018-06-01 01:51:38.773179
NCT00732030|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2009-04-29||2010-03-25|2008-08-08|2008-08-11|Estimate|2010-03-25|2010-04-07|Estimate||||2010-03-25|2010-04-07|Estimate|June 2007||2007-06-30|March 2010|2010-03-31||||March 2009|Actual|2009-03-31||Interventional|||Low Cylinder Toric|Evaluation of the Acrysof Toric Model SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.03 Diopters (D)|Completed||Phase 4|26|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:51:38.882593|2018-06-01 01:51:38.882593
NCT00732017|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2008-08-06|2008-08-06|2008-08-11|Estimate|||||||2008-08-06|2008-08-11|Estimate|February 2004||2004-02-29|August 2008|2008-08-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Effects Of High Voltage Pulsed Current On Post-Traumatic Injuries|Effects Of High Voltage Pulsed Current On Ankle Post-Traumatic Injuries|Completed||N/A|28|Actual|Universidad Industrial de Santander||3|||f||||t||||||||||2018-06-01 01:51:39.073576|2018-06-01 01:51:39.073576
NCT00732004|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2009-06-30|2008-08-08|2008-08-11|Estimate|||||||2009-06-30|2009-07-02|Estimate|August 2008||2008-08-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Time Course Comparison of Contact Lens Maintenance Systems for Hydrogel Lenses||Completed||N/A|132|Anticipated|University of Melbourne||3|||f||||||||||||||2018-06-01 01:51:39.170448|2018-06-01 01:51:39.170448
NCT00731991|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2009-07-31|2008-08-07|2008-08-11|Estimate|||||||2009-07-31|2009-08-03|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Art and Surface Electromyography (EMG)|The Effects of Active Release Technique and Proprioceptive Neurological Facilitation on Surface EMGs of Hypertonic Upper Trapezius Musculature|Completed||Phase 1/Phase 2|30|Anticipated|Logan College of Chiropractic||3|||f||||f||||||||||2018-06-01 01:51:39.350398|2018-06-01 01:51:39.350398
NCT00731978|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2009-10-28|2008-08-08|2008-08-11|Estimate|||||||2009-10-28|2009-10-29|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|NIRF||NIRF Trial: Near-Infrared Spectroscopy for Intraoperative Restriction of Fluids Trial|Near-Infrared Spectroscopy for Intraoperative Restriction of Fluids Trial A Prospective Randomized Study of Near-infrared Spectroscopy Directed Fluid Therapy vs Standard Fluid Therapy in Patients Undergoing Open Elective Colorectal Surgery|Completed||N/A|27|Actual|Hutchinson Technology Inc||2|||f||||t||||||||||2018-06-01 01:51:39.446373|2018-06-01 01:51:39.446373
NCT00731965|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2014-07-29|2008-08-08|2008-08-11|Estimate|||||||2014-07-29|2014-07-30|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|VAART||Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis|Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine|Completed||Phase 4|140|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 01:51:39.520434|2018-06-01 01:51:39.520434
NCT00731952|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2017-05-01|2008-08-08|2008-08-11|Estimate|||||||2017-05-01|2017-05-04|Actual|June 2006||2006-06-30|May 2017|2017-05-31|March 2014|Actual|2014-03-31|December 2012|Actual|2012-12-31||Interventional|||Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer|Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer|Completed||Phase 1|21|Actual|University of Virginia||1|||f||||f||||||||||2018-06-01 01:51:39.677063|2018-06-01 01:51:39.677063
NCT00731939|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2013-09-27||2014-03-07|2008-08-08|2008-08-11|Estimate|2014-03-07|2014-04-14|Estimate||||2014-03-07|2014-04-14|Estimate|November 2007||2007-11-30|March 2014|2014-03-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Titan® One Touch Release Inflatable Penile Prosthesis|Titan® One Touch Release Inflatable Penile Prosthesis|Completed||N/A|124|Actual|Coloplast A/S||1|||f||||f||||||||||2018-06-01 01:51:39.838592|2018-06-01 01:51:39.838592
NCT00731926|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-08-10|2008-08-07|2008-08-11|Estimate|||||||2008-08-10|2008-08-12|Estimate|September 2007||2007-09-30|August 2008|2008-08-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Effect of Antioxidant on Endurance Performance in Healthy Men|Effect of Antioxidant on Endurance Performance in Healthy Men -Double Blind Randomized Placebo and Active Controlled Trial-|Completed||Phase 2/Phase 3|69|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-06-01 01:51:40.946071|2018-06-01 01:51:40.946071
NCT00731913|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2015-03-17|2008-08-08|2008-08-11|Estimate|||||||2015-03-17|2015-03-19|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||A Comparison of Monosyn and Monocryl Sutures in Surgical Wounds|A Randomized, Prospective Trial Evaluating Surgeon-Preference in Selection of Absorbable Suture Material|Completed|||48|Actual|Tufts Medical Center|||2||f||||t||||||||||2018-06-01 01:51:41.128371|2018-06-01 01:51:41.128371
NCT00731900|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-08|2008-08-08|2008-08-11|Estimate|||||||2008-08-08|2008-08-11|Estimate|April 2007||2007-04-30|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction||Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 01:51:41.268872|2018-06-01 01:51:41.268872
NCT00731887|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2014-01-07|2008-08-07|2008-08-11|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|LBO||Large Burn Outcome Study|Assessment of the Treatment of the Severely Burned With Anabolic Agents on Improved Wound Healing, Recovery and Rehabilitation: Large Burn Outcome Study|Withdrawn|||0|Actual|The University of Texas Medical Branch, Galveston||||Personnel involved in this protocol are no longer associated with this study|f||||f||||||Samples Without DNA|"~     Blood and urine collected for this study will be retained for possible re-analysis if needed~     for the duration of the study.~   "|||2018-06-01 01:51:41.400717|2018-06-01 01:51:41.400717
NCT00731874|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2015-12-21||2015-12-21|2008-08-08|2008-08-11|Estimate|2015-12-21|2016-02-01|Estimate||||2015-12-21|2016-02-01|Estimate|August 2008||2008-08-31|December 2015|2015-12-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|TIMELY||Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status|Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status by Biopsy and mRNA Profiles (TIMELY Study)|Terminated||Phase 4|34|Actual|Weill Medical College of Cornell University|The population reported is small because the study was stopped early due to the increase in late antibody mediated rejection (occurring after month 15) that was seen in Arm 2 (target tacrolimus trough 3 to 5 ng/mL).|2||A higher rate of late rejection was seen in the low tacrolimus arm.|f||||f||||||||||2018-06-01 01:51:41.504696|2018-06-01 01:51:41.504696
NCT00731861|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2014-09-10|2008-08-07|2008-08-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|May 2005||2005-05-31|September 2014|2014-09-30|August 2010|Actual|2010-08-31|September 2008|Actual|2008-09-30||Interventional|||Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors|Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors|Completed||Phase 1|28|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 01:51:41.97511|2018-06-01 01:51:41.97511
NCT00731848|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2012-03-15|2008-08-08|2008-08-11|Estimate|||||||2012-03-15|2012-03-16|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer|An Open-label Extension Study of the Effects of Pomegranate Extract on Rising Prostate-specific Antigen Levels in Men Following Primary Therapy for Prostate Cancer.|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Roll International Corporation||1|||f||||t||||||||||2018-06-01 01:51:42.084123|2018-06-01 01:51:42.084123
NCT00731835|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2016-03-10|2008-08-08|2008-08-11|Estimate|||||||2016-03-10|2016-03-11|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone|Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone? A Randomized Controlled Trial|Terminated||N/A|4|Actual|University of Pittsburgh||2||slow enrollment|f||||t||||||||||2018-06-01 01:51:42.187579|2018-06-01 01:51:42.187579
NCT00731822|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2013-06-12|2010-05-14|2016-10-26|2008-08-08|2008-08-11|Estimate|2013-06-12|2013-08-15|Estimate|2013-03-28|2013-04-04|Estimate|2016-10-26|2016-12-08|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)|Study HZC111348, a Repeat-dose Study of GW685698/GW642444 Inhalation Powder Versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|60|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:51:42.330859|2018-06-01 01:51:42.330859
NCT00731809|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-03|||2008-12-22|2008-08-07|2008-08-11|Estimate|||||||2008-12-22|2008-12-23|Estimate|April 2008||2008-04-30|February 2008|2008-02-29|October 2010|Anticipated|2010-10-31|April 2010|Anticipated|2010-04-30||Interventional|||Evaluation of PET CT in the Management of Patients With Crohn's Disease.|Evaluation of PET CT in the Management of Patients With Crohn's Disease.|Unknown status|Recruiting|Phase 4|50|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-06-01 01:51:42.684781|2018-06-01 01:51:42.684781
NCT00731796|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2011-03-05|2008-08-08|2008-08-11|Estimate|||||||2011-03-05|2011-03-08|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|FOM||Testing of a Functional Outcome Measure for Those With Visual Field Defects|Testing of a Functional Outcome Measure for Those With Visual Field Defects|Suspended|||190|Anticipated|NovaVision, Inc.|||4|Lack of funding|f||||f||||||||||2018-06-01 01:51:42.75528|2018-06-01 01:51:42.75528
NCT00731783|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2011-03-02||2012-04-23|2008-08-07|2008-08-11|Estimate|2011-03-02|2011-03-23|Estimate||||2012-04-23|2012-04-30|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|SuDS||Staphylococcus Aureus Decolonization Study|Household vs. Individual Approach to Decolonization of Community-acquired Methicillin-resistant Staphylococcus Aureus.|Completed||N/A|183|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 01:51:42.860589|2018-06-01 01:51:42.860589
NCT00731770|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-08|2008-08-08|2008-08-11|Estimate|||||||2008-08-08|2008-08-11|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Comparing Fluticasone-Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep|TITLE: Double-Blinded, Double-Dummy, Study Comparing Fluticasone-Salmeterol to Placebo in Patients With COPD and Associated Poor Sleep or Daytime Somnolence.|Unknown status|Not yet recruiting|Phase 4|15|Anticipated|Penn State University||2|||f||||f||||||||||2018-06-01 01:51:43.219622|2018-06-01 01:51:43.219622
NCT00731757|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2009-07-21|2008-08-06|2008-08-11|Estimate|||||||2009-07-21|2009-07-23|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis|A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis|Withdrawn||Phase 2|20|Anticipated|Wright State University||1|||||||t||||||||||2018-06-01 01:51:43.308723|2018-06-01 01:51:43.308723
NCT00731744|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-08|2008-08-08|2008-08-11|Estimate|||||||2008-08-08|2008-08-11|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|February 2007|Actual|2007-02-28||Interventional|||Generation of Dendritic Cell Precursors From Cord Blood Stem Cells|Generation of Dendritic Cell Precursors From Cord Blood Stem Cells|Unknown status|Recruiting|N/A|50|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:51:43.373993|2018-06-01 01:51:43.373993
NCT00731731|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|2015-04-28||2018-04-20|2008-08-08|2008-08-11|Estimate|2015-04-28|2015-05-13|Estimate||||2018-04-20|2018-04-24|Actual|July 10, 2009|Actual|2009-07-10|April 2018|2018-04-30||||February 2, 2014|Actual|2014-02-02||Interventional|||Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1/Phase 2|125|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 01:51:43.580395|2018-06-01 01:51:43.580395
NCT00731718|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-08-08|2008-08-08|2008-08-11|Estimate|||||||2008-08-08|2008-08-11|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Control of Head Lice Infestations in Children and Adults|Control of Head Lice in Children and Adults|Completed||N/A|543|Actual|Larada Sciences, Inc.|||||f||||t||||||||||2018-06-01 01:51:44.772252|2018-06-01 01:51:44.772252
NCT00731705|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2014-09-18|2008-08-07|2008-08-11|Estimate|||||||2014-09-18|2014-09-19|Estimate|January 2007||2007-01-31|September 2014|2014-09-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|||In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells|In-Vitro Studies in Depletion of Haplotype Mismatched Alloreactive T Cells|Withdrawn|||0|Actual|Indiana University|||1||f||||t||||||Samples Without DNA|"~     peripheral blood, apheresis samples~   "|||2018-06-01 01:51:44.835543|2018-06-01 01:51:44.835543
NCT00731692|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2015-12-16||2017-05-09|2008-08-07|2008-08-11|Estimate|2017-05-09|2017-06-14|Actual||||2017-05-09|2017-06-14|Actual|July 28, 2008|Actual|2008-07-28|May 2017|2017-05-31|June 22, 2015|Actual|2015-06-22|June 22, 2015|Actual|2015-06-22||Interventional|INFORMS||This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.|A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis|Terminated||Phase 3|970|Actual|Novartis||3||"The extension study was terminated early after the results of the core study showed the study~   did not meet primary endpoint; confirmed disability progression"|f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:51:45.035823|2018-06-01 01:51:45.035823
NCT00731679|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2014-06-30||2014-06-30|2008-08-08|2008-08-11|Estimate|2014-06-30|2014-07-28|Estimate||||2014-06-30|2014-07-28|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|TARGET 1|The analysis population was the intent-to-treat population, defined as subjects who received at least 1 dose of study drug.|Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)|A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome|Completed||Phase 3|623|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 01:51:47.832253|2018-06-01 01:51:47.832253
NCT00731666|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2013-09-27||2013-09-27|2008-08-08|2008-08-11|Estimate|2013-09-27|2013-11-28|Estimate||||2013-09-27|2013-11-28|Estimate|December 2007||2007-12-31|September 2013|2013-09-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)|Prospective, Non-randomized, Multi-center Clinical Trial to Assess the Effectiveness of the Coloplast Titan® IPP at Maintaining or Increasing Penile Length After Implantation|Completed||N/A|40|Actual|Coloplast A/S||1|||f||||f||||||||||2018-06-01 01:51:48.534111|2018-06-01 01:51:48.534111
NCT00731653|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2013-10-24||2013-10-24|2008-08-07|2008-08-11|Estimate|2013-10-24|2013-12-17|Estimate||||2013-10-24|2013-12-17|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)|An Open-Label Extension Study to Assess the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder|Completed||Phase 2|81|Actual|Massachusetts General Hospital|This was an open-label study. Conclusions regarding the efficacy of the combination study drug were not made.|1|||f||||f||||||||||2018-06-01 01:51:48.824524|2018-06-01 01:51:48.824524
NCT00731627|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2014-06-24|2008-08-07|2008-08-11|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2007||2007-01-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|STASH||Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial|Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial|Completed||Phase 3|803|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 01:51:49.461714|2018-06-01 01:51:49.461714
NCT00731614|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2015-03-03||2015-06-01|2008-08-08|2008-08-11|Estimate|2015-06-01|2015-06-18|Estimate||||2015-06-01|2015-06-18|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|December 2012|Actual|2012-12-31|September 2011|Actual|2011-09-30||Interventional||Participants are adults with a single limb amputation who report current phantom limb pain.|Cognitive Behavior Therapy (CBT) and Mirror Training for Phantom Limb Pain|Psychosocial and Visual Feedback Intervention for Phantom Limb Pain|Completed||N/A|59|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:51:49.564171|2018-06-01 01:51:49.564171
NCT00731601|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2009-04-06|2008-08-08|2008-08-11|Estimate|||||||2009-04-06|2009-04-07|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|PPI||Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding|Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial|Completed||Phase 4|120|Actual|Lotung Poh-Ai Hospital||2|||f||||t||||||||||2018-06-01 01:51:49.939204|2018-06-01 01:51:49.939204
NCT00731588|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2014-12-23|2008-08-08|2008-08-11|Estimate|||||||2014-12-23|2014-12-25|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Red Blood Cell (RBC) Survival Following Transfusion in Infants|Red Blood Cell Survival Following Transfusion in Infants|Completed||Phase 2|140|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 01:51:50.011611|2018-06-01 01:51:50.011611
NCT00731575|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2011-08-11|2008-08-08|2008-08-11|Estimate|||||||2011-08-11|2011-08-12|Estimate|June 2007||2007-06-30|August 2011|2011-08-31||||May 2016|Anticipated|2016-05-31||Interventional|VINKU2||Viral Inception of Asthma: Prospective Study From Infancy to School-age|Viral Inception of Asthma: Prospective Study From Infancy to School-age.|Unknown status|Active, not recruiting|N/A|200|Anticipated|University of Turku|||||f||||t||||||||||2018-06-01 01:51:50.139224|2018-06-01 01:51:50.139224
NCT00731562|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2010-01-07|2008-08-07|2008-08-11|Estimate|||||||2010-01-07|2010-01-11|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||An Investigation Of The Effects Of Food On The Absorption Of A Varenicline Controlled Release Formulation|Phase 1, Open-Label, Randomized, Single-Dose, Two-Way Crossover Study To Evaluate The Effect Of Food On The Oral Bioavailability Of A Varenicline Controlled Release Formulation In Healthy Adult Smokers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:51:50.221461|2018-06-01 01:51:50.221461
NCT00731549|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2014-11-04||2014-11-14|2008-08-07|2008-08-11|Estimate|2014-11-04|2014-11-11|Estimate||||2014-11-14|2014-11-26|Estimate|December 2008||2008-12-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ASPIRE||Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia|Completed||Phase 3|1081|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-06-01 01:51:50.415197|2018-06-01 01:51:50.415197
NCT00731536|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2013-10-14|2008-08-07|2008-08-11|Estimate|||||||2013-10-14|2013-10-16|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands|A Retrospective Review of Reports of Hepatosplenic T-cell Lymphoma in the Dutch National Database of Pathology (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief [PALGA]), a Database of Pathology Results for The Netherlands|Completed|||15|Actual|Centocor Ortho Biotech Services, L.L.C.|||1||f||||f||||||||||2018-06-01 01:51:51.164298|2018-06-01 01:51:51.164298
NCT00731523|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2011-02-03|2008-08-08|2008-08-11|Estimate|||||||2011-02-03|2011-02-04|Estimate|July 2008||2008-07-31|February 2011|2011-02-28||||August 2008|Actual|2008-08-31||Interventional|||Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.|An Open-label, Single-dose, Parallel-group Study to Compare the Pharmacokinetics of FTY720 and Metabolites in Subjects With Severe Renal Impairment With That in Matched Healthy Control Subjects|Completed||Phase 1|18|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:51:51.272485|2018-06-01 01:51:51.272485
NCT00731510|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2017-03-30|2008-08-07|2008-08-11|Estimate|||||||2017-03-30|2017-03-31|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||MEDEX Hidden Valley 2008|MEDEX Hidden Valley 2008|Completed||N/A|44|Actual|Medical Expeditions Ltd||2|||f||||f||||||||||2018-06-01 01:51:51.368555|2018-06-01 01:51:51.368555
NCT00731497|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2017-12-15|2008-08-07|2008-08-11|Estimate|||||||2017-12-15|2017-12-19|Actual|September 2004||2004-09-30|December 2017|2017-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|SODIS_Bolivia||Solar Water Disinfection Intervention Trial in Bolivia|Solar Water Disinfections: Randomized Intervention Trial|Completed||Phase 3|1163|Actual|University of California, Berkeley||2|||f||||f||||||||||2018-06-01 01:51:51.452284|2018-06-01 01:51:51.452284
NCT00731484|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2011-04-06||2016-03-14|2008-08-08|2008-08-11|Estimate|2011-04-06|2011-05-03|Estimate||||2016-03-14|2016-04-12|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Validation of TearLab Osmometer - Human Factor Usability Report|Validation of TearLab Osmometer - Human Factor Usability Report|Completed|||233|Actual|TearLab Corporation|As recruitment came from the general clinical population, only 19 subjects were classified as having Sjögren's Syndrome, and few of the subjects had severe dry eye. Therefore, the upper range is lower than we have observed in the following studies.||1||f||||f||||||||Yes|The data was used in the FDA 510(K) submission.|2018-06-01 01:51:51.555877|2018-06-01 01:51:51.555877
NCT00731471|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2011-03-25|2008-08-08|2008-08-11|Estimate|||||||2011-03-25|2011-03-28|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV|Completed||Phase 1|24|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 01:51:51.841206|2018-06-01 01:51:51.841206
NCT00731458|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2013-09-04|2008-08-08|2008-08-11|Estimate|||||||2013-09-04|2013-09-05|Estimate|May 2007||2007-05-31|September 2013|2013-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Prospective Comparison of Cirrus Versus Stratus Ocular Coherence Tomography for Different Retinal Pathology.|Prospective Comparison of Cirrus and Stratus Optical Coherence Tomography for Quantifying Retinal Thickness|Completed||N/A|60|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 01:51:51.910539|2018-06-01 01:51:51.910539
NCT00731445|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2012-06-29|2008-08-08|2008-08-11|Estimate|||||||2012-06-29|2012-07-03|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)|Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral Z-208 in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|43|Anticipated|Zeria Pharmaceutical|||||f||||t||||||||||2018-06-01 01:51:51.972124|2018-06-01 01:51:51.972124
NCT00731432|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2011-07-19|2008-08-08|2008-08-11|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2008||2008-08-31|August 2008|2008-08-31||||||||Interventional|||Herbal Periodontal Patch (THPP) for Gingival Inflammation in Diabetics|The Effect Of A Transmucosal Herbal Periodontal Patch (THPP) on Gingival Inflammation in Diabetic Patients|Suspended||Phase 2|60|Anticipated|Izun Pharma Ltd||2||Failure to recruit|f||||f||||||||||2018-06-01 01:51:52.033382|2018-06-01 01:51:52.033382
NCT00731419|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-05|2008-08-05|2008-08-11|Estimate|||||||2008-08-05|2008-08-11|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|August 2009|Anticipated|2009-08-31|May 2009|Anticipated|2009-05-31||Interventional|||Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice|Distal Malignant Biliary Obstruction: A Prospective Randomised Trial Comparing Metal and Plastic Stents in Palliation of Symptomatic Jaundice|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Cape Town||2|||f||||f||||||||||2018-06-01 01:51:52.106139|2018-06-01 01:51:52.106139
NCT00731393|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2016-09-14|2008-08-07|2008-08-11|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2003||2003-10-31|September 2016|2016-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04|To Determine the Immunogenicity and Reactogenicity of a Thiomersal Free Trivalent Influenza Split Vaccine 2003/2004 or of GSK Biologicals' Standard Formulation Influsplit SSW®/Fluarix™ 2003/2004 in Children Aged From 6 Months Until 6 Years|Completed||Phase 3|157|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:51:52.201006|2018-06-01 01:51:52.201006
NCT00731380|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2016-06-21|2008-08-08|2008-08-11|Estimate|||||||2016-06-21|2016-06-22|Estimate|July 2008||2008-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer|Phase I Trial of ABI-007 (Abraxane) Plus Cisplatin Plus 5-Fluorouracil (APF) as Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With Locally Advanced Squamous Cell Cancers of the Head and Neck (HNSCC)|Completed||Phase 1|12|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 01:51:52.384763|2018-06-01 01:51:52.384763
NCT00731367|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2009-02-02|2008-08-08|2008-08-11|Estimate|||||||2009-02-02|2009-02-03|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Comparative Evaluation of Two AQUACEL Ag Protocols of Care for the Management of Donor Sites|A Phase IIIb, Randomized Comparative Evaluation of Two AQUACEL Ag Protocols of Care for the Management of Donor Sites.|Completed||Phase 3|73|Actual|ConvaTec Inc.||2|||f||||f||||||||||2018-06-01 01:51:52.483374|2018-06-01 01:51:52.483374
NCT00731354|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2011-06-06|2008-08-08|2008-08-11|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|April 2009|Actual|2009-04-30|September 2008|Actual|2008-09-30||Interventional|Contra-Lateral||VASER-Assisted Lipoplasty Compared With Suction-Assisted Lipoplasty|A Multi-Center, Prospective, Randomized, Single-Blind, Controlled Clinical Trial Comparing VASER-Assisted Lipoplasty and Suction-Assisted Lipoplasty.|Completed||Phase 4|21|Anticipated|Sound Surgical Technologies, LLC.||2|||f||||f||||||||||2018-06-01 01:51:52.583394|2018-06-01 01:51:52.583394
NCT00731341|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2010-08-12||2011-10-25|2008-08-07|2008-08-11|Estimate|2011-06-06|2011-07-01|Estimate||||2011-10-25|2011-11-02|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata|Feasibility Study of Hysteroscopic Cryoablation Treatment of Symptomatic Uterine Fibroids in Women Who do Not Desire Further Pregnancies|Completed||N/A|3|Actual|Galil Medical|Due to the nature of this feasibility study, a very small number of participants was evaluated.|1|||f||||f||||||||||2018-06-01 01:51:52.714775|2018-06-01 01:51:52.714775
NCT00731328|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-08|||2015-12-29|2008-08-08|2008-08-11|Estimate|||||||2015-12-29|2015-12-31|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome|HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY|Completed||Phase 2|15|Actual|Asan Medical Center|||||f||||f||||||||||2018-06-01 01:51:52.954638|2018-06-01 01:51:52.954638
NCT00731315|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2015-03-05|2008-08-08|2008-08-11|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|UTI-Kiosk||Computer-Assisted Treatment of Urinary Tract Infection in Emergency Departments and Community Health Centers|Computer-Assisted Treatment in the Management of Adult Female Patients With Symptoms of Urinary Tract Infection in Emergency Departments and Community Health Centers: A Randomized Trial|Terminated||N/A|200|Actual|University of California, San Francisco||4||"Funding Period ended, did not reach full sample size due to limited numbers of eligible~   patients"|f||||t||||||||||2018-06-01 01:51:53.084046|2018-06-01 01:51:53.084046
NCT00731302|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-08-03|2008-08-07|2008-08-08|Estimate|||||||2017-08-03|2017-08-07|Actual|April 2005||2005-04-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Aspirin Resistance in Systemic Lupus Erythematosus (SLE)|Vascular Damage in Systemic Lupus Erythematosus (SLE)|Completed||Phase 1|70|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 01:51:53.205148|2018-06-01 01:51:53.205148
NCT00731289|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|July 2003||2003-07-31|August 2008|2008-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Gait Patterns After Intraarticular Treatment of Patients With Osteoarthritis of the Knee|Efficacy and Safety of Intra-Articular Injections of Durolane® in the Treatment of Osteoarthritis in the Knee|Completed||Phase 4|60|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-06-01 01:51:53.304535|2018-06-01 01:51:53.304535
NCT00731276|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2017-03-29|2008-08-07|2008-08-08|Estimate|||||||2017-03-29|2017-03-31|Actual|April 3, 2008|Actual|2008-04-03|March 2017|2017-03-31|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|||Irinotecan in Treating Asian Patients With Solid Tumors|Phase I Study to Investigate Genotype-based Dose Individualization of Irinotecan in Asian Cancer Patients|Completed||Phase 1|18|Actual|National Cancer Centre, Singapore||1|||f||||f||||||||No||2018-06-01 01:51:53.399057|2018-06-01 01:51:53.399057
NCT00731263|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2012-07-10|2008-08-07|2008-08-08|Estimate|||||||2012-07-10|2012-07-11|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of Tor Kinase Inhibitor in Advanced Tumors|A Phase I/II, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients With Advanced Solid Tumours.|Completed||Phase 1|64|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:51:53.482369|2018-06-01 01:51:53.482369
NCT00731250|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-07-11|2008-08-07|2008-08-08|Estimate|||||||2017-07-11|2017-07-13|Actual|July 22, 2008|Actual|2008-07-22|July 2017|2017-07-31|March 31, 2009|Actual|2009-03-31|March 1, 2009|Actual|2009-03-01||Interventional|||A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model|A Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Oral, Single Dose SB-705498 in a Validated Intranasal Capsaicin Challenge Model in Healthy Volunteers|Completed||Phase 1|45|Actual|GlaxoSmithKline||9|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:51:53.562364|2018-06-01 01:51:53.562364
NCT00731237|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-10-15|2008-08-07|2008-08-08|Estimate|||||||2009-10-15|2009-10-16|Estimate|October 2008||2008-10-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Observational|EXCEED||XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery|Completed|||2517|Actual|Abbott Vascular|||1||f||||f||||||||||2018-06-01 01:51:53.688119|2018-06-01 01:51:53.688119
NCT00731224|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-03-24|2008-08-05|2008-08-08|Estimate|||||||2017-03-24|2017-03-28|Actual|July 2008||2008-07-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CARE||Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.|A 24-week, Multi-center, Open-label Evaluation of Compliance and Tolerability of the Once-daily 10 cm² Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.|Completed||Phase 4|380|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:51:53.808313|2018-06-01 01:51:53.808313
NCT00731211|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2014-12-16||2015-05-18|2008-08-07|2008-08-08|Estimate|2015-05-18|2015-05-20|Estimate||||2015-05-18|2015-05-20|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|September 2012|Actual|2012-09-30|May 2011|Actual|2011-05-31||Interventional||All eligible patients|Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma|A Phase II Trial of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Sunitinib or Bevacizumab|Completed||Phase 2|57|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 01:51:54.222978|2018-06-01 01:51:54.222978
NCT00731198|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2009-09-14||2010-08-31|2008-08-07|2008-08-08|Estimate|2009-11-19|2009-12-23|Estimate||||2010-08-31|2010-09-08|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)|Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial|Completed||Phase 3|650|Actual|Changhai Hospital||2|||f||||t||||||||||2018-06-01 01:51:54.61371|2018-06-01 01:51:54.61371
NCT00731185|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-03-21|2008-08-07|2008-08-08|Estimate|||||||2017-03-21|2017-03-23|Actual|September 1, 2003|Actual|2003-09-01|March 2017|2017-03-31|September 1, 2005|Actual|2005-09-01|September 1, 2005|Actual|2005-09-01||Interventional|||Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)|A Multi-center, Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety of Mometasone Furoate Nasal Spray (MFNS) in the Post Surgical Treatment of Nasal Polyposis|Completed||Phase 3|162|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:51:54.814852|2018-06-01 01:51:54.814852
NCT00731172|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2009-03-01|2008-08-07|2008-08-08|Estimate|||||||2009-03-01|2009-03-03|Estimate|September 2008||2008-09-30|March 2009|2009-03-31|July 2011|Anticipated|2011-07-31|July 2010|Anticipated|2010-07-31||Interventional|Cop1CD||A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease|A Pilot Single Center,Randomized,Double Blind Placebo Controlled Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Inducing Remission in Patients With Moderately Active Crohn's Disease.|Unknown status|Recruiting|Phase 2|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 01:51:54.877452|2018-06-01 01:51:54.877452
NCT00731159|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|July 2009|Anticipated|2009-07-31|January 2009|Anticipated|2009-01-31||Observational|||Sperm Capacitation Assay as a Tool to Predict Sperm Potential to Fertilize in IVF Treatment|Sperm Capacitation Assay as a Tool to Predict Sperm Potential to Fertilize in IVF Treatment|Unknown status|Recruiting||50|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-06-01 01:51:54.975562|2018-06-01 01:51:54.975562
NCT00731146|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-05|2008-08-05|2008-08-08|Estimate|||||||2008-08-05|2008-08-08|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|July 2009|Anticipated|2009-07-31|February 2009|Anticipated|2009-02-28||Interventional|||Effects of Technique on the Local Anesthetic Dose Required for Interscalene Brachial Plexus Block|Effects of Ultrasound Guidance on the Minimum Effective Anesthetic Volume Required for Interscalene Brachial Plexus Block Versus Nerve Stimulator Guidance|Unknown status|Recruiting|N/A|80|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:51:55.054972|2018-06-01 01:51:55.054972
NCT00731133|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2011-11-02||2012-01-20|2008-08-06|2008-08-08|Estimate|2012-01-20|2012-02-27|Estimate||||2012-01-20|2012-02-27|Estimate|August 2008||2008-08-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Open-Label Disulfiram for Methamphetamine Dependence|Open-Label Pilot Study of Disulfiram for Methamphetamine Dependence|Completed||Phase 1/Phase 2|15|Actual|University of Arkansas|Large dropout so few participants had data throughout the trial. No control group so cannot determine whether side effects were related to disulfiram or an artifact of participation.|1|||f||||t||||||||||2018-06-01 01:51:55.14267|2018-06-01 01:51:55.14267
NCT00731120|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2013-10-25||2013-10-25|2008-08-06|2008-08-08|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder|Completed||Phase 3|457|Actual|Takeda||3|||f||||f||||||||||2018-06-01 01:51:56.441778|2018-06-01 01:51:56.441778
NCT00730080|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2014-12-08|2008-08-01|2008-08-08|Estimate|||||||2014-12-08|2014-12-10|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Observational|||Sapropterin in Individuals With Phenylketonuria|Effects of Sapropterin on Brain and Cognition in Individuals With Phenylketonuria|Unknown status|Active, not recruiting||44|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-06-01 01:52:21.378863|2018-06-01 01:52:21.378863
NCT00731107|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||XCEL Bladeless Trocar Versus Veress Needle: A Randomised Controlled Trial Comparing These Two Entry Techniques in Gynaecological Laparoscopic Surgery.|XCEL Bladeless Trocar Versus Veress Needle: A Randomised Controlled Trial Comparing These Two Entry Techniques in Gynaecological Laparoscopic Surgery.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Southern Health||2|||f||||t||||||||||2018-06-01 01:51:57.587545|2018-06-01 01:51:57.587545
NCT00731094|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2014-09-18||2015-04-06|2008-08-07|2008-08-08|Estimate|2014-10-23|2014-10-30|Estimate||||2015-04-06|2015-04-27|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||The VA-STRIDE Study|Expert System-Based Feedback in Sedentary Overweight Veterans|Completed||N/A|232|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:51:57.728426|2018-06-01 01:51:57.728426
NCT00731081|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2014-02-04|2008-08-07|2008-08-08|Estimate|||||||2014-02-04|2014-02-06|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®|Observational Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme|Completed|||8|Actual|Sanofi|||||f||||f||||||Samples Without DNA|"~     urine and plasma oligosaccharides~   "|||2018-06-01 01:51:59.094539|2018-06-01 01:51:59.094539
NCT00731068|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2013-10-23|2008-08-07|2008-08-08|Estimate|||||||2013-10-23|2013-10-24|Estimate|February 2007||2007-02-28|October 2013|2013-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Platelet Rich Plasma (PRP) as a Treatment for ACHILLES Tendon Tears|PRP as a Treatment for ACHILLES Tendon Tears - Randomized-Double-Blind-Placebo Control Trail|Completed||Phase 2/Phase 3|50|Actual|Meir Medical Center||2|||f||||t||||||||||2018-06-01 01:51:59.315551|2018-06-01 01:51:59.315551
NCT00731055|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2014-02-19||2016-05-16|2008-08-06|2008-08-08|Estimate|2015-04-15|2015-05-01|Estimate||||2016-05-16|2016-06-17|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effects of Varenicline on Cigarette Self Administration|Effects of Varenicline on Cigarette Self Administration|Completed||Phase 2|16|Actual|New York State Psychiatric Institute||4|||f||||t||||||||||2018-06-01 01:51:59.402877|2018-06-01 01:51:59.402877
NCT00731042|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2009-01-23||2012-01-24|2008-08-07|2008-08-08|Estimate|2009-06-16|2009-06-17|Estimate||||2012-01-24|2012-01-26|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects|A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects|Completed||Phase 4|33|Actual|3M||2|||f||||f||||||||||2018-06-01 01:51:59.587034|2018-06-01 01:51:59.587034
NCT00731029|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|September 2002||2002-09-30|August 2008|2008-08-31||||April 2003|Actual|2003-04-30||Interventional|||Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03|Comparative Vaccination Study of the Reactogenicity and Immunogenicity of a Thiomersal-Free Formulation of Influsplit SSW® 2002/2003 Versus the Standard Formulation of Influsplit SSW® 2002/2003 in Individuals Over 18 Years|Completed||Phase 3|239|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 01:51:59.904651|2018-06-01 01:51:59.904651
NCT00731016|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2013-07-04|2008-08-05|2008-08-08|Estimate|||||||2013-07-04|2013-07-08|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid|Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid|Completed||Phase 2|15|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-06-01 01:51:59.991175|2018-06-01 01:51:59.991175
NCT00731003|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2014-11-11|2008-08-07|2008-08-08|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2009||2009-04-30|November 2014|2014-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients|The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and IBS Patients|Completed||N/A|60|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-06-01 01:52:00.098008|2018-06-01 01:52:00.098008
NCT00730990|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-12-02|2008-08-07|2008-08-08|Estimate|||||||2008-12-02|2008-12-03|Estimate|May 2008||2008-05-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Phase I, Healthy Volunteer Positron Emission Tomography Study|A8801007 A Phase I, Healthy Volunteer Qualification Of Ligand [C 11] PF 04621053 And Randomized Determination Of H3 Receptor Occupancy Of PF 03654746, Using PET|Completed||Phase 1|10|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:52:00.207477|2018-06-01 01:52:00.207477
NCT00730977|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-09-17|2008-08-07|2008-08-08|Estimate|||||||2009-09-17|2009-09-18|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device|A Pilot Study to Investigate the Tolerability of Inhaled Dry Powder Mannitol (IDPM) Administered Via a Novel Dry Powder Inhaler Device in Healthy Individuals and Subjects With Bronchiectasis.|Completed||Phase 1/Phase 2|15|Actual|Pharmaxis||1|||f||||f||||||||||2018-06-01 01:52:00.709202|2018-06-01 01:52:00.709202
NCT00730964|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2012-04-05||2012-05-09|2008-08-07|2008-08-08|Estimate|2012-05-09|2012-06-12|Estimate||||2012-05-09|2012-06-12|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|OSSAR||A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.|A Post-marketing Surveillance Study of the Occurrence of Serious Adverse Reactions Among Patients Who Receive Optison in Routine Medical Practice|Completed||Phase 4|1039|Actual|GE Healthcare||1|||f||||t||||||||||2018-06-01 01:52:00.820527|2018-06-01 01:52:00.820527
NCT00730951|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2015-07-30|2008-08-06|2008-08-08|Estimate|||||||2015-07-30|2015-07-31|Estimate|June 2007||2007-06-30|July 2015|2015-07-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation|The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation|Completed||Phase 2|18|Actual|St. Michael's Hospital, Toronto||5|||f||||f||||||||||2018-06-01 01:52:01.030067|2018-06-01 01:52:01.030067
NCT00730938|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|February 2008||2008-02-29|August 2008|2008-08-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery|The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery|Completed||N/A|45|Actual|Presbyterian Church East Africa Kikuyu Hospital||2|||f||||f||||||||||2018-06-01 01:52:01.123416|2018-06-01 01:52:01.123416
NCT00730925|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2013-08-09||2014-02-24|2008-08-07|2008-08-08|Estimate|2013-08-09|2013-10-23|Estimate||||2014-02-24|2014-03-26|Estimate|June 2008||2008-06-30|February 2014|2014-02-28||||January 2012|Actual|2012-01-31||Interventional|||Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients|A Phase II Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC|Completed||Phase 2|41|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:52:01.260342|2018-06-01 01:52:01.260342
NCT00730912|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2010-06-03||2017-03-16|2008-08-07|2008-08-08|Estimate|2010-06-03|2010-07-05|Estimate||||2017-03-16|2017-04-13|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)|Protocol for Post-approval Commitment Study of Loratadine for PPK Analysis in Japanese Pediatric and Adults Patients|Completed||Phase 4|261|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:52:01.654994|2018-06-01 01:52:01.654994
NCT00730899|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2008-08-04|2008-08-04|2008-08-08|Estimate|||||||2008-08-04|2008-08-08|Estimate|May 2008||2008-05-31|August 2008|2008-08-31|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Observational|||Association Study of Gene Polymorphisms With Cardiac Performance|Observational Association Study of G Protein Polymorphisms With Cardiac Performance in Coronary Artery Disease Patients Undergoing Coronary Artery Bypass Grafting|Unknown status|Recruiting||500|Anticipated|University Hospital, Essen|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:52:02.016091|2018-06-01 01:52:02.016091
NCT00730886|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2018-05-29|2008-08-05|2008-08-08|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2008||2008-07-31|May 2018|2018-05-31|October 6, 2011|Actual|2011-10-06|July 2011|Actual|2011-07-31||Interventional|||ExAblate Treatment of Uterine Fibroids for Fertility Enhancement|A Randomized Study to Evaluate the Effectiveness and Safety of ExAblate Surgery Compared With Myomectomy for the Enhancement of Fertility Following Treatment of Uterine Fibroids in Women Seeking Pregnancy|Terminated||N/A|2|Actual|InSightec||2|||f||||f||||||||||2018-06-01 01:52:02.11202|2018-06-01 01:52:02.11202
NCT00730873|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate||||August 2008|2008-08-31||||||||Interventional|||Fatty Liver and Obstructive Sleep Apnea|Fatty Liver and Obstructive Sleep Apnea|Completed||N/A|||Assaf-Harofeh Medical Center||1|||f||||||||||||||2018-06-01 01:52:02.209198|2018-06-01 01:52:02.209198
NCT00730860|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2017-03-27|2008-08-06|2008-08-08|Estimate|||||||2017-03-27|2017-03-28|Actual|December 2009|Actual|2009-12-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE|Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation Associated With Postoperative Transhepatic Arterial Chemoembolization——a Prospective Randomized Clinical Trial|Recruiting||N/A|140|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-06-01 01:52:02.263109|2018-06-01 01:52:02.263109
NCT00730847|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2012-11-21||2018-05-24|2008-08-06|2008-08-08|Estimate|2012-11-21|2012-12-21|Estimate||||2018-05-24|2018-05-30|Actual|September 17, 2008|Actual|2008-09-17|February 2018|2018-02-28|January 16, 2012|Actual|2012-01-16|January 16, 2012|Actual|2012-01-16||Interventional|||A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.|A Post-marketing Surveillance (PMS) Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in 3,000 Healthy Female Filipino Subjects When Administered According to the Prescribing Information From the Age of 10 Years Onwards.|Terminated||Phase 4|743|Actual|GlaxoSmithKline||1||GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study.|f||||||||||||||2018-06-01 01:52:02.385141|2018-06-01 01:52:02.385141
NCT00730834|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-08-24|2008-08-07|2008-08-08|Estimate|||||||2009-08-24|2009-08-25|Estimate|June 2007||2007-06-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|CALM||Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis|Phase 4 Study of Use of a Customized Acoustic Stimulus to Reduce the Disturbing Symptoms of Tinnitus and Hyperacusis|Unknown status|Active, not recruiting|Phase 4|53|Actual|Neuromonics, Inc.|||||f||||f||||||||||2018-06-01 01:52:02.921791|2018-06-01 01:52:02.921791
NCT00730821|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-08-20|2008-08-05|2008-08-08|Estimate|||||||2009-08-20|2009-08-21|Estimate|January 2007||2007-01-31|August 2009|2009-08-31||||August 2009|Actual|2009-08-31||Interventional|||Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors|A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors|Completed||Phase 1|28|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 01:52:03.042587|2018-06-01 01:52:03.042587
NCT00730808|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2010-05-18|2008-08-07|2008-08-08|Estimate|||||||2010-05-18|2010-05-19|Estimate|December 2008||2008-12-31|May 2010|2010-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effectiveness and Tolerability of an Oral Nutritional Supplement (PreOP Booster) Given Before Surgery|Efficacy and Tolerability of a Preoperative Oral Nutritional Supplement (PreOP Booster) vs. Placebo in Surgical Patients (Pilot Study)|Completed||N/A|20|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 01:52:03.120237|2018-06-01 01:52:03.120237
NCT00730795|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|January 2004||2004-01-31|August 2008|2008-08-31||||December 2004|Actual|2004-12-31||Interventional|||Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults|A Phase I Open Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Recombinant Mycobacterium Tuberculosis Vaccine, Mtb72F With AS02A Adjuvant, When Administered Intramuscularly to Healthy PPD-Negative Adults|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:52:03.203101|2018-06-01 01:52:03.203101
NCT00730782|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|November 2005||2005-11-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|September 2007|Actual|2007-09-30||Interventional|||Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers|Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial|Completed||Phase 1|56|Actual|European Malaria Vaccine Initiative||3|||f||||f||||||||||2018-06-01 01:52:03.388532|2018-06-01 01:52:03.388532
NCT00730288|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2018-02-23|2008-08-06|2008-08-08|Estimate|||||||2018-02-23|2018-02-27|Actual|August 2006||2006-08-31|February 2018|2018-02-28|January 2008|Actual|2008-01-31|August 2007|Actual|2007-08-31||Interventional|||Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects|Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine|Completed||Phase 2|35|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:52:18.296724|2018-06-01 01:52:18.296724
NCT00730769|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2011-09-19|2008-08-07|2008-08-08|Estimate|||||||2011-09-19|2011-09-21|Estimate|March 2004||2004-03-31|September 2011|2011-09-30|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Interventional|||Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients|Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients.|Completed||Phase 4|21|Actual|Hospital Universitari de Bellvitge||1|||f||||t||||||||||2018-06-01 01:52:03.480793|2018-06-01 01:52:03.480793
NCT00730756|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2009-10-13||2017-02-22|2008-08-07|2008-08-08|Estimate|2009-10-13|2009-11-25|Estimate||||2017-02-22|2017-04-06|Actual|March 2008||2008-03-31|January 2017|2017-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis|A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents With Irritant (Non-Allergic) Rhinitis|Completed||Phase 2|102|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:52:03.625921|2018-06-01 01:52:03.625921
NCT00730743|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2015-02-02|2008-08-06|2008-08-08|Estimate|||||||2015-02-02|2015-02-04|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Study on Clinical Outcome of Vascular Inflow Occlusion in Open Liver Resection|Open Liver Resection With or Without Vascular Inflow Occlusion: a Randomized Control Trial|Completed||N/A|126|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 01:52:04.254599|2018-06-01 01:52:04.254599
NCT00730730|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2010-11-11||2016-03-07|2008-08-07|2008-08-08|Estimate|2011-03-10|2011-03-11|Estimate||||2016-03-07|2016-04-04|Estimate|November 2007||2007-11-30|February 2016|2016-02-29|August 2012|Actual|2012-08-31|February 2009|Actual|2009-02-28||Interventional|||The Complete® Self-Expanding Stent and Stent Delivery System Registry|The Medtronic Complete® Self-Expanding Stent and Stent Delivery System Registry: a Non-randomized Prospective, Multicenter, Consecutive Registry|Completed||N/A|50|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 01:52:04.345262|2018-06-01 01:52:04.345262
NCT00730717|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2009-07-21|2008-08-05|2008-08-08|Estimate|||||||2009-07-21|2009-07-23|Estimate|May 2009||2009-05-31|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum|Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum|Withdrawn||Phase 2|20|Anticipated|Wright State University||2|||f||||t||||||||||2018-06-01 01:52:04.620075|2018-06-01 01:52:04.620075
NCT00730704|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2012-11-02|2008-08-07|2008-08-08|Estimate|||||||2012-11-02|2012-11-05|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|HPV Acceptance||Acceptance of Human Papillomavirus Vaccination in Postpartum Women|Acceptance of Human Papillomavirus Vaccination in Postpartum Women|Completed|||150|Actual|Columbia University|||||f||||f||||||||||2018-06-01 01:52:04.685048|2018-06-01 01:52:04.685048
NCT00730691|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2013-10-25||2013-10-25|2008-08-06|2008-08-08|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder|Completed||Phase 3|781|Actual|Takeda||5|||f||||f||||||||||2018-06-01 01:52:04.802184|2018-06-01 01:52:04.802184
NCT00730678|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2017-09-08|2008-08-07|2008-08-08|Estimate|||||||2017-09-08|2017-09-11|Actual|August 17, 1998|Actual|1998-08-17|September 2017|2017-09-30|March 2034|Anticipated|2034-03-31|December 2033|Anticipated|2033-12-31||Observational|||Pharmacogenetic Determinants Of Treatment Response In Children|Pharmacogenetic Determinants Of Treatment Response In Children|Recruiting|||8800|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     DNA or RNA for genetic testing will typically be obtained simultaneously with blood that is~     drawn for clinical reasons.~   "|||2018-06-01 01:52:07.796064|2018-06-01 01:52:07.796064
NCT00730665|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06||2011-06-07|2011-07-12|2008-08-07|2008-08-08|Estimate||||2011-07-12|2011-07-14|Estimate|2011-07-12|2011-07-14|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)|A Parallel-Group, Randomized, Double-Blind, Multi-Center Dose Response Study To Evaluate The Efficacy And Safety Of PF-00885706, A 5-HT4 Receptor Partial Agonist, As Add-On Therapy To Esomeprazole For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD) Who Have A Poor Response To Proton Pump Inhibitor (PPI) Treatment|Terminated||Phase 2|81|Actual|Pfizer||5||This study has been placed on clinical hold by the sponsor due to operational reasons.|f||||t||||||||||2018-06-01 01:52:07.913674|2018-06-01 01:52:07.913674
NCT00730652|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2010-04-21|2008-08-06|2008-08-08|Estimate|||||||2010-04-21|2010-04-22|Estimate|May 2009||2009-05-31|April 2010|2010-04-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|MDX1411-02||Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma|A Phase I, Open-Label, Multicenter, Dose-escalation, Multidose Study of MDX-1411 Administered Every 7 Days in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma|Withdrawn||Phase 1|34|Anticipated|Bristol-Myers Squibb||1||Sponsor Decision|f||||f||||||||||2018-06-01 01:52:08.088848|2018-06-01 01:52:08.088848
NCT00730639|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2016-02-22||2017-10-19|2008-08-07|2008-08-08|Estimate|2016-03-24|2016-04-15|Estimate||||2017-10-19|2017-11-21|Actual|January 22, 2009|Actual|2009-01-22|October 2017|2017-10-31|May 21, 2018|Anticipated|2018-05-21|February 4, 2013|Actual|2013-02-04||Interventional|MDX1106-03|All treated participants.|A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies|A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies|Active, not recruiting||Phase 1|395|Actual|Bristol-Myers Squibb||5|||f||||t|t|f||||||||2018-06-01 01:52:08.308707|2018-06-01 01:52:08.308707
NCT00730626|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2009-06-19|2008-08-06|2008-08-08|Estimate|||||||2009-06-19|2009-06-22|Estimate|August 2008||2008-08-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|PRO||Dose Response Study of a Fermented Yogurt on the Immune System and Gut Health|Dose Response Study of the Impact of a Yogurt Containing Bifidobacterium Lactis BB-12 and Lactobacillus Acidophilus LA-5 on the Immune System and Gut Health.|Completed||N/A|58|Actual|Laval University||3|||f||||f||||||||||2018-06-01 01:52:12.746183|2018-06-01 01:52:12.746183
NCT00730613|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2017-10-06|2008-08-07|2008-08-08|Estimate|||||||2017-10-06|2017-10-09|Actual|February 2002||2002-02-28|October 2017|2017-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma|Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones|Completed||Phase 1|3|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:52:12.830853|2018-06-01 01:52:12.830853
NCT00730600|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2008-08-06|2008-08-06|2008-08-08|Estimate|||||||2008-08-06|2008-08-08|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Effect of THAI Traditional Massage on Bone Markers|Acute Changes in Biochemical Markers of Bone Resorption and Formation After THAI Traditional Massage|Completed||N/A|30|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 01:52:12.924649|2018-06-01 01:52:12.924649
NCT00730587|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2016-01-06|2008-08-06|2008-08-08|Estimate|||||||2016-01-06|2016-01-07|Estimate||||January 2016|2016-01-31||||||||Observational|||Study of Body Composition Methodology in Young Children (InfantPod)|Development of a Body Composition Method for Infants and Children|Withdrawn|||0|Actual|Arkansas Children's Hospital Research Institute|||1|This study will not be conducted. A new study is replacing this one.|f||||f||||||Samples Without DNA|"~     Urine will be collected from all study participants.~   "|||2018-06-01 01:52:13.040731|2018-06-01 01:52:13.040731
NCT00730574|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2014-09-08|2008-08-07|2008-08-08|Estimate|||||||2014-09-08|2014-09-10|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|||Examining B12 Deficiency Associated With C677T Mutation on MTHFR Gene in Terms of Commonness and Endothelial Function|Examining the Commonness of the C677T Mutation in the MTHFR Gene in Subjects With B12 Deficiency and the Influence of the B12 Deficiency Combined With the C677T Mutation on the MTHFR Gene on Endothelial Function.|Terminated||N/A|100|Actual|Carmel Medical Center||2||completed patient rectuitment|f||||f||||||||||2018-06-01 01:52:13.095918|2018-06-01 01:52:13.095918
NCT00730561|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy|Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy in Patients With Diabetes Mellitus Type 2:A Randomized Controlled Trial.|Completed||N/A|20|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||f||||||||||2018-06-01 01:52:13.310148|2018-06-01 01:52:13.310148
NCT00730548|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2017-02-14|2008-08-04|2008-08-08|Estimate|||||||2017-02-14|2017-02-15|Actual|November 2007||2007-11-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|April 2011|Actual|2011-04-30||Interventional|ConnectOptiVol||Compare Remote Patient Management and Standard Care in CRT-D and ICD-patients to Assess the Effect on Heart Failure|Clinical Evaluation to Assess the Effect of the Combination of a Pre-Defined Management Pathway to Reduce Fluid Overload in Cardiac Decompensation With Carelink Remote Management, Connexus Remote Telemetry and the OptiVol Early Warning System on Health Care Utilization|Completed||N/A|180|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||No||2018-06-01 01:52:13.391484|2018-06-01 01:52:13.391484
NCT00730535|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2011-04-21|2008-08-07|2008-08-08|Estimate|||||||2011-04-21|2011-04-22|Estimate|August 2006||2006-08-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients|Exploring Predictors of Symptoms Relapse After Discontinuation of Successful Treatment With a Tolterodine Prolonged Release Capsules (4 mg, Once Daily) in Overactive Bladder Patients: A Prospective Randomized Multicenter Trial|Completed||Phase 4|173|Actual|Samsung Medical Center||3|||f||||t||||||||||2018-06-01 01:52:13.535431|2018-06-01 01:52:13.535431
NCT00730522|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2012-07-31|2008-08-05|2008-08-08|Estimate|||||||2012-07-31|2012-08-01|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence|Vigabatrin for Treatment of Methamphetamine Dependence: A Phase II Study|Terminated||Phase 2|57|Actual|Catalyst Pharmaceuticals, Inc.||2||To conserve remaining capital, Sponsor decided to terminate the study early.|f||||f||||||||||2018-06-01 01:52:13.624585|2018-06-01 01:52:13.624585
NCT00730509|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2008-08-04|2008-08-04|2008-08-08|Estimate|||||||2008-08-04|2008-08-08|Estimate|April 2004||2004-04-30|May 2008|2008-05-31|March 2006|Actual|2006-03-31|||||Interventional|||Effects of 5-Methyltetrahydrofolate and Vitamin B12 Supplemetation on Red Cell Membrane in Children With Cystic Fibrosis|Preliminary Evidences of Active Form of Folic Acid and Vitamin B12 Supplementation to Ameliorate Cell Membrane in Children With Cystic Fibrosis|Completed||N/A|31|Actual|Universita di Verona|||||f||||f||||||||||2018-06-01 01:52:13.742485|2018-06-01 01:52:13.742485
NCT00730496|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2010-11-04|2008-08-05|2008-08-08|Estimate|||||||2010-11-04|2010-11-05|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates|Injection of Day 2 Embryo Culture Supernatant Into the Uterine Cavity Didn't Improve Implantation and Pregnancy Rates of Day 3 Embryo Transfer: a Randomized Clinical Trial in Patients Who Underwent in Vitro Fertilization- Embryo Transfer.|Completed||Phase 1|90|Actual|Shen-Zhen City Maternity and Child Healthcare Hospital||2|||f||||t||||||||||2018-06-01 01:52:13.958486|2018-06-01 01:52:13.958486
NCT00730483|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2017-04-19||2017-07-24|2008-08-07|2008-08-08|Estimate|2017-07-24|2017-08-25|Actual||||2017-07-24|2017-08-25|Actual|February 2009||2009-02-28|July 2017|2017-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors|Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization|Terminated||N/A|13|Actual|Yale University||1||High incidence of biloma and liver abscess after TACE|f||||||||||||||2018-06-01 01:52:14.090077|2018-06-01 01:52:14.090077
NCT00730470|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2010-07-28|2008-08-07|2008-08-08|Estimate|||||||2010-07-28|2010-07-29|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-Finding Study to Assess the Safety and Tolerability of U3-1287 (AMG 888), a Human Monoclonal Antibody Targeting HER3 in Patients With Advanced Solid Tumors.|Completed||Phase 1|60|Anticipated|U3 Pharma GmbH||1|||f||||f||||||||||2018-06-01 01:52:14.632585|2018-06-01 01:52:14.632585
NCT00730106|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2010-10-18|2008-08-06|2008-08-08|Estimate|||||||2010-10-18|2010-10-19|Estimate|May 2008||2008-05-31|October 2010|2010-10-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Observational|||Endoscopic Findings in Patients With Typical Gastroesophageal Reflux Disease (GERD) Symptoms|Endoscopic Findings in Taiwan Patients Presenting With Characteristic Symptoms of Gastroesophageal Reflux Disease|Completed|||1000|Anticipated|Lotung Poh-Ai Hospital|||2||f||||t||||||||||2018-06-01 01:52:21.255515|2018-06-01 01:52:21.255515
NCT00730457|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2014-09-22|2008-08-04|2008-08-08|Estimate|||||||2014-09-22|2014-09-23|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine|A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study|Completed||Phase 1|56|Actual|VaxInnate Corporation||1|||f||||t||||||||||2018-06-01 01:52:14.730053|2018-06-01 01:52:14.730053
NCT00730444|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-11-05|2008-08-07|2008-08-08|Estimate|||||||2009-11-05|2009-11-09|Estimate||||November 2009|2009-11-30||||||||Expanded Access|||Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma|Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma|Approved for marketing|||||GE Healthcare|||||||||||||||||||2018-06-01 01:52:14.81757|2018-06-01 01:52:14.81757
NCT00730431|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2015-04-22|2008-08-07|2008-08-08|Estimate|||||||2015-04-22|2015-04-23|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)|A Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IDX184 After Oral Administration in Healthy Subjects|Completed||Phase 1|48|Anticipated|Merck Sharp & Dohme Corp.||7|||f||||f||||||||||2018-06-01 01:52:14.880938|2018-06-01 01:52:14.880938
NCT00730418|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|||2010-08-25|2008-08-07|2008-08-08|Estimate|||||||2010-08-25|2010-08-26|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effects of Chronic Use of Doxazosin in Men With Benign Prostatic Hyperplasia|A Prospective Study for the Effects of Chronic Use of Doxazosin on Alpha 1-adrenergic Receptors in Men With Benign Prostatic Hyperplasia|Completed||N/A|25|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 01:52:14.960694|2018-06-01 01:52:14.960694
NCT00730405|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2017-12-04|2012-06-28|2018-02-13|2008-08-07|2008-08-08|Estimate|2018-01-10|2018-02-07|Actual|2012-06-28|2012-07-02|Estimate|2018-02-13|2018-03-12|Actual|July 16, 2008|Actual|2008-07-16|January 2018|2018-01-31|February 19, 2010|Actual|2010-02-19|February 19, 2010|Actual|2010-02-19||Interventional|||Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis|Completed||Phase 2|582|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-06-01 01:52:15.164638|2018-06-01 01:52:15.164638
NCT00730392|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-05|2008-08-05|2008-08-08|Estimate|||||||2008-08-05|2008-08-08|Estimate|October 2002||2002-10-31|August 2008|2008-08-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||Etanercept in New Onset Type 1 Diabetes|"ENBREL® (Etanercept) Administration to Patients Newly Diagnosed With Type 1 Diabetes Mellitus: Feasibility-Safety Study (Study)"|Completed||Phase 1/Phase 2|18|Actual|University at Buffalo||1|||f||||t||||||||||2018-06-01 01:52:16.237923|2018-06-01 01:52:16.237923
NCT00730379|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2015-02-09|2008-08-07|2008-08-08|Estimate|||||||2015-02-09|2015-02-10|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)|A Phase I Study of Ridaforolimus (MK8669) and MK0646 in Patients With Advanced Cancer|Completed||Phase 1|87|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 01:52:16.301282|2018-06-01 01:52:16.301282
NCT00730366|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2010-09-12|2008-08-07|2008-08-08|Estimate|||||||2010-09-12|2010-09-14|Estimate|March 2004||2004-03-31|September 2010|2010-09-30|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa|New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa.|Completed||Phase 3|2766|Actual|Institute of Tropical Medicine, Belgium||3|||f||||f||||||||||2018-06-01 01:52:16.36173|2018-06-01 01:52:16.36173
NCT00730353|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2016-04-29||2017-01-26|2008-08-06|2008-08-08|Estimate|2017-01-26|2017-03-16|Actual||||2017-01-26|2017-03-16|Actual|August 2008||2008-08-31|January 2017|2017-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Sutent + Taxol for Advanced Esophageal Cancer|A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer|Completed||Phase 2|28|Actual|Hoosier Cancer Research Network|Statistical power is based on 26 evaluable patients; However, all objectives other than the primary objective were based on 23 evaluable patients.|1|||f||||t||||||||No||2018-06-01 01:52:16.614378|2018-06-01 01:52:16.614378
NCT00730340|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2010-06-14|2008-08-07|2008-08-08|Estimate|||||||2010-06-14|2010-06-15|Estimate|August 2008||2008-08-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Closure Method Study Following Tonsillectomy in Children|Decreased Morbidity With Closure of the Tonsillar Fossae|Completed||Early Phase 1|14|Actual|University of Oklahoma||2|||f||||f||||||||||2018-06-01 01:52:17.014089|2018-06-01 01:52:17.014089
NCT00730327|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2015-08-27||2015-10-08|2008-08-07|2008-08-08|Estimate|2015-10-08|2015-11-06|Estimate||||2015-10-08|2015-11-06|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||The baseline analysis population consisted of the Intent-to-Treat (ITT) population. All baseline characteristics were calculated at the screening visit.|A Study of BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects|Safety and Effectiveness of the BioEnterics® Intragastric Balloon (BIB®) System to Assist in the Weight Management of Obese Subjects|Completed||N/A|448|Actual|Apollo Endosurgery, Inc.||2|||f||||f||||||||||2018-06-01 01:52:17.181133|2018-06-01 01:52:17.181133
NCT00730314|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2016-06-21|2008-08-07|2008-08-08|Estimate|||||||2016-06-21|2016-06-23|Estimate|August 2008||2008-08-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells|Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor|Completed||Phase 1/Phase 2|25|Actual|Children's Hospital Los Angeles||2|||f||||t||||||||No||2018-06-01 01:52:18.099426|2018-06-01 01:52:18.099426
NCT00730301|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-05|2008-08-05|2008-08-08|Estimate|||||||2008-08-05|2008-08-08|Estimate|July 2007||2007-07-31|August 2008|2008-08-31||||September 2008|Anticipated|2008-09-30||Interventional|EUROPT||EUROPT Clinical Trial to Study the Efficacy of One-Way Valve Implantation (New Treatment Algorithm) in Patients With Heterogeneous Emphysema|A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema|Unknown status|Recruiting|Phase 4|20|Anticipated|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|||||f||||t||||||||||2018-06-01 01:52:18.192458|2018-06-01 01:52:18.192458
NCT00730275|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2011-12-21||2017-04-07|2008-08-06|2008-08-08|Estimate|2011-12-21|2012-01-30|Estimate||||2017-04-07|2017-05-12|Actual|July 18, 2008|Actual|2008-07-18|April 2017|2017-04-30|February 14, 2011|Actual|2011-02-14|December 30, 2010|Actual|2010-12-30||Interventional|||A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)|A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents|Completed||Phase 1|35|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:52:18.436234|2018-06-01 01:52:18.436234
NCT00730262|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2009-12-29|2008-08-07|2008-08-08|Estimate|||||||2009-12-29|2009-12-30|Estimate|August 2008||2008-08-31|December 2009|2009-12-31|June 2010|Anticipated|2010-06-30|April 2010|Anticipated|2010-04-30||Interventional|||Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme|A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme|Terminated||Phase 2|40|Anticipated|Thallion Pharmaceuticals||1||Lack of efficacy|f||||f||||||||||2018-06-01 01:52:18.80941|2018-06-01 01:52:18.80941
NCT00730249|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2010-01-12|2008-08-07|2008-08-08|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2008||2008-09-30|January 2010|2010-01-31||||January 2010|Actual|2010-01-31||Interventional|QUMEA||Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA|Quality Assurance of Administering Methylphenidate in Adults With ADHD|Completed||Phase 3|150|Anticipated|Medice Arzneimittel Pütter GmbH & Co KG||2|||f||||f||||||||||2018-06-01 01:52:18.9199|2018-06-01 01:52:18.9199
NCT00730236|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2013-01-18||2018-02-21|2008-08-07|2008-08-08|Estimate|2013-01-18|2013-02-22|Estimate||||2018-02-21|2018-03-20|Actual|December 2007||2007-12-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|September 2010|Actual|2010-09-30||Interventional|||A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)|A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy|Completed||Phase 3|29|Actual|Aegerion Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 01:52:19.035116|2018-06-01 01:52:19.035116
NCT00730223|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2013-02-12|2008-08-07|2008-08-08|Estimate|||||||2013-02-12|2013-02-15|Estimate|March 2004||2004-03-31|February 2013|2013-02-28|August 2009|Actual|2009-08-31|March 2006|Actual|2006-03-31||Interventional|||Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors|Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors|Completed||Phase 1|33|Actual|Vanderbilt University|||||f||||t||||||||||2018-06-01 01:52:19.523177|2018-06-01 01:52:19.523177
NCT00730210|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2012-10-23|2008-08-07|2008-08-08|Estimate|||||||2012-10-23|2012-10-24|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|HypoPTH||Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life|Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life|Completed||Phase 2|62|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 01:52:19.584686|2018-06-01 01:52:19.584686
NCT00730197|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg|Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets(40 mg; Mylan) and Sular® Extended Release Tablets (40 mg; First Horizon) in Healthy Volunteers|Completed||Phase 1|48|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 01:52:19.669394|2018-06-01 01:52:19.669394
NCT00730184|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Does Potassium Bicarbonate Improve the Effect of Dietary Protein on Bone and Muscle?|Does Potassium Bicarbonate Improve the Effect of Dietary Protein on Bone and Muscle?|Completed||N/A|23|Actual|Tufts University||2|||f||||f||||||||||2018-06-01 01:52:19.745866|2018-06-01 01:52:19.745866
NCT00730171|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2017-12-18||2018-01-19|2008-08-05|2008-08-08|Estimate|2018-01-19|2018-02-16|Estimate||||2018-01-19|2018-02-16|Estimate|September 2008||2008-09-30|January 2018|2018-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Overall Safety Population: enrolled participants who received at least 1 dose of open-label study drug.|An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation|An Open-label, Long-term Safety Study of Oral Linaclotide Administered to Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation|Completed||Phase 3|1743|Actual|Ironwood Pharmaceuticals, Inc.||1|||f|||||t|||||||||2018-06-01 01:52:19.870543|2018-06-01 01:52:19.870543
NCT00730158|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2017-07-28|2008-08-04|2008-08-08|Estimate|||||||2017-07-28|2017-08-01|Actual|December 2008||2008-12-31|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer|A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer|Suspended||Phase 2|165|Anticipated|University of Pittsburgh||2||Temporary suspension for data analysis.|f||||t||||||||||2018-06-01 01:52:20.713409|2018-06-01 01:52:20.713409
NCT00730145|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2010-02-16|2008-08-07|2008-08-08|Estimate|||||||2010-02-16|2010-02-17|Estimate|September 2008||2008-09-30|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis|A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis|Completed||Phase 1|8|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:52:20.800221|2018-06-01 01:52:20.800221
NCT00730132|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-06-30||2015-06-23|2008-08-05|2008-08-08|Estimate|2010-09-23|2010-10-11|Estimate||||2015-06-23|2015-07-16|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)|Observational Study of Approaches to Lipid-lowering Therapy in Russian Patients With Coronary Heart Disease (<<Treat to Goal>>)|Completed|||712|Actual|Merck Sharp & Dohme Corp.|||3||f||||t||||||||||2018-06-01 01:52:20.902321|2018-06-01 01:52:20.902321
NCT00730119|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-08-07|2008-08-05|2008-08-08|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2001|Actual|2001-10-31|August 2017|2017-08-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|||Evaluation Of The GE Monitor Product Line|Evaluation Of The GE Monitor Product Line|Withdrawn|||0|Actual|GE Healthcare|||3|Terminated due to lack of enrollment at target sites|f||||f||||||||||2018-06-01 01:52:21.196052|2018-06-01 01:52:21.196052
NCT00730067|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2012-08-22|2008-08-07|2008-08-08|Estimate|||||||2012-08-22|2012-08-23|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension|Sildenafil for COPD-associated Pulmonary Hypertension. A Randomized Double Blinded Placebo Controlled Study.|Withdrawn||Phase 4|0|Actual|University of Aarhus||2||As a single center, it was not possible to recruit enough patients with pulmonary hypertension|f||||t||||||||||2018-06-01 01:52:21.473491|2018-06-01 01:52:21.473491
NCT00730054|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2011-07-03|2008-08-07|2008-08-08|Estimate|||||||2011-07-03|2011-07-06|Estimate|February 2005||2005-02-28|August 2008|2008-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|Remiclon||Clonidine-Remifentanil. Effect of the Combination on Acute Pain and Respiration in Healthy Volunteers|Clonidine-Remifentanil. Effect of the Combination on Acute Pain and Respiration in Healthy Volunteers|Completed||Phase 1/Phase 2|12|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-06-01 01:52:21.548186|2018-06-01 01:52:21.548186
NCT00730041|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2009-08-07||2010-01-06|2008-08-07|2008-08-08|Estimate|2009-09-30|2009-11-09|Estimate||||2010-01-06|2010-01-12|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|Pillar-CPAP||Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea|Randomized Placebo-Controlled Study of the Pillar® Palatal Implant System With CPAP|Terminated||Phase 4|51|Actual|Medtronic Xomed, Inc.|The study was underpowered for this comparison as only half the planned enrollment occurred. Also, changes occurred with the sleep stage and position as well as the masks used between the two PSGs, which may have affected some of the results.|2||Medtronic acquisition of Restore Medical, business decision|f||||f||||||||||2018-06-01 01:52:21.630253|2018-06-01 01:52:21.630253
NCT00730028|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2016-02-18||2016-02-18|2008-08-07|2008-08-08|Estimate|2016-02-18|2016-03-17|Estimate||||2016-02-18|2016-03-17|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||All participants enrolled in the protocol are included in the baseline analysis population.|Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus|Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus|Completed||Phase 2|1310|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 01:52:21.943776|2018-06-01 01:52:21.943776
NCT00730015|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2012-09-28||2012-12-19|2008-08-05|2008-08-08|Estimate|2012-12-19|2013-01-30|Estimate||||2012-12-19|2013-01-30|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Trial of Linaclotide in Patients With Chronic Constipation|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Chronic Constipation|Completed||Phase 3|643|Actual|Ironwood Pharmaceuticals, Inc.||3|||f||||||||||||||2018-06-01 01:52:22.827481|2018-06-01 01:52:22.827481
NCT00730002|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2015-12-10|2008-08-01|2008-08-08|Estimate|||||||2015-12-10|2015-12-14|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus|Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus|Completed||N/A|66|Actual|University of Michigan||4|||f||||f||||||||||2018-06-01 01:52:23.63971|2018-06-01 01:52:23.63971
NCT00729989|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-03-08|2008-08-07|2008-08-08|Estimate|||||||2017-03-08|2017-03-13|Actual|August 2008|Actual|2008-08-31|March 2017|2017-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety of Gastric Suctioning During Neonatal Resuscitation|Efficacy and Safety of Gastric Suctioning During Neonatal Resuscitation- A Randomized Clinical Trial|Terminated||N/A|173|Actual|University of Iowa||2||Project not funded|f||||t||||||||||2018-06-01 01:52:23.730581|2018-06-01 01:52:23.730581
NCT00729976|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2011-04-04|2008-08-07|2008-08-08|Estimate|||||||2011-04-04|2011-04-05|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.|Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.|Unknown status|Recruiting|Phase 4|40|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 01:52:23.793094|2018-06-01 01:52:23.793094
NCT00729963|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2013-04-09|2008-08-07|2008-08-08|Estimate|||||||2013-04-09|2013-04-11|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients|Efficacy of Sibutramine-induced Weight Loss vs. Continuous Positive Airway Pressure (CPAP) in the Treatment of Obese Patients With Obstructive Sleep Apnea|Completed||Phase 4|45|Actual|Laval University||2|||f||||t||||||||||2018-06-01 01:52:23.86603|2018-06-01 01:52:23.86603
NCT00729950|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2010-04-23|2008-08-07|2008-08-08|Estimate|||||||2010-04-23|2010-04-26|Estimate|July 2003||2003-07-31|April 2010|2010-04-30|June 2007|Actual|2007-06-30|October 2005|Actual|2005-10-31||Interventional|||Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma|An Open-Label Pharmacokinetic and Safety Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma|Completed||Phase 1|92|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-06-01 01:52:23.936075|2018-06-01 01:52:23.936075
NCT00729937|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2014-04-17||2015-01-29|2008-08-07|2008-08-08|Estimate|2014-04-24|2014-05-28|Estimate||||2015-01-29|2015-02-18|Estimate|April 2009||2009-04-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional||The baseline analysis population is the per protocol population. All participants who met enrollment criteria, had none of the exclusion criteria, completed at least 75% of the first 5 days of antimicrobial therapy, and had physical follow-up at the Test of Cure (TOC) visit were included in the per protocol population.|"Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus STOP MRSA"|"Strategies Using Off-Patent Antibiotics for Methicillin-Resistant Staphylococcus Aureus (STOP MRSA) - A Phase IIB, Multi-Center, Randomized, Double-Blind Clinical Trial"|Completed||Phase 2/Phase 3|2265|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 01:52:24.167204|2018-06-01 01:52:24.167204
NCT00729924|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2014-05-27||2015-03-02|2008-08-07|2008-08-08|Estimate|2015-03-02|2015-03-03|Estimate||||2015-03-02|2015-03-03|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid|Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid|Completed||Phase 2/Phase 3|40|Actual|Vanderbilt University|There were no limitations to this trial.|1|||f||||f||||||||||2018-06-01 01:52:28.457597|2018-06-01 01:52:28.457597
NCT00729911|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2018-04-23|2008-08-07|2008-08-08|Estimate|||||||2018-04-23|2018-04-24|Actual|October 2008||2008-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|||Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD|Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD|Active, not recruiting||Phase 4|120|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||Undecided||2018-06-01 01:52:28.664567|2018-06-01 01:52:28.664567
NCT00729898|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2016-10-27|2008-08-05|2008-08-08|Estimate|||||||2016-10-27|2016-10-31|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes|Safety of NovoMix® 30 (Biphasic Insulin Aspart) Treatment in Patients With Type 2 Diabetes|Completed|||243|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:52:28.737609|2018-06-01 01:52:28.737609
NCT00729885|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|November 2006||2006-11-30|August 2008|2008-08-31||||August 2008|Anticipated|2008-08-31||Interventional|||Visual Feedback Goggle for Positional Vertigo Treatment|Visual Feedback Goggle For The Treatment Of Benign Paroxysmal Positional Vertigo in a Randomized Single-Blind Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|Vertigone Inc.||2|||f||||f||||||||||2018-06-01 01:52:28.808389|2018-06-01 01:52:28.808389
NCT00729872|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2009-09-09|2008-08-04|2008-08-08|Estimate|||||||2009-09-09|2009-09-10|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis|A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis|Completed||Phase 1/Phase 2|60|Anticipated|ActoGeniX N.V.||6|||f||||t||||||||||2018-06-01 01:52:28.886026|2018-06-01 01:52:28.886026
NCT00729859|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2011-06-02||2012-09-12|2008-08-05|2008-08-08|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|CEP-1||CEP-1 Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men|Hormonal Regulation of Circulating Endothelial Progenitor Cells and HDL-C in Men Title Changed With New Protocol (12/14/09): Hormonal Regulation of HDL-C in Men|Completed||Phase 2|31|Actual|University of Washington||3|||f||||f||||||||||2018-06-01 01:52:29.140131|2018-06-01 01:52:29.140131
NCT00729846|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2016-02-01||2016-03-21|2008-08-07|2008-08-08|Estimate|2016-03-21|2016-04-20|Estimate||||2016-03-21|2016-04-20|Estimate|May 2006||2006-05-31|March 2016|2016-03-31|July 2009|Actual|2009-07-31|August 2008|Actual|2008-08-31||Interventional|||Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)|Combination Bevacizumab and Verteporfin (Standard and Reduced Fluence)in the Treatment of Neovascular Age-Related Macular Degeneration|Completed||Phase 2|22|Actual|California Retina Consultants||2|||f||||f||||||||||2018-06-01 01:52:29.874362|2018-06-01 01:52:29.874362
NCT00729833|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2014-04-11||2014-05-21|2008-08-07|2008-08-08|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|September 2008||2008-09-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|August 2011|Actual|2011-08-31||Interventional||Full Analysis Set: All enrolled participants who received at least 1 dose of figitumumab plus sunitinib.|Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors|Phase 1, Open Label, Sequential Cohort, Dose Escalation Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors|Terminated||Phase 1|45|Actual|Pfizer|This study was terminated prematurely. Subsequently, ADA samples were not assayed and the pharmacokinetics of sunitinib plus its metabolite were not analyzed.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:52:30.173784|2018-06-01 01:52:30.173784
NCT00729820|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2008-08-07|2008-08-07|2008-08-08|Estimate|||||||2008-08-07|2008-08-08|Estimate|August 2008||2008-08-31|June 2008|2008-06-30||||||||Observational|||The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.|The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.|Unknown status|Not yet recruiting||30|Anticipated|BeerYaakov Mental Health Center|||||f||||||||||||||2018-06-01 01:52:31.564556|2018-06-01 01:52:31.564556
NCT00729807|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-07|2015-12-17||2017-02-28|2008-08-07|2008-08-08|Estimate|2016-08-30|2016-10-21|Estimate||||2017-02-28|2017-03-30|Actual|July 2008||2008-07-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma|Treatment of Melanoma With Wild-type p53 and Detectable S100B Using Pentamidine: a Phase II Trial With Correlative Biomarker Endpoints|Completed||Phase 2|6|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 01:52:31.630528|2018-06-01 01:52:31.630528
NCT00729794|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2016-11-18|2008-08-07|2008-08-08|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|VSE-2||Vasopressin, Epinephrine, and Steroids for Cardiac Arrest|Vasopressin, Epinephrine, and Corticosteroids for Inhospital Cardiac Arrest: A Multicenter Randomized Controlled Trial|Completed||Phase 3|300|Actual|University of Athens||2|||f||||t||||||||||2018-06-01 01:52:31.834986|2018-06-01 01:52:31.834986
NCT00729781|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2011-08-23||2011-12-01|2008-08-07|2008-08-08|Estimate|2011-12-01|2012-01-06|Estimate||||2011-12-01|2012-01-06|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|January 2011|Actual|2011-01-31|November 2009|Actual|2009-11-30||Interventional|NVC||Study of Polyester Implants for the Treatment of External Nasal Valve Collapse (NVC)|Open Label, Baseline Controlled Study to Evaluate the Use of Polyethylene Terephthalate (PET) Implants for the Treatment of External Nasal Valve Collapse and Cosmetic Contour Deformity|Terminated||Phase 1/Phase 2|45|Actual|Medtronic Xomed, Inc.||1||Strategic Business Decision|f||||f||||||||||2018-06-01 01:52:31.943908|2018-06-01 01:52:31.943908
NCT00729768|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-02|||2017-06-21|2008-08-04|2008-08-07|Estimate|||||||2017-06-21|2017-06-22|Actual||||March 2009|2009-03-31||||||||Interventional|||A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation|A Phase II/III, Randomized, Open-Label, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab Compared With Cyclosporine, Both in Combination With Mycophenolate Mofetil and Corticosteroids, As an Immunosuppressant Regimen in De Novo Renal Transplantation|Withdrawn||Phase 2/Phase 3|0|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 01:52:32.184703|2018-06-01 01:52:32.184703
NCT00729755|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2017-07-03|2008-08-04|2008-08-07|Estimate|||||||2017-07-03|2017-07-05|Actual|August 2008||2008-08-31|July 2017|2017-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Creatine Augmentation Treatment in Major Depressive Disorder Subjects|Efficacy and Safety of Augmentation of Creatine for the Patients With Major Depressive Disorder|Completed||N/A|59|Actual|Ewha Womans University||2|||f||||t||||||||||2018-06-01 01:52:32.370984|2018-06-01 01:52:32.370984
NCT00729742|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2016-04-01|2008-08-06|2008-08-07|Estimate|||||||2016-04-01|2016-04-04|Estimate|February 2009||2009-02-28|April 2016|2016-04-30|May 2011|Actual|2011-05-31|June 2010|Actual|2010-06-30||Interventional|||Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)|A Phase 1b, Multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK0646 in Advanced Non-Small-Cell Lung Cancer|Completed||Phase 1|49|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:52:32.474321|2018-06-01 01:52:32.474321
NCT00729729|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-03|||2012-08-27|2008-08-06|2008-08-07|Estimate|||||||2012-08-27|2012-08-28|Estimate|July 2008||2008-07-31|August 2008|2008-08-31|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|PCA 1||Pharmacokinetic Study for PCA Derivate Formulations|Phase 4, Three Way Cross-over, Pharmacokinetic Study for PCA Derivate Formulations in Healthy Subjects|Completed||Phase 4|30|Anticipated|Hadassah Medical Organization||3|||f||||t||||||||||2018-06-01 01:52:32.557507|2018-06-01 01:52:32.557507
NCT00729716|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2012-04-16|2008-08-06|2008-08-07|Estimate|||||||2012-04-16|2012-04-17|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|May 2015|Anticipated|2015-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle|Phase II Study to Investigate the Efficacy and Safety of BioCart™II in the Treatment of Symptomatic Cartilage Defects of the Femoral Condyle in Comparison With Microfracture|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|ProChon Biotech Ltd||2|||f||||f||||||||||2018-06-01 01:52:32.625822|2018-06-01 01:52:32.625822
NCT00729703|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2015-01-12|2008-08-06|2008-08-07|Estimate|||||||2015-01-12|2015-01-13|Estimate|June 2006||2006-06-30|January 2015|2015-01-31|October 2013|Actual|2013-10-31|December 2011|Actual|2011-12-31||Interventional|OPTION||Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications|Optimal Antitachycardia Therapy in ICD Patients Without Pacing Indications|Completed||Phase 4|462|Actual|LivaNova||2|||f||||t||||||||||2018-06-01 01:52:32.73186|2018-06-01 01:52:32.73186
NCT00729690|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2012-10-18||2012-11-20|2008-08-06|2008-08-07|Estimate|2012-11-20|2012-12-19|Estimate||||2012-11-20|2012-12-19|Estimate|August 2008||2008-08-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement|Effects of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Total Knee Replacement (TKA)|Completed||Phase 3|48|Actual|Rush University Medical Center||3|||f||||f||||||||||2018-06-01 01:52:32.90476|2018-06-01 01:52:32.90476
NCT00729677|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2009-09-15||2015-10-05|2008-08-06|2008-08-07|Estimate|2011-03-16|2011-03-18|Estimate||||2015-10-05|2015-10-26|Estimate|June 2005||2005-06-30|October 2015|2015-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Observational|||Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin|Prevalence of Delayed Nausea and Vomiting in Patients Being Treated With Oxaliplatin-based Regimens (mFOLFOX6 or FOLFOX7) for Colorectal Cancer|Completed|||64|Actual|Beth Israel Medical Center|This was a convenience sample of patients seen at 2 medical centers. Subjects were restricted to those who could complete Quality of Life forms in Spanish or English.||||f||||f||||||||||2018-06-01 01:52:33.275297|2018-06-01 01:52:33.275297
NCT00729664|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2015-09-03|2008-08-04|2008-08-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Anti-PDL1||Multiple Ascending Dose (MDX1105-01)|A Phase 1, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors|Completed||Phase 1|281|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 01:52:33.642076|2018-06-01 01:52:33.642076
NCT00729651|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2010-02-05||2017-04-06|2008-08-06|2008-08-07|Estimate|2010-03-18|2010-04-02|Estimate||||2017-04-06|2017-05-12|Actual|March 20, 2008|Actual|2008-03-20|April 2017|2017-04-30|April 10, 2009|Actual|2009-04-10|April 10, 2009|Actual|2009-04-10||Interventional|||Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)|A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women|Completed||Phase 4|343|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:52:33.786403|2018-06-01 01:52:33.786403
NCT00729638|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2014-08-07|2008-08-04|2008-08-07|Estimate|||||||2014-08-07|2014-08-11|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma|An Open-Label Phase I Study of the Safety of and Efficacy of RAD001 in Combination With Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|28|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 01:52:34.476663|2018-06-01 01:52:34.476663
NCT00729625|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2016-05-20|2008-08-05|2008-08-07|Estimate|||||||2016-05-20|2016-05-23|Estimate|April 2005||2005-04-30|April 2005|2005-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Air Muscle and Task Practice in Upper Limb Stroke Rehab|Air Muscle and Task Practice in Upper Limb Stroke Rehab|Completed||Early Phase 1|24|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 01:52:34.560701|2018-06-01 01:52:34.560701
NCT00729612|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2016-04-28||2018-03-06|2008-08-06|2008-08-07|Estimate|2016-04-28|2016-06-06|Estimate||||2018-03-06|2018-04-02|Actual|August 14, 2008|Actual|2008-08-14|March 2018|2018-03-31|December 16, 2011|Actual|2011-12-16|December 16, 2011|Actual|2011-12-16||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Phase II Trial of Abraxane Plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding From VEGF Directed Therapies|Completed||Phase 2|63|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:52:34.63095|2018-06-01 01:52:34.63095
NCT00729599|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2009-03-03|2008-08-06|2008-08-07|Estimate|||||||2009-03-03|2009-03-04|Estimate|July 2008||2008-07-31|March 2009|2009-03-31||||August 2008|Actual|2008-08-31||Interventional|Cepacol Teen||Safety Dermatological Evaluation: Acceptability With Odontological Follow up - Cepacol Teen.|Single Site Study, Phase III, for Safety Dermatological Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Teen.|Completed||Phase 3|31|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:52:34.854166|2018-06-01 01:52:34.854166
NCT00729586|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2017-04-11|2008-08-06|2008-08-07|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2008||2008-09-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer|A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma|Completed||Phase 2|73|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 01:52:34.943859|2018-06-01 01:52:34.943859
NCT00729573|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2016-03-08|2008-08-06|2008-08-07|Estimate|||||||2016-03-08|2016-03-09|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Bone Mineral Density Substudy - An Ancillary Study to MTN-003|Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women|Completed|||518|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Urine and blood samples~   "|||2018-06-01 01:52:35.164327|2018-06-01 01:52:35.164327
NCT00729560|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2014-05-27||2014-09-05|2008-08-05|2008-08-07|Estimate|2014-09-05|2014-09-08|Estimate||||2014-09-05|2014-09-08|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|PCOS||Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome|Determination if Pharmacologic Blockade of Androgen Action Decreases Renal Clearance of D-Chiro-Inositol (DCI), Increases the Circulating Concentration of DCI, and Enhances Insulin-Stimulated Release of the D-chiro-inositol-containing Inositolphosphoglycan (DCI-IPG) Mediator in Obese Women With Polycystic Ovary Syndrome (PCOS)|Terminated||N/A|8|Actual|Virginia Commonwealth University||2||Lack of recruitment|f||||f||||||||||2018-06-01 01:52:35.253961|2018-06-01 01:52:35.253961
NCT00729547|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2008-08-04|2008-08-04|2008-08-07|Estimate|||||||2008-08-04|2008-08-07|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|neurofeedback||The Therapeutic Efficacy of Neurofeedback in Depression|The Therapeutic Efficacy of Frontal EEG Asymmetry Neurofeedback in Depression|Completed||N/A|24|Actual|Korea University||2|||f||||f||||||||||2018-06-01 01:52:35.396127|2018-06-01 01:52:35.396127
NCT00729534|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2017-10-05|2008-08-06|2008-08-07|Estimate|||||||2017-10-05|2017-10-06|Actual|August 1, 2008||2008-08-01|May 29, 2013|2013-05-29|May 29, 2013||2013-05-29|||||Observational|||Research Participants Perceptions of Their Experience in Clinical Studies|Research Participant Perception of Care Project: Part 1: Focus Groups of Research Participants and Research Professionals to Identify Key Dimensions of the Research Participant Experience|Completed|||14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:52:35.615416|2018-06-01 01:52:35.615416
NCT00729521|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2014-09-15||2015-02-03|2008-08-04|2008-08-07|Estimate|2015-02-03|2015-02-05|Estimate||||2015-02-03|2015-02-05|Estimate|July 2007||2007-07-31|February 2015|2015-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Average annual population over residents over 65 years of age.|Dissemination of Injury Interventions|Facilitating Dissemination of Injury Interventions: A Randomized Controlled Trial|Completed||N/A|35037|Actual|Medical College of Wisconsin|E coding of injuries can be incomplete, but 99.7% of records with a diagnostic code in the range 800-995.89 had an E code. We may have included more than one admission for the same fall, but we excluded admissions from an acute care facility.|3|||f||||f||||||||||2018-06-01 01:52:35.681193|2018-06-01 01:52:35.681193
NCT00729508|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2009-07-07|2008-08-04|2008-08-07|Estimate|||||||2009-07-07|2009-07-08|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects|A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Efficacy of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber.|Completed||Phase 2|120|Anticipated|Circassia Limited||5|||f||||f||||||||||2018-06-01 01:52:35.914694|2018-06-01 01:52:35.914694
NCT00729495|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2009-05-12|2008-08-06|2008-08-07|Estimate|||||||2009-05-12|2009-05-14|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib|Phase I, Randomized, Open-Label, 2-Way Crossover Study to Evaluate Relative Bioavailability of Single Oral Dose of Celecoxib Administered as Marketed Product, or Overencapsulated Capsule in Healthy Volunteers|Completed||Phase 1|80|Anticipated|POZEN||2|||f||||f||||||||||2018-06-01 01:52:35.992801|2018-06-01 01:52:35.992801
NCT00729482|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2013-12-31||2013-12-31|2008-08-04|2008-08-07|Estimate|2013-12-31|2014-02-13|Estimate||||2013-12-31|2014-02-13|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|September 2011|Actual|2011-09-30||Interventional||Baseline analysis was based on all enrolled patients.|RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment|A Phase II Study of RAD001 (Everolimus) in Patients With Fluoropyrimidine and Platinum-refractory Advanced Gastric Cancer|Completed||Phase 2|54|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 01:52:36.079111|2018-06-01 01:52:36.079111
NCT00729469|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2013-03-19||2018-04-19|2008-08-06|2008-08-07|Estimate|2013-05-21|2013-06-28|Estimate||||2018-04-19|2018-05-18|Actual|July 2008||2008-07-31|April 2018|2018-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity|Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Dose With Placebo in Postmenopausal Women|Completed||Phase 3|919|Actual|Shionogi Inc.||2|||f||||||||||||||2018-06-01 01:52:36.353022|2018-06-01 01:52:36.353022
NCT00729456|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2008-08-04|2008-08-04|2008-08-07|Estimate|||||||2008-08-04|2008-08-07|Estimate|April 2003||2003-04-30|July 2008|2008-07-31|December 2006|Actual|2006-12-31|April 2006|Actual|2006-04-30||Interventional|ESP||Evaluation of Education in the Secondary Prevention of Foot Ulceration in Diabetes|Evaluation of Education in the Secondary Prevention of Foot Ulceration in Diabetes|Completed||N/A|172|Actual|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||||2018-06-01 01:52:37.052193|2018-06-01 01:52:37.052193
NCT00729443|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2008-11-10|2008-08-06|2008-08-07|Estimate|||||||2008-11-10|2008-11-13|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|SAD||Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers|A Single-Centre, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 Following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers|Completed||Phase 1|64|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:52:37.147702|2018-06-01 01:52:37.147702
NCT00729261|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2015-04-27|2008-08-01|2008-08-07|Estimate|||||||2015-04-27|2015-04-28|Estimate|August 2004||2004-08-31|August 2008|2008-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Prospective Trial of Elective Extubation in Brain Injured Patients.|A Prospective Trial of Elective Extubation in Brain Injured Patients Meeting Extubation Criteria for Ventilatory Support.|Completed||Phase 1|16|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:52:40.958198|2018-06-01 01:52:40.958198
NCT00729430|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2017-02-28||2017-05-25|2008-08-06|2008-08-07|Estimate|2017-05-25|2017-06-01|Actual||||2017-05-25|2017-06-01|Actual|August 2008||2008-08-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|October 2013|Actual|2013-10-31||Interventional|OmegaREMODEL||Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging|Prognostic, Anti-arrhythmic, and Ventricular Remodeling Effects of High Dose Fish Oil in Patients With a Recent Myocardial Infarction|Completed||Phase 3|358|Actual|Brigham and Women's Hospital|The study was not powered to evaluate for clinical heart failure and hard cardiac outcomes. A prospective trial would be necessary to determine the effect of earlier and high-dose omega-3 fatty acid therapy on improving clinical outcomes.|2|||f||||t||||||||Yes|Plan to share data with GISSI Heart Failure group for pooling and meta-analysis|2018-06-01 01:52:37.234394|2018-06-01 01:52:37.234394
NCT00729417|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2008-08-06|2008-08-06|2008-08-07|Estimate|||||||2008-08-06|2008-08-07|Estimate|August 2008||2008-08-31|August 2008|2008-08-31||||August 2010|Anticipated|2010-08-31||Observational|||Obstetrical Risk Factors for the Development of Urinary and/or Fecal Incontinence|Obstetrical Risk Factors for the Development of Urinary and/or Fecal Incontinence|Unknown status|Not yet recruiting||300|Anticipated|Maaynei Hayesha Medical Center|||||f||||f||||||||||2018-06-01 01:52:37.47485|2018-06-01 01:52:37.47485
NCT00729404|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2014-11-27|2008-08-06|2008-08-07|Estimate|||||||2014-11-27|2014-12-02|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene|Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles|Terminated||Phase 2|17|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:52:37.525107|2018-06-01 01:52:37.525107
NCT00729391|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-05-16|2008-08-05|2008-08-07|Estimate|||||||2017-05-16|2017-05-18|Actual|September 26, 2008|Actual|2008-09-26|May 2017|2017-05-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|WC-WHC||Women-Focused HIV Prevention in the Western Cape|Women-Focused HIV Prevention in the Western Cape|Completed||Phase 2/Phase 3|720|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||3|||f||||f||||||||Undecided||2018-06-01 01:52:37.600822|2018-06-01 01:52:37.600822
NCT00729378|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2017-04-24||2017-12-05|2008-08-05|2008-08-07|Estimate|2017-12-05|2017-12-08|Actual||||2017-12-05|2017-12-08|Actual|April 2007||2007-04-30|December 2017|2017-12-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|||Jump-In: Building Better Bones|Exercise and Bone Development in Young Girls|Completed||N/A|509|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||No||2018-06-01 01:52:37.744736|2018-06-01 01:52:37.744736
NCT00729365|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2014-12-30||2015-02-24|2008-08-06|2008-08-07|Estimate|2014-12-30|2015-01-09|Estimate||||2015-02-24|2015-03-17|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PREVENTKD||PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)|Nocturnal Hypertension and Prevention of Microalbuminuria in Type 1 Diabetes|Terminated||Phase 3|65|Actual|Northwestern University|"The study was terminated prematurely because of new information from the literature from other studies showing that this study could not be successful.~Only 59 patients were screened and consented and 46 were found acceptable who were randomized."|3||Data from other studies showed that study could not be completef successfully|f||||t||||||||||2018-06-01 01:52:39.494718|2018-06-01 01:52:39.494718
NCT00729352|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2014-09-25|2008-08-06|2008-08-07|Estimate|||||||2014-09-25|2014-09-29|Estimate|August 2008||2008-08-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|October 2011|Actual|2011-10-31||Observational|||Lung Mucus Hypersecretion and NQO1|Dependency of O3-Induced Lung Mucus Hypersecretion on NQO1|Completed|||60|Actual|National Institute of Environmental Health Sciences (NIEHS)|||2||f||||f||||||Samples With DNA|"~     Bronchoalveolar lavage specimens.~   "|||2018-06-01 01:52:39.925133|2018-06-01 01:52:39.925133
NCT00729339|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2009-05-12|2008-08-04|2008-08-07|Estimate|||||||2009-05-12|2009-05-13|Estimate|June 2008||2008-06-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Role of Mosapride in Patients With Gastroesophageal Reflux Disease|Role of Mosapride in Patients With Gastroesophageal Reflux Disease|Completed||Phase 4|114|Actual|Lotung Poh-Ai Hospital||2|||f||||t||||||||||2018-06-01 01:52:39.98556|2018-06-01 01:52:39.98556
NCT00729326|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2010-10-12||2015-03-20|2008-08-06|2008-08-07|Estimate|2010-12-19|2011-01-20|Estimate||||2015-03-20|2015-04-09|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione|Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione|Completed||Phase 4|83|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:52:40.101863|2018-06-01 01:52:40.101863
NCT00729313|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2012-06-18|2008-08-06|2008-08-07|Estimate|||||||2012-06-18|2012-06-19|Estimate|April 2000||2000-04-30|June 2012|2012-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae|A Phase III Multicentre Randomised Double-blind Comparative Study of Efficacy and Safety of Lanreotide 30 mg Versus Placebo for Treatment of Patients With Digestive Fistulae|Completed||Phase 3|111|Actual|Ipsen||2|||f||||f||||||||||2018-06-01 01:52:40.648217|2018-06-01 01:52:40.648217
NCT00729300|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2016-08-17|2008-08-06|2008-08-07|Estimate|||||||2016-08-17|2016-08-19|Estimate|April 2006||2006-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study of the Relationship Between Disulfiram and Cocaine Self-administration.|Laboratory Models of Cocaine Self-administration|Terminated||Phase 1/Phase 2|60|Actual|National Institute on Drug Abuse (NIDA)||2||Project moved to new university|f||||t||||||||No||2018-06-01 01:52:40.75294|2018-06-01 01:52:40.75294
NCT00729287|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2016-05-10|2008-08-06|2008-08-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SELEBLAT||Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer|Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer|Completed||Phase 3|276|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-06-01 01:52:40.818139|2018-06-01 01:52:40.818139
NCT00729274|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2015-09-04|2008-08-06|2008-08-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|April 2014|Anticipated|2014-04-30|May 2012|Anticipated|2012-05-31||Interventional|||HYPERTONIC SALINE IN ACUTE VIRAL BRONCHIOLITIS: A RANDOMIZED CLINICAL TRIAL|HYPERTONIC SALINE IN ACUTE VIRAL BRONCHIOLITIS: A RANDOMIZED CLINICAL TRIAL|Withdrawn||N/A|0|Actual|Laval University||2||Was not approved by funding organization|f||||f||||||||||2018-06-01 01:52:40.881088|2018-06-01 01:52:40.881088
NCT00728702|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2008-08-05|2008-08-05|2008-08-06|Estimate|||||||2008-08-05|2008-08-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:52:48.582901|2018-06-01 01:52:48.582901
NCT00729248|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2010-08-25||2013-05-23|2008-08-06|2008-08-07|Estimate|2013-05-23|2013-08-28|Estimate||||2013-05-23|2013-08-28|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Observational|||The Differential Effects of 3 Different Immunosuppressive|The Differential Effects of 3 Different Immunosuppressive Agents, Tacrolimus Mycophenolate Mofetil and Sirolimus on the Generation of Tregs and DCregs in in Vitro MLR and T Cell Activation Assays|Completed|||12|Actual|Northwestern University|||||f||||t||||||Samples With DNA|"~     White Cells.~   "|||2018-06-01 01:52:41.022232|2018-06-01 01:52:41.022232
NCT00729235|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2011-12-21|2008-08-06|2008-08-07|Estimate|||||||2011-12-21|2011-12-22|Estimate|May 2006||2006-05-31|June 2010|2010-06-30|November 2011|Actual|2011-11-30|December 2008|Actual|2008-12-31||Interventional|BITAC||Biventricular Tachycardias Outcome Trial|Biventricular Tachycardias Outcome Trial|Completed||Phase 4|481|Actual|LivaNova||2|||f||||t||||||||||2018-06-01 01:52:41.149962|2018-06-01 01:52:41.149962
NCT00729222|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2015-10-19|2008-08-06|2008-08-07|Estimate|||||||2015-10-19|2015-10-20|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Hemodynamic Effects of Rolofylline Injectable Emulsion in the Treatment of Patients With Heart Failure|Completed||Phase 2|60|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 01:52:41.39099|2018-06-01 01:52:41.39099
NCT00729209|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2012-04-23|2008-08-04|2008-08-07|Estimate|||||||2012-04-23|2012-04-24|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of ARRY-371797 in Patients With Rheumatoid Arthritis||Completed||Phase 1|28|Actual|Array BioPharma||3|||f||||f||||||||||2018-06-01 01:52:41.455042|2018-06-01 01:52:41.455042
NCT00729196|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2011-01-31|2008-08-05|2008-08-07|Estimate|||||||2011-01-31|2011-02-01|Estimate|July 2005||2005-07-31|January 2011|2011-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|Two-for-2||A Trial of Two Diets for Weight and Diabetes Management|A Trial of Two Diets for Weight and Diabetes Management|Completed||N/A|80|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 01:52:41.533955|2018-06-01 01:52:41.533955
NCT00729183|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2017-04-13||2017-07-11|2008-08-06|2008-08-07|Estimate|2017-04-13|2017-05-16|Actual||||2017-07-11|2017-08-10|Actual|October 2008||2008-10-31|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)|A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on Bone Micro-architecture in Postmenopausal Women Treated With Vitamin D|Completed||Phase 3|214|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:52:41.649044|2018-06-01 01:52:41.649044
NCT00729170|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2012-06-29|2008-08-06|2008-08-07|Estimate|||||||2012-06-29|2012-07-02|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional|||Milk Supplementation and Energy Balance.|Impact of Milk Supplementation on Body Composition, Bone Density and Satiety in Women Following a Weight Loss Program.|Completed||N/A|41|Actual|Laval University|||||f||||t||||||||||2018-06-01 01:52:42.390342|2018-06-01 01:52:42.390342
NCT00729157|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|2016-02-26||2017-01-24|2008-08-06|2008-08-07|Estimate|2017-01-24|2017-03-15|Actual||||2017-01-24|2017-03-15|Actual|August 2008||2008-08-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy|A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy|Completed||Phase 2|41|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 01:52:42.495386|2018-06-01 01:52:42.495386
NCT00729144|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2011-01-09|2008-08-05|2008-08-07|Estimate|||||||2011-01-09|2011-01-11|Estimate|June 2008||2008-06-30|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|ABBI||Adaptive Behaviors Among Women With Bowel Incontinence: The ABBI Trial|Adaptive Behaviors Among Women With Bowel Incontinence: The ABBI Trial|Completed|||133|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||||||2018-06-01 01:52:42.823902|2018-06-01 01:52:42.823902
NCT00729131|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2014-09-25|2008-08-06|2008-08-07|Estimate|||||||2014-09-25|2014-09-29|Estimate|August 2008||2008-08-31|September 2014|2014-09-30|February 2012|Actual|2012-02-29|January 2010|Actual|2010-01-31||Observational|||Functional Implications of TNF|Functional Implications of TNF|Completed|||10|Actual|National Institute of Environmental Health Sciences (NIEHS)|||2||f||||f||||||Samples With DNA|"~     Bronchoalveolar lavage specimens.~   "|||2018-06-01 01:52:42.899657|2018-06-01 01:52:42.899657
NCT00729118|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-06|||2018-02-23|2008-08-06|2008-08-07|Estimate|||||||2018-02-23|2018-02-27|Actual|September 26, 2008|Actual|2008-09-26|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|Vorinostat (SAHA) and Lenalidomide After Autologous Transplant for Patients With Multiple Myeloma|Active, not recruiting||Phase 1|19|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-06-01 01:52:42.977064|2018-06-01 01:52:42.977064
NCT00729092|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2016-04-26|2008-08-06|2008-08-07|Estimate|||||||2016-04-26|2016-04-28|Estimate|May 2008||2008-05-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|||Additional Positron Emission Tomography (PET) Scan of Brain in Patients Undergoing PET Scan for Diseases Unrelated to Brain|Additional (Positron Emission Tomography)PET Scan of Brain in Patients Undergoing PET Scan for Diseases Unrelated to Brain|Completed|||100|Actual|Rush University Medical Center|||||f||||f||||||||||2018-06-01 01:52:43.076949|2018-06-01 01:52:43.076949
NCT00729079|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2015-10-08|2008-08-05|2008-08-06|Estimate|||||||2015-10-08|2015-10-12|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|DPP||Diabetes Prevention Program Pilot Study|Virtual Translation of Diabetes Prevention to Primary Care: A Pilot Study|Completed||N/A|36|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 01:52:43.134751|2018-06-01 01:52:43.134751
NCT00729053|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2009-01-08|2008-08-05|2008-08-06|Estimate|||||||2009-01-08|2009-01-09|Estimate|June 2004||2004-06-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|||Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma|A Phase 2, Multi-Center, Randomized, Open-Label Study of Two Dose Levels of IMOxine® (IMO-2055 for Injection) in Patients With Metastatic or Locally Recurrent Clear Cell Renal Carcinoma|Completed||Phase 2|224|Anticipated|Idera Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 01:52:43.213329|2018-06-01 01:52:43.213329
NCT00729040|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2009-01-27|2008-08-05|2008-08-06|Estimate|||||||2009-01-27|2009-01-29|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||Enhancing Adherence by Building Online Communities|Enhancing Adherence to an Internet-Mediated Walking Program by Building Online Communities|Completed||Phase 1/Phase 2|324|Actual|Robert Wood Johnson Foundation||2|||f||||f||||||||||2018-06-01 01:52:43.293066|2018-06-01 01:52:43.293066
NCT00729027|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01||2016-04-15|2016-04-15|2008-08-05|2008-08-06|Estimate||||2016-04-15|2016-05-16|Estimate|2016-04-15|2016-05-16|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia|A Multicenter, Double-blind, Randomized, 12-month, Placebo-controlled Study to Evaluate the Lipid-lowering Effect, Safety and Tolerability of AVE5530 25 mg/Day and 50mg/Day When Added to Ongoing Stable Statin Therapy (HMG-CoA Reductase Inhibitors) in Patients With Primary Hypercholesterolemia|Terminated||Phase 3|1015|Actual|Sanofi||3||AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|f||||f||||||||||2018-06-01 01:52:43.353198|2018-06-01 01:52:43.353198
NCT00729014|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2008-08-01|2008-08-01|2008-08-06|Estimate|||||||2008-08-01|2008-08-06|Estimate|May 2008||2008-05-31|May 2008|2008-05-31||||September 2008|Anticipated|2008-09-30||Observational|||A Study of Drug-Induced Kidney Disease|A Study of Drug-Induced Kidney Disease|Unknown status|Recruiting||2000|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:52:43.448934|2018-06-01 01:52:43.448934
NCT00729001|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2016-09-15|2008-08-05|2008-08-06|Estimate|||||||2016-09-15|2016-09-16|Estimate|November 2000||2000-11-30|September 2016|2016-09-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.|Phase II, Double-blind, Randomized, Placebo-controlled Study of 2 Doses of GSK Biologicals' Live Attenuated Human Rotavirus Vaccine at Different Virus Concentrations (10 5.2 and 10 6.4 Ffu) in Healthy Infants Following a 0, 2 Month Schedule and Previously Uninfected With Human Rotavirus.|Completed||Phase 2|529|Actual|GlaxoSmithKline||3|||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:52:43.642603|2018-06-01 01:52:43.642603
NCT00728988|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2011-04-25||2011-09-29|2008-08-05|2008-08-06|Estimate|2011-08-19|2011-09-27|Estimate||||2011-09-29|2011-10-03|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|ALPACS||Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome|A Prospective Randomized, Open-Label, Parallel-Group Comparative Study: Atorvastatin Pre-Treatment Versus Usual Care In Asian Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention|Completed||Phase 4|499|Actual|Pfizer|Defective high-sensitivity C reactive protein reagents showed instability and 20% average positive bias in results, affecting only change from baseline in CRP. Analyses were performed on all samples; results include affected and unaffected samples.|2|||f||||f||||||||||2018-06-01 01:52:43.792107|2018-06-01 01:52:43.792107
NCT00728975|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2010-05-26|2008-08-05|2008-08-06|Estimate|||||||2010-05-26|2010-05-27|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||The Bowel Research Collaborative Data Tracking System Implementation Study|The Bowel Research Collaborative Data Tracking System Implementation Study|Completed|||390|Anticipated|British Columbia Cancer Agency|||13||f||||f||||||||||2018-06-01 01:52:44.236849|2018-06-01 01:52:44.236849
NCT00728962|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2009-06-26||2017-03-20|2008-08-05|2008-08-06|Estimate|2010-01-18|2010-02-05|Estimate||||2017-03-20|2017-04-17|Actual|March 2005||2005-03-31|March 2017|2017-03-31|October 2009|Actual|2009-10-31|May 2006|Actual|2006-05-31||Observational|Fireball||A Study of Osseotite Certain Prevail Implants Used to Support Short Fixed Bridges With Immediate Occlusal Loading.|A Prospective, Observational Study of Osseotite Certain IOL (Immediate Occlusal Loading) Implants in Immediate Occlusal Loading of Short Span Fixed Restorations|Completed|||75|Actual|Zimmer Biomet|||||f||||t||||||||No||2018-06-01 01:52:44.301646|2018-06-01 01:52:44.301646
NCT00728949|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31||2010-09-14|2015-03-02|2008-08-05|2008-08-06|Estimate||||2010-09-14|2010-09-16|Estimate|2015-03-02|2015-03-20|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|March 2012|Actual|2012-03-31||Interventional|||A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer|Phase 2 Randomized, Multicenter Study of IMC-A12 as a Single Agent or in Combination With Antiestrogens in Postmenopausal Women With Hormone Receptor-Positive Advanced or Metastatic Breast Cancer After Progression on Antiestrogen Therapy|Completed||Phase 2|93|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:52:44.439143|2018-06-01 01:52:44.439143
NCT00728936|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2012-05-15|2008-08-05|2008-08-06|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients|A Phase 1, Multi-center, Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin|Completed||Phase 1|40|Actual|Idera Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 01:52:44.563051|2018-06-01 01:52:44.563051
NCT00728923|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2011-08-29||2012-03-30|2008-08-01|2008-08-06|Estimate|2012-03-30|2012-04-02|Estimate||||2012-03-30|2012-04-02|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)|Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)|Completed||Phase 2|9|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-06-01 01:52:45.63575|2018-06-01 01:52:45.63575
NCT00728910|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|2012-11-29||2016-01-28|2008-08-05|2008-08-06|Estimate|2016-01-28|2016-02-29|Estimate||||2016-01-28|2016-02-29|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CENTAUR||Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study|Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study|Completed||Phase 2|25|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 01:52:45.852114|2018-06-01 01:52:45.852114
NCT00728897|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2017-08-02|2008-08-04|2008-08-06|Estimate|||||||2017-08-02|2017-08-04|Actual|July 2, 2008|Actual|2008-07-02|August 2017|2017-08-31|July 29, 2008|Actual|2008-07-29|July 29, 2008|Actual|2008-07-29||Interventional|||A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.|An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of a 100mg Capsule Compared to Four 25mg GSK598809 Capsules and the Effect of Food on the Pharmacokinetics of the 100mg Capsule in Healthy Male and Female Volunteers.|Completed||Phase 1|16|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 01:52:46.085104|2018-06-01 01:52:46.085104
NCT00728884|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2009-07-07||2015-05-14|2008-08-05|2008-08-06|Estimate|2009-07-07|2009-08-17|Estimate||||2015-05-14|2015-06-08|Estimate|October 2005||2005-10-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|July 2009|Actual|2009-07-31||Observational|PrevailMulti||Study of Certain Prevail Implants Used to Treat All Types of Edentulism in the Maxilla and Mandible|Observational Study of Certain Prevail Implant System in Maxillary and Mandibular Regions|Completed|||162|Actual|Zimmer Biomet|||||f||||t||||||||||2018-06-01 01:52:46.172857|2018-06-01 01:52:46.172857
NCT00728871|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2008-08-05|2008-08-05|2008-08-06|Estimate|||||||2008-08-05|2008-08-06|Estimate|December 2005||2005-12-31|August 2008|2008-08-31|December 2011|Anticipated|2011-12-31|January 2006|Anticipated|2006-01-31||Interventional|||The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis|The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and CIN Patients and Their Prognosis|Unknown status|Recruiting|N/A|600|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 01:52:46.365433|2018-06-01 01:52:46.365433
NCT00728858|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-08-01|2008-08-01|2008-08-06|Estimate|||||||2008-08-01|2008-08-06|Estimate|April 2006||2006-04-30|April 2008|2008-04-30|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Observational|||The Efficacy, Safety and Genetic Polymorphism of Hypoca and Adalat OROS in Hypertensive Patients|An Open-Label, Randomized Clinical Study to Evaluate the Efficacy, Safety and Genetic Polymorphism of Hypoca(Barnidipine)and Adalat OROS(Nifedipine) in Mild to Moderate Hypertensive Patients|Completed|||43|Actual|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     Extract DNA from buffy coat. Test drug concentration in plasma.~   "|||2018-06-01 01:52:46.501047|2018-06-01 01:52:46.501047
NCT00728845|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|2013-09-18||2017-04-17|2008-08-05|2008-08-06|Estimate|2013-09-18|2013-11-25|Estimate||||2017-04-17|2017-05-23|Actual|June 16, 2008|Actual|2008-06-16|April 2017|2017-04-30|December 21, 2010|Actual|2010-12-21|December 21, 2010|Actual|2010-12-21||Interventional|||Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer|(NJ 1508) Modulation of Autophagy With Hydroxychloroquine in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced/Recurrent Non-Small Cell Lung Cancer - A Phase I/II Study|Terminated||Phase 1/Phase 2|8|Actual|Rutgers, The State University of New Jersey||2||Slow accrual|f||||f||||||||||2018-06-01 01:52:46.58527|2018-06-01 01:52:46.58527
NCT00728832|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2008-08-12|2008-08-05|2008-08-06|Estimate|||||||2008-08-12|2008-08-14|Estimate|May 2002||2002-05-31|August 2008|2008-08-31||||February 2003|Actual|2003-02-28||Interventional|||A Pharmacokinetic (PK) Study of Extended-Release Epidural Morphine in Upper Abdominal Surgery|A Phase 1 Study to Evaluate the Effects of Lidocaine/Epinephrine Test Dose Administration on the Pharmacokinetic Profile of a Single Dose of Thoracic Extended-Release Epidural Morphine in Patients Undergoing Major Upper Abdominal Surgery|Completed||Phase 1|39|Actual|EKR Therapeutics, Inc||5|||f||||t||||||||||2018-06-01 01:52:46.988854|2018-06-01 01:52:46.988854
NCT00728819|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2018-03-30||2018-03-30|2008-08-05|2008-08-06|Estimate|2018-03-30|2018-04-27|Actual||||2018-03-30|2018-04-27|Actual|August 2008||2008-08-31|March 2018|2018-03-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters|Peripherally Inserted Central Catheter (PICC) Thrombosis: Reverse Taper Versus Non-tapered Catheters|Completed||N/A|339|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 01:52:47.088655|2018-06-01 01:52:47.088655
NCT00728806|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2015-05-21|2008-08-05|2008-08-06|Estimate|||||||2015-05-21|2015-05-22|Estimate|October 2007||2007-10-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Biomarker for Peritoneal Ultrafiltration Failure|Biomarker for Early Detection and Intervention of Peritoneal Ultrafiltration Failure|Completed|||40|Actual|Sun Yat-sen University|||||f||||t||||||Samples Without DNA|"~     peritoneal tissue will be collected at the time of peritoneal dialysis catheter insertion or~     extubation. Serum and dialysate samples will be collected for protein analysis.~   "|||2018-06-01 01:52:47.29549|2018-06-01 01:52:47.29549
NCT00728793|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2018-02-15|2008-08-01|2008-08-06|Estimate|||||||2018-02-15|2018-02-21|Estimate|August 2008||2008-08-31|September 2015|2015-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors|A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced and Refractory Solid Tumors|Completed||Phase 1|25|Actual|Curis, Inc.|||||f||||f||||||||||2018-06-01 01:52:47.363167|2018-06-01 01:52:47.363167
NCT00728780|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2012-09-27|2008-08-01|2008-08-06|Estimate|||||||2012-09-27|2012-09-28|Estimate|August 2008||2008-08-31|September 2012|2012-09-30||||September 2008|Actual|2008-09-30||Interventional|||Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.||Completed||Phase 1|32|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:52:47.43339|2018-06-01 01:52:47.43339
NCT00728767|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2011-04-13|2008-08-05|2008-08-06|Estimate|||||||2011-04-13|2011-04-14|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|December 2009|Actual|2009-12-31|November 2008|Actual|2008-11-30||Interventional|||Brief Intervention for Heavy Drinkers|Brief Intervention for Heavy Drinkers - a Randomized Controlled Trial|Completed||Phase 3|772|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-06-01 01:52:47.498631|2018-06-01 01:52:47.498631
NCT00728754|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2009-06-26||2017-03-20|2008-08-05|2008-08-06|Estimate|2011-10-11|2011-11-17|Estimate||||2017-03-20|2017-04-17|Actual|March 2005||2005-03-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|July 2007|Actual|2007-07-31||Interventional|Cliffhanger||A Study of Certain Prevail Implants Used for the Preservation of Crestal Bone in Short Fixed Bridge Cases.|A Prospective, Randomized-controlled Multicenter Study of the Osseotite Certain Lateralized Implant in Short-span Fixed Bridge Cases for Preservation of Crestal Bone|Completed||N/A|61|Actual|Zimmer Biomet||2|||f||||t||||||||No||2018-06-01 01:52:47.585911|2018-06-01 01:52:47.585911
NCT00728741|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2017-06-30|2008-08-05|2008-08-06|Estimate|||||||2017-06-30|2017-07-02|Actual|August 1, 2008||2008-08-01|May 26, 2010|2010-05-26|May 26, 2010||2010-05-26|||||Observational|||Brain Activity During Strategic Planning|Functional Neuro-Imaging of Strategy Use During Human Behavior|Completed|||16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:52:47.944681|2018-06-01 01:52:47.944681
NCT00728728|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2016-12-19||2016-12-19|2008-08-05|2008-08-06|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|December 2009||2009-12-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia|Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia|Completed||Phase 2|88|Actual|VA Office of Research and Development||2|||f||||t||||||||Undecided||2018-06-01 01:52:48.046321|2018-06-01 01:52:48.046321
NCT00728715|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-07-31|2008-07-31|2008-08-06|Estimate|||||||2008-07-31|2008-08-06|Estimate|January 2004||2004-01-31|July 2008|2008-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Efficacy of Budesonide-Formoterol in Bronchiectasis|Clinical Efficacy and Safety of Budesonide and Formoterol in the Management of Non-Cystic Fibrosis Bronchiectasis|Completed||N/A|40|Anticipated|Hospital General de Requena||2|||f||||f||||||||||2018-06-01 01:52:48.506236|2018-06-01 01:52:48.506236
NCT00728689|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2009-06-10||2015-06-22|2008-08-05|2008-08-06|Estimate|2010-01-21|2010-02-09|Estimate||||2015-06-22|2015-06-29|Estimate|August 2008||2008-08-31|September 2010|2010-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase I Trial of an Investigational Small Pox Medication|A Phase I Randomized, Double-Blind, Crossover, Exploratory Study of the Pharmacokinetics of a Single Oral Dose of Form I Versus Form V Capsules of the Anti-Orthopoxvirus Compound ST-246® in Fed Normal Healthy Volunteers|Completed||Phase 1|12|Actual|SIGA Technologies||2|||f||||t||||||||||2018-06-01 01:52:48.641096|2018-06-01 01:52:48.641096
NCT00728676|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2013-01-17|2008-08-01|2008-08-06|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2008||2008-08-31|January 2013|2013-01-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|||Study to Evaluate the Effects of Kuvan on Individuals With Phenylketonuria (PKU) With Maladaptive Behaviors|Pilot Study to Evaluate the Effects of Kuvan on Adult Individuals With Phenylketonuria With Measurable Maladaptive Behaviors|Completed|||10|Actual|University of Southern California|||||f||||f||||||||||2018-06-01 01:52:48.960384|2018-06-01 01:52:48.960384
NCT00728663|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2013-04-09|2008-08-05|2008-08-06|Estimate|||||||2013-04-09|2013-04-10|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer|Docetaxel and Cetuximab in Patients With Docetaxel-resistant Hormone-refractory Prostate Cancer (HRPC). A Multicenter Phase II Trial|Completed||Phase 2|35|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-06-01 01:52:49.022864|2018-06-01 01:52:49.022864
NCT00728650|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2012-02-06|2008-08-01|2008-08-06|Estimate|||||||2012-02-06|2012-02-07|Estimate|October 2003||2003-10-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Observational|||A Retrospective Review of Malignant Liver Tumors|A Retrospective Review of Malignant Liver Tumors|Completed|||228|Actual|University of Oklahoma|||1||f||||f||||||||||2018-06-01 01:52:49.13055|2018-06-01 01:52:49.13055
NCT00728637|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2013-05-14|2008-08-04|2008-08-06|Estimate|||||||2013-05-14|2013-05-15|Estimate|January 2005||2005-01-31|May 2013|2013-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|FIT-Heart||Evaluating the Effectiveness of a Family Heart Health Educational Program (The FIT-Heart Study)|Effectiveness of a Family Heart Health Intervention Trial (FIT Heart I)|Completed||N/A|501|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 01:52:49.199767|2018-06-01 01:52:49.199767
NCT00728624|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-04|||2017-03-07|2008-08-05|2008-08-06|Estimate|||||||2017-03-07|2017-03-10|Actual|November 2008||2008-11-30|March 2017|2017-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|EGAST 2008||Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns|Expert Group On Antibiotic Susceptibility Testing [EGAST] 2008: A Non-Interventional, Multicenter In-Vitro Study To Evaluate The Prevalence Of Beta-Lactamase Producing Strains Among Clinical Isolates Obtained From Hospital In-Patients And Comparison Of Antimicrobial Susceptibility Using Disc-Diffusion Method|Completed|||2039|Actual|Pfizer|||||f||||f||||||||||2018-06-01 01:52:49.271225|2018-06-01 01:52:49.271225
NCT00728611|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-03|||2011-07-10|2008-08-05|2008-08-06|Estimate|||||||2011-07-10|2011-07-12|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Preparation Rich in Growth Factors (PRGF) Treatment for Osteoarthritis of the Knee|PRP as a Treatment for Knee Osteoarthritis - Randomized-double-blind-placebo Control Trail.|Completed||Phase 2/Phase 3|60|Anticipated|Meir Medical Center||3|||f||||t||||||||||2018-06-01 01:52:49.364639|2018-06-01 01:52:49.364639
NCT00728598|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2008-08-05|2008-08-05|2008-08-06|Estimate|||||||2008-08-05|2008-08-06|Estimate|January 1998||1998-01-31|August 2008|2008-08-31|December 1998|Actual|1998-12-31|December 1998|Actual|1998-12-31||Observational|||Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis|Vitreous Levels of Patients With Proliferative Diabetic Retinopathy.|Completed|||30|Actual|National Taiwan University Hospital|||3||f||||||||||Samples Without DNA|"~     Vitreous sample and blood sample~   "|||2018-06-01 01:52:49.494774|2018-06-01 01:52:49.494774
NCT00728585|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-05|||2013-05-30|2008-08-05|2008-08-06|Estimate|||||||2013-05-30|2013-05-31|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant|A Group-Wide Double-Blind Randomized Placebo-Controlled Trial of Palifermin to Prevent Chemotherapy and/or Radiotherapy Induced Oral Mucositis in Children Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation|Withdrawn||Phase 2|0|Actual|Children's Oncology Group||2||Withdrawn due to lack of drug supply|f||||f||||||||||2018-06-01 01:52:49.556766|2018-06-01 01:52:49.556766
NCT00728572|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2016-09-14|2008-08-01|2008-08-06|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|July 2009|Actual|2009-07-31|November 2008|Actual|2008-11-30||Interventional|||Logan Basic Technique Measured by Surface Electromyography (EMG)|The Effect of Logan Basic Technique Apex Contact Adjustment on the Motor Recruitment Pattern in the Erector Spinae.|Completed||Phase 1/Phase 2|45|Actual|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 01:52:49.656847|2018-06-01 01:52:49.656847
NCT00728559|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2011-02-02|2008-08-05|2008-08-06|Estimate|||||||2011-02-02|2011-02-03|Estimate|September 2010||2010-09-30|August 2008|2008-08-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy|Evaluation of Local Anlagesia Into the Trocar Site During Operative Laparosocpy|Unknown status|Not yet recruiting|N/A|120|Anticipated|The Baruch Padeh Medical Center, Poriya||3|||f||||t||||||||||2018-06-01 01:52:49.742899|2018-06-01 01:52:49.742899
NCT00728546|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2012-12-26|2008-08-05|2008-08-06|Estimate|||||||2012-12-26|2012-12-27|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||NAT2 in Re-challenge of INH in Patients With Hepatitis|The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis|Unknown status|Recruiting|Phase 4|100|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 01:52:49.844266|2018-06-01 01:52:49.844266
NCT00728533|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2011-03-17|2008-08-05|2008-08-06|Estimate|||||||2011-03-17|2011-03-18|Estimate||||March 2011|2011-03-31||||||||Interventional|||Open-Label, Randomised Parallel-Group Study|The Rationale of the Study is to Demonstrate That Degarelix Given at Three-month Dosing Intervals Will Produce and Maintain Androgen Deprivation in Prostate Cancer Patients Through Immediate and Prolonged Testosterone Suppression, and to Provide Confirmatory Evidence of the Safety of Degarelix.|Withdrawn||Phase 3|0|Actual|Ferring Pharmaceuticals||2||Terminated due to awaiting data from Phase II study.|f||||t||||||||||2018-06-01 01:52:49.932157|2018-06-01 01:52:49.932157
NCT00722618|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2016-11-22|2008-07-24|2008-07-25|Estimate|||||||2016-11-22|2016-11-25|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Communication With in Vitro Fertilization (IVF) Patients About Risks|Improving Communication With IVF Patients About Risks Such as Multiple Births|Completed||N/A|264|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 01:54:33.724533|2018-06-01 01:54:33.724533
NCT00728520|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-08-05|2008-08-05|2008-08-06|Estimate|||||||2008-08-05|2008-08-06|Estimate|July 2008||2008-07-31|August 2008|2008-08-31|June 2012|Anticipated|2012-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy|A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Kansas City Veteran Affairs Medical Center|||||f||||t||||||||||2018-06-01 01:52:50.016411|2018-06-01 01:52:50.016411
NCT00728507|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2016-08-03||2017-03-08|2008-07-31|2008-08-05|Estimate|2017-03-08|2017-04-20|Actual||||2017-03-08|2017-04-20|Actual|November 2009||2009-11-30|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis|A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis|Terminated||Phase 2|121|Actual|Johns Hopkins University||2||Funding withdrawn|f||||t||||||||||2018-06-01 01:52:50.113444|2018-06-01 01:52:50.113444
NCT00728494|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2008-12-05||2015-07-20|2008-07-31|2008-08-05|Estimate|2009-07-07|2009-08-19|Estimate||||2015-07-20|2015-07-28|Estimate|October 2005||2005-10-31|July 2015|2015-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)|Evaluation of Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron / Rebetol in Conjunction With a Patient Assistance Program - Non Interventional Observational Study.|Completed|||99|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:52:50.355241|2018-06-01 01:52:50.355241
NCT00728481|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2012-10-05||2016-01-12|2008-08-04|2008-08-05|Estimate|2012-11-08|2012-12-06|Estimate||||2016-01-12|2016-01-14|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis|The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis|Completed||Phase 2/Phase 3|51|Actual|Mayo Clinic|"The index endoscopy was obtained solely for clinical reasons and could have been done as long as 18 months prior to study enrollment.~A single question on the dysphagia questionnaire was used to assess dysphagia symptom response."|2|||f||||t||||||||||2018-06-01 01:52:50.712997|2018-06-01 01:52:50.712997
NCT00728468|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2015-07-17||2017-04-21|2008-08-04|2008-08-05|Estimate|2017-04-21|2017-08-02|Actual||||2017-04-21|2017-08-02|Actual|September 2008||2008-09-30|April 2017|2017-04-30|July 2014|Actual|2014-07-31|April 2011|Actual|2011-04-30||Interventional|||A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients|A Phase 1 Open Label, Single Arm Trial To Evaluate The Effect Of Pf-00299804 On The Pharmacokinetics Of Dextromethorphan In Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|16|Actual|Pfizer|Dextromethorphan AUCinf and t1/2 results not reported as data did not support calculation since levels of dextromethorphan were not tracked long enough for reliable estimation.|1|||f||||||||||||||2018-06-01 01:52:51.124698|2018-06-01 01:52:51.124698
NCT00728455|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2014-10-16|2008-07-31|2008-08-05|Estimate|||||||2014-10-16|2014-10-17|Estimate|July 2008||2008-07-31|October 2014|2014-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers|Single Subcutaneous Dose Rising Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of NNC 0070-0002-0349 in Overweight/Obese Male Subjects|Withdrawn||Phase 1|0|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-06-01 01:52:51.496004|2018-06-01 01:52:51.496004
NCT00728442|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2013-09-02|2008-07-31|2008-08-05|Estimate|||||||2013-09-02|2013-09-04|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|OncoDoc2||Impact of OncoDoc2 on Guideline Compliance in the Management of Breast Cancer|Impact of the OncoDoc2 Decision Support System on Compliance of Multidisciplinary Staff Meeting Decisions With Clinical Practice Guidelines in the Management of Non-metastatic Breast Cancer.|Completed||N/A|816|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:52:51.567939|2018-06-01 01:52:51.567939
NCT00728429|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-02|||2017-05-25|2008-08-02|2008-08-05|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2008||2008-06-30|February 2017|2017-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Aerobic Exercise in Patients Receiving Chemotherapy for Cancer|CCCWFU 99108 - Effect of Exercise Training in Patients Receiving Anthracycline Drugs - A Pilot Study|Terminated||N/A|1|Actual|Wake Forest University Health Sciences||2||slow accrual|f||||f|f|f||||||||2018-06-01 01:52:51.633187|2018-06-01 01:52:51.633187
NCT00728416|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2009-10-09||2016-07-27|2008-07-31|2008-08-05|Estimate|2009-10-09|2009-11-19|Estimate||||2016-07-27|2016-09-16|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 3|333|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:52:51.712748|2018-06-01 01:52:51.712748
NCT00728403|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2015-07-30|2008-08-04|2008-08-05|Estimate|||||||2015-07-30|2015-07-31|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes|Long Term Metabolic and Therapeutic Effects of Combined Treatment of American Ginseng (Panax Quinquefolius L.) Extract and Korean Red Ginseng (Steamed Panax C.A. Meyer) Extract in the Treatment of Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|St. Michael's Hospital, Toronto||3|||f||||f||||||||||2018-06-01 01:52:52.042959|2018-06-01 01:52:52.042959
NCT00728390|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2013-10-07|2008-08-04|2008-08-05|Estimate|||||||2013-10-07|2013-10-08|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|August 2011|Actual|2011-08-31||Interventional|||A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks|Phase 1 Targeted Combination Trial Of PF-00299804 And CP-751,871 In Patients With Advanced Solid Tumors|Completed||Phase 1|74|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:52:52.125785|2018-06-01 01:52:52.125785
NCT00728377|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-02|||2016-10-24|2008-08-02|2008-08-05|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||An Exercise Intervention to Prevent Gestational Diabetes|An Exercise Intervention to Prevent Recurrent GDM|Completed||N/A|488|Actual|University of Massachusetts, Amherst||2|||f||||t||||||||||2018-06-01 01:52:52.224344|2018-06-01 01:52:52.224344
NCT00728364|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2012-04-10|2008-07-31|2008-08-05|Estimate|||||||2012-04-10|2012-04-12|Estimate|October 2008||2008-10-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Observational|||Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy|A Case Finding Study for Anderson-Fabry Disease Among Patients With Chronic Kidney Disease Not on Renal Replacement Therapy|Completed|||4353|Actual|Klinikum Wels-Grieskirchen|||||f||||f||||||||||2018-06-01 01:52:52.324297|2018-06-01 01:52:52.324297
NCT00728351|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31||2013-01-02|2013-01-02|2008-08-04|2008-08-05|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-02|2013-01-04|Estimate|June 2008||2008-06-30|January 2013|2013-01-31||||February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)|A Multicenter, Double-blind, Randomized Study to Compare the Efficacy of 24 Weeks Treatment With Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) Versus Metformin Monotherapy (1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.|Completed||Phase 3|317|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:52:52.410584|2018-06-01 01:52:52.410584
NCT00728338|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-08-07|2008-08-04|2008-08-05|Estimate|||||||2008-08-07|2008-08-08|Estimate|June 2003||2003-06-30|August 2008|2008-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides|Effect of Docosahexenoic Acid (22:6n-3, DHA) Supplementation on Risk Factors for Cardiovascular Disease in Hyperlipidemic Men|Completed||N/A|40|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 01:52:52.564604|2018-06-01 01:52:52.564604
NCT00728325|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2013-12-04|2008-07-31|2008-08-05|Estimate|||||||2013-12-04|2013-12-05|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Impact of Supported Employment Versus Standard Vocational Rehabilitation in Veterans With Post-traumatic Stress Disorder|The Impact of Supported Employment Versus Standard Vocational Rehabilitation in Veterans With PTSD|Unknown status|Active, not recruiting|N/A|100|Anticipated|Tuscaloosa Research & Education Advancement Corporation||2|||f||||f||||||||||2018-06-01 01:52:52.651181|2018-06-01 01:52:52.651181
NCT00728312|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2015-06-25|2008-08-04|2008-08-05|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 2009||2009-08-31|June 2015|2015-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial|Double-blind Placebo Controlled Trial of Aripiprazole for Amphetamine|Withdrawn||Phase 4|0|Actual|VA Office of Research and Development||2||PI left the VA.|f||||f||||||||||2018-06-01 01:52:52.748718|2018-06-01 01:52:52.748718
NCT00728299|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-08-04|2008-08-04|2008-08-05|Estimate|||||||2008-08-04|2008-08-05|Estimate|September 2003||2003-09-30|August 2008|2008-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness|The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness|Completed||N/A|384|Actual|Radiant Research||2|||f||||f||||||||||2018-06-01 01:52:52.820799|2018-06-01 01:52:52.820799
NCT00728286|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2015-10-07|2008-08-01|2008-08-05|Estimate|||||||2015-10-07|2015-10-12|Estimate|October 2008||2008-10-31|October 2015|2015-10-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Observational|||Assessment of Thrombogenicity in Acute Coronary Syndrome|Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model|Completed|||90|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||t||||||||||2018-06-01 01:52:52.894154|2018-06-01 01:52:52.894154
NCT00728273|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2008-12-03|2008-07-31|2008-08-05|Estimate|||||||2008-12-03|2008-12-04|Estimate|January 2007||2007-01-31|November 2008|2008-11-30|June 2007|Actual|2007-06-30|January 2007|Actual|2007-01-31||Interventional|||Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming in Vietnamese School Children|Efficacy of Multiple Micronutrient Fortified Biscuits and Deworming on Reducing Anemia Prevalence, and Improving Micronutrient Status, Cognitive Function, and Growth in Vietnamese School Children|Completed||Phase 2|510|Actual|Neys-van Hoogstraten Foundation, The Netherlands||4|||f||||f||||||||||2018-06-01 01:52:52.973469|2018-06-01 01:52:52.973469
NCT00728260|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2015-01-07||2015-02-10|2008-07-31|2008-08-05|Estimate|2015-02-10|2015-02-12|Estimate||||2015-02-10|2015-02-12|Estimate|July 2005||2005-07-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational||Children 2 through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period.|36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds|Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Recipients 2 to 10 Years of Age.|Completed|||1421|Actual|Sanofi|||1||f||||f||||||||||2018-06-01 01:52:53.083261|2018-06-01 01:52:53.083261
NCT00728247|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2010-09-17|2008-08-04|2008-08-05|Estimate|||||||2010-09-17|2010-09-20|Estimate|July 2008||2008-07-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Objective Kinematic Correlates of Palpatory Diagnosis|Objective Kinematic Correlates of Palpatory Diagnosis|Completed||N/A|10|Anticipated|Michigan State University|||||f||||f||||||||||2018-06-01 01:52:53.347802|2018-06-01 01:52:53.347802
NCT00728234|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-08-06|2008-07-31|2008-08-05|Estimate|||||||2008-08-06|2008-08-07|Estimate|January 2000||2000-01-31|July 2008|2008-07-31|July 2006|Actual|2006-07-31|December 2002|Actual|2002-12-31||Observational|||Analysis of Correlation of Amplitude-Integrated EEG and Neurodevelopmental Outcome in Preterm Infants|Analysis of Amplitude-Integrated Electroencephalography and Its Predictive Value for Neurodevelopmental Outcome in Preterm Infants Born Below 30 Weeks Gestational Age|Completed|||284|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-06-01 01:52:53.414149|2018-06-01 01:52:53.414149
NCT00728221|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2017-01-05|2008-08-01|2008-08-05|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2007||2007-11-30|January 2017|2017-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|ESGC||Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation|Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation|Completed||Phase 2|17|Actual|St. Michael's Hospital, Toronto||4|||f||||f||||||||||2018-06-01 01:52:53.493105|2018-06-01 01:52:53.493105
NCT00728208|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2017-07-11|2008-08-01|2008-08-05|Estimate|||||||2017-07-11|2017-07-13|Actual|July 28, 2008|Actual|2008-07-28|July 2017|2017-07-31|December 29, 2008|Actual|2008-12-29|December 29, 2008|Actual|2008-12-29||Interventional|||GSK372475 PK Study in Healthy Volunteers|A Placebo-controlled, Single-blind, Randomised, Parallel Group, 28-day Repeat Dose Study to Investigate the Tolerability, Safety and Steady State Pharmacokinetics of GSK372475 in Healthy Young and Elderly, Male and Female Subjects|Completed||Phase 1|66|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:52:53.582306|2018-06-01 01:52:53.582306
NCT00714727|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-07-11|2008-07-11|2008-07-14|Estimate|||||||2013-07-11|2013-07-12|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SPAMDA||Set Point Acupuncture for Migraines Using a Digital Assistant|Set Point Acupuncture for Migraines Using a Digital Assistant|Completed||Phase 1|50|Actual|Memorial Medical Center||1|||f||||f||||||||||2018-06-01 01:56:55.463824|2018-06-01 01:56:55.463824
NCT00728195|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2014-03-25|2008-07-31|2008-08-05|Estimate|||||||2014-03-25|2014-03-26|Estimate|November 2008||2008-11-30|March 2014|2014-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schizophrenia|Completed||Phase 2|498|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||5|||f||||t||||||||||2018-06-01 01:52:53.668375|2018-06-01 01:52:53.668375
NCT00728182|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2013-05-08||2013-08-09|2008-08-04|2008-08-05|Estimate|2013-08-09|2013-10-17|Estimate||||2013-08-09|2013-10-17|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|ENACT||Evaluating Neuroprotection in Aneurysm Coiling Therapy|A Phase II, Multicenter, Randomized, Fasting, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Male and Female Patients Undergoing Endovascular Repair of Brain Aneurysms|Completed||Phase 2|185|Actual|NoNO Inc.||2|||f||||t||||||||||2018-06-01 01:52:53.839797|2018-06-01 01:52:53.839797
NCT00728169|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2009-09-17|2008-07-31|2008-08-05|Estimate|||||||2009-09-17|2009-09-18|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Developing Asthma Interventions Using Community Based Research|Feasibility of Developing an Effective Asthma Intervention Using CBPR Methods|Completed|||62|Anticipated|Meharry Medical College|||||f||||t||||||||||2018-06-01 01:52:54.717196|2018-06-01 01:52:54.717196
NCT00728156|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2015-10-07|2008-08-04|2008-08-05|Estimate|||||||2015-10-07|2015-10-12|Estimate|August 2009||2009-08-31|October 2015|2015-10-31|April 2012|Actual|2012-04-30|December 2010|Actual|2010-12-31||Interventional|||Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)|Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease|Completed||Phase 4|90|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 01:52:54.851772|2018-06-01 01:52:54.851772
NCT00728143|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2008-08-04|2008-08-04|2008-08-05|Estimate|||||||2008-08-04|2008-08-05|Estimate|August 1989||1989-08-31|August 2008|2008-08-31|November 1989|Actual|1989-11-30|November 1989|Actual|1989-11-30||Interventional|||Blood Glucose Response to Highly Viscous Polysaccharide Enriched Biscuits in Healthy and Diabetic Subjects|Therapeutic Trials of Low Glycemic Index Foods and Dietary Fiber in the Management of Diabetes, Hyperlipidemia and Renal Disease|Completed||N/A|19|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 01:52:54.964744|2018-06-01 01:52:54.964744
NCT00728130|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2013-05-29||2014-12-12|2008-08-04|2008-08-05|Estimate|2013-05-29|2013-07-29|Estimate||||2014-12-12|2015-01-05|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients|Prospective Study to Assess the Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Patients With Carcinoma of the Upper Aerodigestive Tract|Completed||Phase 1|22|Actual|Southern Illinois University||1|||f||||f||||||||||2018-06-01 01:52:55.072752|2018-06-01 01:52:55.072752
NCT00728117|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2012-11-08|2008-08-04|2008-08-05|Estimate|||||||2012-11-08|2012-11-09|Estimate|July 2008||2008-07-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants|Should Very Low Birth Weight Infants Receive Enteral Nutrition During Indomethacin or Ibuprofen Treatment of a Patent Ductus Arteriosus? A Multi-Center Randomized Controlled Trial|Completed||N/A|177|Actual|University of California, San Francisco||4|||f||||t||||||||||2018-06-01 01:52:55.361358|2018-06-01 01:52:55.361358
NCT00728104|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2017-02-03|2008-08-04|2008-08-05|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2007||2007-10-31|February 2017|2017-02-28|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||The Use of L-Carnitine And CoQ10 Supplements In the Treatment of Cyclic Vomiting Syndrome (CVS)|Co-Enzyme Q10, L-Carnitine and Amitriptyline Usage in Cyclic Vomiting Syndrome (CVS): A Research Study|Withdrawn|||0|Actual|Medical College of Wisconsin|||4|No funding|f||||f||||||||||2018-06-01 01:52:55.477075|2018-06-01 01:52:55.477075
NCT00728091|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31||2016-04-26|2016-04-26|2008-08-04|2008-08-05|Estimate||||2016-04-26|2016-05-26|Estimate|2016-04-26|2016-05-26|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|AQUARIST1||A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia|A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)|Terminated||Phase 3|2|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 01:52:55.556511|2018-06-01 01:52:55.556511
NCT00728078|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2009-02-06|2008-07-31|2008-08-05|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|July 2011|Anticipated|2011-07-31|July 2009|Anticipated|2009-07-31||Interventional|LDT-RFA||Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:52:55.656728|2018-06-01 01:52:55.656728
NCT00728065|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2009-02-17|2008-08-04|2008-08-05|Estimate|||||||2009-02-17|2009-02-18|Estimate|December 2007||2007-12-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional|||The Effects of Salvia Hispanica-Enriched Foods on Glycemic and Insulinemic Responses and Subjective Satiety|The Effects of Salvia Hispanica-Enriched Foods on Glycemic and Insulinemic Responses and Subjective Satiety|Completed||N/A|30|Anticipated|St. Michael's Hospital, Toronto||10|||f||||f||||||||||2018-06-01 01:52:55.763683|2018-06-01 01:52:55.763683
NCT00728052|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2017-08-01|2008-08-01|2008-08-05|Estimate|||||||2017-08-01|2017-08-03|Actual|June 9, 2008|Actual|2008-06-09|August 2017|2017-08-31|August 19, 2008|Actual|2008-08-19|August 19, 2008|Actual|2008-08-19||Interventional|||A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers|A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses (75mg and Above) of GSK598809 in Otherwise Healthy Smokers|Completed||Phase 1|18|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 01:52:55.863205|2018-06-01 01:52:55.863205
NCT00728039|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2017-10-23|2008-08-04|2008-08-05|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2007||2007-04-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Quality of Life (QOL), Coping and Psychological Symptoms in Children and Adolescents With Cyclic Vomiting Syndrome|Quality of Life, Coping and Psychological Symptoms in Children and Adolescents With Cyclic Vomiting Syndrome|Completed|||61|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 01:52:55.955424|2018-06-01 01:52:55.955424
NCT00728026|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2017-08-10|2008-08-04|2008-08-05|Estimate|||||||2017-08-10|2017-08-14|Actual|June 2008||2008-06-30|August 2017|2017-08-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Observational|||Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea|Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome, Irritable Bowel Syndrome, Postural Orthostatic Tachycardia Syndrome, Functional Abdominal Pain or Chronic Nausea|Completed|||19|Actual|Medical College of Wisconsin|||5||f||||f||||||||||2018-06-01 01:52:56.016321|2018-06-01 01:52:56.016321
NCT00728013|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2008-08-22|2008-08-04|2008-08-05|Estimate|||||||2008-08-22|2008-08-25|Estimate|December 2006||2006-12-31|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|December 2008|Anticipated|2008-12-31||Interventional|CHILLAS||China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome|China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome|Unknown status|Recruiting|N/A|1600|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-06-01 01:52:56.086738|2018-06-01 01:52:56.086738
NCT00728000|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2009-04-24|2008-07-31|2008-08-05|Estimate|||||||2009-04-24|2009-04-27|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|August 2010|Anticipated|2010-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma|Phase II Study Of Neoadjuvant Chemotherapy With Gemcitabine, Oxaliplatin And Erlotinib (Gemoxt) In Borderline Resectable Pancreatic Adenocarcinoma|Withdrawn||Phase 2|20|Anticipated|University of Cincinnati||1||study withdrawn due to lack of enrollment|f||||f||||||||||2018-06-01 01:52:56.168816|2018-06-01 01:52:56.168816
NCT00727987|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2013-05-22|2008-08-04|2008-08-05|Estimate|||||||2013-05-22|2013-05-23|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Study of Golimumab (CNTO 148) Administered in Combination With Methotrexate (MTX) in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|269|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 01:52:56.254155|2018-06-01 01:52:56.254155
NCT00727974|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2018-03-22|2008-08-04|2008-08-05|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2008||2008-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines|Genetic Analysis of Children With Cyclic Vomiting Syndrome and Migraines|Recruiting|||880|Anticipated|Medical College of Wisconsin|||2||f||||t||||||Samples With DNA|"~     5 ml of blood will be drawn through venipucture from the study subjects, their biological~     parents and siblings when available. In addition, 4 ml of blood will be drawn for serologic~     testing.~   "|||2018-06-01 01:52:56.404784|2018-06-01 01:52:56.404784
NCT00727961|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-01-29||2017-05-12|2008-07-31|2008-08-05|Estimate|2009-06-04|2009-07-16|Estimate||||2017-05-12|2017-06-08|Actual|November 9, 2004|Actual|2004-11-09|May 2017|2017-05-31|January 10, 2008|Actual|2008-01-10|January 10, 2008|Actual|2008-01-10||Interventional|||A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)|Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy.|Completed||Phase 4|58|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:52:56.48533|2018-06-01 01:52:56.48533
NCT00727948|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2011-04-21|2008-07-30|2008-08-04|Estimate|||||||2011-04-21|2011-04-22|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy|The Impact of the Anti-Platelet Agent Aspirin on Angiogenesis Proteins in Women With Breast Cancer|Unknown status|Active, not recruiting|Early Phase 1|35|Anticipated|University of Vermont|||||f||||t||||||||||2018-06-01 01:52:56.729175|2018-06-01 01:52:56.729175
NCT00727935|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2008-08-04|2008-08-01|2008-08-04|Estimate|||||||2008-08-04|2008-08-05|Estimate|October 2006||2006-10-31|August 2008|2008-08-31||||July 2007|Actual|2007-07-31||Interventional|LiRoPep||Comparison Of The Analgesia Obtained By Infiltration For The Joinings Of Episiotomies (Liropep)|Comparison Of The Analgesia Obtained By Infiltration Of Lidocaïne 1% And Ropivacaïne 0,75% Versus Placebo For The Joinings Of Episiotomies Among Parturients Under Epidural Analgesia|Completed||Phase 4|165|Actual|University Hospital, Angers|||||f||||t||||||||||2018-06-01 01:52:56.809402|2018-06-01 01:52:56.809402
NCT00727922|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2011-12-15|2008-08-01|2008-08-04|Estimate|||||||2011-12-15|2011-12-16|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|April 2011|Actual|2011-04-30|January 2010|Actual|2010-01-31||Interventional|MnDPDP-K04||Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity|Evaluation of Mangafodipir Protective Activity Against Oxaliplatin Neurotoxicity|Completed||Phase 2|23|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:52:56.884949|2018-06-01 01:52:56.884949
NCT00727909|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2013-09-09||2014-06-04|2008-07-30|2008-08-04|Estimate|2014-05-09|2014-06-03|Estimate||||2014-06-04|2014-06-10|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||All Study Participants|Evaluation of Open-canal Behind-the-Ear Hearing Aids and Traditional In-the-ear Hearing Aids.|Evaluation of Open-Ear Canal and Traditional Custom-Fit Hearing Aids|Completed||N/A|290|Actual|VA Office of Research and Development|No limitations or caveats to report.|1|||f||||f||||||||||2018-06-01 01:52:56.975614|2018-06-01 01:52:56.975614
NCT00727896|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2011-06-24|2008-08-01|2008-08-04|Estimate|||||||2011-06-24|2011-06-27|Estimate|August 2008||2008-08-31|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||"Information Technology Methodology for Patient Motivation in Diabetes Management."|"Reinforcement of Adherence to Prescription Recommendations in Diabetic Patients Using Short Message Service (SMS)- A Pilot Study"|Completed||Phase 1|200|Anticipated|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals||2|||f||||t||||||||||2018-06-01 01:52:57.175783|2018-06-01 01:52:57.175783
NCT00727883|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2010-12-09|2008-08-01|2008-08-04|Estimate|||||||2010-12-09|2010-12-10|Estimate|July 2007||2007-07-31|December 2010|2010-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|SOSTA||Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients|Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients|Completed|||190|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:52:57.248877|2018-06-01 01:52:57.248877
NCT00727519|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-27|||2010-03-22|2008-07-31|2008-08-04|Estimate|||||||2010-03-22|2010-03-23|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|||||Interventional|||The Effect of Pomegranate Juice on Oxidative Stress in Hemodialysis Patients|A Randomized Clinical Trial for Estimating the Effects of Pomegranate Juice Consumption by Hemodialysis Patients on Oxidative Stress, Infections, Cardiovascular Events and Mortality|Completed||Phase 3|||Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-06-01 01:53:04.145267|2018-06-01 01:53:04.145267
NCT00727870|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2012-03-01|2008-08-01|2008-08-04|Estimate|||||||2012-03-01|2012-03-02|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|June 2012|Anticipated|2012-06-30|October 2011|Actual|2011-10-31||Interventional|||Evaluation of Preferences of Consumers and Clinicians for the Management of Shave Biopsy Sites With a PolyMem Formulation Dressing or Current Standard of Care.|A Single Site, Three Arm, Open Label Comparative Preference Study to Evaluate the Preference of Consumers and Health Care Professionals for the Use of Shapes by PolyMem Wound Dressings and Shapes by PolyMem Silver Wound Dressings, Each Compared to Antibiotic Ointment Covered With a Band-aid Type Dressing (Current Standard of Practice) and to Each Other in the Post-biopsy Management of Shave Biopsies. Each Participant Serves as Own Control. A Blinded Third Party Physician Will Evaluate and Compare the Wounds Based on Photos Taken at the Various Follow-up Points..|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|Ferris Mfg. Corp.||3|||f||||f||||||||||2018-06-01 01:52:58.306433|2018-06-01 01:52:58.306433
NCT00727857|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-08-28||2011-07-27|2008-07-30|2008-08-04|Estimate|2010-02-15|2010-03-09|Estimate||||2011-07-27|2011-07-29|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.|A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone HCl Monotherapy and to Metformin HCl Monotherapy in the Treatment of Subjects With Type 2 Diabetes|Completed||Phase 3|600|Actual|Takeda||3|||f||||f||||||||||2018-06-01 01:52:58.474502|2018-06-01 01:52:58.474502
NCT00727844|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|2013-09-10||2016-02-12|2008-08-01|2008-08-04|Estimate|2014-02-21|2014-02-24|Estimate||||2016-02-12|2016-03-14|Estimate|July 2008||2008-07-31|May 2014|2014-05-31|November 2014|Actual|2014-11-30|October 2012|Actual|2012-10-31||Interventional||2 patients excluded in immediate start group before receiving any linezolid owing to baseline neuropathy|Linezolid to Treat Extensively-Drug Resistant Tuberculosis|A Phase 2a, Randomized, 2-Arm, Open-Label, Clinical Trial of the Efficacy of Linezolid Combined With Antituberculous Therapy in Subjects With Extensively Drug-Resistant (XDR) Pulmonary Tuberculosis|Completed||Phase 2|41|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Small sample size|2|||f||||t||||||||||2018-06-01 01:52:59.913862|2018-06-01 01:52:59.913862
NCT00727831|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2014-01-24|2008-08-01|2008-08-04|Estimate|||||||2014-01-24|2014-01-27|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|Phase I Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients With Primary Central Nervous Lymphoma (PCNSL)|Completed||Phase 1/Phase 2|4|Actual|University College, London|||||f||||t||||||||||2018-06-01 01:53:00.27555|2018-06-01 01:53:00.27555
NCT00727818|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-07-31|2008-07-31|2008-08-04|Estimate|||||||2008-07-31|2008-08-04|Estimate|May 2006||2006-05-31|July 2008|2008-07-31|February 2007||2007-02-28|||||Interventional|||A Split-Blind Clinical Investigation to Compare the Performance and Safety of Inion GTR™ Biodegradable Membrane System to Resorbable Bilayer Bio-Gide®-Membrane of Geistlich Biomaterials in Enhancing Bone Regeneration After Removal of Wisdom Teeth.||Completed||Phase 4|||University of Zurich|||||f||||||||||||||2018-06-01 01:53:00.364294|2018-06-01 01:53:00.364294
NCT00727805|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2011-10-04|2008-08-01|2008-08-04|Estimate|||||||2011-10-04|2011-10-05|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:53:00.419586|2018-06-01 01:53:00.419586
NCT00727792|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2018-01-22|2008-08-01|2008-08-04|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2009||2009-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams|Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams|Enrolling by invitation||N/A|100|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 01:53:00.461468|2018-06-01 01:53:00.461468
NCT00727779|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2015-02-13|2008-07-31|2008-08-04|Estimate|||||||2015-02-13|2015-02-16|Estimate|January 2008||2008-01-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome|Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome|Completed||N/A|50|Actual|East Tennessee State University||2|||f||||t||||||||||2018-06-01 01:53:00.54655|2018-06-01 01:53:00.54655
NCT00727766|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2014-11-10|2008-07-30|2008-08-04|Estimate|||||||2014-11-10|2014-11-11|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|September 2012|Actual|2012-09-30||Interventional|||Oral Clofarabine for Acute Myeloid Leukemia|Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia|Completed||Phase 1|25|Actual|Washington University School of Medicine||6|||f||||t||||||||||2018-06-01 01:53:00.636772|2018-06-01 01:53:00.636772
NCT00727753|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2015-05-27|2008-08-01|2008-08-04|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Observational|||VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)|Effects of Vascular Endothelial Growth Factor Antagonism With Ranibizumab or Bevacizumab in Patients With Neovascular Macular Degeneration|Completed|||54|Actual|University of Zurich|||3||f||||f||||||||||2018-06-01 01:53:00.736919|2018-06-01 01:53:00.736919
NCT00727740|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2016-08-24||2016-11-23|2008-07-31|2008-08-04|Estimate|2016-11-23|2017-01-18|Estimate||||2016-11-23|2017-01-18|Estimate|August 2005||2005-08-31|November 2016|2016-11-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis|A Prospective, Multicenter, Randomized, Double-blind Controlled Study to Determine Whether a Single Dose of Intraduodenal Indomethacin Can Decrease the Incidence and Severity of Post-ERCP Pancreatitis|Completed||N/A|117|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:53:00.826158|2018-06-01 01:53:00.826158
NCT00727727|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2009-02-24|2008-08-01|2008-08-04|Estimate|||||||2009-02-24|2009-02-25|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)|Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.|Completed|||750|Anticipated|Desitin Arzneimittel GmbH|||1||f||||f||||||||||2018-06-01 01:53:01.082868|2018-06-01 01:53:01.082868
NCT00727714|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2015-11-17||2016-04-13|2008-08-01|2008-08-04|Estimate|2016-04-13|2016-05-20|Estimate||||2016-04-13|2016-05-20|Estimate|April 2008||2008-04-30|April 2016|2016-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|LIS||Lung Function and Inflammatory Markers in Cement Dust Exposed Workers: A Cross-shifts Study|Circulating Inflammatory Markers, Exhaled NO and Lung Function in Cement Production Workers; a Cross-shifts Study|Completed|||95|Actual|Sykehuset Telemark|||||f||||f||||||Samples With DNA|"~     Whole blood serum~   "|No|The individual data is no longer available, due to regulations in Norway requiering individual data to be deleted 5 years after the study was compleeted.|2018-06-01 01:53:01.18395|2018-06-01 01:53:01.18395
NCT00727701|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2015-06-25|2008-07-30|2008-08-04|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2008||2008-07-31|June 2015|2015-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of Individualized Wound Prevention Instruction to Prevent Venous Ulcer Development|Does Use of a Wound After-care Summary for Patients With a History of Venous Ulcers Lower Recurrence Rate?|Terminated||Phase 1|72|Anticipated|VA Office of Research and Development||3||"Study delayed for over a year by research shutdown at Seattle VA and other issues. Study~   designer moved to Ann Arbor in the interim, so the study was closed."|f||||f||||||||||2018-06-01 01:53:01.428948|2018-06-01 01:53:01.428948
NCT00727688|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2012-12-19|2008-08-01|2008-08-04|Estimate|||||||2012-12-19|2012-12-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:53:01.504063|2018-06-01 01:53:01.504063
NCT00727675|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2016-06-28|2008-08-01|2008-08-04|Estimate|||||||2016-06-28|2016-06-29|Estimate|August 2008||2008-08-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|CPODAT||Chronic Pain and Opioid Dependence Assessment and Treatment|Chronic Pain and Opioid Dependence Assessment and Treatment|Completed||N/A|15|Actual|Yale University||1|||f||||f||||||||||2018-06-01 01:53:01.549823|2018-06-01 01:53:01.549823
NCT00727662|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2015-04-13|2008-07-31|2008-08-04|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue|Iyengar Yoga for Breast Cancer Survivors With Persistent Fatigue|Completed||N/A|72|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 01:53:01.651967|2018-06-01 01:53:01.651967
NCT00727649|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2015-01-23||2015-03-18|2008-08-01|2008-08-04|Estimate|2015-03-18|2015-04-01|Estimate||||2015-03-18|2015-04-01|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|FIRM||Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence|Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence|Completed||Phase 2/Phase 3|80|Actual|VA Office of Research and Development|Please note that the data on those lost to follow-up limits our ability to conclude differences between the two interventions.|2|||f||||f||||||||||2018-06-01 01:53:01.764138|2018-06-01 01:53:01.764138
NCT00727636|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2011-05-03||2011-05-03|2008-08-01|2008-08-04|Estimate|2011-05-03|2011-05-27|Estimate||||2011-05-03|2011-05-27|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional|HPV||Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy|Pilot Study of Immunogenicity and Tolerability to the Quadrivalent Human Papillomavirus Virus-like Particle (VLP) Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy Compared to Healthy Children and Youth Adult Females|Completed||N/A|53|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 01:53:02.141026|2018-06-01 01:53:02.141026
NCT00727623|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-08-07|2008-07-30|2008-08-04|Estimate|||||||2016-08-07|2016-08-09|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Mortality Analysis of ST Elevation Myocardial Infarction (STEMI) Patients in Belgium|Prospective Observational Study to Assess Predictors of in Hospital Mortality in STEMI Patients Admitted in Belgian Hospitals|Recruiting|||5000|Anticipated|Universiteit Antwerpen|||||f||||f||||||||||2018-06-01 01:53:02.468693|2018-06-01 01:53:02.468693
NCT00727610|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2011-02-15|2008-07-30|2008-08-04|Estimate|||||||2011-02-15|2011-02-17|Estimate|May 2008||2008-05-31|February 2011|2011-02-28||||||||Observational|||Development of a Screening Strategy for Community-based Adverse Drug Related Events in the Emergency Department|Development of a Screening Strategy for Community-based Adverse Drug Related Events in the Emergency Department|Completed|||1588|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 01:53:02.554378|2018-06-01 01:53:02.554378
NCT00727597|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2012-08-28||2013-06-28|2008-08-01|2008-08-04|Estimate|2013-06-28|2013-07-02|Estimate||||2013-06-28|2013-07-02|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|SUPPoRT||A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT|A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT|Completed||Phase 3|101|Actual|Georgetown University||2|||f||||t||||||||||2018-06-01 01:53:02.650325|2018-06-01 01:53:02.650325
NCT00727584|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2013-08-23|2008-08-01|2008-08-04|Estimate|||||||2013-08-23|2013-08-26|Estimate|November 2007||2007-11-30|June 2009|2009-06-30|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|||Radiation Therapy in Treating Patients With Metastatic Spinal Cord Compression|SCORAD: A Randomised Feasibility Study of Single Fraction Radiotherapy Compared to Multi-fraction Radiotherapy in Patients With Metastatic Spinal Cord Compression|Completed||N/A|100|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:53:02.938074|2018-06-01 01:53:02.938074
NCT00727571|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2009-10-29||2014-07-18|2008-08-01|2008-08-04|Estimate|2013-09-23|2013-11-27|Estimate||||2014-07-18|2014-07-25|Estimate|September 2006||2006-09-30|July 2014|2014-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||LEARN-6™: A Prospective, Observational Nursing Home Study|Prospective Observational Study to Evaluate Physical Performance and Quality of Life in Older Long Stay Nursing Home Residents With Chronic Kidney Disease With and Without Anemia|Completed|||815|Actual|Amgen|21 subjects could not be classified into the defined groups because of missing lab values at enrollment||4||f||||||||||None Retained|"~     N/A (None Retained)~   "|||2018-06-01 01:53:03.089347|2018-06-01 01:53:03.089347
NCT00727558|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-09-24||2015-05-05|2008-08-01|2008-08-04|Estimate|2010-01-28|2010-02-18|Estimate||||2015-05-05|2015-05-21|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Comparison of Daily Disposable Contact Lenses.||Completed||N/A|248|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-06-01 01:53:03.622401|2018-06-01 01:53:03.622401
NCT00727545|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2008-08-04|2008-07-30|2008-08-04|Estimate|||||||2008-08-04|2008-08-06|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Effect of Rice Fortification With Iron on Anemia Among Children|Effect of Weekly Rice Fortification With Iron on Frequency of Anemia and Hemoglobin Concentration Among Children Attending Public Day Care Centers From Rio de Janeiro|Completed||Phase 2/Phase 3|385|Actual|Universidade Federal do Rio de Janeiro||1|||f||||t||||||||||2018-06-01 01:53:03.983241|2018-06-01 01:53:03.983241
NCT00727532|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2013-07-17|2008-08-01|2008-08-04|Estimate|||||||2013-07-17|2013-07-18|Estimate|July 2008||2008-07-31|July 2013|2013-07-31|June 2015|Anticipated|2015-06-30|October 2011|Actual|2011-10-31||Interventional|||Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer|Correlation of Pathologic Findings After Neo-adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma|Terminated||N/A|9|Actual|Northwestern University||1||Low Accrual|f||||t||||||||||2018-06-01 01:53:04.05298|2018-06-01 01:53:04.05298
NCT00727506|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2013-08-08||2017-07-10|2008-08-01|2008-08-04|Estimate|2014-01-02|2014-01-24|Estimate||||2017-07-10|2017-08-15|Actual|July 14, 2008|Actual|2008-07-14|July 2017|2017-07-31|May 25, 2016|Actual|2016-05-25|May 12, 2011|Actual|2011-05-12||Interventional||For Phase I part, all patients who were treated with at least one dose of the study medication. For Phase II part, all patients who were randomized and have taken at least one dose of the study medication.|BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma|Phase I/II Trial of BIBW 2992 (Afatinib) in Treating Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|151|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 01:53:04.315351|2018-06-01 01:53:04.315351
NCT00727493|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-08-01|2008-08-01|2008-08-04|Estimate|||||||2008-08-01|2008-08-04|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|April 2010|Anticipated|2010-04-30|January 2010|Anticipated|2010-01-31||Interventional|OPOZAHN||Osteoporosis and Dental Implant|Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis|Unknown status|Recruiting|Phase 4|45|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-06-01 01:53:06.779044|2018-06-01 01:53:06.779044
NCT00727480|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2015-06-01|2008-07-31|2008-08-04|Estimate|||||||2015-06-01|2015-06-03|Estimate|September 2002||2002-09-30|May 2015|2015-05-31|December 2011|Actual|2011-12-31|July 2008|Actual|2008-07-31||Interventional|||Finger Imaging to Detect Blood Flow in the Fingertips|Finger Imaging and Biometric System|Terminated||N/A|13|Actual|University of Michigan||1||No longer acruing data for this study.|f||||f||||||||||2018-06-01 01:53:06.861912|2018-06-01 01:53:06.861912
NCT00727467|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-12-30|2008-08-01|2008-08-04|Estimate|||||||2008-12-30|2008-12-31|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|March 2009|Anticipated|2009-03-31|December 2008|Anticipated|2008-12-31||Interventional|||A Randomised Controlled Trial (RCT) to Evaluate Use of an Individual Auditory Cueing Device's (IACD's) on Freezing and Gait in People With Parkinson's Disease (PD)|A Randomised Controlled Trial Evaluating the Effect of an Individual Auditory Cueing Device on Freezing and Gait Speed in People With Parkinson's Disease|Unknown status|Not yet recruiting|Phase 1/Phase 2|47|Anticipated|University of Dublin, Trinity College||2|||f||||t||||||||||2018-06-01 01:53:06.924994|2018-06-01 01:53:06.924994
NCT00727454|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2014-11-14|2008-07-30|2008-08-04|Estimate|||||||2014-11-14|2014-11-18|Estimate|July 2007||2007-07-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|OSA-MRI||Effects of Continuous Positive Airway Pressure (CPAP) in Heart Remodeling by Magnetic Resonance Imaging (MRI)|Effects of Continuous Positive Airway Pressure on Heart Remodeling in Patients With Obstructive Sleep Apnea: A Randomized Study With Cardiovascular Magnetic Resonance Imaging|Terminated||Phase 4|24|Actual|University of Sao Paulo||2||Difficulty of recruiting patients and cost limitations.|f||||f||||||||||2018-06-01 01:53:07.0316|2018-06-01 01:53:07.0316
NCT00727441|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2017-01-11|2008-08-01|2008-08-04|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2008||2008-07-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery|A Randomized Three-arm Neoadjuvant and Adjuvant Feasibility and Toxicity Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine Administered Either Alone or in Combination With Either a Single Intravenous Dose or Daily Metronomic Oral Doses of Cyclophosphamide for the Treatment of Patients With Surgically Resected Adenocarcinoma of the Pancreas|Active, not recruiting||N/A|87|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-06-01 01:53:07.098555|2018-06-01 01:53:07.098555
NCT00727428|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2017-05-05|2008-08-01|2008-08-04|Estimate|||||||2017-05-05|2017-05-08|Actual|August 5, 2008|Actual|2008-08-05|May 2017|2017-05-31|February 17, 2009|Actual|2009-02-17|August 29, 2008|Actual|2008-08-29||Interventional|||Immunogenicity and Safety of GSK Biologicals' FluLaval® TF|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral®, Thimerosal-free (FluLaval® TF), in Adults 18 to 60 Years of Age.|Completed||Phase 1|110|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 01:53:07.182154|2018-06-01 01:53:07.182154
NCT00727415|ClinicalTrials.gov processed this data on May 31, 2018|2008-08-01|||2016-08-16|2008-08-01|2008-08-04|Estimate|||||||2016-08-16|2016-08-17|Estimate|February 2008||2008-02-29|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|LLC0606||Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy|A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients.|Completed||Phase 1/Phase 2|52|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-06-01 01:53:07.339279|2018-06-01 01:53:07.339279
NCT00727402|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2010-11-09||2012-02-13|2008-07-31|2008-08-04|Estimate|2011-01-14|2011-02-10|Estimate||||2012-02-13|2012-02-15|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Observational|LASH||Longitudinal Evaluation of Silicone Hydrogel (LASH) Study|The Longitudinal Evaluation of Silicone Hydrogel (LASH) Contact Lens Study|Completed|||205|Actual|National Eye Institute (NEI)|||1||f||||f||||||Samples Without DNA|"~     tear samples contact lenses bacteria isolated from contact lenses~   "|||2018-06-01 01:53:07.458643|2018-06-01 01:53:07.458643
NCT00727389|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-31|2008-07-31|2008-08-04|Estimate|||||||2008-07-31|2008-08-04|Estimate|April 2007||2007-04-30|July 2008|2008-07-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|Incapacity||Prevention of Functional Decline of Aged Women|The Influence of the Support Group on the Functional Incapacity in the Prevention of Functional Decline of Aged Women.|Completed||N/A|31|Actual|Academia Cearense de Odontologia||1|||f||||t||||||||||2018-06-01 01:53:07.671373|2018-06-01 01:53:07.671373
NCT00727376|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2011-08-04|2008-08-01|2008-08-04|Estimate|||||||2011-08-04|2011-08-08|Estimate|March 2008||2008-03-31|January 2010|2010-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Evaluation of Polyflex Stenting in Esophageal Cancer Patients|Clinical Evaluation of Polyflex Stenting in Esophageal Cancer Patients Undergoing Chemotherapy and/or Radiation Therapy|Completed|||26|Anticipated|University of Louisville|||1||f||||f||||||||||2018-06-01 01:53:07.781537|2018-06-01 01:53:07.781537
NCT00727363|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2011-06-21|2008-08-01|2008-08-04|Estimate|||||||2011-06-21|2011-06-22|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|June 2011|Actual|2011-06-30||Interventional|C3P||Prophylactic Probiotics in Premature Infants|Prophylactic Probiotics for the Prevention of Sepsis and NEC in Premature Infants in Colombia. A Randomized Double-Blind, Multicenter Trial|Terminated||Phase 3|751|Actual|Colombian Neonatal Research Network||2||We are underpowered to find a difference in the primary outcome.|f||||t||||||||||2018-06-01 01:53:07.920235|2018-06-01 01:53:07.920235
NCT00727181|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2011-10-17|2008-07-29|2008-08-01|Estimate|||||||2011-10-17|2011-10-18|Estimate|November 2007||2007-11-30|October 2011|2011-10-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||An Observational, Prospective Evaluation of the Trifecta™ Valve|An Observational, Prospective Evaluation of the Trifecta™ Valve|Completed||N/A|120|Anticipated|St. Jude Medical||1|||f||||t||||||||||2018-06-01 01:53:12.711235|2018-06-01 01:53:12.711235
NCT00727350|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2008-08-01|2008-08-01|2008-08-04|Estimate|||||||2008-08-01|2008-08-04|Estimate|March 2007||2007-03-31|August 2008|2008-08-31|December 2012|Anticipated|2012-12-31|March 2012|Anticipated|2012-03-31||Interventional|||Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.|Phase II Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.|Unknown status|Recruiting|Phase 2|44|Anticipated|AZ-VUB||1|||f||||f||||||||||2018-06-01 01:53:08.04335|2018-06-01 01:53:08.04335
NCT00727337|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2014-10-22||2015-01-12|2008-07-30|2008-08-04|Estimate|2015-01-12|2015-01-13|Estimate||||2015-01-12|2015-01-13|Estimate|January 2009||2009-01-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|LACE||Supplementing Hearing Aids With Computerized Auditory Training|Supplementing Hearing Aids With Computerized Auditory Training|Completed||N/A|279|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 01:53:08.126404|2018-06-01 01:53:08.126404
NCT00727324|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2012-03-30|2008-07-30|2008-08-01|Estimate|||||||2012-03-30|2012-04-02|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis|A Pilot, Open-label, Multi-center Clinical Trial to Investigate the Safety and Efficacy of Bovine-Calf Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis.|Completed||Phase 2|22|Actual|AM-Pharma||1|||f||||t||||||||||2018-06-01 01:53:08.451636|2018-06-01 01:53:08.451636
NCT00727311|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2010-12-22||2015-10-08|2008-07-30|2008-08-01|Estimate|2010-12-22|2011-01-10|Estimate||||2015-10-08|2015-10-09|Estimate|August 2005||2005-08-31|October 2015|2015-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)|Treatment of Chronic Hepatitis C With PegIntron Injector and Rebetol (Post Marketing Surveillance Study)|Completed|||2302|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:08.590249|2018-06-01 01:53:08.590249
NCT00727298|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2012-08-10||2015-11-30|2008-07-30|2008-08-01|Estimate|2012-08-10|2012-09-12|Estimate||||2015-11-30|2015-12-01|Estimate|February 2006||2006-02-28|November 2015|2015-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|REMission||Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)|Post Marketing Surveillance Study of the Labeled Use of Remicade® (Infliximab) in Patients With Chronic Inflammatory Diseases|Completed|||4485|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:09.168368|2018-06-01 01:53:09.168368
NCT00727285|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2017-03-27|2008-07-29|2008-08-01|Estimate|||||||2017-03-27|2017-03-29|Actual|February 2008|Actual|2008-02-29|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Observational|||Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies|CF Leukocyte Genes as Biomarkers for Novel Therapies|Completed|||60|Actual|National Jewish Health|||1||f||||t||||||||||2018-06-01 01:53:09.902902|2018-06-01 01:53:09.902902
NCT00727272|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-11-24||2010-01-11|2008-07-31|2008-08-01|Estimate|2009-11-24|2009-12-30|Estimate||||2010-01-11|2010-01-20|Estimate|February 2004||2004-02-29|January 2010|2010-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions|A Relative Bioavailability Study of Quinine Sulfate Capsules Under Fasting and Fed Conditions|Completed||Phase 1|27|Actual|Mutual Pharmaceutical Company, Inc.||3|||f||||f||||||||||2018-06-01 01:53:10.052017|2018-06-01 01:53:10.052017
NCT00727259|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-06-18||2015-04-07|2008-07-30|2008-08-01|Estimate|2009-06-18|2009-08-06|Estimate||||2015-04-07|2015-04-29|Estimate|October 2004||2004-10-31|April 2015|2015-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|SATISFACTION||Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)|Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C|Completed|||1995|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:10.491392|2018-06-01 01:53:10.491392
NCT00727246|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2017-04-07||2017-06-30|2008-07-31|2008-08-01|Estimate|2017-06-30|2017-07-28|Actual||||2017-06-30|2017-07-28|Actual|March 2009||2009-03-31|June 2017|2017-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||CDP-Choline and Working Memory After TBI: A Neuroimaging Study|CDP-Choline and Working Memory After TBI: A Neuroimaging Study.|Completed||Phase 2|19|Actual|University of Pittsburgh|Due to multiple complex issues, recruitment was significantly lower than anticipated. As a result, statistical analyses are presented, however the number of subjects in each comparison group was very low and results should be considered with caution|2|||f||||t||||||||No|Data collected was significantly limited|2018-06-01 01:53:10.790907|2018-06-01 01:53:10.790907
NCT00727233|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2018-05-23|2008-07-31|2008-08-01|Estimate|||||||2018-05-23|2018-05-24|Actual|July 8, 2008||2008-07-08|May 4, 2012|2012-05-04|June 16, 2011|Actual|2011-06-16|June 16, 2011|Actual|2011-06-16||Interventional|||Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas|Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:53:11.322465|2018-06-01 01:53:11.322465
NCT00727220|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2016-02-29||2017-05-17|2008-07-31|2008-08-01|Estimate|2017-05-17|2017-05-19|Actual||||2017-05-17|2017-05-19|Actual|November 1999||1999-11-30|May 2017|2017-05-31|January 2004|Actual|2004-01-31|April 2003|Actual|2003-04-30||Observational|||Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes|A Prospective Study of the Impact of CSII Therapy in Young Children With Type 1 DM|Completed|||42|Actual|Indiana University|||2||f||||f||||||||||2018-06-01 01:53:11.409715|2018-06-01 01:53:11.409715
NCT00727207|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2012-12-13|2008-07-31|2008-08-01|Estimate|||||||2012-12-13|2012-12-17|Estimate|May 2008||2008-05-31|December 2012|2012-12-31|September 2014|Anticipated|2014-09-30|May 2011|Actual|2011-05-31||Interventional|||Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy|Phase II Trial on Efficacy of mTOR Inhibitor RAD001 as Maintenance Therapy for Patients Above 60 Years in Mantle Cell Lymphoma After First and Second Line Chemotherapy|Terminated||Phase 2|35|Anticipated|Technische Universität München||||Lack of participations (8 of 25)|f||||||||||||||2018-06-01 01:53:11.606456|2018-06-01 01:53:11.606456
NCT00727194|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2016-03-22||2016-12-19|2008-07-30|2008-08-01|Estimate|2016-10-18|2016-12-12|Estimate||||2016-12-19|2017-02-10|Actual|October 2008||2008-10-31|December 2016|2016-12-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients With Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Treatment With Immunosuppressants|Terminated||Phase 2|14|Actual|Alexion Pharmaceuticals|"Small sample size limited ability to detect intercohort differences. Carryover effect from Treatment Period (TP) 1 warrants cautious interpretation of TP 2 data.~Study terminated early; 13 patients received eculizumab or placebo in TP2."|2|||f||||t||||||||||2018-06-01 01:53:11.747235|2018-06-01 01:53:11.747235
NCT00727155|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2009-07-09|2008-07-31|2008-08-01|Estimate|||||||2009-07-09|2009-07-10|Estimate|September 2008||2008-09-30|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|ACCESS||Adjusting to Chronic Conditions Using Education Support and Skills|Improving Quality Of Life For Chronically Ill Patients Using Education Support And Skills; A Randomized Controlled Mental Trial|Completed||N/A|3|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:53:12.976094|2018-06-01 01:53:12.976094
NCT00727142|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2018-05-10|2008-07-29|2008-08-01|Estimate|||||||2018-05-10|2018-05-16|Actual|July 2008||2008-07-31|May 2018|2018-05-31|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Interventional|||Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus (INPH)|Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus|Terminated||N/A|14|Actual|University College London Hospitals||2||observed benefit of treatment larger than expected|f||||f||||||||||2018-06-01 01:53:13.162266|2018-06-01 01:53:13.162266
NCT00727129|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2008-09-25|2008-07-31|2008-08-01|Estimate|||||||2008-09-25|2008-09-26|Estimate|July 2004||2004-07-31|September 2008|2008-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms|Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients|Completed||Phase 3|495|Actual|Upsher-Smith Laboratories|||||||||||||||||||2018-06-01 01:53:13.269498|2018-06-01 01:53:13.269498
NCT00727116|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2015-02-06|2008-07-31|2008-08-01|Estimate|||||||2015-02-06|2015-02-09|Estimate|January 2008||2008-01-31|February 2015|2015-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pennsylvania Abusive Head Trauma Prevention Program|Pennsylvania Abusive Head Trauma Prevention Program|Completed||N/A|949609|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 01:53:13.354091|2018-06-01 01:53:13.354091
NCT00727103|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2011-06-02|2008-07-31|2008-08-01|Estimate|||||||2011-06-02|2011-06-03|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia|Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double Blind, Placebo Controlled Trial|Terminated||Phase 4|10|Actual|State University of New York - Upstate Medical University||2||Slow recruitment, high drop-out rate in both arms|f||||t||||||||||2018-06-01 01:53:13.438291|2018-06-01 01:53:13.438291
NCT00727090|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2010-07-21||2013-04-30|2008-07-30|2008-08-01|Estimate|2010-09-02|2010-09-27|Estimate||||2013-04-30|2013-05-06|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients|Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients|Terminated||Phase 4|6|Actual|Northwestern University||2||Enrollment below goal.|f||||f||||||||||2018-06-01 01:53:13.567556|2018-06-01 01:53:13.567556
NCT00727077|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2015-04-07|2008-07-30|2008-08-01|Estimate|||||||2015-04-07|2015-04-08|Estimate|June 2006||2006-06-30|April 2015|2015-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)|Treatment of Chronic Hepatitis C in Children With Intron Vial or Pen and Rebetol According to German Law (§ 67 Abs 6 AMG)|Terminated|||3|Actual|Merck Sharp & Dohme Corp.|||1|"Study halted due to low recruitment. The 3 participants at time of termination transferred into~   study P04538 (NCT00727077). See NCT00727077 for details/results."|f||||f||||||||||2018-06-01 01:53:13.88987|2018-06-01 01:53:13.88987
NCT00727064|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2009-08-31||2010-05-26|2008-07-31|2008-08-01|Estimate|2010-03-30|2010-04-19|Estimate||||2010-05-26|2010-06-02|Estimate|June 2008||2008-06-30|May 2010|2010-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects|A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers|Completed||Phase 1|14|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:53:13.981414|2018-06-01 01:53:13.981414
NCT00727051|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2014-08-15|2008-07-31|2008-08-01|Estimate|||||||2014-08-15|2014-08-19|Estimate|June 2007||2007-06-30|August 2014|2014-08-31||||July 2014|Actual|2014-07-31||Observational|||Comparison of Coronary CT Angiography With Conventional Coronary Angiography in Liver and Lung Transplant Candidates|Comparison of Coronary CT Angiography With Conventional Coronary Angiography in Liver and Lung Transplant Candidates.|Suspended|||20|Anticipated|University of California, San Francisco|||1|No funding|f||||t||||||||||2018-06-01 01:53:14.282201|2018-06-01 01:53:14.282201
NCT00727038|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2010-07-26|2008-07-29|2008-08-01|Estimate|||||||2010-07-26|2010-07-28|Estimate||||July 2008|2008-07-31||||||||Interventional|NVG||Lucentis for New Onset Neovascular Glaucoma|Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma|Withdrawn||Phase 1/Phase 2|30|Anticipated|University of Illinois at Chicago||2||Company withdrew funding/sponsorship|f||||f||||||||||2018-06-01 01:53:14.348381|2018-06-01 01:53:14.348381
NCT00727025|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2012-02-24||2013-05-17|2008-07-31|2008-08-01|Estimate|2013-05-17|2013-05-20|Estimate||||2013-05-17|2013-05-20|Estimate|July 2005||2005-07-31|May 2013|2013-05-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Randomized Controlled Trial of Subcuticular Skin Closure Versus Steri-strip S Closure|Closing Linear Incisions in Plastic Surgery: A Randomized Clinical Trial Comparing a New Coaptive Film Device Versus Standard Subcuticular Sutures for Scar Quality, Patient Comfort, and Closure Time|Completed||N/A|51|Actual|Dartmouth-Hitchcock Medical Center|"patients not blinded~surgeons rated photographs of scars, while the patients were rating their actual scars.~All patients were caucasian"||||f||||t||||||||||2018-06-01 01:53:14.494788|2018-06-01 01:53:14.494788
NCT00727012|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2011-07-12|2008-07-31|2008-08-01|Estimate|||||||2011-07-12|2011-07-13|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|MITRAL||Multicenter International Trial Ring AnnulopLasty|Multicenter International Trial Ring AnnulopLasty|Completed||N/A|180|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 01:53:14.807508|2018-06-01 01:53:14.807508
NCT00726999|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2010-08-19||2011-01-03|2008-07-31|2008-08-01|Estimate|2010-12-28|2010-12-30|Estimate||||2011-01-03|2011-01-04|Estimate|June 2006||2006-06-30|January 2011|2011-01-31|May 2009|Actual|2009-05-31|July 2008|Actual|2008-07-31||Interventional|||Perioperative Use of Gabapentin To Decrease Narcotic Requirements in Spinal Fusion|Perioperative Use of Gabapentin To Decrease Opioid Requirements in Pediatric Spinal Fusion Patients|Completed||N/A|63|Actual|Medical College of Wisconsin||2|||f||||t||||||||||2018-06-01 01:53:15.008302|2018-06-01 01:53:15.008302
NCT00726128|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-03-14|2008-07-30|2008-07-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|August 1998||1998-08-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|VueLock||Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System|A Multi-Center Prospective Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System|Completed|||371|Actual|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-06-01 01:53:32.8316|2018-06-01 01:53:32.8316
NCT00726986|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2014-07-08||2014-11-05|2008-07-31|2008-08-01|Estimate|2014-07-08|2014-08-04|Estimate||||2014-11-05|2014-11-19|Estimate|July 2008||2008-07-31|November 2014|2014-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Sorafenib in Conjunction With Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer|Terminated||Phase 2|18|Actual|Case Comprehensive Cancer Center|This study was terminated after enrolling 18 patients on the basis of excessive toxicity observed and preliminary efficacy data showing that study was unlikely to meet primary end point.|1||Extreme toxicity|f||||t||||||||||2018-06-01 01:53:15.259562|2018-06-01 01:53:15.259562
NCT00726973|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2012-05-09|2008-07-31|2008-08-01|Estimate|||||||2012-05-09|2012-05-10|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)|A Pilot Study With Reduced Fluence Photodynamic Therapy With Visudyne Ranibizumab VS. Ranibizumab Only to Treat Exudative AMD|Withdrawn||N/A|0|Actual|Lahey Clinic||2||Unable to recruit study participants|f||||f||||||||||2018-06-01 01:53:15.641293|2018-06-01 01:53:15.641293
NCT00726960|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2008-07-30|2008-07-30|2008-08-01|Estimate|||||||2008-07-30|2008-08-01|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers|Modulation of Opiate Reward by NK1 Antagonism: A Laboratory-Based Proof of Concept Study|Unknown status|Active, not recruiting|Phase 1|60|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-06-01 01:53:15.7246|2018-06-01 01:53:15.7246
NCT00726947|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-05-23|2008-07-29|2008-08-01|Estimate|||||||2016-05-23|2016-05-24|Estimate|December 2002||2002-12-31|May 2016|2016-05-31|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Ultrasound Elasticity Imaging of Venous Thrombi|Aging Venous Thrombi With Ultrasound Elasticity Imaging|Completed||Early Phase 1|254|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 01:53:15.803221|2018-06-01 01:53:15.803221
NCT00726934|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2017-02-07|2008-07-31|2008-08-01|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2007||2007-09-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients|The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients|Completed||N/A|149|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 01:53:15.883811|2018-06-01 01:53:15.883811
NCT00726921|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2008-07-31|2008-07-31|2008-08-01|Estimate|||||||2008-07-31|2008-08-01|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|August 2011|Anticipated|2011-08-31|August 2009|Anticipated|2009-08-31||Observational|||Imaging Modalities in Detection of Coronary Artery Disease in End-Stage Renal Disease Patients|Detection of Significant Coronary Artery Disease in Nephropathy Patients Utilizing Coronary CTA and Real Time Perfusion DSE: Comparison With Quantitative Coronary Angiography and Patient Outcome|Unknown status|Not yet recruiting||75|Anticipated|University of Nebraska|||||f||||t||||||||||2018-06-01 01:53:15.961558|2018-06-01 01:53:15.961558
NCT00726908|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2012-06-14|2008-07-31|2008-08-01|Estimate|||||||2012-06-14|2012-06-15|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|QuEST||Intramuscular Lipid and Insulin Action:Ethnic Aspects|Intramuscular Lipid and Insulin Action:Ethnic Aspects|Completed||N/A|69|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 01:53:16.054434|2018-06-01 01:53:16.054434
NCT00726895|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-11-24||2010-01-11|2008-07-31|2008-08-01|Estimate|2009-11-24|2009-12-30|Estimate||||2010-01-11|2010-01-20|Estimate|May 2004||2004-05-31|January 2010|2010-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||A Dose Proportionality Study of Quinine Sulfate Capsules Under Fasting Conditions|A Randomized, Two-way Crossover Design Used to Compare the Dose Proportionality of Quinine Sulfate Capsules, 324 mg Following a Single Oral Dose of 1 x 324 mg Capsule Versus 2 x 324 mg Capsules in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 01:53:16.125487|2018-06-01 01:53:16.125487
NCT00726882|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2014-12-29|2011-09-21|2014-12-29|2008-07-31|2008-08-01|Estimate|2014-12-29|2015-01-08|Estimate|2011-09-21|2011-10-05|Estimate|2014-12-29|2015-01-08|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies|A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-333 Clinical Studies|Completed||Phase 2|35|Actual|AbbVie||1|||f||||||||||||||2018-06-01 01:53:16.715494|2018-06-01 01:53:16.715494
NCT00726869|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2012-08-22|2008-07-30|2008-08-01|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.|A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.|Terminated||Phase 1|28|Actual|Abbott||4||Enrollment has been halted|f||||t||||||||||2018-06-01 01:53:16.94906|2018-06-01 01:53:16.94906
NCT00726856|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2015-04-15|2008-07-30|2008-08-01|Estimate|||||||2015-04-15|2015-04-16|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)|A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice|Completed|||1200|Anticipated|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:17.052947|2018-06-01 01:53:17.052947
NCT00726843|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2015-04-06|2008-07-30|2008-08-01|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Yoga for the Treatment of Pediatric Headaches|Evaluation of Yoga for the Treatment of Pediatric Headaches|Terminated||N/A|7|Actual|Medical College of Wisconsin||2||Enrollment proceeded too slowly to conduct study as RCT.|f||||f||||||||||2018-06-01 01:53:17.13986|2018-06-01 01:53:17.13986
NCT00726830|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2012-11-09||2012-11-09|2008-07-31|2008-08-01|Estimate|2012-11-09|2012-12-06|Estimate||||2012-11-09|2012-12-06|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer|"A Randomized Comparison of Oral Methadone as a First-Switch Opioid Versus Opioid Switching Between Sustained-Release Morphine and Oxycodone for Oncology-Hematology Outpatients With Pain Management Problems: The Simply Rotate Study"|Terminated||N/A|1|Actual|M.D. Anderson Cancer Center||2||Low Accrual.|f||||t||||||||||2018-06-01 01:53:17.27857|2018-06-01 01:53:17.27857
NCT00726804|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2015-08-18|2008-07-31|2008-08-01|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2008||2008-03-31|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|SPARTA||Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis|Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares|Terminated||Phase 4|7|Actual|Glostrup University Hospital, Copenhagen||1||It was not possible to recruit patients|f||||t||||||||||2018-06-01 01:53:17.615491|2018-06-01 01:53:17.615491
NCT00726791|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2011-07-21|2008-07-30|2008-08-01|Estimate|||||||2011-07-21|2011-07-25|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Efficacy of rTMS (Repetitive Transcranial Magnetic Stimulation) on Patients With Somatoform Pain Disorder|Efficacy of rTMS (Repetitive Transcranial Magnetic Stimulation) on Patients With Somatoform Pain Disorder|Withdrawn||N/A|10|Actual|Samsung Medical Center||1||patient did not enroll|f||||t||||||||||2018-06-01 01:53:17.748078|2018-06-01 01:53:17.748078
NCT00726778|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2011-03-15|2008-07-31|2008-08-01|Estimate|||||||2011-03-15|2011-03-16|Estimate|May 2004||2004-05-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Observational|AMERICO||Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes|Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes|Completed|||360|Anticipated|University of Alabama at Birmingham|||1||f||||f||||||Samples With DNA|"~     Three 5-ml blood samples will be obtained from each subject and sent to the Laboratory Core~     of the General Clinical Research Center to establish EBV lymphoblastoid cell lines and for~     DNA extraction. EBV lines will be kept at UAB for future genetic analysis. Extracted DNA will~     be sent to Dr. Mark Shriver at the Pennsylvania State University for genotyping of the~     ancestry informative markers (AIMs).~   "|||2018-06-01 01:53:17.811948|2018-06-01 01:53:17.811948
NCT00726765|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2016-01-20|2008-07-30|2008-08-01|Estimate|||||||2016-01-20|2016-01-21|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain (Study P05320)(COMPLETED)|Observational Trial on the Value of Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain|Completed|||1090|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:53:17.925951|2018-06-01 01:53:17.925951
NCT00726752|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2012-02-25||2012-05-17|2008-07-30|2008-08-01|Estimate|2012-02-25|2012-03-26|Estimate||||2012-05-17|2012-05-23|Estimate|July 2008||2008-07-31|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study In Patients With Advanced Solid Tumor|A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 At Single Doses Of 5 mg, 7 mg And 10 mg, And At Multiple Doses|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:53:18.059391|2018-06-01 01:53:18.059391
NCT00726739|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2012-08-29||2017-12-03|2008-07-31|2008-08-01|Estimate|2012-11-07|2012-12-13|Estimate||||2017-12-03|2017-12-28|Actual|June 2008||2008-06-30|December 2017|2017-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Randomized Phase II Study of IL-2 With or Without an Allogeneic Large Multivalent Immunogen (LMI) Vaccine for the Treatment of Stage IV Melanoma|Completed||Phase 2|21|Actual|Masonic Cancer Center, University of Minnesota||3|||f||||t||||||||||2018-06-01 01:53:18.517974|2018-06-01 01:53:18.517974
NCT00726726|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2008-11-04|2008-07-30|2008-08-01|Estimate|||||||2008-11-04|2008-11-05|Estimate|August 2008||2008-08-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Drug Interaction Study With a Potential Alzheimer's Disease Compound|Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail|Completed||Phase 1|22|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:53:18.960977|2018-06-01 01:53:18.960977
NCT00726713|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2013-05-02||2013-07-26|2008-07-31|2008-08-01|Estimate|2013-07-26|2013-08-30|Estimate||||2013-07-26|2013-08-30|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)|A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN)|Completed||Phase 4|214|Actual|Pamlab, Inc.|Adverse Event reporting detailed in the “Other Adverse Events” section was provided only with specificity to the affected Organ System. Additional detail for the “Other Adverse Events” was not available at the time of reporting.|2|||f||||f||||||||||2018-06-01 01:53:19.094321|2018-06-01 01:53:19.094321
NCT00726700|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2013-08-01|2008-07-31|2008-08-01|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2004||2004-05-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|||||Interventional|||Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma|Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab|Completed||Phase 2|109|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:53:19.547075|2018-06-01 01:53:19.547075
NCT00726687|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2012-07-18|2008-07-29|2008-08-01|Estimate|||||||2012-07-18|2012-07-19|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors|Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1/Phase 2|7|Actual|Ziopharm||1|||f||||f||||||||||2018-06-01 01:53:19.649467|2018-06-01 01:53:19.649467
NCT00726674|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2012-03-07|2008-07-31|2008-08-01|Estimate|||||||2012-03-07|2012-03-08|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|Lapas II||Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics|Lantus for Diabetic Patients Treated in Clalit Outpatient Clinics|Completed|||1229|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:53:19.73807|2018-06-01 01:53:19.73807
NCT00726661|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2016-04-05||2017-06-08|2008-07-30|2008-08-01|Estimate|2016-05-23|2016-06-30|Estimate||||2017-06-08|2017-07-11|Actual|June 2008|Actual|2008-06-30|June 2017|2017-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|VIRGO|Baseline characteristics was analyzed for all enrolled participants in respective individual groups (CT Cohort and HT Cohort); therefore, the data for 'mean age' for total population is not applicable for this study.|An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)|An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer|Completed|||1287|Actual|Genentech, Inc.|||2||f||||||||||Samples With DNA|"~     Whole blood and tissue~   "|||2018-06-01 01:53:19.829544|2018-06-01 01:53:19.829544
NCT00726648|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29||2009-08-26|2011-09-02|2008-07-31|2008-08-01|Estimate||||2009-08-26|2009-08-27|Estimate|2011-09-02|2011-09-12|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||CDP323 Biomarker Study|Double-blind, Placebo-controlled, Randomized, Parallel-group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.|Completed||Phase 1/Phase 2|71|Actual|UCB Pharma||5|||f||||t||||||||||2018-06-01 01:53:21.488013|2018-06-01 01:53:21.488013
NCT00726635|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2009-02-15|2008-07-30|2008-08-01|Estimate|||||||2009-02-15|2009-02-17|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies|Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|Rabin Medical Center||3|||f||||f||||||||||2018-06-01 01:53:21.608225|2018-06-01 01:53:21.608225
NCT00726622|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|2016-08-11||2018-04-06|2008-07-31|2008-08-01|Estimate|2016-09-23|2016-11-11|Estimate||||2018-04-06|2018-05-08|Actual|August 2008||2008-08-31|April 2018|2018-04-30||||October 2013|Actual|2013-10-31||Interventional||All patients that were randomized to a treatment arm were available for baseline characteristics. Four patients from Arm 1: Open laparotomy and rectal resection and one patient from Arm 2: Laparoscopic-assisted rectal resection are not shown because of patient refusal or improper consent.|Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer|A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer|Active, not recruiting||Phase 3|486|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 01:53:21.891638|2018-06-01 01:53:21.891638
NCT00726609|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-08-13||2015-02-16|2008-07-31|2008-08-01|Estimate|2009-08-13|2009-09-22|Estimate||||2015-02-16|2015-03-05|Estimate|January 2006||2006-01-31|February 2015|2015-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Post-marketing Surveillance Study of Invasive Mycosis With Posaconazole (Study P04641)|Post-marketing Surveillance (PMS) Management of Invasive Mycosis With Posaconazole|Completed|||214|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:23.05049|2018-06-01 01:53:23.05049
NCT00726596|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-31|||2015-12-16|2008-07-31|2008-08-01|Estimate|||||||2015-12-16|2015-12-17|Estimate|August 2008||2008-08-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|February 2014|Actual|2014-02-28||Interventional|||Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer|NJ 1808: Autophagic Cell Death With Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy For Prostate Cancer.|Unknown status|Active, not recruiting|Phase 2|64|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 01:53:23.464466|2018-06-01 01:53:23.464466
NCT00726583|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2018-05-14|2008-07-30|2008-08-01|Estimate|||||||2018-05-14|2018-05-17|Actual|June 2008||2008-06-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Phase I Trial of Oral PX-866|A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients With Advanced Solid Tumors|Completed||Phase 1|90|Anticipated|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 01:53:23.623612|2018-06-01 01:53:23.623612
NCT00726570|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2013-11-04|2008-07-31|2008-08-01|Estimate|||||||2013-11-04|2013-11-05|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TEGLeg||Alterations of Blood Clotting With the Use of Sequential Compression Devices on the Lower Limbs|Effects of Sequential Compression Devices on Coagulation Parameters Assessed by TEG® in Patients Undergoing Major Abdominal Surgery|Terminated||N/A|40|Actual|University of Parma||2||Failed to reach the expected enrollment rates by the end of 2010|f||||f||||||||||2018-06-01 01:53:23.739964|2018-06-01 01:53:23.739964
NCT00726557|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2010-04-15||2015-10-08|2008-07-30|2008-08-01|Estimate|2010-04-15|2010-05-17|Estimate||||2015-10-08|2015-10-09|Estimate|October 2005||2005-10-31|October 2015|2015-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|SUPPORT||Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)|Quality Assurance of HCV-therapy With PegIntron® Plus Rebetol® in Drug-substituted Patients - SUPPORT Project Post-Marketing Surveillance Study|Completed|||246|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:23.891304|2018-06-01 01:53:23.891304
NCT00726544|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2009-11-24|2008-07-30|2008-08-01|Estimate|||||||2009-11-24|2009-11-26|Estimate|December 2008||2008-12-31|November 2009|2009-11-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy|A Randomized, Double-blind, Placebo Controlled, Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy|Terminated||Phase 2|100|Anticipated|Archemix Corp.||4||Enrollment into study was slower than expected.|f||||t||||||||||2018-06-01 01:53:24.119689|2018-06-01 01:53:24.119689
NCT00726531|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2010-07-07|2008-07-29|2008-08-01|Estimate|||||||2010-07-07|2010-07-08|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|May 2013|Anticipated|2013-05-31|May 2011|Anticipated|2011-05-31||Interventional|ProAct65+||Promoting Physical Activity in the Over 65s|Multi-centre Cluster Randomised Trial Comparing a Community Group Exercise Programme With Home Based Exercise With Usual Care for Over 65s in Primary Care|Unknown status|Recruiting|Phase 3|1200|Anticipated|University College, London||3|||f||||t||||||||||2018-06-01 01:53:24.216453|2018-06-01 01:53:24.216453
NCT00726505|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2016-10-14|2008-07-30|2008-08-01|Estimate|||||||2016-10-14|2016-10-17|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|MOA||Renal Mechanism of Action/Splay vs. TmG|Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 1|1|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:53:24.356835|2018-06-01 01:53:24.356835
NCT00726492|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2008-07-29|2008-07-29|2008-08-01|Estimate|||||||2008-07-29|2008-08-01|Estimate|June 2001||2001-06-30|July 2008|2008-07-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||An Examination of the Value of Shortwave Diathermy and Hydrotherapy for Patients With Osteoarthritis of Their Knees|A Randomised Controlled Trial Evaluating the Effects of Shortwave Diathermy and Hydrotherapy for Patients With Osteoarthritis of Their Knees|Completed||N/A|77|Actual|University College Dublin||4|||f||||f||||||||||2018-06-01 01:53:24.471638|2018-06-01 01:53:24.471638
NCT00726479|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2014-03-26|2008-07-30|2008-08-01|Estimate|||||||2014-03-26|2014-03-27|Estimate|August 2008||2008-08-31|March 2014|2014-03-31||||September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis|A Phase II, Randomised, Double-blind, Placebo-controlled and Parallel Group Study to Evaluate the Safety and Efficacy of Four Weeks Treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) in Patients With COPD Associated With Chronic Bronchitis.|Withdrawn||Phase 2|0|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:53:24.577696|2018-06-01 01:53:24.577696
NCT00726466|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2015-07-06|2008-07-29|2008-08-01|Estimate|||||||2015-07-06|2015-07-07|Estimate|March 2008||2008-03-31|July 2015|2015-07-31||||||||Interventional|SEIRA||Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration|A Phase I Study of the Inhibition of LFA-1 to Intercellular Adhesion Molecule-1 (ICAM-1) Using Subcutaneous Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (SEIRA)|Withdrawn||Phase 1|0|Actual|Vitreous -Retina- Macula Consultants of New York||1||Lack of recruitment|||||f||||||||||2018-06-01 01:53:24.678799|2018-06-01 01:53:24.678799
NCT00726453|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2012-01-31||2016-04-21|2008-07-30|2008-08-01|Estimate|2012-05-23|2012-05-25|Estimate||||2016-04-21|2016-05-23|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|January 2011|Actual|2011-01-31||Interventional|R-US||The Medtronic RESOLUTE US Clinical Trial|A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm|Completed||N/A|1516|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-06-01 01:53:24.91741|2018-06-01 01:53:24.91741
NCT00726440|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2012-02-08|2008-07-30|2008-08-01|Estimate|||||||2012-02-08|2012-02-09|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients?|Are the Continous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients With Poor Metabolic Control?|Completed||N/A|180|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||3|||f||||f||||||||||2018-06-01 01:53:26.611761|2018-06-01 01:53:26.611761
NCT00726427|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2010-12-02|2008-07-31|2008-08-01|Estimate|||||||2010-12-02|2010-12-03|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers|A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Interaction After Single Ascending Oral Doses of AZD1656 in Healthy Male Subjects|Completed||Phase 1|32|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:53:26.755413|2018-06-01 01:53:26.755413
NCT00726414|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2009-12-04||2010-01-13|2008-07-31|2008-08-01|Estimate|2010-01-13|2010-02-03|Estimate||||2010-01-13|2010-02-03|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg|A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg Under Fasting and Fed Conditions|Completed||Phase 1|22|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 01:53:26.882216|2018-06-01 01:53:26.882216
NCT00726401|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2010-10-07|2008-07-30|2008-07-31|Estimate|||||||2010-10-07|2010-10-11|Estimate|May 2008||2008-05-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis|Completed||Phase 2|200|Anticipated|Afexa Life Sciences Inc||2|||f||||f||||||||||2018-06-01 01:53:27.455518|2018-06-01 01:53:27.455518
NCT00726388|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2009-04-17|2008-07-30|2008-07-31|Estimate|||||||2009-04-17|2009-04-21|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|May 2009|Anticipated|2009-05-31|April 2009|Anticipated|2009-04-30||Interventional|||An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain|An Open-Label, Multiple-Dose, Multiple-Day, Non-Randomized, Single-Arm Safety Study Of Repeat-Doses Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain|Unknown status|Active, not recruiting|Phase 3|850|Anticipated|Javelin Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:53:27.615607|2018-06-01 01:53:27.615607
NCT00726375|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2014-07-08||2015-12-04|2008-07-30|2008-07-31|Estimate|2014-07-08|2014-08-04|Estimate||||2015-12-04|2016-01-05|Estimate|May 2008||2008-05-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Interventional|||The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease|The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease|Completed||Phase 3|34|Actual|University of Michigan Cancer Center|Due to difficulties obtaining approval for insurance coverage of the study drug, only 34 of 50 patients were enrolled. The study was terminated prematurely and findings were reported for 34 patients.|1|||f||||t||||||||||2018-06-01 01:53:27.85205|2018-06-01 01:53:27.85205
NCT00726362|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2010-12-02|2008-07-29|2008-07-31|Estimate|||||||2010-12-02|2010-12-03|Estimate|December 2007||2007-12-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia|To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia|Completed|||3270|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:53:28.263411|2018-06-01 01:53:28.263411
NCT00726349|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2011-05-04|2008-07-29|2008-07-31|Estimate|||||||2011-05-04|2011-05-05|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|TRIOS||Transfusion Requirements in Orthopedic Surgery (PHASE 2)|Transfusion Requirements in Orthopedic Surgery (Phase 2): A Prospective Observational Evaluation of the Optimal Transfusion Trigger.|Completed|||305|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||1||f||||f||||||||||2018-06-01 01:53:28.464387|2018-06-01 01:53:28.464387
NCT00726336|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29||2010-10-14|2010-10-14|2008-07-30|2008-07-31|Estimate||||2010-10-14|2010-10-15|Estimate|2010-10-14|2010-10-15|Estimate|August 2008||2008-08-31|October 2010|2010-10-31||||October 2008|Actual|2008-10-31||Interventional|||GSK1349572 Drug Interaction With Tenofovir|A Phase I, Open Label, Single Sequence,Drug Interaction Study Evaluating Plasma GSK1349572 and Tenofovir Pharmacokinetics in Healthy Adult Subjects (ING111604)|Completed||Phase 1|16|Anticipated|GlaxoSmithKline|||||||||||||||||||2018-06-01 01:53:28.541987|2018-06-01 01:53:28.541987
NCT00726323|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2017-09-28|2012-03-01|2017-11-08|2008-07-30|2008-07-31|Estimate|2017-11-08|2017-12-11|Actual|2012-03-01|2012-03-05|Estimate|2017-11-08|2017-12-11|Actual|June 30, 2006|Actual|2006-06-30|September 2017|2017-09-30|August 18, 2010|Actual|2010-08-18|August 18, 2010|Actual|2010-08-18||Interventional||The Safety population included all participants who passed the screening criteria, were enrolled in the study and received at least one dose of the study drug.|A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)|A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects With Papillary Renal-Cell Carcinoma|Completed||Phase 2|74|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:53:28.785956|2018-06-01 01:53:28.785956
NCT00724412|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2012-01-31|2008-07-28|2008-07-29|Estimate|||||||2012-01-31|2012-02-02|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye||Completed||Phase 4|279|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:54:06.056172|2018-06-01 01:54:06.056172
NCT00726310|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-03-14|2008-07-30|2008-07-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|May 2000||2000-05-31|February 2012|2012-02-29|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Observational|||Evaluation Of Spinelink® Fixation In The Treatment Of Degenerative Spondylolisthesis And Spinal Instability|A Multicenter Prospective Patient Outcome Evaluation Of Spinelink® Fixation In The Treatment Of Degenerative Spondylolisthesis And Spinal Instability|Completed|||205|Actual|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-06-01 01:53:30.067991|2018-06-01 01:53:30.067991
NCT00726297|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2012-12-18|2008-07-30|2008-07-31|Estimate|||||||2012-12-18|2012-12-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:53:30.14118|2018-06-01 01:53:30.14118
NCT00726284|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-03-14|2008-07-30|2008-07-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|April 2004||2004-04-30|February 2012|2012-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|SPO||Spine Patient Outcomes Registry for Biomet/EBI|BIOMET/EBI Spine Patient Outcomes Registry|Completed|||651|Actual|Zimmer Biomet|||||f||||f||||||||Undecided||2018-06-01 01:53:30.17844|2018-06-01 01:53:30.17844
NCT00726271|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-30|2008-07-30|2008-07-31|Estimate|||||||2008-07-30|2008-07-31|Estimate|June 2008||2008-06-30|July 2008|2008-07-31|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||Pilot Study of Dietary Modification of Appetite Set Point in Obesity|A Pilot 6 Week Study of the Feasibility and Acceptability of Dietary Modification With the Goal of Changing the Appetite Set Point in People Taking Medications That Cause Weight Gain Through Increased Appetite.|Unknown status|Enrolling by invitation|N/A|50|Anticipated|State University of New York - Upstate Medical University||1|||f||||f||||||||||2018-06-01 01:53:30.266065|2018-06-01 01:53:30.266065
NCT00726258|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2014-08-27|2008-07-30|2008-07-31|Estimate|||||||2014-08-27|2014-08-28|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Association of Intravenous Ketamine With Thoracic Epidural Analgesia: Effects on Pain and Respiratory Function Following Thoracotomy.|Association of Intravenous Ketamine With Thoracic Epidural Analgesia: Effects on Pain and Respiratory Function Following Thoracotomy.|Terminated||N/A|21|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 01:53:30.365763|2018-06-01 01:53:30.365763
NCT00726245|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2011-07-10|2008-07-30|2008-07-31|Estimate|||||||2011-07-10|2011-07-12|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|February 2009|Actual|2009-02-28||Interventional|||Plasma Rich in Growth Factors (PRGF) Treatment for Muscle Tear|PRP as a Treatment for Acute Muscle Tears - Randomized-double-blind-placebo Control Trail.|Completed||Phase 2/Phase 3|50|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-06-01 01:53:30.506024|2018-06-01 01:53:30.506024
NCT00726232|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2012-01-20|2010-06-18|2017-12-07|2008-07-30|2008-07-31|Estimate|2012-01-20|2012-02-24|Estimate|2010-06-18|2010-06-22|Estimate|2017-12-07|2018-01-02|Actual|July 2008||2008-07-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|June 2010|Actual|2010-06-30||Interventional|||Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia|A Phase 2, Open Label, Dose Regimen Ranging Clinical Study to Determine the Safety and Efficacy of INCB018424 in Patients With Advanced Polycythemia Vera or Essential Thrombocythemia Refractory to Hydroxyurea|Active, not recruiting||Phase 2|73|Actual|Incyte Corporation||3|||t||||f||||||||||2018-06-01 01:53:30.662601|2018-06-01 01:53:30.662601
NCT00726219|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2011-02-09|2008-07-30|2008-07-31|Estimate|||||||2011-02-09|2011-02-10|Estimate|December 2008||2008-12-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Insertion Distance of Femoral Perineural Catheters in the Context of Major Knee Surgery.|Influence of the Insertion Distance on Loss of Sensation Produced by Femoral Perineural Catheters in the Context of Major Knee Surgery.|Completed||N/A|72|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-06-01 01:53:32.126238|2018-06-01 01:53:32.126238
NCT00726206|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2014-08-27|2008-07-30|2008-07-31|Estimate|||||||2014-08-27|2014-08-28|Estimate|July 2008||2008-07-31|August 2014|2014-08-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Correlation Between the Analysis of the Rapid Cortical Oscillations, the General Movements of the Preterm's and the Cerebral Palsy|Correlation Between the Analysis of the Rapid Cortical Oscillations, the General Movements of the Preterm's and the Cerebral Palsy|Completed||N/A|44|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-06-01 01:53:32.192331|2018-06-01 01:53:32.192331
NCT00726193|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-03-14|2008-07-30|2008-07-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Study to Analyze the Effects of EBI OsteoGen™ on the Surgical Reconstruction of Tibia Non-unions|A Prospective Randomized Multi - Center Clinical Outcomes Collection Study To Analyze The Effect Of Ebi Osteogen™ Direct Current Stimulator On The Surgical Reconstruction Of Tibia Nonunions|Terminated|||4|Actual|Zimmer Biomet|||2|Slow enrollment|f||||f||||||||Undecided||2018-06-01 01:53:32.300149|2018-06-01 01:53:32.300149
NCT00726180|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2013-03-08||2013-08-09|2008-07-30|2008-07-31|Estimate|2013-08-09|2013-10-15|Estimate||||2013-08-09|2013-10-15|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer|Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer|Terminated||Phase 1/Phase 2|1|Actual|University of Michigan Cancer Center||1||Due to low enrollment|f||||t||||||||||2018-06-01 01:53:32.441927|2018-06-01 01:53:32.441927
NCT00726167|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2016-10-03|2008-07-28|2008-07-31|Estimate|||||||2016-10-03|2016-10-05|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Serum Procalcitonin Study in the Management of Ventilated Patients|Clinical Utility of Serum Procalcitonin in the Management of Ventilator-Associated Pneumonia|Completed|||29|Actual|University of Missouri-Columbia|||||f||||f||||||||No||2018-06-01 01:53:32.569198|2018-06-01 01:53:32.569198
NCT00726154|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2012-01-10|2008-07-30|2008-07-31|Estimate|||||||2012-01-10|2012-01-11|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Rhythms||Pilot Study of the Effects of Circadian Rhythms on the Treatment of Bipolar I Depression.|Rhythmicity as a Moderator of Treatment Outcomes of Bipolar I Depression -Pilot Study|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||This study did not receive funding|f||||f||||||||||2018-06-01 01:53:32.664687|2018-06-01 01:53:32.664687
NCT00726141|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-30|2008-07-30|2008-07-31|Estimate|||||||2008-07-30|2008-07-31|Estimate|October 2004||2004-10-31|July 2008|2008-07-31|October 2007|Actual|2007-10-31|January 2005|Actual|2005-01-31||Interventional|BRISC||Brief Interventions on Smoking for Hormonal Contraceptive Users|Brief Interventions on Smoking for Hormonal Contraceptive Users|Completed||N/A|699|Actual|University of Luebeck|||||f||||f||||||||||2018-06-01 01:53:32.756162|2018-06-01 01:53:32.756162
NCT00726115|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2009-07-29|2008-07-30|2008-07-31|Estimate|||||||2009-07-29|2009-07-30|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531|Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects|Completed||Phase 1|56|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:53:32.99063|2018-06-01 01:53:32.99063
NCT00726102|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2016-04-26|2008-07-30|2008-07-31|Estimate|||||||2016-04-26|2016-04-28|Estimate|November 2008||2008-11-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|May 2012|Actual|2012-05-31||Interventional|||Development and Health of Rural Chinese Children Fed Meat as a Daily Complementary Food From 6-18 Mos of Age|Development and Health of Rural Chinese Children Fed Meat as a Daily Complementary Food From 6-18 Mos of Age|Completed||N/A|1488|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-06-01 01:53:33.079037|2018-06-01 01:53:33.079037
NCT00726076|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2013-12-10|2008-07-30|2008-07-31|Estimate|||||||2013-12-10|2013-12-11|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Managing Epilepsy Well- WebEase Project|Managing Epilepsy Well: Self-Management Intervention Research-Coordinating Center|Completed||N/A|194|Actual|Emory University||2|||f||||f||||||||||2018-06-01 01:53:33.203258|2018-06-01 01:53:33.203258
NCT00726063|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2013-11-19||2017-08-01|2008-07-30|2008-07-31|Estimate|2014-01-15|2014-02-12|Estimate||||2017-08-01|2017-08-30|Actual|April 2008||2008-04-30|August 2017|2017-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|CollegeBowl|Nanotite implants = 239 Osseotite implants = 246|A Prospective Study Evaluating the Performance of Nanotite Osseotite Implants When Placed by Graduate Student Programs|A Prospective Randomized-controlled Evaluation of Nanotite and Osseotite Surfaced Implant Performance in Graduate Student Programs|Completed||N/A|241|Actual|Zimmer Biomet||2|||f||||t||||||||No||2018-06-01 01:53:33.31642|2018-06-01 01:53:33.31642
NCT00726050|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2017-06-30|2008-07-30|2008-07-31|Estimate|||||||2017-06-30|2017-07-02|Actual|July 28, 2008||2008-07-28|April 29, 2010|2010-04-29|April 29, 2010||2010-04-29|||||Observational|||Brain Activity in Time Discrimination and Sensory Input|The Relationship Between Temporal Discrimination and Cortical Excitability in Humans|Completed|||4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:53:33.570836|2018-06-01 01:53:33.570836
NCT00726037|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2013-04-26||2016-08-23|2008-07-30|2008-07-31|Estimate|2016-07-14|2016-08-24|Estimate||||2016-08-23|2016-09-29|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer|A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer|Terminated||Phase 2|7|Actual|Loyola University|This study was prematurely terminated, because the study drug Ontak is no longer supplied by the manufacturer for this study. Data is not analyzed for any outcome measures.|1||Collaborator withdrew support due to a drug supply interruption.|f||||t||||||||No||2018-06-01 01:53:33.630501|2018-06-01 01:53:33.630501
NCT00726024|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2012-12-18|2008-07-30|2008-07-31|Estimate|||||||2012-12-18|2012-12-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:53:33.795895|2018-06-01 01:53:33.795895
NCT00726011|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2012-10-22|2008-07-30|2008-07-31|Estimate|||||||2012-10-22|2012-10-24|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|TEC-006OL||Tetrodotoxin Open-label Efficacy and Safety Continuation Study|A Multicentre, Open-label, Long-term Efficacy and Safety Continuation Study of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Cancer-related Pain|Completed||Phase 3|113|Actual|Wex Pharmaceuticals Inc.||1|||f||||f||||||||||2018-06-01 01:53:33.82533|2018-06-01 01:53:33.82533
NCT00725998|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2018-03-19|2008-07-30|2008-07-31|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2005||2005-01-31|July 2008|2008-07-31||||November 2006|Actual|2006-11-30||Observational|ECAP||Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users|Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users|Completed|||||University of Sao Paulo|||1||f||||||||||||||2018-06-01 01:53:34.098537|2018-06-01 01:53:34.098537
NCT00725985|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|2013-06-11||2017-09-05|2008-07-30|2008-07-31|Estimate|2013-08-02|2013-10-10|Estimate||||2017-09-05|2017-10-03|Actual|December 31, 2008|Actual|2008-12-31|September 2017|2017-09-30|April 30, 2012|Actual|2012-04-30|July 31, 2011|Actual|2011-07-31||Interventional|ORACLE MS|The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).|Oral Cladribine in Early Multiple Sclerosis (MS)|A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS|Completed||Phase 3|617|Actual|EMD Serono|Due to early termination of trial, efficacy data presented from core double blind ITP only. Due to low number of participants entering OLMP and LTFU period and the reduced duration, only descriptive safety data from OLMP and LTFU are presented.|3|||f||||t||||||||||2018-06-01 01:53:34.261565|2018-06-01 01:53:34.261565
NCT00725972|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2017-07-30|2008-07-28|2008-07-31|Estimate|||||||2017-07-30|2017-08-01|Actual|July 2008|Actual|2008-07-31|July 2017|2017-07-31||||||||Interventional|||Pre-emptive Hemodynamic Optimization of High Risk Patients Undergoing Elective Major Surgical Procedures|Pre-emptive Hemodynamic Optimization of High Risk Patients Undergoing Elective Major Surgical Procedures.|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||termination of funding by sponsors|f||||t||||||||||2018-06-01 01:53:36.281262|2018-06-01 01:53:36.281262
NCT00725959|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2014-05-20||2017-11-01|2008-07-29|2008-07-31|Estimate|2017-11-01|2017-11-07|Actual||||2017-11-01|2017-11-07|Actual|September 2008||2008-09-30|October 2017|2017-10-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Online Social Networking for HIV Prevention|Online Social Networking for HIV Prevention|Completed||N/A|1578|Actual|Colorado School of Public Health||2|||f||||f||||||||||2018-06-01 01:53:36.472275|2018-06-01 01:53:36.472275
NCT00725946|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2017-10-09|2008-07-30|2008-07-31|Estimate|||||||2017-10-09|2017-10-11|Actual|February 2008||2008-02-29|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT|A Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT|Terminated||Early Phase 1|7|Actual|Stanford University||1|||f||||||||||||||2018-06-01 01:53:36.654646|2018-06-01 01:53:36.654646
NCT00725933|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2017-01-05|2008-07-29|2008-07-31|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2008||2008-06-30|January 2017|2017-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Administration of BIIB028 to Subjects With Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB028 Administered to Subjects With Advanced Solid Tumors|Completed||Phase 1|43|Actual|Biogen|||||f||||f||||||||||2018-06-01 01:53:36.745479|2018-06-01 01:53:36.745479
NCT00725920|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2010-06-01||2014-08-05|2008-07-30|2008-07-31|Estimate|2014-08-05|2014-08-26|Estimate||||2014-08-05|2014-08-26|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.|Randomized Clinical Trial to Study the Topiramate Efficacy for Posttraumatic Disorder Treatment|Completed||Phase 4|35|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:53:36.814467|2018-06-01 01:53:36.814467
NCT00725907|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2011-07-10|2008-07-30|2008-07-31|Estimate|||||||2011-07-10|2011-07-12|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Treatment of ATFL Tears With PRP|Treatment of ATFL Tears After Ankle Sprains With PRP|Completed||N/A|30|Anticipated|Meir Medical Center||2|||f||||||||||||||2018-06-01 01:53:37.114454|2018-06-01 01:53:37.114454
NCT00725894|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2017-06-19|2008-07-30|2008-07-31|Estimate|||||||2017-06-19|2017-06-21|Actual|November 2007||2007-11-30|June 2017|2017-06-30|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Observational|PLN||Pediatric Locking Nail for the Treatment of Femoral Fractures in Children|A Prospective Multi-Center Clinical Outcomes Study To Assess The Safety and Effectiveness Of The Pediatric Locking Nail For Treatment Of Femoral Fractures In Children|Completed|||33|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 01:53:37.243422|2018-06-01 01:53:37.243422
NCT00725881|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29||2011-06-14|2011-07-01|2008-07-30|2008-07-31|Estimate||||2011-07-01|2011-07-29|Estimate|2011-07-01|2011-07-29|Estimate|August 2008||2008-08-31|July 2011|2011-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication|A Randomized, Double-Blinded, Placebo-Controlled Phase 1/2 Dose-Range-Finding Study to Evaluate the Safety, Efficacy and PK of Multiple Once Daily Intravenous Doses of TSC in Patients With Intermittent Claudication|Completed||Phase 1/Phase 2|48|Actual|Diffusion Pharmaceuticals Inc||9|||f||||t||||||||||2018-06-01 01:53:37.312054|2018-06-01 01:53:37.312054
NCT00725868|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-30|||2011-08-25|2008-07-30|2008-07-31|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention|Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention.|Completed||N/A|170|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-06-01 01:53:37.408164|2018-06-01 01:53:37.408164
NCT00725855|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2008-07-30|2008-07-30|2008-07-31|Estimate|||||||2008-07-30|2008-07-31|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|April 2009|Anticipated|2009-04-30|March 2009|Anticipated|2009-03-31||Interventional|P50||A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients|A Single-Center, Double-Blind, Placebo-Controlled, Randomized Blocks Study Investigating the Effect of 4 Dosages (1 mg, 5 mg, 15 mg, 50 mg) of MEM 3454 on P50 Sensory Gating and Mismatch Negativity (MMN) in Patients With Schizophrenia|Unknown status|Not yet recruiting|Phase 2|12|Anticipated|Memory Pharmaceuticals||5|||f||||f||||||||||2018-06-01 01:53:37.479195|2018-06-01 01:53:37.479195
NCT00725842|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2012-06-13||2015-09-18|2008-07-28|2008-07-31|Estimate|2012-06-25|2012-08-07|Estimate||||2015-09-18|2015-09-21|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|RE-CHUT||Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)|Relapse Rate and Predictive Factors in the Treatment of Hepatitis C in Common Clinical Practice|Terminated|||97|Actual|Merck Sharp & Dohme Corp.|Due to low enrollment some planned analyses were not performed.||1|Low enrollment|f||||f||||||||||2018-06-01 01:53:37.573533|2018-06-01 01:53:37.573533
NCT00725829|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-02-09|2008-07-29|2008-07-31|Estimate|||||||2009-02-09|2009-02-10|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects|Effects of Simvastatin Versus Simvastatin Combined With Ezetimibe on Blood Coagulation in Patients With Acute Coronary Events: Relationship With Cholesterol-Lowering and Anti-Inflammatory Properties|Unknown status|Recruiting|N/A|100|Anticipated|Jagiellonian University||2|||f||||f||||||||||2018-06-01 01:53:37.723368|2018-06-01 01:53:37.723368
NCT00725816|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-03-14|2008-07-30|2008-07-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:53:37.808738|2018-06-01 01:53:37.808738
NCT00725803|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29||2014-01-03|2014-06-11|2008-07-29|2008-07-31|Estimate||||2014-01-03|2014-02-04|Estimate|2014-06-11|2014-06-19|Estimate|April 2008||2008-04-30|June 2014|2014-06-30|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|||Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV|A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects With Chronic Hepatitis C (GS-US-227-0102)|Completed||Phase 2|33|Actual|Gilead Sciences||4|||f||||f||||||||||2018-06-01 01:53:37.844732|2018-06-01 01:53:37.844732
NCT00725790|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-28|2008-07-28|2008-07-30|Estimate|||||||2008-07-28|2008-07-30|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|SCI||A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury|Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury|Unknown status|Not yet recruiting|Phase 4|350|Anticipated|China Rehabilitation Research Center||2|||f||||||||||||||2018-06-01 01:53:37.935757|2018-06-01 01:53:37.935757
NCT00725777|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2012-02-16|2008-07-28|2008-07-30|Estimate|||||||2012-02-16|2012-02-17|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Treatment of Non-falciparum Malaria|Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon|Completed||N/A|40|Actual|Albert Schweitzer Hospital||1|||f||||f||||||||||2018-06-01 01:53:38.03593|2018-06-01 01:53:38.03593
NCT00725764|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2017-07-25|2010-02-05|2017-09-13|2008-07-28|2008-07-30|Estimate|2017-09-13|2017-10-16|Actual|2010-02-05|2010-02-10|Estimate|2017-09-13|2017-10-16|Actual|August 27, 2007|Actual|2007-08-27|July 2017|2017-07-31|May 2, 2009|Actual|2009-05-02|May 2, 2009|Actual|2009-05-02||Interventional|||Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck|A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|14|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:53:38.366825|2018-06-01 01:53:38.366825
NCT00725751|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2012-03-23||2015-10-01|2008-07-25|2008-07-30|Estimate|2012-03-23|2012-04-23|Estimate||||2015-10-01|2015-10-02|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)|Evaluation of Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Patients With/Without Substitution Therapy in Austria|Completed|||353|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:53:38.821787|2018-06-01 01:53:38.821787
NCT00725738|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-29|2008-07-29|2008-07-30|Estimate|||||||2008-07-29|2008-07-30|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|TRACIA||Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA STUDY.|Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA Study.|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|National Heart Institute, Mexico||1|||f||||f||||||||||2018-06-01 01:53:39.139365|2018-06-01 01:53:39.139365
NCT00725725|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2016-08-10|2010-05-12|2017-01-09|2008-07-29|2008-07-30|Estimate|2016-11-01|2016-12-30|Estimate|2010-05-28|2010-06-02|Estimate|2017-01-09|2017-02-23|Actual|July 2008||2008-07-31|January 2017|2017-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)|A Multi-center, Double-blind, Fixed Dose Trial Examining the Efficacy and Safety of Org 25935 Versus Placebo as Augmentation to Cognitive Behavioral Therapy in Subjects With Panic Disorder|Terminated||Phase 2|46|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:53:39.286938|2018-06-01 01:53:39.286938
NCT00725712|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|2017-07-23|2010-08-12|2017-07-23|2008-07-29|2008-07-30|Estimate|2017-07-23|2017-08-24|Actual|2010-08-12|2010-08-18|Estimate|2017-07-23|2017-08-24|Actual|March 31, 2007||2007-03-31|October 2016|2016-10-31|November 30, 2009|Actual|2009-11-30|November 1, 2009|Actual|2009-11-01||Interventional|||Study of GSK1363089 in Metastatic Gastric Cancer|A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer|Completed||Phase 2|74|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:53:39.99521|2018-06-01 01:53:39.99521
NCT00725699|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2011-03-05|2008-07-29|2008-07-30|Estimate|||||||2011-03-05|2011-03-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:53:41.090048|2018-06-01 01:53:41.090048
NCT00725686|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2012-10-05|2008-07-28|2008-07-30|Estimate|||||||2012-10-05|2012-10-10|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)|"A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration (Wet AMD)."|Completed||Phase 1|54|Actual|Quark Pharmaceuticals|||||f||||t||||||||||2018-06-01 01:53:41.12561|2018-06-01 01:53:41.12561
NCT00725673|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2009-11-09|2008-07-29|2008-07-30|Estimate|||||||2009-11-09|2009-11-10|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Observational|||Case Control Study: Determinants of Osteoporosis in GOLD II COPD Patients.|Determination of Risk Factors for Developing Osteoporosis in COPD GOLD II Patients. A Case Control Study to Identify Possible Risk Factors for Developing Osteoporosis in COPD GOLD II Patients.|Completed|||106|Actual|Catharina Ziekenhuis Eindhoven|||2||f||||t||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 01:53:41.202918|2018-06-01 01:53:41.202918
NCT00725660|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2008-07-29|2008-07-29|2008-07-30|Estimate|||||||2008-07-29|2008-07-30|Estimate|September 2008||2008-09-30|July 2008|2008-07-31||||||||Observational|||Pre-Eclampsia Prediction By Doppler Screening Of Uterine Arteries And Angiogenic Factors In Second Trimester Of Pregnancy||Unknown status|Not yet recruiting||3000|Anticipated|Shaare Zedek Medical Center|||1||f||||||||||||||2018-06-01 01:53:41.32238|2018-06-01 01:53:41.32238
NCT00725647|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2009-09-17|2008-07-29|2008-07-30|Estimate|||||||2009-09-17|2009-09-18|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies|A Study of the Value of Plasma N-terminal proBNP Concentrations for Diagnosing Patent Ductus Arteriosus in Preterm Babies.|Completed|||102|Actual|St George's, University of London|||1||f||||f||||||||||2018-06-01 01:53:41.379703|2018-06-01 01:53:41.379703
NCT00725634|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2014-01-23|2008-07-28|2008-07-30|Estimate|||||||2014-01-23|2014-01-27|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2010|Actual|2010-12-31||Interventional|P05538||A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma|A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors|Completed||Phase 1|41|Actual|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 01:53:41.434363|2018-06-01 01:53:41.434363
NCT00725621|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-07-08||2015-09-02|2008-07-25|2008-07-30|Estimate|2011-07-08|2011-08-04|Estimate||||2015-09-02|2015-09-03|Estimate|March 2004||2004-03-31|September 2015|2015-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)|Real Life Dosing Regimen of Remicade in Austria, Monitored Over 9 Consecutive Infusions in Rheumatoid Arthritis Therapy|Completed|||516|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:41.531498|2018-06-01 01:53:41.531498
NCT00725608|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-10-18||2017-01-19|2008-07-25|2008-07-30|Estimate|2012-02-12|2012-03-23|Estimate||||2017-01-19|2017-03-03|Actual|May 2008||2008-05-31|January 2017|2017-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)|Evaluation of Transfer From Subutex or Other Treatment for Opioid Drug Dependence to Suboxone: Acceptability, Safety and Impact on Medication Dispensing|Completed|||339|Actual|Indivior Inc.|||1||f||||f||||||||||2018-06-01 01:53:41.951453|2018-06-01 01:53:41.951453
NCT00725595|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-08-25|2008-07-28|2008-07-30|Estimate|||||||2008-08-25|2008-08-26|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Treatment of Cheyne Stocks Respiration With Adaptive Servo Ventilation and Bilevel Ventilators in Patients With Chronic Heart Failure||Unknown status|Recruiting||12|Anticipated|Nanjing Medical University|||1||f||||t||||||||||2018-06-01 01:53:42.132773|2018-06-01 01:53:42.132773
NCT00724399|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2016-12-15|2008-07-24|2008-07-29|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2006||2006-01-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Preventive Health Practices in Women|Preventive Health Practices in Women|Completed|||1418|Actual|University of Michigan|||2||f||||f||||||||No||2018-06-01 01:54:06.126188|2018-06-01 01:54:06.126188
NCT00725582|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2009-06-01|2008-07-29|2008-07-30|Estimate|||||||2009-06-01|2009-06-02|Estimate|September 2008||2008-09-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma|The Effects of IMA-026 on Allergen-Induced Airway Responses and Airway Inflammation in Subjects With Mild Atopic Asthma|Completed||Phase 1|24|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:53:42.205267|2018-06-01 01:53:42.205267
NCT00725569|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2009-10-18|2008-07-29|2008-07-30|Estimate|||||||2009-10-18|2009-10-20|Estimate|August 2008||2008-08-31|October 2008|2008-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Homeopathy for Post-operative (C. Section) Recovery|Effect of Homeopathic Drugs Bellis Perennis ו- Staphysagria on the Post-operative Recovery, of Women Undergoing Cesarean Section- (an Exploratory) Double Blind, Placebo Controlled Study|Completed||Phase 2/Phase 3|90|Anticipated|Shaare Zedek Medical Center||3|||f||||f||||||||||2018-06-01 01:53:42.264082|2018-06-01 01:53:42.264082
NCT00725556|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-31|2008-07-28|2008-07-30|Estimate|||||||2008-07-31|2008-08-01|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|March 2007|Actual|2007-03-31||Interventional|||The Development of Autistic Children Based on Mothers´Response in Autism Behavior Checklist|The Development of Autistic Children Based on Mother´s Response in Autism Behavior Checklist|Completed||Phase 1/Phase 2|11|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 01:53:42.334047|2018-06-01 01:53:42.334047
NCT00725543|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-06-13||2015-09-28|2008-07-25|2008-07-30|Estimate|2011-06-13|2011-07-07|Estimate||||2015-09-28|2015-09-30|Estimate|June 2004||2004-06-30|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)|Remicade Therapy in Ankylosing Spondylitis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions|Completed|||358|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:42.400528|2018-06-01 01:53:42.400528
NCT00725530|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2009-09-25||2012-07-19|2008-07-29|2008-07-30|Estimate|2012-07-19|2012-08-22|Estimate||||2012-07-19|2012-08-22|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluation of Deposits on Contact Lenses Worn Extended Wear||Completed||N/A|54|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:53:42.640281|2018-06-01 01:53:42.640281
NCT00725517|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-31|2008-07-28|2008-07-30|Estimate|||||||2008-07-31|2008-08-01|Estimate|December 2005||2005-12-31|July 2008|2008-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange|Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange in Continuous Ambulatory Peritoneal Dialysis Patients, Compare to 2.5% Dianeal Peritoneal Dialysis Solution.|Completed||Phase 4|2|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 01:53:42.770204|2018-06-01 01:53:42.770204
NCT00725504|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2017-03-04||2017-03-04|2008-07-28|2008-07-30|Estimate|2017-03-04|2017-04-17|Actual||||2017-03-04|2017-04-17|Actual|September 2008||2008-09-30|March 2017|2017-03-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional||Seventy-one patients with chronic neuropathic pain|Effect of IV Lidocaine Infusions on Pain|Effect of IV Lidocaine Infusions on Pain|Completed||N/A|71|Actual|Stanford University||1|||f||||||||||||||2018-06-01 01:53:42.852265|2018-06-01 01:53:42.852265
NCT00725491|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2009-12-17||2014-11-18|2008-07-29|2008-07-30|Estimate|2009-12-17|2010-01-22|Estimate||||2014-11-18|2014-12-03|Estimate|May 2007||2007-05-31|November 2014|2014-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)|A Phase III, Multi-center, Open-label, Randomized Study to Assess the Efficacy and Safety of Org 37462 Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for IVF or ICSI, Using a Long Protocol of Triptorelin as a Reference Treatment.|Completed||Phase 3|259|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:53:43.081497|2018-06-01 01:53:43.081497
NCT00725478|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2010-03-30|2008-07-29|2008-07-30|Estimate|||||||2010-03-30|2010-03-31|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|PIR-001/K||SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease|Stabilization on, or Change-over to the Non-ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Parkinson Clinic Ambulances and Larger Private Practices.|Completed|||250|Actual|Desitin Arzneimittel GmbH|||||f||||f||||||||||2018-06-01 01:53:43.43799|2018-06-01 01:53:43.43799
NCT00725465|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2012-03-07|2008-07-29|2008-07-30|Estimate|||||||2012-03-07|2012-03-08|Estimate|January 2006||2006-01-31|March 2012|2012-03-31||||||||Observational|||Prospective Evaluation of Combined Laparoscopy With CO2 Intraoperative Colonoscopy Treatment for Colorectal Lesions|Prospective Evaluation of Combined Laparoscopy With CO2 Intraoperative Colonoscopy Treatment for Colorectal Lesions|Unknown status|Recruiting||30|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 01:53:43.507074|2018-06-01 01:53:43.507074
NCT00725452|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-06-13||2015-07-15|2008-07-25|2008-07-30|Estimate|2011-08-02|2011-09-02|Estimate||||2015-07-15|2015-07-28|Estimate|October 2006||2006-10-31|July 2015|2015-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)|Real Life Treatment Regimen of Remicade (Infliximab) in Austria, Monitored Over 5 Years in Plaque Psoriasis Therapy|Completed|||26|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:43.611626|2018-06-01 01:53:43.611626
NCT00725439|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-09-23|2008-07-28|2008-07-30|Estimate|||||||2011-09-23|2011-09-26|Estimate|September 2004||2004-09-30|September 2011|2011-09-30|December 2007|Actual|2007-12-31|July 2005|Actual|2005-07-31||Interventional|||An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne|An Open Label Pilot Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment of Moderate to Severe Facial Acne|Completed||Phase 2|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:53:43.832838|2018-06-01 01:53:43.832838
NCT00725426|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2009-04-24|2008-07-29|2008-07-30|Estimate|||||||2009-04-24|2009-04-27|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Rifampin on Bosutinib When Both Are Given to Healthy People|A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Bosutinib When Administered Concomitantly to Healthy Subjects|Completed||Phase 1|24|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:53:43.892595|2018-06-01 01:53:43.892595
NCT00723541|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2018-01-09|2008-07-24|2008-07-28|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2008||2008-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Breast Lesion Analysis for Tomosynthesis Mammography|Tomosynthesis Mammography: Computer-Aided Analysis of Breast Lesions|Recruiting||Early Phase 1|800|Anticipated|University of Michigan||1|||f||||f||||||||No||2018-06-01 01:54:18.221036|2018-06-01 01:54:18.221036
NCT00725413|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2015-02-06|2008-07-29|2008-07-30|Estimate|||||||2015-02-06|2015-02-09|Estimate|November 2001||2001-11-30|February 2015|2015-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)(P06473)(COMPLETED)|A Study to Investigate the Contraceptive Efficacy and Safety of a Subdermal Etonogestrel Implant (Implanon®)|Completed||Phase 4|210|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 01:53:44.020226|2018-06-01 01:53:44.020226
NCT00725400|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2011-07-19|2008-07-28|2008-07-30|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 2010||2010-02-28|July 2011|2011-07-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma|Phase II Open Label Comparative Study of Cetuximab and Radiation Therapy Vs Surgery Before or After Radiation Therapy in Patients With Stage II to IV Colorectal Carcinoma|Withdrawn||Phase 2|450|Anticipated|American Scitech International||2||"Study is withdrawn due to unavailability of eligible subject population. We will request the~   sponsors to extend the time for enrollment."|f||||f||||||||||2018-06-01 01:53:44.094726|2018-06-01 01:53:44.094726
NCT00725387|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2018-04-20|2008-07-28|2008-07-30|Estimate|||||||2018-04-20|2018-04-23|Actual|August 2007||2007-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy|Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy|Recruiting|||250|Anticipated|Stanford University|||||f||||t||||||||||2018-06-01 01:53:44.19737|2018-06-01 01:53:44.19737
NCT00725374|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2017-05-29|2008-07-29|2008-07-30|Estimate|||||||2017-05-29|2017-05-31|Actual|December 15, 2002|Actual|2002-12-15|May 2017|2017-05-31|April 15, 2005|Actual|2005-04-15|April 15, 2005|Actual|2005-04-15||Interventional|STEM||A Study to Investigate the Effects of Tibolone (Livial®) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)|A Exploratory, Double-blind, Randomized, Placebo-controlled Trial to Investigate the Tissue Specific Effects of 2.5 mg Tibolone on Breast Cancer in Postmenopausal Women, in Particular on Breast Tissue Proliferation.|Completed||Phase 3|102|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:53:44.290739|2018-06-01 01:53:44.290739
NCT00725361|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2016-12-20||2017-03-01|2008-07-28|2008-07-30|Estimate|2017-01-04|2017-02-24|Actual||||2017-03-01|2017-03-31|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).|A Pilot Study to Evaluate the Efficacy of Ambrisentan in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis.|Completed||N/A|20|Actual|Stanford University||1|||f||||||||||||||2018-06-01 01:53:44.383562|2018-06-01 01:53:44.383562
NCT00725348|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-09-23|2008-07-28|2008-07-30|Estimate|||||||2011-09-23|2011-09-26|Estimate|April 2004||2004-04-30|July 2008|2008-07-31|December 2006|Actual|2006-12-31|March 2005|Actual|2005-03-31||Interventional|||An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis|An Open-Label, Multi-Center Pilot Trial to Assess the Efficacy and Safety of Oral R115866 in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis|Completed||Phase 2|19|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:53:44.61513|2018-06-01 01:53:44.61513
NCT00725335|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2012-11-23|2008-07-29|2008-07-30|Estimate|||||||2012-11-23|2012-11-27|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Effect of I/R Injuries by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative Hepatectomy|The Effect of Ischemia/Reperfusion Injuries Elicited by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative Excision:A Multicenter Prospective Randomized Controlled Trial|Completed||N/A|498|Actual|Southwest Hospital, China||2|||f||||t||||||||||2018-06-01 01:53:44.697993|2018-06-01 01:53:44.697993
NCT00725322|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2017-07-11||2017-10-23|2008-07-28|2008-07-30|Estimate|2017-10-23|2017-10-25|Actual||||2017-10-23|2017-10-25|Actual|December 2007||2007-12-31|October 2017|2017-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Subcutaneous Botulinum Toxin for Cutaneous Allodynia|Subcutaneous Botulinum Toxin for Cutaneous Allodynia|Completed||N/A|84|Actual|Stanford University||2|||f||||||||||||||2018-06-01 01:53:44.787826|2018-06-01 01:53:44.787826
NCT00725309|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2012-09-14|2008-07-29|2008-07-30|Estimate|||||||2012-09-14|2012-09-17|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease|Specialized Center of Clinically Oriented Research: Alveolar and Airway Mechanisms for COPD: Genetic Determinants: Elastin Quality and Quantity (Project 2)|Unknown status|Active, not recruiting||255|Actual|Washington University School of Medicine|||||f||||t||||||Samples With DNA|"~     Plasma, serum, isolated RNA and DNA, lung tissue (obtained from other substudies)~   "|||2018-06-01 01:53:45.04155|2018-06-01 01:53:45.04155
NCT00725296|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-07-01||2015-10-13|2008-07-25|2008-07-30|Estimate|2011-07-01|2011-07-29|Estimate||||2015-10-13|2015-11-05|Estimate|December 2004||2004-12-31|October 2015|2015-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)|Remicade Therapy in Psoriatic Arthritis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions|Completed|||178|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:45.113983|2018-06-01 01:53:45.113983
NCT00725283|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2016-07-28|2008-07-29|2008-07-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)|Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients With Acute Myeloid Leukemia|Completed||Phase 1|34|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-06-01 01:53:45.301224|2018-06-01 01:53:45.301224
NCT00725270|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2016-10-11||2017-02-01|2008-07-28|2008-07-30|Estimate|2017-02-01|2017-03-24|Actual||||2017-02-01|2017-03-24|Actual|April 1998||1998-04-30|February 2017|2017-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Treatment of Schizoaffective Disorder Using Mifepristone|Treatment of Schizoaffective Disorder Using Mifepristone|Terminated||Phase 2/Phase 3|12|Actual|Stanford University||2||Lack of funding.|f||||||||||||||2018-06-01 01:53:45.398087|2018-06-01 01:53:45.398087
NCT00725257|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-28|2008-07-28|2008-07-30|Estimate|||||||2008-07-28|2008-07-30|Estimate|June 2004||2004-06-30|July 2008|2008-07-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Dietary Control of Type 2 Diabetes: Low-Carbohydrate Mediterranean Diet Versus Low-Fat Diet|Effect of a Low-Carbohydrate Mediterranean Diet or Low-Fat Diet in Newly-Diagnosed Type 2 Diabetic Patients|Completed||N/A|215|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-06-01 01:53:45.787043|2018-06-01 01:53:45.787043
NCT00725244|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-10-16|2008-07-28|2008-07-30|Estimate|||||||2008-10-16|2008-10-17|Estimate|May 2005||2005-05-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|November 2007|Actual|2007-11-30||Interventional|||Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias|A Randomized Prospective Study of Endoscopy Bipolar Eletrocoagulation and Argon Plasma Coagulation of Chronic Rectal Bleeding From Radiation Telangiectasias|Completed||Phase 4|30|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:53:45.873554|2018-06-01 01:53:45.873554
NCT00725231|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2012-05-04|2008-07-25|2008-07-30|Estimate|||||||2012-05-04|2012-05-07|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|A-CHOP-14||Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP|Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly|Unknown status|Recruiting|Phase 3|274|Anticipated|University of Göttingen||2|||f||||t||||||||||2018-06-01 01:53:45.953658|2018-06-01 01:53:45.953658
NCT00725218|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-08-05|2008-07-28|2008-07-30|Estimate|||||||2008-08-05|2008-08-06|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|FAUCOP||Flurbiprofen Axetil for Uterine Contraction Pain|Phase IV Study of Flurbiprofen Axetil for Uterine Contraction Pain After Abortion|Completed||Phase 4|97|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 01:53:46.036434|2018-06-01 01:53:46.036434
NCT00725205|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-10-10||2015-10-07|2008-07-25|2008-07-30|Estimate|2011-10-10|2011-11-18|Estimate||||2015-10-07|2015-10-08|Estimate|March 2006||2006-03-31|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)|Patient Compliance During PegIntron (Injection Pen) and Rebetol Combination Therapy in Chronic Hepatitis C|Completed|||294|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:46.124439|2018-06-01 01:53:46.124439
NCT00725192|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2011-04-06|2008-07-29|2008-07-30|Estimate|||||||2011-04-06|2011-04-07|Estimate|July 2008||2008-07-31|April 2011|2011-04-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|Hypnosis||Sleep-directed Hypnosis As A Complement To Cognitive Processing Therapy (CPT) In Treating Posttraumatic Stress Disorder (PTSD)|Sleep-directed Hypnosis As A Complement To CPT In Treating PTSD|Unknown status|Active, not recruiting|N/A|50|Anticipated|Center for Trauma Recovery, St Louis||2|||f||||f||||||||||2018-06-01 01:53:46.275828|2018-06-01 01:53:46.275828
NCT00725179|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2011-09-08|2008-07-29|2008-07-30|Estimate|||||||2011-09-08|2011-09-09|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Observational|||Treatment of Acetaminophen Toxicity With N-acetylcysteine|Treatment of Acetaminophen Toxicity With Intravenous vs Oral N-acetylcysteine: A Retrospective Review|Completed|||130|Anticipated|Akron Children's Hospital|||2||f||||f||||||||||2018-06-01 01:53:46.350445|2018-06-01 01:53:46.350445
NCT00725166|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2009-06-09|2008-07-29|2008-07-30|Estimate|||||||2009-06-09|2009-06-11|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|CERA||Human Muscle Gene Expression Profiles in Young and Old Men|Human Muscle Gene Expression Profiles in Young and Old Men|Completed|||41|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples With DNA|"~     Serum, muscle~   "|||2018-06-01 01:53:46.403409|2018-06-01 01:53:46.403409
NCT00725153|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2009-09-25||2012-07-20|2008-07-29|2008-07-30|Estimate|2012-07-20|2012-08-23|Estimate||||2012-07-20|2012-08-23|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of Deposits on Contact Lenses Worn Daily Wear||Completed||N/A|55|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:53:46.469993|2018-06-01 01:53:46.469993
NCT00725140|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2015-05-29|2008-07-29|2008-07-30|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Observational|START||Standardized sTudy With Almotriptan in eaRly Treatment of Migraine|Standardized sTudy With Almotriptan in eaRly Treatment of Migraine, START. An International, Open-label, Single Arm, Effectiveness and Safety Study of Almotriptan in Primary Care Setting|Completed|||501|Actual|Almirall, S.A.|||1||f||||t||||||||||2018-06-01 01:53:46.598594|2018-06-01 01:53:46.598594
NCT00725127|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2017-12-04|2008-07-28|2008-07-30|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2008||2008-10-31|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|CARING||Chronotherapy With Low-dose Aspirin for Primary Prevention|Chronotherapy With Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Subjects With Impaired Fasting Glucose or Diabetes (CARING Study).|Recruiting||Phase 4|3200|Anticipated|University of Vigo||2|||f||||t||||||||Undecided||2018-06-01 01:53:46.663312|2018-06-01 01:53:46.663312
NCT00725114|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2014-07-07|2008-07-29|2008-07-30|Estimate|||||||2014-07-07|2014-07-09|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TEC-006||Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain|A Multicentre , Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Inadequately Controlled Cancer-related Pain|Completed||Phase 3|165|Actual|Wex Pharmaceuticals Inc.||2|||f||||f||||||||||2018-06-01 01:53:47.822386|2018-06-01 01:53:47.822386
NCT00725101|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2012-04-27||2012-11-29|2008-07-29|2008-07-30|Estimate|2012-04-27|2012-06-01|Estimate||||2012-11-29|2012-11-30|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|REFLECTIONS||Fibromyalgia Health Outcome Study on Cost of Treatments|Real World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments (The REFLECTIONS Study)|Completed|||1700|Actual|Eli Lilly and Company|||1||f||||f||||||||||2018-06-01 01:53:47.97638|2018-06-01 01:53:47.97638
NCT00725088|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-08-22|2008-07-29|2008-07-30|Estimate|||||||2008-08-22|2008-08-25|Estimate|December 2006||2006-12-31|July 2008|2008-07-31|December 2010|Anticipated|2010-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Study of Rehabilitation Therapy on Patients After Acute Myocardial Infarction|Study of Rehabilitation Therapy on Patients After Acute Myocardial Infarction|Unknown status|Recruiting|N/A|300|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-06-01 01:53:48.602388|2018-06-01 01:53:48.602388
NCT00725075|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2016-10-19||2016-10-19|2008-07-29|2008-07-30|Estimate|2016-10-19|2016-12-13|Estimate||||2016-10-19|2016-12-13|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|GIANT||Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)|A Multi-center, Double-blind, Flexible-dose Efficacy Trial With Org 25935 Versus Placebo as add-on Therapy in Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia Treated With a Stable Dose of a Second Generation Antipsychotic (GIANT)|Completed||Phase 2|215|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 01:53:48.724276|2018-06-01 01:53:48.724276
NCT00725062|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2017-11-27|2008-07-29|2008-07-30|Estimate|||||||2017-11-27|2017-11-29|Actual|June 2008||2008-06-30|November 2017|2017-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant|Phase I-II Dose Escalation Study of CD4+CD25+ Cells in Adult Patients Undergoing HLA-Identical Sibling Donor Peripheral Blood Progenitor Cell Transplantation|Terminated||Phase 1|3|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual.|f||||t||||||||||2018-06-01 01:53:49.250762|2018-06-01 01:53:49.250762
NCT00725049|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2013-08-06||2017-08-01|2008-07-28|2008-07-30|Estimate|2013-08-06|2013-10-11|Estimate||||2017-08-01|2017-08-30|Actual|February 2009||2009-02-28|August 2017|2017-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Romeo||An Evaluation of Integration Success and Maintenance of Short Implants in Maxillas Needing Sinus Augmentation|A Prospective, Multicenter, Randomized Multicenter Study of Short Implants Used to Obviate the Need for Sinus Augmentation: an Assessment of Clinical Outcomes and Resource Allocation.|Completed||N/A|37|Actual|Zimmer Biomet||2|||f||||t||||||||No||2018-06-01 01:53:49.342946|2018-06-01 01:53:49.342946
NCT00725036|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-29|||2017-02-28|2008-07-29|2008-07-30|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2, 2002|Actual|2002-09-02|February 2017|2017-02-28|December 14, 2004|Actual|2004-12-14|December 14, 2004|Actual|2004-12-14||Interventional|||Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes|A 24-month Multicentre, Open-label, Randomised, Parallel Group, Long Term Safety Trial Comparing Intensive Treatment of Pulmonary Inhaled Human Insulin With Insulin Aspart Administered s.c., Both in Combination With NPH, in Subjects With Type 1 Diabetes|Completed||Phase 3|305|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 01:53:49.558219|2018-06-01 01:53:49.558219
NCT00725023|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2011-09-13|2008-07-29|2008-07-30|Estimate|||||||2011-09-13|2011-09-14|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Use of TPD Heat Lamp for Tennis Elbow Pain - a Randomized-controlled Trial|A Randomized Double-blind Study to Assess the Use of TDP© Heat-lamp as an Effective Therapy for Tennis Elbow Pain (Lateral Epicondylitis Pain)|Terminated||Phase 2/Phase 3|116|Anticipated|Queen's University||2||Slow accrual|f||||f||||||||||2018-06-01 01:53:49.736899|2018-06-01 01:53:49.736899
NCT00725010|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-10-22||2015-09-08|2008-07-25|2008-07-30|Estimate|2010-10-22|2010-11-18|Estimate||||2015-09-08|2015-09-09|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)|Temodal (TMZ) in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program|Completed|||64|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:49.822497|2018-06-01 01:53:49.822497
NCT00724997|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2009-12-07|2008-07-28|2008-07-30|Estimate|||||||2009-12-07|2009-12-08|Estimate|March 2007||2007-03-31|December 2009|2009-12-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|GHBCS-01||Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers|Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers|Completed||Phase 1|48|Actual|AVIR Green Hills Biotechnology AG||5|||f||||t||||||||||2018-06-01 01:53:50.053631|2018-06-01 01:53:50.053631
NCT00724984|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2014-02-27||2014-02-27|2008-07-28|2008-07-30|Estimate|2014-02-27|2014-04-07|Estimate||||2014-02-27|2014-04-07|Estimate|July 2008||2008-07-31|February 2014|2014-02-28||||November 2012|Actual|2012-11-30||Interventional|PCYC-0403||Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma|Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma|Completed||Phase 1/Phase 2|55|Actual|Pharmacyclics LLC.||1|||f||||f||||||||||2018-06-01 01:53:50.200195|2018-06-01 01:53:50.200195
NCT00724971|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-02-14|2008-07-29|2008-07-30|Estimate|||||||2013-02-14|2013-02-15|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab|A Phase 1 Study Of Inotuzumab Ozogamicin (CMC-544) Administered In Combination With Rituximab In Subjects With B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 1|10|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 01:53:51.648573|2018-06-01 01:53:51.648573
NCT00724958|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-07-13||2015-10-01|2008-07-25|2008-07-30|Estimate|2011-09-16|2011-10-26|Estimate||||2015-10-01|2015-10-02|Estimate|December 2004||2004-12-31|October 2015|2015-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)|Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension|Completed|||348|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:53:51.745132|2018-06-01 01:53:51.745132
NCT00724945|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2009-09-25||2015-05-05|2008-07-29|2008-07-30|Estimate|2009-12-23|2010-01-27|Estimate||||2015-05-05|2015-05-21|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Two Soft Bifocal Contact Lenses||Completed||N/A|113|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-06-01 01:53:52.128389|2018-06-01 01:53:52.128389
NCT00724932|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2013-03-14||2017-04-12|2008-07-28|2008-07-30|Estimate|2013-03-14|2013-04-29|Estimate||||2017-04-12|2017-05-16|Actual|July 16, 2008|Actual|2008-07-16|April 2017|2017-04-30|May 3, 2009|Actual|2009-05-03|April 1, 2009|Actual|2009-04-01||Interventional||The Baseline Analysis Population consisted of randomized participants who received investigational medicinal product (IMP). Four participants randomized to Sugammadex did not receive IMP and three participants randomized to receive Neostigmine did not receive IMP.|Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699)|A Multi-center, Randomized, Parallel-group, Comparative, Active-controlled, Safety-assessor Blinded Trial in Adult Subjects Comparing the Efficacy and Safety of Sugammadex (SCH 900616, ORG 25969) Administered at 1-2 PTC With Neostigmine Administered at Reappearance of T2 in Subjects Undergoing Laparoscopic Cholecystectomy or Appendectomy Under Propofol Anesthesia|Completed||Phase 3|140|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 01:53:52.442974|2018-06-01 01:53:52.442974
NCT00724919|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-08-07|2008-07-25|2008-07-30|Estimate|||||||2008-08-07|2008-08-11|Estimate|December 2003||2003-12-31|August 2008|2008-08-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Observational|||A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli|Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)|Completed|||256|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 01:53:53.24407|2018-06-01 01:53:53.24407
NCT00724906|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2010-02-02|2008-07-29|2008-07-30|Estimate|||||||2010-02-02|2010-02-03|Estimate|July 2010||2010-07-31|February 2010|2010-02-28|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|POET-2||Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor|Evaluation of the Diagnostic Accuracy and Safety of 123 I-ALTROPANE® as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes (POET-2)|Unknown status|Not yet recruiting|Phase 3|240|Anticipated|Alseres Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 01:53:53.302182|2018-06-01 01:53:53.302182
NCT00724893|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2013-07-29||2015-07-20|2008-07-25|2008-07-30|Estimate|2013-10-25|2013-11-20|Estimate||||2015-07-20|2015-08-14|Estimate|August 2005||2005-08-31|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)|Pegetron® Redipen™ Prospective Optimal Weight-based Dosing Response Program|Completed|||2430|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:53:53.418292|2018-06-01 01:53:53.418292
NCT00724880|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-28|2008-07-28|2008-07-30|Estimate|||||||2008-07-28|2008-07-30|Estimate|June 2006||2006-06-30|July 2008|2008-07-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery.|Effect of Clopidogrel (Plavix) on Postoperative Bleeding in Patients Undergoing Coronary Artery Bypass Surgery. A Prospective Randomized Controlled Study|Completed||Phase 4|135|Actual|Catharina Ziekenhuis Eindhoven||3|||f||||||||||||||2018-06-01 01:53:54.710455|2018-06-01 01:53:54.710455
NCT00724867|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2015-11-19||2016-03-10|2008-07-29|2008-07-30|Estimate|2016-03-10|2016-03-28|Estimate||||2016-03-10|2016-03-28|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States|A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States|Completed||Phase 3|268|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 01:53:55.082829|2018-06-01 01:53:55.082829
NCT00724854|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-12-23||2015-02-06|2008-07-25|2008-07-30|Estimate|2010-12-23|2011-01-10|Estimate||||2015-02-06|2015-02-25|Estimate|August 2006||2006-08-31|February 2015|2015-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|APEGIN||Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)|Evaluation of Rapid Virological Response in HCV Patients Treated With PegIntron and Ribavirin - APEGIN Trial|Completed|||1146|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:53:58.745291|2018-06-01 01:53:58.745291
NCT00724841|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28||2013-08-28|2016-07-20|2008-07-28|2008-07-30|Estimate||||2013-08-28|2013-09-13|Estimate|2016-07-20|2016-07-22|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|August 2010|Actual|2010-08-31|July 2008|Actual|2008-07-31||Interventional|||A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma|A Multi-Center, Open-Label, Phase I/II Study of GEM1777 in Combination With Temozolomide Administered Every 4 Weeks to Patients With Metastatic Melanoma|Terminated||Phase 1/Phase 2|1|Actual|Teva Pharmaceutical Industries||6||Study terminated prematurely due to financial contraints.|f||||f||||||||||2018-06-01 01:53:59.354443|2018-06-01 01:53:59.354443
NCT00724828|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-29|2008-07-29|2008-07-30|Estimate|||||||2008-07-29|2008-07-30|Estimate|May 2005||2005-05-31|July 2008|2008-07-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Study Evaluating Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Filipino Children|An Evaluation of Streptococcus Pneumoniae Serotype Carriage Rate For Nasopharyngeal Carriage in Filipino Children Attending Well Baby Clinic in Hospitals and Primary Care Centers|Completed|||500|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||t||||||||||2018-06-01 01:53:59.439616|2018-06-01 01:53:59.439616
NCT00724815|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2013-02-15|2012-11-07|2016-02-02|2008-07-29|2008-07-30|Estimate|2013-03-26|2013-05-07|Estimate|2013-02-06|2013-02-07|Estimate|2016-02-02|2016-02-04|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|NP101-007|Per protocol, the safety population was defined as subjects who applied a study patch. In each treatment group there were subjects who were randomized but not treated (NP101=31, placebo patch=30) and are therefore not included in the safety population.|The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine|The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 3|530|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 01:53:59.503744|2018-06-01 01:53:59.503744
NCT00724802|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2011-06-20|2008-07-29|2008-07-30|Estimate|||||||2011-06-20|2011-06-21|Estimate|March 2008||2008-03-31|June 2011|2011-06-30||||August 2008|Actual|2008-08-31||Interventional|||Oral Glyceryl Triacetate (GTA) in Newborns With Canavan|Oral Glyceryl Triacetate (GTA) in Newborns With Canavan|Unknown status|Recruiting|N/A|1|Anticipated|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 01:53:59.895042|2018-06-01 01:53:59.895042
NCT00724789|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2015-07-13|2008-07-28|2008-07-30|Estimate|||||||2015-07-13|2015-07-14|Estimate|November 2000||2000-11-30|July 2015|2015-07-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)|An Open-label, Observational Trial to Monitor the Incidence of Congenital Malformations in Infants of Women With an Ongoing Pregnancy After Controlled Ovarian Hyperstimulation Using Puregon® (recFSH)/Orgalutran® (Ganirelix) Followed by IVF/ICSI, or a Long Protocol With a GnRH Agonist as Historical Controls.|Completed|||2066|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:53:59.97487|2018-06-01 01:53:59.97487
NCT00724776|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2010-08-10|2008-07-28|2008-07-30|Estimate|||||||2010-08-10|2010-08-11|Estimate|July 2008||2008-07-31|August 2010|2010-08-31||||July 2009|Actual|2009-07-31||Interventional|||Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients|A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Single Dose of Albinterferon Alfa 2b (Alb-IFN), Recombinant Human Albumin-interferon Alfa Fusion Protein in Japanese Chronic Hepatitis C Patients.|Completed||Phase 1|30|Anticipated|Novartis||1|||f||||f||||||||||2018-06-01 01:54:00.0515|2018-06-01 01:54:00.0515
NCT00724763|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-29|2008-07-29|2008-07-30|Estimate|||||||2008-07-29|2008-07-30|Estimate|July 2008||2008-07-31|July 2008|2008-07-31||||July 2009|Anticipated|2009-07-31||Interventional|Acupuncture||The Effect of Acupuncture on Blood Pressure and Heart Rate Variability (HRV)|The Effect of Acupuncture on Blood Pressure and HRV|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 01:54:00.111636|2018-06-01 01:54:00.111636
NCT00724750|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2015-07-27||2015-09-24|2008-07-29|2008-07-30|Estimate|2015-09-24|2015-10-19|Estimate||||2015-09-24|2015-10-19|Estimate|July 2006||2006-07-31|September 2015|2015-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Comparison of Two Methods of Negative Pressure Wound Therapy|Prospective Randomized Control Trial Comparing Two Methods of Negative Pressure Wound Therapy: Gauze Suction Versus Vacuum Assisted Closure Device|Completed||N/A|87|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 01:54:00.193097|2018-06-01 01:54:00.193097
NCT00724737|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2017-05-16|2008-07-28|2008-07-29|Estimate|||||||2017-05-16|2017-05-18|Actual|July 2006|Actual|2006-07-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Presurgical Planning With Functional MRI (fMRI) Mapping of Motor Cortex in Patients With Cerebral Tumors|Presurgical Planning With Motion Corrected fMRI Mapping of Motor Cortex in Patients With Cerebral Tumors|Completed||N/A|23|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 01:54:00.445228|2018-06-01 01:54:00.445228
NCT00724724|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-26|||2011-02-23|2008-07-26|2008-07-29|Estimate|||||||2011-02-23|2011-02-24|Estimate|August 2008||2008-08-31|February 2011|2011-02-28|August 2011|Anticipated|2011-08-31|June 2011|Anticipated|2011-06-30||Interventional|ESCAPE||The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial|The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial|Unknown status|Recruiting|Phase 4|1000|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-06-01 01:54:00.523958|2018-06-01 01:54:00.523958
NCT00724711|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2012-03-28||2012-05-22|2008-07-28|2008-07-29|Estimate|2012-03-28|2012-04-19|Estimate||||2012-05-22|2012-05-28|Estimate|July 2008||2008-07-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|SWIFT||Safety and Efficacy Study of Switching From Epzicom to Truvada|A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen|Completed||Phase 4|312|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 01:54:00.704434|2018-06-01 01:54:00.704434
NCT00724698|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2009-05-28||2016-01-22|2008-07-25|2008-07-29|Estimate|2009-05-28|2009-07-17|Estimate||||2016-01-22|2016-02-23|Estimate|October 2005||2005-10-31|January 2016|2016-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|Aerius||Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria|Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients|Completed|||3011|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:02.556325|2018-06-01 01:54:02.556325
NCT00724685|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-02-07|2008-07-28|2008-07-29|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Interest of Continuous Ropivacaine Administration Through an Elastomeric Pump (Pain Buster) for the Surgery of Latissimus Dorsi and Serratus Micro Anastomotic Flaps|Interest of Continuous Ropivacaine Administration Through an Elastomeric Pump (Pain Buster ) for the Surgery of Latissimus Dorsi and Serratus Micro Anastomotic Flaps|Terminated||Phase 4|34|Actual|Nantes University Hospital||2|||f||||||||||||||2018-06-01 01:54:02.715088|2018-06-01 01:54:02.715088
NCT00724672|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-05-29|2008-07-28|2008-07-29|Estimate|||||||2015-05-29|2015-06-01|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Observational|||A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)|Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Rheumatoid Arthritis During Different Forms of Anti-Tumor Necrosis-Alpha Treatments.|Withdrawn|||0|Actual|Merck Sharp & Dohme Corp.|||4||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 01:54:02.783538|2018-06-01 01:54:02.783538
NCT00724659|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2012-05-01|2008-07-28|2008-07-29|Estimate|||||||2012-05-01|2012-05-03|Estimate|September 2004||2004-09-30|May 2012|2012-05-31|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||Pre and Post Arthrogram Ultrasound Images of Joints|An Evaluation of Pre and Post Arthrogram Ultrasound Images of Joints: Does Arthrography Have a Role in Ultrasonography?|Completed||N/A|9|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 01:54:02.867504|2018-06-01 01:54:02.867504
NCT00724646|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2009-09-14|2008-07-28|2008-07-29|Estimate|||||||2009-09-14|2009-09-15|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Observational|||Perspectives on End-of-Life Care for Medically-Fragile Children and Young Adults|Direct Care Staff and Parents'/Legal Guardians' Perspectives on End-of-Life Care in a Long-Term Care Facility for Medically Fragile and Intellectually Disabled Pediatric and Young Adult Residents|Completed|||125|Anticipated|Akron Children's Hospital|||2||f||||f||||||||||2018-06-01 01:54:02.959203|2018-06-01 01:54:02.959203
NCT00724633|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2017-11-02|2008-07-28|2008-07-29|Estimate|||||||2017-11-02|2017-11-06|Actual|November 1, 2011|Actual|2011-11-01|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|June 6, 2017|Actual|2017-06-06||Interventional|||Effect of Lowering the Dialysate Sodium on Blood Pressure in Hemodialysis Patients|Effect of Lowering the Dialysate Sodium on Blood Pressure in Hemodialysis Patients: a Randomized Controlled Trial.|Completed||Phase 3|35|Actual|Lawson Health Research Institute||3|||f||||t||||||||||2018-06-01 01:54:03.047993|2018-06-01 01:54:03.047993
NCT00724620|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-25|2008-07-25|2008-07-29|Estimate|||||||2008-07-25|2008-07-29|Estimate|June 2005||2005-06-30|July 2008|2008-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)|Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response and Tolerability, in These Patients.|Completed||Phase 4|103|Actual|Schering-Plough||3|||f||||f||||||||||2018-06-01 01:54:03.128869|2018-06-01 01:54:03.128869
NCT00724607|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-11-03|2008-07-24|2008-07-29|Estimate|||||||2017-11-03|2017-11-07|Actual|May 6, 2008|Actual|2008-05-06|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|BIO||Brain Injury Outcomes (BIO) Study|Validation of Brief Objective Neurobehavioral Detectors of Mild TBI|Recruiting|||300|Anticipated|VA Office of Research and Development|||3||f||||f|f|f|||f|Samples With DNA|"~     Tissue samples are requested for 1.) current laboratory measures, 2.) current genomic,~     immunologic, angiogenic and endocrine measures, and 3.) future unknown measures.~   "|Undecided||2018-06-01 01:54:03.222979|2018-06-01 01:54:03.222979
NCT00724594|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|2015-01-09||2015-05-08|2008-07-28|2008-07-29|Estimate|2015-04-15|2015-04-30|Estimate||||2015-05-08|2015-06-02|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)|Safety of N-acetylcysteine in Maternal Chorioamnionitis|Completed||Phase 1/Phase 2|46|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 01:54:03.348072|2018-06-01 01:54:03.348072
NCT00724581|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-28|2008-07-28|2008-07-29|Estimate|||||||2008-07-28|2008-07-29|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|PASCART||Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer|Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial|Unknown status|Not yet recruiting|Phase 4|275|Anticipated|Aarhus University Hospital||1|||f||||t||||||||||2018-06-01 01:54:03.909957|2018-06-01 01:54:03.909957
NCT00724568|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2014-09-03||2017-05-03|2008-07-28|2008-07-29|Estimate|2014-09-03|2014-09-10|Estimate||||2017-05-03|2017-06-02|Actual|May 2008||2008-05-31|May 2017|2017-05-31|September 3, 2014|Actual|2014-09-03|April 2009|Actual|2009-04-30||Interventional|RVDD|A total of 74 patients were enrolled in this phase 1/2 study. 2 patients were not evaluable for the Dose Limiting Toxicity (DLT) and therefore only 72 are included in the baseline analysis population.|Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma|A Multi-Institutional Phase I/II Study of Revlimid® (Lenalidomide), Velcade® (Bortezomib), Dexamethasone, and Doxil®, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|Completed||Phase 1/Phase 2|74|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 01:54:04.111414|2018-06-01 01:54:04.111414
NCT00724555|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2014-01-30|2008-07-28|2008-07-29|Estimate|||||||2014-01-30|2014-01-31|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|ASPIRE||Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities|Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities|Completed|||2005|Anticipated|Georgetown University|||1||f||||f||||||||||2018-06-01 01:54:04.345484|2018-06-01 01:54:04.345484
NCT00724542|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-08-22|2008-07-28|2008-07-29|Estimate|||||||2008-08-22|2008-08-25|Estimate|July 2008||2008-07-31|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|EIIGETPCHD||Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.|Evaluation of Lifestyle and Therapeutic Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.|Unknown status|Recruiting|N/A|1600|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-06-01 01:54:04.433816|2018-06-01 01:54:04.433816
NCT00724529|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-01-21|2008-07-25|2008-07-29|Estimate|||||||2013-01-21|2013-01-23|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Post Marketing Surveillance of Remicade|Post Marketing Surveillance of Remicade in Inflammatory Bowel Disease (IBD)|Completed|||938|Actual|Janssen Korea, Ltd., Korea|||3||f||||||||||||||2018-06-01 01:54:04.521314|2018-06-01 01:54:04.521314
NCT00724516|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-07-03|2008-07-24|2008-07-29|Estimate|||||||2017-07-03|2017-07-06|Actual|June 2007||2007-06-30|July 2017|2017-07-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation Of A Novel Breast Compression Paddle For Wire Localization In Mammography|Evaluation Of A Novel Breast Compression Paddle For Wire Localization In Mammography|Completed||N/A|10|Actual|University of Michigan||1|||f||||f||||||||No||2018-06-01 01:54:04.606957|2018-06-01 01:54:04.606957
NCT00724503|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2017-01-27|2008-07-28|2008-07-29|Estimate|||||||2017-01-27|2017-01-30|Estimate|August 2006||2006-08-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|SIRFLOX||FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer|Randomised Comparative Study Of Folfox6m Plus Sir-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma|Completed||N/A|532|Actual|Sirtex Medical||2|||f||||t||||||||||2018-06-01 01:54:04.731715|2018-06-01 01:54:04.731715
NCT00724490|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-28|2008-07-28|2008-07-29|Estimate|||||||2008-07-28|2008-07-29|Estimate|February 2004||2004-02-29|July 2008|2008-07-31|February 2008|Actual|2008-02-29|September 2007|Actual|2007-09-30||Interventional|||Unilateral Deep Brain Stimulation (DBS) of the Nucleus (Nucl.) Accumbens (Acc.) in Patients With Treatment Resistant Obsessive Compulsive Disorder (OCD)|Unilateral Deep Brain Stimulation of the Nucleus Accumbens in Patients With Treatment Resistant Obsessive Compulsive Disorder|Completed||N/A|16|Actual|University of Cologne|||||f||||f||||||||||2018-06-01 01:54:05.012565|2018-06-01 01:54:05.012565
NCT00724477|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2009-11-24||2015-09-28|2008-07-25|2008-07-29|Estimate|2010-02-03|2010-02-26|Estimate||||2015-09-28|2015-09-30|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)|PRAGMATIC (This is the True Official Title of the Protocol for This Study)|Completed|||1663|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:05.083362|2018-06-01 01:54:05.083362
NCT00724464|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-10-04||2015-10-16|2008-07-25|2008-07-29|Estimate|2011-10-04|2011-11-08|Estimate||||2015-10-16|2015-10-19|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)|A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice|Completed|||332|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:05.233585|2018-06-01 01:54:05.233585
NCT00724451|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2012-10-05||2015-09-24|2008-07-25|2008-07-29|Estimate|2012-10-05|2012-10-31|Estimate||||2015-09-24|2015-09-25|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)|Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice|Completed|||1128|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:05.552115|2018-06-01 01:54:05.552115
NCT00724438|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-09-04|2008-07-28|2008-07-29|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2008||2008-07-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|August 2009|Actual|2009-08-31||Observational|||Pharmacokinetics of Implanon in Obese Women|Pharmacokinetics of Implanon in Obese Women|Completed|||18|Actual|University of Chicago|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma~   "|||2018-06-01 01:54:05.897754|2018-06-01 01:54:05.897754
NCT00724425|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-04-14|2008-07-28|2008-07-29|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Phase 1 Dose Escalation Study of IPI-493|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients With Advanced Malignancies|Terminated||Phase 1|53|Actual|Infinity Pharmaceuticals, Inc.||||"Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus exclusively on~   retaspimycin"|f||||f||||||||||2018-06-01 01:54:05.976699|2018-06-01 01:54:05.976699
NCT00724386|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2014-03-06|2008-07-28|2008-07-29|Estimate|||||||2014-03-06|2014-03-07|Estimate|June 1999||1999-06-30|March 2014|2014-03-31|November 2012|Actual|2012-11-30|October 2005|Actual|2005-10-31||Interventional|||Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer|A Phase I Study of Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine With Filgrastim Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer|Completed||Phase 1|26|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 01:54:06.208671|2018-06-01 01:54:06.208671
NCT00724373|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-05-06||2015-09-24|2008-07-25|2008-07-29|Estimate|2010-05-06|2010-06-07|Estimate||||2015-09-24|2015-09-25|Estimate|November 2007||2007-11-30|September 2015|2015-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)|Retrospective Data Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol|Completed|||442|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:06.300709|2018-06-01 01:54:06.300709
NCT00724360|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-10-04|2008-07-28|2008-07-29|Estimate|||||||2013-10-04|2013-10-07|Estimate|November 2006||2006-11-30|October 2013|2013-10-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)|A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-acute Lymphoblastic Leukemia Patients.|Terminated||Phase 2|15|Actual|Nantes University Hospital||||Difficulties of recruitment|f||||||||||||||2018-06-01 01:54:06.505177|2018-06-01 01:54:06.505177
NCT00724347|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2014-11-03||2015-01-15|2008-07-28|2008-07-29|Estimate|2014-12-23|2015-01-13|Estimate||||2015-01-15|2015-01-27|Estimate|July 2008||2008-07-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CINT|Hearing impaired with hearing aids|PC-Based Rehabilitation of Auditory Function|PC-based Rehabilitation of Auditory Function|Completed||N/A|18|Actual|VA Office of Research and Development|Five publications describing the new tests that we developed have appeared.|1|||f||||f||||||||||2018-06-01 01:54:06.592997|2018-06-01 01:54:06.592997
NCT00724334|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17||2016-02-17|2016-02-17|2008-07-25|2008-07-29|Estimate||||2016-02-17|2016-03-17|Estimate|2016-02-17|2016-03-17|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis|An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis|Completed||Phase 1/Phase 2|42|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:54:06.763752|2018-06-01 01:54:06.763752
NCT00724321|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-09-17|2008-07-28|2008-07-29|Estimate|||||||2015-09-17|2015-09-18|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude|Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction With Exercise at High Altitude|Withdrawn||Phase 1|0|Actual|Loma Linda University||1||"PI has left the institution. We are unable to locate any study records to determine if subjects~   were enrolled."|f||||f||||||||||2018-06-01 01:54:06.843643|2018-06-01 01:54:06.843643
NCT00724308|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2014-07-10||2015-04-06|2008-07-23|2008-07-29|Estimate|2014-07-10|2014-08-05|Estimate||||2015-04-06|2015-04-28|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|October 2012|Actual|2012-10-31||Interventional|TeleQuit MH||Telephone Care Coordination for Smokers in VA Mental Health Clinics|Telephone Care Coordination for Smokers in Mental Health Clinics|Completed||N/A|1206|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 01:54:06.920852|2018-06-01 01:54:06.920852
NCT00724295|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-02-03|2008-07-25|2008-07-29|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2005||2005-04-30|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)|PEG Intron/REBETOL Combination Therapy Special Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C-|Completed|||1077|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:07.143521|2018-06-01 01:54:07.143521
NCT00724282|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2015-09-10||2015-10-15|2008-07-25|2008-07-29|Estimate|2015-10-15|2015-10-16|Estimate||||2015-10-15|2015-10-16|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Treatment of Insomnia and Glucose Metabolism|Double-blind Placebo-controlled Study of the Effects of Eszopiclone on Glucose Tolerance, Insulin Secretion, and Insulin Action in Adults With Chronic Insomnia|Completed||Phase 4|20|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 01:54:07.205204|2018-06-01 01:54:07.205204
NCT00724269|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2012-09-28|2008-07-28|2008-07-29|Estimate|||||||2012-09-28|2012-10-01|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparison of OPTI-FREE RepleniSH and ReNu Multi-Plus Lens Care Regimens on Corneal Epithelium||Completed||N/A|20|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:54:07.35045|2018-06-01 01:54:07.35045
NCT00724256|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2012-02-15|2008-07-25|2008-07-29|Estimate|||||||2012-02-15|2012-02-17|Estimate|July 2006||2006-07-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|STUTI||Short-term Antibiotic Therapy for Pyelonephritis in Childhood|Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood.|Terminated||Phase 3|36|Actual|IRCCS Burlo Garofolo||2||other upcoming studies; patients refusal of invasive follow up (DMSA)|f||||t||||||||||2018-06-01 01:54:07.418481|2018-06-01 01:54:07.418481
NCT00724243|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-01-28||2015-09-03|2008-07-25|2008-07-29|Estimate|2010-01-28|2010-02-19|Estimate||||2015-09-03|2015-09-04|Estimate|January 2006||2006-01-31|September 2015|2015-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)|Remicade Treatment Registry in Rheumatoid Arthritis I|Completed|||33|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:07.587423|2018-06-01 01:54:07.587423
NCT00724230|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-02-02|2008-07-25|2008-07-29|Estimate|||||||2015-02-02|2015-02-03|Estimate|February 2006||2006-02-28|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)|"PegIntron/REBETOL Combination Therapy Designated Drug Use Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C Excluding Those With IFN Naive Low Viral Load and Genotype 1 and High Viral Load-"|Completed|||505|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:07.737921|2018-06-01 01:54:07.737921
NCT00724217|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-28|2008-07-28|2008-07-29|Estimate|||||||2008-07-28|2008-07-29|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|SPPP||Standard Process 21 Day Purification Program Project|The Effects of the Standard Process 21 Day Purification Program, on Serum Lipids, C-Reactive Protein, Homocystine, Blood Pressure, and Heart Rate Variability in Normal Weight and Overweight Participants Who Have Total Cholesterol Levels Over 180.|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 01:54:07.806522|2018-06-01 01:54:07.806522
NCT00724204|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2008-07-28|2008-07-28|2008-07-29|Estimate|||||||2008-07-28|2008-07-29|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|P010||Safety Assessment of Lactobacillus Salivarius CECT5713 in 6 Months Old Children|Functional Evaluation of a Follow on Formula Supplemented With Lactobacillus Salivarius CECT5713|Completed||Phase 1|80|Actual|Puleva Biotech||2|||f||||t||||||||||2018-06-01 01:54:07.882587|2018-06-01 01:54:07.882587
NCT00724191|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2018-05-10|2008-07-24|2008-07-29|Estimate|||||||2018-05-10|2018-05-11|Actual|September 1999||1999-09-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)|Quantitation of Human Brain Tumor Therapy Response by MR|Active, not recruiting|||190|Anticipated|University of Michigan|||1||f||||f||||||||No||2018-06-01 01:54:07.957273|2018-06-01 01:54:07.957273
NCT00724178|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2010-01-14|2008-07-28|2008-07-29|Estimate|||||||2010-01-14|2010-01-15|Estimate|July 2003||2003-07-31|January 2010|2010-01-31|December 2006|Actual|2006-12-31|August 2006|Actual|2006-08-31||Interventional|||The Effect of Vitamin D and Calcium on Bone in Pediatric HIV|The Effect of Vitamin D and Calcium on Bone in Pediatric HIV|Completed||Phase 2/Phase 3|59|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 01:54:08.046842|2018-06-01 01:54:08.046842
NCT00724165|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-02-04|2008-07-25|2008-07-29|Estimate|||||||2013-02-04|2013-02-06|Estimate|September 2006||2006-09-30|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Seamos Activas: Increasing Physical Activity Among Latinas|Seamos Activas: Increasing Physical Activity Among Latinas|Completed||Phase 2|106|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 01:54:08.133491|2018-06-01 01:54:08.133491
NCT00724152|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2015-01-06||2015-04-16|2008-07-23|2008-07-29|Estimate|2015-04-14|2015-04-17|Estimate||||2015-04-16|2015-05-06|Estimate|February 2009||2009-02-28|April 2015|2015-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||Period 1 and Period 2|Cognitive Behavioral Therapy (CBT) for Tinnitus|Cognitive-behavioral Therapy for Tinnitus|Completed||Phase 1/Phase 2|33|Actual|VA Office of Research and Development|"During Period 2 only two participants (one completer) were randomized to standard care and only four participants (3 completers) were randomized Cognitive Behavioral Therapy."|3|||f||||f||||||||||2018-06-01 01:54:08.224343|2018-06-01 01:54:08.224343
NCT00724139|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-27|||2008-07-28|2008-07-28|2008-07-29|Estimate|||||||2008-07-28|2008-07-29|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||The Effect of Training With Custom-Made Biomechanical Perturbation Platform on Kinetics, Kinematics and Electromyography in Knee Osteoarthritis Patients||Unknown status|Recruiting|N/A|15|Anticipated|HaEmek Medical Center, Israel||1|||f||||||||||||||2018-06-01 01:54:08.623165|2018-06-01 01:54:08.623165
NCT00724126|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-26|2014-06-30||2014-06-30|2008-07-28|2008-07-29|Estimate|2014-06-30|2014-07-28|Estimate||||2014-06-30|2014-07-28|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|TARGET 2|The analysis population was the intent-to-treat population, defined as subjects who received at least 1 dose of study drug. Two randomized subjects (1 in each group) did not receive study drug and were not included in the intent-to-treat population.|Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin 550 mg TID in the Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome|Completed||Phase 3|637|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 01:54:08.74359|2018-06-01 01:54:08.74359
NCT00724113|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2017-01-03|2008-07-28|2008-07-29|Estimate|||||||2017-01-03|2017-01-04|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional|CAPSULITE||ARTHRO Distension Plus Intensive Mobilisation in Shoulder Capsulitis|Evaluation of the Effectiveness of ARTHRO -Distension Plus Intensive Mobilisation in Shoulder Capsulitis|Completed||Phase 3|66|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:54:09.237279|2018-06-01 01:54:09.237279
NCT00724100|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2014-08-26|2008-07-25|2008-07-29|Estimate|||||||2014-08-26|2014-08-27|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors|A Phase 1, Dose Escalation Study of the Safety and Pharmacokinetics of ALB 109564(a) Administered Intravenously Every 3 Weeks to Subjects With Advanced Solid Tumors|Terminated||Phase 1|46|Actual|Albany Molecular Research, Inc.||||Sponsor's decision|f||||f||||||||||2018-06-01 01:54:09.316313|2018-06-01 01:54:09.316313
NCT00724087|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-09-04|2008-07-25|2008-07-29|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2008||2008-07-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Sleep Loss and Energy Metabolism in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk.|Completed||N/A|12|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:54:09.387135|2018-06-01 01:54:09.387135
NCT00724074|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-25|2008-07-25|2008-07-29|Estimate|||||||2008-07-25|2008-07-29|Estimate||||July 2008|2008-07-31||||||||Interventional|||The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty|The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty|Unknown status|Not yet recruiting|N/A|20|Anticipated|Capital Health, Canada||2|||f||||t||||||||||2018-06-01 01:54:09.465368|2018-06-01 01:54:09.465368
NCT00724061|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-26|2013-11-25||2013-11-25|2008-07-26|2008-07-29|Estimate|2013-11-25|2013-12-02|Estimate||||2013-11-25|2013-12-02|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL|Pilot Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy in Cutaneous T-Cell Lymphoma|Terminated||N/A|7|Actual|Northwestern University|Only 7 patients were enrolled before the study was terminated by the Data Monitoring Committee due to poor accrual. Accrual was limited by a worldwide psoralen shortage and well as the exclusion of patients with prior UV light exposure.|1||Closed early due to poor accrual.|f||||t||||||||||2018-06-01 01:54:09.551269|2018-06-01 01:54:09.551269
NCT00722423|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2015-03-24||2015-09-16|2008-07-23|2008-07-25|Estimate|2015-09-16|2015-10-15|Estimate||||2015-09-16|2015-10-15|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|HCV||An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes|An Integrated Care Model for Improving HCV Patient Outcomes|Completed||N/A|364|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:54:36.353559|2018-06-01 01:54:36.353559
NCT00724048|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24||2013-02-19|2016-07-20|2008-07-28|2008-07-29|Estimate||||2013-03-28|2013-04-04|Estimate|2016-07-20|2016-07-22|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|HART||A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease|A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)|Completed||Phase 2/Phase 3|227|Actual|Teva Pharmaceutical Industries||4|||f||||t||||||||||2018-06-01 01:54:09.76797|2018-06-01 01:54:09.76797
NCT00724035|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2009-07-14|2008-07-25|2008-07-29|Estimate|||||||2009-07-14|2009-07-15|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Ultrasound-Guided Axillary or Infraclavicular Nerve Block for Upper Limb Surgery|Onset Time of Brachial Plexus Anesthesia With the Axillary or Infraclavicular Approach Under Real-Time Ultrasound Guidance: a Randomized Controlled Trial|Completed||Phase 4|52|Anticipated|University of Parma||2|||f||||f||||||||||2018-06-01 01:54:09.875737|2018-06-01 01:54:09.875737
NCT00724022|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2014-09-30|2008-07-28|2008-07-29|Estimate|||||||2014-09-30|2014-10-01|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Harmony||Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation|Triple Arm, Prospectively Randomized Multi Centre Study Phase IV to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation in Non-risk Patients|Completed||Phase 4|600|Anticipated|University Hospital Freiburg||3|||f||||f||||||||||2018-06-01 01:54:09.956061|2018-06-01 01:54:09.956061
NCT00724009|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2014-01-30||2014-01-30|2008-07-28|2008-07-29|Estimate|2014-01-30|2014-03-18|Estimate||||2014-01-30|2014-03-18|Estimate|December 2007||2007-12-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2010|Actual|2010-09-30||Interventional|||Clofarabine Bone Marrow Cytoreduction|Clofarabine Bone Marrow Cytoreduction : Feasibility of Induction as a Bridge to Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Acute Leukemias, Myelodysplastic Syndromes, and Advanced Myeloproliferative Diseases.|Completed||Phase 2|29|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 01:54:10.184338|2018-06-01 01:54:10.184338
NCT00723996|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2016-12-15|2008-07-24|2008-07-29|Estimate|||||||2016-12-15|2016-12-16|Estimate|September 2003||2003-09-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Preventive Health Behavior in Women|Preventive Health Behavior in Women|Completed|||254|Actual|University of Michigan|||3||f||||f||||||||No||2018-06-01 01:54:10.456826|2018-06-01 01:54:10.456826
NCT00723983|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2016-02-02|2008-07-25|2008-07-29|Estimate|||||||2016-02-02|2016-02-03|Estimate|November 2008||2008-11-30|February 2016|2016-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|NP101-011||Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period|A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period|Completed||Phase 1|23|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-06-01 01:54:10.535413|2018-06-01 01:54:10.535413
NCT00723970|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2012-02-07|2008-07-25|2008-07-29|Estimate|||||||2012-02-07|2012-02-08|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression|Seroquel XR for the Treatment of Peri and Postmenopausal Women With Major Depressive Disorder: Impact on Mood, Physical Symptoms, Sleep and Quality of Life|Completed||Phase 4|40|Actual|McMaster University||1|||f||||f||||||||||2018-06-01 01:54:10.632175|2018-06-01 01:54:10.632175
NCT00723957|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-06-20||2016-02-09|2008-07-25|2008-07-29|Estimate|2011-09-08|2011-10-17|Estimate||||2016-02-09|2016-03-10|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|August 2011|Actual|2011-08-31|May 2010|Actual|2010-05-31||Interventional|||A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer|A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|260|Actual|R-Pharm||2|||f||||f||||||||||2018-06-01 01:54:10.771412|2018-06-01 01:54:10.771412
NCT00723944|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2009-06-26||2017-03-20|2008-07-28|2008-07-29|Estimate|2011-10-17|2011-11-22|Estimate||||2017-03-20|2017-04-17|Actual|February 2005||2005-02-28|March 2017|2017-03-31|May 2011|Actual|2011-05-31|April 2007|Actual|2007-04-30||Interventional|RadioCity||A Study of the Performance of Certain Prevail Implants Used in Short Fixed Cases|A Prospective, Randomized-controlled Multicenter Study of the Osseotite Certain Lateralized Implanting Short-span Fixed Bridge Cases for Preservation of Crestal Bone|Completed||N/A|102|Actual|Zimmer Biomet||2|||f||||t||||||||No||2018-06-01 01:54:11.509146|2018-06-01 01:54:11.509146
NCT00723931|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-11-09||2015-11-02|2008-07-25|2008-07-29|Estimate|2010-11-09|2010-12-13|Estimate||||2015-11-02|2015-11-04|Estimate|June 2006||2006-06-30|November 2015|2015-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||PegIntron Injection Surveillance Plan (Study P04123)|PegIntron Injection Surveillance Plan|Completed|||1267|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:11.780304|2018-06-01 01:54:11.780304
NCT00723918|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2018-02-08|2008-07-28|2008-07-29|Estimate|||||||2018-02-08|2018-02-09|Actual|April 2009||2009-04-30|February 2018|2018-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy|NARC 011: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Methadone and Combination of Methadone and SAB378 in HIV-associated Painful Peripheral Neuropathy|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||3||Withdrawal of pharmaceutical support from Novartis - no participants randomized|f||||t||||||||||2018-06-01 01:54:11.943316|2018-06-01 01:54:11.943316
NCT00723905|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-01-14|2008-07-25|2008-07-29|Estimate|||||||2013-01-14|2013-01-15|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|RemiTRAC||Remicade Infusion Management Program|Remicade Infusion Management Program|Completed|||1630|Actual|Janssen Inc.|||||f||||f||||||||||2018-06-01 01:54:12.043966|2018-06-01 01:54:12.043966
NCT00723892|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-08-25||2015-10-29|2008-07-25|2008-07-29|Estimate|2010-08-25|2010-09-20|Estimate||||2015-10-29|2015-10-30|Estimate|July 2005||2005-07-31|October 2015|2015-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)|Observatory on Treatment Adhesion in Patients Suffering From Hepatitis C Chronic Treated With ViraferonPeg® Injected / Rebetol® in Conjunction With a Psychotherapeutic Assistance Program|Completed|||614|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:54:12.108667|2018-06-01 01:54:12.108667
NCT00723879|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-11-02|2008-07-25|2008-07-29|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2004||2004-10-31|November 2015|2015-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)|Evaluation of Adherence Rate in Patients Receiving PegIntron / Rebetol (Weight Based) for Hepatitis C in Conjunction With a Patient Assistance Program.|Terminated|||115|Actual|Merck Sharp & Dohme Corp.|||1|"Because of slow recruitment; Despite the study was started long time ago (Oct 2004), we have~   not reached the projected number of patients (150 patients)"|f||||f||||||||||2018-06-01 01:54:12.325551|2018-06-01 01:54:12.325551
NCT00723866|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-29|2008-07-25|2008-07-29|Estimate|||||||2008-07-29|2008-08-01|Estimate|December 2005||2005-12-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Botulinum Toxin Type A and Modified Constraint-Induced Movement Therapy for Poststroke Upper Extremity Spasticity|Combined Botulinum Toxin Type A With Modified Constraint-Induced Movement Therapy for Chronic Stroke Patients With Upper Extremity Spasticity|Completed||N/A|32|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-06-01 01:54:12.379718|2018-06-01 01:54:12.379718
NCT00723853|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2013-09-04|2008-07-28|2008-07-29|Estimate|||||||2013-09-04|2013-09-05|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|REACH-OUT||REACH-OUT: Chicago Children's Diabetes Prevention Program|REACH-OUT: Chicago Children's Diabetes Prevention Program|Completed||N/A|131|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:54:12.441176|2018-06-01 01:54:12.441176
NCT00723840|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-03-31||2015-07-29|2008-07-25|2008-07-29|Estimate|2011-03-31|2011-04-29|Estimate||||2015-07-29|2015-07-30|Estimate|September 2006||2006-09-30|July 2015|2015-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|COSMO||Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560)|Assessment of the Social Cost of Crohn's Disease (COsto Sociale Della Malattia di CrOhn - COSMO): Economic and Quality of Life Aspects|Completed|||245|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:12.505998|2018-06-01 01:54:12.505998
NCT00723827|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2012-12-05||2015-01-19|2008-07-25|2008-07-29|Estimate|2012-12-05|2013-01-08|Estimate||||2015-01-19|2015-01-30|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)|Temodal (Temozolomide) Post Marketing Surveillance Protocol|Completed|||682|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:13.748455|2018-06-01 01:54:13.748455
NCT00723814|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-27|||2008-07-28|2008-07-28|2008-07-29|Estimate|||||||2008-07-28|2008-07-29|Estimate||||July 2008|2008-07-31||||||||Observational|||Blood Pressure Monitor Clinical Test||Completed|||||Andon Health Co., Ltd|||||f||||||||||||||2018-06-01 01:54:14.025034|2018-06-01 01:54:14.025034
NCT00723801|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2014-08-15||2014-09-08|2008-07-28|2008-07-29|Estimate|2014-08-15|2014-09-01|Estimate||||2014-09-08|2014-09-09|Estimate|October 2007||2007-10-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome|Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome|Completed||Phase 3|40|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 01:54:14.079132|2018-06-01 01:54:14.079132
NCT00723788|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2014-11-05||2014-11-14|2008-07-28|2008-07-29|Estimate|2014-11-14|2014-11-21|Estimate||||2014-11-14|2014-11-21|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Patient referral from Emergency Department for suspected appendicitis with ultrasound and/or CT imaging request (0800 hr – 1700 hr)|Magnetic Resonance Imaging (MRI) of Appendicitis in Children|Magnetic Resonance Evaluation of Appendicitis in Children Aged 8-18|Completed||N/A|21|Actual|Children's Research Institute||1|||f||||f||||||||||2018-06-01 01:54:14.373532|2018-06-01 01:54:14.373532
NCT00723775|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2017-07-19|2008-07-28|2008-07-29|Estimate|||||||2017-07-19|2017-07-21|Actual|July 24, 2008|Actual|2008-07-24|July 2017|2017-07-31|November 8, 2008|Actual|2008-11-08|November 8, 2008|Actual|2008-11-08||Interventional|||GSK706769/KALETRA Drug-drug Interaction Study|Phase I, Open Label Drug-drug Interaction Study in Healthy Volunteers to Evaluate the Effect of KALETRA (Lopinavir-ritonavir) on GSK706769 Pharmacokinetics and to Evaluate the Pharmacokinetics of a New Oral Formulation of GSK706769|Completed||Phase 1|17|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 01:54:14.552348|2018-06-01 01:54:14.552348
NCT00723762|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2011-03-08|2008-07-28|2008-07-29|Estimate|||||||2011-03-08|2011-03-10|Estimate|February 2009||2009-02-28|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|||Valproic Acid-associated Hypoalbuminemia in Medically Fragile Patients|Valproic Acid-associated Hypoalbuminemia in Medically Fragile Pediatric and Young Adult Patients in a Long Term Care Facility Part 1: Potential Mechanism for Decreased Albumin Synthesis|Completed|||90|Anticipated|Akron Children's Hospital|||3||f||||f||||||Samples Without DNA|"~     Serum and urine samples from patients receiving VPA.~   "|||2018-06-01 01:54:14.632855|2018-06-01 01:54:14.632855
NCT00723749|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2012-01-11||2012-04-26|2008-07-25|2008-07-29|Estimate|2012-02-28|2012-04-05|Estimate||||2012-04-26|2012-04-30|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)|Post-marketing Surveillance Study (Paper-AWB) for GPs and Clinics: Treatment of Opioid-dependent Patients With SUBOXONE® 2 mg / 8 mg Sublingual Tablets - Acceptability and Safety Data From a Real Life Scenario.|Completed|||384|Actual|Indivior Inc.|||1||f||||t||||||||||2018-06-01 01:54:14.728981|2018-06-01 01:54:14.728981
NCT00723736|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2009-06-18||2015-04-09|2008-07-25|2008-07-29|Estimate|2009-06-18|2009-08-06|Estimate||||2015-04-09|2015-04-30|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Safety of Aerius Syrup in Pediatric Patients Aged 1-5 Years Old With Allergic Rhinitis or Chronic Idiopathic Urticaria (Study P04446AM1)(COMPLETED)|Non-Interventional Study of the Safe Use of Aerius in Pediatric Patients With Allergic Rhinitis or Chronic Idiopathic Urticaria.|Completed|||100|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:14.928575|2018-06-01 01:54:14.928575
NCT00723723|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-08-11|2008-07-25|2008-07-29|Estimate|||||||2015-08-11|2015-08-13|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)|Compliance With LDL-Lowering Therapy For Secondary Prevention of Coronary Heart Disease in Real Life Practice|Completed|||555|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:15.067987|2018-06-01 01:54:15.067987
NCT00723346|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2012-01-10|2008-07-25|2008-07-28|Estimate|||||||2012-01-10|2012-01-11|Estimate|January 2006||2006-01-31|January 2012|2012-01-31|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|GRASPALL||Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia|Administration of Allogenic of Red Blood Cells Loaded L Asparaginase in Acute Lymphoblastic Leukemia Relapse.|Completed||Phase 1/Phase 2|25|Actual|ERYtech Pharma||4|||f||||t||||||||||2018-06-01 01:54:22.55946|2018-06-01 01:54:22.55946
NCT00723710|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2013-08-21||2015-08-24|2008-07-25|2008-07-29|Estimate|2013-08-21|2013-10-28|Estimate||||2015-08-24|2015-08-26|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)|Guidelines to the Intron A® Health Management Program II: A Nursing Support Program for Patients With High-Risk Melanoma Receiving High Dose Intron A Therapy|Completed|||299|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:15.139292|2018-06-01 01:54:15.139292
NCT00723697|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-04-14||2011-04-14|2008-07-25|2008-07-29|Estimate|2011-04-14|2011-05-10|Estimate||||2011-04-14|2011-05-10|Estimate|May 2007||2007-05-31|July 2010|2010-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|OPUS R||Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)|Etude Observationnelle Prospective de l'Utilisation en Situation Reelle; Prospective Real Situation Observational Study of Subutex® or Its Buprenorphine High Dose Generic (BHD) in the Replacement Treatment of Major Opiate Dependence: Following Parameters With Respect to Misuse and Pharmacovigilance|Completed|||1307|Actual|Indivior Inc.|||1||f||||f||||||||||2018-06-01 01:54:15.335419|2018-06-01 01:54:15.335419
NCT00723684|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-28|||2013-03-07|2008-07-28|2008-07-29|Estimate|||||||2013-03-07|2013-03-08|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Interventional|PANther||Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy|ADHD and EEG-neurofeedback. A Single-blind Randomized Placebo-controlled Treatment Study.|Completed||N/A|63|Actual|Radboud University||2|||f||||t||||||||||2018-06-01 01:54:15.675913|2018-06-01 01:54:15.675913
NCT00723671|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-12-10|2008-07-25|2008-07-29|Estimate|||||||2015-12-10|2015-12-14|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus||Completed||N/A|66|Actual|University of Michigan||1|||f||||||||||||||2018-06-01 01:54:15.752808|2018-06-01 01:54:15.752808
NCT00723658|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-26|||2015-03-05|2008-07-26|2008-07-29|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2008||2008-09-30|March 2015|2015-03-31||||May 2010|Actual|2010-05-31||Interventional|||S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia|S0629, Observational Study of Asymptomatic Waldenstrom's Macroglobulinemia and Phase II Study of Tandem Autologous Transplant and Maintenance Treatment for Patients With Symptomatic Disease|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||2||lack of accrual|f||||t||||||||||2018-06-01 01:54:15.83906|2018-06-01 01:54:15.83906
NCT00723645|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2012-03-23||2015-11-26|2008-07-28|2008-07-29|Estimate|2012-03-23|2012-04-23|Estimate||||2015-11-26|2015-11-30|Estimate|April 2008||2008-04-30|November 2015|2015-11-30|February 2011|Actual|2011-02-28|April 2010|Actual|2010-04-30||Observational|FAST-4||Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)|Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-life Clinical Practice in Spanish Hospitals (FAST-4)|Completed|||279|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:15.997707|2018-06-01 01:54:15.997707
NCT00723632|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2011-11-11||2015-10-01|2008-07-25|2008-07-29|Estimate|2011-11-11|2011-12-20|Estimate||||2015-10-01|2015-10-02|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)|Cost of Treatment of Chronic Hepatitis C Using Combination of Peginterferon α-2b Plus Ribavirin|Completed|||901|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:54:16.173513|2018-06-01 01:54:16.173513
NCT00723619|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2010-02-16|2008-07-25|2008-07-29|Estimate|||||||2010-02-16|2010-02-17|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|LUNOKID-Studie||Investigation of Lungfunction Normal Values in Children and Adolescent in Germany (Spirometry, Ultrasonic Pneumography and Exhaled NO)|Investigation of Lungfunction Normal Values in Children and Adolescent in Germany|Completed|||2007|Actual|Marien Hospital Wesel|||1||f||||f||||||||||2018-06-01 01:54:16.334324|2018-06-01 01:54:16.334324
NCT00723606|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2010-07-29||2015-06-30|2008-07-28|2008-07-29|Estimate|2010-07-29|2010-08-25|Estimate||||2015-06-30|2015-07-23|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation|A Randomized, Open Label, Rater Blind, Flexible Dose Multi-Center Study Comparing The Efficacy And Safety Of Intramuscular Ziprasidone With Haloperidol For Three Days In Patients With Agitation Of Schizophrenia|Completed||Phase 3|376|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:54:16.415282|2018-06-01 01:54:16.415282
NCT00723593|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2017-10-05|2008-07-25|2008-07-28|Estimate|||||||2017-10-05|2017-10-06|Actual|July 23, 2008||2008-07-23|February 4, 2013|2013-02-04|February 4, 2013||2013-02-04|||||Observational|||Natural History and Pathophysiology of Gastrointestinal Graft-versus-Host Disease|Natural History and Pathophysiology of Gastrointestinal Graft Versus Host Disease|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:54:16.724798|2018-06-01 01:54:16.724798
NCT00723580|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2010-09-22||2015-07-28|2008-07-25|2008-07-28|Estimate|2010-11-17|2010-12-14|Estimate||||2015-07-28|2015-08-18|Estimate|May 2008||2008-05-31|July 2015|2015-07-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Actigraphic Analysis of Treatment Response|Actigraphic Analysis of Treatment Response in a Six Year Old Girl With Kabuki Syndrome|Completed||N/A|1|Actual|Child Psychopharmacology Institute|This single case study has limited generalizability in that these results may not apply to others. The methods explored, however, may apply to others and Single-subject repeated measurements can provide valuable clinical and scientific data.|1|||f||||f||||||||||2018-06-01 01:54:16.791148|2018-06-01 01:54:16.791148
NCT00723567|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2009-02-18|2008-07-25|2008-07-28|Estimate|||||||2009-02-18|2009-02-19|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||A Novel Mutation of the Spectrin Gene|Case Report: A Novel Mutation of the Spectrin Gene in a Family of Northern European Descent Is Associated With Three Different Phenotypes|Completed|||12|Actual|University of Utah|||1||f||||f||||||||||2018-06-01 01:54:16.948804|2018-06-01 01:54:16.948804
NCT00723554|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2013-01-14||2013-03-27|2008-07-25|2008-07-28|Estimate|2013-01-14|2013-02-15|Estimate||||2013-03-27|2013-04-04|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|April 2011|Actual|2011-04-30|August 2010|Actual|2010-08-31||Interventional|INHALE-15||Iloprost Power Disc-15 in Pulmonary Arterial Hypertension|A Phase IIIb, Multicenter, Open-label Study of Patients With Pulmonary Arterial Hypertension Treated With Iloprost(Inhalation)Evaluating Safety and Inhalation Times When Converting From Power Disc-6 (PD-6) to Power Disc-15 (PD-15) With the I-neb® AAD®|Terminated||Phase 3|63|Actual|Actelion||1||sponsor's decision|f||||f||||||||||2018-06-01 01:54:17.067568|2018-06-01 01:54:17.067568
NCT00723528|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2013-12-02||2014-04-22|2008-07-25|2008-07-28|Estimate|2014-04-22|2014-05-20|Estimate||||2014-04-22|2014-05-20|Estimate|March 2008||2008-03-31|April 2014|2014-04-30|March 2010|Actual|2010-03-31|January 2009|Actual|2009-01-31||Interventional||"N (number of participants analyzed) signifies the participants evaluable for this measure."|An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis|A Placebo-Controlled Double-Blind Comparative Study of CNTO1275 in Patients With Plaque Type Psoriasis|Completed||Phase 3|158|Actual|Janssen Pharmaceutical K.K.||7|||f||||f||||||||||2018-06-01 01:54:18.371015|2018-06-01 01:54:18.371015
NCT00723515|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2008-07-24|2008-07-24|2008-07-28|Estimate|||||||2008-07-24|2008-07-28|Estimate|February 2007||2007-02-28|July 2008|2008-07-31|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study|Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study|Completed||Phase 4|45|Actual|University of Pernambuco||2|||f||||f||||||||||2018-06-01 01:54:19.747228|2018-06-01 01:54:19.747228
NCT00723502|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2009-06-15|2008-07-25|2008-07-28|Estimate|||||||2009-06-15|2009-06-16|Estimate|September 2008||2008-09-30|October 2008|2008-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|FLASH||Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients|An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection|Completed||Phase 2|30|Anticipated|MerLion Pharmaceuticals GmbH||2|||f||||t||||||||||2018-06-01 01:54:19.814297|2018-06-01 01:54:19.814297
NCT00723489|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2013-07-16||2013-12-11|2008-07-25|2008-07-28|Estimate|2013-07-17|2013-09-30|Estimate||||2013-12-11|2014-01-13|Estimate|August 2008||2008-08-31|December 2013|2013-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis|A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects|Completed||Phase 1/Phase 2|82|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:54:19.975029|2018-06-01 01:54:19.975029
NCT00723476|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-05-19|2008-07-25|2008-07-28|Estimate|||||||2015-05-19|2015-05-21|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families|Family Centered Advanced Care Planning (FCACP)|Completed||N/A|82|Actual|Children's Research Institute||2|||f||||t||||||||||2018-06-01 01:54:20.603597|2018-06-01 01:54:20.603597
NCT00723463|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2016-11-01|2008-07-24|2008-07-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissue|Retrospective - Prospective - Study to Determine if Apparent Diffusion Coefficient (ADC) Values Can Differentiate Tumors From Normal Tissues at 3T MRI|Completed||Early Phase 1|200|Actual|University of Michigan||1|||f||||f||||||||No||2018-06-01 01:54:20.700777|2018-06-01 01:54:20.700777
NCT00723450|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2014-03-27||2016-11-18|2008-07-24|2008-07-28|Estimate|2014-05-08|2014-06-04|Estimate||||2016-11-18|2017-01-09|Estimate|July 2008||2008-07-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients|The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age|Completed||Phase 3|301|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:54:20.863596|2018-06-01 01:54:20.863596
NCT00723437|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2008-07-25|2008-07-25|2008-07-28|Estimate|||||||2008-07-25|2008-07-28|Estimate|January 2005||2005-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|January 2007|Actual|2007-01-31||Interventional|||Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis|Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin|Completed||Phase 4|36|Actual|Istituti Fisioterapici Ospitalieri|||||f||||f||||||||||2018-06-01 01:54:21.889367|2018-06-01 01:54:21.889367
NCT00723424|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2010-11-30|2008-07-24|2008-07-28|Estimate|||||||2010-11-30|2010-12-02|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Drug Interaction Study - Effect of AZD5672 on the Pharmacokinetics of Digoxin|An Open-label Study to Assess the Effect of AZD5672 at Steady State on the Pharmacokinetics of Digoxin Following Single Dose Administration in Healthy Volunteers|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:54:21.963855|2018-06-01 01:54:21.963855
NCT00723411|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2011-10-07|2008-07-25|2008-07-28|Estimate|||||||2011-10-07|2011-10-10|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)|A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus (EU)|Terminated||Phase 3|334|Actual|Diamyd Therapeutics AB||3||The primary endpoint at 15 months was not met.|f||||t||||||||||2018-06-01 01:54:22.079656|2018-06-01 01:54:22.079656
NCT00723398|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2017-05-05|2008-07-24|2008-07-28|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2009||2009-03-31|January 2013|2013-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention|Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer|Completed||N/A|266|Actual|Milton S. Hershey Medical Center||5|||f||||f||||||||Yes||2018-06-01 01:54:22.296018|2018-06-01 01:54:22.296018
NCT00723385|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2015-04-07|2008-07-24|2008-07-28|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Vitamin D on Lipids|Effects of Vitamin D on Lipids|Completed||N/A|130|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:54:22.395903|2018-06-01 01:54:22.395903
NCT00723359|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2013-07-16|2008-07-24|2008-07-28|Estimate|||||||2013-07-16|2013-07-18|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), and Safety of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|32|Actual|Biotest Pharmaceuticals Corporation||1|||f||||||||||||||2018-06-01 01:54:22.47751|2018-06-01 01:54:22.47751
NCT00723333|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2009-10-08|2008-07-25|2008-07-28|Estimate|||||||2009-10-08|2009-10-12|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Bone Marrow Transplant Chart Review for RIC|Chart Review of Reduced Intensity Conditioning (RIC) Allogeneic Transplants in Elderly Patients With Myelofibrosis.|Completed|||30|Actual|University of Utah|||1||f||||f||||||||||2018-06-01 01:54:22.628642|2018-06-01 01:54:22.628642
NCT00723320|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2008-08-22|2008-07-24|2008-07-28|Estimate|||||||2008-08-22|2008-08-25|Estimate|February 2008||2008-02-29|July 2008|2008-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|EALIPPCA||Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis|Effect of Atorvastatin and Lifestyle Intervention on Progression of Carotid Intima-Media Thickness in Chinese People Without Manifest Atherosclerotic Disease|Unknown status|Recruiting|N/A|1200|Anticipated|Ministry of Science and Technology of the People´s Republic of China||4|||f||||t||||||||||2018-06-01 01:54:22.704134|2018-06-01 01:54:22.704134
NCT00723307|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2012-12-07|2008-07-24|2008-07-28|Estimate|||||||2012-12-07|2012-12-11|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CAMERA||Carotid Atherosclerosis: MEtformin for Insulin ResistAnce Study|A Randomised Placebo-controlled Trial of Metformin on Progression of Carotid Atherosclerosis in Non-diabetic Patients With Cardiovascular Disease Treated With Conventional Risk Reducing Agents|Completed||Phase 4|173|Actual|University of Glasgow||2|||f||||f||||||||||2018-06-01 01:54:22.784721|2018-06-01 01:54:22.784721
NCT00723294|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2016-11-28||2017-06-30|2008-07-25|2008-07-28|Estimate|2017-01-17|2017-03-07|Actual||||2017-06-30|2017-08-14|Actual|September 2008||2008-09-30|June 2017|2017-06-30||||September 2013|Actual|2013-09-30||Interventional|||Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer|A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma|Active, not recruiting||Phase 2|99|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 01:54:22.86035|2018-06-01 01:54:22.86035
NCT00723281|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2014-08-15|2008-07-25|2008-07-28|Estimate|||||||2014-08-15|2014-08-19|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|July 2010|Actual|2010-07-31||Observational|||Comparison of CT Angiography With Conventional Angiography and Intravascular Ultrasound in Heart Transplant Patients|Comparison of CT Angiography With Conventional Angiography and Intravascular Ultrasound in Heart Transplant Patients|Completed|||18|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-06-01 01:54:23.106488|2018-06-01 01:54:23.106488
NCT00723268|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2008-07-28|2008-07-25|2008-07-28|Estimate|||||||2008-07-28|2008-07-29|Estimate|May 2007||2007-05-31|July 2008|2008-07-31||||August 2008|Anticipated|2008-08-31||Interventional|||Evaluation of Therapeutic Effect of 0.5 mg Colchicine and 5 mg Prednisolone on Oral Aphthae|Evaluation of Therapeutic Effect of 0.5 mg Colchicine and 5 mg Prednisolone on Oral Aphthae|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:54:23.176412|2018-06-01 01:54:23.176412
NCT00723255|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2015-05-11||2017-12-01|2008-07-25|2008-07-28|Estimate|2015-07-06|2015-08-05|Estimate||||2017-12-01|2017-12-27|Actual|September 2008||2008-09-30|December 2017|2017-12-31|January 25, 2016|Actual|2016-01-25|July 15, 2011|Actual|2011-07-15||Interventional|||Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|53|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:54:23.32933|2018-06-01 01:54:23.32933
NCT00723242|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2008-07-24|2008-07-24|2008-07-28|Estimate|||||||2008-07-24|2008-07-28|Estimate|April 2002||2002-04-30|July 2008|2008-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||The Role of Dendritic Cells in Hepatitis C Infection||Completed||N/A|||University College, London|||||f||||||||||||||2018-06-01 01:54:24.073308|2018-06-01 01:54:24.073308
NCT00723229|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2012-03-23||2017-03-06|2008-07-23|2008-07-28|Estimate|2017-03-06|2017-03-09|Actual||||2017-03-06|2017-03-09|Actual|August 2008||2008-08-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|||A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation|A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults|Completed||Phase 4|48|Actual|University of Washington|The study was performed at a single site and enrolled a mostly white population. Whether these results are generalizable to other populations is not known.|2|||f||||f||||||||||2018-06-01 01:54:24.144735|2018-06-01 01:54:24.144735
NCT00723216|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2010-04-02|2008-07-25|2008-07-28|Estimate|||||||2010-04-02|2010-04-05|Estimate|March 2007||2007-03-31|April 2010|2010-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery|Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates.|Completed||Phase 3|151|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:54:24.469064|2018-06-01 01:54:24.469064
NCT00723203|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|2014-06-12||2014-09-03|2008-07-25|2008-07-28|Estimate|2014-08-19|2014-08-28|Estimate||||2014-09-03|2014-09-09|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60|Terminated||Phase 2|16|Actual|City of Hope Medical Center|There were no responses observed in the first 12 evaluable patients accrued to the first stage of the two-stage Optimum design of Simon. As a result the study was terminated due to a lack of efficacy.|1||Terminated early due to a lack of efficacy|f||||t||||||||||2018-06-01 01:54:24.543556|2018-06-01 01:54:24.543556
NCT00723190|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2011-09-20||2018-04-16|2008-07-25|2008-07-28|Estimate|2012-01-24|2012-02-27|Estimate||||2018-04-16|2018-04-18|Actual|January 2008||2008-01-31|April 2018|2018-04-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-Label, Chronic Exposure Evaluation of the Safety of CLONICEL (Clonidine HCl Sustained Release) in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|303|Actual|Shionogi Inc.|Efficacy results need to be reviewed in the context that the study is an open-label/non-placebo controlled study. No formal statistical testing of efficacy results has been done. No adjustments have been made to account for drop-outs or missing data.|1|||f||||f||||||||||2018-06-01 01:54:24.843008|2018-06-01 01:54:24.843008
NCT00722982|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2014-11-21|2008-07-25|2008-07-28|Estimate|||||||2014-11-21|2014-11-24|Estimate|July 2008||2008-07-31|November 2014|2014-11-30|July 2015|Anticipated|2015-07-31|May 2012|Actual|2012-05-31||Observational|||Migration Pattern of C-stem AMT Versus Exeter in Total Hip Arthroplasty|Migration Pattern of C-stem AMT Versus Exeter in Total Hip Arthroplasty|Unknown status|Active, not recruiting||70|Actual|Oslo University Hospital|||2||f||||f||||||||||2018-06-01 01:54:29.512664|2018-06-01 01:54:29.512664
NCT00723177|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2015-03-23||2016-10-11|2008-07-24|2008-07-28|Estimate|2016-10-11|2016-12-05|Estimate||||2016-10-11|2016-12-05|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|April 2010|Actual|2010-04-30||Interventional|AV411||Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal|The Safety, Tolerability and Preliminary Efficacy of AV411, a Glial Activation Inhibitor, in Heroin Abusers Under Conditions of Morphine Maintenance and Withdrawal|Completed||Phase 2|30|Actual|New York State Psychiatric Institute||3|||f||||f||||||||Yes|Data have been published in a peer-reviewed journal.|2018-06-01 01:54:25.391201|2018-06-01 01:54:25.391201
NCT00723164|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2008-07-25|2008-07-25|2008-07-28|Estimate|||||||2008-07-25|2008-07-28|Estimate|October 2005||2005-10-31|July 2008|2008-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Premedication on Sevoflurane Induction|Low Dose Fentanyl/Midazolam Improves Sevoflurane Induction in Adults|Completed||N/A|80|Actual|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-06-01 01:54:25.752819|2018-06-01 01:54:25.752819
NCT00723151|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2010-10-29|2008-07-24|2008-07-28|Estimate|||||||2010-10-29|2010-11-01|Estimate|July 2005||2005-07-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Effects of Intensity of Early Communication Intervention|Effects of Intensity of Early Communication Intervention|Completed||Phase 2|70|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 01:54:25.849052|2018-06-01 01:54:25.849052
NCT00723125|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2014-07-17||2018-01-17|2008-07-24|2008-07-28|Estimate|2014-07-17|2014-08-08|Estimate||||2018-01-17|2018-02-13|Actual|September 2008||2008-09-30|January 2018|2018-01-31|May 15, 2014|Actual|2014-05-15|May 15, 2014|Actual|2014-05-15||Interventional|||Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer|Q3week Carboplatin With Weekly Abraxaneä And Avastin + Subsequent Dose-Dense Ac With Avastin As Neoadjuvant Therapy In Resectable And Unresectable (Stage Iia-Iiib) Her2-Negative Breast Cancer|Completed||Phase 2|60|Actual|Brown University||2|||f||||t||||||||||2018-06-01 01:54:25.988588|2018-06-01 01:54:25.988588
NCT00723112|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2010-11-22|2008-07-25|2008-07-28|Estimate|||||||2010-11-22|2010-11-23|Estimate|February 2007||2007-02-28|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||The Role of Erythropoietin in Myelodysplastic Syndrome|The Role of Erythropoietin in Myelodysplastic Syndrome|Completed|||8|Actual|University of Utah|||2||f||||f||||||||||2018-06-01 01:54:26.724555|2018-06-01 01:54:26.724555
NCT00723099|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2018-01-17|2008-07-25|2008-07-28|Estimate|||||||2018-01-17|2018-01-19|Actual|June 25, 2008|Actual|2008-06-25|January 2018|2018-01-31|November 13, 2019|Anticipated|2019-11-13|November 13, 2018|Anticipated|2018-11-13||Interventional|||Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer|Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)|Recruiting||Phase 2|76|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 01:54:26.800241|2018-06-01 01:54:26.800241
NCT00723086|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2009-09-30|2008-07-25|2008-07-28|Estimate|||||||2009-09-30|2009-10-01|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer|An Extension Multicenter Phase II Open Label Non-comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer.|Completed||Phase 2|16|Actual|Sanofi|||||f||||f||||||||||2018-06-01 01:54:26.927265|2018-06-01 01:54:26.927265
NCT00723073|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2010-06-07||2010-08-25|2008-07-25|2008-07-28|Estimate|2010-07-07|2010-08-04|Estimate||||2010-08-25|2010-08-31|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia|Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis|Completed|||323|Actual|Brigham and Women's Hospital|Retrospective, observational, sequential cohort study conducted at a single center. Only adult patients were treated at our institution, so these results cannot be extrapolated to a pediatric population.||2||f||||f||||||||||2018-06-01 01:54:27.003189|2018-06-01 01:54:27.003189
NCT00723060|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2011-08-05|2008-07-25|2008-07-28|Estimate|||||||2011-08-05|2011-08-08|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder|Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study)|Completed||Phase 4|176|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 01:54:27.495503|2018-06-01 01:54:27.495503
NCT00723047|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2011-09-02|2008-07-25|2008-07-28|Estimate|||||||2011-09-02|2011-09-05|Estimate|November 2003||2003-11-30|September 2011|2011-09-30|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|Fibrin glue||Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial|Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial|Completed||Phase 3|77|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f||||||||||2018-06-01 01:54:27.563284|2018-06-01 01:54:27.563284
NCT00723021|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2012-12-27|2011-03-16|2012-12-27|2008-07-24|2008-07-28|Estimate|2012-12-27|2013-02-01|Estimate|2011-03-16|2011-03-28|Estimate|2012-12-27|2013-02-01|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||PF-04191834 Single Dose Bronchodilatory Study In Asthma.|A Phase 2a, Randomised, Double-Blind (3rd Party Open), Double-Dummy, Placebo And Active Controlled 5-Way Crossover Study To Assess The Bronchodilatory Action, Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04191834 In Asthmatic Patients.|Completed||Phase 2|15|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 01:54:27.668392|2018-06-01 01:54:27.668392
NCT00723008|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2012-10-09||2013-02-19|2008-07-24|2008-07-28|Estimate|2013-02-19|2013-03-22|Estimate||||2013-02-19|2013-03-22|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|CES||Cranial Electrotherapy Stimulation in Burned Patients|Effect of Cranial Electrotherapy Stimulation on PTSD in Burned Outpatients|Completed||Phase 2|20|Actual|United States Army Institute of Surgical Research|This study had a high study turn-over rate, which led to small data group analysis. All subjects enrolled were active military service men. This made civilian and female comparison impossible. The PI also changed during study course.|2|||f||||f||||||||||2018-06-01 01:54:28.161811|2018-06-01 01:54:28.161811
NCT00722995|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2015-06-01|2008-07-25|2008-07-28|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|SLEEVE||Surgical Treatment for Morbid Obesity by Sleeve Gastrectomy Versus Gastric Bypass|Surgical Treatment for Morbid Obesity by Sleeve Gastrectomy Versus Gastric Bypass. Study Comparing Complications, Efficacy and Quality of Life.|Unknown status|Active, not recruiting|N/A|280|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:54:29.442803|2018-06-01 01:54:29.442803
NCT00722969|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2009-03-02|2008-07-24|2008-07-28|Estimate|||||||2009-03-02|2009-03-03|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|April 2009|Anticipated|2009-04-30|November 2008|Anticipated|2008-11-30||Interventional|||Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Phase II Study of Erlotinib and Sorafenib in Patients With Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy|Unknown status|Active, not recruiting|Phase 2|48|Anticipated|Free University Medical Center||1|||f||||f||||||||||2018-06-01 01:54:29.572785|2018-06-01 01:54:29.572785
NCT00722956|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2010-11-30|2008-07-24|2008-07-28|Estimate|||||||2010-11-30|2010-12-02|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin|A Phase I, Single Centre, Open-label Study to Assess the Pharmacokinetics of Both AZD5672 (Steady-state) and Atorvastatin (Single Dose) When Co Administered in Healthy Volunteers|Completed||Phase 1|12|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:54:29.649065|2018-06-01 01:54:29.649065
NCT00722943|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2013-02-06|2008-07-24|2008-07-28|Estimate|||||||2013-02-06|2013-02-08|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DMT||Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study|Neuroendocrine Mechanisms of Developmental Massage Therapy (DMT) in Preterm Infants: Clinical Study|Completed||N/A|46|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 01:54:29.812181|2018-06-01 01:54:29.812181
NCT00722930|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-07-25|2008-07-25|2008-07-28|Estimate|||||||2008-07-25|2008-07-28|Estimate|April 2008||2008-04-30|July 2008|2008-07-31|April 2013|Anticipated|2013-04-30|April 2011|Anticipated|2011-04-30||Interventional|GOTEL-FL1LC||Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma|Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy|Unknown status|Recruiting|Phase 2|38|Anticipated|Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas||1|||f||||f||||||||||2018-06-01 01:54:29.890619|2018-06-01 01:54:29.890619
NCT00722917|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24||2016-06-20|2016-06-20|2008-07-25|2008-07-28|Estimate||||2016-06-20|2016-06-22|Estimate|2016-06-20|2016-06-22|Estimate|July 2008||2008-07-31|June 2016|2016-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus|A Phase II, Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-center Study to Determine the Efficacy and Safety of TAK-379 in Subjects With Type 2 Diabetes|Terminated||Phase 2|323|Actual|Takeda||5||Animal Toxicity Findings|f||||f||||||||||2018-06-01 01:54:29.982305|2018-06-01 01:54:29.982305
NCT00722904|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2013-10-04|2008-07-25|2008-07-28|Estimate|||||||2013-10-04|2013-10-08|Estimate|June 2007||2007-06-30|October 2013|2013-10-31|September 2010|Actual|2010-09-30|July 2009|Actual|2009-07-31||Observational|||Evaluation of Vascular Pathology With 3D, Time-Resolved Phase Contrast Magnetic Resonance Imaging (MRI)|Evaluation of Vascular Pathology With 3D, Time-Resolved Phase Contrast MRI|Completed|||40|Anticipated|University of California, San Francisco|||2||f||||t||||||||||2018-06-01 01:54:30.07798|2018-06-01 01:54:30.07798
NCT00722891|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2010-11-12|2008-07-24|2008-07-28|Estimate|||||||2010-11-12|2010-11-15|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Ocular Responses to Short and Long-term Lens Wear|Ocular Responses to Acute and Chronic Lens Wear|Completed||Phase 4|30|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 01:54:30.138409|2018-06-01 01:54:30.138409
NCT00722878|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2018-01-24|2008-07-24|2008-07-28|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2008||2008-07-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease|Early Onset and Progression of Primary Ciliary Dyskinesia Lung Disease Prior to 10 Years of Age|Active, not recruiting|||48|Anticipated|University of North Carolina, Chapel Hill|||||f||||t||||||Samples With DNA|"~     Approximately 2 teaspoons of blood and a small amount of urine (if the child is able to~     urinate in a cup) will be collected and held at the specimen bank located at Denver~     Children's Hospital. These samples will be used to help identify markers that may predict the~     clinical course of PCD.~   "|||2018-06-01 01:54:30.414272|2018-06-01 01:54:30.414272
NCT00722865|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2017-01-25||2017-09-18|2008-07-25|2008-07-28|Estimate|2017-03-17|2017-04-28|Actual||||2017-09-18|2017-10-18|Actual|September 2008||2008-09-30|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma|Avastin (Bevacizumab) in Combination With ABVD for the Treatment of Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma|Terminated||Phase 2|25|Actual|Massachusetts General Hospital||1||slow enrollment|f||||t||||||||||2018-06-01 01:54:30.765936|2018-06-01 01:54:30.765936
NCT00722852|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2009-10-02|2008-07-25|2008-07-28|Estimate|||||||2009-10-02|2009-10-05|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee|Multicentre, Randomized, Double-blind, Placebo-controlled Study of Safety and Efficacy of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee|Completed||Phase 3|555|Actual|IDEA AG||2|||f||||f||||||||||2018-06-01 01:54:31.379204|2018-06-01 01:54:31.379204
NCT00722839|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2012-06-21|2008-07-25|2008-07-28|Estimate|||||||2012-06-21|2012-06-25|Estimate|December 2006||2006-12-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants|A Phase I Dose Escalation Study of Peptide Vaccines With Activity Against Human Cytomegalovirus|Completed||Phase 1|68|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 01:54:31.486793|2018-06-01 01:54:31.486793
NCT00722826|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2015-05-29|2008-07-23|2008-07-28|Estimate|||||||2015-05-29|2015-06-02|Estimate|June 2007||2007-06-30|May 2015|2015-05-31||||June 2009|Actual|2009-06-30||Observational|||Tetralogy of Fallot Seed Grant|MRI Assessment of Right Ventricular Function in Patients After Repair of Tetralogy of Fallot|Completed|||82|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 01:54:31.647308|2018-06-01 01:54:31.647308
NCT00722813|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2013-11-20|2008-07-24|2008-07-28|Estimate|||||||2013-11-20|2013-11-21|Estimate|October 2006||2006-10-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|||Cost Effectiveness and Utility of Computed Tomography Angiography (CTA) and Cardiac Cath|Cost Effectiveness and Utility of Coronary Artery Computed Tomography Angiography (CTA) in Screening for Coronary Artery Disease|Completed|||31|Actual|University of Michigan|||||f||||t||||||||||2018-06-01 01:54:31.719086|2018-06-01 01:54:31.719086
NCT00722800|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2013-05-06||2014-01-16|2008-07-25|2008-07-28|Estimate|2013-12-02|2014-01-16|Estimate||||2014-01-16|2014-02-10|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||One subject was excluded because she was regularly taking ibuprofen. The other subject changed her mind about study participation.|A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS|A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy of YAZ Compared With Placebo In The Treatment Of Hidradenitis Suppurativa|Terminated||Phase 2|4|Actual|Massachusetts General Hospital|Very small sample size.|2||Poor recruitment|f||||f||||||||||2018-06-01 01:54:31.785778|2018-06-01 01:54:31.785778
NCT00722774|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2008-11-07|2008-07-25|2008-07-28|Estimate|||||||2008-11-07|2008-11-10|Estimate||||July 2008|2008-07-31||||September 2008|Actual|2008-09-30||Interventional|||Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine|Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H2N2 (A/Ann Arbor/6/60 ca Recombinant), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H2N2 Infection in the Event of a Pandemic|Completed||Phase 1|22|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-06-01 01:54:32.340487|2018-06-01 01:54:32.340487
NCT00722761|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2012-12-17||2013-01-29|2008-07-25|2008-07-28|Estimate|2013-01-29|2013-03-05|Estimate||||2013-01-29|2013-03-05|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne|A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy Of YAZ Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris|Completed||Phase 3|30|Actual|Massachusetts General Hospital|Early termination leading to small number of subjects analyzed|2|||f||||f||||||||||2018-06-01 01:54:32.442792|2018-06-01 01:54:32.442792
NCT00722748|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2018-03-08|2008-07-25|2008-07-28|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2007||2007-06-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Genomic Investigation of Cardiovascular Diseases|The Genebank at Scripps Clinic Registry|Active, not recruiting|||15000|Anticipated|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Cardiac Catheterization Patients~      Blood will be collected from the patients that will undergo heart catheterization for~     establishing a gene bank registry. Informed consent will take place prior to cardiac~     catheterization. 38 cc of blood collected will be processed to create a repository of DNA,~     RNA, and lymphoblastoid cell-line immortalization on selected patient populations, plasma and~     serum. The DNA will be amplified in certain patient populations to preserve the quantity.~   "|||2018-06-01 01:54:32.740986|2018-06-01 01:54:32.740986
NCT00722735|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-25|||2009-06-10|2008-07-25|2008-07-28|Estimate|||||||2009-06-10|2009-06-11|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|FLUT||Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)|A Double-Blind, Double-Dummy, Prospective, Randomized Multiple-Site Study of Oral Finafloxacin 300 mg b.i.d. Versus Oral Ciprofloxacin 250 mg b.i.d. in Patients With Lower Uncomplicated UTI (uUTI) With a Treatment Duration of 3 Days|Completed||Phase 2|36|Anticipated|MerLion Pharmaceuticals GmbH||2|||f||||t||||||||||2018-06-01 01:54:32.822277|2018-06-01 01:54:32.822277
NCT00722722|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2015-04-21||2016-04-28|2008-07-24|2008-07-28|Estimate|2016-04-28|2016-05-09|Estimate||||2016-04-28|2016-05-09|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates|The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates|Completed||Phase 2|18|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 01:54:32.907457|2018-06-01 01:54:32.907457
NCT00722709|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2010-01-12|2008-07-23|2008-07-25|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2008||2008-09-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Intraperitoneal Local Anaesthetic in Colonic Surgery|Randomised Double Blind Trial to Investigate the Effects of Intraperitoneal Local Anaesthetic Following Colonic Surgery.|Completed||Phase 1|60|Anticipated|University of Auckland, New Zealand||2|||f||||t||||||||||2018-06-01 01:54:33.203073|2018-06-01 01:54:33.203073
NCT00722696|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2008-07-24|2008-07-24|2008-07-25|Estimate|||||||2008-07-24|2008-07-25|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Metabolic Effects of Eccentric Endurance Training|Metabolic Effects of Eccentric Endurance Training|Unknown status|Not yet recruiting|N/A|35|Anticipated|Vorarlberg Institute for Vascular Investigation and Treatment|||||f||||f||||||||||2018-06-01 01:54:33.275556|2018-06-01 01:54:33.275556
NCT00722683|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-10-16|2008-07-24|2008-07-25|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2001||2001-04-30|October 2017|2017-10-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Evaluate Breast Masses Using a New Method of Ultrasound Contrast to Detect Abnormal Blood Flow in Breasts|Characterization of Breast Masses Using a New Method of Ultrasound Contrast Agent Imaging in 3D Mapping of Vascular Anomalies|Withdrawn||N/A|0|Actual|University of Michigan||1|||f||||t||||||||No||2018-06-01 01:54:33.360049|2018-06-01 01:54:33.360049
NCT00722670|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2013-05-07|2008-07-23|2008-07-25|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|August 2010|Actual|2010-08-31|February 2009|Actual|2009-02-28||Interventional|||Pregnant Women's CoOp|Woman-Focused HIV Prevention With Pregnant African-Americans|Completed||Phase 1|100|Actual|RTI International||2|||f||||f||||||||||2018-06-01 01:54:33.413599|2018-06-01 01:54:33.413599
NCT00722657|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2008-07-23|2008-07-23|2008-07-25|Estimate|||||||2008-07-23|2008-07-25|Estimate|April 2006||2006-04-30|May 2008|2008-05-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Observational|||Social-Economics Profile of the Asthmatic Patients Attended at Nucleus of Integrated Medical Care|Social-Economics Profile of the Asthmatic Patients Attended at Nucleus of Integrated Medical Care|Completed|||40|Actual|Fortaleza University|||||f||||t||||||None Retained|"~     None Retained - no samples retained~   "|||2018-06-01 01:54:33.478762|2018-06-01 01:54:33.478762
NCT00722644|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-01-10|2008-07-23|2008-07-25|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 1999||1999-09-30|July 2008|2008-07-31|August 2007||2007-08-31|||||Interventional|||Cognitive Behavioral Stress Management for HIV+ Drug Abusers|Cognitive Behavioral Treatment of HIV+ Drug Abusers|Completed||Phase 1|450||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 01:54:33.521255|2018-06-01 01:54:33.521255
NCT00722631|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2012-09-26|2008-07-23|2008-07-25|Estimate|||||||2012-09-26|2012-09-27|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2009|Actual|2009-04-30||Interventional|||Anti-Inflammatory Effects of Pioglitazone|Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT|Completed||N/A|70|Actual|Kurume University||2|||f||||t||||||||||2018-06-01 01:54:33.568678|2018-06-01 01:54:33.568678
NCT00722605|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2013-01-23|2008-07-24|2008-07-25|Estimate|||||||2013-01-23|2013-01-24|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Multiple Respiration-Correlated Cone Beam Computed Tomography (CT) Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer|The Use of Multiple Respiration-Correlated Cone Beam CT Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer.|Completed||Phase 1/Phase 2|16|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:54:33.799632|2018-06-01 01:54:33.799632
NCT00722592|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23||2012-03-07|2014-12-18|2008-07-23|2008-07-25|Estimate||||2012-03-07|2012-03-09|Estimate|2014-12-18|2015-01-07|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|September 2010|Actual|2010-09-30||Interventional|PRECEDENT||Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)|A Randomized Phase II Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination, Versus PLD Alone, in Subjects With Platinum-Resistant Ovarian Cancer|Completed||Phase 2|162|Actual|Endocyte||2|||f||||t||||||||||2018-06-01 01:54:33.883486|2018-06-01 01:54:33.883486
NCT00722579|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2010-06-11|2008-07-24|2008-07-25|Estimate|||||||2010-06-11|2010-06-14|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|December 2008|Actual|2008-12-31||Interventional|PRESILLION||A Study of the Presillion Stent in de Novo Coronary Lesions|A Non-Randomized, Multi-Center, Single-Arm Safety Study of the Presillion Stent in de Novo Native Coronary Artery Lesions|Completed||Phase 3|101|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 01:54:33.967905|2018-06-01 01:54:33.967905
NCT00722566|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2011-08-30||2011-10-06|2008-07-24|2008-07-25|Estimate|2011-08-30|2011-10-04|Estimate||||2011-10-06|2011-10-10|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma|An Open-Label Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma|Completed||Phase 3|222|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 01:54:34.064372|2018-06-01 01:54:34.064372
NCT00722553|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2012-04-30||2013-05-08|2008-07-24|2008-07-25|Estimate|2012-06-12|2012-07-17|Estimate||||2013-05-08|2013-05-10|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Interventional|||Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder|A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder|Completed||Phase 2|30|Actual|Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 01:54:34.719742|2018-06-01 01:54:34.719742
NCT00722540|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-02-06|2008-07-23|2008-07-25|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2008||2008-07-31|February 2017|2017-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083|Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NCC126-0083 in Healthy Male Japanese Subjects.|Completed||Phase 1|40|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-06-01 01:54:35.081827|2018-06-01 01:54:35.081827
NCT00722527|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-11-01|2008-07-24|2008-07-25|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2006||2006-07-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Molecular Biology of Polycythemia and Thrombocytosis|Molecular Biology of Polycythemia and Thrombocytosis|Recruiting|||200|Anticipated|University of Utah|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 01:54:35.258235|2018-06-01 01:54:35.258235
NCT00722514|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-08-14|2008-07-23|2008-07-25|Estimate|||||||2008-08-14|2008-08-18|Estimate|July 1998||1998-07-31|July 2008|2008-07-31|July 2001||2001-07-31|February 2001||2001-02-28||Interventional|||Evaluation of a Patient Education Program for Ankylosing Spondylitis|Evaluation of a Patient Education Program for Ankylosing Spondylitis|Completed||N/A|||Rehazentrum Bad Eilsen||2|||f||||||||||||||2018-06-01 01:54:35.391411|2018-06-01 01:54:35.391411
NCT00722501|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2009-04-24|2008-07-24|2008-07-25|Estimate|||||||2009-04-24|2009-04-28|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects|Completed||Phase 1|48|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:54:35.503047|2018-06-01 01:54:35.503047
NCT00722488|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2013-11-15|2008-07-23|2008-07-25|Estimate|||||||2013-11-15|2013-11-18|Estimate|June 2008||2008-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma|An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma|Completed||Phase 1|56|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 01:54:35.558199|2018-06-01 01:54:35.558199
NCT00722475|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2014-11-05|2008-07-23|2008-07-25|Estimate|||||||2014-11-05|2014-11-06|Estimate|August 2008||2008-08-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage|A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Immunoglobulin for Women With Unexplained Secondary Recurrent Miscarriage|Completed||Phase 3|82|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 01:54:35.612876|2018-06-01 01:54:35.612876
NCT00722462|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2015-07-07|2008-07-24|2008-07-25|Estimate|||||||2015-07-07|2015-07-09|Estimate|August 2008||2008-08-31|July 2015|2015-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|AcuIVF||The Effect of Acupuncture on Pregnancy Rates in Women Undergoing Embryo Transfer|The Effect of Acupuncture on Pregnancy Rates in Women Undergoing Embryo Transfer After in Vitro Fertilization: A Prospective Randomized Sham-controlled Trial|Terminated||Phase 4|30|Actual|Ottawa Fertility Centre||3||Recent abstract publication questioning the need for our study|f||||f||||||||||2018-06-01 01:54:35.704153|2018-06-01 01:54:35.704153
NCT00722436|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2016-09-16||2017-02-10|2008-07-24|2008-07-25|Estimate|2017-02-10|2017-02-15|Actual||||2017-02-10|2017-02-15|Actual|July 2008||2008-07-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Tranexamic Acid for Craniofacial Surgery|Tranexamic Acid for the Reduction of Allogeneic Blood Exposure in Infants and Children Having Craniofacial Surgery|Terminated||Phase 4|20|Actual|University of Pittsburgh|Study terminated because two studies published during the trial demonstrated efficacy of tranexamic acid at a lower dose.|2||Study dose changed based on recent publications|f||||f||||||||No|We stopped the study early because emerging data came out that demonstrated benefit with significantly lower doses than our study. We were compelled to stop enrolling.|2018-06-01 01:54:35.784433|2018-06-01 01:54:35.784433
NCT00722410|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-07-24|2008-07-24|2008-07-25|Estimate|||||||2008-07-24|2008-07-25|Estimate|September 2008||2008-09-30|July 2008|2008-07-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia|Safety and Efficacy Study of Eradication of Carbapenem Resistant Klebsiella Pneumonia From the Gastrointestinal Tract by Probiotics.|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-06-01 01:54:37.030614|2018-06-01 01:54:37.030614
NCT00722397|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2015-06-03|2008-07-23|2008-07-25|Estimate|||||||2015-06-03|2015-06-04|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||TODAY Genetics Study|Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Genetics Study|Completed|||2654|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||Samples With DNA|"~     Collect 27 mL of blood to send (1) for extraction of DNA to the NIDDK Central Repository and~     (2) for measurement of glucose, C-peptide, and autoantibody analysis to a central blood~     laboratory.~   "|||2018-06-01 01:54:37.136497|2018-06-01 01:54:37.136497
NCT00722384|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-07-24|2008-07-24|2008-07-25|Estimate|||||||2008-07-24|2008-07-25|Estimate|August 2004||2004-08-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5|An Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5 by Single Intravitreal Injection in Patients With Wet Age-Related Macular Degeneration|Completed||Phase 1|15|Actual|OPKO Health, Inc.||5|||f||||f||||||||||2018-06-01 01:54:37.217199|2018-06-01 01:54:37.217199
NCT00722371|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2011-09-09||2017-04-07|2008-07-24|2008-07-25|Estimate|2011-09-09|2011-10-17|Estimate||||2017-04-07|2017-05-12|Actual|September 5, 2008|Actual|2008-09-05|April 2017|2017-04-30|March 25, 2011|Actual|2011-03-25|October 26, 2010|Actual|2010-10-26||Interventional|||MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)|A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 3|1615|Actual|Merck Sharp & Dohme Corp.||7|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:54:37.392843|2018-06-01 01:54:37.392843
NCT00722358|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23||2011-06-15|2011-06-15|2008-07-23|2008-07-25|Estimate||||2011-06-15|2011-06-27|Estimate|2011-06-15|2011-06-27|Estimate|December 2008||2008-12-31|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects|Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of BMS-650032 in Subjects Infected With Hepatitis C Virus Genotype 1|Completed||Phase 2|15|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 01:54:39.065007|2018-06-01 01:54:39.065007
NCT00722345|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-07-24|2008-07-24|2008-07-25|Estimate|||||||2008-07-24|2008-07-25|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Exercise Consultation in Obese Youth|Can Exercise Consultation Increase Activity Levels and Improve Metabolic Markers in Obese Adolescents? A Pilot Study.|Completed||N/A|33|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-06-01 01:54:39.152371|2018-06-01 01:54:39.152371
NCT00722332|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2013-10-30|2008-07-23|2008-07-25|Estimate|||||||2013-10-30|2013-11-01|Estimate|February 2008||2008-02-29|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients|Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients|Completed||Phase 4|9|Actual|Cangene Corporation||1|||f||||f||||||||||2018-06-01 01:54:39.281744|2018-06-01 01:54:39.281744
NCT00722319|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2011-08-11|2008-07-23|2008-07-25|Estimate|||||||2011-08-11|2011-08-12|Estimate|March 2009||2009-03-31|January 2010|2010-01-31|October 2011|Anticipated|2011-10-31|July 2010|Actual|2010-07-31||Observational|WAR-STENT||Ongoing WARfarin and Coronary STENTing|Ongoing WARfarin and Coronary STENTing. A Multi-center, Prospective Registry on Antithrombotic Treatment.|Unknown status|Active, not recruiting||1000|Anticipated|War-Stent Investigators|||1||f||||f||||||||||2018-06-01 01:54:39.389691|2018-06-01 01:54:39.389691
NCT00722306|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2011-02-03|2008-07-24|2008-07-25|Estimate|||||||2011-02-03|2011-02-04|Estimate|May 2008||2008-05-31|February 2011|2011-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:54:39.506737|2018-06-01 01:54:39.506737
NCT00722293|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-11-08|2008-07-24|2008-07-25|Estimate|||||||2017-11-08|2017-11-13|Actual|July 8, 2008|Actual|2008-07-08|November 2017|2017-11-30|February 25, 2014|Actual|2014-02-25|June 11, 2012|Actual|2012-06-11||Interventional|||A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors|A Phase I, Open-label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics Dose Escalation of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors|Completed||Phase 1|111|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 01:54:39.564857|2018-06-01 01:54:39.564857
NCT00722280|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-12-05|2008-07-24|2008-07-25|Estimate|||||||2017-12-05|2017-12-07|Actual|December 2008||2008-12-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Human Upper Extremity (Hand and Forearm) Allotransplantation|The Pittsburgh Protocol in Human Upper Extremity Allotransplantation|Terminated||N/A|38|Actual|University of Pittsburgh||1||loss of funding|f||||t||||||||No||2018-06-01 01:54:39.774529|2018-06-01 01:54:39.774529
NCT00722267|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2009-07-24|2008-07-23|2008-07-25|Estimate|||||||2009-07-24|2009-07-28|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|||||Observational|||European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients|Patient Perception of Symptom Variability. A Cross-sectional Study of Patients With Severe COPD.|Completed|||7400|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:54:39.975703|2018-06-01 01:54:39.975703
NCT00722254|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2016-03-17|2008-07-23|2008-07-25|Estimate|||||||2016-03-17|2016-03-21|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder|Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder|Terminated|||15|Actual|University of Utah|||2|This study was stopped due to poor enrollment numbers|f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 01:54:41.085567|2018-06-01 01:54:41.085567
NCT00722241|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-07-24|2008-07-24|2008-07-25|Estimate|||||||2008-07-24|2008-07-25|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System|Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System|Completed|||53|Actual|DexCom, Inc.|||1||f||||f||||||||||2018-06-01 01:54:41.188579|2018-06-01 01:54:41.188579
NCT00722228|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-11-29|2008-07-24|2008-07-25|Estimate|||||||2017-11-29|2017-11-30|Actual|July 2008||2008-07-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors||Recruiting||Phase 1/Phase 2|50|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:54:41.372915|2018-06-01 01:54:41.372915
NCT00722215|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-07-23|2008-07-23|2008-07-25|Estimate|||||||2008-07-23|2008-07-25|Estimate|May 2006||2006-05-31|August 2006|2006-08-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Endothelin Receptor Antagonism in Proteinuric Nephropathy|The Systemic & Renal Effects of Endothelin Receptor Antagonism in Proteinuric Nephropathy|Completed||Phase 1|22|Actual|University of Edinburgh||3|||f||||f||||||||||2018-06-01 01:54:41.469742|2018-06-01 01:54:41.469742
NCT00722202|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2009-04-24|2008-07-24|2008-07-25|Estimate|||||||2009-04-24|2009-04-28|Estimate|October 2008||2008-10-31|April 2009|2009-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study Evaluating the Safety and Pharmacokinetics (PK) of Ascending Single IV Doses of ERB-257 in Healthy Japanese Males|Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Japanese Male Subjects|Completed||Phase 1|48|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:54:41.562594|2018-06-01 01:54:41.562594
NCT00722189|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2015-03-18|2008-07-23|2008-07-25|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Observational|||Observational Study of Efficacy and Safety of Travogen Cream and Travocort Cream in the Treatment of Mycoses|Observational Study of the Efficacy, Safety and Tolerance of Travogen Cream (Isoconazole) and Travocort Cream (Isoconazole, Diflurcortolone) in the Treatment of Patients With Local Skin Mycosis of Various Etiology and Localization|Completed|||900|Actual|Bayer|||1||f||||f||||||||||2018-06-01 01:54:41.645979|2018-06-01 01:54:41.645979
NCT00722176|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2010-06-27|2008-07-24|2008-07-25|Estimate|||||||2010-06-27|2010-06-29|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020|A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone|Completed||Phase 2|220|Anticipated|BioLineRx, Ltd.||3|||f||||t||||||||||2018-06-01 01:54:41.781621|2018-06-01 01:54:41.781621
NCT00722163|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-07-23|2008-07-23|2008-07-25|Estimate|||||||2008-07-23|2008-07-25|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|March 2013|Anticipated|2013-03-31|May 2009|Anticipated|2009-05-31||Interventional|PSTEP||A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis|A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis|Unknown status|Recruiting|Early Phase 1|330|Anticipated|Ontario Mental Health Foundation||3|||f||||f||||||||||2018-06-01 01:54:41.986519|2018-06-01 01:54:41.986519
NCT00722150|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2011-01-24|2008-07-23|2008-07-25|Estimate|||||||2011-01-24|2011-01-25|Estimate|July 2008||2008-07-31|January 2011|2011-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|ARC II||Artemisinin Resistance in Cambodia II|Artemisinin Resistance in Cambodia II|Completed||N/A|143|Actual|Armed Forces Research Institute of Medical Sciences, Thailand||3|||f||||t||||||||||2018-06-01 01:54:42.241433|2018-06-01 01:54:42.241433
NCT00722137|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2014-11-08|2013-02-01|2017-08-14|2008-07-23|2008-07-25|Estimate|2014-11-08|2014-11-17|Estimate|2013-02-01|2013-02-05|Estimate|2017-08-14|2017-09-13|Actual|May 1, 2008|Actual|2008-05-01|August 2017|2017-08-31|June 23, 2017|Actual|2017-06-23|January 1, 2014|Actual|2014-01-01||Interventional||The population consisted of all randomized participants.|Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma|A Randomized, Open-Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant|Completed||Phase 3|487|Actual|Takeda||2|||f|||||t|f||||||||2018-06-01 01:54:42.48376|2018-06-01 01:54:42.48376
NCT00722124|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2011-08-05||2011-08-05|2008-07-24|2008-07-25|Estimate|2011-08-05|2011-09-09|Estimate||||2011-08-05|2011-09-09|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence|S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence|Completed||Phase 2/Phase 3|150|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 01:54:43.694378|2018-06-01 01:54:43.694378
NCT00722111|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2013-10-17||2018-03-12|2008-07-23|2008-07-25|Estimate|2018-03-12|2018-03-21|Actual||||2018-03-12|2018-03-21|Actual|February 2011||2011-02-28|March 2018|2018-03-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional||PI is not available, therefore, no data is available for reporting in this section.Efforts to retrieve data were unsuccessful.|Exercise for Swallowing Problems After Stroke|Rehabilitation Exercise for Dysphagia Subsequent to Stroke|Completed||N/A|83|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 01:54:44.221306|2018-06-01 01:54:44.221306
NCT00722098|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2013-07-05|2008-07-24|2008-07-25|Estimate|||||||2013-07-05|2013-07-08|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|April 2011|Actual|2011-04-30||Interventional|||Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients|Melanoma Peptide-Loaded Dendritic Cell Vaccine in HLA-A*0201 Patients With Stage IV Melanoma: A Phase II Randomized Trial to Compare Vaccination With and Without Cyclophosphamide Treatment.|Terminated||Phase 2|9|Actual|Baylor Research Institute||2||Early termination due to lesser accrual, and data analysis not done.|f||||t||||||||||2018-06-01 01:54:44.352582|2018-06-01 01:54:44.352582
NCT00722085|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-07-23|2008-07-23|2008-07-25|Estimate|||||||2008-07-23|2008-07-25|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Observational|||Amniotic Fluid Sludge in Cerclage Patients as an Indicator for Increased Risk of Preterm Delivery and Neonatal Outcome.|Amniotic Fluid Sludge in Cerclage Patients as an Indicator for Increased Risk of Preterm Delivery and Neonatal Outcome.|Completed|||177|Actual|Center For Maternal Fetal Medicine|||1||f||||t||||||||||2018-06-01 01:54:44.428629|2018-06-01 01:54:44.428629
NCT00721903|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2016-05-03|2008-07-23|2008-07-25|Estimate|||||||2016-05-03|2016-05-05|Estimate|March 2000||2000-03-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies|3D Breast Ultrasound In Predicting Response to Breast Cancer Therapies|Completed||N/A|88|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:54:46.53376|2018-06-01 01:54:46.53376
NCT00722072|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|2011-08-04||2018-01-25|2008-07-24|2008-07-25|Estimate|2011-08-04|2011-09-05|Estimate||||2018-01-25|2018-02-26|Actual|July 2008||2008-07-31|January 2018|2018-01-31|July 2012|Actual|2012-07-31|July 2010|Actual|2010-07-31||Interventional|||Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy|A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment|Terminated||Phase 2|12|Actual|OHSU Knight Cancer Institute||1||Sponsor pulled funding and low accrual|f||||||||||||||2018-06-01 01:54:44.49234|2018-06-01 01:54:44.49234
NCT00722059|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2014-01-31|2008-07-24|2008-07-25|Estimate|||||||2014-01-31|2014-02-03|Estimate|April 2006||2006-04-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Detection and/or Evaluation of Dense Breast Abnormalities Using Tomosynthesis and Digital Mammography|Assessment of Emerging Technology: Comparison of Breast Tomosynthesis and Digital Mammography in the Evaluation of Heterogeneously Dense and Extremely Dense Breasts|Completed||Early Phase 1|50|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 01:54:44.776657|2018-06-01 01:54:44.776657
NCT00722046|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23||2012-10-08|2016-04-08|2008-07-24|2008-07-25|Estimate||||2012-10-08|2012-10-11|Estimate|2016-04-08|2016-05-05|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease|A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease|Completed||Phase 2|198|Actual|Pfizer||6|||f||||t||||||||||2018-06-01 01:54:44.869127|2018-06-01 01:54:44.869127
NCT00722033|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2008-08-13|2008-07-23|2008-07-25|Estimate|||||||2008-08-13|2008-08-18|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|ELECTROPREM||Common Neonatal Procedures Could Affect the aEEG in <30 Weeks of Gestational Age Preterms|Effect of Common Neonatal Procedures Over the Amplitude- Integrated Electroencephalography Register in <30 Weeks Preterms.|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Pontificia Universidad Catolica de Chile||1|||f||||f||||||||||2018-06-01 01:54:44.995545|2018-06-01 01:54:44.995545
NCT00722020|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2015-08-25||2017-07-07|2008-07-24|2008-07-25|Estimate|2015-10-22|2015-11-24|Estimate||||2017-07-07|2017-08-07|Actual|July 2008||2008-07-31|July 2017|2017-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional||Pediatric patients admitted with diagnosis of Asthma|HFCWO in Hospitalized Asthmatic Children|High Frequency Chest Wall Oscillation in Hospital Management of Asthmatic Children|Completed||N/A|43|Actual|Hill-Rom||2|||f||||f||||||||||2018-06-01 01:54:45.08426|2018-06-01 01:54:45.08426
NCT00722007|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2017-07-04|2008-07-24|2008-07-25|Estimate|||||||2017-07-04|2017-07-06|Actual|April 24, 2008|Actual|2008-04-24|July 2017|2017-07-31|May 12, 2014|Actual|2014-05-12|April 11, 2014|Actual|2014-04-11||Interventional|PASNew||Cormet Post-PMA Study: New Enrollment|Cormet Hip Resurfacing System Post-PMA Study Group (New Enrollment)|Completed||N/A|160|Actual|Corin||1|||f||||t||||||||||2018-06-01 01:54:45.25657|2018-06-01 01:54:45.25657
NCT00721994|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2018-02-07|2008-07-24|2008-07-25|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2008||2008-05-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|PAS:IDE||Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects|Cormet Resurfacing Hip System Post PMA Approval Study (PMA #P050016)Pre-market (IDE) Study Group 10 Year Follow-Up With Metal Ion and Renal Function Data Collection Clinical Investigation Plan|Active, not recruiting|||350|Anticipated|Corin|||1||f||||t||||||Samples With DNA|"~     blood specimens for metal ion testing and renal function testing~   "|||2018-06-01 01:54:45.41206|2018-06-01 01:54:45.41206
NCT00721981|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2010-12-09|2008-07-23|2008-07-25|Estimate|||||||2010-12-09|2010-12-10|Estimate|April 2009||2009-04-30|December 2010|2010-12-31|October 2009|Actual|2009-10-31|||||Observational|||An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy|A Non-interventional Study for Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy. With Special Focus on Patients Who Are in Transition From First Line to Second Line Treatment|Terminated|||120|Anticipated|AstraZeneca|||1|Low Recruitment|f||||f||||||||||2018-06-01 01:54:45.510837|2018-06-01 01:54:45.510837
NCT00721968|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2013-04-18||2014-02-04|2008-07-24|2008-07-25|Estimate|2014-02-04|2014-03-06|Estimate||||2014-02-04|2014-03-06|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract|A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Clinical Investigation Of The Trabecular Micro-Bypass Stent Model GTS400 In Conjunction With Cataract Surgery|Completed||Phase 3|62|Actual|Glaukos Corporation|There are no limitations and caveats to report|2|||f||||t||||||||||2018-06-01 01:54:45.595196|2018-06-01 01:54:45.595196
NCT00721955|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2017-03-13||2017-06-28|2008-07-24|2008-07-25|Estimate|2017-05-30|2017-06-29|Actual||||2017-06-28|2017-07-26|Actual|July 2008||2008-07-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Safety Population|Staccato Loxapine in Agitated Patients With Bipolar Disorder|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation|Completed||Phase 3|314|Actual|Alexza Pharmaceuticals, Inc.|Because of the need to provide informed consent, the types of patients enrolled in the study may not have been representative of the most severely agitated patients who present for emergency care.|3|||f||||f|t|f||||||No|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 01:54:45.930493|2018-06-01 01:54:45.930493
NCT00721929|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2012-12-04|2008-07-23|2008-07-25|Estimate|||||||2012-12-04|2012-12-06|Estimate|October 2003||2003-10-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2010|Actual|2010-07-31||Interventional|||Lipid-poor Adrenal Masses: Evaluation With Chemical Shift MRI|Lipid-poor Adrenal Masses: Evaluation With Chemical Shift MRI|Completed||N/A|16|Actual|University of Michigan||1|||f||||||||||||||2018-06-01 01:54:46.365555|2018-06-01 01:54:46.365555
NCT00721916|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2012-10-31|2008-07-24|2008-07-25|Estimate|||||||2012-10-31|2012-11-01|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer|Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus 5-FU, l-LV and Oxaliplatin Combination Therapy (mFOLFOX6) in Patients With Untreated Metastatic Colorectal Cancer|Completed||Phase 2|107|Actual|Taiho Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-06-01 01:54:46.429749|2018-06-01 01:54:46.429749
NCT00721890|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2013-10-22|2008-07-23|2008-07-25|Estimate|||||||2013-10-22|2013-10-24|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|DBGT-OC-CR||Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma|Phase II Study: Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma|Completed||Phase 2|16|Actual|CHU de Quebec-Universite Laval||1|||f||||t||||||||||2018-06-01 01:54:46.685133|2018-06-01 01:54:46.685133
NCT00721877|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-24|||2014-10-07|2008-07-24|2008-07-25|Estimate|||||||2014-10-07|2014-10-08|Estimate|August 2008||2008-08-31|March 2013|2013-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Resveratrol in Healthy Adult Participants|Clinical Study of Resveratrol on Drug and Carcinogen Metabolizing Enzymes|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:54:46.790527|2018-06-01 01:54:46.790527
NCT00721864|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2011-08-05|2008-07-23|2008-07-25|Estimate|||||||2011-08-05|2011-08-09|Estimate|May 2006||2006-05-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)|The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH)|Completed|||10|Actual|University of Utah|||1||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 01:54:46.862023|2018-06-01 01:54:46.862023
NCT00721851|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2011-06-21|2008-07-23|2008-07-25|Estimate|||||||2011-06-21|2011-06-23|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||320-slice Coronary Computed Tomography (CT) Angiography|Coronary Artery Imaging With 320-slice Computed Tomography|Completed|||30|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 01:54:47.240264|2018-06-01 01:54:47.240264
NCT00721838|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2016-08-18|2008-07-23|2008-07-24|Estimate|||||||2016-08-18|2016-08-22|Estimate|February 2009||2009-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|Teen LABS||Dietary Intake and Eating Behaviors in Adolescents Who Undergo Bariatric Surgery|Dietary Intake and Eating Behaviors in Adolescents Who Undergo Bariatric Surgery|Completed|||160|Actual|University of Pennsylvania|||2||f||||f||||||||||2018-06-01 01:54:47.300723|2018-06-01 01:54:47.300723
NCT00721825|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2008-07-23|2008-07-23|2008-07-24|Estimate|||||||2008-07-23|2008-07-24|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|TIERS||Study of NeuroAid In Enhancing Recovery After Stroke|A Double-Blinded, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of a Traditional Chinese Medicine NeuroAid In Enhancing Recovery After Stroke (TIERS)|Completed||Phase 2|40|Actual|Moleac Pte Ltd.||2|||f||||f||||||||||2018-06-01 01:54:47.373813|2018-06-01 01:54:47.373813
NCT00721812|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2017-07-05|2008-07-23|2008-07-24|Estimate|||||||2017-07-05|2017-07-07|Actual|September 25, 2008|Actual|2008-09-25|July 2017|2017-07-31|May 27, 2009|Actual|2009-05-27|May 27, 2009|Actual|2009-05-27||Interventional|||A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686|A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 After Single and Repeated Oral Dosing in Healthy Volunteers Using a Dose-Escalating, Randomized, Placebo-Controlled Study Design|Completed||Phase 1|87|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:54:47.44495|2018-06-01 01:54:47.44495
NCT00721799|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2017-03-29||2017-09-05|2008-07-23|2008-07-24|Estimate|2017-09-05|2017-10-03|Actual||||2017-09-05|2017-10-03|Actual|March 2008|Actual|2008-03-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|December 2014|Actual|2014-12-31||Interventional|||F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients|F-18 Fluorothymidine (FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)|Active, not recruiting||Phase 2|33|Actual|University of Iowa|"HPV (human papilloma virus) status of tumors not available.~Therapy heterogeneity in the therapy; radiotherapy fairly consistent but chemotherapy regimens varied.~Small sample size is limiting."|1|||f||||t|t|f||||||No|Data will be shared through clinicaltrials.gov and in provision with the filed data sharing plan for the grant. Consent was not obtained from participants to share individual patient data.|2018-06-01 01:54:47.731573|2018-06-01 01:54:47.731573
NCT00721786|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2015-05-21|2008-07-22|2008-07-24|Estimate|||||||2015-05-21|2015-05-25|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|TC4||Internet Stop Smoking Study - Phase VI|Internet Health Research Center: Smoking, Latinos, and the Web|Completed||N/A|18154|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 01:54:48.814863|2018-06-01 01:54:48.814863
NCT00721773|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2015-05-18|2008-07-22|2008-07-24|Estimate|||||||2015-05-18|2015-05-20|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients|Effects of Benazepril,Valsartan or Combination of Both on Residual Renal Function in Peritoneal Dialysis Patients|Completed||N/A|200|Actual|Sun Yat-sen University||4|||f||||t||||||||||2018-06-01 01:54:48.906337|2018-06-01 01:54:48.906337
NCT00721760|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22||2010-12-20|2013-01-14|2008-07-22|2008-07-24|Estimate||||2010-12-20|2010-12-28|Estimate|2013-01-14|2013-01-23|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|SAVE-HIP2||Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery|Completed||Phase 3|1003|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:54:49.00145|2018-06-01 01:54:49.00145
NCT00721747|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2012-03-15|2008-07-23|2008-07-24|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|January 2015|Anticipated|2015-01-31|January 2011|Actual|2011-01-31||Interventional|||Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer|Phase II, Open, Not Randomized Clinical Trial, to Evaluate the Sequential Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in her2 Negative Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 2|83|Anticipated|Grupo Oncológico Gallego||1|||f||||t||||||||||2018-06-01 01:54:49.20925|2018-06-01 01:54:49.20925
NCT00721734|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2015-11-02||2017-04-28|2008-07-22|2008-07-24|Estimate|2015-11-02|2015-12-09|Estimate||||2017-04-28|2017-05-02|Actual|November 2008||2008-11-30|April 2017|2017-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function|Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function|Completed||Phase 2|50|Actual|Amgen||1|||f||||f||||||||||2018-06-01 01:54:49.420942|2018-06-01 01:54:49.420942
NCT00721721|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2016-07-28|2008-07-22|2008-07-24|Estimate|||||||2016-07-28|2016-07-29|Estimate|October 2003||2003-10-31|August 2008|2008-08-31|May 2009|Actual|2009-05-31|July 2005|Actual|2005-07-31||Interventional|GenSalt||Analyzing Genetic Factors Involved in Blood Pressure Changes Due to Salt and Potassium Intake (The GenSalt Study)|Genetic Epidemiology Network of Salt Sensitivity|Completed||Phase 3|1906|Actual|National Heart, Lung, and Blood Institute (NHLBI)||1|||f||||t||||||||||2018-06-01 01:54:51.85434|2018-06-01 01:54:51.85434
NCT00721708|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2009-12-14|2008-07-23|2008-07-24|Estimate|||||||2009-12-14|2009-12-15|Estimate|April 2007||2007-04-30|December 2009|2009-12-31|July 2008|Actual|2008-07-31|October 2007|Actual|2007-10-31||Interventional|||Pharmacokinetics of Carnosine|Pharmacokinetics of Carnosine|Completed||N/A|4|Actual|Tufts University||4|||f||||f||||||||||2018-06-01 01:54:51.921225|2018-06-01 01:54:51.921225
NCT00721695|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22||2011-06-17|2014-07-16|2008-07-22|2008-07-24|Estimate||||2011-06-17|2011-06-27|Estimate|2014-07-16|2014-07-18|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.|Randomized, Controlled, Double-Masked, Multicenter, Exploratory Study of the Clinical Benefit and Safety of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR) Using a Coaxial Phacoemulsification Process|Completed||Phase 1/Phase 2|60|Actual|Omeros Corporation||3|||f||||f||||||||||2018-06-01 01:54:52.016629|2018-06-01 01:54:52.016629
NCT00721682|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2013-10-23|2008-07-22|2008-07-24|Estimate|||||||2013-10-23|2013-10-24|Estimate|November 2008||2008-11-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|ANTALPED||Evaluation of Acute Pain in Maltreated Children|Evaluation of Acute Pain in Maltreated Children : a Prospective, Multicentric and Controlled Study|Completed|||78|Actual|Nantes University Hospital|||2||f||||f||||||||||2018-06-01 01:54:52.092543|2018-06-01 01:54:52.092543
NCT00721669|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2013-09-12|2008-07-23|2008-07-24|Estimate|||||||2013-09-12|2013-09-13|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors|A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors|Completed||Phase 1|60|Actual|ImmunoGen, Inc.|||||f||||||||||||||2018-06-01 01:54:52.233224|2018-06-01 01:54:52.233224
NCT00721656|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2009-03-16|2008-07-23|2008-07-24|Estimate|||||||2009-03-16|2009-03-18|Estimate||||March 2009|2009-03-31||||||||Interventional|||Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes|A Randomized, Double Blind, Placebo Controlled, Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes|Completed||Phase 2|80|Anticipated|Kissei Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:54:52.305442|2018-06-01 01:54:52.305442
NCT00721643|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2017-04-24|2008-07-23|2008-07-24|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2008||2008-07-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Absorption Kinetics of Polyphenols in Angel's Plant (Angelica Keiskei)|Absorption Kinetics of Polyphenols in Angel's Plant (Angelica Keiskei)|Completed||Early Phase 1|10|Actual|Tufts University||2|||f||||f||||||||||2018-06-01 01:54:52.393182|2018-06-01 01:54:52.393182
NCT00721630|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2017-06-13||2017-07-14|2008-07-23|2008-07-24|Estimate|2017-07-14|2017-08-15|Actual||||2017-07-14|2017-08-15|Actual|July 2008||2008-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer|Phase II Study of a Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer|Completed||Phase 2|24|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:54:52.53408|2018-06-01 01:54:52.53408
NCT00721617|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2015-05-11||2015-07-23|2008-07-23|2008-07-24|Estimate|2015-07-23|2015-07-27|Estimate||||2015-07-23|2015-07-27|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|FFAADA|All subjects|FFA Hypertension and Inflammation in Lean and Obese Subjects|Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects|Completed||N/A|12|Actual|Emory University|A larger sample size and inclusion of subjects from different ethnicities would be required to generalize the results of this study. Study used healthy volunteers--outcomes cannot be applied to patients with diabetes mellitus or insulin resistance|2|||f||||t||||||||||2018-06-01 01:54:52.897226|2018-06-01 01:54:52.897226
NCT00721604|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2009-07-31|2008-07-22|2008-07-24|Estimate|||||||2009-07-31|2009-08-03|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Observational|||Fluid Responsiveness Prediction at the Bedside|Prediction of Volume Expansion Effectiveness in Hypotensive Critically Ill Patients.|Completed|||30|Anticipated|Fondazione Poliambulanza Istituto Ospedaliero|||1||f||||f||||||||||2018-06-01 01:54:53.426952|2018-06-01 01:54:53.426952
NCT00721591|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2016-10-31|2008-07-23|2008-07-24|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2005||2005-03-31|October 2016|2016-10-31|July 2014|Actual|2014-07-31|January 2013|Actual|2013-01-31||Observational|||Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy|Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy|Completed|||14|Actual|University of Chicago|||2||f||||f||||||Samples Without DNA|"~     Plasma from subjects to obtain concentrations of heparin will be retained~   "|||2018-06-01 01:54:53.523791|2018-06-01 01:54:53.523791
NCT00721578|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2010-07-28||2011-01-06|2008-07-23|2008-07-24|Estimate|2010-07-29|2010-08-26|Estimate||||2011-01-06|2011-01-10|Estimate|April 2009||2009-04-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections|An Observational Study Of Patients Receiving Therapy For Systemic Fungal Infections|Completed|||23|Actual|Pfizer|"Primary and Secondary outcome measured were arbitrarily defined as they were not defined in the protocol.~This study was terminated prematurely due to slow recruitment rate leading to a small (23) number of subjects analyzed."||1||f||||f||||||||||2018-06-01 01:54:53.607636|2018-06-01 01:54:53.607636
NCT00721565|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2015-05-09|2008-07-23|2008-07-24|Estimate|||||||2015-05-09|2015-05-12|Estimate|April 2006||2006-04-30|May 2015|2015-05-31|August 2008|Actual|2008-08-31|February 2008|Actual|2008-02-29||Interventional|BEAT||An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial; Pilot Study)|An Exercise Intervention for Breast Cancer Patients: Feasibility and Effectiveness (BEAT Cancer Trial)|Completed||Phase 1|49|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 01:54:54.025678|2018-06-01 01:54:54.025678
NCT00721071|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2013-08-30|2008-07-21|2008-07-23|Estimate|||||||2013-08-30|2013-09-02|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Utility of Induced Sputum Using Hypertonic Saline to Evaluate Infection and Inflammation in Cystic Fibrosis|Diagnostic Utility of Induced Sputum Using Hypertonic Saline to Evaluate Airway Infection and Inflammation in Cystic Fibrosis|Completed||Phase 2|95|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 01:55:07.184672|2018-06-01 01:55:07.184672
NCT00721552|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2012-06-28|2008-07-22|2008-07-24|Estimate|||||||2012-06-28|2012-07-02|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SPHINX||Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome|Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism and Beta-Cell Dysfunction in Males With the Metabolic Syndrome X: A Randomized, Placebo-controlled, Double-blind Intervention Study With a 2x2 Factorial Design|Completed||N/A|82|Actual|VU University Medical Center||6|||f||||f||||||||||2018-06-01 01:54:54.109156|2018-06-01 01:54:54.109156
NCT00721539|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2014-11-18||2016-11-02|2008-07-23|2008-07-24|Estimate|2016-11-02|2016-11-03|Estimate||||2016-11-02|2016-11-03|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract|A Pilot Study Assessing Transoral Robotic Surgery (TORS) For Oral And Laryngopharyngeal Benign And Malignant Lesions Using The da Vinci® Robotic Surgical System|Terminated||N/A|9|Actual|Stanford University|Early termination leading to small numbers of subjects analyzed secondary to low accrual of subjects.|1||Low Accrual|f||||t||||||||No||2018-06-01 01:54:54.343382|2018-06-01 01:54:54.343382
NCT00721526|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2013-01-28|2008-07-22|2008-07-24|Estimate|||||||2013-01-28|2013-01-30|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder|Disulfiram Combined With Lorazepam for Treatment of Patients With Alcohol Dependence and Primary or Secondary Anxiety Disorder|Completed||Phase 4|45|Actual|University of New Mexico||1|||f||||t||||||||||2018-06-01 01:54:54.676505|2018-06-01 01:54:54.676505
NCT00721513|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|||2015-10-22|2008-07-23|2008-07-24|Estimate|||||||2015-10-22|2015-10-23|Estimate|September 2008||2008-09-30|October 2015|2015-10-31||||September 2017|Anticipated|2017-09-30||Interventional|||Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer|Phase II Study to Evaluate the Efficacy and Toxicity of Multimodality Treatment With Induction Taxotere/Cisplatin?5-FU (TPF) Chemotherapy Followed by Concomitant Cetuximab and Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Unknown status|Active, not recruiting|Phase 2|46|Anticipated|Wake Forest University Health Sciences|||||f||||t||||||||||2018-06-01 01:54:54.74617|2018-06-01 01:54:54.74617
NCT00721500|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2010-05-07||2015-05-05|2008-07-22|2008-07-24|Estimate|2011-02-07|2011-03-02|Estimate||||2015-05-05|2015-05-21|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||All enrolled and completed subjects were included in the baseline summary.|A Comparison of Two Daily Disposable Contact Lenses.|An Evaluation of the Lens Fit of Narafilcon A Soft Contact Lenses|Completed||N/A|25|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||||||||||||2018-06-01 01:54:54.832447|2018-06-01 01:54:54.832447
NCT00721487|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2014-07-21|2008-07-23|2008-07-24|Estimate|||||||2014-07-21|2014-07-23|Estimate|July 2008||2008-07-31|July 2014|2014-07-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections|A Case Series of Investigator-Identified Fluconazole Failures: Outcome Characterization of Patients Who Fail to Respond to Fluconazole Treatment of Severe Infections Caused by Candida Albicans|Completed|||28|Actual|CPL Associates|||1||f||||f||||||||||2018-06-01 01:54:55.112841|2018-06-01 01:54:55.112841
NCT00721474|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2009-02-05|2008-07-23|2008-07-24|Estimate|||||||2009-02-05|2009-02-06|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects|An Open-Label, Randomized, Single-Dose, 2-Period Crossover Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects|Completed||Phase 1|24|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:54:55.222834|2018-06-01 01:54:55.222834
NCT00721461|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2015-08-03|2008-07-23|2008-07-24|Estimate|||||||2015-08-03|2015-08-04|Estimate|July 2005||2005-07-31|August 2015|2015-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)|Probe Study of the Tolerability of an Investigational Electroporation Device, MedPulser (Trademark) DNA Delivery System (DDS) in Healthy Adults 18 to 35 Years of Age|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 01:54:55.281377|2018-06-01 01:54:55.281377
NCT00721448|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2010-12-02|2008-07-23|2008-07-24|Estimate|||||||2010-12-02|2010-12-03|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers|A Two-Cohort, Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Chinese Volunteers Living in China|Completed||Phase 1|24|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 01:54:55.335764|2018-06-01 01:54:55.335764
NCT00721435|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2017-01-22|2008-07-22|2008-07-24|Estimate|||||||2017-01-22|2017-01-24|Estimate|April 2002||2002-04-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|December 2014|Actual|2014-12-31||Interventional|||Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions|Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions|Completed||N/A|183|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 01:54:55.384067|2018-06-01 01:54:55.384067
NCT00721422|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2010-02-16|2008-07-23|2008-07-24|Estimate|||||||2010-02-16|2010-02-17|Estimate|August 2008||2008-08-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.|A Phase 1, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD 0332334 In Subjects With Various Degrees Of Renal Function|Terminated||Phase 1|16|Actual|Pfizer||4||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 01:54:55.445084|2018-06-01 01:54:55.445084
NCT00721409|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2015-03-04|2014-12-05|2018-04-10|2008-07-23|2008-07-24|Estimate|2015-03-04|2015-03-19|Estimate|2014-12-05|2014-12-24|Estimate|2018-04-10|2018-05-10|Estimate|September 15, 2008|Actual|2008-09-15|April 2018|2018-04-30|December 20, 2017|Actual|2017-12-20|November 29, 2013|Actual|2013-11-29||Interventional|||Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer|Phase 1/2, Open-label, Randomized Study Of The Safety, Efficacy, And Pharmacokinetics Of Letrozole Plus Pd 0332991 (Oral Cdk 4/6 Inhibitor) And Letrozole Single Agent For The First-line Treatment Of Er Positive, Her2 Negative Advanced Breast Cancer In Postmenopausal Women|Completed||Phase 2|177|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:54:55.575941|2018-06-01 01:54:55.575941
NCT00721396|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2015-02-18||2015-03-17|2008-07-23|2008-07-24|Estimate|2015-03-17|2015-03-23|Estimate||||2015-03-17|2015-03-23|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules|A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.|Completed||Phase 2|1885|Actual|Novartis||4|||f||||t||||||||||2018-06-01 01:54:59.713805|2018-06-01 01:54:59.713805
NCT00721383|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2014-12-30|2008-07-23|2008-07-24|Estimate|||||||2014-12-30|2014-12-31|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|TRAC||Telephone Resources and Assistance for Caregivers (TRAC)|Clinical Trial to Enhance Caregiver Physical Activity|Completed||N/A|211|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-06-01 01:55:00.941003|2018-06-01 01:55:00.941003
NCT00721370|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2013-02-14|2008-07-22|2008-07-24|Estimate|||||||2013-02-14|2013-02-18|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer|Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer|Completed||Phase 1|12|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-06-01 01:55:01.00216|2018-06-01 01:55:01.00216
NCT00721357|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2015-01-08||2015-07-29|2008-07-23|2008-07-24|Estimate|2015-07-29|2015-07-30|Estimate||||2015-07-29|2015-07-30|Estimate|August 2008||2008-08-31|July 2015|2015-07-31|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Observational|||Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke|Skeletal Muscle Properties and the Metabolic Cost of Walking Post-Stroke|Completed|||30|Actual|VA Office of Research and Development|||2||f||||f||||||None Retained|"~     None retained~   "|||2018-06-01 01:55:01.074573|2018-06-01 01:55:01.074573
NCT00721344|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2012-06-12|2008-07-22|2008-07-24|Estimate|||||||2012-06-12|2012-06-13|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.|A Phase 1, Randomized, Double-Blind, Cross-Over, Placebo- and Active-Controlled Cardiac Safety Study of Therapeutic and Supratherapeutic Doses of Fumaryl Diketopiperazine Administered as Technosphere® Inhalation Powder in Healthy Subjects|Completed||Phase 1|48|Actual|Mannkind Corporation||4|||f||||||||||||||2018-06-01 01:55:01.257022|2018-06-01 01:55:01.257022
NCT00721331|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2008-09-24|2008-07-23|2008-07-24|Estimate|||||||2008-09-24|2008-09-26|Estimate|July 2008||2008-07-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers|A Phase I, Single-Center, Randomized, Vehicle-Controlled Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers|Completed||Phase 1|20|Anticipated|Zalicus||5|||f||||f||||||||||2018-06-01 01:55:01.352977|2018-06-01 01:55:01.352977
NCT00721318|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2008-07-23|2008-07-23|2008-07-24|Estimate|||||||2008-07-23|2008-07-24|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|May 2010|Anticipated|2010-05-31|May 2009|Anticipated|2009-05-31||Observational|||A Prevalence Study of Chronic Widespread Pain (CWP) Among Patients With Rheumatoid Arthritis (RA) and Control Population in Tallinn and Harjumaa County|A Prevalence Study of Chronic Widespread Pain (CWP) Among Patients With Rheumatoid Arthritis (RA) and Control Population Matched by Gender, Age and Place of Residence in Tallinn and Harjumaa County|Unknown status|Active, not recruiting||6000|Anticipated|Estonian Society for Rheumatology|||2||f||||f||||||||||2018-06-01 01:55:01.504906|2018-06-01 01:55:01.504906
NCT00721305|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2011-09-30|2008-07-23|2008-07-24|Estimate|||||||2011-09-30|2011-10-04|Estimate|August 2008||2008-08-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|LIVE||Lovastatin: Immunomodulatory Value Evaluation|Antiretroviral Effect of Lovastatin on HIV-1-infected Individuals Without Highly Active Antiretroviral Therapy (HAART): A Phase-II Randomized Clinical Trial (RCT)|Completed||Phase 2|112|Actual|Universidad de Antioquia||2|||f||||t||||||||||2018-06-01 01:55:01.637163|2018-06-01 01:55:01.637163
NCT00721279|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-23|2009-10-22||2014-05-19|2008-07-23|2008-07-24|Estimate|2009-12-07|2010-01-08|Estimate||||2014-05-19|2014-06-04|Estimate|September 2007||2007-09-30|May 2014|2014-05-31||||October 2008|Actual|2008-10-31||Observational||SAF - Safety Analysis Set|Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome|Sifrol Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary RLS|Completed|||549|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:55:01.791749|2018-06-01 01:55:01.791749
NCT00721266|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-04|||2016-11-01|2008-07-23|2008-07-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.|An Open Label, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Tumor Growth Control Rate of RO5083945, a Glycoengineered Antibody Against EGFR, in Patients With Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.|Completed||Phase 1|102|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:55:02.338228|2018-06-01 01:55:02.338228
NCT00721253|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2009-09-18||2010-03-04|2008-07-23|2008-07-24|Estimate|2010-03-04|2010-03-16|Estimate||||2010-03-04|2010-03-16|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA|Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis Multifocal Intraocular Lens (IOL) or Acri.LISA IOL|Completed||Phase 4|42|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 01:55:02.445323|2018-06-01 01:55:02.445323
NCT00721240|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2010-02-16|2008-07-23|2008-07-24|Estimate|||||||2010-02-16|2010-02-17|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Investigation to Identify Predictors of Response to a Treatment With Montelukast|Investigation to Identify Predictors of Response to a Treatment With Montelukast|Completed||Phase 4|50|Anticipated|Marien Hospital Wesel||1|||f||||f||||||||||2018-06-01 01:55:02.733965|2018-06-01 01:55:02.733965
NCT00721227|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2010-07-21||2010-09-01|2008-07-22|2008-07-24|Estimate|2010-07-21|2010-08-18|Estimate||||2010-09-01|2010-09-08|Estimate|April 2008||2008-04-30|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates|Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates|Completed||N/A|15|Actual|Ethicon Endo-Surgery||2|||f||||f||||||||||2018-06-01 01:55:02.82934|2018-06-01 01:55:02.82934
NCT00721214|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2015-04-29||2016-02-03|2008-07-22|2008-07-24|Estimate|2015-07-06|2015-08-03|Estimate||||2016-02-03|2016-03-02|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Out of the 16 evaluable patients, 12 were able to proceed to transplant.|5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome|A Phase II Study of the Use of 5-Azacytidine as Pre-Transplant Cytoreduction Prior to Allogeneic Stem Cell Transplantation for High Risk Myelodysplastic Syndromes|Completed||Phase 2|16|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 01:55:03.310814|2018-06-01 01:55:03.310814
NCT00721201|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2011-05-26|2008-07-22|2008-07-23|Estimate|||||||2011-05-26|2011-05-27|Estimate|November 2008||2008-11-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Glucocorticoid Receptor Antagonism in Subclinical Cushings|A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings|Completed||Phase 1/Phase 2|6|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||t||||||||||2018-06-01 01:55:03.540836|2018-06-01 01:55:03.540836
NCT00721188|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2011-02-23||2018-01-22|2008-07-21|2008-07-23|Estimate|2011-02-23|2011-03-25|Estimate||||2018-01-22|2018-02-20|Actual|January 2006||2006-01-31|January 2018|2018-01-31|January 2010|Actual|2010-01-31|July 2008|Actual|2008-07-31||Interventional|||Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients|Single-Dose Pharmacokinetics of Venofer (Iron Sucrose Injection) in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients Receiving or Not Receiving Erythropoiesis Stimulating Agents (ESA's)|Completed||Phase 2|11|Actual|Luitpold Pharmaceuticals||1|||f||||||||||||||2018-06-01 01:55:03.625408|2018-06-01 01:55:03.625408
NCT00721175|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2011-08-23||2011-11-21|2008-07-22|2008-07-23|Estimate|2011-11-21|2011-12-23|Estimate||||2011-11-21|2011-12-23|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma|Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial|Completed||Phase 4|108|Actual|Khon Kaen University||2|||f||||f||||||||||2018-06-01 01:55:03.876023|2018-06-01 01:55:03.876023
NCT00721162|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2014-05-16|2010-08-25|2016-08-24|2008-07-22|2008-07-23|Estimate|2014-05-16|2014-06-18|Estimate|2010-08-25|2010-08-27|Estimate|2016-08-24|2016-10-03|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|May 2012|Actual|2012-05-31||Interventional||All participants who received any amount of study drug.|Study of Ramucirumab in Ovarian Cancer|A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|60|Actual|Eli Lilly and Company||1|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 01:55:04.288305|2018-06-01 01:55:04.288305
NCT00721149|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2013-02-08||2013-12-03|2008-07-22|2008-07-23|Estimate|2013-12-03|2014-01-22|Estimate||||2013-12-03|2014-01-22|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|AFTX||NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study|Terminated||Phase 3|10|Actual|Biosense Webster, Inc.|Because of early study termination, the study did not reach its targeted enrollment and study data analysis was not fully conducted, thus study results may not be interpretable.|1||"Enrollment stopped after CDRH Advisory Panel (Nov 20, 2008) recommended NAVISTAR® THERMOCOOL®~   catheter approval."|f||||f||||||||||2018-06-01 01:55:04.664811|2018-06-01 01:55:04.664811
NCT00721136|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2013-04-03||2017-07-31|2008-07-21|2008-07-23|Estimate|2017-07-31|2017-08-31|Actual||||2017-07-31|2017-08-31|Actual|September 2007||2007-09-30|July 2017|2017-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation|Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation|Completed||N/A|104|Actual|Johns Hopkins University|Evaluation period was limited to 4–6 weeks after implantation and mean INR levels in the warfarin continuation group did not reach levels above 2.5. This was a single center trial with experienced electrophysiologists using a common technique.|4|||f||||f||||||||||2018-06-01 01:55:04.880785|2018-06-01 01:55:04.880785
NCT00721123|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2013-07-17||2013-11-05|2008-07-22|2008-07-23|Estimate|2013-10-09|2013-10-21|Estimate||||2013-11-05|2013-11-28|Estimate|August 2005||2005-08-31|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||All-exposure population: All patients who entered the study and received at least one dose of tocilizumab at any time. Baseline was defined as the first dose of study drug, whether that occurred in the WA17822 study or the WA18695 study.|A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis|Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in WA17822|Completed||Phase 3|538|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:55:05.2918|2018-06-01 01:55:05.2918
NCT00721110|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2016-06-20||2017-04-17|2008-07-21|2008-07-23|Estimate|2017-04-17|2017-07-26|Actual||||2017-04-17|2017-07-26|Actual|July 2008||2008-07-31|April 2017|2017-04-30|July 2012|Actual|2012-07-31|October 2010|Actual|2010-10-31||Interventional|||Lidocaine and Ketamine in Abdominal Surgery|Effects of Perioperative Lidocaine and Ketamine Infusions on Acute Functional Recovery After Abdominal Hysterectomy|Terminated||N/A|64|Actual|The Cleveland Clinic||4||Futility|f||||f|f|f||||||No||2018-06-01 01:55:06.480208|2018-06-01 01:55:06.480208
NCT00721097|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2013-09-27|2008-07-21|2008-07-23|Estimate|||||||2013-09-27|2013-09-30|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|EXPRESA||Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics|Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics|Terminated|||40|Actual|Nantes University Hospital||||Number of included patients is sufficient.|f||||t||||||||||2018-06-01 01:55:07.056591|2018-06-01 01:55:07.056591
NCT00721084|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2013-09-04|2008-07-21|2008-07-23|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2008||2008-07-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Fitness and Sleep in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk|Completed|||30|Actual|University of Chicago|||2||f||||f||||||||||2018-06-01 01:55:07.115862|2018-06-01 01:55:07.115862
NCT00720889|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2013-09-04|2008-07-21|2008-07-23|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2008||2008-07-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Glucose Metabolism and Sleep in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk.|Completed|||20|Actual|University of Chicago|||2||f||||f||||||||||2018-06-01 01:55:10.580514|2018-06-01 01:55:10.580514
NCT00721058|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2010-01-04|2008-07-22|2008-07-23|Estimate|||||||2010-01-04|2010-01-05|Estimate|August 2008||2008-08-31|January 2010|2010-01-31||||October 2009|Actual|2009-10-31||Interventional|||Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.|Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.|Completed||N/A|60|Anticipated|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-06-01 01:55:07.267615|2018-06-01 01:55:07.267615
NCT00721045|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2015-05-19|2008-07-22|2008-07-23|Estimate|||||||2015-05-19|2015-05-20|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|July 2013|Actual|2013-07-31|June 2011|Actual|2011-06-30||Interventional|||A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure|A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure|Completed||Phase 2|60|Actual|Mesoblast, Ltd.||6|||f||||t||||||||||2018-06-01 01:55:07.338918|2018-06-01 01:55:07.338918
NCT00721032|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2017-05-09|2008-07-21|2008-07-23|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2012||2012-06-30|May 2017|2017-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia|Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia|Withdrawn||N/A|0|Actual|Johns Hopkins University||2||PI left the institution|f||||f||||||||||2018-06-01 01:55:07.43155|2018-06-01 01:55:07.43155
NCT00721019|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2013-09-04|2008-07-21|2008-07-23|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2008||2008-07-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Sleep Loss and Glucose Metabolism in People With Family History of Type 2 Diabetes.|Sleep, Energy Metabolism and Diabetes Risk.|Completed||N/A|11|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 01:55:07.51182|2018-06-01 01:55:07.51182
NCT00721006|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2014-05-07|2008-07-22|2008-07-23|Estimate|||||||2014-05-07|2014-05-09|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|MESENDO||Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia|Phase II Safety/Efficacy Study of A Combination Stem Cell Therapy That Develops Mature Stable Vessel Formation in Ischemic Limbs|Completed||Phase 2|35|Actual|TCA Cellular Therapy||2|||f||||t||||||||||2018-06-01 01:55:07.582391|2018-06-01 01:55:07.582391
NCT00720993|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2009-04-22|2008-07-21|2008-07-23|Estimate|||||||2009-04-22|2009-04-23|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Observational|CRC screening||Colorectal Cancer Screening Validation Study|"Altered Gene Expression in Colorectal Smears of Individuals With Colon Cancer"|Unknown status|Enrolling by invitation||165|Anticipated|IntelliGeneScan, Inc.|||2||f||||f||||||Samples Without DNA|"~     Rectal smears (cytology brush) samples and RNA recovered from such materials.~   "|||2018-06-01 01:55:07.662902|2018-06-01 01:55:07.662902
NCT00720980|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2008-07-21|2008-07-21|2008-07-23|Estimate|||||||2008-07-21|2008-07-23|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Observational|||Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy|Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy|Completed|||6|Actual|Henry Ford Health System|||||f||||f||||||||||2018-06-01 01:55:07.727413|2018-06-01 01:55:07.727413
NCT00720967|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2008-07-22|2008-07-22|2008-07-23|Estimate|||||||2008-07-22|2008-07-23|Estimate|November 2008||2008-11-30|July 2008|2008-07-31|November 2012|Anticipated|2012-11-30|November 2011|Anticipated|2011-11-30||Interventional|SeRenaD-CPB||Preop Hemodialysis or Intraop Ultrafiltration for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery|Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial|Unknown status|Not yet recruiting|Phase 3|450|Anticipated|University Hospital, Geneva||3|||f||||f||||||||||2018-06-01 01:55:07.797551|2018-06-01 01:55:07.797551
NCT00720954|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2008-07-22|2008-07-22|2008-07-23|Estimate|||||||2008-07-22|2008-07-23|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy|Rigid Thoracoscopy Versus CT-Guided Pleural Needle Biopsy For Diagnosis of Patients With Pleural Effusions: A Randomized Control Trial|Completed||N/A|124|Actual|Eskisehir Osmangazi University||2|||f||||||||||||||2018-06-01 01:55:07.930659|2018-06-01 01:55:07.930659
NCT00720941|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2013-01-04||2017-06-01|2008-07-22|2008-07-23|Estimate|2013-05-09|2013-06-17|Estimate||||2017-06-01|2017-07-02|Actual|August 14, 2008|Actual|2008-08-14|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|May 21, 2012|Actual|2012-05-21||Interventional|COMPARZ||Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma|Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 3|927|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:55:08.119213|2018-06-01 01:55:08.119213
NCT00720928|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-07-28|2008-07-21|2008-07-23|Estimate|||||||2008-07-28|2008-07-29|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Interventional|||Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease|A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease|Unknown status|Recruiting|Phase 4|15|Anticipated|Asan Medical Center||1|||f||||t||||||||||2018-06-01 01:55:10.187538|2018-06-01 01:55:10.187538
NCT00720915|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2016-12-12|2008-07-21|2008-07-23|Estimate|||||||2016-12-12|2016-12-13|Estimate|September 2008||2008-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DODS||D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months|A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing|Completed||N/A|410|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 01:55:10.366469|2018-06-01 01:55:10.366469
NCT00720902|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2013-05-14|2008-07-22|2008-07-23|Estimate|||||||2013-05-14|2013-05-16|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|May 2011|Actual|2011-05-31|March 2010|Actual|2010-03-31||Interventional|||Adult Growth Hormone Deficiency and Cardiovascular Risk|Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas|Terminated||N/A|8|Actual|Columbia University||2||poor enrollment|f||||f||||||||||2018-06-01 01:55:10.483752|2018-06-01 01:55:10.483752
NCT00720876|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2017-06-09|2008-07-22|2008-07-23|Estimate|||||||2017-06-09|2017-06-12|Actual|July 23, 2008|Actual|2008-07-23|June 2017|2017-06-30|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma|A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma|Completed||Phase 2|30|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:55:10.660571|2018-06-01 01:55:10.660571
NCT00720850|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2013-09-26|2008-07-22|2008-07-23|Estimate|||||||2013-09-26|2013-09-27|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|LENAMAINT||Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)|Lenalidomide Maintenance Therapy in Patients With MDS or AML With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Terminated||Phase 2|10|Actual|Technische Universität Dresden||1||"Low recruitment, scientific rationale not applicable anymore to all patients and possible~   induction of GvHD by the study drug"|f||||f||||||||||2018-06-01 01:55:10.742728|2018-06-01 01:55:10.742728
NCT00720837|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2012-10-10|2008-07-22|2008-07-23|Estimate|||||||2012-10-10|2012-10-11|Estimate|July 2008||2008-07-31|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|||Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors|Pilot Study Evaluating the Feasibility of Real-Time, Magnetic Resonance Thermal Imaging (MRTI) and Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors|Terminated||N/A|6|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-06-01 01:55:10.819954|2018-06-01 01:55:10.819954
NCT00720824|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2008-07-22|2008-07-22|2008-07-23|Estimate|||||||2008-07-22|2008-07-23|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Reduction of Immunization Discomfort in Children|Reduction of Immunization Discomfort in 4-6 Year Old Children: A Randomized Clinical Trial.|Completed||N/A|42|Actual|Berberich, F. Ralph, M.D.||2|||f||||f||||||||||2018-06-01 01:55:10.889671|2018-06-01 01:55:10.889671
NCT00720811|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2012-03-15|2008-07-22|2008-07-23|Estimate|||||||2012-03-15|2012-03-16|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs|Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs|Completed||N/A|6456|Actual|Mbarara University of Science and Technology||2|||f||||t||||||||||2018-06-01 01:55:10.96019|2018-06-01 01:55:10.96019
NCT00720798|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|2014-06-10||2014-09-26|2008-07-22|2008-07-23|Estimate|2014-09-26|2014-09-30|Estimate||||2014-09-26|2014-09-30|Estimate|September 2005||2005-09-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study.|An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies|Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies|Completed||Phase 3|2067|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:55:11.107654|2018-06-01 01:55:11.107654
NCT00720785|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2018-05-23|2008-07-22|2008-07-23|Estimate|||||||2018-05-23|2018-05-24|Actual|July 21, 2008||2008-07-21|January 10, 2018|2018-01-10|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Natural Killer Cells and Bortezomib to Treat Cancer|Safety and the Anti-Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK TRAIL Cytotoxicity With Bortezomib|Recruiting||Phase 1|61|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:55:14.103432|2018-06-01 01:55:14.103432
NCT00720772|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2009-12-16|2008-07-21|2008-07-23|Estimate|||||||2009-12-16|2009-12-17|Estimate|July 2008||2008-07-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis|The Treatment Effect of Intravenous Sodium Thiosulfate on Coronary Calcification in Patients on Hemodialysis|Completed||Phase 2|50|Anticipated|Ramathibodi Hospital||2|||f||||f||||||||||2018-06-01 01:55:14.184059|2018-06-01 01:55:14.184059
NCT00720759|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2013-10-07||2014-01-21|2008-07-22|2008-07-23|Estimate|2014-01-21|2014-03-07|Estimate||||2014-01-21|2014-03-07|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine|Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine|Completed||Phase 2|24|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 01:55:14.27473|2018-06-01 01:55:14.27473
NCT00720733|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2015-03-05|2008-07-22|2008-07-23|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|IRISS||Intervention for (Those) Recently Informed of Seropositive Status (IRISS)|A Positive Affect Intervention for Those Recently Diagnosed With HIV|Completed||N/A|160|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:55:14.835463|2018-06-01 01:55:14.835463
NCT00720720|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2010-04-02|2008-07-22|2008-07-23|Estimate|||||||2010-04-02|2010-04-05|Estimate||||July 2008|2008-07-31||||||||Interventional|PHYTOPLAQUES||Effect of Phytosterols Enriched Products Consumption on Carotid Artery Artherosclerotic Plaque|Effect of Phytosterols Enriched Products Consumption on Carotid Artery Artherosclerotic Plaque|Terminated||N/A|0|Actual|French Cardiology Society||2||Recruitment and organizational difficulties|f||||t||||||||||2018-06-01 01:55:14.949085|2018-06-01 01:55:14.949085
NCT00720707|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-22|||2008-07-22|2008-07-22|2008-07-23|Estimate|||||||2008-07-22|2008-07-23|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Coronally Advanced Flap in Combination With Acellular Dermal Matrix and Enamel Matrix Derivatives for Root Coverage|Coronally Advanced Flap in Combination With Acellular Dermal Matrix With or Without Enamel Matrix Derivatives for Root Coverage|Completed||Phase 4|18|Actual|Tabriz University||2|||f||||t||||||||||2018-06-01 01:55:15.117135|2018-06-01 01:55:15.117135
NCT00720694|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2018-02-15|2008-07-22|2008-07-23|Estimate|||||||2018-02-15|2018-02-16|Estimate|June 2006||2006-06-30|February 2018|2018-02-28||||May 2007|Actual|2007-05-31||Interventional|ESWT||Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome|Placebo Controlled Study to Investigate the Effectiveness and Safety of Extracorporeal Shock Wave Therapy in Unsuccessful Conservatively Treated Subject Suffering From Painful Heel Syndrome|Completed||Phase 3|250|Actual|Storz Medical AG||2|||f||||f|f|t|t|f||||||2018-06-01 01:55:15.203681|2018-06-01 01:55:15.203681
NCT00720681|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2016-03-28|2008-07-21|2008-07-23|Estimate|||||||2016-03-28|2016-03-30|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|January 2012|Actual|2012-01-31|June 2009|Actual|2009-06-30||Observational|HUMERUS||Plating of Humeral Shaft Fractures in Multiple Trauma Patients.|Plating of Acute Humeral Diaphyseal Fractures Via an Anterior Lateral Approach in Multiple Trauma Patients.|Completed|||96|Actual|OhioHealth|||||f||||f||||||||No||2018-06-01 01:55:15.301171|2018-06-01 01:55:15.301171
NCT00720668|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2009-02-06|2008-07-21|2008-07-23|Estimate|||||||2009-02-06|2009-02-09|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|March 2009|Anticipated|2009-03-31||Observational|HBV-HCC||The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma|The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma|Unknown status|Recruiting||200|Anticipated|Sun Yat-sen University|||1||f||||t||||||||||2018-06-01 01:55:15.472052|2018-06-01 01:55:15.472052
NCT00720655|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2014-01-21|2008-07-22|2008-07-23|Estimate|||||||2014-01-21|2014-01-22|Estimate|August 2005||2005-08-31|January 2014|2014-01-31||||December 2006|Actual|2006-12-31||Interventional|||Effects of Fatty and Lean Fish Intake on Cardiovascular Risk Factors in Subjects With Coronary Heart Disease|Effects of Fatty and Lean Fish Intake on Cardiovascular Risk Factors in Subjects With Coronary Heart Disease|Completed||N/A|33|Actual|University of Eastern Finland||3|||f||||f||||||||||2018-06-01 01:55:15.563767|2018-06-01 01:55:15.563767
NCT00720642|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2012-09-11|2008-07-22|2008-07-23|Estimate|||||||2012-09-11|2012-09-12|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|I-PET||Percutaneous Excision Trial|Percutaneous Excision Trial (I-Pet): A Multi-Center Clinical Study Of The Intact Breast Lesion Excision System (Bles) To Demonstrate That A Definitive Diagnosis Can Be Made From The Tissue Sample Collected With The Intact Bles.|Completed|||1170|Actual|Intact Medical Corporation|||2||f||||f||||||Samples Without DNA|"~     Breast lesion tissue~   "|||2018-06-01 01:55:15.650263|2018-06-01 01:55:15.650263
NCT00720629|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2014-05-01||2014-07-10|2008-07-21|2008-07-23|Estimate|2014-06-04|2014-07-04|Estimate||||2014-07-10|2014-07-18|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||First Stage: Study Treatment. All participants.|Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation|A Phase II Study of Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation|Terminated||Phase 2|8|Actual|H. Lee Moffitt Cancer Center and Research Institute|Study closed early during the first stage, did not proceed to the second stage comparison as planned. Investigators exercised right to close the study prematurely for lack of efficacy, although no protocol-defined end points had been met.|2|||f||||t||||||||||2018-06-01 01:55:15.749203|2018-06-01 01:55:15.749203
NCT00720616|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2013-02-18|2008-07-22|2008-07-23|Estimate|||||||2013-02-18|2013-02-20|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.|Effects of a Fixed Low Dose Growth Hormone Therapy on Insulin Sensitivity, Metabolic Profile, Adipocyte IGF-I and Insulin Signalling, Intramyocellular and Intrahepatic Lipids, and Cortisol Metabolism in Subjects With Metabolic Syndrome.|Withdrawn||N/A|0|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 01:55:15.986971|2018-06-01 01:55:15.986971
NCT00720603|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2015-03-19|2008-07-22|2008-07-23|Estimate|||||||2015-03-19|2015-03-24|Estimate||||March 2015|2015-03-31||||||||Expanded Access|EAP||This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.|Expanded Acess Study of Plerixafor and G-CSF for the Mobilization and Collection of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease or Multiple Myeloma|No longer available|||||Sanofi|||||||||||||||||||2018-06-01 01:55:16.054749|2018-06-01 01:55:16.054749
NCT00720590|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2017-10-23|2008-07-21|2008-07-23|Estimate|||||||2017-10-23|2017-10-25|Actual|November 2003||2003-11-30|July 2008|2008-07-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors|Effect of HIV-1 Protease Inhibitors on Endothelial Function and Glucose Metabolism in Normal, HIV-Uninfected Subjects: Atazanavir or Lopinavir/Ritonavir or Placebo|Completed||N/A|30|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 01:55:16.105241|2018-06-01 01:55:16.105241
NCT00720577|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2008-07-22|2008-07-22|2008-07-23|Estimate|||||||2008-07-22|2008-07-23|Estimate|December 2005||2005-12-31|July 2008|2008-07-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|LEAP||Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.|Two-Part,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Study to Evaluate the Effect of Simvastatin,Losartan,and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised From Patients w/PAD|Completed||Early Phase 1|164|Actual|ev3||3|||f||||f||||||||||2018-06-01 01:55:16.169404|2018-06-01 01:55:16.169404
NCT00720564|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2010-08-09|2008-07-19|2008-07-22|Estimate|||||||2010-08-09|2010-08-11|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma|A Phase I Study of the Combination of Radiation Therapy (RT), Arsenic Trioxide (ATO) and Temozolomide (TMZ) in Patients With Newly-Diagnosed Glioblastoma Multiforme (GBM)|Completed||Phase 1|18|Anticipated|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 01:55:16.248626|2018-06-01 01:55:16.248626
NCT00720551|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2009-02-12|2008-07-21|2008-07-22|Estimate|||||||2009-02-12|2009-02-13|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Calibration and Validation of the STISIM Driving Simulator|Calibration and Validation of the STISIM Driving Simulator: Simulated Driving Performance Under the Influence of Alcohol (0.05%, 0.08% AND 0.11%), and Placebo|Completed||N/A|27|Actual|Utrecht Institute for Pharmaceutical Sciences|||||f||||f||||||||||2018-06-01 01:55:16.322934|2018-06-01 01:55:16.322934
NCT00720538|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2012-10-25|2008-07-18|2008-07-22|Estimate|||||||2012-10-25|2012-10-26|Estimate|August 2008||2008-08-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Interventional|TALIBDP||Thalidomide in Pediatric Inflammatory Bowel Diseases.|Randomized Controlled Double-blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.|Completed||Phase 3|84|Actual|IRCCS Burlo Garofolo||2|||f||||t||||||||||2018-06-01 01:55:16.399381|2018-06-01 01:55:16.399381
NCT00720525|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2011-07-15|2008-07-18|2008-07-22|Estimate|||||||2011-07-15|2011-07-18|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|||||Observational|||Pulsatile and Steady State Hemodynamics in Diastolic Heart Failure|Diagnostic Value of Measures of Pulsatile Versus Steady State Hemodynamics in Diastolic Heart Failure|Completed|||362|Actual|Klinikum Wels-Grieskirchen|||2||f||||f||||||||||2018-06-01 01:55:16.499189|2018-06-01 01:55:16.499189
NCT00720161|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2011-09-28|2008-07-21|2008-07-22|Estimate|||||||2011-09-28|2011-09-29|Estimate|November 2006||2006-11-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Metformin in Children With Motor Deficit|Metformin in Children With Motor Deficit|Completed||N/A|42|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-06-01 01:55:22.955934|2018-06-01 01:55:22.955934
NCT00720512|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2015-03-10|2008-07-19|2008-07-22|Estimate|||||||2015-03-10|2015-03-11|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|February 2013|Actual|2013-02-28||Interventional|BEBYP||Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab|AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB.|Terminated||Phase 3|184|Actual|Gruppo Oncologico del Nord-Ovest||2|||f||||||||||||||2018-06-01 01:55:16.564368|2018-06-01 01:55:16.564368
NCT00720499|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2015-06-19|2014-03-28|2015-07-20|2008-07-21|2008-07-22|Estimate|2015-07-20|2015-08-17|Estimate|2014-03-28|2014-04-25|Estimate|2015-07-20|2015-08-17|Estimate|July 2008||2008-07-31|July 2015|2015-07-31||||February 2009|Actual|2009-02-28||Interventional|||Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Randomised, Double-blind, Cross-over Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 2 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination (FDC) With 5 Microgram Tiotropium Bromide (Delivered by the Respimat® Inhaler) in Patients With COPD|Completed||Phase 2|141|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:55:16.814655|2018-06-01 01:55:16.814655
NCT00720486|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2014-03-26|2008-07-18|2008-07-22|Estimate|||||||2014-03-26|2014-03-28|Estimate|June 2008||2008-06-30|March 2014|2014-03-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|||Effectiveness of Anger Management Treatment in Reducing Anger-Related Behaviors in Female Juvenile Offenders|Anger Management Treatment for Female Juvenile Offenders|Completed||N/A|75|Actual|Drexel University||2|||f||||t||||||||||2018-06-01 01:55:17.856541|2018-06-01 01:55:17.856541
NCT00720473|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2013-11-26||2017-01-30|2008-07-18|2008-07-22|Estimate|2016-06-07|2016-07-21|Estimate||||2017-01-30|2017-02-01|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional||Baseline scans were available for 37 participants, 23 BPD subjects and 14 for healthy controls. One participant had missing scan data, and twenty one participants with a BPD diagnosis had baseline MADRS scores available.|Lamotrigine Therapy in Geriatric Bipolar Depression|Lamotrigine Therapy in the Treatment of Geriatric Bipolar Depression: An Evaluation of Markers of Cerebral Energy Metabolism|Completed||N/A|69|Actual|Mclean Hospital|Limited data was available for associating changes in MADRS scores with metabolite changes (22 regions from 11 participants with BPD).|2|||f||||t||||||||||2018-06-01 01:55:17.950326|2018-06-01 01:55:17.950326
NCT00720460|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2018-03-27|2008-07-19|2008-07-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 18, 2008||2008-07-18|February 1, 2018|2018-02-01||||||||Observational|||Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging in Normal Volunteers|Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging in Healthy Volunteers|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-06-01 01:55:18.32603|2018-06-01 01:55:18.32603
NCT00720447|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2013-08-01|2008-07-19|2008-07-22|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 2008||2008-11-30|July 2011|2011-07-31||||November 2010|Anticipated|2010-11-30||Interventional|||Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma|Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma|Unknown status|Not yet recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:55:18.38431|2018-06-01 01:55:18.38431
NCT00720434|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2013-06-18|2011-06-03|2013-06-18|2008-07-21|2008-07-22|Estimate|2013-06-18|2013-08-26|Estimate|2011-06-03|2011-06-16|Estimate|2013-06-18|2013-08-26|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study To Evaluate Peginterferon Alfa 2a (Pegasys®) And Ribavirin (Copegus®) With And Without PF-00868554 In Subjects Chronically Infected With Hepatitis C Virus|Completed||Phase 2|35|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 01:55:18.474184|2018-06-01 01:55:18.474184
NCT00720421|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2010-12-08|2008-07-18|2008-07-22|Estimate|||||||2010-12-08|2010-12-10|Estimate|June 2008||2008-06-30|November 2008|2008-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.|A Phase 1, Single Centre, Single Dose, Double-blind, Double-dummy, Four-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effects of AZD7325 on Sedation, Cognition and Electroencephalogram (EEG) in Comparison With Lorazepam in Healthy Male Volunteers.|Completed||Phase 1|16|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:55:19.444986|2018-06-01 01:55:19.444986
NCT00720408|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2009-09-14|2008-07-18|2008-07-22|Estimate|||||||2009-09-14|2009-09-15|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.|A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF and Steroid Withdraw in de Novo Liver Transplant Recipients.|Completed||Phase 3|48|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:55:19.522647|2018-06-01 01:55:19.522647
NCT00720395|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2015-05-06|2008-07-18|2008-07-22|Estimate|||||||2015-05-06|2015-05-08|Estimate|August 2005||2005-08-31|March 2009|2009-03-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Identifying Predictors of Bipolar Disorder Relapse During Pregnancy and the Postpartum Period|Predictors of Postpartum Relapse in Women With Bipolar Disorder|Withdrawn|||0|Actual|National Institute of Mental Health (NIMH)|||1|Withdrawn [Funding was never granted for this study. No participants were ever enrolled.]|f||||t||||||Samples Without DNA|"~     Plasma, serum, and urine samples are processed and stored at each study visit.~   "|||2018-06-01 01:55:19.597575|2018-06-01 01:55:19.597575
NCT00720382|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2009-11-06||2015-05-04|2008-07-21|2008-07-22|Estimate|2009-12-10|2010-01-15|Estimate||||2015-05-04|2015-05-21|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis|Active Controlled Trial of the Safety and Tolerability of MP 03-036 (Astepro 0.15%) in Patients With Perennial Allergic Rhinitis|Completed||Phase 3|703|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:55:19.712254|2018-06-01 01:55:19.712254
NCT00720369|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2011-09-20||2013-11-26|2008-07-18|2008-07-22|Estimate|2013-11-26|2014-01-13|Estimate||||2013-11-26|2014-01-13|Estimate|July 2008||2008-07-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|CoQ10||CoQ10 in Geriatric Bipolar Depression|Oral Administration of CoQ10 and Phosphorus-31 Magnetization Transfer Magnetic Resonance Spectroscopy in Geriatric Bipolar Disorder and Healthy Older Adults|Completed||N/A|42|Actual|Mclean Hospital||2|||f||||t||||||||||2018-06-01 01:55:20.36837|2018-06-01 01:55:20.36837
NCT00720356|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2017-09-12|2008-07-19|2008-07-22|Estimate|||||||2017-09-12|2017-09-13|Actual|March 2009||2009-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation|Active, not recruiting||Phase 2|50|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 01:55:20.567909|2018-06-01 01:55:20.567909
NCT00720343|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2016-03-23||2016-03-23|2008-07-21|2008-07-22|Estimate|2016-03-23|2016-03-25|Estimate||||2016-03-23|2016-03-25|Estimate|February 2009||2009-02-28|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Data per arm is not available. Columbia will never have access to this data.|Effect of Oral Choline Supplementation on Postoperative Pain|Effect of Oral Choline Supplementation on Postoperative Pain|Terminated||Phase 4|54|Actual|Columbia University||2||PI left the institution.|f||||t||||||||||2018-06-01 01:55:20.641312|2018-06-01 01:55:20.641312
NCT00720330|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2017-04-14||2017-04-14|2008-07-21|2008-07-22|Estimate|2017-04-14|2017-05-19|Actual||||2017-04-14|2017-05-19|Actual|July 2008||2008-07-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain|The Effect of Thoracolumbar Paravertebral Block or Intravenous Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain After Inguinal Herniorrhaphy|Terminated||N/A|12|Actual|The Cleveland Clinic||3||Enrollment challenges prohibited study progression.|f||||f||||||||||2018-06-01 01:55:20.877071|2018-06-01 01:55:20.877071
NCT00720317|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2010-09-15|2008-07-21|2008-07-22|Estimate|||||||2010-09-15|2010-09-16|Estimate|May 2008||2008-05-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Diabetic Retinopathy and Sickle Trait|Diabetic Retinopathy and Sickle Cell Trait|Completed|||48|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-06-01 01:55:21.245699|2018-06-01 01:55:21.245699
NCT00720304|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2015-11-25|2008-07-19|2008-07-22|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2007||2007-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck|A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|37|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 01:55:21.317648|2018-06-01 01:55:21.317648
NCT00720291|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2010-01-21|2008-07-18|2008-07-22|Estimate|||||||2010-01-21|2010-01-25|Estimate|February 2006||2006-02-28|January 2010|2010-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Inflammation and Treatment of Bacterial Vaginosis Near Term|Inflammation and Treatment of Bacterial Vaginosis Near Term|Unknown status|Recruiting|N/A|520|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:55:21.406127|2018-06-01 01:55:21.406127
NCT00720278|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2009-09-23||2010-02-19|2008-07-21|2008-07-22|Estimate|2009-09-23|2009-10-27|Estimate||||2010-02-19|2010-03-02|Estimate|August 2007||2007-08-31|February 2010|2010-02-28|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 Compared to Placebo in Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|526|Actual|Meda Pharmaceuticals||3|||f||||f||||||||||2018-06-01 01:55:21.512498|2018-06-01 01:55:21.512498
NCT00720265|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-07-18|2008-07-18|2008-07-22|Estimate|||||||2008-07-18|2008-07-22|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Assess the Safety and Efficacy of Prograf and MR4 in Kidney Transplantation Patients|A PHASE III, Randomized, Open-Label, Comparative, Multi - Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Kidney Transplant Recipients|Completed||Phase 3|135|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:55:22.138478|2018-06-01 01:55:22.138478
NCT00720252|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2015-03-20|2008-07-19|2008-07-22|Estimate|||||||2015-03-20|2015-03-24|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?|Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?|Terminated||N/A|10|Actual|HaEmek Medical Center, Israel||1||TECHNICAL ISSUES|f||||||||||||||2018-06-01 01:55:22.217534|2018-06-01 01:55:22.217534
NCT00720239|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2013-02-20|2008-07-21|2008-07-22|Estimate|||||||2013-02-20|2013-02-22|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|||Taliderm Dressing for Venous Ulcers|Safety and Wound Healing Efficacy of the TalidermR Wound Dressing a Poly-N-acetyl Glucosamine-derived Membrane Material in Humans With Venous Stasis Ulcers: a Pilot Study.|Completed||Early Phase 1|50|Actual|Medical University of South Carolina||4|||f||||t||||||||||2018-06-01 01:55:22.324371|2018-06-01 01:55:22.324371
NCT00720226|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2017-01-24||2017-03-14|2008-07-18|2008-07-22|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|July 2008||2008-07-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy of Losartan in Preventing Progression of COPD|Efficacy of Losartan in Preventing Progression of COPD|Completed||Phase 4|106|Actual|Johns Hopkins University|Study was designed as feasibility study for assessment of variability of outcomes and tolerability of treatment in patients with pre-existing emphysema in association with COPD.|2|||f||||t||||||||Yes|Limited dataset available to qualified investigators with data use agreement.|2018-06-01 01:55:22.406037|2018-06-01 01:55:22.406037
NCT00720213|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2009-11-09|2008-07-21|2008-07-22|Estimate|||||||2009-11-09|2009-11-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:55:22.722167|2018-06-01 01:55:22.722167
NCT00720200|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2014-09-13|2008-07-18|2008-07-22|Estimate|||||||2014-09-13|2014-09-16|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||ICU Family Communication Study|A Randomized Trial of an Interdisciplinary Communication Intervention to Improve Patient and Family Outcomes in the Intensive Care Unit|Completed||Phase 3|593|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 01:55:22.757852|2018-06-01 01:55:22.757852
NCT00720174|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2016-05-16|2008-07-19|2008-07-22|Estimate|||||||2016-05-16|2016-05-17|Estimate|June 2008||2008-06-30|May 2016|2016-05-31||||January 2013|Actual|2013-01-31||Interventional|||Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma|A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:55:22.842417|2018-06-01 01:55:22.842417
NCT00720148|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2014-08-25|2008-07-18|2008-07-22|Estimate|||||||2014-08-25|2014-08-26|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Phase I Trial of Bortezomib and Sunitinib|Phase IB Dose Escalation Study of Bortezomib (VELCADE) Administered Weekly for 4 Weeks and Sunitinib (SU-011248) Administered Daily for 4 Weeks Followed by a 14 Day Rest in Patients With Refractory Solid Tumors|Completed||Phase 1|30|Actual|Emory University|||||f||||f||||||||||2018-06-01 01:55:23.051717|2018-06-01 01:55:23.051717
NCT00720135|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2015-06-03|2008-07-19|2008-07-22|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma|A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma|Completed||Phase 1|9|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:55:23.125674|2018-06-01 01:55:23.125674
NCT00720122|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2012-01-27||2012-02-28|2008-07-21|2008-07-22|Estimate|2012-01-27|2012-02-29|Estimate||||2012-02-28|2012-03-01|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|814||Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa|Effects of Recombinant Human Insulin Like Growth Factor-1 (rhIGF-1) on Bone Metabolism in Adolescent Girls With Anorexia Nervosa|Completed||Phase 2|28|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 01:55:23.229169|2018-06-01 01:55:23.229169
NCT00720109|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|2016-09-08||2016-09-08|2008-07-19|2008-07-22|Estimate|2016-09-08|2016-10-07|Estimate||||2016-09-08|2016-10-07|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Interventional||Since all patients were enrolled under induction therapy and later risk stratified, all patients are grouped under the treatment induction group, including the three ineligible patients.|Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2/Phase 3|63|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:55:23.500636|2018-06-01 01:55:23.500636
NCT00720096|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2010-10-15||2017-12-08|2008-07-21|2008-07-22|Estimate|2011-01-20|2011-02-16|Estimate||||2017-12-08|2018-01-02|Actual|July 2008||2008-07-31|December 2017|2017-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan|A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy|Terminated||N/A|4|Actual|H. Lee Moffitt Cancer Center and Research Institute|Due to limited sample size, we were unable to make definitive conclusions in this trial.|2||Funds for this project have been spent, and it is thereby terminated.|f||||t||||||||||2018-06-01 01:55:24.970799|2018-06-01 01:55:24.970799
NCT00720083|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|2013-03-22||2015-11-14|2008-07-19|2008-07-22|Estimate|2013-03-22|2013-05-08|Estimate||||2015-11-14|2015-11-17|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All eligible patients.|Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer|A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|34|Actual|Radiation Therapy Oncology Group|This study terminated early with 34 subjects accrued out of 170 planned, therefore no analyses were performed.|2||Withdrawal of drug supply.|f||||t||||||||||2018-06-01 01:55:25.297707|2018-06-01 01:55:25.297707
NCT00720070|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2013-08-23|2008-07-19|2008-07-22|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2007||2007-09-30|December 2008|2008-12-31||||August 2012|Anticipated|2012-08-31||Interventional|||PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer|A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer|Unknown status|Recruiting|Phase 3|560|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:55:25.784346|2018-06-01 01:55:25.784346
NCT00720057|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2011-01-03|2009-12-09|2015-08-12|2008-07-21|2008-07-22|Estimate|2011-01-03|2011-01-25|Estimate|2009-12-09|2009-12-10|Estimate|2015-08-12|2015-08-25|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet in Postsurgical Dental Pain|Completed||Phase 3|312|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:55:25.86531|2018-06-01 01:55:25.86531
NCT00720031|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-07-22|2008-07-21|2008-07-22|Estimate|||||||2008-07-22|2008-07-24|Estimate|November 2000||2000-11-30|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones|Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones|Completed||Phase 1/Phase 2|16|Actual|Nantes University Hospital|||||f||||f||||||||||2018-06-01 01:55:27.170729|2018-06-01 01:55:27.170729
NCT00720018|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2016-02-02|2008-07-21|2008-07-22|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|NP101-006||Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers|A Phase I, Single Center, Open Label, Single-Dose, Five-Period Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) in Healthy Volunteers|Completed||Phase 1|4|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-06-01 01:55:27.232387|2018-06-01 01:55:27.232387
NCT00720005|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2010-10-01|2008-07-21|2008-07-22|Estimate|||||||2010-10-01|2010-10-04|Estimate|September 2007||2007-09-30|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction|Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction|Completed|||20|Actual|Medical University of South Carolina|||1||f||||f||||||||||2018-06-01 01:55:27.295501|2018-06-01 01:55:27.295501
NCT00719992|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-07-18|2008-07-18|2008-07-22|Estimate|||||||2008-07-18|2008-07-22|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Diagnostic Value of HS-CRP in Stable Angina.|Diagnostic Value of HS-CRP in Stable Angina Patients With Positive Exercise Test as Compared With Coronary Angiography.|Completed||N/A|97|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:55:27.363967|2018-06-01 01:55:27.363967
NCT00719979|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2014-03-18|2008-07-18|2008-07-22|Estimate|||||||2014-03-18|2014-03-19|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|May 2011|Actual|2011-05-31||Interventional|||Effectiveness of a Technology Assisted Behavioral Intervention in Assisting People With Major Depressive Disorder|Integrated Telemental Health Intervention for Depression in Primary Care|Completed||Phase 1|102|Actual|Northwestern University||3|||f||||t||||||||||2018-06-01 01:55:27.429402|2018-06-01 01:55:27.429402
NCT00719966|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2018-02-05|2008-07-19|2008-07-22|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2008|Actual|2008-06-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer|Effect of Aromatase Inhibitor Therapy for Breast Cancer on Endothelial Function|Active, not recruiting|||150|Anticipated|Mayo Clinic|||2||f||||t||||||||||2018-06-01 01:55:27.498458|2018-06-01 01:55:27.498458
NCT00719953|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2010-01-10||2010-04-18|2008-07-21|2008-07-22|Estimate|2010-01-10|2010-02-04|Estimate||||2010-04-18|2010-04-20|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|Cognitex001||Study to Assess the Efficacy of Cognitex|A Single-Center, Open-label Study to Assess the Efficacy of Cognitex in Elderly Subjects With Memory Impairment|Completed||Phase 4|30|Actual|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 01:55:27.576417|2018-06-01 01:55:27.576417
NCT00719940|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2008-07-18|2008-07-18|2008-07-22|Estimate|||||||2008-07-18|2008-07-22|Estimate|October 2000||2000-10-31|June 2008|2008-06-30|November 2006|Actual|2006-11-30|October 2004|Actual|2004-10-31||Interventional|TCP||Tinnitus Treatment by Structured Cognitive Behavioral Therapy|Randomized Controlled Clinical Trial of Efficacy and Safety of Individual Cognitive Behavioral Therapy (CBT) Within the Setting of the Structured Therapy Program sTCP (Structured Tinnitus Care Program) in Patients With Tinnitus Aurium|Completed||Phase 4|286|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 01:55:27.796952|2018-06-01 01:55:27.796952
NCT00719927|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2009-02-05|2008-07-21|2008-07-22|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Comadres Weight Loss Pilot Program|Comadres Weight Loss Pilot Program|Unknown status|Active, not recruiting|N/A|45|Anticipated|The Miriam Hospital||2|||f||||||||||||||2018-06-01 01:55:27.876808|2018-06-01 01:55:27.876808
NCT00719914|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2012-07-24||2012-07-24|2008-07-18|2008-07-22|Estimate|2012-07-24|2012-08-27|Estimate||||2012-07-24|2012-08-27|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|IC TITAN||A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks|IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial|Terminated||Phase 2|31|Actual|Brigham and Women's Hospital|Early termination due to poor enrollment.|2||Poor enrollment|f||||t||||||||||2018-06-01 01:55:27.956803|2018-06-01 01:55:27.956803
NCT00719901|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|2013-08-08||2015-01-09|2008-07-19|2008-07-22|Estimate|2013-10-17|2013-12-09|Estimate||||2015-01-09|2015-01-12|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|April 2011|Actual|2011-04-30||Interventional||One patient withdrew prior to beginning treatment and was replaced, thus, will be excluded in all analysis.|Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma|Terminated||Phase 1/Phase 2|11|Actual|National Cancer Institute (NCI)|This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open. No results from the phase II portion are available.|1||"This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase~   I; therefore, the phase II portion will never open."|f||||||||||||||2018-06-01 01:55:28.220707|2018-06-01 01:55:28.220707
NCT00719888|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2018-03-23|2008-07-19|2008-07-22|Estimate|||||||2018-03-23|2018-03-27|Actual|November 18, 2005|Actual|2005-11-18|March 2018|2018-03-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease|Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen|Recruiting||Phase 2|75|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 01:55:28.479283|2018-06-01 01:55:28.479283
NCT00719875|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2017-03-01|2008-07-18|2008-07-22|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2008||2008-12-31|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer|A Dose-escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer|Completed||Phase 1|24|Actual|Yale University||1|||f||||f||||||||||2018-06-01 01:55:28.599831|2018-06-01 01:55:28.599831
NCT00719862|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2009-09-30||2010-01-27|2008-07-21|2008-07-22|Estimate|2010-01-04|2010-01-28|Estimate||||2010-01-27|2010-02-02|Estimate|August 2007||2007-08-31|January 2010|2010-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-036 in Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|481|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:55:28.748786|2018-06-01 01:55:28.748786
NCT00719849|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|2017-04-05||2017-05-19|2008-07-19|2008-07-22|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|November 2005||2005-11-30|May 2017|2017-05-31|December 2009|Actual|2009-12-31|November 2008|Actual|2008-11-30||Interventional|||Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease|Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen|Terminated||Phase 2|13|Actual|Fred Hutchinson Cancer Research Center||2||"A new protocol was developed to replace this protocol in 2008, with removal of ATG and~   extension of MMF duration."|f||||f||||||||||2018-06-01 01:55:29.37376|2018-06-01 01:55:29.37376
NCT00719836|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-20|||2012-04-19|2008-07-20|2008-07-22|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies|A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies|Completed||Phase 1/Phase 2|76|Actual|S*BIO|||||f||||f||||||||||2018-06-01 01:55:30.040672|2018-06-01 01:55:30.040672
NCT00719823|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2016-05-03|2008-07-21|2008-07-22|Estimate|||||||2016-05-03|2016-05-04|Estimate|August 2008||2008-08-31|May 2016|2016-05-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Maraviroc Compassionate Use|Maraviroc Compassionate Use|Withdrawn||Phase 3|0|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-06-01 01:55:30.097161|2018-06-01 01:55:30.097161
NCT00719810|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2010-01-07||2014-06-30|2008-07-21|2008-07-22|Estimate|2010-01-07|2010-02-03|Estimate||||2014-06-30|2014-07-14|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections|A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX 3341 Compared With Tigecycline for the Treatment of Complicated Skin and Skin Structure Infections|Completed||Phase 2|150|Actual|Melinta Therapeutics, Inc.||3|||f||||f||||||||||2018-06-01 01:55:30.193764|2018-06-01 01:55:30.193764
NCT00719797|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2015-03-10|2008-07-19|2008-07-22|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2008||2008-07-31|March 2015|2015-03-31||||May 2011|Actual|2011-05-31||Interventional|TRIBE||Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER|Completed||Phase 3|509|Actual|Gruppo Oncologico del Nord-Ovest||2|||f||||t||||||||||2018-06-01 01:55:30.461077|2018-06-01 01:55:30.461077
NCT00719784|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-20|||2017-02-08|2008-07-21|2008-07-22|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2008||2008-07-31|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Vibration Response Imaging in the Diagnosis of Pulmonary Disease|Vibration Response Imaging in the Diagnosis of Pulmonary Disease - an Exploratory Study|Completed||N/A|25|Actual|Singapore General Hospital||1|||f||||f||||||||||2018-06-01 01:55:30.674545|2018-06-01 01:55:30.674545
NCT00719771|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2014-05-20|2008-07-21|2008-07-22|Estimate|||||||2014-05-20|2014-05-22|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Global® AP™ Total Shoulder Arthroplasty|A Multi-center Clinical Study of the Global® AP™ Shoulder in Total Shoulder Arthroplasty|Completed||N/A|64|Actual|DePuy Orthopaedics||1|||f||||f||||||||||2018-06-01 01:55:30.746025|2018-06-01 01:55:30.746025
NCT00719758|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-10-09|2008-07-21|2008-07-22|Estimate|||||||2008-10-09|2008-10-13|Estimate|June 2008||2008-06-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Drug-Drug Interaction Study of TRK-100STP|TRK-100STP Pharmacokinetic Study in Healthy Volunteers - Evaluation of Pharmacokinetic Interaction Between TRK-100STP and Kremezin|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 01:55:30.832996|2018-06-01 01:55:30.832996
NCT00719745|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-07-18|2008-07-18|2008-07-22|Estimate|||||||2008-07-18|2008-07-22|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study to Assess the Safety and Efficacy of Prograf and MR4 in Liver Transplant Recipients|A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf® (Tacrolimus) and MR4 (Modified Release Tacrolimus) in de Novo Liver Transplant Recipients|Completed||Phase 3|74|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:55:30.898446|2018-06-01 01:55:30.898446
NCT00719732|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2009-09-18||2010-03-04|2008-07-21|2008-07-22|Estimate|2010-03-04|2010-03-16|Estimate||||2010-03-04|2010-03-16|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3|Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3|Completed||Phase 4|218|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:55:30.98986|2018-06-01 01:55:30.98986
NCT00719719|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2018-03-27|2008-07-19|2008-07-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 18, 2008||2008-07-18|December 10, 2017|2017-12-10||||||||Observational|||Cause of Unexplained Anaphylaxis|Studies in the Pathogenesis of Idiopathic Anaphylaxis|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:55:31.157583|2018-06-01 01:55:31.157583
NCT00719706|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2012-06-13||2012-06-13|2008-07-18|2008-07-22|Estimate|2012-06-13|2012-07-18|Estimate||||2012-06-13|2012-07-18|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder|The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder: A Randomized, Placebo-Controlled Trial of Acetyl-L-Carnitine and Alpha-Lipoic Acid for the Treatment of Bipolar Depression|Completed||Phase 2|40|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 01:55:31.262553|2018-06-01 01:55:31.262553
NCT00719693|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2012-09-27|2008-07-21|2008-07-22|Estimate|||||||2012-09-27|2012-09-28|Estimate|July 2008||2008-07-31|September 2012|2012-09-30||||September 2008|Actual|2008-09-30||Interventional|||Assessment of the Effect of Food on ABT-143 Bioavailability||Completed||Phase 1|115|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:55:31.673393|2018-06-01 01:55:31.673393
NCT00719680|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|2012-11-27||2014-03-05|2008-07-21|2008-07-22|Estimate|2012-12-20|2013-01-25|Estimate||||2014-03-05|2014-04-02|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)|A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID)|Completed||Phase 3|21|Actual|CSL Behring||1|||f||||||||||||||2018-06-01 01:55:31.770378|2018-06-01 01:55:31.770378
NCT00719667|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-20|||2011-10-17|2008-07-21|2008-07-22|Estimate|||||||2011-10-17|2011-10-18|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|GOPCABE||German Off Pump Coronary Artery Bypass in Elderly Study|German Off Pump Coronary Artery Bypass in Elderly Study|Completed||Phase 3|2000|Anticipated|German Off Pump Coronary Artery Bypass in Elderly Study Group|||||f||||t||||||||||2018-06-01 01:55:32.112157|2018-06-01 01:55:32.112157
NCT00719654|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2018-05-15|2008-07-18|2008-07-22|Estimate|||||||2018-05-15|2018-05-18|Actual|August 2007|Actual|2007-08-31|May 2018|2018-05-31|April 9, 2012|Actual|2012-04-09|April 9, 2012|Actual|2012-04-09||Observational|||Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia|Alterations in the Plasma Proteome of Early-Onset Severe Preeclampsia|Completed|||316|Actual|Medical University of South Carolina|||2||f||||f||||||Samples With DNA|"~     Blood plasma and a portion of placenta is retained~   "|||2018-06-01 01:55:32.171186|2018-06-01 01:55:32.171186
NCT00719641|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-19|||2017-06-30|2008-07-19|2008-07-22|Estimate|||||||2017-06-30|2017-07-02|Actual|July 11, 2008||2008-07-11|September 21, 2016|2016-09-21|September 21, 2016|Actual|2016-09-21|September 21, 2016|Actual|2016-09-21||Interventional|||Experimental Device to Improve Colonoscopy|A Trial of Segmental Stiffening Wires to Improve the Efficiency and Patient Tolerability of Colonoscopy|Completed||Phase 1/Phase 2|42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:55:32.22912|2018-06-01 01:55:32.22912
NCT00719628|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-21|||2009-04-06|2008-07-21|2008-07-22|Estimate|||||||2009-04-06|2009-04-07|Estimate|September 2008||2008-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Depth of Anaesthesia and Cognitive Dysfunction|Depth of Anaesthesia and Presence of Postoperative Cognitive Dysfunction|Completed|||70|Actual|Rigshospitalet, Denmark|||||f||||t||||||||||2018-06-01 01:55:32.297225|2018-06-01 01:55:32.297225
NCT00719615|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2010-01-27||2015-06-02|2008-07-18|2008-07-21|Estimate|2010-03-15|2010-03-30|Estimate||||2015-06-02|2015-06-03|Estimate|March 2008||2008-03-31|March 2010|2010-03-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Observational|||Assess Vitamin D Levels in Those With & Without Thyroid Cancer|The Relationship Between Vitamin D and Thyroid Cancer|Completed|||111|Actual|University of Nebraska|The trial limitations include that it was mostly done on Caucasian subjects; the controls were those with thyroid nodules not subjects without any thyroid disease; the sample size was small; & a small number of Vit D assays used different methods.||3||f||||f||||||Samples With DNA|"~     Whole blood.~   "|||2018-06-01 01:55:32.375479|2018-06-01 01:55:32.375479
NCT00719602|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2016-09-16|2008-07-17|2008-07-21|Estimate|||||||2016-09-16|2016-09-19|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART|P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART|Completed||Early Phase 1|105|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||2|||f||||t||||||||||2018-06-01 01:55:32.703866|2018-06-01 01:55:32.703866
NCT00719589|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2010-03-23|2008-07-17|2008-07-21|Estimate|||||||2010-03-23|2010-03-24|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Outcomes of Pudendal InterStim|Outcomes of Pudendal InterStim|Completed|||84|Actual|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 01:55:32.81067|2018-06-01 01:55:32.81067
NCT00719576|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2017-01-12||2017-05-08|2008-07-18|2008-07-21|Estimate|2017-05-08|2017-12-14|Actual||||2017-05-08|2017-12-14|Actual|July 2008||2008-07-31|May 2017|2017-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|SUMMIT||Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee|A Prospective, Randomized, Open-label, Parallel-group, Multi-center Study to Demonstrate the Superiority of MACI® Versus Arthroscopic Microfracture for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea.|Completed||Phase 3|144|Actual|Vericel Corporation|Because clinical trials are conducted under widely varying conditions, adverse event rates observed in clinical trials cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in practice.|2|||f||||t||||||||No||2018-06-01 01:55:32.886922|2018-06-01 01:55:32.886922
NCT00719563|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2014-07-14||2016-12-19|2008-07-18|2008-07-21|Estimate|2014-07-14|2014-08-06|Estimate||||2016-12-19|2017-02-09|Estimate|October 2008||2008-10-31|December 2016|2016-12-31|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|||American Ginseng in Treating Patients With Fatigue Caused by Cancer|The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study|Completed||Phase 3|364|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 01:55:33.560076|2018-06-01 01:55:33.560076
NCT00719550|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17||2013-04-15|2013-11-13|2008-07-18|2008-07-21|Estimate||||2013-04-15|2013-04-23|Estimate|2013-11-13|2013-12-05|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|June 2013|Actual|2013-06-30|November 2010|Actual|2010-11-30||Interventional|||AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer|A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102|Completed||Phase 1/Phase 2|130|Actual|Amgen||4|||f||||||||||||||2018-06-01 01:55:34.977575|2018-06-01 01:55:34.977575
NCT00719537|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2016-11-02||2017-03-03|2008-07-18|2008-07-21|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|July 2008||2008-07-31|March 2017|2017-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia|Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia in Patients With a Prior History of Preeclampsia: A Prospective, Randomized Clinical Trial|Terminated||N/A|3|Actual|William Beaumont Hospitals||2||inability to find qualifying participants|f||||t||||||||No|No study data is available, will not be shared.|2018-06-01 01:55:35.090361|2018-06-01 01:55:35.090361
NCT00719524|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2013-03-08|2008-07-17|2008-07-21|Estimate|||||||2013-03-08|2013-03-11|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor|An Open-label, Non-randomized, Dose Evaluation, Safety and Pharmacokinetics Phase I Study of AVE8062 in Combination With Platinum Salts (Cisplatin or Carboplatin) and Taxanes (Docetaxel or Paclitaxel), Every 3 Weeks, in Patients With Advanced Solid Tumors.|Completed||Phase 1|71|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:55:35.303145|2018-06-01 01:55:35.303145
NCT00719511|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-02-16|2008-07-18|2008-07-21|Estimate|||||||2011-02-16|2011-02-17|Estimate|February 2008||2008-02-29|February 2011|2011-02-28|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration|Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind, Dose-response Study to Assess the Optimal Dose as Well as Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration|Completed||Phase 2|132|Anticipated|University of Zurich||4|||f||||f||||||||||2018-06-01 01:55:35.370082|2018-06-01 01:55:35.370082
NCT00719498|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-05-16|2008-07-18|2008-07-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|November 2003||2003-11-30|April 2010|2010-04-30|July 2004|Actual|2004-07-31|||||Interventional|||Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)|Early High-dose Erythropoietin Therapy and Hypothermia After Out-of-hospital Cardiac Arrest: A Matched Control Study|Completed||Phase 3|20|Actual|Janssen Cilag S.A.S.|||||f||||||||||||||2018-06-01 01:55:35.436894|2018-06-01 01:55:35.436894
NCT00719485|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2009-02-05|2008-07-18|2008-07-21|Estimate|||||||2009-02-05|2009-02-06|Estimate|April 2009||2009-04-30|July 2008|2008-07-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||A Study on the Use of Educational Programs Prior to Lumbar Spinal Surgery|A Prospective Randomized Control Trial Assessing the Effect of Two Different Educational Programs on Functional Outcome and Quality of Life Scores for Patients Having Posterior Decompressive Lumbar Spinal Surgery for Degenerative Conditions of the Lumbar Spine|Unknown status|Not yet recruiting|N/A|70|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 01:55:35.486042|2018-06-01 01:55:35.486042
NCT00719472|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2012-05-24||2017-04-10|2008-07-18|2008-07-21|Estimate|2012-05-24|2012-06-26|Estimate||||2017-04-10|2017-05-15|Actual|July 2008||2008-07-31|April 2017|2017-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|RATE||A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)|A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma|Completed||Phase 3|451|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 01:55:35.555943|2018-06-01 01:55:35.555943
NCT00719459|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2017-03-20|2008-07-18|2008-07-21|Estimate|||||||2017-03-20|2017-03-21|Actual|June 2008||2008-06-30|June 2015|2015-06-30|July 13, 2008|Actual|2008-07-13|July 2008|Actual|2008-07-31||Interventional|||Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer|A Randomized, Open-Label, Single-Dose, Parallel-Design, Bioequivalence Study of Hospira Iron Sucrose Injection Compared to Venofer® Injection USP in Healthy Subjects.|Completed||Phase 1|60|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:55:35.944181|2018-06-01 01:55:35.944181
NCT00719446|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2015-08-31|2008-07-18|2008-07-21|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2007||2007-10-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|ALTOS||Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials|Patient Outcomes 6 and 12 Months After ALTA, OMEGA, EDEN and SAILS ARDS Network Trials|Completed|||922|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 01:55:36.010013|2018-06-01 01:55:36.010013
NCT00719433|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2013-04-19|2008-07-18|2008-07-21|Estimate|||||||2013-04-19|2013-04-22|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy|Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy|Completed||Phase 2/Phase 3|76|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 01:55:36.088227|2018-06-01 01:55:36.088227
NCT00719420|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-07-18|2008-07-18|2008-07-21|Estimate|||||||2008-07-18|2008-07-21|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Clarithromycin, Amoxicillin, and Metronidazole Based Regimens to Treat Helicobacter Pylori Infections in Colombia|A Randomized Clinical Trial to Examine the Efficacy of a Clarithromycin-, Amoxicillin-, and Metronidazole-Based Regimen to Eradicate Helicobacter Pylori Infections in Pasto, Colombia|Completed||Phase 3|151|Actual|University of North Texas Health Science Center||2|||f||||f||||||||||2018-06-01 01:55:36.231011|2018-06-01 01:55:36.231011
NCT00719407|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2012-11-07|2008-07-17|2008-07-21|Estimate|||||||2012-11-07|2012-11-09|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Interventional|NEAT||Neonatal Erythropoietin in Asphyxiated Term Newborns|Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial|Completed||Phase 1|24|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 01:55:36.304441|2018-06-01 01:55:36.304441
NCT00719394|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2009-07-08|2008-07-18|2008-07-21|Estimate|||||||2009-07-08|2009-07-10|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males|Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects|Completed||Phase 1|72|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:55:36.36938|2018-06-01 01:55:36.36938
NCT00719381|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2012-06-13|2008-07-17|2008-07-21|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Pioglitazone on Inflammation in Cystic Fibrosis|Effect of Pioglitazone on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Cystic Fibrosis|Completed||Phase 1|24|Anticipated|University of Southern California||2|||f||||t||||||||||2018-06-01 01:55:36.444837|2018-06-01 01:55:36.444837
NCT00719368|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2014-04-04|2008-07-18|2008-07-21|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2006||2006-01-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Neurophysiological Characterization of Postherniotomy Pain|Quantitative Sensory Testing in Persistent Postherniotomy Pain Patients|Completed|||48|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-06-01 01:55:36.513052|2018-06-01 01:55:36.513052
NCT00719355|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2012-05-15||2013-02-07|2008-07-17|2008-07-21|Estimate|2012-08-28|2012-09-28|Estimate||||2013-02-07|2013-02-12|Estimate|June 2005||2005-06-30|February 2013|2013-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Polestriding Versus Walking for Subjects With Poor Leg Circulation|Polestriding Versus Walking for PAD Rehabilitation|Completed||Phase 2|146|Actual|University of Illinois at Chicago|Due to the small number of women in the trial, results cannot be generalized to women.|2|||f||||f||||||||||2018-06-01 01:55:36.585295|2018-06-01 01:55:36.585295
NCT00719342|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2014-11-13|2008-07-17|2008-07-21|Estimate|||||||2014-11-13|2014-11-14|Estimate|July 2008||2008-07-31|November 2014|2014-11-30|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Breathing a Mixture of 92% Oxygen (O2) + 8% Carbon Dioxide (CO2) on Flicker Induced Blood Flow Changes in Ocular Perfusion|Effect of Breathing a Mixture of 92% O2 + 8% CO2 on Flicker Induced Blood Flow Changes in Ocular Perfusion|Completed||N/A|24|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 01:55:36.840028|2018-06-01 01:55:36.840028
NCT00719329|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2011-08-10||2012-03-28|2008-07-18|2008-07-21|Estimate|2012-03-28|2012-04-20|Estimate||||2012-03-28|2012-04-20|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Impact of Chlorhexidine Cleansing on Bacteria Colonizing the Umbilical Cord of Infants in Bangladesh|Bacterial Colonization of the Neonatal Umbilical Cord and Impact of 4.0% Chlorhexidine Cleansing on the Bacteriological Profile of the Umbilical Cord of Newborns in Sylhet District, Bangladesh|Completed||N/A|1931|Actual|Johns Hopkins Bloomberg School of Public Health|Not all possible swab data were available for each baby due to staff leave/holiday, unplanned work stoppage, child/mother absent/moved/died, swab collected but not processed - these reasons did not differ between the groups|3|||f||||f||||||||||2018-06-01 01:55:36.991704|2018-06-01 01:55:36.991704
NCT00719316|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2010-01-13|2008-07-18|2008-07-21|Estimate|||||||2010-01-13|2010-01-14|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|January 2010|Anticipated|2010-01-31|July 2009|Anticipated|2009-07-31||Interventional|MSNA||Aliskiren and Muscle Sympathetic Nerve Activity|Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease|Unknown status|Recruiting|Phase 4|30|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-06-01 01:55:37.291353|2018-06-01 01:55:37.291353
NCT00719303|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2018-02-14|2008-07-18|2008-07-21|Estimate|||||||2018-02-14|2018-02-16|Estimate|June 18, 2012|Actual|2012-06-18|February 2018|2018-02-28||||December 31, 2020|Anticipated|2020-12-31||Interventional|||Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?|Recruiting||Phase 3|1070|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 01:55:37.490338|2018-06-01 01:55:37.490338
NCT00718432|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-06-24|2008-07-17|2008-07-18|Estimate|||||||2015-06-24|2015-06-25|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||An Interventional Study of Geriatric Frailty, Osteoporosis, and Depression|Interventional Study of Geriatric Frailty, Osteoporosis, and Depression in a Community Based Randomized Trial.|Completed||N/A|406|Actual|National Health Research Institutes, Taiwan||3|||f||||t||||||||||2018-06-01 01:55:55.224926|2018-06-01 01:55:55.224926
NCT00719290|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2015-08-18|2008-07-18|2008-07-21|Estimate|||||||2015-08-18|2015-08-19|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Primary Angle Closure Glaucoma and Aqueous Dynamics|A Randomised Comparative Study of the Effects of Cataract Extraction With Lens Implant Alone Versus Cataract Extraction With Lens Implant and Goniosynechialysis on Outflow Facility in Patients With Primary Angle Closure Glaucoma.|Completed||N/A|24|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 01:55:39.590611|2018-06-01 01:55:39.590611
NCT00719277|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2009-05-04|2008-07-17|2008-07-21|Estimate|||||||2009-05-04|2009-05-05|Estimate|December 2006||2006-12-31|May 2009|2009-05-31|September 2009|Anticipated|2009-09-30|July 2009|Anticipated|2009-07-31||Interventional|PULSE||Feasibility Study: Sleuth Monitoring System|Pilot Clinical Study of the Sleuth Implantable ECG Monitoring System|Unknown status|Active, not recruiting|N/A|40|Anticipated|Transoma Medical|||||f||||f||||||||||2018-06-01 01:55:39.656566|2018-06-01 01:55:39.656566
NCT00719264|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2014-04-04||2017-02-13|2008-07-18|2008-07-21|Estimate|2014-04-04|2014-05-07|Estimate||||2017-02-13|2017-03-20|Actual|November 12, 2008|Actual|2008-11-12|February 2017|2017-02-28|April 15, 2013|Actual|2013-04-15|December 31, 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer|A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney|Completed||Phase 2|365|Actual|Novartis||2|||f||||||||||||||2018-06-01 01:55:39.75959|2018-06-01 01:55:39.75959
NCT00719251|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2009-03-04|2008-07-18|2008-07-21|Estimate|||||||2009-03-04|2009-03-05|Estimate|March 2004||2004-03-31|March 2009|2009-03-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Effects of High Voltage Pulsed Current (HVPC) and Low Level Laser Therapy (LLLT) on Wound Healing in Diabetic Ulcers|Effects of High Voltage Pulsed Current and Low Level Laser Therapy on Wound Healing in Diabetic Ulcers.|Completed||N/A|28|Actual|Universidad Industrial de Santander||3|||f||||t||||||||||2018-06-01 01:55:40.826219|2018-06-01 01:55:40.826219
NCT00719238|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2008-07-18|2008-07-18|2008-07-21|Estimate|||||||2008-07-18|2008-07-21|Estimate|January 2007||2007-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||A Pilot Study to Promote Maternal and Infant Oral Health|A Pilot Study to Promote Maternal and Infant Oral Health|Completed||N/A|121|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 01:55:40.903827|2018-06-01 01:55:40.903827
NCT00719225|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-07-13|2008-07-17|2008-07-21|Estimate|||||||2011-07-13|2011-07-14|Estimate||||July 2011|2011-07-31||||||||Expanded Access|||A Belatacept Compassionate Use Study for Patients With a Kidney Transplant|Belatacept for Renal Allograft Recipients: A Compassionate Use Program|Approved for marketing|||||Bristol-Myers Squibb|||||||||f||||||||||2018-06-01 01:55:40.962452|2018-06-01 01:55:40.962452
NCT00719212|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2015-10-22||2015-12-08|2008-07-18|2008-07-21|Estimate|2015-10-27|2015-12-01|Estimate||||2015-12-08|2016-01-11|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer|A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer|Completed||Phase 2|61|Actual|Translational Research in Oncology||1|||f||||t||||||||||2018-06-01 01:55:41.039817|2018-06-01 01:55:41.039817
NCT00719199|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2013-10-21|2008-07-17|2008-07-21|Estimate|||||||2013-10-21|2013-10-22|Estimate|January 2009||2009-01-31|October 2013|2013-10-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|||Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer|Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease|Terminated||Phase 1|21|Actual|EMD Serono||1||Sponsor will discontinue further development of EMD 1201081|f||||f||||||||||2018-06-01 01:55:41.533997|2018-06-01 01:55:41.533997
NCT00719186|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2014-03-25||2018-04-16|2008-07-18|2008-07-21|Estimate|2014-05-12|2014-06-09|Estimate||||2018-04-16|2018-05-16|Actual|February 2009||2009-02-28|April 2018|2018-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PPCOSII||Pregnancy in Polycystic Ovary Syndrome II|A 20 Week Double-Blind Randomized Trial of Clomiphene Citrate and Letrozole for the Treatment of Infertility in Women With Polycystic Ovary Syndrome|Completed||Phase 3|750|Actual|Yale University||2|||f||||t||||||||||2018-06-01 01:55:41.631993|2018-06-01 01:55:41.631993
NCT00719173|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2017-02-27|2008-07-18|2008-07-21|Estimate|||||||2017-02-27|2017-03-01|Actual|August 2005||2005-08-31|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|NRR||Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer|Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics|Completed||Phase 1|19|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 01:55:42.017643|2018-06-01 01:55:42.017643
NCT00719160|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2012-01-26||2012-11-30|2008-07-18|2008-07-21|Estimate|2012-11-30|2013-01-04|Estimate||||2012-11-30|2013-01-04|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Protein on Calcium Absorption and Gastric Acid Production|Dietary Protein's Effect on Gastric pH and Calcium Absorption|Completed||Phase 4|12|Actual|Yale University||2|||f||||f||||||||||2018-06-01 01:55:42.086999|2018-06-01 01:55:42.086999
NCT00719147|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-09-26|2008-07-18|2008-07-21|Estimate|||||||2011-09-26|2011-09-27|Estimate|July 2001||2001-07-31|September 2011|2011-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Observational|||AVN of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone|Avascular Necrosis of Weight-Bearing Joints In Patients With Hematologic Malignancies Treated With Dexamethasone Or Prednisone|Completed|||170|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 01:55:42.22794|2018-06-01 01:55:42.22794
NCT00719134|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2015-02-10||2015-04-08|2008-07-18|2008-07-21|Estimate|2015-04-08|2015-04-09|Estimate||||2015-04-08|2015-04-09|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache|The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache|Completed||Phase 4|76|Actual|Beth Israel Deaconess Medical Center|Patients were not asked whether or not they thought the pill they took was maxalt or placebo. Thus, it is not possible to determine their actual level of expectation.|6|||f||||f||||||||||2018-06-01 01:55:43.377029|2018-06-01 01:55:43.377029
NCT00719121|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-09-23|2008-07-17|2008-07-21|Estimate|||||||2011-09-23|2011-09-26|Estimate|November 2006||2006-11-30|July 2008|2008-07-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Study on Anti-inflammatory Effects of Topical R115866 Gel|Placebo-Controlled, Investigator Blinded, Explorative Trial to Evaluate the Anti-inflammatory Effect of Multiple Topical Applications of R115866 Gel (0.35%) in Two Models of Cutaneous Inflammation in Healthy Male Subjects|Completed||Phase 1|12|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 01:55:43.573315|2018-06-01 01:55:43.573315
NCT00719108|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2012-12-26|2008-07-18|2008-07-21|Estimate|||||||2012-12-26|2012-12-27|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.|Randomized,Single Center,Double Blind,Two-period,Crossover Glucose Clamp Trial to Test Bioequivalence Between Two Recombinant Human Soluble Insulins - Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects|Completed||Phase 1|42|Actual|Wockhardt||2|||f||||f||||||||||2018-06-01 01:55:43.651393|2018-06-01 01:55:43.651393
NCT00719095|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2013-04-12|2008-07-17|2008-07-21|Estimate|||||||2013-04-12|2013-04-15|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effective Treatment for Prescription Opioid Abuse|Effective Treatment for Prescription Opioid Abuse|Completed||Phase 2|105|Actual|University of Vermont Medical Center||3|||f||||f||||||||||2018-06-01 01:55:43.72737|2018-06-01 01:55:43.72737
NCT00719082|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2016-01-26|2008-07-17|2008-07-21|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||Fall Prevention:Dynamic Posturographic Measurements in the Geriatric Population|Fall Prevention:Dynamic Posturographic Measurements in the Geriatric Population|Withdrawn|||0|Actual|Carrick Institute for Graduate Studies|||1|Lack of Funding|f||||t||||||||No||2018-06-01 01:55:43.806369|2018-06-01 01:55:43.806369
NCT00719069|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2008-07-21|2008-07-18|2008-07-21|Estimate|||||||2008-07-21|2008-07-22|Estimate|April 2008||2008-04-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke|A Double-Blind, Placebo-Controlled, Randomized, Single-Dose, 2-Period Crossover Study of the Pharmacodynamics of Orally Administered PSI-697 in Healthy Subjects Who Smoke|Completed||Phase 1|30|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:55:43.864723|2018-06-01 01:55:43.864723
NCT00719056|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-18|2008-07-18|2008-07-21|Estimate|||||||2008-07-18|2008-07-21|Estimate|August 2004||2004-08-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|December 2005|Actual|2005-12-31||Interventional|||Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty|Efficacy of Teicoplanin for the Prevention of Surgical Site Infections After Total Hip or Knee Arthroplasty: A Prospective, Open-Label Randomized Study|Completed||Phase 4|616|Actual|University of Athens||2|||f||||f||||||||||2018-06-01 01:55:43.921346|2018-06-01 01:55:43.921346
NCT00719043|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2013-12-19|2010-12-23|2016-09-09|2008-07-18|2008-07-21|Estimate|2013-12-19|2014-02-07|Estimate|2010-12-23|2010-12-30|Estimate|2016-09-09|2016-10-20|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|February 2011|Actual|2011-02-28|April 2010|Actual|2010-04-30||Interventional|||Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years|A Trial to Evaluate the Safety and Immunogenicity of Monovalent H5N1 Vaccine in Adults >=18 Yrs of Age|Completed||Phase 2|841|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:55:44.228358|2018-06-01 01:55:44.228358
NCT00719030|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2016-07-28|2008-07-17|2008-07-21|Estimate|||||||2016-07-28|2016-08-01|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|May 2012|Actual|2012-05-31|April 2010|Actual|2010-04-30||Interventional|||A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy|A Randomized, Placebo-controlled, Pre-surgical Study of the Effects of Pomegranate Pills in Men With Prostate Cancer Prior to Radical Prostatectomy|Completed||N/A|25|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-06-01 01:55:46.355682|2018-06-01 01:55:46.355682
NCT00719017|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2013-04-05|2008-07-18|2008-07-21|Estimate|||||||2013-04-05|2013-04-08|Estimate|September 2007||2007-09-30|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery|Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery: a Randomized Controlled Study.|Unknown status|Recruiting|Phase 4|24|Anticipated|University Magna Graecia||3|||f||||t||||||||||2018-06-01 01:55:46.422085|2018-06-01 01:55:46.422085
NCT00719004|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2016-04-06|2008-07-18|2008-07-21|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Sonographic Features of Normal Soft Tissues of the Feet|Sonographic Features of Normal Soft Tissues of the Feet|Completed||N/A|10|Actual|University of Michigan||1|||f||||f||||||||No||2018-06-01 01:55:46.499881|2018-06-01 01:55:46.499881
NCT00718991|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2015-03-06|2008-07-18|2008-07-21|Estimate|||||||2015-03-06|2015-03-09|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|EXCELLENT-BTK||EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study|A Physician Initiated Prospective Multicenter Study on Excimer Laser Recanalisation in the Treatment of Long Infrapopliteal Lesions in Patients With Critical Limb Ischemia|Terminated||Phase 2/Phase 3|14|Actual|Flanders Medical Research Program||1||too slow enrollment|f||||f||||||||||2018-06-01 01:55:46.561829|2018-06-01 01:55:46.561829
NCT00718978|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-09-05|2008-07-18|2008-07-21|Estimate|||||||2008-09-05|2008-09-09|Estimate|June 2003||2003-06-30|July 2008|2008-07-31|July 2007|Actual|2007-07-31|July 2004|Actual|2004-07-31||Interventional|||Clinical Application of Autologous Three-Cellular Cultured Skin Substitutes (CSS)|Clinical Application of Autologous Three-Cellular Cultured Skin Substitutes (CSS) Based on Esterified Hyaluronic Acid Scaffold: Our Experience|Completed||N/A|11|Actual|University of Roma La Sapienza||3|||f||||f||||||||||2018-06-01 01:55:46.637213|2018-06-01 01:55:46.637213
NCT00718965|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18||2016-04-15|2016-04-15|2008-07-18|2008-07-21|Estimate||||2016-04-15|2016-05-16|Estimate|2016-04-15|2016-05-16|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia|A Double-blind, Randomized, 12-month, Placebo-controlled, Parallel Group, Fixed-dose Study to Evaluate the Efficacy and Safety of AVE5530 25mg/Day and AVE5530 50 mg/Day in Patients With Primary Hypercholesterolemia|Terminated||Phase 3|826|Actual|Sanofi||3||AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy|f||||f||||||||||2018-06-01 01:55:46.714566|2018-06-01 01:55:46.714566
NCT00718952|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2010-02-11|2008-07-18|2008-07-21|Estimate|||||||2010-02-11|2010-02-12|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|EVALUATION||The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension|Multi-centre, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Treatment of Pulmonary Arterial Hypertension With Vardenafil in China|Completed||Phase 3|60|Anticipated|Tongji University||2|||f||||t||||||||||2018-06-01 01:55:46.783345|2018-06-01 01:55:46.783345
NCT00718939|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2016-10-19|2008-07-17|2008-07-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Rheos® Diastolic Heart Failure Trial|Rheos® Diastolic Heart Failure Trial|Completed||N/A|6|Actual|CVRx, Inc.||2|||f||||f||||||||||2018-06-01 01:55:46.865732|2018-06-01 01:55:46.865732
NCT00718926|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2008-07-18|2008-07-18|2008-07-21|Estimate|||||||2008-07-18|2008-07-21|Estimate|August 2008||2008-08-31|May 2008|2008-05-31|March 2010|Anticipated|2010-03-31|December 2008|Anticipated|2008-12-31||Observational|||The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients|The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients|Unknown status|Not yet recruiting||50|Anticipated|Meiji University of Oriental Medicine|||4||f||||t||||||Samples Without DNA|"~     After application of anethesia eyedrops, nitrocel membrane is put ocular surface. Then,~     removed the membrane. This method is commonly used clinically.~   "|||2018-06-01 01:55:47.038684|2018-06-01 01:55:47.038684
NCT00718913|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2015-05-14|2008-07-18|2008-07-21|Estimate|||||||2015-05-14|2015-05-18|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer|A Phase II Trial of Postoperative Chemotherapy and Chemo-radiotherapy for Resected Adenocarcinoma of the Stomach and Gastro-esophageal Junction|Completed||Phase 2|40|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 01:55:47.105673|2018-06-01 01:55:47.105673
NCT00718887|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2012-10-17||2013-01-04|2008-07-18|2008-07-21|Estimate|2013-01-04|2013-02-11|Estimate||||2013-01-04|2013-02-11|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Interventional|||Suboptimal Responders to Adefovir Switching to Entecavir|A Comparative Study of the Week 12 Antiviral Efficacy and Safety of Switching to Entecavir vs. Continuing Adefovir Treatment in Adults With Chronic Hepatitis B and Suboptimal Response to Adefovir|Completed||Phase 4|228|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 01:55:47.207777|2018-06-01 01:55:47.207777
NCT00718874|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2012-04-18|2008-07-18|2008-07-21|Estimate|||||||2012-04-18|2012-04-19|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PRIMO||A Specialized Diet for the Unique Metabolic Characteristics of Peripubertal African American Girls|Dietary Intervention to Improve Insulin Dynamics During the Pubertal Transition|Completed||N/A|30|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 01:55:47.544475|2018-06-01 01:55:47.544475
NCT00718861|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2013-11-08||2014-10-02|2008-07-18|2008-07-21|Estimate|2013-11-08|2013-12-30|Estimate||||2014-10-02|2014-10-09|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||The intent-to-treat (ITT) population included all patients who were enrolled in the extension study at Visit 12. This included patients who were randomized to Z9 and Z6P3 groups.|3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs|A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|190|Actual|Novartis||2|||f||||t||||||||||2018-06-01 01:55:47.630631|2018-06-01 01:55:47.630631
NCT00718848|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2015-10-13|2008-07-18|2008-07-21|Estimate|||||||2015-10-13|2015-10-14|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease|Impact of In-centre Nocturnal Hemodialysis on Ventricular Remodeling and Function in End-stage Renal Disease|Completed|||67|Actual|St. Michael's Hospital, Toronto|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma.~   "|||2018-06-01 01:55:48.363621|2018-06-01 01:55:48.363621
NCT00718835|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2014-02-20|2008-07-17|2008-07-21|Estimate|||||||2014-02-20|2014-02-21|Estimate|June 2007||2007-06-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Incentive-based Smoking Cessation for Methadone Patients|Incentive-based Smoking Cessation for Methadone Patients|Completed||Phase 2|170|Anticipated|University of Vermont Medical Center||2|||f||||f||||||||||2018-06-01 01:55:48.428416|2018-06-01 01:55:48.428416
NCT00718822|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2008-07-18|2008-07-18|2008-07-21|Estimate|||||||2008-07-18|2008-07-21|Estimate|August 2006||2006-08-31|July 2008|2008-07-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Outcome of Embryo Culture at Two Oxygen Tensions|Does Reduced Oxygen Tension in Embryo Culture Influence Clinical Outcome of ICSI Cycles? A Prospective Randomized Trial|Completed||N/A|647|Actual|University Clinical Centre, Maribor||2|||f||||f||||||||||2018-06-01 01:55:48.554973|2018-06-01 01:55:48.554973
NCT00718809|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|2015-05-15||2015-06-05|2008-07-18|2008-07-21|Estimate|2015-06-05|2015-06-10|Estimate||||2015-06-05|2015-06-10|Estimate|June 2008||2008-06-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|August 2010|Actual|2010-08-31||Interventional|||Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer|Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)|Terminated||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 01:55:48.638932|2018-06-01 01:55:48.638932
NCT00718796|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2010-05-14|2008-07-18|2008-07-21|Estimate|||||||2010-05-14|2010-05-17|Estimate|April 2008||2008-04-30|May 2010|2010-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|Cardio pilot||Naturopathic Treatment for the Prevention of Cardiovascular Disease|Naturopathic Treatment for the Prevention of Cardiovascular Disease: a Pragmatic Randomized Controlled Trial|Completed||Phase 3|300|Anticipated|The Canadian College of Naturopathic Medicine||2|||f||||t||||||||||2018-06-01 01:55:49.176197|2018-06-01 01:55:49.176197
NCT00718783|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2016-12-13|2008-07-18|2008-07-21|Estimate|||||||2016-12-13|2016-12-14|Estimate|April 2007||2007-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Molecular Analysis of Retinoblastoma|Molecular Analysis of Retinoblastoma|Completed|||41|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples With DNA|"~     -  Each tumor sample will be immediately transferred to a sterile cryovial and flash frozen~          in liquid nitrogen.~        -  White blood cells will be isolated from the blood sample as a source of genomic DNA.~   "|||2018-06-01 01:55:49.262039|2018-06-01 01:55:49.262039
NCT00718770|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2013-08-02||2013-12-16|2008-07-18|2008-07-21|Estimate|2013-12-16|2014-01-17|Estimate||||2013-12-16|2014-01-17|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression|Rexinoid Therapy for Poorly Differentiated Thyroid Cancer: A Pilot Clinical Trial and Correlation to Retinoid and PPARy Receptor Expression|Completed||Early Phase 1|10|Actual|University of Colorado, Denver|Small numbers of participants with higher than expected numbers of patients not eligible and who could not complete trial due to lack of efficacy or drug side effects|1|||f||||t||||||||||2018-06-01 01:55:49.332385|2018-06-01 01:55:49.332385
NCT00718757|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2013-08-26|2008-07-18|2008-07-21|Estimate|||||||2013-08-26|2013-08-28|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies|A Phase I Trial Using Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies|Completed||Phase 1|4|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 01:55:49.463597|2018-06-01 01:55:49.463597
NCT00718744|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2010-08-04|2008-07-17|2008-07-21|Estimate|||||||2010-08-04|2010-08-05|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units|Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units|Completed||Phase 2|30|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-06-01 01:55:49.527629|2018-06-01 01:55:49.527629
NCT00718731|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2010-04-01|2008-07-18|2008-07-21|Estimate|||||||2010-04-01|2010-04-02|Estimate|March 2008||2008-03-31|April 2010|2010-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study GSI-136 in Healthy Young and Healthy Elderly Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI 136 Administered Orally to Healthy Young and Healthy Elderly Subjects|Completed||Phase 1|80|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:55:49.60981|2018-06-01 01:55:49.60981
NCT00718718|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2017-10-22|2011-09-15|2017-12-22|2008-07-17|2008-07-21|Estimate|2017-10-22|2017-12-04|Actual|2011-09-15|2011-09-21|Estimate|2017-12-22|2018-01-23|Actual|August 11, 2008|Actual|2008-08-11|December 2017|2017-12-31|March 3, 2011|Actual|2011-03-03|March 3, 2011|Actual|2011-03-03||Interventional|||A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, Dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 2|187|Actual|Centocor, Inc.||7|||f||||t|t|||||||||2018-06-01 01:55:49.843024|2018-06-01 01:55:49.843024
NCT00718705|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-12-27|2008-07-18|2008-07-21|Estimate|||||||2011-12-27|2011-12-29|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PREMYC||Reduction of Spontaneous Prematurity by Antibiotic Treatment (Josamycin)|Reduction of Spontaneous Prematurity: Impact of Antibiotic Treatment (Josamycin) in Case of Positive PCR for Ureaplasma Spp and/or Mycoplasma Hominis in Amniotic Fluid|Completed||Phase 3|3200|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:55:51.487376|2018-06-01 01:55:51.487376
NCT00718692|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18||2015-11-25|2018-02-13|2008-07-18|2008-07-21|Estimate||||2016-04-11|2016-05-12|Estimate|2018-02-13|2018-02-15|Actual|July 2008||2008-07-31|February 2018|2018-02-28|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)|A Multi-centre, Single Intravenous Dose, Exploratory Dose-finding, Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) in RhD Positive, Non-splenectomized Adult Subjects.|Completed||Phase 2|61|Actual|Symphogen A/S||1|||f||||t||||||||No||2018-06-01 01:55:51.573388|2018-06-01 01:55:51.573388
NCT00718679|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-18|||2010-02-10|2008-07-18|2008-07-21|Estimate|||||||2010-02-10|2010-02-11|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|IVN-CAT-001B||Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial|Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial|Completed||Phase 1|20|Anticipated|University of Zurich||2|||f||||f||||||||||2018-06-01 01:55:51.707815|2018-06-01 01:55:51.707815
NCT00718666|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17||2013-12-05|2016-08-08|2008-07-18|2008-07-21|Estimate||||2013-12-05|2013-12-30|Estimate|2016-08-08|2016-08-09|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers|Long Term Antibody Persistence Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered as 1 or 2 Doses to Healthy Toddlers at 9-12 Months of Age and as a Booster Dose at 5 Years Post-primary Vaccination|Completed||Phase 2|387|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:55:51.771451|2018-06-01 01:55:51.771451
NCT00718653|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2009-02-27|2008-07-17|2008-07-21|Estimate|||||||2009-02-27|2009-03-03|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Antioxidants on Human Macular Pigments|Effects of Antioxidants on Human Macular Pigments|Completed||N/A|40|Actual|National Eye Institute (NEI)||2|||f||||f||||||||||2018-06-01 01:55:52.011109|2018-06-01 01:55:52.011109
NCT00718640|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2013-06-21||2013-09-25|2008-07-17|2008-07-21|Estimate|2013-06-21|2013-08-28|Estimate||||2013-09-25|2013-10-29|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function|Safety and Efficacy of Velcade in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function|Terminated||Phase 2|10|Actual|Janssen-Ortho Inc., Canada|Participants’ recruitment was limited due to pre-defined criteria of renal disease and requirement of repeated evaluation of creatinine clearance. Due to insufficient number of participants the outcome measure data was not analyzed.|1||Study stopped due to lagging enrolment.|f||||f||||||||||2018-06-01 01:55:52.101452|2018-06-01 01:55:52.101452
NCT00718627|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2016-02-05|2008-07-17|2008-07-18|Estimate|||||||2016-02-05|2016-02-08|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders|Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children With Urea Cycle Disorders (UCDs)|Completed||Phase 2|12|Actual|Cytonet GmbH & Co. KG||1|||f||||t||||||||||2018-06-01 01:55:52.335401|2018-06-01 01:55:52.335401
NCT00718614|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2014-11-24|2008-07-16|2008-07-18|Estimate|||||||2014-11-24|2014-11-25|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With Insulin-dependent Diabetes Mellitus (IDDM)|Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With IDDM|Terminated||N/A|80|Anticipated|Medical University of Vienna||4|||f||||t||||||||||2018-06-01 01:55:52.404434|2018-06-01 01:55:52.404434
NCT00718601|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-12-22|2008-07-17|2008-07-18|Estimate|||||||2015-12-22|2015-12-24|Estimate|July 2008||2008-07-31|December 2015|2015-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma|A Phase I Study of GRN163L in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|40|Anticipated|Geron Corporation||1|||f||||f||||||||||2018-06-01 01:55:52.52939|2018-06-01 01:55:52.52939
NCT00718588|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2012-03-06|2008-07-16|2008-07-18|Estimate|||||||2012-03-06|2012-03-07|Estimate|July 2008||2008-07-31|March 2012|2012-03-31||||December 2009|Actual|2009-12-31||Interventional|||A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A in Patients With Rheumatoid Arthritis|Terminated||Phase 1|66|Actual|Genentech, Inc.||||"Study had completed enrollment but drug injection was halted due to an unacceptable incidence~   of rash."|f||||||||||||||2018-06-01 01:55:52.599989|2018-06-01 01:55:52.599989
NCT00718575|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2014-07-24|2008-07-16|2008-07-18|Estimate|||||||2014-07-24|2014-07-25|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|June 2010|Actual|2010-06-30||Interventional|||The Effects of Glucose/Ischemic Preconditioning on Reperfusion Injury in Deceased-Donor Liver Transplantation|A Prospective, Randomized Trial to Investigate the Effects of Glucose/ Ischemic Preconditioning Donor Pre-treatment on Reperfusion Injury in Deceased-Donor Liver Transplantation|Terminated||Phase 3|50|Actual|University Health Network, Toronto||2||too few patients meeting current eligibility criteria|f||||f||||||||||2018-06-01 01:55:52.65543|2018-06-01 01:55:52.65543
NCT00718562|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2017-02-20|2008-07-17|2008-07-18|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2008||2008-09-30|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib|A Multi-center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib|Completed||Phase 2|35|Actual|Novartis||1|||f||||f||||||||||2018-06-01 01:55:52.72663|2018-06-01 01:55:52.72663
NCT00718549|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2016-11-01|2008-07-16|2008-07-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia|A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With MabThera vs no Treatment, After Induction With MabThera, Cladribine and Cyclophosphamide on Progression-free Survival in Previously Untreated Patients With Progressive B-CLL. The Trial Conducted With PALG Sites|Completed||Phase 3|128|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:55:52.810558|2018-06-01 01:55:52.810558
NCT00718536|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2009-04-08|2008-07-17|2008-07-18|Estimate|||||||2009-04-08|2009-04-10|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy|Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy|Completed||Phase 4|15|Anticipated|Germans Trias i Pujol Hospital||1|||f||||f||||||||||2018-06-01 01:55:52.890034|2018-06-01 01:55:52.890034
NCT00718523|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2015-10-22||2015-12-08|2008-07-17|2008-07-18|Estimate|2015-12-08|2016-01-12|Estimate||||2015-12-08|2016-01-12|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|September 2013|Actual|2013-09-30||Interventional|||Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer|A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer|Terminated||Phase 2|170|Actual|Translational Research in Oncology||2||The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial.|f||||t||||||||||2018-06-01 01:55:52.999858|2018-06-01 01:55:52.999858
NCT00718510|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2017-05-01||2017-09-01|2008-07-17|2008-07-18|Estimate|2017-09-01|2017-09-05|Actual||||2017-09-01|2017-09-05|Actual|September 2009||2009-09-30|September 2017|2017-09-30|October 2012|Actual|2012-10-31|July 2011|Actual|2011-07-31||Interventional|||L-arginine in Treatment as Usual in Schizophrenia|A Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia|Completed||N/A|13|Actual|University of Alberta||2|||f||||t||||||||No||2018-06-01 01:55:54.272491|2018-06-01 01:55:54.272491
NCT00718497|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-03-01|2008-07-16|2008-07-18|Estimate|||||||2013-03-01|2013-03-05|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population|Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population|Completed|||25|Actual|Drexel University|||1||f||||f||||||||||2018-06-01 01:55:54.747925|2018-06-01 01:55:54.747925
NCT00718484|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2014-01-29|2008-07-17|2008-07-18|Estimate|||||||2014-01-29|2014-01-30|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|April 2012|Actual|2012-04-30||Interventional|PICASSO||A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma|A Phase II Multicenter, Parallel Group, Randomized Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Subjects With Unresectable or Metastatic Soft-tissue Sarcoma|Unknown status|Active, not recruiting|Phase 2|67|Actual|Ziopharm||2|||f||||f||||||||||2018-06-01 01:55:54.812083|2018-06-01 01:55:54.812083
NCT00718471|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2012-12-17|2008-07-17|2008-07-18|Estimate|||||||2012-12-17|2012-12-18|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|ATOLL||STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)|Acute STEMI Treated With Primary Angioplasty and Intravenous 0.5 mg/kg Lovenox or UFH to Lower Ischemic and Bleeding Events|Completed||Phase 3|910|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:55:54.911464|2018-06-01 01:55:54.911464
NCT00718458|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2017-03-28|2008-07-16|2008-07-18|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2007||2007-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|BCI||EEG-Based Brain-Computer Interface Project for Individuals With Amyotrophic Lateral Sclerosis (ALS)|EEG-Based Brain-Computer Interface Project for Individuals With ALS|Completed|||102|Actual|Drexel University|||2||f||||f||||||||||2018-06-01 01:55:55.053142|2018-06-01 01:55:55.053142
NCT00718445|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2016-06-23|2008-07-16|2008-07-18|Estimate|||||||2016-06-23|2016-06-27|Estimate|March 2008||2008-03-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Pennsylvania Consortium: Clinical Database|Pennsylvania Consortium: Clinical Database|Terminated|||25|Actual|Drexel University|||1|Terminated due to lack of funding and support staff|f||||f||||||||||2018-06-01 01:55:55.160119|2018-06-01 01:55:55.160119
NCT00718419|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16||2011-06-13|2012-09-07|2008-07-16|2008-07-18|Estimate||||2011-06-13|2011-06-27|Estimate|2012-09-07|2012-09-11|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|September 2010|Actual|2010-09-30||Interventional|||A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma|An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma|Completed||Phase 2|46|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:55:55.442554|2018-06-01 01:55:55.442554
NCT00718406|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2008-07-16|2008-07-16|2008-07-18|Estimate|||||||2008-07-16|2008-07-18|Estimate||||August 2002|2002-08-31||||||||Interventional|||Pain Relief of Metoprolol Versus Metoprolol Plus Morphine in Acute Chest Pain||Completed||Phase 4|||Sahlgrenska University Hospital, Sweden||2|||f||||||||||||||2018-06-01 01:55:55.779383|2018-06-01 01:55:55.779383
NCT00718393|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2017-03-07|2008-07-16|2008-07-18|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2007||2007-06-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Compassionate Use of Ceftriaxone in Patients With Amyotrophic Lateral Sclerosis (ALS)|Compassionate Use of Ceftriaxone in Patients With ALS|Completed|||1|Actual|Drexel University|||1||f||||f||||||||No||2018-06-01 01:55:56.045057|2018-06-01 01:55:56.045057
NCT00718380|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2017-11-17|2008-07-17|2008-07-18|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2008||2008-09-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Phase 1 Study of ABT-869 in Subjects With Solid Tumors|An Open Label, Phase I Study Evaluating Pharmacokinetics, Safety, and Tolerability of ABT-869 in Subjects With Solid Tumors|Completed||Phase 1|18|Actual|AbbVie||4|||f||||||||||||||2018-06-01 01:55:56.171713|2018-06-01 01:55:56.171713
NCT00718367|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2014-01-13|2008-07-17|2008-07-18|Estimate|||||||2014-01-13|2014-01-14|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|||||Observational|||Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens|Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens|Completed|||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 01:55:56.251764|2018-06-01 01:55:56.251764
NCT00718354|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-05-12|2008-07-17|2008-07-18|Estimate|||||||2015-05-12|2015-05-13|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|GASTRANOX||Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT|Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer|Completed||Phase 3|740|Actual|Thrombosis Research Institute||2|||f||||t||||||||||2018-06-01 01:55:56.309074|2018-06-01 01:55:56.309074
NCT00718341|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2010-05-05|2008-07-17|2008-07-18|Estimate|||||||2010-05-05|2010-05-06|Estimate|June 2008||2008-06-30|May 2010|2010-05-31||||February 2009|Actual|2009-02-28||Interventional|||Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients|A Multi-centre, Randomized, Double-blind, Placebo Controlled, Two-period, Crossover Proof-of-concept Study in Male Patients With Fragile X Syndrome to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of AFQ056|Completed||Phase 2|30|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:55:56.414511|2018-06-01 01:55:56.414511
NCT00718328|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2017-05-07||2017-09-08|2008-07-16|2008-07-18|Estimate|2017-05-07|2017-06-12|Actual||||2017-09-08|2017-10-09|Actual|October 2008||2008-10-31|September 2017|2017-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Simvastatin For Intracerebral Hemorrhage Study|Simvastatin For Intracerebral Hemorrhage Study|Terminated||Phase 2|1|Actual|Johns Hopkins University||2||Poor recruitment, trial terminated|f||||t||||||||||2018-06-01 01:55:56.479438|2018-06-01 01:55:56.479438
NCT00718315|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2015-01-09||2015-01-09|2008-07-16|2008-07-18|Estimate|2015-01-09|2015-01-15|Estimate||||2015-01-09|2015-01-15|Estimate|April 2009||2009-04-30|January 2015|2015-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Intention to treat (ITT) population covered all participants who had at least one application of study drug and who had at least one post-treatment assessment, irrespective of compliance extent with protocol criteria.|A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.|A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer.|Completed||Phase 3|201|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:55:56.840093|2018-06-01 01:55:56.840093
NCT00718302|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2015-01-28||2017-02-14|2008-07-17|2008-07-18|Estimate|2017-02-14|2017-03-29|Actual||||2017-02-14|2017-03-29|Actual|June 2008||2008-06-30|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Multicenter Randomized Trial Comparing Antiglide and Lateral Plate Fixation in Ankle Fractures|Ankle Fracture Plating: A Multicenter Randomized Trial Comparing Lateral and Antiglide Plating in Displaced Lateral Malleolus Fractures|Completed||N/A|249|Actual|Boston Medical Center||2|||f||||t||||||||No||2018-06-01 01:55:57.601657|2018-06-01 01:55:57.601657
NCT00718289|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2008-07-17|2008-07-17|2008-07-18|Estimate|||||||2008-07-17|2008-07-18|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes|Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes|Completed||Phase 4|25|Actual|Ospedale Regionale di Locarno||2|||f||||f||||||||||2018-06-01 01:55:57.968708|2018-06-01 01:55:57.968708
NCT00718276|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2011-12-22|2008-07-17|2008-07-18|Estimate|||||||2011-12-22|2011-12-23|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Pharmacokinetic Study: Effect of 25(OH)D and Vitamin D3 on Serum 25(OH)D|Pharmacokinetic Study in Healthy Postmenopausal Women to Compare Supplementation of Vitamin D3 to 25(OH)D|Completed||Phase 1|35|Actual|University of Zurich||2|||f||||t||||||||||2018-06-01 01:55:58.055838|2018-06-01 01:55:58.055838
NCT00718263|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2017-10-23|2008-07-16|2008-07-18|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2008||2008-04-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PHCHBS-WD4070||Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)|Extension Study to a Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Recruiting||Phase 3|90|Anticipated|Novartis||2|||f||||||||||||||2018-06-01 01:55:58.143452|2018-06-01 01:55:58.143452
NCT00718250|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2008-07-16|2008-07-16|2008-07-18|Estimate|||||||2008-07-16|2008-07-18|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|February 2012|Anticipated|2012-02-29|May 2011|Anticipated|2011-05-31||Interventional|RFUSIN2-AML1||Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2|A Phase I Study of Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) Expressing B7.1 (CD80) and IL-2 for the Potential Enhancement of Graft Versus Leukaemia(GvL) Effect in Poor Prognosis AML|Unknown status|Recruiting|Phase 1|24|Anticipated|King's College Hospital NHS Trust||4|||f||||t||||||||||2018-06-01 01:55:58.462566|2018-06-01 01:55:58.462566
NCT00718237|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2010-06-23||2017-03-16|2008-07-16|2008-07-18|Estimate|2010-06-23|2010-07-23|Estimate||||2017-03-16|2017-04-13|Actual|August 2008||2008-08-31|March 2017|2017-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)|A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of V260 in Healthy Infants in Japan|Completed||Phase 3|762|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:55:58.781776|2018-06-01 01:55:58.781776
NCT00718224|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17||2010-12-20|2013-01-14|2008-07-17|2008-07-18|Estimate||||2010-12-20|2010-12-28|Estimate|2013-01-14|2013-01-23|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|SAVE-KNEE||Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery|A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of Semuloparin (AVE5026) With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery|Completed||Phase 3|1150|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:55:59.0724|2018-06-01 01:55:59.0724
NCT00718211|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2008-07-18|2008-07-17|2008-07-18|Estimate|||||||2008-07-18|2008-07-21|Estimate|May 2006||2006-05-31|July 2008|2008-07-31||||||||Observational|||A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore|A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore.|Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 01:55:59.162271|2018-06-01 01:55:59.162271
NCT00718198|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2009-02-10|2008-07-16|2008-07-18|Estimate|||||||2009-02-10|2009-02-11|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Observational|||Effects of a Computerized Physician Order Entry (CPOE)-Based Inpatient Insulin Protocol on Glycemic Outcomes|Effects of a Computerized Physician Order Entry (CPOE)-Based Inpatient Insulin Protocol on Glycemic Outcomes|Completed|||413|Actual|John H. Stroger Hospital|||2||f||||f||||||||||2018-06-01 01:55:59.2092|2018-06-01 01:55:59.2092
NCT00718185|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-03-11|2008-07-17|2008-07-18|Estimate|||||||2015-03-11|2015-03-12|Estimate|May 2008||2008-05-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|||Pharmacokinetics and Pharmacdynamics of Sildenafil|The Pharmacokinetics and Pharmacodynamics of Sildenafil in Pediatric and Adult Patients|Terminated|||9|Actual|Children's Hospital of Philadelphia|||1|Similar study completed.|f||||f||||||Samples Without DNA|"~     Blood specimens~   "|||2018-06-01 01:55:59.266151|2018-06-01 01:55:59.266151
NCT00718172|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2018-05-19|2008-07-17|2008-07-18|Estimate|||||||2018-05-19|2018-05-22|Actual|July 11, 2008||2008-07-11|August 19, 2014|2014-08-19|August 19, 2014|Actual|2014-08-19|||||Interventional|||Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C|Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C|Completed||Phase 1|81|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:55:59.32134|2018-06-01 01:55:59.32134
NCT00718159|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2012-02-10|2008-07-16|2008-07-18|Estimate|||||||2012-02-10|2012-02-13|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia|Phase 1 Study of LY573636-sodium in Patients With Essential Thrombocythemia and Acute Myeloid Leukemia|Completed||Phase 1|45|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 01:55:59.385833|2018-06-01 01:55:59.385833
NCT00718146|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2014-01-16|2008-07-16|2008-07-18|Estimate|||||||2014-01-16|2014-01-17|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)|Completed||Phase 2|130|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:55:59.583253|2018-06-01 01:55:59.583253
NCT00718133|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2010-09-13|2008-07-17|2008-07-18|Estimate|||||||2010-09-13|2010-09-14|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2009|Actual|2009-08-31||Interventional|||The Effect of Air Pollution on Lung Health Among Children Living in Haifa Bay Region, Israel|The Effect of Air Pollution on Lung Health Among Children Living in Haifa Bay Region, Israel.|Completed||N/A|15|Actual|Carmel Medical Center||1|||f||||f||||||||||2018-06-01 01:55:59.660305|2018-06-01 01:55:59.660305
NCT00718120|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|2009-07-16||2016-10-26|2008-07-17|2008-07-18|Estimate|2009-07-16|2009-08-25|Estimate||||2016-10-26|2016-12-08|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years|Immunogenicity and Safety Study of a Single Injection of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2008 - 2009 Season) in Adults Aged 18 to 60 Years and Over 60 Years.|Completed||Phase 3|110|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:55:59.760521|2018-06-01 01:55:59.760521
NCT00718107|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-03-01|2008-07-16|2008-07-18|Estimate|||||||2013-03-01|2013-03-05|Estimate|June 2005||2005-06-30|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Satisfaction Survey for Amyotrophic Lateral Sclerosis (ALS) Patients Comparing Rooms With and Without Assistive Technology|Satisfaction Survey for ALS Patients Comparing Rooms With and Without Assistive Technology|Terminated|||5|Actual|Drexel University|||1|"The study was discontinued due to low enrollment. A survey has been implemented in place of a~   formal study."|f||||f||||||||||2018-06-01 01:56:00.145002|2018-06-01 01:56:00.145002
NCT00718094|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2017-04-12||2017-11-14|2008-07-16|2008-07-18|Estimate|2017-11-14|2017-12-14|Actual||||2017-11-14|2017-12-14|Actual|March 2008||2008-03-31|November 2017|2017-11-30|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis|A Phase IIa Pilot Study to Determine the Safety of an Oral Dose of Green Tea Extract (Polyphenon E®) and Provide Preliminary Evidence to Support Its Efficacy in Ulcerative Colitis|Completed||Phase 2|20|Actual|University of Louisville||2|||f||||t||||||||||2018-06-01 01:56:00.206339|2018-06-01 01:56:00.206339
NCT00718081|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2013-10-18||2014-12-18|2008-07-16|2008-07-18|Estimate|2014-12-18|2015-01-22|Estimate||||2014-12-18|2015-01-22|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery|A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery|Completed||Phase 2|88|Actual|AcelRx Pharmaceuticals, Inc.||3|||f||||||||||||||2018-06-01 01:56:00.510416|2018-06-01 01:56:00.510416
NCT00718068|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2010-07-26|2008-07-16|2008-07-18|Estimate|||||||2010-07-26|2010-07-27|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|ASPIC||Safety of Continuous Potassium Chloride Infusion in Critical Care|Assessing the Safety of a Continuous Potassium Chloride Infusion in Critical Care: A Randomised Controlled Trial|Completed||Phase 4|160|Actual|The Queen Elizabeth Hospital||2|||f||||f||||||||||2018-06-01 01:56:00.913733|2018-06-01 01:56:00.913733
NCT00718055|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2009-02-09|2008-07-17|2008-07-18|Estimate|||||||2009-02-09|2009-02-10|Estimate|November 2006||2006-11-30|February 2009|2009-02-28||||||||Observational|||Magnetic Resonance Imaging (MRI) Using Liverspecific Oral Contrast Agent in Metastatic Colorectal Cancer Patients|MR Skanning Med Leverspecifikt Oralt Kontraststof Sammenlignet Med CT Skanning Hos Colorectalcancer Patienter Med Levermetastaser|Withdrawn|||50|Anticipated|Copenhagen University Hospital at Herlev|||||f||||||||||||||2018-06-01 01:56:00.988547|2018-06-01 01:56:00.988547
NCT00718042|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2011-12-16||2012-03-02|2008-07-16|2008-07-18|Estimate|2011-12-16|2012-01-23|Estimate||||2012-03-02|2012-03-07|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Evaluation of Chagas Blood Screening and Confirmatory Assays|Evaluation of ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Completed||N/A|41862|Actual|Abbott Diagnostics Division||2|||f||||f||||||||||2018-06-01 01:56:01.085442|2018-06-01 01:56:01.085442
NCT00718029|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2008-07-23|2008-07-17|2008-07-18|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2008||2008-07-31|July 2008|2008-07-31||||July 2009|Anticipated|2009-07-31||Observational|||Cerebrospinal Fluid (CSF) Raltegravir Substudy|MK: Raltegravir Concentrations in Cerebrospinal Fluid|Unknown status|Enrolling by invitation||15|Anticipated|University of California, San Diego|||||f||||||||||Samples With DNA|"~     CSF, PBMC, plasma~   "|||2018-06-01 01:56:01.625183|2018-06-01 01:56:01.625183
NCT00718016|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-03-01|2008-07-16|2008-07-18|Estimate|||||||2013-03-01|2013-03-05|Estimate|December 2004||2004-12-31|March 2013|2013-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Assessment of the Cyberlink Control System for Use by the Amyotrophic Lateral Sclerosis (ALS) Patient|Assessment of the Cyberlink Control System for Use by the ALS Patient|Terminated|||1|Actual|Drexel University|||1|New protocol was developed based on preliminary results from this study.|f||||f||||||||||2018-06-01 01:56:01.672708|2018-06-01 01:56:01.672708
NCT00718003|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-03-01|2008-07-16|2008-07-18|Estimate|||||||2013-03-01|2013-03-05|Estimate|May 2005||2005-05-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).|Noninvasive Examination of the Work of Breathing in Patients With Amyotrophic Lateral Sclerosis (ALS).|Terminated|||10|Actual|Drexel University|||1|Terminated due to difficulty enrolling subjects.|f||||f||||||||||2018-06-01 01:56:01.731795|2018-06-01 01:56:01.731795
NCT00717990|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-10-06|2008-07-16|2008-07-18|Estimate|||||||2015-10-06|2015-10-07|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment|A Phase II Study of Irinotecan, Capecitabine and Avastin in Patients With Metastatic Colorectal Cancer, Who Have Progressed After 1ST Line Therapy With Folfox/Avastin.|Terminated||Phase 2|15|Actual|University Hospital of Crete||1||Poor Accrual|f||||f||||||||||2018-06-01 01:56:01.783755|2018-06-01 01:56:01.783755
NCT00717977|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2010-08-02||2016-09-02|2008-07-16|2008-07-18|Estimate|2010-09-30|2010-10-18|Estimate||||2016-09-02|2016-10-19|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Continuous Glucose Sensor Profiles in Non-Diabetic Subjects|A Study to Assess Continuous Glucose Sensor Profiles in Healthy Non-Diabetic Subjects|Completed||Phase 4|74|Actual|Jaeb Center for Health Research|||||f||||t||||||||||2018-06-01 01:56:01.874131|2018-06-01 01:56:01.874131
NCT00717951|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-24|2008-07-17|2008-07-18|Estimate|||||||2008-07-24|2008-07-25|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Interventional|||A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer|A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer|Unknown status|Active, not recruiting|Phase 2|120|Actual|Academy Military Medical Science, China||2|||f||||t||||||||||2018-06-01 01:56:02.509693|2018-06-01 01:56:02.509693
NCT00717938|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2017-08-24|2008-07-16|2008-07-18|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2008||2008-06-30|September 2016|2016-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|RASTEN||A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer|A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer|Completed||Phase 3|390|Actual|Lund University Hospital||2|||f||||f||||||||||2018-06-01 01:56:02.586058|2018-06-01 01:56:02.586058
NCT00717925|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-12-07|2008-07-17|2008-07-18|Estimate|||||||2015-12-07|2015-12-09|Estimate|March 2007||2007-03-31|December 2015|2015-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)|A Phase 1 Study Of CMC-544 Administered As A Single Agent In Subjects With B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 1|13|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||t||||||||||2018-06-01 01:56:02.680423|2018-06-01 01:56:02.680423
NCT00717912|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2012-11-29||2017-07-12|2008-07-17|2008-07-18|Estimate|2017-07-12|2017-07-13|Actual||||2017-07-12|2017-07-13|Actual|July 2008||2008-07-31|July 2017|2017-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Determination of the Glycemic Index and the Insulinemic Index of a Sweetener Syrup|Determination of the Glycemic Index and the Insulinemic Index of a Sweetener|Completed||N/A|6|Actual|Routin SA||6|||f||||t||||||||||2018-06-01 01:56:02.763803|2018-06-01 01:56:02.763803
NCT00717899|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2010-09-13|2008-07-17|2008-07-18|Estimate|||||||2010-09-13|2010-09-14|Estimate|December 2008||2008-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2009|Actual|2009-08-31||Interventional|||The Effect of Air Pollution on Lung Health Among School Children Living in Haifa Bay Region|The Effect of Air Pollution on Lung Health Among School Children Living in Haifa Bay Region|Completed||N/A|1200|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-06-01 01:56:02.96703|2018-06-01 01:56:02.96703
NCT00717886|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2015-10-19||2015-10-19|2008-07-16|2008-07-18|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Upper Extremity Lymphatic Mapping for Breast Cancer Patients|Upper Extremity Lymphatic Mapping for Breast Cancer Patients: A Pilot Study|Completed||N/A|13|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:56:03.044165|2018-06-01 01:56:03.044165
NCT00717873|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2015-08-25||2017-07-07|2008-07-16|2008-07-18|Estimate|2015-08-25|2015-09-25|Estimate||||2017-07-07|2017-08-07|Actual|June 2008||2008-06-30|July 2017|2017-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of High-Frequency Chest Wall Oscillation|Evaluation of High-Frequency Chest Wall Oscillation Using the Vest Airway Clearance System Compared to Conventional Chest Physical Therapy at Barnes-Jewish Hospital|Completed||N/A|105|Actual|Hill-Rom||2|||f||||f||||||||||2018-06-01 01:56:04.164672|2018-06-01 01:56:04.164672
NCT00717860|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2011-07-28||2017-02-20|2008-07-16|2008-07-18|Estimate|2011-07-28|2011-08-26|Estimate||||2017-02-20|2017-03-23|Actual|August 2008||2008-08-31|February 2017|2017-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)|A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections|Completed||Phase 3|121|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:56:04.345185|2018-06-01 01:56:04.345185
NCT00717847|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2013-12-10|2008-07-17|2008-07-18|Estimate|||||||2013-12-10|2013-12-11|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib|A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib|Completed|||||National University Hospital, Singapore|||2||f||||||||||||||2018-06-01 01:56:04.678746|2018-06-01 01:56:04.678746
NCT00717834|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-17|||2015-10-07|2008-07-17|2008-07-18|Estimate|||||||2015-10-07|2015-10-09|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine|A Blinded Phase 1/2 Dose Escalation Study to Assess Safety and Immunogenicity and Investigate the Optimal Dose Level of a Formalin-Treated, UV-Inactivated, Vero Cell-Derived Ross River Virus (RRV) Vaccine in Healthy Volunteers Aged 18 to 40 Years|Completed||Phase 1/Phase 2|400|Anticipated|Ology Bioservices||8|||f||||t||||||||||2018-06-01 01:56:04.738189|2018-06-01 01:56:04.738189
NCT00717821|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2013-10-07|2008-07-16|2008-07-18|Estimate|||||||2013-10-07|2013-10-08|Estimate|October 2008||2008-10-31|October 2013|2013-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of Once Monthly Intravenous or Subcutaneous Mircera in Patients With Chronic Kidney Disease on Hemodialysis.|A Randomized, Controlled, Open Label, French Multicenter Parallel Group Study to Compare the Hemoglobin Maintenance With Once Monthly Administration of Mircera Versus Epoetin Beta or Darbepoetin Alfa in Patients With Chronic Kidney Disease on Hemodialysis|Completed||Phase 3|421|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:56:04.968671|2018-06-01 01:56:04.968671
NCT00717808|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2015-05-27|2008-07-16|2008-07-18|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2008||2008-09-30|September 2011|2011-09-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)|A Phase 1, Blinded, Randomised, Crossover Pilot Study to Investigate the Safety, Tolerability and Pharmacokinetics of Tranilast in Patients With Rheumatoid Arthritis on Methotrexate|Withdrawn||Phase 1|0|Actual|Imperial College London||2||Due to unforeseen circumstances this study will not now start.|f||||f||||||||||2018-06-01 01:56:05.167508|2018-06-01 01:56:05.167508
NCT00717795|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2018-05-21|2008-07-17|2008-07-18|Estimate|||||||2018-05-21|2018-05-22|Actual|June 2008||2008-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Physical Activity Intervention for Lung Cancer Survivors|Physical Activity Intervention for Lung Cancer Survivors|Active, not recruiting|||52|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 01:56:05.255168|2018-06-01 01:56:05.255168
NCT00717782|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2008-07-17|2008-07-17|2008-07-18|Estimate|||||||2008-07-17|2008-07-18|Estimate|January 2003||2003-01-31|July 2008|2008-07-31|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||Pain Relief for Thrombosed External Haemorrhoids|Randomized Clinical Trial of Botulinum Toxin Injection for Pain Relief in Patients With Thrombosed External Haemorrhoids|Completed||Phase 4|30|Actual|University of Palermo||2|||f||||f||||||||||2018-06-01 01:56:05.334081|2018-06-01 01:56:05.334081
NCT00717769|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16||2011-04-04|2015-10-19|2008-07-16|2008-07-17|Estimate||||2011-04-04|2011-04-12|Estimate|2015-10-19|2015-11-06|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis|Completed||Phase 2|270|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 01:56:05.415762|2018-06-01 01:56:05.415762
NCT00717756|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2014-02-20||2014-06-26|2008-07-15|2008-07-17|Estimate|2014-02-20|2014-04-03|Estimate||||2014-06-26|2014-07-11|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial|Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial|Completed||Phase 2|41|Actual|Brown University||1|||f||||t||||||||||2018-06-01 01:56:05.834197|2018-06-01 01:56:05.834197
NCT00717743|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2010-04-07|2008-07-16|2008-07-17|Estimate|||||||2010-04-07|2010-04-09|Estimate|March 2007||2007-03-31|April 2010|2010-04-30||||||||Observational|||T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)|T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)|Completed|||||National University Hospital, Singapore|||1||f||||||||||||||2018-06-01 01:56:06.12129|2018-06-01 01:56:06.12129
NCT00717730|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-07-27|2008-07-16|2008-07-17|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Folic Acid and Vitamin B12 in Young Indian Children|Routine Administration of Folic Acid and Vitamin B12 to Prevent Childhood Infections in Young Indian Children|Completed||Phase 2|1000|Actual|Centre For International Health||4|||f||||t||||||||||2018-06-01 01:56:06.239831|2018-06-01 01:56:06.239831
NCT00717717|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2015-10-26|2008-07-16|2008-07-17|Estimate|||||||2015-10-26|2015-10-28|Estimate|November 2006||2006-11-30|October 2015|2015-10-31|February 2012|Actual|2012-02-29|February 2010|Actual|2010-02-28||Interventional|PACT||A Clinical Controlled Trial on the Effect of Physical Activity After Cancer Treatment (PACT)|Physical Activity After Cancer Treatment (PACT)- A Clinical Controlled Trial on the Effect of a One-year Physical Activity Program for Cancer Patients Following Cytostatic Treatment|Completed||N/A|214|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 01:56:06.393478|2018-06-01 01:56:06.393478
NCT00717678|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2015-12-16|2008-07-16|2008-07-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2007||2007-12-31|December 2015|2015-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients|A Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF and Extended Release (XL) Tacrolimus /MMF in de Novo Kidney Transplant Recipients|Completed||Phase 3|73|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 01:56:06.735139|2018-06-01 01:56:06.735139
NCT00717665|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2011-06-24|2008-07-15|2008-07-17|Estimate|||||||2011-06-24|2011-06-28|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Self-monitoring of Blood Pressure in Primary Care|Self-monitoring of Blood Pressure in Primary Care in Older Diabetic Patients With Uncontrolled Systolic Hypertension|Completed||N/A|110|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 01:56:06.829916|2018-06-01 01:56:06.829916
NCT00717652|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2010-10-22|2008-07-16|2008-07-17|Estimate|||||||2010-10-22|2010-10-25|Estimate|July 2008||2008-07-31|July 2008|2008-07-31||||July 2008|Anticipated|2008-07-31||Interventional|melasma||Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma|Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).|Suspended||Phase 2/Phase 3|110|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:56:06.931249|2018-06-01 01:56:06.931249
NCT00717639|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2011-08-05|2008-07-15|2008-07-17|Estimate|||||||2011-08-05|2011-08-08|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Vasovist Magnetic Resonance Angiography (MRA) in Peripheral Arterial Occlusive Disease|Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients With Peripheral Artery Disease|Terminated||Phase 4|150|Anticipated|Heidelberg University||1||Required contrast media (Vasovist) withdrawn from market|f||||f||||||||||2018-06-01 01:56:07.037247|2018-06-01 01:56:07.037247
NCT00717626|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-12-17|2008-07-15|2008-07-17|Estimate|||||||2013-12-17|2013-12-19|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A|Pilot Study of Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A|Completed||Phase 2|14|Actual|The Hospital for Sick Children||1|||f||||t||||||||||2018-06-01 01:56:07.144049|2018-06-01 01:56:07.144049
NCT00717613|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2018-01-18|2008-07-16|2008-07-17|Estimate|||||||2018-01-18|2018-01-23|Actual|July 2007||2007-07-31|January 2018|2018-01-31|October 2011|Actual|2011-10-31|October 2009|Actual|2009-10-31||Observational|||Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting|Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting|Completed|||50|Actual|Baylor College of Medicine|||1||f||||f||||||||||2018-06-01 01:56:07.207298|2018-06-01 01:56:07.207298
NCT00717600|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2008-07-16|2008-07-16|2008-07-17|Estimate|||||||2008-07-16|2008-07-17|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|BERP||Bacteriuria Eradication Through Probiotics|Bacteriuria Eradication Through Probiotics|Unknown status|Enrolling by invitation|Phase 1|10|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 01:56:07.274812|2018-06-01 01:56:07.274812
NCT00717587|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2014-01-09|2008-07-16|2008-07-17|Estimate|||||||2014-01-09|2014-01-10|Estimate|June 2008||2008-06-30|January 2009|2009-01-31||||July 2010|Anticipated|2010-07-31||Interventional|||Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer|A Histopathologic and Imaging Study of Renal Cell Carcinoma Vasculature in the Setting of Sunitinib Therapy Prior to Cytoreductive Nephrectomy|Unknown status|Recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:56:07.460071|2018-06-01 01:56:07.460071
NCT00717574|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2017-04-07||2017-06-29|2008-07-16|2008-07-17|Estimate|2017-05-26|2017-06-28|Actual||||2017-06-29|2017-07-31|Actual|March 2008||2008-03-31|June 2017|2017-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|N20||Addition of Nitrous Oxide and Its Effects on Depth of Anesthesia|Addition of Nitrous Oxide to a Sevoflurane or Propofol Based Anesthetic and Its Effects on Depth of Anesthesia Indices (N20)|Completed||N/A|32|Actual|University of Oklahoma|"We did not measure the blood concentrations of Sevoflurane.~Variety of surgical procedures might have lead to different levels of noxious stimuli.~Noxious stimuli and administration of opioids may affect EEG-derived indices."|2|||f||||t||||||||No||2018-06-01 01:56:07.550984|2018-06-01 01:56:07.550984
NCT00717561|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2014-11-02|2008-07-16|2008-07-17|Estimate|||||||2014-11-02|2014-11-04|Estimate|February 2008||2008-02-29|October 2014|2014-10-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia|A National, Prospective, Randomized, Open Label Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin vs IV Ceftriaxone + IV Azithromycin Followed by PO Amoxicilline/Clavulanate and PO Clarithromycin in Subjects With Community-acquired Pneumonia|Completed||Phase 3|60|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:56:07.860935|2018-06-01 01:56:07.860935
NCT00717548|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2012-11-02|2008-07-15|2008-07-17|Estimate|||||||2012-11-02|2012-11-05|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy of Narrative Exposure Therapy (NET) in Treating Women After Human Trafficking or Forced Prostitution|The Effectiveness of Narrative Exposure Therapy in Treating Women After Trafficking and Forced Prostitution|Completed||N/A|10|Actual|University of Konstanz||1|||f||||f||||||||||2018-06-01 01:56:07.983013|2018-06-01 01:56:07.983013
NCT00717535|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2013-04-25|2008-07-16|2008-07-17|Estimate|||||||2013-04-25|2013-04-29|Estimate|August 2005||2005-08-31|April 2013|2013-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Studying Umbilical Cord Blood From African-American Donors|Investigation of the Total Nucleated Cell Yield of Cord Blood Units Collected From African-American Donors in Correlation With Gestational and Other Health Variables|Withdrawn|||0|Actual|Barbara Ann Karmanos Cancer Institute||||Funding unavailable|f||||t||||||None Retained|"~     Cord blood unit (CBU)will be collected in utero and transported to the Stem Cell Processing~     Laboratory. The volume of the CBU will be measured and cell count will be obtained.~   "|||2018-06-01 01:56:08.07725|2018-06-01 01:56:08.07725
NCT00717522|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2013-03-06|2012-10-08|2013-03-06|2008-07-16|2008-07-17|Estimate|2013-03-06|2013-04-16|Estimate|2012-10-08|2012-10-11|Estimate|2013-03-06|2013-04-16|Estimate|August 2008||2008-08-31|March 2013|2013-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma|A Phase 2, Multicenter, Open-label, Single Arm, Two-stage Study to Evaluate the Efficacy and Safety of CC-4047 (Pomalidomide) in Patients With Advanced Soft Tissue Sarcomas Who Have Relapsed or Are Refractory to Systemic Anticancer Therapy|Terminated||Phase 2|7|Actual|Celgene||1||"Study enrollment was terminated due to a corporate strategic decision unrelated to patient~   safety."|f||||t||||||||||2018-06-01 01:56:08.1594|2018-06-01 01:56:08.1594
NCT00717509|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2009-06-09|2008-07-16|2008-07-17|Estimate|||||||2009-06-09|2009-06-12|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|October 2009|Anticipated|2009-10-31|January 2009|Actual|2009-01-31||Observational|||Association of Multiple Genetic Polymorphisms With Clozapine-Associated Metabolic Change in Schizophrenia|Cross-Sectional Study of the Association Between Multiple Genetic Polymorphisms and the Metabolic Side Effects in Patients With Schizophrenia Taking Clozapine More Than 1 Year|Unknown status|Recruiting||150|Anticipated|Seoul National Hospital|||1||f||||t||||||Samples With DNA|"~     peripheral blood~   "|||2018-06-01 01:56:08.417579|2018-06-01 01:56:08.417579
NCT00717496|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2013-01-04|2008-07-15|2008-07-17|Estimate|||||||2013-01-04|2013-01-08|Estimate|April 2005||2005-04-30|July 2008|2008-07-31|August 2006|Actual|2006-08-31|May 2006|Actual|2006-05-31||Interventional|||Telephone Support Intervention to Improve Breastfeeding|Telephone Support Intervention to Improve Breastfeeding Rates in Low-Income Women|Completed||N/A|339|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:56:08.496161|2018-06-01 01:56:08.496161
NCT00717483|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2016-07-19|2008-07-16|2008-07-17|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2008||2008-07-31|July 2016|2016-07-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Observational|||BMI and Its Relationship to Hypoglycemic Seizures in Children With Insulin-requiring Diabetes|BMI and Its Relationship to Hypoglycemic Seizures in Children With Insulin-requiring Diabetes|Completed|||108|Actual|Baylor College of Medicine|||1||f||||f||||||||No||2018-06-01 01:56:08.574012|2018-06-01 01:56:08.574012
NCT00717470|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2017-11-20|2008-07-16|2008-07-17|Estimate|||||||2017-11-20|2017-11-22|Actual|May 14, 2008|Actual|2008-05-14|November 2017|2017-11-30|March 2, 2010|Actual|2010-03-02|March 2, 2010|Actual|2010-03-02||Interventional|OSAKA||A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection|A Multicenter, Four Arm, Randomized, Open Label Clinical Study Investigating Optimized Dosing in a Prograf®-/Advagraf®-Based Immunosuppressive Regimen in Kidney Transplant Subjects (OSAKA Study)|Completed||Phase 4|1252|Actual|Astellas Pharma Inc||4|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 01:56:08.662717|2018-06-01 01:56:08.662717
NCT00717457|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16||2016-07-20|2016-11-01|2008-07-16|2008-07-17|Estimate||||2016-07-20|2016-07-22|Estimate|2016-11-01|2016-11-02|Estimate|July 2008||2008-07-31|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.|Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|1189|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 01:56:08.88383|2018-06-01 01:56:08.88383
NCT00717444|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2013-07-23|2008-07-16|2008-07-17|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|HAPI||Healthy Activities for Prize Incentives|Healthy Activities for Prize Incentives|Completed||Phase 1|75|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 01:56:09.359444|2018-06-01 01:56:09.359444
NCT00717431|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2012-03-28|2008-07-15|2008-07-17|Estimate|||||||2012-03-28|2012-04-02|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|METTLE||A Multicenter Study of Hippocampal Electrical Stimulation (HS, in Mesial Temporal Lobe Epilepsy|Medical vs Electrical Therapy for Temporal Lobe Epilepsy|Terminated||Phase 3|8|Actual|University of Calgary||2||insufficient enrolment|f||||t||||||||||2018-06-01 01:56:09.443806|2018-06-01 01:56:09.443806
NCT00717418|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2011-12-05||2011-12-05|2008-07-16|2008-07-17|Estimate|2011-12-05|2012-01-12|Estimate||||2011-12-05|2012-01-12|Estimate|September 2004||2004-09-30|December 2011|2011-12-31|August 2008|Actual|2008-08-31|August 2006|Actual|2006-08-31||Observational|||Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease||Completed|||781|Actual|Allergan|Due to actual dry eye treatment used, data were not interpretable by separate treatment arms. Hence, Outcomes are only reported as a single group.||1||f||||||||||||||2018-06-01 01:56:09.539748|2018-06-01 01:56:09.539748
NCT00717405|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2015-12-01||2016-07-05|2008-07-16|2008-07-17|Estimate|2015-12-01|2016-01-06|Estimate||||2016-07-05|2016-08-02|Estimate|October 2008||2008-10-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|April 2010|Actual|2010-04-30||Interventional||Intent to treat population (ITT): Included all enrolled participants who had at least 1 post baseline assessment.|A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.|An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy|Completed||Phase 2|52|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:56:09.798027|2018-06-01 01:56:09.798027
NCT00717392|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2013-02-28|2008-07-16|2008-07-17|Estimate|||||||2013-02-28|2013-03-01|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Observational|||Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders|Evaluation of the Efficacy of Hippotherapy for Children With Developmental Disorders|Completed|||40|Actual|Sheba Medical Center|||4||f||||f||||||||||2018-06-01 01:56:10.184574|2018-06-01 01:56:10.184574
NCT00717379|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2009-04-13|2008-07-16|2008-07-17|Estimate|||||||2009-04-13|2009-04-15|Estimate|May 2007||2007-05-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation|Open-Label, Randomized, Multicenter, Parallel-Group Efficacy and Safety Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation|Completed||Phase 4|50|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 01:56:10.243742|2018-06-01 01:56:10.243742
NCT00717366|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2016-09-29||2017-08-08|2008-07-16|2008-07-17|Estimate|2017-08-08|2017-09-08|Actual||||2017-08-08|2017-09-08|Actual|July 2008||2008-07-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Intention-to-treat (ITT) population included all enrolled participants.|Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis|An Open-Label Multi-center, Multiple Dose Study to Determine the Optimum Starting Dose of Intravenous MIRCERA for Maintenance Treatment of Anemia in Pediatric Participants With Chronic Kidney Disease on Hemodialysis|Completed||Phase 2|64|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:56:10.347432|2018-06-01 01:56:10.347432
NCT00717353|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2014-01-13|2008-07-16|2008-07-17|Estimate|||||||2014-01-13|2014-01-14|Estimate|October 2005||2005-10-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Observational|||Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype|Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype|Unknown status|Active, not recruiting||||National University Hospital, Singapore|||1||f||||||||||||||2018-06-01 01:56:11.068772|2018-06-01 01:56:11.068772
NCT00717340|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2012-06-27|2008-07-16|2008-07-17|Estimate|||||||2012-06-27|2012-06-28|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer|A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer|Completed||Phase 1|18|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 01:56:11.139462|2018-06-01 01:56:11.139462
NCT00717327|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2009-06-24|2008-07-15|2008-07-17|Estimate|||||||2009-06-24|2009-06-25|Estimate|July 2008||2008-07-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Adolescent Knowledge of Their Medications|Medication Reconciliation List and Adolescent Functional Health Literacy|Completed|||384|Anticipated|Brooke Army Medical Center|||||f||||t||||||||||2018-06-01 01:56:11.234238|2018-06-01 01:56:11.234238
NCT00717314|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|2014-06-04||2014-09-23|2008-07-16|2008-07-17|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Per-Protocol (PP) population: all participants who received at least 1 dose of the treatment-group specific medication who did not dropout from the study prematurely.|A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.|A Randomized, Open Label Study Comparing the Effect of CellCept Combined With 2 Regimens of Reduced Calcineurin Inhibitors on Kidney Function in Liver Transplant Patients|Completed||Phase 4|87|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 01:56:11.326511|2018-06-01 01:56:11.326511
NCT00717301|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2015-06-10|2008-07-16|2008-07-17|Estimate|||||||2015-06-10|2015-06-12|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||S-100B as Pre-Head CT Scan Screening Test After Mild Traumatic Brain Injury|Accuracy of S-100B as Pre-Head CT Scan Screening Test After Mild Traumatic Brain Injury|Completed|||1252|Actual|University of Rochester|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:56:11.755589|2018-06-01 01:56:11.755589
NCT00717288|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2011-07-20||2011-08-30|2008-07-16|2008-07-17|Estimate|2011-08-30|2011-10-03|Estimate||||2011-08-30|2011-10-03|Estimate|July 2008||2008-07-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir|Transitioning Post-cardiothoracic Surgery Patients From Intravenous Insulin to the Subcutaneous Route With Insulin Detemir.|Completed||Phase 4|82|Actual|Ohio State University||3|||f||||t||||||||||2018-06-01 01:56:11.829595|2018-06-01 01:56:11.829595
NCT00717275|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2012-07-10||2012-09-14|2008-07-16|2008-07-17|Estimate|2012-07-10|2012-07-12|Estimate||||2012-09-14|2012-10-01|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Study of Temozolomide to Treat Newly Diagnosed Brain Metastases|A Phase II Study of Temozolomide (TMZ) Following Stereotactic Radiosurgery (SRS) for Patients With Newly Diagnosed Brain Metastases|Terminated||Phase 2|3|Actual|University of Florida|This single center study was terminated early due to slow accrual; therefore, statistical analysis of the 3 participants was not done.|1||Slow accrual.|f||||t||||||||||2018-06-01 01:56:12.109765|2018-06-01 01:56:12.109765
NCT00717262|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2009-01-15|2008-07-15|2008-07-17|Estimate|||||||2009-01-15|2009-01-16|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects|A Phase 1, Double-Blind, Placebo Controlled, Repeat-Dose Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Volunteers|Completed||Phase 1|41|Anticipated|HemaQuest Pharmaceuticals Inc.||2|||f||||f||||||||||2018-06-01 01:56:12.254164|2018-06-01 01:56:12.254164
NCT00717249|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2016-04-20||2016-04-20|2008-07-15|2008-07-17|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||All subjects that were dispensed a study lens.|Vistakon Investigational Contact Lenses Worn for Daily Wear||Completed||N/A|529|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 01:56:12.320306|2018-06-01 01:56:12.320306
NCT00717236|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2011-03-10||2012-03-02|2008-07-15|2008-07-17|Estimate|2011-04-11|2011-05-06|Estimate||||2012-03-02|2012-03-23|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|REALISTIC||Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis|A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.|Completed||Phase 3|1648|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 01:56:12.75449|2018-06-01 01:56:12.75449
NCT00717223|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-16|||2016-07-19|2008-07-16|2008-07-17|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2007||2007-06-30|July 2016|2016-07-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Observational|||A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes|A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes|Completed|||110|Actual|Baylor College of Medicine|||1||f||||f||||||||No||2018-06-01 01:56:15.211037|2018-06-01 01:56:15.211037
NCT00717210|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2008-07-16|2008-07-16|2008-07-17|Estimate|||||||2008-07-16|2008-07-17|Estimate|June 1999||1999-06-30|July 2008|2008-07-31|March 2008|Actual|2008-03-31|February 2005|Actual|2005-02-28||Interventional|NOA-04||Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide|NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide|Completed||Phase 3|318|Actual|Neuro-Oncology Working Group of the German Cancer Society||2|||f||||t||||||||||2018-06-01 01:56:15.291372|2018-06-01 01:56:15.291372
NCT00717197|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2013-02-18||2013-06-24|2008-07-16|2008-07-17|Estimate|2013-02-18|2013-03-25|Estimate||||2013-06-24|2013-07-02|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|March 2012|Actual|2012-03-31||Interventional|||Study of Capecitabine to Treat Recurrent High Grade Gliomas|Pilot Study to Determine Therapeutic Response of Oral Capecitabine (Xeloda) in Recurrent High Grade Gliomas (HGGs) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria|Completed||Phase 2|30|Actual|University of Florida||1|||f||||t||||||||||2018-06-01 01:56:15.485749|2018-06-01 01:56:15.485749
NCT00717184|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2010-04-07|2008-07-16|2008-07-17|Estimate|||||||2010-04-07|2010-04-09|Estimate|May 2007||2007-05-31|April 2010|2010-04-30||||||||Interventional|||A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma|A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma|Completed||Phase 1|||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 01:56:15.718936|2018-06-01 01:56:15.718936
NCT00714363|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2010-10-15|2008-07-08|2008-07-14|Estimate|||||||2010-10-15|2010-10-19|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of LASIK and SBK|Comparison of Laser-Assisted in Situ Keratomeleusis (LASIK) vs Sub-Bowman's Keratomileusis (SBK): Assessment of Visual Function and Patient Satisfaction|Completed||N/A|40|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 01:56:58.952147|2018-06-01 01:56:58.952147
NCT00717171|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2009-01-08|2008-07-14|2008-07-16|Estimate|||||||2009-01-08|2009-01-12|Estimate|July 2006||2006-07-31|January 2009|2009-01-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Efficacy of the SurgiStim3 Electrical Stimulation Device in Persons Undergoing Anterior Cruciate Ligament Repair|Efficacy of the SurgiStim3 Electrical Stimulation Device in Persons Undergoing Anterior Cruciate Ligament Repair|Terminated||Phase 4|100|Anticipated|VQ OrthoCare||2||Low enrollment|f||||f||||||||||2018-06-01 01:56:15.779731|2018-06-01 01:56:15.779731
NCT00717158|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-14|2008-07-14|2008-07-16|Estimate|||||||2008-07-14|2008-07-16|Estimate|May 2001||2001-05-31|August 2007|2007-08-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|ICAN||Lifestyle Intervention's Impact on Health Care Costs|Evaluating Healthcare Utilization, Costs and Health-Related Outcomes of a Medical Nutrition Therapy Intervention on Obese Patients With Type 2 Diabetes - A Pilot Study|Completed||N/A|147|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 01:56:15.842131|2018-06-01 01:56:15.842131
NCT00717145|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2011-10-07|2008-07-15|2008-07-16|Estimate|||||||2011-10-07|2011-10-12|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Food Effects on the Relative Bioavailability of Different Dosages of Risedronate|Food Effects on the Relative Bioavailability of a Risedronate 20 mg Delayed-release [DR] Tablet and to Compare the 20 mg DR Tablet to 35 mg DR and 35 mg Immediate-release Tablets|Completed||Phase 1|94|Actual|Warner Chilcott||4|||f||||f||||||||||2018-06-01 01:56:15.949716|2018-06-01 01:56:15.949716
NCT00717132|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2016-08-16|2008-07-10|2008-07-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Cost-effectiveness of Family Based Pediatric Obesity Treatment|Cost-effectiveness of Family Based Pediatric Obesity Treatment|Completed||N/A|50|Actual|State University of New York at Buffalo||2|||f||||f||||||||Yes|Data will be submitted|2018-06-01 01:56:16.032975|2018-06-01 01:56:16.032975
NCT00717119|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-09-12|2008-07-15|2008-07-16|Estimate|||||||2008-09-12|2008-09-15|Estimate|April 2008||2008-04-30|July 2008|2008-07-31|August 2008|Actual|2008-08-31|||||Observational|||Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.|Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.|Completed|||6356|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:56:16.114081|2018-06-01 01:56:16.114081
NCT00717106|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2009-05-04|2008-07-15|2008-07-16|Estimate|||||||2009-05-04|2009-05-05|Estimate|July 2008||2008-07-31|May 2009|2009-05-31||||||||Observational|OBSERV-ECG||Observational Study of the Sleuth Implantable ECG Monitoring System|Observational Study of the Sleuth Implantable ECG Monitoring System|Unknown status|Enrolling by invitation||250|Anticipated|Transoma Medical|||||f||||f||||||||||2018-06-01 01:56:16.18344|2018-06-01 01:56:16.18344
NCT00717093|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2010-04-15||2015-06-30|2008-07-15|2008-07-16|Estimate|2010-04-15|2010-05-18|Estimate||||2015-06-30|2015-07-23|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use|A Randomized, Multicenter, Double Blind, Placebo Controlled Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use|Completed||Phase 4|432|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:56:16.265595|2018-06-01 01:56:16.265595
NCT00717080|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2012-01-24|2008-07-15|2008-07-16|Estimate|||||||2012-01-24|2012-01-25|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|ACO||The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction|Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients|Completed||Phase 4|40|Actual|Aurolab||2|||f||||t||||||||||2018-06-01 01:56:16.625291|2018-06-01 01:56:16.625291
NCT00717067|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2009-11-16||2010-11-10|2008-07-15|2008-07-16|Estimate|2009-11-16|2009-12-21|Estimate||||2010-11-10|2010-11-19|Estimate|July 2008||2008-07-31|November 2010|2010-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function|An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function|Completed||Phase 4|30|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-06-01 01:56:16.799105|2018-06-01 01:56:16.799105
NCT00717054|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2014-03-05||2014-05-01|2008-07-15|2008-07-16|Estimate|2014-03-27|2014-04-29|Estimate||||2014-05-01|2014-05-20|Estimate|February 2008||2008-02-29|September 2013|2013-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting|A Randomized, Double-blind Comparison of Oral Aprepitant Alone vs Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting|Completed||N/A|115|Actual|Drexel University||2|||f||||t||||||||||2018-06-01 01:56:17.844477|2018-06-01 01:56:17.844477
NCT00717041|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2015-05-22||2015-06-12|2008-07-14|2008-07-16|Estimate|2015-06-12|2015-06-15|Estimate||||2015-06-12|2015-06-15|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Observational|||Epidemiology of Depression, Anxiety, and Cognitive Impairment|Epidemiology of Depression, Anxiety, and Cognitive Impairment Among Emergency Department Patients|Completed|||1206|Actual|University of Rochester|"Single center, limited generalizability~Large proportion of individuals lost to follow up~ED visit may have heightened symptoms~Validity of instruments in the ED setting is unknown"||1||f||||f||||||||||2018-06-01 01:56:18.075088|2018-06-01 01:56:18.075088
NCT00717028|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-14|2008-07-14|2008-07-16|Estimate|||||||2008-07-14|2008-07-16|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Functional Endoscopic Evaluation of Swallowing|Achados da avaliação videoendoscópica da deglutição em crianças Com Paralisia Cerebral.|Completed|||9|Actual|Fortaleza University|||||f||||f||||||||||2018-06-01 01:56:18.282374|2018-06-01 01:56:18.282374
NCT00717015|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2012-04-02|2008-07-15|2008-07-16|Estimate|||||||2012-04-02|2012-04-03|Estimate|November 2005||2005-11-30|April 2012|2012-04-30||||||||Observational|||Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer|Tamoxifen Pharmacokinetics and CYP2D6 Polymorphisms in Asian Women With Hormone Receptor Positive Breast Cancer|Completed|||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 01:56:18.361501|2018-06-01 01:56:18.361501
NCT00717002|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-12-10|2008-07-14|2008-07-16|Estimate|||||||2013-12-10|2013-12-11|Estimate|February 2008||2008-02-29|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study|Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study|Completed|||||National University Hospital, Singapore|||2||f||||f||||||||||2018-06-01 01:56:18.432977|2018-06-01 01:56:18.432977
NCT00716989|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2010-12-22|2008-07-15|2008-07-16|Estimate|||||||2010-12-22|2010-12-23|Estimate|November 2008||2008-11-30|December 2010|2010-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|LBP003||Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections|LBP003: Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections|Terminated||N/A|36|Actual|Hospices Civils de Lyon||||"Third group realisation has not been necessary regarding the results of the first two groups~   (no sufficient modifications in the immune response)"|f||||t||||||||||2018-06-01 01:56:18.484484|2018-06-01 01:56:18.484484
NCT00716976|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2016-12-09|2014-04-14|2017-11-07|2008-07-15|2008-07-16|Estimate|2014-01-07|2014-02-26|Estimate|2014-04-15|2014-04-17|Estimate|2017-11-07|2017-12-11|Actual|June 2008||2008-06-30|November 2017|2017-11-30||||April 2015|Actual|2015-04-30||Interventional|||Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy|A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children|Completed||Phase 3|131|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 01:56:18.609045|2018-06-01 01:56:18.609045
NCT00716963|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2015-04-14||2018-03-15|2008-07-14|2008-07-16|Estimate|2015-04-30|2015-05-15|Estimate||||2018-03-15|2018-05-28|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Does Fluticasone Propionate Reduce the Late Allergic Reaction When the Drug is Given Post-allergen?|Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction?|Completed||Phase 4|7|Actual|McMaster University||3|||f||||f||||||||||2018-06-01 01:56:19.42138|2018-06-01 01:56:19.42138
NCT00716950|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-16|2008-07-14|2008-07-16|Estimate|||||||2008-07-16|2008-07-17|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients|Evaluation of Antihypertensive Activity of Valsartan and Amlodipine Compared to Losartan and Amlodipine Through Ambulatory Blood Pressure Monitoring in Moderate Hypertensive Patients in a Randomized, Controlled, Double-Blind Study|Unknown status|Recruiting|Phase 4|187|Anticipated|University of Pavia||2|||f||||t||||||||||2018-06-01 01:56:19.610762|2018-06-01 01:56:19.610762
NCT00716937|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2014-12-15|2008-07-15|2008-07-16|Estimate|||||||2014-12-15|2014-12-16|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Karydakis Procedure Versus Excision With Healing by Secondary Intention (EHSI) in Sacrococcygeal Pilonidal Sinus|Recurrence, Complications, Work-off Date, Healing Time and Patients Willingness in Karydakis Technique for Treatment of Sacrococcygeal Pilonidal Sinus Versus Excision With Healing by Secondary Intention (EHSI)Technique|Completed||Phase 4|321|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:56:19.677119|2018-06-01 01:56:19.677119
NCT00716924|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2009-09-24|2008-07-15|2008-07-16|Estimate|||||||2009-09-24|2009-09-25|Estimate|May 2004||2004-05-31|September 2009|2009-09-30||||February 2006|Actual|2006-02-28||Interventional|CASTLE||CASTLE (Clopidogrel And Serum Troponin Level Elevation)|Clopidogrel 600 mg and 300 mg as a Loading Dose Prior to Percutaneous Coronary Intervention And Serum Troponin Level Elevation: A Pilot Study|Completed||Phase 3|155|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:56:19.736873|2018-06-01 01:56:19.736873
NCT00716911|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2015-06-03|2008-07-15|2008-07-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2000||2000-01-31|June 2015|2015-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant|CMV Specific Cellular Immunity in Recipients of Allogeneic Bone Marrow Transplantation: Association of CMV-Specific HLA-Peptide Tetramer Binding With Cytotoxic T-Cell Function, CMV Infection and Other Clinical Events|Completed||N/A|100|Anticipated|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 01:56:19.813293|2018-06-01 01:56:19.813293
NCT00716898|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2016-04-14|2008-07-15|2008-07-16|Estimate|||||||2016-04-14|2016-04-15|Estimate|February 2009||2009-02-28|April 2016|2016-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients|Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase|Completed|||25|Actual|Shaare Zedek Medical Center|||2||f||||t||||||||||2018-06-01 01:56:19.892269|2018-06-01 01:56:19.892269
NCT00716885|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-14|2008-07-14|2008-07-16|Estimate|||||||2008-07-14|2008-07-16|Estimate|September 2008||2008-09-30|May 2008|2008-05-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Observational|OXIS-PACING||The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing|The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing|Unknown status|Not yet recruiting||20|Anticipated|VU University Medical Center|||2||f||||t||||||Samples Without DNA|"~     Bloodsamples~   "|||2018-06-01 01:56:19.980335|2018-06-01 01:56:19.980335
NCT00716872|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-02-24|2008-07-14|2008-07-16|Estimate|||||||2010-02-24|2010-02-25|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|SHUTi-C||Improving the Sleep of Cancer Patients Using an Internet-Based Program|Evaluating Internet-Based Interventions for Insomnia in Cancer Patients|Completed||N/A|22|Anticipated|University of Virginia||4|||f||||f||||||||||2018-06-01 01:56:20.113908|2018-06-01 01:56:20.113908
NCT00716859|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2010-11-01||2011-01-31|2008-07-14|2008-07-16|Estimate|2010-11-01|2010-12-02|Estimate||||2011-01-31|2011-02-02|Estimate|July 2008||2008-07-31|January 2011|2011-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.|A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.|Completed||Phase 3|139|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 01:56:20.215348|2018-06-01 01:56:20.215348
NCT00716846|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2011-09-05|2008-07-14|2008-07-16|Estimate|||||||2011-09-05|2011-09-07|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|H-17-21||Effects of Statins on the Pharmacokinetics for Midazolam in Healthy Volunteers|Effects of Three Statins, Simvastatin, Atorvastatin, and Pitavastatin, on the Pharmacokinetics for Midazolam in Healthy Volunteers|Completed||N/A|11|Actual|Hamamatsu University||3|||f||||f||||||||||2018-06-01 01:56:20.643955|2018-06-01 01:56:20.643955
NCT00716833|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2015-01-15|2008-07-15|2008-07-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|February 2006||2006-02-28|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|EPPA||Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery|Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery|Terminated||Phase 3|87|Actual|Ludwig-Maximilians - University of Munich||2||poor recruitment|f||||t||||||||||2018-06-01 01:56:20.708326|2018-06-01 01:56:20.708326
NCT00716820|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2016-08-29||2017-11-07|2008-07-15|2008-07-16|Estimate|2016-08-29|2016-10-21|Estimate||||2017-11-07|2017-11-09|Actual|April 2008|Actual|2008-04-30|November 2017|2017-11-30|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Observational|||Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).|Outcome Survey Of Specific Use Of 12.5 Mg Sutent Capsule Against Gastrointestinal Stromal Tumor: Implementation Guidelines.|Completed|||472|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:56:20.79318|2018-06-01 01:56:20.79318
NCT00716807|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2013-08-13||2016-05-19|2008-07-15|2008-07-16|Estimate|2013-10-17|2013-10-22|Estimate||||2016-05-19|2016-05-20|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Co-investigators have spent many hours with computer-support personnel trying to locate data on the deceased investigators' computer, but could find nothing other than the gender and treatment assignment for 46 enrolled participants.|Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain|Modeling Kappa Opioid Analgesic Mechanisms in Chronic Orofacial Pain Disorders|Terminated||N/A|46|Actual|University of California, San Francisco|Dr. Robert Gear led this study and maintained data on his computer. Co-investigators have spent many hours trying to locate data on the deceased investigators' computer, but could find nothing other than the minimal results data entered here.|4||Unable to recruit a sufficient number of subjects.|f||||t||||||||||2018-06-01 01:56:21.469531|2018-06-01 01:56:21.469531
NCT00716794|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2011-03-08|2008-07-14|2008-07-16|Estimate|||||||2011-03-08|2011-03-09|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Phase I/II Study of HE3235 in Patients With Prostate Cancer|A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer|Completed||Phase 1/Phase 2|64|Actual|Harbor Therapeutics|||||f||||f||||||||||2018-06-01 01:56:21.704276|2018-06-01 01:56:21.704276
NCT00716781|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-14|2008-07-14|2008-07-16|Estimate|||||||2008-07-14|2008-07-16|Estimate|July 2004||2004-07-31|July 2008|2008-07-31|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Observational|||Management of Infants Born to Group B Streptococcus Positive Mothers.|Management of Infants Born to Group B Streptococcus Positive Mothers: Laboratory Tests vs Physical Examination|Completed|||16394|Actual|IRCCS Burlo Garofolo|||2||f||||f||||||||||2018-06-01 01:56:21.769105|2018-06-01 01:56:21.769105
NCT00716768|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-01-31|2008-07-14|2008-07-16|Estimate|||||||2013-01-31|2013-02-01|Estimate|October 2007||2007-10-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Trial of Laparoscopic Compared to Open Inguinal Hernia Repair in Children Younger Than 3 Years|Randomized Controlled Trial of Laparoscopic Compared to Open Inguinal Hernia Repair in Children Younger Than 3 Years of Age|Unknown status|Recruiting|N/A|152|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:56:21.834267|2018-06-01 01:56:21.834267
NCT00716755|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2016-02-25|2008-07-14|2008-07-16|Estimate|||||||2016-02-25|2016-02-26|Estimate|October 2009||2009-10-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.|The Minimal Effective Dose of Antipsychotic Medication in Older Patients With Schizophrenia: a PET Study.|Completed||N/A|45|Actual|Centre for Addiction and Mental Health||1|||f||||t||||||||No||2018-06-01 01:56:21.908369|2018-06-01 01:56:21.908369
NCT00716742|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2011-11-30||2011-11-30|2008-07-15|2008-07-16|Estimate|2011-11-30|2012-01-06|Estimate||||2011-11-30|2012-01-06|Estimate|September 2004||2004-09-30|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2007|Actual|2007-09-30||Observational|||Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)||Completed|||1099|Actual|Allergan|Data for 2-year and 3-year follow-up not interpretable due to extremely high drop out rates.||1||f||||||||||||||2018-06-01 01:56:21.998338|2018-06-01 01:56:21.998338
NCT00716729|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2010-10-18|2008-07-15|2008-07-16|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2009||2009-07-31|July 2008|2008-07-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Observational|||Development of Outcome-measures for Physically Active Patients With Hip and Groin Pain|Development of Outcome-measures for Physically Active Patients With Hip and Groin Pain|Completed|||150|Anticipated|Amager Hospital|||1||f||||f||||||||||2018-06-01 01:56:22.248231|2018-06-01 01:56:22.248231
NCT00716716|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2017-02-27|2008-07-14|2008-07-16|Estimate|||||||2017-02-27|2017-02-28|Actual|April 2008||2008-04-30|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase I/IIa Study of FIXFc in Hemophilia B Patients|A Phase I/IIa Safety and Pharmacokinetic Study of Intravenous FIXFc in Previously Treated Hemophilia B Patients|Completed||Phase 1|10|Actual|Bioverativ Therapeutics Inc.||1|||f||||t||||||||||2018-06-01 01:56:22.326841|2018-06-01 01:56:22.326841
NCT00716703|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-15|2008-07-15|2008-07-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|November 2003||2003-11-30|July 2008|2008-07-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||CT Scan Using IV Contrast Alone for Pediatric Appendicitis|CT Scan Using IV Contrast Alone for Pediatric Appendicitis|Completed||N/A|250|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 01:56:22.434385|2018-06-01 01:56:22.434385
NCT00716690|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2016-02-18|2008-07-15|2008-07-16|Estimate|||||||2016-02-18|2016-02-19|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Multi Donor Mismatched Stem Cell Transplantation (MDT)|Enhancement of Hematopoietic Stem Cell Engraftment by Multi Donor Stem Cell Transplantation (MDT) From 2 Mismatched Donors, a Phase I-II Open Study|Recruiting||Phase 1/Phase 2|10|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:56:22.519022|2018-06-01 01:56:22.519022
NCT00716677|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2012-12-31|2008-07-15|2008-07-16|Estimate|||||||2012-12-31|2013-01-03|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|December 2010|Anticipated|2010-12-31|October 2010|Anticipated|2010-10-31||Observational|||Dysfunctional Breathing in Difficult Asthma.|Ambulatory Respiratory Inductance Plethysmography (RIP). Can it be Used to Help Identify Dysfunctional Breathing in Difficult Asthma?|Withdrawn|||0|Actual|Royal Brompton & Harefield NHS Foundation Trust|||2|Life shirt technology no longer available|f||||f||||||||||2018-06-01 01:56:22.592642|2018-06-01 01:56:22.592642
NCT00716664|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2009-03-10|2008-07-15|2008-07-16|Estimate|||||||2009-03-10|2009-03-11|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Do Musculoskeletal Techniques Improve Forced Expiratory Volume in One Second in Adults With Cystic Fibrosis?|Pilot Study: Do Physiotherapy Musculoskeletal Techniques Improve Forced Expiratory Volume in One Second in Adults With Cystic Fibrosis?|Completed||N/A|20|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:56:22.656137|2018-06-01 01:56:22.656137
NCT00714350|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2014-12-11|2008-07-11|2008-07-14|Estimate|||||||2014-12-11|2014-12-12|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Evaluation of Information Displays A Paper & Pencil, Computer, Simulator, and ICU Based Study|Evaluation of Information Displays A Paper & Pencil, Computer, Simulator, and ICU Based Study|Completed|||32|Actual|University of Utah|||2||f||||t||||||||||2018-06-01 01:56:59.008868|2018-06-01 01:56:59.008868
NCT00716651|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2012-06-14|2008-07-14|2008-07-16|Estimate|||||||2012-06-14|2012-06-15|Estimate|July 2008||2008-07-31|June 2012|2012-06-30||||July 2010|Actual|2010-07-31||Interventional|MEPOCHUSS||Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome|A Phase II, Single Center Open Label, Prospective Trial to Evaluate the Efficacy and Safety of Mepolizumab for Patients With Refractory or Relapsing Churg Strauss Syndrome|Completed||Phase 2|10|Actual|University of Schleswig-Holstein|||||f||||t||||||||||2018-06-01 01:56:22.772017|2018-06-01 01:56:22.772017
NCT00716638|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-10-31|2008-07-14|2008-07-16|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Trauma-focused CBT Versus EMDR in the Treatment of Posttraumatic Stress Disorder|Trauma-focused CBT vs. EMDR in the Treatment of Posttraumatic Stress Disorder|Unknown status|Recruiting|Phase 2/Phase 3|90|Anticipated|VU University of Amsterdam||2|||f||||f||||||||||2018-06-01 01:56:22.825012|2018-06-01 01:56:22.825012
NCT00716625|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2016-08-29||2016-11-17|2008-07-15|2008-07-16|Estimate|2016-11-17|2017-01-18|Estimate||||2016-11-17|2017-01-18|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational||In total, 1674 participants were enrolled in the study. Of the 1674 participants, 1 participant was excluded from the baseline analysis because the safety was not assessable.|Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)|Special Investigation For RCC Of Sutent (Regulatory Post Marketing Commitment Plan).|Completed|||1674|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:56:22.921138|2018-06-01 01:56:22.921138
NCT00716612|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-01-24|2008-07-15|2008-07-16|Estimate|||||||2013-01-24|2013-01-25|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|COSMIC||Does Coenzyme Q 10 Supplementation Reduce Muscle Pain Caused by Statins? (Cholesterol Lowering Medications)|Effect of Coenzyme Q 10 Supplementation on Myalgia Induced by HMG-CoA Reductase Inhibitors|Completed||N/A|37|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 01:56:23.831303|2018-06-01 01:56:23.831303
NCT00716599|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-15|2008-07-15|2008-07-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Training in Fever Case Management With Rapid Diagnostic Tests (RDTs) for Malaria in Uganda|Effectiveness and Safety of Training in Fever Case Management Incorporating Rapid Diagnostic Tests (RDTs) for Malaria at Peripheral Health Centers in Uganda|Completed||N/A|14000|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:56:23.917767|2018-06-01 01:56:23.917767
NCT00716586|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2014-12-12|2008-07-14|2008-07-16|Estimate|||||||2014-12-12|2014-12-15|Estimate|October 2005||2005-10-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration|Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration|Unknown status|Recruiting|Phase 4|70|Anticipated|University of Illinois at Chicago||1|||f||||f||||||||||2018-06-01 01:56:24.056719|2018-06-01 01:56:24.056719
NCT00716573|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2017-06-19|2008-07-15|2008-07-16|Estimate|||||||2017-06-19|2017-06-20|Actual|September 16, 2008|Actual|2008-09-16|June 2017|2017-06-30|April 17, 2014|Actual|2014-04-17|April 17, 2014|Actual|2014-04-17||Interventional|COREV||Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure|COREV : A Multi-center, Randomized, Open-label Study Evaluating the Efficacy on Renal Function of Everolimus in Heart Transplant Recipients With Established Chronic Renal Failure|Completed||Phase 4|120|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 01:56:24.152748|2018-06-01 01:56:24.152748
NCT00716560|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2016-10-19|2008-07-14|2008-07-16|Estimate|||||||2016-10-19|2016-10-21|Estimate|May 2005||2005-05-31|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin|Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin|Terminated|||8|Actual|Thomas Jefferson University|||1|Administratively terminated.|f||||f||||||||||2018-06-01 01:56:24.245468|2018-06-01 01:56:24.245468
NCT00716547|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2009-10-15|2008-07-15|2008-07-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)|Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Study of Safety and Efficacy of Two Dosages of Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel) for the Treatment of Osteoarthritis of the Knee|Completed||Phase 3|1399|Actual|IDEA AG||4|||f||||f||||||||||2018-06-01 01:56:24.337609|2018-06-01 01:56:24.337609
NCT00716534|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14||2013-04-04|2013-04-19|2008-07-14|2008-07-16|Estimate||||2013-04-04|2013-04-11|Estimate|2013-04-19|2013-04-29|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment|Completed||Phase 2|145|Actual|AbbVie||3|||f||||||||||||||2018-06-01 01:56:24.441798|2018-06-01 01:56:24.441798
NCT00716521|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2009-04-22|2008-07-15|2008-07-16|Estimate|||||||2009-04-22|2009-04-24|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers|Subject- And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 3-Way Crossover Study To Study Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers|Completed||Phase 1|11|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:56:24.578537|2018-06-01 01:56:24.578537
NCT00716508|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2013-09-17|2008-07-15|2008-07-16|Estimate|||||||2013-09-17|2013-09-19|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Surgical Treatment for Acute Patella Tendon Rupture|Surgical Treatment for Acute Patella Tendon Rupture: a Prospective, Randomized Study Comparing Transpatellar Suture Tunnels Method vs. Suture Anchors.|Terminated||Phase 4|3|Actual|Emory University||2||Our PI left our institutions as we could not longer continue.|f||||f||||||||||2018-06-01 01:56:24.655046|2018-06-01 01:56:24.655046
NCT00716495|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2016-04-21|2008-07-15|2008-07-16|Estimate|||||||2016-04-21|2016-04-22|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma|A Phase I/IIa, Open-label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 Month Extended Dosing With AGI - 101H Vaccine in the Treatment of Patients With Advanced Melanoma|Terminated||Phase 1/Phase 2|5|Actual|AGIRx Ltd.||||problems in funding|f||||t||||||||||2018-06-01 01:56:24.72843|2018-06-01 01:56:24.72843
NCT00716482|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2013-04-04||2013-09-02|2008-07-14|2008-07-16|Estimate|2013-09-02|2013-09-09|Estimate||||2013-09-02|2013-09-09|Estimate|July 2008||2008-07-31|September 2013|2013-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|BE1|"There were 1681 started participants and 1562 completed participants. Reasons for rejected participants are listed in participant flow section"|Ultrasound Elastography of Breast Lesions|Assessment of the Clinical Value of SuperSonic Shear Wave Elastography in the Ultrasonic Evaluation of Breast Lesions|Completed|||1681|Actual|SuperSonic Imagine|"follow up on BI-RADS 2 lesions was not performed~operators knew the BI-RADS score of the lesion before performing SWE~more BI-RADS 3 and 4 lesions were recruited because of the study design"||||f||||f||||||||||2018-06-01 01:56:24.813684|2018-06-01 01:56:24.813684
NCT00716469|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2015-04-14|2008-07-15|2008-07-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PDT||Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas|Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using Intratumoral Delivery of Non-coherent Light for Photoactivation of LS11 in Children With Plexiform Neurofibromas|Terminated||Phase 1|7|Actual|Children's Hospital of Philadelphia||1||The study is terminated due to expiration of study materials.|f||||t||||||||||2018-06-01 01:56:25.102124|2018-06-01 01:56:25.102124
NCT00716456|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2015-03-31||2015-04-13|2008-07-15|2008-07-16|Estimate|2015-04-13|2015-04-30|Estimate||||2015-04-13|2015-04-30|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||"Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed Acquired Resistance to Erlotinib"|"A Phase I/II Trial of Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed Acquired Resistance to Erlotinib"|Completed||Phase 1/Phase 2|21|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:56:25.178761|2018-06-01 01:56:25.178761
NCT00716443|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2009-09-25||2012-09-21|2008-07-15|2008-07-16|Estimate|2010-01-08|2010-02-01|Estimate||||2012-09-21|2012-10-02|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections|Open-Label, Randomized, Split-Face Study to Evaluate the Efficacy, Safety and Subject Satisfaction of Pain Management During and After Restylane® Dermal Filler Injections for the Correction of Nasolabial Folds|Terminated||Phase 4|51|Actual|Galderma Laboratories, L.P.||2||Sponsor decision|f||||f||||||||||2018-06-01 01:56:25.560712|2018-06-01 01:56:25.560712
NCT00716430|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-07-15|2008-07-15|2008-07-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|February 2009|Anticipated|2009-02-28|December 2008|Anticipated|2008-12-31||Interventional|EQUIP-ACS||European Quality Improvement Programme for Acute Coronary Syndromes|Improving the Management of Non-ST Elevation Acute Coronary Syndrome: Systematic Evaluation of a Quality Improvement Programme|Unknown status|Recruiting|N/A|3500|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:56:25.923196|2018-06-01 01:56:25.923196
NCT00716417|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2013-08-08||2014-06-03|2008-07-15|2008-07-16|Estimate|2013-08-08|2013-10-16|Estimate||||2014-06-03|2014-06-09|Estimate|July 2008||2008-07-31|August 2013|2013-08-31||||July 2010|Actual|2010-07-31||Interventional|||Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours|A Phase Ib Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Continuous Dosing With BIBW 2992 Combined With Two Different Regimens of Backbone Chemotherapy: Cisplatin Combined With 5 Fluorouracil and Cisplatin Combined With Paclitaxel in Patients With Advanced Solid Tumors.|Completed||Phase 1|47|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:56:26.953991|2018-06-01 01:56:26.953991
NCT00716404|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2010-02-03|2008-07-15|2008-07-16|Estimate|||||||2010-02-03|2010-02-05|Estimate|April 2008||2008-04-30|February 2010|2010-02-28||||||||Observational|PROVIDE||Post-Market Observational Study of Intra-Renal Drug Delivery|Post-Market Observational Study of Intra-Renal Drug Delivery|Withdrawn|||1000|Anticipated|FlowMedica, Inc.|||1|FlowMedica was purchased by AngioDynamics. Study will be re-started by AngioDynamics.|f||||f||||||||||2018-06-01 01:56:29.363532|2018-06-01 01:56:29.363532
NCT00716391|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2011-02-12|2008-07-14|2008-07-16|Estimate|||||||2011-02-12|2011-02-15|Estimate|July 2008||2008-07-31|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.|Open Label Randomized, Multi-centre Phase III Trial of TPF Plus Conc. Treatment With Cisplatin and Radiotherapy Versus Conc. Cetuximab and Radiotherapy in Locally Advanced, Unresectable Head and Neck Cancer.|Unknown status|Recruiting|Phase 3|458|Anticipated|Grupo Español de Tratamiento de Tumores de Cabeza y Cuello||2|||f||||f||||||||||2018-06-01 01:56:29.448363|2018-06-01 01:56:29.448363
NCT00716378|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2017-06-30|2008-07-15|2008-07-16|Estimate|||||||2017-06-30|2017-07-02|Actual|July 11, 2008||2008-07-11|November 15, 2010|2010-11-15|November 15, 2010|Actual|2010-11-15|November 15, 2010|Actual|2010-11-15||Interventional|||Teenage Passenger Influences on Driving Performance of Teenage Drivers|Teenage Passenger Influences on the Simulated Driving Performance of Teenage Drivers|Completed||N/A|36|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:56:29.611541|2018-06-01 01:56:29.611541
NCT00716365|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2011-08-15|2008-07-15|2008-07-16|Estimate|||||||2011-08-15|2011-08-16|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|January 2009|Actual|2009-01-31||Interventional|USF-Hemostasis||USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous Procedures|USF Hemostasis: USage of HemCon for Femoral Hemostasis After Percutaneous|Completed||Phase 4|278|Actual|Meir Medical Center||1|||f||||||||||||||2018-06-01 01:56:29.692813|2018-06-01 01:56:29.692813
NCT00716352|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2008-07-15|2008-07-15|2008-07-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|March 2004||2004-03-31|July 2008|2008-07-31|November 2005|Actual|2005-11-30|||||Interventional|||Prospective Registry of Outcomes and Management of Acute Ischaemic Syndromes|Prospective Registry of Outcomes and Management of Acute Ischaemic Syndromes|Completed||N/A|1340|Actual|Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 01:56:29.852315|2018-06-01 01:56:29.852315
NCT00716339|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-14|2008-07-14|2008-07-16|Estimate|||||||2008-07-14|2008-07-16|Estimate||||July 2008|2008-07-31||||||||Interventional|||Pseudophakic Accommodation||Completed||N/A|40||Medical University of Vienna||2|||f||||||||||||||2018-06-01 01:56:29.954167|2018-06-01 01:56:29.954167
NCT00716326|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-12-17|2008-07-15|2008-07-16|Estimate|||||||2008-12-17|2008-12-18|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||The Use of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Pain of Predominantly Peripheral Neuropathic Origin|The Use of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Pain of Predominantly Peripheral Neuropathic Origin|Completed||N/A|115|Anticipated|Norwegian Fund for Postgraduate Training in Physiotherapy||2|||f||||f||||||||||2018-06-01 01:56:30.01457|2018-06-01 01:56:30.01457
NCT00716300|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2009-02-17|2008-07-15|2008-07-16|Estimate|||||||2009-02-17|2009-02-18|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Observational|||High Density Lipoprotein (HDL) Functionality in Metabolic Syndrome|Functional Studies of High Density Lipoprotein in the Metabolic Syndrome|Unknown status|Recruiting||30|Anticipated|The University of Western Australia|||2||f||||t||||||Samples With DNA|"~     DNA plasma~   "|||2018-06-01 01:56:30.11948|2018-06-01 01:56:30.11948
NCT00716287|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2014-01-13|2008-07-15|2008-07-16|Estimate|||||||2014-01-13|2014-01-14|Estimate|March 2007||2007-03-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Observational|||Characterisation of Gene Variants in the Angiogenic Pathway|Characterisation of Gene Variants in the Angiogenic Pathway|Unknown status|Active, not recruiting||||National University Hospital, Singapore|||1||f||||||||||||||2018-06-01 01:56:30.176748|2018-06-01 01:56:30.176748
NCT00716274|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2017-06-26||2018-04-02|2008-07-14|2008-07-16|Estimate|2018-01-09|2018-02-07|Actual||||2018-04-02|2018-05-07|Actual|September 2008||2008-09-30|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia|Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment|Completed||Phase 4|110|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:56:30.319192|2018-06-01 01:56:30.319192
NCT00716261|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-15|2008-07-15|2008-07-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|November 2009|Anticipated|2009-11-30|September 2009|Anticipated|2009-09-30||Interventional|||Bio-Feedback to Improving Stability in Elderly Population|Using Bio-Feedback for Improving Stability in Walking and Everyday Activity|Unknown status|Active, not recruiting|N/A|||Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 01:56:32.529238|2018-06-01 01:56:32.529238
NCT00716248|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-01-04|2008-07-14|2008-07-16|Estimate|||||||2011-01-04|2011-01-05|Estimate|January 2007||2007-01-31|September 2009|2009-09-30||||December 2011|Anticipated|2011-12-31||Interventional|||Bucillamine Study of Holding Remission After Infliximab Dose-off|The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Saitama Medical University||2|||f||||||||||||||2018-06-01 01:56:32.58274|2018-06-01 01:56:32.58274
NCT00716235|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2009-01-15|2008-07-15|2008-07-16|Estimate|||||||2009-01-15|2009-01-16|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Characterization of Executive Functions and Patterns of Eye Movements in Children With Developmental Disabilities|Characterization of Executive Functions and Patterns of Eye Movements in Children With Developmental Disabilities|Unknown status|Recruiting||160|Anticipated|Sheba Medical Center|||4||f||||f||||||||||2018-06-01 01:56:32.651429|2018-06-01 01:56:32.651429
NCT00716222|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2009-01-20|2008-07-15|2008-07-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|May 2009|Anticipated|2009-05-31|||||Observational|SOM||Hormonal and Metabolic Consequences of Sleep Disorders in Young Obese Patients|Hormonal and Metabolic Consequences of Sleep Disorders in Young Obese Patients|Unknown status|Recruiting||70|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||3||f||||t||||||||||2018-06-01 01:56:32.745663|2018-06-01 01:56:32.745663
NCT00716209|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2014-03-03|2008-07-15|2008-07-16|Estimate|||||||2014-03-03|2014-03-05|Estimate|September 2012||2012-09-30|March 2014|2014-03-31||||December 2014|Anticipated|2014-12-31||Observational|||Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers|Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers|Unknown status|Active, not recruiting||||National University Hospital, Singapore|||1||f||||||||||||||2018-06-01 01:56:32.803191|2018-06-01 01:56:32.803191
NCT00716196|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2012-09-11|2008-07-15|2008-07-16|Estimate|||||||2012-09-11|2012-09-12|Estimate|March 2005||2005-03-31|September 2012|2012-09-30|July 2008|Actual|2008-07-31|April 2007|Actual|2007-04-30||Observational|||A Prospective Study of Thin Prep Versus Papanicolau in Suspected Malignant Lesions During Endoscopic Ultrasound (EUS)|A Prospective Study of Thin Prep Versus Papanicolau in Suspected Malignant Lesions During EUS|Completed|||||Indiana University|||||f||||f||||||||||2018-06-01 01:56:32.857676|2018-06-01 01:56:32.857676
NCT00716183|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2009-05-22|2008-07-14|2008-07-16|Estimate|||||||2009-05-22|2009-05-25|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|July 2008|Actual|2008-07-31||Interventional|||Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis|Phase 2/3 Evaluation of Three Lactobacilli Strains Isolated From Human Milk for the Treatment of Infectious Mastitis During the Lactation Period|Completed||Phase 2/Phase 3|300|Actual|Universidad Complutense de Madrid||4|||f||||t||||||||||2018-06-01 01:56:32.909853|2018-06-01 01:56:32.909853
NCT00716170|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-11-27|2008-07-14|2008-07-16|Estimate|||||||2013-11-27|2013-11-28|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia|The Role of GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia|Completed|||10|Actual|Herlev Hospital|||1||f||||t||||||Samples With DNA|"~     Blood plasma and leucocytes~   "|||2018-06-01 01:56:32.992538|2018-06-01 01:56:32.992538
NCT00716157|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2014-12-03|2008-07-15|2008-07-16|Estimate|||||||2014-12-03|2014-12-05|Estimate|October 2004||2004-10-31|December 2014|2014-12-31|September 2011|Actual|2011-09-30|August 2008|Actual|2008-08-31||Observational|||Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation|A Prospective Study to Evaluate the Incidence and Patterns of Nausea and Vomiting in Patients Receiving Combined Chemotherapy and Radiation|Completed|||40|Anticipated|Thomas Jefferson University|||1||f||||f||||||||||2018-06-01 01:56:33.144857|2018-06-01 01:56:33.144857
NCT00716144|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2017-03-10||2017-06-28|2008-07-15|2008-07-16|Estimate|2017-06-28|2018-01-29|Actual||||2017-06-28|2018-01-29|Actual|June 1, 2006||2006-06-01|May 2017|2017-05-31|May 1, 2007|Actual|2007-05-01|May 1, 2007|Actual|2007-05-01||Interventional|||Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis|A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Study of the Safety and Efficacy of Oral R115866 and R115866 Placebo in the Treatment of Plaque Psoriasis|Completed||Phase 2|176|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 01:56:33.237756|2018-06-01 01:56:33.237756
NCT00716131|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2017-01-05|2008-07-14|2008-07-16|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2007||2007-04-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program|ALS Tissue Donation Program|Completed|||205|Actual|Drexel University|||4||f||||f||||||Samples With DNA|"~     Blood (Serum and DNA) Urine (Serum and DNA) CSF Blood specimens and tissue specimens (from~     brain, spinal cord, gastrointestinal tract, skeletal muscle and peripheral nerve)~   "|No|The purpose of this protocol is to collect and bank tissue specimens.|2018-06-01 01:56:33.973988|2018-06-01 01:56:33.973988
NCT00716118|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2011-01-05|2008-07-14|2008-07-16|Estimate|||||||2011-01-05|2011-01-06|Estimate|July 2008||2008-07-31|January 2011|2011-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|WCFC||Oocyte Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.|Oocytes Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.|Completed|||20|Anticipated|West Coast Fertility Centers|||1||f||||t||||||||||2018-06-01 01:56:34.032833|2018-06-01 01:56:34.032833
NCT00716105|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2015-05-18|2008-07-15|2008-07-16|Estimate|||||||2015-05-18|2015-05-19|Estimate|August 2008||2008-08-31|October 2014|2014-10-31|February 2015|Actual|2015-02-28|July 2010|Actual|2010-07-31||Interventional|||Effect of the Level of Dietary Protein on Infant Growth|Effect of the Level of Dietary Protein on Infant Growth and Body Composition in the First Year of Life|Completed||N/A|405|Actual|Nestlé||3|||f||||f||||||||||2018-06-01 01:56:34.086913|2018-06-01 01:56:34.086913
NCT00716092|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|2011-05-13||2014-06-18|2008-07-15|2008-07-16|Estimate|2011-05-13|2011-06-15|Estimate||||2014-06-18|2014-06-27|Estimate|July 2008||2008-07-31|January 2014|2014-01-31||||November 2008|Actual|2008-11-30||Interventional|||The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients|A 4-week, Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group Study Comparing the Influence of BI 1356 (5 mg) and Sitagliptin (100 mg) Administered Orally Once Daily on Various Biomarkers in Type 2 Diabetic Patients|Completed||Phase 2|121|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 01:56:34.175235|2018-06-01 01:56:34.175235
NCT00716079|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2013-08-21||2013-11-19|2008-07-14|2008-07-16|Estimate|2013-08-21|2013-10-28|Estimate||||2013-11-19|2013-12-13|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|INTERACT2||The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial|An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage.|Completed||N/A|2839|Actual|The George Institute||2|||f||||t||||||||||2018-06-01 01:56:34.538207|2018-06-01 01:56:34.538207
NCT00716066|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2018-01-16|2008-07-15|2008-07-16|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2008||2008-06-30|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy|High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases|Recruiting||Phase 2|40|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 01:56:35.165523|2018-06-01 01:56:35.165523
NCT00716053|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2010-01-14|2008-07-15|2008-07-16|Estimate|||||||2010-01-14|2010-01-18|Estimate|December 2008||2008-12-31|January 2010|2010-01-31|December 2009||2009-12-31|December 2009||2009-12-31||Interventional|||Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema|Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema|Withdrawn||Phase 3|225|Anticipated|Aeris Therapeutics||2|||f||||t||||||||||2018-06-01 01:56:35.309031|2018-06-01 01:56:35.309031
NCT00716040|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-15|2008-07-15|2008-07-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|March 2008||2008-03-31|July 2008|2008-07-31|November 2008|Anticipated|2008-11-30|September 2008|Anticipated|2008-09-30||Interventional|SPIAH-Q||Social-Psychological Intervention to Improve Adherence to HAART|Effectiveness of a Social-Psychological Intervention to Improve Adherence to Antiretroviral Drug Regimens for AIDS: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|121|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 01:56:35.37142|2018-06-01 01:56:35.37142
NCT00716027|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2010-09-28|2008-07-15|2008-07-16|Estimate|||||||2010-09-28|2010-09-29|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Applying Social Comparison Theory to Behavioral Weight Loss: Does Modifying Group Membership Improve Outcome?|Applying Social Comparison Theory to Behavioral Weight Loss: Does Modifying Group Membership Improve Outcome?|Completed||N/A|80|Anticipated|The Miriam Hospital||2|||f||||t||||||||||2018-06-01 01:56:35.433024|2018-06-01 01:56:35.433024
NCT00716014|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-15|||2008-11-18|2008-07-15|2008-07-16|Estimate|||||||2008-11-18|2008-11-19|Estimate|January 2008||2008-01-31|November 2008|2008-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita|A Single-Center, Placebo-Controlled, Rising Dose to Tolerance and Safety Study of TD101, an siRNA Designed for Treatment of Pachyonychia Congenita|Completed||Phase 1|1|Anticipated|Pachyonychia Congenita Project||2|||f||||t||||||||||2018-06-01 01:56:35.491162|2018-06-01 01:56:35.491162
NCT00716001|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2008-07-11|2008-07-11|2008-07-15|Estimate|||||||2008-07-11|2008-07-15|Estimate|July 2008||2008-07-31|July 2008|2008-07-31||||June 2009|Anticipated|2009-06-30||Interventional|||Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure||Unknown status|Not yet recruiting|Phase 4|||Osaka General Medical Center||2|||f||||f||||||||||2018-06-01 01:56:35.61184|2018-06-01 01:56:35.61184
NCT00715988|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2017-04-08|2008-07-14|2008-07-15|Estimate|||||||2017-04-08|2017-04-11|Actual|October 2007||2007-10-31|April 2017|2017-04-30|February 10, 2017|Actual|2017-02-10|September 2012|Actual|2012-09-30||Interventional|||Methadone Pharmacokinetics and Cardiac Effects in Newborns|Safety and Single Dose Population Pharmacokinetics and Bioavailability of Methadone and Its Enantiomers in Newborns and Young Infants At 29-48 Weeks Post Menstrual Age|Completed||Phase 1|7|Actual|University of Utah||2|||f||||t|t|f|||f|||Yes|Data shared with other investigators leading to publication of the pediatric population pharmacokinetics of methadone|2018-06-01 01:56:35.696075|2018-06-01 01:56:35.696075
NCT00715975|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2010-08-31|2008-07-14|2008-07-15|Estimate|||||||2010-08-31|2010-09-02|Estimate|July 2008||2008-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|halobetasol||Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis|Clinical Trial of Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis Plate, and as Comparator the Product Psorex (Clobetasol Propionate).|Completed||Phase 2/Phase 3|140|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 01:56:35.77048|2018-06-01 01:56:35.77048
NCT00715793|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2016-07-29||2017-09-05|2008-07-11|2008-07-15|Estimate|2017-09-05|2017-10-03|Actual||||2017-09-05|2017-10-03|Actual|June 2008||2008-06-30|September 2017|2017-09-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|UPCI-07-008||Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma|Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|39|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 01:56:38.76569|2018-06-01 01:56:38.76569
NCT00715962|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2016-01-22||2016-02-23|2008-07-11|2008-07-15|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional||Participants were 100 patients aged 65 years or older admitted to the medical wards of the Birmingham Veterans Affairs Medical Center (BVAMC).|Efficacy and Safety of a Hospital Walking Program for Older Adults|Efficacy and Safety of a Hospital Walking Program for Older Adults|Completed||Phase 2|100|Actual|VA Office of Research and Development|Study may not be generalizable as subjects mostly male and not demented or delirious. Study sample is small and needs to be replicated in a larger cohort.|2|||f||||t||||||||Yes|Persons interested in obtaining the dataset will be asked to complete a data sharing agreement and procure IRB approval from their institution. At that time a de-identified dataset will be provided to them.|2018-06-01 01:56:35.839382|2018-06-01 01:56:35.839382
NCT00715949|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2013-07-29||2015-04-14|2008-07-14|2008-07-15|Estimate|2014-10-13|2014-10-15|Estimate||||2015-04-14|2015-05-04|Estimate|December 2005||2005-12-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|December 2007|Actual|2007-12-31||Observational|||Neurocognitive Evaluation of Mild Traumatic Brain Injury in the Hospitalized Pediatric Population|Neurocognitive Evaluation of Minor Traumatic Brain Injury in the Hospitalized Pediatric Population|Completed|||120|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-06-01 01:56:36.221767|2018-06-01 01:56:36.221767
NCT00715936|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2017-06-27|2008-07-14|2008-07-15|Estimate|||||||2017-06-27|2017-06-28|Actual|July 2009||2009-07-31|June 2017|2017-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PEDS||The Pakistan Early Childhood Development Scale Up Trial|Phase 1 Study of Integration of Early Child Development Interventions in a Community Health Service in Sindh, Pakistan|Completed||Phase 2/Phase 3|1489|Actual|Aga Khan University||4|||f||||t||||||||||2018-06-01 01:56:36.376648|2018-06-01 01:56:36.376648
NCT00715923|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2015-12-01|2008-07-11|2008-07-15|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Modified Consent Form Utility|CTSA Utility of Modified Consent Forms in Clinical Research: Fraga Tea Study|Terminated||N/A|30|Anticipated|University of California, Davis||2||funding|f||||f||||||||||2018-06-01 01:56:36.454278|2018-06-01 01:56:36.454278
NCT00715910|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2014-04-25|2013-08-22|2014-11-20|2008-07-14|2008-07-15|Estimate|2014-05-01|2014-05-29|Estimate|2013-08-22|2013-08-30|Estimate|2014-11-20|2014-11-27|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional||The overall number of baseline subjects correspond to the subjects at Year 1 persistence phase and another cohort of subjects (naive control group) which was offered a dose of Nimenrix vaccine at Year 5 within the same study.|The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults|Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra® in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination|Completed||Phase 2|818|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 01:56:36.544903|2018-06-01 01:56:36.544903
NCT00715897|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2011-12-23|2008-07-14|2008-07-15|Estimate|||||||2011-12-23|2011-12-26|Estimate|August 2008||2008-08-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2010|Actual|2010-10-31||Interventional|||Hyperbaric Oxygen Therapy Induced Neuroplasticity in Post Stroke Patients Suffering Chronic Neurological Deficiencies||Completed||N/A|74|Actual|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-06-01 01:56:37.367551|2018-06-01 01:56:37.367551
NCT00715884|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2011-02-25||2013-12-17|2008-07-11|2008-07-15|Estimate|2011-04-12|2011-05-06|Estimate||||2013-12-17|2014-01-20|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|September 2014|Anticipated|2014-09-30|March 2010|Actual|2010-03-31||Interventional|ELITE||Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems|A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER® ELITE™ to the CYPHER® Bx VELOCITY® Sirolimus-Eluting Stent Systems (ELITE).|Unknown status|Active, not recruiting|N/A|678|Actual|Cordis Corporation|The study was terminated early by the Sponsor for business reasons. Hence the data was under powered for hypothesis testing. No definitive conclusions can be made from this data.|2|||f||||t||||||||||2018-06-01 01:56:37.442456|2018-06-01 01:56:37.442456
NCT00715871|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2014-11-17|2008-07-12|2008-07-15|Estimate|||||||2014-11-17|2014-11-19|Estimate|February 2008||2008-02-29|November 2014|2014-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Clinical Study of Smoke-Break Liquid Cigarettes|Phase II Study to Measure Effectiveness and to Monitor Side Effects of Smoke-Break Nicotine Delivery Device|Completed||Phase 2|52|Actual|Smoke-Break, Inc.||1|||f||||f||||||||||2018-06-01 01:56:38.246983|2018-06-01 01:56:38.246983
NCT00715858|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2009-02-03|2008-07-11|2008-07-15|Estimate|||||||2009-02-03|2009-02-04|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|October 2009|Anticipated|2009-10-31|August 2009|Anticipated|2009-08-31||Interventional|||A Pilot Study of Inflammatory Markers in Alzheimer's Disease|A Pilot Study Comparing Inflammatory Biomarkers in Blood and CSF in Patients With Alzheimer's Disease and Age-Matched Controls|Unknown status|Recruiting|Phase 3|21|Anticipated|McMaster University||5|||f||||f||||||||||2018-06-01 01:56:38.319062|2018-06-01 01:56:38.319062
NCT00715845|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-10-25|2008-07-11|2008-07-15|Estimate|||||||2011-10-25|2011-10-26|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|April 2010|Actual|2010-04-30||Interventional|||Carbon Dioxide Insufflation on Cerebral Microemboli|Effects of Carbon Dioxide Insufflation on Cerebral Microemboli During Cardiopulmonary Bypass: A Randomised Trial Correlating Embolic Load & Neurologic Outcomes.|Terminated||Phase 2/Phase 3|20|Actual|University Health Network, Toronto||1||ran out of funding|f||||f||||||||||2018-06-01 01:56:38.415564|2018-06-01 01:56:38.415564
NCT00715832|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2009-08-25|2008-07-14|2008-07-15|Estimate|||||||2009-08-25|2009-08-26|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|February 2015|Anticipated|2015-02-28|February 2010|Anticipated|2010-02-28||Interventional|||A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer|A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 1|25|Anticipated|Southern Cancer Center|||||f||||t||||||||||2018-06-01 01:56:38.492869|2018-06-01 01:56:38.492869
NCT00715819|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2009-02-17|2008-07-11|2008-07-15|Estimate|||||||2009-02-17|2009-02-19|Estimate|April 2008||2008-04-30|February 2009|2009-02-28||||December 2009|Anticipated|2009-12-31||Observational|||Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma|Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma|Unknown status|Recruiting||30|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 01:56:38.574271|2018-06-01 01:56:38.574271
NCT00715806|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2011-06-21|2008-07-11|2008-07-15|Estimate|||||||2011-06-21|2011-06-23|Estimate|June 2008||2008-06-30|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CLAUSTRO||Claustrophobia and Magnetic Resonance Imaging|Reduction of Claustrophobia During Magnetic Resonance Imaging: Randomized, Controlled Trial|Completed||N/A|174|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 01:56:38.630413|2018-06-01 01:56:38.630413
NCT00715780|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2016-11-04|2008-07-14|2008-07-15|Estimate|||||||2016-11-04|2016-11-07|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents|Observational Safety and Efficacy Study in Subjects Using Insulin for the Treatment of Type 2 Diabetes Mellitus Failing on Oral Anti-diabetic Agents|Completed|||1667|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:56:39.033975|2018-06-01 01:56:39.033975
NCT00715767|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2010-10-13|2008-07-14|2008-07-15|Estimate|||||||2010-10-13|2010-10-14|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|BLSinBotswana||Basic Life Support (BLS) and Barriers to Cross-Cultural Education|Correlation of Cognitive and Technical Skills Assessment for Basic Life Support and Identification of Barriers to Cross-Cultural Education|Completed||N/A|215|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 01:56:39.124309|2018-06-01 01:56:39.124309
NCT00715754|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2009-07-21||2017-12-22|2008-07-11|2008-07-15|Estimate|2009-11-24|2010-01-11|Estimate||||2017-12-22|2018-01-23|Actual|September 2006||2006-09-30|December 2017|2017-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|FEMA||Antecedents of Obesity: Fetal Measures of Adiposity|"Antecedents of Obesity: Fetal Measures of Adiposity, A Plan for Obesity Disaster Management"|Completed|||47|Actual|University of Utah|||||f||||f||||||||||2018-06-01 01:56:39.20053|2018-06-01 01:56:39.20053
NCT00715741|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2009-08-11||2010-02-02|2008-07-14|2008-07-15|Estimate|2009-11-24|2010-01-11|Estimate||||2010-02-02|2010-02-18|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Does High Intraoperative Inspired Oxygen Reduce Postoperative Arterial Oxygen Saturation?|Does High Intraoperative Inspired Oxygen Reduce Postoperative Arterial Oxygen Saturation?|Completed||Phase 2/Phase 3|100|Actual|University of Utah|This data for this outcome measure is identical|4|||f||||f||||||||||2018-06-01 01:56:39.355461|2018-06-01 01:56:39.355461
NCT00715728|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2009-06-18|2008-07-11|2008-07-15|Estimate|||||||2009-06-18|2009-06-19|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Efficacy of Warming Device During Surgery|Efficacy of a New Intraoperative Resistive Warming Device|Unknown status|Recruiting||30|Anticipated|Outcomes Research Consortium|||2||f||||f||||||||||2018-06-01 01:56:39.733822|2018-06-01 01:56:39.733822
NCT00715715|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2012-04-18|2008-07-14|2008-07-15|Estimate|||||||2012-04-18|2012-04-20|Estimate|April 2008||2008-04-30|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients|A Pilot Study of Adefovir Dipivoxil Alone and After Prednisone Priming for the Treatment of Asian Patients With HBeAg-positive Chronic Hepatitis B|Withdrawn||N/A|0|Actual|Maimonides Medical Center||2||Withdrawn studies.|f||||f||||||||||2018-06-01 01:56:39.808187|2018-06-01 01:56:39.808187
NCT00715702|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2009-04-28|2008-07-11|2008-07-15|Estimate|||||||2009-04-28|2009-04-29|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety Study of AZD5672 in Renally Impaired Subjects|An Open-Label, Single-Centre, Parallel Group, Phase I Study To Compare the Pharmacokinetics of AZD5672 Single Dose in Patients With Renal Impairment and Healthy Volunteers|Completed||Phase 1|40|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:56:39.884156|2018-06-01 01:56:39.884156
NCT00715689|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2017-02-06|2008-07-14|2008-07-15|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2008||2008-07-31|February 2017|2017-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083|Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC126-0083 in Growth Hormone Deficient Adults (GHDA)|Completed||Phase 2|33|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 01:56:39.948817|2018-06-01 01:56:39.948817
NCT00715676|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2009-09-16||2009-12-07|2008-07-14|2008-07-15|Estimate|2009-12-07|2010-01-11|Estimate||||2009-12-07|2010-01-11|Estimate|March 2007||2007-03-31|December 2009|2009-12-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|2MD-3H-2B||Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density|A Phase 2, Double-blind, Randomized, Placebo-Controlled, Daily-dose, Proof-of-concept Study of a Vitamin D Compound in Postmenopausal Women With Osteopenia|Completed||Phase 2|157|Actual|Deltanoid Pharmaceuticals||3|||f||||t||||||||||2018-06-01 01:56:40.051741|2018-06-01 01:56:40.051741
NCT00715663|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2016-12-12|2008-07-14|2008-07-15|Estimate|||||||2016-12-12|2016-12-13|Estimate|February 2007||2007-02-28|December 2016|2016-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes|A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoMix® 30 FlexPen® as Monotherapy, or in Combination With OHA, in Treatment of Type 2 Diabetic Patients in Routine Clinical Practice: A Post-Marketing Surveillance Study|Completed|||1584|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:56:40.461161|2018-06-01 01:56:40.461161
NCT00715650|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2014-10-06||2016-02-10|2008-07-11|2008-07-15|Estimate|2014-10-09|2014-10-17|Estimate||||2016-02-10|2016-03-11|Estimate|December 2008||2008-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2012|Actual|2012-06-30||Interventional|||Benefits Counseling to Preserve Function Among Disability Applicants|Benefits Counseling to Preserve Function Among Disability Applicants|Completed||Phase 2|92|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:56:40.531318|2018-06-01 01:56:40.531318
NCT00715637|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2010-10-12|2008-07-14|2008-07-15|Estimate|||||||2010-10-12|2010-10-13|Estimate|June 2007||2007-06-30|October 2010|2010-10-31||||June 2010|Anticipated|2010-06-30||Interventional|||Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study|Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study|Unknown status|Active, not recruiting|Phase 3|420|Anticipated|Antisoma Research||2|||f||||t||||||||||2018-06-01 01:56:41.049407|2018-06-01 01:56:41.049407
NCT00715624|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2016-08-18|2012-02-21|2016-10-14|2008-07-11|2008-07-15|Estimate|2016-08-18|2016-10-11|Estimate|2012-02-21|2012-02-23|Estimate|2016-10-14|2016-11-28|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|GETGOAL-L|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin|Completed||Phase 3|496|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:56:41.340645|2018-06-01 01:56:41.340645
NCT00715611|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2018-01-05|2008-07-14|2008-07-15|Estimate|||||||2018-01-05|2018-01-08|Actual|July 11, 2008||2008-07-11|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma|Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma|Recruiting||Phase 2|81|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:56:42.88879|2018-06-01 01:56:42.88879
NCT00715598|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2012-05-07|2008-07-11|2008-07-15|Estimate|||||||2012-05-07|2012-05-09|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|PQAS||Cognitive Testing for the Pain Quality Assessment Scale (PQAS)|Cognitive Testing for the Pain Quality Assessment Scale (PQAS)|Completed|||213|Actual|University of Washington|||2||f||||f||||||||||2018-06-01 01:56:42.989601|2018-06-01 01:56:42.989601
NCT00715585|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-06-11|2008-07-14|2008-07-15|Estimate|||||||2013-06-11|2013-06-13|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|DiNES||Addressing The Role of Nutrition Education & Health Literacy in Diabetes Care|Addressing The Role of Nutrition Education & Health Literacy in Diabetes Care|Completed||N/A|150|Actual|Vanderbilt University||3|||f||||t||||||||||2018-06-01 01:56:43.068848|2018-06-01 01:56:43.068848
NCT00715572|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-07-14|2008-07-14|2008-07-15|Estimate|||||||2008-07-14|2008-07-15|Estimate|March 2002||2002-03-31|July 2008|2008-07-31|May 2004|Actual|2004-05-31|February 2004|Actual|2004-02-29||Interventional|||Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone|Combined Therapy With L-Thyroxine and L-Triiodothyronine Compared to L-Thyroxine Alone in the Treatment of Primary Hypothyroidism|Completed||N/A|36|Actual|I.M. Sechenov First Moscow State Medical University||2|||f||||f||||||||||2018-06-01 01:56:43.135401|2018-06-01 01:56:43.135401
NCT00715559|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2011-04-18||2017-04-05|2008-07-11|2008-07-15|Estimate|2011-05-15|2011-06-16|Estimate||||2017-04-05|2017-04-07|Actual|July 2008||2008-07-31|April 2017|2017-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Cysteamine Therapy for Major Depressive Disorder|An Open-Label Study of Cysteamine Bitartrate in Treatment-Resistant Major Depression|Terminated||N/A|3|Actual|Icahn School of Medicine at Mount Sinai||1||Change in resources available for study procedures.|f||||f||||||||||2018-06-01 01:56:43.204485|2018-06-01 01:56:43.204485
NCT00715546|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2011-06-21|2008-07-12|2008-07-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|November 2011|Anticipated|2011-11-30|August 2011|Anticipated|2011-08-31||Interventional|AADSCTPL||Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy|Phase 1 Study of Autologous-Derived Stem Cell Transplantation in Patients With Lipodystrophy|Unknown status|Active, not recruiting|Phase 1|5|Actual|Irmandade Santa Casa de Misericórdia de Porto Alegre|||||f||||t||||||||||2018-06-01 01:56:44.112708|2018-06-01 01:56:44.112708
NCT00715533|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2014-06-23|2008-07-11|2008-07-15|Estimate|||||||2014-06-23|2014-06-24|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|1000Plus||3 Tesla (3T) Stroke Medical Radiologic Technology (MRT) for Examining Mismatch in 1000+|3T Stroke MRT for Examining Mismatch in the CSB of the Charité Universitätsmedizin Berlin (3Tesla in 1000+)|Completed|||1500|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 01:56:44.170985|2018-06-01 01:56:44.170985
NCT00715520|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2017-10-12||2017-10-12|2008-07-11|2008-07-15|Estimate|2017-10-12|2017-10-16|Actual||||2017-10-12|2017-10-16|Actual|April 2007||2007-04-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Participants included in the baseline analysis received a study intervention and completed all study procedures.|Neurobiological Principles Applied to the Rehabilitation of Stroke Patients|Neurobiological Principles Applied to the Rehabilitation of Stroke Patients|Completed||N/A|33|Actual|Emory University|Target enrollment for aim 3 was not me due to difficulty identifying participants that met the inclusion criteria. Therefore the study team did not have a sufficient sample size to complete any data analysis for this aim.|3|||f||||f||||||||||2018-06-01 01:56:44.258487|2018-06-01 01:56:44.258487
NCT00715507|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2016-08-08|2008-07-11|2008-07-15|Estimate|||||||2016-08-08|2016-08-10|Estimate|July 2003||2003-07-31|August 2016|2016-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Evaluation of Drug Display in Critical Care Setting|Evaluation of Drug Display in Critical Care Setting|Completed|||200|Anticipated|University of Utah|||2||f||||t||||||||||2018-06-01 01:56:44.776467|2018-06-01 01:56:44.776467
NCT00715494|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2018-02-28|2008-07-14|2008-07-15|Estimate|||||||2018-02-28|2018-03-01|Actual|July 2008||2008-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|September 2009|Actual|2009-09-30||Interventional|RETURN||A Pilot Study of Rehabilitation Among Intensive Care Unit (ICU) Survivors: the RETURN Trial|Returning to Everyday Tasks Utilizing Rehabilitation Networks (RETURN)|Active, not recruiting||N/A|130|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-06-01 01:56:44.844107|2018-06-01 01:56:44.844107
NCT00715481|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2015-02-09|2008-07-10|2008-07-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|November 2008|Actual|2008-11-30||Observational|RIACE||Renal Insufficiency And Cardiovascular Events|Reduced Estimated Glomerular Filtration Rate (eGFR)and Prediction of Cardiovascular Disease and Renal Outcome in Subjects With Type 2 Diabetes: Italian Multicenter Study|Completed|||15628|Actual|Diabetic Nephropathy Study Group|||||f||||f||||||||||2018-06-01 01:56:44.921036|2018-06-01 01:56:44.921036
NCT00715468|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2014-12-11|2008-07-14|2008-07-15|Estimate|||||||2014-12-11|2014-12-12|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Observational|||Prospective, 6 Month, Open Label, Conversion Study From Mycophenolate Mofetil (MMF) to PRMYFORTIC*|Prospective, 6 Month, Open Label, Conversion Study From MMF to MYFORTIC* Evaluating the Severity of GI Symptoms and MPA Metabolite as a Surrogate Marker of MYFORTIC|Completed|||59|Actual|Maisonneuve-Rosemont Hospital|||||f||||f||||||||||2018-06-01 01:56:45.023619|2018-06-01 01:56:45.023619
NCT00715455|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2013-05-29|2008-07-14|2008-07-15|Estimate|||||||2013-05-29|2013-05-31|Estimate|October 2007||2007-10-31|May 2013|2013-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|REVERSAL-PCI||Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI|Phase 2a, Multi-Center, Open Label, Randomized, Feasibility/Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Subjects Undergoing Elective PCI After Pretreatment With Clopidogrel and Aspirin|Completed||Phase 2|26|Actual|Regado Biosciences, Inc.||3|||f||||t||||||||||2018-06-01 01:56:45.086968|2018-06-01 01:56:45.086968
NCT00715442|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2018-02-27|2008-07-14|2008-07-15|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2008|Actual|2008-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)|Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy|Active, not recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:56:45.175711|2018-06-01 01:56:45.175711
NCT00715429|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-01-14|2008-07-14|2008-07-15|Estimate|||||||2013-01-14|2013-01-16|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Vitamin D for Painful Nocturnal Leg Cramps|Nocturnal Leg Cramps in the Elderly: Randomized Controlled Trial of Ergocalciferol (Vitamin D2) for a Painful and Distressing Problem|Terminated||N/A|29|Actual|University of Wisconsin, Madison||2||"We exhausted potential candidates before reaching goal of 70; recruited 29, 29 completed the~   study"|f||||t||||||||||2018-06-01 01:56:45.251135|2018-06-01 01:56:45.251135
NCT00715416|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-07-11|2008-07-11|2008-07-15|Estimate|||||||2008-07-11|2008-07-15|Estimate|June 2004||2004-06-30|January 2006|2006-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents|Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial|Completed||Phase 4|76|Actual|Vienna General Hospital||2|||f||||f||||||||||2018-06-01 01:56:45.324458|2018-06-01 01:56:45.324458
NCT00715403|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2014-11-14||2014-11-24|2008-07-14|2008-07-15|Estimate|2014-11-24|2014-12-02|Estimate||||2014-11-24|2014-12-02|Estimate|October 2004||2004-10-31|November 2014|2014-11-30||||September 2009|Actual|2009-09-30||Interventional||Treated set which comprised of all patients who received at least one dose of Nintedanib in both their previous Nintedanib trial and in this extension trial|A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120|Extension Study to Establish Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Patients With Previous Clinical Benefit From BIBF 1120|Completed||Phase 1|41|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:56:45.501828|2018-06-01 01:56:45.501828
NCT00715390|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2009-04-03||2012-12-13|2008-07-11|2008-07-15|Estimate|2011-02-02|2011-03-01|Estimate||||2012-12-13|2012-12-27|Estimate|October 2004||2004-10-31|December 2012|2012-12-31|August 2006|Actual|2006-08-31|August 2005|Actual|2005-08-31||Observational|||Dysrhythmias During General Anesthesia in Children|Dysrhythmias During General Anesthesia in Children|Completed|||234|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-06-01 01:56:48.091996|2018-06-01 01:56:48.091996
NCT00715377|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2015-08-21|2008-07-14|2008-07-15|Estimate|||||||2015-08-21|2015-08-24|Estimate|June 2007||2007-06-30|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Anticholinergic Burden in Schizophrenia|Anticholinergic Burden in Schizophrenia|Terminated||N/A|2|Actual|Centre for Addiction and Mental Health||1||Insufficient subject accrual|f||||f||||||||||2018-06-01 01:56:48.218346|2018-06-01 01:56:48.218346
NCT00715364|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2011-09-02|2008-07-14|2008-07-15|Estimate|||||||2011-09-02|2011-09-05|Estimate|August 2009||2009-08-31|September 2011|2011-09-30|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|REGENESIS||REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|Withdrawn||Phase 2|30|Anticipated|Stem Cell Therapeutics Corp.||2|||f||||t||||||||||2018-06-01 01:56:48.291806|2018-06-01 01:56:48.291806
NCT00715351|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2016-11-23|2008-07-11|2008-07-15|Estimate|||||||2016-11-23|2016-11-25|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes|Efficacy and Safety of Glycaemic Control of Levemir® or Insulatard® in Patients With Type 2 Diabetes|Completed|||342|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 01:56:48.37052|2018-06-01 01:56:48.37052
NCT00715338|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2017-04-19|2008-07-14|2008-07-15|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2008|Actual|2008-06-30|April 2017|2017-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Effects of Oxygen on Lung Tissue During Anesthesia|Effects of Oxygen on Lung Tissue During Anesthesia|Terminated|||10|Actual|Vanderbilt University Medical Center||||poor enrollment|f||||t||||||None Retained|"~     serum~   "|||2018-06-01 01:56:48.442661|2018-06-01 01:56:48.442661
NCT00715325|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-13|||2008-09-17|2008-07-14|2008-07-15|Estimate|||||||2008-09-17|2008-09-18|Estimate|October 2008||2008-10-31|September 2008|2008-09-30|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|||ProtectiScope CS Intended for Diagnostic and Therapeutic Colonoscopy|Evaluation of Safety and Efficacy of a New Colonoscope, ProtectiScope CS, to Diagnose Large Bowel Diseases|Unknown status|Not yet recruiting|Phase 1/Phase 2|200|Anticipated|Stryker GI Ltd.||1|||f||||f||||||||||2018-06-01 01:56:48.500901|2018-06-01 01:56:48.500901
NCT00715312|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-07-14|2008-07-14|2008-07-15|Estimate|||||||2008-07-14|2008-07-15|Estimate|February 2008||2008-02-29|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Oleic Acid on Inflammation Markers and Blood Lipid Metabolites: A Randomised, Double-Blind, Crossover Study|Effect of Oleic Acid on Inflammation Markers and Blood Lipid Metabolites: A Randomised, Double-Blind, Crossover Study.|Completed||N/A|43|Actual|Malaysia Palm Oil Board||1|||f||||f||||||||||2018-06-01 01:56:48.556485|2018-06-01 01:56:48.556485
NCT00715299|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2014-12-03||2015-02-17|2008-07-14|2008-07-15|Estimate|2015-02-17|2015-03-05|Estimate||||2015-02-17|2015-03-05|Estimate|June 2005||2005-06-30|February 2015|2015-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||Individuals greater than 6 months post stroke, 18-80 years of age. Subjects who have experienced more than one stroke will be accepted only if all strokes are on the same side of the brain.|Locomotor Training (Walking Therapy) Post Stroke|Mechanisms of Response to Locomotor Training After Stroke|Completed||N/A|38|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:56:48.626125|2018-06-01 01:56:48.626125
NCT00715286|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2008-07-14|2008-07-14|2008-07-15|Estimate|||||||2008-07-14|2008-07-15|Estimate|November 2001||2001-11-30|July 2008|2008-07-31|June 2009|Anticipated|2009-06-30|April 2007|Anticipated|2007-04-30||Interventional|||Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study|Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study|Unknown status|Recruiting|Phase 3|180|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 01:56:48.747985|2018-06-01 01:56:48.747985
NCT00715273|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2018-02-07|2008-07-11|2008-07-15|Estimate|||||||2018-02-07|2018-02-09|Actual|June 2001||2001-06-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|CPC||Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication|Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy|Active, not recruiting||Phase 4|217|Actual|University of Washington||3|||f||||t||||||||No||2018-06-01 01:56:48.879386|2018-06-01 01:56:48.879386
NCT00715260|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2008-07-14|2008-07-14|2008-07-15|Estimate|||||||2008-07-14|2008-07-15|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Observational|ITCH Registry||An Observational Study of Pruritus Amongst Hemodialysis Patients|A Multicenter, Prospective, Observational Study of Pruritus Amongst Hemodialysis Patients: The ITCH National Registry|Unknown status|Active, not recruiting||80|Anticipated|Acologix, Inc.|||1||f||||f||||||||||2018-06-01 01:56:48.967663|2018-06-01 01:56:48.967663
NCT00715247|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2017-11-01|2008-07-14|2008-07-15|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2006||2006-07-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes|Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes|Recruiting|||700|Anticipated|University of Utah|||2||f||||f||||||Samples With DNA|"~     Whole blood and bone marrow aspirate~   "|||2018-06-01 01:56:49.022472|2018-06-01 01:56:49.022472
NCT00715234|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-06-21|2008-07-14|2008-07-15|Estimate|||||||2013-06-21|2013-06-25|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|||Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients|Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients|Completed||N/A|4807|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:56:49.15879|2018-06-01 01:56:49.15879
NCT00715221|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2017-07-28|2008-07-14|2008-07-15|Estimate|||||||2017-07-28|2017-08-01|Actual|July 2007||2007-07-31|July 2017|2017-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Multi-Tracer Pet Quantitation of Insulin Action|Multi-Tracer Pet Quantitation of Insulin Action|Completed|||30|Actual|University of Pittsburgh|||3||f||||f||||||Samples Without DNA|"~     Aliquotted blood samples~   "|||2018-06-01 01:56:49.225306|2018-06-01 01:56:49.225306
NCT00715208|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2012-02-03||2013-04-26|2008-07-14|2008-07-15|Estimate|2013-04-26|2013-04-29|Estimate||||2013-04-26|2013-04-29|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma|A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.|Completed||Phase 2|55|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||||||||||||2018-06-01 01:56:49.317029|2018-06-01 01:56:49.317029
NCT00715195|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2013-12-18|2008-07-11|2008-07-15|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|Aquavip||Improving Quality of Life of Fibromyalgia Patients|Evaluation of Improving Quality of Life of Fibromyalgia Patients Treated With a Plurifocal Program : a Controlled Study With 12 Months Monitoring.|Completed||N/A|115|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:56:49.8052|2018-06-01 01:56:49.8052
NCT00715182|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2013-01-15|2008-07-14|2008-07-15|Estimate|||||||2013-01-15|2013-01-17|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer|A Phase I/II Multi-center, Open Label Study of TKI258 Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC)|Completed||Phase 1|87|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:56:49.862923|2018-06-01 01:56:49.862923
NCT00715169|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-07-14|2008-07-14|2008-07-15|Estimate|||||||2008-07-14|2008-07-15|Estimate|August 2005||2005-08-31|July 2008|2008-07-31||||April 2006|Actual|2006-04-30||Interventional|||Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease|Phase 2 A, Double-Blind, Randomized, Placebo-Controlled Trial Measuring the Effects of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease|Completed||Phase 2|108|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 01:56:50.103362|2018-06-01 01:56:50.103362
NCT00715156|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2012-02-20|2008-07-14|2008-07-15|Estimate|||||||2012-02-20|2012-02-22|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|October 2009|Actual|2009-10-31||Observational|||Role of Recombinants in Peach Allergy|Classification of Different Forms of Peach Allergy and the Role of Recombinant Allergens in the Diagnosis|Completed|||148|Actual|Niguarda Hospital|||2||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 01:56:50.235433|2018-06-01 01:56:50.235433
NCT00715143|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2015-02-09|2008-07-14|2008-07-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Post Approval Study: NOVATION Ceramic Articulation Hip System|Post Approval Study: NOVATION Ceramic Articulation Hip System A Multi-Center, Open-Label Study to Evaluate the Mid and Long-Term Safety and Effectiveness of the Exactech NOVATION Ceramic Articulation Hip System|Recruiting||Phase 4|125|Anticipated|Exactech||1|||f||||f||||||||||2018-06-01 01:56:50.303728|2018-06-01 01:56:50.303728
NCT00715130|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2011-12-06|2008-07-14|2008-07-15|Estimate|||||||2011-12-06|2011-12-07|Estimate|September 2005||2005-09-30|December 2011|2011-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|MOVE'M||Move and Moderate in Balance|Move and Moderate in Balance (MOVE'M): A TREC Worksite Health Study|Completed||N/A|31|Actual|Fred Hutchinson Cancer Research Center|||||f||||t||||||||||2018-06-01 01:56:50.384305|2018-06-01 01:56:50.384305
NCT00715117|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|2011-08-04||2013-05-29|2008-07-14|2008-07-15|Estimate|2013-05-29|2013-05-30|Estimate||||2013-05-29|2013-05-30|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|LDN-Ped||The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease|The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease|Completed||Phase 2|14|Actual|Penn State University|This was a pseudo-crossover trial where 6 subjects received placebo for 8 wks then were crossed over to active drug for 8 wks to increase the N treated with active drug. A smaller cohort of subjects on placebo were for safety & toxicity comparison.|2|||f||||t||||||||||2018-06-01 01:56:50.468738|2018-06-01 01:56:50.468738
NCT00715104|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2015-02-27||2015-04-14|2008-07-14|2008-07-15|Estimate|2015-03-17|2015-04-01|Estimate||||2015-04-14|2015-05-04|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|NeoACT||Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer|An Open Label, Phase 2 Trial of Immunotherapy With Sipuleucel-T (Provenge®) as Neoadjuvant Treatment in Men With Localized Prostate Cancer|Completed||Phase 2|42|Actual|Dendreon||2|||f||||t||||||||||2018-06-01 01:56:50.951753|2018-06-01 01:56:50.951753
NCT00715091|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2014-08-22|2008-07-14|2008-07-15|Estimate|||||||2014-08-22|2014-08-25|Estimate|September 2008||2008-09-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ENRADAS||Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis|Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial|Completed||Phase 4|180|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 01:56:51.707675|2018-06-01 01:56:51.707675
NCT00715078|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2014-02-19||2017-04-21|2008-07-14|2008-07-15|Estimate|2014-04-10|2014-05-12|Estimate||||2017-04-21|2017-05-23|Actual|October 2008||2008-10-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|April 2012|Actual|2012-04-30||Interventional|||To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen|A Randomized, Multicenter, Single Blind Study in Men With Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen|Completed||Phase 2|122|Actual|Dendreon||3|||f||||t||||||||Undecided||2018-06-01 01:56:51.825547|2018-06-01 01:56:51.825547
NCT00715065|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-01-07|2008-07-14|2008-07-15|Estimate|||||||2013-01-07|2013-01-09|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|||fMRI in Blood Phobia Syncope|Neuroimaging in Blood Phobia Syncope|Withdrawn|||0|Actual|Vanderbilt University|||2|Could not get funding for fMRI studies at this time.|f||||f||||||||||2018-06-01 01:56:52.658976|2018-06-01 01:56:52.658976
NCT00715052|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-14|||2013-05-06|2008-07-14|2008-07-15|Estimate|||||||2013-05-06|2013-05-07|Estimate|August 2008||2008-08-31|October 2008|2008-10-31||||June 2012|Actual|2012-06-30||Interventional|||The Effect of Hyperbaric Oxygen Therapy on Patients Suffering From Neurologic Deficiency Due Traumatic Brain Injury||Completed||N/A|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 01:56:52.728602|2018-06-01 01:56:52.728602
NCT00715039|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-10-01|2008-07-14|2008-07-15|Estimate|||||||2008-10-01|2008-10-03|Estimate|October 2003||2003-10-31|October 2008|2008-10-31|May 2004|Actual|2004-05-31|||||Interventional|||Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder|A 4-Week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients With Generalized Anxiety Disorder: Assessment of a New Instrument Intended to Capture Rapid Onset|Completed||N/A|169|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 01:56:52.801565|2018-06-01 01:56:52.801565
NCT00715026|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2013-11-13||2014-11-25|2008-07-11|2008-07-15|Estimate|2014-11-25|2014-11-26|Estimate||||2014-11-25|2014-11-26|Estimate|April 2009||2009-04-30|November 2014|2014-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Trilogy AB Acetabular Hip System Post Approval Study|Multicenter Post Approval Study of the Trilogy AB(R) Acetabular System|Terminated||Phase 4|31|Actual|Zimmer Biomet|A business decision unrelated to device performance led to the early termination of the study and withdrawal of the study device(s) from the US market. Early termination of the study limits the usefulness of the available data.|1||Sponsor business decision unrelated to clinical performance.|f||||f||||||||||2018-06-01 01:56:52.953677|2018-06-01 01:56:52.953677
NCT00715013|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2011-09-14|2008-07-11|2008-07-14|Estimate|||||||2011-09-14|2011-09-15|Estimate|July 2008||2008-07-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma|Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma Multiforme Prior to and After Secondary Resection: an Open-label Phase I/II Trial.|Completed||Phase 1/Phase 2|9|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 01:56:53.132371|2018-06-01 01:56:53.132371
NCT00715000|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2013-04-24|2008-07-11|2008-07-14|Estimate|||||||2013-04-24|2013-04-25|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|SROPREMA||Oral Versus Intravenous Rehydration for Prevention of Dehydration in Premature Babies, During the First Days of Life.|Prevention of Dehydration in Premature Babies Between 32 and 34+6 Gestational Age, Weighing Between 1700 and 2200 g, During the First Days of Life, Using Oral Rehydration Solution in Alternative to Intravenous Infusion|Completed||Phase 4|49|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:56:53.215833|2018-06-01 01:56:53.215833
NCT00714987|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-09-16|2008-07-11|2008-07-14|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Observational|||The EVLW for Set the Positive End Expiratory Pressure (PEEP) in the Acute Respiratory Distress Syndrome (ARDS)|Predictive Value of the Extra-Vascular Lung Water (EVLW) for the Alveolar Recruitment in the Acute Respiratory Distress Syndrome ( ARDS ).|Withdrawn|||40|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-06-01 01:56:53.284992|2018-06-01 01:56:53.284992
NCT00714974|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2008-07-08|2008-07-08|2008-07-14|Estimate|||||||2008-07-08|2008-07-14|Estimate|February 2000||2000-02-29|July 2008|2008-07-31|October 2007|Actual|2007-10-31|February 2003|Actual|2003-02-28||Interventional|||A Prospective, Randomized, Blinded Study of BIS Analysis in ICU Patients Requiring Neuromuscular Blocking Agents|A Prospective, Randomized, Blinded Study of BIS Analysis in ICU Patients Requiring Neuromuscular Blocking Agents|Completed||N/A|56|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 01:56:53.363641|2018-06-01 01:56:53.363641
NCT00714961|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2009-03-24|2008-07-10|2008-07-14|Estimate|||||||2009-03-24|2009-03-25|Estimate|February 2003||2003-02-28|March 2009|2009-03-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|CLARITY-TIMI28||Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction|A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy|Completed||Phase 3|3491|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:56:53.423705|2018-06-01 01:56:53.423705
NCT00714948|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2015-04-14||2015-10-18|2008-07-11|2008-07-14|Estimate|2015-10-18|2015-11-16|Estimate||||2015-10-18|2015-11-16|Estimate|July 2008||2008-07-31|October 2015|2015-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Phase II Study of Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Terminated||Phase 2|2|Actual|Memorial Sloan Kettering Cancer Center|Early termination leading to no subjects analyzed. Only two participants were enrolled and treated on this study. Neither completed the study as they both came off due to adverse events.|1||Lack of accrual|f||||||||||||||2018-06-01 01:56:53.5289|2018-06-01 01:56:53.5289
NCT00714935|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2015-11-03|2008-07-11|2008-07-14|Estimate|||||||2015-11-03|2015-11-04|Estimate|April 2008||2008-04-30|November 2015|2015-11-30|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Shared Decision-making: Effects on Cardiac Risk Factor Modification Behavior|Effects of a Decision Aid for Patients With Coronary Artery Disease on Cardiac Risk Factor Modification Behavior and Health Outcomes|Completed||N/A|363|Actual|Oslo University Hospital||3|||f||||f||||||||||2018-06-01 01:56:53.691879|2018-06-01 01:56:53.691879
NCT00714922|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2010-09-14|2008-07-11|2008-07-14|Estimate|||||||2010-09-14|2010-09-16|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Comparison of Photorefractive Keratectomy (PRK) and Sub-Bowman's Keratomileusis (SBK)|Comparison of Photorefractive Keratectomy (PRK) and Sub-Bowman's Keratomileusis (SBK): Assessment of Visual Function and Patient Satisfaction|Completed||N/A|60|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 01:56:53.783443|2018-06-01 01:56:53.783443
NCT00714909|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2011-02-22|2008-07-11|2008-07-14|Estimate|||||||2011-02-22|2011-02-23|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|May 2012|Anticipated|2012-05-31|November 2011|Anticipated|2011-11-30||Observational|CAVECCAS||Determination of Predictive Value of Echography Doppler Abnormalities|CAVECCAS Value of Risk Factors for Symptomatic Catheter Related Thrombosis in Patients With Breast Cancer Treated With Adjuvant Chemotherapy|Unknown status|Recruiting||600|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-06-01 01:56:53.840497|2018-06-01 01:56:53.840497
NCT00714896|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2013-05-25|2008-07-09|2008-07-14|Estimate|||||||2013-05-25|2013-05-29|Estimate|April 2007||2007-04-30|May 2013|2013-05-31|August 2009|Actual|2009-08-31|June 2008|Actual|2008-06-30||Interventional|INSPIRE||Interventions for Smoking Among Persons in Recovery|A Stepped-Care Intervention for Current and Former Smokers in Outpatient Chemical Dependency Treatment|Completed||N/A|75|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:56:53.91054|2018-06-01 01:56:53.91054
NCT00714883|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2012-10-24|2008-07-11|2008-07-14|Estimate|||||||2012-10-24|2012-10-25|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|November 2009|Actual|2009-11-30||Interventional|NEVO RES-II||Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution in Native Coronary Artery Lesions|A Prospective, Multi-Center Study of the Conor Cobalt Chromium Reservoir Based Stent (NevoTM) With Sirolimus Elution in Native Coronary Artery Lesions (NEVO RES-II)|Terminated||Phase 2|3|Actual|Cordis Corporation||||"The NEVO™ stent will not be commercialized. Cordis decided to close the study after 3 years.~   This decision took the absence of safety signals into account."|f||||t||||||||||2018-06-01 01:56:54.070167|2018-06-01 01:56:54.070167
NCT00714870|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2013-03-28||2013-05-29|2008-07-11|2008-07-14|Estimate|2013-05-29|2013-05-31|Estimate||||2013-05-29|2013-05-31|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pediatric Quality of Life Among Population With Body Mass Index (BMI) Greater Than or Equal to 85%|Pediatric Quality of Life Among Population With BMI Greater Than or Equal to 85%: Impact of a Behavioral Intervention Program|Completed||N/A|76|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.||1|||f||||t||||||||||2018-06-01 01:56:54.205285|2018-06-01 01:56:54.205285
NCT00714857|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2014-01-02|2008-07-11|2008-07-14|Estimate|||||||2014-01-02|2014-01-03|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Dex-Pop-PK||Population Pharmacokinetics of Dexmedetomidine in ICU Patients|Population Pharmacokinetics of Dexmedetomidine in ICU Patients|Completed||Phase 2/Phase 3|21|Actual|University of Turku||1|||f||||f||||||||||2018-06-01 01:56:54.590856|2018-06-01 01:56:54.590856
NCT00714844|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-07|2008-07-07|2008-07-14|Estimate|||||||2008-07-07|2008-07-14|Estimate|January 2007||2007-01-31|April 2008|2008-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Insulin Detemir and Waist Circumference|Waist Circumference Reduction After Insulin Detemir Treatment in Type 2 Diabetes Patients Previously Treated With NPH Insulin|Completed|||20|Actual|University of Roma La Sapienza|||||f||||f||||||||||2018-06-01 01:56:54.656051|2018-06-01 01:56:54.656051
NCT00714831|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2008-07-11|2008-07-11|2008-07-14|Estimate|||||||2008-07-11|2008-07-14|Estimate|September 2008||2008-09-30|July 2008|2008-07-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Referral From Primary Health Care Centers to a Physical Activity Program. A Randomized Controlled Trial|Referral From Primary Health Care Centers to a Physical Activity Program: Establishing Long-Term Adherence? A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|424|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-06-01 01:56:54.704793|2018-06-01 01:56:54.704793
NCT00714818|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-11-21|2008-07-11|2008-07-14|Estimate|||||||2011-11-21|2011-11-23|Estimate|August 2008||2008-08-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Impact of Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness|Genetic Counseling for Female First Degree Relatives of Individuals With Mental Illness: Impact on Knowledge, Risk Perception, Perceived Control and Internalized Stigma.|Completed||Phase 3|13|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 01:56:54.782237|2018-06-01 01:56:54.782237
NCT00714805|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2017-01-05|2008-07-10|2008-07-14|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|GIDysmotility||Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)|Non-Invasive Measurement of GI Motility in Patients With ALS|Completed|||41|Actual|Drexel University|||2||f||||f||||||||||2018-06-01 01:56:54.868292|2018-06-01 01:56:54.868292
NCT00714792|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2011-09-27||2017-04-26|2008-07-11|2008-07-14|Estimate|2017-04-26|2017-04-28|Actual||||2017-04-26|2017-04-28|Actual|June 2008||2008-06-30|April 2017|2017-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?|Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?|Completed|||18|Actual|University of Rochester|||2||f||||f||||||Samples Without DNA|"~     Urine specimen~   "|||2018-06-01 01:56:54.936721|2018-06-01 01:56:54.936721
NCT00714779|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-07|2008-07-07|2008-07-14|Estimate|||||||2008-07-07|2008-07-14|Estimate|January 2000||2000-01-31|July 2008|2008-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Fluoxetine vs. Brief Psychotherapy for Major Depression|Fluoxetine vs. Brief Psychotherapy in the Treatment of Major Depression - a Randomized Comparative Study|Completed||N/A|85|Actual|University of Turku||2|||f||||f||||||||||2018-06-01 01:56:55.120806|2018-06-01 01:56:55.120806
NCT00714766|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2009-02-13|2008-07-10|2008-07-14|Estimate|||||||2009-02-13|2009-02-16|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Heat Stress and Volume Administration|Heat Stress and Volume Administration|Completed||N/A|10|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-06-01 01:56:55.265751|2018-06-01 01:56:55.265751
NCT00714753|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2016-06-03|2008-07-11|2008-07-14|Estimate|||||||2016-06-03|2016-06-06|Estimate|August 2008||2008-08-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer|Pilot Evaluation of High Dose-Rate Brachytherapy ± Image-Guided Intensity Modulated Hypofractionated External Radiotherapy for Localized Prostate Cancer|Completed||Phase 2|5|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 01:56:55.332175|2018-06-01 01:56:55.332175
NCT00714740|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2014-05-18|2008-07-08|2008-07-14|Estimate|||||||2014-05-18|2014-05-20|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude|Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude|Completed||Phase 4|49|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 01:56:55.400362|2018-06-01 01:56:55.400362
NCT00714714|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2009-04-01||2012-02-14|2008-07-10|2008-07-14|Estimate|2009-07-24|2009-09-02|Estimate||||2012-02-14|2012-02-15|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.|An Investigator-Blind, Phase 4 Study Assessing the Facial Irritation Potential of Two Acne Treatment Products Using a Split-Face Model|Completed||Phase 4|25|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 01:56:55.535723|2018-06-01 01:56:55.535723
NCT00714701|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2017-03-21|2008-07-11|2008-07-14|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2008||2008-06-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|CAPS4||Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)|Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study)|Completed|||631|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||9||f||||f||||||Samples With DNA|"~     blood, pancreatic juices~   "|Yes|This study data is part of the CAPS Consortium Registry, an International registry for people screened for pancreas cancer.|2018-06-01 01:56:55.715501|2018-06-01 01:56:55.715501
NCT00714688|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2010-04-02||2014-04-24|2008-07-11|2008-07-14|Estimate|2010-04-02|2010-04-21|Estimate||||2014-04-24|2014-05-08|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder|A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS Methylphenidate (54 and 72 mg/Day) in Adults With Attention Deficit/Hyperactivity Disorder|Completed||Phase 3|279|Actual|Janssen-Cilag International NV|Study was not designed to statistically compare the 54 mg with the 72 mg dose. Study medication was not titrated to the assigned dose as in clinical practice. This could have differentially affected treatment emergence of AEs and patient retention.|3|||f||||f||||||||||2018-06-01 01:56:55.813057|2018-06-01 01:56:55.813057
NCT00714675|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2013-12-29|2008-07-11|2008-07-14|Estimate|||||||2013-12-29|2013-12-31|Estimate|December 2009||2009-12-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|CIPROAGE||Citrulline and Protein Metabolism in the Malnourished Elderly People|Citrulline Supplementation in Elderly Malnourished and Hospitalised Subjects: Effects on Protein Metabolism|Completed||N/A|27|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:56:56.297672|2018-06-01 01:56:56.297672
NCT00714662|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-11|2008-07-11|2008-07-14|Estimate|||||||2008-07-11|2008-07-14|Estimate|June 2008||2008-06-30|July 2008|2008-07-31|March 2009|Anticipated|2009-03-31|February 2009|Anticipated|2009-02-28||Interventional|||High Flux Hemodialysis Thrice Versus Once|Effects of Different Frequencies of High-Flux Membranes on Blood Pressure, Fluid Balance, and Indices of Nutrition, Inflammation, and Dialysis Adequacy in Chronic Hemodialysis Patients - Comparisons Between Thrice vs Once Weekly|Unknown status|Recruiting|Phase 3|80|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 01:56:56.381765|2018-06-01 01:56:56.381765
NCT00714649|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-11-13|2008-07-11|2008-07-14|Estimate|||||||2012-11-13|2012-11-14|Estimate|July 2008||2008-07-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|CHIRON||Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery|Neoadjuvant Cetuximab Monotherapy Followed by Surgery in Squamous Cell Carcinoma of Head and Neck: Phase I/II Study|Completed||Phase 1/Phase 2|34|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-06-01 01:56:56.443049|2018-06-01 01:56:56.443049
NCT00714636|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2017-03-07|2008-07-10|2008-07-14|Estimate|||||||2017-03-07|2017-03-09|Actual|October 2006||2006-10-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|CSF||Cerebrospinal Fluid Repository|Cerebrospinal Fluid Repository|Completed|||11|Actual|Drexel University|||2||f||||f||||||Samples With DNA|"~     Cerebrospinal Fluid from Lumbar Puncture.~   "|||2018-06-01 01:56:56.504558|2018-06-01 01:56:56.504558
NCT00714623|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-12-20|2008-07-11|2008-07-14|Estimate|||||||2012-12-20|2012-12-24|Estimate|March 2005||2005-03-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||The SCRIPPS DES REAL WORLD Registry|A Prospective Registry for the Use of CypherTM Sirolimus-Eluting Stents In Patients With Coronary Artery Disease Treated With Percutaneous Coronary Interventions at Scripps Clinic|Completed|||859|Actual|Scripps Health|||||f||||t||||||||||2018-06-01 01:56:56.558878|2018-06-01 01:56:56.558878
NCT00714610|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2014-02-03|2008-07-11|2008-07-14|Estimate|||||||2014-02-03|2014-02-04|Estimate|August 2007||2007-08-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Serum Metal Ion Concentrations Following Primary Hip Arthroplasty|Serum Metal Ion Concentrations Following Unilateral Versus Bilateral Large Head Metal on Metal Primary Hip Arthroplasty|Completed|||39|Actual|University of Utah|||1||f||||t||||||Samples Without DNA|"~     Blood will be drawn for analysis.~   "|||2018-06-01 01:56:56.618659|2018-06-01 01:56:56.618659
NCT00714597|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09||2010-12-20|2013-01-14|2008-07-09|2008-07-14|Estimate||||2010-12-20|2010-12-28|Estimate|2013-01-14|2013-01-23|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|SAVE-VEMED||Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility|Terminated||Phase 3|421|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:56:56.671907|2018-06-01 01:56:56.671907
NCT00714584|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2011-05-18|2008-07-11|2008-07-14|Estimate|||||||2011-05-18|2011-05-19|Estimate|May 2003||2003-05-31|April 2010|2010-04-30|June 2003|Actual|2003-06-30|||||Interventional|||Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers|Pharmacokinetics of Naltrexone Hydrochloride (HCl) Following Intravenous (i.v.) and Oral Routes of Administration in Healthy Subjects|Completed||Phase 1|18|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 01:56:56.903238|2018-06-01 01:56:56.903238
NCT00714571|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2016-11-03||2016-11-03|2008-07-11|2008-07-14|Estimate|2016-11-03|2017-01-04|Estimate||||2016-11-03|2017-01-04|Estimate|July 2008||2008-07-31|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||"One participant from MST Healthy older adults Stage 1 excluded after study completion due to ongoing chemotherapy treatment (undisclosed during study).~One participant from MST MCI Stage 1 excluded due to being diagnosed with Alzheimer's dementia within 1 month of completing study"|Behavioral and Neuroimaging Changes After Cognitive Rehab in Traumatic Brain Injuries (TBI) and Mild Cognitive Impairment (MCI)|Behavioral and Neuroimaging Changes After Cognitive Rehab in TBI and MCI|Completed||Phase 1|82|Actual|VA Office of Research and Development||6|||f||||f||||||||||2018-06-01 01:56:56.974374|2018-06-01 01:56:56.974374
NCT00714558|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2011-05-18|2008-07-11|2008-07-14|Estimate|||||||2011-05-18|2011-05-19|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|May 2003|Actual|2003-05-31|||||Interventional|||Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers|Pharmacokinetics of Fentanyl Citrate Following Intravenous (i.v.) and Oral Routes of Administration in Healthy Subjects|Completed||Phase 1|18|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 01:56:57.31298|2018-06-01 01:56:57.31298
NCT00714545|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-12-20|2008-07-11|2008-07-14|Estimate|||||||2012-12-20|2012-12-24|Estimate|April 2006||2006-04-30|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|||SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents|Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V|Unknown status|Recruiting|Phase 4|60|Anticipated|Scripps Health||1|||f||||t||||||||||2018-06-01 01:56:57.368203|2018-06-01 01:56:57.368203
NCT00714532|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2013-07-09|2008-07-09|2008-07-14|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Smoking Reduction and Cessation Interventions for Chinese|A Stage-Based Scheduled Smoking Intervention for Chinese|Completed||N/A|298|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:56:57.440188|2018-06-01 01:56:57.440188
NCT00714519|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-08-29|2008-07-11|2008-07-14|Estimate|||||||2013-08-29|2013-08-30|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Feasibility Study of the Execution of an Efficacy Trial in the Nursing Home Setting|A Phase II Feasibility Study of Xenaderm® Ointment Exploring Design Issues for Phase III Efficacy in Partial-Thickness Wounds|Withdrawn||Phase 2|0|Actual|Healthpoint||2||"The study was terminated due to the inability to enroll subjects. No subjects were or ever will~   be enrolled into this study."|f||||f||||||||||2018-06-01 01:56:57.511817|2018-06-01 01:56:57.511817
NCT00714506|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2016-01-12|2008-07-09|2008-07-14|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2008||2008-03-31|January 2016|2016-01-31||||December 2009|Actual|2009-12-31||Interventional|||Effects of a Weight Reduction and Lifestyle Program in Older Adults|Effects of a Weight Reduction and Lifestyle Program in Older Adults|Completed||N/A|36|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 01:56:57.577462|2018-06-01 01:56:57.577462
NCT00714493|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2011-01-14||2013-08-29|2008-07-11|2008-07-14|Estimate|2011-01-14|2011-02-09|Estimate||||2013-08-29|2013-09-12|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||RESTART C0168Z05 Rheumatoid Arthritis Study|A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).|Completed||Phase 4|203|Actual|Centocor Ortho Biotech Services, L.L.C.||1|||f||||f||||||||||2018-06-01 01:56:57.735675|2018-06-01 01:56:57.735675
NCT00714480|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2011-08-02|2008-07-11|2008-07-14|Estimate|||||||2011-08-02|2011-08-04|Estimate|July 2008||2008-07-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment|Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment|Completed||N/A|3|Actual|Swedish Medical Center||3|||f||||t||||||||||2018-06-01 01:56:58.204124|2018-06-01 01:56:58.204124
NCT00714467|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2013-05-26|2008-07-09|2008-07-14|Estimate|||||||2013-05-26|2013-05-29|Estimate|August 2004||2004-08-31|May 2013|2013-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Expert System and Family Assisted Interventions for Chinese Smokers|Expert System and Family Assisted Interventions for Chinese Smokers|Completed||N/A|1280|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:56:58.282671|2018-06-01 01:56:58.282671
NCT00714454|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2008-07-11|2008-07-11|2008-07-14|Estimate|||||||2008-07-11|2008-07-14|Estimate||||July 2008|2008-07-31||||||||Interventional|||5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris|5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris: A Double-Blind, Placebo Controlled Trial|Completed||N/A|||University of Miami||2|||f||||f||||||||||2018-06-01 01:56:58.357314|2018-06-01 01:56:58.357314
NCT00714441|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-04-17|2008-07-09|2008-07-14|Estimate|||||||2012-04-17|2012-04-19|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|REDEEM||Reducing Distress and Improving Self-Care in Diabetes|Reducing Distress and Improving Self-Care in Diabetes|Completed||N/A|392|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-06-01 01:56:58.428794|2018-06-01 01:56:58.428794
NCT00714428|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2015-09-03|2008-07-08|2008-07-14|Estimate|||||||2015-09-03|2015-09-07|Estimate|April 2009||2009-04-30|September 2015|2015-09-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Observational|TBIQOL||Development of Quality of Life Tool for TBI|Development of a Quality of Life Tool for Deployment Related TBI|Completed|||485|Actual|VA Office of Research and Development|||3||f||||f||||||None Retained|"~     None retained~   "|||2018-06-01 01:56:58.508328|2018-06-01 01:56:58.508328
NCT00714415|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2017-08-09|2008-07-11|2008-07-14|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2008||2008-01-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Registry For Patients Treated With BeneFix In Usual Care Setting In Germany|Pharmacovigilance Evaluation Of Benefix (Registered) In Germany And Austria|Completed|||80|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:56:58.577956|2018-06-01 01:56:58.577956
NCT00714402|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2011-05-17|2008-07-11|2008-07-14|Estimate|||||||2011-05-17|2011-05-18|Estimate|August 2008||2008-08-31|January 2009|2009-01-31||||||||Observational|||Procalcitonin Level and Kinetics in Children With Bacterial Infections|Procalcitonin Level as a Prognostic Marker and Its' Kinetics in Children With Bacterial Infections|Completed|||50|Anticipated|Shaare Zedek Medical Center|||1||f||||||||||None Retained|"~     whole blood~   "|||2018-06-01 01:56:58.684133|2018-06-01 01:56:58.684133
NCT00714389|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2010-01-05||2013-01-31|2008-07-11|2008-07-14|Estimate|2010-01-05|2010-01-29|Estimate||||2013-01-31|2013-02-06|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Uroflow Measurements in Healthy Volunteers|Uroflow Measurements in Healthy Volunteers|Completed|||12|Actual|University of Rochester|Limited number of participants||||f||||f||||||||||2018-06-01 01:56:58.753255|2018-06-01 01:56:58.753255
NCT00714376|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2012-10-30|2008-07-10|2008-07-14|Estimate|||||||2012-10-30|2012-10-31|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|TAX1||Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients|Phase II Single Center Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients With an Early Rising PSA Following Radical Prostatectomy|Terminated||Phase 2|6|Actual|CHU de Quebec-Universite Laval||1||Prematurely terminated due to financial considerations|f||||t||||||||||2018-06-01 01:56:58.885603|2018-06-01 01:56:58.885603
NCT00714337|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2010-12-08|2008-07-11|2008-07-14|Estimate|||||||2010-12-08|2010-12-10|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Formulation and Food Effect Study of AZD1386 in Healthy Volunteers|A Phase I, Single-Centre, Randomised, Open-Label, Five-Way Cross-Over Formulation- and Food-Effect Study in Healthy Volunteers to Assess the Pharmacokinetics of AZD1386 After Single Doses of Two Oral Solid Formulations and an Oral Solution|Completed||Phase 1|12|Anticipated|AstraZeneca||5|||f||||f||||||||||2018-06-01 01:56:59.206155|2018-06-01 01:56:59.206155
NCT00714324|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2009-01-02|2008-07-11|2008-07-14|Estimate|||||||2009-01-02|2009-01-05|Estimate|July 2008||2008-07-31|January 2009|2009-01-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Observational|||Simplified Nutritional Screening for Patient Use|Validation of Nutritional Screening for Patient Use|Unknown status|Recruiting||2200|Anticipated|University of Southampton|||2||f||||f||||||||||2018-06-01 01:56:59.285935|2018-06-01 01:56:59.285935
NCT00714311|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2015-02-04||2015-02-04|2008-07-09|2008-07-14|Estimate|2015-02-04|2015-02-16|Estimate||||2015-02-04|2015-02-16|Estimate|October 2004||2004-10-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy of Transference-Focused Psychotherapy for Borderline Personality Disorder|A Randomized-Controlled Trial of Transference-Focused Psychotherapy vs. Treatment by Experienced Community Psychotherapists for Borderline Personality Disorder|Completed||N/A|104|Actual|University Hospital Muenster||2|||f||||f||||||||||2018-06-01 01:56:59.35782|2018-06-01 01:56:59.35782
NCT00714298|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-11|2008-07-11|2008-07-14|Estimate|||||||2008-07-11|2008-07-14|Estimate|May 2006||2006-05-31|July 2008|2008-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Diagnostic Value of Heart-Fatty Acid Binding Protein and Ischemia Modified Albumin as Biochemical Markers on Non ST Segment Elevation Acute Coronary Syndrome at the Emergency Room.|Analyse en médecine d'Urgence d'Une stratégie d'Utilisation combinée de Deux Marqueurs Biologiques Dans le Diagnostic de Syndrome Coronaire Aigu Non ST+: étude Des Performances de la Heart-Fatty Acid Binding Protein et de l' Ischemia Modified Albumin dès la première Heure de Prise en Charge|Completed||N/A|700|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-06-01 01:56:59.60309|2018-06-01 01:56:59.60309
NCT00714285|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|2013-07-11||2017-03-21|2008-07-11|2008-07-14|Estimate|2013-07-11|2013-09-16|Estimate||||2017-03-21|2017-03-23|Actual|July 2008||2008-07-31|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.|Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults.|Completed||Phase 1|420|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:56:59.720354|2018-06-01 01:56:59.720354
NCT00714272|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-07-11|2008-07-11|2008-07-14|Estimate|||||||2008-07-11|2008-07-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 01:57:00.495162|2018-06-01 01:57:00.495162
NCT00714259|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2015-11-05||2017-06-22|2008-07-11|2008-07-14|Estimate|2017-03-23|2017-05-04|Actual||||2017-06-22|2017-07-24|Actual|July 2008||2008-07-31|June 2017|2017-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies|UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies|Terminated||Phase 2/Phase 3|5|Actual|University of Alabama at Birmingham||1||Accrual goals could not be met within a timely manner|f||||t||||||||No||2018-06-01 01:57:00.531913|2018-06-01 01:57:00.531913
NCT00714246|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2017-01-26|2008-07-10|2008-07-14|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2008|Actual|2008-10-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|May 2013|Actual|2013-05-31||Interventional|||Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer|Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|6|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||Undecided|Once study is completed we will provide updates to data|2018-06-01 01:57:01.675806|2018-06-01 01:57:01.675806
NCT00714233|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2011-04-08||2015-04-29|2008-07-11|2008-07-14|Estimate|2011-08-12|2011-09-16|Estimate||||2015-04-29|2015-05-15|Estimate|August 2002||2002-08-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|April 2004|Actual|2004-04-30||Interventional|||Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)|Treatment of Polycystic Ovary Syndrome (POS) in Overweight Adolescents|Completed||Phase 3|43|Actual|University of Rochester||4|||f||||f||||||||||2018-06-01 01:57:01.790605|2018-06-01 01:57:01.790605
NCT00714220|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2015-10-28|2008-07-10|2008-07-14|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2006||2006-11-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)|Quantitative Measurement of Nutritional Substrate Utilization in Patients With ALS|Terminated|||107|Actual|Drexel University|||3|Lack of funding and support staff.|f||||f||||||||||2018-06-01 01:57:02.30007|2018-06-01 01:57:02.30007
NCT00714207|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2008-07-10|2008-07-10|2008-07-14|Estimate|||||||2008-07-10|2008-07-14|Estimate|July 2002||2002-07-31|July 2008|2008-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Evaluation of Adolescent Smoking Cessation Programs|Evaluation of Adolescent Smoking Cessation Programs|Completed||N/A|407|Actual|Johns Hopkins University||4|||f||||f||||||||||2018-06-01 01:57:02.378303|2018-06-01 01:57:02.378303
NCT00714194|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2015-05-06|2008-07-09|2008-07-14|Estimate|||||||2015-05-06|2015-05-08|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|ICUDelirium||Effect of Daily Interruption of Continuous Sedation on Delirium, Sleep Perception in Intensive Care Unit (ICU) Patients|The Effect of Daily Interruption of Continuous Sedation on the Occurrence of Delirium and Perception of Sleep in ICU Patients|Completed||Early Phase 1|52|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 01:57:02.563715|2018-06-01 01:57:02.563715
NCT00714181|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-11|||2016-02-17|2008-07-11|2008-07-14|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|June 2013|Actual|2013-06-30|July 2011|Actual|2011-07-31||Interventional|||Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Hydroxychloroquine in Combination With Temozolomide in Patients With Advanced Solid Tumors|Completed||Phase 1|38|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 01:57:02.678163|2018-06-01 01:57:02.678163
NCT00713635|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2017-07-14|2008-07-10|2008-07-11|Estimate|||||||2017-07-14|2017-07-18|Actual|December 2010||2010-12-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|November 2014|Actual|2014-11-30||Observational|||Prenatal Effects of Congenital Heart Disease (CHD) on Neurodevelopmental Outcome|The Prenatal Effects of Congenital Heart Disease on Neurodevelopmental Outcome|Completed|||51|Actual|Columbia University|||4||f||||f||||||||||2018-06-01 01:57:09.387685|2018-06-01 01:57:09.387685
NCT00714168|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2013-01-06||2015-12-23|2008-07-10|2008-07-14|Estimate|2015-12-23|2016-02-01|Estimate||||2015-12-23|2016-02-01|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|Step-Up||Evaluating the Effectiveness of a Stepped-Care Approach to Long-Term Weight Loss (The Step-Up Study)|The Effect of a Stepped-care Approach to Long-term Weight Loss|Completed||N/A|363|Actual|University of Pittsburgh|This study was not designed to test for weight loss equivalency between conditions. This study is unable to determined if an alternative intensity or frequency of intervention steps would be more or less effective for weight loss.|2|||f||||t||||||||||2018-06-01 01:57:02.789175|2018-06-01 01:57:02.789175
NCT00714155|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-06-13|2008-07-11|2008-07-14|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2006||2006-07-31|November 2011|2011-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Outcomes and Patient Satisfaction After Colpocleisis for Pelvic Organ Prolapse|Outcomes and Patient Satisfaction After Colpocleisis for Pelvic Organ Prolapse|Completed|||48|Actual|University of Rochester|||3||f||||f||||||||||2018-06-01 01:57:03.195855|2018-06-01 01:57:03.195855
NCT00714142|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2017-04-17|2008-07-11|2008-07-14|Estimate|||||||2017-04-17|2017-04-19|Actual|August 2008||2008-08-31|April 2017|2017-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Renal Blood Flow Measurement With Positron Emission Tomography (PET)|Renal Blood Flow Measurement With PET|Completed||Phase 2|30|Actual|Proportional Technologies, Inc.||3|||f||||t||||||||||2018-06-01 01:57:03.306053|2018-06-01 01:57:03.306053
NCT00714129|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2017-10-24|2008-07-11|2008-07-14|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2007||2007-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LINC||De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease|De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease|Active, not recruiting||N/A|60|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:57:03.415551|2018-06-01 01:57:03.415551
NCT00714116|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-12-20|2008-07-08|2008-07-14|Estimate|||||||2012-12-20|2012-12-24|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus|An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|30|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:57:03.511875|2018-06-01 01:57:03.511875
NCT00714103|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2016-10-12|2008-07-10|2008-07-14|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||8-Chloro-Adenosine in Chronic Lymphocytic Leukemia|A Phase I Study of 8-Chloro-Adenosine in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma|Completed||Phase 1|11|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 01:57:03.58956|2018-06-01 01:57:03.58956
NCT00714090|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2013-07-18|2008-07-11|2008-07-14|Estimate|||||||2013-07-18|2013-07-19|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression|Repetitive Transcranial Magnetic Stimulation Efficacy for Major Resistant Depression Compared or Associated With Venlafaxine : a Multicentric Study.|Completed||Phase 3|170|Actual|Club rTMS et Psychiatrie||3|||f||||t||||||||||2018-06-01 01:57:03.662169|2018-06-01 01:57:03.662169
NCT00714077|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2016-02-15|2008-07-10|2008-07-14|Estimate|||||||2016-02-15|2016-02-17|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer|Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer|Recruiting|||570|Anticipated|Chinese Academy of Medical Sciences|||2||f||||t||||||||||2018-06-01 01:57:03.778604|2018-06-01 01:57:03.778604
NCT00714064|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2014-07-09|2008-07-11|2008-07-14|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2006||2006-06-30|July 2014|2014-07-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|PneuMum||PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers|PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease|Completed||Phase 3|227|Actual|Menzies School of Health Research||3|||f||||t||||||||||2018-06-01 01:57:03.863834|2018-06-01 01:57:03.863834
NCT00714051|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2014-09-26||2014-10-02|2008-07-08|2008-07-14|Estimate|2014-10-02|2014-10-08|Estimate||||2014-10-02|2014-10-08|Estimate|October 2008||2008-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|February 2012|Actual|2012-02-29||Interventional|||Fall Prevention Program for Older Adults|Fall Prevention Program for Older Adults|Completed||Phase 1/Phase 2|55|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:57:03.96919|2018-06-01 01:57:03.96919
NCT00714038|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2011-03-08|2008-07-10|2008-07-14|Estimate|||||||2011-03-08|2011-03-09|Estimate|May 2008||2008-05-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.|CARE - Quality Development in Asthma in General Practice|Completed|||2122|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:57:04.436238|2018-06-01 01:57:04.436238
NCT00714025|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-01-23|2008-07-11|2008-07-14|Estimate|||||||2012-01-23|2012-01-24|Estimate|November 2008||2008-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|April 2009|Actual|2009-04-30||Interventional|||A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy|A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma After Failure of Platinum-based Chemotherapy|Completed||Phase 2|40|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-06-01 01:57:04.631141|2018-06-01 01:57:04.631141
NCT00714012|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2016-08-18|2008-07-11|2008-07-14|Estimate|||||||2016-08-18|2016-08-22|Estimate|October 2004||2004-10-31|August 2016|2016-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Evaluation of Information Displays-A Paper, Computer and Simulator Based Study|Evaluation of Information Displays-A Paper, Computer and Simulator Based Study|Completed|||200|Anticipated|University of Utah|||1||f||||t||||||||||2018-06-01 01:57:04.73397|2018-06-01 01:57:04.73397
NCT00713999|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2008-07-11|2008-07-11|2008-07-14|Estimate|||||||2008-07-11|2008-07-14|Estimate|August 2001||2001-08-31|July 2008|2008-07-31|September 2003|Actual|2003-09-30|April 2002|Actual|2002-04-30||Interventional|FGS/MGS/STI||Urogenital Schistosomiasis and Sexually Transmitted Infections in Madagascar|Study of Reproductive Health in Rural Madagascar With Emphasis on Urogenital Schistosomiasis and Sexually Transmitted Infections|Completed||N/A|680|Actual|University of Aarhus||1|||f||||t||||||||||2018-06-01 01:57:04.810472|2018-06-01 01:57:04.810472
NCT00713986|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2008-07-11|2008-07-11|2008-07-14|Estimate|||||||2008-07-11|2008-07-14|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|October 2007|Actual|2007-10-31||Interventional|||Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B|Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B: a Comparison Between Skin-to-Skin Contact, Glucose 25% and Both of Them|Completed||Phase 3|640|Actual|Federal University of São Paulo||4|||f||||f||||||||||2018-06-01 01:57:04.886956|2018-06-01 01:57:04.886956
NCT00713973|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2008-10-17|2008-07-08|2008-07-14|Estimate|||||||2008-10-17|2008-10-20|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|||||Observational|||Comparative Study Between Thrombosis Prophylaxis Protocols|Comparative Study Between American and Brazilian Protocols for Deep Venous Thrombosis Prophylaxis: a New Proposal|Completed|||212|Actual|UPECLIN HC FM Botucatu Unesp|||3||f||||t||||||||||2018-06-01 01:57:04.978402|2018-06-01 01:57:04.978402
NCT00713960|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2012-01-13|2008-07-11|2008-07-14|Estimate|||||||2012-01-13|2012-01-16|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.|CARE - Quality Development in Cardiovascular Disease in General Practice|Completed|||2193|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 01:57:05.0633|2018-06-01 01:57:05.0633
NCT00713947|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2015-04-20|2008-07-11|2008-07-14|Estimate|||||||2015-04-20|2015-04-21|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Interventional|Aspylori||Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control|Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course|Withdrawn||Phase 4|0|Actual|Assistance Publique - Hôpitaux de Paris||3||no inclusion|f||||t||||||||||2018-06-01 01:57:05.209828|2018-06-01 01:57:05.209828
NCT00713934|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2011-10-01|2008-07-11|2008-07-14|Estimate|||||||2011-10-01|2011-10-04|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Autologous Bone Marrow Stem Cells in Cirrhosis Patients|Autologous Transplantation of Bone Marrow Derived CD 133 Positive Stem Cell and Mono Nuclear Cell (MNC) Transplantation in Patients With Decompensate Cirrhosis: Randomized Clinical Trial|Completed||Phase 1/Phase 2|7|Actual|Royan Institute||2|||f||||t||||||||||2018-06-01 01:57:05.300558|2018-06-01 01:57:05.300558
NCT00713921|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-12-11|2008-07-11|2008-07-14|Estimate|||||||2012-12-11|2012-12-13|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients|Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients|Unknown status|Recruiting|N/A|20|Anticipated|Saint Thomas Health||1|||f||||t||||||||||2018-06-01 01:57:05.373557|2018-06-01 01:57:05.373557
NCT00713908|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2009-12-15|2008-07-11|2008-07-14|Estimate|||||||2009-12-15|2009-12-16|Estimate|November 2007||2007-11-30|December 2009|2009-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Voiding Dysfunction in the Postoperative Period Following Placement of the TVT|Voiding Dysfunction in the Postoperative Period Following Placement of the TVT|Terminated|||2|Actual|University of Rochester||||"The Co-Principal Investigator has moved and is no longer interested in continuing this study at~   this site."|f||||f||||||||||2018-06-01 01:57:05.451096|2018-06-01 01:57:05.451096
NCT00713895|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-09|2008-07-09|2008-07-14|Estimate|||||||2008-07-09|2008-07-14|Estimate|August 2001||2001-08-31|June 2008|2008-06-30|August 2005|Actual|2005-08-31|January 2004|Actual|2004-01-31||Interventional|||Treating Chinese Smokers With Interactive Expert System|Treating Chinese Smokers With Interactive Expert System|Completed||N/A|363|Actual|University of California, San Francisco||2|||f||||||||||||||2018-06-01 01:57:05.501103|2018-06-01 01:57:05.501103
NCT00713882|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-03-10|2008-07-11|2008-07-14|Estimate|||||||2009-03-10|2009-03-12|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors|Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors|Completed|||130|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 01:57:05.680954|2018-06-01 01:57:05.680954
NCT00713869|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2011-01-05|2008-07-09|2008-07-14|Estimate|||||||2011-01-05|2011-01-06|Estimate|April 2006||2006-04-30|January 2011|2011-01-31|April 2011|Anticipated|2011-04-30|November 2009|Anticipated|2009-11-30||Observational|Slow-freeze||Oocyte Cryopreservation: Evaluation of an Oocyte Freezing and Thawing Technique|Evaluation of the Affects of an Oocyte Freezing and Thawing Technique in Patients Undergoing In-vitro Fertilization (IVF)|Unknown status|Active, not recruiting||50|Anticipated|West Coast Fertility Centers|||2||f||||t||||||||||2018-06-01 01:57:05.73997|2018-06-01 01:57:05.73997
NCT00713856|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2010-10-15|2008-07-11|2008-07-14|Estimate|||||||2010-10-15|2010-10-19|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Comparison of Conventional and Custom Photorefractive Keratectomy (PRK)|Comparison of Conventional and Custom With Iris Registration PRK Ablations: Assessment of Visual Function and Patient Satisfaction|Completed||N/A|44|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 01:57:05.79622|2018-06-01 01:57:05.79622
NCT00713843|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2015-03-16|2008-07-11|2008-07-14|Estimate|||||||2015-03-16|2015-03-18|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|May 2013|Actual|2013-05-31||Interventional|NECKproject||Effectiveness of Manual Therapy in Patients With Neck Pain.|Effectiveness of Manual Therapy and Physical Therapy in Patients With Subacute and Chronic Non-specific Neck Pain. A Randomized Controlled Trial.|Completed||N/A|180|Actual|Radboud University||2|||f||||t||||||||||2018-06-01 01:57:05.865198|2018-06-01 01:57:05.865198
NCT00713830|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2016-08-18|2012-02-21|2016-10-21|2008-07-10|2008-07-14|Estimate|2016-10-21|2016-12-14|Estimate|2012-02-21|2012-02-23|Estimate|2016-10-21|2016-12-14|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|GETGOAL-S|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.The one patient in the placebo group who received Lixisenatide was described in the Lixisenatide group.|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea|Completed||Phase 3|859|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:57:06.014552|2018-06-01 01:57:06.014552
NCT00713817|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2012-07-11||2012-07-11|2008-07-10|2008-07-11|Estimate|2012-07-11|2012-08-16|Estimate||||2012-07-11|2012-08-16|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain|A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex® in the Treatment of Subjects With Neuropathic Pain. This Will be Followed by a Randomised-withdrawal Phase (Part B) for a Subset of Patients|Completed||Phase 3|19|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 01:57:06.944578|2018-06-01 01:57:06.944578
NCT00713804|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2012-07-11|2008-07-10|2008-07-11|Estimate|||||||2012-07-11|2012-07-12|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||Impact of Genetic Counseling for Individuals With Mental Illness|Genetic Counseling for Individuals With Mental Illness: Impact on Knowledge, Risk Perception, Perceived Control and Internalized Stigma.|Completed||Phase 3|120|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 01:57:07.249493|2018-06-01 01:57:07.249493
NCT00713791|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2010-11-10|2008-07-09|2008-07-11|Estimate|||||||2010-11-10|2010-11-15|Estimate|June 2008||2008-06-30|November 2010|2010-11-30|August 2008|Actual|2008-08-31|||||Interventional|||Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.|A Phase I, Randomised, Single-blind, Single-centre, Incomplete-block Crossover, Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets|Completed||Phase 1|20|Anticipated|AstraZeneca||1|||f||||||||||||||2018-06-01 01:57:07.313853|2018-06-01 01:57:07.313853
NCT00713778|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-08-15|2008-07-07|2008-07-11|Estimate|||||||2008-08-15|2008-08-18|Estimate|November 2003||2003-11-30|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst|The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Exc|Completed||Phase 4|192|Actual|Shandong Provincial Hospital||3|||f||||t||||||||||2018-06-01 01:57:07.382733|2018-06-01 01:57:07.382733
NCT00713765|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2014-08-12|2008-07-09|2008-07-11|Estimate|||||||2014-08-12|2014-08-15|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic Interaction Between AZD3480 and Donepezil|A Double-blind, Randomised, Cross-over, Placebo-controlled Study of Repeated Oral Doses of AZD3480 and a Single Dose of Donepezil to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Donepezil in Healthy Extensive and Poor Metabolisers of CYP2D6|Terminated||Phase 1|33|Actual|AstraZeneca||1||Ended prematurely - The trial never commenced.|f||||f||||||||||2018-06-01 01:57:07.451521|2018-06-01 01:57:07.451521
NCT00713752|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2014-09-25|2008-07-10|2008-07-11|Estimate|||||||2014-09-25|2014-09-26|Estimate|February 2008||2008-02-29|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Establishing Normal Values for Neuropsychological Testing in HIV-negative Thais||Completed|||494|Actual|South East Asia Research Collaboration with Hawaii|||||f||||t||||||||||2018-06-01 01:57:07.602208|2018-06-01 01:57:07.602208
NCT00713739|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2012-04-25|2008-07-07|2008-07-11|Estimate|||||||2012-04-25|2012-04-27|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2012|Anticipated|2012-12-31|December 2010|Actual|2010-12-31||Interventional|MET||Alfuzosin for Medical Expulsion Therapy of Ureteral Stones|Evaluation of Alfuzosin as Medical Expulsion Therapy for Ureteral Stones|Unknown status|Recruiting|Phase 3|240|Anticipated|United States Naval Medical Center, San Diego||4|||f||||t||||||||||2018-06-01 01:57:07.657924|2018-06-01 01:57:07.657924
NCT00713726|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-10|2008-07-10|2008-07-11|Estimate|||||||2008-07-10|2008-07-11|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Tramadol Versus Fentanyl for Post-Operative Analgesia in Newborn Infants|Post-Operatory Analgesia in Newborn Infants: a Comparative Study of Fentanyl Versus Tramadol|Completed||Phase 3|160|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 01:57:07.754699|2018-06-01 01:57:07.754699
NCT00713713|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2009-07-31|2008-07-10|2008-07-11|Estimate|||||||2009-07-31|2009-08-03|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|VITALI||Effect of Different Ventilatory Strategies on Cardiac Function in Patients With Acute Respiratory Failure|Hemodynamic Impact of Low and High Tidal Volume Mechanical Ventilation in Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) Patients|Completed||N/A|16|Anticipated|Fondazione Poliambulanza Istituto Ospedaliero||1|||f||||f||||||||||2018-06-01 01:57:07.840757|2018-06-01 01:57:07.840757
NCT00713700|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2013-10-25||2017-07-24|2008-07-10|2008-07-11|Estimate|2013-10-25|2013-12-16|Estimate||||2017-07-24|2017-08-23|Actual|August 2008||2008-08-31|July 2017|2017-07-31|October 5, 2016|Actual|2016-10-05|October 2011|Actual|2011-10-31||Interventional|ADO II||AMPLATZER Duct Occluder II Clinical Study|Closure of Patent Ductus Arteriosus With the AMPLATZER DUCT Occluder II|Completed||N/A|192|Actual|St. Jude Medical||1|||f||||t||||||||||2018-06-01 01:57:07.932942|2018-06-01 01:57:07.932942
NCT00713687|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2012-08-09|2008-07-10|2008-07-11|Estimate|||||||2012-08-09|2012-08-10|Estimate|August 2008||2008-08-31|July 2008|2008-07-31|December 2011||2011-12-31|||||Interventional|GemOx-PDT||Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma|Sequential Combination of Chemotherapy With Gemcitabine/Oxaliplatin and Photodynamic Therapy in Advanced Cholangiocarcinoma|Withdrawn||Phase 2|0|Actual|Technische Universität München||1||recruiting failed|f||||f||||||||||2018-06-01 01:57:08.122716|2018-06-01 01:57:08.122716
NCT00713674|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2017-03-21|2008-07-10|2008-07-11|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2008||2008-03-31|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|SJMRSA||Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx|Comparison of Decolonization of MRSA Using Theraworx|Withdrawn||N/A|0|Actual|Mercy Research||3||Lack of patient recruitment.|f||||f||||||||||2018-06-01 01:57:08.195492|2018-06-01 01:57:08.195492
NCT00713661|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2011-12-20||2012-05-04|2008-07-10|2008-07-11|Estimate|2012-02-01|2012-03-02|Estimate||||2012-05-04|2012-05-08|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Interventional|||Evaluation of TachoSil® Application on a Colorectal Anastomosis (TC-029-IM)|Non-randomised, Open, Multi-center Trial Evaluating Feasibility and Safety of TachoSil® Application on a Colorectal Anastomosis.|Completed||Phase 2|25|Actual|Nycomed||1|||f||||t||||||||||2018-06-01 01:57:08.314284|2018-06-01 01:57:08.314284
NCT00713648|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2014-01-22|2010-11-04|2017-01-10|2008-07-10|2008-07-11|Estimate|2014-06-11|2014-07-14|Estimate|2011-01-07|2011-01-20|Estimate|2017-01-10|2017-02-24|Actual|August 2008||2008-08-31|January 2017|2017-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency|A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency|Completed||Phase 3|41|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 01:57:08.675783|2018-06-01 01:57:08.675783
NCT00713622|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2015-11-02|2008-07-09|2008-07-11|Estimate|||||||2015-11-02|2015-11-03|Estimate|June 2008||2008-06-30|November 2015|2015-11-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate|A Multicentre, Randomised, Active Comparator, Parallel Group Study To Compare The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate|Completed||Phase 4|2|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 01:57:09.714867|2018-06-01 01:57:09.714867
NCT00713609|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2016-11-12|2010-09-07|2017-01-13|2008-07-07|2008-07-11|Estimate|2017-01-13|2017-03-06|Actual|2010-09-07|2010-09-09|Estimate|2017-01-13|2017-03-06|Actual|June 2008||2008-06-30|January 2017|2017-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne|A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl Peroxide/Clindamycin Gel and Tazarotene Cream When Used in Combination in the Treatment of Acne Vulgaris|Completed||Phase 2|591|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 01:57:09.947805|2018-06-01 01:57:09.947805
NCT00713596|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2012-04-19||2016-03-18|2008-07-10|2008-07-11|Estimate|2012-07-23|2012-07-24|Estimate||||2016-03-18|2016-04-18|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study Evaluating Benefit of Using Fibrin Glue in Septorhinoplasty|The Use of Fibrin Sealant During Septorhinoplasty: Short and Long Term Benefits|Terminated||N/A|25|Actual|Mayo Clinic|Study was terminated due to principal investigator leaving the institution.|3||Lead investigator moved to a new medical center; study was stopped when he left.|f||||t||||||||||2018-06-01 01:57:11.300328|2018-06-01 01:57:11.300328
NCT00713583|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2018-02-16||2018-03-23|2008-07-09|2008-07-11|Estimate|2018-02-16|2018-03-19|Actual||||2018-03-23|2018-04-23|Actual|January 2008||2008-01-31|March 2018|2018-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence|Contingency Management Plus Levodopa/Carbidopa for Treatment of Cocaine Dependence|Completed||Phase 2|85|Actual|The University of Texas Health Science Center, Houston|Lower than expected rates of retention and medication compliance likely reduced the statistical power of the study for estimating treatment effects of the medication intervention.|2|||f||||t|t|f|||f|||||2018-06-01 01:57:11.752782|2018-06-01 01:57:11.752782
NCT00713570|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2010-12-10|2008-07-10|2008-07-11|Estimate|||||||2010-12-10|2010-12-13|Estimate|August 2006||2006-08-31|December 2010|2010-12-31||||July 2012|Anticipated|2012-07-31||Observational|||Explore the Nature Factors Relevant to Learning-Pioneering Natural Factors That Influences Science Learning II|the Cognitive Ability Dose Associate With COMT, 5HT6, BDNF and Biological Systemic Pathway Candidate Genes in General Population|Unknown status|Recruiting||2800|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 01:57:12.117604|2018-06-01 01:57:12.117604
NCT00713557|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2016-10-12|2008-07-10|2008-07-11|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2005||2005-03-31|October 2016|2016-10-31||||January 2018|Anticipated|2018-01-31||Observational|||Shanghai Registry of Acute Coronary Events|Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS|Terminated|||20000|Anticipated|Shanghai Jiao Tong University School of Medicine|||6|"devices applied in the study were no more available in the market, and medical intervention~   section was completed."|f||||t||||||||||2018-06-01 01:57:12.479941|2018-06-01 01:57:12.479941
NCT00713544|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2010-07-22||2011-08-26|2008-07-10|2008-07-11|Estimate|2011-08-26|2011-10-03|Estimate||||2011-08-26|2011-10-03|Estimate|July 2008||2008-07-31|August 2011|2011-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ESCAPE||A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis|A Randomised, Double Blind, Placebo Controlled, Phase IIb Dose Ranging Study (With Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate.|Completed||Phase 2|373|Actual|AstraZeneca|Hybrid ACR, ACRn, individual ACR components, Erythrocyte sedimentation rate (ESR), Short-form-36 (SF-36), Rheumatoid Arthritis Quality of Life (RAQoL) and Patient Insight Questionnaire (PIQ) did not provide extra information so are not presented|6|||f||||f||||||||||2018-06-01 01:57:13.011937|2018-06-01 01:57:13.011937
NCT00713531|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2015-05-27|2008-07-07|2008-07-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Observational|||Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, Thailand||Completed|||992|Actual|South East Asia Research Collaboration with Hawaii|||||f||||f||||||Samples Without DNA|"~     Plasma, CD4, HIV-RNA~   "|||2018-06-01 01:57:14.314418|2018-06-01 01:57:14.314418
NCT00713518|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07||2012-10-05|2012-10-10|2008-07-09|2008-07-11|Estimate||||2012-10-05|2012-10-10|Estimate|2012-10-10|2012-10-12|Estimate|November 2009||2009-11-30|October 2012|2012-10-31|July 2011|Actual|2011-07-31|November 2010|Actual|2010-11-30||Interventional|MONET||Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).|Phase II Open Label Multicenter, Prospective, Randomized, Age Related Macular Degeneration, Comparator Controlled Study Evaluating PF-04523655 Versus Ranibizumab In The Treatment Of Subjects With Choroidal Neovascularization (MONET Study).|Completed||Phase 2|152|Actual|Quark Pharmaceuticals||5|||f||||f||||||||||2018-06-01 01:57:14.38025|2018-06-01 01:57:14.38025
NCT00713505|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2010-10-11|2008-07-10|2008-07-11|Estimate|||||||2010-10-11|2010-10-13|Estimate|May 2008||2008-05-31|October 2010|2010-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction|A Behavioral Intervention Trial for Parents of Childhood Cancer Survivors With Neurobehavioral Late Effects|Completed||N/A|56|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 01:57:14.518244|2018-06-01 01:57:14.518244
NCT00713492|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2018-05-08|2008-07-10|2008-07-11|Estimate|||||||2018-05-08|2018-05-09|Actual|July 8, 2008||2008-07-08|April 24, 2018|2018-04-24|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Computer-Assisted Self-Administration of Ethanol|Computer-Assisted Self-Administration of Ethanol (CASE) in Humans|Recruiting||N/A|320|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:57:14.797755|2018-06-01 01:57:14.797755
NCT00713479|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2013-03-26||2018-02-13|2008-07-10|2008-07-11|Estimate|2013-12-19|2014-01-27|Estimate||||2018-02-13|2018-03-13|Actual|July 2008||2008-07-31|February 2018|2018-02-28|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional||This is a crossover design wherein each subject completed both the sugar pill treatment condition and the varenicline(medication under study) condition. Two subjects in the placebo condition did not complete the first component of the trial.|An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers|A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline in Methamphetamine-dependent Volunteers Receiving Methamphetamine|Completed||Phase 1|8|Actual|University of California, Los Angeles|Small sample size|2|||f||||t||||||||||2018-06-01 01:57:14.986559|2018-06-01 01:57:14.986559
NCT00713466|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-30|2008-07-10|2008-07-11|Estimate|||||||2008-07-30|2008-07-31|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|CLIPP||The Use of Computer-Assisted Learning Pediatrics Program (CLIPP) in the Pediatric Clerkship|The Use of Computer-Assisted Learning Pediatrics Program (CLIPP) in the Pediatric Clerkship|Completed|||198|Actual|Medical College of Wisconsin|||1||f||||f||||||||||2018-06-01 01:57:15.320146|2018-06-01 01:57:15.320146
NCT00713453|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2015-03-21|2008-07-09|2008-07-11|Estimate|||||||2015-03-21|2015-03-24|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Muscle Response to Enzyme Replacement Therapy in Pompe Disease|Muscle Response to Enzyme Replacement Therapy in Pompe Disease|Recruiting|||16|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:57:15.402977|2018-06-01 01:57:15.402977
NCT00713440|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-08-05|2008-07-09|2008-07-11|Estimate|||||||2009-08-05|2009-08-06|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Incretin Physiology Associated With Steroid Hormone Treatment|Incretin Physiology and Beta-Cell Function Before and After Treatment With Steroid Hormone in Healthy Individuals|Completed||N/A|10|Actual|Glostrup University Hospital, Copenhagen||1|||f||||t||||||||||2018-06-01 01:57:15.51278|2018-06-01 01:57:15.51278
NCT00713427|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2009-08-31|2008-07-09|2008-07-11|Estimate|||||||2009-08-31|2009-09-01|Estimate|July 2007||2007-07-31|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction|A Multi-Center, Single Arm, Prospective Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction|Completed||N/A|70|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-06-01 01:57:15.674608|2018-06-01 01:57:15.674608
NCT00713414|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2017-10-05|2008-07-10|2008-07-11|Estimate|||||||2017-10-05|2017-10-06|Actual|July 9, 2008||2008-07-09|September 21, 2016|2016-09-21|September 21, 2016||2016-09-21|||||Observational|||Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia|Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia and Other Focal Dystonias|Completed|||37|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:57:15.83386|2018-06-01 01:57:15.83386
NCT00713401|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09||2014-01-03|2014-02-10|2008-07-10|2008-07-11|Estimate||||2014-01-03|2014-02-04|Estimate|2014-02-10|2014-03-11|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Safety Study of Tecadenoson to Treat Atrial Fibrillation|An Open-Label, Sequential-Group, Dose-Escalation Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Tecadenoson Alone and in Combination With a Beta-Blocker in Adults With Rapid Atrial Fibrillation (CVT 4129)|Completed||Phase 2|21|Actual|Gilead Sciences||5|||f||||f||||||||||2018-06-01 01:57:16.034882|2018-06-01 01:57:16.034882
NCT00713375|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-10|2008-07-10|2008-07-11|Estimate|||||||2008-07-10|2008-07-11|Estimate|April 2008||2008-04-30|July 2008|2008-07-31||||April 2008|Anticipated|2008-04-30||Observational|||Time Frequency Analysis of Electrocardiogram and Blood Pressure in Intracranial Hemorrhage Patients|Multiscale Entropy and Time-Frequency Analysis of Electrocardiogram and Blood Pressure in Patients With Spontaneous Intracranial Hemorrhage|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     Whole blood. Cerebral spinal fluids~   "|||2018-06-01 01:57:16.10147|2018-06-01 01:57:16.10147
NCT00713362|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-12-13|2008-07-09|2008-07-11|Estimate|||||||2012-12-13|2012-12-17|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|September 2013|Anticipated|2013-09-30|November 2012|Actual|2012-11-30||Interventional|||Chest Tube Drainage or Thoracoscopic Surgery for Failed Aspiration of Spontaneous Pneumothorax|Comparison of Chest Tube Drainage Versus Thoracoscopic Surgery for Unsuccessful Aspiration of Primary Spontaneous Pneumothorax: a Prospective Randomized Trial|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 01:57:16.16581|2018-06-01 01:57:16.16581
NCT00713349|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2013-10-09||2013-10-09|2008-07-10|2008-07-11|Estimate|2013-10-09|2013-12-06|Estimate||||2013-10-09|2013-12-06|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing|A Randomized, Evaluator Blinded, Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing of Induced Thermal Wounds|Completed||Phase 2|25|Actual|Healthpoint||2|||f||||f||||||||||2018-06-01 01:57:16.288468|2018-06-01 01:57:16.288468
NCT00713336|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2010-09-27|2008-07-10|2008-07-11|Estimate|||||||2010-09-27|2010-09-28|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|November 2008|Actual|2008-11-30|||||Interventional|||Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval|A Phase I, Double-blind, Double-dummy, Placebo-controlled, Randomised, Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Volunteers Aged 18 to 45 Years.|Completed||Phase 1|40|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:57:16.624558|2018-06-01 01:57:16.624558
NCT00713323|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|2012-07-11||2012-08-16|2008-07-10|2008-07-11|Estimate|2012-08-16|2012-09-14|Estimate||||2012-08-16|2012-09-14|Estimate|October 2005||2005-10-31|August 2012|2012-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.|A Multicentre, Open Label, Follow on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex® in the Treatment of Subjects With Neuropathic Pain. This Will be Followed by a Randomised-withdrawal Phase (Part B) for a Subset of Patients.|Completed||Phase 3|380|Actual|GW Pharmaceuticals Ltd.||1|||f||||f||||||||||2018-06-01 01:57:16.752211|2018-06-01 01:57:16.752211
NCT00713310|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2012-03-06||2012-04-03|2008-07-10|2008-07-11|Estimate|2012-03-06|2012-04-04|Estimate||||2012-04-03|2012-04-05|Estimate|December 2008||2008-12-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis|Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis|Completed||Phase 3|83|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 01:57:17.107737|2018-06-01 01:57:17.107737
NCT00713297|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-09|2008-07-09|2008-07-11|Estimate|||||||2008-07-09|2008-07-11|Estimate|September 2007||2007-09-30|June 2008|2008-06-30|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Observational|||Implementation of a Novel Computerized Physician Order Entry System|Implementation of a Novel Computerized Physician Order Entry System to Reduce Medication Errors|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 01:57:17.562174|2018-06-01 01:57:17.562174
NCT00713284|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-08-01|2008-07-10|2008-07-11|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|MYFIIRP||Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic|A Pilot Study to Evaluate the Safety and Efficacy of Mycophenolate Sodium (Myfortic®) in Combination With Sirolimus (Rapamune®) in Stable Renal Allograft Recipients|Completed||Phase 4|13|Actual|California Pacific Medical Center Research Institute||1|||f||||f||||||||||2018-06-01 01:57:17.663819|2018-06-01 01:57:17.663819
NCT00713271|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2014-04-09|2008-07-10|2008-07-11|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|AZD3199MAD||Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group, Single-centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD3199 (a B2-agonist) Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men|Completed||Phase 1|27|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 01:57:17.758591|2018-06-01 01:57:17.758591
NCT00713258|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2011-07-28||2012-05-04|2008-07-10|2008-07-11|Estimate|2011-09-02|2011-10-07|Estimate||||2012-05-04|2012-05-08|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)|A 24-week, International, Multi Centre, Randomised, Double-blind, Double-dummy, Parallel Group, Phase IV Clinical Trial Investigating Changes in Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) Treated With Either 100 µg PTH(1-84) Daily or 70 mg Alendronate Weekly|Terminated||Phase 4|75|Actual|Nycomed|Early termination leading to small number of subjects analyzed.|2||Slow enrolment|f||||f||||||||||2018-06-01 01:57:17.971686|2018-06-01 01:57:17.971686
NCT00713245|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2013-12-03|2008-07-09|2008-07-11|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Long Term Follow up Study in Late-onset Pompe Disease|A Long Term Follow up Study in Late-onset Pompe Disease|Recruiting|||70|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:57:18.254361|2018-06-01 01:57:18.254361
NCT00713232|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-09|2008-07-09|2008-07-11|Estimate|||||||2008-07-09|2008-07-11|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Observational|||The Construction of a Chinese Picture Naming Test and Its Preliminary Normative Data|The Construction of a Chinese Picture Naming Test and Its Preliminary Normative Data|Completed|||522|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 01:57:18.324003|2018-06-01 01:57:18.324003
NCT00713219|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2015-04-07||2015-04-21|2008-07-10|2008-07-11|Estimate|2015-04-21|2015-04-23|Estimate||||2015-04-21|2015-04-23|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer|Phase II Study of Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity -Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer|Completed||Phase 2|14|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:57:18.430705|2018-06-01 01:57:18.430705
NCT00713206|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2013-08-06||2017-08-01|2008-07-10|2008-07-11|Estimate|2013-08-06|2013-10-11|Estimate||||2017-08-01|2017-08-30|Actual|September 2006||2006-09-30|August 2017|2017-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Prospective Study of NanoTite Implants Placed Into Fresh Sinus-Lift Augmentation Sites (VSSL)|A Prospective, Randomized-Controlled, Multicenter Study of NanoTite Implants Placed Into Fresh Sinus Lift Augmentation Sites|Completed||N/A|92|Actual|Zimmer Biomet||2|||f||||t||||||||No||2018-06-01 01:57:18.622937|2018-06-01 01:57:18.622937
NCT00713193|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2017-09-20|2008-07-09|2008-07-11|Estimate|||||||2017-09-20|2017-09-25|Actual|November 2007||2007-11-30|September 2017|2017-09-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)|A Multi-Center, Randomized Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in the Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP)|Completed||Phase 3|16|Actual|Ohio State University||2|||f||||t||||||||Yes|data being evaluated and reviewed, manuscript in preparation for final report to FDA|2018-06-01 01:57:19.074834|2018-06-01 01:57:19.074834
NCT00713180|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2015-06-24|2008-07-10|2008-07-11|Estimate|||||||2015-06-24|2015-06-25|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Determinants of Pterygium Occurrence and Recurrence in a Rural African Population|Determinants of Pterygium Occurrence and Recurrence in a Rural African Population|Completed||N/A|355|Anticipated|Anguria, Peter, M.D.||2|||f||||t||||||||||2018-06-01 01:57:19.152499|2018-06-01 01:57:19.152499
NCT00713167|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2009-05-20|2008-07-08|2008-07-11|Estimate|||||||2009-05-20|2009-05-21|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|GSE||The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL)|Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia|Completed||Phase 2/Phase 3|55|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:57:19.265079|2018-06-01 01:57:19.265079
NCT00713154|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-10|2008-07-10|2008-07-11|Estimate|||||||2008-07-10|2008-07-11|Estimate|April 2007||2007-04-30|July 2008|2008-07-31|September 2008|Anticipated|2008-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Preliminary Efficacy Study of MTS-01 for the Prevention of Alopecia Induced by WHole Brain Radiotherapy|A Phase II, Double-Blind Placebo-Controlled, Parallel Group Study of the Safety and Preliminary Efficacy of MTS-01, for the Prevention of Alopecia Induced by Whole Brain Radiotherapy|Terminated||Phase 2|16|Actual|Mitos Pharmaceuticals||2||Major planned study protocol modifications|f||||f||||||||||2018-06-01 01:57:19.385585|2018-06-01 01:57:19.385585
NCT00713141|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-10|||2010-08-30|2008-07-10|2008-07-11|Estimate|||||||2010-08-30|2010-08-31|Estimate|November 2004||2004-11-30|August 2010|2010-08-31||||||||Observational|||Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer|Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer|Completed|||30||National University Hospital, Singapore|||1||f||||||||||||||2018-06-01 01:57:19.452915|2018-06-01 01:57:19.452915
NCT00713128|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2011-04-11|2008-07-10|2008-07-11|Estimate|||||||2011-04-11|2011-04-12|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy|Prospective Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy|Completed|||50|Anticipated|Steward St. Elizabeth's Medical Center of Boston, Inc.|||||f||||f||||||||||2018-06-01 01:57:19.525739|2018-06-01 01:57:19.525739
NCT00713115|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2008-07-09|2008-07-09|2008-07-11|Estimate|||||||2008-07-09|2008-07-11|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Prospective Randonmized Comparison of Needlescopic Versus Conventional Laparoscopic Adrenalectomy|Prospective Randonmized Comparison of Needlescopic Versus Conventional Laparoscopic Adrenalectomy for Benign Adrenal Tumors Less Than 5 cm in Diameter|Unknown status|Recruiting|N/A|60|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 01:57:19.604146|2018-06-01 01:57:19.604146
NCT00713102|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2016-10-03|2008-07-10|2008-07-11|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Surgical and Medical Emergencies on Board of European Aircraft Carriers|Surgical and Medical Emergencies on Board of European Aircraft Carriers|Completed|||10189|Actual|Ruhr University of Bochum|||1||f||||t||||||||||2018-06-01 01:57:19.704381|2018-06-01 01:57:19.704381
NCT00713089|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2014-01-07|2008-07-07|2008-07-11|Estimate|||||||2014-01-07|2014-01-08|Estimate|March 2006||2006-03-31|January 2014|2014-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Study of Stool Microbiota in Two Diverse Cohorts of Asian and Its Influence on Allergy Development|A 2 Year Prospective Study of Stool Microbiota in Two Diverse Cohorts of Asian (Singaporean and Indonesian) Newborns and Its Influence on Allergy Development|Completed|||74|Actual|National University Hospital, Singapore|||2||f||||f||||||Samples With DNA|"~     Stools samples will be collected between 72 to 120 hours (or 3 to 5 days) and at 1, 3 and 12~     months of age.~   "|||2018-06-01 01:57:19.77766|2018-06-01 01:57:19.77766
NCT00713076|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2014-08-18|2008-07-10|2008-07-11|Estimate|||||||2014-08-18|2014-08-20|Estimate|October 2007||2007-10-31|July 2008|2008-07-31||||March 2008|Actual|2008-03-31||Interventional|||Wettability of Contact Lenses With a Multi-Purpose Solution||Completed||N/A|30|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:57:19.837439|2018-06-01 01:57:19.837439
NCT00713063|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2015-01-29|2008-07-09|2008-07-11|Estimate|||||||2015-01-29|2015-01-30|Estimate|April 2006||2006-04-30|January 2015|2015-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Behavioral Exercise Intervention for Smoking Cessation|Behavioral Exercise Intervention for Smoking Cessation|Completed||Phase 2|61|Actual|Butler Hospital||2|||f||||f||||||||||2018-06-01 01:57:19.930247|2018-06-01 01:57:19.930247
NCT00713050|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2013-06-10|2008-07-09|2008-07-11|Estimate|||||||2013-06-10|2013-06-11|Estimate|August 2007||2007-08-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Speech and Language Therapy After Stroke|Neurophysiological Measurement in Aphasia Treatment|Terminated||N/A|34|Actual|University of Chicago||2||Protocol expired; PI retired|f||||f||||||||||2018-06-01 01:57:20.038233|2018-06-01 01:57:20.038233
NCT00713037|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2017-02-02|2008-07-10|2008-07-11|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2008||2008-06-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas|Hypoxia-PET and IMPT Dose Painting in Patients With Chordomas: A Pilot Study|Completed||N/A|20|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 01:57:20.125926|2018-06-01 01:57:20.125926
NCT00713024|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2010-06-28|2008-07-09|2008-07-11|Estimate|||||||2010-06-28|2010-06-29|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Patterns of Cerebral Activation to Innocuous and Noxious Heat Stimulations in Neuropathic Pain|Patterns of Cerebral Activation to Innocuous and Noxious Heat Stimulations in Neuropathic Pain|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-06-01 01:57:20.228466|2018-06-01 01:57:20.228466
NCT00713011|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-11-14|2008-07-10|2008-07-11|Estimate|||||||2012-11-14|2012-11-16|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|CARDINAL||Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients|Randomized Open-label 2-arm Parallel Design Comparator Study of the Effect of Adalat® XL® Compared to Diltiazem on Proteinuria and Blood Pressure in Patients With Diabetes and Mild to Moderate Hypertension When Used as an Add on to Avalide®|Withdrawn||Phase 3|0|Actual|Bayer||2||"Study was stopped by sponsor prior to first patient assignment to groups due to operational~   reasons."|f||||f||||||||||2018-06-01 01:57:20.311089|2018-06-01 01:57:20.311089
NCT00712998|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2009-05-17|2008-07-10|2008-07-11|Estimate|||||||2009-05-17|2009-05-19|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Observational|||X-Ray Computed Tomography and Blood Reactive Oxygen Species Level|Effect of X-Ray Computed Tomography Examination on the Blood Reactive Oxygen Species Level in Apparently Healthy Adults|Terminated|||60|Anticipated|National Taiwan University Hospital|||3|Beacuse of unexpected administrative barriers, only 5 cases were enrolled in a year.|f||||f||||||None Retained|"~     only peripheral blood will be collected for measurement of reactive oxygen species.~   "|||2018-06-01 01:57:20.377987|2018-06-01 01:57:20.377987
NCT00712985|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|2013-06-11||2014-03-24|2008-07-09|2008-07-11|Estimate|2014-03-24|2014-04-24|Estimate||||2014-03-24|2014-04-24|Estimate|September 2005||2005-09-30|March 2014|2014-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|CTIBL|18 patients signed consent & 1 withdrew due to family not wishing her to continue with trial.|Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)|Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)|Completed||Phase 3|18|Actual|Milton S. Hershey Medical Center|18 patients were able to be enrolled in this trial & only 13 were able to be analyzed. This was an insufficient number to analyze/interpret data.|1|||f||||f||||||||||2018-06-01 01:57:20.44694|2018-06-01 01:57:20.44694
NCT00712972|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2009-07-16|2008-07-08|2008-07-11|Estimate|||||||2009-07-16|2009-07-17|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Evaluation of the Medial Parapatellar Knee Injection Technique|Evaluation of the Effectiveness of the Medial Parapatellar Knee Injection Technique|Completed|||45|Anticipated|Oklahoma State University Center for Health Sciences|||1||f||||t||||||||||2018-06-01 01:57:20.757096|2018-06-01 01:57:20.757096
NCT00712959|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2014-02-18|2011-03-01|2014-04-01|2008-07-09|2008-07-10|Estimate|2014-04-01|2014-04-30|Estimate|2011-03-01|2011-03-16|Estimate|2014-04-01|2014-04-30|Estimate|June 2008||2008-06-30|April 2014|2014-04-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose|Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose|Completed||Phase 4|769|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:57:20.834903|2018-06-01 01:57:20.834903
NCT00712946|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-04-27|2008-07-08|2008-07-10|Estimate|||||||2011-04-27|2011-04-28|Estimate|March 2006||2006-03-31|March 2010|2010-03-31|December 2010|Actual|2010-12-31|||||Observational|Barosleep||Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages|Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages|Completed|||103|Actual|GE Healthcare|||2||f||||t||||||||||2018-06-01 01:57:21.282784|2018-06-01 01:57:21.282784
NCT00712933|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2017-11-08||2017-12-15|2008-07-09|2008-07-10|Estimate|2017-12-15|2018-01-16|Actual||||2017-12-15|2018-01-16|Actual|May 1, 2008||2008-05-01|November 2017|2017-11-30|December 9, 2016|Actual|2016-12-09|December 1, 2016|Actual|2016-12-01||Interventional||Modified Intention to Treat (MITT) includes all participants who were enrolled in BEL112234 and were treated with at least one dose of belimumab in the continuation study.|A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057|A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057|Completed||Phase 3|738|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 01:57:21.580402|2018-06-01 01:57:21.580402
NCT00712920|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2009-09-30||2011-06-06|2008-07-09|2008-07-10|Estimate|2009-12-10|2010-01-15|Estimate||||2011-06-06|2011-06-08|Estimate|January 2007||2007-01-31|June 2011|2011-06-30||||May 2008|Actual|2008-05-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 in Patients With Perennial Allergic Rhinitis|Completed||Phase 3|581|Actual|Meda Pharmaceuticals|Standard deviations for primary endpoint are not available.|3|||f||||f||||||||||2018-06-01 01:57:25.306711|2018-06-01 01:57:25.306711
NCT00712907|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2008-07-09|2008-07-09|2008-07-10|Estimate|||||||2008-07-09|2008-07-10|Estimate|February 2003||2003-02-28|July 2008|2008-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow|Effects of Vitamin C on Hyperoxia-Induced Reduction of Retinal Blood Flow|Completed||N/A|12|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:57:26.285257|2018-06-01 01:57:26.285257
NCT00712894|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-09-20|2008-07-08|2008-07-10|Estimate|||||||2012-09-20|2012-09-24|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|EDUCATE-AMI||Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction|Reversal of No-reflow/Slow-flow During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction--a Prospective Randomized Study Comparing Intracoronary Infusion of Diltiazem, Verapamil and Nitroglycerin|Completed||Phase 4|102|Actual|Fudan University||3|||f||||t||||||||||2018-06-01 01:57:26.36075|2018-06-01 01:57:26.36075
NCT00712881|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2016-02-05|2008-07-09|2008-07-10|Estimate|||||||2016-02-05|2016-02-09|Estimate|October 2008||2008-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer|Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer|Completed||Phase 2|126|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 01:57:26.47063|2018-06-01 01:57:26.47063
NCT00712868|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-07-17|2008-07-09|2008-07-10|Estimate|||||||2009-07-17|2009-07-20|Estimate|June 2008||2008-06-30|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|LACTAFEM||Acceptability of Lactacyd Femina|Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up Lactacyd Femina|Completed||Phase 4|559|Actual|Sanofi||1|||f||||||||||||||2018-06-01 01:57:26.66498|2018-06-01 01:57:26.66498
NCT00712855|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-10-26|2008-07-09|2008-07-10|Estimate|||||||2012-10-26|2012-10-30|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|HCC||A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma|A Phase 1B, Multi-center, Open Label, Dose Escalation Study of Mapatumumab ([HGS1012], a Fully-human Monoclonal Antibody to TRAIL-R1) in Combination With Sorafenib as a First Line Therapy in Subjects With Advanced Hepatocellular Carcinoma|Completed||Phase 1|23|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 01:57:26.769528|2018-06-01 01:57:26.769528
NCT00712842|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2012-07-19|2008-07-07|2008-07-10|Estimate|||||||2012-07-19|2012-07-20|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Neurovascular Coupling in Patients With Early Stage Diabetes Retinopathy|Neurovascular Coupling in Patients With Early Stage Diabetes Retinopathy|Completed|||100|Actual|Medical University of Vienna|||2||f||||t||||||||||2018-06-01 01:57:26.882316|2018-06-01 01:57:26.882316
NCT00712829|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-10-07|2008-07-09|2008-07-10|Estimate|||||||2011-10-07|2011-10-12|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents|A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for 123-I-MIP-1072 and 123-I-MIP-1095|Completed||Phase 1|12|Anticipated|Molecular Insight Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 01:57:26.983991|2018-06-01 01:57:26.983991
NCT00712816|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2012-03-19|2008-07-09|2008-07-10|Estimate|||||||2012-03-19|2012-03-20|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|May 2012|Anticipated|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Use of Cold and Compression Therapy With Total Knee Replacement Patients|Investigating the Use of a Cryopneumatic Therapy Device in Primary Total Knee Arthroplasty Patients|Unknown status|Active, not recruiting|Phase 4|224|Anticipated|CoolSystems, Inc.||2|||f||||f||||||||||2018-06-01 01:57:27.083357|2018-06-01 01:57:27.083357
NCT00712803|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-12-31|2008-07-08|2008-07-10|Estimate|||||||2012-12-31|2013-01-03|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults|A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3-3'Ddelta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3|Completed||Phase 1|29|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 01:57:27.28398|2018-06-01 01:57:27.28398
NCT00712790|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2016-01-04|2008-07-09|2008-07-10|Estimate|||||||2016-01-04|2016-01-06|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|April 2014|Actual|2014-04-30|June 2009|Actual|2009-06-30||Interventional|||Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)|Phase I/II Study of SIR-Spheres Plus Sorafenib as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|35|Actual|Singapore Clinical Research Institute||1|||f||||f||||||||||2018-06-01 01:57:27.521713|2018-06-01 01:57:27.521713
NCT00712777|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2014-11-20|2008-07-09|2008-07-10|Estimate|||||||2014-11-20|2014-11-21|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism|Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism|Withdrawn||N/A|0|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:57:27.653411|2018-06-01 01:57:27.653411
NCT00712764|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2008-07-08|2008-07-08|2008-07-10|Estimate|||||||2008-07-08|2008-07-10|Estimate|January 2005||2005-01-31|December 2006|2006-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure.|Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure.|Completed||N/A|20|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:57:27.729347|2018-06-01 01:57:27.729347
NCT00712751|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2017-07-05|2008-07-07|2008-07-10|Estimate|||||||2017-07-05|2017-07-06|Actual|June 2008|Actual|2008-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Sexual Health of Rectal Cancer Patients|The Sexual Health of Rectal Cancer Patients: A Pilot Study|Active, not recruiting|||192|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 01:57:27.896626|2018-06-01 01:57:27.896626
NCT00712738|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2017-06-30|2008-07-09|2008-07-10|Estimate|||||||2017-06-30|2017-07-02|Actual|June 20, 2008||2008-06-20|September 22, 2010|2010-09-22|September 22, 2010|Actual|2010-09-22|September 22, 2010|Actual|2010-09-22||Interventional|||Oral Nifedipine to Treat Iron Overload|A Trial of Oral Nifedipine for the Treatment of Iron Overload|Completed||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:57:28.02618|2018-06-01 01:57:28.02618
NCT00712725|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2010-10-22||2015-01-23|2008-07-09|2008-07-10|Estimate|2010-10-22|2010-11-22|Estimate||||2015-01-23|2015-02-02|Estimate|July 2008||2008-07-31|January 2015|2015-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||MK3207 for Treatment of Acute Migraines (3207-005)|A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-finding Study of MK3207 in the Treatment of Acute Migraine|Completed||Phase 2|676|Actual|Merck Sharp & Dohme Corp.||7|||f||||||||||||||2018-06-01 01:57:28.126757|2018-06-01 01:57:28.126757
NCT00712712|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2009-12-13|2008-07-09|2008-07-10|Estimate|||||||2009-12-13|2009-12-15|Estimate|October 2007||2007-10-31|July 2009|2009-07-31||||December 2010|Anticipated|2010-12-31||Interventional|||Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer|Evaluation of the Effectiveness of the Radiofrequency Ablation for Reducing Refractory Pain From Bone Metastases|Unknown status|Recruiting|Phase 2|63|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:57:29.468715|2018-06-01 01:57:29.468715
NCT00712699|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08||2013-08-10|2013-08-10|2008-07-08|2008-07-10|Estimate||||2013-08-10|2013-08-23|Estimate|2013-08-10|2013-08-23|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effectiveness of an Extended Release Stimulant Medication in Treating Preschool Children With ADHD|Placebo vs. Extended Release Stimulant Crossover Trial in Preschoolers With ADHD|Completed||N/A|27|Actual|Baystate Medical Center||2|||f||||f||||||||||2018-06-01 01:57:29.573768|2018-06-01 01:57:29.573768
NCT00712686|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2013-11-07|2008-07-08|2008-07-10|Estimate|||||||2013-11-07|2013-11-08|Estimate|June 2000||2000-06-30|June 2010|2010-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia|A Multicenter, Double-Blind, Randomized, Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia|Completed||Phase 3|690|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-06-01 01:57:29.677605|2018-06-01 01:57:29.677605
NCT00712673|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2016-08-18|2012-04-13|2016-10-24|2008-07-07|2008-07-10|Estimate|2016-10-24|2016-12-15|Estimate|2012-04-13|2012-04-16|Estimate|2016-10-24|2016-12-15|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|GETGOAL-M|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin|Completed||Phase 3|680|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 01:57:29.889073|2018-06-01 01:57:29.889073
NCT00712660|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2013-03-31|2008-07-09|2008-07-10|Estimate|||||||2013-03-31|2013-04-02|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|November 2009|Actual|2009-11-30||Interventional|||Study With Information Technology (IT) - Aided Preventive Program in Schizophrenia|ITAREPS Trial: A Prospective Randomized Double-blind Controlled Study in IT-aided Mobile Phone-based Relapse Prevention Program in Schizophrenia.|Completed||N/A|146|Actual|Prague Psychiatric Center||2|||f||||f||||||||||2018-06-01 01:57:31.840985|2018-06-01 01:57:31.840985
NCT00712647|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-09-25|2008-07-09|2008-07-10|Estimate|||||||2012-09-25|2012-09-26|Estimate|May 1985||1985-05-31|September 2012|2012-09-30|June 2005|Actual|2005-06-30|December 2004|Actual|2004-12-31||Interventional|CARET||Carotene and Retinol Efficacy Trial|Caret and Retinol Efficacy Trial: The Caret Coordinating Center|Completed||Phase 4|18314|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 01:57:31.922109|2018-06-01 01:57:31.922109
NCT00712634|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2009-12-18|2008-07-09|2008-07-10|Estimate|||||||2009-12-18|2009-12-21|Estimate|November 1997||1997-11-30|December 2009|2009-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Cytomegalovirus Vaccine in Healthy Participants|A Phase I Dose Escalation Study of Lipopeptide Vaccines With Activity Against Human Cytomegalovirus|Completed||Phase 1|46|Anticipated|City of Hope Medical Center||2|||f||||||||||||||2018-06-01 01:57:31.996486|2018-06-01 01:57:31.996486
NCT00712621|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2009-11-20|2008-07-09|2008-07-10|Estimate|||||||2009-11-20|2009-11-24|Estimate|February 2010||2010-02-28|November 2009|2009-11-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination|Phase II Two Arm Randomized Controlled Clinical Trial to Study Quality of Life and Survival of Breast Cancer Patients After Completion of Chemotherapy or Radiation Therapy or Surgery or Any Combination Therapy in Stage I to IV Carcinoma|Withdrawn||Phase 2|460|Anticipated|American Scitech International||2||"Study is withdrawn due to unavailability of eligible subject population. We will request the~   sponsors to extend the time for enrollment."|f||||f||||||||||2018-06-01 01:57:32.079717|2018-06-01 01:57:32.079717
NCT00712608|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2010-01-26|2008-07-09|2008-07-10|Estimate|||||||2010-01-26|2010-01-28|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||The Evaluation of Cow's Milk Formula - Study B|The Evaluation of Cow's Milk Formula - Study B|Completed||N/A|399|Anticipated|Mead Johnson Nutrition||3|||f||||f||||||||||2018-06-01 01:57:32.17214|2018-06-01 01:57:32.17214
NCT00712595|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2009-04-22|2008-07-09|2008-07-10|Estimate|||||||2009-04-22|2009-04-23|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|January 2007|Actual|2007-01-31||Interventional|Mifemyo||Mifepristone for Treatment of Uterine Fibroids|Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial.|Completed||Phase 2/Phase 3|200|Actual|Mediterranea Medica S. L.||2|||f||||t||||||||||2018-06-01 01:57:32.282261|2018-06-01 01:57:32.282261
NCT00712582|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2017-09-06|2008-07-08|2008-07-10|Estimate|||||||2017-09-06|2017-09-07|Actual|July 2008||2008-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma|Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma|Active, not recruiting||Phase 2|101|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 01:57:32.348069|2018-06-01 01:57:32.348069
NCT00712569|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2015-02-05|2008-07-07|2008-07-10|Estimate|||||||2015-02-05|2015-02-06|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety|Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety|Completed|||85|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 01:57:32.422734|2018-06-01 01:57:32.422734
NCT00712556|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2013-02-25|2008-07-09|2008-07-10|Estimate|||||||2013-02-25|2013-02-26|Estimate|May 2008||2008-05-31|February 2013|2013-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||PET Study in Patients With Non-Hodgkin Lymphoma|Positron Emission Tomography Study in Patients With Non-Hodgkin Lymphoma|Completed|||55|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||||||2018-06-01 01:57:32.48919|2018-06-01 01:57:32.48919
NCT00712543|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2011-04-07||2011-08-19|2008-07-09|2008-07-10|Estimate|2011-08-19|2011-09-27|Estimate||||2011-08-19|2011-09-27|Estimate|June 2009||2009-06-30|August 2011|2011-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Preference Study Comparing Kristalose® and Liquid Lactulose|A Preference Study Comparing Kristalose® and Liquid Lactulose in the Treatment of Constipation|Completed||Phase 4|50|Actual|Cumberland Pharmaceuticals||2|||f||||f||||||||||2018-06-01 01:57:32.564464|2018-06-01 01:57:32.564464
NCT00712530|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-04|2013-02-19||2013-02-19|2008-07-08|2008-07-10|Estimate|2013-02-19|2013-03-26|Estimate||||2013-02-19|2013-03-26|Estimate|January 2005||2005-01-31|February 2013|2013-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|GIHU004||Single DermaVir Immunization in HIV-1 Infected Patients on HAART|A Phase I Study to Evaluate the Tolerability and Safety of LC002, a DermaVir Vaccine, in HIV-1-infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 1|9|Actual|Genetic Immunity|This is a Phase I small sample study that was not powered for the secondary efficacy endpoints.|3|||f||||t||||||||||2018-06-01 01:57:32.940567|2018-06-01 01:57:32.940567
NCT00712517|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2016-07-18|2008-07-09|2008-07-10|Estimate|||||||2016-07-18|2016-07-20|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Propofol Versus Volatile Anesthesia in Post Operative Pain Management|Do Patients Anesthetized With Propofol Have Less Pain Than Those Anesthetized With Volatile?|Terminated||N/A|90|Actual|The Cleveland Clinic||2||Enrolling of participants has halted and the results are being gathered|f||||f||||||||No||2018-06-01 01:57:33.313371|2018-06-01 01:57:33.313371
NCT00712504|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-11-07|2008-07-07|2008-07-10|Estimate|||||||2008-11-07|2008-11-11|Estimate|July 2004||2004-07-31|November 2008|2008-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer|A Phase 1 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Solid Tumors|Completed||Phase 1|49|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:57:33.38608|2018-06-01 01:57:33.38608
NCT00712491|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2013-01-08|2008-07-08|2008-07-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|September 2008||2008-09-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration|A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|Terminated||Phase 1/Phase 2|20|Actual|Santen Inc.||2|||f||||f||||||||||2018-06-01 01:57:33.489317|2018-06-01 01:57:33.489317
NCT00712478|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2016-03-03|2008-07-09|2008-07-10|Estimate|||||||2016-03-03|2016-03-07|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|INTENSE3MIX||Observational Study Describing Conditions for Intensification of Insulin Therapy in Type 2 Diabetes|Observational Study on Efficacy of Intensification of Insulin Therapy to at Least 3 Daily Injections in Type 2 Diabetes|Completed|||114|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:57:33.573148|2018-06-01 01:57:33.573148
NCT00712465|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2010-12-02|2008-07-09|2008-07-10|Estimate|||||||2010-12-02|2010-12-03|Estimate|August 2008||2008-08-31|December 2010|2010-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||An Interaction Study With Digoxin and AZD1305|A Phase I, Randomised, Open, Single-centre, Three-period Crossover Study to Evaluate the Effect of AZD1305 on the Pharmacokinetics of Digoxin After Repeated Oral Administration of AZD1305 and Digoxin to Young Healthy Male Volunteers|Completed||Phase 1|18|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:57:33.638749|2018-06-01 01:57:33.638749
NCT00712452|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2013-05-13|2008-07-09|2008-07-10|Estimate|||||||2013-05-13|2013-05-14|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|IROCHIM||Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve|Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve.|Terminated||N/A|19|Actual|Assistance Publique - Hôpitaux de Paris||3||problems of insuffisant recruitment|f||||f||||||||||2018-06-01 01:57:33.705193|2018-06-01 01:57:33.705193
NCT00712439|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-06-06|2008-07-09|2008-07-10|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy|Completed||Phase 2|147|Actual|Depomed||2|||f||||f||||||||||2018-06-01 01:57:33.778047|2018-06-01 01:57:33.778047
NCT00712426|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08||2016-02-10|2016-02-10|2008-07-09|2008-07-10|Estimate||||2016-02-10|2016-03-11|Estimate|2016-02-10|2016-03-11|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|CREST-E||Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)|Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)|Terminated||Phase 3|553|Actual|Massachusetts General Hospital||2||"Results of an interim analysis showed that it was unlikely that creatine was effective in~   slowing loss of function in early symptomatic Huntington's Disease."|f||||t||||||||||2018-06-01 01:57:33.841364|2018-06-01 01:57:33.841364
NCT00712413|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2017-02-08|2008-07-09|2008-07-10|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2008||2008-08-31|February 2017|2017-02-28|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori|Pilot Study Assessing the Safety, Tolerability, Compliance and Efficacy of Twice Daily Dosed Pylera Plus Omeprazole as a First Line Treatment of Helicobacter Pylori Infection|Withdrawn||Phase 3|0|Actual|Forest Laboratories||||Sponsor's decision|f||||f||||||||||2018-06-01 01:57:34.126333|2018-06-01 01:57:34.126333
NCT00712400|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2012-01-24|2008-07-08|2008-07-10|Estimate|||||||2012-01-24|2012-01-25|Estimate|June 2005||2005-06-30|January 2012|2012-01-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects|Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects|Completed||N/A|24|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:57:34.19265|2018-06-01 01:57:34.19265
NCT00712387|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-02-23|2008-07-09|2008-07-10|Estimate|||||||2009-02-23|2009-02-24|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Trial of Proficiency- Based Simulation Training for General Surgical Trainees|A National, Prospective,Randomised, Single Blinded Controlled Trial of Proficiency- Based Simulation Training for General Surgical Trainees|Unknown status|Active, not recruiting|N/A|24|Anticipated|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-06-01 01:57:34.257804|2018-06-01 01:57:34.257804
NCT00712374|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2009-09-21|2008-07-09|2008-07-10|Estimate|||||||2009-09-21|2009-09-22|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|July 2012|Anticipated|2012-07-31|December 2011|Anticipated|2011-12-31||Interventional|||Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal|Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal|Unknown status|Enrolling by invitation|Phase 4|100000|Anticipated|London School of Hygiene and Tropical Medicine||1|||f||||t||||||||||2018-06-01 01:57:34.348533|2018-06-01 01:57:34.348533
NCT00712361|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2014-12-04|2008-07-09|2008-07-10|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2008||2008-07-31|December 2009|2009-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Comparative Study of the SoftTouch Non-Invasive Finger-Mounted Device|A Comparative Clinical Trial to Assess the Accuracy of the SoftTouch. A Novel Non-invasive Device for Measuring Peripheral Blood Glucose, Carbon Dioxide, pH, Hemoglobin, Hematocrit, SpO2, Peripheral Pulse and Blood Pressure.|Completed||N/A|70|Actual|Cnoga Medical Ltd.||1|||f||||t||||||||||2018-06-01 01:57:34.413825|2018-06-01 01:57:34.413825
NCT00712348|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2014-04-30||2014-05-30|2008-07-07|2008-07-10|Estimate|2014-05-30|2014-06-05|Estimate||||2014-05-30|2014-06-05|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase|A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase in Patients With Gaucher Disease Treated With Imiglucerase|Completed||Phase 3|31|Actual|Protalix||1|||f||||t||||||||||2018-06-01 01:57:34.51211|2018-06-01 01:57:34.51211
NCT00712335|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2011-11-16||2012-04-18|2008-07-07|2008-07-09|Estimate|2012-04-18|2012-05-16|Estimate||||2012-04-18|2012-05-16|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Effects of Montelukast on Smokers With Asthma|The Effects of Montelukast on Sputum Cells and Inflammatory Markers in Smokers With Asthma|Completed||Phase 4|105|Actual|Inje University|It is difficult attaining representative gender ratios (i.e., representative of the general population) when conducting a smoking study in Korea, as smoking by females is still considered culturally taboo.|5|||f||||t||||||||||2018-06-01 01:57:34.887848|2018-06-01 01:57:34.887848
NCT00712322|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-11-21|2008-07-03|2008-07-09|Estimate|||||||2017-11-21|2017-11-24|Actual|October 31, 2008|Actual|2008-10-31|November 2017|2017-11-30|May 23, 2013|Actual|2013-05-23|May 23, 2013|Actual|2013-05-23||Interventional|||2 Week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Yrs) With Neurogenic Detrusor Overactivity|A 14-day, Open-label, Multicenter, Dose-escalating, Sequential Cohort Study to Evaluate Pharmacodynamics (Urodynamics) and Pharmacokinetics, Clinical Efficacy, Tolerability and Safety, Following Multiple Doses (mg/kg/Day) of Darifenacin Liquid Oral Suspension Given b.i.d. (Twice Daily) in Children, Ages 2 - 15 Years, With Neurogenic Detrusor Overactivity|Terminated||Phase 2|9|Actual|Warner Chilcott||4||Due to extremely difficult enrollment.|f||||t||||||||||2018-06-01 01:57:35.388184|2018-06-01 01:57:35.388184
NCT00712309|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2009-02-09|2008-07-08|2008-07-09|Estimate|||||||2009-02-09|2009-02-10|Estimate|February 2007||2007-02-28|February 2009|2009-02-28||||June 2010|Anticipated|2010-06-30||Interventional|ETAP||Endovascular Treatment of Popliteal Artery - Balloon Angioplasty Versus Primary Stenting|Endovascular Treatment of Atherosclerotic Popliteal Artery Lesions - Balloon Angioplasty Versus Primary Stenting|Unknown status|Recruiting|N/A|250|Anticipated|Herz-Zentrums Bad Krozingen||2|||f||||t||||||||||2018-06-01 01:57:35.485714|2018-06-01 01:57:35.485714
NCT00712296|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-12-29|2008-07-07|2008-07-09|Estimate|||||||2009-12-29|2009-12-30|Estimate|August 2008||2008-08-31|December 2009|2009-12-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Effectiveness of Chinese Herbal Therapy for Asthma|Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase II|Suspended||Phase 2|50|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||||2018-06-01 01:57:35.556772|2018-06-01 01:57:35.556772
NCT00712283|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2009-12-04|2008-07-08|2008-07-09|Estimate|||||||2009-12-04|2009-12-07|Estimate|July 2008||2008-07-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers|A Single Center, Randomized, Double-blind, Placebo-controlled, Parallel Group Design Study to Investigate the Effect of 12,5 mg, 25 mg, 50 mg and 75 mg Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers|Completed||Phase 1|64|Anticipated|Merz Pharmaceuticals GmbH||4|||f||||||||||||||2018-06-01 01:57:35.638026|2018-06-01 01:57:35.638026
NCT00712270|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2016-02-25|2008-07-07|2008-07-09|Estimate|||||||2016-02-25|2016-02-26|Estimate|April 2005||2005-04-30|February 2016|2016-02-29|November 2010|Actual|2010-11-30|December 2008|Actual|2008-12-31||Interventional|BEST||Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia|A Randomized Double-blind Trial of Aripiprazole and Risperidone in Schizophrenia: An Evaluation of Neuroimaging, Neuropsychological, and Pharmacogenomic Markers of Differential Treatment Response|Terminated||Phase 4|21|Actual|Kettering Health Network||3||Study terminated due to failure to meet sufficient enrollment for valid analysis|f||||f||||||||No||2018-06-01 01:57:35.709626|2018-06-01 01:57:35.709626
NCT00497575|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate|October 1999||1999-10-31|July 2007|2007-07-31|September 2006|Actual|2006-09-30|||||Observational|CHRO1||Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism||Completed|||||Zhejiang University|||||f||||t||||||||||2018-06-01 03:06:08.570006|2018-06-01 03:06:08.570006
NCT00712257|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2014-06-02|2008-07-08|2008-07-09|Estimate|||||||2014-06-02|2014-06-04|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|August 2009|Actual|2009-08-31|September 2008|Actual|2008-09-30||Interventional|SALVAGE||Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis|A Prospective, Multicenter Trial to Evaluate the Safety and Performance of Spectranetics Laser With Adjunct PTA and GORE VIABAHN Endoprosthesis for the Treatment of SFA Instent Restenosis.|Terminated||N/A|27|Actual|VIVA Physicians||1||Due to safety concerns|f||||t||||||||||2018-06-01 01:57:35.796686|2018-06-01 01:57:35.796686
NCT00712244|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2009-04-27||2010-09-10|2008-07-08|2008-07-09|Estimate|2009-04-27|2009-06-16|Estimate||||2010-09-10|2010-09-14|Estimate|October 2007||2007-10-31|September 2010|2010-09-30||||April 2009|Actual|2009-04-30||Interventional|||DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus|DisCoVisc Versus Competitor|Completed||Phase 4|112|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 01:57:35.892614|2018-06-01 01:57:35.892614
NCT00712231|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-08|2008-07-08|2008-07-09|Estimate|||||||2008-07-08|2008-07-09|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Limitations of Using a Sheimpflug Image-Based Device for Measuring Anterior Chamber Depth in Pseudophakic Eyes|To Assess the Degree of Agreement of Anterior Chamber Depth Measurements by 2 Optical Devices (Pentacam and IOLMaster) and Compare Them With Contact Ultrasound A-Scan in Phakic and Pseudophakic Eyes.|Completed|||184|Actual|Far Eastern Memorial Hospital|||2||f||||f||||||None Retained|"~     no specimen~   "|||2018-06-01 01:57:36.338187|2018-06-01 01:57:36.338187
NCT00712218|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2018-04-27|2008-07-08|2008-07-09|Estimate|||||||2018-04-27|2018-05-01|Actual|December 2008||2008-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|LION||Lymphadenectomy In Ovarian Neoplasms|Randomized, Multicentre Trial for Lymphadenectomy In Ovarian Neoplasms|Completed||N/A|640|Actual|Philipps University Marburg Medical Center||2|||f||||t||||||||||2018-06-01 01:57:36.408075|2018-06-01 01:57:36.408075
NCT00712205|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2009-08-12|2008-07-08|2008-07-09|Estimate|||||||2009-08-12|2009-08-13|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Vitamin D for the Treatment of Severe Asthma|Asthma and Vitamin D (a Clinical Pilot Study)|Unknown status|Enrolling by invitation|Phase 4|20|Anticipated|Kantonsspital Baselland Bruderholz||2|||f||||f||||||||||2018-06-01 01:57:36.733719|2018-06-01 01:57:36.733719
NCT00712192|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-08|2008-07-08|2008-07-09|Estimate|||||||2008-07-08|2008-07-09|Estimate|January 2007||2007-01-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Endoscopic Saphenous Vein Harvest for Coronary Artery Bypass Grafting|The Impact on Endothelial Function and Integrity by Endoscopic Saphenous Vein Harvest for Coronary Artery Bypass Grafting|Completed||N/A|34|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 01:57:36.823363|2018-06-01 01:57:36.823363
NCT00712179|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2016-03-09||2016-04-07|2008-07-03|2008-07-09|Estimate|2016-04-07|2016-05-13|Estimate||||2016-04-07|2016-05-13|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|October 2011|Actual|2011-10-31||Observational|||Understanding Different Parameters in Locomotor Training (a Type of Walking Training) for Person After a Stroke|Developing Evidence-based Parameter Selection for Locomotor Training|Completed|||49|Actual|VA Office of Research and Development|||1||f||||f||||||||Undecided||2018-06-01 01:57:36.886349|2018-06-01 01:57:36.886349
NCT00712166|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2010-09-10||2010-11-19|2008-07-08|2008-07-09|Estimate|2010-11-19|2010-12-20|Estimate||||2010-11-19|2010-12-20|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|AIR-CF4||Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa|A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine For Inhalation in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)|Completed||Phase 3|160|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 01:57:37.136361|2018-06-01 01:57:37.136361
NCT00712153|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2010-08-05|2008-07-08|2008-07-09|Estimate|||||||2010-08-05|2010-08-09|Estimate|November 2006||2006-11-30|July 2008|2008-07-31||||November 2007|Actual|2007-11-30||Observational|||Follow-up of Coronary Artery Bypass Graft Patency by Multislice Computed Tomography|Follow-up of Coronary Artery Bypass Graft Patency by Multislice Computed Tomography|Completed|||36|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 01:57:37.82657|2018-06-01 01:57:37.82657
NCT00712140|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-09-01|2008-07-08|2008-07-09|Estimate|||||||2011-09-01|2011-09-02|Estimate|October 2007||2007-10-31|November 2008|2008-11-30||||October 2011|Anticipated|2011-10-31||Interventional|||Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer|Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve|Unknown status|Recruiting|Phase 3|4000|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 01:57:37.875473|2018-06-01 01:57:37.875473
NCT00712127|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-07-26|2008-07-08|2008-07-09|Estimate|||||||2017-07-26|2017-07-31|Actual|June 2006||2006-06-30|July 2017|2017-07-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|RENEW||Re-energize With Nutrition, Exercise and Weight Loss|Preventing Adverse Effects In Class II and Class III Obesity|Completed||N/A|310|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 01:57:37.975643|2018-06-01 01:57:37.975643
NCT00712114|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-06|||2011-06-11|2008-07-08|2008-07-09|Estimate|||||||2011-06-11|2011-06-14|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis|A Phase I/II, Open Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Anti-Inflammatory Activity of HE3286 When Administered Orally for 29 Days to Patients With Rheumatoid Arthritis on a Stable Dose of Methotrexate|Completed||Phase 1/Phase 2|14|Actual|Harbor Therapeutics||3|||f||||f||||||||||2018-06-01 01:57:38.058179|2018-06-01 01:57:38.058179
NCT00712101|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2011-04-19|2008-07-03|2008-07-09|Estimate|||||||2011-04-19|2011-04-20|Estimate|July 2008||2008-07-31|August 2009|2009-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|AIDA STEMI||Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction|Prospective Randomized Controlled Clinical Study to Compare Abciximab-bolus i.v. Versus i.c. in Primary PCI in Patients With Acute ST-elevation Myocardial Infarction|Completed||Phase 3|1912|Anticipated|University of Leipzig||2|||f||||t||||||||||2018-06-01 01:57:38.18475|2018-06-01 01:57:38.18475
NCT00712088|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2010-03-10|2008-07-08|2008-07-09|Estimate|||||||2010-03-10|2010-03-11|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Project ICARE: Intervening for Community Awareness, Respect, & Empowerment|Project ICARE: Intervening for Community Awareness, Respect, & Empowerment - Behavioral Intervention to Reduce Sexual Risk Behavior of African American Men Who Have Sex With Men|Completed||N/A|275|Anticipated|Centers for Disease Control and Prevention||2|||f||||||||||||||2018-06-01 01:57:38.294469|2018-06-01 01:57:38.294469
NCT00712075|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2015-04-15||2015-05-12|2008-07-03|2008-07-09|Estimate|2015-05-12|2015-06-01|Estimate||||2015-05-12|2015-06-01|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|FROPS||Functional Rehabilitation for Older Patients With Schizophrenia|Functional Rehabilitation for Older Patients With Schizophrenia (FROPS)|Terminated||N/A|107|Actual|VA Office of Research and Development|"Early termination leading to small sample size and loss of follow-up data.~No 50% CBSST comparison group without mobile computer to test efficacy of shorter treatment alone."|3||Loss of funding|f||||t||||||||||2018-06-01 01:57:38.422618|2018-06-01 01:57:38.422618
NCT00712062|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2011-09-16|2008-07-08|2008-07-09|Estimate|||||||2011-09-16|2011-09-20|Estimate|February 2009||2009-02-28|September 2011|2011-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma|Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria|Withdrawn||Phase 2|0|Actual|University of Florida||1||Lack of accrual|f||||t||||||||||2018-06-01 01:57:38.749579|2018-06-01 01:57:38.749579
NCT00712049|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2011-07-20|2008-07-03|2008-07-09|Estimate|||||||2011-07-20|2011-07-22|Estimate|June 2008||2008-06-30|July 2011|2011-07-31||||||||Interventional|NASCIT||Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)|Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:57:38.81133|2018-06-01 01:57:38.81133
NCT00712036|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2015-01-08|2008-07-08|2008-07-09|Estimate|||||||2015-01-08|2015-01-09|Estimate|June 2008||2008-06-30|January 2015|2015-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Entry Into Comprehensive Methadone Treatment Via Interim Maintenance|Entry Into Comprehensive Methadone Treatment Via Interim Maintenance|Completed||N/A|230|Actual|Friends Research Institute, Inc.||3|||f||||t||||||||||2018-06-01 01:57:38.898394|2018-06-01 01:57:38.898394
NCT00712023|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2009-09-27|2008-07-08|2008-07-09|Estimate|||||||2009-09-27|2009-09-29|Estimate|July 2007||2007-07-31|April 2008|2008-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effect of Forced-air Warming and Circulating-water Mattress in Preventing Heat Loss During Vascular Surgery|Effect of Forced-air Warming and Circulating-water Mattress in Preventing Heat Loss During Vascular Surgery|Completed||Phase 2|44|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 01:57:38.97456|2018-06-01 01:57:38.97456
NCT00712010|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2013-04-09||2013-07-12|2008-07-08|2008-07-09|Estimate|2013-07-12|2013-08-14|Estimate||||2013-07-12|2013-08-14|Estimate|July 2008||2008-07-31|July 2013|2013-07-31|April 2011|Actual|2011-04-30|July 2009|Actual|2009-07-31||Interventional|OPTI-PROT|Participants were recruited amoung the Nestlé Research Center staff.|Metabolic Effect of High-protein Meals in Men|Acute Metabolic Effect of the Protein Quality of a High-protein Meal Replacement in Healthy Men|Completed||N/A|25|Actual|Nestlé||7|||f||||f||||||||||2018-06-01 01:57:39.070584|2018-06-01 01:57:39.070584
NCT00711997|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2012-08-14||2013-09-29|2008-07-08|2008-07-09|Estimate|2013-09-29|2013-12-02|Estimate||||2013-09-29|2013-12-02|Estimate|August 2009||2009-08-31|September 2013|2013-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer|Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 in Patients With Unresectable Pancreatic Cancer|Completed||Phase 1/Phase 2|9|Actual|BioCancell Ltd.||1|||f||||f||||||||||2018-06-01 01:57:39.380573|2018-06-01 01:57:39.380573
NCT00711984|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2011-07-25|2008-07-08|2008-07-09|Estimate|||||||2011-07-25|2011-07-26|Estimate|February 2004||2004-02-29|July 2011|2011-07-31||||||||Interventional|||Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Trial in Patients With Advanced Atherosclerosis|Comparison of Stenting Versus Best Medical Therapy for Treatment of Ostial Renal Artery Stenosis: a Randomized Controlled Trial in Patients With Advanced Atherosclerosis.|Unknown status|Recruiting|Phase 4|120|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:57:39.736019|2018-06-01 01:57:39.736019
NCT00711971|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2016-11-02||2017-03-17|2008-07-07|2008-07-09|Estimate|2017-03-17|2017-04-28|Actual||||2017-03-17|2017-04-28|Actual|September 2008||2008-09-30|March 2017|2017-03-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional||All intent to treat - (all but lost to follow up) are included in baseline measures|Does Fish Oil Prevent Depression in Pregnancy and Postpartum?|Does EPA or DHA Prevent Depressive Symptoms in Pregnancy and Postpartum?|Completed||Phase 2/Phase 3|126|Actual|University of Michigan||3|||f||||t||||||||||2018-06-01 01:57:39.859297|2018-06-01 01:57:39.859297
NCT00711958|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2017-04-24||2017-08-04|2008-07-08|2008-07-09|Estimate|2017-04-24|2017-08-02|Actual||||2017-08-04|2017-09-05|Actual|November 2004||2004-11-30|August 2017|2017-08-31|December 2005|Actual|2005-12-31|July 2005|Actual|2005-07-31||Interventional||50 patients found to have a major protocol violation , excluded from the ITT population only (31 and 19 in EPO HEXAL and ERYPO groups), none from the Safety Analysis population. Major deviations: early patient withdrawal (consent or due to AE), and lack of endpoint value in observation period (no Hemoglobin value over weeks 5 to 12)|Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients|Double-blind, Randomized, Multicenter, Clinical Phase III Study to Evaluate the Efficacy and Safety of HX575 for the Treatment of Chemotherapy Associated Anemia in Cancer Patients|Completed||Phase 3|114|Actual|Sandoz||2|||f||||f||||||||No||2018-06-01 01:57:40.509911|2018-06-01 01:57:40.509911
NCT00711945|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-08|2008-07-08|2008-07-09|Estimate|||||||2008-07-08|2008-07-09|Estimate|March 2008||2008-03-31|July 2008|2008-07-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|GROWTH1||Growth Relapse and Outcomes With Therapy 1|"Growth Relapse and Outcomes With Therapy 1:Factors Determining Poor Outcomes in Pediatric Crohns Disease"|Unknown status|Recruiting||300|Anticipated|European Society of Pediatric Gastroenterology, Hepatology and Nutrition|||||f||||t||||||Samples Without DNA|"~     Serum for antiglycan antibodies stool for calprotectin~   "|||2018-06-01 01:57:41.032371|2018-06-01 01:57:41.032371
NCT00711932|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2013-09-10|2008-07-08|2008-07-09|Estimate|||||||2013-09-10|2013-09-11|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Observational|||The Effect of TRA-8 on Ovarian Cancer Tissue|Death Receptor-Mediated Apoptosis and Therapy Strategies in Ovarian Cancer|Completed|||478|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 01:57:41.084953|2018-06-01 01:57:41.084953
NCT00711919|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-09-09|2008-07-08|2008-07-09|Estimate|||||||2009-09-09|2009-09-10|Estimate|July 2007||2007-07-31|September 2009|2009-09-30||||December 2009|Anticipated|2009-12-31||Interventional|PEACE||Pitavastatin on Carotid Intima-media Thickness|Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-Lowering Therapy|Unknown status|Active, not recruiting|N/A|300|Anticipated|Kyoto Prefectural University of Medicine||2|||f||||f||||||||||2018-06-01 01:57:41.147996|2018-06-01 01:57:41.147996
NCT00711906|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2016-01-15|2008-07-08|2008-07-09|Estimate|||||||2016-01-15|2016-01-18|Estimate|February 2009||2009-02-28|January 2016|2016-01-31|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Interventional|||Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy|The Role of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria And Its Effects in Pregnancy|Terminated||Phase 3|352|Actual|Institute of Tropical Medicine, Belgium||4||Malaria prev. fell in the study area, so we cannot evaluate the primary endpoint|f||||f||||||||||2018-06-01 01:57:41.239637|2018-06-01 01:57:41.239637
NCT00711893|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2017-02-17|2008-07-07|2008-07-09|Estimate|||||||2017-02-17|2017-02-23|Actual|June 2008||2008-06-30|February 2017|2017-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|FASt-IBP||Feature Assessment Study for Indications Based Programming|Feature Assessment Study for Indications Based Programming|Completed|||301|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-06-01 01:57:41.331731|2018-06-01 01:57:41.331731
NCT00711880|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2012-07-19||2013-06-13|2008-07-07|2008-07-09|Estimate|2012-08-28|2012-09-28|Estimate||||2013-06-13|2013-06-24|Estimate|May 2002||2002-05-31|June 2013|2013-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.|A Double Blind, Randomised, Placebo Controlled Parallel Group Study of Cannabis Based Medicine Extract (CBME), in the Treatment of Peripheral Neuropathic Pain Characterised by Allodynia.|Completed||Phase 3|125|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 01:57:41.455533|2018-06-01 01:57:41.455533
NCT00711867|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2009-10-28||2009-12-09|2008-07-08|2008-07-09|Estimate|2009-10-28|2009-12-02|Estimate||||2009-12-09|2009-12-15|Estimate|July 2008||2008-07-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Intraoperative Warming Devices|Intraoperative Warming: Comparison of Performance of the Dynatherm Medical vitalHeat™ Temperature Management System (vH2) and the Arizant Bair Hugger System|Completed||Phase 3|55|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 01:57:41.917595|2018-06-01 01:57:41.917595
NCT00711854|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2014-08-04|2008-07-03|2008-07-09|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2009||2009-01-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection|Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole (TMP-SMX) Plus Rifampicin With a Regimen of Linezolid in the Treatment of Infections Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)|Completed||Phase 4|150|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 01:57:42.156794|2018-06-01 01:57:42.156794
NCT00711841|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2018-03-05|2008-07-07|2008-07-09|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2011||2011-07-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|COHELLP||Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome|Postpartum Dexamethasone for Women With Class I HELLP Syndrome: a Double-blind, Placebo-controled, Randomized Clinical Trial|Active, not recruiting||Phase 4|400|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-06-01 01:57:42.234423|2018-06-01 01:57:42.234423
NCT00711828|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2015-01-16||2018-03-05|2008-07-08|2008-07-09|Estimate|2015-01-16|2015-01-27|Estimate||||2018-03-05|2018-03-30|Actual|August 2008|Actual|2008-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|November 2013|Actual|2013-11-30||Interventional|||Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma|A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma|Active, not recruiting||Phase 2|21|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 01:57:42.323222|2018-06-01 01:57:42.323222
NCT00711815|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2011-08-04|2008-07-08|2008-07-09|Estimate|||||||2011-08-04|2011-08-05|Estimate|January 2007||2007-01-31|August 2011|2011-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||A Study to Identify Markers in Blood and Tissue of HPV Clearance|Biomarkers of HPV Clearance: A Prospective Study|Completed|||197|Actual|University of Alabama at Birmingham|||1||f||||t||||||Samples With DNA|"~     Whole blood, cervical cells~   "|||2018-06-01 01:57:42.537564|2018-06-01 01:57:42.537564
NCT00711802|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2015-05-27||2017-05-26|2008-07-08|2008-07-09|Estimate|2015-05-27|2015-06-10|Estimate||||2017-05-26|2017-06-20|Actual|July 23, 2008|Actual|2008-07-23|May 2017|2017-05-31|October 11, 2013|Actual|2013-10-11|October 11, 2013|Actual|2013-10-11||Interventional||All participants who received at least 1 dose of study drug|Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections|An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens|Completed||Phase 4|396|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:57:42.614927|2018-06-01 01:57:42.614927
NCT00711789|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2011-06-22|2008-07-08|2008-07-09|Estimate|||||||2011-06-22|2011-06-23|Estimate|February 2010||2010-02-28|January 2009|2009-01-31||||February 2013|Anticipated|2013-02-28||Interventional|ASK-IT||Angiotensin in Septic Kidney Injury Trial|A Pilot Crossover Randomised Controlled Trial of Angiotensin II in Critically Ill Patients With Severe Sepsis and Acute Renal Failure|Unknown status|Recruiting|Phase 2|12|Anticipated|Austin Health||2|||f||||f||||||||||2018-06-01 01:57:43.420604|2018-06-01 01:57:43.420604
NCT00711776|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-08-02|2008-07-08|2008-07-09|Estimate|||||||2017-08-02|2017-08-04|Actual|April 10, 2008|Actual|2008-04-10|August 2017|2017-08-31|August 17, 2008|Actual|2008-08-17|August 17, 2008|Actual|2008-08-17||Interventional|||Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers|Bioequivalence Study of Aciclovir 5% Cream - Bioequivalence Study of Aciclovir Cream Between Current and New Formulation in Japanese Healthy Volunteers -|Completed||Phase 1|27|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 01:57:43.504422|2018-06-01 01:57:43.504422
NCT00711763|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2011-05-04|2008-07-03|2008-07-09|Estimate|||||||2011-05-04|2011-05-06|Estimate|July 2008||2008-07-31|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|April 2011|Actual|2011-04-30||Observational|||Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants|Calciuric Effect and Cyclic Parenteral Nutrition in Preterm Infants|Suspended|||1|Anticipated|Louisiana State University Health Sciences Center Shreveport||||failure to recruit more patients and lack of supporting personnel.|f||||f||||||||||2018-06-01 01:57:44.529416|2018-06-01 01:57:44.529416
NCT00711750|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-08|2008-07-08|2008-07-09|Estimate|||||||2008-07-08|2008-07-09|Estimate|January 2008||2008-01-31|July 2008|2008-07-31||||||||Observational|||Immediate Maintained Cannulation of a Newly Implanted Prosthetic Arteriovenous Access for Acute Hemodialysis||Unknown status|Recruiting||39|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 01:57:44.587469|2018-06-01 01:57:44.587469
NCT00711737|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-06-15|2008-07-08|2008-07-09|Estimate|||||||2011-06-15|2011-06-17|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months|Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months|Completed|||27|Actual|Changi General Hospital|||||f||||f||||||||||2018-06-01 01:57:44.640064|2018-06-01 01:57:44.640064
NCT00711724|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2010-06-21|2008-07-03|2008-07-09|Estimate|||||||2010-06-21|2010-06-23|Estimate|July 2007||2007-07-31|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD|Comparison of Self and Clinician Administered Rating Scales in Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Completed|||50|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-06-01 01:57:44.709266|2018-06-01 01:57:44.709266
NCT00711711|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2011-04-13|2008-07-08|2008-07-09|Estimate|||||||2011-04-13|2011-04-14|Estimate|June 2008||2008-06-30|April 2011|2011-04-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Manual Lymphatic Drainage Following Total Knee Arthroplasty Surgery|Outcome of Manual Lymphatic Drainage Following Total Knee Arthroplasty Surgery|Completed||N/A|60|Actual|Haute Ecole Cantonale Vaudoise de Santé||2|||f||||f||||||||||2018-06-01 01:57:44.776348|2018-06-01 01:57:44.776348
NCT00711698|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2017-03-22|2008-07-08|2008-07-09|Estimate|||||||2017-03-22|2017-03-24|Actual|September 2007||2007-09-30|March 2017|2017-03-31|September 1, 2009|Anticipated|2009-09-01|September 2009|Anticipated|2009-09-30||Interventional|||Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)|PCA for Pain Control in Adults With Sickle Cell Disease in the Emergency Department (ED) Decreases Admission Rates Over Standard Bolus Therapy|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||2||technical difficulties coordinating study|f||||f||||||||||2018-06-01 01:57:44.862277|2018-06-01 01:57:44.862277
NCT00711685|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-08|2008-07-08|2008-07-09|Estimate|||||||2008-07-08|2008-07-09|Estimate|January 2007||2007-01-31|July 2008|2008-07-31||||December 2007|Actual|2007-12-31||Interventional|||Topical Vancomycin in Prevention of Methicillin-Resistant Staphylococcal Related Mediastinitis in Patients Receiving Coronary Artery Bypass Graft|Topical Vancomycin in Prevention of Methicillin-Resistant Staphylococcal Related Mediastinitis in Patients Receiving Coronary Artery Bypass Graft|Completed||N/A|50|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 01:57:44.924365|2018-06-01 01:57:44.924365
NCT00711672|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2015-06-02|2008-07-07|2008-07-09|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Study of the Therapeutic Use of Language in Patients With Metastatic Colorectal Cancer|Critical Negotiations: Narrative Agreement, Negotiation, and Register Use in Encounters Between Patients With Metastatic Colorectal Carcinoma and Their Oncologists|Completed|||5|Actual|Hematology and Oncology Associates of NE Pennsylvania|||2||f||||t||||||||||2018-06-01 01:57:45.07106|2018-06-01 01:57:45.07106
NCT00711659|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2013-11-25|2008-07-08|2008-07-09|Estimate|||||||2013-11-25|2013-11-27|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|Head to Toe||Standardizing Educational Opportunities on the Complete Pediatric Physical Exam|Standardizing Educational Opportunities on the Complete Pediatric Physical Exam|Completed|||519|Actual|Medical College of Wisconsin|||1||f||||f||||||||||2018-06-01 01:57:45.164641|2018-06-01 01:57:45.164641
NCT00711646|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2012-07-11||2013-06-13|2008-07-08|2008-07-09|Estimate|2012-08-16|2012-09-14|Estimate||||2013-06-13|2013-06-24|Estimate|June 2002||2002-06-30|June 2013|2013-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.|A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.|Completed||Phase 3|189|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 01:57:45.252299|2018-06-01 01:57:45.252299
NCT00711633|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-04|||2008-07-04|2008-07-04|2008-07-09|Estimate|||||||2008-07-04|2008-07-09|Estimate|December 2002||2002-12-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|February 2005|Actual|2005-02-28||Interventional|||Evaluation of Safety, Tolerance and Effects on the Intestinal Flora of a New Fermented Milk for Preterm Infants|Evaluation of a Fermented Formula Without Live Bacteria for Preterm Infants: Effects on Microbiota Species and Intestinal Inflammatory Markers|Completed||N/A|58|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 01:57:45.686934|2018-06-01 01:57:45.686934
NCT00711620|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2011-06-13|2008-07-03|2008-07-09|Estimate|||||||2011-06-13|2011-06-14|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|ETASS||Efficacy of Thymosin alpha1 for Severe Sepsis|Multicenter, Randomized, Controlled Study to Evaluate the Efficacy of Thymosin alpha1 in Patients With Severe Sepsis|Completed||N/A|366|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 01:57:45.757388|2018-06-01 01:57:45.757388
NCT00711607|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2015-08-18|2008-07-08|2008-07-09|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Trial to Assess the Pharmacokinetic Profile (e.g., Uptake, Distribution and Excretion of a Substance in the Body) of Nomegestrol Acetate (NOMAC), Estradiol (E2) and Estrone (E1) After Multiple and Single Dose Administration of the Combined Oral Contraception NOMAC-E2 (COMPLETED)(P05822)|A Combined Multiple Dose and Single Dose Trial to Assess the Pharmacokinetic Profile of NOMAC, E2 and E1 After Oral Administration of NOMAC-E2 in Healthy Female Volunteers|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 01:57:45.822175|2018-06-01 01:57:45.822175
NCT00711594|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2013-08-08||2015-01-13|2008-07-08|2008-07-09|Estimate|2013-10-21|2013-11-13|Estimate||||2015-01-13|2015-01-15|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Until the snapshot for CTR|LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib|Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib.|Completed||Phase 2|74|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:57:45.95885|2018-06-01 01:57:45.95885
NCT00711581|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2014-04-09|2008-07-08|2008-07-09|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2008||2008-08-31|June 2008|2008-06-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Evaluation of Laparoscopic Internal Retractor Device|Evaluation of the Efficacy and Safety of the Endograb: A Laparoscopic Internal Retractor Device|Completed||N/A|10|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 01:57:47.085268|2018-06-01 01:57:47.085268
NCT00711568|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2013-03-29|2008-07-03|2008-07-09|Estimate|||||||2013-03-29|2013-04-01|Estimate|October 2001||2001-10-31|March 2013|2013-03-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||A Clinical Trial of Magnetic Stimulation in Depression|A Clinical Trial of Magnetic Stimulation in Depression|Completed||Phase 2|48|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 01:57:47.15978|2018-06-01 01:57:47.15978
NCT00711555|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2009-06-11||2009-08-06|2008-07-08|2008-07-09|Estimate|2009-06-11|2009-08-03|Estimate||||2009-08-06|2009-08-11|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Emend for Multiple-day Emetogenic Chemotherapy|An Open Label Phase II Study of Aprepitant for Multi-day Moderately-high to Highly Emetogenic Chemotherapy Regimens|Completed||Phase 2|22|Actual|University of Illinois at Chicago|||||f||||f||||||||||2018-06-01 01:57:47.241621|2018-06-01 01:57:47.241621
NCT00711542|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|||2017-01-11|2008-07-08|2008-07-09|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2008||2008-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|REPAIR-ACS||Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI|Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome: REPAIR - ACS|Terminated||Phase 1/Phase 2|31|Actual|Johann Wolfgang Goethe University Hospital||2||Slow recruitment|f||||f||||||||||2018-06-01 01:57:47.381778|2018-06-01 01:57:47.381778
NCT00711529|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2012-03-05||2013-05-14|2008-07-03|2008-07-09|Estimate|2013-05-14|2013-06-24|Estimate||||2013-05-14|2013-06-24|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Of the 13 women randomized to the hypnotherapy arm, 2 women were ineligible and therefore not included in analysis. Two women were unable to initate treatment and did not submit diaries. Two women lost their diaries, leaving 7 diaries for analysis. Of the 14 women randomized to receive gabapentin, 6 dropped out and did not submit diaries.|Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes.|Comparison of Hypnotherapy Versus Gabapentin in the Treatment of Hot Flashes in Breast Cancer Survivors or Women at Risk of Developing Breast Cancer.|Completed||Phase 3|27|Actual|Women and Infants Hospital of Rhode Island|We were unable to meet recruitment goals because of 1) lower-than-anticipated rate of referrals, and 2) subjects' unwillingness to randomization. This resulted in small numbers that limit interpretation of results.|2|||f||||t||||||||||2018-06-01 01:57:47.477247|2018-06-01 01:57:47.477247
NCT00711516|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2010-09-30||2013-07-12|2008-07-08|2008-07-09|Estimate|2011-01-18|2011-02-14|Estimate||||2013-07-12|2013-07-19|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance|Double-Blind, Placebo-Controlled, Functional Neuroimaging Study of Armodafinil (200 mg/Day) on Prefrontal Cortical Activation in Patients With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea|Completed||Phase 4|40|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 01:57:47.892192|2018-06-01 01:57:47.892192
NCT00711503|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2012-08-31|2008-07-03|2008-07-09|Estimate|||||||2012-08-31|2012-09-03|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|AIDA||Anti-Interleukin-1 in Diabetes Action|A Randomised Clinical Trial of the Effect of Interleukin-1 Receptor Antagonism on the Insulin Production in Patients With New Onset Type 1 Diabetes|Completed||Phase 2/Phase 3|69|Actual|Steno Diabetes Center||2|||f||||t||||||||||2018-06-01 01:57:48.921603|2018-06-01 01:57:48.921603
NCT00711490|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-08|2011-05-10||2016-09-22|2008-07-08|2008-07-09|Estimate|2011-05-10|2011-06-03|Estimate||||2016-09-22|2016-09-26|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SDME||Sirolimus to Treat Diabetic Macular Edema|Pilot Study of the Evaluation of Sirolimus in the Treatment of Diabetic Macular Edema|Completed||Phase 1/Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 01:57:49.06646|2018-06-01 01:57:49.06646
NCT00711477|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2014-10-08|2012-10-23|2015-01-05|2008-07-03|2008-07-09|Estimate|2015-01-05|2015-01-06|Estimate|2012-10-23|2012-10-30|Estimate|2015-01-05|2015-01-06|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Randomized subjects|A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects|Naltrexone Sustained Release (SR) 32 mg and Bupropion Sustained Release (SR) 360 mg Combination Therapy in Functional Magnetic Resonance Imaging (fMRI) Changes in Overweight or Obese Subjects|Completed||Phase 2|46|Actual|Orexigen Therapeutics, Inc||2|||f||||f||||||||||2018-06-01 01:57:49.36112|2018-06-01 01:57:49.36112
NCT00711464|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2017-05-03||2017-08-31|2008-07-07|2008-07-08|Estimate|2017-08-31|2017-09-29|Actual||||2017-08-31|2017-09-29|Actual|May 2008||2008-05-31|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|InO||Modafinil Effects on Cognition in Schizophrenia Patients|A Dose-response Study of Modafinil Effects on Cognition in Schizophrenia Patients.|Completed||Phase 4|29|Actual|University of California, Los Angeles||4|||f||||f||||||||No||2018-06-01 01:57:49.923133|2018-06-01 01:57:49.923133
NCT00711451|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2012-07-12|2008-07-02|2008-07-08|Estimate|||||||2012-07-12|2012-07-16|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional|||Manual and Expressed Placental Removal at Cesarean Delivery and Its Effects on Various Cardiac Indices|Manual and Expressed Placental Removal at Planned Cesarean Delivery and Its Effects on Various Cardiac Indices as Measured By Continuous Wave Doppler Ultrasonography|Terminated||N/A|19|Actual|William Beaumont Hospitals||2||unable to recruit patients|f||||f||||||||||2018-06-01 01:57:50.168338|2018-06-01 01:57:50.168338
NCT00711438|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2008-07-07|2008-07-07|2008-07-08|Estimate|||||||2008-07-07|2008-07-08|Estimate|April 2006||2006-04-30|October 2006|2006-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|BIS-PhIInm||Pilot Randomized Controlled Trial of a Breathlessness Intervention Service for Chronic Obstructive Pulmonary Disease|Phase II Pilot Pragmatic Single-Blinded Fast Track Randomised Controlled Trial of the Breathlessness Intervention Service Versus Standard Care for Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|13|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 01:57:50.245009|2018-06-01 01:57:50.245009
NCT00711425|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2011-06-07||2013-08-22|2008-07-07|2008-07-08|Estimate|2011-08-19|2011-09-26|Estimate||||2013-08-22|2013-09-09|Estimate|February 2004||2004-02-29|August 2013|2013-08-31||||January 2010|Actual|2010-01-31||Interventional||Per protocol analysis presented, this includes implants loaded 0 to 56 days from implant placement (134 implants in 44 patients).|Study on OsseoSpeed™ Implants in Patients Missing 2-5 Teeth in the Posterior Lower Jaw, Restored With Permanent Teeth Attached 6-7 Weeks Later|An Open, Prospective Study to Evaluate Implant Stability, Marginal Bone Adaptation and the Survival Rate of Astra Tech Dental Implant System, Fixture Osseospeed™, in Patients With Tooth Loss in the Posterior Mandible in an Early Loading Protocol.|Completed||N/A|45|Actual|Dentsply Sirona Implants||1|||f||||f||||||||||2018-06-01 01:57:50.348831|2018-06-01 01:57:50.348831
NCT00711412|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-05|||2017-12-11|2008-07-05|2008-07-08|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2005||2005-10-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer|A Phase II Study of Capecitabine and Oxaliplatin With Radiation for Esophageal and Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 2|45|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 01:57:50.532466|2018-06-01 01:57:50.532466
NCT00711399|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-09-13|2008-07-06|2008-07-08|Estimate|||||||2010-09-13|2010-09-14|Estimate|September 2008||2008-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Observational|||Assessment of Cough and Wheeze With Breath Sound Documenting Device|Use of Objective Cough Counting and Breath Sounds Documenting Device, to Assess the Severity and Duration of Cough and Wheeze in Children and Adults Suffer From Acute or Chronic Respiratory Disease.|Completed|||55|Actual|Carmel Medical Center|||1||f||||t||||||||||2018-06-01 01:57:50.619852|2018-06-01 01:57:50.619852
NCT00711386|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-08-02|2008-07-07|2008-07-08|Estimate|||||||2017-08-02|2017-08-03|Actual|May 16, 2008|Actual|2008-05-16|August 2017|2017-08-31|September 12, 2008|Actual|2008-09-12|September 12, 2008|Actual|2008-09-12||Interventional|||GSK706769 Repeat Dose Study|A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects|Completed||Phase 1|40|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 01:57:50.729172|2018-06-01 01:57:50.729172
NCT00711373|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2018-01-23|2008-07-07|2008-07-08|Estimate|||||||2018-01-23|2018-01-25|Actual|June 1998||1998-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|HandCTA||Vascularized Composite Allotransplantation of the Hand|Vascularized Composite Allotransplantation of the Hand|Recruiting||Phase 2|20|Anticipated|Christine M. Kleinert Institute for Hand and Microsurgery||1|||f||||t||||||||No||2018-06-01 01:57:50.812393|2018-06-01 01:57:50.812393
NCT00711360|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2012-09-25|2008-07-07|2008-07-08|Estimate|||||||2012-09-25|2012-09-26|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|January 2012|Actual|2012-01-31||Interventional|HomeCARE II||Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement (HomeCARE II)|Monitoring of Fluid Status in Heart Failure Patients by Intrathoracic Impedance Measurement|Completed||Phase 4|303|Actual|Biotronik SE & Co. KG|||||f||||f||||||||||2018-06-01 01:57:50.888663|2018-06-01 01:57:50.888663
NCT00711347|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2009-09-09||2010-08-04|2008-07-07|2008-07-08|Estimate|2010-07-07|2010-08-04|Estimate||||2010-08-04|2010-08-10|Estimate|June 2007||2007-06-30|August 2010|2010-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Intraoperative Floppy Iris Syndrome||Completed||Phase 4|28|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 01:57:50.997829|2018-06-01 01:57:50.997829
NCT00711321|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-04|||2010-05-26|2008-07-07|2008-07-08|Estimate|||||||2010-05-26|2010-05-27|Estimate|November 2008||2008-11-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Long-term Safety and Tolerability of AFFITOPE AD02|Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD02 Applied During AFFiRiS 002|Completed|||23|Actual|Affiris AG|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 01:57:51.294207|2018-06-01 01:57:51.294207
NCT00711308|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2009-02-12|2008-07-03|2008-07-08|Estimate|||||||2009-02-12|2009-02-13|Estimate|April 2005||2005-04-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Tinzaparin in the Treatment of the Acute Pulmonary Embolism|Long Term Subcutaneous Tinzaparin Compared With Tinzaparin and Oral Anticoagulants in the Treatment of the Acute Pulmonary Embolism|Completed||Phase 4|102|Actual|Complejo Hospitalario Xeral-Calde||2|||f||||f||||||||||2018-06-01 01:57:51.351074|2018-06-01 01:57:51.351074
NCT00711295|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2015-10-07|2008-07-07|2008-07-08|Estimate|||||||2015-10-07|2015-10-09|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|July 2009|Actual|2009-07-31||Interventional|||Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups|An Open-Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as Well as in Specified Risk Groups|Completed||Phase 3|3583|Actual|Ology Bioservices||6|||f||||t||||||||||2018-06-01 01:57:51.441897|2018-06-01 01:57:51.441897
NCT00711282|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2014-06-26|2008-07-07|2008-07-08|Estimate|||||||2014-06-26|2014-06-27|Estimate|December 2005||2005-12-31|June 2014|2014-06-30||||June 2011|Actual|2011-06-30||Interventional|||Study of Bone Preservation When OsseoSpeed™ Implants Are Placed Immediately Following Tooth Extraction|A Prospective, Randomized, Controlled Study to Evaluate Buccal Bone Preservation Using Fixture MicroThread™ OsseoSpeed™ Placed in Fresh Extraction Sockets the Maxilla.|Completed||N/A|104|Actual|Dentsply Sirona Implants||2|||f||||f||||||||||2018-06-01 01:57:51.565716|2018-06-01 01:57:51.565716
NCT00711269|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2012-06-11|2008-07-04|2008-07-08|Estimate|||||||2012-06-11|2012-06-13|Estimate|July 2008||2008-07-31|June 2012|2012-06-30||||||||Interventional|||Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia|Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase III Study>|Completed||Phase 3|440|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||4|||f||||||||||||||2018-06-01 01:57:51.632512|2018-06-01 01:57:51.632512
NCT00711256|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2008-07-07|2008-07-07|2008-07-08|Estimate|||||||2008-07-07|2008-07-08|Estimate|July 2008||2008-07-31|April 2008|2008-04-30|November 2008|Anticipated|2008-11-30|August 2008|Anticipated|2008-08-31||Interventional|sunscreen||Sunscreen: Persistence of Sun Protection Factor and the Influence on Vitamin D|Sunscreen Removal by Clothing Meassured in Vivo. Sun Protection Factor Persistence During a Day Indoor Without Physical Activity. Does Sunscreen Reduce Vitamin D?|Unknown status|Recruiting|N/A|80|Anticipated|Bispebjerg Hospital||4|||f||||f||||||||||2018-06-01 01:57:51.70667|2018-06-01 01:57:51.70667
NCT00711243|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-05|||2017-11-21|2008-07-05|2008-07-08|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2005||2005-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor|A Phase I/II Study of Taxotere, Oxaliplatin, and 5- Fluorouracil|Active, not recruiting||Phase 1/Phase 2|58|Actual|Northwestern University||5|||f||||t||||||||||2018-06-01 01:57:51.859848|2018-06-01 01:57:51.859848
NCT00711230|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-04|||2013-02-19|2008-07-07|2008-07-08|Estimate|||||||2013-02-19|2013-02-20|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|January 2015|Anticipated|2015-01-31|December 2011|Actual|2011-12-31||Interventional|GIEU006||Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients|A Phase II Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antiretroviral Activity of DermaVir Patch (LC002) in Treatment-Naïve HIV-1-Infected Patients|Unknown status|Active, not recruiting|Phase 2|36|Actual|Genetic Immunity||6|||f||||t||||||||||2018-06-01 01:57:51.941591|2018-06-01 01:57:51.941591
NCT00711217|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2011-11-01|2008-07-03|2008-07-08|Estimate|||||||2011-11-01|2011-11-02|Estimate|June 2008||2008-06-30|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of a Medical Food for Chronic Wounds|Evaluation of a Medical Food for Chronic Wounds|Completed||Phase 3|271|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-06-01 01:57:52.025865|2018-06-01 01:57:52.025865
NCT00711204|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2012-12-06|2008-07-07|2008-07-08|Estimate|||||||2012-12-06|2012-12-10|Estimate|January 2008||2008-01-31|December 2012|2012-12-31||||June 2009|Actual|2009-06-30||Interventional|||Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease|A 12-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease|Withdrawn||Phase 4|0|Actual|Eisai Inc.||2||No patients were enrolled in the study.|f||||||||||||||2018-06-01 01:57:52.144805|2018-06-01 01:57:52.144805
NCT00711191|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2012-05-03||2013-11-26|2008-07-07|2008-07-08|Estimate|2012-05-03|2012-06-06|Estimate||||2013-11-26|2013-12-24|Estimate|June 2008||2008-06-30|November 2013|2013-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas|A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer|Completed||Phase 1|22|Actual|Hoffmann-La Roche||1|||f||||f||||||||||2018-06-01 01:57:52.226646|2018-06-01 01:57:52.226646
NCT00711178|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2010-11-01|2008-07-07|2008-07-08|Estimate|||||||2010-11-01|2010-11-02|Estimate|June 2008||2008-06-30|March 2008|2008-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Randomized Multicenter Study of Daylight Mediated Photodynamic Therapy (PDT)||Completed||N/A|150|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||||2018-06-01 01:57:52.887346|2018-06-01 01:57:52.887346
NCT00711165|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2008-07-03|2008-07-03|2008-07-08|Estimate|||||||2008-07-03|2008-07-08|Estimate|August 2005||2005-08-31|July 2008|2008-07-31|August 2006|Actual|2006-08-31|April 2006|Actual|2006-04-30||Interventional|||Mometasone and Markers of Airway Inflammation|The Effects of Mometasone on Markers of Airway Inflammation|Completed||Phase 4|12|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 01:57:52.961669|2018-06-01 01:57:52.961669
NCT00711152|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2015-09-05|2008-07-07|2008-07-08|Estimate|||||||2015-09-05|2015-09-09|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|JADE-MOS||Community Health Worker Reduces Care Utilization|Inclusion Of a Community Health Worker in a Collaborative Diabetes Care Program Reduces Health Care Utilization (JADE)|Completed||Phase 4|661|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 01:57:53.050422|2018-06-01 01:57:53.050422
NCT00711139|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-04|||2010-05-26|2008-07-07|2008-07-08|Estimate|||||||2010-05-26|2010-05-27|Estimate|June 2008||2008-06-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Long-term Safety and Tolerability of AFFITOPE AD01|Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD01 Applied During AFFiRiS 001|Completed|||22|Actual|Affiris AG|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 01:57:53.121786|2018-06-01 01:57:53.121786
NCT00711126|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-07-19|2008-07-07|2008-07-08|Estimate|||||||2017-07-19|2017-07-21|Actual|October 21, 2008|Actual|2008-10-21|July 2017|2017-07-31|December 17, 2008|Actual|2008-12-17|December 17, 2008|Actual|2008-12-17||Interventional|||A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection|A Single-centre, Open-label, Sequential, Dose-ascending Study to Examine Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Intravenous, Inhaled and Oral Doses of GW642444 in Healthy Male Subjects|Completed||Phase 1|9|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:57:53.183918|2018-06-01 01:57:53.183918
NCT00711113|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2013-08-22||2014-01-09|2008-07-07|2008-07-08|Estimate|2014-01-09|2014-02-07|Estimate||||2014-01-09|2014-02-07|Estimate|December 2003||2003-12-31|January 2014|2014-01-31||||September 2011|Actual|2011-09-30||Interventional||Per protocol analysis presented, this includes implants loaded 0 to 56 days from implant placement (80 implants in 32 patients).|Study on OsseoSpeed™ Implants Replacing 2-5 Teeth in the Posterior Upper Jaw, Restored With Provisional Teeth Attached 6-7 Weeks Later|An Open, Prospective Study to Evaluate Implant Stability, Marginal Bone Adaptation and the Survival Rate of Astra Tech Dental Implant System, Fixture Osseospeed™, in Patients With Tooth Loss in the Posterior Maxilla in an Early Loading Protocol.|Completed||N/A|47|Actual|Dentsply Sirona Implants||1|||f||||f||||||||||2018-06-01 01:57:53.304803|2018-06-01 01:57:53.304803
NCT00711100|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2013-10-17||2017-04-06|2008-07-02|2008-07-08|Estimate|2015-08-14|2015-09-16|Estimate||||2017-04-06|2017-05-12|Actual|August 2008||2008-08-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers|Preference, Health Effects and Efficacy of Four Oral Tobacco Products for Smoking Cessation|Completed||N/A|104|Actual|University of Minnesota - Clinical and Translational Science Institute||5|||f||||t||||||||No||2018-06-01 01:57:53.464835|2018-06-01 01:57:53.464835
NCT00711087|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2015-09-11||2015-09-11|2008-07-07|2008-07-08|Estimate|2015-09-11|2015-10-09|Estimate||||2015-09-11|2015-10-09|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)|Botulinum Toxin A Treatment of Detrusor External Sphincter Dyssynergia During Early Spinal Cord Injury (Protocol #H-20344)|Terminated||Phase 2|1|Actual|Baylor College of Medicine||2||Funds no longer available|f||||f||||||||||2018-06-01 01:57:53.68282|2018-06-01 01:57:53.68282
NCT00711074|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2009-04-08|2008-07-03|2008-07-08|Estimate|||||||2009-04-08|2009-04-09|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|July 2008|Actual|2008-07-31|||||Interventional|||Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers|An Open-Label, Phase I Study to Assess the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following a Single Oral Dose of [14C]AZD5672 in Healthy Male Volunteers|Completed||Phase 1|4|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:57:53.834052|2018-06-01 01:57:53.834052
NCT00711061|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2009-02-09|2008-07-07|2008-07-08|Estimate|||||||2009-02-09|2009-02-10|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy|Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy.|Completed|||24|Actual|Children's Mercy Hospital Kansas City|||2||f||||f||||||||||2018-06-01 01:57:53.934165|2018-06-01 01:57:53.934165
NCT00710866|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2011-07-11||2011-07-11|2008-07-07|2008-07-08|Estimate|2011-07-11|2011-08-04|Estimate||||2011-07-11|2011-08-04|Estimate|August 2008||2008-08-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|TITRE||Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity||Completed||Phase 3|262|Actual|British Columbia Centre for Disease Control||2|||f||||t||||||||||2018-06-01 01:57:59.701936|2018-06-01 01:57:59.701936
NCT00711048|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|||2009-08-27|2008-07-07|2008-07-08|Estimate|||||||2009-08-27|2009-08-28|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|||||Interventional|||Esophageal Hypersensitivity Study in Healthy Volunteers|A Phase I, Two Centre, Double-blind, Randomized, Cross-over Study to Evaluate AZD1386 in Single Doses of 30 mg and 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity and Development of Sensitization in Healthy Male Volunteers|Completed||Phase 1|45|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:57:54.004522|2018-06-01 01:57:54.004522
NCT00711035|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20||2014-03-03|2016-03-25|2008-07-02|2008-07-08|Estimate||||2014-03-03|2014-03-31|Estimate|2016-03-25|2016-04-26|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|CHALLAH||Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)|Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)|Completed||Phase 1/Phase 2|50|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 01:57:54.065977|2018-06-01 01:57:54.065977
NCT00711022|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2014-03-12||2014-07-04|2008-07-07|2008-07-08|Estimate|2014-05-05|2014-05-13|Estimate||||2014-07-04|2014-07-16|Estimate|May 2005||2005-05-31|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study on ASTRA TECH Implant System, OsseoSpeed™ Implants in Patients Missing All Teeth in the Upper Jaw, Restored With Provisional Teeth Within 24 Hours|An Open, Prospective, Multicenter Study to Evaluate the Outcome of ASTRA TECH Implant System, OsseoSpeed™ Implants, in Patients With Totally Edentulous Maxillas and Poor Bone Quality and Quantity in an Immediate Loading Protocol.|Completed||N/A|51|Actual|Dentsply Sirona Implants||1|||f||||f||||||||||2018-06-01 01:57:54.136517|2018-06-01 01:57:54.136517
NCT00711009|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2010-11-16||2012-02-13|2008-07-03|2008-07-08|Estimate|2011-01-11|2011-02-02|Estimate||||2012-02-13|2012-02-14|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|November 2009|Actual|2009-11-30||Interventional|PROGRESS||Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)|A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects|Completed||Phase 3|206|Actual|Abbott||2|||f||||||||||||||2018-06-01 01:57:54.490678|2018-06-01 01:57:54.490678
NCT00710996|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2009-09-18||2010-01-29|2008-07-07|2008-07-08|Estimate|2010-01-06|2010-01-29|Estimate||||2010-01-29|2010-02-02|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Blue Light Intraocular Lenses (IOLs) and Photostress|Blue Light Intraocular Lenses (IOLs) and Photostress|Completed|||58|Actual|Alcon Research|||3||f||||f||||||||||2018-06-01 01:57:56.466814|2018-06-01 01:57:56.466814
NCT00710983|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2013-11-14|2008-07-07|2008-07-08|Estimate|||||||2013-11-14|2013-11-15|Estimate|July 2008||2008-07-31|November 2013|2013-11-30|January 2015|Anticipated|2015-01-31|June 2014|Anticipated|2014-06-30||Interventional|||Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth|Investigating the Mortality and the Morbidity Impact of Oral Polio Vaccine at Birth|Unknown status|Active, not recruiting|N/A|||Bandim Health Project||2|||f||||f||||||||||2018-06-01 01:57:56.648577|2018-06-01 01:57:56.648577
NCT00710970|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2012-12-27||2013-07-22|2008-07-07|2008-07-08|Estimate|2013-07-22|2013-08-22|Estimate||||2013-07-22|2013-08-22|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment|H-16848 - Phase II Pilot Study With Correlative Markers of Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy|Completed||Phase 2|28|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 01:57:56.709373|2018-06-01 01:57:56.709373
NCT00710957|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2013-11-14|2008-07-02|2008-07-08|Estimate|||||||2013-11-14|2013-11-15|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Vitamin D and Physical Function in Older Adults|Role of Vitamin D Status on Physical Function and Falls in Adults of Advanced Age|Completed|||1100|Actual|Wake Forest University Health Sciences|||1||f||||f||||||||||2018-06-01 01:57:56.924867|2018-06-01 01:57:56.924867
NCT00710944|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-07|2014-03-12||2014-06-26|2008-07-07|2008-07-08|Estimate|2014-04-28|2014-05-22|Estimate||||2014-06-26|2014-07-11|Estimate|April 2005||2005-04-30|June 2014|2014-06-30|November 2012|Actual|2012-11-30|June 2008|Actual|2008-06-30||Interventional|||Study to Compare Survival for ASTRA TECH Implant System, OsseoSpeed™ Implants Following Immediate Loading in Extraction Sockets Versus Immediate Loading in Healed Ridges|An Open, Prospective, Controlled Study in the Maxilla to Evaluate Clinical Outcome of ASTRA TECH Implant System, OsseoSpeed™ Implants in Single Tooth Replacement Using an Immediate Loading Protocol in Extraction Sockets and Healed Ridges.|Completed||N/A|132|Actual|Dentsply Sirona Implants||3|||f||||f||||||||||2018-06-01 01:57:56.975575|2018-06-01 01:57:56.975575
NCT00710931|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2011-10-04||2011-12-05|2008-07-07|2008-07-08|Estimate|2011-10-04|2011-11-08|Estimate||||2011-12-05|2011-12-12|Estimate|October 2008||2008-10-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1|Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1|Completed||Phase 4|35|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 01:57:57.166301|2018-06-01 01:57:57.166301
NCT00710905|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2011-10-04||2011-11-21|2008-07-07|2008-07-08|Estimate|2011-10-04|2011-11-08|Estimate||||2011-11-21|2011-11-24|Estimate|October 2009||2009-10-31|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3|Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3|Terminated||Phase 4|50|Actual|Alcon Research||1||Postmarket study terminated as the SN6AD3 is no longer promoted.|f||||f||||||||||2018-06-01 01:57:57.273278|2018-06-01 01:57:57.273278
NCT00710892|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-10-02|2008-07-07|2008-07-08|Estimate|||||||2017-10-02|2017-10-04|Actual|December 2008||2008-12-31|October 2017|2017-10-31|July 2026|Anticipated|2026-07-31|November 2011|Actual|2011-11-30||Interventional|CASPALLO||CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene|CASPALLO: A Phase I Study Evaluating the Use of Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene After Haploidentical Stem Cell Transplantation|Active, not recruiting||Phase 1|10|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-06-01 01:57:58.630501|2018-06-01 01:57:58.630501
NCT00710879|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2011-01-14||2011-12-07|2008-07-07|2008-07-08|Estimate|2011-01-14|2011-02-08|Estimate||||2011-12-07|2011-12-13|Estimate|July 2008||2008-07-31|December 2011|2011-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Evaluation of a Multi-Purpose Solution|A Study to Evaluate the Clinical Performance of a Multi-Purpose Solution.|Completed||N/A|180|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 01:57:58.929532|2018-06-01 01:57:58.929532
NCT00710853|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2009-07-09|2008-07-03|2008-07-04|Estimate|||||||2009-07-09|2009-07-13|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effects of Qigong, Tai Chi and Yoga Practice in Older Adults|Effects of Qigong, Tai Chi and Yog Practice on Indicators of Health and Quality of Life in Older Adults|Completed||N/A|50|Anticipated|Bastyr University||3|||f||||f||||||||||2018-06-01 01:58:00.128296|2018-06-01 01:58:00.128296
NCT00710840|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2015-03-18||2015-05-14|2008-07-02|2008-07-04|Estimate|2015-04-28|2015-05-15|Estimate||||2015-05-14|2015-06-10|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional|||Effectiveness of Minimally Invasive Total Knee Replacement in Improving Rehabilitation and Function|Functional Outcomes Following Minimally Invasive Total Knee Arthroplasty|Completed||Phase 2|44|Actual|University of Colorado, Denver|Small sample size; Relatively short follow-up time|2|||f||||||||||||||2018-06-01 01:58:00.224108|2018-06-01 01:58:00.224108
NCT00710827|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2012-11-22|2008-07-03|2008-07-04|Estimate|||||||2012-11-22|2012-11-27|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|October 2008|Anticipated|2008-10-31|||||Interventional|||Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks|A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH)|Withdrawn||Phase 4|0|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:58:00.593112|2018-06-01 01:58:00.593112
NCT00710814|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2015-08-11||2015-10-16|2008-07-03|2008-07-04|Estimate|2015-10-16|2015-11-16|Estimate||||2015-10-16|2015-11-16|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|August 2012|Actual|2012-08-31||Interventional|||Trial of Leptin Administration After Roux-en-Y Gastric Bypass|Effects of Leptin on Body Weight and Neuroendocrine Axes After Gastric Bypass|Completed||Phase 1/Phase 2|31|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 01:58:00.720524|2018-06-01 01:58:00.720524
NCT00710801|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2011-09-14|2008-07-02|2008-07-04|Estimate|||||||2011-09-14|2011-09-15|Estimate|May 2005||2005-05-31|September 2011|2011-09-30||||||||Observational|||Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation|Randomized, Open-label Study to Evaluate the Hepatitis C Virus (HCV) Burden in Patients Receiving Cyclosporine (Neoral or CSA) Versus Tacrolimus (Prograf) in de Novo Liver Recipients Receiving Mycophenolate Sodium (Myfortic): Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation|Completed|||40|Anticipated|University of Alberta|||||f||||||||||Samples With DNA|"~     Serum Tissue~   "|||2018-06-01 01:58:00.912045|2018-06-01 01:58:00.912045
NCT00710788|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2013-02-09|2008-07-03|2008-07-04|Estimate|||||||2013-02-09|2013-02-12|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|Independent||Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis|Interventional, Multicenter, Prospective, Randomized Trial to Slow Down the Progression of Cardiovascular Calcifications to Reduce QTd in Incident Dialysis Patients|Completed||N/A|360|Actual|Azienda Sanitaria ASL Avellino 2||2|||f||||t||||||||||2018-06-01 01:58:00.973981|2018-06-01 01:58:00.973981
NCT00710775|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2009-10-09|2008-07-03|2008-07-04|Estimate|||||||2009-10-09|2009-10-12|Estimate|November 2007||2007-11-30|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|HLT||Heart Leaflet Technologies Valve Study|Temporary Intra-operative Placement of HLT Percutaneous Aortic Valve|Unknown status|Recruiting|N/A|7|Anticipated|Centro Cardiologico Monzino||1|||f||||f||||||||||2018-06-01 01:58:01.054815|2018-06-01 01:58:01.054815
NCT00710762|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2014-11-14|2014-05-06|2016-07-13|2008-07-03|2008-07-04|Estimate|2014-11-14|2014-12-04|Estimate|2014-05-06|2014-05-21|Estimate|2016-07-13|2016-08-15|Estimate|March 2006||2006-03-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|September 2008|Actual|2008-09-30||Interventional||"Treated set consist of all patients who received at least 1 dose of nintedanib or placebo.~Note: 43 patients were included in the analyses instead of 44 patients in nintedanib arm as one patient was excluded after drug administration due to important protocol violation."|A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer|A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer|Completed||Phase 2|89|Actual|Boehringer Ingelheim|Data from all randomised patients collected upto NOV’08 were included in all above sections,unless stated otherwise.5 patients continued on BIBF1120 after database lock(DBL)-NOV’08 upto Mar’14,but due to limited data no further analyses were done.|2|||f||||||||||||||2018-06-01 01:58:01.155773|2018-06-01 01:58:01.155773
NCT00710749|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2011-03-18||2012-09-27|2008-07-03|2008-07-04|Estimate|2011-05-30|2011-06-23|Estimate||||2012-09-27|2012-10-04|Estimate|July 2008||2008-07-31|September 2012|2012-09-30||||April 2009|Actual|2009-04-30||Interventional|||The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects|An Open Prospective Multicenter Study Comparing the Urine Flow Measurements of Standard Clinic Flow Measurements vs Comercially Available Portable Digital Flow Meters and a Disposable Flow Meter in a Crossover and Randomized Order on Male BPH Subjects|Completed||N/A|60|Actual|Wellspect HealthCare||2|||f||||f||||||||||2018-06-01 01:58:01.721498|2018-06-01 01:58:01.721498
NCT00710736|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2012-09-28|2008-07-02|2008-07-04|Estimate|||||||2012-09-28|2012-10-01|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer||Completed||Phase 1|29|Actual|Array BioPharma||1|||f||||f||||||||||2018-06-01 01:58:01.967191|2018-06-01 01:58:01.967191
NCT00710723|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-07-03|2008-07-03|2008-07-04|Estimate|||||||2008-07-03|2008-07-04|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Vitrification Versus Slow Freezing of Human Day 3 Embryos|Vitrification Versus Slow Freezing of Human Day 3 Embryos|Unknown status|Active, not recruiting|N/A|901|Actual|University Hospital, Gasthuisberg||2|||f||||||||||||||2018-06-01 01:58:02.058514|2018-06-01 01:58:02.058514
NCT00710710|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03||2014-04-30|2014-04-30|2008-07-03|2008-07-04|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|August 2006||2006-08-31|April 2014|2014-04-30||||October 2008|Actual|2008-10-31||Interventional|||Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer|An Open, Randomised, Clinical Phase II Trial in Patients With Unresectable Advanced Pancreatic Cancer Investigating the Efficacy, Safety, and Pharmacokinetics of BI 2536 Administered in Repeated 3-week Cycles as a Single i.v. Dose of 200 mg on Day 1 or as 60 mg Doses on Days 1, 2, and 3|Completed||Phase 2|89|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:58:02.154426|2018-06-01 01:58:02.154426
NCT00710697|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2009-09-23|2008-07-02|2008-07-04|Estimate|||||||2009-09-23|2009-09-24|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|July 2009|Anticipated|2009-07-31|March 2009|Anticipated|2009-03-31||Interventional|||Cardiac Safety Assessment Study of Picoplatin in Solid Tumors|A Phase 1 Study of Picoplatin in Subjects With Advanced Non-Hematological Malignancies With Emphasis on Cardiac Repolarization|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Poniard Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:58:02.25364|2018-06-01 01:58:02.25364
NCT00710684|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2017-08-18|2011-03-17|2017-11-03|2008-07-03|2008-07-04|Estimate|2017-11-03|2017-12-07|Actual|2011-04-21|2011-04-28|Estimate|2017-11-03|2017-12-07|Actual|July 1, 2008|Actual|2008-07-01|November 2017|2017-11-30|November 16, 2010|Actual|2010-11-16|May 21, 2010|Actual|2010-05-21||Interventional||Out of 682 participants, 5 participants did not have at least one post-Baseline or health outcomes assessment. Hence a total of 677 participants were included in intent-to-treat (ITT) population and they were used to assess Baseline characteristics.|A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease|Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease|Completed||Phase 2|682|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 01:58:02.449956|2018-06-01 01:58:02.449956
NCT00710671|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2017-02-27|2008-07-02|2008-07-04|Estimate|||||||2017-02-27|2017-02-28|Actual|March 2008||2008-03-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Psychosocial Needs of YMSM|Psychosocial Needs of HIV+ Young Men Who Have Sex With Men (YMSM)|Completed|||254|Actual|University of North Carolina, Chapel Hill|||2||f||||t||||||||||2018-06-01 01:58:03.890028|2018-06-01 01:58:03.890028
NCT00710658|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2013-05-22|2008-07-03|2008-07-04|Estimate|||||||2013-05-22|2013-05-23|Estimate|May 2006||2006-05-31|May 2013|2013-05-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|WebChoice||Internet Support for Cancer Patients|A Randomized Clincial Trial to Evaluate the Effects of an Internett-based Support System for Cancer Patients on Symptom Distress, Depression, and Quality of Life.|Completed||N/A|325|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:58:03.992202|2018-06-01 01:58:03.992202
NCT00710645|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2017-02-22|2008-07-02|2008-07-04|Estimate|||||||2017-02-22|2017-02-24|Actual|April 2003||2003-04-30|February 2017|2017-02-28|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Lido Workset Study|Assessment of Spasticity in MS Patients Using a Lido Workset|Completed|||31|Actual|University of California, Davis|||2||f||||f||||||||No||2018-06-01 01:58:04.064768|2018-06-01 01:58:04.064768
NCT00710632|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2013-09-16|2008-07-03|2008-07-04|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2007||2007-09-30|July 2009|2009-07-31||||August 2008|Anticipated|2008-08-31||Interventional|||Screening to Predict Weight Loss in Patients With Cancer|Predicting Weight Loss in People With Cancer: Development of a Screening Tool|Unknown status|Active, not recruiting|N/A|220|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 01:58:04.13842|2018-06-01 01:58:04.13842
NCT00710619|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2016-11-16|2008-07-03|2008-07-04|Estimate|||||||2016-11-16|2016-11-17|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|DOSE||Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX|Dosing Observational Study in Hemophilia Subjects With Inhibitors: A Phase IV Diary Study in Subjects Prescribed NovoSeven® as First Line on Demand Therapy for Acute Bleeding Episodes|Completed|||52|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:58:04.205055|2018-06-01 01:58:04.205055
NCT00710606|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2013-08-22||2015-04-14|2008-07-03|2008-07-04|Estimate|2015-04-14|2015-04-30|Estimate||||2015-04-14|2015-04-30|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®|Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®|Completed||N/A|40|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 01:58:04.290052|2018-06-01 01:58:04.290052
NCT00710593|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2013-11-15||2017-06-01|2008-07-02|2008-07-04|Estimate|2017-04-13|2017-05-22|Actual||||2017-06-01|2017-07-02|Actual|February 2008||2008-02-29|April 2017|2017-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women|Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women|Completed||Phase 2|99|Actual|University of North Carolina, Chapel Hill|The small number of participants (99 started and 79 completed the study) limits generalizability of safety/tolerability data.|2|||f||||t||||||||||2018-06-01 01:58:04.557959|2018-06-01 01:58:04.557959
NCT00710580|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02||2011-08-23|2013-01-10|2008-07-03|2008-07-04|Estimate||||2011-08-23|2011-08-25|Estimate|2013-01-10|2013-01-18|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|350|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 01:58:05.201875|2018-06-01 01:58:05.201875
NCT00710567|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2018-03-29|2008-07-02|2008-07-04|Estimate|||||||2018-03-29|2018-03-30|Actual|July 2008||2008-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of the Safety and Effectiveness of the DuraHeart™ LVAS|Evaluation of the Safety and Effectiveness of the DuraHeart™ Left Ventricular Assist System in Patients Awaiting Transplantation|Active, not recruiting||N/A|66|Actual|Terumo Heart Inc.||1|||f||||f||||||||No||2018-06-01 01:58:05.305932|2018-06-01 01:58:05.305932
NCT00710554|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|2012-07-11||2014-01-20|2008-07-03|2008-07-04|Estimate|2012-08-16|2012-09-14|Estimate||||2014-01-20|2014-02-13|Estimate|August 2005||2005-08-31|January 2014|2014-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex® in the Treatment of Subjects With Peripheral Neuropathic Pain, Associated With Allodynia|Completed||Phase 3|246|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 01:58:05.411534|2018-06-01 01:58:05.411534
NCT00710541|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2013-08-12|2008-07-03|2008-07-04|Estimate|||||||2013-08-12|2013-08-14|Estimate|October 2004||2004-10-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|||Non-invasive Ventilation in Severe Chronic Obstructive Pulmonary Disease(COPD)|Non-invasive Ventilation in Patients With Severe Chronic Obstructive Pulmonary Disease and Lung Emphysema (COPD)|Terminated||N/A|195|Actual|Deutsche Lungenstiftung e.V.||2||The publication of a national guideline on NPPV precluded further recruitment.|f||||t||||||||||2018-06-01 01:58:05.937149|2018-06-01 01:58:05.937149
NCT00710528|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2012-08-29|2008-07-02|2008-07-04|Estimate|||||||2012-08-29|2012-08-31|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies|A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients With Select, Relapsed or Refractory Hematologic Malignancies|Completed||Phase 1|192|Actual|Gilead Sciences||1|||f||||f||||||||||2018-06-01 01:58:06.011204|2018-06-01 01:58:06.011204
NCT00543868|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-10|2007-10-12|2007-10-15|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2004||2004-06-30|June 2015|2015-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001)||Completed||Phase 2|462|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:05.032965|2018-06-01 02:51:05.032965
NCT00710515|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2014-08-12|2008-07-03|2008-07-04|Estimate|||||||2014-08-12|2014-08-13|Estimate|July 2008||2008-07-31|August 2014|2014-08-31|June 2010|Actual|2010-06-30|April 2009|Actual|2009-04-30||Interventional|||Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies|A Phase I, Open-Label Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies|Completed||Phase 1|30|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:58:06.090493|2018-06-01 01:58:06.090493
NCT00710502|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2009-12-14|2008-07-02|2008-07-04|Estimate|||||||2009-12-14|2009-12-15|Estimate|January 2009||2009-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Transvaginal NOTES Cholecystectomy: Phase I/II Mexico Clinical Trial|Transvaginal Natural Orifice Translumenal and Endoscopic Surgery (NOTES) Cholecystectomy vs. Laparoscopic Cholecystectomy: Phase I/II Clinical Trial|Completed||Phase 1/Phase 2|40|Anticipated|North Texas Veterans Healthcare System||3|||f||||f||||||||||2018-06-01 01:58:06.179139|2018-06-01 01:58:06.179139
NCT00710489|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2018-03-01|2008-07-02|2008-07-04|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2008||2008-05-31|March 2018|2018-03-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||Potential Research Study Participant Registry|Potential Research Study Participant Registry|Recruiting|||200|Anticipated|University of California, Davis|||||f||||f||||||||||2018-06-01 01:58:06.246625|2018-06-01 01:58:06.246625
NCT00710476|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-07-02|2008-07-02|2008-07-04|Estimate|||||||2008-07-02|2008-07-04|Estimate|August 2006||2006-08-31|January 2008|2008-01-31||||||||Interventional|||Effect of the Number of Inseminated Spermatozoa on Subsequent Human Embryonic Development in Vitro|Effect of the Number of Inseminated Spermatozoa on Subsequent Human Embryonic Development in Vitro|Completed||N/A|82|Actual|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-06-01 01:58:06.315437|2018-06-01 01:58:06.315437
NCT00710463|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2008-07-03|2008-07-03|2008-07-04|Estimate|||||||2008-07-03|2008-07-04|Estimate|May 2003||2003-05-31|July 2008|2008-07-31|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Observational|||Evaluation of the Role of Nocturnal Non-Invasive Ventilation in Pulmonary Rehabilitation|Evaluation of the Role of Nocturnal Non-Invasive Ventilation in Pulmonary Rehabilitation|Completed|||80|Actual|Deutsche Lungenstiftung e.V.|||2||f||||f||||||||||2018-06-01 01:58:06.369465|2018-06-01 01:58:06.369465
NCT00710450|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2011-09-22|2008-07-03|2008-07-04|Estimate|||||||2011-09-22|2011-09-23|Estimate|May 2008||2008-05-31|September 2011|2011-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||Effect of Montelukast on Basophils, In-vitro|The Effect of Montelukast In-vitro on Basophil Histamine and Leukotriene, IL-4 Adn IL-13 Release in Subjects With Allergic Rhinitis or Allergic Asthma|Unknown status|Active, not recruiting||15|Anticipated|Creighton University|||2||f||||f||||||Samples Without DNA|"~     Supernatents from stimulation assays will be kept for batch assay.~   "|||2018-06-01 01:58:06.431374|2018-06-01 01:58:06.431374
NCT00710437|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2017-05-24|2008-07-02|2008-07-04|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2005||2005-04-30|May 2017|2017-05-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Observational|||Effects of Dexmedetomidine on the Intraoperative Electroencephalogram During Endarterectomy Surgery|Effects of Dexmedetomidine on the Intraoperative Electroencephalogram During Endarterectomy Surgery|Completed|||22|Actual|University of California, Davis|||2||f||||f||||||||||2018-06-01 01:58:06.486572|2018-06-01 01:58:06.486572
NCT00710424|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2012-06-26||2012-07-31|2008-07-03|2008-07-04|Estimate|2012-06-26|2012-07-31|Estimate||||2012-07-31|2012-08-01|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex in the Treatment of Subjects With Pain Due to Diabetic Neuropathy|Completed||Phase 3|297|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 01:58:06.56624|2018-06-01 01:58:06.56624
NCT00710411|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2015-12-16|2008-07-02|2008-07-04|Estimate|||||||2015-12-16|2015-12-17|Estimate|April 2009||2009-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|IRAMST||Inflammatory Response After Muscle and Skeleton Trauma|Inflammatory Response in Polytraumatized Patients|Completed|||48|Actual|University of Ulm|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, white cells, and tissues will be retained.~   "|||2018-06-01 01:58:07.143641|2018-06-01 01:58:07.143641
NCT00710398|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2011-07-19|2008-07-03|2008-07-04|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|May 2010|Actual|2010-05-31||Interventional|||"Improving Diet, Exercise And Lifestyle (IDEAL) for Women Study"|"The Impact of Higher Dairy and Dietary Protein on the Quality of Hypoenergetic diet-and Exercise-induced Weight Loss in Pre-menopausal, Overweight and Obese Young Women"|Completed||N/A|90|Anticipated|McMaster University||3|||f||||f||||||||||2018-06-01 01:58:07.21133|2018-06-01 01:58:07.21133
NCT00710385|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2011-08-19||2016-10-11|2008-07-01|2008-07-04|Estimate|2016-10-11|2016-12-05|Estimate||||2016-10-11|2016-12-05|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Abuse Liability of Suboxone Versus Subutex|Reinforcing Effects of Intravenous Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intravenous Drug Users (P05207)|Completed||Phase 3|19|Actual|New York State Psychiatric Institute|The stringent criteria for enrollment, qualification and retention in this trial were highly selective for a certain subpopulation of opioid-dependent individuals.|7|||f||||f||||||||Yes|Data have been published in a peer-reviewed journal.|2018-06-01 01:58:07.298731|2018-06-01 01:58:07.298731
NCT00710372|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2010-11-11|2008-07-03|2008-07-04|Estimate|||||||2010-11-11|2010-11-15|Estimate|June 2008||2008-06-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension|A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 2|83|Actual|Cytos Biotechnology AG||2|||f||||f||||||||||2018-06-01 01:58:07.531098|2018-06-01 01:58:07.531098
NCT00710359|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2010-08-13|2008-07-03|2008-07-04|Estimate|||||||2010-08-13|2010-08-16|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Cobalamin Status in Young Children With Gastrointestinal Symptoms or Feeding Problems|Cobalamin Status in Young Children With Gastrointestinal Symptoms or Feeding Problems|Completed||N/A|100|Anticipated|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 01:58:07.592564|2018-06-01 01:58:07.592564
NCT00710346|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2017-10-05|2008-07-03|2008-07-04|Estimate|||||||2017-10-05|2017-10-06|Actual|June 30, 2008||2008-06-30|September 1, 2016|2016-09-01|September 1, 2016||2016-09-01|||||Observational|||Establishment of Fibroid Tissue Bank|Establishment of a Fibroid Tissue Bank|Terminated|||43|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:58:07.664213|2018-06-01 01:58:07.664213
NCT00710333|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2010-03-08|2008-07-03|2008-07-04|Estimate|||||||2010-03-08|2010-03-09|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|RN1001-0093||Safety of Juvista When Administered Following Excision of Ear Lobe Keloids|A Single-centre, Double Blind, Randomised, Tolerance Study to Investigate the Safety of Juvista 500ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids.|Completed||Phase 1/Phase 2|10|Anticipated|Renovo||2|||f||||f||||||||||2018-06-01 01:58:07.722957|2018-06-01 01:58:07.722957
NCT00710320|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-03|||2010-02-03|2008-07-03|2008-07-04|Estimate|||||||2010-02-03|2010-02-04|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Temperature Changes During Induction of General Anesthesia in Pediatric Patients|Temperature Changes During Induction of General Anesthesia in Pediatric Patients|Completed|||44|Actual|University of Oklahoma|||1||f||||t||||||||||2018-06-01 01:58:07.787359|2018-06-01 01:58:07.787359
NCT00710307|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2010-09-09|2008-07-03|2008-07-04|Estimate|||||||2010-09-09|2010-09-10|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|EPIGROW||Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)|Descriptive, Cross-sectional and Prospective Epidemiology Study, on the Identification of Insulin-like Growth Factor-1 Status in Idiopathic Short Stature Children (EPIGROW Study)|Completed|||275|Actual|Ipsen|||||f||||||||||Samples With DNA|"~     Whole blood will be collected. The blood sample will be kept as long as necessary and for a~     maximum of 5 years.~   "|||2018-06-01 01:58:07.867244|2018-06-01 01:58:07.867244
NCT00710294|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2011-10-28|2008-07-03|2008-07-04|Estimate|||||||2011-10-28|2011-10-31|Estimate|August 2005||2005-08-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|DEBuT-HET||Device Based Therapy in Hypertension Extension Trial|DEBuT - HET: Device Based Therapy in Hypertension Extension Trial: Long-Term Follow-Up Trial for Patients Who Completed the DEBuT-HT Study|Completed||N/A|50|Anticipated|CVRx, Inc.|||||f||||f||||||||||2018-06-01 01:58:07.925077|2018-06-01 01:58:07.925077
NCT00710281|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2013-09-17|2008-07-01|2008-07-04|Estimate|||||||2013-09-17|2013-09-18|Estimate|March 2008||2008-03-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Analysis Of Intracranial Artery Lesions Using 2-D/3D Phase Contrast MR|Hemodynamic Analysis Of Intracranial Artery And Associated Lesions Using 2-D/3D Phase Contrast MR Angiography Focused On Wall Shear Stress Measurement|Withdrawn||N/A|0|Actual|Lahey Clinic||1||Investigator is no longer at study site|f||||f||||||||||2018-06-01 01:58:07.998628|2018-06-01 01:58:07.998628
NCT00710268|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2015-01-13|2008-07-03|2008-07-04|Estimate|||||||2015-01-13|2015-01-14|Estimate|June 2008||2008-06-30|January 2015|2015-01-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours|A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin®) In Patients With Advanced Solid Tumours|Completed||Phase 1|18|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 01:58:08.081812|2018-06-01 01:58:08.081812
NCT00710255|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2016-10-27|2008-07-03|2008-07-04|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Observational|||Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm|Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm Determined by Dynamic Analysis of Exhaled Breath Condensate.|Completed|||8|Actual|University of Vermont|||1||f||||f||||||||||2018-06-01 01:58:08.150969|2018-06-01 01:58:08.150969
NCT00710242|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2009-05-18|2008-07-03|2008-07-04|Estimate|||||||2009-05-18|2009-05-19|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Assess the Safety and Efficacy or Pre-Treatment With DF01 During Late Pregnancy in Reducing Prolonged Labor|Completed||Phase 2|263|Actual|Dilafor AB||2|||f||||f||||||||||2018-06-01 01:58:08.216151|2018-06-01 01:58:08.216151
NCT00710229|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-06-08|2008-07-03|2008-07-04|Estimate|||||||2010-06-08|2010-06-09|Estimate|July 2008||2008-07-31|June 2010|2010-06-30||||December 2011|Anticipated|2011-12-31||Interventional|MANTA||Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration|A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age-related Macular Degeneration Multicenter Anti VEGF Trial in Austria (MANTA)|Unknown status|Recruiting|Phase 3|320|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||||2018-06-01 01:58:08.29383|2018-06-01 01:58:08.29383
NCT00710216|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2009-04-16|2008-07-02|2008-07-04|Estimate|||||||2009-04-16|2009-04-20|Estimate||||April 2009|2009-04-30||||||||Interventional|EVD||Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B|Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study)|Withdrawn||Phase 4|40|Anticipated|University of Ulm||2||Sponsor withdraw|f||||f||||||||||2018-06-01 01:58:08.369779|2018-06-01 01:58:08.369779
NCT00710203|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2011-06-07||2015-04-06|2008-07-03|2008-07-04|Estimate|2014-02-12|2014-03-31|Estimate||||2015-04-06|2015-04-28|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|DPN||Dermatosis Papulosa Nigra|Efficacy of a 585 nm Pulsed Dye Laser (PDL) for the Treatment of Dermatosis Papulosa Nigra, and Compare it to Therapy With Curettage and Electrodesiccation.|Completed||N/A|10|Actual|University of California, Davis||4|||f||||f||||||||||2018-06-01 01:58:08.452507|2018-06-01 01:58:08.452507
NCT00710190|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2016-10-19|2008-07-03|2008-07-04|Estimate|||||||2016-10-19|2016-10-21|Estimate|July 2003||2003-07-31|October 2016|2016-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|DEBuT-HT||Device Based Therapy in Hypertension Trial|A Study of Baroreflex Hypertension Therapy in Refractory Hypertension|Completed||N/A|46|Actual|CVRx, Inc.||1|||f||||f||||||||||2018-06-01 01:58:08.673658|2018-06-01 01:58:08.673658
NCT00710177|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2018-03-26|2008-07-03|2008-07-04|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2006||2006-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|PPHN||PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn|Prostaglandin G/H Synthase-1 (PTGS1) Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn (PPHN)|Recruiting|||120|Anticipated|Medical College of Wisconsin|||2||f||||f||||||Samples With DNA|"~     whole blood, meconium~   "|No||2018-06-01 01:58:08.735584|2018-06-01 01:58:08.735584
NCT00710164|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-05-27|2008-07-03|2008-07-04|Estimate|||||||2010-05-27|2010-05-28|Estimate|September 2008||2008-09-30|September 2009|2009-09-30||||July 2010|Anticipated|2010-07-31||Interventional|||Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke||Unknown status|Recruiting|Phase 2/Phase 3|130|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 01:58:08.797377|2018-06-01 01:58:08.797377
NCT00710151|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2017-04-19|2008-07-02|2008-07-04|Estimate|||||||2017-04-19|2017-04-21|Actual|July 2008||2008-07-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|||Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors|Neurotoxicity in Primary Central Nervous System Lymphoma: An International, Collaborative, Observational Study of Cognition in Long-Term Survivors|Terminated|||80|Actual|OHSU Knight Cancer Institute|||1||f||||t||||||||||2018-06-01 01:58:08.984009|2018-06-01 01:58:08.984009
NCT00710138|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2010-08-13|2008-07-03|2008-07-04|Estimate|||||||2010-08-13|2010-08-16|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Cobalamin Status in Young Children With Developmental Delay|Cobalamin Status in Young Children With Developmental Delay and Regression|Completed||N/A|100|Anticipated|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 01:58:09.070935|2018-06-01 01:58:09.070935
NCT00710125|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2014-08-04|2008-07-03|2008-07-04|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety Study of GPX-150 in Patients With Solid Tumors|Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors|Completed||Phase 1|27|Actual|Gem Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:58:09.157849|2018-06-01 01:58:09.157849
NCT00710112|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2018-03-26|2008-07-03|2008-07-04|Estimate|||||||2018-03-26|2018-03-29|Actual|June 2006||2006-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|CLD||Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants|Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants|Recruiting|||900|Anticipated|Medical College of Wisconsin|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 01:58:09.23094|2018-06-01 01:58:09.23094
NCT00710099|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2011-10-05|2008-07-03|2008-07-04|Estimate|||||||2011-10-05|2011-10-06|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|INFLUX-VS||Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers|Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate on Cutaneous Blood Flow in Healthy Volunteers|Completed||N/A|40|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-06-01 01:58:09.318634|2018-06-01 01:58:09.318634
NCT00710086|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2009-09-17|2008-07-03|2008-07-04|Estimate|||||||2009-09-17|2009-09-18|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|IRELAN||Intravenous Remifentanil for Labor Analgesia|Remifentanil Intravenous Patient-controlled Labor Analgesia for Nulliparous Women|Completed||Phase 4|1000|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 01:58:09.404082|2018-06-01 01:58:09.404082
NCT00710073|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2008-07-02|2008-07-02|2008-07-03|Estimate|||||||2008-07-02|2008-07-03|Estimate|May 2006||2006-05-31|July 2008|2008-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Sono-Electro-Magnetic Therapy for Refractory Chronic Pelvic Pain Syndrome|Sono-Electro-Magnetic Therapy for the Treatment of Chronic Pelvic Pain Syndrome: A Pilot Study|Completed||N/A|12|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 01:58:09.487859|2018-06-01 01:58:09.487859
NCT00710060|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2013-11-01|2008-06-30|2008-07-03|Estimate|||||||2013-11-01|2013-11-04|Estimate|September 2002||2002-09-30|July 2008|2008-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations|NIMH Collaborative HIV/STD Prevention Trial|Completed||Phase 3|18147|Actual|RTI International||2|||f||||t||||||||||2018-06-01 01:58:09.574172|2018-06-01 01:58:09.574172
NCT00710047|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-11-10|2008-07-02|2008-07-03|Estimate|||||||2010-11-10|2010-11-15|Estimate|June 2008||2008-06-30|November 2010|2010-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Food Effect Study of a Single Dose of ZD4054 (Zibotentan)|A Randomised, Open-label, Single-centre, Crossover Study in Healthy Male Volunteers to Assess the Effect of Food on the Pharmacokinetics of a 10 mg Single Oral Dose of ZD4054 (Zibotentan)|Completed||Phase 1|30|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:58:09.702798|2018-06-01 01:58:09.702798
NCT00710034|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2016-11-30||2017-10-31|2008-07-02|2008-07-03|Estimate|2017-10-31|2017-12-06|Actual||||2017-10-31|2017-12-06|Actual|April 2010||2010-04-30|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine|Oral Tobacco as a Harm Reduction Product: Study 2 - Efficacy of Oral Tobacco Products Compared to Medicinal Nicotine for Complete Cigarette Substitution and Among Non-abstainers, for Reduction in Cigarette Smoking|Completed||Phase 2|391|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||Yes|We will share data with both internal and external researchers. Those external researchers interested in accessing the data will be required to submit a data analyses proposal with specific aims, hypotheses, and data analyses plan. These proposals will be reviewed by the investigative team. The requested data will then be provided that includes the variable list, raw data and description of the measures and methods of data collection.|2018-06-01 01:58:09.812967|2018-06-01 01:58:09.812967
NCT00710021|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2014-01-09||2017-03-24|2008-07-01|2008-07-03|Estimate|2014-03-25|2014-04-25|Estimate||||2017-03-24|2017-04-26|Actual|November 2008||2008-11-30|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Modified Intent-to-Treat|Vitamin D3 in Systemic Lupus Erythematosus|Effect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02)|Completed||Phase 2|57|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||Yes|Data access is provided to the public in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers.|2018-06-01 01:58:10.199021|2018-06-01 01:58:10.199021
NCT00710008|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2008-08-19|2008-07-02|2008-07-03|Estimate|||||||2008-08-19|2008-08-20|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|RECO1||Effect of Short-Term Exercise Training on ATP Synthesis in Relatives of Type 2 Diabetic Humans|Effect of Short-Term Exercise Training on ATP Synthesis in Relatives of Type 2 Diabetic Humans|Completed||N/A|26|Actual|Landsteiner Institut|||||f||||f||||||||||2018-06-01 01:58:11.140723|2018-06-01 01:58:11.140723
NCT00709995|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30||2010-12-09|2017-08-25|2008-07-02|2008-07-03|Estimate||||2010-12-09|2010-12-15|Estimate|2017-08-25|2017-08-29|Actual|June 2008||2008-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|February 2010|Actual|2010-02-28||Interventional|||A Study for Participants With Metastatic Renal Cell Carcinoma|Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 2|122|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 01:58:11.195183|2018-06-01 01:58:11.195183
NCT00709982|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2011-06-06|2008-07-02|2008-07-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2005||2005-05-31|April 2010|2010-04-30|July 2005|Actual|2005-07-31|||||Interventional|||A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) /Ethinyl Estradiol (EE) in Healthy Women.|An Open-label Pharmacokinetic Drug Interaction Study of Folic Acid and 250 Mcg NGM/35 Mcg EE (ORTHO-CYCLEN) in Healthy Women..|Completed||Phase 1|47|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:58:11.261624|2018-06-01 01:58:11.261624
NCT00709969|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2008-07-02|2008-07-02|2008-07-03|Estimate|||||||2008-07-02|2008-07-03|Estimate|July 2002||2002-07-31|July 2008|2008-07-31|February 2003|Actual|2003-02-28|||||Interventional|||Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria|Open Label, Multicenter Study for Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets (6-Dose Regimen) in African Infants and Children in the Treatment of Acute Uncomplicated Falciparum Malaria|Completed||Phase 3|310|Actual|Novartis||1|||f||||||||||||||2018-06-01 01:58:11.311433|2018-06-01 01:58:11.311433
NCT00709956|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2010-10-07||2015-09-10|2008-07-02|2008-07-03|Estimate|2012-09-27|2012-10-26|Estimate||||2015-09-10|2015-09-28|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PROWESS 15||Iloprost Power 15 in Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension|Completed||Phase 3|64|Actual|Actelion||2|||f||||f||||||||||2018-06-01 01:58:11.381977|2018-06-01 01:58:11.381977
NCT00709930|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2009-03-30|2008-07-01|2008-07-03|Estimate|||||||2009-03-30|2009-03-31|Estimate|December 2007||2007-12-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Fields in Mild and Moderate Essential Hypertension|Randomized Placebo-Controlled Trial of Efficacy and Safety of Weak Extremely Low Frequency Electromagnetic Field in Mild and Moderate Essential Hypertension|Completed||Phase 2|20|Anticipated|Kyoto University||2|||f||||t||||||||||2018-06-01 01:58:12.557224|2018-06-01 01:58:12.557224
NCT00709917|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2016-03-02|2008-06-30|2008-07-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2007||2007-03-31|March 2016|2016-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|REPAMET||Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes|Observational Study Investigating the Efficacy of Switching From Metformin Monotherapy to a Dual Therapy of Metformin and Repaglinide on Glycaemic Control in Type 2 Diabetes|Completed|||2171|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:58:12.618744|2018-06-01 01:58:12.618744
NCT00709904|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01||2011-03-07|2013-06-06|2008-07-01|2008-07-03|Estimate||||2011-03-07|2011-03-17|Estimate|2013-06-06|2013-06-14|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|SAVE-HIP3||Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery|Completed||Phase 3|469|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:58:12.69406|2018-06-01 01:58:12.69406
NCT00709891|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2015-01-20||2015-02-05|2008-07-02|2008-07-03|Estimate|2015-02-05|2015-02-09|Estimate||||2015-02-05|2015-02-09|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Eligible population: All participants who met the study inclusion/exclusion criteria, had not been enrolled in the study previously, and had not withdrawn consent before undergoing any study procedures. Of the enrolled population, 321 participants did not meet these criteria.|Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease|Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease in Women Undergoing Routine Cervical Cancer Screening|Completed||N/A|47208|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 01:58:12.816769|2018-06-01 01:58:12.816769
NCT00709878|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2010-08-27||2015-02-24|2008-07-02|2008-07-03|Estimate|2010-08-27|2010-09-23|Estimate||||2015-02-24|2015-03-17|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors|Histological Characterization and Differentiation of Rash From Other EGFR Inhibitors|Completed|||32|Actual|Northwestern University|Small sample size||4||f||||f||||||Samples With DNA|"~     Skin tissue biopsies.~   "|||2018-06-01 01:58:13.133697|2018-06-01 01:58:13.133697
NCT00709865|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01||2015-12-10|2015-12-10|2008-07-02|2008-07-03|Estimate||||2015-12-10|2016-01-12|Estimate|2015-12-10|2016-01-12|Estimate|July 2008||2008-07-31|December 2015|2015-12-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|TRIDENT-1||Phase 2b Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Tolerability of Intravenous Tonapofylline in Subjects With Acute Decompensated Heart Failure and Renal Insufficiency|Completed||Phase 2/Phase 3|420|Actual|Biogen||4|||f||||t||||||||||2018-06-01 01:58:13.549022|2018-06-01 01:58:13.549022
NCT00709852|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2011-08-19||2014-12-08|2008-07-01|2008-07-03|Estimate|2012-02-01|2012-03-06|Estimate||||2014-12-08|2014-12-30|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging|A Multicenter, Randomized, Double-blind, Crossover, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)|Completed||Phase 3|402|Actual|Bayer||2|||f||||f||||||||||2018-06-01 01:58:14.048654|2018-06-01 01:58:14.048654
NCT00709839|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2011-05-31|2008-07-02|2008-07-03|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans|Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans|Completed||Phase 4|10|Actual|Medical University of Vienna|||||f||||f||||||||||2018-06-01 01:58:15.84354|2018-06-01 01:58:15.84354
NCT00709826|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2012-06-18||2012-10-08|2008-07-02|2008-07-03|Estimate|2012-10-08|2012-11-07|Estimate||||2012-10-08|2012-11-07|Estimate|August 2008||2008-08-31|October 2012|2012-10-31|May 2011|Actual|2011-05-31|June 2010|Actual|2010-06-30||Interventional|||APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer|APRiCOT-P (Apricoxib in Combination Oncology Treatment - Pancreas): Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Gemcitabine and Erlotinib in the Treatment of Patients With Advanced Pancreatic Cancer|Completed||Phase 2|109|Actual|Tragara Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 01:58:15.941478|2018-06-01 01:58:15.941478
NCT00709813|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2011-07-03|2008-07-02|2008-07-03|Estimate|||||||2011-07-03|2011-07-06|Estimate|December 2003||2003-12-31|March 2009|2009-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study to Test a Computer-assisted Support System to Improve Patient-centered Care and Symptom Relief in Cancer Patients|Including Patient Preferences in Symptom Management of Cancer Patients: A Randomized Clinical Trial|Completed||N/A|145|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 01:58:16.429713|2018-06-01 01:58:16.429713
NCT00709800|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2009-02-11|2008-07-01|2008-07-03|Estimate|||||||2009-02-11|2009-02-12|Estimate|August 2007||2007-08-31|February 2009|2009-02-28||||September 2008|Actual|2008-09-30||Interventional|||Pandemic Influenza Plasmid DNA Vaccines (Needle)|A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines|Completed||Phase 1|56|Actual|Vical||5|||f||||t||||||||||2018-06-01 01:58:16.493458|2018-06-01 01:58:16.493458
NCT00709787|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2017-03-07|2008-07-01|2008-07-03|Estimate|||||||2017-03-07|2017-03-10|Actual|June 2008||2008-06-30|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management|Epidemiological Study In Hypertensive Patients: Assessment Of Risk Factors Prevalence And Of Patients' Management|Completed|||899|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:58:16.578739|2018-06-01 01:58:16.578739
NCT00709774|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-07-02|2008-07-02|2008-07-03|Estimate|||||||2008-07-02|2008-07-03|Estimate|July 2008||2008-07-31|June 2008|2008-06-30||||June 2010|Anticipated|2010-06-30||Interventional|||Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block|Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Osaka General Medical Center|||||f||||||||||||||2018-06-01 01:58:16.659012|2018-06-01 01:58:16.659012
NCT00709761|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2011-10-13||2018-03-08|2008-07-02|2008-07-03|Estimate|2011-10-13|2011-11-22|Estimate||||2018-03-08|2018-04-03|Actual|July 2, 2008|Actual|2008-07-02|March 2018|2018-03-31|January 3, 2018|Actual|2018-01-03|January 5, 2011|Actual|2011-01-05||Interventional|||Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC|LPT 111111- A Single-arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE®) and Lapatinib (TYKERB®) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer|Completed||Phase 2|60|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 01:58:16.735957|2018-06-01 01:58:16.735957
NCT00709748|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-07-02|2008-07-02|2008-07-03|Estimate|||||||2008-07-02|2008-07-03|Estimate|February 2008||2008-02-29|July 2008|2008-07-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|E-STIM||E-STIM Trial: Comparing the Efficacy of the Empi Select TENS to a Control for the Treatment of Chronic Lower Back Pain|The E-STIM Trial: A Randomized, Double-Blind, Multicenter Trial Comparing the Efficacy of the Empi Select Transcutaneous Electrical Nerve Stimulation (TENS) to a Control for the Treatment of Chronic Lower Back Pain|Unknown status|Recruiting|N/A|300|Anticipated|Empi, A DJO Company||2|||f||||f||||||||||2018-06-01 01:58:17.038198|2018-06-01 01:58:17.038198
NCT00709735|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2012-05-01||2017-04-06|2008-07-02|2008-07-03|Estimate|2017-04-06|2017-04-10|Actual||||2017-04-06|2017-04-10|Actual|May 2007|Actual|2007-05-31|April 2017|2017-04-30|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional||All randomized participants who completed the study.|A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol|A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol|Completed||Phase 4|23|Actual|Massachusetts General Hospital|Small participant sample due to recruitment difficulties.|2|||f||||f||||||||||2018-06-01 01:58:17.208027|2018-06-01 01:58:17.208027
NCT00709722|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2016-04-13||2016-11-13|2008-07-02|2008-07-03|Estimate|2016-11-13|2017-01-10|Estimate||||2016-11-13|2017-01-10|Estimate|October 2003||2003-10-31|July 2008|2008-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional||ITT population|Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis|Safety and Efficacy Study on Deoxyspergualin (NKT-01) in Patients With Uncontrolled Lupus Nephritis Receiving Oral Corticosteroids and Prior Treatment of Standard Immunosuppressive Therapy|Completed||Phase 1/Phase 2|21|Actual|Nippon Kayaku Co.,Ltd.||1|||f||||f||||||||||2018-06-01 01:58:17.443532|2018-06-01 01:58:17.443532
NCT00709709|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2014-11-13|2008-07-02|2008-07-03|Estimate|||||||2014-11-13|2014-11-14|Estimate|June 2006||2006-06-30|July 2008|2008-07-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|EVASCAN||Medical Evaluation of Scanner in Coronary Syndrome|Medical and Economic Medical Evaluation of Scan Multislice of Coronary Artery in Exploration of Stable Coronary Syndrome. Comparison With Quantitative Coronarography|Completed||N/A|1500|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 01:58:17.738383|2018-06-01 01:58:17.738383
NCT00709696|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2017-01-26||2017-12-01|2008-07-02|2008-07-03|Estimate|2017-12-01|2017-12-27|Actual||||2017-12-01|2017-12-27|Actual|April 2008||2008-04-30|December 2017|2017-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||Treatment seeking cigarette smokers|Human Laboratory Study Of Varenicline in Smokers|Human Laboratory Study Of Varenicline in Smokers|Completed||N/A|7|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 01:58:17.804339|2018-06-01 01:58:17.804339
NCT00709683|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2016-03-04|2008-07-01|2008-07-03|Estimate|||||||2016-03-04|2016-03-07|Estimate|May 2008||2008-05-31|March 2016|2016-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®|An Observational Study Evaluating the Safety and Efficacy of the Treatment With Biphasic Insulin Aspart (NovoMix® 30 FlexPen®) in the Treatment of Type 2 Diabetics After Failing on Basal/ Intermediate Mono or Combination Therapy|Completed|||216|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:58:18.075147|2018-06-01 01:58:18.075147
NCT00709670|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2013-09-17|2008-07-02|2008-07-03|Estimate|||||||2013-09-17|2013-09-18|Estimate|September 2008||2008-09-30|July 2008|2008-07-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|PEPSI||ComParative Diagnostic Study Between Multislice Computed Tomography (MSCT) and Stress Echography in Coronarin Patients.|ComParative Diagnostic Study Between MSCT and Stress Echography in Patients Presenting With Suspected Acute Coronary Syndrome Without ST Segment Elevation.|Completed||N/A|217|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 01:58:18.136895|2018-06-01 01:58:18.136895
NCT00396396|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2006-11-03|2006-11-03|2006-11-06|Estimate|||||||2006-11-03|2006-11-06|Estimate|October 2006||2006-10-31|November 2006|2006-11-30||||||||Interventional|||Role of Acetylcysteine in Creatinine Clearance||Unknown status|Recruiting|N/A|35||Eastern Virginia Medical School|||||f||||||||||||||2018-06-01 03:39:21.730828|2018-06-01 03:39:21.730828
NCT00709657|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2014-11-13|2008-07-02|2008-07-03|Estimate|||||||2014-11-13|2014-11-14|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|November 2011|Actual|2011-11-30|July 2010|Actual|2010-07-31||Interventional|||The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion|The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion|Terminated||N/A|8|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 01:58:18.259623|2018-06-01 01:58:18.259623
NCT00709644|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2011-06-06|2008-07-02|2008-07-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2005||2005-04-30|March 2010|2010-03-31|August 2005|Actual|2005-08-31|||||Interventional|||Bioequivalence Study of the Oral Contraceptive (OC) Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.|A Pivotal Bioequivalence Study of 250 Mcg NGM/25 Mcg EE With or Without Folic Acid in Healthy Female Subjects|Completed||Phase 1|54|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:58:18.341347|2018-06-01 01:58:18.341347
NCT00709631|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2015-02-24|2008-07-02|2008-07-03|Estimate|||||||2015-02-24|2015-02-25|Estimate|December 2006||2006-12-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|June 2009|Actual|2009-06-30||Observational|ULCERE||Interest of a Systematic Biopsy for Hard-to-heal Leg Ulcers|Prospective Evaluation of the Interest of a Systematic Biopsy for Hard-to-heal Leg Ulcers|Completed|||155|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 01:58:18.395529|2018-06-01 01:58:18.395529
NCT00709618|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|2012-12-13||2014-06-30|2008-07-02|2008-07-03|Estimate|2012-12-13|2013-01-18|Estimate||||2014-06-30|2014-07-14|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects|A Phase II, Single-Arm, Multi-Center Study Evaluating the Combination of Vinorelbine and Lapatinib in Women With ErbB2 Overexpressing Metastatic Breast Cancer|Terminated||Phase 2|44|Actual|GlaxoSmithKline|The study was terminated due to low screening and a low enrollment rate after 3 years.|||"Evolving standard of care practices in this disease setting was limiting enrolment and leading~   to a delay in delivering this study information to the public."|f||||f||||||||||2018-06-01 01:58:18.466016|2018-06-01 01:58:18.466016
NCT00709605|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-28|||2018-05-23|2008-07-02|2008-07-03|Estimate|||||||2018-05-23|2018-05-24|Actual|June 25, 2008||2008-06-25|May 20, 2014|2014-05-20|May 20, 2014|Actual|2014-05-20|May 20, 2014|Actual|2014-05-20||Interventional|||Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection|A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP In Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection|Completed||Phase 1|31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:58:18.893054|2018-06-01 01:58:18.893054
NCT00709592|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2015-02-01||2017-09-14|2008-07-02|2008-07-03|Estimate|2015-02-01|2015-02-12|Estimate||||2017-09-14|2017-09-18|Actual|July 21, 2008|Actual|2008-07-21|September 2017|2017-09-30|June 28, 2017|Actual|2017-06-28|February 15, 2014|Actual|2014-02-15||Interventional||Subjects able to proceed to transplant.|Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT|Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation|Completed||Phase 2|42|Actual|Virginia Commonwealth University||2|||f||||t|t|f|||t|||||2018-06-01 01:58:18.98247|2018-06-01 01:58:18.98247
NCT00709579|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2008-07-03|2008-07-02|2008-07-03|Estimate|||||||2008-07-03|2008-07-08|Estimate|June 2008||2008-06-30|July 2008|2008-07-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids|Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|Pierre Fabre Dermo Cosmetique||2|||f||||t||||||||||2018-06-01 01:58:19.333114|2018-06-01 01:58:19.333114
NCT00709566|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-07-22|2008-07-02|2008-07-03|Estimate|||||||2010-07-22|2010-07-23|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|EMPART||EMPART - Exercise and Manual Physiotherapy Arthritis Research Trial|The Effectiveness of Exercise Therapy and Manual Therapy in Hip Osteoarthritis - A Multicentre Randomised Controlled Trial|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|Royal College of Surgeons, Ireland||3|||f||||f||||||||||2018-06-01 01:58:19.430198|2018-06-01 01:58:19.430198
NCT00709553|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-09-27|2008-07-02|2008-07-03|Estimate|||||||2010-09-27|2010-09-28|Estimate|July 2008||2008-07-31|September 2010|2010-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Drug Interaction Study to Asses Multiple Doses of ZD4054 (Zibotentan)|A Randomised, Open-label, Crossover, Phase I Study to Assess the Effect of Multiple Oral Doses of ZD4054 (Zibotentan) on the Pharmacokinetics of a CYP450 3A Probe (Midazolam) in Healthy Male Subjects|Completed||Phase 1|12|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 01:58:19.518782|2018-06-01 01:58:19.518782
NCT00709540|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-12-08|2008-07-01|2008-07-03|Estimate|||||||2008-12-08|2008-12-09|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women|Completed||Phase 1|40|Anticipated|Acceleron Pharma, Inc.||1|||f||||t||||||||||2018-06-01 01:58:19.587329|2018-06-01 01:58:19.587329
NCT00709527|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2012-06-14|2008-07-02|2008-07-03|Estimate|||||||2012-06-14|2012-06-18|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration|A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability AND Pharmacokinetic Profile Of Multiple Intravitreous Injections Of ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Multiple Doses Of Lucentis® 0.5 mg/Eye, Or With One Induction Dose Of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 1|60|Actual|Ophthotech Corporation||1|||f||||||||||||||2018-06-01 01:58:19.687965|2018-06-01 01:58:19.687965
NCT00709514|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2013-07-08|2008-06-30|2008-07-03|Estimate|||||||2013-07-08|2013-07-09|Estimate|December 2008||2008-12-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|April 2011|Actual|2011-04-30||Interventional|||Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers|A Phase II, Double-blind, Placebo-controlled Clinical Evaluation of DCB-WH1 in Healing of Chronic Diabetic Foot Ulcers|Completed||Phase 2|41|Actual|Oneness Biotech Co., Ltd.||2|||f||||f||||||||||2018-06-01 01:58:19.747384|2018-06-01 01:58:19.747384
NCT00709501|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2015-10-19|2008-07-01|2008-07-03|Estimate|||||||2015-10-19|2015-10-21|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Disseminating Effective Habits for Long-Term Weight Loss|Disseminating Effective Habits for Long-Term Weight Loss|Completed||N/A|100|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 01:58:19.81614|2018-06-01 01:58:19.81614
NCT00709488|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2012-11-14|2008-07-02|2008-07-03|Estimate|||||||2012-11-14|2012-11-16|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|A Phase 1 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy|Completed||Phase 1|12|Actual|Light Sciences Oncology||1|||f||||f||||||||||2018-06-01 01:58:19.891047|2018-06-01 01:58:19.891047
NCT00709475|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2016-10-27|2008-06-30|2008-07-03|Estimate|||||||2016-10-27|2016-10-28|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|LevSafeQD||Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus|Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus|Completed|||747|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:58:20.07882|2018-06-01 01:58:20.07882
NCT00709462|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-07-23|2008-07-01|2008-07-03|Estimate|||||||2010-07-23|2010-07-26|Estimate|March 2004||2004-03-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)|A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX-1307-01)|Completed||Phase 1|48|Anticipated|Celldex Therapeutics|||||f||||f||||||||||2018-06-01 01:58:20.160331|2018-06-01 01:58:20.160331
NCT00709449|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2009-11-30|2008-07-02|2008-07-03|Estimate|||||||2009-11-30|2009-12-01|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects|An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects|Completed||Phase 2/Phase 3|60|Anticipated|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 01:58:20.226006|2018-06-01 01:58:20.226006
NCT00709436|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2012-01-10|2008-07-01|2008-07-03|Estimate|||||||2012-01-10|2012-01-11|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery|Randomized, Multiple-center, Double-blind, Placebo-controlled Study of the Safety and Analgesic Efficacy of Repeated Dosing of PMI-150 (Intranasal Ketamine) to Treat Acute Post-operative Pain Following Orthopedic Trauma, Injury, or Surgery.|Completed||Phase 3|250|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:58:20.326539|2018-06-01 01:58:20.326539
NCT00709423|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-07-02|2008-07-02|2008-07-03|Estimate|||||||2008-07-02|2008-07-03|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effects of Moxaverine and Placebo on Ocular Blood Flow|A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow|Completed||Phase 2|16|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:58:20.428471|2018-06-01 01:58:20.428471
NCT00709410|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2012-03-29|2008-07-01|2008-07-03|Estimate|||||||2012-03-29|2012-03-30|Estimate|January 2009||2009-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|February 2009|Actual|2009-02-28||Interventional|||Mass Oral Cholera Vaccination in Zanzibar|Mass Oral Cholera Vaccination in High-risk Populations in Zanzibar: Assessment of Effectiveness and Herd Protection|Completed||N/A|51151|Actual|International Vaccine Institute||1|||f||||f||||||||||2018-06-01 01:58:20.499344|2018-06-01 01:58:20.499344
NCT00709397|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-07-29|2008-07-02|2008-07-03|Estimate|||||||2010-07-29|2010-08-02|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy|HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy|Terminated|||3|Actual|Brigham and Women's Hospital|||1|lack of accrual|f||||f||||||Samples With DNA|"~     Peripheral blood mononuclear cells will be tested for HIV-1 DNA levels. The cell pellets~     obtained from each of the samples will be tested for 1) total HIV-1 DNA and 2-LTR circles~     using real-time quantitative PCR and 2) integrated proviral DNA using Alu real-time nested~     PCR.~   "|||2018-06-01 01:58:20.570723|2018-06-01 01:58:20.570723
NCT00709384|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2009-09-18|2008-07-02|2008-07-03|Estimate|||||||2009-09-18|2009-09-21|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Prevention of Atrial Tachycardia After a Right Atriotomy II|Prevention of Atrial Tachycardia After a Right Atriotomy II|Completed||Phase 2|14|Actual|Aarhus University Hospital Skejby||1|||f||||f||||||||||2018-06-01 01:58:20.713705|2018-06-01 01:58:20.713705
NCT00709371|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29||2012-11-26|2012-11-27|2008-06-29|2008-07-03|Estimate||||2012-11-27|2012-11-29|Estimate|2012-11-27|2012-11-29|Estimate|July 2008||2008-07-31|November 2012|2012-11-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity|A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity|Completed||Phase 2|729|Actual|Orexigen Therapeutics, Inc||6|||f||||f||||||||||2018-06-01 01:58:20.782006|2018-06-01 01:58:20.782006
NCT00709358|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2011-12-26|2008-07-02|2008-07-03|Estimate|||||||2011-12-26|2011-12-29|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|EVAMICA||Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections|Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units|Completed||Phase 4|2000|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 01:58:20.929358|2018-06-01 01:58:20.929358
NCT00709345|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2015-04-16|2008-06-30|2008-07-03|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks|Effectiveness of a Cognitive Behavioral Treatment for Reducing Atypical Antipsychotic Medication Health Risks in People With Serious Mental Illness|Completed||Phase 1/Phase 2|333|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-06-01 01:58:21.011667|2018-06-01 01:58:21.011667
NCT00709332|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2011-06-06|2008-07-02|2008-07-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 2005||2005-01-31|April 2010|2010-04-30|February 2005|Actual|2005-02-28|||||Interventional|||A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) in Healthy Women.|An Open-label Pharmacokinetic Drug Interaction Study of Folic Acid and 250 Mcg NGM/35 Mcg E E (ORTHO-CYCLEN) in Healthy Women.|Completed||Phase 1|47|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:58:21.086139|2018-06-01 01:58:21.086139
NCT00709319|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2011-07-27||2016-08-25|2008-07-01|2008-07-03|Estimate|2012-02-16|2012-04-02|Estimate||||2016-08-25|2016-10-07|Estimate|July 2005||2005-07-31|August 2016|2016-08-31|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Observational|Vitrectomy-D||Evaluation of Vitrectomy for Diabetic Macular Edema|Evaluation of Vitrectomy for Diabetic Macular Edema Study|Completed|||87|Actual|Jaeb Center for Health Research|||1||f||||f||||||||||2018-06-01 01:58:21.187457|2018-06-01 01:58:21.187457
NCT00709306|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2017-11-10||2018-01-25|2008-07-01|2008-07-03|Estimate|2018-01-25|2018-02-22|Actual||||2018-01-25|2018-02-22|Actual|March 2006||2006-03-31|January 2018|2018-01-31|June 2010|Actual|2010-06-30|June 2008|Actual|2008-06-30||Interventional|||The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention|The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention|Completed||N/A|197|Actual|Fox Chase Cancer Center||4|||f||||f||||||||||2018-06-01 01:58:21.710089|2018-06-01 01:58:21.710089
NCT00709293|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2013-06-17|2008-07-02|2008-07-03|Estimate|||||||2013-06-17|2013-06-18|Estimate|July 2008||2008-07-31|June 2013|2013-06-30||||May 2009|Anticipated|2009-05-31||Interventional|||Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients|Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients|Withdrawn||N/A|0|Actual|University of California, Los Angeles||2||Insufficient funding|f||||f||||||||||2018-06-01 01:58:22.13698|2018-06-01 01:58:22.13698
NCT00709280|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2013-02-11|2008-07-01|2008-07-03|Estimate|||||||2013-02-11|2013-02-12|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|ISIS||Infant Study of Inhaled Saline in Cystic Fibrosis|Infant Study of Inhaled Saline in Cystic Fibrosis|Completed||N/A|321|Actual|CF Therapeutics Development Network Coordinating Center||2|||f||||t||||||||||2018-06-01 01:58:22.19384|2018-06-01 01:58:22.19384
NCT00709267|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2011-06-06|2008-07-02|2008-07-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2004||2004-10-31|April 2010|2010-04-30|December 2004|Actual|2004-12-31|||||Interventional|||Bioavailability Study of Folic Acid in Healthy Women|A Randomized, Open Label Absolute Bioavailability Study of Folic Acid.|Completed||Phase 1|12|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:58:22.378161|2018-06-01 01:58:22.378161
NCT00709254|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-07-02|2008-07-02|2008-07-03|Estimate|||||||2008-07-02|2008-07-03|Estimate|December 2001||2001-12-31|July 2008|2008-07-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|LEF-2495||Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects|Phase I, 3-Period, Fasting, Bioavailability, Safety Assessment and PK Study Evaluating Single Dose Administration of i.v. Fentanyl (200 µg) and Single and Multiple Doses of 3 mL of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 µg/mL) Administered in Normal Healthy Subjects|Completed||Phase 1|12|Actual|YM BioSciences||3|||f||||f||||||||||2018-06-01 01:58:22.431023|2018-06-01 01:58:22.431023
NCT00709241|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2014-10-22|2008-07-02|2008-07-03|Estimate|||||||2014-10-22|2014-10-23|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|PANIC||Psychosocial Patterns and Prognosis in Patients With Heart Failure|Prognostic Value of Negative Affectivity in Patients With Heart Failure|Completed|||325|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     serum, urine.~   "|||2018-06-01 01:58:22.495806|2018-06-01 01:58:22.495806
NCT00709228|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-11-09||2015-01-14|2008-07-02|2008-07-03|Estimate|2010-01-28|2010-02-22|Estimate||||2015-01-14|2015-01-26|Estimate|May 2006||2006-05-31|January 2015|2015-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)|PREDICT - Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24|Completed|||496|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||Samples With DNA|"~     Blood sample for PCR~   "|||2018-06-01 01:58:22.55482|2018-06-01 01:58:22.55482
NCT00709215|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2009-01-08|2008-07-02|2008-07-03|Estimate|||||||2009-01-08|2009-01-09|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia|A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|44|Anticipated|OncoVista, Inc.|||||f||||t||||||||||2018-06-01 01:58:22.683957|2018-06-01 01:58:22.683957
NCT00709202|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2016-12-14|2008-07-02|2008-07-03|Estimate|||||||2016-12-14|2016-12-16|Estimate|July 2008||2008-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain in Adolescents and Young Adults|The Attenuation of Second Generation Antipsychotic Induced Weight Gain in Adolescents and Adults Using Betahistine: A Double-Blind, Placebo-Controlled Trial|Completed||Phase 2|39|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||No||2018-06-01 01:58:22.762087|2018-06-01 01:58:22.762087
NCT00709189|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2011-06-06|2008-07-02|2008-07-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2005||2005-05-31|April 2010|2010-04-30|August 2005|Actual|2005-08-31|||||Interventional|||Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.|A Pivotal Bioequivalence Study of 250 Mcg NGM/35 Mcg EE With or Without Folic Acid in Healthy Female Subjects.|Completed||Phase 1|53|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 01:58:22.832002|2018-06-01 01:58:22.832002
NCT00709176|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2014-02-10|2008-07-02|2008-07-03|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2005||2005-06-30|October 2013|2013-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|FOCUS-Triage||Outcomes of Triaged Family Care in Advanced Cancer|Outcomes of Triaged Family Care in Advanced Cancer|Completed||N/A|484|Actual|University of Michigan||3|||f||||t||||||||||2018-06-01 01:58:22.888572|2018-06-01 01:58:22.888572
NCT00709163|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-07-02|2008-07-02|2008-07-03|Estimate|||||||2008-07-02|2008-07-03|Estimate|December 2003||2003-12-31|June 2008|2008-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Nesiritide - Dilated Cardiomyopathy|Nesiritide as an Adjunctive Therapy for Children With Dilated Cardiomyopathy Admitted to the Intensive Care Unit|Completed||N/A|20|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 01:58:22.96364|2018-06-01 01:58:22.96364
NCT00709150|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2013-07-25|2008-06-30|2008-07-03|Estimate|||||||2013-07-25|2013-07-29|Estimate|March 2005||2005-03-31|July 2013|2013-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MDDP||Collaborative Depression Care Management in Treating Depressed Low-income Hispanics With Diabetes|Multifaceted Depression Diabetes Program for Hispanics|Completed||Phase 4|387|Actual|University of Southern California||2|||f||||t||||||||||2018-06-01 01:58:23.030775|2018-06-01 01:58:23.030775
NCT00709137|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2014-05-27|2008-07-02|2008-07-03|Estimate|||||||2014-05-27|2014-05-28|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension|Randomized Trial of Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension|Withdrawn||N/A|0|Actual|VA Salt Lake City Health Care System||2||lack of enrollment|f||||t||||||||||2018-06-01 01:58:23.085739|2018-06-01 01:58:23.085739
NCT00709124|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2015-03-30||2018-01-12|2008-07-02|2008-07-03|Estimate|2015-04-13|2015-04-16|Estimate||||2018-01-12|2018-01-23|Actual|June 2008||2008-06-30|January 2018|2018-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|NMES||Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness|Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness|Completed||N/A|36|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 01:58:23.167239|2018-06-01 01:58:23.167239
NCT00709111|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2011-07-26||2016-01-04|2008-07-01|2008-07-03|Estimate|2012-01-23|2012-02-24|Estimate||||2016-01-04|2016-02-03|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression|A Pilot Trial of Maraviroc for Treatment of Subjects on Antiretroviral Therapy With Suboptimal CD4 T-cell Count Recovery Despite Sustained Virologic Suppression|Completed||N/A|34|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-06-01 01:58:24.53917|2018-06-01 01:58:24.53917
NCT00709098|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2012-09-27||2015-09-10|2008-07-02|2008-07-03|Estimate|2012-09-27|2012-10-29|Estimate||||2015-09-10|2015-09-28|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PROWESS 15 Ext||Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Randomized Study Comparing the Safety and Tolerability of Iloprost Inhalation Solution Delivered by I-neb Utilizing Power Disc-15 and Power Disc-6 in Patients With Symptomatic Pulmonary Arterial Hypertension|Completed||Phase 3|49|Actual|Actelion||2|||f||||f||||||||||2018-06-01 01:58:25.290921|2018-06-01 01:58:25.290921
NCT00709085|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2009-11-23|2008-07-02|2008-07-03|Estimate|||||||2009-11-23|2009-11-25|Estimate|April 2008||2008-04-30|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||To Study the Effects of Host Genetic Factors on Liver Cirrhosis and Hepatocellular Carcinoma (HCC)|Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4)|Unknown status|Recruiting||320|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples With DNA|"~     liver tissue (non-tumor part)~   "|||2018-06-01 01:58:25.730989|2018-06-01 01:58:25.730989
NCT00709072|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2010-04-22|2008-07-02|2008-07-03|Estimate|||||||2010-04-22|2010-04-26|Estimate|February 2009||2009-02-28|June 2009|2009-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Follow-up of Children After Stuttering Treatment|Relapse Following the Lidcombe Program for Preschool Children Who Stutter|Unknown status|Recruiting|Phase 2|180|Anticipated|University of Sydney||2|||f||||f||||||||||2018-06-01 01:58:25.794256|2018-06-01 01:58:25.794256
NCT00709059|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2010-12-22||2015-11-03|2008-07-02|2008-07-03|Estimate|2010-12-22|2011-01-10|Estimate||||2015-11-03|2015-11-04|Estimate|December 2004||2004-12-31|November 2015|2015-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|PRACTICE||Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)|A Non-interventional Phase IV Survey to Assess the Antiviral Effectiveness of PegIntron® and Rebetol® Treatment According to the Stage of Liver Fibrosis in Previously Untreated Patients With Genotype 1/4/5/6 Chronic Hepatitis C (CHC) (PRACTICE)|Completed|||538|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:58:25.960048|2018-06-01 01:58:25.960048
NCT00709046|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2010-01-11|2008-07-02|2008-07-03|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2008||2008-01-31|January 2010|2010-01-31||||January 2010|Anticipated|2010-01-31||Interventional|||High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment|High Dose Versus Standard Dose Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Hemostasis: A Prospective Randomized Comparative Study|Unknown status|Recruiting|N/A|150|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 01:58:26.133442|2018-06-01 01:58:26.133442
NCT00709033|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2017-08-24|2008-07-02|2008-07-03|Estimate|||||||2017-08-24|2017-08-25|Actual|July 2009||2009-07-31|August 2017|2017-08-31|April 2027|Anticipated|2027-04-30|May 2012|Actual|2012-05-31||Interventional|ATECRAB||T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL|Phase I Study Of The Administration Of Peripheral Activated T-Cells and EBV Specific CTLs Expressing CD19 Chimeric Receptors For Advanced B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia (ATECRAB)|Active, not recruiting||Phase 1|3|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 01:58:26.243268|2018-06-01 01:58:26.243268
NCT00709020|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2015-06-03|2008-07-02|2008-07-03|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2008||2008-06-30|June 2015|2015-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||White Button Mushroom Extract in Preventing the Recurrence of Breast Cancer in Postmenopausal Breast Cancer Survivors|A Translational Breast Cancer Prevention Trial of Mushroom Powder in Postmenopausal Breast Cancer Survivors|Completed||Phase 1|16|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:58:26.325382|2018-06-01 01:58:26.325382
NCT00709007|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2015-04-14|2008-07-01|2008-07-03|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|July 2011|Anticipated|2011-07-31|July 2010|Anticipated|2010-07-31||Interventional|DAART+||Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India|Evaluating the Role of Directly Administered Antiretroviral Therapy (DAART) in Conjunction With Opiate Substitution in Delivery of Highly Active Antiretroviral Therapy to HIV-1-infected Injecting Drug Users (IDUs) in Chennai, India|Withdrawn||Phase 2/Phase 3|0|Actual|Johns Hopkins University||2||"No participants satisfied eligibility criteria and were enrolled into the study since July~   2008."|f||||f||||||||||2018-06-01 01:58:26.406557|2018-06-01 01:58:26.406557
NCT00708994|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2017-11-28|2008-07-01|2008-07-03|Estimate|||||||2017-11-28|2017-11-30|Actual|April 2008||2008-04-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|THC-Gamma||Cannabinoids, Neural Synchrony, and Information Processing|Cannabinoids, Psychosis, Neural Synchrony, and Information Processing|Active, not recruiting||Phase 1|36|Anticipated|Yale University||2|||f||||||||||||||2018-06-01 01:58:26.476556|2018-06-01 01:58:26.476556
NCT00708981|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-09-30|2008-07-01|2008-07-03|Estimate|||||||2014-09-30|2014-10-02|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)|Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)|Completed||Phase 4|120|Actual|John H. Stroger Hospital||2|||f||||t||||||||||2018-06-01 01:58:26.546438|2018-06-01 01:58:26.546438
NCT00708968|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2015-06-15|2008-07-02|2008-07-03|Estimate|||||||2015-06-15|2015-06-16|Estimate|September 2001||2001-09-30|July 2008|2008-07-31|December 2005|Actual|2005-12-31|October 2005|Actual|2005-10-31||Interventional|||Prostate Cancer: Family Care for Patients and Spouses|Prostate Cancer: Family Care for Patients and Spouses|Completed||N/A|263|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 01:58:26.612629|2018-06-01 01:58:26.612629
NCT00708955|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-02|||2018-05-24|2008-07-02|2008-07-03|Estimate|||||||2018-05-24|2018-05-25|Actual|June 25, 2008||2008-06-25|July 12, 2017|2017-07-12|July 12, 2017||2017-07-12|||||Observational|||Evaluation and Treatment of People With Eye Diseases|Evaluation and Treatment Protocol for Potential Research Participants With Ocular Diseases|Completed|||2164|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:58:26.697245|2018-06-01 01:58:26.697245
NCT00708942|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2013-03-04||2013-04-17|2008-07-02|2008-07-03|Estimate|2013-03-04|2013-04-15|Estimate||||2013-04-17|2013-04-24|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1|A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-grade Cervical Intraepithelial Neoplasia (CIN1)|Terminated||Phase 2|83|Actual|Photocure|Slow recruitment lead to early terminaiton of the second part of the trial, including arms 4 and 5, after enrolment of 13 patients. No formal statistical analysis conducted on this part of the data.|5||"Slow recruitment, study stopped with only 13 of 70 patients included in second part of the~   study"|f||||f||||||||||2018-06-01 01:58:26.774158|2018-06-01 01:58:26.774158
NCT00708929|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2013-03-15|2008-07-02|2008-07-03|Estimate|||||||2013-03-15|2013-03-19|Estimate|June 2009||2009-06-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid?|Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid?|Completed||N/A|100|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 01:58:27.259063|2018-06-01 01:58:27.259063
NCT00708916|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2012-12-10|2008-07-02|2008-07-03|Estimate|||||||2012-12-10|2012-12-11|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients|Clinical and Immune-modulating Effects of CC-10004 in Discoid Lupus Erythematosus|Completed||Phase 1/Phase 2|10|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 01:58:27.322284|2018-06-01 01:58:27.322284
NCT00708903|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2012-05-10|2008-07-01|2008-07-02|Estimate|||||||2012-05-10|2012-05-14|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)|A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects|Completed||Phase 1|60|Actual|Puma Biotechnology, Inc.||3|||f||||f||||||||||2018-06-01 01:58:27.444787|2018-06-01 01:58:27.444787
NCT00708890|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2014-04-15|2008-07-01|2008-07-02|Estimate|||||||2014-04-15|2014-04-16|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|TSF_Norway||Twelve Step Based Self-help Groups for Substance Related Disorders|Twelve Step Based Self-help Groups for Substance Related Disorders - A Randomized Controlled Trial on a Detoxification Center|Completed||N/A|140|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-06-01 01:58:27.50701|2018-06-01 01:58:27.50701
NCT00708877|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2011-12-13||2013-07-23|2008-06-27|2008-07-02|Estimate|2012-03-06|2012-04-04|Estimate||||2013-07-23|2013-07-30|Estimate|March 2007||2007-03-31|July 2013|2013-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Liver Transplantation for Cholangiocarcinoma|Liver Transplantation for Cholangiocarcinoma|Terminated||N/A|5|Actual|University of Utah||1||"study procedures have become standard of care as patients seeking Model for End-Stage Liver~   Disease (MELD) exception points for cholangiocarcinoma"|f||||t||||||||||2018-06-01 01:58:27.56426|2018-06-01 01:58:27.56426
NCT00708851|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2014-11-13||2015-04-02|2008-07-01|2008-07-02|Estimate|2015-04-02|2015-04-20|Estimate||||2015-04-02|2015-04-20|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional||12 participants with bilateral, symmetrical plaque psorasis|NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study|A Clinical Evaluation of Safety & Efficacy of Adding an At-home Topical LCD Solution Regimen to Standard Narrowband UVB Phototherapy Administered 3 Times Weekly to Adults With Generalized Plaque Psoriasis.|Completed||N/A|12|Actual|NeoStrata Company, Inc.|This is a bilateral pilot study including 12 subjects. Subjects will apply the liquor carbonis distillate (LCD) solution to one half of their body, while receiving narrow-band ultraviolet B (NB-UVB) light therapy across their whole body.|2|||f||||f||||||||||2018-06-01 01:58:27.699249|2018-06-01 01:58:27.699249
NCT00708838|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|January 2002||2002-01-31|July 2008|2008-07-31|February 2007|Actual|2007-02-28|January 2006|Actual|2006-01-31||Observational|||Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors|VLA-1 Receptors on Peripheral T Cells in Ischemic Heart Disease Patients|Completed|||151|Actual|Sheba Medical Center|||5||f||||f||||||None Retained|"~     Blood samples isolated from patients included in the study and anallysed by FACS~   "|||2018-06-01 01:58:27.935273|2018-06-01 01:58:27.935273
NCT00708825|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2008-06-30|2008-06-30|2008-07-02|Estimate|||||||2008-06-30|2008-07-02|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Reverse-Loop Upper Arm Arteriovenous Graft|Reverse-Loop Upper Arm Arteriovenous Graft for Chronic Hemodialysis|Suspended|||7|Actual|Far Eastern Memorial Hospital|||1||f||||t||||||Samples Without DNA|"~     prosthetic vascular graft (ePTFE)~   "|||2018-06-01 01:58:27.985746|2018-06-01 01:58:27.985746
NCT00708812|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-21|||2011-07-20|2008-07-01|2008-07-02|Estimate|||||||2011-07-20|2011-07-21|Estimate|July 2007||2007-07-31|July 2011|2011-07-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer|Paclitaxel Plus Carboplatin (TC) Versus TC Plus Endostar in Patients With Advanced Non-small Cell Lung Cancer(NSCLC): a Randomized, Double-blind, Placebo-controlled, Multicentre Study|Completed||Phase 2|126|Actual|Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-06-01 01:58:28.062515|2018-06-01 01:58:28.062515
NCT00708799|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2017-04-19|2008-07-01|2008-07-02|Estimate|||||||2017-04-19|2017-04-21|Actual|November 2007|Actual|2007-11-30|April 2017|2017-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Macrolide Immunomodulation in Severe Sepsis.|Efficacy of Macrolide Immunomodulation in Severe Sepsis|Terminated||Phase 2|100|Anticipated|VA Office of Research and Development||2||Safety evaluation due to recent publications.|f||||f||||||||||2018-06-01 01:58:28.156449|2018-06-01 01:58:28.156449
NCT00293995|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-12-22|2006-02-17|2006-02-20|Estimate|||||||2006-12-22|2006-12-25|Estimate||||December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Minimal Access Repair of Contralateral Hernias (MARCH Trial)||Unknown status|Recruiting|N/A|360||Institute of Child Health|||||f||||||||||||||2018-06-01 04:09:32.768818|2018-06-01 04:09:32.768818
NCT00708786|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-06-30|2008-06-30|2008-07-02|Estimate|||||||2008-06-30|2008-07-02|Estimate|April 2004||2004-04-30|June 2008|2008-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in Implantable Cardioverter-Defibrillator (ICD) Patients|Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in ICD Patients|Completed||Phase 4|755|Anticipated|LivaNova|||||f||||t||||||||||2018-06-01 01:58:28.228081|2018-06-01 01:58:28.228081
NCT00708773|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2017-01-03|2008-07-01|2008-07-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|February 2006||2006-02-28|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors|A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors|Completed||Phase 1|68|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 01:58:28.36697|2018-06-01 01:58:28.36697
NCT00708760|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2012-03-06|2008-06-30|2008-07-02|Estimate|||||||2012-03-06|2012-03-07|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Observational|||Moderate Sedation Educational Software|Moderate Sedation Education Software|Unknown status|Active, not recruiting||80|Anticipated|University of Utah|||2||f||||t||||||||||2018-06-01 01:58:28.429952|2018-06-01 01:58:28.429952
NCT00708747|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|July 1996||1996-07-31|July 2008|2008-07-31|September 2003|Actual|2003-09-30|June 2001|Actual|2001-06-30||Interventional|||Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients|Biseko Versus Albumin in the Treatment of High Risk Patients With Systemic Inflammatory Response Syndrome - a Randomized Controlled Trial|Completed||Phase 4|40|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 01:58:28.491553|2018-06-01 01:58:28.491553
NCT00708734|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2014-10-01||2014-10-21|2008-07-01|2008-07-02|Estimate|2014-10-21|2014-10-23|Estimate||||2014-10-21|2014-10-23|Estimate|July 2008||2008-07-31|October 2014|2014-10-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional||age over 50 and gender|Exercise Intervention to Reduce Postural Instability in Osteoarthritis|Exercise Intervention to Reduce Postural Instability in Osteoarthritis|Completed||N/A|10|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 01:58:28.586755|2018-06-01 01:58:28.586755
NCT00708721|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2016-07-21||2017-05-25|2008-07-01|2008-07-02|Estimate|2017-05-25|2017-06-01|Actual||||2017-05-25|2017-06-01|Actual|March 2008||2008-03-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia|Phase I/II Study of Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (Dysplastic Type) Patients Who Have Failed Hypomethylating Therapy|Terminated||Phase 1/Phase 2|11|Actual|University of Utah||1||Data analysis revealed sufficient data for safety and efficacy|f||||t||||||||||2018-06-01 01:58:28.725416|2018-06-01 01:58:28.725416
NCT00708708|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2014-12-19||2015-07-24|2008-07-01|2008-07-02|Estimate|2015-07-24|2015-07-27|Estimate||||2015-07-24|2015-07-27|Estimate|June 2008||2008-06-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||Safety analysis set included all participants with available post-baseline safety data.|Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings|A Prospective Non-interventional Study (Nis) Of The Routine Use Of Etanercept In The Long-term Treatment Of Patients With Plaque-type Psoriasis In Everyday Practice: An Efficacy, Safety, And Health Economic Evaluation|Completed|||926|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 01:58:29.166953|2018-06-01 01:58:29.166953
NCT00708695|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2016-03-01|2008-07-01|2008-07-02|Estimate|||||||2016-03-01|2016-03-03|Estimate|May 2008||2008-05-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|MemphisY17||Age-17 Follow-up of Home Visiting Intervention|Age-17 Follow-up of Home Visiting Intervention|Completed|||1138|Actual|University of Colorado, Denver|||4||f||||t||||||Samples With DNA|"~     Spit samples will be taken.~   "|||2018-06-01 01:58:30.665103|2018-06-01 01:58:30.665103
NCT00708682|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2011-01-28||2011-10-24|2008-07-01|2008-07-02|Estimate|2011-01-28|2011-02-25|Estimate||||2011-10-24|2011-10-25|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico|A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Mexico|Completed||Phase 3|225|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:58:30.799507|2018-06-01 01:58:30.799507
NCT00708669|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2014-11-04|2008-07-01|2008-07-02|Estimate|||||||2014-11-04|2014-11-05|Estimate|March 2008||2008-03-31|April 2012|2012-04-30||||September 2013|Actual|2013-09-30||Interventional|J-DESsERT®||Japan-Drug Eluting Stents Evaluation; a Randomized Trial|A Japanese Prospective, Randomized, Multi-center Trial Comparing the TAXUS Stent and the CYPHER Stent in Patients With Coronary Artery Disease Eligible for PCI.|Completed||N/A|3500|Anticipated|Associations for Establishment of Evidence in Interventions||2|||f||||t||||||||||2018-06-01 01:58:31.550224|2018-06-01 01:58:31.550224
NCT00708656|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2010-09-16|2008-07-01|2008-07-02|Estimate|||||||2010-09-16|2010-09-17|Estimate|October 2006||2006-10-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|CODA||The Colitis Once Daily Asacol Study|A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.|Completed||Phase 3|213|Actual|Cardiff and Vale University Health Board||2|||f||||t||||||||||2018-06-01 01:58:31.772392|2018-06-01 01:58:31.772392
NCT00708643|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2010-11-01||2015-05-05|2008-07-01|2008-07-02|Estimate|2010-11-01|2010-12-01|Estimate||||2015-05-05|2015-05-21|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Clinical Performance of a New Daily Disposable Contact Lens Worn in an Established Contact Lens Wearing Population||Completed||N/A|80|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-06-01 01:58:31.929213|2018-06-01 01:58:31.929213
NCT00708630|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2012-07-26|2008-07-01|2008-07-02|Estimate|||||||2012-07-26|2012-07-30|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination|The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination|Completed||N/A|100|Actual|University of Auckland, New Zealand||2|||f||||f||||||||||2018-06-01 01:58:32.176621|2018-06-01 01:58:32.176621
NCT00707980|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2013-10-24||2013-10-24|2008-07-01|2008-07-02|Estimate|2013-10-24|2013-12-13|Estimate||||2013-10-24|2013-12-13|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder|A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder|Completed||Phase 3|836|Actual|Takeda||1|||f||||f||||||||||2018-06-01 01:58:51.576065|2018-06-01 01:58:51.576065
NCT00708617|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2014-01-22|2008-07-01|2008-07-02|Estimate|||||||2014-01-22|2014-01-23|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|FIBROMAF||FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease|Non Invasive Diagnostic Methods for Fibrosis in Alcoholic Liver Disease : FIBROSCAN Validation and Comparison of Fibrotest - FIBROSCAN Association With FIBROSCAN Alone|Completed|||227|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 01:58:32.423788|2018-06-01 01:58:32.423788
NCT00708604|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2014-07-02|2008-06-30|2008-07-02|Estimate|||||||2014-07-02|2014-07-04|Estimate|August 2005||2005-08-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes|Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes Using a Sirolimus/Tacrolimus/MMF-Based Immunosuppressive Regimen|Completed||Phase 1|3|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:58:32.499206|2018-06-01 01:58:32.499206
NCT00708591|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2014-01-16|2008-07-01|2008-07-02|Estimate|||||||2014-01-16|2014-01-17|Estimate|October 2004||2004-10-31|January 2014|2014-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Rapamycin Plus Ketoconazole in Advanced Cancers|A Phase Ib Study Administering Rapamycin (Sirolimus) With Ketoconazole in Patients With Advanced Malignancies|Completed||Phase 1|57|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 01:58:32.593054|2018-06-01 01:58:32.593054
NCT00708578|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2011-01-24|2008-06-27|2008-07-02|Estimate|||||||2011-01-24|2011-01-25|Estimate|May 2008||2008-05-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)|Insulin Glargine Combined With Sulfonylurea Versus Metformin in Patients With Type 2 Diabetes: A Randomized, Controlled Trial.|Completed||Phase 4|99|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 01:58:32.665052|2018-06-01 01:58:32.665052
NCT00708565|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude|Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude|Unknown status|Recruiting|Phase 1|50|Anticipated|VA Loma Linda Health Care System|||||f||||f||||||||||2018-06-01 01:58:32.743794|2018-06-01 01:58:32.743794
NCT00708552|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2017-07-24|2012-02-23|2018-02-13|2008-06-30|2008-07-02|Estimate|2017-07-24|2018-02-12|Actual|2012-02-23|2012-02-28|Estimate|2018-02-13|2018-03-12|Actual|July 4, 2008||2008-07-04|July 2017|2017-07-31|March 9, 2010|Actual|2010-03-09|March 1, 2010|Actual|2010-03-01||Interventional||The population used to define the Baseline Characteristics was the Intent-to-Treat (ITT Population) which comprised of all participants randomized to treatment, and who received at least one dose of study medication and who had at least one post baseline assessment.|Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease|Study AZ3110865, a Study Comparing SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease|Completed||Phase 2|576|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 01:58:32.98493|2018-06-01 01:58:32.98493
NCT00708539|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.|A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone.|Unknown status|Recruiting|Phase 4|2686|Anticipated|Nordica Fertility Clinic||2|||f||||t||||||||||2018-06-01 01:58:35.598696|2018-06-01 01:58:35.598696
NCT00708526|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2009-01-30||2016-08-19|2008-06-30|2008-07-02|Estimate|2011-10-18|2011-10-19|Estimate||||2016-08-19|2016-09-28|Estimate|March 2008||2008-03-31|August 2016|2016-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea|Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea|Completed||Phase 2|22|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 01:58:35.728223|2018-06-01 01:58:35.728223
NCT00708513|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2013-10-18|2008-07-01|2008-07-02|Estimate|||||||2013-10-18|2013-10-21|Estimate|December 2003||2003-12-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|Cellsaver||Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.|Phase I/II Evaluation of Intraoperative Autotransfusion Filtration for Major Surgical Oncology Operations|Completed|||98|Actual|University of Louisville|||||f||||t||||||||||2018-06-01 01:58:35.945743|2018-06-01 01:58:35.945743
NCT00708500|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2011-05-13||2017-03-09|2008-06-27|2008-07-02|Estimate|2011-05-13|2011-06-15|Estimate||||2017-03-09|2017-04-07|Actual|August 2008||2008-08-31|March 2017|2017-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)|A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin|Completed||Phase 3|404|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:58:36.037654|2018-06-01 01:58:36.037654
NCT00708487|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|August 1999||1999-08-31|June 2008|2008-06-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|Oxygen||Live Births With Low Oxygen Blastocyst Culture|A Controlled Randomized Trial Evaluating the Effect of Lowered Incubator Oxygen Tension on Live Births in a Predominantly Blastocyst Transfer Program|Completed||N/A|230|Actual|Texas Health Resources||2|||f||||t||||||||||2018-06-01 01:58:36.583466|2018-06-01 01:58:36.583466
NCT00708474|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2012-02-29|2008-06-30|2008-07-02|Estimate|||||||2012-02-29|2012-03-01|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||OsseoFit™ Prospective Data Collection|OsseoFit™ Porous Tissue Matrix™ Prospective Data Collection|Withdrawn||N/A|0|Actual|Zimmer Biomet||2||Planning new study protocol|f||||f||||||||||2018-06-01 01:58:36.652127|2018-06-01 01:58:36.652127
NCT00708461|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2011-12-13||2013-06-17|2008-06-27|2008-07-02|Estimate|2013-06-17|2013-07-18|Estimate||||2013-06-17|2013-07-18|Estimate|January 2006||2006-01-31|June 2013|2013-06-30|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Interventional|HealthWorks||Environmental Intervention for Weight Gain Prevention|Environmental Intervention for Weight Gain Prevention|Completed||N/A|1747|Actual|University of Minnesota - Clinical and Translational Science Institute|The recruitment goal of 6 sites represents only 3% of those initially contacted for participation, or 16% of eligible and interested sites. The design limits power due to the small sample size at the group level.|2|||f||||t||||||||||2018-06-01 01:58:36.710824|2018-06-01 01:58:36.710824
NCT00708448|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2018-05-08|2008-06-27|2008-07-02|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2008||2008-01-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients|Development of an Integrated Molecular Biomarker ofEarly Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients Using Imaging Assessments and Genomic Modeling|Active, not recruiting||Phase 1|26|Actual|University of Utah||1|||f||||t|t|f||||||||2018-06-01 01:58:37.039069|2018-06-01 01:58:37.039069
NCT00708435|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2013-06-07|2011-07-12|2014-01-01|2008-07-01|2008-07-02|Estimate|2013-06-07|2013-08-13|Estimate|2011-07-12|2011-07-14|Estimate|2014-01-01|2014-02-03|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||The Intention-to-treat population comprised all subjects who were (1) eligible for the study and had (2) signed informed consent and were randomized to 1 of the 2 treatment groups regardless of whether the subjects received study product. In the ITT population, subjects were analyzed “as randomized”.|Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy|An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Coumarin Derivatives in Subjects With Acute Major Bleeding|Completed||Phase 3|216|Actual|CSL Behring||2|||f||||||||||||||2018-06-01 01:58:37.168117|2018-06-01 01:58:37.168117
NCT00708422|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2012-03-30||2012-03-30|2008-07-01|2008-07-02|Estimate|2012-03-30|2012-04-23|Estimate||||2012-03-30|2012-04-23|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Travatan Z and Xalatan on Ocular Surface Health|Examination of Ocular Surface Effects With Administration of TRAVATAN Z® and Xalatan®|Completed||Phase 4|231|Actual|Alcon Research|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge (Pflugfelder and Baudoin, 2011).|2|||f||||f||||||||||2018-06-01 01:58:37.891602|2018-06-01 01:58:37.891602
NCT00708409|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2009-02-12|2008-06-27|2008-07-02|Estimate|||||||2009-02-12|2009-02-16|Estimate|January 2001||2001-01-31|January 2009|2009-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Long-Term Follow-up After the Autograft Aortic Valve Procedure (Ross Operation)|Long-Term Follow-up After the Autograft Aortic Valve Procedure (Ross Operation)-the German-Dutch- Ross Registry|Unknown status|Enrolling by invitation||1800|Anticipated|University of Luebeck|||2||f||||f||||||||||2018-06-01 01:58:38.087806|2018-06-01 01:58:38.087806
NCT00708396|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2009-01-26|2008-07-01|2008-07-02|Estimate|||||||2009-01-26|2009-01-27|Estimate|July 2008||2008-07-31|January 2009|2009-01-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study||Unknown status|Recruiting|Phase 4|20|Anticipated|BeerYaakov Mental Health Center||1|||f||||t||||||||||2018-06-01 01:58:38.161783|2018-06-01 01:58:38.161783
NCT00708383|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|September 2001||2001-09-30|June 2008|2008-06-30|November 2003|Actual|2003-11-30|November 2002|Actual|2002-11-30||Interventional|SSS||in Vitro Fertilization (IVF) Media Protein and Live Birth Rates|A Randomized Controlled Study of Human Serum Albumin and Serum Substitute Supplement as Protein Supplements for IVF Culture and the Effect on Live Birth Rates|Completed||N/A|538|Actual|Texas Health Resources||2|||f||||t||||||||||2018-06-01 01:58:38.254285|2018-06-01 01:58:38.254285
NCT00708370|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2011-04-12|2008-06-27|2008-07-02|Estimate|||||||2011-04-12|2011-04-14|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|DISSEMINATE||A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.|An Outcome Research on the Impact of a Disease Management Program (COACH) on the Attainment of Better Cardiovascular Risk Control in Dyslipidemic Patients at Primary Care Centers (DISSEMINATE).|Completed||Phase 4|297|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:58:38.336772|2018-06-01 01:58:38.336772
NCT00708357|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-11-14|2008-06-30|2008-07-02|Estimate|||||||2014-11-14|2014-11-17|Estimate|May 2005||2005-05-31|November 2014|2014-11-30|January 2013|Actual|2013-01-31|December 2009|Actual|2009-12-31||Interventional|||Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?|Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?|Terminated||Early Phase 1|12|Actual|Medical University of Vienna||2|||f||||||||||||||2018-06-01 01:58:38.438337|2018-06-01 01:58:38.438337
NCT00708344|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2010-07-15|2008-06-27|2008-07-02|Estimate|||||||2010-07-15|2010-07-16|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ACTUAL||ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination|Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination: A Comparison of Active and Usual Titration Regimen in the Treatment of Hypertensive Patients Insufficiently Controlled by Monotherapy|Completed||Phase 4|832|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 01:58:38.515124|2018-06-01 01:58:38.515124
NCT00708331|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2008-07-01|2008-06-30|2008-07-02|Estimate|||||||2008-07-01|2008-07-04|Estimate|August 2002||2002-08-31|July 2008|2008-07-31||||May 2007|Actual|2007-05-31||Interventional|||Hydrophilic Acrylic Intraocular Lens|SC25-FOLD Hydrophilic Acrylic Intraocular Lens|Unknown status|Active, not recruiting|N/A|354|Actual|EyeKon Medical, Inc.||1|||f||||t||||||||||2018-06-01 01:58:38.597778|2018-06-01 01:58:38.597778
NCT00708318|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|October 2001||2001-10-31|July 2008|2008-07-31|June 2002|Actual|2002-06-30|November 2001|Actual|2001-11-30||Interventional|||Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects|A Pilot, Phase I, 2-Period, Fasting, Bioavailability, Safety and PK Study Evaluating A Single Dose Intravenous Fentanyl 200 µg) and Single Doses of 2 or 3 mL AeroLEF (Liposome-Encapsulated Fentanyl 500 µg/mL) in Normal Healthy Non Subjects|Completed||Phase 1|6|Actual|YM BioSciences||1|||f||||f||||||||||2018-06-01 01:58:38.669828|2018-06-01 01:58:38.669828
NCT00708305|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2010-09-14|2010-09-14|2014-12-11|2008-07-01|2008-07-02|Estimate|2013-05-02|2013-06-10|Estimate|2013-05-02|2013-06-10|Estimate|2014-12-11|2015-01-01|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes|Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes|Completed||Phase 3|65|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 01:58:38.756135|2018-06-01 01:58:38.756135
NCT00707967|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2016-11-07|2009-09-03|2016-11-07|2008-06-27|2008-07-01|Estimate|2016-11-07|2017-01-06|Estimate|2009-09-03|2009-09-04|Estimate|2016-11-07|2017-01-06|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.|Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine (692342) in HIV-positive Adults.|Completed||Phase 2|37|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 01:58:52.916773|2018-06-01 01:58:52.916773
NCT00708292|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27||2012-05-01|2015-06-30|2008-07-01|2008-07-02|Estimate||||2012-05-01|2012-05-03|Estimate|2015-06-30|2015-07-22|Estimate|July 2008||2008-07-31|June 2015|2015-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.|An Open-label, Multi-center, Phase I-Ib/II Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma.|Completed||Phase 1/Phase 2|29|Actual|Novartis||3|||f||||||||||||||2018-06-01 01:58:39.307692|2018-06-01 01:58:39.307692
NCT00708279|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2011-04-13|2008-07-01|2008-07-02|Estimate|||||||2011-04-13|2011-04-14|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|SOMMA||Study of Osteopathic Manipulation in the Management of Angina|Study of Osteopathic Manipulation in the Management of Angina|Completed||N/A|1|Actual|University of New England||1|||f||||f||||||||||2018-06-01 01:58:39.382757|2018-06-01 01:58:39.382757
NCT00708266|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2008-06-27|2008-06-27|2008-07-02|Estimate|||||||2008-06-27|2008-07-02|Estimate|February 2007||2007-02-28|June 2008|2008-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|TNF4||The Influence of Fatty-Acids on Systemic and Subcutaneous Cytokines|A Mono-Centre Randomized Study to Investigate the Effect of Elevated Plasma Fatty Acid Concentrations on Cytokines in Interstitial Fluid of Subcutaneous Adipose Tissue|Completed||N/A|10|Actual|Medical University of Graz||2|||f||||f||||||||||2018-06-01 01:58:39.441732|2018-06-01 01:58:39.441732
NCT00708253|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2010-04-09|2008-07-01|2008-07-02|Estimate|||||||2010-04-09|2010-04-12|Estimate|June 2008||2008-06-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|SBE_vs_DBE||Single- Versus Double-balloon Enteroscopy in Small Bowel Diagnostics|Single- vs. Double-balloon Enteroscopy in Small Bowel Diagnostics: A Randomized Controlled Single-blind Multicenter Trial|Completed||N/A|150|Anticipated|University Hospital Muenster||2|||f||||t||||||||||2018-06-01 01:58:39.519037|2018-06-01 01:58:39.519037
NCT00708240|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-06-30|2008-06-30|2008-07-02|Estimate|||||||2008-06-30|2008-07-02|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|December 2010|Anticipated|2010-12-31|August 2010|Anticipated|2010-08-31||Interventional|||Treatment Youth With Obsessive-Compulsive Disorder|Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations.|Unknown status|Recruiting|Phase 4|40|Anticipated|University of Ottawa||1|||f||||t||||||||||2018-06-01 01:58:39.648179|2018-06-01 01:58:39.648179
NCT00708227|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2017-12-20||2018-02-20|2008-07-01|2008-07-02|Estimate|2018-02-20|2018-02-21|Estimate||||2018-02-20|2018-02-21|Estimate|September 2007||2007-09-30|February 2018|2018-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Pharmacogenetics of b2-Agonists in Asthma.|Pharmacogenetics of b2-Agonists in Asthma.|Completed|||88|Actual|Nemours Children's Clinic|||4||f||||f||||||Samples With DNA|"~     The purpose of the epigenetic substudy is to collecting blood is for exploratory research~     into epigenetic effects of salmeterol therapy. Blood was collected at Visit 2 and Visit 3.~      Steps:~        -  Obtain informed consent~        -  Label vacutainer tube with patient's study ID number, visit number, date of collection~          (use a sharpee pen)~        -  Collect 10mL blood sample into purple top tube before starting methacholine challenge~          (must be done before any albuterol is given at the visit)~        -  Immediately place tube in crushed ice or in refrigerator~        -  Spin tube; freeze tube with cells for future genotyping/methylation studies; divide~          plasma as equally as possible between the 3 cryotubes, freeze the EDTA tube and 3~          cryotubes.~   "|||2018-06-01 01:58:39.742638|2018-06-01 01:58:39.742638
NCT00708214|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2013-08-08||2013-12-05|2008-07-01|2008-07-02|Estimate|2013-10-21|2013-11-19|Estimate||||2013-12-05|2013-12-30|Estimate|January 2007||2007-01-31|October 2013|2013-10-31||||February 2010|Actual|2010-02-28||Interventional||Treated set (TS). TS consisted of all patients who were dispensed study medication and have taken at least 1 dose of Afatinib.|BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer|A Phase II Study of BIBW 2992 Administration in Patients With Hormone Refractory Metastatic Breast Cancer|Completed||Phase 2|28|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 01:58:40.312546|2018-06-01 01:58:40.312546
NCT00708201|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2013-09-10||2016-01-06|2008-06-27|2008-07-02|Estimate|2015-06-04|2015-07-02|Estimate||||2016-01-06|2016-01-08|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||All study participants|A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy|A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy.|Completed||Phase 4|280|Actual|Cubist Pharmaceuticals LLC||2|||f||||t||||||||||2018-06-01 01:58:41.109142|2018-06-01 01:58:41.109142
NCT00708188|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2013-07-25|2008-06-30|2008-07-02|Estimate|||||||2013-07-25|2013-07-26|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|COCASE||Multidetector Raw CT as a Single Tool in the Setting of Ischemic Stroke|"Evaluation of Multidetector Raw Computerized Tomography in the Etiological Analysis of Acute Ischemic Stroke: the COCASE Protocol."|Completed||N/A|49|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-06-01 01:58:41.980796|2018-06-01 01:58:41.980796
NCT00708175|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2012-01-03||2012-01-03|2008-07-01|2008-07-02|Estimate|2012-01-03|2012-02-03|Estimate||||2012-01-03|2012-02-03|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.|A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment|Completed||Phase 4|156|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:58:42.072269|2018-06-01 01:58:42.072269
NCT00708162|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2014-10-23|2011-08-23|2016-04-21|2008-06-30|2008-07-02|Estimate|2014-10-30|2014-11-06|Estimate|2011-08-23|2011-08-25|Estimate|2016-04-21|2016-05-30|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|December 2010|Actual|2010-12-31||Interventional||Safety Analysis Set: participants who were randomized and received at least one dose of study drug|Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir|A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults|Completed||Phase 3|724|Actual|Gilead Sciences|10 participants from a single study site were excluded from Intent-to-Treat (ITT) Analysis Set due to critical and multiple protocol violations (elvitegravir arm: n = 3; raltegravir arm: n = 7).|2|||f||||t||||||||||2018-06-01 01:58:42.675489|2018-06-01 01:58:42.675489
NCT00234780|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2007-08-15|2005-10-05|2005-10-07|Estimate|||||||2007-08-15|2007-08-16|Estimate|October 1997||1997-10-31|October 2005|2005-10-31|August 2000||2000-08-31|||||Interventional|||In Home Hospital Care Program|In Home Hospital Care Program|Completed||N/A|200||University of Rochester|||||f||||||||||||||2018-06-01 04:25:31.412795|2018-06-01 04:25:31.412795
NCT00708149|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2013-01-06|2008-07-01|2008-07-02|Estimate|||||||2013-01-06|2013-01-08|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial|Phase IV Study of Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial|Completed||Phase 4|120|Actual|Far Eastern Memorial Hospital||2|||f||||f||||||||||2018-06-01 01:58:44.840953|2018-06-01 01:58:44.840953
NCT00708136|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29|||2008-07-01|2008-07-01|2008-07-02|Estimate|||||||2008-07-01|2008-07-02|Estimate|January 2006||2006-01-31|November 2005|2005-11-30|June 2007|Actual|2007-06-30|January 2007|Actual|2007-01-31||Interventional|EWEB||Effect of Water-Exercise on Balance Function of Healthy Elderly Individuals|Effect of Water-Exercise on Balance Function of Healthy Elderly Individuals - A Randomized Control Study|Completed||N/A|37|Actual|Soroka University Medical Center|||||f||||t||||||||||2018-06-01 01:58:44.911602|2018-06-01 01:58:44.911602
NCT00708123|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2010-09-14|2010-09-14|2013-04-18|2008-07-01|2008-07-02|Estimate|2012-10-18|2012-11-19|Estimate|2012-10-18|2012-11-19|Estimate|2013-04-18|2013-04-22|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||In Situ Caries of Fluoride Toothpastes|Comparison of the Clinical Efficacy From the Retention Phase of Fluoride Delivery of Fluoride Toothpastes Using an in Situ Caries Model|Completed||Phase 3|60|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-06-01 01:58:44.975837|2018-06-01 01:58:44.975837
NCT00708110|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2013-08-22|2009-07-22|2013-11-07|2008-06-30|2008-07-02|Estimate|2013-08-22|2013-10-30|Estimate|2009-07-22|2009-08-10|Estimate|2013-11-07|2013-12-05|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults|A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults (ING111521)|Completed||Phase 2|35|Actual|ViiV Healthcare||3|||f||||||||||||||2018-06-01 01:58:45.288631|2018-06-01 01:58:45.288631
NCT00708097|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01|2011-09-15|2011-09-15|2014-12-11|2008-07-01|2008-07-02|Estimate|2013-05-16|2013-06-24|Estimate|2013-05-16|2013-06-24|Estimate|2014-12-11|2015-01-01|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||In Situ Caries Efficacy of Fluoride Toothpastes|Clinical Efficacy of Fluoride Toothpastes Using an in Situ Caries Model|Completed||Phase 3|57|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-06-01 01:58:47.504972|2018-06-01 01:58:47.504972
NCT00708084|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-01||2009-07-31|2012-03-19|2008-07-01|2008-07-02|Estimate||||2009-07-31|2009-08-10|Estimate|2012-03-19|2012-03-20|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents|A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents|Completed||Phase 2|48|Actual|Crucell Holland BV||2|||f||||t||||||||||2018-06-01 01:58:47.986301|2018-06-01 01:58:47.986301
NCT00708071|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2011-10-06|2010-01-13|2012-10-19|2008-06-30|2008-07-02|Estimate|2012-08-14|2012-08-27|Estimate|2010-01-13|2010-01-18|Estimate|2012-10-19|2012-10-23|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety Study of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS VH S/D 4) in Face-Lift Procedures|An Exploratory Phase 2 Clinical Study to Evaluate Efficacy and Safety of the Adjuvant Use of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) in Subjects Undergoing Rhytidectomy|Completed||Phase 2|45|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-06-01 01:58:48.183438|2018-06-01 01:58:48.183438
NCT00708058|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2012-03-19|2008-06-27|2008-07-02|Estimate|||||||2012-03-19|2012-03-20|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|March 2010|Actual|2010-03-31|September 2008|Actual|2008-09-30||Observational|||Use of Defibrillator Information in the Emergency Department|Can Pacemakers, Defibrillators, and Internal Heart Failure Devices Be Used to Evaluate and Guide Management in the Emergency Department?|Completed|||50|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 01:58:49.042261|2018-06-01 01:58:49.042261
NCT00708045|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2017-08-31|2008-06-27|2008-07-02|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2007||2007-05-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|February 2015|Actual|2015-02-28||Interventional|Chemobrain||A Multi-modality Imaging Assessment of Chemobrain|A Multi-modality Imaging Assessment of Chemobrain|Active, not recruiting||N/A|34|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:58:49.108794|2018-06-01 01:58:49.108794
NCT00708032|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2011-11-03||2015-05-05|2008-06-27|2008-07-02|Estimate|2011-11-03|2011-12-08|Estimate||||2015-05-05|2015-05-21|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||There were 74 subjects enrolled with 48 completing the study.|Clinical Performance of a New Daily Disposable Contact Lens Worn in a Neophyte Population.|Clinical Performance of a New Daily Disposable Contact Lens Worn in a Neophyte Population.|Completed||N/A|74|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 01:58:49.210566|2018-06-01 01:58:49.210566
NCT00708019|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2015-01-22||2016-04-01|2008-07-01|2008-07-02|Estimate|2016-04-01|2016-05-05|Estimate||||2016-04-01|2016-05-05|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Improving Cancer Pain Management Through Self-Care|Improving Cancer Pain Management Through Self-Care|Completed||N/A|185|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 01:58:49.549549|2018-06-01 01:58:49.549549
NCT00708006|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2013-11-05|2008-06-30|2008-07-02|Estimate|||||||2013-11-05|2013-11-07|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors|A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors|Completed||Phase 1|66|Actual|Human Genome Sciences Inc.||1|||f||||f||||||||||2018-06-01 01:58:49.847417|2018-06-01 01:58:49.847417
NCT00707993|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2013-02-17||2013-05-22|2008-06-27|2008-07-02|Estimate|2013-05-22|2013-05-24|Estimate||||2013-05-22|2013-05-24|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics|A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects With Type 2 Diabetes|Completed||Phase 3|441|Actual|Takeda||2|||f||||f||||||||||2018-06-01 01:58:49.978865|2018-06-01 01:58:49.978865
NCT00707954|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2014-03-26||2014-03-26|2008-06-27|2008-07-01|Estimate|2014-03-26|2014-04-28|Estimate||||2014-03-26|2014-04-28|Estimate|June 2008||2008-06-30|March 2014|2014-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients|A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|61|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 01:58:55.099396|2018-06-01 01:58:55.099396
NCT00707941|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29|||2011-07-11|2008-06-30|2008-07-01|Estimate|||||||2011-07-11|2011-07-12|Estimate|May 2008||2008-05-31|June 2008|2008-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Oseltamivir Randomised Controlled Efficacy Trial|Efficacy of Oseltamivir in Reducing the Duration of Clinical Illness, Viral Shedding, and Transmissibility Reduction Within Households Among Participants in an Influenza Disease Burden Surveillance Cohort in Urban Dhaka, Bangladesh|Completed||Phase 3|700|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-06-01 01:58:55.581917|2018-06-01 01:58:55.581917
NCT00707928|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-28|||2011-03-06|2008-06-30|2008-07-01|Estimate|||||||2011-03-06|2011-03-08|Estimate|February 2008||2008-02-29|June 2008|2008-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study|Intravenous Nitroglycerin for Retained Placenta Extraction: a Multicenter Study|Completed||Phase 4|100|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 01:58:55.764556|2018-06-01 01:58:55.764556
NCT00707915|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2011-07-20||2012-03-24|2008-06-30|2008-07-01|Estimate|2012-02-20|2012-03-26|Estimate||||2012-03-24|2012-03-27|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons|Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons: a Pilot Study|Completed||Phase 4|30|Actual|Minamihanno Hospital||1|||f||||f||||||||||2018-06-01 01:58:55.859501|2018-06-01 01:58:55.859501
NCT00707902|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2008-06-30|2008-06-30|2008-07-01|Estimate|||||||2008-06-30|2008-07-01|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|August 2006||2006-08-31|||||Interventional|||Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray Compared to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats|Multicentric Randomized Double Blind Double Dummy Placebo Controlled Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray in Comparison to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats|Completed||Phase 3|154|Actual|Bioforce AG||2|||f||||t||||||||||2018-06-01 01:58:56.124824|2018-06-01 01:58:56.124824
NCT00707889|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27||2013-05-07|2013-05-07|2008-06-27|2008-07-01|Estimate||||2013-05-07|2013-05-15|Estimate|2013-05-07|2013-05-15|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer|An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment of Subjects With Advanced Colorectal Cancer|Completed||Phase 2|159|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 01:58:56.24201|2018-06-01 01:58:56.24201
NCT00707876|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2016-09-19|2008-06-30|2008-07-01|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2008||2008-09-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|July 2010|Actual|2010-07-31||Interventional|||Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)|A Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA Versus Ferumoxytol Vascular Enhanced MRI (VE-MRI) for the Detection of Clinically Significant Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in Subjects With Peripheral Arterial Disease Scheduled for Digital Subtraction Angiography (DSA)|Active, not recruiting||Phase 2|108|Anticipated|AMAG Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 01:58:56.432012|2018-06-01 01:58:56.432012
NCT00707863|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|2016-07-12||2016-08-23|2008-06-30|2008-07-01|Estimate|2016-08-23|2016-10-17|Estimate||||2016-08-23|2016-10-17|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram|fMRI and Genotype Markers of Antidepressant Side Effects and Response in Young Adults Compare to Older Adults|Completed||Phase 4|17|Actual|Indiana University|Small number of subjects were studied|2|||f||||f||||||||No||2018-06-01 01:58:56.512572|2018-06-01 01:58:56.512572
NCT00707850|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2010-08-30|2008-06-30|2008-07-01|Estimate|||||||2010-08-30|2010-08-31|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection|A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Thalassemic Patients With Chronic Hepatitis C Infection|Completed||Phase 4|300|Anticipated|Baqiyatallah Medical Sciences University||1|||f||||t||||||||||2018-06-01 01:58:56.920302|2018-06-01 01:58:56.920302
NCT00707837|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2009-04-24|2008-06-27|2008-07-01|Estimate|||||||2009-04-24|2009-04-27|Estimate|May 2005||2005-05-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Nutritional Study in Preterm Infants|Effect of Supplemental Infant Formula on Blood Levels in Preterm Infants|Completed||Phase 3|206|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-06-01 01:58:57.057308|2018-06-01 01:58:57.057308
NCT00707824|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29|||2008-07-07|2008-06-29|2008-07-01|Estimate|||||||2008-07-07|2008-07-08|Estimate|June 2000||2000-06-30|February 2006|2006-02-28|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||Epidural Nalbuphine for Postcesarean Epidural Morphine Induced Pruritus|Study of Epidural Nalbuphine for Prevention of Epidural Morphine Induced Pruritus|Completed||Phase 4|165|Actual|Mahidol University||3|||f||||f||||||||||2018-06-01 01:58:57.153222|2018-06-01 01:58:57.153222
NCT00707811|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2008-06-27|2008-06-27|2008-07-01|Estimate|||||||2008-06-27|2008-07-01|Estimate|April 2008||2008-04-30|June 2008|2008-06-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Observational|||Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing|Evaluation of ST2 and IL-33 for Risk Stratification and Diagnosis in Patients Presenting to the Emergency Department With Dyspnea|Unknown status|Recruiting||200|Anticipated|The Cleveland Clinic|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:58:57.26086|2018-06-01 01:58:57.26086
NCT00707798|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2017-05-09|2008-06-30|2008-07-01|Estimate|||||||2017-05-09|2017-05-10|Actual|June 30, 2008|Actual|2008-06-30|May 2017|2017-05-31|January 15, 2009|Actual|2009-01-15|January 15, 2009|Actual|2009-01-15||Interventional|||Evaluation of Pneumococcal Vaccine Formulations in Young Adults|A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189242A) in Young Adults.|Completed||Phase 1|157|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:58:57.370878|2018-06-01 01:58:57.370878
NCT00707785|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2013-09-24|2008-06-27|2008-07-01|Estimate|||||||2013-09-24|2013-09-25|Estimate|December 2006||2006-12-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis|Effect of Vitamin A in the Treatment of Sepsis and Necrotizing Enterocolitis in Hospitalized Neonates|Completed||Phase 3|424|Actual|Johns Hopkins University||4|||f||||t||||||||||2018-06-01 01:58:57.487168|2018-06-01 01:58:57.487168
NCT00707772|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2009-09-16|2008-06-27|2008-07-01|Estimate|||||||2009-09-16|2009-09-17|Estimate|March 2007||2007-03-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection|A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection|Completed||Phase 4|400|Anticipated|Baqiyatallah Medical Sciences University||2|||f||||t||||||||||2018-06-01 01:58:57.589693|2018-06-01 01:58:57.589693
NCT00707759|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2015-10-13||2015-10-13|2008-06-27|2008-07-01|Estimate|2015-10-13|2015-11-10|Estimate||||2015-10-13|2015-11-10|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection|Multicenter, Open-Label, Randomized Study on Steroid-Free Immunosuppression, in Comparison With Daily Steroid Therapy, in Pediatric Renal Transplant : Impact on Growth, Bone Metabolism and Acute Rejection|Completed||Phase 3|28|Actual|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile||2|||f||||t||||||||||2018-06-01 01:58:57.71735|2018-06-01 01:58:57.71735
NCT00707746|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2013-02-25|2011-02-17|2016-08-01|2008-06-30|2008-07-01|Estimate|2013-02-25|2013-04-05|Estimate|2011-02-17|2011-02-23|Estimate|2016-08-01|2016-09-09|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|ASSIST||Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects|A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of ISIS 301012 Administration in High Risk Statin Intolerant Subjects|Completed||Phase 2|34|Actual|Kastle Therapeutics, LLC||2|||f||||f||||||||||2018-06-01 01:58:57.957338|2018-06-01 01:58:57.957338
NCT00707720|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2013-04-09|2008-06-30|2008-07-01|Estimate|||||||2013-04-09|2013-04-10|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Multi-Center Feasibility Study of Trans-oral Endoscopic Restrictive Implant System (TERIS) for Treatment of Obesity|Multi-center Feasibility Study to Evaluate the Safety of the Trans-oral Endoscopic Restrictive Implant System (TERIS) for the Treatment of Obesity|Completed||Phase 1|40|Actual|BaroSense Inc.||1|||f||||f||||||||||2018-06-01 01:58:59.247872|2018-06-01 01:58:59.247872
NCT00707707|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2018-03-05|2008-06-27|2008-07-01|Estimate|||||||2018-03-05|2018-03-06|Actual|September 15, 2008|Actual|2008-09-15|February 2018|2018-02-28|February 19, 2018|Actual|2018-02-19|November 9, 2009|Actual|2009-11-09||Interventional|||Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer|Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Given in Combination With Paclitaxel in the 1st or 2nd Line Treatment of Patients With Metastatic Triple Negative Breast Cancer.|Completed||Phase 1|19|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 01:58:59.318945|2018-06-01 01:58:59.318945
NCT00707694|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2009-01-29|2008-06-30|2008-07-01|Estimate|||||||2009-01-29|2009-01-30|Estimate|July 1998||1998-07-31|January 2009|2009-01-31||||||||Observational|||The Longevity Genes in Founder Populations Project|Searching for Longevity Genes in the Historically Unique Ashkenazi Jewish Population|Unknown status|Recruiting||1500|Anticipated|Albert Einstein College of Medicine, Inc.|||3||f||||t||||||||||2018-06-01 01:58:59.412928|2018-06-01 01:58:59.412928
NCT00707681|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2010-02-24|2008-06-30|2008-07-01|Estimate|||||||2010-02-24|2010-02-26|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)|A Phase II Randomized, Controlled Study to Evaluate the Quality of Life, Survival and Therapeutic Benefits of MS-20 in Patient With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|60|Anticipated|Microbio Co Ltd||2|||f||||t||||||||||2018-06-01 01:58:59.478318|2018-06-01 01:58:59.478318
NCT00707668|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2014-07-25|2008-06-27|2008-07-01|Estimate|||||||2014-07-25|2014-07-28|Estimate|May 2007||2007-05-31|July 2014|2014-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|||Chung-ju Metabolic Disease Cohort (CMC) Study|Chung-ju Metabolic Disease Cohort (CMC) Study|Unknown status|Recruiting||10000|Anticipated|The Catholic University of Korea|||1||f||||f||||||Samples With DNA|"~     Plasma Serum Whole blood Urine~   "|||2018-06-01 01:58:59.576765|2018-06-01 01:58:59.576765
NCT00707655|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2011-10-07||2011-11-21|2008-06-30|2008-07-01|Estimate|2011-11-21|2011-12-23|Estimate||||2011-11-21|2011-12-23|Estimate|September 2008||2008-09-30|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy|An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy|Terminated||Phase 1/Phase 2|8|Actual|Genmab|All adverse events were collected during the 8 week treatment period and for 4 additional weeks. Serious adverse events were collected for the extended follow-up period of 2 years.|2||The decision is based on company re-evaluation of indications to be pursued within SCCHN|f||||t||||||||||2018-06-01 01:58:59.754921|2018-06-01 01:58:59.754921
NCT00707642|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29|||2009-06-13|2008-06-29|2008-07-01|Estimate|||||||2009-06-13|2009-06-16|Estimate|May 2008||2008-05-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety Study of HBV-002 West Nile Vaccine in Healthy Adults|Phase 1, Open-Label, Safety Study of HBV-002 (West Nile Recombinant Subunit Vaccine) in Healthy Adults|Completed||Phase 1|25|Actual|Hawaii Biotech, Inc.||4|||f||||t||||||||||2018-06-01 01:59:00.537519|2018-06-01 01:59:00.537519
NCT00707629|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2016-02-29|2008-06-30|2008-07-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|August 2005||2005-08-31|February 2016|2016-02-29|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Long Term Effects of Diabetes of Very Young Children|Long Term Effects of Diabetes of Very Young Children|Completed|||25|Actual|Indiana University|||1||f||||f||||||||||2018-06-01 01:59:00.826696|2018-06-01 01:59:00.826696
NCT00707616|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2013-01-18|2008-06-30|2008-07-01|Estimate|||||||2013-01-18|2013-01-23|Estimate|March 2006||2006-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Common Genetic Variation and Type 2 Diabetes|The Effect of Diabetes-associated Gene Variation on Glucose Metabolism in Humans|Completed|||190|Actual|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     Samples for hormone measurement and DNA extraction~   "|||2018-06-01 01:59:01.038166|2018-06-01 01:59:01.038166
NCT00707603|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-29|||2015-07-13|2008-06-30|2008-07-01|Estimate|||||||2015-07-13|2015-07-14|Estimate|May 2006||2006-05-31|July 2015|2015-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Chronic Hepatitis C and Insulin Resistance|Understanding the Relationship Between Insulin Resistance and Chronic Hepatitis C Infection|Completed|||50|Actual|Garvan Institute of Medical Research|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 01:59:01.091637|2018-06-01 01:59:01.091637
NCT00707590|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2009-02-09|2008-06-30|2008-07-01|Estimate|||||||2009-02-09|2009-02-10|Estimate|August 2008||2008-08-31|February 2009|2009-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)|Randomized, Double-Blind, Placebo-Controlled Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 1|120|Anticipated|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:59:01.147639|2018-06-01 01:59:01.147639
NCT00707577|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2017-03-21||2017-03-21|2008-06-27|2008-07-01|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|February 2008||2008-02-29|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Maintenance Program for the Be Fit Employee Wellness Program|A Randomized Controlled Trial of a Maintenance Program for the Be Fit Employee Wellness Program at Massachusetts General Hospital|Completed||N/A|330|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:59:01.210229|2018-06-01 01:59:01.210229
NCT00707564|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2012-09-20|2008-06-30|2008-07-01|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of Hemostatic Efficacy of the HemCon Dental Dressing in a Population Treated With Anticoagulant Medications|A Randomized, Self-Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing in a Population Treated With Anticoagulant Medications|Withdrawn||N/A|0|Actual|HemCon Medical Technologies, Inc||2||unable to enroll patient population|f||||f||||||||||2018-06-01 01:59:01.590391|2018-06-01 01:59:01.590391
NCT00707551|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2010-12-02|2008-06-27|2008-07-01|Estimate|||||||2010-12-02|2010-12-03|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||An Interaction Study of Ketoconazole/Verapamil Versus AZD1305|A Phase I, Single-centre, Randomised, Open, Three-way Crossover Study to Evaluate the Effect of Ketoconazole and Verapamil, Respectively, on the Pharmacokinetics of AZD1305 After Repeated Oral Adm of Ketoconazole and Verapamil and Single Oral Dosing of AZD1305 to Young Healthy Male Volunteers|Completed||Phase 1|27|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 01:59:01.670431|2018-06-01 01:59:01.670431
NCT00707538|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2011-08-17|2008-06-30|2008-07-01|Estimate|||||||2011-08-17|2011-08-18|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress|A Phase I Dosimetry, Biodistribution and Safety Study of BMS747158 in Healthy Subjects Undergoing 2-Day Rest/Stress Positron Emission Tomography|Completed||Phase 1|12|Actual|Lantheus Medical Imaging||1|||f||||t||||||||||2018-06-01 01:59:01.742776|2018-06-01 01:59:01.742776
NCT00707525|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-30|||2010-03-25|2008-06-30|2008-07-01|Estimate|||||||2010-03-25|2010-03-26|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Embryo Aneuploidies and Ovarian Stimulation|Incidence of EmbyoO Aneuploidies in Natural Versus Stimulated Cycles in the Same Women.|Completed||Phase 4|||Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 01:59:01.813494|2018-06-01 01:59:01.813494
NCT00707512|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2015-07-16|2008-06-30|2008-07-01|Estimate|||||||2015-07-16|2015-07-20|Estimate|June 2008||2008-06-30|June 2015|2015-06-30|August 2050|Anticipated|2050-08-31|August 2050|Anticipated|2050-08-31||Observational|INFORM||CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring|INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring|Terminated|||87|Actual|Biogen||||Sponsor's decision.|f||||f||||||||||2018-06-01 01:59:01.890614|2018-06-01 01:59:01.890614
NCT00707499|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2011-10-14|2008-06-30|2008-07-01|Estimate|||||||2011-10-14|2011-10-17|Estimate|September 2007||2007-09-30|October 2011|2011-10-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158|A Single-Dose, Phase I, Dosimetry, Biodistribution, and Safety Trial of BMS 747158 in Healthy Subjects|Completed||Phase 1|13|Actual|Lantheus Medical Imaging||1|||f||||t||||||||||2018-06-01 01:59:02.007214|2018-06-01 01:59:02.007214
NCT00707486|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2010-04-02||2012-12-06|2008-06-27|2008-07-01|Estimate|2012-12-06|2013-01-09|Estimate||||2012-12-06|2013-01-09|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|||A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing|A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing|Completed||Phase 3|72|Actual|HemCon Medical Technologies, Inc||2|||f||||f||||||||||2018-06-01 01:59:02.156474|2018-06-01 01:59:02.156474
NCT00707473|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2017-08-25|2008-06-27|2008-06-30|Estimate|||||||2017-08-25|2017-08-28|Actual|June 2008|Actual|2008-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses|Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses|Recruiting||Phase 2|45|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 01:59:02.378181|2018-06-01 01:59:02.378181
NCT00707460|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2010-01-18|2008-06-27|2008-06-30|Estimate|||||||2010-01-18|2010-01-20|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SLHDP||The Effect of a Traditional Dietary Intervention on Diabetes Mellitus and Cardiovascular Disease Risk Factors in a First Nation Community: A Pilot Study|Objective 3: Pilot Dietary Trial; The Sandy Lake Health & Diabetes Project (SLHDP): Understanding and Addressing Metabolic Syndrome, Diabetes and Associated Complications in Aboriginal Canadians|Completed||Phase 1|60|Anticipated|University of Toronto||3|||f||||f||||||||||2018-06-01 01:59:02.475614|2018-06-01 01:59:02.475614
NCT00707447|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2012-09-03||2014-08-08|2008-06-27|2008-06-30|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-08|2014-08-25|Estimate|April 2004||2004-04-30|August 2014|2014-08-31|May 2008|Actual|2008-05-31|December 2005|Actual|2005-12-31||Interventional|PREDIAS||Evaluation of a Primary Type 2 Diabetes Prevention Programme|Evaluation of a Teaching and Treatment Programme for Primary Prevention of Type 2 Diabetes|Completed||Phase 4|182|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||||2018-06-01 01:59:02.583031|2018-06-01 01:59:02.583031
NCT00707434|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2016-09-28|2008-06-26|2008-06-30|Estimate|||||||2016-09-28|2016-09-29|Estimate|June 2008||2008-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Continuous Glucose Monitoring in Critically Ill|Continuous Glucose Monitoring Device Compared With Point-of-Care Glucose Testing in the ICU|Terminated||N/A|6|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 01:59:02.973297|2018-06-01 01:59:02.973297
NCT00707421|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2009-05-28|2008-06-27|2008-06-30|Estimate|||||||2009-05-28|2009-05-29|Estimate|July 2005||2005-07-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes|A Randomized Clinical Trial Comparing Preoperative Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Compared to Placebo With Regard to Clinical Outcomes Following Trabeculectomy.|Completed||Phase 3|62|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||||||||||||2018-06-01 01:59:03.076707|2018-06-01 01:59:03.076707
NCT00707408|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2009-01-30|2008-06-27|2008-06-30|Estimate|||||||2009-01-30|2009-02-02|Estimate|February 2004||2004-02-29|January 2009|2009-01-31|January 2009|Actual|2009-01-31|||||Interventional|||High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)|A Phase II Trial Evaluating the Safety and the Efficacy of High-Dose Imatinib in Relapsed/Refractory c-Kit Positive and BCR-Abl Negative AML Patients|Completed||Phase 2|15|Actual|Nantes University Hospital|||||f||||f||||||||||2018-06-01 01:59:03.142213|2018-06-01 01:59:03.142213
NCT00707382|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2012-02-09|2008-06-27|2008-06-30|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment|A Three-armed Randomised Controled Trial on the Effect of Genotyping for CYP450 Polymorphisms and Intense Clinical Monitoring on Antipsychotic Drug Treatment.|Completed||N/A|311|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-06-01 01:59:03.199277|2018-06-01 01:59:03.199277
NCT00707369|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2015-03-02|2008-06-27|2008-06-30|Estimate|||||||2015-03-02|2015-03-03|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|ABPARO-Studie||Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization|Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization|Completed||Phase 4|540|Actual|University Hospital Muenster||2|||f||||t||||||||||2018-06-01 01:59:03.268569|2018-06-01 01:59:03.268569
NCT00707356|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2016-04-17|2008-06-27|2008-06-30|Estimate|||||||2016-04-17|2016-04-19|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|||Study of WST11 in Patients With Localized Prostate Cancer|Vascular-Targeted Photodynamic Therapy Using WST 11 in Patients With Localized Prostate Cancer|Completed||Phase 2|42|Actual|Steba Biotech S.A.||1|||f||||t||||||||Yes|The data are available in case report form for each patient|2018-06-01 01:59:03.353667|2018-06-01 01:59:03.353667
NCT00707343|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2015-10-14||2016-01-04|2008-06-27|2008-06-30|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|May 2007||2007-05-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors|Preliminary Evaluation of the Efficacy of [F-18] Fluorothymidine (FLT) to Differentiate Radiation Necrosis From Tumor Recurrence and as a Marker of Proliferation in Patients With Primary Brain Tumors|Completed||Phase 1|15|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:59:03.435792|2018-06-01 01:59:03.435792
NCT00707330|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-08-08|2008-06-27|2008-06-30|Estimate|||||||2008-08-08|2008-08-11|Estimate|May 2008||2008-05-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|CLAROX||Study of the Ability of Clarithromycin to Induce Oxidative Stress|A Randomized, Single Blinded, Open-Label Crossover-Study of the Possible Induction of Oxidative Stress by Clarithromycin in Healthy Subjects|Completed||Phase 1|26|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 01:59:03.55163|2018-06-01 01:59:03.55163
NCT00707317|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2015-12-15|2008-06-27|2008-06-30|Estimate|||||||2015-12-15|2015-12-16|Estimate|June 2008||2008-06-30|December 2015|2015-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|TBNET-TIPS||T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals|Prospective Head-to-head Comparison of the Two Commercially Available Approved TIGRA (QuantiFERON-TB Gold In-Tube and T.SPOT.TB) With the Established Mendel-Mantoux Skin-test in Immunocompromized Patients|Completed|||1843|Actual|Tuberculosis Network European Trialsgroup|||7||f||||f||||||Samples Without DNA|"~     Plasma supernatants of stimulated samples for cytokine analysis.~   "|||2018-06-01 01:59:03.636633|2018-06-01 01:59:03.636633
NCT00707304|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26||2012-08-13|2012-08-13|2008-06-26|2008-06-30|Estimate||||2012-08-13|2012-08-21|Estimate|2012-08-13|2012-08-21|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|March 2011|Actual|2011-03-31||Interventional|FORTIS-M||Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer|FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens|Completed||Phase 3|742|Actual|Agennix||2|||f||||t||||||||||2018-06-01 01:59:03.765464|2018-06-01 01:59:03.765464
NCT00707291|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-07-04|2008-06-27|2008-06-30|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2008||2008-07-31|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface|Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface|Completed|||61|Actual|University of Miami|||||f||||f||||||||||2018-06-01 01:59:04.170765|2018-06-01 01:59:04.170765
NCT00707278|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-10-29|2008-06-27|2008-06-30|Estimate|||||||2014-10-29|2014-10-31|Estimate|September 2005||2005-09-30|October 2014|2014-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma|A Prospective Phase I Study of Radiation Therapy and Concurrent Capecitabine and Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma|Completed||Phase 1|13|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:59:04.226776|2018-06-01 01:59:04.226776
NCT00707265|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2013-08-01|2008-06-27|2008-06-30|Estimate|||||||2013-08-01|2013-08-02|Estimate|March 2002||2002-03-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|May 2005|Actual|2005-05-31||Interventional|CRM||rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study|A Prospective, Randomized Clinical Investigation of rhBMP-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease|Completed||Phase 3|463|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 01:59:04.367393|2018-06-01 01:59:04.367393
NCT00543491|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-11|2007-10-12|2007-10-15|Estimate|||||||2015-06-11|2015-06-12|Estimate|May 2003||2003-05-31|June 2015|2015-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||MK0767 and Sulfonylurea Combination Study (0767-027)||Terminated||Phase 3|129|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:14.47534|2018-06-01 02:51:14.47534
NCT00707252|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2015-04-20|2008-06-27|2008-06-30|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer|Phase I/II Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer|Terminated||Phase 1|11|Actual|Louisiana State University Health Sciences Center Shreveport||1||Phase II not initiated due to cancellation of supply of Poly E by collaborator.|f||||t||||||||||2018-06-01 01:59:04.492732|2018-06-01 01:59:04.492732
NCT00707239|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2012-06-05||2012-06-05|2008-06-27|2008-06-30|Estimate|2012-06-05|2012-07-10|Estimate||||2012-06-05|2012-07-10|Estimate|December 2008||2008-12-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia|A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study Of The Safety And Efficacy of 2 Doses Of Tigecycline Versus Imipenem/Cilastatin For The Treatment Of Subjects With Hospital-Acquired Pneumonia|Terminated||Phase 2|108|Actual|Pfizer|Formal statistical conclusions could not be made due to premature termination of study, because of enrollment difficulties, and small number of enrolled participants.|3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 01:59:04.643881|2018-06-01 01:59:04.643881
NCT00707226|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-06-27|2008-06-27|2008-06-30|Estimate|||||||2008-06-27|2008-06-30|Estimate|November 2000||2000-11-30|June 2008|2008-06-30|December 2001|Actual|2001-12-31|||||Observational|||Circadian Variations in Ocular Blood Flow in Glaucomatous and Normal Eyes|Circadian Variations in Ocular Blood Flow in Glaucomatous and Normal Eyes|Completed|||30|Actual|Medical University of Vienna|||2||f||||||||||||||2018-06-01 01:59:05.559114|2018-06-01 01:59:05.559114
NCT00707213|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2016-06-07|2008-06-27|2008-06-30|Estimate|||||||2016-06-07|2016-06-09|Estimate|August 2007||2007-08-31|June 2016|2016-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients|FDG-PET/CT In the Evaluation of Persistent Febrile Neutropenia in Cancer Patients|Terminated||N/A|19|Actual|University of Utah||1||Funding from the NIH ended and not all patients had been accrued|f||||t||||||||||2018-06-01 01:59:05.61051|2018-06-01 01:59:05.61051
NCT00707200|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2010-01-22|2008-06-27|2008-06-30|Estimate|||||||2010-01-22|2010-01-26|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|CPM||The Cytoadherence in Pediatric Malaria (CPM) Study|Clinical Outcomes in Pediatric Plasmodium Falciparum Malaria According to Host Cytoadherence Factors|Completed|||2000|Anticipated|University Health Network, Toronto|||2||f||||f||||||Samples With DNA|"~     Freshly frozen citrated plasma aliquots, frozen spun red cell pellets, and whole blood blots~     onto nucleic acid storage cards (Whatman FTA).~   "|||2018-06-01 01:59:05.676075|2018-06-01 01:59:05.676075
NCT00707187|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2008-06-27|2008-06-27|2008-06-30|Estimate|||||||2008-06-27|2008-06-30|Estimate|July 2001||2001-07-31|June 2008|2008-06-30|July 2002||2002-07-31|July 2002||2002-07-31||Interventional|||Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction|Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis|Completed||Phase 2|120|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 01:59:05.738048|2018-06-01 01:59:05.738048
NCT00707174|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2012-06-04||2013-07-23|2008-06-27|2008-06-30|Estimate|2012-07-11|2012-08-20|Estimate||||2013-07-23|2013-07-31|Estimate|March 2005||2005-03-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna|Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna|Completed||N/A|90|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 01:59:05.811437|2018-06-01 01:59:05.811437
NCT00707161|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2011-04-20||2017-03-01|2008-06-27|2008-06-30|Estimate|2012-03-06|2012-04-04|Estimate||||2017-03-01|2017-03-31|Actual|September 2005||2005-09-30|March 2017|2017-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma|A Prospective Phase II Study of Radiation Therapy and Concurrent Cisplatin Chemotherapy in the Treatment of Locally Advanced or Metastatic Malignant Melanoma|Terminated||Phase 2|6|Actual|University of Utah|Early termination due to low enrollment.|1||discontinued due to low enrollment|f||||t||||||||No||2018-06-01 01:59:06.175263|2018-06-01 01:59:06.175263
NCT00707148|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-07-24|2008-06-26|2008-06-30|Estimate|||||||2014-07-24|2014-07-25|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pertussis Vaccine in Healthy Pregnant Women|Safety and Immunogenicity of Tdap Vaccine in Healthy Pregnant Women, Safety in Their Neonates, and Effect of Maternal Immunization on Infant Immune Responses to DTaP Vaccine|Completed||Phase 1|80|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 01:59:06.305199|2018-06-01 01:59:06.305199
NCT00707135|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-01-16|2008-06-26|2008-06-30|Estimate|||||||2014-01-16|2014-01-17|Estimate|June 2005||2005-06-30|January 2014|2014-01-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Rapamycin in Advanced Cancers|A Phase Ib Study of Rapamycin (Sirolimus) in Patients With Advanced Malignancies|Completed||Phase 1|40|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 01:59:06.386174|2018-06-01 01:59:06.386174
NCT00707122|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2015-11-07|2008-06-27|2008-06-30|Estimate|||||||2015-11-07|2015-11-10|Estimate|July 2008||2008-07-31|November 2015|2015-11-30|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|ALBIOS||Volume Replacement With Albumin in Severe Sepsis|Efficacy of Albumin Administration for Volume Replacement in Patients With Severe Sepsis or Septic Shock - the ALBumin Italian Outcome Sepsis (ALBIOS) Study|Completed||Phase 3|1818|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||t||||||||||2018-06-01 01:59:06.465656|2018-06-01 01:59:06.465656
NCT00707083|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|||2018-04-04|2008-06-27|2008-06-30|Estimate|||||||2018-04-04|2018-04-06|Actual|May 1, 2008|Actual|2008-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia|A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008.|Active, not recruiting||Phase 3|2500|Anticipated|Prince of Wales Hospital, Shatin, Hong Kong||2|||f||||f||||||||No||2018-06-01 01:59:06.546279|2018-06-01 01:59:06.546279
NCT00707070|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-06-27|2008-06-27|2008-06-30|Estimate|||||||2008-06-27|2008-06-30|Estimate|September 2008||2008-09-30|June 2008|2008-06-30|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|CobAcE||Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis|Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Universita di Verona||2|||f||||f||||||||||2018-06-01 01:59:06.638315|2018-06-01 01:59:06.638315
NCT00707057|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2009-05-21||2011-03-22|2008-06-26|2008-06-30|Estimate|2011-03-17|2011-03-23|Estimate||||2011-03-22|2011-03-24|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Ibuprofen Extended-Release Dental Pain Study|Ibuprofen 600 mg Extended-Release (ER) Multiple-Dose Dental Pain Study|Completed||Phase 3|256|Actual|SCOLR Pharma, Inc.|Of the 12 subjects who prematurely discontinued all 4 doses of the study drug, 6 subjects received 1 dose of study drug, 2 subjects received 2 doses, and 4 subjects received 3 doses.|2|||f||||f||||||||||2018-06-01 01:59:06.723948|2018-06-01 01:59:06.723948
NCT00707044|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2017-02-22|2008-06-27|2008-06-30|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2001||2001-01-31|June 2008|2008-06-30|May 2004|Actual|2004-05-31|October 2003|Actual|2003-10-31||Interventional|||Short-Stay Intensive Care for Coronary Artery Bypass Patients|Short-Stay Intensive Care for Coronary Artery Bypass Patients,Development of a Guideline for Giving Adequate Care on the Cardiosurgical Intensive Care|Completed||Phase 3|597|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 01:59:07.195271|2018-06-01 01:59:07.195271
NCT00707031|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2016-08-18|2012-02-01|2016-10-20|2008-06-26|2008-06-30|Estimate|2016-08-18|2016-10-11|Estimate|2012-02-01|2012-02-03|Estimate|2016-10-20|2016-12-02|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|GETGOAL-X|Safety population included all randomized patients who received at least 1 dose of study drug, regardless of the amount of treatment administered. In addition, 5 patients from one site with serious noncompliance issues were excluded from all analysis populations.|GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin|A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin|Completed||Phase 3|639|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 01:59:08.306828|2018-06-01 01:59:08.306828
NCT00707018|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2016-05-20|2008-06-27|2008-06-30|Estimate|||||||2016-05-20|2016-05-24|Estimate|September 2004||2004-09-30|May 2016|2016-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Immobilization in External Rotation After First Time Anterior Shoulder Dislocation|Immobilization in External Rotation After First Time Anterior Shoulder Dislocation: A Prospective Randomized Study|Completed||Phase 3|50|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 01:59:09.036804|2018-06-01 01:59:09.036804
NCT00707005|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2016-10-30|2008-06-26|2008-06-30|Estimate|||||||2016-10-30|2016-11-01|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients|Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients|Completed|||105|Actual|Yonsei University|||||f||||f||||||Samples Without DNA|"~     Conjunctival swab samples~   "|||2018-06-01 01:59:09.203441|2018-06-01 01:59:09.203441
NCT00706992|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2012-12-18||2015-10-06|2008-06-27|2008-06-30|Estimate|2013-02-06|2013-03-19|Estimate||||2015-10-06|2015-10-28|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients|Transfer of Autologous T Cells Transduced With the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma|Terminated||Phase 2|50|Actual|National Institutes of Health Clinical Center (CC)||7||<11 subjects were enrolled to each Arm|f||||t||||||||||2018-06-01 01:59:09.313829|2018-06-01 01:59:09.313829
NCT00706979|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2011-11-07||2011-11-07|2008-06-26|2008-06-30|Estimate|2011-11-07|2011-12-09|Estimate||||2011-11-07|2011-12-09|Estimate|September 2008||2008-09-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers|A Novel Treatment to Boost Quit Attempts and Cessation Among Unmotivated Smokers|Completed||N/A|849|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 01:59:10.117803|2018-06-01 01:59:10.117803
NCT00706966|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-27|2013-12-02||2013-12-02|2008-06-27|2008-06-30|Estimate|2013-12-02|2014-01-17|Estimate||||2013-12-02|2014-01-17|Estimate|June 2005||2005-06-30|December 2013|2013-12-31|August 2011|Actual|2011-08-31|December 2008|Actual|2008-12-31||Interventional|||MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate Cancer|A Pilot Study of MRI and Spectroscopy Imaging Changes With 6-months of Dutasteride in Patients With Symptomatic Benign Prostatic Hypertrophy and Low-risk Prostate Cancer on Watchful Waiting or Requiring Neoadjuvant Androgen Suppression Prior to Prostate Brachytherapy|Completed||N/A|10|Actual|University of California, San Francisco|The inclusion of only men with low volume disease may have limited our ability to accurately assess response rates after dutasteride due to the background effects on normal prostate metabolism.|1|||f||||t||||||||||2018-06-01 01:59:10.383361|2018-06-01 01:59:10.383361
NCT00706953|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2015-04-02|2008-06-26|2008-06-30|Estimate|||||||2015-04-02|2015-04-06|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib|A Phase II Single Arm Study of VELCADE and DOXIL (PLD) in Patients With Relapsed Multiple Myeloma Previously Treated With VELCADE|Withdrawn||Phase 2|0|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 01:59:10.661268|2018-06-01 01:59:10.661268
NCT00706940|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2017-04-24|2008-06-27|2008-06-30|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2011||2011-08-31|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Tear Dynamics After Restasis Treatment in Dry Eye Patients|Tear Dynamics After Restasis Treatment in Dry Eye Patients Phase II Clinical Trial and Phase IIb 6-month Follow-up After Discontinuation of Study Treatment|Completed|||60|Actual|University of Miami|||||f||||f||||||||||2018-06-01 01:59:10.818542|2018-06-01 01:59:10.818542
NCT00706927|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-11-13|2008-06-27|2008-06-30|Estimate|||||||2014-11-13|2014-11-14|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|A Double-masked Randomized Cross-over Study Comparing of the Effect of Xalacom® (Latanoprost/Timolol)and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|Completed||N/A|16|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 01:59:10.881689|2018-06-01 01:59:10.881689
NCT00706758|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2011-07-19|2008-06-27|2008-06-30|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2004||2004-08-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Structured Patient Education Versus Written Information for Patients With Irritable Bowel Syndrome|Structured Patient Education Versus Written Information for Patients With Irritable Bowel Syndrome|Completed||N/A|143|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-06-01 01:59:15.077609|2018-06-01 01:59:15.077609
NCT00706914|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2017-02-03|2011-09-30|2017-05-08|2008-06-27|2008-06-30|Estimate|2017-05-08|2017-05-15|Actual|2011-09-30|2011-10-05|Estimate|2017-05-08|2017-05-15|Actual|June 30, 2008|Actual|2008-06-30|April 2017|2017-04-30|November 11, 2008|Actual|2008-11-11|November 11, 2008|Actual|2008-11-11||Interventional|||Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 4-Week Pilot Study to Assess Symptoms in Stable, Moderate to Severe COPD Patients Taking Aclidinium Bromide 200 mcg Once Daily in Combination With Formoterol Fumarate Once or Twice Daily Versus Formoterol Fumarate Twice Daily|Terminated||Phase 2|156|Actual|AstraZeneca|"Due to early termination of the study, the actual sample size is different from the study design (200 patients)~Actual sample size was 156, but because this was an exploratory study, this was considered sufficient to estimate the clinical outcomes"|3||Actual sample size of 156 was sufficient to estimate the clinical outcomes.|f||||f||||||||||2018-06-01 01:59:10.984443|2018-06-01 01:59:10.984443
NCT00706901|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2014-10-30||2018-01-30|2008-06-27|2008-06-30|Estimate|2015-02-02|2015-02-04|Estimate||||2018-01-30|2018-02-28|Actual|May 3, 2010|Actual|2010-05-03|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2013|Actual|2013-06-30||Interventional|GMI-IHMDs||Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans|Impact of Group Motivational Interviewing for Dually Diagnosed Veterans|Active, not recruiting||N/A|180|Actual|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-06-01 01:59:11.346321|2018-06-01 01:59:11.346321
NCT00706888|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2009-07-03|2008-06-27|2008-06-30|Estimate|||||||2009-07-03|2009-07-07|Estimate||||July 2009|2009-07-31||||||||Interventional|||Study on Effects of a Dairy Product Based on Polyphenols and Enriched With Vitamins B6, B9 and B12 on Some Cardiovascular Factor of Risk||Completed||N/A|64|Anticipated|Elvir SAS||4|||f||||||||||||||2018-06-01 01:59:11.802739|2018-06-01 01:59:11.802739
NCT00706875|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2018-04-27|2008-06-27|2008-06-30|Estimate|||||||2018-04-27|2018-04-30|Actual|June 2008|Actual|2008-06-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors|A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors|Completed|||59|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 01:59:11.877119|2018-06-01 01:59:11.877119
NCT00706862|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2012-03-13|2008-06-26|2008-06-30|Estimate|||||||2012-03-13|2012-03-15|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|March 2016|Anticipated|2016-03-31|June 2015|Anticipated|2015-06-30||Interventional|FORTIS-C||Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer|FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 3|1100|Anticipated|Agennix||2|||f||||t||||||||||2018-06-01 01:59:11.946498|2018-06-01 01:59:11.946498
NCT00706849|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2013-02-15|2010-10-02|2016-08-01|2008-06-27|2008-06-30|Estimate|2013-02-15|2013-03-21|Estimate|2010-10-02|2010-10-05|Estimate|2016-08-01|2016-09-09|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|RADICHOL II||Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects With Coronary Artery Disease|Completed||Phase 3|124|Actual|Kastle Therapeutics, LLC||2|||f||||t||||||||||2018-06-01 01:59:12.160346|2018-06-01 01:59:12.160346
NCT00706836|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2014-12-03||2014-12-19|2008-06-27|2008-06-30|Estimate|2014-12-19|2014-12-22|Estimate||||2014-12-19|2014-12-22|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||16 healthy subjects (10 male; mean age=23.2±2.6)|PharmacofMRI of Anxiolytic Medications (Pregabalin)|PharmacofMRI of Anxiolytic Medications (Pregabalin)|Completed||Phase 4|16|Actual|University of California, San Diego||3|||f||||f||||||||||2018-06-01 01:59:13.426771|2018-06-01 01:59:13.426771
NCT00706823|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2011-03-08||2017-01-03|2008-06-27|2008-06-30|Estimate|2011-03-08|2011-04-05|Estimate||||2017-01-03|2017-02-20|Actual|February 2008||2008-02-29|January 2017|2017-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|I-gel||Comparison of I-gel to the Laryngeal Mask Airway|A Randomized Clinical Comparison of the Intersurgical I-gel and the Laryngeal Mask Airway Unique in Non-Obese Adult Patients During General Surgery|Completed||N/A|50|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||Undecided||2018-06-01 01:59:13.605057|2018-06-01 01:59:13.605057
NCT00706810|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2016-10-12||2017-03-01|2008-06-26|2008-06-30|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|December 2007||2007-12-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Combination of Hydroxyurea and Verapamil for Refractory Meningiomas|Combination of Hydroxyurea and Verapamil for Refractory Meningiomas|Completed||Phase 2|8|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 01:59:13.910457|2018-06-01 01:59:13.910457
NCT00706797|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2010-12-22||2011-06-16|2008-06-27|2008-06-30|Estimate|2010-12-22|2011-01-10|Estimate||||2011-06-16|2011-06-21|Estimate|September 2008||2008-09-30|June 2011|2011-06-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects|An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) Added to Methotrexate in Comparison With Usual Treatment in Subjects With Moderate Rheumatoid Arthritis Disease Activity|Terminated||Phase 4|141|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Following early termination of the study, only disposition of randomized participants, description of demographic data on safety population, and safety analyses were performed.|2|||f||||f||||||||||2018-06-01 01:59:14.101469|2018-06-01 01:59:14.101469
NCT00706784|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2014-04-16||2014-06-12|2008-06-27|2008-06-30|Estimate|2014-06-10|2014-06-13|Estimate||||2014-06-12|2014-06-26|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|VaginalRing||Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System Study|Inducing a Medical Castration With a GnRH Agonist While Simultaneously Replacing Physiologic Levels and Patterns of Human Sex Steroid Hormones Using an Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Terminated||Phase 1/Phase 2|6|Actual|Massachusetts General Hospital|Early termination leading to small numbers of subjects analyzed.|1||Sponsor making changes to manufacturing of vaginal ring.|f||||t||||||||||2018-06-01 01:59:14.796803|2018-06-01 01:59:14.796803
NCT00706771|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-06-26|2008-06-27|2008-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|BLISS||Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study|A Randomized Double-blind Controlled Pilot Feasibility and Safety Trial of NGAL-directed Sodium Bicarbonate to Protect Renal Function in Patients With the Systemic Inflammatory Response Syndrome, Oliguria and Elevated Lipocalin Levels|Completed||Phase 2|70|Anticipated|Austin Health||2|||f||||f||||||||||2018-06-01 01:59:14.99861|2018-06-01 01:59:14.99861
NCT00706745|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2015-06-11|2008-06-27|2008-06-30|Estimate|||||||2015-06-11|2015-06-15|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Conjugated Linoleic Acid and Atherosclerosis|Possible Effects of Supplementation With Cis-9, Trans-11 Conjugated Linoleic Acid on Markers of Atherosclerosis|Completed||Phase 3|401|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 01:59:15.174061|2018-06-01 01:59:15.174061
NCT00706732|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2012-07-11|2008-06-26|2008-06-30|Estimate|||||||2012-07-11|2012-07-12|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|AVX502-003||A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza|A Single-Site, Phase I/II, Double Blinded, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Adult Volunteers 65 Years of Age or Older|Completed||Phase 1/Phase 2|28|Actual|AlphaVax, Inc.||4|||f||||f||||||||||2018-06-01 01:59:15.257643|2018-06-01 01:59:15.257643
NCT00706719|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2010-08-25||2015-07-22|2008-06-25|2008-06-27|Estimate|2010-09-21|2010-10-08|Estimate||||2015-07-22|2015-08-19|Estimate|June 2008||2008-06-30|July 2015|2015-07-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone|A Randomized, Open-Label, Fixed Dose, Active-Control, Multi-Center Phase IIB Study to Evaluate Fertility in Men With Secondary Hypogonadism, Comparing Androxal® to a Topical Testosterone in Men Previously Treated With Topical Testosterone.|Completed||Phase 2|17|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-06-01 01:59:15.356877|2018-06-01 01:59:15.356877
NCT00706706|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2012-08-24||2013-01-14|2008-06-26|2008-06-27|Estimate|2012-11-19|2012-12-20|Estimate||||2013-01-14|2013-01-18|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MRCC RCC||Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma|A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study)|Completed||Phase 4|105|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 01:59:15.806773|2018-06-01 01:59:15.806773
NCT00706693|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2008-07-07|2008-06-25|2008-06-27|Estimate|||||||2008-07-07|2008-07-09|Estimate|August 2003||2003-08-31|July 2008|2008-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Skittles(TM) Effective for Treating Hypoglycemia in Children With Type 1 Diabetes|The Effectiveness of Glucose, Sucrose and Fructose in Treating Hypoglycemia in Children With Type 1 Diabetes|Completed||N/A|33|Actual|University of Calgary||3|||f||||f||||||||||2018-06-01 01:59:16.054012|2018-06-01 01:59:16.054012
NCT00706680|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2008-06-25|2008-06-25|2008-06-27|Estimate|||||||2008-06-25|2008-06-27|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|June 2009|Anticipated|2009-06-30|February 2009|Anticipated|2009-02-28||Interventional|||Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol|The Use of Thymoglobulin in a Calcineurin Inhibitor and Steroid Minimization Protocol|Unknown status|Recruiting|Phase 4|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 01:59:16.125976|2018-06-01 01:59:16.125976
NCT00706667|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2013-06-19|2008-06-25|2008-06-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery|Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin for the Correction of Preoperative Anaemia in Patients Undergoing Orthopaedic Surgery|Terminated||Phase 4|75|Actual|University of Zurich||3||Not being able to recuit sufficient patients due to a lack of complience|f||||f||||||||||2018-06-01 01:59:16.211458|2018-06-01 01:59:16.211458
NCT00706654|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2013-03-29||2013-07-12|2008-06-26|2008-06-27|Estimate|2013-07-12|2013-08-14|Estimate||||2013-07-12|2013-08-14|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ASPIRE|Baseline measures are based on the participants from the Depot Maintenance Phase.|Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia|Completed||Phase 3|937|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-06-01 01:59:16.304561|2018-06-01 01:59:16.304561
NCT00706641|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2015-12-10||2015-12-10|2008-06-25|2008-06-27|Estimate|2015-12-10|2016-01-15|Estimate||||2015-12-10|2016-01-15|Estimate|June 2008||2008-06-30|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All subjects who started treatment on dastanib were included for age, gender, and ECOG PS characteristics. One patient was removed from the study because they were found to be ineligible based on histology after they started treatment and thus were not included in the T-Stage characteristics.|Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder|A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder|Completed||N/A|25|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||||2018-06-01 01:59:17.16842|2018-06-01 01:59:17.16842
NCT00706628|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2014-11-14|2014-05-05|2015-01-14|2008-06-26|2008-06-27|Estimate|2015-01-14|2015-01-15|Estimate|2014-05-05|2014-05-21|Estimate|2015-01-14|2015-01-15|Estimate|March 2006||2006-03-31|January 2015|2015-01-31||||December 2008|Actual|2008-12-31||Interventional||Treated Set: The Treated Set consisted of all patients who received at least 1 dose of study medication.|A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer|A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer|Completed||Phase 2|87|Actual|Boehringer Ingelheim|Data from the ComBI 70 group were not included in analyses of efficacy, data was available for one patient for this group for the primary outcome however is not reported to avoid reporting patient level data.||||f||||||||||||||2018-06-01 01:59:17.53769|2018-06-01 01:59:17.53769
NCT00706615|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2015-10-28|2008-06-26|2008-06-27|Estimate|||||||2015-10-28|2015-10-30|Estimate|July 2008||2008-07-31|July 2012|2012-07-31||||April 2009|Actual|2009-04-30||Interventional|||Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer|A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer|Withdrawn||Phase 1|0|Actual|Jonsson Comprehensive Cancer Center||||no accrual|f||||t||||||||||2018-06-01 01:59:18.385083|2018-06-01 01:59:18.385083
NCT00705562|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2009-01-02|2008-06-24|2008-06-26|Estimate|||||||2009-01-02|2009-01-05|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Tolerance of Healthy Term Infants Fed Infant Formulas|Tolerance of Healthy Term Infants Fed Infant Formulas|Completed||Phase 2|190|Actual|Abbott Nutrition||5|||f||||t||||||||||2018-06-01 01:59:45.608942|2018-06-01 01:59:45.608942
NCT00706602|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2010-06-24|2008-06-26|2008-06-27|Estimate|||||||2010-06-24|2010-06-28|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|ICECOLDERIC||Predicting the Course of Chronic Obstructive Pulmonary Disease (COPD) in Primary Care|International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts|Unknown status|Active, not recruiting||450|Anticipated|University of Zurich|||2||f||||f||||||||||2018-06-01 01:59:18.447047|2018-06-01 01:59:18.447047
NCT00706589|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2011-01-27||2013-06-19|2008-06-26|2008-06-27|Estimate|2013-06-19|2013-07-26|Estimate||||2013-06-19|2013-07-26|Estimate|October 2008||2008-10-31|June 2013|2013-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder|A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder|Completed||Phase 3|61|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-06-01 01:59:18.503357|2018-06-01 01:59:18.503357
NCT00706576|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2017-07-31|2008-06-25|2008-06-27|Estimate|||||||2017-07-31|2017-08-02|Actual|June 2008|Actual|2008-06-30|July 2017|2017-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor|Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study|Completed||Phase 1|14|Actual|University of Missouri-Columbia||1|||f||||t||||||||Undecided||2018-06-01 01:59:18.700672|2018-06-01 01:59:18.700672
NCT00706563|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2009-07-16||2016-10-26|2008-06-26|2008-06-27|Estimate|2009-07-16|2009-08-25|Estimate||||2016-10-26|2016-12-08|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in People Aged 18 Years or Above|Completed||Phase 3|120|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 01:59:18.773946|2018-06-01 01:59:18.773946
NCT00706550|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2013-09-26||2014-03-27|2008-06-26|2008-06-27|Estimate|2013-09-26|2013-12-12|Estimate||||2014-03-27|2014-04-24|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects|Immune Responses to Pneumococcal Vaccination Among HIV-Infected Subjects|Completed||N/A|107|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 01:59:19.184543|2018-06-01 01:59:19.184543
NCT00706537|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25||2009-08-11|2009-08-11|2008-06-25|2008-06-27|Estimate||||2009-08-11|2009-08-13|Estimate|2009-08-11|2009-08-13|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH|A Multiple Dose, Randomized, Double-Blind (3rd Party Open), Placebo-Controlled Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of CP-945598 In Subjects With Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 1|9|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 01:59:19.564738|2018-06-01 01:59:19.564738
NCT00706511|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2016-09-29|2008-06-25|2008-06-27|Estimate|||||||2016-09-29|2016-10-03|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Metabolic Study of Sleep Apnea in Men and Women|Sleep and Metabolism in Obesity: Impact of Gender|Active, not recruiting||N/A|60|Anticipated|University of Chicago||2|||f||||t||||||||||2018-06-01 01:59:19.673353|2018-06-01 01:59:19.673353
NCT00706498|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24||2014-04-30|2014-04-30|2008-06-26|2008-06-27|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|September 2006||2006-09-30|April 2014|2014-04-30||||February 2008|Actual|2008-02-29||Interventional|||Phase II Study of BI 2536 in Prostate Cancer|A Single Arm Phase II Study to Investigate the Efficacy, Safety and Pharmacokinetics of a Single Dose of 200 mg of i.v. BI 2536, Administered Once Every 3 Weeks in Patients With Advanced Metastatic Hormone-refractory Prostate Cancer.|Completed||Phase 2|20|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 01:59:19.761282|2018-06-01 01:59:19.761282
NCT00706485|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2016-10-18||2016-10-18|2008-06-25|2008-06-27|Estimate|2016-10-18|2016-10-19|Estimate||||2016-10-18|2016-10-19|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators|Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators|Terminated||N/A|5|Actual|Massachusetts General Hospital||1||New device for dural plaque irradiation was approved by FDA.|f||||t||||||||||2018-06-01 01:59:19.83235|2018-06-01 01:59:19.83235
NCT00706459|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2012-11-13|2008-06-26|2008-06-27|Estimate|||||||2012-11-13|2012-11-14|Estimate|March 2005||2005-03-31|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study|Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study|Terminated|||53|Actual|University of California, San Francisco|||5|Due to funding issue, study has been terminated.|f||||f||||||Samples Without DNA|"~     Disc specimens are taken out during back surgery and will be studied using techniques for~     tissue analysis to explain the properties and characteristics of disc tissue from patients~     with back pain.~   "|||2018-06-01 01:59:19.975509|2018-06-01 01:59:19.975509
NCT00706446|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2017-03-17|2012-05-17|2017-05-05|2008-06-25|2008-06-27|Estimate|2017-03-17|2017-05-01|Actual|2012-05-17|2012-05-22|Estimate|2017-05-05|2017-05-31|Actual|June 2008||2008-06-30|May 2017|2017-05-31|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Interventional|GABLE||The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations|Genotype Stratified Treatment With Anticholinergic vs. Beta-agonist (Long Acting) and Exacerbations (GABLE)|Terminated||N/A|255|Actual|Brigham and Women's Hospital||6||Funding was terminated|f||||f||||||||No||2018-06-01 01:59:20.062958|2018-06-01 01:59:20.062958
NCT00706433|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2009-07-09||2011-10-20|2008-06-26|2008-06-27|Estimate|2009-07-09|2009-08-21|Estimate||||2011-10-20|2011-10-24|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne|A Randomized, Evaluator-blinded, Parallel Group Light Dose Ranging Study of Photodynamic Therapy With Levulan Topical Solution + Blue Light Versus Levulan Topical Solution Vehicle + Blue Light on Moderate to Severe Facial Acne Vulgaris|Completed||Phase 2|266|Actual|DUSA Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 01:59:20.676695|2018-06-01 01:59:20.676695
NCT00706420|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2018-05-18|2008-06-25|2008-06-27|Estimate|||||||2018-05-18|2018-05-22|Actual|January 2002||2002-01-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen|Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen|Active, not recruiting||Phase 1|20|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 01:59:24.65773|2018-06-01 01:59:24.65773
NCT00706407|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2017-03-17||2018-03-12|2008-06-25|2008-06-27|Estimate|2018-03-12|2018-03-13|Actual||||2018-03-12|2018-03-13|Actual|April 2008||2008-04-30|March 2018|2018-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|Uro-NIRS||Uro-NIRS Clinical Study|Uro-NIRS Clinical Study|Completed||N/A|42|Actual|Weill Medical College of Cornell University|Study limitations include sample size and the lack of a control group without LUTS.|1|||f||||f||||||||||2018-06-01 01:59:24.79202|2018-06-01 01:59:24.79202
NCT00706394|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2011-09-12|2008-06-26|2008-06-27|Estimate|||||||2011-09-12|2011-09-14|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms|Prospective, Multicenter, Single Arm Phase II Study of the Powerlink 34mm Cuff for the Endovascular Repair of Abdominal Aortic Aneurysms|Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Actual|Endologix||1|||t||||t||||||||||2018-06-01 01:59:25.090366|2018-06-01 01:59:25.090366
NCT00706381|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2017-10-18|2008-06-26|2008-06-27|Estimate|||||||2017-10-18|2017-10-19|Actual|June 23, 2008||2008-06-23|August 4, 2017|2017-08-04|August 21, 2012|Actual|2012-08-21|August 21, 2012|Actual|2012-08-21||Interventional|||Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)|Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)|Completed||N/A|39|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:59:25.184649|2018-06-01 01:59:25.184649
NCT00706368|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2008-06-25|2008-06-25|2008-06-27|Estimate|||||||2008-06-25|2008-06-27|Estimate|April 2006||2006-04-30|May 2008|2008-05-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females|Taking Charge of my Health: A Trial to Investigate the Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females|Unknown status|Recruiting|N/A|300|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-06-01 01:59:25.244773|2018-06-01 01:59:25.244773
NCT00706355|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2012-04-26||2012-06-15|2008-06-25|2008-06-27|Estimate|2012-04-26|2012-05-31|Estimate||||2012-06-15|2012-06-25|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study of PF-04217903 in Patients With Advanced Cancer|Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-4217903 in Patients With Advanced Cancer|Terminated||Phase 1|16|Actual|Pfizer|Insufficient number of participants had been enrolled in the study due to a strategic development decision; therefore some of the objectives for this study were either not investigated or not fully investigated.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 01:59:25.409309|2018-06-01 01:59:25.409309
NCT00706342|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2014-07-23||2016-05-03|2008-06-25|2008-06-27|Estimate|2014-07-23|2014-08-13|Estimate||||2016-05-03|2016-06-03|Estimate|January 2007||2007-01-31|May 2016|2016-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)|A Phase II, Open-Label, Efficacy and Safety, Ascending Dose, Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura|Completed||Phase 2|18|Actual|Rigel Pharmaceuticals||1|||f||||t||||||||No||2018-06-01 01:59:27.152846|2018-06-01 01:59:27.152846
NCT00706329|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2013-06-05||2017-10-04|2008-06-26|2008-06-27|Estimate|2013-06-05|2013-08-28|Estimate||||2017-10-04|2017-11-06|Actual|April 2008||2008-04-30|October 2017|2017-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|MIC|The study was terminated prematurely by the IRB due to data integrity and compliance concerns.|Minimally Invasive Closure of Umbilical Hernias|Study of Minimally Invasive Closure of Umbilical Hernias|Terminated||N/A|25|Actual|South Shore Hospital|The study was terminated prematurely by the IRB due to data integrity and compliance concerns. Results are not shared due to data integrity concerns. These concerns are outlined in an FDA warning letter.|1||"The study was terminated prematurely by the IRB due to data integrity and protocol compliance~   issues"|f||||f||||||||||2018-06-01 01:59:27.57002|2018-06-01 01:59:27.57002
NCT00706316|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2015-07-08|2008-06-26|2008-06-27|Estimate|||||||2015-07-08|2015-07-10|Estimate|December 2007||2007-12-31|July 2015|2015-07-31|November 2012|Actual|2012-11-30|August 2009|Actual|2009-08-31||Interventional|NPC-CTL||Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer|A Phase I Trial Evaluating the Administration of Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) to Patients With Recurrent or Metastatic EBV-Positive Nasopharygneal Cancer (NPC)|Completed||Phase 1|5|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 01:59:27.695678|2018-06-01 01:59:27.695678
NCT00706303|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2008-06-26|2008-06-26|2008-06-27|Estimate|||||||2008-06-26|2008-06-27|Estimate|June 2007||2007-06-30|June 2008|2008-06-30|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|GSuST||Glasgow Supported Self Management Trial (GSuST)|Glasgow Supported Self-Management Randomised Controlled Trial for Patients With Moderate/ Severe COPD - GSuST|Unknown status|Recruiting|N/A|500|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-06-01 01:59:27.771003|2018-06-01 01:59:27.771003
NCT00706290|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2014-06-05|2008-06-26|2008-06-27|Estimate|||||||2014-06-05|2014-06-06|Estimate|April 2007||2007-04-30|June 2014|2014-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Brief CBT for Anxiety and Advanced Cancer|Brief CBT for Anxiety and Advanced Cancer|Completed||Phase 2|49|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:59:27.840989|2018-06-01 01:59:27.840989
NCT00706277|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2009-02-09|2008-06-26|2008-06-27|Estimate|||||||2009-02-09|2009-02-10|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|||||Interventional|||Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function|Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function|Completed||Phase 4|60|Anticipated|Medical University Innsbruck||2|||f||||||||||||||2018-06-01 01:59:27.910976|2018-06-01 01:59:27.910976
NCT00706264|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2014-07-25|2008-06-26|2008-06-27|Estimate|||||||2014-07-25|2014-07-28|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PECEP||Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix|Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP)|Completed||Phase 4|2780|Actual|Maternal-Infantil Vall d´Hebron Hospital||2|||f||||t||||||||||2018-06-01 01:59:27.981248|2018-06-01 01:59:27.981248
NCT00706251|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-06-26|2008-06-26|2008-06-27|Estimate|||||||2008-06-26|2008-06-27|Estimate|January 2000||2000-01-31|June 2008|2008-06-30||||December 2007|Actual|2007-12-31||Observational|||Follow up of Nasolacrimal Intubation in Adults|Long Term Follow up of Nasolacrimal Intubation in Adults With Mild Epiphora|Completed|||180|Actual|Shaare Zedek Medical Center|||1||f||||f||||||||||2018-06-01 01:59:28.075901|2018-06-01 01:59:28.075901
NCT00695630|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Flumazenil Reversal of Oral Triazolam|Flumazenil Rescue Strategy|Completed||Phase 1/Phase 2|14|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:03:28.658216|2018-06-01 02:03:28.658216
NCT00706238|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25||2011-12-20|2014-06-19|2008-06-26|2008-06-27|Estimate||||2011-12-20|2011-12-22|Estimate|2014-06-19|2014-06-23|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma|Study of GSK1203486A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma|Terminated||Phase 2|6|Actual|GlaxoSmithKline||1||"The study was terminated early due to difficulties in recruiting subjects, not following~   concerns for the safety or absence of clinical activity in patients."|f||||||||||||||2018-06-01 01:59:28.16091|2018-06-01 01:59:28.16091
NCT00706225|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2010-09-21|2008-06-25|2008-06-27|Estimate|||||||2010-09-21|2010-09-23|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women|An Open-Label, Single/Multiple Dose, Non-Randomized, 3-Period, Crossover Study To Determine The Potential Drug Interaction Of Bazedoxifene On Conjugated Estrogens (CE) In Healthy Postmenopausal Women|Completed||Phase 1|30|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 01:59:28.242229|2018-06-01 01:59:28.242229
NCT00706212|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-06-26|2008-06-26|2008-06-27|Estimate|||||||2008-06-26|2008-06-27|Estimate|June 2008||2008-06-30|May 2008|2008-05-31||||||||Observational|GS-PET-2008||The Accuracy of CHOLINE PET CT in the Diagnosis of Urological Malignancies|A Comparative Study to Examine the Accuracy of CHOLINE PET CT in the Diagnosis|Unknown status|Recruiting||60|Anticipated|Rabin Medical Center|||||f||||||||||||||2018-06-01 01:59:28.311722|2018-06-01 01:59:28.311722
NCT00706199|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2018-02-01|2008-06-26|2008-06-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|July 3, 2008||2008-07-03|February 2018|2018-02-28|January 23, 2009|Actual|2009-01-23|January 23, 2009|Actual|2009-01-23||Observational|||The Expression of Antigens in Bone Marrow Samples From Volunteering Donors.|Analysis of Expression of Antigens in Bone Marrow Samples From Volunteering Donors.|Completed|||48|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 01:59:28.357474|2018-06-01 01:59:28.357474
NCT00706186|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2010-07-06|2008-06-26|2008-06-27|Estimate|||||||2010-07-06|2010-07-07|Estimate||||July 2010|2010-07-31||||||||Interventional|ALD||Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients|Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.|Terminated||Phase 4|4|Actual|Clayton Sleep Insititute||||Withdrawn by Investigator, protocol in revision|f||||t||||||||||2018-06-01 01:59:28.411|2018-06-01 01:59:28.411
NCT00706173|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2015-06-02|2008-06-25|2008-06-27|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2009||2009-08-31|August 2011|2011-08-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD)|A Randomized Double-blind Placebo-controlled Cross-over Trial of Hydrocortisone for Post-traumatic Stress Disorder|Withdrawn||Phase 4|0|Actual|University of California, San Diego||2||Unable to recruit eligible subjects for the trial.|f||||f||||||||||2018-06-01 01:59:28.472222|2018-06-01 01:59:28.472222
NCT00706160|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2018-05-23|2008-06-26|2008-06-27|Estimate|||||||2018-05-23|2018-05-24|Actual|June 13, 2008||2008-06-13|April 4, 2013|2013-04-04|April 4, 2013||2013-04-04|||||Observational|||Language Mapping in Patients With Epilepsy|Noninvasive Language Mapping in Patients With Localization-Related Epilepsy|Completed|||153|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:59:28.623975|2018-06-01 01:59:28.623975
NCT00706147|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24||2017-08-10|2017-08-15|2008-06-26|2008-06-27|Estimate||||2017-08-10|2017-08-14|Actual|2017-08-15|2017-08-18|Actual|January 2009||2009-01-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|December 2014|Actual|2014-12-31||Interventional|||Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis|Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2/Phase 3|38|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 01:59:28.686223|2018-06-01 01:59:28.686223
NCT00706134|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2011-01-10||2011-06-24|2008-06-26|2008-06-27|Estimate|2011-05-18|2011-06-17|Estimate||||2011-06-24|2011-06-28|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study|An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal|Completed||Phase 3|756|Actual|Novartis||4|||f||||f||||||||||2018-06-01 01:59:28.780346|2018-06-01 01:59:28.780346
NCT00706121|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|2017-02-15||2017-05-23|2008-06-26|2008-06-27|Estimate|2017-02-15|2017-04-04|Actual||||2017-05-23|2017-06-20|Actual|June 2008||2008-06-30|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ACP||S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000|S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT|Completed||Phase 3|8094|Actual|Southwest Oncology Group||4|||f||||t||||||||Yes|http://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-06-01 01:59:29.229898|2018-06-01 01:59:29.229898
NCT00706108|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2011-01-10|2008-06-26|2008-06-27|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|March 2010|Actual|2010-03-31|||||Observational|RACoP||Adaptive Coordination in Anaesthesia Teams and Its Relationship to Clinical Performance.|Adaptive Coordination in Anaesthesia Teams and Its Relationship to Clinical Performance. (Cooperative Project ETHZ, OAT, Prof. G. Grote, and IfA/USZ; Founding by Swiss National Science Foundation to Both Institutions)|Completed|||161|Actual|University of Zurich|||3||f||||f||||||||||2018-06-01 01:59:30.161962|2018-06-01 01:59:30.161962
NCT00706095|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2011-12-22||2012-03-21|2008-06-26|2008-06-27|Estimate|2011-12-22|2012-01-30|Estimate||||2012-03-21|2012-03-27|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System|An Open-label, Parallel Group Study to Explore the Pharmacokinetics of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors and Normal or Reduced Hepatic Function According to the Child-Pugh System|Completed||Phase 1|18|Actual|Eisai Inc.||3|||f||||f||||||||||2018-06-01 01:59:30.236694|2018-06-01 01:59:30.236694
NCT00706082|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2012-06-21|2008-06-26|2008-06-27|Estimate|||||||2012-06-21|2012-06-25|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Observational|DETECT||Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)|A Two-stage Prospective Observational Cohort Study in Scleroderma Patients to Evaluate Screening Tests and the Incidence of Pulmonary Arterial Hypertension and Pulmonary Hypertension|Terminated|||490|Actual|Actelion|||||f||||f||||||Samples Without DNA|"~     Serum and plasma samples will be stored at a central laboratory for at least two additional~     years after official study termination.~   "|||2018-06-01 01:59:30.727007|2018-06-01 01:59:30.727007
NCT00706069|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2009-12-14|2008-06-26|2008-06-27|Estimate|||||||2009-12-14|2009-12-15|Estimate|June 2008||2008-06-30|December 2009|2009-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer|A Phase I Study Of Vinorelbine Oral Plus Capecitabine Combination In Patients With Metastatic Breast Cancer|Completed||Phase 1|40|Anticipated|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 01:59:30.885608|2018-06-01 01:59:30.885608
NCT00706056|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2017-02-17|2008-06-25|2008-06-27|Estimate|||||||2017-02-17|2017-02-23|Actual|September 2008|Actual|2008-09-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure|A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure|Completed|||85|Actual|Weill Medical College of Cornell University|||||f||||f||||||||No|No Plan to Share IPD|2018-06-01 01:59:30.962747|2018-06-01 01:59:30.962747
NCT00706043|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2008-06-26|2008-06-26|2008-06-27|Estimate|||||||2008-06-26|2008-06-27|Estimate|June 2008||2008-06-30|May 2008|2008-05-31||||||||Observational|||French Validation Orebro Musculoskeletal Pain Screening Questionnaire (OMPSQ) Questionnaire|Validation of a French Translation of the Orebro Musculoskeletal Pain Screening Questionnaire (OMPSQ): A Prospective One-Year Follow-up Study|Unknown status|Not yet recruiting||120|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-06-01 01:59:31.018583|2018-06-01 01:59:31.018583
NCT00706030|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2017-08-10|2013-01-29|2018-04-06|2008-06-25|2008-06-27|Estimate|2018-04-06|2018-05-08|Actual|2013-01-29|2013-01-31|Estimate|2018-04-06|2018-05-08|Actual|April 2008|Actual|2008-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2009|Actual|2009-10-31||Interventional|||Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer|A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|92|Actual|Puma Biotechnology, Inc.||4|||f||||f|t|f||||||||2018-06-01 01:59:31.101078|2018-06-01 01:59:31.101078
NCT00706017|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2016-10-27|2008-06-26|2008-06-27|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|PREDICTIVE™||Observational Study to Evaluate the Safety of Levemir® in Diabetes|Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|Completed|||2282|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:59:32.129634|2018-06-01 01:59:32.129634
NCT00706004|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2011-02-16||2011-03-14|2008-06-26|2008-06-27|Estimate|2011-03-14|2011-04-18|Estimate||||2011-03-14|2011-04-18|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis|Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis|Completed||N/A|9|Actual|University of Arkansas|||||f||||f||||||||||2018-06-01 01:59:32.219002|2018-06-01 01:59:32.219002
NCT00705991|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2013-01-22|2008-06-26|2008-06-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|October 2008||2008-10-31|||||Observational|||Validation of Thrombelastometry (ROTEM®)||Completed|||||University of Zurich|||||f||||f||||||||||2018-06-01 01:59:32.631918|2018-06-01 01:59:32.631918
NCT00705978|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-26|||2011-08-16|2008-06-26|2008-06-27|Estimate|||||||2011-08-16|2011-08-18|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis|A One Week Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study With Creon 40,000 MMS in Subjects With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Followed by an Open-Label Long-Term Extension|Completed||Phase 3|62|Actual|Abbott||2|||f||||f||||||||||2018-06-01 01:59:32.6927|2018-06-01 01:59:32.6927
NCT00705965|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2016-08-26|2008-06-26|2008-06-27|Estimate|||||||2016-08-26|2016-08-30|Estimate|November 2008||2008-11-30|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|SPIRR-CAD||Effects of a Psychotherapy Intervention in Depressed Patients With Coronary Artery Disease|A Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease - a Randomised Controlled Trial (SPIRR-CAD)|Completed||N/A|570|Actual|University of Göttingen||2|||f||||t||||||||||2018-06-01 01:59:32.779596|2018-06-01 01:59:32.779596
NCT00705952|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2010-11-29|2008-06-26|2008-06-27|Estimate|||||||2010-11-29|2010-11-30|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|GLP4Health||Group Lifestyle Intervention for People With New Onset Type 2 Diabetes.|Effect of Intensive Lifestyle Intervention on Hormonal Factors Regulating Food Intake and Blood Glucose Control in Patients With New Onset Type 2 Diabetes.|Completed||N/A|22|Actual|The Royal Bournemouth Hospital||1|||f||||f||||||||||2018-06-01 01:59:32.887978|2018-06-01 01:59:32.887978
NCT00705939|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|2014-04-30||2014-07-14|2008-06-25|2008-06-27|Estimate|2014-07-14|2014-07-15|Estimate||||2014-07-14|2014-07-15|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|May 2012|Actual|2012-05-31||Interventional||All treated patients are included in the analysis|Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial|A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease|Completed||Phase 3|45|Actual|Protalix||3|||t||||t||||||||||2018-06-01 01:59:32.979775|2018-06-01 01:59:32.979775
NCT00705926|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2017-08-30|2008-06-25|2008-06-27|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2008||2008-10-31|August 2017|2017-08-31|July 16, 2017|Actual|2017-07-16|February 7, 2013|Actual|2013-02-07||Interventional|||Effectiveness of Antiretroviral Therapy During Acute HIV Infection|A Phase 1 Clinical Trial to Evaluate the Initiation of Treatment Versus no Treatment During Acute HIV-1 Infection|Completed||Phase 1|25|Actual|Massachusetts General Hospital||3|||f||||||||||||||2018-06-01 01:59:33.691231|2018-06-01 01:59:33.691231
NCT00705913|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2012-01-06|2008-06-25|2008-06-27|Estimate|||||||2012-01-06|2012-01-09|Estimate|June 2008||2008-06-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Randomized Sizing and Hemodynamic Study Mitroflow vs. Magna|A Randomized Study to Compare Sizing, Implant Techniques and Hemodynamic Performance Between the Mitroflow and the Carpentier-Edwards Magna Pericardial Tissue Valves in the Aortic Position|Terminated||N/A|368|Actual|Sorin Group USA, Inc.||2|||f||||f||||||||||2018-06-01 01:59:33.777077|2018-06-01 01:59:33.777077
NCT00705900|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2008-11-17|2008-06-26|2008-06-27|Estimate|||||||2008-11-17|2008-11-19|Estimate|January 2007||2007-01-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis|A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis|Completed||N/A|60|Anticipated|NeoStrata Company, Inc.||2|||f||||t||||||||||2018-06-01 01:59:33.855253|2018-06-01 01:59:33.855253
NCT00705887|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2008-06-25|2008-06-25|2008-06-27|Estimate|||||||2008-06-25|2008-06-27|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Motivational Enhancement Approach to Skin Cancer Prevention|The Feasibility of a Motivational Enhancement Approach to Skin Cancer Prevention in a Sample of Young Adult Patients|Completed||N/A|82|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 01:59:33.944121|2018-06-01 01:59:33.944121
NCT00705874|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2011-11-17||2016-06-21|2008-06-25|2008-06-26|Estimate|2012-01-22|2012-02-27|Estimate||||2016-06-21|2016-07-21|Estimate|May 2006||2006-05-31|June 2016|2016-06-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma|A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|172|Actual|Progen Pharmaceuticals||7|||f||||f||||||||||2018-06-01 01:59:34.043796|2018-06-01 01:59:34.043796
NCT00705861|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2013-04-16|2008-06-25|2008-06-26|Estimate|||||||2013-04-16|2013-04-18|Estimate|November 2007||2007-11-30|April 2013|2013-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus|A 12 Week, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel Group, Fixed Dose Study to Assess the Efficacy and Safety of SK3530 on Erectile Dysfunction in Patients With Diabetes Mellitus|Completed||Phase 3|112|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||||2018-06-01 01:59:35.126784|2018-06-01 01:59:35.126784
NCT00705848|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2017-03-17|2008-06-24|2008-06-26|Estimate|||||||2017-03-17|2017-03-21|Actual|July 2008||2008-07-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Matrix Biology of Tracheobronchomalacia and Tracheal Stenosis|Matrix Biology of Tracheobronchomalacia and Tracheal Stenosis|Completed|||16|Actual|Beth Israel Deaconess Medical Center|||3||f||||t||||||Samples With DNA|"~     Airway biopsies and brushings are to be used for staining and culture, respectively~   "|No||2018-06-01 01:59:35.282427|2018-06-01 01:59:35.282427
NCT00705835|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2012-01-06|2008-06-24|2008-06-26|Estimate|||||||2012-01-06|2012-01-09|Estimate|January 2003||2003-01-31|January 2012|2012-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel|Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel: A Trial Studying RsPMSA Doses|Completed||Phase 1|14|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 01:59:35.33961|2018-06-01 01:59:35.33961
NCT00705822|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2010-11-29|2008-06-25|2008-06-26|Estimate|||||||2010-11-29|2010-11-30|Estimate|August 2006||2006-08-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|PROSTATA||Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer|Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage|Terminated||Phase 3|54|Actual|Sanofi||2||low recruitment rate|f||||||||||||||2018-06-01 01:59:35.407467|2018-06-01 01:59:35.407467
NCT00705809|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2017-06-30|2008-06-25|2008-06-26|Estimate|||||||2017-06-30|2017-07-02|Actual|June 18, 2008||2008-06-18|July 20, 2011|2011-07-20|July 20, 2011||2011-07-20|||||Observational|||T-Cell Project: Epidemiologic Component|T-Cell Project: Epidemiologic Component|Completed|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 01:59:35.493211|2018-06-01 01:59:35.493211
NCT00705796|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2018-03-09|2008-06-25|2008-06-26|Estimate|||||||2018-03-09|2018-03-13|Actual||||March 2018|2018-03-31||||||||Interventional|||Influence of Administration Route of Testosterone on Male Fertility|Influence on Human Male Fertility of Testosterone After Intranasal (MPP10) or Transdermal (AndroGel™) Application|Withdrawn||Phase 1|0|Actual|Acerus Pharmaceuticals Corporation||2||financial constraints|f||||f||||||||||2018-06-01 01:59:35.553675|2018-06-01 01:59:35.553675
NCT00705783|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2013-03-29|2011-09-02|2013-06-16|2008-06-25|2008-06-26|Estimate|2013-06-16|2013-07-19|Estimate|2011-09-02|2011-09-12|Estimate|2013-06-16|2013-07-19|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Interventional|ASPIRE|Baseline measures are based on the participants from the Depot Maintenance Phase.|Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia|Completed||Phase 3|843|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-06-01 01:59:35.668239|2018-06-01 01:59:35.668239
NCT00705770|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2012-05-29|2008-06-25|2008-06-26|Estimate|||||||2012-05-29|2012-05-30|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Multi-Dose Study With a Treatment for Open-Angle Glaucoma||Withdrawn||Phase 2/Phase 3|0|Actual|Alcon Research||4||Change in study design|f||||f||||||||||2018-06-01 01:59:36.452308|2018-06-01 01:59:36.452308
NCT00705757|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2014-12-25||2015-12-14|2008-06-25|2008-06-26|Estimate|2015-12-14|2016-01-18|Estimate||||2015-12-14|2016-01-18|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye|The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation|Completed||Phase 4|89|Actual|Summa Health System||3|||f||||f||||||||||2018-06-01 01:59:36.532101|2018-06-01 01:59:36.532101
NCT00705744|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2009-04-14|2008-06-25|2008-06-26|Estimate|||||||2009-04-14|2009-04-15|Estimate|April 2008||2008-04-30|April 2009|2009-04-30||||May 2008|Actual|2008-05-31||Interventional|||Dermacyd Femina (Lactic Acid) - Photo Dermatological Evaluation of the Irritation and Sensitivity Potential.|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Femina.|Completed||Phase 3|26|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:59:36.840268|2018-06-01 01:59:36.840268
NCT00705731|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2012-06-11|2008-06-24|2008-06-26|Estimate|||||||2012-06-11|2012-06-12|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Adherence and the Economics of Colon Cancer Screening|Adherence and the Economics of Colon Cancer Screening|Completed|||1000|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 01:59:36.893603|2018-06-01 01:59:36.893603
NCT00705380|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2015-03-04|2008-06-24|2008-06-26|Estimate|||||||2015-03-04|2015-03-05|Estimate|July 1998||1998-07-31|March 2015|2015-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder|Cognitive-Behavioral Treatment of Panic in Adolescence|Completed||Phase 2|25|Actual|Boston University||2|||f||||t||||||||||2018-06-01 01:59:49.735634|2018-06-01 01:59:49.735634
NCT00705718|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2014-01-31||2017-02-01|2008-06-25|2008-06-26|Estimate|2014-01-31|2014-03-21|Estimate||||2017-02-01|2017-03-13|Actual|June 2008|Actual|2008-06-30|January 2017|2017-01-31|September 26, 2016|Actual|2016-09-26|September 2012|Actual|2012-09-30||Interventional|||Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System|Endurant Stent Graft System US Clinical Study|Completed||N/A|194|Actual|Medtronic Endovascular|Adverse Events and Serious Adverse Events listed in ClinicalTrials.gov were re-coded, using MeDRA codes. To do so, events were reclassified. As a result, data in listings may not match those in Clinical Update reports, SSEDs, or Instructions for Use.|2|||f||||t||||||||No||2018-06-01 01:59:36.973848|2018-06-01 01:59:36.973848
NCT00705705|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2011-11-10|2008-06-25|2008-06-26|Estimate|||||||2011-11-10|2011-11-11|Estimate|July 2004||2004-07-31|November 2011|2011-11-30|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Effectiveness of an HIV Prevention Program That Targets the Inner Workings of High-risk Social Networks|Targeted Social Network HIV Prevention Intervention|Completed||Phase 2|852|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-06-01 01:59:37.635739|2018-06-01 01:59:37.635739
NCT00705692|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2013-07-24|2008-06-25|2008-06-26|Estimate|||||||2013-07-24|2013-07-26|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients|Effect of Levamisole Supplementation on Tetanus Vaccination Response Rates in Hemodialysis Patients: A Randomized Double-Blind Placebo-Controlled Trial|Completed||Phase 2|40|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-06-01 01:59:37.737778|2018-06-01 01:59:37.737778
NCT00705679|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2016-01-12|2015-05-28|2016-02-15|2008-06-24|2008-06-26|Estimate|2016-01-12|2016-02-10|Estimate|2015-07-02|2015-07-24|Estimate|2016-02-15|2016-03-14|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Includes all participants enrolled and randomized to a study arm|Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women|Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women|Completed||Phase 2|5029|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|In September 2011, the oral TDF arm was discontinued for futility; in November 2011, the TFV gel and gel placebo arms were discontinued for futility. The TDF-FTC and oral placebo arms continued follow-up until the end of study in August 2012.|5|||f||||||||||||||2018-06-01 01:59:37.845236|2018-06-01 01:59:37.845236
NCT00705666|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2010-03-30||2015-10-01|2008-06-25|2008-06-26|Estimate|2010-05-27|2010-06-24|Estimate||||2015-10-01|2015-10-02|Estimate|February 2006||2006-02-28|October 2015|2015-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|ADEQUATION||Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)|Real Situation Observational Study of VIRAFERONPEG® in Patients With Chronic Hepatitis C|Completed|||789|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:40.291437|2018-06-01 01:59:40.291437
NCT00705653|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2011-11-06||2012-03-21|2008-06-25|2008-06-26|Estimate|2012-01-22|2012-02-27|Estimate||||2012-03-21|2012-03-27|Estimate|March 2005||2005-03-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors|A Phase I Study of CGC-11047 in Subjects With Advanced Refractory Solid Tumors|Completed||Phase 1|46|Actual|Progen Pharmaceuticals||1|||f||||f||||||||||2018-06-01 01:59:40.542014|2018-06-01 01:59:40.542014
NCT00705640|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2016-12-15|2008-06-25|2008-06-26|Estimate|||||||2016-12-15|2016-12-16|Estimate|May 2008||2008-05-31|December 2016|2016-12-31||||June 2009|Actual|2009-06-30||Interventional|Mel48||Vaccine Therapy in Treating Patients With Advanced Melanoma|A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment|Completed||Phase 1|45|Actual|University of Virginia||10|||f||||t||||||||||2018-06-01 01:59:40.751136|2018-06-01 01:59:40.751136
NCT00705627|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2014-05-26|2008-06-25|2008-06-26|Estimate|||||||2014-05-26|2014-05-28|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|June 2017|Anticipated|2017-06-30|February 2015|Anticipated|2015-02-28||Interventional|||A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|A Multicenter Trial Comparing Neoadjuvant Chemotherapy Followed by CCRT v.s. CCRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 3|400|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-06-01 01:59:40.841582|2018-06-01 01:59:40.841582
NCT00705614|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2014-02-25||2017-02-17|2008-06-25|2008-06-26|Estimate|2014-08-11|2014-08-26|Estimate||||2017-02-17|2017-03-22|Actual|July 2003||2003-07-31|February 2017|2017-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|ENCORE|298 of the 1121 participants enrolled in the Standard Therapy Group switched to Remicade during follow-up. They are included in both the Standard Therapy and Switched to Remicade treatment groups, but baseline measures (obtained at the time of their switch to Remicade) are shown as separate rows in the Baseline Measures table.|Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)|Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy|Completed|||2662|Actual|Merck Sharp & Dohme Corp.|||3||f||||t||||||||||2018-06-01 01:59:40.998616|2018-06-01 01:59:40.998616
NCT00705601|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2011-02-01|2008-06-25|2008-06-26|Estimate|||||||2011-02-01|2011-02-03|Estimate|August 2008||2008-08-31|February 2011|2011-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Nonrestorative Sleep RSQ (Restorative Sleep Questionnaire) Development-- Methodology Study|Refinement Of Patient Reported Outcomes Instruments In Subjects With Insomnia Characterized By Nonrestorative Sleep|Terminated||Phase 1|64|Actual|Pfizer||1||See Detailed Description|f||||f||||||||||2018-06-01 01:59:45.163754|2018-06-01 01:59:45.163754
NCT00705588|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2008-06-25|2008-06-25|2008-06-26|Estimate|||||||2008-06-25|2008-06-26|Estimate|August 2008||2008-08-31|May 2008|2008-05-31||||January 2010|Anticipated|2010-01-31||Interventional|||Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.||Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 01:59:45.264954|2018-06-01 01:59:45.264954
NCT00705575|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2010-12-22||2011-05-24|2008-06-25|2008-06-26|Estimate|2010-12-22|2011-01-21|Estimate||||2011-05-24|2011-05-30|Estimate|June 2008||2008-06-30|May 2011|2011-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ACQUIRE||Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension|A 12 Week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension|Completed||Phase 3|688|Actual|Novartis||2|||f||||f||||||||||2018-06-01 01:59:45.36543|2018-06-01 01:59:45.36543
NCT00705549|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2013-02-12|2008-06-25|2008-06-26|Estimate|||||||2013-02-12|2013-02-13|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer|Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer|Terminated||Phase 2|88|Actual|Hellenic Oncology Research Group||11||Due to poor accrual|f||||f||||||||||2018-06-01 01:59:45.690091|2018-06-01 01:59:45.690091
NCT00705536|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2011-06-07||2014-07-11|2008-06-25|2008-06-26|Estimate|2014-07-11|2014-07-14|Estimate||||2014-07-11|2014-07-14|Estimate|December 2007||2007-12-31|July 2014|2014-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||All participants who received at least 1 dose of Humalog or Humulin-R with or without rHuPH20.|Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20|A Phase I, Randomized, Double-Blind Crossover Pharmacokinetic, Pharmacodynamic, and Safety Study of Subcutaneously Administered Humalog® (Insulin Lispro Injection; Rapid-Acting Insulin) With and Without Recombinant Human Hyaluronidase (rHuPH20) Versus Subcutaneously Administered Humulin R® (Regular Insulin Injection) With and Without rHuPH20|Completed||Phase 1|26|Actual|Halozyme Therapeutics||4|||f||||f||||||||||2018-06-01 01:59:45.819598|2018-06-01 01:59:45.819598
NCT00705523|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2013-07-17||2015-06-01|2008-06-24|2008-06-26|Estimate|2015-06-01|2015-06-02|Estimate||||2015-06-01|2015-06-02|Estimate|June 2008||2008-06-30|June 2015|2015-06-30|December 2011|Actual|2011-12-31|March 2010|Actual|2010-03-31||Interventional|ChA||Varenicline (Chantix™) for the Treatment of Alcohol Dependence|A Phase II, Randomized, Double-Blind Pilot Trial of Varenicline (Chantix™) for the Treatment of Alcohol Dependence|Completed||Phase 2|40|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 01:59:46.541823|2018-06-01 01:59:46.541823
NCT00705510|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2010-11-08|2008-06-25|2008-06-26|Estimate|||||||2010-11-08|2010-11-09|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction|Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction|Completed||Phase 4|70|Actual|Mahidol University||2|||f||||t||||||||||2018-06-01 01:59:46.80849|2018-06-01 01:59:46.80849
NCT00705497|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2017-04-24|2008-06-25|2008-06-26|Estimate|||||||2017-04-24|2017-04-26|Actual|January 2003||2003-01-31|June 2011|2011-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Radiofrequency Ablation of Tumors|Radiofrequency Ablation of Tumors (RFA) A Phase I Study|Completed||Phase 1|31|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 01:59:46.878742|2018-06-01 01:59:46.878742
NCT00705484|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2017-01-03|2008-06-25|2008-06-26|Estimate|||||||2017-01-03|2017-01-04|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||European Safety Registry in Ulcerative Colitis (Study P04808AM3)|Ulcerative Colitis European Registry: A Prospective, Observational, Non-interventional, Post-Marketing Safety Surveillance Program|Completed|||2237|Actual|Merck Sharp & Dohme Corp.|||3||f||||t||||||||||2018-06-01 01:59:47.119216|2018-06-01 01:59:47.119216
NCT00705471|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2015-04-07|2008-06-25|2008-06-26|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)|Infliximab Use in Fistulizing Crohn's Disease: Impact on Health Care Resources|Terminated|||42|Actual|Merck Sharp & Dohme Corp.|||1|Study stopped prematurely due to enrolment challenges.|f||||f||||||||||2018-06-01 01:59:47.201252|2018-06-01 01:59:47.201252
NCT00705458|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2015-08-21|2008-06-24|2008-06-26|Estimate|||||||2015-08-21|2015-08-25|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|PROSPECT||Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain|A Randomized Trial Comparing Multi-Detector Coronary CT Angiography and Stress Myocardial Perfusion Imaging as the Initial Test for the Diagnosis of Coronary Artery Disease in Intermediate Risk Patients Admitted for Chest Pain|Completed||N/A|400|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-06-01 01:59:47.261717|2018-06-01 01:59:47.261717
NCT00705445|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2012-08-27|2008-06-25|2008-06-26|Estimate|||||||2012-08-27|2012-08-28|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional|||Evaluation of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Children of Pakistan|Prospective Cluster Randomized Controlled Evaluation of the Impact of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Cohorts of Children in Pakistan|Completed||Phase 2/Phase 3|2745|Actual|Aga Khan University||3|||f||||t||||||||||2018-06-01 01:59:47.339168|2018-06-01 01:59:47.339168
NCT00705432|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2011-05-13||2017-03-09|2008-06-24|2008-06-26|Estimate|2011-05-13|2011-06-14|Estimate||||2017-03-09|2017-04-07|Actual|August 2008||2008-08-31|March 2017|2017-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|SPRINT-2||Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)|A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1|Completed||Phase 3|1472|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 01:59:47.477509|2018-06-01 01:59:47.477509
NCT00705419|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2015-02-04|2008-06-25|2008-06-26|Estimate|||||||2015-02-04|2015-02-05|Estimate|July 2007||2007-07-31|February 2015|2015-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|COVER||Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)|COVER - Continuing Observation After Vicriviroc (VCV) Exposure Registry|Completed|||180|Actual|Merck Sharp & Dohme Corp.|||3||f||||t||||||||||2018-06-01 01:59:48.908343|2018-06-01 01:59:48.908343
NCT00705406|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2015-01-16|2012-08-06|2015-02-12|2008-06-25|2008-06-26|Estimate|2015-02-12|2015-02-16|Estimate|2012-08-06|2012-08-15|Estimate|2015-02-12|2015-02-16|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional||Intent-to-Treat (ITT)|A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza|A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza|Completed||Phase 2|405|Actual|BioCryst Pharmaceuticals|The majority of the subjects enrolled in this study with a laboratory confirmed influenza infection were infected with an influenza A/H1N1 virus containing an H275Y mutation associated with reduced susecptibility to peramivir and oseltamivir.|2|||f||||t||||||||||2018-06-01 01:59:49.015417|2018-06-01 01:59:49.015417
NCT00705367|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2010-05-04||2013-07-23|2008-06-24|2008-06-26|Estimate|2010-05-04|2010-06-03|Estimate||||2013-07-23|2013-07-30|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|July 2011|Actual|2011-07-31|January 2009|Actual|2009-01-31||Interventional|||Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg|A Single Center, Randomized, Placebo-Controlled, Double Blind, Parallel Group Study to Evaluate the Tolerability of a Single Dose of Abatacept 30 mg/kg Via Intravenous Infusion in Chinese SLE Subjects With Lupus Nephritis|Completed||Phase 1|13|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 01:59:49.841677|2018-06-01 01:59:49.841677
NCT00705354|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2012-04-12|2008-06-25|2008-06-26|Estimate|||||||2012-04-12|2012-04-13|Estimate|January 2009||2009-01-31|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery|Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following|Withdrawn||N/A|0|Actual|Lahey Clinic||2||Principal Investigator left the institution requested termination.|f||||f||||||||||2018-06-01 01:59:50.436071|2018-06-01 01:59:50.436071
NCT00705341|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2012-08-01||2013-02-11|2008-06-25|2008-06-26|Estimate|2013-02-11|2013-02-12|Estimate||||2013-02-11|2013-02-12|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|MeCIS||MethaCholine Bronchoprovocation Study (MeCIS)|MethaCholine Bronchoprovocation - Influence of High Potency Inhaled corticoSteroids in Asthma (MeCIS) Study|Completed||Phase 4|219|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||t||||||||||2018-06-01 01:59:50.526701|2018-06-01 01:59:50.526701
NCT00705328|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2016-04-20|2008-06-25|2008-06-26|Estimate|||||||2016-04-20|2016-04-21|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|FFE||Families First Edmonton (FFE)|Families First Edmonton: The Comparative Effects and Expense of Four Models of Augmenting Services for Low-income Families|Completed||Phase 2|2400|Actual|University of Alberta||3|||f||||f||||||||||2018-06-01 01:59:50.825272|2018-06-01 01:59:50.825272
NCT00705315|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2010-08-18|2008-06-24|2008-06-26|Estimate|||||||2010-08-18|2010-08-19|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer|Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study|Completed||Phase 1/Phase 2|46|Anticipated|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 01:59:50.885784|2018-06-01 01:59:50.885784
NCT00705302|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2017-02-10|2008-06-25|2008-06-26|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2007|Actual|2007-09-30|February 2017|2017-02-28|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Patient Education in Patients With Chronic Obstructive Pulmonary Disease (COPD) - Effect and Costs|A Randomised Controlled Trial of the Effect of a Patient Education Program for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|88|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-06-01 01:59:50.965326|2018-06-01 01:59:50.965326
NCT00705289|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-09-03||2015-07-29|2008-06-25|2008-06-26|Estimate|2010-05-12|2010-06-10|Estimate||||2015-07-29|2015-07-30|Estimate|December 2005||2005-12-31|July 2015|2015-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|REMARK||A Study to Observe Characteristics of Rheumatoid Arthritis in Patients Using Infliximab (Study P04250)|Epidemiology, Correlation and Predictive Value of Disease Activity and Biomarkers in RA Patients Initiated on Infliximab in Clinical Practice|Completed|||728|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||Samples Without DNA|"~     Blood and Urine samples~   "|||2018-06-01 01:59:51.211143|2018-06-01 01:59:51.211143
NCT00705276|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-25|||2009-04-14|2008-06-25|2008-06-26|Estimate|||||||2009-04-14|2009-04-15|Estimate|April 2008||2008-04-30|April 2009|2009-04-30||||May 2008|Actual|2008-05-31||Interventional|||Dermacyd Femina Delicata (Lactic Acid)- Photo Dermatological Evaluation of the Irritation and Sensitivity Potential|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Femina Delicata|Completed||Phase 3|26|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 01:59:51.536677|2018-06-01 01:59:51.536677
NCT00705263|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-05-28||2009-08-20|2008-06-23|2008-06-26|Estimate|2009-05-28|2009-07-17|Estimate||||2009-08-20|2009-08-25|Estimate|October 2005||2005-10-31|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)|Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Slovenia|Completed|||113|Actual|Schering-Plough|||1||f||||f||||||||||2018-06-01 01:59:51.600523|2018-06-01 01:59:51.600523
NCT00705250|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2016-11-21||2017-01-18|2008-06-25|2008-06-26|Estimate|2016-11-21|2017-01-19|Estimate||||2017-01-18|2017-03-03|Actual|June 2008||2008-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma|A Phase II Study of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma.|Completed||Phase 2|36|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 01:59:51.753362|2018-06-01 01:59:51.753362
NCT00705237|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2009-02-17|2008-06-24|2008-06-25|Estimate|||||||2009-02-17|2009-02-18|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|May 2008|Actual|2008-05-31||Interventional|||Study of the Use of LUMA Lightwire|LUMA Lightwire Study|Terminated||Phase 4|50|Actual|Lahey Clinic||||Insufficient findings for data analysis|f||||f||||||||||2018-06-01 01:59:51.96771|2018-06-01 01:59:51.96771
NCT00705224|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2011-08-09||2015-06-04|2008-06-24|2008-06-25|Estimate|2011-08-09|2011-09-16|Estimate||||2015-06-04|2015-07-01|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)|Observational Multicenter Study to Evaluate Influence of Insulin Resistance on the Safety and Efficacy (as Measured by Sustained Virological Response) of Treatment With Any Pegylated Interferon and Ribavirin (Standard of Care) in Different Populations of HCV Patients in Russia.|Completed|||250|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:52.047956|2018-06-01 01:59:52.047956
NCT00705211|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2015-02-24|2008-06-23|2008-06-25|Estimate|||||||2015-02-24|2015-02-25|Estimate|June 2007||2007-06-30|February 2015|2015-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)|Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy|Completed|||1794|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 01:59:52.26468|2018-06-01 01:59:52.26468
NCT00704821|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2012-04-06|2008-06-24|2008-06-25|Estimate|||||||2012-04-06|2012-04-09|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|June 2014|Anticipated|2014-06-30|December 2012|Anticipated|2012-12-31||Interventional|||PTC299 for Treatment of Advanced Cancer|A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer|Suspended||Phase 1|76|Anticipated|PTC Therapeutics||1|||f||||f||||||||||2018-06-01 01:59:58.520668|2018-06-01 01:59:58.520668
NCT00705198|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2016-11-11|2008-06-23|2008-06-25|Estimate|||||||2016-11-11|2016-11-15|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)|Temodal Capsule All-Case-Registered Surveillance (Designated Drug Use Investigation) - Evaluation of The Safety and Efficacy of Temodal in Patients With Newly Diagnosed Malignant Glioma (Concomitant With Radiotherapy and Then as Monotherapy) and Relapsed Malignant Glioma (as Monotherapy)|Completed|||1804|Actual|Merck Sharp & Dohme Corp.|||3||f||||f||||||||||2018-06-01 01:59:52.335736|2018-06-01 01:59:52.335736
NCT00705185|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2010-06-07|2008-06-23|2008-06-25|Estimate|||||||2010-06-07|2010-06-08|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|Bio-TestMDD||Exploring a Potential Blood Test to Diagnose Major Depressive Disorder|"Exploring Potential Serum/Plasma-Based Biomarkers as a Test for Major Depressive Disorder Diagnostics (Bio-Test MDD)"|Completed|||120|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     serum, plasma~   "|||2018-06-01 01:59:52.407141|2018-06-01 01:59:52.407141
NCT00705172|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2014-12-19|2008-06-24|2008-06-25|Estimate|||||||2014-12-19|2014-12-23|Estimate|November 2008||2008-11-30|December 2014|2014-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome|Efficacy and Safety of Norditropin® (Somatropin) in Children With Prader-Willi Syndrome (PWS)|Completed|||41|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 01:59:52.483929|2018-06-01 01:59:52.483929
NCT00705159|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2011-06-14||2015-03-04|2008-06-23|2008-06-25|Estimate|2011-07-15|2011-08-11|Estimate||||2015-03-04|2015-03-24|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis|Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis|Completed||Phase 4|137|Actual|Bausch & Lomb Incorporated||4|||f||||f||||||||||2018-06-01 01:59:52.560094|2018-06-01 01:59:52.560094
NCT00705146|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2012-05-01||2014-12-09|2008-06-24|2008-06-25|Estimate|2014-12-09|2014-12-11|Estimate||||2014-12-09|2014-12-11|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||CMC (Carpometacarpal) OA (Osteoarthritis) Thumb Splint Study|Comparison of Two Carpometacarpal Stabilizing Splints for People With Thumb Osteoarthritis|Completed||Phase 2|56|Actual|University of British Columbia|The main limitation of this cross-over trial was that the therapists who collected the data were not blinded to the splinting intervention, as they were required to fabricate and fit each splint.|2|||f||||f||||||||||2018-06-01 01:59:52.864688|2018-06-01 01:59:52.864688
NCT00705133|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2018-03-02|2008-06-24|2008-06-25|Estimate|||||||2018-03-02|2018-03-06|Actual|July 2008|Actual|2008-07-31|March 2018|2018-03-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension|Using Either Intravenous (IV) or Subcutaneous (SQ) Treprostinil to Treat Pulmonary Hypertension Related to Underlying Interstitial Lung Disease|Completed||Phase 2|15|Actual|University of California, Los Angeles||1|||f||||f||||||||No||2018-06-01 01:59:53.094164|2018-06-01 01:59:53.094164
NCT00705120|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-23|2008-06-23|2008-06-25|Estimate|||||||2008-06-23|2008-06-25|Estimate|November 1995||1995-11-30|June 2008|2008-06-30|October 2007|Actual|2007-10-31|July 2000|Actual|2000-07-31||Interventional|||Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation|Treatment of Severe (Types II and III) Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation|Completed||Phase 1|9|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 01:59:53.174253|2018-06-01 01:59:53.174253
NCT00705107|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-02-11||2015-06-03|2008-06-23|2008-06-25|Estimate|2009-04-08|2009-06-02|Estimate||||2015-06-03|2015-06-30|Estimate|November 2004||2004-11-30|June 2015|2015-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)|Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C|Terminated|||267|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:53.250593|2018-06-01 01:59:53.250593
NCT00705094|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2014-09-29|2008-06-24|2008-06-25|Estimate|||||||2014-09-29|2014-10-01|Estimate|September 2008||2008-09-30|September 2014|2014-09-30|July 2012|Actual|2012-07-31|May 2011|Actual|2011-05-31||Observational|||Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients|Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients|Completed|||30|Anticipated|AHS Cancer Control Alberta|||2||f||||f||||||||||2018-06-01 01:59:53.376529|2018-06-01 01:59:53.376529
NCT00705081|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-03-26||2015-06-08|2008-06-23|2008-06-25|Estimate|2009-06-11|2009-08-03|Estimate||||2015-06-08|2015-07-03|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)|Observational Study Evaluating the LDL-C Lowering Effects of Ezetimibe With a Statin as Prescribed in Daily Routine Practice in an Indonesian Population|Completed|||453|Actual|Merck Sharp & Dohme Corp.|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.||2||f||||f||||||||||2018-06-01 01:59:53.441707|2018-06-01 01:59:53.441707
NCT00705055|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2017-08-08|2008-06-24|2008-06-25|Estimate|||||||2017-08-08|2017-08-09|Actual|November 2007||2007-11-30|November 2013|2013-11-30|December 30, 2013|Actual|2013-12-30|December 30, 2013|Actual|2013-12-30||Observational|DW-6/2007||Face Anthropometric Pattern Recognition Technology for Computer Aided Diagnosis of Human Genetic Disorders.|Face Anthropometric Pattern Recognition Technology, Based on 3D Reconstruction Technology, for Computer Aided Diagnosis of Human Genetic Disorders. Multicenter Collaborative Study.|Completed|||1000|Actual|Carmel Medical Center|||4||f||||t||||||||||2018-06-01 01:59:53.779265|2018-06-01 01:59:53.779265
NCT00705042|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2009-07-27|2008-06-23|2008-06-25|Estimate|||||||2009-07-27|2009-07-28|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Study Evaluating Enbrel Drug Levels in Healthy Male Chinese Subjects|A Randomized, Open-Label, Single-Dose Administration, Parallel-Group, Multisite Study of the Pharmacokinetics of Etanercept, 25 or 50 mg, Administered Subcutaneously to Healthy Chinese Male Subjects|Completed||Phase 1|60|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 01:59:53.844739|2018-06-01 01:59:53.844739
NCT00704834|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2017-07-13|2008-06-23|2008-06-25|Estimate|||||||2017-07-13|2017-07-18|Actual|March 2006||2006-03-31|July 2017|2017-07-31|August 2027|Anticipated|2027-08-31|August 2027|Anticipated|2027-08-31||Observational|||Gene Expression Profiles in Multiple Sclerosis (MS)|Gene Expression Profiles in Patients With Multiple Sclerosis|Suspended|||120|Anticipated|University of California, Davis|||4|Temporarily suspended due to funding issues|f||||f||||||Samples With DNA|"~     35cc of peripheral blood will be obtained from each subject via venipuncture.~   "|No||2018-06-01 01:59:58.440353|2018-06-01 01:59:58.440353
NCT00705016|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2014-03-28||2014-03-28|2008-06-24|2008-06-25|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|September 2011|Actual|2011-09-30||Interventional|ADVANTAGE|Intention-to-treat (ITT) population included all participants who were randomized to trial treatment.|Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Open-label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck|Completed||Phase 1/Phase 2|184|Actual|Merck KGaA||3|||f||||t||||||||||2018-06-01 01:59:54.000695|2018-06-01 01:59:54.000695
NCT00705003|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2013-03-12||2014-06-17|2008-06-24|2008-06-25|Estimate|2014-06-17|2014-06-18|Estimate||||2014-06-17|2014-06-18|Estimate|May 2008||2008-05-31|June 2014|2014-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)|A Double-Blind, Placebo-Controlled Study of a Combination Product (BCI-024 and BCI-049) in Patients With Major Depressive Disorder (MDD)|Completed||Phase 2|142|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-06-01 01:59:55.498847|2018-06-01 01:59:55.498847
NCT00704990|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2015-10-15|2008-06-24|2008-06-25|Estimate|||||||2015-10-15|2015-10-19|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD)|The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder: A Pilot Study|Completed||Phase 2/Phase 3|28|Actual|The Canadian College of Naturopathic Medicine||1|||f||||t||||||||||2018-06-01 01:59:55.790005|2018-06-01 01:59:55.790005
NCT00704977|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2008-06-24|2008-06-24|2008-06-25|Estimate|||||||2008-06-24|2008-06-25|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Alcohol 20% for Separation of Pterygium and Comparison of Different Wound Closure Methods|Evaluation of Alcohol 20% for Separation of Pterygium Tissue During Pterygium Surgery and Comparison of Three Different Methods of Wound Closure in Pterygium Surgery: Bare Sclera, Sliding Flap, Amniotic Membrane With Biological Glue|Unknown status|Recruiting|N/A|150|Anticipated|Soroka University Medical Center||3|||f||||f||||||||||2018-06-01 01:59:55.856121|2018-06-01 01:59:55.856121
NCT00704964|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2011-03-24||2015-10-05|2008-06-23|2008-06-25|Estimate|2011-03-24|2011-04-21|Estimate||||2015-10-05|2015-10-06|Estimate|May 2005||2005-05-31|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|@dhere||Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)|Impact of Patient Support From Medical Staff on the Adherence to Therapy With PegIntron Plus Rebetol|Completed|||746|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:55.933264|2018-06-01 01:59:55.933264
NCT00704951|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2015-08-24|2008-06-23|2008-06-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|June 2011|Anticipated|2011-06-30|May 2011|Anticipated|2011-05-31||Observational|||Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)|P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.|Withdrawn|||0|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:56.109122|2018-06-01 01:59:56.109122
NCT00704938|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2012-07-10||2015-10-06|2008-06-24|2008-06-25|Estimate|2012-07-10|2012-08-14|Estimate||||2015-10-06|2015-10-28|Estimate|June 2008||2008-06-30|September 2015|2015-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer|Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated prior to completing accrual due to the withdrawal of support from our collaborator.|2||Terminated due to withdrawal of support from our collaborator.|f||||t||||||||||2018-06-01 01:59:56.27952|2018-06-01 01:59:56.27952
NCT00704925|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2018-05-16|2008-06-23|2008-06-25|Estimate|||||||2018-05-16|2018-05-21|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Treatment of Lambert-Eaton Syndrome With 3,4 DAP|Treatment of Lambert-Eaton Syndrome With 3, 4-Diaminopyridine|Available|||||University of California, Davis|||||||||||||||||||2018-06-01 01:59:56.617869|2018-06-01 01:59:56.617869
NCT00704912|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2015-11-13||2016-11-03|2008-06-23|2008-06-25|Estimate|2015-11-13|2015-12-17|Estimate||||2016-11-03|2016-11-07|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|OWL-PCOS||Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women|Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women|Completed||Phase 2|217|Actual|Milton S. Hershey Medical Center||3|||f||||t||||||||||2018-06-01 01:59:56.72545|2018-06-01 01:59:56.72545
NCT00704899|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-25|2008-06-23|2008-06-25|Estimate|||||||2008-06-25|2008-07-04|Estimate|March 2006||2006-03-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Anti-Depressants vs Physiotherapy in Management of Fibromyalgia|Effect of Anti-Depressants vs Physiotherapy in Management of Fibromyalgia Syndrome: What Predicts a Clinical Benefit?|Completed||Phase 3|175|Actual|Mahatma Gandhi Institute of Medical Sciences||2|||f||||f||||||||||2018-06-01 01:59:57.483171|2018-06-01 01:59:57.483171
NCT00704886|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2009-06-22|2008-06-24|2008-06-25|Estimate|||||||2009-06-22|2009-06-23|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Randomized Controlled Trial of Using Video Images in Dementia|A Randomized Controlled Trial of Using Video Images in Dementia|Completed||N/A|200|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 01:59:57.547727|2018-06-01 01:59:57.547727
NCT00704860|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2011-01-18|2008-06-23|2008-06-25|Estimate|||||||2011-01-18|2011-01-19|Estimate|February 2005||2005-02-28|February 2009|2009-02-28|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism|Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism|Completed||Phase 4|27|Actual|University of Ottawa||1|||f||||f||||||||||2018-06-01 01:59:57.609522|2018-06-01 01:59:57.609522
NCT00704847|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2012-08-13||2012-10-22|2008-06-24|2008-06-25|Estimate|2012-08-13|2012-09-12|Estimate||||2012-10-22|2012-10-29|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis|Terminated||Phase 3|1030|Actual|Nordic Bioscience A/S|The study showed an underexposure to calcitonin compared to what was expected from phase I trials.|2||Male subjects were terminated due to an imbalance in prostate cancer events|f||||t||||||||||2018-06-01 01:59:57.712856|2018-06-01 01:59:57.712856
NCT00704808|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2010-03-17||2015-09-08|2008-06-23|2008-06-25|Estimate|2010-03-17|2010-04-02|Estimate||||2015-09-08|2015-09-09|Estimate|May 2006||2006-05-31|September 2015|2015-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)|Post Marketing Surveillance of Radiotherapy With Concomitant and Adjuvant Chemotherapy With Temozolomide for Patients With Newly Diagnosed and Operated Glioblastoma Multiforme|Completed|||180|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:58.60454|2018-06-01 01:59:58.60454
NCT00704795|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2008-06-25|2008-06-24|2008-06-25|Estimate|||||||2008-06-25|2008-06-26|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|October 2009|Anticipated|2009-10-31|March 2009|Anticipated|2009-03-31||Observational|||Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes|Glucagon Responses Following Oral Glucose and Isoglycemic iv Glucose in Patients With Type 1 Diabetes - a Role for the Gastrointestinal Tract in Diabetic Hyperglucagonemia?|Unknown status|Active, not recruiting||20|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 01:59:58.776509|2018-06-01 01:59:58.776509
NCT00704782|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23||2015-11-13|2015-11-13|2008-06-23|2008-06-25|Estimate||||2015-11-13|2015-12-10|Estimate|2015-11-13|2015-12-10|Estimate|April 2008||2008-04-30|November 2015|2015-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease|An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease|Terminated||Phase 2|50|Actual|Medivation, Inc.||1||The study was halted after a Phase 3 study of dimebon failed to show efficacy.|f||||||||||||||2018-06-01 01:59:58.849166|2018-06-01 01:59:58.849166
NCT00704769|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-03-12||2015-05-27|2008-06-23|2008-06-25|Estimate|2009-06-24|2009-08-11|Estimate||||2015-05-27|2015-06-22|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)|Observational Study Evaluating the Safety and Efficacy of Desloratadine Syrup for Perennial Allergic Rhinitis in Indonesian Pediatric Patients|Completed|||591|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:58.913397|2018-06-01 01:59:58.913397
NCT00704756|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2014-08-08|2008-06-23|2008-06-25|Estimate|||||||2014-08-08|2014-08-11|Estimate|January 2009||2009-01-31|August 2014|2014-08-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Observational|PEGIMPACT||An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)|An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT|Withdrawn|||0|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 01:59:59.054813|2018-06-01 01:59:59.054813
NCT00704743|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-24|2008-06-24|2008-06-25|Estimate|||||||2008-06-24|2008-06-25|Estimate|November 1998||1998-11-30|June 2008|2008-06-30|January 2004|Actual|2004-01-31|||||Interventional|||A Trial Comparing Circumferential Casting Versus Splinting in Displaced Colles' Fractures|A Prospective Randomized Controlled Trial Comparing Circumferential Casting Versus Splinting in Displaced Colles' Fractures|Completed||Phase 3|120|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 01:59:59.110192|2018-06-01 01:59:59.110192
NCT00704730|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2014-04-08||2015-08-19|2008-06-23|2008-06-25|Estimate|2014-08-29|2014-09-09|Estimate||||2015-08-19|2015-08-27|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|October 2011|Actual|2011-10-31||Interventional|EXAM||Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer|An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer|Unknown status|Active, not recruiting|Phase 3|330|Actual|Exelixis||2|||f||||t||||||||||2018-06-01 01:59:59.309769|2018-06-01 01:59:59.309769
NCT00704717|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-02-11||2015-04-08|2008-06-23|2008-06-25|Estimate|2009-04-08|2009-06-02|Estimate||||2015-04-08|2015-04-29|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)|Evaluation of Satisfaction in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C|Completed|||185|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 02:00:00.782082|2018-06-01 02:00:00.782082
NCT00704704|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-24|2008-06-24|2008-06-25|Estimate|||||||2008-06-24|2008-06-25|Estimate|September 2008||2008-09-30|June 2008|2008-06-30|April 2011|Anticipated|2011-04-30|September 2010|Anticipated|2010-09-30||Interventional|IMDS001||Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)|A Phase 2, Single Arm Study to Determine the Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk Myelodysplastic Syndrome|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 02:00:00.923681|2018-06-01 02:00:00.923681
NCT00704691|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-21|||2012-04-18|2008-06-24|2008-06-25|Estimate|||||||2012-04-18|2012-04-20|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas|Open-Label, One Arm Pilot Investigation of Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas|Terminated||Early Phase 1|1|Actual|University of Alabama at Birmingham||1||Closed due to futility with only 1 patient accrued|f||||t||||||||||2018-06-01 02:00:01.049358|2018-06-01 02:00:01.049358
NCT00704678|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2016-09-22|2008-06-24|2008-06-25|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2008||2008-08-31|September 2016|2016-09-30||||June 2010|Actual|2010-06-30||Interventional|SBR759||Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis|A 12-week, Open Label, Multicenter, Titration Study, With a 12 Month Extension, to Determine the Optimal Titration Regimen for SBR759, Compared to Sevelamer HCl, in Lowering Serum Phosphate Levels in Asian Patients With Chronic Kidney Disease on Hemodialysis|Completed||Phase 2|203|Actual|Novartis||4|||f||||||||||||||2018-06-01 02:00:01.129077|2018-06-01 02:00:01.129077
NCT00704665|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-24|2008-06-24|2008-06-25|Estimate|||||||2008-06-24|2008-06-25|Estimate|December 1998||1998-12-31|June 2008|2008-06-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma|A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Scleroderma|Completed||Phase 3|231|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 02:00:01.238141|2018-06-01 02:00:01.238141
NCT00703313|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-02-04|2008-06-20|2008-06-23|Estimate|||||||2009-02-04|2009-02-06|Estimate|May 2008||2008-05-31|February 2009|2009-02-28||||June 2008|Actual|2008-06-30||Interventional|||Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators||Completed||Phase 4|72|Anticipated|Santen Inc.||3|||f||||f||||||||||2018-06-01 02:00:36.91796|2018-06-01 02:00:36.91796
NCT00704652|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2015-04-06|2008-06-23|2008-06-25|Estimate|||||||2015-04-06|2015-04-07|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|EPOinDR||Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus|Evaluation of Functional and Morphological Retinal Changes in the Course of Systemic Aranesp Treatment in Patients With Diabetes Mellitus|Terminated|||5|Actual|Medical University of Vienna|||2|Patient recruitment was not sufficient to achieve the needed patient numbers.|f||||f||||||||||2018-06-01 02:00:01.338996|2018-06-01 02:00:01.338996
NCT00704639|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-22|||2017-07-10|2008-06-22|2008-06-25|Estimate|||||||2017-07-10|2017-07-12|Actual|April 2008||2008-04-30|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Chemoradiation Treatment for Head and Neck Cancer|A Phase II Study of Cetuximab, Carboplatin and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma|Completed||Phase 1/Phase 2|60|Actual|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||f||||||||||2018-06-01 02:00:01.524813|2018-06-01 02:00:01.524813
NCT00704626|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2018-03-06|2008-06-23|2008-06-25|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2002||2002-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|SAA||Serum Auto-Antibodies in Neurological Diseases|CCRC: Serum Auto-Antibodies in Neurological Disease|Enrolling by invitation|||120|Anticipated|University of California, Davis|||1||f||||f||||||Samples With DNA|"~     5cc of serum will be obtained from patients with multiple sclerosis and other autoimmune and~     inflammatory diseases of the nervous system. Samples may be processed immediately or at a~     later time. Samples will be stored frozen in the freezer located in the Neuroscience building~     at Research Park in Davis, CA. Samples are identified with initials only.~   "|No||2018-06-01 02:00:02.008167|2018-06-01 02:00:02.008167
NCT00704613|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2011-11-29|2008-06-23|2008-06-25|Estimate|||||||2011-11-29|2011-12-01|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Planning Margin Requirements for Pediatric Radiation Oncology|Planning Margin Requirements for Pediatric Radiation Oncology|Completed|||375|Actual|St. Jude Children's Research Hospital|||||f||||f||||||||||2018-06-01 02:00:02.343375|2018-06-01 02:00:02.343375
NCT00704600|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2014-12-05|2008-06-24|2008-06-25|Estimate|||||||2014-12-05|2014-12-08|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|September 2010|Actual|2010-09-30||Interventional|Nelfinavir||Nelfinavir, a Phase I/Phase II Rectal Cancer Study|A Phase I/II Trial Testing Nelfinavir, an Inhibitor of Akt Signaling, in Combination With Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer|Completed||Phase 1/Phase 2|15|Actual|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-06-01 02:00:02.622543|2018-06-01 02:00:02.622543
NCT00704587|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2016-04-05|2008-06-23|2008-06-25|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2006||2006-11-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|ProFaCo||Prognostic Factors for All Types of Cancer Combined|Flow Cytometrical Analysis of the Human Immune System to Assess Tumor-related Material Piling up in Activated Macrophages in All Relevant Cancer Types.|Completed|||520|Actual|Atrium Medical Center|||||f||||f||||||Samples With DNA|"~     white cells~      tissue~      plasma~      serum~   "|||2018-06-01 02:00:02.942571|2018-06-01 02:00:02.942571
NCT00704574|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2017-01-30|2008-06-23|2008-06-25|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|PREDICTIVE™||Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes|Safety of Levemir® (Insulin Detemir) Treatment in Children and Adolescents With Type 1 Diabetes (PREDICTIVE™ - Youth)|Completed|||159|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:00:03.11437|2018-06-01 02:00:03.11437
NCT00704561|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2010-02-09|2008-06-24|2008-06-25|Estimate|||||||2010-02-09|2010-02-10|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|OCTAMI||Six-month Coverage and Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography|Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).|Completed||Phase 3|44|Actual|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-06-01 02:00:03.603291|2018-06-01 02:00:03.603291
NCT00704548|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2009-06-25|2008-06-23|2008-06-25|Estimate|||||||2009-06-25|2009-06-26|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Antihypertensive Effect of Simvastatin in Hypertensive Patients|Antihypertensive Effect of Simvastatin in Hypertensive Patients: a Randomized Clinical Trial With Ambulatory Blood Pressure Monitoring|Unknown status|Recruiting|Phase 4|92|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||||||||||||2018-06-01 02:00:04.03771|2018-06-01 02:00:04.03771
NCT00704535|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-05-21||2015-04-09|2008-06-23|2008-06-25|Estimate|2009-05-21|2009-07-14|Estimate||||2015-04-09|2015-04-30|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)|Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Ezetimibe Among Filipino Patients|Completed|||4105|Actual|Merck Sharp & Dohme Corp.|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.||1||f||||f||||||||||2018-06-01 02:00:04.210604|2018-06-01 02:00:04.210604
NCT00704522|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2010-04-21||2015-10-05|2008-06-23|2008-06-25|Estimate|2010-04-21|2010-05-17|Estimate||||2015-10-05|2015-10-06|Estimate|March 2005||2005-03-31|October 2015|2015-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)|Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program.|Completed|||601|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 02:00:06.489489|2018-06-01 02:00:06.489489
NCT00704509|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2010-09-24|2008-06-24|2008-06-25|Estimate|||||||2010-09-24|2010-09-27|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Efficacy of Bifeprunox in Patients With Schizophrenia|A Multinational, Randomised, Double-Blind, Fixed-Dose, Bifeprunox Study Combining a 12-Week Placebo-Controlled, Quetiapine-Referenced Phase With a 12-Month Quetiapine-Controlled Phase in Patients With Schizophrenia|Terminated||Phase 3|346|Actual|H. Lundbeck A/S||3||Interim analysis showed inadequate efficacy of bifeprunox|f||||f||||||||||2018-06-01 02:00:07.046074|2018-06-01 02:00:07.046074
NCT00704496|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|2017-09-20||2017-09-20|2008-06-24|2008-06-25|Estimate|2017-09-20|2017-10-18|Actual||||2017-09-20|2017-10-18|Actual|June 2007||2007-06-30|September 2017|2017-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||data disposed of and no longer in existence|The Effect of Pseudoephedrine on Rhinitis and Sleep|The Effect of Pseudoephedrine on Rhinitis and Sleep|Completed||Phase 3|34|Actual|Milton S. Hershey Medical Center|data disposed of and no longer in existence|2|||f||||f|t|f||||||||2018-06-01 02:00:07.393073|2018-06-01 02:00:07.393073
NCT00704483|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2016-11-16|2008-06-24|2008-06-25|Estimate|||||||2016-11-16|2016-11-18|Estimate|July 2008||2008-07-31|November 2016|2016-11-30||||August 2010|Actual|2010-08-31||Interventional|SBR759||Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis|A 12-week, Open Label, Multicenter, Titration Study, With a 9-month Maintenance Treatment Extension, to Demonstrate Efficacy of SBR759 Compared to Sevelamer HCl in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis|Completed||Phase 2|321|Actual|Novartis||4|||f||||||||||||||2018-06-01 02:00:07.808549|2018-06-01 02:00:07.808549
NCT00704470|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2008-06-25|2008-06-24|2008-06-25|Estimate|||||||2008-06-25|2008-06-27|Estimate|April 2005||2005-04-30|June 2008|2008-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Performance and Stress During Full Scale Simulator Training|Excellence in Performance and Stress Reduction During Two Different Full Scale Simulator Training Courses: A Pilot Study|Completed||N/A|32|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 02:00:08.105669|2018-06-01 02:00:08.105669
NCT00704457|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-24|||2013-08-01|2008-06-24|2008-06-25|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2004||2004-02-29|August 2013|2013-08-31|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Observational|||Impact Of Sacral Neuromodulation On Urine Markers For Interstitial Cystitis (IC)|Impact Of Sacral Neuromodulation On Urine Markers For IC|Completed|||11|Actual|William Beaumont Hospitals|||1||f||||f||||||Samples Without DNA|"~     Urines were collected and sent for urine marker analysis.~   "|||2018-06-01 02:00:08.350457|2018-06-01 02:00:08.350457
NCT00704444|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2015-02-24|2008-06-23|2008-06-25|Estimate|||||||2015-02-24|2015-02-25|Estimate|June 2007||2007-06-30|February 2015|2015-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)|Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy|Completed|||11332|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:00:08.529733|2018-06-01 02:00:08.529733
NCT00704431|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2016-11-03|2008-06-20|2008-06-24|Estimate|||||||2016-11-03|2016-11-04|Estimate|May 2008||2008-05-31|November 2016|2016-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study With Darapladib to Collect Tolerability Information|An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects|Completed||Phase 1|2|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:00:08.696238|2018-06-01 02:00:08.696238
NCT00704418|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2010-11-15||2013-01-11|2008-06-20|2008-06-24|Estimate|2011-01-07|2011-01-26|Estimate||||2013-01-11|2013-01-18|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery||Completed||Phase 3|156|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:00:08.921093|2018-06-01 02:00:08.921093
NCT00704405|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2014-09-26||2017-03-03|2008-06-23|2008-06-24|Estimate|2014-09-26|2014-09-29|Estimate||||2017-03-03|2017-03-31|Actual|March 2009||2009-03-31|March 2017|2017-03-31|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional||The Baseline Population consists of all randomized C and NC participants.|Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)|A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Experienced Patients With Chronic Genotype 1 Hepatitis C Virus Infection|Completed||Phase 2|285|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 02:00:09.343763|2018-06-01 02:00:09.343763
NCT00704392|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2015-08-19|2008-06-23|2008-06-24|Estimate|||||||2015-08-19|2015-08-20|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL647 and XL147 Administered in Combination Daily to Subjects With Solid Tumors|Withdrawn||Phase 1|0|Actual|Exelixis||1||Study not initiated|f||||||||||||||2018-06-01 02:00:11.142232|2018-06-01 02:00:11.142232
NCT00704379|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2015-04-24||2015-08-10|2008-06-23|2008-06-24|Estimate|2015-04-24|2015-05-12|Estimate||||2015-08-10|2015-08-25|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury|Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury|Completed||Phase 2/Phase 3|94|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:00:11.3382|2018-06-01 02:00:11.3382
NCT00704366|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2011-05-13|2008-06-23|2008-06-24|Estimate|||||||2011-05-13|2011-05-16|Estimate|June 2008||2008-06-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours|A Phase I, Open-label, Dose-escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignancies|Completed||Phase 1|18|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 02:00:12.27212|2018-06-01 02:00:12.27212
NCT00704353|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2013-09-16||2018-01-22|2008-06-23|2008-06-24|Estimate|2013-09-16|2013-11-25|Estimate||||2018-01-22|2018-02-20|Actual|June 2008||2008-06-30|January 2018|2018-01-31|March 2011|Actual|2011-03-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia|A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent|Completed||Phase 3|735|Actual|Luitpold Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:00:12.422278|2018-06-01 02:00:12.422278
NCT00704340|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2010-04-26||2017-08-07|2008-06-23|2008-06-24|Estimate|2010-07-27|2010-07-28|Estimate||||2017-08-07|2017-09-07|Actual|September 2005||2005-09-30|August 2017|2017-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||DuraSeal Sealant Post Market Study|DuraSeal Sealant Post Market Study|Completed||N/A|237|Actual|Integra LifeSciences Corporation||2|||f||||f||||||||||2018-06-01 02:00:13.09067|2018-06-01 02:00:13.09067
NCT00704327|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2017-12-19|2008-06-20|2008-06-24|Estimate|||||||2017-12-19|2017-12-21|Actual|February 2008|Actual|2008-02-29|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Evaluating the Impact of Cerebral Ischemic And Degenerative Changes On Cognition|Evaluating the Impact of Cerebral Ischemic And Degenerative Changes On Cognition|Terminated|||170|Actual|Lahey Clinic||||Investigator left the Institution|f||||f||||||||||2018-06-01 02:00:13.769678|2018-06-01 02:00:13.769678
NCT00530478|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-17|Estimate|||||||2007-09-13|2007-09-17|Estimate||||July 2007|2007-07-31||||||||Interventional|||Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment||Unknown status|Recruiting|N/A|||Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:55:23.499947|2018-06-01 02:55:23.499947
NCT00704314|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-23|2008-06-23|2008-06-24|Estimate|||||||2008-06-23|2008-06-24|Estimate|October 2002||2002-10-31|June 2008|2008-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?|Effects of High Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Non-Obese Type 2 Diabetic Patients|Completed||N/A|20|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 02:00:14.04434|2018-06-01 02:00:14.04434
NCT00704301|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2010-08-12|2008-06-23|2008-06-24|Estimate|||||||2010-08-12|2010-08-13|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Rivastigmine for Intensive Care Unit (ICU) Delirium|Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial|Terminated||Phase 4|104|Actual|UMC Utrecht||2||The study is prematurely terminated due to a safety issue|f||||t||||||||||2018-06-01 02:00:14.18982|2018-06-01 02:00:14.18982
NCT00704288|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2014-07-15|2008-06-20|2008-06-24|Estimate|||||||2014-07-15|2014-07-16|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme|A Phase 2 Study of XL184 in Subjects With Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse|Completed||Phase 2|222|Actual|Exelixis||1|||f||||||||||||||2018-06-01 02:00:14.546725|2018-06-01 02:00:14.546725
NCT00704275|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-06-23|2008-06-23|2008-06-24|Estimate|||||||2008-06-23|2008-06-24|Estimate|June 2007||2007-06-30|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|July 2008|Anticipated|2008-07-31||Interventional|||Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes|Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes|Unknown status|Recruiting|Phase 4|60|Anticipated|Chulalongkorn University||2|||f||||f||||||||||2018-06-01 02:00:14.669151|2018-06-01 02:00:14.669151
NCT00704262|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2013-10-30|2008-06-23|2008-06-24|Estimate|||||||2013-10-30|2013-10-31|Estimate|May 2008||2008-05-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds|Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and on the Intertriginous Areas|Completed||Phase 2|33|Actual|LEO Pharma||1|||f||||f||||||||||2018-06-01 02:00:14.906897|2018-06-01 02:00:14.906897
NCT00704249|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-22|||2009-02-10|2008-06-23|2008-06-24|Estimate|||||||2009-02-10|2009-02-11|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|VENICE||VENICE Study Nevirapine Full Dose/Dose Escalation|Randomized Multicenter Study to Compare Starting Nevirapine at the Full Dose With Dose Escalation in Patients Who Require Efavirenz to be Withdrawn Due to Adverse Reactions|Completed||Phase 4|80|Anticipated|Clinical Trial Agency of HIV Study Group||2|||f||||||||||||||2018-06-01 02:00:15.105012|2018-06-01 02:00:15.105012
NCT00704236|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2008-12-10|2008-06-23|2008-06-24|Estimate|||||||2008-12-10|2008-12-11|Estimate|September 2006||2006-09-30|December 2008|2008-12-31|February 2008|Actual|2008-02-29|||||Interventional|||Improvement of Insulin Resistance With Traditional Chinese Treatment in Patients With Type 2 Diabetes|Phase 4 Study on the Effect of Insulin Resistance With Traditional Chinese Treatment in Type 2 Diabetes|Completed||Phase 4|43|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 02:00:15.398969|2018-06-01 02:00:15.398969
NCT00704223|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2014-06-23|2008-06-20|2008-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|May 2008||2008-05-31|June 2014|2014-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|INTENSIV||Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes|Observational Study on Safety and Efficacy in Subjects Using NovoMix® 70 (Biphasic Insulin Aspart) for Treatment of Type 2 Diabetes Mellitus|Completed|||619|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 02:00:15.501491|2018-06-01 02:00:15.501491
NCT00704210|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2016-10-14|2008-06-23|2008-06-24|Estimate|||||||2016-10-14|2016-10-18|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|July 2009|Anticipated|2009-07-31|December 2008|Anticipated|2008-12-31||Interventional|SpiDERS||Effectiveness of Mechanical Decompression for Low Back Pain Relief|Effectiveness of Mechanical Decompression for Low Back Pain Relief|Withdrawn||N/A|0|Actual|State University of New York - Upstate Medical University||2||Study withdrawn by sponsor|f||||f||||||||||2018-06-01 02:00:15.686953|2018-06-01 02:00:15.686953
NCT00704197|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2016-01-22|2008-06-23|2008-06-24|Estimate|||||||2016-01-22|2016-01-25|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|December 2013|Actual|2013-12-31||Observational|ISIS||"ISIS Study of Sex Differences in Characteristics of Adiposity and Metabolism"|Study of Sex Differences in Characteristics of Adiposity and Metabolism|Unknown status|Active, not recruiting||23|Actual|Pennington Biomedical Research Center|||||f||||t||||||Samples With DNA|"~     whole blood, urine, adipose tissue~   "|||2018-06-01 02:00:15.815337|2018-06-01 02:00:15.815337
NCT00704184|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2014-09-26||2017-03-03|2008-06-23|2008-06-24|Estimate|2014-09-26|2014-10-01|Estimate||||2017-03-03|2017-03-31|Actual|July 2008||2008-07-31|March 2017|2017-03-31|April 2010|Actual|2010-04-30|December 2008|Actual|2008-12-31||Interventional||The baseline population consists of all participants treated with study medication. One participant was randomized to the placebo group but withdrew from the study prior to taking any study medication.|Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)|A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Hepatitis C Infection|Completed||Phase 2|95|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 02:00:15.966917|2018-06-01 02:00:15.966917
NCT00704171|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2009-12-21||2016-09-22|2008-06-23|2008-06-24|Estimate|2010-03-03|2010-03-15|Estimate||||2016-09-22|2016-10-27|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||PleuraSeal Post Market Study (Europe)|Prospective Multi-Center Randomized Post Market Study to Evaluate the PleuraSeal Sealant System as Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy|Completed||Phase 4|121|Actual|Integra LifeSciences Corporation||2|||f||||f||||||||||2018-06-01 02:00:17.813463|2018-06-01 02:00:17.813463
NCT00704158|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23||2015-02-02|2015-02-02|2008-06-23|2008-06-24|Estimate||||2015-02-02|2015-02-19|Estimate|2015-02-02|2015-02-19|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer|A Phase I/II Study of CR011-vcMMAE in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|42|Actual|Celldex Therapeutics|||||f||||f||||||||||2018-06-01 02:00:18.498286|2018-06-01 02:00:18.498286
NCT00704145|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2010-02-05|2008-06-23|2008-06-24|Estimate|||||||2010-02-05|2010-02-09|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|OCTAXUS||Optical Coherence Tomography Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease|A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease|Completed||Phase 4|30|Anticipated|A.O. Ospedale Papa Giovanni XXIII||1|||f||||t||||||||||2018-06-01 02:00:18.711862|2018-06-01 02:00:18.711862
NCT00704132|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|2011-04-21||2017-04-06|2008-06-23|2008-06-24|Estimate|2011-04-21|2011-05-16|Estimate||||2017-04-06|2017-05-12|Actual|February 14, 2007|Actual|2007-02-14|April 2017|2017-04-30|April 28, 2010|Actual|2010-04-28|April 28, 2010|Actual|2010-04-28||Interventional|||Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)|A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 1|57|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:00:18.883165|2018-06-01 02:00:18.883165
NCT00704119|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2010-03-23|2008-06-23|2008-06-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|May 2008||2008-05-31|March 2010|2010-03-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation|CT 5002 An Open-label, Non-randomized, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® Using a Tablet Formulation|Terminated||Phase 1|12|Actual|MediGene||||"Following an SAE, study was put on hold. After performing preclinical follow-up studies,~   volunteers were no longer available for continuation."|f||||t||||||||||2018-06-01 02:00:19.175805|2018-06-01 02:00:19.175805
NCT00704106|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2012-05-08|2008-06-23|2008-06-24|Estimate|||||||2012-05-08|2012-05-10|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|||||Observational|ADVPR||Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders|HBV Viral Suppression by Entecavir in Adefovir Partial Responders|Unknown status|Active, not recruiting||120|Anticipated|Pacific Health Foundation|||4||f||||f||||||||||2018-06-01 02:00:19.313907|2018-06-01 02:00:19.313907
NCT00704093|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-07-03|2008-06-23|2008-06-24|Estimate|||||||2008-07-03|2008-07-04|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Effect of Right Ventricular Pacing on Myocardial Oxidative Metabolism and Efficiency|The Effect of Right Ventricular Pacing on Myocardial Oxidative Metabolism and Efficiency|Completed||N/A|10|Actual|University of Turku|||||f||||f||||||||||2018-06-01 02:00:19.495325|2018-06-01 02:00:19.495325
NCT00704080|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2013-04-09|2008-06-20|2008-06-24|Estimate|||||||2013-04-09|2013-04-10|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Interventional|||A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas|A Phase 1 Dose-Escalation Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Subjects With Malignant Gliomas|Completed||Phase 1|54|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:00:19.602782|2018-06-01 02:00:19.602782
NCT00704067|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2015-02-11|2008-06-20|2008-06-24|Estimate|||||||2015-02-11|2015-02-12|Estimate|September 2008||2008-09-30|February 2015|2015-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Improving Work Outcomes for Veterans With Traumatic Brain Injury|Improving Work Outcomes for Veterans With Traumatic Brain Injury|Completed||N/A|50|Actual|United States Department of Defense||2|||f||||f||||||||||2018-06-01 02:00:19.799344|2018-06-01 02:00:19.799344
NCT00704054|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2015-02-12|2008-06-23|2008-06-24|Estimate|||||||2015-02-12|2015-02-13|Estimate|January 2008||2008-01-31|February 2015|2015-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)|A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors|Completed||Phase 1|15|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 02:00:19.913797|2018-06-01 02:00:19.913797
NCT00704028|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2013-09-16||2018-01-22|2008-06-23|2008-06-24|Estimate|2013-09-16|2013-11-25|Estimate||||2018-01-22|2018-02-20|Estimate|June 2008||2008-06-30|January 2018|2018-01-31|March 2011|Actual|2011-03-31|January 2010|Actual|2010-01-31||Interventional||Safety population|Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia|A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in Treating Iron Deficiency Anemia|Completed||Phase 3|161|Actual|Luitpold Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:00:20.11161|2018-06-01 02:00:20.11161
NCT00704015|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-23|2008-06-23|2008-06-24|Estimate|||||||2008-06-23|2008-06-24|Estimate|February 2004||2004-02-29|June 2008|2008-06-30|June 2008|Anticipated|2008-06-30|December 2006|Actual|2006-12-31||Interventional|||Smoking Cessation Intervention in Acute Orthopedic Surgery|Smoking Cessation Intervention in Acute Orthopedic Surgery - A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|105|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 02:00:20.51479|2018-06-01 02:00:20.51479
NCT00704002|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2013-03-27|2008-06-23|2008-06-24|Estimate|||||||2013-03-27|2013-03-29|Estimate|December 2006||2006-12-31|March 2013|2013-03-31|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|CONFraM||Conservative Versus Operative Treatment of Displaced Neck Fractures of the Fifth Metacarpal|Conservative Versus Operative Treatment of Displaced Neck Fractures of the Fifth Metacarpal|Terminated||N/A|9|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||||2018-06-01 02:00:20.592248|2018-06-01 02:00:20.592248
NCT00703989|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2008-06-23|2008-06-23|2008-06-24|Estimate|||||||2008-06-23|2008-06-24|Estimate|February 2005||2005-02-28|June 2008|2008-06-30|February 2008|Actual|2008-02-29|October 2006|Actual|2006-10-31||Interventional|||Reactive Oxygen Species in the Pathogenesis of Diabetic Complications|The Role of the Glucosamine Pathway and Reactive Oxygen Species in the Pathogenesis of Diabetic Complications|Completed||N/A|21|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-06-01 02:00:20.690015|2018-06-01 02:00:20.690015
NCT00703976|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2016-01-14||2017-02-15|2008-06-23|2008-06-24|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|October 2008||2008-10-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer|Phase II Randomized Trial of Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer|Completed||Phase 2|80|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:00:20.847195|2018-06-01 02:00:20.847195
NCT00703963|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2014-08-18||2014-08-18|2008-06-23|2008-06-24|Estimate|2014-08-18|2014-08-28|Estimate||||2014-08-18|2014-08-28|Estimate|March 2007||2007-03-31|August 2014|2014-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care|Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care: A Randomized Controlled Trial|Completed||N/A|200|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:00:21.691399|2018-06-01 02:00:21.691399
NCT00703950|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2015-08-10|2008-06-23|2008-06-24|Estimate|||||||2015-08-10|2015-08-11|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Sucking Pattern of Preterm Infants Using Cup or Bottle Before Breastfeeding|Effects of the Use of a Bottle and a Cup on Breast Sucking Patterns of Premature Infants: Safety and Efficacy|Terminated||Phase 4|56|Actual|Instituto Fernandes Figueira||2||Sample size was re- calculated considering sucking pattern parameters|f||||f||||||||||2018-06-01 02:00:22.175877|2018-06-01 02:00:22.175877
NCT00703937|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2013-09-16||2018-01-22|2008-06-23|2008-06-24|Estimate|2013-09-16|2013-11-25|Estimate||||2018-01-22|2018-02-20|Actual|July 2008||2008-07-31|January 2018|2018-01-31|March 2011|Actual|2011-03-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia|A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia|Completed||Phase 3|708|Actual|Luitpold Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:00:22.50908|2018-06-01 02:00:22.50908
NCT00703924|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2016-12-21||2017-04-25|2008-06-23|2008-06-24|Estimate|2016-12-21|2017-02-15|Actual||||2017-04-25|2017-05-30|Actual|March 2003||2003-03-31|April 2017|2017-04-30|November 2005|Actual|2005-11-30|November 2004|Actual|2004-11-30||Interventional|||Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World|Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: a Phase 2 Study in the Old World|Completed||Phase 2|92|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||Yes|Data will be shared with WRAIR|2018-06-01 02:00:22.868275|2018-06-01 02:00:22.868275
NCT00703911|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2011-07-29||2016-11-22|2008-06-23|2008-06-24|Estimate|2011-11-14|2011-12-19|Estimate||||2016-11-22|2017-01-11|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|ONE||Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors|A Prospective Observational Registry on the Use of NovoSeven® (Activated Recombinant Human Factor VIIa) for on Demand Treatment of Mild to Moderate Bleeds in Haemophilia A and B Patients With Inhibitors|Completed|||102|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:00:23.76105|2018-06-01 02:00:23.76105
NCT00703898|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-07-07|2008-06-23|2008-06-24|Estimate|||||||2008-07-07|2008-07-08|Estimate|November 2004||2004-11-30|June 2008|2008-06-30|April 2010||2010-04-30|December 2009||2009-12-31||Interventional|||Durability of Nevirapine-Based Antiretroviral Regimen|Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study|Completed||Phase 4|140|Actual|Bamrasnaradura Infectious Diseases Institute|||||f||||t||||||||||2018-06-01 02:00:24.746021|2018-06-01 02:00:24.746021
NCT00703885|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2013-06-19||2014-12-19|2008-06-23|2008-06-24|Estimate|2014-12-19|2014-12-22|Estimate||||2014-12-19|2014-12-22|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)|PharmacofMRI of Anxiolytic Medications (Alprazolam)|Completed||Phase 4|16|Actual|University of California, San Diego|"This is a single dose cross-over study in 16 healthy subjects.~BOLD fMRI analyses for this study were not completed by the investigators."|3|||f||||f||||||||||2018-06-01 02:00:24.830255|2018-06-01 02:00:24.830255
NCT00703872|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2009-01-08|2008-06-23|2008-06-24|Estimate|||||||2009-01-08|2009-01-09|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients|An Evaluation of Two Dose Routes of HDV-Interferon Administered With Ribavarin in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Hepasome Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:00:25.040337|2018-06-01 02:00:25.040337
NCT00703859|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2016-02-18|2008-06-23|2008-06-24|Estimate|||||||2016-02-18|2016-02-22|Estimate|July 2008||2008-07-31|September 2011|2011-09-30||||January 2010|Anticipated|2010-01-31||Interventional|||Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma|A Phase I Single Arm Trial Combining Radiotherapy and Temozolomide With Dichloroacetate (DCA) in Patients With Newly Diagnosed Glioblastoma Multiform Tumours|Withdrawn||Phase 1|0|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 02:00:25.152872|2018-06-01 02:00:25.152872
NCT00703846|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2012-01-19||2016-12-01|2008-06-20|2008-06-24|Estimate|2012-01-19|2012-02-23|Estimate||||2016-12-01|2017-01-30|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%|A PHASE 4, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% IN THE TREATMENT OF SEBORRHEIC DERMATITIS|Completed||Phase 4|498|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:00:25.410399|2018-06-01 02:00:25.410399
NCT00703833|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-22|||2015-10-30|2008-06-23|2008-06-24|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2002||2002-09-30|October 2015|2015-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)|A Double-Blind, Multicenter, Placebo-Controlled Study of MK0777 Gel Extrusion Module (GEM) 1.5 mg b.i.d. in the Treatment of Outpatients With Generalized Anxiety Disorder|Completed||Phase 2|51|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:00:25.837293|2018-06-01 02:00:25.837293
NCT00703820|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2018-03-02||2018-03-29|2008-06-23|2008-06-24|Estimate|2018-03-29|2018-04-02|Actual||||2018-03-29|2018-04-02|Actual|August 4, 2008|Actual|2008-08-04|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|March 30, 2017|Actual|2017-03-30||Interventional|||Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia|AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia|Active, not recruiting||Phase 3|324|Actual|St. Jude Children's Research Hospital||2|||f||||t|t|t|t|f||||||2018-06-01 02:00:25.966269|2018-06-01 02:00:25.966269
NCT00690001|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-01|||2008-07-07|2008-06-03|2008-06-04|Estimate|||||||2008-07-07|2008-07-08|Estimate|April 2008||2008-04-30|April 2008|2008-04-30||||||||Observational|||The Detection of Drug-Resistant HIV-1 in Taiwan|The Detection of Drug-Resistant HIV-1 in Taiwan|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 02:04:51.519099|2018-06-01 02:04:51.519099
NCT00703807|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2014-01-13|2008-06-23|2008-06-24|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers|A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers|Completed||Phase 1|10|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:00:27.225718|2018-06-01 02:00:27.225718
NCT00703794|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-23|||2017-09-27|2008-06-23|2008-06-24|Estimate|||||||2017-09-27|2017-09-29|Actual|June 2008||2008-06-30|September 2017|2017-09-30|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31|6 Months|Observational [Patient Registry]|RACER||Researching AXIUM Coiling Experience and Recanalization (RACER)|ev3 Researching AXIUM Coiling Experience and Recanalization (RACER)|Completed|||119|Actual|Medtronic Neurovascular Clinical Affairs|||1||f||||t||||||||||2018-06-01 02:00:27.333652|2018-06-01 02:00:27.333652
NCT00703781|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2011-11-07||2015-03-04|2008-06-23|2008-06-24|Estimate|2011-11-07|2011-12-09|Estimate||||2015-03-04|2015-03-24|Estimate|June 2008||2008-06-30|March 2015|2015-03-31||||November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery||Completed||Phase 3|126|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:00:27.529809|2018-06-01 02:00:27.529809
NCT00703768|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-02-13|2008-06-19|2008-06-23|Estimate|||||||2009-02-13|2009-02-17|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|June 2010|Anticipated|2010-06-30||Observational|||Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year|An Open-Label, Phase ll Trial Comparing FACT-P Scores For Subjects Who Are Indicated To Receive Androgen Deprivation Therapy And Have A Doubling In PSA Post Curative Therapy Of Either Less Than Or Greater Than One Year|Unknown status|Recruiting||300|Anticipated|Urology South Shore Research Inc.|||2||f||||f||||||||||2018-06-01 02:00:27.873855|2018-06-01 02:00:27.873855
NCT00703755|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-06-24|2008-06-20|2008-06-23|Estimate|||||||2008-06-24|2008-06-25|Estimate|March 2003||2003-03-31|June 2008|2008-06-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.|A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.|Completed||Phase 2|2288|Actual|Solvay Pharmaceuticals||7|||f||||f||||||||||2018-06-01 02:00:27.971385|2018-06-01 02:00:27.971385
NCT00703742|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2011-06-24|2008-06-20|2008-06-23|Estimate|||||||2011-06-24|2011-06-27|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression|A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression|Completed||N/A|50|Anticipated|Kunming Medical University||1|||f||||t||||||||||2018-06-01 02:00:28.444395|2018-06-01 02:00:28.444395
NCT00703729|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2015-07-15||2015-08-10|2008-06-20|2008-06-23|Estimate|2015-08-10|2015-09-10|Estimate||||2015-08-10|2015-09-10|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Compression and Cold Therapy on the Post-Operative Shoulder|The Effectiveness of Simultaneous Intermittent Compression and Continuous Cold Therapy on the Post-Operative Shoulder: A Randomized Controlled Trial|Completed||N/A|58|Actual|University of Colorado, Denver|"Some patients were removed from the trial due to non-compliance, most commonly for failing to complete the pain diaries.~There is also some inherent recall bias in asking a patient to fill out a diary."|2|||f||||f||||||||||2018-06-01 02:00:28.621227|2018-06-01 02:00:28.621227
NCT00703716|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2014-09-10|2008-06-20|2008-06-23|Estimate|||||||2014-09-10|2014-09-11|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|TRAUMAX||Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX|Stabilization of Trochanteric Fracture Using a Screw-plate TRAUMAX|Completed|||190|Actual|Integra LifeSciences Services|||||f||||f||||||||||2018-06-01 02:00:29.157487|2018-06-01 02:00:29.157487
NCT00703703|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2012-08-01|2008-06-19|2008-06-23|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects|A 3-way Cross-over, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess Pharmacologic Effects of a 7-day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older|Completed||Phase 1|117|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:00:29.248516|2018-06-01 02:00:29.248516
NCT00703690|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2015-06-11|2008-06-20|2008-06-23|Estimate|||||||2015-06-11|2015-06-12|Estimate|January 2002||2002-01-31|June 2015|2015-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)|A Multicenter, Double-Blind, Randomized, Placebo and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of MK0767 in Patients With Metabolic Syndrome and Dyslipidemia|Terminated||Phase 2|436|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-06-01 02:00:29.469549|2018-06-01 02:00:29.469549
NCT00703677|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2010-04-30||2015-06-09|2008-06-20|2008-06-23|Estimate|2010-04-30|2010-06-11|Estimate||||2015-06-09|2015-07-15|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration|A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration|Completed||Phase 1/Phase 2|17|Actual|Westat|The majority of subjects did not tolerate study drug, therefore, evaluations of subjects on study drug are limited in number.|1|||f||||f||||||||||2018-06-01 02:00:29.585399|2018-06-01 02:00:29.585399
NCT00703664|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2018-03-26|2008-06-20|2008-06-23|Estimate|||||||2018-03-26|2018-03-27|Actual|July 9, 2008|Actual|2008-07-09|October 2017|2017-10-31||||December 1, 2017|Actual|2017-12-01||Interventional|||Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma|Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-Cell Lymphomas|Completed||Phase 2|65|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:00:30.030015|2018-06-01 02:00:30.030015
NCT00703651|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2014-01-09|2008-06-20|2008-06-23|Estimate|||||||2014-01-09|2014-01-13|Estimate|September 2003||2003-09-30|January 2014|2014-01-31|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults|Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Vaxigrip® in Adults|Completed||Phase 2|1150|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 02:00:30.247743|2018-06-01 02:00:30.247743
NCT00407316|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-02|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|June 2006||2006-06-30|December 2006|2006-12-31|November 2006||2006-11-30|||||Observational|||Quality of Life and Visual Function in Uveitis Patients||Unknown status|Recruiting||50||The New York Eye & Ear Infirmary|||||f||||||||||||||2018-06-01 03:35:54.878995|2018-06-01 03:35:54.878995
NCT00703638|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2017-11-27|2008-06-20|2008-06-23|Estimate|||||||2017-11-27|2017-11-29|Actual|May 2008||2008-05-31|November 2017|2017-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.|Completed||Phase 1|16|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:00:30.379235|2018-06-01 02:00:30.379235
NCT00703625|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2017-03-05|2008-06-20|2008-06-23|Estimate|||||||2017-03-05|2017-03-07|Actual|March 8, 2008|Actual|2008-03-08|March 2017|2017-03-31|June 1, 2011|Actual|2011-06-01|May 1, 2011|Actual|2011-05-01||Interventional|||Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies|Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies|Completed||Phase 1|26|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 02:00:30.484874|2018-06-01 02:00:30.484874
NCT00703612|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-06-28|2008-06-20|2008-06-23|Estimate|||||||2008-06-28|2008-07-01|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|||Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Type 2 Diabetics|Phase I/II Study of Intravenous Administration of Activated Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 1/Phase 2|34|Actual|Adistem Ltd||1|||f||||f||||||||||2018-06-01 02:00:30.652396|2018-06-01 02:00:30.652396
NCT00703599|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-06-28|2008-06-20|2008-06-23|Estimate|||||||2008-06-28|2008-07-01|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes|Phase I/II Study of Intravenous Administration of Activated Autologous Adipose-Derived Stromal Vascular Fraction in Patients With Type 1 Diabetes|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Adistem Ltd||1|||f||||f||||||||||2018-06-01 02:00:30.991425|2018-06-01 02:00:30.991425
NCT00703586|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2012-10-22|2008-06-20|2008-06-23|Estimate|||||||2012-10-22|2012-10-23|Estimate|September 2007||2007-09-30|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc|A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02)|Completed||Phase 1|8|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 02:00:31.113072|2018-06-01 02:00:31.113072
NCT00703573|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20||2018-04-26|2018-05-04|2008-06-20|2008-06-23|Estimate||||2018-04-26|2018-05-01|Actual|2018-05-04|2018-05-08|Actual|May 2008||2008-05-31|May 2018|2018-05-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of S-777469 (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis|Completed||Phase 2|209|Actual|Shionogi Inc.||3|||f||||f||||||||||2018-06-01 02:00:31.251942|2018-06-01 02:00:31.251942
NCT00703560|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2013-01-18|2008-06-20|2008-06-23|Estimate|||||||2013-01-18|2013-01-21|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|September 2011|Actual|2011-09-30||Observational|VK||Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients|Molecular Basis of Interferon Response in HCV|Completed|||72|Anticipated|University of Texas Southwestern Medical Center|||2||f||||f||||||Samples With DNA|"~     serum, peripheral blood mononuclear cells~   "|||2018-06-01 02:00:31.440062|2018-06-01 02:00:31.440062
NCT00703547|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2017-08-21|2008-06-20|2008-06-23|Estimate|||||||2017-08-21|2017-08-22|Actual|January 28, 2008|Actual|2008-01-28|August 2017|2017-08-31|April 11, 2008|Actual|2008-04-11|April 11, 2008|Actual|2008-04-11||Interventional|||A First Time in Human Study of GSK586529 in Healthy Volunteers|A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers|Completed||Phase 1|21|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:00:31.560845|2018-06-01 02:00:31.560845
NCT00703534|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2011-02-04||2011-05-20|2008-06-19|2008-06-23|Estimate|2011-05-20|2011-06-20|Estimate||||2011-05-20|2011-06-20|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|C27||Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms|Validation of Patient-reported Outcomes Measures for the Assessment of GERD Symptoms and Their Subsequent Impact on Patients With Partial Response to Proton Pump Inhibitor (PPI) Treatment in a Two Part Multi-center Phase IIa Study Including a Four Week Randomised, Double-blind, Placebo-controlled, Parallel-group Treatment Period|Completed||Phase 2|478|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:00:31.703572|2018-06-01 02:00:31.703572
NCT00703521|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-10-23|2008-06-20|2008-06-23|Estimate|||||||2008-10-23|2008-10-24|Estimate|August 2002||2002-08-31|June 2008|2008-06-30|September 2005|Actual|2005-09-30|October 2002|Actual|2002-10-31||Interventional|||Rabies Immunization Concomitant With JEV in Children|A Three-Year Clinical Study on Immunogenicity, Safety and Booster Response of Purified Chick Embryo Cell Rabies Vaccine (Pcecv) Administered Intramuscularly or Intradermally to 12- to 18-Month-Old Thai Children Concomitantly With Japanese Encephalitis Vaccine|Completed||Phase 2|200|Anticipated|Mahidol University||1|||f||||f||||||||||2018-06-01 02:00:32.280542|2018-06-01 02:00:32.280542
NCT00703508|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2017-01-05||2017-06-09|2008-06-20|2008-06-23|Estimate|2017-03-14|2017-04-25|Actual||||2017-06-09|2017-06-14|Actual|July 2008||2008-07-31|June 2017|2017-06-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Pharmacogenetics of Metformin Action in PCOS|Pharmacogenetics of Metformin Action in PCOS|Completed||N/A|55|Actual|Virginia Commonwealth University|Interpretations of our findings are limited by our small sample size.|1|||f||||t||||||||||2018-06-01 02:00:32.364249|2018-06-01 02:00:32.364249
NCT00703495|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-04-03|2008-06-20|2008-06-23|Estimate|||||||2009-04-03|2009-04-06|Estimate|July 2008||2008-07-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Invasive and Non-Invasive Assessment of Cerebral Oxygenation in Patients With Severe Traumatic Brain Injury (TBI)|Validation of Non- Invasive Regional Transcranial Oxygen Saturation (rSO2) by Comparison With Invasive Brain Tissue Oxygenation (PbtO 2) Measurement in Patients With Severe Traumatic Brain Injury|Completed|||20|Anticipated|Hospitales Universitarios Virgen del Rocío|||||f||||t||||||||||2018-06-01 02:00:32.731741|2018-06-01 02:00:32.731741
NCT00703482|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-06-24|2008-06-20|2008-06-23|Estimate|||||||2008-06-24|2008-06-25|Estimate|May 2003||2003-05-31|June 2008|2008-06-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes|A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes|Completed||Phase 2|278|Actual|Solvay Pharmaceuticals||7|||f||||f||||||||||2018-06-01 02:00:32.875526|2018-06-01 02:00:32.875526
NCT00703469|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2010-04-22|2008-06-19|2008-06-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|October 2008||2008-10-31|April 2010|2010-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|MDX1106-02||A Study of MDX-1106 to Treat Patients With Hepatitis C Infection|A Phase I, Double-blind,Multicenter,Randomized,Placebo-controlled,Safety and Pharmacokinetic Dose-escalation Study of a Single Intravenous Administration of MDX-1106, a Fully Human Monoclonal Antibody to PD-1, in Subjects With Active Hepatitis C Genotype 1 Infection|Completed||Phase 1|54|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:00:33.007541|2018-06-01 02:00:33.007541
NCT00703456|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2016-04-15|2008-06-20|2008-06-23|Estimate|||||||2016-04-15|2016-04-19|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Effect of Balance Training on Unloading Reaction in Individuals With Functional Ankle Instability|The Effect of Balance Training on Unloading Reaction in Individuals With Functional Ankle Instability|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 02:00:33.143759|2018-06-01 02:00:33.143759
NCT00703443|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2010-02-01|2008-06-19|2008-06-23|Estimate|||||||2010-02-01|2010-02-02|Estimate|April 2007||2007-04-30|April 2009|2009-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||The Genetics of Cardiomyopathy and Heart Failure|The Genetics of Cardiomyopathy and Heart Failure|Unknown status|Active, not recruiting||200|Anticipated|University of California, Irvine|||||f||||f||||||Samples With DNA|"~     Whole blood, Saliva, Buccal cells~   "|||2018-06-01 02:00:33.280878|2018-06-01 02:00:33.280878
NCT00703430|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2013-01-24|2008-06-20|2008-06-23|Estimate|||||||2013-01-24|2013-01-25|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Memantine on Aggression and Agitation of Alzheimer's Disease (AD)|The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study|Unknown status|Recruiting|N/A|50|Anticipated|Peking University||1|||f||||t||||||||||2018-06-01 02:00:33.35915|2018-06-01 02:00:33.35915
NCT00703417|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2011-06-06|2008-06-20|2008-06-23|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Does Bone Structure Explain the Increased Fracture Risk in Type II Diabetes Patients? A Pilot Study|Does Bone Structure Explain the Increased Fracture Risk in Type II Diabetes Patients? A Pilot Study|Completed|||40|Anticipated|University of California, San Francisco|||3||f||||f||||||||||2018-06-01 02:00:33.462155|2018-06-01 02:00:33.462155
NCT00703404|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2018-04-04|2008-06-20|2008-06-23|Estimate|||||||2018-04-04|2018-04-05|Actual|June 18, 2008||2008-06-18|February 24, 2016|2016-02-24|February 24, 2016||2016-02-24|||||Observational|||Response to Standard HIV Treatment in Bamako, Mali|A Cohort Observational Study to Assess the Virologic Response to Standard HIV Treatment in Bamako, Mali|Completed|||76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:00:33.531311|2018-06-01 02:00:33.531311
NCT00703391|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2010-11-30||2012-01-24|2008-06-20|2008-06-23|Estimate|2010-11-30|2010-12-29|Estimate||||2012-01-24|2012-01-26|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A 2-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Tolerability and Pharmacokinetics of Orally Administered AZD9668 in Patients With COPD|Completed||Phase 2|18|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:00:33.632003|2018-06-01 02:00:33.632003
NCT00703378|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2012-03-27|2008-06-20|2008-06-23|Estimate|||||||2012-03-27|2012-03-28|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle|Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle|Completed||Phase 1/Phase 2|33|Actual|National University Hospital, Singapore||3|||f||||||||||||||2018-06-01 02:00:34.298362|2018-06-01 02:00:34.298362
NCT00703365|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-08-25|2008-06-20|2008-06-23|Estimate|||||||2011-08-25|2011-08-29|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|August 2011|Actual|2011-08-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)|A Multicenter, Open Label, Single Arm, Phase II Study to Investigate the Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 2|45|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 02:00:34.392851|2018-06-01 02:00:34.392851
NCT00703352|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2017-03-21|2008-06-20|2008-06-23|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2008||2008-07-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|EVEDES||Eplerenone in Systemic Right Ventricle|Aldosterone Antagonists in Systemic Right Ventricle: a Randomized Clinical Trial.|Completed||Phase 4|26|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-06-01 02:00:34.499718|2018-06-01 02:00:34.499718
NCT00703339|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2011-02-25||2018-04-11|2008-06-19|2008-06-23|Estimate|2012-04-11|2012-05-10|Estimate||||2018-04-11|2018-05-10|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|A Single-Dose, Dose-Escalating Study Exploring the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Inhaled Treprostinil Sodium Using the Nebu-Tec OPTINEB Inhalation Device in Patients With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|Terminated||Phase 2|1|Actual|Lung Biotechnology PBC|Study was closed on December 31, 2009 and enrolled a total of 1 patient with complete assessment and 4 screened failures. The reason for the closure was lack of enrollment. No data will be analyzed.|||Lack of enrollment to the trial. Very difficult population to recruit.|f||||t||||||||||2018-06-01 02:00:34.585623|2018-06-01 02:00:34.585623
NCT00703326|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2014-05-16|2010-07-29|2017-10-11|2008-06-20|2008-06-23|Estimate|2014-05-16|2014-06-17|Estimate|2010-07-29|2010-08-02|Estimate|2017-10-11|2017-11-13|Actual|August 2008||2008-08-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|March 2013|Actual|2013-03-31||Interventional||Intent-to-Treat (ITT) Population: All randomized participants.|Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer|A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer|Active, not recruiting||Phase 3|1144|Actual|Eli Lilly and Company|One participant assigned to placebo + docetaxel (doc) treatment and was given ramucirumab (ram) in Cycle 1. Considered ram + doc treatment arm for safety population, for ITT population the participant was analyzed according to assigned treatment.|2|||f||||t||||||||||2018-06-01 02:00:34.867821|2018-06-01 02:00:34.867821
NCT00197847|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|December 2002||2002-12-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Infection Surveillance in Intensive Care Patients||Unknown status|Active, not recruiting||549||Herlev Hospital|||||f||||||||||||||2018-06-01 04:32:47.326375|2018-06-01 04:32:47.326375
NCT00703300|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2014-11-06|2008-06-20|2008-06-23|Estimate|||||||2014-11-06|2014-11-07|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|October 2014|Actual|2014-10-31|March 2010|Actual|2010-03-31||Interventional|||Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia|Phase I Study of Decitabine (Dacogen) and Bortezomib (Velcade) in Acute Myeloid Leukemia|Completed||Phase 1|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:00:37.054973|2018-06-01 02:00:37.054973
NCT00703287|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2013-02-01|2008-06-20|2008-06-23|Estimate|||||||2013-02-01|2013-02-04|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Specialized Physiotherapy Program for Cervical Dystonia|Randomized Trial of a Specialized Physiotherapy Program Versus Standard Physiotherapy Advice in Patients With Cervical Dystonia (Spasmodic Torticollis).|Completed||N/A|110|Actual|South Glasgow University Hospitals NHS Trust||2|||f||||f||||||||||2018-06-01 02:00:37.183157|2018-06-01 02:00:37.183157
NCT00703274|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2013-02-20|2008-06-20|2008-06-23|Estimate|||||||2013-02-20|2013-02-21|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PROTECT DC||Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia|Preventing Recurrence of Thromboembolic Events Through Coordinated Treatment in the District of Columbia|Completed||Phase 2|230|Actual|Georgetown University||2|||f||||f||||||||||2018-06-01 02:00:37.477398|2018-06-01 02:00:37.477398
NCT00703261|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2011-10-25||2015-10-08|2008-06-20|2008-06-23|Estimate|2011-10-25|2011-11-30|Estimate||||2015-10-08|2015-10-09|Estimate|August 2008||2008-08-31|October 2015|2015-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED)|A Randomized, Double-Blind, Parallel Group Study to Evaluate the Effects of High Dose Statin Therapy on 18Fluorine Fluorodeoxyglucose (18FDG) Uptake in Arteries of Patients With Atherosclerotic Vascular Disease|Completed||Phase 1|83|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:00:37.611661|2018-06-01 02:00:37.611661
NCT00703248|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-07-07|2008-06-20|2008-06-23|Estimate|||||||2008-07-07|2008-07-08|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|HOME||The Human Immunodeficiency Virus and Osteopathic Manipulation Evaluation Study||Completed||N/A|||Nova Southeastern University||2|||f||||||||||||||2018-06-01 02:00:37.985634|2018-06-01 02:00:37.985634
NCT00703235|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-06-20|2008-06-20|2008-06-23|Estimate|||||||2008-06-20|2008-06-23|Estimate||||June 2008|2008-06-30||||||||Interventional|||Intravitreal Bevacizumab for Diabetic Macular Edema||Unknown status|Enrolling by invitation|Phase 2/Phase 3|||Isfahan Ophthalmology Research Center|||||f||||||||||||||2018-06-01 02:00:38.064152|2018-06-01 02:00:38.064152
NCT00703222|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20||2013-07-25|2018-03-29|2008-06-20|2008-06-23|Estimate||||2013-07-25|2013-08-01|Estimate|2018-03-29|2018-04-02|Actual|June 2008||2008-06-30|March 2018|2018-03-31|May 2024|Anticipated|2024-05-31|May 2011|Actual|2011-05-31||Interventional|CHESAT||A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells|A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma|Active, not recruiting||Phase 1/Phase 2|7|Actual|Baylor College of Medicine||1|||f||||t|t|||||||No|We will not share IPD with other researchers. Study outcomes will be published in aggregate.|2018-06-01 02:00:38.133943|2018-06-01 02:00:38.133943
NCT00703209|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2015-05-27|2008-06-20|2008-06-23|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|DNND||Study on the Role of Decompression of Lower Extremity Nerves for the Treatment of Patients With Symptomatic Diabetic Neuropathy With Chronic Nerve Compression|Controlled, Randomized, Double-Blinded, Prospective Study On the Role of Decompression of Lower Extremity Nerves for the Treatment of Patients With Symptomatic Diabetic Neuropathy With Chronic Nerve Compression|Completed||N/A|138|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:00:38.340983|2018-06-01 02:00:38.340983
NCT00703196|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2015-10-06|2008-06-20|2008-06-23|Estimate|||||||2015-10-06|2015-10-08|Estimate|March 2007||2007-03-31|January 2014|2014-01-31||||May 2014|Actual|2014-05-31||Interventional|||Folic Acid Clinical Trial for the Prevention of Cervical Cancer|HPV Clearance by Folic Acid Supplementation (FACT for HPV)|Completed||Phase 2|368|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 02:00:38.44299|2018-06-01 02:00:38.44299
NCT00703183|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2012-06-25|2008-06-20|2008-06-23|Estimate|||||||2012-06-25|2012-06-27|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Tolerability of ACU-4429|A Single Center, Randomized, Double-Masked, Dose-Escalating, Placebo-Controlled Study of the Safety and Tolerability ACU-4429 in Healthy Volunteers|Completed||Phase 1|46|Actual|Acucela Inc.||2|||f||||t||||||||||2018-06-01 02:00:38.540047|2018-06-01 02:00:38.540047
NCT00703170|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2013-05-22|2008-06-20|2008-06-23|Estimate|||||||2013-05-22|2013-05-24|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies|Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Resistant Solid Malignancies|Completed||Phase 1|28|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 02:00:38.686366|2018-06-01 02:00:38.686366
NCT00703157|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2017-03-22||2017-05-15|2008-06-20|2008-06-23|Estimate|2017-05-15|2017-05-16|Actual||||2017-05-15|2017-05-16|Actual|November 2007||2007-11-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|August 2015|Actual|2015-08-31||Interventional|SCALAF||Surgical or Catheter Ablation of Lone Atrial Fibrillation (AF) Patients|Surgical or Catheter Ablations in Patients With Lone Atrial Fibrillation: Determination of Acute and Long Term Success Rate (SCALAF Success Trial)|Terminated||N/A|80|Actual|Medtronic Cardiovascular|The study stopped early, prior to meeting the target number of subjects per group. The reported results and conclusions are based on these limited data.|2||Enrollments slowed down significantly, despite several attempts to re-launch.|f||||f||||||||No|There is no plan or intention to share individual participant data (IPD)|2018-06-01 02:00:38.889479|2018-06-01 02:00:38.889479
NCT00703144|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2013-01-23|2008-06-20|2008-06-23|Estimate|||||||2013-01-23|2013-01-24|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PTCRRT||Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy|Pharmacokinetics of Piperacillin and Tazobactam in Anuric Septic Patients Treated by Continuous Veno Venous Hemodiafiltration|Completed||Phase 4|10|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-06-01 02:00:39.600627|2018-06-01 02:00:39.600627
NCT00703131|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2015-02-10|2008-06-20|2008-06-23|Estimate|||||||2015-02-10|2015-02-11|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|SurgiSIS AFP||Surgisis Anal Fistula Plug Study: An Experience in Saudi Arabia|A Single-center Single Arm Prospective Study Evaluating the Surgisis Biodesign Anal Fistula Plug|Completed|||35|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-06-01 02:00:39.71568|2018-06-01 02:00:39.71568
NCT00703118|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2011-07-18||2013-12-05|2008-06-19|2008-06-23|Estimate|2011-07-18|2011-08-11|Estimate||||2013-12-05|2014-01-22|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment|A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Infection Who Failed Prior Standard Treatment|Completed||Phase 3|663|Actual|Tibotec BVBA||3|||f||||t||||||||||2018-06-01 02:00:39.915378|2018-06-01 02:00:39.915378
NCT00703105|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2017-12-14|2008-06-20|2008-06-23|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2008||2008-10-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Ovarian Dendritic Cell Vaccine Trial|Defining the Role of CD4+CD25+ Immunoregulatory T-cells in the Treatment of Patients With Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies|Recruiting||Phase 2|36|Anticipated|Loyola University||3|||f||||f||||||||||2018-06-01 02:00:41.411019|2018-06-01 02:00:41.411019
NCT00703092|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|2014-05-27||2017-09-08|2008-06-20|2008-06-23|Estimate|2014-06-27|2014-06-30|Estimate||||2017-09-08|2017-10-09|Actual|February 2008||2008-02-29|September 2017|2017-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pilot Study:Role of Dietary Fiber in PCOS Anovulation|Pilot Study: Role of Dietary Fiber in PCOS Anovulation|Terminated||Phase 4|2|Actual|Virginia Commonwealth University||1||P.I. left University. Study terminated|f||||t||||||||||2018-06-01 02:00:41.554107|2018-06-01 02:00:41.554107
NCT00703079|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-06-20|2008-06-20|2008-06-23|Estimate|||||||2008-06-20|2008-06-23|Estimate|January 1997||1997-01-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|GLUSSA||Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly|Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly: Results of a 5 Years Observational, Open, Prospective Study|Completed|||100|Actual|Federico II University|||4||f||||f||||||Samples Without DNA|"~     Sera from most patients on a yearly bases are stored in our freezed at minus 80° for eventual~     further studies. No experimental parameters are included in the current study.~   "|||2018-06-01 02:00:41.780902|2018-06-01 02:00:41.780902
NCT00703066|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2008-11-23|2008-06-20|2008-06-23|Estimate|||||||2008-11-23|2008-11-25|Estimate|June 2008||2008-06-30|November 2008|2008-11-30|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Interventional|||Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years|A Phase I, Randomized, Controlled, Double-Blind, Single Centre Trial to Evaluate the Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|African Malaria Network Trust||3|||f||||t||||||||||2018-06-01 02:00:41.881741|2018-06-01 02:00:41.881741
NCT00703053|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2010-06-17||2013-08-15|2008-06-19|2008-06-23|Estimate|2010-06-17|2010-07-16|Estimate||||2013-08-15|2013-08-23|Estimate|September 2008||2008-09-30|September 2009|2009-09-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||H5N1 Priming and Boosting Strategies|A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults|Completed||Phase 2|505|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||9|||f||||||||||||||2018-06-01 02:00:41.990852|2018-06-01 02:00:41.990852
NCT00703040|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-20|||2017-02-27|2008-06-20|2008-06-23|Estimate|||||||2017-02-27|2017-02-28|Actual|March 2008||2008-03-31|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Linkage to Care - Part I|HIV-Related Care Engagement: Linkage to Care and Care-Seeking for HIV-Infected Adolescents, Phase I|Completed|||35|Actual|University of North Carolina, Chapel Hill|||3||f||||t||||||||||2018-06-01 02:00:45.127172|2018-06-01 02:00:45.127172
NCT00703027|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2012-03-26|2008-06-19|2008-06-20|Estimate|||||||2012-03-26|2012-03-27|Estimate|October 2002||2002-10-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|||||Observational|||Diabetes Mellitus Care Decision Making Model Through Data Mining|Diabetes Mellitus Care Decision Making Model Through Data Mining|Completed|||2000|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 02:00:45.232593|2018-06-01 02:00:45.232593
NCT00703014|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2014-11-18||2017-03-20|2008-06-18|2008-06-20|Estimate|2014-11-18|2014-11-24|Estimate||||2017-03-20|2017-04-17|Actual|July 13, 2006|Actual|2006-07-13|March 2017|2017-03-31|March 15, 2009|Actual|2009-03-15|April 18, 2008|Actual|2008-04-18||Observational||Eligible mothers from the Base Trial P05787 (NCT00696800) who enrolled in Follow Up Trial P05712|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38819 for Org 36286 (Corifollitropin Alfa)|Completed|||541|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:00:45.381712|2018-06-01 02:00:45.381712
NCT00703001|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2010-09-03|2008-06-19|2008-06-20|Estimate|||||||2010-09-03|2010-09-06|Estimate|April 2008||2008-04-30|September 2010|2010-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Waukesha Smiles: Dental Outreach to Low-income Waukesha Children|Waukesha Smiles: Dental Outreach to Low-income Waukesha Children|Completed||N/A|400|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-06-01 02:00:48.151956|2018-06-01 02:00:48.151956
NCT00702988|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-06-22|2008-06-18|2008-06-20|Estimate|||||||2017-06-22|2017-06-23|Actual|October 1, 2003|Actual|2003-10-01|June 2017|2017-06-30|February 28, 2005|Actual|2005-02-28|February 28, 2005|Actual|2005-02-28||Observational|||Pregnancy & Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 (Study 38827)(P06056)(COMPLETED)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Clinical Trial 38826 for the Development of Org 36286 (Corifollitropin Alfa).|Completed|||44|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:00:48.259506|2018-06-01 02:00:48.259506
NCT00702975|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2013-07-12|2008-06-19|2008-06-20|Estimate|||||||2013-07-12|2013-07-15|Estimate|September 2008||2008-09-30|April 2012|2012-04-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy|A Phase II Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy|Completed||Phase 2|35|Actual|Radboud University|||||f||||f||||||||||2018-06-01 02:00:48.400881|2018-06-01 02:00:48.400881
NCT00702962|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2017-05-08|2008-06-19|2008-06-20|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2008|Actual|2008-09-30|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer|Phase I/II Study of Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|5|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||Undecided|To determine if data is valuable|2018-06-01 02:00:48.538664|2018-06-01 02:00:48.538664
NCT00702949|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2015-01-21||2016-07-01|2008-06-19|2008-06-20|Estimate|2015-03-09|2015-03-11|Estimate||||2016-07-01|2016-08-01|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|February 2010|Actual|2010-02-28||Interventional|||Pregabalin in Treating Women With Hot Flashes|A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes|Completed||Phase 3|207|Actual|Alliance for Clinical Trials in Oncology||3|||f||||||||||||||2018-06-01 02:00:48.761086|2018-06-01 02:00:48.761086
NCT00702936|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-06-19|2008-06-19|2008-06-20|Estimate|||||||2008-06-19|2008-06-20|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|November 2008|Anticipated|2008-11-30|August 2008|Anticipated|2008-08-31||Interventional|TERACS||Telmisartan Versus Ramipril After Acute Coronary Syndrome|Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome|Unknown status|Recruiting|Phase 4|50|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-06-01 02:00:49.982978|2018-06-01 02:00:49.982978
NCT00702923|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2014-02-24||2014-04-07|2008-06-19|2008-06-20|Estimate|2014-04-07|2014-05-07|Estimate||||2014-04-07|2014-05-07|Estimate|July 2008||2008-07-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|September 2011|Actual|2011-09-30||Interventional|||CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer|Phase I Dose Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer|Terminated||Phase 1|12|Actual|University of Wisconsin, Madison||1||Enrollment was halted prematurely due to slow accrual.|f||||t||||||||||2018-06-01 02:00:50.126487|2018-06-01 02:00:50.126487
NCT00702910|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-08-08|2008-06-19|2008-06-20|Estimate|||||||2017-08-08|2017-08-10|Actual|April 27, 2008|Actual|2008-04-27|August 2017|2017-08-31|October 4, 2008|Actual|2008-10-04|October 4, 2008|Actual|2008-10-04||Interventional|||A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients|A Randomised, Single-dose, Double-blind, Placebo-controlled, 5-way Crossover Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With and Without Magnesium Stearate in Asthmatic Patients|Completed||Phase 1|24|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:00:50.429952|2018-06-01 02:00:50.429952
NCT00702897|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2008-06-19|2008-06-19|2008-06-20|Estimate|||||||2008-06-19|2008-06-20|Estimate|January 2008||2008-01-31|June 2008|2008-06-30||||||||Observational|||Ambulatory Surgery of Lower Extremity Varicose Vein||Unknown status|Recruiting||300|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-06-01 02:00:50.615225|2018-06-01 02:00:50.615225
NCT00702884|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2016-02-04||2017-01-31|2008-06-19|2008-06-20|Estimate|2017-01-31|2017-03-21|Actual||||2017-01-31|2017-03-21|Actual|June 30, 2008|Actual|2008-06-30|January 2017|2017-01-31|December 30, 2013|Actual|2013-12-30|September 17, 2013|Actual|2013-09-17||Interventional|||Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer|A Mechanistic Radiographic and Biologic Phase 2 Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastroesophageal Cancers|Completed||Phase 2|25|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:00:50.734733|2018-06-01 02:00:50.734733
NCT00702871|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-06-19|2008-06-19|2008-06-20|Estimate|||||||2008-06-19|2008-06-20|Estimate|March 2005||2005-03-31|June 2008|2008-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia|A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study|Completed||Phase 4|50|Actual|Maulana Azad Medical College||2|||f||||f||||||||||2018-06-01 02:00:51.171228|2018-06-01 02:00:51.171228
NCT00702858|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2013-08-27|2008-06-19|2008-06-20|Estimate|||||||2013-08-27|2013-08-28|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer|Pilot, Single Center Randomized Controlled, Double-Blind, Cross Over, Intent to Treat Trial of Blue Citrus to Placebo in Those Breast Cancer Patients Receiving Aromatase Inhibitor Therapy|Completed||N/A|30|Actual|Legacy Health System||2|||f||||t||||||||||2018-06-01 02:00:51.320967|2018-06-01 02:00:51.320967
NCT00702845|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2015-04-10||2017-03-20|2008-06-19|2008-06-20|Estimate|2015-04-10|2015-04-27|Estimate||||2017-03-20|2017-04-17|Actual|December 2006||2006-12-31|March 2017|2017-03-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|Ensure|Intent-to-Treat group, which consisted of all randomized participants who received corifollitropin alfa or recFSH.|To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)|A Phase III, Randomized, Double-blind, Active-controlled, Equivalence Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of 100 µg Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference|Completed||Phase 3|397|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:00:51.501348|2018-06-01 02:00:51.501348
NCT00702832|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2017-02-10|2008-06-19|2008-06-20|Estimate|||||||2017-02-10|2017-02-13|Actual|January 2008|Actual|2008-01-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Vestibular Rehabilitation - a Randomized Controlled Trial|Effects of Vestibular Rehabilitation in the Treatment of Patients With Acute Vestibular Loss. - A Randomized Controlled Trial|Completed||N/A|54|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||Undecided||2018-06-01 02:00:52.365645|2018-06-01 02:00:52.365645
NCT00702819|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2010-01-26|2008-06-19|2008-06-20|Estimate|||||||2010-01-26|2010-01-27|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|BLOCK-ROP||Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity|Phase 1 Trial of Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity|Terminated||Phase 1|2|Actual|Vision Research Foundation||||Low enrollment due to the stringent enrollment criteria. Unable to answer study questions|f||||t||||||||||2018-06-01 02:00:52.452852|2018-06-01 02:00:52.452852
NCT00702806|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-05-17|2008-06-19|2008-06-20|Estimate|||||||2017-05-17|2017-05-19|Actual|July 1, 2001|Actual|2001-07-01|May 2017|2017-05-31|October 15, 2002|Actual|2002-10-15|October 15, 2002|Actual|2002-10-15||Interventional|||Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)|A Phase II, Open Label, Prospective, Randomized, Comparative Clinical Trial to Investigate the Appropriate Dose of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI.|Completed||Phase 2|99|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-06-01 02:00:52.717354|2018-06-01 02:00:52.717354
NCT00702793|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-11-27|2008-06-18|2008-06-20|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2008||2008-04-30|November 2017|2017-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)|Safety and Tolerability of Varenicline When Used for Smoking Cessation/Reduction in Individuals With Severe and Persistent Mental Illness: An Open Label Pilot Trial|Withdrawn||Phase 4|0|Actual|University of British Columbia||1||No participants enrolled|f||||f||||||||||2018-06-01 02:00:52.860025|2018-06-01 02:00:52.860025
NCT00702780|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-15|2014-04-10||2014-05-13|2008-06-18|2008-06-20|Estimate|2014-05-13|2014-06-13|Estimate||||2014-05-13|2014-06-13|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ESAD||Progression Delaying Effect of Escitalopram in Alzheimer's Disease|Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease|Completed||N/A|74|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:00:53.006283|2018-06-01 02:00:53.006283
NCT00702767|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-06-23|2008-06-19|2008-06-20|Estimate|||||||2008-06-23|2008-06-24|Estimate|July 2005||2005-07-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|October 2006|Actual|2006-10-31||Interventional|||Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants|Tolerance of Increased Infusion Rates of Intravenous Fat Emulsions in Very Low Birth Weight Infants During the First Week of Life|Completed||N/A|110|Actual|OSF Healthcare System|||||f||||f||||||||||2018-06-01 02:00:53.30171|2018-06-01 02:00:53.30171
NCT00702754|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2009-05-12||2009-09-22|2008-06-19|2008-06-20|Estimate|2009-08-13|2009-09-23|Estimate||||2009-09-22|2009-10-02|Estimate|June 2001||2001-06-30|September 2009|2009-09-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia|An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia|Completed||Phase 4|502|Actual|Solstice Neurosciences|||||f||||f||||||||||2018-06-01 02:00:53.408985|2018-06-01 02:00:53.408985
NCT00702741|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2014-12-02|2008-06-19|2008-06-20|Estimate|||||||2014-12-02|2014-12-04|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy|A Long-Term Follow-up Study of Chondrogen - Adult Human Stem Cells Delivered by Intra-articular Injection Following Meniscectomy in Subjects 18-60 Years|Completed||Phase 1/Phase 2|55|Actual|Mesoblast, Ltd.||3|||f||||f||||||||||2018-06-01 02:00:54.075985|2018-06-01 02:00:54.075985
NCT00702728|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2009-10-09|2008-06-19|2008-06-20|Estimate|||||||2009-10-09|2009-10-12|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|MYTHOS||Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy (CIN) Prevention|A Study to Evaluate the Effectiveness of Induced Diuresis With Matched Hydration Therapy Compared to Standard Overnight Hydration in the Prevention of Contrast Induced Nephropathy -MYTHOS Study|Unknown status|Recruiting|Phase 3|120|Anticipated|Centro Cardiologico Monzino||2|||f||||f||||||||||2018-06-01 02:00:54.194933|2018-06-01 02:00:54.194933
NCT00702715|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2011-03-15||2017-04-12|2008-06-19|2008-06-20|Estimate|2011-03-15|2011-04-11|Estimate||||2017-04-12|2017-05-16|Actual|September 24, 2008|Actual|2008-09-24|April 2017|2017-04-30|March 15, 2010|Actual|2010-03-15|March 15, 2010|Actual|2010-03-15||Interventional|||Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769)|A Multi-center, Parallel-group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of 4.0 mg/kg Sugammadex Administered at 1-2 PTC in Subjects With Normal or Severely Impaired Renal Function|Completed||Phase 3|69|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:00:54.333518|2018-06-01 02:00:54.333518
NCT00702702|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2014-06-23||2014-08-05|2008-06-19|2008-06-20|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated for safety reasons|Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids|A Multi-Center, Placebo Controlled, Safety and Efficacy Study of the Selective Progesterone Receptor Modulator Proellex® (CDB-4124) in Anemic, Pre-Menopausal Women With Symptomatic Uterine Fibroids Requiring Hysterectomy|Terminated||Phase 3|56|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped study for safety and FDA put study on hold because of safety.|f||||t||||||||||2018-06-01 02:00:54.789554|2018-06-01 02:00:54.789554
NCT00702689|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2012-09-05||2017-11-22|2008-06-19|2008-06-20|Estimate|2012-10-17|2012-11-19|Estimate||||2017-11-22|2017-12-19|Actual|December 15, 2008|Actual|2008-12-15|November 2017|2017-11-30|January 9, 2014|Actual|2014-01-09|May 18, 2011|Actual|2011-05-18||Interventional|||Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease|A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease|Completed||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 02:00:55.062482|2018-06-01 02:00:55.062482
NCT00702676|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-07-15|2008-06-19|2008-06-20|Estimate|||||||2009-07-15|2009-07-16|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison|A Double-blind, Double-dummy, Randomized, Crossover Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (SEROQUEL®) With Quetiapine Fumarate Extended Release (SEROQUEL XR®) During Initial Dose Escalation in Healthy Volunteers|Completed||Phase 1|63|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:00:56.523428|2018-06-01 02:00:56.523428
NCT00702663|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2008-06-19|2008-06-19|2008-06-20|Estimate|||||||2008-06-19|2008-06-20|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|||||Observational|||Seroprevalence of Hepatitis B Infection and Effect of Booster Response Amongst Taiwanese Young Adults|Seroprevalence of Hepatitis B Infection, Effect of Booster Response, and Significance of Anti-HBc Positivity Amongst Taiwanese Young Adults|Unknown status|Recruiting||1800|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||Samples With DNA|"~     Hepatitis B DNA~   "|||2018-06-01 02:00:56.619684|2018-06-01 02:00:56.619684
NCT00702650|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2010-12-15|2010-09-13|2011-07-21|2008-06-19|2008-06-20|Estimate|2010-12-15|2011-01-05|Estimate|2010-09-13|2010-09-15|Estimate|2011-07-21|2011-07-25|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations|A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion® (Cutaneous Solution) in Hypogonadal Men|Completed||Phase 3|155|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:00:56.811512|2018-06-01 02:00:56.811512
NCT00702637|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-06-10|2008-06-19|2008-06-20|Estimate|||||||2010-06-10|2010-06-14|Estimate|October 2002||2002-10-31|June 2010|2010-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study of Modafinil to Treat Fatigue in Persons With Traumatic Brain Injury|Modafinil for the Treatment of Fatigue and Excessive Daytime Sleepiness in Individuals With Traumatic Brain Injury|Completed||Phase 1|60||Craig Hospital|||||f||||||||||||||2018-06-01 02:00:57.299974|2018-06-01 02:00:57.299974
NCT00702624|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2015-04-13||2017-03-17|2008-06-18|2008-06-20|Estimate|2015-04-13|2015-04-30|Estimate||||2017-03-17|2017-03-21|Actual|April 2007||2007-04-30|March 2017|2017-03-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Observational|Care|Individuals who participated in base study P05690 (NCT00702845) and received at least one dose of either corifollitropin alfa or recFSH, who had an ongoing pregnancy confirmed by ultrasound at least 10 weeks after ET in base study P05690 and were able and willing to give written informed consent.|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 107012 for the Development of Org 36286 (Corifollitropin Alfa)|Completed|||113|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:00:57.401095|2018-06-01 02:00:57.401095
NCT00702611|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2015-09-04|2008-06-19|2008-06-20|Estimate|||||||2015-09-04|2015-09-07|Estimate|June 2008||2008-06-30|September 2015|2015-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ATICCA||Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis|An Open Randomized Multicenter Clinical Investigation to Compare the Efficacy and Safety of Prednisone Plus Adacolumn® GMA Apheresis vs Prednisone Alone in the Treatment of Patients With Mild or Moderately Active Steroid Dependent Ulcerative Colitis|Terminated||Phase 4|133|Actual|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa||2||Lack of enrollment|f||||t||||||||||2018-06-01 02:00:58.243374|2018-06-01 02:00:58.243374
NCT00702598|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2012-05-07|2008-06-19|2008-06-20|Estimate|||||||2012-05-07|2012-05-09|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||The WORKER Study: Escitalopram and Telephone-based Cognitive Behaviour Therapy (CBT) for Depressed Working People|The WORKER Study: A Randomized Controlled Trial of Escitalopram and Telephone-based Cognitive Behaviour Therapy in Working Patients With Major Depressive Disorder|Completed||N/A|105|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 02:00:58.396223|2018-06-01 02:00:58.396223
NCT00702585|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-05-17|2008-06-19|2008-06-20|Estimate|||||||2017-05-17|2017-05-19|Actual|August 1, 2001|Actual|2001-08-01|May 2017|2017-05-31|October 15, 2002|Actual|2002-10-15|October 15, 2002|Actual|2002-10-15||Interventional|||Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)|A Phase II, Randomized, Double-blind, Placebo-controlled, Comparative Trial to Investigate the Optimal Dose of a Single Administration of Org 36286 (Corifollitropin Alfa) to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility|Completed||Phase 2|55|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 02:00:58.478202|2018-06-01 02:00:58.478202
NCT00702572|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2016-09-21|2008-06-19|2008-06-20|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2008||2008-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer|Phase I Study of Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|25|Actual|Milton S. Hershey Medical Center||2||Low Enrollment|f||||t||||||||||2018-06-01 02:00:58.584187|2018-06-01 02:00:58.584187
NCT00702559|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2008-06-19|2008-06-19|2008-06-20|Estimate|||||||2008-06-19|2008-06-20|Estimate|January 2008||2008-01-31|June 2008|2008-06-30||||||||Observational|||Design the Home Care Platform for the Monitoring of A Hemodialysis Arteriovenous Graft by Intelligent Physiological Signal||Unknown status|Recruiting||50|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 02:00:58.689691|2018-06-01 02:00:58.689691
NCT00702546|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2015-02-09||2015-05-04|2008-06-18|2008-06-20|Estimate|2015-05-04|2015-05-05|Estimate||||2015-05-04|2015-05-05|Estimate|December 2006||2006-12-31|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational||Eligible participants from base study P05690 (NCT00702845) who enrolled in follow up study P05711|Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)|Follow-up Protocol to Collect the Outcome of Frozen-thawed Embryo Transfer Cycles After Cryopreservation of Embryos in Clinical Trial 107012|Completed|||102|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:00:58.902343|2018-06-01 02:00:58.902343
NCT00702533|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2018-05-17|2008-06-19|2008-06-20|Estimate|||||||2018-05-17|2018-05-18|Actual|June 18, 2008||2008-06-18|July 21, 2017|2017-07-21||||||||Observational|||A New Method for Determining Gastric Acid Output Using a Wireless Capsule|A New Method for Determining Gastric Acid Output Using a Wireless Capsule|Completed|||80|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:00:59.253785|2018-06-01 02:00:59.253785
NCT00702520|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2014-05-20||2017-03-21|2008-06-18|2008-06-20|Estimate|2014-05-20|2014-06-20|Estimate||||2017-03-21|2017-04-18|Actual|April 1, 2006|Actual|2006-04-01|March 2017|2017-03-31|January 15, 2008|Actual|2008-01-15|November 7, 2007|Actual|2007-11-07||Observational|Care|The overall number of baseline participants reflects the number of participants that started the P05783 follow-up study and not the number of participants in the P05788 base study.|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38833 for Org 36286 (Corifollitropin Alfa)|Completed|||15|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:00:59.380282|2018-06-01 02:00:59.380282
NCT00702507|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2011-09-01||2012-03-22|2008-06-19|2008-06-20|Estimate|2011-09-01|2011-10-07|Estimate||||2012-03-22|2012-03-27|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants|Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis|Completed||Phase 4|200|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:01:00.115474|2018-06-01 02:01:00.115474
NCT00702494|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-12-03|2008-06-19|2008-06-20|Estimate|||||||2009-12-03|2009-12-04|Estimate|June 2008||2008-06-30|December 2009|2009-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours|An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.|Completed||Phase 1|21|Anticipated|BioInvent International AB||1|||f||||t||||||||||2018-06-01 02:01:00.508175|2018-06-01 02:01:00.508175
NCT00702481|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2018-04-24|2008-06-19|2008-06-20|Estimate|||||||2018-04-24|2018-04-25|Actual|April 2008||2008-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer|Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Active, not recruiting||Phase 2|37|Actual|National Cancer Centre, Singapore||1|||f||||f||||||||||2018-06-01 02:01:00.616187|2018-06-01 02:01:00.616187
NCT00702468|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2011-03-14||2013-06-13|2008-06-19|2008-06-20|Estimate|2011-05-17|2011-06-17|Estimate||||2013-06-13|2013-06-24|Estimate|November 2007||2007-11-30|June 2013|2013-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis|A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex®.|Completed||Phase 3|36|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 02:01:00.727632|2018-06-01 02:01:00.727632
NCT00702455|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2012-11-19|2008-06-19|2008-06-20|Estimate|||||||2012-11-19|2012-11-21|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|July 2012|Actual|2012-07-31|February 2010|Actual|2010-02-28||Interventional|KIO||Keep It Off: A Weight Loss Maintenance Study|Novel Approaches to Weight Loss Maintenance|Completed||N/A|419|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-06-01 02:01:01.253757|2018-06-01 02:01:01.253757
NCT00702442|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2011-07-25|2008-06-19|2008-06-20|Estimate|||||||2011-07-25|2011-07-26|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Role of Droperidol in Postoperative Vomiting|Role of Droperidol in Postoperative Vomiting: Phase IV Study|Completed||Phase 4|100|Actual|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-06-01 02:01:01.359816|2018-06-01 02:01:01.359816
NCT00702429|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2014-08-27|2008-06-19|2008-06-20|Estimate|||||||2014-08-27|2014-08-28|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Immunoregulation of Periodontal Disease|Immunoregulation of Periodontal Disease|Completed||N/A|23|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 02:01:01.473045|2018-06-01 02:01:01.473045
NCT00702416|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-11-13|2008-06-19|2008-06-20|Estimate|||||||2009-11-13|2009-11-16|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Ultrasound Guidance for Interscalene Brachial Plexus Block|Ultrasound Guidance or Electrical Nerve Stimulation for Interscalene Brachial Plexus Block: a Randomized, Controlled Trial|Completed||Phase 4|50|Anticipated|University of Parma||2|||f||||f||||||||||2018-06-01 02:01:01.578392|2018-06-01 02:01:01.578392
NCT00702403|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2017-01-25||2017-07-11|2008-06-19|2008-06-20|Estimate|2017-04-06|2017-05-15|Actual||||2017-07-11|2017-08-10|Actual|August 14, 2008|Actual|2008-08-14|July 2017|2017-07-31|December 1, 2013|Actual|2013-12-01|December 2013|Actual|2013-12-31||Interventional|||Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML|A Multicenter Phase I/II Study of the Prophylactic Inhibition of BCR-ABL Tyrosine Kinase by Tasigna ® (Nilotinib) After Hematopoietic Cell Transplantation for Philadelphia Chromosome-Positive Leukemias.|Completed||Phase 1/Phase 2|40|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||No||2018-06-01 02:01:01.728594|2018-06-01 02:01:01.728594
NCT00702377|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2009-09-23||2012-01-31|2008-06-19|2008-06-20|Estimate|2010-01-22|2010-02-10|Estimate||||2012-01-31|2012-02-02|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of SYSTANE Ultra Lubricant Eye Drops||Completed||N/A|109|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:01:02.241009|2018-06-01 02:01:02.241009
NCT00702364|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2013-09-03||2014-08-28|2008-06-19|2008-06-20|Estimate|2014-08-28|2014-09-15|Estimate||||2014-08-28|2014-09-15|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Baseline analysis was completed on the 55 randomized participants.|Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)|Strattera(Atomoxetine) for the Treatment of Attention Disorders in Individuals With Traumatic Brain Injury|Completed||N/A|60|Actual|Craig Hospital||2|||f||||t||||||||||2018-06-01 02:01:02.677187|2018-06-01 02:01:02.677187
NCT00702351|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2018-05-02|2008-06-19|2008-06-20|Estimate|||||||2018-05-02|2018-05-03|Actual|December 1, 2005|Actual|2005-12-01|April 2018|2018-04-30|July 11, 2007|Actual|2007-07-11|March 26, 2007|Actual|2007-03-26||Interventional|Realize||A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)|A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 μg or 150 μg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI Using a Long Protocol of GnRH Agonist (Study 38833)|Completed||Phase 2|50|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:01:02.986029|2018-06-01 02:01:02.986029
NCT00702338|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2014-03-31||2017-03-20|2008-06-19|2008-06-20|Estimate|2014-05-14|2014-06-05|Estimate||||2017-03-20|2017-04-17|Actual|May 15, 2008|Actual|2008-05-15|March 2017|2017-03-31|December 15, 2008|Actual|2008-12-15|August 9, 2008|Actual|2008-08-09||Observational|Care|The Baseline Analysis Population consisted of one mother with confirmed pregnancy who was treated with corifollitropin alfa + hCG in base study P05693 (NCT00697255) and enrolled in the current follow-up study. Baseline characteristics were not summarized for the infants born on study.|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Ovulation Induction in Clinical Trial 107010 for the Development of Org 36286 (Corifollitropin Alfa)|Completed|||1|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:01:03.135707|2018-06-01 02:01:03.135707
NCT00702325|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2010-09-20||2012-10-10|2008-06-19|2008-06-20|Estimate|2012-10-10|2012-11-09|Estimate||||2012-10-10|2012-11-09|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Titan||Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans|A 12-wk, Rand., Double-blind, Double Dummy, Multi-ctr., Phase IV Study Comparing Efficacy and Safety of SYMBICORT® pMDI 160/4.5 ug x 2 Actuations Twice Daily Versus Pulmicort® (Budesonide Inhalation Powder DPI) 180 ug x 2 Inhalations Twice Daily, in Adult and Adolescent African American Subjects With Asthma|Completed||Phase 4|311|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:01:03.441986|2018-06-01 02:01:03.441986
NCT00702312|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-07-28|2008-06-19|2008-06-20|Estimate|||||||2009-07-28|2009-07-29|Estimate|June 2008||2008-06-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||A Bengali Dietary Salt Study to Control Blood Pressure|A Multi-method Study of a Low-salt Dietary Approach to Control Blood Pressure in the Bangladeshi Chronic Kidney Disease Population.|Completed||Phase 3|56|Actual|Barts & The London NHS Trust||2|||f||||f||||||||||2018-06-01 02:01:04.342689|2018-06-01 02:01:04.342689
NCT00702299|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2012-10-01||2015-12-02|2008-06-19|2008-06-20|Estimate|2013-07-17|2013-07-19|Estimate||||2015-12-02|2016-01-01|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|October 2012|Actual|2012-10-31|January 2012|Actual|2012-01-31||Interventional|||Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer|Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer|Completed||Phase 1|15|Actual|University of Arizona|A limitation of this study is that max treatment dose was not definitively determined, in that the trial did not proceed at accrue patients at a dose level less than 1,000 mg/m2.|1|||f||||t||||||||||2018-06-01 02:01:04.483384|2018-06-01 02:01:04.483384
NCT00702286|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-06-19|2008-06-19|2008-06-20|Estimate|||||||2008-06-19|2008-06-20|Estimate|August 2008||2008-08-31|May 2008|2008-05-31||||||||Observational|NV-US-04-001||Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy Catheters|Phase II Prospective Comparison Randomized Placebo Controlled Double Blind Study to Evaluate the Efficacy of the UroShieldTM Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy|Unknown status|Not yet recruiting||24|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||None Retained|"~     urine culture~   "|||2018-06-01 02:01:04.807772|2018-06-01 02:01:04.807772
NCT00702273|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2014-05-14||2017-03-21|2008-06-19|2008-06-20|Estimate|2014-11-18|2014-11-20|Estimate||||2017-03-21|2017-04-18|Actual|April 19, 2006|Actual|2006-04-19|March 2017|2017-03-31|May 31, 2009|Actual|2009-05-31|May 19, 2009|Actual|2009-05-19||Observational||Eligible participants from base study P05787 (NCT00696800) who enrolled in follow up study P05716|Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)|Follow-up Protocol to Collect the Outcome of Frozen-thawed Embryo Transfer Cycles After Cryopreservation of Embryos in Clinical Trial 38819|Completed|||344|Actual|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-06-01 02:01:04.908845|2018-06-01 02:01:04.908845
NCT00702260|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2018-01-19|2008-06-19|2008-06-20|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2005||2005-01-31|January 2018|2018-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ramipril 10 mg Capsules Under Fed Conditions|Completed||N/A|39|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:01:05.268825|2018-06-01 02:01:05.268825
NCT00702247|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-06-19|2008-06-19|2008-06-20|Estimate|||||||2008-06-19|2008-06-20|Estimate|July 1999||1999-07-31|June 2008|2008-06-30||||||||Interventional|||Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)|Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Two Step Approach to Reduce Toxicity Involving High-Dose Melphalan and Autologous Stem Cell Transplant Followed by PBSC Allografting After Low-Dose TBI|Unknown status|Recruiting|Phase 2|||Azienda Ospedaliera San Giovanni Battista||1|||f||||||||||||||2018-06-01 02:01:05.328729|2018-06-01 02:01:05.328729
NCT00702234|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2015-04-09||2017-03-21|2008-06-18|2008-06-20|Estimate|2015-04-09|2015-04-27|Estimate||||2017-03-21|2017-04-18|Actual|February 15, 2007|Actual|2007-02-15|March 2017|2017-03-31|January 15, 2010|Actual|2010-01-15|October 22, 2009|Actual|2009-10-22||Observational|Care|Individuals who participated in base study P05714 (NCT00696878) and received at least one dose of corifollitropin alfa, who had an ongoing pregnancy confirmed by ultrasound at least 10 weeks after fresh ET in base study P05714 and were able and willing to give written informed consent to be enrolled in the follow-up study.|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established After Controlled Ovarian Stimulation in Clinical Trial 38825 for Org 36286 (Corifollitropin Alfa)|Completed|||268|Actual|Merck Sharp & Dohme Corp.|||1||f||||f||||||||||2018-06-01 02:01:05.449899|2018-06-01 02:01:05.449899
NCT00702221|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2014-09-10||2016-06-20|2008-06-19|2008-06-20|Estimate|2016-06-20|2016-07-29|Estimate||||2016-06-20|2016-07-29|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional||All analyzed subjects|Safety and Efficacy Study of Angiotensin Therapeutic Vaccine in Subjects With Mild to Moderate Hypertension|A Randomised, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Subjects With Mild to Moderate Hypertension|Terminated||Phase 2|20|Actual|BTG International Inc.|Study prematurely terminated|2||Dose limiting adverse effects|f||||t||||||||Yes|Investigators provide information to participants|2018-06-01 02:01:06.140656|2018-06-01 02:01:06.140656
NCT00702208|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2013-07-29||2013-12-12|2008-06-19|2008-06-20|Estimate|2013-12-12|2014-01-13|Estimate||||2013-12-12|2014-01-13|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Feasibility of Delphi Screener for Cervical Cytology|The Feasibility and Acceptability of Using the Delphi Screener for Cervical Cytology Testing Among Low Income Women in New York City|Completed||Phase 2|198|Actual|Columbia University||1|||f||||f||||||||||2018-06-01 02:01:06.46986|2018-06-01 02:01:06.46986
NCT00702195|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-06-23|2008-06-19|2008-06-20|Estimate|||||||2017-06-23|2017-06-26|Actual|January 1, 2002|Actual|2002-01-01|June 2017|2017-06-30|September 15, 2003|Actual|2003-09-15|September 15, 2003|Actual|2003-09-15||Observational|||Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)|Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials for the Development of Org 36286 (Corifollitropin Alfa).|Completed|||29|Actual|Merck Sharp & Dohme Corp.|||4||f||||f||||||||||2018-06-01 02:01:06.650999|2018-06-01 02:01:06.650999
NCT00702182|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2012-10-17|2008-06-19|2008-06-20|Estimate|||||||2012-10-17|2012-10-19|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer|Phase 1 Study of Oral Vinorelbine in Combination With Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules|Completed||Phase 1|30|Actual|National Cancer Centre, Singapore||2|||f||||f||||||||||2018-06-01 02:01:06.738678|2018-06-01 02:01:06.738678
NCT00702169|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2009-03-29|2008-06-19|2008-06-20|Estimate|||||||2009-03-29|2009-03-31|Estimate|December 2007||2007-12-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Continuous Monitoring of the Lungs Ventilation Dynamics During Mechanical Ventilation|Continuous Monitoring of the Lungs Ventilation Dynamics During Mechanical Ventilation by Small Surface Patches That Include Safe Motion Sensors|Completed|||15|Actual|Carmel Medical Center|||1||f||||t||||||||||2018-06-01 02:01:06.842335|2018-06-01 02:01:06.842335
NCT00701987|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-02-02|2008-06-17|2008-06-19|Estimate|||||||2010-02-02|2010-02-03|Estimate|June 2008||2008-06-30|February 2010|2010-02-28||||June 2009|Anticipated|2009-06-30||Interventional|||Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma|Dose-escalating, Pilot Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ALS-357 Topically Administered to Patients With Cutaneous Metastatic Melanoma|Unknown status|Recruiting|Phase 1|12|Anticipated|Advanced Life Sciences, Inc.||4|||f||||t||||||||||2018-06-01 02:01:09.649476|2018-06-01 02:01:09.649476
NCT00702156|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2008-09-02|2008-06-19|2008-06-20|Estimate|||||||2008-09-02|2008-09-03|Estimate|March 2005||2005-03-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|||Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease|Cardioselective Beta-Blockade Using Bisoprolol in Patients With Chronic Heart Failure (CHF) and Coexistent Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) With or Without Significant Reversibility.|Terminated||Phase 2|27|Actual|NHS Greater Glasgow and Clyde||2||Inadequate patient recruitment|f||||t||||||||||2018-06-01 02:01:06.919051|2018-06-01 02:01:06.919051
NCT00702143|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|2012-04-06|2011-11-21|2012-05-08|2008-06-19|2008-06-20|Estimate|2012-04-06|2012-05-03|Estimate|2011-11-21|2011-11-23|Estimate|2012-05-08|2012-05-10|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)|An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-45 in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)|Completed||Phase 2|184|Actual|Avid Radiopharmaceuticals||3|||f||||f||||||||||2018-06-01 02:01:07.004043|2018-06-01 02:01:07.004043
NCT00702130|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2011-11-29|2008-06-19|2008-06-20|Estimate|||||||2011-11-29|2011-11-30|Estimate|June 2008||2008-06-30|November 2011|2011-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|EPRAVAP||Pravastatin and Ventilatory Associated Pneumonia|The Effect of Pravastatin on the Incidence and in the Natural Course of Ventilatory Associated Pneumonia in the Intensive Care Unit Patients|Completed||Early Phase 1|152|Actual|University of Thessaly||2|||f||||t||||||||||2018-06-01 02:01:07.329491|2018-06-01 02:01:07.329491
NCT00702117|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2010-12-14|2008-06-19|2008-06-20|Estimate|||||||2010-12-14|2010-12-15|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|AJUAR||Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias|Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias|Completed||Phase 4|123|Actual|Hospital Clinic of Barcelona||6|||f||||f||||||||||2018-06-01 02:01:08.459866|2018-06-01 02:01:08.459866
NCT00702104|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2013-05-13|2008-06-19|2008-06-20|Estimate|||||||2013-05-13|2013-05-14|Estimate|January 2003||2003-01-31|May 2013|2013-05-31||||January 2008|Actual|2008-01-31||Observational|||Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area|PSA Screening of African-American Men in The San Francisco Area|Completed|||||University of California, San Francisco|||||f||||f||||||||||2018-06-01 02:01:08.55456|2018-06-01 02:01:08.55456
NCT00702091|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2018-01-19|2008-06-19|2008-06-20|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2005||2005-01-31|January 2018|2018-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions|Completed||N/A|39|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:01:08.639863|2018-06-01 02:01:08.639863
NCT00702078|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2017-01-09|2008-06-19|2008-06-20|Estimate|||||||2017-01-09|2017-01-11|Estimate|April 2008||2008-04-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|COPD-HOME||Home-based Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD)|Randomised Clinical Study on the Effect of Home-based Treatment of Patients With COPD. Improved Cooperation Between Hospital and Primary Healthcare System.|Completed||N/A|172|Actual|St. Olavs Hospital||2|||f||||t||||||||||2018-06-01 02:01:08.718982|2018-06-01 02:01:08.718982
NCT00702065|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2014-06-16|2008-06-19|2008-06-20|Estimate|||||||2014-06-16|2014-06-17|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|MusiQoL||A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment|A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment|Completed|||599|Actual|EMD Serono|||2||f||||||||||||||2018-06-01 02:01:08.830244|2018-06-01 02:01:08.830244
NCT00702052|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-19|||2013-05-10|2008-06-19|2008-06-20|Estimate|||||||2013-05-10|2013-05-14|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|PILLAR-1||Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy.|An Open-label, Single-arm Phase II Study of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® (Bortezomib).|Completed||Phase 2|58|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:01:08.981943|2018-06-01 02:01:08.981943
NCT00702039|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2018-01-12|2008-06-16|2008-06-19|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2007||2007-02-28|January 2018|2018-01-31|June 2011|Actual|2011-06-30|February 2009|Actual|2009-02-28||Observational|||Effect of Music Therapy on Patients Undergoing Intravitreal Injections|Effect of Music Therapy on Patients Undergoing Intravitreal Injections|Completed|||50|Actual|Yale University|||2||f||||t||||||||||2018-06-01 02:01:09.226767|2018-06-01 02:01:09.226767
NCT00702026|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2013-01-28|2008-06-18|2008-06-19|Estimate|||||||2013-01-28|2013-01-29|Estimate|August 2008||2008-08-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients|The Effect of a Multispecies Probiotic on Hypersensitivity in IBS Patients|Completed||N/A|40|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 02:01:09.333768|2018-06-01 02:01:09.333768
NCT00702013|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-11-10|2008-06-18|2008-06-19|Estimate|||||||2010-11-10|2010-11-11|Estimate|March 2007||2007-03-31|October 2010|2010-10-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Observational|Onto-Pgp||Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics|Ontogenesis of the P-glycoprotein in Human Lymphocytes: Influence of the Human Immunodeficiency Virus (HIV) and Antiretroviral Therapeutics|Completed|||310|Actual|Assistance Publique - Hôpitaux de Paris|||8||f||||f||||||Samples With DNA|"~     blood sample for DNA extraction and genetic polymorphism of Mdr1~   "|||2018-06-01 02:01:09.437531|2018-06-01 02:01:09.437531
NCT00702000|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2016-01-15|2008-06-18|2008-06-19|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Study of Intensive Care Unit (ICU)-Acquired Weakness (Handgrip Strength Study)|Clinical Determinants of Handgrip Strength in Critically Ill Adults: Pilot Study|Completed|||49|Actual|Ohio State University|||1||f||||t||||||||||2018-06-01 02:01:09.561081|2018-06-01 02:01:09.561081
NCT00616460|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2015-06-11|2008-02-14|2008-02-15|Estimate|||||||2015-06-11|2015-06-12|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ACRIPAB||ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding||Completed||Phase 3|100|Actual|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-06-01 02:27:25.6311|2018-06-01 02:27:25.6311
NCT00701974|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-10-22|2008-06-18|2008-06-19|Estimate|||||||2010-10-22|2010-10-25|Estimate|February 2008||2008-02-29|February 2008|2008-02-29||||February 2008|Actual|2008-02-29||Interventional|||Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers|Study of Non Inferiority of Product Kollagenase ®, Manufactured by Laboratory Cristália When Compared With Iruxol ®, Manufactured by Abbott Laboratory, in the Treatment of Cutaneous Ulcers|Suspended||Phase 2/Phase 3|66|Anticipated|Azidus Brasil||2|||f||||f||||||||||2018-06-01 02:01:09.761258|2018-06-01 02:01:09.761258
NCT00701961|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-09-12|2008-06-18|2008-06-19|Estimate|||||||2010-09-12|2010-09-14|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy|The Pharmacokinetic of the Fixed-dose Combination of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnant Women|Completed||Phase 2/Phase 3|48|Actual|Institute of Tropical Medicine, Belgium||2|||f||||t||||||||||2018-06-01 02:01:09.829489|2018-06-01 02:01:09.829489
NCT00701948|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-04-27|2008-06-18|2008-06-19|Estimate|||||||2010-04-27|2010-04-28|Estimate|July 2008||2008-07-31|April 2010|2010-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|NOSODIAG||New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn|Interest of New Dosages of Inflammatory Markers for the Early Diagnosis of Nosocomial Bacterial Infections of the Newborn|Unknown status|Recruiting||240|Anticipated|University Hospital, Strasbourg, France|||4||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:01:09.922745|2018-06-01 02:01:09.922745
NCT00701935|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2013-01-11||2015-03-23|2008-06-18|2008-06-19|Estimate|2013-01-11|2013-02-13|Estimate||||2015-03-23|2015-04-10|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin|Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin|Terminated||Phase 2|80|Actual|AstraZeneca|The dropout rate in the study was higher than anticipated (of 80 patients randomized, only 53 completed Study Period II), and enrollment was much slower than anticipated, leading to a decision to terminate the study early for enrollment futility.|2||"Enrollment was much slower than anticipated, leading to a decision to terminate the study early~   for enrollment futility."|f||||f||||||||||2018-06-01 02:01:10.092745|2018-06-01 02:01:10.092745
NCT00701922|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-10-27|2008-06-18|2008-06-19|Estimate|||||||2011-10-27|2011-10-28|Estimate|October 2005||2005-10-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Surveillance Study of Viral Infections Following Lung Transplantation|Season Surveillance Study of Viral Infections in Lung Transplant Recipients|Completed|||388|Actual|Hannover Medical School|||||f||||f||||||Samples Without DNA|"~     Nasopharyngeal and oropharyngeal swabs~      bronchoalveolar lavage~      blood samples~   "|||2018-06-01 02:01:10.687286|2018-06-01 02:01:10.687286
NCT00701909|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2014-01-14|2008-06-18|2008-06-19|Estimate|||||||2014-01-14|2014-01-16|Estimate|June 2008||2008-06-30|January 2014|2014-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pain Medicine for Wound Care Procedures|The Effectiveness of Small Doses of Ketamine With Morphine on Decreasing Pain Responses During Open Wound Care|Completed||Phase 3|12|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:01:10.791701|2018-06-01 02:01:10.791701
NCT00701896|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2017-02-10|2008-06-18|2008-06-19|Estimate|||||||2017-02-10|2017-02-13|Actual|June 2008||2008-06-30|February 2017|2017-02-28|June 20, 2013|Actual|2013-06-20|April 20, 2013|Actual|2013-04-20||Interventional|||Smoking Cessation Using Motivational Therapy and Varenicline|Smoking Cessation and the Natural History of HIV-Associated Emphysema|Completed||N/A|368|Actual|Ohio State University||4|||f||||t||||||||||2018-06-01 02:01:10.906154|2018-06-01 02:01:10.906154
NCT00701883|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17||2015-02-16|2015-05-19|2008-06-18|2008-06-19|Estimate||||2015-04-29|2015-05-18|Estimate|2015-05-19|2015-06-12|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|MBX-8025||Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol|"Multicenter Randomized Double-Blind Placebo and Active Comparator Controlled Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MBX-8025 in Moderately Obese Hyperlipidemic Patients With/Out Concomitant Atorvastatin"|Completed||Phase 2|183|Actual|CymaBay Therapeutics, Inc.||6|||f||||t||||||||||2018-06-01 02:01:11.035972|2018-06-01 02:01:11.035972
NCT00701870|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2013-11-25|2008-06-18|2008-06-19|Estimate|||||||2013-11-25|2013-11-27|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non‑Small Cell Lung Cancer|Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Chemotherapy Induced Neutropenia in Patients With Locally Advanced or Metastatic Non‑Small Cell Lung Cancer Receiving First-Line Chemotherapy|Terminated||Phase 2|1|Actual|Telik||2||Study TLK199.2102 was terminated for lack of enrollment.|f||||f||||||||||2018-06-01 02:01:11.190681|2018-06-01 02:01:11.190681
NCT00701857|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2016-04-19|2008-06-18|2008-06-19|Estimate|||||||2016-04-19|2016-04-20|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Interventional|||Pemetrexed, Cisplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer|Phase I Study of Concomitant Pemetrexed and CDDP Plus Radiation Therapy in Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal (GEJ) Carcinomas|Completed||Phase 1|10|Actual|University of Arizona||1|||f||||t||||||||||2018-06-01 02:01:11.369329|2018-06-01 02:01:11.369329
NCT00701844|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2017-11-14|2008-06-18|2008-06-19|Estimate|||||||2017-11-14|2017-11-17|Actual|July 2007||2007-07-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors|Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors|Completed||N/A|315|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-06-01 02:01:11.483565|2018-06-01 02:01:11.483565
NCT00701831|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-11-03|2008-06-18|2008-06-19|Estimate|||||||2010-11-03|2010-11-04|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|LANTIT||Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control|Assessment of Forced Titration to Reach the Effective Dose for Good Glycemic Control in Lantus Treated Type 2 Patients|Completed||Phase 4|241|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:01:11.613328|2018-06-01 02:01:11.613328
NCT00701818|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2015-06-02|2008-06-18|2008-06-19|Estimate|||||||2015-06-02|2015-06-03|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|CORAIS||Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke|Coronary Arteriosclerosis in Patients With Acute Ischemic Stroke Prevalence and Characteristics as Measured by CT Angiography, Echocardiography and Biomarkers|Completed|||25|Actual|Vejle Hospital|||||f||||f||||||||||2018-06-01 02:01:11.69613|2018-06-01 02:01:11.69613
NCT00701805|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2010-12-28||2011-03-18|2008-06-17|2008-06-19|Estimate|2011-03-18|2011-04-19|Estimate||||2011-03-18|2011-04-19|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)|Phase II Study of Paricalcitol Injection Extension Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism|Completed||Phase 2|107|Actual|Abbott|The dose titration scheme was revised because of the incidence of hypercalcemia in the early weeks of the study.|4|||f||||f||||||||||2018-06-01 02:01:11.821038|2018-06-01 02:01:11.821038
NCT00701792|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-18|2008-06-18|2008-06-19|Estimate|||||||2008-06-18|2008-06-19|Estimate|March 1994||1994-03-31|June 2008|2008-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|TRANSCIAL||Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis|Randomized Trial Comparing Liver Transplantation to Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis|Completed||N/A|120|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-06-01 02:01:13.080604|2018-06-01 02:01:13.080604
NCT00701779|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2014-07-28||2014-12-18|2008-06-18|2008-06-19|Estimate|2014-12-18|2015-01-01|Estimate||||2014-12-18|2015-01-01|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||"Enrollment of ~ 60 subjects will allow the proportion of subjects able to discontinue Tamsulosin, (assuming 50% able to discontinue), usage within 13% using a 95% confidence interval.~Assuming 75% of the subjects are able to discontinue Tamsulosin, the proportion of subjects can be estimated to within 11% using a 95% confidence interval."|Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia|Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH|Completed||Phase 4|63|Actual|Siami, Paul F., M.D.||1|||f||||t||||||||||2018-06-01 02:01:13.201453|2018-06-01 02:01:13.201453
NCT00701766|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18||2014-04-30|2014-04-30|2008-06-18|2008-06-19|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|October 2006||2006-10-31|October 2013|2013-10-31||||October 2009|Actual|2009-10-31||Interventional|||BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia|An Open, Randomised Clinical Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Efficacy, Safety and Pharmacokinetics of Repeated Three-week Courses of a Single Dose i.v. BI 2536 on Day 1 in Comparison to Single Doses i.v. BI 2536 on Days 1, 2 and 3 in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia|Completed||Phase 2|71|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:01:13.500897|2018-06-01 02:01:13.500897
NCT00701753|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2009-03-11|2008-06-17|2008-06-19|Estimate|||||||2009-03-11|2009-03-12|Estimate|May 2008||2008-05-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses|A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses|Terminated|||24|Actual|TheraGenetics Limited|||3|Insufficient subject recruitment.|f||||f||||||Samples With DNA|"~     Whole blood DNA RNA~   "|||2018-06-01 02:01:13.586634|2018-06-01 02:01:13.586634
NCT00701740|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2008-06-18|2008-06-18|2008-06-19|Estimate|||||||2008-06-18|2008-06-19|Estimate|July 2007||2007-07-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Oral Isotretinoin for Photoaging: Results of a Randomized Controlled Phase II Trial|Phase II Randomized Controlled Trial to Evaluate the Clinical and Histological Effects of Oral Isotretinoin for the Treatment of Photoaging on Face and Forearms|Completed||Phase 2|32|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 02:01:13.659195|2018-06-01 02:01:13.659195
NCT00701727|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2011-01-10||2011-03-14|2008-06-17|2008-06-19|Estimate|2011-03-14|2011-04-18|Estimate||||2011-03-14|2011-04-18|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study|Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study|Completed||Phase 4|31|Actual|Radiant Research||2|||f||||f||||||||||2018-06-01 02:01:13.75896|2018-06-01 02:01:13.75896
NCT00701714|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2017-04-03||2017-07-13|2008-06-18|2008-06-19|Estimate|2017-07-13|2018-02-02|Estimate||||2017-07-13|2018-02-02|Estimate|September 2007||2007-09-30|July 2017|2017-07-31|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|||Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients|Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients|Terminated||Phase 3|337|Actual|Sandoz||2||investigation of adverse events|f||||f||||||||||2018-06-01 02:01:14.136033|2018-06-01 02:01:14.136033
NCT00701701|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2018-03-22|2008-06-17|2008-06-19|Estimate|||||||2018-03-22|2018-03-23|Actual|December 14, 2008|Actual|2008-12-14|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Immune Tolerance Induction Study|An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme|Active, not recruiting||Phase 4|4|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:01:15.664214|2018-06-01 02:01:15.664214
NCT00701688|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2012-03-22|2008-06-18|2008-06-19|Estimate|||||||2012-03-22|2012-03-23|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Phase I Study Of The Use Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 1|19|Actual|St. Jude Children's Research Hospital||3|||f||||f||||||||||2018-06-01 02:01:15.748672|2018-06-01 02:01:15.748672
NCT00701675|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2014-01-16||2016-11-02|2008-06-18|2008-06-19|Estimate|2016-11-02|2016-12-29|Estimate||||2016-11-02|2016-12-29|Estimate|October 2005||2005-10-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|Sert-GAD||Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly|Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly|Completed||Phase 4|42|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 02:01:15.8369|2018-06-01 02:01:15.8369
NCT00701662|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2013-06-02||2013-06-02|2008-06-18|2008-06-19|Estimate|2013-06-02|2013-08-01|Estimate||||2013-06-02|2013-08-01|Estimate|November 2007||2007-11-30|June 2013|2013-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)|A Multicentre Study of Subcutaneous Immunoglobulin (SCIG) in Patients With Multifocal Motor Neuropathy (MMN)|Completed||Phase 2|8|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 02:01:16.171094|2018-06-01 02:01:16.171094
NCT00701649|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2009-12-01|2008-06-18|2008-06-19|Estimate|||||||2009-12-01|2009-12-02|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension|A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (CYT006-AngQb) in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 2|60|Anticipated|Cytos Biotechnology AG||2|||f||||f||||||||||2018-06-01 02:01:16.491086|2018-06-01 02:01:16.491086
NCT00701636|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2012-03-28||2016-07-19|2008-06-18|2008-06-19|Estimate|2016-07-19|2016-08-29|Estimate||||2016-07-19|2016-08-29|Estimate|July 2008||2008-07-31|July 2016|2016-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||Our protocol says we will enroll 32 subjects, with the assumption that 2 may not finish the study, have protocol violations, or have data that is corrupt and unusable. Our target was 30 analyzable subjects. Since we had no subjects withdraw from the trial, and no protocol violations or data problems, we halted enrollment at 30 subjects.|Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery|Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery|Completed||Phase 3|30|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||Yes|Data may be shared upon written request to the principal investigator.|2018-06-01 02:01:16.639731|2018-06-01 02:01:16.639731
NCT00701623|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-10-26|2008-06-18|2008-06-19|Estimate|||||||2010-10-26|2010-10-27|Estimate|June 2008||2008-06-30|February 2008|2008-02-29||||June 2008|Anticipated|2008-06-30||Interventional|SODIC HEPARIN||Sodic Heparin Effectiveness of the Treatment of Burns|Clinical Efficacy of Product Alimax ® (Sodic Heparin) in Treatment of Burns: Comparative Study of Raw Materials Between Two Suppliers|Withdrawn||Phase 2/Phase 3|84|Anticipated|Azidus Brasil||3|||f||||f||||||||||2018-06-01 02:01:16.918904|2018-06-01 02:01:16.918904
NCT00701610|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2008-06-18|2008-06-18|2008-06-19|Estimate|||||||2008-06-18|2008-06-19|Estimate|August 2007||2007-08-31|July 2007|2007-07-31|August 2009|Anticipated|2009-08-31|August 2008|Anticipated|2008-08-31||Observational|||Levels of Von Willebrand Factor Multimers and VWF-Cleaving Protease (ADAMTS-13) in Preterm and Neonate|Levels of Von Willebrand Factor Multimers and VWF-Cleaving Protease (ADAMTS-13) in Preterm and Neonate|Unknown status|Recruiting||100|Anticipated|Sheba Medical Center|||1||f||||f||||||Samples Without DNA|"~     blood will be taken from cord blood at birth from fullterm and preterm infantsinfants~   "|||2018-06-01 02:01:16.984775|2018-06-01 02:01:16.984775
NCT00701597|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2008-06-18|2008-06-18|2008-06-19|Estimate|||||||2008-06-18|2008-06-19|Estimate|April 2007||2007-04-30|June 2008|2008-06-30|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma|Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma.|Completed||Phase 1|28|Actual|Medical University of Vienna|||||f||||t||||||||||2018-06-01 02:01:17.058536|2018-06-01 02:01:17.058536
NCT00701584|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2014-05-19|2008-06-13|2008-06-19|Estimate|||||||2014-05-19|2014-05-20|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|August 2010|Actual|2010-08-31||Observational|DietCompLyf||The Role of Diet and Lifestyle in Breast Cancer Survival|The Role of Diet, Complementary Treatment and Lifestyle in Breast Cancer Progression and Survival|Unknown status|Active, not recruiting||3390|Actual|University College London Hospitals|||||f||||t||||||Samples With DNA|"~     Serum, plasma, buffy coat, urine~   "|||2018-06-01 02:01:17.124851|2018-06-01 02:01:17.124851
NCT00701571|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-09-12|2008-06-18|2008-06-19|Estimate|||||||2011-09-12|2011-09-13|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Video/Audio Distraction Analgesia for Simulated Oncology Procedure Pain|Video/Audio Distraction Analgesia for Simulated Oncology Procedure Pain|Completed||N/A|180|Anticipated|University of Washington||1|||f||||f||||||||||2018-06-01 02:01:17.180094|2018-06-01 02:01:17.180094
NCT00701558|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2016-04-14||2016-05-24|2008-06-18|2008-06-19|Estimate|2016-04-14|2016-05-19|Estimate||||2016-05-24|2016-06-24|Estimate|August 2008||2008-08-31|May 2016|2016-05-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer|An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Disease Progression in Patients With Unresectable Advanced and/or Metastatic Non-small Cell Lung Cancer|Completed||Phase 2|20|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:01:17.259468|2018-06-01 02:01:17.259468
NCT00701545|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2011-02-10|2008-06-18|2008-06-19|Estimate|||||||2011-02-10|2011-02-11|Estimate|February 2008||2008-02-29|February 2011|2011-02-28|April 2009|Actual|2009-04-30|||||Observational|||A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)|A Canadian, Multi-center, Prospective, Open-label, Observational, Pharmacovigilance Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) in Patients Transitioning From Treatment With Currently Available Humate-P®|Completed|||21|Actual|CSL Behring|||1||f||||f||||||||||2018-06-01 02:01:17.428175|2018-06-01 02:01:17.428175
NCT00701532|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2013-04-10|2008-06-18|2008-06-19|Estimate|||||||2013-04-10|2013-04-11|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|CAIMAN||Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction|Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study|Completed||Phase 3|29|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:01:17.490049|2018-06-01 02:01:17.490049
NCT00701519|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2017-01-13|2008-06-18|2008-06-19|Estimate|||||||2017-01-13|2017-01-16|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||The Prevalence of Sleep Disordered Breathing in Hospitalized Patients With Acutely Decompensated Heart Failure Syndrome|The Prevalence of Sleep Disordered Breathing in Hospitalized Patients With Acutely Decompensated Heart Failure Syndrome|Completed|||1600|Actual|Ohio State University|||||f||||f||||||||No||2018-06-01 02:01:17.559058|2018-06-01 02:01:17.559058
NCT00701506|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-12-07|2008-06-17|2008-06-19|Estimate|||||||2011-12-07|2011-12-09|Estimate|May 2008||2008-05-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Patterned Electrical Neuromuscular Stimulation and Therapeutic Exercise for Osteoarthritis of the Knee: Pilot Study|Patterned Electrical Neuromuscular Stimulation and Therapeutic Exercise for Osteoarthritis of the Knee: Pilot Study|Completed||Phase 4|13|Actual|RS Medical||2|||f||||f||||||||||2018-06-01 02:01:17.808554|2018-06-01 02:01:17.808554
NCT00701324|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2014-07-21|2008-06-18|2008-06-19|Estimate|||||||2014-07-21|2014-07-22|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||BI 811283 in Various Solid Tumours|An Open Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 811283 Administered Intravenously Over 24 h Continuous Infusion in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|124|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:01:23.692337|2018-06-01 02:01:23.692337
NCT00701493|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-06-06|2008-06-17|2008-06-19|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2004||2004-11-30|March 2010|2010-03-31|December 2004|Actual|2004-12-31|||||Interventional|||A Phase 1 Bioavailability Study of Topiramate Oral Liquid Formulation Compared to the Marketed Sprinkle Capsule Formulation in Healthy Adults|An Open-Label, Randomized, 2-Way Crossover Study of the Bioavailability of an Oral Liquid Formulation Relative to the Marketed Sprinkle Capsule Formulation of Topiramate RWJ-17021-000 in Healthy Subjects|Completed||Phase 1|40|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:01:17.895204|2018-06-01 02:01:17.895204
NCT00701480|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-06-17|2008-06-17|2008-06-19|Estimate|||||||2008-06-17|2008-06-19|Estimate|April 2008||2008-04-30|June 2008|2008-06-30|September 2008|Anticipated|2008-09-30|July 2008|Anticipated|2008-07-31||Interventional|||Safety and Efficacy of Skin Cleanser Contained Roselle Extract in Acne|Randomized Double-Blind Case Control Study of Safety and Efficacy of Skin Cleanser Contained Hibiscus Sabdariffa Extract in Acne Treatment.|Unknown status|Recruiting|Phase 2|50|Anticipated|Thammasat University||2|||f||||t||||||||||2018-06-01 02:01:17.958715|2018-06-01 02:01:17.958715
NCT00701467|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2013-11-17|2008-06-18|2008-06-19|Estimate|||||||2013-11-17|2013-11-19|Estimate|March 2008||2008-03-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2010|Actual|2010-03-31||Observational|HRV||Change in Heart Rate Variability Prior to Tachyarrhythmia in ICD Implanted Patients|HRV Registry to Investigate Changes During the Time Before a Spontaneous Episode of Ventricular Tachyarrhythmia|Completed|||50|Actual|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 02:01:18.069283|2018-06-01 02:01:18.069283
NCT00701454|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-06-17|2008-06-17|2008-06-19|Estimate|||||||2008-06-17|2008-06-19|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Survey of Thai-Muslim Health Status|Survey of Thai-Muslim Health Status|Completed|||1488|Actual|Mahidol University|||1||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-06-01 02:01:18.144924|2018-06-01 02:01:18.144924
NCT00701441|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2011-08-12||2013-10-29|2008-06-17|2008-06-19|Estimate|2013-10-29|2013-10-30|Estimate||||2013-10-29|2013-10-30|Estimate|February 2007||2007-02-28|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea|The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea|Completed|||25|Actual|Ohio State University|Small Feasibility trial only.||2||f||||f||||||Samples With DNA|"~     Blood and tissue biopsy~   "|||2018-06-01 02:01:18.21999|2018-06-01 02:01:18.21999
NCT00701428|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2014-11-17|2008-06-18|2008-06-19|Estimate|||||||2014-11-17|2014-11-18|Estimate|June 2008||2008-06-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|LosartanPAP||Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment|Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment|Completed||Phase 4|90|Actual|Skaraborg Hospital||3|||f||||t||||||||||2018-06-01 02:01:18.470899|2018-06-01 02:01:18.470899
NCT00701415|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2016-05-20||2016-05-20|2008-06-18|2008-06-19|Estimate|2016-05-20|2016-06-29|Estimate||||2016-05-20|2016-06-29|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|FIELD||A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms|A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms|Completed||Phase 3|31|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:01:18.671303|2018-06-01 02:01:18.671303
NCT00701402|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2009-08-04|2008-06-18|2008-06-19|Estimate|||||||2009-08-04|2009-08-06|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|January 2009|Actual|2009-01-31|||||Observational|PRYSME||National Survey on Dyslipidemic Patients|Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.|Completed|||3655|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:01:19.546126|2018-06-01 02:01:19.546126
NCT00701389|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2014-08-27||2017-04-06|2008-06-18|2008-06-19|Estimate|2014-08-27|2014-09-08|Estimate||||2017-04-06|2017-05-12|Actual|November 20, 2007|Actual|2007-11-20|April 2017|2017-04-30|April 10, 2008|Actual|2008-04-10|April 10, 2008|Actual|2008-04-10||Interventional|||Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)|A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Single Dose Crossover Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 in Migraine Patients|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 02:01:21.496196|2018-06-01 02:01:21.496196
NCT00701376|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2018-03-09|2008-06-18|2008-06-19|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2008||2008-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|||Hepatic Effects of Gastric Bypass Surgery|Long Term Hepatic Effects of Gastric Bypass Surgery|Active, not recruiting||N/A|100|Anticipated|The Cleveland Clinic||1|||f||||f||||||||||2018-06-01 02:01:21.868381|2018-06-01 02:01:21.868381
NCT00701363|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2015-09-11||2015-11-10|2008-06-18|2008-06-19|Estimate|2015-11-10|2015-12-14|Estimate||||2015-11-10|2015-12-14|Estimate|October 2008||2008-10-31|November 2015|2015-11-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|LEAD|Phase 1: 15 subjects participated only in phase 1 and did not enter in phase 2.|Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects|A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg|Completed||Phase 4|124|Actual|Ipsen||1|||f||||||||||||||2018-06-01 02:01:22.018955|2018-06-01 02:01:22.018955
NCT00701350|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2010-07-19|2008-06-18|2008-06-19|Estimate|||||||2010-07-19|2010-07-21|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|PPROM||Biomarkers of Intra-amniotic Infection in Women With Preterm Premature Ruptured Amniotic Membranes|Identification of Proteomic Markers of Intra-amniotic Infection (IAI) in Patients With Preterm Premature Rupture of Amniotic Membranes (PPROM)|Completed|||79|Actual|ProteoGenix, Inc.|||1||f||||f||||||Samples Without DNA|"~     Cervical-vaginal Fluid, Amniotic Fluid, Maternal Serum, Neonatal Cord Blood, Placental and~     Umbilical Cord Tissues~   "|||2018-06-01 02:01:23.518211|2018-06-01 02:01:23.518211
NCT00701337|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-05-10|2008-06-18|2008-06-19|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2006||2006-09-30|May 2017|2017-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route|Effect of 17ß-estradiol on Inflammatory-immune Responses in Post-menopausal Women According to Administration Route: Pilot Study|Completed||Phase 4|40|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 02:01:23.591628|2018-06-01 02:01:23.591628
NCT00701311|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2013-12-19||2014-09-25|2008-06-18|2008-06-19|Estimate|2014-04-17|2014-05-16|Estimate||||2014-09-25|2014-10-06|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome|An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome|Completed||Phase 2|21|Actual|William Beaumont Hospitals|The limitation of this study is that only 9 of 17 participants completed full 12 weeks of treatment and there was no placebo arm.|1|||f||||t||||||||||2018-06-01 02:01:23.773495|2018-06-01 02:01:23.773495
NCT00701298|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2014-02-21|2008-06-18|2008-06-19|Estimate|||||||2014-02-21|2014-02-24|Estimate|April 2009||2009-04-30|October 2011|2011-10-31||||October 2010|Actual|2010-10-31||Interventional|||Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors|Inhibition of DNA Methylation by 1-Hr Infusion of 5-aza-2'-Deoxycitidine (Decitabine) x 10 Days (M-F) With Escalating Doses of Sub-Q Pegylated (PEG) Interferon-alpha 2B (PEG-Intron): A Phase I Study With Molecular Correlates|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 02:01:23.938604|2018-06-01 02:01:23.938604
NCT00701285|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2014-05-12|2008-06-18|2008-06-19|Estimate|||||||2014-05-12|2014-05-14|Estimate|July 2008||2008-07-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|SAPHIRE||South Korean Pitavastatin Heart Failure Study|A Prospective, Randomized, Two Group Comparison Study to Evaluate the Effect of Statin on Heart Function in Patients With Chronic Ischemic Heart Failure.|Completed||Phase 4|70|Anticipated|JW Pharmaceutical||2|||f||||||||||||||2018-06-01 02:01:24.118762|2018-06-01 02:01:24.118762
NCT00701272|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2013-07-24|2008-06-18|2008-06-19|Estimate|||||||2013-07-24|2013-07-25|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation|FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of HCV Recurrence and Progression Post Liver Transplantation|Unknown status|Enrolling by invitation||70|Anticipated|University Health Network, Toronto|||2||f||||f||||||Samples With DNA|"~     Blood samples; liver biopsy tissue~   "|||2018-06-01 02:01:24.198531|2018-06-01 02:01:24.198531
NCT00701259|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-01-13|2008-06-18|2008-06-19|Estimate|||||||2010-01-13|2010-01-15|Estimate|January 2007||2007-01-31|January 2010|2010-01-31|August 2007|Actual|2007-08-31|||||Interventional|||Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn|A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn|Completed||Phase 3|852|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:01:24.260196|2018-06-01 02:01:24.260196
NCT00701246|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2014-03-12|2008-06-18|2008-06-19|Estimate|||||||2014-03-12|2014-03-13|Estimate|April 2005||2005-04-30|March 2014|2014-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Treatment and Prevention of Anemia With Ferrous Sulfate Plus Folic Acid in Children in Goiania - Goias, Brazil|Nutritional Anemia: Prevention and Treatment in Early Childhood|Completed||N/A|196|Actual|Universidade Federal de Goias||4|||f||||f||||||||||2018-06-01 02:01:24.335868|2018-06-01 02:01:24.335868
NCT00701233|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2017-06-28|2008-06-17|2008-06-19|Estimate|||||||2017-06-28|2017-06-29|Actual|June 2012||2012-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Botulinum Toxin for Carpal Tunnel Syndrome|Evaluation of Intercarpal Botox Versus Steroid Injections for Carpal Tunnel Syndrome|Active, not recruiting||Phase 2|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 02:01:24.43473|2018-06-01 02:01:24.43473
NCT00701220|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-04-12|2008-06-17|2008-06-19|Estimate|||||||2011-04-12|2011-04-13|Estimate|April 2007||2007-04-30|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Statin Therapy for Ischemic and Nonischemic Cardiomyopathy|Statin Induced Augmentation of Circulating Endothelial Progenitor Cells and Myocardial Viability in Patients With Ischemic and Nonischemic Cardiomyopathy|Completed||Phase 4|30|Anticipated|Ohio State University||3|||f||||f||||||||||2018-06-01 02:01:24.511758|2018-06-01 02:01:24.511758
NCT00701207|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2013-05-02|2008-06-18|2008-06-19|Estimate|||||||2013-05-02|2013-05-06|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of Nicotine Patches in Patients With Sarcoidosis|Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors|Suspended||Phase 4|64|Anticipated|Ohio State University||3||Interim Analysis|f||||t||||||||||2018-06-01 02:01:24.623576|2018-06-01 02:01:24.623576
NCT00701194|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-06-18|2008-06-18|2008-06-19|Estimate|||||||2008-06-18|2008-06-19|Estimate|December 1999||1999-12-31|June 2008|2008-06-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|EIFC||Early Intervention Foster Care: A Prevention Trial|Early Intervention Foster Care: A Prevention Trial|Unknown status|Active, not recruiting|N/A|177|Actual|Oregon Social Learning Center||3|||f||||f||||||||||2018-06-01 02:01:24.695635|2018-06-01 02:01:24.695635
NCT00701181|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17||2012-10-09|2012-10-09|2008-06-18|2008-06-19|Estimate||||2012-10-09|2012-10-11|Estimate|2012-10-09|2012-10-11|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|DEGAS||Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema|A Phase II Prospective, Randomized, Multi-Center, Diabetic Macular Edema Dose Ranging, Comparator Study Evaluating The Efficacy And Safety Of PF-04523655 Versus Laser Therapy (DEGAS)|Terminated||Phase 2|184|Actual|Quark Pharmaceuticals||4||See termination reason in detailed description.|f||||t||||||||||2018-06-01 02:01:24.791252|2018-06-01 02:01:24.791252
NCT00701168|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2017-08-22|2008-06-18|2008-06-19|Estimate|||||||2017-08-22|2017-08-23|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer|A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006|No longer available|||||Leo W. Jenkins Cancer Center|||||f||||||||||||||2018-06-01 02:01:24.949422|2018-06-01 02:01:24.949422
NCT00701155|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2016-02-18|2008-06-18|2008-06-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|July 2007||2007-07-31|February 2016|2016-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Observational Study to Evaluate the Safety While Using Levemir®|Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|Completed|||3593|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:01:25.063942|2018-06-01 02:01:25.063942
NCT00701142|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2013-09-18|2008-06-18|2008-06-19|Estimate|||||||2013-09-18|2013-09-20|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Haemocomplettan® P During Aortic Replacement|Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery|Completed||Phase 2|80|Actual|CSL Behring||2|||f||||f||||||||||2018-06-01 02:01:25.144286|2018-06-01 02:01:25.144286
NCT00701129|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2014-02-24||2014-04-09|2008-06-17|2008-06-19|Estimate|2014-04-09|2014-05-13|Estimate||||2014-04-09|2014-05-13|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Safety population included all patients who received at least one dose of alglucosidase alfa.|An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease|An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme®-Naive, CRIM(-) Patients With Infantile-onset Pompe Disease|Completed||Phase 4|4|Actual|Sanofi|Due to the small number of patients assessed in this study the results must be interpreted with caution.|1|||f||||t||||||||||2018-06-01 02:01:25.246096|2018-06-01 02:01:25.246096
NCT00701103|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2017-01-31||2017-04-05|2008-06-18|2008-06-19|Estimate|2017-01-31|2017-03-21|Actual||||2017-04-05|2017-05-11|Actual|January 2006||2006-01-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||The population consisted of all participants who received at least one dose of study drug.|Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)|An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a Once Weekly, Every Other Week, or Every Three Week Infusion in Patients With Advanced Solid Tumors and Multiple Myeloma|Completed||Phase 1|80|Actual|Merck Sharp & Dohme Corp.||11|||f||||f||||||||||2018-06-01 02:01:25.927261|2018-06-01 02:01:25.927261
NCT00701090|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2010-09-13||2017-01-30|2008-06-18|2008-06-19|Estimate|2010-09-13|2010-10-05|Estimate||||2017-01-30|2017-03-10|Actual|May 2008||2008-05-31|January 2017|2017-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)|A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin|Completed||Phase 3|1035|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:01:28.04162|2018-06-01 02:01:28.04162
NCT00701077|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2008-07-01|2008-06-18|2008-06-19|Estimate|||||||2008-07-01|2008-07-04|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|DAPREB||DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome|DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome|Unknown status|Not yet recruiting|Phase 3|42|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:01:28.458779|2018-06-01 02:01:28.458779
NCT00701064|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2015-03-26||2016-04-05|2008-06-18|2008-06-19|Estimate|2015-04-08|2015-04-29|Estimate||||2016-04-05|2016-05-10|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|November 2012|Actual|2012-11-30||Interventional||Veterans with PTSD|Bright Light: An Adjunct Treatment for Combat Posttraumatic Stress Disorder (PTSD)|Bright Light: An Adjunct Treatment for Combat PTSD|Unknown status|Active, not recruiting|Phase 1|71|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:01:28.548192|2018-06-01 02:01:28.548192
NCT00701051|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2015-01-26||2015-03-23|2008-06-18|2008-06-19|Estimate|2015-03-23|2015-04-06|Estimate||||2015-03-23|2015-04-06|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Exercise Training and Glucose Metabolism in Aging|Aging, Angiogenesis and Metabolic Responses to Aerobic Exercise|Completed||N/A|90|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 02:01:29.10457|2018-06-01 02:01:29.10457
NCT00701038|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2011-08-12||2013-01-29|2008-06-17|2008-06-19|Estimate|2011-11-09|2011-12-14|Estimate||||2013-01-29|2013-02-04|Estimate|August 2006||2006-08-31|January 2013|2013-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure|The Role of Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure|Completed||N/A|54|Actual|Ohio State University||2|||f||||f||||||||||2018-06-01 02:01:29.439972|2018-06-01 02:01:29.439972
NCT00701025|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-02-08|2008-06-18|2008-06-19|Estimate|||||||2011-02-08|2011-02-09|Estimate|April 2008||2008-04-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Mechanisms of Exercise-induced Bronchospasm|Mechanisms of Exercise-induced Bronchospasm|Completed|||70|Anticipated|Ohio State University|||2||f||||t||||||Samples Without DNA|"~     blood, sputum, urine for pregnancy testing~   "|||2018-06-01 02:01:29.773335|2018-06-01 02:01:29.773335
NCT00701012|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2013-12-17|2008-06-17|2008-06-19|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|January 2008|Actual|2008-01-31||Interventional|||Comparison of Low and High Ligation in the Rectal Cancer|Comparison of Functional Results of High Ligation and Low Ligation After Anterior Resection for Rectal Cancer - Randomized Controlled Trial-|Completed||N/A|100|Actual|Wakayama Medical University||2|||f||||t||||||||||2018-06-01 02:01:29.890766|2018-06-01 02:01:29.890766
NCT00700999|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2013-09-09||2014-05-28|2008-06-18|2008-06-19|Estimate|2014-05-28|2014-06-03|Estimate||||2014-05-28|2014-06-03|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||The Baseline Participants have been determined by the number of participants that completed the first MRI scan.|Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)|Neurofunctional Markers of SSRI Treatment Response in PTSD|Completed||Phase 4|65|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 02:01:29.994029|2018-06-01 02:01:29.994029
NCT00700986|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-11-30|2008-06-18|2008-06-19|Estimate|||||||2010-11-30|2010-12-01|Estimate|June 2008||2008-06-30|November 2010|2010-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056|A Randomised, Double-Blind, Placebo-Controlled, 2-Period Cross-Over Study in Healthy Male Volunteers, to Investigate Retinal Function Following a Single 800mg Oral Dose of AZD9056|Completed||Phase 1|12|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:01:30.294006|2018-06-01 02:01:30.294006
NCT00700973|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2014-05-16||2015-04-06|2008-06-17|2008-06-19|Estimate|2014-09-03|2014-09-11|Estimate||||2015-04-06|2015-04-27|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|November 2013|Actual|2013-11-30|January 2012|Actual|2012-01-31||Interventional|||Treating Violence-Prone Substance Use Disorder Patients|Treating Violence-Prone Substance Use Disorder Patients|Completed||Phase 2/Phase 3|141|Actual|VA Office of Research and Development|A limitation of the trial (not a result or conclusion) is that high proportions of patients reported abstinence at baseline.|2|||f||||f||||||||||2018-06-01 02:01:30.389024|2018-06-01 02:01:30.389024
NCT00699959|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-08-04|2008-06-16|2008-06-18|Estimate|||||||2009-08-04|2009-08-06|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|January 2009|Actual|2009-01-31|||||Observational|COMPAR||National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups|Comparison and Description of Coronary Patients Management With or Without Heart Failure in Cardiology Consulting|Completed|||1650|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 02:02:05.66054|2018-06-01 02:02:05.66054
NCT00700960|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-01-30|2008-06-18|2008-06-19|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|LIGHT||Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control|Observational Study on Efficacy on Glycaemic Control of Slow-acting Insulin Analogue in Type 2 Diabetes|Completed|||2745|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:01:30.647158|2018-06-01 02:01:30.647158
NCT00700947|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-01-04|2008-06-18|2008-06-19|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2007|Actual|2007-10-31|January 2018|2018-01-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|REGURG||Using Beta Blockers to Treat Mitral Regurgitation|Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation|Terminated||Phase 1|27|Actual|Wake Forest University Health Sciences||3||Funding terminated|f||||f|t|f||||||No|We currently have no plan to share participant data.|2018-06-01 02:01:30.74124|2018-06-01 02:01:30.74124
NCT00700934|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-12-06|2008-06-18|2008-06-19|Estimate|||||||2010-12-06|2010-12-07|Estimate|February 2005||2005-02-28|June 2008|2008-06-30|February 2012|Anticipated|2012-02-29|February 2011|Anticipated|2011-02-28||Observational|||Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema|Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema. A National Registry.|Unknown status|Recruiting||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 02:01:30.912126|2018-06-01 02:01:30.912126
NCT00700921|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2012-11-26|2008-06-18|2008-06-19|Estimate|||||||2012-11-26|2012-11-28|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)|Lovastatin as a Potential Modulator of Apoptosis in COPD|Completed||Phase 2|30|Actual|National Jewish Health||2|||f||||t||||||||||2018-06-01 02:01:30.992291|2018-06-01 02:01:30.992291
NCT00700908|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2013-02-20|2008-06-18|2008-06-19|Estimate|||||||2013-02-20|2013-02-22|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes|The Impact of an Automated Telephone Intervention on HbA1c in Type 2 Diabetes: A Randomized Controlled Trial|Completed||N/A|120|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 02:01:31.312523|2018-06-01 02:01:31.312523
NCT00700895|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2016-06-06|2008-06-18|2008-06-19|Estimate|||||||2016-06-06|2016-06-07|Estimate|August 2006||2006-08-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose|A Randomized Controlled Trial to Assess the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regimen for Calculating Warfarin Maintenance Dose|Recruiting||Phase 3|320|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 02:01:31.417457|2018-06-01 02:01:31.417457
NCT00700882|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-12-12|2008-06-18|2008-06-19|Estimate|||||||2017-12-12|2017-12-14|Actual|May 1, 2009|Actual|2009-05-01|December 2017|2017-12-31|May 6, 2021|Anticipated|2021-05-06|May 6, 2016|Actual|2016-05-06||Interventional|||Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery|A Phase II Trial of Dasatinib in Patients With Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas|Active, not recruiting||Phase 2|87|Actual|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 02:01:31.549609|2018-06-01 02:01:31.549609
NCT00700869|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2011-10-04|2008-06-18|2008-06-19|Estimate|||||||2011-10-04|2011-10-05|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ORGAR||Evaluation of a New Mechanical Ventilation Weaning Strategy for Patients With Altered Level of Consciousness|Phase 2 Study of a New Mechanical Ventilation Weaning Strategy Governs by a Respiratory Behaviour Status Assessment for Patients With Altered Level of Consciousness|Completed||Phase 2/Phase 3|34|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 02:01:32.053075|2018-06-01 02:01:32.053075
NCT00700856|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2015-08-26|2008-06-18|2008-06-19|Estimate|||||||2015-08-26|2015-08-27|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TOSCA IT||Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial|Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.|Active, not recruiting||Phase 4|3371|Anticipated|Italian Society of Diabetology||2|||f||||t||||||||||2018-06-01 02:01:32.176753|2018-06-01 02:01:32.176753
NCT00700843|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2015-05-13|2008-06-18|2008-06-19|Estimate|||||||2015-05-13|2015-05-15|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Long-Term Follow-up of Ohio State University Medical Center (OSUMC) Bariatric Patients|Long-Term Follow-up of Ohio State University Medical Center (OSUMC) Bariatric Patients|Terminated|||23|Actual|Ohio State University||||Difficulty recruiting|f||||f||||||||||2018-06-01 02:01:32.39666|2018-06-01 02:01:32.39666
NCT00700830|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2014-08-13|2008-06-18|2008-06-19|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|IDEALS||Observational Study to Evaluate the Safety and Efficacy of Levemir® in Type 2 Diabetes|Assessment of Safety and Efficacy of Levemir® (Insulin Detemir) Treatment for Insulin Naive Patients With Type 2 Diabetes Mellitus|Completed|||1976|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:01:32.53358|2018-06-01 02:01:32.53358
NCT00700817|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2010-06-11||2017-01-25|2008-06-18|2008-06-19|Estimate|2010-08-02|2010-08-04|Estimate||||2017-01-25|2017-03-08|Actual|June 2008||2008-06-30|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus|The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension|Completed||Phase 3|665|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-06-01 02:01:32.834119|2018-06-01 02:01:32.834119
NCT00700804|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2008-12-30||2011-05-31|2008-06-18|2008-06-19|Estimate|2009-04-09|2009-06-02|Estimate||||2011-05-31|2011-06-02|Estimate|June 2003||2003-06-30|May 2011|2011-05-31|January 2005|Actual|2005-01-31|July 2004|Actual|2004-07-31||Interventional|||Meat Protein and Calcium: Do They Interact Synergistically or Antagonistically?|Meat Protein and Calcium: Do They Interact Synergistically or Antagonistically?|Completed||N/A|34|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 02:01:37.419241|2018-06-01 02:01:37.419241
NCT00700791|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2018-01-25|2008-06-18|2008-06-19|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2008||2008-07-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars|Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars|Active, not recruiting||Early Phase 1|168|Anticipated|Ohio State University||9|||f||||f||||||||||2018-06-01 02:01:37.637644|2018-06-01 02:01:37.637644
NCT00700778|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2016-12-20|2008-06-18|2008-06-19|Estimate|||||||2016-12-20|2016-12-22|Estimate|July 2008||2008-07-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations|Genomic Markers of Breast Cancer Prevention Induced by HCG in Women at High Risk|Terminated||N/A|2|Actual|Fox Chase Cancer Center||1||Unable to recruit volunteers|f||||f||||||||||2018-06-01 02:01:37.848859|2018-06-01 02:01:37.848859
NCT00700765|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2016-10-27|2008-06-18|2008-06-19|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes|Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|Completed|||1531|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:01:37.956455|2018-06-01 02:01:37.956455
NCT00700752|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2010-08-25||2015-05-05|2008-06-18|2008-06-19|Estimate|2010-08-25|2010-09-20|Estimate||||2015-05-05|2015-05-21|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Comparison of Two Contact Lenses||Completed||N/A|40|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 02:01:38.131764|2018-06-01 02:01:38.131764
NCT00700739|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|2015-07-13||2015-09-02|2008-06-18|2008-06-19|Estimate|2015-07-13|2015-08-10|Estimate||||2015-09-02|2015-09-21|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease|A Multi-Centre, Prospective, Randomized, Post Marketing Surveillance Study Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Cervical Degenerative Disc Disease|Terminated||Phase 4|60|Actual|DePuy International|Study was terminated early therefore the latest clinical data available is at the 12 month post-operative timepoint and the latest radiographic data available is at the 6 month post-operative timepoint.|2||study progress and recruitment rate too low|f||||t||||||||||2018-06-01 02:01:38.34867|2018-06-01 02:01:38.34867
NCT00700726|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2014-02-11|2008-06-18|2008-06-19|Estimate|||||||2014-02-11|2014-02-13|Estimate|June 2008||2008-06-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma|Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma|Completed|||26|Actual|Ohio State University|||1||f||||t||||||Samples Without DNA|"~     blood, nasal lavage (optional)~   "|||2018-06-01 02:01:39.007147|2018-06-01 02:01:39.007147
NCT00700713|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2016-01-16|2010-09-02|2016-01-16|2008-06-18|2008-06-19|Estimate|2016-01-16|2016-02-15|Estimate|2010-09-02|2010-09-08|Estimate|2016-01-16|2016-02-15|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26|Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Three Years Earlier in Study MTA26|Completed||Phase 2|181|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 02:01:39.095176|2018-06-01 02:01:39.095176
NCT00700700|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2011-07-04|2008-06-18|2008-06-19|Estimate|||||||2011-07-04|2011-07-06|Estimate|October 2008||2008-10-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Cardiac Resynchronization Therapy, Dyspnea and Exercise Tolerance in Patients With Congestive Heart Failure (CHF)|Effects of Cardiac Resynchronization Therapy on Dyspnea and Exercise Tolerance in Patients With Congestive Heart Failure|Terminated||Phase 4|2|Actual|Queen's University||2||Stopped due to an inability to recruit eligible subjects.|f||||f||||||||||2018-06-01 02:01:39.822312|2018-06-01 02:01:39.822312
NCT00700687|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-01-09|2008-06-17|2008-06-19|Estimate|||||||2009-01-09|2009-01-12|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PA32540-109||Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib|Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib|Completed||Phase 1|90|Anticipated|POZEN||3|||f||||f||||||||||2018-06-01 02:01:39.935403|2018-06-01 02:01:39.935403
NCT00700674|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2010-02-24|2008-06-18|2008-06-19|Estimate|||||||2010-02-24|2010-02-25|Estimate|January 2008||2008-01-31|February 2010|2010-02-28||||||||Observational|||Effect of Usage of Electroencephalogram (EEG) Entropy on the Incidence of Postoperative Cognitive Dysfunction in Geriatric Patients|Is the Ese of EEG Entropy as Intra-operative Monitor Improves Postoperative Cognitive Dysfunction|Unknown status|Recruiting||60|Anticipated|King Khaled Eye Specialist Hospital|||2||f||||t||||||||||2018-06-01 02:01:40.075613|2018-06-01 02:01:40.075613
NCT00700661|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2017-03-17|2008-06-18|2008-06-19|Estimate|||||||2017-03-17|2017-03-21|Actual|January 2001||2001-01-31|March 2017|2017-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907)|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Study to Determine the Efficacy of Montelukast in the Treatment of Exacerbations in Asthmatic Patients Aged 2-to-5 Years|Completed||Phase 3|500|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:01:40.148944|2018-06-01 02:01:40.148944
NCT00700648|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-18|||2017-01-02|2008-06-18|2008-06-19|Estimate|||||||2017-01-02|2017-01-04|Estimate|March 2008||2008-03-31|January 2017|2017-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects|A Multicenter, Open Label, Nonrandomized, Non Interventional, Observational, Safety and Efficacy Study in Hospitalized Subjects Using Intravenous NovoRapid® (Insulin Aspart)|Completed|||3024|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:01:40.277066|2018-06-01 02:01:40.277066
NCT00700635|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2010-12-11|2010-09-02|2016-04-12|2008-06-18|2008-06-19|Estimate|2010-12-11|2010-12-23|Estimate|2010-10-04|2010-10-06|Estimate|2016-04-12|2016-04-14|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||Dose Comparison Study of Menactra® in US Children|Exploratory Evaluation of a Two-dose Schedule Versus a One-dose Schedule of Menactra® (Meningococcal [Groups A, C, Y and W 135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) in Children in the US|Completed||Phase 2|333|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 02:01:40.400194|2018-06-01 02:01:40.400194
NCT00700622|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2014-07-22|2009-06-09|2014-10-09|2008-06-16|2008-06-18|Estimate|2014-10-09|2014-10-16|Estimate|2009-10-01|2009-10-05|Estimate|2014-10-09|2014-10-16|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks|A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination With Lantus® Versus Humalog® in Combination With Lantus® in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period|Terminated||Phase 3|130|Actual|Mannkind Corporation|- Early termination of trial leading to small numbers of subjects analyzed.|2||"Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2~   inhaler)"|f||||f||||||||||2018-06-01 02:01:41.561657|2018-06-01 02:01:41.561657
NCT00700609|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2015-07-30|2008-06-13|2008-06-18|Estimate|||||||2015-07-30|2015-07-31|Estimate|June 2008||2008-06-30|July 2015|2015-07-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|BudFam||Family Based Treatment of Depressed Adolescents|Family-Based Treatment of Depressed Adolescents: An Empirical Study With Norwegian Adolescents in Specialty Mental Health Care|Terminated||Phase 2|20|Actual|Helse Stavanger HF||2||The PI moved to another city and position|f||||t||||||||||2018-06-01 02:01:42.31328|2018-06-01 02:01:42.31328
NCT00700596|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-02-22|2008-06-17|2008-06-18|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2009||2009-01-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effects of Salvinorin A in Healthy Controls|Psychotomimetic Effects of Kappa Opioid Receptor Agonist Salvinorin A in Healthy Controls|Active, not recruiting||Phase 1|41|Anticipated|Yale University||2|||f||||||||||||||2018-06-01 02:01:42.414603|2018-06-01 02:01:42.414603
NCT00700583|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2011-05-09|2008-06-16|2008-06-18|Estimate|||||||2011-05-09|2011-05-10|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men|Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men With LUTS: a Pilot Study|Completed||N/A|72|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-06-01 02:01:42.488081|2018-06-01 02:01:42.488081
NCT00700570|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2015-08-19||2016-11-01|2008-06-17|2008-06-18|Estimate|2015-09-01|2015-10-01|Estimate||||2016-11-01|2016-11-02|Estimate|August 2008||2008-08-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Intent-to-Treat (ITT) Population: All enrolled participants who received at least one dose of study drug.|A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer|An Open Label Study to Assess the Resection Rate of Liver Metastases Following Neoadjuvant Therapy With Avastin in Combination With Oxaliplatin and Capecitabine (XELOX) in Patients With Metastatic Colorectal Cancer With Unresectable Liver Metastasis|Completed||Phase 2|45|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:01:42.618694|2018-06-01 02:01:42.618694
NCT00700557|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2009-08-24|2008-06-17|2008-06-18|Estimate|||||||2009-08-24|2009-08-25|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Probiotics at the Treatment of Antibiotic Associated Diarrhea|Lactobacillus Casei e Bifidobacterium Breve as Probiotics at the Treatment of Antibiotic Associated Diarrhea: a Randomized Double Blind Study|Completed||Phase 4|70|Actual|Federal University of Uberlandia||2|||f||||t||||||||||2018-06-01 02:01:43.485801|2018-06-01 02:01:43.485801
NCT00700544|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-13|2008-06-13|2008-06-18|Estimate|||||||2008-06-13|2008-06-18|Estimate|June 2002||2002-06-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|April 2005|Actual|2005-04-30||Interventional|||Treatment Outcome in Elderly Patients|Adjonction of Androgenotheapy for Post-Remission Treatment of Elderly Patients With Acute Myeloid Leukemia - Results of the Multicenter Goelams SA-2002 Trial.|Completed||Phase 3|330|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 02:01:43.735693|2018-06-01 02:01:43.735693
NCT00700531|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2016-10-04|2008-06-17|2008-06-18|Estimate|||||||2016-10-04|2016-10-05|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|January 2014|Actual|2014-01-31||Interventional|EuLITE||European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy|European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy|Completed||N/A|90|Actual|University Hospital Birmingham||2|||f||||t||||||||Undecided|Under consideration|2018-06-01 02:01:43.84753|2018-06-01 02:01:43.84753
NCT00700518|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-12-29|2008-06-17|2008-06-18|Estimate|||||||2008-12-29|2008-12-30|Estimate|June 2008||2008-06-30|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon|A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon|Completed||Phase 1|10|Anticipated|Procris Pharmaceuticals||5|||f||||f||||||||||2018-06-01 02:01:44.007073|2018-06-01 02:01:44.007073
NCT00700505|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2012-08-13|2008-06-13|2008-06-18|Estimate|||||||2012-08-13|2012-08-14|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy|A Study to Determine the Safety and Efficacy of a New Non-invasive Heating Garment to Reduce Urinary Hesitancy|Completed||N/A|20|Actual|ThermaRx, Inc.||1|||f||||t||||||||||2018-06-01 02:01:44.171541|2018-06-01 02:01:44.171541
NCT00700492|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2015-06-24|2008-06-17|2008-06-18|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2004||2004-05-31|June 2015|2015-06-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Does Hormonal Luteal Support After Intra-uterine Insemination (IUI) Increase the Pregnancy Rate?|Luteal Support With Vaginal Progesterone Capsules Following Ovulation Induction With Human Menopausal Gonadotropins (hMG) for Intra Uterine Insemination: A Comparative Study|Terminated||N/A|82|Actual|University Hospital, Gasthuisberg||2||Change in Belgian law on the use of hMG in IUI|f||||f||||||||||2018-06-01 02:01:44.266658|2018-06-01 02:01:44.266658
NCT00700479|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2008-06-17|2008-06-17|2008-06-18|Estimate|||||||2008-06-17|2008-06-18|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Studies on Aldosterone and Vascular Function|Studies on Aldosterone and Vascular Function|Completed||Phase 1|20|Anticipated|Yale University||4|||f||||f||||||||||2018-06-01 02:01:44.4506|2018-06-01 02:01:44.4506
NCT00700466|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2010-01-15|2008-06-17|2008-06-18|Estimate|||||||2010-01-15|2010-01-18|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Observational|||Intravenous Beta-blockade for Improvement of Autonomic Activity|Beta-adrenoceptor Blockade Prior to Induction of Anesthesia for Improvement of Depressed Autonomic Regulation|Completed|||100|Anticipated|University of Schleswig-Holstein|||2||f||||t||||||||||2018-06-01 02:01:44.575341|2018-06-01 02:01:44.575341
NCT00700453|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2012-05-02|2008-06-17|2008-06-18|Estimate|||||||2012-05-02|2012-05-03|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|December 2018|Anticipated|2018-12-31|March 2011|Actual|2011-03-31||Interventional|||Video Game-Brain Functioning Reversibility Study|Video Game-Brain Functioning Reversibility Study|Active, not recruiting||N/A|60|Anticipated|Indiana University||4|||f||||t||||||||||2018-06-01 02:01:44.732881|2018-06-01 02:01:44.732881
NCT00700440|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2010-01-11||2010-03-09|2008-06-17|2008-06-18|Estimate|2010-03-09|2010-03-26|Estimate||||2010-03-09|2010-03-26|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ENCORE||Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy|Phase II Study of Cetuximab Combined With Intensity Modulated Radiotherapy (IMRT) and Concurrent Chemotherapy of Cisplatin in Nasopharyngeal Carcinoma|Completed||Phase 2|100|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-06-01 02:01:44.858022|2018-06-01 02:01:44.858022
NCT00700427|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2012-08-23||2014-06-12|2008-06-17|2008-06-18|Estimate|2013-04-18|2013-05-29|Estimate||||2014-06-12|2014-06-26|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|October 2013|Actual|2013-10-31|August 2011|Actual|2011-08-31||Interventional||All enrolled participants.|A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study|Completed||Phase 3|2017|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:01:45.248626|2018-06-01 02:01:45.248626
NCT00700414|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-11-10|2008-06-13|2008-06-18|Estimate|||||||2017-11-10|2017-11-14|Actual|October 1, 2001|Actual|2001-10-01|November 2017|2017-11-30|December 2040|Anticipated|2040-12-31|December 2040|Anticipated|2040-12-31||Observational|||International Pediatric Adrenocortical Tumor Registry|International Pediatric Adrenocortical Tumor Registry|Recruiting|||9999|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Peripheral blood sample with DNA and RNA; Tumor Tissue (of any histology); Adrenocortical~     tumors;~   "|||2018-06-01 02:01:46.246754|2018-06-01 02:01:46.246754
NCT00700401|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2016-03-28||2016-05-12|2008-06-17|2008-06-18|Estimate|2016-05-12|2016-06-21|Estimate||||2016-05-12|2016-06-21|Estimate|November 2008||2008-11-30|May 2016|2016-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational||Intention-to-treat (ITT) population included all participants who received at least one dose of study drug.|POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).|A Prospective, Observational Study to Assess the Virological Response at Week 4 to the Therapy With PEGASYS® (Peginterferon Alfa 2a) Plus COPEGUS® (Ribavirin) in a Population of Treatment Naïve Patients With Chronic Hepatitis C, Genotype 2 or 3.|Completed|||262|Actual|Hoffmann-La Roche|||1||f||||f||||||||||2018-06-01 02:01:46.464833|2018-06-01 02:01:46.464833
NCT00700388|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-08-02|2008-06-17|2008-06-18|Estimate|||||||2011-08-02|2011-08-04|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|UNIKO||Efficacy of Temporary Positive Expiratory Pressure (TPEP) in Chronic Hypersecretion|Multicenter Controlled Trial on Efficacy of TPEP Device in Adult Patients With Chronic Hypersecretion|Completed||Phase 4|100|Actual|Villa Pineta Hospital||2|||f||||t||||||||||2018-06-01 02:01:46.872301|2018-06-01 02:01:46.872301
NCT00700375|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2010-03-23||2010-07-12|2008-06-17|2008-06-18|Estimate|2010-06-14|2010-07-09|Estimate||||2010-07-12|2010-07-20|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection|Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate Bolus Injection in Patients Undergoing an Emergent Coronary Procedure|Completed||Phase 4|59|Actual|Osaka General Medical Center|Single center trial|2|||f||||t||||||||||2018-06-01 02:01:46.988321|2018-06-01 02:01:46.988321
NCT00700362|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2015-04-08|2008-06-17|2008-06-18|Estimate|||||||2015-04-08|2015-04-09|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|||Insulin Infusion and Infectious Diabetic Foot Ulcers (IIIFU)|The Effect of Insulin-Glucose Infusion on Metabolic Control (Primary) and Inflammation (Secondary) in Diabetic Patients Treated for Acute Foot Ulcer Infection or Surgical Wound Infection|Withdrawn|||0|Actual|Karolinska Institutet||||This study is a part of the IINDU study|f||||t||||||||||2018-06-01 02:01:47.473472|2018-06-01 02:01:47.473472
NCT00700349|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2008-06-17|2008-06-17|2008-06-18|Estimate|||||||2008-06-17|2008-06-18|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Evaluation of Impacts of Access to Credit and Loan Size for Microcredit Clients in South Africa|Evaluation of Impacts of Access to Credit and Loan Size for Microcredit Clients in South Africa|Completed||N/A|3000|Actual|Innovations for Poverty Action||2|||f||||||||||||||2018-06-01 02:01:47.614689|2018-06-01 02:01:47.614689
NCT00700336|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2012-12-19|2008-06-17|2008-06-18|Estimate|||||||2012-12-19|2012-12-21|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)|Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma|Completed||Phase 1/Phase 2|71|Actual|CanBas Co. Ltd.||2|||f||||f||||||||||2018-06-01 02:01:47.683417|2018-06-01 02:01:47.683417
NCT00700323|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-06-17|2008-06-17|2008-06-18|Estimate|||||||2008-06-17|2008-06-18|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|ADHD-3||PS-Omega3 Supplementation to Attention Deficit Hyperactivity Disorder (ADHD) Children|Phase 2b Study of PS-Omega3 Conjugate Supplementation to ADHD Diagnosed Children|Unknown status|Not yet recruiting|Phase 2|45|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 02:01:47.799493|2018-06-01 02:01:47.799493
NCT00700310|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2012-10-23||2015-12-17|2008-06-17|2008-06-18|Estimate|2012-10-23|2012-11-22|Estimate||||2015-12-17|2016-01-21|Estimate|August 2008||2008-08-31|November 2015|2015-11-30|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Completed||Phase 3|712|Actual|Eisai Inc.||4|||f||||||||||||||2018-06-01 02:01:47.890848|2018-06-01 02:01:47.890848
NCT00700297|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-06-17|2008-06-17|2008-06-18|Estimate|||||||2008-06-17|2008-06-18|Estimate|August 2002||2002-08-31|May 2008|2008-05-31|May 2006|Actual|2006-05-31|October 2005|Actual|2005-10-31||Interventional|||Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's Disease|A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet`s Disease|Completed||Phase 2|169|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:01:50.803959|2018-06-01 02:01:50.803959
NCT00700284|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-08-31|2008-06-17|2008-06-18|Estimate|||||||2009-08-31|2009-09-01|Estimate|October 2004||2004-10-31|August 2009|2009-08-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)|Phase I Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine) as a Vaginal Microbicide|Completed||Phase 1|12|Actual|International Partnership for Microbicides, Inc.||2|||f||||f||||||||||2018-06-01 02:01:50.918034|2018-06-01 02:01:50.918034
NCT00700271|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2010-12-15||2011-05-16|2008-06-17|2008-06-18|Estimate|2010-12-15|2011-01-06|Estimate||||2011-05-16|2011-05-19|Estimate|October 2007||2007-10-31|May 2011|2011-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day|Efficacy of a Combination of Amlodipine / Valsartan on Blood Pressure Control, With One Nocturnal or Diurnal Intake a Day, in Ambulatory Blood Pressure Monitoring Setting, in Essential Uncontrolled Hypertensive Patients With Amlodipine 5mg ; The ExPERT Study|Completed||Phase 4|478|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:01:51.01878|2018-06-01 02:01:51.01878
NCT00700258|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2018-05-24|2008-06-17|2008-06-18|Estimate|||||||2018-05-24|2018-05-25|Actual|January 4, 2008|Actual|2008-01-04|May 2018|2018-05-31|December 1, 2023|Anticipated|2023-12-01|December 1, 2023|Anticipated|2023-12-01||Observational|STAR-TOR||Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]|Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And Gastro-intestinal Stroma Tumor (Gist).|Recruiting|||1600|Anticipated|Pfizer|||5||f||||f||||||||||2018-06-01 02:01:51.497493|2018-06-01 02:01:51.497493
NCT00700245|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-06-17|2008-06-17|2008-06-18|Estimate|||||||2008-06-17|2008-06-18|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|March 2009|Anticipated|2009-03-31|June 2008|Anticipated|2008-06-30||Interventional|||The Effect of Acute and Chronic Exercise at the Metabolic Syndrome and Markers of Inflammation in Obese Subjects|The Effect of Acute and Chronic Exercise at the Metabolic Syndrome and Markers of Inflammation in Obese Subjects|Unknown status|Recruiting|N/A|100|Anticipated|Aarhus University Hospital||3|||f||||f||||||||||2018-06-01 02:01:51.679142|2018-06-01 02:01:51.679142
NCT00700232|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2010-06-16|2008-06-17|2008-06-18|Estimate|||||||2010-06-16|2010-06-17|Estimate|July 2006||2006-07-31|June 2010|2010-06-30|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Observational|||ABCB4 Gene Mutations in Intrahepatic Cholestasis of Pregnancy and Controls|Mutations and Polymorphisms of Gene ABCB4 Among Women Suffering From Intrahepatic Cholestasis of Pregnancy. A Study With a Control Group.|Completed|||120|Actual|University Hospital, Tours|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 02:01:51.787037|2018-06-01 02:01:51.787037
NCT00700219|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2010-07-19|2008-06-17|2008-06-18|Estimate|||||||2010-07-19|2010-07-21|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Observational|IAI||Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes|Development of a Non-invasive Test to Detect Intra-amniotic Infection and Predict Preterm Birth in Women Presenting With Preterm Labor and and Intact Amniotic Membranes|Unknown status|Recruiting||900|Anticipated|ProteoGenix, Inc.|||1||f||||f||||||Samples Without DNA|"~     Cervical-vaginal Fluid, Amniotic Fluid, Maternal Serum, Neonatal Cord Blood, Maternal Urine,~     Placental and Umbilical Cord Tissues~   "|||2018-06-01 02:01:51.876261|2018-06-01 02:01:51.876261
NCT00700206|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2011-10-10|2008-06-13|2008-06-18|Estimate|||||||2011-10-10|2011-10-12|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)|Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 2|86|Anticipated|Telik||2|||f||||f||||||||||2018-06-01 02:01:52.061345|2018-06-01 02:01:52.061345
NCT00700193|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2016-07-17|2008-06-17|2008-06-18|Estimate|||||||2016-07-17|2016-07-19|Estimate|March 2005||2005-03-31|November 2008|2008-11-30||||June 2006|Actual|2006-06-30||Interventional|||A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric Population|An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (= or >6 Months to < 9 Years of Age).|Completed||Phase 3|298|Actual|Seqirus||2|||f||||f||||||||||2018-06-01 02:01:52.17565|2018-06-01 02:01:52.17565
NCT00700180|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2014-09-16||2014-09-23|2008-06-17|2008-06-18|Estimate|2014-09-23|2014-09-25|Estimate||||2014-09-23|2014-09-25|Estimate|September 2008||2008-09-30|September 2014|2014-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Intent-to-treat (ITT) population. The ITT population included all participants randomized into the study.|A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.|A Randomized, Open-label Study to Explore the Correlation of Biomarkers With Response Rate in Chemo-naive Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Who Receive Treatment With Avastin in Addition to Carboplatin-based Chemotherapy|Completed||Phase 2|303|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:01:52.389872|2018-06-01 02:01:52.389872
NCT00700167|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-04-19|2008-06-17|2008-06-18|Estimate|||||||2011-04-19|2011-04-20|Estimate|September 2001||2001-09-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy|Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy - A Phase I Trial in Melanoma|Completed||Phase 1|43|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:01:53.548008|2018-06-01 02:01:53.548008
NCT00700154|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2015-04-08|2008-06-17|2008-06-18|Estimate|||||||2015-04-08|2015-04-09|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|November 2017|Anticipated|2017-11-30|December 2016|Anticipated|2016-12-31||Interventional|IINDU||Insulin Infusion Diabetes Ulcer|The Effect of Insulin Infusion on Metabolic Control and Inflammation in Diabetic Patients During Cardio-vascular Intervention and/or Treatment for Acute Foot Ulcer Infection.|Unknown status|Enrolling by invitation|Phase 4|40|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 02:01:53.695527|2018-06-01 02:01:53.695527
NCT00700141|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2010-03-11||2012-05-04|2008-06-17|2008-06-18|Estimate|2010-03-11|2010-04-06|Estimate||||2012-05-04|2012-05-08|Estimate|September 2008||2008-09-30|April 2010|2010-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®|Non-Interventional Study on the Use of TachoSil® During Thyroid Surgery|Completed|||482|Actual|Nycomed|||||f||||f||||||||||2018-06-01 02:01:53.819667|2018-06-01 02:01:53.819667
NCT00700128|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-07-22|2008-06-17|2008-06-18|Estimate|||||||2011-07-22|2011-07-25|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|MAM||Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals|Prevention of Menstrual Migraines: Effects of Continuous Oral Contraceptives to Combination With Prophylactic Frovatriptan Use During Hormone Free Intervals|Completed||N/A|30|Actual|Scott and White Hospital & Clinic||2|||f||||f||||||||||2018-06-01 02:01:54.515575|2018-06-01 02:01:54.515575
NCT00700115|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2012-06-07||2014-11-25|2008-06-17|2008-06-18|Estimate|2013-08-15|2013-10-22|Estimate||||2014-11-25|2014-12-12|Estimate|June 2008||2008-06-30|November 2014|2014-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|KITE||Kaletra-isentress Treatment Evaluation|A Pilot Study to Assess the Safety, Efficacy, and PK Profile of a Switch in Antiretroviral Therapy to a RTI Sparing Combination of LPV/r and RAL in Virologically Suppressed HIV-infected Patients|Completed||Phase 4|60|Actual|Emory University|The findings of the KITE study should be interpreted in the context of a pilot study with a small sample size. Furthermore, adverse effects were self-reported, and the lack of blinding may have introduced biases in the collection of the data.|2|||f||||f||||||||||2018-06-01 02:01:54.666192|2018-06-01 02:01:54.666192
NCT00700102|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2015-07-02||2015-07-02|2008-06-17|2008-06-18|Estimate|2015-07-02|2015-07-30|Estimate||||2015-07-02|2015-07-30|Estimate|February 2006||2006-02-28|July 2015|2015-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.|A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination|Completed||Phase 3|820|Actual|Hoffmann-La Roche|Patients in the study who were randomized to receive bevacizumab could continue to receive bevacizumab following discontinuation of chemotherapy, thereby minimizing any potential bias introduced by differential follow-up time in the treatment arms.|2|||f||||||||||||||2018-06-01 02:01:55.037657|2018-06-01 02:01:55.037657
NCT00700089|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2016-10-24|2008-06-17|2008-06-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|AID||AID-trial Assertive Intervention After Deliberate Self-harm|AID-trial:A Randomized Clinical Trial Comparing the Effect on Repeated Self-harm of Assertive Intervention and Standard Treatment After Deliberate Self-harm|Completed||Phase 4|243|Actual|University of Copenhagen||2|||f||||t||||||||||2018-06-01 02:01:56.492024|2018-06-01 02:01:56.492024
NCT00700076|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-11-28|2008-06-17|2008-06-18|Estimate|||||||2017-11-28|2017-11-30|Actual|December 2006||2006-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects|Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects|Active, not recruiting||Phase 1|18|Anticipated|Yale University||2|||f||||t||||||||||2018-06-01 02:01:56.581395|2018-06-01 02:01:56.581395
NCT00700063|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-15|2012-06-13||2015-03-24|2008-06-17|2008-06-18|Estimate|2012-07-18|2012-08-22|Estimate||||2015-03-24|2015-04-14|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)|A Multicenter, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)|Completed||Phase 2|265|Actual|Peplin||8|||f||||f||||||||||2018-06-01 02:01:56.725721|2018-06-01 02:01:56.725721
NCT00700050|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2008-06-17|2008-06-17|2008-06-18|Estimate|||||||2008-06-17|2008-06-18|Estimate|April 2008||2008-04-30|June 2008|2008-06-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways|Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways - A Pilot Study|Unknown status|Recruiting|Phase 3|32|Anticipated|The Hospital for Sick Children||4|||f||||f||||||||||2018-06-01 02:01:58.148564|2018-06-01 02:01:58.148564
NCT00700037|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2014-10-28|2008-06-13|2008-06-18|Estimate|||||||2014-10-28|2014-10-29|Estimate|August 2009||2009-08-31|October 2014|2014-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|EASY-FIT||Change in Plaque Characteristics With Atorvastatin|Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography|Completed||Phase 4|70|Actual|Wakayama Medical University||2|||f||||f||||||||||2018-06-01 02:01:58.242341|2018-06-01 02:01:58.242341
NCT00700024|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-09-18|2008-06-17|2008-06-18|Estimate|||||||2009-09-18|2009-09-21|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|February 2010|Anticipated|2010-02-28|January 2010|Anticipated|2010-01-31||Interventional|||Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men|The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Odense University Hospital||3|||f||||t||||||||||2018-06-01 02:01:58.317791|2018-06-01 02:01:58.317791
NCT00700011|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2012-12-06||2013-03-12|2008-06-17|2008-06-18|Estimate|2012-12-06|2013-01-09|Estimate||||2013-03-12|2013-03-15|Estimate|March 2008||2008-03-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)|A Pilot Study of IV Clofarabine for Patients With Myelodysplastic Syndrome Who Have Failed 5-azacytidine|Terminated||Phase 2|10|Actual|Texas Oncology Cancer Center||2||poor accrual|f||||t||||||||||2018-06-01 02:01:58.437208|2018-06-01 02:01:58.437208
NCT00699998|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2013-03-21||2013-03-21|2008-06-16|2008-06-18|Estimate|2013-03-21|2013-05-07|Estimate||||2013-03-21|2013-05-07|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|TRILOGY ACS||A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects|A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed|Completed||Phase 3|9326|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:01:59.000168|2018-06-01 02:01:59.000168
NCT00699985|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-08-13|2008-06-17|2008-06-18|Estimate|||||||2010-08-13|2010-08-16|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|December 2007|Actual|2007-12-31|||||Observational|SCL90-R||Psychological Symptoms in Patients With Behcet's Disease by SCL90-R|Comparison of Psychological Symptoms in Patients With Behcet's Disease and Control Patients by Symptom Check List 90-Revised (SCL-90-R)|Completed|||400|Actual|Tehran University of Medical Sciences|||2||f||||t||||||||||2018-06-01 02:02:04.915598|2018-06-01 02:02:04.915598
NCT00699972|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2012-10-23|2012-08-23|2015-10-30|2008-06-17|2008-06-18|Estimate|2013-01-02|2013-02-05|Estimate|2012-08-23|2012-08-30|Estimate|2015-10-30|2015-11-26|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Completed||Phase 3|390|Actual|Eisai Inc.||3|||f||||f||||||||||2018-06-01 02:02:05.049745|2018-06-01 02:02:05.049745
NCT00699946|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-01-19|2008-06-16|2008-06-18|Estimate|||||||2009-01-19|2009-01-21|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery|A Double-Blind, Randomized, Placebo-Controlled Study of Perioperative Administration of Olanzapine to Prevent Postoperative Delirium in Joint Replacement Patients|Completed||N/A|495|Actual|The New England Baptist Hospital||2|||f||||f||||||||||2018-06-01 02:02:06.61552|2018-06-01 02:02:06.61552
NCT00699933|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2011-08-08|2008-06-17|2008-06-18|Estimate|||||||2011-08-08|2011-08-09|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Diagnostic and Interventional Therapy in Acute Pancreatitis|Diagnostic and Interventional Therapy in Acute Pancreatitis|Unknown status|Recruiting||50|Anticipated|University of Regensburg|||1||f||||f||||||Samples With DNA|"~     Bacterial DNA~   "|||2018-06-01 02:02:06.727196|2018-06-01 02:02:06.727196
NCT00699920|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2010-06-28|2008-06-17|2008-06-18|Estimate|||||||2010-06-28|2010-06-29|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|SMART-CURE||Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks|A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During the 2 Years of Follow-up, in Children in Uganda.|Completed||Phase 4|413|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:02:06.883296|2018-06-01 02:02:06.883296
NCT00699907|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2016-04-20||2017-12-08|2008-06-17|2008-06-18|Estimate|2017-12-08|2018-01-05|Actual||||2017-12-08|2018-01-05|Actual|January 2005||2005-01-31|December 2017|2017-12-31|November 2014|Actual|2014-11-30|November 2012|Actual|2012-11-30||Interventional||The Overall Number of Participants Analyzed represents all participants with a modified Histo-score that could be evaluated|Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer|A Prospective, Phase IIA Study of the Effect of Flutamide (125 MG/DAY) Taken for 6 Weeks on Expression of Potential Biomarkers of Flutamide Action in the Ovaries of Women at Increased Risk for Ovarian Cancer|Completed||Phase 2|127|Actual|University of Arizona||3|||f||||t|t|f||||||No||2018-06-01 02:02:07.031815|2018-06-01 02:02:07.031815
NCT00699894|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2013-08-08|2008-06-17|2008-06-18|Estimate|||||||2013-08-08|2013-08-12|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting|Comparison of Aprepitant PO and Ondansetron IV for Prevention of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Orthognathic Surgery and General Anesthesia.|Withdrawn||N/A|0|Actual|Northwell Health||2||Logistical difficulties running the study|f||||t||||||||||2018-06-01 02:02:07.741909|2018-06-01 02:02:07.741909
NCT00699881|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2009-12-21|2008-06-17|2008-06-18|Estimate|||||||2009-12-21|2009-12-23|Estimate|May 2008||2008-05-31|June 2008|2008-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|STAGE||Study of Cetuximab to Treat Gastric Cancer|Phase II Study of Cetuximab (Erbitux®) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-line Chemotherapy|Completed||Phase 2|61|Actual|Fudan University||1|||f||||f||||||||||2018-06-01 02:02:07.842259|2018-06-01 02:02:07.842259
NCT00699868|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2012-06-01|2008-06-17|2008-06-18|Estimate|||||||2012-06-01|2012-06-04|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|2006/25||Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients|Cellular Immunity, Cytomegalovirus Infection and Septic Shock in ICU Patients|Completed||N/A|29|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 02:02:07.964936|2018-06-01 02:02:07.964936
NCT00699855|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2014-02-17|2008-06-17|2008-06-18|Estimate|||||||2014-02-17|2014-02-19|Estimate|September 2008||2008-09-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|PREDICT LT FUP||Long Term Follow up Study of Predictive Markers in GHD and TS Children|Observational Long-term Follow-up of the Phase IV Open-label Trial of Predictive Markers in GHD and TS Pre-pubertal Children Treated With Saizen|Completed|||182|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 02:02:08.076762|2018-06-01 02:02:08.076762
NCT00699842|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|2014-02-27||2016-10-19|2008-06-17|2008-06-18|Estimate|2014-05-06|2014-06-03|Estimate||||2016-10-19|2016-11-29|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|May 2012|Actual|2012-05-31|January 2011|Actual|2011-01-31||Interventional|||A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients|A Phase I/II Optimal Dose Study of Lenalidomide in the Non-5q- LOW and INT-1 Risk MDS Patients|Terminated||Phase 1/Phase 2|8|Actual|Thomas Jefferson University|Study was terminated as the objectives of this study have already been addressed in a larger study, and therefore the study is unlikely to yield any new information. The study closed before any data for the outcome measures was able to be collected.|1||Administratively terminated per FDA recommendation|f||||t||||||||||2018-06-01 02:02:08.188367|2018-06-01 02:02:08.188367
NCT00699829|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-02-12|2008-06-17|2008-06-18|Estimate|||||||2009-02-12|2009-02-16|Estimate|June 2008||2008-06-30|February 2009|2009-02-28||||||||Observational|BACHIMO||Mohs Versus Traditional Surgery - Basal-Cell Carcinomas (BCC)|Comparative Medico-Economic Evaluation of Micrographic Mohs Surgery (MMS) and Traditional Surgical Excision With Immediate or Differed Reconstruction to Treat High Recurrence Risk Basal-Cell Carcinomas (BCC)|Unknown status|Recruiting||450|Anticipated|Hospital Ambroise Paré Paris|||2||f||||t||||||||||2018-06-01 02:02:08.806901|2018-06-01 02:02:08.806901
NCT00699816|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2015-06-18||2017-09-25|2008-06-17|2008-06-18|Estimate|2015-08-23|2015-09-24|Estimate||||2017-09-25|2017-10-26|Actual|July 2008||2008-07-31|August 2015|2015-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||A total of 230 eligible participants were assigned randomly to either the immunotherapy group(n=115) or the control group(n=115). Among these randomized patients, 226(114 in the immunotherapy group and 112 in the control group) were included in the efficacy analysis. 4 patients were excluded due to violation of the inclusion and exclusion criteria.|Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients|Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'Green Cross CELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection(PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea|Completed||Phase 3|230|Actual|Green Cross Cell Corporation||2|||f||||f||||||||||2018-06-01 02:02:08.8901|2018-06-01 02:02:08.8901
NCT00699803|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16||2011-09-02|2014-04-04|2008-06-17|2008-06-18|Estimate||||2011-09-02|2011-09-12|Estimate|2014-04-04|2014-05-01|Estimate|May 2008||2008-05-31|April 2014|2014-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of T-PRED(TM) Compared to Pred Forte(R)||Completed||Phase 2|56|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:02:09.732324|2018-06-01 02:02:09.732324
NCT00699790|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17||2015-09-23|2015-09-23|2008-06-17|2008-06-18|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|February 2009||2009-02-28|September 2015|2015-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance|A 12-Week Randomized, Double-Blinded Study to Evaluate the Effects of Daily Oral Doses of BMS-741672 in Drug-Naive Type 2 Diabetic Patients|Completed||Phase 2|58|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:02:09.818388|2018-06-01 02:02:09.818388
NCT00699777|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2013-04-15|2008-06-16|2008-06-18|Estimate|||||||2013-04-15|2013-04-17|Estimate|January 2008||2008-01-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects|A Randomized, Open-label, 2-period, Crossover Study to Assess the Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets Administered as a Single Oral Dose in Healthy Male and Female Subjects|Completed||Phase 1|96|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 02:02:09.91078|2018-06-01 02:02:09.91078
NCT00699764|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2016-09-06|2008-06-17|2008-06-18|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 1996||1996-03-31|September 2016|2016-09-30|October 1999|Actual|1999-10-31|October 1999|Actual|1999-10-31||Interventional|||Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease|Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease|Completed||Phase 3|2491|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:02:10.033323|2018-06-01 02:02:10.033323
NCT00699751|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2013-06-29||2016-04-27|2008-06-17|2008-06-18|Estimate|2014-04-08|2014-05-07|Estimate||||2016-04-27|2016-05-27|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|February 2014|Actual|2014-02-28|July 2011|Actual|2011-07-31||Interventional|ALSYMPCA||A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases|A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases|Completed||Phase 3|921|Actual|Bayer||2|||f||||t||||||||||2018-06-01 02:02:10.333031|2018-06-01 02:02:10.333031
NCT00699738|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2012-05-23|2008-06-17|2008-06-18|Estimate|||||||2012-05-23|2012-05-24|Estimate|July 2008||2008-07-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Influence of Pregnancy and Post-partum Feeding Method (Breastfeeding Versus Bottlefeeding) on Maternal Hemodynamics (Central and Peripheral) and Vascular Function|Influence of Pregnancy and Post-partum Feeding Method (Breastfeeding Versus Bottlefeeding) on Maternal Hemodynamics (Central and Peripheral) and Vascular Function|Completed||N/A|150|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 02:02:12.860401|2018-06-01 02:02:12.860401
NCT00699725|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-12-06|2008-06-17|2008-06-18|Estimate|||||||2010-12-06|2010-12-07|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|GADES||Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients|Compliance of Gastroprotection Treatment in the Prevention of Gastrointestinal Risk in Non-Steroidal Anti-inflammatory Drug (NSAID) Using Patients|Completed|||2000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:02:12.962607|2018-06-01 02:02:12.962607
NCT00699712|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2009-03-23|2008-06-17|2008-06-18|Estimate|||||||2009-03-23|2009-03-25|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PreCONDITION||Study to Assess Hemodynamic Effects, Safety and Tolerability of Chimeric Natriuretic Peptide (CD-NP) in Patients With Stabilized Acute Heart Failure (AHF)|Multi-Center, Open Label, Dose Escalating, Sequential Group Study to Assess the Hemodynamic Effects, Safety and Tolerability of CD-NP in Patients With Stabilized Acute Heart Failure (AHF)|Completed||Phase 2|30|Anticipated|Nile Therapeutics||3|||f||||t||||||||||2018-06-01 02:02:13.222753|2018-06-01 02:02:13.222753
NCT00699699|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2010-01-13||2014-03-12|2008-06-17|2008-06-18|Estimate|2010-02-26|2010-03-12|Estimate||||2014-03-12|2014-04-10|Estimate|June 2008||2008-06-30|March 2014|2014-03-31||||January 2009|Actual|2009-01-31||Observational|||Observational Non-Interventional Study With Spiriva Respimat in COPD Patients|Assessment of Physical Activity (PF10 Sub Domain of SF-36 Activity Score) and Tolerability in COPD Patients During Treatment With Spiriva® Respimat®|Completed|||1280|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:02:13.340282|2018-06-01 02:02:13.340282
NCT00699686|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2010-08-16|2008-06-17|2008-06-18|Estimate|||||||2010-08-16|2010-08-17|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Endothelial Effects of Basal Insulin: Detemir Versus Glargine|Effects of Optimized Glycemic Control Achieved With add-on Basal Insulin Therapy on Indexes of Endothelial Damage and Regeneration in Type 2 Diabetic Patients With Macroangiopathy. A Randomized Cross-over Trial Comparing Detemir vs Glargine|Completed||Phase 4|50|Anticipated|University of Padova||2|||f||||f||||||||||2018-06-01 02:02:13.837594|2018-06-01 02:02:13.837594
NCT00699673|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2015-08-06|2008-06-16|2008-06-18|Estimate|||||||2015-08-06|2015-08-07|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of the Brain Natriuretic Peptide as a Predictor of Morbidity and Mortality in Cardiac Surgery|Evaluation of the Brain Natriuretic Peptide as a Predictor of Morbidity and Mortality in Cardiac Surgery|Unknown status|Active, not recruiting||500|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 02:02:14.008644|2018-06-01 02:02:14.008644
NCT00699660|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2014-09-23||2015-04-06|2008-06-17|2008-06-18|Estimate|2014-10-14|2014-10-16|Estimate||||2015-04-06|2015-04-28|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|E-3PTSD|Veterans undergoing compensation and pension examination for PTSD|Enhancing Equitable and Effective (E-3) Post Traumatic Stress Disorder (PTSD) Disability Assessment|Enhancing Equitable and Effective PTSD Disability Assessment|Completed||N/A|406|Actual|VA Office of Research and Development|Information external to interview such as psychological testing or charts were not available to the expert reviewers. Another limitation is that Veterans in our study did not undergo a concurrent, independent evaluation for assessment of PTSD.|2|||f||||t||||||||||2018-06-01 02:02:14.111622|2018-06-01 02:02:14.111622
NCT00699634|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2011-04-28|2008-06-17|2008-06-18|Estimate|||||||2011-04-28|2011-04-29|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Nabilone for the Treatment of Phantom Limb Pain|A Randomized Double-blind Placebo Controlled Trial Assessing the Effect of the Oral Cannabinoid Nabilone on Pain and Quality of Life in Patients With Phantom Limb Pain|Completed||Phase 2|50|Anticipated|University of Manitoba|||||f||||t||||||||||2018-06-01 02:02:14.536091|2018-06-01 02:02:14.536091
NCT00699621|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2010-07-01|2008-06-17|2008-06-18|Estimate|||||||2010-07-01|2010-07-02|Estimate|January 2009||2009-01-31|July 2010|2010-07-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Platelet Transfusion in Acute Intracerebral Hemorrhage|Platelet Transfusion in Acute Primary Intracerebral Hemorrhage for Patients on Platelet Inhibitors|Unknown status|Recruiting|N/A|100|Anticipated|University of Oulu||2|||f||||t||||||||||2018-06-01 02:02:14.599023|2018-06-01 02:02:14.599023
NCT00699608|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2009-10-06||2012-05-31|2008-06-17|2008-06-18|Estimate|2010-04-22|2010-05-12|Estimate||||2012-05-31|2012-06-05|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.|A Randomised, Double-blind, Double-dummy, Placebo-controlled, 3-way Crossover Study to Evaluate Potential Next-day Residual Effects of a Single Evening Dose of 3mg Eszopiclone and 7.5mg Zopiclone in Healthy Adult Subjects.|Completed||Phase 3|91|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 02:02:14.725233|2018-06-01 02:02:14.725233
NCT00699595|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2014-11-08|2008-06-13|2008-06-18|Estimate|||||||2014-11-08|2014-11-11|Estimate|September 2008||2008-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|HEPP||Hormonal Effects on Pain Perception|Hormonal Effects on Pain Perception|Completed|||50|Actual|University of Alabama at Birmingham|||1||f||||f||||||None Retained|"~     Plasma for progesterone levels~   "|||2018-06-01 02:02:15.732971|2018-06-01 02:02:15.732971
NCT00699582|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2012-10-23|2012-08-23|2014-06-26|2008-06-17|2008-06-18|Estimate|2012-10-23|2012-11-22|Estimate|2012-08-23|2012-08-30|Estimate|2014-06-26|2014-07-11|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures|Completed||Phase 3|389|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 02:02:15.809416|2018-06-01 02:02:15.809416
NCT00699569|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|||2008-07-22|2008-06-17|2008-06-18|Estimate|||||||2008-07-22|2008-07-23|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|Mucositis||Hyperimmune Colostrum and Oral Mucositis|The Effect of Hyperimmune Colostrum on Radiation-Induce Oral Mucositis of Patients With Head and Neck Cancer|Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 02:02:16.582185|2018-06-01 02:02:16.582185
NCT00699556|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2017-11-20||2018-02-12|2008-06-13|2008-06-18|Estimate|2018-02-12|2018-03-12|Actual||||2018-02-12|2018-03-12|Actual|January 2006||2006-01-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy|Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy|Completed||Phase 2|22|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:02:16.664044|2018-06-01 02:02:16.664044
NCT00699543|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2013-12-15|2008-06-17|2008-06-18|Estimate|||||||2013-12-15|2013-12-17|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention|The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention: Comparison or Efficacy Between COroflex PLEASe ANd TaxusTM Stent|Unknown status|Active, not recruiting|Phase 3|915|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:02:16.821708|2018-06-01 02:02:16.821708
NCT00699530|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2017-12-21|2008-06-13|2008-06-18|Estimate|||||||2017-12-21|2017-12-22|Actual|May 2008||2008-05-31|December 2014|2014-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment|Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment|Withdrawn|||0|Actual|University of Aarhus|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, muscle samples, fat samples~   "|||2018-06-01 02:02:16.975637|2018-06-01 02:02:16.975637
NCT00699517|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07||2015-11-18|2015-11-18|2008-06-17|2008-06-18|Estimate||||2015-11-18|2015-12-21|Estimate|2015-11-18|2015-12-21|Estimate|June 2008||2008-06-30|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies|A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.|Completed||Phase 3|355|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:02:17.077947|2018-06-01 02:02:17.077947
NCT00699504|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2012-01-13|2008-06-17|2008-06-18|Estimate|||||||2012-01-13|2012-01-18|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers|A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers|Completed||Phase 1|67|Actual|The Medicines Company||5|||f||||f||||||||||2018-06-01 02:02:17.237368|2018-06-01 02:02:17.237368
NCT00699491|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2015-05-05||2018-04-03|2008-06-17|2008-06-18|Estimate|2015-05-05|2015-05-21|Estimate||||2018-04-03|2018-05-03|Actual|October 31, 2008|Actual|2008-10-31|March 2018|2018-03-31||||September 9, 2013|Actual|2013-09-09||Interventional|||Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|Phase I/II Trial of IMC-A12 in Combination With Temsirolimus in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:02:17.396572|2018-06-01 02:02:17.396572
NCT00699478|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2012-07-18|2008-06-13|2008-06-18|Estimate|||||||2012-07-18|2012-07-19|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy|Effect of Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy|Completed||Phase 2|30|Actual|Yonsei University||1|||f||||f||||||||||2018-06-01 02:02:18.526193|2018-06-01 02:02:18.526193
NCT00699465|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2010-07-01|2008-06-17|2008-06-18|Estimate|||||||2010-07-01|2010-07-02|Estimate|August 2008||2008-08-31|July 2010|2010-07-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage|A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH)|Unknown status|Recruiting|Phase 4|320|Anticipated|University of Oulu||2|||f||||t||||||||||2018-06-01 02:02:18.621919|2018-06-01 02:02:18.621919
NCT00699452|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-05-18|2008-06-17|2008-06-18|Estimate|||||||2009-05-18|2009-05-19|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|ROCK-AS||The Potential of Candesartan to Retard the Progression of Aortic Stenosis|The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves|Unknown status|Recruiting|Phase 3|120|Anticipated|Helsinki University||2|||f||||t||||||||||2018-06-01 02:02:18.730397|2018-06-01 02:02:18.730397
NCT00699439|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2009-08-19|2008-06-17|2008-06-18|Estimate|||||||2009-08-19|2009-08-20|Estimate|July 2009||2009-07-31|August 2009|2009-08-31|January 2011|Anticipated|2011-01-31|May 2010|Anticipated|2010-05-31||Interventional|||A Reminder System for Paper-Based Asthma Guidelines in the Pediatric Emergency Department|A Reminder System for Paper-Based Asthma Guidelines in the Pediatric Emergency Department|Unknown status|Enrolling by invitation|N/A|400|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:02:18.921838|2018-06-01 02:02:18.921838
NCT00699426|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2012-08-31|2008-06-17|2008-06-18|Estimate|||||||2012-08-31|2012-09-03|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Nexium||The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes|The Effect of Nexium and Cardi-04 Yoghurt on Insulin Secretion and Effect and Cardi Vascular Risk Factors Associated With the Insulin Syndrome in Patients With Type 2 Diabetes - a Randomized Double-blind, Prospective, Placebo Controlled 2 x 2 Factorial Design 3 Month's Study.|Completed||Phase 3|41|Actual|Steno Diabetes Center||4|||f||||t||||||||||2018-06-01 02:02:19.005512|2018-06-01 02:02:19.005512
NCT00699413|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2011-09-23||2017-03-29|2008-06-17|2008-06-18|Estimate|2017-03-29|2017-05-11|Actual||||2017-03-29|2017-05-11|Actual|February 2008||2008-02-29|March 2017|2017-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|SCORE|2 participants dropped out.|Supplements for Controlling Resistance to Insulin|Supplements for Controlling Resistance to Insulin|Terminated||Phase 4|8|Actual|University of Southern California||2||Sponsor decided to withdraw from study.|f||||f||||||||||2018-06-01 02:02:19.114647|2018-06-01 02:02:19.114647
NCT00699400|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|2013-05-16||2013-12-09|2008-06-13|2008-06-18|Estimate|2013-12-09|2014-01-24|Estimate||||2013-12-09|2014-01-24|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational||"Subjects were analyzed based on the freeze cycle(s) that were used, therefore, the 4 subjects that used both types of cryopreservation techniques are summarized in both the slow freeze and vitrification arms. These 4 subjects will be double-counted in the Total (calculated) column."|Oocyte Cryopreservation Registry (HOPE Registry)|A Phase IV, Prospective, Multicenter, Observational Oocyte Cryopreservation Registry|Completed|||204|Actual|EMD Serono|||||f||||||||||||||2018-06-01 02:02:19.336345|2018-06-01 02:02:19.336345
NCT00699387|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2011-07-29|2008-06-17|2008-06-18|Estimate|||||||2011-07-29|2011-08-01|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Population Pharmacokinetics of Benznidazole in Children With Chagas Disease|Population Pharmacokinetics Study of Benznidazole in Children With Chagas Disease|Completed||N/A|37|Actual|Hospital de Niños R. Gutierrez de Buenos Aires||1|||f||||t||||||||||2018-06-01 02:02:19.99006|2018-06-01 02:02:19.99006
NCT00699374|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2012-12-07||2012-12-07|2008-06-16|2008-06-18|Estimate|2012-12-07|2013-01-14|Estimate||||2012-12-07|2013-01-14|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer|A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma|Terminated||Phase 3|1075|Actual|Pfizer|Study terminated early due to futility. Subsequently, EQ-5D data were not collected or analyzed.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 02:02:20.328272|2018-06-01 02:02:20.328272
NCT00699361|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2014-02-10|2008-06-17|2008-06-18|Estimate|||||||2014-02-10|2014-02-11|Estimate|August 2008||2008-08-31|June 2008|2008-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure|Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure|Withdrawn||Phase 3|0|Actual|Johann Wolfgang Goethe University Hospital||2||Study withdrawn for financial issues|f||||t||||||||||2018-06-01 02:02:23.795832|2018-06-01 02:02:23.795832
NCT00699348|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2016-03-08||2016-03-08|2008-06-17|2008-06-18|Estimate|2016-03-08|2016-04-06|Estimate||||2016-03-08|2016-04-06|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CARISMA|The safety population included all participants who were treated with at least 1 dose of C.E.R.A. and had a safety follow-up, whether withdrawn prematurely or not.|A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Anaemia|Completed||Phase 3|351|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:02:23.903871|2018-06-01 02:02:23.903871
NCT00699335|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-17|2010-07-15||2012-05-04|2008-06-17|2008-06-18|Estimate|2010-07-15|2010-08-12|Estimate||||2012-05-04|2012-05-08|Estimate|June 2008||2008-06-30|May 2012|2012-05-31||||July 2009|Actual|2009-07-31||Observational|Matrix LQ||Matrifen® for Therapy of Severe Chronic Pain®|Efficacy of Matrifen® in Patients Older Than 18 Years With Severe, Chronic Pain Including Quality of Life Questionnaire|Completed|||5308|Actual|Nycomed|||||f||||||||||||||2018-06-01 02:02:24.693679|2018-06-01 02:02:24.693679
NCT00699322|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-10-28|2008-06-16|2008-06-17|Estimate|||||||2009-10-28|2009-10-29|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress|The Comparative Study of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on the Effect of Improving Glucose Variability and Oxidative Stress in Type 2 Diabetic Patients With Inadequate Glycemic Control on Metformin|Unknown status|Recruiting|Phase 4|36|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-06-01 02:02:27.327645|2018-06-01 02:02:27.327645
NCT00699309|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|August 2005||2005-08-31|June 2017|2017-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||A Clinical Investigation of the Taperloc® Microplasty™ Hip System|A Prospective, Non-controlled, Clinical Investigation of the Taperloc® Microplasty™ Hip System|Completed|||98|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 02:02:27.479026|2018-06-01 02:02:27.479026
NCT00699296|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2012-11-26|2008-06-16|2008-06-17|Estimate|||||||2012-11-26|2012-11-27|Estimate|May 2008||2008-05-31|November 2012|2012-11-30||||December 2008|Actual|2008-12-31||Interventional|||Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma|A Phase II Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma|Terminated||Phase 2|4|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:02:27.594613|2018-06-01 02:02:27.594613
NCT00699283|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2016-03-14|2011-04-08|2018-03-08|2008-06-12|2008-06-17|Estimate|2016-11-21|2017-01-18|Estimate|2011-04-08|2011-04-25|Estimate|2018-03-08|2018-04-03|Actual|August 2008||2008-08-31|March 2018|2018-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Baseline Characteristics refer to the Intent-to-Treat Set (ITT), consisting of all randomized subjects with at least 1 intake of study medication.|A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures|An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.|Terminated||Phase 3|62|Actual|UCB Pharma||2||"An interim analysis revealed the study was unlikely to attain a positive outcome for the~   efficacy analysis. No safety concerns were detected"|f||||f||||||||||2018-06-01 02:02:27.781295|2018-06-01 02:02:27.781295
NCT00699270|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|August 2007||2007-08-31|June 2017|2017-06-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Observational|||A Clinical Investigation of the Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems|A Prospective, Non-Controlled, Clinical Investigation of the Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems|Withdrawn|||0|Actual|Zimmer Biomet|||1|Business need changed.|f||||f||||||||||2018-06-01 02:02:28.227827|2018-06-01 02:02:28.227827
NCT00699257|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|July 2004||2004-07-31|June 2017|2017-06-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Observational|||A Clinical Investigation of the Oxford® Partial Knee System|A Prospective, Non-controlled, Clinical Investigation of the Oxford® Partial Knee System|Terminated|||85|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 02:02:28.287512|2018-06-01 02:02:28.287512
NCT00699244|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2017-06-09|2008-06-12|2008-06-17|Estimate|||||||2017-06-09|2017-06-12|Actual|December 2006||2006-12-31|June 2017|2017-06-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Comparison of Central Versus Peripheral Placement of Local Anesthetic|Selective Local Anesthetic Placement Using Ultrasound-guidance and Neurostimulation for the Infraclavicularbrachial Plexus Block|Completed||N/A|218|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-06-01 02:02:28.348021|2018-06-01 02:02:28.348021
NCT00699231|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|February 1992||1992-02-29|June 2008|2008-06-30|December 1992|Actual|1992-12-31|December 1992|Actual|1992-12-31||Interventional|||Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients|Study to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine Versus Engerix™-B, in Haemodialysis Patients|Completed||Phase 1|30|Actual|GlaxoSmithKline||8|||f||||||||||||||2018-06-01 02:02:28.445533|2018-06-01 02:02:28.445533
NCT00699218|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2012-10-10|2008-06-16|2008-06-17|Estimate|||||||2012-10-10|2012-10-12|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|April 2010|Actual|2010-04-30|July 2009|Actual|2009-07-31||Interventional|TMS-BD||A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression|A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment of Bipolar Depression|Completed||Phase 1/Phase 2|15|Actual|University of California, Davis||1|||f||||f||||||||||2018-06-01 02:02:28.521186|2018-06-01 02:02:28.521186
NCT00699192|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2011-01-11||2011-05-04|2008-06-13|2008-06-17|Estimate|2011-05-04|2011-06-06|Estimate||||2011-05-04|2011-06-06|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension|A Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients With Essential Hypertension Not Adequately Controlled After Four Weeks on Amlodipine 5 mg Once Daily|Completed||Phase 3|965|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:02:28.613504|2018-06-01 02:02:28.613504
NCT00699179|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2016-10-27|2008-06-16|2008-06-17|Estimate|||||||2016-10-27|2016-10-31|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|EFFECTIVE||Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes|EFFicacious glycaEmia Control, Treatment Goal achIevement Very simplE With NovoMix 30: A Single-country, Multicentre, Prospective, Open Label, Non-controlled, Observational, 26-week Study in Serbian Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Diabetes Mellitus in Everyday Clinical Practice|Completed|||2308|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:02:29.139025|2018-06-01 02:02:29.139025
NCT00699166|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-12|2008-06-12|2008-06-17|Estimate|||||||2008-06-12|2008-06-17|Estimate|April 2004||2004-04-30|June 2008|2008-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|CDNK333B2201||Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter 2-Week Pilot Study to Evaluate the Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) Given Orally in Female Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|Completed||Phase 2|135|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:02:29.226597|2018-06-01 02:02:29.226597
NCT00699153|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|2010-07-09||2015-03-04|2008-06-16|2008-06-17|Estimate|2010-09-01|2010-09-23|Estimate||||2015-03-04|2015-03-24|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery|Safety and Efficacy of Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery|Completed||Phase 3|400|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:02:29.34494|2018-06-01 02:02:29.34494
NCT00699140|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2015-06-16||2016-01-09|2008-06-16|2008-06-17|Estimate|2016-01-09|2016-02-08|Estimate||||2016-01-09|2016-02-08|Estimate|February 2008||2008-02-29|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ITP||Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura|Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura|Completed||Phase 3|18|Actual|Grifols Biologicals Inc.|The patient number was based on European Medicines Agency guidance to evaluate IVIG products in ITP patients (EMEA/CPMP/BPWG/388/95 rev.1, June 2000, in force when the study was designed): at least 15 subjects were sufficient for the analysis.|1|||f||||f||||||||||2018-06-01 02:02:29.771152|2018-06-01 02:02:29.771152
NCT00699127|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-14|||2008-07-03|2008-06-16|2008-06-17|Estimate|||||||2008-07-03|2008-07-04|Estimate|July 2008||2008-07-31|July 2008|2008-07-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||Organizing the Information Given to Parents of NICU Infants in Order to Reduce Their Anxiety|Dose Organizing the Information Given to Parents of NICU Infants Reduce Their Anxiety?|Withdrawn||N/A|0|Actual|Hillel Yaffe Medical Center||2||After a discussion, we decided to withdraw the study.|f||||f||||||||||2018-06-01 02:02:30.101065|2018-06-01 02:02:30.101065
NCT00699114|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2011-07-03|2008-06-16|2008-06-17|Estimate|||||||2011-07-03|2011-07-06|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain|Analgesic Effect of Ibuprofen 400, 600 and 800 mg, Paracetamol 500 and 1000 mg, and Paracetamol 1000 mg Plus 60 mg Codeine: Single-dose, Randomized, Placebo-controlled and Double-blind Study on Acute Pain After Third Molar Surgery|Completed||Phase 4|350|Anticipated|Oslo University Hospital||7|||f||||f||||||||||2018-06-01 02:02:30.175604|2018-06-01 02:02:30.175604
NCT00699101|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2013-06-14|2008-06-12|2008-06-17|Estimate|||||||2013-06-14|2013-06-17|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|March 2011|Actual|2011-03-31||Interventional|||Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy|A Multi-site Prospective, Non Randomized Study Utilizing the Conture® Multi-Lumen Balloon (MLB) Breast Brachytherapy Applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use|Terminated||Phase 4|342|Actual|SenoRx, Inc.||1|||f||||t||||||||||2018-06-01 02:02:30.277137|2018-06-01 02:02:30.277137
NCT00699088|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|January 2005||2005-01-31|June 2017|2017-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||A Clinical Investigation of the Balance® Microplasty™ Hip System|A Prospective, Non-controlled, Clinical Investigation of the Balance® Microplasty™ Hip System|Completed|||70|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 02:02:30.343128|2018-06-01 02:02:30.343128
NCT00699062|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2012-01-03|2008-06-16|2008-06-17|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Montelukast on the Airway Remodeling|Effect of Montelukast on the Airway Remodeling in Asthma Patients: Physiological-radiological Correlation|Completed||Phase 4|40|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:02:30.406512|2018-06-01 02:02:30.406512
NCT00699049|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2016-01-06|2008-06-16|2008-06-17|Estimate|||||||2016-01-06|2016-01-07|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Comparison of the Efficacy and Safety of Any Alpha Blocker Monotherapy and Any Alpha Blocker Plus Solifenacin in Men With Residual Overactive Bladder Symptoms of Urinary Frequency and Urgency With/Without Urgency Incontinence After Previous Monotherapy With Any Alpha Blocker|Completed||Phase 4|94|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 02:02:30.476245|2018-06-01 02:02:30.476245
NCT00699036|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-06-18|2008-06-16|2008-06-17|Estimate|||||||2009-06-18|2009-06-19|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|August 2009|Anticipated|2009-08-31|July 2009|Anticipated|2009-07-31||Interventional|||Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)|Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial|Unknown status|Recruiting|Phase 2|165|Anticipated|Brooke Army Medical Center||3|||f||||t||||||||||2018-06-01 02:02:30.551736|2018-06-01 02:02:30.551736
NCT00699023|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2009-11-03|2008-06-16|2008-06-17|Estimate|||||||2009-11-03|2009-11-04|Estimate|June 2008||2008-06-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|EZE||Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes|Effects of Ezetimibe in Association With Statins on Postprandial Lipemia in Type 2 Diabetic Patients|Completed||Phase 4|13|Anticipated|Federico II University||2|||f||||f||||||||||2018-06-01 02:02:30.631247|2018-06-01 02:02:30.631247
NCT00699010|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-10-22|2008-06-16|2008-06-17|Estimate|||||||2008-10-22|2008-10-23|Estimate|March 2008||2008-03-31|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse|A Phase II, Single-Center, Randomized, Double-Blind Assessment of the Abuse Liability of Acurox (Oxycodone HCl and Niacin) Tablets in Subjects With a History of Opioid Abuse|Completed||Phase 2|30|Anticipated|Acura Pharmaceuticals Inc.||5|||f||||f||||||||||2018-06-01 02:02:30.702431|2018-06-01 02:02:30.702431
NCT00698997|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2017-07-21|2008-06-12|2008-06-17|Estimate|||||||2017-07-21|2017-07-25|Actual|April 2008|Actual|2008-04-30|July 2017|2017-07-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Intensive Intervention for Toddlers With Autism (EARLY STEPS)|Intensive Intervention for Toddlers With Autism|Completed||N/A|96|Actual|University of California, Davis||2|||f||||t||||||||Yes|Individual participant data will be entered into NDAR as soon as primary analyses have been completed.|2018-06-01 02:02:30.774156|2018-06-01 02:02:30.774156
NCT00698984|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2009-01-15|2008-06-16|2008-06-17|Estimate|||||||2009-01-15|2009-01-16|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health|Pilot Study To Investigate The Effect Of Bonistein(R) Bone Blend Containing Genistein, Polyunsaturated Fatty Acids (N-3 PUFAS) And Vitamins K1 And D3 On Bone Mineral Density (BMD), Bone Mineral Content (BMC) And Biomarkers Of Bone Health In Early Postmenopausal Women|Completed||N/A|70|Actual|DSM Nutritional Products, Inc.||2|||f||||t||||||||||2018-06-01 02:02:30.845384|2018-06-01 02:02:30.845384
NCT00698958|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|June 2003||2003-06-30|June 2008|2008-06-30||||||||Interventional|||Ambulatory Adaptation to Non-Invasive Mechanical Ventilation|A Randomized Trial to Compare the Effectiveness of Hospital or Ambulatory Approach for Adaptation to Non-Invasive Mechanical Ventilation in Patients With Chronic Respiratory Failure Secondary to Neuromuscular Diseases or Thoracic Cage Alterations|Completed||Phase 4|52|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:02:30.910213|2018-06-01 02:02:30.910213
NCT00698633|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2001||2001-12-31|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||A Clinical Investigation of the M2a- Taper™ Hip System|M2a- Taper™ Hip System Prospective Data Collection|Terminated|||43|Actual|Zimmer Biomet|||1|due to low follow up|f||||||||||||||2018-06-01 02:02:37.434005|2018-06-01 02:02:37.434005
NCT00698945|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-12-02|2008-06-16|2008-06-17|Estimate|||||||2008-12-02|2008-12-04|Estimate|June 2008||2008-06-30|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)|Randomized, Investigator Masked Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)|Completed||Phase 4|40|Anticipated|Bp Consulting, Inc||2|||f||||||||||||||2018-06-01 02:02:30.964981|2018-06-01 02:02:30.964981
NCT00698932|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2010-09-20||2011-08-17|2008-06-16|2008-06-17|Estimate|2011-08-17|2011-09-21|Estimate||||2011-08-17|2011-09-21|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control|A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise.|Completed||Phase 3|568|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:02:31.181737|2018-06-01 02:02:31.181737
NCT00698919|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|September 2008||2008-09-30|June 2008|2008-06-30|November 2010|Anticipated|2010-11-30|September 2010|Anticipated|2010-09-30||Observational|||Bacterial Infection Diagnosis Using Blood DNA|Bacterial DNA Detection as a Diagnostic Tool of Infection in Critical Ill Patients With SIRS|Unknown status|Not yet recruiting||400|Anticipated|Delafontaine Hospital|||2||f||||f||||||Samples With DNA|"~     Sample with bacterial DNA (and no human DNA will be studied)~      We will have also some blood and plasma for cytokines,peptidoglycan and endotoxin~     measurement.~   "|||2018-06-01 02:02:31.598585|2018-06-01 02:02:31.598585
NCT00698906|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|June 1997||1997-06-30|June 2008|2008-06-30||||February 1998|Actual|1998-02-28||Interventional|||Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y|Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 19-40 Years|Completed||Phase 2|160|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 02:02:31.749278|2018-06-01 02:02:31.749278
NCT00698893|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-01|2008-06-16|2008-06-17|Estimate|||||||2017-06-01|2017-06-02|Actual|May 1, 1992|Actual|1992-05-01|June 2017|2017-06-30|July 1, 1992|Actual|1992-07-01|July 1, 1992|Actual|1992-07-01||Interventional|||Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults|An Open Study in Healthy Herpes Simplex Virus (HSV)-Positive Adults to Evaluate the Safety of GSK Biologicals' Candidate gD Vaccine, With or Without 3D MPL|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:02:31.888487|2018-06-01 02:02:31.888487
NCT00698880|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization|Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy|Completed||Phase 2/Phase 3|13|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 02:02:31.978188|2018-06-01 02:02:31.978188
NCT00698867|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|2016-09-20||2017-04-28|2008-06-13|2008-06-17|Estimate|2017-04-28|2017-08-07|Actual||||2017-04-28|2017-08-07|Actual|June 2002||2002-06-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational||Elbows with preoperative data|A Clinical Investigation of the Discovery™ Elbow System|A Prospective, Non-controlled, Clinical Investigation of the Discovery™ Elbow System|Completed|||118|Actual|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-06-01 02:02:32.105524|2018-06-01 02:02:32.105524
NCT00698854|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-22|2008-06-13|2008-06-17|Estimate|||||||2017-06-22|2017-06-23|Actual|March 2004||2004-03-31|June 2017|2017-06-30|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Observational|||A Clinical Investigation of the Vanguard™ Complete Knee System|A Prospective, Non-controlled, Clinical Investigation of the Vanguard™ Complete Knee System|Enrolling by invitation|||600|Anticipated|Zimmer Biomet|||2||f||||f||||||||Undecided||2018-06-01 02:02:32.414601|2018-06-01 02:02:32.414601
NCT00698841|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2011-04-14||2015-11-24|2008-06-16|2008-06-17|Estimate|2011-04-14|2011-05-11|Estimate||||2015-11-24|2015-12-24|Estimate|February 2009||2009-02-28|November 2015|2015-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors|A Study to Evaluate the Relationship Between Cetuximab Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors|Completed||Phase 2|79|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:02:32.544016|2018-06-01 02:02:32.544016
NCT00698828|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01||2011-04-04|2015-10-19|2008-06-13|2008-06-17|Estimate||||2011-04-04|2011-04-12|Estimate|2015-10-19|2015-11-06|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|225|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-06-01 02:02:33.034308|2018-06-01 02:02:33.034308
NCT00698815|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-14|2015-02-17||2017-12-11|2008-06-14|2008-06-17|Estimate|2015-03-05|2015-03-19|Estimate||||2017-12-11|2018-01-05|Actual|April 15, 2008|Actual|2008-04-15|November 2017|2017-11-30||||December 31, 2013|Actual|2013-12-31||Interventional|||Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer|Completed||Phase 2|130|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 02:02:33.20068|2018-06-01 02:02:33.20068
NCT00698802|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2015-04-13|2008-06-16|2008-06-17|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of Biphasic Human Insulin Compared to EX1000 in Type 2 Diabetes|Assessment of Safety and Efficacy of Biphasic Human Insulin IU 100 to EX1000 on Glycaemic Control in Subjects With Type 2 Diabetes|Completed||Phase 2|397|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 02:02:34.837734|2018-06-01 02:02:34.837734
NCT00355953|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2008-04-18|2006-07-24|2006-07-25|Estimate|||||||2008-04-18|2008-04-22|Estimate|January 2003||2003-01-31|April 2008|2008-04-30|June 2005||2005-06-30|||||Interventional|||Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women||Completed||Phase 2/Phase 3|400||University of Messina|||||f||||||||||||||2018-06-01 03:52:55.285878|2018-06-01 03:52:55.285878
NCT00698789|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13||2012-10-11|2012-10-25|2008-06-16|2008-06-17|Estimate||||2012-10-11|2012-10-15|Estimate|2012-10-25|2012-10-30|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes|A Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety and Tolerability of INCB019602 Plus Metformin Compared to Metformin Alone in Type 2 Diabetic Subjects|Terminated||Phase 2|48|Actual|Incyte Corporation||6||Study ended after diabetes development plan review. .|f||||f||||||||||2018-06-01 02:02:34.915719|2018-06-01 02:02:34.915719
NCT00698776|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2016-06-20|2008-06-12|2008-06-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma|Phase I/II Trial of Combination of Lenalidomide (Revlimid, LEN) and Autologous Mature Dendritic Cells Pulsed With α-galactosyl Ceramide (α-GalCer; KRN7000) in Myeloma|Completed||Phase 1|6|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:02:35.01818|2018-06-01 02:02:35.01818
NCT00698763|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2009-11-23|2008-06-16|2008-06-17|Estimate|||||||2009-11-23|2009-11-25|Estimate|August 2008||2008-08-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|Electro||Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables|Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables and Cerebrovascular Reactivity in Patients With Recent Stroke or TIA.|Completed||Phase 2|32|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 02:02:35.085046|2018-06-01 02:02:35.085046
NCT00698750|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|April 2004||2004-04-30|June 2017|2017-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||A Clinical Investigation of the Copeland™ Humeral Resurfacing Head|A Prospective, Non-controlled, Clinical Investigation of the Copeland™ Humeral Resurfacing Head|Terminated|||34|Actual|Zimmer Biomet|||1|Sponsor terminated study early due to limited enrollment and follow-up.|f||||f||||||||||2018-06-01 02:02:35.176674|2018-06-01 02:02:35.176674
NCT00698737|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2012-11-20|2008-06-13|2008-06-17|Estimate|||||||2012-11-20|2012-11-22|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|ARC||Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)|Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)|Completed|||22|Actual|Wayne State University|||||f||||t||||||||||2018-06-01 02:02:35.361619|2018-06-01 02:02:35.361619
NCT00698724|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2009-06-08|2008-06-16|2008-06-17|Estimate|||||||2009-06-08|2009-06-10|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care|A Prospective, Randomized Single-Masked Clinical Trial Comparing OCT and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care|Completed||Phase 4|200|Anticipated|Bp Consulting, Inc||2|||f||||||||||||||2018-06-01 02:02:35.427132|2018-06-01 02:02:35.427132
NCT00698711|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2012-01-27|2008-06-13|2008-06-17|Estimate|||||||2012-01-27|2012-01-31|Estimate|November 1997||1997-11-30|January 2012|2012-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21|Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Comparing MUC-2-KLH Doses|Completed||Phase 1|15|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:02:35.499366|2018-06-01 02:02:35.499366
NCT00698698|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2009-01-30|2008-06-16|2008-06-17|Estimate|||||||2009-01-30|2009-02-02|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Observational|||Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics|Tear Proteins and Diabetic Retinopathy|Unknown status|Active, not recruiting||350|Anticipated|Dow University of Health Sciences|||5||f||||t||||||||||2018-06-01 02:02:35.567423|2018-06-01 02:02:35.567423
NCT00698685|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-14|2010-12-28||2017-03-23|2008-06-14|2008-06-17|Estimate|2011-01-10|2011-01-12|Estimate||||2017-03-23|2017-03-31|Actual|January 23, 2006|Actual|2006-01-23|March 2017|2017-03-31|April 26, 2011|Actual|2011-04-26|April 13, 2009|Actual|2009-04-13||Interventional|||Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation|Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)|Terminated||Phase 2|14|Actual|University of Arizona|We did not meet criteria to stop the study because of nonrelapse mortality (safety endpoint). However, we stopped accrual to the study because of failure to meet minimal criteria for engraftment (efficacy endpoint).|1||Pentostatin/alemtuzumab regimen had greater risk of graft failure.|f||||t||||||||||2018-06-01 02:02:35.6577|2018-06-01 02:02:35.6577
NCT00698672|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2017-02-27|2008-06-16|2008-06-17|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2004||2004-11-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2007|Actual|2007-06-30||Interventional|||RSA-Study of Cemented Hip Prostheses With Five Different Articulations|A Prospective Randomized RSA-Study of Cemented Hip Prostheses With Five Different Articulations|Active, not recruiting||N/A|150|Actual|Haukeland University Hospital||5|||f||||f||||||||No|Not planned|2018-06-01 02:02:35.915383|2018-06-01 02:02:35.915383
NCT00698659|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-15|||2013-12-10|2008-06-16|2008-06-17|Estimate|||||||2013-12-10|2013-12-11|Estimate|August 2007||2007-08-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies|A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth|Terminated|||||National University Hospital, Singapore|||1||f||||f||||||||||2018-06-01 02:02:35.982069|2018-06-01 02:02:35.982069
NCT00698646|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|2010-11-16||2011-04-15|2008-06-16|2008-06-17|Estimate|2010-11-16|2010-12-15|Estimate||||2011-04-15|2011-04-19|Estimate|April 2008||2008-04-30|April 2011|2011-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.|A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very Elderly Patients With Essential Hypertension|Completed||Phase 4|384|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:02:36.050642|2018-06-01 02:02:36.050642
NCT00531375|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2008-11-17|2007-09-17|2007-09-18|Estimate|||||||2008-11-17|2008-11-19|Estimate|September 2007||2007-09-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||The Effect of Silicone Hydrogel Contact Lenses on Conjunctival Flora||Completed||N/A|60|Actual|University of Melbourne|||||f||||||||||||||2018-06-01 02:54:57.5831|2018-06-01 02:54:57.5831
NCT00698607|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-15|||2010-06-28|2008-06-16|2008-06-17|Estimate|||||||2010-06-28|2010-06-29|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|April 2014|Anticipated|2014-04-30|April 2010|Anticipated|2010-04-30||Interventional|EXCELLENT||Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing|Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions|Unknown status|Active, not recruiting|Phase 4|1466|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-06-01 02:02:37.513323|2018-06-01 02:02:37.513323
NCT00698594|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2011-08-19|2008-06-16|2008-06-17|Estimate|||||||2011-08-19|2011-08-22|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis|Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis Allergic to Grass Pollen|Completed||Phase 4|60|Actual|Medical Universtity of Lodz||3|||f||||t||||||||||2018-06-01 02:02:37.652199|2018-06-01 02:02:37.652199
NCT00698581|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2016-03-14|2011-02-09|2018-03-08|2008-06-12|2008-06-17|Estimate|2016-03-14|2016-04-13|Estimate|2011-02-09|2011-02-11|Estimate|2018-03-08|2018-04-03|Actual|August 2008||2008-08-31|March 2018|2018-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional||Demographics refer to the Randomized Set (RS).|A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures|An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization|Terminated||Phase 3|88|Actual|UCB Pharma||2||"An interim analysis revealed the study was unlikely to attain a positive outcome for the~   efficacy analysis. No safety concerns were detected."|f||||t||||||||||2018-06-01 02:02:37.746588|2018-06-01 02:02:37.746588
NCT00698568|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|October 1996||1996-10-31|June 2008|2008-06-30|April 1999|Actual|1999-04-30|April 1999|Actual|1999-04-30||Interventional|||Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects|Study to Evaluate the Safety of GSK Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease|Completed||Phase 3|7460|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:02:38.284988|2018-06-01 02:02:38.284988
NCT00698555|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|March 1997||1997-03-31|June 2008|2008-06-30||||May 1998|Actual|1998-05-31||Interventional|||Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y|Study Comparing the Immunogenicity and Reactogenicity of Different Formulations of GSK Bio's HBV-MPL Vaccine Injected as a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in Healthy Adults Aged 18-40 Years|Completed||Phase 2|163|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 02:02:38.432661|2018-06-01 02:02:38.432661
NCT00698542|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2017-04-19|2008-06-16|2008-06-17|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2008||2008-05-31|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Evaluation of the Patient Safety Screening Tool (PSST) for Sepsis|A Validation of a Patient Safety Screening Tool for Sepsis|Terminated|||221|Actual|Vanderbilt University Medical Center|||1|The study design failed and the data was not able to be analyzed.|f||||t||||||||||2018-06-01 02:02:38.530089|2018-06-01 02:02:38.530089
NCT00698529|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2018-04-09|2008-06-13|2008-06-17|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2008||2008-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|February 2013|Actual|2013-02-28||Interventional|||Effectiveness of Communication Technology in Disseminating HIV Prevention Training to Non-governmental Organizations|Communication Technology to Disseminate Evidence-Based HIV Interventions to NGOs|Active, not recruiting||Phase 2|99|Anticipated|Medical College of Wisconsin||3|||f||||f||||||||||2018-06-01 02:02:38.609736|2018-06-01 02:02:38.609736
NCT00698516|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|2011-01-13||2012-03-22|2008-06-16|2008-06-17|Estimate|2011-01-13|2011-02-03|Estimate||||2012-03-22|2012-03-27|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer|An Open-label, Multicenter, Non-comparative, Phase II Study of Oral Topotecan in Combination With Bevacizumab for Second-line Treatment in Subjects With Relapsed Small-cell Lung Cancer (SCLC)|Completed||Phase 2|50|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:02:38.740248|2018-06-01 02:02:38.740248
NCT00698503|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|January 2002||2002-01-31|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||A Clinical Investigation of the M2a- 38™ Hip System|M2a- 38™ Hip System Prospective Data Collection|Terminated|||190|Actual|Zimmer Biomet|||1|due to low follow up|f||||||||||||||2018-06-01 02:02:39.080607|2018-06-01 02:02:39.080607
NCT00698490|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|August 1995||1995-08-31|June 2008|2008-06-30|January 1997|Actual|1997-01-31|January 1997|Actual|1997-01-31||Interventional|||Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines|Study to Compare, in Healthy HSV Seronegative and HSV Seropositive Subjects, the Humoral and Cellular Immune Response of Herpes Simplex Candidate Vaccines Containing gD From Two Different Cell Lines and Using gD-Alum as Control|Completed||Phase 1/Phase 2|130|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 02:02:39.136232|2018-06-01 02:02:39.136232
NCT00698477|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-15|||2008-06-15|2008-06-15|2008-06-17|Estimate|||||||2008-06-15|2008-06-17|Estimate|October 2007||2007-10-31|June 2008|2008-06-30||||||||Observational|||Chemotherapy on Methylation Patterns in Breast Tumor Tissue Correlating With Clinical Response and Outcomes|Study of the Effect of Chemotherapy on Methylation Patterns in Breast Tumor Tissue and Paired Plasma Samples and Correlation With Clinical Response and Outcomes|Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 02:02:39.308339|2018-06-01 02:02:39.308339
NCT00698464|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-11-03|2008-06-13|2008-06-17|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2008||2008-07-31|November 2016|2016-11-30||||April 2009|Actual|2009-04-30||Interventional|||Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function|A Phase I, Open-label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function|Completed||Phase 1|34|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:02:39.378467|2018-06-01 02:02:39.378467
NCT00698451|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2011-12-10||2013-08-20|2008-06-13|2008-06-17|Estimate|2013-06-06|2013-07-12|Estimate||||2013-08-20|2013-09-06|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers|A Phase II Single Arm Study of Carboplatin and DOXIL (PLD) Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers|Completed||Phase 2|54|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 02:02:39.490213|2018-06-01 02:02:39.490213
NCT00698438|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-06-12|2008-06-12|2008-06-17|Estimate|||||||2008-06-12|2008-06-17|Estimate|March 2005||2005-03-31|June 2008|2008-06-30||||August 2007||2007-08-31||Interventional|XVT-USF||Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study|Prospective, Randomized Clinical Trial,to Compare Standard Trabeculectomy to the Ex-PRESS Mini Glaucoma Shunt Implantation Under a Scleral Flap in Eyes With Open-Angle Glaucoma|Completed||Phase 4|30||University of Witwatersrand, South Africa||2|||f||||t||||||||||2018-06-01 02:02:39.837794|2018-06-01 02:02:39.837794
NCT00698425|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2010-08-20|2008-06-16|2008-06-17|Estimate|||||||2010-08-20|2010-08-23|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System|Single Center, Single-masked, Randomized, Dose Escalation Study to Evaluate Safety and Tolerability of Transscleral Iontophoresis Using Citrate Buffer Delivered by the EyeGate® II Drug Delivery Device System in Healthy Adult Volunteers|Completed||Phase 1|105|Actual|Eyegate Pharmaceuticals, Inc.||19|||f||||f||||||||||2018-06-01 02:02:39.929877|2018-06-01 02:02:39.929877
NCT00698412|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-13|2008-06-13|2008-06-17|Estimate|||||||2008-06-13|2008-06-17|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effectiveness of Cane in Osteoarthritis (OA) Patients|The Impact of Daily Cane Use on Pain, Function, Quality of Life and Energy Consumption During the Gait in Patients With Knee Osteoarthritis|Completed||Phase 4|64|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 02:02:40.054925|2018-06-01 02:02:40.054925
NCT00698399|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2018-02-27|2008-06-12|2008-06-17|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2008||2008-03-31|February 2018|2018-02-28|February 2, 2010|Actual|2010-02-02|February 2, 2010|Actual|2010-02-02||Observational|||Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients|Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients, Phase II|Completed|||20|Actual|Vanderbilt University Medical Center|||2||f||||f||||||Samples Without DNA|"~     serum of patients who are undergoing liver transplantation surgery~   "|||2018-06-01 02:02:40.14236|2018-06-01 02:02:40.14236
NCT00698386|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2009-09-14|2008-06-16|2008-06-17|Estimate|||||||2009-09-14|2009-09-15|Estimate|February 2008||2008-02-29|June 2008|2008-06-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients|Efficacy of Oral Zinc Administration as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters (Double-blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial|Unknown status|Recruiting|Phase 3|150|Anticipated|Ministry of Science and Technology, India|||||f||||t||||||||||2018-06-01 02:02:40.247702|2018-06-01 02:02:40.247702
NCT00698373|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate||||June 2008|2008-06-30||||||||Observational|||Evaluation of Thoracic Tumors With 18F-FMT and 18F-FDG PET-CT A Clinicopathological Study|Evaluation of Thoracic Tumors With 18F-FMT and 8F-FDG PET-CT: A Clinicopathological Study|Completed|||||Gunma University|||1||f||||f||||||||||2018-06-01 02:02:40.337296|2018-06-01 02:02:40.337296
NCT00698360|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|July 2007||2007-07-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|CREAM 1||Circadian Rhythm of Erythropoietin And Melatonin in Renal Disease|Circadian Rhythm of Erythropoietin and Melatonin in Patients With Various Degrees of Renal Insufficiency|Completed|||34|Actual|Meander Medical Center|||4||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:02:40.388061|2018-06-01 02:02:40.388061
NCT00698347|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2017-06-19|2008-06-13|2008-06-17|Estimate|||||||2017-06-19|2017-06-21|Actual|November 2004||2004-11-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||A Clinical Investigation of the M2a-Magnum™ Hip System|A Prospective, Non-controlled, Clinical Investigation of the M2a-Magnum™ Hip System|Terminated|||249|Actual|Zimmer Biomet|||1|Centers would not continue follow-up; two centers transitioned patients to a new study.|f||||f||||||||||2018-06-01 02:02:40.464624|2018-06-01 02:02:40.464624
NCT00698334|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2011-11-05|2008-06-16|2008-06-17|Estimate|||||||2011-11-05|2011-11-08|Estimate|April 2006||2006-04-30|November 2011|2011-11-30|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis|Efficacy of Thrice Weekly Intermittent Short Course Antituberculosis Chemotherapy in Tuberculosis Patients With and Without HIV Infection|Completed||Phase 3|150|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 02:02:40.552563|2018-06-01 02:02:40.552563
NCT00698321|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2013-05-17|2008-06-13|2008-06-17|Estimate|||||||2013-05-17|2013-05-20|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A School-Based HIV/STD Prevention Program to Reduce Risky Sexual Behaviors Among Adolescents in Liberia|Liberia School-Based HIV/STD Prevention Program|Completed||N/A|866|Actual|Pacific Institute for Research and Evaluation||2|||f||||f||||||||||2018-06-01 02:02:40.651901|2018-06-01 02:02:40.651901
NCT00698295|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-15|||2009-09-15|2008-06-16|2008-06-17|Estimate|||||||2009-09-15|2009-09-16|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|September 2010|Anticipated|2010-09-30|||||Observational|||Linear and Non-linear Analysis of EEG Changes in Schizophrenia After Atypical Antipsychotics Medication|Study of the Relationship Between EEG and Clinical Changes in Drug-Naive or Drug-Free Patients With Schizophrenia After Atypical Antipsychotic Treatment Based on Linear and Non-Linear EEG Analysis|Unknown status|Active, not recruiting||60|Anticipated|Seoul National University Hospital|||||f||||t||||||Samples Without DNA|"~     routine lab for changes in medical condition~   "|||2018-06-01 02:02:40.727251|2018-06-01 02:02:40.727251
NCT00698282|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2010-11-30|2008-06-16|2008-06-17|Estimate|||||||2010-11-30|2010-12-01|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|JSAD/JMAD||Single and Multiple Ascending Doses of AZD1981 in Japan|A Randomised, Placebo-Controlled, Double-Blind, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of AZD1981 in Healthy Male Japanese and Caucasian Subjects|Completed||Phase 1|47|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:02:40.801244|2018-06-01 02:02:40.801244
NCT00698269|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2016-10-26|2008-06-16|2008-06-17|Estimate|||||||2016-10-26|2016-10-28|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment|Efficacy and Safety Study in Subjects Using Levemir® (Insulin Detemir), NovoMix®30 (Biphasic Insulin Aspart 30) and/or NovoRapid® (Insulin Aspart) for the Treatment of Type 1 or Type 2 Diabetes Mellitus|Completed|||5926|Actual|Novo Nordisk A/S|||3||f||||f||||||||||2018-06-01 02:02:40.861589|2018-06-01 02:02:40.861589
NCT00308477|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2012-02-09|2006-03-27|2006-03-29|Estimate|||||||2012-02-09|2012-02-13|Estimate||||February 2012|2012-02-29||||||||Interventional|||A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion||Completed||Phase 1/Phase 2|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 04:05:30.621156|2018-06-01 04:05:30.621156
NCT00698256|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2012-04-16|2008-06-16|2008-06-17|Estimate|||||||2012-04-16|2012-04-17|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|maxsta||Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins|Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins|Completed||N/A|50|Actual|University of Eastern Finland||2|||f||||f||||||||||2018-06-01 02:02:40.953675|2018-06-01 02:02:40.953675
NCT00698243|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2013-04-11|2008-06-16|2008-06-17|Estimate|||||||2013-04-11|2013-04-15|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma|A Phase 1 Dose-escalation Study of Intermittent, Once Weekly, and Continuous Daily Oral OSI-027 Dosing in Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|128|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 02:02:41.097059|2018-06-01 02:02:41.097059
NCT00698230|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13||2010-06-17|2018-02-12|2008-06-16|2008-06-17|Estimate||||2010-06-17|2010-06-22|Estimate|2018-02-12|2018-02-14|Actual|May 2008||2008-05-31|February 2018|2018-02-28|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics|Randomized Study to Evaluate the Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetic Subjects|Completed||Phase 2|302|Actual|Incyte Corporation||6|||f||||f||||||||||2018-06-01 02:02:41.209739|2018-06-01 02:02:41.209739
NCT00698204|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2014-05-07||2014-05-07|2008-06-16|2008-06-17|Estimate|2014-05-07|2014-06-05|Estimate||||2014-05-07|2014-06-05|Estimate|July 2003||2003-07-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional||Intent-to-treat analysis performed for 40 participants. Per-protocol analysis performed for the period in which individual participants were taking study medication (celecoxib or placebo).|Cox-2 Inhibition in Radiation-induced Oral Mucositis|Cyclooxygenase-2 Inhibition in Radiation-Induced Oral Mucositis|Completed||Phase 2|43|Actual|UConn Health||2|||f||||t||||||||||2018-06-01 02:02:41.418148|2018-06-01 02:02:41.418148
NCT00698191|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2008-06-16|2008-06-16|2008-06-17|Estimate|||||||2008-06-16|2008-06-17|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)|Phase I/IIa: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Nanjing Medical University||1|||f||||t||||||||||2018-06-01 02:02:41.765317|2018-06-01 02:02:41.765317
NCT00698178|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2010-10-18|2008-06-16|2008-06-17|Estimate|||||||2010-10-18|2010-10-19|Estimate|June 2008||2008-06-30|October 2010|2010-10-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|||Waist Circumference Versus Body Mass Index to Predict Severity of Gastroesophageal Reflux Disease|Waist Circumference Versus Body Mass Index to Predict Severity of Gastroesophageal Reflux Disease|Completed|||500|Anticipated|Lotung Poh-Ai Hospital|||3||f||||t||||||||||2018-06-01 02:02:41.870214|2018-06-01 02:02:41.870214
NCT00698165|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-16|||2009-02-19|2008-06-16|2008-06-17|Estimate|||||||2009-02-19|2009-02-20|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|January 2009|Actual|2009-01-31|||||Observational|||Observational Study on Costs and Caregiver Burden in Alzheimer's Disease|Observational Study on Costs and Caregiver Burden in Alzheimer's Disease|Completed|||2400|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 02:02:41.972523|2018-06-01 02:02:41.972523
NCT00698152|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2015-06-17|2008-06-13|2008-06-17|Estimate|||||||2015-06-17|2015-06-18|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||A Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement|A Prospective, Non-controlled, Clinical Investigation of ArComXL® Polyethylene in Total Hip Replacement|Unknown status|Active, not recruiting||149|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-06-01 02:02:42.152074|2018-06-01 02:02:42.152074
NCT00698139|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2014-01-28||2018-03-30|2008-06-16|2008-06-17|Estimate|2014-07-11|2014-07-14|Estimate||||2018-03-30|2018-04-27|Actual|April 2011||2011-04-30|July 2014|2014-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate|Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate for Six Hours in Patients With Congestive Heart Failure, Heart Rate <70 Beats Per Minute and Fluid Overload.|Terminated||N/A|3|Actual|Columbia University|Early termination leading to small numbers of subjects analyzed|3||Closed by Sponsor|f||||f||||||||||2018-06-01 02:02:42.221988|2018-06-01 02:02:42.221988
NCT00698126|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-13|||2016-10-26|2008-06-13|2008-06-17|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|UPGRADE||Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes|A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Aspart (NovoRapid® ) or Soluble Human Insulin for the Treatment of Diabetes Mellitus the UPGRADE Study|Completed|||4099|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 02:02:42.541433|2018-06-01 02:02:42.541433
NCT00698113|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2009-06-17|2008-06-12|2008-06-16|Estimate|||||||2009-06-17|2009-06-19|Estimate|April 2007||2007-04-30|June 2008|2008-06-30|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Interventional|||Parent-Delivered Massage in Paediatric Cancer|Parent-Delivered Massage in Paediatric Cancer|Unknown status|Recruiting|N/A|24|Anticipated|Centennial College||2|||f||||t||||||||||2018-06-01 02:02:42.638436|2018-06-01 02:02:42.638436
NCT00698100|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2011-09-15|2008-06-13|2008-06-16|Estimate|||||||2011-09-15|2011-09-16|Estimate|June 2002||2002-06-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines|Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines: A Phase I Trial to Assess Safety and Immune Response|Completed||Phase 1|18|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:02:42.7754|2018-06-01 02:02:42.7754
NCT00698087|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|January 1995||1995-01-31|June 2008|2008-06-30|February 1996|Actual|1996-02-29|February 1996|Actual|1996-02-29||Interventional|||Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B|Study to Compare the Safety, Immunogenicity and Reactogenicity of Different Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B|Completed||Phase 3|60|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 02:02:42.844144|2018-06-01 02:02:42.844144
NCT00698074|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate||||June 2008|2008-06-30||||||||Interventional|||Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy|Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy|Unknown status|Recruiting|Phase 3|32|Anticipated|University Hospital Birmingham||1|||f||||||||||||||2018-06-01 02:02:42.91196|2018-06-01 02:02:42.91196
NCT00698061|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2017-05-25|2008-06-13|2008-06-16|Estimate|||||||2017-05-25|2017-05-30|Actual|November 1999||1999-11-30|May 2017|2017-05-31|May 2001|Actual|2001-05-31|September 2000|Actual|2000-09-30||Interventional|||Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y|A Study to Compare the Immunogenicity and Safety of GSK Biologicals Adjuvanted HBV Vaccine to Engerix™-B, in a Non-responder Population ≥ 15 Years of Age, When Administered Intramuscularly, According to a 0, 1, 2, 12 Month Schedule|Completed||Phase 3|145|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:02:42.966457|2018-06-01 02:02:42.966457
NCT00698048|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2015-09-07|2008-06-13|2008-06-16|Estimate|||||||2015-09-07|2015-09-09|Estimate|August 2008||2008-08-31|September 2015|2015-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|VaCoSS||Serial Vasopressin and Copeptin Levels in Children With Sepsis and Septic Shock|Serial Vasopressin and Copeptin Levels in Children With Sepsis and Septic Shock|Completed|||136|Actual|KK Women's and Children's Hospital|||3||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 02:02:43.045213|2018-06-01 02:02:43.045213
NCT00698035|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2014-04-29||2014-05-27|2008-06-13|2008-06-16|Estimate|2014-05-27|2014-06-02|Estimate||||2014-05-27|2014-06-02|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|E-String|Baseline Characteristics for 75 participants who initiated treatment. One participant consented and was assigned to ESTRING, but did not insert ESTRING prior to withdrawing from the study.|Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients|A Phase II Study of Vaginal Testosterone Cream vs. the ESTRING for Vaginal Dryness or Decreased Libido in Early Breast Cancer Patients Treated With Aromatase Inhibitors|Completed||Phase 2|76|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:02:43.11967|2018-06-01 02:02:43.11967
NCT00698022|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2010-11-04||2012-05-01|2008-06-13|2008-06-16|Estimate|2012-05-01|2012-05-04|Estimate||||2012-05-01|2012-05-04|Estimate|November 2008||2008-11-30|May 2012|2012-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers|A 4-week, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers|Completed||Phase 2|76|Actual|Corcept Therapeutics||3|||f||||f||||||||||2018-06-01 02:02:43.548563|2018-06-01 02:02:43.548563
NCT00698009|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2012-10-23||2012-10-23|2008-06-13|2008-06-16|Estimate|2012-10-23|2012-11-22|Estimate||||2012-10-23|2012-11-22|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma|Study to Infuse Haploidentical Natural Killer Cells in Patients With Relapsed or Refractory Neuroblastoma|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 02:02:43.859974|2018-06-01 02:02:43.859974
NCT00697996|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-12-19|2008-06-13|2008-06-16|Estimate|||||||2008-12-19|2008-12-23|Estimate|June 2005||2005-06-30|December 2008|2008-12-31|August 2007||2007-08-31|||||Interventional|||Rituximab for Pediatric Renal Transplant Rejection|A Prospective Open-Labeled Randomized Study of Rituximab Versus Standard of Care, for Treatment of Acute Allograft Rejection in Pediatric Renal Transplantation|Completed||Phase 2/Phase 3|20||Stanford University|||||||||||||||||||2018-06-01 02:02:44.049706|2018-06-01 02:02:44.049706
NCT00697983|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2011-04-19|2008-06-13|2008-06-16|Estimate|||||||2011-04-19|2011-04-20|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|ATPBone||Cohort Study on Associations Between Purinergic Receptor SNPs and Osteoporosis Risk|Purinergic Signalling in Human Osteoporosis: Evaluation of Variability in Purinergic Receptor Genes and Receptor Function|Completed|||1000|Anticipated|Maastricht University Medical Center|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-06-01 02:02:44.121962|2018-06-01 02:02:44.121962
NCT00697970|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|November 1993||1993-11-30|June 2008|2008-06-30|April 1995|Actual|1995-04-30|April 1995|Actual|1995-04-30||Interventional|||Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine|Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine in Healthy Adult Volunteers|Completed||Phase 3|321|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 02:02:44.206409|2018-06-01 02:02:44.206409
NCT00697957|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|May 2002||2002-05-31|June 2008|2008-06-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Bone Adaptation to Impact Loading|Bone Adaptation to Impact Loading - Significance of Loading Intensity|Completed||N/A|120|Actual|University of Oulu||2|||f||||f||||||||||2018-06-01 02:02:44.297694|2018-06-01 02:02:44.297694
NCT00697944|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|March 2008||2008-03-31|March 2009|2009-03-31|March 2009|Anticipated|2009-03-31|February 2009|Anticipated|2009-02-28||Interventional|AMBIDEX||Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients|Ambisome® Preemptive Treatment of Multiple Colonizations by Candida in Intensive Care Patients With a Sepsis|Unknown status|Recruiting|Phase 4|30|Anticipated|Fovea|||||f||||t||||||||||2018-06-01 02:02:44.399816|2018-06-01 02:02:44.399816
NCT00697931|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|May 1997||1997-05-31|June 2008|2008-06-30|June 1998|Actual|1998-06-30|June 1998|Actual|1998-06-30||Interventional|||Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders|Study to Compare the Immunogenicity and Reactogenicity of GSK Biologicals; (Previously SmithKline Beecham Biologicals') MPL-Adjuvanted Recombinant Hepatitis B Vaccine With That of Engerix™-B in an Adult Non-Responder Population|Completed||Phase 3|116|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:02:44.522179|2018-06-01 02:02:44.522179
NCT00697918|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12||2013-01-15|2013-01-15|2008-06-12|2008-06-16|Estimate||||2013-01-15|2013-01-24|Estimate|2013-01-15|2013-01-24|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Long Term Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures|An Extension Study to Evaluate the Safety and Effectiveness of RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures|Completed||Phase 3|11|Actual|SK Life Science||1|||f||||||||||||||2018-06-01 02:02:44.617124|2018-06-01 02:02:44.617124
NCT00697905|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2014-11-20|2008-06-13|2008-06-16|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2008||2008-01-31|April 2010|2010-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma|An Open Labeled, Multicentre, Randomized Phase II Trial of Combination Gemcitabine and Carboplatin Chemotherapy in Patients With Metastatic or Recurrent Nasopharyngeal Carcinoma|Completed||Phase 2|18|Actual|Ministry of Health, Malaysia||2|||f||||f||||||||||2018-06-01 02:02:44.684054|2018-06-01 02:02:44.684054
NCT00697892|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2013-06-04|2008-06-11|2008-06-16|Estimate|||||||2013-06-04|2013-06-06|Estimate|July 2005||2005-07-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations|Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combinations, Artesunate/Amodiaquine and Artemether/Lumefantrine.|Completed||Phase 1|38|Actual|University of California, San Francisco||2|||f||||||||||||||2018-06-01 02:02:44.77393|2018-06-01 02:02:44.77393
NCT00697879|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2011-11-25|2008-06-13|2008-06-16|Estimate|||||||2011-11-25|2011-11-28|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours|A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours|Completed||Phase 1|40|Actual|Chroma Therapeutics||1|||f||||f||||||||||2018-06-01 02:02:44.854144|2018-06-01 02:02:44.854144
NCT00697866|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2016-09-15|2008-06-13|2008-06-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|August 2000||2000-08-31|September 2016|2016-09-30||||February 2001|Actual|2001-02-28||Interventional|||Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control|Evaluating the Consistency of 3 Consecutive Lots of GSK Biologicals' Novel Adjuvanted HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as a Control, Administered According to a 0, 1, 2-month Schedule in Healthy Volunteers (15-50y).|Completed||Phase 3|951|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:02:44.928816|2018-06-01 02:02:44.928816
NCT00697853|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|November 1998||1998-11-30|June 2008|2008-06-30||||July 1999|Actual|1999-07-31||Interventional|||Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults|Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine Administered According to a 0, 6 Month Schedule and of Engerix™-B Administered According to a 0, 1, 6 Month Schedule in Healthy Adults|Completed||Phase 2|200|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 02:02:45.044879|2018-06-01 02:02:45.044879
NCT00697840|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|June 1995||1995-06-30|June 2008|2008-06-30|January 1996|Actual|1996-01-31|January 1996|Actual|1996-01-31||Interventional|||Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B|Study to Assess the Safety, Immunogenicity and Reactogenicity of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Adjuvanted Recombinant Hepatitis B Vaccine, Recombinant Hepatitis B Vaccine New Formulation and Engerix™-B|Completed||Phase 3|150|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 02:02:45.129946|2018-06-01 02:02:45.129946
NCT00697827|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2012-05-03||2012-06-05|2008-06-13|2008-06-16|Estimate|2012-05-03|2012-06-05|Estimate||||2012-06-05|2012-06-11|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|In-Space||A Study of the In-Space Device for Treatment of Moderate Spinal Stenosis|A Multi-Center Randomized Controlled Trial of the In-Space Compared to X STOP® for Treatment of Moderate Degenerative Lumbar Spinal Stenosis|Terminated||Phase 3|44|Actual|Synthes USA HQ, Inc.|Study terminated early secondary to low enrollment leading to small number of subjects available for analyses.|2||Study terminated due to low enrollment.|f||||f||||||||||2018-06-01 02:02:45.218821|2018-06-01 02:02:45.218821
NCT00697814|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Clomiphene in Males With Prolactinomas and Persistent Hypogonadism|Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism|Completed||Phase 2|15|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-06-01 02:02:45.482284|2018-06-01 02:02:45.482284
NCT00697801|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2013-08-19||2013-12-09|2008-06-13|2008-06-16|Estimate|2013-08-19|2013-10-23|Estimate||||2013-12-09|2014-01-09|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional||The baseline characteristics are summarized on the Intent-to-treat population (those patients with at least 1 on treatment efficacy evaluation including 1 electronic diary entry).|Study of MAP0010 in Asthmatic Children and Adolescents|A Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group, Phase 2 Study Investigating the Efficacy, Tolerability and Pharmacokinetics of MAP0010 in Asthmatic Children and Adolescents Over 6 Weeks|Completed||Phase 2|208|Actual|Allergan||3|||f||||f||||||||||2018-06-01 02:02:45.553696|2018-06-01 02:02:45.553696
NCT00697788|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2016-12-06||2017-06-19|2008-06-12|2008-06-16|Estimate|2017-06-19|2017-07-17|Actual||||2017-06-19|2017-07-17|Actual|July 16, 2007|Actual|2007-07-16|June 2017|2017-06-30|December 30, 2008|Actual|2008-12-30|December 30, 2008|Actual|2008-12-30||Interventional|||Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients|Cardiovascular Safety of Dexmedetomidine in Pediatric Burn Patients.|Completed||Phase 2|8|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-06-01 02:02:45.840476|2018-06-01 02:02:45.840476
NCT00697775|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|March 1998||1998-03-31|June 2008|2008-06-30||||May 1999|Actual|1999-05-31||Interventional|||Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents|Study to Assess the Feasibility of GSK Bio's Candidate HBV / MPL Vaccines Following Different Schedules and Formulations and to Compare Their Safety and Immunogenicity to That of Engerix™-B in Healthy Adolescents Aged 11 to 15|Completed||Phase 2|200|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 02:02:46.404412|2018-06-01 02:02:46.404412
NCT00697762|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12||2013-01-07|2013-01-14|2008-06-12|2008-06-16|Estimate||||2013-01-07|2013-01-11|Estimate|2013-01-14|2013-01-23|Estimate|October 2007||2007-10-31|January 2013|2013-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures|A Double-Blind Study to Evaluate the Effectiveness and Safety of RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures|Terminated||Phase 3|56|Actual|SK Life Science||3||The trial was stopped based on information from the global phase 3 studies.|f||||f||||||||||2018-06-01 02:02:46.496368|2018-06-01 02:02:46.496368
NCT00697424|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-12-07|2008-06-12|2008-06-13|Estimate|||||||2008-12-07|2008-12-09|Estimate|May 2008||2008-05-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Comparison of Breathing Events Detected by the SleepStyle 200 Auto Continuous Positive Airway Pressure (CPAP) Device to Attended Polysomnography|Investigation of Methods to Detect Respiratory Irregularities in Obstructive Sleep Apnea (OSA)|Completed||N/A|20|Anticipated|Fisher and Paykel Healthcare||1|||f||||t||||||||||2018-06-01 02:02:51.352342|2018-06-01 02:02:51.352342
NCT00697749|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-09-15|2008-06-13|2008-06-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|April 1999||1999-04-30|September 2016|2016-09-30|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype|Phase III Study to Compare Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine Adminstered Intramuscularly, According to a 0, 6 Month Schedule, to Engerix™-B 20 mcg Administered According to a 0,1,6 Month Schedule in Healthy Volunteers Positive for the HLA-DQ2 Genotype|Completed||Phase 3|230|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:02:46.580135|2018-06-01 02:02:46.580135
NCT00697736|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2015-11-12|2008-06-13|2008-06-16|Estimate|||||||2015-11-12|2015-11-13|Estimate|March 2007||2007-03-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|HTAP-SCLERO||Cardiac Repercussion of Systemic Sclerodermias|Cardiac Repercussion of Systemic Sclerodermias : Detection of Infra-clinical Abnormalities by Analysis of the Myocardic Regional Function Using Myocardial Tissular Doppler Mode.|Completed||N/A|148|Actual|Hospices Civils de Lyon|||||f||||t||||||||||2018-06-01 02:02:46.721381|2018-06-01 02:02:46.721381
NCT00697723|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Arterial Versus Venous Graft Recruitment by Intra-Aortic Balloon Pump||Completed||Phase 4|138|Actual|University Magna Graecia|||||f||||||||||||||2018-06-01 02:02:46.800057|2018-06-01 02:02:46.800057
NCT00697710|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11||2018-04-26|2018-04-26|2008-06-13|2008-06-16|Estimate||||2018-04-26|2018-05-01|Actual|2018-04-26|2018-05-01|Actual|July 2007||2007-07-31|April 2018|2018-04-30|September 2008|Actual|2008-09-30|February 2008|Actual|2008-02-29||Interventional|||A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis|A Phase Ib/IIa, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Mild to Moderate Atopic Dermatitis|Completed||Phase 1/Phase 2|37|Actual|Shionogi Inc.||3|||f||||f||||||||||2018-06-01 02:02:46.878062|2018-06-01 02:02:46.878062
NCT00697697|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2013-08-19||2013-12-09|2008-06-12|2008-06-16|Estimate|2013-08-19|2013-10-23|Estimate||||2013-12-09|2014-01-09|Estimate|April 2008||2008-04-30|December 2013|2013-12-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional||Subjects were randomly assigned to treatment.|A Study of 2 Doses of MAP0010 in Asthmatic Children|A Randomized, Double-blind, Active-controlled, Phase 3 Extension Study Investigating the Safety and Efficacy Over 40 Weeks of 2 Doses of MAP0010 in Asthmatic Children (12 Months to 8 Years Old at the Time of Enrollment Into the MAP0010-CL-P301 Study)|Terminated||Phase 3|192|Actual|Allergan|The study was terminated due to a corporate decision before all subjects had completed the study.|2||Corporate decision|f||||f||||||||||2018-06-01 02:02:47.001181|2018-06-01 02:02:47.001181
NCT00697684|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2018-05-10|2008-06-13|2008-06-16|Estimate|||||||2018-05-10|2018-05-11|Actual|June 2008||2008-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant|A Reduced Intensity Conditioning With Clofarabine Antithymocyte Globulin and Total Lymphoid Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 1|30|Anticipated|Dana-Farber Cancer Institute||4|||f||||t||||||||||2018-06-01 02:02:47.274901|2018-06-01 02:02:47.274901
NCT00697671|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2013-07-15|2008-06-13|2008-06-16|Estimate|||||||2013-07-15|2013-07-16|Estimate|March 2007||2007-03-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies|Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies|Completed||Phase 1|48|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 02:02:47.375093|2018-06-01 02:02:47.375093
NCT00697658|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2014-04-24|2008-06-13|2008-06-16|Estimate|||||||2014-04-24|2014-04-28|Estimate|March 2008||2008-03-31|April 2014|2014-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia|INVega Is Studied In an Observational Design in the Netherlands|Completed|||27|Actual|Janssen-Cilag B.V.|||1||f||||f||||||||||2018-06-01 02:02:47.481623|2018-06-01 02:02:47.481623
NCT00697645|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2017-08-08|2008-06-13|2008-06-16|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2010||2010-12-31|August 2017|2017-08-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|tmstroke||Use of Deep Transcranial Magnetic Stimulation After Stroke|Phase 2 Double Blind Randomized Clinical Trial of Deep Transcranial Magnetic Stimulation After Stroke|Completed||N/A|15|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 02:02:47.574829|2018-06-01 02:02:47.574829
NCT00697632|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2018-02-26|2008-06-12|2008-06-16|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2008||2008-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies|Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies|Active, not recruiting||Phase 1|180|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 02:02:47.649164|2018-06-01 02:02:47.649164
NCT00697619|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2011-12-19||2012-03-04|2008-06-13|2008-06-16|Estimate|2012-01-31|2012-03-02|Estimate||||2012-03-04|2012-03-07|Estimate|September 2005||2005-09-30|December 2011|2011-12-31|September 2009|Actual|2009-09-30|January 2009|Actual|2009-01-31||Interventional|||To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer|A Prospective, Open-label, Randomized Phase III Study to Evaluate the Efficacy of ZOMETA® (Zoledronic Acid) in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer|Completed||Phase 2|60|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-06-01 02:02:47.754203|2018-06-01 02:02:47.754203
NCT00697606|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2015-12-29|2008-06-12|2008-06-16|Estimate|||||||2015-12-29|2015-12-30|Estimate|July 2008||2008-07-31|December 2015|2015-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SPARC||Seprafilm® for Prevention of Adhesions at Repeat Cesarean|Randomized Double-Blind Controlled Study to Determine if Seprafilm® Reduces Adhesions After Primary Cesarean Section|Terminated||Phase 3|450|Actual|Abington Memorial Hospital||2||lack of funding|f||||t||||||||||2018-06-01 02:02:48.00864|2018-06-01 02:02:48.00864
NCT00697086|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2009-07-28|2008-06-12|2008-06-13|Estimate|||||||2009-07-28|2009-07-30|Estimate|August 2002||2002-08-31|July 2009|2009-07-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|ERATO||European Study of Dronedarone in Atrial Fibrillation|Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO)|Completed||Phase 3|174|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:02:55.457754|2018-06-01 02:02:55.457754
NCT00697593|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2010-06-29||2014-01-20|2008-06-13|2008-06-16|Estimate|2010-08-04|2010-08-30|Estimate||||2014-01-20|2014-02-13|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|EASY||ChangE From Any Systemic psoriasiS therapY to Raptiva|A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or Psoralen-Ultraviolet Light A (PUVA), Narrow-Band Ultraviolet Light B (NBUVB) to Raptiva 1mg/kg/ Week Therapy.|Terminated||Phase 4|70|Actual|Merck KGaA||1||"The study was terminated after the European Medicines Agency recommended to suspend the~   marketing authorisation of Raptiva in the European Union"|f||||||||||||||2018-06-01 02:02:48.162528|2018-06-01 02:02:48.162528
NCT00697580|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2017-03-29|2008-06-11|2008-06-16|Estimate|||||||2017-03-29|2017-03-31|Actual|May 2005||2005-05-31|March 2017|2017-03-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|SANO LA||Strength and Nutrition Outcomes for Latino Adolescents|Intra-Abdominal Fat and Risk of Disease in Adolescents|Completed||N/A|104|Actual|University of Southern California||4|||f||||t||||||||No||2018-06-01 02:02:48.757826|2018-06-01 02:02:48.757826
NCT00697567|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2008-06-13|2008-06-13|2008-06-16|Estimate|||||||2008-06-13|2008-06-16|Estimate|September 1992||1992-09-30|June 2008|2008-06-30|December 1997|Actual|1997-12-31|December 1997|Actual|1997-12-31||Interventional|||Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant|Study in Healthy HSV Positive and HSV Negative Adults to Evaluate the Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Herpes Simplex (gD) Candidate Vaccine With or Without Adjuvant|Completed||Phase 2|80|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 02:02:48.82713|2018-06-01 02:02:48.82713
NCT00697554|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2016-09-08|2008-06-13|2008-06-16|Estimate|||||||2016-09-08|2016-09-09|Estimate|January 2000||2000-01-31|September 2016|2016-09-30||||May 2002|Actual|2002-05-31||Interventional|||Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age|Study to Compare the Immunogenicity and Safety of GSK Biologicals' Novel Adjuvanted HBV Vaccine (0, 21-day Schedule) to a Double Dose of Engerix™ -B (0, 7, 21-day Schedule), in Pre-liver Transplant Patients ≥ 18 y, Boosted at Month 6-12|Completed||Phase 3|93|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:02:48.893741|2018-06-01 02:02:48.893741
NCT00697541|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|2013-09-19|2010-10-16|2014-08-06|2008-06-12|2008-06-16|Estimate|2014-08-06|2014-08-07|Estimate|2010-12-02|2010-12-06|Estimate|2014-08-06|2014-08-07|Estimate|May 2008||2008-05-31|August 2014|2014-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%|A Phase II, Single-Center, Two-Way Crossover Relative Systemic Bioavailability Study of Col-118 Administered Topically as a 0.18 % Facial Gel and Brimonidine Ophthalmic Solution 0.2% Administered to the Eye in Subjects With Moderate to Severe Erythematous Rosacea|Completed||Phase 2|20|Actual|Galderma||2|||f||||f||||||||||2018-06-01 02:02:48.989477|2018-06-01 02:02:48.989477
NCT00697528|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2013-12-18|2008-06-13|2008-06-16|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy|Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy|Completed|||66|Actual|University of Sao Paulo|||3||f||||t||||||||||2018-06-01 02:02:50.145331|2018-06-01 02:02:50.145331
NCT00697515|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2009-11-20||2011-12-06|2008-06-13|2008-06-16|Estimate|2010-01-06|2010-02-01|Estimate||||2011-12-06|2011-12-12|Estimate|July 2008||2008-07-31|December 2011|2011-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|142|Actual|Shire||2|||f||||f||||||||||2018-06-01 02:02:50.241042|2018-06-01 02:02:50.241042
NCT00697502|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2012-10-31|2008-06-13|2008-06-16|Estimate|||||||2012-10-31|2012-11-01|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of Capecitabine In Patients With Solid Tumors|A Phase I Study of Capecitabine In Patients With Solid Tumors|Completed||Phase 1|23|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-06-01 02:02:50.874008|2018-06-01 02:02:50.874008
NCT00697489|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2013-04-05|2008-06-13|2008-06-16|Estimate|||||||2013-04-05|2013-04-08|Estimate|June 2008||2008-06-30|April 2013|2013-04-30||||August 2010|Actual|2010-08-31||Interventional|||Treatment of Urinary Stress Incontinence During or Following Correction of Pelvic Organ Prolapse|Pelvic Organ Prolapse Correction Plus Preventive Treatment of Urinary Stress Incontinence vs. Correction of Pelvic Organ Prolapse Followed by Treatment of Urinary Stress Incontinence|Withdrawn||Phase 4|0|Actual|University Magna Graecia||2|||f||||t||||||||||2018-06-01 02:02:50.955841|2018-06-01 02:02:50.955841
NCT00697476|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2013-05-27|2008-06-12|2008-06-13|Estimate|||||||2013-05-27|2013-05-29|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC|Phase I-II Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With Topotecan in Patients With Chemosensitive Recurrent Small Cell Lung Cancer (SCLC)|Terminated||Phase 1/Phase 2|2|Actual|Istituto Clinico Humanitas||1||insufficient enrollment|f||||f||||||||||2018-06-01 02:02:51.039551|2018-06-01 02:02:51.039551
NCT00697463|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-04-13|2008-06-11|2008-06-13|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2008||2008-08-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|IOPForteo||Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal Women|Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women|Unknown status|Active, not recruiting|Phase 2/Phase 3|27|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 02:02:51.111809|2018-06-01 02:02:51.111809
NCT00697450|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-11-22|2008-06-11|2008-06-13|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 2008||2008-07-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics|Observational Study Evaluating the Body Weight Progress During the Treatment With Insulin Detemir (Levemir®) in Type 2 Patients, Previously Treated With Other Basal Insulins|Completed|||206|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:02:51.215312|2018-06-01 02:02:51.215312
NCT00697437|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2013-12-08|2008-06-12|2008-06-13|Estimate|||||||2013-12-08|2013-12-10|Estimate|October 2006||2006-10-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel|Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel|Completed||Phase 2|10|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 02:02:51.285737|2018-06-01 02:02:51.285737
NCT00697411|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2018-01-07|2008-06-12|2008-06-13|Estimate|||||||2018-01-07|2018-01-09|Actual|October 2002|Actual|2002-10-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Study of Selected X-Linked Disorders: Aicardi Syndrome|Pathogenesis of Selected X-Linked Dominant Disorders and New Strategies to Identify the Gene Mutated in Aicardi Syndrome|Recruiting|||300|Anticipated|Baylor College of Medicine|||1||f||||f||||||Samples With DNA|"~     lymphoblast DNA; tissue~   "|Yes|patient data with all identification removed will be published following peer review in journals and/or presented at scientific meetings.|2018-06-01 02:02:51.422302|2018-06-01 02:02:51.422302
NCT00697398|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2014-08-27|2008-06-12|2008-06-13|Estimate|||||||2014-08-27|2014-08-28|Estimate|October 2008||2008-10-31|January 2010|2010-01-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Repetitive Trans-cranial Magnetic Stimulation of the Motor Cortex in Fibromyalgia: A Study Evaluating the Clinical Efficiency and the Metabolic Correlate in 18FDG-PET|Repetitive Trans-cranial Magnetic Stimulation of the Motor Cortex in Fibromyalgia: A Prospective Randomized Blinded Placebo-controlled Study Evaluating the Clinical Efficiency and the Metabolic Correlate in 18FDG-PET|Completed||N/A|38|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 02:02:51.505439|2018-06-01 02:02:51.505439
NCT00697385|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-09-18|2008-06-11|2008-06-13|Estimate|||||||2008-09-18|2008-09-19|Estimate|April 2003||2003-04-30|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders|Open Label Continuation Study for the Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders|Completed||N/A|13|Actual|Mary M. Gooley Hemophilia Center||1|||f||||f||||||||||2018-06-01 02:02:51.580898|2018-06-01 02:02:51.580898
NCT00697372|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2010-06-14|2008-06-12|2008-06-13|Estimate|||||||2010-06-14|2010-06-15|Estimate|September 2007||2007-09-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|October 2008|Actual|2008-10-31||Interventional|SEA-SIDE||SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis|Completed||Phase 4|150|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 02:02:51.768304|2018-06-01 02:02:51.768304
NCT00697359|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-09-27|2008-06-11|2008-06-13|Estimate|||||||2016-09-27|2016-09-28|Estimate|June 2008||2008-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Implantable Loop Recorder Versus Conventional Ambulatory Monitoring in Detecting Atrial Fibrillation After Pulmonary Vein Isolation|An Observational Study to Assess the Efficacy of Continuous Subcutaneous Arrhythmia Monitoring Versus Conventional Ambulatory ECG-monitoring in Detecting Atrial Fibrillation in Patients After Pulmonary Vein Isolation|Completed||N/A|57|Actual|Odense University Hospital||1|||f||||f||||||||No||2018-06-01 02:02:51.886084|2018-06-01 02:02:51.886084
NCT00697346|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2017-03-29|2008-06-12|2008-06-13|Estimate|||||||2017-03-29|2017-03-31|Actual|October 7, 2008|Actual|2008-10-07|March 2017|2017-03-31|November 27, 2016|Actual|2016-11-27|October 1, 2016|Actual|2016-10-01||Interventional|||Study of MLN8237 in Participants With Advanced Hematological Malignancies|An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies|Completed||Phase 1|58|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:02:51.976191|2018-06-01 02:02:51.976191
NCT00697333|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-07-13|2008-06-12|2008-06-13|Estimate|||||||2016-07-13|2016-07-14|Estimate|May 2009||2009-05-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|PET-Plan||Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC|Optimisation of Radiotherapy-Planning in Patients With Inoperable Locally Advanced Non-Small-Cell Lung Cancer by FDG-PET|Recruiting||Phase 2|200|Anticipated|Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DEGRO und DGN||2|||f||||t||||||||Yes||2018-06-01 02:02:52.103659|2018-06-01 02:02:52.103659
NCT00697320|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-12-06|2008-06-12|2008-06-13|Estimate|||||||2016-12-06|2016-12-07|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|WIRK||"Observational Study on the Efficacy and Safety of NovoSeven® During Real-life Usage in Germany"|Efficacy of NovoSeven® (Activated Recombinant Human Factor VII): Non-interventional Study in Patients With Congenital Haemophilia With Inhibitors, Acquired Haemophilia, Factor FVII Deficiency, and Glanzmann's Thrombasthenia|Completed|||64|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:02:52.214849|2018-06-01 02:02:52.214849
NCT00697307|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2011-06-06|2008-06-11|2008-06-13|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2003||2003-03-31|March 2010|2010-03-31|July 2003|Actual|2003-07-31|||||Observational|||Bioequivalence Study of Patches With Different Release Profiles|A Bioequivalence Study Of A Low Cumulative Release Lot Of Norelgestromin (NGMN)/Ethinyl Estradiol (EE) Transdermal Contraceptive Systems Compared With Currently Marketed Ortho-Evra In Healthy Female Volunteers|Completed|||43|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:02:52.300401|2018-06-01 02:02:52.300401
NCT00697294|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2011-12-02|2008-06-11|2008-06-13|Estimate|||||||2011-12-02|2011-12-05|Estimate|July 2008||2008-07-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Impact of Vitamin D Status on Bones in Breastfed Infants|Vitamin D Status and Impact on Bone Mineralization in Human Milk Fed Hispanic and Caucasian Infants|Completed||N/A|80|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 02:02:52.374854|2018-06-01 02:02:52.374854
NCT00697281|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2009-02-23|2008-06-12|2008-06-13|Estimate|||||||2009-02-23|2009-02-24|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||OC000459 Dose Finding Study in Hay Fever Sufferers.|A Dose Finding Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis.|Completed||Phase 2|120|Anticipated|Oxagen Ltd||5|||f||||f||||||||||2018-06-01 02:02:52.480197|2018-06-01 02:02:52.480197
NCT00697268|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2017-10-05|2008-06-12|2008-06-13|Estimate|||||||2017-10-05|2017-10-06|Actual|June 3, 2008||2008-06-03|July 28, 2016|2016-07-28|July 28, 2016||2016-07-28|||||Observational|||p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram|An Investigation to Determine Whether Levels of P11 Protein in Peripheral Blood Cells Correlate With Treatment Response to Citalopram in Patients With Major Depressive Disorder|Completed|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:02:52.590437|2018-06-01 02:02:52.590437
NCT00697073|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2011-06-07||2013-05-24|2008-06-12|2008-06-13|Estimate|2011-07-11|2011-08-04|Estimate||||2013-05-24|2013-06-04|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|IONIA-E||Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|Completed||Phase 3|68|Actual|Santhera Pharmaceuticals||1|||f||||t||||||||||2018-06-01 02:02:55.550464|2018-06-01 02:02:55.550464
NCT00697255|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2014-03-28||2017-03-17|2008-06-12|2008-06-13|Estimate|2014-05-20|2014-06-09|Estimate||||2017-03-17|2017-04-14|Actual|May 2007||2007-05-31|March 2017|2017-03-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)|A Phase II, Randomized, Controlled, Open-label, Feasibility Trial to Evaluate if a Single or Repeated Dose of Org 36286 (Corifollitropin Alfa) Followed by a Low Daily Dose of Either hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility|Terminated||Phase 2|8|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:02:52.701044|2018-06-01 02:02:52.701044
NCT00697242|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|January 1994||1994-01-31|June 2008|2008-06-30|November 1995|Actual|1995-11-30|November 1995|Actual|1995-11-30||Interventional|||Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults|Study to Compare the Immunogenicity, Safety and Reactogenicity of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccines With and Without Adjuvant in Healthy Older Adult Volunteers|Completed||Phase 3|362|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 02:02:53.031154|2018-06-01 02:02:53.031154
NCT00697229|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|September 1992||1992-09-30|June 2008|2008-06-30|December 1998|Actual|1998-12-31|May 1996|Actual|1996-05-31||Interventional|||Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules|Study to Evaluate the Immunogenicity and Reactogenicity of GSK Biologicals' MPL-Adjuvanted Recombinant Hepatitis B Vaccine in Comparison With Those of Engerix™-B in Healthy Adult Volunteers Following 2 Different Schedules|Completed||Phase 2|99|Actual|GlaxoSmithKline||8|||f||||||||||||||2018-06-01 02:02:53.122488|2018-06-01 02:02:53.122488
NCT00697216|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|March 1997||1997-03-31|June 2008|2008-06-30||||March 1999|Actual|1999-03-31||Interventional|||Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).|Study Comparing the Immunogenicity and Reactogenicity of GSK Biologicals' HBV-MPL Vaccine Injected According to a 0, 6 Months Schedule With That of Engerix™-B Injected as a 0, 1, 6 Months Schedule in a Healthy Adult Population (15-40 Years)|Completed||Phase 3|340|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:02:53.203296|2018-06-01 02:02:53.203296
NCT00697203|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2016-11-01|2008-06-11|2008-06-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2005||2005-07-31|November 2016|2016-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)|A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels|Completed||Phase 2|292|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 02:02:53.281359|2018-06-01 02:02:53.281359
NCT00697190|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2010-09-09||2015-05-06|2008-06-12|2008-06-13|Estimate|2010-09-09|2010-10-01|Estimate||||2015-05-06|2015-05-22|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Clinical Performance of Atypical Contact Lens Powers on Subjects With Astigmatism||Completed||N/A|39|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 02:02:53.486709|2018-06-01 02:02:53.486709
NCT00697177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-02-12|2008-06-12|2008-06-13|Estimate|||||||2013-02-12|2013-02-15|Estimate|July 2005||2005-07-31|September 2005|2005-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||The Prevalence of Gastro-oesophageal Reflux in Chronic Lung Disease|The Prevalence of Gastro-oesophageal Reflux in Chronic Obstructive Pulmonary Disease and Bronchiectasis and the Effects of Medications, Physiotherapy Airway Clearance Techniques and Exercise on Gastro-oesophageal Function.|Completed|||75|Actual|Bayside Health|||||f||||||||||||||2018-06-01 02:02:53.973207|2018-06-01 02:02:53.973207
NCT00697164|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-12|2008-06-12|2008-06-13|Estimate|||||||2008-06-12|2008-06-13|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|March 2009|Anticipated|2009-03-31|December 2008|Anticipated|2008-12-31||Interventional|EPOMAL||Randomized Trial of Erythropoietin During Cerebral Malaria|Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|Claude Bernard University||2|||f||||t||||||||||2018-06-01 02:02:54.042352|2018-06-01 02:02:54.042352
NCT00697151|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2011-09-14|2008-06-11|2008-06-13|Estimate|||||||2011-09-14|2011-09-15|Estimate|June 1993||1993-06-30|September 2011|2011-09-30|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|PICSS||Patent Foramen Ovale in Cryptogenic Stroke Study|Patent Foramen Ovale in Cryptogenic Stroke Study|Completed||Phase 4|630|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 02:02:54.182142|2018-06-01 02:02:54.182142
NCT00697138|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2012-02-29|2008-06-11|2008-06-13|Estimate|||||||2012-02-29|2012-03-01|Estimate|June 2006||2006-06-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Agonist Replacement Therapy for Cocaine Dependence|Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications|Completed||Phase 1|46|Actual|University of Kentucky||1|||f||||t||||||||||2018-06-01 02:02:54.265016|2018-06-01 02:02:54.265016
NCT00697125|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|June 1993||1993-06-30|June 2008|2008-06-30|July 1994|Actual|1994-07-31|July 1994|Actual|1994-07-31||Interventional|||Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants|Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of GSK Biologicals' (Previously SmithKline Beecham Biologicals') Recombinant Hepatitis B Vaccine With Different Adjuvants in Healthy Adult Volunteers|Completed||Phase 2|60|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 02:02:54.348605|2018-06-01 02:02:54.348605
NCT00697112|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2013-12-03||2013-12-03|2008-06-12|2008-06-13|Estimate|2013-12-03|2014-01-22|Estimate||||2013-12-03|2014-01-22|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational||Safety population included all participants who had received at least 1 dose of Rapamune and were subsequently interrogated.|Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)|Surveillance Registry Of Sirolimus Use In Recipients Of Kidney Allograft From Expanded Criteria Donors (ECD)|Completed|||53|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:02:54.509189|2018-06-01 02:02:54.509189
NCT00697099|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12||2010-12-20|2013-01-14|2008-06-12|2008-06-13|Estimate||||2010-12-20|2010-12-28|Estimate|2013-01-14|2013-01-23|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SAVE-HIP1||Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery|A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery|Completed||Phase 3|2326|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:02:55.286316|2018-06-01 02:02:55.286316
NCT00697060|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2015-06-22|2008-06-12|2008-06-13|Estimate|||||||2015-06-22|2015-06-24|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Interventional|||A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer|A Multicenter, Phase II Trial of the Safety and Efficacy of Amplimexon® (Imexon for Injection) in Combination With Taxotere® (Docetaxel) for Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|AmpliMed Corporation||1||Study cancelled prior to start due to change in company priorities.|f||||||||||||||2018-06-01 02:02:55.809208|2018-06-01 02:02:55.809208
NCT00697047|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2018-03-15|2008-06-12|2008-06-13|Estimate|||||||2018-03-15|2018-03-19|Actual|July 2008||2008-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SOS||Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up|Systems of Support to Increase Colon Cancer Screening and Follow-up|Active, not recruiting||N/A|4653|Actual|Kaiser Permanente||4|||f||||f||||||||Yes|Yes, a de-identified data set will be available and shared upon request.|2018-06-01 02:02:55.896821|2018-06-01 02:02:55.896821
NCT00697034|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-02-15|2008-06-12|2008-06-13|Estimate|||||||2017-02-15|2017-02-17|Actual|June 2006||2006-06-30|February 2017|2017-02-28|December 2008|Actual|2008-12-31|August 2007|Actual|2007-08-31||Interventional|||Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin|Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin|Terminated||Phase 4|12|Actual|Wake Forest University Health Sciences||1||Lack of qualified and willing volunteers.|f||||f||||||||||2018-06-01 02:02:56.007991|2018-06-01 02:02:56.007991
NCT00697021|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-12|2008-06-12|2008-06-13|Estimate|||||||2008-06-12|2008-06-13|Estimate|June 2008||2008-06-30|April 2008|2008-04-30|October 2009|Anticipated|2009-10-31|June 2009|Anticipated|2009-06-30||Interventional|TEG||Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance|Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI|Unknown status|Recruiting|Phase 3|50|Anticipated|Assaf-Harofeh Medical Center||2|||f||||t||||||||||2018-06-01 02:02:56.080452|2018-06-01 02:02:56.080452
NCT00697008|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-02-09|2008-06-12|2008-06-13|Estimate|||||||2009-02-09|2009-02-10|Estimate|December 2007||2007-12-31|February 2009|2009-02-28||||January 2009|Actual|2009-01-31||Observational|Prospect||Asociación Española de Gastroenterologia (Spanish Gastroenterology Association) Gastroesophageal Reflux Disease Guideline - Prospective Study|Symptomatic Assessment and Therapeutic Outcomes in Typical GERD Patients Following a New CP Guideline in the Clinical Practice|Completed|||300|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:02:56.179917|2018-06-01 02:02:56.179917
NCT00696995|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2017-01-06|2008-06-11|2008-06-13|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|Start||An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment|An Observational, Prospective Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix® 30 (Biphasic Insulin Aspart) Treatment|Completed|||509|Actual|Novo Nordisk A/S|||1||f||||f||||||None Retained|"~     Venous blood samples drawn as part of routine clinical evaluation~   "|||2018-06-01 02:02:56.299607|2018-06-01 02:02:56.299607
NCT00696982|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-12|2008-06-12|2008-06-13|Estimate|||||||2008-06-12|2008-06-13|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation|The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation|Unknown status|Recruiting|N/A|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 02:02:56.395144|2018-06-01 02:02:56.395144
NCT00696969|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2010-02-10|2008-06-12|2008-06-13|Estimate|||||||2010-02-10|2010-02-11|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis|Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL).|Completed||Phase 3|634|Actual|Drugs for Neglected Diseases||4|||f||||t||||||||||2018-06-01 02:02:56.503808|2018-06-01 02:02:56.503808
NCT00696956|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-12|2008-06-12|2008-06-13|Estimate|||||||2008-06-12|2008-06-13|Estimate|April 2008||2008-04-30|May 2008|2008-05-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|Piccolo||Drug Coated Balloons for Prevention of Restenosis|Paclitaxel Coated Balloons for Prevention of Restenosis in Small Arteries Below the Knee Compared to Angioplasty Using Uncoated Balloons|Unknown status|Recruiting|Phase 2/Phase 3|114|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 02:02:56.593412|2018-06-01 02:02:56.593412
NCT00696943|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2013-02-13|2008-06-11|2008-06-13|Estimate|||||||2013-02-13|2013-02-15|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||18F ML-10 for Early Detection of Response of Brain Metastases to SRS|An Open-label, Multi-center Study to Evaluate [18F]-ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Stereotactic Radio Surgery (SRS)|Terminated||Phase 2|1|Actual|Aposense Ltd.||1||Replaced by a global study protocol NST-CA004|f||||t||||||||||2018-06-01 02:02:56.710924|2018-06-01 02:02:56.710924
NCT00696930|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2015-11-24|2008-06-12|2008-06-13|Estimate|||||||2015-11-24|2015-11-26|Estimate|June 2008||2008-06-30|November 2015|2015-11-30||||June 2008|Actual|2008-06-30||Interventional|||Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors|A Phase II Open-label Multi-center Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors|Withdrawn||Phase 2|0|Actual|Molecular Insight Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 02:02:56.83018|2018-06-01 02:02:56.83018
NCT00696917|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|April 1999||1999-04-30|June 2008|2008-06-30||||February 2000|Actual|2000-02-29||Interventional|||Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y|Safety and Immunogenicity of 3 Lots of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine, Administered According to a 2 Dose Schedule, and Engerix™-B Administered According to a 3 Dose Schedule to Healthy Volunteers ≥ 15 Years of Age|Completed||Phase 3|1303|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 02:02:56.892069|2018-06-01 02:02:56.892069
NCT00696904|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2017-11-17|2008-06-12|2008-06-13|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2008||2008-06-30|September 2010|2010-09-30||||February 2009|Actual|2009-02-28||Interventional|||Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects||Completed||Phase 1|133|Actual|AbbVie||3|||f||||||||||||||2018-06-01 02:02:56.98682|2018-06-01 02:02:56.98682
NCT00696891|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|June 1997||1997-06-30|June 2008|2008-06-30||||May 1999|Actual|1999-05-31||Interventional|||Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults|Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine With That of Engerix™-B When Both Are Injected According to 3 Dose Schedule (0, 1, 6 Months) in an Adult Population Aged Between 50 and 70 Years|Completed||Phase 3|380|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:02:57.060821|2018-06-01 02:02:57.060821
NCT00696878|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2015-04-06||2017-03-20|2008-06-11|2008-06-13|Estimate|2015-04-06|2015-04-23|Estimate||||2017-03-20|2017-04-17|Actual|September 26, 2006|Actual|2006-09-26|March 2017|2017-03-31|May 15, 2009|Actual|2009-05-15|February 17, 2009|Actual|2009-02-17||Interventional|Trust||Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)|A Phase III, Uncontrolled Trial to Assess the Non-immunogenicity and Safety of Org 36286 in Patients Undergoing Repeated Controlled Ovarian Stimulation Cycles Using a Multiple Dose GnRH Antagonist Protocol|Completed||Phase 3|682|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:02:57.235293|2018-06-01 02:02:57.235293
NCT00696865|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2009-07-15|2008-06-12|2008-06-13|Estimate|||||||2009-07-15|2009-07-16|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|||||Interventional|JMAD||AZD2624 Multiple Ascending Dose Study in Japan|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2624 When Given in Multiple Ascending Oral Doses in Young Healthy Male Japanese Subjects|Completed||Phase 1|30|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:02:58.4289|2018-06-01 02:02:58.4289
NCT00696852|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2012-09-20|2008-06-12|2008-06-13|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Mindfulness, Yoga, and Cardiovascular Disease|Effects of Mindfulness and Yoga on Heart Rate Variability and Immune Markers|Completed||N/A|64|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-06-01 02:02:58.514904|2018-06-01 02:02:58.514904
NCT00696839|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2010-03-01|2008-06-12|2008-06-13|Estimate|||||||2010-03-01|2010-03-02|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Trial of Cognitive Behavioral Therapy to Reduce Antiretroviral Therapy Side Effects|Clinical Trial Of Cognitive-behavioral Therapy To Reduce Antiretroviral Side Effects In HIV Patients|Completed||N/A|29|Actual|Duquesne University||2|||f||||t||||||||||2018-06-01 02:02:58.616287|2018-06-01 02:02:58.616287
NCT00696826|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2015-08-18|2008-06-11|2008-06-13|Estimate|||||||2015-08-18|2015-08-19|Estimate|April 2004||2004-04-30|August 2015|2015-08-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)|An Open-Label, Single Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK0431|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:02:58.724253|2018-06-01 02:02:58.724253
NCT00696813|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2013-02-04|2008-06-11|2008-06-13|Estimate|||||||2013-02-04|2013-02-05|Estimate|June 2008||2008-06-30|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|PILAR||Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral Antipsychotics|PILAR: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry|Completed|||3064|Actual|Janssen-Cilag International NV|||2||f||||f||||||||||2018-06-01 02:02:58.813808|2018-06-01 02:02:58.813808
NCT00696800|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2014-08-06|2009-05-14|2017-03-22|2008-06-11|2008-06-13|Estimate|2014-08-06|2014-08-21|Estimate|2009-10-02|2009-10-06|Estimate|2017-03-22|2017-04-18|Actual|June 27, 2006|Actual|2006-06-27|March 2017|2017-03-31|January 15, 2008|Actual|2008-01-15|November 19, 2007|Actual|2007-11-19||Interventional||The ITT group consisting of randomized participants treated with Corifollitropin Alfa or recFSH|A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)|A Phase III, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as Reference|Completed||Phase 3|1509|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:02:59.067772|2018-06-01 02:02:59.067772
NCT00696787|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2010-01-29||2013-02-20|2008-06-12|2008-06-13|Estimate|2010-01-29|2010-02-23|Estimate||||2013-02-20|2013-02-25|Estimate|June 2008||2008-06-30|February 2013|2013-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of DVS SR in Adult Female Outpatients With Fibromyalgia Syndrome|Terminated||Phase 2|125|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 02:02:59.720939|2018-06-01 02:02:59.720939
NCT00696774|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2010-07-15||2010-09-02|2008-06-11|2008-06-13|Estimate|2010-07-15|2010-08-11|Estimate||||2010-09-02|2010-09-08|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ARDENT||Switching to Duloxetine in Patients With Depression|Attributes of Response in Depressed Patients Switched to Treatment With Duloxetine (ARDENT Study)|Completed||Phase 4|242|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:03:00.086997|2018-06-01 02:03:00.086997
NCT00696761|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2013-07-22||2018-02-08|2008-06-12|2008-06-13|Estimate|2014-01-15|2014-03-04|Estimate||||2018-02-08|2018-02-12|Actual|May 2006||2006-05-31|February 2018|2018-02-28|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients|The Long Term Effects of Alfuzosin(Xatral XL) in LUTS/BPH Patients: Evaluation of Voiding and Storage Function According to Bladder Outlet Obstruction Grade and Bladder Contractility|Completed||Phase 4|232|Actual|Asan Medical Center|Patients were not divided into three groups according to the ICS nomogram (obstructed [BOOI <40], equivocally obstructed (20 <BOOI <40), and unobstructed [BOOI <20]).|4|||f||||f||||||||||2018-06-01 02:03:01.9234|2018-06-01 02:03:01.9234
NCT00696748|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|October 2005||2005-10-31|June 2008|2008-06-30|December 2010|Anticipated|2010-12-31|January 2009|Anticipated|2009-01-31||Interventional|NePlaM3||The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men|A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men|Unknown status|Recruiting|Phase 3|250|Anticipated|Russian Academy of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:03:02.345691|2018-06-01 02:03:02.345691
NCT00696735|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-10-23|2008-06-12|2008-06-13|Estimate|||||||2008-10-23|2008-10-24|Estimate|June 1994||1994-06-30|September 2006|2006-09-30|May 2006|Actual|2006-05-31|May 2003|Actual|2003-05-31||Interventional|||High-Dose Therapy Treatment in Patients With Follicular Lymphoma|Randomized Phase III Study Comparison Between Conventional Chemotherapy and High-Dose Therapy Followed by Autologous Purged Stem-Cell Transplantation in Patients With Follicular Lymphoma Stage III,IV First-Line Treatment for Patients Younger Than 60 Years Old With a High Tumor Burden|Completed||Phase 3|172|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||||2018-06-01 02:03:02.435498|2018-06-01 02:03:02.435498
NCT00696722|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2010-01-24|2008-06-12|2008-06-13|Estimate|||||||2010-01-24|2010-01-26|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|DM2ATV||Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction|Influence of Atazanavir Treatment on Endothelial Dysfunction, Vascular Inflammation and Heme Oxygenase Activity in Type 2 Diabetes Mellitus|Completed||Phase 2|16|Anticipated|Radboud University||2|||f||||||||||||||2018-06-01 02:03:02.511042|2018-06-01 02:03:02.511042
NCT00696709|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2015-10-05|2008-06-12|2008-06-13|Estimate|||||||2015-10-05|2015-10-06|Estimate|December 2008||2008-12-31|October 2015|2015-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)|A Phase I, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults|Completed||Phase 1|160|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 02:03:02.594877|2018-06-01 02:03:02.594877
NCT00696696|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2011-11-18||2016-05-31|2008-06-12|2008-06-13|Estimate|2011-11-18|2011-12-21|Estimate||||2016-05-31|2016-06-30|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|June 2013|Actual|2013-06-30|November 2010|Actual|2010-11-30||Interventional|||Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer|A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer|Completed||Phase 2|45|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 02:03:02.77826|2018-06-01 02:03:02.77826
NCT00696683|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2008-06-11|2008-06-11|2008-06-13|Estimate|||||||2008-06-11|2008-06-13|Estimate|August 2004||2004-08-31|June 2008|2008-06-30|July 2005|Actual|2005-07-31|August 2004|Actual|2004-08-31||Observational|||Establishment of Natural History of Scorpion Envenomation|Establishment of Natural History of Scorpion Envenomation in the Absence of Antivenom Treatment in Pediatric Patients|Completed|||97|Actual|Instituto Bioclon S.A. de C.V.|||1||f||||f||||||||||2018-06-01 02:03:03.089285|2018-06-01 02:03:03.089285
NCT00696657|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11||2010-11-09|2017-02-24|2008-06-12|2008-06-13|Estimate||||2011-03-03|2011-03-16|Estimate|2017-02-24|2017-02-27|Actual|June 3, 2008|Actual|2008-06-03|February 2017|2017-02-28|February 5, 2009|Actual|2009-02-05|February 5, 2009|Actual|2009-02-05||Interventional|||A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide|Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial|Completed||Phase 2|415|Actual|Novo Nordisk A/S||14|||f||||f||||||||||2018-06-01 02:03:03.226837|2018-06-01 02:03:03.226837
NCT00696644|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2011-05-05|2008-06-11|2008-06-13|Estimate|||||||2011-05-05|2011-05-09|Estimate|June 2008||2008-06-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|ISSO||A Study for Teriparatide in Severe Osteoporosis|An Italian Observational Study to Evaluate Fracture Outcomes, Compliance to Treatment, Back Pain, Health-related Quality of Life in Patients With Severe Osteoporosis Treated According to Common Clinical Practice|Completed|||794|Actual|Eli Lilly and Company|||1||f||||f||||||||||2018-06-01 02:03:03.498202|2018-06-01 02:03:03.498202
NCT00696631|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-12|||2010-02-12|2008-06-12|2008-06-13|Estimate|||||||2010-02-12|2010-02-15|Estimate|June 2002||2002-06-30|February 2010|2010-02-28|August 2003|Actual|2003-08-31|January 2003|Actual|2003-01-31||Interventional|ANDROMEDA||European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure|Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease|Terminated||Phase 3|653|Actual|Sanofi||2||Terminated as the active treatment was associated with an increased hazard|f||||t||||||||||2018-06-01 02:03:03.593875|2018-06-01 02:03:03.593875
NCT00696618|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2016-12-05||2017-03-20|2008-06-11|2008-06-13|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|July 2007||2007-07-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|July 2009|Actual|2009-07-31||Interventional|||Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men|A Randomized, Blinded, Comparative Study of the Mucosal Toxicity, Colorectal Distribution, and Participant Acceptability of Three Different Preparatory Enemas (Hypo-, Iso-, and Hyper-osmolar)|Completed||N/A|9|Actual|Johns Hopkins University||3|||f||||t||||||||No||2018-06-01 02:03:03.719077|2018-06-01 02:03:03.719077
NCT00696605|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2017-02-23|2008-06-11|2008-06-12|Estimate|||||||2017-02-23|2017-02-27|Actual|July 2008||2008-07-31|February 2017|2017-02-28|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Observational|||Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion|Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion|Completed|||20|Actual|Hospital Centre Biel/Bienne|||||f||||f||||||||||2018-06-01 02:03:04.064366|2018-06-01 02:03:04.064366
NCT00696592|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-10|2008-06-10|2008-06-12|Estimate|||||||2008-06-10|2008-06-12|Estimate|January 2007||2007-01-31|April 2007|2007-04-30||||||||Interventional|ARMAST||Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-Related Macular Degeneration|A Randomized, Controlled, Open Label, Phase II Study of Visudyne® Photodynamic Therapy (PDT) Combined With Bevacizumab (Avastin) vs Avastin Alone in Patients With Neovascular Age-Related Macular Degeneration (AMD)|Unknown status|Recruiting|Phase 2|80|Anticipated|University of Padova|||||f||||t||||||||||2018-06-01 02:03:04.24811|2018-06-01 02:03:04.24811
NCT00696579|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-10|2008-06-10|2008-06-12|Estimate|||||||2008-06-10|2008-06-12|Estimate|January 2004||2004-01-31|June 2008|2008-06-30||||March 2008||2008-03-31||Interventional|||Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer|BCG vs. Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer: A Randomized Prospective Study|Completed||Phase 1/Phase 2|64|Actual|University Of Perugia||2|||f||||f||||||||||2018-06-01 02:03:04.339543|2018-06-01 02:03:04.339543
NCT00696566|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Healthy Volunteer Study of Clopidogrel and Rifampicin|Study of the Potentiation of the Effects of Clopidogrel by Rifampicin in Healthy Volunteers|Completed||Phase 1|12|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-06-01 02:03:04.41929|2018-06-01 02:03:04.41929
NCT00696553|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2011-07-25|2008-06-09|2008-06-12|Estimate|||||||2011-07-25|2011-07-27|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|ELAF||Nutrition and Resistance Training in Head and Neck Cancer|Randomized Trial of Specialized Nutrition Therapy (SNT) Versus SNT Plus Resistance Training (RT) in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation Therapy (CCR)|Completed||Phase 3|60|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:03:04.511182|2018-06-01 02:03:04.511182
NCT00696540|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-09|2008-06-09|2008-06-12|Estimate|||||||2008-06-09|2008-06-12|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|September 2008|Anticipated|2008-09-30||Interventional|Hypertonic||Hypertonic Saline for Outpatient Bronchiolitis|Safety and Efficacy of Hypertonic Vrs. Normal Saline as Diluent of Salbutamol to Reduce Respiratory Distress in Outpatients With the Clinical Diagnosis of Bronchiolitis During the RSV Epidemic.|Unknown status|Recruiting|Phase 2|74|Anticipated|University Diego Portales||2|||f||||t||||||||||2018-06-01 02:03:04.579477|2018-06-01 02:03:04.579477
NCT00696527|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2010-12-09|2008-06-11|2008-06-12|Estimate|||||||2010-12-09|2010-12-10|Estimate|June 2007||2007-06-30|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|CSI||National Survey on Infiltrative Breast Cancer|National Prospective Survey on Women With a Diagnosis of Infiltrative Breast Cancer|Completed|||1500|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:03:04.715272|2018-06-01 02:03:04.715272
NCT00696514|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2011-08-24|2008-06-09|2008-06-12|Estimate|||||||2011-08-24|2011-08-25|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|B-PROOF||Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People|Vitamin B12 and Folic Acid Supplementation for Preventing Fractures in Elderly People|Unknown status|Active, not recruiting|Phase 1|3000|Anticipated|Wageningen University||2|||f||||t||||||||||2018-06-01 02:03:05.003298|2018-06-01 02:03:05.003298
NCT00696501|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2017-08-22|2008-06-10|2008-06-12|Estimate|||||||2017-08-22|2017-08-24|Actual|May 2006||2006-05-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Direct Stimulation Of Spinal Nerve Roots To Determine Sensory And Motor Innervation Patterns|Direct Stimulation Of Spinal Nerve Roots To Determine Sensory And Motor Innervation Patterns|Terminated|||203|Actual|Lahey Clinic||||One of the investigators left the Institution|f||||f||||||||||2018-06-01 02:03:05.137669|2018-06-01 02:03:05.137669
NCT00696488|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2017-02-06||2017-11-01|2008-06-10|2008-06-12|Estimate|2017-02-06|2017-03-27|Actual||||2017-11-01|2017-12-06|Actual|April 2007||2007-04-30|November 2017|2017-11-30|October 2008|Actual|2008-10-31|August 2007|Actual|2007-08-31||Interventional|||Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population|Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population|Completed||Phase 4|20|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-06-01 02:03:05.229076|2018-06-01 02:03:05.229076
NCT00696475|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2010-11-04|2008-06-10|2008-06-12|Estimate|||||||2010-11-04|2010-11-08|Estimate|June 2008||2008-06-30|November 2010|2010-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Diazoxide Choline in Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects|Completed||Phase 2|80|Anticipated|Essentialis, Inc.||4|||f||||f||||||||||2018-06-01 02:03:05.36026|2018-06-01 02:03:05.36026
NCT00696462|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2012-09-11|2008-06-09|2008-06-12|Estimate|||||||2012-09-11|2012-09-13|Estimate|March 2007||2007-03-31|September 2012|2012-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||The Effect of Forced Air Warming During Cesarean Section on Postoperative Infectious Morbidity|The Effect of Forced Air Warming During Cesarean Section on Postoperative Infectious Morbidity|Withdrawn||N/A|0|Actual|Vanderbilt University||2||Study terminated for lack of funds to initiate study|f||||t||||||||||2018-06-01 02:03:05.445466|2018-06-01 02:03:05.445466
NCT00696449|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2017-02-10||2017-11-01|2008-06-10|2008-06-12|Estimate|2017-02-10|2017-03-30|Actual||||2017-11-01|2017-12-06|Actual|June 2006||2006-06-30|November 2017|2017-11-30|October 2009|Actual|2009-10-31|May 2007|Actual|2007-05-31||Interventional|||Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris|An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris|Completed||Phase 4|61|Actual|Wake Forest University Health Sciences||4|||f||||f||||||||No||2018-06-01 02:03:05.524748|2018-06-01 02:03:05.524748
NCT00696436|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2011-03-24||2011-03-24|2008-06-10|2008-06-12|Estimate|2011-03-24|2011-04-19|Estimate||||2011-03-24|2011-04-19|Estimate|April 2008||2008-04-30|March 2011|2011-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.|A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension|Completed||Phase 3|1291|Actual|Takeda||5|||f||||f||||||||||2018-06-01 02:03:05.868645|2018-06-01 02:03:05.868645
NCT00696423|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2009-07-17||2016-10-26|2008-06-10|2008-06-12|Estimate|2009-07-17|2009-08-26|Estimate||||2016-10-26|2016-12-08|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children|Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children|Completed||Phase 3|467|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:07.310915|2018-06-01 02:03:07.310915
NCT00696410|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2013-02-14||2017-10-05|2008-06-09|2008-06-12|Estimate|2017-08-01|2017-10-04|Actual||||2017-10-05|2017-11-06|Actual|June 2008||2008-06-30|October 2017|2017-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy|Pilot Study to Assess the Impact of Zinc Supplementation on Left Ventricular Remodeling, Function, and Oxidative Stress in Nonischemic Cardiomyopathy|Completed||Phase 1|48|Actual|University of Michigan|Zinc acetate was poorly tolerated by some patients. Patients often commented on GI upset (nausea) and reflux symptoms at follow-up encounter. The myeloperoxidase assay demonstrated marked variability and test validity/quality is in question.|2|||f||||t||||||||||2018-06-01 02:03:07.7139|2018-06-01 02:03:07.7139
NCT00696397|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-03-14|2008-06-10|2008-06-12|Estimate|||||||2017-03-14|2017-03-16|Actual|March 2006||2006-03-31|August 2012|2012-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology|Sleep Disturbance in Atopic Dermatitis: A Comprehensive Investigation of Opiates, Neuropeptides, Barrier Function, Scratching and Sleep Physiology|Completed|||31|Actual|Wake Forest University Health Sciences|||1||f||||f||||||Samples With DNA|"~     Blood, dermal microdialysate~   "|||2018-06-01 02:03:08.114041|2018-06-01 02:03:08.114041
NCT00696384|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2011-03-24||2011-11-29|2008-06-10|2008-06-12|Estimate|2011-11-29|2012-01-04|Estimate||||2011-11-29|2012-01-04|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension|An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension|Completed||Phase 3|418|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:03:08.197937|2018-06-01 02:03:08.197937
NCT00696371|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2018-05-23|2008-06-11|2008-06-12|Estimate|||||||2018-05-23|2018-05-24|Actual|June 6, 2008||2008-06-06|August 19, 2014|2014-08-19|August 19, 2014||2014-08-19|||||Observational|||PET Imaging of Peripheral Benzodiazepine Receptors|PET Imaging of Peripheral Benzodiazepine Receptors Using [11C](R)-PK 11195 and [11C]PBR28|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:03:08.83932|2018-06-01 02:03:08.83932
NCT00696358|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-10-30|2008-06-11|2008-06-12|Estimate|||||||2008-10-30|2008-10-31|Estimate||||October 2008|2008-10-31||||||||Interventional|||Excimer Lamp Versus Excimer Laser in Vitiligo Treatment|Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo|Completed||Phase 3|||Centre Hospitalier Universitaire de Nice||2|||f||||||||||||||2018-06-01 02:03:09.102286|2018-06-01 02:03:09.102286
NCT00696345|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-13|2008-06-10|2008-06-12|Estimate|||||||2008-06-13|2008-06-17|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|February 2007|Actual|2007-02-28|October 2006|Actual|2006-10-31||Observational|||Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay|Feasibility Study for Performance of Septin 9 in Plasma From Cases With Colorectal Cancer and Controls With Non-Diseased, Non-Colorectal Disease and Non-Colorectal Cancers|Completed|||700|Actual|Epigenomics, Inc|||2||f||||f||||||Samples With DNA|"~     Residual plasma samples retained according to protocol.~   "|||2018-06-01 02:03:09.374681|2018-06-01 02:03:09.374681
NCT00696332|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10||2011-08-16|2011-10-20|2008-06-11|2008-06-12|Estimate||||2011-08-16|2011-08-23|Estimate|2011-10-20|2011-10-21|Estimate|September 2008||2008-09-30|October 2011|2011-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|ALS||Talampanel for Amyotrophic Lateral Sclerosis (ALS)|A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of Talampanel in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|559|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 02:03:09.654411|2018-06-01 02:03:09.654411
NCT00696319|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2011-06-30|2008-06-11|2008-06-12|Estimate|||||||2011-06-30|2011-07-01|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Dynamic Stability of the Anterior Cruciate Ligament (ACL) Deficient Knee|Dynamic Stability of the ACL Deficient Knee - a Prospective Cohort Study|Suspended||N/A|150|Anticipated|Oslo University Hospital||2||Study was suspended due to lack of resources.|f||||f||||||||||2018-06-01 02:03:09.99781|2018-06-01 02:03:09.99781
NCT00696306|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2011-04-11|2008-06-09|2008-06-12|Estimate|||||||2011-04-11|2011-04-12|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||MRI-SWI as a Predictor of Functional Outcome in Acute Ischemic Stroke|Diffusion Tensor Imaging (DTI) and Susceptibility Weighted Imaging (SWI) as a Predictor of Functional Outcome in Acute Ischemic Stroke|Completed|||30|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-06-01 02:03:10.289673|2018-06-01 02:03:10.289673
NCT00696293|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2016-01-05||2017-01-30|2008-06-09|2008-06-12|Estimate|2016-04-20|2016-05-26|Estimate||||2017-01-30|2017-02-01|Estimate|May 2007||2007-05-31|January 2017|2017-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|ACHIEVE2||Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults|Optimizing Outcomes in Older Adults With Low Back Pain and Depression|Completed||Phase 4|30|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-06-01 02:03:10.550095|2018-06-01 02:03:10.550095
NCT00696280|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2013-06-11|2008-06-11|2008-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|DelayedNaus||Observational Study of Delayed Nausea and Vomiting|Observational Study of Delayed Nausea and Vomiting Following Administration of Carboplatin Containing Regimens for Treatment of Cancer|Completed|||106|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-06-01 02:03:11.103765|2018-06-01 02:03:11.103765
NCT00696254|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2009-06-02|2008-06-11|2008-06-12|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|December 2008||2008-12-31|||||Observational|||Impact of General Anaesthetics on Excitability of the Peripheral Sensory Nerve||Completed|||||University of Zurich|||||f||||||||||||||2018-06-01 02:03:11.205983|2018-06-01 02:03:11.205983
NCT00696241|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2011-03-24||2011-07-27|2008-06-10|2008-06-12|Estimate|2011-03-24|2011-04-19|Estimate||||2011-07-27|2011-07-29|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension|Completed||Phase 3|1275|Actual|Takeda||5|||f||||f||||||||||2018-06-01 02:03:11.291811|2018-06-01 02:03:11.291811
NCT00696228|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2015-06-01|2008-06-09|2008-06-12|Estimate|||||||2015-06-01|2015-06-03|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|AFN||High Fat Diet: Oxidative and Cardiovascular Effects|High Fat Diet: Oxidative Effects and Cardiovascular Risk|Completed||Phase 3|144|Actual|Vanderbilt University||4|||f||||f||||||||||2018-06-01 02:03:12.656816|2018-06-01 02:03:12.656816
NCT00696215|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|June 2007||2007-06-30|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|June 2008|Anticipated|2008-06-30||Interventional|||The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease|The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months|Unknown status|Recruiting|Phase 4|40|Anticipated|Istanbul University||2|||f||||t||||||||||2018-06-01 02:03:12.73049|2018-06-01 02:03:12.73049
NCT00696202|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2014-12-30|2008-06-11|2008-06-12|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2003||2003-09-30|December 2014|2014-12-31|March 2005|Actual|2005-03-31|||||Interventional|||Mirena Efficiency and Tolerability During the First Year of Use|A Multicentre, Open Label, Uncontrolled Study of the Tolerance, Acceptability and Contraceptive Efficacy of Mirena 52 mg®, an Intra-uterine Levonorgestrel Device, During the First Year After Insertion Post-partum|Completed||Phase 4|199|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:03:12.817716|2018-06-01 02:03:12.817716
NCT00696189|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2015-04-23|2008-06-11|2008-06-12|Estimate|||||||2015-04-23|2015-04-24|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Observational|||Effects of Nitrous Oxide on Intraocular Pressure|The Effects of Nitrous Oxide on Intraocular Pressure and Ocular Perfusion|Terminated|||30|Actual|Rutgers, The State University of New Jersey||||PI is no longer at this institution|f||||f||||||||||2018-06-01 02:03:12.903075|2018-06-01 02:03:12.903075
NCT00696176|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2015-07-22|2008-06-11|2008-06-12|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||STAT3 DECOY in Head and Neck Cancer|Preliminary Assessment of the Safety and Biological Activity of Intratumoral STAT3 DECOY in Surgically Resectable Head and Neck Squamous Cell Carcinoma|Completed||Early Phase 1|32|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:03:12.962592|2018-06-01 02:03:12.962592
NCT00696163|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2016-10-27|2008-06-10|2008-06-12|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2008||2008-04-30|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|IMPROVE Life||Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes|A Multicentre, Open Label, Nonrandomised, Non- Interventional, A Multicentre, Open Label, Nonrandomised, Non- Interventional, Observational Study to Evaluate the Quality of Life and Clinical Outcomes in Subjects Using Biphasic Insulin Aspart 30 (NovoMix® 30) for the Treatment of Diabetes Mellitus|Completed|||24975|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:03:13.052054|2018-06-01 02:03:13.052054
NCT00696150|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|August 2010|Anticipated|2010-08-31|July 2010|Anticipated|2010-07-31||Interventional|||Can the Femoral Nerve Block be Improved by Ultrasound Guidance?|Can the Use of Ultrasound to Guide the Insertion of a Needle for an Anterior Psoas Compartment Nerve Block Increase Its Efficacy in Comparison to Traditional Techniques Utilising Loss of Resistance and Nerve Stimulation?|Unknown status|Not yet recruiting|Phase 4|269|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f||||||||||2018-06-01 02:03:13.11801|2018-06-01 02:03:13.11801
NCT00696137|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2012-04-16|2008-06-10|2008-06-12|Estimate|||||||2012-04-16|2012-04-17|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Long-term Extension Study of BEMA™ Fentanyl|Open-label, Long-term Extension Study for Treatment of Breakthrough Cancer Pain With BEMA™ Fentanyl|Completed||Phase 3|5|Actual|BioDelivery Sciences International||1|||f||||f||||||||||2018-06-01 02:03:13.267861|2018-06-01 02:03:13.267861
NCT00696124|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2010-07-21|2008-06-10|2008-06-12|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2007||2007-03-31|July 2010|2010-07-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Safety Study of Gene Therapy in Treating Lower Leg Ischemia|Phase 1, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Critical Limb Ischemia|Completed||Phase 1|15|Anticipated|ViroMed Co., Ltd.||4|||f||||t||||||||||2018-06-01 02:03:13.328508|2018-06-01 02:03:13.328508
NCT00696111|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2016-08-23|2008-06-09|2008-06-12|Estimate|||||||2016-08-23|2016-08-24|Estimate|December 2007||2007-12-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea|PCOS, Sleep Apnea and Metabolic Risk in Women|Active, not recruiting||N/A|80|Anticipated|University of Chicago||3|||f||||t||||||||||2018-06-01 02:03:13.411435|2018-06-01 02:03:13.411435
NCT00696098|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-02-22|2008-06-09|2008-06-12|Estimate|||||||2017-02-22|2017-02-24|Actual|May 2007||2007-05-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Effects of Butyrate on Colonic Health of Patients With Diarrhoea Predominant IBS and UC in Remission|Effects of Butyrate on Colonic Health of Patients With Diarrhoea Predominant|Completed||N/A|80|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 02:03:13.502196|2018-06-01 02:03:13.502196
NCT00696085|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|March 2004||2004-03-31|June 2008|2008-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Fetal Alcohol Damage Prevention Study|Prevention of Fetal Alcohol Damage Using Maternal Blood Markers|Completed||N/A|612|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 02:03:13.563329|2018-06-01 02:03:13.563329
NCT00696072|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2016-03-09||2016-05-10|2008-06-10|2008-06-12|Estimate|2016-04-06|2016-05-11|Estimate||||2016-05-10|2016-06-13|Estimate|August 2008||2008-08-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Intent to treat (ITT) population|Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic|Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic|Completed||Phase 2|120|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 02:03:13.66193|2018-06-01 02:03:13.66193
NCT00696059|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|August 2004||2004-08-31|June 2008|2008-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|HURRAH||Humira in Rheumatoid Arthritis - Do Bone Erosions Heal?|Can Bone Erosions Heal in Adalimumab (Humira) Treated Rheumatoid Arthritis Patients. An Imaging Study Using Computed Tomography and Magnetic Resonance Imaging.|Completed||Phase 4|52|Actual|Hvidovre University Hospital||1|||f||||f||||||||||2018-06-01 02:03:14.16231|2018-06-01 02:03:14.16231
NCT00696046|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-09|2008-06-09|2008-06-12|Estimate|||||||2008-06-09|2008-06-12|Estimate|March 2006||2006-03-31|June 2008|2008-06-30|June 2009|Anticipated|2009-06-30|December 2008|Anticipated|2008-12-31||Interventional|CB01||Intra Bone Marrow Injection Of Unrelated Cord Blood Cells|Direct Intra Bone Marrow Injection Of Unrelated Cord Blood Cells To Improve Engraftment And Reduce Acute Graft-Versus-Host Disease|Unknown status|Recruiting|Phase 1/Phase 2|47|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||||f||||f||||||||||2018-06-01 02:03:15.182516|2018-06-01 02:03:15.182516
NCT00696033|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2009-09-16|2008-06-11|2008-06-12|Estimate|||||||2009-09-16|2009-09-17|Estimate|July 2007||2007-07-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ibid||Exploring the Effects of Diazepam and Lorazepam|Exploring the Effects of Diazepam and Lorazepam on the Neural Correlates of Perceptual Priming and Explicit Memory in Healthy Volunteers|Completed||N/A|22|Actual|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-06-01 02:03:15.249802|2018-06-01 02:03:15.249802
NCT00695864|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2015-11-13||2017-05-09|2008-06-10|2008-06-12|Estimate|2017-05-09|2017-05-15|Actual||||2017-05-09|2017-05-15|Actual|May 2008||2008-05-31|May 2017|2017-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Ondansetron for Withdrawal Symptoms|Effect of Ondansetron for Withdrawal Symptoms|Completed||N/A|31|Actual|Stanford University||2|||f||||||||||||||2018-06-01 02:03:18.836631|2018-06-01 02:03:18.836631
NCT00695851|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2009-03-27|2008-06-11|2008-06-12|Estimate|||||||2009-03-27|2009-03-30|Estimate|March 2005||2005-03-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.|A Phase I Randomized Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.|Completed||Phase 1|36|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:03:19.027231|2018-06-01 02:03:19.027231
NCT00696020|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2015-06-19|2014-03-28|2015-07-20|2008-06-11|2008-06-12|Estimate|2015-07-20|2015-08-13|Estimate|2014-03-28|2014-04-25|Estimate|2015-07-20|2015-08-13|Estimate|June 2008||2008-06-30|July 2015|2015-07-31||||February 2009|Actual|2009-02-28||Interventional||Treated Set (TS). The TS included all randomized patients who received at least 1 dose of study medication.|Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)|Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD|Completed||Phase 2|360|Actual|Boehringer Ingelheim|"Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information."|4|||f||||||||||||||2018-06-01 02:03:15.404912|2018-06-01 02:03:15.404912
NCT00696007|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2012-02-16|2008-06-11|2008-06-12|Estimate|||||||2012-02-16|2012-02-17|Estimate|April 2008||2008-04-30|February 2012|2012-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer|Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer|Withdrawn||Phase 2|0|Actual|Lahey Clinic||2||Study was unable to recruit subjects meeting the study requirements.|f||||f||||||||||2018-06-01 02:03:16.655231|2018-06-01 02:03:16.655231
NCT00695994|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2012-10-31|2008-06-11|2008-06-12|Estimate|||||||2012-10-31|2012-11-01|Estimate|October 2006||2006-10-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Effect of Docetaxel or Gemcitabine-based Chemotherapy in East Asian and Caucasian Patients|The Effect of Pharmacogenetics on Treatment Toxicities and Outcomes in East Asian and Caucasian Patients Undergoing Docetaxel or Gemcitabine-based Chemotherapy|Completed||Phase 2|300|Actual|National University Hospital, Singapore||2|||f||||||||||||||2018-06-01 02:03:16.737423|2018-06-01 02:03:16.737423
NCT00695981|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2017-11-14|2008-06-11|2008-06-12|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2008|Actual|2008-06-30|November 2017|2017-11-30|June 2023|Anticipated|2023-06-30|January 2017|Actual|2017-01-31||Interventional|||Operative Versus Non-operative Management of Rotator Cuff Tear|The Effectiveness and Cost-Effectiveness of Operative and Non-operative Management of Rotator Cuff Tear|Active, not recruiting||N/A|100|Anticipated|Central Finland Hospital District||2|||f||||t||||||||Undecided||2018-06-01 02:03:16.842865|2018-06-01 02:03:16.842865
NCT00695968|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2012-07-10|2008-06-10|2008-06-12|Estimate|||||||2012-07-10|2012-07-12|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI|A Prospective Study Evaluating Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography, and Magnetic Resonance Imaging in the Detection of Breast Cancer|Terminated|||9|Actual|Stanford University||||low accrual|f||||||||||||||2018-06-01 02:03:16.9641|2018-06-01 02:03:16.9641
NCT00695955|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2011-03-24||2011-03-24|2008-06-10|2008-06-12|Estimate|2011-03-24|2011-04-19|Estimate||||2011-03-24|2011-04-19|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension|A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension|Completed||Phase 3|669|Actual|Takeda||1|||f||||f||||||||||2018-06-01 02:03:17.053565|2018-06-01 02:03:17.053565
NCT00695942|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2012-05-16|2008-06-10|2008-06-12|Estimate|||||||2012-05-16|2012-05-17|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|AngioPred||Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease|Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease: Role of Angiogenic Factors, Hemostasis and Uterine Artery Doppler|Completed|||200|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||t||||||Samples Without DNA|"~     plasma and serum samples~   "|||2018-06-01 02:03:17.763478|2018-06-01 02:03:17.763478
NCT00695929|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2010-01-25|2008-06-11|2008-06-12|Estimate|||||||2010-01-25|2010-01-26|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Levosimendan in Congenital Cardiac Surgery||Completed||N/A|50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||||||||||||2018-06-01 02:03:17.873435|2018-06-01 02:03:17.873435
NCT00695916|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2017-01-30|2008-06-10|2008-06-12|Estimate|||||||2017-01-30|2017-02-01|Estimate||||January 2017|2017-01-31||||||||Interventional|||MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery|Randomized Trial of Breast MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery|Withdrawn||Phase 3|0|Actual|Stanford University||||PI|f||||||||||||||2018-06-01 02:03:17.962869|2018-06-01 02:03:17.962869
NCT00695903|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2011-08-23||2017-02-22|2008-06-10|2008-06-12|Estimate|2011-11-01|2011-12-06|Estimate||||2017-02-22|2017-03-24|Actual|September 2008||2008-09-30|February 2017|2017-02-28|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|HDSAB||Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia|A Phase 2 Multicenter, Randomized, Double-blinded, Study to Describe the Safety, Efficacy, and Pharmacokinetics of Daptomycin 10 mg/kg/Day and Vancomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia|Terminated||Phase 2|38|Actual|Cubist Pharmaceuticals LLC|Because the study was terminated early due to lack of enrollment, there were not sufficient patients to provide meaningful analysis for the following secondary outcomes: persistent/recurrent bacteremia and time to defervescence/clearance.|2||terminated due to lack of enrollment|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:03:18.07898|2018-06-01 02:03:18.07898
NCT00695890|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2014-12-17|2008-06-11|2008-06-12|Estimate|||||||2014-12-17|2014-12-19|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Effects of Sevoflurane and Propofol on Light Flash Evoked Pupillometry|Effects of Sevoflurane and Propofol on Light Flash Evoked Pupillometry.|Completed|||30|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||||||2018-06-01 02:03:18.657711|2018-06-01 02:03:18.657711
NCT00695877|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2018-05-08|2008-06-10|2008-06-12|Estimate|||||||2018-05-08|2018-05-09|Actual|February 8, 2009|Actual|2009-02-08|May 2018|2018-05-31|October 14, 2016|Actual|2016-10-14|December 11, 2012|Actual|2012-12-11||Interventional|||Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults|A Phase I Randomized, Double-blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 5 HVR48 HIV-1 Vaccine (Ad5HVR48.ENVA.01) in Healthy, HIV-1 Uninfected Adults (Ad5HVR48.ENVA.01 (rAd5HVR48) HIV-1/IPCAVD-002 Vaccine Study)|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 02:03:18.738297|2018-06-01 02:03:18.738297
NCT00695838|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2009-08-04|2008-06-11|2008-06-12|Estimate|||||||2009-08-04|2009-08-06|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|||||Observational|LINEA||National Survey on Gastroesophageal Reflux Disease (GERD) Patients|Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice|Completed|||5084|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:03:19.254865|2018-06-01 02:03:19.254865
NCT00695825|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2018-04-25|2008-06-09|2008-06-12|Estimate|||||||2018-04-25|2018-04-26|Actual|April 1, 2006|Actual|2006-04-01|April 2018|2018-04-30|December 31, 2008|Actual|2008-12-31|November 30, 2006|Actual|2006-11-30||Interventional|||Effects the Glycemic Index on Metabolic Risk Markers|Postprandial Effects of a Low vs. a High Glycemic Index Food Product on Metabolic Risk Markers in Lean and Obese Subjects|Completed||N/A|30|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 02:03:21.726385|2018-06-01 02:03:21.726385
NCT00695812|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|September 2008||2008-09-30|June 2008|2008-06-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|||The Development of Younger Siblings of Children With Autism Now at 10 Years of Age|The Development of Younger Siblings of Children With Autism Now at 10 Years of Age|Unknown status|Not yet recruiting||104|Anticipated|Shaare Zedek Medical Center|||2||f||||f||||||||||2018-06-01 02:03:21.819089|2018-06-01 02:03:21.819089
NCT00695799|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2013-12-10|2008-06-11|2008-06-12|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Propofol Concentration In The Ambient Air Of The Operating Room And In The Blood Of Anesthesia Care Providers|Measurement Of Propofol Concentration In The Ambient Air Of The Operating Room And In The Blood Of Anesthesia Care Providers During Propofol -Based General Anesthesia|Completed|||20|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||Samples Without DNA|"~     Standard blood draw~   "|||2018-06-01 02:03:21.937412|2018-06-01 02:03:21.937412
NCT00695786|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2018-02-13|2008-06-10|2008-06-12|Estimate|||||||2018-02-13|2018-02-14|Actual|June 2008|Actual|2008-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma|A Phase II Study of Revlimid in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Hodgkin's Lymphoma (NHL)|Active, not recruiting||Phase 2|155|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-06-01 02:03:22.007772|2018-06-01 02:03:22.007772
NCT00695773|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-11-28|2008-06-11|2008-06-12|Estimate|||||||2008-11-28|2008-12-01|Estimate|February 2006||2006-02-28|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Laparoscopic Vs. Open Prostatectomy Outcomes|Laparoscopic Vs. Open Prostatectomy Outcomes|Terminated|||158|Actual|Lahey Clinic||||Insufficient findings for data analysis|f||||f||||||||||2018-06-01 02:03:22.447041|2018-06-01 02:03:22.447041
NCT00695747|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2009-01-21|2008-06-10|2008-06-12|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 1998||1998-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy|Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy|Completed||N/A|95|Actual|Lahey Clinic||2|||f||||f||||||||||2018-06-01 02:03:22.841414|2018-06-01 02:03:22.841414
NCT00695734|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-10|2008-06-10|2008-06-12|Estimate|||||||2008-06-10|2008-06-12|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Detection of Latent Tuberculosis in Hemodialysis Patients|Interferon-Gamma Release Assays (IGRA) Versus Tuberculin Skin Testing for Detection of Latent Tuberculosis Infection (TB) in Chronic Hemodialysis Patients|Completed|||62|Actual|University Hospital, Geneva|||1||f||||f||||||||||2018-06-01 02:03:23.059603|2018-06-01 02:03:23.059603
NCT00695708|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2010-04-12|2008-06-09|2008-06-12|Estimate|||||||2010-04-12|2010-04-13|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||Training-induced Cerebral Reorganization in Schizophrenia|Training-induced Cerebral Reorganization in Schizophrenia|Completed||N/A|60|Anticipated|University of Konstanz||3|||f||||t||||||||||2018-06-01 02:03:23.294957|2018-06-01 02:03:23.294957
NCT00695695|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|||2018-05-11|2008-06-11|2008-06-12|Estimate|||||||2018-05-11|2018-05-14|Actual|May 14, 2008||2008-05-14|February 3, 2014|2014-02-03|February 3, 2014||2014-02-03|||||Observational|||The Experience of Caregivers of Children With Down Syndrome|The Role of Hope in Adaptation to Uncertainty: The Experience of Caregivers of Children With Down Syndrome|Completed|||546|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:03:23.45199|2018-06-01 02:03:23.45199
NCT00695682|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2008-06-11|2008-06-11|2008-06-12|Estimate|||||||2008-06-11|2008-06-12|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|ITVR||Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV)|The Safety and Tolerability of Intravitreal Infliximab (Remicade) in Patients With Refractory Diabetic Macular Edema or Choroidal Neovascularization Secondary to Age Related Macular Degeneration- A Pilot Study|Unknown status|Recruiting|Phase 1|4|Anticipated|Retina Research Foundation|||||f||||f||||||||||2018-06-01 02:03:23.537902|2018-06-01 02:03:23.537902
NCT00695669|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2013-12-19|2009-05-20|2016-10-18|2008-06-11|2008-06-12|Estimate|2013-12-19|2014-02-07|Estimate|2009-09-28|2009-09-30|Estimate|2016-10-18|2016-11-29|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64|A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64|Completed||Phase 2|312|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:23.793711|2018-06-01 02:03:23.793711
NCT00695656|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2009-08-04|2008-06-11|2008-06-12|Estimate|||||||2009-08-04|2009-08-06|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|November 2008|Actual|2008-11-30|||||Observational|Prophyl GP||National Survey on Hypertension in General Practitioner (GP) Consultation|Profile of Hypertensive Patients Seen in General Practitioner Consultation|Completed|||2853|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:03:25.536731|2018-06-01 02:03:25.536731
NCT00695643|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2017-07-20|2008-06-11|2008-06-12|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2008||2008-01-31|July 2017|2017-07-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis|Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis|Terminated||Phase 3|345|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-06-01 02:03:28.579013|2018-06-01 02:03:28.579013
NCT00695617|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2009-03-04|2008-06-10|2008-06-12|Estimate|||||||2009-03-04|2009-03-05|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Citrate Anticoagulation During MARS Treatment|Citrate Anticoagulation During MARS Treatment|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-06-01 02:03:28.744696|2018-06-01 02:03:28.744696
NCT00695604|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2018-05-04|2008-06-11|2008-06-12|Estimate|||||||2018-05-04|2018-05-08|Actual|May 2008|Actual|2008-05-31|May 2018|2018-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ReHICS||Repeated High-dose Inhaled Corticosteroids for Asthma|Repeated High-dose Inhaled Corticosteroids for Asthma|Withdrawn||Phase 2|0|Actual|University of Chicago||2||Study was not able to be completed, no results analyzed.|f||||t||||||||||2018-06-01 02:03:28.843114|2018-06-01 02:03:28.843114
NCT00695591|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-08-12|2008-06-11|2008-06-12|Estimate|||||||2014-08-12|2014-08-13|Estimate|July 2008||2008-07-31|August 2014|2014-08-31|July 2009|Actual|2009-07-31|September 2008|Actual|2008-09-30||Observational|HSTNMD||Home Sleep Testing in Neuromuscular Disease Patients|Home Sleep Testing in Neuromuscular Disease Patients|Completed|||9|Actual|Landon Pediatric Foundation|||4||f||||f||||||||||2018-06-01 02:03:28.924721|2018-06-01 02:03:28.924721
NCT00695578|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2009-02-12|2008-06-10|2008-06-12|Estimate|||||||2009-02-12|2009-02-13|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|February 2008|Actual|2008-02-29|June 2007|Actual|2007-06-30||Interventional|||Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy|A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy|Completed||Phase 4|20|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 02:03:29.003928|2018-06-01 02:03:29.003928
NCT00695565|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2013-07-11||2016-09-21|2008-06-10|2008-06-12|Estimate|2016-09-21|2016-11-08|Estimate||||2016-09-21|2016-11-08|Estimate|May 2008||2008-05-31|September 2016|2016-09-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional||ITT (Intent-to-Treat)|Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy|A Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Topical Gel, 0.1% With Placebo in the Management of Pain Associated With Painful Diabetic Neuropathy|Completed||Phase 2|180|Actual|Arcion Therapeutics Inc||2|||f||||t||||||||Undecided||2018-06-01 02:03:29.205519|2018-06-01 02:03:29.205519
NCT00695552|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2010-03-17|2008-06-10|2008-06-12|Estimate|||||||2010-03-17|2010-03-18|Estimate|September 2008||2008-09-30|June 2008|2008-06-30|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Interventional|DEMOII||The Effect of Exercise on Depressive Symptoms in Unmedicated Patients|DEMO II: A Randomized, Parallel-group, Observer-blinded Clinical Trial of Aerobic Exercise Versus Stretching Exercise for Patients With Light to Moderate Depression|Unknown status|Recruiting|N/A|200|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-06-01 02:03:29.885728|2018-06-01 02:03:29.885728
NCT00695539|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2009-10-02|2008-06-11|2008-06-12|Estimate|||||||2009-10-02|2009-10-05|Estimate|December 2007||2007-12-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|||||Observational|RESEARCH||Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients|A Multi-centre, Open Label, Non-randomised, Non Interventional, 24 Weeks Study for the Efficacy and Safety of Rosuvastatin Following Its Administration in Real Life Clinical Practice in Greek Hypercholesterolaemic Patients|Completed|||810|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:03:30.045285|2018-06-01 02:03:30.045285
NCT00695526|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2008-06-14|2008-06-11|2008-06-12|Estimate|||||||2008-06-14|2008-06-17|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Effects of Cranberry Extractive on the Lipid Profiles in Subjects With Type 2 Diabetes|Phase 3 Study of Cranberry on Lipid Profiles in Type 2 Diabetes|Completed||Phase 3|30|Actual|Taichung Veterans General Hospital||1|||f||||f||||||||||2018-06-01 02:03:30.140013|2018-06-01 02:03:30.140013
NCT00695513|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2011-09-14|2008-06-10|2008-06-12|Estimate|||||||2011-09-14|2011-09-15|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Inulin and Protein Fermentation in Hemodialysis Patients|A Phase 1/2 Study on the Effects of BENEO synergy1 on the Generation Rate and Serum Concentration of P-cresol and Related Protein-fermentation Endproducts in Haemodialysis Patients|Completed||Phase 1/Phase 2|22|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-06-01 02:03:30.297592|2018-06-01 02:03:30.297592
NCT00695500|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-11|2016-04-05||2016-07-05|2008-06-11|2008-06-12|Estimate|2016-07-05|2016-08-15|Estimate||||2016-07-05|2016-08-15|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|||Varenicline to Reduce Alcohol Consumption in Heavy Drinkers|A Randomized, Double-blind, Placebo Controlled Trial (RCT) of Varenicline to Reduce Alcohol Consumption in Heavy Drinkers|Completed||Phase 1/Phase 2|50|Actual|National Institutes of Health Clinical Center (CC)|The IV alcohol self-administration method may have shown ceiling effects limiting the interpretation of results.|2|||f||||f||||||||No||2018-06-01 02:03:30.490982|2018-06-01 02:03:30.490982
NCT00695487|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2014-03-11|2008-06-11|2008-06-12|Estimate|||||||2014-03-11|2014-03-12|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|THC||Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?|Does Intravenous Cannabis Reduce Postoperative Nausea and Vomiting (PONV)?|Terminated||N/A|320|Actual|University Hospital Inselspital, Berne||2||In the intermediate analysis, no effect could be shown, not even a tendency.|f||||f||||||||||2018-06-01 02:03:30.949961|2018-06-01 02:03:30.949961
NCT00695474|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2009-07-10|2008-06-09|2008-06-11|Estimate|||||||2009-07-10|2009-07-14|Estimate|June 2008||2008-06-30|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Vitamin D and Type 2 Diabetes - a Cross Sectional Study|Vitamin D and Type 2 Diabetes - a Cross Sectional Study|Completed|||150|Actual|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood samples, urine.~   "|||2018-06-01 02:03:31.10126|2018-06-01 02:03:31.10126
NCT00695461|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-10|2008-06-10|2008-06-11|Estimate|||||||2008-06-10|2008-06-11|Estimate|January 2001||2001-01-31|June 2008|2008-06-30|August 2006|Actual|2006-08-31|June 2004|Actual|2004-06-30||Interventional|Lp 299v||Lactobacillus Plantarum 299v in Colon Surgery|L Plantarum 299v to Patients Undergoing Colon Resection - a Randomized Placebo-Controlled Study|Completed||N/A|72|Actual|Skane University Hospital||2|||f||||f||||||||||2018-06-01 02:03:31.189445|2018-06-01 02:03:31.189445
NCT00695448|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-07-23|2008-06-09|2008-06-11|Estimate|||||||2017-07-23|2017-07-25|Actual|June 24, 2008|Actual|2008-06-24|July 2017|2017-07-31|March 31, 2009|Actual|2009-03-31|March 31, 2009|Actual|2009-03-31||Interventional|||Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma|A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients With Solid Tumors or Lymphoma|Terminated||Phase 1|11|Actual|GlaxoSmithKline||1||"This study was terminated prematurely due to lack of sufficient exposure following single- and~   repeat-dosing."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:31.281473|2018-06-01 02:03:31.281473
NCT00695435|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2009-04-27||2010-02-23|2008-06-09|2008-06-11|Estimate|2010-01-15|2010-02-05|Estimate||||2010-02-23|2010-03-02|Estimate|June 2008||2008-06-30|February 2010|2010-02-28||||June 2008|Actual|2008-06-30||Interventional|||Tobramycin Tear Concentrations|Evaluation of Tobramycin Tear Concentrations of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Versus TOBREX® Ophthalmic Solution in Normal Volunteers|Completed||Phase 1|21|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 02:03:31.397984|2018-06-01 02:03:31.397984
NCT00695422|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-07|||2017-04-19|2008-06-07|2008-06-11|Estimate|||||||2017-04-19|2017-04-20|Actual|May 14, 2008|Actual|2008-05-14|April 2017|2017-04-30|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Observational|||Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials|A Companion Protocol to Evaluate Anogenital Human Papillomavirus (HPV) Infection and Anogenital Squamous Intraepithelial Lesions (ASIL) in Subjects Participating in AMC Clinical Trials|Completed|||47|Actual|AIDS Malignancy Consortium|||1||f||||f|f|f||||Samples With DNA|"~     Blood specimens, anal cytology and biopsy of any lesions observed, cervical cytology and~     biopsy of any lesions observed.~   "|No||2018-06-01 02:03:31.637269|2018-06-01 02:03:31.637269
NCT00695409|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|||2017-12-15|2008-06-10|2008-06-11|Estimate|||||||2017-12-15|2017-12-19|Actual|March 18, 2008|Actual|2008-03-18|December 2017|2017-12-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, and High-Dose Combination Chemotherapy Followed By Peripheral Blood Stem Cell Transplant in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma|A Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody in Combination With High-Dose Beam (BCNU, Etoposide, Cytarabine and Melphalan) Followed by Autologous Stem Cell Transplantation for Patients With Poor Risk/Relapsed B-Cell Lymphoma|Completed||Phase 2|122|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:03:31.839743|2018-06-01 02:03:31.839743
NCT00695396|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2011-02-08||2012-10-02|2008-06-09|2008-06-11|Estimate|2011-02-17|2011-03-17|Estimate||||2012-10-02|2012-10-05|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion|A Randomized, Double Blind, Placebo Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes at Risk For Transfusion|Terminated||Phase 3|25|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Because this study was terminated prematurely due to slow enrollment, only limited data were collected. No formal statistical testing was performed. Only descriptive statistics were provided.|4||"The study was stopped due to low subject enrollment. No safety issue or other concern factored~   into this decision."|f||||t||||||||||2018-06-01 02:03:32.049456|2018-06-01 02:03:32.049456
NCT00695383|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-10|2008-06-10|2008-06-11|Estimate|||||||2008-06-10|2008-06-11|Estimate|December 2005||2005-12-31|June 2008|2008-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Early Exercise Training in Critically Ill Patients|Early Exercise in Critically Ill Patients Enhances Short-Term Functional Recovery|Completed||N/A|90|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 02:03:32.851381|2018-06-01 02:03:32.851381
NCT00695370|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-12|2008-06-10|2008-06-11|Estimate|||||||2008-06-12|2008-06-13|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|January 2008|Anticipated|2008-01-31|December 2007|Anticipated|2007-12-31||Interventional|||Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children|Hematopoietic Progenitor Cell Mobilization in Children With Malignancies: Evaluation of Pegfilgrastim at 300µg/kg in Hematological Steady State|Terminated||Phase 2|30|Anticipated|University Hospital, Clermont-Ferrand||||Recruiting or enrolling participants has halted and will not resume|f||||||||||||||2018-06-01 02:03:32.996741|2018-06-01 02:03:32.996741
NCT00695357|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2009-04-29|2008-06-09|2008-06-11|Estimate|||||||2009-04-29|2009-04-30|Estimate|April 2008||2008-04-30|April 2009|2009-04-30|June 2008|Actual|2008-06-30|||||Observational|EPAGGELIA||Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006|Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006|Completed|||832|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:03:33.162181|2018-06-01 02:03:33.162181
NCT00695344|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2009-01-29|2008-06-10|2008-06-11|Estimate|||||||2009-01-29|2009-01-30|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|EVEROSTAT||Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant|Prospective and Randomized Study to Evaluate the Effect of Everolimus in the Clinical and Intra-Cardiac Ecography Progression of Heart Graft Vascular Illness.|Unknown status|Active, not recruiting|Phase 4|52|Actual|Fundacion Investigacion y Desarrollo||2|||f||||t||||||||||2018-06-01 02:03:33.347981|2018-06-01 02:03:33.347981
NCT00695331|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-08|||2008-07-08|2008-06-08|2008-06-11|Estimate|||||||2008-07-08|2008-07-10|Estimate|February 2008||2008-02-29|July 2008|2008-07-31|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|||Efficacy and Safety Study of Titrated Oral Misoprostol Solution for Labor Augmentation|A Comparison of Titrated Oral Misoprostol Solution to Intravenous Oxytocin for Labor Augmentation: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|143|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-06-01 02:03:33.494875|2018-06-01 02:03:33.494875
NCT00695318|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2015-04-17||2015-05-11|2008-06-10|2008-06-11|Estimate|2015-05-11|2015-05-29|Estimate||||2015-05-11|2015-05-29|Estimate|December 2008||2008-12-31|May 2015|2015-05-31||||October 2013|Actual|2013-10-31||Interventional||Patients received either the 0.2µ/day or 0.5µ /day dose as well as a sham injection in the fellow eye. The total number of subjects enrolled/analyzed was 17.|Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy|A Randomized, Double-Masked, Fellow-Eye Comparison Of The Safety And Efficacy Of 0.2 And 0.5 µg/Day Fluocinolone Acetonide Intravitreal Insert To Sham Injection In Subjects With Bilateral Geographic Atrophy Due To AMD|Terminated||Phase 2|17|Actual|Alimera Sciences||2|||f||||f||||||||||2018-06-01 02:03:33.666676|2018-06-01 02:03:33.666676
NCT00695305|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09||2011-03-17|2016-11-30|2008-06-09|2008-06-11|Estimate||||2011-03-17|2011-03-28|Estimate|2016-11-30|2016-12-01|Estimate|November 2008||2008-11-30|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks|A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis|Completed||Phase 2|83|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:34.220348|2018-06-01 02:03:34.220348
NCT00695292|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2013-01-14||2013-02-22|2008-06-09|2008-06-11|Estimate|2013-01-14|2013-02-15|Estimate||||2013-02-22|2013-02-28|Estimate|June 2008||2008-06-30|February 2013|2013-02-28|September 2012|Actual|2012-09-30|June 2011|Actual|2011-06-30||Interventional|||Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer|Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|37|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:03:34.35495|2018-06-01 02:03:34.35495
NCT00695279|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-11-16|2008-06-09|2008-06-11|Estimate|||||||2017-11-16|2017-11-20|Actual|January 4, 2007|Actual|2007-01-04|November 2017|2017-11-30|December 2036|Anticipated|2036-12-31|December 2036|Anticipated|2036-12-31||Observational|||Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products|Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products at St. Jude Children's Research Hospital|Recruiting|||100|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 02:03:34.746639|2018-06-01 02:03:34.746639
NCT00695266|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2009-08-04|2008-06-10|2008-06-11|Estimate|||||||2009-08-04|2009-08-06|Estimate|December 2007||2007-12-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|||||Observational|PROPHYL HO||National Survey on Hypertension at Hospital|Profile of Hypertensive Patients Seen in Hospital Outpatient's Department|Completed|||655|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:03:34.901268|2018-06-01 02:03:34.901268
NCT00695253|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2016-03-01|2008-06-10|2008-06-11|Estimate|||||||2016-03-01|2016-03-03|Estimate|January 2002||2002-01-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With Abdominal Aortic Aneurysms (AAA)|Physician-Sponsored IDE for Talent Endoluminal Spring Graft System in Patients With AAA|Completed||N/A|49|Actual|Los Angeles Biomedical Research Institute||1|||f||||t||||||||Undecided||2018-06-01 02:03:35.199789|2018-06-01 02:03:35.199789
NCT00695240|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-10|2008-06-10|2008-06-11|Estimate|||||||2008-06-10|2008-06-11|Estimate|April 2007||2007-04-30|June 2008|2008-06-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Post-Operative Pain Control Using Direct Continuous Bupivacaine Infusion After Pelvic Organ Prolapse Repair|Post-Operative Pain Control Using Direct Continuous Bupivacaine Infusion After Pelvic Organ Prolapse Repair|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|St. Luke's Hospital, Kansas City, Missouri||1|||f||||f||||||||||2018-06-01 02:03:35.289592|2018-06-01 02:03:35.289592
NCT00695227|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2018-03-02|2008-06-09|2008-06-11|Estimate|||||||2018-03-02|2018-03-06|Actual|May 2004|Actual|2004-05-31|March 2018|2018-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SCE||Screening for Barrett's Esophagus in Otolaryngology Patients|Screening for Barrett's Esophagus in Otolaryngology Patients|Completed||N/A|295|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t||||||||||2018-06-01 02:03:35.373826|2018-06-01 02:03:35.373826
NCT00695214|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2018-04-27|2008-06-10|2008-06-11|Estimate|||||||2018-04-27|2018-04-30|Actual|February 2004||2004-02-29|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea|Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea|Recruiting||Phase 2|800|Anticipated|University of Southern California||1|||f||||f||||||||||2018-06-01 02:03:35.475563|2018-06-01 02:03:35.475563
NCT00695201|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-09-05|2008-06-09|2008-06-11|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2000||2000-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer|A Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer.|Active, not recruiting||Phase 1|72|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:03:35.570681|2018-06-01 02:03:35.570681
NCT00695188|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2010-12-20||2011-02-15|2008-06-10|2008-06-11|Estimate|2011-01-19|2011-02-15|Estimate||||2011-02-15|2011-02-17|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis|Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis A Multicenter, Randomized, Double-blind, Controlled Phase IV Trial|Completed||Phase 4|19|Actual|Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation||2|||f||||t||||||||||2018-06-01 02:03:35.690116|2018-06-01 02:03:35.690116
NCT00695175|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2009-08-04|2008-06-10|2008-06-11|Estimate|||||||2009-08-04|2009-08-06|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|September 2008|Actual|2008-09-30|||||Observational|Prophyl C||National Survey on Hypertension in Cardiologic Private Practice|Profile of Hypertensive Patients Seen in Private Cardiology Consultation|Completed|||1800|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:03:36.136824|2018-06-01 02:03:36.136824
NCT00695162|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2011-02-15|2008-06-09|2008-06-11|Estimate|||||||2011-02-15|2011-02-16|Estimate|January 2010||2010-01-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Speech Intelligibility and Cognition: Are Inpatients Impaired by Noise?|Speech Intelligibility and Cognition: Are Inpatients Impaired by Noise?|Completed||N/A|84|Actual|Portland VA Medical Center||2|||f||||f||||||||||2018-06-01 02:03:36.878411|2018-06-01 02:03:36.878411
NCT00695149|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2011-06-01|2008-06-10|2008-06-11|Estimate|||||||2011-06-01|2011-06-02|Estimate|July 2005||2005-07-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|December 2008|Actual|2008-12-31||Interventional|||Treatment for Acute Spinal Cord Injury|Clinical Study of Treatment for Acute Spinal Cord Injury Using Cultured Bone Marrow Stromal Cells|Terminated||Phase 1/Phase 2|5|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||||||||||||2018-06-01 02:03:36.960299|2018-06-01 02:03:36.960299
NCT00695136|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-10|2013-04-22||2013-04-22|2008-06-10|2008-06-11|Estimate|2013-04-22|2013-04-24|Estimate||||2013-04-22|2013-04-24|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||16 subjects completed screening and had baseline data. However, only 8 of them were eligible for further study participation and only 5 completed the drug and provided data for analysis.|The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism|An Investigation of the Relationship Between Donepezil Enhanced REM Sleep, Sleep Architecture and Behavior in the Prepubertal Child With Autism|Completed||Phase 1/Phase 2|17|Actual|National Institutes of Health Clinical Center (CC)|No controls and small number of patients.|1|||f||||f||||||||||2018-06-01 02:03:37.031397|2018-06-01 02:03:37.031397
NCT00695123|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-07|||2018-04-03|2008-06-07|2008-06-11|Estimate|||||||2018-04-03|2018-04-04|Actual|June 3, 2008||2008-06-03|March 27, 2018|2018-03-27||||||||Observational|||Screening for Subjects to Participate in Studies of Blood Disorders|Screening of Subjects to Determine Eligibility to Safely Participate in Blood Disorders Studies|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:03:37.209441|2018-06-01 02:03:37.209441
NCT00695110|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09||2010-08-17|2010-08-23|2008-06-10|2008-06-11|Estimate||||2010-08-17|2010-08-19|Estimate|2010-08-23|2010-08-27|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men|Phase II, Repeat Dose, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men|Completed||Phase 2|29|Actual|Clarus Therapeutics, Inc.||4|||f||||f||||||||||2018-06-01 02:03:37.289066|2018-06-01 02:03:37.289066
NCT00695097|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2013-11-13||2014-02-07|2008-06-10|2008-06-11|Estimate|2014-02-07|2014-03-26|Estimate||||2014-02-07|2014-03-26|Estimate|August 2004||2004-08-31|February 2014|2014-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Per protocol|The Effect of Rituximab on the Development of Anti-Donor Antibodies|The Effect of Rituximab on the Development of Anti-Donor Antibodies and Resolution of B Cell Infiltration in the Renal Allograft of Patients Undergoing Rejection|Completed||N/A|18|Actual|University of California, San Francisco|The limitations were small number of participants and short follow up time of only 12 months.|2|||f||||f||||||||||2018-06-01 02:03:37.394017|2018-06-01 02:03:37.394017
NCT00695084|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-10|2008-06-10|2008-06-11|Estimate|||||||2008-06-10|2008-06-11|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)|Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis|Completed||Phase 1|7|Actual|National Multiple Sclerosis Society||1|||f||||f||||||||||2018-06-01 02:03:37.661134|2018-06-01 02:03:37.661134
NCT00695071|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2011-09-23|2008-06-10|2008-06-11|Estimate|||||||2011-09-23|2011-09-26|Estimate|June 2008||2008-06-30|September 2011|2011-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Assess Blood Levels of Itraconazole During a Two-Week Period|Assessment of the Steady State Pharmacokinetics of Itraconazole and Hydroxy-Itraconazole in Healthy Subjects After Administration of a New Itraconazole 200 mg Film Coated Tablet Once Daily for Fourteen Days in Fed Condition|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:03:37.729818|2018-06-01 02:03:37.729818
NCT00695058|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2012-02-23|2008-06-10|2008-06-11|Estimate|||||||2012-02-23|2012-02-24|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|TMNS||Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence|Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Treatment of Incontinence|Withdrawn||Phase 3|0|Actual|Copenhagen University Hospital at Herlev||6||Failure to include|f||||t||||||||||2018-06-01 02:03:37.844273|2018-06-01 02:03:37.844273
NCT00695045|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-09|2008-06-09|2008-06-11|Estimate|||||||2008-06-09|2008-06-11|Estimate|July 2003||2003-07-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|||Intrathecal Morphine in Knee Arthroplasty|Determination of the Efficacy and Side-Effect Profile of Lower Doses of Intrathecal Morphine in Patients Undergoing Total Knee Arthroplasty|Completed||N/A|60|Actual|University College Hospital Galway||3|||f||||f||||||||||2018-06-01 02:03:37.927036|2018-06-01 02:03:37.927036
NCT00695032|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-07|||2014-11-04|2008-06-07|2008-06-11|Estimate|||||||2014-11-04|2014-11-05|Estimate|October 2007||2007-10-31|November 2014|2014-11-30||||September 2012|Actual|2012-09-30||Interventional|||Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors|Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)|Suspended||N/A|80|Anticipated|Institut Claudius Regaud|||||f||||f||||||||||2018-06-01 02:03:38.063465|2018-06-01 02:03:38.063465
NCT00695019|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|2013-02-05||2013-08-27|2008-06-10|2008-06-11|Estimate|2013-08-27|2013-10-31|Estimate||||2013-08-27|2013-10-31|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Low-Dose Human Interferon-alpha by the Oral Mucosal Route During the 6-Month Follow-up Period of Standard Combination Therapy for Hepatitis C Virus Infection|Completed||Phase 2|169|Actual|Amarillo Biosciences, Inc.||3|||f||||f||||||||||2018-06-01 02:03:38.259668|2018-06-01 02:03:38.259668
NCT00695006|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-24|2008-06-10|2008-06-11|Estimate|||||||2008-06-24|2008-06-25|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|July 2008|Anticipated|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Manual Therapy, Exercise and Traction for Patients With Cervical Radiculopathy: A RCT|Manual Therapy, Exercise and Traction for Patients With Cervical Radiculopathy: A RCT|Unknown status|Active, not recruiting|N/A|81|Actual|Rocky Mountain University of Health Professions||2|||f||||||||||||||2018-06-01 02:03:38.888231|2018-06-01 02:03:38.888231
NCT00694993|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-08-09|2008-06-09|2008-06-11|Estimate|||||||2017-08-09|2017-08-10|Actual|December 17, 2007|Actual|2007-12-17|August 2017|2017-08-31|May 26, 2008|Actual|2008-05-26|May 26, 2008|Actual|2008-05-26||Interventional|||Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects|A Double-blind, Placebo-controlled, Randomized Single Dose Escalation Study and a Double-blind, Placebo-controlled, Randomised Parallel Group 14-days Once Daily Repeat Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of an Intranasal H1/H3 Dual Antagonist Compound in Healthy Male Subjects|Completed||Phase 1|19|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:38.949411|2018-06-01 02:03:38.949411
NCT00694980|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-07|||2016-11-01|2008-06-07|2008-06-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2008||2008-09-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis|A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta7 Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Ulcerative Colitis|Completed||Phase 1|48|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 02:03:39.035608|2018-06-01 02:03:39.035608
NCT00694967|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-07|||2008-06-07|2008-06-07|2008-06-11|Estimate|||||||2008-06-07|2008-06-11|Estimate|November 2003||2003-11-30|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix|Histologic Evaluation of the Cervix at Risk for Preterm Birth Trial:Medical Versus Surgical Therapy|Terminated||N/A|92|Actual|Lehigh Valley Hospital||2||Interim analysis showed no difference in outcome between treatment groups.|f||||f||||||||||2018-06-01 02:03:39.144582|2018-06-01 02:03:39.144582
NCT00694954|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-12-01|2008-06-10|2008-06-11|Estimate|||||||2017-12-01|2017-12-05|Actual|February 2007||2007-02-28|December 2017|2017-12-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Capsule Endoscopy vs Standard of Care for Obscure Intestinal Bleeding|A Randomized Controlled Trial of Capsule Endoscopy vs Standard Care in Patients With Iron Deficiency Anemia With Suspected Obscure / Occult Gastrointestinal Bleeding|Completed||N/A|160|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 02:03:39.279459|2018-06-01 02:03:39.279459
NCT00694941|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2012-06-12|2008-06-10|2008-06-11|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2008||2008-06-30|June 2012|2012-06-30||||December 2008|Actual|2008-12-31||Interventional|||A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)|A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|15|Actual|Ono Pharmaceutical Co. Ltd||1|||f||||f||||||||||2018-06-01 02:03:39.356546|2018-06-01 02:03:39.356546
NCT00694928|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09||2010-11-02|2012-02-29|2008-06-10|2008-06-11|Estimate||||2011-01-27|2011-01-31|Estimate|2012-02-29|2012-03-05|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Vaginal Infection Study 2||Completed||Phase 3|843|Actual|Lumara Health, Inc.||2|||f||||||||||||||2018-06-01 02:03:39.466157|2018-06-01 02:03:39.466157
NCT00694915|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2012-05-03|2008-06-10|2008-06-11|Estimate|||||||2012-05-03|2012-05-04|Estimate|August 2008||2008-08-31|May 2012|2012-05-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|STCC||Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder|Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence|Unknown status|Active, not recruiting|Phase 2|122|Actual|Cadila Pharnmaceuticals||2|||f||||t||||||||||2018-06-01 02:03:39.635507|2018-06-01 02:03:39.635507
NCT00694902|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2017-08-08|2008-06-09|2008-06-11|Estimate|||||||2017-08-08|2017-08-10|Actual|May 26, 2008|Actual|2008-05-26|August 2017|2017-08-31|September 23, 2008|Actual|2008-09-23|September 23, 2008|Actual|2008-09-23||Interventional|||Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677|A Single-centre, Randomized, Double-blind , Placebo Controlled, Dose Escalating Cross-over Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Inhaled Doses of GSK610677 and Placebo in Healthy Male Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||9|||f||||f||||||||||2018-06-01 02:03:39.780234|2018-06-01 02:03:39.780234
NCT00694889|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2016-05-12|2008-06-10|2008-06-11|Estimate|||||||2016-05-12|2016-05-16|Estimate|August 2007||2007-08-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia|Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia|Completed||Phase 1/Phase 2|144|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-06-01 02:03:39.859762|2018-06-01 02:03:39.859762
NCT00694876|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-07|||2012-11-29|2008-06-07|2008-06-11|Estimate|||||||2012-11-29|2012-11-30|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India|Impact of Health Literacy and Other Factors on Glaucoma Patient Adherence in South India|Completed|||250|Actual|Robin, Alan L., M.D.|||2||f||||f||||||||||2018-06-01 02:03:39.930483|2018-06-01 02:03:39.930483
NCT00694863|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2013-01-04|2008-06-10|2008-06-11|Estimate|||||||2013-01-04|2013-01-07|Estimate|July 2008||2008-07-31|December 2010|2010-12-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|ACTHiMeN||Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy|Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study|Completed||Phase 2|20|Actual|Radboud University||1|||f||||f||||||||||2018-06-01 02:03:39.997867|2018-06-01 02:03:39.997867
NCT00694850|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2018-05-24|2008-06-10|2008-06-11|Estimate|||||||2018-05-24|2018-05-25|Actual|August 2, 2008|Actual|2008-08-02|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)|A Multi-center, Non-randomized, Non Blinded, Non-controlled Study to Investigate the Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease Associated Pulmonary Hypertension.|Active, not recruiting||Phase 2|22|Actual|Bayer||1|||f||||t|f|f||||||||2018-06-01 02:03:40.086389|2018-06-01 02:03:40.086389
NCT00694837|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2015-04-09|2008-06-10|2008-06-11|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma|Phase I/II Study for Patients With Newly Diagnosed Glioblastoma Testing Nelfinavir in Combination With Concomitant Temozolomide and Radiotherapy.|Completed||Phase 1|6|Actual|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-06-01 02:03:40.177259|2018-06-01 02:03:40.177259
NCT00694824|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-10|2008-06-10|2008-06-11|Estimate|||||||2008-06-10|2008-06-11|Estimate|November 2004||2004-11-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Vascular Calcification's Risk Factors in Haemodialysis Patients|Traditional and Not Traditional Risk Factors in Appearance and Progression of Vascular Calcification in Haemodialysis Patients.|Completed|||253|Actual|St. Orsola Hospital|||1||f||||f||||||Samples Without DNA|"~     For each patient a blood sample was drawn to check the basal values of hemoglobin,~     hematocrit, folates, vitamin B12, C reactive protein, PTH, calcium, phosphorus, albumin,~     alkaline phosphatase, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,~     uric acid, fibrinogen, homocysteine. To better understand the mineral methabolism TGFb1,~     fetuin A, OPG, FGF 23, OPN and MGP will be checked. The values for each patient will be the~     median of 4 determinations, each sample was drawn before the midweek dialysis session.~   "|||2018-06-01 02:03:40.262709|2018-06-01 02:03:40.262709
NCT00694811|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-09|||2008-06-10|2008-06-10|2008-06-11|Estimate|||||||2008-06-10|2008-06-11|Estimate|August 2004||2004-08-31|June 2008|2008-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects of Re-Feeding Duration on Weight Maintenance After Weight Loss With Very-Low-Energy Diets (VLEDs)|Liquid Very-Low-Energy Diets (VLEDs) in Obesity Treatment. Effects of Re-Feeding Duration On Weight Maintenance, Eating Behaviour and Health-Related Quality of Life|Completed||Phase 4|169|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 02:03:40.356342|2018-06-01 02:03:40.356342
NCT00694798|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-05-02|2008-06-10|2008-06-11|Estimate|||||||2012-05-02|2012-05-03|Estimate|October 2008||2008-10-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|STCC||Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder|Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium w (Mw) in BCG Refractory Superficial Transitional Cell Carcinoma|Completed||Phase 1|22|Actual|Cadila Pharnmaceuticals||1|||f||||t||||||||||2018-06-01 02:03:40.577854|2018-06-01 02:03:40.577854
NCT00303407|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2006-03-15|2006-03-15|2006-03-16|Estimate|||||||2006-03-15|2006-03-16|Estimate|January 2001||2001-01-31|December 2005|2005-12-31|July 2002||2002-07-31|||||Observational|||Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care||Terminated|||||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:07:03.745775|2018-06-01 04:07:03.745775
NCT00694785|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2009-08-20|2008-06-09|2008-06-10|Estimate|||||||2009-08-20|2009-08-21|Estimate|October 2008||2008-10-31|August 2009|2009-08-31||||June 2009|Anticipated|2009-06-30||Interventional|||A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B|A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B|Withdrawn||Phase 2|2|Anticipated|Archemix Corp.||4||Sponsor decided not to go forward with the study.|f||||||||||||||2018-06-01 02:03:40.728056|2018-06-01 02:03:40.728056
NCT00694772|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2008-06-09|2008-06-09|2008-06-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Coblation-Tonsillotomy vs Electrocautery-Tonsillectomy for the Treatment of Obstructive Sleep Apnea (OSA) in Children|Coblation-Tonsillotomy Versus Electrocautery-Tonsillectomy for Treatment of Moderate and Severe Obstructive Sleep Apnea in Children: A Randomized, Prospective, Single-Blinded Study|Unknown status|Recruiting|N/A|100|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 02:03:40.83663|2018-06-01 02:03:40.83663
NCT00694759|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2010-08-03|2008-06-09|2008-06-10|Estimate|||||||2010-08-03|2010-08-04|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)|Cortisol Regulation in Polycystic Ovary Syndrome|Unknown status|Recruiting|N/A|107|Anticipated|Oregon Health and Science University||3|||f||||f||||||||||2018-06-01 02:03:40.966263|2018-06-01 02:03:40.966263
NCT00694746|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2016-01-28|2008-06-09|2008-06-10|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of Fish Oil to Reduce ALT Levels in Adolescents|Randomized Trial of Fish Oil Versus Placebo to Reduce ALT Levels in Overweight Adolescents|Terminated||Phase 1|3|Actual|Boston University||2||Study closed for slow recruitment|f||||f||||||||No|Design with difficult enrollement|2018-06-01 02:03:41.136661|2018-06-01 02:03:41.136661
NCT00694733|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2012-06-04|2008-06-09|2008-06-10|Estimate|||||||2012-06-04|2012-06-06|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Regulation of Cortisol Metabolism and Fat Patterning|Regulation of Cortisol Metabolism and Fat Patterning|Completed||N/A|140|Actual|Oregon Health and Science University||5|||f||||f||||||||||2018-06-01 02:03:41.289584|2018-06-01 02:03:41.289584
NCT00694720|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2009-04-30|2008-06-06|2008-06-10|Estimate|||||||2009-04-30|2009-05-01|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Evaluation of the Effect of AVE0657 in Cheynes-Stokes Breathing Syndrome Patients|A Double-Blind, Randomized, Placebo-Controlled, Study Evaluating the Safety and Activity of Four Escalating Single Doses of AVE0657 in Congestive Heart Failure Patients Presenting as Cheyne-Stokes Breathing Syndrome|Terminated||Phase 2|8|Actual|Sanofi||5||Termination following reassessment of the potential benefit-risk of AVE0657|f||||t||||||||||2018-06-01 02:03:41.472962|2018-06-01 02:03:41.472962
NCT00694707|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06||2012-03-02|2012-03-02|2008-06-09|2008-06-10|Estimate||||2012-03-02|2012-03-06|Estimate|2012-03-02|2012-03-06|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia|Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia|Completed||Phase 2|732|Actual|Forest Laboratories||5|||f||||f||||||||||2018-06-01 02:03:41.576276|2018-06-01 02:03:41.576276
NCT00694694|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2016-10-19|2008-06-09|2008-06-10|Estimate|||||||2016-10-19|2016-10-20|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|CAZAMS||Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.|A Randomized Trial of Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria in Tanzanian Children.|Completed||Phase 3|261|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 02:03:41.738067|2018-06-01 02:03:41.738067
NCT00694681|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2012-03-23|2008-06-09|2008-06-10|Estimate|||||||2012-03-23|2012-03-27|Estimate|October 2004||2004-10-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|WtW||Working Toward Wellness|Enhanced Services for the Hard to Employ Demonstration: Telephonic Care Management for Depressed Medicaid Recipients|Completed||N/A|499|Actual|MDRC|||||f||||f||||||||||2018-06-01 02:03:41.819006|2018-06-01 02:03:41.819006
NCT00694668|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-11-05|2008-06-09|2008-06-10|Estimate|||||||2009-11-05|2009-11-06|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|October 2012|Anticipated|2012-10-31|November 2010|Anticipated|2010-11-30||Interventional|DSH||The (Cost-) Effectiveness of Mindfulness-training and Cognitive Behavioural Therapy in Adolescents and Young Adults With Deliberate Self Harm|The (Cost-) Effectiveness of Mindfulness-training and Cognitive Behavioural Therapy in Adolescents and Young Adults With Deliberate Self Harm|Unknown status|Recruiting|Phase 2/Phase 3|84|Anticipated|Leiden University Medical Center||2|||f||||f||||||||||2018-06-01 02:03:41.879354|2018-06-01 02:03:41.879354
NCT00694655|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2017-09-20|2008-06-09|2008-06-10|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2008||2008-05-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Human Immune Responses to The Yellow Fever Virus Vaccine|Human Immune Responses to Yellow Fever Vaccination|Recruiting||N/A|200|Anticipated|Emory University||1|||f||||f||||||||||2018-06-01 02:03:42.048912|2018-06-01 02:03:42.048912
NCT00694642|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2013-08-04|2008-06-09|2008-06-10|Estimate|||||||2013-08-04|2013-08-06|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|February 2012|Actual|2012-02-29|May 2009|Actual|2009-05-31||Interventional|PROGENITOR||Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis|Safety and Efficacy of Transendocardial Injection of Autologous Endothelial Progenitor Cell CD 133 for Therapeutics Angiogenesis|Completed||Phase 1/Phase 2|28|Actual|Hospital San Carlos, Madrid||2|||f||||t||||||||||2018-06-01 02:03:42.170033|2018-06-01 02:03:42.170033
NCT00694629|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2014-05-07|2008-06-09|2008-06-10|Estimate|||||||2014-05-07|2014-05-08|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment|TBTC Study 29: Evaluation of a Rifapentine-containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis|Completed||Phase 2|865|Actual|Centers for Disease Control and Prevention||4|||f||||t||||||||||2018-06-01 02:03:42.260754|2018-06-01 02:03:42.260754
NCT00694616|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2013-06-22|2008-06-09|2008-06-10|Estimate|||||||2013-06-22|2013-06-25|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Prevalence of Metabolic Syndrome in Obstructive Sleep Apnea (OSA) and Effect of Treatment With Continuous Positive Airway Pressure (Auto-CPAP) on Metabolic Syndrome|Prevalence of Metabolic Syndrome in Obstructive Sleep Apnea and the Effect of Treatment With Auto-titrating Continuous Positive Airway Pressure (Auto-CPAP) on Metabolic Syndrome|Completed||N/A|90|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 02:03:42.419786|2018-06-01 02:03:42.419786
NCT00694603|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2012-04-28||2012-08-02|2008-06-06|2008-06-10|Estimate|2012-08-02|2012-09-06|Estimate||||2012-08-02|2012-09-06|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy|A Phase II Trial of Cetuximab (c225) as Therapy for Recurrent Non-Small Cell Lung Cancer in Patients Who Have Received Prior Therapy With Tyrosine Kinase Inhibitor Directed Against the EGFR Pathway|Terminated||Phase 2|56|Actual|Massachusetts General Hospital||1||Slow accrual|f||||t||||||||||2018-06-01 02:03:42.682753|2018-06-01 02:03:42.682753
NCT00694590|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2015-03-19|2008-06-06|2008-06-10|Estimate|||||||2015-03-19|2015-03-20|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Interventional|||Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Completed||Phase 1|24|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:03:42.905196|2018-06-01 02:03:42.905196
NCT00694577|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2018-04-03|2008-06-09|2008-06-10|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2003||2003-09-30|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer|Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer: A Phase I Feasibility/Pilot Study|Active, not recruiting||N/A|330|Actual|Massachusetts General Hospital||3|||f||||t||||||||No||2018-06-01 02:03:43.081995|2018-06-01 02:03:43.081995
NCT00694564|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2013-03-20||2018-02-20|2008-06-09|2008-06-10|Estimate|2013-08-28|2013-09-13|Estimate||||2018-02-20|2018-03-16|Actual|June 2007||2007-06-30|January 2016|2016-01-31|July 2012|Actual|2012-07-31|March 2011|Actual|2011-03-31||Interventional|||Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children|A Pilot Open-labeled Trial of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children|Completed||N/A|8|Actual|Huang, Jeannie, M.D.||1|||f||||t||||||||||2018-06-01 02:03:43.229264|2018-06-01 02:03:43.229264
NCT00694551|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2014-01-06||2018-02-26|2008-06-09|2008-06-10|Estimate|2014-01-06|2014-02-19|Estimate||||2018-02-26|2018-03-26|Estimate|December 2, 2008|Actual|2008-12-02|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 28, 2013|Actual|2013-02-28||Interventional||All patients who received any amount of study treatment were considered evaluable for toxicity.|PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment|Pilot Immunotherapy Study of Combination PSMA and TARP Peptide With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment|Active, not recruiting||N/A|29|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f||||||||||2018-06-01 02:03:43.430669|2018-06-01 02:03:43.430669
NCT00694538|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2009-11-12|2008-06-09|2008-06-10|Estimate|||||||2009-11-12|2009-11-13|Estimate|January 2008||2008-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Interventional|PI070046||Efficacy of Interferential Laser Therapy in Shoulder Pain|Efficacy of Interferential Laser Therapy in Pain Reduction in Shoulder Musculoskeletal Pathologies.|Completed||Phase 2|200|Anticipated|Hospital Universitario Ramon y Cajal||2|||f||||t||||||||||2018-06-01 02:03:43.760551|2018-06-01 02:03:43.760551
NCT00694525|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2009-06-01|2008-06-09|2008-06-10|Estimate|||||||2009-06-01|2009-06-02|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Observational|||Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia|Potential Modulatory Role of Osteoprotegerin in Bone Metabolism of Patients With 21-Hydroxylase Deficiency|Unknown status|Recruiting||40|Anticipated|Office of Rare Diseases (ORD)|||2||f||||f||||||Samples With DNA|"~     With participant's permission, 5 mL of blood will be stored for potential new blood markers~     in the future.~   "|||2018-06-01 02:03:43.829036|2018-06-01 02:03:43.829036
NCT00694512|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2012-05-14|2008-06-06|2008-06-10|Estimate|||||||2012-05-14|2012-05-15|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Ghrelin Regulation and Structure: Effect of Diet Composition on Ghrelin|Ghrelin Regulation and Structure: Effect of Diet Composition on Ghrelin|Completed||N/A|51|Actual|Oregon Health and Science University||3|||f||||f||||||||||2018-06-01 02:03:43.901839|2018-06-01 02:03:43.901839
NCT00694499|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2008-06-09|2008-06-09|2008-06-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|January 2000||2000-01-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|||||Observational|NOMLI||Non-Operative Management of High Grade Blunt Hepatic Injury: Clinical Complications and the Role of Collateral Damage|Retrospective Single Centre Study Which Investigates the Safety of the Non-Operative Management of Patients With High Grade Blunt Liver Injuries (NOMLI) and the Impact of to the LI Collateral Intra- and Extra-Abdominal Damage on Interventions and Outcome|Completed|||183|Actual|University of Bern|||1||f||||f||||||||||2018-06-01 02:03:43.992383|2018-06-01 02:03:43.992383
NCT00694486|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2017-10-24|2008-06-05|2008-06-10|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2008||2008-01-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Eustachian Tube Testing in a Pressure Chamber -- Validation Study|Eustachian Tube Testing in a Pressure Chamber -- Validation|Completed|||30|Anticipated|University of Pittsburgh|||1||f||||f||||||||||2018-06-01 02:03:44.143348|2018-06-01 02:03:44.143348
NCT00694473|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2016-11-23||2018-02-07|2008-06-09|2008-06-10|Estimate|2017-10-04|2017-10-06|Actual||||2018-02-07|2018-03-08|Actual|June 2008||2008-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2010|Actual|2010-12-31||Interventional||76 were enrolled, analysis was completed for 69|Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery|Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery|Completed||N/A|76|Actual|Massachusetts General Hospital|Analysis used recalibrated data from Abbot; possible bias. Time of A-line removal was not always documented; estimate of arterial vs. venous POC reference BGs is estimated.|1|||f||||f||||||||||2018-06-01 02:03:44.220703|2018-06-01 02:03:44.220703
NCT00694460|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-06-09|2008-06-09|2008-06-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|August 2002||2002-08-31|June 2008|2008-06-30|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers|A Phase II, Pilot, Randomized, Open-Label, Single-Center Study to Evaluate Immunogenicity, Safety and Booster Response of 3 Full Intramuscular Doses Versus 3 Half Intramuscular Doses Versus 3 Intradermal Doses Versus 2 Intradermal Doses of PCEC Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine as a Pre-Exposure Regimen in 12 to 18 Months Old Toddlers in Thailand.|Completed||Phase 2|200|Actual|Novartis||5|||f||||||||||||||2018-06-01 02:03:44.414832|2018-06-01 02:03:44.414832
NCT00692666|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|August 2007|Actual|2007-08-31|May 2006|Actual|2006-05-31||Observational|||Letigen® and Cardiovascular Morbidity|Letigen® and Cardiovascular Morbidity. A Register-Based Epidemiological Study|Completed|||300000||University of Southern Denmark|||||f||||f||||||||||2018-06-01 02:04:11.357012|2018-06-01 02:04:11.357012
NCT00694447|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2013-11-19|2008-06-09|2008-06-10|Estimate|||||||2013-11-19|2013-11-21|Estimate|February 2007||2007-02-28|November 2013|2013-11-30||||April 2008|Actual|2008-04-30||Interventional|||Acupuncture for Pain and Sleep Disturbance in Knee Osteoarthritis|Exploring Outcomes and Mechanisms of Acupuncture in Treating Pain and Sleep Disturbance in Knee Osteoarthritis|Completed||N/A|||Emory University||2|||f||||f||||||||||2018-06-01 02:03:44.499954|2018-06-01 02:03:44.499954
NCT00694434|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2008-06-09|2008-06-09|2008-06-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|January 2002||2002-01-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|GES/FET||Graduated Embryo Score (GES) in the Fresh Cycle Predicts Outcome From Frozen Embryo Transfer|Graduated Embryo Score (GES) Int he Fresh Cycle Predicts Outcome From Frozen Embryo Transfer|Completed|||183|Actual|Sher Institute for Reproductive Medicine, Las Vegas|||2||f||||f||||||||||2018-06-01 02:03:44.567329|2018-06-01 02:03:44.567329
NCT00694421|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2016-11-02|2008-06-05|2008-06-10|Estimate|||||||2016-11-02|2016-11-04|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Observational|||Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 2|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 2|Completed|||139|Actual|University of Pittsburgh|||2||f||||f||||||||No||2018-06-01 02:03:44.629849|2018-06-01 02:03:44.629849
NCT00694408|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2017-01-19|2008-06-09|2008-06-10|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2008||2008-06-30|January 2017|2017-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Pilot Trial of Pediatric Liver Transplantation Without Steroids|A Randomized Pilot Trial of a Steroid-free Immunosuppressant Regimen in Pediatric Liver Transplantation|Terminated||Phase 3|15|Actual|Birmingham Women's and Children's NHS Foundation Trust||2||Study terminated due to withdrawal from market of Daclizumab|f||||t||||||||||2018-06-01 02:03:44.704724|2018-06-01 02:03:44.704724
NCT00694395|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-09|2008-06-09|2008-06-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|August 2006||2006-08-31|July 2006|2006-07-31|July 2007|Actual|2007-07-31|May 2007|Actual|2007-05-31||Observational|||A Qualitative Study of Delays in Hospital Admission in Patient With Acute Stroke|Decision Making Process in Patients With Symptoms of Acute Ischemic Stroke Why do They Delay in Seeking Medical Help? A Qualitative Study|Completed|||20|Anticipated|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-06-01 02:03:44.869093|2018-06-01 02:03:44.869093
NCT00694382|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07||2011-12-14|2013-01-14|2008-06-06|2008-06-10|Estimate||||2011-12-14|2011-12-22|Estimate|2013-01-14|2013-01-23|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|SAVE-ONCO||Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy|A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy|Completed||Phase 3|3212|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:03:44.956388|2018-06-01 02:03:44.956388
NCT00694369|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2009-11-13||2016-02-19|2008-06-09|2008-06-10|Estimate|2010-01-04|2010-01-29|Estimate||||2016-02-19|2016-03-21|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)|A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Multiple-Dose Clinical Trial to Study the Efficacy and Safety of MK0663/Etoricoxib 90 and 120 mg, Ibuprofen 600 mg, and Acetaminophen 600 mg/Codeine 60 mg in the Treatment of Patients With Postoperative Dental Pain|Completed||Phase 3|588|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 02:03:46.621296|2018-06-01 02:03:46.621296
NCT00694356|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2017-03-28||2017-03-28|2008-06-09|2008-06-10|Estimate|2017-03-28|2017-06-15|Actual||||2017-03-28|2017-06-15|Actual|August 4, 2008||2008-08-04|March 2017|2017-03-31|April 28, 2009|Actual|2009-04-28|March 18, 2009|Actual|2009-03-18||Interventional|||Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)|A Phase I Study of MK-0646 in Patients With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|15|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 02:03:47.919992|2018-06-01 02:03:47.919992
NCT00694343|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2012-05-30|2008-06-09|2008-06-10|Estimate|||||||2012-05-30|2012-05-31|Estimate|June 2008||2008-06-30|May 2012|2012-05-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|CAESAR||Efficacy of Voluven® for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section|Evaluation of the Efficacy of 6% Hydroxyethyl Starch (HES, 130/0.4) in Normal Saline Compared to Ringer's Lactate Solution for the Prevention of Hypotension During Spinal Anesthesia for Cesarean Section|Completed||Phase 4|167|Actual|Fresenius Kabi||2|||f||||f||||||||||2018-06-01 02:03:48.445446|2018-06-01 02:03:48.445446
NCT00694330|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2017-06-20|2008-06-06|2008-06-10|Estimate|||||||2017-06-20|2017-06-22|Actual|June 2008|Actual|2008-06-30|March 2017|2017-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor|A Phase I Study of Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor|Completed||Phase 1|11|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:03:48.551103|2018-06-01 02:03:48.551103
NCT00694317|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2018-01-19|2008-06-09|2008-06-10|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2004||2004-02-29|January 2018|2018-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions.|Completed||N/A|40|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:03:48.636319|2018-06-01 02:03:48.636319
NCT00694304|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2013-10-28||2014-02-17|2008-06-09|2008-06-10|Estimate|2014-02-17|2014-04-01|Estimate||||2014-02-17|2014-04-01|Estimate|May 2008||2008-05-31|February 2014|2014-02-28|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional||Age and Sex: all-patients-treated set (APTS) – all patients who took at least one dose of Vortioxetine after Baseline; MADRS, HAM-D-24, HAM-A, CGI-S and SDS: full-analysis set (FAS) – all patients in the APTS who had at least one valid post-Baseline assessment of the MADRS total score.|Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults|A Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder|Completed||Phase 3|535|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-06-01 02:03:48.718278|2018-06-01 02:03:48.718278
NCT00694291|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2015-03-04|2008-06-05|2008-06-10|Estimate|||||||2015-03-04|2015-03-06|Estimate|June 2008||2008-06-30|March 2015|2015-03-31||||June 2010|Anticipated|2010-06-30||Interventional|||Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer|Phase II Double Blind Randomized Placebo Controlled Study of Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer|Withdrawn||Phase 2|0|Actual|Fox Chase Cancer Center||2|||f||||t||||||||||2018-06-01 02:03:48.969436|2018-06-01 02:03:48.969436
NCT00694278|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-05|2008-06-05|2008-06-10|Estimate|||||||2008-06-05|2008-06-10|Estimate|June 2008||2008-06-30|June 2008|2008-06-30||||||||Observational|||Clinical Evaluation of the Effect of Duodenal-Jejunal Bypass on Type 2 Diabetes|Clinical Evaluation of the Effect of Duodenal-Jejunal Bypass on Type 2 Diabetes in Adults|Unknown status|Recruiting||15|Anticipated|Ferzli, George S., M.D. F.A.C.S.|||||f||||||||||||||2018-06-01 02:03:49.049019|2018-06-01 02:03:49.049019
NCT00694265|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2008-08-25|2008-06-09|2008-06-10|Estimate|||||||2008-08-25|2008-08-26|Estimate|January 2002||2002-01-31|August 2008|2008-08-31|December 2003|Actual|2003-12-31|June 2003|Actual|2003-06-30||Observational|CTS||Sonographic Follow-up of Patients With Carpal Tunnel Syndrome Undergoing Surgical or Conservative Treatment|Sonographic Follow-up of Patients With Carpal Tunnel Syndrome Undergoing Surgical or Conservative Treatment: Prospective Cohort Study.|Completed|||55|Actual|University of Bern|||2||f||||f||||||||||2018-06-01 02:03:49.212658|2018-06-01 02:03:49.212658
NCT00694252|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2015-09-25|2008-06-06|2008-06-10|Estimate|||||||2015-09-25|2015-09-28|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Lapatinib and Circulating Tumor Cells in Breast Cancer|A Pilot Feasibility Study to Evaluate the Efficacy of Lapatinib in Eliminating Cytokeratin-positive Tumour Cells Circulating in the Blood of Women With Breast Cancer|Completed||Phase 2|20|Actual|University Hospital of Crete||1|||f||||f||||||||||2018-06-01 02:03:49.297937|2018-06-01 02:03:49.297937
NCT00694239|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2011-06-29|2008-06-06|2008-06-10|Estimate|||||||2011-06-29|2011-06-30|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|RATCHET||Risk Assessment and Treat Compliance in Hypertension Education Trial|Evaluation of the Effect of Cardiovascular Risk Assessment in Treatment Compliance in Hypertension|Completed||N/A|100|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 02:03:49.389621|2018-06-01 02:03:49.389621
NCT00694226|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2008-06-09|2008-06-09|2008-06-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|March 2004||2004-03-31|June 2008|2008-06-30||||September 2005|Actual|2005-09-30||Interventional|||Brief Intervention in Substance Use in Adolescent Psychiatric Patients|Brief Intervention in Substance Use Among Adolescent Psychiatric Patients: A Randomized Controlled Trial|Completed||N/A|143|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:03:49.458203|2018-06-01 02:03:49.458203
NCT00694213|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2009-02-11|2008-06-06|2008-06-10|Estimate|||||||2009-02-11|2009-02-12|Estimate|August 2007||2007-08-31|February 2009|2009-02-28||||September 2008|Actual|2008-09-30||Interventional|||Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)|A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines Administered With the Biojector® 2000 Needle-Free System|Completed||Phase 1|47|Actual|Vical||4|||f||||t||||||||||2018-06-01 02:03:49.524871|2018-06-01 02:03:49.524871
NCT00694200|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2015-05-27|2008-06-09|2008-06-10|Estimate|||||||2015-05-27|2015-05-29|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer|Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Patients With Metastatic Breast Cancer. A Multicenter Phase II Study|Terminated||Phase 2|13|Actual|Hellenic Oncology Research Group||1||Not reached the statistical hypothesis at the interim analysis|f||||f||||||||||2018-06-01 02:03:49.622662|2018-06-01 02:03:49.622662
NCT00694187|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2018-01-19|2008-06-09|2008-06-10|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2004||2004-01-31|January 2018|2018-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions.|Completed||N/A|39|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:03:49.716546|2018-06-01 02:03:49.716546
NCT00694174|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-09|2008-06-09|2008-06-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants|Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants|Completed||Phase 4|56|Actual|Children's Hospital of Michigan||2|||f||||t||||||||||2018-06-01 02:03:49.781723|2018-06-01 02:03:49.781723
NCT00694161|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2012-11-16|2010-10-12|2013-01-04|2008-06-09|2008-06-10|Estimate|2012-11-16|2012-12-18|Estimate|2011-06-03|2011-06-16|Estimate|2013-01-04|2013-01-11|Estimate|August 2008||2008-08-31|January 2013|2013-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy|The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy|Completed||Phase 2|35|Actual|Pfizer|Results for Holter monitoring parameters, increased interstitial markings, pleural effusions, PtGA and cardiothoracic ratio are presented as absolute values at specified time points and not as change from baseline as planned.|1|||f||||f||||||||||2018-06-01 02:03:49.934204|2018-06-01 02:03:49.934204
NCT00694148|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2012-10-29|2008-06-09|2008-06-10|Estimate|||||||2012-10-29|2012-10-30|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines|NT 201 is a Botulinum Toxin Type A Preparation Free of Complexing Proteins. Injected Into the Muscle, NT 201 Causes a Reversible Local Relaxation of the Injected Muscle. Botulinum Toxin Type A is Widely Used for Aesthetic Treatment of Mimic Wrinkles. This Study Will Investigate the Safety and Efficacy of NT 201 in the Treatment of Glabellar Frown Lines.|Completed||Phase 3|108|Actual|Merz Pharmaceuticals GmbH|||||f||||f||||||||||2018-06-01 02:03:51.156453|2018-06-01 02:03:51.156453
NCT00694135|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05||2010-08-20|2010-08-27|2008-06-09|2008-06-10|Estimate||||2010-08-20|2010-08-25|Estimate|2010-08-27|2010-08-31|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis|A Prospective, Multi-Center, Randomized, Double-Masked, Safety, Tolerability and Efficacy Study of Four Iontophoretic Doses of Dexamethasone Phosphate Ophthalmic Solution in Patients With Non-Infectious Anterior Segment Uveitis|Completed||Phase 2|40|Actual|Eyegate Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 02:03:51.258044|2018-06-01 02:03:51.258044
NCT00694122|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2013-11-04||2014-10-14|2008-06-06|2008-06-10|Estimate|2014-10-14|2014-10-21|Estimate||||2014-10-14|2014-10-21|Estimate|June 2005||2005-06-30|October 2014|2014-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|DAWN||Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon|Comparison of Lantus and NPH Insulin in the Dawn Phenomenon|Completed||Phase 3|27|Actual|Massachusetts General Hospital|Limitation: delayed and slow participant recruitment due to expansive use of insulin pumps and participants unwilling to cross over to alternate insulin.|2|||f||||t||||||||||2018-06-01 02:03:51.392046|2018-06-01 02:03:51.392046
NCT00694109|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2015-09-11||2016-08-01|2008-06-05|2008-06-10|Estimate|2015-11-17|2015-12-21|Estimate||||2016-08-01|2016-09-09|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Safety set: All enrolled participants who received at least 1 injection of study drug.|An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia|An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia|Completed||Phase 3|144|Actual|Kastle Therapeutics, LLC||1|||f||||f||||||||||2018-06-01 02:03:51.820997|2018-06-01 02:03:51.820997
NCT00694096|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2015-10-28||2015-10-28|2008-06-09|2008-06-10|Estimate|2015-10-28|2015-12-01|Estimate||||2015-10-28|2015-12-01|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response|Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response|Completed||Phase 1|25|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 02:03:52.918361|2018-06-01 02:03:52.918361
NCT00694083|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2015-02-12|2008-06-09|2008-06-10|Estimate|||||||2015-02-12|2015-02-13|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)|A Phase I Study of MK-8669 in Patients With Metastatic or Locally Advanced Solid Tumors|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 02:03:53.104161|2018-06-01 02:03:53.104161
NCT00694070|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2009-07-01||2016-01-29|2008-06-06|2008-06-10|Estimate|2009-08-13|2009-09-23|Estimate||||2016-01-29|2016-02-29|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Evaluation of a Diabetes Data Management System|Evaluation of a Diabetes Data Management System In a Clinical Setting|Completed|||51|Actual|Ascensia Diabetes Care|||1||f||||f||||||||||2018-06-01 02:03:53.183161|2018-06-01 02:03:53.183161
NCT00694057|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2011-06-11|2008-06-06|2008-06-10|Estimate|||||||2011-06-11|2011-06-14|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus|A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerance and Activity of HE3286 When Administered Orally for 12 Weeks to Adult Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|164|Actual|Harbor Therapeutics||2|||f||||f||||||||||2018-06-01 02:03:53.363602|2018-06-01 02:03:53.363602
NCT00694044|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-06-01|2008-06-06|2008-06-10|Estimate|||||||2009-06-01|2009-06-02|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects|A Randomized, Investigator and Subject Blind, Sponsor Open Parallel Group Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pro-Cognitive Effects of Varenicline, Under Various Titration Schemes, in Healthy Elderly Non-Smoking Subjects|Completed||Phase 1|50|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:03:53.480767|2018-06-01 02:03:53.480767
NCT00694031|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2014-02-27|2008-06-09|2008-06-10|Estimate|||||||2014-02-27|2014-02-28|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ESHOL||Survival Study in Patients Undergoing On-line Hemodiafiltration|A Randomized Study to Evaluate Survival in Patients Undergoing Hemodialysis or On-line Hemodiafiltration|Completed||Phase 4|906|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 02:03:53.549007|2018-06-01 02:03:53.549007
NCT00694018|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2014-10-06||2015-04-06|2008-06-06|2008-06-10|Estimate|2014-10-14|2014-10-17|Estimate||||2015-04-06|2015-04-27|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Veterans Walk to Beat Back Pain|Veterans Walk to Beat Back Pain|Completed||N/A|229|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:03:53.743825|2018-06-01 02:03:53.743825
NCT00694005|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2015-11-17|2008-06-06|2008-06-09|Estimate|||||||2015-11-17|2015-11-20|Estimate|January 2008||2008-01-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CROSS||Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch|Phase IV Study of the Choice of Optimal Strategy for Bifurcation Lesions With Normal Side Branch|Completed||Phase 4|504|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 02:03:54.107812|2018-06-01 02:03:54.107812
NCT00693992|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2016-12-08||2017-07-11|2008-06-06|2008-06-09|Estimate|2016-12-08|2017-02-02|Estimate||||2017-07-11|2017-08-10|Actual|June 2008||2008-06-30|July 2017|2017-07-31|May 2015|Actual|2015-05-31|November 2013|Actual|2013-11-30||Interventional|||Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy|Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511) as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-small Cell Lung Cancer|Completed||Phase 3|210|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 02:03:54.388606|2018-06-01 02:03:54.388606
NCT00693979|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-06-05|2008-06-05|2008-06-09|Estimate|||||||2008-06-05|2008-06-09|Estimate||||June 2008|2008-06-30||||||||Interventional|||A Prospective Evaluation in a Randomized Trial of TAXUS in the Treatment of De Novo Coronary Artey Lesions|A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions|Unknown status|Not yet recruiting|Phase 1|||National University Hospital, Singapore|||||f||||f||||||||||2018-06-01 02:03:56.105454|2018-06-01 02:03:56.105454
NCT00693966|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2016-09-15|2008-06-05|2008-06-09|Estimate|||||||2016-09-15|2016-09-16|Estimate|October 1999||1999-10-31|September 2016|2016-09-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females|A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers|Completed||Phase 2|210|Actual|GlaxoSmithKline||4|||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:56.161372|2018-06-01 02:03:56.161372
NCT00693953|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-10-01|2008-06-06|2008-06-09|Estimate|||||||2009-10-01|2009-10-02|Estimate|January 2010||2010-01-31|October 2009|2009-10-31|December 2012|Anticipated|2012-12-31|January 2011|Anticipated|2011-01-31||Observational|||Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism|Using the Digital EEG Spectral Analysis in Assessing Neuroelectrical Processing Abnormalities in Autism|Withdrawn|||200|Anticipated|Yellen & Associates, Inc.|||2|grant was not approved.|f||||f||||||||||2018-06-01 02:03:56.381861|2018-06-01 02:03:56.381861
NCT00693940|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2015-10-27|2008-06-05|2008-06-09|Estimate|||||||2015-10-27|2015-10-29|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Group Walking Sessions for Increasing Activity in People With Peripheral Arterial Disease (The Group Oriented Arterial Leg Study [GOALS])|Increasing Activity in Peripheral Arterial Disease|Completed||Phase 3|194|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 02:03:56.445029|2018-06-01 02:03:56.445029
NCT00693927|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2011-09-01|2008-06-06|2008-06-09|Estimate|||||||2011-09-01|2011-09-02|Estimate|March 2002||2002-03-31|September 2011|2011-09-30|May 2008|Actual|2008-05-31|May 2005|Actual|2005-05-31||Interventional|||Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC)|Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells: A Prospective Randomized Phase II Trial|Completed||Phase 2|54|Actual|University Hospital of Liege||2|||f||||f||||||||||2018-06-01 02:03:56.525476|2018-06-01 02:03:56.525476
NCT00693914|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2017-04-24|2008-06-06|2008-06-09|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2007||2007-04-30|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Working Memory Performance Among Childhood Brain Tumor Survivors|Working Memory Performance Among Childhood Brain Tumor Survivors Treated With Conformal Radiation Therapy: A Pilot Study|Completed|||130|Actual|St. Jude Children's Research Hospital|||3||f||||f||||||||||2018-06-01 02:03:56.598612|2018-06-01 02:03:56.598612
NCT00693901|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2012-12-13|2008-06-05|2008-06-09|Estimate|||||||2012-12-13|2012-12-17|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Influence of Public Parks on Physical Activity Levels of Diverse Communities|Parks and Physical Activity in Diverse Communities|Completed||N/A|50|Actual|RAND||3|||f||||t||||||||||2018-06-01 02:03:56.673819|2018-06-01 02:03:56.673819
NCT00693888|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2010-08-16|2008-06-06|2008-06-09|Estimate|||||||2010-08-16|2010-08-17|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|September 2010|Anticipated|2010-09-30|February 2010|Anticipated|2010-02-28||Interventional|ULTDEM||Lighthouse Project on Dementia, Ulm, Germany|Lighthouse Project on Dementia, Ulm, Germany - Improvement of Advice and Diagnostics for People Suffering From Dementia After the Classification of Their Level of Care (ULTDEM Study).|Unknown status|Recruiting|N/A|200|Anticipated|University of Ulm||2|||f||||t||||||||||2018-06-01 02:03:56.748303|2018-06-01 02:03:56.748303
NCT00693875|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-01-27|2008-06-06|2008-06-09|Estimate|||||||2009-01-27|2009-01-28|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Observational|||The Incidence of Intra-Operative Awareness in China and Analysis of Relevant Factors: a Multicentre Study|The Incidence of Intra-Operative Awareness in China and Analysis of Relevant Factors: a Multicentre Study|Completed|||11197|Actual|Capital Medical University|||||f||||t||||||||||2018-06-01 02:03:56.843119|2018-06-01 02:03:56.843119
NCT00693862|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-06|2008-06-06|2008-06-09|Estimate|||||||2008-06-06|2008-06-09|Estimate|December 2006||2006-12-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Pharmacokinetic Study With Repeated Doses of Stalevo|Levodopa Concentration Profile After Repeated Doses of Stalevo|Completed||Phase 1|19|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 02:03:57.026628|2018-06-01 02:03:57.026628
NCT00693849|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2017-01-19|2008-06-06|2008-06-09|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|iSPOT-D||International Study to Predict Optimised Treatment - in Depression|International Study to Predict Optimised Treatment - in Depression|Unknown status|Recruiting|Phase 4|2688|Anticipated|BRC Operations Pty. Ltd.||4|||f||||f||||||||||2018-06-01 02:03:57.111194|2018-06-01 02:03:57.111194
NCT00693836|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2013-08-09|2008-06-06|2008-06-09|Estimate|||||||2013-08-09|2013-08-12|Estimate|January 2006||2006-01-31|December 2008|2008-12-31||||October 2010|Anticipated|2010-10-31||Observational|||Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) Region|Resource for the Study of Lung Cancer Epidemiology in North Trent|Unknown status|Recruiting||2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:03:57.247665|2018-06-01 02:03:57.247665
NCT00693823|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-06|2008-06-06|2008-06-09|Estimate|||||||2008-06-06|2008-06-09|Estimate|September 2003||2003-09-30|June 2008|2008-06-30|January 2008|Actual|2008-01-31|May 2007|Actual|2007-05-31||Interventional|||Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusive Disease|A Prospective Randomized Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Superficial Femoral Artery Occlusion|Completed||N/A|86|Actual|Texas Vascular Associates||2|||f||||t||||||||||2018-06-01 02:03:57.31151|2018-06-01 02:03:57.31151
NCT00693797|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-04-27|2008-06-06|2008-06-09|Estimate|||||||2009-04-27|2009-04-28|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Clinical Significance of Collagen Metabolism Changes in Left Cardiac Ventricle|Clinical Significance of Collagen Metabolism Changes in Patients With Failing and Pressure Overloaded Left Cardiac Ventricle.|Completed|||50|Anticipated|Charles University, Czech Republic|||2||f||||f||||||Samples Without DNA|"~     frozen serum for collagen metabolism detection~   "|||2018-06-01 02:03:57.381533|2018-06-01 02:03:57.381533
NCT00693784|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2010-03-08||2015-05-26|2008-06-06|2008-06-09|Estimate|2010-04-07|2010-04-29|Estimate||||2015-05-26|2015-06-22|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|January 2011|Actual|2011-01-31|February 2009|Actual|2009-02-28||Interventional|||Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System: A Pilot Study|A Multicenter Pilot Study of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System|Completed||N/A|15|Actual|Spinal Restoration, Inc.||1|||f||||t||||||||||2018-06-01 02:03:57.45303|2018-06-01 02:03:57.45303
NCT00693771|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2011-01-24|2008-06-06|2008-06-09|Estimate|||||||2011-01-24|2011-01-25|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|OPTIMIZATION||Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin|A Prospective Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin|Completed||Phase 4|313|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:03:57.635762|2018-06-01 02:03:57.635762
NCT00693758|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-10-02|2008-06-05|2008-06-09|Estimate|||||||2011-10-02|2011-10-04|Estimate|January 2006||2006-01-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Assessment of Oxygen Changes in the Heart With Cardio-vascular Magnetic Resonance Imaging|Magnetic Resonance Imaging for the Detection of Oxygen Changes in the Heart|Completed||Early Phase 1|100|Actual|University of Calgary||7|||f||||t||||||||||2018-06-01 02:03:57.71318|2018-06-01 02:03:57.71318
NCT00693745|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2010-10-21|2008-06-06|2008-06-09|Estimate|||||||2010-10-21|2010-10-22|Estimate|September 2008||2008-09-30|October 2010|2010-10-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Observational|GALLANT||Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF|NGAL Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF|Completed|||231|Actual|Biosite|||||f||||f||||||||||2018-06-01 02:03:57.804836|2018-06-01 02:03:57.804836
NCT00693732|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2014-01-06|2008-06-06|2008-06-09|Estimate|||||||2014-01-06|2014-01-07|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS)|Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS)|Completed||Phase 4|30|Actual|National University Hospital, Singapore||2|||f||||||||||||||2018-06-01 02:03:58.024075|2018-06-01 02:03:58.024075
NCT00693719|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|2013-06-12||2015-10-15|2008-06-06|2008-06-09|Estimate|2013-06-12|2013-08-21|Estimate||||2015-10-15|2015-11-20|Estimate|August 2007||2007-08-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer|A Phase II Study: Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer|Completed||Phase 2|31|Actual|University of Arizona||1|||f||||t||||||||||2018-06-01 02:03:58.115882|2018-06-01 02:03:58.115882
NCT00693706|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2012-12-19||2016-10-11|2008-06-02|2008-06-09|Estimate|2013-02-07|2013-03-12|Estimate||||2016-10-11|2016-11-23|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix|Safety and Immunogenicity Study of GSK Biologicals' Cell Culture-based Influenza Virus Vaccine 1388442A Compared With US Licensed TIV in Healthy Adults|Completed||Phase 1|200|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:58.362689|2018-06-01 02:03:58.362689
NCT00693693|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2017-01-27||2017-11-01|2008-06-06|2008-06-09|Estimate|2017-01-27|2017-03-17|Actual||||2017-11-01|2017-12-06|Actual|November 2006||2006-11-30|November 2017|2017-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis|Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis|Completed||Phase 4|26|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||No||2018-06-01 02:03:58.805239|2018-06-01 02:03:58.805239
NCT00693680|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-09|2008-06-06|2008-06-09|Estimate|||||||2008-06-09|2008-06-13|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Zinc Supplementation of Imipramine Therapy|The Role of Zinc in Therapy of Unipolar Depression|Completed||N/A|60|Actual|Polish Academy of Sciences||2|||f||||t||||||||||2018-06-01 02:03:59.125097|2018-06-01 02:03:59.125097
NCT00693667|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2011-11-03|2008-06-06|2008-06-09|Estimate|||||||2011-11-03|2011-11-04|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PH3||Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women|A Phase II, Double-Blind, Randomized, Placebo-controlled, Clinical Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women|Completed||Phase 2|92|Actual|PhytoHealth Corporation||4|||f||||f||||||||||2018-06-01 02:03:59.217677|2018-06-01 02:03:59.217677
NCT00693654|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2010-11-12||2017-03-14|2008-06-06|2008-06-09|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|November 2006||2006-11-30|March 2017|2017-03-31|October 2008|Actual|2008-10-31|November 2006|Actual|2006-11-30||Interventional|||Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients|A Controlled Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Pruritus in Adult Hemodialysis Patients|Completed||Phase 4|28|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-06-01 02:03:59.319512|2018-06-01 02:03:59.319512
NCT00693641|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2011-06-03|2008-06-06|2008-06-09|Estimate|||||||2011-06-03|2011-06-06|Estimate|July 2008||2008-07-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|||Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief|Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief|Completed||Phase 4|39|Actual|University of Oslo||2|||f||||f||||||||||2018-06-01 02:03:59.565683|2018-06-01 02:03:59.565683
NCT00693628|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-03-22||2017-05-03|2008-06-05|2008-06-09|Estimate|2017-03-22|2017-05-03|Actual||||2017-05-03|2017-06-05|Actual|March 2007||2007-03-31|May 2017|2017-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Early termination of the study due to poor enrollment numbers, i.e., only 4 subjects were enrolled. No analysis was performed due to insufficient data to assess outcome measures. The number of patients in each group is unknown.|Effects of Shrinker Use on Healing and Volume|Effects of Shrinker Use on Healing and Volume for Transtibial Amputees|Terminated||N/A|4|Actual|University of Oklahoma|Early termination of the study due to poor enrollment numbers, (only 4 subjects were enrolled). No analysis was performed due to insufficient data to assess outcome measures.|3||Terminated due to lack of enrollment|f||||f||||||||No||2018-06-01 02:03:59.658336|2018-06-01 02:03:59.658336
NCT00693615|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2016-09-15|2008-06-05|2008-06-09|Estimate|||||||2016-09-15|2016-09-16|Estimate|October 2000||2000-10-31|September 2016|2016-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females|Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, When Formulated With Aluminum Hydroxide, AS04, or Without Adjuvant, in Healthy Adult Female Volunteers|Completed||Phase 2|60|Actual|GlaxoSmithKline||3|||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:03:59.830041|2018-06-01 02:03:59.830041
NCT00693602|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2017-04-24|2008-06-06|2008-06-09|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2006||2006-06-30|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma|Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma|Completed||Phase 1|87|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 02:03:59.925236|2018-06-01 02:03:59.925236
NCT00693407|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2014-01-06|2008-06-06|2008-06-09|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation|Activation of Endogenous Inhibitory Modulation During Gastric and Somatic Stimulation in Functional Dyspepsia Patients and Healthy Controls|Completed||N/A|80|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 02:04:02.57125|2018-06-01 02:04:02.57125
NCT00693589|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-06|2008-06-06|2008-06-09|Estimate|||||||2008-06-06|2008-06-09|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|February 2007|Actual|2007-02-28||Interventional|||Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-Dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease|Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-Dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease|Completed||Phase 2|36|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:03:59.98748|2018-06-01 02:03:59.98748
NCT00693576|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-05|2008-06-05|2008-06-09|Estimate|||||||2008-06-05|2008-06-09|Estimate|April 2007||2007-04-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates|The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates|Completed||Phase 2/Phase 3|82|Actual|Shiraz University of Medical Sciences||1|||f||||t||||||||||2018-06-01 02:04:00.047646|2018-06-01 02:04:00.047646
NCT00693563|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2013-01-10|2008-06-06|2008-06-09|Estimate|||||||2013-01-10|2013-01-11|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|SCILink||Scheduled Telephone Intervention for Individuals With Spinal Cord Injury and Their Families|Scheduled Telephone Intervention for Individuals With Spinal Cord Injury and Their Families: A Randomized Controlled Trial|Completed||N/A|168|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:04:00.114473|2018-06-01 02:04:00.114473
NCT00693550|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2011-06-06|2008-06-06|2008-06-09|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2000||2000-08-31|June 2011|2011-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer|Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma?|Completed|||115|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 02:04:00.195993|2018-06-01 02:04:00.195993
NCT00693537|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-06|2008-06-06|2008-06-09|Estimate|||||||2008-06-06|2008-06-09|Estimate||||June 2008|2008-06-30||||||||Interventional|||Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease|Long- But Not Short-Term Exercise Training Improves Coronary Endothelial Dysfunction in Diabetes Mellitus Type 2 and Coronary Artery Disease|Completed||Phase 4|||Paracelsus Medical University||2|||f||||||||||||||2018-06-01 02:04:00.249721|2018-06-01 02:04:00.249721
NCT00693524|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2014-08-25|2008-06-05|2008-06-09|Estimate|||||||2014-08-25|2014-08-26|Estimate|November 2002||2002-11-30|August 2014|2014-08-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|TAST||Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX|An Open, Randomized, Multicentre Clinical Study to Compare the Safety and Efficacy of a Combination of Sequential Therapy of Tacrolimus (FK506) With Monoclonal Anti-IL2R Antibodies and Mycophenolate Mofetil Versus Tacrolimus (FK506) With Steroids in Liver Allograft Transplantation|Completed||Phase 2|94|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:04:00.302169|2018-06-01 02:04:00.302169
NCT00693511|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2017-09-20|2008-06-05|2008-06-09|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2007||2007-10-31|September 2017|2017-09-30|August 31, 2012|Actual|2012-08-31|August 31, 2010|Actual|2010-08-31||Interventional|||Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth|Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth|Completed||N/A|45|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 02:04:00.394307|2018-06-01 02:04:00.394307
NCT00693498|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2011-11-30||2018-01-04|2008-06-06|2008-06-09|Estimate|2012-11-28|2012-11-29|Estimate||||2018-01-04|2018-01-08|Actual|July 2008||2008-07-31|January 2018|2018-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Washed Versus Standard Blood Cell Transfusions in Pediatric Open Heart Surgery|Standard vs. Washed Blood Cell Transfusions in Pediatric Cardiac Surgery: Impact on Post-operative Inflammation as Evidenced by the IL-6 to IL-10 Ratio.|Completed||N/A|162|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 02:04:00.628165|2018-06-01 02:04:00.628165
NCT00693485|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2013-03-13|2012-01-26|2013-03-13|2008-06-05|2008-06-09|Estimate|2013-03-13|2013-04-24|Estimate|2012-01-26|2012-01-30|Estimate|2013-03-13|2013-04-24|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy||Completed||Phase 2|70|Actual|Allergan||3|||f||||t||||||||||2018-06-01 02:04:00.884029|2018-06-01 02:04:00.884029
NCT00693472|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2017-02-08|2009-04-17|2017-04-21|2008-06-06|2008-06-09|Estimate|2017-04-21|2017-05-24|Actual|2009-09-30|2009-10-02|Estimate|2017-04-21|2017-05-24|Actual|August 15, 2007||2007-08-15|April 2017|2017-04-30|January 9, 2009|Actual|2009-01-09|December 12, 2008|Actual|2008-12-12||Interventional|||Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)|Efficacy of SCH 420814 to Reduce the Frequency or Severity of Neuroleptic Induced Akathisia|Terminated||Phase 2|46|Actual|Merck Sharp & Dohme Corp.|The study was terminated early by the sponsor due to lack of enrollment.|4|||f||||f||||||||||2018-06-01 02:04:01.256425|2018-06-01 02:04:01.256425
NCT00693459|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-01-16|2008-06-05|2008-06-09|Estimate|||||||2013-01-16|2013-01-17|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of a New Circular Anal Dilator|Feasibility Study of a New Circular Anal Dilator for Transanal Hemorrhoidectomy|Completed||Phase 1/Phase 2|20|Actual|University Hospitals Cleveland Medical Center|||||f||||f||||||||||2018-06-01 02:04:01.839104|2018-06-01 02:04:01.839104
NCT00693446|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2015-05-11|2008-06-06|2008-06-09|Estimate|||||||2015-05-11|2015-05-12|Estimate|April 2004||2004-04-30|May 2015|2015-05-31|April 2017|Anticipated|2017-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids|An Open-Label, Comparative, Randomized, Prospective Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids|Unknown status|Active, not recruiting|Phase 4|118|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 02:04:01.910667|2018-06-01 02:04:01.910667
NCT00693433|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2015-12-03|2008-06-06|2008-06-09|Estimate|||||||2015-12-03|2015-12-04|Estimate|December 2008||2008-12-31|June 2013|2013-06-30||||August 2010|Actual|2010-08-31||Interventional|||Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma|A Phase 1 Study of CCI-779 in Combination With Dexamethasone in Multiple Myeloma|Completed||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:04:02.019981|2018-06-01 02:04:02.019981
NCT00693420|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2009-01-14||2013-09-26|2008-06-06|2008-06-09|Estimate|2009-03-26|2009-05-12|Estimate||||2013-09-26|2013-10-30|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence||Completed||Phase 3|278|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:04:02.132609|2018-06-01 02:04:02.132609
NCT00693381|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-09-17|2008-06-06|2008-06-09|Estimate|||||||2014-09-17|2014-09-18|Estimate|February 2003||2003-02-28|September 2014|2014-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|DISTAMP||Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation|An Open, Multicentre, Randomised, Parallel Group Pilot-Study to Compare Safety and Efficacy of Discontinuation of Mycophenolate Mofetil From a Tacrolimus/MMF/Steroid Triple Regimen Following Kidney Transplantation|Completed||Phase 3|152|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:04:02.645399|2018-06-01 02:04:02.645399
NCT00693355|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2017-02-22|2008-06-06|2008-06-09|Estimate|||||||2017-02-22|2017-02-24|Actual|December 2005||2005-12-31|February 2017|2017-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Butyrate Enemas on Colonic Health|Effects of Butyrate Enemas on Colonic Health|Completed||N/A|16|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 02:04:02.74851|2018-06-01 02:04:02.74851
NCT00693342|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-06|||2013-04-08|2008-06-06|2008-06-09|Estimate|||||||2013-04-08|2013-04-09|Estimate|August 2008||2008-08-31|July 2008|2008-07-31||||January 2012|Anticipated|2012-01-31||Interventional|||Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission|A Randomized Phase III Trial in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer With a Polyvalent Vaccine-KLH Conjugate + OPT-821 Versus OPT-821|Withdrawn||Phase 3|0|Actual|Gynecologic Oncology Group||2||Never opened to accrual, a GOG working number, not developed into a clinical trial.|f||||||||||||||2018-06-01 02:04:02.823067|2018-06-01 02:04:02.823067
NCT00693329|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-12-17|2008-06-06|2008-06-09|Estimate|||||||2009-12-17|2009-12-18|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|ENCINO||Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy|Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy|Completed|||260|Anticipated|Biosite|||||f||||t||||||Samples Without DNA|"~     Blood sample taken at 8 timepoints over 2 days.~   "|||2018-06-01 02:04:02.887545|2018-06-01 02:04:02.887545
NCT00693316|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2010-02-10|2008-06-06|2008-06-09|Estimate|||||||2010-02-10|2010-02-11|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Tolerability Study With Single Ascending Doses of ORM-12741|Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Single Ascending Doses of ORM-12741|Completed||Phase 1|120|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-06-01 02:04:02.935801|2018-06-01 02:04:02.935801
NCT00693303|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2009-07-10||2017-06-20|2008-06-05|2008-06-09|Estimate|2009-07-10|2009-08-25|Estimate||||2017-06-20|2017-12-15|Actual|June 2008||2008-06-30|June 2017|2017-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Examining the Effectiveness of My Scrivener on Handwriting Legibility|Examining the Effectiveness of My Scrivener on Handwriting Legibility|Completed||N/A|21|Actual|Shenandoah University||1|||f||||f||||||||No||2018-06-01 02:04:03.003071|2018-06-01 02:04:03.003071
NCT00693290|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-06|2008-06-06|2008-06-09|Estimate|||||||2008-06-06|2008-06-09|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy|Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Ulster||2|||f||||t||||||||||2018-06-01 02:04:03.213298|2018-06-01 02:04:03.213298
NCT00693277|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-10-06|2008-06-06|2008-06-09|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 2006||2006-09-30|October 2015|2015-10-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Assessing Novel Methods of Improving Patient Education of Nutrition|Assessing Novel Methods of Improving Patient Education of Nutrition: eHealth, Health Literacy and Chronic Kidney Disease|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 02:04:03.283358|2018-06-01 02:04:03.283358
NCT00693264|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-03-27|2008-06-06|2008-06-09|Estimate|||||||2009-03-27|2009-03-30|Estimate|May 2008||2008-05-31|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Hoodia on Blood Pressure and Heart Function|The Hemodynamic and Electrocardiographic Effects of Hoodia Gordonii in Healthy Volunteers|Completed||N/A|15|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-06-01 02:04:03.324712|2018-06-01 02:04:03.324712
NCT00693251|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2015-11-16|2008-06-06|2008-06-09|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2008||2008-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PERFECT||Optimal Stenting Strategy For True Bifurcation Lesions|Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions|Completed||Phase 4|420|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 02:04:03.534748|2018-06-01 02:04:03.534748
NCT00693238|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2013-03-14||2017-08-10|2008-06-05|2008-06-06|Estimate|2013-07-23|2013-07-24|Estimate||||2017-08-10|2017-08-23|Actual|April 2008||2008-04-30|August 2017|2017-08-31|December 2033|Anticipated|2033-12-31|June 2012|Actual|2012-06-30||Interventional|PR04||Proton Therapy for Low and Intermediate Risk Prostate Cancer|A Phase II Study of Hypofractionated Image Guided Proton Radiation Therapy for Low and Intermediate Risk Adenocarcinoma of the Prostate|Active, not recruiting||N/A|228|Actual|University of Florida||2|||f||||t|f|f||||||||2018-06-01 02:04:03.654135|2018-06-01 02:04:03.654135
NCT00693225|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2012-08-21||2012-08-21|2008-06-05|2008-06-06|Estimate|2012-08-21|2012-09-20|Estimate||||2012-08-21|2012-09-20|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study|Impact of Timing on the Efficacy of Omeprazole/Sodium Bicarbonate Zegerid 40 mg in Healing Reflux Esophagitis|Completed||Phase 4|91|Actual|Mayo Clinic|Our methods relied upon pill counting as a proxy for adherence to medical therapy. Now that PPIs are available over the counter, few patients present de novo with LA C and LA D esophagitis. We didn't control for other factors that can affect GERD.|2|||f||||f||||||||||2018-06-01 02:04:03.922208|2018-06-01 02:04:03.922208
NCT00693212|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|February 1986||1986-02-28|June 2008|2008-06-30|November 1994|Actual|1994-11-30|November 1994|Actual|1994-11-30||Interventional|||Further Studies of Attention Deficit Disorder - Residual Type (RT)|Further Studies of Attention Deficit Disorder - Residual Type|Completed||Phase 3|116|Actual|University of Utah||3|||t||||f||||||||||2018-06-01 02:04:04.18302|2018-06-01 02:04:04.18302
NCT00693199|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-08-07|2008-06-05|2008-06-06|Estimate|||||||2008-08-07|2008-08-08|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension||Completed||N/A|360|Actual|Anhui Medical University||3|||f||||t||||||||||2018-06-01 02:04:04.330599|2018-06-01 02:04:04.330599
NCT00693186|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2017-09-08|2008-06-05|2008-06-06|Estimate|||||||2017-09-08|2017-09-11|Actual|October 2008|Actual|2008-10-31|September 2017|2017-09-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA|An Open-label, Randomised, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Booster Dose of Two Different Hepatitis B Vaccines to Explore the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children Previously Vaccinated at About 3, 5 and 11 to 13 Months of Age With Either HEXAVAC® or INFANRIX®-HEXA|Completed||Phase 3|410|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:04:04.419606|2018-06-01 02:04:04.419606
NCT00693173|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2013-02-11|2008-06-05|2008-06-06|Estimate|||||||2013-02-11|2013-02-12|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients|Genital Drop Technique With Intensity-Modulated Radiation Therapy (IMRT) in Male Anal and Distal Rectal Cancer Patients: A Dosimetric Comparison|Completed|||14|Actual|The University of Texas Medical Branch, Galveston|||||f||||f||||||||||2018-06-01 02:04:04.504609|2018-06-01 02:04:04.504609
NCT00693160|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2013-05-15||2017-11-06|2008-06-03|2008-06-06|Estimate|2014-03-07|2014-04-14|Estimate||||2017-11-06|2017-11-08|Actual|December 2007||2007-12-31|January 2017|2017-01-31|January 2011|Actual|2011-01-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Spinal Ketorolac After Acute Opioid Exposure|Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity Following Acute Opioid Exposure|Terminated||Phase 2|30|Actual|Wake Forest University Health Sciences||2||the manufacturing of preservative free ketorolac (Acular-PF) was discontinued|f||||t||||||||||2018-06-01 02:04:04.579785|2018-06-01 02:04:04.579785
NCT00693147|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2012-09-29|2008-06-05|2008-06-06|Estimate|||||||2012-09-29|2012-10-02|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|December 2009|Actual|2009-12-31||Interventional|||Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T)|Late Postoperative Course of Patients With Mini Video Assisted Thyroidectomy (miVAT) Versus Classic Thyroidectomy (T)|Completed||N/A|100|Actual|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-06-01 02:04:04.855513|2018-06-01 02:04:04.855513
NCT00693134|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|March 2004||2004-03-31|February 2008|2008-02-29|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Role of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Children With Myocarditis|The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Children With Acute Inflammatory Cardiomyopathy|Completed|||36|Actual|University of Texas Southwestern Medical Center|||2||f||||f||||||Samples Without DNA|"~     Biopsy tissue, if available.~   "|||2018-06-01 02:04:04.925422|2018-06-01 02:04:04.925422
NCT00693121|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|April 2003||2003-04-30|June 2008|2008-06-30|June 2008|Anticipated|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Amantadine for Treatment of Symptoms of the Post-Traumatic Confusional State|Amantadine Hydrochloride for Treatment of Symptoms of the Post-Traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial|Unknown status|Active, not recruiting|Phase 4|79|Actual|Methodist Rehabilitation Center||2|||f||||f||||||||||2018-06-01 02:04:04.98871|2018-06-01 02:04:04.98871
NCT00693108|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|September 2006||2006-09-30|June 2008|2008-06-30||||||||Interventional|||Androgens for Poor Responders in In Vitro Fertilization|Transdermal Testosterone to Improve Ovarian Response to Gonadotropins in Poor Responder IVF Patients With Normal Basal Concentrations of FSH|Completed||Phase 3|||Hospital Clinic of Barcelona||2|||f||||||||||||||2018-06-01 02:04:05.084592|2018-06-01 02:04:05.084592
NCT00693095|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2018-01-26|2008-06-05|2008-06-06|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2008||2008-09-30|January 2018|2018-01-31|April 2015|Actual|2015-04-30|December 2013|Actual|2013-12-31||Interventional|ERaDICATe||Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer|Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer|Completed||Phase 1|23|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:04:05.152793|2018-06-01 02:04:05.152793
NCT00693082|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-11-19|2008-06-05|2008-06-06|Estimate|||||||2012-11-19|2012-11-20|Estimate|August 2007||2007-08-31|November 2012|2012-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Polycystic Ovarian Syndrome: Impact of Flaxseed Supplementation|Polycystic Ovarian Syndrome: Impact of Flaxseed Supplementation|Terminated||Phase 2|4|Actual|Duke University||1||recruitment and pilot funding issues|f||||t||||||||||2018-06-01 02:04:05.2513|2018-06-01 02:04:05.2513
NCT00693069|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-08-20|2008-06-05|2008-06-06|Estimate|||||||2012-08-20|2012-08-21|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|April 2006|Actual|2006-04-30|||||Interventional|||Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function|Effect of Different Dosing Regimens of Clopidogrel Given Before Elective Percutaneous Coronary Intervention on Platelet Function|Completed||Phase 3|120|Actual|Hopital du Sacre-Coeur de Montreal||4|||f||||f||||||||||2018-06-01 02:04:05.320956|2018-06-01 02:04:05.320956
NCT00693056|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-05-04|2008-06-04|2008-06-06|Estimate|||||||2009-05-04|2009-05-05|Estimate|June 2008||2008-06-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)|A Double-Blinded, Randomized, Placebo-Controlled, Dose-Exploring Study of RX-10100 for Eight Weeks of On-Demand Administration in Subjects With Erectile Dysfunction (ED)|Completed||Phase 2|40|Anticipated|Rexahn Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 02:04:05.416664|2018-06-01 02:04:05.416664
NCT00693043|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-12-21|2008-06-05|2008-06-06|Estimate|||||||2017-12-21|2017-12-26|Actual|February 2008|Actual|2008-02-29|March 2014|2014-03-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy|A Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy|Withdrawn||N/A|0|Actual|Lahey Clinic||2||Principal Investigator left the institution requested termination|f||||f||||||||||2018-06-01 02:04:05.501499|2018-06-01 02:04:05.501499
NCT00693030|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|June 2008|Anticipated|2008-06-30||Interventional|ODESSA||Optical Coherence Tomography for Drug Eluting Stent Safety|In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography|Unknown status|Recruiting|Phase 4|77|Anticipated|A.O. Ospedale Papa Giovanni XXIII||4|||f||||t||||||||||2018-06-01 02:04:05.572509|2018-06-01 02:04:05.572509
NCT00693017|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2012-08-13||2015-12-21|2008-06-05|2008-06-06|Estimate|2012-08-13|2012-09-12|Estimate||||2015-12-21|2015-12-24|Estimate|June 2008||2008-06-30|November 2015|2015-11-30||||November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy|A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy|Terminated||Phase 3|10|Actual|Eisai Inc.|Due to early termination of the study by the Sponsor. No formal analyses were conducted.|2||Sponsor's decision|f||||||||||||||2018-06-01 02:04:05.673842|2018-06-01 02:04:05.673842
NCT00693004|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-07-28|2008-06-05|2008-06-06|Estimate|||||||2009-07-28|2009-07-30|Estimate|May 2008||2008-05-31|July 2009|2009-07-31||||January 2010|Anticipated|2010-01-31||Interventional|||Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease|Terminated||Phase 2|236|Anticipated|Epix Pharmaceuticals, Inc.||3|||f||||||||||||||2018-06-01 02:04:06.058595|2018-06-01 02:04:06.058595
NCT00692991|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2016-02-22|2008-06-04|2008-06-06|Estimate|||||||2016-02-22|2016-02-23|Estimate|October 1999||1999-10-31|February 2013|2013-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Using Magnetic Resonance Imaging to Evaluate Heart Vessel Function After Angioplasty or Stent Placement Procedures|Microvascular Obstruction by Contrast-enhanced MRI Following Percutaneous Coronary Interventions|Completed|||144|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-06-01 02:04:06.176325|2018-06-01 02:04:06.176325
NCT00692978|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2013-04-05|2008-06-05|2008-06-06|Estimate|||||||2013-04-05|2013-04-08|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate|The Pharmacokinetics of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols|Completed||Phase 4|23|Actual|Imperial College London||4|||f||||f||||||||||2018-06-01 02:04:06.25077|2018-06-01 02:04:06.25077
NCT00692965|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2012-08-23|2008-06-04|2008-06-06|Estimate|||||||2012-08-23|2012-08-27|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Sleep Quality and Presence of Sleep Disordered Breathing|Sleep Quality and Presence of Sleep Disordered Breathing In An Inner City African American HIV Infected Population Aged 50 Years and Older|Completed|||74|Actual|University of Florida|||||f||||f||||||||||2018-06-01 02:04:06.338117|2018-06-01 02:04:06.338117
NCT00692952|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-07-09|2008-06-05|2008-06-06|Estimate|||||||2009-07-09|2009-07-10|Estimate|March 2004||2004-03-31|June 2008|2008-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|BZK||Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial|Effectiveness of BenZalkonium Chloride Gel as Vaginal Contraceptive: a Multicentric Randomized Controlled Trial|Completed||Phase 2|240|Actual|Shanghai Institute of Planned Parenthood Research||2|||f||||t||||||||||2018-06-01 02:04:06.418125|2018-06-01 02:04:06.418125
NCT00692939|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2018-02-12|2008-06-05|2008-06-06|Estimate|||||||2018-02-12|2018-02-14|Actual|June 26, 2012|Actual|2012-06-26|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Autologous Stem Cell Transplantation for Crohn's Disease|Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients With Severe Crohn's Disease|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||No||2018-06-01 02:04:06.495868|2018-06-01 02:04:06.495868
NCT00692926|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2017-06-27|2008-06-05|2008-06-06|Estimate|||||||2017-06-27|2017-06-29|Actual|October 2005||2005-10-31|June 2017|2017-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells|A Pilot Trial of Unrelated Umbilical Cord Blood Transplantation Augmented With Ex Vivo CytokinePrimed ALDHbr Umbilical Cord Blood Cells|Completed||Phase 1|37|Actual|Duke University||4|||f||||t||||||||||2018-06-01 02:04:06.586706|2018-06-01 02:04:06.586706
NCT00692913|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2011-07-20||2017-02-14|2008-06-04|2008-06-06|Estimate|2011-07-20|2011-08-15|Estimate||||2017-02-14|2017-03-21|Actual|June 2008||2008-06-30|February 2017|2017-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)|A Phase III (Phase V Program), Open-Label, Randomized, Referred-Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK -0217A/Alendronate Sodium-70 mg/Vitamin D3 5600 I.U. Combination Tablet on Vitamin D Inadequacy in the Treatment of Osteoporosis in Postmenopausal Women|Completed||Phase 3|515|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:04:06.666313|2018-06-01 02:04:06.666313
NCT00692900|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2016-01-31|2008-06-05|2008-06-06|Estimate|||||||2016-01-31|2016-02-02|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer|Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|Completed||Phase 1|25|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:04:08.167452|2018-06-01 02:04:08.167452
NCT00692887|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2009-01-27|2008-06-05|2008-06-06|Estimate|||||||2009-01-27|2009-01-28|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|PHP||Correlation Between Visual Field Defects on Foresee Preferential Hyperacuity Perimeter(PHP) and on Optical Coherence Tomography (OCT) in Patients With Choroidal Neovascularization (CNV)|Correlation Between Visual Field Defects on Foresee PHP and OCT in Patients With CNV Before and After Treatment|Completed|||15|Actual|Notal Vision Ltd|||1||f||||t||||||||||2018-06-01 02:04:08.24487|2018-06-01 02:04:08.24487
NCT00692874|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2010-12-09|2008-06-05|2008-06-06|Estimate|||||||2010-12-09|2010-12-10|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Observational|AZTEK EXT||Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex Therapy|Quality of Life Analysis of Prostate Cancer Patient's Therapy|Completed|||1646|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:04:08.326586|2018-06-01 02:04:08.326586
NCT00692861|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2018-04-28|2008-06-05|2008-06-06|Estimate|||||||2018-04-28|2018-05-01|Actual|June 2, 2008||2008-06-02|January 3, 2014|2014-01-03|January 3, 2014||2014-01-03|||||Observational|||Autoimmunity in Neurologic Complications of Celiac Disease|The Role of Autoimmunity in Neurologic Complications of Celiac Disease|Completed|||14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:04:08.404623|2018-06-01 02:04:08.404623
NCT00692848|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Impact of Procalcitonin on the Management of Children Aged 1 to 36 Month Presenting With a Fever Without a Source|The Impact of Procalcitonin on the Management of Children Aged 1 to 36 Month Presenting With a Fever Without a Source|Completed||N/A|384|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-06-01 02:04:08.463381|2018-06-01 02:04:08.463381
NCT00692835|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2012-09-29|2008-06-05|2008-06-06|Estimate|||||||2012-09-29|2012-10-02|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|December 2009|Actual|2009-12-31||Interventional|||Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT)|Immediate Postoperative Course of Patients With Mini Video Assisted Total Thyroidectomy (miVAT) Versus Classic Total Thyroidectomy (cTT)|Completed||N/A|100|Actual|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-06-01 02:04:08.543139|2018-06-01 02:04:08.543139
NCT00692822|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2012-03-06|2008-06-04|2008-06-06|Estimate|||||||2012-03-06|2012-03-07|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Observational|||Antimicrobial Susceptibility Patterns of N. Gonorrhea Isolates in an Era of Quinolone Resistance|Antimicrobial Susceptibility Patterns of Neisseria Gonorrhea Isolates in an Era of Quinolone Resistance|Completed|||60|Actual|University of Florida|||||f||||f||||||Samples Without DNA|"~     Urethral discharge for Neisseria gonorrheae culture~   "|||2018-06-01 02:04:08.608452|2018-06-01 02:04:08.608452
NCT00692809|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-09-14|2008-06-05|2008-06-06|Estimate|||||||2009-09-14|2009-09-15|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Observational|HIV-TB||Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection|Impact of HIV Infection on Latent TB Among Patients With HIV-TB Co-infection|Unknown status|Recruiting||180|Anticipated|Ministry of Science and Technology, India|||4||f||||f||||||||||2018-06-01 02:04:08.781301|2018-06-01 02:04:08.781301
NCT00692796|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2017-03-27|2008-06-04|2008-06-06|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2008||2008-04-30|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis|Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis|Completed||N/A|60|Actual|National Jewish Health||1|||f||||f||||||||||2018-06-01 02:04:08.87067|2018-06-01 02:04:08.87067
NCT00692783|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2015-05-07|2008-06-05|2008-06-06|Estimate|||||||2015-05-07|2015-05-08|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Observational|ICONIC||Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility|Incidence of Oral Candidiasis, Prevalence of Candida Dubliniensis in HIV Patients and In-vitro Azole Susceptibility. (I.C.O.N.I.C.)|Terminated|||10|Actual|University of Florida||||Dr. Vindas completed his fellowship + low enrollment|f||||f||||||||||2018-06-01 02:04:08.950412|2018-06-01 02:04:08.950412
NCT00692770|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|2014-11-24||2017-09-13|2008-06-05|2008-06-06|Estimate|2014-11-24|2014-12-01|Estimate||||2017-09-13|2017-10-16|Actual|August 15, 2008|Actual|2008-08-15|September 2017|2017-09-30|November 28, 2014|Actual|2014-11-28|November 29, 2013|Actual|2013-11-29||Interventional|STORM||Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)|A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.|Completed||Phase 3|1114|Actual|Bayer||2|||f||||t|t|f||||||||2018-06-01 02:04:09.139422|2018-06-01 02:04:09.139422
NCT00692757|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-10-20|2008-06-05|2008-06-06|Estimate|||||||2008-10-20|2008-10-21|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|March 2009|Anticipated|2009-03-31|January 2009|Anticipated|2009-01-31||Interventional|WASH||Wound Antiseptic Study With Hypochlorous Acid & Iodopovidone|Comparative Study of Two Antiseptics Solutions for the Prevention of Surgical Site Infection|Unknown status|Recruiting|Phase 2|432|Anticipated|Universidad Tecnológica de Pereira||2|||f||||t||||||||||2018-06-01 02:04:10.751834|2018-06-01 02:04:10.751834
NCT00692744|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-09-01|2008-06-05|2008-06-06|Estimate|||||||2014-09-01|2014-09-03|Estimate|October 2008||2008-10-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|FASHE||Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH)|Study of Quality of Life After Aneurysmal Subarachnoid Hemorrhage in Patients Aged 70 Years or Older.|Completed|||353|Actual|University Hospital, Rouen|||5||f||||t||||||None Retained|"~     2 randomized arms (clipping and coiling) and 3 prospective observational arms (clipping,~     coiling, conservative) For the randomized arms, we anticipated 20 patients in each arm.~   "|||2018-06-01 02:04:10.868496|2018-06-01 02:04:10.868496
NCT00692731|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-04|2008-06-04|2008-06-06|Estimate|||||||2008-06-04|2008-06-06|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Observational|||Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss|A Randomized, Double-Blind, Controlled Study to Assess the Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss|Completed|||132|Actual|Provident Clinical Research|||2||f||||f||||||||||2018-06-01 02:04:11.012463|2018-06-01 02:04:11.012463
NCT00692718|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-06-18|2008-06-04|2008-06-06|Estimate|||||||2008-06-18|2008-06-19|Estimate|July 2008||2008-07-31|June 2008|2008-06-30||||June 2010|Anticipated|2010-06-30||Interventional|||N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure|N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Osaka General Medical Center|||||f||||||||||||||2018-06-01 02:04:11.086127|2018-06-01 02:04:11.086127
NCT00692705|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2009-01-22|2008-06-05|2008-06-06|Estimate|||||||2009-01-22|2009-01-23|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PET||Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid|Open Label Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease|Completed||Phase 1|13|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:04:11.131713|2018-06-01 02:04:11.131713
NCT00692692|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2013-08-03||2018-03-13|2008-06-05|2008-06-06|Estimate|2013-08-03|2013-10-11|Estimate||||2018-03-13|2018-03-19|Actual|June 2007||2007-06-30|March 2018|2018-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Available data lists demographic data as a single group. Breakdown by arms is not available.|Use of Dermal Matrix in Breast Reconstruction|The Use of An Acellular Dermal Matrix Sling in a Two-stage Breast REconstruciton After Mastectomy: A Double-blinded Randomized Trial|Terminated||N/A|36|Actual|Vanderbilt University Medical Center|Unable to contact PI after he left Vanderbilt. Results were entered with available data.|2||higher rate of post-operative infection in the Dermal Matrix arm of the study|f||||f||||||||||2018-06-01 02:04:11.196509|2018-06-01 02:04:11.196509
NCT00692653|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-04-30|2008-06-05|2008-06-06|Estimate|||||||2015-04-30|2015-05-04|Estimate|February 2007||2007-02-28|April 2015|2015-04-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|P4||Personal Patient Profile Prostate (P4) Randomized, Multisite Trial|Personal Patient Profile Prostate (P4) Randomized, Multisite Trial|Completed||N/A|498|Actual|Dana-Farber Cancer Institute||2|||f||||f||||||||||2018-06-01 02:04:11.418964|2018-06-01 02:04:11.418964
NCT00692640|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-03-22|2008-06-05|2008-06-06|Estimate|||||||2012-03-22|2012-03-23|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of XL147 (SAR245408) in Combination With Erlotinib in Subjects With Solid Tumors|Completed||Phase 1|35|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:04:11.503171|2018-06-01 02:04:11.503171
NCT00692627|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-01-21|2008-06-05|2008-06-06|Estimate|||||||2015-01-21|2015-01-22|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|PRiSM||Evaluation of Volume Status, Haemodynamics and Microcirculatory Flow in Adult Patients With Severe Falciparum Malaria|Evaluation of Volume Status, Haemodynamics and Microcirculatory Flow in Adult Patients With Severe Falciparum Malaria|Completed|||80|Anticipated|University of Oxford|||||f||||f||||||||||2018-06-01 02:04:11.584097|2018-06-01 02:04:11.584097
NCT00692614|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2015-10-30|2008-06-04|2008-06-06|Estimate|||||||2015-10-30|2015-11-02|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001)|A Phase IIb, Randomized, Masked, Sham-Controlled, Clinical Trial to Study the Efficacy and Safety of the Helical Triamcinolone Acetonide Implant (MK0140) in Diabetic Patients With Clinically Significant Macular Edema|Terminated||Phase 2|2|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 02:04:11.64277|2018-06-01 02:04:11.64277
NCT00692601|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-09-15|2008-06-04|2008-06-06|Estimate|||||||2008-09-15|2008-09-16|Estimate|April 2008||2008-04-30|June 2008|2008-06-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||The Acute Effects of Capsiate During Exercise|Effect of Differing Doses of A Sweet Pepper Extract - Capsiate (A Capsaicin Analogue) - On Energy Expenditure and Blood Parameters in Humans During Exercise|Completed||Phase 1|12|Actual|McMaster University||3|||f||||f||||||||||2018-06-01 02:04:11.710008|2018-06-01 02:04:11.710008
NCT00692588|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2011-04-05|2008-06-04|2008-06-06|Estimate|||||||2011-04-05|2011-04-06|Estimate|June 2008||2008-06-30|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|DARAD-MRI||MRI to Measure Treatment With Antibiotics in Alzheimer's Disease|Magnetic Resonance Imaging to Measure Treatment Effects of Doxycycline and Rifampicin in Alzheimer's Disease|Completed|||58|Actual|St. Joseph's Healthcare Hamilton|||5||f||||f||||||||||2018-06-01 02:04:11.793328|2018-06-01 02:04:11.793328
NCT00692575|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-04-10|2008-06-03|2008-06-06|Estimate|||||||2014-04-10|2014-04-14|Estimate|June 2008||2008-06-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|September 2012|Actual|2012-09-30||Interventional|||Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury|Modular Scheduled Telephone Intervention for Caregivers of Persons With Traumatic Brain Injury: A Randomized Controlled Trial|Completed||Phase 2|153|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:04:11.877971|2018-06-01 02:04:11.877971
NCT00692562|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2011-09-15|2008-06-05|2008-06-06|Estimate|||||||2011-09-15|2011-09-16|Estimate|June 2005||2005-06-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease|Simultaneous Islet-Kidney Transplantation in Patients of Type 1 Diabetes With End-stage Renal Disease|Completed||Phase 1/Phase 2|7|Actual|Fuzhou General Hospital||1|||f||||t||||||||||2018-06-01 02:04:11.949505|2018-06-01 02:04:11.949505
NCT00692549|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|June 2005||2005-06-30|June 2008|2008-06-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Ultrasound Guidance for Intravenous Cannulation in Emergency Department Patients.|Ultrasound-Guided Peripheral Intravenous Cannulation in Emergency Department Patients With Difficult IV Access: a Randomized Trial.|Completed||N/A|60|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:04:12.015978|2018-06-01 02:04:12.015978
NCT00692536|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2015-09-01|2008-06-05|2008-06-06|Estimate|||||||2015-09-01|2015-09-03|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|KNOTA||Diet Composition - Metabolic Regulation and Long-term Compliance|Diet Composition - Metabolic Regulation and Long-term Compliance|Completed||N/A|70|Actual|Umeå University||2|||f||||f||||||||||2018-06-01 02:04:12.163998|2018-06-01 02:04:12.163998
NCT00692523|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-10-01|2008-06-05|2008-06-06|Estimate|||||||2009-10-01|2009-10-02|Estimate|November 2008||2008-11-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|EVREST||Effectiveness of Virtual Reality Exercises in STroke Rehabilitation (EVREST)|A Pilot Randomised, Two Parallel Group Study Comparing Wii Gaming Versus Recreational Activity in Patients Receiving Standard Rehabilitation After Stroke|Completed||N/A|30|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 02:04:12.239921|2018-06-01 02:04:12.239921
NCT00692510|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-11-25|2008-06-05|2008-06-06|Estimate|||||||2008-11-25|2008-11-26|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Cocktail||Drug Interaction Study Between AZD3480 and Cytochrome P450|A Phase I, Double Blind, Randomized, Two-Way Cross Over, Single- Centre Study in Healthy CYP2D6 Extensive Metabolizers and Poor Metabolizers to Investigate the Potential of AZD3480 to Inhibit Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 Activity|Completed||Phase 1|18|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:04:12.310905|2018-06-01 02:04:12.310905
NCT00692497|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2016-01-26|2008-06-05|2008-06-06|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|one-stop||Electronic Referral and Booking of Outpatient Day Case Surgery Compared With Traditional Referral Routines.|Costs-effectiveness and Waiting Time for Direct Electronic Referral and Booking of Outpatient Day Case Surgery Compared With Traditional Referral Routines. A Randomised Controlled Trial|Completed||N/A|120|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 02:04:12.382134|2018-06-01 02:04:12.382134
NCT00692484|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04||2013-02-19|2013-03-21|2008-06-05|2008-06-06|Estimate||||2013-02-19|2013-02-22|Estimate|2013-03-21|2013-04-01|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Pilot Evaluation of the Application Procedure on the Antimicrobial Effects of 2 Antiseptics|Pilot Evaluation of the Effect of Application Procedure on the Antimicrobial Effects of an Aqueous CHG and a Traditional Iodophor Scrub Paint|Completed||Phase 3|25|Actual|CareFusion||2|||f||||f||||||||||2018-06-01 02:04:12.458837|2018-06-01 02:04:12.458837
NCT00692471|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2018-03-26|2008-06-05|2008-06-06|Estimate|||||||2018-03-26|2018-03-27|Actual|June 2008||2008-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Sleep Actigraphy in Postural Tachycardia Syndrome (POTS)|Assessment of Objective Sleep Disturbances in Orthostatic Intolerance Using Actigraphy|Active, not recruiting|||100|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-06-01 02:04:12.599389|2018-06-01 02:04:12.599389
NCT00692458|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2016-08-11|2008-06-05|2008-06-06|Estimate|||||||2016-08-11|2016-08-12|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)|A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Reducing the Risk of Bone Metastasis in Women With Breast Cancer|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2||Withdrawn for administrative reasons|f||||||||||||||2018-06-01 02:04:12.688397|2018-06-01 02:04:12.688397
NCT00692445|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04||2011-01-04|2013-06-13|2008-06-04|2008-06-06|Estimate||||2011-01-07|2011-01-20|Estimate|2013-06-13|2013-06-21|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||TC-5214 as add-on the Treatment of Major Depressive Disorder|A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of TC-5214 in the Treatment of MDD With Subjects Who Are Partial Responders or Non-Responders to Citalopram Therapy|Completed||Phase 2|574|Actual|Targacept Inc.||2|||f||||f||||||||||2018-06-01 02:04:12.76746|2018-06-01 02:04:12.76746
NCT00692432|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2017-05-09|2008-06-05|2008-06-06|Estimate|||||||2017-05-09|2017-05-10|Actual|September 2001||2001-09-30|May 2017|2017-05-31|December 2008|Actual|2008-12-31|September 2003|Actual|2003-09-30||Observational|||Macrophage Inhibitory Factor and High-Mobility Group-1 Protein in Children Undergoing Cardiopulmonary Bypass|Macrophage Inhibitory Factor (MIF) and High-Mobility Group-1 Protein (HMG-1) in Children Undergoing Cardiopulmonary Bypass|Completed|||30|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||Samples Without DNA|"~     cardiac tissue serum~   "|No||2018-06-01 02:04:12.884709|2018-06-01 02:04:12.884709
NCT00692419|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2014-10-30||2015-04-06|2008-06-04|2008-06-06|Estimate|2014-11-17|2014-11-19|Estimate||||2015-04-06|2015-04-27|Estimate|November 2008||2008-11-30|September 2014|2014-09-30|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|SMILE||Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients|Pain, Sexual Dysfunction and Depression in Hemodialysis Patients|Completed||N/A|315|Actual|VA Office of Research and Development|Individual providers were overseeing the care of patients from both study arms. The sample size was relatively small. Single geographic area. No control arm. Symptoms assessed during dialysis. No formal assessment of treatment compliance.|2|||f||||t||||||||||2018-06-01 02:04:12.954137|2018-06-01 02:04:12.954137
NCT00692406|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2009-02-22||2013-02-21|2008-06-03|2008-06-06|Estimate|2013-02-21|2013-03-28|Estimate||||2013-02-21|2013-03-28|Estimate|June 2005||2005-06-30|February 2013|2013-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|SmokeAtt01||Neuroimaging Attentional Impairment During Abstinence|Neuroimaging Attentional Impairment During Abstinence|Completed||N/A|80|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:04:13.204013|2018-06-01 02:04:13.204013
NCT00692393|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-06-18|2008-06-05|2008-06-06|Estimate|||||||2014-06-18|2014-06-19|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|DIVERTI||Primary vs. Secondary Anastomosis for Hinchey Stage III-IV Diverticulitis a Prospective Randomized Trial|Primary vs. Secondary Anastomosis After Sigmoid Colon Resection for Perforated Diverticulitis (Hinchey Stage III and IV): a Prospective Multicentric Randomized Trial|Completed||N/A|102|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-06-01 02:04:13.440743|2018-06-01 02:04:13.440743
NCT00692380|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2016-04-28|2008-06-03|2008-06-06|Estimate|||||||2016-04-28|2016-05-02|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable NSCLC|A Phase I Dose Intensification Study Using Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Patients With Inoperable, Non-Small Cell Lung Cancer|Terminated||Phase 1|28|Actual|Virginia Commonwealth University||1||insufficient accrual|f||||t||||||||||2018-06-01 02:04:13.504628|2018-06-01 02:04:13.504628
NCT00692367|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2014-11-02|2008-06-05|2008-06-06|Estimate|||||||2014-11-02|2014-11-04|Estimate|December 2007||2007-12-31|November 2014|2014-11-30|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||Physical Activity Following Surgery Induced Weight Loss|Physical Activity Following Surgery Induced Weight Loss|Completed||N/A|128|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:04:13.569284|2018-06-01 02:04:13.569284
NCT00692354|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2010-08-05|2008-06-05|2008-06-06|Estimate|||||||2010-08-05|2010-08-06|Estimate|October 2004||2004-10-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours|A Phase I Study to Evaluate the Safety and Tolerability, of the Aminopeptidase Inhibitor, CHR-2797, in Patients With Advanced Tumours|Completed||Phase 1|41|Actual|Chroma Therapeutics|||||f||||t||||||||||2018-06-01 02:04:13.63852|2018-06-01 02:04:13.63852
NCT00692341|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2012-02-25||2012-04-05|2008-06-04|2008-06-06|Estimate|2012-02-25|2012-03-27|Estimate||||2012-04-05|2012-04-11|Estimate|May 2008||2008-05-31|April 2012|2012-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics|A Phase 1 Study To Evaluate The Pharmacokinetics Of AG-013736 In Subjects With Impaired Hepatic Function|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:04:13.724428|2018-06-01 02:04:13.724428
NCT00692328|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2015-05-04|2008-06-04|2008-06-06|Estimate|||||||2015-05-04|2015-05-05|Estimate|August 2005||2005-08-31|May 2015|2015-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Expectation and Response to Levodopa and Acupuncture in Parkinson's Disease|Expectation and Response to Levodopa & Acupuncture in Parkinson's Disease|Completed||N/A|63|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 02:04:14.15005|2018-06-01 02:04:14.15005
NCT00692315|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2016-04-13|2008-06-05|2008-06-06|Estimate|||||||2016-04-13|2016-04-15|Estimate|September 2006||2006-09-30|April 2016|2016-04-30|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Treating Oxidative Stress in Children With Autism|Efficacy of Methylcobalamin and Folinic Acid Treatment on Glutathione Redox Status and Core Behavior in Children With Autism|Completed||N/A|40|Actual|Arkansas Children's Hospital Research Institute||2|||f||||t||||||||||2018-06-01 02:04:14.213337|2018-06-01 02:04:14.213337
NCT00692302|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2013-06-05|2008-06-04|2008-06-06|Estimate|||||||2013-06-05|2013-06-06|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Effectiveness of a Family-Based Intervention for Adolescent Suicide Attempters (The SAFETY Study)|Family Based Intervention for Adolescent Suicide Attempters|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|University of California, Los Angeles||3|||f||||f||||||||||2018-06-01 02:04:14.347863|2018-06-01 02:04:14.347863
NCT00692289|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2012-06-05|2008-06-05|2008-06-06|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|RADAR II E||Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer|Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer|Completed|||1510|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:04:14.4249|2018-06-01 02:04:14.4249
NCT00692276|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2017-06-06|2008-06-05|2008-06-06|Estimate|||||||2017-06-06|2017-06-07|Actual|June 2008||2008-06-30|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Investigating Superion™ In Spinal Stenosis|A Prospective, Multi-Center, Randomized Study Comparing the VertiFlex® Superion™ Interspinous Spacer (ISS) to the X-STOP® Interspinous Process Decompression (IPD®) System in Patients With Moderate Lumbar Spinal Stenosis|Completed||N/A|400|Anticipated|VertiFlex, Incorporated||2|||f||||t||||||||||2018-06-01 02:04:14.497718|2018-06-01 02:04:14.497718
NCT00692263|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-09-09|2008-06-05|2008-06-06|Estimate|||||||2008-09-09|2008-09-10|Estimate|February 2008||2008-02-29|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects|The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects|Completed||Phase 4|15|Actual|University of Southern Denmark||3|||f||||t||||||||||2018-06-01 02:04:14.621492|2018-06-01 02:04:14.621492
NCT00692250|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-05-04|2008-06-05|2008-06-06|Estimate|||||||2015-05-04|2015-05-05|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|December 2007|Actual|2007-12-31|||||Interventional|||A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers|A Phase I Open Label, Randomised, Single Dose, 2-way Crossover, 2-Sequence Pharmacokinetic Study on the Interaction of Colesevelam and Ciclosporin in Healthy Volunteers|Completed||Phase 1|14|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:04:14.746081|2018-06-01 02:04:14.746081
NCT00692237|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2011-08-23||2013-05-05|2008-06-05|2008-06-06|Estimate|2012-04-17|2012-05-15|Estimate||||2013-05-05|2013-05-08|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|CECSID||Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes|Cardiovascular Effects of Chronic Sildenafil (Viagra) Treatment in Diabetic Subjects With Endothelial Dysfunction.|Completed||Phase 4|59|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-06-01 02:04:14.81427|2018-06-01 02:04:14.81427
NCT00692224|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|October 2005||2005-10-31|June 2008|2008-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial|Effect of Oral Zinc Given Daily Between Days 2 and 7 of Life to Term or Near Term Neonates With Serum Bilirubin Levels of More Than 6 mg/dL at 24 ± 6 Hours of Life on Hyperbilirubinemia and Phototherapy|Completed||Phase 1/Phase 2|294|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 02:04:15.060875|2018-06-01 02:04:15.060875
NCT00692211|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2014-08-11||2015-04-28|2008-06-05|2008-06-06|Estimate|2014-08-11|2014-08-26|Estimate||||2015-04-28|2015-05-13|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Interventions to Improve Colorectal Cancer Screening|Interventions to Improve Colorectal Cancer Screening Rates and Adherence|Completed||N/A|404|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:04:15.159596|2018-06-01 02:04:15.159596
NCT00692198|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2016-11-10||2017-04-03|2008-06-04|2008-06-06|Estimate|2017-02-16|2017-04-04|Actual||||2017-04-03|2017-05-10|Actual|January 2009||2009-01-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|LOTT||Long-term Oxygen Treatment Trial|Effectiveness of Long-term Oxygen Therapy in Treating People With Chronic Obstructive Pulmonary Disease With Moderate Desaturation|Completed||Phase 3|738|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||Yes|Datasets and associated documentation will be deposited with the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center (NHLBI BioLINCC) repository once the contract ends, currently scheduled for May 2017. Data will be deidentified per BioLINCC requirements; datasets will include baseline and follow-up data collected during the trial. The BioLINCC Repository website includes instructions regarding accessing data on deposit in their repository.|2018-06-01 02:04:15.403776|2018-06-01 02:04:15.403776
NCT00692185|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2009-05-28||2017-10-17|2008-06-04|2008-06-06|Estimate|2009-07-16|2009-07-17|Estimate||||2017-10-17|2017-11-20|Actual|October 2005||2005-10-31|October 2017|2017-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa|Atypical Antipsychotic Medication in Anorexia Nervosa|Completed||Phase 2|18|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 02:04:16.131073|2018-06-01 02:04:16.131073
NCT00692172|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2014-09-17|2008-06-04|2008-06-06|Estimate|||||||2014-09-17|2014-09-18|Estimate|December 2001||2001-12-31|September 2014|2014-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis|An Open-Label, Multi-center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis Who Have Completed Studies C99-717 or C99-712|Completed||Phase 3|175|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:04:16.323481|2018-06-01 02:04:16.323481
NCT00692159|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2010-09-08|2008-06-05|2008-06-06|Estimate|||||||2010-09-08|2010-09-10|Estimate|June 2008||2008-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Study of TRC102 in Combination With Pemetrexed in Cancer Patients|Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable|Completed||Phase 1|28|Actual|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||||2018-06-01 02:04:16.432562|2018-06-01 02:04:16.432562
NCT00692146|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)|A Double-Blind, Randomized, Single-Centre, Placebo-Controlled, Crossover Study to Investigate the Effects of a Single Oral Dose of AZD1386 on Intradermal Capsaicin Evoked Pain Symptoms and Heat Sensitivity in Healthy Volunteers|Completed||Phase 1|36|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:04:16.499554|2018-06-01 02:04:16.499554
NCT00692133|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2010-12-08|2008-06-05|2008-06-06|Estimate|||||||2010-12-08|2010-12-10|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|TOOL||Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment|Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment|Completed|||250|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:04:16.571895|2018-06-01 02:04:16.571895
NCT00692120|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2015-10-01|2008-06-05|2008-06-06|Estimate|||||||2015-10-01|2015-10-05|Estimate|February 2007||2007-02-28|April 2010|2010-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|D2/D3||Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy|Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy|Completed||N/A|64|Actual|University of Wisconsin, Madison||4|||f||||f||||||||||2018-06-01 02:04:16.651767|2018-06-01 02:04:16.651767
NCT00692107|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|June 1997||1997-06-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|May 2005|Actual|2005-05-31||Interventional|||Radiotherapy for Prostate Cancer: Conventional Dose Versus High Dose|Phase III Study for Prostate Cancer, Randomizing Between Two Radiation Dose Levels (68 Gy vs. 78 Gy) and Utilizing Three Dimensional Conformal Radiotherapy|Completed||Phase 3|669|Actual|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-06-01 02:04:16.714076|2018-06-01 02:04:16.714076
NCT00692094|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2014-04-08|2008-06-04|2008-06-06|Estimate|||||||2014-04-08|2014-04-09|Estimate|August 2004||2004-08-31|April 2014|2014-04-30|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Blind Elderly Melatonin Treatment Study|Melatonin Entrainment of Elderly Blind Free-runners|Completed||N/A|12|Actual|Oregon Health and Science University||4|||f||||t||||||||||2018-06-01 02:04:16.842425|2018-06-01 02:04:16.842425
NCT00692081|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate||||June 2008|2008-06-30||||||||Interventional|SCT-ABI||Social Competence Training for Adolescents With Borderline Intellectual Functioning|A Randomized Controlled Trial of a Social Competence Group Training for Adolescents With Borderline Intellectual Functioning|Completed||Phase 2/Phase 3|77|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 02:04:16.917667|2018-06-01 02:04:16.917667
NCT00692068|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate||||June 2008|2008-06-30||||||||Observational|||Relations Between Residual Renal Function and Oxidative and Carbonyl Stress in Peritoneal Dialysis Patients|Relations Between Residual Renal Function and Oxidative and Carbonyl Stress in Peritoneal Dialysis Patients|Completed|||||Iwata City Hospital|||2||f||||||||||||||2018-06-01 02:04:16.965468|2018-06-01 02:04:16.965468
NCT00692055|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-09-04|2008-06-05|2008-06-06|Estimate|||||||2008-09-04|2008-09-05|Estimate|June 2008||2008-06-30|September 2008|2008-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations|Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations|Completed||Phase 1|30|Actual|POZEN||2|||f||||f||||||||||2018-06-01 02:04:17.015373|2018-06-01 02:04:17.015373
NCT00692042|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2008-06-23|2008-06-05|2008-06-06|Estimate|||||||2008-06-23|2008-06-24|Estimate|March 2008||2008-03-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Investigate Safety, Tolerability and Pharmacokinetics of a Single Ascending Dose of AZD1704|A Phase I, First Time in Man, Single-Centre, Randomised, Double-Blind (Within Panels), Placebo-Controller Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1704 After Administration of Oral Single Ascending Doses in Healthy Volunteers|Completed||Phase 1|80|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:04:17.072802|2018-06-01 02:04:17.072802
NCT00692029|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2011-02-18|2008-06-05|2008-06-06|Estimate|||||||2011-02-18|2011-02-21|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|ATV||Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles|Kinematics of Youth (Age 12-15) on Stationary All Terrain Vehicles|Completed|||40|Anticipated|University of Kentucky|||||f||||f||||||||||2018-06-01 02:04:17.18515|2018-06-01 02:04:17.18515
NCT00692016|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2013-05-01|2008-06-05|2008-06-06|Estimate|||||||2013-05-01|2013-05-03|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|Keifer||Fast & Fed Pharmacokinetic (PK) Study|An Open Label, Randomized, Two-Way Crossover Study to Determine the Bioavailability of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet Under Fasting and Fed Conditions|Completed||Phase 1|32|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:04:17.248579|2018-06-01 02:04:17.248579
NCT00692003|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2012-08-13||2017-02-01|2008-06-05|2008-06-06|Estimate|2012-09-11|2012-10-12|Estimate||||2017-02-01|2017-03-14|Actual|August 1, 2008|Actual|2008-08-01|February 2017|2017-02-28|January 9, 2009|Actual|2009-01-09|November 2008|Actual|2008-11-30||Interventional|||Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures|A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures|Terminated||Phase 3|21|Actual|Eisai Inc.|This study was terminated early at the Sponsor’s discretion. When this study was discontinued, only 6 subjects had been treated. Data from the 5 subjects treated with zonisamide were insufficient to draw firm conclusions regarding efficacy.|2||Sponsor's decision|f||||||||||||||2018-06-01 02:04:17.35682|2018-06-01 02:04:17.35682
NCT00691990|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2011-08-03|2008-06-05|2008-06-06|Estimate|||||||2011-08-03|2011-08-04|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|||Classic Total Thyroidectomy With or Without Drains|Classic Total Thyroidectomy With or Without Drains|Completed||N/A|100|Anticipated|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-06-01 02:04:17.691758|2018-06-01 02:04:17.691758
NCT00691977|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2013-04-23|2008-06-03|2008-06-06|Estimate|||||||2013-04-23|2013-04-24|Estimate|September 2007||2007-09-30|April 2013|2013-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate|A Phase I Dose-Escalation Study of Preoperative Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk, Localized Carcinoma of the Prostate|Withdrawn||Phase 1|0|Actual|Virginia Commonwealth University||1||poor accrual|f||||f||||||||||2018-06-01 02:04:17.777251|2018-06-01 02:04:17.777251
NCT00691964|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04||2011-09-09|2013-01-11|2008-06-05|2008-06-06|Estimate||||2011-09-09|2011-09-21|Estimate|2013-01-11|2013-01-21|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|347|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 02:04:17.859659|2018-06-01 02:04:17.859659
NCT00691951|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2008-10-17|2008-06-05|2008-06-06|Estimate|||||||2008-10-17|2008-10-21|Estimate||||June 2008|2008-06-30||||||||Interventional|D5890L00013||Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects|Comparative Effects of Budesonide and Budesonide/Formoterol (Symbicort) on Asthma Control in Smoking Asthmatic Subjects: A Pilot Study|Completed||Phase 3|||Laval University|||||f||||||||||||||2018-06-01 02:04:17.980514|2018-06-01 02:04:17.980514
NCT00655447|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-08|2008-04-08|2008-04-09|Estimate|||||||2008-04-08|2008-04-09|Estimate|January 1980||1980-01-31|April 2008|2008-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Observational|||Examining the Long-Term Risks of Oophorectomy|Ovarian Conservation: Long-Term Health Outcomes From the Nurse's Health Study.|Completed|||32175|Actual|Parker, William H., M.D.|||2||f||||f||||||||||2018-06-01 02:16:07.015895|2018-06-01 02:16:07.015895
NCT00691938|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2016-08-18||2016-08-18|2008-06-05|2008-06-06|Estimate|2016-08-18|2016-10-13|Estimate||||2016-08-18|2016-10-13|Estimate|June 2008||2008-06-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)|A Phase I/II Study of LBH589 Plus Decitabine for Patients Age ≥ 60 Years With High Risk MDS or AML|Completed||Phase 1/Phase 2|52|Actual|Washington University School of Medicine||7|||f||||t||||||||||2018-06-01 02:04:18.131828|2018-06-01 02:04:18.131828
NCT00691925|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-06-02|2008-06-05|2008-06-06|Estimate|||||||2009-06-02|2009-06-03|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|||Mitigating Pain Following Refractive Surgery|Contact Lens for Mitigating Pain Following Refractive Procedure|Completed|||4|Actual|FORSIGHT Vision3|||1||f||||t||||||||||2018-06-01 02:04:19.574881|2018-06-01 02:04:19.574881
NCT00691912|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2014-09-01|2008-06-05|2008-06-06|Estimate|||||||2014-09-01|2014-09-03|Estimate|December 2006||2006-12-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MyoPac||Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin|Extended Dose Frequency 1st-line Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (Myocet®)|Terminated||Phase 2|26|Actual|University of Magdeburg||1||Study was stopped due because recrutation.was much slower as anticipated.|f||||f||||||||||2018-06-01 02:04:19.674971|2018-06-01 02:04:19.674971
NCT00691899|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2016-08-11|2008-06-05|2008-06-06|Estimate|||||||2016-08-11|2016-08-12|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)|A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK0822 (Odanacatib) in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2||Withdrawn for administrative reasons|f||||||||||||||2018-06-01 02:04:19.755047|2018-06-01 02:04:19.755047
NCT00691886|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2012-05-09|2008-06-05|2008-06-06|Estimate|||||||2012-05-09|2012-05-10|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Safety and Efficacy of Intravenous (IV) Dexmedetomidine During Flexible Bronchoscopy and Endobronchial Ultrasound|Safety and Efficacy of Intravenous Dexmedetomidine Infusion During Flexible Bronchoscoy and Endobronchical Ultrasound|Withdrawn||Phase 4|0|Actual|Lahey Clinic||2||PI left institution prior to enrollment|f||||f||||||||||2018-06-01 02:04:19.825922|2018-06-01 02:04:19.825922
NCT00691873|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-05|2008-06-05|2008-06-06|Estimate|||||||2008-06-05|2008-06-06|Estimate|May 2006||2006-05-31|January 2007|2007-01-31|October 2007|Actual|2007-10-31|May 2007|Actual|2007-05-31||Interventional|||Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids|A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab) on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids|Completed||Phase 4|14|Actual|University of Mississippi Medical Center||2|||f||||t||||||||||2018-06-01 02:04:19.893763|2018-06-01 02:04:19.893763
NCT00691860|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2015-09-14|2008-06-05|2008-06-06|Estimate|||||||2015-09-14|2015-09-15|Estimate|April 2006||2006-04-30|June 2008|2008-06-30|February 2008|Actual|2008-02-29|January 2007|Actual|2007-01-31||Interventional|||Use of a Mesh to Prevent Parastomal Hernia|Randomized, Controlled, Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia|Completed||N/A|54|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-06-01 02:04:19.96714|2018-06-01 02:04:19.96714
NCT00691847|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-06-02|2008-06-05|2008-06-06|Estimate|||||||2009-06-02|2009-06-03|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|||Reducing Edema Following Refractive Surgery|Reducing Edema Following Refractive Surgery|Completed|||3|Actual|FORSIGHT Vision3|||1||f||||t||||||||||2018-06-01 02:04:20.027869|2018-06-01 02:04:20.027869
NCT00691834|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2013-08-12|2008-06-03|2008-06-06|Estimate|||||||2013-08-12|2013-08-13|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|ReNeW||Safety and Efficacy on Cell-based Therapy in Patients With Recent Large Acute Myocardial Infarction|ReNEW: A Phase 2, Randomized, Placebo-Controlled, Double-Blinded Study of the Efficacy and Safety of Autologous Bone Marrow Mononuclear Cell Transfer for Myocardial Salvage in Acute Myocardial Infarction|Withdrawn||Phase 2|0|Actual|Duke University||2||Study never received IRB approval. Study was never pursued.|f||||t||||||||||2018-06-01 02:04:20.084808|2018-06-01 02:04:20.084808
NCT00691821|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2011-07-25|2008-06-03|2008-06-05|Estimate|||||||2011-07-25|2011-07-26|Estimate|April 2009||2009-04-30|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|NPWT||Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds|A 12-week, Prospective, Open-label, Randomized, Controlled Clinical Trial Comparing Negative Pressure Wound Therapy (NPWT) to Standard Wound Care for the Treatment of Chronic Pressure Wounds of the Pelvic Region|Terminated||Phase 4|184|Anticipated|St. Joseph's Healthcare Hamilton||2||"Patients not meeting inclusion criteria, therefore recruitment rate low, terminated due to the~   lack of feasibility to complete the study in a timely manner."|f||||f||||||||||2018-06-01 02:04:20.151017|2018-06-01 02:04:20.151017
NCT00691808|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2009-11-17||2010-02-17|2008-06-03|2008-06-05|Estimate|2010-02-17|2010-03-03|Estimate||||2010-02-17|2010-03-03|Estimate|February 2008||2008-02-29|February 2010|2010-02-28||||October 2008|Actual|2008-10-31||Interventional|||Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment|A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI)|Completed||Phase 2|103|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:04:20.232747|2018-06-01 02:04:20.232747
NCT00691795|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-02-13|2008-06-04|2008-06-05|Estimate|||||||2012-02-13|2012-02-14|Estimate||||February 2012|2012-02-29|December 2011|Actual|2011-12-31|||||Interventional|||Epidural Fentanyl-bupivacaine Versus Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor|Comparison of Fentanyl-bupivacaine and Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor in Patients With Continuous Epidural Analgesia|Withdrawn||Phase 4|0|Actual|Columbia University||2||Study was recently terminated due to poor enrollment - never enrolled.|f||||f||||||||||2018-06-01 02:04:23.046852|2018-06-01 02:04:23.046852
NCT00691782|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-11-01|2008-06-02|2008-06-05|Estimate|||||||2017-11-01|2017-11-06|Actual|September 19, 2007|Actual|2007-09-19|January 2017|2017-01-31|January 30, 2013|Actual|2013-01-30|January 30, 2013|Actual|2013-01-30||Observational|||The Impact of African American Women's Hair Care Practices and Hair Attitudes on Exercise Habits|The Impact of African American Women's Hair Care Practices and Hair Attitudes on Exercise Habits|Completed|||100|Actual|Wake Forest University Health Sciences|||1||f||||f||||||||No||2018-06-01 02:04:23.130941|2018-06-01 02:04:23.130941
NCT00691769|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-11-01|2008-06-04|2008-06-05|Estimate|||||||2017-11-01|2017-11-06|Actual|April 26, 2006|Actual|2006-04-26|November 2017|2017-11-30|November 26, 2012|Actual|2012-11-26|November 26, 2012|Actual|2012-11-26||Observational|||Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia|Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia|Completed|||8|Actual|Wake Forest University Health Sciences|||3||f||||f||||||Samples With DNA|"~     Two, 4mm punch biopsies will be obtained of skin tissue.~   "|No||2018-06-01 02:04:23.185463|2018-06-01 02:04:23.185463
NCT00691756|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-04|2008-06-04|2008-06-05|Estimate|||||||2008-06-04|2008-06-05|Estimate|January 2002||2002-01-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Comparison of Renal Perfusion in Thoracoabdominal Aortic Aneurysm (TAAA) Repair|A Comparison of Cold Blood Versus Cold Crystalloid Renal Perfusion for Prevention of Acute Renal Failure Following Thoracoabdominal Aortic Aneurysm Repair: A Randomized Study|Completed||N/A|172|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:04:23.254147|2018-06-01 02:04:23.254147
NCT00691743|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2009-01-09|2008-06-04|2008-06-05|Estimate|||||||2009-01-09|2009-01-12|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|||||Observational|NSAIDS II||Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2|Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2|Completed|||850|Anticipated|AstraZeneca|||1||f||||||||||||||2018-06-01 02:04:23.348082|2018-06-01 02:04:23.348082
NCT00691730|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2017-11-06|2008-06-04|2008-06-05|Estimate|||||||2017-11-06|2017-11-08|Actual|February 2008||2008-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2012|Actual|2012-06-30||Interventional|||Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer|The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure|Active, not recruiting||N/A|60|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 02:04:23.441448|2018-06-01 02:04:23.441448
NCT00691717|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03||2012-11-27|2012-11-27|2008-06-04|2008-06-05|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2/Phase 3|201|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 02:04:23.624003|2018-06-01 02:04:23.624003
NCT00691704|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2014-03-04||2014-08-14|2008-06-04|2008-06-05|Estimate|2014-03-04|2014-04-10|Estimate||||2014-08-14|2014-08-19|Estimate|August 2008||2008-08-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|December 2012|Actual|2012-12-31||Interventional||Subjects enrolled and able to initiate induction therapy.|Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy|Lenalidomide and Low Dose Dexamethasone Induction Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy for Newly Diagnosed High-risk Multiple Myeloma|Completed||Phase 2|18|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:04:23.762611|2018-06-01 02:04:23.762611
NCT00691691|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-01-18|2008-06-04|2008-06-05|Estimate|||||||2012-01-18|2012-01-19|Estimate|November 2007||2007-11-30|August 2011|2011-08-31||||||||Interventional|||Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors|A Phase II Study of Fractionated Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors|Unknown status|Recruiting|Phase 2|71|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||||2018-06-01 02:04:24.254914|2018-06-01 02:04:24.254914
NCT00691678|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2017-06-15|2008-06-04|2008-06-05|Estimate|||||||2017-06-15|2017-06-19|Actual|October 2008||2008-10-31|June 2017|2017-06-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer|Pase II Study of Glucosamine With Chondroitin on Joint Symptoms Induced By Aromatase Inhibitors in Breast Cancer Patients|Completed||Phase 2|53|Actual|Columbia University||1|||f||||t||||||||Undecided||2018-06-01 02:04:24.336421|2018-06-01 02:04:24.336421
NCT00691665|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2010-01-26||2010-03-23|2008-06-04|2008-06-05|Estimate|2010-02-23|2010-03-10|Estimate||||2010-03-23|2010-03-30|Estimate|May 2008||2008-05-31|March 2010|2010-03-31||||January 2009|Actual|2009-01-31||Interventional|||Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial|A Double-masked, Randomized, Parallel Group, Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial|Completed||Phase 4|130|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:04:24.437049|2018-06-01 02:04:24.437049
NCT00691652|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2011-08-11||2011-09-22|2008-06-04|2008-06-05|Estimate|2011-08-11|2011-09-16|Estimate||||2011-09-22|2011-10-03|Estimate|May 2008||2008-05-31|September 2011|2011-09-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma|Phase I/II Study of Oral Clofarabine + Rituximab in Relapsed B Cell NHL|Terminated||Phase 1/Phase 2|2|Actual|OHSU Knight Cancer Institute|||||f||||||||||||||2018-06-01 02:04:24.691062|2018-06-01 02:04:24.691062
NCT00691639|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2009-09-30|2008-06-04|2008-06-05|Estimate|||||||2009-09-30|2009-10-01|Estimate|March 2008||2008-03-31|September 2009|2009-09-30||||August 2009|Actual|2009-08-31||Observational|||Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)|Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)|Completed|||1000|Anticipated|Alcon Research|||1||f||||f||||||||||2018-06-01 02:04:24.831573|2018-06-01 02:04:24.831573
NCT00691626|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2018-05-14|2008-06-02|2008-06-05|Estimate|||||||2018-05-14|2018-05-15|Actual|April 1, 2009|Actual|2009-04-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|January 1, 2015|Actual|2015-01-01||Interventional|||Cognitive Behavioral Therapy (CBT) for Nightmares in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans|CBT for Nightmares in OEF/OIF Veterans|Active, not recruiting||N/A|140|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-06-01 02:04:24.970946|2018-06-01 02:04:24.970946
NCT00691613|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2010-03-11|2008-06-03|2008-06-05|Estimate|||||||2010-03-11|2010-03-12|Estimate|July 2010||2010-07-31|March 2010|2010-03-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|IPIIR||Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model|Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model - A Randomised Cross-over Study to Evaluate if Infusion of a Single Dose of EPO Protects Against Ischemia-reperfusion Injury in Man|Unknown status|Not yet recruiting|N/A|12|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 02:04:25.07907|2018-06-01 02:04:25.07907
NCT00691600|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2010-12-02|2008-06-03|2008-06-05|Estimate|||||||2010-12-02|2010-12-06|Estimate|December 2007||2007-12-31|December 2010|2010-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage|Phase 3 Study Comparing Bactrim to Placebo in the Management of Abscesses < 5cm and 23 hr Observation Unit to Inpatient Treatment in the Management of Abscesses 5-10cm in the Pediatric Population.|Completed||Phase 3|472|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 02:04:25.180679|2018-06-01 02:04:25.180679
NCT00691587|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2009-07-29|2008-06-04|2008-06-05|Estimate|||||||2009-07-29|2009-07-31|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa|A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa|Completed||Phase 1/Phase 2|36|Anticipated|Humanigen, Inc.||3|||f||||f||||||||||2018-06-01 02:04:25.260774|2018-06-01 02:04:25.260774
NCT00691574|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-11-09|2008-06-03|2008-06-05|Estimate|||||||2013-11-09|2013-11-13|Estimate|September 1998||1998-09-30|November 2013|2013-11-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Melatonin Levels in Smith Magenis Syndrome (SMS)|Melatonin Levels in Sleep-disordered Smith-Magenis Syndrome: a Pilot Study|Completed||N/A|5|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:04:25.365626|2018-06-01 02:04:25.365626
NCT00691561|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2010-03-10|2008-06-04|2008-06-05|Estimate|||||||2010-03-10|2010-03-11|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|Project ABLE||Culturally-Tailored HIV Risk Reduction for African-American MSM|Culturally-Tailored HIV Risk Reduction for African-American MSM (Project ABLE: African-Americans Building Life Empowerment|Completed||N/A|220|Anticipated|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:04:25.476158|2018-06-01 02:04:25.476158
NCT00691548|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2015-04-09|2008-06-04|2008-06-05|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Cetuximab Zr89||Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients|Non Invasive Imaging of Cetuximab-Zirconium-89 Uptake With PET: a Phase I Trial in Stage IV Cancer|Completed||Phase 1|9|Actual|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-06-01 02:04:25.553094|2018-06-01 02:04:25.553094
NCT00691535|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-04|2008-06-04|2008-06-05|Estimate|||||||2008-06-04|2008-06-05|Estimate|October 2003||2003-10-31|June 2008|2008-06-30||||||||Observational|||Genetics of Symptomatology and Treatment Response in Psychotic Major Depression|Association of BDNF, COMT, MDRI, CRH, CRF, and GC Receptor Genetic Polymorphisms With Symptomatology and Treatment Response in Psychotic Major Depression|Unknown status|Recruiting||500||Stanford University|||||f||||||||||||||2018-06-01 02:04:25.6272|2018-06-01 02:04:25.6272
NCT00691522|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2009-01-08|2008-06-04|2008-06-05|Estimate|||||||2009-01-08|2009-01-09|Estimate|November 2008||2008-11-30|January 2009|2009-01-31|October 2009|Anticipated|2009-10-31|August 2009|Anticipated|2009-08-31||Interventional|||Imaging Study of XERECEPT® Treatment for Peritumoral Brain Edema (PBE)|Open-Label, Imaging Study of Human Corticotropin-Releasing Factor (hCRF) for The Reduction of Peritumoral Brain Edema (PBE) in Patients With Primary Malignant or Metastatic Brain Tumors|Terminated||Phase 2|60|Anticipated|PharmaNet|||||t||||f||||||||||2018-06-01 02:04:25.70584|2018-06-01 02:04:25.70584
NCT00691509|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2013-08-23|2008-06-04|2008-06-05|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2005||2005-01-31|June 2008|2008-06-30||||December 2010|Anticipated|2010-12-31||Observational|||Dietary Phytoestrogens, Complementary and Alternative Medicine, and Lifestyle in Predicting Survival of Women With Breast Cancer|The Role of Diet, Complementary Treatment and Lifestyle in Breast Cancer Survival|Unknown status|Recruiting||2300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:04:25.765527|2018-06-01 02:04:25.765527
NCT00691496|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-06-12|2008-06-04|2008-06-05|Estimate|||||||2012-06-12|2012-06-13|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men|A Behavioral Intervention to Reduce Sexual Risk Among African-American Men Who Have Sex With Men|Completed||N/A|326|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:04:25.841516|2018-06-01 02:04:25.841516
NCT00691483|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2010-09-09||2015-10-16|2008-06-03|2008-06-05|Estimate|2010-09-09|2010-09-30|Estimate||||2015-10-16|2015-11-20|Estimate|September 2008||2008-09-30|October 2015|2015-10-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date|A Phase 4, Prospective, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Smoking Cessation With Varenicline Tartrate Compared With Placebo In The Setting Of Patient Self-Selected (Flexible) Quit Date|Completed||Phase 4|659|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:04:25.948432|2018-06-01 02:04:25.948432
NCT00691470|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2010-02-01|2008-06-04|2008-06-05|Estimate|||||||2010-02-01|2010-02-02|Estimate|May 2008||2008-05-31|October 2008|2008-10-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|EmbraceAC||Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation|A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation|Unknown status|Active, not recruiting|Phase 2/Phase 3|600|Anticipated|ARYx Therapeutics||2|||f||||t||||||||||2018-06-01 02:04:26.401468|2018-06-01 02:04:26.401468
NCT00691457|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-09-28|2008-06-04|2008-06-05|Estimate|||||||2012-09-28|2012-10-01|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina|Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina|Completed||N/A|15|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 02:04:26.520625|2018-06-01 02:04:26.520625
NCT00691444|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-11-04|2008-06-04|2008-06-05|Estimate|||||||2014-11-04|2014-11-06|Estimate|September 2002||2002-09-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Blind Child Melatonin Treatment Study|Melatonin Studies of Blind Children|Unknown status|Recruiting|N/A|26|Anticipated|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 02:04:26.674517|2018-06-01 02:04:26.674517
NCT00691431|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2011-06-01|2008-06-03|2008-06-05|Estimate|||||||2011-06-01|2011-06-02|Estimate|May 2004||2004-05-31|June 2008|2008-06-30|November 2005||2005-11-30|||||Interventional|||IntraLase vs Hansatome Flaps in LASIK|Comparison of the IntraLaser Femtosecond Laser and Hansatome Mechanical Keratome for Laser In Situ Keratomileusis|Completed||N/A|51||Stanford University|||||f||||||||||||||2018-06-01 02:04:26.7865|2018-06-01 02:04:26.7865
NCT00691418|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-03-04|2008-06-04|2008-06-05|Estimate|||||||2015-03-04|2015-03-06|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Docosahexaenoic Acid (DHA) Administration and Length of Gestation: a Feasibility Study|DHA Administration and Length of Gestation: a Feasibility Study|Withdrawn||N/A|0|Actual|Kaiser Permanente||2||decision made not to proceed -- no subjects were ever enrolled|f||||f||||||||||2018-06-01 02:04:26.839781|2018-06-01 02:04:26.839781
NCT00690534|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2016-12-08|2008-05-30|2008-06-04|Estimate|||||||2016-12-08|2016-12-12|Estimate|September 2005||2005-09-30|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Insulin and Sarcopenia in the Elderly|Insulin and Sarcopenia in the Elderly|Completed||Phase 1|88|Actual|The University of Texas Medical Branch, Galveston||11|||f||||f||||||||No|No sharing. Drug was used off label for collection of measures for research project.|2018-06-01 02:04:42.62545|2018-06-01 02:04:42.62545
NCT00691405|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2012-02-21|2008-06-04|2008-06-05|Estimate|||||||2012-02-21|2012-02-22|Estimate|October 2003||2003-10-31|February 2012|2012-02-29|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Double-blind, Randomized, Multicenter, Two-part Parallel-group, Dose-ranging Study of Twice-daily and Once-daily (R,R) Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|215|Actual|Sunovion||8|||f||||f||||||||||2018-06-01 02:04:26.943964|2018-06-01 02:04:26.943964
NCT00691392|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-08-15|2008-06-04|2008-06-05|Estimate|||||||2012-08-15|2012-08-17|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|S30PK||Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)|Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis|Completed||Phase 1/Phase 2|26|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 02:04:27.128586|2018-06-01 02:04:27.128586
NCT00691379|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2016-09-21|2008-06-03|2008-06-05|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2008||2008-04-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer|Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negative (ER-,PR-,HER2-) Metastatic Breast Cancer. A Multicenter Phase I-II Study|Completed||Phase 1/Phase 2|46|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 02:04:27.218682|2018-06-01 02:04:27.218682
NCT00691366|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-03-14|2008-06-02|2008-06-05|Estimate|||||||2017-03-14|2017-03-16|Actual|March 2007||2007-03-31|June 2008|2008-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis|Autonomic Nervous System Physiology and Chronic Pruritus: A Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis|Completed|||45|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 02:04:27.335741|2018-06-01 02:04:27.335741
NCT00691353|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-12-02|2008-06-04|2008-06-05|Estimate|||||||2008-12-02|2008-12-03|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|DIDAXI||Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers|Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers|Completed|||540|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:04:27.40329|2018-06-01 02:04:27.40329
NCT00691340|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-03-09|2008-06-04|2008-06-05|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease|Systematic Characterization of the Cellular Proteome From Human Leukocytes of Glaucoma Patients in Comparison With Patients With Alzheimer's Disease|Withdrawn|||0|Actual|University Hospital, Basel, Switzerland|||4|was replaced by another study. Problems with recruitment.|f||||f||||||None Retained|"~     plasma~   "|||2018-06-01 02:04:27.507675|2018-06-01 02:04:27.507675
NCT00691327|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2013-12-30||2014-10-06|2008-06-04|2008-06-05|Estimate|2013-12-30|2014-02-12|Estimate||||2014-10-06|2014-10-13|Estimate|December 1997||1997-12-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants|Adjunct Study of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants|Completed||N/A|84329|Actual|Allergan||3|||f||||f||||||||||2018-06-01 02:04:27.868656|2018-06-01 02:04:27.868656
NCT00691314|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-12|||2011-02-23|2008-06-04|2008-06-05|Estimate|||||||2011-02-23|2011-02-24|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|ESSCAS||Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis|Safety and Efficacy of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis|Completed||N/A|300|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-06-01 02:04:28.119955|2018-06-01 02:04:28.119955
NCT00691301|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2016-11-29||2017-12-12|2008-06-04|2008-06-05|Estimate|2017-12-12|2018-01-09|Actual||||2017-12-12|2018-01-09|Actual|September 2008||2008-09-30|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix|Completed||Phase 2|55|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 02:04:28.250447|2018-06-01 02:04:28.250447
NCT00691288|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2014-06-10|2008-06-03|2008-06-05|Estimate|||||||2014-06-10|2014-06-12|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children|Effect of Omega-3 Fatty Acid Supplementation on Hypertriglyceridemia in HIV-infected Children Taking Highly Active Antiretroviral Therapy (HAART): a Randomized Cross-over Study|Terminated||Phase 2|13|Actual|The Hospital for Sick Children||2||Unable to enroll sufficient patients|f||||f||||||||||2018-06-01 02:04:28.978373|2018-06-01 02:04:28.978373
NCT00691275|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-07-13|2008-06-04|2008-06-05|Estimate|||||||2015-07-13|2015-07-14|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration|Ondansetron vs. Placebo in the Management of Children With Dehydration Due to Acute Gastroenteritis|Withdrawn||N/A|0|Actual|Children's Hospitals and Clinics of Minnesota||2|||f||||f||||||||||2018-06-01 02:04:29.067829|2018-06-01 02:04:29.067829
NCT00691262|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-08-29|2008-06-04|2008-06-05|Estimate|||||||2014-08-29|2014-09-01|Estimate|October 2003||2003-10-31|August 2014|2014-08-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis|A Long Term, Non-comparative, Multi-centre Study to Further Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis.|Completed||Phase 3|166|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:04:29.150496|2018-06-01 02:04:29.150496
NCT00691249|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2009-06-30|2008-06-04|2008-06-05|Estimate|||||||2009-06-30|2009-07-02|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes|Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes|Completed||N/A|10|Actual|Kansas State University||5|||f||||f||||||||||2018-06-01 02:04:29.251938|2018-06-01 02:04:29.251938
NCT00691236|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2011-06-22|2008-06-03|2008-06-05|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|ZOL||Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma|Evaluation of Zoledronic Acid as a Single Agent and as an Adjuvant to Chemotherapy in the Management of High Grade Osteosarcoma|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Tata Memorial Hospital||3|||f||||t||||||||||2018-06-01 02:04:29.372564|2018-06-01 02:04:29.372564
NCT00691223|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2018-01-07|2008-06-04|2008-06-05|Estimate|||||||2018-01-07|2018-01-09|Actual|June 2007|Actual|2007-06-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Study of Selected X-linked Disorders: Goltz Syndrome|Pathogenesis of Focal Dermal Hypoplasia or Goltz Syndrome and Related Disorders|Active, not recruiting|||84|Actual|Baylor College of Medicine|||1||f||||f||||||Samples With DNA|"~     lymphoblast DNA; tissue~   "|Yes|Deidentified patient data will be published following peer review in journals and/or presented at scientific meetings.|2018-06-01 02:04:29.47328|2018-06-01 02:04:29.47328
NCT00691210|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2014-03-07||2016-08-09|2008-06-04|2008-06-05|Estimate|2015-02-25|2015-03-10|Estimate||||2016-08-09|2016-09-19|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|SAHA||Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies|Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies|Completed||Phase 1|38|Actual|Columbia University||8|||f||||t||||||||No||2018-06-01 02:04:29.643384|2018-06-01 02:04:29.643384
NCT00691197|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2009-11-06||2015-06-26|2008-06-04|2008-06-05|Estimate|2009-11-06|2009-12-10|Estimate||||2015-06-26|2015-07-22|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear|Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear|Completed||Phase 2/Phase 3|246|Actual|Allergan||2|||f||||f||||||||||2018-06-01 02:04:31.924807|2018-06-01 02:04:31.924807
NCT00691184|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-03|2008-06-03|2008-06-05|Estimate|||||||2008-06-03|2008-06-05|Estimate|February 2005||2005-02-28|June 2008|2008-06-30|December 2005|Actual|2005-12-31|June 2005|Actual|2005-06-30||Interventional|||Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis|A Double-Blind, Randomized, Parallel Design Study To Assess the Safety and Pharmacokinetics of Terbinafine Hydrogen Cloride (HCl) Nail Lacquer Applied for 28 Days in Patients With Onychomycosis|Completed||Phase 1|56|Actual|NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)||4|||f||||||||||||||2018-06-01 02:04:32.251411|2018-06-01 02:04:32.251411
NCT00691171|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2015-04-14|2008-06-04|2008-06-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use|Using an Electronic Health Record-based Intervention and Broad Education Reach Strategies to Improve Quality of Care for GERD and Gastroprotection for Patients on NSAIDs: a Randomized Controlled Trial|Completed|||5234|Actual|AstraZeneca|||3||f||||f||||||||||2018-06-01 02:04:32.371633|2018-06-01 02:04:32.371633
NCT00691158|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2012-06-04|2008-06-04|2008-06-05|Estimate|||||||2012-06-04|2012-06-06|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide|A Pilot Study of the fMRI Response to Leptin and Pramlintide|Unknown status|Active, not recruiting|N/A|10|Anticipated|Oregon Health and Science University||4|||f||||t||||||||||2018-06-01 02:04:32.440711|2018-06-01 02:04:32.440711
NCT00691145|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-08-28|2008-06-04|2008-06-05|Estimate|||||||2014-08-28|2014-09-01|Estimate|October 2002||2002-10-31|August 2014|2014-08-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis|A Long-term, Non-comparative, Multi-centre Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus (FK506) Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis FG-506-06-IT-01|Completed||Phase 3|350|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:04:32.536132|2018-06-01 02:04:32.536132
NCT00691132|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2017-02-14||2017-04-06|2008-06-04|2008-06-05|Estimate|2017-02-14|2017-04-04|Actual||||2017-04-06|2017-05-12|Actual|February 2009||2009-02-28|April 2017|2017-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers|Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers|Completed||Phase 2|107|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-06-01 02:04:32.685578|2018-06-01 02:04:32.685578
NCT00691119|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2013-05-08|2008-06-03|2008-06-05|Estimate|||||||2013-05-08|2013-05-10|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Relaxation and Visualization Therapy for Breast Cancer Patients|A Feasibility Study of Relaxation and Visualization Therapy for Breast Cancer Patients|Terminated||N/A|9|Anticipated|National University of Natural Medicine||3||Inadequate recruitment|f||||f||||||||||2018-06-01 02:04:33.256474|2018-06-01 02:04:33.256474
NCT00691093|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2010-03-15||2011-02-16|2008-06-04|2008-06-05|Estimate|2010-10-21|2010-11-18|Estimate||||2011-02-16|2011-02-21|Estimate|July 2008||2008-07-31|February 2011|2011-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy|Observational Study In Patients With Overactive Bladder (OAB) Treated With Toviaz® After Failure Of Previous Antimuscarinic Therapy Due To Ineffectivity Or Intolerance.|Completed|||823|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:04:33.352414|2018-06-01 02:04:33.352414
NCT00691080|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2016-01-12|2008-06-04|2008-06-05|Estimate|||||||2016-01-12|2016-01-13|Estimate|September 2007||2007-09-30|January 2016|2016-01-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Observational|REST||Understanding Sleep Problems in Children With Autism Spectrum Disorder|Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.|Completed|||58|Actual|Baylor College of Medicine|||2||f||||t||||||None Retained|"~     SAMPLE: Saliva What is the purpose of the sample collection? Determination of dim light~     melatonin onset (DMLO), as measured by salivary melatonin secretion.~      SAMPLE: Urine What is the purpose of the sample collection? Measurement of secreted~     6-suplhatoxymaltonin, a metabolite of melatonin.~   "|||2018-06-01 02:04:33.929665|2018-06-01 02:04:33.929665
NCT00691067|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2017-01-30|2008-06-04|2008-06-05|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2008||2008-05-31|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Controlled Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness|A Randomized, Double-blind Placebo-controlled Crossover Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness|Completed||Phase 4|65|Actual|Bronx Veterans Medical Research Foundation, Inc||2|||f||||t||||||||||2018-06-01 02:04:34.007473|2018-06-01 02:04:34.007473
NCT00691054|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2013-09-03||2017-04-04|2008-06-04|2008-06-05|Estimate|2013-09-03|2013-11-15|Estimate||||2017-04-04|2017-05-11|Actual|June 2008||2008-06-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy|Phase II Trial of Abraxane® in the Treatment of Patients With Pancreatic Cancer Who Have Failed First-Line Treatment With Gemcitabine-Based Therapy|Completed||Phase 2|20|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 02:04:34.075287|2018-06-01 02:04:34.075287
NCT00691041|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-06-12|2008-06-04|2008-06-05|Estimate|||||||2012-06-12|2012-06-13|Estimate|August 2008||2008-08-31|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|UDP||A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)|A Network Intervention for Reducing Sexual Risk for HIV With African American Men Who Have Sex With Men (AA MSM)|Completed||N/A|233|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:04:34.275367|2018-06-01 02:04:34.275367
NCT00691028|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2013-01-29||2014-01-30|2008-06-03|2008-06-05|Estimate|2013-05-16|2013-05-20|Estimate||||2014-01-30|2014-03-04|Estimate|September 2005||2005-09-30|January 2014|2014-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis|Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis|Completed||Phase 3|327|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-06-01 02:04:34.353193|2018-06-01 02:04:34.353193
NCT00691015|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2015-12-09||2017-05-26|2008-06-04|2008-06-05|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|May 2008||2008-05-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant|A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin®, as Graft-versus-Host- Disease Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation|Completed||Phase 2|48|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 02:04:36.116141|2018-06-01 02:04:36.116141
NCT00691002|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2013-11-08|2008-06-03|2008-06-05|Estimate|||||||2013-11-08|2013-11-11|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds|Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas|Completed||Phase 3|1245|Actual|LEO Pharma||4|||f||||f||||||||||2018-06-01 02:04:37.261234|2018-06-01 02:04:37.261234
NCT00690989|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-03-31|2008-06-04|2008-06-05|Estimate|||||||2015-03-31|2015-04-03|Estimate|July 2005||2005-07-31|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2007|Actual|2007-06-30||Observational|||Retrospective Evaluation of Patient Failure to Follow-up at a Community Based Headache Clinic|If You Build it, They Will Come; But Will They Return for Follow-up? A Retrospective Assessment of Potential Risk Factors for Patient Failure to Follow-up at a Community Based Headache Clinic|Completed|||200|Actual|Kilgo Headache Clinic|||||f||||f||||||||||2018-06-01 02:04:37.35955|2018-06-01 02:04:37.35955
NCT00690976|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2010-03-10|2008-06-04|2008-06-05|Estimate|||||||2010-03-10|2010-03-11|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Proyecto SOL: A Risk Reduction Intervention for Hispanic Men Who Have Sex With Men (MSM)|Proyecto SOL: A Risk Reduction Intervention for Hispanic MSM|Completed||N/A|220|Anticipated|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:04:37.417682|2018-06-01 02:04:37.417682
NCT00690963|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2016-04-05|2008-06-04|2008-06-05|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating|A Phase I/II Dose Escalation Trial Using Hypofractionation With Individualized Differential Boosting With Respiratory Gated Intensity-modulated Radiation Therapy (IMRT) in the Treatment of Non-small Cell Lung Cancer.|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 02:04:37.491424|2018-06-01 02:04:37.491424
NCT00690950|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-04|2008-06-04|2008-06-05|Estimate|||||||2008-06-04|2008-06-05|Estimate|May 2008||2008-05-31|June 2008|2008-06-30||||July 2009|Anticipated|2009-07-31||Interventional|||A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart|Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride?|Unknown status|Enrolling by invitation|Phase 4|50|Anticipated|Urologic Consultants of Southeastern PA|||||f||||t||||||||||2018-06-01 02:04:37.640552|2018-06-01 02:04:37.640552
NCT00690937|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2014-03-17|2008-06-04|2008-06-05|Estimate|||||||2014-03-17|2014-03-19|Estimate|February 2008||2008-02-29|March 2014|2014-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|Sevelamer ECS||A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia|A Multicenter, Single-blind, Active and Placebo-controlled, Parallel-group, Randomized Study of Two Dosing Regimens of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesterolemia|Completed||Phase 2|120|Actual|Sanofi||5|||f||||f||||||||||2018-06-01 02:04:37.728766|2018-06-01 02:04:37.728766
NCT00690924|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|2017-07-13||2018-01-04|2008-06-04|2008-06-05|Estimate|2017-09-13|2017-10-11|Actual||||2018-01-04|2018-01-08|Actual|July 17, 2008|Actual|2008-07-17|January 2018|2018-01-31|March 7, 2018|Anticipated|2018-03-07|March 7, 2017|Actual|2017-03-07||Interventional||All treated and eligible patients|Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer|A Pilot Study of Oral Calcitriol in Patients at High Risk for Lung Cancer|Active, not recruiting||N/A|16|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 02:04:37.862366|2018-06-01 02:04:37.862366
NCT00690911|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-11-01|2008-06-04|2008-06-05|Estimate|||||||2017-11-01|2017-11-06|Actual||||November 2017|2017-11-30||||||||Interventional|||Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis|A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36)|Withdrawn||Phase 2|0|Actual|Wake Forest University Health Sciences||1||"Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the~   study started."|f||||f||||||||||2018-06-01 02:04:38.125046|2018-06-01 02:04:38.125046
NCT00690898|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2013-11-04||2014-02-27|2008-06-03|2008-06-05|Estimate|2013-11-04|2013-12-23|Estimate||||2014-02-27|2014-03-27|Estimate|May 2008||2008-05-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|PRIMARYS||Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma|Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma|Completed||Phase 3|108|Actual|Ipsen||1|||f||||t||||||||||2018-06-01 02:04:38.261158|2018-06-01 02:04:38.261158
NCT00690885|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-04-20|2008-06-04|2008-06-05|Estimate|||||||2012-04-20|2012-04-24|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis|Evaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF)|Terminated||Phase 2|1|Actual|Amarillo Biosciences, Inc.||2||Insufficient patient accrual|f||||f||||||||||2018-06-01 02:04:38.727743|2018-06-01 02:04:38.727743
NCT00690872|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-04|||2009-06-26|2008-06-04|2008-06-05|Estimate|||||||2009-06-26|2009-06-29|Estimate|July 2008||2008-07-31|June 2009|2009-06-30||||December 2014|Anticipated|2014-12-31||Interventional|||Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer|Phase II Trial Evaluating Efficacy of a Strategy Employing Combination Gemcitabine and Carboplatin Chemotherapy Followed by EBV-Specific Cytotoxic T-Lymphocytes in Patients With Metastatic or Locally Recurrent EBV-Positive Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:04:38.837518|2018-06-01 02:04:38.837518
NCT00690859|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2009-05-28|2008-06-04|2008-06-05|Estimate|||||||2009-05-28|2009-05-29|Estimate|June 2007||2007-06-30|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|PREBIS||Predictors of Recurrence in Bipolar Disorder in Spain|Evaluation of Predictor Factors of Recurrence in Bipolar Disorder in Spain|Completed|||595|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:04:39.031637|2018-06-01 02:04:39.031637
NCT00690846|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2015-12-14|2008-06-04|2008-06-05|Estimate|||||||2015-12-14|2015-12-15|Estimate||||December 2015|2015-12-31||||||||Interventional|||Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum|A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)|Withdrawn||Phase 2|0|Actual|Wake Forest University Health Sciences||1||"Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the~   study started."|f||||f||||||||||2018-06-01 02:04:39.162483|2018-06-01 02:04:39.162483
NCT00690833|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2017-02-08||2017-11-01|2008-06-02|2008-06-05|Estimate|2017-02-08|2017-03-28|Actual||||2017-11-01|2017-12-06|Actual|August 2007||2007-08-31|November 2017|2017-11-30|November 2009|Actual|2009-11-30|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis|Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis|Completed||Phase 4|41|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-06-01 02:04:39.245712|2018-06-01 02:04:39.245712
NCT00690820|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2009-11-30||2010-05-26|2008-06-04|2008-06-05|Estimate|2010-02-03|2010-03-10|Estimate||||2010-05-26|2010-06-02|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)|A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 12,000 Unit Capsules in Subjects Aged 7 - 11 With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Completed||Phase 3|17|Actual|Solvay Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:04:39.426765|2018-06-01 02:04:39.426765
NCT00690807|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2009-09-24|2008-06-03|2008-06-05|Estimate|||||||2009-09-24|2009-09-28|Estimate|June 2008||2008-06-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis|A Phase 2 Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Atopic Dermatitis|Completed||Phase 2|30|Anticipated|Provectus Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:04:39.839023|2018-06-01 02:04:39.839023
NCT00690794|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|2012-03-30||2012-07-20|2008-06-04|2008-06-05|Estimate|2012-05-31|2012-07-03|Estimate||||2012-07-20|2012-07-24|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension|An Evaluation of the Ocular Surface Health in Subjects Using TRAVATAN Z® Ophthalmic Solution Versus XALATAN® Ophthalmic Solution|Completed||Phase 3|726|Actual|Alcon Research|The subjective nature of the OSDI may not be sensitive enough to detect the effects of preservatives on the corneal surface. The measurement and quantification of OSD remains a considerable clinical challenge. (Pflugfelder and Baudoin, 2011)|2|||f||||f||||||||||2018-06-01 02:04:39.925361|2018-06-01 02:04:39.925361
NCT00690781|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2011-01-26|2008-06-04|2008-06-05|Estimate|||||||2011-01-26|2011-01-27|Estimate|May 2008||2008-05-31|January 2011|2011-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SURPROL-CF-H||Protein Nutrition During Weight Loss|Effect of Milk Proteins and Protein Feeding Pattern on Body Composition and Protein Metabolism in Energy Restricted Obese Subjects|Completed||N/A|48|Anticipated|Institut National de la Recherche Agronomique||4|||f||||f||||||||||2018-06-01 02:04:40.206095|2018-06-01 02:04:40.206095
NCT00690768|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-06-03|2008-06-03|2008-06-05|Estimate|||||||2008-06-03|2008-06-05|Estimate|March 2008||2008-03-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|IBETRA||Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)|Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study)|Completed||Phase 2|20|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 02:04:40.290684|2018-06-01 02:04:40.290684
NCT00690755|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2015-05-22||2016-04-12|2008-06-04|2008-06-05|Estimate|2016-04-12|2016-05-19|Estimate||||2016-04-12|2016-05-19|Estimate|May 2000||2000-05-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome|Defective Atypical PKC Activation in Diabetes and Metabolic Syndrome|Completed|||157|Actual|VA Office of Research and Development|As the study progressed, it was determined that there was not scientific merit to the Groups 2, 5 or 7. These groups were, therefore, not pursued.||7||f||||t||||||None Retained|"~     Muscle biopsies taken before and after insulin stimulation in euglycemic clamp studies~   "|No|Individual participant data will not be shared, as data is presented in the published paper as a mean plus or minus SEM.|2018-06-01 02:04:40.36931|2018-06-01 02:04:40.36931
NCT00690742|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-04|2008-06-04|2008-06-05|Estimate|||||||2008-06-04|2008-06-05|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:04:40.727801|2018-06-01 02:04:40.727801
NCT00690729|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2010-08-26|2008-06-03|2008-06-05|Estimate|||||||2010-08-26|2010-08-30|Estimate|July 2005||2005-07-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|||Cognitive-Behavioral Bibliotherapy for the Treatment of Obsessive Compulsive Disorder in Children and Adolescents|Cognitive-Behavioral Treatment of Obsessive Compulsive Disorder in Children and Adolescents|Completed||N/A|22|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 02:04:40.760669|2018-06-01 02:04:40.760669
NCT00690716|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03||2010-08-17|2012-08-06|2008-06-03|2008-06-05|Estimate||||2010-08-18|2010-08-20|Estimate|2012-08-06|2012-08-15|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Mild Headache in People Who Experience Migraines|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Nasal Carbon Dioxide in the Treatment of Mild Headache in Migraineurs|Completed||Phase 2|292|Actual|Capnia, Inc.||2|||f||||f||||||||||2018-06-01 02:04:40.823237|2018-06-01 02:04:40.823237
NCT00690703|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-04|2008-06-04|2008-06-05|Estimate|||||||2008-06-04|2008-06-05|Estimate|July 2001||2001-07-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|RAPTURE||Radiofrequency Ablation of Pulmonary Tumors Response Evaluation|Radiofrequency Ablation of Pulmonary Tumors Response Evaluation: a Prospective, Intention-to-Treat, Multicenter Clinical Trial|Completed||Phase 2|106|Actual|Angiodynamics, Inc.||1|||f||||f||||||||||2018-06-01 02:04:41.003575|2018-06-01 02:04:41.003575
NCT00690690|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2010-03-08|2008-06-04|2008-06-05|Estimate|||||||2010-03-08|2010-03-09|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks|No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks|Completed||Phase 2/Phase 3|370|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:04:41.101134|2018-06-01 02:04:41.101134
NCT00690677|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2012-01-16|2008-06-03|2008-06-05|Estimate|||||||2012-01-16|2012-01-18|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Phase II Trial of LBH589 in Refractory Colorectal Cancer|Phase II Trial of LBH589 in Refractory Colorectal Cancer|Completed||Phase 2|29|Actual|Swedish Medical Center|||||f||||f||||||||||2018-06-01 02:04:41.176911|2018-06-01 02:04:41.176911
NCT00690664|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-11-01|2008-06-02|2008-06-05|Estimate|||||||2017-11-01|2017-11-06|Actual|April 24, 2007|Actual|2007-04-24|November 2017|2017-11-30|July 14, 2014|Actual|2014-07-14|July 14, 2014|Actual|2014-07-14||Observational|||Evaluation of Scalp and Hair Shaft With Biologic Markers in African American and Caucasian Hair|Evaluation of Scalp and Hair Shaft With Biologic Markers in African American and Caucasian Hair|Completed|||60|Actual|Wake Forest University Health Sciences|||2||f||||f||||||Samples With DNA|"~     Hair, both broken strands and those that release from the scalp with bulb intact.~   "|No||2018-06-01 02:04:41.248766|2018-06-01 02:04:41.248766
NCT00690651|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-06-08|2008-06-03|2008-06-04|Estimate|||||||2010-06-08|2010-06-09|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Rest Easy: Is Bed Rest Really Necessary After Surgical Repair of an Ankle Fracture?|Randomized Controlled Study Into Early Mobilization Following Internal Fixation of Isolated Ankle Fractures.|Completed||N/A|104|Actual|The Alfred||2|||f||||t||||||||||2018-06-01 02:04:41.325081|2018-06-01 02:04:41.325081
NCT00690638|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-04-12|2008-06-03|2008-06-04|Estimate|||||||2010-04-12|2010-04-13|Estimate|July 2008||2008-07-31|January 2010|2010-01-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|480|Anticipated|Phenomix||3|||f||||f||||||||||2018-06-01 02:04:41.424924|2018-06-01 02:04:41.424924
NCT00690625|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2008-12-08|2008-06-03|2008-06-04|Estimate|||||||2008-12-08|2008-12-09|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream|Topical Application of MyoRx (Omega 3 Fatty Acids Containing) Cream; Randomized Double Blind Clinical Trial|Completed||Phase 1|40|Anticipated|University of Washington||2|||f||||f||||||||||2018-06-01 02:04:41.606241|2018-06-01 02:04:41.606241
NCT00690612|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2010-08-31||2011-07-07|2008-06-02|2008-06-04|Estimate|2011-06-01|2011-06-29|Estimate||||2011-07-07|2011-07-12|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|HIP||Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)|An Open-label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: a Long Term Study|Completed||Phase 3|35|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 02:04:41.694355|2018-06-01 02:04:41.694355
NCT00690599|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|April 2006||2006-04-30|May 2008|2008-05-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Observational|Satisfaction||Socioeconomic Profile and Patient Satisfaction Assessment|Socioeconomic Profile and Patient Satisfaction Assessment in an Academic Dental General Clinic|Completed|||80|Anticipated|Fortaleza University|||||f||||t||||||||||2018-06-01 02:04:41.89234|2018-06-01 02:04:41.89234
NCT00690586|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-06-07|2008-06-03|2008-06-04|Estimate|||||||2010-06-07|2010-06-08|Estimate|December 2007||2007-12-31|June 2008|2008-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Fluid Balance, Hormones and Urine Proteomics in Nephrotic Syndrome in Childhood|Fluid Balance, Hormones and Urine Proteomics in Nephrotic Syndrome in Childhood|Completed|||21|Actual|Aarhus University Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood samples for hormone analyzes Urine samples for urine protomis, AQP II and ENaC~   "|||2018-06-01 02:04:41.958564|2018-06-01 02:04:41.958564
NCT00690573|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2011-03-04||2012-09-05|2008-06-03|2008-06-04|Estimate|2011-03-04|2011-04-01|Estimate||||2012-09-05|2012-09-10|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|March 2010|Actual|2010-03-31||Interventional|||Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis|A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis|Completed||Phase 3|25|Actual|Abbott||1|||f||||f||||||||||2018-06-01 02:04:42.072117|2018-06-01 02:04:42.072117
NCT00690560|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2015-02-08|2008-06-03|2008-06-04|Estimate|||||||2015-02-08|2015-02-10|Estimate|May 2007||2007-05-31|February 2015|2015-02-28|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|||Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma|International Phase II Study Evaluating the Association of CHOP-rituximab With Consolidation by Early Ibritumomab Tiuxetan-Y90 in Patients Aged 65 to 80 Years With CD20+ Large Cell Malignant Lymphoma and no Prior Therapy|Completed||Phase 2|30|Actual|Centre Antoine Lacassagne||1|||f||||||||||||||2018-06-01 02:04:42.450447|2018-06-01 02:04:42.450447
NCT00690547|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-11-27|2008-06-03|2008-06-04|Estimate|||||||2009-11-27|2009-11-30|Estimate|October 2008||2008-10-31|November 2009|2009-11-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|||Force Enhancement of Musculus Quadriceps Femoris During and After Excentric Muscle Activity in Vivo|Force Enhancement of m. Quadriceps Femoris During and After Excentric Muscle Activity in Vivo by Maximal and Sub-maximal Deliberately Activation.|Unknown status|Active, not recruiting||60|Anticipated|German Research Foundation|||1||f||||f||||||||||2018-06-01 02:04:42.555372|2018-06-01 02:04:42.555372
NCT00690521|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|January 2003||2003-01-31|June 2008|2008-06-30|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients|A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients|Unknown status|Recruiting|Phase 4|13|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-06-01 02:04:42.749639|2018-06-01 02:04:42.749639
NCT00690508|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-06-02|2008-06-02|2008-06-04|Estimate|||||||2008-06-02|2008-06-04|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|SSTTP||Validation of Supra-Sternal Tube-Tip Palpation|Validation of Supra-Sternal Tube-Tip Palpation (SSTTP): A Method to Identify Correct Depth of Intubation in Infants and Children|Unknown status|Recruiting|N/A|150|Anticipated|University of Ottawa|||||f||||f||||||||||2018-06-01 02:04:42.835983|2018-06-01 02:04:42.835983
NCT00690495|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2011-08-17||2012-01-02|2008-06-03|2008-06-04|Estimate|2011-08-17|2011-09-22|Estimate||||2012-01-02|2012-01-05|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Use of a Modified Propofol Emulsion in Adults|Prospective, Monocentric Controlled, Randomized, Double-blind Study to Compare the Two Different Propofol Emulsions Regarding Tolerability and Injection Pain During the Induction of Anesthesia in Adults|Completed||Phase 3|100|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-06-01 02:04:42.898278|2018-06-01 02:04:42.898278
NCT00690482|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2013-07-01||2013-12-13|2008-06-02|2008-06-04|Estimate|2013-10-11|2013-12-06|Estimate||||2013-12-13|2014-01-15|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|Columbus|One patient randomised to placebo withdrew consent immediately after the first dose of investigational product on the day of randomisation. No clinical measurements were performed and no reports of AEs were received for this patient. Since the patient is non-informative both in terms of efficacy and safety, he has been excluded from the analyses.|Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 4 Week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|118|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:04:43.253788|2018-06-01 02:04:43.253788
NCT00690469|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2017-04-20|2008-06-03|2008-06-04|Estimate|||||||2017-04-20|2017-04-24|Actual|June 2008|Actual|2008-06-30|April 2017|2017-04-30|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Observational|||Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers|Carcinogen Metabolism, DNA Repair, Parental Exposures and Retinoblastoma|Active, not recruiting|||245|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     saliva samples, blood and tumor samples if enrolled on ARET0332~   "|||2018-06-01 02:04:43.682711|2018-06-01 02:04:43.682711
NCT00690456|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07||2016-04-18|2016-04-18|2008-06-02|2008-06-04|Estimate||||2016-04-18|2016-05-18|Estimate|2016-04-18|2016-05-18|Estimate|May 2008||2008-05-31|April 2016|2016-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|TOCCATA||Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Glycemic Effect of Rimonabant Added to Metformin in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy|Terminated||Phase 3|403|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 02:04:43.898095|2018-06-01 02:04:43.898095
NCT00690443|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2013-01-18||2018-02-21|2008-06-03|2008-06-04|Estimate|2013-01-18|2013-02-25|Estimate||||2018-02-21|2018-02-23|Actual|May 2008||2008-05-31|February 2018|2018-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia|A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia|Completed||Phase 2|44|Actual|Aegerion Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:04:44.030534|2018-06-01 02:04:44.030534
NCT00690430|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2013-04-05||2013-06-25|2008-06-03|2008-06-04|Estimate|2013-06-25|2013-07-30|Estimate||||2013-06-25|2013-07-30|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease|A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues.|Completed||Phase 3|186|Actual|Novartis||2|||f||||t||||||||||2018-06-01 02:04:44.489615|2018-06-01 02:04:44.489615
NCT00690417|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2011-11-23|2008-06-03|2008-06-04|Estimate|||||||2011-11-23|2011-11-24|Estimate|August 2007||2007-08-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Vitamin D Inadequacy in Rural Populations, Evaluation of Correction by Food Supplementation|Vitamin D Inadequacy: Documentation in Rural Populations and Evaluation of Correction by Food Supplementation (Phase III; Manitowoc Prevalence Study)|Completed||N/A|108|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 02:04:46.061924|2018-06-01 02:04:46.061924
NCT00690404|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-12-08|2008-06-03|2008-06-04|Estimate|||||||2010-12-08|2010-12-10|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers|A Phase 1, Single-center, Randomized, Open-label, Two-way Crossover, Formulation and Food Effect Study in Healthy Volunteers, to Assess the Pharmacokinetics of AZD 2066 After Single Doses of a New Oral Solid Formulation and an Oral Solution|Completed||Phase 1|20|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:04:46.131093|2018-06-01 02:04:46.131093
NCT00690391|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-05-30|2008-05-30|2008-06-04|Estimate|||||||2008-05-30|2008-06-04|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|May 2013|Anticipated|2013-05-31|May 2009|Anticipated|2009-05-31||Observational|||Analysis of Palliative Surgery in View of Quality of Life and Prognosis|Analysis of Palliative Surgery in View of Quality of Life and Prognosis|Unknown status|Recruiting||250|Anticipated|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||||||2018-06-01 02:04:46.281705|2018-06-01 02:04:46.281705
NCT00690378|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2017-09-01||2018-04-27|2008-06-03|2008-06-04|Estimate|2018-04-27|2018-05-25|Actual||||2018-04-27|2018-05-25|Actual|November 2008||2008-11-30|March 2018|2018-03-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional||Safety population included all participants who received at least 1 dose of study drug.|Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections|Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults|Completed||Phase 2|137|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:04:46.373254|2018-06-01 02:04:46.373254
NCT00690365|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-12-08|2008-06-03|2008-06-04|Estimate|||||||2010-12-08|2010-12-09|Estimate|June 2007||2007-06-30|December 2010|2010-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|Q-chase||Safety and Efficacy of Switching to Quetiapine in Outpatients With Schizophrenia|A Non-interventional, Open Label, Phase IV Observational Study for the Safety and Efficacy of Switching to Quetiapine (Seroquel) in Outpatients With Schizophrenia Who Have Been Unsuccessfully Treated With Other Antipsychotics|Completed|||576|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:04:47.078753|2018-06-01 02:04:47.078753
NCT00690352|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2014-05-30|2008-05-30|2008-06-04|Estimate|||||||2014-05-30|2014-06-02|Estimate|March 2008||2008-03-31|May 2014|2014-05-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Observational|SSAS||Specialized Substance Abuse Supervision (SSAS) Versus Non-SSAS Recidivism Rates Among Nebraska Felony Drug Offenders|Comparing Recidivism Rates of Felony Drug Offenders in Nebraska Who Were Sentenced to, and/or Participated in, Specialized Substance Abuse Supervision (SSAS) to Those Without SSAS|Completed|||344|Actual|University of Nebraska|||||f||||f||||||||||2018-06-01 02:04:47.13325|2018-06-01 02:04:47.13325
NCT00690339|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2013-12-17||2014-10-06|2008-06-02|2008-06-04|Estimate|2013-12-18|2014-02-04|Estimate||||2014-10-06|2014-10-13|Estimate|February 2001||2001-02-28|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study||Completed||N/A|941|Actual|Allergan||4|||f||||||||||||||2018-06-01 02:04:47.241539|2018-06-01 02:04:47.241539
NCT00690326|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Interventional|BCC||Behavioral Change Communication (BCC) to Promote Physical Activity Among Females With Type 2 Diabetes Mellitus Attending Diabetic Clinic|Behavioral Change Communication to Promote Physical Activity Among Females With Type 2 Diabetes Mellitus Attending Diabetic Clinic.|Completed||N/A|86|Actual|Thiruvananthapuram Medical College||2|||f||||t||||||||||2018-06-01 02:04:47.688438|2018-06-01 02:04:47.688438
NCT00690313|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|July 2008||2008-07-31|May 2008|2008-05-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|||Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections|To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Illinois Retina Associates||2|||f||||||||||||||2018-06-01 02:04:47.779295|2018-06-01 02:04:47.779295
NCT00690300|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-03-02|2008-06-03|2008-06-04|Estimate|||||||2010-03-02|2010-03-03|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer|Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer|Unknown status|Recruiting|Phase 2|44|Anticipated|University of Ulm|||||f||||t||||||||||2018-06-01 02:04:47.873203|2018-06-01 02:04:47.873203
NCT00690287|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2012-01-10|2008-06-03|2008-06-04|Estimate|||||||2012-01-10|2012-01-11|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients|A Dose-Ranging Study to Evaluate Fasting and Postprandial P-Glucose, Safety and Tolerability After Oral Single, B.I.D and Q.I.D Dosing of AZD6370 in Patients With Diabetes Mellitus: a Randomized, Single-Blind, Placebo-Controlled, Phase I Study|Completed||Phase 1|24|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:04:47.991837|2018-06-01 02:04:47.991837
NCT00690274|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2012-08-15|2008-06-02|2008-06-04|Estimate|||||||2012-08-15|2012-08-17|Estimate|June 2008||2008-06-30|June 2010|2010-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study to Demonstrate Cognitive Enhancing Effects of BF2.649|A Randomized, Double Blind, Placebo Controlled, Study to Demonstrate the Cognitive Enhancing Effects of BF2.649 in People With Schizophrenia and Schizoaffective Disorder|Completed||Phase 2|52|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 02:04:48.138678|2018-06-01 02:04:48.138678
NCT00690261|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-01|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|August 2010|Anticipated|2010-08-31|||||Observational|||The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction|The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis Prediction|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     Pleural effusions and lung cancer tissue~   "|||2018-06-01 02:04:48.297153|2018-06-01 02:04:48.297153
NCT00690248|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-12-07|2008-06-02|2008-06-04|Estimate|||||||2010-12-07|2010-12-09|Estimate|November 2007||2007-11-30|December 2010|2010-12-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Observational|MM1||Depressive Symptoms in Acute Manic Episode|Prevalence of Depressive Symptoms in Manic Episodes of Bipolar Patients: an Observational Study|Completed|||250|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:04:48.393822|2018-06-01 02:04:48.393822
NCT00690235|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2012-06-21|2008-06-03|2008-06-04|Estimate|||||||2012-06-21|2012-06-22|Estimate|November 2007||2007-11-30|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Effects of Pramlintide on Weight Reduction in Clozapine- and Olanzapine-Induced Weight Gain in Obese People Diagnosed With Schizophrenia|Completed||Phase 4|33|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 02:04:48.553593|2018-06-01 02:04:48.553593
NCT00690222|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2015-03-24|2008-05-30|2008-06-04|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2008||2008-03-31|May 2008|2008-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery|A Comparison of Intracameral Phenylephrine 2% and Tropicamide 0.2% With Topical Phenylephrine 2.5% and Tropicamide 1% for Pupillary Dilation During Cataract Surgery on Patients With and Without Pseudoexfoliation Syndrome.|Terminated||N/A|80|Actual|Nova Scotia Health Authority||4||Funding|f||||f||||||||||2018-06-01 02:04:48.837487|2018-06-01 02:04:48.837487
NCT00690209|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2014-07-04|2008-06-03|2008-06-04|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||By Pass Surgery With Stem Cell Therapy in Chronic Ischemic Cardiopathy|Efficacy of Surgical Coronary Revascularization Associated With Stem Cells Injection in Patients With Severe Chronic Ischemic Heart Disease With Residual Viability. A Prospective, Controlled Pilot Trial.|Completed||Phase 2|12|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 02:04:48.911013|2018-06-01 02:04:48.911013
NCT00690014|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-03-31|2008-06-03|2008-06-04|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2006|Actual|2006-08-31|March 2017|2017-03-31|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Evaluation of Renal Drug Transport in Healthy Volunteers|Evaluation of Renal Drug Transport in Healthy Volunteers|Completed||N/A|10|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 02:04:51.389999|2018-06-01 02:04:51.389999
NCT00690196|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2016-07-05|2008-05-30|2008-06-04|Estimate|||||||2016-07-05|2016-07-07|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanisms|Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune Mechanism|Completed||N/A|90|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:04:48.986656|2018-06-01 02:04:48.986656
NCT00690183|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2013-01-16|2008-06-02|2008-06-04|Estimate|||||||2013-01-16|2013-01-17|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Observational|||Relationship Between Physical Activity and Stem Cells in Older Adults|Relationship Between Physical Activity and Stem Cells in Older Adults|Completed|||39|Actual|University of Nebraska|||||f||||f||||||Samples Without DNA|"~     Plasma will be retained for cytokine analysis.~   "|||2018-06-01 02:04:49.197025|2018-06-01 02:04:49.197025
NCT00690170|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2012-05-08|2008-05-30|2008-06-04|Estimate|||||||2012-05-08|2012-05-09|Estimate|December 2002||2002-12-31|May 2012|2012-05-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects|Nicotinic Modulation of (NMDA) Receptor Antagonist Schizophrenia-like Information Processing Deficits in Humans|Completed||Phase 1|30|Actual|Yale University||4|||f||||t||||||||||2018-06-01 02:04:49.483142|2018-06-01 02:04:49.483142
NCT00690157|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2009-09-14|2008-06-03|2008-06-04|Estimate|||||||2009-09-14|2009-09-15|Estimate|October 2003||2003-10-31|September 2009|2009-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|POLKARD HF||Registry of Patients Referred for Heart Transplantation|National Polish Registry of Patients Referred for Heart Transplantation. POLKARD HF|Completed|||999|Actual|Institute of Cardiology, Warsaw, Poland|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 02:04:49.563061|2018-06-01 02:04:49.563061
NCT00690144|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-06-28|2008-06-03|2008-06-04|Estimate|||||||2010-06-28|2010-06-29|Estimate|July 2007||2007-07-31|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||High-fidelity Simulation in Health Care Education|Prospective Study Focusing on Impact of High-fidelity Simulation in Health Care Education|Unknown status|Recruiting|N/A|500|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 02:04:49.658718|2018-06-01 02:04:49.658718
NCT00690131|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2017-03-28|2008-06-03|2008-06-04|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2009|Actual|2009-08-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||An Integrated Approach to Smoking Cessation in Severe Mental Illness (SMI)|An Integrated Approach to Smoking Cessation in SMI|Completed||N/A|219|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 02:04:49.746576|2018-06-01 02:04:49.746576
NCT00690118|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2015-05-28|2008-06-03|2008-06-04|Estimate|||||||2015-05-28|2015-05-29|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis|Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)|Terminated||Phase 2|219|Actual|University of Ulm||2||"The interim analysis showed no tendency in favour of the verum group. Therefore it was decided~   to stop the study prematurely."|f||||t||||||||||2018-06-01 02:04:49.855384|2018-06-01 02:04:49.855384
NCT00690105|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2014-08-28|2008-06-03|2008-06-04|Estimate|||||||2014-08-28|2014-09-01|Estimate|February 2004||2004-02-29|August 2014|2014-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Protopic Ointment in Adult Atopic Eczema of the Face|Comparative, Multicentre, Randomized, Double-blind Study to Assess the Efficacy of Tacrolimus 0.1% Ointment Versus Fluticasone 0.005% Ointment in Adult Patients Suffering From Moderate to Severe Atopic Dermatitis and Presenting With So-called 'Red Face' Lesions of the Head and Neck.|Completed||Phase 4|577|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:04:50.051772|2018-06-01 02:04:50.051772
NCT00690092|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2013-10-28|2008-06-03|2008-06-04|Estimate|||||||2013-10-28|2013-10-29|Estimate|May 2005||2005-05-31|October 2013|2013-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Multi-center Study of Spherule-Derived Coccidioidin|Safety, Sensitivity and Specificity of Spherule-derived Coccidioidin in Naive Adults, in Adults With a History of Pulmonary Coccidioidomycosis and in Adults With a History of Pulmonary Histoplasmosis|Completed||Phase 3|113|Actual|Nielsen BioSciences, Inc.||3|||f||||f||||||||||2018-06-01 02:04:50.304898|2018-06-01 02:04:50.304898
NCT00690079|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2010-12-08|2008-06-03|2008-06-04|Estimate|||||||2010-12-08|2010-12-10|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|MAD||Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386|A Phase I, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1386 in Healthy Caucasian Young and Elderly Subjects After Oral Multiple Doses.|Completed||Phase 1|69|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:04:50.483199|2018-06-01 02:04:50.483199
NCT00690066|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2014-12-02|2008-06-02|2008-06-04|Estimate|||||||2014-12-02|2014-12-04|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for Recently Diagnosed Type 1 Diabetes Mellitus|Completed||Phase 2|63|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-06-01 02:04:50.599293|2018-06-01 02:04:50.599293
NCT00690053|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2009-06-29|2008-06-03|2008-06-04|Estimate|||||||2009-06-29|2009-06-30|Estimate|August 2008||2008-08-31|February 2009|2009-02-28||||February 2009|Actual|2009-02-28||Interventional|HX-4||Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET)|Non-Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PAT): A Phase I Study|Completed||Phase 1|12|Anticipated|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-06-01 02:04:50.759747|2018-06-01 02:04:50.759747
NCT00690040|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-31|2013-03-19||2016-09-01|2008-06-03|2008-06-04|Estimate|2016-09-01|2016-10-24|Estimate||||2016-09-01|2016-10-24|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Single Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable Cervix|Single Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable Cervix|Completed||N/A|293|Actual|HaEmek Medical Center, Israel|Blinding was not performed among patients and providers. However, other than the catheter type, management was standardized. Accordingly,such unblinding is not expected to affect the objectively measured outcomeS.|2|||f||||f||||||||||2018-06-01 02:04:50.895033|2018-06-01 02:04:50.895033
NCT00690027|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|April 1988||1988-04-30|June 2008|2008-06-30|December 2005|Actual|2005-12-31|August 1996|Actual|1996-08-31||Interventional|||San Diego Bleeding Esophageal Varices Study|San Diego Bleeding Esophageal Varices Study|Completed||N/A|211|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 02:04:51.273628|2018-06-01 02:04:51.273628
NCT00689988|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|July 2005||2005-07-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|October 2007|Actual|2007-10-31||Interventional|||Augmentative and Alternative Communication (AAC) and Lexical Gain in Children With Down Syndrome|Augmentative and Alternative Communication and Lexical Gain in Children With Down Syndrome: Pilot Study|Completed||N/A|5|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 02:04:51.704458|2018-06-01 02:04:51.704458
NCT00689975|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2013-08-23|2008-06-03|2008-06-04|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2006||2006-02-28|December 2009|2009-12-31||||October 2008|Actual|2008-10-31||Interventional|||Diet and Exercise or Normal Care in Overweight or Obese Women Who Have Undergone Treatment for Stage I, Stage II, or Stage III Breast Cancer|The Effects of a Combined Diet and Exercise Intervention on Biomarkers Associated With Disease Recurrence After Breast Cancer Treatment: The Sheffield DEBRA Trial|Completed||N/A|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:04:51.79848|2018-06-01 02:04:51.79848
NCT00689962|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-31|||2017-01-13|2008-06-03|2008-06-04|Estimate|||||||2017-01-13|2017-01-18|Estimate|July 2008||2008-07-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Lisfranc||A Comparison of Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|A Randomized, Prospective Comparison of Stainless Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries|Completed||Phase 4|50|Actual|Rothman Institute Orthopaedics||2|||f||||t||||||||||2018-06-01 02:04:51.910162|2018-06-01 02:04:51.910162
NCT00689949|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2012-12-21|2008-05-30|2008-06-04|Estimate|||||||2012-12-21|2012-12-24|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|October 2008|Actual|2008-10-31||Interventional|||Validation of Urinary Biomarkers of Folate Status|Determination of the Suitability of Urinary Total P-aminobenzoylglutamate (p-ABG)and Formiminoglutamate (FIGLU) as a Markers for Folate Status|Completed||N/A|53|Actual|Ludwig-Maximilians - University of Munich||1|||f||||f||||||||||2018-06-01 02:04:51.987627|2018-06-01 02:04:51.987627
NCT00689936|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2017-07-13||2018-04-24|2008-06-03|2008-06-04|Estimate|2017-07-13|2017-08-11|Actual||||2018-04-24|2018-04-26|Actual|August 21, 2008|Actual|2008-08-21|April 2018|2018-04-30|July 14, 2016|Actual|2016-07-14|July 14, 2016|Actual|2016-07-14||Interventional|FIRST|Intent to Treat (ITT) population includes all participants who were randomized, independent of whether they received study treatment or not|Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma|A Phase III, Randomized, Open-label, 3-arm Study to Determine the Efficacy and Safety of Lenalidomide(REVLIMID) Plus Low-dose Dexamethasone When Given Until Progressive Disease or for 18 Four-week Cycles Versus the Combination of Melphalan, Prednisone, and Thalidomide Given for 12 Six-week Cycles in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates for Stem Cell Transplantation.|Completed||Phase 3|1623|Actual|Celgene||3|||f||||t||||||||||2018-06-01 02:04:52.387485|2018-06-01 02:04:52.387485
NCT00689923|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-01|||2008-06-03|2008-06-03|2008-06-04|Estimate|||||||2008-06-03|2008-06-04|Estimate|November 2007||2007-11-30|May 2008|2008-05-31||||October 2008|Anticipated|2008-10-31||Observational|||Vertebroplasty Using Real-Time, Fluoroscopy-Controlled, Catheter-Assisted, Low-Viscosity Cement Injection|Vertebroplasty Using Real-Time, Fluoroscopy-Controlled, Catheter-Assisted, Low-Viscosity Cement Injection|Unknown status|Active, not recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 02:05:00.765317|2018-06-01 02:05:00.765317
NCT00689910|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2012-03-28|2008-06-03|2008-06-04|Estimate|||||||2012-03-28|2012-03-29|Estimate|February 2008||2008-02-29|March 2012|2012-03-31||||||||Observational|||Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum|Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum|Withdrawn|||0|Actual|University of California, San Francisco|||||f||||||||||Samples Without DNA|"~     Plasma Cervicovaginal lavage fluid Endocervical canal fluid~   "|||2018-06-01 02:05:00.840281|2018-06-01 02:05:00.840281
NCT00689897|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2011-06-22|2008-05-30|2008-06-04|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|July 2011|Anticipated|2011-07-31|September 2010|Actual|2010-09-30||Interventional|||Psychological Outcomes From a Study of Acupuncture Treatment on Experimentally Primary Dysmenorrhea|Psychological Outcomes From a Study of Acupuncture Treatment on Experimentally Primary Dysmenorrhea|Unknown status|Recruiting|Phase 3|60|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-06-01 02:05:00.965065|2018-06-01 02:05:00.965065
NCT00689884|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2012-01-16||2018-03-22|2008-06-03|2008-06-04|Estimate|2012-07-31|2012-08-31|Estimate||||2018-03-22|2018-04-20|Actual|January 2007||2007-01-31|March 2018|2018-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies|A Prospective Feasibility and Cost Analysis of Peripheral Blood Stem Cell Mobilization Using Pegfilgrastim in Patients With Hematologic Malignancies|Terminated||N/A|7|Actual|Dartmouth-Hitchcock Medical Center|Outcome was not reported. The study was terminated for lack of enrollment. Data collection was terminated. No data analysis was performed.|1||Lack of enrollment.|f||||t||||||||||2018-06-01 02:05:01.166987|2018-06-01 02:05:01.166987
NCT00689871|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2011-12-19||2014-10-06|2008-06-02|2008-06-04|Estimate|2011-12-19|2012-01-23|Estimate||||2014-10-06|2014-10-13|Estimate|January 1999||1999-01-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Effectiveness of Natrelle(TM) Cohesive Round Silicone-Filled Breast Implants||Completed||N/A|715|Actual|Allergan|The Revision-reconstruction arm only had 15 patients enrolled, which makes the data for that arm difficult to interpret.|4|||f||||||||||||||2018-06-01 02:05:01.401548|2018-06-01 02:05:01.401548
NCT00689858|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2009-01-12|2008-06-03|2008-06-04|Estimate|||||||2009-01-12|2009-01-13|Estimate|May 2007||2007-05-31|June 2008|2008-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Assess the Effect of Pharmacokinetics/Pharmacodynamics (PK/PD) Interaction After co-Administration of Cilostazol With Ginkgo Biloba or Placebo|Clinical Trial to Assessment the PK/PD Characteristics and Safety After co-Administration of Cilostazol With Ginkgo Biloba or Placebo in Healthy Subject.|Completed||Phase 1|40|Actual|SK Chemicals Co.,Ltd.||2|||f||||||||||||||2018-06-01 02:05:02.255549|2018-06-01 02:05:02.255549
NCT00689845|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-03|||2009-07-07|2008-06-03|2008-06-04|Estimate|||||||2009-07-07|2009-07-08|Estimate|June 2007||2007-06-30|July 2009|2009-07-31||||||||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma|A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma (IELSG 26)|Unknown status|Recruiting|N/A|120|Anticipated|National Cancer Institute (NCI)||5|||f||||||||||||||2018-06-01 02:05:02.38147|2018-06-01 02:05:02.38147
NCT00689832|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2014-08-28|2008-06-03|2008-06-04|Estimate|||||||2014-08-28|2014-09-01|Estimate|February 2004||2004-02-29|August 2014|2014-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Protopic Ointment in Children Atopic Eczema|Comparative, Multicentre, Randomised, Double-blind Study to Assess the Efficacy of Tacrolimus 0.03% Ointment Versus Fluticasone 0.005% Ointment in Children Aged 2 Years or Over Suffering From Moderate to Severe Atopic Dermatitis.|Completed||Phase 4|487|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:05:02.608615|2018-06-01 02:05:02.608615
NCT00689819|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|2013-06-14||2013-11-07|2008-06-03|2008-06-04|Estimate|2013-08-30|2013-11-05|Estimate||||2013-11-07|2013-12-03|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients|Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients in an Urban Emergency Department: Is a Program Focused on Early Detection and Blood Pressure Control Clinically and Cost Effective?|Completed||N/A|123|Actual|Wayne State University|Despite our best efforts, study retention was hindered by a higher than expected drop-out rate (26.0% overall; 27.7% control and 24.1% intervention).|2|||f||||t||||||||||2018-06-01 02:05:02.795055|2018-06-01 02:05:02.795055
NCT00689806|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2013-06-20|2008-06-03|2008-06-04|Estimate|||||||2013-06-20|2013-06-21|Estimate||||June 2013|2013-06-30||||||||Interventional|||Evaluation of Lovastatin in Severe Persistent Asthma|Evaluation of Lovastatin in Severe Persistent Asthma|Withdrawn||Phase 1/Phase 2|0|Actual|University of Chicago||2||Study never opened|f||||t||||||||||2018-06-01 02:05:03.175501|2018-06-01 02:05:03.175501
NCT00689793|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2012-05-18||2013-01-15|2008-06-02|2008-06-04|Estimate|2013-01-15|2013-02-15|Estimate||||2013-01-15|2013-02-15|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|ferdon||Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors|Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors : a Randomized Controlled Trial|Completed||Phase 4|154|Actual|University of Lausanne||2|||f||||t||||||||||2018-06-01 02:05:03.336078|2018-06-01 02:05:03.336078
NCT00689780|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2010-12-08|2008-06-03|2008-06-04|Estimate|||||||2010-12-08|2010-12-10|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940|A Phase I, Multi-Centre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study, After Administration of Oral Multiple Ascending Doses in Adult Subjects With Chronic Low Back Pain|Completed||Phase 1|60|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:04.01759|2018-06-01 02:05:04.01759
NCT00689767|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2013-04-16|2008-06-03|2008-06-04|Estimate|||||||2013-04-16|2013-04-17|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|June 2009|Actual|2009-06-30||Interventional|CONFIRM 1||COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)|COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms|Terminated||N/A|103|Actual|Atrium Medical Corporation||2||"Terminated ahead of schedule after completion of the 3-year follow-up time point due to Sponsor~   decision."|f||||t||||||||||2018-06-01 02:05:04.110268|2018-06-01 02:05:04.110268
NCT00689754|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2011-11-16|2008-06-03|2008-06-04|Estimate|||||||2011-11-16|2011-11-18|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|NG||Efficacy and Safety Study on Nasogastric (NG) Tube in Patients With Upper Gastrointestinal Bleed|The Role of Routine Placement of Nasogastric Tube in Patients With Suspected Upper Gastrointestinal Hemorrhage|Completed||N/A|282|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:05:04.238484|2018-06-01 02:05:04.238484
NCT00689741|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2016-09-09|2008-05-30|2008-06-04|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2001||2001-01-31|September 2016|2016-09-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women|A Double-blind, Placebo-controlled, Randomised Study of the Efficacy of an HPV-16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil.|Completed||Phase 2|1113|Actual|GlaxoSmithKline||2|||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:05:04.326366|2018-06-01 02:05:04.326366
NCT00689728|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02||2010-12-09|2010-12-09|2008-06-02|2008-06-04|Estimate||||2010-12-09|2010-12-15|Estimate|2010-12-09|2010-12-15|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy|A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor Therapy|Completed||Phase 2|100|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:05:04.503034|2018-06-01 02:05:04.503034
NCT00689715|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-02|||2016-07-24|2008-06-03|2008-06-04|Estimate|||||||2016-07-24|2016-07-26|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|EUS-EP||Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas|Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas|Active, not recruiting||Phase 2/Phase 3|50|Anticipated|Asan Medical Center||1|||f||||t||||||||||2018-06-01 02:05:04.742152|2018-06-01 02:05:04.742152
NCT00689702|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2012-03-23|2008-05-30|2008-06-04|Estimate|||||||2012-03-23|2012-03-26|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|May 2013|Anticipated|2013-05-31|April 2009|Actual|2009-04-30||Interventional|XERT||Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer|Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study|Unknown status|Active, not recruiting|Phase 2|43|Actual|Institute of Oncology Ljubljana|||||f||||t||||||||||2018-06-01 02:05:04.894492|2018-06-01 02:05:04.894492
NCT00689689|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2012-02-15|2008-05-30|2008-06-04|Estimate|||||||2012-02-15|2012-02-16|Estimate|July 1998||1998-07-31|May 2008|2008-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Randomized Clinical Study Comparing a Fully-Coated Cementless Stem Versus a Cemented Stem for Total Hip Replacements|A Randomized Clinical Study Comparing a Fully-Coated Cementless Stem Versus a Cemented Stem for Total Hip Replacements|Completed||Phase 4|48|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-06-01 02:05:05.02619|2018-06-01 02:05:05.02619
NCT00689676|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2009-02-13|2008-06-02|2008-06-03|Estimate|||||||2009-02-13|2009-02-16|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Expressive Language and Cognitive Early Development in Very Low Birth-Weight Preterm Toddlers|Expressive Language and Cognitive Early Development in Very Low Birth-Weight Preterm Toddlers|Completed|||32|Actual|University of Sao Paulo|||2||f||||t||||||||||2018-06-01 02:05:05.180134|2018-06-01 02:05:05.180134
NCT00689663|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2008-05-29|2008-05-29|2008-06-03|Estimate|||||||2008-05-29|2008-06-03|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Laparoscopic Cholecystectomy - Fundus First and Harmonic Ace Compared With Conventional Technique|Randomized Multicentre Trial: Comparison of Harmonic Ace and Eletrocautery; Comparison of Fundus First and Conventional Dissection|Completed||N/A|233|Actual|Sundsvall Hospital||3|||f||||f||||||||||2018-06-01 02:05:05.252531|2018-06-01 02:05:05.252531
NCT00689650|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-05-30|2008-05-30|2008-06-03|Estimate|||||||2008-05-30|2008-06-03|Estimate|November 2007||2007-11-30|May 2008|2008-05-31||||||||Interventional|||Fractional Nonablative 1540 nm Laser Resurfacing for Burn Scars- A Randomised Controlled Trial|Fractional Nonablative 1540 nm Laser Resurfacing for Burn Scars- A Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|||Bispebjerg Hospital||2|||f||||||||||||||2018-06-01 02:05:05.441922|2018-06-01 02:05:05.441922
NCT00689637|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2009-06-30|2008-06-02|2008-06-03|Estimate|||||||2009-06-30|2009-07-02|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|February 2009|Actual|2009-02-28|||||Interventional|DDI||Drug Interaction Study Between AZD3480 and Warfarin|A Single-Centre, Double Blind, Randomized, Two-Way Cross-Over Study of Repeated Doses of AZD3480 and Single Dose of Warfarin to Evaluate the Pharmacokinetic Interaction of AZD3480 and Warfarin and the Effect of AZD3480 Pharmacodynamic in Healthy Male Subjects (Phase I|Completed||Phase 1|26|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:05.554606|2018-06-01 02:05:05.554606
NCT00689624|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2015-09-25|2008-06-02|2008-06-03|Estimate|||||||2015-09-25|2015-09-28|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer|A Triplet Combination With Irinotecan Plus Oxaliplatin,Continuous Infusion 5-Fluorouracil And Leucovorin Plus Cetuximab As First Line Treatment In Metastatic Colorectal Cancer. A Pilot Phase II Trial|Completed||Phase 2|30|Actual|University Hospital of Crete||1|||f||||f||||||||||2018-06-01 02:05:05.641865|2018-06-01 02:05:05.641865
NCT00689611|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2013-12-11||2015-04-10|2008-05-30|2008-06-03|Estimate|2015-04-10|2015-04-23|Estimate||||2015-04-10|2015-04-23|Estimate|December 2005||2005-12-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ZESCA|All enrolled participants were included in the baseline analyses.|Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial|Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome: The ZESCA Trial|Completed||Phase 3|392|Actual|McGill University|Relatively high number who withdrew or were lost to follow-up (22.2%), but within expectations for smoking cessation trials; Relatively small numbers of serious adverse events occurred, limiting power to examine secondary safety end points.|2|||f||||t||||||||||2018-06-01 02:05:05.794328|2018-06-01 02:05:05.794328
NCT00689598|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-06-04|2008-06-02|2008-06-03|Estimate|||||||2008-06-04|2008-06-05|Estimate|March 2008||2008-03-31|June 2008|2008-06-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Spironolactone for Paroxysmal Atrial Fibrillation|Use of Spironolactone to Treat Patients With Paroxysmal Atrial Fibrillation- A Multi-Center, Prospective, Randomized, Placebo-Controlled, Double Blind Study|Unknown status|Recruiting|N/A|30|Anticipated|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-06-01 02:05:06.434033|2018-06-01 02:05:06.434033
NCT00689585|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2011-05-11|2008-05-29|2008-06-03|Estimate|||||||2011-05-11|2011-05-13|Estimate|September 2008||2008-09-30|May 2011|2011-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)|A Single Centre. Parallel-Group, Double-Blinded, Randomized, Placebo-Controlled Pilot Clinical Trial on Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)|Terminated||Phase 2|4|Actual|McGill University Health Center||2||Recruitment difficult and enrolment low: decision was made to stop the study.|f||||f||||||||||2018-06-01 02:05:06.642486|2018-06-01 02:05:06.642486
NCT00689572|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2017-03-31|2008-05-29|2008-06-03|Estimate|||||||2017-03-31|2017-04-04|Actual|July 2008||2008-07-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||New Medication Treatment for Stimulant Dependence|New Medication Treatment for Stimulant Dependence|Completed||Phase 2|117|Actual|University of Virginia||2|||f||||t|t|f||||||No||2018-06-01 02:05:06.752414|2018-06-01 02:05:06.752414
NCT00689559|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2009-06-30|2008-06-02|2008-06-03|Estimate|||||||2009-06-30|2009-07-02|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|||||Interventional|||Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects|A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)|Completed||Phase 1|52|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:06.843711|2018-06-01 02:05:06.843711
NCT00689546|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-05-30|2008-05-30|2008-06-03|Estimate|||||||2008-05-30|2008-06-03|Estimate|February 2007||2007-02-28|January 2007|2007-01-31||||||||Observational|||Acute Viral Hepatitis and Diabetes Mellitus|Natural Course of Acute Icteric Viral Hepatitis in Type II Diabetes Mellitus Patients and Non-Diabetic Patients:A Pilot Cohort Study|Unknown status|Recruiting||250|Anticipated|All India Institute of Medical Sciences, New Delhi|||4||f||||f||||||||||2018-06-01 02:05:06.922102|2018-06-01 02:05:06.922102
NCT00689533|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-05-29|2008-05-29|2008-06-03|Estimate|||||||2008-05-29|2008-06-03|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|January 2016|Anticipated|2016-01-31|January 2012|Anticipated|2012-01-31||Observational|||VEPTR Implantation to Treat Children With Early Onset Scoliosis Without Rib Abnormalities|VEPTR Implantation to Treat Children With Early Onset Scoliosis Without Rib Abnormalities: a Prospective Multicenter Study|Unknown status|Recruiting||250|Anticipated|Shriners Hospitals for Children|||||f||||f||||||||||2018-06-01 02:05:07.035553|2018-06-01 02:05:07.035553
NCT00689520|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-06-02|2008-06-02|2008-06-03|Estimate|||||||2008-06-02|2008-06-03|Estimate|January 2002||2002-01-31|May 2008|2008-05-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis|Phase IV, Randomized, Open-Label Trial Comparing Long-Term Subcutaneous Low-Molecular Weight Heparin With Oral Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis|Completed||Phase 4|241|Actual|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-06-01 02:05:07.128345|2018-06-01 02:05:07.128345
NCT00689507|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2015-06-25|2008-05-29|2008-06-03|Estimate|||||||2015-06-25|2015-06-29|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|January 2013|Actual|2013-01-31||Interventional|||A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib|A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|48|Actual|Applied Molecular Evolution||3|||f||||f||||||||||2018-06-01 02:05:07.212599|2018-06-01 02:05:07.212599
NCT00689494|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-06-02|2008-06-02|2008-06-03|Estimate|||||||2008-06-02|2008-06-03|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|May 2010|Anticipated|2010-05-31|December 2008|Anticipated|2008-12-31||Interventional|NANOPAZ||Cervical Device Contraception-2 (Nanopaz)|Cervical Device Contraception|Unknown status|Not yet recruiting|Phase 1/Phase 2|10|Anticipated|Bnai Zion Medical Center|||||f||||t||||||||||2018-06-01 02:05:07.33075|2018-06-01 02:05:07.33075
NCT00684619|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2018-03-02|2008-05-23|2008-05-26|Estimate|||||||2018-03-02|2018-03-06|Actual|June 2003||2003-06-30|March 2018|2018-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)|Phase II-Study With Nelarabine in Patients With Refractory Oder Relapsed T- ALL or T-lymphoblastic Lymphoma (Amend.7)|Completed||Phase 2|120|Actual|Goethe University||1|||f||||f||||||||||2018-06-01 02:06:46.431099|2018-06-01 02:06:46.431099
NCT00689481|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2010-11-05|2010-09-07|2016-08-25|2008-06-02|2008-06-03|Estimate|2010-11-05|2010-12-08|Estimate|2010-09-07|2010-09-09|Estimate|2016-08-25|2016-10-07|Estimate|March 2008||2008-03-31|August 2016|2016-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies|A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267 , Versus Vehicle Foam in Subjects With Plaque-type Psoriasis|Completed||Phase 3|323|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:05:07.535811|2018-06-01 02:05:07.535811
NCT00689468|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-05-30|2008-05-30|2008-06-03|Estimate|||||||2008-05-30|2008-06-03|Estimate|July 1999||1999-07-31|May 2008|2008-05-31|October 2002|Actual|2002-10-31|September 2002|Actual|2002-09-30||Interventional|||Echinacea Purpurea and Osteopathy in Children With Recurrent Otitis Media|Echinacea Purpurea and Cranial Osteopathic Manipulative Treatment in Children With Recurrent Otitis Media: a Randomized Controlled Trial.|Completed||N/A|90|Actual|University of Arizona||4|||f||||t||||||||||2018-06-01 02:05:08.326703|2018-06-01 02:05:08.326703
NCT00689455|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2010-12-02|2008-06-02|2008-06-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|October 2007||2007-10-31|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|ORSA||Regional Observatory on Metabolic Syndrome- LAZIO|Regional Observatory on Metabolic Syndrome in Italy- LAZIO|Completed|||1574|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:05:08.411069|2018-06-01 02:05:08.411069
NCT00689442|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-06-02|2008-06-02|2008-06-03|Estimate|||||||2008-06-02|2008-06-03|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|March 2006|Actual|2006-03-31|November 2004|Actual|2004-11-30||Interventional|||Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels|A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Atorvastatin 20 mg in Patients With Low HDL Levels|Completed||Phase 2|105|Actual|Akros Pharma Inc.||2|||f||||f||||||||||2018-06-01 02:05:08.549414|2018-06-01 02:05:08.549414
NCT00689429|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2017-06-16|2008-05-30|2008-06-03|Estimate|||||||2017-06-16|2017-06-20|Actual|May 2008||2008-05-31|June 2017|2017-06-30|April 9, 2010|Actual|2010-04-09|April 9, 2010|Actual|2010-04-09||Observational|||Operatively Treated Open Pilon Fractures|Natural History and Functional Outcome of Operatively Treated Open Pilon Fractures|Completed|||37|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-06-01 02:05:08.642088|2018-06-01 02:05:08.642088
NCT00689416|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-06-29|2008-05-30|2008-06-03|Estimate|||||||2009-06-29|2009-06-30|Estimate|December 2007||2007-12-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|||||Interventional|||Effects of Crestor on Inflammation of Atherosclerotic Plaques|Exploratory Study of New Imaging Biomarkers for Measurement of Carotid Plaque Inflammation|Completed||Early Phase 1|74|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:08.727186|2018-06-01 02:05:08.727186
NCT00689403|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2010-12-01|2008-06-02|2008-06-03|Estimate|||||||2010-12-01|2010-12-03|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|2007-005765-38||Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305|A Phase I, Two-part, Randomised, Open, Single-centre, Crossover Study to Evaluate Different Extended-release Formulations of AZD1305 When Given as Single Oral Doses to Healthy Male Volunteers|Completed||Phase 1|50|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:08.838732|2018-06-01 02:05:08.838732
NCT00689390|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2015-09-01||2017-03-10|2008-05-29|2008-06-03|Estimate|2015-09-01|2015-10-06|Estimate||||2017-03-10|2017-04-10|Actual|February 2007||2007-02-28|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||All Enrolled Participants|Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)|Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C|Terminated||Phase 2/Phase 3|1954|Actual|Merck Sharp & Dohme Corp.||2||The study was terminated due to satisfaction of post-marketing commitments|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:05:08.962195|2018-06-01 02:05:08.962195
NCT00689377|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2012-03-19|2008-06-02|2008-06-03|Estimate|||||||2012-03-19|2012-03-20|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|PANDORA||Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention|Prevalence of Peripheral Arterial Disease in Subjects With a Moderate CVD Risk, With No Overt Vascular Diseases nOR diAbetes Mellitus|Completed|||9000|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:05:09.888754|2018-06-01 02:05:09.888754
NCT00689364|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2011-07-20|2008-06-02|2008-06-03|Estimate|||||||2011-07-20|2011-07-22|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|March 2014|Anticipated|2014-03-31|March 2012|Anticipated|2012-03-31||Observational|||Comprehensive Therapy to Relieving the Risk of Recurrence and Metastasis for Colorectal Cancer|Retrospective-Prospective Cohort Study Effectiveness of Comprehensive Therapy of TCM to Relieving the Risk of Recurrence and Metastasis for Stage II & III Colorectal Cancer Based on Conventional Western Medicine Therapy|Unknown status|Active, not recruiting||480|Anticipated|Ministry of Science and Technology of the People´s Republic of China|||2||f||||t||||||||||2018-06-01 02:05:10.458643|2018-06-01 02:05:10.458643
NCT00689351|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2010-12-10||2011-06-24|2008-06-02|2008-06-03|Estimate|2010-12-10|2011-01-11|Estimate||||2011-06-24|2011-06-28|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea|Phase 2, Randomized, Active-Controlled, Double-Blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine Pediatric Vaccinations In Korea|Completed||Phase 2|180|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:05:10.577942|2018-06-01 02:05:10.577942
NCT00689338|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2011-04-21||2011-05-25|2008-05-29|2008-06-03|Estimate|2011-04-21|2011-05-17|Estimate||||2011-05-25|2011-05-30|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|ICE||Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study|Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations|Completed||Phase 3|216|Actual|Pfizer|In a change to the protocol, time to first negative blood/tissue culture will only concern time to first negative blood culture. Lack of regular tissue sampling meant that analysis of time to first tissue culture could not be meaningfully performed.|1|||f||||f||||||||||2018-06-01 02:05:13.484398|2018-06-01 02:05:13.484398
NCT00684086|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-05-23|2008-05-23|2008-05-26|Estimate|||||||2008-05-23|2008-05-26|Estimate|April 2007||2007-04-30|May 2008|2008-05-31||||||||Interventional|||English Diabetes Self-Management Program|English Diabetes Self-Management Program|Completed||N/A|350||Stanford University|||||f||||||||||||||2018-06-01 02:06:59.423165|2018-06-01 02:06:59.423165
NCT00689325|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2010-10-26|2008-06-02|2008-06-03|Estimate|||||||2010-10-26|2010-10-27|Estimate|April 2008||2008-04-30|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|Xperience||Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics|A Non-interventional Study Evaluating Well-being/Quality of Life in Schizophrenic Patients Treated With Seroquel XR® (Quetiapine) and Other Atypical Antipsychotics.A 9-month, Observational, Multicentric Prospective Study.|Completed|||158|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:05:14.117826|2018-06-01 02:05:14.117826
NCT00689312|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2018-04-16|2008-06-02|2008-06-03|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2008||2008-05-31|April 2018|2018-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Palatability of Oral Rehydration Solutions|Palatability of Oral Rehydration Solutions|Completed||Phase 3|66|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-06-01 02:05:14.223852|2018-06-01 02:05:14.223852
NCT00689299|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2011-05-24||2014-04-14|2008-05-30|2008-06-03|Estimate|2014-02-27|2014-04-07|Estimate||||2014-04-14|2014-05-01|Estimate|October 2008||2008-10-31|April 2014|2014-04-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Phase 2 Study in Adults Sensitized to Cat|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (Felis Domesticus)|Completed||Phase 2|167|Actual|Antigen Laboratories, Inc.|Adverse events: 41%, 58%, and 45% > 5% in Group A, B, and C, respectively.|3|||f||||f||||||||||2018-06-01 02:05:14.465433|2018-06-01 02:05:14.465433
NCT00689286|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2015-06-01|2008-05-29|2008-06-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||BION Treatment of Knee Osteoarthritis|BION Implantable Microstimulator System|Withdrawn||Phase 1|0|Actual|University of Southern California||3|||f||||f||||||||||2018-06-01 02:05:14.821171|2018-06-01 02:05:14.821171
NCT00689273|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30||2009-04-06|2012-09-25|2008-05-30|2008-06-03|Estimate||||2009-10-01|2009-10-05|Estimate|2012-09-25|2012-10-01|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee|A 2-Week, Randomized, Double Blind, Placebo Controlled, Parallel-Group, Phase 2, Multicenter Study Of Pf-04136309 In Subjects With Osteoarthritic Pain Of The Knee|Completed||Phase 2|157|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:05:14.907259|2018-06-01 02:05:14.907259
NCT00689260|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2010-06-17||2015-04-27|2008-06-02|2008-06-03|Estimate|2010-06-17|2010-07-20|Estimate||||2015-04-27|2015-05-15|Estimate|March 2008||2008-03-31|April 2015|2015-04-30|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||Easypod United States User Trial|A Randomized, Multicenter, 3 Month Phase IV Study to Evaluate the Effect on Subject Adherence With Injection Schedule by Using the Easypod™ rhGH Delivery Device|Completed||Phase 4|42|Actual|EMD Serono|Enrollment ended early due to slow enrollment. Only 44 enrolled of the 100 subjects needed. Of the 44 enrolled, only 35 subjects had valid device data for analysis.|2|||f||||f||||||||||2018-06-01 02:05:15.01845|2018-06-01 02:05:15.01845
NCT00689247|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2010-12-02|2008-06-02|2008-06-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305|A Phase I, Open, Randomised, Single-Centre, Crossover Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) After Oral and Intravenous Administration of 14C-labelled and Non-labelled AZD1305 to Healthy Male Volunteers|Completed||Phase 1|10|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:15.493865|2018-06-01 02:05:15.493865
NCT00689234|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-08-05|2008-06-02|2008-06-03|Estimate|||||||2013-08-05|2013-08-07|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Diaphragm Plication in Adults With Phrenic Nerve Paralysis|Diaphragm Plication in Adults With Phrenic Nerve Paralysis: a Randomised Controlled Study|Unknown status|Recruiting|N/A|12|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 02:05:15.574156|2018-06-01 02:05:15.574156
NCT00689221|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2014-08-28||2014-10-28|2008-06-02|2008-06-03|Estimate|2014-10-28|2014-11-04|Estimate||||2014-10-28|2014-11-04|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|August 2013|Actual|2013-08-31|November 2012|Actual|2012-11-30||Interventional|CENTRIC|Intent-to-treat (ITT) population included all the participants who were randomized to study treatment.|Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status|Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)|Completed||Phase 3|545|Actual|EMD Serono||2|||f||||t||||||||||2018-06-01 02:05:15.747199|2018-06-01 02:05:15.747199
NCT00689208|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-03-12|2008-05-30|2008-06-03|Estimate|||||||2009-03-12|2009-03-13|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity|Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity - a Concept Study in Mani|Completed||Early Phase 1|12|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:05:16.97649|2018-06-01 02:05:16.97649
NCT00689195|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2011-06-22|2008-05-29|2008-06-03|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|OSCAT||Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma|"Evaluation of Curcumin Formulation, and Ashwagandha Root Powder Extract in the Management of Advanced High Grade Osteosarcoma"|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:05:17.056613|2018-06-01 02:05:17.056613
NCT00689182|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2017-01-30|2008-05-30|2008-06-03|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2007||2007-05-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Efficacy of Iron Reduction by Phlebotomy|A Phase II Trial of the Safety and Efficacy of Iron Reduction by Phlebotomy in Recipients of Hematopoietic Stem Cell Transplants|Completed||Phase 2|23|Actual|Nova Scotia Health Authority||1|||f||||f||||||||Undecided||2018-06-01 02:05:17.144756|2018-06-01 02:05:17.144756
NCT00689169|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2018-03-06|2008-06-02|2008-06-03|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2007||2007-08-31|March 2018|2018-03-31|January 2014|Actual|2014-01-31|January 2011|Actual|2011-01-31||Interventional|ZBEAM2||Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma|Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transplantation (ASCT)|Completed||Phase 2|75|Actual|Lymphoma Study Association||1|||f||||t||||||||No||2018-06-01 02:05:17.233791|2018-06-01 02:05:17.233791
NCT00689156|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2018-04-03|2008-06-02|2008-06-03|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2008||2008-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|READ||Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer|Randomized Trial of Epirubicin and Cyclophosphamide Followed by Docetaxel Against Docetaxel and Cyclophosphamide in Patients With TOP2A Normal Early Breast Cancer|Completed||Phase 3|2015|Actual|Danish Breast Cancer Cooperative Group||2|||f||||f||||||||||2018-06-01 02:05:17.323384|2018-06-01 02:05:17.323384
NCT00689143|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-10-28|2008-06-02|2008-06-03|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 2008||2008-08-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva|A Phase I, Open-Label, Single Center, Safety/Tolerability and Pharmacokinetic Study of Leukine® Administrated in the Gingiva as Three Single Doses on Separate Days|Completed||Phase 1|10|Actual|Innoventus Project AB|||||f||||f||||||||||2018-06-01 02:05:17.42516|2018-06-01 02:05:17.42516
NCT00689130|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2012-03-06|2008-06-02|2008-06-03|Estimate|||||||2012-03-06|2012-03-07|Estimate|May 2008||2008-05-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|CVI||ADVANCE: Assessment for Defining Variability in Anesthesia Through Novel Clinical EEG|"Advance: Assessment for Defining Variability in Anesthesia"|Completed|||120|Actual|Medtronic - MITG|||||f||||f||||||||||2018-06-01 02:05:17.549991|2018-06-01 02:05:17.549991
NCT00689117|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2010-11-02|2010-09-07|2017-05-25|2008-06-02|2008-06-03|Estimate|2010-11-02|2010-12-02|Estimate|2010-09-07|2010-09-09|Estimate|2017-05-25|2017-05-30|Actual|April 2008||2008-04-30|May 2017|2017-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel|A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of CT Gel in Subjects With Acne Vulgaris|Completed||Phase 3|1649|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 02:05:17.655953|2018-06-01 02:05:17.655953
NCT00689104|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2012-07-17|2010-03-23|2017-11-09|2008-06-02|2008-06-03|Estimate|2012-09-17|2012-10-17|Estimate|2010-03-23|2010-03-25|Estimate|2017-11-09|2017-12-11|Actual|April 28, 2008|Actual|2008-04-28|November 2017|2017-11-30|March 24, 2009|Actual|2009-03-24|March 24, 2009|Actual|2009-03-24||Interventional|SCORPIO||Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder|Completed||Phase 3|2336|Actual|Astellas Pharma Inc||4|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 02:05:18.651702|2018-06-01 02:05:18.651702
NCT00689091|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2013-12-12||2017-11-03|2008-05-29|2008-06-03|Estimate|2014-11-14|2014-11-17|Estimate||||2017-11-03|2017-12-07|Actual|May 2008||2008-05-31|November 2017|2017-11-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|MACS||Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study|A Prospective, Randomized, Controlled Trial Comparing Bispectral Index Monitoring to Electronic Alerts for Prevention of Awareness During Anesthesia in the General Population|Completed||N/A|22185|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 02:05:21.238556|2018-06-01 02:05:21.238556
NCT00689078|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-05-13|2008-05-30|2008-06-03|Estimate|||||||2009-05-13|2009-05-14|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model|A Single-Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model|Completed||Phase 4|36|Actual|ORA, Inc.||4|||f||||f||||||||||2018-06-01 02:05:21.531769|2018-06-01 02:05:21.531769
NCT00689065|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2013-10-30|2008-05-29|2008-06-03|Estimate|||||||2013-10-30|2013-11-01|Estimate|May 2008||2008-05-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety Study of CALAA-01 to Treat Solid Tumor Cancers|A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies|Terminated||Phase 1|24|Actual|Calando Pharmaceuticals||1|||f||||t||||||||||2018-06-01 02:05:21.640369|2018-06-01 02:05:21.640369
NCT00689052|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2009-10-23||2014-06-03|2008-06-02|2008-06-03|Estimate|2009-10-23|2009-11-25|Estimate||||2014-06-03|2014-06-09|Estimate|July 2008||2008-07-31|May 2014|2014-05-31||||November 2008|Actual|2008-11-30||Interventional||Treated Set, All patients randomized and received treatment|Pramipexole ER vs. Placebo in Fibromyalgia|A Randomized, Double-blind, Placebo-controlled, Dose Titration Efficacy and Safety Study of Pramipexole ER (0.75 to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients Diagnosed With Fibromyalgia, as Assessed by the American College of Rheumatology (ACR) Criteria Followed by a 24-week Open-label Extension Phase|Terminated||Phase 2|61|Actual|Boehringer Ingelheim|Early termination leading to no number of subjects analysed for any outcome measure|2|||f||||||||||||||2018-06-01 02:05:21.737973|2018-06-01 02:05:21.737973
NCT00689039|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2010-12-01|2008-06-02|2008-06-03|Estimate|||||||2010-12-01|2010-12-03|Estimate|April 2007||2007-04-30|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of an Extended Release (ER) Tablet, Single and Repeated Dosing|A Two-part, Single-centre, Open (Part A) Single Blind (Part B), Randomised, Placebo-controlled Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Doses With and Without Food and Multiple Ascending Oral Doses of AZD1305 Extended-release Tablet in Healthy & Elderly Subj|Completed||Phase 1|94|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:22.281828|2018-06-01 02:05:22.281828
NCT00689026|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2014-09-30||2014-10-17|2008-06-02|2008-06-03|Estimate|2014-10-17|2014-10-20|Estimate||||2014-10-17|2014-10-20|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy of Lubiprostone in Combination With Standard PEG Preparation|Efficacy of Lubiprostone Used With Polyethylene Glycol to Enhance Colonoscopy Preparation Quality in Diabetic Patients: A Randomized Single-Blind Controlled Trial|Terminated||N/A|60|Actual|Augusta University||2|||f||||f||||||||||2018-06-01 02:05:22.38719|2018-06-01 02:05:22.38719
NCT00689013|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-04-22|2008-05-29|2008-06-03|Estimate|||||||2009-04-22|2009-04-23|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting|The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting|Completed||N/A|205|Actual|University of Tennessee||2|||f||||f||||||||||2018-06-01 02:05:22.753215|2018-06-01 02:05:22.753215
NCT00528749|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2007-09-11|2007-09-11|2007-09-12|Estimate|||||||2007-09-11|2007-09-12|Estimate|February 2007||2007-02-28|August 2007|2007-08-31||||||||Interventional|||Non-Invasive Measurement of Respiratory Effort|Non-Invasive Measurement of Respiratory Effort|Unknown status|Recruiting|N/A|20|Anticipated|Walter Reed Army Medical Center|||||f||||f||||||||||2018-06-01 02:56:04.287564|2018-06-01 02:56:04.287564
NCT00689000|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2010-10-21|2008-06-02|2008-06-03|Estimate|||||||2010-10-21|2010-10-22|Estimate|May 2006||2006-05-31|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)|A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma|Completed||Phase 1/Phase 2|57|Actual|Chroma Therapeutics||1|||f||||t||||||||||2018-06-01 02:05:22.857957|2018-06-01 02:05:22.857957
NCT00688987|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-06-04|2008-05-30|2008-06-03|Estimate|||||||2008-06-04|2008-06-05|Estimate|August 2000||2000-08-31|June 2008|2008-06-30|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation|Cortisol, Central Obesity, and Insulin Resistance: Long Term Studies in Addison's Patients|Completed||N/A|24|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 02:05:23.028269|2018-06-01 02:05:23.028269
NCT00688974|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2016-08-17|2008-06-02|2008-06-03|Estimate|||||||2016-08-17|2016-08-18|Estimate|May 2004||2004-05-31|August 2016|2016-08-31|September 2012|Actual|2012-09-30|November 2006|Actual|2006-11-30||Observational|OBEDIAB||Longitudinal Cohort Study Comparing 2 Surgical Techniques in Patients With Class 3 Obesity and Type 2 Diabetes|Longitudinal Cohort Study Comparing 2 Surgical Techniques (Roux-en-Y Gastric Bypass and Adjustable Gastric Banding) in Patients With Class 3 Obesity and Type 2 Diabetes|Completed|||56|Actual|University Hospital, Lille|||3||f||||t||||||Samples Without DNA|"~     serum and plasma during meal test (0, 30, 60, 90, 120, 180 min)~   "|||2018-06-01 02:05:23.105558|2018-06-01 02:05:23.105558
NCT00688961|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-06-02|2008-06-02|2008-06-03|Estimate|||||||2008-06-02|2008-06-03|Estimate|June 2007||2007-06-30|May 2008|2008-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effects of Omacor and Aspirin on Platelet Function|A Pilot Study of the Effects of Omacor (Alone and With Aspirin) on Platelet Function in Healthy Subjects|Completed||Early Phase 1|10|Actual|Sanford Research||4|||f||||t||||||||||2018-06-01 02:05:23.188682|2018-06-01 02:05:23.188682
NCT00688948|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2011-06-23|2008-06-02|2008-06-03|Estimate|||||||2011-06-23|2011-06-27|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)|A Pilot Study Looking At The Use Of Alfuzosin In The Treatment Of Bladder Dysfunction In Patients With Multiple Sclerosis|Terminated||Phase 2/Phase 3|20|Anticipated|Nova Scotia Health Authority||||Lack of funding|f||||f||||||||||2018-06-01 02:05:23.281639|2018-06-01 02:05:23.281639
NCT00688935|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-11-09|2008-06-02|2008-06-03|Estimate|||||||2013-11-09|2013-11-13|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Young Blind Child Melatonin Treatment Study|Identification of Free-Running Rhythms in Blind Children|Unknown status|Active, not recruiting|N/A|25|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-06-01 02:05:23.346021|2018-06-01 02:05:23.346021
NCT00688922|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-11-28|2008-06-02|2008-06-03|Estimate|||||||2008-11-28|2008-12-02|Estimate|July 2008||2008-07-31|November 2008|2008-11-30|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Interventional|PRACTIC||Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study|Pravastatin for Acute Myocardial Infarction With Minimally to Mildly Increased Levels of Serum Cholesterol Study That Evaluates the Effects of Pravastatin for Acute Myocardial Infarction With LDL-Cholesterol Levels of 70-129 mg/dl|Unknown status|Recruiting|Phase 4|400|Anticipated|Osaka Acute Coronary Insufficiency Study Group|||||f||||t||||||||||2018-06-01 02:05:23.426831|2018-06-01 02:05:23.426831
NCT00688909|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2017-02-22|2008-06-02|2008-06-03|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2008||2008-03-31|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|REAL||Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer|Open-label, Single-arm, Multicenter Study to Evaluate the Rheumatological Tolerability of Letrozole as an Adjuvant Breast Cancer Treatment in Postmenopausal Women Who Are Intolerant and Discontinue Anastrozole Due to Grade 2-3 Arthralgia-myalgia|Completed||Phase 4|261|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:05:23.55522|2018-06-01 02:05:23.55522
NCT00688896|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-06-02|2008-06-02|2008-06-03|Estimate|||||||2008-06-02|2008-06-03|Estimate|June 2002||2002-06-30|May 2008|2008-05-31|March 2004|Actual|2004-03-31|April 2003|Actual|2003-04-30||Interventional|||Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia|A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia|Completed||Phase 2|155|Actual|Akros Pharma Inc.||3|||f||||f||||||||||2018-06-01 02:05:23.751713|2018-06-01 02:05:23.751713
NCT00688883|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-12-02|2008-06-02|2008-06-03|Estimate|||||||2013-12-02|2013-12-04|Estimate|February 2003||2003-02-28|December 2013|2013-12-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Fludara (Oral) Phase II Study for Indolent Lymphoma|A Multicenter, Open Study to Assess the Antitumor Effect and Safety of Oral Fludarabine Phosphate (Fludara (SH T 586): 40 mg/m2/Day) Administered in 3 - 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by a Observation Period of 23 Days) in Patients With Indolent Lymphoma|Completed||Phase 2|52|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:05:23.821914|2018-06-01 02:05:23.821914
NCT00688870|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2011-01-13||2011-10-31|2008-06-02|2008-06-03|Estimate|2011-04-18|2011-05-12|Estimate||||2011-10-31|2011-11-02|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine Pediatric Vaccinations In Taiwan|Completed||Phase 3|168|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Geometric Mean Concentration Outcome Measures were identified as secondary analysis in the study protocol, but are included to maintain consistency with other postings for this program.|2|||f||||f||||||||||2018-06-01 02:05:24.357335|2018-06-01 02:05:24.357335
NCT00688857|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-11-04|2008-05-29|2008-06-03|Estimate|||||||2010-11-04|2010-11-08|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations|A Randomized, Open-label, Multi-dose Crossover Study Assessing the Pharmacokinetic Profiles of Diazoxide Choline Coated Versus Uncoated Formulations in Healthy Volunteers|Completed||Phase 1|12|Anticipated|Essentialis, Inc.||2|||f||||f||||||||||2018-06-01 02:05:26.244243|2018-06-01 02:05:26.244243
NCT00528736|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2007-09-12|2007-09-10|2007-09-12|Estimate|||||||2007-09-12|2007-09-14|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Observational|||Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks||Completed|||82|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 02:56:04.375778|2018-06-01 02:56:04.375778
NCT00688844|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2013-08-05||2015-05-13|2008-06-02|2008-06-03|Estimate|2014-07-30|2014-08-20|Estimate||||2015-05-13|2015-06-08|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|BH4&PKU||Nutritional and Neurotransmitter Changes in PKU Subjects on BH4|Baseline Evaluation and Long-term Follow-up of Nutritional Status and Neurotransmitter Concentrations in Phenylketonuria Patients Initiating Treatment With Sapropterin Dihydrochloride (KuvanTM), a Tetrahydrobiopterin Analog.|Completed|||58|Actual|Emory University|||1||f||||f||||||Samples With DNA|"~     Blood plasma Blood platelets Whole blood Urine~   "|||2018-06-01 02:05:26.454304|2018-06-01 02:05:26.454304
NCT00688831|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2010-12-01|2008-06-02|2008-06-03|Estimate|||||||2010-12-01|2010-12-02|Estimate|January 2008||2008-01-31|December 2010|2010-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|2006-006253-27||Single Ascending Dose Study (SAD) iv Formulation|A Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Ascending Intravenous Doses of AZD1305 in Helahty Male Volunteers|Completed||Phase 1|36|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:26.717224|2018-06-01 02:05:26.717224
NCT00688818|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2014-08-20|2008-05-30|2008-06-03|Estimate|||||||2014-08-20|2014-08-21|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Quetiapine in Co-Morbid Depressive and Anxiety Disorders|Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Co-Morbid Depressive and Anxiety Disorders|Completed||N/A|108|Actual|Centre for Addiction and Mental Health||2|||f||||t||||||||||2018-06-01 02:05:26.832794|2018-06-01 02:05:26.832794
NCT00688805|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2018-05-23|2008-05-30|2008-06-03|Estimate|||||||2018-05-23|2018-05-24|Actual|December 12, 2007||2007-12-12|December 16, 2013|2013-12-16|December 16, 2013|Actual|2013-12-16|December 16, 2013|Actual|2013-12-16||Interventional|||Effects of Propranolol on Responses to Drug-Related Imagery Scripts|Effects of Propranolol on Responses to Drug-Related Imagery Scripts|Terminated||Phase 1|40|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 02:05:26.925319|2018-06-01 02:05:26.925319
NCT00688792|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-06-02|2008-06-02|2008-06-03|Estimate|||||||2008-06-02|2008-06-03|Estimate|July 2008||2008-07-31|May 2008|2008-05-31|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Observational|asthma||Maternal Variables Associated With Adherence in Children With Asthma|Reasons for Poor Adherence for Long-Term Preventing Therapy in Children With Asthma|Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 02:05:27.063375|2018-06-01 02:05:27.063375
NCT00688779|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2015-08-13|2008-06-02|2008-06-03|Estimate|||||||2015-08-13|2015-08-14|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|April 2009|Actual|2009-04-30|May 2008|Actual|2008-05-31||Interventional|SAD||Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season|A Double Blind, Placebo Controlled, Randomised, First Time In Man. Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD8848 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out Of Season|Completed||Phase 1|130|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:27.15612|2018-06-01 02:05:27.15612
NCT00688766|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29||2012-12-06|2012-12-07|2008-06-02|2008-06-03|Estimate||||2012-12-06|2012-12-10|Estimate|2012-12-07|2012-12-11|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib|Terminated||Phase 3|47|Actual|Infinity Pharmaceuticals, Inc.||2||Based on Independent Data Monitoring Committee (IDMC) recommendation.|f||||t||||||||||2018-06-01 02:05:27.251292|2018-06-01 02:05:27.251292
NCT00688753|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2015-10-21||2016-07-26|2008-05-30|2008-06-03|Estimate|2015-10-21|2015-11-26|Estimate||||2016-07-26|2016-09-02|Estimate|July 2009||2009-07-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|MACS0460||RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe|A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer|Completed||Phase 2|92|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:05:27.358785|2018-06-01 02:05:27.358785
NCT00688740|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2011-01-25||2011-02-14|2008-05-29|2008-06-03|Estimate|2011-01-25|2011-02-14|Estimate||||2011-02-14|2011-02-16|Estimate|June 1997||1997-06-30|February 2011|2011-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|TAX316||Docetaxel in Node Positive Adjuvant Breast Cancer|A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.|Completed||Phase 3|1491|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:05:27.82315|2018-06-01 02:05:27.82315
NCT00688727|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-01-21|2008-06-02|2008-06-03|Estimate|||||||2009-01-21|2009-01-22|Estimate|March 2001||2001-03-31|January 2009|2009-01-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Cognitive Behavioural Therapy in Dissociative Seizures|Cognitive Behavioural Therapy in Dissociative Seizures: A Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|70|Anticipated|South London and Maudsley NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 02:05:28.521791|2018-06-01 02:05:28.521791
NCT00688714|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2008-05-30|2008-05-30|2008-06-03|Estimate|||||||2008-05-30|2008-06-03|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study to Investigate Safety and Tolerability of a Single Dose of AZD6482|A Randomised, Double-Blind, Placebo-Controlled Phase I Study to Assess the Tolerability, Safety, Pharmacokinetic, and Pharmacodynamic Properties of AZD6482, Alone and co-Administered With ASA, After Single Ascending Intravenous Doses to Healthy Male Subjects|Completed||Phase 1|49|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:28.61153|2018-06-01 02:05:28.61153
NCT00688701|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2016-08-16|2011-04-05|2016-10-18|2008-05-29|2008-06-03|Estimate|2016-10-18|2016-12-12|Estimate|2011-04-05|2011-04-13|Estimate|2016-10-18|2016-12-12|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|GETGOAL-MONO|Safety population included all randomized patients who were exposed to at least 1 dose of study drug, regardless of the amount of treatment administered.|GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents|Completed||Phase 3|361|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 02:05:28.6913|2018-06-01 02:05:28.6913
NCT00527176|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2007-09-07|2007-09-07|2007-09-10|Estimate|||||||2007-09-07|2007-09-10|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|September 2007||2007-09-30|||||Observational|||Pulse Corticosteroid Therapy and Effect on Brain Water Diffusivity||Unknown status|Recruiting||||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||t||||||||||2018-06-01 02:56:37.786129|2018-06-01 02:56:37.786129
NCT00688688|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2012-07-23|2011-05-10|2017-11-09|2008-06-02|2008-06-03|Estimate|2012-09-20|2012-10-19|Estimate|2011-05-10|2011-05-17|Estimate|2017-11-09|2017-12-11|Actual|April 25, 2008|Actual|2008-04-25|November 2017|2017-11-30|May 6, 2010|Actual|2010-05-06|May 6, 2010|Actual|2010-05-06||Interventional|TAURUS||Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder|Completed||Phase 3|2792|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 02:05:29.757246|2018-06-01 02:05:29.757246
NCT00688675|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2010-12-06|2008-06-02|2008-06-03|Estimate|||||||2010-12-06|2010-12-07|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments|GERD Segmentation: Document How Swiss GPs Allocate Their GERD Patients to the Three GERD Patient Segments|Completed|||2912|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:05:32.45466|2018-06-01 02:05:32.45466
NCT00688662|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2015-04-13||2018-03-20|2008-05-30|2008-06-03|Estimate|2016-06-17|2016-07-28|Estimate||||2018-03-20|2018-04-19|Actual|July 2008||2008-07-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2013|Actual|2013-12-31||Interventional|EPISOD||Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction|A Phase III Randomized Multicenter Clinical Trial of Sphincterotomy for the Treatment of SOD III Patients|Completed||N/A|214|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 02:05:32.540256|2018-06-01 02:05:32.540256
NCT00688649|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-02-03|2008-05-29|2008-06-03|Estimate|||||||2009-02-03|2009-02-04|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|NSCS||Nutritional Supplement Compliance Study|An Investigation of the Effects of Different Modes of Delivery of Oral Nutritional Supplements in Participants at Risk of Malnutrition - A Pilot Study|Completed||Phase 3|80|Actual|Nutricia UK Ltd||2|||f||||f||||||||||2018-06-01 02:05:33.607818|2018-06-01 02:05:33.607818
NCT00688636|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2016-04-01||2016-09-09|2008-06-02|2008-06-03|Estimate|2016-09-09|2016-09-26|Estimate||||2016-09-09|2016-09-26|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery|Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery|Completed||Phase 4|24|Actual|University of Pittsburgh|Limitations to our study included a small sample size, a disproportionate number of smokers in the infliximab group, more patients on immunomodulators in the placebo group, and inclusion of patients who had previously received infliximab.|2|||f||||t||||||||||2018-06-01 02:05:33.916511|2018-06-01 02:05:33.916511
NCT00688623|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2017-06-30|2008-05-30|2008-06-03|Estimate|||||||2017-06-30|2017-07-02|Actual|June 24, 2009|Actual|2009-06-24|June 2017|2017-06-30|November 7, 2016|Actual|2016-11-07|November 7, 2016|Actual|2016-11-07||Interventional|RAMSETE/CDE16||RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe|A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors|Completed||Phase 2|73|Actual|Novartis||1|||f|||||f|f||||||||2018-06-01 02:05:35.043456|2018-06-01 02:05:35.043456
NCT00688610|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2009-01-27|2008-06-02|2008-06-03|Estimate|||||||2009-01-27|2009-01-28|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter|Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter|Completed||Phase 2|571|Actual|Hannover Medical School|||||f||||f||||||||||2018-06-01 02:05:35.388004|2018-06-01 02:05:35.388004
NCT00688597|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30||2011-05-16|2011-05-16|2008-05-30|2008-06-03|Estimate||||2011-05-16|2011-05-19|Estimate|2011-05-16|2011-05-19|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study to Evaluate the Safety of AT2220 in Pompe Disease|An Open-Label, Multicenter, Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Three Dosing Regimens of Oral AT2220 in Patients With Pompe Disease|Terminated||Phase 2|3|Actual|Amicus Therapeutics||3|||f||||f||||||||||2018-06-01 02:05:35.668329|2018-06-01 02:05:35.668329
NCT00688584|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-04-08|2008-06-02|2008-06-03|Estimate|||||||2013-04-08|2013-04-09|Estimate|December 2008||2008-12-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Ultra-brief Intervention for Problem Drinkers|Ultra-brief Intervention for Problem Drinkers|Completed||N/A|1767|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 02:05:36.032567|2018-06-01 02:05:36.032567
NCT00688571|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2015-10-28|2008-06-02|2008-06-03|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Melody Transcatheter Pulmonary Valve (TPV) Post-Market Surveillance Study|Melody TPV Post-Market Surveillance Study|Completed||N/A|63|Actual|Medtronic Cardiovascular||1|||f||||f||||||||||2018-06-01 02:05:36.373689|2018-06-01 02:05:36.373689
NCT00688558|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2008-06-02|2008-06-02|2008-06-03|Estimate|||||||2008-06-02|2008-06-03|Estimate|February 2004||2004-02-29|May 2008|2008-05-31|March 2006|Actual|2006-03-31|December 2004|Actual|2004-12-31||Interventional|||Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels|A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of JTT-705 600 mg Versus Placebo Administered Once Daily in Combination With Simvastatin 40 mg in Patients With Low HDL Levels|Completed||Phase 2|92|Actual|Akros Pharma Inc.||2|||f||||f||||||||||2018-06-01 02:05:36.666918|2018-06-01 02:05:36.666918
NCT00688545|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2013-05-07||2013-07-22|2008-05-29|2008-06-03|Estimate|2013-05-07|2013-07-19|Estimate||||2013-07-22|2013-08-15|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|SINCERE||Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis|SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs|Terminated|||275|Actual|Pfizer|Study terminated prematurely: Sponsor released by FDA from post-marketing commitment. As a result, only a small number of participants/analyses could be performed, data must be interpreted with caution. Endpoints arbitrarily assigned as primary.||2|See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:05:36.999548|2018-06-01 02:05:36.999548
NCT00688532|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-01-30|2008-06-02|2008-06-03|Estimate|||||||2013-01-30|2013-01-31|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not|A Pharmacoepidemiological Study on the Association Between Bicalutamide Treated Prostate Cancer and Risk of Coronary Heart Disease (CHD) and Heart Failure (HF) in the General Practice Research Database (GPRD)|Completed|||5103|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 02:05:38.260795|2018-06-01 02:05:38.260795
NCT00688519|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2010-11-05|2010-09-07|2016-11-15|2008-06-02|2008-06-03|Estimate|2010-11-05|2010-12-08|Estimate|2010-09-07|2010-09-09|Estimate|2016-11-15|2017-01-02|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies|A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, Versus Vehicle in Subjects With Plaque-type Psoriasis|Completed||Phase 3|336|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:05:38.338456|2018-06-01 02:05:38.338456
NCT00688506|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2012-07-02|2008-06-02|2008-06-03|Estimate|||||||2012-07-02|2012-07-03|Estimate|November 2009||2009-11-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Combined Sono-electro-magnetic Therapy for Treatment of Refractory Chronic Pelvic Pain Syndrome|Combined Sono-electro-magnetic Therapy for Treatment of Refractory Chronic Pelvic Pain Syndrome: A Prospective, Randomized, Double-blind, Placebo-controlled Trial|Completed||N/A|60|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:05:39.14109|2018-06-01 02:05:39.14109
NCT00688493|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2012-03-20|2008-06-02|2008-06-03|Estimate|||||||2012-03-20|2012-03-21|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|||||Interventional|||Effects of Single Oral Dose Dapagliflozin QT Study|A Double-blind, Randomized, Four-period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years|Completed||Phase 1|36|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:05:39.218484|2018-06-01 02:05:39.218484
NCT00688480|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2016-11-02|2008-06-02|2008-06-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?|Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?|Completed||Phase 4|67|Actual|University of Dundee||2|||f||||t||||||||||2018-06-01 02:05:39.299656|2018-06-01 02:05:39.299656
NCT00688467|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2014-09-26||2017-03-09|2008-06-02|2008-06-03|Estimate|2014-09-26|2014-10-06|Estimate||||2017-03-09|2017-04-07|Actual|June 2008||2008-06-30|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of SCH 527123 in Subjects With Allergen-Induced Asthma|Completed||Phase 2|19|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:05:39.378552|2018-06-01 02:05:39.378552
NCT00688454|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2009-04-08|2008-06-02|2008-06-03|Estimate|||||||2009-04-08|2009-04-09|Estimate|February 2007||2007-02-28|April 2009|2009-04-30|January 2008|Actual|2008-01-31|||||Observational|||C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients|C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients|Completed|||3392|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:05:39.739811|2018-06-01 02:05:39.739811
NCT00688441|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29||2010-08-17|2010-08-18|2008-05-29|2008-06-03|Estimate||||2010-08-18|2010-08-20|Estimate|2010-08-18|2010-08-20|Estimate|July 2008||2008-07-31|August 2010|2010-08-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||The Effect of Nasal Carbon Dioxide (CO2) in the Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 2|453|Actual|Capnia, Inc.||2|||f||||f||||||||||2018-06-01 02:05:39.792146|2018-06-01 02:05:39.792146
NCT00688428|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-03-11|2008-06-02|2008-06-03|Estimate|||||||2009-03-11|2009-03-12|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination|A Phase I, Open-Label, Randomized, Single-Center, 2-Stage Group Sequential Design, 2-Way Crossover Bioequivalence Study Comparing a Fixed-Dose Combination Capsule of Esomeprazole 40mg and Low-Dose Acetylsalicylic Acid (ASA) 325mg With a Free Combination of Esomeprazole Capsule 40mg and Low-Dose ASA|Completed||Phase 1|84|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:05:39.870739|2018-06-01 02:05:39.870739
NCT00688415|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2010-12-21|2008-06-02|2008-06-03|Estimate|||||||2010-12-21|2010-12-22|Estimate|November 2008||2008-11-30|December 2010|2010-12-31|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer|A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacology of VTX-2337 When Administered to Adult Subjects With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|33|Actual|VentiRx Pharmaceuticals Inc.|||||f||||||||||||||2018-06-01 02:05:40.904046|2018-06-01 02:05:40.904046
NCT00688402|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2010-12-02|2008-05-30|2008-06-03|Estimate|||||||2010-12-02|2010-12-03|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Compare Different Formulations of AZD3355|A Double-blind, Randomized, Cross-over Design, Phase 1 Pharmacodynamic Study to Investigate the Effect of Different Formulations of AZD3355 for the Development of Paresthesiae After Dosing in Healthy Subjects|Completed||Phase 1|48|Anticipated|AstraZeneca||5|||f||||f||||||||||2018-06-01 02:05:41.012819|2018-06-01 02:05:41.012819
NCT00688389|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2018-03-06|2008-05-30|2008-06-02|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2007||2007-07-31|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection|Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection|Recruiting|||700|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||3||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 02:05:41.088526|2018-06-01 02:05:41.088526
NCT00682357|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2016-10-05||2016-10-05|2008-05-21|2008-05-22|Estimate|2016-10-05|2016-11-29|Estimate||||2016-10-05|2016-11-29|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis|Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis|Completed||N/A|25|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-06-01 02:07:36.288003|2018-06-01 02:07:36.288003
NCT00688376|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2009-09-22|2008-05-30|2008-06-02|Estimate|||||||2009-09-22|2009-09-23|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment|Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment|Completed||Phase 3|300|Actual|Eisai Inc.||2|||f||||f||||||||||2018-06-01 02:05:41.17451|2018-06-01 02:05:41.17451
NCT00688363|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2011-07-29|2008-05-30|2008-06-02|Estimate|||||||2011-07-29|2011-08-01|Estimate|February 2003||2003-02-28|July 2011|2011-07-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Blood Glucose Self Monitoring and HbA1c Effects on Glucose Control|The Benefit of the Blood Glucose Self Monitoring and a Regular Three-monthly Hemoglobin A1c Profile in Patients With Type 2-diabetes and Conventional Insulin Therapy|Completed||Phase 4|300|Actual|Deutsche Diabetes Gesellschaft||4|||f||||f||||||||||2018-06-01 02:05:41.331674|2018-06-01 02:05:41.331674
NCT00688350|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2016-10-03|2008-05-30|2008-06-02|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Medication Adherence in Hypertension Study|Interventions to Improve Medication-Taking Behavior in Older Adults With Hypertension: An Exploratory Study|Completed||N/A|15|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 02:05:42.292247|2018-06-01 02:05:42.292247
NCT00688337|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-30|2008-05-30|2008-06-02|Estimate|||||||2008-05-30|2008-06-02|Estimate|June 2008||2008-06-30|May 2008|2008-05-31|June 2010|Anticipated|2010-06-30|June 2009|Anticipated|2009-06-30||Observational|||Correlation Between Fluorodeoxyglucose (FDG) and FLT Uptake and Gene-Expression Oncotype Assay in Patients With Breast Cancer||Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||None Retained|"~     not relevant~   "|||2018-06-01 02:05:42.426043|2018-06-01 02:05:42.426043
NCT00688324|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2016-10-24||2017-12-21|2008-05-30|2008-06-02|Estimate|2017-12-21|2018-01-23|Actual||||2017-12-21|2018-01-23|Actual|June 2008|Actual|2008-06-30|October 2017|2017-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Biomarker Study of Acamprosate in Schizophrenia|Biomarker Study of Acamprosate in Schizophrenia|Completed||Phase 4|36|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 02:05:42.595059|2018-06-01 02:05:42.595059
NCT00688311|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2009-11-19|2008-05-30|2008-06-02|Estimate|||||||2009-11-19|2009-11-23|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Pilot Trial of a Synbiotic in HIV+ Patients|Pilot Trial of a Synbiotic in HIV+ Patients|Completed||N/A|34|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 02:05:43.371315|2018-06-01 02:05:43.371315
NCT00688298|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-30|2008-05-30|2008-06-02|Estimate|||||||2008-05-30|2008-06-02|Estimate|May 2004||2004-05-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence|A Prospective, Single-Arm, Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence|Completed||Phase 4|100|Actual|Boston Scientific Corporation||1|||f||||||||||||||2018-06-01 02:05:43.489729|2018-06-01 02:05:43.489729
NCT00688285|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2011-03-24|2008-05-30|2008-06-02|Estimate|||||||2011-03-24|2011-03-25|Estimate|December 2008||2008-12-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ACRinCKD||Automated Clinical Reminders in the Care of Chronic Kidney Disease Patients|Automated Clinical Reminders in the Care of Chronic Kidney Disease Patients|Completed||N/A|248|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 02:05:43.589275|2018-06-01 02:05:43.589275
NCT00688272|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2017-11-13|2008-05-30|2008-06-02|Estimate|||||||2017-11-13|2017-11-17|Actual|June 2, 2008|Actual|2008-06-02|November 2017|2017-11-30|September 25, 2008|Actual|2008-09-25|September 25, 2008|Actual|2008-09-25||Interventional|||Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag|A Phase I, Double-blind, Placebo and Observer-blind Positive Controlled, Randomized, Parallel Group Study in Healthy Subjects to Investigate the Photoirritant Potential of Eltrombopag|Completed||Phase 1|36|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 02:05:43.684333|2018-06-01 02:05:43.684333
NCT00688259|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2016-12-19||2017-05-09|2008-05-28|2008-06-02|Estimate|2017-05-09|2017-12-14|Actual||||2017-05-09|2017-12-14|Actual|April 2009||2009-04-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|||Cognitive-Behavioral Therapy in Veterans With Schizophrenia|Cognitive-Behavioral Therapy in Veterans With Schizophrenia|Completed||N/A|88|Actual|VA Office of Research and Development||2|||f||||t||||||||Yes|De-identified data on major outcomes can be shared. Investigators can contact PI.|2018-06-01 02:05:43.795198|2018-06-01 02:05:43.795198
NCT00688246|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-11-11|2008-05-30|2008-06-02|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|January 2013|Actual|2013-01-31|October 2011|Actual|2011-10-31||Observational|||Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3|The Influence of Five Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer|Completed|||238|Actual|Canadian Cancer Trials Group|||||f||||t||||||Samples With DNA|"~     Serum~   "|||2018-06-01 02:05:44.172203|2018-06-01 02:05:44.172203
NCT00688233|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2008-05-28|2008-05-28|2008-06-02|Estimate|||||||2008-05-28|2008-06-02|Estimate|December 2007||2007-12-31|May 2008|2008-05-31|May 2009|Anticipated|2009-05-31|October 2008|Anticipated|2008-10-31||Interventional|Seifi-Fx||Effect of the Innovated Seifi's Functional Appliance on Skeletal and Dentoalveolar Changes of Class II/ 1, Deep Bite|Phase 1 Effect of the Innovated Seifi's Functional Appliance on the Skeletal and Dentoalveolar Changes of Class II/Division 1, Deep Bite Cases|Unknown status|Recruiting|Phase 1|20|Anticipated|Shahid Beheshti University of Medical Sciences||1|||f||||||||||||||2018-06-01 02:05:44.354913|2018-06-01 02:05:44.354913
NCT00688220|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-06-02|2008-05-30|2008-06-02|Estimate|||||||2010-06-02|2010-06-04|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Effect of Celliant Materials on Pain and Blood Oxygenation in Subjects With Chronic Elbow and Wrist Pain|Effect of Celliant Materials on Pain and Blood Oxygenation in Subjects With Chronic Elbow and Wrist Pain|Terminated|||0|Actual|Southern California Institute for Research and Education|||2|PI closed study due to lack of enrollment|f||||f||||||||||2018-06-01 02:05:44.447796|2018-06-01 02:05:44.447796
NCT00688038|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2017-09-14|2008-05-28|2008-06-02|Estimate|||||||2017-09-14|2017-09-15|Actual|May 13, 2008|Actual|2008-05-13|September 2017|2017-09-30|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy|A Study to Determine Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Therapy of Metastases to Bone|Completed||Phase 4|24|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:05:46.532143|2018-06-01 02:05:46.532143
NCT00688207|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2016-11-04|2008-05-30|2008-06-02|Estimate|||||||2016-11-04|2016-11-07|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)|An Open Label Single Oral Dose Study in Patients With Mild Alzheimer's Disease to Assess the Pharmacokinetics of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population|Completed||Phase 1|14|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:05:44.520787|2018-06-01 02:05:44.520787
NCT00688194|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2013-08-23|2008-05-30|2008-06-02|Estimate|||||||2013-08-23|2013-08-26|Estimate|May 2008||2008-05-31|May 2008|2008-05-31||||May 2013|Anticipated|2013-05-31||Interventional|||Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy|Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy|Unknown status|Recruiting|Phase 3|396|Anticipated|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 02:05:44.63422|2018-06-01 02:05:44.63422
NCT00688181|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2009-03-30|2008-05-28|2008-06-02|Estimate|||||||2009-03-30|2009-03-31|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|April 2009|Anticipated|2009-04-30|November 2008|Actual|2008-11-30||Observational|||The Prefyx PPS™ System eRegistry|The Prefyx PPS™ System eRegistry|Unknown status|Active, not recruiting||44|Actual|Boston Scientific Corporation|||1||f||||||||||||||2018-06-01 02:05:44.750209|2018-06-01 02:05:44.750209
NCT00688168|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2018-01-22|2008-05-30|2008-06-02|Estimate|||||||2018-01-22|2018-01-25|Actual|May 2008|Actual|2008-05-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Inflammatory Cytokines in Symptom Production in Multiple Myeloma|Identifying the Role of Inflammatory Cytokines in Symptom Production in Multiple Myeloma|Active, not recruiting|||625|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Tissue sample by inserting a swab into mouth and rubbing firmly against the inside of cheeck~     or underneath lower or upper lip for about a minute during a regularly schedule clinic visit.~   "|||2018-06-01 02:05:44.835565|2018-06-01 02:05:44.835565
NCT00688155|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2017-05-25||2017-12-08|2008-05-29|2008-06-02|Estimate|2017-11-02|2017-12-07|Actual||||2017-12-08|2018-01-04|Actual|May 2008|Actual|2008-05-31|December 2017|2017-12-31|June 30, 2010|Actual|2010-06-30|June 30, 2009|Actual|2009-06-30||Interventional|SHARP-P||Seniors Health and Activity Research Program-Pilot|Seniors Health and Activity Research Program-Pilot|Completed||N/A|73|Actual|Wake Forest University Health Sciences|While large enough to meet its objectives, our pilot trial involved a modest sample size and short follow-up.|4|||f||||t|f|f||||||Yes|Available on request and development of a data sharing agreement.|2018-06-01 02:05:44.940223|2018-06-01 02:05:44.940223
NCT00688142|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-03-30|2008-05-28|2008-06-02|Estimate|||||||2010-03-30|2010-03-31|Estimate|February 2008||2008-02-29|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Sleepiness and Brain Function: The Effect of Armodafinil in Shift Work Sleep Disorder|Magnetoencephalographic Imaging of Sleepiness: The Effect of Armodafinil in Shift Work Sleep Disorder|Completed|||24|Actual|Henry Ford Health System|||2||f||||f||||||||||2018-06-01 02:05:45.367566|2018-06-01 02:05:45.367566
NCT00688129|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2017-09-18|2008-05-28|2008-06-02|Estimate|||||||2017-09-18|2017-09-19|Actual|September 2005||2005-09-30|September 2017|2017-09-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|KITS||KITS: School Readiness in Foster Care Efficacy Trial|KITS: School Readiness in Foster Care Efficacy Trial|Completed||N/A|192|Actual|Oregon Social Learning Center||2|||f||||f||||||||||2018-06-01 02:05:45.435098|2018-06-01 02:05:45.435098
NCT00688116|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2014-09-17|2008-05-30|2008-06-02|Estimate|||||||2014-09-17|2014-09-18|Estimate|October 2007||2007-10-31|September 2014|2014-09-30|November 2014|Anticipated|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice-Weekly in Patients With Solid Tumors|Unknown status|Active, not recruiting|Phase 1|45|Anticipated|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-06-01 02:05:45.513653|2018-06-01 02:05:45.513653
NCT00688103|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-25|2012-03-29||2015-09-01|2008-05-30|2008-06-02|Estimate|2015-09-01|2015-10-01|Estimate||||2015-09-01|2015-10-01|Estimate|June 2005||2005-06-30|September 2015|2015-09-30|October 2010|Actual|2010-10-31|October 2008|Actual|2008-10-31||Interventional|JESMR||Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan|Efficacy and Safety of Etanercept in Active Rheumatoid Arthritis Despite Methotrexate Therapy in Japan|Completed||Phase 4|151|Actual|Japan Biological Agent Study Integrated Consortium||2|||f||||t||||||||||2018-06-01 02:05:45.602303|2018-06-01 02:05:45.602303
NCT00688090|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-08-02|2008-05-30|2008-06-02|Estimate|||||||2010-08-02|2010-08-03|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.|A Phase 1/2, Open Label, Non-Randomized Dose Escalation Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma|Completed||Phase 1|19|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-06-01 02:05:45.902622|2018-06-01 02:05:45.902622
NCT00688077|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2016-06-27|2008-05-30|2008-06-02|Estimate|||||||2016-06-27|2016-06-28|Estimate|May 2008||2008-05-31|June 2016|2016-06-30||||December 2012|Actual|2012-12-31||Interventional|||FGF-23 Suppressibility by Calcitonin|Evaluation of FGF-23 Suppressibility by Calcitonin in Healthy Men - Pilot Study|Completed||N/A|49|Actual|Rijnstate Hospital||2|||f||||||||||||||2018-06-01 02:05:45.969914|2018-06-01 02:05:45.969914
NCT00688064|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2010-02-23||2010-03-31|2008-05-30|2008-06-02|Estimate|2010-03-18|2010-03-31|Estimate||||2010-03-31|2010-04-06|Estimate|August 2008||2008-08-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|ACCESS I||Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris|Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With Doxycycline Hyclate 100 mg Tablets Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel Associated With Doxycycline Hyclate 100 mg Tablets in the Treatment of Severe Acne Vulgaris.|Completed||Phase 3|459|Actual|Galderma||2|||f||||f||||||||||2018-06-01 02:05:46.038736|2018-06-01 02:05:46.038736
NCT00688051|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2014-09-03|2008-05-30|2008-06-02|Estimate|||||||2014-09-03|2014-09-05|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||"Changes in Adherence After Playing My Life With CF Game"|Changes in Adherence to Diet, Treatment and Medication in the Cystic Fibrosis Patient as a Result of Participation in a Simulation Game.|Completed||N/A|30|Actual|Children's Mercy Hospital Kansas City||1|||f||||t||||||||||2018-06-01 02:05:46.466659|2018-06-01 02:05:46.466659
NCT00688025|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-03-30|2008-05-30|2008-06-02|Estimate|||||||2010-03-30|2010-03-31|Estimate|May 2008||2008-05-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Magnetoencephalographic (MEG) Localization of Ramelteon's Effects on Brain Function and Cortical Arousal in Insomnia|Magnetoencephalographic Localization of Ramelteon's Effects on Brain Function and Cortical Arousal in Insomnia|Completed|||24|Actual|Henry Ford Health System|||2||f||||f||||||||||2018-06-01 02:05:46.623949|2018-06-01 02:05:46.623949
NCT00688012|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2009-09-17|2008-05-30|2008-06-02|Estimate|||||||2009-09-17|2009-09-18|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety Study of SPC3649 in Healthy Men|A Placebo-controlled, Double-blind, Randomized, Single Dose, Dose Escalating Trial in Healthy Men to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPC3649|Completed||Phase 1|64||Santaris Pharma A/S|||||f||||f||||||||||2018-06-01 02:05:46.689173|2018-06-01 02:05:46.689173
NCT00687999|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2009-08-03|2008-05-30|2008-06-02|Estimate|||||||2009-08-03|2009-08-06|Estimate|December 2005||2005-12-31|May 2008|2008-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||NIDDM and IR in Combination Therapy for CHC|Non-insulin-dependent Diabetes Mellitus and Insulin Resistance in Chronic Hepatitis C Patients Treated With Combination Therapy With Pegylated Interferon and Ribavirin in Taiwan|Completed||N/A|400|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||t||||||||||2018-06-01 02:05:46.760625|2018-06-01 02:05:46.760625
NCT00687986|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2015-06-02|2008-05-28|2008-06-02|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2008||2008-10-31|January 2011|2011-01-31|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Interventional|ROSEL||Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer|A Randomized Clinical Trial of Surgery Versus Radiosurgery (Stereotactic Radiotherapy) in Patients With Stage IA NSCLC Who Are Fit to Undergo Primary Resection|Terminated||Phase 3|960|Anticipated|VU University Medical Center||2||Poor recruitment|f||||t||||||||||2018-06-01 02:05:46.836107|2018-06-01 02:05:46.836107
NCT00687973|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2010-12-22||2011-03-08|2008-05-30|2008-06-02|Estimate|2010-12-22|2011-01-21|Estimate||||2011-03-08|2011-03-11|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|EXPLOR||Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg|Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg|Completed||Phase 4|393|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:05:46.923416|2018-06-01 02:05:46.923416
NCT00687960|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-05-28|2008-05-28|2008-06-02|Estimate|||||||2008-05-28|2008-06-02|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Interventional|||Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults|Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults|Completed||N/A|13|Actual|Kansas State University||4|||f||||f||||||||||2018-06-01 02:05:47.417474|2018-06-01 02:05:47.417474
NCT00687947|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2009-07-31|2008-05-30|2008-06-02|Estimate|||||||2009-07-31|2009-08-03|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|CGRP-2008||Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)|CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls|Completed||N/A|30|Anticipated|Danish Headache Center||3|||f||||f||||||||||2018-06-01 02:05:47.513549|2018-06-01 02:05:47.513549
NCT00687934|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2014-09-17|2008-05-30|2008-06-02|Estimate|||||||2014-09-17|2014-09-18|Estimate|October 2007||2007-10-31|September 2014|2014-09-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors|A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors|Completed||Phase 1|53|Actual|Synta Pharmaceuticals Corp.||1|||f||||f||||||||||2018-06-01 02:05:47.690253|2018-06-01 02:05:47.690253
NCT00687921|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-30|2008-05-30|2008-06-02|Estimate|||||||2008-05-30|2008-06-02|Estimate|June 2008||2008-06-30|May 2008|2008-05-31|June 2009|Anticipated|2009-06-30|March 2009|Anticipated|2009-03-31||Observational|||F18-Flouride PET/CT in Acute Knee Injury|F18-Flouride PET/CT in Acute Knee Injury. A Prospective Study|Unknown status|Not yet recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||None Retained|"~     not relevant~   "|||2018-06-01 02:05:47.765851|2018-06-01 02:05:47.765851
NCT00687908|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2010-07-16||2010-09-30|2008-05-30|2008-06-02|Estimate|2010-08-26|2010-09-24|Estimate||||2010-09-30|2010-10-05|Estimate|November 2008||2008-11-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ACCESS II||Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance|Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Vehicle Gel as a 6-month Acne Maintenance Treatment|Completed||Phase 3|243|Actual|Galderma||2|||f||||f||||||||||2018-06-01 02:05:47.842985|2018-06-01 02:05:47.842985
NCT00687895|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-28|2008-05-28|2008-06-02|Estimate|||||||2008-05-28|2008-06-02|Estimate|July 2003||2003-07-31|May 2008|2008-05-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania|Quality Malaria Case Management In Under- Fives In Primary Health Care (Phc) Institutions In Bagamoyo And Kibaha Districts Of Coastal Tanzania:a Multicomponent Controlled Intervention Study|Completed||Phase 4|3131|Actual|Muhimbili University of Health and Allied Sciences||3|||f||||t||||||||||2018-06-01 02:05:48.249032|2018-06-01 02:05:48.249032
NCT00687882|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2018-03-18|2008-05-28|2008-06-02|Estimate|||||||2018-03-18|2018-03-20|Actual|March 2008||2008-03-31|March 2018|2018-03-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|Kids-DOTT||Evaluation of the Duration of Therapy for Thrombosis in Children|Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children|Recruiting||Phase 3|815|Anticipated|Johns Hopkins All Children's Hospital||4|||f||||t||||||||No||2018-06-01 02:05:48.335839|2018-06-01 02:05:48.335839
NCT00687869|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2013-09-18|2008-05-28|2008-06-02|Estimate|||||||2013-09-18|2013-09-19|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PaReSiS||Participative Rehabilitation in Stroke Patients|"Participative Rehabilitation Process Management Stroke in Saxony-Anhalt"|Completed||Phase 3|322|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-06-01 02:05:48.6721|2018-06-01 02:05:48.6721
NCT00687856|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2016-01-13||2017-06-22|2008-05-29|2008-06-02|Estimate|2016-01-13|2016-02-11|Estimate||||2017-06-22|2017-07-21|Actual|April 2008||2008-04-30|June 2017|2017-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|RECOVER||Identifying and Facilitating Ventricular Recovery on Mechanical Support|Identifying and Facilitating Ventricular Recovery on Mechanical Support|Completed|||211|Actual|University of Pittsburgh|||1||f||||t||||||||||2018-06-01 02:05:48.767455|2018-06-01 02:05:48.767455
NCT00687843|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2012-03-20|2008-05-30|2008-06-02|Estimate|||||||2012-03-20|2012-03-22|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|TMOG-GC01||Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients|Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients|Unknown status|Active, not recruiting|Phase 3|480|Anticipated|Tokyo Metropolitan Oncology Group||2|||f||||t||||||||||2018-06-01 02:05:48.92116|2018-06-01 02:05:48.92116
NCT00687830|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2015-02-19||2017-04-17|2008-05-30|2008-06-02|Estimate|2016-03-11|2016-04-11|Estimate||||2017-04-17|2017-05-17|Actual|February 2008||2008-02-29|February 2016|2016-02-29|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|CCF||Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.|A Randomized Endoscopist-blinded Clinical Trial Comparing the Bowel Cleansing Effect and Patient Tolerability of Same Day Polyethylene Glycol Bowel Preparation Regimen v Regimen Given on the Day Before Colonoscopy|Completed||Phase 3|136|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 02:05:49.017569|2018-06-01 02:05:49.017569
NCT00687817|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2011-03-23|2008-05-30|2008-06-02|Estimate|||||||2011-03-23|2011-03-24|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer|A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|49|Actual|Peregrine Pharmaceuticals|||||f||||f||||||||||2018-06-01 02:05:49.254697|2018-06-01 02:05:49.254697
NCT00687804|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-01-19||2013-03-26|2008-05-30|2008-06-02|Estimate|2011-03-23|2011-04-19|Estimate||||2013-03-26|2013-04-01|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2010|Actual|2010-01-31||Interventional|RESTORE||A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study|A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema|Completed||Phase 3|345|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:05:49.378153|2018-06-01 02:05:49.378153
NCT00687791|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-06-17|2008-05-30|2008-06-02|Estimate|||||||2008-06-17|2008-06-18|Estimate|December 2007||2007-12-31|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study|Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study|Unknown status|Recruiting|Phase 3|20|Anticipated|Pro Top & Mediking Company Limited||1|||f||||t||||||||||2018-06-01 02:05:51.738393|2018-06-01 02:05:51.738393
NCT00687778|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-30|2008-05-30|2008-06-02|Estimate|||||||2008-05-30|2008-06-02|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|June 2010|Anticipated|2010-06-30|June 2009|Anticipated|2009-06-30||Observational|||11C-Acetate PET/CT Non-FDG-Avid Tumors||Unknown status|Recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||||||2018-06-01 02:05:52.062588|2018-06-01 02:05:52.062588
NCT00687765|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2015-07-10|2008-05-30|2008-06-02|Estimate|||||||2015-07-10|2015-07-13|Estimate|July 2008||2008-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma|Phase I/II Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma|Completed||Phase 1/Phase 2|126|Actual|Sanofi||1|||t||||f||||||||||2018-06-01 02:05:52.355729|2018-06-01 02:05:52.355729
NCT00687752|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-30|2008-05-30|2008-06-02|Estimate|||||||2008-05-30|2008-06-02|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|May 2009|Anticipated|2009-05-31|April 2008|Anticipated|2008-04-30||Observational|FD||Sonographic Assessment of Fetal Deglutition Associated With Hydramnion:Its Absence is Indicative of Central Nervous System (CNS) Pathology|Sonographic Assessment of Fetal Deglutition Associated With Hydramnion:Its Absence is Indicative of CNS Pathology? a Report on Two Cases.|Unknown status|Enrolling by invitation||310|Actual|Hippocration General Hospital|||2||f||||t||||||||||2018-06-01 02:05:52.826618|2018-06-01 02:05:52.826618
NCT00687739|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2016-03-08|2008-05-29|2008-06-02|Estimate|||||||2016-03-08|2016-03-09|Estimate|May 2008||2008-05-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|POWER||Prevention of Obesity in Women Via Estradiol Regulation|Estrogen Deficiency and Mechanisms of Fat Accumulation|Completed||Phase 3|150|Actual|University of Colorado, Denver||4|||f||||t||||||||||2018-06-01 02:05:53.067495|2018-06-01 02:05:53.067495
NCT00687726|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-28|2008-05-28|2008-06-02|Estimate|||||||2008-05-28|2008-06-02|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|February 2008|Actual|2008-02-29|August 2007|Actual|2007-08-31||Interventional|||Simple Home-Based Exercise for Knee Osteoarthritis|The Relationship of Knee Joint Osteoarthritis to Balance and Walking Ability.|Completed||N/A|48|Actual|Srinakharinwirot University||2|||f||||f||||||||||2018-06-01 02:05:53.148004|2018-06-01 02:05:53.148004
NCT00687713|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2016-12-22||2017-02-14|2008-05-29|2008-06-02|Estimate|2016-12-22|2017-02-15|Actual||||2017-02-14|2017-03-21|Actual|May 2008||2008-05-31|February 2017|2017-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence|Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence|Completed||Phase 2|200|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||No||2018-06-01 02:05:53.224417|2018-06-01 02:05:53.224417
NCT00687700|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2017-08-10|2008-05-30|2008-06-02|Estimate|||||||2017-08-10|2017-08-11|Actual|March 10, 2008|Actual|2008-03-10|August 2017|2017-08-31|May 27, 2008|Actual|2008-05-27|May 27, 2008|Actual|2008-05-27||Interventional|||A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers|A Study to Investigate the Relative Pharmacological Activity of Aninhaled B2-agonist/Anticholinergic Dual Pharmacophore Inhealthy Volunteers|Completed||Phase 1|23|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:05:53.48938|2018-06-01 02:05:53.48938
NCT00687687|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28||2012-06-15|2012-08-01|2008-05-30|2008-06-02|Estimate||||2012-06-15|2012-06-18|Estimate|2012-08-01|2012-08-07|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma|A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma|Completed||Phase 2|22|Actual|Sanofi||1|||t||||f||||||||||2018-06-01 02:05:53.622778|2018-06-01 02:05:53.622778
NCT00687674|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|2011-11-23||2012-03-07|2008-05-30|2008-06-02|Estimate|2011-11-23|2011-12-26|Estimate||||2012-03-07|2012-03-09|Estimate|August 2008||2008-08-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase I/II Study of Sorafenib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1/Phase 2|13|Actual|Mayo Clinic||1||"Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II~   portion."|f||||t||||||||||2018-06-01 02:05:53.794547|2018-06-01 02:05:53.794547
NCT00687661|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2015-09-25|2008-05-30|2008-06-02|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2008||2008-10-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|QUICK||Queen's University Investigation of Calcification in Chronic Kidney Disease|The Use of Bisphosphonates to Prevent or Delay the Progression of Vascular Calcification in End-Stage Renal Disease: A Randomized Controlled Trial|Completed||Phase 3|25|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 02:05:54.07067|2018-06-01 02:05:54.07067
NCT00687648|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-30|||2009-06-16|2008-05-30|2008-06-02|Estimate|||||||2009-06-16|2009-06-17|Estimate|May 2008||2008-05-31|June 2009|2009-06-30||||April 2010|Anticipated|2010-04-30||Interventional|||Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer|Randomised Phase II Study of Metronomic Chemotherapy Plus the Same Aromatase Inhibitor Compared to Metronomic Chemotherapy Alone in Women With Hormone Receptor Positive, Her-2 Non-Overexpressing Advanced Breast Cancer Whose Disease Has Progressed While Receiving an Aromatase Inhibitor, Correlating Response With Circulating Endothelial Progenitor Cells, VEGF and VEGFR|Unknown status|Recruiting|Phase 2|70|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 02:05:54.164089|2018-06-01 02:05:54.164089
NCT00687622|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2017-11-08|2008-05-30|2008-06-02|Estimate|||||||2017-11-08|2017-11-13|Actual|July 28, 2008|Actual|2008-07-28|November 2017|2017-11-30|November 8, 2011|Actual|2011-11-08|June 7, 2011|Actual|2011-06-07||Interventional|||Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma|An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor GSK1120212 in Subjects With Solid Tumors or Lymphoma|Completed||Phase 1|206|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 02:05:54.293766|2018-06-01 02:05:54.293766
NCT00687609|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2010-07-22||2010-08-18|2008-05-30|2008-06-02|Estimate|2010-07-22|2010-08-19|Estimate||||2010-08-18|2010-08-24|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PEACE||Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE|An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse.|Terminated||Phase 4|7|Actual|Eli Lilly and Company|The study was discontinued early, owing to difficulties in recruiting the target sample after seven patients had been recruited. Therefore, only disposition, demographic, and safety data are reported.|1||"The study was discontinued early, owing to difficulties in recruiting the target sample after~   seven patients had been recruited."|f||||f||||||||||2018-06-01 02:05:54.405241|2018-06-01 02:05:54.405241
NCT00687596|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28||2013-06-04|2013-06-04|2008-05-30|2008-06-02|Estimate||||2013-06-04|2013-06-12|Estimate|2013-06-04|2013-06-12|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy|A Phase 2, Double-blind, Placebo-controlled, Randomized, International, Multicenter Study of Oral TAC 101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy|Terminated||Phase 2|52|Actual|Taiho Oncology, Inc.||2||Terminated due to safety concerns|f||||f||||||||||2018-06-01 02:05:54.818538|2018-06-01 02:05:54.818538
NCT00687583|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2016-05-03|2008-05-28|2008-06-02|Estimate|||||||2016-05-03|2016-05-04|Estimate|April 2007||2007-04-30|May 2016|2016-05-31|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Observational|||Head Movement Effect on Different Tracheal Tubes|Effect of Head Movement on the Position of Different Tracheal Tubes Determined Radiologically|Withdrawn|||0|Actual|The Hospital for Sick Children||||Research question deemed not of enough clinical importance to proceed.|f||||f||||||||||2018-06-01 02:05:54.893469|2018-06-01 02:05:54.893469
NCT00687570|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2015-02-19|2008-05-30|2008-06-02|Estimate|||||||2015-02-19|2015-02-20|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Bowel Preparation Before Rectal Cancer Surgery|Bowel Preparation With Nutritional Drinks Instead of Traditional Bowel Preparation Before Rectal Cancer Surgery|Completed||N/A|32|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 02:05:55.075561|2018-06-01 02:05:55.075561
NCT00687544|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-09-22||2017-03-08|2008-05-29|2008-05-30|Estimate|2011-12-22|2012-01-30|Estimate||||2017-03-08|2017-04-06|Actual|December 2005||2005-12-31|March 2017|2017-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)|Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon|Terminated||Phase 4|11|Actual|Merck Sharp & Dohme Corp.|The study was terminated early due to low enrollment. The primary and secondary outcomes were not evaluated. A formal safety analysis was not performed for the 11 participants enrolled in the study.|1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:05:55.178371|2018-06-01 02:05:55.178371
NCT00687531|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-06-17||2017-03-15|2008-05-29|2008-05-30|Estimate|2011-06-17|2011-07-20|Estimate||||2017-03-15|2017-04-12|Actual|November 2006||2006-11-30|March 2017|2017-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|APEGO||Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)|Open Label, 12-week Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate Dry Powder 400 mcg Once-daily in Persistent Mild-moderate Asthmatic Patients at Least 12 Years Old|Terminated||Phase 4|385|Actual|Merck Sharp & Dohme Corp.|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.|1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:05:55.382801|2018-06-01 02:05:55.382801
NCT00681785|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-05-19|2008-05-19|2008-05-21|Estimate|||||||2008-05-19|2008-05-21|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Thrombophylaxis in Transurethral Surgery With Dalteparine|Thromboseprophylaxe Mit Niedermolekularem Heparin Bei Transurethralen Eingriffen|Completed||N/A|250|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 02:07:43.790175|2018-06-01 02:07:43.790175
NCT00687518|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-05-29|2008-05-29|2008-05-30|Estimate|||||||2008-05-29|2008-05-30|Estimate|March 2008||2008-03-31|May 2008|2008-05-31|February 2009|Anticipated|2009-02-28|November 2008|Anticipated|2008-11-30||Interventional|HEPEPO||Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers|Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers|Unknown status|Recruiting|N/A|14|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-06-01 02:05:55.603812|2018-06-01 02:05:55.603812
NCT00687505|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2013-03-05|2008-05-27|2008-05-30|Estimate|||||||2013-03-05|2013-03-06|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Safety Study of FP-1039 To Treat Cancer|A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors|Completed||Phase 1|39|Actual|Five Prime Therapeutics, Inc.||1|||f||||f||||||||||2018-06-01 02:05:55.757212|2018-06-01 02:05:55.757212
NCT00687492|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-12-01|2008-05-29|2008-05-30|Estimate|||||||2010-12-01|2010-12-02|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|CEPHEUS||Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia|Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia|Completed|||8000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:05:55.838969|2018-06-01 02:05:55.838969
NCT00687479|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2014-12-17|2008-05-29|2008-05-30|Estimate|||||||2014-12-17|2014-12-18|Estimate|January 2006||2006-01-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Observational|DRM||Insulin Action During Pregnancy in Woman at High Risk for Gestational Diabetes|Clinically Useful Methods for Assessment of Insulin Sensitivity and Beta Cell Function in Women at High Risk for Gestational Diabetes: Does Race Matter?|Completed|||175|Actual|Woman's|||3||f||||f||||||Samples Without DNA|"~     Blood samples for insulin measurements~   "|||2018-06-01 02:05:56.01393|2018-06-01 02:05:56.01393
NCT00687466|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-08-03|2008-05-29|2008-05-30|Estimate|||||||2009-08-03|2009-08-04|Estimate|August 2005||2005-08-31|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay|Phase 3 Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay|Unknown status|Active, not recruiting|Phase 3|70|Anticipated|Fondazione per la ricerca sulla Fibrosi Cistica||2|||f||||t||||||||||2018-06-01 02:05:56.131572|2018-06-01 02:05:56.131572
NCT00687453|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2010-09-15||2014-02-07|2008-05-29|2008-05-30|Estimate|2010-09-15|2010-10-07|Estimate||||2014-02-07|2014-02-11|Estimate|February 2003||2003-02-28|February 2014|2014-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Insulin Glargine Versus Twice-Daily NPH|The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy|Completed||Phase 4|27|Actual|Charles Drew University of Medicine and Science|Early termination leading to smaller than anticipated enrollment.|2|||f||||t||||||||||2018-06-01 02:05:56.257033|2018-06-01 02:05:56.257033
NCT00687440|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2010-01-21||2017-05-12|2008-05-29|2008-05-30|Estimate|2010-01-21|2010-02-15|Estimate||||2017-05-12|2017-06-08|Actual|May 18, 2005|Actual|2005-05-18|May 2017|2017-05-31|October 24, 2008|Actual|2008-10-24|October 24, 2008|Actual|2008-10-24||Interventional|||A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)|Pegylated Liposomal Doxorubicin (Caelyx) in Combination With Herceptin and Taxotere as First-line Chemotherapy in Metastatic Breast Cancer Patients: A 2 Stage Phase II, Open Label, Multicenter Study.|Completed||Phase 2|27|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:05:56.631797|2018-06-01 02:05:56.631797
NCT00687427|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-05-29|2008-05-29|2008-05-30|Estimate|||||||2008-05-29|2008-05-30|Estimate|June 2008||2008-06-30|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|||||Observational|||Return to Work After Hand Injury: the Role of Medical, Demographic and Psycho-Social Factors|Return to Work After Hand Injury: The Role of Medical, Demographic and Psychosocial Factors|Unknown status|Not yet recruiting||75|Anticipated|Soroka University Medical Center|||3||f||||||||||||||2018-06-01 02:05:56.840626|2018-06-01 02:05:56.840626
NCT00687414|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2010-01-08|2008-05-29|2008-05-30|Estimate|||||||2010-01-08|2010-01-11|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Observational|||Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders|Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders|Completed|||60|Anticipated|Spectrum Health Hospitals|||2||f||||f||||||Samples With DNA|"~     peripheral blood~   "|||2018-06-01 02:05:56.92353|2018-06-01 02:05:56.92353
NCT00687401|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2010-12-02||2017-03-13|2008-05-27|2008-05-30|Estimate|2010-12-02|2010-12-24|Estimate||||2017-03-13|2017-04-11|Actual|June 2006||2006-06-30|March 2017|2017-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|ESAQUALITY||A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)|A Multi-center, Open Label Trial Evaluating the Efficacy , SAfety and the Impact on QUAlity of Life of Infliximab TherapY in Patients With Moderate-to-severe Psoriasis Not Responding to Standard or Biologic Therapy|Completed||Phase 3|215|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:05:57.005628|2018-06-01 02:05:57.005628
NCT00687388|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2013-06-07|2008-05-29|2008-05-30|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 2008||2008-05-31|June 2013|2013-06-30||||March 2012|Anticipated|2012-03-31||Interventional|||The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia|The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia: A Prospective Randomized Multicenter Trial|Withdrawn||Phase 4|0|Actual|Samsung Medical Center||3||in order to prepare a new clinical trial to evaluate with pathological change|f||||t||||||||||2018-06-01 02:05:57.128983|2018-06-01 02:05:57.128983
NCT00687375|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-29|2008-05-29|2008-05-30|Estimate|||||||2008-05-29|2008-05-30|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|March 2009|Anticipated|2009-03-31|May 2008|Anticipated|2008-05-31||Interventional|||Laparoscopic Inguinal Hernia Repair- Transabdominal Preperitoneal (TAPP) Versus Totally Extra Peritoneal (TEP)|A Randomized Controlled Trial of Laparoscopic Inguinal Hernia Repair- Transabdominal Preperitoneal (TAPP) Versus Totally Extra Peritoneal (TEP) Approach|Unknown status|Recruiting|N/A|90|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 02:05:57.22498|2018-06-01 02:05:57.22498
NCT00680888|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2010-12-07|2008-05-16|2008-05-20|Estimate|||||||2010-12-07|2010-12-09|Estimate|August 2005||2005-08-31|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Adherence in Adolescents and Children Treated on Quetiapine|Adherence in Adolescents and Children Treated on Quetiapine|Completed|||30|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:07:57.065928|2018-06-01 02:07:57.065928
NCT00687362|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2010-02-17||2017-04-04|2008-05-27|2008-05-30|Estimate|2010-02-17|2010-03-09|Estimate||||2017-04-04|2017-05-10|Actual|May 30, 2006|Actual|2006-05-30|April 2017|2017-04-30|November 11, 2008|Actual|2008-11-11|November 11, 2008|Actual|2008-11-11||Interventional|||A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)|A Multicenter, Multinational, Open Label Study on the Efficacy and Safety of Infliximab Monotherapy in Moderate-to-severe Chronic Plaque Psoriasis in Middle Eastern Population|Completed||Phase 2|22|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:05:57.376985|2018-06-01 02:05:57.376985
NCT00687349|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2014-09-13|2008-05-28|2008-05-30|Estimate|||||||2014-09-13|2014-09-16|Estimate|April 2007||2007-04-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|ICCS||Improving Clinician Communication Skills (ICCS)|Improving Patient Outcomes in End-of-Life Care Provided by Physicians and Nurses|Completed||Phase 3|6086|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:05:57.502399|2018-06-01 02:05:57.502399
NCT00687336|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-07-07|2008-05-29|2008-05-30|Estimate|||||||2009-07-07|2009-07-08|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|HETUB||Helicobacter Pylori Empiric Treatment in Ulcer Bleeding|Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding|Unknown status|Recruiting|Phase 4|178|Anticipated|Hospital de Sabadell||2|||f||||f||||||||||2018-06-01 02:05:57.584107|2018-06-01 02:05:57.584107
NCT00687323|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2012-05-04||2017-05-15|2008-05-27|2008-05-30|Estimate|2012-06-13|2012-07-18|Estimate||||2017-05-15|2017-06-07|Actual|July 30, 2007|Actual|2007-07-30|May 2017|2017-05-31|December 23, 2012|Actual|2012-12-23|May 9, 2011|Actual|2011-05-09||Interventional|TALL||Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)|Phase II Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Subjects Unsuitable for Standard Induction Therapy Exhibiting Low MGMT Expression|Completed||Phase 2|47|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:05:57.679902|2018-06-01 02:05:57.679902
NCT00687310|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2011-01-21|2008-05-29|2008-05-30|Estimate|||||||2011-01-21|2011-01-24|Estimate|December 2005||2005-12-31|January 2011|2011-01-31|January 2007|Actual|2007-01-31|||||Interventional|||Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial|Does Tailored Education in Asthma Care Help Improve Patient Satisfaction, Adherence, and Quality of Life (TEACH) Trial|Completed||Phase 4|160|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:05:58.012167|2018-06-01 02:05:58.012167
NCT00687297|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2012-06-06||2018-04-30|2008-05-27|2008-05-30|Estimate|2012-06-06|2012-07-10|Estimate||||2018-04-30|2018-05-30|Actual|April 2008||2008-04-30|April 2018|2018-04-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer|A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination With Docetaxel and Carboplatin Followed by Placebo or Maintenance Therapy With Vandetanib in Patients With IIIb, IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|162|Actual|PrECOG, LLC.||2|||f||||t||||||||||2018-06-01 02:05:58.109827|2018-06-01 02:05:58.109827
NCT00687284|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2016-10-27|2008-05-27|2008-05-30|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|START||Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus|Observational Study on Evaluation of Glycaemic Control in Patients Using Levemir® (Insulin Detemir) as Initiation Insulin Therapy by Levemir® (Insulin Detemir) Administered Once Daily as the Treatment for Type 2 Diabetes Mellitus.|Completed|||2188|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:05:59.714068|2018-06-01 02:05:59.714068
NCT00687271|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2015-09-25|2008-05-29|2008-05-30|Estimate|||||||2015-09-25|2015-09-29|Estimate|June 2008||2008-06-30|September 2015|2015-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study of MK6213 Co-Administered With Atorvastatin in Patients With Hypercholesterolemia (MK-6213-006)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy, and Tolerability of MK6213 Co-Administered With Atorvastatin in Patients With Primary Hypercholesterolemia|Completed||Phase 2|330|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 02:05:59.78782|2018-06-01 02:05:59.78782
NCT00687258|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2012-04-10|2008-05-29|2008-05-30|Estimate|||||||2012-04-10|2012-04-11|Estimate|July 2006||2006-07-31|April 2012|2012-04-30|July 2007|Actual|2007-07-31|March 2007|Actual|2007-03-31||Interventional|Vi-E||Evaluation Of A New Vitamin E-Bonded Membrane On Anemia And Oxidative Stress In End-Stage Renal Disease Patients|Evaluation Of The Impact Of A New Synthetic Vitamin E-Bonded Membrane On The Anemia And Oxidative Stress In End-Stage Renal Disease (ESRD) Patients|Completed||Phase 2|20|Actual|A. Manzoni Hospital||2|||f||||t||||||||||2018-06-01 02:05:59.864137|2018-06-01 02:05:59.864137
NCT00687245|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-06-10|2008-05-29|2008-05-30|Estimate|||||||2008-06-10|2008-06-11|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)|A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)|Completed||Phase 1|40|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:05:59.948861|2018-06-01 02:05:59.948861
NCT00687232|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-11-30|2008-05-29|2008-05-30|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers|A Randomised, Placebo-controlled Single-blind, Single-centre Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers|Completed||Phase 1|30|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:06:00.024364|2018-06-01 02:06:00.024364
NCT00687050|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2010-05-25|2008-05-29|2008-05-30|Estimate|||||||2010-05-25|2010-05-26|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|September 2009|Actual|2009-09-30||Interventional|||Peroral Supplemental Nutrition in End-stage Renal Disease With and Without HIV Comorbidity|MRT-based Pilot Study to Evaluate Peroral Supplemental Nutrition for Prevention of Cachexia in End-stage Renal Disease With and Without HIV Comorbidity|Completed||N/A|30|Anticipated|Johann Wolfgang Goethe University Hospital||3|||f||||f||||||||||2018-06-01 02:06:04.629824|2018-06-01 02:06:04.629824
NCT00687219|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-10-27||2017-03-09|2008-05-29|2008-05-30|Estimate|2011-10-27|2011-12-02|Estimate||||2017-03-09|2017-04-07|Actual|June 2007||2007-06-30|March 2017|2017-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)|Treatment of Patients With Compensated Liver Cirrhosis With SCH 54031 + Ribavirin|Completed||Phase 3|102|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:00.215816|2018-06-01 02:06:00.215816
NCT00687206|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-01-28|2008-05-29|2008-05-30|Estimate|||||||2009-01-28|2009-01-29|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Patients With Slight Hypertension and Target Organ Damage|Efficacy and Safety of Valsartan 160 mg Plus Hydrochlorothiazide 25 mg Once a Day in Patients With Slight Hypertension and Target Organ Damage|Completed||Phase 4|20|Anticipated|Federico II University||1|||f||||t||||||||||2018-06-01 02:06:00.480856|2018-06-01 02:06:00.480856
NCT00687193|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2012-11-26|2010-11-19|2013-03-19|2008-05-23|2008-05-30|Estimate|2012-11-26|2012-12-25|Estimate|2010-11-19|2010-11-29|Estimate|2013-03-19|2013-03-25|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD|Completed||Phase 2|318|Actual|Pfizer||6|||f||||t||||||||||2018-06-01 02:06:00.641203|2018-06-01 02:06:00.641203
NCT00687180|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2008-05-29|2008-05-29|2008-05-30|Estimate|||||||2008-05-29|2008-05-30|Estimate||||May 2008|2008-05-31||||||||Interventional|||Mycophenolate vs Azathioprin in Autoimmune Hepatitis||Completed||Phase 4|||Rigshospitalet, Denmark||2|||f||||||||||||||2018-06-01 02:06:02.584855|2018-06-01 02:06:02.584855
NCT00687167|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-11-24||2010-01-11|2008-05-27|2008-05-30|Estimate|2009-11-24|2009-12-30|Estimate||||2010-01-11|2010-01-26|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Fed Bioavailability Study of Zonisamide Capsules|A Relative Bioavailability Study of 100 mg Zonisamide Capsules Under Non-Fasting Conditions|Completed||Phase 1|34|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:02.674218|2018-06-01 02:06:02.674218
NCT00687154|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2016-08-25|2008-05-28|2008-05-30|Estimate|||||||2016-08-25|2016-08-26|Estimate|September 2005||2005-09-30|August 2016|2016-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|PRP||Observational Study of DME Following Scatter Laser Photocoagulation|An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation|Completed||N/A|155|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 02:06:02.951459|2018-06-01 02:06:02.951459
NCT00687141|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2010-12-08|2008-05-29|2008-05-30|Estimate|||||||2010-12-08|2010-12-10|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects|A Phase I, Randomized, Double-blind (with-in Panel), Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Healthy Elderly Volunteers After Oral Multiple Ascending Doses of AZD0328|Completed||Phase 1|112|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:06:03.05376|2018-06-01 02:06:03.05376
NCT00687128|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2012-02-24|2008-05-29|2008-05-30|Estimate|||||||2012-02-24|2012-02-28|Estimate|October 2004||2004-10-31|February 2012|2012-02-29|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||Exercise Dose-Response on Features of the Metabolic Syndrome|Dose-Response Effects of Aerobic Exercise on Insulin Sensitivity and the Metabolic Syndrome|Completed||N/A|93|Actual|Charles Drew University of Medicine and Science||3|||f||||t||||||||||2018-06-01 02:06:03.156286|2018-06-01 02:06:03.156286
NCT00687115|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2018-02-03|2008-05-29|2008-05-30|Estimate|||||||2018-02-03|2018-02-06|Actual|May 16, 2008||2008-05-16|January 26, 2018|2018-01-26|March 31, 2020|Anticipated|2020-03-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting|Predicting Adaptive Thermogenesis|Recruiting||Phase 2|140|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:06:03.25799|2018-06-01 02:06:03.25799
NCT00687102|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2017-08-04||2018-04-10|2008-05-28|2008-05-30|Estimate|2017-12-20|2018-01-23|Actual||||2018-04-10|2018-04-12|Actual|October 2001||2001-10-31|April 2018|2018-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Co-STAR||Cognition in the Study of Tamoxifen and Raloxifene|Effects of Selective Estrogen Receptor Modulators on Cognitive Aging: Cognition in the Study of Tamoxifen and Raloxifene|Completed||Phase 3|1498|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f|||f|||No||2018-06-01 02:06:03.401694|2018-06-01 02:06:03.401694
NCT00687089|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-01-25|2008-05-29|2008-05-30|Estimate|||||||2009-01-25|2009-01-27|Estimate|June 2008||2008-06-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Examination of Cognitive Function in Patients Treated With Subutex|Examination of Cognitive Function, Weight, Sexual Function in Patients Receiving Treatment With Subutex at 3 Months Without Using Opiates|Completed|||60|Anticipated|BeerYaakov Mental Health Center|||1||f||||t||||||||||2018-06-01 02:06:04.093315|2018-06-01 02:06:04.093315
NCT00687076|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2014-07-16||2014-08-07|2008-05-28|2008-05-30|Estimate|2014-08-07|2014-08-25|Estimate||||2014-08-07|2014-08-25|Estimate|April 2004||2004-04-30|August 2014|2014-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Baseline characteristics were compared using analysis of variance, chi-square tests. Multilevel statistical models were used to analyze the primary outcome. Complete baseline characteristics were availabe for 95 patients. Between randomization and baseline visit, 1 patient withdrew from study, and 6 patients declined blood collection.|Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)|"Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention (The ELIMIT Trial)"|Completed||Phase 4|102|Actual|Baylor College of Medicine|MRI was performed in the distal SFA. Ethnicity which was not part of the randomization protocol differed significantly between mono- and triple-therapy groups. The attrition rate was high in ELIMIT. ELIMIT was not powered to assess clinical outcomes.|2|||f||||t||||||||||2018-06-01 02:06:04.180909|2018-06-01 02:06:04.180909
NCT00687063|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2014-08-13|2008-05-27|2008-05-30|Estimate|||||||2014-08-13|2014-08-15|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|DIABESITY||Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes|An Observational, Safety and Efficacy Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus.|Completed|||10008|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:06:04.533411|2018-06-01 02:06:04.533411
NCT00687037|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-02-12|2008-05-29|2008-05-30|Estimate|||||||2009-02-12|2009-02-13|Estimate|January 2008||2008-01-31|February 2009|2009-02-28||||February 2008|Actual|2008-02-29||Interventional|||Safety Oral Mucosa Evaluation - Acceptability With Odontological Follow up - Cepacol Canela Power|Uni Centric Study, Phase III, for Safety Oral Mucosa Evaluation: Basic Acceptability With Odontological Follow up - Cepacol Canela Power|Completed||Phase 3|30|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:06:04.744778|2018-06-01 02:06:04.744778
NCT00687024|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2013-09-04|2008-05-26|2008-05-30|Estimate|||||||2013-09-04|2013-09-05|Estimate|May 2007||2007-05-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|FCP||Determining the Extent of Diffusion Tensor Abnormalities in Focal Cortical Dysplasia|Determining the Extent of Diffusion Tensor Abnormalities in Focal Cortical Dysplasia|Completed|||12|Actual|The Hospital for Sick Children|||||f||||f||||||||||2018-06-01 02:06:04.80829|2018-06-01 02:06:04.80829
NCT00687011|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2017-05-12|2008-05-29|2008-05-30|Estimate|||||||2017-05-12|2017-05-15|Actual|October 10, 2006|Actual|2006-10-10|May 2017|2017-05-31|October 27, 2008|Actual|2008-10-27|October 27, 2008|Actual|2008-10-27||Interventional|||Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)|Open-label Clinical Trial to Assess the Efficacy, Tolerability and Safety of a Single IV Dose of Palonosetron 0.25 mg + Dexamethasone IV in the Prevention of Moderately Emetogenic Chemotherapy-induced Nausea and Vomit (CINV).|Completed||Phase 4|118|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:04.876974|2018-06-01 02:06:04.876974
NCT00686998|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2010-04-28||2013-03-20|2008-05-28|2008-05-30|Estimate|2011-05-31|2011-06-23|Estimate||||2013-03-20|2013-03-29|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Phase IIA Study in Patients With Schizophrenia|A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD2624 in Adult Schizophrenia Patients|Completed||Phase 2|106|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:06:04.96779|2018-06-01 02:06:04.96779
NCT00686985|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-05-29|2008-05-29|2008-05-30|Estimate|||||||2008-05-29|2008-05-30|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|July 2010|Anticipated|2010-07-31|||||Interventional|DOCAR||Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer|A Phase II Study of Docetaxel - Carboplatin as Second Line Treatment in Patients With Refractory or Relapsed Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|55|Anticipated|Jeroen Bosch Ziekenhuis||1|||f||||f||||||||||2018-06-01 02:06:05.238959|2018-06-01 02:06:05.238959
NCT00686972|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2017-05-01||2017-06-01|2008-05-27|2008-05-30|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|May 2007|Actual|2007-05-31|June 2017|2017-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition|The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition|Terminated||Phase 2|51|Actual|Johns Hopkins University||1||PI left JHU|f||||f||||||||||2018-06-01 02:06:05.339619|2018-06-01 02:06:05.339619
NCT00686959|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2015-10-22||2016-05-20|2008-05-28|2008-05-30|Estimate|2015-10-22|2015-11-26|Estimate||||2016-05-20|2016-06-28|Estimate|September 2008||2008-09-30|May 2016|2016-05-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|PROCLAIM|All randomized participants|Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer|Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology|Completed||Phase 3|598|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:06:05.580612|2018-06-01 02:06:05.580612
NCT00686946|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2018-03-12|2008-05-29|2008-05-30|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2005|Actual|2005-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|NRAMP||The National Register of Antipsychotic Medication in Pregnancy (NRAMP)|The National Register of Antipsychotic Medication in Pregnancy (NRAMP)|Recruiting|||500|Anticipated|The Alfred|||1||f||||f||||||||Yes|Individual participant data will be shared, for example, in Case Studies, where personal identification is not compromised, which also allows for an aggregate view of data.|2018-06-01 02:06:07.111876|2018-06-01 02:06:07.111876
NCT00686933|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28||2011-08-19|2013-01-11|2008-05-28|2008-05-30|Estimate||||2011-08-19|2011-08-23|Estimate|2013-01-11|2013-01-21|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Study M10-346|Completed||Phase 2|117|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 02:06:07.200723|2018-06-01 02:06:07.200723
NCT00686920|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2011-02-02|2008-05-27|2008-05-30|Estimate|||||||2011-02-02|2011-02-03|Estimate|March 2007||2007-03-31|February 2011|2011-02-28||||December 2010|Actual|2010-12-31||Interventional|||Safety Study for Patients With a History of Hepatic Encephalopathy||Completed||Phase 3|500|Anticipated|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 02:06:07.303228|2018-06-01 02:06:07.303228
NCT00686907|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2012-10-23|2008-05-28|2008-05-30|Estimate|||||||2012-10-23|2012-10-24|Estimate|March 2007||2007-03-31|October 2012|2012-10-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Blind Adult Melatonin Treatment Study|Melatonin for Circadian Sleep Disorders in the Blind|Unknown status|Active, not recruiting|N/A|200|Anticipated|National Eye Institute (NEI)||1|||f||||t||||||||||2018-06-01 02:06:07.433301|2018-06-01 02:06:07.433301
NCT00686894|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2009-11-24||2017-01-31|2008-05-27|2008-05-30|Estimate|2010-02-18|2010-03-05|Estimate||||2017-01-31|2017-03-13|Actual|January 2008||2008-01-31|January 2017|2017-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|EUSpA||Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)|Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab|Terminated||Phase 4|7|Actual|Merck Sharp & Dohme Corp.||1||Poor Enrollment|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:07.514163|2018-06-01 02:06:07.514163
NCT00686569|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2014-08-03|2008-05-29|2008-05-30|Estimate|||||||2014-08-03|2014-08-05|Estimate|April 2007||2007-04-30|August 2014|2014-08-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Observational|||Mediastinal Microdialysis in Patients With Oesophageal or Cardia Cancer Treated by Resection|Mediastinal Microdialysis in Early Diagnosis of Anastomotic Leakage After Resection for Esophageal Cancer: Preliminary Results|Completed|||40|Actual|Odense University Hospital|||||f||||f||||||||||2018-06-01 02:06:12.665326|2018-06-01 02:06:12.665326
NCT00686881|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2012-02-03||2017-03-08|2008-05-29|2008-05-30|Estimate|2012-02-03|2012-03-06|Estimate||||2017-03-08|2017-04-06|Actual|December 2006||2006-12-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)|A Clinical Study of SCH 54031 as Monotherapy in IFN-treated Patients With Chronic Hepatitis C|Terminated||Phase 3|261|Actual|Merck Sharp & Dohme Corp.|This study was prematurely discontinued because of low enrollment.|2||This study was terminated due to low enrollment|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:07.692487|2018-06-01 02:06:07.692487
NCT00686868|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2017-06-23|2008-05-28|2008-05-30|Estimate|||||||2017-06-23|2017-06-26|Actual|June 13, 2008|Actual|2008-06-13|June 2017|2017-06-30|May 2, 2011|Actual|2011-05-02|March 11, 2011|Actual|2011-03-11||Interventional|||Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients|Clinical Phase I/IIA Study of Subcutaneously Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate|Completed||Phase 1|35|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 02:06:08.181521|2018-06-01 02:06:08.181521
NCT00686855|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2013-11-20||2014-02-24|2008-05-27|2008-05-30|Estimate|2014-01-05|2014-02-19|Estimate||||2014-02-24|2014-03-20|Estimate|August 2008||2008-08-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease|An Open Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease|Completed||Phase 2|46|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 02:06:08.27623|2018-06-01 02:06:08.27623
NCT00686842|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|2012-01-30||2018-02-05|2008-05-29|2008-05-30|Estimate|2012-01-30|2012-03-05|Estimate||||2018-02-05|2018-03-06|Actual|September 2008||2008-09-30|January 2018|2018-01-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma|A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma|Terminated||Phase 1/Phase 2|17|Actual|AIDS Malignancy Consortium||1||Drug supply unavailable.|f||||f||||||||||2018-06-01 02:06:08.51769|2018-06-01 02:06:08.51769
NCT00686829|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2015-02-20|2008-05-29|2008-05-30|Estimate|||||||2015-02-20|2015-02-23|Estimate|June 2005||2005-06-30|February 2015|2015-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Study P04100AM4)(COMPLETED)|Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Protocol No. P04100)|Completed||Phase 2|79|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:06:08.73638|2018-06-01 02:06:08.73638
NCT00686816|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-10-15|2008-05-29|2008-05-30|Estimate|||||||2009-10-15|2009-10-16|Estimate|July 2008||2008-07-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Weight Loss in Pre-diabetic, Obese Women|A Study Among Pre-diabetic, Obese Women to Evaluate the Weight Loss Effects of a Non-Digestible Fat Substitute|Completed||Phase 2|80|Actual|Procter and Gamble||2|||f||||f||||||||||2018-06-01 02:06:08.797865|2018-06-01 02:06:08.797865
NCT00686803|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-08-24||2013-07-08|2008-05-29|2008-05-30|Estimate|2013-05-13|2013-06-21|Estimate||||2013-07-08|2013-07-19|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension|A Single-Center, Single-Dose, Placebo-Controlled, Randomized, Double-Blind, Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension|Completed||Phase 2|21|Actual|Palatin Technologies||6|||f||||f||||||||||2018-06-01 02:06:08.945001|2018-06-01 02:06:08.945001
NCT00686790|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2010-12-21||2017-03-08|2008-05-29|2008-05-30|Estimate|2010-12-21|2011-01-17|Estimate||||2017-03-08|2017-04-06|Actual|December 2005||2005-12-31|March 2017|2017-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)|An Open Label, Uncontrolled, Study to Assess the Response of Peg-Intron in naïve Patients With Chronic Hepatitis B and D Co-infection|Completed||Phase 3|68|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:09.30272|2018-06-01 02:06:09.30272
NCT00686777|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-12-12||2017-03-09|2008-05-29|2008-05-30|Estimate|2011-12-12|2012-01-18|Estimate||||2017-03-09|2017-04-07|Actual|January 2008||2008-01-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)|Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight|Completed||Phase 4|75|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:09.550471|2018-06-01 02:06:09.550471
NCT00686764|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2015-12-10|2008-05-27|2008-05-30|Estimate|||||||2015-12-10|2015-12-14|Estimate|May 2008||2008-05-31|December 2015|2015-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above-Knee Amputees|Evaluation of Ultrasonic Neuroma Size With Residual Limb Pain in Above Knee Amputees|Completed|||7|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-06-01 02:06:09.832694|2018-06-01 02:06:09.832694
NCT00686751|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-05-12|2008-05-29|2008-05-30|Estimate|||||||2009-05-12|2009-05-13|Estimate|December 2004||2004-12-31|May 2009|2009-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Immune Effects of Vitamin D in Hemodialysis Patients|Immunomodulatory Effects of Vitamin D in Chronic Hemodialysis Patients|Completed||Phase 2|20|Actual|Renal Research Institute||1|||f||||t||||||||||2018-06-01 02:06:09.903855|2018-06-01 02:06:09.903855
NCT00686738|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2016-03-22|2008-05-29|2008-05-30|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2007||2007-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2012|Actual|2012-11-30||Observational|||Development of Indices Predicting Response to Pre-operative Chemotherapy in Osteosarcoma Patients|Validity Verification of Indices Utilizing TGF-b1, NF-kB, PET/CT, and MRS Predicting Response to Neoadjuvant Chemotherapy in Osteosarcoma Patients|Completed|||20|Actual|National Cancer Center, Korea|||1||f||||t||||||Samples Without DNA|"~     NF-kB expression status will be determined on initial biopsy and surgically removed tumor~     specimen.~   "|||2018-06-01 02:06:10.001711|2018-06-01 02:06:10.001711
NCT00686725|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2013-02-25|2012-09-28|2017-05-18|2008-05-29|2008-05-30|Estimate|2013-02-25|2013-04-04|Estimate|2012-09-28|2012-10-04|Estimate|2017-05-18|2017-06-14|Actual|June 24, 2008|Actual|2008-06-24|May 2017|2017-05-31|September 28, 2011|Actual|2011-09-28|September 28, 2011|Actual|2011-09-28||Interventional|||Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)|A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)|Completed||Phase 4|99|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:10.09999|2018-06-01 02:06:10.09999
NCT00686712|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2010-09-15||2017-04-18|2008-05-29|2008-05-30|Estimate|2010-09-15|2010-10-07|Estimate||||2017-04-18|2017-05-22|Actual|February 2003||2003-02-28|April 2017|2017-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Insulin Glargine at Bedtime or in AM Versus NPH|The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy|Completed||Phase 4|108|Actual|Charles Drew University of Medicine and Science|Early termination leading to smaller than anticipated enrollment.|3|||f||||t||||||||No||2018-06-01 02:06:10.532808|2018-06-01 02:06:10.532808
NCT00686699|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2016-03-10|2009-04-13|2017-06-02|2008-05-29|2008-05-30|Estimate|2016-10-13|2016-12-07|Estimate|2009-10-16|2009-10-20|Estimate|2017-06-02|2017-07-02|Actual|July 10, 2006|Actual|2006-07-10|June 2017|2017-06-30|March 6, 2008|Actual|2008-03-06|March 6, 2008|Actual|2008-03-06||Interventional|||Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)|A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders|Terminated||Phase 2|11|Actual|Merck Sharp & Dohme Corp.|This study was terminated due to low enrollment.|2||The study was terminated after 9 participants completed due to lack of enrollment for 6 months.|f||||f||||||||||2018-06-01 02:06:11.01018|2018-06-01 02:06:11.01018
NCT00686686|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-01-27||2017-03-13|2008-05-27|2008-05-30|Estimate|2011-01-27|2011-02-23|Estimate||||2017-03-13|2017-04-11|Actual|December 2007||2007-12-31|March 2017|2017-03-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|TIPS||Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)|A Multi Center, Open Label, Single-Arm Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP), Including the Pustular Form (PsPPP)|Completed||Phase 3|23|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:11.382055|2018-06-01 02:06:11.382055
NCT00686673|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2011-02-14|2008-05-29|2008-05-30|Estimate|||||||2011-02-14|2011-02-15|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|June 2008|Actual|2008-06-30||Interventional|||Effect of a Decision Aid on Decision Making for Family Member's Disclosure of Terminal Illness|Effect of a Decision Aid on Decision Making for Family Member's Disclosure of Terminal Illness to Patient With Terminal Cancer|Completed||N/A|440|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-06-01 02:06:11.531319|2018-06-01 02:06:11.531319
NCT00686660|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-06-13|2008-05-29|2008-05-30|Estimate|||||||2008-06-13|2008-06-17|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||A Multi-Center Study of Rehabilitation to Stable Chronic Obstructive Pulmonary Disease (COPD) Patients||Unknown status|Recruiting|N/A|300|Anticipated|Beijing Chao Yang Hospital||4|||f||||t||||||||||2018-06-01 02:06:11.608389|2018-06-01 02:06:11.608389
NCT00686647|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2011-06-17||2011-07-14|2008-05-29|2008-05-30|Estimate|2011-07-14|2011-08-10|Estimate||||2011-07-14|2011-08-10|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|January 2011|Actual|2011-01-31|April 2010|Actual|2010-04-30||Interventional|AGILITY||AngioSculpt® Coronary Bifurcation Study|AngioSculpt® Scoring Balloon Catheter Multi-Center Coronary Bifurcation Study|Completed||N/A|93|Actual|AngioScore, Inc.|||||f||||f||||||||||2018-06-01 02:06:11.683571|2018-06-01 02:06:11.683571
NCT00686634|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2012-02-24||2014-11-25|2008-05-29|2008-05-30|Estimate|2014-11-25|2014-11-26|Estimate||||2014-11-25|2014-11-26|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Sitagliptin in Combination With Metformin and Sulfonylurea|Sitagliptin in Combination Oral Agent Therapy for Type 2 Diabetes|Completed||Phase 4|108|Actual|Charles Drew University of Medicine and Science||1|||f||||t||||||||||2018-06-01 02:06:11.818715|2018-06-01 02:06:11.818715
NCT00686621|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2017-03-09|2008-05-27|2008-05-30|Estimate|||||||2017-03-09|2017-03-10|Actual|January 2007||2007-01-31|March 2017|2017-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)|Single Patient Emergency Treatment Use of Posaconazole in Invasive Fungal Infections|Completed||Phase 3|1|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:12.004022|2018-06-01 02:06:12.004022
NCT00686608|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2012-06-04|2008-05-28|2008-05-30|Estimate|||||||2012-06-04|2012-06-06|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients|Hypothalamic fMRI Response to Nutrients|Unknown status|Recruiting|N/A|50|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 02:06:12.129698|2018-06-01 02:06:12.129698
NCT00686595|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-01-27||2017-03-15|2008-05-27|2008-05-30|Estimate|2011-01-27|2011-02-24|Estimate||||2017-03-15|2017-04-12|Actual|October 2007||2007-10-31|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|TANGO||A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)|swiTching From etAnercept to iNfliximab in the Treatment of Moderate to Severe Psoriasis; a Multi-center, Open Label Trial evaluatinG the Efficacy, tOlerance and Safety (TANGO)|Completed||Phase 4|48|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:12.225335|2018-06-01 02:06:12.225335
NCT00686582|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2010-05-21|2008-05-29|2008-05-30|Estimate|||||||2010-05-21|2010-05-24|Estimate|August 2008||2008-08-31|May 2010|2010-05-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees|An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees|Completed||Phase 2|304|Actual|Bavarian Nordic||3|||f||||t||||||||||2018-06-01 02:06:12.573485|2018-06-01 02:06:12.573485
NCT00686556|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-29|||2017-12-03|2008-05-29|2008-05-30|Estimate|||||||2017-12-03|2017-12-05|Actual|August 2012|Actual|2012-08-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Total Marrow Irradiation for Refractory Acute Leukemia|Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord BloodTransplantation In Patients With Refractory Acute Leukemia|Completed||Phase 1|12|Actual|Masonic Cancer Center, University of Minnesota||5|||f||||t||||||||||2018-06-01 02:06:12.770142|2018-06-01 02:06:12.770142
NCT00686543|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2010-04-15||2017-03-09|2008-05-29|2008-05-30|Estimate|2010-04-15|2010-05-14|Estimate||||2017-03-09|2017-04-07|Actual|December 2007||2007-12-31|March 2017|2017-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)|A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection|Completed||Phase 4|75|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:12.944158|2018-06-01 02:06:12.944158
NCT00686530|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2013-12-02|2008-05-23|2008-05-30|Estimate|||||||2013-12-02|2013-12-03|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|February 2010|Anticipated|2010-02-28|August 2009|Anticipated|2009-08-31||Observational|||Comparison of Abnormal Cortical Development in Brain Malformations on Postmortem Imaging With Autopsy|Comparison of Abnormal Cortical Development in Brain Malformations on Postmortem Imaging With Autopsy|Withdrawn|||0|Actual|The Hospital for Sick Children|||1||f||||f||||||Samples With DNA|"~     Macroscopic examination of the fetus will be performed initially follwed by organ removal for~     tissue fixation for a period of two weeks.~   "|||2018-06-01 02:06:13.692358|2018-06-01 02:06:13.692358
NCT00686517|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-12-22||2017-03-08|2008-05-27|2008-05-30|Estimate|2011-12-22|2012-01-31|Estimate||||2017-03-08|2017-04-05|Actual|December 2003||2003-12-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)|An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-week Course of PEG-Interferon Alpha-2b Versus a 12-week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C|Completed||Phase 3|130|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:13.788353|2018-06-01 02:06:13.788353
NCT00686504|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2010-12-08|2008-05-28|2008-05-29|Estimate|||||||2010-12-08|2010-12-10|Estimate|April 2008||2008-04-30|August 2008|2008-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|PET||Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066|An Open Label, Non-randomized Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 After Oral Administration to Healthy Subjects|Completed||Phase 1|6|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:06:14.198986|2018-06-01 02:06:14.198986
NCT00686491|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2011-02-21|2008-05-28|2008-05-29|Estimate|||||||2011-02-21|2011-02-23|Estimate|June 2007||2007-06-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|cold air||Respiratory Health of Elite Athletes|Center of Excellence in CardioRespiratory Health of High-level Athletes: Evaluation of Long-term Effects of Training.|Completed|||133|Actual|Laval University|||5||f||||f||||||Samples With DNA|"~     Serum - plasma - sputum~   "|||2018-06-01 02:06:14.255089|2018-06-01 02:06:14.255089
NCT00686478|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2014-01-28|2008-05-28|2008-05-29|Estimate|||||||2014-01-28|2014-01-30|Estimate||||January 2014|2014-01-31||||||||Interventional|||Intron A for the Treatment of Hypertrophic Scar|A Double-blind Placebo Controlled Trial Using Subcutaneous Injections of Intron A for the Treatment of Hypertrophic Scar|Withdrawn||Phase 3|0|Actual|University of Alberta||2||The trial is not being done at this time|f||||f||||||||||2018-06-01 02:06:14.337758|2018-06-01 02:06:14.337758
NCT00686465|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2013-02-15|2008-05-23|2008-05-29|Estimate|||||||2013-02-15|2013-02-18|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Interventional|PETREC||Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study|Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study. PET in Recurrent Cancer(PETREC)|Completed||N/A|101|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||t||||||||||2018-06-01 02:06:14.416723|2018-06-01 02:06:14.416723
NCT00686452|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2008-12-18|2008-05-28|2008-05-29|Estimate|||||||2008-12-18|2008-12-22|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Observational|proto nage||Airway Dysfunction and Remodelling in Athletes Following Swimming Training in Chlorinated Pools|Airway Dysfunction and Remodelling in Athletes Following Swimming Training in Chlorinated Pools|Unknown status|Recruiting||100|Anticipated|Laval University|||7||f||||f||||||Samples With DNA|"~     Serum, plasma, bronchial biopsies~   "|||2018-06-01 02:06:14.503266|2018-06-01 02:06:14.503266
NCT00686439|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2012-06-12|2008-05-28|2008-05-29|Estimate|||||||2012-06-12|2012-06-14|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Adalimumab for Inflammatory Osteoarthritis|HUM 06-087: Proof of Concept Study : Adalimumab for the Treatment of Osteoarthritis|Completed||Phase 1/Phase 2|20|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 02:06:14.569492|2018-06-01 02:06:14.569492
NCT00686426|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-05-28|2008-05-28|2008-05-29|Estimate|||||||2008-05-28|2008-05-29|Estimate|November 2003||2003-11-30|May 2008|2008-05-31|July 2007|Actual|2007-07-31|February 2007|Actual|2007-02-28||Interventional|||Role of Dairy Products in Weight Maintenance|Role of Dairy Products in Weight Maintenance: Prevention of Weight Regain Following Weight Loss|Completed||N/A|338|Actual|University of Tennessee||2|||f||||f||||||||||2018-06-01 02:06:14.641281|2018-06-01 02:06:14.641281
NCT00686413|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2010-12-08|2008-05-28|2008-05-29|Estimate|||||||2010-12-08|2010-12-10|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|PET||Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects|An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (Non Nicotine Users)|Completed||Phase 1|9|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:06:14.719195|2018-06-01 02:06:14.719195
NCT00686244|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-03-11|2008-05-28|2008-05-29|Estimate|||||||2009-03-11|2009-03-12|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|SPRINT||IT-Based Training in Metabolic Syndrome|Effect of Personal and IT Based Training to Performance, Metabolic Profil and Quality of Life by Patients With Metabolic Syndrome|Completed||N/A|125|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-06-01 02:06:17.66765|2018-06-01 02:06:17.66765
NCT00686400|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2010-01-22|2008-05-28|2008-05-29|Estimate|||||||2010-01-22|2010-01-25|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|May 2011|Anticipated|2011-05-31|December 2010|Anticipated|2010-12-31||Observational|||A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia|A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia|Unknown status|Recruiting||360|Anticipated|Martin-Luther-Universität Halle-Wittenberg|||2||f||||f||||||Samples With DNA|"~     serum, CSF if patients agree to lumbar puncture all frozen and stored at -80 degree Celsius~     until analysis~   "|||2018-06-01 02:06:14.783154|2018-06-01 02:06:14.783154
NCT00686387|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2011-04-11|2008-05-28|2008-05-29|Estimate|||||||2011-04-11|2011-04-12|Estimate|May 2008||2008-05-31|April 2011|2011-04-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Establishment of a Brain and Spinal Tumor Tissue Bank|Establishment of a Brain and Spinal Tumor Tissue Bank and Clinical Data Repository for Identifying Molecular Markers of Clinical Outcome|Unknown status|Recruiting||70|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood, Fresh tissue~   "|||2018-06-01 02:06:14.856846|2018-06-01 02:06:14.856846
NCT00686374|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2018-03-20||2018-03-20|2008-05-27|2008-05-29|Estimate|2018-03-20|2018-04-20|Actual||||2018-03-20|2018-04-20|Actual|May 1, 2008||2008-05-01|March 2018|2018-03-31|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional||ITT Population: all participants who received ≥ 1 dose of adalimumab in Study M06-807 and also had ≥ 1 non-missing efficacy measurement during the study.|Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806|A Multi-center, Open-label Study of the Human Anti−TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Crohn's Disease Who Have Demonstrated a Clinical Response in the M06-806 Study|Completed||Phase 3|100|Actual|AbbVie||1|||f||||t|t|f||||||Undecided||2018-06-01 02:06:15.923198|2018-06-01 02:06:15.923198
NCT00686361|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2011-06-06|2008-05-28|2008-05-29|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Choline Nutrition in Children With Cystic Fibrosis (CF)|To Investigate Whether Choline Supplementation in Children With CF Will Correct Biochemical Markers of Choline Deficiency and Improve Plasma Indices of Methylation Capacity and Redox Status and Result in Decreased Pro-inflammatory Cytokines|Completed||N/A|34|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 02:06:16.620019|2018-06-01 02:06:16.620019
NCT00686348|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2016-05-27|2008-05-28|2008-05-29|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2008||2008-05-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|SODA||Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study|Somatuline® Depot (Lanreotide) Injection for Acromegaly (SODA): A Post-marketing Observational Study|Completed|||260|Actual|Ipsen|||||f||||f||||||Samples Without DNA|"~     Routine clinical laboratory assessments will be performed: GH and IGF-1~   "|||2018-06-01 02:06:16.689629|2018-06-01 02:06:16.689629
NCT00686335|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|2012-10-26||2012-11-27|2008-05-28|2008-05-29|Estimate|2012-11-27|2012-12-28|Estimate||||2012-11-27|2012-12-28|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|MONA||A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma|A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma|Completed||Phase 2|12|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|This was an explorative study to collect data for a subsequent controlled trial and therefore no hypothesis testing was performed. The size of the efficacy population (N=7) is too small to detect any statistically significant changes.|2|||f||||f||||||||||2018-06-01 02:06:16.77107|2018-06-01 02:06:16.77107
NCT00686322|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2011-09-13|2008-05-28|2008-05-29|Estimate|||||||2011-09-13|2011-09-15|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)|Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer|Completed||Phase 4|6|Actual|Taipei Veterans General Hospital, Taiwan||1|||f||||t||||||||||2018-06-01 02:06:16.980515|2018-06-01 02:06:16.980515
NCT00686309|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2009-08-15|2008-05-28|2008-05-29|Estimate|||||||2009-08-15|2009-08-18|Estimate|July 2010||2010-07-31|August 2009|2009-08-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Comparison of On-line and Off-line Measurements of Exhaled Nitric Oxide (NO)|Comparison of On-line and Off-line Measurements of Exhaled NO|Unknown status|Not yet recruiting||200|Anticipated|Ziv Hospital|||||f||||f||||||||||2018-06-01 02:06:17.068517|2018-06-01 02:06:17.068517
NCT00686296|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2015-03-16|2008-05-28|2008-05-29|Estimate|||||||2015-03-16|2015-03-17|Estimate|December 2008||2008-12-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Pilot Study Comparing Taliderm™ Dressing Versus Standard of Care for Open Incision and Drainage of Wounds|Pilot Study Comparing Taliderm™ Dressing Versus Standard of Care for Open Incision and Drainage of Wounds|Completed||N/A|56|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-06-01 02:06:17.126597|2018-06-01 02:06:17.126597
NCT00686283|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2014-05-19|2008-05-28|2008-05-29|Estimate|||||||2014-05-19|2014-05-20|Estimate|August 2007||2007-08-31|May 2014|2014-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Personalized Exercise for Adolescents With Diabetes|Personalized Exercise for Adolescents With Diabetes|Completed||Phase 1|39|Actual|University of Arizona||1|||f||||f||||||||||2018-06-01 02:06:17.196578|2018-06-01 02:06:17.196578
NCT00686270|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2011-06-22|2008-05-28|2008-05-29|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||A Long Term Safety Study of Apricitabine in HIV-infected Patients|A Phase 3, Open Label 96-week Extension Study of the Safety of Apricitabine in Treatment-experienced HIV-1 Infected Patients Who Have Completed Protocol AVX-301 or AVX-302 or Who Have Met the Criteria for Open-label Access to ATC Because of Virological Failure/Lack of Response|Withdrawn||Phase 3|0|Actual|Avexa||1||Study was withdrawn owing to Sponsor decision|f||||f||||||||||2018-06-01 02:06:17.272069|2018-06-01 02:06:17.272069
NCT00686257|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2012-05-30||2012-07-24|2008-05-28|2008-05-29|Estimate|2012-07-24|2012-08-27|Estimate||||2012-07-24|2012-08-27|Estimate|January 2003||2003-01-31|July 2012|2012-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure|Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure|Completed||Phase 4|60|Actual|Tufts Medical Center|Could not blind subjects or investigators|2|||f||||f||||||||||2018-06-01 02:06:17.356208|2018-06-01 02:06:17.356208
NCT00686049|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2017-02-27|2008-05-27|2008-05-29|Estimate|||||||2017-02-27|2017-02-28|Actual|May 2008||2008-05-31|February 2016|2016-02-29|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||HIV Treatment-Readiness Measure (HTRM) Validation|Validation of the HIV Treatment Readiness Measure (HTRM)|Completed|||200|Actual|University of North Carolina, Chapel Hill|||1||f||||t||||||||||2018-06-01 02:06:24.435235|2018-06-01 02:06:24.435235
NCT00686231|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2009-11-12||2013-07-17|2008-05-28|2008-05-29|Estimate|2010-06-23|2010-07-22|Estimate||||2013-07-17|2013-07-22|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Radial Artery Dilation Study: The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter|The Effect of Topical Administration of Nitroglycerin and Lidocaine Versus Lidocaine Alone of the Radial Artery Diameter|Completed||Phase 1|19|Actual|University of California, San Francisco|a|3|||f||||f||||||||||2018-06-01 02:06:17.784507|2018-06-01 02:06:17.784507
NCT00686218|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|||2014-08-14|2008-05-28|2008-05-29|Estimate|||||||2014-08-14|2014-08-15|Estimate|May 2008||2008-05-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|March 2013|Actual|2013-03-31||Interventional|||Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia|A Phase I Dose Escalation Study of LBH589 in Combination With Imatinib Mesylate for Patients With Chronic Myeloid Leukemia in Cytogenetic Remission With Residual Disease Detectable by Q-PCR|Completed||Phase 1|9|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:06:18.118722|2018-06-01 02:06:18.118722
NCT00686205|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2010-01-13||2011-12-16|2008-05-28|2008-05-29|Estimate|2010-06-04|2010-07-05|Estimate||||2011-12-16|2011-12-28|Estimate|August 2007||2007-08-31|December 2011|2011-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay||Completed||Phase 3|24111|Actual|Abbott Diagnostics Division||2|||f||||f||||||||||2018-06-01 02:06:18.240879|2018-06-01 02:06:18.240879
NCT00686192|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-07-21|2008-05-28|2008-05-29|Estimate|||||||2008-07-21|2008-07-22|Estimate|September 2001||2001-09-30|May 2008|2008-05-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Calcium and Lipid Metabolism|The Effects of Calcium Supplementation on Adipocyte Metabolism in Overweight Women|Completed||N/A|15|Actual|USDA, Western Human Nutrition Research Center|||||f||||f||||||||||2018-06-01 02:06:18.509874|2018-06-01 02:06:18.509874
NCT00686179|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-09-24|2008-05-28|2008-05-29|Estimate|||||||2008-09-24|2008-09-25|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|TQT||Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days|A Double-Blind, Randomised, Multicentre, Placebo-Controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days, Using Moxifloxacin as a Positive Control, in Healthy Male Volunteers, CYP2D6 Extensive and Poor Metabolisers.|Completed||Phase 1|75|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:06:18.594946|2018-06-01 02:06:18.594946
NCT00686166|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-28|2016-01-26||2018-04-18|2008-05-28|2008-05-29|Estimate|2016-01-26|2016-02-24|Estimate||||2018-04-18|2018-05-18|Actual|February 2009||2009-02-28|April 2018|2018-04-30|March 2018|Actual|2018-03-31|July 2014|Actual|2014-07-31||Interventional||Eligible patients who began protocol therapy.|S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer|A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-Operative Therapy of Rectal Cancer|Completed||Phase 2|83|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 02:06:18.777363|2018-06-01 02:06:18.777363
NCT00686140|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-10|||2016-07-10|2008-05-28|2008-05-29|Estimate|||||||2016-07-10|2016-07-12|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia|Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in First-Episode and Drug-naive Patients With Schizophrenia|Completed||N/A|200|Actual|Beijing HuiLongGuan Hospital||2|||f||||t||||||||||2018-06-01 02:06:20.105626|2018-06-01 02:06:20.105626
NCT00686127|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2014-02-14||2014-04-02|2008-05-28|2008-05-29|Estimate|2014-04-02|2014-05-01|Estimate||||2014-04-02|2014-05-01|Estimate|September 2003||2003-09-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2009|Actual|2009-12-31||Interventional|||Symptom Management After Breast Cancer Surgery|A Randomized, Double-Blind, Placebo-Controlled Trial (RDBPCT) of the Effectiveness of the Lidocaine Patch in the Management of Neuropathic Pain After Breast Cancer Surgery|Completed||Phase 4|21|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:06:20.198255|2018-06-01 02:06:20.198255
NCT00686114|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2014-04-28|2008-05-28|2008-05-29|Estimate|||||||2014-04-28|2014-04-29|Estimate|May 2008||2008-05-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer|Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial.|Unknown status|Recruiting|Phase 3|344|Anticipated|Wenzhou Medical University||4|||f||||t||||||||||2018-06-01 02:06:20.482874|2018-06-01 02:06:20.482874
NCT00686101|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2009-10-08|2008-05-28|2008-05-29|Estimate|||||||2009-10-08|2009-10-09|Estimate|December 2007||2007-12-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|SmokCess||Knowledge and Perception of Smoking Risks/Consequences|Knowledge and Perception of Smoking Risks/Consequences, Smoking Habits and Motivators for Smoking Cessation Among People With Schizophrenia|Completed|||200|Actual|University of Maryland|||2||f||||f||||||||||2018-06-01 02:06:20.582085|2018-06-01 02:06:20.582085
NCT00686088|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2009-10-27|2008-05-28|2008-05-29|Estimate|||||||2009-10-27|2009-10-29|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy|An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy|Completed||Phase 2|30|Anticipated|Sophiris Bio Corp|||||f||||f||||||||||2018-06-01 02:06:20.656178|2018-06-01 02:06:20.656178
NCT00686075|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2014-09-22||2014-09-22|2008-05-28|2008-05-29|Estimate|2014-09-22|2014-09-26|Estimate||||2014-09-22|2014-09-26|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Intent-to-treat (ITT) population included all randomized participants.|A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants|A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-old Children and in 2 Month-old Infants|Completed||Phase 1/Phase 2|1338|Actual|MedImmune LLC||10|||f||||f||||||||||2018-06-01 02:06:20.875179|2018-06-01 02:06:20.875179
NCT00686062|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-05-28|2008-05-28|2008-05-29|Estimate|||||||2008-05-28|2008-05-29|Estimate|April 2001||2001-04-30|May 2008|2008-05-31|April 2004|Actual|2004-04-30|April 2003|Actual|2003-04-30||Interventional|||Evaluation of a Decision Assisting Tool for Prenatal Testing|Adaptation and Implementation of a Prenatal Genetic Testing Decision-Assisting Tool for Clinical Use|Completed||N/A|494||University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:06:24.36626|2018-06-01 02:06:24.36626
NCT00686036|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-04-27||2016-10-27|2008-05-27|2008-05-29|Estimate|2011-04-27|2011-05-24|Estimate||||2016-10-27|2016-12-21|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|ZENITH||Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy|A Randomized, Double-blind, Multicentre, Phase II Controlled Trial Assessing ZACTIMATM (Vandetanib) Against Placebo in Prolonging the Off-treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy|Terminated||Phase 2|17|Actual|Sanofi|It was planned that approx 100 patients would be recruited over a period of approx 2 years, due to slow recruitment the study was terminated early. No statistical analyses was done and no conclusion can be drawn about the outcomes in this study.|2||Slow recruitment|f||||f||||||||||2018-06-01 02:06:24.534766|2018-06-01 02:06:24.534766
NCT00686023|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2008-05-28|2008-05-28|2008-05-29|Estimate|||||||2008-05-28|2008-05-29|Estimate|June 2008||2008-06-30|May 2008|2008-05-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Comparing Surgical Techniques for CRIF of Pertrochanteric Fractures|Comparing Surgical Techniques for CRIF of Pertrochanteric Fractures|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 02:06:24.881002|2018-06-01 02:06:24.881002
NCT00686010|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2008-05-28|2008-05-28|2008-05-29|Estimate|||||||2008-05-28|2008-05-29|Estimate|May 2000||2000-05-31|May 2008|2008-05-31|June 2001|Actual|2001-06-30|January 2001|Actual|2001-01-31||Interventional|||Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia|A 4-Weeks Treatment, Randomised, Double-Blind, Parallel-Group Study Evaluating The Efficacy and Safety of JTT-705 300 to 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia|Completed||Phase 2|198|Actual|Japan Tobacco Inc.||4|||f||||f||||||||||2018-06-01 02:06:24.965309|2018-06-01 02:06:24.965309
NCT00685997|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2013-07-02|2008-05-27|2008-05-29|Estimate|||||||2013-07-02|2013-07-03|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Observational|||Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas|Whole-body MR Imaging for Staging Malignant Lymphomas|Completed|||135|Actual|UMC Utrecht|||||f||||f||||||||||2018-06-01 02:06:25.028776|2018-06-01 02:06:25.028776
NCT00685984|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2011-10-27|2008-05-28|2008-05-29|Estimate|||||||2011-10-27|2011-10-28|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|PEFDIA||Peripheral Endothelial Function and Coronary Status in Asymptomatic Diabetic Patients|Peripheral Endothelial Function and Coronary Status in Asymptomatic Type 2 Diabetic Patients: Relations With Coronary Microcirculation Assessed With Trans-thoracic Echo-doppler|Completed|||173|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-06-01 02:06:25.108237|2018-06-01 02:06:25.108237
NCT00685971|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2014-11-20|2008-05-28|2008-05-29|Estimate|||||||2014-11-20|2014-11-21|Estimate|December 2008||2008-12-31|July 2011|2011-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Cholecalciferol for Vitamin D in Adult Cystic Fibrosis (CF) Patients|Randomized Placebo-Controlled Trial of Cholecalciferol for Vitamin D Deficiency in Adults With Cystic Fibrosis|Completed||N/A|200|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 02:06:25.189212|2018-06-01 02:06:25.189212
NCT00685958|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|||2009-10-01|2008-05-26|2008-05-29|Estimate|||||||2009-10-01|2009-10-02|Estimate|July 2006||2006-07-31|October 2009|2009-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery|Multicenter, Non-comparative, Open-label Study to Evaluate the Safety and Efficacy of Enoxaparin Sodium (RP54563) 20 mg Bid for 14 Days in Patients With Hip Fracture Surgery|Completed||Phase 3|54|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:06:25.428156|2018-06-01 02:06:25.428156
NCT00685945|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-08-25||2013-01-21|2008-05-28|2008-05-29|Estimate|2013-01-21|2013-02-25|Estimate||||2013-01-21|2013-02-25|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3|Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3|Completed||N/A|24|Actual|Vanderbilt University||4|||f||||t||||||||||2018-06-01 02:06:25.528295|2018-06-01 02:06:25.528295
NCT00685932|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|2013-06-17||2018-03-19|2008-05-28|2008-05-29|Estimate|2018-03-19|2018-04-18|Actual||||2018-03-19|2018-04-18|Actual|July 2008||2008-07-31|March 2018|2018-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Mobius® Post-cesarean Pain Randomized Control Trial|Mobius Pain Study: A Randomized Controlled Trial of Standard Versus Mobius® Retraction at Cesarean Delivery|Completed||N/A|154|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 02:06:25.809582|2018-06-01 02:06:25.809582
NCT00685919|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2018-03-26|2008-05-27|2008-05-29|Estimate|||||||2018-03-26|2018-03-27|Actual|May 2008||2008-05-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Peripheral Dopamine in Postural Tachycardia Syndrome|Kidney Dopamine Effects on Urinary Sodium Excretion in Postural Tachycardia Syndrome|Active, not recruiting||Phase 2/Phase 3|70|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 02:06:26.029814|2018-06-01 02:06:26.029814
NCT00685906|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2010-12-01|2008-05-28|2008-05-29|Estimate|||||||2010-12-01|2010-12-02|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||AZD6140 Oral Contraceptive Interaction Study|A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers|Completed||Phase 1|24|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:06:26.105598|2018-06-01 02:06:26.105598
NCT00685893|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2013-06-25|2008-05-27|2008-05-29|Estimate|||||||2013-06-25|2013-06-27|Estimate|June 2003||2003-06-30|June 2013|2013-06-30|October 2010|Actual|2010-10-31|March 2008|Actual|2008-03-31||Interventional|IPACC||Integrating Palliative and Critical Care (IPACC) Study|An ICU Intervention to Improve End-of-Life Care|Completed||Phase 3|3498|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:06:26.256647|2018-06-01 02:06:26.256647
NCT00685880|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-26|2012-07-27||2012-07-27|2008-05-28|2008-05-29|Estimate|2012-07-27|2012-08-30|Estimate||||2012-07-27|2012-08-30|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Prolotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis|Randomized, Double Blind Comparison Trial of Prolotherapy (Dextrose) Compared to Corticosteroid Injection for the Treatment of Symptomatic Thumb Carpo-metacarpal Joint Arthritis|Terminated||N/A|2|Actual|Mayo Clinic|Early termination due to low enrollment; no subject data was analyzed.|2||Unable to recruit adequate numbers of patients|f||||f||||||||||2018-06-01 02:06:26.361452|2018-06-01 02:06:26.361452
NCT00685191|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2009-11-06|2008-05-27|2008-05-28|Estimate|||||||2009-11-06|2009-11-09|Estimate|June 2008||2008-06-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain|HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain|Completed||Phase 4|15|Actual|Germans Trias i Pujol Hospital||1|||f||||f||||||||||2018-06-01 02:06:37.573745|2018-06-01 02:06:37.573745
NCT00685867|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|||2012-08-20|2008-05-28|2008-05-29|Estimate|||||||2012-08-20|2012-08-21|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MOSAR-04||Two Strategies for Methicillin-resistant Staphylococcus Aureus (MRSA) Infection Prevention in Surgical Patients|An Interventional Study to Evaluate the Impact of Two Innovative Strategies in Preventing Nosocomial MRSA Infection in Surgical Patients|Completed||N/A|126750|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 02:06:26.583946|2018-06-01 02:06:26.583946
NCT00685854|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|||2017-06-30|2008-05-24|2008-05-28|Estimate|||||||2017-06-30|2017-07-02|Actual|May 21, 2008||2008-05-21|March 24, 2011|2011-03-24|March 24, 2011|Actual|2011-03-24|March 24, 2011|Actual|2011-03-24||Interventional|||Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization (MACTEL 2)|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:06:26.674146|2018-06-01 02:06:26.674146
NCT00685841|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-11-01|2008-05-27|2008-05-28|Estimate|||||||2012-11-01|2012-11-02|Estimate|February 2002||2002-02-28|November 2012|2012-11-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|717|Actual|Sunovion||5|||f||||t||||||||||2018-06-01 02:06:26.762716|2018-06-01 02:06:26.762716
NCT00685828|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2014-07-03|2008-05-23|2008-05-28|Estimate|||||||2014-07-03|2014-07-04|Estimate|January 2001||2001-01-31|July 2014|2014-07-31||||February 2002|Actual|2002-02-28||Interventional|||Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor|Phase III Randomized, Intergroup, International Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117)|Unknown status|Active, not recruiting|Phase 3|946|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 02:06:26.916842|2018-06-01 02:06:26.916842
NCT00685815|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2017-05-09|2008-05-23|2008-05-28|Estimate|||||||2017-05-09|2017-05-11|Actual|November 2006||2006-11-30|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Intravenous Iron Metabolism in Restless Legs Syndrome|Intravenous Iron Metabolism in Restless Legs Syndrome|Completed||Phase 2|36|Actual|Luitpold Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:06:26.985825|2018-06-01 02:06:26.985825
NCT00685802|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-11-18||2009-11-18|2008-05-24|2008-05-28|Estimate|2009-11-18|2009-12-22|Estimate||||2009-11-18|2009-12-22|Estimate|June 2004||2004-06-30|November 2009|2009-11-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Fasted Bioavailability Study of Cilostazol Tablets, 50mg|A Comparative Bioavailability Study of Cilostazol Tablets, 50mg, Under Fasting Conditions|Completed||Phase 1|32|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:27.065027|2018-06-01 02:06:27.065027
NCT00685789|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2011-09-28|2008-05-27|2008-05-28|Estimate|||||||2011-09-28|2011-09-29|Estimate|October 2008||2008-10-31|June 2008|2008-06-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|ADAPT||Acupuncture With Deqi And Psychological Effects in Treatment of Bell's Palsy|Study of Effects of Deqi and Neuropsychological Factors on Acupuncture Effects in Treatment of Bell's Palsy|Completed||N/A|355|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-06-01 02:06:27.30854|2018-06-01 02:06:27.30854
NCT00685776|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2017-12-07|2008-05-27|2008-05-28|Estimate|||||||2017-12-07|2017-12-11|Actual|March 24, 2008|Actual|2008-03-24|December 2017|2017-12-31|November 23, 2017|Actual|2017-11-23|July 2, 2009|Actual|2009-07-02||Interventional|DEFINE||Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)|A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease|Completed||Phase 3|1623|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:06:27.405588|2018-06-01 02:06:27.405588
NCT00685763|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2014-05-23||2017-07-21|2008-05-27|2008-05-28|Estimate|2014-07-01|2014-07-03|Estimate||||2017-07-21|2017-08-24|Actual|March 2008||2008-03-31|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|October 2013|Actual|2013-10-31||Interventional|PC01|Unresectable Carcinoma of the Pancreas|Proton Therapy for Unresectable Cancer (CA) of Pancreas|A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas|Completed||N/A|13|Actual|University of Florida||1|||f||||t|f|f||||||Undecided||2018-06-01 02:06:27.515904|2018-06-01 02:06:27.515904
NCT00685750|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2017-03-02|2008-05-27|2008-05-28|Estimate|||||||2017-03-02|2017-03-03|Actual|April 2008||2008-04-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma|Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma|Terminated||N/A|219|Actual|GlaxoSmithKline||7||"Slow enrolment over the last 2 years with none in the past 1 year. No increase in the number of~   completed subjects for 1 year and no more ongoing study subjects"|f||||||||||||||2018-06-01 02:06:27.672028|2018-06-01 02:06:27.672028
NCT00685737|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2008-06-25|2008-05-23|2008-05-28|Estimate|||||||2008-06-25|2008-06-27|Estimate|December 2007||2007-12-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|PNAI-002||Safety of a Hypolipidemic Agent in Healthy Normal Volunteers|A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of 1-MNA, (A Hypolipidemic Agent) in Healthy Volunteers|Completed||Phase 1|20|Actual|Pharmena North America||3|||f||||f||||||||||2018-06-01 02:06:27.950771|2018-06-01 02:06:27.950771
NCT00685724|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2011-11-17|2008-05-23|2008-05-28|Estimate|||||||2011-11-17|2011-11-21|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SMART||A Pilot SMART Design for Pathological Gamblers|A Pilot SMART Design for Pathological Gamblers|Completed||Phase 2|66|Actual|UConn Health||3|||f||||f||||||||||2018-06-01 02:06:28.037851|2018-06-01 02:06:28.037851
NCT00685711|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-08-05|2008-05-23|2008-05-28|Estimate|||||||2008-08-05|2008-08-06|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety of Cat-PAD in Cat Allergic Subjects|An Escalating Single Intradermal or Subcutaneous Dose Study in Cat Allergic Subjects to Assess the Safety of Cat-PAD.|Completed||Phase 1/Phase 2|88|Actual|Circassia Limited||4|||f||||t||||||||||2018-06-01 02:06:28.111467|2018-06-01 02:06:28.111467
NCT00685178|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2017-04-17||2017-06-09|2008-05-27|2008-05-28|Estimate|2017-06-09|2017-07-11|Actual||||2017-06-09|2017-07-11|Actual|February 2007||2007-02-28|June 2017|2017-06-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Clinical Trial of Topiramate for Cocaine Addiction|Clinical Trial of Topiramate for Cocaine Addiction|Completed||Phase 2|250|Actual|Johns Hopkins University||4|||f||||t||||||||||2018-06-01 02:06:37.698879|2018-06-01 02:06:37.698879
NCT00685698|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2014-12-16||2014-12-25|2008-05-22|2008-05-28|Estimate|2014-12-25|2015-01-09|Estimate||||2014-12-25|2015-01-09|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional||The ITT population consists of all patients from the Enrolled population who took at least one whole dose of study medication (three capsules) and who exhibited at least one Gram-positive pathogen at Baseline (Visit 1) as confirmed by culture of wound tissue by the central (or local) laboratory.|Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections|An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens|Completed||Phase 2|40|Actual|TaiGen Biotechnology Co., Ltd.||1|||f||||f||||||||||2018-06-01 02:06:28.247412|2018-06-01 02:06:28.247412
NCT00685685|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-11-24||2010-01-11|2008-05-24|2008-05-28|Estimate|2009-11-24|2009-12-30|Estimate||||2010-01-11|2010-01-20|Estimate|September 2004||2004-09-30|January 2010|2010-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Fasting Bioavailability Study of Lovastatin Tablets and Mevacor Tablets|A Single Dose Crossover Comparative Bioavailability Study of Lovastatin 40mg Tablets in Healthy Male Volunteers/Fasting State|Completed||Phase 1|54|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:29.072069|2018-06-01 02:06:29.072069
NCT00685672|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2016-03-29|2008-05-23|2008-05-28|Estimate|||||||2016-03-29|2016-03-30|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety of Epidural Fentanyl and Adrenalin During Childbirth|Pharmacokinetic Interaction Effects of Combined Fentanyl and Adrenalin in Epidural Analgesia During Child Birth|Completed||Phase 4|40|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 02:06:29.339236|2018-06-01 02:06:29.339236
NCT00685659|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2016-02-15||2017-06-28|2008-05-23|2008-05-28|Estimate|2016-10-20|2016-12-14|Estimate||||2017-06-28|2017-08-07|Actual|May 2007||2007-05-31|June 2017|2017-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ETDD||Effectiveness of Extended Treatments for Drug Dependence|Effectiveness of Extended Treatments for Drug Dependence|Completed||N/A|332|Actual|University of Pennsylvania||3|||f||||f||||||||No||2018-06-01 02:06:29.458308|2018-06-01 02:06:29.458308
NCT00685646|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2015-10-15|2008-05-24|2008-05-28|Estimate|||||||2015-10-15|2015-10-16|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ZAPCA||Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases|A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease|Completed||Phase 3|227|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-06-01 02:06:30.293009|2018-06-01 02:06:30.293009
NCT00685633|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|||2013-08-16|2008-05-24|2008-05-28|Estimate|||||||2013-08-16|2013-08-20|Estimate|December 2008||2008-12-31|November 2008|2008-11-30||||June 2010|Anticipated|2010-06-30||Interventional|||Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer|Phase II, Randomized Study of Patients With Rising PSA at High-Risk of Progression After Primary Therapy to Assess the Clinical and Molecular Efficacy of the Enzastaurin - Bicalutamide Combination to Suppress the Androgen Receptor Without Testosterone Ablation|Withdrawn||Phase 2|0|Actual|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-06-01 02:06:30.367579|2018-06-01 02:06:30.367579
NCT00685620|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2017-01-10|2008-05-23|2008-05-28|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2002||2002-08-31|May 2008|2008-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|CASA||Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers|Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers|Completed||Phase 4|463|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||f||||||||||2018-06-01 02:06:30.429172|2018-06-01 02:06:30.429172
NCT00685607|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2011-10-04|2008-05-27|2008-05-28|Estimate|||||||2011-10-04|2011-10-06|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Determine the Best Way to Measure How Quickly the Drug Can Give Relief From Sudden Diarrhea|A Placebo-Controlled, Double-Blind, Randomized Pilot Study to Evaluate the Appropriateness of Multiple Endpoints in Measuring the Onset of Clinical Efficacy of Loperamide-Simethicone Caplets in the Treatment of Acute Non-specific Diarrhea|Completed||Phase 4|45|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 02:06:30.496982|2018-06-01 02:06:30.496982
NCT00685594|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2015-09-18|2008-05-27|2008-05-28|Estimate|||||||2015-09-18|2015-09-22|Estimate|March 2008||2008-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Vitamin D for the Prevention of Diabetes Type 2|Prevention of Type 2 Diabetes With Vitamin D Supplementation in Subjects With Reduced Glucose Tolerance Detected in the Tromso Study 2007/2008|Completed||Phase 2/Phase 3|511|Actual|University of Tromso||2|||f||||t||||||||||2018-06-01 02:06:30.569554|2018-06-01 02:06:30.569554
NCT00685581|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2009-03-13|2008-05-27|2008-05-28|Estimate|||||||2009-03-13|2009-03-16|Estimate|April 2007||2007-04-30|March 2009|2009-03-31|May 2008|Actual|2008-05-31|||||Interventional|TRANSQUAL WPC||Impact of Vaccenic Acid Consumption on the Metabolism of Saturated Fatty Acids: Relationship With Cardiovascular Risk Factors|Rationale, Study Design and Baseline Data of the TRANSQUAL Clinical Trial: A Study to Evaluate the Impact of Different Milk Fatty Acid Profiles on Cardiovascular Risk Factors in Healthy Volunteers; Focus on Trans Fatty Acids|Completed||N/A|107|Actual|Institut National de la Recherche Agronomique||3|||f||||t||||||||||2018-06-01 02:06:30.766199|2018-06-01 02:06:30.766199
NCT00685568|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-11-16|2008-05-23|2008-05-28|Estimate|||||||2012-11-16|2012-11-20|Estimate|December 2002||2002-12-31|November 2012|2012-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis|Phase I Pilot Toxicity/Methods Validation Study of Celecoxib in Genotype-Positive Children With Familial Adenomatous Polyposis|Completed||Phase 1|22|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:06:30.84415|2018-06-01 02:06:30.84415
NCT00685555|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2011-06-22|2008-05-27|2008-05-28|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2005||2005-10-31|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|SWITCH||Healthy Futures Project: A Community Based Obesity Prevention Program|SWITCH: Rationale, Design, and Implementation of a Community, School, and Family-based Intervention to Modify Behaviors Related to Childhood Obesity|Completed||Early Phase 1|1300|Actual|National Institute on Media and the Family|||||f||||f||||||||||2018-06-01 02:06:30.928534|2018-06-01 02:06:30.928534
NCT00685542|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|||2010-12-02|2008-05-27|2008-05-28|Estimate|||||||2010-12-02|2010-12-03|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Diacerein on Hand Osteoarthritis|Phase IV Study of Diacerein in Human Hand Osteoarthritis|Completed||Phase 4|86|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:06:31.021584|2018-06-01 02:06:31.021584
NCT00685529|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-27|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)|An Open-Label, Randomized, Multiple Dose, 3-Way Crossover Study of Arformoterol Tartrate Inhalation Solution and Foradil® (Racemic Formoterol) in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|24|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 02:06:31.106469|2018-06-01 02:06:31.106469
NCT00685516|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2016-02-18||2017-09-12|2008-05-23|2008-05-28|Estimate|2016-04-27|2016-06-06|Estimate||||2017-09-12|2017-10-13|Actual|September 1, 2007|Actual|2007-09-01|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|January 1, 2017|Actual|2017-01-01||Interventional||93 subjects completed the intervention (Arm I, GT: 34, Arm II, control: 33, Arm III, BT: 26).|Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery|Effects of Brewed Green and Black Tea on Inflammation, Apoptosis and Oxidation in Men With Prostate Cancer|Active, not recruiting||N/A|113|Actual|Jonsson Comprehensive Cancer Center||3|||f||||t||||||||||2018-06-01 02:06:31.216517|2018-06-01 02:06:31.216517
NCT00685503|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|||2017-06-30|2008-05-24|2008-05-28|Estimate|||||||2017-06-30|2017-07-02|Actual|May 21, 2008||2008-05-21|April 12, 2011|2011-04-12|April 12, 2011|Actual|2011-04-12|April 12, 2011|Actual|2011-04-12||Interventional|||Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization (MACTEL 1)|Completed||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:06:31.803756|2018-06-01 02:06:31.803756
NCT00685490|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-05-23|2008-05-23|2008-05-28|Estimate|||||||2008-05-23|2008-05-28|Estimate|July 1995||1995-07-31|May 2008|2008-05-31|November 2006|Actual|2006-11-30|||||Observational|||Vitrectomy for Branch Retinal Vein Occlusion|Vitrectomy for Persistent Macular Edema in Branch Retinal Vein Occlusion|Completed|||70|Actual|Shinjo Ophthalmologic Institute|||1||f||||t||||||||||2018-06-01 02:06:31.898172|2018-06-01 02:06:31.898172
NCT00685477|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2016-12-28||2016-12-28|2008-05-27|2008-05-28|Estimate|2016-12-28|2017-02-17|Actual||||2016-12-28|2017-02-17|Actual|May 2008||2008-05-31|December 2016|2016-12-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional||Each of the 60 subjects had 3 infusion studies at least 2 days apart.|Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying|Dose Response of Intravenous Sincalide (CCK-8) for Gallbladder Emptying|Completed||N/A|60|Actual|Temple University||6|||f||||f||||||||||2018-06-01 02:06:32.016195|2018-06-01 02:06:32.016195
NCT00685464|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2011-08-09|2008-05-27|2008-05-28|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Intravenous Versus Intracoronary Use of Abciximab|Intravenous vs. Intracoronary Use of Abciximab|Completed||N/A|355|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-06-01 02:06:32.290379|2018-06-01 02:06:32.290379
NCT00685451|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2011-09-28|2008-05-23|2008-05-28|Estimate|||||||2011-09-28|2011-09-29|Estimate|November 2004||2004-11-30|September 2011|2011-09-30|November 2006|Actual|2006-11-30|August 2006|Actual|2006-08-31||Interventional|||Cognitive Therapy for PTSD in Addiction Treatment|Cognitive Therapy for PTSD in Addiction Treatment|Completed||Phase 1/Phase 2|49|Actual|Dartmouth-Hitchcock Medical Center|||||f||||f||||||||||2018-06-01 02:06:32.382529|2018-06-01 02:06:32.382529
NCT00685438|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-05-27|2008-05-27|2008-05-28|Estimate|||||||2008-05-27|2008-05-28|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|June 2007|Actual|2007-06-30|||||Observational|||Ultraviolet Exposure, Antioxidant Use and Skin Erythema at Extreme High Altitude|Observational Study of Skin Erythema by Spectrophotometer, and UV Exposure With Viospore Ultraviolet Monitors at Extreme Altitude (Mt. Everest, North Side)|Completed|||25|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 02:06:32.461974|2018-06-01 02:06:32.461974
NCT00685425|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-23|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|October 2002||2002-10-31|February 2012|2012-02-29|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol|A Dose Response and PharmacoDynamic Study of Levalbuterol and Racemic Albuterol HFA MDI in Subjects Twelve Years of Age and Older With Asthma|Completed||Phase 3|62|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:06:32.542493|2018-06-01 02:06:32.542493
NCT00685412|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2017-09-11|2008-05-27|2008-05-28|Estimate|||||||2017-09-11|2017-09-13|Actual|May 2008||2008-05-31|September 2017|2017-09-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3|Phase I Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Post Surgical or Ablative Treatment of Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN)|Completed||Phase 1|18|Actual|Inovio Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:06:32.633129|2018-06-01 02:06:32.633129
NCT00685399|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2015-02-12||2017-06-15|2008-05-27|2008-05-28|Estimate|2017-06-15|2017-07-17|Actual||||2017-06-15|2017-07-17|Actual|June 2008||2008-06-30|June 2017|2017-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy of AIN457 in Noninfectious Uveitis|An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis|Completed||Phase 2|76|Actual|Novartis||8|||f||||f||||||||No||2018-06-01 02:06:32.789051|2018-06-01 02:06:32.789051
NCT00685386|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2013-01-22|2008-05-27|2008-05-28|Estimate|||||||2013-01-22|2013-01-24|Estimate|June 2008||2008-06-30|April 2011|2011-04-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP)|A Randomized, Controlled, Double-blind Trial of CO2 Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography|Completed||N/A|74|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:06:34.602279|2018-06-01 02:06:34.602279
NCT00685373|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-27|2011-04-25||2016-11-03|2008-05-27|2008-05-28|Estimate|2011-04-28|2011-05-27|Estimate||||2016-11-03|2016-11-04|Estimate|May 2008||2008-05-31|September 2016|2016-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease|An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease|Completed||Phase 3|166|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:06:34.708497|2018-06-01 02:06:34.708497
NCT00680875|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2011-10-13|2008-05-16|2008-05-20|Estimate|||||||2011-10-13|2011-10-14|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|Intranet||Intranet-based Tobacco Prevention Program for Children||Completed||N/A|3225|Anticipated|Oregon Research Institute||2|||f||||f||||||||||2018-06-01 02:07:58.169677|2018-06-01 02:07:58.169677
NCT00685360|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20||2011-05-06|2015-08-13|2008-05-23|2008-05-28|Estimate||||2011-05-24|2011-06-02|Estimate|2015-08-13|2015-08-27|Estimate|April 2008||2008-04-30|August 2015|2015-08-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)|A Multi Center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC 67683 in Patients With Pulmonary Sputum Culture-Positive, Multidrug-resistant Tuberculosis|Completed||Phase 2|481|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-06-01 02:06:34.97558|2018-06-01 02:06:34.97558
NCT00685347|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-23|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|January 2003||2003-01-31|February 2012|2012-02-29|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Dose Response Study of Levalbuterol in the Prevention of Exercise Induced Bronchoconstriction Compared to Racemic Albuterol in Pediatric Subjects|A Dose Response Study of Levalbuterol and Racemic Albuterol HFA MDI in Pediatric Subjects With Asthma|Completed||Phase 2|33|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:06:35.061731|2018-06-01 02:06:35.061731
NCT00685334|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2009-08-03||2013-09-25|2008-05-23|2008-05-28|Estimate|2010-01-15|2010-02-04|Estimate||||2013-09-25|2013-10-29|Estimate|November 2003||2003-11-30|September 2013|2013-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa|Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa|Completed||Phase 4|22|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 02:06:35.137077|2018-06-01 02:06:35.137077
NCT00685321|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-25|||2012-01-04|2008-05-27|2008-05-28|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Tolerability, Safety and Efficacy of the H1-coil Deep Transcranial Magnetic Stimulation in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia|A Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia|Unknown status|Recruiting|N/A|45|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-06-01 02:06:35.417604|2018-06-01 02:06:35.417604
NCT00685308|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2008-05-27|2008-05-27|2008-05-28|Estimate|||||||2008-05-27|2008-05-28|Estimate|December 2007||2007-12-31|May 2008|2008-05-31|October 2010|Anticipated|2010-10-31|October 2009|Anticipated|2009-10-31||Observational|WingspanSSIR||Wingspan Stenting for Symptomatic Severe Stenosis of Intracranial Atherosclerosis Registry in China|Wingspan Stenting for Symptomatic Severe Stenosis of Intracranial Atherosclerosis Registry in China|Unknown status|Recruiting||200|Anticipated|Ministry of Health, China|||||f||||t||||||||||2018-06-01 02:06:36.551487|2018-06-01 02:06:36.551487
NCT00685295|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2009-02-25||2016-12-17|2008-05-27|2008-05-28|Estimate|2016-12-17|2017-02-09|Estimate||||2016-12-17|2017-02-09|Estimate|August 2008||2008-08-31|December 2016|2016-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|FAIRTOP||Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain|Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain in the ED|Completed||Phase 1/Phase 2|60|Actual|Massachusetts General Hospital||2|||f||||t||||||||No|There is no plan to make individual participant data available to other researchers.|2018-06-01 02:06:36.631113|2018-06-01 02:06:36.631113
NCT00685282|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-25|||2013-02-11|2008-05-25|2008-05-28|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2008||2008-11-30|February 2013|2013-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Effect of Stress on DNA Integrity and the Effect of Cognitive Behavioral Therapy on Stress and Infertility in Women|The Effect of Stress on DNA Integrity and the Effect of Cognitive Behavioral Therapy on Stress and Infertility in Women Undergoing IVF Treatment.|Completed||N/A|70|Actual|Soroka University Medical Center||1|||f||||t||||||||||2018-06-01 02:06:36.85599|2018-06-01 02:06:36.85599
NCT00685269|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-27|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|August 2003||2003-08-31|February 2012|2012-02-29|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)|The Safety and Efficacy of Eszopiclone in Subjects With Mild to Moderate Obstructive Sleep Apnea Syndrome|Completed||Phase 2|20|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:06:36.924997|2018-06-01 02:06:36.924997
NCT00685256|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|||2017-05-16|2008-05-24|2008-05-28|Estimate|||||||2017-05-16|2017-05-17|Actual|March 2008||2008-03-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|February 2013|Actual|2013-02-28||Interventional|||Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children|Parent Communication Study II - Randomized Controlled Trial of Decision Support vs. Education for Parent Communication of BRCA 1/2 Cancer Genetic Test Results to Children|Completed||Phase 3|245|Actual|Georgetown University|||||f||||f||||||||||2018-06-01 02:06:37.014452|2018-06-01 02:06:37.014452
NCT00685243|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2008-05-27|2008-05-27|2008-05-28|Estimate|||||||2008-05-27|2008-05-28|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|July 2008|Anticipated|2008-07-31|June 2008|Anticipated|2008-06-30||Interventional|||Treatment of Surgical Scars With Fractional Photothemolysis Versus Pulse Dye Laser|Treatment of Surgical Scars With Fractional Photothemolysis Versus Pulse Dye Laser|Unknown status|Active, not recruiting|N/A|12|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-06-01 02:06:37.103717|2018-06-01 02:06:37.103717
NCT00685230|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2011-06-01|2008-05-27|2008-05-28|Estimate|||||||2011-06-01|2011-06-02|Estimate|May 2004||2004-05-31|June 2011|2011-06-30|October 2005|Actual|2005-10-31|August 2005|Actual|2005-08-31||Interventional|||Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients|Prospective, Randomized, Double-Blind, Controlled Study of Alacramyn® vs. Placebo in Pediatric Patients With Systemic Signs of Scorpion Sting Envenomation|Completed||Phase 2/Phase 3|15|Actual|Instituto Bioclon S.A. de C.V.||2|||f||||f||||||||||2018-06-01 02:06:37.266494|2018-06-01 02:06:37.266494
NCT00685217|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2016-08-29|2008-05-27|2008-05-28|Estimate|||||||2016-08-29|2016-08-31|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|||Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT)|Tension-free Vaginal Tape Management of Stress Incontinence in Women: Randomized Trial of TVT Secur Versus TVT|Terminated||Phase 3|74|Actual|University of Calgary||2||poor recruitment|f||||f||||||||Undecided|The decision to share would depend on the protocol of an IPD analysis protocol|2018-06-01 02:06:37.395516|2018-06-01 02:06:37.395516
NCT00685204|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2008-05-22|2008-05-22|2008-05-28|Estimate|||||||2008-05-22|2008-05-28|Estimate|March 2008||2008-03-31|May 2008|2008-05-31||||||||Interventional|TL139||An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma|A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma|Unknown status|Recruiting|Phase 2|90|Anticipated|Taxolog Inc.||1|||f||||t||||||||||2018-06-01 02:06:37.475847|2018-06-01 02:06:37.475847
NCT00685165|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-11-18||2009-12-16|2008-05-24|2008-05-28|Estimate|2009-12-16|2010-01-20|Estimate||||2009-12-16|2010-01-20|Estimate|May 2004||2004-05-31|November 2009|2009-11-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets|A Randomized, Two-Way, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Primidone 50 mg, Compared to an Equivalent Dose of Primidone (Mysoline®) in Healthy Adult Subjects|Completed||Phase 1|22|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:38.26972|2018-06-01 02:06:38.26972
NCT00685152|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2015-12-14|2008-05-27|2008-05-28|Estimate|||||||2015-12-14|2015-12-16|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)|High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Post-traumatic Stress Disorder (PTSD)|Completed||N/A|15|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:06:38.470844|2018-06-01 02:06:38.470844
NCT00685139|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-11-24||2010-01-11|2008-05-24|2008-05-28|Estimate|2009-11-24|2009-12-30|Estimate||||2010-01-11|2010-01-26|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Fasting Bioavailability Study of Zonisamide Capsules|A Relative Bioavailability Study of 100 mg Zonisamide Capsules Under Fasting Conditions|Completed||Phase 1|34|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:38.558774|2018-06-01 02:06:38.558774
NCT00685126|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-23|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|February 2001||2001-02-28|February 2012|2012-02-29|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)|A Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects Birth to 48 Months Old With Reactive Airways Disease in an Acute Setting|Completed||Phase 3|117|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 02:06:38.873606|2018-06-01 02:06:38.873606
NCT00685113|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23||2011-06-08|2016-07-18|2008-05-23|2008-05-28|Estimate||||2011-06-08|2011-06-22|Estimate|2016-07-18|2016-07-20|Estimate|May 2008||2008-05-31|July 2016|2016-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder|A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Doses of DR-3001 Versus Placebo in Women With Overactive Bladder|Completed||Phase 3|1104|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 02:06:39.023921|2018-06-01 02:06:39.023921
NCT00685100|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2015-04-14|2008-05-27|2008-05-28|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|January 2007|Actual|2007-01-31|January 2006|Actual|2006-01-31||Interventional|||Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone||Completed||Phase 3|40||Medical University of Vienna|||||f||||||||||||||2018-06-01 02:06:39.230056|2018-06-01 02:06:39.230056
NCT00685087|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2013-05-17|2008-05-27|2008-05-28|Estimate|||||||2013-05-17|2013-05-21|Estimate|September 2004||2004-09-30|May 2008|2008-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||A Prospective Study of Natural History of Pancreatitis|A Prospective Study of Natural History of Pancreatitis|Completed|||300|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 02:06:39.297051|2018-06-01 02:06:39.297051
NCT00685074|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2011-10-12|2008-05-23|2008-05-28|Estimate|||||||2011-10-12|2011-10-14|Estimate|September 2007||2007-09-30|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Computer-based Brief Intervention for Perinatal Substance Abuse|Computer-based Brief Intervention for Perinatal Drug, Alcohol, and Tobacco Abuse|Completed||Phase 1/Phase 2|143|Actual|Wayne State University||2|||f||||t||||||||||2018-06-01 02:06:39.349582|2018-06-01 02:06:39.349582
NCT00685061|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2008-05-27|2008-05-27|2008-05-28|Estimate|||||||2008-05-27|2008-05-28|Estimate|November 2002||2002-11-30|May 2008|2008-05-31|September 2005|Actual|2005-09-30|September 2004|Actual|2004-09-30||Interventional|||Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation|Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Cadaver Donor Renal Transplantation: A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy|Completed||Phase 4|90|Actual|University of Miami||3|||f||||t||||||||||2018-06-01 02:06:39.438905|2018-06-01 02:06:39.438905
NCT00685048|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2014-02-24|2008-05-23|2008-05-28|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2007||2007-07-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Brief Therapies for Problem Gambling Substance Abusers|Brief Therapies for Problem Gambling Substance Abusers|Completed||Phase 2|220|Actual|UConn Health||3|||f||||f||||||||||2018-06-01 02:06:39.517357|2018-06-01 02:06:39.517357
NCT00685035|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2012-12-18||2016-06-24|2008-05-27|2008-05-28|Estimate|2016-06-24|2016-07-25|Estimate||||2016-06-24|2016-07-25|Estimate|May 2008||2008-05-31|June 2016|2016-06-30|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings|Comparison of Sine Waveform High Frequency Chest Wall Oscillation Using Different Settings in Cystic Fibrosis|Completed||Phase 4|17|Actual|University of Minnesota - Clinical and Translational Science Institute|"Sputum weights varied more than anticipated and the study was underpowered to detect differences in the primary outcomes.~Study not generalizable to patients that do not produce sputum or have an FEV1 < 40% predicted."|2|||f||||t||||||||||2018-06-01 02:06:39.595992|2018-06-01 02:06:39.595992
NCT00685022|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-23|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|June 2003||2003-06-30|February 2012|2012-02-29|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma|A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Subjects Twelve Years of Age and Older With Asthma|Completed||Phase 2|49|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:06:39.911387|2018-06-01 02:06:39.911387
NCT00685009|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2015-10-16|2008-05-23|2008-05-28|Estimate|||||||2015-10-16|2015-10-19|Estimate|January 1996||1996-01-31|October 2015|2015-10-31|March 2008|Actual|2008-03-31|September 1997|Actual|1997-09-30||Observational|||The Women's Health Initiative Memory Study (The WHIMS Study)|Women's Health Initiative Memory Study|Completed|||7525|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||3||f||||t||||||||||2018-06-01 02:06:39.996537|2018-06-01 02:06:39.996537
NCT00684996|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2013-11-25||2014-04-28|2008-05-24|2008-05-28|Estimate|2013-11-25|2014-01-14|Estimate||||2014-04-28|2014-05-15|Estimate|June 2008||2008-06-30|April 2013|2013-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase I and a Randomized Phase II Study of Maximal Angiogenic Blockade in Advanced Renal Carcinoma: Bevacizumab (NSC-704865) With or Without MEDI-522 (NSC-719850)|Terminated||Phase 1/Phase 2|5|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 02:06:40.098679|2018-06-01 02:06:40.098679
NCT00684983|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2014-10-01||2017-08-29|2008-05-24|2008-05-28|Estimate|2014-10-01|2014-10-06|Estimate||||2017-08-29|2017-09-27|Actual|July 2008|Actual|2008-07-31|August 2017|2017-08-31||||January 2014|Actual|2014-01-31||Interventional||Total of 68 patient were accrued. Three are cancels and one is ineligible. Sixty four (64) started the study treatment.|Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer|Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 Positive Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane|Active, not recruiting||Phase 2|64|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 02:06:40.544696|2018-06-01 02:06:40.544696
NCT00684970|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2013-12-04|2008-05-27|2008-05-28|Estimate|||||||2013-12-04|2013-12-05|Estimate|March 2009||2009-03-31|December 2013|2013-12-31||||February 2014|Anticipated|2014-02-28||Interventional|TLH-202||Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)|A Phase IIB Clinical Trial of the Anti-Angiogenic Drug Combination Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)|Unknown status|Recruiting|Phase 2|100|Anticipated|Tiltan Pharma Ltd.||1|||f||||t||||||||||2018-06-01 02:06:41.689786|2018-06-01 02:06:41.689786
NCT00684957|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-11-02|2008-05-27|2008-05-28|Estimate|||||||2012-11-02|2012-11-06|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors|Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors in Adult Patients With Growth Hormone Deficiency|Terminated||N/A|5|Actual|Columbia University||2||Poor enrollment|f||||f||||||||||2018-06-01 02:06:41.795153|2018-06-01 02:06:41.795153
NCT00684944|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22||2018-04-25|2018-04-25|2008-05-27|2008-05-28|Estimate||||2018-04-25|2018-04-27|Actual|2018-04-25|2018-04-27|Actual|September 13, 2007|Actual|2007-09-13|April 2018|2018-04-30|December 2, 2010|Actual|2010-12-02|December 2, 2010|Actual|2010-12-02||Interventional|||Open Label Study of TRx0014 in Alzheimer's Disease|An Open Label Continuation Study of the Effects of TRx0014 30 mg TID and 60 mg TID in Patients With Alzheimer's Disease|Completed||Phase 2|111|Actual|TauRx Therapeutics Ltd||2|||f||||f|t|f||||||||2018-06-01 02:06:41.877292|2018-06-01 02:06:41.877292
NCT00684931|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2009-06-22|2008-05-22|2008-05-28|Estimate|||||||2009-06-22|2009-06-23|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|TDA/H||Cerebellar Loops and Attention Deficit Hyperactivity Disorder (ADHD)|Alterations of Fronto-Cerebello-Frontal Loops in Attention Deficit Hyperactivity Disorder (ADHD) : A Study Using Magnetic Resonance Imaging (MRI)|Terminated||N/A|19|Actual|University Hospital, Bordeaux||2||Difficulties in the organisation|f||||f||||||||||2018-06-01 02:06:41.931273|2018-06-01 02:06:41.931273
NCT00684918|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23||2013-08-16|2013-08-16|2008-05-27|2008-05-28|Estimate||||2013-08-16|2013-08-26|Estimate|2013-08-16|2013-08-26|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)|A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered For Three Consecutive Days Every 2 Weeks to Older Patients With Previously Untreated Acute Myeloid Leukemia (AML)|Completed||Phase 2|18|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 02:06:42.10146|2018-06-01 02:06:42.10146
NCT00684905|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2012-11-09|2008-05-23|2008-05-28|Estimate|||||||2012-11-09|2012-11-12|Estimate|April 2000||2000-04-30|November 2012|2012-11-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy|Phase II Interstitial Brachytherapy Combined With Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Prior External Beam Irradiation|Completed||Phase 2|50|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:06:42.200269|2018-06-01 02:06:42.200269
NCT00684892|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2009-01-20|2008-05-27|2008-05-28|Estimate|||||||2009-01-20|2009-01-22|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)|A Safety and Feasibility Study of the Chartis System in Subjects With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)|Completed||Phase 1/Phase 2|25|Actual|Pulmonx, Inc.||1|||f||||f||||||||||2018-06-01 02:06:42.280311|2018-06-01 02:06:42.280311
NCT00684879|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|||2018-05-19|2008-05-24|2008-05-28|Estimate|||||||2018-05-19|2018-05-22|Actual|May 21, 2008||2008-05-21|January 7, 2016|2016-01-07|January 7, 2016||2016-01-07|||||Observational|||Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia|Illness Perceptions and the Health Belief Model: Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia|Completed|||320|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:06:42.369353|2018-06-01 02:06:42.369353
NCT00684866|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-23|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|January 2003||2003-01-31|February 2012|2012-02-29|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma|A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatric Subjects With Asthma|Completed||Phase 2|31|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:06:42.439309|2018-06-01 02:06:42.439309
NCT00684853|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2008-05-27|2008-05-27|2008-05-28|Estimate|||||||2008-05-27|2008-05-28|Estimate|November 2007||2007-11-30|May 2008|2008-05-31||||May 2008|Actual|2008-05-31||Interventional|||Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD|Intravitreal Bevacizumab Combined With PDT (Full Fluence) Versus Bevacizumab to Treat Exudative Age-Related Macular Degeneration|Unknown status|Recruiting|Phase 2|50|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 02:06:42.543163|2018-06-01 02:06:42.543163
NCT00684840|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-06-01|2008-05-23|2008-05-28|Estimate|||||||2012-06-01|2012-06-05|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|DSS||Effects of Stress and Other Factors on Opiate Drug Choice.|Biobehavioral Study of Opioid Drug Seeking Behavior: Study 4|Completed|||16|Anticipated|Wayne State University|||||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 02:06:42.636463|2018-06-01 02:06:42.636463
NCT00684827|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2012-02-21|2008-05-23|2008-05-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|October 2002||2002-10-31|February 2012|2012-02-29|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma|A Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Subjects Twelve Years of Age and Older With Asthma|Completed||Phase 2|32|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:06:42.703546|2018-06-01 02:06:42.703546
NCT00680849|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2011-10-11|2008-05-16|2008-05-20|Estimate|||||||2011-10-11|2011-10-13|Estimate|December 2003||2003-12-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Enhancing Support for Women With Type 2 Diabetes: Follow-Up|Enhancing Support for Women With Type 2 Diabetes: Follow-Up|Completed|||227|Actual|Oregon Research Institute|||2||f||||t||||||||||2018-06-01 02:07:58.47264|2018-06-01 02:07:58.47264
NCT00684814|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-12-04||2012-04-18|2008-05-27|2008-05-28|Estimate|2009-12-04|2010-01-08|Estimate||||2012-04-18|2012-04-20|Estimate|May 2004||2004-05-31|April 2012|2012-04-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Under Fasting Conditions|A Randomized, Two-way Crossover, Single-Dose, Open-Label Study to Evaluate the Relative Bioequivalence of a Test Tablet Formulation of Zolpidem Tartrate 10 mg, Compared to an Equivalent Dose of Ambien® in Healthy Adult Subjects.|Completed||Phase 1|38|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:42.829851|2018-06-01 02:06:42.829851
NCT00684801|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2015-10-08|2008-05-23|2008-05-28|Estimate|||||||2015-10-08|2015-10-09|Estimate|August 2007||2007-08-31|October 2015|2015-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers|Improving the Quality of Advanced Cancer Care With Disease Management|Completed|||605|Actual|Case Comprehensive Cancer Center|||2||f||||t||||||||||2018-06-01 02:06:43.103846|2018-06-01 02:06:43.103846
NCT00684788|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2016-08-30||2017-11-29|2008-05-23|2008-05-28|Estimate|2017-11-29|2017-12-26|Actual||||2017-11-29|2017-12-26|Actual|May 2006|Actual|2006-05-31|November 2017|2017-11-30|May 3, 2009|Actual|2009-05-03|May 2009|Actual|2009-05-31||Interventional|||Employment-Based Depot Naltrexone Clinical Trial|Employment-Based Depot Naltrexone Clinical Trial|Completed||Phase 2|35|Actual|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-06-01 02:06:43.190726|2018-06-01 02:06:43.190726
NCT00684775|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2016-08-30||2017-12-27|2008-05-23|2008-05-28|Estimate|2017-11-30|2017-12-26|Actual||||2017-12-27|2018-01-23|Actual|May 2008|Actual|2008-05-31|December 2017|2017-12-31|April 30, 2010|Actual|2010-04-30|April 30, 2010|Actual|2010-04-30||Interventional|||Employment-Based Depot Naltrexone Clinical Trial II|Employment-Based Depot Naltrexone Clinical Trial II|Completed||Phase 2|38|Actual|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-06-01 02:06:43.557059|2018-06-01 02:06:43.557059
NCT00684762|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-11-18||2009-11-18|2008-05-24|2008-05-28|Estimate|2009-11-18|2009-12-22|Estimate||||2009-11-18|2009-12-22|Estimate|March 2004||2004-03-31|November 2009|2009-11-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Fasted Bioavailability Study of Cilostazol Tablets, 100 mg|A Comparative Bioavailability Study of Cilostazol Tablets, 100mg Under Fasting Conditions|Completed||Phase 1|32|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:43.949664|2018-06-01 02:06:43.949664
NCT00684749|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2013-02-20||2015-02-19|2008-05-27|2008-05-28|Estimate|2015-02-19|2015-02-23|Estimate||||2015-02-19|2015-02-23|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||A Pilot Study to Evaluate the BodyLogic TM System (Mentor) in Augmentation Mammaplasty|Pilot Study to Investigate The BodyLogic TM System (Mentor) in Breast Augmentation.|Completed|||142|Actual|University of Minnesota - Clinical and Translational Science Institute|snap shot view, responder bias||||f||||f||||||||||2018-06-01 02:06:44.182505|2018-06-01 02:06:44.182505
NCT00684736|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-08-07|2008-05-27|2008-05-28|Estimate|||||||2008-08-07|2008-08-08|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2007|Actual|2007-04-30||Observational|TSK||Tryptophan, Serotonin and Kynurenine in Septic Shock|Tryptophan, Serotonin and Kynurenine in Septic Shock|Completed|||30|Actual|Versailles Hospital|||||f||||f||||||||||2018-06-01 02:06:44.313557|2018-06-01 02:06:44.313557
NCT00684723|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-24|2009-11-24||2010-01-11|2008-05-27|2008-05-28|Estimate|2009-11-24|2009-12-30|Estimate||||2010-01-11|2010-01-20|Estimate|July 2004||2004-07-31|January 2010|2010-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Fed Bioavailability Study of Lovastatin Tablets and Mevacor Tablets|A Single Dose Crossover Comparative Bioavailability Study of Lovastatin 40mg Tablets in Healthy Male Volunteers/Fed State|Completed||Phase 1|54|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:06:44.390349|2018-06-01 02:06:44.390349
NCT00684710|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2009-01-28|2008-05-27|2008-05-28|Estimate|||||||2009-01-28|2009-01-30|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects|Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects|Completed||Phase 1|56|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:06:44.662666|2018-06-01 02:06:44.662666
NCT00684697|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2018-03-15|2008-05-27|2008-05-28|Estimate|||||||2018-03-15|2018-03-19|Actual|May 2008||2008-05-31|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Piron||Iron Status and Myelination in Premature Infants|Double Blind Randomized Placebo Controlled Trial of Iron Supplementation in Premature Infants|Active, not recruiting||N/A|100|Actual|University of Rochester||3|||f||||t||||||||||2018-06-01 02:06:44.814634|2018-06-01 02:06:44.814634
NCT00684684|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|||2009-01-20|2008-05-27|2008-05-28|Estimate|||||||2009-01-20|2009-01-22|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Feasibility Study of the Chartis System|A Safety and Feasibility Study of the Chartis System During Diagnostic Bronchoscopy|Completed||Phase 1|18|Actual|Pulmonx, Inc.||1|||f||||f||||||||||2018-06-01 02:06:44.8811|2018-06-01 02:06:44.8811
NCT00684671|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-23|2009-10-29||2017-03-21|2008-05-27|2008-05-28|Estimate|2009-10-29|2009-12-03|Estimate||||2017-03-21|2017-03-23|Actual|May 2008||2008-05-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination|Challenge Dose Administration of Twinrix™ or Comparator 4 Years After Primary Vaccination.|Completed||Phase 4|506|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:06:44.984905|2018-06-01 02:06:44.984905
NCT00684658|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2012-10-16|2008-05-22|2008-05-26|Estimate|||||||2012-10-16|2012-10-18|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||TEENCOPE: An Internet Coping Skills Training Program for Teens With Type 1 Diabetes|An Internet Coping Skills Training Program for Teens With Type 1 Diabetes|Completed||Phase 3|320|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:06:45.481102|2018-06-01 02:06:45.481102
NCT00684645|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2012-04-18||2012-07-17|2008-05-22|2008-05-26|Estimate|2012-07-17|2012-08-21|Estimate||||2012-07-17|2012-08-21|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®|Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®|Completed|||186|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:06:45.639844|2018-06-01 02:06:45.639844
NCT00684632|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2017-01-03|2008-05-23|2008-05-26|Estimate|||||||2017-01-03|2017-01-05|Estimate|March 2008||2008-03-31|December 2016|2016-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients|A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients|Completed||Phase 3|51|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||No||2018-06-01 02:06:46.36339|2018-06-01 02:06:46.36339
NCT00684606|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-06-18|2008-05-23|2008-05-26|Estimate|||||||2008-06-18|2008-06-19|Estimate|May 2008||2008-05-31|June 2008|2008-06-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Transcervical Foley Catheter With or Without Oxytocin for Induction of Labor|Transcervical Foley Catheter With or Without IV Oxytocin Infusion for Induction of Labor: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 02:06:46.519498|2018-06-01 02:06:46.519498
NCT00684593|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2014-09-26||2017-04-04|2008-05-22|2008-05-26|Estimate|2014-09-26|2014-10-06|Estimate||||2017-04-04|2017-05-10|Actual|June 1, 2007|Actual|2007-06-01|April 2017|2017-04-30|October 1, 2007|Actual|2007-10-01|October 1, 2007|Actual|2007-10-01||Interventional|||A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)|A Study to Assess the Clinical Effects of SCH 527123 in Psoriasis|Completed||Phase 2|31|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:06:46.614302|2018-06-01 02:06:46.614302
NCT00684580|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2017-12-13|2008-05-22|2008-05-26|Estimate|||||||2017-12-13|2017-12-15|Actual|June 8, 2000|Actual|2000-06-08|December 2017|2017-12-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Observational|||Protocol For Collecting Data On Patients With Childhood Cancer|Protocol For Collecting Data On Patients With Childhood Cancer|Recruiting|||12000|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-06-01 02:06:46.861308|2018-06-01 02:06:46.861308
NCT00684567|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2008-10-31||2017-05-15|2008-05-22|2008-05-26|Estimate|2009-02-11|2009-03-12|Estimate||||2017-05-15|2017-06-07|Actual|September 27, 2005|Actual|2005-09-27|May 2017|2017-05-31|October 31, 2007|Actual|2007-10-31|October 31, 2007|Actual|2007-10-31||Interventional|||Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)|SCH 52365 Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|30|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:46.950593|2018-06-01 02:06:46.950593
NCT00684554|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2015-05-19||2018-05-10|2008-05-22|2008-05-26|Estimate|2015-12-07|2016-01-11|Estimate||||2018-05-10|2018-05-15|Actual|December 2007||2007-12-31|May 2018|2018-05-31|April 2010|Actual|2010-04-30|August 2008|Actual|2008-08-31||Interventional||Adult Opioid Dependent treatment seekers|Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial|Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial of At-Home Versus In-Office Buprenorphine Induction|Completed||Phase 2/Phase 3|20|Actual|New York State Psychiatric Institute|The primary pilot study limitations are sample size and treatment setting, which restricts statistical comparison of outcomes and generalizability.|2|||f||||f||||||||||2018-06-01 02:06:47.268971|2018-06-01 02:06:47.268971
NCT00684541|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2013-12-13||2014-04-02|2008-05-23|2008-05-26|Estimate|2014-04-02|2014-05-01|Estimate||||2014-04-02|2014-05-01|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SP Interp||Interpretation Modification Program for Social Phobia|Interpretation Modification Program for Social Phobia|Completed||N/A|49|Actual|San Diego State University||2|||f||||t||||||||||2018-06-01 02:06:47.461623|2018-06-01 02:06:47.461623
NCT00684528|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2012-03-16|2008-05-23|2008-05-26|Estimate|||||||2012-03-16|2012-03-19|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin||Unknown status|Recruiting|Phase 3|1000|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-06-01 02:06:47.757822|2018-06-01 02:06:47.757822
NCT00684515|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2014-05-09|2008-10-09|2017-03-31|2008-05-22|2008-05-26|Estimate|2014-07-28|2014-07-29|Estimate|2009-10-21|2009-10-22|Estimate|2017-03-31|2017-05-05|Actual|September 21, 2006|Actual|2006-09-21|March 2017|2017-03-31|November 8, 2007|Actual|2007-11-08|November 8, 2007|Actual|2007-11-08||Interventional|||Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)|Phase II Study of SCH 530348 in Subjects With Cerebral Infarction|Completed||Phase 2|90|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 02:06:47.887408|2018-06-01 02:06:47.887408
NCT00684502|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2010-12-08|2008-05-23|2008-05-26|Estimate|||||||2010-12-08|2010-12-10|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects|A Phase I, Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects After Oral Multiple Ascending Doses|Completed||Phase 1|110|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:06:48.561876|2018-06-01 02:06:48.561876
NCT00684489|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-05-22|2008-05-22|2008-05-26|Estimate|||||||2008-05-22|2008-05-26|Estimate|September 2003||2003-09-30|May 2008|2008-05-31|September 2005|Actual|2005-09-30|March 2005|Actual|2005-03-31||Interventional|Renin||Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension|Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled or Complicated Hypertension|Completed||N/A|52|Actual|Medical University of South Carolina||4|||f||||f||||||||||2018-06-01 02:06:48.655783|2018-06-01 02:06:48.655783
NCT00684476|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2008-05-23|2008-05-23|2008-05-26|Estimate|||||||2008-05-23|2008-05-26|Estimate|June 2004||2004-06-30|March 2004|2004-03-31|May 2006||2006-05-31|||||Interventional|||Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings||Completed||Phase 4|60||Meir Medical Center|||||f||||||||||||||2018-06-01 02:06:48.744084|2018-06-01 02:06:48.744084
NCT00684463|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2017-05-15|2008-05-23|2008-05-26|Estimate|||||||2017-05-15|2017-05-16|Actual|April 11, 2007|Actual|2007-04-11|May 2017|2017-05-31|February 22, 2008|Actual|2008-02-22|February 22, 2008|Actual|2008-02-22||Interventional|||Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)|Study to Evaluate the Efficacy and Safety of Single IV Doses of Onicit® (Palonosetron) 0.25 mg in the Prevention of Acute and Delayed Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in Colombia|Completed||Phase 4|59|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:06:48.81725|2018-06-01 02:06:48.81725
NCT00684450|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2011-08-24|2008-05-23|2008-05-26|Estimate|||||||2011-08-24|2011-08-25|Estimate|June 2008||2008-06-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Protamine||Cardiac Surgery: In Vivo Titration of Protamine|Cardiac Surgery : In Vivo Titration of Protamine|Completed||N/A|138|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-06-01 02:06:48.91125|2018-06-01 02:06:48.91125
NCT00684437|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2017-10-04|2008-05-22|2008-05-26|Estimate|||||||2017-10-04|2017-10-05|Actual|May 2008|Actual|2008-05-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Literacy and Smoking Risk Communications|Literacy and Smoking Risk Communications|Active, not recruiting||N/A|495|Anticipated|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-06-01 02:06:49.045847|2018-06-01 02:06:49.045847
NCT00684424|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2010-03-09||2010-05-27|2008-05-22|2008-05-26|Estimate|2010-05-27|2010-06-24|Estimate||||2010-05-27|2010-06-24|Estimate|July 2008||2008-07-31|May 2010|2010-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency|Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency|Completed|||199|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:06:49.21767|2018-06-01 02:06:49.21767
NCT00684411|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2016-09-11||2016-11-08|2008-05-22|2008-05-26|Estimate|2016-11-08|2017-01-05|Estimate||||2016-11-08|2017-01-05|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma|A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|12|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 02:06:49.865089|2018-06-01 02:06:49.865089
NCT00684398|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2018-05-24|2008-05-22|2008-05-26|Estimate|||||||2018-05-24|2018-05-25|Actual|May 15, 2008||2008-05-15|November 27, 2015|2015-11-27|November 27, 2015||2015-11-27|||||Observational|||Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I|Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I|Completed|||645|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:06:50.118151|2018-06-01 02:06:50.118151
NCT00684385|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-12-15|2008-05-23|2008-05-26|Estimate|||||||2017-12-15|2017-12-18|Actual|August 8, 2001|Actual|2001-08-08|December 2017|2017-12-31|September 16, 2014|Actual|2014-09-16|September 16, 2014|Actual|2014-09-16||Interventional|||An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck|An International Expanded Access Clinical Programme With ZD1839 (IRESSA) for Patients With Advanced Non-small Cell Lung Cancer(NSCLC) and Patients With Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck (H&NC)|Completed||Phase 4|264|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 02:06:50.20894|2018-06-01 02:06:50.20894
NCT00684372|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-02-05|2008-05-23|2008-05-26|Estimate|||||||2009-02-05|2009-02-06|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||BK Viremia After Renal Transplantation|BK Viremia After Renal Transplantation: Screening, Early Diagnosis, Early Reduction in Immunosuppression and Treatment With Leflunomide (Arava)|Unknown status|Active, not recruiting|N/A|100|Anticipated|Karolinska University Hospital|||||f||||t||||||||||2018-06-01 02:06:50.378563|2018-06-01 02:06:50.378563
NCT00684359|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2010-05-28|2008-05-23|2008-05-26|Estimate|||||||2010-05-28|2010-05-31|Estimate|June 2007||2007-06-30|May 2010|2010-05-31|February 2010|Actual|2010-02-28|||||Observational|PRACTICE I||Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I|Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I|Completed|||30|Anticipated|Medstar Health Research Institute|||||f||||t||||||||||2018-06-01 02:06:50.441914|2018-06-01 02:06:50.441914
NCT00684346|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2013-08-30|2008-05-22|2008-05-26|Estimate|||||||2013-08-30|2013-09-02|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients|A Pilot Study of 18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients After Treatment for a Pulmonary Exacerbation|Completed||Phase 3|20|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 02:06:50.491204|2018-06-01 02:06:50.491204
NCT00684333|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-01-10|2008-05-23|2008-05-26|Estimate|||||||2009-01-10|2009-01-14|Estimate|June 2009||2009-06-30|January 2009|2009-01-31|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Interventional|||Safety and Efficacy of EZ-Ject Injector a Pain-Free Subcutaneous Automatic Injection in Healthy Volunteers|Assessment of Safety and Efficacy of EZ-Ject Injector a Novel Device for Pain-Free Subcutaneous Automatic Injection in Healthy Volunteers|Suspended||N/A|42|Anticipated|Sindolor||1|||f||||f||||||||||2018-06-01 02:06:50.562465|2018-06-01 02:06:50.562465
NCT00684320|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2013-12-18||2014-04-02|2008-05-23|2008-05-26|Estimate|2014-04-02|2014-05-01|Estimate||||2014-04-02|2014-05-01|Estimate|September 2006||2006-09-30|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SPAttn||Attention Disengagement Training for Social Phobia|Attention Disengagement Training for Social Phobia|Completed||N/A|48|Actual|San Diego State University||2|||f||||t||||||||||2018-06-01 02:06:50.710084|2018-06-01 02:06:50.710084
NCT00684307|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2011-08-17||2012-03-20|2008-05-23|2008-05-26|Estimate|2011-08-17|2011-09-22|Estimate||||2012-03-20|2012-03-23|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation|A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation|Completed||Phase 2|1084|Actual|AstraZeneca||5|||f||||t||||||||||2018-06-01 02:06:51.137831|2018-06-01 02:06:51.137831
NCT00684294|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2018-04-02|2008-05-23|2008-05-26|Estimate|||||||2018-04-02|2018-04-04|Actual|May 27, 2008|Actual|2008-05-27|April 2018|2018-04-30||||May 2009|Actual|2009-05-31||Interventional|Auto TAG||Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer|Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer|Active, not recruiting||Phase 1|50|Anticipated|Mary Crowley Medical Research Center||2|||f||||t||||||||||2018-06-01 02:06:53.521657|2018-06-01 02:06:53.521657
NCT00684281|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2014-08-27|2008-05-23|2008-05-26|Estimate|||||||2014-08-27|2014-08-28|Estimate|July 2008||2008-07-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment|Early Diagnosis of Alzheimer's Disease: Clinical, Neuropsychological and Neuroimaging Follow-up of a Cohort of Patients With an Isolated Memory Impairment|Completed||N/A|60|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-06-01 02:06:53.707835|2018-06-01 02:06:53.707835
NCT00684268|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2017-03-22|2008-05-21|2008-05-26|Estimate|||||||2017-03-22|2017-03-27|Actual|October 2007||2007-10-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|NRSily||Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders|Multicenter Study To Evaluate The Efficacy Of Silymarin In Addition To Combination-Therapy With Pegylated Interferon Alfa 2a (Peg-Ifn Alfa 2a) And Ribavirin In Patients With Chronic Hepatitis C|Completed||Phase 2|70|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:06:53.876433|2018-06-01 02:06:53.876433
NCT00682344|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2014-08-27|2008-05-20|2008-05-22|Estimate|||||||2014-08-27|2014-08-28|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pharmacokinetic of levobupivacaïne After Sciatic Nerve Block in Children|Pharmacokinetic of levobupivacaïne After Sciatic Nerve Block in Children|Terminated||Phase 3|7|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 02:07:36.593764|2018-06-01 02:07:36.593764
NCT00684255|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2008-12-22||2014-02-06|2008-05-23|2008-05-26|Estimate|2009-11-23|2009-12-02|Estimate||||2014-02-06|2014-04-01|Estimate|August 2007||2007-08-31|February 2014|2014-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)|Reduced Intensity Conditioning And Allogeneic Stem Cell Transplantation in Patients With Medically Refractory Systemic Lupus Erythematosus and Medically Refractory Systemic Sclerosis (SSc)|Terminated||Phase 1|1|Actual|New York Medical College|Study closed due to low accrual. Did not meet enrollment goals.|2||inactive|f||||t||||||||||2018-06-01 02:06:54.070181|2018-06-01 02:06:54.070181
NCT00684242|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2012-12-20||2012-12-20|2008-05-22|2008-05-26|Estimate|2012-12-20|2013-01-28|Estimate||||2012-12-20|2013-01-28|Estimate|May 2008||2008-05-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain|A Pilot Clinical Trial of Lenalidomide (Revlimid®) for the Treatment of Refractory Cancer Pain|Terminated||Phase 2|4|Actual|M.D. Anderson Cancer Center||1||Low accrual.|f||||f||||||||||2018-06-01 02:06:54.412071|2018-06-01 02:06:54.412071
NCT00684229|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2016-09-13|2008-05-22|2008-05-26|Estimate|||||||2016-09-13|2016-09-15|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Regional Anesthesia in Colon Rectal Surgery|Regional Anesthesia in Patients Undergoing Colon-Rectal Surgery|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||investigator could not identify any patients|f||||t||||||||||2018-06-01 02:06:54.745008|2018-06-01 02:06:54.745008
NCT00684216|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2017-09-13|2008-05-23|2008-05-26|Estimate|||||||2017-09-13|2017-09-14|Actual|April 2008||2008-04-30|May 2012|2012-05-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer|Randomized Phase II/III Study of Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic Estrogen Receptor Positive Breast Cancer|Terminated||Phase 2/Phase 3|10|Actual|The Netherlands Cancer Institute||2||acrual too slow|f||||f||||||||||2018-06-01 02:06:54.835654|2018-06-01 02:06:54.835654
NCT00684203|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2014-05-09|2008-10-09|2017-03-31|2008-05-22|2008-05-26|Estimate|2014-07-28|2014-08-15|Estimate|2009-10-21|2009-10-22|Estimate|2017-03-31|2017-05-05|Actual|December 1, 2006|Actual|2006-12-01|March 2017|2017-03-31|October 1, 2007|Actual|2007-10-01|October 1, 2007|Actual|2007-10-01||Interventional|||Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)|Phase II Study of SCH 530348 in Subjects With Acute Coronary Syndrome|Completed||Phase 2|120|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 02:06:55.038217|2018-06-01 02:06:55.038217
NCT00684190|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2010-12-02|2008-05-23|2008-05-26|Estimate|||||||2010-12-02|2010-12-03|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Drug Interaction Study Between AZD3355 and Nexium|An Open, Randomised, Three Period Cross, Single Centre, Phase 1 Pharmacokinetic Interaction Study of the Reflux Inhibitor AZD3355 150 mg Bid and Esomeprazole 40 mg od After 7 Days of Treatment in Healthy Volunteers|Completed||Phase 1|30|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:06:56.752458|2018-06-01 02:06:56.752458
NCT00684177|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2010-06-03||2016-10-11|2008-05-22|2008-05-26|Estimate|2010-07-07|2010-08-04|Estimate||||2016-10-11|2016-11-23|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)|A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL|Completed||Phase 3|508|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:06:56.876379|2018-06-01 02:06:56.876379
NCT00684164|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2015-03-05|2008-05-22|2008-05-26|Estimate|||||||2015-03-05|2015-03-06|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|June 2010|Anticipated|2010-06-30|November 2009|Anticipated|2009-11-30||Interventional|||Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients|Safety and Efficacy of Conivaptan for the Correction of Euvolemic and Hypervolemic Hyponatremia in Critically Ill Neurological Patients|Withdrawn||Phase 3|0|Actual|Columbia University||2||Unable to complete a contract with the Sponsor|f||||t||||||||||2018-06-01 02:06:57.55245|2018-06-01 02:06:57.55245
NCT00684151|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2011-12-09|2008-05-23|2008-05-26|Estimate|||||||2011-12-09|2011-12-12|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|November 2011|Actual|2011-11-30|||||Observational|||Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand|Lipid-lowering Therapy in Patients With High Cardiovascular Risk and Their 3-year Mortality Rate in General Practice in Thailand|Completed|||1240|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:06:57.797559|2018-06-01 02:06:57.797559
NCT00684138|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2009-01-30||2010-07-06|2008-05-23|2008-05-26|Estimate|2010-02-23|2010-03-11|Estimate||||2010-07-06|2010-07-13|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)|Completed||Phase 4|300|Actual|Alcon Research|Data from one investigator, who implanted 20 subjects, were excluded from analysis due to non compliance with data collection and documentation. This resulted in 280 implanted subjects that were considered evaluable.|2|||f||||f||||||||||2018-06-01 02:06:58.148706|2018-06-01 02:06:58.148706
NCT00684125|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2011-07-21|2008-05-23|2008-05-26|Estimate|||||||2011-07-21|2011-07-22|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|July 2010|Actual|2010-07-31|May 2010|Actual|2010-05-31||Interventional|Blake||Evaluation of Different Strategies of Pericardial Drainage After Aortic Valvular Surgery|Evaluation of Different Strategies of Pericardial Drainage After Aortic Valvular Surgery: A Prospective Randomized Trial|Completed||N/A|150|Anticipated|Montreal Heart Institute||2|||f||||f||||||||||2018-06-01 02:06:58.763275|2018-06-01 02:06:58.763275
NCT00684112|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2013-08-15|2008-05-22|2008-05-26|Estimate|||||||2013-08-15|2013-08-16|Estimate|May 2008||2008-05-31|August 2013|2013-08-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Analgesic Effects of Gabapentin After Scoliosis Surgery in Children|Analgesic Effects of Gabapentin After Scoliosis Surgery in Children|Completed||Phase 3|35|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 02:06:59.023547|2018-06-01 02:06:59.023547
NCT00684099|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2009-12-14|2008-05-23|2008-05-26|Estimate|||||||2009-12-14|2009-12-15|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Study Of The Docetaxel/Pemetrexed Combination As First Line Treatment In Patients With Advanced/Metastatic NSCLC|Completed||Phase 1/Phase 2|70|Anticipated|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 02:06:59.290928|2018-06-01 02:06:59.290928
NCT00684073|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2008-12-17||2011-04-14|2008-05-23|2008-05-26|Estimate|2009-11-24|2010-01-01|Estimate||||2011-04-14|2011-04-19|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)|Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy|Completed||Phase 4|60|Actual|Indivior Inc.||1|||f||||f||||||||||2018-06-01 02:06:59.643596|2018-06-01 02:06:59.643596
NCT00684060|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2012-04-09||2015-07-07|2008-05-23|2008-05-26|Estimate|2012-04-09|2012-05-04|Estimate||||2015-07-07|2015-07-10|Estimate|July 2008||2008-07-31|July 2015|2015-07-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Interventional|||Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)|A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction|Completed||Phase 2|87|Actual|The University of Texas Health Science Center, Houston|Lack of in-vivo testing of cell product. While there are several different approaches to measure myocardial strain (myocardial tagging, DENSE, etc.), these were not employed in this study due to the need for specialized expertise at each site.|2|||f||||t||||||||||2018-06-01 02:06:59.923695|2018-06-01 02:06:59.923695
NCT00684047|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2015-09-25||2015-12-17|2008-05-22|2008-05-26|Estimate|2015-12-17|2016-01-25|Estimate||||2015-12-17|2016-01-25|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional||Demographic information is summarized for the subjects in the Intent to treat population.|Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis|A Prospective, Single-blind, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Peripheral Vascular Surgery|Completed||Phase 2/Phase 3|239|Actual|Grifols Biologicals Inc.||3|||f||||f||||||||||2018-06-01 02:07:00.620705|2018-06-01 02:07:00.620705
NCT00684034|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2014-08-27|2008-05-23|2008-05-26|Estimate|||||||2014-08-27|2014-08-28|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality|Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality|Completed||N/A|131|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 02:07:01.281621|2018-06-01 02:07:01.281621
NCT00684021|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2013-01-18||2015-06-02|2008-05-23|2008-05-26|Estimate|2013-02-22|2013-04-04|Estimate||||2015-06-02|2015-06-30|Estimate|July 2008||2008-07-31|June 2015|2015-06-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|||Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)|Transplantation in Myocardial Infarction Evaluation (TIME) Protocol: A Phase II, Randomized, Controlled, Double-Blind Trial Evaluating the Effect of Timing on the Administration of Bone Marrow Mononuclear Cells (BMMNCs) Versus Placebo in Patients With Acute Myocardial Infarction|Completed||Phase 2|120|Actual|The University of Texas Health Science Center, Houston|The choice of Day 3 or Day 7 as randomization points while based on the literature were nevertheless somewhat arbitrary. cMR-baseed ejection fractions tended to be high.|4|||f||||t||||||||||2018-06-01 02:07:01.450179|2018-06-01 02:07:01.450179
NCT00684008|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2012-07-25|2008-05-23|2008-05-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|||||Interventional|||Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant|A Phase I Study of CYT107 (Recombinant Glycosylated Human IL-7) in Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant|Completed||Phase 1|12|Actual|Cytheris, Inc.||1|||f||||t||||||||||2018-06-01 02:07:02.146961|2018-06-01 02:07:02.146961
NCT00683995|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2017-01-03|2008-05-22|2008-05-26|Estimate|||||||2017-01-03|2017-01-05|Estimate|March 2008||2008-03-31|December 2016|2016-12-31||||July 2009|Actual|2009-07-31||Interventional|||A Phase III Clinical Study of KW-2246|A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients|Completed||Phase 3|43|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 02:07:02.244233|2018-06-01 02:07:02.244233
NCT00683982|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-05-23|2008-05-23|2008-05-26|Estimate|||||||2008-05-23|2008-05-26|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to Rotavirus|Nitazoxanide vs Probiotics in the Treatment of Acute Rotavirus Diarrhea in Children: A Randomized Single Blind Controlled Trial in Bolivian Children|Completed||N/A|75|Actual|Centro Pediatrico Albina de Patino||3|||f||||f||||||||||2018-06-01 02:07:02.364446|2018-06-01 02:07:02.364446
NCT00683969|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-05-23|2008-05-23|2008-05-26|Estimate|||||||2008-05-23|2008-05-26|Estimate|August 2004||2004-08-31|May 2008|2008-05-31|May 2007|Actual|2007-05-31|||||Interventional|||A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis|Completed||Phase 3|136|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:07:02.535473|2018-06-01 02:07:02.535473
NCT00683956|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2011-11-22|2008-05-22|2008-05-26|Estimate|||||||2011-11-22|2011-11-24|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Evaluation of a Closed-Loop Control System for Administering Patient-Specific Anesthesia|Evaluation of a Closed-Loop Control System for Patient-Specific Induction and Maintenance of Propofol Hypnosis|Completed||Phase 1|35|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 02:07:02.890221|2018-06-01 02:07:02.890221
NCT00683943|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2018-05-18|2008-05-22|2008-05-26|Estimate|||||||2018-05-18|2018-05-21|Actual|May 18, 2008||2008-05-18|February 27, 2014|2014-02-27|February 25, 2010|Actual|2010-02-25|February 25, 2010|Actual|2010-02-25||Interventional|||Lithium Treatment for Patients With Spinocerebellar Ataxia Type I|Pilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1)|Completed||Phase 1|13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:07:03.040424|2018-06-01 02:07:03.040424
NCT00683930|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2009-11-18||2011-05-25|2008-05-23|2008-05-26|Estimate|2011-05-25|2011-06-22|Estimate||||2011-05-25|2011-06-22|Estimate|May 2004||2004-05-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)|A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel Group, Mult-center, 52-week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Achieve Remission With Reduced Corticosteroid in Subjects With Pemphigus Vulgaris|Completed||Phase 3|96|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 02:07:03.236577|2018-06-01 02:07:03.236577
NCT00683917|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2014-06-25||2014-08-05|2008-05-23|2008-05-26|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|May 2008||2008-05-31|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Study prematurely terminated|Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids|A Multi-center, Active Controlled, Pharmacokinetic, Safety and Efficacy Study of Proellex in Pre-Menopausal Women With Symptomatic Uterine Fibroids to Assess Persistence of Response|Terminated||Phase 2|10|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.|3||Repros stopped the study for safety and FDA put the study on hold for safety.|f||||t||||||||||2018-06-01 02:07:04.290974|2018-06-01 02:07:04.290974
NCT00683904|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2011-02-08||2016-02-09|2008-05-23|2008-05-26|Estimate|2011-03-15|2011-04-15|Estimate||||2016-02-09|2016-03-10|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer|A Phase I Study of Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer as First-line Treatment|Completed||Phase 1|12|Actual|R-Pharm||2|||f||||t||||||||||2018-06-01 02:07:04.565075|2018-06-01 02:07:04.565075
NCT00683891|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|||2008-06-18|2008-05-23|2008-05-26|Estimate|||||||2008-06-18|2008-06-19|Estimate||||June 2008|2008-06-30||||||||Observational|FOCUS||FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey|FazaClo Outcomes in the Control of Schizophrenia (FOCUS)|Completed|||||Azur Pharma, Inc|||||f||||||||||||||2018-06-01 02:07:05.466978|2018-06-01 02:07:05.466978
NCT00683878|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2016-10-06|2011-06-21|2017-01-03|2008-05-23|2008-05-26|Estimate|2017-01-03|2017-02-23|Actual|2014-06-06|2014-06-18|Estimate|2017-01-03|2017-02-23|Actual|July 2008||2008-07-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional||All randomized patients who received at least one dose of study medication.|Add-on to Thiazolidinedione (TZD) Failures|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone|Completed||Phase 3|972|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:07:05.666643|2018-06-01 02:07:05.666643
NCT00683865|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2014-10-12|2008-05-23|2008-05-26|Estimate|||||||2014-10-12|2014-10-15|Estimate|April 2003||2003-04-30|October 2014|2014-10-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|MAIDEN||Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.|Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID)|Completed||Phase 3|749|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:07:06.640846|2018-06-01 02:07:06.640846
NCT00683852|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2012-11-12||2017-06-21|2008-05-23|2008-05-26|Estimate|2017-06-21|2017-07-19|Actual||||2017-06-21|2017-07-19|Actual|September 2008||2008-09-30|June 2017|2017-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||This data was analyzed for the study by comparing placebo vs. drug. Therefore the two groups (placebo/placebo and placebo/drug) that started with placebo during the first phase of the study are combined as one group called Placebo. The patients who were took the study drug in both phases are in the Drug/Drug group.|A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy|A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT|Completed||Phase 3|225|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-06-01 02:07:06.910982|2018-06-01 02:07:06.910982
NCT00683839|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2011-10-24|2008-05-23|2008-05-26|Estimate|||||||2011-10-24|2011-10-26|Estimate|January 2006||2006-01-31|October 2011|2011-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|PHD2||Tobacco Cessation Via Public Health Dental Clinics|Tobacco Cessation Via Public Health Dental Clinics (PHD2)|Completed||Phase 2|2637|Actual|Oregon Research Institute||2|||f||||t||||||||||2018-06-01 02:07:07.553034|2018-06-01 02:07:07.553034
NCT00683826|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-22|2011-03-01||2013-03-04|2008-05-22|2008-05-26|Estimate|2011-07-12|2011-08-09|Estimate||||2013-03-04|2013-03-05|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Effects of Leucine on Body Weight|Effects of Leucine Supplement on Body Weight and Cardiometabolic Changes|Completed||N/A|8|Actual|Columbia University||3|||f||||t||||||||||2018-06-01 02:07:07.646175|2018-06-01 02:07:07.646175
NCT00683813|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2015-05-18|2008-05-21|2008-05-23|Estimate|||||||2015-05-18|2015-05-20|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|vCRP||Trial of a Cardiac Rehabilitation Program Delivered Remotely Through the Internet|Randomized Trial of a Cardiac Rehabilitation Program Delivered Remotely Through the Internet|Completed||N/A|79|Actual|Simon Fraser University||2|||f||||f||||||||||2018-06-01 02:07:08.082966|2018-06-01 02:07:08.082966
NCT00683800|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2011-04-21||2011-07-21|2008-05-22|2008-05-23|Estimate|2011-07-21|2011-08-17|Estimate||||2011-07-21|2011-08-17|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women|A Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety And Efficacy Of DVS SR For The Treatment Of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|2186|Actual|Pfizer|GCS scales were analyzed only for main study efficacy population.|2|||f||||t||||||||||2018-06-01 02:07:08.499384|2018-06-01 02:07:08.499384
NCT00683787|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2014-05-12||2014-12-29|2008-05-21|2008-05-23|Estimate|2014-12-29|2015-01-08|Estimate||||2014-12-29|2015-01-08|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|March 2011|Actual|2011-03-31|April 2009|Actual|2009-04-30||Interventional||All treated and eligible patients.|Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer|Multicenter Randomized Phase II Trial of Docetaxel With/Without VANDETANIB for Advanced Gastroesophageal Cancer|Terminated||Phase 2|8|Actual|Roswell Park Cancer Institute|Due to the study's early termination and inadequate number of patients no statistical inference of the primary and secondary aims were carried forth.|3||low accrual|f||||t||||||||||2018-06-01 02:07:11.705124|2018-06-01 02:07:11.705124
NCT00683774|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2014-05-30||2017-06-09|2008-05-22|2008-05-23|Estimate|2014-08-19|2014-08-21|Estimate||||2017-06-09|2017-06-14|Actual|November 2005||2005-11-30|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||Obese women with and without PCOS between the ages of 18-40 years selected after examination and eligibility screening|Insulin and Polycystic Ovary Syndrome|Determination if Direct Inhibition of Insulin Release With Diazoxide Decreases Renal Clearance of D-Chiroinositol (DCI) and Increases Circulating DCI in Obese Women With Polycystic Ovary Syndrome (PCOS)|Completed||N/A|21|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 02:07:12.159079|2018-06-01 02:07:12.159079
NCT00683761|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-07-16|2008-05-21|2008-05-23|Estimate|||||||2009-07-16|2009-07-17|Estimate|August 2008||2008-08-31|July 2009|2009-07-31|April 2010|Anticipated|2010-04-30|February 2010|Anticipated|2010-02-28||Interventional|||A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma|A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma|Unknown status|Active, not recruiting|Phase 1/Phase 2|64|Anticipated|TransMolecular||1|||f||||f||||||||||2018-06-01 02:07:12.681569|2018-06-01 02:07:12.681569
NCT00683748|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-02-04|2008-05-21|2008-05-23|Estimate|||||||2009-02-04|2009-02-05|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Observational|||Monitoring Cellular Immunity After Kidney and Liver Transplantation|Monitoring Cellular Immunity After Kidney and Liver Transplantation|Unknown status|Active, not recruiting||100|Anticipated|Karolinska University Hospital|||2||f||||f||||||Samples Without DNA|"~     Serum, whole blood~   "|||2018-06-01 02:07:12.771081|2018-06-01 02:07:12.771081
NCT00683735|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2015-12-17|2008-05-21|2008-05-23|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2009||2009-02-28|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis|Quantification of the DPP-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis|Completed||Phase 2/Phase 3|20|Actual|Diabeteszentrum Bad Lauterberg im Harz||4|||f||||t||||||||||2018-06-01 02:07:12.839213|2018-06-01 02:07:12.839213
NCT00683722|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2014-12-03|2008-05-21|2008-05-23|Estimate|||||||2014-12-03|2014-12-04|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL™ (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|62|Actual|Mesoblast, Ltd.||2|||f||||||||||||||2018-06-01 02:07:12.921947|2018-06-01 02:07:12.921947
NCT00683709|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2011-08-02|2008-05-21|2008-05-23|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2007||2007-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder|Metabolic Side Effects, Diet and Exercise Counseling and Brain Function in a Naturalistic Clinical Trial of Clozapine for Treatment Resistant Bipolar and Schizoaffective Disorder|Completed|||48|Anticipated|St. Joseph's Healthcare Hamilton|||2||f||||f||||||||||2018-06-01 02:07:13.010953|2018-06-01 02:07:13.010953
NCT00683696|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2014-03-12||2018-01-12|2008-05-21|2008-05-23|Estimate|2014-03-12|2014-04-17|Estimate||||2018-01-12|2018-01-17|Actual|August 2008||2008-08-31|January 2018|2018-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EchoCRT|Baseline characterisics were analzed for the randomized population.|Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)|Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)|Terminated||Phase 2/Phase 3|1680|Actual|Biotronik, Inc.|Endpoint results should be interpreted with caution and take into consideration the early study closure and subsequent reduction in sample size (809 vs. 1258) and events (218 vs. 381). These changes impact the statistical power of the findings.|2|||f||||t||||||||||2018-06-01 02:07:13.123018|2018-06-01 02:07:13.123018
NCT00683683|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2015-05-25|2008-05-21|2008-05-23|Estimate|||||||2015-05-25|2015-05-27|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|SPARC||The Strategies for Post Arrest Resuscitation and Care Network|The Strategies for Post Arrest Resuscitation and Care Network|Completed||N/A|32|Actual|St. Michael's Hospital, Toronto||1|||f||||t||||||||||2018-06-01 02:07:13.91652|2018-06-01 02:07:13.91652
NCT00683670|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2017-02-21|2008-05-19|2008-05-23|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2008||2008-08-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma|Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma|Completed||Phase 1|17|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 02:07:14.006974|2018-06-01 02:07:14.006974
NCT00683657|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2010-02-19||2015-05-08|2008-05-21|2008-05-23|Estimate|2010-02-19|2010-03-10|Estimate||||2015-05-08|2015-06-01|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone|A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial To Evaluate The Efficacy And Safety Of Saxagliptin In Comparison To Placebo As Add On Treatment To Metformin XR In Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet And Exercise And A Stable Dose Of Metformin ≥1500 mg/Day|Completed||Phase 3|93|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:07:14.131807|2018-06-01 02:07:14.131807
NCT00683644|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2017-03-01||2017-11-10|2008-05-21|2008-05-23|Estimate|2017-11-10|2017-12-13|Actual||||2017-11-10|2017-12-13|Actual|January 2008||2008-01-31|November 2017|2017-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Zinc to Treat Tinnitus in the Elderly|Zinc to Treat Tinnitus in the Elderly: A Randomized Placebo Controlled Crossover Trial.|Completed||Phase 2|116|Actual|University of Iowa|"For data analysis purposes subjects were divided per intervention. Zinc: subjects who completed 4 mo with zinc from baseline to month 4, or after washout. Placebo: subjects who completed 4 mo with placebo from baseline to month 4, or after washout."|2|||f||||f|t|f|||f|||No||2018-06-01 02:07:14.720645|2018-06-01 02:07:14.720645
NCT00683631|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2013-10-18|2008-05-22|2008-05-23|Estimate|||||||2013-10-18|2013-10-21|Estimate|January 2004||2004-01-31|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|TheraSphere||TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)|TheraSphere HUD For Treatment of Unresectable HCC|Completed||N/A|150|Actual|University of Louisville||1|||f||||t||||||||||2018-06-01 02:07:15.032354|2018-06-01 02:07:15.032354
NCT00683618|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2010-07-09||2012-03-19|2008-05-22|2008-05-23|Estimate|2012-02-08|2012-03-12|Estimate||||2012-03-19|2012-03-21|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia|A Randomised, Double-blind Trial to Compare the Efficacy of Rosuvastatin 5 and 10 mg to Atorvastatin 10 mg in the Treatment of High Risk Patients With Hypercholesterolemia Followed by an Open Label Treatment Period With Rosuvastatin Up-titrated to the Maximum Dose of 20 mg for Those Patients Who do Not Achieve Goal|Completed||Phase 3|934|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:07:15.168274|2018-06-01 02:07:15.168274
NCT00680303|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-15|2008-05-15|2008-05-20|Estimate|||||||2008-05-15|2008-05-20|Estimate|January 2008||2008-01-31|April 2008|2008-04-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Spacing Lidcombe Program Clinic Visits|The Effect of Spacing of Lidcombe Program Clinic Visits|Unknown status|Recruiting|Phase 2|120|Anticipated|University of Sydney||3|||f||||t||||||||||2018-06-01 02:08:06.820109|2018-06-01 02:08:06.820109
NCT00683592|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2010-07-19||2010-10-05|2008-05-22|2008-05-23|Estimate|2010-10-05|2010-10-27|Estimate||||2010-10-05|2010-10-27|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)|A Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD)|Completed||Phase 3|481|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 02:07:15.889383|2018-06-01 02:07:15.889383
NCT00683579|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-02-27|2008-05-22|2008-05-23|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2007||2007-12-31|February 2016|2016-02-29|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Neurocognitive Assessment in Youth Initiating HAART|Neurocognitive Assessment in Youth Initiating HAART|Completed|||220|Actual|University of North Carolina, Chapel Hill|||4||f||||t||||||||||2018-06-01 02:07:16.213391|2018-06-01 02:07:16.213391
NCT00683566|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2014-08-27|2008-05-22|2008-05-23|Estimate|||||||2014-08-27|2014-08-28|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||State Dependent Resonance in the BG-cortical Loops|State Dependent Resonance in the BG-cortical Loops|Completed||N/A|10|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-06-01 02:07:16.29592|2018-06-01 02:07:16.29592
NCT00683553|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2010-11-12|2008-05-22|2008-05-23|Estimate|||||||2010-11-12|2010-11-16|Estimate|May 2008||2008-05-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)|A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients at High Risk of Acute Kidney Injury Undergoing Major Cardiovascular Surgery|Terminated||Phase 1|3|Actual|Quark Pharmaceuticals||2||Lack of an available patient population|f||||t||||||||||2018-06-01 02:07:16.360349|2018-06-01 02:07:16.360349
NCT00683540|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2017-06-02|2008-05-22|2008-05-23|Estimate|||||||2017-06-02|2017-06-06|Actual|January 23, 2009|Actual|2009-01-23|June 2017|2017-06-30|March 31, 2009|Actual|2009-03-31|March 30, 2009|Actual|2009-03-30||Observational|||Formative Evaluation in Implementation Research: Guideline Development|Formative Evaluation in Implementation Research: Guideline Development|Completed|||9|Actual|VA Office of Research and Development|||||f||||f||||||||||2018-06-01 02:07:16.435115|2018-06-01 02:07:16.435115
NCT00683527|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2008-05-21|2008-05-21|2008-05-23|Estimate|||||||2008-05-21|2008-05-23|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|January 2007|Actual|2007-01-31|November 2006|Actual|2006-11-30||Interventional|||Timing of Iron Supplementation in Very Low Birth Weight Infants|New Versus Standard Enteral Iron Supplementation Regime in Very Low Birth Weight Infants - A Randomized Controlled Trial|Completed||N/A|46|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 02:07:16.583656|2018-06-01 02:07:16.583656
NCT00683514|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2016-10-03|2008-05-22|2008-05-23|Estimate|||||||2016-10-03|2016-10-04|Estimate|April 2005||2005-04-30|October 2016|2016-10-31||||September 2011|Actual|2011-09-30||Interventional|||Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer|Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized Phase III Study|Completed||Phase 3|201|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-06-01 02:07:16.676339|2018-06-01 02:07:16.676339
NCT00683501|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-06-02|2008-05-22|2008-05-23|Estimate|||||||2009-06-02|2009-06-03|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|DNB-001||Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure|A Phase II Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in Previously Untreated Patients With Elevated Intraocular Hypertension|Completed||Phase 1/Phase 2|54|Actual|Danube Pharmaceuticals, Inc.||5|||f||||t||||||||||2018-06-01 02:07:16.737339|2018-06-01 02:07:16.737339
NCT00683488|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-03-02|2008-05-22|2008-05-23|Estimate|||||||2017-03-02|2017-03-06|Actual|April 2008||2008-04-30|February 2016|2016-02-29|April 2011|Actual|2011-04-30|August 2010|Actual|2010-08-31||Interventional|||Integrated Treatment of Marijuana Abuse for HIV+ Youth|Integrated Treatment of Alcohol and/or Marijuana Abuse for HIV-Infected Youth - Phase I|Completed||N/A|46|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-06-01 02:07:16.802484|2018-06-01 02:07:16.802484
NCT00683475|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2014-05-16|2010-08-25|2014-10-07|2008-05-21|2008-05-23|Estimate|2014-05-16|2014-06-18|Estimate|2010-08-25|2010-08-27|Estimate|2014-10-07|2014-10-16|Estimate|August 2008||2008-08-31|October 2014|2014-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Modified intent to treat population (mITT): All participants who received any quantity of study drug.|A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer|A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy|Completed||Phase 2|138|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:07:16.910501|2018-06-01 02:07:16.910501
NCT00683462|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-10-29|2008-05-21|2008-05-23|Estimate|||||||2009-10-29|2009-10-30|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|||||Interventional|||An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)|An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|24|Anticipated|AstraZeneca||3|||f||||||||||||||2018-06-01 02:07:18.717006|2018-06-01 02:07:18.717006
NCT00683449|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2011-02-16||2011-10-05|2008-05-21|2008-05-23|Estimate|2011-06-30|2011-07-29|Estimate||||2011-10-05|2011-10-07|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma|A Phase II, Randomized, Modified Single-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma|Terminated||Phase 2|29|Actual|MediciNova||2||"Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more~   appropriate dosing scheme for MN-221 in subjects with asthma."|f||||f||||||||||2018-06-01 02:07:18.819445|2018-06-01 02:07:18.819445
NCT00683436|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2008-07-21|2008-05-21|2008-05-23|Estimate|||||||2008-07-21|2008-07-22|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|November 2008|Anticipated|2008-11-30|October 2008|Anticipated|2008-10-31||Interventional|||Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs|A Multi-Center, Randomized, Blinded, Active and Placebo-Controlled, Crossover Study of the Efficacy and Safety of Two Doses of Adipiplon Bilayer Tablets in Primary Insomniacs|Terminated||Phase 2|84|Anticipated|Neurogen Corporation||4|||f||||f||||||||||2018-06-01 02:07:19.27115|2018-06-01 02:07:19.27115
NCT00683423|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21||2010-09-10|2015-09-23|2008-05-21|2008-05-23|Estimate||||2010-09-13|2010-09-15|Estimate|2015-09-23|2015-10-12|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||BMS-741672 for Diabetic Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial to Evaluate the Efficacy and Safety of BMS-741672 in Patients With Diabetic Neuropathic Pain|Completed||Phase 2|50|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:07:19.362781|2018-06-01 02:07:19.362781
NCT00683410|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2010-10-15||2010-10-15|2008-05-22|2008-05-23|Estimate|2010-10-15|2010-11-16|Estimate||||2010-10-15|2010-11-16|Estimate|April 2007||2007-04-30|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)|A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Pneumococcal Conjugate Vaccine, 7-valent (Prevenar) 0.5 mL by Intramuscular Injection|Completed|||3366|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 02:07:19.553989|2018-06-01 02:07:19.553989
NCT00683397|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-04-18|2008-05-22|2008-05-23|Estimate|||||||2017-04-18|2017-04-19|Actual|May 2008||2008-05-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Frankfurt Thrombophilia Registry|Frankfurt Thrombophilia Registry - Evaluation of Patients With Venous Thromboembolism|Completed|||2000|Actual|Cardioangiologisches Centrum Bethanien|||1||f||||||||||Samples With DNA|"~     whole blood, serum~   "|||2018-06-01 02:07:19.73103|2018-06-01 02:07:19.73103
NCT00683384|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2010-10-15||2010-10-15|2008-05-22|2008-05-23|Estimate|2010-10-15|2010-11-16|Estimate||||2010-10-15|2010-11-16|Estimate|January 2007||2007-01-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Study Evaluating the Safety of Enbrel (Etanercept)|A Prospective, Observational Study to Monitor Safety in Patients Who Were Administered With Etanercept (Enbrel) 25 mg by Subcutaneous Injection|Completed|||93|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 02:07:19.805911|2018-06-01 02:07:19.805911
NCT00683371|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-10-30|2008-05-22|2008-05-23|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2007||2007-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis|Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis|Active, not recruiting||N/A|20|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:07:19.974194|2018-06-01 02:07:19.974194
NCT00683358|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2009-05-06|2008-05-22|2008-05-23|Estimate|||||||2009-05-06|2009-05-07|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer|Phase Ⅰ/Ⅱ Trial of Human Leukocyte Antigen (HLA)-A*2402-Restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination Combined With Gemcitabine for Advanced Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|14|Anticipated|Tokyo University||1|||f||||t||||||||||2018-06-01 02:07:20.133119|2018-06-01 02:07:20.133119
NCT00683345|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2015-08-18|2008-05-22|2008-05-23|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome|Fatigue and IL-1 Blockade in Primary Sjøgrens Syndrome|Completed||Phase 2|28|Actual|Helse Stavanger HF||2|||f||||f||||||||||2018-06-01 02:07:20.303032|2018-06-01 02:07:20.303032
NCT00683332|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2011-05-02||2011-06-09|2008-05-22|2008-05-23|Estimate|2011-06-09|2011-07-08|Estimate||||2011-06-09|2011-07-08|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)|A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release)|Completed|||621|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:07:20.387172|2018-06-01 02:07:20.387172
NCT00683319|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2013-09-19|2008-05-21|2008-05-23|Estimate|||||||2013-09-19|2013-09-20|Estimate|April 2008||2008-04-30|June 2009|2009-06-30||||March 2034|Anticipated|2034-03-31||Observational|||Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy|CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday|Active, not recruiting|||50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:07:20.57129|2018-06-01 02:07:20.57129
NCT00683306|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-12-15|2008-05-22|2008-05-23|Estimate|||||||2017-12-15|2017-12-18|Actual|January 17, 2005|Actual|2005-01-17|December 2017|2017-12-31|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|||Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment|Multicentre, Open Label, Extension Study of Treatment With Gefitinib(IRESSA™) for Patients Completing Other Gefitinib Clinical Studies Who May Benefit From Gefitinib Treatment|Completed||Phase 3|94|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 02:07:20.666679|2018-06-01 02:07:20.666679
NCT00683293|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2013-11-12||2014-03-11|2008-05-21|2008-05-23|Estimate|2014-03-11|2014-04-16|Estimate||||2014-03-11|2014-04-16|Estimate|November 2008||2008-11-30|March 2014|2014-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy|Laparoscopic Hysterectomy: a Clinical Randomized Trial Comparing Conventional and Robot-assisted(Da Vinci®)Techniques|Completed||N/A|100|Actual|Kantonsspital Aarau||2|||f||||f||||||||||2018-06-01 02:07:20.884733|2018-06-01 02:07:20.884733
NCT00683280|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2018-01-11|2008-05-22|2008-05-23|Estimate|||||||2018-01-11|2018-01-16|Actual|May 2008||2008-05-31|January 2018|2018-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|Donaghue||Contingency Management and Pharmacotherapy for Smoking Cessation|Contingency Management and Pharmacotherapy for Smoking Cessation|Completed||N/A|59|Actual|UConn Health||2|||f||||f|f|f||||||||2018-06-01 02:07:21.133512|2018-06-01 02:07:21.133512
NCT00683267|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2009-05-01|2008-05-21|2008-05-23|Estimate|||||||2009-05-01|2009-05-04|Estimate|September 2007||2007-09-30|May 2009|2009-05-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Intraoperative Localized Instillation of 4975 in Patients Undergoing Primary Unilateral Total Hip Arthroplasty|Terminated||Phase 2|118|Actual|Anesiva, Inc.||2||"Enrollment of patients has halted prematurely and will not resume. No future patients will be~   enrolled or treated."|f||||f||||||||||2018-06-01 02:07:21.211996|2018-06-01 02:07:21.211996
NCT00683254|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-05-10|2008-05-22|2008-05-23|Estimate|||||||2017-05-10|2017-05-11|Actual|May 2008|Actual|2008-05-31|May 2017|2017-05-31|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Observational|||Analysis of Impact on Nasal Obstruction by Commercially Available Internal Nasal Stents|Analysis of Impact on Nasal Obstruction by Commercially Available Internal Nasal Stents|Withdrawn|||0|Actual|University of Iowa||||Principal Investigator left institution. Project never started.|f||||f||||||||||2018-06-01 02:07:21.306259|2018-06-01 02:07:21.306259
NCT00683241|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2013-02-25|2008-05-22|2008-05-23|Estimate|||||||2013-02-25|2013-02-26|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer|A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine Leaded With Autologous Tumor Cell Lysate for Recurrent Ovarian or Primary Peritoneal Cancer|Completed||Phase 1|36|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||f||||||||||2018-06-01 02:07:21.377024|2018-06-01 02:07:21.377024
NCT00683228|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2014-11-26|2008-05-22|2008-05-23|Estimate|||||||2014-11-26|2014-12-02|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Using a Structured Tobacco Cessation Education Program|Effect of Using a Structured Tobacco Cessation Education Program in Resident Training on Reducing Secondhand Smoke Exposure in Children|Completed||N/A|31|Actual|State University of New York - Upstate Medical University||1|||f||||f||||||||||2018-06-01 02:07:21.451635|2018-06-01 02:07:21.451635
NCT00683202|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2008-05-22|2008-05-22|2008-05-23|Estimate|||||||2008-05-22|2008-05-23|Estimate|March 2001||2001-03-31|March 2001|2001-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Low-Dose Aspirin in in Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Treatments|The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study|Completed||N/A|374|Actual|University of Oulu||2|||f||||t||||||||||2018-06-01 02:07:21.523072|2018-06-01 02:07:21.523072
NCT00683189|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2011-03-18|2008-05-22|2008-05-23|Estimate|||||||2011-03-18|2011-03-21|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy|Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy|Completed||N/A|10|Anticipated|The Cooper Health System|||||f||||f||||||||||2018-06-01 02:07:21.603816|2018-06-01 02:07:21.603816
NCT00683176|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2011-08-24|2008-05-22|2008-05-23|Estimate|||||||2011-08-24|2011-08-26|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Choline Fenofibrate (SLV348) on Macular Edema|Effect of Choline Fenofibrate (SLV348) on Macular Edema Measured by Optical Coherence Tomography in Subjects With Diabetic Macular Edema - a One-year, Placebo-Controlled, Randomized Study|Completed||Phase 2|110|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:07:21.696475|2018-06-01 02:07:21.696475
NCT00683163|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2013-04-01||2013-08-29|2008-05-22|2008-05-23|Estimate|2013-08-29|2013-11-05|Estimate||||2013-08-29|2013-11-05|Estimate|May 2008||2008-05-31|August 2013|2013-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PICS||PTH & Ibandronate Combination Study (PICS)|PTH & Ibandronate Combination Study (PICS): Optimizing the Use of PTH With Boniva (Pilot Randomized Controlled Trial)|Completed||Phase 2/Phase 3|44|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:07:21.887094|2018-06-01 02:07:21.887094
NCT00683150|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2012-07-27|2008-05-21|2008-05-23|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Perioperative Kinetics of Reactive Hyperemia Using Noninvasive Digital Thermal Monitoring|Characterizing the Perioperative Kinetics of Reactive Hyperemia Using Noninvasive Digital Thermal Monitoring: an Observational Study of a Surrogate Marker of Endothelial Function|Completed|||59|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:07:22.318389|2018-06-01 02:07:22.318389
NCT00683137|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-05-22|2008-05-22|2008-05-23|Estimate|||||||2008-05-22|2008-05-23|Estimate|October 2002||2002-10-31|May 2008|2008-05-31|February 2003|Actual|2003-02-28|||||Interventional|||Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery|Clinical Protocol for a Multiple Dose Randomized, Double-Blind, Placebo Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Bunionectomy Surgery|Completed||Phase 3|450|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:07:22.457099|2018-06-01 02:07:22.457099
NCT00683124|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2011-07-20|2008-05-22|2008-05-23|Estimate|||||||2011-07-20|2011-07-22|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|MaNeLo||Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients|Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.|Unknown status|Recruiting|Phase 3|291|Anticipated|IRCCS Policlinico S. Matteo||3|||f||||t||||||||||2018-06-01 02:07:22.749847|2018-06-01 02:07:22.749847
NCT00683111|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2012-06-05|2008-05-22|2008-05-23|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease|Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction|Completed||Phase 4|500|Anticipated|Ruttonjee Hospital||2|||f||||t||||||||||2018-06-01 02:07:22.911522|2018-06-01 02:07:22.911522
NCT00683098|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2016-04-15|2008-05-22|2008-05-23|Estimate|||||||2016-04-15|2016-04-18|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Observational|||Long-term Results After Endoscopic Total Extraperitoneal Repair of Recurrent Inguinal Hernia|Long-term Results After Endoscopic Total Extraperitoneal Repair of Recurrent Inguinal Hernia|Completed|||300|Actual|St. Claraspital AG|||1||f||||f||||||||||2018-06-01 02:07:23.027155|2018-06-01 02:07:23.027155
NCT00683085|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2009-06-09||2011-07-20|2008-05-22|2008-05-23|Estimate|2010-11-22|2010-12-17|Estimate||||2011-07-20|2011-07-22|Estimate|May 2008||2008-05-31|July 2011|2011-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer|Phase I/II Trial of Human Leukocyte Antigen (HLA)-A*02:01-restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination Combined With Conventional Dose of Gemcitabine for Advanced Pancreatic Cancer|Terminated||Phase 1/Phase 2|2|Actual|Tokyo University|Early termination leading to small numbers of subjects analyzed|1||Lack of eligible patient|f||||t||||||||||2018-06-01 02:07:23.207497|2018-06-01 02:07:23.207497
NCT00683072|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2008-05-22|2008-05-22|2008-05-23|Estimate|||||||2008-05-22|2008-05-23|Estimate|March 2008||2008-03-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Patient-Ventilator Dyssynchrony: How is the Effect of Management?|Patient-Ventilator Dyssynchrony: How is the Effect of Management?|Unknown status|Recruiting||40|Anticipated|National Cheng-Kung University Hospital|||1||f||||||||||||||2018-06-01 02:07:23.588363|2018-06-01 02:07:23.588363
NCT00677547|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2011-09-13|2008-05-12|2008-05-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Observational|||Cell-mediated Immune Response to Influenza Vaccine|Humoral and Cell-mediated Immune Response to Influenza Vaccine in Kidney Tranpslant Recipients.|Completed|||100|Anticipated|University of Alberta|||2||f||||f||||||||||2018-06-01 02:09:06.97184|2018-06-01 02:09:06.97184
NCT00683059|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2016-10-14|2008-05-21|2008-05-23|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Single Agent Abraxane as Second Line Therapy in Bladder Cancer|A Multi-Institutional Phase II Study of Single Agent Abraxane as Second Line Therapy in Patients With Advanced Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|48|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-06-01 02:07:23.792863|2018-06-01 02:07:23.792863
NCT00683046|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2014-02-14||2016-10-07|2008-05-22|2008-05-23|Estimate|2014-02-14|2014-03-31|Estimate||||2016-10-07|2016-11-22|Estimate|November 2001||2001-11-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies|T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies|Completed||Phase 2|204|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 02:07:23.983446|2018-06-01 02:07:23.983446
NCT00683033|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2011-11-17|2008-05-22|2008-05-23|Estimate|||||||2011-11-17|2011-11-21|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|R21||Contingency Management for Smoking in Substance Abusers|Contingency Management for Smoking in Substance Abusers|Completed||Phase 2|51|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 02:07:24.266115|2018-06-01 02:07:24.266115
NCT00683020|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2012-12-10||2013-05-14|2008-05-21|2008-05-23|Estimate|2013-05-14|2013-05-15|Estimate||||2013-05-14|2013-05-15|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|SMARTSteps|Data is based on the 252 participants with both baseline and 6-month follow-up measures.|Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan|Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan|Completed||N/A|362|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:07:24.46225|2018-06-01 02:07:24.46225
NCT00683007|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2017-05-24|2008-05-22|2008-05-23|Estimate|||||||2017-05-24|2017-05-30|Actual|May 2011||2011-05-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Esophageal Echo Assessment of LV Function During Acute Normovolemic Hemodilution Using Crystalloid or Hypertonic Saline|Use of Transesophageal Echocardiography to Assess Left Ventricular Performance During Acute Normovolemic Hemodilution and Randomized Replacement With Intravenous Crystalloid or Hypertonic Saline|Completed||N/A|9|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 02:07:25.543625|2018-06-01 02:07:25.543625
NCT00682994|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2016-02-17|2008-05-21|2008-05-23|Estimate|||||||2016-02-17|2016-02-19|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Patient and Family Decision Making in the Palliative Care Setting|Patient and Family Decision Making and Information Disclosure Preferences in the Palliative Care Setting: a Multi-Center Survey in Chile, Guatemala, and U.S.|Completed||N/A|780|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:07:25.618081|2018-06-01 02:07:25.618081
NCT00682981|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20||2013-08-27|2016-07-19|2008-05-22|2008-05-23|Estimate||||2013-08-27|2013-09-12|Estimate|2016-07-19|2016-07-21|Estimate|May 2008||2008-05-31|July 2016|2016-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)|A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide With or Without Obatoclax Administered Every 3 Weeks to Patients With Extensive- Stage Small Cell Lung Cancer (ES-SCLC)|Completed||Phase 1/Phase 2|218|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-06-01 02:07:25.703662|2018-06-01 02:07:25.703662
NCT00682968|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2017-06-02|2008-05-22|2008-05-23|Estimate|||||||2017-06-02|2017-06-06|Actual|July 20, 2008|Actual|2008-07-20|June 2017|2017-06-30|October 1, 2008|Actual|2008-10-01|September 30, 2008|Actual|2008-09-30||Observational|||Evidence Synthesis: Hypertension Medication Adherence & Intensification|Evidence Synthesis: Hypertension Medication Adherence & Intensification|Completed|||20|Actual|VA Office of Research and Development|||||f||||f||||||||||2018-06-01 02:07:25.933255|2018-06-01 02:07:25.933255
NCT00682955|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-21|2008-05-21|2008-05-23|Estimate|||||||2008-05-21|2008-05-23|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|Zinc||Comparing the Efficacy of Different Zinc Formulations in the Treatment of Diarrhea|Comparing the Efficacy of Different Zinc Formulations in the Treatment of Acute Diarrhea Among Young Children at Hospital Based Setting in Pakistan|Completed||N/A|300|Actual|Aga Khan University||2|||f||||f||||||||||2018-06-01 02:07:25.993377|2018-06-01 02:07:25.993377
NCT00682942|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2011-11-30|2008-05-22|2008-05-23|Estimate|||||||2011-11-30|2011-12-01|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||How to Predict Lung Recruitment at the Bedside in Patients Affected by Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)|How to Predict Lung Recruitment at the Bedside in Patients Affected by Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS)|Completed|||50|Actual|Policlinico Hospital|||||f||||f||||||||||2018-06-01 02:07:26.110559|2018-06-01 02:07:26.110559
NCT00682929|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2018-01-11||2018-04-17|2008-05-22|2008-05-23|Estimate|2018-04-17|2018-05-18|Actual||||2018-04-17|2018-05-18|Actual|April 14, 2004|Actual|2004-04-14|April 2018|2018-04-30|August 17, 2011|Actual|2011-08-17|August 17, 2011|Actual|2011-08-17||Interventional|||Cannabis for Spasticity in Multiple Sclerosis|Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study|Terminated||Phase 1/Phase 2|41|Actual|University of California, Davis|This study was terminated early due to difficulty with enrollment and logistical issues, despite the enrollment period being extended over several years. Data not analyzed due to insufficient enrollment and funds, as well as the departure of the PI.|3||Unable to complete subject recruitment|f||||t||||||||No||2018-06-01 02:07:26.223025|2018-06-01 02:07:26.223025
NCT00682916|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|||2017-05-25|2008-05-22|2008-05-23|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2007||2007-04-30|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Compare Effects of a Soluble Fiber on Weight and Blood Cholesterol|CCRC: FBCx® And Body Weight Regulation in Overweight Humans|Completed||N/A|42|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 02:07:28.115423|2018-06-01 02:07:28.115423
NCT00682903|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2014-08-27|2008-05-22|2008-05-23|Estimate|||||||2014-08-27|2014-08-28|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Use of a Bearable Continuous Interstitial Glucose Monitoring Device (GuardianR) During Teaching Sessions to Functional Insulin Therapy Concept in Patients Suffering From Type 1 Diabetes: Evaluation at 6 and 12 Months|Use of a Bearable Continuous Interstitial Glucose Monitoring Device (GuardianR) During Teaching Sessions to Functional Insulin Therapy Concept in Patients Suffering From Type 1 Diabetes: Evaluation at 6 and 12 Months|Completed||N/A|64|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-06-01 02:07:28.196453|2018-06-01 02:07:28.196453
NCT00682890|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-21|2014-01-21||2014-08-01|2008-05-22|2008-05-23|Estimate|2014-08-01|2014-08-20|Estimate||||2014-08-01|2014-08-20|Estimate|November 2005||2005-11-30|August 2014|2014-08-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)|Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)|Terminated||Phase 4|28|Actual|Virginia Commonwealth University|study duration was relatively brief,earlier serum markers of the inflammatory process,e.g.,IL-6, were not evaluated,sample size planned was not achieved despite intensive recruitment efforts.|2||Lack of recruitment|f||||t||||||||||2018-06-01 02:07:28.300696|2018-06-01 02:07:28.300696
NCT00682877|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-22|2008-05-22|2008-05-23|Estimate|||||||2008-05-22|2008-05-23|Estimate|July 2007||2007-07-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Observational|GETOver65||A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old|A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time - In Subjects Over 65 Years of Age|Completed|||23|Actual|The SmartPill Corporation|||2||f||||f||||||||||2018-06-01 02:07:28.535495|2018-06-01 02:07:28.535495
NCT00682851|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2011-07-08||2016-08-15|2008-05-21|2008-05-22|Estimate|2011-07-08|2011-08-08|Estimate||||2016-08-15|2016-09-22|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test|A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test|Completed|||519|Actual|University of Pittsburgh|A major limitation of this study was that in the first 122 women, 24% of the cohort, the vaginal swabs used for the diagnostic tests were collected in random order, which resulted in decreased sensitivity of the OSOM Rapid and BVBLue tests.||||f||||f||||||||No||2018-06-01 02:07:28.609314|2018-06-01 02:07:28.609314
NCT00682838|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|2015-07-08||2016-07-20|2008-05-19|2008-05-22|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|July 2009||2009-07-31|July 2016|2016-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional||The target population for this study is all Veterans with OSA. It was expected that most participants would be middle-aged and older men and women, from a variety of ethnic backgrounds and with a full range of medical co-morbidities.|Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring|Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring|Completed||Phase 2/Phase 3|280|Actual|VA Office of Research and Development||4|||f||||f||||||||No||2018-06-01 02:07:28.970457|2018-06-01 02:07:28.970457
NCT00682825|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2011-01-03|2008-05-21|2008-05-22|Estimate|||||||2011-01-03|2011-01-04|Estimate|March 2008||2008-03-31|January 2011|2011-01-31||||December 2010|Actual|2010-12-31||Interventional|BAG-RECALL||Study Evaluating Whether the Bispectral Index Prevents Patients at Higher Risk From Being Awake During Surgery and Anesthesia|BAG-RECALL Study: BIS or Anesthesia Gas to Reduce Explicit Recall|Completed||Phase 4|6000|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:07:29.256774|2018-06-01 02:07:29.256774
NCT00682812|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2014-08-27|2008-05-21|2008-05-22|Estimate|||||||2014-08-27|2014-08-28|Estimate|June 2008||2008-06-30|January 2010|2010-01-31|December 2014|Anticipated|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Significance of the High-risk Hpv Viral Load|Significance of the High-risk Hpv Viral Load|Unknown status|Active, not recruiting|N/A|149|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-06-01 02:07:29.341254|2018-06-01 02:07:29.341254
NCT00682799|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2015-01-14|2008-05-16|2008-05-22|Estimate|||||||2015-01-14|2015-01-15|Estimate|April 2007||2007-04-30|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC)|Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC) EWOG MDS SCT RC RIC-06|Completed|||112|Actual|University Hospital Freiburg|||||f||||f||||||Samples With DNA|"~     Hematopoietic chimerism will be investigated from PB samples. Prior to transplant 5 ml EDTA~     PB from patient and donor are required and will be sent to the laboratory of the Coordinating~     Investigator (P.B.). Post transplant PB samples (5 -10 ml EDTA blood) from day +30 (4 days),~     +60(4 days), +100 (7 days) and +180 (7 days) will also being sent to the laboratory of the~     Coordinating Investigator (P.B.) From EDTA PB cell subpopulations will be isolated and DNA~     will be extracted and stored for further investigations.~   "|||2018-06-01 02:07:29.412304|2018-06-01 02:07:29.412304
NCT00682786|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2014-07-14||2017-09-07|2008-05-16|2008-05-22|Estimate|2014-09-05|2014-09-08|Estimate||||2017-09-07|2017-10-06|Actual|October 2002||2002-10-31|September 2017|2017-09-30|August 2010|Actual|2010-08-31|December 2008|Actual|2008-12-31||Interventional|||Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma|Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma|Completed||Phase 2|135|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:07:29.548135|2018-06-01 02:07:29.548135
NCT00682773|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-08-02|2008-05-20|2008-05-22|Estimate|||||||2011-08-02|2011-08-04|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|||Enhancing the Safety of Warfarin in Nursing Homes|Enhancing the Safety of Warfarin in Nursing Homes|Completed||N/A|26|Anticipated|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 02:07:30.638121|2018-06-01 02:07:30.638121
NCT00682760|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-21|2008-05-21|2008-05-22|Estimate|||||||2008-05-21|2008-05-22|Estimate|October 2005||2005-10-31|May 2008|2008-05-31|August 2006|Actual|2006-08-31|February 2006|Actual|2006-02-28||Interventional|||Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm|Double-Blind, Randomized, Phase 3, Comparative Study of a New Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm|Completed||Phase 3|60|Actual|Pacific Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:07:30.71049|2018-06-01 02:07:30.71049
NCT00682747|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2016-10-26|2008-05-16|2008-05-22|Estimate|||||||2016-10-26|2016-10-27|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Hyperbaric Oxygen for the Treatment of a Dry Mouth Which Occurred After Radiotherapy|Randomized Phase II Trial of Hyperbaric Oxygen for the Treatment of Radiation-induced Xerostomia|Terminated||Phase 2|13|Actual|Martin-Luther-Universität Halle-Wittenberg||2||poor recruitment|f||||f||||||||||2018-06-01 02:07:30.780067|2018-06-01 02:07:30.780067
NCT00682734|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2011-07-24||2018-05-01|2008-05-21|2008-05-22|Estimate|2012-11-28|2012-12-31|Estimate||||2018-05-01|2018-05-31|Estimate|April 2008||2008-04-30|May 2018|2018-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|MDFS||Metoclopramide for Migraine: A Dose Finding Study|Metoclopramide for Acute Migraine: A Dose Finding Study|Completed||Phase 3|349|Actual|Montefiore Medical Center||3|||f||||t||||||||||2018-06-01 02:07:30.849249|2018-06-01 02:07:30.849249
NCT00680862|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2014-08-27||2014-09-26|2008-05-19|2008-05-20|Estimate|2014-09-26|2014-09-29|Estimate||||2014-09-26|2014-09-29|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational||VA employees|Qualitative Assessment of Implementing Routine Rapid HIV Testing|Qualitative Assessment of Implementing Routine Rapid HIV Testing|Completed|||25|Actual|VA Office of Research and Development|||1||f||||t||||||||||2018-06-01 02:07:58.280466|2018-06-01 02:07:58.280466
NCT00682721|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2012-02-29|2008-05-21|2008-05-22|Estimate|||||||2012-02-29|2012-03-02|Estimate|February 2009||2009-02-28|February 2012|2012-02-29|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women|Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||Sponsor has withdrawn support for this study and it will not be performed|f||||f||||||||||2018-06-01 02:07:31.055191|2018-06-01 02:07:31.055191
NCT00682708|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-05-21|2008-05-21|2008-05-22|Estimate|||||||2008-05-21|2008-05-22|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Sentinel Surveillance of Malnutrition, Niger|Sentinel Surveillance of Acute Malnutrition in the Region of Maradi, Niger, Children Under 5: Impact of a Preventive Intervention|Completed||N/A|||Epicentre|||||f||||f||||||||||2018-06-01 02:07:31.147793|2018-06-01 02:07:31.147793
NCT00682695|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2017-07-19|2008-05-20|2008-05-22|Estimate|||||||2017-07-19|2017-07-21|Actual|September 1997||1997-09-30|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|GERFHS||Genetic and Environmental Risk Factors for Hemorrhagic Stroke|Genetic and Environmental Risk Factors for Hemorrhagic Stroke|Recruiting|||1000|Anticipated|University of Cincinnati|||1||f||||f||||||Samples With DNA|"~     whole blood DNA, RNA and CBA~   "|||2018-06-01 02:07:31.204183|2018-06-01 02:07:31.204183
NCT00682682|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-09-12|2008-05-20|2008-05-22|Estimate|||||||2011-09-12|2011-09-13|Estimate|December 2007||2007-12-31|September 2011|2011-09-30|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|4DO||Reducing Brief Thermal and Electrical Pain (Four Study Days)|Reducing Brief Thermal and Electrical Pain (Four Study Days)|Completed||N/A|20|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:07:31.371657|2018-06-01 02:07:31.371657
NCT00682669|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-08-18|2008-05-20|2008-05-22|Estimate|||||||2011-08-18|2011-08-19|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Asthma and Mindfulness-Based Stress Reduction (MBSR)|Asthma and Mindfulness-Based Stress Reduction (MBSR)|Completed||Phase 1/Phase 2|83|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 02:07:31.458277|2018-06-01 02:07:31.458277
NCT00682656|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2014-10-16|2008-05-21|2008-05-22|Estimate|||||||2014-10-16|2014-10-17|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|PCL01||Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis|Open Label Randomized Study to Assess Safety and Efficacy of Azithromycin Versus Meglumine Antimoniate to Treat Cutaneous Leishmaniasis|Terminated||Phase 2/Phase 3|48|Actual|Oswaldo Cruz Foundation||2||Efficacy issues on test arm|f||||f||||||||||2018-06-01 02:07:31.523316|2018-06-01 02:07:31.523316
NCT00682643|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2011-12-08||2016-11-29|2008-05-20|2008-05-22|Estimate|2012-02-09|2012-03-13|Estimate||||2016-11-29|2017-01-13|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescents 12 Years of Age and Older With Perennial Allergic Rhinitis|Completed||Phase 4|550|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:07:31.655419|2018-06-01 02:07:31.655419
NCT00682630|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-01-21|2008-05-21|2008-05-22|Estimate|||||||2009-01-21|2009-01-22|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|SP-C-009-07||Bioequivalence of Pyronaridine Artesunate to-be-Marketed Tablet to the Clinical Trial Reference Tablet|Bioequivalence Trial of Pyronaridine:Artesunate to-be-Marketed Tablet to the Clinical Trial Reference Tablet|Completed||Phase 1|42|Anticipated|Medicines for Malaria Venture||2|||f||||t||||||||||2018-06-01 02:07:32.898294|2018-06-01 02:07:32.898294
NCT00682617|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2013-05-06|2008-05-21|2008-05-22|Estimate|||||||2013-05-06|2013-05-08|Estimate|August 2006||2006-08-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Hip Osteoarthritis: Effects of Exercise Programs on Pain and Disability|Hip Osteoarthritis: Effects of Structured Exercise Programs on Pain and Long-term Disability|Unknown status|Recruiting|N/A|30|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 02:07:32.979781|2018-06-01 02:07:32.979781
NCT00682604|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-20|2008-05-20|2008-05-22|Estimate|||||||2008-05-20|2008-05-22|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|October 2006|Actual|2006-10-31|||||Observational|||The Nutritional Status and Food Intake of Community Health Agents|Community Health Agents From East Zone of Sao Paulo City, Brazil: A Look at Their Nutritional Status and Food Intake|Completed|||88|Actual|Unidade Itaquera|||||f||||f||||||||||2018-06-01 02:07:33.072768|2018-06-01 02:07:33.072768
NCT00682591|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2009-02-03|2008-05-21|2008-05-22|Estimate|||||||2009-02-03|2009-02-04|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy|Evaluation of Neurocognitive Performance, Quality of Life, and Emotional State in Drug Substituted Patients (Methadone, Buprenorphine, Suboxone) Under Hepatitis C Therapy (Peginterferon Alfa and Ribavirin)|Withdrawn|||190|Anticipated|University of Wuerzburg||||Study had to be withdrawn because financial support was cancelled.|f||||t||||||||||2018-06-01 02:07:33.141396|2018-06-01 02:07:33.141396
NCT00682578|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2018-05-03|2008-05-21|2008-05-22|Estimate|||||||2018-05-03|2018-05-09|Actual|July 2007|Actual|2007-07-31|May 2018|2018-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan|Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan|Completed||Phase 3|1086|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 02:07:33.215068|2018-06-01 02:07:33.215068
NCT00682565|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2009-11-30||2010-02-03|2008-05-21|2008-05-22|Estimate|2010-02-03|2010-02-25|Estimate||||2010-02-03|2010-02-25|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Pharmacokinetics (PK) and Tolerability of Intravenous (IV) and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina|Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina|Completed||Phase 2|94|Actual|Cytokinetics||2|||f||||||||||||||2018-06-01 02:07:33.316547|2018-06-01 02:07:33.316547
NCT00681954|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2015-01-14|2008-05-19|2008-05-21|Estimate|||||||2015-01-14|2015-01-16|Estimate|October 2005||2005-10-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2012|Actual|2012-01-31||Observational|||Mild Pulmonary Function Changes With Transfusion|Mild Pulmonary Function Changes With Transfusion|Completed|||92|Actual|University of California, San Francisco|||1||f||||f||||||Samples Without DNA|"~     Biospecimens are retained for cytokine and inflammatory marker analyses.~   "|||2018-06-01 02:07:38.929298|2018-06-01 02:07:38.929298
NCT00682552|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2014-08-27|2008-05-21|2008-05-22|Estimate|||||||2014-08-27|2014-08-28|Estimate|May 2008||2008-05-31|August 2014|2014-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence|Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence|Terminated||N/A|14|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-06-01 02:07:33.936518|2018-06-01 02:07:33.936518
NCT00682539|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2015-11-06||2016-03-03|2008-05-21|2008-05-22|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|October 2007||2007-10-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TRIASTIN|The sample size will be calculated so that a true group difference in changes of macular edema of 50 μm can be detected with a probability of 90 %. Repeated-measures-ANOVA will be used to reveal differences between macular edema measurements before and after treatment and between groups|Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema|A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema|Completed||Phase 4|71|Actual|Medical University of Vienna||3|||f||||t||||||||No||2018-06-01 02:07:34.167185|2018-06-01 02:07:34.167185
NCT00682526|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-02-21|2008-05-20|2008-05-22|Estimate|||||||2012-02-21|2012-02-23|Estimate|June 2003||2003-06-30|February 2012|2012-02-29|May 2010|Actual|2010-05-31|September 2008|Actual|2008-09-30||Observational|||Pre-Hospital Wireless Transmission of Electrocardiograms to a Cardiologist Via a Hand-Held Device|Pre-hospital Wireless Transmission of Electrocardiograms to a Cardiologist Via a Hand-held Device: The TIME Multicenter Study|Completed|||527|Actual|Welch Allyn|||3||f||||f||||||||||2018-06-01 02:07:34.843248|2018-06-01 02:07:34.843248
NCT00682513|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2017-10-31|2008-05-21|2008-05-22|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2008||2008-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders|Clinical, Genetic, and Cellular Consequences of Mutations in the NA,K-ATPase ATP1A3|Recruiting|||130|Anticipated|Wake Forest University Health Sciences|||1||f||||f||||||Samples With DNA|"~     whole blood, tissue (saliva samples)~   "|No||2018-06-01 02:07:34.92755|2018-06-01 02:07:34.92755
NCT00682500|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2012-07-23|2008-05-21|2008-05-22|Estimate|||||||2012-07-23|2012-07-24|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|CARDS||Calfactant for Direct Acute Respiratory Distress Syndrome|Calfactant Therapy for Direct Acute Respiratory Distress Syndrome & Direct Acute Lung Injury in Adults and Children|Terminated||Phase 3|332|Actual|Pneuma Pharmaceuticals Incorporated||2||Expected mortality rates in placebo and treatment groups lower than predicted|f||||t||||||||||2018-06-01 02:07:35.143409|2018-06-01 02:07:35.143409
NCT00682487|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2009-06-18|2008-05-20|2008-05-22|Estimate|||||||2009-06-18|2009-06-19|Estimate|June 2008||2008-06-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Hair Cortisol and the Risk of Acute Myocardial Infarction|Hair Cortisol and the Risk of Acute Myocardial Infarction|Completed|||120|Actual|Meir Medical Center|||2||f||||t||||||||||2018-06-01 02:07:35.308556|2018-06-01 02:07:35.308556
NCT00682474|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-08-18|2008-05-20|2008-05-22|Estimate|||||||2011-08-18|2011-08-19|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|February 2010|Actual|2010-02-28|June 2009|Actual|2009-06-30||Interventional|||School Nurse-Delivered Smoking Cessation Intervention|School Nurse-Delivered Smoking Cessation Intervention|Completed||Phase 2/Phase 3|1058|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 02:07:35.388032|2018-06-01 02:07:35.388032
NCT00682461|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2013-01-24||2013-01-24|2008-05-20|2008-05-22|Estimate|2013-01-24|2013-03-01|Estimate||||2013-01-24|2013-03-01|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Oral Tolerability Of Two Nicotine Dosage Forms|A Randomized, Open Label Study to Evaluate the Oral Tolerability of a Nicotine Prototype|Completed||Phase 1|200|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:07:35.459274|2018-06-01 02:07:35.459274
NCT00682448|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20||2012-11-29|2012-12-10|2008-05-21|2008-05-22|Estimate||||2012-12-10|2012-12-12|Estimate|2012-12-10|2012-12-12|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Metformin for the Prevention of the Metabolic Side-effects of Zyprexa|Metformin to Prevent the Metabolic Complications of Olanzapine|Completed||Phase 4|27|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 02:07:35.683821|2018-06-01 02:07:35.683821
NCT00682435|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-05-21|2008-05-21|2008-05-22|Estimate|||||||2008-05-21|2008-05-22|Estimate|June 2007||2007-06-30|May 2008|2008-05-31||||November 2007|Actual|2007-11-30||Interventional|||Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients|Safety and Speed of Onsent of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg in the Treatment of Adult ED Patients With Moderate to Severe Pain|Unknown status|Active, not recruiting|Phase 4|350|Anticipated|Montefiore Medical Center|||||f||||f||||||||||2018-06-01 02:07:35.790989|2018-06-01 02:07:35.790989
NCT00682422|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2015-10-01|2008-05-21|2008-05-22|Estimate|||||||2015-10-01|2015-10-05|Estimate|February 2008||2008-02-29|June 2010|2010-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Kid STRIDE: Exploring Participation in a Family-based Intervention|Kid STRIDE: Exploring Participation in a Family-based Intervention|Completed|||10|Actual|University of Wisconsin, Madison|||1||f||||f||||||||||2018-06-01 02:07:35.926519|2018-06-01 02:07:35.926519
NCT00682409|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2014-08-27|2008-05-20|2008-05-22|Estimate|||||||2014-08-27|2014-08-28|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Magnetic Resonance (MR) Imaging in the Post Operative Follow-up of Cholesteatoma in Children||Completed||N/A|37|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-06-01 02:07:36.011872|2018-06-01 02:07:36.011872
NCT00682383|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2012-10-29|2008-05-21|2008-05-22|Estimate|||||||2012-10-29|2012-10-30|Estimate|September 2003||2003-09-30|October 2012|2012-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)|Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC|Completed||Phase 2|26|Actual|Mt. Sinai Medical Center, Miami||1|||f||||t||||||||||2018-06-01 02:07:36.098767|2018-06-01 02:07:36.098767
NCT00682370|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2013-01-13|2008-05-21|2008-05-22|Estimate|||||||2013-01-13|2013-01-15|Estimate|October 2007||2007-10-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|HEMAHS||Effects of Heme Arginate in Healthy Male Subjects|Dose Escalation, Randomized, Placebo Controlled Study to Investigate the Effects of Intravenous Heme Arginate on Heme Oxygenase-1 (HO-1) and Heme Metabolism in Association With HO-1 Gene GTn Promoter Polymorphism in Healthy Male Subjects|Completed||Phase 1|15|Actual|Medical University of Vienna||4|||f||||f||||||||||2018-06-01 02:07:36.179671|2018-06-01 02:07:36.179671
NCT00682318|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2018-01-14|2008-05-21|2008-05-22|Estimate|||||||2018-01-14|2018-01-17|Actual|May 2008||2008-05-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers|Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers: a Randomized Double-blinded Trial on the Modulation of the Eicosanoid and Isoprostane Pathways in Healthy Subjects by Omega-3 Polyunsaturated Fatty Acids and Red Wine.|Active, not recruiting||N/A|40|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 02:07:36.66722|2018-06-01 02:07:36.66722
NCT00682305|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2015-05-12|2008-05-21|2008-05-22|Estimate|||||||2015-05-12|2015-05-13|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional|||Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)|Allogeneic Stem Cell Transplantation With Treosulfan, VP-16 and Cyclophosphamide for Patients With Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-containing Conditioning Regimen: A Phase II-study|Completed||Phase 2|50|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-06-01 02:07:36.765908|2018-06-01 02:07:36.765908
NCT00682292|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-21|2008-05-21|2008-05-22|Estimate|||||||2008-05-21|2008-05-22|Estimate|May 2001||2001-05-31|February 2004|2004-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|TAXI||Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk|Multicenter Randomized Study to Compare Induction Therapy With Polyclonal Antithymocytes Globulins (ATG) Versus Monoclonal Anti-IL2R Antibody (Daclizumab) in a Triple Drug Regimen in Renal Transplant Recipients With High Immunological Risk.|Completed||Phase 3|227|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-06-01 02:07:36.845145|2018-06-01 02:07:36.845145
NCT00682279|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2015-04-15|2008-05-20|2008-05-22|Estimate|||||||2015-04-15|2015-04-17|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors|A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Oral Topotecan in Combination With Lapatinib in Subjects With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1||Cancelled before enrollment|f||||||||||||||2018-06-01 02:07:36.944764|2018-06-01 02:07:36.944764
NCT00682266|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2012-01-05|2008-05-21|2008-05-22|Estimate|||||||2012-01-05|2012-01-06|Estimate|February 2004||2004-02-29|January 2012|2012-01-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||High-intensity Exercise Training or Multidisciplinary Treatment in Extremely Obese Adolescents|Reducing Cardiovascular Risk Factors In Overweight Adolescents: Multidisciplinary Treatment and Intensity Controlled Interval Training|Completed||N/A|54|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 02:07:37.02533|2018-06-01 02:07:37.02533
NCT00682253|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2009-09-08|2008-05-21|2008-05-22|Estimate|||||||2009-09-08|2009-09-10|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Use of Bone Scintigraphy, CT and MRI in Breast Cancer|Use og Bone Scintigraphy, CT and MRI for Detection of Metastases in Patients With Breast Cancer|Unknown status|Recruiting||180|Anticipated|University of Aarhus|||||f||||||||||||||2018-06-01 02:07:37.100277|2018-06-01 02:07:37.100277
NCT00682240|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2015-02-13|2008-05-21|2008-05-22|Estimate|||||||2015-02-13|2015-02-16|Estimate|October 2007||2007-10-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|pascal||Morphological and Functional Retinal Changes Following Retinal Photocoagulation|Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion|Completed||Phase 4|64|Actual|Medical University of Vienna||4|||f||||||||||||||2018-06-01 02:07:37.160834|2018-06-01 02:07:37.160834
NCT00682227|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-23|2008-05-20|2008-05-22|Estimate|||||||2008-05-23|2008-05-29|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Peptide Vaccination in Treating Patients With Esophageal Cancer|Phase I Study of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 1|10|Anticipated|University of Yamanashi||1|||f||||t||||||||||2018-06-01 02:07:37.246256|2018-06-01 02:07:37.246256
NCT00682214|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-06-14|2008-05-20|2008-05-22|Estimate|||||||2011-06-14|2011-06-15|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|MRVD||Cholecalciferol Supplementation, Muscle Strength|Skeletal Muscle Strength Including Its Energy Metabolism, Bone Mineral Homeostasis and Th1/Th2 Cytokines Expression in Asian Indians With Chronic Hypovitaminosis D Before and After Oral Cholecalciferol Supplementation|Completed||Phase 1|40|Actual|Indian Council of Medical Research||2|||f||||f||||||||||2018-06-01 02:07:37.329124|2018-06-01 02:07:37.329124
NCT00682201|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-07-03|2008-05-21|2008-05-22|Estimate|||||||2011-07-03|2011-07-06|Estimate|August 2007||2007-08-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Hemodynamic Changes During Normal Pregnancy|Hemodynamic Changes During Normal Pregnancy: A Prospective Cohort Study of 100 Healthy Pregnant Women|Completed|||120|Anticipated|Oslo University Hospital|||1||f||||t||||||||||2018-06-01 02:07:37.427535|2018-06-01 02:07:37.427535
NCT00682188|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2014-03-12|2008-05-20|2008-05-22|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 2008||2008-09-30|March 2014|2014-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A School Nurse-Delivered Intervention for Overweight and At Risk Adolescents|A School Nurse-Delivered Intervention for Overweight and At Risk Adolescents|Completed||Phase 1|84|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 02:07:37.491176|2018-06-01 02:07:37.491176
NCT00682175|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2009-03-25|2008-05-20|2008-05-22|Estimate|||||||2009-03-25|2009-03-26|Estimate|May 2008||2008-05-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Metabolic Derangements in Acute Heart Failure Syndrome|Metabolic Derangements in Acute Heart Failure Syndrome|Terminated|||100|Anticipated|The Cleveland Clinic|||1|Project not initiated|f||||f||||||Samples Without DNA|"~     serum, plasma~   "|||2018-06-01 02:07:37.561852|2018-06-01 02:07:37.561852
NCT00682162|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2015-01-12|2008-05-20|2008-05-22|Estimate|||||||2015-01-12|2015-01-13|Estimate|January 1998||1998-01-31|May 2008|2008-05-31|June 1999|Actual|1999-06-30|January 1999|Actual|1999-01-31||Interventional|||Impact of Acupuncture on Vasomotor Rhinitis|Impact of Acupuncture on Vasomotor Rhinitis: a Randomised Placebo Controlled Pilot Study|Completed||Phase 3|24|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-06-01 02:07:37.633569|2018-06-01 02:07:37.633569
NCT00682149|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-20|2008-05-20|2008-05-22|Estimate|||||||2008-05-20|2008-05-22|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|October 2008|Anticipated|2008-10-31|July 2008|Anticipated|2008-07-31||Interventional|||Effects of Polyphenol Containing Antioxidants on Oxidative Stress in Diabetic Patients|Effects Polyphenol Containing Antioxidants on Oxidative Stress in Diabetic Patients|Unknown status|Recruiting|N/A|120|Anticipated|Yeditepe University Hospital||2|||f||||f||||||||||2018-06-01 02:07:37.71019|2018-06-01 02:07:37.71019
NCT00682136|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2010-06-02|2008-05-21|2008-05-22|Estimate|||||||2010-06-02|2010-06-03|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Analgesic Efficacy of Local Anesthetic Transversus Abdominis Plane (TAP) Blocks in Abdominal Surgery|Efficacy of Local Anesthetic TAP Blocks in Providing Pain Relief Following Laparoscopic and Open Abdominal Surgery|Completed||Phase 1|206|Anticipated|Hunter Colorectal Research||2|||f||||f||||||||||2018-06-01 02:07:37.792142|2018-06-01 02:07:37.792142
NCT00682123|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-05-20|2008-05-20|2008-05-22|Estimate|||||||2008-05-20|2008-05-22|Estimate|March 2006||2006-03-31|May 2008|2008-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Risk of Positive Doping Tests Following Ingestion of Supplements Contaminated With Trace Quantities of Nandrolone Metabolites|Supplement Contamination: Detection of Nandrolone Metabolites in Urine After Administration of Small Doses of a Nandrolone Precursor|Completed||Phase 1/Phase 2|20|Actual|Loughborough University|||||f||||f||||||||||2018-06-01 02:07:37.858361|2018-06-01 02:07:37.858361
NCT00682110|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2010-03-31|2008-05-21|2008-05-22|Estimate|||||||2010-03-31|2010-04-01|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|January 2009|Actual|2009-01-31||Observational|OLT||Hemodynamic Measurements During Liver Transplantation|Comparing Different Methods For Measurement of Cardiac Output During Orthotopic Liver Transplantation|Completed|||30|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 02:07:37.909036|2018-06-01 02:07:37.909036
NCT00682097|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2016-11-01|2008-05-20|2008-05-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2008||2008-05-31|November 2016|2016-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.|A Randomized, Double-Blind, Multiple-Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO4998452 Following Oral Administrations in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|55|Actual|Hoffmann-La Roche||7|||f||||||||||||||2018-06-01 02:07:37.961308|2018-06-01 02:07:37.961308
NCT00682084|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2017-12-21|2008-05-20|2008-05-22|Estimate|||||||2017-12-21|2017-12-22|Actual|April 2008||2008-04-30|December 2014|2014-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome|Insulin Sensitivity and Substrate Metabolism in Patients With Cushing's Syndrome Before and After Surgical Treatment|Terminated|||1|Actual|University of Aarhus|||1|Recruitment problems|f||||f||||||Samples Without DNA|"~     Whole blood, serum, muscle samples, fat samples~   "|||2018-06-01 02:07:38.033553|2018-06-01 02:07:38.033553
NCT00682071|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2015-10-01|2008-05-16|2008-05-22|Estimate|||||||2015-10-01|2015-10-05|Estimate|August 2003||2003-08-31|May 2008|2008-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Ultrasound Guided Embryo Transfer: Abdominal Versus Transvaginal, a RCT|Abdominal Versus Transvaginal Ultrasound Guided Embryo Transfer: Results of a Randomized Clinical Trial|Completed|||224|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-06-01 02:07:38.093014|2018-06-01 02:07:38.093014
NCT00682058|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2016-06-01|2008-05-20|2008-05-22|Estimate|||||||2016-06-01|2016-06-03|Estimate|October 2006||2006-10-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Body Composition & REE Responses to Bariatric Surgery|Body Composition & REE Responses to Bariatric Surgery|Active, not recruiting|||106|Actual|Columbia University|||1||f||||t||||||||Undecided||2018-06-01 02:07:38.14662|2018-06-01 02:07:38.14662
NCT00682045|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2010-06-01|2008-05-20|2008-05-21|Estimate|||||||2010-06-01|2010-06-02|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Latent Tuberculosis Infection in Renal Transplant Recipients|A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Renal Transplant Recipients|Completed|||240|Anticipated|Asan Medical Center|||1||f||||t||||||Samples With DNA|"~     peripheral blood mononuclear cells~   "|||2018-06-01 02:07:38.358354|2018-06-01 02:07:38.358354
NCT00682032|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2018-03-01|2008-05-20|2008-05-21|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2008||2008-04-30|March 2018|2018-03-31|March 2029|Anticipated|2029-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Effect of Beta-glucan in Non-Small Cell Lung Cancer|Beta-glucan's Immuno-modulatory Effect on Non-Small Cell Lung Cancer|Recruiting||N/A|300|Anticipated|University of Louisville||2|||f||||t||||||||||2018-06-01 02:07:38.415801|2018-06-01 02:07:38.415801
NCT00682019|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2013-10-10|2008-05-20|2008-05-21|Estimate|||||||2013-10-10|2013-10-14|Estimate|December 2003||2003-12-31|October 2013|2013-10-31|August 2004|Actual|2004-08-31|||||Interventional|||Study Evaluation the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction for 10 Weeks|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Duration of Efficacy and Safety of Vardenafil Administered for 10 Weeks in a Flexible-Dose Regimen Compared to Placebo in Subjects With Erectile Dysfunction|Completed||Phase 3|383|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:07:38.551541|2018-06-01 02:07:38.551541
NCT00682006|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2011-07-07|2008-05-20|2008-05-21|Estimate|||||||2011-07-07|2011-07-08|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|Chlorhexidine||Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan|Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan: A Community-based Randomized Control Trial|Completed||Phase 3|9800|Actual|Aga Khan University||4|||f||||f||||||||||2018-06-01 02:07:38.621469|2018-06-01 02:07:38.621469
NCT00681993|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2012-11-15|2008-05-20|2008-05-21|Estimate|||||||2012-11-15|2012-11-16|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|July 2017|Anticipated|2017-07-31|June 2014|Anticipated|2014-06-30||Interventional|PBIC||Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens|"A Feasibility Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens (PBIC)"|Unknown status|Active, not recruiting|N/A|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||5|||f||||t||||||||||2018-06-01 02:07:38.708726|2018-06-01 02:07:38.708726
NCT00681980|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2015-12-01|2008-05-19|2008-05-21|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2009|Actual|2009-09-30||Interventional|||Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)|Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil|Completed||Phase 3|60|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-06-01 02:07:38.794831|2018-06-01 02:07:38.794831
NCT00681967|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2010-09-21|2008-05-20|2008-05-21|Estimate|||||||2010-09-21|2010-09-23|Estimate|February 2004||2004-02-29|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|IRESSA&H&N||Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer|Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial|Completed||Phase 1|30|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:07:38.861561|2018-06-01 02:07:38.861561
NCT00681941|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2015-03-19|2008-05-20|2008-05-21|Estimate|||||||2015-03-19|2015-03-20|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis|An Open Label, Dose Titration of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis|Completed||Phase 3|49|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:07:38.989855|2018-06-01 02:07:38.989855
NCT00681928|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-11-30|2008-05-20|2008-05-21|Estimate|||||||2011-11-30|2011-12-02|Estimate|October 2007||2007-10-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy|The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients With Breast Cancer|Completed|||72|Actual|City of Hope Medical Center|||2||f||||t||||||||||2018-06-01 02:07:40.018677|2018-06-01 02:07:40.018677
NCT00681915|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2010-12-07|2008-05-19|2008-05-21|Estimate|||||||2010-12-07|2010-12-09|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|MAD||AZD7325 Multiple Ascending Dose Study|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7325 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-child Bearing Potential|Completed||Phase 1|48|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:07:40.128266|2018-06-01 02:07:40.128266
NCT00681902|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-02-04|2008-05-20|2008-05-21|Estimate|||||||2009-02-04|2009-02-06|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|November 2007|Actual|2007-11-30||Interventional|||Jet Lidocaine for Pain Relief During Needle Insertion in a Pediatric Emergency Department|Jet Lidocaine for Pain Relief During Needle Insertion in a Pediatric Emergency Department.|Completed||N/A|150|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 02:07:40.239974|2018-06-01 02:07:40.239974
NCT00681889|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2012-10-10||2012-10-10|2008-05-20|2008-05-21|Estimate|2012-10-10|2012-11-08|Estimate||||2012-10-10|2012-11-08|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)|Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)|Completed||Phase 1|9|Actual|Massachusetts Eye and Ear Infirmary|Further and larger studies are needed to better establish the efficacy profile of this drug and optimize its dosing and formulation.|1|||f||||f||||||||||2018-06-01 02:07:40.322602|2018-06-01 02:07:40.322602
NCT00681876|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2013-02-12|2008-05-20|2008-05-21|Estimate|||||||2013-02-12|2013-02-13|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer|Phase II Study of Avastin Plus Erbitux Plus Irinotecan as 2nd Line Treatment of Locally Advanced or Metastatic Colorectal Cancer in Patients Achieving Disease Progression as Best Response After 1st Line Treatment With FOLFIRI+Avastin or XELIRI+Avastin|Terminated||Phase 2|16|Actual|Hellenic Oncology Research Group||1||Due to poor accrual|f||||f||||||||||2018-06-01 02:07:40.466767|2018-06-01 02:07:40.466767
NCT00681863|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2010-10-13||2014-05-07|2008-05-20|2008-05-21|Estimate|2010-11-23|2010-12-17|Estimate||||2014-05-07|2014-05-23|Estimate|May 2008||2008-05-31|May 2014|2014-05-31||||October 2009|Actual|2009-10-31||Interventional||Treated Set (TS) included all patients who were entered, were dispensed study medication and were documented to have taken at least one dose of study medication.|Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome|Open Label Extension Study With Pramipexole (PPX) in Children With Tourette Syndrome|Terminated||Phase 3|45|Actual|Boehringer Ingelheim|The sponsor cancelled this trial prematurely. Thus, enrollment for 248.642 (NCT00681863) was significantly less than what was planned (120 planned vs. 45 entered). Therefore, the objectives of this study could not be fully assessed.|5||Terminated for slow enrollment.|f||||||||||||||2018-06-01 02:07:41.372064|2018-06-01 02:07:41.372064
NCT00681850|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2010-06-01|2008-05-20|2008-05-21|Estimate|||||||2010-06-01|2010-06-02|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|Optimise||OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.|OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.|Completed|||4027|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 02:07:42.060903|2018-06-01 02:07:42.060903
NCT00681837|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-11-17|2008-05-20|2008-05-21|Estimate|||||||2008-11-17|2008-11-18|Estimate|May 2008||2008-05-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|||||Observational|||Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France|Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France|Completed|||2500|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:07:42.577809|2018-06-01 02:07:42.577809
NCT00681824|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2013-03-12|2011-05-06|2013-05-21|2008-05-20|2008-05-21|Estimate|2013-05-21|2013-06-27|Estimate|2011-05-06|2011-05-13|Estimate|2013-05-21|2013-06-27|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||"Primary Safety Dataset Note: This includes 13 initial run-in participants in the FS VH S/D 500 s-apr arm (one for each site permitted to familiarize the investigators with the study procedures)"|Fibrin Sealant for the Sealing of Dura Sutures|An Exploratory Phase 2 Study Evaluating the Efficacy and Safety of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated (FS VH S/D) 500 S-APR for the Sealing of Dura Defect Sutures in Posterior Fossa Surgery|Completed||Phase 2|95|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 02:07:42.699135|2018-06-01 02:07:42.699135
NCT00681811|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2012-09-26||2015-08-04|2008-05-19|2008-05-21|Estimate|2013-09-05|2013-11-08|Estimate||||2015-08-04|2015-08-05|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD|A Multi-center, Open-Label Extension Study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) Treatment in Patients With Late Infantile Metachromatic Leukodystrophy (MLD)|Terminated||Phase 2|11|Actual|Shire|Early termination due to lack of efficacy.|2||Terminated prior to planned completion date due to lack of efficacy.|f||||f||||||||||2018-06-01 02:07:43.243742|2018-06-01 02:07:43.243742
NCT00681798|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2016-08-26|2008-05-20|2008-05-21|Estimate|||||||2016-08-26|2016-08-29|Estimate|July 2006||2006-07-31|August 2016|2016-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma|Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 1|8|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 02:07:43.692341|2018-06-01 02:07:43.692341
NCT00489762|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-19|2007-06-19|2007-06-21|Estimate|||||||2007-06-19|2007-06-21|Estimate|June 2005||2005-06-30|June 2007|2007-06-30|October 2006|Actual|2006-10-31|||||Interventional|||Does Improving Insulation and Heating Improve Health?|Housing, Heating and Health Study:a Randomised Community Trial|Completed||N/A|409|Actual|University of Otago|||||f||||f||||||||||2018-06-01 03:08:32.445406|2018-06-01 03:08:32.445406
NCT00681772|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-12-10|2008-05-20|2008-05-21|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2003||2003-03-31|December 2014|2014-12-31|November 2003|Actual|2003-11-30|||||Interventional|||Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction|Open-label, Multi-centre, Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in Males With Erectile Dysfunction|Completed||Phase 4|333|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:07:43.864228|2018-06-01 02:07:43.864228
NCT00681759|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2008-10-30|2008-05-20|2008-05-21|Estimate|||||||2008-10-30|2008-10-31|Estimate|January 2008||2008-01-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|||||Observational|||An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients|A Prospective Descriptive, Multi-National, Multi-Centre Observational Study of Burden of Upper GI-Symptoms in Subjects With Cardiovascular Risk or Disease Receiving Treatment With Low-Dose Aspirin|Completed|||1836|Actual|AstraZeneca|||3||f||||f||||||||||2018-06-01 02:07:43.924799|2018-06-01 02:07:43.924799
NCT00681746|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2010-12-08|2008-05-20|2008-05-21|Estimate|||||||2010-12-08|2010-12-10|Estimate|February 2008||2008-02-29|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|PET||Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280|An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 After Oral Administration to Healthy Volunteers|Completed||Phase 1|8|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:07:44.123231|2018-06-01 02:07:44.123231
NCT00681733|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-05-20|2008-05-20|2008-05-21|Estimate|||||||2008-05-20|2008-05-21|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|NASH||Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)|A Study Of Metabolic Factors And Efficacy Of Pentoxifylline Versus Pioglitazone In Lean And Obese Nash (Non-Alcoholic Steatohepatitis) Patients.|Unknown status|Recruiting|N/A|20|Anticipated|Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-06-01 02:07:44.196121|2018-06-01 02:07:44.196121
NCT00681720|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-08-20|2008-05-20|2008-05-21|Estimate|||||||2008-08-20|2008-08-21|Estimate|February 2008||2008-02-29|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PET||Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325|An Open Label Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 After Oral Administration to Healthy Volunteers|Completed||Phase 1|4|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:07:44.294158|2018-06-01 02:07:44.294158
NCT00681707|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-07-08|2008-05-20|2008-05-21|Estimate|||||||2009-07-08|2009-07-09|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|July 2008|Actual|2008-07-31|||||Observational|SAPPHIRE||Retrospective Treatment Pattern Survey for the Patients With Hypertension and Stroke|A Retrospective, Multi Centre, Non-Interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Post Stroke Patients With Hypertension.|Completed|||1000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:07:44.37299|2018-06-01 02:07:44.37299
NCT00681694|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2010-04-27|2008-05-20|2008-05-21|Estimate|||||||2010-04-27|2010-04-28|Estimate|March 2002||2002-03-31|April 2010|2010-04-30|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer|Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer|Unknown status|Recruiting||414|Anticipated|Massachusetts General Hospital|||3||f||||t||||||||||2018-06-01 02:07:44.460839|2018-06-01 02:07:44.460839
NCT00681681|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2017-11-06|2008-05-20|2008-05-21|Estimate|||||||2017-11-06|2017-11-08|Actual|February 2008||2008-02-29|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|SAVVY||Sex Differences in Vascular Markers of Stroke Risk|Sex Differences in Vascular Markers of Stroke Risk|Completed|||117|Actual|Wake Forest University Health Sciences|||1||f||||f||||||Samples With DNA|"~     RNA and DNA samples collected~   "|||2018-06-01 02:07:44.550091|2018-06-01 02:07:44.550091
NCT00681668|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2009-10-29||2010-12-07|2008-05-20|2008-05-21|Estimate|2010-08-24|2010-09-17|Estimate||||2010-12-07|2010-12-21|Estimate|August 2007||2007-08-31|December 2010|2010-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Quetiapine in Postpartum Depression|The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorder With Psychotic Symptoms|Terminated||Phase 2|5|Actual|AstraZeneca|Study termination (the study could not finalised in the planned,nor in an acceptable time).|1||Recruitment behind plan, no increase expected|f||||f||||||||||2018-06-01 02:07:44.646773|2018-06-01 02:07:44.646773
NCT00681655|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2017-12-05|2008-05-19|2008-05-21|Estimate|||||||2017-12-05|2017-12-07|Actual|May 2008||2008-05-31|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|GPRA||GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)|GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)|Active, not recruiting||N/A|141|Actual|Indiana University||1|||f||||t||||||||Undecided|Requests for data sharing will be considered on a case by case basis. No sharing of HIPPA sensitive data will be allowed.|2018-06-01 02:07:44.853508|2018-06-01 02:07:44.853508
NCT00681642|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2011-01-06|2008-05-19|2008-05-21|Estimate|||||||2011-01-06|2011-01-10|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Corneal Epithelial Wound Healing Difference Between Human Autoserum and Cord Blood Serum|Phase 1 Study of Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Autoserum and Cord Blood Serum—in Vitro Cell Culture Experiment|Completed|||7|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-06-01 02:07:44.936119|2018-06-01 02:07:44.936119
NCT00681629|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|2010-04-07||2012-06-22|2008-05-20|2008-05-21|Estimate|2012-06-22|2012-07-30|Estimate||||2012-06-22|2012-07-30|Estimate|July 2008||2008-07-31|June 2012|2012-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|CARE II||Schizophrenic Patients in Integrated Care|CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Phase IV Study|Terminated||Phase 4|7|Actual|AstraZeneca|The study was stopped due to poor enrollment and no data analysis was performed.|2||"Difficulty finding eligible sites/patients; current situation in health policy cause negative~   effect on existing/planned contracts for integrated care program"|f||||f||||||||||2018-06-01 02:07:45.036207|2018-06-01 02:07:45.036207
NCT00681616|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-03-03|2008-05-20|2008-05-21|Estimate|||||||2009-03-03|2009-03-04|Estimate|January 2009||2009-01-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|TS2||Study of New Catheter & Pressure Monitor System to Help Prevent Compartment Syndrome From Developing in the Injured Leg|Randomized Clinical Trial of Tissue Ultrafiltration and Pressure Monitoring for the Diagnosis and Prevention of Compartment Syndrome|Unknown status|Recruiting|N/A|90|Anticipated|Twin Star Medical, Inc.||2|||f||||t||||||||||2018-06-01 02:07:45.388518|2018-06-01 02:07:45.388518
NCT00681603|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-05-20|2008-05-20|2008-05-21|Estimate|||||||2008-05-20|2008-05-21|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization|The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization|Completed||N/A|13|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 02:07:45.546581|2018-06-01 02:07:45.546581
NCT00681590|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2016-02-05||2016-12-02|2008-05-19|2008-05-21|Estimate|2016-02-05|2016-03-07|Estimate||||2016-12-02|2017-01-26|Estimate|April 2008||2008-04-30|December 2016|2016-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety of Vitamin D Supplementation in Older Persons|Safety of Vitamin D Supplementation in the Elderly|Completed||Phase 3|105|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 02:07:45.62663|2018-06-01 02:07:45.62663
NCT00681577|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-11-18|2008-05-19|2008-05-21|Estimate|||||||2009-11-18|2009-11-19|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Gastric Cancer|Completed||Phase 1/Phase 2|14|Anticipated|Tokyo University||1|||f||||t||||||||||2018-06-01 02:07:45.819746|2018-06-01 02:07:45.819746
NCT00681564|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2013-11-26||2014-03-31|2008-05-19|2008-05-21|Estimate|2014-02-14|2014-04-01|Estimate||||2014-03-31|2014-04-17|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|||Periodontal Infection and Endothelial Dysfunction|Impact of Periodontal Therapy on Endothelial Function|Completed||Phase 3|102|Actual|Universidad del Valle, Colombia|1. Patient recruitment take more time that previously expected, 2. Longer time than expected for the standardization for laboratory techniques, 3. Changes of the study personnel during patient recruitment and laboratory analysis of biological samples|2|||f||||t||||||||||2018-06-01 02:07:46.000338|2018-06-01 02:07:46.000338
NCT00681551|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-12-11|2008-05-20|2008-05-21|Estimate|||||||2014-12-11|2014-12-15|Estimate|February 2003||2003-02-28|December 2014|2014-12-31|March 2004|Actual|2004-03-31|||||Interventional|||Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis|Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor|Completed||Phase 3|45|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:07:46.724545|2018-06-01 02:07:46.724545
NCT00681538|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2011-03-23||2015-03-09|2008-05-20|2008-05-21|Estimate|2011-11-02|2011-12-07|Estimate||||2015-03-09|2015-03-27|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)|A Two-phase, Phase 3 Study of the Safety and Efficacy of Sativex, in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis: Phase A - Single-blind Response Assessment; Phase B - Double-blind, Randomised, Placebo Controlled, Parallel Group Study.|Completed||Phase 3|572|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 02:07:46.882874|2018-06-01 02:07:46.882874
NCT00681525|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2010-10-18|2008-05-20|2008-05-21|Estimate|||||||2010-10-18|2010-10-19|Estimate|April 2008||2008-04-30|September 2010|2010-09-30||||June 2008|Actual|2008-06-30||Interventional|||A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe||Completed||Phase 1|18|Actual|Abbott||3|||f||||||||||||||2018-06-01 02:07:47.555448|2018-06-01 02:07:47.555448
NCT00681512|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2018-02-03|2008-05-20|2008-05-21|Estimate|||||||2018-02-03|2018-02-06|Actual|April 2008||2008-04-30|February 2018|2018-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Berries on Lung Cancer Tumors|Berry Interventional Trial (BIT) in Resected Non-Small Cell Lung Cancer|Terminated||N/A|6|Actual|University of Louisville||||slow accrual|f||||t||||||||||2018-06-01 02:07:47.628089|2018-06-01 02:07:47.628089
NCT00681499|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2015-11-12|2008-05-19|2008-05-21|Estimate|||||||2015-11-12|2015-11-13|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Quality of Life After Liver Resection|Long-term Evaluation of the Quality of Life After Major Hepatic Resection for Malignant and Benign Diseases.|Completed|||198|Actual|University of Bern|||2||f||||f||||||||||2018-06-01 02:07:47.712004|2018-06-01 02:07:47.712004
NCT00681486|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-08-20|2008-05-20|2008-05-21|Estimate|||||||2009-08-20|2009-08-21|Estimate|October 2003||2003-10-31|August 2009|2009-08-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|Phase 3||Ghrelin - A Possible Opportunity to Improve Appetite|Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss|Completed||Phase 3|30|Anticipated|Göteborg University||2|||f||||||||||||||2018-06-01 02:07:47.777528|2018-06-01 02:07:47.777528
NCT00681473|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2017-01-06||2017-01-24|2008-05-19|2008-05-21|Estimate|2017-01-06|2017-01-09|Estimate||||2017-01-24|2017-03-07|Actual|July 2007||2007-07-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||All 20 baseline participants were included in analysis.|Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma|Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma|Completed||N/A|20|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:07:47.849791|2018-06-01 02:07:47.849791
NCT00681460|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2015-05-23|2008-05-20|2008-05-21|Estimate|||||||2015-05-23|2015-05-27|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|MetGDM||Metformin in Gestational Diabetes Mellitus|Effects of Insulin and/or Metformin Treatment on Perinatal Outcome and Metabolic Parameters in Women With Gestational Diabetes Mellitus: Prospective Randomized Trial.|Completed||N/A|78|Actual|K. Marcinkowski University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:07:48.011502|2018-06-01 02:07:48.011502
NCT00681447|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2015-10-20|2008-05-19|2008-05-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|December 2014|Actual|2014-12-31|February 2010|Actual|2010-02-28||Interventional|||Treatment of Chronic Low Back and Lower Extremity Pain|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Lumbar Interlaminar Epidural Injections in Lumbar Disc Herniation, and Discogenic Pain|Completed||N/A|120|Actual|Pain Management Center of Paducah||2|||f||||f||||||||||2018-06-01 02:07:48.099231|2018-06-01 02:07:48.099231
NCT00681434|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2014-08-01|2008-05-19|2008-05-21|Estimate|||||||2014-08-01|2014-08-04|Estimate|May 2005||2005-05-31|August 2014|2014-08-31||||August 2007|Actual|2007-08-31||Interventional|||Bilateral Training Versus Unilateral Training in Stroke|Bilateral Training for Upper Extremity Hemiparesis in Stroke|Completed||Phase 2|24|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 02:07:48.163676|2018-06-01 02:07:48.163676
NCT00681421|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-11-18|2008-05-19|2008-05-21|Estimate|||||||2009-11-18|2009-11-19|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Esophageal Cancer|Completed||Phase 1/Phase 2|14|Anticipated|Tokyo University||1|||f||||t||||||||||2018-06-01 02:07:48.362078|2018-06-01 02:07:48.362078
NCT00681408|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2015-05-27|2008-05-20|2008-05-21|Estimate|||||||2015-05-27|2015-05-29|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)|Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)|Completed||Phase 2/Phase 3|41|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 02:07:48.440169|2018-06-01 02:07:48.440169
NCT00681395|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2012-09-27|2008-05-19|2008-05-21|Estimate|||||||2012-09-27|2012-09-28|Estimate|May 2008||2008-05-31|September 2012|2012-09-30||||August 2008|Actual|2008-08-31||Interventional|||Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium||Completed||Phase 1|64|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:07:48.514237|2018-06-01 02:07:48.514237
NCT00681382|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2011-01-21|2008-05-20|2008-05-21|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2006||2006-10-31|January 2011|2011-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland|INSPIRE Asthma Patient Survey to Clarify the Use of Asthma Medication and Effects of Asthma in Everyday Life in Finland|Completed|||142|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:07:48.582179|2018-06-01 02:07:48.582179
NCT00681369|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2011-01-21|2008-05-20|2008-05-21|Estimate|||||||2011-01-21|2011-01-24|Estimate|May 2007||2007-05-31|January 2011|2011-01-31|June 2007|Actual|2007-06-30|||||Observational|||Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France|Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France|Completed|||217|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:07:48.666644|2018-06-01 02:07:48.666644
NCT00681356|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2009-05-01|2008-05-16|2008-05-21|Estimate|||||||2009-05-01|2009-05-04|Estimate|September 2007||2007-09-30|May 2009|2009-05-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement|A Phase 3, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, Safety, and Pharmacokinetics of 4975 in Patients Undergoing Primary Unilateral Total Knee Arthroplasty|Completed||Phase 3|214|Anticipated|Anesiva, Inc.||3|||f||||t||||||||||2018-06-01 02:07:48.731616|2018-06-01 02:07:48.731616
NCT00681343|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-05-23|2008-05-20|2008-05-21|Estimate|||||||2008-05-23|2008-05-29|Estimate|September 2002||2002-09-30|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Interventional|||Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation|Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy|Completed||Phase 4|38|Actual|University of Miami||3|||f||||t||||||||||2018-06-01 02:07:48.845826|2018-06-01 02:07:48.845826
NCT00681330|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-11-18|2008-05-19|2008-05-21|Estimate|||||||2009-11-18|2009-11-19|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Esophageal Cancer|Completed||Phase 1/Phase 2|14|Anticipated|Tokyo University||1|||f||||t||||||||||2018-06-01 02:07:48.924707|2018-06-01 02:07:48.924707
NCT00681317|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2010-12-07|2008-05-19|2008-05-21|Estimate|||||||2010-12-07|2010-12-09|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|MAD||AZD6280 Multiple Ascending Dose Study|A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6280 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-child Bearing Potential|Completed||Phase 1|48|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:07:49.015316|2018-06-01 02:07:49.015316
NCT00681304|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2012-11-15|2008-05-19|2008-05-21|Estimate|||||||2012-11-15|2012-11-16|Estimate|August 2007||2007-08-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Ultrasound Based Localization of Lumpectomy Bed in Anatomical Coordinate System|"Ultrasound Based Localization of Lumpectomy Bed in Anatomical Coordinate System (J-0728)"|Completed|||50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1||f||||f||||||||||2018-06-01 02:07:49.089117|2018-06-01 02:07:49.089117
NCT00681291|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2013-09-18||2016-04-06|2008-05-19|2008-05-21|Estimate|2016-02-22|2016-03-23|Estimate||||2016-04-06|2016-05-10|Estimate|April 2008||2008-04-30|April 2016|2016-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|RING||Strattice in Repair of Inguinal Hernias|Prospective, Randomized, Controlled, Third-Party Blinded Multicenter Evaluation of Strattice/LTM in the Repair of Inguinal Hernias|Completed||Phase 4|172|Actual|LifeCell||2|||f||||f||||||||||2018-06-01 02:07:49.217197|2018-06-01 02:07:49.217197
NCT00681278|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2010-12-01|2008-05-20|2008-05-21|Estimate|||||||2010-12-01|2010-12-02|Estimate|April 2008||2008-04-30|December 2010|2010-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|CRYSTAL||Retrospective Survey for Patients With Hypertension and Diabetes Mellitus|A Retrospective, Multi Centre, Non-interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Type II Diabetes Mellitus Patients With Hypertension.|Completed|||2000|Anticipated|AstraZeneca|||1||f||||||||||||||2018-06-01 02:07:49.48506|2018-06-01 02:07:49.48506
NCT00681265|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2012-09-16||2012-10-24|2008-05-20|2008-05-21|Estimate|2012-10-24|2012-10-26|Estimate||||2012-10-24|2012-10-26|Estimate|June 2008||2008-06-30|October 2012|2012-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Tear Film Break-up Time After Instillation of Artificial Tears|A Randomized, Masked Exploratory Trial Comparing the Effect of Two Different Over-the-Counter Artificial Tear Preparations on Tear Film Break-up Time|Completed||N/A|16|Actual|Eyeon Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 02:07:49.581302|2018-06-01 02:07:49.581302
NCT00681252|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-11-18|2008-05-19|2008-05-21|Estimate|||||||2009-11-18|2009-11-19|Estimate|May 2008||2008-05-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Gastric Cancer|Completed||Phase 1/Phase 2|14|Anticipated|Tokyo University||1|||f||||t||||||||||2018-06-01 02:07:49.770378|2018-06-01 02:07:49.770378
NCT00681239|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2009-12-30|2008-05-20|2008-05-21|Estimate|||||||2009-12-30|2009-12-31|Estimate|May 2008||2008-05-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Atkins Plus KetoCal for Childhood Epilepsy|An Open-label Evaluation of KetoCal in Initial Combination With the Modified Atkins Diet for the Treatment of Intractable Childhood Epilepsy|Completed||Phase 3|30|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 02:07:49.852456|2018-06-01 02:07:49.852456
NCT00681226|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2012-04-04|2008-05-20|2008-05-21|Estimate|||||||2012-04-04|2012-04-05|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|||Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease|ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease|Completed||Phase 4|200|Actual|Bayside Health|||||f||||f||||||||||2018-06-01 02:07:49.93466|2018-06-01 02:07:49.93466
NCT00681213|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2008-05-23|2008-05-19|2008-05-21|Estimate|||||||2008-05-23|2008-05-29|Estimate|May 2000||2000-05-31|May 2008|2008-05-31|December 2002|Actual|2002-12-31|December 2001|Actual|2001-12-31||Interventional|||Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation|Tacrolimus and Mycophenolate Versus Tacrolimus and Sirolimus vs. Neoral and Sirolimus Used in Combination in Cadaver and Non-HLA Identical Living Related Kidney Transplants|Completed||Phase 4|150|Actual|University of Miami||3|||f||||t||||||||||2018-06-01 02:07:50.009609|2018-06-01 02:07:50.009609
NCT00681200|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2013-03-11|2008-05-19|2008-05-21|Estimate|||||||2013-03-11|2013-03-13|Estimate|April 2008||2008-04-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|July 2011|Actual|2011-07-31||Interventional|HMEC||Evaluating Mechanisms of Blood Pressure Reduction Using Meditation in Hypertensive African Americans|Mechanisms of Meditation in Hypertension in Blacks|Completed||N/A|152|Actual|Maharishi University of Management||2|||f||||t||||||||||2018-06-01 02:07:50.092031|2018-06-01 02:07:50.092031
NCT00681187|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2011-09-01||2012-02-09|2008-05-20|2008-05-21|Estimate|2012-02-09|2012-03-13|Estimate||||2012-02-09|2012-03-13|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|SAPHE||Somatuline Autogel Preference and Health Economy Study|A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.|Completed||Phase 4|26|Actual|Ipsen|||||f||||f||||||||||2018-06-01 02:07:50.189999|2018-06-01 02:07:50.189999
NCT00681174|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2012-01-05|2008-05-19|2008-05-21|Estimate|||||||2012-01-05|2012-01-06|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Controlled-Release Oxycodone For Postoperative Analgesia After Video-Assisted Thoracic Surgery|Preoperative Controlled-Release Oxycodone or Intraoperative Morphine As Transition Opioid After Intravenous Anesthesia For Video-Assisted Thoracic Surgery: a Randomized, Double-blind, Controlled Trial.|Terminated||Phase 4|22|Actual|University of Parma||2||Failure to enroll sufficient patients by expected deadline.|f||||t||||||||||2018-06-01 02:07:50.731566|2018-06-01 02:07:50.731566
NCT00681161|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2017-02-23|2008-05-20|2008-05-21|Estimate|||||||2017-02-23|2017-02-24|Actual|March 2006|Actual|2006-03-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Autonomic Function in Obstructive Sleep Apnea|Autonomic Function in Obstructive Sleep Apnea (OSA)|Completed||N/A|70|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 02:07:50.819396|2018-06-01 02:07:50.819396
NCT00681148|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2013-11-19|2008-05-20|2008-05-21|Estimate|||||||2013-11-19|2013-11-21|Estimate||||November 2013|2013-11-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Botulinum Toxin Injection With Prostate Brachytherapy|Botulinum Toxin Injection With Prostate Brachytherapy: A Randomized, Placebo-controlled Study Monitoring Urinary Symptoms and PSA|Withdrawn||Phase 2|0|Actual|Emory University||2||No funding|f||||f||||||||||2018-06-01 02:07:50.887754|2018-06-01 02:07:50.887754
NCT00681135|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2012-02-21|2008-05-19|2008-05-21|Estimate|||||||2012-02-21|2012-02-22|Estimate|April 2008||2008-04-30|February 2012|2012-02-29|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Mechanical Plaque Control and Gingivitis Reduction in Fixed Appliance Patients|Mechanical Plaque Control and Gingivitis Reduction in Fixed Appliance Patients: Comparison of Different Toothbrushing Protocols|Completed||N/A|118|Actual|University of Jena||4|||f||||f||||||||||2018-06-01 02:07:51.060154|2018-06-01 02:07:51.060154
NCT00681122|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-20|||2016-01-15|2008-05-20|2008-05-21|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|CARIATIDE||CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)|An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman|Completed|||2600|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 02:07:51.193718|2018-06-01 02:07:51.193718
NCT00681109|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|2011-12-19||2017-12-19|2008-05-20|2008-05-21|Estimate|2012-11-15|2012-11-27|Estimate||||2017-12-19|2018-01-19|Actual|January 2008||2008-01-31|December 2017|2017-12-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Topical IL-1-Ra for Treatment of Posterior Blepharitis|Safety and Efficacy of Topical Interleukin-1-Receptor Antagonist in the Treatment of Signs and Symptoms of Posterior Blepharitis|Completed||Phase 1/Phase 2|75|Actual|Massachusetts Eye and Ear Infirmary||3|||f||||f||||||||No||2018-06-01 02:07:51.476293|2018-06-01 02:07:51.476293
NCT00681096|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-18|||2008-05-20|2008-05-20|2008-05-21|Estimate|||||||2008-05-20|2008-05-21|Estimate|June 2008||2008-06-30|May 2008|2008-05-31||||||||Observational|||Causes of Low Back Pain in Nurses in Israeli Hospitals||Unknown status|Not yet recruiting||350|Anticipated|Hillel Yaffe Medical Center|||||f||||||||||||||2018-06-01 02:07:51.891605|2018-06-01 02:07:51.891605
NCT00681083|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2011-07-10|2008-05-20|2008-05-21|Estimate|||||||2011-07-10|2011-07-12|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Titration Pressures in Sleep Apnea Patients Using ThermoSmart® Versus Conventional Humidification|Titrations Pressures in Sleep Apnea Patients Using ThermoSmart® Versus Conventional Humidification|Completed||N/A|20|Anticipated|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-06-01 02:07:51.955931|2018-06-01 02:07:51.955931
NCT00681070|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-19|||2017-02-08|2008-05-20|2008-05-21|Estimate|||||||2017-02-08|2017-02-10|Actual|April 2008|Actual|2008-04-30|February 2017|2017-02-28|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|Catgut||Cosmetic Outcomes of Absorbable Versus Non-absorbable Sutures in Pediatric Facial Lacerations|Cosmetic Outcomes of Absorbable Versus Non-absorbable Sutures in Pediatric Facial Lacerations, Part 2|Completed||N/A|74|Actual|Temple University||2|||f||||f||||||||||2018-06-01 02:07:52.059585|2018-06-01 02:07:52.059585
NCT00681057|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2009-08-13|2008-05-20|2008-05-21|Estimate|||||||2009-08-13|2009-08-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:07:52.1372|2018-06-01 02:07:52.1372
NCT00681044|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-18|2017-01-26||2017-03-28|2008-05-18|2008-05-20|Estimate|2017-01-26|2017-03-15|Actual||||2017-03-28|2017-04-28|Actual|October 2006||2006-10-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||HD Melphalan and SCT in Patients With IGDD or LCDD|High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT) in Light-Chain Deposition Disease (LCDD) and Immunoglobulin Deposition Disease (IGDD)|Terminated||Phase 2|5|Actual|Boston Medical Center||1||Poor accrual|f||||t||||||||No||2018-06-01 02:07:52.187969|2018-06-01 02:07:52.187969
NCT00681031|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2017-08-29||2017-08-29|2008-05-16|2008-05-20|Estimate|2017-08-29|2017-09-26|Actual||||2017-08-29|2017-09-26|Actual|May 31, 2008|Actual|2008-05-31|August 2017|2017-08-31|October 31, 2008|Actual|2008-10-31|June 30, 2008|Actual|2008-06-30||Interventional|||Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)|An Open-label, Single-arm, Phase IV Study Assessing the Immunogenicity and Safety of ZOSTAVAX® at Minimum Release Specification Approaching Expiry Potency in Subjects ≥50 Years Old.|Completed||Phase 4|96|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-06-01 02:07:52.443949|2018-06-01 02:07:52.443949
NCT00681018|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2010-08-30|2008-05-19|2008-05-20|Estimate|||||||2010-08-30|2010-08-31|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Feeding Study in Premature Infants|Feeding Study in Premature Infants|Completed||N/A|143|Anticipated|Mead Johnson Nutrition||2|||f||||f||||||||||2018-06-01 02:07:52.568544|2018-06-01 02:07:52.568544
NCT00681005|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2013-12-09|2008-05-19|2008-05-20|Estimate|||||||2013-12-09|2013-12-11|Estimate|April 2006||2006-04-30|December 2013|2013-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes|A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes|Completed||N/A|178|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 02:07:52.655327|2018-06-01 02:07:52.655327
NCT00680992|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-05-30|2008-05-15|2008-05-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 9, 2008|Actual|2008-09-09|May 2018|2018-05-31|May 17, 2018|Actual|2018-05-17|May 17, 2018|Actual|2018-05-17||Interventional|||Study of Denosumab in Subjects With Giant Cell Tumor of Bone|An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone|Completed||Phase 2|536|Actual|Amgen||1|||f||||||||||||||2018-06-01 02:07:52.752363|2018-06-01 02:07:52.752363
NCT00680979|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-17|||2017-10-05|2008-05-17|2008-05-20|Estimate|||||||2017-10-05|2017-10-06|Actual|May 15, 2008||2008-05-15|August 20, 2015|2015-08-20|April 16, 2015|Actual|2015-04-16|April 16, 2015|Actual|2015-04-16||Interventional|||Preventing Excessive Weight Gain in Adolescent Girls at High-Risk for Adult Obesity|Preventing Excessive Weight Gain in Adolescent Girls at High-Risk for Adult Obesity|Completed||Phase 2|166|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:07:52.877459|2018-06-01 02:07:52.877459
NCT00680966|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2014-03-10|2008-05-16|2008-05-20|Estimate|||||||2014-03-10|2014-03-12|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|Sequencing||Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD|Sequenced vs. Integrated Delivery of Treatment for Adolescent Depression and SUD|Completed||N/A|180|Actual|Oregon Research Institute||3|||f||||f||||||||||2018-06-01 02:07:52.943764|2018-06-01 02:07:52.943764
NCT00680953|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2013-07-12||2015-02-19|2008-05-19|2008-05-20|Estimate|2014-01-24|2014-02-26|Estimate||||2015-02-19|2015-03-12|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|DIRECT|The demography information shows the number of participants included in the full analysis set (FAS) for efficacy analyses, which includes all randomized subjects except for those who did not have osteoporosis, did not receive the investigational product, or had no available efficacy data after the first dose of the investigational product.|Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis|A Randomized, Double-Blind, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of Denosumab in Japanese Osteoporotic Subjects With Prevalent Fragility Vertebral Fracture(s)|Completed||Phase 3|1262|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-06-01 02:07:53.067413|2018-06-01 02:07:53.067413
NCT00680940|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2012-08-04|2008-05-16|2008-05-20|Estimate|||||||2012-08-04|2012-08-07|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|NSCLC||A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer|Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel and Cisplatin in Advanced Non Small Cell Lung Cancer.|Completed||Phase 2|221|Actual|Cadila Pharnmaceuticals||2|||f||||t||||||||||2018-06-01 02:07:53.987024|2018-06-01 02:07:53.987024
NCT00680927|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2015-06-02|2008-05-15|2008-05-20|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Reveal® XT Performance Trial (XPECT)|Reveal® XT Performance Trial|Completed||Phase 4|247|Actual|Medtronic BRC|||||f||||f||||||||||2018-06-01 02:07:54.156871|2018-06-01 02:07:54.156871
NCT00680914|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2010-05-13|2009-05-20|2016-10-11|2008-05-19|2008-05-20|Estimate|2010-05-13|2010-06-14|Estimate|2009-09-29|2009-09-30|Estimate|2016-10-11|2016-11-23|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A or Prevenar™ Co-administered With Hiberix™|Completed||Phase 3|503|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:07:54.431907|2018-06-01 02:07:54.431907
NCT00680901|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2013-05-16||2017-06-06|2008-05-15|2008-05-20|Estimate|2013-08-22|2013-10-29|Estimate||||2017-06-06|2017-07-11|Actual|June 4, 2008|Actual|2008-06-04|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|September 24, 2012|Actual|2012-09-24||Interventional|||LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib|A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib|Active, not recruiting||Phase 3|545|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 02:07:55.774264|2018-06-01 02:07:55.774264
NCT00680836|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2013-12-09||2014-08-19|2008-05-16|2008-05-20|Estimate|2014-08-19|2014-08-29|Estimate||||2014-08-19|2014-08-29|Estimate|October 2007||2007-10-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|October 2008|Actual|2008-10-31||Interventional||A total of 54 patients were randomized. Of that 54 patients,10 patients were excluded from the analyses. Reasons included, patient withdrawal, physician decision, and loss to follow up.Total of 44 patients were analysed. All data presented here, includes the 44 patients only.|Gulf War Digestive Health Study|Diarrhea-Predominant Irritable Bowel Syndrome in Persian Gulf Veterans|Completed||N/A|54|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:07:58.58832|2018-06-01 02:07:58.58832
NCT00680823|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2017-11-16||2018-02-22|2008-05-19|2008-05-20|Estimate|2017-11-16|2017-12-13|Actual||||2018-02-22|2018-02-26|Actual|January 2009||2009-01-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache|Is Paraspinal Intramuscular Ropivacaine Injection an Effective Treatment for Headache in a Pediatric Emergency Department?|Completed||N/A|150|Actual|University of Pittsburgh||3|||f||||t||||||||No||2018-06-01 02:07:59.007773|2018-06-01 02:07:59.007773
NCT00680797|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2014-07-24||2017-05-22|2008-05-16|2008-05-20|Estimate|2016-02-19|2016-03-21|Estimate||||2017-05-22|2017-06-15|Actual|January 1, 2005|Actual|2005-01-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2013|Actual|2013-12-31||Interventional|||Metabolic Effects of Androgenicity in Aging Men and Women|Metabolic Effects of Androgenicity in Aging Men and Women|Completed||N/A|33|Actual|VA Office of Research and Development|Small sample size may limit generalizability of these results. Follow-up studies are being conducted to further evaluate these results.|4|||f||||t|f|f|||f|||Undecided||2018-06-01 02:07:59.542342|2018-06-01 02:07:59.542342
NCT00680784|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16||2015-03-17|2015-05-12|2008-05-19|2008-05-20|Estimate||||2015-05-12|2015-06-04|Estimate|2015-05-12|2015-06-04|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||HKT-500 in Adult Patients With Ankle Sprain|Protocol HKT-500-US10: A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Grade I or Grade II Ankle Sprain|Completed||Phase 3|260|Actual|Hisamitsu Pharmaceutical Co., Inc.||2|||f||||t||||||||||2018-06-01 02:07:59.940518|2018-06-01 02:07:59.940518
NCT00680771|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2011-09-26||2012-09-14|2008-05-15|2008-05-20|Estimate|2012-09-14|2012-10-17|Estimate||||2012-09-14|2012-10-17|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||The Psychoneuroimmunology of Insomnia|The Psychoneuroimmunology of Insomnia: Response to a Vaccine Challenge|Completed|||28|Actual|University of Rochester|Sample size limited by much higher than expected number of otherwise eligible participants having alrady been exposed to Hep B vaccine or virus.||2||f||||f||||||||||2018-06-01 02:08:00.08533|2018-06-01 02:08:00.08533
NCT00680758|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-18|||2013-03-07|2008-05-18|2008-05-20|Estimate|||||||2013-03-07|2013-03-08|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|December 2010|Actual|2010-12-31|August 2009|Actual|2009-08-31||Interventional|||Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer|A Phase I Study of Cisplatin, Paclitaxel, and RAD001 Patients With Metastatic Breast Cancer|Completed||Phase 1|18|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:08:00.2695|2018-06-01 02:08:00.2695
NCT00680745|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2011-04-13||2013-08-09|2008-05-19|2008-05-20|Estimate|2013-08-09|2013-10-14|Estimate||||2013-08-09|2013-10-14|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients|A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone|Completed||Phase 3|597|Actual|AstraZeneca|For participants who did not complete 24 weeks LOCF (last observation carried forward) was used. Only values prior to rescue medication were used.|4|||f||||f||||||||||2018-06-01 02:08:00.421103|2018-06-01 02:08:00.421103
NCT00680732|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2010-09-12|2008-05-15|2008-05-20|Estimate|||||||2010-09-12|2010-09-14|Estimate|June 2003||2003-06-30|September 2010|2010-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component|Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso: the Malaria Component|Completed||Phase 4|1370|Actual|Institute of Tropical Medicine, Belgium||4|||f||||f||||||||||2018-06-01 02:08:01.562971|2018-06-01 02:08:01.562971
NCT00680719|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2014-08-04|2008-05-16|2008-05-20|Estimate|||||||2014-08-04|2014-08-05|Estimate|June 2004||2004-06-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Preventing HIV/Aids in Drug Abusing Youth|Preventing HIV/Aids in Tx-Resistant Drug-Abusing Youth|Completed||Phase 1|111|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-06-01 02:08:01.684354|2018-06-01 02:08:01.684354
NCT00680706|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2012-07-27||2013-08-12|2008-05-16|2008-05-20|Estimate|2012-08-29|2012-09-28|Estimate||||2013-08-12|2013-08-21|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|February 2010|Actual|2010-02-28||Interventional|||Thiamine and Acute Decompensated Heart Failure: Pilot Study|Targeting Myocardial Energy Metabolism for the Treatment of Acute Heart Failure: The Effect of Thiamine on Biochemical, Electrocardiographic and Respiratory Parameters in Hospitalized Patients.|Completed||Phase 2|131|Actual|Baystate Medical Center||2|||f||||f||||||||||2018-06-01 02:08:01.810006|2018-06-01 02:08:01.810006
NCT00680693|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2011-11-17|2008-05-15|2008-05-20|Estimate|||||||2011-11-17|2011-11-18|Estimate|October 2006||2006-10-31|February 2010|2010-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|M-IBS||Mindfulness vs. Support Groups for Irritable Bowel Syndrome|Mindfulness for Irritable Bowel Syndrome|Completed||N/A|75|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 02:08:02.067435|2018-06-01 02:08:02.067435
NCT00680680|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2008-05-19|2008-05-19|2008-05-20|Estimate|||||||2008-05-19|2008-05-20|Estimate|May 2004||2004-05-31|May 2008|2008-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|AUR||Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker|Phase 4 Study of Dual Five Alpha Reductase Inhibition Combined With Alpha Blockade in Men With Refractory Urinary Retention Secondary to BPH|Completed||N/A|20|Anticipated|Franklin D. Gaylis, MD Inc.|||||f||||f||||||||||2018-06-01 02:08:02.150242|2018-06-01 02:08:02.150242
NCT00680667|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-18|||2017-11-27|2008-05-18|2008-05-20|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2007||2007-04-30|November 2017|2017-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Clinical Trial of Trametes Versicolor in Women With Breast Cancer|Phase I Clinical Trial of Trametes Versicolor in Women With Breast Cancer|Completed||Phase 1|11|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:08:02.228035|2018-06-01 02:08:02.228035
NCT00680654|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2015-12-14|2008-05-19|2008-05-20|Estimate|||||||2015-12-14|2015-12-16|Estimate|October 2008||2008-10-31|December 2015|2015-12-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID|Interaction Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics of Single Doses of 0.5 and 1 mg of BAY 63-2521 in Patients With PAH and Stable Treatment of Sildenafil 20 mg TID in a Non-randomized, Non-blinded Design|Completed||Phase 1|7|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:08:02.307123|2018-06-01 02:08:02.307123
NCT00680641|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2011-08-04|2008-05-16|2008-05-20|Estimate|||||||2011-08-04|2011-08-05|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|February 2012|Anticipated|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||Simvastatin in Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|University of East Anglia||2|||f||||f||||||||||2018-06-01 02:08:02.384749|2018-06-01 02:08:02.384749
NCT00680628|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2013-10-29||2014-07-22|2008-05-19|2008-05-20|Estimate|2014-07-22|2014-08-11|Estimate||||2014-07-22|2014-08-11|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional||see manuscript|Clot Dissolving Treatment for Blood Clots in the Lungs|Randomized Trial of Tenecteplase to Treat Severe Submassive Pulmonary Embolism|Terminated||Phase 3|83|Actual|Carolinas Healthcare System||2||PI changed institution and impossible to solve problem with contract's sites|f||||t||||||||||2018-06-01 02:08:02.484923|2018-06-01 02:08:02.484923
NCT00680615|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2012-09-03|2008-05-19|2008-05-20|Estimate|||||||2012-09-03|2012-09-05|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||An Internet-Based Smokeless Tobacco Cessation Program for Teens|QuitSpit: An Internet-Based Smokeless Tobacco Cessation Program for Teens|Completed||Phase 2|1716|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-06-01 02:08:02.989292|2018-06-01 02:08:02.989292
NCT00680602|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2009-02-13|2008-05-19|2008-05-20|Estimate|||||||2009-02-13|2009-02-16|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|GCBTVF||Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial|Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient.|Completed||Phase 4|158|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 02:08:03.167356|2018-06-01 02:08:03.167356
NCT00680589|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2011-03-25|2008-05-15|2008-05-20|Estimate|||||||2011-03-25|2011-03-28|Estimate|July 2006||2006-07-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response|Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response|Completed||Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:08:03.393374|2018-06-01 02:08:03.393374
NCT00680576|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2014-10-08|2008-05-19|2008-05-20|Estimate|||||||2014-10-08|2014-10-10|Estimate|March 2008||2008-03-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|ADAPT||Adolescent Substance Abuse: Progressive Treatment||Completed||Phase 1|140|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-06-01 02:08:03.577564|2018-06-01 02:08:03.577564
NCT00680563|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2013-11-04|2008-05-16|2008-05-20|Estimate|||||||2013-11-04|2013-11-05|Estimate|April 2009||2009-04-30|November 2013|2013-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.|An Open Label Study of the Safety, Tolerability and Effect on Hemoglobin Levels of Once-monthly Subcutaneous Mircera in Predialysis Patients With Chronic Renal Anemia Not Currently Treated With ESA.|Terminated||Phase 3|4|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:08:03.654509|2018-06-01 02:08:03.654509
NCT00680550|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2013-10-15|2008-05-19|2008-05-20|Estimate|||||||2013-10-15|2013-10-16|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||INSIGHT (R)XT. Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT|Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT.|Completed|||1003|Actual|Medtronic BRC|||||f||||f||||||||||2018-06-01 02:08:03.76069|2018-06-01 02:08:03.76069
NCT00680537|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2010-02-17|2008-05-19|2008-05-20|Estimate|||||||2010-02-17|2010-02-18|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2011|Anticipated|2011-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Physical Therapy Program for Prevention of Shoulder Pain After Device Implant|Physical Therapy Program for Prevention of Shoulder Pain After Device Implant|Unknown status|Recruiting|N/A|100|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:08:03.902581|2018-06-01 02:08:03.902581
NCT00680524|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2014-06-25||2015-04-06|2008-05-16|2008-05-20|Estimate|2014-09-25|2014-09-26|Estimate||||2015-04-06|2015-04-28|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Telephone-based Care for OEF/OIF Veterans With PTSD|Telephone Based Care for OIF/OEF Veterans With PTSD|Completed||N/A|20|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 02:08:03.984514|2018-06-01 02:08:03.984514
NCT00680511|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2014-08-04|2008-05-19|2008-05-20|Estimate|||||||2014-08-04|2014-08-05|Estimate|September 2007||2007-09-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|AIMS||Development of a Family-Based Treatment for Adolescent Methamphetamine Use|Development of a Family-Based Treatment for Adolescent Methamphetamine Use|Completed||Phase 1|60|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-06-01 02:08:04.152989|2018-06-01 02:08:04.152989
NCT00680498|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2012-03-27|2008-05-19|2008-05-20|Estimate|||||||2012-03-27|2012-03-28|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|CLOVER||Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment|Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment|Completed||Phase 4|10|Actual|Illinois Retina Associates||2|||f||||||||||||||2018-06-01 02:08:04.306167|2018-06-01 02:08:04.306167
NCT00680485|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2017-01-19|2008-05-16|2008-05-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416|A Three Part Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeat Escalating Oral Doses of GSK580416; the Safety, Tolerability, and Pharmacokinetics of GSK580416 Following a Loading Dose Regimen; and the Effect of Ketoconazole on the Pharmacokinetics of GSK580416|Terminated||Phase 1|96||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:08:04.454921|2018-06-01 02:08:04.454921
NCT00487968|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2012-03-15|2007-06-15|2007-06-19|Estimate|||||||2012-03-15|2012-03-19|Estimate|May 2007||2007-05-31|February 2011|2011-02-28||||||||Interventional|||Eltrombopag Taste Testing in Healthy Adult Volunteers|Eltrombopag Pediatric Formulation Taste Testing in Healthy Adult Volunteers|Completed||Phase 1|12|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:09:13.283451|2018-06-01 03:09:13.283451
NCT00680472|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16||2015-03-17|2015-05-12|2008-05-19|2008-05-20|Estimate||||2015-05-12|2015-06-04|Estimate|2015-05-12|2015-06-04|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|Pain||HKT-500 in Adult Patients With Shoulder Pain|Protocol HKT-500-US08: A Randomized, Multicenter, Double-blind, Placebo-controlled, Two-week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Acute Shoulder Pain|Completed||Phase 3|368|Actual|Hisamitsu Pharmaceutical Co., Inc.||2|||f||||t||||||||||2018-06-01 02:08:04.733816|2018-06-01 02:08:04.733816
NCT00680459|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2013-09-03||2014-01-29|2008-05-19|2008-05-20|Estimate|2014-01-29|2014-03-12|Estimate||||2014-01-29|2014-03-12|Estimate|May 2008||2008-05-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Ethanol Locks for the Treatment of Central Venous Line Infections|Ethanol Locks for the Treatment of Central Venous Line Infections|Terminated||Phase 3|13|Actual|Baystate Medical Center||2||inability to enroll adequate number of patients|f||||f||||||||||2018-06-01 02:08:04.949737|2018-06-01 02:08:04.949737
NCT00680446|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2013-06-18|2008-05-19|2008-05-20|Estimate|||||||2013-06-18|2013-06-19|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency|An Open-Label Study of Ig NextGen 16% Administered by Subcutaneous Infusion in Patients With Primary Immunodeficiency (PID).|Completed||Phase 3|41|Actual|CSL Limited||1|||f||||f||||||||||2018-06-01 02:08:05.213074|2018-06-01 02:08:05.213074
NCT00680433|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2013-03-27|2008-05-19|2008-05-20|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2008||2008-04-30|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)|A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)|Completed||Phase 4|83|Actual|Northside Clinic, Australia||2|||f||||f||||||||||2018-06-01 02:08:05.294304|2018-06-01 02:08:05.294304
NCT00680420|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2013-03-06|2008-05-16|2008-05-20|Estimate|||||||2013-03-06|2013-03-07|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Observational|||DNA Microarray Study of Pancreas Cancer|DNA Microarray Analysis of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsies to Discriminate Benign From Malignant Pancreatic Lesions|Completed|||27|Actual|Oregon Health and Science University|||||f||||t||||||||||2018-06-01 02:08:05.430584|2018-06-01 02:08:05.430584
NCT00680407|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2015-12-23||2015-12-23|2008-05-15|2008-05-20|Estimate|2015-12-23|2016-01-29|Estimate||||2015-12-23|2016-01-29|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SyNCH||Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis|A Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Orally Administered Silymarin Preparation (Legalon®) for the Treatment of Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis|Completed||Phase 2|78|Actual|Madaus Inc||3|||f||||t||||||||||2018-06-01 02:08:05.527823|2018-06-01 02:08:05.527823
NCT00680394|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2013-03-11|2008-05-19|2008-05-20|Estimate|||||||2013-03-11|2013-03-13|Estimate|July 2007||2007-07-31|March 2013|2013-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone|Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone|Completed||N/A|440|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 02:08:05.896669|2018-06-01 02:08:05.896669
NCT00680381|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2014-08-04|2008-05-19|2008-05-20|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2004||2004-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Transitions||Transitional Treatment of Adolescents in Family Therapy|Transitional Treatment of Adolescents in Family Therapy|Completed||Phase 1|90|Actual|Oregon Research Institute||3|||f||||f||||||||||2018-06-01 02:08:06.004566|2018-06-01 02:08:06.004566
NCT00680368|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2014-08-29||2015-04-06|2008-05-19|2008-05-20|Estimate|2014-12-15|2014-12-16|Estimate||||2015-04-06|2015-04-28|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational||Physician residents who consented to participate in the study.|Resident Supervision Index: Assessing Feasibility and Validity|Resident Supervision Index: Assessing Feasibility and Validity|Completed|||97|Actual|VA Office of Research and Development|Single site study limiting generalizability of findings||1||f||||f||||||None Retained|"~     The study did not involve a biospecimen. None was collected. None was retained.~   "|||2018-06-01 02:08:06.10754|2018-06-01 02:08:06.10754
NCT00680355|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2013-06-28|2008-05-16|2008-05-20|Estimate|||||||2013-06-28|2013-07-01|Estimate|August 2004||2004-08-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bioavailability of Golden Rice Carotenoids in Humans|Bioavailability of Golden Rice Carotenoids in Humans|Completed||N/A|14|Actual|Tufts University||3|||f||||f||||||||||2018-06-01 02:08:06.298376|2018-06-01 02:08:06.298376
NCT00680342|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15||2013-03-11|2013-03-11|2008-05-15|2008-05-20|Estimate||||2013-03-11|2013-03-18|Estimate|2013-03-11|2013-03-18|Estimate|April 2008||2008-04-30|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SyNCH||Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment|A Multicenter, Randomized, Double-masked, Placebo-controlled Phase II Study to Assess the Safety and Efficacy of a Standardized Orally Administered Silymarin Preparation (Legalon) for the Treatment of Patients With Chronic Hepatitis C Who Failed Conventional Antiviral Therapy|Completed||Phase 2|154|Actual|National Center for Complementary and Integrative Health (NCCIH)||3|||f||||t||||||||||2018-06-01 02:08:06.37843|2018-06-01 02:08:06.37843
NCT00680329|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2012-05-29|2008-05-19|2008-05-20|Estimate|||||||2012-05-29|2012-05-31|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|GAS||Glaucoma Adherence Study, Spain|A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening|Completed|||55|Actual|Alcon Research|||1||f||||f||||||||||2018-06-01 02:08:06.479973|2018-06-01 02:08:06.479973
NCT00680316|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2010-08-31||2016-11-25|2008-05-19|2008-05-20|Estimate|2011-05-18|2011-06-17|Estimate||||2016-11-25|2017-01-12|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis|A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme® in 3- to 5-Year-Old Patients With Cystic Fibrosis|Terminated||Phase 4|3|Actual|Genentech, Inc.|Children were unable to perform forced oscillometry (FOT) or did not remain stable during the study. No efficacy analyses were performed because no patients had complete (pre- or post-treatment) data for pulmonary function tests, including FOT.|2||"Most patients were unable to perform the test being used to measure lung function, thus it~   became clear the study would not yield clinically meaningful data"|f||||||||||||||2018-06-01 02:08:06.568491|2018-06-01 02:08:06.568491
NCT00680290|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-19|2008-05-19|2008-05-20|Estimate|||||||2008-05-19|2008-05-20|Estimate|July 2007||2007-07-31|May 2008|2008-05-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||The Effect of Low Intensity Exercise on Quality of Life and Hemodynamics in Patients With Permanent Atrial Fibrillation|The Effect of Low Intensity Exercise on Quality of Life and Hemodynamics in Patients With Permanent Atrial Fibrillation|Unknown status|Recruiting|N/A|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-06-01 02:08:06.901648|2018-06-01 02:08:06.901648
NCT00680277|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2017-10-11|2008-05-19|2008-05-20|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2004||2004-04-30|October 2017|2017-10-31|December 31, 2008|Actual|2008-12-31|December 31, 2008|Actual|2008-12-31||Interventional|||Vitamin A Value of Spirulina Carotenoids in Humans|Vitamin A Value of Spirulina Carotenoids in Humans|Completed||Phase 1/Phase 2|20|Anticipated|Tufts University||2|||f||||f||||||||||2018-06-01 02:08:06.982603|2018-06-01 02:08:06.982603
NCT00680264|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2018-04-10|2008-05-16|2008-05-20|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2008||2008-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PCPS||Prospective Database Registry Study of Scoliosis in Children With Cerebral Palsy|Prospective Database Registry Study of Scoliosis in Children With Cerebral Palsy|Recruiting|||402|Anticipated|Setting Scoliosis Straight Foundation|||2||f||||f||||||||||2018-06-01 02:08:07.056842|2018-06-01 02:08:07.056842
NCT00680251|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2017-06-22|2008-05-16|2008-05-20|Estimate|||||||2017-06-22|2017-06-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:08:07.159356|2018-06-01 02:08:07.159356
NCT00680238|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-19|2008-05-19|2008-05-20|Estimate|||||||2008-05-19|2008-05-20|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)|Pregnancy and Implantation Rates When Embryos Are Selected Based on a Single Day 3 Score (Day 3)vs Graduated Embryo Score(GES) Plus Soluble Human Leukocyte Antigen-G Expression.|Completed||N/A|214|Actual|University of Stellenbosch||2|||f||||t||||||||||2018-06-01 02:08:07.197136|2018-06-01 02:08:07.197136
NCT00680225|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2017-04-10||2017-04-10|2008-05-15|2008-05-20|Estimate|2017-04-10|2017-04-12|Actual||||2017-04-10|2017-04-12|Actual|September 2007||2007-09-30|April 2017|2017-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Baseline Data available for 8 participants|Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma|Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma|Completed||Phase 3|10|Actual|New England Retina Associates||1|||f||||f||||||||||2018-06-01 02:08:07.270621|2018-06-01 02:08:07.270621
NCT00680212|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|||2009-02-17|2008-05-16|2008-05-20|Estimate|||||||2009-02-17|2009-02-18|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Vitamin A Equivalence of Plant Carotenoids in Children|Phase 2 Study of VITAMIN A EQUIVALENCE OF PLANT CAROTENOIDS IN CHILDREN|Completed||Phase 2|72|Anticipated|Tufts University||1|||f||||t||||||||||2018-06-01 02:08:07.53517|2018-06-01 02:08:07.53517
NCT00680199|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2015-10-26|2008-05-15|2008-05-20|Estimate|||||||2015-10-26|2015-10-28|Estimate|June 2008||2008-06-30|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|COTE||Information Processing at Sleep Onset and During Sleep in Patients With Insomnia|Information Processing at Sleep Onset and During Sleep in Patients With Insomnia|Completed|||50|Anticipated|University of Rochester|||2||f||||f||||||||||2018-06-01 02:08:07.634301|2018-06-01 02:08:07.634301
NCT00680186|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-16|2012-05-04||2014-05-08|2008-05-19|2008-05-20|Estimate|2012-05-04|2012-06-14|Estimate||||2014-05-08|2014-05-19|Estimate|April 2008||2008-04-30|December 2013|2013-12-31||||May 2011|Actual|2011-05-31||Interventional|RE-COVER II||Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)|A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication|Completed||Phase 3|2589|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:08:07.786432|2018-06-01 02:08:07.786432
NCT00680173|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2016-03-11|2008-05-16|2008-05-19|Estimate|||||||2016-03-11|2016-03-14|Estimate|August 2006||2006-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PBMC||Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients|Analysis of Gene Expression of PBMC in the Hepatitis C Virus Genotype 1b-infected Patients During Peg-interferon-α Plus Ribavirin Combination Therapy|Completed||Phase 4|30|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:08:09.351864|2018-06-01 02:08:09.351864
NCT00680160|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-02-16|2008-05-15|2008-05-19|Estimate|||||||2018-02-16|2018-02-20|Estimate|April 30, 2006|Actual|2006-04-30|February 2018|2018-02-28|May 31, 2007|Actual|2007-05-31|May 31, 2007|Actual|2007-05-31||Interventional|||Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)|An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis|Completed||Phase 2|15|Actual|Pfizer|||||f||||f||||||||||2018-06-01 02:08:09.471009|2018-06-01 02:08:09.471009
NCT00680147|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2015-05-19|2008-05-16|2008-05-19|Estimate|||||||2015-05-19|2015-05-21|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers|HPV Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers|Completed||Phase 2|614|Actual|Syracuse University||1|||f||||f||||||||||2018-06-01 02:08:09.538066|2018-06-01 02:08:09.538066
NCT00680134|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-02-16|2008-05-15|2008-05-19|Estimate|||||||2018-02-16|2018-02-20|Estimate|June 30, 2006|Actual|2006-06-30|February 2018|2018-02-28|August 31, 2007|Actual|2007-08-31|August 31, 2007|Actual|2007-08-31||Interventional|||Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis|An Open Label, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 1% And 5% Solutions For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail|Completed||Phase 2|60|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:08:09.609949|2018-06-01 02:08:09.609949
NCT00680121|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2014-04-28||2014-09-23|2008-05-16|2008-05-19|Estimate|2014-09-23|2014-09-25|Estimate||||2014-09-23|2014-09-25|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|August 2011|Actual|2011-08-31||Interventional|B1AS||High Dose Vitamin B1 to Reduce Abusive Alcohol Use|The Effectiveness of Benfotiamine in Reducing Abusive Drinking Among Family History Positive and Negative Alcoholics|Completed||Phase 4|120|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 02:08:09.691155|2018-06-01 02:08:09.691155
NCT00680108|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2015-08-26|2008-05-16|2008-05-19|Estimate|||||||2015-08-26|2015-08-27|Estimate|September 1999||1999-09-30|August 2015|2015-08-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution|A Double-Masked, Randomized, Placebo-Controlled, Rising-Dose Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution in Patients With Mild to Moderate Dry Eye Disease.|Completed||Phase 2|62|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:08:10.104714|2018-06-01 02:08:10.104714
NCT00680095|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2017-12-06|2008-05-15|2008-05-19|Estimate|||||||2017-12-06|2017-12-08|Actual|January 31, 2007|Actual|2007-01-31|December 2017|2017-12-31|February 28, 2007|Actual|2007-02-28|February 28, 2007|Actual|2007-02-28||Interventional|||Cumulative Irritation Test|21-day Cumulative Irritation Test|Completed||Phase 1|37|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 02:08:10.181038|2018-06-01 02:08:10.181038
NCT00680082|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2010-12-01|2008-05-16|2008-05-19|Estimate|||||||2010-12-01|2010-12-02|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Observational Usage Study of Statins in Primary Care in France|Observational Usage Study of Statins in Primary Care in France|Completed|||2100|Actual|AstraZeneca|||1||f||||t||||||||||2018-06-01 02:08:10.288701|2018-06-01 02:08:10.288701
NCT00680069|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15||2011-07-20|2016-12-22|2008-05-15|2008-05-19|Estimate||||2011-07-20|2011-07-22|Estimate|2016-12-22|2016-12-30|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||H5N1 (Clade 2) Vaccination of Adults and Elderly|A Randomized, Double-Blinded, Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of an Inactivated Influenza Vaccine Derived From A/H5N1/Indonesia/05/05 (Clade 2) in Healthy Adults and Elderly Who Participated in a Previous A/H5N1/Vietnam/1203/2004 (Clade 1) Vaccine Study|Completed||Phase 1/Phase 2|517|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 02:08:10.365642|2018-06-01 02:08:10.365642
NCT00680056|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2009-01-26||2010-01-12|2008-05-15|2008-05-19|Estimate|2009-10-30|2009-12-03|Estimate||||2010-01-12|2010-01-20|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients|Randomised Cross-over Study to Compare the Effect of Formoterol Plus Tiotropium Versus Formoterol Monotherapy on Breathlessness, Dynamic Hyperinflation and Exercise Tolerance in Moderate-to-severe Stable COPD Patients|Completed||Phase 4|33|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 02:08:10.444932|2018-06-01 02:08:10.444932
NCT00680043|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2012-04-26|2010-08-12|2012-06-22|2008-05-16|2008-05-19|Estimate|2012-04-26|2012-05-30|Estimate|2010-08-12|2010-08-17|Estimate|2012-06-22|2012-06-29|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA|AFX01-15: A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Undergoing Hemodialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment|Completed||Phase 2|114|Actual|Affymax||3|||f||||f||||||||||2018-06-01 02:08:10.919358|2018-06-01 02:08:10.919358
NCT00680030|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-15|2008-05-15|2008-05-19|Estimate|||||||2008-05-15|2008-05-19|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|September 2008|Anticipated|2008-09-30||Observational|||Reversibility of Dysmotility After Gastric Banding|Reversibility of Esophageal Dysmotilities Associated With Gastric Banding After Conversion to Gastric Bypass|Unknown status|Enrolling by invitation||50|Anticipated|Cantonal Hospital of St. Gallen|||1||f||||t||||||||||2018-06-01 02:08:11.542941|2018-06-01 02:08:11.542941
NCT00680017|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2012-04-25|2011-09-26|2012-09-27|2008-05-15|2008-05-19|Estimate|2012-06-13|2012-07-16|Estimate|2011-09-26|2011-10-05|Estimate|2012-09-27|2012-10-03|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease|A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease|Completed||Phase 3|280|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:08:11.666076|2018-06-01 02:08:11.666076
NCT00680004|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-16|2008-05-16|2008-05-19|Estimate|||||||2008-05-16|2008-05-19|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|September 2008|Anticipated|2008-09-30||Observational|||Dynamic Computed Tomography Angiography (CTA) Follow-up for EndoVascular Aortic Replacement (EVAR)|The Value of Dynamic CTA During the Follow-up of EndoVascular Aortic Replacement (EVAR): a Pilot Study|Unknown status|Recruiting||40|Anticipated|Radboud University|||2||f||||t||||||||||2018-06-01 02:08:12.20643|2018-06-01 02:08:12.20643
NCT00679991|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15||2011-11-10|2015-04-08|2008-05-16|2008-05-19|Estimate||||2011-11-10|2011-11-16|Estimate|2015-04-08|2015-04-30|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients|A Phase 1-2, Multi-Center, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease|Completed||Phase 1/Phase 2|66|Actual|Proteon Therapeutics||2|||f||||t||||||||||2018-06-01 02:08:12.29966|2018-06-01 02:08:12.29966
NCT00679978|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2009-09-17|2008-05-15|2008-05-19|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2001||2001-01-31|September 2009|2009-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Vertebral Fracture and Osteonecrosis Associated With High-dose Glucocorticoid|Vertebral Fracture and Osteonecrosis of the Femoral Head Associated With High-dose Glucocorticoid Therapy|Completed|||60|Actual|Saitama Medical University|||1||f||||f||||||||||2018-06-01 02:08:12.379371|2018-06-01 02:08:12.379371
NCT00679965|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15||2012-07-26|2012-07-26|2008-05-16|2008-05-19|Estimate||||2012-07-26|2012-08-02|Estimate|2012-07-26|2012-08-02|Estimate|February 2006||2006-02-28|July 2012|2012-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study of Different Doses of a Novel Treatment for Onychomycosis|A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 2.5%, 5.0%, and 7.5% Solutions vs. Vehicle for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail|Completed||Phase 2|159|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:08:12.452014|2018-06-01 02:08:12.452014
NCT00679952|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2011-03-13||2014-05-08|2008-05-16|2008-05-19|Estimate|2011-04-13|2011-05-09|Estimate||||2014-05-08|2014-05-19|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Interventional|||Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy|Randomised Prospective Study of Clinical Outcomes After Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy After Pancreatoduodenectomy|Completed||Phase 3|168|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:08:12.621364|2018-06-01 02:08:12.621364
NCT00679939|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2011-01-07||2018-03-19|2008-05-15|2008-05-19|Estimate|2011-02-10|2011-03-07|Estimate||||2018-03-19|2018-04-18|Actual|April 21, 2008||2008-04-21|March 2018|2018-03-31|September 16, 2010|Actual|2010-09-16|September 16, 2010|Actual|2010-09-16||Interventional|||Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health|A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus|Completed||Phase 4|226|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:08:12.928777|2018-06-01 02:08:12.928777
NCT00679926|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2012-10-09|2008-05-16|2008-05-19|Estimate|||||||2012-10-09|2012-10-10|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Kaletra and Viread in Antiretroviral Naïve Patients|A Phase IV Open Label Investigation of the Efficacy and Durability of Once Daily Antiretroviral Therapy With Kaletra and Viread in Antiretroviral Naïve Patients.|Terminated||Phase 4|6|Actual|Oklahoma State University Center for Health Sciences||1||Lack of enrollment|f||||f||||||||||2018-06-01 02:08:17.980882|2018-06-01 02:08:17.980882
NCT00679913|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2014-04-07||2014-05-08|2008-05-16|2008-05-19|Estimate|2014-05-08|2014-06-06|Estimate||||2014-05-08|2014-06-06|Estimate|November 2005||2005-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Standardization of Surgery on the Pancreatic Cancer|Randomized Controlled Study: Comparison Between Extended and Standard Pancreatoduodenectomy|Completed||Phase 3|244|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:08:18.403864|2018-06-01 02:08:18.403864
NCT00679900|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2010-11-29|2008-05-15|2008-05-19|Estimate|||||||2010-11-29|2010-11-30|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|DREAMS||Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties|Comparison of the Safety and Efficacy of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week, Randomized, Double-blind,Comparative, Parallel-group Study|Completed||Phase 3|283|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:08:19.230173|2018-06-01 02:08:19.230173
NCT00679887|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-16|2008-05-16|2008-05-19|Estimate|||||||2008-05-16|2008-05-19|Estimate|September 2003||2003-09-30|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Chronic Shoulder Pain Treated by Pressures With the Thumbs on the Trigger Points|Chronic Shoulder Pain of Myofascial Origin,a Randomised Clinical Trial Using Ischemic Compression Therapy.|Completed||Phase 1/Phase 2|59|Actual|Guy Hains Chiropractor||1|||f||||t||||||||||2018-06-01 02:08:19.560187|2018-06-01 02:08:19.560187
NCT00679874|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2011-10-02|2008-05-16|2008-05-19|Estimate|||||||2011-10-02|2011-10-04|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|Cardiotox||Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)|Characterization of the Cardiotoxic Effects of Chemotherapies With Anthracyclines and Trastuzumab for Breast Cancer by Contrast-enhanced Cardiovascular Magnetic Resonance Imaging (CMR).|Terminated|||66|Anticipated|University of Calgary|||1|No subjects indentifiable|f||||t||||||||||2018-06-01 02:08:19.8423|2018-06-01 02:08:19.8423
NCT00679861|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-16|2008-05-16|2008-05-19|Estimate|||||||2008-05-16|2008-05-19|Estimate|October 2004||2004-10-31|May 2008|2008-05-31|June 2009|Anticipated|2009-06-30|August 2008|Anticipated|2008-08-31||Interventional|PRO GP||Smoking Interventions in General Medical Practices|Different Types of Proactive Smoking Interventions for General Medical Practices: An Implementation Study|Unknown status|Active, not recruiting|Phase 2|3215|Anticipated|University Medicine Greifswald||3|||f||||t||||||||||2018-06-01 02:08:20.165844|2018-06-01 02:08:20.165844
NCT00679848|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2017-01-09|2008-05-15|2008-05-19|Estimate|||||||2017-01-09|2017-01-11|Estimate|May 2008||2008-05-31|January 2017|2017-01-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|TRIM||Transoral Gastric Volume Reduction as an Intervention for Weight Management|Transoral Gastric Volume Reduction as an Intervention for Weight Management (TRIM): A Non-Randomized Multicenter Feasibility Study of Subjects With Class II or Low Grade Class III Obesity|Completed||Phase 1|18|Actual|C. R. Bard||1|||f||||f||||||||||2018-06-01 02:08:20.401613|2018-06-01 02:08:20.401613
NCT00679835|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-01-07|2008-05-16|2008-05-19|Estimate|||||||2018-01-07|2018-01-09|Actual|June 3, 2008|Actual|2008-06-03|January 2018|2018-01-31|November 20, 2008|Actual|2008-11-20|November 20, 2008|Actual|2008-11-20||Interventional|||PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections|An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Two to Six Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection|Completed||Phase 1|24|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:08:20.653636|2018-06-01 02:08:20.653636
NCT00679822|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2014-02-12|2008-05-16|2008-05-19|Estimate|||||||2014-02-12|2014-02-13|Estimate|June 2007||2007-06-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||The Prevalence and Risk Factors of Sleep Disordered Breathing in a Heart Failure Program|The Prevalence and Risk Factors of Sleep Disordered Breathing in a Heart Failure Program|Completed|||195|Actual|Ohio State University|||1||f||||f||||||||||2018-06-01 02:08:20.902|2018-06-01 02:08:20.902
NCT00679809|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2015-05-28|2008-05-16|2008-05-19|Estimate|||||||2015-05-28|2015-06-01|Estimate|October 2008||2008-10-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|July 2009|Actual|2009-07-31||Observational|||Safety, Fatigue, and Continuity in the Intensive Care Unit (ICU)|Safety, Fatigue, and Continuity in the ICU: a Pragmatic Mixed-methods Study|Completed|||19|Actual|The Hospital for Sick Children|||||f||||t||||||||||2018-06-01 02:08:21.379669|2018-06-01 02:08:21.379669
NCT00679796|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2012-10-25|2008-05-16|2008-05-19|Estimate|||||||2012-10-25|2012-10-29|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||The Effectiveness of Varicella Vaccination in Children in Germany|The Effectiveness of Varicella Vaccination in Children in Germany|Completed|||1012|Actual|GlaxoSmithKline|||2||f||||f||||||Samples With DNA|"~     samples from skin lesions~   "|||2018-06-01 02:08:21.633658|2018-06-01 02:08:21.633658
NCT00679627|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2013-04-23||2013-09-10|2008-05-15|2008-05-19|Estimate|2013-07-30|2013-09-02|Estimate||||2013-09-10|2013-09-19|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease|Terminated||Phase 3|2051|Actual|Janssen Research & Development, LLC||2||"Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early~   termination of the trial"|f||||||||||||||2018-06-01 02:08:25.125964|2018-06-01 02:08:25.125964
NCT00679783|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|2011-07-19||2018-03-05|2008-05-15|2008-05-19|Estimate|2011-07-19|2011-08-12|Estimate||||2018-03-05|2018-03-06|Actual|July 8, 2008|Actual|2008-07-08|March 2018|2018-03-31|December 28, 2018|Anticipated|2018-12-28|March 26, 2010|Actual|2010-03-26||Interventional|||Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer|Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response|Active, not recruiting||Phase 2|91|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:08:22.096646|2018-06-01 02:08:22.096646
NCT00679770|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-02-16|2008-05-15|2008-05-19|Estimate|||||||2018-02-16|2018-02-20|Estimate|June 30, 2006|Actual|2006-06-30|February 2018|2018-02-28|August 31, 2007|Actual|2007-08-31|August 31, 2007|Actual|2007-08-31||Interventional|||Study of Different Doses of a Novel Treatment for Onychomycosis|A Randomized, Double-blind, Vehicle-controlled, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 2.5%, 5.0%, And 7.5% Solutions Vs. Vehicle For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail.|Completed||Phase 2|28|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:08:23.612806|2018-06-01 02:08:23.612806
NCT00679757|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2010-06-09|2008-05-16|2008-05-19|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||The Prevalence and Implications of Obstructive Sleep Apnea in the Population of a Wound Center|The Prevalence and Implications of Obstructive Sleep Apnea in the Population of a Wound Center|Completed|||300|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 02:08:23.711237|2018-06-01 02:08:23.711237
NCT00679744|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2013-02-21|2008-05-16|2008-05-19|Estimate|||||||2013-02-21|2013-02-25|Estimate|May 2008||2008-05-31|February 2013|2013-02-28||||March 2010|Actual|2010-03-31||Interventional|||A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis|A Dose-Escalated, Double-Blind, Placebo-Controlled, Randomized Phase I Clinical Trial of Pyrimethamine in Patients Affected With Chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff Variants)|Withdrawn||Phase 1|0|Actual|Exsar Corporation||1||Due to lack of funding|f||||f||||||||||2018-06-01 02:08:23.787632|2018-06-01 02:08:23.787632
NCT00679731|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15||2011-08-24|2013-01-22|2008-05-15|2008-05-19|Estimate||||2011-08-24|2011-08-29|Estimate|2013-01-22|2013-01-29|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|317|Actual|AbbVie||2|||f||||t||||||||||2018-06-01 02:08:23.960221|2018-06-01 02:08:23.960221
NCT00679718|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2015-08-26|2008-05-16|2008-05-19|Estimate|||||||2015-08-26|2015-08-27|Estimate|January 2000||2000-01-31|August 2015|2015-08-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Patients With Moderate to Severe Dry Eye Disease|Completed||Phase 2|150|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:08:24.12229|2018-06-01 02:08:24.12229
NCT00679705|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2009-04-17|2008-05-16|2008-05-19|Estimate|||||||2009-04-17|2009-04-20|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself|Pilot Study: A Dose-Response Finding Study of Ritodrine (Pre-Par®) to Find the Highest Well Tolerated Dose in Young, Healthy, Female Volunteers. To Find the Size-Order of the Hemodynamical Effects of Ritodrine (PrePar®) and Atosiban (Tractocile®) to Determine the Relevance of a PK/PD-Modelling in the Final Study. Final Study: Investigating the Influence of Tocolytical Medications: Ritodrine (PrePar®) and Atosiban (Tractocile®) at the Clinical Dose on the Hemodynamics and Arterial Function in Healthy Female Volunteers, Compared to Placebo During Continuous Intravenous Infusion.|Completed||Phase 1|23|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 02:08:24.21498|2018-06-01 02:08:24.21498
NCT00679692|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-16|2008-05-16|2008-05-19|Estimate|||||||2008-05-16|2008-05-19|Estimate|September 2006||2006-09-30|January 2006|2006-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Evaluation the Growth Factors(IGF-1,IGFBP-3and HGH)in Patients With Chronic Liver Disease|Insulin-Like Growth Factor-1,Insulin-Like Growth Factor Binding Protein-3 and Human Growth Hormone in Serum of Patients With Chronic Liver Disease and Possible Clinical Applications.|Completed|||210|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:08:24.289395|2018-06-01 02:08:24.289395
NCT00679679|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-16|2008-05-16|2008-05-19|Estimate|||||||2008-05-16|2008-05-19|Estimate|January 2003||2003-01-31|May 2008|2008-05-31|December 2005|Actual|2005-12-31|September 2005|Actual|2005-09-30||Interventional|||Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome|Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial|Completed||Phase 4|30|Actual|Hospital Privado de Cordoba, Argentina||2|||f||||f||||||||||2018-06-01 02:08:24.356285|2018-06-01 02:08:24.356285
NCT00679666|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2017-04-18|2008-05-16|2008-05-19|Estimate|||||||2017-04-18|2017-04-20|Actual|April 2008||2008-04-30|April 2017|2017-04-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|CXL||Corneal Crosslinking in Keratoconus and Corneal Ectasia|Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia|Withdrawn||Phase 2/Phase 3|0|Actual|Ohio State University||2||Investigator no longer at university|f||||f||||||||||2018-06-01 02:08:24.500093|2018-06-01 02:08:24.500093
NCT00679653|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-05-16|2008-05-16|2008-05-19|Estimate|||||||2008-05-16|2008-05-19|Estimate|February 2002||2002-02-28|May 2008|2008-05-31||||December 2003|Actual|2003-12-31||Interventional|HOS||Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives|Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives|Completed||Phase 3|171|Actual|Abbott||3|||f||||f||||||||||2018-06-01 02:08:24.577568|2018-06-01 02:08:24.577568
NCT00679640|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2010-12-01|2008-05-15|2008-05-19|Estimate|||||||2010-12-01|2010-12-02|Estimate|January 2008||2008-01-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Observational|SISTOLA||Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France|Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France|Completed|||450|Actual|AstraZeneca|||1||f||||t||||||||||2018-06-01 02:08:24.670606|2018-06-01 02:08:24.670606
NCT00679614|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2017-08-25|2008-05-16|2008-05-19|Estimate|||||||2017-08-25|2017-08-28|Actual|December 17, 2007|Actual|2007-12-17|August 2017|2017-08-31|May 31, 2011|Actual|2011-05-31|May 31, 2011|Actual|2011-05-31||Interventional|||Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery|The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in Elderly Patients Having Joint Replacement Surgery: a Randomized Controlled Study.|Completed||Phase 3|45|Actual|Lawson Health Research Institute||3|||f||||f||||||||||2018-06-01 02:08:26.419325|2018-06-01 02:08:26.419325
NCT00679601|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-02-16|2008-05-15|2008-05-19|Estimate|||||||2018-02-16|2018-02-20|Actual|March 31, 2007|Actual|2007-03-31|February 2018|2018-02-28|May 31, 2007|Actual|2007-05-31|May 31, 2007|Actual|2007-05-31||Interventional|||Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)|An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis|Completed||Phase 2|20|Actual|Pfizer|||||f||||f||||||||||2018-06-01 02:08:26.494033|2018-06-01 02:08:26.494033
NCT00679588|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07||2011-07-22|2013-11-21|2008-05-16|2008-05-19|Estimate||||2011-07-22|2011-08-01|Estimate|2013-11-21|2013-12-16|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|SAVE-ABDO||Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery|A Multinational, Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of AVE5026 With Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery|Completed||Phase 3|4413|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:08:26.601087|2018-06-01 02:08:26.601087
NCT00679575|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2010-12-06|2008-05-15|2008-05-19|Estimate|||||||2010-12-06|2010-12-08|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Statins and Risk of Myocardial Infarction in Real Life in France|Statins and Risk of Myocardial Infarction in Real Life in France|Completed|||13171|Actual|AstraZeneca|||2||f||||t||||||||||2018-06-01 02:08:27.236791|2018-06-01 02:08:27.236791
NCT00679562|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2009-02-05|2008-05-15|2008-05-19|Estimate|||||||2009-02-05|2009-02-06|Estimate|March 2008||2008-03-31|February 2009|2009-02-28||||April 2008|Actual|2008-04-30||Interventional|||Lactacyd Radiance (Lactic Acid) Prophetic Patch Test|Skin Irritation : Prophetic Patch Test of Lactacyd Radiance|Completed||Phase 2|200|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:08:27.385117|2018-06-01 02:08:27.385117
NCT00679549|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-04-03|2008-05-16|2008-05-19|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2008||2008-03-31|April 2018|2018-04-30|March 22, 2014|Actual|2014-03-22|March 22, 2014|Actual|2014-03-22||Interventional|||The Role of Sleep Apnea in the Acute Exacerbation of Heart Failure|The Role of Sleep Apnea in the Acute Exacerbation of Heart Failure|Completed||N/A|154|Actual|Ohio State University||2|||f||||t||||||||||2018-06-01 02:08:27.453673|2018-06-01 02:08:27.453673
NCT00679536|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2014-01-22|2008-05-16|2008-05-19|Estimate|||||||2014-01-22|2014-01-23|Estimate|May 2008||2008-05-31|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors|Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Using Fludarabine, Busulfan, 400 cGy Total Body Irradiation, and Thymoglobulin|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||t||||||||||2018-06-01 02:08:27.530209|2018-06-01 02:08:27.530209
NCT00679523|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2008-05-16|2008-05-16|2008-05-19|Estimate|||||||2008-05-16|2008-05-19|Estimate|November 2005||2005-11-30|May 2008|2008-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail|An Open-Label, Rising Multiple-Dose, Multi-Center Study to Evaluate the Safety and Efficacy of Topically Applied AN2690 5.0% and 7.5% Solution for the Treatment of Adult Subjects With Onychomycosis of the Great Toenail|Completed||Phase 2|60|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:08:27.617676|2018-06-01 02:08:27.617676
NCT00679510|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2016-01-07|2008-05-15|2008-05-19|Estimate|||||||2016-01-07|2016-01-08|Estimate|February 2004||2004-02-29|January 2016|2016-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|RORA||Rosuvastatin in Rheumatoid Arthritis (RORA)|Phase 2: Effects of Rosuvastatin on Surrogate Markers for Cardiovascular Events in Patients With Rheumatoid Arthritis|Completed||Phase 2/Phase 3|50|Actual|University of Dundee||2|||f||||t||||||||Yes||2018-06-01 02:08:27.712405|2018-06-01 02:08:27.712405
NCT00679497|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2013-02-21|2008-05-16|2008-05-19|Estimate|||||||2013-02-21|2013-02-22|Estimate|June 2008||2008-06-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|RisVac02||A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection|A Phase I Study of MVA-B in Healthy Volunteers at Low Risk of HIV Infection|Completed||Phase 1|30|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 02:08:27.792496|2018-06-01 02:08:27.792496
NCT00679484|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2010-08-06|2008-05-14|2008-05-16|Estimate|||||||2010-08-06|2010-08-09|Estimate|June 2008||2008-06-30|August 2010|2010-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|OLMEBNP||Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24|A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)|Terminated||Phase 3|400|Anticipated|Daiichi Sankyo, Inc.||2||Lack of subject recruitment|f||||f||||||||||2018-06-01 02:08:27.871281|2018-06-01 02:08:27.871281
NCT00679471|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2013-06-03|2008-05-15|2008-05-16|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 2007||2007-11-30|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Brain Structure and Development in Pre-Term and Full-Term Infants|The Relationship Between Early Brain Structure and Development in Full-Term and Pre-Term Infants|Completed|||47|Actual|Christiana Care Health Services|||2||f||||f||||||||||2018-06-01 02:08:27.959199|2018-06-01 02:08:27.959199
NCT00679458|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2010-01-06|2008-05-15|2008-05-16|Estimate|||||||2010-01-06|2010-01-07|Estimate|September 2008||2008-09-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine|A Randomized, Double-blind, Cross-over Trial Comparing the Analgesic Potency and Side Effects of Buprenorphine and Ultra-low-dose Naloxone to Buprenorphine Alone|Completed||N/A|12|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:08:28.180023|2018-06-01 02:08:28.180023
NCT00679302|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2013-01-29||2018-04-02|2008-05-14|2008-05-16|Estimate|2014-03-28|2014-04-29|Estimate||||2018-04-02|2018-05-04|Actual|July 2006||2006-07-31|March 2014|2014-03-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management|A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics|Completed||Phase 4|161|Actual|St. Louis University|Small sample size with large number of loss to follow up at the 3 month mark.|2|||f||||t||||||||||2018-06-01 02:08:31.977178|2018-06-01 02:08:31.977178
NCT00679445|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2011-07-26|2008-05-15|2008-05-16|Estimate|||||||2011-07-26|2011-07-27|Estimate|December 2007||2007-12-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|ROSE||A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy|A Feasibility Study to Evaluate the Safety And Tolerability of the EPI-RAD90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization (CNV) in Patients With Age-Related Macular Degeneration (AMD) That Have Failed Primary Anti-VEGF Therapy|Completed||Phase 2|20|Anticipated|NeoVista||1|||f||||f||||||||||2018-06-01 02:08:28.269985|2018-06-01 02:08:28.269985
NCT00679432|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2014-04-25|2011-12-01|2014-07-03|2008-05-15|2008-05-16|Estimate|2014-07-03|2014-08-01|Estimate|2012-02-09|2012-02-13|Estimate|2014-07-03|2014-08-01|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional||Intent-to-Treat (ITT) population= primary population for efficacy/baseline characteristics analyses. ITT population= randomized patients who received study drug, and did not include patients with major entry criteria/GCP violations or normal histology at baseline (N= 509 randomized - 3[infectious colitis] - 17[normal histology at baseline] = 489).|(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis|Efficacy and Safety of New Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablet Formulations in Patients With Mild or Moderate, Active Ulcerative Colitis. A Multicenter, Randomized, Double-blind, Double Dummy Comparative Study Versus Placebo, With an Additional Reference Arm Evaluating Asacol® 2400 mg.|Completed||Phase 3|510|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||||2018-06-01 02:08:28.42441|2018-06-01 02:08:28.42441
NCT00679419|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2012-11-01|2008-05-14|2008-05-16|Estimate|||||||2012-11-01|2012-11-02|Estimate|December 2007||2007-12-31|October 2012|2012-10-31|May 2013|Anticipated|2013-05-31|May 2011|Actual|2011-05-31||Observational|CAD-REF||Coronary Artery Disease and Renal Failure Registry|Coronary Artery Disease and Renal Failure Registry|Unknown status|Active, not recruiting||3352|Anticipated|Institut für Klinisch-Kardiovaskuläre Forschung GmbH|||6||f|||||||||||"~     Urine, whole blood, serum~   "|||2018-06-01 02:08:29.306113|2018-06-01 02:08:29.306113
NCT00679406|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2012-06-15|2008-05-15|2008-05-16|Estimate|||||||2012-06-15|2012-06-18|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|BBTIMV1||Brief Behavioral Treatment of Insomnia in Military Veterans: Phase 1|Treatment of Insomnia in Military Veterans:Phase 1|Completed||N/A|12|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:08:29.420183|2018-06-01 02:08:29.420183
NCT00679393|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2015-02-10|2008-05-14|2008-05-16|Estimate|||||||2015-02-10|2015-02-11|Estimate|February 2004||2004-02-29|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Sanders IV||Comparative Study of Fixation or Fusion of Calcaneal Fractures|A Prospective Randomized Multicentre Clinical Trial Comparing Open Reduction Internal Fixation With Primary Subtalar Fusion in Patients With Severely Comminuted (Sanders IV), Displaced, Intra-articular Fractures of the Calcaneus|Completed||N/A|26|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 02:08:29.52898|2018-06-01 02:08:29.52898
NCT00679380|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2014-04-25|2011-12-01|2014-07-03|2008-05-15|2008-05-16|Estimate|2014-07-03|2014-08-01|Estimate|2012-02-09|2012-02-13|Estimate|2014-07-03|2014-08-01|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional||Baseline characteristics were analyzed with the ITT population, defined as randomized patients who received study drug, had no entry criteria/GCP violation, and had abnormal mucosal histology at baseline. ITT population=410 patients: 511 - 101 patients who were not randomized, had entry criteria/GCP violation, or had normal histology at baseline.|(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis|Efficacy and Safety of Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablets in Patients With Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Double-Dummy, Comparative Study Versus Placebo With an Additional Reference Arm Evaluating Entocort®EC|Completed||Phase 3|514|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||||2018-06-01 02:08:29.652502|2018-06-01 02:08:29.652502
NCT00679367|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2016-09-09||2016-12-28|2008-05-14|2008-05-16|Estimate|2016-12-28|2017-02-20|Actual||||2016-12-28|2017-02-20|Actual|May 2008||2008-05-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MRD||Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis|A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis|Completed||Phase 2|16|Actual|Boston Medical Center||1|||f||||t||||||||No||2018-06-01 02:08:30.48659|2018-06-01 02:08:30.48659
NCT00679354|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2014-01-06||2014-05-05|2008-05-14|2008-05-16|Estimate|2014-01-06|2014-02-20|Estimate||||2014-05-05|2014-05-21|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy|Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:08:30.934276|2018-06-01 02:08:30.934276
NCT00679341|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2013-02-22||2013-12-09|2008-05-14|2008-05-16|Estimate|2013-04-10|2013-05-20|Estimate||||2013-12-09|2014-01-09|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|May 2012|Actual|2012-05-31|November 2010|Actual|2010-11-30||Interventional|||A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease|A Randomized, Multicenter, Phase ii Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease|Completed||Phase 2|137|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:08:31.257826|2018-06-01 02:08:31.257826
NCT00679328|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2011-06-09|2008-05-14|2008-05-16|Estimate|||||||2011-06-09|2011-06-10|Estimate|February 1992||1992-02-29|June 2011|2011-06-30|December 1999|Actual|1999-12-31|August 1996|Actual|1996-08-31||Interventional|||OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions|Study #91-01 - A Randomized Study of the Stryker OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions|Completed||N/A|122|Actual|Olympus Biotech Corporation||2|||f||||f||||||||||2018-06-01 02:08:31.768917|2018-06-01 02:08:31.768917
NCT00679315|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2013-06-07|2008-05-15|2008-05-16|Estimate|||||||2013-06-07|2013-06-10|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female|Efficacy and Safety of Alfuzosin for the Treatment of Non-neurogenic Voiding Dysfunction in Female: An 8 Week Prospective, Randomized Double Blind, Placebo-Controlled, Parallel Group Study (Phase Ⅱ)|Completed||Phase 2|190|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 02:08:31.868324|2018-06-01 02:08:31.868324
NCT00679289|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2018-01-09||2018-02-19|2008-05-14|2008-05-16|Estimate|2018-01-11|2018-02-09|Actual||||2018-02-19|2018-03-16|Actual|March 28, 2008|Actual|2008-03-28|February 2018|2018-02-28|February 3, 2014|Actual|2014-02-03|February 3, 2014|Actual|2014-02-03||Interventional||Safety Analysis Set (includes all patients who received at least 1 dose of KW2871 and initial treatment with HDI)|Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma|Phase II Study of the Anti-Ganglioside GD3 Mouse/Human Chimeric Antibody KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma|Completed||Phase 2|36|Actual|Ludwig Institute for Cancer Research||3|||f||||t|t|f||||||Undecided||2018-06-01 02:08:32.260628|2018-06-01 02:08:32.260628
NCT00679276|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2010-06-04|2008-05-14|2008-05-16|Estimate|||||||2010-06-04|2010-06-07|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Treatment Outcomes of Vaginal Prolapse Repair|Treatment Outcomes of Vaginal Prolapse Repair|Completed|||291|Actual|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 02:08:33.201349|2018-06-01 02:08:33.201349
NCT00679263|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2011-02-16||2011-12-14|2008-05-14|2008-05-16|Estimate|2011-11-10|2011-12-15|Estimate||||2011-12-14|2011-12-19|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma|A Randomized, Single-blind, Parallel Group, Placebo-controlled, Dose Rate Escalation Study Evaluating the Safety and Effects of MN-221 in Subjects Diagnosed With Moderate to Severe Asthma|Completed||Phase 2|17|Actual|MediciNova||2|||f||||f||||||||||2018-06-01 02:08:33.255518|2018-06-01 02:08:33.255518
NCT00679250|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2018-05-01|2008-05-15|2008-05-16|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2005||2005-11-30|May 2018|2018-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||To Evaluate Adenosine Monophosphate and Allergen Challenge in Allergic Rhinitis|A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis|Completed||Phase 4|25|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 02:08:33.555045|2018-06-01 02:08:33.555045
NCT00679237|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2017-08-08|2008-05-14|2008-05-16|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2007|Actual|2007-09-30|August 2017|2017-08-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|SPREK!||Risk Reduction in Coronary Heart Disease|Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study|Active, not recruiting||N/A|1600|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-06-01 02:08:33.780185|2018-06-01 02:08:33.780185
NCT00679224|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2017-03-21|2008-05-14|2008-05-16|Estimate|||||||2017-03-21|2017-03-23|Actual|June 2008||2008-06-30|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|VOLT||An Observational Study For Ambrisentan|A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)|Completed|||800|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 02:08:33.887288|2018-06-01 02:08:33.887288
NCT00679211|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2013-03-12||2017-03-02|2008-05-14|2008-05-16|Estimate|2013-03-12|2013-04-23|Estimate||||2017-03-02|2017-03-31|Actual|August 2008||2008-08-31|May 2013|2013-05-31|April 2011|Actual|2011-04-30|September 2009|Actual|2009-09-30||Interventional|||A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer|A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer|Completed||Phase 2|110|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 02:08:34.224035|2018-06-01 02:08:34.224035
NCT00679198|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2013-01-14|2008-05-15|2008-05-16|Estimate|||||||2013-01-14|2013-01-15|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Improving Osteoporosis Care in High-Risk Home Health Patients|Improving Osteoporosis Care in High-Risk Home Health Patients Through a High-Intensity Intervention|Completed||N/A|667|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:08:34.641579|2018-06-01 02:08:34.641579
NCT00679185|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2017-04-07|2008-05-14|2008-05-16|Estimate|||||||2017-04-07|2017-04-10|Actual|January 2007||2007-01-31|April 2017|2017-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Expressive Writing in Improving Quality of Life in Patients With Breast Cancer and Lymphedema|Effects of Expressive Writing in Breast Cancer Survivors With Lymphedema|Completed||N/A|107|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 02:08:34.731255|2018-06-01 02:08:34.731255
NCT00679172|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2017-05-02||2017-06-06|2008-05-15|2008-05-16|Estimate|2017-06-06|2017-06-07|Actual||||2017-06-06|2017-06-07|Actual|May 2008||2008-05-31|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults|A Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study to Determine the Immunogenicity, Safety and Tolerability of S. Typhi (Ty2 aroC‾ssaV‾) ZH9 at Doses of 5.0 x 10E9 CFU, 7.5 x 10E9 CFU, 1.1 x 10E10 and 1.7 x 10E10 CFU and 1.7 x 10E10 CFU, Following Oral Administration to Healthy, Typhoid Vaccine naïve Subjects in the USA.|Completed||Phase 2|187|Actual|Emergent BioSolutions||4|||f||||f||||||||No||2018-06-01 02:08:34.874417|2018-06-01 02:08:34.874417
NCT00679159|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2010-02-08|2008-05-14|2008-05-16|Estimate|||||||2010-02-08|2010-02-09|Estimate|February 2008||2008-02-29|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of MVA85A in Healthy Children and Infants|A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth|Completed||Phase 2|168|Actual|University of Oxford||5|||f||||t||||||||||2018-06-01 02:08:35.724466|2018-06-01 02:08:35.724466
NCT00679146|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2010-06-10|2008-05-15|2008-05-16|Estimate|||||||2010-06-10|2010-06-11|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TIOKET||Efficacy Safety of a Combination Thiocolchicoside+Ketoprofen Compared to Thiocolchicoside Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain|Efficacy and Safety of a Fixed Combination (Thiocolchicoside 8 mg + Ketoprofen 100 mg ) Compared to Thiocolchicoside 8 mg Administered Twice a Day for 7 Days in Patients Suffering From Acute Non Specific Low Back Pain|Completed||Phase 3|334|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:08:35.801814|2018-06-01 02:08:35.801814
NCT00679133|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2015-01-06|2008-05-14|2008-05-16|Estimate|||||||2015-01-06|2015-01-08|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies|Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies|Completed||Phase 1|47|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 02:08:35.874843|2018-06-01 02:08:35.874843
NCT00678925|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2010-06-16|2008-05-14|2008-05-16|Estimate|||||||2010-06-16|2010-06-22|Estimate|December 2004||2004-12-31|June 2010|2010-06-30|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||Supplemental Choline and Brain Development in Humans|Supplemental Choline and Neurodevelopment in Humans|Completed||N/A|150|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 02:08:38.675109|2018-06-01 02:08:38.675109
NCT00679120|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2014-10-21|2008-05-15|2008-05-16|Estimate|||||||2014-10-21|2014-10-22|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Oxford Partial Knee Replacement. A Randomized Clinical Trial of Three Implant Types|Oxford Partial Knee Replacement: A Randomized Clinical Trial of Three Implant Types.|Unknown status|Active, not recruiting|N/A|75|Anticipated|University of Aarhus||3|||f||||t||||||||||2018-06-01 02:08:35.942211|2018-06-01 02:08:35.942211
NCT00679107|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2011-06-09|2008-05-14|2008-05-16|Estimate|||||||2011-06-09|2011-06-10|Estimate|June 1999||1999-06-30|June 2011|2011-06-30|July 2005|Actual|2005-07-31|December 2000|Actual|2000-12-31||Interventional|||A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions|A Prospective, Randomized, Controlled, Multicenter, Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions|Completed||N/A|48|Actual|Olympus Biotech Corporation||2|||f||||f||||||||||2018-06-01 02:08:36.016232|2018-06-01 02:08:36.016232
NCT00679094|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2016-12-28|2008-05-14|2008-05-16|Estimate|||||||2016-12-28|2016-12-29|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Bowman-Birk Inhibitor Concentrate in Healthy Men|Phase I Single Dose Safety and Pharmacokinetic Study of a New Formulation of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:08:36.078352|2018-06-01 02:08:36.078352
NCT00679081|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2011-10-10||2012-01-09|2008-05-14|2008-05-16|Estimate|2011-10-10|2011-11-21|Estimate||||2012-01-09|2012-01-11|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage|A Prospective, Randomized, Controlled Pilot Study of CelTx(TM) (Apligraf®) as an Alternative to Tissue From the Palate in the Treatment of Gingival Recession Requiring Root Coverage|Terminated||Phase 1/Phase 2|15|Actual|Organogenesis|This study was terminated early due to suboptimal clinical outcomes. Due to two study design changes, the data could not be combined and analyzed for effectiveness (ie, no secondary effectiveness endpoints were tested).|2|||f||||f||||||||||2018-06-01 02:08:36.159756|2018-06-01 02:08:36.159756
NCT00679068|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2015-08-19|2008-05-14|2008-05-16|Estimate|||||||2015-08-19|2015-08-20|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Effects of Bosentan on Respiratory Mechanics|Effects of 12 Weeks Treatment With Bosentan on Respiratory Mechanics in Patients With Pulmonary Hypertension|Terminated||Phase 4|4|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1||lack of recruitment of patients|f||||t||||||||||2018-06-01 02:08:36.511273|2018-06-01 02:08:36.511273
NCT00679055|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2015-01-30||2017-03-30|2008-05-15|2008-05-16|Estimate|2015-01-30|2015-02-16|Estimate||||2017-03-30|2017-05-03|Actual|March 31, 2007|Actual|2007-03-31|March 2017|2017-03-31|August 26, 2008|Actual|2008-08-26|August 26, 2008|Actual|2008-08-26||Interventional|||A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)|An Exploratory Double-Blind, Placebo Controlled, Randomized, 12-Week Oral Dose Study to Evaluate the Effects of MK0736 on Atherosclerotic Disease Biomarkers in Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease|Terminated||Phase 1|14|Actual|Merck Sharp & Dohme Corp.|Study terminated due to lack of recruitment.|2||Lack of recruitment|f||||f||||||||||2018-06-01 02:08:36.607106|2018-06-01 02:08:36.607106
NCT00679042|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2018-05-17|2008-05-15|2008-05-16|Estimate|||||||2018-05-17|2018-05-22|Actual|June 2007||2007-06-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|April 2018|Actual|2018-04-30||Interventional|||Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol|Islet Transplantation in Type 1 Diabetic Patients Using the UIC Protocol, Phase 3|Completed||Phase 3|36|Actual|University of Illinois at Chicago||1|||f||||t||||||||No||2018-06-01 02:08:36.85083|2018-06-01 02:08:36.85083
NCT00679029|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-15|||2018-01-23|2008-05-15|2008-05-16|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2008||2008-05-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer|Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express HER-2/Neu|Active, not recruiting||Phase 2|26|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:08:36.933927|2018-06-01 02:08:36.933927
NCT00679003|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2015-04-14|2008-05-15|2008-05-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Managing IBD||Managing Inflammatory Bowel Disease|Psychosocial Intervention for Children With IBD|Completed||N/A|190|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:08:37.028817|2018-06-01 02:08:37.028817
NCT00678990|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2017-08-18|2008-05-14|2008-05-16|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Heparinized Islets in Clinical Islet Transplantation|Open Study to Evaluate Safety and Efficacy of Allogenic Islet Transplantation Using Islets Coated With Immobilised Heparin|Not yet recruiting||N/A|10|Anticipated|Corline Biomedical AB||1|||f||||t|f|f||||||No||2018-06-01 02:08:37.088053|2018-06-01 02:08:37.088053
NCT00678977|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2017-11-09|2008-05-15|2008-05-16|Estimate|||||||2017-11-09|2017-11-14|Actual|April 3, 2008|Actual|2008-04-03|November 2017|2017-11-30|June 30, 2011|Actual|2011-06-30|March 30, 2010|Actual|2010-03-30||Interventional|||A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors|A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors|Completed||Phase 1|22|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:08:37.210825|2018-06-01 02:08:37.210825
NCT00678964|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2008-05-15|2008-05-15|2008-05-16|Estimate|||||||2008-05-15|2008-05-16|Estimate|June 2006||2006-06-30|May 2008|2008-05-31||||November 2008|Anticipated|2008-11-30||Interventional|TIE||Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Multicentre Randomised Phase II Trial of Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients (=/> 70 Years) With Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|260|Anticipated|LungenClinic Grosshansdorf||2|||f||||t||||||||||2018-06-01 02:08:37.292393|2018-06-01 02:08:37.292393
NCT00678938|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2008-05-14|2008-05-14|2008-05-16|Estimate|||||||2008-05-14|2008-05-16|Estimate|October 2004||2004-10-31|May 2008|2008-05-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Smoking Interventions in the General Population|General Population Based Interventions for Smokers Not Ready to Quit: Testing Smoking Reduction vs. Abstinence Oriented Computer Expert Systems|Unknown status|Active, not recruiting|Phase 2|1462|Actual|University Medicine Greifswald||3|||f||||t||||||||||2018-06-01 02:08:38.588056|2018-06-01 02:08:38.588056
NCT00678912|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2012-09-18|2008-05-15|2008-05-16|Estimate|||||||2012-09-18|2012-09-19|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Weaning Children From Mechanical Ventilation:Computer-driven System Versus Usual Care|Single Center Randomized Clinical Trial Comparing Weaning From Mechanical Ventilation With Computer-driven System vs Usual Care in Children|Completed||Phase 3|30|Actual|St. Justine's Hospital||2|||f||||t||||||||||2018-06-01 02:08:38.757013|2018-06-01 02:08:38.757013
NCT00678899|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2014-09-10||2015-06-19|2008-05-14|2008-05-16|Estimate|2014-09-26|2014-09-29|Estimate||||2015-06-19|2015-07-15|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|June 2012|Actual|2012-06-30||Interventional|||Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System|Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant|Completed||N/A|50|Actual|Cochlear||1|||f||||f||||||||||2018-06-01 02:08:38.867416|2018-06-01 02:08:38.867416
NCT00678886|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2017-07-19|2013-01-04|2017-09-05|2008-05-15|2008-05-16|Estimate|2017-09-05|2017-10-03|Actual|2013-01-04|2013-01-10|Estimate|2017-09-05|2017-10-03|Actual|July 29, 2008|Actual|2008-07-29|July 2017|2017-07-31|January 31, 2012|Actual|2012-01-31|January 31, 2012|Actual|2012-01-31||Interventional|DEFEND-1||Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1|Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND|Completed||Phase 3|272|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 02:08:39.156379|2018-06-01 02:08:39.156379
NCT00678873|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2009-12-14|2008-05-15|2008-05-16|Estimate|||||||2009-12-14|2009-12-15|Estimate|March 2008||2008-03-31|August 2008|2008-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SILC||Single Incision Laparoscopic Cholecystectomy|Single Incision Laparoscopic Cholecystectomy|Completed||Phase 1|20|Anticipated|North Texas Veterans Healthcare System||1|||f||||f||||||||||2018-06-01 02:08:40.423273|2018-06-01 02:08:40.423273
NCT00678860|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2017-06-30|2008-05-14|2008-05-16|Estimate|||||||2017-06-30|2017-07-02|Actual|May 9, 2008||2008-05-09|October 31, 2011|2011-10-31|October 31, 2011||2011-10-31|||||Observational|||Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires|Pilot Validation Study of Computer Administration of Vision Targeted Quality of Life Instruments|Completed|||147|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:08:40.602983|2018-06-01 02:08:40.602983
NCT00678847|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-05-15|2008-05-15|2008-05-16|Estimate|||||||2008-05-15|2008-05-16|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy|Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Kingfisher Healthcare||2|||f||||f||||||||||2018-06-01 02:08:40.678098|2018-06-01 02:08:40.678098
NCT00678834|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2014-07-02||2014-09-08|2008-05-14|2008-05-16|Estimate|2014-09-08|2014-09-16|Estimate||||2014-09-08|2014-09-16|Estimate|March 2006||2006-03-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||The healthy participants included: age 21–40 y, good health, nonsmoker, nonpregnant or nonbreastfeeding, and no recent (past 6 mo) or current use of supplements containing vitamin E. The surgical participants group included adipose, brain, cardiac muscle, and liver tissue of the surgical participants age 21 and older.|Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol|Human Tissue Distribution of Orally Supplemented Natural Vitamin E Tocotrienol|Completed||Early Phase 1|80|Actual|Ohio State University||3|||f||||t||||||||||2018-06-01 02:08:40.800426|2018-06-01 02:08:40.800426
NCT00678821|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2018-04-03|2008-05-15|2008-05-16|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 13, 2008||2008-05-13|July 28, 2017|2017-07-28|September 23, 2015|Actual|2015-09-23|September 23, 2015|Actual|2015-09-23||Interventional|||Aerobic Exercise in Patients With Pulmonary Hypertension|The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Pulmonary Hypertension: Initial Studies for Establishing Guidelines|Completed||Phase 2|97|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:08:41.113732|2018-06-01 02:08:41.113732
NCT00678808|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2016-09-01|2008-05-14|2008-05-16|Estimate|||||||2016-09-01|2016-09-05|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:08:41.187192|2018-06-01 02:08:41.187192
NCT00678795|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2012-07-18||2013-06-13|2008-05-15|2008-05-16|Estimate|2012-08-21|2012-09-21|Estimate||||2013-06-13|2013-06-24|Estimate|August 2002||2002-08-31|June 2013|2013-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis|A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis.|Completed||Phase 3|135|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 02:08:41.252851|2018-06-01 02:08:41.252851
NCT00678782|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2008-05-15|2008-05-15|2008-05-16|Estimate|||||||2008-05-15|2008-05-16|Estimate|April 2005||2005-04-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis|Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence|Completed||Phase 2|31|Actual|University of Padova|||||f||||t||||||||||2018-06-01 02:08:41.772243|2018-06-01 02:08:41.772243
NCT00678769|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2015-11-03|2008-05-14|2008-05-16|Estimate|||||||2015-11-03|2015-11-04|Estimate|May 2008||2008-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|June 2013|Actual|2013-06-30||Interventional|||Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer|Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers|Completed||Phase 1|72|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 02:08:41.841772|2018-06-01 02:08:41.841772
NCT00678756|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2010-06-07|2008-05-14|2008-05-16|Estimate|||||||2010-06-07|2010-06-08|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|VITAKET||Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol|Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol|Unknown status|Active, not recruiting|Phase 2|12|Anticipated|Technische Universität Dresden|||||f||||t||||||||||2018-06-01 02:08:41.93881|2018-06-01 02:08:41.93881
NCT00677898|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2014-09-05||2015-04-06|2008-05-14|2008-05-15|Estimate|2014-09-05|2014-09-12|Estimate||||2015-04-06|2015-04-27|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|March 2012|Actual|2012-03-31||Interventional|||A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)|A Patient-Centered Approach to Improve Screening for Side Effects of SGAs|Completed||N/A|239|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:09:01.669652|2018-06-01 02:09:01.669652
NCT00678743|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2008-05-14|2008-05-14|2008-05-16|Estimate|||||||2008-05-14|2008-05-16|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|||An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin|An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia|Unknown status|Active, not recruiting|Phase 4|13|Actual|Provident Clinical Research|||||f||||f||||||||||2018-06-01 02:08:42.017916|2018-06-01 02:08:42.017916
NCT00678730|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2017-06-21|2008-05-13|2008-05-15|Estimate|||||||2017-06-21|2017-06-23|Actual|July 2007||2007-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pharmacogenetics of Cannabinoid Response|Pharmacogenetics of Cannabinoid Response|Active, not recruiting||Phase 1|162|Anticipated|Yale University||2|||f||||||||||||||2018-06-01 02:08:42.095346|2018-06-01 02:08:42.095346
NCT00678717|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2018-03-14|2008-05-14|2008-05-15|Estimate|||||||2018-03-14|2018-03-16|Actual|February 2008|Actual|2008-02-29|March 2018|2018-03-31|January 23, 2009|Actual|2009-01-23|January 23, 2009|Actual|2009-01-23||Interventional|AFTSCSCVP||Microneurography and Spinal Cord Stimulation in Chronic Visceral Pain|Autonomic Function Testing and Spinal Cord Stimulation: Implications for Successful Therapy in Chronic Visceral Pain|Terminated||N/A|36|Actual|Vanderbilt University Medical Center||2||Lack of funding|f||||f|f|f||||||No||2018-06-01 02:08:42.169002|2018-06-01 02:08:42.169002
NCT00678704|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-12-18|2008-05-14|2008-05-15|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|November 2004|Actual|2004-11-30|||||Interventional|||BAY38-9456 - Pivotal Trial for Diabetes Patient|A Randomized, Placebo-controlled, Double-blind, Multi-centre, Parallel Group Study to Investigate the Efficacy and Safety of BAY 38-9456 in Males With Diabetes Suffering From Erectile Dysfunction|Completed||Phase 3|790|Actual|Bayer||3|||f||||f||||||||||2018-06-01 02:08:42.240444|2018-06-01 02:08:42.240444
NCT00678691|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2012-09-06||2014-12-09|2008-05-14|2008-05-15|Estimate|2014-12-09|2014-12-18|Estimate||||2014-12-09|2014-12-18|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue||Completed||Phase 4|55|Actual|State University of New York - Upstate Medical University||2|||f||||f||||||||||2018-06-01 02:08:42.319589|2018-06-01 02:08:42.319589
NCT00678678|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-05-13|2008-05-13|2008-05-15|Estimate|||||||2008-05-13|2008-05-15|Estimate||||April 2008|2008-04-30||||||||Interventional|||Chest Physiotherapy After Bariatric Aurgery - A Comparison Between Incentive Spirometry and Expiratory Positive Airway Pressure (Epap)|Chest Physiotherapy After Bariatric Surgery - a Comparison Between Incentive Spirometry and Epap|Completed||N/A|||Universidade Metodista de Piracicaba||2|||f||||||||||||||2018-06-01 02:08:42.637424|2018-06-01 02:08:42.637424
NCT00678665|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2008-05-14|2008-05-14|2008-05-15|Estimate|||||||2008-05-14|2008-05-15|Estimate|May 2008||2008-05-31|May 2008|2008-05-31||||||||Observational|||Changes in Heart Rate in Response to Heat Pressure and Neural Stimulation|Initial Study for the Definition in Heart Rate Changes in Response to Heat Pressure and Neural Stimulation|Unknown status|Not yet recruiting||20|Anticipated|Soroka University Medical Center|||||f||||t||||||||||2018-06-01 02:08:42.756032|2018-06-01 02:08:42.756032
NCT00678652|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2016-11-01||2017-12-15|2008-05-08|2008-05-15|Estimate|2017-12-15|2017-12-18|Actual||||2017-12-15|2017-12-18|Actual|April 2008||2008-04-30|December 2017|2017-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|HOPS||Phase 1 Safety and Immunogenicity of Meningococcal Vaccine|Ph 1 Dose-Escalation Study of Safety and Immunogenicity of 3 Injections, at 0, 6, 2 Wks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Adm Intramuscularly to Healthy Subjects at 10, 25, 50, 75 μg With Adjuvant|Completed||Phase 1|36|Actual|U.S. Army Medical Research and Materiel Command||4|||f||||t||||||||Undecided||2018-06-01 02:08:42.863457|2018-06-01 02:08:42.863457
NCT00678639|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2010-03-19||2017-11-09|2008-05-08|2008-05-15|Estimate|2010-04-15|2010-04-28|Estimate||||2017-11-09|2017-12-18|Actual|January 2008||2008-01-31|February 2017|2017-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain|Randomized Cost Comparison of Cardiac MRI Use in ED Patients With Chest Pain|Completed||N/A|110|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 02:08:43.992432|2018-06-01 02:08:43.992432
NCT00678626|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2015-04-30|2008-05-12|2008-05-15|Estimate|||||||2015-04-30|2015-05-04|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer|A Randomized Phase 2, Open-Label Study Of CP-751,871 In Combination With Docetaxel And Docetaxel Alone As A First Line Treatment Of Patients With Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:08:44.423791|2018-06-01 02:08:44.423791
NCT00678613|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2008-05-14|2008-05-14|2008-05-15|Estimate|||||||2008-05-14|2008-05-15|Estimate|July 2007||2007-07-31|May 2008|2008-05-31||||||||Interventional|||Role of Probiotics in the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Placebo Control Trial||Unknown status|Recruiting|Phase 2/Phase 3|250|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||||||||||||2018-06-01 02:08:44.509679|2018-06-01 02:08:44.509679
NCT00678600|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2013-11-19|2008-05-13|2008-05-15|Estimate|||||||2013-11-19|2013-11-20|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Provider Computer Alerts Designed to Improve Delivery of HIV Care|Optimizing HIV Disease-Specific Provider Alerts: A Randomized Controlled Informatics Trial Comparing Electronic Health Record (EHR) vs. Non-EHR Provider Alerts|Completed||N/A|1011|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-06-01 02:08:44.592075|2018-06-01 02:08:44.592075
NCT00678587|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2010-10-10|2010-08-12|2013-02-07|2008-05-13|2008-05-15|Estimate|2010-10-10|2010-11-08|Estimate|2010-08-12|2010-08-18|Estimate|2013-02-07|2013-02-12|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|ELEVATE||Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures|Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures|Terminated||Phase 3|292|Actual|GlaxoSmithKline||2||GSK decision|f||||t||||||||||2018-06-01 02:08:44.717217|2018-06-01 02:08:44.717217
NCT00678574|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2017-03-10||2017-07-14|2008-05-13|2008-05-15|Estimate|2017-06-19|2017-07-17|Actual||||2017-07-14|2017-08-17|Actual|March 1998||1998-03-31|July 2017|2017-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder|The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder|Completed||Phase 4|45|Actual|University of Pennsylvania|Data from this study has not yet been analyzed nor peer reviewed. As much information as possible was entered into the results section of this trial, however information is missing as it pertains to specific measurements collected.|2|||f||||f||||||||||2018-06-01 02:08:45.802972|2018-06-01 02:08:45.802972
NCT00678561|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13||2010-08-24|2010-11-12|2008-05-13|2008-05-15|Estimate||||2010-11-12|2010-11-23|Estimate|2010-11-12|2010-11-23|Estimate|October 2008||2008-10-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Topical CP-690,550 For Chronic Plaque Psoriasis|Phase 2A Randomized, Double-Blind, Vehicle-Controlled, Intra-Individual Comparison Trial Assessing Safety, Toleration, Pharmacokinetics And Pilot Efficacy Of 4 Weeks Treatment With Topical CP-690,550 In Chronic Plaque Psoriasis|Completed||Phase 2|81|Actual|Pfizer||8|||f||||f||||||||||2018-06-01 02:08:46.009952|2018-06-01 02:08:46.009952
NCT00678548|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2015-04-07|2008-05-14|2008-05-15|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Guided Imagery on Patients With Chronic Pain Related to Spinal Cord Injury|Effect of Positive Guided Imagery on Patients With in or Below-level Chronic Pain Related to Spinal Cord Injury|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||2||Due to other projects priority|f||||f||||||||||2018-06-01 02:08:46.121472|2018-06-01 02:08:46.121472
NCT00678535|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2013-03-30||2014-07-11|2008-05-14|2008-05-15|Estimate|2013-03-30|2013-05-16|Estimate||||2014-07-11|2014-07-21|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|February 2013|Actual|2013-02-28|March 2012|Actual|2012-03-31||Interventional|EXPAND||Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer|Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction|Completed||Phase 3|904|Actual|Merck KGaA||2|||f||||t||||||||||2018-06-01 02:08:46.269649|2018-06-01 02:08:46.269649
NCT00678522|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2008-05-14|2008-05-14|2008-05-15|Estimate|||||||2008-05-14|2008-05-15|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes|The Acute Effect of Atorvastatin on Renal Sodium Excretion, Glomerular Filtration Rate, Tubular Function and Vasoactive Hormones in Patients With Non-Insulin Dependent Type II Diabetes.|Completed||Phase 4|25|Anticipated|Regional Hospital Holstebro|||||f||||t||||||||||2018-06-01 02:08:47.603226|2018-06-01 02:08:47.603226
NCT00678509|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-12-28|2008-05-14|2008-05-15|Estimate|||||||2009-12-28|2009-12-29|Estimate|May 2008||2008-05-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Breast Cancer|Terminated||Phase 1/Phase 2|14|Anticipated|Tokyo University||1||Lack of financial support|f||||t||||||||||2018-06-01 02:08:47.729276|2018-06-01 02:08:47.729276
NCT00678496|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2009-09-23|2008-05-14|2008-05-15|Estimate|||||||2009-09-23|2009-09-24|Estimate|October 2008||2008-10-31|September 2009|2009-09-30||||||||Interventional|CoSMoS||Cognitive Behavioural Therapy Software for the Treatment of Depression in People With Multiple Sclerosis|Computerised Cognitive Behavioural Therapy for Treatment of Depression in MS (CoSMoS): Clinical Trial Pilot Study|Completed||Phase 2|24|Anticipated|University of Sheffield||3|||f||||f||||||||||2018-06-01 02:08:47.840191|2018-06-01 02:08:47.840191
NCT00678483|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2009-06-16|2008-05-14|2008-05-15|Estimate|||||||2009-06-16|2009-06-17|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|MODERATO||Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients|A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overweight or Obese Patients|Terminated||Phase 3|331|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 02:08:47.961251|2018-06-01 02:08:47.961251
NCT00678470|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2012-11-20||2013-02-19|2008-05-14|2008-05-15|Estimate|2013-01-15|2013-02-15|Estimate||||2013-02-19|2013-02-22|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis|A Single Arm, Open Label Study to Explore if Response to Intralesional Alefacept Injections Prior to the Standard Course of Intramuscular Treatment Can Predict Clinical Outcomes in Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||N/A|18|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 02:08:48.084009|2018-06-01 02:08:48.084009
NCT00678457|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2009-01-29|2008-05-14|2008-05-15|Estimate|||||||2009-01-29|2009-01-30|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial|Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial|Completed||Phase 2|40|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 02:08:48.27181|2018-06-01 02:08:48.27181
NCT00678444|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-10|||2016-01-27|2008-05-14|2008-05-15|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2008||2008-04-30|January 2016|2016-01-31|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|||Patient Satisfaction Regarding Timing of Clean Intermittent Self-Catheterization Teaching After Prolapse or Incontinence Surgery||Completed||N/A|199|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:08:48.343594|2018-06-01 02:08:48.343594
NCT00678431|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-11-13|2008-05-14|2008-05-15|Estimate|||||||2012-11-13|2012-11-15|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Randomized Trial of a Nutritional Supplement in Alzheimer's Disease|A Single Center, Multi-site, Randomized, Double-blind, Placebo-controlled Trial of Resveratrol With Glucose and Malate (RGM) to Slow the Progression of Alzheimer's Disease|Completed||Phase 3|27|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:08:48.414291|2018-06-01 02:08:48.414291
NCT00678418|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2010-12-20||2016-12-21|2008-05-14|2008-05-15|Estimate|2010-12-20|2011-01-21|Estimate||||2016-12-21|2017-02-10|Actual|June 2008||2008-06-30|December 2016|2016-12-31|November 2010|Actual|2010-11-30|October 2009|Actual|2009-10-31||Interventional|||ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence|Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence|Completed||Phase 3|250|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-06-01 02:08:48.493047|2018-06-01 02:08:48.493047
NCT00678405|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2010-06-24|2008-05-14|2008-05-15|Estimate|||||||2010-06-24|2010-06-25|Estimate|August 2008||2008-08-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Trial of a Breathlessness Intervention Service for Intractable Breathlessness|Phase III Randomized Controlled Trial of a Breathlessness Intervention Service for Intractable Breathlessness.|Unknown status|Recruiting|Phase 3|120|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 02:08:48.84391|2018-06-01 02:08:48.84391
NCT00678392|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|2012-02-25|2010-10-02|2017-02-21|2008-05-12|2008-05-15|Estimate|2012-02-25|2012-03-27|Estimate|2010-10-02|2010-10-05|Estimate|2017-02-21|2017-03-24|Actual|September 2008||2008-09-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|August 2010|Actual|2010-08-31||Interventional||Full analysis set (FAS) included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or receive a different drug from that to which they were randomized.|Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer|Axitinib (Ag-013736) As Second Line Therapy For Metastatic Renal Cell Cancer: Axis Trial|Completed||Phase 3|723|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:08:49.20063|2018-06-01 02:08:49.20063
NCT00678379|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2017-05-01||2017-06-05|2008-05-14|2008-05-15|Estimate|2017-06-05|2017-07-02|Actual||||2017-06-05|2017-07-02|Actual|April 2008||2008-04-30|June 2017|2017-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Pediatric Tonsillectomy Pain Reduction Study|Pediatric Tonsillectomy Pain Reduction Study, a Randomized, Placebo Controlled, Double-Blind Clinical Trial Using Clonidine and Local Anesthetics|Completed||Phase 3|120|Actual|Vanderbilt University Medical Center||3|||f||||t||||||||Undecided|No plan to share unless specifically requested within 5 year storage of data period.|2018-06-01 02:08:51.487501|2018-06-01 02:08:51.487501
NCT00678366|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2011-10-25|2008-05-14|2008-05-15|Estimate|||||||2011-10-25|2011-10-26|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Evaluation of Adding Small Amounts of Oxygen to the CO2 Pneumoperitoneum Upon Pain and Inflammation|Evaluation of Adding Small Amounts of Oxygen to the CO2 Pneumoperitoneum Upon Pain and Inflammation|Completed||Phase 3|60|Anticipated|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-06-01 02:08:51.952764|2018-06-01 02:08:51.952764
NCT00678353|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2011-06-09|2008-05-14|2008-05-15|Estimate|||||||2011-06-09|2011-06-10|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|August 2007|Actual|2007-08-31|||||Observational|||Study of OP-1 Putty in Uninstrumented Posterolateral Fusions|Prospective Data Collection From the Stryker Biotech Pivotal IDE Study of OP-1 Putty in Uninstrumented Posterolateral Fusions|Completed|||202|Actual|Olympus Biotech Corporation|||1||f||||f||||||||||2018-06-01 02:08:52.015637|2018-06-01 02:08:52.015637
NCT00678340|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2013-03-05|2008-05-13|2008-05-15|Estimate|||||||2013-03-05|2013-03-06|Estimate|September 2007||2007-09-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Randomized Trial of Two Ablation Catheters in Paroxysmal Atrial Fibrillation|A Single Centre, Randomized, Single Blinded Trial of Wide Area Circumferential Ablation With Pulmonary Vein Isolation Compared to a Multipolar, Circular Ablation Catheter in Patients With Paroxysmal Atrial Fibrillation|Completed||Phase 4|178|Actual|University College London Hospitals||2|||f||||t||||||||||2018-06-01 02:08:52.086629|2018-06-01 02:08:52.086629
NCT00678327|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2018-01-24|2008-05-13|2008-05-15|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2008||2008-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma|A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma|Active, not recruiting||Phase 3|1202|Actual|University College, London||4|||f||||t||||||||||2018-06-01 02:08:52.149837|2018-06-01 02:08:52.149837
NCT00678314|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2008-05-13|2008-05-13|2008-05-15|Estimate|||||||2008-05-13|2008-05-15|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Patient Controlled Regional Analgesia Following Carpal Tunnel Release: A Double-Blind Study Using Distal Perineural Catheters|Patient Controlled Regional Analgesia Following Carpal Tunnel Release: A Double-Blind Study Using Distal Perineural Catheters|Completed||Phase 4|88|Actual|Region Örebro County||3|||f||||t||||||||||2018-06-01 02:08:52.267498|2018-06-01 02:08:52.267498
NCT00678301|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2017-05-04|2009-09-25|2017-05-04|2008-05-14|2008-05-15|Estimate|2017-05-04|2017-10-27|Actual|2009-09-25|2009-09-28|Estimate|2017-05-04|2017-10-27|Actual|June 18, 2008|Actual|2008-06-18|May 2017|2017-05-31|December 10, 2009|Actual|2009-12-10|November 9, 2009|Actual|2009-11-09||Interventional|||Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Zilbrix™ Hib and Polio Sabin™|Completed||Phase 3|365|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:08:52.524279|2018-06-01 02:08:52.524279
NCT00678288|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|2010-09-10||2014-11-24|2008-05-14|2008-05-15|Estimate|2010-09-10|2010-10-01|Estimate||||2014-11-24|2014-12-11|Estimate|April 2008||2008-04-30|November 2014|2014-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.|A Phase II, Randomized, Open-label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|16|Actual|Bayer|The study was terminated early by the Sponsor due to low accrual. No efficacy analyses were performed.|2|||f||||f||||||||||2018-06-01 02:08:53.384482|2018-06-01 02:08:53.384482
NCT00678275|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2015-05-12|2008-05-14|2008-05-15|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|||Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia|Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study|Completed||Phase 3|161|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-06-01 02:08:53.809154|2018-06-01 02:08:53.809154
NCT00678262|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2010-09-19|2008-05-14|2008-05-15|Estimate|||||||2010-09-19|2010-09-21|Estimate|May 2008||2008-05-31|September 2010|2010-09-30|October 2008||2008-10-31|October 2008|Actual|2008-10-31||Observational|HRVW1||Changes in Heart Rate in Response to Cold Pressor Test|Changes in Heart Rate in Response to Cold Pressor Test|Completed|||20|Anticipated|Soroka University Medical Center|||||f||||f||||||||||2018-06-01 02:08:53.996663|2018-06-01 02:08:53.996663
NCT00678249|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2009-02-20||2011-05-10|2008-05-14|2008-05-15|Estimate|2011-04-07|2011-05-09|Estimate||||2011-05-10|2011-05-11|Estimate|January 2001||2001-01-31|May 2011|2011-05-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Pivotal Study for the FLAIR Endovascular Stent Graft|A Prospective, Multi-Center, Randomized Evaluation of an IMPRA/Bard ePTFE Encapsulated Carbon Lined Nitinol Endoluminal Device for AV Access Graft Stenoses|Completed||N/A|227|Actual|C. R. Bard||3|||f||||t||||||||||2018-06-01 02:08:54.099635|2018-06-01 02:08:54.099635
NCT00678236|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2013-08-19|2008-05-14|2008-05-15|Estimate|||||||2013-08-19|2013-08-20|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Migration and Bone Density Study Comparing 2 Types of Bone Cement in the OptiPac Bone Cement Mixing System|A Migration and Bone Density Study Comparing Refobacin Bone Cement R vs. Refobacin Plus Bone Cement in the OptiPac Bone Cement Mixing System. A Prospective Randomized Study on Primary Total Knee Arthroplasty|Completed||N/A|54|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:08:54.650137|2018-06-01 02:08:54.650137
NCT00678210|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2012-11-19|2011-03-24|2012-11-19|2008-05-13|2008-05-15|Estimate|2012-11-19|2012-12-19|Estimate|2011-03-24|2011-04-01|Estimate|2012-11-19|2012-12-19|Estimate|July 2008||2008-07-31|November 2012|2012-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 2B, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Evaluating The Efficacy And Safety Of Dose Regimens With Oral CP-690,550 In The Treatment Of Subjects With Moderate To Severe Chronic Plaque Psoriasis|Completed||Phase 2|197|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:08:54.778703|2018-06-01 02:08:54.778703
NCT00678197|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2015-04-30|2008-05-14|2008-05-15|Estimate|||||||2015-04-30|2015-05-04|Estimate|April 2003||2003-04-30|April 2015|2015-04-30|September 2007||2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Philippine Child Health and Policy Experiment|Philippine Child Health and Policy Experiment|Completed||N/A|||University of California, San Francisco||3|||f||||||||||||||2018-06-01 02:08:57.265336|2018-06-01 02:08:57.265336
NCT00678184|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2008-05-14|2008-05-14|2008-05-15|Estimate|||||||2008-05-14|2008-05-15|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake|The Effect of Acute HMG-CoA-Reductase Inhibition (Atorvastatin) on Renal Sodium Excretion, Renal Hemodynamics, Tubular Function and Vasoactive Hormones in Healthy Subjects During Normal and High Sodium Intake|Completed||Phase 4|23|Actual|Regional Hospital Holstebro|||||f||||t||||||||||2018-06-01 02:08:57.542556|2018-06-01 02:08:57.542556
NCT00678171|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13||2014-01-03|2014-01-03|2008-05-14|2008-05-15|Estimate||||2014-01-03|2014-02-05|Estimate|2014-01-03|2014-02-05|Estimate|February 2007||2007-02-28|January 2014|2014-01-31|March 2010|Actual|2010-03-31|March 2008|Actual|2008-03-31||Interventional|||A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System|A Pilot Study to Evaluate an OP-1 Putty Spinal System and an Autograft Spinal System in Patients Requiring Transforaminal Lumbar Interbody Fusion of the Spine|Completed||N/A|30|Actual|Olympus Biotech Corporation||2|||f||||f||||||||||2018-06-01 02:08:57.812851|2018-06-01 02:08:57.812851
NCT00678158|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2015-11-16|2008-05-14|2008-05-15|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2006||2006-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone|Phase I Dose Escalation Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone|Completed||Phase 1|68|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 02:08:58.399282|2018-06-01 02:08:58.399282
NCT00678145|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2018-01-16|2008-05-14|2008-05-15|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2008|Actual|2008-03-31|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|HAAF||Mechanisms Responsible for Hypoglycemia Associated Autonomic Failure|Mechanisms of Hypoglycemia Associated Autonomic Failure|Recruiting||Phase 2|116|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|t|f||||||No||2018-06-01 02:08:58.499355|2018-06-01 02:08:58.499355
NCT00678132|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2018-02-13|2008-05-13|2008-05-15|Estimate|||||||2018-02-13|2018-02-14|Actual|April 24, 2008||2008-04-24|September 7, 2012|2012-09-07|November 23, 2010|Actual|2010-11-23|November 23, 2010|Actual|2010-11-23||Interventional|||AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers|A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors|Completed||Phase 1|23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:08:58.60892|2018-06-01 02:08:58.60892
NCT00678119|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14||2013-07-09|2013-07-11|2008-05-14|2008-05-15|Estimate||||2013-07-09|2013-07-12|Estimate|2013-07-11|2013-07-15|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment|A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib|Completed||Phase 2|25|Actual|Argos Therapeutics||1|||f||||t||||||||||2018-06-01 02:08:58.701199|2018-06-01 02:08:58.701199
NCT00678106|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2009-10-09|2008-05-12|2008-05-15|Estimate|||||||2009-10-09|2009-10-12|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections|A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Adolescents, Aged 12 Through 17 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections|Completed||Phase 1|10|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:08:58.806213|2018-06-01 02:08:58.806213
NCT00678093|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-05-13|2008-05-13|2008-05-15|Estimate|||||||2008-05-13|2008-05-15|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|Mulligan||Effects of a Mulligan Mobilisation in the Lumbar Flexion Range of Asymptomatic Subjects|The Effects of the Mulligan Mobilisation Sustained Natural Apophyseal Glide (SNAG) in the Lumbar Flexion Range of Asymptomatic Subjects as Measured by the Zebris CMS20 3-D Motion Analysis System|Completed||N/A|49|Actual|University of Manchester||1|||f||||f||||||||||2018-06-01 02:08:58.876456|2018-06-01 02:08:58.876456
NCT00678080|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2014-07-23|2008-05-14|2008-05-15|Estimate|||||||2014-07-23|2014-07-25|Estimate|September 2008||2008-09-30|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes|A Randomized, Controlled Trial of Metformin Versus Insulin in Women With Type 2 Diabetes Mellitus During Pregnancy in a Population With Severe Health Disparities|Unknown status|Recruiting|N/A|100|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 02:08:58.940685|2018-06-01 02:08:58.940685
NCT00678067|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-05-16|2008-05-14|2008-05-15|Estimate|||||||2008-05-16|2008-05-19|Estimate|June 2005||2005-06-30|May 2008|2008-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|DHA-RICHOIL||Effects of Docosahexaenoic and Eicosapentaenoic Acids in Hypercholesterolemic Children Plus Diet on Docosahexaenoic Acid (DHA) Status|Effects of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid(EPA)Supplementation on DHA Plasmatic Status and Blood Lipid Profile in Hypercholesterolemic Children in Addition to National Cholesterol Education Program Step I Diet|Completed||N/A|36|Actual|University of Milan||3|||f||||f||||||||||2018-06-01 02:08:59.052595|2018-06-01 02:08:59.052595
NCT00678054|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-08-21|2008-05-14|2008-05-15|Estimate|||||||2017-08-21|2017-08-23|Actual|April 1999||1999-04-30|August 2017|2017-08-31|October 23, 2015|Actual|2015-10-23|August 11, 2000|Actual|2000-08-11||Interventional|||Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)|A Phase II Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Patients With Evidence of Serologic (PSA) Progression After Definitive Therapy for Localized Prostate Cancer|Completed||Phase 2|30|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 02:08:59.256455|2018-06-01 02:08:59.256455
NCT00678041|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-10|2016-05-10||2016-08-03|2008-05-14|2008-05-15|Estimate|2016-06-21|2016-08-02|Estimate||||2016-08-03|2016-09-27|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|APPIC|This is a randomized, double-blind, placebo-controlled clinical trial|Nitrofurantoin and Urinary Tract Infections (UTIs)|A Randomized, Double-blind, Placebo-controlled Trial Examining the Effect of Nitrofurantoin Prophylaxis in Women Performing Clean Intermittent Self-catheterization (CISC) After Surgery for Urinary Incontinence and/or Pelvic Organ Prolapse|Terminated||N/A|10|Actual|University of Pittsburgh|Study terminated prior to accumulation of any data. Participating subjects were withdrawn prior to measuring any outcome data|2||Inadequate patient recruitment|f||||f||||||||No||2018-06-01 02:08:59.38378|2018-06-01 02:08:59.38378
NCT00678028|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-17|||2009-04-22|2008-05-14|2008-05-15|Estimate|||||||2009-04-22|2009-04-23|Estimate|February 2008||2008-02-29|April 2009|2009-04-30||||||||Observational|||Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection|Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection|Completed|||200|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||Samples With DNA|"~     whole blood for genetic test and serum for MBL test~   "|||2018-06-01 02:08:59.605189|2018-06-01 02:08:59.605189
NCT00678015|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|2014-01-28||2014-03-11|2008-05-14|2008-05-15|Estimate|2014-03-11|2014-04-09|Estimate||||2014-03-11|2014-04-09|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer|A Phase II Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non-Metastatic Recurrent Prostate Cancer|Terminated||Phase 2|12|Actual|University of California, San Francisco|Per protocol - accrual was stopped early after a pre-planned interim analysis showed no significant PSA declines after 3 cycles of treatment among the first 12 patients enrolled.|1||"Per protocol - interim analysis showed no significant PSA declines among the first 12 patients~   after 3 cycles of treatment"|f||||t||||||||||2018-06-01 02:08:59.670368|2018-06-01 02:08:59.670368
NCT00678002|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2017-09-06|2008-05-12|2008-05-15|Estimate|||||||2017-09-06|2017-09-07|Actual|October 2008||2008-10-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Quality of Life in Pediatric Transplant Patients|Quality of Life and Vulnerability in Pediatric Solid Organ Transplant Recipients|Enrolling by invitation|||150|Anticipated|Medical College of Wisconsin|||1||f||||f||||||||||2018-06-01 02:08:59.886307|2018-06-01 02:08:59.886307
NCT00677989|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2009-02-06|2008-05-14|2008-05-15|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Study on Laparoscopic Operation for Perforated Appendicitis|The Role of Oxidized Proteins and Free Radicals on Laparoscopic Operation for Perforated Appendicitis|Unknown status|Recruiting||60|Anticipated|Far Eastern Memorial Hospital|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:08:59.961317|2018-06-01 02:08:59.961317
NCT00677976|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2018-03-13|2008-05-12|2008-05-15|Estimate|||||||2018-03-13|2018-03-15|Actual|June 2007||2007-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|June 2013|Actual|2013-06-30||Observational|fMRI||Use of Functional Magnetic Resonance Imaging (fMRI) to Study Brain Activation in Children With Irritable Bowel Syndrome|Use of Functional Magnetic Resonance Imaging (fMRI) to Study Brain Activation Following Rectal Stimulation in Children With Irritable Bowel Syndrome|Active, not recruiting|||17|Actual|Medical College of Wisconsin|||2||f||||f||||||||||2018-06-01 02:09:00.056852|2018-06-01 02:09:00.056852
NCT00677963|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2011-04-19|2008-05-14|2008-05-15|Estimate|||||||2011-04-19|2011-04-20|Estimate|June 2009||2009-06-30|April 2011|2011-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation|Contrast-enhanced Ultrasound and Magnetic Resonance Imaging for the Evaluation of Neovascularisation in Carotid Artery Plaques|Completed||N/A|18|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 02:09:00.13515|2018-06-01 02:09:00.13515
NCT00677950|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2011-06-09|2008-05-13|2008-05-15|Estimate|||||||2011-06-09|2011-06-10|Estimate|October 2001||2001-10-31|June 2011|2011-06-30|November 2005|Actual|2005-11-30|November 2003|Actual|2003-11-30||Interventional|||OP-1 Putty for Posterolateral Fusions|OP-1 Putty for Posterolateral Fusions|Completed||N/A|336|Actual|Olympus Biotech Corporation||2|||f||||f||||||||||2018-06-01 02:09:00.205727|2018-06-01 02:09:00.205727
NCT00677937|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2014-12-04|2008-05-13|2008-05-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|PREVENTION||A Diabetes Prevention Study Targeting High Risk Individuals With Education and Ongoing Support|A Randomised Controlled Trial to Investigate an Educational Programme and Continuous Monitoring to Prevent Diabetes in Individuals With Screen Detected Pre-diabetes in a Multi-ethnic Population|Completed||N/A|748|Actual|University Hospitals, Leicester||2|||f||||t||||||||||2018-06-01 02:09:00.288459|2018-06-01 02:09:00.288459
NCT00677924|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2011-09-12||2011-11-21|2008-05-14|2008-05-15|Estimate|2011-11-21|2011-12-23|Estimate||||2011-11-21|2011-12-23|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|GEN206||Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer|A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy|Terminated||Phase 1/Phase 2|9|Actual|Genmab|The trial was prematurely closed when 9 out of 97 patients were enrolled. The trial design was originally divided in two parts. Patient allocation was terminated before Part 2 was started.|2||Due to changes in portfolio review|f||||t||||||||||2018-06-01 02:09:00.357034|2018-06-01 02:09:00.357034
NCT00677911|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2008-05-13|2008-05-13|2008-05-15|Estimate|||||||2008-05-13|2008-05-15|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Immunologic Response to Negative Cognition in Persons With Chronic Pain|Immunologic Response to Negative Cognition in Persons With Chronic Pain|Completed||Early Phase 1|47|Actual|Oregon Health and Science University|||||f||||t||||||||||2018-06-01 02:09:01.588731|2018-06-01 02:09:01.588731
NCT00677885|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2018-05-17|2008-05-14|2008-05-15|Estimate|||||||2018-05-17|2018-05-18|Actual|May 9, 2008||2008-05-09|August 25, 2014|2014-08-25|August 25, 2014||2014-08-25|||||Observational|||P-glycoprotein Function in Brain Diseases|Measurement of P-Glycoprotein Function in Alzheimer Disease, Parkinson Disease, and Frontotemporal Dementia Using Positron Emission Tomography|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:09:01.970812|2018-06-01 02:09:01.970812
NCT00677872|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2009-07-28|2008-05-14|2008-05-15|Estimate|||||||2009-07-28|2009-07-30|Estimate|May 2008||2008-05-31|July 2009|2009-07-31||||December 2008|Anticipated|2008-12-31||Interventional|||An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease||Terminated||Phase 2|40|Anticipated|Epix Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 02:09:02.0553|2018-06-01 02:09:02.0553
NCT00677859|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-14|||2012-01-03|2008-05-14|2008-05-15|Estimate|||||||2012-01-03|2012-01-05|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia|A Phase I, Multicenter, Dose-Escalation Trial Evaluating Maximum-Tolerated Dose of Single and Repeated Administration of Allogeneic MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia|Completed||Phase 1|36|Actual|Athersys, Inc||2|||f||||t||||||||||2018-06-01 02:09:02.21391|2018-06-01 02:09:02.21391
NCT00677846|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2008-05-13|2008-05-13|2008-05-15|Estimate|||||||2008-05-13|2008-05-15|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|August 2008|Anticipated|2008-08-31|July 2008|Anticipated|2008-07-31||Observational|||Venous Thrombus Investigation With Contrast Enhanced Ultrasound Imaging|Venous Thrombus Investigation With Contrast Enhanced Ultrasound Imaging, a Follow up Study|Unknown status|Recruiting||31|Anticipated|University Hospital Freiburg|||1||f||||f||||||||||2018-06-01 02:09:02.324703|2018-06-01 02:09:02.324703
NCT00677833|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|2014-05-27|2010-11-05|2014-05-27|2008-05-12|2008-05-15|Estimate|2014-05-27|2014-06-26|Estimate|2010-11-05|2010-11-16|Estimate|2014-05-27|2014-06-26|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa|Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa|Completed||Phase 2/Phase 3|361|Actual|Pfizer|Cohort 1 was a screening cohort, meant for safety evaluation, but not included in the efficacy assessments.|2|||f||||t||||||||||2018-06-01 02:09:02.481424|2018-06-01 02:09:02.481424
NCT00677820|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2010-08-20||2010-10-12|2008-05-13|2008-05-15|Estimate|2010-08-20|2010-09-15|Estimate||||2010-10-12|2010-10-22|Estimate|June 2008||2008-06-30|October 2010|2010-10-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|MI-MA182||A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Trivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|Completed||Phase 4|300|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 02:09:03.6074|2018-06-01 02:09:03.6074
NCT00677807|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|2011-07-22||2011-08-18|2008-05-14|2008-05-15|Estimate|2011-07-22|2011-08-18|Estimate||||2011-08-18|2011-08-22|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Extension to a 26-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|415|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:09:04.258061|2018-06-01 02:09:04.258061
NCT00677794|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-13|||2015-09-23|2008-05-14|2008-05-15|Estimate|||||||2015-09-23|2015-09-25|Estimate|March 2008||2008-03-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|August 2013|Actual|2013-08-31||Interventional|||Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination|Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination: a Randomized, Blinded, Controlled Trial|Completed||Phase 4|198|Actual|Queen's University||3|||f||||f||||||||||2018-06-01 02:09:05.113262|2018-06-01 02:09:05.113262
NCT00677781|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2011-09-05|2008-05-14|2008-05-15|Estimate|||||||2011-09-05|2011-09-07|Estimate|February 2008||2008-02-29|September 2011|2011-09-30|January 2010|Actual|2010-01-31|December 2008|Actual|2008-12-31||Observational|||Impact of Microparticles on Postoperative Complications in Surgical Patients|The Impact of Microparticles on Inflammatory Responses During Visceral and Cardiac Surgery|Completed|||108|Actual|University of Bern|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:09:05.259325|2018-06-01 02:09:05.259325
NCT00677768|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2016-06-02|2008-05-13|2008-05-14|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2008||2008-04-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|BIO_ALS-01||Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)|A Multicenter Study for the Validation of ALS Biomarkers|Completed|||475|Actual|Massachusetts General Hospital|||4||f||||f||||||Samples With DNA|"~     650 blood samples (plasma and serum)will be collected from four groups: ALS volunteers~     diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases,~     volunteers with other neurological diseases and healthy control volunteers.~      300 cerebrospinal fluid (CSF) samples will be collected from all four groups: ALS volunteers~     diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases,~     volunteers with other neurological diseases and healthy control volunteers.~      Up to 600 DNA samples will also be collected from all 4 groups: ALS volunteers diagnosed with~     ALS, volunteers with pure lower or pure upper motor neuron diseases, volunteers with other~     neurological diseases and healthy control volunteers.~   "|||2018-06-01 02:09:05.334661|2018-06-01 02:09:05.334661
NCT00677755|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2008-05-15|2008-05-12|2008-05-14|Estimate|||||||2008-05-15|2008-05-16|Estimate|October 2004||2004-10-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Medical Abortion for Emergency Contraception Failure|Medical Termination of Pregnancy Due to Emergency Contraception Failure: A Randomized Trial Comparing Mifepristone Combined Misoprostol and Misoprostol Alone.|Completed||N/A|394|Actual|Taizhou Hospital||2|||f||||f||||||||||2018-06-01 02:09:05.448847|2018-06-01 02:09:05.448847
NCT00677742|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-12-11|2008-05-13|2008-05-14|Estimate|||||||2012-12-11|2012-12-12|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|April 2009|Actual|2009-04-30||Interventional|SixPack||The Impact of Pack Supply on Birth Control Pill Continuation|Impact of Pack Supply on Oral Contraception Continuation|Completed||N/A|700|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 02:09:05.531249|2018-06-01 02:09:05.531249
NCT00655096|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2018-03-27|2008-04-08|2008-04-09|Estimate|||||||2018-03-27|2018-03-29|Actual|April 7, 2008||2008-04-07|December 13, 2017|2017-12-13||||||||Observational|||Screening for Research Participants|Screening Study for the Evaluation and Diagnosis of Potential Research Participants|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:16:09.781833|2018-06-01 02:16:09.781833
NCT00677729|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-11-12|2008-05-13|2008-05-14|Estimate|||||||2015-11-12|2015-11-13|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Hypertonic Saline to Reduce Hospital Admissions in Bronchiolitis|Inhaled Hypertonic Saline to Reduce Hospital Admissions in Infants With Viral Bronchiolitis (HS in ER Study)|Completed||Phase 2|81|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 02:09:05.595862|2018-06-01 02:09:05.595862
NCT00677716|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2014-04-23|2008-05-13|2008-05-14|Estimate|||||||2014-04-23|2014-04-24|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse|Open-label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse|Completed||Phase 2|41|Actual|Peregrine Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:09:05.667501|2018-06-01 02:09:05.667501
NCT00677703|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-11-16|2008-05-13|2008-05-14|Estimate|||||||2012-11-16|2012-11-19|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|April 2010|Actual|2010-04-30||Interventional|||Txt Now 2 Decrease Pregnancies L8r: A Study to Evaluate the Effect of Daily Text Message Reminders on Pill Continuation|The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial|Completed||N/A|968|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 02:09:05.768042|2018-06-01 02:09:05.768042
NCT00677690|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2009-01-05||2011-11-04|2008-05-12|2008-05-14|Estimate|2009-04-17|2009-04-20|Estimate||||2011-11-04|2011-11-16|Estimate|January 2007||2007-01-31|November 2011|2011-11-30|January 2009|Actual|2009-01-31|March 2008|Actual|2008-03-31||Interventional|||Neuromuscular Electrical Stimulation in Chronic Obstructive Pulmonary Disease (COPD)|Combination of Pulmonary Rehabilitation and Neuromuscular Electrical Stimulation and in COPD Patients: a Randomized Clinical Trial of Efficacy|Completed||Phase 3|83|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||||2018-06-01 02:09:05.861707|2018-06-01 02:09:05.861707
NCT00677677|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2014-12-30|2008-05-13|2008-05-14|Estimate|||||||2014-12-30|2015-01-01|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|April 2011|Actual|2011-04-30||Interventional|||Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients|Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients.|Completed||Phase 3|50|Actual|University of Alberta|||||f||||f||||||||||2018-06-01 02:09:06.196054|2018-06-01 02:09:06.196054
NCT00677664|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-05-13|2008-05-13|2008-05-14|Estimate|||||||2008-05-13|2008-05-14|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|September 2008|Anticipated|2008-09-30|July 2008|Anticipated|2008-07-31||Interventional|||Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation|Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial.|Unknown status|Active, not recruiting|Phase 4|30|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 02:09:06.291796|2018-06-01 02:09:06.291796
NCT00677651|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-08-17|2008-05-12|2008-05-14|Estimate|||||||2009-08-17|2009-08-18|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Sex Differences in Gene Expression in Human Adipose Tissue|Sex Differences in Gene Expression in Human Adipose Tissue|Completed|||10|Anticipated|University of California, San Diego|||2||f||||t||||||Samples With DNA|"~     Blood, Fat tissue from abdomen and buttock~   "|||2018-06-01 02:09:06.377763|2018-06-01 02:09:06.377763
NCT00677638|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-12-02|2008-05-12|2008-05-14|Estimate|||||||2009-12-02|2009-12-03|Estimate|June 2008||2008-06-30|December 2009|2009-12-31|December 2014|Anticipated|2014-12-31|January 2010|Anticipated|2010-01-31||Interventional|||Transapical Implantation of Ventor Embracer™ Valve in Patients With Severe Aortic Valve Disease|Catheter-Based Transapical Implantation of the Ventor Embracer™ Heart Valve Prosthesis in Patients With Severe Aortic Valve Disease|Unknown status|Active, not recruiting|N/A|30|Anticipated|Ventor Technologies||1|||f||||f||||||||||2018-06-01 02:09:06.455284|2018-06-01 02:09:06.455284
NCT00677625|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2017-11-15|2008-05-09|2008-05-14|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2003||2003-06-30|November 2017|2017-11-30|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15||Observational|||Pediatric Liver Database|Pediatric Liver Disease and Liver Transplant Database|Completed|||401|Actual|Medical College of Wisconsin|||1||f||||f||||||||||2018-06-01 02:09:06.538707|2018-06-01 02:09:06.538707
NCT00677612|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-12-28|2008-05-12|2008-05-14|Estimate|||||||2009-12-28|2009-12-29|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Combination With Tegafur/Uracil/Folinate in Treating Patients With Refractory Colorectal Cancer|Terminated||Phase 1/Phase 2|14|Anticipated|Tokyo University||1||Lack of financial support|f||||t||||||||||2018-06-01 02:09:06.597728|2018-06-01 02:09:06.597728
NCT00677599|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2011-05-12|2008-05-12|2008-05-14|Estimate|||||||2011-05-12|2011-05-13|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|FLAVO||The FLAVO Trial: Dietary Flavonoids and Cardiovascular Disease Risk Reduction in Postmenopausal Women With Type 2 Diabetes|Reducing Cardiovascular Risk With Dietary Flavonoids in Post Menopausal Women With Type 2 Diabetes|Completed||N/A|152|Anticipated|University of East Anglia||2|||f||||f||||||||||2018-06-01 02:09:06.676293|2018-06-01 02:09:06.676293
NCT00677586|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-03-24|2008-05-13|2008-05-14|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2000||2000-01-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||I Phase Surgery Versus Staged Surgery for Synchronous Liver Metastasis of Colorectal Cancer||Completed||Phase 4|120|Actual|Fudan University||2|||f||||t||||||||||2018-06-01 02:09:06.751398|2018-06-01 02:09:06.751398
NCT00677573|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2008-05-09|2008-05-09|2008-05-14|Estimate|||||||2008-05-09|2008-05-14|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|November 2008|Anticipated|2008-11-30|October 2008|Anticipated|2008-10-31||Interventional|||Efficacy of Urinary Follicle-Stimulating Hormone (FSH) Among Poor Responders|Comparison of Urinary Purified Follicle-Stimulating Hormone (FSH) and Rec-FSH Among Poor Responders Undergoing Ovarian Stimulation With GnRH Antagonist|Unknown status|Not yet recruiting|N/A|||German Hospital, Istanbul||1|||f||||f||||||||||2018-06-01 02:09:06.820833|2018-06-01 02:09:06.820833
NCT00677560|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-05-13|2008-05-13|2008-05-14|Estimate|||||||2008-05-13|2008-05-14|Estimate|August 2008||2008-08-31|May 2008|2008-05-31||||||||Observational|||Impulse Oscillometry and Airway Inflammation in Chronic Obstructive Pulmonary Disease|Impulse Oscillometry and Airway Inflammation in Chronic Obstructive Pulmonary Disease|Unknown status|Not yet recruiting||105|Anticipated|Imperial College London|||3||f||||t||||||||||2018-06-01 02:09:06.901703|2018-06-01 02:09:06.901703
NCT00442182|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|September 2006||2006-09-30|February 2007|2007-02-28||||||||Interventional|||The Efficacy and Safety of ITF2357 in AIS|The Effects and Side Effects of ITS2357 in Autoinflammatory Syndromes|Unknown status|Recruiting|Phase 2|20||Radboud University|||||f||||||||||||||2018-06-01 03:24:03.606558|2018-06-01 03:24:03.606558
NCT00677534|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|2012-06-11||2014-04-10|2008-05-13|2008-05-14|Estimate|2014-01-30|2014-03-21|Estimate||||2014-04-10|2014-04-29|Estimate|May 2008||2008-05-31|April 2014|2014-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||A total of 11 subjects were consented to the study. 1 subject was hospitalized before starting any procedures and did not complete any study procedures. 1 subject did not qualify for the study after consenting. Two subjects withdrew after consenting.|Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease|Exploring the Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease|Completed||N/A|7|Actual|University of Kansas Medical Center|This was a pilot study using a small number of patients. Further studies are needed to validate these findings in larger groups of patients.|1|||f||||f||||||||||2018-06-01 02:09:07.044373|2018-06-01 02:09:07.044373
NCT00677521|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2013-08-16|2008-05-12|2008-05-14|Estimate|||||||2013-08-16|2013-08-19|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)|A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)|Terminated||Phase 2|1|Actual|The Hospital for Sick Children||1||poor recruitment and no student currently interested in working on this project.|f||||f||||||||||2018-06-01 02:09:07.226504|2018-06-01 02:09:07.226504
NCT00677508|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2018-03-13|2008-05-09|2008-05-14|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2005|Actual|2005-09-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|March 2012|Actual|2012-03-31||Observational|||Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling|Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling|Active, not recruiting|||800|Anticipated|Medical College of Wisconsin|||3||f||||f||||||||||2018-06-01 02:09:07.35408|2018-06-01 02:09:07.35408
NCT00677495|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2018-01-29|2008-05-12|2008-05-14|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2007|Actual|2007-05-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Gluten-free Diet in Gluten-genetically Predisposed Subjects|Usefulness of Gluten-free Diet in Gluten-genetically Predisposed Subjects Positive to Intestinal-mucosa Anti-transglutaminase Antibodies|Active, not recruiting||N/A|30|Anticipated|IRCCS Burlo Garofolo||1|||f||||f||||||||Undecided||2018-06-01 02:09:07.43064|2018-06-01 02:09:07.43064
NCT00677482|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2015-05-26|2008-05-13|2008-05-14|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Observational|||Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates|Cytomegalovirus (CMV) microRNA Expression in Vivo and Immune Evasion Correlates|Unknown status|Active, not recruiting||30|Anticipated|University of Alberta|||1||f||||f||||||||||2018-06-01 02:09:07.516973|2018-06-01 02:09:07.516973
NCT00677469|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-05-13|2008-05-13|2008-05-14|Estimate|||||||2008-05-13|2008-05-14|Estimate|July 2007||2007-07-31|May 2008|2008-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Low Doses of Cholestyramine in the Treatment of Hyperthyroidism|Low Doses of Cholestyramine in the Treatment of Hyperthyroidism|Completed||N/A|45|Actual|Shiraz University of Medical Sciences||3|||f||||f||||||||||2018-06-01 02:09:07.5873|2018-06-01 02:09:07.5873
NCT00677456|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-05-12|2008-05-12|2008-05-14|Estimate|||||||2008-05-12|2008-05-14|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2013|Anticipated|2013-01-31|February 2010|Anticipated|2010-02-28||Interventional|||Evaluation of Four Reconstructions After Total Gastrectomy|Postoperative Life Quality Evaluation of Four Reconstructions After Total Gastrectomy|Unknown status|Recruiting|Phase 1|80|Anticipated|Tang-Du Hospital||4|||f||||t||||||||||2018-06-01 02:09:07.672499|2018-06-01 02:09:07.672499
NCT00677443|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2013-06-12|2008-05-13|2008-05-14|Estimate|||||||2013-06-12|2013-06-14|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|January 2011|Actual|2011-01-31|September 2009|Actual|2009-09-30||Interventional|||Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer|A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer|Completed||Phase 3|344|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 02:09:07.788972|2018-06-01 02:09:07.788972
NCT00677430|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2017-11-22|2008-05-09|2008-05-14|Estimate|||||||2017-11-22|2017-11-27|Actual|May 2008|Actual|2008-05-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Quantitative Analysis of Outcomes in Breast Reconstruction|Multimodality Anthropometric Analysis for Quantitative Assessment of Outcomes in Breast Reconstructive Surgery|Active, not recruiting|||300|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:09:07.891564|2018-06-01 02:09:07.891564
NCT00677417|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-10-15|2008-05-12|2008-05-14|Estimate|||||||2012-10-15|2012-10-16|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Diagnostic Value of Hyperbilirubinaemia as a Predictive Factor for Appendiceal Perforation in Acute Appendicitis|A Retrospective Study Investigating the Diagnostic Value of Hyperbilirubinaemia as a Predictive Factor for Appendiceal Perforation in Acute Appendicitis|Completed|||538|Actual|Ruhr University of Bochum|||||f||||f||||||||||2018-06-01 02:09:07.985114|2018-06-01 02:09:07.985114
NCT00677404|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2011-07-27|2008-05-13|2008-05-14|Estimate|||||||2011-07-27|2011-07-29|Estimate|January 2008||2008-01-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Autologous Transplantation of Bone Marrow Mononuclear Cell (BM-MNC) With and Without Granulocyte-Colony Stimulation Factor (G-CSF) for Treatment of Chronic Lower Limb Ischemic Patients|Evaluation of Clinical Outcome in Advanced Chronic Lower Limb Ischemia by Stem Cell Transplantation With or Without (Granulocyte-colony Stimulation Factor) G-CSF Injection|Completed||Phase 1/Phase 2|20|Actual|Royan Institute||1|||f||||t||||||||||2018-06-01 02:09:08.061393|2018-06-01 02:09:08.061393
NCT00677391|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-05-13|2008-05-13|2008-05-14|Estimate|||||||2008-05-13|2008-05-14|Estimate|December 2002||2002-12-31|May 2008|2008-05-31||||November 2004|Actual|2004-11-30||Interventional|||Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population|Randomized Trial of Obese Non-Diabetic Malaysians Using Sibutramine: A Randomized Double-Blind Placebo-Controlled Study of Sibutramine in the Management of Obese Subjects in Malaysia|Completed||Phase 3|103|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:09:08.156059|2018-06-01 02:09:08.156059
NCT00677378|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2015-10-21|2008-05-13|2008-05-14|Estimate|||||||2015-10-21|2015-10-22|Estimate|December 2006||2006-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Observational|TRPV1||Transient Receptor Potential Vanilloid One (TRPV1) Receptor Expression in Children With Retrosternal Pain|Capsaicin-sensitive Transient Receptor Potential Vanilloid One (TRPV1) and Tyrosine Kinase (TrkA) Receptor Expression in Children With Retrosternal Pain|Completed|||77|Actual|Medical College of Wisconsin|||2||f||||f||||||Samples Without DNA|"~     We are collecting a single mucosal biopsy during an endoscopy procedure.~   "|||2018-06-01 02:09:08.222847|2018-06-01 02:09:08.222847
NCT00677365|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|2011-09-04||2018-01-17|2008-05-13|2008-05-14|Estimate|2012-05-08|2012-06-12|Estimate||||2018-01-17|2018-01-19|Actual|June 2008||2008-06-30|January 2018|2018-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients|Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients|Completed||Phase 2|151|Actual|Horizon Pharma USA, Inc.||4|||f||||t||||||||||2018-06-01 02:09:08.346557|2018-06-01 02:09:08.346557
NCT00677352|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2011-01-19||2011-05-17|2008-05-13|2008-05-14|Estimate|2011-04-11|2011-05-06|Estimate||||2011-05-17|2011-05-20|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder|A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder|Completed||Phase 4|321|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:09:08.983984|2018-06-01 02:09:08.983984
NCT00677339|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-01-17|2008-05-13|2008-05-14|Estimate|||||||2012-01-17|2012-01-18|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|AVDAPT||L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)|Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia.|Completed||Phase 3|200|Actual|Menzies School of Health Research||4|||f||||t||||||||||2018-06-01 02:09:09.489271|2018-06-01 02:09:09.489271
NCT00677326|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-12-28|2008-05-12|2008-05-14|Estimate|||||||2009-12-28|2009-12-29|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|April 2009|Anticipated|2009-04-30||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Breast Cancer|Terminated||Phase 1/Phase 2|1|Actual|Tokyo University||1||Difficulty in recruiting|f||||t||||||||||2018-06-01 02:09:09.600102|2018-06-01 02:09:09.600102
NCT00677313|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12||2013-10-15|2015-04-08|2008-05-12|2008-05-14|Estimate||||2014-07-18|2014-07-21|Estimate|2015-04-08|2015-04-30|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy|An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy|Completed||N/A|41|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 02:09:09.688442|2018-06-01 02:09:09.688442
NCT00677300|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2014-09-05|2008-05-12|2008-05-14|Estimate|||||||2014-09-05|2014-09-08|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|RADAR||Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients|Evaluation of Safety and Efficacy of Raltegravir/Darunavir Combination in Antiretroviral-Naive Patients|Completed||Phase 4|85|Actual|Dallas VA Medical Center||2|||f||||t||||||||||2018-06-01 02:09:09.764057|2018-06-01 02:09:09.764057
NCT00677287|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-12-28|2008-05-12|2008-05-14|Estimate|||||||2009-12-28|2009-12-29|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Combination With Tegafur/Uracil/Folinate in Treating Patients With Refractory Colorectal Cancer|Terminated||Phase 1/Phase 2|14|Anticipated|Tokyo University||1||Lack of financial support|f||||t||||||||||2018-06-01 02:09:09.876294|2018-06-01 02:09:09.876294
NCT00677274|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2009-02-11|2008-05-12|2008-05-14|Estimate|||||||2009-02-11|2009-02-12|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|EACDRCD||Epidural Analgesia in Different Cervix Diameter and the Rate of Cesarean Delivery|Epidural Labor Analgesia in Different Cervical Dilation Diameter and the Risk of Cesarean Delivery|Completed||N/A|780|Actual|Nanjing Medical University||8|||f||||t||||||||||2018-06-01 02:09:10.004407|2018-06-01 02:09:10.004407
NCT00677261|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2014-11-19|2008-05-13|2008-05-14|Estimate|||||||2014-11-19|2014-11-21|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Comparing Postoperative Functional Recovery and Analgesic Efficacy of a Single Shot Sciatic Nerve Block Versus Posterior Capsule/Fat Pad Infiltration of Local Anesthetic for Total Knee Arthroplasty|A Prospective, Unicenter, Randomized, Placebo Controlled, Clinical Interventional Trial, Comparing the Postoperative Functional Recovery as Well as Analgesic Efficacy of a Single Shot Sciatic Nerve Block Versus Posterior Capsule/Fat Pad Infiltration of Local Anesthetic for Total Knee Arthroplasty.|Completed||N/A|104|Actual|Sunnybrook Health Sciences Centre||3|||f||||t||||||||||2018-06-01 02:09:10.112823|2018-06-01 02:09:10.112823
NCT00677248|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-11-27|2008-05-13|2008-05-14|Estimate|||||||2008-11-27|2008-12-01|Estimate|April 2008||2008-04-30|May 2008|2008-05-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe|A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia|Completed||Phase 2|120|Anticipated|Karo Bio AB||4|||f||||t||||||||||2018-06-01 02:09:10.206599|2018-06-01 02:09:10.206599
NCT00677235|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|2014-01-20||2017-01-30|2008-05-13|2008-05-14|Estimate|2014-08-06|2014-08-07|Estimate||||2017-01-30|2017-03-10|Actual|December 2008||2008-12-31|January 2017|2017-01-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|RENOVA|Subjects with hemodynamically significant stenosis fifty percent, clinical evidence of graft dysfunction (without thrombotic occlusion) at the synthetic AV access graft anastomosis, and who were selected from the Investigator’s general subject population were eligible for participation in this study.|Post-Approval Study for the FLAIR Endovascular Stent Graft|A Prospective, Randomized, Concurrently-Controlled Post-Approval Study of the FLAIR Endovascular Stent Graft|Completed||N/A|270|Actual|C. R. Bard||2|||f||||f||||||||||2018-06-01 02:09:10.31807|2018-06-01 02:09:10.31807
NCT00677222|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-05-10|2008-05-12|2008-05-14|Estimate|||||||2012-05-10|2012-05-11|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|February 2012|Actual|2012-02-29|March 2010|Actual|2010-03-31||Interventional|||Safety Study of AMI MultiStem® to Treat Heart Attacks|A Phase I, Multicenter, Dose-Escalation Trial Evaluating the Safety of Allogeneic AMI MultiStem® in Patients With Acute Myocardial Infarction|Completed||Phase 1|25|Actual|Athersys, Inc||2|||f||||t||||||||||2018-06-01 02:09:10.904707|2018-06-01 02:09:10.904707
NCT00677209|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2010-12-28|2008-05-12|2008-05-14|Estimate|||||||2010-12-28|2010-12-29|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|December 2010|Actual|2010-12-31|August 2008|Actual|2008-08-31||Interventional|FIAVS||The Effect of Autologous Autovaccine in Patients With Allergy on House-dust-mite|Frankfurt Investigator-initiated Autovaccine-study|Completed||Phase 1|8|Actual|Johann Wolfgang Goethe University Hospital||1|||f||||t||||||||||2018-06-01 02:09:11.003088|2018-06-01 02:09:11.003088
NCT00677196|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2010-09-23|2008-05-13|2008-05-14|Estimate|||||||2010-09-23|2010-09-27|Estimate|February 2008||2008-02-29|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The StoneBreakerTM Trial|The Canadian StoneBreakerTM Trial: A Randomized, Multicentre Trial Comparing The LMA StoneBreakerTM and the Swiss LithoClastR During Percutaneous Nephrolithotripsy.|Completed||Phase 3|40|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 02:09:11.07205|2018-06-01 02:09:11.07205
NCT00677183|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2015-08-21|2008-05-09|2008-05-14|Estimate|||||||2015-08-21|2015-08-25|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|NASH||Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children|Development of a Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children|Withdrawn|||0|Actual|Medical College of Wisconsin|||2|PI did not receive funding for this PI-initiated study. PI subsequently left the institution.|f||||f||||||Samples With DNA|"~     10mL of blood will be retained from each participant and their parents. 5mL of this blood~     will undergo DNA extraction and genotyping for several known NASH related genes. The other~     5mL of blood will be saved as serum for future analysis.~   "|||2018-06-01 02:09:11.143866|2018-06-01 02:09:11.143866
NCT00677170|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2013-07-15|2008-05-13|2008-05-14|Estimate|||||||2013-07-15|2013-07-16|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|||Study of MLN4924 in Adult Patients With Nonhematologic Malignancies|An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies|Completed||Phase 1|62|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 02:09:11.22129|2018-06-01 02:09:11.22129
NCT00677157|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2018-03-27|2008-05-09|2008-05-13|Estimate|||||||2018-03-27|2018-03-29|Actual|May 8, 2008||2008-05-08|November 15, 2017|2017-11-15||||||||Observational|||Evaluation and Diagnosis of People With Pain and Fatigue Syndromes|Evaluation and Diagnosis of Potential Research Subjects With Pain and Fatigue Syndromes|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:09:11.28854|2018-06-01 02:09:11.28854
NCT00677144|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2012-10-04|2008-05-09|2008-05-13|Estimate|||||||2012-10-04|2012-10-05|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer|A Randomized Phase II Study of Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Advanced or Recurrent Colorectal Cancer|Completed||Phase 2|88|Actual|Hallym University Medical Center||2|||f||||f||||||||||2018-06-01 02:09:11.359053|2018-06-01 02:09:11.359053
NCT00677131|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2009-12-02|2008-05-12|2008-05-13|Estimate|||||||2009-12-02|2009-12-04|Estimate|April 2008||2008-04-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of the Evaluation of Patient Education Efficacy in Pharmacy of National Taiwan University Hospital|Study of the Evaluation of Patient Education Efficacy: Reconstitution, Storage, and Administration of Oral Antibiotic Suspension From Powder Dosage Form at Pharmacy of National Taiwan University Hospital|Completed||N/A|500|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-06-01 02:09:11.435503|2018-06-01 02:09:11.435503
NCT00677118|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2013-07-11|2008-05-09|2008-05-13|Estimate|||||||2013-07-11|2013-07-12|Estimate|June 2006||2006-06-30|March 2010|2010-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting|Phase 3|506|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:09:11.525647|2018-06-01 02:09:11.525647
NCT00677105|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2012-09-14|2008-05-12|2008-05-13|Estimate|||||||2012-09-14|2012-09-17|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.|An Open-Label Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-26481585 in Subjects With Advanced Stage and/or Refractory Solid Malignancies and Lymphomas|Completed||Phase 1|92|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||t||||||||||2018-06-01 02:09:11.60434|2018-06-01 02:09:11.60434
NCT00677092|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2017-04-10||2017-04-10|2008-05-12|2008-05-13|Estimate|2017-04-10|2017-05-19|Actual||||2017-04-10|2017-05-19|Actual|December 2007|Actual|2007-12-31|April 2017|2017-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|GENESYF|All enrolled participants with available Baseline data.|Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis|An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis|Completed||Phase 2|12|Actual|Massachusetts General Hospital|PI left institution in 2009; Data collected cannot be associated with specific participants and analyzed for secondary outcome measure or adverse event data entry.|1|||f||||f||||||||No||2018-06-01 02:09:11.673954|2018-06-01 02:09:11.673954
NCT00677079|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09||2012-12-21|2013-09-23|2008-05-12|2008-05-13|Estimate||||2012-12-21|2012-12-28|Estimate|2013-09-23|2013-10-01|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase 2, Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed||Phase 2|12|Actual|Sanofi||1|||t||||f||||||||||2018-06-01 02:09:11.838181|2018-06-01 02:09:11.838181
NCT00677066|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-05-12|2008-05-12|2008-05-13|Estimate|||||||2008-05-12|2008-05-13|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety Study of Home Oxygen Therapy for Children With Acute Bronchiolitis|A Randomised Controlled Trial: Home Oxygen Therapy Versus Hospital Oxygen Therapy for Children With Acute Bronchiolitis|Completed||Phase 3|44|Actual|Princess Margaret Hospital for Children||2|||f||||t||||||||||2018-06-01 02:09:11.947385|2018-06-01 02:09:11.947385
NCT00677053|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09||2016-03-13|2016-03-13|2008-05-09|2008-05-13|Estimate||||2016-03-13|2016-04-13|Estimate|2016-03-13|2016-04-13|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes|A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes|Completed||Phase 2|2753|Actual|Takeda||9|||f||||t||||||||||2018-06-01 02:09:12.03387|2018-06-01 02:09:12.03387
NCT00677040|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2011-09-19|2008-05-09|2008-05-13|Estimate|||||||2011-09-19|2011-09-20|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Observational|||Normal Tissue Oxygenation Following Radiotherapy|Normal Tissue Oxygenation Following Radiotherapy|Completed|||20|Actual|Essentia Health|||||f||||f||||||||||2018-06-01 02:09:12.228174|2018-06-01 02:09:12.228174
NCT00677027|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2008-05-12|2008-05-12|2008-05-13|Estimate|||||||2008-05-12|2008-05-13|Estimate|February 2008||2008-02-29|May 2008|2008-05-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Dose Escalation Safety Study of MM-10-001 in Healthy Subjects|Dose Escalation Safety Study of MM-10-001|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|GlycaNova Norge AS||2|||f||||t||||||||||2018-06-01 02:09:13.257145|2018-06-01 02:09:13.257145
NCT00677014|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2012-07-27||2013-04-17|2008-05-09|2008-05-13|Estimate|2012-07-27|2012-08-30|Estimate||||2013-04-17|2013-04-24|Estimate|May 2008||2008-05-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SMART-AV||Comparison of AV Optimization Methods Used in Cardiac Resynchronization Therapy (CRT)|SMARTDELAY Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy|Completed||Phase 4|1060|Actual|Boston Scientific Corporation||3|||f||||f||||||||||2018-06-01 02:09:13.33695|2018-06-01 02:09:13.33695
NCT00677001|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2010-04-26|2008-05-12|2008-05-13|Estimate|||||||2010-04-26|2010-04-27|Estimate|September 2005||2005-09-30|April 2010|2010-04-30|October 2006|Actual|2006-10-31|||||Interventional|||A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies.|A Phase I Study to Evaluate the Safety and Pharmacokinetics of R306465 in Subjects With Advanced Solid Malignancies|Completed||Phase 1|15|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 02:09:13.616769|2018-06-01 02:09:13.616769
NCT00676988|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2012-06-13|2008-05-12|2008-05-13|Estimate|||||||2012-06-13|2012-06-14|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|X-Sectional||Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients|A Cross Sectional Study To Determine The Relationship Between Serum Infliximab Concentration And Efficacy In Patients With Luminal Crohn's Disease|Completed|||327|Actual|University of Western Ontario, Canada|||1||f||||t||||||Samples Without DNA|"~     Serum infliximab concentrations and CRP levels.~   "|||2018-06-01 02:09:13.681654|2018-06-01 02:09:13.681654
NCT00676975|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2017-04-24|2008-05-12|2008-05-13|Estimate|||||||2017-04-24|2017-04-25|Actual|May 26, 2008|Actual|2008-05-26|April 2017|2017-04-30|August 30, 2011|Actual|2011-08-30|December 30, 2010|Actual|2010-12-30||Interventional|TCM-IBS||The Efficacy of Tradition Chinese Medicine in Patients With Irritable Bowel Syndrome|Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome(TCM- IBS)|Completed||Phase 2|104|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-06-01 02:09:13.768541|2018-06-01 02:09:13.768541
NCT00676962|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2015-09-21|2008-05-09|2008-05-13|Estimate|||||||2015-09-21|2015-09-23|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Facilitating Implementation of Cognitive Behavioral Therapy in Primary Care and Community Clinics|Facilitating Implementation of Cognitive Behavioral Therapy in Primary Care and Community Clinics|Completed||N/A|23|Actual|South Central VA Mental Illness Research, Education & Clinical Center||1|||f||||f||||||||||2018-06-01 02:09:13.844516|2018-06-01 02:09:13.844516
NCT00676949|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2011-06-22|2008-05-09|2008-05-13|Estimate|||||||2011-06-22|2011-06-23|Estimate|November 2007||2007-11-30|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|peptidevac||Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors|Phase I Study of Tumor Specific Potentiated Vaccine Therapy Using Cyclophosphamide Combined Epitope Peptide Cocktail for Progressive/Relapsed Solid Tumors(GI/Lung/Cervical Cancer)|Completed||Phase 1|18|Actual|Kyushu University||1|||f||||t||||||||||2018-06-01 02:09:13.996628|2018-06-01 02:09:13.996628
NCT00676936|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2016-07-27|2008-05-12|2008-05-13|Estimate|||||||2016-07-27|2016-07-28|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Corticosteroids for Cancer Pain|Corticosteroids for Cancer Pain|Completed||Phase 3|50|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 02:09:14.096432|2018-06-01 02:09:14.096432
NCT00676923|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2012-11-12|2008-05-09|2008-05-13|Estimate|||||||2012-11-12|2012-11-14|Estimate|March 2008||2008-03-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|LABS-3||Improving Diabetes After Bariatric Surgery|LABS-3 Diabetes: Mechanisms for Improvement of Type 2 Diabetes Following Bariatric Surgery|Completed|||63|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     serum, plasma~   "|||2018-06-01 02:09:14.198947|2018-06-01 02:09:14.198947
NCT00676910|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2010-03-24|2008-05-12|2008-05-13|Estimate|||||||2010-03-24|2010-03-26|Estimate|November 2006||2006-11-30|March 2010|2010-03-31|February 2010|Actual|2010-02-28|||||Interventional|||A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.|A Phase I Study to Determine the Safety, Pharmacology, and Pharmacodynamics of JNJ26854165 in Subjects With Advanced Stage and/or Refractory Solid Tumors|Completed||Phase 1|71|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 02:09:14.267401|2018-06-01 02:09:14.267401
NCT00676897|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2017-03-10||2017-05-15|2008-05-09|2008-05-13|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|February 2008||2008-02-29|May 2017|2017-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Statin Therapy in the Treatment of Sepsis|Study of Statin Therapy in the Treatment of Sepsis|Completed||Phase 2/Phase 3|18|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-06-01 02:09:14.359471|2018-06-01 02:09:14.359471
NCT00676884|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2008-05-09|2008-05-09|2008-05-13|Estimate|||||||2008-05-09|2008-05-13|Estimate|February 2006||2006-02-28|May 2008|2008-05-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema|A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema|Completed||Phase 2|25|Actual|Aerovance, Inc.||2|||f||||f||||||||||2018-06-01 02:09:14.714922|2018-06-01 02:09:14.714922
NCT00676871|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-09-04|2008-05-08|2008-05-13|Estimate|||||||2008-09-04|2008-09-05|Estimate|June 2008||2008-06-30|September 2008|2008-09-30|June 2011|Anticipated|2011-06-30|March 2010|Anticipated|2010-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)|A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 In Adults With B-Cell Chronic Lymphocytic Leukemia(CLL)Who Have Residual Disease Following Previous Therapy for CLL|Withdrawn||Phase 1/Phase 2|30|Anticipated|MedImmune LLC||7||Replacing this trial with a new trial.|f||||f||||||||||2018-06-01 02:09:14.800898|2018-06-01 02:09:14.800898
NCT00676858|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2017-03-24|2008-05-12|2008-05-13|Estimate|||||||2017-03-24|2017-03-28|Actual|July 2008||2008-07-31|March 2017|2017-03-31|July 5, 2011|Actual|2011-07-05|July 5, 2011|Actual|2011-07-05||Observational|||Gas Embolism With Use of Argon Plasma Coagulation|Gas Embolism With Use of Argon Plasma Coagulation|Completed|||42|Actual|Beth Israel Deaconess Medical Center|||||f||||t||||||||No|IPD was not shared|2018-06-01 02:09:14.878933|2018-06-01 02:09:14.878933
NCT00676845|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2012-04-26|2008-05-12|2008-05-13|Estimate|||||||2012-04-26|2012-04-27|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ArtStiff||Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection|Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome|Completed||Phase 3|133|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-06-01 02:09:14.93582|2018-06-01 02:09:14.93582
NCT00676832|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09||2010-09-16|2010-09-27|2008-05-12|2008-05-13|Estimate||||2010-09-27|2010-09-29|Estimate|2010-09-27|2010-09-29|Estimate|May 2008||2008-05-31|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis|Completed||Phase 2|190|Actual|Prometheus Laboratories||5|||f||||f||||||||||2018-06-01 02:09:15.042796|2018-06-01 02:09:15.042796
NCT00676819|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2017-03-15|2008-05-09|2008-05-13|Estimate|||||||2017-03-15|2017-03-16|Actual|January 10, 2002|Actual|2002-01-10|March 2017|2017-03-31|July 19, 2002|Actual|2002-07-19|July 19, 2002|Actual|2002-07-19||Interventional|||Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes|Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Soluble Insulin in Geriatric Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|19|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:09:15.353035|2018-06-01 02:09:15.353035
NCT00676806|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2016-05-02||2017-05-01|2008-05-09|2008-05-13|Estimate|2016-06-10|2016-07-22|Estimate||||2017-05-01|2017-06-01|Actual|July 2005||2005-07-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||A Phase II Study of Umbilical Cord Blood Transplantation|A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning|Terminated||Phase 2|7|Actual|Tufts Medical Center|Early termination leading to small numbers of subjects analyzed.|2||Slow accrual|f||||t||||||||No||2018-06-01 02:09:15.451976|2018-06-01 02:09:15.451976
NCT00676793|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2011-09-02||2017-08-23|2008-05-12|2008-05-13|Estimate|2012-09-25|2012-10-26|Estimate||||2017-08-23|2017-09-21|Actual|May 2004||2004-05-31|August 2017|2017-08-31|July 2013|Actual|2013-07-31|December 2009|Actual|2009-12-31||Interventional|||A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression|Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression|Completed||Phase 2|32|Actual|Louisiana State University Health Sciences Center Shreveport||1|||f||||t||||||||||2018-06-01 02:09:15.785361|2018-06-01 02:09:15.785361
NCT00676780|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2011-08-29||2012-06-29|2008-05-09|2008-05-13|Estimate|2012-06-29|2012-08-08|Estimate||||2012-06-29|2012-08-08|Estimate|May 2004||2004-05-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Green Tea Extract and Prostate Cancer|Green Tea Extract and Prostate Cancer|Completed||Phase 2|33|Actual|Louisiana State University Health Sciences Center Shreveport|Patient compliance was an issue.|1|||f||||t||||||||||2018-06-01 02:09:16.015218|2018-06-01 02:09:16.015218
NCT00676767|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-05-22|2008-05-12|2008-05-13|Estimate|||||||2008-05-22|2008-05-23|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Resistant Starch on Glycemic Response in Older Adults|Resistant Starch Type 4 on the Glycemic Response in Older Adults|Completed||N/A|9|Actual|Kansas State University||3|||f||||f||||||||||2018-06-01 02:09:16.217481|2018-06-01 02:09:16.217481
NCT00676754|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2013-03-27|2008-05-12|2008-05-13|Estimate|||||||2013-03-27|2013-03-29|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|Estudio Epi||Epidemiology of MDR-TB in Peru|Epidemiology of Multidrug-Resistant Tuberculosis in Peru|Unknown status|Active, not recruiting||18544|Actual|Harvard University Faculty of Medicine|||||f||||f||||||Samples With DNA|"~     whole blood, sputum~   "|||2018-06-01 02:09:16.294283|2018-06-01 02:09:16.294283
NCT00676741|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2016-10-27|2008-05-09|2008-05-13|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|COMMIT||Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin|Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart) or Levemir® (Insulin Detemir) - for Treatment of Diabetes Mellitus|Completed|||3809|Actual|Novo Nordisk A/S|||3||f||||f||||||||||2018-06-01 02:09:16.362141|2018-06-01 02:09:16.362141
NCT00676728|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2012-09-13|2008-05-12|2008-05-13|Estimate|||||||2012-09-13|2012-09-14|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome|A Phase 1 Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Subjects With Advanced or Refractory Leukemia or Myelodysplastic Syndrome|Terminated||Phase 1|10|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1||Sponsor Decision|f||||f||||||||||2018-06-01 02:09:16.460589|2018-06-01 02:09:16.460589
NCT00676715|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2017-03-31|2013-03-25|2018-03-20|2008-05-09|2008-05-13|Estimate|2017-03-31|2017-05-11|Actual|2013-03-25|2013-04-01|Estimate|2018-03-20|2018-04-18|Actual|July 31, 2008|Actual|2008-07-31|March 2018|2018-03-31|December 10, 2020|Anticipated|2020-12-10|March 9, 2012|Actual|2012-03-09||Interventional||The safety population included all participants who received any study drug and underwent at least one assessment of safety.|A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis|Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS|Active, not recruiting||Phase 2|220|Actual|Genentech, Inc.||4|||f||||||||||||||2018-06-01 02:09:16.60469|2018-06-01 02:09:16.60469
NCT00676702|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2011-05-18|2008-05-12|2008-05-13|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)|A Single-Dose, Open-Label, Randomized, Crossover Study to Evaluate Intraduodenal Enzyme Delivery of PANCREASE MT in Subjects With Severe Exocrine Pancreatic Insufficiency|Completed||Phase 1|13|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 02:09:17.664174|2018-06-01 02:09:17.664174
NCT00676520|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2012-06-07||2012-10-10|2008-05-12|2008-05-13|Estimate|2012-10-10|2012-11-20|Estimate||||2012-10-10|2012-11-20|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|XVU-Phase 1||XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study|Completed|||8053|Actual|Abbott Vascular|||1||f||||t||||||||||2018-06-01 02:09:20.814761|2018-06-01 02:09:20.814761
NCT00676689|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2016-05-04||2017-09-07|2008-05-12|2008-05-13|Estimate|2016-07-21|2016-09-01|Estimate||||2017-09-07|2017-10-05|Actual|April 8, 2008|Actual|2008-04-08|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2015|Actual|2015-11-30||Interventional||Safety Population (SP): All enrolled subjects for whom the procedure has begun, regardless of whether the valve was successfully implanted. The definition of “procedure has begun” is “the time of the creation of vascular access - incision or puncture.”|COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV|Implantation of the SAPIEN Transcatheter Heart Valve (THV) in the Pulmonic Position|Active, not recruiting||N/A|81|Actual|Edwards Lifesciences||1|||f||||t|f|t|f|f||||No||2018-06-01 02:09:17.777695|2018-06-01 02:09:17.777695
NCT00676676|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2012-05-10||2012-11-01|2008-05-08|2008-05-13|Estimate|2012-11-01|2012-11-30|Estimate||||2012-11-01|2012-11-30|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effects of Testosterone in Women With Depression|Effects of Testosterone in Women With Depression: A Pilot Study|Completed||N/A|9|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:09:18.064347|2018-06-01 02:09:18.064347
NCT00676663|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2014-03-19|2008-05-09|2008-05-13|Estimate|||||||2014-03-19|2014-03-20|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|December 2010|Actual|2010-12-31||Interventional|ENCORE301||Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer|A Ph 2, Randomized, Double-Blind, Multicenter Study of Exemestane +/- Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer, Progressing on Treatment With a Non-Steroidal AI|Completed||Phase 2|130|Actual|Syndax Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:09:18.293133|2018-06-01 02:09:18.293133
NCT00676650|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2012-12-20||2013-02-05|2008-05-12|2008-05-13|Estimate|2013-02-05|2013-03-08|Estimate||||2013-02-05|2013-03-08|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SUN 1120||Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy|A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen|Terminated||Phase 3|873|Actual|Pfizer|A complete analysis was not performed due to the sponsors early termination of the clinical trial.|2||"Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or~   unexpected safety issues were identified."|f||||t||||||||||2018-06-01 02:09:18.464263|2018-06-01 02:09:18.464263
NCT00676637|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-05-29|2008-05-12|2008-05-13|Estimate|||||||2012-05-29|2012-05-31|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|GAS||Glaucoma Adherence Study|A Pilot Study of Adherence Assessment With the Travalert™ Dosing Aid in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma Who Are Treated With the Travoprost/Timolol Maleate Fixed Combination Every Evening|Completed|||55|Actual|Alcon Research|||1||f||||f||||||||||2018-06-01 02:09:19.836471|2018-06-01 02:09:19.836471
NCT00676624|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2014-05-14|2008-05-12|2008-05-13|Estimate|||||||2014-05-14|2014-05-15|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Infectious Causes of Uveitis|Infectious Causes of Uveitis, With Special Focus on Infection With Leptospira|Completed|||100|Anticipated|Statens Serum Institut|||2||f||||t||||||Samples With DNA|"~     Corpus vitreum (vitreus body) Aqua from the anterior champer Whole blood in dry container~     Whole blood in container containing EDTA Whole blood in QuantiFERON test KIT for tuberculosis~     Urine~   "|||2018-06-01 02:09:19.931914|2018-06-01 02:09:19.931914
NCT00676611|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2017-06-16|2008-05-12|2008-05-13|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2008||2008-05-31|June 2017|2017-06-30|February 28, 2014|Actual|2014-02-28|February 28, 2014|Actual|2014-02-28||Observational|||Acetabular Fractures of Both Columns|Both Column Acetabular Fractures With Associated Posterior Deformity Patterns: Implications for Surgical Treatment and Prognosis|Completed|||52|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-06-01 02:09:19.999177|2018-06-01 02:09:19.999177
NCT00676598|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-01-04|2008-05-12|2008-05-13|Estimate|||||||2012-01-04|2012-01-06|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Observational|||A Prospective Analysis of the Effect of Therapeutic Hypothermia After Cardiac Arrest|A Prospective Analysis of the Effect of Therapeutic Hypothermia After Cardiac Arrest|Completed|||70|Actual|Advocate Hospital System|||||f||||f||||||||||2018-06-01 02:09:20.054709|2018-06-01 02:09:20.054709
NCT00676585|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2017-03-28||2017-05-15|2008-05-09|2008-05-13|Estimate|2017-05-15|2017-05-17|Actual||||2017-05-15|2017-05-17|Actual|October 2007||2007-10-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest|Corticosteroids Therapy in Refractory Shock Following Cardiac Arrest|Completed||Phase 1/Phase 2|50|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-06-01 02:09:20.123083|2018-06-01 02:09:20.123083
NCT00676572|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2016-02-23|2008-05-12|2008-05-13|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|January 2013|Actual|2013-01-31||Observational|||p38 Mitogen−Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma|p38 MAPK Activation as the Basis for Corticosteroid Insensitivity in Severe Asthma|Unknown status|Active, not recruiting||120|Anticipated|Imperial College London|||2||f||||f||||||Samples With DNA|"~     sputum cell pellets and supernatant; BAL supernatant; endobronchial biopsies; smooth muscle~     cell culture from biopsies~   "|||2018-06-01 02:09:20.328954|2018-06-01 02:09:20.328954
NCT00676559|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2016-08-25|2008-05-08|2008-05-13|Estimate|||||||2016-08-25|2016-08-26|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|April 2010|Anticipated|2010-04-30|April 2009|Anticipated|2009-04-30||Interventional|CAPTURE||Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study|Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study|Withdrawn||Phase 1|0|Actual|Johns Hopkins University||3||Unrelated serious adverse events involving one of the proposed medications|f||||t||||||||||2018-06-01 02:09:20.392859|2018-06-01 02:09:20.392859
NCT00676546|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2008-05-09|2008-05-09|2008-05-13|Estimate|||||||2008-05-09|2008-05-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:09:20.567507|2018-06-01 02:09:20.567507
NCT00676533|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2013-10-10|2008-05-12|2008-05-13|Estimate|||||||2013-10-10|2013-10-14|Estimate|June 2003||2003-06-30|October 2013|2013-10-31|January 2004|Actual|2004-01-31|||||Interventional|||Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections|Cipro® XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections|Completed||Phase 4|276|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:09:20.618535|2018-06-01 02:09:20.618535
NCT00676507|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2015-05-06|2008-05-12|2008-05-13|Estimate|||||||2015-05-06|2015-05-08|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|STOP||Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy|Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Maintenance Therapy for Stages III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based Combination Chemotherapy|Completed||Phase 3|532|Actual|NovaRx Corporation||2|||f||||t||||||||||2018-06-01 02:09:21.751797|2018-06-01 02:09:21.751797
NCT00676494|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2009-02-23||2009-05-18|2008-05-12|2008-05-13|Estimate|2009-05-18|2009-07-09|Estimate||||2009-05-18|2009-07-09|Estimate|February 2006||2006-02-28|May 2009|2009-05-31|February 2008|Actual|2008-02-29|July 2007|Actual|2007-07-31||Interventional|||The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions|A Prospective, Single Arm, Multi-Center Study to Assess Performance of the Pathway PV Atherectomy System During Percutaneous Peripheral Vascular (PV) Interventions|Completed||N/A|172|Actual|Pathway Medical Technologies Inc.|||||f||||t||||||||||2018-06-01 02:09:22.019629|2018-06-01 02:09:22.019629
NCT00676481|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2015-03-05|2008-05-09|2008-05-13|Estimate|||||||2015-03-05|2015-03-09|Estimate|July 2004||2004-07-31|May 2008|2008-05-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Rapid HIV Testing for Emergency Department Patients|Rapid HIV Testing for Emergency Department Patients|Completed||N/A|570|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-06-01 02:09:22.156558|2018-06-01 02:09:22.156558
NCT00676468|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2009-10-08|2008-05-12|2008-05-13|Estimate|||||||2009-10-08|2009-10-09|Estimate|September 2008||2008-09-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Comparative Effects of Fish Oil Supplementation and a Montelukast on EIB and Airway Inflammation in Asthma|Comparative Effects of Fish Oil Supplementation and a Leukotriene Receptor Antagonist on EIB and Airway Inflammation in Asthma|Completed||Phase 1|20|Actual|Indiana University||3|||f||||f||||||||||2018-06-01 02:09:22.222591|2018-06-01 02:09:22.222591
NCT00676455|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2009-08-26||2013-05-09|2008-05-12|2008-05-13|Estimate|2011-06-30|2011-07-29|Estimate||||2013-05-09|2013-05-10|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions|Computer Assisted Volumetric Analysis of CT-Identified Metastatic Pulmonary Or Hepatic Lesions|Terminated|||14|Actual|Lahey Clinic||||Low participant enrollment, Insufficient findings for data analysis|f||||f||||||||||2018-06-01 02:09:22.304497|2018-06-01 02:09:22.304497
NCT00676442|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-09-04|2008-05-12|2008-05-13|Estimate|||||||2008-09-04|2008-09-05|Estimate|May 2008||2008-05-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Evaluating the Effect of Food on the Bioavailability of PN400 Components|An Open-Label, Randomized, Four-Way Crossover Study to Evaluate the Effect of Food on the Bioavailability of Naproxen and Esomeprazole From a PN 400 Tablet in Healthy Subjects|Completed||Phase 1|24|Actual|POZEN||4|||f||||f||||||||||2018-06-01 02:09:22.417539|2018-06-01 02:09:22.417539
NCT00676429|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2008-11-17|2008-05-09|2008-05-13|Estimate|||||||2008-11-17|2008-11-18|Estimate|July 2006||2006-07-31|November 2008|2008-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders|Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial|Completed||Phase 2|51|Actual|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 02:09:22.475296|2018-06-01 02:09:22.475296
NCT00676416|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2009-03-30|2008-05-12|2008-05-13|Estimate|||||||2009-03-30|2009-03-31|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|PAMAP||Influence of Propofol on Alveolar Macrophage in Asthmatic Patients|Influence of Propofol on Alveolar Macrophage Immunity in Asthmatic Patients Undergoing General Anesthesia|Completed|||80|Anticipated|Nanjing Medical University|||2||f||||t||||||||||2018-06-01 02:09:22.604716|2018-06-01 02:09:22.604716
NCT00676403|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2010-01-08||2010-06-28|2008-05-12|2008-05-13|Estimate|2010-01-08|2010-02-04|Estimate||||2010-06-28|2010-07-07|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients|Randomized, Double-Blind, 6-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome|Completed||Phase 2|137|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 02:09:22.851101|2018-06-01 02:09:22.851101
NCT00676390|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2013-10-25|2008-05-09|2008-05-13|Estimate|||||||2013-10-25|2013-10-28|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|H2OBis||Estimated Physical Activity of Congestive Heart Failure Patients by a Physical Activity Questionnaire|Estimated Physical Activity of Congestive Heart Failure Patients by a Physical Activity Questionnaire : Concordance Study.|Completed||N/A|25|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 02:09:27.783215|2018-06-01 02:09:27.783215
NCT00676377|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-05-12|2008-05-12|2008-05-13|Estimate|||||||2008-05-12|2008-05-13|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||A New Approach of Neostigmine in Unavoidable Post Operative Ileus|A New Approach of Neostigmine in Unavoidable Post Operative Ileus After Surgery|Completed||Phase 4|3|Actual|Baqiyatallah Medical Sciences University||2|||f||||t||||||||||2018-06-01 02:09:27.867388|2018-06-01 02:09:27.867388
NCT00676364|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2012-05-01||2012-08-24|2008-05-09|2008-05-13|Estimate|2012-08-24|2012-09-25|Estimate||||2012-08-24|2012-09-25|Estimate|March 2003||2003-03-31|August 2012|2012-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Randomized Control Trial of a Topical Anesthetic to Evaluate Pain and Anxiety During Venipuncture|A Randomized, Placebo-Controlled Trial to Evaluate Pain and Anxiety During Venipuncture in Pediatric Patients With or Without Pre-treatment by a Topical Anesthetic|Completed||Phase 4|114|Actual|Lehigh Valley Hospital|Convenience sample at one hospital site during dayshift hours Monday through Friday. Variable ages may increase the variance among pain measurements. Analyzed IV cannulation and lab draw together. We did not conduct interrater reliability testing.|2|||f||||t||||||||||2018-06-01 02:09:27.972066|2018-06-01 02:09:27.972066
NCT00676351|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2008-05-12|2008-05-12|2008-05-13|Estimate|||||||2008-05-12|2008-05-13|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Follow up of Ventilatory Function in Infant After Bronchiolitis During the First Year of Life|Follow up of Ventilatory Function in Infant After One (or More) Bronchiolitis During the First Year of Life. Course Towards Asthma|Completed||N/A|29|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 02:09:28.229263|2018-06-01 02:09:28.229263
NCT00674830|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2013-08-14|2008-05-07|2008-05-08|Estimate|||||||2013-08-14|2013-08-15|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Self-help Treatment for Insomnia in Breast Cancer Patients|Self-help Treatment for Insomnia in Breast Cancer Patients|Completed||N/A|240|Actual|CHU de Quebec-Universite Laval||3|||f||||f||||||||||2018-06-01 02:09:50.129463|2018-06-01 02:09:50.129463
NCT00676338|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|2012-02-14|2011-06-15|2015-03-20|2008-05-09|2008-05-13|Estimate|2012-10-24|2012-11-26|Estimate|2011-06-17|2011-06-27|Estimate|2015-03-20|2015-04-09|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)|Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes|Completed||Phase 3|820|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:09:28.344266|2018-06-01 02:09:28.344266
NCT00676325|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2008-05-12|2008-05-12|2008-05-13|Estimate|||||||2008-05-12|2008-05-13|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|Nazcatc™||Surgical Treatment To Greater Anterior Vaginal Prolapse|A Randomized Controlled Trial Study, To Compare Colporrhaphy Versus NAZCA TC™ ,Macroporous Polypropylene Mesh, In Surgical Treatment To Greater Anterior Vaginal Prolapse .|Unknown status|Enrolling by invitation|Phase 4|70|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 02:09:29.56179|2018-06-01 02:09:29.56179
NCT00676312|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-12-10|2008-05-12|2008-05-13|Estimate|||||||2008-12-10|2008-12-11|Estimate|May 2008||2008-05-31|December 2008|2008-12-31||||August 2008|Actual|2008-08-31||Interventional|||Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects|A Partially-Blinded, Randomized, Placebo and Active Controlled, Ascending Single-Dose Crossover Phase I Study to Explore the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of PTH134 Formulated With Different Concentrations of 5-CNAC in Healthy Postmenopausal Women|Completed||Phase 1|32|Anticipated|Novartis||1|||f||||||||||||||2018-06-01 02:09:29.650353|2018-06-01 02:09:29.650353
NCT00676299|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2010-04-22|2008-05-12|2008-05-13|Estimate|||||||2010-04-22|2010-04-26|Estimate|August 2006||2006-08-31|April 2010|2010-04-30|July 2008|Actual|2008-07-31|||||Interventional|||A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.|An Open-label, Phase I Study to Determine the Safety and Pharmacokinetics of JNJ-26483327, a Multi-targeted Kinase Inhibitor, Administered to Subjects With Advanced Stage and/or Refractory Solid Malignancies|Completed||Phase 1|19|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 02:09:29.736083|2018-06-01 02:09:29.736083
NCT00676286|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2016-07-04|2008-05-12|2008-05-13|Estimate|||||||2016-07-04|2016-07-06|Estimate|November 2008||2008-11-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers|Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19|Completed||Phase 1|26|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 02:09:29.806481|2018-06-01 02:09:29.806481
NCT00676273|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2008-05-12|2008-05-12|2008-05-13|Estimate|||||||2008-05-12|2008-05-13|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|March 2009|Anticipated|2009-03-31||Interventional|||TVT-Secur Versus TVT-Obturator: A Randomized Trial of Suburethral Sling Operative Procedures|TVT-Secur Versus TVT-Obturator: A Randomized Trial of Suburethral Sling Operative Procedures|Unknown status|Recruiting|Phase 4|140|Anticipated|Boston Urogynecology Associates||2|||f||||f||||||||||2018-06-01 02:09:29.885668|2018-06-01 02:09:29.885668
NCT00676260|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-09|||2012-02-27|2008-05-09|2008-05-13|Estimate|||||||2012-02-27|2012-02-28|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin|Effect of Pioglitazone 15 mg or 30 mg on Microcirculation in Type 2 Diabetes Patients Treated With Insulin|Completed||Phase 2|29|Actual|Takeda||2|||f||||f||||||||||2018-06-01 02:09:29.965171|2018-06-01 02:09:29.965171
NCT00676247|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2009-01-19|2008-05-09|2008-05-12|Estimate|||||||2009-01-19|2009-01-21|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Cerebral Blood Flow Parameters and Neurobehavioral Development in Infants at Term Age|Cerebral Blood Flow Parameters and Neurobehavioral Development in Full-Term Infants and Very Low Birth Weight Preterm Infants at Term Age|Completed|||1|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-06-01 02:09:30.042984|2018-06-01 02:09:30.042984
NCT00676234|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2009-06-26|2008-05-09|2008-05-12|Estimate|||||||2009-06-26|2009-06-30|Estimate|May 2008||2008-05-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure|Recombinant Human Erythropoietin Use in ICU Patients: Does it Prevent Acute Renal Failure?|Completed||Phase 2|80|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 02:09:30.100684|2018-06-01 02:09:30.100684
NCT00676221|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2008-05-14|2008-05-08|2008-05-12|Estimate|||||||2008-05-14|2008-05-15|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|September 2008|Anticipated|2008-09-30|August 2008|Anticipated|2008-08-31||Interventional|||Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)|Patient Reported Outcomes in Renal Transplant Patients Tolerating GI Symptoms Converted to Myfortic (EC-MPS).|Unknown status|Active, not recruiting|Phase 4|110|Anticipated|Foothills Medical Centre|||||f||||f||||||||||2018-06-01 02:09:30.167455|2018-06-01 02:09:30.167455
NCT00676208|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2014-09-29||2015-04-06|2008-05-09|2008-05-12|Estimate|2014-12-03|2014-12-04|Estimate||||2015-04-06|2015-04-28|Estimate|April 2008||2008-04-30|August 2014|2014-08-31|February 2012|Actual|2012-02-29|September 2008|Actual|2008-09-30||Interventional|||Improving Medical Training for the Care of Chronic Conditions|Improving Medical Training for the Care of Chronic Conditions|Completed||N/A|33|Actual|VA Office of Research and Development|The small sample sizes and the reliance on one site for the data. This was a pilot study, both limitations were recognized from the outset and indeed seen as an advantage given the focus on trying to identify measures to include in a larger study.|2|||f||||f||||||||||2018-06-01 02:09:30.238122|2018-06-01 02:09:30.238122
NCT00676195|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2016-08-12||2017-02-08|2008-05-09|2008-05-12|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|June 2008||2008-06-30|February 2017|2017-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Open-Label Study of N-Acetyl Cysteine in Children With Autism|An Open-Label Study of N-Acetyl Cysteine in Autism|Completed||Phase 2|24|Actual|Stanford University|This is an open-label trial with a small sample size.|1|||f||||t||||||||Yes||2018-06-01 02:09:30.548499|2018-06-01 02:09:30.548499
NCT00676182|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2016-03-24||2016-03-24|2008-05-09|2008-05-12|Estimate|2016-03-24|2016-03-25|Estimate||||2016-03-24|2016-03-25|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Observational|||Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury|Telerehabilitation for OIF/OEF Returnees With Combat-Related Traumatic Brain Injury|Completed|||81|Actual|VA Office of Research and Development|||1||f||||f||||||||No||2018-06-01 02:09:30.749114|2018-06-01 02:09:30.749114
NCT00676169|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2015-02-23|2008-05-08|2008-05-12|Estimate|||||||2015-02-23|2015-02-25|Estimate|October 2004||2004-10-31|February 2015|2015-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|EPIC OBS||The EPIC Observational Study|Longitudinal Assessment of Risk Factors For and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children With CF|Active, not recruiting|||1700|Anticipated|CF Therapeutics Development Network Coordinating Center|||1||f||||f||||||Samples With DNA|"~     For study purposes, OP swabs or expectorated sputum for bacterial culture will be obtained~     annually beginning in the calendar year of first isolation of Pa from a respiratory culture~     at the local site laboratory. A serum sample for serology assessment and banking will be~     obtained annually in conjunction with a scheduled clinical blood draw whenever possible.~     Under a separate consent, additional blood (6 ml) will be collected for DNA use and banking~     for studies of genetic factors that may be associated with CF pathogenesis, disease~     progression, and clinical outcomes. These studies will test for association between gene~     variants and various CF-related phenotypes using either a targeted (i.e., candidate gene)~     approach or by performing a whole-genome scan.~   "|||2018-06-01 02:09:31.316804|2018-06-01 02:09:31.316804
NCT00676156|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2012-11-02|2008-05-07|2008-05-12|Estimate|||||||2012-11-02|2012-11-06|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|November 2008|Actual|2008-11-30|February 2008|Actual|2008-02-29||Interventional|||A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis|A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis|Completed||Phase 1|40|Actual|Oregon Health and Science University||3|||f||||f||||||||||2018-06-01 02:09:31.436583|2018-06-01 02:09:31.436583
NCT00676143|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2013-10-14||2016-05-03|2008-05-09|2008-05-12|Estimate|2016-05-03|2016-06-10|Estimate||||2016-05-03|2016-06-10|Estimate|January 2008||2008-01-31|May 2016|2016-05-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional||Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.|Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients|A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers|Terminated||Phase 3|1100|Actual|Pfizer||2||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical~   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2018-06-01 02:09:31.561069|2018-06-01 02:09:31.561069
NCT00676130|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2012-07-03||2012-08-12|2008-05-08|2008-05-12|Estimate|2012-08-12|2012-08-14|Estimate||||2012-08-12|2012-08-14|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients|Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Placebo Added to Standard Treatment of Uncomplicated Cellulitis in Emergency Department Patients|Completed||N/A|153|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:09:33.335535|2018-06-01 02:09:33.335535
NCT00676117|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2009-03-11|2008-05-09|2008-05-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males|A Single-Centre, Open, Randomised, Three-Way Cross-Over Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Healthy Male Subjects|Completed||Phase 1|30|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:09:33.579501|2018-06-01 02:09:33.579501
NCT00676104|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2013-12-19|2008-05-09|2008-05-12|Estimate|||||||2013-12-19|2013-12-20|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|October 2008|Actual|2008-10-31|August 2007|Actual|2007-08-31||Interventional|||Discrete Hypothermia in the Management of Traumatic Brain Injury|Discrete Hypothermia in the Management of Traumatic Brain Injury|Completed||Phase 3|25|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:09:33.654947|2018-06-01 02:09:33.654947
NCT00676091|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2010-09-22||2011-08-04|2008-05-07|2008-05-12|Estimate|2010-09-22|2010-10-15|Estimate||||2011-08-04|2011-08-08|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Brazil|Completed||Phase 3|354|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:09:33.78359|2018-06-01 02:09:33.78359
NCT00676078|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-09-29|2008-05-07|2008-05-12|Estimate|||||||2014-09-29|2014-09-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:09:35.396575|2018-06-01 02:09:35.396575
NCT00676065|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2014-11-13||2014-11-13|2008-05-09|2008-05-12|Estimate|2014-11-13|2014-11-19|Estimate||||2014-11-13|2014-11-19|Estimate|February 2001||2001-02-28|November 2014|2014-11-30|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Observational|||Long-term Active Surveillance Study for Oral Contraceptives (LASS)|Long-term Active Surveillance Study for Oral Contraceptives (LASS)|Completed|||58303|Actual|Center for Epidemiology and Health Research, Germany|In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.||3||f||||t||||||||||2018-06-01 02:09:35.433519|2018-06-01 02:09:35.433519
NCT00676052|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2017-08-08|2012-03-29|2017-09-08|2008-05-08|2008-05-12|Estimate|2017-08-08|2017-09-07|Actual|2012-03-29|2012-04-02|Estimate|2017-09-08|2017-10-09|Actual|May 16, 2008|Actual|2008-05-16|August 2017|2017-08-31|December 22, 2008|Actual|2008-12-22|December 22, 2008|Actual|2008-12-22||Interventional||ITT Population comprised of all participants randomized to treatment who received at least one dose of study medication.|Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD|Completed||Phase 2|576|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:09:35.85398|2018-06-01 02:09:35.85398
NCT00676039|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2009-02-10|2008-05-07|2008-05-12|Estimate|||||||2009-02-10|2009-02-11|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Comparison of the Pharmacokinetics of Two Generic Antidepressants and Their Respective Brand Preparations|Examination of the Pharmacokinetic Properties of Two Generic Antidepressants and Their Respective Brand Preparations in Healthy Male Volunteers|Completed||Phase 1|18|Actual|University of Ottawa||2|||f||||f||||||||||2018-06-01 02:09:36.755083|2018-06-01 02:09:36.755083
NCT00676026|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2017-03-20||2017-05-25|2008-05-09|2008-05-12|Estimate|2017-05-25|2017-06-01|Actual||||2017-05-25|2017-06-01|Actual|May 2005||2005-05-31|May 2017|2017-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||As far as we know, data was never analyzed for this study. We only know that 8 participants completed.|Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women|The Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women|Completed||N/A|8|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 02:09:36.860403|2018-06-01 02:09:36.860403
NCT00676013|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-09-06|2008-05-07|2008-05-12|Estimate|||||||2011-09-06|2011-09-07|Estimate|December 1997||1997-12-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Quad||Skin Substitutes in Burn Care|The Use of Alloderm and Other Skin Substitutes in Acute Burn Treatment and Burn Scar Reconstruction|Terminated||Phase 2/Phase 3|158|Actual|The University of Texas Medical Branch, Galveston||4|||f||||t||||||||||2018-06-01 02:09:36.981331|2018-06-01 02:09:36.981331
NCT00676000|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2009-03-17|2008-05-08|2008-05-12|Estimate|||||||2009-03-17|2009-03-19|Estimate|April 2008||2008-04-30|March 2009|2009-03-31||||December 2009|Anticipated|2009-12-31||Interventional|||Randomized Trial of Interrupted Versus Continuous Vaginal Closure of Anterior Repair With Mesh|Randomized Trial of Interrupted Versus Continuous Vaginal Closure of Anterior Repair With Mesh|Withdrawn||N/A|350|Anticipated|Brigham and Women's Hospital||2||Due to decrease in Avaulta mesh kit usage & inability to recruit study subjects.|f||||t||||||||||2018-06-01 02:09:37.088928|2018-06-01 02:09:37.088928
NCT00675987|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2011-07-19||2013-02-04|2008-05-09|2008-05-12|Estimate|2012-07-11|2012-08-21|Estimate||||2013-02-04|2013-02-11|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients|Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose|Completed||Phase 4|53|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:09:37.157844|2018-06-01 02:09:37.157844
NCT00675974|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-11-13|2008-05-09|2008-05-12|Estimate|||||||2012-11-13|2012-11-15|Estimate|August 2005||2005-08-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|Jobst||Use of Pressure Garments for Burn Scars|Prospective Randomized Study of the Effectiveness of Prospective Randomized Study on the Effectiveness of Pressure Garment Therapy for the Prevention of Hypertrophic Scarring in Burned Children|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-06-01 02:09:37.386705|2018-06-01 02:09:37.386705
NCT00675961|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2017-10-24|2008-05-08|2008-05-12|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2007||2007-01-31|October 2017|2017-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|IMPACT||Effectiveness of Alcohol Interventions Among Tuberculosis (TB) Patients in Tomsk Oblast, Russia|Effectiveness of Alcohol Interventions Among TB Patients in Tomsk Oblast, Russia|Completed||N/A|400|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-06-01 02:09:37.451868|2018-06-01 02:09:37.451868
NCT00675948|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2012-07-05||2013-06-13|2008-05-09|2008-05-12|Estimate|2012-08-14|2012-09-13|Estimate||||2013-06-13|2013-06-24|Estimate|April 2002||2002-04-30|June 2013|2013-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain|An Open-label, Extension Study, to Investigate the Long-term Safety and Tolerability of Cannabis Based Medicine Extracts in Patients With Cancer-related Pain.|Completed||Phase 3|43|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 02:09:37.53665|2018-06-01 02:09:37.53665
NCT00675935|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2010-07-22|2008-05-09|2008-05-12|Estimate|||||||2010-07-22|2010-07-26|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|Falls TIPS||Falls - Tailoring Interventions for Patient Safety|Translating Fall Risk Status Into Interventions to Prevent Patient Falls: Falls TIPS (Tailoring Interventions for Patient Safety)|Completed||Phase 1/Phase 2|2000|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:09:38.204643|2018-06-01 02:09:38.204643
NCT00675922|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-08-06||2012-12-10|2008-05-07|2008-05-12|Estimate|2012-12-10|2013-01-18|Estimate||||2012-12-10|2013-01-18|Estimate|July 1995||1995-07-31|December 2012|2012-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|Soaks||Study of the Treatment of Burn Wounds With Antimicrobial Topical Soaks|Comparing the Use of Sulfamylon 5%, Dakins 0.025%, Cerium, Silver Nitrate 5% and/or Other Topical Antimicrobial Products for the Treatment of Excised and/or Grafted Burn Wounds|Terminated||Phase 2/Phase 3|98|Actual|The University of Texas Medical Branch, Galveston||1||Data inconclusive.|f||||t||||||||||2018-06-01 02:09:38.332807|2018-06-01 02:09:38.332807
NCT00675909|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2011-07-29||2018-04-18|2008-05-08|2008-05-12|Estimate|2012-05-02|2012-06-07|Estimate||||2018-04-18|2018-05-18|Actual|November 2006||2006-11-30|April 2018|2018-04-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Improving Sedation of Children Undergoing Procedures in the Emergency Department|Improving Sedation of Children Undergoing Procedures in the Emergency Department: Evaluation of Different Dosages and Routes of Administration of the Sedative Midazolam|Completed||N/A|180|Actual|Seattle Children's Hospital||3|||f||||t||||||||||2018-06-01 02:09:38.502645|2018-06-01 02:09:38.502645
NCT00675896|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2011-07-03|2008-05-09|2008-05-12|Estimate|||||||2011-07-03|2011-07-06|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome|A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Quetiapine Fumarate Sustained Release(Seroquel SRTM) in the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome.|Completed||Phase 4|120|Anticipated|Dr Alexander McIntyre Inc.||2|||f||||f||||||||||2018-06-01 02:09:38.754823|2018-06-01 02:09:38.754823
NCT00675883|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2012-01-26|2008-05-09|2008-05-12|Estimate|||||||2012-01-26|2012-01-30|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|COMPASS||COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS|COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS|Completed|||1000|Actual|Biogen|||2||f||||f||||||||||2018-06-01 02:09:38.916486|2018-06-01 02:09:38.916486
NCT00675870|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2008-05-09|2008-05-09|2008-05-12|Estimate|||||||2008-05-09|2008-05-12|Estimate|April 2008||2008-04-30|May 2008|2008-05-31||||April 2010|Anticipated|2010-04-30||Interventional|||Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia|Phase II Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia|Unknown status|Recruiting|Phase 2|65|Anticipated|NuRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:09:38.988097|2018-06-01 02:09:38.988097
NCT00673946|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2013-12-06|2008-05-05|2008-05-07|Estimate|||||||2013-12-06|2013-12-09|Estimate|March 2008||2008-03-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Impact of Oximetry on Hospitalization in Acute Bronchiolitis|Impact of Oximetry on Hospitalization|Completed||Phase 4|213|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 02:10:09.069929|2018-06-01 02:10:09.069929
NCT00675857|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2010-08-23|2008-05-08|2008-05-12|Estimate|||||||2010-08-23|2010-08-24|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes|A Phase IIa Study of the Safety and Clinical Proof-of-concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome|Completed||Phase 2|200|Anticipated|Bellus Health Inc||2|||f||||||||||||||2018-06-01 02:09:39.067345|2018-06-01 02:09:39.067345
NCT00675844|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08||2014-01-20|2014-01-20|2008-05-09|2008-05-12|Estimate||||2014-01-20|2014-02-13|Estimate|2014-01-20|2014-02-13|Estimate|May 2008||2008-05-31|January 2014|2014-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment|An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment for 48-Weeks in Subjects Who Have Completed 96 -Weeks of Elvucitabine Therapy in Protocol ACH443-015 or 48 Weeks of Therapy in Protocol ACH443-018|Completed||Phase 2|7|Actual|Achillion Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:09:39.164993|2018-06-01 02:09:39.164993
NCT00675831|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2016-09-28|2008-05-08|2008-05-12|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies|Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies After Matched Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 1|24|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 02:09:39.246241|2018-06-01 02:09:39.246241
NCT00675818|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2012-03-09|2008-05-07|2008-05-12|Estimate|||||||2012-03-09|2012-03-12|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|OMAKI||The Optimal Mode of Renal Replacement Therapy in Acute Kidney Injury (OMAKI) Study|The Optimal Mode of Renal Replacement Therapy in Acute Kidney Injury (OMAKI) Study: A Pilot Randomized Controlled Trial of Convective Versus Diffusive Clearance|Completed||Phase 4|78|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-06-01 02:09:39.323738|2018-06-01 02:09:39.323738
NCT00675805|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2014-09-19|2008-05-09|2008-05-12|Estimate|||||||2014-09-19|2014-09-22|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Preventing Intravenous Immunoglobulin-associated Adverse Reactions|Prospective Assessment of 0.2 um Pore-sized Filters in Preventing Intravenous Immunoglobulin-associated Adverse Reactions|Completed||N/A|42|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 02:09:39.400311|2018-06-01 02:09:39.400311
NCT00675792|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2013-05-21|2009-05-04|2015-02-24|2008-05-07|2008-05-12|Estimate|2013-05-21|2013-07-11|Estimate|2009-10-02|2009-10-06|Estimate|2015-02-24|2015-03-13|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)|A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety-assessor Blinded, Anesthesiologist-TOF-Watch® SX Blinded Trial Comparing T4/T1 Ratio at Time of Tracheal Extubation Using 4 mg/kg Sugammadex Administered at 1-2 PTCs or Better After the Last Dose of Rocuronium Bromide to 50 µg/kg Neostigmine Administered as Per Standard of Care in Adult Subjects Undergoing Elective Open Abdominal Procedures Requiring Neuromuscular Blockade Reversal|Completed||Phase 3|100|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:09:39.492953|2018-06-01 02:09:39.492953
NCT00675779|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-09|2008-05-09|2008-05-12|Estimate|||||||2008-05-09|2008-05-12|Estimate|April 2008||2008-04-30|May 2008|2008-05-31|March 2011|Anticipated|2011-03-31|November 2010|Anticipated|2010-11-30||Interventional|EndoStatin||Efficacy Study of Atorvastatin in Pelvic Pain Relief in Women With Endometriosis|Comparison of Pain Relief and Inflammatory Status in Women With Surgically Confirmed Endometriosis Treated With Atorvastatin, Oral Contraceptive or Combined Oral Contraceptives and Atorvastatin: Open Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|44|Anticipated|Poznan University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:09:39.820812|2018-06-01 02:09:39.820812
NCT00675766|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2015-02-13||2015-04-29|2008-05-09|2008-05-12|Estimate|2015-04-29|2015-05-04|Estimate||||2015-04-29|2015-05-04|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences|Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences|Completed|||223|Actual|VA Office of Research and Development|Large number of subjects who were lost to follow up (i.e moved from community, did not answer follow up calls to schedule visits) resulted in a reduced sample size of subjects who completed the study.||4||f||||t||||||||||2018-06-01 02:09:39.901712|2018-06-01 02:09:39.901712
NCT00675753|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2015-12-16|2008-05-09|2008-05-12|Estimate|||||||2015-12-16|2015-12-17|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Three Interacting Single Nucleotide Polymorphisms (SNPs) and the Risk of Preterm Birth in Black Families|Genetic Variations in Three Interacting Single Nucleotide Polymorphisms and the Risk of Preterm Birth in Black Families|Terminated|||258|Actual|University of Miami|||2|Study site did not have sufficient subjects for the case group|f||||t||||||Samples With DNA|"~     Blood spot specimens were collected from the mother and her infant.~   "|||2018-06-01 02:09:40.381414|2018-06-01 02:09:40.381414
NCT00675740|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2010-02-01|2008-05-07|2008-05-12|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2004||2004-01-31|January 2010|2010-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Physical Exercise Versus Rosiglitazone in CAD and Prediabetes|Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes|Completed||Phase 4|45|Actual|University of Leipzig||3|||f||||f||||||||||2018-06-01 02:09:40.460406|2018-06-01 02:09:40.460406
NCT00675727|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2009-06-10|2008-05-08|2008-05-12|Estimate|||||||2009-06-10|2009-06-11|Estimate|December 2006||2006-12-31|June 2009|2009-06-30||||December 2010|Anticipated|2010-12-31||Interventional|||Safety Study of CADI-05 in Patients With Advanced Stage Melanoma|Open Label, Single Arm, Phase I/II Study of CADI-05 in Patients With Advanced Stage III or Stage IV Melanoma|Terminated||Phase 1/Phase 2|20|Anticipated|Cadila Pharnmaceuticals||||"DSMB reviewed data of 1st 10 subjects; determined no safety concerns. Efficacy as a single~   agent in this patient population was unlikely. Voluntary Termination"|f||||t||||||||||2018-06-01 02:09:40.522515|2018-06-01 02:09:40.522515
NCT00675714|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-26|2008-05-09|2008-05-12|Estimate|||||||2017-05-26|2017-05-31|Actual|January 2004||2004-01-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation|Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation|Recruiting||Phase 2/Phase 3|1100|Anticipated|The University of Texas Medical Branch, Galveston||9|||f||||t||||||||No||2018-06-01 02:09:40.582208|2018-06-01 02:09:40.582208
NCT00675701|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2011-06-20|2008-05-09|2008-05-12|Estimate|||||||2011-06-20|2011-06-21|Estimate|May 2008||2008-05-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study|A Double Blind, Randomized, Repeat-Dose, Parallel Group Study to Define the ECG Effects of Lixivaptan Using a Clinical and a Supratherapeutic Dose, Compared to Placebo and Moxifloxacin (a Positive Control), in Healthy Adult Men and Women: A Thorough ECG Study|Completed||Phase 1|298|Actual|CardioKine Inc.||3|||f||||t||||||||||2018-06-01 02:09:40.694363|2018-06-01 02:09:40.694363
NCT00675688|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2008-05-09|2008-05-09|2008-05-12|Estimate|||||||2008-05-09|2008-05-12|Estimate|April 2002||2002-04-30|May 2008|2008-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women|A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women|Completed||Phase 3|3544|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 02:09:40.753204|2018-06-01 02:09:40.753204
NCT00675675|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2015-08-19|2008-05-09|2008-05-12|Estimate|||||||2015-08-19|2015-08-21|Estimate|July 2007||2007-07-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders|TRECC: Neurocognitive Correlates of Behavioral Treatment for Childhood Tic Disorders|Completed||N/A|53|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 02:09:40.969711|2018-06-01 02:09:40.969711
NCT00675662|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2016-01-12|2008-05-09|2008-05-12|Estimate|||||||2016-01-12|2016-01-13|Estimate|April 2008||2008-04-30|September 2015|2015-09-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|TrimTots||Trim Tots Pre-school Obesity Prevention Programme|TrimTots Pre-school Obesity Prevention Programme|Completed||N/A|173|Actual|Institute of Child Health||2|||f||||f||||||||||2018-06-01 02:09:41.054613|2018-06-01 02:09:41.054613
NCT00675649|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2015-04-09|2008-05-08|2008-05-12|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2008||2008-05-31|April 2015|2015-04-30||||||||Interventional|||A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Parallel-group Study Evaluating the Efficacy and Safety of Golimumab Administered Subcutaneously in Symptomatic Subjects With Severe, Persistent Asthma|Withdrawn||Phase 2|0|Actual|Centocor, Inc.||2|||f||||t||||||||||2018-06-01 02:09:41.142486|2018-06-01 02:09:41.142486
NCT00675636|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2017-08-01|2008-05-08|2008-05-09|Estimate|||||||2017-08-01|2017-08-02|Actual|January 2007||2007-01-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer|Vanderbilt Hereditary Colorectal Cancer Registry|Completed|||730|Actual|Vanderbilt University Medical Center|||||f||||f||||||||||2018-06-01 02:09:41.219538|2018-06-01 02:09:41.219538
NCT00675623|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07||2016-09-24|2016-09-24|2008-05-08|2008-05-09|Estimate||||2016-09-24|2016-09-27|Estimate|2016-09-24|2016-09-27|Estimate|May 2008||2008-05-31|September 2016|2016-09-30||||December 2009|Actual|2009-12-31||Interventional|CONNECTION||A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease|A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)|Completed||Phase 3|598|Actual|Medivation, Inc.||3|||f||||t||||||||||2018-06-01 02:09:41.296417|2018-06-01 02:09:41.296417
NCT00675610|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2015-03-31|2008-05-07|2008-05-09|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|ECHO||Enhancing Communication and HIV Outcomes|Enhancing Communication and HIV Outcomes|Completed||Phase 3|186|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:09:41.417184|2018-06-01 02:09:41.417184
NCT00675597|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2015-10-20||2015-10-20|2008-05-08|2008-05-09|Estimate|2015-10-20|2015-11-20|Estimate||||2015-10-20|2015-11-20|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer|A Pilot Study of Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer|Completed||N/A|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:09:41.576218|2018-06-01 02:09:41.576218
NCT00675584|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2012-04-30||2017-12-27|2008-05-07|2008-05-09|Estimate|2012-04-30|2012-06-01|Estimate||||2017-12-27|2018-01-23|Actual|August 2008||2008-08-31|December 2017|2017-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MIST||CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)|Childhood Asthma Research and Education (CARE) Network Trial - Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)|Completed||Phase 3|278|Actual|Milton S. Hershey Medical Center|May not be applicable to young children whose asthma is more severe than that of the children in the study. Daily or intermittent use of inhaled glucocorticoids may not be efficacious in preschool-age children with transient or infrequent wheezing.|2|||f||||t||||||||||2018-06-01 02:09:41.811868|2018-06-01 02:09:41.811868
NCT00675558|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2012-12-06||2013-07-14|2008-05-07|2008-05-09|Estimate|2013-02-06|2013-03-11|Estimate||||2013-07-14|2013-07-26|Estimate|November 2006||2006-11-30|July 2013|2013-07-31|March 2012|Actual|2012-03-31|April 2011|Actual|2011-04-30||Observational|||Bariatric Surgery for Morbid Obesity|Bariatric Surgery for Morbid Obesity: Clinical and Pathophysiologic Consequences|Completed|||50|Actual|Columbia University|||3||f||||f||||||Samples With DNA|"~     Blood samples and biopsies of omental and subcutaneous fat.~   "|||2018-06-01 02:09:42.156894|2018-06-01 02:09:42.156894
NCT00675545|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2012-03-30|2008-05-08|2008-05-09|Estimate|||||||2012-03-30|2012-04-02|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients|A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients|Completed||Phase 2|2|Actual|National University Hospital, Singapore||1|||f||||f||||||||||2018-06-01 02:09:42.486691|2018-06-01 02:09:42.486691
NCT00675532|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2013-07-19|2008-05-07|2008-05-09|Estimate|||||||2013-07-19|2013-07-22|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).|Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).|Withdrawn||N/A|0|Actual|Yale University||2||Resources|f||||t||||||||||2018-06-01 02:09:42.568465|2018-06-01 02:09:42.568465
NCT00673764|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2009-09-18||2012-01-31|2008-05-06|2008-05-07|Estimate|2010-01-22|2010-02-10|Estimate||||2012-01-31|2012-02-02|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance||Completed||N/A|48|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:10:13.818617|2018-06-01 02:10:13.818617
NCT00675519|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2015-04-06|2008-05-08|2008-05-09|Estimate|||||||2015-04-06|2015-04-08|Estimate|January 2004||2004-01-31|April 2015|2015-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|BI||An Evaluation of the Brief Interventional for Problem Drinkers Among Medical Inpatients|Effects of Brief Intervention for General Hospital Inpatients With Unhealthy Alcohol Use in Taiwan: A Randomized, Controlled Trial|Completed||N/A|300|Actual|Mackay Memorial Hospital||1|||f||||t||||||||||2018-06-01 02:09:42.644933|2018-06-01 02:09:42.644933
NCT00675506|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2012-10-23||2017-11-16|2008-05-07|2008-05-09|Estimate|2012-12-03|2013-01-07|Estimate||||2017-11-16|2017-12-13|Actual|July 2008||2008-07-31|November 2017|2017-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese|Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity|Completed||Phase 2|60|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:09:42.735818|2018-06-01 02:09:42.735818
NCT00675493|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2016-02-18|2008-05-07|2008-05-09|Estimate|||||||2016-02-18|2016-02-19|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Type 1 and Type 2 Diabetes Mellitus in Romania|Completed|||942|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:09:43.062271|2018-06-01 02:09:43.062271
NCT00675480|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2009-01-28|2008-05-08|2008-05-09|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 2004||2004-11-30|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|TAMI||Thrombectomy in Acute Myocardial Infarction|Aspiration Thrombectomy as an Adjunctive Therapy to Primary Angioplasty in Patients With ST Segment Elevation Myocardial Infarction|Completed||Phase 3|140|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-06-01 02:09:43.129407|2018-06-01 02:09:43.129407
NCT00675467|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2016-04-07|2008-05-08|2008-05-09|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2008||2008-04-30|April 2016|2016-04-30||||April 2016|Actual|2016-04-30||Observational|||Palliative Care and Symptom Management for the Pediatric Oncology Patient|Palliative Care and Symptom Management for the Pediatric Oncology Patient|Completed|||13|Actual|M.D. Anderson Cancer Center|||7||f||||f||||||||||2018-06-01 02:09:43.190977|2018-06-01 02:09:43.190977
NCT00675454|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2013-08-19|2008-05-07|2008-05-09|Estimate|||||||2013-08-19|2013-08-20|Estimate|January 2000||2000-01-31|August 2013|2013-08-31||||November 2004|Actual|2004-11-30||Observational|||Evaluating the Effects of Surgical and Non-Surgical Treatment Options in People With Emphysema|Emphysema: Outcomes and Technology Assessment|Unknown status|Enrolling by invitation||300|Anticipated|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 02:09:43.272398|2018-06-01 02:09:43.272398
NCT00675441|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2013-10-21||2013-10-21|2008-05-08|2008-05-09|Estimate|2013-10-21|2013-12-11|Estimate||||2013-10-21|2013-12-11|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)|A Phase II Study of Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Versus-Host Disease (GVHD)|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center|The study did not meet all primary and secondary objectives due to slow patient accrual.|1||Terminated due to slow accrual.|f||||f||||||||||2018-06-01 02:09:43.4604|2018-06-01 02:09:43.4604
NCT00675428|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2014-09-15||2014-09-15|2008-05-08|2008-05-09|Estimate|2014-09-15|2014-09-19|Estimate||||2014-09-15|2014-09-19|Estimate|September 2008||2008-09-30|September 2014|2014-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of Natalizumab in Relapsed/Refractory Multiple Myeloma|A Phase 1/2, Two-Arm, Dose-Finding Study of Natalizumab for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1/Phase 2|6|Actual|Biogen||2||Sponsor decision due to low enrollment and not safety concerns.|f||||t||||||||||2018-06-01 02:09:43.63506|2018-06-01 02:09:43.63506
NCT00675415|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|2017-04-20||2017-10-24|2008-05-08|2008-05-09|Estimate|2017-04-20|2017-05-30|Actual||||2017-10-24|2017-11-28|Actual|September 2006||2006-09-30|October 2017|2017-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Does Capnography Prevent Hypoxemia During Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound?|Does Capnography Prevent Hypoxemia During ERCP and EUS? A Randomized, Controlled Trial|Completed||N/A|263|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 02:09:43.958022|2018-06-01 02:09:43.958022
NCT00675402|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2011-03-21|2008-05-08|2008-05-09|Estimate|||||||2011-03-21|2011-03-22|Estimate|January 2009||2009-01-31|March 2011|2011-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|VAPAV||Micro- and Macrovascular Adaptations in Patients With Peripheral Arterial Disease During Supervised Exercise Therapy|Micro- and Macrovascular Adaptations in Patients With Peripheral Arterial Disease During Supervised Exercise Therapy: a MRI Study|Unknown status|Recruiting||117|Anticipated|Maastricht University Medical Center|||1||f||||f||||||||||2018-06-01 02:09:44.176555|2018-06-01 02:09:44.176555
NCT00675389|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2012-03-28|2008-05-08|2008-05-09|Estimate|||||||2012-03-28|2012-03-29|Estimate|March 2006||2006-03-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|April 2008|Actual|2008-04-30||Interventional|||Impact of Peer Health Workers and Mobile Phones on HIV Care|Impact of Peer Health Workers and Mobile Phones on HIV Care|Completed||N/A|1200|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-06-01 02:09:44.262922|2018-06-01 02:09:44.262922
NCT00675376|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2013-08-19|2008-05-07|2008-05-09|Estimate|||||||2013-08-19|2013-08-20|Estimate|January 2006||2006-01-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Evaluating Quality of Life for Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Lung Transplantation|Lung Transplant for COPD: Outcomes/Technology|Unknown status|Enrolling by invitation||350|Anticipated|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 02:09:44.348162|2018-06-01 02:09:44.348162
NCT00675363|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2018-03-22|2008-05-08|2008-05-09|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2008||2008-01-31|March 2018|2018-03-31|October 17, 2012|Actual|2012-10-17|August 2011|Actual|2011-08-31||Interventional|SLEAP||Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol|A Randomized Trial of Daily Sedative Interruption in Critically Ill, Mechanically Ventilated Patients Being Managed With a Sedation Protocol|Completed||N/A|410|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-06-01 02:09:44.397421|2018-06-01 02:09:44.397421
NCT00675350|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2014-05-09|2008-05-08|2008-05-09|Estimate|||||||2014-05-09|2014-05-12|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors|A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors|Completed||Phase 1|12|Actual|Teva Pharmaceutical Industries||1|||f||||t||||||||||2018-06-01 02:09:44.4846|2018-06-01 02:09:44.4846
NCT00675337|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2008-12-30|2008-05-08|2008-05-09|Estimate|||||||2008-12-30|2008-12-31|Estimate|June 2008||2008-06-30|December 2008|2008-12-31|April 2009|Anticipated|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Effect of Infant Placement on Iron Stores in Infancy: A Pilot Study|The Effect of Infant Placement at Delivery on Iron Stores in Early Infancy: A Pilot Study|Unknown status|Active, not recruiting|N/A|30|Anticipated|Davison, James, D.O.||2|||f||||t||||||||||2018-06-01 02:09:44.548799|2018-06-01 02:09:44.548799
NCT00675324|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2012-09-17|2008-05-08|2008-05-09|Estimate|||||||2012-09-17|2012-09-18|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Bowel Preparation Before Colonoscopy|Bowel Preparation With Nutritional Drinks Instead of Traditional Bowel Preparation|Terminated||N/A|47|Actual|Karolinska Institutet||2||The bowel was not clean when the colonoscopy was performed|f||||f||||||||||2018-06-01 02:09:44.625463|2018-06-01 02:09:44.625463
NCT00675311|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2009-12-17|2008-05-08|2008-05-09|Estimate|||||||2009-12-17|2009-12-18|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Remote Monitoring in Diabetes Disease Management|A Randomized Study of the Clinical and Economic Impact of Remote Monitoring Program With Disease Management Compared to Conventional Diabetes Disease Management Interventions|Completed||N/A|300|Anticipated|LifeScan||2|||f||||f||||||||||2018-06-01 02:09:44.681278|2018-06-01 02:09:44.681278
NCT00675298|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2017-02-02|2008-05-07|2008-05-09|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2006||2006-01-31|February 2014|2014-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|IC||Linkage Analysis in Interstitial Cystitis|Genetic Studies of Urologic Chronic Pelvic Pain Syndrome|Completed|||300|Anticipated|Beth Israel Deaconess Medical Center|||5||f||||f||||||Samples With DNA|"~     Saliva and urine~   "|||2018-06-01 02:09:45.780075|2018-06-01 02:09:45.780075
NCT00675285|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2008-05-08|2008-05-08|2008-05-09|Estimate|||||||2008-05-08|2008-05-09|Estimate|September 2005||2005-09-30|May 2008|2008-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effects of Montelukast in Children With Asthma|Effects of Oral Montelukast on Airway Inflammation in Children With Mild Asthma|Completed||Phase 3|26|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-06-01 02:09:45.845147|2018-06-01 02:09:45.845147
NCT00675272|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2015-04-03|2008-05-08|2008-05-09|Estimate|||||||2015-04-03|2015-04-06|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|HYDRO||Organ Donation and Hydrocortisone Treatment|Organ Donation and Vasopressor Use: Effects of Hydrocortisone Treatment|Terminated||N/A|38|Actual|Kuopio University Hospital||2||Routine use of corticoids became standard therapy|f||||f||||||||||2018-06-01 02:09:45.938776|2018-06-01 02:09:45.938776
NCT00675259|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|2015-11-10||2016-11-22|2008-05-08|2008-05-09|Estimate|2016-07-14|2016-08-24|Estimate||||2016-11-22|2017-01-11|Estimate|July 2008||2008-07-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|May 2011|Actual|2011-05-31||Interventional|||Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer|Phase II Trial of Neoadjuvant Chemotherapy [NCT] With Weekly Nanoparticle Albumin-bound Paclitaxel [Nab-paclitaxel; Abraxane®] in Combination With Carboplatin and Bevacizumab in Women With Clinical Stages I-III Breast Cancer|Completed||Phase 2|33|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:09:46.030717|2018-06-01 02:09:46.030717
NCT00675246|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2010-06-08|2008-05-08|2008-05-09|Estimate|||||||2010-06-08|2010-06-09|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|ACTLPT||Antenatal Corticoid Therapy for Late Preterm Babies|Antenatal Corticoid Therapy for Fetal Lung Maturation in Late Preterm Pregnancies: a Randomized Controlled Trial|Completed||N/A|320|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||1|||f||||t||||||||||2018-06-01 02:09:46.294657|2018-06-01 02:09:46.294657
NCT00675233|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2017-08-30|2008-05-08|2008-05-09|Estimate|||||||2017-08-30|2017-08-31|Actual|April 25, 2008|Actual|2008-04-25|August 2017|2017-08-31|June 28, 2018|Anticipated|2018-06-28|June 28, 2013|Actual|2013-06-28||Interventional|||Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx|Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Larynx|Active, not recruiting||Phase 1|29|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 02:09:46.467095|2018-06-01 02:09:46.467095
NCT00675220|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2016-10-26|2008-05-07|2008-05-09|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™|A Prospective, Open-Labelled, Non-Controlled, Observational Study to Assess the Efficacy and Safety of NovoRapid™ FlexPen™ in the Treatment of Acute Hyperglycemia: A Post-Marketing Surveillance Study|Completed|||373|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:09:46.5547|2018-06-01 02:09:46.5547
NCT00675207|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2008-05-06|2008-05-06|2008-05-08|Estimate|||||||2008-05-06|2008-05-08|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs|Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs|Completed||Phase 4|120|Actual|Northwestern Ophthalmic Institute S.C.||3|||f||||t||||||||||2018-06-01 02:09:46.626097|2018-06-01 02:09:46.626097
NCT00675194|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2008-05-16|2008-05-07|2008-05-08|Estimate|||||||2008-05-16|2008-05-20|Estimate|October 2003||2003-10-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer|A Prospective, Open, Comparative Multicentre Phase II Study for the Evaluation of Irinotecan and Capecitabine Versus Cisplatin and Capecitabine in Advanced Gastric Adenocarcinoma or Gastric-Oesophagal Junction|Completed||Phase 2|120|Anticipated|Johannes Gutenberg University Mainz|||||f||||t||||||||||2018-06-01 02:09:46.716697|2018-06-01 02:09:46.716697
NCT00675181|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2012-09-10|2008-05-07|2008-05-08|Estimate|||||||2012-09-10|2012-09-11|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|MelO2||Effects of Melatonin and Oxygen Consumption and Choroidal Blood Flow|Effects of Melatonin on Oxygen Consumption and Choroidal Blood Flow in Women With Vasospastic Syndrome in Comparison to Controls|Completed||N/A|16|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 02:09:46.791455|2018-06-01 02:09:46.791455
NCT00675168|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-02-18|2008-05-07|2008-05-08|Estimate|||||||2009-02-18|2009-02-19|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|June 2012|Anticipated|2012-06-30|June 2010|Anticipated|2010-06-30||Interventional|PROLOG||Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice|PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice|Unknown status|Recruiting|Phase 4|1700|Anticipated|Odense University Hospital|||||f||||t||||||||||2018-06-01 02:09:46.866276|2018-06-01 02:09:46.866276
NCT00675155|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-01-02|2008-05-07|2008-05-08|Estimate|||||||2009-01-02|2009-01-05|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Far Infrared Irradiation for Stroke Rehabilitation|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:09:46.952318|2018-06-01 02:09:46.952318
NCT00675142|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2015-06-21|2008-05-07|2008-05-08|Estimate|||||||2015-06-21|2015-06-23|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Optimal Timing of Intrauterine Insemination (IUI) When Utilizing Superovulation Combined With GnRH Antagonists|A Randomized Open Three Arm Prospective Trial To Determine The Optimal Timing for Intrauterine Insemination After Superovulation With Recombinant Gonadotropins Utilizing GnRH Antagonists|Completed||N/A|107|Actual|HaEmek Medical Center, Israel||3|||f||||||||||||||2018-06-01 02:09:47.029564|2018-06-01 02:09:47.029564
NCT00675129|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2014-10-22|2008-05-07|2008-05-08|Estimate|||||||2014-10-22|2014-10-23|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||Treatment for Adolescents With Deliberate Self Harm|A Randomized Controlled Trial for Repetitive Deliberate Self-harm and Suicidal Behaviours Among Norwegian Adolescents: a Comparison Between Dialectical Behaviour Therapy Adapted for Adolescents (DBT-A) and Enhanced Usual Care (EUC)|Completed||Phase 2|77|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 02:09:47.105147|2018-06-01 02:09:47.105147
NCT00675116|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24||2010-10-14|2010-10-14|2008-05-07|2008-05-08|Estimate||||2010-10-14|2010-10-15|Estimate|2010-10-14|2010-10-15|Estimate|April 2008||2008-04-30|October 2010|2010-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||GW823296 Repeat Dose Study In Healthy Male And Female Subjects|A Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 After Once-Daily Repeated Oral Doses in Healthy Male and Female Subjects|Completed||Phase 1|30|Anticipated|GlaxoSmithKline|||||f||||||||||||||2018-06-01 02:09:47.178687|2018-06-01 02:09:47.178687
NCT00675103|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2011-06-07||2011-06-07|2008-05-07|2008-05-08|Estimate|2011-06-07|2011-06-28|Estimate||||2011-06-07|2011-06-28|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients|Multicenter, Open-Label, 24 Week Regimen of 8 mg Pegloticase i.v. in Symptomatic Gout Subjects Who Participated in Previous Studies of Pegloticase i.v.|Completed||Phase 3|7|Actual|Savient Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:09:47.248954|2018-06-01 02:09:47.248954
NCT00675090|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2017-07-05|2008-05-07|2008-05-08|Estimate|||||||2017-07-05|2017-07-07|Actual|February 21, 2008|Actual|2008-02-21|July 2017|2017-07-31|June 16, 2009|Actual|2009-06-16|June 16, 2009|Actual|2009-06-16||Interventional|||Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease|A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:09:47.415818|2018-06-01 02:09:47.415818
NCT00675077|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-01-02|2008-05-07|2008-05-08|Estimate|||||||2009-01-02|2009-01-05|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD|Unknown status|Active, not recruiting|Phase 1|5|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:09:47.543392|2018-06-01 02:09:47.543392
NCT00675064|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-08-02|2008-05-07|2008-05-08|Estimate|||||||2017-08-02|2017-08-04|Actual|May 2, 2008|Actual|2008-05-02|August 2017|2017-08-31|October 12, 2008|Actual|2008-10-12|October 12, 2008|Actual|2008-10-12||Interventional|||Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects|Single-blind, Placebo-controlled, Randomized Study Testing Single Ascending Doses of GSK369796 in Healthy Subjects|Completed||Phase 1|41|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:09:47.674678|2018-06-01 02:09:47.674678
NCT00675051|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2016-10-25|2008-05-07|2008-05-08|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension|Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension|Completed|||20|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 02:09:47.744329|2018-06-01 02:09:47.744329
NCT00675038|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2011-09-14|2008-05-07|2008-05-08|Estimate|||||||2011-09-14|2011-09-15|Estimate|October 2005||2005-10-31|September 2011|2011-09-30|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Observational|||Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload|Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* MRI In Patients With Iron Overload|Completed|||52|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 02:09:47.798469|2018-06-01 02:09:47.798469
NCT00675025|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2008-12-10|2008-05-07|2008-05-08|Estimate|||||||2008-12-10|2008-12-11|Estimate|April 2008||2008-04-30|December 2008|2008-12-31||||February 2009|Anticipated|2009-02-28||Interventional|||Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial|An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial|Terminated||Phase 2|128|Anticipated|Eisai Inc.||1||Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.|f||||||||||||||2018-06-01 02:09:47.873777|2018-06-01 02:09:47.873777
NCT00675012|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2014-05-29|2008-05-06|2008-05-08|Estimate|||||||2014-05-29|2014-05-30|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|December 2010|Actual|2010-12-31||Interventional|||NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer|NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|24|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 02:09:48.000649|2018-06-01 02:09:48.000649
NCT00649428|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2012-02-09||2012-02-09|2008-03-31|2008-04-01|Estimate|2012-02-09|2012-03-13|Estimate||||2012-02-09|2012-03-13|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|May 2009|Actual|2009-05-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles||Completed||Phase 3|203|Actual|Fibrocell Technologies, Inc.||2|||f||||f||||||||||2018-06-01 02:17:30.924177|2018-06-01 02:17:30.924177
NCT00674999|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-11-13|2008-05-06|2008-05-08|Estimate|||||||2012-11-13|2012-11-15|Estimate|June 2005||2005-06-30|November 2012|2012-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Amnion||Use of Amnion on Partial Thickness Burns|Project Title The Treatment of Partial Thickness Burns: Treated Amnion Versus Currently in Use Topical Medications|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||3||Hurricane- terminated study due to skin bank being destroyed|f||||f||||||||||2018-06-01 02:09:48.092861|2018-06-01 02:09:48.092861
NCT00674986|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2013-05-03||2013-08-19|2008-05-07|2008-05-08|Estimate|2013-08-19|2013-10-21|Estimate||||2013-08-19|2013-10-21|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||Intent to treat population included all enrolled participants who completed the baseline training visit.|A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes|A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes|Completed||N/A|522|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:09:48.224393|2018-06-01 02:09:48.224393
NCT00674973|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2016-03-24||2016-05-13|2008-05-07|2008-05-08|Estimate|2016-03-24|2016-04-26|Estimate||||2016-05-13|2016-06-17|Estimate|June 2008||2008-06-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|December 2010|Actual|2010-12-31||Interventional|||A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer|A Phase II Biomarker Identification Trial for Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Carcinoma|Completed||Phase 2|207|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:09:48.746357|2018-06-01 02:09:48.746357
NCT00674960|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-08-14|2008-05-07|2008-05-08|Estimate|||||||2009-08-14|2009-08-17|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|May 2009|Anticipated|2009-05-31||Interventional|||Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)|Unknown status|Active, not recruiting|Phase 1|0|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:09:49.303235|2018-06-01 02:09:49.303235
NCT00674947|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2013-09-12|2008-05-07|2008-05-08|Estimate|||||||2013-09-12|2013-09-16|Estimate|June 2008||2008-06-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors|A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors|Completed||Phase 1|55|Actual|Biogen|||||f||||||||||||||2018-06-01 02:09:49.382149|2018-06-01 02:09:49.382149
NCT00674934|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-01-02|2008-05-07|2008-05-08|Estimate|||||||2009-01-02|2009-01-05|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Multiple Sclerosis.|Unknown status|Active, not recruiting|Phase 1|5|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:09:49.453007|2018-06-01 02:09:49.453007
NCT00674921|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2008-06-04|2008-05-06|2008-05-08|Estimate|||||||2008-06-04|2008-06-05|Estimate|June 2008||2008-06-30|May 2008|2008-05-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|CCS||Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda|Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda|Unknown status|Not yet recruiting|Phase 4|1650|Anticipated|MRC/UVRI Uganda Research Unit on Aids||4|||f||||f||||||||||2018-06-01 02:09:49.533309|2018-06-01 02:09:49.533309
NCT00674908|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-06-24|2008-05-07|2008-05-08|Estimate|||||||2009-06-24|2009-06-25|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine|A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants.|Completed||Phase 4|144|Actual|Shantha Biotechnics Limited||2|||f||||f||||||||||2018-06-01 02:09:49.63348|2018-06-01 02:09:49.63348
NCT00674895|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-01-02|2008-05-07|2008-05-08|Estimate|||||||2009-01-02|2009-01-05|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Far Infrared Irradiation for Management and Treating of Parkinson's Disease (PD)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control and Treatment of Parkinson's Disease.|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:09:49.743993|2018-06-01 02:09:49.743993
NCT00674882|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2018-02-06|2008-05-07|2008-05-08|Estimate|||||||2018-02-06|2018-02-07|Actual|February 20, 2002|Actual|2002-02-20|February 2018|2018-02-28|December 2045|Anticipated|2045-12-31|December 2040|Anticipated|2040-12-31||Observational|||Protocol For Collecting Long-Term Follow-Up Data On Recipients of Bone Marrow and Blood Stem Cell Transplant|Protocol For Collecting Long-Term Follow-Up Data On Recipients of Hematopoietic Stem Cell Transplant|Recruiting|||600|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-06-01 02:09:49.822369|2018-06-01 02:09:49.822369
NCT00674869|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-02-20|2008-05-06|2008-05-08|Estimate|||||||2012-02-20|2012-02-22|Estimate|December 2004||2004-12-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effectiveness of Pit and Fissure Sealants in the Prevention of Dental Caries|Effectiveness of Pit and Fissure Sealants in the Prevention of Dental Caries|Completed||N/A|400|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 02:09:49.899873|2018-06-01 02:09:49.899873
NCT00674856|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-01-27|2008-05-07|2008-05-08|Estimate|||||||2009-01-27|2009-01-28|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|HCT3012-X-106||A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function|A Phase 1 Repeated Dose Open Label Study to Investigate the Pharmacokinetics and Safety of Naproxcinod 750mg Bid Administered to Patients With Impaired Renal Function Compared to Matching Healthy Subjects|Completed||Phase 1|32|Anticipated|NicOx||1|||f||||t||||||||||2018-06-01 02:09:49.978074|2018-06-01 02:09:49.978074
NCT00674843|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-08-14|2008-05-07|2008-05-08|Estimate|||||||2009-08-14|2009-08-17|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.|Unknown status|Active, not recruiting|Phase 1|4|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:09:50.053234|2018-06-01 02:09:50.053234
NCT00441805|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2016-07-11|2007-02-28|2007-03-01|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 2006||2006-11-30|September 2007|2007-09-30|September 2007||2007-09-30|||||Interventional|||The Treatment of Acne Vulgaris With Radiofrequency Device|The Treatment of Acne Vulgaris With Radiofrequency Device|Withdrawn||N/A|0|Actual|Alma Lasers|||||f||||f||||||||||2018-06-01 03:24:07.68048|2018-06-01 03:24:07.68048
NCT00674817|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2017-02-03||2017-04-04|2008-05-07|2008-05-08|Estimate|2017-02-03|2017-03-27|Actual||||2017-04-04|2017-05-10|Actual|April 1, 2008||2008-04-01|February 2017|2017-02-28|October 19, 2008|Actual|2008-10-19|October 1, 2008|Actual|2008-10-01||Interventional||All subjects population included all participants who received at least one dose of the study drug.|An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.|A Randomized, Double-blind, Crossover Study to Investigate the Bronchodilatation Post-inhalation of GSK961081 Alone and With the Addition of Cumulative Doses of Short Acting Bronchodilators (Salbutamol and Ipratropium Bromide) in Patients With COPD|Completed||Phase 2|45|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:09:50.395079|2018-06-01 02:09:50.395079
NCT00674804|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2017-06-30|2008-05-07|2008-05-08|Estimate|||||||2017-06-30|2017-07-02|Actual|April 24, 2008||2008-04-24|July 16, 2009|2009-07-16|July 16, 2009|Actual|2009-07-16|July 16, 2009|Actual|2009-07-16||Observational|||Communicating a Cancer Diagnosis-Current Methods and Their Effects|Communicating a Cancer Diagnosis: Current Methods and Their Effects|Completed|||1100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:09:52.674665|2018-06-01 02:09:52.674665
NCT00674791|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2013-06-18|2008-05-07|2008-05-08|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease|A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA 51) Following Completion of Prescribed Chemotherapy or Trastuzumab for TXN2-3M0 or Metastatic Breast Cancer With No Evidence of Disease|Completed||Phase 1|13|Actual|Duke University|||||f||||f||||||||||2018-06-01 02:09:52.728336|2018-06-01 02:09:52.728336
NCT00674778|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-07|2008-05-07|2008-05-08|Estimate|||||||2008-05-07|2008-05-08|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|June 2006||2006-06-30|||||Interventional|PREVAIL||Prospective Registry on Vascular Access in Interventions in Lazio Region|Prospective Registry on Vascular Access in Interventions in Lazio Region|Completed||Phase 4|1052|Actual|San Filippo Neri General Hospital||2|||f||||f||||||||||2018-06-01 02:09:52.795923|2018-06-01 02:09:52.795923
NCT00674765|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2014-05-01||2014-09-16|2008-05-07|2008-05-08|Estimate|2014-09-16|2014-09-17|Estimate||||2014-09-16|2014-09-17|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Seroquel for Frequent, Heavy Drinkers|A Phase II Double-blind, Placebo-controlled Trial of Quetiapine for Frequent, Heavy Drinkers (Seroquel2)|Completed||Phase 2|156|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:09:52.882356|2018-06-01 02:09:52.882356
NCT00674752|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2011-04-22|2008-05-07|2008-05-08|Estimate|||||||2011-04-22|2011-04-26|Estimate|March 2006||2006-03-31|April 2011|2011-04-30|August 2006|Actual|2006-08-31|||||Interventional|||A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study Of Gabapentin 250 mg And 500 mg In Transient Insomnia Induced By A Sleep Phase Advance|Completed||Phase 3|377|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:09:53.127985|2018-06-01 02:09:53.127985
NCT00674739|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2011-04-24||2011-05-19|2008-05-07|2008-05-08|Estimate|2011-04-24|2011-05-18|Estimate||||2011-05-19|2011-05-24|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts|Completed||Phase 3|470|Actual|Graceway Pharmaceuticals, LLC||3|||f||||f||||||||||2018-06-01 02:09:53.230713|2018-06-01 02:09:53.230713
NCT00674726|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2012-10-29|2008-05-07|2008-05-08|Estimate|||||||2012-10-29|2012-10-31|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Observational|||Study on the Difference of Axilo-rectal Temperature in Appendicitis|Prospective Study on the Difference of Axilar-rectal Temperature in Acute Appendicitis|Withdrawn|||0|Actual|Cirujanos la Serena|||2||f||||f||||||||||2018-06-01 02:09:53.712474|2018-06-01 02:09:53.712474
NCT00674713|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-07|2008-05-07|2008-05-08|Estimate|||||||2008-05-07|2008-05-08|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effect of Acupuncture on Postoperative Nausea and Vomiting||Completed||Phase 4|140|Actual|Catholic University of the Sacred Heart||4|||f||||||||||||||2018-06-01 02:09:53.824533|2018-06-01 02:09:53.824533
NCT00674700|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2016-01-25||2016-04-12|2008-05-07|2008-05-08|Estimate|2016-04-12|2016-05-19|Estimate||||2016-04-12|2016-05-19|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional||The Full Analysis Set included all participants who received at least one dose of the investigational product and had at least one Adjusted Symptom Score evaluation in the year.|Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis|A Randomized, DBPC, Multi-national Phase II/III Study of the Safety and Efficacy of Two Doses of Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Adult Patients Suffering From HDM Allergic Rhinitis|Completed||Phase 2/Phase 3|509|Actual|Stallergenes Greer||3|||f||||f||||||||||2018-06-01 02:09:53.977494|2018-06-01 02:09:53.977494
NCT00674687|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2008-05-08|2008-05-06|2008-05-08|Estimate|||||||2008-05-08|2008-05-12|Estimate|July 2004||2004-07-31|May 2008|2008-05-31|June 2006|Actual|2006-06-30|||||Interventional|||A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing|A Randomized Double-Blind, Placebo-Controlled, Crossover Study To Assess The Reproducibility And The Effect Of Gabapentin On Quantitative Sensory Testing In Neuropathic Pain Patients|Completed||N/A|23|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:09:54.647692|2018-06-01 02:09:54.647692
NCT00674674|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-05-11|2008-05-07|2008-05-08|Estimate|||||||2012-05-11|2012-05-15|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|PBTC-019||Phase 1 Intrathecal Topotecan for Neoplastic Meningitis|A Phase I Pharmacokinetic Optimal Dosing Study of Intrathecal Topotecan for Children With Neoplastic Meningitis|Completed||Phase 1|22|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 02:09:54.766019|2018-06-01 02:09:54.766019
NCT00674661|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2016-08-17|2012-05-18|2017-12-04|2008-05-06|2008-05-08|Estimate|2016-12-02|2017-01-27|Estimate|2012-05-18|2012-05-30|Estimate|2017-12-04|2017-12-06|Actual|December 2007||2007-12-31|December 2017|2017-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|CXL||Corneal Collagen Cross-Linking for Ectasia (CXL)|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery|Completed||Phase 3|130|Actual|Avedro, Inc.||2|||f||||f||||||||||2018-06-01 02:09:54.89165|2018-06-01 02:09:54.89165
NCT00619437|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-10|||2008-02-10|2008-02-10|2008-02-21|Estimate|||||||2008-02-10|2008-02-21|Estimate|April 2008||2008-04-30|February 2008|2008-02-29|December 2009|Anticipated|2009-12-31|||||Observational|||Genetics of Schizophrenia|Genetics of Schizophrenia|Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||||f||||f||||||Samples With DNA|"~     Cell Lines / DNA~   "|||2018-06-01 02:26:25.854473|2018-06-01 02:26:25.854473
NCT00674648|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2017-02-27|2008-05-06|2008-05-08|Estimate|||||||2017-02-27|2017-03-01|Actual|August 2007|Actual|2007-08-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants|A Phase I Dose Escalation Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants|Completed||Phase 1|30|Actual|Atara Biotherapeutics||1|||t||||||||||||||2018-06-01 02:09:55.71244|2018-06-01 02:09:55.71244
NCT00674635|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22||2012-03-15|2016-11-30|2008-05-07|2008-05-08|Estimate||||2012-03-22|2012-03-28|Estimate|2016-11-30|2016-12-01|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Bayesian Adaptive Dose Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Intravenous Infusions GSK315234A in Patients With Active Rheumatoid Arthritis (RA)|Completed||Phase 2|135|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:09:55.777871|2018-06-01 02:09:55.777871
NCT00674622|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2016-01-08||2016-05-13|2008-05-07|2008-05-08|Estimate|2016-05-13|2016-05-16|Estimate||||2016-05-13|2016-05-16|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||Prolotherapy for the Treatment of Chronic Lateral Epicondylitis|Prolotherapy for the Treatment of Chronic Lateral Epicondylitis|Completed||Phase 2/Phase 3|67|Actual|University of Pittsburgh||3|||f||||t||||||||Yes|Presented at conference.|2018-06-01 02:09:56.151945|2018-06-01 02:09:56.151945
NCT00674609|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2012-07-05||2013-06-13|2008-05-07|2008-05-08|Estimate|2012-07-05|2012-08-13|Estimate||||2013-06-13|2013-06-20|Estimate|February 2002||2002-02-28|June 2013|2013-06-30|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|SPRAY||A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy|A Double Blind, Randomized, Parallel Group, Placebo Controlled, Comparative Study of the Efficacy, Safety and Tolerability of Cannabis Based Medicine (CBM) Extracts in Patients With Cancer-related Pain.|Completed||Phase 3|177|Actual|GW Pharmaceuticals Ltd.||3|||f||||f||||||||||2018-06-01 02:09:56.748639|2018-06-01 02:09:56.748639
NCT00674596|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2008-05-07|2008-05-07|2008-05-08|Estimate|||||||2008-05-07|2008-05-08|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|March 2008||2008-03-31|March 2008||2008-03-31||Interventional|||The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria||Completed||Phase 4|60|Anticipated|Gulhane School of Medicine|||||||||||||||||||2018-06-01 02:09:57.808376|2018-06-01 02:09:57.808376
NCT00674583|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|2017-05-22|2009-09-03|2017-05-22|2008-05-07|2008-05-08|Estimate|2017-05-22|2017-10-19|Actual|2009-09-03|2009-09-04|Estimate|2017-05-22|2017-10-19|Actual|May 9, 2008||2008-05-09|October 2016|2016-10-31|January 8, 2009|Actual|2009-01-08|September 2, 2008|Actual|2008-09-02||Interventional|||Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children|Non-inferiority of GSK Biologicals' Meningococcal Vaccine (GSK134612) Compared to Licensed MenC-CRM197 Conjugate Vaccine in Healthy Children|Completed||Phase 3|414|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:09:57.919689|2018-06-01 02:09:57.919689
NCT00674570|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2017-09-06|2008-05-06|2008-05-08|Estimate|||||||2017-09-06|2017-09-11|Actual|July 1, 2008|Actual|2008-07-01|September 2017|2017-09-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|VSL||Veteran Stress and Learning Study|Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder|Completed||Phase 4|138|Actual|VA Office of Research and Development||3|||f||||f|t|f|||t|||No||2018-06-01 02:09:59.183686|2018-06-01 02:09:59.183686
NCT00674557|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2013-07-09|2008-05-07|2008-05-08|Estimate|||||||2013-07-09|2013-07-10|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|||||Interventional|||Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer|A Cancer Research UK Randomised Phase II Trial of ATN-224 (Copper Binding Agent) in Combination With Exemestane Versus Exemestane Alone in Post-menopausal Women With Recurrent or Advanced, Oestrogen and/or Progesterone Receptor Positive Breast Cancer|Terminated||Phase 2|111|Anticipated|National Cancer Institute (NCI)||||"Withdrawn as the clinical development of ATN-224 was terminated by the drug company who was~   providing ATN-224 for the study"|f||||||||||||||2018-06-01 02:09:59.28407|2018-06-01 02:09:59.28407
NCT00674544|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2011-01-27|2008-05-07|2008-05-08|Estimate|||||||2011-01-27|2011-01-28|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Ballabeina||Influence of a Lifestyle Intervention in Preschool Children on Physiological and Psychological Parameters|Influence of a Lifestyle Intervention in Preschool Children on Physiological and Psychological Parameters (Ballabeina)|Completed||N/A|650|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||||2018-06-01 02:09:59.469165|2018-06-01 02:09:59.469165
NCT00674531|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-07|||2014-10-08|2008-05-07|2008-05-08|Estimate|||||||2014-10-08|2014-10-09|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ATH-ENTE||Detection of Enterovirus RNA in Atheromatous Lesions|Detection of Enterovirus RNA by RT-PCR in Atheromatous Lesions|Completed||N/A|100|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 02:09:59.540988|2018-06-01 02:09:59.540988
NCT00674518|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2008-05-06|2008-05-06|2008-05-08|Estimate|||||||2008-05-06|2008-05-08|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|March 2009|Anticipated|2009-03-31|June 2008|Anticipated|2008-06-30||Interventional|CHOICE||Changing Healthy Outcomes In Clinic Environments|Health Promotion Intervention: Sedentary Primary Care Patients|Unknown status|Active, not recruiting|N/A|100|Anticipated|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 02:09:59.704575|2018-06-01 02:09:59.704575
NCT00674505|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2010-02-16|2008-05-07|2008-05-08|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2008||2008-01-31|February 2010|2010-02-28||||June 2009|Anticipated|2009-06-30||Interventional|FORTRESS||Safety & Performance Study of Lumen Biomedical's FiberNet Distal Protection System for the Treatment of Renal Artery Stenosis|FiberNet Renal Artery Embolic Protection Study: A Prospective, Single-arm Feasibility Trial of Renal Artery Distal Protection Using the Lumen Biomedical FiberNet Embolic Protection System|Unknown status|Active, not recruiting|N/A|20|Actual|VIVA Physicians||1|||f||||t||||||||||2018-06-01 02:09:59.781997|2018-06-01 02:09:59.781997
NCT00674492|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2015-02-05||2015-04-27|2008-05-07|2008-05-08|Estimate|2015-02-20|2015-03-09|Estimate||||2015-04-27|2015-05-15|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational||patients who initiated antiviral treatment|Hepatitis C Virus (HCV) Treatment Completion or Withdrawal|Patients' View of Hepatitis C Treatment Completion or Withdrawal|Completed|||21|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 02:09:59.899021|2018-06-01 02:09:59.899021
NCT00674479|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2017-03-27|2008-05-05|2008-05-07|Estimate|||||||2017-03-27|2017-03-29|Actual|May 12, 2008|Actual|2008-05-12|March 2017|2017-03-31|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||INCB018424 in Patients With Advanced Hematologic Malignancies|Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies|Completed||Phase 2|56|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:10:00.230859|2018-06-01 02:10:00.230859
NCT00674466|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2017-05-02||2017-05-02|2008-05-06|2008-05-07|Estimate|2017-05-02|2017-06-02|Actual||||2017-05-02|2017-06-02|Actual|March 2008||2008-03-31|May 2017|2017-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional||Safety Population|A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy|A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Twice-a-week Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy|Completed||Phase 2|90|Actual|ConjuChem||3|||f||||t||||||||||2018-06-01 02:10:00.450237|2018-06-01 02:10:00.450237
NCT00674453|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2011-08-08|2008-05-01|2008-05-07|Estimate|||||||2011-08-08|2011-08-10|Estimate|September 2004||2004-09-30|August 2011|2011-08-31|September 2007|Actual|2007-09-30|||||Interventional|LACE||The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation|The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis|Completed||Phase 2|51|Actual|Ligand Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:10:01.195442|2018-06-01 02:10:01.195442
NCT00674440|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05||2013-01-25|2018-02-15|2008-05-05|2008-05-07|Estimate||||2013-01-25|2013-01-29|Estimate|2018-02-15|2018-02-19|Actual|December 2004||2004-12-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 2008|Actual|2008-12-31||Interventional|||Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism|Localization of Focal Forms of Hyperinsulinism of Infancy With 18F-labeled L-fluoro-DOPA PET Scan|Completed||Phase 2|105|Actual|Children's Hospital of Philadelphia||3|||f||||t||||||||||2018-06-01 02:10:01.328939|2018-06-01 02:10:01.328939
NCT00674427|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05||2016-11-14|2017-06-26|2008-05-05|2008-05-07|Estimate||||2016-12-01|2016-12-02|Estimate|2017-06-26|2017-07-02|Actual|January 2008||2008-01-31|June 2017|2017-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant|A Phase I/II Trial Of DLI And Activated DLI (ADLI) Followed By Either Repetitive Dosing Of ADLI Or Dose Escalated ADLI For Patients With Relapse After Allogeneic Stem Cell Transplantation|Terminated||Phase 1/Phase 2|13|Actual|University of Pennsylvania||2||Insufficient funds|f||||f|t|f||||||No||2018-06-01 02:10:01.614329|2018-06-01 02:10:01.614329
NCT00674414|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2013-01-17|2008-05-06|2008-05-07|Estimate|||||||2013-01-17|2013-01-18|Estimate|April 2008||2008-04-30|January 2013|2013-01-31||||January 2013|Actual|2013-01-31||Interventional|||Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery|A Phase II, Randomized, Multi-center Study, Assessing Value of Adding Everolimus (RAD001) to Trastuzumab as Preoperative Therapy of HER-2 Positive Primary Breast Cancer Amenable to Surgery.|Terminated||Phase 2|82|Actual|UNICANCER||2||IDMC decision due to accrual issue (82 pts accrued / 120 expected)|f||||||||||||||2018-06-01 02:10:01.862618|2018-06-01 02:10:01.862618
NCT00674401|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2013-09-21|2008-05-06|2008-05-07|Estimate|||||||2013-09-21|2013-09-24|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|RADAR-AF||Radiofrequency Ablation of Drivers of Atrial Fibrillation|RADAR-AF: Radiofrequency Ablation of Drivers of Atrial Fibrillation|Completed||N/A|232|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||||2018-06-01 02:10:02.017|2018-06-01 02:10:02.017
NCT00674388|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2017-05-02|2008-05-05|2008-05-07|Estimate|||||||2017-05-02|2017-05-05|Actual|February 2008||2008-02-29|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|2 Weeks|Observational [Patient Registry]|WUS||The Pediatric Anesthesia Quality Improvement Project|The Pediatric Anesthesia Quality Improvement Project|Recruiting|||3000000|Anticipated|The Society for Pediatric Anesthesia|||||f||||f||||||||||2018-06-01 02:10:02.252471|2018-06-01 02:10:02.252471
NCT00674375|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2015-03-17|2008-05-06|2008-05-07|Estimate|||||||2015-03-17|2015-03-18|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Risk Score Alerts for Chest Pain Care|Can Risk Score Alerts Improve Office Care for Chest Pain?|Completed||Phase 3|8000|Actual|Harvard Vanguard Medical Associates||2|||f||||t||||||||||2018-06-01 02:10:02.593992|2018-06-01 02:10:02.593992
NCT00674362|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2011-12-09|2011-05-19|2011-12-09|2008-05-06|2008-05-07|Estimate|2011-12-09|2012-01-18|Estimate|2011-05-19|2011-05-23|Estimate|2011-12-09|2012-01-18|Estimate|June 2008||2008-06-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|CERTAIN||Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study|A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis|Completed||Phase 3|194|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 02:10:02.762202|2018-06-01 02:10:02.762202
NCT00674349|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2008-07-21|2008-05-06|2008-05-07|Estimate|||||||2008-07-21|2008-07-22|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|December 2011|Anticipated|2011-12-31|January 2007|Anticipated|2007-01-31||Interventional|||Screening of Biomarkers on Endometrial Cancers|Screening and Identification of Novel Diagnostic and Prognostic Biomarkers on Endometrial Cancers|Unknown status|Recruiting|N/A|250|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 02:10:03.953415|2018-06-01 02:10:03.953415
NCT00674336|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2013-11-18|2008-05-06|2008-05-07|Estimate|||||||2013-11-18|2013-11-19|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional|Shellfish||Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study|Norwalk Virus Inactivation by High Hydrostatic Pressure Processing: A Comprehensive and Integrated Program for Research and Outreach|Completed||N/A|51|Actual|Emory University||1|||f||||t||||||||||2018-06-01 02:10:04.019633|2018-06-01 02:10:04.019633
NCT00674323|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2010-12-21||2011-04-15|2008-05-06|2008-05-07|Estimate|2011-01-04|2011-01-25|Estimate||||2011-04-15|2011-04-19|Estimate|April 2008||2008-04-30|April 2011|2011-04-30||||May 2009|Actual|2009-05-31||Interventional|PCV||Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy|A Multicentre, Randomized, Double Masked, Exploratory, Indocyanine Green Angiography (ICGA) Guided Study of 6 Months Duration to Compare the Safety and Effect on Polyp Regression of Verteporfin Photodynamic Therapy (PDT) Alone or Added to Ranibizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy|Completed||Phase 4|61|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:10:04.106397|2018-06-01 02:10:04.106397
NCT00673751|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-06|2008-05-06|2008-05-07|Estimate|||||||2008-05-06|2008-05-07|Estimate||||May 2008|2008-05-31||||||||Interventional|||Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome|GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome|Unknown status|Enrolling by invitation|N/A|8|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-06-01 02:10:14.049514|2018-06-01 02:10:14.049514
NCT00674310|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2018-01-19|2008-05-06|2008-05-07|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2004||2004-02-29|January 2018|2018-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions|A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions|Completed||N/A|29|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:10:04.490604|2018-06-01 02:10:04.490604
NCT00674297|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2017-04-21||2018-03-29|2008-05-06|2008-05-07|Estimate|2018-03-29|2018-05-01|Actual||||2018-03-29|2018-05-01|Actual|May 2008||2008-05-31|March 2018|2018-03-31|February 2013|Actual|2013-02-28|July 2011|Actual|2011-07-31||Interventional|||Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients|Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients|Completed||Phase 2|41|Actual|Hospital for Special Surgery, New York||1|||f||||t||||||||No||2018-06-01 02:10:04.553061|2018-06-01 02:10:04.553061
NCT00674284|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2009-11-23|2008-05-05|2008-05-07|Estimate|||||||2009-11-23|2009-11-25|Estimate|February 2008||2008-02-29|November 2009|2009-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Adrenal Exhaustion Syndrome in Critically Ill Patients Without Improvement|Change of Serum Cortisol Levels in Patients Without Improvement in Intensive Care Unit|Completed|||80|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 02:10:04.987387|2018-06-01 02:10:04.987387
NCT00674271|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2011-11-03|2008-05-05|2008-05-07|Estimate|||||||2011-11-03|2011-11-04|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|May 2018|Anticipated|2018-05-31|March 2011|Actual|2011-03-31||Observational|IMPACT||Immune Profile and Complication Risk in Type 2 Diabetes|Immune Profile and Complications Risk in Type 2 Diabetes|Unknown status|Active, not recruiting||200|Anticipated|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Whole blood, urine~   "|||2018-06-01 02:10:05.040723|2018-06-01 02:10:05.040723
NCT00674258|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-12|2008-05-05|2008-05-07|Estimate|||||||2008-05-12|2008-05-14|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 1/Phase 2|14|Anticipated|Tokyo University||1|||f||||t||||||||||2018-06-01 02:10:05.270596|2018-06-01 02:10:05.270596
NCT00674245|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2010-08-18|2008-05-05|2008-05-07|Estimate|||||||2010-08-18|2010-08-19|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.|The Effect Of Pantoprazole 40 mg Once Daily Versus Placebo On The Power Spectral Analysis Of The Sleep Electroencephalogram (EEG) Of Patients With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 2/Phase 3|40|Actual|Southern Arizona VA Health Care System||2|||f||||f||||||||||2018-06-01 02:10:05.419418|2018-06-01 02:10:05.419418
NCT00674232|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-05-05|2008-05-05|2008-05-07|Estimate|||||||2008-05-05|2008-05-07|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Treatment of Incomplete Abortion With 600 Mcg Oral Misoprostol Compared to Standard Surgical Treatment|Misoprostol for Treatment of Incomplete Abortion|Completed||N/A|311|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 02:10:05.556509|2018-06-01 02:10:05.556509
NCT00674219|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2014-05-19|2008-05-06|2008-05-07|Estimate|||||||2014-05-19|2014-05-20|Estimate|May 2005||2005-05-31|May 2014|2014-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder|Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial|Completed||Phase 3|17|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-06-01 02:10:05.751218|2018-06-01 02:10:05.751218
NCT00674206|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2012-03-30||2013-11-18|2008-05-06|2008-05-07|Estimate|2012-06-20|2012-07-26|Estimate||||2013-11-18|2013-12-12|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer|A Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2NEU- (Triple Negative) Metastatic Breast Cancer|Terminated||Phase 2|6|Actual|Emory University|Early termination of the study due to slow accrual|1||Sponsor funding stopped|f||||t||||||||||2018-06-01 02:10:05.845995|2018-06-01 02:10:05.845995
NCT00674193|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2017-05-15|2008-05-06|2008-05-07|Estimate|||||||2017-05-15|2017-05-17|Actual|February 2008||2008-02-29|May 2017|2017-05-31||||June 30, 2016|Actual|2016-06-30||Observational|||Evaluating Dactinomycin and Vincristine in Young Patients With Cancer|A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children With Cancer|Completed|||158|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     blood and urine~   "|||2018-06-01 02:10:06.114978|2018-06-01 02:10:06.114978
NCT00674180|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2018-05-14|2008-05-06|2008-05-07|Estimate|||||||2018-05-14|2018-05-17|Actual|April 2008||2008-04-30|May 2018|2018-05-31||||April 2008|Actual|2008-04-30||Observational|||Data Analysis of a Managed Care Weight Reduction Trial|Data Analysis of a Managed Care Weight Reduction Trial|Active, not recruiting|||588|Actual|Albert Einstein College of Medicine, Inc.|||3||f||||f||||||||||2018-06-01 02:10:06.357169|2018-06-01 02:10:06.357169
NCT00674167|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2015-06-11|2008-05-06|2008-05-07|Estimate|||||||2015-06-11|2015-06-12|Estimate|May 2007||2007-05-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma|The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.|Unknown status|Active, not recruiting|Phase 2|21|Actual|National University Hospital, Singapore||3|||f||||t||||||||||2018-06-01 02:10:06.472115|2018-06-01 02:10:06.472115
NCT00674154|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2013-08-06||2013-10-23|2008-05-05|2008-05-07|Estimate|2013-08-06|2013-10-16|Estimate||||2013-10-23|2013-11-18|Estimate|May 2008||2008-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effect of Vitamin D Treatment in Primary Hyperparathyroidism|Effect of Vitamin D Treatment in Primary Hyperparathyroidism|Completed||Phase 2/Phase 3|46|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:10:06.609123|2018-06-01 02:10:06.609123
NCT00674141|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2010-06-02|2008-05-06|2008-05-07|Estimate|||||||2010-06-02|2010-06-03|Estimate|July 2008||2008-07-31|May 2008|2008-05-31|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|||Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment|Nasal Administration of Dexamethasone for MS Treatment|Withdrawn||Phase 1|10|Anticipated|Hadassah Medical Organization||1||was not approved by the ministry of health|f||||f||||||||||2018-06-01 02:10:06.995267|2018-06-01 02:10:06.995267
NCT00674128|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2010-10-05||2010-12-01|2008-05-06|2008-05-07|Estimate|2010-12-01|2010-12-29|Estimate||||2010-12-01|2010-12-29|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Cyanoacrylate Tissue Adhesive and Suture for Closure of Cardiac Device Pockets|Prospective Comparison of Cyanoacrylate Tissue Adhesive (Dermabond) and Suture (Vicryl) for Closure of Cardiac Device Pockets|Terminated||N/A|103|Actual|Mayo Clinic||2||Slow accrual.|f||||f||||||||||2018-06-01 02:10:07.079965|2018-06-01 02:10:07.079965
NCT00674115|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2009-09-17||2015-02-20|2008-05-02|2008-05-07|Estimate|2010-04-08|2010-04-30|Estimate||||2015-02-20|2015-03-11|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)|Randomized, Crossover Pharmacodynamic Study Comparing the Effects of Zegerid® (20 mg Omeprazole/Sodium Bicarbonate) and Prilosec OTC® (20 Mg-equivalent Omeprazole)|Completed||Phase 3|60|Actual|Bayer||3|||f||||f||||||||||2018-06-01 02:10:07.399771|2018-06-01 02:10:07.399771
NCT00674102|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2016-04-15|2008-05-06|2008-05-07|Estimate|||||||2016-04-15|2016-04-19|Estimate|April 2008||2008-04-30|April 2016|2016-04-30||||March 2009|Actual|2009-03-31||Interventional|||An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With NSCLC|Completed||Phase 1|15|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:10:07.713643|2018-06-01 02:10:07.713643
NCT00674089|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2011-08-09|2008-05-06|2008-05-07|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2007||2007-01-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|VA||Newborn Vitamin A (VA) Supplementation Pilot Project, Pakistan|Evaluation of the Effectiveness of Vitamin A Supplementation (VAS) as Part of a Neonatal Post Partum Care Package in Rural Pakistan|Completed||N/A|7400|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 02:10:07.799162|2018-06-01 02:10:07.799162
NCT00674076|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2012-07-08|2008-05-05|2008-05-07|Estimate|||||||2012-07-08|2012-07-10|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Clinical Application of Ultrasound in Obstructive Sleep Apnea|Clinical Application of Ultrasound in Obstructive Sleep Apnea|Completed|||105|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-06-01 02:10:07.883582|2018-06-01 02:10:07.883582
NCT00674063|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2014-08-25|2008-05-06|2008-05-07|Estimate|||||||2014-08-25|2014-08-26|Estimate|July 2003||2003-07-31|August 2014|2014-08-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis|A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Weekly Intravenous Administration of 7.5mg and 0.075mg/kg Alefacept in Subjects Weighing Between 100kg and 150kg, With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|78|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:10:07.954179|2018-06-01 02:10:07.954179
NCT00674050|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2012-06-12|2008-05-05|2008-05-07|Estimate|||||||2012-06-12|2012-06-13|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||A Study Designed to Determine if the Drugs Albuterol (Salbutamol) and Fluticasone Have an Effect on the Pharmacokinetics of the Investigational Product Technosphere® Insulin Inhalation Powder in Healthy Volunteers|A Phase 1, Open-Label Study to Investigate the Effect of Albuterol (Salbutamol) and Fluticasone on the Pharmacokinetics of Inhaled Technosphere® Insulin Inhalation Powder in Healthy Subjects|Completed||Phase 1|13|Actual|Mannkind Corporation||1|||f||||||||||||||2018-06-01 02:10:08.08627|2018-06-01 02:10:08.08627
NCT00674037|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2014-10-31|2008-05-06|2008-05-07|Estimate|||||||2014-10-31|2014-11-03|Estimate|September 2006||2006-09-30|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|COFRASAanc||Efficacy of Monetary Incentives for Primary Care Physicians on Patients|Efficacy of Monetary Incentives for Primary Care Physicians on Patients' Recruitment|Terminated||N/A|170|Actual|Assistance Publique - Hôpitaux de Paris||2||default inclusion|f||||f||||||||||2018-06-01 02:10:08.169121|2018-06-01 02:10:08.169121
NCT00674024|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2018-05-09|2008-05-06|2008-05-07|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 7, 2008||2008-10-07|January 22, 2013|2013-01-22|January 22, 2013|Actual|2013-01-22|January 22, 2013|Actual|2013-01-22||Interventional|||Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function|A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction|Completed||Phase 1|8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:10:08.261883|2018-06-01 02:10:08.261883
NCT00674011|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2014-05-05|2008-05-06|2008-05-07|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Hypertension in Breast Cancer Patients Receiving Bevacizumab|A Pilot Study of Hypertension in Breast Cancer Patients Receiving Bevacizumab|Terminated|||10|Actual|Dana-Farber Cancer Institute||||Slow accrual|f||||f||||||||||2018-06-01 02:10:08.352566|2018-06-01 02:10:08.352566
NCT00673998|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2008-05-06|2008-05-06|2008-05-07|Estimate|||||||2008-05-06|2008-05-07|Estimate|February 2005||2005-02-28|May 2008|2008-05-31|November 2006|Actual|2006-11-30|March 2006|Actual|2006-03-31||Interventional|||Isokinetic Testing Protocol in Elderly and Young Men|The Effects of Rest Interval on Quadriceps Torque During an Isokinetic Testing Protocol in Elderly and Young Men|Completed||N/A|38|Actual|University of Brasilia|||||f||||f||||||||||2018-06-01 02:10:08.497797|2018-06-01 02:10:08.497797
NCT00673985|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2017-07-12|2008-05-06|2008-05-07|Estimate|||||||2017-07-12|2017-07-14|Actual|July 2004||2004-07-31|July 2017|2017-07-31|October 2010|Actual|2010-10-31|August 2006|Actual|2006-08-31||Interventional|RESILIENT||Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study|A Randomized Study Comparing the Edwards Self-ExpandIng LifeStent Versus Angioplasty-alone In LEsions INvolving The SFA and/or Proximal Popliteal Arter|Completed||N/A|246|Actual|C. R. Bard||2|||f||||t||||||||||2018-06-01 02:10:08.598374|2018-06-01 02:10:08.598374
NCT00673972|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2010-03-08|2008-05-05|2008-05-07|Estimate|||||||2010-03-08|2010-03-10|Estimate|April 2008||2008-04-30|March 2010|2010-03-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome|A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment|Withdrawn||Phase 4|80|Anticipated|National Taiwan University Hospital||2||difficulty in recruiting patients|f||||t||||||||||2018-06-01 02:10:08.680277|2018-06-01 02:10:08.680277
NCT00673959|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2009-09-10||2012-01-31|2008-05-06|2008-05-07|Estimate|2010-02-23|2010-03-10|Estimate||||2012-01-31|2012-02-02|Estimate|December 2007||2007-12-31|January 2012|2012-01-31||||February 2008|Actual|2008-02-29||Interventional|||Acute Comfort of Lubricant Eye Drop FID 111421||Completed||N/A|20|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:10:08.909222|2018-06-01 02:10:08.909222
NCT00673933|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2013-02-14||2013-07-11|2008-05-05|2008-05-07|Estimate|2013-07-11|2013-07-12|Estimate||||2013-07-11|2013-07-12|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris|A Blinded, Randomized, Intra-individual, Vehicle-controlled and Multi-centre Study of Photodynamic Therapy With MAL Cream in Patients With Skin Type V or VI With Acne Vulgaris|Completed||Phase 2|20|Actual|Photocure||2|||f||||f||||||||||2018-06-01 02:10:09.255313|2018-06-01 02:10:09.255313
NCT00673920|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05||2013-06-28|2017-05-10|2008-05-05|2008-05-07|Estimate||||2013-06-28|2013-07-04|Estimate|2017-05-10|2017-05-11|Actual|April 2008|Actual|2008-04-30|May 2017|2017-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|FEATURE||A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy|A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy|Terminated||Phase 3|314|Actual|Genentech, Inc.||3||"Based on analysis of results and consideration of available treatments, the overall benefit to~   risk profile of ocrelizumab was not favorable in RA."|f||||||||||||||2018-06-01 02:10:09.625216|2018-06-01 02:10:09.625216
NCT00673907|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2012-02-01|2008-05-05|2008-05-07|Estimate|||||||2012-02-01|2012-02-02|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Interventional|HIPWOODS||HIPWOODS - Health Effects Related to Exposure to Particle Pollution From Woodburning Stoves|Health Effects Related to Exposure to Particle Pollution From Woodburning|Completed||N/A|20|Actual|University of Aarhus||3|||f||||f||||||||||2018-06-01 02:10:09.689925|2018-06-01 02:10:09.689925
NCT00673894|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2008-06-19|2008-05-06|2008-05-07|Estimate|||||||2008-06-19|2008-06-20|Estimate|April 2008||2008-04-30|June 2008|2008-06-30|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Effects of Glutamine on GLP-1 and Insulin Secretion in Man|Study of the Effects of Glutamine on GLP-1, Insulin Secretion and Glycaemia in Man|Unknown status|Recruiting|Phase 1|20|Anticipated|Garvan Institute of Medical Research|||||f||||f||||||||||2018-06-01 02:10:09.805225|2018-06-01 02:10:09.805225
NCT00673881|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2011-01-24||2011-03-25|2008-05-05|2008-05-07|Estimate|2011-03-25|2011-04-20|Estimate||||2011-03-25|2011-04-20|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study|ABT-335 (Choline Fenofibrate)Reverse Cholesterol Transport (RCT) Study|Completed||Phase 1/Phase 2|25|Actual|Radiant Research||1|||f||||f||||||||||2018-06-01 02:10:09.913691|2018-06-01 02:10:09.913691
NCT00673868|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2017-06-30|2008-05-06|2008-05-07|Estimate|||||||2017-06-30|2017-07-02|Actual|October 2007||2007-10-31|June 2017|2017-06-30|August 6, 2008|Actual|2008-08-06|August 6, 2008|Actual|2008-08-06||Interventional|||Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants|A Phase I-II Randomized Trial to Examine the Clinical, Immunologic and Virologic Effects of CMV Specific CTL When Used for Prophylaxis Against CMV Disease in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants|Completed||Phase 1|2|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-06-01 02:10:10.243264|2018-06-01 02:10:10.243264
NCT00673855|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2009-09-10||2012-01-31|2008-05-06|2008-05-07|Estimate|2010-02-23|2010-03-10|Estimate||||2012-01-31|2012-02-02|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Acute Comfort of Lubricant Eye Drops FID 112903||Completed||N/A|20|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:10:10.330825|2018-06-01 02:10:10.330825
NCT00673842|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2016-07-07|2008-05-01|2008-05-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|January 2019|Anticipated|2019-01-31||Interventional|REFINE-ICD||Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction|Risk Estimation Following Infarction Noninvasive Evaluation - ICD Efficacy|Recruiting||Phase 3|1000|Anticipated|University of Calgary||2|||f||||t||||||||Undecided|uncertain|2018-06-01 02:10:11.550655|2018-06-01 02:10:11.550655
NCT00673829|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2016-06-16|2008-05-05|2008-05-07|Estimate|||||||2016-06-16|2016-06-17|Estimate|May 2008||2008-05-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer|Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer|Suspended||Phase 1|26|Anticipated|Roger Williams Medical Center||2||Funding|f||||t||||||||||2018-06-01 02:10:11.928797|2018-06-01 02:10:11.928797
NCT00673816|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2011-09-27||2011-11-14|2008-05-06|2008-05-07|Estimate|2011-11-14|2011-12-19|Estimate||||2011-11-14|2011-12-19|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|VHL3||Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome|Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome|Terminated||Phase 1/Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)|Early termination of the trial resulted in a small number of participants being analyzed, and Microperimetry (MP-1) results were not accurate for either participant due to fixation issues.|1||Inability to recruit and adequate number of participants|f||||t||||||||||2018-06-01 02:10:12.8864|2018-06-01 02:10:12.8864
NCT00673803|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2010-08-16|2008-05-06|2008-05-07|Estimate|||||||2010-08-16|2010-08-17|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|June 2010|Actual|2010-06-30|July 2009|Actual|2009-07-31||Interventional|||Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification|Influence of Two Sharp-edged Hydrophobic Acrylic Micro-incision-IOLs on Posterior Capsule Opacification. A Randomized, Double-masked Study With Intraindividual Comparison.|Completed||Phase 4|40|Actual|Hospital Hietzing||2|||f||||f||||||||||2018-06-01 02:10:13.22752|2018-06-01 02:10:13.22752
NCT00673790|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2010-09-22|2008-05-01|2008-05-07|Estimate|||||||2010-09-22|2010-09-23|Estimate|May 2008||2008-05-31|September 2010|2010-09-30||||July 2010|Actual|2010-07-31||Interventional|||The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose|Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose|Completed||Phase 4|543|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 02:10:13.351371|2018-06-01 02:10:13.351371
NCT00673777|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-12|2008-05-05|2008-05-07|Estimate|||||||2008-05-12|2008-05-14|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer|Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 1/Phase 2|14|Anticipated|Tokyo University||1|||f||||t||||||||||2018-06-01 02:10:13.681539|2018-06-01 02:10:13.681539
NCT00673738|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2013-09-18||2015-09-23|2008-05-05|2008-05-07|Estimate|2014-01-16|2014-03-04|Estimate||||2015-09-23|2015-10-08|Estimate|April 2008||2008-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|December 2013|Actual|2013-12-31||Interventional|||Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)|Safety and Efficacy (Phase II) Study of Concurrent Cetuximab Plus Conformal Thoracic Radiotherapy in (Poor Prognosis) Patients With Inoperable or Unresectable, Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)|Completed||Phase 2|27|Actual|H. Lee Moffitt Cancer Center and Research Institute|Accrual, and therefore treatment ended earlier than planned due to pulmonary toxicity. Three participants remain on follow-up.|1|||f||||t||||||||||2018-06-01 02:10:14.165485|2018-06-01 02:10:14.165485
NCT00673725|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2014-08-22|2008-05-06|2008-05-07|Estimate|||||||2014-08-22|2014-08-25|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis|A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment|Completed||Phase 4|49|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:10:14.46601|2018-06-01 02:10:14.46601
NCT00673712|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2015-04-03||2017-12-18|2008-05-06|2008-05-07|Estimate|2015-04-16|2015-05-04|Estimate||||2017-12-18|2018-01-19|Actual|April 2008||2008-04-30|April 2015|2015-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Multicenter Infection Surveillance Study Following Open Heart Surgery|Phase 4 Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures|Completed||Phase 4|647|Actual|Halyard Health||2|||f||||f||||||||||2018-06-01 02:10:14.556712|2018-06-01 02:10:14.556712
NCT00673699|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-05|2008-05-05|2008-05-07|Estimate|||||||2008-05-05|2008-05-07|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|February 2009|Anticipated|2009-02-28|January 2009|Anticipated|2009-01-31||Observational|||The Role of Narrow-Band Imaging Endoscopy in Diagnosing Gastric Intestinal Metaplasia|Observational: Studies in Human Beings Health Outcomes|Unknown status|Not yet recruiting||70|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||Samples Without DNA|"~     Gastric mucosal biopsy during upper gastrointestinal endoscopy~   "|||2018-06-01 02:10:14.970062|2018-06-01 02:10:14.970062
NCT00673686|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2014-10-10|2008-05-06|2008-05-07|Estimate|||||||2014-10-10|2014-10-13|Estimate|May 2004||2004-05-31|October 2014|2014-10-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D|Single Center, Double-blind, Randomized Study to Compare the Effect of SH T 00186 D on Follicular Development in a 24-day Regimen Versus a 21-day Regimen in Healthy Female Volunteers|Completed||Phase 2|105|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:10:15.189294|2018-06-01 02:10:15.189294
NCT00673673|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2014-05-13||2015-01-21|2008-05-05|2008-05-07|Estimate|2014-06-12|2014-07-14|Estimate||||2015-01-21|2015-02-04|Estimate|May 2008||2008-05-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|May 2013|Actual|2013-05-31||Interventional|||FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer|Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer|Completed||Phase 2|39|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:10:15.289314|2018-06-01 02:10:15.289314
NCT00673660|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2010-10-06||2010-11-05|2008-05-01|2008-05-07|Estimate|2010-10-06|2010-11-04|Estimate||||2010-11-05|2010-11-17|Estimate|October 2007||2007-10-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels|Assessment Of Statin Treatment Compliance In Dyslipidemia Patients: An Observational Study|Completed|||375|Actual|Pfizer|The registered endpoint - observing reasons of compliance or non-compliance to statin treatment - was separated into outcome measure 6 and 7 because observing reasons for compliance with statin treatment were not collected or analyzed.||1||f||||f||||||None Retained|"~     No biospecimen is retained~   "|||2018-06-01 02:10:15.529609|2018-06-01 02:10:15.529609
NCT00673647|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2009-08-25|2008-05-06|2008-05-07|Estimate|||||||2009-08-25|2009-08-26|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|CANDIS-II||CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS|Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II)|Unknown status|Active, not recruiting|Phase 3|450|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-06-01 02:10:15.933588|2018-06-01 02:10:15.933588
NCT00673634|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-06-10|2008-05-06|2008-05-07|Estimate|||||||2008-06-10|2008-06-12|Estimate|March 2008||2008-03-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficiency of Preoxygenation in Obese Patients: Pressure Assisted Versus Traditional Method|Efficiency of Preoxygenation in Obese Patients: Evaluation of Traditional Method Versus Pressure Assisted Preoxygenation.|Completed||N/A|30|Actual|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-06-01 02:10:16.035317|2018-06-01 02:10:16.035317
NCT00673621|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2012-06-12|2008-05-05|2008-05-07|Estimate|||||||2012-06-12|2012-06-13|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics|A Phase 1, Open-Label, Controlled Clinical Trial to Evaluate Pharmacokinetics After Administration of Technosphere® Insulin Inhalation Powder Alone and With Salbutamol (Albuterol) and/or After Methacholine Challenge Testing in Subjects With Asthma Versus Matched Healthy Subjects Without Asthma|Completed||Phase 1|30|Actual|Mannkind Corporation||1|||f||||||||||||||2018-06-01 02:10:16.114655|2018-06-01 02:10:16.114655
NCT00673608|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2017-02-20|2008-05-06|2008-05-07|Estimate|||||||2017-02-20|2017-02-23|Actual|November 2007||2007-11-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload|A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study)|Completed||Phase 4|118|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:10:16.213657|2018-06-01 02:10:16.213657
NCT00673595|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2012-02-21||2012-02-21|2008-05-06|2008-05-07|Estimate|2012-02-21|2012-03-16|Estimate||||2012-02-21|2012-03-16|Estimate|March 2007||2007-03-31|February 2012|2012-02-29|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional|||Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo|Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo|Terminated||N/A|19|Actual|Mayo Clinic|This study was terminated early due to difficulty with recruiting subjects and with subjects complying with the protocol.|2||Difficulty with recruiting sujects and subjects complying with the protocol|f||||t||||||||||2018-06-01 02:10:16.314245|2018-06-01 02:10:16.314245
NCT00673582|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2009-08-24|2008-05-06|2008-05-07|Estimate|||||||2009-08-24|2009-08-25|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients|Randomized, Multicentre, Double- Blind, Placebo Controlled Trial of Rosuvastatin 10 mg for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Ultrasound in HIV-positive Patients Treated With Antiretrovirals|Terminated||Phase 4|250|Anticipated|University of British Columbia||2||Sponsor has withdrawn the funding|f||||t||||||||||2018-06-01 02:10:16.624187|2018-06-01 02:10:16.624187
NCT00673569|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2010-08-05|2008-05-06|2008-05-07|Estimate|||||||2010-08-05|2010-08-09|Estimate|September 2006||2006-09-30|August 2010|2010-08-31||||July 2007|Actual|2007-07-31||Interventional|||Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment|A Phase II Single-Arm Trial Assessing the Use of an Ex Vivo Sensitivity Assay to Predict Response of Relapsed Metastatic Non-Small Cell Lung Cancer Patients to Erlotinib|Completed||Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 02:10:16.747833|2018-06-01 02:10:16.747833
NCT00673556|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2014-08-25|2008-05-06|2008-05-07|Estimate|||||||2014-08-25|2014-08-26|Estimate|October 2003||2003-10-31|August 2014|2014-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate|A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study Examining the Efficacy and Safety of Weekly Intramuscular Administration of 15mg Alefacept Over 12 Weeks in a Population of Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate|Completed||Phase 3|195|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 02:10:16.854837|2018-06-01 02:10:16.854837
NCT00673543|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2017-05-09|2008-05-05|2008-05-07|Estimate|||||||2017-05-09|2017-05-11|Actual|May 2008||2008-05-31|May 2017|2017-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Corticosteroid Therapy on Glucose Control in Pregnant Women With Diabetes|The Effects of Corticosteroid Therapy on Glucose Control in Pregnant Women With Insulin Requiring Diabetes Mellitus|Completed|||16|Actual|The University of Texas Health Science Center, Houston|||2||f||||f||||||||||2018-06-01 02:10:16.962393|2018-06-01 02:10:16.962393
NCT00673530|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2016-03-07|2008-05-06|2008-05-07|Estimate|||||||2016-03-07|2016-03-08|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|NUTRICORE||Clinical Nutrition Concept for Hospitalized Patients With Malnutrition|Effect of an Evidence Based Clinical Nutrition Concept on Clinical Outcomes in Hospitalized Patients With Malnutrition When Severity of Disease is Taken Into Consideration|Completed||N/A|10242|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:10:17.022479|2018-06-01 02:10:17.022479
NCT00673517|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-11-14|2008-05-05|2008-05-07|Estimate|||||||2008-11-14|2008-11-17|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||The Effect of High Frequency Oscillation on Biological Markers of Lung Injury|The Effect of High Frequency Oscillation on Biological Markers of Ventilator Induced Lung Injury (VILI): Nested Translational Biology Sub-Study of the OSCILLATE Pilot Study|Completed|||20|Anticipated|St. Michael's Hospital, Toronto|||2||f||||f||||||Samples With DNA|"~     Known biomarkers: IL6, IL8, IL10, IL-1Beta, ICAM-1, TGFBeta, Chemokine ligand 10, FGFBeta,~     VEGF, and INFGamma Novel biomarkers: ACE, surfactant protein D, clara cell protetin, von~     Willerbrand Facotr, Ang1, Ang2, and TF, PCIII, neuropeptide Y, PBEF, APCRc, and PAI-1~   "|||2018-06-01 02:10:17.191447|2018-06-01 02:10:17.191447
NCT00673504|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2011-11-30|2008-05-06|2008-05-07|Estimate|||||||2011-11-30|2011-12-01|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer|Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer|Completed||Phase 2|105|Actual|Central European Society for Anticancer Drug Research||2|||f||||f||||||||||2018-06-01 02:10:17.270404|2018-06-01 02:10:17.270404
NCT00673491|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-06|2008-05-06|2008-05-07|Estimate|||||||2008-05-06|2008-05-07|Estimate|July 2005||2005-07-31|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Clinical Pathways for Effective and Appropriate Care|Diffusion of Clinical Pathways for the Implementation of Effective and Appropriate Care|Completed||N/A|448|Actual|Agenzia Regionale Sanitaria delle Marche||2|||f||||t||||||||||2018-06-01 02:10:17.416815|2018-06-01 02:10:17.416815
NCT00673478|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06||2014-04-30|2014-04-30|2008-05-06|2008-05-07|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|May 2008||2008-05-31|April 2014|2014-04-30||||June 2009|Actual|2009-06-30||Interventional|||Tiotropium and Salmeterol PK Study in COPD Patients|A Randomised, Open-label, 4-way Crossover Study to Characterize the Pharmacokinetics, Safety and Efficacy of FDC Tiotropium/Salmeterol, Tiotropium, Salmeterol and a Free Combination of Tiotropium Plus Salmeterol Following 4-week Treatment Periods in Patients With COPD.|Completed||Phase 3|50|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:10:17.494768|2018-06-01 02:10:17.494768
NCT00673465|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2016-10-13||2017-03-21|2008-05-05|2008-05-07|Estimate|2016-12-22|2017-02-15|Actual||||2017-03-21|2017-04-18|Actual|April 2008||2008-04-30|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||All treated participants.|Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)|A Randomized, Placebo-controlled, Three-Way Crossover Study to Evaluate the Effect of SCH 497079 on Metabolic Parameters and to Determine the Influence of Race/Ethnic Origin on Therapeutic Response|Completed||Phase 1|17|Actual|Merck Sharp & Dohme Corp.|Part 2 of the study was not conducted. Part 2 of the study was to be conducted if the analysis of Part 1 indicated a clinically significant decrease in blood glucose in participants type 2 diabetes mellitus compared to placebo.|6|||f||||f||||||||||2018-06-01 02:10:17.623105|2018-06-01 02:10:17.623105
NCT00673452|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2010-04-14||2010-05-28|2008-05-06|2008-05-07|Estimate|2010-05-28|2010-06-24|Estimate||||2010-05-28|2010-06-24|Estimate|June 2008||2008-06-30|May 2010|2010-05-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia|Flexible Dosed Duloxetine Versus Placebo in the Treatment of Fibromyalgia|Completed||Phase 4|530|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:10:18.353241|2018-06-01 02:10:18.353241
NCT00673439|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2013-05-03||2018-03-01|2008-05-06|2008-05-07|Estimate|2013-05-03|2013-06-24|Estimate||||2018-03-01|2018-03-29|Actual|November 2007||2007-11-30|March 2018|2018-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)|A Phase II Trial Using Fondaparinux in Patients With Confirmed or Suspected Heparin-Induced Thrombocytopenia (HIT)|Terminated||Phase 2|3|Actual|University of Louisville|Study terminated, results data not available|||study terminated due to low accrual|f||||t||||||||||2018-06-01 02:10:19.537711|2018-06-01 02:10:19.537711
NCT00673426|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-06|2008-05-06|2008-05-07|Estimate|||||||2008-05-06|2008-05-07|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|Enoxaparin||Safety Evaluation of Use Sodic Enoxaparin|Safety Evaluation of Use Sodic Enoxaparin Produced by the Laboratory Blausiegel When Compared With Product Clexane of Sanofi-Aventis Ltda in Chronic Renal Desease Patients.|Completed||Phase 3|60|Actual|Azidus Brasil||1|||f||||f||||||||||2018-06-01 02:10:19.693306|2018-06-01 02:10:19.693306
NCT00673413|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-05|2008-05-05|2008-05-07|Estimate|||||||2008-05-05|2008-05-07|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||The Perception of the Estomy-Individual Regarding of Its Situation|The Perception of the Estomy-Individual Regarding of Its Situation|Completed|||||Universidade da Regiao da Campanha|||||f||||f||||||||||2018-06-01 02:10:19.763133|2018-06-01 02:10:19.763133
NCT00673400|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2012-07-16||2012-10-01|2008-05-06|2008-05-07|Estimate|2012-10-01|2012-10-02|Estimate||||2012-10-01|2012-10-02|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|STARR||Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM|Morbidity and Functional Outcome of Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM in Obstructed Defecation|Completed||N/A|52|Actual|Cantonal Hospital of St. Gallen||1|||f||||f||||||||||2018-06-01 02:10:19.841763|2018-06-01 02:10:19.841763
NCT00673387|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2013-08-12|2010-08-13|2015-03-26|2008-05-06|2008-05-07|Estimate|2013-11-13|2013-11-14|Estimate|2011-09-29|2011-10-05|Estimate|2015-03-26|2015-04-15|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional||Intent to treat population. All participants randomized to a treatment and received at least 1 dose. Drug Randomization stratified:sex,3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total:8 treatment groups).|Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects.|Completed||Phase 2|636|Actual|AstraZeneca|Drug Randomization stratified:sex,3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total:8 treatment groups).|8|||f||||f||||||||||2018-06-01 02:10:20.231901|2018-06-01 02:10:20.231901
NCT00673374|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2014-02-23|2008-05-04|2008-05-07|Estimate|||||||2014-02-23|2014-02-25|Estimate|May 2008||2008-05-31|February 2014|2014-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients|Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients|Completed|||102|Actual|Duke University|||1||f||||f||||||||||2018-06-01 02:10:22.498728|2018-06-01 02:10:22.498728
NCT00673361|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|2013-03-20||2016-01-11|2008-05-04|2008-05-07|Estimate|2013-03-20|2013-04-26|Estimate||||2016-01-11|2016-01-13|Estimate|March 2007||2007-03-31|December 2012|2012-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||"Pilot Trial of Chemo-Switch Regimen to Treat Advanced Melanoma"|"Phase II Pilot Trial of Chemo-Switch Regimen of Biochemotherapy Followed by Daily Low-Dose Temozolomide Plus Sorafenib in Advanced Melanoma"|Terminated||Phase 2|9|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:10:22.5821|2018-06-01 02:10:22.5821
NCT00673348|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-07-22|2008-05-06|2008-05-07|Estimate|||||||2008-07-22|2008-07-24|Estimate|May 2008||2008-05-31|June 2008|2008-06-30|April 2010|Anticipated|2010-04-30|April 2009|Anticipated|2009-04-30||Observational|||Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations|A Prospective Observational Study of Plasma Voriconazole Concentration Measurement and Its Correlation With CYP2C19 Genotype in Korean Patients|Unknown status|Recruiting||40|Anticipated|The Catholic University of Korea|||1||f||||f||||||Samples With DNA|"~     -  Two times of venous blood sampling will be carried out at steady state. Three ml of~          venous blood is sampled right before the morning dose (trough sampling). The second~          sampling is carried out at any time point within 2-4 hours after the morning dose (peak~          sampling). To obtain the exact dose and sampling history, at least three dosing times~          around the trough and peak sampling will be recorded to the minute. Sampling time will~          also be recorded as clock time.~        -  Genotyping of CYP2C19 will also be performed using 3 ml of peripheral blood sampled into~          EDTA tubes.~   "|||2018-06-01 02:10:22.75571|2018-06-01 02:10:22.75571
NCT00673335|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2017-05-03|2008-05-06|2008-05-07|Estimate|||||||2017-05-03|2017-05-04|Actual|May 2008||2008-05-31|May 2017|2017-05-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|LIBER||Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation|Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation|Active, not recruiting||Phase 3|386|Anticipated|UNICANCER||2|||f||||f||||||||||2018-06-01 02:10:22.843398|2018-06-01 02:10:22.843398
NCT00673322|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2016-06-16|2008-05-05|2008-05-07|Estimate|||||||2016-06-16|2016-06-17|Estimate|May 2008||2008-05-31|June 2016|2016-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Trial of Second Generation Designer T Cells in Colorectal Carcinoma|Phase II/Pilot Trial of Second Generation Designer T Cells in Colorectal Cancer|Terminated||Phase 1|1|Actual|Roger Williams Medical Center||1||This study will be incorporated into another study.|f||||t||||||||||2018-06-01 02:10:22.957295|2018-06-01 02:10:22.957295
NCT00673309|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-05-04|2008-05-05|2008-05-07|Estimate|||||||2012-05-04|2012-05-07|Estimate|July 2002||2002-07-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Assessment of Mechanisms of Improved Wound Healing|Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients|Completed||Phase 2/Phase 3|644|Actual|The University of Texas Medical Branch, Galveston||13|||f||||t||||||||||2018-06-01 02:10:23.048988|2018-06-01 02:10:23.048988
NCT00673296|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-05|2008-05-05|2008-05-07|Estimate|||||||2008-05-05|2008-05-07|Estimate|January 2007||2007-01-31|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation|Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation|Unknown status|Active, not recruiting|N/A|6|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 02:10:23.220452|2018-06-01 02:10:23.220452
NCT00673283|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2014-07-31|2008-05-04|2008-05-07|Estimate|||||||2014-07-31|2014-08-01|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging|Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging|Completed||Early Phase 1|86|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:10:23.307153|2018-06-01 02:10:23.307153
NCT00673270|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2012-03-01|2008-05-05|2008-05-07|Estimate|||||||2012-03-01|2012-03-02|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|AFLUCO2||Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression|Hemodynamic and Biological Effects of Fludrocortisone and Hydrocortisone, in Healthy Volunteers With Aldosterone Induced Suppression|Terminated||Phase 1/Phase 2|13|Actual|Rennes University Hospital||4|||f||||f||||||||||2018-06-01 02:10:23.403102|2018-06-01 02:10:23.403102
NCT00673257|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2013-10-08||2016-09-06|2008-05-06|2008-05-07|Estimate|2014-08-07|2014-08-11|Estimate||||2016-09-06|2016-09-08|Estimate|January 2007||2007-01-31|September 2016|2016-09-30||||July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetics of Daunorubicin in Treating Young Patients With Cancer|Pharmacokinetics of Daunomycin in Children|Active, not recruiting||N/A|107|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 02:10:23.486009|2018-06-01 02:10:23.486009
NCT00673244|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-02-18|2008-05-05|2008-05-07|Estimate|||||||2014-02-18|2014-02-19|Estimate|April 2008||2008-04-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|AKI||Protocol to Assess the Severity of Acute Kidney Injury|Protocol to Assess the Severity of Acute Kidney Injury|Completed||N/A|44|Actual|George Washington University||1|||f||||f||||||||||2018-06-01 02:10:23.781086|2018-06-01 02:10:23.781086
NCT00673231|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2013-01-21||2013-09-25|2008-05-06|2008-05-07|Estimate|2013-07-19|2013-08-23|Estimate||||2013-09-25|2013-10-29|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|January 2011|Actual|2011-01-31|May 2009|Actual|2009-05-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin|A 24-week International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Patients With Type 2 Diabetes With Inadequate Glycaemic Control on Insulin|Completed||Phase 3|1240|Actual|AstraZeneca|For participants who did not complete 24 weeks LOCF (last observation carried forward) was used. Only values prior to insulin up-titration were used for outcome measures except for mean daily insulin dose which was evaluated regardless of.|4|||f||||f||||||||||2018-06-01 02:10:24.026735|2018-06-01 02:10:24.026735
NCT00673218|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2012-07-03|2008-05-06|2008-05-07|Estimate|||||||2012-07-03|2012-07-06|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils|The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils|Unknown status|Active, not recruiting|Phase 4|25|Anticipated|Creighton University||2|||f||||f||||||||||2018-06-01 02:10:25.042857|2018-06-01 02:10:25.042857
NCT00673205|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2010-12-09|2008-05-06|2008-05-07|Estimate|||||||2010-12-09|2010-12-10|Estimate|September 1995||1995-09-30|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Capri||(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer|A Randomized, Double-Blind, Parallel-Group Trial Comparing Bicalutamide (Casodex) 150mg Once Daily With Placebo in Patients With Non-metastatic Prostate Cancer|Completed||Phase 3|3588|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:10:25.165447|2018-06-01 02:10:25.165447
NCT00673192|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2008-05-06|2008-05-06|2008-05-07|Estimate|||||||2008-05-06|2008-05-07|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|December 2008|Anticipated|2008-12-31|January 2008|Anticipated|2008-01-31||Interventional|||Evaluation of ELISA Assay on Human Papilloma Viruses (HPV) Infection Population|Evaluation of ELISA Assay on HPV Infection Population|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 02:10:25.417568|2018-06-01 02:10:25.417568
NCT00673179|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2013-06-12||2014-09-03|2008-05-06|2008-05-07|Estimate|2014-09-03|2014-09-10|Estimate||||2014-09-03|2014-09-10|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy|Outpatient Chemotherapy in Pediatric Osteosarcoma: Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy|Terminated||N/A|7|Actual|M.D. Anderson Cancer Center|Study could not meet accrual goal due to logistical considerations, terminated early.|2||Low accrual.|f||||f||||||||||2018-06-01 02:10:25.502645|2018-06-01 02:10:25.502645
NCT00673166|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2017-01-25|2008-05-06|2008-05-07|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Local Mechanisms for Staff Motivation to Reduce Hospital Mortality|Evaluation of Local Mechanisms for Staff Motivation to Improve Treatment and Reduce Mortality Due to Malaria at the Paediatric Ward|Completed||N/A|900|Actual|London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-06-01 02:10:25.758082|2018-06-01 02:10:25.758082
NCT00673153|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|2017-03-15||2017-05-30|2008-05-06|2008-05-07|Estimate|2017-05-30|2017-06-01|Actual||||2017-05-30|2017-06-01|Actual|March 2008||2008-03-31|May 2017|2017-05-31||||August 2010|Actual|2010-08-31||Interventional|||Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia|Terminated||Phase 2|31|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||No||2018-06-01 02:10:25.846255|2018-06-01 02:10:25.846255
NCT00673140|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2009-08-14|2008-05-06|2008-05-07|Estimate|||||||2009-08-14|2009-08-17|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|June 2010|Anticipated|2010-06-30|May 2010|Anticipated|2010-05-31||Interventional|||Far Infrared Irradiation for Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS)|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Control, Management and Treatment of Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease|Unknown status|Active, not recruiting|Phase 1|7|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:10:26.104272|2018-06-01 02:10:26.104272
NCT00673127|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2013-07-09||2015-04-20|2008-05-05|2008-05-07|Estimate|2015-04-20|2015-04-22|Estimate||||2015-04-20|2015-04-22|Estimate|February 2005||2005-02-28|April 2015|2015-04-30|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|KHAD||Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer|A Phase II Trial of Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer|Completed||Phase 2|57|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 02:10:26.189707|2018-06-01 02:10:26.189707
NCT00671892|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2013-07-15|2008-05-02|2008-05-05|Estimate|||||||2013-07-15|2013-07-16|Estimate|September 2001||2001-09-30|July 2013|2013-07-31|April 2008|Actual|2008-04-30|August 2006|Actual|2006-08-31||Interventional|||Role of TLR4 in Environmental Asthma|Role of TLR4 in Environmental Asthma|Completed||Phase 1|855|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:10:48.671405|2018-06-01 02:10:48.671405
NCT00673114|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-05-08||2015-03-16|2008-05-04|2008-05-07|Estimate|2013-11-05|2013-12-24|Estimate||||2015-03-16|2015-04-03|Estimate|August 2007||2007-08-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies|A Prospective, Phase I/II Trial Determining the Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Banked Unrelated Umbilical Cord Blood Supplemented With Related, Haplo-Identical T-Cell Depleted Stem Cells in Subjects With High Risk Malignancies|Completed||Phase 1/Phase 2|3|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:10:26.48539|2018-06-01 02:10:26.48539
NCT00673101|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2017-01-23|2008-05-06|2008-05-07|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2006||2006-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|Methoscan||Prospective Evaluation of FibroScan in Patients Treated With Methotrexate|Evaluation of Liver Fibrosis Using FibroScan and Non-invasive Biochemical Markers in Patients Treated With Methotrexate|Recruiting|||500|Anticipated|Association HGE CHU Bordeaux Sud|||||f||||f||||||||||2018-06-01 02:10:26.703072|2018-06-01 02:10:26.703072
NCT00673088|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2018-01-19|2008-05-06|2008-05-07|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2004||2004-02-29|January 2018|2018-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:10:26.765159|2018-06-01 02:10:26.765159
NCT00673075|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2010-09-02||2010-09-02|2008-05-01|2008-05-07|Estimate|2010-09-02|2010-09-28|Estimate||||2010-09-02|2010-09-28|Estimate|May 2008||2008-05-31|September 2010|2010-09-30||||September 2009|Actual|2009-09-30||Interventional|||The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease|Efficacy and Tolerability of Nebivolol Compared With Carvedilol in Patients With Coronary Artery Disease and Stage I or II Hypertension|Completed||Phase 4|39|Actual|Forest Laboratories|The study was terminated early because of difficulties with enrollment. Only 39 out of 160 planned patients were randomized.|2|||f||||f||||||||||2018-06-01 02:10:26.8421|2018-06-01 02:10:26.8421
NCT00673062|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05||2009-04-14|2015-10-08|2008-05-05|2008-05-07|Estimate||||2009-10-16|2009-10-20|Estimate|2015-10-08|2015-11-02|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)|Study of the Decongestant Effect of SCH 900538 Compared With Placebo and Pseudoephedrine as Active Control in Subjects With Seasonal Allergic Rhinitis (SAR) Exposed to Pollen in an Environmental Exposure Unit|Completed||Phase 2|265|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 02:10:27.375009|2018-06-01 02:10:27.375009
NCT00673049|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|2013-04-26|2011-04-22|2013-07-22|2008-05-05|2008-05-07|Estimate|2013-07-22|2013-07-24|Estimate|2011-06-17|2011-06-28|Estimate|2013-07-22|2013-07-24|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|NSCLC||Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer|Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology|Terminated||Phase 3|583|Actual|Pfizer||2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 02:10:27.620944|2018-06-01 02:10:27.620944
NCT00673036|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2017-01-24|2008-05-05|2008-05-07|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2005||2005-10-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31||Observational|Fast-MI||French Registry of Acute Coronary Syndrome|French Registry of Acute Coronary Syndrome With or Without ST Elevation|Active, not recruiting|||3750|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum and DNA~   "|||2018-06-01 02:10:29.833605|2018-06-01 02:10:29.833605
NCT00673023|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2008-05-04|2008-05-04|2008-05-07|Estimate|||||||2008-05-04|2008-05-07|Estimate|October 2007||2007-10-31|May 2008|2008-05-31||||December 2007|Actual|2007-12-31||Interventional|||Study the Role of Genetic Variation in the Determining Lipid Profile Response to Dietary Change|Study the Role of Polymorphism at the CETP Gene Locuse in the Determining Lipid Profile Response to Dietary Change|Completed||N/A|102|Actual|Tabriz University||3|||f||||t||||||||||2018-06-01 02:10:29.924782|2018-06-01 02:10:29.924782
NCT00673010|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-06|||2018-02-23|2008-05-06|2008-05-07|Estimate|||||||2018-02-23|2018-02-26|Actual|March 2005||2005-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma|Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma|Active, not recruiting||Phase 1|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:10:29.983303|2018-06-01 02:10:29.983303
NCT00672997|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02||2014-07-10|2014-07-14|2008-05-02|2008-05-06|Estimate||||2014-07-10|2014-07-14|Estimate|2014-07-14|2014-07-16|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Six-Week, Multi-Center, Double-Masked, Safety and Efficacy Study of Travoprost 0.004%/Timolol 0.5% BAC-free Compared to Travoprost 0.004%/Timolol 0.5% in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|301|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:10:30.053861|2018-06-01 02:10:30.053861
NCT00672984|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2009-09-23||2017-02-13|2008-05-05|2008-05-06|Estimate|2009-11-13|2009-12-21|Estimate||||2017-02-13|2017-03-20|Actual|April 2008||2008-04-30|February 2017|2017-02-28|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Guanfacine Immediate-release Electrocardiogram Results (QTc) Study|A Phase I, Randomized, Gender Stratified, Double-Blind, Placebo- and Positive-Controlled, Three Period Crossover Trial to Assess the Effect of Guanfacine Hydrochloride on QT/QTc Interval in Healthy Men and Women|Completed||Phase 1|83|Actual|Shire||3|||f||||||||||||||2018-06-01 02:10:30.133133|2018-06-01 02:10:30.133133
NCT00672971|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2008-05-05|2008-05-05|2008-05-06|Estimate|||||||2008-05-05|2008-05-06|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice|An Open Label Randomized Study to Compare the Safety and Efficacy of Silcap Plus (Approximately 4% Dimeticone) Against Nix Cream Rinse.|Completed||N/A|31|Actual|Oystershell NV||2|||f||||f||||||||||2018-06-01 02:10:31.772752|2018-06-01 02:10:31.772752
NCT00672958|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2013-04-19||2013-10-24|2008-05-05|2008-05-06|Estimate|2013-10-24|2013-12-13|Estimate||||2013-10-24|2013-12-13|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults With Major Depressive Disorder|Completed||Phase 3|600|Actual|Takeda||2|||f||||f||||||||||2018-06-01 02:10:31.900822|2018-06-01 02:10:31.900822
NCT00672945|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2009-07-28|2008-05-05|2008-05-06|Estimate|||||||2009-07-28|2009-07-30|Estimate|April 2008||2008-04-30|July 2009|2009-07-31||||January 2010|Anticipated|2010-01-31||Interventional|||A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil|Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil|Terminated||Phase 2|420|Anticipated|Epix Pharmaceuticals, Inc.||2|||f||||||||||||||2018-06-01 02:10:33.570235|2018-06-01 02:10:33.570235
NCT00672932|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2012-06-18||2013-05-29|2008-05-02|2008-05-06|Estimate|2013-05-29|2013-07-05|Estimate||||2013-05-29|2013-07-05|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Interventional|||Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients|Pilot Study of Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients|Completed||N/A|18|Actual|University of California, San Francisco|The underlying hypothesis might not have actually been addressed because of the particular makeup of the subject group with minimal CNS infection and immunoactivation that left little room to discern a therapeutic effect.|2|||f||||f||||||||||2018-06-01 02:10:33.8062|2018-06-01 02:10:33.8062
NCT00672919|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2012-02-27|2008-05-02|2008-05-06|Estimate|||||||2012-02-27|2012-02-28|Estimate|November 2003||2003-11-30|February 2012|2012-02-29|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|COMPLEMENT||Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.|A Single-Arm, Open-Label, Multicenter Study Evaluating the Triglyceride Changes in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia Following Treatment Conversion From Rosiglitazone to Pioglitazone HCl in Combination With Stable Statin Therapy|Completed||Phase 4|305|Actual|Takeda||1|||f||||f||||||||||2018-06-01 02:10:34.132399|2018-06-01 02:10:34.132399
NCT00672906|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2014-09-12|2008-05-04|2008-05-06|Estimate|||||||2014-09-12|2014-09-16|Estimate|July 2005||2005-07-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GPT-AN||Group Parent Training for Adolescent Eating Disorders|Group Parent Training for Adolescent Eating Disorders|Completed||N/A|124|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:10:34.290576|2018-06-01 02:10:34.290576
NCT00672893|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2009-06-15|2008-05-05|2008-05-06|Estimate|||||||2009-06-15|2009-06-16|Estimate|February 2006||2006-02-28|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Vibration Response Imaging (VRI) in Patients That Are Undergoing Pulmonary Interventional Procedure|Vibration Response Imaging (VRI) in Patients That Are Undergoing Pulmonary Interventional Procedure|Completed|||200|Anticipated|Deep Breeze|||1||f||||f||||||||||2018-06-01 02:10:34.362615|2018-06-01 02:10:34.362615
NCT00672880|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2015-03-24|2008-05-05|2008-05-06|Estimate|||||||2015-03-24|2015-03-26|Estimate|October 2003||2003-10-31|March 2015|2015-03-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|Low Back Pain||Self System Therapy and Chronic Low Back Pain Trial|The Use of Self-System Therapy to Alter Self-Discrepancies in Chronic Low Back Pain Patients|Completed||Phase 4|137|Actual|Duke University||3|||f||||t||||||||||2018-06-01 02:10:34.465129|2018-06-01 02:10:34.465129
NCT00672867|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2014-12-17|2008-05-02|2008-05-06|Estimate|||||||2014-12-17|2014-12-18|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|September 2014|Actual|2014-09-30|November 2012|Actual|2012-11-30||Interventional|||A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B|A Open Randomized Clinical Trial Comparing the Efficacy and Safety of Clevudine 30mg Versus Adefovir 10mg in Patients With LC-B|Completed||Phase 3|102|Anticipated|Bukwang Pharmaceutical||2|||f||||||||||||||2018-06-01 02:10:34.55274|2018-06-01 02:10:34.55274
NCT00672854|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2014-07-02||2014-07-02|2008-05-05|2008-05-06|Estimate|2014-07-02|2014-08-01|Estimate||||2014-07-02|2014-08-01|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|TPN 2||Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in Intensive Care Unit Patients|StudyComparing a Soybean Oil-Based vs Olive Oil-Based Lipid Emulsion: Effects on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function,Insulin Sensitivity and Carb Metabolism Intensive Care Unit Patients|Completed||Phase 2/Phase 3|100|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:10:34.633863|2018-06-01 02:10:34.633863
NCT00672841|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|2012-02-21||2015-01-20|2008-05-05|2008-05-06|Estimate|2013-03-13|2013-04-22|Estimate||||2015-01-20|2015-02-06|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients|Randomized Comparison of β-D-Glucan Surveillance With Preemptive Anidulafungin Versus Standard Care for the Management of Invasive Candidiasis in Surgical Intensive Care Unit Patients|Completed||N/A|64|Actual|Duke University|This study represents a 1st attempt at preemptive antifungal therapy based on the fungal biomarker 1,3-Beta-D-Glucan in the intensive care unit. Main limitation: the small number of subjects with proven/probable invasive candidiasis.|2|||f||||t||||||||||2018-06-01 02:10:34.975323|2018-06-01 02:10:34.975323
NCT00672828|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-03|||2013-08-16|2008-05-03|2008-05-06|Estimate|||||||2013-08-16|2013-08-20|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|PACT||Interactive Computer Program or Brochure in Increasing Colorectal Cancer Screening Among African Americans|Promoting Colon Cancer Screening Among African Americans|Completed||N/A|693|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 02:10:35.388631|2018-06-01 02:10:35.388631
NCT00672815|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2010-01-20|2008-05-02|2008-05-06|Estimate|||||||2010-01-20|2010-01-21|Estimate|April 2006||2006-04-30|January 2010|2010-01-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Observational|TXSB42||The Impact of Texas Senate Bill 42 on Middle School Children's Level of Physical Activity|The Impact of Texas Senate Bill 42 on Middle School Children's Level of Physical Activity|Completed|||141|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-06-01 02:10:35.497392|2018-06-01 02:10:35.497392
NCT00672802|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2012-02-27|2008-05-05|2008-05-06|Estimate|||||||2012-02-27|2012-02-28|Estimate|August 2003||2003-08-31|February 2012|2012-02-29|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease|A Phase II Safety Study of TAK-375 in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease|Completed||Phase 2|26|Actual|Takeda||1|||f||||f||||||||||2018-06-01 02:10:35.581356|2018-06-01 02:10:35.581356
NCT00672789|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2013-05-24|2008-05-04|2008-05-06|Estimate|||||||2013-05-24|2013-05-27|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Adherence to Hydroxyurea in Children With Sickle Cell Anemia|Adherence to Hydroxyurea in Children With Sickle Cell Anemia|Completed||N/A|31|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:10:35.726788|2018-06-01 02:10:35.726788
NCT00672776|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2017-02-28|2008-05-05|2008-05-06|Estimate|||||||2017-02-28|2017-03-01|Actual|May 2003||2003-05-31|February 2017|2017-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD)|Effects of Paxil CR on Neural Circuits in PTSD|Completed||Phase 4|40|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:10:35.813994|2018-06-01 02:10:35.813994
NCT00672763|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-06-03|2008-05-05|2008-05-06|Estimate|||||||2015-06-03|2015-06-08|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|IBDVit1||Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease|The Immunomodulatory Role of Vitamin D in Inflammatory Bowel Disease (The IBDVit Study): Double-Blind, Placebo-Controlled Trial of Adjuvant Vitamin D (Colecalciferol) With Corticosteroids in Active Crohn's Disease|Withdrawn||Phase 4|0|Actual|Imperial College London||2||Unable to recruit adequate trial participants|f||||t||||||||||2018-06-01 02:10:35.886136|2018-06-01 02:10:35.886136
NCT00672750|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2017-01-24|2008-05-05|2008-05-06|Estimate|||||||2017-01-24|2017-01-26|Estimate|February 2008||2008-02-29|January 2017|2017-01-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Observational|retromyo||A Retrospective Review Of Outcomes Following Laparoscopic Myomectomy|A Retrospective Review Of Outcomes Following Laparoscopic Myomectomy|Terminated|||70|Actual|The Advanced Gynecologic Surgery Institute|||1|did not have resources to continue this study|f||||f||||||||||2018-06-01 02:10:35.992305|2018-06-01 02:10:35.992305
NCT00672737|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2016-10-15||2017-04-25|2008-05-05|2008-05-06|Estimate|2017-04-25|2017-08-07|Actual||||2017-04-25|2017-08-07|Actual|February 2008||2008-02-29|January 2017|2017-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational||56 volunteers signed informed consent; 3 of withdrew before participation in any procedure. The remaining 53 who underwent a polysomnography study are included for Baseline Characteristics.|Study of Pain Processing in Subjects Suffering From Obstructive Sleep Apnea|Experimental Pain Processing and Autonomic Function in Subjects Suffering From Obstructive Sleep Apnea|Completed|||56|Actual|Stanford University|||1||f||||t||||||||No||2018-06-01 02:10:36.069015|2018-06-01 02:10:36.069015
NCT00672724|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2012-02-27|2008-05-02|2008-05-06|Estimate|||||||2012-02-27|2012-02-28|Estimate|February 2005||2005-02-28|February 2012|2012-02-29|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy of Ramelteon in Adults With Chronic Insomnia|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment With Ramelteon in Adult Subjects With Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data|Terminated||Phase 3|1081|Actual|Takeda||2||Issues with data collection tool|f||||f||||||||||2018-06-01 02:10:36.312262|2018-06-01 02:10:36.312262
NCT00672711|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2017-01-23|2008-05-02|2008-05-06|Estimate|||||||2017-01-23|2017-01-25|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Susceptibility to Chronic Post-Traumatic Extremity Pain|Susceptibility to Chronic Post-Traumatic Extremity Pain|Completed|||250|Actual|William Beaumont Hospitals|||3||f||||f||||||Samples With DNA|"~     Whole blood serum~   "|||2018-06-01 02:10:36.449348|2018-06-01 02:10:36.449348
NCT00672698|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2012-10-29|2008-05-02|2008-05-06|Estimate|||||||2012-10-29|2012-10-31|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Evaluation of Surgical Risk in Elderly Patients Submitted to Elective Surgery|Evaluation of Surgical Risk in Elderly Patients Submitted to Elective Surgery: Comparative Study of Elective Vascular, Digestive and Biliary Surgery|Withdrawn|||0|Actual|Cirujanos la Serena|||3|NOT ENOUGH DATA AVAILABLE|f||||f||||||||||2018-06-01 02:10:36.519596|2018-06-01 02:10:36.519596
NCT00672685|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-04-16|2008-05-02|2008-05-06|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|MAPT||Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline|Assessment of the Efficacy of Omega-3 Fatty Acids Supplementation, Multi-domain Intervention or Their Combination on the Change of Cognitive Functions in Frail Elderly Subjects|Completed||N/A|1680|Actual|University Hospital, Toulouse||4|||f||||f||||||||||2018-06-01 02:10:36.599098|2018-06-01 02:10:36.599098
NCT00672672|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2018-04-09|2008-05-05|2008-05-06|Estimate|||||||2018-04-09|2018-04-11|Actual|January 2009|Actual|2009-01-31|April 2018|2018-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients|Autologous Platelet Gel in Wound Healing of Coronary Artery Bypass Grafting (CABG) Patients|Withdrawn||Phase 3|0|Actual|University of Nebraska||1||Study closed with no subjects accrued. PI decided to stop study.|f||||t||||||||||2018-06-01 02:10:36.712474|2018-06-01 02:10:36.712474
NCT00672659|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2011-04-29|2008-05-05|2008-05-06|Estimate|||||||2011-04-29|2011-05-02|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)|Phase IIa Proof of Concept Study of Pipamperone/Citalopram (PipCit) Versus Citalopram in the Treatment of Major Depressive Disorder (MDD)|Completed||Phase 2|165|Actual|PharmaNeuroBoost N.V.||2|||f||||t||||||||||2018-06-01 02:10:36.891489|2018-06-01 02:10:36.891489
NCT00672646|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2011-08-31||2012-05-07|2008-05-05|2008-05-06|Estimate|2012-05-07|2012-06-08|Estimate||||2012-05-07|2012-06-08|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386|A Double-blind, Randomized, Placebo and Naproxen Controlled Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386, in Patients Undergoing Impacted Mandibular Third Molar Extraction|Completed||Phase 2|103|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 02:10:36.992263|2018-06-01 02:10:36.992263
NCT00672633|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2013-03-08||2013-05-24|2008-05-05|2008-05-06|Estimate|2013-05-24|2013-05-29|Estimate||||2013-05-24|2013-05-29|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides|A Double Blind Randomized Controlled Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides.|Terminated||Phase 2|25|Actual|Boston Children’s Hospital|Early termination leading to small numbers of subjects analyzed|2||Very slow recruitment.|f||||t||||||||||2018-06-01 02:10:37.406145|2018-06-01 02:10:37.406145
NCT00672620|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2013-10-25||2013-10-25|2008-05-05|2008-05-06|Estimate|2013-10-25|2013-12-18|Estimate||||2013-10-25|2013-12-18|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder|Completed||Phase 3|611|Actual|Takeda||4|||f||||f||||||||||2018-06-01 02:10:37.845362|2018-06-01 02:10:37.845362
NCT00672607|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2009-09-30|2008-05-05|2008-05-06|Estimate|||||||2009-09-30|2009-10-01|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|ACT-RCT-C 01||a Clinical Trial to Evaluate the Efficacy and Safety of Agnucaston Tablets in the Treatment of Premenstrual Syndrome (PMS)||Completed||Phase 2|217|Actual|Schwabe-Wenex International Ltd||2|||f||||t||||||||||2018-06-01 02:10:39.162952|2018-06-01 02:10:39.162952
NCT00672594|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|2013-10-25||2014-07-31|2008-05-04|2008-05-06|Estimate|2014-05-19|2014-06-16|Estimate||||2014-07-31|2014-08-04|Estimate|July 2006||2006-07-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy|Investigator-Initiated Pilot Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy|Completed||Phase 2|30|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:10:39.324855|2018-06-01 02:10:39.324855
NCT00672581|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2010-09-27|2008-05-01|2008-05-06|Estimate|||||||2010-09-27|2010-09-28|Estimate|April 2008||2008-04-30|September 2010|2010-09-30|March 2009|Actual|2009-03-31|||||Interventional|||Pharmacokinetics, Safety & Tolerability of ZD4054 (Zibotentan) in Subjects With Normal, Mild, Moderate and Severe Hepatic Impairment|An Open-label Comparative Study of the Pharmacokinetics, Safety and Tolerability of ZD4054 (Zibotentan) Following a 10 mg Single Oral Dose of ZD4054(Zibotentan) to Healthy Subjects and to Subjects With Mild, Moderate and Severe Hepatic Impairment|Completed||Phase 1|32|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:10:39.666916|2018-06-01 02:10:39.666916
NCT00672568|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2009-05-01|2008-05-02|2008-05-06|Estimate|||||||2009-05-01|2009-05-04|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Tolerability of 4975 in Patients Undergoing Arthroscopic Surgery to Repair the Rotator Cuff of the Shoulder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Stage Exploratory Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of Intraoperative Subacromial Injection With 4975 in Patients Undergoing Arthroscopic Rotator Cuff Repair of the Shoulder|Terminated||Phase 2|24|Actual|Anesiva, Inc.||4||"Study has been halted after completing Stage 1, for corporate reasons. No future patients will~   be enrolled or treated."|f||||f||||||||||2018-06-01 02:10:39.786743|2018-06-01 02:10:39.786743
NCT00672555|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2010-04-28||2011-06-03|2008-05-05|2008-05-06|Estimate|2011-06-03|2011-06-29|Estimate||||2011-06-03|2011-06-29|Estimate|August 2006||2006-08-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|January 2009|Actual|2009-01-31||Interventional|||Limberg-flap: Prospective Data Collection|Prospective Evaluation of Feasibility and Results of the Treatment of Pilonidal Sinus by Excision and Covering of the Defect With a Limberg-flap.|Completed||N/A|70|Actual|Cantonal Hospital of St. Gallen|Study was conducted as planned. A long time was needed to get the follow-up information.|1|||f||||t||||||||||2018-06-01 02:10:39.926363|2018-06-01 02:10:39.926363
NCT00672542|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-03|||2014-01-21|2008-05-04|2008-05-06|Estimate|||||||2014-01-21|2014-01-23|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells|Phase I Study of Active Immunotherapy of Metastatic Melanoma With Mature Autologous Dendritic Cells Transfected With Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing|Completed||Phase 1|12|Actual|Duke University||3|||f||||f||||||||||2018-06-01 02:10:40.130392|2018-06-01 02:10:40.130392
NCT00672529|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2011-02-02|2008-05-05|2008-05-06|Estimate|||||||2011-02-02|2011-02-04|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Orthomolecular Therapy and Asthma in Children|Orthomolecular Treatment as add-on Therapy for Childhood Asthma|Unknown status|Recruiting|Phase 2|90|Anticipated|Canadian Institute of Natural and Integrative Medicine||2|||f||||f||||||||||2018-06-01 02:10:40.22927|2018-06-01 02:10:40.22927
NCT00672516|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-05-26|2008-05-02|2008-05-06|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Management of Bleeding Following Cardiopulmonary Bypass|Management of Excessive Bleeding Following Cardiopulmonary Bypass: A Pilot Feasibility Study|Completed|||43|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 02:10:40.320395|2018-06-01 02:10:40.320395
NCT00672503|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2011-10-07|2008-05-05|2008-05-06|Estimate|||||||2011-10-07|2011-10-12|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit|"Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit"|Completed|||321|Actual|Children's Mercy Hospital Kansas City|||4||f||||f||||||||||2018-06-01 02:10:40.38787|2018-06-01 02:10:40.38787
NCT00672490|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2010-06-24||2012-06-11|2008-05-05|2008-05-06|Estimate|2012-06-11|2012-07-12|Estimate||||2012-06-11|2012-07-12|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|MANIA||Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder|An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder|Completed||Phase 4|376|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:10:40.488059|2018-06-01 02:10:40.488059
NCT00672477|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2018-02-07||2018-02-07|2008-05-05|2008-05-06|Estimate|2018-02-07|2018-03-08|Actual||||2018-02-07|2018-03-08|Actual|June 2008||2008-06-30|February 2018|2018-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||The analysis population included subjects who received ≥ 1 dose of study drug.|Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness|A Randomized, Double-Blind, Placebo-Controlled Study Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Adults With Advanced Illness And Opioid-Induced Constipation: Efficacy, Safety, And Additional Health Outcomes|Completed||Phase 4|237|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 02:10:40.827494|2018-06-01 02:10:40.827494
NCT00672464|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2014-07-29|2008-05-05|2008-05-06|Estimate|||||||2014-07-29|2014-07-31|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Interventional|CRASOD||Cardio Risk of Acute Schizophrenia Olanzapine Duke|Combined Treatment of Cardiovascular Risk Factors In Newly Admitted Patients With Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine And Matched Controls|Withdrawn||Phase 4|0|Actual|Duke University||5||lack of funding|f||||f||||||||||2018-06-01 02:10:41.362554|2018-06-01 02:10:41.362554
NCT00672451|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2017-11-01|2008-05-05|2008-05-06|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2008||2008-01-31|November 2017|2017-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|RACE II||Rhubarb and Angiotensin Converting Enzyme Inhibitor|Rhubarb and Angiotensin Converting Enzyme Inhibitor|Terminated||N/A|8|Actual|Wake Forest University Health Sciences||2||unable to meet recruitment goal|f||||t||||||||||2018-06-01 02:10:41.436616|2018-06-01 02:10:41.436616
NCT00672438|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2013-05-28||2017-01-04|2008-05-05|2008-05-06|Estimate|2016-06-10|2016-07-21|Estimate||||2017-01-04|2017-01-06|Estimate|May 2008||2008-05-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Baseline data collected for all enrolled participants.|Heritability of Opioid Effects: A Twin Study|Heritability of Opioid Effects: A Twin Study|Completed||N/A|242|Actual|Stanford University|The study was completed as intended, enrolling 121 twin pairs for a total of 114 evaluable pairs. There are no unexpected adverse events to report.|2|||f||||f||||||||||2018-06-01 02:10:41.59739|2018-06-01 02:10:41.59739
NCT00672412|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02||2010-12-20|2012-09-11|2008-05-02|2008-05-06|Estimate||||2011-04-15|2011-04-27|Estimate|2012-09-11|2012-09-13|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand|A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), and Nevirapine (NVP) as GPO-Vir Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children Greater Than or Equal to Five Months and Less Than 13 Years of Age in Thailand|Completed||Phase 1/Phase 2|42|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 02:10:41.977383|2018-06-01 02:10:41.977383
NCT00672399|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2015-02-23|2008-05-05|2008-05-06|Estimate|||||||2015-02-23|2015-02-24|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects|A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects|Completed||Phase 1|70|Actual|AstraZeneca||6|||f||||f||||||||||2018-06-01 02:10:42.098204|2018-06-01 02:10:42.098204
NCT00672386|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02||2011-06-03|2014-07-10|2008-05-02|2008-05-06|Estimate||||2009-12-18|2009-12-23|Estimate|2014-07-10|2014-07-14|Estimate|December 2007||2007-12-31|July 2014|2014-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes|A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110 (R256918)|Completed||Phase 2|352|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||t||||||||||2018-06-01 02:10:42.248488|2018-06-01 02:10:42.248488
NCT00672373|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2008-05-05|2008-05-05|2008-05-06|Estimate|||||||2008-05-05|2008-05-06|Estimate|December 2006||2006-12-31|May 2008|2008-05-31|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|EGBTD||Extract of Ginkgo Biloba and Tardive Dyskinesia|A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia|Completed||Phase 3|157|Actual|Beijing HuiLongGuan Hospital||2|||f||||t||||||||||2018-06-01 02:10:42.421695|2018-06-01 02:10:42.421695
NCT00672360|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05|||2015-09-10|2008-05-05|2008-05-06|Estimate|||||||2015-09-10|2015-09-14|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Folate Rechallenge|Folate Rechallenge: A Pilot Study|Completed||Phase 2|13|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:10:42.51172|2018-06-01 02:10:42.51172
NCT00672347|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2010-03-18|2008-05-02|2008-05-06|Estimate|||||||2010-03-18|2010-03-19|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Clonidine and Morphine in Caudal Anesthesia|Comparison of Clonidine and Morphine Plus Bupivacaine in Caudal Peridural Anesthesia for Postoperative Analgesia After Pediatric Urogenital Surgery|Completed||Phase 1/Phase 2|80|Actual|Federal University of Minas Gerais||4|||f||||t||||||||||2018-06-01 02:10:42.582078|2018-06-01 02:10:42.582078
NCT00672334|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-07-31|2008-05-01|2008-05-06|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|Bic-MC||Sodium Bicarbonate in Cardiac Surgery Study|A Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Sodium Bicarbonate on Postoperative Renal Function in Patients Undergoing Elective Cardiopulmonary Bypass|Terminated||Phase 2/Phase 3|350|Actual|Austin Health||2|||f||||t||||||||||2018-06-01 02:10:42.685238|2018-06-01 02:10:42.685238
NCT00672321|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-03|||2013-08-09|2008-05-03|2008-05-06|Estimate|||||||2013-08-09|2013-08-12|Estimate|December 2007||2007-12-31|July 2009|2009-07-31||||September 2010|Anticipated|2010-09-30||Observational|||Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma|Melanoma Lifestyle Study|Unknown status|Recruiting||2774|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:10:42.797957|2018-06-01 02:10:42.797957
NCT00672308|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-03|||2008-05-05|2008-05-05|2008-05-06|Estimate|||||||2008-05-05|2008-05-06|Estimate|May 2003||2003-05-31|December 2004|2004-12-31|August 2006|Actual|2006-08-31|February 2005|Actual|2005-02-28||Interventional|ORS||Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults|Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults|Completed||Phase 2|195|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||f||||||||||2018-06-01 02:10:42.886781|2018-06-01 02:10:42.886781
NCT00672295|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2012-12-27|2008-05-05|2008-05-06|Estimate|||||||2012-12-27|2012-12-28|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Interventional|||PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer|A Phase I Trial of A SRC Kinase Inhibitor, Dasatinib,in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian, Peritoneal, and Tubal Cancer|Completed||Phase 1|11|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:10:42.966079|2018-06-01 02:10:42.966079
NCT00672282|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2009-05-26|2008-05-05|2008-05-06|Estimate|||||||2009-05-26|2009-05-27|Estimate|October 1995||1995-10-31|March 2009|2009-03-31|August 2008|Actual|2008-08-31|||||Interventional|SPCG6||Casodex vs Placebo in Non-Metastatic Early Prostate Cancer|A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.|Completed||Phase 3|1218|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:10:43.077238|2018-06-01 02:10:43.077238
NCT00672269|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2009-02-03|2008-05-05|2008-05-06|Estimate|||||||2009-02-03|2009-02-04|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|April 2009|Anticipated|2009-04-30||Observational|||Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors|A Pilot Study to Investigate Germ-Line MEN1 and SDHD Gene Mutation in Familial Cases of Carcinoid Cancer|Unknown status|Recruiting||25|Anticipated|Rutgers University|||1||f||||f||||||Samples With DNA|"~     Blood: a small sample of 2 tubes (2 - 4 teaspoons, or 20 ml). One tube will be used to~     prepare the DNA (your genetic material) for the test. The other would be used for further~     gene evaluation. The DNA will be stored with Rutgers University Cell and DNA Repository~     (RUCDR).~   "|||2018-06-01 02:10:43.205666|2018-06-01 02:10:43.205666
NCT00672256|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|2009-03-30||2014-07-14|2008-05-04|2008-05-06|Estimate|2013-01-11|2013-02-15|Estimate||||2014-07-14|2014-07-23|Estimate|January 2007||2007-01-31|March 2013|2013-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|SmokeAtt02||Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence|Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence|Completed||N/A|62|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:10:43.281441|2018-06-01 02:10:43.281441
NCT00672243|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2011-03-30||2013-08-02|2008-05-05|2008-05-06|Estimate|2013-02-22|2013-04-04|Estimate||||2013-08-02|2013-08-07|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme|Phase II Trial of Erlotinib Plus Sirolimus for Patients With Recurrent Malignant Glioma Multiforme|Completed||Phase 2|32|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:10:43.475593|2018-06-01 02:10:43.475593
NCT00672230|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2008-05-05|2008-05-05|2008-05-06|Estimate|||||||2008-05-05|2008-05-06|Estimate|August 2005||2005-08-31|May 2008|2008-05-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Dietary Lutein and the Retinopathy of Prematurity|The Placental and Mammary Transfer of Lutein and Zeaxanthin Into the Fetus and the Breast-Fed Infant|Unknown status|Recruiting|N/A|80|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 02:10:43.802181|2018-06-01 02:10:43.802181
NCT00672217|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-05-26|2008-05-02|2008-05-06|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|REST||Cognitive-Behavioral Therapy for Chronic Insomnia After Breast Cancer Treatment|Cognitive-Behavioral Therapy for Chronic Insomnia After Breast Cancer Treatment|Completed||N/A|64|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 02:10:43.872162|2018-06-01 02:10:43.872162
NCT00672204|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2013-02-20||2017-09-22|2008-05-02|2008-05-06|Estimate|2013-02-20|2013-03-27|Estimate||||2017-09-22|2017-10-25|Actual|November 2007||2007-11-30|September 2017|2017-09-30|August 2012|Actual|2012-08-31|December 2010|Actual|2010-12-31||Interventional|RAPTIVA||Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes|Efalizumab (Raptiva) Combined With Sirolimus in Type 1 Diabetic Islet Allograft Recipients|Terminated||Phase 1/Phase 2|23|Actual|University of Minnesota - Clinical and Translational Science Institute|Early termination due to Raptiva being withdrawn from market|1||Raptiva was withdrawn from the market|f||||t||||||||||2018-06-01 02:10:43.950004|2018-06-01 02:10:43.950004
NCT00672191|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-05||2013-01-22|2013-01-22|2008-05-05|2008-05-06|Estimate||||2013-01-22|2013-01-29|Estimate|2013-01-22|2013-01-29|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|November 2011|Actual|2011-11-30|August 2010|Actual|2010-08-31||Interventional|||Phase II Study of AGS‑004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV|A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption|Completed||Phase 2|59|Actual|Argos Therapeutics||1|||f||||t||||||||||2018-06-01 02:10:44.153375|2018-06-01 02:10:44.153375
NCT00672178|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|2010-09-21||2016-11-23|2008-05-04|2008-05-06|Estimate|2010-11-16|2010-12-15|Estimate||||2016-11-23|2017-01-12|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)|Phase I/II Trial Evaluating Toxicity and Efficacy of Adding Stereotactic Body Radiotherapy to Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer|Terminated||Phase 1/Phase 2|1|Actual|Duke University|Early termination due to low accrual, only one subject enrolled.|||Slow accrual|f||||f||||||||||2018-06-01 02:10:44.265522|2018-06-01 02:10:44.265522
NCT00672165|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-02-24|2008-05-05|2008-05-06|Estimate|||||||2015-02-24|2015-02-26|Estimate|July 2005||2005-07-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies|Phase I Trial of Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies|Completed||Phase 1|23|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:10:44.412856|2018-06-01 02:10:44.412856
NCT00672152|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2013-12-07|2008-05-05|2008-05-06|Estimate|||||||2013-12-07|2013-12-10|Estimate|June 2007||2007-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|WT-1||A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation|A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies|Terminated||Phase 1|8|Actual|Duke University||1||low accrual|f||||f||||||||||2018-06-01 02:10:44.504897|2018-06-01 02:10:44.504897
NCT00672139|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2018-02-07||2018-02-07|2008-05-02|2008-05-06|Estimate|2018-02-07|2018-03-07|Actual||||2018-02-07|2018-03-07|Actual|July 2008||2008-07-31|February 2018|2018-02-28|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional||The analysis population included subjects who received study drug and had laxation data and drug administration data. Two subjects in the 12 mg/day group had no drug administration data and were not included in efficacy analyses (but they were included in baseline characteristics and safety analyses).|Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness|Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation|Completed||Phase 4|156|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 02:10:44.627281|2018-06-01 02:10:44.627281
NCT00672113|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2014-12-18|2008-05-05|2008-05-06|Estimate|||||||2014-12-18|2014-12-19|Estimate|December 2003||2003-12-31|December 2014|2014-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Effects of Adalat LA and Coracten on Drug Levels, Blood Pressure, and Heart Rate in Fed Patients With Hypertension|Effects of Adalat LA 30 mg and Coracten 30 mg on Nifedipine Plasma Concentration , Plasma Catecholamines, Blood Pressure Response and Heart Rate in Fed Mild to Moderate Hypertensive Patients.|Completed||Phase 4|43|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:10:45.250385|2018-06-01 02:10:45.250385
NCT00672100|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2011-07-12||2017-01-23|2008-05-02|2008-05-06|Estimate|2013-05-22|2013-05-23|Estimate||||2017-01-23|2017-03-07|Actual|January 2009||2009-01-31|May 2013|2013-05-31|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional|||Initial Local Anesthetic Dose With Continuous Interscalene Analgesia|The Effect Of Initial Local Anesthetic Dose With Continuous Interscalene Analgesia On Postoperative Pain And Diaphragmatic Function In Arthroscopic Shoulder Surgery Patients: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study|Completed||N/A|36|Actual|William Beaumont Hospitals||3|||f||||f||||||||||2018-06-01 02:10:45.345652|2018-06-01 02:10:45.345652
NCT00672087|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2017-02-02|2008-05-02|2008-05-06|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2003||2003-09-30|February 2014|2014-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Diagnostic Challenges in IC (and Male CPPS)|Diagnostic Challenges in IC (and Male CPPS)|Completed|||1000|Anticipated|Beth Israel Deaconess Medical Center|||3||f||||f||||||Samples With DNA|"~     saliva, whole blood, serum, white cells, urine, prostatic fluid, prostate/bladder tissue~   "|||2018-06-01 02:10:45.630809|2018-06-01 02:10:45.630809
NCT00619086|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-06-06|2008-02-19|2008-02-20|Estimate|||||||2008-06-06|2008-06-09|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Steroid Before Thyroidectomy|Does a Single Dose of Steroid Before Thyroidectomy Improve Postoperative Nausea, Pain and Vocal Function?|Completed||N/A|72|Actual|University of Bern||2|||f||||f||||||||||2018-06-01 02:26:32.959836|2018-06-01 02:26:32.959836
NCT00672074|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02||2011-06-08|2017-04-12|2008-05-02|2008-05-06|Estimate||||2011-06-08|2011-06-23|Estimate|2017-04-12|2017-04-14|Actual|April 2008||2008-04-30|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus|A Phase II, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Management of Post-Operative Ileus in Patients|Completed||Phase 2|117|Actual|Helsinn Therapeutics (U.S.), Inc||2|||f||||f||||||||||2018-06-01 02:10:45.706928|2018-06-01 02:10:45.706928
NCT00672061|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2012-02-27|2008-05-02|2008-05-06|Estimate|||||||2012-02-27|2012-02-28|Estimate|July 2003||2003-07-31|February 2012|2012-02-29|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea|A Phase II Safety Study of TAK-375 in Subjects With Mild to Moderate Obstructive Sleep Apnea|Completed||Phase 2|26|Actual|Takeda||1|||f||||f||||||||||2018-06-01 02:10:45.793354|2018-06-01 02:10:45.793354
NCT00672048|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2014-01-03|2008-05-04|2008-05-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2007||2007-10-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Partnership for Glaucoma|Expanding Quality Care for Glaucoma Through a Provider-Patient Partnership|Completed||N/A|721|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:10:45.95362|2018-06-01 02:10:45.95362
NCT00672035|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2012-03-13|2008-05-02|2008-05-06|Estimate|||||||2012-03-13|2012-03-14|Estimate|October 2006||2006-10-31|March 2012|2012-03-31|July 2008|Actual|2008-07-31|December 2006|Actual|2006-12-31||Interventional|||Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study|Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging Study to Assess the Immunogenicity and Safety of LT Application in Healthy Adults|Completed||Phase 2|406|Actual|Intercell USA, Inc.||10|||f||||f||||||||||2018-06-01 02:10:46.035882|2018-06-01 02:10:46.035882
NCT00672022|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2008-05-05|2008-05-05|2008-05-06|Estimate|||||||2008-05-05|2008-05-06|Estimate|July 2004||2004-07-31|July 2005|2005-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses|Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset GM2 Gangliosidosis: Single and Steady State Oral Doses|Completed||Phase 3|10|Anticipated|Children's Research Institute|||||f||||||||||||||2018-06-01 02:10:46.119298|2018-06-01 02:10:46.119298
NCT00672009|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2014-09-03|2008-05-01|2008-05-06|Estimate|||||||2014-09-03|2014-09-05|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|August 2012|Actual|2012-08-31|April 2011|Actual|2011-04-30||Interventional|||A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer|A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer|Terminated||Phase 2|11|Actual|Cedars-Sinai Medical Center||1||The sponsor terminated funding for the study.|f||||f||||||||||2018-06-01 02:10:46.194124|2018-06-01 02:10:46.194124
NCT00671996|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-04|||2010-05-03|2008-05-04|2008-05-06|Estimate|||||||2010-05-03|2010-05-04|Estimate|June 2008||2008-06-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|MANFOL||Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C|A Local Feasibility Study on Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Patients Operated Upon Colon Cancer Stage Dukes' C|Completed||Phase 2|14|Actual|PledPharma AB||2|||f||||f||||||||||2018-06-01 02:10:46.271732|2018-06-01 02:10:46.271732
NCT00671983|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2016-10-17|2008-05-05|2008-05-06|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2010||2010-03-31|October 2016|2016-10-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||The Effect of Obstructive Sleep Apnea on Medical Outcomes After Gastric Bypass Surgery|The Effect of Obstructive Sleep Apnea on Medical and Neurobehavioral Outcomes After Gastric Bypass Surgery - An Exploratory Investigation|Withdrawn||Phase 1/Phase 2|0|Actual|Stanford University||||not adequate resources|f||||||||||||||2018-06-01 02:10:46.341185|2018-06-01 02:10:46.341185
NCT00671970|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2012-12-28||2013-03-29|2008-05-05|2008-05-06|Estimate|2013-03-29|2013-05-13|Estimate||||2013-03-29|2013-05-13|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|April 2010|Actual|2010-04-30|November 2008|Actual|2008-11-30||Interventional|||Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)|Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Recurrent Malignant Glioma|Completed||Phase 2|57|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:10:46.413091|2018-06-01 02:10:46.413091
NCT00671957|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2018-04-05|2008-05-05|2008-05-06|Estimate|||||||2018-04-05|2018-04-09|Actual|February 2006||2006-02-28|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|July 2007|Actual|2007-07-31||Observational|Energy||Energy Expenditure and Gastric Bypass Surgery Study|Energy Expenditure and Gastric Bypass Surgery Study|Suspended|||40|Anticipated|Oregon Health and Science University|||1|Funding hiatus|f||||t||||||||||2018-06-01 02:10:47.720042|2018-06-01 02:10:47.720042
NCT00671944|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2010-06-30|2008-05-01|2008-05-05|Estimate|||||||2010-06-30|2010-07-01|Estimate|May 2003||2003-05-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Long-term Nutritional Intervention Study to Determine How Protein Affects Calcium Metabolism|Long-term Impact of Protein on Calcium Kinetics|Completed||Phase 1|11|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:10:47.785449|2018-06-01 02:10:47.785449
NCT00671931|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2011-06-24||2013-08-22|2008-05-02|2008-05-05|Estimate|2013-08-22|2013-08-23|Estimate||||2013-08-22|2013-08-23|Estimate|April 2007||2007-04-30|August 2013|2013-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine|Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine|Completed||Phase 1|44|Actual|Children's Hospital Medical Center, Cincinnati||5|||f||||t||||||||||2018-06-01 02:10:47.875294|2018-06-01 02:10:47.875294
NCT00671918|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2013-04-13|2010-08-31|2013-06-06|2008-05-02|2008-05-05|Estimate|2013-04-13|2013-06-03|Estimate|2011-05-03|2011-05-05|Estimate|2013-06-06|2013-06-17|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional||Of the 186 participants who enrolled in the trial, 179 were administered the study agent, Lymphoseek, and therefore this participant number is used for the baseline analysis.|Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma|A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping|Completed||Phase 3|186|Actual|Navidea Biopharmaceuticals||1|||f||||f||||||||||2018-06-01 02:10:48.241973|2018-06-01 02:10:48.241973
NCT00671905|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2013-04-10|2008-04-30|2008-05-05|Estimate|||||||2013-04-10|2013-04-11|Estimate|May 2008||2008-05-31|April 2013|2013-04-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)|Circumferential vs Ganglionated Plexi Ablation in Patients With Paroxysmal Atrial Fibrillation: A Randomized Study|Completed||N/A|150|Anticipated|Cardiovascular Research Society, Greece||3|||f||||t||||||||||2018-06-01 02:10:48.588313|2018-06-01 02:10:48.588313
NCT00671879|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2011-07-13||2012-10-22|2008-05-02|2008-05-05|Estimate|2012-10-22|2012-11-21|Estimate||||2012-10-22|2012-11-21|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back|Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back|Completed||Phase 3|830|Actual|Meda Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:10:48.78521|2018-06-01 02:10:48.78521
NCT00671866|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2008-05-04|2008-05-04|2008-05-05|Estimate|||||||2008-05-04|2008-05-05|Estimate||||April 2008|2008-04-30||||||||Observational|||Neurotoxic Health Hazards of Long-Term Low-Level Exposure to Organophosphate (OP) Compounds in in Hula Valley||Unknown status|Not yet recruiting||||Shaare Zedek Medical Center|||3||f||||||||||||||2018-06-01 02:10:49.200572|2018-06-01 02:10:49.200572
NCT00671853|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2012-04-16||2016-11-09|2008-05-01|2008-05-05|Estimate|2013-09-30|2013-10-11|Estimate||||2016-11-09|2016-12-29|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)|Quetiapine XR in the Treatment of Comorbid Generalized Anxiety Disorder in Bipolar Depression With or Without Substance Use Disorder|Completed||Phase 3|120|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 02:10:49.274123|2018-06-01 02:10:49.274123
NCT00671827|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2018-03-20|2008-05-04|2008-05-05|Estimate|||||||2018-03-20|2018-03-22|Actual|April 29, 2008|Actual|2008-04-29|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|||Evaluation of Robot-Assisted Surgery in Gynecologic Oncology|Prospective Evaluation of Robot-Assisted Surgery in Gynecologic Oncology|Active, not recruiting|||588|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 02:10:49.573796|2018-06-01 02:10:49.573796
NCT00671814|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2017-08-30|2008-05-01|2008-05-05|Estimate|||||||2017-08-30|2017-08-31|Actual|January 6, 2008|Actual|2008-01-06|August 2017|2017-08-31|June 6, 2008|Actual|2008-06-06|June 6, 2008|Actual|2008-06-06||Interventional|SAD/MAD||Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults|A Double-Blind, Placebo and Active Controlled, Single and Multiple Rising Dose, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults|Completed||Phase 1|80|Actual|Trius Therapeutics LLC||3|||f||||f||||||||||2018-06-01 02:10:49.638034|2018-06-01 02:10:49.638034
NCT00671801|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2015-02-16|2008-05-04|2008-05-05|Estimate|||||||2015-02-16|2015-02-18|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I|Phase I Trial of Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme|Terminated||Phase 1|24|Actual|M.D. Anderson Cancer Center||1||Poor accrual.|f||||f||||||||||2018-06-01 02:10:49.708809|2018-06-01 02:10:49.708809
NCT00671788|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|2014-01-31||2016-03-17|2008-05-02|2008-05-05|Estimate|2014-06-17|2014-07-18|Estimate||||2016-03-17|2016-04-15|Estimate|June 2008||2008-06-30|March 2016|2016-03-31||||December 2010|Actual|2010-12-31||Interventional||Eligible and treated participants|A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|35|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 02:10:49.90183|2018-06-01 02:10:49.90183
NCT00671775|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2018-03-05|2008-05-01|2008-05-05|Estimate|||||||2018-03-05|2018-03-07|Actual|September 2005|Actual|2005-09-30|March 2018|2018-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Cognitive Effects of Bariatric Surgery|Cognitive Effects of Bariatric Surgery|Completed|||253|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||2||f||||f||||||||||2018-06-01 02:10:50.225809|2018-06-01 02:10:50.225809
NCT00671749|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2014-08-12||2016-02-16|2008-04-30|2008-05-05|Estimate|2016-02-16|2016-03-16|Estimate||||2016-02-16|2016-03-16|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris|A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris|Completed||Phase 4|100|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||No||2018-06-01 02:10:50.297651|2018-06-01 02:10:50.297651
NCT00671736|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2009-08-26|2008-05-02|2008-05-05|Estimate|||||||2009-08-26|2009-08-27|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis|A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults With Cystic Fibrosis|Completed||Phase 2|160|Anticipated|AOP Orphan Pharmaceuticals AG||4|||f||||t||||||||||2018-06-01 02:10:50.645233|2018-06-01 02:10:50.645233
NCT00671723|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2014-02-06||2017-06-01|2008-04-30|2008-05-05|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|October 2006||2006-10-31|June 2017|2017-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Mechanically ventilated patients with new onset ( < 48 h) lobar or multilobar atelectasis|Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients|Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis|Completed||N/A|33|Actual|University of Oklahoma||3|||f||||t||||||||||2018-06-01 02:10:50.730896|2018-06-01 02:10:50.730896
NCT00671710|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2011-01-13|2008-05-02|2008-05-05|Estimate|||||||2011-01-13|2011-01-14|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|A Phase 1 and 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain|Completed||Phase 1|26|Anticipated|Advocate Hospital System|||||f||||f||||||||||2018-06-01 02:10:51.01756|2018-06-01 02:10:51.01756
NCT00671697|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2013-05-31|2008-05-01|2008-05-05|Estimate|||||||2013-05-31|2013-06-04|Estimate|May 2008||2008-05-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|January 2010|Actual|2010-01-31||Interventional|||Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia|A Phase I Study of Intravenous Decitabine in Combination With Arsenic Trioxide and Ascorbic Acid in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia|Completed||Phase 1|13|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 02:10:51.088|2018-06-01 02:10:51.088
NCT00671684|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2008-05-02|2008-05-02|2008-05-05|Estimate|||||||2008-05-02|2008-05-05|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|EDGE||Endoscopic Mucosal Resection (EMR) for Diagnosis of Hirschsprung's Disease|Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial|Unknown status|Enrolling by invitation|Phase 1/Phase 2|50|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 02:10:51.17322|2018-06-01 02:10:51.17322
NCT00671671|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2013-11-25||2013-11-25|2008-04-29|2008-05-05|Estimate|2013-11-25|2014-01-14|Estimate||||2013-11-25|2014-01-14|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.|A Phase 1, Non- Randomized, Open Label, Sequential Group, Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects.|Completed||Phase 1|20|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:10:51.250692|2018-06-01 02:10:51.250692
NCT00671658|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2013-08-23|2008-05-04|2008-05-05|Estimate|||||||2013-08-23|2013-08-26|Estimate|November 2002||2002-11-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia|Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia|Completed||Phase 2|220|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:10:51.697914|2018-06-01 02:10:51.697914
NCT00671645|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2009-03-12|2008-04-30|2008-05-05|Estimate|||||||2009-03-12|2009-03-13|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy|Preoperative Combined RadioChemo-MolecularTargetTherapy of the Locally Advanced Rectum Carcinoma (cT3NxM0) - a Phase II Pilot Study With Preoperative Application of Capecitabine, Bevacizumab and Radiotherapy (RTx)|Terminated||Phase 2|8|Actual|Austrian Breast & Colorectal Cancer Study Group||1||"reaching of step 1 (recruitment of 8 patients) per protocol -> risk assessment -> termination~   because of occurance of toxicity Grade 3 and 4"|f||||f||||||||||2018-06-01 02:10:51.846721|2018-06-01 02:10:51.846721
NCT00671632|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-02-27|2008-05-02|2008-05-05|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2003||2003-06-30|February 2012|2012-02-29|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse|A Randomized, Single Center, Double-Blind, Multiple-Dose, Placebo-Controlled, Crossover, Double-Dummy Study of The Acute Behavioral and Subjective Effects of Ramelteon in Subjects With a History of Polydrug Abuse.|Completed||Phase 2|14|Actual|Takeda||1|||f||||f||||||||||2018-06-01 02:10:51.959701|2018-06-01 02:10:51.959701
NCT00671619|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-08-22|2008-05-02|2008-05-05|Estimate|||||||2008-08-22|2008-08-25|Estimate|April 2008||2008-04-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study of ESBA105 Eye Drops in Healthy Subjects|A Phase I, Randomized, Vehicle-Controlled, Double-Blind, Mono-Centric, Single and Repeated Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ESBA105 Eye Drops in Healthy Subjects|Completed||Phase 1|27|Actual|ESBATech AG|||||f||||f||||||||||2018-06-01 02:10:52.045738|2018-06-01 02:10:52.045738
NCT00671606|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2011-06-30||2016-04-29|2008-04-29|2008-05-05|Estimate|2011-06-30|2011-07-27|Estimate||||2016-04-29|2016-05-27|Estimate|April 2008||2008-04-30|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Hysteroscopic Lymphatic Mapping for Endometrial Cancer|Hysteroscopic Injection of Tracers for Sentinel Node Identification in Women With Endometrial Cancer|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center|Early termination due to low detection rate of sentinel lymph nodes in the five participants.|1||Slow accrual.|f||||f||||||||||2018-06-01 02:10:52.105275|2018-06-01 02:10:52.105275
NCT00671593|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2013-07-15|2008-05-02|2008-05-05|Estimate|||||||2013-07-15|2013-07-16|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge|Genetics of Environmental Asthma: Differential Gene Expression in the Lung and Peripheral Blood After Inhaled Allergen Challenge|Terminated||Phase 1|40|Actual|Duke University||1||funding terminated|f||||t||||||||||2018-06-01 02:10:52.256817|2018-06-01 02:10:52.256817
NCT00671580|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2009-06-02|2008-05-02|2008-05-05|Estimate|||||||2009-06-02|2009-06-03|Estimate|May 2008||2008-05-31|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection|A Phase II Randomized, Observer-Blind, Multi-Center Study to Evaluate the Safety, Potential Efficacy, and Pharmacokinetics of Two Dosing Regimens of Intravenous PZ-601 and Standard of Care in the Treatment of Complicated Skin and Skin Structure Infections|Completed||Phase 2|99|Anticipated|Protez Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 02:10:52.352497|2018-06-01 02:10:52.352497
NCT00671567|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-11-16|2008-05-02|2008-05-05|Estimate|||||||2012-11-16|2012-11-20|Estimate|December 2002||2002-12-31|November 2012|2012-11-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Ramelteon in Adults With Chronic Insomnia|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Adults With Chronic Insomnia|Completed||Phase 3|848|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:10:52.461993|2018-06-01 02:10:52.461993
NCT00671554|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2012-04-03||2014-05-16|2008-05-02|2008-05-05|Estimate|2014-05-16|2014-06-04|Estimate||||2014-05-16|2014-06-04|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma|Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG|Terminated||Phase 1/Phase 2|3|Actual|Greenville Health System||1||Due to business considerations; not due to toxicities or adverse events.|f||||f||||||||||2018-06-01 02:10:52.666332|2018-06-01 02:10:52.666332
NCT00671541|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-02-16|2008-05-02|2008-05-05|Estimate|||||||2012-02-16|2012-02-17|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Nasospore Stent For Use in Enodscopic Sinus Surgery|Nasospore Stent For The Use in Endoscopic Sinus Surgery|Withdrawn||Phase 4|0|Actual|Lahey Clinic||2||Principal Investigator left the institution requested study terminated.|f||||f||||||||||2018-06-01 02:10:52.820122|2018-06-01 02:10:52.820122
NCT00671528|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2011-05-19||2014-12-29|2008-05-02|2008-05-05|Estimate|2011-05-19|2011-06-16|Estimate||||2014-12-29|2015-01-13|Estimate|July 2009||2009-07-31|December 2014|2014-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)|Double-blind Evaluation of the Safety and Efficacy of Quadriderme® (Betamethasone Diproprionate, Clotrimazole and Gentamicin) Compared With Betamethasone Diproprionate Combined With Gentamicin Sulfate and With Betamethasone Diproprionate in the Treatment of Impetiginous Eczema|Terminated||Phase 4|3|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to lack of recruitment (only 3 of 201 participants were enrolled). Statistical analyses were not performed.|3||terminated early due to lack of recruitment [only 3 of 207 subjects were enrolled]|f||||f||||||||||2018-06-01 02:10:52.9008|2018-06-01 02:10:52.9008
NCT00671515|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2013-10-31||2016-11-30|2008-05-01|2008-05-05|Estimate|2014-10-09|2014-10-17|Estimate||||2016-11-30|2017-01-26|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome|Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome|Completed||Phase 2|23|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-06-01 02:10:53.181248|2018-06-01 02:10:53.181248
NCT00671502|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2011-06-28||2011-10-04|2008-05-01|2008-05-05|Estimate|2011-10-04|2011-11-09|Estimate||||2011-10-04|2011-11-09|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back|Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back|Completed||Phase 3|840|Actual|Meda Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:10:53.366103|2018-06-01 02:10:53.366103
NCT00671489|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2012-07-02|2008-05-02|2008-05-05|Estimate|||||||2012-07-02|2012-07-03|Estimate|May 2008||2008-05-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study|Phase 2 Study of Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study|Completed||Phase 1/Phase 2|15|Actual|Japan Science and Technology Agency|||||f||||t||||||||||2018-06-01 02:10:53.714204|2018-06-01 02:10:53.714204
NCT00671476|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2014-01-09|2008-05-02|2008-05-05|Estimate|||||||2014-01-09|2014-01-10|Estimate|February 2008||2008-02-29|June 2009|2009-06-30||||February 2011|Anticipated|2011-02-28||Interventional|||Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery|Intraductal Therapy of DCIS: A Presurgery Study|Unknown status|Recruiting|N/A|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:10:53.862156|2018-06-01 02:10:53.862156
NCT00671463|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2013-06-10|2008-05-02|2008-05-05|Estimate|||||||2013-06-10|2013-06-11|Estimate|April 2008||2008-04-30|June 2013|2013-06-30||||April 2010|Anticipated|2010-04-30||Interventional|LEAPS||Pancreatic Stent to Prevent Leak After Distal Pancreatectomy|Leak Elimination After Pancreatic Stenting, a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||Anticipated high risk of pancreatitis|f||||t||||||||||2018-06-01 02:10:54.076812|2018-06-01 02:10:54.076812
NCT00671450|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2013-01-24|2008-05-04|2008-05-05|Estimate|||||||2013-01-24|2013-01-28|Estimate|October 2008||2008-10-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|VDMTBI||Visual Dysfunction in Mild Traumatic Brain Injury (MTBI): A Comparison Group Study|Visual Dysfunction in MTBI: A Comparison Group Study|Completed|||75|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 02:10:54.187508|2018-06-01 02:10:54.187508
NCT00671437|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2015-07-02||2017-02-02|2008-05-02|2008-05-05|Estimate|2015-07-31|2015-08-10|Estimate||||2017-02-02|2017-03-14|Actual|June 2008||2008-06-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|December 2011|Actual|2011-12-31||Interventional|SCCHN|Baseline participants are based on the number of evaluable patients. 15 out of the 42 enrolled patients were not considered evaluable for analyses.|Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer|Determination of Tumor SUV by FDG-PET/CT Before and After Cetuximab in Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|42|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:10:54.274233|2018-06-01 02:10:54.274233
NCT00671424|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2012-03-15|2008-05-02|2008-05-05|Estimate|||||||2012-03-15|2012-03-19|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide|An Evaluation of the Safety, Tolerability, and Pharmacodynamic Effects of GSK189075 When Administered With Furosemide or Hydrochlorothiazide|Completed||Phase 1|48|Anticipated|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:10:54.870509|2018-06-01 02:10:54.870509
NCT00671411|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2015-12-23|2008-05-02|2008-05-05|Estimate|||||||2015-12-23|2015-12-28|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast|Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast|Completed||Phase 1|42|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:10:54.944555|2018-06-01 02:10:54.944555
NCT00671398|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-02-27|2008-05-02|2008-05-05|Estimate|||||||2012-02-27|2012-02-28|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Efficacy of Ramelteon on Transient Insomnia in Healthy Adults|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model of Transient Insomnia|Completed||Phase 3|289|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:10:55.023268|2018-06-01 02:10:55.023268
NCT00671385|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2011-01-30|2008-05-02|2008-05-05|Estimate|||||||2011-01-30|2011-02-01|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|April 2011|Anticipated|2011-04-30|April 2009|Anticipated|2009-04-30||Observational|||Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning|Early Screening of Breast Cancer Using Radiation-Free Pressure-Free Optical Scanning|Unknown status|Recruiting||2000|Anticipated|Spectros Corporation|||1||f||||t||||||||||2018-06-01 02:10:55.169004|2018-06-01 02:10:55.169004
NCT00671372|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2016-11-01|2008-04-30|2008-05-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Multiple Doses of Dulanermin Administered Intravenously in Combination With Camptosar®/Erbitux® Chemotherapy or the Folfiri Regimen With or Without Bevacizumab in Subjects With Previously Treated Metastatic Colorectal Cancer|Completed||Phase 1|42|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 02:10:55.260514|2018-06-01 02:10:55.260514
NCT00671359|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2018-04-03|2008-05-02|2008-05-05|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 10, 2008|Actual|2008-03-10|April 2018|2018-04-30|May 15, 2008|Actual|2008-05-15|May 15, 2008|Actual|2008-05-15||Interventional|||Food Effects of Single Oral Dose of 600mg TR-701|An Open-Label, Single-Dose, Two-Treatment, Randomized, Two-Way Crossover, Safety, Tolerance, and Pharmacokinetic Study of TR-701 in Normal Healthy Adults in the Fed and Fasted State|Completed||Phase 1|12|Actual|Trius Therapeutics LLC||2|||f||||f||||||||||2018-06-01 02:10:55.382689|2018-06-01 02:10:55.382689
NCT00426166|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2011-05-09|2007-01-23|2007-01-24|Estimate|||||||2011-05-09|2011-05-10|Estimate|January 2007||2007-01-31|March 2010|2010-03-31|May 2011|Actual|2011-05-31|March 2009|Actual|2009-03-31||Interventional|||Assessment Of Infrared Photobiotherapy for Improved Wound Healing||Completed||N/A|50|Anticipated|University of Toledo Health Science Campus||2|||f||||||||||||||2018-06-01 03:29:14.512413|2018-06-01 03:29:14.512413
NCT00671346|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2015-11-04|2008-04-29|2008-05-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|December 1998||1998-12-31|November 2015|2015-11-30|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Observational|NORVITWENBIT||NORVIT and WENBIT - Long-term Follow-up|Combined Analyses and Long-term Follow-up in the Two Norwegian Homocysteine-Lowering B-Vitamin Trials NORVIT and WENBIT|Active, not recruiting|||6839|Anticipated|Haukeland University Hospital|||4||f||||f||||||||||2018-06-01 02:10:55.454917|2018-06-01 02:10:55.454917
NCT00671333|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2018-04-30|2008-05-02|2008-05-05|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2008||2008-04-30|April 2018|2018-04-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|TMC/PyroDisk||PRCT: Ligament Reconstruction & Tendon Interposition With a Joint Spacer for Trapeziometacarpal OA|A Randomized Prospective Study Comparing Ligament Reconstruction and Tendon Interposition (LRTI) With a Joint Spacer (Ascension PyroDisk) for Trapeziometacarpal Osteoarthritis.|Terminated||N/A|82|Actual|Simon Fraser Orthopaedic Fund||2||Study fatigue|f||||f||||||||||2018-06-01 02:10:55.550364|2018-06-01 02:10:55.550364
NCT00671320|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-04-30|2008-04-30|2008-05-05|Estimate|||||||2008-04-30|2008-05-05|Estimate|December 2002||2002-12-31|April 2008|2008-04-30|October 2003|Actual|2003-10-31|||||Interventional|||A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle|A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib Vs. Diclofenac In Ankle Sprain|Completed||Phase 4|202|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:10:55.624964|2018-06-01 02:10:55.624964
NCT00671307|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2010-09-27|2008-04-30|2008-05-05|Estimate|||||||2010-09-27|2010-09-29|Estimate|March 2008||2008-03-31|April 2010|2010-04-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels|Phase 1b Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Infusion Trial of the Pharmacokinetics of Rhu-pGelsolin in Patients With Decreased Natural Gelsolin Levels|Completed||Phase 1/Phase 2|40|Anticipated|Critical Biologics Corporation||4|||f||||t||||||||||2018-06-01 02:10:55.718651|2018-06-01 02:10:55.718651
NCT00671294|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-02-27|2008-05-01|2008-05-05|Estimate|||||||2012-02-27|2012-02-28|Estimate|October 2002||2002-10-31|February 2012|2012-02-29|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety and Efficacy of TAK-375 in Elderly Subjects With Chronic Insomnia.|Completed||Phase 3|100|Actual|Takeda||1|||f||||f||||||||||2018-06-01 02:10:55.823574|2018-06-01 02:10:55.823574
NCT00671281|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2010-09-02|2008-05-04|2008-05-05|Estimate|||||||2010-09-02|2010-09-03|Estimate|October 2008||2008-10-31|September 2010|2010-09-30|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery|The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery: A Randomized, Prospective, Double-Blinded Study|Withdrawn||N/A|74|Anticipated|University of Calgary||2||Study was cancelled|f||||f||||||||||2018-06-01 02:10:55.929575|2018-06-01 02:10:55.929575
NCT00671268|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2013-11-07|2008-05-02|2008-05-05|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2008||2008-03-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|AMETHYST||Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma|Multicentre, Multinational Randomised DBPC Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma|Completed||Phase 3|256|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 02:10:56.033501|2018-06-01 02:10:56.033501
NCT00671255|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-02-27|2008-05-02|2008-05-05|Estimate|||||||2012-02-27|2012-02-28|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Elderly Subjects With Chronic Insomnia|Completed||Phase 3|829|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:10:56.158714|2018-06-01 02:10:56.158714
NCT00671242|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2008-05-02|2008-05-02|2008-05-05|Estimate|||||||2008-05-02|2008-05-05|Estimate||||January 2008|2008-01-31||||||||Observational|angiogenesis||Angiogenesis With Positron Emission Tomography (PET) Tracer Uptake|Correlation of Angiogenesis With 18F-FMT and 18F-FDG Uptake in Non-Small Cell Lung Cancer|Completed|||||Gunma University|||2||f||||t||||||||||2018-06-01 02:10:56.489377|2018-06-01 02:10:56.489377
NCT00671229|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-04-13|2008-05-02|2008-05-05|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2003||2003-05-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1|Nitric Oxide, LPS and the Pathogenesis of Asthma Phase 1|Completed|||420|Actual|National Institute of Environmental Health Sciences (NIEHS)|||2||f||||f||||||Samples With DNA|"~     Serum samples, DNA, Exhaled Breah Condensate~   "|||2018-06-01 02:10:56.556138|2018-06-01 02:10:56.556138
NCT00671216|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2017-10-02|2008-05-02|2008-05-05|Estimate|||||||2017-10-02|2017-10-04|Actual|May 20, 2008|Actual|2008-05-20|October 2017|2017-10-31|July 7, 2008|Actual|2008-07-07|July 7, 2008|Actual|2008-07-07||Interventional|||A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.|A Single Centre, Randomised, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705 and GW642444 as Monotherapies and in Combination in Healthy Subjects.|Completed||Phase 1|16|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:10:56.635272|2018-06-01 02:10:56.635272
NCT00671203|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2011-01-30|2008-05-02|2008-05-05|Estimate|||||||2011-01-30|2011-02-01|Estimate|June 2007||2007-06-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Prevention of Colon Ischemia During Aortic Aneurysm (AAA) Repair|Prevention of Colon Ischemia During Aortic Aneurysm (AAA) Repair|Completed||Phase 3|500|Anticipated|Spectros Corporation|||||f||||t||||||||||2018-06-01 02:10:56.792508|2018-06-01 02:10:56.792508
NCT00671190|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-02-27|2008-05-01|2008-05-05|Estimate|||||||2012-02-27|2012-02-28|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Safety and Efficacy of Ramelteon in Healthy Subjects|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Phase-Shifting Effects of Repeated Daily Dosing of Ramelteon in Healthy Subjects|Completed||Phase 2|75|Actual|Takeda||5|||f||||f||||||||||2018-06-01 02:10:56.90368|2018-06-01 02:10:56.90368
NCT00671177|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2017-01-17||2017-03-20|2008-05-01|2008-05-05|Estimate|2017-03-20|2017-05-01|Actual||||2017-03-20|2017-05-01|Actual|September 2007||2007-09-30|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique|Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique|Completed||N/A|229|Actual|VA Palo Alto Health Care System||2|||f||||t||||||||No||2018-06-01 02:10:57.050999|2018-06-01 02:10:57.050999
NCT00671151|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2008-05-02|2008-05-02|2008-05-05|Estimate|||||||2008-05-02|2008-05-05|Estimate|June 2005||2005-06-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline|Completed||N/A|35|Actual|Hospital Universitari Son Dureta||2|||f||||f||||||||||2018-06-01 02:10:57.298304|2018-06-01 02:10:57.298304
NCT00671138|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2016-01-31|2008-05-01|2008-05-05|Estimate|||||||2016-01-31|2016-02-02|Estimate|October 2007||2007-10-31|January 2016|2016-01-31|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|||Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity|A Phase 2a, Randomized, Double Blinded, Placebo Controlled, Study Evaluating Immunity and Gluten-sensitivity by Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus.|Completed||Phase 2|20|Actual|Princess Alexandra Hospital, Brisbane, Australia||2|||f||||t||||||||||2018-06-01 02:10:57.393674|2018-06-01 02:10:57.393674
NCT00671125|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-11-08|2008-05-02|2008-05-05|Estimate|||||||2012-11-08|2012-11-12|Estimate|January 2003||2003-01-31|November 2012|2012-11-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Study of Efficacy of Ramelteon in Adults With Chronic Insomnia|A Phase III, Randomized, Double-Blind Placebo-Controlled, PSG Plus Outpatient Study to Determine the Safety and Efficacy of TAK-375 in Adults With Chronic Insomnia|Completed||Phase 3|405|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:10:57.518512|2018-06-01 02:10:57.518512
NCT00671112|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-02|||2015-10-27|2008-05-02|2008-05-05|Estimate|||||||2015-10-27|2015-10-28|Estimate|June 2008||2008-06-30|October 2015|2015-10-31||||October 2015|Actual|2015-10-31||Interventional|||Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma|A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma|Terminated||Phase 1|30|Actual|Case Comprehensive Cancer Center||1||Treatment ineffective|f||||t||||||||||2018-06-01 02:10:57.671337|2018-06-01 02:10:57.671337
NCT00671099|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2014-01-20|2008-05-02|2008-05-05|Estimate|||||||2014-01-20|2014-01-22|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study|Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study|Completed||Phase 3|110|Actual|Japan Science and Technology Agency||2|||f||||t||||||||||2018-06-01 02:10:57.774811|2018-06-01 02:10:57.774811
NCT00671086|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2012-02-27|2008-05-01|2008-05-05|Estimate|||||||2012-02-27|2012-02-28|Estimate|February 2003||2003-02-28|February 2012|2012-02-29|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Efficacy of Ramelteon in Subjects With Chronic Insomnia|A Phase 3, Open-label, Fixed-dose Study to Determine the Safety of Long-term Administration of TAK-375 in Subjects With Chronic Insomnia|Completed||Phase 3|1213|Actual|Takeda||2|||f||||f||||||||||2018-06-01 02:10:57.882389|2018-06-01 02:10:57.882389
NCT00671073|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29||2012-03-01|2012-03-01|2008-04-29|2008-05-02|Estimate||||2012-03-01|2012-03-05|Estimate|2012-03-01|2012-03-05|Estimate|April 2008||2008-04-30|March 2012|2012-03-31||||May 2009|Actual|2009-05-31||Interventional|||Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD|Completed||Phase 2|427|Actual|Forest Laboratories||4|||f||||f||||||||||2018-06-01 02:10:58.142541|2018-06-01 02:10:58.142541
NCT00671060|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2013-02-13||2013-05-06|2008-04-29|2008-05-02|Estimate|2013-05-02|2013-05-06|Estimate||||2013-05-06|2013-05-08|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy|Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy, Inclusive, Not Accompanied by Complete Expulsion of the Contents of the Uterus|Completed||Phase 3|153|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-06-01 02:10:58.276256|2018-06-01 02:10:58.276256
NCT00671047|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2008-12-29|2008-05-01|2008-05-02|Estimate|||||||2008-12-29|2008-12-31|Estimate|December 2007||2007-12-31|December 2008|2008-12-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|SAGE||The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study|The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study|Unknown status|Active, not recruiting||1000|Anticipated|XDx|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum~   "|||2018-06-01 02:10:58.500722|2018-06-01 02:10:58.500722
NCT00671034|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2016-12-14|2008-05-01|2008-05-02|Estimate|||||||2016-12-14|2016-12-15|Estimate|July 2008||2008-07-31|December 2016|2016-12-31||||February 2011|Actual|2011-02-28||Interventional|||Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia|A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase, IND# 100594) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting||N/A|166|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 02:10:59.631686|2018-06-01 02:10:59.631686
NCT00671021|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2012-08-20|2008-05-01|2008-05-02|Estimate|||||||2012-08-20|2012-08-21|Estimate|July 2008||2008-07-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Duration of Platelet Inhibition by Aspirin|Evaluation of Duration of Platelet Inhibition by Aspirin in a Standard 24-hour Interval Dosing Regimen|Completed|||10|Actual|Hopital du Sacre-Coeur de Montreal|||1||f||||t||||||||||2018-06-01 02:10:59.839304|2018-06-01 02:10:59.839304
NCT00671008|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2016-03-02|2008-04-30|2008-05-02|Estimate|||||||2016-03-02|2016-03-03|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes|Efficacy of Glycaemic Control of Biphasic Insulin Aspart (NovoMix® 30) or Insulin Detemir (Levemir®) in Patients With Type 1 or 2 Diabetes Mellitus|Completed|||400|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 02:10:59.924775|2018-06-01 02:10:59.924775
NCT00670995|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2012-02-16|2008-05-01|2008-05-02|Estimate|||||||2012-02-16|2012-02-17|Estimate|November 2009||2009-11-30|February 2012|2012-02-29|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Tobacco Zero: Interactive Tobacco Education for Teens|Tobacco World: Interactive Tobacco Education for Teens|Completed||Phase 2|1864|Actual|Deschutes Research, Inc.|||||f||||f||||||||||2018-06-01 02:10:59.997657|2018-06-01 02:10:59.997657
NCT00293982|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-17|2006-02-17|2006-02-20|Estimate|||||||2006-02-17|2006-02-20|Estimate|June 2004||2004-06-30|February 2005|2005-02-28|August 2005||2005-08-31|||||Interventional|||The Influence of Expectations on Patient Satisfaction in the Pediatric Emergency Department||Completed||N/A|948||Medical College of Wisconsin|||||f||||||||||||||2018-06-01 04:09:32.836728|2018-06-01 04:09:32.836728
NCT00670982|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2013-02-15||2013-03-29|2008-04-29|2008-05-02|Estimate|2013-03-29|2013-05-13|Estimate||||2013-03-29|2013-05-13|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer|Phase 2 Study of Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer|Completed||Phase 2|29|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 02:11:00.082259|2018-06-01 02:11:00.082259
NCT00670969|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2017-06-16|2008-05-01|2008-05-02|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2008||2008-05-31|June 2017|2017-06-30|February 10, 2014|Actual|2014-02-10|February 10, 2014|Actual|2014-02-10||Observational|||Validation of Hand Held Indirect Calorimeter in Overweight and Obese Patients|Validation of Handheld Indirect Calorimeter in Overweight and Obese Patients|Completed|||101|Actual|Milton S. Hershey Medical Center|||2||f||||f||||||||||2018-06-01 02:11:00.65407|2018-06-01 02:11:00.65407
NCT00670956|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2015-03-18||2015-03-18|2008-05-01|2008-05-02|Estimate|2015-03-18|2015-03-30|Estimate||||2015-03-18|2015-03-30|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|CCAM Steroids|Only one participant was enrolled to the study before it was terminated; no participants were enrolled to the control arm|Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)|Investigation of Prenatal Steroids for Treatment of Prenatally Diagnosed CCAMs|Terminated||Phase 1/Phase 2|1|Actual|University of California, San Francisco||2||"Recruitment has been poor. Study drug is being offered as part of standard care of women~   carrying a pregnancy diagnosed with CCAM"|f||||t||||||||||2018-06-01 02:11:00.758019|2018-06-01 02:11:00.758019
NCT00670943|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2009-03-24|2008-05-01|2008-05-02|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Effect of Abrupt Plavix® Discontinuation on Platelet Function|Effect of Abrupt Plavix® Discontinuation on Platelet Function|Completed|||52|Anticipated|Université de Montréal|||2||f||||t||||||||||2018-06-01 02:11:01.025014|2018-06-01 02:11:01.025014
NCT00670930|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2012-11-16||2012-12-12|2008-05-01|2008-05-02|Estimate|2012-12-12|2013-01-18|Estimate||||2012-12-12|2013-01-18|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|eXplore||Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists|A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Trial to Explore the Effects of 78 Weeks Omalizumab Treatment Given as Add on Therapy on Markers of Airway Inflammation and Remodeling in Patients With Moderate to Severe Persistent Allergic Asthma Receiving Inhaled Corticosteroids and Long Acting Beta-agonists|Completed||Phase 4|36|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:11:01.128818|2018-06-01 02:11:01.128818
NCT00670917|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2010-04-09|2008-05-01|2008-05-02|Estimate|||||||2010-04-09|2010-04-12|Estimate|April 2008||2008-04-30|July 2009|2009-07-31||||April 2009|Anticipated|2009-04-30||Interventional|||Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy|A Randomized Controlled Trial Assessing the Effect of Magnetic Acupressure in Reducing Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy|Unknown status|Recruiting|N/A|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:11:01.482951|2018-06-01 02:11:01.482951
NCT00670904|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2010-01-11|2008-05-01|2008-05-02|Estimate|||||||2010-01-11|2010-01-12|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation|Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation|Completed||N/A|101|Actual|University of Montana||2|||f||||f||||||||||2018-06-01 02:11:01.579977|2018-06-01 02:11:01.579977
NCT00670891|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-05-26|2008-05-01|2008-05-02|Estimate|||||||2008-05-26|2008-05-29|Estimate|July 2007||2007-07-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|VPH||A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children|A Prospective, Non-Randomized, Open-Label Study on the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children|Completed||Phase 1|7|Actual|Vachira Phuket Hospital||1|||f||||t||||||||||2018-06-01 02:11:01.723513|2018-06-01 02:11:01.723513
NCT00670878|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2012-03-31|2008-05-01|2008-05-02|Estimate|||||||2012-03-31|2012-04-03|Estimate|June 2008||2008-06-30|March 2012|2012-03-31||||October 2011|Actual|2011-10-31||Interventional|||Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer|Prospectively Randomized Phase III Trial, Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer|Completed||Phase 3|799|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 02:11:01.789706|2018-06-01 02:11:01.789706
NCT00670865|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2010-04-15|2008-04-30|2008-05-02|Estimate|||||||2010-04-15|2010-04-16|Estimate|May 2008||2008-05-31|April 2010|2010-04-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Automated Versus Conventional Hospital Discharge Summaries and Prescriptions|Automated Versus Conventional Hospital Discharge Summaries and Prescriptions: A Randomized Controlled Trial|Completed||N/A|209|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 02:11:01.877046|2018-06-01 02:11:01.877046
NCT00670852|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2011-04-25|2008-05-01|2008-05-02|Estimate|||||||2011-04-25|2011-04-27|Estimate|April 2008||2008-04-30|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Observational|Glenoid||Followup of Glenoid Fix Utilizing Auto Bone Graft in Shoulder Replacement|Computed Tomographic and Functional Follow-up of Glenoid Anchor Peg Component Fixation Utilizing Autologous Bone Graft in Total Shoulder Arthroplasty|Unknown status|Recruiting||70|Anticipated|University of Nebraska|||1||f||||f||||||||||2018-06-01 02:11:01.966067|2018-06-01 02:11:01.966067
NCT00670839|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2013-08-08|2008-05-01|2008-05-02|Estimate|||||||2013-08-08|2013-08-12|Estimate|May 2008||2008-05-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|December 2011|Actual|2011-12-31||Interventional|B-BOOST||Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)|Open-label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of Double-dose (40 µg at S0, S4 and S24), Versus Standard Dose Vaccination (20 µg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost|Completed||Phase 3|178|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 02:11:02.093831|2018-06-01 02:11:02.093831
NCT00669123|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2008-04-28|2008-04-28|2008-04-29|Estimate|||||||2008-04-28|2008-04-29|Estimate||||April 2008|2008-04-30||||||||Interventional|||Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis|Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis|Completed||Phase 4|126|Actual|Bioiberica||2|||f||||f||||||||||2018-06-01 02:11:28.807187|2018-06-01 02:11:28.807187
NCT00670826|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-05-01|2008-05-01|2008-05-02|Estimate|||||||2008-05-01|2008-05-02|Estimate|July 2008||2008-07-31|April 2008|2008-04-30|November 2008|Anticipated|2008-11-30|September 2008|Anticipated|2008-09-30||Interventional|||Comparison Study of Intraoperative Patient Warming Systems|Intraoperative Warming: Comparison of Performance of the Dynatherm Medical vitalHEAT Temperature Management System(vH2)With the Arizant Bair Hugger System|Unknown status|Not yet recruiting|N/A|100|Anticipated|Dynatherm Medical Inc.||2|||f||||f||||||||||2018-06-01 02:11:02.228795|2018-06-01 02:11:02.228795
NCT00670813|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2011-07-19|2008-05-01|2008-05-02|Estimate|||||||2011-07-19|2011-07-20|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil|Verstärkung Der Therapeutischen Wirkung Von Schlafentzug Durch Modafinil - Eine Doppelblinde, Randomisierte, Placebokontrollierte Monozentrische Studie Der Phase II (Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil - a Double Blind, Placebo-controlled Monocentric Phase II Study)|Withdrawn||Phase 2|30|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-06-01 02:11:02.360839|2018-06-01 02:11:02.360839
NCT00670800|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2013-01-02||2014-05-15|2008-05-01|2008-05-02|Estimate|2014-04-14|2014-05-15|Estimate||||2014-05-15|2014-05-21|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Two controls were excluded from data analysis as they were later found to be insulin resistant.|Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome|Influence of Insulin Resistance on Cognitive, Emotional and Opioid System Functioning in Women With Polycystic Ovary Syndrome|Completed||N/A|14|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 02:11:02.522933|2018-06-01 02:11:02.522933
NCT00670787|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2011-03-04|2008-05-01|2008-05-02|Estimate|||||||2011-03-04|2011-03-07|Estimate|June 2008||2008-06-30|March 2011|2011-03-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|COMFORT||Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial|A Randomized Trial to Establish the Effects of Combination Pill of Losartan Potassium and Hydrochlorothiazide on Medication Compliance Among Patients With High Blood Pressure.|Completed||Phase 3|207|Actual|Kyushu University||2|||f||||t||||||||||2018-06-01 02:11:03.109806|2018-06-01 02:11:03.109806
NCT00670774|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2015-06-03|2008-04-30|2008-05-02|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant|A Single Center, Open-label Study to Determine the Safety and Efficacy of a Dosing Regimen of Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection (AMR) in Positive Crossmatch Living Donor Kidney Transplantation|Unknown status|Active, not recruiting|N/A|20|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:11:03.218557|2018-06-01 02:11:03.218557
NCT00670761|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2016-07-26|2008-05-01|2008-05-02|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2004||2004-07-31|July 2016|2016-07-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Misoprostol for the Treatment of Incomplete Abortion|Misoprostol for the Treatment of Incomplete Abortion: Comparison of Treatment Options|Completed||N/A|720|Actual|Gynuity Health Projects||3|||f||||f||||||||||2018-06-01 02:11:03.310955|2018-06-01 02:11:03.310955
NCT00670748|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|2016-05-19||2016-10-26|2008-05-01|2008-05-02|Estimate|2016-05-19|2016-06-27|Estimate||||2016-10-26|2016-12-08|Estimate|April 2008||2008-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|May 2013|Actual|2013-05-31||Interventional|||Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer|Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes|Terminated||Phase 2|45|Actual|National Institutes of Health Clinical Center (CC)||4||A more highly selected protocol with ESO TCR opened for pts with melanoma|f||||f||||||||No||2018-06-01 02:11:03.453477|2018-06-01 02:11:03.453477
NCT00670735|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2017-10-26|2008-04-30|2008-05-02|Estimate|||||||2017-10-26|2017-10-30|Actual|April 2008||2008-04-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)|HCRN Core Data Project: Characterizing Patient Populations in the Hydrocephalus Clinical Research Network (HCRN)|Recruiting|||1400|Anticipated|University of Utah|||||f||||f||||||||||2018-06-01 02:11:04.149182|2018-06-01 02:11:04.149182
NCT00670722|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2016-10-27|2008-04-30|2008-05-02|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin|Observational Study on Evaluation of Glycaemic Control in Patients Using a Modern Insulin - NovoRapid® (Insulin Aspart), NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus|Completed|||6500|Actual|Novo Nordisk A/S|||4||f||||f||||||||||2018-06-01 02:11:04.341403|2018-06-01 02:11:04.341403
NCT00670709|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2009-06-16||2013-02-04|2008-04-30|2008-05-02|Estimate|2010-07-20|2010-08-16|Estimate||||2013-02-04|2013-02-11|Estimate|September 2006||2006-09-30|February 2013|2013-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|HD||Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease|Examination of Quantitative Electroencephalographic Biomarkers in Huntington's Disease: A Pilot Project|Completed|||42|Actual|University of California, Los Angeles|||2||f||||f||||||||||2018-06-01 02:11:04.439582|2018-06-01 02:11:04.439582
NCT00670696|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2012-04-24|2008-05-01|2008-05-02|Estimate|||||||2012-04-24|2012-04-25|Estimate|April 2008||2008-04-30|April 2012|2012-04-30||||December 2008|Anticipated|2008-12-31||Interventional|||A Study to Compare the Efficacy of Rapydan Versus Tetracaine Gel|A Randomised, Controlled, Single-blinded, Cross Over Comparison Study to Compare the Efficacy of the Rapydan Medicated Plaster Versus Tetracaine Gel|Withdrawn||Phase 4|0|Actual|Jazz Pharmaceuticals||2||No longer sponsor of trial|f||||f||||||||||2018-06-01 02:11:04.688137|2018-06-01 02:11:04.688137
NCT00670683|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2016-03-02|2008-04-30|2008-05-02|Estimate|||||||2016-03-02|2016-03-03|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Observational Study of Patients With Diabetes Using Levemir® FlexPen®|Safety and Efficacy of Insulin Detemir (Levemir® FlexPen®) in Patients With Diabetes Mellitus|Completed|||797|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:11:04.76663|2018-06-01 02:11:04.76663
NCT00670670|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2014-12-04|2008-05-01|2008-05-02|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Prospective, Randomized Clinical Study on the Effects of Casein Phosphopeptide-amorphous Calcium Phosphate (CPP-ACP) Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 1|A Prospective, Randomized Clinical Study on the Effects of CPP-ACP Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 1|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 02:11:04.846219|2018-06-01 02:11:04.846219
NCT00670657|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2009-03-26|2008-05-01|2008-05-02|Estimate|||||||2009-03-26|2009-03-27|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|CRITIC||CRITIC - Treatment of Candidemia and Invasive Candidiasis|CRITIC: Phase II Pilot Multicenter Study on Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) at 2 mg/kg/Day in the Treatment of Candidemia and Invasive Candidiasis in Non-Neutropenic Patients|Completed||Phase 4|39|Anticipated|Gilead Sciences||1|||f||||f||||||||||2018-06-01 02:11:04.925396|2018-06-01 02:11:04.925396
NCT00670644|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2017-04-07|2008-05-01|2008-05-02|Estimate|||||||2017-04-07|2017-04-10|Actual|May 2006||2006-05-31|April 2017|2017-04-30|March 2011|Actual|2011-03-31|May 2007|Actual|2007-05-31||Observational|||Self-Care for Lymphedema in Patients With Breast Cancer|Breast Cancer Treatment Related Lymphedema Self Care Practices|Completed|||51|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 02:11:05.00036|2018-06-01 02:11:05.00036
NCT00670631|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2017-08-29||2017-08-29|2008-05-01|2008-05-02|Estimate|2017-08-29|2017-08-31|Actual||||2017-08-29|2017-08-31|Actual|February 2008||2008-02-29|August 2017|2017-08-31|April 2014|Actual|2014-04-30|May 2012|Actual|2012-05-31||Interventional||Data not available. Study conducted at University of Utah. Upon PI leaving Utah and coming to the University of Iowa, record NCT00670631 was transferred to Iowa by ClinicalTrials.gov staff. No research activities under NCT00670631 were conducted at Iowa. PRS staff at Iowa and Utah have corresponded and neither party (including PI) have the data.|Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment|Tandem Autotransplantation for Multiple Myeloma Patients With Less Than 12 Months of Preceding Therapy, Incorporating Bortezomib With the Transplant Chemotherapy and During Maintenance|Completed||Phase 2|46|Actual|University of Iowa|Data not available. Study conducted at Utah. Upon PI leaving & coming to Iowa, record was transferred to IA by ClinicalTrials.gov. No research activities under NCT00670631 were conducted at IA. PRS staff have corresponded and neither party have data.|1|||f||||t||||||||||2018-06-01 02:11:05.074604|2018-06-01 02:11:05.074604
NCT00670618|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2014-12-04|2008-05-01|2008-05-02|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Prospective, Randomized Clinical Study on the Effects of Casein Phosphopeptide-amorphous Calcium Phosphate (CPP-ACP) Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 2|A Prospective, Randomized Clinical Study on the Effects of CPP-ACP Paste on Plaque, Gingivitis and White Spot Lesions in Orthodontic Patients - Part 2|Unknown status|Recruiting|N/A|400|Anticipated|University Hospital, Ghent||4|||f||||f||||||||||2018-06-01 02:11:05.198707|2018-06-01 02:11:05.198707
NCT00670605|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-01|||2011-03-23|2008-05-01|2008-05-02|Estimate|||||||2011-03-23|2011-03-24|Estimate|June 2007||2007-06-30|March 2011|2011-03-31||||December 2009|Actual|2009-12-31||Observational|||Cancer Occurrence and Outcome in Young Patients Undergoing Cancer Treatment at the Vanderbilt-Ingram Cancer Center|VICC Adolescent and Young Adult Oncology Review|Terminated|||||Vanderbilt University|||||f||||||||||||||2018-06-01 02:11:05.271149|2018-06-01 02:11:05.271149
NCT00670592|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2014-01-21|2008-05-01|2008-05-02|Estimate|||||||2014-01-21|2014-01-23|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies|A Phase IA/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (CHIR-12.12-LYM-01)|Completed||Phase 1/Phase 2|111|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:11:05.334479|2018-06-01 02:11:05.334479
NCT00670579|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2011-08-22|2008-04-30|2008-05-02|Estimate|||||||2011-08-22|2011-08-23|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|September 2010|Actual|2010-09-30|October 2009|Actual|2009-10-31||Observational|||Study About Complications of Totally Implanted Venous Access Devices (TIVADs) in People With Cystic Fibrosis (CF)|A Prospective Study About Complications of Totally Implantable Central Venous Access Ports in People With CF|Completed|||80|Actual|University of Florence|||||f||||||||||||||2018-06-01 02:11:05.435348|2018-06-01 02:11:05.435348
NCT00670566|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2009-09-14|2008-05-01|2008-05-02|Estimate|||||||2009-09-14|2009-09-15|Estimate|April 2008||2008-04-30|September 2009|2009-09-30||||March 2009|Actual|2009-03-31||Interventional|||Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients|Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients|Completed||Phase 4|503|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:11:05.496678|2018-06-01 02:11:05.496678
NCT00670553|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2017-05-15|2008-05-01|2008-05-02|Estimate|||||||2017-05-15|2017-05-17|Actual|September 2008||2008-09-30|May 2017|2017-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer|A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer|Completed||Phase 1|7|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:11:05.572569|2018-06-01 02:11:05.572569
NCT00670540|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2012-02-09||2012-05-04|2008-05-01|2008-05-02|Estimate|2012-04-05|2012-05-03|Estimate||||2012-05-04|2012-05-08|Estimate|November 2004||2004-11-30|May 2012|2012-05-31|February 2010|Actual|2010-02-28|January 2009|Actual|2009-01-31||Observational|OPTIMEV||Epidemiology of Thromboembolism Disease: A Cohort Study|A Prospective Epidemiological Multicenter Cohort Study on Patients Clinically Suspected of Deep Vein Thrombosis or Pulmonary Embolism|Completed|||8256|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-06-01 02:11:05.70513|2018-06-01 02:11:05.70513
NCT00670527|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2012-10-05|2008-04-30|2008-05-01|Estimate|||||||2012-10-05|2012-10-08|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Interventional|PROPET||[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases|Evaluation of [18F] Fluorocholine PET/CT for Detection of Regional Lymph Node Metastases From Prostate Cancer|Unknown status|Recruiting|N/A|205|Anticipated|Odense University Hospital|||||f||||t||||||||||2018-06-01 02:11:06.331669|2018-06-01 02:11:06.331669
NCT00670514|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate|April 2003||2003-04-30|April 2008|2008-04-30||||||||Interventional|||Smoking Cessation in a Dentistry Setting|A Comparing Study of the Smoking Cessation Program NIX Individual and the Self-Help Program Fimpa Dig Fri|Completed||N/A|300||Uppsala University||2|||f||||f||||||||||2018-06-01 02:11:06.412416|2018-06-01 02:11:06.412416
NCT00670501|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-29|2008-04-29|2008-05-01|Estimate|||||||2008-04-29|2008-05-01|Estimate|August 1996||1996-08-31|April 2008|2008-04-30|April 1999|Actual|1999-04-30|April 1999|Actual|1999-04-30||Interventional|||Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis|Effects of LY333334 in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|1637|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-06-01 02:11:06.489137|2018-06-01 02:11:06.489137
NCT00670488|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2015-02-02|2008-04-30|2008-05-01|Estimate|||||||2015-02-02|2015-02-03|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dose Escalation Study With MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors (2206-002)|A Phase I Dose Escalation Study of Oral MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|104|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:11:06.621761|2018-06-01 02:11:06.621761
NCT00670475|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2010-04-28|2008-04-29|2008-05-01|Estimate|||||||2010-04-28|2010-04-29|Estimate|April 2008||2008-04-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|May 2009|Actual|2009-05-31||Interventional|||Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee|Comparative Study of Olive Oil With Piroxicam Gel in Osteoarthritis of the Knee|Completed||Phase 2|60|Actual|Ardabil University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:11:06.692846|2018-06-01 02:11:06.692846
NCT00670462|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|2014-11-12||2017-02-17|2008-04-30|2008-05-01|Estimate|2014-11-12|2014-11-20|Estimate||||2017-02-17|2017-03-22|Actual|October 2004||2004-10-31|February 2017|2017-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|LIFE||Maintenance-Tailored Obesity Treatment|Maintenance-Tailored Obesity Treatment|Completed||N/A|213|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 02:11:06.794269|2018-06-01 02:11:06.794269
NCT00670449|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2013-03-08||2013-06-26|2008-04-30|2008-05-01|Estimate|2013-06-26|2013-09-04|Estimate||||2013-06-26|2013-09-04|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis|An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis|Completed||Phase 2|143|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:11:07.386096|2018-06-01 02:11:07.386096
NCT00670436|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2014-06-07|2008-04-30|2008-05-01|Estimate|||||||2014-06-07|2014-06-10|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|March 2014|Actual|2014-03-31|September 2009|Actual|2009-09-30||Interventional|PEPCAD-CTO||The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions|The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions|Completed||Phase 2|48|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 02:11:08.047267|2018-06-01 02:11:08.047267
NCT00670423|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2016-02-24|2008-04-30|2008-05-01|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|October 2013|Actual|2013-10-31|July 2012|Actual|2012-07-31||Interventional|||A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation|A Phase I Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation|Completed||Phase 1|27|Actual|Indiana University|||||f||||t||||||||||2018-06-01 02:11:08.115141|2018-06-01 02:11:08.115141
NCT00670410|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2016-06-22|2008-04-30|2008-05-01|Estimate|||||||2016-06-22|2016-06-24|Estimate|November 2003||2003-11-30|June 2016|2016-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma|A Pilot Study of Sequential Autologous Stem Cell Transplantation and Immunotherapy With Reduced Intensity Allogeneic Stem Cell Transplant for High Risk Neuroblastoma|Terminated||Phase 1|15|Actual|Columbia University||2||Poor accrual|f||||t||||||||Undecided|Unknown.|2018-06-01 02:11:08.238102|2018-06-01 02:11:08.238102
NCT00670397|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2016-03-14|2008-04-30|2008-05-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|November 2011|Actual|2011-11-30||Interventional|||Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer|Phase I Trial of Photodynamic Therapy With HPPH (2-1[Hexyloxyethyl]-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and Stage I Carcinoma of the Oral Cavity|Terminated||Phase 1|11|Actual|Roswell Park Cancer Institute||1||safety issues|f||||t||||||||||2018-06-01 02:11:08.336787|2018-06-01 02:11:08.336787
NCT00670384|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2014-01-08|2008-04-29|2008-05-01|Estimate|||||||2014-01-08|2014-01-09|Estimate||||January 2014|2014-01-31||||||||Interventional|||Phase 2 Study in Adults Sensitized to Short Ragweed|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy in Adults Sensitized to the Standardized Allergenic Extract, Short Ragweed (Ambrosia Artemisiifolia)|Withdrawn||Phase 2|0|Actual|Antigen Laboratories, Inc.||3||No funding.|f||||f||||||||||2018-06-01 02:11:08.399617|2018-06-01 02:11:08.399617
NCT00670371|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2009-11-24|2008-04-29|2008-05-01|Estimate|||||||2009-11-24|2009-11-25|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|||||Observational|||Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study|Factors of Importance for the Subjective and Objective Burden of Informal Caregivers to Patients With Functional Psychoses - a Descriptive and Comparative Study|Completed|||100|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-06-01 02:11:08.459269|2018-06-01 02:11:08.459269
NCT00670358|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2018-03-15|2008-04-30|2008-05-01|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2008||2008-08-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma|Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma|Recruiting||Phase 1/Phase 2|47|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:11:08.591584|2018-06-01 02:11:08.591584
NCT00670345|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2014-04-04|2008-04-30|2008-05-01|Estimate|||||||2014-04-04|2014-04-07|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|TRANEX-URO||Tranexamic Acid in Urologic Surgery|Efficacy of Tranexamic Acid in Reducing Perioperative Bleeding in Patients Undergoing Radical Prostatectomy. A Randomized Controlled Double-blind Study.|Completed||Phase 4|||Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-06-01 02:11:08.723705|2018-06-01 02:11:08.723705
NCT00670332|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-29|2008-04-29|2008-05-01|Estimate|||||||2008-04-29|2008-05-01|Estimate|July 2007||2007-07-31|April 2008|2008-04-30||||||||Observational|PACE||Prognostic Assessment of Contrast Echocardiography (PACE Study)|Prognostic Assessment of Contrast Echocardiography (PACE Study): An Observational Follow-up Study of Patients With Chest Pain Evaluated With AI-700 Contrast Echocardiography|Terminated|||773|Anticipated|Acusphere|||||t||||||||||||||2018-06-01 02:11:08.787772|2018-06-01 02:11:08.787772
NCT00267462|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-05-03|2005-12-19|2005-12-21|Estimate|||||||2007-05-03|2007-05-07|Estimate|January 1996||1996-01-31|May 2007|2007-05-31||||||||Observational|||Hypertrophic Myopathy in Children|Retrospective Review of Hypertrophic Myopathy in Children|Terminated|||75||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:16:08.181522|2018-06-01 04:16:08.181522
NCT00670319|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate|November 1994||1994-11-30|April 2008|2008-04-30|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|MORE||Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis|Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|7705|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-06-01 02:11:08.847374|2018-06-01 02:11:08.847374
NCT00670306|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2010-10-18||2011-04-01|2008-04-29|2008-05-01|Estimate|2010-12-15|2011-01-19|Estimate||||2011-04-01|2011-04-05|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|AEZS-102-Z041||Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)|Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: an Open-Labeled Safety and Efficacy Assessment Study|Completed||Phase 3|528|Actual|AEterna Zentaris||1|||f||||f||||||||||2018-06-01 02:11:08.980898|2018-06-01 02:11:08.980898
NCT00670293|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2016-04-06|2008-04-29|2008-05-01|Estimate|||||||2016-04-06|2016-04-07|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Observational|||Changes in Dopamine Levels Before and After Weight Restoration in People With Anorexia Nervosa|Imaging of Dopamine Systems in Anorexia Nervosa|Completed|||50|Actual|New York State Psychiatric Institute|||2||f||||f||||||||||2018-06-01 02:11:09.361299|2018-06-01 02:11:09.361299
NCT00670280|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2016-01-05|2008-04-30|2008-05-01|Estimate|||||||2016-01-05|2016-01-06|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Reducing Environmental Tobacco Smoke in Neonatal Intensive Care Unit (NICU) Infants' Homes|Reducing Environmental Tobacco Smoke in NICU Infants' Homes|Completed||N/A|144|Actual|The University of Texas Health Science Center, Houston||3|||f||||t||||||||||2018-06-01 02:11:09.457766|2018-06-01 02:11:09.457766
NCT00670267|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2015-06-16||2016-04-06|2008-04-29|2008-05-01|Estimate|2016-04-06|2016-05-11|Estimate||||2016-04-06|2016-05-11|Estimate|January 2007||2007-01-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Oral Nadolol for the Treatment of Adults With Mild Asthma|An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma|Completed||Phase 1/Phase 2|10|Actual|Invion, Inc.||1|||f||||f||||||||||2018-06-01 02:11:09.548174|2018-06-01 02:11:09.548174
NCT00670254|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2013-09-26|2008-04-29|2008-05-01|Estimate|||||||2013-09-26|2013-09-27|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|HYPRESS||Hydrocortisone for Prevention of Septic Shock|Placebo-controlled, Randomised, Double-blind Study to Investigate the Efficacy and Safety of Low Dose Hydrocortisone to Prevent the Development of Septic Shock in Patients With Severe Sepsis|Completed||Phase 3|380|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:11:09.752262|2018-06-01 02:11:09.752262
NCT00670241|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2010-11-23||2015-03-25|2008-04-30|2008-05-01|Estimate|2011-02-14|2011-03-08|Estimate||||2015-03-25|2015-04-14|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris|A Phase 3 Study Comparing a Gel Containing Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) With Tacalcitol Ointment (4 mcg/g) and Gel Vehicle, Used Once Daily in the Treatment of Psoriasis Vulgaris|Completed||Phase 3|458|Actual|LEO Pharma||3|||f||||f||||||||||2018-06-01 02:11:09.903623|2018-06-01 02:11:09.903623
NCT00670228|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2010-11-16||2011-01-14|2008-04-30|2008-05-01|Estimate|2011-01-14|2011-02-11|Estimate||||2011-01-14|2011-02-11|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|INTENSIVE||Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction|A Multi-center, Phase 3b, Stratified, Randomized, Open-label Clinical Trial to Evaluate the Efficacy of Intensive Apidra®/Lantus® Therapy vs Sliding Scale Insulin on Infarct Size in Hyperglycemic Subjects With Anterior STEMI (ST Elevation Myocardial Infarction) Undergoing PCI (Percutaneous Coronary Intervention)|Terminated||Phase 3|34|Actual|Sanofi|Early termination leading to small numbers of subjects analyzed. Only descriptive statistics were presented for primary and key secondary efficacy endpoints. The analysis focused on a review of safety Adverse Events (AEs) data.|2||"Due to Negative feasibility assessment of recruiting the planned number of subjects within the~   study timelines"|f||||t||||||||||2018-06-01 02:11:10.33234|2018-06-01 02:11:10.33234
NCT00670215|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2014-12-18|2008-04-29|2008-05-01|Estimate|||||||2014-12-18|2014-12-19|Estimate|April 2004||2004-04-30|December 2014|2014-12-31|October 2004|Actual|2004-10-31|||||Interventional|||BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis|Prospective, Randomized, Double-blind, Comparison of Ciprofloxacin Extended-release 1000 mg Tablets Given as Two Different Prophylactic Dosing Regimens (Regimen I - Single-dose Ciprofloxacin MR 1000 mg or Regimen II - Multiple-dose Ciprofloxacin MR 1000 mg Once Daily for 3 Days) for the Prevention of Post-operative Infectious Complications in Patients Undergoing Transrectal Needle Biopsy of the Prostate|Completed||Phase 3|497|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:11:10.769723|2018-06-01 02:11:10.769723
NCT00670202|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2017-02-10||2017-02-10|2008-04-30|2008-05-01|Estimate|2017-02-10|2017-03-29|Actual||||2017-02-10|2017-03-29|Actual|March 13, 2008|Actual|2008-03-13|February 2017|2017-02-28|January 20, 2011|Actual|2011-01-20|January 20, 2011|Actual|2011-01-20||Interventional|||Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis|The Effect of Fasudil on Rho Kinase Activity in Patients Scheduled for Elective Carotid Endarterectomy|Terminated||Phase 2|2|Actual|Brigham and Women's Hospital|Study was terminated early due to poor enrollment. The patients and physicians remained blinded to study drug assignment for the 2 patients who completed the protocol and no analyses were performed.|2||Slow enrollment|f||||f||||||||||2018-06-01 02:11:10.968863|2018-06-01 02:11:10.968863
NCT00670189|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2014-08-13|2008-04-29|2008-05-01|Estimate|||||||2014-08-13|2014-08-15|Estimate|July 2008||2008-07-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer|A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|53|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:11:11.233547|2018-06-01 02:11:11.233547
NCT00670176|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate||||April 2008|2008-04-30|June 2005|Actual|2005-06-30|||||Interventional|||Pre- and Postoperative Cardiopulmonary Rehabilitation Reduces Complications After Coronary Artery Bypass Surgery: A Randomized Trial|Pre- and Postoperative Cardiopulmonary Rehabilitation Reduces Complications After Coronary Artery Bypass Surgery: A Randomized Trial|Completed||N/A|56||Universidade do Sul de Santa Catarina||1|||f||||t||||||||||2018-06-01 02:11:11.311385|2018-06-01 02:11:11.311385
NCT00252408|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-09-03|2005-11-10|2005-11-11|Estimate|||||||2009-09-03|2009-09-04|Estimate|October 1990||1990-10-31|September 2009|2009-09-30|December 2003||2003-12-31|||||Interventional|||Danish Osteoporosis Prevention Study|Danish Osteoporosis Prevention Study|Completed||Phase 4|2000||University of Aarhus|||||f||||||||||||||2018-06-01 04:20:51.638366|2018-06-01 04:20:51.638366
NCT00670163|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2013-12-11|2008-04-29|2008-05-01|Estimate|||||||2013-12-11|2013-12-13|Estimate|April 2008||2008-04-30|December 2013|2013-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effectiveness of Community-Level Behavioral and Biomedical Interventions for Reducing HIV/STIs in Men in Peru|Comunidades Positivas and Enhanced Partner Therapy in Peru|Completed||N/A|718|Actual|University of California, Los Angeles||4|||f||||t||||||||||2018-06-01 02:11:11.359508|2018-06-01 02:11:11.359508
NCT00670150|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2015-10-24|2008-04-29|2008-05-01|Estimate|||||||2015-10-24|2015-10-27|Estimate|May 2010||2010-05-31|October 2015|2015-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia|Phase II Study of NRX 195183 Induction and NRX 195183 Combined With Arsenic Trioxide (As2o3) as Initial Consolidation Therapy Followed by Continuous NRX 195183 Maintenance Therapy for Patients With Untreated Acute Promyelocytic Leukemia|Withdrawn||Phase 2|0|Actual|University of Southern California||||sponsor withdrew support|f||||f||||||||||2018-06-01 02:11:11.498122|2018-06-01 02:11:11.498122
NCT00670137|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:11:11.580364|2018-06-01 02:11:11.580364
NCT00670124|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2014-11-04|2008-04-29|2008-05-01|Estimate|||||||2014-11-04|2014-11-05|Estimate|January 2005||2005-01-31|November 2014|2014-11-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Hypothermia to Prevent High Intracranial Pressure in Patients With Acute Liver Failure|Pilot Trial on the Effect of Mild Hypothermia on Intracranial Pressure in Patients With Hyperacute Liver Failure|Completed||N/A|50|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:11:11.628381|2018-06-01 02:11:11.628381
NCT00670111|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2012-05-03||2017-05-17|2008-04-29|2008-05-01|Estimate|2017-05-17|2017-05-19|Actual||||2017-05-17|2017-05-19|Actual|July 2008||2008-07-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|RESET|"All participants were RAP On for months 1 through 6. All participants were 'Rap On' for months 6 to 12."|Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction|Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction|Terminated||N/A|32|Actual|Boston Scientific Corporation|Early study termination leading to small numbers of subjects analyzed and an inability to test study hypothesis.|2||Difficulty in enrollment|f||||t||||||||No||2018-06-01 02:11:11.751138|2018-06-01 02:11:11.751138
NCT00670098|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2015-10-20|2008-04-30|2008-05-01|Estimate|||||||2015-10-20|2015-10-22|Estimate|August 2005||2005-08-31|November 2011|2011-11-30|September 2013|Actual|2013-09-30|October 2007|Actual|2007-10-31||Interventional|||Changes in Sexual Function Following Bariatric Surgery|Psychosocial Changes Associated With Weight Loss|Completed||N/A|207|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 02:11:12.261495|2018-06-01 02:11:12.261495
NCT00670059|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|June 2007|Actual|2007-06-30||Interventional|||Pre-Implantation Genetic Screening in Women Under the Age of 36 Years With Single Embryo Transfer|Pre-Implantation Genetic Screening in Women Under the Age of 36 With Single-Embryo Transfer|Terminated||N/A|240|Actual|Vrije Universiteit Brussel||2||At the first prespecified interim analysis|f||||f||||||||||2018-06-01 02:11:12.345428|2018-06-01 02:11:12.345428
NCT00670046|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2011-02-18|2008-04-30|2008-05-01|Estimate|||||||2011-02-18|2011-02-21|Estimate|May 2008||2008-05-31|July 2009|2009-07-31||||April 2009|Anticipated|2009-04-30||Interventional|||Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer|Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer|Unknown status|Recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 02:11:12.432772|2018-06-01 02:11:12.432772
NCT00670033|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29||2014-07-09|2014-07-09|2008-04-30|2008-05-01|Estimate||||2014-07-09|2014-07-10|Estimate|2014-07-09|2014-07-10|Estimate|April 2008||2008-04-30|June 2014|2014-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension|Comparison of Safety and IOP-Lowering Efficacy of Three Alternative Travoprost Formulations to Vehicle and TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|158|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 02:11:12.533668|2018-06-01 02:11:12.533668
NCT00670020|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate|January 2001||2001-01-31|April 2008|2008-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Supplemental Perioperative Oxygen to Reduce the Incidence of Post-Cesarean Endometritis and Wound Infection|Supplemental Perioperative Oxygen to Reduce the Incidence of Post-Cesarean Endometritis and Wound Infection|Completed||N/A|143|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:11:12.631716|2018-06-01 02:11:12.631716
NCT00670007|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2016-06-02|2015-09-02|2016-07-13|2008-04-30|2008-05-01|Estimate|2016-06-02|2016-07-12|Estimate|2015-09-02|2015-09-18|Estimate|2016-07-13|2016-08-15|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.|An Open-label, Non-controlled, Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Zemaira® Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency Who Completed Clinical Study CE1226_4001|Completed||Phase 4|140|Actual|CSL Behring||1|||f||||||||||||||2018-06-01 02:11:12.756784|2018-06-01 02:11:12.756784
NCT00669994|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2014-12-18|2008-04-29|2008-05-01|Estimate|||||||2014-12-18|2014-12-19|Estimate|July 2003||2003-07-31|December 2014|2014-12-31|October 2003|Actual|2003-10-31|||||Interventional|||Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections|Prospective, Open Label Non-comparative, Multi-center Trial to Evaluate the Efficacy and Safety of Cipro® XR 500 mg Once Daily for 3 Days in Treating Female Patients With Acute, Uncomplicated, Symptomatic Lower Urinary Tract Infections|Completed||Phase 4|180|Actual|Bayer||1|||f||||||||||||||2018-06-01 02:11:13.293551|2018-06-01 02:11:13.293551
NCT00669981|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2013-11-22|2008-04-29|2008-05-01|Estimate|||||||2013-11-22|2013-11-26|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effectiveness of Cognitive Behavioral Couples Therapy for Post-traumatic Stress Disorder|Cognitive-Behavioral Couples Therapy for Posttraumatic Stress Disorder|Completed||Phase 2/Phase 3|80|Actual|Ryerson University||2|||f||||f||||||||||2018-06-01 02:11:13.414103|2018-06-01 02:11:13.414103
NCT00669656|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2017-04-18|2008-04-29|2008-04-30|Estimate|||||||2017-04-18|2017-04-20|Actual|July 6, 2008|Actual|2008-07-06|April 2017|2017-04-30|October 14, 2014|Actual|2014-10-14|July 8, 2014|Actual|2014-07-08||Interventional|||Herbal Therapy for Treatment of Recurrent Prostate Cancer|A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy|Completed||Phase 2|43|Actual|University of Southern California||1|||f||||t|t|f||||||||2018-06-01 02:11:20.587266|2018-06-01 02:11:20.587266
NCT00669968|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2012-05-30|2008-04-30|2008-05-01|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Study of Value of Cardiac PET Scans With or Without CT Angiography and/or Measurement of Coronary Flow Reserve|PET Myocardial Perfusion Imaging With CT Angiography and Measurement of Coronary Flow Reserve: A Prospective Study of Effectiveness, Impact on Patient Management, Prognostic Value, and Downstream Costs|Completed|||17|Actual|Kettering Health Network|||||f||||f||||||||||2018-06-01 02:11:13.572295|2018-06-01 02:11:13.572295
NCT00669955|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2010-06-21||2017-02-08|2008-04-30|2008-05-01|Estimate|2010-08-03|2010-08-05|Estimate||||2017-02-08|2017-03-16|Actual|June 2008||2008-06-30|February 2017|2017-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy|Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days|Completed||Phase 3|440|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 02:11:13.649704|2018-06-01 02:11:13.649704
NCT00669942|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2015-01-28|2012-05-31|2015-03-27|2008-04-30|2008-05-01|Estimate|2015-03-27|2015-03-30|Estimate|2012-05-31|2012-06-06|Estimate|2015-03-27|2015-03-30|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients|A Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients With Pharmacodynamics Assessed in an Expanded Cohort at the Maximum Tolerated Dose|Completed||Phase 1/Phase 2|104|Actual|Novartis||12|||f||||f||||||||||2018-06-01 02:11:14.072061|2018-06-01 02:11:14.072061
NCT00669929|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2009-02-18|2008-04-29|2008-05-01|Estimate|||||||2009-02-18|2009-02-19|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Observational|||Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea|Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea|Unknown status|Recruiting||200|Anticipated|Yonsei University|||3||f||||f||||||||||2018-06-01 02:11:16.681487|2018-06-01 02:11:16.681487
NCT00669916|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2015-01-28||2015-04-09|2008-04-30|2008-05-01|Estimate|2015-04-09|2015-04-10|Estimate||||2015-04-09|2015-04-10|Estimate|February 2007||2007-02-28|April 2015|2015-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis|Phase 2a Single-Dose, Randomized, Double Blind, Multi-Center, Parallel-Group, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety, Tolerability, and Population Pharmacokinetics of AIN457 in Patients With Stable Plaque-type Psoriasis|Completed||Phase 1/Phase 2|36|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:11:16.83405|2018-06-01 02:11:16.83405
NCT00669903|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2010-02-04||2010-07-09|2008-04-29|2008-05-01|Estimate|2010-07-09|2010-08-06|Estimate||||2010-07-09|2010-08-06|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Oral Multiple Ascending Doses of AZD0328 in Patients With Schizophrenia|Terminated||Phase 2|100|Actual|AstraZeneca||4||"Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to~   stop further development of AZD0328"|f||||||||||||||2018-06-01 02:11:17.203558|2018-06-01 02:11:17.203558
NCT00669890|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2015-04-20|2008-04-29|2008-05-01|Estimate|||||||2015-04-20|2015-04-22|Estimate|May 2004||2004-05-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|High Risk||Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML|Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamid and Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ Acute Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia|Terminated||Phase 1|12|Actual|New York Medical College||1||PI left institution|f||||t||||||||||2018-06-01 02:11:17.781024|2018-06-01 02:11:17.781024
NCT00669877|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2016-10-19||2018-04-18|2008-04-30|2008-05-01|Estimate|2018-04-18|2018-05-16|Actual||||2018-04-18|2018-05-16|Actual|August 2002||2002-08-31|April 2018|2018-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma|Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma|Completed||Phase 2|56|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:11:17.906798|2018-06-01 02:11:17.906798
NCT00669864|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2010-04-29||2016-03-03|2008-04-30|2008-05-01|Estimate|2010-06-04|2010-07-05|Estimate||||2016-03-03|2016-04-01|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin|Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin|Completed||Phase 4|293|Actual|Novo Nordisk A/S|This single-armed trial does not permit a comprehensive comparison between BIAsp30 and basal insulin. Otherwise, this could have proffered greater clarity on the putative benefits that BIAsp30 brings to subjects with type 2 diabetes.|1|||f||||f||||||||||2018-06-01 02:11:18.212329|2018-06-01 02:11:18.212329
NCT00669851|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-29|2008-04-29|2008-05-01|Estimate|||||||2008-04-29|2008-05-01|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Acquiring Consensus for Contrast Echocardiography System Settings - ACCESS Study|A Phase 3, International, Exploratory, Open-Label, Multicenter, Dual-Injection, Echocardiographic Imaging Settings and Safety Study of AI-700 in Normal Volunteers and Stable Cardiac Patients|Completed||Phase 3|39|Actual|Acusphere|||||||||||||||||||2018-06-01 02:11:18.606074|2018-06-01 02:11:18.606074
NCT00669838|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate|January 2003||2003-01-31|April 2008|2008-04-30|July 2005|Actual|2005-07-31|||||Observational|||Anesthesia for Dental Treatment in Cardiac Patients: Lidocaine Comparative Study|Loco Regional Anesthesia for Dental Treatment in Cardiac Patients: Comparative Study Between Plain Lidocaine 2% and Lidocaine 2% With Epinephrine 1:100.000|Completed|||59|Actual|University of Sao Paulo|||2||f||||f||||||||||2018-06-01 02:11:18.670055|2018-06-01 02:11:18.670055
NCT00669643|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2017-05-31|2008-04-28|2008-04-30|Estimate|||||||2017-05-31|2017-06-01|Actual|February 2007||2007-02-28|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|September 2012|Actual|2012-09-30||Interventional|U-MDT||Uniform Multidrug Therapy Regimen for Leprosy Patients|Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients|Completed||Phase 4|859|Actual|University of Brasilia||4|||f||||t||||||||No|Data sharing was not previously requested to the Ethical Committee. Therefore, if there will be a request for it, new ethical approval must be obtained.|2018-06-01 02:11:20.703071|2018-06-01 02:11:20.703071
NCT00669825|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2010-02-17|2008-04-30|2008-05-01|Estimate|||||||2010-02-17|2010-02-19|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|FED||Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal|A Phase 1, Two Stage, Single-Blind, Single Dose, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal|Completed||Phase 1|36|Anticipated|Alvine Pharmaceuticals Inc.||2|||f||||f||||||||||2018-06-01 02:11:18.777501|2018-06-01 02:11:18.777501
NCT00669812|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-30|||2013-08-23|2008-04-30|2008-05-01|Estimate|||||||2013-08-23|2013-08-26|Estimate|February 2008||2008-02-29|November 2008|2008-11-30||||||||Interventional|||High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma|A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas|Unknown status|Recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:11:18.870039|2018-06-01 02:11:18.870039
NCT00669799|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2015-05-27|2008-04-30|2008-05-01|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study|Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study|Withdrawn||N/A|0|Actual|University of South Florida||2||UNABLE TO PROCEED WITH STUDY DUE TO STAFFING OF COLLABORATIVE INVESTIGATORS|f||||f||||||||||2018-06-01 02:11:18.977559|2018-06-01 02:11:18.977559
NCT00669786|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2008-04-30|2008-04-30|2008-05-01|Estimate|||||||2008-04-30|2008-05-01|Estimate||||April 2008|2008-04-30||||||||Interventional|||Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles|Highly Purified Human Menopausal Gonadotropin Versus Recombinant Follicle Stimulating Hormone in Ovarian Hyperstimulation With Gonadotropin Releasing Hormone Antagonists. A Randomized Study.|Completed||Phase 3|||Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 02:11:19.135878|2018-06-01 02:11:19.135878
NCT00669773|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-27|||2013-12-08|2008-04-28|2008-04-30|Estimate|||||||2013-12-08|2013-12-10|Estimate|February 2007||2007-02-28|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient|Phase 2 Randomized Study of Adriamycin & Docetaxel in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor to Validate Gene Expression & Proteomic Signatures Predictive of Treatment Response|Unknown status|Active, not recruiting|Phase 2|49|Actual|National University Hospital, Singapore||2|||f||||||||||||||2018-06-01 02:11:19.222089|2018-06-01 02:11:19.222089
NCT00669760|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2015-01-06|2008-04-29|2008-04-30|Estimate|||||||2015-01-06|2015-01-07|Estimate|July 2008||2008-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|July 2011|Actual|2011-07-31||Observational|StaphCI||Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients|Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients, a Non-interventional, Prospective, Longitudinal Multicenter Study.|Completed|||195|Actual|University Hospital Muenster|||1||f||||f||||||None Retained|"~     Sera~   "|||2018-06-01 02:11:19.350551|2018-06-01 02:11:19.350551
NCT00669747|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-10-01|2008-04-29|2008-04-30|Estimate|||||||2008-10-01|2008-10-02|Estimate|May 2008||2008-05-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)|A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ|Unknown status|Recruiting|Phase 2|45|Anticipated|Windy Hill Medical, Inc.||3|||f||||f||||||||||2018-06-01 02:11:19.680368|2018-06-01 02:11:19.680368
NCT00669734|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2018-05-23|2008-04-29|2008-04-30|Estimate|||||||2018-05-23|2018-05-24|Actual|February 1, 2010|Actual|2010-02-01|May 2018|2018-05-31||||November 19, 2013|Actual|2013-11-19||Interventional|||Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery|Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)|Active, not recruiting||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:11:19.787451|2018-06-01 02:11:19.787451
NCT00669721|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2008-04-28|2008-04-28|2008-04-30|Estimate|||||||2008-04-28|2008-04-30|Estimate|March 2008||2008-03-31|April 2008|2008-04-30|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis|Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients|Unknown status|Recruiting|N/A|40|Anticipated|St. Orsola Hospital||2|||f||||t||||||||||2018-06-01 02:11:19.881417|2018-06-01 02:11:19.881417
NCT00669708|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2010-02-01|2008-04-29|2008-04-30|Estimate|||||||2010-02-01|2010-02-02|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Topical Therapy With Cooling Effect in Dry Itchy Skin|kühlender Effekt Der Eucerin pH5 Lotion Und Der Eucerin pH5 Lotion Mit Cooling Compound Bei Trockener, Juckender Haut|Completed||N/A|70|Anticipated|University Hospital Muenster||2|||f||||f||||||||||2018-06-01 02:11:20.018134|2018-06-01 02:11:20.018134
NCT00669695|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2013-09-23|2008-04-28|2008-04-30|Estimate|||||||2013-09-23|2013-09-24|Estimate|May 2008||2008-05-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|StatinflaSAS||Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin|Systemic Inflammation and Obstructive Sleep Apnea Syndrome: Effect of Atorvastatin|Terminated||Phase 2|54|Actual|University Hospital, Grenoble||4||Interim analysis performed without efficient results|f||||t||||||||||2018-06-01 02:11:20.12287|2018-06-01 02:11:20.12287
NCT00669682|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2013-02-15||2013-04-11|2008-04-29|2008-04-30|Estimate|2013-02-15|2013-03-28|Estimate||||2013-04-11|2013-04-19|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||T-wave Alternans and Intrathoracic Impedance Measurements|T-wave Alternans and Intrathoracic Impedance Measurements|Completed|||9|Actual|Columbia University|||1||f||||f||||||||||2018-06-01 02:11:20.245412|2018-06-01 02:11:20.245412
NCT00669669|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2018-01-08|2008-04-29|2008-04-30|Estimate|||||||2018-01-08|2018-01-09|Actual|February 25, 2009|Actual|2009-02-25|January 2018|2018-01-31|December 31, 2027|Anticipated|2027-12-31|March 24, 2018|Anticipated|2018-03-24||Interventional|||O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas|Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 02:11:20.454587|2018-06-01 02:11:20.454587
NCT00669630|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2010-01-11|2008-04-29|2008-04-30|Estimate|||||||2010-01-11|2010-01-12|Estimate|September 2008||2008-09-30|January 2010|2010-01-31|June 2012|Anticipated|2012-06-30|September 2011|Anticipated|2011-09-30||Interventional|GoodNEWS||The GoodNEWS Lifestyle Enhancement Program|The GoodNEWS (Genes, Nutrition, Exercise, Wellness, and Spiritual Growth) Trial|Unknown status|Recruiting|N/A|400|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 02:11:20.841821|2018-06-01 02:11:20.841821
NCT00669617|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2011-07-22||2011-09-07|2008-04-29|2008-04-30|Estimate|2011-07-22|2011-08-17|Estimate||||2011-09-07|2011-09-12|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Randomized, Double-blind, Triple-dummy, Placebo Controlled, Multicenter, 5-period, Single-dose Complete Block Crossover Study to Determine the Onset of Action of Indacaterol (150 and 300 μg) in Patients With Moderate to Severe COPD Using Salbutamol (200 μg) and Salmeterol/Fluticasone (50/500 μg) as Active Controls|Completed||Phase 3|89|Actual|Novartis||5|||f||||f||||||||||2018-06-01 02:11:20.955452|2018-06-01 02:11:20.955452
NCT00669604|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-04-29|2008-04-29|2008-04-30|Estimate|||||||2008-04-29|2008-04-30|Estimate|March 2004||2004-03-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||HIV Vertical Transmission in Vietnam|Counseling on Formula Feeding and Antiretroviral Prophylaxis Successfully Reduced Transmission of HIV-1 From Mother to Child in Northern Vietnam|Completed|||135|Actual|National Institute of Hygiene and Epidemiology, Vietnam|||||f||||f||||||Samples With DNA|"~     Peripheral EDTA blood samples were collected from the child at birth (1-2 days), at 1, 3, 6,~     12, and 18 months of age and processed at the Molecular Laboratory in the Hanoi Obstetric and~     Gynaecology hospital. The maternal blood samples were taken at the same day as the first~     sample of their child. Three ml EDTA blood was taken from the mother and 2 ml from the child.~     The blood was processed within 8 hours. Cells and plasma were stored separately at - 20~     Celcius degree.~   "|||2018-06-01 02:11:21.197394|2018-06-01 02:11:21.197394
NCT00669591|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2017-04-19|2008-04-29|2008-04-30|Estimate|||||||2017-04-19|2017-04-21|Actual|January 2008||2008-01-31|April 2017|2017-04-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer|A Phase II Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|46|Actual|Peregrine Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:11:21.257316|2018-06-01 02:11:21.257316
NCT00669578|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2012-11-07||2015-10-29|2008-04-29|2008-04-30|Estimate|2014-04-09|2014-05-09|Estimate||||2015-10-29|2015-11-25|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|July 2010|Actual|2010-07-31||Interventional|||CC-4047 in Treating Patients With Myelofibrosis|A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis®|Completed||Phase 1/Phase 2|77|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:11:21.425058|2018-06-01 02:11:21.425058
NCT00669565|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2011-03-23|2008-04-29|2008-04-30|Estimate|||||||2011-03-23|2011-03-24|Estimate|July 2008||2008-07-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer|A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|46|Actual|Peregrine Pharmaceuticals|||||f||||f||||||||||2018-06-01 02:11:21.779433|2018-06-01 02:11:21.779433
NCT00669552|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2013-02-15||2013-04-11|2008-04-29|2008-04-30|Estimate|2013-02-15|2013-03-28|Estimate||||2013-04-11|2013-04-19|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Intracardiac T-wave Alternans and Ischemia|Intracardiac T-wave Alternans and Ischemia During Percutaneous Coronary Interventions|Completed|||11|Actual|Columbia University|||1||f||||f||||||||||2018-06-01 02:11:21.857012|2018-06-01 02:11:21.857012
NCT00669539|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2012-04-16||2016-07-07|2008-04-28|2008-04-30|Estimate|2012-04-16|2012-05-21|Estimate||||2016-07-07|2016-07-13|Estimate|May 2008||2008-05-31|July 2016|2016-07-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Observational|ATS13||Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old|An Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old|Completed|||156|Actual|Jaeb Center for Health Research|||2||f||||f||||||||||2018-06-01 02:11:22.014968|2018-06-01 02:11:22.014968
NCT00669526|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-04-29|2008-04-29|2008-04-30|Estimate|||||||2008-04-29|2008-04-30|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Clinical and Cost Effectiveness of Brief Cognitive-Behavioral Therapy (CBT) for Pediatric Internalizing Disorders|Clinical and Cost Effectiveness of Brief CBT for Pediatric Internalizing Disorders|Completed||Phase 2|60|Actual|Robert Wood Johnson Foundation||2|||f||||f||||||||||2018-06-01 02:11:22.524736|2018-06-01 02:11:22.524736
NCT00669513|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-04-29|2008-04-29|2008-04-30|Estimate|||||||2008-04-29|2008-04-30|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Cardiovascular Effects of Partial Sleep Deprivation|Cardiovascular Effects of Partial Sleep Deprivation in Healthy Volunteers|Completed||Phase 3|15|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 02:11:22.603057|2018-06-01 02:11:22.603057
NCT00669500|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2011-09-27|2008-04-28|2008-04-30|Estimate|||||||2011-09-27|2011-09-28|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Body Worlds 3 Nutrition Display|Body Worlds 3 - Nutrition and College of Pharmacy Weeks Exhibit and Lifestyle Intervention|Completed||N/A|3188|Actual|Oregon Health and Science University|||||f||||f||||||||||2018-06-01 02:11:22.675328|2018-06-01 02:11:22.675328
NCT00669487|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2015-05-27|2008-04-28|2008-04-30|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP||Completed||Phase 3|150|Actual|South East Asia Research Collaboration with Hawaii||3|||f||||t||||||||||2018-06-01 02:11:22.74771|2018-06-01 02:11:22.74771
NCT00669474|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2015-06-03|2008-04-29|2008-04-30|Estimate|||||||2015-06-03|2015-06-04|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.|Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.|Terminated||Phase 4|25|Anticipated|University Hospital, Ghent||2||Study never started|f||||f||||||||||2018-06-01 02:11:22.832882|2018-06-01 02:11:22.832882
NCT00669461|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2011-10-25||2016-11-09|2008-04-28|2008-04-30|Estimate|2012-04-16|2012-05-15|Estimate||||2016-11-09|2016-12-30|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Lubiprostone as a Treatment for Constipation in Parkinson's Disease|Lubiprostone as a Treatment for Constipation in Parkinson's Disease|Terminated||N/A|1|Actual|University of Arkansas|Early termination leading to small numbers of subjects analyzed|1||Lack of recruitment|f||||f||||||||||2018-06-01 02:11:22.922086|2018-06-01 02:11:22.922086
NCT00669448|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2011-08-18|2008-04-28|2008-04-30|Estimate|||||||2011-08-18|2011-08-19|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||A Pilot Trial on Effect of Mindfulness-based Cognitive Therapy for Individuals With Multiple Chemical Sensitivities (MCS)|"A Pilot Trial on the Effect of Mindfulness-based Cognitive Therapy Versus Treatment as Usual for Individuals With Multiple Chemical Sensitivities"|Completed||N/A|39|Actual|University Hospital, Gentofte, Copenhagen|||||f||||f||||||||||2018-06-01 02:11:23.079573|2018-06-01 02:11:23.079573
NCT00669435|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2008-04-28|2008-04-28|2008-04-30|Estimate|||||||2008-04-28|2008-04-30|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2009|Anticipated|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis|Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients|Unknown status|Recruiting|Phase 4|75|Anticipated|University of Pavia||2|||f||||f||||||||||2018-06-01 02:11:23.144421|2018-06-01 02:11:23.144421
NCT00669422|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2012-10-04|2008-04-28|2008-04-30|Estimate|||||||2012-10-04|2012-10-05|Estimate|October 2006||2006-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|||||Observational|||ChemoFx® PRO - A Post-Market Data Collection Study|ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes|Terminated|||2756|Actual|Precision Therapeutics|||||f||||f||||||Samples With DNA|"~     Leftover tumor cells from the test and pathology slides will be collected and stored to look~     for potential genetic variations related to drug pathway genes to identify patterns~     associated with clinical outcome.~   "|||2018-06-01 02:11:23.240956|2018-06-01 02:11:23.240956
NCT00669409|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25||2011-01-03|2011-01-10|2008-04-29|2008-04-30|Estimate||||2011-01-04|2011-01-10|Estimate|2011-01-10|2011-01-20|Estimate|June 2008||2008-06-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee|A Phase 1/2A, Randomized, Placebo-Controlled, Double Blind, Dose-Escalation, Multicenter Study Of The Safety, Tolerability, Efficacy And Pharmacokinetics, Of A Single Intravenous Dose Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee|Completed||Phase 1/Phase 2|83|Actual|Pfizer||6|||f||||t||||||||||2018-06-01 02:11:23.395938|2018-06-01 02:11:23.395938
NCT00669396|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2009-06-18||2014-12-04|2008-04-28|2008-04-30|Estimate|2009-08-04|2009-08-06|Estimate||||2014-12-04|2014-12-22|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Copper T380 IUD Versus Oral Levonorgestrel for Emergency Contraception vs. Plan B for Emergency Contraception|A Pilot Study of Copper T380A IUDs Versus Oral Levonorgestrel for Emergency Contraception|Completed||N/A|57|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 02:11:23.484171|2018-06-01 02:11:23.484171
NCT00669383|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2012-01-17|2008-04-29|2008-04-30|Estimate|||||||2012-01-17|2012-01-19|Estimate|June 2001||2001-06-30|January 2012|2012-01-31||||July 2007|Actual|2007-07-31||Interventional|||Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants|Rescue Antenatal Steroids and Lung Volumes in Preterm Infants|Unknown status|Active, not recruiting|N/A|80|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:11:23.843264|2018-06-01 02:11:23.843264
NCT00669370|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-04-29|2008-04-29|2008-04-30|Estimate|||||||2008-04-29|2008-04-30|Estimate|June 2006||2006-06-30|April 2008|2008-04-30||||March 2009|Anticipated|2009-03-31||Interventional|GAST-TaxXel||Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer|Biweekly Docetaxel (Taxotere®)in Combination With Capecitabine (Xeloda®)as First-Line Treatment in Patients With Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|50|Anticipated|University of Turku|||||f||||f||||||||||2018-06-01 02:11:23.935975|2018-06-01 02:11:23.935975
NCT00669357|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2013-05-01|2008-04-29|2008-04-30|Estimate|||||||2013-05-01|2013-05-03|Estimate||||May 2013|2013-05-31||||||||Expanded Access|||AbioCor Implantable Replacement Heart|AbioCor Implantable Replacement Heart|No longer available|||||Abiomed Inc.|||||f||||||||||||||2018-06-01 02:11:24.032758|2018-06-01 02:11:24.032758
NCT00669344|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2017-02-09|2008-04-29|2008-04-30|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2006||2006-02-28|February 2017|2017-02-28|February 2008|Actual|2008-02-29|April 2007|Actual|2007-04-30||Interventional|RIVIVE||RIVastigmine In Vascular cognitivE Impairment|A 24-week Prospective, Double Blind, Randomized, Placebo-controlled Pilot Study of 9 mg/Day Rivastigmine in Patients With Vascular Cognitive Impairment Not Dementia to Evaluate Efficacy, Safety and Tolerability in Asian Patients|Completed||Phase 4|50|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-06-01 02:11:24.084044|2018-06-01 02:11:24.084044
NCT00669331|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2015-11-22||2016-03-29|2008-04-29|2008-04-30|Estimate|2016-03-29|2016-04-29|Estimate||||2016-03-29|2016-04-29|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Patients randomised and treated with at least one dose of study medication|Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis|: A Phase III Multicenter, Randomized, Parallel Group, Controlled, Double Blind Study to Investigate the Safety and Efficacy of Inhaled Mannitol Over 12 Months in the Treatment of Bronchiectasis.|Completed||Phase 3|485|Actual|Pharmaxis|Relatively few studies in this area -ideal choice of endpoints not well-defined. No widely accepted exacerbation definition. Relies on patients’ accurate & timely symptom reporting.Unclear event end-dates may impact on counting of subsequent events.|2|||f||||t||||||||||2018-06-01 02:11:24.240575|2018-06-01 02:11:24.240575
NCT00669318|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|2014-05-20||2014-06-20|2008-04-29|2008-04-30|Estimate|2014-05-20|2014-06-20|Estimate||||2014-06-20|2014-07-01|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Pentostatin, Alemtuzumab, and Low Dose Rituximab: A Phase II Clinical Trial|Completed||Phase 2|41|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:11:25.186739|2018-06-01 02:11:25.186739
NCT00669305|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2018-02-12|2008-04-28|2008-04-30|Estimate|||||||2018-02-12|2018-02-13|Actual|May 15, 2008|Actual|2008-05-15|February 2018|2018-02-28|July 2024|Anticipated|2024-07-31|July 2023|Anticipated|2023-07-31||Observational|||Bone Marrow for Hemoglobinopathy Research|Bone Marrow for Hemoglobinopathy Research|Recruiting|||28|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Stem Cells through Bone Marrow Aspiration~   "|||2018-06-01 02:11:25.454589|2018-06-01 02:11:25.454589
NCT00669292|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2010-09-08|2008-04-29|2008-04-30|Estimate|||||||2010-09-08|2010-09-09|Estimate|November 2006||2006-11-30|September 2010|2010-09-30||||November 2009|Anticipated|2009-11-30||Interventional|||PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer|Phase I/II Study of URLC10-177 and TTK-567, Novel Tumor Specific Epitope Peptides Restricted to HLA-A*2402 Derived From Tumor Associated Antigens, Combined With CpG7909, a TLR9 Agonist, in Patients With Advanced or Recurrent Esophageal Cancer.|Unknown status|Recruiting|Phase 1/Phase 2|29|Anticipated|Wakayama Medical University|||||f||||t||||||||||2018-06-01 02:11:25.534728|2018-06-01 02:11:25.534728
NCT00669279|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2011-12-05||2017-09-06|2008-04-29|2008-04-30|Estimate|2012-02-17|2012-03-23|Estimate||||2017-09-06|2017-10-05|Actual|April 2008||2008-04-30|September 2017|2017-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure|Non-Invasive Determination of Central Aortic Blood Pressure in Hypertensive Patients Treated With Controlled-Release Carvedilol or Atenolol|Completed||Phase 4|41|Actual|University of Florida|Small sample size, short duration.|2|||f||||f|f|f||||||||2018-06-01 02:11:25.63307|2018-06-01 02:11:25.63307
NCT00669266|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2016-10-28|2008-04-29|2008-04-30|Estimate|||||||2016-10-28|2016-11-01|Estimate|September 2002||2002-09-30|October 2016|2016-10-31|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Observational|||Adrenal Tumors - Pathogenesis and Therapy|Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen|Recruiting|||500|Anticipated|University of Wuerzburg|||2||f||||f||||||Samples With DNA|"~     Germline DNA Tumor samples Serum Plasma Urine~   "|||2018-06-01 02:11:25.848993|2018-06-01 02:11:25.848993
NCT00669253|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2014-12-04|2008-04-29|2008-04-30|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Periodontitis Using Er:YAG Laser vs. Conventional Treatment Modalities|Randomized Controlled Trial to Evaluate the Efficacy of Er:YAG Laser and Surgical Therapy in Treatment of Chronic Periodontitis|Completed||N/A|60|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 02:11:25.917644|2018-06-01 02:11:25.917644
NCT00669240|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2010-06-07||2015-06-30|2008-04-25|2008-04-30|Estimate|2010-06-07|2010-07-07|Estimate||||2015-06-30|2015-07-23|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Observational|CHOICES||Varenicline Observational Investigation In The Cessation of Smoking|Champix Observational Investigation In The Cessation of Smoking|Completed|||567|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:11:26.035023|2018-06-01 02:11:26.035023
NCT00669227|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2014-06-07|2008-04-29|2008-04-30|Estimate|||||||2014-06-07|2014-06-10|Estimate|October 2005||2005-10-31|June 2014|2014-06-30||||January 2009|Actual|2009-01-31||Interventional|SCAMI||Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction (SCAMI)|Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction - A Randomized, Double-blind, Placebo Controlled Trial (SCAMI)|Completed||Phase 2|42|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 02:11:26.661013|2018-06-01 02:11:26.661013
NCT00669214|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2010-08-24||2017-05-12|2008-04-28|2008-04-30|Estimate|2011-01-18|2011-02-14|Estimate||||2017-05-12|2017-06-06|Actual|February 2008|Actual|2008-02-29|May 2017|2017-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|SCALP||A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp|A Phase IV Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp|Completed||Phase 4|89|Actual|Genentech, Inc.|Since the completion of this study, efalizumab has been voluntarily withdrawn from the U.S. market because of a safety issue.|2|||f||||||||||||||2018-06-01 02:11:26.807555|2018-06-01 02:11:26.807555
NCT00669201|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-04-29|2008-04-29|2008-04-30|Estimate|||||||2008-04-29|2008-04-30|Estimate|December 2007||2007-12-31|April 2008|2008-04-30||||||||Observational|||Wrist Cartilage - High Resolution in Vivo MR T2 Mapping- a Feasibility Study|Wrist Cartilage - High Resolution in Vivo MR T2 Mapping- a Feasibility Study|Unknown status|Recruiting||70|Anticipated|Sheba Medical Center|||3||f||||f||||||||||2018-06-01 02:11:27.810604|2018-06-01 02:11:27.810604
NCT00669188|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2018-05-26|2008-04-29|2008-04-30|Estimate|||||||2018-05-26|2018-05-30|Actual|April 21, 2008||2008-04-21|May 23, 2018|2018-05-23|June 28, 2020|Anticipated|2020-06-28|April 21, 2008|Actual|2008-04-21||Interventional|||Patient Provider Communication and Interaction in a Virtual Clinical Setting|Patient-Provider Communication and Interaction in a Virtual Clinical Setting|Recruiting||N/A|350|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:11:27.99516|2018-06-01 02:11:27.99516
NCT00669175|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2011-07-19|2008-04-28|2008-04-29|Estimate|||||||2011-07-19|2011-07-21|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|June 2011|Actual|2011-06-30|||||Observational|||Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients|Safety and Efficacy of a Low Dose Naloxone Infusion in NICU Patients|Completed|||25|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 02:11:28.069129|2018-06-01 02:11:28.069129
NCT00669162|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2017-01-24|2008-04-25|2008-04-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|August 2016|Actual|2016-08-31||Interventional|||Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer|A Phase I/II Trial of Post-Prostatectomy Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic T2-T3NO Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|27|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 02:11:28.23135|2018-06-01 02:11:28.23135
NCT00669149|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2011-07-01|2008-04-28|2008-04-29|Estimate|||||||2011-07-01|2011-07-04|Estimate|June 2008||2008-06-30|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|August 2012|Anticipated|2012-08-31||Interventional|TACA||Anticoagulant Treatments and Percutaneous Coronary Angioplasty|Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients|Unknown status|Recruiting|Phase 4|480|Anticipated|Centre Hospitalier de PAU||4|||f||||t||||||||||2018-06-01 02:11:28.527129|2018-06-01 02:11:28.527129
NCT00669136|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2015-12-01|2008-04-28|2008-04-29|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma|A Phase I/II Trial Testing Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma|Terminated||Phase 1|2|Actual|University of Pittsburgh||1||"Poor accrual and limited target patient population for future accrual. Did not complete the~   Phase 1 portion of the trial."|f||||t||||||||||2018-06-01 02:11:28.691009|2018-06-01 02:11:28.691009
NCT00413465|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2006-12-18|2006-12-18|2006-12-19|Estimate|||||||2006-12-18|2006-12-19|Estimate|November 2006||2006-11-30|December 2006|2006-12-31|December 2007||2007-12-31|||||Interventional|||Study of Renal Blood Flow During Human Endotoxemia|Renal Plasma Flow During Experimental Human Endotoxemia|Unknown status|Recruiting|N/A|32||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:33:38.290009|2018-06-01 03:33:38.290009
NCT00669110|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2011-04-21||2011-04-21|2008-04-25|2008-04-29|Estimate|2011-04-21|2011-05-16|Estimate||||2011-04-21|2011-05-16|Estimate|May 2008||2008-05-31|April 2011|2011-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder|6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder|Completed||Phase 2|40|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:11:29.157247|2018-06-01 02:11:29.157247
NCT00669097|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2011-08-31|2008-04-25|2008-04-29|Estimate|||||||2011-08-31|2011-09-02|Estimate|April 2008||2008-04-30|August 2011|2011-08-31||||January 2010|Actual|2010-01-31||Interventional|||Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies|An Open-Label, Non-Randomized, Single-Center, Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion (ADME) of TKI258 After a Single Oral Administration of TKI258 500mg and to Assess the Preliminary Safety of TK258 400mg Once Daily in Patients With Advanced Solid Malignancies|Completed||Phase 1|13|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:11:31.589666|2018-06-01 02:11:31.589666
NCT00669084|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-26|||2018-05-17|2008-04-28|2008-04-29|Estimate|||||||2018-05-17|2018-05-18|Actual|April 21, 2008||2008-04-21|November 19, 2013|2013-11-19|November 19, 2013||2013-11-19|||||Observational|||Innate and Acquired Resistance to Plasmodium Falciparum Malaria in Mali|Studies of Innate and Acquired Resistance to P. Falciparum Malaria in Mali|Completed|||1718|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:11:31.685854|2018-06-01 02:11:31.685854
NCT00669071|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2009-09-25||2012-09-21|2008-04-28|2008-04-29|Estimate|2010-01-08|2010-01-11|Estimate||||2012-09-21|2012-10-02|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma|Split-Face, Randomized, Open-Label Study of Sequential Treatment With Tri-Luma® Cream With Intense Pulsed Light (IPL) vs. a Mild Inactive Control Cream With Intense Pulsed Light (IPL) in Subjects With Melasma|Terminated||Phase 4|56|Actual|Galderma Laboratories, L.P.||2||Enrollment closed|f||||f||||||||||2018-06-01 02:11:31.849136|2018-06-01 02:11:31.849136
NCT00669058|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-01-27|2008-04-28|2008-04-29|Estimate|||||||2009-01-27|2009-01-29|Estimate|December 2007||2007-12-31|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Tangerina Mix|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Tina Gel Tangerina Mix.|Completed||Phase 3|52|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:32.533293|2018-06-01 02:11:32.533293
NCT00669045|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-27|||2017-02-13|2008-04-27|2008-04-29|Estimate|||||||2017-02-13|2017-02-15|Actual|September 1, 2000|Actual|2000-09-01|February 2017|2017-02-28|March 31, 2006|Actual|2006-03-31|March 31, 2006|Actual|2006-03-31||Observational|||An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)|A Phase IV, Prospective, Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)|Completed|||253668|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 02:11:32.714769|2018-06-01 02:11:32.714769
NCT00669032|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2015-11-19||2016-01-19|2008-04-25|2008-04-29|Estimate|2016-01-19|2016-02-15|Estimate||||2016-01-19|2016-02-15|Estimate|October 2003||2003-10-31|January 2016|2016-01-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional||Considering a statistical power of 80% and assuming up to a 40% dropout rate, the sample size was planned to include a total of 300 patients (150 per treatment arm). Analysis was performed based on the modified intention-to-treat population. The imputation method for handling missing data was the last observation carried forward.|Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid in Patients With OA of the Knee|Random, Phase IV, Multicentre, Double Blind, Placebo Controlled, Parallel Study to Assess Long-term Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid (ADANT®) in Patients With Knee OA of the Knee|Completed||Phase 4|446|Actual|Tedec-Meiji Farma, S.A.|Control of rescue medication: patients were asked at every assessment visit about the frequency and doses of consumption, but it was not delivered in hand.|2|||f||||f||||||||||2018-06-01 02:11:32.845905|2018-06-01 02:11:32.845905
NCT00669019|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-26|2013-12-10||2014-05-06|2008-04-26|2008-04-29|Estimate|2013-12-10|2014-01-27|Estimate||||2014-05-06|2014-05-21|Estimate|July 2006||2006-07-31|January 2014|2014-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase 2 Study of AZD0530 in Metastatic Melanoma|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)|Trial was designed with a maximum target accrual of 37 patients. Per protocol, the trial was stopped after the first stage based on an interim analysis of the response rate among the first 23 patients.|1|||f||||t||||||||||2018-06-01 02:11:33.542049|2018-06-01 02:11:33.542049
NCT00669006|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2016-03-19|2008-04-28|2008-04-29|Estimate|||||||2016-03-19|2016-03-22|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|December 2012|Actual|2012-12-31||Observational|NePDatabase||Neuropathic Pain Database|National Neuropathic Pain Database Study|Unknown status|Active, not recruiting||900|Anticipated|Lawson Health Research Institute|||1||f||||t||||||||||2018-06-01 02:11:33.952116|2018-06-01 02:11:33.952116
NCT00668993|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-27|||2009-09-19|2008-04-28|2008-04-29|Estimate|||||||2009-09-19|2009-09-22|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Randomized Clinical Trial Investigating Efficacy of EFT (Emotional Freedom Technique) for Food Cravings|The Emotional Freedom Technique (EFT) Versus a Waitlist for Food Cravings: A Randomized Clinical Trial|Completed||N/A|60|Anticipated|Soul Medicine Institute||1|||f||||f||||||||||2018-06-01 02:11:34.052758|2018-06-01 02:11:34.052758
NCT00668980|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2010-01-13|2008-04-25|2008-04-29|Estimate|||||||2010-01-13|2010-01-14|Estimate|July 2006||2006-07-31|January 2010|2010-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Symbolic Representation in Young Children With Down Syndrome|The Constitution of Symbolic Representation in Young Children With Down Syndrome|Completed|||25|Actual|University of Sao Paulo|||2||f||||t||||||||||2018-06-01 02:11:34.120599|2018-06-01 02:11:34.120599
NCT00668967|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-07-07|2008-04-25|2008-04-29|Estimate|||||||2009-07-07|2009-07-08|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Bioequivalence Study Of Verapamil|Bioequivalence Study Of Verapamil (Covera HS) 240 Mg Extended Release Tablets Produced By Alza Corporation, Vacaville And Pfizer Inc, Puerto Rico: A Two Sequence, Four-Way Crossover Design, Single Dose, Open-Label, Randomized Study In Healthy Volunteers|Completed||Phase 1|79|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:11:34.200225|2018-06-01 02:11:34.200225
NCT00668954|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2015-07-29|2008-04-25|2008-04-29|Estimate|||||||2015-07-29|2015-07-31|Estimate|April 2008||2008-04-30|July 2015|2015-07-31|November 2010|Actual|2010-11-30|April 2009|Actual|2009-04-30||Interventional|||Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus|Antioxidant Effects of Pomegranate Juice Versus Placebo in Adults With Type 2 Diabetes Mellitus Following a Glucose Load|Completed||N/A|26|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 02:11:34.354657|2018-06-01 02:11:34.354657
NCT00668941|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-27|||2017-08-09|2008-04-28|2008-04-29|Estimate|||||||2017-08-09|2017-08-10|Actual|September 2005||2005-09-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|February 2016|Actual|2016-02-29||Interventional|||Cyclic Versus Daily Teriparatide on Bone Mass|Cyclic Versus Daily Teriparatide on Bone Mass|Active, not recruiting||Phase 2|140|Anticipated|Helen Hayes Hospital||6|||f||||f||||||||||2018-06-01 02:11:34.632863|2018-06-01 02:11:34.632863
NCT00668928|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-28|2008-04-28|2008-04-29|Estimate|||||||2008-04-28|2008-04-29|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Dietary Polyphenols on Insulin Sensitivity|Effect of Dietary Polyphenols on Insulin Sensitivity|Completed||Phase 1|20|Actual|USDA Beltsville Human Nutrition Research Center|||||f||||t||||||||||2018-06-01 02:11:34.901522|2018-06-01 02:11:34.901522
NCT00668915|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-04-28|2008-04-28|2008-04-29|Estimate|||||||2008-04-28|2008-04-29|Estimate||||April 2008|2008-04-30||||||||Observational|||Arthroplasty Rehabilitation Score - Can we Predict the Short Term Postoperative Outcome?|Arthroplasty Rehabilitation Score - Can we Predict the Short Term Postoperative Outcome?|Unknown status|Not yet recruiting||200|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 02:11:35.066646|2018-06-01 02:11:35.066646
NCT00668902|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2014-12-08||2014-12-15|2008-04-24|2008-04-29|Estimate|2014-12-15|2014-12-17|Estimate||||2014-12-15|2014-12-17|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole|Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole|Completed||N/A|25|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 02:11:35.193629|2018-06-01 02:11:35.193629
NCT00668889|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-01-28|2008-04-28|2008-04-29|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 2007||2007-11-30|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Dermacyd Tina Gel Tangerina Mix - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Tina Gel Tangerina Mix.|Completed||Phase 3|25|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:35.646428|2018-06-01 02:11:35.646428
NCT00668876|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2008-12-02|2008-04-28|2008-04-29|Estimate|||||||2008-12-02|2008-12-03|Estimate|May 2006||2006-05-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|||Effects of Immunonutrition in Patients Undergoing Pancreaticoduodenectomy|Effects of Immunonutrition on Surgical Site Infection and Th1/Th2/Th17 Differentiation in Patients Undergoing Pancreaticoduodenectomy|Completed||Phase 4|30|Actual|Chiba University||3|||f||||f||||||||||2018-06-01 02:11:35.818442|2018-06-01 02:11:35.818442
NCT00668863|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2011-09-02||2011-10-11|2008-04-25|2008-04-29|Estimate|2011-09-02|2011-10-07|Estimate||||2011-10-11|2011-10-17|Estimate|May 2008||2008-05-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study Of Sunitinib With FOLFIRI In Colorectal Cancer|A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer|Completed||Phase 2|71|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:11:35.953665|2018-06-01 02:11:35.953665
NCT00668850|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2011-06-06|2008-04-28|2008-04-29|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|September 2011|Anticipated|2011-09-30|August 2011|Anticipated|2011-08-31||Interventional|||Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin|A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|Generex Biotechnology Corp.||2|||f||||f||||||||||2018-06-01 02:11:36.497433|2018-06-01 02:11:36.497433
NCT00668837|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2011-06-06|2008-04-28|2008-04-29|Estimate|||||||2011-06-06|2011-06-08|Estimate|February 2004||2004-02-29|March 2010|2010-03-31|June 2006|Actual|2006-06-30|||||Interventional|||A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.|Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.|Completed||Phase 3|407|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:11:36.677827|2018-06-01 02:11:36.677827
NCT00668824|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2009-07-31|2008-04-24|2008-04-29|Estimate|||||||2009-07-31|2009-08-03|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|July 2008|Anticipated|2008-07-31||Interventional|CHD Vasovist||Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist|Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist|Unknown status|Recruiting|Phase 4|||Guy's Hospital|||||f||||f||||||||||2018-06-01 02:11:36.750873|2018-06-01 02:11:36.750873
NCT00668811|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2018-03-19||2018-04-17|2008-04-25|2008-04-29|Estimate|2018-03-19|2018-04-18|Actual||||2018-04-17|2018-05-15|Actual|April 2008||2008-04-30|April 2018|2018-04-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|IIT Sutent||Sutent Adjunctive Treatment of Differentiated Thyroid Cancer|Sutent Adjunctive Treatment of Differentiated Thyroid Cancer|Completed||Phase 2|23|Actual|Washington Hospital Center||1|||f||||t||||||||||2018-06-01 02:11:36.958214|2018-06-01 02:11:36.958214
NCT00668798|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2008-04-28|2008-04-28|2008-04-29|Estimate|||||||2008-04-28|2008-04-29|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|March 2008|Anticipated|2008-03-31|January 2008|Anticipated|2008-01-31||Observational|||Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms|Incidence and Clinical Outcome of Human Cytomegalovirus Transmission Via Thawed Frozen Breast Milk in Preterm Infants <31 Weeks. A Prospective Trial.|Suspended|||58|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     thawed frozen breast milk of lactating mothers~   "|||2018-06-01 02:11:37.332942|2018-06-01 02:11:37.332942
NCT00668785|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2013-09-06||2018-03-07|2008-04-28|2008-04-29|Estimate|2015-04-07|2015-04-24|Estimate||||2018-03-07|2018-04-03|Actual|March 2007||2007-03-31|March 2018|2018-03-31|March 2012|Actual|2012-03-31|June 2010|Actual|2010-06-30||Interventional|||Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)|Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)|Terminated||Phase 2|6|Actual|Jumper, J. Michael, M.D.|Study was terminated by Sponsor and Investigator due to low enrollment. Data not analyzed. Technical problems with measurement leading to unreliable or uninterpretable data.|1||Study was terminated due to low enrollment|f||||f||||||||||2018-06-01 02:11:37.41559|2018-06-01 02:11:37.41559
NCT00609999|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2014-07-15|2008-01-25|2008-02-07|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Ph I Dasatinib + Erlotinib in Recurrent MG|Phase I Study of Dasatinib Plus Erlotinib in Recurrent Malignant Glioma|Completed||Phase 1|47|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:29:35.484976|2018-06-01 02:29:35.484976
NCT00668772|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17||2014-04-30|2014-04-30|2008-04-28|2008-04-29|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|April 2008||2008-04-30|April 2014|2014-04-30||||October 2008|Actual|2008-10-31||Interventional|||Tiotropium/Salmeterol Inhalation Powder in COPD|1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)|Terminated||Phase 3|207|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-06-01 02:11:37.758053|2018-06-01 02:11:37.758053
NCT00668759|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-12-12|2008-04-28|2008-04-29|Estimate|||||||2009-12-12|2009-12-15|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|AVRO||A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation|A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation|Completed||Phase 3|254|Actual|Cardiome Pharma||2|||f||||f||||||||||2018-06-01 02:11:38.039587|2018-06-01 02:11:38.039587
NCT00668746|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2010-02-26||2011-12-06|2008-04-24|2008-04-29|Estimate|2010-02-26|2010-03-16|Estimate||||2011-12-06|2011-12-12|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Long-term Safety of Minocycline in Patients With Gum Disease|Long-term Safety Evaluation of Minocycline Resistance After Treatment With Minocycline HCl Microspheres, 1 mg in Subjects With Chronic Periodontitis|Completed||Phase 4|35|Actual|OraPharma||2|||f||||f||||||||||2018-06-01 02:11:38.378214|2018-06-01 02:11:38.378214
NCT00668733|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2010-06-15||2010-07-13|2008-04-24|2008-04-29|Estimate|2010-06-15|2010-07-13|Estimate||||2010-07-13|2010-07-20|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year|Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year After Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705|Completed|||179|Actual|Graceway Pharmaceuticals, LLC|||||f||||f||||||||||2018-06-01 02:11:39.313641|2018-06-01 02:11:39.313641
NCT00668720|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2011-06-29|2008-04-25|2008-04-29|Estimate|||||||2011-06-29|2011-06-30|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) for Tinnitus|Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment in Patients With Chronic Tinnitus|Completed||N/A|52|Actual|UMC Utrecht||2|||f||||f||||||||||2018-06-01 02:11:39.528792|2018-06-01 02:11:39.528792
NCT00668707|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2017-06-08|2008-04-28|2008-04-29|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2007||2007-09-30|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2017|Actual|2017-05-31||Interventional|AMPLCaRe||Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality|Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial|Active, not recruiting||Phase 3|711|Actual|The Canadian College of Naturopathic Medicine||2|||f||||t||||||||||2018-06-01 02:11:39.614506|2018-06-01 02:11:39.614506
NCT00668694|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-27|||2018-05-27|2008-04-28|2008-04-29|Estimate|||||||2018-05-27|2018-05-30|Actual|October 2007||2007-10-31|April 2008|2008-04-30|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|IDA||Iron Deficiency Anemia and Psychosocial Stimulation|Effect of Psychosocial Stimulation on Development of Iron-deficient Anemic Infants: A Randomized Controlled Trial|Completed||N/A|434|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||f||||||||||2018-06-01 02:11:39.761045|2018-06-01 02:11:39.761045
NCT00668681|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2012-10-15|2008-04-28|2008-04-29|Estimate|||||||2012-10-15|2012-10-17|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|February 2009|Anticipated|2009-02-28|December 2008|Actual|2008-12-31||Interventional|EndoRefix||Evaluation of EndoRefix Endovascular Delivery System and Staple|Safety Data Collection for Delivery System and Use of Staple in Endovascular Procedures|Withdrawn||N/A|0|Actual|Lombard Medical||1||Company business decision, IDE closed, no commercialization planned|f||||f||||||||||2018-06-01 02:11:39.886454|2018-06-01 02:11:39.886454
NCT00668668|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-01-27|2008-04-28|2008-04-29|Estimate|||||||2009-01-27|2009-01-29|Estimate|December 2007||2007-12-31|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Sweet Flower|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Tina Gel Sweet Flower.|Completed||Phase 3|52|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:40.096094|2018-06-01 02:11:40.096094
NCT00668655|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2012-09-11|2008-04-28|2008-04-29|Estimate|||||||2012-09-11|2012-09-13|Estimate|February 2008||2008-02-29|September 2012|2012-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%|An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%|Completed|||30|Actual|Galderma Laboratories, L.P.|||1||f||||f||||||||||2018-06-01 02:11:40.162602|2018-06-01 02:11:40.162602
NCT00668642|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2014-02-13|2008-04-28|2008-04-29|Estimate|||||||2014-02-13|2014-02-14|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer|Effect of Dutasteride on Androgen-Response Gene Expression During the Tumor Regrowth Phase of Intermittent Androgen Ablation Therapy in Patients With Advanced Prostate Cancer|Completed||Phase 2|21|Actual|NorthShore University HealthSystem Research Institute||2|||f||||t||||||||||2018-06-01 02:11:40.245937|2018-06-01 02:11:40.245937
NCT00668629|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-01-27|2008-04-28|2008-04-29|Estimate|||||||2009-01-27|2009-01-29|Estimate|November 2007||2007-11-30|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Dermacyd Tina Gel Sweet Flower - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Tina Gel Sweet Flower.|Completed||Phase 3|25|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:40.34359|2018-06-01 02:11:40.34359
NCT00668616|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2010-07-28|2008-04-28|2008-04-29|Estimate|||||||2010-07-28|2010-07-29|Estimate|March 2000||2000-03-31|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2005|Actual|2005-07-31||Interventional|||Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes|Cyclophosphamid + Farmorubicin® With Subsequent Administration of Taxol® (q3w) Versus Intensified Administration of Farmorubicin® Followed by Taxol® (q2w) in the Adjuvant Treatment of Breast Cancer in Patients With 1-3 Afflicted Lymph Nodes (1-3 LK+)|Completed||Phase 3|1034|Actual|North Eastern Germany Society of Gynaecologic Oncology||2|||f||||||||||||||2018-06-01 02:11:40.432834|2018-06-01 02:11:40.432834
NCT00668603|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2016-02-18|2008-04-24|2008-04-29|Estimate|||||||2016-02-18|2016-02-19|Estimate|August 2005||2005-08-31|February 2016|2016-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|SYMPTOM||Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy (HRT)|Comparison of Vascular Findings Between Symptomatic and Asymptomatic Postmenopausal Women Before and During Hormone Therapy: A Randomized, Placebo-controlled Prospective Study|Completed||N/A|160|Actual|Helsinki University||2|||f||||t||||||||||2018-06-01 02:11:40.533987|2018-06-01 02:11:40.533987
NCT00668590|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2011-04-08|2008-04-25|2008-04-29|Estimate|||||||2011-04-08|2011-04-11|Estimate|August 2008||2008-08-31|April 2011|2011-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Improving Diabetes Care With Patient Decision Aids - A Trial in Community-based Primary Care|Improving Diabetes Care With Patient Decision Aids - A Randomized Controlled Trial in Community-based Primary Care|Completed||N/A|201|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:11:40.64962|2018-06-01 02:11:40.64962
NCT00668577|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-02-09|2008-04-28|2008-04-29|Estimate|||||||2009-02-09|2009-02-10|Estimate|December 2007||2007-12-31|February 2009|2009-02-28||||February 2008|Actual|2008-02-29||Interventional|||Dermatological Evaluation of Topic Compatibility - Dermacyd Breeze|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Breeze.|Completed||Phase 3|52|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:40.726871|2018-06-01 02:11:40.726871
NCT00668564|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2011-06-14||2017-12-03|2008-04-28|2008-04-29|Estimate|2011-06-14|2011-07-13|Estimate||||2017-12-03|2017-12-28|Actual|March 2008||2008-03-31|December 2017|2017-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism|Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation|Terminated||Phase 2|18|Actual|Masonic Cancer Center, University of Minnesota|Other secondary objectives outlined in study protocol were not analyzed; number of patients were too few to be relevant.|1||Replaced by another study|f||||t||||||||||2018-06-01 02:11:40.804765|2018-06-01 02:11:40.804765
NCT00668551|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-04-10|2008-04-25|2008-04-29|Estimate|||||||2009-04-10|2009-04-13|Estimate|April 2008||2008-04-30|April 2009|2009-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|Tele-PD||Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population|Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population|Completed|||14|Actual|University of Rochester|||2||f||||f||||||||||2018-06-01 02:11:41.024658|2018-06-01 02:11:41.024658
NCT00668538|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2008-10-16|2008-04-28|2008-04-29|Estimate|||||||2008-10-16|2008-10-17|Estimate|April 2008||2008-04-30|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans|Uptake of the Antifungal Miconazole and Effect on Estrogen Metabolizing Enzymes in Humans|Completed||N/A|20|Actual|University of Southern Denmark|||||f||||t||||||||||2018-06-01 02:11:41.115859|2018-06-01 02:11:41.115859
NCT00668525|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2010-03-22||2010-05-07|2008-04-28|2008-04-29|Estimate|2010-04-12|2010-05-06|Estimate||||2010-05-07|2010-05-11|Estimate|April 2008||2008-04-30|May 2010|2010-05-31||||February 2009|Actual|2009-02-28||Interventional|||Escitalopram in Adult Patients With Major Depressive Disorder|A Double-blind, Fixed-dose Study of Escitalopram in Adult Patients With Major Depressive Disorder|Completed||Phase 3|877|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 02:11:41.249975|2018-06-01 02:11:41.249975
NCT00668512|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2015-03-17|2008-04-25|2008-04-29|Estimate|||||||2015-03-17|2015-03-19|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Intratumoral Injection Of Alpha-Gal Glycosphingolipids|Phase I Study To Evaluate The Toxicity And Feasibility Of Intratumoral Injection Of Alpha-Gal (Beta-galactosidase ) Glycosphingolipids In Patients With Advanced Melanoma|Completed||Phase 1|12|Actual|University of Massachusetts, Worcester||1|||f||||t||||||||||2018-06-01 02:11:41.690761|2018-06-01 02:11:41.690761
NCT00668499|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2014-05-19|2008-04-28|2008-04-29|Estimate|||||||2014-05-19|2014-05-21|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma|A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma|Withdrawn||Phase 1/Phase 2|0|Actual|University of Southern California||||Sponsor withdrew support|f||||f||||||||||2018-06-01 02:11:41.767938|2018-06-01 02:11:41.767938
NCT00668486|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-02-09|2008-04-28|2008-04-29|Estimate|||||||2009-02-09|2009-02-10|Estimate|January 2008||2008-01-31|February 2009|2009-02-28||||February 2008|Actual|2008-02-29||Interventional|||Dermacyd Delicata Breeze - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Breeze.|Completed||Phase 3|28|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:41.831394|2018-06-01 02:11:41.831394
NCT00668473|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2016-10-24|2008-04-25|2008-04-29|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|January 2012|Actual|2012-01-31|May 2008|Actual|2008-05-31||Observational|||Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis|Endostatin and Other Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis|Completed|||30|Actual|University of Michigan|||2||f||||f||||||Samples Without DNA|"~     skin serum~   "|||2018-06-01 02:11:41.896975|2018-06-01 02:11:41.896975
NCT00668460|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-01-28|2008-04-28|2008-04-29|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 2007||2007-11-30|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Dermatological Evaluation of Topic Compatibility-Dermacyd Delicata Pocket BR|Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Delicata Pocket BR.|Completed||Phase 3|52|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:41.977016|2018-06-01 02:11:41.977016
NCT00668447|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2008-04-25|2008-04-25|2008-04-29|Estimate|||||||2008-04-25|2008-04-29|Estimate|November 2001||2001-11-30|April 2008|2008-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Soy and Isoflavones Effect on Bone|Soy Proteins and Isoflavones Impact Bone Mineral Density in Older Women|Completed||Phase 4|97|Actual|National Institute on Aging (NIA)||4|||f||||f||||||||||2018-06-01 02:11:42.058654|2018-06-01 02:11:42.058654
NCT00668434|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2014-10-20||2015-04-09|2008-04-25|2008-04-29|Estimate|2015-04-09|2015-04-28|Estimate||||2015-04-09|2015-04-28|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|ACT FAST||Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica|A Corticosteroid Taper for Acute Sciatica Treatment (The ACT FAST Study)|Completed||Phase 2|269|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 02:11:42.290289|2018-06-01 02:11:42.290289
NCT00668421|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2014-11-24|2008-04-28|2008-04-29|Estimate|||||||2014-11-24|2014-11-26|Estimate|April 2008||2008-04-30|November 2014|2014-11-30|January 2015|Anticipated|2015-01-31|September 2013|Actual|2013-09-30||Interventional|||CEP-701 (Lestaurtinib) in Myelofibrosis|A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults With Myelofibrosis|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-06-01 02:11:42.645101|2018-06-01 02:11:42.645101
NCT00667082|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-11-20|2008-04-24|2008-04-25|Estimate|||||||2017-11-20|2017-11-22|Actual|March 2008||2008-03-31|November 2017|2017-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma|NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma|Completed||Phase 1|22|Actual|Celgene||1|||f||||f||||||||Undecided||2018-06-01 02:12:16.365871|2018-06-01 02:12:16.365871
NCT00668408|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|||2009-08-27|2008-04-28|2008-04-29|Estimate|||||||2009-08-27|2009-08-28|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|October 2012|Anticipated|2012-10-31|March 2012|Anticipated|2012-03-31||Interventional|||LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure|Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF)|Unknown status|Recruiting|Phase 4|1000|Anticipated|Azienda Ospedaliero-Universitaria Careggi||2|||f||||t||||||||||2018-06-01 02:11:42.742565|2018-06-01 02:11:42.742565
NCT00668395|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2013-04-10||2014-09-18|2008-04-28|2008-04-29|Estimate|2014-09-18|2014-09-26|Estimate||||2014-09-18|2014-09-26|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics|Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics, Autoinduction and Drug Interactions in Healthy Volunteers.|Completed||N/A|73|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 02:11:43.038735|2018-06-01 02:11:43.038735
NCT00668382|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2012-10-25||2013-05-10|2008-04-28|2008-04-29|Estimate|2012-10-25|2012-11-26|Estimate||||2013-05-10|2013-05-15|Estimate|July 2007||2007-07-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection|Phase I Study To Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection Of Alpha-Gal Glycosphingolipids In Patients With Advanced Or Refractory Solid Tumors|Completed||Phase 1|11|Actual|University of Massachusetts, Worcester|No allergic/immune toxicity. The single toxicity/AE was bacterial infection with UGI flora at injection site following EUS (endoscopic ultra-sound) guided injection of pancreatic cancer. Added injections covered with antibiotic prophylaxis.|1|||f||||t||||||||||2018-06-01 02:11:43.50899|2018-06-01 02:11:43.50899
NCT00668369|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2013-12-19|2008-04-28|2008-04-29|Estimate|||||||2013-12-19|2013-12-20|Estimate|April 2008||2008-04-30|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation|Effect of Immunosuppression Drug Weaning on Hepatitis C Virus Induced Liver Damage After Liver Transplantation.|Completed||Phase 2|34|Actual|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-06-01 02:11:43.735072|2018-06-01 02:11:43.735072
NCT00668356|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-02-06|2008-04-28|2008-04-29|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 2009||2009-09-30|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|ddI||Bioequivalence Study of Didanosine in Children Treated for HIV|PKPOP Study of Didanosine in HIV Treated Children, at Fasting Period and During the Meal|Suspended||Phase 2|26|Anticipated|Assistance Publique - Hôpitaux de Paris||2||questions of the benefit efficacy/risks of ddI during the meal not resolved|f||||f||||||||||2018-06-01 02:11:43.82875|2018-06-01 02:11:43.82875
NCT00668343|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-27|||2010-07-29|2008-04-28|2008-04-29|Estimate|||||||2010-07-29|2010-07-30|Estimate|April 2005||2005-04-30|July 2010|2010-07-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|irmsrct||Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo||Completed||Phase 3|80|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:11:43.935996|2018-06-01 02:11:43.935996
NCT00668330|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2012-02-10|2008-04-28|2008-04-29|Estimate|||||||2012-02-10|2012-02-13|Estimate|April 2007||2007-04-30|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus|Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment|Completed||Phase 4|40|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 02:11:44.043058|2018-06-01 02:11:44.043058
NCT00668317|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2012-03-16||2012-10-16|2008-04-24|2008-04-29|Estimate|2012-10-16|2012-11-16|Estimate||||2012-10-16|2012-11-16|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Bronchial Hyper-responsiveness in Reflux Cough|An 8 Week Non-selected Cohort Study to Investigate Whether the Treatment of Reflux Induced Cough Alters Associated Bronchial Hyper-responsiveness|Terminated||Phase 3|5|Actual|Hull and East Yorkshire Hospitals NHS Trust||1||Primary care physicians began prescribing antacid therapy for chronic cough|f||||t||||||||||2018-06-01 02:11:44.148486|2018-06-01 02:11:44.148486
NCT00668304|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2014-12-18|2008-04-28|2008-04-29|Estimate|||||||2014-12-18|2014-12-19|Estimate|June 2004||2004-06-30|December 2014|2014-12-31|January 2005|Actual|2005-01-31|||||Interventional|SPEED||Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox|Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD|Completed||Phase 4|192|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:11:44.312569|2018-06-01 02:11:44.312569
NCT00668291|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2016-07-05|2008-04-28|2008-04-29|Estimate|||||||2016-07-05|2016-07-06|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Observational|EVACARNEY||Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)|Assessment of the Clinical Symptoms of the Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC).|Completed|||133|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     2 tubes EDTA 5 mL each (DNA) and 2 tubes heparine 5 mL each (cellular biology)~   "|||2018-06-01 02:11:44.442538|2018-06-01 02:11:44.442538
NCT00668278|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-01-27|2008-04-28|2008-04-29|Estimate|||||||2009-01-27|2009-01-29|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|IGE(L)MA||I-Gel Versus Disposable Laryngeal Mask (LMA) for General Anesthesia (GA) With Controlled Ventilation|I-Gel Versus Disposable Laryngeal Mask Airway for General Anesthesia With Controlled Ventilation|Completed||N/A|200|Anticipated|Northern Health and Social Care Trust||2|||f||||f||||||||||2018-06-01 02:11:44.50908|2018-06-01 02:11:44.50908
NCT00668265|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-28|2012-10-19||2013-02-15|2008-04-28|2008-04-29|Estimate|2013-02-15|2013-02-18|Estimate||||2013-02-15|2013-02-18|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Anxiety in Recovering Opiate Dependence|A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence|Terminated||Phase 4|14|Actual|Beth Israel Medical Center||1||The study was not completed, the funding sponsor lost interest.|f||||f||||||||||2018-06-01 02:11:44.600928|2018-06-01 02:11:44.600928
NCT00668252|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2008-04-28|2008-04-28|2008-04-29|Estimate|||||||2008-04-28|2008-04-29|Estimate|April 2006||2006-04-30|March 2006|2006-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|Oestropec||Circulating Endothelium Progenitor Cells and Endogenous Oestrogen in Healthy Subjects|Impact of Endogenous Sexual Hormones (Oestrogens and Testosterone) on the Endothelium Circulatory on Rolling at the Young and Old Healthy Volunteer.|Completed|||48|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||None Retained|"~     whole peripheral blood (150 ml)~   "|||2018-06-01 02:11:44.893304|2018-06-01 02:11:44.893304
NCT00668239|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2008-04-28|2008-04-28|2008-04-29|Estimate|||||||2008-04-28|2008-04-29|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|June 2006|Actual|2006-06-30|April 2006|Actual|2006-04-30||Interventional|||Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser|Treatment of Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone and Laser Photocoagulation: Randomized Clinical Trial With Morphological and Functional Evaluation|Completed||N/A|14|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 02:11:44.957226|2018-06-01 02:11:44.957226
NCT00668226|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-01-28|2008-04-28|2008-04-29|Estimate|||||||2009-01-28|2009-01-29|Estimate|December 2007||2007-12-31|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Dermacyd Delicata Pocket BR - Photo Evaluation|Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Delicata Pocket BR.|Completed||Phase 3|25|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:11:45.044985|2018-06-01 02:11:45.044985
NCT00668213|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-01-08|2008-04-28|2008-04-29|Estimate|||||||2014-01-08|2014-01-10|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Antioxidant Systems and Age-Related Macular Degeneration|Antioxidant Systems and Age-Related Macular Degeneration|Completed|||143|Actual|Vanderbilt University|||||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-06-01 02:11:45.13941|2018-06-01 02:11:45.13941
NCT00668200|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2013-11-04||2015-02-17|2008-04-25|2008-04-29|Estimate|2014-01-27|2014-03-03|Estimate||||2015-02-17|2015-03-06|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||The ITT population includes 80 enrolled patients and the Safety population includes 81enrolled patients. During monitoring it was discovered that one patient signed the consent form from another Paget’s study; therefore, this patient was excluded from the ITT population but included in the safety population.Baseline used ITT data set|Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®|Post US Approval Voluntary Registry Study to Determine Incidence of Hypocalcemia Post Reclast® Treatment in Patients With Paget's Disease After Institution of Educational Strategies to Improve Adherence to Calcium and Vitamin D Supplementation|Completed||Phase 4|81|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:11:45.209442|2018-06-01 02:11:45.209442
NCT00668187|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2017-08-16|2008-04-25|2008-04-29|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2010|Actual|2010-12-31|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||A Natural History Study of the Gangliosidoses|A Natural History Study of the Gangliosidoses|Recruiting|||52|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t|f|f||||||Yes|"De-identified individual data is input to the NIH-funded Rare Diseases Clinical Research Network's Data Management & Coordinating Center (DMCC). Eventually this data will become part of the database of Genotypes and Phenotypes (dbGaP), which is part of the National Center for Biotechnology Information, U.S. National Library of Medicine."|2018-06-01 02:11:45.393155|2018-06-01 02:11:45.393155
NCT00668174|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2012-11-26|2008-04-25|2008-04-29|Estimate|||||||2012-11-26|2012-11-28|Estimate|January 1997||1997-01-31|November 2012|2012-11-30|December 2004|Actual|2004-12-31|December 2003|Actual|2003-12-31||Interventional|||Effect of Exercise on Sex Hormones in Postmenopausal Women|Physical Activity and Total Health Trial|Completed||Phase 2/Phase 3|173|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 02:11:45.48242|2018-06-01 02:11:45.48242
NCT00668161|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2012-11-26|2008-04-28|2008-04-29|Estimate|||||||2012-11-26|2012-11-28|Estimate|January 2001||2001-01-31|November 2012|2012-11-30|February 2005|Actual|2005-02-28|December 2004|Actual|2004-12-31||Interventional|APPEAL||Effect of Exercise on Biomarkers of Colon Cancer Risk|Exercise Intervention Trial for Colorectal Polyp Patients|Completed||Phase 2/Phase 3|202|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 02:11:45.548367|2018-06-01 02:11:45.548367
NCT00668148|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25||2010-09-01|2012-05-08|2008-04-28|2008-04-29|Estimate||||2010-09-01|2010-09-06|Estimate|2012-05-08|2012-05-10|Estimate|July 2008||2008-07-31|September 2011|2011-09-30|February 2012|Actual|2012-02-29|October 2010|Actual|2010-10-31||Interventional|||A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma|A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously-Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET|Completed||Phase 2|111|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 02:11:45.618016|2018-06-01 02:11:45.618016
NCT00668135|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2014-12-15|2008-04-28|2008-04-29|Estimate|||||||2014-12-15|2014-12-17|Estimate|March 2003||2003-03-31|December 2014|2014-12-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia|Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia|Completed||Phase 4|348|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:45.748024|2018-06-01 02:11:45.748024
NCT00668122|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2009-06-29|2008-04-27|2008-04-28|Estimate|||||||2009-06-29|2009-06-30|Estimate|March 2004||2004-03-31|June 2009|2009-06-30|January 2006|Actual|2006-01-31|||||Interventional|EMERON||Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections|Efficacy and Safety of Ciprofloxacin Extended-Release 1000 mg Once-Daily Versus Ciprofloxacin Immediate-Release 500 mg Twice-Daily Given 7-14 Days in Patients With Complicated Urinary Tract Infections: Prospective, Randomized, Double-Blind Trial.|Completed||Phase 3|212|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:45.841648|2018-06-01 02:11:45.841648
NCT00668109|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-12-18|2008-04-27|2008-04-28|Estimate|||||||2014-12-18|2014-12-23|Estimate|December 2003||2003-12-31|December 2014|2014-12-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|LUTECIA||Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia|A Randomized, Open-label, Multi-center, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil in Comparison to Tadalafil in Males With Erectile Dysfunction and a Diagnosis of Diabetes, Hypertension or Hyperlipidemia|Completed||Phase 3|614|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:46.972787|2018-06-01 02:11:46.972787
NCT00668096|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-12-23|2008-04-27|2008-04-28|Estimate|||||||2014-12-23|2014-12-25|Estimate|May 2004||2004-05-31|December 2014|2014-12-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|FINDER||A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy.|A Randomized, Double Blind, Placebo Controlled, Flexible Dose, Multicentre Study of Levitra in a Broad Population of Men With Erectile Dysfunction and Previously Untreated With PDE5 Inhibitors.|Completed||Phase 4|260|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:47.16324|2018-06-01 02:11:47.16324
NCT00668083|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2010-12-09|2008-04-27|2008-04-28|Estimate|||||||2010-12-09|2010-12-10|Estimate|September 2007||2007-09-30|December 2010|2010-12-31|July 2008|Actual|2008-07-31|October 2007|Actual|2007-10-31||Observational|Sorse||Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer|Observational Retrospective Trial on Sequential Hormonal Therapy in Patients|Completed|||214|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:11:47.409941|2018-06-01 02:11:47.409941
NCT00668070|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2013-03-19|2008-04-27|2008-04-28|Estimate|||||||2013-03-19|2013-03-21|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|ASTER||A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831|Protocol for a Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week Treatment, Adaptive Proof-of-principle Study of Twice Daily Oral Dosing of a Novel PDE4 Inhibitor (ASP9831) in Subjects With Non-alcoholic Steatohepatitis (NASH)|Completed||Phase 2|114|Actual|Astellas Pharma Inc||3|||f||||t||||||||||2018-06-01 02:11:47.501472|2018-06-01 02:11:47.501472
NCT00668057|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2015-03-05|2008-04-27|2008-04-28|Estimate|||||||2015-03-05|2015-03-06|Estimate|December 2002||2002-12-31|March 2015|2015-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.|Randomized, Double-blind, Multi-centre, Parallel-goup Study to Investigate the Efficacy and Safety of Three Doses of BAY38-9456 (5 mg, 10 mg and 20 mg) Versus Placebo in the Treatment of Patients With Erectile Dysfunction|Completed||Phase 3|624|Actual|Bayer||6|||f||||f||||||||||2018-06-01 02:11:47.66957|2018-06-01 02:11:47.66957
NCT00668044|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2009-10-26|2008-04-27|2008-04-28|Estimate|||||||2009-10-26|2009-10-27|Estimate|November 2002||2002-11-30|October 2009|2009-10-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Ciprofloxacin on Burned Patients|A Population Pharmacokinetics Study of Plasma Levels of Ciprofloxacin Following a Regimen of Repeated Dose I.V. Administration (400 mg TID) on Burn Patients|Completed||Phase 3|18|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:47.864984|2018-06-01 02:11:47.864984
NCT00668031|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2014-12-26|2008-04-27|2008-04-28|Estimate|||||||2014-12-26|2014-12-30|Estimate|February 2005||2005-02-28|December 2014|2014-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement Surgery|Completed||Phase 3|359|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:47.971213|2018-06-01 02:11:47.971213
NCT00668018|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-12-18|2008-04-27|2008-04-28|Estimate|||||||2014-12-18|2014-12-23|Estimate|January 2003||2003-01-31|December 2014|2014-12-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Assess Efficacy of Vardenafil 10mg in Erectile Dysfunction Within Intake of 6 Hours|An Open-label, Multicenter Study to Assess Safety, Tolerability, Efficacy and Impact on Quality of Life of Vardenafil 10mg in Patients With Erectile Dysfunction Within a Time Window of up to 6 Hours After Intake of Study Drug|Completed||Phase 3|887|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:11:48.174253|2018-06-01 02:11:48.174253
NCT00668005|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-12-15|2008-04-27|2008-04-28|Estimate|||||||2014-12-15|2014-12-16|Estimate|February 2003||2003-02-28|December 2014|2014-12-31|September 2003|Actual|2003-09-30|||||Interventional|||Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension|A Randomized, Double-blind, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administration for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Men With Arterial Hypertension and Erectile Dysfunction|Completed||Phase 3|388|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:48.254788|2018-06-01 02:11:48.254788
NCT00667992|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2010-05-12||2012-10-09|2008-04-27|2008-04-28|Estimate|2012-10-09|2012-11-07|Estimate||||2012-10-09|2012-11-07|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma|A Phase 3, Randomised, Open-label, Crossover Study to Compare HFA vs CFC pMDI Formulations of Budesonide on Methacholine Hyper-reactivity in Patients With Stable, Persistent, Mild to Moderate Asthma|Completed||Phase 3|99|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:11:48.446104|2018-06-01 02:11:48.446104
NCT00667979|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2009-06-29|2008-04-27|2008-04-28|Estimate|||||||2009-06-29|2009-06-30|Estimate|September 2004||2004-09-30|June 2009|2009-06-30|December 2004|Actual|2004-12-31|||||Interventional|||Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse|A Pilot, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Vardenafil Versus Placebo Administered 12, 18 and 24 Hours Prior to Initiation of Sexual Intercourse in Subjects With ED|Completed||Phase 4|264|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:49.015648|2018-06-01 02:11:49.015648
NCT00667966|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2015-05-05|2008-04-27|2008-04-28|Estimate|||||||2015-05-05|2015-05-06|Estimate|July 2005||2005-07-31|May 2015|2015-05-31|February 2007|Actual|2007-02-28|||||Interventional|LEMDE||Assess Efficacy in Subjects With Traumatic Spinal Cord Injury|Double-blind, Cross-over, Placebo Controlled Pilot Study to Characterize the Profile of Those Patients With Spinal Cord Injury Diagnosed by Electrophysiological, Urodynamic and Clinical (ASIA Group) Assessment Who May Respond to Vardenafil Treatment. (LEMDE)|Completed||Phase 4|45|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:11:49.095164|2018-06-01 02:11:49.095164
NCT00667953|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2016-09-23|2008-04-25|2008-04-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2003||2003-01-31|September 2016|2016-09-30||||March 2011|Actual|2011-03-31||Interventional|||Study of Temzolomide and Gleevec in Advanced Melanoma|Phase I/II Study of Temozolomide and Gleevec (Imatinib Mesylate, Formerly Known as STI571) in Advanced Melanoma|Active, not recruiting||Phase 1/Phase 2|56|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||f||||||||||2018-06-01 02:11:49.186957|2018-06-01 02:11:49.186957
NCT00667940|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-25|2008-04-25|2008-04-28|Estimate|||||||2008-04-25|2008-04-28|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|June 2007|Actual|2007-06-30|June 2006|Actual|2006-06-30||Interventional|||Faculty Development to Improve Mini-CEX Ratings|Effect of Faculty Development on Mini-CEX Score Reliability and Accuracy: A Randomized, Controlled Trial|Completed||N/A|52|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:11:49.270583|2018-06-01 02:11:49.270583
NCT00667927|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2008-04-25|2008-04-25|2008-04-28|Estimate|||||||2008-04-25|2008-04-28|Estimate|March 1991||1991-03-31|April 2008|2008-04-30|January 2008|Actual|2008-01-31|January 1995|Actual|1995-01-31||Interventional|||Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission|Autologous Bone Marrow Transplant for Children With AML in First Complete Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse|Completed||Phase 1|17|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 02:11:49.352657|2018-06-01 02:11:49.352657
NCT00667914|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-09-11|2008-04-25|2008-04-28|Estimate|||||||2017-09-11|2017-09-12|Actual|April 2008|Actual|2008-04-30|September 2017|2017-09-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||A New Clinical Pathway for Patients With Fractured Neck of Femur|A New Clinical Pathway for Patients With Fractured Neck of Femur - The Orthopedics Operate, the Geriatricians Manage the Medical Work-up|Completed||N/A|397|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 02:11:49.437285|2018-06-01 02:11:49.437285
NCT00667901|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2009-12-10|2008-04-25|2008-04-28|Estimate|||||||2009-12-10|2009-12-11|Estimate|February 2007||2007-02-28|December 2009|2009-12-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery|A Phase 0 Trial of Riluzole in Patients With Resectable Stage III and IV Melanoma|Terminated||Phase 1|15|Anticipated|Rutgers, The State University of New Jersey||||All enrollment, treatment, follow-up & data analysis completed|f||||t||||||||||2018-06-01 02:11:49.510522|2018-06-01 02:11:49.510522
NCT00667888|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2018-03-07|2008-04-25|2008-04-28|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2001|Actual|2001-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation|A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation|Active, not recruiting||Phase 3|225|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:11:49.580131|2018-06-01 02:11:49.580131
NCT00667875|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2016-03-17||2017-08-31|2008-04-24|2008-04-28|Estimate|2016-03-17|2016-04-18|Estimate||||2017-08-31|2017-09-29|Actual|April 2008||2008-04-30|August 2017|2017-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|NALAPZ||An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence|An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence|Completed||Phase 2|65|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-06-01 02:11:49.728747|2018-06-01 02:11:49.728747
NCT00667862|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2016-11-15|2008-04-25|2008-04-28|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer|A Phase II, Open Label, Single Arm Study of i.v. Panobinostat (LBH589) in Patients With Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|35|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:11:50.008014|2018-06-01 02:11:50.008014
NCT00667849|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2015-09-24||2015-11-04|2008-04-24|2008-04-28|Estimate|2015-11-04|2015-12-08|Estimate||||2015-11-04|2015-12-08|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TRUST||Trial to Evaluate UltraSound in the Treatment of Tibial Fractures|Trial to Evaluate UltraSound in the Treatment of Tibial Fractures|Terminated||N/A|501|Actual|Bioventus LLC|Poor Compliance: Protocol defined compliance as ≥18 minutes use per day. Devices have a treatment monitor that showed average compliance of 42.3% (sham) and 44.6% (active) in 80% of treatment days. Poor treatment adherence confounds results.|2||Study was terminated due to futility|f||||t||||||||||2018-06-01 02:11:50.272621|2018-06-01 02:11:50.272621
NCT00667836|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2008-04-24|2008-04-24|2008-04-28|Estimate|||||||2008-04-24|2008-04-28|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Observational|||Multi-Center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients|Multi-Center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients|Unknown status|Recruiting||300|Anticipated|Shriners Hospitals for Children|||||f||||f||||||||||2018-06-01 02:11:50.94983|2018-06-01 02:11:50.94983
NCT00667823|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2018-02-07|2008-04-24|2008-04-28|Estimate|||||||2018-02-07|2018-02-08|Actual|October 17, 2008|Actual|2008-10-17|February 2018|2018-02-28|September 15, 2021|Anticipated|2021-09-15|September 15, 2021|Anticipated|2021-09-15||Interventional|SERAPHIN OL||Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension|Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension|Active, not recruiting||Phase 3|550|Actual|Actelion||1|||f||||t||||||||||2018-06-01 02:11:51.274324|2018-06-01 02:11:51.274324
NCT00667810|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2013-10-22||2015-12-04|2008-04-25|2008-04-28|Estimate|2015-12-04|2016-01-08|Estimate||||2015-12-04|2016-01-08|Estimate|June 2008||2008-06-30|December 2015|2015-12-31|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional||Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.|Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers|Terminated||Phase 3|901|Actual|Pfizer|The impact of study termination, the shorter observational periods and the resulting small sample size coupled with not having enough participants with post baseline assessments for various reasons were limiting factors for data interpretation.|3||"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical~   benefit. This decision was not based on any new safety concerns."|f||||t||||||||||2018-06-01 02:11:52.273986|2018-06-01 02:11:52.273986
NCT00667797|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2012-02-21|2008-04-25|2008-04-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|March 2003||2003-03-31|February 2012|2012-02-29|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|POLARIS||Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects|Pharmacoeconomic Outcomes of Levalbuterol and Racemic Albuterol in Inpatients Requiring Nebulization (POLARIS)|Completed||Phase 4|486|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:11:57.870415|2018-06-01 02:11:57.870415
NCT00667784|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2012-03-29|2008-04-24|2008-04-28|Estimate|||||||2012-03-29|2012-04-02|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Long Term Minor Sibling Donor Well-Being|Long Term Minor Sibling Donor Well-Being|Terminated|||2|Actual|M.D. Anderson Cancer Center|||1|Slow accrual.|f||||f||||||||||2018-06-01 02:11:58.16354|2018-06-01 02:11:58.16354
NCT00667771|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2017-06-30|2008-04-25|2008-04-28|Estimate|||||||2017-06-30|2017-07-02|Actual|April 22, 2008||2008-04-22|April 4, 2011|2011-04-04|April 4, 2011|Actual|2011-04-04|December 27, 2010|Actual|2010-12-27||Interventional|||The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion|Effect of Naltrexone on Craving and Ethanol-Induced Brain Activity|Completed||Early Phase 1|70|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:11:58.374042|2018-06-01 02:11:58.374042
NCT00667758|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2012-08-03|2008-04-25|2008-04-28|Estimate|||||||2012-08-03|2012-08-06|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|AGRA||Gonadotropin-Releasing Hormone (GnRH)-Antagonist Therapy in Rheumatoid Arthritis|Antagonist to Gonadotropin-Releasing Hormone in Rheumatoid Arthritis (AGRA): A Double-blind, Randomized, Placebo Controlled Trial|Completed||Phase 2|104|Actual|Betanien Hospital||2|||f||||t||||||||||2018-06-01 02:11:58.456102|2018-06-01 02:11:58.456102
NCT00667745|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2012-10-25||2018-01-17|2008-04-24|2008-04-28|Estimate|2013-04-30|2013-06-28|Estimate||||2018-01-17|2018-02-13|Actual|April 2008||2008-04-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|LiTMUS||Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder|Lithium Use for Bipolar Disorder (LiTMUS): A Randomized Controlled Effectiveness Trial|Completed||Phase 4|283|Actual|National Institute of Mental Health (NIMH)||2|||f||||t||||||||||2018-06-01 02:11:58.54626|2018-06-01 02:11:58.54626
NCT00667732|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2012-12-11||2013-02-04|2008-04-25|2008-04-28|Estimate|2013-02-04|2013-02-06|Estimate||||2013-02-04|2013-02-06|Estimate|March 2007||2007-03-31|February 2013|2013-02-28|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|MEXELIN||How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics|Metformin, Exenatide, and Glargine Insulin in Combination for Treatment of Patients With Type 2 Diabetes|Completed||Phase 4|41|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:11:58.980881|2018-06-01 02:11:58.980881
NCT00667719|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2016-11-15|2008-04-25|2008-04-28|Estimate|||||||2016-11-15|2016-11-16|Estimate|June 2008||2008-06-30|November 2012|2012-11-30||||October 2009|Actual|2009-10-31||Interventional|||A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension|A 28 to 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension|Completed||Phase 3|564|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:11:59.556026|2018-06-01 02:11:59.556026
NCT00667706|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-25|2008-04-25|2008-04-28|Estimate|||||||2008-04-25|2008-04-28|Estimate|April 2008||2008-04-30|April 2008|2008-04-30||||April 2013|Anticipated|2013-04-30||Interventional|||Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy|Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 02:11:59.639607|2018-06-01 02:11:59.639607
NCT00667693|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2016-07-18||2018-02-07|2008-04-24|2008-04-28|Estimate|2016-09-13|2016-10-31|Estimate||||2018-02-07|2018-03-08|Actual|February 2008||2008-02-29|January 2018|2018-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pentax Airway Scope (AWS) Intubation|Pentax AWS Intubation Study|Completed||N/A|101|Actual|The Cleveland Clinic|It focused on obese patients; did not include patients with a history of difficult intubation; protocol did not include use of adjunctive devices; was impossible to blind the operator to the device being used; only the Mallampati score was recorded|2|||f||||f||||||||||2018-06-01 02:11:59.715305|2018-06-01 02:11:59.715305
NCT00667680|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2009-11-13|2008-04-25|2008-04-28|Estimate|||||||2009-11-13|2009-11-16|Estimate|March 2007||2007-03-31|November 2009|2009-11-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression|Transcranial Direct Current Stimulation (tDCS) in Treatment-resistant Depression - Effect on Clinical and Neurophysiological Parameters|Completed||Phase 2|20|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 02:11:59.968926|2018-06-01 02:11:59.968926
NCT00667667|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2015-05-27|2008-04-24|2008-04-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Effects of Whole Body Vibration on Postmenopausal Risk-factors in Elderly Women|Effect of Whole Body Vibration Training on Two Different Devices on Osteoporotic Risk Factors in Postmenopausal Women. A Randomized Controlled Trial.|Terminated||Phase 3|108|Actual|University of Erlangen-Nürnberg Medical School||3|||f||||f||||||||||2018-06-01 02:12:00.057961|2018-06-01 02:12:00.057961
NCT00667654|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23||2016-10-11|2016-12-05|2008-04-25|2008-04-28|Estimate||||2016-10-11|2016-10-12|Estimate|2016-12-05|2016-12-06|Estimate|August 2007||2007-08-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|June 2008|Actual|2008-06-30||Interventional|||Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)|A Phase 2, Open-label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis|Completed||Phase 2|54|Actual|Centrexion Therapeutics||5|||f||||f||||||||||2018-06-01 02:12:00.158867|2018-06-01 02:12:00.158867
NCT00667641|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|||2011-05-09|2008-04-25|2008-04-28|Estimate|||||||2011-05-09|2011-05-10|Estimate|March 2007||2007-03-31|May 2011|2011-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors|Phase I Study of Paclitaxel (Taxol) and Bortezomib (Velcade) in Patients With Refractory Solid Tumor Malignancies Involving an Activated MAPK Pathway|Completed||Phase 1|16|Actual|Rutgers, The State University of New Jersey|||||f||||t||||||||||2018-06-01 02:12:00.286385|2018-06-01 02:12:00.286385
NCT00667628|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24||2013-06-04|2013-06-04|2008-04-25|2008-04-28|Estimate||||2013-06-04|2013-06-12|Estimate|2013-06-04|2013-06-12|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma|Terminated||Phase 2|52|Actual|Taiho Oncology, Inc.||2||Terminated due to safety concerns.|f||||f||||||||||2018-06-01 02:12:00.364456|2018-06-01 02:12:00.364456
NCT00667615|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2017-09-07||2017-12-07|2008-04-25|2008-04-28|Estimate|2017-10-05|2017-11-07|Actual||||2017-12-07|2018-01-05|Actual|April 2008|Actual|2008-04-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)|A Multi-Center Phase I/II Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 1/Phase 2|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:12:00.474121|2018-06-01 02:12:00.474121
NCT00667602|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2013-02-18|2011-02-18|2013-09-03|2008-04-25|2008-04-28|Estimate|2013-09-03|2013-11-07|Estimate|2011-02-18|2011-02-25|Estimate|2013-09-03|2013-11-07|Estimate|March 2008||2008-03-31|September 2013|2013-09-30|October 2010|Actual|2010-10-31|July 2009|Actual|2009-07-31||Interventional||As one site has been excluded, the number of subjects included in the analysis are MenACWY-CRM197 (2dose) + Concomitant Vaccines N= 196, MenACWY-CRM197 (1dose) + Concomitant Vaccines N= 205 and MenC (1dose) + Concomitant Vaccines N= 193|Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers|A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers|Completed||Phase 3|662|Actual|Novartis|GCP compliance issues were identified at one site, data collected for this site were not used in this data posting.|3|||f||||||||||||||2018-06-01 02:12:00.815926|2018-06-01 02:12:00.815926
NCT00666575|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|December 2004||2004-12-31|April 2008|2008-04-30|May 2005|Actual|2005-05-31|||||Interventional|||A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Actual Use Study of the Safety and Tolerability of Gabapentin 500 mg in a Potential OTC Population|Completed||Phase 3|2105|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 02:12:31.727465|2018-06-01 02:12:31.727465
NCT00667589|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2013-02-26||2013-05-28|2008-04-25|2008-04-28|Estimate|2013-04-22|2013-05-27|Estimate||||2013-05-28|2013-06-05|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Sorafenib-induced Hand- Foot Skin Reaction Treatment|Four-arm Study to Evaluate Urea 40% Cream, Fluocinonide 0.05% Cream, Tazarotene 0.1% Cream, and an Emollient Cream for the Treatment of Hand-foot Skin Reaction Related to the Use of Multi-targeted Tyrosine Kinase Inhibitor Sorafenib.|Terminated||Phase 2|6|Actual|Northwestern University||4||Study was halted due to poor subject accrual.|f||||f||||||||||2018-06-01 02:12:02.194394|2018-06-01 02:12:02.194394
NCT00667576|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2010-03-18||2012-01-18|2008-04-25|2008-04-28|Estimate|2010-03-18|2010-04-02|Estimate||||2012-01-18|2012-01-20|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis|Late Phase 2 Study of Paricalcitol Injection: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism (Examination of Initial Dose and Incremental Dose)|Completed||Phase 2|153|Actual|Abbott|Different PTH thresholds were applied for suspending study drug: paricalcitol groups <60 pg/mL, maxacalcitol group ≤150 pg/mL. This study was not statistically powered to compare treatments.|5|||f||||f||||||||||2018-06-01 02:12:02.551371|2018-06-01 02:12:02.551371
NCT00667563|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2014-01-23||2016-02-01|2008-04-25|2008-04-28|Estimate|2014-03-07|2014-04-11|Estimate||||2016-02-01|2016-02-29|Estimate|August 2009||2009-08-31|February 2016|2016-02-29|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||Enrolled in study|Vaccine Therapy in Preventing HPV in HIV-Positive Women in India|A Single-Arm, Open-Label Pilot Study of the Safety and Immunogenicity of the Merck Quadrivalent Human Papillomavirus Vaccine Among HIV-Positive Women in India|Completed||Phase 1|150|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 02:12:03.313717|2018-06-01 02:12:03.313717
NCT00667550|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2010-07-13|2008-04-24|2008-04-28|Estimate|||||||2010-07-13|2010-07-15|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders|Lower Urinary Tract and Sexual Function in Women Following Surgery for Colorectal Disorders|Completed|||34|Actual|University of California, Irvine|||||f||||t||||||||||2018-06-01 02:12:03.561206|2018-06-01 02:12:03.561206
NCT00667537|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2015-12-11|2008-04-25|2008-04-28|Estimate|||||||2015-12-11|2015-12-14|Estimate|July 2007||2007-07-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||PK in Pts With HRPC & Skeletal Metastes|A Phase I, Open-label, Dosimetry, Biodistribution and Pharmacokinetic Study of Alpharadin™ in Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases|Completed||Phase 1|6|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:12:03.632553|2018-06-01 02:12:03.632553
NCT00667524|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2009-12-24|2008-04-25|2008-04-28|Estimate|||||||2009-12-24|2009-12-29|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Eosinophilic Esophagitis: Influence of Dilation on Dysphagia and Inflammation|Eosinophilic Esophagitis: Influence of Esophageal Dilation on the Underlying Inflammation and Efficacy/Safety of the Procedure|Completed|||207|Actual|University of Bern|||1||f||||f||||||Samples Without DNA|"~     formalin-fixed esophageal biopsies (blinded review of histology slides)~   "|||2018-06-01 02:12:03.717918|2018-06-01 02:12:03.717918
NCT00667511|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2014-12-22||2015-01-12|2008-04-25|2008-04-28|Estimate|2015-01-12|2015-01-14|Estimate||||2015-01-12|2015-01-14|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||58 patients were enrolled in the cross-over study. Patients were required to complete the home short daily hemodialysis phase before transitioning to the home nocturnal hemodialysis phase.|Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™|Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™|Completed||N/A|58|Actual|NxStage Medical||2|||f||||t||||||||||2018-06-01 02:12:03.787847|2018-06-01 02:12:03.787847
NCT00667498|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2009-02-16|2008-04-25|2008-04-28|Estimate|||||||2009-02-16|2009-02-18|Estimate|March 2004||2004-03-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance|Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance|Completed||Phase 4|28|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:12:04.109268|2018-06-01 02:12:04.109268
NCT00667485|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-01-16|2008-04-24|2008-04-28|Estimate|||||||2014-01-16|2014-01-17|Estimate|April 2008||2008-04-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Rapamycin Plus Bevacizumab in Advanced Cancers|A Phase I Study of Rapamycin (Sirolimus) With Bevacizumab in Patients With Advanced Malignancies|Completed||Phase 1|28|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 02:12:04.22366|2018-06-01 02:12:04.22366
NCT00667472|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2017-02-08|2008-04-25|2008-04-28|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2008||2008-03-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks|Withdrawn||Phase 1|0|Actual|University of California, Irvine||2||No participants enrolled|f||||t||||||||||2018-06-01 02:12:04.329901|2018-06-01 02:12:04.329901
NCT00667459|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2014-08-22|2012-07-17|2015-01-22|2008-04-24|2008-04-28|Estimate|2014-09-18|2014-09-22|Estimate|2012-07-17|2012-07-25|Estimate|2015-01-22|2015-02-05|Estimate|January 2005||2005-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|January 2008|Actual|2008-01-31||Interventional|||Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD|A Prospective, Multicenter, Controlled Clinical Trial of an Artificial Cervical Disc LP at a Single Level for Symptomatic Cervical Disc Disease|Completed||Phase 3|280|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 02:12:04.483484|2018-06-01 02:12:04.483484
NCT00667446|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2013-10-16||2014-01-08|2008-04-24|2008-04-28|Estimate|2013-10-16|2013-12-10|Estimate||||2014-01-08|2014-01-09|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional||Participants who received at least 1 dose of study drug in this extension study.|Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty|A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty|Completed||Phase 3|72|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 02:12:05.777676|2018-06-01 02:12:05.777676
NCT00667433|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-03-01|2008-04-25|2008-04-28|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|REAL||Raltegravir as Early Therapy in African-Americans Living With HIV Study|CID 0706 - Safety, Tolerability, Pharmacokinetic, and Metabolic Features of Raltegravir Among African-American Men and Women With HIV Infection|Completed||Phase 1|38|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 02:12:06.352664|2018-06-01 02:12:06.352664
NCT00667420|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2014-06-27||2014-07-03|2008-04-25|2008-04-28|Estimate|2014-07-03|2014-07-04|Estimate||||2014-07-03|2014-07-04|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2011|Actual|2011-06-30||Interventional|EOXP|17 patients with adenocarcinoma of the stomach were enrolled on this study of perioperative EOX-P.|Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma|A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma|Terminated||Phase 1/Phase 2|17|Actual|Massachusetts General Hospital|This study was stopped early due to poor tolerability. We will not further study this regimen in this patient population.|1||Closed due to slow accrual|f||||f||||||||||2018-06-01 02:12:06.495379|2018-06-01 02:12:06.495379
NCT00667407|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2012-02-21|2008-04-25|2008-04-28|Estimate|||||||2012-02-21|2012-02-22|Estimate|November 2000||2000-11-30|February 2012|2012-02-29|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma|A Randomized, Double-Blind Study to Determine the Efficacy of Levalbuterol Versus Racemic Albuterol in the Treatment of Acute Asthma|Completed||Phase 3|627|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 02:12:06.711325|2018-06-01 02:12:06.711325
NCT00667394|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2012-07-30||2015-10-13|2008-04-25|2008-04-28|Estimate|2012-07-30|2012-08-31|Estimate||||2015-10-13|2015-11-05|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors|A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas|Completed||Phase 2|42|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 02:12:06.825724|2018-06-01 02:12:06.825724
NCT00667381|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2010-09-27||2010-10-19|2008-04-25|2008-04-28|Estimate|2010-10-19|2010-11-16|Estimate||||2010-10-19|2010-11-16|Estimate|April 2008||2008-04-30|October 2010|2010-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|FAUST||Femoral Arterial Access With Ultrasound Trial|Femoral Arterial Access With Ultrasound Trial|Completed||N/A|1014|Actual|University of California, Irvine||2|||f||||f||||||||||2018-06-01 02:12:07.442999|2018-06-01 02:12:07.442999
NCT00667368|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2015-09-24||2015-11-05|2008-04-24|2008-04-28|Estimate|2015-09-24|2015-10-29|Estimate||||2015-11-05|2015-12-07|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All randomized participants|Bacterial Vaginosis Home Screening to Prevent STDs|Home Screening for Bacterial Vaginosis to Prevent STDs|Completed||Phase 3|1370|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 02:12:08.99043|2018-06-01 02:12:08.99043
NCT00667355|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2010-05-28||2012-01-24|2008-04-24|2008-04-28|Estimate|2010-07-12|2010-08-11|Estimate||||2012-01-24|2012-01-26|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|January 2011|Actual|2011-01-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis|A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis|Completed||Phase 3|41|Actual|Abbott||1|||f||||f||||||||||2018-06-01 02:12:09.741537|2018-06-01 02:12:09.741537
NCT00667342|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2014-06-09||2017-04-17|2008-04-25|2008-04-28|Estimate|2014-07-11|2014-08-04|Estimate||||2017-04-17|2017-05-16|Actual|June 2008|Actual|2008-06-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|May 2014|Actual|2014-05-31||Interventional||Participants were eligible if they were ≤30 years of age on date of diagnostic biopsy confirmation of high-grade osteosarcoma or malignant fibrous histiocytoma (MFH) of bone. Participants had no previous chemotherapy or radiation therapy.|A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma|A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma|Active, not recruiting||Phase 2|43|Actual|St. Jude Children's Research Hospital|Accrual to this study was stopped early after 4.5 years due to slow accrual of participants. No eligible participants were enrolled on Stratum B. All enrolled participants continue on study and results will be reported when available.|3|||f||||t|t|f||||||||2018-06-01 02:12:10.702664|2018-06-01 02:12:10.702664
NCT00667329|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2018-04-23|2008-04-24|2008-04-28|Estimate|||||||2018-04-23|2018-04-24|Actual|July 1999|Actual|1999-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab|Primary Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab|Active, not recruiting||Phase 1|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:12:11.557042|2018-06-01 02:12:11.557042
NCT00667316|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-03-11|2008-04-25|2008-04-28|Estimate|||||||2014-03-11|2014-03-13|Estimate|February 2008||2008-02-29|March 2014|2014-03-31|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Observational|||The Influence of Different Factors on Workers' Disability Due to Low Back Pain|Study to Identify the Influence of Different Factors on Workers' Disability Due to Low Back Pain|Unknown status|Recruiting||7200|Anticipated|Kovacs Foundation|||1||f||||t||||||||||2018-06-01 02:12:11.659103|2018-06-01 02:12:11.659103
NCT00667303|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2012-09-06|2008-04-25|2008-04-28|Estimate|||||||2012-09-06|2012-09-07|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Observational|||Prospective Surveillance For Respiratory Virus Infections In Children Undergoing Hematopoietic Stem Cell Transplantation|Prospective Surveillance For Respiratory Virus Infections In Children Undergoing Hematopoietic Stem Cell Transplantation|Completed|||51|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||Samples Without DNA|"~     Nasopharyngeal washes Fluorescent antibody detection Respiratory viral culture~   "|||2018-06-01 02:12:11.755681|2018-06-01 02:12:11.755681
NCT00667290|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2008-04-24|2008-04-24|2008-04-28|Estimate|||||||2008-04-24|2008-04-28|Estimate|July 2000||2000-07-31|April 2008|2008-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Exercise for Elderly Peripheral Revascularized Patients|Exercise for Elderly Peripheral Revascularized Patients|Completed||N/A|80|Actual|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 02:12:11.836697|2018-06-01 02:12:11.836697
NCT00667277|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2014-04-11||2014-08-08|2008-04-24|2008-04-28|Estimate|2014-08-08|2014-08-22|Estimate||||2014-08-08|2014-08-22|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis|Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis|Terminated||Phase 2|13|Actual|Icahn School of Medicine at Mount Sinai|The study was terminated due to lack of response activity in the setting of an unacceptable toxicity profile at the completion of the first stage.|1||lack of response activity in the setting of an unacceptable toxicity profile|f||||t||||||||||2018-06-01 02:12:11.924566|2018-06-01 02:12:11.924566
NCT00667264|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2012-06-26|2008-04-24|2008-04-28|Estimate|||||||2012-06-26|2012-06-28|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain|Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain|Completed||N/A|7|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 02:12:12.14536|2018-06-01 02:12:12.14536
NCT00667251|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-25|2013-09-24||2018-01-08|2008-04-25|2008-04-28|Estimate|2014-06-17|2014-06-18|Estimate||||2018-01-08|2018-02-01|Actual|October 7, 2008|Actual|2008-10-07|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|August 1, 2012|Actual|2012-08-01||Interventional|||Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer|A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/Neu Positive Metastatic Breast Cancer|Active, not recruiting||Phase 3|649|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 02:12:12.391474|2018-06-01 02:12:12.391474
NCT00667238|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2008-04-25|2008-04-25|2008-04-28|Estimate|||||||2008-04-25|2008-04-28|Estimate|November 2006||2006-11-30|April 2008|2008-04-30||||||||Observational|||Chronic Pediatric Pain|Functional Impact of Chronic Pediatric Pain|Unknown status|Recruiting||300||Stanford University|||||f||||||||||||||2018-06-01 02:12:14.405841|2018-06-01 02:12:14.405841
NCT00667225|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2011-04-28||2011-06-16|2008-04-25|2008-04-28|Estimate|2011-04-28|2011-06-01|Estimate||||2011-06-16|2011-06-21|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Cantharidin in Molluscum Contagiosum|Efficacy of Cantharidin in Molluscum Contagiosum: A Randomized, Blinded, Placebo-Controlled Prospective Study|Completed||N/A|29|Actual|University of North Carolina, Chapel Hill|Small sample size and random disproportionate assignment to the vehicle group. Other limitations include short duration of follow up and interval between treatments. Finally, matching subjects in each group with comparable lesion counts.|2|||f||||f||||||||||2018-06-01 02:12:14.483811|2018-06-01 02:12:14.483811
NCT00667212|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2013-06-11|2008-04-24|2008-04-28|Estimate|||||||2013-06-11|2013-06-13|Estimate|August 2006||2006-08-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Psychotherapy for Intermittent Explosive Disorder|Individual Cognitive Behavioral Psychotherapy for Intermittent Explosive Disorder|Completed||Phase 2|60|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 02:12:14.758829|2018-06-01 02:12:14.758829
NCT00667199|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-06-24|2008-04-25|2008-04-28|Estimate|||||||2014-06-24|2014-06-25|Estimate|May 2005||2005-05-31|June 2014|2014-06-30|October 2009|Actual|2009-10-31|April 2008|Actual|2008-04-30||Interventional|||BAY88-8223, Does Response Study in HRPC Patients|A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin®) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients|Completed||Phase 2|100|Actual|Bayer||4|||f||||f||||||||||2018-06-01 02:12:14.834704|2018-06-01 02:12:14.834704
NCT00667186|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2012-10-29||2013-01-30|2008-04-23|2008-04-25|Estimate|2012-12-14|2013-01-24|Estimate||||2013-01-30|2013-02-04|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||HIV Screening in the Emergency Department Setting|HIV Screening in the Emergency Department Setting|Completed||N/A|9572|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 02:12:14.921696|2018-06-01 02:12:14.921696
NCT00667173|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23||2010-09-02|2012-02-16|2008-04-23|2008-04-25|Estimate||||2010-09-02|2010-09-08|Estimate|2012-02-16|2012-02-20|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea|A Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-115 in the Treatment of Rosacea|Completed||Phase 2|140|Actual|Dow Pharmaceutical Sciences||3|||f||||f||||||||||2018-06-01 02:12:15.129656|2018-06-01 02:12:15.129656
NCT00667160|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-09-17|2008-04-23|2008-04-25|Estimate|||||||2014-09-17|2014-09-18|Estimate|December 2002||2002-12-31|September 2014|2014-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis|A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis|Completed||Phase 4|426|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:12:15.23757|2018-06-01 02:12:15.23757
NCT00667147|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-11-18|2008-04-23|2008-04-25|Estimate|||||||2014-11-18|2014-11-19|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|May 2012|Actual|2012-05-31||Interventional|||Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib|Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination With Vandetanib|Completed||Phase 1|65|Actual|University of Southern California||2|||f||||f||||||||||2018-06-01 02:12:15.379829|2018-06-01 02:12:15.379829
NCT00667134|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2016-10-24|2008-04-23|2008-04-25|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|February 2012|Actual|2012-02-29|August 2008|Actual|2008-08-31||Observational|||Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis|Stimulatory Autoantibodies to the PDGFR and Phosphorylation of the PDGFR in Patients With Systemic Sclerosis|Completed|||26|Actual|University of Michigan|||3||f||||f||||||Samples Without DNA|"~     skin serum~   "|||2018-06-01 02:12:15.467873|2018-06-01 02:12:15.467873
NCT00667121|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2017-08-28|2008-04-24|2008-04-25|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2008||2008-03-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline|The Effect of Antidepressants and Gabapentin on Tamoxifen Pharmacokinetics: A Prospective Study|Active, not recruiting|||85|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:12:15.526859|2018-06-01 02:12:15.526859
NCT00667108|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|January 2005|Actual|2005-01-31|||||Interventional|||A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance|Completed||Phase 3|784|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:12:15.622852|2018-06-01 02:12:15.622852
NCT00667095|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2014-05-09||2014-07-10|2008-04-23|2008-04-25|Estimate|2014-07-10|2014-07-11|Estimate||||2014-07-10|2014-07-11|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Over Active Bladder Instillation Study - Botox|Evaluation of the Efficacy of Botulinum-A Toxin/DMSO Instillation in the Treatment of Women With Over Active Bladder (OAB) Syndrome and/or Urinary Urge Incontinence|Terminated||Phase 3|25|Actual|Mayo Clinic||2||Study terminated early due to PI's extended medical leave.|f||||t||||||||||2018-06-01 02:12:15.724128|2018-06-01 02:12:15.724128
NCT00667069|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2018-05-14|2008-04-24|2008-04-25|Estimate|||||||2018-05-14|2018-05-17|Actual|April 2008|Actual|2008-04-30|May 2018|2018-05-31||||April 2022|Anticipated|2022-04-30||Interventional|||Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer|Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk.|Active, not recruiting||Phase 3|718|Anticipated|UNICANCER|||||f||||||||||||||2018-06-01 02:12:16.45312|2018-06-01 02:12:16.45312
NCT00667056|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-09-17|2008-04-23|2008-04-25|Estimate|||||||2014-09-17|2014-09-18|Estimate|July 2004||2004-07-31|September 2014|2014-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis|Completed||Phase 4|98|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:12:16.541498|2018-06-01 02:12:16.541498
NCT00667043|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2012-04-25|2008-04-24|2008-04-25|Estimate|||||||2012-04-25|2012-04-26|Estimate|April 2008||2008-04-30|April 2012|2012-04-30|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|Cool Sedation||Remifentanil and Propofol Versus Fentanyl and Midazolam for Sedation During Therapeutic Hypothermia. A Randomised, Controlled Trial|Remifentanil and Propofol Versus Fentanyl and Midazolam for Sedation During Therapeutic Hypothermia. A Randomised, Controlled Trial|Completed||Phase 4|60|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 02:12:16.625579|2018-06-01 02:12:16.625579
NCT00667030|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-04-19|2008-04-23|2008-04-25|Estimate|||||||2017-04-19|2017-04-21|Actual|July 2005||2005-07-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ALIVE||Aging, Lifestyle and Inflammation in Veterans Exercising|Aging, Lifestyle and Inflammation in Veterans Exercising|Active, not recruiting||N/A|100|Anticipated|University of Maryland||1|||f||||t||||||||||2018-06-01 02:12:16.689805|2018-06-01 02:12:16.689805
NCT00667017|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2010-02-04|2008-04-24|2008-04-25|Estimate|||||||2010-02-04|2010-02-05|Estimate|July 2008||2008-07-31|February 2010|2010-02-28||||February 2010|Actual|2010-02-28||Interventional|||RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Phase II Study of IMTOX25 in Relapsed/Refractory Cutaneous T-Cell Lymphoma|Completed||Phase 2|29|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 02:12:16.788613|2018-06-01 02:12:16.788613
NCT00667004|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23||2011-09-02|2013-01-03|2008-04-24|2008-04-25|Estimate||||2011-09-02|2011-09-12|Estimate|2013-01-03|2013-01-08|Estimate|April 2008||2008-04-30|January 2013|2013-01-31||||December 2008|Actual|2008-12-31||Interventional|||Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease||Completed||Phase 2|183|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:12:16.87072|2018-06-01 02:12:16.87072
NCT00666991|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-02-26|2008-04-23|2008-04-25|Estimate|||||||2014-02-26|2014-02-27|Estimate|July 2008||2008-07-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers|A Phase 1 Study of Intraperitoneal Nanoparticle Paclitaxel in Patients With Peritoneal Malignancies|Completed||Phase 1|22|Actual|CritiTech, Inc.||6|||f||||t||||||||||2018-06-01 02:12:16.940351|2018-06-01 02:12:16.940351
NCT00666978|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2017-04-17||2017-10-11|2008-04-24|2008-04-25|Estimate|2017-06-23|2017-07-24|Actual||||2017-10-11|2017-11-13|Actual|December 2007||2007-12-31|October 2017|2017-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking|Enhancing Tobacco Use Treatment for African American Light Smokers|Completed||Phase 4|540|Actual|University of Kansas Medical Center|Over half of the participants who expressed interest in this study were ineligible according to study protocol. The lack of assessment between standardized assessment points limited the ability to characterize the process of relapse.|2|||f||||f||||||||||2018-06-01 02:12:17.058506|2018-06-01 02:12:17.058506
NCT00666965|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2014-02-03||2014-03-26|2008-04-24|2008-04-25|Estimate|2014-03-26|2014-04-25|Estimate||||2014-03-26|2014-04-25|Estimate|June 2008||2008-06-30|March 2014|2014-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||3 subjects (1 for each placebo, 4.5 mg/day and 6.75 mg/day arm) were excluded by criteria|A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients|A Placebo-Controlled Study for SPM 962 in RLS Patients|Completed||Phase 2|230|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 02:12:17.681657|2018-06-01 02:12:17.681657
NCT00666952|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-10-11|2008-04-23|2008-04-25|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2008||2008-05-31|October 2017|2017-10-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|POINT of View||Study Testing Patient Decision Tools Related to the Risks and Benefits of Weight Loss Surgery|Randomized Trial of a Patient Decision Aid for Bariatric Surgery|Completed||N/A|150|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 02:12:18.302958|2018-06-01 02:12:18.302958
NCT00666939|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|January 2005|Actual|2005-01-31|||||Interventional|||A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter Study Of Gabapentin 100 mg and 250 mg in Transient Insomnia Induced By A Sleep Phase Advance|Completed||Phase 3|773|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:12:18.367319|2018-06-01 02:12:18.367319
NCT00666926|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2012-05-11||2013-03-14|2008-04-23|2008-04-25|Estimate|2012-05-11|2012-06-14|Estimate||||2013-03-14|2013-03-21|Estimate|December 2005||2005-12-31|March 2013|2013-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms|A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies|Completed||Phase 1|99|Actual|Verastem, Inc.|PET and RECIST Response Analysis Sets as defined in Protocol Amendment 3 dated 20Mar2007 are reported in Basic Results per the revised definitions in Statistical Analysis Plan version 2 dated 11Apr2008.|4|||f||||f||||||||||2018-06-01 02:12:18.675709|2018-06-01 02:12:18.675709
NCT00666913|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2015-09-28|2008-04-24|2008-04-25|Estimate|||||||2015-09-28|2015-09-29|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial|Menopausal Symptoms in Women With Breast Cancer|Completed|||183|Actual|Case Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 02:12:23.325428|2018-06-01 02:12:23.325428
NCT00663598|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2014-12-18|2008-04-21|2008-04-22|Estimate|||||||2014-12-18|2014-12-19|Estimate|October 2003||2003-10-31|December 2014|2014-12-31|September 2004|Actual|2004-09-30|||||Interventional|REALISE||Levitra® - Real Life Safety and Efficacy of Levitra|REALISE Levitra® - Real Life Safety and Efficacy of Levitra|Completed||Phase 4|30825|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:13:19.147266|2018-06-01 02:13:19.147266
NCT00666900|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23||2010-09-15|2012-02-16|2008-04-23|2008-04-25|Estimate||||2010-09-15|2010-09-17|Estimate|2012-02-16|2012-02-20|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris|A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris With Nodules|Completed||Phase 2|366|Actual|Dow Pharmaceutical Sciences||3|||f||||f||||||||||2018-06-01 02:12:23.400781|2018-06-01 02:12:23.400781
NCT00666887|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-02-23|2008-04-24|2008-04-25|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2009||2009-01-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|MinoCIS||Minocycline in Clinically Isolated Syndromes (CIS)|A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)|Completed||Phase 3|142|Actual|University of Calgary||2|||f||||t||||||||No|Consent to share IPD was not obtained from subjects so data cannot be shared except amongst investigators.|2018-06-01 02:12:23.522818|2018-06-01 02:12:23.522818
NCT00666874|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|February 1999||1999-02-28|April 2008|2008-04-30|February 2002|Actual|2002-02-28|December 2001|Actual|2001-12-31||Interventional|||Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women|Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women|Completed||N/A|120|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-06-01 02:12:23.632619|2018-06-01 02:12:23.632619
NCT00666861|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-07-28|2008-04-24|2008-04-25|Estimate|||||||2009-07-28|2009-07-30|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Observational|||Type 2 Diabetes and Exercise - A Pilot Study|Understanding the Acute Effects of Prolonged Sedentary Behaviour (Sitting) on Post-meal Glucose and Lipids - A Pilot Study|Terminated|||2|Actual|Bayside Health||||Pilot study superseded by a larger NHMRC funded trial|f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-06-01 02:12:23.725153|2018-06-01 02:12:23.725153
NCT00666848|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2011-09-04||2012-04-12|2008-04-24|2008-04-25|Estimate|2012-04-12|2012-05-11|Estimate||||2012-04-12|2012-05-11|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome|Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome|Completed||Phase 4|24|Actual|Vanderbilt University||3|||f||||f||||||||||2018-06-01 02:12:23.80232|2018-06-01 02:12:23.80232
NCT00666835|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2017-04-24||2017-08-04|2008-04-24|2008-04-25|Estimate|2017-04-24|2017-08-02|Actual||||2017-08-04|2017-09-05|Actual|April 2004|Actual|2004-04-30|August 2017|2017-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional||All randomized patients who received at least 1 dose of the study medication and for whom at least 1 post-baseline value of the primary endpoint Hb was available. A prerequisite for patients to be included in the Intention To Treat (ITT) population is that they were treated for four weeks with Hb values available during this period.|Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients|Randomized, Double-blind, Multicenter, Parallel-group, Equivalence Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients|Completed||Phase 3|478|Actual|Sandoz||2|||f||||f||||||||Undecided||2018-06-01 02:12:24.407749|2018-06-01 02:12:24.407749
NCT00666822|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2016-02-04|2008-04-24|2008-04-25|Estimate|||||||2016-02-04|2016-02-05|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2009|Actual|2009-09-30||Observational|||Compliance to a Hormone Therapy Regimen in Breast Cancer|Adherence to Endocrine Therapy in Women With Breast Cancer in Clinical Practice Settings|Completed|||178|Actual|Case Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 02:12:25.148693|2018-06-01 02:12:25.148693
NCT00666809|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-12-08|2008-04-24|2008-04-25|Estimate|||||||2014-12-08|2014-12-09|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Vardenafil in Tinnitus|Evaluation of Vardenafil for the Treatment of Subjective Tinnitus: A Controlled Pilot Study|Completed||Phase 2|43|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:12:25.23429|2018-06-01 02:12:25.23429
NCT00666796|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|April 2005||2005-04-30|April 2008|2008-04-30|May 2005|Actual|2005-05-31|||||Interventional|||A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects|A Randomized, Double-Blind, 4-Way Crossover, Placebo-Controlled, Single Center Trial to Evaluate the Potential Pharmacodynamic Interaction Between Gabapentin 500 mg and Ethanol in Healthy Volunteers|Completed||Phase 4|20|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:12:25.31866|2018-06-01 02:12:25.31866
NCT00666783|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-24|2008-04-24|2008-04-25|Estimate|||||||2008-04-24|2008-04-25|Estimate||||August 2006|2006-08-31||||||||Interventional|||An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients|A Phase II, Multicenter,Double-Blind, Randomized Trial of Palonosetron Compared With Granisetron in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in the Chinese Cancer Patients|Completed||Phase 2|208|Actual|Xijing Hospital||2|||f||||||||||||||2018-06-01 02:12:25.397105|2018-06-01 02:12:25.397105
NCT00666770|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|November 2004|Actual|2004-11-30|||||Interventional|||A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study of Gabapentin 250 mg and 500 mg in Transient Insomnia Induced by a Sleep Phase Advance|Completed||Phase 3|309|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:12:25.470141|2018-06-01 02:12:25.470141
NCT00666757|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2010-02-16||2010-05-12|2008-04-24|2008-04-25|Estimate|2010-05-12|2010-06-15|Estimate||||2010-05-12|2010-06-15|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|TRY FIRST||A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression|TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode|Completed||Phase 4|750|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 02:12:25.601622|2018-06-01 02:12:25.601622
NCT00666744|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-10-28|2008-04-23|2008-04-25|Estimate|||||||2008-10-28|2008-10-29|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|FAME||A Randomised Controlled Trial of Family Mediated Exercises (FAME) Following Stroke|A Randomised Controlled Trial of Family Mediated Exercises (FAME) Following Stroke|Unknown status|Recruiting|Phase 3|40|Anticipated|University of Dublin, Trinity College||2|||f||||f||||||||||2018-06-01 02:12:27.168304|2018-06-01 02:12:27.168304
NCT00252031|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2005-11-17|2005-11-09|2005-11-11|Estimate|||||||2005-11-17|2005-11-21|Estimate||||November 2005|2005-11-30||||||||Interventional|||DBT in Borderline Personality Disorder|Dialectical Behavioral Therapy for Patients With Borderline Personality Disorder|Unknown status|Recruiting|N/A|||Bronx VA Medical Center|||||f||||||||||||||2018-06-01 04:20:56.916303|2018-06-01 04:20:56.916303
NCT00666731|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2017-05-11|2008-04-24|2008-04-25|Estimate|||||||2017-05-11|2017-05-15|Actual|October 2006|Actual|2006-10-31|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|BCCR||Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer|Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)|Completed|||4945|Actual|University of Nebraska|||||f||||f|f|f||||Samples With DNA|"~     Tissue, blood~   "|Yes|Collaborating centers may ask other centers to participate in future studies. Only shared among centers belonging to the BCCR|2018-06-01 02:12:27.293292|2018-06-01 02:12:27.293292
NCT00666718|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2011-02-18||2011-05-11|2008-04-23|2008-04-25|Estimate|2011-02-18|2011-03-25|Estimate||||2011-05-11|2011-05-13|Estimate|April 2008||2008-04-30|May 2011|2011-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients|A Prospective Randomized Trial to Compare Basal Bolus Therapies That Use Either Insulin Lispro Protamine Suspension or Insulin Glargine Together With Lispro Insulin in Patients With Type 2 Diabetes|Completed||Phase 3|374|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:12:27.501259|2018-06-01 02:12:27.501259
NCT00666705|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2009-03-05||2013-01-16|2008-04-23|2008-04-25|Estimate|2009-04-10|2009-06-04|Estimate||||2013-01-16|2013-01-25|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects|An Open Label Phase 4 Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects|Completed||Phase 4|18|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-06-01 02:12:28.65846|2018-06-01 02:12:28.65846
NCT00666692|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2012-04-25|2008-04-24|2008-04-25|Estimate|||||||2012-04-25|2012-04-27|Estimate|April 2008||2008-04-30|April 2012|2012-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)|Phase 1b Trial Evaluating the Safety of Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Subjects With Previously Untreated Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|7|Actual|Abbott||1|||f||||t||||||||||2018-06-01 02:12:29.039469|2018-06-01 02:12:29.039469
NCT00666679|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2010-01-07||2017-03-10|2008-04-23|2008-04-25|Estimate|2010-01-07|2010-02-03|Estimate||||2017-03-10|2017-04-10|Actual|May 2008||2008-05-31|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)|Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma|Completed||Phase 2|134|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:12:29.147255|2018-06-01 02:12:29.147255
NCT00666666|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2013-10-08||2014-12-17|2008-04-24|2008-04-25|Estimate|2014-12-17|2014-12-18|Estimate||||2014-12-17|2014-12-18|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|May 2011|Actual|2011-05-31||Interventional|||R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer|A Phase II Study of AT101, to Abrogate BCL-2 Mediated Resistance to Androgen Ablation Therapy in Patients With Newly Diagnosed Stage D2 Prostate Cancer|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 02:12:29.604664|2018-06-01 02:12:29.604664
NCT00666653|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-24|2008-04-24|2008-04-25|Estimate|||||||2008-04-24|2008-04-25|Estimate|July 2003||2003-07-31|April 2008|2008-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|DALI||Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease|Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease: a Double-Blind Placebo Controlled Crossover Study|Completed||Phase 1|13|Actual|Oregon Health and Science University|||||f||||t||||||||||2018-06-01 02:12:29.932775|2018-06-01 02:12:29.932775
NCT00666640|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-09-18|2008-04-23|2008-04-25|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|3DScans||3D Imaging of the Hip Using DXA|Parameters Derived From DXA-based Structural Engineering Models of the Proximal Femur as a Biomarker for Hip Fracture Prediction.|Completed|||100|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||2||f||||f||||||||||2018-06-01 02:12:30.002976|2018-06-01 02:12:30.002976
NCT00666627|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2018-03-05|2008-04-24|2008-04-25|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2007|Actual|2007-04-30|March 2018|2018-03-31|December 2014|Actual|2014-12-31|September 2012|Actual|2012-09-30||Interventional|||Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects|A 2-year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care.|Completed||Phase 2|410|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||4|||f||||t||||||||||2018-06-01 02:12:30.083355|2018-06-01 02:12:30.083355
NCT00666614|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2012-01-03|2008-04-24|2008-04-25|Estimate|||||||2012-01-03|2012-01-05|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Pilot Study to Examine Sleep and Fatigue in Pediatric Brain Tumor Patients Hospitalized for High Dose Chemotherapy|A Pilot Study to Examine Sleep and Fatigue in Pediatric Brain Tumor Patients Hospitalized for High Dose Chemotherapy|Completed||N/A|43|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 02:12:30.187855|2018-06-01 02:12:30.187855
NCT00666601|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-09-21|2008-04-24|2008-04-25|Estimate|||||||2017-09-21|2017-09-25|Actual|April 4, 2008|Actual|2008-04-04|September 2017|2017-09-30|August 12, 2008|Actual|2008-08-12|August 12, 2008|Actual|2008-08-12||Interventional|||Microdialysis and Pharmacokinetic Study of TR-701|An Open Label, Single Dose, Microdialysis and Pharmacokinetic Study of TR-701 in Normal Healthy Adults|Completed||Phase 1|15|Actual|Trius Therapeutics LLC||2|||f||||f||||||||||2018-06-01 02:12:30.255358|2018-06-01 02:12:30.255358
NCT00666588|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2013-12-18||2018-05-21|2008-04-24|2008-04-25|Estimate|2013-12-18|2014-02-06|Estimate||||2018-05-21|2018-05-22|Actual|April 2008||2008-04-30|May 2018|2018-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia|A Phase II Pilot Study of Bortezomib (PS-341, Velcade) Combined With Reinduction Chemotherapy in Children and Young Adults With Recurrent, Refractory or Secondary Acute Myeloid Leukemia|Completed||Phase 2|52|Actual|National Cancer Institute (NCI)|"The secondary outcome measure Protein Expression Assessed by Western Blot will never be reported as the investigators decided not to perform quantitative biologic analysis."|4|||f||||t||||||||||2018-06-01 02:12:30.359104|2018-06-01 02:12:30.359104
NCT00361816|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-06-30|2006-08-08|2006-08-09|Estimate|||||||2017-06-30|2017-07-02|Actual|May 3, 2002||2002-05-03|March 29, 2011|2011-03-29|March 29, 2011||2011-03-29|||||Observational|||Human MATER and Idiopathic Infertility|Human MATER and Idiopathic Infertility|Completed|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:05.862503|2018-06-01 03:51:05.862503
NCT00666562|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|2016-01-20||2017-10-17|2008-04-24|2008-04-25|Estimate|2016-02-24|2016-03-28|Estimate||||2017-10-17|2017-11-17|Actual|July 2, 2008|Actual|2008-07-02|October 2017|2017-10-31|June 9, 2017|Actual|2017-06-09|April 26, 2012|Actual|2012-04-26||Interventional|||Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer|A Phase II Randomized, Placebo-Controlled Trial of Polyphenon E to Evaluate Bladder Tissue Levels of EGCG|Completed||Phase 2|31|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 02:12:31.888125|2018-06-01 02:12:31.888125
NCT00666549|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-10-04|2008-04-24|2008-04-25|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2007||2007-09-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Research Tissue Bank|Research Tissue Bank|Recruiting|||400|Anticipated|Icahn School of Medicine at Mount Sinai|||||f||||t||||||Samples With DNA|"~     Blood, bone marrow, bone marrow biopsy, toenail clippings, phlebotomized blood, spleen cells~   "|||2018-06-01 02:12:32.734826|2018-06-01 02:12:32.734826
NCT00666536|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2010-11-16||2016-09-20|2008-04-24|2008-04-25|Estimate|2010-11-17|2010-12-10|Estimate||||2016-09-20|2016-10-27|Estimate|March 2008||2008-03-31|April 2011|2011-04-30||||January 2009|Actual|2009-01-31||Interventional|EXTRA||The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy|A Multicenter, Randomized, Double Blind, Parallel Design Trial to Evaluate the Blood Pressure Lowering Efficacy Comparing Moderate Versus Aggressive Treatment Regimen of Valsartan + Amlodipine in Patients Uncontrolled on ARB Monotherapy|Completed||Phase 4|728|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:12:32.841046|2018-06-01 02:12:32.841046
NCT00666523|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|January 2007||2007-01-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Effect of Phytalgic in Osteoarthritis (OA)|Randomized Double-Blind Study of Food Supplement Phytalgic on Symptoms of Osteoarthritis|Completed||N/A|81|Actual|Université Victor Segalen Bordeaux 2||2|||f||||f||||||||||2018-06-01 02:12:33.221729|2018-06-01 02:12:33.221729
NCT00666510|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-25|Estimate|||||||2008-04-23|2008-04-25|Estimate|January 1999||1999-01-31|April 2008|2008-04-30|December 2004|Actual|2004-12-31|||||Observational|||Bronchospasm Associated With High Nitric Oxide|Higher Exhaled Nitric Oxide (NO) is Associated With Intraoperative Bronchospasm|Completed|||31|Actual|University of Sao Paulo|||3||f||||f||||||Samples Without DNA|"~     Sputum~   "|||2018-06-01 02:12:33.283749|2018-06-01 02:12:33.283749
NCT00666497|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23||2015-04-06|2015-04-22|2008-04-23|2008-04-25|Estimate||||2015-04-22|2015-05-08|Estimate|2015-04-22|2015-05-08|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|A Phase 2, Randomized, Open-Label Study of Azacitidine (Vidaza) vs MGCD0103 vs Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Diagnosed AML or Intermediate-2 or High-Risk MDS|Terminated||Phase 2|6|Actual|Mirati Therapeutics Inc.||3||"Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.~   All Celgene-sponsored trials with MGCD0103 with be closed."|f||||t||||||||||2018-06-01 02:12:33.533975|2018-06-01 02:12:33.533975
NCT00666484|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-24|||2014-12-03|2008-04-24|2008-04-25|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma|Phase II Study Evaluating the Toxicity and Efficacy of a Modified German Paediatric Hodgkin's Lymphoma Protocol (HD95) in Young Adults (Aged 18-30 Years) With Hodgkin's Lymphoma|Completed||Phase 2|47|Actual|University College, London||3|||f||||t||||||||||2018-06-01 02:12:33.635003|2018-06-01 02:12:33.635003
NCT00666471|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-06-10|2008-04-24|2008-04-25|Estimate|||||||2009-06-10|2009-06-12|Estimate|June 2008||2008-06-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|MICE||Minimally Invasive Control of Epistaxis (MICE)|Minimally Invasive Control of Epistaxis: Efficacy and Economic Analysis|Terminated||Phase 2/Phase 3|3|Actual|University of Calgary||2||"one PI (BM) no longer felt he had clinical equipoise regarding the intervention. No adverse~   events."|f||||f||||||||||2018-06-01 02:12:33.737411|2018-06-01 02:12:33.737411
NCT00666458|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2010-03-05||2010-03-05|2008-04-24|2008-04-25|Estimate|2010-03-05|2010-04-15|Estimate||||2010-03-05|2010-04-15|Estimate|April 2008||2008-04-30|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)|18-wk, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Comparison With Sitagliptin in Combination With Metformin in Adult Patients With T2D Who Have Inadequate Glycaemic Control on Metformin Alone|Completed||Phase 3|822|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:12:33.829259|2018-06-01 02:12:33.829259
NCT00666445|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2010-08-12|2008-04-24|2008-04-25|Estimate|||||||2010-08-12|2010-08-13|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test|Improved Diagnosis of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test: AD Template Development Study|Completed|||150|Anticipated|Orasi Medical, Inc.|||2||f||||f||||||||||2018-06-01 02:12:34.192774|2018-06-01 02:12:34.192774
NCT00666432|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2017-07-13|2008-04-23|2008-04-24|Estimate|||||||2017-07-13|2017-07-18|Actual|May 2008||2008-05-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2012|Actual|2012-09-30||Observational|||Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes|Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes|Active, not recruiting|||3500|Anticipated|University of Maryland|||3||f||||t||||||Samples With DNA|"~     Blood or saliva will be stored for future genetic analysis.~   "|||2018-06-01 02:12:34.249815|2018-06-01 02:12:34.249815
NCT00666419|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2011-06-26|2008-04-23|2008-04-24|Estimate|||||||2011-06-26|2011-06-28|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Prevalence of Back Pain and Associated Risk Factors in 10-12 Year Old Schoolchildren|Prevalence of Back Pain and Associated Risk Factors in 10-12 Year Old Schoolchildren|Withdrawn|||8000|Anticipated|Kovacs Foundation||||Recruiting at schools was slower than planned. Missing data higher than acceptable.|f||||t||||||||||2018-06-01 02:12:34.312576|2018-06-01 02:12:34.312576
NCT00666406|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2013-02-13||2017-10-19|2008-04-22|2008-04-24|Estimate|2013-02-13|2013-03-26|Estimate||||2017-10-19|2017-11-22|Actual|March 2008||2008-03-31|February 2013|2013-02-28|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A|Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A: a Phase IV, Prospective, Randomized, Controlled, Cross-over, Single Center Study|Completed||Phase 4|9|Actual|Shire||2|||f||||f||||||||||2018-06-01 02:12:35.432139|2018-06-01 02:12:35.432139
NCT00666393|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2014-02-28|2008-04-23|2008-04-24|Estimate|||||||2014-02-28|2014-03-03|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients|An Open-Label Evaluation of Safety of the IONSYS System [Fentanyl Iontophoretic Transdermal System (40ug) for Management of Acute Post-Operative Pain in Pediatric Patients|Withdrawn||Phase 3|0|Actual|Alza Corporation, DE, USA||1||Program Cancelled.|f||||f||||||||||2018-06-01 02:12:36.309162|2018-06-01 02:12:36.309162
NCT00666380|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2015-05-27|2008-04-23|2008-04-24|Estimate|||||||2015-05-27|2015-05-29|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya|Phase 1a Open-label Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B in Healthy Malaria-Naïve Adults|Completed||Phase 1|26|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-06-01 02:12:36.387061|2018-06-01 02:12:36.387061
NCT00666367|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2010-12-23|2008-04-23|2008-04-24|Estimate|||||||2010-12-23|2010-12-24|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Vitamin D as Treatment for Chronic Obstructive Pulmonary Disease (COPD)|High Dosis of Vitamin D as Treatment for COPD.|Completed||Phase 4|182|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 02:12:36.473986|2018-06-01 02:12:36.473986
NCT00666354|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2009-02-09|2008-04-23|2008-04-24|Estimate|||||||2009-02-09|2009-02-10|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|January 2009|Anticipated|2009-01-31|September 2008|Anticipated|2008-09-30||Interventional|||Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis|Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the Treatment of Fingernail Psoriasis|Unknown status|Active, not recruiting|Phase 2|83|Anticipated|MediQuest Therapeutics||3|||f||||t||||||||||2018-06-01 02:12:36.576067|2018-06-01 02:12:36.576067
NCT00666341|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2013-11-07|2008-04-23|2008-04-24|Estimate|||||||2013-11-07|2013-11-08|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|May 2010|Actual|2010-05-31|January 2009|Actual|2009-01-31||Interventional|||Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens|A Double-blind Placebo-controlled Dose-response Study for Evaluation of Safety and Efficacy of Immunotherapy With a Cocktail of Recombinant Major Allergens of Timothy Grass Pollen (Phleum Pratense) Adsorbed to Aluminium Hydroxide in Patients With IgE-mediated Allergic Rhinitis/Rhinoconjunctivitis With or Without Bronchial Asthma|Completed||Phase 2|50|Actual|Allergopharma GmbH & Co. KG||5|||f||||t||||||||||2018-06-01 02:12:36.69143|2018-06-01 02:12:36.69143
NCT00666328|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2012-07-25||2014-08-21|2008-04-22|2008-04-24|Estimate|2013-02-22|2013-04-08|Estimate||||2014-08-21|2014-08-29|Estimate|June 2008||2008-06-30|August 2014|2014-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|ACCELERATE||Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)|The Evaluation of Patients With Acute Hypertension and Intracerebral Hemorrhage With Intravenous Clevidipine Treatment (ACCELERATE)|Completed||Phase 3|37|Actual|The Medicines Company||1|||f||||f||||||||||2018-06-01 02:12:36.802352|2018-06-01 02:12:36.802352
NCT00666315|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2008-05-21|2008-04-23|2008-04-24|Estimate|||||||2008-05-21|2008-05-22|Estimate|December 2007||2007-12-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease|Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease -A Prospective, Comparative, Multicenter, Observational Study|Completed|||80|Actual|Ethicon Endo-Surgery (Europe) GmbH|||2||f||||f||||||||||2018-06-01 02:12:37.230136|2018-06-01 02:12:37.230136
NCT00666302|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-09-17|2008-04-23|2008-04-24|Estimate|||||||2014-09-17|2014-09-18|Estimate|October 2002||2002-10-31|September 2014|2014-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis|A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis|Completed||Phase 4|413|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:12:37.295456|2018-06-01 02:12:37.295456
NCT00666289|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-09-01|2008-04-23|2008-04-24|Estimate|||||||2017-09-01|2017-09-05|Actual|March 2008||2008-03-31|September 2017|2017-09-30|June 20, 2015|Actual|2015-06-20|January 20, 2015|Actual|2015-01-20||Observational|||Familial Myeloproliferative Disorders|Molecular Biology of Familial Myeloproliferative Disorders|Completed|||17|Actual|Icahn School of Medicine at Mount Sinai|||||f||||t||||||Samples With DNA|"~     Blood samples from subjects and family members with myeloproliferative disease.~   "|||2018-06-01 02:12:37.396056|2018-06-01 02:12:37.396056
NCT00666276|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2012-03-28||2012-05-29|2008-04-23|2008-04-24|Estimate|2012-05-29|2012-07-02|Estimate||||2012-05-29|2012-07-02|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)|Completed|||1004|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:12:37.512826|2018-06-01 02:12:37.512826
NCT00666263|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2012-10-19||2017-10-19|2008-04-23|2008-04-24|Estimate|2013-02-08|2013-03-13|Estimate||||2017-10-19|2017-11-24|Actual|August 2008||2008-08-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy|A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy|Completed||Phase 3|50|Actual|Shire||2|||f||||t||||||||||2018-06-01 02:12:38.04706|2018-06-01 02:12:38.04706
NCT00666250|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2016-02-04|2008-04-23|2008-04-24|Estimate|||||||2016-02-04|2016-02-08|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors|Effects of Xoçai Antioxidant Supplements on Atherosclerosis Risk Factors|Completed||N/A|10|Actual|University of Utah||3|||f||||f||||||||||2018-06-01 02:12:39.215149|2018-06-01 02:12:39.215149
NCT00666237|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-06-23|2008-04-23|2008-04-24|Estimate|||||||2017-06-23|2017-06-27|Actual|April 2008||2008-04-30|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Primary Tube Versus Trabeculectomy Study|Primary Tube Versus Trabeculectomy Study|Active, not recruiting||N/A|242|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 02:12:39.313137|2018-06-01 02:12:39.313137
NCT00340886|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 1, 2001||2001-10-01|May 19, 2010|2010-05-19|May 19, 2010||2010-05-19|||||Observational|||NIEHS/UNC Environmental Polymorphism Study|Environmental Polymorphism Study (EPS)|Completed|||485|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.845081|2018-06-01 03:56:27.845081
NCT00666224|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2012-05-03||2012-06-19|2008-04-23|2008-04-24|Estimate|2012-05-03|2012-06-13|Estimate||||2012-06-19|2012-06-25|Estimate|January 2004||2004-01-31|June 2012|2012-06-30|June 2010|Actual|2010-06-30|October 2007|Actual|2007-10-31||Interventional|PreCISe||Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome|A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With Clinically Isolated Syndrome (CIS)|Completed||Phase 3|481|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 02:12:39.459053|2018-06-01 02:12:39.459053
NCT00666211|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2011-10-21||2012-08-04|2008-04-23|2008-04-24|Estimate|2012-08-04|2012-09-06|Estimate||||2012-08-04|2012-09-06|Estimate|May 2005||2005-05-31|August 2012|2012-08-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain|Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain.|Completed||Phase 3|98|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||f||||||||||2018-06-01 02:12:40.590614|2018-06-01 02:12:40.590614
NCT00666198|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2017-02-28||2017-04-18|2008-04-23|2008-04-24|Estimate|2017-04-18|2017-04-24|Actual||||2017-04-18|2017-04-24|Actual|May 2008||2008-05-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational||A total of 3304 participants received sildenafil citrate at least once in this study. Of the 3304 participants, 33 participants were excluded from the baseline analysis due to following reasons: protocol violation, no visit after first day of treatment, safety not assessable and no drug administration.|Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)|Special Investigation For Long-term Use Of Revatio (Regulatory Post Marketing Commitment Plan)|Completed|||3337|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:12:41.362207|2018-06-01 02:12:41.362207
NCT00666185|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2014-09-17|2008-04-23|2008-04-24|Estimate|||||||2014-09-17|2014-09-18|Estimate|August 2003||2003-08-31|September 2014|2014-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis|A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis|Completed||Phase 3|523|Actual|Astellas Pharma Inc||2|||f||||||||||||||2018-06-01 02:12:42.678655|2018-06-01 02:12:42.678655
NCT00666172|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2018-05-05|2008-04-23|2008-04-24|Estimate|||||||2018-05-05|2018-05-08|Actual|April 8, 2008||2008-04-08|August 18, 2015|2015-08-18|November 1, 2012|Actual|2012-11-01|November 1, 2012|Actual|2012-11-01||Interventional|||Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women|Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women|Completed||Phase 2|270|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:12:42.998273|2018-06-01 02:12:42.998273
NCT00666159|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-09-17|2008-04-23|2008-04-24|Estimate|||||||2014-09-17|2014-09-18|Estimate|December 2002||2002-12-31|September 2014|2014-09-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis|A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 4|226|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:12:43.112849|2018-06-01 02:12:43.112849
NCT00666146|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2018-02-21|2008-04-23|2008-04-24|Estimate|||||||2018-02-21|2018-02-22|Actual|July 2004||2004-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2010|Actual|2010-07-31||Observational|||Familial Schizophrenia and Spectrum Personality Disorders|Familial Schizophrenia and Spectrum Personality Disorders|Active, not recruiting|||539|Actual|University of Maryland|||3||f||||t||||||Samples With DNA|"~     Blood sample for DNA extraction~   "|No||2018-06-01 02:12:43.488128|2018-06-01 02:12:43.488128
NCT00666133|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2009-12-08|2008-04-22|2008-04-24|Estimate|||||||2009-12-08|2009-12-09|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Treatment Approaches for Preeclampsia in Low-Resource Settings|Treatment Approaches for Preeclampsia in Low-Resource Settings|Completed||N/A|304|Anticipated|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 02:12:43.614099|2018-06-01 02:12:43.614099
NCT00666120|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2008-04-23|2008-04-23|2008-04-24|Estimate|||||||2008-04-23|2008-04-24|Estimate|June 2005||2005-06-30|April 2008|2008-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Assessment of Feeding Tolerance in Infants Fed Cow Milk Formula|Assessment of Feeding Tolerance in Infants Fed Cow Milk Formula|Completed||N/A|333|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-06-01 02:12:43.815604|2018-06-01 02:12:43.815604
NCT00666107|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-03-12|2008-04-23|2008-04-24|Estimate|||||||2012-03-12|2012-03-14|Estimate|June 2008||2008-06-30|November 2010|2010-11-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|MIRB #862||Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men|Pilot Study to Evaluate the Immunogenicity and Safety of the HPV Quadrivalent Vaccine (Gardasil) in HIV-infected Men|Unknown status|Active, not recruiting|N/A|150|Anticipated|Southern California Institute for Research and Education|||||f||||f||||||||||2018-06-01 02:12:43.902973|2018-06-01 02:12:43.902973
NCT00666094|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-02-07|2008-04-23|2008-04-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|August 2008|Actual|2008-08-31|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Randomized Controlled Trial of Exercise Training Among Men With Type 2-diabetes|A Randomized Controlled Trial of Strength Versus Aerobic Exercise Training to Improve Glycemic Control in Men With Type 2-diabetes|Completed||N/A|26|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 02:12:44.001315|2018-06-01 02:12:44.001315
NCT00666081|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2015-04-15|2008-04-22|2008-04-24|Estimate|||||||2015-04-15|2015-04-17|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies|A Phase I Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Potential Anti-cancer Activity of the AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1||Study Cancelled before enrollment|f||||||||||||||2018-06-01 02:12:44.096518|2018-06-01 02:12:44.096518
NCT00666068|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2011-05-11|2008-04-23|2008-04-24|Estimate|||||||2011-05-11|2011-05-12|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Effects of Corticotropin Releasing Hormone (CRH) on the Sleep in Patients With Hypopituitarism|Effects of CRH on the Sleep in Patients With Hypopituitarism|Completed||N/A|30|Anticipated|Max-Planck-Institute of Psychiatry||2|||f||||f||||||||||2018-06-01 02:12:44.159275|2018-06-01 02:12:44.159275
NCT00666055|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-09-18|2008-04-23|2008-04-24|Estimate|||||||2012-09-18|2012-09-20|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Sex, Aging and Antiretroviral Pharmacokinetics|CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics|Completed|||11|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     blood; genital secretions; genital tissue~   "|||2018-06-01 02:12:44.225027|2018-06-01 02:12:44.225027
NCT00666042|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-01-18|2008-04-23|2008-04-24|Estimate|||||||2012-01-18|2012-01-19|Estimate|February 2009||2009-02-28|August 2009|2009-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Bioequivalence of Eye Drops and Spray Administration of Vigamox|Laboratory-masked, Randomized Parallel, Comparative, Pilot Study on the Bioavailability of Vigamox in the Aqueous Humor When Administered Either as Commercially Available Eye Drops or in a Spray Form|Completed||N/A|16|Anticipated|Advanced Ophthalmic Pharma||2|||f||||f||||||||||2018-06-01 02:12:44.416446|2018-06-01 02:12:44.416446
NCT00666029|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2016-04-21||2016-06-08|2008-04-23|2008-04-24|Estimate|2016-06-08|2016-06-09|Estimate||||2016-06-08|2016-06-09|Estimate|February 2006||2006-02-28|June 2016|2016-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||"Age 18-75 years, body mass index (BMI) 20-35 kg/m2, with > 3 criteria for the metabolic syndrome.~(One person in the placebo arm did not have complete baseline data)."|Implications for Treatment of the Metabolic Syndrome|Implications for Treatment of the Metabolic Syndrome|Completed||Phase 2|40|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||No||2018-06-01 02:12:44.504487|2018-06-01 02:12:44.504487
NCT00666016|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2016-11-21|2008-04-23|2008-04-24|Estimate|||||||2016-11-21|2016-11-22|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)|Double-Blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients With Non-Alcoholic Steatohepatitis (NASH)|Completed||Phase 2|35|Actual|Hoffmann-La Roche||1|||f||||f||||||||||2018-06-01 02:12:44.726513|2018-06-01 02:12:44.726513
NCT00666003|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2011-02-07|2008-04-23|2008-04-24|Estimate|||||||2011-02-07|2011-02-08|Estimate|April 2008||2008-04-30|February 2011|2011-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|APCOvC-Line||Hemodynamic Assessment APCO Monitor vs Crit Line for Renal Replacement Rx|Hemodynamic Assessment Comparison Between Arterial Pressure Cardiac Output Monitor and Crit Line Utilized During Renal Replacement Therapy|Completed|||26|Actual|Baystate Medical Center|||||f||||f||||||||||2018-06-01 02:12:44.786562|2018-06-01 02:12:44.786562
NCT00665990|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2015-01-08|2008-04-23|2008-04-24|Estimate|||||||2015-01-08|2015-01-09|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia|Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia|Completed||Phase 1|49|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 02:12:44.838622|2018-06-01 02:12:44.838622
NCT00665977|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-07-06|2008-04-22|2008-04-24|Estimate|||||||2010-07-06|2010-07-07|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|Thermosmart||Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure|Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure|Completed||Phase 3|44|Anticipated|Clayton Sleep Insititute||3|||f||||f||||||||||2018-06-01 02:12:44.913559|2018-06-01 02:12:44.913559
NCT00665964|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2018-03-28|2008-04-23|2008-04-24|Estimate|||||||2018-03-28|2018-03-29|Actual|May 2008||2008-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Comparing X-3 To N2vac Polyethylene With the Triathlon Total Knee System|A Prospective, Randomized, Multi-center Study Comparing the Ten-Year Survival for X-3 Polyethylene to N2vac Polyethylene When Used With the Triathlon Posterior Stabilized (PS) Total Knee System|Withdrawn||Phase 4|0|Actual|Dalhousie University||2||Not funded at this time.|f||||f||||||||||2018-06-01 02:12:45.002257|2018-06-01 02:12:45.002257
NCT00665951|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-02-24|2008-04-23|2008-04-24|Estimate|||||||2009-02-24|2009-02-25|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|SURF||Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)|The Pharmacokinetics of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children: a Pilot Study of Lopimune vs. the Branded Product (SURF Study).|Completed||Phase 1|12|Actual|Radboud University||3|||f||||f||||||||||2018-06-01 02:12:45.101207|2018-06-01 02:12:45.101207
NCT00665938|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2012-01-27|2008-04-23|2008-04-24|Estimate|||||||2012-01-27|2012-01-31|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Followup of Infants Fed Non-routine Infant Formula||Completed||N/A|183|Anticipated|Mead Johnson Nutrition||3|||f||||f||||||||||2018-06-01 02:12:45.197177|2018-06-01 02:12:45.197177
NCT00665925|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2016-05-03||2016-08-05|2008-04-23|2008-04-24|Estimate|2016-05-03|2016-06-13|Estimate||||2016-08-05|2016-09-16|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Taski-2||Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate|Completed||Phase 2|457|Actual|Rigel Pharmaceuticals|The 2 placebo groups (bid and qd) were pooled for all efficacy data summaries and analysis since the observed ACR20 response rate difference between the placebo groups was <15 percentage points (prospectively defined in protocol).|3|||f||||t||||||||No||2018-06-01 02:12:45.348058|2018-06-01 02:12:45.348058
NCT00665912|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2017-03-10|2008-04-22|2008-04-24|Estimate|||||||2017-03-10|2017-03-13|Actual|January 2008||2008-01-31|March 2017|2017-03-31|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||Platelet-Rich and Concentrated Platelet-Poor Plasma to Reduce Air Leak Post-Lobectomy: A Randomized Controlled Trial|Platelet-Rich and Concentrated Platelet Poor Plasma to Reduce Air Leak Post Lobectomy: A Randomized Controlled Trial|Completed||N/A|204|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-06-01 02:12:47.948026|2018-06-01 02:12:47.948026
NCT00665899|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2016-10-25|2008-04-23|2008-04-24|Estimate|||||||2016-10-25|2016-10-27|Estimate|July 2004||2004-07-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|CanThrive||A Couples Approach to Enhance Breast Cancer Survivorship|A Couples Approach to Enhance Breast Cancer Survivorship|Completed||N/A|163|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-06-01 02:12:48.112383|2018-06-01 02:12:48.112383
NCT00665886|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2009-04-10|2008-04-23|2008-04-24|Estimate|||||||2009-04-10|2009-04-13|Estimate|March 2008||2008-03-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|June 2008|Actual|2008-06-30||Interventional|COSMOS||Compact Closed System Versus Mounted Open System (COSMOS)|Randomized Study of Closed Peripheral Intravenous Systems Versus Mounted Open Systems|Completed||Phase 4|1200|Actual|Hospital San Carlos, Madrid||2|||f||||t||||||||||2018-06-01 02:12:48.224394|2018-06-01 02:12:48.224394
NCT00665873|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-05-07|2008-04-22|2008-04-24|Estimate|||||||2008-05-07|2008-05-08|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|TIVAD||Antibiotic Therapy is Not Necessary to Implant Totally Implantable Venous Access Devices: Randomized Prospective Study|Antibiotic Therapy is Not Necessary to Implant Totally Implantable Venous Access Devices: Randomized Prospective Study|Completed||Phase 4|100|Actual|Universita degli Studi di Catania||2|||f||||t||||||||||2018-06-01 02:12:48.337724|2018-06-01 02:12:48.337724
NCT00665860|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2008-04-22|2008-04-22|2008-04-24|Estimate|||||||2008-04-22|2008-04-24|Estimate|April 2001||2001-04-30|April 2008|2008-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|OPUS||Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss|Safety, Efficacy, and Optimal Dosage of Soy Isoflavones to Prevent Osteoporosis|Completed||N/A|403|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 02:12:48.423594|2018-06-01 02:12:48.423594
NCT00665847|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2012-06-14||2015-04-02|2008-04-23|2008-04-24|Estimate|2012-11-20|2012-12-21|Estimate||||2015-04-02|2015-04-23|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents|A Phase II, Open-label Trial, to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents|Completed||Phase 2|103|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||t||||||||||2018-06-01 02:12:48.571332|2018-06-01 02:12:48.571332
NCT00665834|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2016-03-28|2008-04-23|2008-04-24|Estimate|||||||2016-03-28|2016-03-29|Estimate|April 2006||2006-04-30|March 2016|2016-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome|Comparison of the Effect Noted in The Apo/Apo-1 Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome CENTAURUS Study|Completed||Phase 4|18|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 02:12:49.067673|2018-06-01 02:12:49.067673
NCT00665821|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2009-05-14|2008-04-23|2008-04-24|Estimate|||||||2009-05-14|2009-05-15|Estimate|September 2008||2008-09-30|May 2009|2009-05-31|February 2011|Anticipated|2011-02-28|November 2010|Anticipated|2010-11-30||Interventional|||The Effect of Two Short Education Programs for Nonspecific Low Back Pain in a Workers' Health Care Organization|Study of the Effect of Two Short Education Programs for the Treatment of Nonspecific Low Back Pain in Patients Seen at a Workers' Health Care Organization|Terminated||N/A|657|Anticipated|Kovacs Foundation||||"From Sept./08 to April/09 only 30 subjects were recruited. It has proved extremely difficult to~   recruit subjects."|f||||t||||||||||2018-06-01 02:12:49.157173|2018-06-01 02:12:49.157173
NCT00665808|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2016-10-27|2008-04-23|2008-04-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||"Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During Real-life Usage in Germany"|Insulin Detemir (Levemir®) Versus Isophane (NPH) Insulin (Protaphane®) in Combination With Oral Antidiabetic Agents (OAD) in Patients With Diabetes Mellitus Type 2 Comparing Treatment Satisfaction, Diabetes-related and General Health-related Quality of Life, as Well as Diabetes-control|Completed|||8125|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 02:12:49.257424|2018-06-01 02:12:49.257424
NCT00665795|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2013-11-17|2008-04-22|2008-04-24|Estimate|||||||2013-11-17|2013-11-19|Estimate|July 2005||2005-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy|Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy Using Multidetector Computed Tomography Scan and Color Doppler Imaging.|Completed|||80|Actual|University of Sao Paulo|||2||f||||f||||||||||2018-06-01 02:12:49.358135|2018-06-01 02:12:49.358135
NCT00665782|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2017-05-30|2008-04-23|2008-04-24|Estimate|||||||2017-05-30|2017-06-01|Actual|March 2008||2008-03-31|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast|Stress Measures in Women With Newly Diagnosed Breast Cancer|Completed|||24|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 02:12:49.428175|2018-06-01 02:12:49.428175
NCT00665769|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-02-03|2008-04-22|2008-04-24|Estimate|||||||2017-02-03|2017-02-07|Estimate|June 2008||2008-06-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|November 2015|Actual|2015-11-30||Interventional|PhysDis||Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage|Physiological Disturbances Associated With Neonatal Intraventricular Hemorrhage|Terminated||N/A|103|Actual|Baylor University||2||Recruitment was proceeding too slowly|f||||t||||||||||2018-06-01 02:12:49.513593|2018-06-01 02:12:49.513593
NCT00665756|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-24|Estimate|||||||2008-04-23|2008-04-24|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|July 2008|Anticipated|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves and Second Trabeculectomy in Glaucoma Patients|Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves and Second Trabeculectomy in Glaucoma Patients|Unknown status|Active, not recruiting|N/A|40|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 02:12:49.599705|2018-06-01 02:12:49.599705
NCT00665743|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-06-09|2008-04-23|2008-04-24|Estimate|||||||2008-06-09|2008-06-10|Estimate|March 2008||2008-03-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations|An Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Naproxen 500 mg Administered as PN 400 (Naproxen / Esomeprazole), as the [Active Comparator 1], or as [Active Comparator 2] in Healthy Volunteers|Completed||Phase 1|30|Anticipated|POZEN||3|||f||||f||||||||||2018-06-01 02:12:49.687682|2018-06-01 02:12:49.687682
NCT00665730|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2015-05-07|2008-04-23|2008-04-24|Estimate|||||||2015-05-07|2015-05-08|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of the Safety and Effectiveness of Sepraspray™ in Reducing Post-surgical Adhesions|Evaluation of the Safety and Effectiveness of Sepraspray™ in Limiting the Formation of Postoperative Adhesions to Serosal Tissue (Abdominal Surgery)|Terminated||N/A|5|Actual|Sanofi||2||Study terminated due to low enrollment.|f||||t||||||||||2018-06-01 02:12:49.746078|2018-06-01 02:12:49.746078
NCT00581880|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-01-14|2007-12-21|2007-12-28|Estimate|||||||2009-01-14|2009-01-15|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Measuring Hope and Hopelessness in Cancer|Measuring Hope and Hopelessness in Cancer|Completed|||288|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:53.536503|2018-06-01 02:37:53.536503
NCT00665717|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2011-06-06|2008-04-23|2008-04-24|Estimate|||||||2011-06-06|2011-06-07|Estimate|May 2008||2008-05-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|GRAPPA||The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)|The Influence of Raltegravir on Pravastatin Pharmacokinetics in Healthy Volunteers (GRAPPA)|Completed||Phase 1|24|Actual|Radboud University||3|||f||||f||||||||||2018-06-01 02:12:49.805432|2018-06-01 02:12:49.805432
NCT00665704|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2014-06-25||2015-04-06|2008-04-23|2008-04-24|Estimate|2014-06-25|2014-07-23|Estimate||||2015-04-06|2015-04-28|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Tobacco Tactics Website for Veteran Smokers|Tobacco Tactics Website for Veteran Smokers|Completed||Phase 1|9|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 02:12:49.882157|2018-06-01 02:12:49.882157
NCT00665691|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-04-24|2008-04-22|2008-04-24|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2003||2003-09-30|June 2011|2011-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Pilot Test for a Newly Developed Nutrition Screening Method: Pediatric Subjective Global Assessment|Pilot Test for a Newly Developed Nutrition Screening Method: Pediatric Subjective Global Assessment|Completed|||132|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 02:12:50.019282|2018-06-01 02:12:50.019282
NCT00665678|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-07-10|2008-04-23|2008-04-24|Estimate|||||||2012-07-10|2012-07-11|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)|Neural Correlates of Early Intervention for PTSD|Terminated||Phase 4|160|Anticipated|Atlanta Research and Education Foundation||2|||f||||t||||||||||2018-06-01 02:12:50.073068|2018-06-01 02:12:50.073068
NCT00665665|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2016-12-22|2008-04-23|2008-04-24|Estimate|||||||2016-12-22|2016-12-23|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers|Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Healthy Male and Female Volunteers|Terminated||Phase 1|101|Actual|Novo Nordisk A/S||4||The trial is terminated due to re-evaluation of the compound|f||||f||||||||||2018-06-01 02:12:50.223267|2018-06-01 02:12:50.223267
NCT00665652|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2018-04-23|2008-04-23|2008-04-24|Estimate|||||||2018-04-23|2018-04-24|Actual|April 2008||2008-04-30|April 2018|2018-04-30|May 19, 2011|Actual|2011-05-19|May 19, 2011|Actual|2011-05-19||Interventional|MGUS||Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance|A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)|Terminated||Phase 2|8|Actual|Dartmouth-Hitchcock Medical Center||||The study has been suspended for slower than anticipated enrollment to date.|f||||t||||||||||2018-06-01 02:12:50.299317|2018-06-01 02:12:50.299317
NCT00665639|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2014-08-19|2008-04-23|2008-04-24|Estimate|||||||2014-08-19|2014-08-20|Estimate|June 2004||2004-06-30|August 2014|2014-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis|A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis|Completed||Phase 3|454|Actual|Astellas Pharma Inc||3|||f||||||||||||||2018-06-01 02:12:50.374417|2018-06-01 02:12:50.374417
NCT00665626|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2016-06-06||2017-03-29|2008-04-23|2008-04-24|Estimate|2016-06-06|2016-07-15|Estimate||||2017-03-29|2017-05-01|Actual|May 2008||2008-05-31|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Taski-3||Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic|Completed||Phase 2|219|Actual|Rigel Pharmaceuticals||2|||f||||t||||||||No||2018-06-01 02:12:50.517499|2018-06-01 02:12:50.517499
NCT00665613|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2015-10-13|2008-04-23|2008-04-24|Estimate|||||||2015-10-13|2015-10-14|Estimate|October 2004||2004-10-31|October 2015|2015-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin|The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin|Completed|||300|Actual|Northwell Health|||||f||||t||||||||||2018-06-01 02:12:52.117618|2018-06-01 02:12:52.117618
NCT00665600|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-02-21|2008-04-23|2008-04-24|Estimate|||||||2012-02-21|2012-02-22|Estimate|February 2002||2002-02-28|February 2012|2012-02-29|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)|A Double-Blind, Randomized, Multicenter, Parallel-Group Study of Levalbuterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|257|Actual|Sunovion||4|||f||||f||||||||||2018-06-01 02:12:52.195493|2018-06-01 02:12:52.195493
NCT00665587|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2008-04-23|2008-04-23|2008-04-24|Estimate|||||||2008-04-23|2008-04-24|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|June 2012|Anticipated|2012-06-30|June 2009|Anticipated|2009-06-30||Observational|AmP||AMAZING PRAGUE (PRAGUE-12)|Surgical Treatment of Atrial Fibrillation - Prospective Randomized Study|Unknown status|Enrolling by invitation||220|Anticipated|Charles University, Czech Republic|||2||f||||t||||||||||2018-06-01 02:12:52.341487|2018-06-01 02:12:52.341487
NCT00665574|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2009-07-13|2008-04-22|2008-04-24|Estimate|||||||2009-07-13|2009-07-14|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee|A Prospective, Multi-center, Randomized, Double-blind Feasibility Study to Evaluate the Safety and Performance of ActaVisc and ActaVisc Mx Intra-articular Injection for Management of Pain Associated With Osteoarthritis in the Knee.|Terminated||N/A|23|Actual|Carbylan Therapeutics, Inc.||4||Business decision|f||||f||||||||||2018-06-01 02:12:52.418942|2018-06-01 02:12:52.418942
NCT00665561|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2018-01-29|2008-04-23|2008-04-24|Estimate|||||||2018-01-29|2018-01-31|Actual|March 31, 2008|Actual|2008-03-31|January 2018|2018-01-31|February 26, 2019|Anticipated|2019-02-26|February 26, 2019|Anticipated|2019-02-26||Observational|POEM||Prospective Observational Epidemiologic Study of Maraviroc's Safety|An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients|Active, not recruiting|||2454|Actual|ViiV Healthcare|||2||f||||f||||||||||2018-06-01 02:12:52.54745|2018-06-01 02:12:52.54745
NCT00665548|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2009-04-16|2008-04-23|2008-04-24|Estimate|||||||2009-04-16|2009-04-17|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Weight-Bearing Magnetic Resonance Imaging (MRI) for Analysis of Knee Osteoarthritis (OA)|Weight-Bearing MRI for Analysis of Knee OA|Completed|||33|Anticipated|University of California, San Francisco|||2||f||||||||||||||2018-06-01 02:12:53.907127|2018-06-01 02:12:53.907127
NCT00665535|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-03-20|2008-04-23|2008-04-24|Estimate|||||||2012-03-20|2012-03-21|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|TURN||Pressure Ulcer Prevention: Turning for Ulcer Reduction|Preventing Pressure Ulcers: A Multi-site RCT in Nursing Facilities|Completed||Phase 3|967|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 02:12:54.03159|2018-06-01 02:12:54.03159
NCT00665522|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2015-04-09|2008-04-22|2008-04-24|Estimate|||||||2015-04-09|2015-04-10|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||A Prospective Safety Surveillance Study of Fentanyl Iontophoretic Transdermal System (40 Mcg)|A Prospective Safety Surveillance Study of IONSYS (Fentanyl HCl)|Terminated|||218|Actual|Alza Corporation, DE, USA|||2|"Study was terminated at the request of the company due to the recall of marketed product in~   Europe."|f||||f||||||||||2018-06-01 02:12:54.14759|2018-06-01 02:12:54.14759
NCT00665509|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-08-12|2008-04-22|2008-04-24|Estimate|||||||2008-08-12|2008-08-13|Estimate|June 2008||2008-06-30|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 08/09 Season.|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2008/2009. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects|Completed||Phase 3|120|Actual|Solvay Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:12:54.273138|2018-06-01 02:12:54.273138
NCT00665496|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|||2014-12-15|2008-04-23|2008-04-24|Estimate|||||||2014-12-15|2014-12-17|Estimate|June 2003||2003-06-30|December 2014|2014-12-31|November 2003|Actual|2003-11-30|||||Interventional|||A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction|A Randomized, Double Blind, Double Dummy, Parallel Group, Multi-center Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction.|Completed||Phase 3|732|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:12:54.365321|2018-06-01 02:12:54.365321
NCT00665483|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2013-11-07|2008-04-23|2008-04-24|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|September 2007|Actual|2007-09-30||Interventional|||Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.|Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a 6-grass Pollen Mixture, House Dust Mite (Dermatophagoides Pteronyssinus), Birch Pollen, and Mugwort Pollen|Completed||Phase 4|||Allergopharma GmbH & Co. KG||1|||f||||f||||||||||2018-06-01 02:12:54.794005|2018-06-01 02:12:54.794005
NCT00665470|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-23|2012-12-12||2015-09-28|2008-04-23|2008-04-24|Estimate|2012-12-12|2013-01-22|Estimate||||2015-09-28|2015-10-19|Estimate|April 2008||2008-04-30|September 2015|2015-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma|Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 02:12:54.897848|2018-06-01 02:12:54.897848
NCT00665457|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-10-24|2008-04-22|2008-04-23|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2004||2004-04-30|October 2017|2017-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery|Neoadjuvant Therapy and Biomarker Analysis of Stage II and III Breast Cancer With Docetaxel/Capecitabine and Celecoxib Followed by Doxorubicin/Cyclophosphamide and Celecoxib|Completed||Phase 2|3|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:12:55.333677|2018-06-01 02:12:55.333677
NCT00665444|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2016-01-14||2017-10-19|2008-04-21|2008-04-23|Estimate|2016-01-14|2016-02-12|Estimate||||2017-10-19|2017-11-22|Actual|April 2008||2008-04-30|October 2017|2017-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder|Reducing Medical Risks in Individuals With Bipolar Disorder: Enhancing Outcomes With Aripiprazole|Terminated||N/A|3|Actual|University of Pittsburgh|the study was terminated early by the study sponsor due to low enrol...|1||The study was terminated by the sponser due to low study enrollment.|f||||f||||||||||2018-06-01 02:12:55.453476|2018-06-01 02:12:55.453476
NCT00665431|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2010-05-27|2009-12-02|2011-11-01|2008-04-22|2008-04-23|Estimate|2011-11-01|2011-12-06|Estimate|2009-12-02|2009-12-04|Estimate|2011-11-01|2011-12-06|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis|Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee|Completed||Phase 3|610|Actual|POZEN||3|||f||||f||||||||||2018-06-01 02:12:55.666528|2018-06-01 02:12:55.666528
NCT00665418|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2009-03-11|2008-04-22|2008-04-23|Estimate|||||||2009-03-11|2009-03-12|Estimate|February 2008||2008-02-29|March 2009|2009-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Sevoflurane and Laryngeal Reflex Responses in Pediatric Patients|Impact of High Concentrations of Sevoflurane on Laryngeal Reflex Responses in Pediatric Patients|Terminated||Phase 4|40|Actual|University Hospital, Basel, Switzerland||1||Recruitment finished earlier, because all 40 patients enrolled|f||||f||||||||||2018-06-01 02:12:56.112844|2018-06-01 02:12:56.112844
NCT00665405|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-04-21|2008-04-21|2008-04-23|Estimate|||||||2008-04-21|2008-04-23|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|||||Observational|||Atelectasis During Delivery - Comparing Cesarian (c) -Section and Labor|CT Study of Atelectasis After Delivery - Comparison Between Cesarian Section and Labor|Completed|||20|Actual|University of Sao Paulo|||2||f||||f||||||||||2018-06-01 02:12:56.277149|2018-06-01 02:12:56.277149
NCT00665392|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-08-21|2008-04-22|2008-04-23|Estimate|||||||2012-08-21|2012-08-22|Estimate|February 2008||2008-02-29|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery|Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV|Completed||Phase 2|42|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||||2018-06-01 02:12:56.349619|2018-06-01 02:12:56.349619
NCT00665379|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2012-05-19|2008-04-22|2008-04-23|Estimate|||||||2012-05-19|2012-05-22|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Comparative Trial in Compression Therapy in Leg Lymphedema|Prospective, Randomized Controlled Trial Comparing the Effect of 3M Coban 2 Layer Compression System Versus Trico Bandages in the Treatment of Leg Lymphedema.|Completed||N/A|30|Actual|Nij Smellinghe Hosptial||2|||f||||f||||||||||2018-06-01 02:12:56.454665|2018-06-01 02:12:56.454665
NCT00665366|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2012-09-28||2013-11-07|2008-04-22|2008-04-23|Estimate|2013-02-01|2013-02-04|Estimate||||2013-11-07|2013-12-02|Estimate|June 2008||2008-06-30|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder|A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patients Treated on Valproate or Lithium and in Need of Further Clinical Improvement|Completed||Phase 3|493|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-06-01 02:12:56.585214|2018-06-01 02:12:56.585214
NCT00665353|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|2012-06-07||2013-05-14|2008-04-22|2008-04-23|Estimate|2012-08-14|2012-09-13|Estimate||||2013-05-14|2013-07-02|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance|A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy|Completed||Phase 2|19|Actual|AIDS Clinical Trials Group|The study did not fully enroll and the small sample size precluded subgroup analysis.|1|||f||||t||||||||||2018-06-01 02:12:57.475161|2018-06-01 02:12:57.475161
NCT00665340|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2013-10-10|2008-04-22|2008-04-23|Estimate|||||||2013-10-10|2013-10-11|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)|A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction.|Completed||Phase 4|219|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:12:57.946273|2018-06-01 02:12:57.946273
NCT00665327|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-11-17|2008-04-22|2008-04-23|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2002||2002-11-30|November 2014|2014-11-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia|A Study of Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia|Completed||Phase 4|401|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:12:58.068617|2018-06-01 02:12:58.068617
NCT00665314|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2014-02-10|2008-04-22|2008-04-23|Estimate|||||||2014-02-10|2014-02-11|Estimate|November 2007||2007-11-30|February 2014|2014-02-28|June 2009|Actual|2009-06-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).|A Multicenter, Randomized, Comparative, Patient-blinded Study to Evaluate the Safety and Efficacy of G-CSF Alone Versus AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Adult Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkins Disease (HD) or Multiple Myeloma (MM) Who Have Previously Failed Stem Cell Collections or Collection Attempts|Completed||Phase 2|5|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:12:58.253844|2018-06-01 02:12:58.253844
NCT00665301|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-07-07|2008-04-22|2008-04-23|Estimate|||||||2008-07-07|2008-07-08|Estimate|March 2008||2008-03-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000|Validation Study Comparing the Cardiac Output Pulmonary Arterial Catheter (Swan Ganz) to the FloWave™ 1000 Device|Completed|||54|Actual|Woolsthorpe Technologies, LLC|||||f||||f||||||||||2018-06-01 02:12:58.354196|2018-06-01 02:12:58.354196
NCT00665288|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2012-03-26|2008-04-22|2008-04-23|Estimate|||||||2012-03-26|2012-03-27|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|August 2010|Actual|2010-08-31|March 2009|Actual|2009-03-31||Observational|||Survey of Attitudes and Factors Associated With CPR in an Older Population|A Survey of Attitudes and Factors Associated With Successful Cardiopulmonary Resuscitation (CPR) Knowledge Transfer in an Older Population Most Likely to Witness Cardiac Arrest|Completed|||413|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 02:12:58.42454|2018-06-01 02:12:58.42454
NCT00665275|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-04-18|2008-04-18|2008-04-23|Estimate|||||||2008-04-18|2008-04-23|Estimate|March 2007||2007-03-31|April 2008|2008-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Complementary and Alternative Medicine Among Outpatients With Inflammatory Rheumatic Diseases in Western Sweden|The Use of Complementary and Alternative Medicine Among Outpatients With Inflammatory Rheumatic Diseases in Western Sweden.|Completed|||200|Actual|Göteborg University|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:12:58.504703|2018-06-01 02:12:58.504703
NCT00665262|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-08-25|2008-04-18|2008-04-23|Estimate|||||||2017-08-25|2017-08-28|Actual|December 17, 2007|Actual|2007-12-17|August 2017|2017-08-31|August 12, 2011|Actual|2011-08-12|November 30, 2010|Actual|2010-11-30||Interventional|||The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in the Elderly|The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in Elderly Patients Having Joint Replacement Surgery: a Prospective Feasibility Study|Completed||Phase 4|10|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-06-01 02:12:58.588044|2018-06-01 02:12:58.588044
NCT00665249|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-04-27|2008-04-21|2008-04-23|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Project Motion, A Study of Motivational Interviewing to Reduce Heavy or Problematic Drinking|Component Analysis of Motivational Interviewing|Completed||N/A|89|Actual|Northwell Health||3|||f||||t||||||||||2018-06-01 02:12:58.688454|2018-06-01 02:12:58.688454
NCT00665236|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2012-11-30|2008-04-21|2008-04-23|Estimate|||||||2012-11-30|2012-12-04|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|September 2010|Actual|2010-09-30|May 2009|Actual|2009-05-31||Interventional|||Craniosacral Therapy in Migraine: A Feasibility Study|Craniosacral Therapy in Migraine: A Feasibility Study|Completed||N/A|66|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 02:12:58.782769|2018-06-01 02:12:58.782769
NCT00665223|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22||2013-02-19|2016-07-19|2008-04-22|2008-04-23|Estimate||||2013-03-28|2013-04-04|Estimate|2016-07-19|2016-07-21|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|MermaiHD||A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease|A Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's Disease|Completed||Phase 3|437|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 02:12:58.875115|2018-06-01 02:12:58.875115
NCT00665210|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-10-24|2008-04-22|2008-04-23|Estimate|||||||2011-10-24|2011-10-26|Estimate|October 2007||2007-10-31|October 2011|2011-10-31||||||||Observational|||Digital Sizing for Orthopaedic Hip Implants|Photo-manipulation of Digital Radiographs and Digitized Templates as a Method for Preoperative Sizing of Total Hip Arthroplasties|Unknown status|Recruiting||100|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 02:12:58.995374|2018-06-01 02:12:58.995374
NCT00665197|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2011-10-12|2008-04-22|2008-04-23|Estimate|||||||2011-10-12|2011-10-13|Estimate|February 2007||2007-02-28|October 2011|2011-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia|Improving Outcomes in Radiotherapy Using New Strategies of Treatment Delivery With Focus on Oesophageal Cancer.|Completed||Phase 3|200|Actual|International Atomic Energy Agency||2|||f||||f||||||||||2018-06-01 02:12:59.065567|2018-06-01 02:12:59.065567
NCT00665184|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-09-20|2008-04-22|2008-04-23|Estimate|||||||2011-09-20|2011-09-21|Estimate|August 2007||2007-08-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease|High Force Resistance Training and Dopamine Replacement Effects on Hypokinesia in Parkinson Disease|Completed||N/A|41|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 02:12:59.163071|2018-06-01 02:12:59.163071
NCT00665171|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-04-22|2008-04-22|2008-04-23|Estimate|||||||2008-04-22|2008-04-23|Estimate|June 2008||2008-06-30|April 2008|2008-04-30||||||||Observational|||Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome|Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome - a Study on Multigenerational Families|Unknown status|Not yet recruiting||1500|Anticipated|Maaynei Hayesha Medical Center|||||f||||f||||||Samples With DNA|"~     The study aims to perform a whole genome analysis for the detection of genes, associated with~     the polycystic ovary syndrome. Therefore, the main clinical effort is the diagnosis of index~     cases and recruitment of family members to give DNA samples.~   "|||2018-06-01 02:12:59.254575|2018-06-01 02:12:59.254575
NCT00665158|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-10-27|2008-04-22|2008-04-23|Estimate|||||||2011-10-27|2011-10-31|Estimate|September 2003||2003-09-30|October 2008|2008-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|PROACTIVE||Prevention and Reduction of Obesity Through Active Living|Prevention and Reduction of Obesity Through Active Living|Completed||N/A|500|Anticipated|Queen's University||2|||f||||t||||||||||2018-06-01 02:12:59.316229|2018-06-01 02:12:59.316229
NCT00665145|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21||2012-10-30|2012-10-30|2008-04-22|2008-04-23|Estimate||||2012-10-30|2012-11-01|Estimate|2012-10-30|2012-11-01|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509|A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509|Completed||Phase 2|23|Actual|Sangamo Therapeutics||4|||f||||f||||||||||2018-06-01 02:12:59.380556|2018-06-01 02:12:59.380556
NCT00665132|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2016-02-02||2016-05-01|2008-04-21|2008-04-23|Estimate|2016-05-01|2016-06-06|Estimate||||2016-05-01|2016-06-06|Estimate|April 2008||2008-04-30|May 2016|2016-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|StimRouter|">/=18 years of age~Carpal Tunnel chronic peripheral pain >/=3 mo with mean pain >/=5/10~Failed prior carpal tunnel release surgery >/=3 mo~Tolerates transcutaneous electrical nerve stimulation (TENS)~6. Pain relief by local anesthetic block of target nerve 7. Give informed consent 8. Quantify pain using 0 to 10 NRS"|Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves|Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves|Completed||Phase 1/Phase 2|10|Actual|Bioness Inc||1|||f||||f||||||||||2018-06-01 02:12:59.469243|2018-06-01 02:12:59.469243
NCT00665119|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-12-17|2008-04-22|2008-04-23|Estimate|||||||2008-12-17|2008-12-18|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effects of Remifentanil on Respiratory Function in Mechanically Ventilated Patients|Effects of Remifentanil on Breathing Pattern, Respiratory Effort and Gas Exchange in Mechanically Ventilated Patients.|Completed||Phase 4|14|Actual|Fondazione Poliambulanza Istituto Ospedaliero||1|||f||||f||||||||||2018-06-01 02:12:59.648991|2018-06-01 02:12:59.648991
NCT00665106|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2015-05-26|2008-04-22|2008-04-23|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||"Safety and Tolerability of NOVA63035 Corticosteroid in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy"|A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of NOVA63035 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy|Completed||Phase 1|20|Actual|Santen SAS||4|||f||||||||||||||2018-06-01 02:12:59.727385|2018-06-01 02:12:59.727385
NCT00665093|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-01-06|2008-04-22|2008-04-23|Estimate|||||||2017-01-06|2017-01-09|Estimate|May 2007||2007-05-31|January 2017|2017-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes|A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) or Levemir® (Insulin Detemir) for Treatment of Type 1 or Type 2 Diabetes Mellitus in Macedonia|Completed|||1569|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 02:12:59.796923|2018-06-01 02:12:59.796923
NCT00665067|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2017-10-04|2008-04-21|2008-04-23|Estimate|||||||2017-10-04|2017-10-05|Actual|April 2007||2007-04-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Correlative Biomarker Study in Patients With Myeloproliferative Disorders|Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD|Recruiting|||860|Anticipated|Icahn School of Medicine at Mount Sinai|||||f||||t||||||Samples With DNA|"~     Leftover tissue will be asked for to be stored in the MPD-RC Tissue Bank~   "|||2018-06-01 02:12:59.88201|2018-06-01 02:12:59.88201
NCT00665054|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-12-23|2008-04-22|2008-04-23|Estimate|||||||2014-12-23|2014-12-25|Estimate|August 2004||2004-08-31|December 2014|2014-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction|Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction.|Completed||Phase 4|160|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:13:00.089603|2018-06-01 02:13:00.089603
NCT00665041|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-09-16|2008-04-22|2008-04-23|Estimate|||||||2009-09-16|2009-09-17|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome|A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome|Completed||Phase 2|30|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 02:13:00.382616|2018-06-01 02:13:00.382616
NCT00665028|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-01-06|2008-04-22|2008-04-23|Estimate|||||||2015-01-06|2015-01-08|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Perioperative Ischemia Reduction Study (PROSE) Pilot|Perioperative Ischemia Reduction Study (PROSE) Pilot|Completed|||30|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-06-01 02:13:00.454144|2018-06-01 02:13:00.454144
NCT00665015|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-04-21|2008-04-21|2008-04-23|Estimate|||||||2008-04-21|2008-04-23|Estimate|January 2004||2004-01-31|April 2008|2008-04-30|October 2006|Actual|2006-10-31|December 2005|Actual|2005-12-31||Observational|||Pleural Effusion Following Cardiac Surgery: Prevalence, Risk Factors and Clinical Features|Pleural Effusions Following Cardiac Surgery: Prevalence, Risk Factors and Clinical Features.|Completed|||2892|Actual|Laval University|||||f||||f||||||||||2018-06-01 02:13:00.554461|2018-06-01 02:13:00.554461
NCT00665002|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2014-06-25||2015-02-11|2008-04-22|2008-04-23|Estimate|2014-06-25|2014-07-24|Estimate||||2015-02-11|2015-02-27|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|July 2013|Actual|2013-07-31||Interventional||All participants|Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms|Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms|Completed||N/A|16|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 02:13:00.665766|2018-06-01 02:13:00.665766
NCT00664989|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-10-21|2008-04-22|2008-04-23|Estimate|||||||2015-10-21|2015-10-22|Estimate|August 2007||2007-08-31|August 2010|2010-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Resurfacing Hemiarthoplasty Versus Conventional Stemmed Arthroplasty|Resurfacing Hemiarthroplasty Versus Conventional Stemmed Hemiarthroplasty|Completed|||10|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 02:13:00.980045|2018-06-01 02:13:00.980045
NCT00664976|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2017-01-15|2008-04-22|2008-04-23|Estimate|||||||2017-01-15|2017-01-18|Estimate|April 2008||2008-04-30|January 2017|2017-01-31|September 2013|Actual|2013-09-30|May 2011|Actual|2011-05-31||Interventional|||Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy|Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy|Completed||N/A|73|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 02:13:01.044932|2018-06-01 02:13:01.044932
NCT00664963|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-12-16|2008-04-18|2008-04-23|Estimate|||||||2014-12-16|2014-12-17|Estimate|April 2006||2006-04-30|December 2014|2014-12-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|YUKON-BTK||YUKON-drug-eluting Stent Below The Knee - Randomised Double-blind Study|YUKON-drug-eluting Stent Below The Knee - Prospective Randomized Double-blind Multicenter Study|Completed||Phase 4|130|Actual|Herz-Zentrums Bad Krozingen||2|||f||||f||||||||||2018-06-01 02:13:01.148195|2018-06-01 02:13:01.148195
NCT00664950|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2015-09-01|2008-04-22|2008-04-23|Estimate|||||||2015-09-01|2015-09-02|Estimate|November 2007||2007-11-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||InterTAN IM Nail Versus Sliding Hip Screw in Geriatric Fractures|A Multi-centre Randomized Control Trail Comparing a Novel Intramedullary Device (InterTAN) Versus Conventional Treatment (Sliding Hip Screw) of Geriatric Fractures.|Completed||N/A|240|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 02:13:01.259597|2018-06-01 02:13:01.259597
NCT00664937|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-03-09|2008-04-22|2008-04-23|Estimate|||||||2017-03-09|2017-03-10|Actual|May 2007||2007-05-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Exercise Induced Bronchoconstriction (0476-359)|A 3 Period, Double-Blind, Randomized Crossover Study to Evaluate the Effects of a Single Dose of Montelukast Compared With Placebo on Exercise-Induced Bronchoconstriction as Assessed by Hyperpolarized Gas Magnetic Resonance Imaging.|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:13:01.348126|2018-06-01 02:13:01.348126
NCT00664924|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2017-01-20|2008-04-22|2008-04-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|October 2007||2007-10-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Comparative in Patient, Non-intervention Study of the Remote Physiological Monitoring System (RPM™) vs Standard Physiological Monitoring Devices|Comparative In-patient, Non-intervention Study of the Remote Physiological Monitoring System (RPM™), a Non-invasive, Remote, Ambulatory Vital Signs Monitoring Device, Versus Standard Physiological Monitoring Devices by Simultaneous Monitoring of Heart Rate, ECG, SpO2, Blood Pressure, Body Temperature, and Respiration Rate in a 24 hr Monitoring Period (BRYTECH #BRY-C-01-06-RPM)|Completed|||40|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 02:13:01.421456|2018-06-01 02:13:01.421456
NCT00664911|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2013-10-15|2008-04-22|2008-04-23|Estimate|||||||2013-10-15|2013-10-16|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|April 2012|Actual|2012-04-30||Interventional|OLD||Combination Chemotherapy in Treating Older Patients With Solid Tumour,|Study of a Scale Predicting the Feasibility of Chemotherapy in Patients Aged 75 Years or Older With Solid Tumour|Completed||Phase 4|516|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||||2018-06-01 02:13:01.507802|2018-06-01 02:13:01.507802
NCT00664898|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-11-11|2008-04-21|2008-04-23|Estimate|||||||2011-11-11|2011-11-15|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma|An Open-Label, Phase Ib, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Bortezomib (Velcade®, PS-341) in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|18|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 02:13:01.594292|2018-06-01 02:13:01.594292
NCT00664885|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-01-08|2008-04-22|2008-04-23|Estimate|||||||2014-01-08|2014-01-09|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Effectiveness of Cultural Sensitive Collaborative Treatment of Depressed Chinese|Effectiveness of Cultural Sensitive Collaborative Treatment of Depressed Chinese in Primary Care|Completed||N/A|280|Actual|Mackay Memorial Hospital||1|||f||||||||||||||2018-06-01 02:13:01.653012|2018-06-01 02:13:01.653012
NCT00664872|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-01-08|2008-04-22|2008-04-23|Estimate|||||||2014-01-08|2014-01-09|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||Effect of Psychosocial Treatment by the Case Manager in Patients After a Suicide Attempt|Effect of Proactive Psychosocial Treatment by the Case Manager in Patients After a Suicide Attempt: a Randomised Controlled Trial|Completed||N/A|147|Actual|Mackay Memorial Hospital||1|||f||||t||||||||||2018-06-01 02:13:01.709917|2018-06-01 02:13:01.709917
NCT00664859|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2014-12-18|2008-04-21|2008-04-23|Estimate|||||||2014-12-18|2014-12-19|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia|A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of LCP-AtorFen in Subjects With Dyslipidemia|Completed||Phase 2/Phase 3|220|Actual|Veloxis Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:13:01.770861|2018-06-01 02:13:01.770861
NCT00340873|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-24|2006-06-19|2006-06-21|Estimate|||||||2018-04-24|2018-04-25|Actual|December 12, 1994||1994-12-12|April 11, 2018|2018-04-11||||||||Observational|||Molecular Epidemiology of Dioxin-Related Illness in Seveso|Molecular Epidemiology of Dioxin-Related Illness in Seveso|Completed|||300|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.897911|2018-06-01 03:56:27.897911
NCT00664846|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-12|||2011-04-08|2008-04-22|2008-04-23|Estimate|||||||2011-04-08|2011-04-11|Estimate|April 2008||2008-04-30|February 2011|2011-02-28|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|SMART||Standard Medical Management in Secondary Prevention of Ischemic Stroke in China|Standard Medical Management in Secondary Prevention of Ischemic Stroke in China.|Completed||N/A|4000|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-06-01 02:13:01.850054|2018-06-01 02:13:01.850054
NCT00664833|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-12-08|2008-04-22|2008-04-23|Estimate|||||||2014-12-08|2014-12-09|Estimate|May 2004||2004-05-31|December 2014|2014-12-31|October 2005|Actual|2005-10-31|||||Interventional|||Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction|An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes.|Completed||Phase 4|1029|Actual|Bayer||4|||f||||f||||||||||2018-06-01 02:13:01.995856|2018-06-01 02:13:01.995856
NCT00664820|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-09-14|2008-04-18|2008-04-23|Estimate|||||||2017-09-14|2017-09-15|Actual|March 2008||2008-03-31|September 2017|2017-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects of Probiotics on Rheumatoid Arthritis Patients|Effects of Probiotics on Rheumatoid Arthritis Patients|Completed||N/A|50|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-06-01 02:13:02.056696|2018-06-01 02:13:02.056696
NCT00664807|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2009-08-24|2008-04-21|2008-04-23|Estimate|||||||2009-08-24|2009-08-25|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Observational|GAME||Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)|Medtronic Genetic Arrhythmia Markers for Early Detection|Completed|||1023|Actual|Medtronic Corporate Technologies and New Ventures|||||f||||f||||||||||2018-06-01 02:13:02.119045|2018-06-01 02:13:02.119045
NCT00664794|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2011-07-19|2008-04-21|2008-04-23|Estimate|||||||2011-07-19|2011-07-21|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Rotator Cuff Repair With Arthroscopic Acromioplasty (Shaving the Acromion Bone) Versus Repair Without Acromioplasty|Arthroscopic Rotator Cuff Repair With and Without Arthroscopic Acromioplasty in the Treatment of Full Thickness Rotator Cuff Tears|Completed||N/A|48|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 02:13:02.173484|2018-06-01 02:13:02.173484
NCT00664781|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2016-05-23|2008-04-22|2008-04-23|Estimate|||||||2016-05-23|2016-05-24|Estimate|December 2007||2007-12-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer|A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer|Completed||Phase 2|78|Actual|Cancer Research UK|||||f||||||||||||||2018-06-01 02:13:02.235122|2018-06-01 02:13:02.235122
NCT00664768|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-03-05|2008-04-22|2008-04-23|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2008||2008-03-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CMA||A Growth and Hypoallergenicity Study of a New Formula for Infants With Cow Milk Allergy|A Prospective, Randomized, Double-Blind Controlled Study to Evaluate the Nutritional Safety (Growth) of an Amino Acid Based Formula With Prebiotics and Probiotics in Infants Diagnosed With Cow Milk Allergy, With or Without Other Food Allergies.|Completed||N/A|126|Actual|Nutricia North America||2|||f||||f||||||||||2018-06-01 02:13:03.320416|2018-06-01 02:13:03.320416
NCT00664755|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2018-04-23||2018-04-23|2008-04-22|2008-04-23|Estimate|2018-04-23|2018-05-24|Actual||||2018-04-23|2018-05-24|Actual|July 2007||2007-07-31|April 2018|2018-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity|Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity|Completed||Phase 2|140|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 02:13:03.453429|2018-06-01 02:13:03.453429
NCT00664742|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2011-01-05||2011-04-19|2008-04-22|2008-04-23|Estimate|2011-04-19|2011-05-17|Estimate||||2011-04-19|2011-05-17|Estimate|September 2006||2006-09-30|April 2011|2011-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome|The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome|Completed||Phase 4|614|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:13:03.762165|2018-06-01 02:13:03.762165
NCT00664729|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2010-01-12|2008-04-21|2008-04-23|Estimate|||||||2010-01-12|2010-01-13|Estimate|November 2002||2002-11-30|April 2008|2008-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|DEMO||Diet, Exercise, Metabolism, and Obesity in Older Women|Diet, Exercise, Metabolism, and Obesity in Older Women:DEMO|Completed||N/A|112|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||||2018-06-01 02:13:03.946685|2018-06-01 02:13:03.946685
NCT00664716|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21||2015-12-17|2015-12-17|2008-04-22|2008-04-23|Estimate||||2015-12-17|2016-01-21|Estimate|2015-12-17|2016-01-21|Estimate|July 2007||2007-07-31|December 2015|2015-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|RESPOND||Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants|Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.|Completed||Phase 2|391|Actual|Biogen||6|||f||||t||||||||||2018-06-01 02:13:04.029982|2018-06-01 02:13:04.029982
NCT00664703|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2013-06-19|2008-04-21|2008-04-23|Estimate|||||||2013-06-19|2013-06-20|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients|A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients|Completed||Phase 2|13|Actual|Yaupon Therapeutics||7|||f||||t||||||||||2018-06-01 02:13:04.226594|2018-06-01 02:13:04.226594
NCT00664690|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-08-25|2008-04-22|2008-04-23|Estimate|||||||2017-08-25|2017-08-28|Actual||||August 2017|2017-08-31||||||||Interventional|||Effect of Celecoxib on Transitional Pain After Outpatient Surgery|Effect of Celecoxib on Transitional Pain After Outpatient Surgery|Withdrawn||Phase 4|0|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 02:13:04.323491|2018-06-01 02:13:04.323491
NCT00664677|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2016-02-20|2008-04-21|2008-04-23|Estimate|||||||2016-02-20|2016-02-23|Estimate|August 2007||2007-08-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia|Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia|Terminated||Phase 1|16|Actual|Erimos Pharmaceuticals||1||Funding constraints|f||||f||||||||No||2018-06-01 02:13:04.386187|2018-06-01 02:13:04.386187
NCT00664664|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-12-29|2008-04-22|2008-04-23|Estimate|||||||2008-12-29|2008-12-30|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia|A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of APD125 in Patients With Primary Insomnia Characterized by Difficulty Maintaining Sleep|Completed||Phase 2|675|Anticipated|Arena Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:13:04.482061|2018-06-01 02:13:04.482061
NCT00664651|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-04-22|2008-04-22|2008-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|December 2006||2006-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Joint Stiffness Following Knee Replacement Surgery|Capsular Changes in Joint Contractures Post-Knee Arthroplasty:A Case-Control Study|Withdrawn|||0|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 02:13:04.556984|2018-06-01 02:13:04.556984
NCT00664638|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2013-11-01|2008-04-21|2008-04-23|Estimate|||||||2013-11-01|2013-11-05|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|HTN-1||Renal Denervation in Patients With Refractory Hypertension|Renal Denervation in Patients With Refractory Hypertension|Completed||N/A|45|Actual|Medtronic Vascular|||||f||||f||||||||||2018-06-01 02:13:04.61953|2018-06-01 02:13:04.61953
NCT00664625|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18||2010-09-10|2015-09-23|2008-04-22|2008-04-23|Estimate||||2010-09-10|2010-09-13|Estimate|2015-09-23|2015-10-09|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects|Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1|Completed||Phase 1/Phase 2|24|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 02:13:04.694759|2018-06-01 02:13:04.694759
NCT00664612|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-10-15|2008-04-22|2008-04-23|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2008||2008-01-31|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Comparison of AirTraq Laryngoscope to Macintosh Laryngoscope for Intubation of Patients With Potential Cervical Spine Injury|Comparison of AirTraq Laryngoscope to Macintosh Laryngoscope for Intubation of Patients With Potential Cervical Spine Injury|Completed||N/A|24|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 02:13:04.7776|2018-06-01 02:13:04.7776
NCT00664599|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-20|||2008-04-27|2008-04-22|2008-04-23|Estimate|||||||2008-04-27|2008-04-30|Estimate|April 2006||2006-04-30|April 2008|2008-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease|Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)|Completed||Phase 2|20|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:13:04.837043|2018-06-01 02:13:04.837043
NCT00664586|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2016-02-20|2008-04-22|2008-04-23|Estimate|||||||2016-02-20|2016-02-23|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors|A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors.|Terminated||Phase 1|21|Actual|Erimos Pharmaceuticals||1||Funding constraints|f||||f||||||||No||2018-06-01 02:13:04.926986|2018-06-01 02:13:04.926986
NCT00664573|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21||2015-12-17|2015-12-17|2008-04-22|2008-04-23|Estimate||||2015-12-17|2016-01-21|Estimate|2015-12-17|2016-01-21|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|RESPOND-EXT||104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants|Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.|Terminated||Phase 2|339|Actual|Biogen||4||Analysis of data from 104RA202 failed to meet primary endpoint|f||||t||||||||||2018-06-01 02:13:04.994593|2018-06-01 02:13:04.994593
NCT00664560|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2010-05-27|2009-12-01|2012-01-20|2008-04-22|2008-04-23|Estimate|2012-01-20|2012-02-27|Estimate|2009-12-01|2009-12-03|Estimate|2012-01-20|2012-02-27|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis|Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Study Evaluating the Efficacy of PN400 (VIMOVO) Twice Daily (Bid) and Celecoxib Once Daily (qd) in Patients With Osteoarthritis of the Knee|Completed||Phase 3|614|Actual|POZEN||3|||f||||f||||||||||2018-06-01 02:13:05.108784|2018-06-01 02:13:05.108784
NCT00664547|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-04-22|2008-04-22|2008-04-23|Estimate|||||||2008-04-22|2008-04-23|Estimate|September 1997||1997-09-30|April 2008|2008-04-30|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||Reduction in Cardiovascular Risk Factors and Visceral Adipose Tissue in Men: Separate Effects of Diet- and Exercise-Induced Weight Loss|Reduction in Cardiovascular Risk Factors and Visceral Adipose Tissue in Men: Separate Effects of Diet- and Exercise-Induced Weight Loss|Completed||N/A|||Queen's University||4|||f||||f||||||||||2018-06-01 02:13:05.764821|2018-06-01 02:13:05.764821
NCT00664534|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2011-11-09||2011-11-09|2008-04-21|2008-04-23|Estimate|2011-11-09|2011-12-13|Estimate||||2011-11-09|2011-12-13|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast|Comparison of Premixed Insulin Lispro Low-Mixture and Mid-Mixture Regimens With Separate Basal and Bolus Insulin Injections in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Oral Therapy Who Consume Light Breakfast|Completed||Phase 4|344|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:13:05.906138|2018-06-01 02:13:05.906138
NCT00664521|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2016-09-16||2016-11-04|2008-04-22|2008-04-23|Estimate|2016-11-04|2016-12-30|Estimate||||2016-11-04|2016-12-30|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|August III|Intent-to-treat (ITT) population included all randomized participants.|Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)|A Randomized, Double-blind, Placebo Controlled, Multi-centre, Exploratory, Pilot, Phase II Trial of 150mg Atacicept Given Subcutaneously in Combination With Rituximab in Subjects With Rheumatoid Arthritis.|Completed||Phase 2|27|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 02:13:06.730405|2018-06-01 02:13:06.730405
NCT00664508|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2018-03-29|2008-04-21|2008-04-23|Estimate|||||||2018-03-29|2018-04-02|Actual|November 2007||2007-11-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mobility Assessment of Patients With Total Hip Arthroplasty|Mobility Assessment of Patients With Total Hip Arthroplasty: Joint Mechanics and Rehabilitation|Active, not recruiting||N/A|30|Anticipated|Ottawa Hospital Research Institute||3|||f||||f||||||||||2018-06-01 02:13:07.494491|2018-06-01 02:13:07.494491
NCT00664495|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-04-22|2008-04-22|2008-04-23|Estimate|||||||2008-04-22|2008-04-23|Estimate|April 1999||1999-04-30|April 2008|2008-04-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Reduction of Abdominal Obesity and Insulin Resistance in Women|Reduction of Abdominal Obesity and Insulin Resistance in Women|Completed||N/A|||Queen's University||4|||f||||f||||||||||2018-06-01 02:13:07.580506|2018-06-01 02:13:07.580506
NCT00664482|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21||2013-01-22|2013-01-22|2008-04-22|2008-04-23|Estimate||||2013-01-22|2013-01-29|Estimate|2013-01-22|2013-01-29|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Single-Patient Study Using AGS 006|A Single-Patient Study Using AGS 006 as an Immunotherapeutic in a Subject With Newly Diagnosed Resectable Pancreatic Cancer|Completed||N/A|1|Actual|Argos Therapeutics||1|||f||||f||||||||||2018-06-01 02:13:07.673345|2018-06-01 02:13:07.673345
NCT00664469|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-07-27|2008-04-21|2008-04-23|Estimate|||||||2011-07-27|2011-07-28|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Interventional|INFINITY||INdians Followed for INtensive Lipid Lowering Treatment and Its safetY|INdians Followed for INtensive Lipid Lowering Treatment and Its safetY: To Assess The Safety And Effectiveness Of Ezetimibe Co-Administered With Any Statin Compared To Doubling Of Current Statin Daily Dose In South Asian Canadians|Terminated||Phase 3|64|Actual|Sunnybrook Health Sciences Centre||2||Poor enrollment|f||||f||||||||||2018-06-01 02:13:07.758776|2018-06-01 02:13:07.758776
NCT00664456|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2017-12-18|2008-04-22|2008-04-23|Estimate|||||||2017-12-18|2017-12-19|Actual|April 2008||2008-04-30|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|SHIP0804||Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer|A Phase III, Multicenter, Randomized, Controlled Study of Neoadjuvant LHRH-agonist Therapy and Permanent I-125 Implantation With vs. Without Adjuvant LHRH-agonist Therapy in Patients With Untreated Intermediate-risk Prostate Cancer.|Active, not recruiting||Phase 3|421|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-06-01 02:13:07.845518|2018-06-01 02:13:07.845518
NCT00664443|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-10-21|2008-04-22|2008-04-23|Estimate|||||||2015-10-21|2015-10-22|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Effectiveness of Dispatch-Assisted Cardiopulmonary Resuscitation (CPR) Instructions|Effectiveness of Dispatch-Assisted Cardiopulmonary Resuscitation (CPR) Instructions: An Evaluation of 9-1-1 Calls.|Completed|||8357|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-06-01 02:13:07.930606|2018-06-01 02:13:07.930606
NCT00664430|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2010-06-03||2012-01-18|2008-04-22|2008-04-23|Estimate|2010-07-20|2010-08-18|Estimate||||2012-01-18|2012-01-20|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects|Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects|Terminated||Phase 4|13|Actual|Abbott|Early termination leading to no efficacy evaluation. All adverse events occurred during calcitriol challenge phase.|1||Low enrollment rate|f||||f||||||||||2018-06-01 02:13:08.039965|2018-06-01 02:13:08.039965
NCT00664417|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-22|||2012-04-16|2008-04-22|2008-04-23|Estimate|||||||2012-04-16|2012-04-17|Estimate|April 2008||2008-04-30|April 2012|2012-04-30|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|||Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine|Safety and Immunogenicity of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine in Healthy Adults|Completed||Phase 1|375|Actual|Sanofi||9|||f||||t||||||||||2018-06-01 02:13:08.236037|2018-06-01 02:13:08.236037
NCT00664404|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2012-10-23|2008-04-22|2008-04-23|Estimate|||||||2012-10-23|2012-10-24|Estimate|April 2008||2008-04-30|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|||Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal|Pharmacogenetics, Emotional Reactivity and Smoking Cessation: Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal|Completed||Phase 3|64|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 02:13:08.339228|2018-06-01 02:13:08.339228
NCT00664391|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-02-09|2008-04-21|2008-04-22|Estimate|||||||2009-02-09|2009-02-10|Estimate|January 2008||2008-01-31|February 2009|2009-02-28||||February 2008|Actual|2008-02-29||Interventional|||Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Breeze|Completed||Phase 3|32|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:13:08.414527|2018-06-01 02:13:08.414527
NCT00664378|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18||2013-04-25|2013-04-25|2008-04-21|2008-04-22|Estimate||||2013-04-25|2013-05-03|Estimate|2013-04-25|2013-05-03|Estimate|January 2008||2008-01-31|April 2013|2013-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy Study of CYT997 in Multiple Myeloma|A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma|Terminated||Phase 2|5|Actual|Gilead Sciences||1||Difficulty enrolling patients|f||||t||||||||||2018-06-01 02:13:08.477206|2018-06-01 02:13:08.477206
NCT00664365|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2017-07-31|2008-04-21|2008-04-22|Estimate|||||||2017-07-31|2017-08-01|Actual|April 12, 2008|Actual|2008-04-12|July 2017|2017-07-31|August 22, 2008|Actual|2008-08-22|August 22, 2008|Actual|2008-08-22||Interventional|||FTIH Study With GSK958108|A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK958108 in Healthy Male Subjects|Completed||Phase 1|21|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:13:08.547953|2018-06-01 02:13:08.547953
NCT00664352|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2009-01-05|2008-04-21|2008-04-22|Estimate|||||||2009-01-05|2009-01-06|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Juvidex (Mannose-6-Phosphate) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites|A Double Blind, Placebo Controlled Trial to Investigate the Efficacy and Safety of Two Concentrations of Juvidex (Mannose-6-Phosphate) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites Using Different Dosing Regimes|Completed||Phase 1/Phase 2|195|Anticipated|Renovo||5|||f||||f||||||||||2018-06-01 02:13:08.651553|2018-06-01 02:13:08.651553
NCT00664339|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-04-17|2008-04-17|2008-04-22|Estimate|||||||2008-04-17|2008-04-22|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|FLUVACS-IC||Flu Vaccination in Congestive Heart Failure|Influenza Vaccine Pilot Study in Severe Congestive Heart Failure Patients. The Flu Vaccination Heart Failure (FLUVACS II) Study|Completed||Phase 4|117|Actual|La Fundacion Favaloro para la Investigacion y la Docencia Medica||2|||f||||t||||||||||2018-06-01 02:13:08.744656|2018-06-01 02:13:08.744656
NCT00664326|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2012-10-28||2018-04-20|2008-04-17|2008-04-22|Estimate|2012-10-28|2012-11-28|Estimate||||2018-04-20|2018-04-24|Actual|April 30, 2008|Actual|2008-04-30|April 2018|2018-04-30|January 18, 2019|Anticipated|2019-01-18|May 31, 2009|Actual|2009-05-31||Interventional|||A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC|A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer (RCC)|Active, not recruiting||Phase 2|49|Actual|Bayer||1|||f||||t|t|f||||||||2018-06-01 02:13:08.835304|2018-06-01 02:13:08.835304
NCT00664313|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2012-10-01|2008-04-21|2008-04-22|Estimate|||||||2012-10-01|2012-10-02|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|LiMiT||TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB|TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis|Completed||Phase 1/Phase 2|36|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 02:13:09.377819|2018-06-01 02:13:09.377819
NCT00664300|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-01-18|2008-04-21|2008-04-22|Estimate|||||||2011-01-18|2011-01-19|Estimate|August 2007||2007-08-31|January 2011|2011-01-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Observational|||Facial Expression Recognition of Emotion and Categorization of Emotional Words in Gilles de la Tourette's Syndrome|Facial Expression Recognition of Emotion and Categorization of Emotional Words in Gilles de la Tourette's Syndrome|Completed|||60|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-06-01 02:13:09.46235|2018-06-01 02:13:09.46235
NCT00664287|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-04-08|2008-04-21|2008-04-22|Estimate|||||||2015-04-08|2015-04-09|Estimate|September 2008||2008-09-30|April 2015|2015-04-30||||November 2009|Anticipated|2009-11-30||Interventional|||Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients Deemed Appropriate for Further Lipid Modification.|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:13:09.527956|2018-06-01 02:13:09.527956
NCT00664274|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2015-04-16|2008-04-21|2008-04-22|Estimate|||||||2015-04-16|2015-04-17|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|October 2016|Anticipated|2016-10-31|January 2015|Actual|2015-01-31||Interventional|COMT||Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia|COMT Genotype and Response to Cognitive Remediation in Schizophrenia|Unknown status|Active, not recruiting|N/A|142|Anticipated|Manhattan Psychiatric Center||1|||f||||t||||||||||2018-06-01 02:13:09.597546|2018-06-01 02:13:09.597546
NCT00664261|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-19|||2013-12-17|2008-04-19|2008-04-22|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|July 2013|Actual|2013-07-31|September 2011|Actual|2011-09-30||Interventional|||Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking|Addressing Parental Smoking by Changing Pediatric Office Systems|Completed||N/A|3000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:13:09.684911|2018-06-01 02:13:09.684911
NCT00664248|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-18|2008-04-18|2008-04-22|Estimate|||||||2008-04-18|2008-04-22|Estimate|October 2006||2006-10-31|April 2008|2008-04-30||||August 2007|Actual|2007-08-31||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris||Completed||Phase 3|1414|Actual|Dow Pharmaceutical Sciences||4|||f||||||||||||||2018-06-01 02:13:09.786227|2018-06-01 02:13:09.786227
NCT00664235|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-04-21|2008-04-21|2008-04-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|February 2008||2008-02-29|April 2008|2008-04-30|June 2008|Anticipated|2008-06-30|April 2008|Anticipated|2008-04-30||Observational|||The Analysis of Skin Temperature by Long Wave Infrared Imaging to Determine Its Effectiveness as a Predictor of Tissue Injury|Study of Thermal Imaging as an Objective RISK Indicator; The Evaluation of Skin Blood Flow and Temperature by Long Wave Infra-Red Imaging to Determine Effectiveness as a Predictor of Pressure Ulcer or Non-Visible Deep Tissue Damage|Unknown status|Recruiting||100|Anticipated|Trillennium Medical Imaging, Inc.|||||f||||f||||||||||2018-06-01 02:13:09.928721|2018-06-01 02:13:09.928721
NCT00664222|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-04-21|2008-04-21|2008-04-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|January 2004||2004-01-31|April 2008|2008-04-30|December 2005||2005-12-31|||||Interventional|||Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)|Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure|Completed||Phase 4|16|Actual|Tottori University Hospital|||||f||||||||||||||2018-06-01 02:13:10.010805|2018-06-01 02:13:10.010805
NCT00664209|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2017-10-31||2017-10-31|2008-04-21|2008-04-22|Estimate|2017-10-31|2017-12-02|Actual||||2017-10-31|2017-12-02|Actual|January 2008||2008-01-31|October 2017|2017-10-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Treating H. Pylori in Parkinson's Patients With Motor Fluctuations|Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease|Terminated||Phase 3|64|Actual|University of California, Los Angeles|Screening yield was much lower than anticipated based on the literature which prohibited completion of the study|2||Prevalence of H Pylori in the study population was much lower than anticipated|f||||f||||||||||2018-06-01 02:13:10.096572|2018-06-01 02:13:10.096572
NCT00664196|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2016-06-16|2008-04-21|2008-04-22|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2008||2008-04-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning|Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning|Suspended||Phase 1|18|Anticipated|Roger Williams Medical Center||1||Funding|f||||t||||||||||2018-06-01 02:13:10.347987|2018-06-01 02:13:10.347987
NCT00664183|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-10-19|2008-04-18|2008-04-22|Estimate|||||||2009-10-19|2009-10-20|Estimate|March 2008||2008-03-31|October 2009|2009-10-31||||December 2009|Anticipated|2009-12-31||Interventional|||A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects|A Phase 3 Safety and Efficacy Study of Vitreosolve® for Ophthalmic Intravitreal Injection in Retinopathy Subjects|Terminated||Phase 2/Phase 3|400|Anticipated|Vitreoretinal Technologies, Inc.||2||slow enrollment , interim analysis conducted.|f||||f||||||||||2018-06-01 02:13:10.476062|2018-06-01 02:13:10.476062
NCT00664170|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-05-27|2008-04-18|2008-04-22|Estimate|||||||2009-05-27|2009-05-28|Estimate|April 2008||2008-04-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer|A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer|Completed||Phase 1|39|Actual|Mast Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 02:13:10.568488|2018-06-01 02:13:10.568488
NCT00664157|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-01-18|2008-04-21|2008-04-22|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2007||2007-09-30|January 2011|2011-01-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus|Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus .|Completed||N/A|80|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-06-01 02:13:10.68639|2018-06-01 02:13:10.68639
NCT00664144|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2012-03-06|2008-04-21|2008-04-22|Estimate|||||||2012-03-06|2012-03-07|Estimate|July 2002||2002-07-31|March 2012|2012-03-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|GRAAL2||Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma|Study of Efficacy and Safety of Rasburicase for the Treatment/Prevention of Hyperuricemia Related to Tumor Lysis Syndrome in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma, Previously Treated or Not With Urate Oxidase Presenting With Hyperuricemia and/or Bulky Disease|Terminated||Phase 2|33|Actual|Sanofi||||due to poor enrollment|f||||||||||||||2018-06-01 02:13:10.792285|2018-06-01 02:13:10.792285
NCT00330538|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2007-04-05|2006-05-26|2006-05-29|Estimate|||||||2007-04-05|2007-04-06|Estimate|March 2004||2004-03-31|April 2007|2007-04-30|October 2006|Actual|2006-10-31|||||Observational|||Osteoporosis in Children With ALL|Incidence of Osteoporosis in Children With Acute Lymphoblastic Leukemia Undergoing Therapy|Completed|||20||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 03:58:48.185322|2018-06-01 03:58:48.185322
NCT00664131|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-09-22|2008-04-21|2008-04-22|Estimate|||||||2011-09-22|2011-09-23|Estimate|August 2005||2005-08-31|September 2011|2011-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors|Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors|Completed|||165|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 02:13:10.925298|2018-06-01 02:13:10.925298
NCT00664118|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-05-26|2008-04-21|2008-04-22|Estimate|||||||2009-05-26|2009-05-27|Estimate|April 2008||2008-04-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|DCLEAP||Doula Combined Latent Phrase Epidural Analgesia in Primiparous Women|In Combination of Doula and Epidural Analgesia in the Latent Phrase of Labor in Primiparous Women|Completed||N/A|500|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 02:13:11.121811|2018-06-01 02:13:11.121811
NCT00664105|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-19|2010-09-30||2012-08-30|2008-04-19|2008-04-22|Estimate|2011-02-23|2011-03-22|Estimate||||2012-08-30|2012-09-07|Estimate|February 2004||2004-02-29|August 2012|2012-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)|PhII Study of Concurrent Chemoradiotherapy With Weekly Docetaxel, Carboplatin and Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|63|Actual|Vanderbilt-Ingram Cancer Center|"Outcome measure #4, Number of participants with AEs by grade, will not match the total number of participants in this study. Some participants have multiple events in one or more grade designations or some participants have no events at all."|1||Treatment became standard.|f||||t||||||||||2018-06-01 02:13:11.210359|2018-06-01 02:13:11.210359
NCT00664092|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2015-02-10|2008-04-18|2008-04-22|Estimate|||||||2015-02-10|2015-02-11|Estimate|October 2007||2007-10-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Evaluating Alternative Aftercare Models for Ex-Offenders|Evaluating Alternative Aftercare Models for Ex-Offenders|Completed||Phase 2|300|Actual|DePaul University||3|||f||||t||||||||||2018-06-01 02:13:11.676077|2018-06-01 02:13:11.676077
NCT00664079|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2015-03-11|2008-04-18|2008-04-22|Estimate|||||||2015-03-11|2015-03-12|Estimate|October 2005||2005-10-31|July 2008|2008-07-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Observational|Thyroid||Thyroid Hormones in Critically Ill Children|Thyroid Hormone Deficiency in Critically Ill Children|Terminated|||22|Actual|Children's Hospital of Philadelphia|||1|Sluggish enrollment.|f||||f||||||Samples Without DNA|"~     Whole blood and serum~   "|||2018-06-01 02:13:11.837327|2018-06-01 02:13:11.837327
NCT00664066|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2009-08-18||2009-09-28|2008-04-21|2008-04-22|Estimate|2009-08-18|2009-09-28|Estimate||||2009-09-28|2009-09-30|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|DELFT||DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)|A Non-Interventional, Post-Authorisation Study to Assess Adverse Events and Drug Utilisation Among Chronic Kidney Disease Patients Treated With DYNEPO|Terminated|||3|Actual|Shire|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.|||"The termination of the study is not linked to a product recall or result of any safety signal.~   Rather it was sponsor's commercial decision to withdraw the MA"|f||||||||||||||2018-06-01 02:13:11.99154|2018-06-01 02:13:11.99154
NCT00664053|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-04-25|2008-04-18|2008-04-22|Estimate|||||||2008-04-25|2008-04-29|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Effects of DHEA/Exercise on Bone, Muscle and Balance|Effects of DHEA/Exercise on Bone, Muscle and Balance|Completed||Phase 4|99|Actual|National Institute on Aging (NIA)||4|||f||||f||||||||||2018-06-01 02:13:12.258993|2018-06-01 02:13:12.258993
NCT00664040|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-04-05|2008-04-18|2008-04-22|Estimate|||||||2017-04-05|2017-04-07|Actual|May 2003||2003-05-31|April 2017|2017-04-30|August 2006|Actual|2006-08-31|||||Interventional|HAPI||Heredity and Phenotype Intervention (HAPI) Heart Study|Heredity and Phenotype Intervention (HAPI) Heart Study|Completed||N/A|868|Actual|University of Maryland|||||f||||t||||||||||2018-06-01 02:13:12.444313|2018-06-01 02:13:12.444313
NCT00664027|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18||2012-11-29|2012-11-29|2008-04-18|2008-04-22|Estimate||||2012-11-29|2012-12-03|Estimate|2012-11-29|2012-12-03|Estimate|April 2008||2008-04-30|November 2012|2012-11-30||||May 2009|Actual|2009-05-31||Interventional|||Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy|An Open-Label, Randomized, Dose-ranging Phase IIa Trial to Determine the Effects of RTA 402 (Bardoxolone Methyl) on Renal Function in Patients With Diabetic Nephropathy|Completed||Phase 2|80|Actual|Reata Pharmaceuticals, Inc.||4|||f||||||||||||||2018-06-01 02:13:12.540166|2018-06-01 02:13:12.540166
NCT00664014|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2010-03-05|2008-04-21|2008-04-22|Estimate|||||||2010-03-05|2010-03-08|Estimate|May 2008||2008-05-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia|Randomized, Double-blind, Multicenter, Placebo-controlled (Standard Therapy + Placebo), Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia|Completed||Phase 2|240|Anticipated|Otsuka Beijing Research Institute||2|||f||||f||||||||||2018-06-01 02:13:12.66805|2018-06-01 02:13:12.66805
NCT00664001|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-21|2008-04-21|2008-04-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|March 2003||2003-03-31|April 2008|2008-04-30|December 2003|Actual|2003-12-31|August 2003|Actual|2003-08-31||Interventional|||Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness|Randomized Double-Blind Placebo-Controlled Trial of Oral Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness.|Completed||Phase 3|83|Actual|Altitude Physiology Expeditions||2|||f||||f||||||||||2018-06-01 02:13:12.799791|2018-06-01 02:13:12.799791
NCT00663988|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-20|||2008-04-20|2008-04-20|2008-04-22|Estimate|||||||2008-04-20|2008-04-22|Estimate|April 2006||2006-04-30|February 2006|2006-02-28||||April 2006|Actual|2006-04-30||Interventional|||Human Partial Facial Allotransplantation|Human Partial Facial Allotransplantation|Completed||Phase 3|1|Actual|Xijing Hospital||1|||f||||t||||||||||2018-06-01 02:13:12.948342|2018-06-01 02:13:12.948342
NCT00663975|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2010-05-12|2008-04-21|2008-04-22|Estimate|||||||2010-05-12|2010-05-13|Estimate|February 2009||2009-02-28|May 2010|2010-05-31|November 2009|Anticipated|2009-11-30|August 2009|Anticipated|2009-08-31||Interventional|||Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients|An Open-Label, Multi-Center Safety and Efficacy Study of DCI-1020 in Pediatric Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency|Withdrawn||N/A|24|Anticipated|Digestive Care, Inc.||1||Study not being conducted|f||||t||||||||||2018-06-01 02:13:13.182788|2018-06-01 02:13:13.182788
NCT00663585|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2016-07-28|2008-04-21|2008-04-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Intensive Meditation and Migraines: Effects on Health and Well Being|Intensive Meditation and Migraines: Effects on Health and Well Being|Completed||N/A|36|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 02:13:19.217255|2018-06-01 02:13:19.217255
NCT00663962|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2013-01-31||2016-01-29|2008-04-21|2008-04-22|Estimate|2016-01-29|2016-02-29|Estimate||||2016-01-29|2016-02-29|Estimate|April 2008||2008-04-30|January 2016|2016-01-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional||Of the 7 participants randomized to the pregabalin group, 3 receieved 150mg of pregabalin while 4 recieved 300mg pregabalin.|Pregabalin and Post-thoracotomy Pain|A Prospective, Randomized, Double Blinded, Placebo Controlled Pilot Study Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome|Completed||Phase 4|15|Actual|Queen's University||2|||f||||t||||||||No||2018-06-01 02:13:13.28547|2018-06-01 02:13:13.28547
NCT00663949|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-04-21|2008-04-21|2008-04-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy|Phase 2 Trial of Effect of Combine Pentoxifylline and Captopril on Proteinuria in Diabetic Nephropathy|Completed||Phase 2/Phase 3|70|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:13:13.521965|2018-06-01 02:13:13.521965
NCT00663936|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18||2012-12-09|2013-10-09|2008-04-21|2008-04-22|Estimate||||2012-12-10|2012-12-12|Estimate|2013-10-09|2013-11-05|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease|A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|373|Actual|Toyama Chemical Co., Ltd.||2|||f||||t||||||||||2018-06-01 02:13:13.627995|2018-06-01 02:13:13.627995
NCT00663923|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2009-12-30||2012-03-10|2008-04-21|2008-04-22|Estimate|2011-11-26|2011-12-30|Estimate||||2012-03-10|2012-03-13|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|PRK||Comparison of Cross-cylinder and Conventional Photorefractive Keratectomy(PRK) in Correcting Medium-high Astigmatism|Comparison of Cross-cylinder and Conventional PRK for Laser Correction of Astigmatism: A Randomized Clinical Trial.|Completed||Phase 3|50|Actual|Tabriz University||2|||f||||t||||||||||2018-06-01 02:13:13.743936|2018-06-01 02:13:13.743936
NCT00663910|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-19|||2016-12-30|2008-04-19|2008-04-22|Estimate|||||||2016-12-30|2017-01-02|Estimate|March 2008||2008-03-31|December 2016|2016-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer|Evaluation of Protoporphyrin Formation in Non-Melanoma Skin Cancers After Topical Application of 5-Aminolevulinic Acid: A Pilot Study|Terminated||Early Phase 1|18|Actual|The Cleveland Clinic||||Of the 8 histologically proven tumors, detection of PpIX proved to be ambiguous.|f||||t||||||||No|IPD will not be shared.|2018-06-01 02:13:13.999726|2018-06-01 02:13:13.999726
NCT00663897|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2009-10-08|2008-04-21|2008-04-22|Estimate|||||||2009-10-08|2009-10-09|Estimate|May 2008||2008-05-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Lansoprazole Versus Mosapride for Functional Dyspepsia|A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome|Completed||Phase 4|329|Actual|Lotung Poh-Ai Hospital||2|||f||||t||||||||||2018-06-01 02:13:14.073373|2018-06-01 02:13:14.073373
NCT00663884|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2012-03-28|2008-04-21|2008-04-22|Estimate|||||||2012-03-28|2012-03-30|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|GLORIA||Glufast On Insulin Glargine Trial in Type 2 DM|A Prospective, Randomized and Multi-center Clinical Study to Evaluate Efficacy and Safety of Combination Therapy of Mitiglinide or Voglibose With Long-acting Insulin in Type 2 Diabetic Patients|Completed||Phase 4|167|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-06-01 02:13:14.170198|2018-06-01 02:13:14.170198
NCT00663871|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2012-07-05|2008-04-18|2008-04-22|Estimate|||||||2012-07-05|2012-07-09|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluating the Effects of Omega-3 Fatty Acids on Heart Disease and Behavior|BioBehavioral Studies of Cardiovascular Disease|Completed||Phase 2/Phase 3|275|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 02:13:14.254821|2018-06-01 02:13:14.254821
NCT00663858|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2010-11-11||2010-12-15|2008-04-17|2008-04-22|Estimate|2010-12-15|2011-01-17|Estimate||||2010-12-15|2011-01-17|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)|Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: a Double-blind Placebo-controlled Efficacy Study|Completed||Phase 3|420|Actual|AEterna Zentaris||3|||f||||t||||||||||2018-06-01 02:13:14.346419|2018-06-01 02:13:14.346419
NCT00663845|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2013-10-10|2008-04-17|2008-04-22|Estimate|||||||2013-10-10|2013-10-11|Estimate|May 2006||2006-05-31|October 2013|2013-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia.|Completed||Phase 4|395|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:13:16.022391|2018-06-01 02:13:16.022391
NCT00663832|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2012-05-15|2008-04-21|2008-04-22|Estimate|||||||2012-05-15|2012-05-17|Estimate|February 2008||2008-02-29|May 2012|2012-05-31||||December 2011|Actual|2011-12-31||Interventional|||A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer|An Open Label, Single Arm, Phase Ib Dose Finding Study of i.v. Panobinostat (LBH589) With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 1|44|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:13:16.098067|2018-06-01 02:13:16.098067
NCT00663819|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2014-08-21||2018-03-16|2008-04-21|2008-04-22|Estimate|2014-09-02|2014-09-10|Estimate||||2018-03-16|2018-04-17|Actual|April 2008||2008-04-30|March 2018|2018-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Patients were considered for the study if they were at least 18 years of age and scheduled to undergo one the following (with the anastomosis < 10 cm from the anal verge): low anterior resection, proctectomy, proctocolectomy or a restorative anastomosis by means of Hartmann’s reversal, coloanal anastomosis, or ileo-pouch-anal anastomosis.|Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses|Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal, Coloanal and Ileoanal Anastomoses: A Prospective Randomized Study|Terminated||N/A|258|Actual|W.L.Gore & Associates||2||Per SAP|f||||f||||||||||2018-06-01 02:13:16.20174|2018-06-01 02:13:16.20174
NCT00663806|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2014-12-01|2008-04-21|2008-04-22|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2003||2003-02-28|December 2014|2014-12-31|July 2003|Actual|2003-07-31|||||Interventional|EXPRESS||A Phase IV Study of Cipro XR in Uncomplicated UTI|EXPRESS: Evaluating Cipro XR Patient Response, Education, Safety, and Satisfaction|Completed||Phase 4|7614|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:13:16.443863|2018-06-01 02:13:16.443863
NCT00663793|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2010-06-25||2010-12-27|2008-04-18|2008-04-22|Estimate|2010-12-27|2011-01-24|Estimate||||2010-12-27|2011-01-24|Estimate|October 2008||2008-10-31|December 2010|2010-12-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|ORAL-T-6||ORAL T-6: Oral Androgens in Man-6|Oral Androgens in Man-6: Pharmacokinetics of Slow and Fast Release, External Matrix Oral Testosterone Formulations in Normal Men With Experimental Hypogonadism|Completed||Phase 1|16|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:13:16.650687|2018-06-01 02:13:16.650687
NCT00663780|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2009-01-05|2008-04-21|2008-04-22|Estimate|||||||2009-01-05|2009-01-06|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Pharmacogenomic Analysis of Samples From Subjects in Study RN1004-0082|Pharmacogenomic Analysis of Blood Samples to Identify Polymorphisms That Segregate Responders From Non-Responders Following Treatment With Juvidex of Split Skin Donor Sites in Renovo's Clinical Study RN1004-0082|Completed|||195|Anticipated|Renovo|||||f||||f||||||Samples With DNA|"~     Plasma retained until samples analysed then destroyed~   "|||2018-06-01 02:13:17.017572|2018-06-01 02:13:17.017572
NCT00663767|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18||2009-12-09|2011-11-29|2008-04-21|2008-04-22|Estimate||||2009-12-09|2009-12-11|Estimate|2011-11-29|2011-12-02|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction||Completed||Phase 2|250|Actual|Array BioPharma||6|||f||||||||||||||2018-06-01 02:13:17.089938|2018-06-01 02:13:17.089938
NCT00663754|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2014-03-03|2008-04-21|2008-04-22|Estimate|||||||2014-03-03|2014-03-04|Estimate|March 2005||2005-03-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II)|Eating Disorder Prevention Program Effectiveness Trial|Completed||N/A|306|Actual|Oregon Research Institute||3|||f||||t||||||||||2018-06-01 02:13:17.181326|2018-06-01 02:13:17.181326
NCT00663741|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2013-06-09|2008-04-17|2008-04-22|Estimate|||||||2013-06-09|2013-06-11|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Sorafenib Gastric Cancer Asian Phase I Study|Phase I Study to Investigate Safety, Pharmacokinetics and Preliminary Efficacy Profile of Sorafenib (BAY 43-9006) in Combination With S-1 Plus CDDP in Asian Patients With Unresectable / Recurrent Gastric Cancer|Completed||Phase 1|13|Actual|Bayer||3|||f||||t||||||||||2018-06-01 02:13:17.277943|2018-06-01 02:13:17.277943
NCT00663728|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2014-12-26|2008-04-17|2008-04-22|Estimate|||||||2014-12-26|2014-12-30|Estimate|September 2004||2004-09-30|December 2014|2014-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Assessment of Duration of Erection With Vardenafil 10 mg|A Randomized, Double-blind, Crossover Study to Evaluate the Duration of Erection Following Vardenafil (10mg) Administration for Four Weeks in a Fixed Dose Regimen Compared to Placebo in Males With ED|Completed||Phase 4|201|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:13:17.364241|2018-06-01 02:13:17.364241
NCT00663715|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2015-03-11|2008-04-18|2008-04-22|Estimate|||||||2015-03-11|2015-03-12|Estimate|April 2009||2009-04-30|April 2010|2010-04-30|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|||Ultrasound Description of the Sciatic Nerve|Anatomical Description of the Sciatic Nerve Via a Lateral Mid-Thigh Approach Using Ultrasound|Withdrawn|||0|Actual|Children's Hospital of Philadelphia|||1|No subjects were enrolled. Sciatic blocks infrequently used for pain control.|f||||f||||||||||2018-06-01 02:13:17.432169|2018-06-01 02:13:17.432169
NCT00663702|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2012-01-19||2015-02-17|2008-04-21|2008-04-22|Estimate|2012-02-22|2012-03-26|Estimate||||2015-02-17|2015-03-09|Estimate|May 2008||2008-05-31|February 2015|2015-02-28|January 2012|Actual|2012-01-31|December 2009|Actual|2009-12-31||Interventional|||Phase IIIB Switching From Intravenous to Subcutaneous Study|A Phase 3B Multi-center Open-Label Study to Evaluate the Safety of Abatacept in Subjects Who Switch From Intravenous to Subcutaneous Abatacept Therapy|Completed||Phase 3|123|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:13:17.574042|2018-06-01 02:13:17.574042
NCT00663689|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-04-21|2008-04-21|2008-04-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|March 2008||2008-03-31|April 2008|2008-04-30|January 2012|Anticipated|2012-01-31|March 2011|Anticipated|2011-03-31||Interventional|||Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer|A Phase II Study of Erlotinib in Benefitted Patients With Asymptomatic Brain Metastases Advanced Non-Small Cell Lung Cancer By Chemotherapy.|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|Guangdong Provincial People's Hospital||1|||f||||t||||||||||2018-06-01 02:13:18.681965|2018-06-01 02:13:18.681965
NCT00663663|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2013-08-29|2008-04-18|2008-04-22|Estimate|||||||2013-08-29|2013-08-30|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TIPS||Telephone Intervention for Pain Study (TIPS)|Efficacy of Telephone-Delivered Cognitive Behavioral Therapy for Chronic Pain|Completed||N/A|207|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:13:18.775587|2018-06-01 02:13:18.775587
NCT00663650|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2011-07-11|2008-04-21|2008-04-22|Estimate|||||||2011-07-11|2011-07-12|Estimate|August 2008||2008-08-31|July 2011|2011-07-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control|A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control|Unknown status|Recruiting|Phase 3|290|Anticipated|Queen's University||2|||f||||f||||||||||2018-06-01 02:13:18.850273|2018-06-01 02:13:18.850273
NCT00663637|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-05-28|2008-04-21|2008-04-22|Estimate|||||||2008-05-28|2008-05-29|Estimate|April 2008||2008-04-30|April 2008|2008-04-30||||||||Interventional|RESCUE||Removal of Endotracheal Tube Secretions Comprehensively Until Extubation|Evaluation of the Safety and Efficacy of CAM (Complete Airway Management) Catheters: Phase II Study|Unknown status|Recruiting|Phase 2|30|Anticipated|O. M. Neotech, Inc.|||||f||||f||||||||||2018-06-01 02:13:18.926235|2018-06-01 02:13:18.926235
NCT00663624|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2013-11-20|2008-04-21|2008-04-22|Estimate|||||||2013-11-20|2013-11-21|Estimate||||November 2013|2013-11-30||||||||Interventional|NOVO ER||Management of Hyperglycemia in the ER: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care|Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care|Withdrawn||Phase 4|0|Actual|Emory University||2||Lack of funding for the study at the Emory site|f||||t||||||||||2018-06-01 02:13:19.006338|2018-06-01 02:13:19.006338
NCT00663611|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2018-04-04|2008-04-21|2008-04-22|Estimate|||||||2018-04-04|2018-04-05|Actual|October 19, 2006||2006-10-19|November 30, 2017|2017-11-30|October 6, 2014|Actual|2014-10-06|October 6, 2014|Actual|2014-10-06||Interventional|||Growth Hormone Administration and the Human Immune System|Growth Hormone Administration and the Human Immune System|Completed||Phase 1|66|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 02:13:19.07641|2018-06-01 02:13:19.07641
NCT00663572|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2013-09-02|2008-04-21|2008-04-22|Estimate|||||||2013-09-02|2013-09-04|Estimate|March 2008||2008-03-31|September 2013|2013-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|Polynuca||Food Habit Programming: Influence of Genetics and Early Nutrition in a Population of Preterm Infants|Food Habit Programming: Influence of Genetics and Early Nutrition in a Population of Preterm Infants|Terminated|||234|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 02:13:19.279647|2018-06-01 02:13:19.279647
NCT00663559|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2014-12-17|2008-04-21|2008-04-22|Estimate|||||||2014-12-17|2014-12-18|Estimate|February 2008||2008-02-29|November 2007|2007-11-30|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|SOGUG/0107||Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy|Study Phase II to Determinate the Efficacy of Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy|Completed||Phase 2|59|Actual|Spanish Oncology Genito-Urinary Group||1|||f||||t||||||||||2018-06-01 02:13:19.328386|2018-06-01 02:13:19.328386
NCT00663546|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-19|||2018-04-04|2008-04-19|2008-04-22|Estimate|||||||2018-04-04|2018-04-05|Actual|March 24, 2008||2008-03-24|December 5, 2013|2013-12-05|December 5, 2013||2013-12-05|||||Observational|||Malaria Studies in Cambodia|Studies of P. Vivax and P. Falciparum Malaria in Cambodia|Completed|||1978|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:13:19.51162|2018-06-01 02:13:19.51162
NCT00663533|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2014-12-02|2008-04-21|2008-04-22|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2008|Actual|2008-07-31||Interventional|VAS-2||VAS-2 Vasectomy With the Vax-X|Vasectomy With the Vas-X, a Simple, Minimally Invasive Device for Male Sterilization: A Pilot Study|Completed||Phase 1|10|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:13:19.571019|2018-06-01 02:13:19.571019
NCT00663520|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2018-04-16|2008-04-18|2008-04-22|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2008||2008-01-31|April 2018|2018-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|MVD||Elucidating the Role of Microvascular Dysfunction in Heart Disease in Women|Elucidating the Role of Microvascular Dysfunction in Heart Disease in Women|Completed|||40|Actual|Oregon Health and Science University|||2||f||||t|f|f||||||No|No Plan to share data.|2018-06-01 02:13:19.641069|2018-06-01 02:13:19.641069
NCT00663507|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2013-02-25|2008-04-21|2008-04-22|Estimate|||||||2013-02-25|2013-02-27|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Kidney Transplantation in Patients With Sickle Cell Disease|Kidney Transplantation in Patients With Sickle Cell Disease|Terminated|||2|Actual|Emory University||||"Only 1 patient was enrolled. No funding, small number of eligible patients so would not achieve~   statistical power."|f||||t||||||Samples With DNA|"~     100 mLs of whole blood will be collected at designated time points. Baseline, and at~     1,3,6,9,12,18 and 24 months post-transplant~   "|||2018-06-01 02:13:19.711975|2018-06-01 02:13:19.711975
NCT00663494|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2011-07-20|2008-04-18|2008-04-22|Estimate|||||||2011-07-20|2011-07-21|Estimate|February 2003||2003-02-28|April 2008|2008-04-30|July 2006|Actual|2006-07-31|||||Observational|||Matrix Metalloproteinase (MMP) in Heart Failure|MMP is Produced in Failing Hearts|Completed|||22|Anticipated|Tottori University Hospital|||||f||||||||||||||2018-06-01 02:13:19.772611|2018-06-01 02:13:19.772611
NCT00663481|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-05-27|2008-04-18|2008-04-22|Estimate|||||||2009-05-27|2009-05-28|Estimate|April 2008||2008-04-30|May 2009|2009-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.|A Single Dose, Within Subject, 3 Period, Pharmacokinetic Bridging Study of CoFactor Formulations and of Leucovorin Administered Intravenously in Healthy, Adult Subjects.|Completed||Phase 1|15|Anticipated|Mast Therapeutics, Inc.||3|||f||||f||||||||||2018-06-01 02:13:19.830764|2018-06-01 02:13:19.830764
NCT00663468|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2012-09-21|2008-04-21|2008-04-22|Estimate|||||||2012-09-21|2012-09-24|Estimate|April 2008||2008-04-30|September 2012|2012-09-30||||||||Observational|||Treatment of Sub-capital Fractures of Hip Joint by Using TriboFit™ Acetabular Buffer||Unknown status|Active, not recruiting||11|Actual|Active Implants|||1||f||||||||||||||2018-06-01 02:13:19.923256|2018-06-01 02:13:19.923256
NCT00663455|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-06-03|2008-04-21|2008-04-22|Estimate|||||||2015-06-03|2015-06-04|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|Recaltox||Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant Recipients|A Multicenter, Randomized, Parallel-group, Trial to Reduce Toxicity of Calcineurininhibitor-therapy in Steroid-free Longterm Immunosuppression in Pediatric and Adolescent Kidney Transplant Recipients|Terminated||Phase 4|50|Actual|University of Erlangen-Nürnberg Medical School||2||"Recruitment goals were not achieved. Extension of the trial concept had to be abjected due to~   methodological reasons."|f||||t||||||||||2018-06-01 02:13:19.99085|2018-06-01 02:13:19.99085
NCT00663442|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-04-21|2008-04-21|2008-04-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|December 1999||1999-12-31|April 2008|2008-04-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)|Dose Response Pharmacogenetic Study of ADHD|Completed||Phase 4|48|Actual|University of Illinois at Chicago||1|||f||||f||||||||||2018-06-01 02:13:20.088048|2018-06-01 02:13:20.088048
NCT00663429|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2011-08-30|2008-04-21|2008-04-22|Estimate|||||||2011-08-30|2011-08-31|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma|A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma|Completed||Phase 2|10|Actual|Callisto Pharmaceuticals|||||f||||f||||||||||2018-06-01 02:13:20.157441|2018-06-01 02:13:20.157441
NCT00663416|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-08-10|2008-04-21|2008-04-22|Estimate|||||||2009-08-10|2009-08-12|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|January 2009|Anticipated|2009-01-31|October 2008|Anticipated|2008-10-31||Interventional|REGENESIS||REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients|A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)|Terminated||Phase 2|134|Anticipated|Stem Cell Therapeutics Corp.||2|||f||||t||||||||||2018-06-01 02:13:20.240136|2018-06-01 02:13:20.240136
NCT00663403|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2010-04-29||2015-12-01|2008-04-18|2008-04-22|Estimate|2010-08-03|2010-08-26|Estimate||||2015-12-01|2015-12-30|Estimate|February 2007||2007-02-28|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)|Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)|Completed||Phase 4|8|Actual|University of Michigan|Transmembrane and total body clearance results limited to continuous venovenous hemodialysis run at ~2 L/h dialysate flow. Clinical outcomes (such as infection cure rate, length of hospital stay, mortality rate) of subjects was not assessed.||||f||||f||||||||||2018-06-01 02:13:20.366921|2018-06-01 02:13:20.366921
NCT00663390|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-01-28|2008-04-21|2008-04-22|Estimate|||||||2009-01-28|2009-01-29|Estimate|December 2007||2007-12-31|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR|Completed||Phase 3|30|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:13:20.572456|2018-06-01 02:13:20.572456
NCT00663377|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-04-18|2008-04-18|2008-04-22|Estimate|||||||2008-04-18|2008-04-22|Estimate|April 2006||2006-04-30|April 2008|2008-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Effects of Losartan on Insulin Resistance in Patients With Heart Failure|Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors|Completed||Phase 4|16|Anticipated|Tottori University Hospital|||||f||||f||||||||||2018-06-01 02:13:20.642347|2018-06-01 02:13:20.642347
NCT00663364|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2010-07-06|2008-04-21|2008-04-22|Estimate|||||||2010-07-06|2010-07-07|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Care of the Dry Skin With Physiogel AI Lotion® (W0156)|Klinische Untersuchung Zur Pflege Trockener Haut Mit Physiogel AI Lotion Und Physiogel Lotion|Completed||N/A|100|Actual|University Hospital Muenster||2|||f||||t||||||||||2018-06-01 02:13:20.734023|2018-06-01 02:13:20.734023
NCT00663351|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2015-03-18|2008-04-18|2008-04-22|Estimate|||||||2015-03-18|2015-03-20|Estimate|December 2004||2004-12-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|RCH||Safety and Effectiveness Study of the Reflection Ceramic Acetabular System|Post Approval Study: Reflection Ceramic Acetabular System|Completed||N/A|456|Actual|Smith & Nephew, Inc.||2|||f||||||||||||||2018-06-01 02:13:20.808437|2018-06-01 02:13:20.808437
NCT00663338|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2011-02-18|2008-04-21|2008-04-22|Estimate|||||||2011-02-18|2011-02-21|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke|A Multi-centre Exploratory Study to Evaluate the Efficacy of the Dopamine Receptor Agonist Rotigotine in the Treatment of Hemispatial Neglect and Motor Deficits Following Stroke|Completed||Phase 2|20|Anticipated|University College, London||1|||f||||t||||||||||2018-06-01 02:13:20.89213|2018-06-01 02:13:20.89213
NCT00663325|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-01-07|2008-04-21|2008-04-22|Estimate|||||||2009-01-07|2009-01-08|Estimate|December 2007||2007-12-31|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Tangerina Mix|Completed||Phase 3|30|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:13:20.968275|2018-06-01 02:13:20.968275
NCT00663312|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-10-07|2008-04-21|2008-04-22|Estimate|||||||2008-10-07|2008-10-08|Estimate|April 2008||2008-04-30|October 2008|2008-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's Disease|Impact of Deep Brain Stimulation of Subthalamic Nucleus on the Hepatic Glucose Production in Parkinson's Disease|Terminated||N/A|8|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 02:13:21.033736|2018-06-01 02:13:21.033736
NCT00663299|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2012-05-15|2008-04-21|2008-04-22|Estimate|||||||2012-05-15|2012-05-17|Estimate|June 2004||2004-06-30|May 2012|2012-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|COMPLEX||COMPLEX Post Market Surveillance Electronic Registry|COMPLEX Post Market Surveillance Electronic Registry|Completed||N/A|299|Actual|Codman & Shurtleff||1|||f||||f||||||||||2018-06-01 02:13:21.102273|2018-06-01 02:13:21.102273
NCT00663286|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-18|2008-04-18|2008-04-22|Estimate|||||||2008-04-18|2008-04-22|Estimate|October 2006||2006-10-31|April 2008|2008-04-30||||August 2007|Actual|2007-08-31||Interventional|||A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris||Completed||Phase 3|1399|Actual|Dow Pharmaceutical Sciences||4|||f||||||||||||||2018-06-01 02:13:21.182555|2018-06-01 02:13:21.182555
NCT00663273|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2009-01-07|2008-04-21|2008-04-22|Estimate|||||||2009-01-07|2009-01-08|Estimate|December 2007||2007-12-31|January 2009|2009-01-31||||January 2008|Actual|2008-01-31||Interventional|||Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower|Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower|Completed||Phase 3|30|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:13:21.382524|2018-06-01 02:13:21.382524
NCT00663260|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2016-09-28||2016-12-20|2008-04-21|2008-04-22|Estimate|2016-12-20|2017-02-10|Actual||||2016-12-20|2017-02-10|Actual|June 2008||2008-06-30|December 2016|2016-12-31|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional||All randomized participants who received at least 1 dose of study medication|Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control|Completed||Phase 2/Phase 3|631|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 02:13:21.495128|2018-06-01 02:13:21.495128
NCT00663247|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2012-06-13|2008-04-21|2008-04-22|Estimate|||||||2012-06-13|2012-06-14|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Mechanistic Randomized Controlled Trial (RCT) of Mesalazine in Symptomatic Diverticular Disease|Mechanistic Randomized Controlled Trial of Mesalazine in Symptomatic Diverticular Disease|Completed||N/A|40|Actual|University of Nottingham||2|||f||||t||||||||||2018-06-01 02:13:22.253243|2018-06-01 02:13:22.253243
NCT00663234|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|2015-12-03||2016-03-08|2008-04-21|2008-04-22|Estimate|2016-03-08|2016-04-06|Estimate||||2016-03-08|2016-04-06|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All participants who initiated Atorvastatin were included in the baseline characteristics.|IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia|Phase I/II Safety and Efficacy Investigation of Atorvastatin for Treatment of PI-Associated Increased LDL Cholesterol in HIV-Infected Children and Adolescents|Terminated||Phase 1/Phase 2|28|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Target enrollment was 40 participants (20 in each age cohort). However, the study was prematurely discontinued due to administrative reasons, having enrolled only 28 participants (21 participants aged 10 to 14 and 7 participants aged 15 to 23).|2||The study was prematurely discontinued due to administrative reasons.|f||||t||||||||||2018-06-01 02:13:22.369502|2018-06-01 02:13:22.369502
NCT00663221|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2009-07-03|2008-04-21|2008-04-22|Estimate|||||||2009-07-03|2009-07-07|Estimate|March 2008||2008-03-31|July 2009|2009-07-31||||||||Interventional|||Study of the Osteoprotector Effects of a Milk Product Based on Anthocyans and Enriched in Calcium and Vitamin D||Completed||Phase 2|56|Anticipated|Elvir SAS||2|||f||||||||||||||2018-06-01 02:13:22.864356|2018-06-01 02:13:22.864356
NCT00663208|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2015-08-14||2015-09-16|2008-04-21|2008-04-22|Estimate|2015-09-16|2015-10-14|Estimate||||2015-09-16|2015-10-14|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||The analysis was performed on all treated participants.|A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects|Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of Daclatasvir in Subjects Infected With Hepatitis C Virus Genotype 1|Completed||Phase 2|167|Actual|Bristol-Myers Squibb||6|||f||||f||||||||||2018-06-01 02:13:22.975134|2018-06-01 02:13:22.975134
NCT00663195|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2008-04-18|2008-04-18|2008-04-22|Estimate|||||||2008-04-18|2008-04-22|Estimate|January 2004||2004-01-31|April 2008|2008-04-30|December 2005|Actual|2005-12-31|||||Interventional|||Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure|Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure|Completed||Phase 4|16|Actual|Tottori University Hospital|||||f||||||||||||||2018-06-01 02:13:24.540844|2018-06-01 02:13:24.540844
NCT00663182|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2008-04-22|2008-04-21|2008-04-22|Estimate|||||||2008-04-22|2008-04-23|Estimate|January 2008||2008-01-31|April 2008|2008-04-30|December 2012|Anticipated|2012-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis|Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 4|200|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-06-01 02:13:24.604321|2018-06-01 02:13:24.604321
NCT00663169|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2012-08-30|2012-05-22|2012-12-04|2008-04-21|2008-04-22|Estimate|2012-12-04|2013-01-07|Estimate|2012-05-22|2012-05-31|Estimate|2012-12-04|2013-01-07|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout|A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of a Single Dose of ACZ885 in Hospitalized Patients With Acute Gout|Completed||Phase 2|6|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:13:24.733935|2018-06-01 02:13:24.733935
NCT00663156|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2013-02-14|2008-04-21|2008-04-22|Estimate|||||||2013-02-14|2013-02-15|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Prospective Study of Autologous Fat Grafting for Breast Augmentation||Completed||N/A|13|Actual|Georgetown University||2|||f||||||||||||||2018-06-01 02:13:25.128796|2018-06-01 02:13:25.128796
NCT00663143|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2015-03-30|2008-04-21|2008-04-22|Estimate|||||||2015-03-30|2015-04-01|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Observational|TZDBONE||Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation|Thiazolidinedione-Induced Bone Loss: Effects on Bone Marrow Stromal Cell Differentiation Capacity and Osteoblast Formation|Completed|||9|Actual|Emory University|||1||f||||t||||||Samples Without DNA|"~     Bone Marrow~   "|||2018-06-01 02:13:25.219443|2018-06-01 02:13:25.219443
NCT00663130|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2013-10-09|2008-04-17|2008-04-22|Estimate|||||||2013-10-09|2013-10-11|Estimate|April 2004||2004-04-30|October 2013|2013-10-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)|A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction|Completed||Phase 4|759|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:13:25.292578|2018-06-01 02:13:25.292578
NCT00663117|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2012-11-30||2013-05-16|2008-04-18|2008-04-22|Estimate|2013-05-16|2013-05-17|Estimate||||2013-05-16|2013-05-17|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|LDN||The Effects of Naltrexone on Active Crohn's Disease|The Effects of Naltrexone in Active Crohn's Disease|Completed||Phase 2|40|Actual|Penn State University||2|||f||||t||||||||||2018-06-01 02:13:25.367148|2018-06-01 02:13:25.367148
NCT00663104|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-21|||2015-05-27|2008-04-21|2008-04-22|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause|Effect of Exercise and Exercise + Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause|Terminated||Phase 3|126|Actual|University of Erlangen-Nürnberg Medical School||3|||f||||f||||||||||2018-06-01 02:13:25.652559|2018-06-01 02:13:25.652559
NCT00663091|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2011-09-06|2008-04-21|2008-04-22|Estimate|||||||2011-09-06|2011-09-07|Estimate|September 2006||2006-09-30|September 2011|2011-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|WPP-201||A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers|A Prospective, Randomized Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers|Completed||Phase 1|64|Actual|Southwest Regional Wound Care Center||1|||f||||t||||||||||2018-06-01 02:13:25.730788|2018-06-01 02:13:25.730788
NCT00663078|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2010-01-13|2008-04-18|2008-04-22|Estimate|||||||2010-01-13|2010-01-14|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|BackonTrack||Group Cognitive Behavioral Therapy (CBT) Intervention for Women With Mild to Moderate Depression|A Pilot Study to Develop a Brief Group Intervention for Women With Mild and Moderate Depression|Completed||Early Phase 1|75|Actual|University of Bristol||2|||f||||f||||||||||2018-06-01 02:13:25.800752|2018-06-01 02:13:25.800752
NCT00663065|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2009-08-03|2008-04-19|2008-04-21|Estimate|||||||2009-08-03|2009-08-04|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of the Safety of PAZ-417 in Healthy Elderly Adults|An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PAZ-417 Administered Orally to Elderly Subjects|Terminated||Phase 1|40|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:13:25.857539|2018-06-01 02:13:25.857539
NCT00663052|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2011-01-18||2012-03-29|2008-04-17|2008-04-21|Estimate|2012-03-29|2012-04-23|Estimate||||2012-03-29|2012-04-23|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|PRISTINE||Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis|A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis|Completed||Phase 4|273|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:13:26.010211|2018-06-01 02:13:26.010211
NCT00663039|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17||2017-03-28|2017-11-06|2008-04-19|2008-04-21|Estimate||||2017-04-13|2017-04-20|Actual|2017-11-06|2017-11-08|Actual|October 2009|Actual|2009-10-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|July 2015|Actual|2015-07-31||Interventional|||Effects of Oxytocin Nasal Spray on Social Affiliation|Effects of Oxytocin Nasal Spray on Social Affiliation|Active, not recruiting||Phase 2|29|Actual|University of Maryland||2|||f||||t||||||||No||2018-06-01 02:13:28.796195|2018-06-01 02:13:28.796195
NCT00663026|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2013-09-11|2012-03-27|2013-09-11|2008-04-19|2008-04-21|Estimate|2013-09-11|2013-11-15|Estimate|2012-03-27|2012-03-30|Estimate|2013-09-11|2013-11-15|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study Evaluating Bapineuzumab In Alzheimer Disease Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD|Completed||Phase 2|79|Actual|Pfizer|Designation of outcomes as primary, secondary was based on study team’s input as study did not specify them as primary or secondary.|3|||f||||t||||||||||2018-06-01 02:13:28.897408|2018-06-01 02:13:28.897408
NCT00663013|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2011-01-03|2008-04-19|2008-04-21|Estimate|||||||2011-01-03|2011-01-04|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Virtual Reality for Burn Wound Care Pain Control|Virtual Reality for Burn Wound Care Pain Control|Unknown status|Recruiting|N/A|12|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:13:29.415682|2018-06-01 02:13:29.415682
NCT00663000|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2014-09-13|2008-04-17|2008-04-21|Estimate|||||||2014-09-13|2014-09-16|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|April 2011|Actual|2011-04-30||Observational|||Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance|Observational, Cross-sectional, Longitudinal, Multi-center, Diagnostic Study to Evaluate the Influence of Acromegaly on Glucose Tolerance and to Evaluate the Changes of Impaired Glucose Tolerance During Standard Treatment of Acromegaly.|Completed|||138|Actual|University Hospital Tuebingen|||1||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:13:29.497417|2018-06-01 02:13:29.497417
NCT00662987|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-04-17|2008-04-17|2008-04-21|Estimate|||||||2008-04-17|2008-04-21|Estimate|September 2005||2005-09-30|April 2008|2008-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effect of Duration of Antibiotic Therapy on Recovery Following Tonsillectomy|Effect of Duration of Antibiotic Therapy on Recovery Following Tonsillectomy|Completed||N/A|50|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:13:29.586321|2018-06-01 02:13:29.586321
NCT00662974|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-04-18|2008-04-18|2008-04-21|Estimate|||||||2008-04-18|2008-04-21|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|March 2009|Anticipated|2009-03-31|December 2008|Anticipated|2008-12-31||Interventional|||Searching for the Perfect Oil to Protect the Perineum: A Randomized-Controlled, Double-Blind Trial|A Randomised Double Blind Clinical Trial to Verify if Perineal Massage Increases the Chances of Delivering With an Intact Perineum Comparing the Two Oils. As Secondary Objective, we Will Evaluate the Effects of Perineal Massage on Specific Tear Location, the Severity of Perineal Tears and the Amount of Suture Material Required for Repair|Unknown status|Not yet recruiting|N/A|300|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-06-01 02:13:29.663497|2018-06-01 02:13:29.663497
NCT00662961|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-17|2008-04-17|2008-04-21|Estimate|||||||2008-04-17|2008-04-21|Estimate|January 2007||2007-01-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|Forehead||Forehead Lift Fixation|Periosteum Versus Bone for the Fixation of Forehead Lift: A Prospective, Randomized, Controlled, Split-Face Trial.|Completed||N/A|12|Actual|Federal University of Uberlandia||2|||f||||f||||||||||2018-06-01 02:13:29.803997|2018-06-01 02:13:29.803997
NCT00662948|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2017-04-23|2008-04-17|2008-04-21|Estimate|||||||2017-04-23|2017-04-25|Actual|December 2008||2008-12-31|May 2016|2016-05-31||||October 2014|Actual|2014-10-31||Interventional|||ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)|Open Study in Phase II to Evaluate Efficacy of Initial R-CHOP Combination in Folicular Lymphoma no Treated Previously. Consolidation w Ith One Dose of 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)|Suspended||Phase 2|140|Anticipated|PETHEMA Foundation||2||No inclusion|f||||t||||||||||2018-06-01 02:13:29.895786|2018-06-01 02:13:29.895786
NCT00662935|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-04-17|2008-04-17|2008-04-21|Estimate|||||||2008-04-17|2008-04-21|Estimate|May 2005||2005-05-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)|Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH)|Completed||N/A|12|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 02:13:30.021189|2018-06-01 02:13:30.021189
NCT00662922|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2010-01-08|2008-04-17|2008-04-21|Estimate|||||||2010-01-08|2010-01-11|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Consequences of Hypoglycemia on Intensive Care Unit (ICU) Patients|Does Hypoglycemia Under Intensive Insulin Therapy During Critical Illness Lead to Neurocognitive Dysfunction|Completed|||74|Actual|University Hospital Muenster|||2||f||||f||||||||||2018-06-01 02:13:30.122912|2018-06-01 02:13:30.122912
NCT00662909|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2012-07-11|2010-04-15|2017-11-09|2008-04-17|2008-04-21|Estimate|2012-09-17|2012-10-17|Estimate|2010-04-15|2010-04-16|Estimate|2017-11-09|2017-12-11|Actual|March 28, 2008|Actual|2008-03-28|November 2017|2017-11-30|April 22, 2009|Actual|2009-04-22|April 22, 2009|Actual|2009-04-22||Interventional|ARIES||A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder|A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder|Completed||Phase 3|2149|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 02:13:30.273504|2018-06-01 02:13:30.273504
NCT00662896|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2011-06-16|2008-04-16|2008-04-21|Estimate|||||||2011-06-16|2011-06-17|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|HCT3012-X-112||To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension|A 16-week, Phase 1, Multicenter, Double-Blind, Randomized, Naproxen and Ibuprofen-controlled, Parallel-Group Pharmacological Study, to Assess the Effect of Naproxcinod (375mg and750mg, Bid) Compared to Doses of Naproxen (250mg and 500mg, Bid) and to Ibuprofen (600mg, Tid) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension.|Completed||Phase 1|300|Anticipated|NicOx||5|||f||||t||||||||||2018-06-01 02:13:32.351621|2018-06-01 02:13:32.351621
NCT00662402|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2017-10-25|2008-04-18|2008-04-21|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2008||2008-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Impact of Extensive Consultation on Career Development Grant Outcomes|Impact of Extensive Consultation on Career Development Grant Outcomes|Active, not recruiting||N/A|132|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:13:41.078651|2018-06-01 02:13:41.078651
NCT00662883|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-21|2008-04-18|2008-04-21|Estimate|||||||2008-04-21|2008-04-22|Estimate|November 2007||2007-11-30|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)|A Randomized, Open Label Study to Assess the Effects of a Nasal Corticosteroid on the Pharmacokinetics, Safety, and Tolerability of PMI-150 (Intranasal Ketamine Hydrochloride) 30 mg|Completed||Phase 1|18|Actual|Javelin Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:13:32.481983|2018-06-01 02:13:32.481983
NCT00662870|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2012-01-26|2008-04-18|2008-04-21|Estimate|||||||2012-01-26|2012-01-31|Estimate|May 2001||2001-05-31|January 2012|2012-01-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine|Safety, Immunogenicity and Lot Comparability of DAPTACEL™ (Aventis Pasteur Classic Five-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) When Administered With Other Recommended Vaccines at 2, 4, 6, and 15 to 16 Months of Age.|Completed||Phase 3|1941|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 02:13:32.693708|2018-06-01 02:13:32.693708
NCT00662857|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2014-07-22|2009-06-09|2014-10-09|2008-04-16|2008-04-21|Estimate|2014-10-09|2014-10-16|Estimate|2014-10-09|2014-10-16|Estimate|2014-10-09|2014-10-16|Estimate|April 2008||2008-04-30|October 2014|2014-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro|"A Phase 2, Open-Label, Randomized, 2-Way Crossover, Clinical Trial to Compare the Pharmacokinetics of 2 Formulations of Intended Commercial Product Technosphere® Insulin Inhalation Powder and to Determine the Bioavailability of a 30 Unit Cartridge of Intended Commercial Product Technosphere® Insulin Inhalation Powder Versus a 10 Unit Subcutaneous Injection of Insulin Lispro in Subjects With Type 1 Diabetes Mellitus"|Completed||Phase 2|29|Actual|Mannkind Corporation||3|||f||||||||||||||2018-06-01 02:13:32.851916|2018-06-01 02:13:32.851916
NCT00662844|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2016-03-24|2008-04-18|2008-04-21|Estimate|||||||2016-03-24|2016-03-25|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|VITADAS||Vitamin D Supplementation in Younger Women|Optimum Vitamin D Nutrition in Young Women|Completed||N/A|198|Actual|Creighton University||5|||f||||t||||||||No||2018-06-01 02:13:33.132843|2018-06-01 02:13:33.132843
NCT00662831|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2011-08-11||2011-12-01|2008-04-17|2008-04-21|Estimate|2011-12-01|2012-01-13|Estimate||||2011-12-01|2012-01-13|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|FEENICS||Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients|A 6 Month, Prospective, Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multiple Center Trial To Evaluate The Efficacy And Safety Of Fragmin In The Treatment Of Chronic Neuroischaemic Foot Ulcers In Diabetic Patients|Completed||Phase 2/Phase 3|276|Actual|Pfizer|Study enrollment was terminated before planned number of participants was obtained. Although randomized participants were allowed to complete entire course of therapy according to protocol and study status was therefore designated as completed.|2|||f||||t||||||||||2018-06-01 02:13:33.263171|2018-06-01 02:13:33.263171
NCT00662818|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2014-09-05||2017-04-06|2008-04-17|2008-04-21|Estimate|2014-09-15|2014-09-17|Estimate||||2017-04-06|2017-05-12|Actual|March 17, 2008|Actual|2008-03-17|April 2017|2017-04-30|September 2, 2009|Actual|2009-09-02|September 2, 2009|Actual|2009-09-02||Interventional||All treated participants|Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)|A Multicenter, Randomized, Double-Blind, Placebo- and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stable Vascular Disease|Completed||Phase 3|165|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:13:34.222475|2018-06-01 02:13:34.222475
NCT00662805|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2014-01-16|2008-04-16|2008-04-21|Estimate|||||||2014-01-16|2014-01-20|Estimate|June 2004||2004-06-30|January 2014|2014-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)|A 2-year Observational Study to Evaluate Safety of Seretide 50/500μg Twice Daily Administered by DISKUS, in Patients With COPD|Completed|||762|Actual|GlaxoSmithKline|||1||f||||f||||||Samples Without DNA|"~     Participants will undergo physical examination and blood pressure measurement. A complete~     medical history will be taken, as well as blood and urine samples.~   "|||2018-06-01 02:13:34.620929|2018-06-01 02:13:34.620929
NCT00662792|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17||2014-04-30|2014-04-30|2008-04-18|2008-04-21|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|April 2008||2008-04-30|April 2014|2014-04-30||||August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD|A Randomised, Double-blind Clinical Efficacy and Safety Comparison of Tiotropium/Salmeterol 7.5/25 Inhalation Powder in the Morning Via Tiotropium/Salmeterol HandiHaler, Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler, Salmeterol 50 Mcg MDPI in the Morning and Evening and the Free Combination Tiotropium 18 Mcg Inhalation Powder in the Morning Via Spiriva HandiHaler Plus Salmeterol 50 Mcg MDPI in the Morning and Evening Following Chronic Administration (6-week Treatment Periods) in Patients With COPD|Completed||Phase 3|147|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:13:34.711714|2018-06-01 02:13:34.711714
NCT00662779|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2015-12-09|2008-04-17|2008-04-21|Estimate|||||||2015-12-09|2015-12-11|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|EIB||Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)|Evaluation of the Bronchoprotective Effect of Arformoterol in Children With Exercise Induced Bronchospasm|Withdrawn||Phase 3|0|Actual|University of New Mexico||3||High number of screen failures-couldn't find qualified subjects in timely manner|f||||t||||||||||2018-06-01 02:13:34.835398|2018-06-01 02:13:34.835398
NCT00662766|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-04-16|2008-04-16|2008-04-21|Estimate|||||||2008-04-16|2008-04-21|Estimate|September 2005||2005-09-30|April 2008|2008-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Intervention With Black Currant Seed Press Residues in Healthy Subjects|Intervention Study on the Health Beneficial Effects of Bread Enriched With Black Currant Seed Press Residues in Healthy Subjects|Completed||N/A|36|Actual|University of Jena|||||f||||t||||||||||2018-06-01 02:13:34.945041|2018-06-01 02:13:34.945041
NCT00662753|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2016-02-23|2008-04-17|2008-04-21|Estimate|||||||2016-02-23|2016-02-25|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study in the Use of Home Blood Pressure Monitoring and Telephone Follow-up to Control Blood Pressure|A Structured Program for Hypertension Control in Community Clinics: A Randomized Trial|Completed||Phase 1|111|Actual|George Washington University||2|||f||||f||||||||||2018-06-01 02:13:35.203899|2018-06-01 02:13:35.203899
NCT00662740|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17||2014-04-30|2014-04-30|2008-04-18|2008-04-21|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|April 2008||2008-04-30|April 2014|2014-04-30||||November 2008|Actual|2008-11-30||Interventional|||Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol PE Capsule) in COPD|1-yr Study Comparing TioSal Combo Regimens Versus Single Agent Therapies (Spiriva HandiHaler and Salmeterol PE Capsule)|Terminated||Phase 3|220|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-06-01 02:13:35.314589|2018-06-01 02:13:35.314589
NCT00662727|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2013-02-17|2008-04-18|2008-04-21|Estimate|||||||2013-02-17|2013-02-20|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris|Randomized, Placebo Controlled, Double Blind Clinical Trial Evaluating the Treatment of Patients With Refractory Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device|Completed||Phase 2|28|Actual|Medispec||2|||f||||f||||||||||2018-06-01 02:13:35.529463|2018-06-01 02:13:35.529463
NCT00662714|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2012-07-06|2008-04-18|2008-04-21|Estimate|||||||2012-07-06|2012-07-10|Estimate|September 2001||2001-09-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis|Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus|Completed||Phase 3|73|Actual|Mukoviszidose Institut gGmbH||2|||f||||f||||||||||2018-06-01 02:13:35.674728|2018-06-01 02:13:35.674728
NCT00662701|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2015-11-18|2008-04-17|2008-04-21|Estimate|||||||2015-11-18|2015-11-20|Estimate|May 2007||2007-05-31|November 2015|2015-11-30|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|FAST||Ablation or Surgery for Atrial Fibrillation (AF) Treatment|Atrial Fibrillation: Ablation or Surgical Treatment; A Randomized Study Comparing Non-pharmacologic Therapy in Patients With Drug-refractory Atrial Fibrillation|Completed||N/A|120|Actual|St. Antonius Hospital||2|||f||||t||||||||||2018-06-01 02:13:35.820062|2018-06-01 02:13:35.820062
NCT00662688|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2013-03-12|2008-04-18|2008-04-21|Estimate|||||||2013-03-12|2013-03-13|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PAM07||Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer|Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas|Terminated||Phase 3|42|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||2||recruitment prematurely stopped due to a lack of eligible patients.|f||||f||||||||||2018-06-01 02:13:35.896044|2018-06-01 02:13:35.896044
NCT00662675|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2010-02-05||2014-04-24|2008-04-17|2008-04-21|Estimate|2010-02-25|2010-03-17|Estimate||||2014-04-24|2014-05-09|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency|A Randomized Double-blind (Withdrawal) Phase 3 Study to Evaluate the Efficacy and Tolerability of Pancrelipase MT Capsules Compared With Placebo in the Treatment of Subjects With Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency|Completed||Phase 3|40|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 02:13:35.981196|2018-06-01 02:13:35.981196
NCT00662662|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2018-02-20|2008-04-17|2008-04-21|Estimate|||||||2018-02-20|2018-02-22|Actual|April 2008|Actual|2008-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||Sexual Behavior in Head and Neck Cancer Patients|Sexual Behavior in Head and Neck Cancer Patients|Active, not recruiting|||1500|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 02:13:36.342826|2018-06-01 02:13:36.342826
NCT00662649|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2012-06-09||2012-06-09|2008-04-17|2008-04-21|Estimate|2012-06-09|2012-07-12|Estimate||||2012-06-09|2012-07-12|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|An Extension of the 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing Efficacy and Safety of Fingolimod (FTY720) 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 3|920|Actual|Novartis||5|||f||||||||||||||2018-06-01 02:13:36.458219|2018-06-01 02:13:36.458219
NCT00662636|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-03-21|2008-04-18|2008-04-21|Estimate|||||||2017-03-21|2017-03-23|Actual|August 2008|Actual|2008-08-31|April 2016|2016-04-30|December 18, 2014|Actual|2014-12-18|December 18, 2014|Actual|2014-12-18||Interventional|||Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery|Phase I Trial of the Combination of Dasatinib and Lapatinib|Completed||Phase 1|27|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:13:37.536185|2018-06-01 02:13:37.536185
NCT00662623|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2016-05-12|2008-04-16|2008-04-21|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2008||2008-04-30|May 2016|2016-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Enabling Sleep Apnea Patient-Centered Care Via an Internet Intervention|Enabling Sleep Apnea Patient-Centered Care Via an Internet Intervention|Completed||Phase 2/Phase 3|200|Anticipated|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-06-01 02:13:37.607219|2018-06-01 02:13:37.607219
NCT00662610|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2011-06-16|2008-04-16|2008-04-21|Estimate|||||||2011-06-16|2011-06-17|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|HCT3012-X-111||A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure|A 12-Week, Phase 1, Multicenter, Double-Blind, Randomized, Dose Ranging, Forced Titration, Naproxen-Controlled, Parallel-Group, Pharmacodynamic Study, to Assess the Effects Different Doses of Naproxcinod and Naproxen on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension|Completed||Phase 1|120|Anticipated|NicOx||2|||f||||t||||||||||2018-06-01 02:13:37.669415|2018-06-01 02:13:37.669415
NCT00662597|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17||2012-05-01|2012-05-03|2008-04-17|2008-04-21|Estimate||||2012-05-01|2012-05-03|Estimate|2012-05-03|2012-05-08|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|ATRACT-1||ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer|A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|1285|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:13:37.956568|2018-06-01 02:13:37.956568
NCT00662389|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2009-07-22||2009-07-22|2008-04-17|2008-04-21|Estimate|2009-07-22|2009-08-28|Estimate||||2009-07-22|2009-08-28|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Application of the Apsara Thermal Wand System|TP-1013 Pilot 1: Application of the Apsara Thermal Wand System|Completed||Early Phase 1|4|Actual|Apsara Medical Corporation||1|||f||||||||||||||2018-06-01 02:13:41.189881|2018-06-01 02:13:41.189881
NCT00662584|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-08-17|2008-04-17|2008-04-21|Estimate|||||||2016-08-17|2016-08-19|Estimate|August 2006||2006-08-31|August 2016|2016-08-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD)|The Efficacy of Functional Magnetic Resonance Imaging (fMRI) Guided Low Frequency Repetitive Magnetic Transcranial Stimulation (rTMS) Therapy on Symptoms of Generalized Anxiety Disorder (GAD)|Completed||Phase 3|10|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-06-01 02:13:38.484675|2018-06-01 02:13:38.484675
NCT00662571|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2013-03-20|2008-04-17|2008-04-21|Estimate|||||||2013-03-20|2013-03-22|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|ACAM||Acamprosate: Genes Associated With Response|A Probe Study of Acamprosate: Genes Associated With Response|Completed|||485|Actual|Mayo Clinic|||1||f||||t||||||Samples With DNA|"~     Samples obtained from study Developing a DNA Repository for Genomic Studies of Addiction: A~     Pilot Study~   "|||2018-06-01 02:13:38.563571|2018-06-01 02:13:38.563571
NCT00662558|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2009-09-10||2009-10-21|2008-04-17|2008-04-21|Estimate|2009-10-21|2009-11-23|Estimate||||2009-10-21|2009-11-23|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain|A Six Week Double-Blind, Randomized, Multicenter Comparison Study Of The Analgesic Effectiveness Of Celecoxib 200 Mg BID Compared To Tramadol Hydrochloride 50 Mg QID In Subjects With Chronic Low Back Pain|Completed||Phase 3|802|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:13:38.708705|2018-06-01 02:13:38.708705
NCT00662545|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2013-05-14||2013-05-17|2008-04-17|2008-04-21|Estimate|2013-05-15|2013-05-16|Estimate||||2013-05-17|2013-05-27|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection|Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection|Completed||Phase 4|10|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:13:39.474365|2018-06-01 02:13:39.474365
NCT00662532|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2010-04-27||2011-12-06|2008-04-17|2008-04-21|Estimate|2010-04-30|2010-05-27|Estimate||||2011-12-06|2011-12-12|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Antibiotic Study for Dental Implants|Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects With Peri-Implantitis|Completed||Phase 3|44|Actual|OraPharma||2|||f||||f||||||||||2018-06-01 02:13:39.718273|2018-06-01 02:13:39.718273
NCT00662519|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2015-04-08|2008-04-16|2008-04-21|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Neulasta in Type 1 Diabetes|Short Course of Pegylated GCSF (Neulasta®) as Immunomodulatory Therapy for Type 1 Diabetes|Completed||Phase 1|21|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 02:13:40.108608|2018-06-01 02:13:40.108608
NCT00662506|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18||2017-09-15|2017-09-15|2008-04-18|2008-04-21|Estimate||||2017-09-15|2017-09-21|Actual|2017-09-15|2017-09-21|Actual|April 2008||2008-04-30|September 2017|2017-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma|A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs|Completed||Phase 1/Phase 2|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:13:40.252708|2018-06-01 02:13:40.252708
NCT00662493|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-18|2008-04-18|2008-04-21|Estimate|||||||2008-04-18|2008-04-21|Estimate|March 2003||2003-03-31|April 2008|2008-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Comparison of Two Exercise Programs on Knee Motor Control|The Effect of Specific Versus Generalised Quadriceps Exercise on Neural Control of the Vasti|Completed||Phase 2|60|Actual|University of Melbourne||1|||f||||f||||||||||2018-06-01 02:13:40.398963|2018-06-01 02:13:40.398963
NCT00662480|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2016-02-24|2008-04-15|2008-04-21|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2008||2008-09-30|February 2009|2009-02-28|December 2023|Anticipated|2023-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark|Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark|Recruiting||Phase 4|40000|Anticipated|Central Jutland Regional Hospital||2|||f||||t||||||||||2018-06-01 02:13:40.528705|2018-06-01 02:13:40.528705
NCT00662467|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-04-18|2008-04-18|2008-04-21|Estimate|||||||2008-04-18|2008-04-21|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Warfarin After Anterior ST-Elevation Myocardial Infarction|Warfarin After Anterior ST-Elevation Myocardial Infarction|Completed||N/A|20|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 02:13:40.638618|2018-06-01 02:13:40.638618
NCT00662454|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2011-08-03|2008-04-16|2008-04-21|Estimate|||||||2011-08-03|2011-08-04|Estimate|January 2006||2006-01-31|August 2011|2011-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Oral Contraceptive Efficacy and Body Weight|Oral Contraceptive Efficacy and Body Weight: Does Obesity Affect the Risk of Contraceptive Failure?|Completed||Phase 4|120|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:13:40.754051|2018-06-01 02:13:40.754051
NCT00662441|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2009-06-19|2008-04-18|2008-04-21|Estimate|||||||2009-06-19|2009-06-22|Estimate|September 2003||2003-09-30|June 2009|2009-06-30|June 2004|Actual|2004-06-30|||||Interventional|||Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction|Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals|Completed||Phase 4|102|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:13:40.846803|2018-06-01 02:13:40.846803
NCT00662428|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-06-20|2008-04-15|2008-04-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|May 2008||2008-05-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|September 2010|Actual|2010-09-30||Interventional|INCA||Increasing Cost-effectiveness of Inpatient Treatment of Affective Disorders|Evaluation of a Guideline-based Net Care Intervention to Reduce the Duration of Inpatient Depression Treatment|Completed||N/A|202|Actual|University Hospital Freiburg||2|||f||||||||||||||2018-06-01 02:13:40.904518|2018-06-01 02:13:40.904518
NCT00662415|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-04-14|2008-04-14|2008-04-21|Estimate|||||||2008-04-14|2008-04-21|Estimate|February 2008||2008-02-29|April 2008|2008-04-30|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Examining Brain Changes Using Functional Magnetic Resonance Imaging (fMRI) in Amputees With Phantom Limb Pain Following Mirror Therapy|Study Using Functional MRI to Examine Changes in the Brain in Unilateral Lower Limb Amputees Treated With Mirror Therapy for Phantom Limb Pain.|Unknown status|Recruiting|N/A|42|Anticipated|Walter Reed Army Medical Center||2|||f||||f||||||||||2018-06-01 02:13:40.996423|2018-06-01 02:13:40.996423
NCT00662376|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-12-05|2008-04-18|2008-04-21|Estimate|||||||2008-12-05|2008-12-08|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study on Safety, Tolerance and Metabolic Effects of a Nutritional Supplement, Given as a Drink Before Gallbladder Surgery|Safety, Tolerance and Metabolic Effects of Using a Preoperative Oral Nutritional Supplement (PreOP Booster) in Gastrointestinal Surgery|Completed||N/A|40|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 02:13:41.422066|2018-06-01 02:13:41.422066
NCT00662363|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2012-10-23||2013-02-27|2008-04-17|2008-04-21|Estimate|2013-01-17|2013-02-21|Estimate||||2013-02-27|2013-03-06|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation|Lubiprostone (Amitiza®) Compared to Standard Care in the Treatment of Postoperative Opioid-induced Constipation in Inpatient Rehabilitation Patients Following Orthopedic Procedures|Completed||N/A|64|Actual|Shirley Ryan AbilityLab|Additional laxatives were frequently required for symptom control|2|||f||||f||||||||||2018-06-01 02:13:42.533069|2018-06-01 02:13:42.533069
NCT00662350|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2010-02-03|2008-04-17|2008-04-21|Estimate|||||||2010-02-03|2010-02-04|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|WT-DK-TMW08||Temperature Mapping of the Prostate With the Wallterm™ System|Temperature Mapping of the Prostate With the Wallterm™ System|Completed|||6|Actual|Pnn Medical A/S|||1||f||||f||||||||||2018-06-01 02:13:42.938768|2018-06-01 02:13:42.938768
NCT00662337|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2011-09-07|2008-04-18|2008-04-21|Estimate|||||||2011-09-07|2011-09-08|Estimate|October 2006||2006-10-31|September 2011|2011-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride|A Randomized, Two-Way Crossover Evaluation of the Bioequivalence Between Two Oral Formulations of Diphenhydramine: ULTRATAB Tablet Versus KAPSEALS Capsule|Completed||Phase 1|36|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 02:13:43.081709|2018-06-01 02:13:43.081709
NCT00662324|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2013-05-29|2008-04-18|2008-04-21|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Development of a Clinical Trial Specific Question Prompt List|Development of a Clinical Trial Specific Question Prompt List|Completed|||67|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 02:13:43.168977|2018-06-01 02:13:43.168977
NCT00662311|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2017-03-28||2017-05-16|2008-04-18|2008-04-21|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|March 2008||2008-03-31|May 2017|2017-05-31|September 2011|Actual|2011-09-30|January 2010|Actual|2010-01-31||Interventional|||Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery|Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined With Paclitaxel and Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin|Terminated||Phase 1/Phase 2|5|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:13:43.279098|2018-06-01 02:13:43.279098
NCT00662298|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2015-03-25|2008-04-18|2008-04-21|Estimate|||||||2015-03-25|2015-03-26|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Prednisolone Pharmacokinetics in Severe Asthma|The Pharmacokinetics and Anti-inflammatory Effects of Prednisolone in Severe Asthma|Completed||Phase 4|5|Actual|Imperial College London||1|||f||||f||||||||||2018-06-01 02:13:44.56792|2018-06-01 02:13:44.56792
NCT00662285|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-18|2008-04-18|2008-04-21|Estimate|||||||2008-04-18|2008-04-21|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2009|Anticipated|2009-04-30|April 2008|Anticipated|2008-04-30||Interventional|||Description of Iron Status in Blood Donors|Description of Iron Status in Blood Donors|Unknown status|Enrolling by invitation|N/A|400|Anticipated|Haukeland University Hospital||1|||f||||t||||||||||2018-06-01 02:13:44.65711|2018-06-01 02:13:44.65711
NCT00662272|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2010-03-15|2008-04-17|2008-04-21|Estimate|||||||2010-03-15|2010-03-17|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|H-100-001||Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant|Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Fluzone® Inactivated Trivalent Influenza Virus Vaccine Administered With Ascending Doses of JVRS-100 Adjuvant|Completed||Phase 1|128|Actual|Colby Pharmaceutical Company||3|||f||||t||||||||||2018-06-01 02:13:44.832186|2018-06-01 02:13:44.832186
NCT00662259|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2009-05-21|2008-04-18|2008-04-21|Estimate|||||||2009-05-21|2009-05-22|Estimate|April 2008||2008-04-30|May 2009|2009-05-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder|Randomized, Double-Blind, Placebo-Controlled Study of a Benzodiazepine vs Placebo on Functional Magnetic Resonance Imaging (fMRI) of the Brain, and on Behavioral/Clinical Measures in Patients With Generalized Anxiety Disorder|Unknown status|Recruiting|Phase 4|36|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 02:13:44.953367|2018-06-01 02:13:44.953367
NCT00662246|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-04-02|2008-04-17|2008-04-21|Estimate|||||||2012-04-02|2012-04-03|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma|A Phase I Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma|Completed||Phase 1|24|Actual|National Cancer Center, Korea||1|||f||||||||||||||2018-06-01 02:13:45.082827|2018-06-01 02:13:45.082827
NCT00662233|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-05-23|2008-04-18|2008-04-21|Estimate|||||||2017-05-23|2017-05-25|Actual|October 1991|Actual|1991-10-31|April 2016|2016-04-30|October 21, 2013|Actual|2013-10-21|October 21, 2013|Actual|2013-10-21||Interventional|||Combination Chemotherapy in Treating Patients With Sarcoma|A Pilot Study for Soft Tissue Sarcoma|Completed||N/A|28|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:13:45.165099|2018-06-01 02:13:45.165099
NCT00662220|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2014-07-11|2008-04-17|2008-04-21|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|VIRID||High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4|High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4|Terminated||Phase 3|110|Actual|Foundation for Liver Research||2||"Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study~   had to be terminated."|f||||t||||||||||2018-06-01 02:13:45.384088|2018-06-01 02:13:45.384088
NCT00662207|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2014-11-04||2014-11-04|2008-04-14|2008-04-21|Estimate|2014-11-04|2014-11-05|Estimate||||2014-11-04|2014-11-05|Estimate|October 2008||2008-10-31|November 2014|2014-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||baseline anal pressure|Two Devices for Reflex Voiding Following Spinal Cord Injury|Two Devices for Reflex Voiding Following SCI: Urodynamic Evaluation|Completed||Phase 1|3|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 02:13:45.547937|2018-06-01 02:13:45.547937
NCT00662194|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2014-03-06|2008-04-18|2008-04-21|Estimate|||||||2014-03-06|2014-03-10|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Observational|||Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)|A Study of Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C or Hepatitis B|Unknown status|Recruiting||40|Anticipated|Bayside Health|||8||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-06-01 02:13:45.784419|2018-06-01 02:13:45.784419
NCT00662181|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-18|2008-04-18|2008-04-21|Estimate|||||||2008-04-18|2008-04-21|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|January 2009|Anticipated|2009-01-31|October 2008|Anticipated|2008-10-31||Observational|||Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone|Follow-up on the HIGH: Low Study - the Longterm Effect of Growth Hormone|Unknown status|Not yet recruiting||46|Anticipated|Hvidovre University Hospital|||1||f||||t||||||||||2018-06-01 02:13:45.883353|2018-06-01 02:13:45.883353
NCT00662168|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-04-17|2008-04-17|2008-04-21|Estimate|||||||2008-04-17|2008-04-21|Estimate|January 2008||2008-01-31|April 2008|2008-04-30|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Observational|||An Investigation of Small Intestinal Carcinoid Carcinoma in Families|An Investigation of Eight Reported Cases of Small Intestinal Carcinoid Carcinoma in Multiple Family Members|Unknown status|Recruiting||8|Anticipated|Rutgers University|||1||f||||f||||||||||2018-06-01 02:13:45.983156|2018-06-01 02:13:45.983156
NCT00662155|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2016-12-07||2017-07-31|2008-04-17|2008-04-21|Estimate|2017-07-31|2017-08-07|Actual||||2017-07-31|2017-08-07|Actual|July 2006||2006-07-31|July 2017|2017-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ADER|Analyses were only conducted among participants who were compliant with their medication regimens during Phase 3.|The Role of Partial Reinforcement in the Long Term Management of Insomnia|The Role of Partial Reinforcement in the Long Term Management of Insomnia|Completed||N/A|129|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 02:13:46.09609|2018-06-01 02:13:46.09609
NCT00662142|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2013-05-15|2008-04-17|2008-04-21|Estimate|||||||2013-05-15|2013-05-17|Estimate|January 2006||2006-01-31|May 2013|2013-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function|Effect of 8-Week Dietary DHA Supplementation on Cerebral Blood Flow and Metabolic Function|Completed||Phase 3|30|Actual|University of Cincinnati||1|||f||||||||||||||2018-06-01 02:13:46.431053|2018-06-01 02:13:46.431053
NCT00662129|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2017-01-13||2017-03-06|2008-04-18|2008-04-21|Estimate|2017-03-06|2017-04-17|Actual||||2017-03-06|2017-04-17|Actual|November 2008||2008-11-30|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2010|Actual|2010-08-31||Interventional||One patient had a major violation (sequence of drugs was incorrect on Day 8 of Cycle 1), one patient canceled treatment prior to beginning treatment, and one patient was ineligible. The ineligible patient was included in the final analysis, whereas the two patients were excluded.|Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Albumin-Bound Paclitaxel in Combination With Gemcitabine and Bevacizumab in Patients With Metastatic Breast Cancer|Completed||Phase 2|50|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:13:46.554555|2018-06-01 02:13:46.554555
NCT00662116|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2009-01-29|2008-04-17|2008-04-21|Estimate|||||||2009-01-29|2009-01-30|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|BREAK-DHF-I||Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure|Terminated||Phase 2|160|Anticipated|Synvista Therapeutics, Inc||2||Study has been terminated early due to financial constraints.|f||||t||||||||||2018-06-01 02:13:47.161683|2018-06-01 02:13:47.161683
NCT00662103|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2015-10-13|2008-04-18|2008-04-21|Estimate|||||||2015-10-13|2015-10-15|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Aerobic Exercise, Resistance Exercise, or Flexibility and Relaxation Training in Inactive Older Female Breast Cancer Survivors|Comparison of Aerobic and Resistance Exercise in Older Breast Cancer Survivors|Completed||N/A|115|Actual|OHSU Knight Cancer Institute||3|||f||||||||||||||2018-06-01 02:13:47.300302|2018-06-01 02:13:47.300302
NCT00662090|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2017-05-02|2008-04-18|2008-04-21|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2006||2006-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EWOG MDS 2006||Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood|Prospective Non-randomized Multi-center Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood|Recruiting|||260|Anticipated|University Hospital Freiburg|||||f||||f||||||Samples With DNA|"~     At diagnosis, prior to HSCT and at relapse material form peripheral blood and bone marrow~     will be retrieved and stored for research purposes. If there are other diagnostic bone marrow~     examinations at other time points (prior to HSCT), the material will be handled the same way.~      The following material will be retrieved:~        -  8 smears from PB~        -  8 smears from BM~        -  at least 5 ml of heparinized PB~        -  at least 5 ml of heparinized BM~   "|||2018-06-01 02:13:47.403221|2018-06-01 02:13:47.403221
NCT00662077|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-07-31|2008-04-18|2008-04-21|Estimate|||||||2008-07-31|2008-08-01|Estimate||||July 2008|2008-07-31||||||||Interventional|||Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort|Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort|Suspended||Phase 4|65|Anticipated|Germans Trias i Pujol Hospital||2||Financial difficulties|f||||f||||||||||2018-06-01 02:13:47.47751|2018-06-01 02:13:47.47751
NCT00662064|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-06-19|2008-04-17|2008-04-21|Estimate|||||||2008-06-19|2008-06-20|Estimate|February 2002||2002-02-28|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Pharmacology and Physiology of the Lower Urinary Tract|Pharmacology and Physiology of the Lower Urinary Tract|Unknown status|Recruiting||200|Anticipated|University College London Hospitals|||2||f||||f||||||Samples Without DNA|"~     bladder biopsies from patients with lower urinary tract dysfunction and from healthy controls~   "|||2018-06-01 02:13:47.558512|2018-06-01 02:13:47.558512
NCT00662051|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2013-08-07|2008-04-15|2008-04-21|Estimate|||||||2013-08-07|2013-08-09|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Oral Contraceptives and Asthma Control|Oral Contraceptives and Asthma Control|Withdrawn|||0|Actual|University of Kentucky|||2||f||||f||||||||||2018-06-01 02:13:47.636174|2018-06-01 02:13:47.636174
NCT00661232|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-16|2008-04-16|2008-04-18|Estimate|||||||2008-04-16|2008-04-18|Estimate|August 2003||2003-08-31|February 2006|2006-02-28||||October 2008|Anticipated|2008-10-31||Observational|||Multicenter Myocardial Viability Trial|An International, Multicenter Trial Assessing Myocardial Viability With Contrast - Enhanced Magnetic Resonance Imaging|Unknown status|Active, not recruiting||235|Actual|CHI St. Luke's Health, Texas|||||f||||f||||||||||2018-06-01 02:14:09.816392|2018-06-01 02:14:09.816392
NCT00662038|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2017-02-09||2017-02-09|2008-04-18|2008-04-21|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|August 2008||2008-08-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PIPF-012|All treated participants|Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 3|1058|Actual|Genentech, Inc.||1|||f||||f||||||||||2018-06-01 02:13:47.76625|2018-06-01 02:13:47.76625
NCT00662025|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2010-09-20||2013-05-22|2008-04-17|2008-04-21|Estimate|2010-09-20|2010-10-13|Estimate||||2013-05-22|2013-05-27|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|December 2009|Actual|2009-12-31||Interventional|||Study Of Sunitinib With Capecitabine In Breast Cancer|A Phase II Study Of Sunitinib Malate In Combination With Capecitabine In Patients With Advanced Or Metastatic Breast Cancer|Completed||Phase 2|63|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 02:13:48.576691|2018-06-01 02:13:48.576691
NCT00662012|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2016-09-28||2017-01-18|2008-04-18|2008-04-21|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|June 2002||2002-06-30|November 2016|2016-11-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional||Intent to treat, evaluable, and safety populations included all patients who received at least 1 dose of SSG. Data were displayed by regimen and overall for patients with CL.|Sodium Stibogluconate Treatment of Leishmaniasis|Sodium Stibogluconate Treatment of Leishmaniasis|Completed||Phase 2|414|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||Yes|Walter Reed Army Medical Center|2018-06-01 02:13:49.17852|2018-06-01 02:13:49.17852
NCT00661999|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|2011-02-14||2011-05-13|2008-04-18|2008-04-21|Estimate|2011-03-15|2011-04-18|Estimate||||2011-05-13|2011-05-17|Estimate|January 2006||2006-01-31|May 2011|2011-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer|A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia|Completed||Phase 3|502|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 02:13:49.658814|2018-06-01 02:13:49.658814
NCT00661986|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2010-02-01|2008-04-17|2008-04-21|Estimate|||||||2010-02-01|2010-02-02|Estimate|February 2008||2008-02-29|January 2010|2010-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients|Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients|Completed||Phase 4|102|Actual|University of Leipzig||2|||f||||f||||||||||2018-06-01 02:13:51.018003|2018-06-01 02:13:51.018003
NCT00661973|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2015-06-03|2008-04-18|2008-04-21|Estimate|||||||2015-06-03|2015-06-04|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|March 2011|Anticipated|2011-03-31|December 2010|Anticipated|2010-12-31||Interventional|||Inhaled Corticosteroids on Airway Smooth Muscle in Asthma|The Effect of Inhaled Corticosteroids (ICS) on Airway Smooth Muscle in Asthma|Withdrawn||Phase 4|0|Actual|Imperial College London||||The study was withdrawn for administrative reasons|f||||f||||||||||2018-06-01 02:13:51.087124|2018-06-01 02:13:51.087124
NCT00661960|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2013-01-18||2017-05-24|2008-04-17|2008-04-21|Estimate|2017-01-11|2017-01-16|Estimate||||2017-05-24|2017-05-30|Actual|March 2008||2008-03-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|September 2010|Actual|2010-09-30||Interventional|||Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy|A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy|Completed||N/A|25|Actual|University of California, Davis|Limitations of the study include small numbers of subjects over all - Several subjects dropped out due to moving out of the region and lost to follow up.|3|||f||||f||||||||||2018-06-01 02:13:51.163831|2018-06-01 02:13:51.163831
NCT00661947|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2012-02-14|2008-04-17|2008-04-21|Estimate|||||||2012-02-14|2012-02-16|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Pharmacokinetics and Pharmacodynamics of Fructose|Pharmacokinetics and Pharmacodynamics of Fructose Following Soft Drink Consumption: Sucrose vs High Fructose Corn Syrup|Completed|||40|Actual|University of Florida|||1||f||||t||||||Samples With DNA|"~     DNA, whole blood, serum, plasma, and urine~   "|||2018-06-01 02:13:51.452826|2018-06-01 02:13:51.452826
NCT00661934|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-07-30|2008-04-18|2008-04-21|Estimate|||||||2008-07-30|2008-07-31|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Observational|||Recording of Heart Signals From the Chest Wall|Recording of Heart Signals From the Chest Wall|Unknown status|Recruiting||200|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-06-01 02:13:51.527594|2018-06-01 02:13:51.527594
NCT00661921|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2009-02-05|2008-04-17|2008-04-21|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|October 2009|Anticipated|2009-10-31|June 2009|Anticipated|2009-06-30||Interventional|||A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus|A Mutiple Dose, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous AMG 108 in Patients With Type 2 Diabetes Mellitus|Withdrawn||Phase 2|200|Anticipated|Amgen||4||Program Development discontinued|f||||||||||||||2018-06-01 02:13:51.597758|2018-06-01 02:13:51.597758
NCT00661908|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-16|2008-04-16|2008-04-21|Estimate|||||||2008-04-16|2008-04-21|Estimate|March 2004||2004-03-31|April 2008|2008-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Diabetes-Related Discrimination at Workplace and by Insurances|Discrimination of Insulin-Treated Diabetic Subjects at the Workplace and by Insurances|Completed|||509|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-06-01 02:13:51.665327|2018-06-01 02:13:51.665327
NCT00661895|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-08-04||2012-11-06|2008-04-17|2008-04-21|Estimate|2012-11-06|2012-12-04|Estimate||||2012-11-06|2012-12-04|Estimate|August 2005||2005-08-31|November 2012|2012-11-30|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|BEAT||Black Education and Treatment of Hypertension (BEAT HTN)|Black Education and Treatment of Hypertension (BEAT HTN)|Completed||Phase 4|99|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 02:13:51.731382|2018-06-01 02:13:51.731382
NCT00661882|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-18|||2017-05-09|2008-04-18|2008-04-21|Estimate|||||||2017-05-09|2017-05-11|Actual|February 2003||2003-02-28|May 2017|2017-05-31|September 9, 2013|Actual|2013-09-09|September 9, 2013|Actual|2013-09-09||Observational|||Pancreatic Cancer Collaborative Registry|Integrated Cancer Repository for Cancer Research (iCaRe2)- Subproject: Pancreatic Cancer Collaborative Registry|Completed|||379|Actual|University of Nebraska|||||f||||f|f|f||||Samples With DNA|"~     Questionnaire Blood: 30ml Access to leftover tissue: release a portion of leftover tissue~     collected and saved from surgery/biopsy.~   "|Yes|Request for data and/or specimen will need to be approved by the center's PI.|2018-06-01 02:13:51.988255|2018-06-01 02:13:51.988255
NCT00659906|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2015-05-26|2008-04-11|2008-04-17|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Optimizing Body Composition & Health After Breast Cancer|Optimizing Body Composition & Health After Breast Cancer|Completed||N/A|71|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 02:14:38.085704|2018-06-01 02:14:38.085704
NCT00661869|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2010-08-06|2008-04-18|2008-04-21|Estimate|||||||2010-08-06|2010-08-09|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|January 2008|Actual|2008-01-31|September 2007|Actual|2007-09-30||Interventional|Wellness||Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness|Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness|Completed||N/A|295|Actual|Manhattan Psychiatric Center||1|||f||||t||||||||||2018-06-01 02:13:52.074167|2018-06-01 02:13:52.074167
NCT00661856|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2008-04-17|2008-04-17|2008-04-21|Estimate|||||||2008-04-17|2008-04-21|Estimate|January 2001||2001-01-31|April 2008|2008-04-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|SoyPTI||Effect of Soy Isoflavones on Bone Mineral Density and Physical Performance Indices|The Effect of Increased Soy Protein Intake on Bone Metabolism|Completed||N/A|203|Actual|Creighton University||3|||f||||t||||||||||2018-06-01 02:13:52.144075|2018-06-01 02:13:52.144075
NCT00661843|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2010-10-04|2008-04-16|2008-04-18|Estimate|||||||2010-10-04|2010-10-05|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||A Study of Yoga for Treating Geriatric Insomnia|A Mixed Design, With Wait List Control Crossover to Intervention, Clinical Trial of Integrated Yoga Style Practice Intervention for Improving Sleep and Quality of Life in the Elderly Population|Completed||N/A|74|Actual|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-06-01 02:13:52.291428|2018-06-01 02:13:52.291428
NCT00661830|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2012-08-27||2013-09-18|2008-04-15|2008-04-18|Estimate|2013-09-18|2013-11-21|Estimate||||2013-09-18|2013-11-21|Estimate|May 2008||2008-05-31|September 2013|2013-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)|A Randomized, Double-blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract|Completed||Phase 2|103|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-06-01 02:13:52.428353|2018-06-01 02:13:52.428353
NCT00661817|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2012-03-03|2008-04-16|2008-04-18|Estimate|||||||2012-03-03|2012-03-06|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|BFBW||Evaluating a Blood Pressure Reduction and Weight Loss Program in a Low Income, Ethnically Diverse Population (The Be Fit, Be Well [BFBW] Study)|Integrated Weight Loss Technologies for Weight and Blood Pressure Control in Urban Clinics|Completed||N/A|365|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:13:53.298579|2018-06-01 02:13:53.298579
NCT00661804|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2011-11-09|2008-04-16|2008-04-18|Estimate|||||||2011-11-09|2011-11-11|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Observational|||Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study|A Longitudinal Cohort Study of Patients With Thalassemia in the Thalassemia Clinical Research Network|Completed|||416|Actual|New England Research Institutes|||2||f||||t||||||Samples With DNA|"~     DNA and frozen plasma genetic biorepository~   "|||2018-06-01 02:13:53.375127|2018-06-01 02:13:53.375127
NCT00661791|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-17|2008-04-17|2008-04-18|Estimate|||||||2008-04-17|2008-04-18|Estimate|February 2003||2003-02-28|April 2008|2008-04-30|October 2007|Actual|2007-10-31|April 2007|Actual|2007-04-30||Interventional|||Effects of Massage Therapy and Kinesthetic Stimulation on Pre-Term Infants|Effects of Massage Therapy and Kinesthetic Stimulation on Pre-Term Infants|Completed||N/A|60|Actual|George Washington University||3|||f||||f||||||||||2018-06-01 02:13:53.451793|2018-06-01 02:13:53.451793
NCT00661778|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2014-05-27||2014-07-09|2008-04-17|2008-04-18|Estimate|2014-07-09|2014-07-10|Estimate||||2014-07-09|2014-07-10|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Intent-to-treat population: All enrolled participants who received at least 1 treatment.|A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer|An Open Label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Docetaxel and Cisplatin on Progression-free Survival in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer|Completed||Phase 2|50|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:13:53.526806|2018-06-01 02:13:53.526806
NCT00661765|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2009-04-22|2008-04-14|2008-04-18|Estimate|||||||2009-04-22|2009-04-23|Estimate|April 2008||2008-04-30|April 2009|2009-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.|A Phase I, Open-Label, Randomized, Single Dose, Cross Over Study to Estimate the Relative Bioavailability of a Varenicline (CP-526,555) Transdermal Delivery System to the Chantix Immediate Release Tablet Formulation in Adult Smokers|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:13:53.938761|2018-06-01 02:13:53.938761
NCT00661752|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-08-25|2008-04-17|2008-04-18|Estimate|||||||2008-08-25|2008-08-26|Estimate|May 2007||2007-05-31|August 2008|2008-08-31|January 2008|Actual|2008-01-31|August 2007|Actual|2007-08-31||Observational|||Protocol for Evaluation of Quarter-Time Cardiac Imaging: 5-Minutes Rest and 3-Minutes Stress Wide Beam Reconstruction (WBR) Versus Full-Time Filtered Back Projection (FBP)|Quarter-Time Myocardial Perfusion SPECT|Completed|||134|Actual|St. Luke's-Roosevelt Hospital Center|||4||f||||t||||||||||2018-06-01 02:13:54.109567|2018-06-01 02:13:54.109567
NCT00661739|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2011-08-31|2008-04-17|2008-04-18|Estimate|||||||2011-08-31|2011-09-02|Estimate|July 2005||2005-07-31|September 2010|2010-09-30|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|RiTa||A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer|A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer|Completed||Phase 1|38|Actual|German Breast Group||1|||f||||t||||||||||2018-06-01 02:13:54.195172|2018-06-01 02:13:54.195172
NCT00661726|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2012-05-01||2014-04-09|2008-04-16|2008-04-18|Estimate|2014-02-24|2014-04-08|Estimate||||2014-04-09|2014-04-25|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia|A Phase IIA Study of Subcutaneous 5-aza-2'- Deoxycytidine (Decitabine) in Patients With Thalassemia Intermedia|Completed||Phase 2|6|Actual|New England Research Institutes||1|||f||||t||||||||||2018-06-01 02:13:54.337271|2018-06-01 02:13:54.337271
NCT00661713|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2015-02-03||2015-10-07|2008-04-16|2008-04-18|Estimate|2015-10-07|2015-11-04|Estimate||||2015-10-07|2015-11-04|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules|A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged 11-17 Years According to Different Vaccination Schedules|Completed||Phase 2/Phase 3|1631|Actual|Novartis||8|||f||||||||||||||2018-06-01 02:13:54.993464|2018-06-01 02:13:54.993464
NCT00661700|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-11-17|2008-04-17|2008-04-18|Estimate|||||||2014-11-17|2014-11-18|Estimate|April 2003||2003-04-30|November 2014|2014-11-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||"A Double-blind Preferred Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction"|"A Double-blind Preferred Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction"|Completed||Phase 3|611|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:13:57.145596|2018-06-01 02:13:57.145596
NCT00661687|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2009-02-20||2011-12-07|2008-04-16|2008-04-18|Estimate|2010-09-27|2010-10-15|Estimate||||2011-12-07|2011-12-12|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Comparative Performance of PureVision Lens Designs|A Study to Evaluate the Product Performance of the Redesigned Bausch & Lomb PureVision® Contact Lens (Test) Compared to the Currently Marketed Bausch & Lomb PureVision® Contact Lens (Control) When Worn on an Extended Wear Basis.|Completed||Phase 3|206|Actual|Bausch & Lomb Incorporated|2 participants discontinued due to adverse events, not classified as serious. One subject in the test group developed corneal ulcer, one subject in the control group developed a central epithelial defect, both conditions resolved following treatment.|2|||f||||f||||||||||2018-06-01 02:13:57.24586|2018-06-01 02:13:57.24586
NCT00661674|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2016-02-08||2017-04-25|2008-04-17|2008-04-18|Estimate|2017-04-25|2017-06-05|Actual||||2017-04-25|2017-06-05|Actual|April 2008||2008-04-30|April 2017|2017-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||10 healthy male volunteers recruited from the San Francisco Bay Area. All study sessions took place at the Stanford University School of Medicine, Department of Anesthesia.|Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal|Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study|Completed||N/A|10|Actual|Stanford University|Results are not necessarily generalizable to patients with chronic opioid exposure.|6|||f||||f||||||||No||2018-06-01 02:13:57.563899|2018-06-01 02:13:57.563899
NCT00661661|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2015-02-17||2015-04-23|2008-04-15|2008-04-18|Estimate|2015-04-23|2015-05-12|Estimate||||2015-04-23|2015-05-12|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan|A Long-term, Open-label Study Of Cp-690,550 to Confirm The Safety Following Long Term Administration Of Cp-690,550 In The Treatment Of Rheumatoid Arthritis|Completed||Phase 3|487|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:13:57.968901|2018-06-01 02:13:57.968901
NCT00661648|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2009-01-28|2008-04-17|2008-04-18|Estimate|||||||2009-01-28|2009-01-29|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Interventional|||Effect of an Artificial Pancreas in Patients Undergoing Pancreatic Resection|Prevention for Surgical Site Infection After Pancreatic Resection|Unknown status|Recruiting|Phase 4|50|Anticipated|Kochi University||2|||f||||t||||||||||2018-06-01 02:14:01.432623|2018-06-01 02:14:01.432623
NCT00661635|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-04-21|2008-04-15|2008-04-18|Estimate|||||||2008-04-21|2008-04-23|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|July 2003|Actual|2003-07-31|||||Interventional|||A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain|A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Placebo in Patients for Treatment of Post-Surgical Pain From Laparoscopic Cholecystectomy Surgery|Completed||Phase 3|490|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:14:01.564704|2018-06-01 02:14:01.564704
NCT00661622|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2015-03-24||2016-10-19|2008-04-17|2008-04-18|Estimate|2015-05-15|2015-06-01|Estimate||||2016-10-19|2016-11-29|Estimate|October 2004||2004-10-31|October 2016|2016-10-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF|Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF)|Completed||Phase 2|53|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 02:14:01.809651|2018-06-01 02:14:01.809651
NCT00661609|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2010-07-19||2010-12-13|2008-04-17|2008-04-18|Estimate|2010-12-13|2011-01-12|Estimate||||2010-12-13|2011-01-12|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer|A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer|Completed||Phase 2|54|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 02:14:02.439927|2018-06-01 02:14:02.439927
NCT00661596|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-12-28|2008-04-17|2008-04-18|Estimate|||||||2014-12-28|2014-12-30|Estimate|May 2003||2003-05-31|December 2014|2014-12-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction|Multi-centre, Randomised, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy of Vardenafil and Its Influence on Self-esteem and Self-confidence in Patients With Erectile Dysfunction|Completed||Phase 3|129|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:14:02.949601|2018-06-01 02:14:02.949601
NCT00661583|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2016-07-01||2016-08-19|2008-04-17|2008-04-18|Estimate|2016-08-19|2016-10-13|Estimate||||2016-08-19|2016-10-13|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|OCTOPUS||Use of Ranibizumab With Mitomycin C During Trabeculectomy|Occlusion Prevention for Trabeculectomy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study)|Completed||Phase 1/Phase 2|30|Actual|University of Colorado, Denver||3|||f||||f||||||||No|"Subject medical information obtained by this study is confidential, and disclosure to third parties other than those noted below is prohibited.~Upon the subject's permission, medical information may be given to his/her personal physician or other appropriate medical personnel responsible for his/her welfare.~Data generated by this study will be available for inspection upon request by representatives of the U.S. FDA, national and local health authorities, the drug manufacturer and the IRB/EC, if appropriate."|2018-06-01 02:14:03.092029|2018-06-01 02:14:03.092029
NCT00661570|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2010-08-02||2017-01-30|2008-04-17|2008-04-18|Estimate|2010-10-13|2010-11-03|Estimate||||2017-01-30|2017-03-10|Actual|March 2008||2008-03-31|January 2017|2017-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis|Amendment on Phase I Trial NO7VEG 'Assessment of a Next Generation Indwelling Provox Voice Rehabilitation System (Vega)|Terminated||N/A|26|Actual|Atos Medical AB||1||Primary endpoint reached, slow accrual, leakage around|f||||f||||||||||2018-06-01 02:14:03.432881|2018-06-01 02:14:03.432881
NCT00659724|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2011-03-07||2017-04-04|2008-04-14|2008-04-16|Estimate|2011-05-27|2011-06-27|Estimate||||2017-04-04|2017-05-10|Actual|March 2008||2008-03-31|April 2017|2017-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer|The Gambro Polyflux HD-C4 Big Ease Of Use And Thrombogenicity Study|Completed|||33|Actual|Baxter Healthcare Corporation|||||f||||f||||||||||2018-06-01 02:14:40.425717|2018-06-01 02:14:40.425717
NCT00661557|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14||2009-09-03|2016-09-09|2008-04-15|2008-04-18|Estimate||||2009-09-03|2009-09-04|Estimate|2016-09-09|2016-09-23|Estimate|May 2008||2008-05-31|September 2016|2016-09-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects|Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 Administered in Healthy Subjects Either Previously Primed With Mencevax™ ACWY or naïve to Meningococcal Vaccination.|Completed||Phase 2|272|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:14:03.71728|2018-06-01 02:14:03.71728
NCT00661544|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2009-03-13||2013-02-26|2008-04-17|2008-04-18|Estimate|2009-05-21|2009-07-14|Estimate||||2013-02-26|2013-03-04|Estimate|March 2004||2004-03-31|February 2013|2013-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients|Phase I/II Study of the Combination of Arsenic Trioxide With Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|48|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:14:03.844824|2018-06-01 02:14:03.844824
NCT00661531|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2017-01-16||2017-03-15|2008-04-17|2008-04-18|Estimate|2017-01-16|2017-03-07|Actual||||2017-03-15|2017-04-12|Actual|April 2008||2008-04-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy|A Single Arm Phase II Study of Pharmacologic Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies|Terminated||Phase 2|11|Actual|Georgetown University||1||Poor accrual|f||||t||||||||||2018-06-01 02:14:04.050767|2018-06-01 02:14:04.050767
NCT00661518|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-14|2008-04-14|2008-04-18|Estimate|||||||2008-04-14|2008-04-18|Estimate|October 2007||2007-10-31|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|October 2008|Anticipated|2008-10-31||Observational|ASAP||PET/CT Imaging of Aneurysm Wall Inflammation|Imaging of Aneurysm Wall Inflammation Using Positron Emission Tomography.|Unknown status|Recruiting||35|Anticipated|Radboud University|||2||f||||f||||||||||2018-06-01 02:14:04.346389|2018-06-01 02:14:04.346389
NCT00661505|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2016-06-08||2017-11-02|2008-04-17|2008-04-18|Estimate|2016-06-08|2016-07-19|Estimate||||2017-11-02|2017-12-06|Actual|May 14, 2008|Actual|2008-05-14|November 2017|2017-11-30|June 22, 2010|Actual|2010-06-22|June 22, 2010|Actual|2010-06-22||Interventional||Baseline characteristics are presented for the safety population which included all participants who received at least one dose C.E.R.A. and underwent a safety follow-up, whether withdrawn prematurely or not.|A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia|A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Haemodialysis Patients With Chronic Renal Anaemia.|Completed||Phase 3|132|Actual|Hoffmann-La Roche|Low number of participants completed the study as per the protocol. Administration of iron (oral/IV) was as per discretion of individual centers; therefore, C.E.R.A. responses have been limited by iron levels too low for efficient erythropoiesis.|1|||f|||||f|f||||||||2018-06-01 02:14:04.439166|2018-06-01 02:14:04.439166
NCT00661492|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2013-07-31||2016-10-13|2008-04-14|2008-04-18|Estimate|2016-10-13|2016-12-09|Estimate||||2016-10-13|2016-12-09|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)|A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy|Completed||Phase 2|115|Actual|US Oncology Research||2|||f||||f||||||||||2018-06-01 02:14:05.13914|2018-06-01 02:14:05.13914
NCT00661479|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2013-03-13|2011-02-02|2013-03-13|2008-04-16|2008-04-18|Estimate|2013-03-13|2013-04-24|Estimate|2011-02-02|2011-02-09|Estimate|2013-03-13|2013-04-24|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa||Completed||Phase 1/Phase 2|21|Actual|Allergan||4|||f||||t||||||||||2018-06-01 02:14:06.083301|2018-06-01 02:14:06.083301
NCT00661466|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-09-12|2008-04-15|2008-04-18|Estimate|||||||2012-09-12|2012-09-13|Estimate|April 2008||2008-04-30|February 2011|2011-02-28|February 2010|Actual|2010-02-28|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery|A Phase II, Randomized, Single-dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx Bupivacaine Implant in Patients After Gastrointestinal Surgery|Terminated||Phase 2|7|Actual|Innocoll||2||Business decision|f||||f||||||||||2018-06-01 02:14:06.465106|2018-06-01 02:14:06.465106
NCT00661453|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2015-06-01||2015-06-01|2008-04-14|2008-04-18|Estimate|2015-06-01|2015-06-15|Estimate||||2015-06-01|2015-06-15|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I|Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)|Completed||Phase 1/Phase 2|40|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 02:14:06.544204|2018-06-01 02:14:06.544204
NCT00661440|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2009-11-25|2008-04-17|2008-04-18|Estimate|||||||2009-11-25|2009-11-26|Estimate|May 2008||2008-05-31|November 2009|2009-11-30||||||||Interventional|||Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus|Efficacy and Safety of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus: a Randomized, Double-blind, Placebo-controlled, Single Center, Proof of Concept Study Using a Two-period Cross-over Design|Completed||Phase 2|48|Anticipated|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 02:14:06.928613|2018-06-01 02:14:06.928613
NCT00661427|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2015-10-19||2017-12-11|2008-04-15|2008-04-18|Estimate|2015-10-19|2015-11-20|Estimate||||2017-12-11|2018-01-11|Actual|November 2007||2007-11-30|December 2017|2017-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer|A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m^2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer.|Completed||Phase 2|61|Actual|Memorial Sloan Kettering Cancer Center|For safety data please see adverse events|2|||f||||t||||||||||2018-06-01 02:14:07.025654|2018-06-01 02:14:07.025654
NCT00661414|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-01-27|2008-04-17|2008-04-18|Estimate|||||||2012-01-27|2012-01-31|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ASONEP||Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors|A Multi-Center, Open-Label, Single-Arm, Phase 1, Dose Escalation Study of ASONEP (Sonepcizumab/LT1009) Administered as a Single Agent Weekly to Subjects With Refractory Advanced Solid Tumors|Completed||Phase 1|37|Actual|Lpath, Inc.|||||f||||f||||||||||2018-06-01 02:14:07.432597|2018-06-01 02:14:07.432597
NCT00661401|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-15|2008-04-15|2008-04-18|Estimate|||||||2008-04-15|2008-04-18|Estimate|January 2002||2002-01-31|April 2008|2008-04-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin|Serum IgG Antibody to Streptococcus Pneumoniae, Haemophilus Influenzae Type b and Tetanus Toxoid in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin Infusions|Completed||N/A|5|Actual|Federal University of São Paulo|||||f||||t||||||||||2018-06-01 02:14:07.501003|2018-06-01 02:14:07.501003
NCT00661388|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2016-06-09||2016-07-28|2008-04-17|2008-04-18|Estimate|2016-06-09|2016-07-22|Estimate||||2016-07-28|2016-08-30|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Safety population included all participants who received at least one dose of the trial medication and underwent a safety follow-up, whether withdrawn prematurely or not.|A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Pre-dialysis Patients Not Currently Treated With ESA.|Completed||Phase 3|75|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:14:07.669908|2018-06-01 02:14:07.669908
NCT00661375|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-12-23|2008-04-17|2008-04-18|Estimate|||||||2014-12-23|2014-12-25|Estimate|November 2004||2004-11-30|December 2014|2014-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||BAY43-9006 Phase II Study for Renal Cell Carcinoma|Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma|Completed||Phase 2|131|Actual|Bayer||1|||f||||t||||||||||2018-06-01 02:14:08.09831|2018-06-01 02:14:08.09831
NCT00661362|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2010-09-20||2012-02-06|2008-04-17|2008-04-18|Estimate|2012-02-06|2012-03-08|Estimate||||2012-02-06|2012-03-08|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes|A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy|Completed||Phase 3|570|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:14:08.248974|2018-06-01 02:14:08.248974
NCT00661349|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2009-04-22|2008-04-15|2008-04-18|Estimate|||||||2009-04-22|2009-04-23|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients|Prospective, Open Label and Randomized Clinical Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients|Terminated||Phase 4|9|Actual|Germans Trias i Pujol Hospital||2||It has been impossible to achieve the number of patients defined by protocol|f||||f||||||||||2018-06-01 02:14:08.821683|2018-06-01 02:14:08.821683
NCT00661336|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|||2015-03-12|2008-04-17|2008-04-18|Estimate|||||||2015-03-12|2015-03-13|Estimate|April 2008||2008-04-30|April 2010|2010-04-30||||December 2009|Actual|2009-12-31||Interventional|||A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma|An Open-Label, Multicenter, Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic Buthionine Sulfoximine (BSO) in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma|Withdrawn||Phase 1|0|Actual|Duke University||||The study was withdrawn due to lack of patients.|||||||||||||||2018-06-01 02:14:08.914771|2018-06-01 02:14:08.914771
NCT00661323|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2016-06-22|2008-04-16|2008-04-18|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Evaluating a New Echocardiography Imaging Procedure for Evaluating Heart Function|Left Ventricular Strain Quantification From 4D Echocardiography|Completed|||1|Actual|Yale University|||2||f||||f||||||||||2018-06-01 02:14:08.997686|2018-06-01 02:14:08.997686
NCT00661310|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-12-04|2008-04-17|2008-04-18|Estimate|||||||2008-12-04|2008-12-05|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|June 2007|Actual|2007-06-30|June 2006|Actual|2006-06-30||Interventional|||Optimizing Drug-Therapy in Patients 80 Years and Older|Optimizing Drug-Therapy in Patients, 80 Years and Older, in Order to Reduce Drug-Related Morbidity and Usage of Secondary Care - a Randomized Controlled Trial|Completed||N/A|400|Actual|Uppsala University Hospital||2|||f||||f||||||||||2018-06-01 02:14:09.075743|2018-06-01 02:14:09.075743
NCT00661297|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-12-01|2008-04-17|2008-04-18|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2003||2003-06-30|December 2014|2014-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Study Evaluating the Efficacy, Safety, and Reliability of Vardenafil|A Randomised, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy, Safety, and Reliability of 10mg Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction|Completed||Phase 3|523|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:14:09.1507|2018-06-01 02:14:09.1507
NCT00661284|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-07-31|2008-04-17|2008-04-18|Estimate|||||||2012-07-31|2012-08-02|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|March 2009|Actual|2009-03-31||Observational|||A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)|A Study to Investigate the Duration of Maintained Efficacy in Patients With Rheumatoid Arthritis Who Had Treated With MRA|Completed|||189|Actual|Chugai Pharmaceutical|||1||f||||||||||||||2018-06-01 02:14:09.225381|2018-06-01 02:14:09.225381
NCT00661271|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-07-18|2008-04-15|2008-04-18|Estimate|||||||2012-07-18|2012-07-19|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Mindfulness-based Stress Reduction for Urban Youth|Mindfulness-based Stress Reduction for Urban Youth|Completed||Phase 1/Phase 2|60|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 02:14:09.362184|2018-06-01 02:14:09.362184
NCT00661258|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2013-04-19||2017-05-11|2008-04-15|2008-04-18|Estimate|2017-05-11|2017-05-15|Actual||||2017-05-11|2017-05-15|Actual|June 2006||2006-06-30|May 2017|2017-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|AFL||China Antiretroviral Treatment Adherence for Life|Antiretroviral Treatment Adherence for Life Pilot Study: Phases II and III|Completed||N/A|80|Actual|Boston University||2|||f||||f|f|f||||||No||2018-06-01 02:14:09.461401|2018-06-01 02:14:09.461401
NCT00661245|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2009-05-04|2008-04-15|2008-04-18|Estimate|||||||2009-05-04|2009-05-05|Estimate|July 2008||2008-07-31|May 2009|2009-05-31||||October 2010|Anticipated|2010-10-31||Interventional|TOGA®||Transoral Gastroplasty for the Treatment of Morbid Obesity||Unknown status|Active, not recruiting|Phase 3|275|Anticipated|Satiety, Inc.||2|||f||||t||||||||||2018-06-01 02:14:09.735632|2018-06-01 02:14:09.735632
NCT00661219|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-12-18|2008-04-17|2008-04-18|Estimate|||||||2014-12-18|2014-12-23|Estimate|December 2002||2002-12-31|December 2014|2014-12-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|DRIVER||Depression Related Improvement With Vardenafil for Erectile Response|A Randomized Double-blind Multi-center Parallel Group Three Month Study to Compare the Tolerability and Efficacy of Flexible Dose Vardenafil Versus Placebo in Men With Depression and Erectile Dysfunction.|Completed||Phase 3|280|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:14:09.892913|2018-06-01 02:14:09.892913
NCT00661206|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-10-08|2008-04-17|2008-04-18|Estimate|||||||2014-10-08|2014-10-09|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|ISAR-SAFE||Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting|Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent|Unknown status|Active, not recruiting|Phase 4|4005|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:14:10.041601|2018-06-01 02:14:10.041601
NCT00661193|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-17|2016-11-04||2018-01-31|2008-04-17|2008-04-18|Estimate|2016-11-04|2017-01-04|Estimate||||2018-01-31|2018-03-01|Actual|December 2008||2008-12-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)|Completed||Phase 2|59|Actual|Southwest Oncology Group||2|||f||||f||||||||||2018-06-01 02:14:10.213741|2018-06-01 02:14:10.213741
NCT00661180|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-12-18|2008-04-15|2008-04-18|Estimate|||||||2014-12-18|2014-12-23|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|ORACLE||Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec|Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib)|Completed||Phase 2|10|Actual|Bayer||1|||t||||||||||||||2018-06-01 02:14:10.996264|2018-06-01 02:14:10.996264
NCT00661167|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2012-01-16|2008-04-17|2008-04-18|Estimate|||||||2012-01-16|2012-01-18|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Phase II Study of ABI-007 for Gastric Cancer|Phase II Study of ABI-007 by Tri-weekly Schedule for Patients With Unresectable or Recurrent Gastric Cancer Refractory to 5-FU Containing Regimen.|Completed||Phase 2|56|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-06-01 02:14:11.068458|2018-06-01 02:14:11.068458
NCT00661154|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2012-08-08|2008-04-17|2008-04-18|Estimate|||||||2012-08-08|2012-08-10|Estimate|February 2008||2008-02-29|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Observational|||Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project|Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project|Completed|||7|Actual|Stanford University|||||f||||t||||||||||2018-06-01 02:14:11.147105|2018-06-01 02:14:11.147105
NCT00661141|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2013-05-22||2017-08-16|2008-04-17|2008-04-18|Estimate|2017-08-16|2017-09-15|Actual||||2017-08-16|2017-09-15|Actual|April 2008||2008-04-30|August 2017|2017-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism|A Phase IIa, Prospective, Randomized, Blinded, Intra-Subject Controlled, Single Dose, Dose Escalation Study of Antizol® for Mitigation of Acetaldehyde Related Toxicity in Human Subjects With Symptoms of Inborn Altered Ethanol Metabolism With Concomitant Ethanol Exposure|Completed||Phase 2|32|Actual|Horizon Pharma USA, Inc.||4|||f||||f||||||||||2018-06-01 02:14:11.296473|2018-06-01 02:14:11.296473
NCT00661128|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2017-04-17|2008-04-16|2008-04-18|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2007||2007-09-30|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|GenSCA||Evaluating the Genetic Factors That May Lead to Sudden Cardiac Arrest (The GenSCA Study)|Genomics of Sudden Cardiac Arrest|Enrolling by invitation|||8750|Anticipated|University of Washington|||4||f||||t||||||Samples With DNA|"~     De-identified white blood cells, red blood cells, plasma, and DNA~   "|||2018-06-01 02:14:13.464676|2018-06-01 02:14:13.464676
NCT00661115|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-12-15|2008-04-17|2008-04-18|Estimate|||||||2014-12-15|2014-12-16|Estimate|May 2003||2003-05-31|December 2014|2014-12-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction.|A Randomised, Double Blind, Placebo Controlled, Multi-center, Fixed Dose, Parallel Group Study to Investigate the Efficacy and Safety of Vardenafil (BAY 38-9456) in Men With Erectile Dysfunction .|Completed||Phase 3|173|Actual|Bayer||2|||f||||t||||||||||2018-06-01 02:14:13.570649|2018-06-01 02:14:13.570649
NCT00661102|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2016-11-01|2008-04-16|2008-04-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).|A Randomized, Open Label Study Comparing the Efficacy of Topical Corticosteroids or Bepantol in the Prophylaxis of Hand-foot Syndrome in Patients Receiving Oral Xeloda for Treatment of Metastatic Breast Cancer or Colorectal Cancer.|Completed||Phase 3|598|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 02:14:13.836142|2018-06-01 02:14:13.836142
NCT00661089|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2011-10-01||2017-10-17|2008-04-17|2008-04-18|Estimate|2012-01-03|2012-02-06|Estimate||||2017-10-17|2017-11-20|Actual|September 2003||2003-09-30|October 2017|2017-10-31|February 2010|Actual|2010-02-28|March 2009|Actual|2009-03-31||Interventional|||Randomized DB Controlled Trial of Botulinum Toxin A in Hemiplegic Shoulder Pain and Spasticity|"A Randomized Double-Blind Placebo-Controlled Trial of Botulinum Toxin Type A (BOTOX ) in the Treatment of Hemiplegic Shoulder Pain and Spasticity"|Completed||N/A|21|Actual|Shirley Ryan AbilityLab|Best and Worst pain collected, which may have limited the ability to detect overall pain. At the time of enrollment, subjects were on average very impaired by the Fugl-Meyer Scale measure, and pain on average had been present for several years.|2|||f||||f||||||||||2018-06-01 02:14:13.984003|2018-06-01 02:14:13.984003
NCT00661076|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2016-11-01|2008-04-17|2008-04-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2008||2008-08-31|November 2016|2016-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B|A Randomized, Open Label Study to Compare the Effect of Combination Treatment With PEGASYS + Adefovir Dipivoxil Versus PEGASYS Monotherapy on HBV-DNA and ALT Levels in Patients With HBeAg-negative, Chronic Hepatitis B.'|Completed||Phase 3|10|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 02:14:14.296403|2018-06-01 02:14:14.296403
NCT00661063|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-17|2008-04-17|2008-04-18|Estimate|||||||2008-04-17|2008-04-18|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Interventional|||Diabetic Neuropathy Topical Treatment|Diabetic Neuropathic Pain Topical Treatment- Comparative Study|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Irmandade da Santa Casa de Misericordia de Sao Paulo||4|||f||||t||||||||||2018-06-01 02:14:14.426034|2018-06-01 02:14:14.426034
NCT00661050|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2011-03-18|2008-04-17|2008-04-18|Estimate|||||||2011-03-18|2011-03-21|Estimate|April 2008||2008-04-30|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Treatment of Interstitial Cystitis/Painful Bladder Syndrome Using Alternative Techniques: Exercise, Meditation, Tai Chi|Exercise and Meditation: A Pilot Study of Alternative Techniques in the Treatment of Chronic Pelvic Pain Related to Painful Bladder Syndrome (PBS)/Interstitial Cystitis (IC) PI: Dr. Christopher Payne|Terminated|||0|Actual|Stanford University||||Terminated due to low enrollment.|f||||f||||||||||2018-06-01 02:14:14.548246|2018-06-01 02:14:14.548246
NCT00661037|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2017-02-20||2017-06-22|2008-04-17|2008-04-18|Estimate|2017-04-06|2017-06-20|Actual||||2017-06-22|2017-07-21|Actual|March 2008||2008-03-31|June 2017|2017-06-30|September 2011|Actual|2011-09-30|May 2011|Actual|2011-05-31||Observational|SAFE-ICD||SAFEty of Two Strategies of ICD Management at Implantation|SAFEty of Two Strategies of ICD Management at Implantation|Completed|||2120|Actual|Boston Scientific Corporation|||2||f||||t||||||||||2018-06-01 02:14:14.604208|2018-06-01 02:14:14.604208
NCT00661024|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-17|2008-04-17|2008-04-18|Estimate|||||||2008-04-17|2008-04-18|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|June 2007|Actual|2007-06-30||Interventional|||Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves in Thyroid Surgery|Randomized Clinical Trial Evaluating Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves in Thyroid Surgery|Completed||N/A|1000|Actual|Jagiellonian University||2|||f||||t||||||||||2018-06-01 02:14:14.840955|2018-06-01 02:14:14.840955
NCT00661011|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2015-02-11|2008-04-17|2008-04-18|Estimate|||||||2015-02-11|2015-02-12|Estimate|January 2007||2007-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy|A Phase II Study Assessing the Curative Effect of the Combination of Lobectomy Followed by Mediastinal Concomitant Radiochemotherapy in Patients With Locally Advanced Unresectable Stage III Non-small Cell Lung Cancer Responding to Induction Chemotherapy|Terminated||Phase 2|75|Actual|European Lung Cancer Working Party||1||The study was terminated due to too slow recruitment|f||||t||||||||||2018-06-01 02:14:15.023348|2018-06-01 02:14:15.023348
NCT00660998|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-12-10|2008-04-17|2008-04-18|Estimate|||||||2014-12-10|2014-12-11|Estimate|February 2003||2003-02-28|December 2014|2014-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes|A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction|Completed||Phase 4|318|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:14:15.093145|2018-06-01 02:14:15.093145
NCT00660985|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2009-10-15||2011-01-19|2008-04-15|2008-04-18|Estimate|2009-11-23|2009-12-29|Estimate||||2011-01-19|2011-01-21|Estimate|May 2008||2008-05-31|January 2011|2011-01-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%|A Pharmacokinetic Study to Compare the Systemic Exposure to Adapalene During Dermal Application of Either Differin® Gel, 0.3% (Adapalene 0.3%) or Differin® Gel, 0.1% (Adapalene 0.1%) for 30 Days in Subjects With Acne Vulgaris|Completed||Phase 4|51|Actual|Galderma||2|||f||||||||||||||2018-06-01 02:14:16.160556|2018-06-01 02:14:16.160556
NCT00660972|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2015-06-08|2008-04-16|2008-04-18|Estimate|||||||2015-06-08|2015-06-10|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|April 2010|Actual|2010-04-30|January 2009|Actual|2009-01-31||Interventional|||Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)|First-Phase Viral Decay Rates in Treatment-Naive Subjects Initiating Treatment With Raltegravir (RAL) and Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF): A Pilot Study|Completed||Phase 1|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 02:14:16.593698|2018-06-01 02:14:16.593698
NCT00660959|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15||2011-06-20|2011-06-20|2008-04-17|2008-04-18|Estimate||||2011-06-20|2011-06-28|Estimate|2011-06-20|2011-06-28|Estimate|April 2008||2008-04-30|November 2010|2010-11-30||||June 2010|Actual|2010-06-30||Interventional|||Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia|Completed||Phase 3|106|Actual|CardioKine Inc.||2|||f||||t||||||||||2018-06-01 02:14:16.756331|2018-06-01 02:14:16.756331
NCT00660946|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2008-04-16|2008-04-16|2008-04-17|Estimate|||||||2008-04-16|2008-04-17|Estimate|June 2005||2005-06-30|April 2008|2008-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Comparison of Point of Care to Lab INR in Dialysis Patients on Warfarin|Correlation of Point of Care INR to Laboratory INR in Hemodialysis Patients Taking Warfarin|Completed|||37|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 02:14:17.101335|2018-06-01 02:14:17.101335
NCT00660933|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-03-07|2008-04-14|2008-04-17|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia|Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia Randomized Trial|Completed||Phase 4|70|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:14:17.248113|2018-06-01 02:14:17.248113
NCT00660920|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2018-05-15|2008-04-16|2008-04-17|Estimate|||||||2018-05-15|2018-05-16|Actual|June 2008|Actual|2008-06-30|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies|A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies|Completed||Phase 1|81|Actual|Takeda||1|||t||||f||||||||||2018-06-01 02:14:17.469998|2018-06-01 02:14:17.469998
NCT00660907|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2013-01-21||2015-03-10|2008-04-15|2008-04-17|Estimate|2013-07-19|2013-08-23|Estimate||||2015-03-10|2015-03-30|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|December 2009|Actual|2009-12-31||Interventional||Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during double-blind treatment period.|Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients|A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.|Completed||Phase 3|1217|Actual|AstraZeneca|For participants who did not complete 52 weeks LOCF (last observation carried forward) was used.|2|||f||||f||||||||||2018-06-01 02:14:17.622691|2018-06-01 02:14:17.622691
NCT00660894|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2016-08-02|2008-04-16|2008-04-17|Estimate|||||||2016-08-02|2016-08-03|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|June 2012|Actual|2012-06-30||Interventional|||Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery|Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for Stage III Colon Cancer , and Investigate Predictive Factors Based on Gene Expression|Completed||Phase 3|1535|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||f||||||||||2018-06-01 02:14:18.582652|2018-06-01 02:14:18.582652
NCT00660881|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15||2012-07-03|2012-07-03|2008-04-16|2008-04-17|Estimate||||2012-07-03|2012-07-12|Estimate|2012-07-03|2012-07-12|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease|A Phase IIb Multi-Center, Open-label, Follow-up Study to Assess Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Who Participated in Study SL0007|Completed||Phase 2|210|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:14:18.856857|2018-06-01 02:14:18.856857
NCT00660868|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2016-02-04|2008-04-16|2008-04-17|Estimate|||||||2016-02-04|2016-02-05|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Is Pentoxifylline Able to Improve Olfactory Sensitivity?|Agapurin Retard Used in Patients With Smell Disorder- A Post-marketing Observational Study|Completed|||7|Actual|Technische Universität Dresden|||1||f||||f||||||||||2018-06-01 02:14:18.990737|2018-06-01 02:14:18.990737
NCT00660855|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-21|2008-04-16|2008-04-17|Estimate|||||||2008-04-21|2008-04-22|Estimate|June 2004||2004-06-30|April 2008|2008-04-30|July 2004|Actual|2004-07-31|||||Interventional|||A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain|A Multicenter, Open Label Trial To Evaluate Analgesic Effect Of Intravenous And Subsequent Oral Therapy With Parecoxib/Valdecoxib (Bextra® IM/IV And Bextra®) 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain|Terminated||Phase 4|4|Actual|Pfizer||1||See Detailed Description.|f||||f||||||||||2018-06-01 02:14:19.109515|2018-06-01 02:14:19.109515
NCT00660842|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2017-07-14|2008-04-15|2008-04-17|Estimate|||||||2017-07-14|2017-07-17|Actual|November 2008||2008-11-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2013|Actual|2013-12-31||Interventional|MITO-7||Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer|Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study|Active, not recruiting||Phase 3|800|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||||2018-06-01 02:14:19.25377|2018-06-01 02:14:19.25377
NCT00660829|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2009-09-30||2015-04-09|2008-04-16|2008-04-17|Estimate|2010-01-04|2010-01-28|Estimate||||2015-04-09|2015-04-13|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|536|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:14:19.440974|2018-06-01 02:14:19.440974
NCT00660816|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2014-07-10||2015-10-08|2008-04-16|2008-04-17|Estimate|2014-07-10|2014-08-05|Estimate||||2015-10-08|2015-10-12|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|April 2013|Actual|2013-04-30||Interventional|||Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer|Completed||Phase 2|46|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:14:20.311213|2018-06-01 02:14:20.311213
NCT00660803|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2010-01-20|2008-04-15|2008-04-17|Estimate|||||||2010-01-20|2010-01-21|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer|Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer|Completed|||200|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:14:21.466328|2018-06-01 02:14:21.466328
NCT00660790|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2012-10-30|2008-04-16|2008-04-17|Estimate|||||||2012-10-30|2012-11-01|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|CARDIONOR||Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders|Multifactorial Treatment of Cardiovascular Risk in Patients With Diabetes Mellitus Type-2: Identification of Treatment Non-Responders (The CARDIONOR Study)|Completed|||97|Actual|Medical University of Graz|||1||f||||f||||||Samples Without DNA|"~     plasma, serum~   "|||2018-06-01 02:14:21.636079|2018-06-01 02:14:21.636079
NCT00660777|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-15|2008-04-15|2008-04-17|Estimate|||||||2008-04-15|2008-04-17|Estimate|February 2004||2004-02-29|April 2008|2008-04-30|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Interventional|||Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea|Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea: A Randomized, Controlled Study|Completed||Phase 3|30|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 02:14:21.779014|2018-06-01 02:14:21.779014
NCT00660764|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2009-03-13|2008-04-16|2008-04-17|Estimate|||||||2009-03-13|2009-03-16|Estimate|May 2003||2003-05-31|March 2009|2009-03-31|April 2005|Actual|2005-04-30|||||Observational|HEROS||Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)|Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)|Completed|||||AstraZeneca|||1||f||||||||||||||2018-06-01 02:14:22.147847|2018-06-01 02:14:22.147847
NCT00660751|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2017-10-10|2008-04-16|2008-04-17|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2007|Actual|2007-08-31|October 2017|2017-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control|The Role of Central Serotonergic and Adrenergic Systems in the Effectiveness of DNIC (Diffuse Noxious Inhibitory Control|Completed||N/A|64|Actual|Rambam Health Care Campus||2|||f||||||||||||||2018-06-01 02:14:22.41942|2018-06-01 02:14:22.41942
NCT00660738|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-01-22|2008-04-15|2008-04-17|Estimate|||||||2012-01-22|2012-01-24|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Functional Tests in Individuals With Chronic Obstructive Pulmonary Disease (COPD)|Comparison of Different Functional Tests and Relation With Functional State and Quality of Life in Individuals With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||11|Actual|Universidade Federal de Sao Carlos|||1||f||||t||||||||||2018-06-01 02:14:22.513964|2018-06-01 02:14:22.513964
NCT00660725|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2014-01-21|2008-04-10|2008-04-17|Estimate|||||||2014-01-21|2014-01-23|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Study of GemOx and Vandetanib in Advanced Solid Malignancy|An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025)|Completed||Phase 1|22|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:14:22.62935|2018-06-01 02:14:22.62935
NCT00660712|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2009-05-22|2008-04-15|2008-04-17|Estimate|||||||2009-05-22|2009-05-25|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|March 2009|Actual|2009-03-31|||||Observational|||Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey|Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey|Completed|||1018|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:14:22.775539|2018-06-01 02:14:22.775539
NCT00660699|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2015-03-30||2015-05-07|2008-04-16|2008-04-17|Estimate|2015-05-07|2015-05-27|Estimate||||2015-05-07|2015-05-27|Estimate|September 2002||2002-09-30|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2010|Actual|2010-09-30||Interventional|||A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers|A Feasibility Phase II Study of Gemcitabine With Docetaxel With Concurrent 3-D Conformal Radiation Plus Continuous Infusion 5-Fluorouracil in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers|Completed||Phase 2|50|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 02:14:22.939806|2018-06-01 02:14:22.939806
NCT00660686|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2015-10-20|2008-04-11|2008-04-17|Estimate|||||||2015-10-20|2015-10-21|Estimate|January 2006||2006-01-31|October 2015|2015-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Exercise for Physical Health in Men With Prostate Cancer|Exercise for Physical Health in Men With Prostate Cancer|Completed||N/A|56|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 02:14:23.633679|2018-06-01 02:14:23.633679
NCT00660673|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2018-05-04|2008-04-15|2008-04-17|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 13, 2009|Actual|2009-11-13|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|September 15, 2020|Anticipated|2020-09-15||Interventional|||Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD|Open-Label Continuation Treatment Study With Levodopa - Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positive Effect To Treatment In Previous Studies|Active, not recruiting||Phase 3|262|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-06-01 02:14:23.82451|2018-06-01 02:14:23.82451
NCT00660660|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2009-06-12||2015-02-19|2008-04-16|2008-04-17|Estimate|2015-02-19|2015-03-02|Estimate||||2015-02-19|2015-03-02|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 4|276|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:14:24.3127|2018-06-01 02:14:24.3127
NCT00660647|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2015-11-23|2008-04-15|2008-04-17|Estimate|||||||2015-11-23|2015-11-24|Estimate|September 2007||2007-09-30|November 2015|2015-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|OPERA||Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)|Optimized Treatment Algorithm in Early Rheumatoid Arthritis: Methotrexate and Intra-articular Glucocorticosteroid Plus Adalimumab or Placebo in the Treatment of Early Rheumatoid Arthritis|Completed||Phase 3|180|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:14:25.653236|2018-06-01 02:14:25.653236
NCT00660634|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-04-25|2008-04-15|2008-04-17|Estimate|||||||2008-04-25|2008-04-28|Estimate|December 2004||2004-12-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|PTA-PAD-FMD||Angioplasty in Peripheral Arterial Disease and Endothelial Function|The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function|Completed||Phase 4|33|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 02:14:25.781154|2018-06-01 02:14:25.781154
NCT00660621|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2010-01-18|2008-04-16|2008-04-17|Estimate|||||||2010-01-18|2010-01-20|Estimate|April 2008||2008-04-30|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|KARE004||A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma|A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma|Unknown status|Recruiting|Phase 2|40|Anticipated|Kentuckiana Cancer Institute|||||f||||t||||||||||2018-06-01 02:14:25.864361|2018-06-01 02:14:25.864361
NCT00660608|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2010-07-02|2008-04-15|2008-04-17|Estimate|||||||2010-07-02|2010-07-05|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Conservation of Red Cell Mass , Oxygen Supply and Demand in Cardiac Surgery|Conservation of Red Cell Mass, Oxygen Supply and Demand in Cardiac Surgery|Completed|||50|Anticipated|Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 02:14:25.959603|2018-06-01 02:14:25.959603
NCT00660595|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2009-12-04||2010-08-24|2008-04-16|2008-04-17|Estimate|2010-08-24|2010-09-17|Estimate||||2010-08-24|2010-09-17|Estimate|September 2008||2008-09-30|August 2010|2010-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose|A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose|Terminated||Phase 3|29|Actual|AstraZeneca||2||To difficult to recruit patients in the acute setting|f||||f||||||||||2018-06-01 02:14:26.032474|2018-06-01 02:14:26.032474
NCT00660582|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2015-01-20|2008-04-16|2008-04-17|Estimate|||||||2015-01-20|2015-01-21|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|February 2013|Actual|2013-02-28|May 2011|Actual|2011-05-31||Interventional|||FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor|FLOX + Cetuximab (Erbitux®): First Line Treatment for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor, A Phase II Study|Completed||Phase 2|152|Actual|Odense University Hospital|||||f||||t||||||||||2018-06-01 02:14:26.349904|2018-06-01 02:14:26.349904
NCT00660569|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2010-11-30|2008-04-15|2008-04-17|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|February 2009|Actual|2009-02-28|||||Observational|||Utilization Patterns of Pulmicort in Real Life Practice|Utilization Patterns of Pulmicort HFA in Real Life Practice|Completed|||260|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:14:26.429656|2018-06-01 02:14:26.429656
NCT00660556|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2017-06-19|2008-04-16|2008-04-17|Estimate|||||||2017-06-19|2017-06-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:14:26.49647|2018-06-01 02:14:26.49647
NCT00660543|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2016-02-12||2017-04-19|2008-04-11|2008-04-17|Estimate|2016-04-08|2016-05-16|Estimate||||2017-04-19|2017-05-16|Actual|December 2006||2006-12-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy|Early Assessment of Tumor Response to Therapy Using Ferumoxytol (Code 7228) as an MR Contrast Agent in Patients With Glioblastoma Multiforme (MedDRA Code 10018337)|Completed||N/A|14|Actual|OHSU Knight Cancer Institute||3|||f||||t||||||||||2018-06-01 02:14:26.551024|2018-06-01 02:14:26.551024
NCT00660530|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2013-12-16|2008-04-10|2008-04-17|Estimate|||||||2013-12-16|2013-12-18|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients|An Evaluation of Chewed vs. Crushed Lanthanum Carbonate in the Efficacy of Phosphate Binding in Hemodialysis Patients|Completed||Phase 2|14|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 02:14:26.764608|2018-06-01 02:14:26.764608
NCT00660517|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2012-05-17|2011-06-23|2012-07-23|2008-04-16|2008-04-17|Estimate|2012-06-18|2012-07-23|Estimate|2011-07-12|2011-07-14|Estimate|2012-07-23|2012-07-27|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|607|Actual|Meda Pharmaceuticals||4|||f||||f||||||||||2018-06-01 02:14:26.903278|2018-06-01 02:14:26.903278
NCT00660504|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2013-11-21||2014-07-09|2008-04-10|2008-04-17|Estimate|2014-06-03|2014-07-04|Estimate||||2014-07-09|2014-07-18|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer|Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC|Completed||Phase 3|300|Actual|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:14:27.313978|2018-06-01 02:14:27.313978
NCT00660491|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-01-05|2008-04-15|2008-04-17|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Endothelial Dysfunction Induced by Postprandial Lipemia|Endothelial Dysfunction Induced by Postprandial Lipemia: Complete Protection Afforded by High Intensity Aerobic Interval Exercise|Completed||Phase 2|8|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-06-01 02:14:27.711155|2018-06-01 02:14:27.711155
NCT00660478|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2013-08-28|2008-04-15|2008-04-17|Estimate|||||||2013-08-28|2013-08-29|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|October 2009|Actual|2009-10-31|December 2007|Actual|2007-12-31||Interventional|SORT-OUTIII||Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris Patients|Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris Patients|Completed||Phase 3|2342|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-06-01 02:14:27.779278|2018-06-01 02:14:27.779278
NCT00660465|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2014-11-09|2008-04-16|2008-04-17|Estimate|||||||2014-11-09|2014-11-11|Estimate|May 2008||2008-05-31|February 2008|2008-02-29||||||||Observational|||Exploring the Relationship Between Varying CO2 Levels and the Regional BOLD Signal, by Using Breathing Exercises|Exploring the Relationship Between Varying CO2 Levels and the Regional BOLD Signal, by Using Breathing Exercises .|Unknown status|Not yet recruiting||6|Anticipated|Soroka University Medical Center|||1||f||||f||||||||||2018-06-01 02:14:27.849305|2018-06-01 02:14:27.849305
NCT00660452|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2011-10-10|2008-04-15|2008-04-17|Estimate|||||||2011-10-10|2011-10-12|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites|A Randomised, Double-blind, Placebo-controlled, Multi-centre, Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Chinese Asthmatic Patients Allergic to House-dust Mites|Completed||Phase 3|484|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-06-01 02:14:27.927277|2018-06-01 02:14:27.927277
NCT00660439|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-04-15|2008-04-15|2008-04-17|Estimate|||||||2008-04-15|2008-04-17|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|November 2010|Anticipated|2010-11-30|December 2009|Anticipated|2009-12-31||Interventional|||Treatment Effects of Narrative Exposure Therapy|Treatment Effects of Narrative Exposure Therapy on Psychiatric Symptoms and Cortisol Levels in Patients With Posttraumatic Stress Disorder|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Bergen||2|||f||||f||||||||||2018-06-01 02:14:27.998168|2018-06-01 02:14:27.998168
NCT00660426|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2013-04-22|2008-04-16|2008-04-17|Estimate|||||||2013-04-22|2013-04-23|Estimate|March 2005||2005-03-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|October 2006|Actual|2006-10-31||Interventional|||Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors|Phase I Study Of Oxaliplatin, Gemcitabine And Capecitabine In Advanced Gastrointestinal Malignancies And Other Solid Tumors|Completed||Phase 1|30|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 02:14:28.081048|2018-06-01 02:14:28.081048
NCT00660413|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-15|2008-04-15|2008-04-17|Estimate|||||||2008-04-15|2008-04-17|Estimate|December 2007||2007-12-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Comparison of Acceleromyography (AMG) and Mechanomyography (MMG) for Establishing Potency of Neuromuscular Blocking Agents|Comparison of Acceleromyography and Mechanomyography for Establishing Potency of Neuromuscular Blocking Agents, A Randomized Controlled Study|Completed||Phase 4|40|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:14:28.162275|2018-06-01 02:14:28.162275
NCT00660400|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2014-05-27||2014-09-11|2008-04-16|2008-04-17|Estimate|2014-06-16|2014-07-16|Estimate||||2014-09-11|2014-09-22|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional||21 of 25 participants proceeded to allogeneic HCT and were evaluated for most measures.|Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant|A Pilot Study Of Pre-Transplant 5-Azacitidine (Vidaza) In Patients With High-Risk Myelodysplastic Syndrome (MDS) Who Are Candidates For Allogeneic Hematopoietic Cell Transplantation|Completed||N/A|25|Actual|H. Lee Moffitt Cancer Center and Research Institute|Limitation: Small single center pilot study to show the use of pre-treatment 5-Azacitidine and successfully proceeding to transplant.|1|||f||||f||||||||||2018-06-01 02:14:28.230018|2018-06-01 02:14:28.230018
NCT00659711|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-12-17|2008-04-10|2008-04-16|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|1928||The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects|The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects|Unknown status|Active, not recruiting|N/A|40|Anticipated|Kaleida Health||2|||f||||f||||||||||2018-06-01 02:14:40.712639|2018-06-01 02:14:40.712639
NCT00660387|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2015-01-12|2012-10-26|2015-01-12|2008-04-15|2008-04-17|Estimate|2015-01-12|2015-01-16|Estimate|2012-10-26|2012-10-31|Estimate|2015-01-12|2015-01-16|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects|A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations|Completed||Phase 3|35|Actual|AbbVie||2|||f||||t||||||||||2018-06-01 02:14:28.531122|2018-06-01 02:14:28.531122
NCT00660374|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2015-05-04|2008-04-14|2008-04-17|Estimate|||||||2015-05-04|2015-05-05|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation in Subjects With Type 2 Diabetes|Assessment of Safety and Efficacy of Insulin NPH Compared to a New Insulin Formulation on Glycaemic Control in Subjects With Type 2 Diabetes|Completed||Phase 2|402|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 02:14:29.45587|2018-06-01 02:14:29.45587
NCT00660361|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-04-16|2008-04-16|2008-04-17|Estimate|||||||2008-04-16|2008-04-17|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|September 2010|Anticipated|2010-09-30|April 2010|Anticipated|2010-04-30||Observational|||A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients|A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir (TDF) in HIV-HBV co-Infected Patients|Unknown status|Recruiting||92|Anticipated|Bayside Health|||1||f||||f||||||Samples Without DNA|"~     Stored serum samples~   "|||2018-06-01 02:14:29.546508|2018-06-01 02:14:29.546508
NCT00660348|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2014-05-21||2014-10-07|2008-04-16|2008-04-17|Estimate|2014-10-07|2014-10-08|Estimate||||2014-10-07|2014-10-08|Estimate|March 2008||2008-03-31|October 2014|2014-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer|A Randomized Study of Optimal Pain Management: Standard Pain Control Versus Early Intervention With Intrathecal Therapy in Patients With Advanced Pancreatic Cancer|Terminated||N/A|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Subject started study 7/14/2010, but withdrew her consent on 7/24/2010 due to increased upper quadrant pain. One subject enrolled. She withdrew consent before study team could collect any follow-up data. We do not have any participants to analyze.|2||Low enrollment|f||||||||||||||2018-06-01 02:14:29.633645|2018-06-01 02:14:29.633645
NCT00660335|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2009-12-02|2008-04-16|2008-04-17|Estimate|||||||2009-12-02|2009-12-03|Estimate|March 2008||2008-03-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas|Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)- Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects With a History of Acute or Acute Recurrent Pancreatitis|Completed||Phase 3|258|Actual|Repligen Corporation||1|||f||||f||||||||||2018-06-01 02:14:29.942108|2018-06-01 02:14:29.942108
NCT00660322|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-15|2008-04-15|2008-04-17|Estimate|||||||2008-04-15|2008-04-17|Estimate|January 2004||2004-01-31|April 2008|2008-04-30|June 2007|Actual|2007-06-30|January 2006|Actual|2006-01-31||Interventional|||Using the Telephone to Improve Care in Childhood Asthma|Using the Telephone to Improve Care in Childhood Asthma|Completed||N/A|362|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||f||||||||||2018-06-01 02:14:30.006915|2018-06-01 02:14:30.006915
NCT00660309|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2012-07-20||2012-08-27|2008-04-16|2008-04-17|Estimate|2012-08-27|2012-08-29|Estimate||||2012-08-27|2012-08-29|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus|An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|45|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:14:30.121118|2018-06-01 02:14:30.121118
NCT00660296|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-16|2008-04-16|2008-04-17|Estimate|||||||2008-04-16|2008-04-17|Estimate|February 2008||2008-02-29|April 2008|2008-04-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Randomized Controlled Trial Comparing Co2 vs. Air in Colonoscopy in Sedated Patients|Randomized Controlled Trial Comparing Co2 vs. Air in Colonoscopy in Sedated Patients|Unknown status|Recruiting|N/A|300|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:14:30.597208|2018-06-01 02:14:30.597208
NCT00660283|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2010-01-18|2008-04-16|2008-04-17|Estimate|||||||2010-01-18|2010-01-20|Estimate|January 2009||2009-01-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|KARE003||A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma|A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Kentuckiana Cancer Institute|||||f||||t||||||||||2018-06-01 02:14:30.669182|2018-06-01 02:14:30.669182
NCT00660270|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2013-04-22|2008-04-16|2008-04-17|Estimate|||||||2013-04-22|2013-04-23|Estimate|May 2002||2002-05-31|April 2013|2013-04-30|February 2009|Actual|2009-02-28|November 2006|Actual|2006-11-30||Interventional|||Chemotherapy and Radiation Following Pancreatic Surgery|A Phase II Trial Of Adjuvant Chemoradiation Following Pancreatic Resection For Adenocarcinomas Of The Pancreas Using 3-D Conformal Radiation With Cisplatin, 5FU, And Alpha-Interferon As Radiosensitizing Agents Followed By Gemcitabine|Completed||Phase 2|53|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:14:30.736172|2018-06-01 02:14:30.736172
NCT00660257|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2008-04-16|2008-04-16|2008-04-17|Estimate|||||||2008-04-16|2008-04-17|Estimate|January 2007||2007-01-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine|Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza (H5N1)Vaccine in Two-Dose Primed Healthy Adults: A Single Center, Non-Randomized Clinical Trial|Completed||Phase 1|57|Actual|Sinovac Biotech Co., Ltd||4|||f||||t||||||||||2018-06-01 02:14:30.816367|2018-06-01 02:14:30.816367
NCT00660244|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-06-05|2008-04-15|2008-04-17|Estimate|||||||2012-06-05|2012-06-06|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|December 2009|Actual|2009-12-31|||||Observational|||Breast Cancer Tumor Care Observational Programme|Breast Cancer Tumor Care Patient Observation Programme|Completed|||150|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:14:30.87448|2018-06-01 02:14:30.87448
NCT00325975|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2018-05-24|2006-05-13|2006-05-15|Estimate|||||||2018-05-24|2018-05-25|Actual|February 4, 2003||2003-02-04|March 15, 2016|2016-03-15|March 15, 2016||2016-03-15|||||Observational|||Immune Responses to Smallpox Vaccination|Immune Responses to Vaccinia Virus Vaccination|Completed|||69|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:00:12.22109|2018-06-01 04:00:12.22109
NCT00660231|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2014-12-02|2008-04-16|2008-04-17|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|September 2011|Actual|2011-09-30||Interventional|GemBex||Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|A Phase II Study of Gemcitabine and Bexarotene (Gembex) in the Treatment of Cutaneous T-cell Lymphoma|Completed||Phase 2|36|Actual|University College, London||1|||f||||t||||||||||2018-06-01 02:14:30.94631|2018-06-01 02:14:30.94631
NCT00660218|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2015-03-19|2008-04-11|2008-04-17|Estimate|||||||2015-03-19|2015-03-23|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer|A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|State University of New York - Upstate Medical University||1|||f||||t||||||||||2018-06-01 02:14:31.037609|2018-06-01 02:14:31.037609
NCT00660205|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-03-23|2008-04-15|2008-04-17|Estimate|||||||2012-03-23|2012-03-26|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|GIVTE||Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer|Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer|Completed|||285|Actual|University of Aarhus|||3||f||||f||||||Samples Without DNA|"~     Blood samples with seperation in plasma and serum. Urin samples. tumour tissue samples.~   "|||2018-06-01 02:14:31.118034|2018-06-01 02:14:31.118034
NCT00660192|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2014-08-18||2016-02-15|2008-04-10|2008-04-17|Estimate|2016-02-15|2016-03-14|Estimate||||2016-02-15|2016-03-14|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2012|Actual|2012-07-31||Interventional|||Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches|Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches|Completed||Phase 2/Phase 3|25|Actual|Yale University|Small study- results could have been different if numbers were larger Technique of injection different from PREEMPT study. Larger doses were injected into temporal and posterior neck muscles. No trapezius injection.|2|||f||||t||||||||||2018-06-01 02:14:31.203628|2018-06-01 02:14:31.203628
NCT00660179|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2013-11-05|2012-10-23|2015-09-10|2008-04-16|2008-04-17|Estimate|2014-04-03|2014-05-05|Estimate|2012-10-23|2012-10-29|Estimate|2015-09-10|2015-09-28|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|SERAPHIN|For the baseline measures of age, gender, and World Health Organization (WHO) functional class, data were missing for 1 patient in the placebo group and for 2 patients in the 3 mg macitentan group.|Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension|Completed||Phase 3|742|Actual|Actelion||3|||f||||t||||||||||2018-06-01 02:14:31.604665|2018-06-01 02:14:31.604665
NCT00660166|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2012-06-25|2008-04-16|2008-04-17|Estimate|||||||2012-06-25|2012-06-27|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions|HLA Class I Haplotype Mismatched Natural Killer Cell Infusions After Autologous Stem Cell Transplant for Hematological Malignancies|Completed||Phase 1|13|Actual|Tufts Medical Center||1|||f||||t||||||||||2018-06-01 02:14:33.997967|2018-06-01 02:14:33.997967
NCT00660153|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2012-08-24|2008-04-16|2008-04-17|Estimate|||||||2012-08-24|2012-08-28|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers|A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers|Completed||Phase 1|30|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:14:34.067958|2018-06-01 02:14:34.067958
NCT00660140|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2013-08-09|2008-04-16|2008-04-17|Estimate|||||||2013-08-09|2013-08-13|Estimate|March 2002||2002-03-31|August 2013|2013-08-31|April 2009|Actual|2009-04-30|January 2007|Actual|2007-01-31||Interventional|||Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer|A Phase II Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer|Completed||Phase 2|49|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 02:14:34.145662|2018-06-01 02:14:34.145662
NCT00660127|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2017-03-14|2008-04-10|2008-04-17|Estimate|||||||2017-03-14|2017-03-16|Actual|October 2007||2007-10-31|April 2008|2008-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||The Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients|The Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients|Completed|||25|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 02:14:34.218485|2018-06-01 02:14:34.218485
NCT00660114|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2009-05-27|2008-04-15|2008-04-17|Estimate|||||||2009-05-27|2009-05-28|Estimate|April 2008||2008-04-30|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|PUL NIS||Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients|A Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Patient Aged 5-Year Old or Younger in Outpatient Department|Completed|||914|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:14:34.266572|2018-06-01 02:14:34.266572
NCT00660101|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2015-12-02|2008-04-16|2008-04-17|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2008||2008-06-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer|OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse:|Unknown status|Active, not recruiting|Phase 1/Phase 2|34|Actual|AVAX Technologies||3|||f||||f||||||||||2018-06-01 02:14:35.342063|2018-06-01 02:14:35.342063
NCT00660088|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2008-10-07|2008-04-15|2008-04-17|Estimate|||||||2008-10-07|2008-10-08|Estimate|April 2008||2008-04-30|October 2008|2008-10-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Observational|||Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly|Tolerability, Safety, And Pharmacokinetics Of Three Formulations Of Oral Ketasyn™ (Ac-1202) Administered For Fourteen Days, With Or Without Titration, In Healthy Elderly Volunteers|Completed|||60|Anticipated|Accera, Inc.|||6||f||||f||||||Samples Without DNA|"~     plasma beta-hydroxybutyrate~   "|||2018-06-01 02:14:35.434483|2018-06-01 02:14:35.434483
NCT00222053|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2010-04-01|2005-09-15|2005-09-22|Estimate|||||||2010-04-01|2010-04-02|Estimate|April 2000||2000-04-30|April 2010|2010-04-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||IFM 99-02 Thalidomide in Myeloma||Completed||Phase 3|800|Actual|University Hospital, Toulouse||3|||f||||f||||||||||2018-06-01 04:28:02.909137|2018-06-01 04:28:02.909137
NCT00660075|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2011-05-18||2012-11-13|2008-04-16|2008-04-17|Estimate|2012-11-13|2012-12-11|Estimate||||2012-11-13|2012-12-11|Estimate|February 2008||2008-02-29|November 2012|2012-11-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Effects of Sitagliptin on Postprandial Plasma Lipoprotein Concentrations in Men With Type 2 Diabetes|Completed||Phase 3|36|Actual|Laval University||2|||f||||t||||||||||2018-06-01 02:14:35.514231|2018-06-01 02:14:35.514231
NCT00660062|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2014-12-07|2008-04-16|2008-04-17|Estimate|||||||2014-12-07|2014-12-09|Estimate|August 2009||2009-08-31|April 2011|2011-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DUAG-7||Relapse Prevention With Escitalopram or Nortriptyline Following Electro-Convulsive Treatment (DUAG-7)|Relapse Prevention in Patients With a Major Depressive Episode Treated With Electroconvulsive Treatment Using a Fixed Dose Range of Escitalopram Compared to a Fixed Dose of Nortriptyline (DUAG-7) A Randomised Controlled 6 Month Double-blind Study|Terminated||Phase 4|47|Actual|Hillerod Hospital, Denmark||4||Slow inclusion|f||||f||||||||||2018-06-01 02:14:35.738821|2018-06-01 02:14:35.738821
NCT00660049|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2016-05-26||2017-11-15|2008-04-15|2008-04-17|Estimate|2016-11-23|2017-01-20|Estimate||||2017-11-15|2017-12-13|Actual|March 2008||2008-03-31|November 2017|2017-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional||12|Feasibility Study of a Novel Device for Chronic Wounds|Feasibility Study of a Novel Device for Chronic Wounds|Completed||N/A|12|Actual|Stanford University|Open label design without comparator arm|1|||f||||t||||||||No|No sharing|2018-06-01 02:14:35.84786|2018-06-01 02:14:35.84786
NCT00660036|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2016-01-14|2008-04-11|2008-04-17|Estimate|||||||2016-01-14|2016-01-15|Estimate|September 2008||2008-09-30|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia|Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)|Terminated||Phase 1|5|Actual|University of Pittsburgh||1||due to new safety information|f||||t||||||||||2018-06-01 02:14:36.10652|2018-06-01 02:14:36.10652
NCT00660023|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2016-02-16||2016-02-16|2008-04-16|2008-04-17|Estimate|2016-02-16|2016-03-15|Estimate||||2016-02-16|2016-03-15|Estimate|August 2008||2008-08-31|February 2016|2016-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Intent-to-Treat (ITT) Population: All participants who received at least one dose of Mircera/CERA and for whom data from at least one follow-up assessment were available.|A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis|A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia|Completed||Phase 3|124|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:14:36.219197|2018-06-01 02:14:36.219197
NCT00660010|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2010-04-22||2011-04-08|2008-04-15|2008-04-17|Estimate|2010-06-18|2010-07-20|Estimate||||2011-04-08|2011-04-12|Estimate|January 1991||1991-01-31|April 2011|2011-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study of Lupron Depot In The Treatment of Central Precocious Puberty|Study of Lupron Depot In The Treatment of Central Precocious Puberty|Completed||Phase 3|55|Actual|Abbott|Study drug was discontinued usually at the initiation of puberty (12 years for males and 11 years for females) with the concurrence of the investigator, or at the discretion of the investigator. Adverse events are coded with the COSTART dictionary.|1|||f||||f||||||||||2018-06-01 02:14:36.572928|2018-06-01 02:14:36.572928
NCT00659997|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-04-15|2008-04-15|2008-04-17|Estimate|||||||2008-04-15|2008-04-17|Estimate|June 2006||2006-06-30|April 2008|2008-04-30|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Interventional|ALBvLEV||Efficacy Albendazole and Levamisole Against STH on Unguja|Longitudinal Study of Efficacy of Standard Albendazole Treatment Versus Levamisole/Pyrantel Pamoate on Soil Transmitted Helminth Infections|Completed||Phase 4|20|Actual|Natural History Museum, United Kingdom||2|||f||||f||||||||||2018-06-01 02:14:36.980749|2018-06-01 02:14:36.980749
NCT00659984|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|2015-12-15||2017-09-06|2008-04-16|2008-04-17|Estimate|2017-01-27|2017-03-16|Actual||||2017-09-06|2017-10-04|Actual|June 2008||2008-06-30|September 2017|2017-09-30|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma|A Phase 2a Study of Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma|Completed||Phase 2|15|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 02:14:37.066856|2018-06-01 02:14:37.066856
NCT00659971|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-06-25|2008-04-16|2008-04-17|Estimate|||||||2008-06-25|2008-06-26|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis|A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113|Completed||Phase 2|223|Actual|Pacgen Biopharmaceuticals Corporation||4|||f||||t||||||||||2018-06-01 02:14:37.430421|2018-06-01 02:14:37.430421
NCT00659958|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2013-05-09|2008-04-16|2008-04-17|Estimate|||||||2013-05-09|2013-05-13|Estimate|April 2008||2008-04-30|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs|Post-authorization, Observational and Prospective Follow up Study to Evaluate Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs|Completed||Phase 4|32|Actual|Eisai Inc.||1|||f||||f||||||||||2018-06-01 02:14:37.5195|2018-06-01 02:14:37.5195
NCT00659945|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2011-08-10||2013-02-01|2008-04-16|2008-04-17|Estimate|2011-11-02|2011-12-07|Estimate||||2013-02-01|2013-02-06|Estimate|June 2008||2008-06-30|February 2013|2013-02-28|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery|Efficacy of Pre-operative Aprepitant Plus Ondansetron vs Ondansetron Plus Placebo in Patients at Moderate-to-High Risk Post-operative Nausea (PONV) Undergoing Ambulatory Plastic Surgery|Completed||Phase 4|150|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:14:37.62084|2018-06-01 02:14:37.62084
NCT00659932|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-14|2008-04-14|2008-04-17|Estimate|||||||2008-04-14|2008-04-17|Estimate|May 2002||2002-05-31|December 2007|2007-12-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Dealing With Anxiety: A Cognitive Behavioural Program for Diabetes|Dealing With Anxiety: A Pilot Cognitive Behavioural Program for Diabetic Clinic Outpatient Attendees|Completed||N/A|64|Actual|Hunter and New England Health||2|||f||||f||||||||||2018-06-01 02:14:37.876616|2018-06-01 02:14:37.876616
NCT00659919|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-16|||2008-06-15|2008-04-16|2008-04-17|Estimate|||||||2008-06-15|2008-06-17|Estimate|November 2000||2000-11-30|June 2008|2008-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Treatment of Neuroleptic Induced Acute Akathisia With Trazodone||Completed||Phase 4|13|Actual|BeerYaakov Mental Health Center||2|||f||||||||||||||2018-06-01 02:14:37.959033|2018-06-01 02:14:37.959033
NCT00659893|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2015-09-11|2008-04-16|2008-04-17|Estimate|||||||2015-09-11|2015-09-14|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2|A Multi-center, Open Label, Dose-area Escalation, Cohort Study to Evaluate the Safety and Tolerability of 0.05% PEP005 Topical Gel Applied for Two Consecutive Days to Treatment Area(s) of up to a Total of 100 cm2 in Patients With Actinic Keratoses on the Extensor (Dorsal Aspect) Forearm(s)|Completed||Phase 1|64|Actual|Peplin||8|||f||||f||||||||||2018-06-01 02:14:38.235016|2018-06-01 02:14:38.235016
NCT00659880|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2016-09-12||2017-04-10|2008-04-15|2008-04-16|Estimate|2017-04-10|2017-06-26|Actual||||2017-04-10|2017-06-26|Actual|April 2008||2008-04-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|Meniscus||Clinical Application of BioCleanse Meniscus|Clinical Application of BioCleanse Meniscus Registry|Completed|||9|Actual|RTI Surgical|||||f||||f||||||||No||2018-06-01 02:14:38.339191|2018-06-01 02:14:38.339191
NCT00659867|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-09-26|2008-04-14|2008-04-16|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|||Endomicroscopy in Ulcerative Colitis|Chromoscopy-guided Endomicroscopy With the PENTAX EC-3870CIFK / EC-3870CILK Confocal Colonoscopes for the Detection of Intraepithelial Neoplasias in Subjects With Long Standing Ulcerative Colitis|Terminated||N/A|182|Actual|PENTAX Europe GmbH||2||Recruitment problems|f||||f||||||||||2018-06-01 02:14:38.494987|2018-06-01 02:14:38.494987
NCT00659854|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-05-05|2008-04-15|2008-04-16|Estimate|||||||2008-05-05|2008-05-07|Estimate|April 2008||2008-04-30|April 2008|2008-04-30||||April 2010|Anticipated|2010-04-30||Interventional|||Cow's Milk Allergy in Infants With Obstructive Sleep Apnea (OSA)|Cow's Milk Allergy in Infants With Obstructive Sleep Apnea|Unknown status|Not yet recruiting|N/A|50|Anticipated|Soroka University Medical Center||2|||f||||t||||||||||2018-06-01 02:14:38.577621|2018-06-01 02:14:38.577621
NCT00659841|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-12-01|2008-04-15|2008-04-16|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2003||2003-12-31|October 2016|2016-10-31|February 2005|Actual|2005-02-28|December 2004|Actual|2004-12-31||Interventional|||To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200µg Once Daily) in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 12 Years and Older|Completed||Phase 3|302|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:14:38.658774|2018-06-01 02:14:38.658774
NCT00659828|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2008-04-14|2008-04-14|2008-04-16|Estimate|||||||2008-04-14|2008-04-16|Estimate|June 2005||2005-06-30|April 2008|2008-04-30|December 2010|Anticipated|2010-12-31|January 2010|Anticipated|2010-01-31||Interventional|||Effects of Leptin Replacement in Children|Effects of Leptin Replacement in Children|Unknown status|Active, not recruiting|Phase 2|1|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 02:14:38.735018|2018-06-01 02:14:38.735018
NCT00659815|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-12|2010-09-07||2011-12-07|2008-04-15|2008-04-16|Estimate|2010-10-18|2010-11-15|Estimate||||2011-12-07|2011-12-12|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a New Packaging Configuration|Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a Clear Polyethylene Terephthalate (PET) Bottle.|Completed||N/A|312|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:14:38.814747|2018-06-01 02:14:38.814747
NCT00659802|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2012-09-04|2008-04-15|2008-04-16|Estimate|||||||2012-09-04|2012-09-06|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase II Study of HMPL-004 in Patients With Ulcerative Colitis|A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis With or Without Mesalamine|Completed||Phase 2|224|Actual|Hutchison Medipharma Limited||3|||f||||f||||||||||2018-06-01 02:14:39.064234|2018-06-01 02:14:39.064234
NCT00659789|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2015-07-22||2017-01-05|2008-04-15|2008-04-16|Estimate|2016-11-08|2017-01-05|Estimate||||2017-01-05|2017-02-23|Actual|August 2008||2008-08-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional||ITT population|Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV|A Phase II, Randomized, Double-blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART|Completed||Phase 2|137|Actual|Bionor Immuno AS||2|||f||||t||||||||No|Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.|2018-06-01 02:14:39.229515|2018-06-01 02:14:39.229515
NCT00659776|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-11-28|2008-04-15|2008-04-16|Estimate|||||||2012-11-28|2012-11-29|Estimate|July 2004||2004-07-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation|Multi-Disciplinary Study: MR, Histologic And EM Imaging Of Intravenous Superparamagnetic Crystalline Particles (Ferumoxytol) In CNS Inflammation|Unknown status|Recruiting|Phase 2|120|Anticipated|Oregon Health and Science University||4|||f||||t||||||||||2018-06-01 02:14:39.883689|2018-06-01 02:14:39.883689
NCT00659763|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2012-02-17|2008-04-14|2008-04-16|Estimate|||||||2012-02-17|2012-02-20|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Diagnostic Strategies in Patients Suspected of Irritable Bowel Syndrome|Diagnostic Strategies in Patients Suspected of Irritable Bowel Syndrome and the Prevalence of Intestinal Parasites in Patients Suspected of Irritable Bowel Syndrome|Completed|||149|Actual|Zealand University Hospital|||2||f||||f||||||Samples With DNA|"~     Blood and fecal sample~   "|||2018-06-01 02:14:39.982635|2018-06-01 02:14:39.982635
NCT00659750|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-12-01|2008-04-15|2008-04-16|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2003||2003-12-31|October 2016|2016-10-31|April 2005|Actual|2005-04-30|May 2004|Actual|2004-05-31||Interventional|||To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200 mg Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older|Completed||Phase 3|418|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:14:40.086128|2018-06-01 02:14:40.086128
NCT00659737|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2014-03-27||2014-05-01|2008-04-14|2008-04-16|Estimate|2014-03-27|2014-04-29|Estimate||||2014-05-01|2014-05-15|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting|A Randomized, Double-blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting|Completed||N/A|115|Actual|Drexel University||2|||f||||f||||||||||2018-06-01 02:14:40.20869|2018-06-01 02:14:40.20869
NCT00659698|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2008-04-15|2008-04-15|2008-04-16|Estimate|||||||2008-04-15|2008-04-16|Estimate|April 2007||2007-04-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of an Artificial Pancreas in Patients Undergoing Hepatic Resection|Prevention for Surgical Site Infection After Hepatic Resection|Completed||Phase 4|70|Actual|Kochi University||2|||f||||t||||||||||2018-06-01 02:14:40.783615|2018-06-01 02:14:40.783615
NCT00659685|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-04-15|2008-04-15|2008-04-16|Estimate|||||||2008-04-15|2008-04-16|Estimate|November 2003||2003-11-30|March 2008|2008-03-31||||||||Interventional|||Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 16 mg ODT With That of GlaxoSmithKine's Zofran 16 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:14:40.862603|2018-06-01 02:14:40.862603
NCT00659672|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2011-02-08|2008-04-15|2008-04-16|Estimate|||||||2011-02-08|2011-02-09|Estimate|September 2008||2008-09-30|February 2011|2011-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Whey Protein on Blood Pressure|Effect of Whey Protein on Blood Pressure|Completed||N/A|35|Actual|USDA Beltsville Human Nutrition Research Center|||||f||||t||||||||||2018-06-01 02:14:40.938391|2018-06-01 02:14:40.938391
NCT00659659|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2012-10-09|2008-04-11|2008-04-16|Estimate|||||||2012-10-09|2012-10-10|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma|A Phase 1, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Effects of MEDI-563, A Humanized Anti-Interleukin-5 Receptor Alpha Monoclonal Antibody, on Airway Eosinophils in Adults With Atopic Asthma|Completed||Phase 1|27|Actual|MedImmune LLC||4|||f||||f||||||||||2018-06-01 02:14:40.996252|2018-06-01 02:14:40.996252
NCT00659646|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2013-04-29|2008-04-11|2008-04-16|Estimate|||||||2013-04-29|2013-04-30|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|||The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers|A Randomized, Controlled, Open Label Study of the Safety and Efficacy of a Topical Gentamicin Collagen Sponge Combined With An Antibiotic Compared to Antibiotic Therapy Alone in Diabetic Patients With Moderately Infected Foot Ulcers|Completed||Phase 2|56|Actual|Innocoll||2|||f||||f||||||||||2018-06-01 02:14:41.077685|2018-06-01 02:14:41.077685
NCT00659633|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2017-04-18||2017-06-22|2008-04-14|2008-04-16|Estimate|2017-06-06|2017-06-08|Actual||||2017-06-22|2017-07-21|Actual|December 2008||2008-12-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||The Effect of Intravenous Lidocaine on Allodynia|The Effect of Intravenous Lidocaine on Allodynia (Carl Koller Grant)|Completed||N/A|10|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 02:14:41.155204|2018-06-01 02:14:41.155204
NCT00659620|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-14|2008-04-14|2008-04-16|Estimate|||||||2008-04-14|2008-04-16|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|May 2010|Anticipated|2010-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy|Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Organ Transplant Institute, China||1|||f||||t||||||||||2018-06-01 02:14:41.320761|2018-06-01 02:14:41.320761
NCT00659607|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2009-07-29||2014-05-08|2008-04-15|2008-04-16|Estimate|2009-09-22|2009-10-22|Estimate||||2014-05-08|2014-06-06|Estimate|September 2003||2003-09-30|May 2014|2014-05-31||||July 2008|Actual|2008-07-31||Observational|||Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension|PMS Study of MicardisPlus Tablet|Completed|||6901|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:14:41.528148|2018-06-01 02:14:41.528148
NCT00659594|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-12-01|2008-04-15|2008-04-16|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2004||2004-11-30|October 2016|2016-10-31|September 2005|Actual|2005-09-30|February 2005|Actual|2005-02-28||Interventional|||Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older|Completed||Phase 3|500|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:14:42.543142|2018-06-01 02:14:42.543142
NCT00659581|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2011-12-16||2016-07-25|2008-04-15|2008-04-16|Estimate|2012-02-15|2012-03-20|Estimate||||2016-07-25|2016-08-25|Estimate|April 2006||2006-04-30|July 2016|2016-07-31||||June 2010|Actual|2010-06-30||Observational|||J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation|Special Survey (Survey on Cerebrovascular and Cardiovascular Events Under Long-term Use) of Micardis Tablets (Telmisartan)|Completed|||21471|Actual|Boehringer Ingelheim|This study is prospective observational study with no limitation of other antihypertensive treatment in compliance with Japanese Pharmaceutical Affairs Law (JPAL) and Good Post-marketing Study Practice (GPSP).||1||f||||||||||||||2018-06-01 02:14:42.686078|2018-06-01 02:14:42.686078
NCT00659568|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2013-05-29|2008-04-15|2008-04-16|Estimate|||||||2013-05-29|2013-05-30|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|August 2010||2010-08-31|February 2010|Actual|2010-02-28||Interventional|||Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma|A Phase I Study of Temsirolimus in Combination With Metformin in Advanced Solid Tumours|Completed||Phase 1|28|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:14:43.335691|2018-06-01 02:14:43.335691
NCT00659555|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2017-11-08|2008-04-10|2008-04-16|Estimate|||||||2017-11-08|2017-11-13|Actual|April 4, 2008|Actual|2008-04-04|November 2017|2017-11-30|May 10, 2008|Actual|2008-05-10|May 10, 2008|Actual|2008-05-10||Interventional|||Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops|An Open-label, Two-period, Fixed-sequence Study in Healthy Volunteers to Evaluate the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Dose of Pazopanib (GW786034) Administered as Eye Drops|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:14:43.559856|2018-06-01 02:14:43.559856
NCT00659542|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2010-03-10|2008-04-15|2008-04-16|Estimate|||||||2010-03-10|2010-03-11|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|Cyanoacr||Glubran Mesh Fixation in Lichtenstein Hernioplasty|Randomized Study of Mesh Fixation With Absorbable Sutures or Glubran Tissue Sealant in Lichtenstein Hernioplasty|Completed||Phase 2|300|Anticipated|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 02:14:43.671152|2018-06-01 02:14:43.671152
NCT00659529|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2014-04-01||2017-03-27|2008-04-15|2008-04-16|Estimate|2014-04-01|2014-05-02|Estimate||||2017-03-27|2017-04-26|Actual|August 2008|Actual|2008-08-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional||All patiens who received at least one dose of study drug.|Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease|The Role of Phosphodiesterase Inhibitors in CF Lung Disease|Completed||Phase 1/Phase 2|36|Actual|National Jewish Health||1|||f||||t||||||||||2018-06-01 02:14:43.754742|2018-06-01 02:14:43.754742
NCT00659516|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-15|2008-04-15|2008-04-16|Estimate|||||||2008-04-15|2008-04-16|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|August 2008|Anticipated|2008-08-31||Observational|||Smart Capnography Respiratory Index in Post Anesthesia Patients|Smart Capnography Respiratory Index: Clinical Evaluation|Unknown status|Not yet recruiting||40|Anticipated|Shaare Zedek Medical Center|||2||f||||f||||||||||2018-06-01 02:14:43.922206|2018-06-01 02:14:43.922206
NCT00659503|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-12-01|2008-04-15|2008-04-16|Estimate|||||||2016-12-01|2016-12-02|Estimate|February 2005||2005-02-28|October 2016|2016-10-31|November 2005|Actual|2005-11-30|April 2005|Actual|2005-04-30||Interventional|||Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older|Completed||Phase 3|420|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:14:44.01196|2018-06-01 02:14:44.01196
NCT00659490|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2010-05-04||2012-06-05|2008-04-15|2008-04-16|Estimate|2012-02-14|2012-03-26|Estimate||||2012-06-05|2012-06-11|Estimate|February 2008||2008-02-29|May 2010|2010-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940|A Randomised, Double Blind, Placebo-Controlled Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940, in Patients Undergoing Impacted Mandibular Third Molar Extraction|Completed||Phase 2|151|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:14:44.1279|2018-06-01 02:14:44.1279
NCT00659477|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2010-07-29|2008-04-15|2008-04-16|Estimate|||||||2010-07-29|2010-07-30|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|COBIN 2||Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)|Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With OADs in Patients With DMT2, Assessed by Continuous Glucose Monitoring System (CGMS). Multicentre, Prospective, Open- Label, Single Arm, Comparative Study in Patients Switched From NPH Insulin to Insulin Lantus®.|Completed||Phase 4|117|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:14:44.80524|2018-06-01 02:14:44.80524
NCT00659464|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-02-09|2008-04-10|2008-04-16|Estimate|||||||2012-02-09|2012-02-13|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|NIRS & Tilt||Multi-Site Near Infrared Spectroscopy (NIRS) Monitoring of Children During Tilt Table Testing|Use of Multi-site Near Infrared Spectroscopy (NIRS) Monitoring for Hemodynamic Assessment During Tilt Table Testing in Children|Completed|||22|Actual|Medical College of Wisconsin|||1||f||||f||||||||||2018-06-01 02:14:44.885868|2018-06-01 02:14:44.885868
NCT00659451|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-14|2008-04-14|2008-04-16|Estimate|||||||2008-04-14|2008-04-16|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2009|Anticipated|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular|Effects Of Losartan On Myocardial Structure And Function And On Epicardial Fat Deposition In Diabetic Hypertensive Patients With Left Ventricular: Qualitative And Quantitative Alteration|Unknown status|Recruiting|Phase 3|100|Anticipated|University of Pavia||2|||f||||f||||||||||2018-06-01 02:14:44.960477|2018-06-01 02:14:44.960477
NCT00659438|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2011-11-14|2011-03-28|2016-10-11|2008-04-10|2008-04-16|Estimate|2012-06-14|2012-07-18|Estimate|2011-04-08|2011-04-14|Estimate|2016-10-11|2016-12-05|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|July 2011|Actual|2011-07-31|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer|A Randomized, Double-blind Phase II Trial to Assess the Efficacy and Safety of Bicalutamide (Casodex® ) Associated to ZD6474 (Zactima™ ) or to Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression|Completed||Phase 2|95|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:14:45.088194|2018-06-01 02:14:45.088194
NCT00659425|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2017-02-24||2017-08-28|2008-04-11|2008-04-16|Estimate|2017-08-28|2017-10-02|Actual||||2017-08-28|2017-10-02|Actual|September 2008||2008-09-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Safety Population includes all participants who received any treatment of study drug.|CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)|Completed||Phase 1|57|Actual|MedImmune LLC||10|||f||||f||||||||||2018-06-01 02:14:45.662053|2018-06-01 02:14:45.662053
NCT00659412|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2014-09-17|2008-04-15|2008-04-16|Estimate|||||||2014-09-17|2014-09-18|Estimate|September 2003||2003-09-30|September 2014|2014-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Alefacept When Given in Combination With Methotrexate in Subjects With Psoriatic Arthritis With an Open-label Retreatment Course|Completed||Phase 2|185|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 02:14:49.257006|2018-06-01 02:14:49.257006
NCT00659399|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2015-03-16|2008-04-10|2008-04-16|Estimate|||||||2015-03-16|2015-03-18|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|November 2010|Anticipated|2010-11-30|September 2010|Anticipated|2010-09-30||Interventional|||Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression|07-742 Phase I/ Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression|Withdrawn||Phase 1|0|Actual|New York University School of Medicine||||Low accrual|f||||t||||||||||2018-06-01 02:14:49.500091|2018-06-01 02:14:49.500091
NCT00659386|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2009-02-03|2008-04-14|2008-04-16|Estimate|||||||2009-02-03|2009-02-04|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|February 2010|Anticipated|2010-02-28||Interventional|||IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load|Intravenous Immunoglobulin Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load|Unknown status|Recruiting|Phase 1|40|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 02:14:49.611307|2018-06-01 02:14:49.611307
NCT00659373|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2015-07-14||2016-07-11|2008-04-15|2008-04-16|Estimate|2016-07-11|2016-07-25|Estimate||||2016-07-11|2016-07-25|Estimate|December 2007||2007-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|Co-SOFT||Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02|Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers|Completed||Phase 3|86|Actual|International Breast Cancer Study Group||3|||f||||t||||||||||2018-06-01 02:14:49.723621|2018-06-01 02:14:49.723621
NCT00659360|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|2014-06-19||2015-07-02|2008-04-15|2008-04-16|Estimate|2015-07-02|2015-07-30|Estimate||||2015-07-02|2015-07-30|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|November 2012|Actual|2012-11-30|January 2009|Actual|2009-01-31||Interventional|||AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma|A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma|Completed||Phase 2|17|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:14:50.127838|2018-06-01 02:14:50.127838
NCT00659347|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2008-12-04|2008-04-15|2008-04-16|Estimate|||||||2008-12-04|2008-12-05|Estimate|March 2008||2008-03-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DOV 21,947 in Patients With Major Depressive Disorder|Terminated||Phase 2|200|Anticipated|DOV Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:14:50.483155|2018-06-01 02:14:50.483155
NCT00659334|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2012-05-15||2017-04-19|2008-04-15|2008-04-16|Estimate|2012-10-10|2012-11-09|Estimate||||2017-04-19|2017-05-16|Actual|August 2000||2000-08-31|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation|Multi-disciplinary Study: MR, Histologic and EM Imaging of Intravenous Superparamagnetic Crystalline Particles (Combidex) to Brain, Intra-cerebral Tumors and in CNS Inflammation|Terminated||Phase 2|116|Actual|OHSU Knight Cancer Institute|Early trial termination due to study drug Combidex no longer manufactured.|7||AMAG not continuing with Combidex, the study drug|f||||t||||||||||2018-06-01 02:14:50.600492|2018-06-01 02:14:50.600492
NCT00659321|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-01-10|2008-04-10|2008-04-16|Estimate|||||||2012-01-10|2012-01-11|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome|Placebokontrollierte Untersuchung Zur Wirkung Von Nikotinsäure Auf Die Dyslipidämie Bei Metabolischem Syndrom Und Das Arterioskleroserisiko (Placebo Controlled Investigation of Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome and the Risk of Atherosclerosis)|Completed||Phase 3|68|Actual|GWT-TUD GmbH||2|||f||||||||||||||2018-06-01 02:14:51.113994|2018-06-01 02:14:51.113994
NCT00659308|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-14|2008-04-14|2008-04-16|Estimate|||||||2008-04-14|2008-04-16|Estimate|June 2005||2005-06-30|January 2008|2008-01-31|June 2007|Actual|2007-06-30|July 2005|Actual|2005-07-31||Interventional|||Amniotic Membrane and Anterior Stromal Puncture to the Treatment of Symptomatic Bullous Keratopathy|Amniotic Membrane and Anterior Stromal Puncture: a Comparative Study in the Treatment of Symptomatic Bullous Keratopathy|Completed||N/A|38|Actual|Federal University of São Paulo|||||f||||f||||||||||2018-06-01 02:14:51.181542|2018-06-01 02:14:51.181542
NCT00659295|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2011-06-16||2017-01-30|2008-04-10|2008-04-16|Estimate|2011-07-20|2011-08-16|Estimate||||2017-01-30|2017-03-10|Actual|June 2004||2004-06-30|January 2017|2017-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|PREDICTIVE™||Observational Study to Evaluate the Safety of Levemir® in Diabetes|A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study: Predictable Results and Experience in Diabetes Through Intensification and Control to Target: an International Variability Evaluation|Completed|||51170|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 02:14:51.300958|2018-06-01 02:14:51.300958
NCT00659282|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2018-01-11|2008-04-10|2008-04-16|Estimate|||||||2018-01-11|2018-01-12|Actual|September 11, 2006|Actual|2006-09-11|January 2018|2018-01-31|November 15, 2008|Actual|2008-11-15|November 15, 2008|Actual|2008-11-15||Observational|IMPROVE™||Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes|Observational Study of Safety and Effectiveness of NovoMix® 30 (Biphasic Insulin Aspart) for the Treatment of Diabetes Mellitus|Completed|||57610|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:14:52.191851|2018-06-01 02:14:52.191851
NCT00659269|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2015-06-18||2016-01-27|2008-04-15|2008-04-16|Estimate|2015-12-16|2016-01-25|Estimate||||2016-01-27|2016-02-26|Estimate|July 2006||2006-07-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|||A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients|A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients.|Completed||Phase 3|319|Actual|New Mexico Cancer Care Alliance|The number of completed surveys decreased as time went on for each group of patients. This resulted in small numbers of patients to analyze, especially in Group 3 (Vinca Alkaloids), since there weren't many patients in this group to begin with.|2|||f||||t||||||||||2018-06-01 02:14:52.370927|2018-06-01 02:14:52.370927
NCT00659256|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2018-05-15|2008-04-15|2008-04-16|Estimate|||||||2018-05-15|2018-05-16|Actual|April 8, 2008||2008-04-08|March 24, 2015|2015-03-24|March 24, 2015||2015-03-24|||||Observational|||Hepatitis C Treatment and Atherosclerosis|Hepatitis C Eradication and Progression of Atherosclerosis|Completed|||70|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:14:52.905625|2018-06-01 02:14:52.905625
NCT00659243|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2014-10-31|2008-04-15|2008-04-16|Estimate|||||||2014-10-31|2014-11-03|Estimate|March 2008||2008-03-31|October 2014|2014-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Pasteurized Breast Milk for Preterm Infants|A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Pasteurized Breast Milk Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age|Completed||Phase 2|32|Actual|Swedish Orphan Biovitrum||2|||f||||t||||||||||2018-06-01 02:14:52.986911|2018-06-01 02:14:52.986911
NCT00659230|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2017-04-24||2017-09-12|2008-04-15|2008-04-16|Estimate|2017-04-24|2017-06-01|Actual||||2017-09-12|2017-10-13|Actual|July 1, 2009|Actual|2009-07-01|September 2017|2017-09-30|August 30, 2012|Actual|2012-08-30|July 5, 2012|Actual|2012-07-05||Interventional|Nepicastat|Placebo: 2 did not return post-randomization & were excluded from outcome analysis; 5 lost source documents & were excluded from baseline, safety, & outcomes analyses. Nepicastast: 3 did not return post-randomization and were excluded from outcome analysis, 4 lost source documents and were excluded from baseline, safety, and outcome analyses|Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans|A Randomized, Placebo-Controlled Trial of the Dopamine-B-Hydroxylase (DBH) Inhibitor, Nepicastat, for the Treatment of PTSD in OIF/OEF Veterans|Completed||Phase 2|100|Actual|Tuscaloosa Research & Education Advancement Corporation|Limitations: short duration of placebo-controlled phase (six-weeks).|2|||f||||t|t|f||||||No||2018-06-01 02:14:53.119787|2018-06-01 02:14:53.119787
NCT00659217|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-14|2008-04-14|2008-04-16|Estimate|||||||2008-04-14|2008-04-16|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis|Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Organ Transplant Institute, China||1|||f||||t||||||||||2018-06-01 02:14:53.662541|2018-06-01 02:14:53.662541
NCT00659204|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2008-04-15|2008-04-15|2008-04-16|Estimate|||||||2008-04-15|2008-04-16|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Interventional|||Efficacy of Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel|A Randomized Controlled Trial of the Efficacy of a Novel Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel Against Bacterial Hand Flora|Unknown status|Recruiting|Phase 3|40|Anticipated|Madigan Army Medical Center||2|||f||||f||||||||||2018-06-01 02:14:53.750769|2018-06-01 02:14:53.750769
NCT00659191|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10||2010-10-14|2010-10-14|2008-04-15|2008-04-16|Estimate||||2010-10-14|2010-10-15|Estimate|2010-10-14|2010-10-15|Estimate|February 2008||2008-02-29|October 2010|2010-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1265744 in Healthy Male and Female Subjects and Subjects Infected With HIV|Completed||Phase 1|58|Anticipated|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:14:53.867108|2018-06-01 02:14:53.867108
NCT00659178|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2017-07-18|2008-04-10|2008-04-16|Estimate|||||||2017-07-18|2017-07-21|Actual|June 18, 2008|Actual|2008-06-18|July 2017|2017-07-31|February 18, 2011|Actual|2011-02-18|February 18, 2011|Actual|2011-02-18||Interventional|||Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer|A Phase I, Dose Escalation Study to Assess the Safety & Biological Activity of Interleukin 18 (SB-485232) Administered by IV Infusion in Combination With Pegylated Liposomal Doxorubicin (Doxil) in Advanced Stage Epithelial Ovarian Cancer|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:14:53.967649|2018-06-01 02:14:53.967649
NCT00659165|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2011-01-19||2018-02-22|2008-04-14|2008-04-16|Estimate|2011-09-06|2011-10-05|Estimate||||2018-02-22|2018-03-22|Actual|April 2008||2008-04-30|February 2018|2018-02-28|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes|Exploration of the Weight Neutral Effects of Insulin Detemir Compared to Insulin Glargine: A Measure of Satiety and Calories Consumed in Type 1 Diabetes|Completed||N/A|10|Actual|University of New Mexico||2|||f||||f||||||||||2018-06-01 02:14:54.239488|2018-06-01 02:14:54.239488
NCT00659152|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2015-04-27|2008-04-15|2008-04-16|Estimate|||||||2015-04-27|2015-04-28|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Morphofunctional Lung Analysis by Positron Emission Tomography|Morphofunctional Lung Analysis by Positron Emission Tomography in ALI-ARDS Patients|Completed|||30|Actual|Policlinico Hospital|||1||f||||f||||||||||2018-06-01 02:14:54.542775|2018-06-01 02:14:54.542775
NCT00659139|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-04-10|2008-04-10|2008-04-16|Estimate|||||||2008-04-10|2008-04-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:14:54.602216|2018-06-01 02:14:54.602216
NCT00659126|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2018-05-02|2008-04-14|2008-04-16|Estimate|||||||2018-05-02|2018-05-07|Actual|November 16, 2006|Actual|2006-11-16|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors|A Phase II Study of Ferumoxytol and Gadolinium Magnetic Resonance Imaging at 3T and 7T in Subjects With Primary or Metastatic Brain Tumors Either Before or After Therapy|Recruiting||Phase 2|150|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 02:14:54.641569|2018-06-01 02:14:54.641569
NCT00659113|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-15|||2011-12-03|2008-04-15|2008-04-16|Estimate|||||||2011-12-03|2011-12-06|Estimate|March 2008||2008-03-31|December 2008|2008-12-31||||||||Interventional|||S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery|A Phase II Trial of a TS-1/Cisplatin Based Definitive Chemoradiotherapy for Resectable Esophageal Cancer|Unknown status|Recruiting|Phase 2|32|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:14:54.74848|2018-06-01 02:14:54.74848
NCT00659100|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-04-22|2008-04-10|2008-04-16|Estimate|||||||2011-04-22|2011-04-26|Estimate|August 2006||2006-08-31|April 2011|2011-04-30|January 2007|Actual|2007-01-31|||||Interventional|||A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter Environment|A 3-Month, Open-Label, Pharmacy-Based, Actual-Use Trial in a Simulated Over-The-Counter (OTC) Environment to Assess Self-Selection and Consumer Use Patterns of Gabapentin 250 mg for Occasional Sleeplessness|Completed||Phase 3|1254|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:14:54.810565|2018-06-01 02:14:54.810565
NCT00659087|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2016-08-02|2008-04-10|2008-04-16|Estimate|||||||2016-08-02|2016-08-03|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Effectiveness of a Femoral Block Following Total Knee Arthroplasty (TKA)|A Pilot Study of the Feasibility of Early Discharge After Total Knee Arthroplasty Using a Femoral Nerve Block|Completed||Phase 4|20|Actual|Edmonton Civic Employees Research Fund||2|||f||||f||||||||||2018-06-01 02:14:54.921406|2018-06-01 02:14:54.921406
NCT00659074|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2008-04-15|2008-04-15|2008-04-16|Estimate|||||||2008-04-15|2008-04-16|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|February 2004|Actual|2004-02-29|January 2004|Actual|2004-01-31||Interventional|||Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 24 mg ODT With That of GlaxoSmithKine's Zofran 24 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:14:55.001594|2018-06-01 02:14:55.001594
NCT00659061|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|2008-12-15||2018-01-08|2008-04-14|2008-04-16|Estimate|2009-04-02|2009-05-27|Estimate||||2018-01-08|2018-02-01|Actual|August 2007||2007-08-31|January 2018|2018-01-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|Sprinkles||Monitoring and Evaluation of Micronutrients (Sprinkles) Project|Monitoring and Evaluation of Micronutrients (Sprinkles) Project|Completed||N/A|610|Actual|Aga Khan University|The attrition rate was high (6.8% in intervention group and 5.0% in the control group) due to unforeseen migration because of political unrest in the region.|2|||f||||f||||||||||2018-06-01 02:14:55.113221|2018-06-01 02:14:55.113221
NCT00659048|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-11-30|2008-04-15|2008-04-16|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2004||2004-12-31|October 2016|2016-10-31|December 2005|Actual|2005-12-31|April 2005|Actual|2005-04-30||Interventional|||Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)|Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|106|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:14:55.709185|2018-06-01 02:14:55.709185
NCT00659035|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2017-09-26|2008-04-15|2008-04-16|Estimate|||||||2017-09-26|2017-09-27|Actual|April 2008||2008-04-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|OpDrive||Use of Driving Tests to Evaluate Patient Performance on Oral Opioids|Use of Driving Tests to Evaluate Patient Performance on Oral Opioids|Active, not recruiting|||450|Anticipated|Rush University Medical Center|||5||f||||f||||||||||2018-06-01 02:14:55.802077|2018-06-01 02:14:55.802077
NCT00659022|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-09-09|2008-04-10|2008-04-16|Estimate|||||||2011-09-09|2011-09-12|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth|Accelerated Growth of Synchronous Colorectal Liver Metastases: Effects of Neo-adjuvant Therapy|Unknown status|Recruiting|Phase 2|60|Anticipated|Radboud University||4|||f||||t||||||||||2018-06-01 02:14:55.889956|2018-06-01 02:14:55.889956
NCT00659009|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2012-08-14|2008-04-15|2008-04-16|Estimate|||||||2012-08-14|2012-08-15|Estimate|May 2008||2008-05-31|February 2010|2010-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Mild Hypobaric Hypoxia on Oxygen Saturation During Sleep|The Effects of Mild Hypobaric Hypoxia on Oxygen Saturation During Sleep: An Investigation of the Physiologic Mechanisms and Significance|Completed||N/A|16|Actual|The Boeing Company||3|||f||||f||||||||||2018-06-01 02:14:56.001721|2018-06-01 02:14:56.001721
NCT00658996|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-12|2010-12-14||2011-12-07|2008-04-15|2008-04-16|Estimate|2011-01-20|2011-02-16|Estimate||||2011-12-07|2011-12-12|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Product Performance of a Toric Contact Lens|A Study to Evaluate the Product Performance of a Prism-Ballasted Toric Contact Lens When Worn by Currently Adapted Soft Contact Lens Wearers.|Completed||N/A|220|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:14:56.100136|2018-06-01 02:14:56.100136
NCT00658983|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2014-12-04|2008-04-14|2008-04-16|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2008||2008-04-30|February 2014|2014-02-28|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers|Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:14:56.406839|2018-06-01 02:14:56.406839
NCT00658970|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-06-07|2008-04-10|2008-04-16|Estimate|||||||2011-06-07|2011-06-08|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of KX2-391 in Patients With Advanced Malignancies|A Combined Rising Single-dose (RSD) and Rising Multiple-dose (RMD)Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies|Completed||Phase 1|50|Anticipated|Athenex, Inc.|||||f||||f||||||||||2018-06-01 02:14:56.514795|2018-06-01 02:14:56.514795
NCT00658957|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-03-22|2008-04-10|2008-04-16|Estimate|||||||2012-03-22|2012-03-23|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer|A Phase II, Randomized, Parallel, Double-blind, Placebo-controlled Study to Assess Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With Uninfected Lower Extremity Skin Ulcers|Terminated||Phase 2|49|Actual|Innocoll||2||Business Decision|f||||f||||||||||2018-06-01 02:14:56.589357|2018-06-01 02:14:56.589357
NCT00658944|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2008-04-15|2008-04-15|2008-04-16|Estimate|||||||2008-04-15|2008-04-16|Estimate|May 2002||2002-05-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Observational|||Predictive Objective Parameters for Outcome of the Treatment of Stress Urinary Incontinence|Preoperative MUCP and VLPP Failed to Predict Long Term (4-Years) Outcome in Patients Who Underwent Transobturator Mid-Urethral Slings. a Prospective Observational Descriptive Study|Completed|||65|Actual|University Of Perugia|||1||f||||f||||||||||2018-06-01 02:14:56.687042|2018-06-01 02:14:56.687042
NCT00658931|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2010-02-10|2008-04-15|2008-04-16|Estimate|||||||2010-02-10|2010-02-12|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Cymbalta for Depression as a Complication of Bereavement|Cymbalta for Depression as a Complication of Bereavement|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|Jefferson Clinic, P.C.||1|||f||||f||||||||||2018-06-01 02:14:56.767215|2018-06-01 02:14:56.767215
NCT00658918|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2016-12-01|2008-04-15|2008-04-16|Estimate|||||||2016-12-01|2016-12-02|Estimate|September 2004||2004-09-30|October 2016|2016-10-31|November 2005|Actual|2005-11-30|April 2005|Actual|2005-04-30||Interventional|||To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Clinical Trial Designed to Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, 200µg, 100µg or 25µg Once Daily for Six Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age.|Completed||Phase 3|120|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 02:14:56.847329|2018-06-01 02:14:56.847329
NCT00658905|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-14|||2014-10-31|2008-04-15|2008-04-16|Estimate|||||||2014-10-31|2014-11-03|Estimate|April 2008||2008-04-30|October 2014|2014-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants|A Prospective, Randomized, Double-blind Crossover Study Comparing 0.15 g/L rhBSSL Added to Infant Formula Versus Placebo During One Week of Treatment in Preterm Infants Born Before Week 32 of Gestational Age|Completed||Phase 2|33|Actual|Swedish Orphan Biovitrum||2|||f||||t||||||||||2018-06-01 02:14:56.946574|2018-06-01 02:14:56.946574
NCT00658892|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-12|||2017-05-23|2008-04-12|2008-04-15|Estimate|||||||2017-05-23|2017-05-25|Actual|April 8, 2008|Actual|2008-04-08|May 2017|2017-05-31|May 22, 2012|Actual|2012-05-22|February 15, 2010|Actual|2010-02-15||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma|B7-DC Xab Plasma Therapy for the Treatment of Metastatic Melanoma. A Feasibility/Pilot Study|Completed||Phase 1|7|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 02:14:57.044317|2018-06-01 02:14:57.044317
NCT00658879|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2017-03-06|2008-04-09|2008-04-15|Estimate|||||||2017-03-06|2017-03-07|Actual|August 7, 2007|Actual|2007-08-07|March 2017|2017-03-31|November 9, 2016|Actual|2016-11-09|November 9, 2016|Actual|2016-11-09||Observational|||Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan|Special Investigation Of Somavert -Long Term Use-|Completed|||251|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:14:57.119908|2018-06-01 02:14:57.119908
NCT00658866|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2011-08-08|2008-04-14|2008-04-15|Estimate|||||||2011-08-08|2011-08-09|Estimate|February 2008||2008-02-29|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|2007-005020-33||Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection|Target Site Pharmacokinetics of Ertapenem After Multiple Doses in Diabetes Patients With Soft Tissue Infection|Completed||Phase 4|10|Actual|Medical University of Vienna|||||f||||f||||||||||2018-06-01 02:14:57.182716|2018-06-01 02:14:57.182716
NCT00658853|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2016-07-15|2008-04-14|2008-04-15|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Effective High Aerobic Intensity Endurance Training Regimes in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effective High Aerobic Intensity Interval Training to Improve Maximal Oxygen Uptake in COPD Patients|Completed||N/A|26|Actual|Norwegian University of Science and Technology||3|||f||||t||||||||||2018-06-01 02:14:57.247085|2018-06-01 02:14:57.247085
NCT00658840|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2012-04-02|2008-04-10|2008-04-15|Estimate|||||||2012-04-02|2012-04-03|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma|A Phase II Study of Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma|Unknown status|Recruiting|Phase 2|55|Anticipated|National Cancer Center, Korea||1|||f||||||||||||||2018-06-01 02:14:57.32775|2018-06-01 02:14:57.32775
NCT00658827|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2017-09-01|2008-04-14|2008-04-15|Estimate|||||||2017-09-01|2017-09-06|Actual|January 1, 2007|Actual|2007-01-01|September 2017|2017-09-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|||Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis|Exposure to Remicade (Infliximab) During Pregnancy in Patients With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: a Review and Analysis of Birth Outcomes From the Swedish, Danish and Finnish Medical Birth Registers|Completed|||370|Actual|Janssen Biotech, Inc.|||8||f||||f||f||||||||2018-06-01 02:14:57.424626|2018-06-01 02:14:57.424626
NCT00658814|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-12|2013-07-22||2018-04-20|2008-04-12|2008-04-15|Estimate|2013-11-13|2014-01-06|Estimate||||2018-04-20|2018-04-24|Actual|December 1, 2008|Actual|2008-12-01|April 2018|2018-04-30||||June 1, 2013|Actual|2013-06-01||Interventional||Eligible patients who began protocol therapy|Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia|Active, not recruiting||Phase 2|133|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:14:57.574542|2018-06-01 02:14:57.574542
NCT00658801|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2011-07-07|2008-04-10|2008-04-15|Estimate|||||||2011-07-07|2011-07-08|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma|A Phase II Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma|Terminated||Phase 1|4|Actual|National Cancer Center, Korea||||difficult to register|f||||||||||||||2018-06-01 02:14:59.508753|2018-06-01 02:14:59.508753
NCT00658788|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2014-08-12||2014-08-12|2008-04-09|2008-04-15|Estimate|2014-08-12|2014-08-27|Estimate||||2014-08-12|2014-08-27|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis|A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of a Consecutive Treatment Regimen of Clobetasol Propionate 0.05% Spray, Followed by Calcitriol Ointment 3µg/g, in the Management of Moderate to Severe Plaque Psoriasis|Completed||Phase 3|305|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-06-01 02:14:59.697566|2018-06-01 02:14:59.697566
NCT00658775|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2015-06-08||2015-11-19|2008-04-14|2008-04-15|Estimate|2015-06-08|2015-06-23|Estimate||||2015-11-19|2015-12-21|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|1069|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 02:15:00.921742|2018-06-01 02:15:00.921742
NCT00658762|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09||2010-08-25|2012-11-09|2008-04-09|2008-04-15|Estimate||||2010-08-25|2010-08-30|Estimate|2012-11-09|2012-11-16|Estimate|May 2008||2008-05-31|November 2012|2012-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder|Terminated||Phase 3|286|Actual|Pfizer||4||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 02:15:01.808334|2018-06-01 02:15:01.808334
NCT00658749|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2009-06-24|2008-04-14|2008-04-15|Estimate|||||||2009-06-24|2009-06-25|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|AIR645-CS1||A Phase 1 Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of AIR645 in Healthy Subjects and Subjects With Controlled Asthma|Completed||Phase 1|80|Actual|Altair Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 02:15:02.147861|2018-06-01 02:15:02.147861
NCT00658736|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2017-03-13||2017-05-17|2008-04-14|2008-04-15|Estimate|2017-05-17|2017-06-14|Actual||||2017-05-17|2017-06-14|Actual|March 2008||2008-03-31|May 2017|2017-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis|A Randomized, Triple-Blinded Study of Endoscopic Ultrasound Guided Celiac Plexus Blockade (EUS-CPB) With Bupivicaine and Triamcinolone vs. Bupivicaine Alone for the Treatment of Pain in Chronic Pancreatitis|Completed||Phase 3|40|Actual|The Cleveland Clinic||2|||f||||t||||||||No|The IPD will not be shared.|2018-06-01 02:15:02.374471|2018-06-01 02:15:02.374471
NCT00658723|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2014-03-29|2010-08-20|2014-09-09|2008-04-14|2008-04-15|Estimate|2014-09-09|2014-09-11|Estimate|2010-08-30|2010-09-01|Estimate|2014-09-09|2014-09-11|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||The Fibrin Patch Soft Tissue Study|A Prospective, Randomized, Controlled, Superiority Evaluation of Fibrin Patch as an Adjunct to Control Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery|Completed||Phase 2|141|Actual|Ethicon, Inc.||2|||f||||t||||||||||2018-06-01 02:15:02.98668|2018-06-01 02:15:02.98668
NCT00658710|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2013-11-06|2008-04-14|2008-04-15|Estimate|||||||2013-11-06|2013-11-07|Estimate|June 2008||2008-06-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|HEMIMARCHE||Impact of Prolonged Physical Therapy on Gait Performance of Chronic Phase Stroke Patients|Impact of Prolonged Physical Therapy on Gait Performance of Chronic Phase Stroke Patients|Terminated||N/A|70|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t||||||||||2018-06-01 02:15:05.119469|2018-06-01 02:15:05.119469
NCT00658697|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2015-07-29||2017-04-27|2008-04-09|2008-04-15|Estimate|2015-07-29|2015-08-26|Estimate||||2017-04-27|2017-05-25|Actual|June 2008||2008-06-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional||41 (One patient never started any study treatment, and was excluded from analysis).|Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer|A Phase II Trial of Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising Prostate Specific Antigen (PSA) After Local Therapy|Completed||Phase 2|42|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 02:15:05.296106|2018-06-01 02:15:05.296106
NCT00658684|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2010-07-14||2010-10-05|2008-04-14|2008-04-15|Estimate|2010-07-14|2010-08-11|Estimate||||2010-10-05|2010-10-13|Estimate|February 2008||2008-02-29|October 2010|2010-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.|An Open-Label, Multicenter, Long Term Study to Evaluate the Safety, Tolerability and Efficacy of Fesoterodine in Patients With Overactive Bladder.|Completed||Phase 3|153|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:15:05.776822|2018-06-01 02:15:05.776822
NCT00658671|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2016-01-26|2008-04-11|2008-04-15|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2008||2008-04-30|January 2016|2016-01-31|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|||A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer|An Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer|Completed||Phase 1|67|Actual|CASI Pharmaceuticals, Inc.||4|||f||||f||||||||Undecided||2018-06-01 02:15:07.037466|2018-06-01 02:15:07.037466
NCT00658658|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2016-01-20||2016-04-12|2008-04-14|2008-04-15|Estimate|2016-04-12|2016-05-18|Estimate||||2016-04-12|2016-05-18|Estimate|March 2008||2008-03-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Panitumumab in Children With Solid Tumors|A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children With Solid Tumors|Completed||Phase 1|31|Actual|Amgen||1|||f||||f||||||||||2018-06-01 02:15:07.199555|2018-06-01 02:15:07.199555
NCT00658645|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2010-09-24|2008-04-09|2008-04-15|Estimate|||||||2010-09-24|2010-09-27|Estimate|March 2008||2008-03-31|September 2010|2010-09-30|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Efficacy of Bifeprunox in Patients With Schizophrenia|A Multinational, Randomised, Double-blind, Fixed-dose, Bifeprunox Study Combining a 12-Week Placebo-controlled, Quetiapine-referenced Phase With a 12-month Quetiapine-controlled Phase in Patients With Schizophrenia|Terminated||Phase 3|227|Actual|H. Lundbeck A/S||3||Interim analysis showed inadequate efficacy of bifeprunox|f||||f||||||||||2018-06-01 02:15:09.124627|2018-06-01 02:15:09.124627
NCT00658632|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2015-06-08||2016-03-28|2008-04-14|2008-04-15|Estimate|2015-06-08|2015-06-23|Estimate||||2016-03-28|2016-05-04|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional||The analysis was performed using the Intent-to-Treat (ITT) population, defined as all randomized subjects who received at least 1 dose of study drug, minus two participants from one site who were excluded from the ITT Population per an agreement with the FDA due to concerns of possible misconduct.|Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|1397|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 02:15:09.2811|2018-06-01 02:15:09.2811
NCT00658619|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|2013-03-13|2011-06-30|2013-03-13|2008-04-14|2008-04-15|Estimate|2013-03-13|2013-04-26|Estimate|2011-06-30|2011-07-13|Estimate|2013-03-13|2013-04-26|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)|Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to AMD|Completed||Phase 2|119|Actual|Allergan||5|||f||||f||||||||||2018-06-01 02:15:09.778078|2018-06-01 02:15:09.778078
NCT00658606|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2011-02-17||2013-01-03|2008-04-10|2008-04-15|Estimate|2011-03-28|2011-04-22|Estimate||||2013-01-03|2013-01-08|Estimate|October 2007||2007-10-31|January 2013|2013-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects|Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 4|98|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||t||||||||||2018-06-01 02:15:10.508043|2018-06-01 02:15:10.508043
NCT00658593|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-12|||2012-12-17|2008-04-12|2008-04-15|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|||||Interventional|||Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer|A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer|Terminated||Phase 3|19|Actual|Canadian Cancer Trials Group||||due to poor accrual|f||||||||||||||2018-06-01 02:15:11.120014|2018-06-01 02:15:11.120014
NCT00658580|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2015-02-11|2008-04-14|2008-04-15|Estimate|||||||2015-02-11|2015-02-12|Estimate|April 2000||2000-04-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|December 2013|Actual|2013-12-31||Interventional|||Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer|A Phase III Randomized Study Comparing A Chemotherapy With Cisplatin And Etoposide To A Etoposide Regimen Without Cisplatin For Patients With Extensive Small-Cell Lung Cancer|Completed||Phase 3|361|Actual|European Lung Cancer Working Party||2|||f||||t||||||||||2018-06-01 02:15:11.221015|2018-06-01 02:15:11.221015
NCT00658567|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2014-02-06||2017-04-18|2008-04-10|2008-04-15|Estimate|2014-08-29|2014-09-09|Estimate||||2017-04-18|2017-05-19|Actual|March 2008||2008-03-31|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis||Completed||Phase 3|123|Actual|ACADIA Pharmaceuticals Inc.||3|||f||||f|t|f||||||No||2018-06-01 02:15:11.340199|2018-06-01 02:15:11.340199
NCT00658554|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2008-06-18|2008-04-14|2008-04-15|Estimate|||||||2008-06-18|2008-06-19|Estimate|April 2008||2008-04-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers|Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers|Completed||Phase 1|24|Actual|ArQule|||||t||||f||||||||||2018-06-01 02:15:11.824871|2018-06-01 02:15:11.824871
NCT00658541|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2009-12-16||2011-04-29|2008-04-14|2008-04-15|Estimate|2009-12-16|2010-01-20|Estimate||||2011-04-29|2011-05-03|Estimate|May 2004||2004-05-31|April 2011|2011-04-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets|A Randomized, Two-way Crossover, Single-dose, Open-label Study to Evaluate the Relative Bioequivalence of a Test Tablet Formulation of Zolpidem Tartrate 10mg, Compared to an Equivalent Dose of Ambien® in Fed, Healthy, Adult Subjects|Completed||Phase 1|38|Actual|Mutual Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:15:11.895036|2018-06-01 02:15:11.895036
NCT00658528|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2015-06-08||2015-11-19|2008-04-14|2008-04-15|Estimate|2015-06-08|2015-06-23|Estimate||||2015-11-19|2015-12-21|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)|A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|1061|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 02:15:12.151354|2018-06-01 02:15:12.151354
NCT00658515|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28||2016-08-09|2016-11-01|2008-04-10|2008-04-15|Estimate||||2016-09-01|2016-09-02|Estimate|2016-11-01|2016-11-02|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome|A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome|Completed||Phase 3|15865|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:15:12.653636|2018-06-01 02:15:12.653636
NCT00658502|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2008-04-14|2008-04-14|2008-04-15|Estimate|||||||2008-04-14|2008-04-15|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Observational|||Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment|Ocular Response Analyzer Assessment of Intraocular Pressure and Corneal Biomechanical Properties in Myopic and Anisometropic Patients Under Atropine Treatment|Unknown status|Recruiting||100|Anticipated|Far Eastern Memorial Hospital|||2||f||||||||||||||2018-06-01 02:15:14.472671|2018-06-01 02:15:14.472671
NCT00658489|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2011-11-09|2008-04-14|2008-04-15|Estimate|||||||2011-11-09|2011-11-11|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Implementation and Evaluation of Bright Futures Curriculum Within CORNET Continuity Practice|Implementation and Evaluation of Bright Futures Curriculum Within CORNET Continuity Practice|Completed||N/A|10|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-06-01 02:15:14.531662|2018-06-01 02:15:14.531662
NCT00658476|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2012-03-26|2008-04-14|2008-04-15|Estimate|||||||2012-03-26|2012-03-27|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|PUFA||Omega-3 Fatty Acids for Treatment of Depression in Adolescents|Treating Adolescent Depression With Fish Oils|Completed||Phase 3|4|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-06-01 02:15:14.619243|2018-06-01 02:15:14.619243
NCT00658463|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-14|2008-04-14|2008-04-15|Estimate|||||||2008-04-14|2008-04-15|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Effects of Rosuvastatin on the, in Vivo, Kinetic of apoB and apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients|Effects of Rosuvastatin on the, in Vivo, Kinetic of VLDL apoB, IDL apoB, LDL apoB and HDL apoA1, Using Stable Isotopes, in Type 2 Diabetic Patients|Completed||Phase 4|8|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-06-01 02:15:14.740199|2018-06-01 02:15:14.740199
NCT00658450|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2012-12-05|2008-04-14|2008-04-15|Estimate|||||||2012-12-05|2012-12-06|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Rehabilitation Program for Cognitive Deficits in Ugandan Children After Cerebral Malaria|A Randomised Trial to Investigate the Effect of a Rehabilitation Program for Cognitive Deficits in Ugandan Children After Cerebral Malaria.|Completed||N/A|123|Actual|Makerere University||2|||f||||t||||||||||2018-06-01 02:15:14.827771|2018-06-01 02:15:14.827771
NCT00658437|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2011-06-07|2008-04-09|2008-04-15|Estimate|||||||2011-06-07|2011-06-08|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional|||CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy|A Phase II Multicenter Study to Test Progression-free and Overall Survival of CY-503 in the Treatment of Patients With Unresectable Stage IV Metastatic Melanoma After Antineoplastic Treatment Failure|Completed||Phase 2|31|Actual|Cytavis Biopharma GmbH|||||f||||f||||||||||2018-06-01 02:15:14.899565|2018-06-01 02:15:14.899565
NCT00658411|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2012-12-04||2013-04-05|2008-04-09|2008-04-15|Estimate|2013-04-05|2013-04-09|Estimate||||2013-04-05|2013-04-09|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation|A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload|Terminated||N/A|5|Actual|Dana-Farber Cancer Institute|The number of patients enrolled on this study is far too small to draw reliable conclusions.|1||Closed due to slow patient accrual|f||||t||||||||||2018-06-01 02:15:15.099576|2018-06-01 02:15:15.099576
NCT00658398|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2015-05-19|2008-04-14|2008-04-15|Estimate|||||||2015-05-19|2015-05-20|Estimate|May 2008||2008-05-31|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|BREVALCO||The BREVALCO Study, Effect of an Interactive Computer Program to Prevent Alcohol Misuse|Effect of an Interactive Computer Program to Prevent Alcohol Misuse. A Multicentre Randomized Controlled Trial. The BREVALCO Study.|Completed||Phase 3|601|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:15:15.303578|2018-06-01 02:15:15.303578
NCT00658385|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2015-04-07||2016-10-04|2008-04-10|2008-04-15|Estimate|2016-10-04|2016-11-25|Estimate||||2016-10-04|2016-11-25|Estimate|April 2008||2008-04-30|October 2016|2016-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major|A Pilot Trial to Assess the Feasibility and Safety of GCSF Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major|Completed||N/A|5|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:15:15.391775|2018-06-01 02:15:15.391775
NCT00658034|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2011-10-25|2008-04-08|2008-04-14|Estimate|||||||2011-10-25|2011-10-26|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue|Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: a Randomized Phase III Trial|Unknown status|Recruiting|Phase 3|20|Anticipated|Alta Bates Summit Medical Center||2|||f||||f||||||||||2018-06-01 02:15:25.383379|2018-06-01 02:15:25.383379
NCT00658372|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09||2010-08-25|2012-11-09|2008-04-09|2008-04-15|Estimate||||2010-08-25|2010-08-30|Estimate|2012-11-09|2012-11-16|Estimate|May 2008||2008-05-31|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder|Terminated||Phase 3|360|Actual|Pfizer||4||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 02:15:15.533594|2018-06-01 02:15:15.533594
NCT00658359|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2016-06-07||2018-02-20|2008-04-09|2008-04-15|Estimate|2018-02-20|2018-02-23|Actual||||2018-02-20|2018-02-23|Actual|August 2008|Actual|2008-08-31|February 2018|2018-02-28|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional||The safety analysis set was defined as those participants who received at least 1 dose of study drug in Study A3921050.|Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients|A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients|Completed||Phase 2|178|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 02:15:15.919838|2018-06-01 02:15:15.919838
NCT00658346|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2017-01-11|2008-04-14|2008-04-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|August 2015|Actual|2015-08-31||Observational|||Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon|Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon|Completed|||141|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||2||f||||t||||||Samples With DNA|"~     plasma and mononucleus cells~   "|||2018-06-01 02:15:21.74519|2018-06-01 02:15:21.74519
NCT00658333|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2010-12-02||2012-07-31|2008-04-14|2008-04-15|Estimate|2011-02-15|2011-03-11|Estimate||||2012-07-31|2012-08-07|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms|A Multicenter, Randomized, Double Blind, Double Dummy Controlled Study to Assess the Tolerability of an Increased Dose of Enteric Coated MPA After Conversion From MMF in Renal Transplant Recipients Who Required MMF Dose Reductions Due to Gastrointestinal Symptoms|Terminated||Phase 4|30|Actual|Novartis|Due to the insufficient number of patients enrolled in the study, no conclusions can be made from the data.|2|||f||||||||||||||2018-06-01 02:15:22.049193|2018-06-01 02:15:22.049193
NCT00658320|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2011-08-10||2013-05-13|2008-04-14|2008-04-15|Estimate|2011-08-10|2011-09-14|Estimate||||2013-05-13|2013-06-21|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|May 2012|Actual|2012-05-31|August 2010|Actual|2010-08-31||Interventional||Baseline Measures are based on the data obtained in the Core Study.|Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids|A 12-month, Multicenter, Randomized, Open-label Study to Investigate Efficacy and Safety of Concentration Controlled Everolimus With Reduced Dose Cyclosporine A Versus Mycophenolate Mofetil With Standard Dose Cyclosporine A in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids|Completed||Phase 3|122|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:15:22.427965|2018-06-01 02:15:22.427965
NCT00658307|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2014-05-01|2008-04-14|2008-04-15|Estimate|||||||2014-05-01|2014-05-02|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effects of Repetitive Transcranial Magnetic Stimulation in Healthy Human Subjects|The Effects of Repetitive Transcranial Magnetic Stimulation in Healthy Human Subjects|Completed||N/A|56|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 02:15:23.19519|2018-06-01 02:15:23.19519
NCT00658294|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2017-10-16|2008-04-11|2008-04-14|Estimate|||||||2017-10-16|2017-10-17|Actual|January 2008|Actual|2008-01-31|October 2017|2017-10-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|||Analysis of the Potentially Parasitocidal Effect of a Long Term Chemotherapy With Benzimidazoles|Analysis of the Potentially Parasitocidal Effect of a Long Term Chemotherapy With Benzimidazoles in Patients With Inoperable Alveolar Echinococcosis Using PET-CT and EmII/3-10 Serology|Completed|||34|Actual|University of Zurich|||||f||||f||||||||No||2018-06-01 02:15:23.281914|2018-06-01 02:15:23.281914
NCT00658281|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2015-10-05|2008-04-08|2008-04-14|Estimate|||||||2015-10-05|2015-10-07|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients|A Pilot Study of Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients Using On-Board Imaging System With Linear Accelerator|Completed|||28|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:15:23.374799|2018-06-01 02:15:23.374799
NCT00658268|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2017-08-11|2008-04-09|2008-04-14|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2008|Actual|2008-03-31|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Bisphosphonates and Impaction Grafting in Hip Revision|Bisphosphonates and Impaction Grafting in Hip Revision Evaluated With Radiostereophotogrametri. A Randomized, Double-blind Study in Patients Operated for Aseptic Loosening and Osteolysis.|Completed||Phase 2|32|Actual|Region Skane||2|||f||||f||||||||||2018-06-01 02:15:23.473052|2018-06-01 02:15:23.473052
NCT00658255|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-01-21|2008-04-08|2008-04-14|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2002||2002-10-31|January 2011|2011-01-31|May 2003|Actual|2003-05-31|||||Interventional|||Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler|A Randomized, Multicenter, Open-label, Active-controlled, Single-dose, 5-period, Incomplete Block, Cross-over Study to Evaluate the Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort pMDI or Oxis Turbuhaler to Adults With Stable Asthma|Completed||Phase 2|175|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:15:23.570566|2018-06-01 02:15:23.570566
NCT00658242|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2013-08-07|2008-04-11|2008-04-14|Estimate|||||||2013-08-07|2013-08-09|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Craniofacial Surgery Perioperative Registry|Craniofacial Surgery Perioperative Registry|Completed|||249|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-06-01 02:15:23.723322|2018-06-01 02:15:23.723322
NCT00658229|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2012-10-12|2008-04-11|2008-04-14|Estimate|||||||2012-10-12|2012-10-15|Estimate|November 2008||2008-11-30|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PEPC||The Physical Exercise and Prostate Cancer Study|Physical Exercise for Patients With Prostate Cancer During Androgen Deprivation Therapy - A Randomized Trial|Completed||Phase 3|60|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 02:15:23.785289|2018-06-01 02:15:23.785289
NCT00658216|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2013-08-02|2008-04-11|2008-04-14|Estimate|||||||2013-08-02|2013-08-05|Estimate|June 2007||2007-06-30|July 2013|2013-07-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Observational|BED||Brain Natriuretic Peptide (BNP) Usefulness In Elderly Dyspneic Patients (BED)|Usefulness of Measuring Plasma Brain Natriuretic Peptide for Diagnosis and Prognosis in Very Elderly Patients.|Completed|||390|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Blood sample for brain natriuretic peptide measurement~   "|||2018-06-01 02:15:23.901561|2018-06-01 02:15:23.901561
NCT00658203|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-04-07|2008-04-14|Estimate|||||||2008-04-07|2008-04-14|Estimate|November 2005||2005-11-30|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Clinical Evaluation on Advanced Resynchronization|Clinical Evaluation on Advanced Resynchronization|Completed||Phase 4|310|Anticipated|LivaNova||2|||f||||t||||||||||2018-06-01 02:15:24.046508|2018-06-01 02:15:24.046508
NCT00658190|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2015-04-06|2008-04-09|2008-04-14|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2003||2003-10-31|April 2012|2012-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|IBCCSP||Internet-Based Cervical Cytology Screening Program|Internet-Based Cervical Cytology Screening Program|Completed|||175|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-06-01 02:15:24.226697|2018-06-01 02:15:24.226697
NCT00658177|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2014-12-01|2008-04-09|2008-04-14|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2003||2003-06-30|December 2014|2014-12-31|February 2004|Actual|2004-02-29|||||Interventional|||Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects|Completed||Phase 3|463|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:15:24.323714|2018-06-01 02:15:24.323714
NCT00658164|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2008-04-11|2008-04-11|2008-04-14|Estimate|||||||2008-04-11|2008-04-14|Estimate|October 2007||2007-10-31|July 2007|2007-07-31||||March 2009|Anticipated|2009-03-31||Interventional|||Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores||Unknown status|Recruiting|Phase 3|150|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||1|||f||||||||||||||2018-06-01 02:15:24.420016|2018-06-01 02:15:24.420016
NCT00658151|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-04-11|2008-04-11|2008-04-14|Estimate|||||||2008-04-11|2008-04-14|Estimate|April 2008||2008-04-30|April 2008|2008-04-30||||January 2009|Anticipated|2009-01-31||Observational|||Ultrasound Diagnosis of Antibiotic Associated Diarrhea||Unknown status|Not yet recruiting||100|Anticipated|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 02:15:24.491786|2018-06-01 02:15:24.491786
NCT00658138|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2011-12-29||2012-02-23|2008-04-08|2008-04-14|Estimate|2012-02-23|2012-03-26|Estimate||||2012-02-23|2012-03-26|Estimate|December 2008||2008-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|||Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults|Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults|Completed||N/A|61|Actual|3M|Main limitation of study was small sample size and short duratrion. Study was a pilot of one year's duration.|2|||f||||f||||||||||2018-06-01 02:15:24.556803|2018-06-01 02:15:24.556803
NCT00658125|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2010-04-07|2008-04-11|2008-04-14|Estimate|||||||2010-04-07|2010-04-08|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Deep Brain Stimulation (DBS) for Alzheimer's Disease|Modulation of Cognitive Function Using Electrical Brain Stimulation in Patients With Early Alzheimer Disease|Unknown status|Active, not recruiting|Phase 1|6|Anticipated|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 02:15:24.743004|2018-06-01 02:15:24.743004
NCT00658112|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2017-01-27||2017-11-01|2008-04-09|2008-04-14|Estimate|2017-01-27|2017-03-17|Actual||||2017-11-01|2017-12-06|Actual|July 2006||2006-07-31|November 2017|2017-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne|Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne|Completed||Phase 4|20|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-06-01 02:15:24.805017|2018-06-01 02:15:24.805017
NCT00658099|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2017-01-30|2008-04-11|2008-04-14|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2007||2007-11-30|January 2017|2017-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|EVIDENCE||Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®|Change in Weight on Insulin Detemir (Levemir®) or Isophane (NPH) Insulin (Insulatard®) in Patients With Type 2 Diabetes Mellitus|Completed|||699|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-06-01 02:15:24.977652|2018-06-01 02:15:24.977652
NCT00658086|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09||2018-01-24|2018-01-26|2008-04-11|2008-04-14|Estimate||||2018-01-26|2018-01-29|Actual|2018-01-26|2018-01-29|Actual|April 2008||2008-04-30|January 2018|2018-01-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)|A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)|Completed||Phase 2|24|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:15:25.057414|2018-06-01 02:15:25.057414
NCT00658073|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2011-03-07|2008-04-11|2008-04-14|Estimate|||||||2011-03-07|2011-03-08|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Recipients of Living Kidney Allografts|Completed||N/A|165|Actual|Fuzhou General Hospital||3|||f||||t||||||||||2018-06-01 02:15:25.147211|2018-06-01 02:15:25.147211
NCT00658060|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-04-11|2008-04-11|2008-04-14|Estimate|||||||2008-04-11|2008-04-14|Estimate|September 2007||2007-09-30|April 2008|2008-04-30||||||||Observational|||Magnetic Resonance (MR) Spectroscopy In Familial Mediterranean Fever (FMF) Patients|Exertional Muscle Fatigue In FMF Patients Evaluated By MRI And MR Spectroscopy Of The Thigh|Unknown status|Recruiting||20|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-06-01 02:15:25.235586|2018-06-01 02:15:25.235586
NCT00658047|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08||2013-03-27|2013-04-09|2008-04-11|2008-04-14|Estimate||||2013-03-27|2013-04-04|Estimate|2013-04-09|2013-04-15|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|CH-1504-201||A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis|A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|201|Actual|Chelsea Therapeutics||4|||f||||t||||||||||2018-06-01 02:15:25.310398|2018-06-01 02:15:25.310398
NCT00658021|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2018-05-08|2008-04-08|2008-04-14|Estimate|||||||2018-05-08|2018-05-09|Actual|May 30, 2008|Actual|2008-05-30|May 2018|2018-05-31|March 6, 2023|Anticipated|2023-03-06|March 10, 2020|Anticipated|2020-03-10||Interventional|||Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes|Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes.|Recruiting||Phase 3|195|Anticipated|AstraZeneca||3|||f||||t||||||||||2018-06-01 02:15:25.589486|2018-06-01 02:15:25.589486
NCT00658008|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08||2010-08-25|2012-11-09|2008-04-08|2008-04-14|Estimate||||2010-08-25|2010-08-30|Estimate|2012-11-09|2012-11-16|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)|A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder|Terminated||Phase 3|501|Actual|Pfizer||5||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 02:15:25.82685|2018-06-01 02:15:25.82685
NCT00657995|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-08|2008-04-08|2008-04-14|Estimate|||||||2008-04-08|2008-04-14|Estimate|April 2007||2007-04-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Tight Glycemic Control by Artificial Pancreas|Continuous Postoperative Blood Glucose Monitoring and Control by an Artificial Pancreas in Patients Undergoing Pancreatic Resection: A Prospective Randomized Clinical Trial|Completed||N/A|32|Actual|Kochi University||1|||f||||t||||||||||2018-06-01 02:15:26.050989|2018-06-01 02:15:26.050989
NCT00657982|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2009-01-19|2008-04-08|2008-04-14|Estimate|||||||2009-01-19|2009-01-21|Estimate|April 2008||2008-04-30|January 2009|2009-01-31||||March 2010|Anticipated|2010-03-31||Interventional|||Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer|Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer|Unknown status|Recruiting|Phase 2|15|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:15:26.14882|2018-06-01 02:15:26.14882
NCT00657969|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2009-10-20|2008-04-11|2008-04-14|Estimate|||||||2009-10-20|2009-10-21|Estimate|July 2005||2005-07-31|October 2009|2009-10-31|September 2009|Anticipated|2009-09-30|January 2009|Actual|2009-01-31||Observational|CADISP||Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections|Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections|Unknown status|Active, not recruiting||4169|Actual|Cervical Artery Dissections and Ischemic Stroke Patients - Consortium|||3||f||||||||||Samples With DNA|"~     DNA, plasma, serum~   "|||2018-06-01 02:15:26.251831|2018-06-01 02:15:26.251831
NCT00657956|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2014-03-28|2008-04-11|2008-04-14|Estimate|||||||2014-03-28|2014-03-31|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Roentgen Stereophotogrammetric Analysis (RSA) to Evaluate Fixation of Biofoam Advance Total Knee Arthroplasty Components|Prospective RCT Using Roentgen Stereophotogrammetric Analysis (RSA) to Evaluate Fixation of the Biofoam Advance Total Knee Arthroplasty Components With and Without Screw Augmentation|Completed||N/A|50|Actual|Dalhousie University|||||f||||f||||||||||2018-06-01 02:15:26.347974|2018-06-01 02:15:26.347974
NCT00657943|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2014-02-02|2008-04-11|2008-04-14|Estimate|||||||2014-02-02|2014-02-04|Estimate|April 2008||2008-04-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CIMT||The Copenhagen Insulin and Metformin Therapy Trial|The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial|Completed||Phase 4|415|Actual|Steno Diabetes Center||6|||f||||t||||||||||2018-06-01 02:15:26.414787|2018-06-01 02:15:26.414787
NCT00657930|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2016-03-02|2008-04-11|2008-04-14|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|LEONCET2||Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)|Evaluation on Glycaemic Control and Weight Change of Once Daily Levemir® (Insulin Detemir) in Type 2 Diabetes Mellitus Treated by an Intensive Insulin Treatment (ICT)|Completed|||2289|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:15:26.514058|2018-06-01 02:15:26.514058
NCT00657917|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2011-11-29|2008-04-08|2008-04-14|Estimate|||||||2011-11-29|2011-12-01|Estimate|November 2004||2004-11-30|November 2011|2011-11-30|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396|Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396|Completed||Phase 2|1|Actual|U.S. Army Medical Research and Materiel Command|||||f||||f||||||||||2018-06-01 02:15:26.589614|2018-06-01 02:15:26.589614
NCT00657904|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2012-06-05|2008-04-11|2008-04-14|Estimate|||||||2012-06-05|2012-06-06|Estimate|August 1995||1995-08-31|June 2012|2012-06-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer|A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.|Completed||Phase 3|3618|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:15:26.683959|2018-06-01 02:15:26.683959
NCT00657891|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2013-09-30|2008-04-11|2008-04-14|Estimate|||||||2013-09-30|2013-10-01|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Effect of Xolair (Omalizumab) on Allergy Blood Cells|The Effect of Xolair (Omalizumab) on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils|Completed||Phase 4|49|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 02:15:26.882702|2018-06-01 02:15:26.882702
NCT00657878|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2015-10-28|2008-04-08|2008-04-14|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|July 2016|Anticipated|2016-07-31||Interventional|MITO-8||Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval|Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy.|Unknown status|Active, not recruiting|Phase 3|215|Actual|National Cancer Institute, Naples||2|||f||||f||||||||||2018-06-01 02:15:26.984344|2018-06-01 02:15:26.984344
NCT00657865|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2011-08-19|2008-04-11|2008-04-14|Estimate|||||||2011-08-19|2011-08-22|Estimate|March 2008||2008-03-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|March 2010|Actual|2010-03-31||Interventional|||Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril|Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril|Completed||Phase 4|18|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:15:27.10544|2018-06-01 02:15:27.10544
NCT00657852|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-04-08|2008-04-08|2008-04-14|Estimate|||||||2008-04-08|2008-04-14|Estimate|December 2000||2000-12-31|April 2008|2008-04-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Efficacy of Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Disodium Pamidronate in the Treatment of Bone Loss Associated With Liver Transplant|Completed||Phase 4|79|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:15:27.166628|2018-06-01 02:15:27.166628
NCT00657839|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2014-10-27|2008-04-09|2008-04-14|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2005||2005-10-31|October 2014|2014-10-31|June 2006|Actual|2006-06-30|||||Interventional|||Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia|A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Assess the Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia|Completed||Phase 2|222|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:15:27.231162|2018-06-01 02:15:27.231162
NCT00657826|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04||2016-06-20|2016-06-20|2008-04-08|2008-04-14|Estimate||||2016-06-20|2016-06-22|Estimate|2016-06-20|2016-06-22|Estimate|October 2001||2001-10-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm|ATS 3f(r) Aortic Bioprosthesis Model 1000|Terminated||N/A|22|Actual|Medtronic Cardiovascular||1||Business decision to end study due to limited enrollment and study population|f||||t||||||||No||2018-06-01 02:15:27.305866|2018-06-01 02:15:27.305866
NCT00657813|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2010-10-07|2008-04-11|2008-04-14|Estimate|||||||2010-10-07|2010-10-11|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|July 2008|Actual|2008-07-31|June 2008|Anticipated|2008-06-30||Interventional|||Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition|Evaluation of [123I] MNI-330 and Single Photon Emission Computed Tomography (SPECT) as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Terminated||Phase 1|3|Actual|Institute for Neurodegenerative Disorders||1||Data did not evidence [123I]MNI-330 as a useful tool in the detection of AD.|f||||f||||||||||2018-06-01 02:15:27.374627|2018-06-01 02:15:27.374627
NCT00657800|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2010-09-21|2008-04-08|2008-04-14|Estimate|||||||2010-09-21|2010-09-22|Estimate|December 2007||2007-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|October 2009|Actual|2009-10-31||Interventional|||The Effect of a Coordinated Inpatient Diabetes Education Program in the Outpatient Setting|The Effect of a Coordinated Inpatient Diabetes Education Program on Glycemic Control, Diabetes Self-Management, Patient Satisfaction, and Quality of Life in the Outpatient Setting|Completed||N/A|60|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:15:27.545574|2018-06-01 02:15:27.545574
NCT00657787|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2016-01-20|2008-04-11|2008-04-14|Estimate|||||||2016-01-20|2016-01-21|Estimate|September 2008||2008-09-30|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|||||Observational|||Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans|Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans|Unknown status|Active, not recruiting||1600|Anticipated|Boston VA Research Institute, Inc.|||3||f||||f||||||||||2018-06-01 02:15:27.623017|2018-06-01 02:15:27.623017
NCT00657774|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-11-28|2008-04-08|2008-04-14|Estimate|||||||2008-11-28|2008-12-01|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group, 6-Week Study to Evaluate the Effect of Multiple Doses of FlutiForm™ 250/10 Microgram HFA pMDI Twice Daily, FlutiForm™ 100/10 Microgram HFA pMDI Twice Daily, Prednisone and Placebo on the Hypothalmic-Pituitary-Adrenal Axis in Adult Subjects With Mild to Moderate Asthma.|Completed||Phase 1|160|Anticipated|SkyePharma AG||4|||f||||f||||||||||2018-06-01 02:15:27.740348|2018-06-01 02:15:27.740348
NCT00657761|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-04-08|2008-04-08|2008-04-14|Estimate|||||||2008-04-08|2008-04-14|Estimate|September 2005||2005-09-30|April 2008|2008-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Metabolic Effects of Enfuvirtide in Healthy Volunteers|Effect of Enfuvirtide on Lipid and Glucose Metabolism and Mitochondrial Function in Healthy Volunteers|Completed||Phase 4|15|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:15:27.853917|2018-06-01 02:15:27.853917
NCT00657748|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2015-04-20|2008-04-11|2008-04-14|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||Lithium and Acetate for Canavan Disease|Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease|Withdrawn||Phase 2|0|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 02:15:27.920333|2018-06-01 02:15:27.920333
NCT00657735|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2012-01-04|2008-04-11|2008-04-14|Estimate|||||||2012-01-04|2012-01-05|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Double Blind Randomized Controlled, H1 Coil In Subjects With Bipolar Depression|A Prospective Double Blind Randomized Controlled Trial To Explore The Tolerability, Safety And Efficacy Of The H1-Coil Deep Transcranial Magnetic Stimulation (TMS) In Subjects With Bipolar Depression|Unknown status|Recruiting|N/A|50|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-06-01 02:15:28.003802|2018-06-01 02:15:28.003802
NCT00657722|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2013-04-10|2008-04-11|2008-04-14|Estimate|||||||2013-04-10|2013-04-11|Estimate|January 2008||2008-01-31|April 2013|2013-04-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|ETHAPE||Identification of Criteria of the Success of the Endarterectomy in Chronic Pulmonary Post Embolic Hypertension|Identification Of The Predictive Angiographic And Computed Tomographic (CT) Criteria Of The Success Of The Thromboendarterectomy In Chronic Pulmonary Hypertension|Completed||N/A|249|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 02:15:28.145241|2018-06-01 02:15:28.145241
NCT00657709|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2015-02-13||2017-09-11|2008-04-11|2008-04-14|Estimate|2015-04-09|2015-04-10|Estimate||||2017-09-11|2017-10-10|Actual|March 2008||2008-03-31|September 2017|2017-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants|A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants|Completed||Phase 3|3630|Actual|Novartis||5|||f||||t||||||||||2018-06-01 02:15:28.313137|2018-06-01 02:15:28.313137
NCT00657696|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2017-06-02|2008-04-09|2008-04-14|Estimate|||||||2017-06-02|2017-06-06|Actual|January 28, 2009|Actual|2009-01-28|June 2017|2017-06-30|March 30, 2012|Actual|2012-03-30|March 30, 2012|Actual|2012-03-30||Observational|Learn & Relate||Learning and Relationships in Primary Care|Learning and Relationships in Primary Care Clinical Microsystems|Completed|||7905|Actual|VA Office of Research and Development|||2||f||||f||||||||||2018-06-01 02:15:30.032789|2018-06-01 02:15:30.032789
NCT00657683|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-12-07|2008-04-08|2008-04-14|Estimate|||||||2011-12-07|2011-12-08|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age|A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age|Completed||Phase 1|65|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:15:30.107381|2018-06-01 02:15:30.107381
NCT00657670|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2009-10-08|2008-04-11|2008-04-14|Estimate|||||||2009-10-08|2009-10-09|Estimate|April 2008||2008-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|November 2008|Actual|2008-11-30||Interventional|RECS||Evaluation of Effectiveness of Correcting Refractive Error With Ready-made Spectacles|Evaluation of the Feasibility of Correcting Refractive Error From a Limited Inventory of Ready-made Spectacles: Wearer Retention, Vision Function, Quality of Life and Cost|Completed||N/A|800|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:15:30.235748|2018-06-01 02:15:30.235748
NCT00657657|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2009-08-06||2016-10-26|2008-04-11|2008-04-14|Estimate|2009-08-06|2009-09-14|Estimate||||2016-10-26|2016-12-21|Estimate|April 2008||2008-04-30|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine|Immune Response to a Hepatitis B Vaccine Challenge Dose in Healthy Subjects Who Received Primary Vaccination of GlaxoSmithKline Biologicals' Hepatitis B Vaccine, Approximately 20 Years Ago.|Completed||Phase 4|29|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:15:30.363246|2018-06-01 02:15:30.363246
NCT00657644|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2014-12-23|2008-04-11|2008-04-14|Estimate|||||||2014-12-23|2014-12-25|Estimate|August 2003||2003-08-31|December 2014|2014-12-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction|Open-label Multi-centre Non Randomised Study of Efficacy and Safety of Vardenafil (BAY 38-9456; SB-782528) Administered in Flexible-dose Regimen in Males With Erectile Dysfunction of Broad Aetiology.|Completed||Phase 3|130|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:15:30.667999|2018-06-01 02:15:30.667999
NCT00657631|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2009-10-09|2008-04-11|2008-04-14|Estimate|||||||2009-10-09|2009-10-12|Estimate|April 2008||2008-04-30|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ACT||Acceptance and Commitment Therapy for Delusions|Acceptance and Commitment Therapy for Delusions|Completed||N/A|4|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 02:15:30.746949|2018-06-01 02:15:30.746949
NCT00657618|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2017-10-25||2018-01-29|2008-04-10|2008-04-14|Estimate|2018-01-29|2018-02-27|Actual||||2018-01-29|2018-02-27|Actual|October 2004|Actual|2004-10-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2010|Actual|2010-04-30||Interventional||Due to low enrollment the protocol was amended to remove efficacy objective and only collect safety data for subjects. No data entry or statistical analyses of patient data was conducted.|Use of Sodium Stibogluconate as a Treatment for Leishmaniasis|Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis|Completed||Phase 1/Phase 2|77|Actual|U.S. Army Medical Research and Materiel Command|Due to low enrollment protocol was amended to remove efficacy objective and only collect safety data. No data entry or statistical analyses of patient data was conducted.|1|||f||||f||||||||||2018-06-01 02:15:30.811498|2018-06-01 02:15:30.811498
NCT00657605|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2008-04-14|2008-04-09|2008-04-14|Estimate|||||||2008-04-14|2008-04-15|Estimate|June 2001||2001-06-30|April 2008|2008-04-30|December 2010|Anticipated|2010-12-31|January 2010|Anticipated|2010-01-31||Interventional|||Effects of Human Leptin Replacement|Effects of Human Leptin Replacement|Unknown status|Active, not recruiting|Phase 2|3|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 02:15:30.964936|2018-06-01 02:15:30.964936
NCT00657579|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2009-03-12|2008-04-11|2008-04-14|Estimate|||||||2009-03-12|2009-03-16|Estimate||||March 2009|2009-03-31||||||||Interventional|||Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Double-Masked, Parallel-Group, Dose-Response Trial of DE-104 Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|||Santen Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 02:15:31.036626|2018-06-01 02:15:31.036626
NCT00657566|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2018-05-18|2008-04-10|2008-04-14|Estimate|||||||2018-05-18|2018-05-22|Actual|September 2008||2008-09-30|May 2018|2018-05-31|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional|||SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection|SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection|Completed||Phase 3|518|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 02:15:31.134692|2018-06-01 02:15:31.134692
NCT00657553|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2011-04-14||2017-10-17|2008-04-11|2008-04-14|Estimate|2011-06-13|2011-07-12|Estimate||||2017-10-17|2017-11-20|Actual|February 2008||2008-02-29|October 2017|2017-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|2007-77||Preemptive Strike With Bortezomib in Multiple Myeloma Patients|Preemptive Strike With Bortezomib (VELCADE) in Participants With Multiple Myeloma Still Event-free on Total Therapy 2 (UARK 98-026)|Terminated||Phase 3|10|Actual|University of Arkansas|Early termination leading to small numbers of subjects analyzed|2||Due to poor accrual|f||||t||||||||||2018-06-01 02:15:32.339601|2018-06-01 02:15:32.339601
NCT00657540|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2017-08-16||2018-03-07|2008-04-09|2008-04-14|Estimate|2017-08-16|2017-09-18|Actual||||2018-03-07|2018-04-03|Actual|October 2009|Actual|2009-10-31|March 2018|2018-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BWSP3|The analysis population consists of all patients that were randomized and received any study drug (modified intent-to-treat population).|Black Widow Spider Antivenin for Patients With Systemic Latrodectism|A Phase III Multicenter Clinical Trial of Analatro® [Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2] in Patients With Systemic Latrodectism|Completed||Phase 3|60|Actual|Instituto Bioclon S.A. de C.V.|The study is limited by the small sample size; however this trial was powered appropriately for an orphan indication. The study is also limited by the difficulty in confirming latrodectism without a spider or clear history of seeing a spider.|2|||f||||t||||||||Undecided||2018-06-01 02:15:32.612928|2018-06-01 02:15:32.612928
NCT00657527|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2009-03-13|2008-04-08|2008-04-14|Estimate|||||||2009-03-13|2009-03-16|Estimate|December 2001||2001-12-31|March 2009|2009-03-31|December 2002|Actual|2002-12-31|||||Interventional|||Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease|An 8-Week Randomized Double Blind Placebo Controlled Multicenter Trial to Evaluate the Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease.|Completed||Phase 3|280|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:15:33.053651|2018-06-01 02:15:33.053651
NCT00657514|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2014-08-13|2008-04-11|2008-04-14|Estimate|||||||2014-08-13|2014-08-15|Estimate|May 2008||2008-05-31|August 2014|2014-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease|Evaluation of Ranolazine on Skeletal Muscle Endpoints During Exercise In Subjects With Chronic Angina and Peripheral Arterial Disease|Withdrawn||Phase 4|0|Actual|Colorado Prevention Center||2||Insufficient enrollment|f||||t||||||||||2018-06-01 02:15:33.222975|2018-06-01 02:15:33.222975
NCT00657501|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08||2013-01-04|2013-01-04|2008-04-08|2008-04-14|Estimate||||2013-01-04|2013-01-10|Estimate|2013-01-04|2013-01-10|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|BLOOM||Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|Completed||Phase 3|575|Actual|BioSante Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:15:33.344917|2018-06-01 02:15:33.344917
NCT00657488|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2016-11-29|2008-04-11|2008-04-14|Estimate|||||||2016-11-29|2016-12-01|Estimate|December 2001||2001-12-31|November 2016|2016-11-30|April 2006|Actual|2006-04-30|October 2005|Actual|2005-10-31||Interventional|||Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma|Multicenter, Randomized Study Comparing the Efficacy and Safety of Two Doses of Thalidomide (100 mg/Day Versus 400 mg/Day) in the Treatment of Subjects With Refractory or Relapsed Multiple Myeloma.|Completed||Phase 2/Phase 3|400|Actual|Celgene Corporation||2|||f||||f||||||||||2018-06-01 02:15:33.54393|2018-06-01 02:15:33.54393
NCT00657475|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2013-05-06|2008-04-08|2008-04-14|Estimate|||||||2013-05-06|2013-05-07|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|APPACHES||Coronary Bypass and Artotic Leaflet Surgery : Heparin Low Dose vs Full Dose|A Prospective Study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement With Conventional Versus Half Heparin Dose Under Closed and Coated Extra Corporeal Circulation System (MECC) - APPACHES Study.|Completed||Phase 4|238|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 02:15:33.689988|2018-06-01 02:15:33.689988
NCT00657462|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2017-01-30|2008-04-11|2008-04-14|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2008||2008-04-30|January 2017|2017-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PAMLTIPS||Efficacy of the Pre-Admission Medication List (PAML) Builder Reminder Prompts|Effect of Reminder Prompts on Utilization of the PAML Builder Application Features|Completed||N/A|14122|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:15:33.766916|2018-06-01 02:15:33.766916
NCT00657449|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-04-08|2008-04-08|2008-04-14|Estimate|||||||2008-04-08|2008-04-14|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Double-Blind, Double-Dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain|A Double-Blind, Double-Dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg vs. Rofecoxib 50 mg in the Symptomatic Treatment of Patients With Ankle Sprain|Terminated||Phase 4|256|Actual|Pfizer||2||See Detailed Description|f||||f||||||||||2018-06-01 02:15:33.847669|2018-06-01 02:15:33.847669
NCT00657436|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2012-05-30|2008-04-08|2008-04-14|Estimate|||||||2012-05-30|2012-05-31|Estimate|March 2008||2008-03-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|MyRiAD||Myeloid-Related Protein in Evaluation of Acute Chest Pain in the Emergency Departement|Study of Myeloid-related Protein 8/14 and Additional Biomarkers (Multi Marker Approach) for Early Diagnosis and Risk Stratification in Patients Presenting With Acute Chest Pain at the Emergency Department|Completed|||403|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 02:15:33.932028|2018-06-01 02:15:33.932028
NCT00657423|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2010-09-15|2008-04-11|2008-04-14|Estimate|||||||2010-09-15|2010-09-17|Estimate|April 2008||2008-04-30|August 2008|2008-08-31|April 2009|Anticipated|2009-04-30|December 2008|Anticipated|2008-12-31||Interventional|||Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)|Study of Endostar Combined With Docetaxel and Cisplatin on the Angiogenesis of Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 3|80|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-06-01 02:15:33.99534|2018-06-01 02:15:33.99534
NCT00657410|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2017-02-17|2008-04-11|2008-04-14|Estimate|||||||2017-02-17|2017-02-20|Actual|April 2008||2008-04-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ITP0207||Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura|Randomized Study of the Treatment of Primary Immune Thrombocytopenic Purpura (ITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone Versus High-dose Dexamethasone.|Completed||Phase 3|150|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto||2|||f||||f||||||||||2018-06-01 02:15:34.081453|2018-06-01 02:15:34.081453
NCT00657397|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2012-07-23|2008-04-08|2008-04-14|Estimate|||||||2012-07-23|2012-07-24|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Methaville||Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices|Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville|Completed||Phase 3|197|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 02:15:34.341731|2018-06-01 02:15:34.341731
NCT00657384|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2013-09-06|2008-04-10|2008-04-14|Estimate|||||||2013-09-06|2013-09-09|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy|Tranexamic Acid Versus Placebo to Reduce Perioperative Bleeding After Major Hepatectomy : a Prospective Randomized Double-blinding Study|Unknown status|Recruiting|Phase 3|130|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 02:15:34.433839|2018-06-01 02:15:34.433839
NCT00657371|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2013-10-11||2013-10-11|2008-04-11|2008-04-14|Estimate|2013-10-11|2013-12-09|Estimate||||2013-10-11|2013-12-09|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Of the 288 registered, only 249 had a screening colonoscopy to meet inclusion in the study.|Efficacy of the Third Eye Retroscope Auxiliary Imaging System|A Prospective Efficacy Evaluation of the Third Eye Retroscope Auxiliary Imaging System|Completed||N/A|288|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:15:34.541684|2018-06-01 02:15:34.541684
NCT00656318|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2009-08-24|2008-04-10|2008-04-11|Estimate|||||||2009-08-24|2009-08-25|Estimate|August 2008||2008-08-31|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Impact of Oral Contraceptives on GABA and Neurosteroids|Impact of Oral Contraceptives on GABA and Neurosteroids|Terminated|||6|Actual|Yale University|||2|Funding withdrawn from study sponsor.|f||||f||||||||||2018-06-01 02:15:50.443231|2018-06-01 02:15:50.443231
NCT00657358|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2012-05-24||2017-04-11|2008-04-11|2008-04-14|Estimate|2013-11-24|2014-01-13|Estimate||||2017-04-11|2017-05-17|Actual|April 2008||2008-04-30|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers|The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers (Carl Koller Grant) (The Effect of Intravenous Lidocaine on Allodynia)|Completed||N/A|22|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 02:15:34.794206|2018-06-01 02:15:34.794206
NCT00657345|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2013-11-04|2008-04-10|2008-04-14|Estimate|||||||2013-11-04|2013-11-05|Estimate|March 2008||2008-03-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||IRS Proteins and Trastuzumab Resistance|IRS Proteins and Trastuzumab Resistance|Completed|||9|Actual|University of Massachusetts, Worcester|||1||f||||f||||||||||2018-06-01 02:15:35.138047|2018-06-01 02:15:35.138047
NCT00657332|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2010-02-26|2008-04-11|2008-04-14|Estimate|||||||2010-02-26|2010-03-02|Estimate|July 2007||2007-07-31|February 2010|2010-02-28|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Observational|||Clinical and Pathologic Studies in Neuroendocrine Tumors|Clinical and Pathologic Studies in Neuroendocrine Tumors|Terminated|||200|Anticipated|Stanford University|||||f||||||||||Samples Without DNA|"~     biopsy of tumor, blood sample and/or urine samples.~   "|||2018-06-01 02:15:35.292421|2018-06-01 02:15:35.292421
NCT00657319|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2017-01-06|2008-04-08|2008-04-14|Estimate|||||||2017-01-06|2017-01-09|Estimate|October 2007||2007-10-31|January 2017|2017-01-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Observational|||Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins|Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins|Completed|||3495|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:15:35.43773|2018-06-01 02:15:35.43773
NCT00657306|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2008-04-11|2008-04-11|2008-04-14|Estimate|||||||2008-04-11|2008-04-14|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|May 2009|Anticipated|2009-05-31|December 2008|Anticipated|2008-12-31||Interventional|AILD||Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function|Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Stress Doses of Hydrocortisone on Renal Function and on Liver and Systemic Haemodynamics|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|University of Turin, Italy||2|||f||||t||||||||||2018-06-01 02:15:35.737135|2018-06-01 02:15:35.737135
NCT00657293|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2010-02-19|2008-04-08|2008-04-14|Estimate|||||||2010-02-19|2010-02-22|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Arm Training in Patients With Chronic Obstructive Pulmonary Disease|Arm Training in COPD: Short and Medium Term Effects on Dyspnoea, Health-related Quality of Life, Arm Function and Arm Exercise Capacity.|Completed||N/A|34|Actual|West Park Healthcare Centre||2|||f||||f||||||||||2018-06-01 02:15:35.870656|2018-06-01 02:15:35.870656
NCT00657280|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2014-05-13||2014-12-04|2008-04-11|2008-04-14|Estimate|2014-12-04|2014-12-05|Estimate||||2014-12-04|2014-12-05|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|S-001|Adult patients diagnosis of nonischemic dilated cardiomyopathy with Class I-III symptoms. all patients were required to have been on a stable comprehensive heart failure regimen for at least three months, including therapy with beta-blockers and angiotensin-converting-enzyme inhibitors or angiotensin-receptor-blockers unless they were intolerant.|Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure|Effect of Sitagliptin on Insulin Resistance and Myocardial Metabolism in Heart Failure|Completed||Early Phase 1|16|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 02:15:36.022041|2018-06-01 02:15:36.022041
NCT00657267|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2013-06-16||2014-02-13|2008-04-08|2008-04-14|Estimate|2014-02-13|2014-03-14|Estimate||||2014-02-13|2014-03-14|Estimate|May 2008||2008-05-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|November 2011|Actual|2011-11-30||Interventional||Of the 58 participants who registered and started study treatment, 3 were ineligible for analysis and 1 withdrew before response assessment.|Dose-Intense Temozolomide in Recurrent Glioblastoma|Phase 2 Study of Dose-Intense Temozolomide in Recurrent Glioblastoma|Completed||Phase 2|58|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 02:15:36.285215|2018-06-01 02:15:36.285215
NCT00657254|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2014-12-18|2008-04-08|2008-04-14|Estimate|||||||2014-12-18|2014-12-23|Estimate|December 2002||2002-12-31|December 2014|2014-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Extension Program for Bay 43-9006|Extension Program for Bay 43-9006|Completed||Phase 2|9|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:15:36.92802|2018-06-01 02:15:36.92802
NCT00657241|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2010-06-30|2008-04-11|2008-04-14|Estimate|||||||2010-06-30|2010-07-01|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril|Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril|Completed||Phase 3|30|Actual|State University of New York at Buffalo||2|||f||||t||||||||||2018-06-01 02:15:37.051769|2018-06-01 02:15:37.051769
NCT00657228|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2017-01-05|2008-04-11|2008-04-14|Estimate|||||||2017-01-05|2017-01-09|Estimate|December 2009||2009-12-31|January 2017|2017-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department|Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic/Anaphylactoid Reactions in the Emergency Department|Withdrawn||N/A|0|Actual|University of Missouri, Kansas City||2||Study did not start.|f||||t||||||||||2018-06-01 02:15:37.167446|2018-06-01 02:15:37.167446
NCT00657202|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2016-07-06|2008-04-09|2008-04-14|Estimate|||||||2016-07-06|2016-07-07|Estimate|March 2008||2008-03-31|July 2016|2016-07-31|December 2013|Actual|2013-12-31|October 2009|Actual|2009-10-31||Interventional|||Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1|Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1|Completed||Early Phase 1|11|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:15:37.271729|2018-06-01 02:15:37.271729
NCT00657189|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09||2016-08-05|2016-08-05|2008-04-11|2008-04-14|Estimate||||2016-08-05|2016-08-09|Estimate|2016-08-05|2016-08-09|Estimate|July 2008||2008-07-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus|A Phase 2A , Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Subjects With Systemic Lupus Erythematosus|Completed||Phase 2|87|Actual|MedImmune LLC||5|||f||||f||||||||||2018-06-01 02:15:37.3739|2018-06-01 02:15:37.3739
NCT00657176|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2008-04-17|2008-04-11|2008-04-14|Estimate|||||||2008-04-17|2008-04-18|Estimate|March 2008||2008-03-31|April 2008|2008-04-30|June 2009|Anticipated|2009-06-30|March 2009|Anticipated|2009-03-31||Interventional|||An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Non-Randomized Study of OPB-31121 in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|36|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||f||||||||||2018-06-01 02:15:37.5194|2018-06-01 02:15:37.5194
NCT00657163|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2011-09-15|2008-04-11|2008-04-14|Estimate|||||||2011-09-15|2011-09-16|Estimate|March 2005||2005-03-31|July 2009|2009-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|FLAME||Fluoxetine on Motor Rehabilitation After Ischemic Stroke|Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial|Completed||Phase 2|100|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 02:15:37.59715|2018-06-01 02:15:37.59715
NCT00657150|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2010-11-18||2014-06-23|2008-04-11|2008-04-14|Estimate|2010-11-18|2010-12-17|Estimate||||2014-06-23|2014-07-02|Estimate|March 2008||2008-03-31|December 2013|2013-12-31||||September 2009|Actual|2009-09-30||Interventional||Treated set|Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty|A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)|Completed||Phase 3|2055|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:15:37.789595|2018-06-01 02:15:37.789595
NCT00657137|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2012-03-13|2008-04-11|2008-04-14|Estimate|||||||2012-03-13|2012-03-15|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|APRiCOT-B||APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)|A Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of Patients With HER2/Neu+ Breast Cancer Who Have Failed Trastuzumab and Chemotherapy Including a Taxane|Terminated||Phase 2|12|Actual|Tragara Pharmaceuticals, Inc.||2||Slow accrual|f||||t||||||||||2018-06-01 02:15:38.576217|2018-06-01 02:15:38.576217
NCT00657124|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-11|2008-04-11|2008-04-14|Estimate|||||||2008-04-11|2008-04-14|Estimate|April 2007||2007-04-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Preoperative Supplementation in Insulin Resistance|Preoperative Oral Supplementation of Carbohydrate and Branched-Chain Amino Acids-Enriched Nutrient Improves Insulin Resistance in Patients With Hepatectomy; Prospective Randomized Clinical Trial by Using Artificial Pancreas|Completed||Phase 4|26|Actual|Kochi University||2|||f||||t||||||||||2018-06-01 02:15:38.710703|2018-06-01 02:15:38.710703
NCT00657111|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2018-05-29|2008-04-10|2008-04-14|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2008||2008-04-30|May 2018|2018-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||CS-8958 Single Inhaled Dose in Elderly|CS-8958 - A Phase I, Double-Blind, Placebo Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Elderly Subjects|Completed||Phase 1|38|Actual|Vaxart||8|||f||||t||||||||||2018-06-01 02:15:38.858408|2018-06-01 02:15:38.858408
NCT00657098|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2015-10-05|2008-04-08|2008-04-14|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|Mabtornib||Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy|Mabtornib Protocol.Vascular, Metabolic and Hormonal Effects of Angiogenesis Inhibitors and Epidermal Growth Factor Receptor Inhibitors|Terminated|||73|Actual|University Medical Center Groningen|||1|slow inclusion rate|f||||f||||||Samples With DNA|"~     Serum Plasma Urine DNA~   "|||2018-06-01 02:15:38.933195|2018-06-01 02:15:38.933195
NCT00657085|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2008-12-10|2008-04-11|2008-04-14|Estimate|||||||2008-12-10|2008-12-12|Estimate|March 2008||2008-03-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction|Evaluation of the LightSheer HS Hand Piece as Compared to the LightSheer ET Hand Piece for the Intended Use of Hair Removal and Permanent Hair Reduction|Completed|||5|Anticipated|Lumenis Ltd.|||||f||||f||||||Samples With DNA|"~     Biopsied hair follicles retained and analzed through horizontal sectioning and viability~     staining~   "|||2018-06-01 02:15:39.002767|2018-06-01 02:15:39.002767
NCT00657072|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2015-11-20|2008-04-11|2008-04-14|Estimate|||||||2015-11-20|2015-11-23|Estimate|May 2003||2003-05-31|November 2015|2015-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Biomechanical Evaluation of Wrist Ligament Injuries: Diagnostic Tool to Detect Wrist Instability|Biomechanical Evaluation of Wrist Ligament Injuries: Diagnostic Tool to Detect Wrist Instability|Completed|||50|Anticipated|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:15:39.064218|2018-06-01 02:15:39.064218
NCT00657059|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2018-01-21|2008-04-11|2008-04-14|Estimate|||||||2018-01-21|2018-01-23|Actual|September 2007||2007-09-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)|A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)|Active, not recruiting||Phase 3|151|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-06-01 02:15:39.128668|2018-06-01 02:15:39.128668
NCT00657046|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2014-04-24|2013-03-27|2014-05-27|2008-04-11|2008-04-14|Estimate|2014-05-27|2014-06-27|Estimate|2013-03-27|2013-04-04|Estimate|2014-05-27|2014-06-27|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|IDH201||Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension|A Phase II, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit and Safety of Droxidopa in Patients With Intradialytic Hypotension|Completed||Phase 2|85|Actual|Chelsea Therapeutics||3|||f||||f||||||||||2018-06-01 02:15:39.254245|2018-06-01 02:15:39.254245
NCT00657033|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2013-10-10|2008-04-11|2008-04-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|October 2003||2003-10-31|October 2013|2013-10-31|August 2004|Actual|2004-08-31|||||Interventional|||Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction|A Randomized, Double Blind, Parallel Group, Multi-center Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction, and Their Female Partners' Sexual Quality of Life.|Completed||Phase 3|229|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:15:39.956059|2018-06-01 02:15:39.956059
NCT00657020|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2009-10-12||2015-02-12|2008-04-11|2008-04-14|Estimate|2010-03-18|2010-04-06|Estimate||||2015-02-12|2015-03-02|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms|Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated With Nicotine Withdrawal|Completed||Phase 4|23|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:15:40.101779|2018-06-01 02:15:40.101779
NCT00222040|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2010-04-29|2005-09-15|2005-09-22|Estimate|||||||2010-04-29|2010-04-30|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Microbubbles and Ultrasound in Stroke Trial: MUST Study||Terminated||Phase 2|20|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 04:28:03.017388|2018-06-01 04:28:03.017388
NCT00657007|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2013-08-01|2008-04-08|2008-04-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2002||2002-02-28|August 2013|2013-08-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 1, Multi-Center, Double-Blind, Single and Double Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|70|Actual|Human Genome Sciences Inc.||5|||f||||f||||||||||2018-06-01 02:15:40.628195|2018-06-01 02:15:40.628195
NCT00656994|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2012-02-27|2008-04-09|2008-04-14|Estimate|||||||2012-02-27|2012-02-28|Estimate|January 2003||2003-01-31|February 2012|2012-02-29|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia|A Phase III Safety Study to Evaluate the Long-term Effects of TAK-375 on Endocrine Function in Adult Subjects With Chronic Insomnia|Completed||Phase 3|122|Actual|Takeda||2|||f||||f||||||||||2018-06-01 02:15:40.729862|2018-06-01 02:15:40.729862
NCT00656981|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2014-12-29|2008-04-11|2008-04-14|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2003||2003-01-31|December 2014|2014-12-31|June 2004|Actual|2004-06-30|||||Interventional|||Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women With Moderate Acne Vulgaris|Completed||Phase 3|541|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:15:40.862326|2018-06-01 02:15:40.862326
NCT00656968|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2010-08-17||2015-09-14|2008-04-11|2008-04-14|Estimate|2011-07-05|2011-08-02|Estimate||||2015-09-14|2015-09-30|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|960025||Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection|Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection|Completed||Phase 4|232|Actual|Kaohsiung Veterans General Hospital.|The trial was performed in a single country|2|||f||||f||||||||||2018-06-01 02:15:40.96714|2018-06-01 02:15:40.96714
NCT00656955|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-11|||2018-04-04|2008-04-11|2008-04-14|Estimate|||||||2018-04-04|2018-04-05|Actual|April 10, 2008||2008-04-10|August 23, 2017|2017-08-23||||||||Observational|||Follow-Up Study of Kidney Cancer Patients|Follow-up of Kidney Cancer Patients From the Central European Multicenter Case-Control Study|Completed|||1002|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:15:41.283196|2018-06-01 02:15:41.283196
NCT00656942|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2018-03-20|2008-04-09|2008-04-14|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2006||2006-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2013|Actual|2013-10-31||Observational|||Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain|Pain Responses in Patients on Long-Term Opioid Therapy for Chronic Pain|Active, not recruiting|||419|Actual|Massachusetts General Hospital|||3||f||||t||||||||||2018-06-01 02:15:41.349559|2018-06-01 02:15:41.349559
NCT00656929|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-10|2008-04-10|2008-04-11|Estimate|||||||2008-04-10|2008-04-11|Estimate|December 2006||2006-12-31|April 2008|2008-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Randomized Controlled Trial of Vitamin D3 Supplementation for Viral Upper Respiratory Tract Infections (URI) Prevention|A Randomized Controlled Trial of Vitamin D3 Supplementation for the Prevention of Viral Upper Respiratory Tract Infections|Completed||N/A|167|Actual|Winthrop University Hospital||2|||f||||f||||||||||2018-06-01 02:15:41.436256|2018-06-01 02:15:41.436256
NCT00656916|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2012-02-07||2012-03-29|2008-04-07|2008-04-11|Estimate|2012-03-29|2012-04-23|Estimate||||2012-03-29|2012-04-23|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status|Randomized Study of Early Treatment With Inhaled Corticosteroids Versus Observation for Patients Who Have Decreased Lung Function Status Post Allogeneic Stem Cell Transplantation|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||2||Terminated due to slow accrual.|f||||f||||||||||2018-06-01 02:15:41.529325|2018-06-01 02:15:41.529325
NCT00656903|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2018-05-11|2008-04-10|2008-04-11|Estimate|||||||2018-05-11|2018-05-14|Actual|April 7, 2008||2008-04-07|August 19, 2014|2014-08-19|August 19, 2014||2014-08-19|||||Observational|||High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration|High Speed Indocyanine Green Angiography Findings in Induction/PRN Regimen of Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration|Completed|||75|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:15:41.705734|2018-06-01 02:15:41.705734
NCT00656890|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04||2015-09-23|2015-09-23|2008-04-10|2008-04-11|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|April 2008||2008-04-30|September 2015|2015-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MDX1100-06||A Study of MDX-1100 in Subjects With Active Ulcerative Colitis|A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis|Completed||Phase 2|110|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 02:15:41.768744|2018-06-01 02:15:41.768744
NCT00656877|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-04-04|2008-04-04|2008-04-11|Estimate|||||||2008-04-04|2008-04-11|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|Fat Embolism||Incidence of Fat Embolism With Computer Assisted Total Knee Arthroplasty|Incidence of Fat Embolism With Computer Assisted Total Knee Arthroplasty|Completed|||50|Anticipated|Marshall University|||||f||||f||||||||||2018-06-01 02:15:41.899106|2018-06-01 02:15:41.899106
NCT00656864|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2011-02-01|2008-04-10|2008-04-11|Estimate|||||||2011-02-01|2011-02-02|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pioglitazone Incretin Study|Effects of Pioglitazone on the Regulation of Insulin Secretion in Patients With Type 2 Diabetes|Completed||Phase 4|24|Actual|University of Vermont||2|||f||||f||||||||||2018-06-01 02:15:41.965331|2018-06-01 02:15:41.965331
NCT00656851|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2013-04-30||2013-08-19|2008-04-10|2008-04-11|Estimate|2013-07-16|2013-08-20|Estimate||||2013-08-19|2013-08-28|Estimate|September 2005||2005-09-30|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|WU197||Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome|Myocardial Function, Free Fatty Acid and Glucose Metabolism in HIV Metabolic Syndrome|Completed||N/A|24|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|We did not perform the myocardial metabolic measurements under insulin-stimulated conditions (i.e. hyperinsulinemic clamps). Small number of participants and high measurement variability, efficacy was not found. Study ended to minimize risk/benefit.|2|||f||||f||||||||||2018-06-01 02:15:42.063044|2018-06-01 02:15:42.063044
NCT00656838|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-02-19|2008-04-10|2008-04-11|Estimate|||||||2014-02-19|2014-02-20|Estimate|April 2008||2008-04-30|October 2011|2011-10-31|February 2013|Actual|2013-02-28|April 2011|Actual|2011-04-30||Interventional|FIBER||Focusing Implementation to Bring Effective Reminders (FIBER)|Focusing Implementation to Bring Effective Reminders (FIBER)|Completed||N/A|85289|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 02:15:42.438091|2018-06-01 02:15:42.438091
NCT00656825|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-11-04|2008-04-10|2008-04-11|Estimate|||||||2008-11-04|2008-11-05|Estimate|March 2007||2007-03-31|November 2008|2008-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers|Multicentre, Placebo-Controlled, Multi-Dosis, Phase I Clinical Trial to Evaluate the Tolerability and Bioavailability of TGF β1 Inhibitor Peptide 144 After Topical Administration in Healthy Volunteers.|Completed||Phase 1|36|Actual|ISDIN||4|||f||||f||||||||||2018-06-01 02:15:42.502635|2018-06-01 02:15:42.502635
NCT00656812|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2013-12-23|2008-04-10|2008-04-11|Estimate|||||||2013-12-23|2013-12-24|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma|Phase II Trial of Rituximab Plus 2CdA in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)|Completed||Phase 2|40|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||||2018-06-01 02:15:42.583463|2018-06-01 02:15:42.583463
NCT00656799|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2013-05-21||2015-02-20|2008-04-07|2008-04-11|Estimate|2013-07-29|2013-07-31|Estimate||||2015-02-20|2015-03-10|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)|A Single Center, Open-Label Trial in Subjects With Severe Renal Impairment Evaluating the Dialysability of the Sugammadex-Rocuronium Complex|Completed||Phase 3|6|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:15:42.714002|2018-06-01 02:15:42.714002
NCT00656786|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2017-10-16|2008-04-07|2008-04-11|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2008||2008-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash|A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash|Active, not recruiting||Phase 1|24|Anticipated|Spectrum Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 02:15:43.068404|2018-06-01 02:15:43.068404
NCT00656773|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2017-05-10|2008-04-07|2008-04-11|Estimate|||||||2017-05-10|2017-05-12|Actual|January 2008||2008-01-31|May 2017|2017-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Randomized, Double-blind Comparison of Morphine and Sufentanil for Prehospital Traumatic Severe Acute Pain|A Randomized, Double-blind Comparison of Morphine and Sufentanil for Treatment of Prehospital Traumatic Severe Acute Pain.|Completed||Phase 3|108|Actual|University Hospital, Toulouse||2|||f||||t||||||||No||2018-06-01 02:15:43.177895|2018-06-01 02:15:43.177895
NCT00656760|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2016-05-17|2008-04-10|2008-04-11|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer|The Clinical Utility of PET-CT in the Management of Squamous Cell Carcinoma of Neck Nodes With an Unknown Primary Malignancy.|Completed||N/A|20|Actual|University of Calgary||1|||f||||f||||||||||2018-06-01 02:15:43.243227|2018-06-01 02:15:43.243227
NCT00656747|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-11-27|2008-04-10|2008-04-11|Estimate|||||||2014-11-27|2014-12-01|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis|MAESTRAL - A Prospective, Multinational, Multicenter, Randomized, Double Blind, Double Dummy, Controlled Study Comparing the Efficacy and Safety of Moxifloxacin to That of Amoxicillin Clavulanic Acid for the Treatment of Subjects With Acute Exacerbations of Chronic Bronchitis.|Completed||Phase 4|1372|Actual|Bayer||2|||f||||t||||||||||2018-06-01 02:15:43.321147|2018-06-01 02:15:43.321147
NCT00656734|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2013-05-13|2008-04-10|2008-04-11|Estimate|||||||2013-05-13|2013-05-14|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MDX1411-01||Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.|A Phase 1, Open-Label, Multicenter Dose-escalation, Multidose Study of MDX1411 Administered Every 14 Days in Subjects With Advanced or Recurrent Clear Cell Renal Cell Carcinoma|Completed||Phase 1|27|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:15:43.800176|2018-06-01 02:15:43.800176
NCT00656721|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2015-06-18|2008-04-07|2008-04-11|Estimate|||||||2015-06-18|2015-06-22|Estimate|September 2004||2004-09-30|June 2015|2015-06-30|June 2006|Actual|2006-06-30|November 2005|Actual|2005-11-30||Interventional|||Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients|Flutter Valve Improves Respiratory Mechanics and Sputum Production in Bronchiectasis Patients|Completed||N/A|8|Actual|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-06-01 02:15:43.890487|2018-06-01 02:15:43.890487
NCT00656708|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2017-04-19|2008-04-10|2008-04-11|Estimate|||||||2017-04-19|2017-04-21|Actual|August 2008||2008-08-31|August 2009|2009-08-31|January 2011|Actual|2011-01-31|June 2009|Actual|2009-06-30||Interventional|||Kerlix Gauze Study in a Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients|Kerlix AMD Gauze Study In A Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients|Completed||N/A|108|Actual|University of Iowa||1|||f||||t||||||||No||2018-06-01 02:15:43.972997|2018-06-01 02:15:43.972997
NCT00656695|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2012-06-21|2008-04-07|2008-04-11|Estimate|||||||2012-06-21|2012-06-22|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation|The Comparison Between Clinical and Paraclinical Effect of Iminoral Vs Neoral in Prevention of Acute Rejection in the First Year Afer Transplantation in De Novo Renal Transplant Patients|Completed||Phase 4|208|Actual|Imam Khomeini Hospital||2|||f||||t||||||||||2018-06-01 02:15:44.062025|2018-06-01 02:15:44.062025
NCT00656682|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2018-03-27|2008-04-10|2008-04-11|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2008||2008-04-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|RAPID||Primary Care Community Partnerships to Prevent Diabetes|Primary Care Community Partnerships to Prevent Diabetes|Completed||N/A|509|Actual|Northwestern University||2|||f||||t||||||||No||2018-06-01 02:15:44.143855|2018-06-01 02:15:44.143855
NCT00656669|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2014-06-18||2014-07-21|2008-04-07|2008-04-11|Estimate|2014-07-21|2014-08-12|Estimate||||2014-07-21|2014-08-12|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer|An Exploratory Study of the Biological and Clinical Activity of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer|Completed||N/A|23|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 02:15:44.278037|2018-06-01 02:15:44.278037
NCT00217776|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-01-16|2005-09-19|2005-09-22|Estimate|||||||2013-01-16|2013-01-17|Estimate|February 2003||2003-02-28|January 2013|2013-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|DMSP||School-based Approaches to Help Pre-teens Manage Asthma||Completed||N/A|1292|Actual|University of Michigan||3|||f||||||||||||||2018-06-01 04:28:50.494211|2018-06-01 04:28:50.494211
NCT00656656|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2016-10-28||2017-01-31|2008-04-07|2008-04-11|Estimate|2016-10-28|2016-12-22|Estimate||||2017-01-31|2017-03-13|Actual|January 2008||2008-01-31|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus|Combined Treatment of Autoimmune Bullous Diseases With Protein A Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab|Completed||Phase 2|23|Actual|University of Luebeck||1|||f||||t||||||||No||2018-06-01 02:15:44.720925|2018-06-01 02:15:44.720925
NCT00656643|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2013-01-08|2008-04-04|2008-04-11|Estimate|||||||2013-01-08|2013-01-10|Estimate|June 2008||2008-06-30|July 2010|2010-07-31|May 2012|Actual|2012-05-31|November 2009|Actual|2009-11-30||Interventional|||Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema|A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy|Completed||Phase 2|131|Actual|Santen Inc.||4|||f||||f||||||||||2018-06-01 02:15:44.854916|2018-06-01 02:15:44.854916
NCT00656630|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2016-12-14||2017-02-08|2008-04-10|2008-04-11|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|December 2007||2007-12-31|February 2017|2017-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Medication Development in Alcoholism: Acamprosate Versus Naltrexone|Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone|Completed||Phase 2|68|Actual|The Scripps Research Institute||3|||f||||f||||||||||2018-06-01 02:15:44.944394|2018-06-01 02:15:44.944394
NCT00656617|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2015-02-26||2015-02-26|2008-04-10|2008-04-11|Estimate|2015-02-26|2015-03-09|Estimate||||2015-02-26|2015-03-09|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Three participants completed the first run-in portion of the study while 99 of remaining 103 additional participants were evaluable for the second phase of the study.|Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)|Phase II Study of Idarubicin, Cytarabine, and Vorinostat in Patients With High-Risk MDS and AML|Completed||Phase 2|106|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:15:45.300784|2018-06-01 02:15:45.300784
NCT00656604|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|||2013-03-04|2008-04-10|2008-04-11|Estimate|||||||2013-03-04|2013-03-05|Estimate|November 2003||2003-11-30|March 2013|2013-03-31|January 2008|Actual|2008-01-31|October 2005|Actual|2005-10-31||Interventional|||Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics|Evaluation of Patients With Breast Cancer Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, and Proteomics|Completed||N/A|30|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-06-01 02:15:45.572085|2018-06-01 02:15:45.572085
NCT00656591|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2008-04-07|2008-04-07|2008-04-11|Estimate|||||||2008-04-07|2008-04-11|Estimate|March 2005||2005-03-31|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Community-Based Interventions for Infant Health in Nepal|An Evaluation of the Cost-Effectiveness of Community-Based Participatory Interventions for Pregnant Women in Nepal to Reduce Fetal and Infant Mortality, and to Improve Fetal Growth and Cognitive Development in Infancy.|Unknown status|Recruiting||192000|Anticipated|Institute of Child Health|||||f||||||||||||||2018-06-01 02:15:45.652301|2018-06-01 02:15:45.652301
NCT00656578|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2009-05-01|2008-04-10|2008-04-11|Estimate|||||||2009-05-01|2009-05-04|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy and Safety of a Single Intraoperative Administration of 4975 in Patients Undergoing Unilateral Transpositional First Metatarsal Osteotomy for the Correction of Hallux Valgus Deformity|Completed||Phase 3|300|Anticipated|Anesiva, Inc.||2|||f||||f||||||||||2018-06-01 02:15:45.718914|2018-06-01 02:15:45.718914
NCT00656565|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-08-05|2008-04-10|2008-04-11|Estimate|||||||2008-08-05|2008-08-06|Estimate|June 2008||2008-06-30|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Inspiratory Flow and Volumes in Bronchiectatics|Inspiratory Flow Rates and Volumes in Subjects With Bronchiectasis Using Low and High Resistance Dry Powder Inhaler Devices|Completed|||15|Anticipated|Pharmaxis|||1||f||||f||||||||||2018-06-01 02:15:45.791368|2018-06-01 02:15:45.791368
NCT00656552|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-10|2008-04-10|2008-04-11|Estimate|||||||2008-04-10|2008-04-11|Estimate|May 2008||2008-05-31|April 2008|2008-04-30||||December 2008|Anticipated|2008-12-31||Interventional|||Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation|Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study|Unknown status|Not yet recruiting|Early Phase 1|100|Anticipated|Cairo University|||||f||||t||||||||||2018-06-01 02:15:45.845529|2018-06-01 02:15:45.845529
NCT00656539|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07||2009-03-24|2011-09-20|2008-04-07|2008-04-11|Estimate||||2009-11-13|2009-11-17|Estimate|2011-09-20|2011-09-26|Estimate|April 2008||2008-04-30|September 2011|2011-09-30||||November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis|A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Four Weeks in Subjects With Posterior Blepharitis|Completed||Phase 4|20|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:15:45.911496|2018-06-01 02:15:45.911496
NCT00656526|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-10|2008-04-10|2008-04-11|Estimate|||||||2008-04-10|2008-04-11|Estimate|September 2007||2007-09-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Preemptive Analgesia for Postlaminectomy|Intraoperative Perineural Injection of Lidocaine for Postlaminectomy Pain|Completed||Phase 4|40|Actual|Harran University||2|||f||||f||||||||||2018-06-01 02:15:46.922453|2018-06-01 02:15:46.922453
NCT00656513|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-10|2017-06-22||2017-07-21|2008-04-10|2008-04-11|Estimate|2017-07-21|2017-08-21|Actual||||2017-07-21|2017-08-21|Actual|September 2008||2008-09-30|July 2017|2017-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Eligible patients (i.e. without protocol violation)|Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer|A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia|Completed||Phase 2/Phase 3|196|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-06-01 02:15:47.043853|2018-06-01 02:15:47.043853
NCT00656500|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2012-02-02|2008-04-04|2008-04-11|Estimate|||||||2012-02-02|2012-02-03|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|February 2010|Actual|2010-02-28||Interventional|||Quitline Use in Surgical Patients|Increasing QUITPLAN Helpline Utilization in Surgical Patients|Completed||N/A|300|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:15:47.736307|2018-06-01 02:15:47.736307
NCT00194272|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-08|2005-09-13|2005-09-19|Estimate|||||||2011-08-08|2011-08-09|Estimate|March 2001||2001-03-31|August 2011|2011-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Two-Dose Methotrexate for Ectopic Pregnancy|Two-Dose Methotrexate for Ectopic Pregnancy|Completed||Phase 3|100|Actual|University of Pennsylvania|||||f||||f||||||||||2018-06-01 04:33:47.806308|2018-06-01 04:33:47.806308
NCT00656487|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2017-04-05||2017-05-23|2008-04-10|2008-04-11|Estimate|2017-04-05|2017-05-15|Actual||||2017-05-23|2017-06-19|Actual|April 30, 2008|Actual|2008-04-30|May 2017|2017-05-31|January 6, 2011|Actual|2011-01-06|December 28, 2010|Actual|2010-12-28||Interventional|SCCAN|Per study design specifying that non-completers would be replaced to yield n=60 completers, two enrolled participants in the rimonabant group and four enrolled participants in the placebo group were not included in baseline (or additional) analyses.|Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults|Translational Center on the Clinical Neurobiology of Cannabis Addiction|Completed||Phase 2|66|Actual|The Scripps Research Institute||3|||f||||f|t|f||||||No||2018-06-01 02:15:48.057898|2018-06-01 02:15:48.057898
NCT00656474|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2011-06-23||2011-07-22|2008-04-10|2008-04-11|Estimate|2011-06-23|2011-07-25|Estimate||||2011-07-22|2011-07-26|Estimate|March 2008||2008-03-31|July 2011|2011-07-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation|Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.|Completed||Phase 1/Phase 2|12|Actual|Glycotex, Inc.||2|||f||||||||||||||2018-06-01 02:15:48.575331|2018-06-01 02:15:48.575331
NCT00656461|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2009-11-23|2008-04-07|2008-04-11|Estimate|||||||2009-11-23|2009-11-25|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Phase 1 Study of MKC-1 in Patients With Advanced Cancer|Phase 1 Study of MKC-1 in Patients With Advanced or Metastatic Solid Malignancies|Completed||Phase 1|24|Anticipated|CASI Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:15:48.804965|2018-06-01 02:15:48.804965
NCT00656448|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|2013-11-04||2018-05-01|2008-04-07|2008-04-11|Estimate|2013-11-04|2013-12-23|Estimate||||2018-05-01|2018-05-30|Actual|March 2008||2008-03-31|May 2018|2018-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS|Randomized Study of Procrit vs no Procrit in Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Undergoing Frontline Myelosuppressive Induction/Consolidation Chemotherapy|Completed||Phase 3|51|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:15:48.88675|2018-06-01 02:15:48.88675
NCT00656435|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-04-07|2008-04-07|2008-04-11|Estimate|||||||2008-04-07|2008-04-11|Estimate|December 2006||2006-12-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|August 2007|Actual|2007-08-31||Interventional|||Bevacizumab and Long Acting Gas in Diabetic Vitrectomy|Bevacizumab Pretreatment and Long Acting Gas Infusion on the Vitreous Clear-up After Diabetic Vitrectomy|Completed||Phase 3|16|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 02:15:49.207127|2018-06-01 02:15:49.207127
NCT00656422|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2012-10-31|2008-04-07|2008-04-11|Estimate|||||||2012-10-31|2012-11-01|Estimate|November 2007||2007-11-30|October 2012|2012-10-31||||||||Interventional|||Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine|Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine|Terminated||Phase 3|66|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 02:15:49.321817|2018-06-01 02:15:49.321817
NCT00656409|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-10|2008-04-10|2008-04-11|Estimate|||||||2008-04-10|2008-04-11|Estimate|June 2006||2006-06-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|||||Interventional|||Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)|Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)|Completed||Phase 3|30|Actual|Institute of Child Health|||||f||||f||||||||||2018-06-01 02:15:49.631445|2018-06-01 02:15:49.631445
NCT00656396|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2015-09-07|2008-04-10|2008-04-11|Estimate|||||||2015-09-07|2015-09-09|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|POC-OP||Point of Care Coagulation Testing in Patients Undergoing Major Surgery|Does Point of Care Coagulation Testing Reduce the Transfusion of Non-erythrocyte Blood Products in Patients Undergoing Major Surgery? A Randomized-Controlled Trial|Completed||Phase 3|228|Actual|University of Bern||2|||f||||f||||||||||2018-06-01 02:15:49.737329|2018-06-01 02:15:49.737329
NCT00656383|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2015-11-18|2008-04-10|2008-04-11|Estimate|||||||2015-11-18|2015-11-20|Estimate|October 2000||2000-10-31|November 2015|2015-11-30|March 2005|Actual|2005-03-31|March 2004|Actual|2004-03-31||Interventional|||Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population|Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population|Completed||N/A|401|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:15:49.825127|2018-06-01 02:15:49.825127
NCT00656370|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2010-02-18||2010-04-27|2008-04-10|2008-04-11|Estimate|2010-04-27|2010-05-14|Estimate||||2010-04-27|2010-05-14|Estimate|December 2007||2007-12-31|April 2010|2010-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|INFUSE-NSLR||Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)|The INcreased Flow Utilizing Subcutaneously-Enabled Normal Saline and Lactated Ringer's (INFUSE-NSLR) Study: A Phase IV, Double-Blind, Randomized Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) in Volunteer Subjects|Completed||Phase 4|15|Actual|Halozyme Therapeutics||2|||f||||f||||||||||2018-06-01 02:15:49.994975|2018-06-01 02:15:49.994975
NCT00656357|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04||2009-12-03|2018-01-17|2008-04-04|2008-04-11|Estimate||||2009-12-03|2009-12-07|Estimate|2018-01-17|2018-01-19|Actual|June 2008|Actual|2008-06-30|August 2017|2017-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers|A Human Laboratory Assessment of the Safety and Potential Efficacy of SYN117 (Nepicastat) in Cocaine-dependent Volunteers Receiving Cocaine|Completed||Phase 1/Phase 2|20|Actual|Biotie Therapies Inc.||2|||f||||t||||||||||2018-06-01 02:15:50.213418|2018-06-01 02:15:50.213418
NCT00656344|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2013-12-06|2008-04-07|2008-04-11|Estimate|||||||2013-12-06|2013-12-10|Estimate|October 2006||2006-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Cognitive Behavioral Treatment of Posttraumatic Stress Disorder Enhanced by Virtual Reality for Individuals With PTSD and Substance Abuse|Cognitive Behavioral Treatment of Posttraumatic Stress Disorder Enhanced by Virtual Reality for Individuals With PTSD and Substance Abuse|Completed||N/A|3|Actual|Weill Medical College of Cornell University|||||f||||t||||||||||2018-06-01 02:15:50.292131|2018-06-01 02:15:50.292131
NCT00656331|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2012-04-11|2008-04-07|2008-04-11|Estimate|||||||2012-04-11|2012-04-12|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.|The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications: A Comparison of Amlodipine and Hydrochlorothiazide|Terminated||N/A|20|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-06-01 02:15:50.367352|2018-06-01 02:15:50.367352
NCT00656305|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2014-08-07|2008-04-07|2008-04-11|Estimate|||||||2014-08-07|2014-08-08|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic and Multiple Myeloma Bone Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation Therapy|Completed||Phase 3|147|Actual|InSightec||2|||f||||||||||||||2018-06-01 02:15:50.610338|2018-06-01 02:15:50.610338
NCT00656292|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2017-04-10||2017-04-10|2008-04-10|2008-04-11|Estimate|2017-04-10|2017-05-19|Actual||||2017-04-10|2017-05-19|Actual|April 2008||2008-04-30|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||"Assessing the Role of Statin Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery"|"Perioperative HMG-CoA-Reductase-Inhibitors: A Pilot Study Assessing the Role of Statin Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery"|Completed||Phase 4|61|Actual|Mayo Clinic||2|||f||||t|t|f|||t|||No||2018-06-01 02:15:50.750877|2018-06-01 02:15:50.750877
NCT00656279|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2013-05-07|2008-04-07|2008-04-11|Estimate|||||||2013-05-07|2013-05-09|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Intensive Dietary Education to Lower Serum Phosphorus in Patients With Chronic Kidney Disease|Intensive Patient Education Using the Phosphorus Point System© Tool to Improve Serum Phosphorus Levels in Patients With Chronic Kidney Disease|Completed||N/A|24|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 02:15:51.278283|2018-06-01 02:15:51.278283
NCT00656266|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-22|2008-04-10|2008-04-11|Estimate|||||||2008-04-22|2008-04-25|Estimate|November 2004||2004-11-30|April 2008|2008-04-30|July 2008|Anticipated|2008-07-31|April 2008|Anticipated|2008-04-30||Interventional|||Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation|A Prospective Randomized Trial of Prednisone and Tacrolimus Versus Prednisone, Tacrolimus and Mycophenolate Mofetil in Pediatric Liver Transplantation|Terminated||Phase 4|13|Actual|Baylor College of Medicine||2||insufficient funding|f||||f||||||||||2018-06-01 02:15:51.481641|2018-06-01 02:15:51.481641
NCT00656253|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2011-03-21|2008-04-07|2008-04-11|Estimate|||||||2011-03-21|2011-03-22|Estimate|August 2008||2008-08-31|September 2009|2009-09-30|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease||Completed||Phase 2/Phase 3|158|Actual|Fudan University||2|||f||||t||||||||||2018-06-01 02:15:51.594203|2018-06-01 02:15:51.594203
NCT00656240|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2009-03-12|2008-04-10|2008-04-11|Estimate|||||||2009-03-12|2009-03-16|Estimate||||March 2009|2009-03-31||||||||Interventional|||To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Double-Masked, Parallel-Group Trial of DE-104 Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|||Santen Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 02:15:51.666355|2018-06-01 02:15:51.666355
NCT00656227|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-10|2008-04-10|2008-04-11|Estimate|||||||2008-04-10|2008-04-11|Estimate|April 2004||2004-04-30|April 2008|2008-04-30|July 2012|Anticipated|2012-07-31|July 2007|Actual|2007-07-31||Interventional|||A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision|A Double Blind, Placebo Controlled Randomised Trial to Investigate the Scar Improvement Efficacy of a Single Intradermal Application of RN1001 (Avotermin) in Subjects Undergoing Excision of Benign Head and Neck Naevi.|Unknown status|Active, not recruiting|Phase 2|239|Actual|Renovo|||||f||||f||||||||||2018-06-01 02:15:51.942543|2018-06-01 02:15:51.942543
NCT00656214|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-09|2008-04-09|2008-04-10|Estimate|||||||2008-04-09|2008-04-10|Estimate|December 2004||2004-12-31|November 2004|2004-11-30|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||Treatmant of Oral Lichen Planus With Lycopene|Efficacy of Oral Lycopene in the Management of Oral Lichen Planus|Completed||Phase 2|30|Actual|College of Dental Sciences, India||2|||f||||||||||||||2018-06-01 02:15:52.104732|2018-06-01 02:15:52.104732
NCT00656201|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2011-06-27||2011-09-20|2008-04-04|2008-04-10|Estimate|2011-09-19|2011-09-20|Estimate||||2011-09-20|2011-09-22|Estimate|July 2003||2003-07-31|September 2011|2011-09-30|July 2009|Actual|2009-07-31|November 2008|Actual|2008-11-30||Interventional|||Comparison of Crinone 8% Intravaginal Gel and IM Progesterone Supplementation for In Vitro Fertilization (IVF)|Comparison of Crinone 8% Intravaginal Gel or Intramuscular Progesterone Supplementation for In Vitro Fertilization (IVF) and Embryo Transfer (ET) Cycles in Women Under Age 40 Years Old|Completed||Phase 4|468|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:15:52.232822|2018-06-01 02:15:52.232822
NCT00656188|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2013-10-09|2008-04-04|2008-04-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|October 2002||2002-10-31|October 2013|2013-10-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Male Erectile Dysfunction Subjects|Completed||Phase 2/Phase 3|463|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:15:52.516797|2018-06-01 02:15:52.516797
NCT00656175|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2012-06-12||2012-12-17|2008-04-04|2008-04-10|Estimate|2012-12-17|2012-12-19|Estimate||||2012-12-17|2012-12-19|Estimate|September 2008||2008-09-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Raltegravir Therapy for Women With HIV and Fat Accumulation|Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation|Completed||Phase 2|39|Actual|University of California, Los Angeles|High prevalence of generalized obesity; small sample size; short follow-up; not designed to assess the potential contribution of NRTIs to lipohypertrophy, nor could we exclude the NRTI backbone as a confounding factor.|2|||f||||f||||||||||2018-06-01 02:15:52.627963|2018-06-01 02:15:52.627963
NCT00656162|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-06|||2010-11-04|2008-04-09|2008-04-10|Estimate|||||||2010-11-04|2010-11-05|Estimate|January 2009||2009-01-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Ultrasound Detection of Radiographically Negative Fractures of Elbow in Children||Completed|||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:15:52.944955|2018-06-01 02:15:52.944955
NCT00656149|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-01-10|2008-04-04|2008-04-10|Estimate|||||||2017-01-10|2017-01-12|Estimate|May 2007||2007-05-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|SCI-IHT||In-home Telerehabilitation for Quadriplegic Hand Function|Outcome Evaluation of Exercise and Electrical Therapy for Quadriplegic Hand Function|Completed||Phase 2/Phase 3|13|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 02:15:53.005344|2018-06-01 02:15:53.005344
NCT00655954|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-09|2008-04-09|2008-04-10|Estimate|||||||2008-04-09|2008-04-10|Estimate||||April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Osteoprotegerin (OPG) in Induced Chronic Obstructive Pulmonary Disease (COPD) Sputum|Osteoprotegerin (OPG) in Induced Sputum as a Novel Biomarker for COPD|Completed|||||Imperial College London|||||f||||||||||||||2018-06-01 02:15:56.296818|2018-06-01 02:15:56.296818
NCT00656136|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2013-08-08||2016-06-24|2008-04-09|2008-04-10|Estimate|2013-11-04|2013-11-27|Estimate||||2016-06-24|2016-07-26|Estimate|April 2008||2008-04-30|June 2016|2016-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Randomized Set (RS) included all patients randomised to receive treatment|BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)|Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)|Completed||Phase 3|585|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:15:53.196366|2018-06-01 02:15:53.196366
NCT00656123|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2013-12-17|2008-04-09|2008-04-10|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2008||2008-03-31|July 2009|2009-07-31||||February 2009|Anticipated|2009-02-28||Interventional|||Vaccine Therapy and Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer|A Phase I Clinical Trial of an Allogeneic Colon Cancer Cell Vaccine Administered With a GM-CSF Producing Bystander Cell Line in Patients With Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 02:15:54.106841|2018-06-01 02:15:54.106841
NCT00656110|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-06|||2009-03-09|2008-04-06|2008-04-10|Estimate|||||||2009-03-09|2009-03-10|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Neuroma Injections to Treat Restless Legs Syndrome - RCT|Randomized, Placebo-Controlled Trial of Bilateral 3rd/4th Common Digital Foot Nerve Injections to Treat Restless Legs Syndrome|Unknown status|Recruiting|N/A|60|Anticipated|Lowcountry Infectious Diseases||2|||f||||f||||||||||2018-06-01 02:15:54.289677|2018-06-01 02:15:54.289677
NCT00656097|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04||2009-06-24|2011-09-15|2008-04-09|2008-04-10|Estimate||||2009-07-31|2009-08-10|Estimate|2011-09-15|2011-09-21|Estimate|March 2008||2008-03-31|September 2011|2011-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects|A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects|Completed||Phase 2|140|Actual|Crucell Holland BV||3|||f||||f||||||||||2018-06-01 02:15:54.373439|2018-06-01 02:15:54.373439
NCT00656084|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2016-02-02||2016-09-15|2008-04-09|2008-04-10|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|December 2004||2004-12-31|September 2016|2016-09-30|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional||ITT population|Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell|A Phase II Study of Gemzar, Novantrone and Rituxan in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (B9E-US-X436)|Completed||Phase 2|16|Actual|US Oncology Research||1|||f||||f||||||||||2018-06-01 02:15:54.464258|2018-06-01 02:15:54.464258
NCT00656071|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2012-09-05|2008-04-04|2008-04-10|Estimate|||||||2012-09-05|2012-09-07|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Retrospective Postoperative ARDS Study at Vanderbilt University|Intraoperative Anesthetic Characteristics and the Development of ARDS|Completed|||89|Actual|Vanderbilt University|||2||f||||f||||||||||2018-06-01 02:15:54.786301|2018-06-01 02:15:54.786301
NCT00656058|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2016-08-29||2018-04-06|2008-04-09|2008-04-10|Estimate|2016-08-29|2016-10-21|Estimate||||2018-04-06|2018-04-09|Actual|June 17, 2008|Actual|2008-06-17|April 2018|2018-04-30|February 22, 2018|Actual|2018-02-22|May 2, 2014|Actual|2014-05-02||Interventional|||Montelukast to Treat Bronchiolitis Obliterans|Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults|Completed||Phase 2|25|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f|||f|||No||2018-06-01 02:15:54.862059|2018-06-01 02:15:54.862059
NCT00656045|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2018-04-03|2008-04-04|2008-04-10|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2008||2008-03-31|April 2018|2018-04-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|LEAN||Leisure Time Activity and Nutrition Program|The Effects of Two Different Leisure-time Activity Prescriptions on Eating and Activity Behaviors During Behavioral Weight Loss Treatment|Completed||N/A|24|Actual|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-06-01 02:15:55.268297|2018-06-01 02:15:55.268297
NCT00656032|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2012-01-09|2008-04-04|2008-04-10|Estimate|||||||2012-01-09|2012-01-11|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Vitamin D, Insulin Resistance and Inflammation in ESRD|Vitamin D, Insulin Resistance and Inflammation in ESRD|Completed||Phase 2|12|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:15:55.35796|2018-06-01 02:15:55.35796
NCT00656019|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2017-01-31||2017-10-26|2008-04-04|2008-04-10|Estimate|2017-10-26|2017-12-02|Actual||||2017-10-26|2017-12-02|Actual|April 2008||2008-04-30|October 2017|2017-10-31|December 2011|Actual|2011-12-31|August 2010|Actual|2010-08-31||Interventional|||Development of Vitamin D as a Therapy for Breast Cancer - Phase 2|Development of Vitamin D as a Therapy for Breast Cancer - Phase 2|Completed||Phase 2|63|Actual|Stanford University||4|||f||||t|t|f||||||No||2018-06-01 02:15:55.473691|2018-06-01 02:15:55.473691
NCT00656006|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2013-08-01|2008-04-09|2008-04-10|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 2005||2005-11-30|August 2013|2013-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3|A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 OR 3|Completed||Phase 2|43|Actual|Human Genome Sciences Inc.|||||f||||t||||||||||2018-06-01 02:15:55.95068|2018-06-01 02:15:55.95068
NCT00655993|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-09|2008-04-09|2008-04-10|Estimate|||||||2008-04-09|2008-04-10|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|December 2009|Anticipated|2009-12-31|March 2009|Anticipated|2009-03-31||Interventional|||Effect of Statin Therapy on C-Reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)|Effect of Statin Therapy on C-Reactive Protein Levels in Patients With COPD|Unknown status|Recruiting|Phase 1|40|Anticipated|VA Loma Linda Health Care System||2|||f||||f||||||||||2018-06-01 02:15:56.019934|2018-06-01 02:15:56.019934
NCT00655980|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2017-12-14|2008-04-04|2008-04-10|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2008||2008-02-29|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|VINO||Vitamins in Nitrous Oxide Study|Pharmacogenetics of Adverse Outcomes After Nitrous Oxide Anesthesia|Completed||N/A|625|Actual|Washington University School of Medicine||3|||f||||t||||||||No||2018-06-01 02:15:56.101279|2018-06-01 02:15:56.101279
NCT00655967|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2009-07-24|2008-04-09|2008-04-10|Estimate|||||||2009-07-24|2009-07-28|Estimate|December 2006||2006-12-31|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|SAFADIE||Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)|Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study|Unknown status|Recruiting|Phase 4|25|Anticipated|University of New Mexico||1|||f||||f||||||||||2018-06-01 02:15:56.200335|2018-06-01 02:15:56.200335
NCT00655941|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2012-01-05|2008-04-04|2008-04-10|Estimate|||||||2012-01-05|2012-01-06|Estimate|April 2008||2008-04-30|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CAROT||Influence of Weight Loss or Exercise on Cartilage in Obese Knee Osteoarthritis Patients|Influence of Weight Loss or Exercise on CARtilage in Obese Knee Osteoarthritis Patients: a Randomized Controlled Trial (CAROT).|Completed||N/A|192|Actual|Frederiksberg University Hospital||3|||f||||f||||||||||2018-06-01 02:15:56.357282|2018-06-01 02:15:56.357282
NCT00655928|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2011-12-22|2008-04-04|2008-04-10|Estimate|||||||2011-12-22|2011-12-23|Estimate|August 2007||2007-08-31|December 2011|2011-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Modulation of Lung Injury Complicating Lung Resection|Modulation of Lung Injury Complicating Lung Resection|Completed||Phase 2|47|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 02:15:56.468794|2018-06-01 02:15:56.468794
NCT00655915|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2011-03-08|2008-04-04|2008-04-10|Estimate|||||||2011-03-08|2011-03-09|Estimate|December 2007||2007-12-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release|Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release|Terminated|||200|Anticipated|Vanderbilt University|||1|Study was terminated by principal investigator|f||||f||||||||||2018-06-01 02:15:56.541796|2018-06-01 02:15:56.541796
NCT00655902|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2011-04-28|2008-04-09|2008-04-10|Estimate|||||||2011-04-28|2011-04-29|Estimate|April 2008||2008-04-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|COBRA||Copenhagen Obesity Risk Assessment Study|Copenhagen Obesity Risk Assessment Study - A Double Blind Randomized Dietary Intervention Study Examining the Effect of a High Intake of Trans Fatty Acids on Abdominal Obesity and Risk Markers of Type 2 Diabetes and Cardiovascular Disease.|Completed||N/A|52|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 02:15:56.612161|2018-06-01 02:15:56.612161
NCT00655889|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2013-06-04||2013-06-04|2008-04-04|2008-04-10|Estimate|2013-06-04|2013-08-15|Estimate||||2013-06-04|2013-08-15|Estimate|January 2006||2006-01-31|June 2013|2013-06-30|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency||Completed||Phase 2|13|Actual|Fibrocell Technologies, Inc.|This was a small, open-label study without a placebo control, and was not powered to provide statistically significant demonstrations of product efficacy.|1|||f||||f||||||||||2018-06-01 02:15:56.687174|2018-06-01 02:15:56.687174
NCT00655876|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|2017-12-20||2018-02-14|2008-04-09|2008-04-10|Estimate|2018-02-14|2018-03-14|Actual||||2018-02-14|2018-03-14|Actual|June 2008||2008-06-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2015|Actual|2015-04-30||Interventional||Eligible patients|Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer|A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery|Active, not recruiting||Phase 3|344|Actual|Radiation Therapy Oncology Group|After a United Kingdom trial failed to show a benefit for cetuximab, accrual was suspended and the 3rd planned interim analysis done. After discussions with the Data Monitoring Committee, the study permanently closed to accrual on 2/8/2013.|2|||f||||t||||||||||2018-06-01 02:15:56.899812|2018-06-01 02:15:56.899812
NCT00655863|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2013-02-17||2013-05-23|2008-04-09|2008-04-10|Estimate|2013-05-23|2013-05-27|Estimate||||2013-05-23|2013-05-27|Estimate|July 2007||2007-07-31|May 2013|2013-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.|Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes|Completed||Phase 3|71|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:15:58.131771|2018-06-01 02:15:58.131771
NCT00655850|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2017-03-03||2017-06-19|2008-04-04|2008-04-10|Estimate|2017-04-24|2017-05-24|Actual||||2017-06-19|2017-07-17|Actual|March 2008||2008-03-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional||Patients were required to be over 18 years of age, have stage IV, histologically proven non-squamous NSCLC, have Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1, have received no prior systemic therapy for cancer, and have adequate organ function.|Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer|Pilot Phase II Study of Metronomic Chemotherapy in Combination With Avastin in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 2|39|Actual|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-06-01 02:15:59.228433|2018-06-01 02:15:59.228433
NCT00655837|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-12-17|2008-04-04|2008-04-10|Estimate|||||||2014-12-17|2014-12-18|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL|A Phase Ib Study of SGN-40 in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 1|33|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 02:15:59.418346|2018-06-01 02:15:59.418346
NCT00655824|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2012-03-26||2017-11-27|2008-04-09|2008-04-10|Estimate|2012-03-26|2012-04-18|Estimate||||2017-11-27|2017-12-05|Actual|January 1, 2008||2008-01-01|October 2017|2017-10-31|March 19, 2013|Actual|2013-03-19|May 25, 2011|Actual|2011-05-25||Interventional|||Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403|An Open-label, International, Multi-center, Phase II, Extension Trial Investigating Long-term Efficacy and Safety of Repeated Treatment Courses of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Adult Patients With Active Rheumatoid Arthritis Who Previously Received Ofatumumab or Placebo|Terminated||Phase 2|124|Actual|GlaxoSmithKline|Development of the IV route of ofatumumab (OFA) administration in RA will no longer be pursued. This study was prematurely terminated; OFA treatment was discontinued. Participants could complete only <=7 treatment courses and a follow-up evaluation.|1||"The clinical development of intravenously administered ofatumumab in RA will no longer be~   pursued, so this study was prematurely terminated by the Sponsor."|f||||f||||||||||2018-06-01 02:15:59.677692|2018-06-01 02:15:59.677692
NCT00655811|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2017-03-16||2017-11-06|2008-04-09|2008-04-10|Estimate|2017-08-10|2017-08-14|Actual||||2017-11-06|2017-11-08|Actual|February 2008||2008-02-29|August 2017|2017-08-31|October 2009|Actual|2009-10-31|August 2008|Actual|2008-08-31||Interventional|||Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects|Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects|Completed||Phase 4|40|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-06-01 02:16:01.21979|2018-06-01 02:16:01.21979
NCT00655798|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-04|2008-04-04|2008-04-10|Estimate|||||||2008-04-04|2008-04-10|Estimate|December 2006||2006-12-31|April 2008|2008-04-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Effect of Nutritional Interventions on Inflammatory Status in Healthy Overweight Men|Effect of Nutritional Interventions on Inflammatory Status in Healthy Overweight Men|Completed||N/A|42|Actual|TNO||4|||f||||||||||||||2018-06-01 02:16:01.442326|2018-06-01 02:16:01.442326
NCT00655785|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2013-03-13|2008-04-04|2008-04-10|Estimate|||||||2013-03-13|2013-03-14|Estimate|September 2007||2007-09-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2)|Phase Ｉ/Ⅱ Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|17|Actual|Fukushima Medical University||1|||f||||f||||||||||2018-06-01 02:16:01.537591|2018-06-01 02:16:01.537591
NCT00655772|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-04|2008-04-04|2008-04-10|Estimate|||||||2008-04-04|2008-04-10|Estimate|February 2007||2007-02-28|March 2008|2008-03-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||A Clinical Trial to Assess the Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor|A Randomized, Double Blind, Crossover, Placebo-Controlled Clinical Trial to Assess the Effects of a Mouthwash Containing Chlorine Dioxide on Oral Malodor|Completed||Phase 1|15|Actual|Tokyo Medical and Dental University|||||f||||f||||||||||2018-06-01 02:16:01.608097|2018-06-01 02:16:01.608097
NCT00655746|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2009-06-11||2009-12-08|2008-04-09|2008-04-10|Estimate|2009-06-11|2009-07-31|Estimate||||2009-12-08|2009-12-15|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects|The Effect of Omeprazole on the Pharmacokinetics of Dasatinib (BMS-354825) in Healthy Subjects|Completed||Phase 1|14|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:16:01.704048|2018-06-01 02:16:01.704048
NCT00655733|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-06|2011-04-18||2012-11-04|2008-04-09|2008-04-10|Estimate|2012-11-04|2012-12-03|Estimate||||2012-11-04|2012-12-03|Estimate|April 2006||2006-04-30|November 2012|2012-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase II Study of HMPL-004 in Subjects With Crohn's Disease||Completed||Phase 2|101|Actual|Hutchison Medipharma Limited||2|||f||||f||||||||||2018-06-01 02:16:01.928013|2018-06-01 02:16:01.928013
NCT00655720|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-10|2008-04-09|2008-04-10|Estimate|||||||2008-04-10|2008-04-15|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Effects on Growth of a Non-Routine Infant Formula|The Effects on Growth and Tolerance of Hydrolyzed Formulas Fed to Term Infants|Completed||N/A|293|Actual|Mead Johnson Nutrition||3|||f||||f||||||||||2018-06-01 02:16:02.148182|2018-06-01 02:16:02.148182
NCT00655707|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2015-06-04|2008-04-04|2008-04-10|Estimate|||||||2015-06-04|2015-06-08|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency|A Phase I/II Safety and Tolerability Dose Escalation Study Following the Autologous Infusion of Expanded Adult Haematopoietic Stem Cells to Patients With Liver Insufficiency|Completed||Phase 1/Phase 2|5|Actual|Imperial College London||1|||f||||t||||||||||2018-06-01 02:16:02.210827|2018-06-01 02:16:02.210827
NCT00655694|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2015-06-03|2008-04-09|2008-04-10|Estimate|||||||2015-06-03|2015-06-04|Estimate||||April 2008|2008-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)|A Non Interventional Study to Asses the Utility of Genomic/ Proteomic/ Metabonomic Profiling Approaches to the Classification and Pathological Basis of Inflammatory Lung Disease in Smokers, and Ex-smokers vs. Non-smokers and Asthmatics|Completed|||||Imperial College London|||||f||||||||||||||2018-06-01 02:16:02.262852|2018-06-01 02:16:02.262852
NCT00655681|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2012-02-29|2008-04-09|2008-04-10|Estimate|||||||2012-02-29|2012-03-01|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Prevention of Post Operative Bone Loss in Children|Prevention of Post Operative Bone Loss in Children|Completed||N/A|24|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 02:16:02.304981|2018-06-01 02:16:02.304981
NCT00655668|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2011-11-30||2017-01-17|2008-04-09|2008-04-10|Estimate|2011-11-30|2012-01-05|Estimate||||2017-01-17|2017-03-01|Actual|March 2008||2008-03-31|January 2017|2017-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|EXPECT||A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma|Terminated||Phase 2|54|Actual|Celgene||1||Decision not to pursue as single agent in the study population.|f||||t||||||||||2018-06-01 02:16:03.428609|2018-06-01 02:16:03.428609
NCT00655655|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2018-01-12|2008-04-09|2008-04-10|Estimate|||||||2018-01-12|2018-01-17|Actual|December 2004|Actual|2004-12-31|January 2018|2018-01-31|January 11, 2018|Actual|2018-01-11|September 15, 2009|Actual|2009-09-15||Interventional|||Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors|A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors|Completed||Phase 1|96|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:16:03.964316|2018-06-01 02:16:03.964316
NCT00655642|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2011-03-21||2013-09-30|2008-04-04|2008-04-10|Estimate|2011-04-12|2011-05-09|Estimate||||2013-09-30|2013-10-30|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED|A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department.|Terminated||N/A|171|Actual|Vanderbilt University|Early termination resulted in failure to meet our predetermined sample size.|4||"Conditional analysis showed observed differences were significantly less than power~   calculations"|f||||f||||||||||2018-06-01 02:16:04.082043|2018-06-01 02:16:04.082043
NCT00655629|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2010-10-07|2010-02-08|2014-07-29|2008-04-09|2008-04-10|Estimate|2010-12-21|2011-01-21|Estimate|2010-02-08|2010-02-10|Estimate|2014-07-29|2014-08-01|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.|Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-dose, Double-blind, Randomized Multi-center Trial|Completed||Phase 3|339|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:16:04.447491|2018-06-01 02:16:04.447491
NCT00655616|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2011-03-23|2008-04-09|2008-04-10|Estimate|||||||2011-03-23|2011-03-24|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics|A Proof-of-concept Study to Evaluate the Benefit From add-on Therapy With Montelukast Versus Salmeterol in Children With Asthma Carrying the Arg/Arg-16 beta2-receptor Genotype|Completed||N/A|64|Actual|University of Dundee||2|||f||||t||||||||||2018-06-01 02:16:05.235046|2018-06-01 02:16:05.235046
NCT00655603|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2009-04-03|2008-04-04|2008-04-10|Estimate|||||||2009-04-03|2009-04-06|Estimate|March 2008||2008-03-31|April 2009|2009-04-30|September 2009|Anticipated|2009-09-30|May 2009|Anticipated|2009-05-31||Interventional|||Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus|Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of GLP-1 in Patients With Type 2 Diabetes Mellitus.|Unknown status|Enrolling by invitation|N/A|20|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-06-01 02:16:05.31094|2018-06-01 02:16:05.31094
NCT00655590|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-12-26|2008-04-04|2008-04-10|Estimate|||||||2014-12-26|2014-12-30|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function|A Randomized, Double-blind, Placebo Controlled, Parallel Arm, Multicenter Trial Assessing the Effect of Daily Treatment of Vardenafil 20 mg or Sildenafil 100 mg Compared to Placebo on Spermatogenesis|Completed||Phase 4|200|Actual|Bayer||3|||f||||||||||||||2018-06-01 02:16:05.373416|2018-06-01 02:16:05.373416
NCT00655577|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-04|2008-04-04|2008-04-10|Estimate|||||||2008-04-04|2008-04-10|Estimate|August 1998||1998-08-31|April 2008|2008-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Exercise and Prevention of Hip Fractures|Role of Exercise in Prevention of Osteoporotic Fractures in Elderly Women|Completed||N/A|160|Actual|University of Oulu||2|||f||||f||||||||||2018-06-01 02:16:05.49247|2018-06-01 02:16:05.49247
NCT00655564|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2012-06-27||2017-11-01|2008-04-04|2008-04-10|Estimate|2012-06-27|2012-08-03|Estimate||||2017-11-01|2017-12-07|Actual|May 2008||2008-05-31|November 2017|2017-11-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis|Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis|Completed||Phase 4|15|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-06-01 02:16:05.575679|2018-06-01 02:16:05.575679
NCT00655551|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2010-09-23||2017-07-28|2008-04-09|2008-04-10|Estimate|2010-09-23|2010-10-20|Estimate||||2017-07-28|2017-08-28|Actual|April 2008||2008-04-30|July 2017|2017-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures|A Multicenter, Open-label Trial to Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Lacosamide Maintenance as Adjunctive Therapy in Subjects With Partial-onset Seizures|Completed||Phase 3|100|Actual|UCB Pharma||3|||f||||t||||||||||2018-06-01 02:16:05.782091|2018-06-01 02:16:05.782091
NCT00655538|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2016-11-01|2008-04-09|2008-04-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2008||2008-02-29|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients|A Randomized, Placebo-controlled Study of the Safety, Tolerability and Effect on Endothelial Function, as Measured by Flow Mediated Dilatation, of RO4607381 in Patients With Coronary Heart Disease (CHD) or CHD Risk Equivalents.|Completed||Phase 2|476|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:16:06.170813|2018-06-01 02:16:06.170813
NCT00655525|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-04-22|2008-04-04|2008-04-10|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Omega-3 Fatty Acid Administration in Dialysis Patients|Omega-3 Fatty Acid Administration in Dialysis Patients|Completed||Phase 2|38|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 02:16:06.274429|2018-06-01 02:16:06.274429
NCT00655512|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-06-10|2008-04-09|2008-04-10|Estimate|||||||2014-06-10|2014-06-11|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|OCT||Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound|Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream (Elidel® 1% Cream), Hydrocortisonacetat 1% Cream (Hydrogalen® Cream), Betamethasonvalerat 0,1% Cream (Betagalen® Cream) and Clobetasol-17-propionat 0,05% Cream (Clobegalen® Cream) Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound - a Single Blind, Placebo-controlled, Randomized, Monocenter Clinical Trial|Completed||Phase 1|40|Actual|Technische Universität Dresden||5|||f||||f||||||||||2018-06-01 02:16:06.34269|2018-06-01 02:16:06.34269
NCT00655499|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-09|||2012-08-22|2008-04-09|2008-04-10|Estimate|||||||2012-08-22|2012-08-23|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|An Open-label Phase II Clinical Trial of Panitumumab in Combination With Irinotecan for Patients With Advanced Metastatic Colorectal Cancer Without KRAS Mutation (Wild Type) in Third Line Chemotherapy (Patients Pretreated With FOLFOX or XELOX ± Bevacizumab and Irinotecan Alone or FOLFIRI or CAPIRI ± Bevacizumab) [PIMABI]|Completed||Phase 2|68|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group|||||f||||f||||||||||2018-06-01 02:16:06.418616|2018-06-01 02:16:06.418616
NCT00655486|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2011-06-15||2017-07-28|2008-04-04|2008-04-10|Estimate|2011-06-15|2011-07-15|Estimate||||2017-07-28|2017-08-28|Actual|April 2008||2008-04-30|July 2017|2017-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures|A Multicenter, Open-label Extension Trial to Assess the Long-term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects With Partial-onset Seizures|Completed||Phase 3|97|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:16:06.518912|2018-06-01 02:16:06.518912
NCT00655473|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28||2016-07-08|2016-11-01|2008-04-04|2008-04-10|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease|A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors|Completed||Phase 2|130|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:16:06.805064|2018-06-01 02:16:06.805064
NCT00655460|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2015-02-24|2008-04-07|2008-04-09|Estimate|||||||2015-02-24|2015-02-26|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 1|Clinical Process Improvement With A Bedside Computerized Insulin Therapy Protocol For Blood Glucose Control (eProtocol-insulin) in Adult And Pediatric ICU Patients:Further Refinement and Validation of eProtocol-insulin|Recruiting||Phase 2|200|Anticipated|Intermountain Health Care, Inc.||1|||f||||t||||||||||2018-06-01 02:16:06.898868|2018-06-01 02:16:06.898868
NCT00655434|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-01-08|2008-04-08|2008-04-09|Estimate|||||||2009-01-08|2009-01-09|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population|HerpeSelect® Express Rapid Test Study Protocol Sexually Active Adult Population|Completed|||400|Anticipated|Focus Diagnostics, Inc.|||1||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 02:16:07.099759|2018-06-01 02:16:07.099759
NCT00655421|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-07-02|2008-04-03|2008-04-09|Estimate|||||||2009-07-02|2009-07-03|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Oral Cancer Screening in Mumbai, India by Primary Health Care Workers|Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India.|Unknown status|Active, not recruiting|Phase 3|329|Actual|Tata Memorial Hospital||3|||f||||t||||||||||2018-06-01 02:16:07.177659|2018-06-01 02:16:07.177659
NCT00655408|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-03|2008-04-03|2008-04-09|Estimate|||||||2008-04-03|2008-04-09|Estimate|April 2003||2003-04-30|April 2008|2008-04-30|January 2004|Actual|2004-01-31|September 2003|Actual|2003-09-30||Interventional|IDA||Iron-Deficiency Anemia in Infants in Two Weekly Programs|Iron-Deficiency Anemia in Infants: Comparative Study of Two Weekly Supplement Programs|Completed||N/A|130|Actual|Sao Jose do Rio Preto Medical School||1|||f||||f||||||||||2018-06-01 02:16:07.25372|2018-06-01 02:16:07.25372
NCT00655395|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2010-03-08|2008-04-08|2008-04-09|Estimate|||||||2010-03-08|2010-03-09|Estimate|March 2008||2008-03-31|March 2010|2010-03-31|October 2010|Anticipated|2010-10-31|April 2010|Anticipated|2010-04-30||Interventional|||Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine|A Phase I/Phase II Evaluation of Laromustine (VNP40101M), A Sulfonylhydrazine Alkylating Agent, Combined With Infusional Cytarabine in Elderly Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome|Unknown status|Active, not recruiting|Phase 1/Phase 2|52|Anticipated|Weill Medical College of Cornell University||5|||f||||||||||||||2018-06-01 02:16:07.321616|2018-06-01 02:16:07.321616
NCT00655382|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2010-05-20|2008-04-08|2008-04-09|Estimate|||||||2010-05-20|2010-05-21|Estimate|October 2007||2007-10-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Dynamic MRI Evaluation Post Operative Stapled Trans Anal Rectal Resection (STARR) Procedure|Dynamic MRI Evaluation Post op STARR Procedure|Completed|||10|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:16:07.403101|2018-06-01 02:16:07.403101
NCT00655369|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03||2009-12-10|2012-07-17|2008-04-03|2008-04-09|Estimate||||2009-12-10|2009-12-14|Estimate|2012-07-17|2012-07-25|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep|PD 0200390 Dose-Ranging Trial: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Outpatient Trial of PD 0200390 in Adults With Nonrestorative Sleep|Completed||Phase 2|306|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 02:16:07.472036|2018-06-01 02:16:07.472036
NCT00655356|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2012-02-09||2012-02-09|2008-04-03|2008-04-09|Estimate|2012-02-09|2012-03-13|Estimate||||2012-02-09|2012-03-13|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|May 2009|Actual|2009-05-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles||Completed||Phase 3|218|Actual|Fibrocell Technologies, Inc.||2|||f||||f||||||||||2018-06-01 02:16:07.626503|2018-06-01 02:16:07.626503
NCT00655343|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-12-09|2008-04-08|2008-04-09|Estimate|||||||2011-12-09|2011-12-12|Estimate|February 2003||2003-02-28|December 2011|2011-12-31|March 2009|Actual|2009-03-31|March 2007|Actual|2007-03-31||Interventional|||Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)|GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S|Completed||Phase 3|202|Actual|Neovii Biotech||2|||f||||t||||||||||2018-06-01 02:16:08.022512|2018-06-01 02:16:08.022512
NCT00655330|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2016-08-23|2008-04-08|2008-04-09|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy|A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy|Active, not recruiting||N/A|170|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-06-01 02:16:08.114289|2018-06-01 02:16:08.114289
NCT00655317|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-03-10|2008-04-08|2008-04-09|Estimate|||||||2011-03-10|2011-03-14|Estimate|August 2007||2007-08-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Acupuncture and Post-Operative Ileus|Acupuncture and Post-Operative Ileus: A Prospective Randomized Study to Evaluate the Effects of Electrostimulated Acupuncture on Recovery From Ileus Following Standard Elective Colon Surgery|Completed||N/A|107|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:16:08.186262|2018-06-01 02:16:08.186262
NCT00655304|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-07-26|2008-04-04|2008-04-09|Estimate|||||||2011-07-26|2011-07-27|Estimate|March 2007||2007-03-31|July 2010|2010-07-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure|The Effect of Prometheus (R) Liver Support Dialysis on Intracranial Pressure, Cerebral Oxidative Metabolism and Hemodynamics in Patients With Acute Liver Failure|Completed||N/A|8|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:16:08.262377|2018-06-01 02:16:08.262377
NCT00655291|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-10-07|2008-04-03|2008-04-09|Estimate|||||||2008-10-07|2008-10-08|Estimate|April 2008||2008-04-30|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy of XP20B Following Bunionectomy Surgery|Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Analgesic Efficacy of XP20B in Subjects With Pain Following Bunionectomy Surgery|Completed||Phase 3|190|Anticipated|Xanodyne Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:16:08.329023|2018-06-01 02:16:08.329023
NCT00655278|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2013-12-19|2008-04-03|2008-04-09|Estimate|||||||2013-12-19|2013-12-23|Estimate|August 2007||2007-08-31|November 2013|2013-11-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||T2000 in Essential Tremor - Open Label Continuation|Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study|Terminated||Phase 2|5|Actual|Taro Pharmaceuticals USA||1|||f||||t||||||||||2018-06-01 02:16:08.397786|2018-06-01 02:16:08.397786
NCT00654264|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-10-27|2008-04-04|2008-04-07|Estimate|||||||2011-10-27|2011-10-28|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Water Immersion in Right-Sided Heart Failure: A Pilot Study|Water Immersion in Right-Sided Heart Failure: A Pilot Study|Completed||Phase 4|13|Anticipated|University of Maryland||2|||f||||t||||||||||2018-06-01 02:16:25.77274|2018-06-01 02:16:25.77274
NCT00655265|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2014-02-10|2008-04-08|2008-04-09|Estimate|||||||2014-02-10|2014-02-11|Estimate|August 2007||2007-08-31|February 2014|2014-02-28|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication|A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, MultiCentre Study of Colesevelam as Add-on Therapy in Patients With Familial Hypercholesterolaemia|Completed||Phase 4|86|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:16:08.471639|2018-06-01 02:16:08.471639
NCT00655252|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2011-08-18|2008-04-08|2008-04-09|Estimate|||||||2011-08-18|2011-08-19|Estimate||||August 2011|2011-08-31||||||||Expanded Access|||Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy|An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy|No longer available|||||Novartis|||||||||||||||||||2018-06-01 02:16:08.639396|2018-06-01 02:16:08.639396
NCT00655239|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2016-05-12|2008-04-07|2008-04-09|Estimate|||||||2016-05-12|2016-05-16|Estimate|June 2008||2008-06-30|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis|Neuroscience-Guided Cognitive Remediation in Adolescents at Risk for Psychosis|Unknown status|Active, not recruiting|Phase 1/Phase 2|100|Anticipated|University of California, San Francisco||3|||f||||f||||||||||2018-06-01 02:16:08.806155|2018-06-01 02:16:08.806155
NCT00655226|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-08-05|2008-04-03|2008-04-09|Estimate|||||||2011-08-05|2011-08-09|Estimate|March 2008||2008-03-31|August 2011|2011-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients|Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients|Terminated||N/A|26|Actual|Icahn School of Medicine at Mount Sinai||2||low enrollment|f||||t||||||||||2018-06-01 02:16:08.890819|2018-06-01 02:16:08.890819
NCT00655213|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-09|Estimate|||||||2008-04-03|2008-04-09|Estimate|November 2003||2003-11-30|April 2008|2008-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|SAVER||Spontaneous Atrio Ventricular Conduction Preservation|Spontaneous Atrio Ventricular Conduction Preservation|Completed||Phase 4|622|Actual|LivaNova||4|||f||||t||||||||||2018-06-01 02:16:09.018973|2018-06-01 02:16:09.018973
NCT00655200|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-08-13|2008-04-04|2008-04-09|Estimate|||||||2014-08-13|2014-08-15|Estimate|February 2008||2008-02-29|November 2012|2012-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus|Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus|Completed|||2286|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:16:09.192648|2018-06-01 02:16:09.192648
NCT00655187|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-05-25|2008-04-03|2008-04-09|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2008||2008-04-30|May 2017|2017-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Effectiveness of Human Rotavirus Vaccine, Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants|Case-control Study to Evaluate the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children < 5 Years of Age in KK Hospital, Singapore|Completed|||1270|Actual|GlaxoSmithKline|||2||f||||||||||Samples With DNA|"~     Stool samples~   "|||2018-06-01 02:16:09.263715|2018-06-01 02:16:09.263715
NCT00655174|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-04|2008-04-04|2008-04-09|Estimate|||||||2008-04-04|2008-04-09|Estimate|June 1999||1999-06-30|April 2008|2008-04-30|January 2007|Actual|2007-01-31|September 2006|Actual|2006-09-30||Interventional|||Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?|A Double-Blind Placebo-Controlled Randomized Clinical Trial of Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?|Completed||Phase 3|108|Actual|The Hospital for Sick Children||3|||f||||t||||||||||2018-06-01 02:16:09.339618|2018-06-01 02:16:09.339618
NCT00655161|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2014-01-28|2008-04-08|2008-04-09|Estimate|||||||2014-01-28|2014-01-29|Estimate|April 2008||2008-04-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation|A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation|Completed||Phase 2|24|Actual|GlobeImmune|||||f||||t||||||||||2018-06-01 02:16:09.414657|2018-06-01 02:16:09.414657
NCT00655148|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2013-01-18|2008-04-03|2008-04-09|Estimate|||||||2013-01-18|2013-01-21|Estimate|September 2003||2003-09-30|January 2013|2013-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination Vaccine|Clinical Trial Comparing the Safety and Immunogenicity of Two Combined Diphtheria, Tetanus, Acellular Pertussis, and Inactivated Poliovirus (DTaP-IPV) Vaccines Administered to Healthy Children at 2, 3½, and 16 Months of Age|Completed||Phase 3|817|Actual|Statens Serum Institut||2|||f||||f||||||||||2018-06-01 02:16:09.495268|2018-06-01 02:16:09.495268
NCT00655135|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-08|2008-04-08|2008-04-09|Estimate|||||||2008-04-08|2008-04-09|Estimate|February 2000||2000-02-29|April 2008|2008-04-30||||June 2002|Actual|2002-06-30||Interventional|||Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients|Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients With Mildly to Moderately Active Crohn's Disease|Completed||Phase 2|185|Actual|Millennium Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 02:16:09.563867|2018-06-01 02:16:09.563867
NCT00655122|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-09-25|2008-04-04|2008-04-09|Estimate|||||||2008-09-25|2008-09-29|Estimate|April 2003||2003-04-30|September 2008|2008-09-30|December 2003|Actual|2003-12-31|||||Interventional|||Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study|Double-Blind, Placebo-Controlled, Pilot Study, In Medical Patients With Prophylaxis Of Venous Thromboembolism in Primary Care|Terminated||Phase 4|8|Actual|Pfizer||2||See Detailed Description.|f||||f||||||||||2018-06-01 02:16:09.620527|2018-06-01 02:16:09.620527
NCT00655109|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-02|2008-04-02|2008-04-09|Estimate|||||||2008-04-02|2008-04-09|Estimate|February 2008||2008-02-29|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis|A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis|Completed||Phase 4|60|Actual|Greiner, Jack V., OD DO PhD||4|||f||||f||||||||||2018-06-01 02:16:09.698812|2018-06-01 02:16:09.698812
NCT00655083|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2010-05-27||2011-10-11|2008-04-03|2008-04-09|Estimate|2010-08-03|2010-08-25|Estimate||||2011-10-11|2011-10-17|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants|Pilot Study to Evaluate the Oral Absorption, Safety, and Tolerability of Nepadutant Administered as Single Oral Doses to Infants With Colic and Other Functional Gastrointestinal Disorders|Completed||Phase 1|21|Actual|Menarini Group|No infants aged 18-24 weeks were dosed at 0.5 mg/kg dose when the trial was stopped because of slow recruitment and drug expiration.|2|||f||||f||||||||||2018-06-01 02:16:09.854945|2018-06-01 02:16:09.854945
NCT00655070|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2012-04-02|2008-04-08|2008-04-09|Estimate|||||||2012-04-02|2012-04-04|Estimate|April 2008||2008-04-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Effect of Timi3 Ultrasound on Myocardial Blow Flow in the Hibernating Myocardium|Evaluation of the Effect of T3US on Myocardial Blow Flow in the Hibernating|Terminated||Early Phase 1|9|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 02:16:10.147809|2018-06-01 02:16:10.147809
NCT00655057|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2012-07-26|2008-04-07|2008-04-09|Estimate|||||||2012-07-26|2012-07-30|Estimate|October 2005||2005-10-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression|SPECT Brain Imaging as a Bio-Marker of Major Depression|Completed||Phase 2/Phase 3|66|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 02:16:10.209795|2018-06-01 02:16:10.209795
NCT00655044|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2016-10-27|2008-04-08|2008-04-09|Estimate|||||||2016-10-27|2016-10-28|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|PREDICTIVE™||Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes|Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus|Completed|||3637|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 02:16:10.281341|2018-06-01 02:16:10.281341
NCT00655031|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-08-14|2008-04-04|2008-04-09|Estimate|||||||2008-08-14|2008-08-18|Estimate|April 2008||2008-04-30|August 2008|2008-08-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection|A Placebo Controlled, Randomized, Double Blind Pilot Study to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection in Human Subjects|Completed||Phase 2|150|Anticipated|POM Wonderful LLC||2|||f||||f||||||||||2018-06-01 02:16:10.348551|2018-06-01 02:16:10.348551
NCT00655018|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-08|2008-04-08|2008-04-09|Estimate|||||||2008-04-08|2008-04-09|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|VITENAFLD||Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)|Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial|Completed||Phase 2/Phase 3|90|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||t||||||||||2018-06-01 02:16:10.417096|2018-06-01 02:16:10.417096
NCT00655005|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|||2012-09-07|2008-04-08|2008-04-09|Estimate|||||||2012-09-07|2012-09-10|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Observational|||Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer|Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck Cancer|Completed|||100|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||||||2018-06-01 02:16:10.499388|2018-06-01 02:16:10.499388
NCT00654992|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2009-03-17||2009-04-28|2008-04-04|2008-04-09|Estimate|2009-04-28|2009-06-16|Estimate||||2009-04-28|2009-06-16|Estimate|September 2006||2006-09-30|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|EPO-CABG||Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery|Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial|Completed||Phase 2/Phase 3|71|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-06-01 02:16:10.564579|2018-06-01 02:16:10.564579
NCT00654979|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2013-05-30|2008-04-03|2008-04-09|Estimate|||||||2013-05-30|2013-05-31|Estimate|July 2003||2003-07-31|May 2013|2013-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter|A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter|Completed||N/A|117|Actual|RMT Medical Technologies, Ltd.||1|||f||||f||||||||||2018-06-01 02:16:10.776922|2018-06-01 02:16:10.776922
NCT00654966|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-07-19|2008-04-03|2008-04-09|Estimate|||||||2011-07-19|2011-07-20|Estimate|June 2009||2009-06-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers|Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers.|Completed||Phase 2|16|Actual|Monash University||2|||f||||f||||||||||2018-06-01 02:16:10.839941|2018-06-01 02:16:10.839941
NCT00654953|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2011-03-28||2011-03-28|2008-04-04|2008-04-09|Estimate|2011-03-28|2011-04-25|Estimate||||2011-03-28|2011-04-25|Estimate|January 2006||2006-01-31|March 2011|2011-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans|Sertraline Augmented With GABA Agents for Cocaine Dependence|Completed||Phase 2|102|Actual|University of Arkansas||3|||f||||t||||||||||2018-06-01 02:16:11.000368|2018-06-01 02:16:11.000368
NCT00654940|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2010-01-05||2010-02-08|2008-04-03|2008-04-09|Estimate|2010-02-08|2010-02-24|Estimate||||2010-02-08|2010-02-24|Estimate|May 2008||2008-05-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study To Assess The Ability Of A Crossover Study Design To Detect The Efficacy Of Pregabalin In Post-Traumatic Neuropathic Pain Patients|Methodology Study To Assess The Ability Of A Randomized, Double-Blind, Placebo-Controlled, Two Period Crossover Study To Detect The Effect Of Pregabalin In Post-Traumatic Neuropathic Pain Patients|Completed||Phase 1|25|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:16:11.420516|2018-06-01 02:16:11.420516
NCT00654927|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2012-01-31||2012-03-01|2008-04-04|2008-04-09|Estimate|2012-01-31|2012-02-29|Estimate||||2012-03-01|2012-03-02|Estimate|November 2003||2003-11-30|January 2012|2012-01-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis|Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis|Completed||Phase 3|177|Actual|Acorda Therapeutics|||||f||||t||||||||||2018-06-01 02:16:11.869283|2018-06-01 02:16:11.869283
NCT00578604|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-03-28|2007-12-20|2007-12-21|Estimate|||||||2017-03-28|2017-03-30|Actual|September 2007||2007-09-30|March 2017|2017-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Non-Invasive Assessment of Wound Healing With Optical Methods|Non-Invasive Assessment of Wound Healing With Optical Methods|Completed|||38|Actual|Drexel University|||2||f||||f||||||||||2018-06-01 02:38:49.47609|2018-06-01 02:38:49.47609
NCT00654914|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2014-12-18|2008-04-08|2008-04-09|Estimate|||||||2014-12-18|2014-12-23|Estimate|May 2003||2003-05-31|December 2014|2014-12-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|VIS||A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction|A National, Multicentre, Open Label, Flexible Dose, Twelve Week Treatment to Assess the Efficacy and Safety of 5mg, 10mg and 20mg Bay 38-9456, a Phosphodiesterase Type V Inhibitor, in the Treatment of Male Patients With Erectile Dysfunction|Completed||Phase 3|527|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:16:12.37714|2018-06-01 02:16:12.37714
NCT00654901|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2013-05-06||2016-04-08|2008-04-03|2008-04-09|Estimate|2013-05-06|2013-06-26|Estimate||||2016-04-08|2016-05-13|Estimate|March 2008||2008-03-31|April 2016|2016-04-30|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™|Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants|Completed||Phase 3|881|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 02:16:12.465093|2018-06-01 02:16:12.465093
NCT00654888|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-10|2008-04-03|2008-04-09|Estimate|||||||2008-04-10|2008-04-11|Estimate|March 2005||2005-03-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|March 2006|Actual|2006-03-31||Interventional|ALKSBK||Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy|Study of Automated Lamellar Keratectomy With a New Option in Treatment in Symptomatic Patients With Bullous Keratopathy.|Completed||N/A|28|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 02:16:13.113789|2018-06-01 02:16:13.113789
NCT00654875|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2010-12-13||2011-06-24|2008-04-08|2008-04-09|Estimate|2011-05-13|2011-06-15|Estimate||||2011-06-24|2011-06-28|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.|A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.|Completed||Phase 4|328|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:16:13.179677|2018-06-01 02:16:13.179677
NCT00654862|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-02-17|2008-04-03|2008-04-09|Estimate|||||||2009-02-17|2009-02-18|Estimate|October 2007||2007-10-31|February 2009|2009-02-28||||September 2008|Actual|2008-09-30||Interventional|||Acute Hemodynamic Effects of Cocoa Polyphenols in Subjects With Hypertension and Optimal Blood Pressure|Randomized Controlled, Double-Blind, Sample Size-Calculated, Three-Period Crossover, Phase 1 Study to Investigate the Efficacy of a Single Oral Dose of Cocoa Phenols on Blood, Pressure, Heart Rate and Plasma Levels of Phenols, Bioactive Nitric Oxide and Oxidation Markers in Subjects With Stage 1 Essential Hypertension and Optimal Blood Pressure|Completed||Phase 1|48|Actual|University of Cologne||2|||f||||f||||||||||2018-06-01 02:16:13.411632|2018-06-01 02:16:13.411632
NCT00654849|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-21|2008-04-08|2008-04-09|Estimate|||||||2008-04-21|2008-04-22|Estimate|February 2007||2007-02-28|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|PKAHRCT||Electrosurgical Bipolar Plasmakinetic Vessel Sealing During Abdominal Hysterectomy: A Randomized Controlled Trial|Electrosurgical Bipolar Plasmakinetic Vessel Sealing During Abdominal Hysterectomy: A Randomized Controlled Trial|Completed||N/A|94|Actual|Hospital de Concentracion Norte de Petroleos||2|||f||||f||||||||||2018-06-01 02:16:13.474154|2018-06-01 02:16:13.474154
NCT00654836|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-08|2016-08-19||2017-08-16|2008-04-08|2008-04-09|Estimate|2017-08-16|2017-09-14|Actual||||2017-08-16|2017-09-14|Actual|October 2007||2007-10-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|February 2012|Actual|2012-02-29||Interventional||All enrolled participants are included in the baseline analysis population|Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|A Phase II Study of Carboplatin, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Avastin as the First Line Therapy in Metastatic Breast Cancer.|Completed||Phase 2|32|Actual|Loyola University|There are no limitations or caveats to disclose.|1|||f||||f||||||||No||2018-06-01 02:16:14.466355|2018-06-01 02:16:14.466355
NCT00654823|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-04|2008-04-04|2008-04-09|Estimate|||||||2008-04-04|2008-04-09|Estimate|June 2008||2008-06-30|April 2008|2008-04-30|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Observational|PGxWarfarin||Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial|Prospective Study Comparing Between the Commonly-Used and Pharmacogenetically-Guided Warfarin Administration Protocols|Unknown status|Not yet recruiting||500|Anticipated|Sheba Medical Center|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:16:14.729477|2018-06-01 02:16:14.729477
NCT00654810|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2008-04-07|2008-04-07|2008-04-09|Estimate|||||||2008-04-07|2008-04-09|Estimate|February 1994||1994-02-28|April 2008|2008-04-30|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Exercise Rehabilitation of Younger and Older People With Claudication|Exercise Rehabilitation of Younger and Older People With Claudication|Completed||N/A|64|Actual|National Institute on Aging (NIA)||2|||f||||f||||||||||2018-06-01 02:16:14.793761|2018-06-01 02:16:14.793761
NCT00654797|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-07|||2015-02-24|2008-04-07|2008-04-09|Estimate|||||||2015-02-24|2015-02-26|Estimate|September 2007||2007-09-30|February 2015|2015-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2|Clinical Process Improvement With A Bedside Computerized Insulin Therapy Protocol For Blood Glucose Control (eProtocol-insulin) in Adult And Pediatric Intensive Care Unit Patients-Second Phase (Phase-2): Distribution and Implementation of Validated eProtocol-insulin in Naïve ICUs|Recruiting||Phase 2|200|Anticipated|Intermountain Health Care, Inc.||1|||f||||t||||||||||2018-06-01 02:16:14.872661|2018-06-01 02:16:14.872661
NCT00654784|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2011-06-07||2011-07-29|2008-04-03|2008-04-09|Estimate|2011-06-29|2011-07-29|Estimate||||2011-07-29|2011-08-01|Estimate|October 2005||2005-10-31|July 2011|2011-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|DELPHI||Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy|A Phase IIa Double Blind, Randomised, Placebo Controlled, Single Centre Study at the University of Leuven to Assess the Efficacy and Tolerability of Idebenone in 8 - 16 Year Old Males With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy|Completed||Phase 2|21|Actual|Santhera Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:16:14.981572|2018-06-01 02:16:14.981572
NCT00654771|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2012-08-14|2008-04-03|2008-04-09|Estimate|||||||2012-08-14|2012-08-16|Estimate|July 2005||2005-07-31|August 2012|2012-08-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Observational|UPREE||Comparison of Catheterized and Clean Catch Urine Specimens for Protein/Creatinine Ratio in Preeclampsia Evaluation|Prospective Comparison of Catheterized and Clean Catch Urine Specimens for Determination of Protein/Creatinine Ratio in Evaluation of Preeclampsia|Completed|||76|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-06-01 02:16:15.341465|2018-06-01 02:16:15.341465
NCT00654758|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2017-11-17|2008-04-08|2008-04-09|Estimate|||||||2017-11-17|2017-11-21|Actual|December 2007||2007-12-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of Volociximab (M200) in Combination With Carboplatin and Paclitaxel in Subjects With Previously Untreated Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|33|Actual|AbbVie||1|||f||||t||||||||||2018-06-01 02:16:15.420457|2018-06-01 02:16:15.420457
NCT00654745|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|2010-04-21||2010-07-09|2008-04-08|2008-04-09|Estimate|2010-05-26|2010-07-02|Estimate||||2010-07-09|2010-07-13|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics|A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects|Completed||Phase 4|207|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 02:16:15.598501|2018-06-01 02:16:15.598501
NCT00654732|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2017-10-04|2008-04-03|2008-04-09|Estimate|||||||2017-10-04|2017-10-06|Actual|March 2008|Actual|2008-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma|A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2)|Active, not recruiting||Phase 2|120|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 02:16:16.784158|2018-06-01 02:16:16.784158
NCT00654719|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-03|2008-04-03|2008-04-09|Estimate|||||||2008-04-03|2008-04-09|Estimate|April 2001||2001-04-30|April 2008|2008-04-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Enteral Nutrition in Congestive Heart Failure and Cardiac Cachexia|The Influence of Enteral Nutrition on Functional Status and Inflammatory Activation in Patients With Congestive Heart Failure and Cardiac Cachexia.|Completed||Phase 2|29|Actual|National Heart and Lung Institute||2|||f||||t||||||||||2018-06-01 02:16:16.889341|2018-06-01 02:16:16.889341
NCT00654706|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03||2014-05-14|2014-05-14|2008-04-03|2008-04-09|Estimate||||2014-05-14|2014-05-28|Estimate|2014-05-14|2014-05-28|Estimate|March 2008||2008-03-31|May 2014|2014-05-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia|A Randomised, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of Sertindole Versus Comparator in Patients With Schizophrenia Using the MATRICS Consensus Cognitive Battery (MCCB)|Completed||Phase 3|264|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 02:16:17.002134|2018-06-01 02:16:17.002134
NCT00654693|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2012-09-06|2008-04-03|2008-04-09|Estimate|||||||2012-09-06|2012-09-07|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Observational|||NTX Wireless Patient Monitoring System|A Pilot Study to Evaluate the Performance of Nihon Kohden's NTX Wireless Patient Monitoring System|Completed|||26|Actual|Vanderbilt University|||1||f||||t||||||||||2018-06-01 02:16:17.120025|2018-06-01 02:16:17.120025
NCT00654680|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2013-09-26|2008-04-04|2008-04-09|Estimate|||||||2013-09-26|2013-09-30|Estimate|October 2002||2002-10-31|September 2013|2013-09-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury|A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Subjects With ED Solely Secondary to Traumatic Spinal Cord Injury|Completed||Phase 3|418|Actual|Bayer||2|||f||||||||||||||2018-06-01 02:16:17.195899|2018-06-01 02:16:17.195899
NCT00654667|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2015-03-03|2008-04-08|2008-04-09|Estimate|||||||2015-03-03|2015-03-04|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|RSV||Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome|Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome.|Withdrawn||Phase 2|0|Actual|University of California, San Francisco||2||no participant enrollment|f||||f||||||||||2018-06-01 02:16:17.261569|2018-06-01 02:16:17.261569
NCT00654654|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2012-02-09||2012-02-09|2008-04-03|2008-04-09|Estimate|2012-02-09|2012-03-13|Estimate||||2012-02-09|2012-03-13|Estimate|March 2007||2007-03-31|February 2012|2012-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases||Completed||Phase 2|50|Actual|Fibrocell Technologies, Inc.||1|||f||||f||||||||||2018-06-01 02:16:17.349305|2018-06-01 02:16:17.349305
NCT00654641|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2010-02-03||2012-12-18|2008-04-07|2008-04-08|Estimate|2012-12-18|2013-01-30|Estimate||||2012-12-18|2013-01-30|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy|Prevention of Abdominal Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy|Terminated||N/A|54|Actual|West Virginia University|Slow enrollment caused the closure of the trial prior to meeting enrollment target.|2||Poor enrollment. No apparent treatment effect.|f||||f||||||||||2018-06-01 02:16:17.62426|2018-06-01 02:16:17.62426
NCT00654628|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2010-07-30||2017-03-31|2008-04-07|2008-04-08|Estimate|2010-07-30|2010-08-26|Estimate||||2017-03-31|2017-05-05|Actual|August 1, 2007|Actual|2007-08-01|March 2017|2017-03-31|July 1, 2009|Actual|2009-07-01|July 1, 2009|Actual|2009-07-01||Interventional|BRAVO||Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)|Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients|Completed||Phase 4|173|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:16:17.860374|2018-06-01 02:16:17.860374
NCT00654615|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2017-04-03||2017-11-16|2008-04-02|2008-04-08|Estimate|2017-10-30|2017-11-13|Actual||||2017-11-16|2017-12-13|Actual|May 2008||2008-05-31|October 2017|2017-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Fixation of Unstable Distal Radius Fractures|The Fixation of Unstable Metaphyseal Distal Radius Fractures: A Randomized, Controlled Trial|Completed||N/A|60|Actual|Wake Forest University Health Sciences||2|||f||||t|f|t||||||||2018-06-01 02:16:18.136298|2018-06-01 02:16:18.136298
NCT00654602|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-05-27|2008-04-03|2008-04-08|Estimate|||||||2009-05-27|2009-05-28|Estimate|February 2002||2002-02-28|May 2009|2009-05-31|November 2004|Actual|2004-11-30|||||Interventional|||48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety|A 48 Week, Open Label, Non-Comparative, Multicentre, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects With Fredrickson Type IIa and Type IIb Dyslipidaemia, Including Heterozygous Familial Hypercholesterolaemia.|Completed||Phase 3|1500|Anticipated|AstraZeneca|||||||||||||||||||2018-06-01 02:16:18.448366|2018-06-01 02:16:18.448366
NCT00654589|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2016-11-16|2008-04-07|2008-04-08|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2008||2008-02-29|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload|A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/d) in Patients Three to Six Months After Allogeneic Hematopoietic Cell Transplantation in Whom Iron Overload is Present|Completed||Phase 4|75|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:16:18.549301|2018-06-01 02:16:18.549301
NCT00654576|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-07|2008-04-07|2008-04-08|Estimate|||||||2008-04-07|2008-04-08|Estimate|February 2005||2005-02-28|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|ACPIOS||Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia|Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia:One-Year Follow up.|Completed||Phase 4|1400|Anticipated|Central South University||2|||f||||t||||||||||2018-06-01 02:16:18.640756|2018-06-01 02:16:18.640756
NCT00654563|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2012-03-26|2008-04-03|2008-04-08|Estimate|||||||2012-03-26|2012-03-27|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Memory Disorders Registry|Memory Disorders Registry|Completed|||12|Actual|Cedars-Sinai Medical Center|||||f||||f||||||Samples Without DNA|"~     The main Memory Disorders Registry only involves records-keeping to follow subjects' care,~     and does not involve any biospecimen collection. The optional postmortem exam (brain-only~     autopsy) obtains brain tissue, and it would be performed after death, so that no risks will~     impact the subject involved in the postmortem examination. With regard to cosmetic concerns,~     the incision is made from ear to ear through the neck region, leaving no disfiguration. The~     postmortem exam is not a genetic screen, but in rare instances it might find brain atrophy,~     although no specific inclusions. If found, the subject's family would be informed of this~     finding.~   "|||2018-06-01 02:16:18.731524|2018-06-01 02:16:18.731524
NCT00654550|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-01-06|2008-04-03|2008-04-08|Estimate|||||||2009-01-06|2009-01-08|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||A Study to Assess the Safety, Tolerability and Effect of Nexagon™ Applied to the Eye After PRK Laser Eye Surgery for Nearsightedness|A Phase 1 Randomized, Prospective, Double-Masked, Vehicle-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Clinical Effect of Nexagon™ in Subjects Following Bilateral Photorefractive Keratectomy (PRK) for the Correction of Mild to Moderate Myopia.|Completed||Phase 1|24|Anticipated|CoDa Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 02:16:18.869965|2018-06-01 02:16:18.869965
NCT00654537|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-03-13|2008-04-07|2008-04-08|Estimate|||||||2009-03-13|2009-03-16|Estimate|April 2001||2001-04-30|March 2009|2009-03-31|October 2004|Actual|2004-10-31|||||Interventional|STELLAR||STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges|A 6 Week Open Label, Dose Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Subjects With Hypercholesterolemia.|Completed||Phase 3|5625|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:16:19.033996|2018-06-01 02:16:19.033996
NCT00654524|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2011-03-14|2008-04-07|2008-04-08|Estimate|||||||2011-03-14|2011-03-15|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis|A Randomized Study Comparing Goserelin or Expectant Management Following Laparoscopic Surgery for Advanced Endometriosis|Unknown status|Recruiting|Phase 4|60|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-06-01 02:16:19.120674|2018-06-01 02:16:19.120674
NCT00654511|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2011-02-23||2011-03-28|2008-04-07|2008-04-08|Estimate|2011-03-28|2011-04-26|Estimate||||2011-03-28|2011-04-26|Estimate|January 2005||2005-01-31|March 2011|2011-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|DexT&A||Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy|Dexmedetomidine for Immediate Perioperative Analgesia in Pediatric Patients Undergoing Tonsillectomy.|Completed||Phase 4|101|Actual|Children's Research Institute||4|||f||||t||||||||||2018-06-01 02:16:19.303099|2018-06-01 02:16:19.303099
NCT00654498|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2009-12-18||2014-06-03|2008-04-03|2008-04-08|Estimate|2010-02-18|2010-03-03|Estimate||||2014-06-03|2014-06-09|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Safety Set, all randomized patients that received treatment|Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)|A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks|Completed||Phase 3|306|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:16:19.796952|2018-06-01 02:16:19.796952
NCT00654485|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-03-13|2008-04-03|2008-04-08|Estimate|||||||2009-03-13|2009-03-16|Estimate|May 2002||2002-05-31|March 2009|2009-03-31|February 2005|Actual|2005-02-28|||||Interventional|||COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects|A 12 Week Randomized, Double-Blind, Force-Titration, Parallel Group, Multi Centre, Phase IIIb Study to Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects With Raised LDL-C and a 10 Year Risk of CHD >10%|Completed||Phase 3|940|Anticipated|AstraZeneca||2|||||||||||||||||2018-06-01 02:16:20.72609|2018-06-01 02:16:20.72609
NCT00654472|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-07|2008-04-07|2008-04-08|Estimate|||||||2008-04-07|2008-04-08|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Observational|||Mitral Valve Area Assessment: Comparison With Transthoracic Echocardiography and Magnetic Resonance Imaging|Quantification of Rheumatic Mitral Stenosis With Cardiac Magnetic Resonance Imaging and Comparison With Transthoracic Echocardiography|Unknown status|Recruiting||30|Anticipated|Florence Nightingale Hospital, Istanbul|||2||f||||t||||||||||2018-06-01 02:16:20.833335|2018-06-01 02:16:20.833335
NCT00654459|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-14|2008-04-07|2008-04-08|Estimate|||||||2008-04-14|2008-04-16|Estimate|July 2007||2007-07-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Observational|||Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function|Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function|Completed|||50|Actual|Federico II University|||2||f||||t||||||||||2018-06-01 02:16:20.909481|2018-06-01 02:16:20.909481
NCT00654446|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-03-13|2008-04-03|2008-04-08|Estimate|||||||2009-03-13|2009-03-16|Estimate|September 2002||2002-09-30|March 2009|2009-03-31|April 2004|Actual|2004-04-30|||||Interventional|||IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin|A 6-wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study, Which Describes the Renal Effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the Treatment of Sub's With Fredrickson Type IIa & Type IIb Dyslipidaemia, Inc. Heterozygous Familial Hypercholesterolaemia|Completed||Phase 3|442||AstraZeneca||2|||f||||||||||||||2018-06-01 02:16:21.075791|2018-06-01 02:16:21.075791
NCT00654433|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2014-07-07|2008-04-07|2008-04-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|UCBT-002||ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases|A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism|Terminated||Phase 3|40|Anticipated|Aldagen||1||Terminated - Sponsor Decision|f||||t||||||||||2018-06-01 02:16:21.156842|2018-06-01 02:16:21.156842
NCT00654420|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2016-10-28||2017-03-06|2008-04-02|2008-04-08|Estimate|2016-10-28|2016-12-28|Estimate||||2017-03-06|2017-04-04|Actual|March 2008||2008-03-31|March 2017|2017-03-31|February 2012|Actual|2012-02-29|November 2009|Actual|2009-11-30||Interventional|||A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)|An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer|Completed||Phase 2|95|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:16:21.286713|2018-06-01 02:16:21.286713
NCT00654407|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-03-13|2008-04-07|2008-04-08|Estimate|||||||2009-03-13|2009-03-16|Estimate|November 2001||2001-11-30|March 2009|2009-03-31|September 2004|Actual|2004-09-30|||||Interventional|||Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia|An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.|Completed||Phase 3|4875|Anticipated|AstraZeneca||3|||||||f||||||||||2018-06-01 02:16:22.244364|2018-06-01 02:16:22.244364
NCT00654394|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-03-13|2008-04-03|2008-04-08|Estimate|||||||2009-03-13|2009-03-16|Estimate|January 2000||2000-01-31|March 2009|2009-03-31|August 2004|Actual|2004-08-31|||||Interventional|||Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects|Randomized, Double-Blind, Multicenter, Trial to Assess the Effect of High & Low Doses of ZD4522 on Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects With Asymptomatic Carotid Stenosis After 24 Months of Dosing.|Completed||Phase 3|200|Anticipated|AstraZeneca||1|||||||f||||||||||2018-06-01 02:16:22.308484|2018-06-01 02:16:22.308484
NCT00654381|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2011-05-18||2013-12-11|2008-04-03|2008-04-08|Estimate|2011-07-05|2011-08-02|Estimate||||2013-12-11|2014-01-27|Estimate|April 2008||2008-04-30|December 2013|2013-12-31||||January 2010|Actual|2010-01-31||Interventional|||Japanese P III vs Voglibose and Placebo|A Double-blind Phase III Study to Evaluate the Efficacy of BI 1356 5 mg and 10 mg vs. Placebo for 12 Weeks and vs. Voglibose 0.6 mg for 26 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control, Followed by an Extension Study to 52 Weeks to Evaluate Long-term Safety|Completed||Phase 3|561|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 02:16:22.408385|2018-06-01 02:16:22.408385
NCT00654368|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2014-02-10||2014-07-14|2008-04-07|2008-04-08|Estimate|2014-06-11|2014-06-13|Estimate||||2014-07-14|2014-07-23|Estimate|June 2008||2008-06-30|July 2014|2014-07-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||CAMEO: Canadian Methotrexate and Etanercept Outcome Study|Canadian Methotrexate and Etanercept Outcome Study: An Open Label Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in the Treatment of Rheumatoid Arthritis (CAMEO)|Completed||Phase 4|258|Actual|Amgen||2|||f||||f||||||||||2018-06-01 02:16:23.604652|2018-06-01 02:16:23.604652
NCT00654355|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2017-01-27||2017-11-01|2008-04-07|2008-04-08|Estimate|2017-05-03|2017-06-06|Actual||||2017-11-01|2017-12-06|Actual|April 2008||2008-04-30|November 2017|2017-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit|Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit|Completed||Phase 4|30|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-06-01 02:16:24.656567|2018-06-01 02:16:24.656567
NCT00654342|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-02|2008-04-02|2008-04-08|Estimate|||||||2008-04-02|2008-04-08|Estimate|October 2007||2007-10-31|April 2008|2008-04-30||||February 2009|Anticipated|2009-02-28||Interventional|||Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer|Comparison Between ex Vivo and in Vivo Injection of Blue Dye in Sentinel Lymph Node Mapping for Colon Cancer|Unknown status|Recruiting|N/A|100|Anticipated|Chung-Ang University||2|||f||||f||||||||||2018-06-01 02:16:24.891169|2018-06-01 02:16:24.891169
NCT00654329|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2011-02-23||2011-03-28|2008-04-03|2008-04-08|Estimate|2011-03-28|2011-04-25|Estimate||||2011-03-28|2011-04-25|Estimate|August 2005||2005-08-31|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|DexBMT||Dexmedetomidine vs Fentanyl for BMT|Dexmedetomidine for Peri-operative Sedation and Analgesia in Children Undergoing Bilateral Myringotomy With Tube Placement (BMT)|Completed||Phase 4|101|Actual|Children's Research Institute||4|||f||||t||||||||||2018-06-01 02:16:25.01582|2018-06-01 02:16:25.01582
NCT00654316|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-04|2008-04-04|2008-04-07|Estimate|||||||2008-04-04|2008-04-07|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine|A Phase I Study of the Safety and Immunogenicity of BCG (Bacille Calmette-Guerin) Vaccine Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG.|Completed||Phase 1|11|Actual|University of Oxford||1|||f||||t||||||||||2018-06-01 02:16:25.374815|2018-06-01 02:16:25.374815
NCT00654303|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-03-13|2008-04-02|2008-04-07|Estimate|||||||2009-03-13|2009-03-16|Estimate|August 1999||1999-08-31|March 2009|2009-03-31|February 2005|Actual|2005-02-28|||||Interventional|||OLE Study to Evaluate Safety / Efficacy of ZD4522|ZD4522 Long Term Extension Trial|Completed||Phase 3|3500|Anticipated|AstraZeneca||1|||f||||||||||||||2018-06-01 02:16:25.467301|2018-06-01 02:16:25.467301
NCT00654290|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-04|2008-04-04|2008-04-07|Estimate|||||||2008-04-04|2008-04-07|Estimate|March 2007||2007-03-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft|Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft, A Prospective Double-Blind Randomized Study|Completed||N/A|240|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-06-01 02:16:25.612832|2018-06-01 02:16:25.612832
NCT00654277|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2008-04-10|2008-04-04|2008-04-07|Estimate|||||||2008-04-10|2008-04-11|Estimate|August 2002||2002-08-31|April 2008|2008-04-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability of Kali's Ondansetron 8 mg ODT With That of GlaxoSmithKine's Zofran 8 mg ODT in Healthy, Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|32|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:25.698517|2018-06-01 02:16:25.698517
NCT00654251|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2009-04-28|2008-04-01|2008-04-07|Estimate|||||||2009-04-28|2009-04-29|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Measuring Neurological Impairment and Functional Visual Assessment In Spinocerebellar Ataxias|Utility Of Home Based Gait Monitoring, Performance Scores And Functional Visual Assessment In Spinocerebellar Ataxias (SCA)|Completed|||20|Actual|University of Mississippi Medical Center|||||f||||f||||||||||2018-06-01 02:16:25.836588|2018-06-01 02:16:25.836588
NCT00654238|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-06-20|2008-04-01|2008-04-07|Estimate|||||||2014-06-20|2014-06-23|Estimate|February 2006||2006-02-28|June 2014|2014-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer|Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Cancer|Completed||Phase 2|61|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 02:16:25.901114|2018-06-01 02:16:25.901114
NCT00654225|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-03-13|2008-04-04|2008-04-07|Estimate|||||||2009-03-13|2009-03-16|Estimate|October 2002||2002-10-31|March 2009|2009-03-31|March 2005|Actual|2005-03-31|||||Interventional|IRIS||Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)|A 6-Week, Randomized,Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in South Asian Subjects.|Completed||Phase 3|2340|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:16:25.984366|2018-06-01 02:16:25.984366
NCT00654212|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2015-05-03|2008-04-04|2008-04-07|Estimate|||||||2015-05-03|2015-05-05|Estimate|January 2002||2002-01-31|May 2015|2015-05-31|December 2007|Actual|2007-12-31|May 2005|Actual|2005-05-31||Interventional|||Endo-Laparoscopic Approach Versus Conventional Open Surgery in Obstructing Left-sided Colon Cancer: RCT|Endo-Laparoscopic Approach Versus Conventional Open Surgery in the Management of Obstructing Left-sided Colon Cancer: A Randomized Trial|Completed||Phase 4|50|Actual|Pamela Youde Nethersole Eastern Hospital||2|||f||||t||||||||||2018-06-01 02:16:26.044711|2018-06-01 02:16:26.044711
NCT00654199|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2012-03-07|2008-04-01|2008-04-07|Estimate|||||||2012-03-07|2012-03-08|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Observational|||Ventricular Asynchrony in Cardiac Surgery Patients|Ventricular Asynchrony in Cardiac Surgery Patients|Completed|||20|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 02:16:26.119288|2018-06-01 02:16:26.119288
NCT00654186|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2014-01-15||2014-02-28|2008-04-04|2008-04-07|Estimate|2014-01-15|2014-02-28|Estimate||||2014-02-28|2014-03-28|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||32 patients started the study. 27 patients had two or mor cycles of study medication. 5 patients withdrew from the study before completing one cycle, making them not evaluable for response|Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients|A Phase II Study Evaluating the Toxicity and Efficacy of Single Agent Lenalidomide (Revlimid®) in Chemotherapy-Naïve Androgen-Independent Prostate Cancer Patients|Completed||Phase 2|32|Actual|Oncology Specialists, S.C.||1|||f||||f||||||||||2018-06-01 02:16:26.174802|2018-06-01 02:16:26.174802
NCT00654173|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-03-13|2008-04-02|2008-04-07|Estimate|||||||2009-03-13|2009-03-16|Estimate|June 2002||2002-06-30|March 2009|2009-03-31|September 2004|Actual|2004-09-30|||||Interventional|SOLAR||Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)|A 12-Week, Randomized, Open-Label, 3 Arm Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin Achieving NCEP ATP III LDL-C Goals in High Risk Subjects With Hypercholesterolaemia in the Managed Care Setting.|Completed||Phase 3|4444|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:16:26.422734|2018-06-01 02:16:26.422734
NCT00654160|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2017-05-23|2008-04-04|2008-04-07|Estimate|||||||2017-05-23|2017-05-25|Actual|June 2008|Actual|2008-06-30|September 2016|2016-09-30|December 3, 2012|Actual|2012-12-03|November 2010|Actual|2010-11-30||Interventional|||Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer|A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer|Completed||Phase 1|7|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:16:26.73431|2018-06-01 02:16:26.73431
NCT00654147|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2015-01-20||2015-07-11|2008-04-04|2008-04-07|Estimate|2015-07-07|2015-07-13|Estimate||||2015-07-11|2015-08-03|Estimate|April 2008||2008-04-30|July 2015|2015-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|HIV||Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects|A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects|Completed||Phase 2|44|Actual|University of Miami|Pilot study with 44 subjects and generalization f results is limited by the small sample size.|2|||f||||t||||||||||2018-06-01 02:16:26.83123|2018-06-01 02:16:26.83123
NCT00654134|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2013-08-06|2008-04-04|2008-04-07|Estimate|||||||2013-08-06|2013-08-09|Estimate|October 2005||2005-10-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Entox||Inhalation of 20,000 Endotoxin Units(EU) of Clinical Center Reference Endotoxin in Healthy Volunteers|Inhalation of 20,000 EU of Clinical Center Reference Endotoxin in Healthy Volunteers|Completed||Phase 1|20|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 02:16:27.226817|2018-06-01 02:16:27.226817
NCT00654121|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-04|2008-04-04|2008-04-07|Estimate|||||||2008-04-04|2008-04-07|Estimate|February 2000||2000-02-29|April 2008|2008-04-30|November 2007|Actual|2007-11-30|April 2004|Actual|2004-04-30||Interventional|||Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives|Prevention of Clinical Onset of Type 1 Diabetes by Daily Administration of Metabolically Active Insulin in High Risk First Degree Relatives.|Completed||Phase 2|112|Actual|AZ-VUB||2|||f||||f||||||||||2018-06-01 02:16:27.28012|2018-06-01 02:16:27.28012
NCT00654108|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-02-03|2008-04-03|2008-04-07|Estimate|||||||2011-02-03|2011-02-07|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled Dose Escalation, Inpatient Phase I Study to Determine the Safety and Immunogenicity of a Single Oral Dose of a Combined Live, Attenuated, Enterotoxigenic Escherichia Coli (ETEC)-Cholera Vaccine (Peru-15 pCTB) in Healthy Adult Subjects|Completed||Phase 1|62|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 02:16:27.35248|2018-06-01 02:16:27.35248
NCT00654095|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2010-05-27||2017-04-03|2008-04-01|2008-04-07|Estimate|2010-09-14|2010-10-05|Estimate||||2017-04-03|2017-05-09|Actual|December 1, 2007|Actual|2007-12-01|April 2017|2017-04-30|June 1, 2009|Actual|2009-06-01|June 1, 2009|Actual|2009-06-01||Interventional|||Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)|Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors|Completed||Phase 3|146|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:16:27.496421|2018-06-01 02:16:27.496421
NCT00654082|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-04-02|2008-04-02|2008-04-07|Estimate|||||||2008-04-02|2008-04-07|Estimate|September 2002||2002-09-30|April 2008|2008-04-30|August 2003|Actual|2003-08-31|||||Interventional|||A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction|A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction|Completed||Phase 4|88|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:16:27.685132|2018-06-01 02:16:27.685132
NCT00654069|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-02|2008-04-02|2008-04-07|Estimate|||||||2008-04-02|2008-04-07|Estimate|September 2007||2007-09-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Repeat-Dose Study of the Safety and Efficacy of OxyADF (Oxycodone HCl and Niacin) Tablets for the Treatment of Acute, Moderate to Severe Postoperative Pain Following Bunionectomy Surgery in Adult Patients|Completed||Phase 3|405|Actual|Acura Pharmaceuticals Inc.||3|||f||||f||||||||||2018-06-01 02:16:27.763278|2018-06-01 02:16:27.763278
NCT00654056|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2013-03-08|2008-04-02|2008-04-07|Estimate|||||||2013-03-08|2013-03-11|Estimate|March 2008||2008-03-31|March 2013|2013-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Severe Insulin Resistance in Patients With Type 2 Diabetes|Severe Insulin Resistance in Patients With Type 2 Diabetes: Mechanisms Behind Insulin Resistance.|Completed||N/A|8|Actual|University of Aarhus||4|||f||||f||||||||||2018-06-01 02:16:27.823637|2018-06-01 02:16:27.823637
NCT00654043|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-10|2008-04-04|2008-04-07|Estimate|||||||2008-04-10|2008-04-11|Estimate|April 2001||2001-04-30|April 2008|2008-04-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Bioavailability Study of Torsemide Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|24|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:27.900435|2018-06-01 02:16:27.900435
NCT00654030|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2011-08-17||2018-03-11|2008-04-04|2008-04-07|Estimate|2013-04-08|2013-05-20|Estimate||||2018-03-11|2018-04-09|Actual|October 2006||2006-10-31|March 2018|2018-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer|Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|12|Actual|University of Kentucky||1|||f||||t||||||||||2018-06-01 02:16:27.985789|2018-06-01 02:16:27.985789
NCT00654017|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-04-02|2008-04-02|2008-04-07|Estimate|||||||2008-04-02|2008-04-07|Estimate|October 2002||2002-10-31|April 2008|2008-04-30|April 2005|Actual|2005-04-30|||||Interventional|||A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis|Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Flexible, Titration Dose Administered on an As Needed Basis (PRN) to Evaluate the Efficacy and the Safety of Sildenafil for the Treatment of Erectile Dysfunction in Male Patients on Hemodialysis|Completed||Phase 4|100|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 02:16:28.232877|2018-06-01 02:16:28.232877
NCT00654004|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2012-12-11||2013-04-18|2008-04-03|2008-04-07|Estimate|2013-04-18|2013-04-22|Estimate||||2013-04-18|2013-04-22|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Observational|||Fatty Acid Oxidation Disorders & Body Weight Regulation Grant|Fatty Acid Oxidation Disorders & Body Weight Regulation|Completed|||26|Actual|Oregon Health and Science University|Trial included small number of subjects with a rare disorder of long-chain fatty acid oxidation. Subjects were predominately children and adolescents. There were some technical difficulties with recruitment and collection of all the outcomes.||2||f||||f||||||Samples Without DNA|"~     Blood and urine samples. Body composition and energy expenditure data. MRI/MRS images.~   "|||2018-06-01 02:16:28.367094|2018-06-01 02:16:28.367094
NCT00653991|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2009-03-10|2008-04-03|2008-04-07|Estimate|||||||2009-03-10|2009-03-11|Estimate|October 2010||2010-10-31|March 2009|2009-03-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|SOLVE-IT||Effectiveness of Interactive Virtual Environment Games in Reducing Risky Sexual Behavior Among Men Who Have Sex With Men (The SOLVE-IT Study)|SOLVE IT: Real Risk Reduction for MSM|Unknown status|Not yet recruiting|N/A|4000|Anticipated|National Institute of Mental Health (NIMH)||2|||f||||f||||||||||2018-06-01 02:16:28.644977|2018-06-01 02:16:28.644977
NCT00653978|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2011-06-21|2008-04-02|2008-04-07|Estimate|||||||2011-06-21|2011-06-22|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures|Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|150|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-06-01 02:16:28.745544|2018-06-01 02:16:28.745544
NCT00653965|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-03-13|2008-04-04|2008-04-07|Estimate|||||||2009-03-13|2009-03-16|Estimate|May 2003||2003-05-31|March 2009|2009-03-31|February 2005|Actual|2005-02-28|||||Interventional|STARSHIP||Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)|A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolaemia in Hispanic Subjects.|Completed||Phase 3|3000|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:16:28.826654|2018-06-01 02:16:28.826654
NCT00653952|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2010-04-23|2008-04-04|2008-04-07|Estimate|||||||2010-04-23|2010-04-27|Estimate|May 1997||1997-05-31|April 2010|2010-04-30|April 2000|Actual|2000-04-30|||||Interventional|||CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|A Phase 3, Randomized, Open-Label, Comparative Study of CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|Terminated||Phase 3|220|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Poor accrual|f||||t||||||||||2018-06-01 02:16:28.889251|2018-06-01 02:16:28.889251
NCT00653939|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2015-01-14||2015-01-22|2008-04-04|2008-04-07|Estimate|2015-01-22|2015-02-09|Estimate||||2015-01-22|2015-02-09|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|FALCON||A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer|A Phase II Study to Assess the Safety and Efficacy of the Combination of Carboplatin, Paclitaxel, and Bevacizumab ± Combretastatin A4 Phosphate (CA4P) Followed by Bevacizumab ± CA4P in Subjects With Chemotherapy Naïve Stage IIIB/IV Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|63|Actual|Mateon Therapeutics||2|||f||||t||||||||||2018-06-01 02:16:29.116798|2018-06-01 02:16:29.116798
NCT00653926|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-04|2008-04-04|2008-04-07|Estimate|||||||2008-04-04|2008-04-07|Estimate|September 2005||2005-09-30|April 2008|2008-04-30|September 2007|Actual|2007-09-30|March 2007|Actual|2007-03-31||Interventional|||Local Infiltration Analgesia Following Unicompartmental Knee Arthroplasty|Local Infiltration Analgesia (LIA) With Ropivacaine, Ketorolac and Epinephrine Intra- and Postoperatively in Unicompartmental Knee Arthroplasty|Completed||N/A|40|Actual|Region Örebro County||2|||f||||t||||||||||2018-06-01 02:16:30.123472|2018-06-01 02:16:30.123472
NCT00653913|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-04-07|2008-04-04|2008-04-07|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2004||2004-03-31|April 2015|2015-04-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)|Evaluation of Potential for Pharmacokinetic Drug Interaction Between SCH 58235 and Pitavastatin|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 02:16:30.205905|2018-06-01 02:16:30.205905
NCT00653900|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-02|2008-04-02|2008-04-07|Estimate|||||||2008-04-02|2008-04-07|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Observational|||Platelet Function Testing Help and Intraoperative Bleeding Risk for Patients Who Are on Plavix Prior to Surgery|Does Platelet Function Testing Help us Assess Intraoperative Bleeding Risk in Cardiac and Vascular Surgery for Patients Who Are on Plavix Prior to Admission?|Unknown status|Recruiting||20|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||Samples Without DNA|"~     1 drop of blood for the verify now test, which is done before the procedure.~   "|||2018-06-01 02:16:30.284243|2018-06-01 02:16:30.284243
NCT00653887|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2012-02-14|2008-04-04|2008-04-07|Estimate|||||||2012-02-14|2012-02-16|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|Biofeedback||Biofeedback and Cortical Excitability|Modifications of the Anal Muscle Cortical Excitability Area After Biofeedback Training|Terminated||N/A|24|Anticipated|University Hospital, Rouen||2||Procedure needs to be changed|f||||t||||||||||2018-06-01 02:16:30.353608|2018-06-01 02:16:30.353608
NCT00653874|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-04-04|2008-04-04|2008-04-07|Estimate|||||||2008-04-04|2008-04-07|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates|Routine Use of Transcutaneous Bilirubinometry Reduces the Need for Blood Sampling in Neonates With Jaundice|Completed||Phase 3|617|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 02:16:30.438589|2018-06-01 02:16:30.438589
NCT00653861|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|2009-07-22||2014-10-06|2008-04-02|2008-04-07|Estimate|2009-11-30|2009-12-30|Estimate||||2014-10-06|2014-10-13|Estimate|April 2008||2008-04-30|December 2013|2013-12-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Safety and Effectiveness of JUVÉDERM™ Injectable Gel With Lidocaine||Completed||N/A|72|Actual|Allergan||2|||f||||t||||||||||2018-06-01 02:16:30.527868|2018-06-01 02:16:30.527868
NCT00653848|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2018-04-25|2008-04-04|2008-04-07|Estimate|||||||2018-04-25|2018-04-26|Actual|May 2007||2007-05-31|November 2017|2017-11-30|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|AdRad||Adjuvant Treatment of Prostate Cancer With Docetaxel or Not After Radical Radiotherapy|Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-risk Prostate Cancer Treated With Radical Radiotherapy|Active, not recruiting||Phase 3|378|Actual|Scandinavian Prostate Cancer Group||2|||f||||t||||||||||2018-06-01 02:16:30.82064|2018-06-01 02:16:30.82064
NCT00653835|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-05-10|2008-04-04|2008-04-07|Estimate|||||||2017-05-10|2017-05-11|Actual|September 1, 2003|Actual|2003-09-01|May 2017|2017-05-31|August 1, 2004|Actual|2004-08-01|August 1, 2004|Actual|2004-08-01||Interventional|||Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)|SCH 58235: A Multicenter, Randomised, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, and Tolerability Of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg vs Ezetimibe Placebo With Simvastatin 20 mg in Untreated Subjects With Primary Hypercholesterolaemia And Coronary Heart Disease (Protocol P03435)|Completed||Phase 4|153|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:16:30.891808|2018-06-01 02:16:30.891808
NCT00653822|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2013-02-26|2008-04-02|2008-04-07|Estimate|||||||2013-02-26|2013-02-28|Estimate|March 2008||2008-03-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Dose Study to Assess the Tolerability, Safety, and Pharmacokinetics of Alefacept in Caucasian and Japanese Healthy Volunteers|Completed||Phase 1|75|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-06-01 02:16:30.960918|2018-06-01 02:16:30.960918
NCT00653809|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2012-04-05|2008-04-04|2008-04-07|Estimate|||||||2012-04-05|2012-04-06|Estimate|June 2007||2007-06-30|April 2012|2012-04-30|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Observational|||Racial Differences: Nitric Oxide(NO) and Endothelin-1(ET-1) in Preeclampsia (PreE)|Elucidating the Role of Nitric Oxide and Endothelin-1 Activation in Endothelial Cells Co-cultured With Placental Explants From African-american and Caucasian High Risk Pregnancies|Completed|||52|Actual|University of Mississippi Medical Center|||8||f||||f||||||Samples With DNA|"~     Placental Tissue~   "|||2018-06-01 02:16:31.037866|2018-06-01 02:16:31.037866
NCT00653796|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-05-10|2008-04-04|2008-04-07|Estimate|||||||2017-05-10|2017-05-11|Actual|September 1, 2003|Actual|2003-09-01|May 2017|2017-05-31|August 1, 2004|Actual|2004-08-01|August 1, 2004|Actual|2004-08-01||Interventional|||Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)|SCH 58235: A Multicentre, Randomised, Parallel Group, Placebo-Controlled Study Comparing the Efficacy, Safety, And Tolerability of the Daily Co-Administration of Ezetimibe 10 mg With Atorvastatin 10 mg vs. Ezetimibe Placebo With Atorvastatin 10 mg in Untreated Subjects With Primary Hypercholesterolaemia and Coronary Heart Disease|Completed||Phase 4|148|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:16:31.094624|2018-06-01 02:16:31.094624
NCT00653783|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2008-12-30|2008-04-02|2008-04-07|Estimate|||||||2008-12-30|2008-12-31|Estimate|August 2007||2007-08-31|December 2008|2008-12-31||||July 2008|Anticipated|2008-07-31||Observational|PROBE||Diagnostic and Prognostic Biomarkers in Parkinson Disease|Blood Alpha-Synuclein, Gene Expression, and Smell Testing as Diagnostic and Prognostic Biomarkers in Parkinson's Disease|Unknown status|Active, not recruiting||200|Anticipated|The Parkinson Study Group|||||f||||f||||||Samples With DNA|"~     Whole Blood, serum~   "|||2018-06-01 02:16:31.163082|2018-06-01 02:16:31.163082
NCT00653770|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2010-02-08|2008-04-04|2008-04-07|Estimate|||||||2010-02-08|2010-02-09|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A|A Phase I Study to Assess the Safety and Immunogenicity of New TB Vaccine Candidates FP85A and MVA85A, in Healthy Adults Who Have Previously Been Immunized With BCG, Using a Prime-boost Delivery Schedule|Completed||Phase 1|31|Actual|University of Oxford||3|||f||||t||||||||||2018-06-01 02:16:31.236822|2018-06-01 02:16:31.236822
NCT00653757|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2012-03-15|2008-04-04|2008-04-07|Estimate|||||||2012-03-15|2012-03-19|Estimate|March 2002||2002-03-31|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Intensity-Modulated Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Prostate Cancer|Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer|Completed||Phase 1/Phase 2|100|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:16:31.303168|2018-06-01 02:16:31.303168
NCT00653744|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-03-13|2008-04-04|2008-04-07|Estimate|||||||2009-03-13|2009-03-16|Estimate|March 2002||2002-03-31|March 2009|2009-03-31|March 2004|Actual|2004-03-31|||||Interventional|ARIES||Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)|A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects. (ARIES)|Completed||Phase 3|1700|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:16:31.406294|2018-06-01 02:16:31.406294
NCT00653731|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2011-08-30|2008-04-04|2008-04-07|Estimate|||||||2011-08-30|2011-08-31|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|WISDE||Effective Strategies for Dementia Care|Testing Three Interventions for Clinical Effectiveness in Long Term Care Residents With Dementia: Snoezelen, Structured Reminiscence Therapy, 10-minutes Activation. A Cluster-randomized Controlled Trial.|Completed||N/A|327|Actual|Martin-Luther-Universität Halle-Wittenberg||4|||f||||f||||||||||2018-06-01 02:16:31.479981|2018-06-01 02:16:31.479981
NCT00653718|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-07-30|2008-04-02|2008-04-07|Estimate|||||||2009-07-30|2009-07-31|Estimate|May 2008||2008-05-31|September 2008|2008-09-30|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Observational|AIMS||Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study|Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study|Completed|||30|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-06-01 02:16:31.545016|2018-06-01 02:16:31.545016
NCT00653705|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2013-05-30|2008-04-04|2008-04-07|Estimate|||||||2013-05-30|2013-05-31|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||The Effect of Yogurt Containing BB12 on Children's Health and Child Care Absenteeism|The Effect of Daily Consumption of Yogurt Containing Bifidobacterium Lactis (BB12) on Children's' Health and Child Care Absenteeism|Completed||N/A|181|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:16:31.5919|2018-06-01 02:16:31.5919
NCT00653692|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2013-02-20|2008-04-03|2008-04-07|Estimate|||||||2013-02-20|2013-02-21|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Observational|||Fetal Neurobehavior in Poly-drug Dependent Women|Methadone, Buprenorphine and Fetal Neurobehavior|Completed|||29|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-06-01 02:16:31.649403|2018-06-01 02:16:31.649403
NCT00653679|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2015-04-13|2008-04-04|2008-04-07|Estimate|||||||2015-04-13|2015-04-14|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Exercise and Muscle Protein Signalling|The Impact of Resistance Versus Endurance Exercise on the Muscle Protein Signalling Response|Withdrawn||N/A|0|Actual|Maastricht University Medical Center||||A paper on the same topic came out just before we wanted to start our study.|f||||f||||||||||2018-06-01 02:16:31.870464|2018-06-01 02:16:31.870464
NCT00653666|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2010-02-24|2008-04-03|2008-04-07|Estimate|||||||2010-02-24|2010-02-25|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Metabolic Consequences of CPT-1 Deficiency|Metabolic Consequences of CPT1A Deficiency in Alaska Native Children|Completed||N/A|12|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||||2018-06-01 02:16:31.935051|2018-06-01 02:16:31.935051
NCT00653653|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-04-07|2008-04-04|2008-04-07|Estimate|||||||2009-04-07|2009-04-08|Estimate|August 2008||2008-08-31|April 2009|2009-04-30|October 2009|Anticipated|2009-10-31|June 2009|Anticipated|2009-06-30||Observational|MORE||Medication Optimisation for Reducing Events in a Private Practice Setting|Observational Study of the Pharmaco-Economic and Medical Effects of Optimising Medication Using Pharmacokinetic Pharmacogenomics and Medication Interaction Analysis in Private Practice.|Unknown status|Active, not recruiting||500|Anticipated|Awenydd GmbH|||1||f||||t||||||||||2018-06-01 02:16:32.020946|2018-06-01 02:16:32.020946
NCT00653640|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2012-06-19|2008-04-01|2008-04-07|Estimate|||||||2012-06-19|2012-06-20|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Physical Work Capacity After Traumatic Brain Injury|Physical Work Capacity After Traumatic Brain Injury|Completed||N/A|88|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-06-01 02:16:32.09795|2018-06-01 02:16:32.09795
NCT00653627|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2010-06-30|2008-04-04|2008-04-07|Estimate|||||||2010-06-30|2010-07-01|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination|A Human Pilot Study to Quantify BCG From the BCG Vaccination Site, and to More Fully Characterise the Immune Response to BCG|Completed||Phase 1|40|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 02:16:32.177716|2018-06-01 02:16:32.177716
NCT00653614|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2015-04-21|2008-04-04|2008-04-07|Estimate|||||||2015-04-21|2015-04-23|Estimate|March 2008||2008-03-31|April 2015|2015-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Cycle Control and Safety of E2-DRSP|A Multi-center, Double-blind, Randomized, Parallel-group Study to Evaluate Cycle Control and Safety of 6 Different Regimens of an Oral Contraceptive Containing Estradiol and Drospirenone in Healthy Female Volunteers Aged Between 18 and 35 Years Over 7 Cycles|Completed||Phase 2|635|Actual|Bayer||6|||f||||f||||||||||2018-06-01 02:16:32.261413|2018-06-01 02:16:32.261413
NCT00653601|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-09-03|2008-04-02|2008-04-07|Estimate|||||||2009-09-03|2009-09-04|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Observational|||Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery|Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery|Unknown status|Recruiting||20|Anticipated|Cedars-Sinai Medical Center|||2||f||||f||||||Samples Without DNA|"~     2 mL of blood for testing X 5 per patient~   "|||2018-06-01 02:16:32.44252|2018-06-01 02:16:32.44252
NCT00653588|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-03-13|2008-04-04|2008-04-07|Estimate|||||||2009-03-13|2009-03-16|Estimate|April 2003||2003-04-30|March 2009|2009-03-31|September 2004|Actual|2004-09-30|||||Interventional|POLARIS||Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks|A 26-Week, Double Blind, Randomised, Multi-Centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin (40 mg) With Atorvastatin (80 mg) in Subjects With Hypercholesterolaemia and Coronary Heart Disease or CHD Risk Equivalents|Completed||Phase 3|||AstraZeneca||2|||f||||f||||||||||2018-06-01 02:16:32.52245|2018-06-01 02:16:32.52245
NCT00653575|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2013-04-12|2008-04-03|2008-04-07|Estimate|||||||2013-04-12|2013-04-15|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Adult Sexual Risk Behavior Among Women With a History of Childhood Sexual Abuse|HIV Risk Among Women With a History of Childhood Sexual Abuse|Completed|||481|Actual|Syracuse University|||2||f||||f||||||||||2018-06-01 02:16:32.592285|2018-06-01 02:16:32.592285
NCT00653562|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2017-02-15|2008-04-02|2008-04-07|Estimate|||||||2017-02-15|2017-02-17|Actual|November 2006||2006-11-30|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography|Single Blind, Multi-center, Post Marketing Clinical Study of Zolpidem (Myslee) in Adolescent Patients With Insomnia - Evaluation With Polysomnography|Completed||Phase 4|11|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:16:32.686527|2018-06-01 02:16:32.686527
NCT00653549|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-06-16|2008-04-04|2008-04-07|Estimate|||||||2011-06-16|2011-06-17|Estimate|April 2001||2001-04-30|June 2011|2011-06-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Bioavailability Study of Torsemide Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|26|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:32.785306|2018-06-01 02:16:32.785306
NCT00653536|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2017-01-11|2008-04-02|2008-04-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2008||2008-03-31|January 2017|2017-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PAO||A Study to Evaluate the Effects of the Neuroflo Device in People Who Have Had a Stroke|Feasibility and Safety of NeuroFlo™ in Patients With Persistent Arterial Occlusion (PAO) After Failed Mechanical Revascularization|Withdrawn||Phase 1|0|Actual|University of California, Los Angeles||||No Patients enrolled; sponsor not providing devices anymore|f||||t||||||||||2018-06-01 02:16:32.86576|2018-06-01 02:16:32.86576
NCT00653523|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2010-05-27||2017-04-04|2008-04-01|2008-04-07|Estimate|2010-05-27|2010-06-30|Estimate||||2017-04-04|2017-05-10|Actual|December 1, 2007|Actual|2007-12-01|April 2017|2017-04-30|June 1, 2009|Actual|2009-06-01|June 1, 2009|Actual|2009-06-01||Interventional|||Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)|Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors|Completed||Phase 3|151|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:16:32.970958|2018-06-01 02:16:32.970958
NCT00653510|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2012-09-17|2008-04-02|2008-04-07|Estimate|||||||2012-09-17|2012-09-18|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Metabolic Effects of Acute Hyperglycemia in Patients With Type 2 Diabetes|The Effect of Acute Hyperglycemia on Cardiac Output, Amino Acid, Lipid and Glucose Metabolism in Patients With Type 2 Diabetes|Completed||N/A|18|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:16:33.178537|2018-06-01 02:16:33.178537
NCT00653497|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-07|Estimate|||||||2008-04-01|2008-04-07|Estimate|March 1997||1997-03-31|April 2008|2008-04-30|June 1998|Actual|1998-06-30|June 1998|Actual|1998-06-30||Interventional|||Effectiveness and Cost-Efficiency of Aquatic Exercise for Management of Osteoarthritis|Effectiveness and Cost-Efficiency of Aquatic Exercise for Management of Osteoarthritis|Completed||N/A|249|Actual|University of Washington||2|||f||||||||||||||2018-06-01 02:16:33.259763|2018-06-01 02:16:33.259763
NCT00653484|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2013-12-16|2008-04-04|2008-04-07|Estimate|||||||2013-12-16|2013-12-17|Estimate|March 2008||2008-03-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|May 2009|Actual|2009-05-31||Interventional|||Energy Balance Interventions for Colorectal Cancer Prevention|Energy Balance Interventions for Colorectal Cancer Prevention|Completed||N/A|40|Actual|Vanderbilt University||3|||f||||t||||||||||2018-06-01 02:16:33.33517|2018-06-01 02:16:33.33517
NCT00653471|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2016-07-18|2008-04-02|2008-04-07|Estimate|||||||2016-07-18|2016-07-20|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Micro-stream Capnography in Non-intubated Lean and Obese Patients With and Without Obstructive Sleep Apnea|The Accuracy of End-tidal PCO2 Measurements With Main-stream and Micro-stream Capnography in Non-intubated Lean and Obese Patients With and Without Obstructive Sleep Apnea|Completed||Early Phase 1|60|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-06-01 02:16:33.554406|2018-06-01 02:16:33.554406
NCT00653458|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-04|||2008-04-10|2008-04-04|2008-04-07|Estimate|||||||2008-04-10|2008-04-11|Estimate|August 2002||2002-08-31|April 2008|2008-04-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions|Comparative, Randomized, Single-Dose, Cross Over Bioavailability Study of Kali's Ondansetron ODT 8 mg With That of GlaxoSmithKine's Zofran ODT 8 mg in Healthy Adult Subjects Under Fed Conditions|Completed||Phase 1|18|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:33.729018|2018-06-01 02:16:33.729018
NCT00653445|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2009-03-25|2008-04-04|2008-04-07|Estimate|||||||2009-03-25|2009-03-26|Estimate|June 2004||2004-06-30|March 2009|2009-03-31|June 2005|Actual|2005-06-30|||||Interventional|EXPLORER||Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg|A 6wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel Group Study to Compare the Safety & Efficacy of Rosuvastatin 40mg in Comb.With Ezetimibe 10mg in Subjects With Hypercholesterolaemia & CHD or Atherosclerosis or a CHD Risk Equiv. (10 yr Risk Score >20%).|Completed||Phase 3|||AstraZeneca||2|||f||||f||||||||||2018-06-01 02:16:33.797582|2018-06-01 02:16:33.797582
NCT00653432|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2010-06-21|2008-04-02|2008-04-07|Estimate|||||||2010-06-21|2010-06-22|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Safety and Effectiveness Study of Hyaluronic Acid for Osteoarthritis of the Knee||Completed||N/A|350|Anticipated|Anika Therapeutics, Inc.||1|||f||||f||||||||||2018-06-01 02:16:33.860945|2018-06-01 02:16:33.860945
NCT00653419|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-04|Estimate|||||||2008-04-01|2008-04-04|Estimate|June 1998||1998-06-30|April 2008|2008-04-30|September 1998|Actual|1998-09-30|September 1998|Actual|1998-09-30||Interventional|||Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets in Healthy Adult Males Under Fasting Conditions Following Administration of a 30 mg Dose|Completed||Phase 1|48|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:33.94|2018-06-01 02:16:33.94
NCT00653406|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-05-16|2008-04-01|2008-04-04|Estimate|||||||2011-05-16|2011-05-17|Estimate|November 2002||2002-11-30|March 2010|2010-03-31|October 2003|Actual|2003-10-31|||||Interventional|||A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients|Multiple-dosing Study of Long Acting Injectable of Risperidone in Schizophrenic Patients|Completed||Phase 1/Phase 2|29|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 02:16:34.011197|2018-06-01 02:16:34.011197
NCT00653393|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions|To Compare Bioavailability of Kali Tranylcypromine 10mg Tablets to That of Parnate 10 mg Tablets Under Fasting Conditions.|Completed||Phase 1|39|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:34.067611|2018-06-01 02:16:34.067611
NCT00653380|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-04|Estimate|||||||2008-04-01|2008-04-04|Estimate|September 1999||1999-09-30|April 2008|2008-04-30|October 1999|Actual|1999-10-31|October 1999|Actual|1999-10-31||Interventional|||Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions|Randomized, Open-Label, 2-Way Crossover, Comparative Bioavailability Study of Par's and Oclassen's (Monodox) Doxycycline Monohydrate Capsules Administered as 1 x 100 mg Capsule in Healthy Adult Males Under Fasting Conditions|Completed||Phase 1|24|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:34.131234|2018-06-01 02:16:34.131234
NCT00653367|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2012-02-23|2008-04-03|2008-04-04|Estimate|||||||2012-02-23|2012-02-24|Estimate|December 2011||2011-12-31|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|April 2012|Anticipated|2012-04-30||Interventional|||Evaluation of Chronic Pain After Nerve Section During Thoracotomy|Post Thoracotomy Pain After Nerve Section|Withdrawn||N/A|0|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:16:34.204899|2018-06-01 02:16:34.204899
NCT00653354|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-07|2008-04-03|2008-04-04|Estimate|||||||2008-04-07|2008-04-10|Estimate|December 2002||2002-12-31|April 2008|2008-04-30|March 2003|Actual|2003-03-31|||||Interventional|||Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Assessment Of The Analgesic Efficacy Of The Dosing Regimen Of Valdecoxib Compared To Placebo Patients In Pain Following Bunionectomy|Completed||Phase 3|360|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:16:34.408909|2018-06-01 02:16:34.408909
NCT00653341|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2009-04-17|2008-04-03|2008-04-04|Estimate|||||||2009-04-17|2009-04-20|Estimate|January 2000||2000-01-31|April 2009|2009-04-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)|Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or NPH Human Insulin.|Completed||Phase 3|764|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:16:34.507643|2018-06-01 02:16:34.507643
NCT00653328|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2010-09-30||2012-05-16|2008-04-03|2008-04-04|Estimate|2011-03-22|2011-04-21|Estimate||||2012-05-16|2012-05-23|Estimate|May 2003||2003-05-31|May 2012|2012-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma|A Phase II Study of Atrasentan (ABT-627) Plus DOXIL in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Serous Papillary Adenocarcinoma Following Platinum + Taxane Therapy|Terminated||Phase 2|15|Actual|Vanderbilt-Ingram Cancer Center||1||Abbott (drug manufacturer) discontinued manufacture of ABT-627|f||||t||||||||||2018-06-01 02:16:34.599084|2018-06-01 02:16:34.599084
NCT00653315|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-09|2008-04-01|2008-04-04|Estimate|||||||2008-04-09|2008-04-11|Estimate|May 2002||2002-05-31|April 2008|2008-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Bioavailability Study of Tramadol/APAP Tablets Under Fasting Conditions|To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fasting Conditions.|Completed||Phase 1|28|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:34.895344|2018-06-01 02:16:34.895344
NCT00653302|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-12-02|2008-04-03|2008-04-04|Estimate|||||||2008-12-02|2008-12-03|Estimate|April 2003||2003-04-30|December 2008|2008-12-31|October 2005|Actual|2005-10-31|September 2004|Actual|2004-09-30||Interventional|GALATEE||Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)|Assessment of the Phenotype of the Type 2 Diabetic Responders to the First Insulinisation Using Lantus (Insulin Glargine) Plus Glucophage (Metformin) Combination After Failure in OADs Treatment|Completed||Phase 4|280|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:16:34.964024|2018-06-01 02:16:34.964024
NCT00653276|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-03-07|2008-04-01|2008-04-04|Estimate|||||||2017-03-07|2017-03-10|Actual|November 2003||2003-11-30|March 2017|2017-03-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||MD Ezetimibe Cyclosporine Interaction (0653-057)|An Open-Label, 2-Period, Crossover Study to Determine the Effect of Multiple Oral Doses of Ezetimibe 20 mg on the Pharmacokinetics of a Single Oral Dose of Cyclosporine in Young, Healthy, Normal, Male and Female Subjects|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:16:35.043349|2018-06-01 02:16:35.043349
NCT00653263|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2009-10-22||2010-02-22|2008-04-01|2008-04-04|Estimate|2010-02-22|2010-03-09|Estimate||||2010-02-22|2010-03-09|Estimate|August 2006||2006-08-31|February 2010|2010-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study|Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study|Completed|||8|Actual|University of Arkansas|The small sample size (N=6) is a significant limitation of the current study.||1||f||||t||||||||||2018-06-01 02:16:35.134661|2018-06-01 02:16:35.134661
NCT00653250|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2013-05-20|2008-04-03|2008-04-04|Estimate|||||||2013-05-20|2013-05-21|Estimate|December 2000||2000-12-31|May 2013|2013-05-31|January 2008|Actual|2008-01-31|March 2006|Actual|2006-03-31||Interventional|||Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|COX-2 Activity in Early and Advanced NSCLC and The Effect of Short-Term Administration of Specific COX-2 Inhibitors (Celecoxib)|Completed||N/A|22|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:16:35.298508|2018-06-01 02:16:35.298508
NCT00653237|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-03-11|2008-04-03|2008-04-04|Estimate|||||||2014-03-11|2014-03-12|Estimate|March 2008||2008-03-31|March 2014|2014-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Laryngeal Mask Supreme™ Versus the I-gel™|A Comparison of The Laryngeal Mask Supreme™ and the I-gel™ in a Simulated Difficult Airway Scenario in Anesthetized and Ventilated Patients|Completed||N/A|60|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 02:16:35.35905|2018-06-01 02:16:35.35905
NCT00653224|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2009-07-28||2011-08-29|2008-04-03|2008-04-04|Estimate|2009-10-07|2009-11-17|Estimate||||2011-08-29|2011-08-31|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis|Completed||Phase 4|580|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 02:16:36.493092|2018-06-01 02:16:36.493092
NCT00653211|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2015-04-14|2008-04-01|2008-04-04|Estimate|||||||2015-04-14|2015-04-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:16:38.957411|2018-06-01 02:16:38.957411
NCT00652197|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2016-05-25|2008-03-31|2008-04-03|Estimate|||||||2016-05-25|2016-05-27|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Monitoring Patient Cerebro-Spinal Fluid Drainage With an Ultrasonic Flow Sensor|A Flow Monitor for Pediatric Hydrocephalic Shunts - Flow Sensor Study|Completed|||16|Actual|Transonic Systems Inc.|||1||f||||f||||||||||2018-06-01 02:16:55.207938|2018-06-01 02:16:55.207938
NCT00653198|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2017-09-01|2008-04-01|2008-04-04|Estimate|||||||2017-09-01|2017-09-05|Actual|March 19, 2008|Actual|2008-03-19|September 2017|2017-09-30|March 18, 2011|Actual|2011-03-18|March 18, 2011|Actual|2011-03-18||Observational|||Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama|Hospital-based, Case-control Study to Assess the Vaccine Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) Among Hospitalised Children Born After 1 March 2006 and at Least 12 Weeks of Age, in Panama|Completed|||885|Actual|GlaxoSmithKline|||2||f||||||||||Samples With DNA|"~     Stool samples~   "|||2018-06-01 02:16:38.990361|2018-06-01 02:16:38.990361
NCT00653185|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01||2016-06-20|2016-06-20|2008-04-01|2008-04-04|Estimate||||2016-06-20|2016-06-22|Estimate|2016-06-20|2016-06-22|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment With SYR-472 in Subjects With Type 2 Diabetes|Completed||Phase 2|369|Actual|Takeda||5|||f||||f||||||||||2018-06-01 02:16:39.071641|2018-06-01 02:16:39.071641
NCT00653172|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2009-01-08|2008-04-03|2008-04-04|Estimate|||||||2009-01-08|2009-01-09|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia|A Double-Blind, Multicenter, Randomized, Double Dummy, Three-Arm Parallel-Group Comparative Study of the Efficacy, Safety and Tolerance of Oral NXL 103 Versus Oral Comparator in the Treatment of Community-Acquired Pneumonia in Adults|Completed||Phase 2|302|Actual|Novexel Inc||3|||f||||f||||||||||2018-06-01 02:16:39.245961|2018-06-01 02:16:39.245961
NCT00653159|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2012-09-18||2012-10-17|2008-04-03|2008-04-04|Estimate|2012-09-18|2012-10-18|Estimate||||2012-10-17|2012-10-19|Estimate|July 2007||2007-07-31|October 2012|2012-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MINT||Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial|Intrauterine Contraception for Adolescents Aged 14 to 18: A Multi-center Randomized Controlled Feasibility Trial of Levonorgestrel-releasing Intrauterine System Compared to the Copper T 380A|Completed||Phase 4|23|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:16:39.501072|2018-06-01 02:16:39.501072
NCT00653146|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2016-12-01|2008-04-03|2008-04-04|Estimate|||||||2016-12-01|2016-12-05|Estimate|September 2007||2007-09-30|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effects of MBSR in Improving Immune Response to Human Papillomavirus in Patients With Cervical Dysplasia|Effects of Mindfulness-Based Stress Reduction (MBSR) on Immune Response to HPV|Completed||N/A|186|Actual|Fox Chase Cancer Center||2|||f||||f||||||||||2018-06-01 02:16:40.063438|2018-06-01 02:16:40.063438
NCT00653133|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2011-05-19||2014-12-10|2008-04-02|2008-04-04|Estimate|2013-08-16|2013-08-19|Estimate||||2014-12-10|2014-12-11|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|cpnb||Multicenter Continuous Peripheral Nerve Block Surveillance Study|Multicenter Continuous Peripheral Nerve Block Surveillance Study Comparing Ultrasound Guided Catheter Placement to Non Ultrasound Guided Catheter Placement Techniques|Completed||Phase 4|1821|Actual|Halyard Health||2|||f||||f||||||||||2018-06-01 02:16:40.154389|2018-06-01 02:16:40.154389
NCT00653120|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-04|Estimate|||||||2008-04-01|2008-04-04|Estimate|May 2005||2005-05-31|April 2008|2008-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Bioavailability Study of Propranolol Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fasting Conditions.|Completed||Phase 2|48|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:40.487133|2018-06-01 02:16:40.487133
NCT00653107|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2012-04-12|2008-04-03|2008-04-04|Estimate|||||||2012-04-12|2012-04-13|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|May 2020|Anticipated|2020-05-31|April 2012|Actual|2012-04-30||Interventional|PACO||Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only|Palliation of Dysphagia in Patients With Advanced Cancer of the Oesophagus by Comparing Stent Followed by 3 Courses of Brachytherapy With 3 Courses of Brachytherapy Only. A Randomised Phase III Study (PACO)|Terminated||Phase 3|41|Actual|Oslo University Hospital||2||The study was closed prematurely due to slow recruitment|f||||f||||||||||2018-06-01 02:16:40.675064|2018-06-01 02:16:40.675064
NCT00653094|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|June 2008||2008-06-30|April 2008|2008-04-30|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Interventional|||An Open Label, Prospective, One Arm, Feasibility, Study for The Use of Halevy Kit for the Treatment of Perianal Fistulas in Patients With Crohn's Disease|An Open Label, Prospective, One Arm, Feasibility, Study for The Use of Halevy Kit for the Treatment of Perianal Fistulas in Patients With Crohn's Disease|Unknown status|Not yet recruiting|N/A|10|Anticipated|ResQ Medical Ltd||1|||f||||t||||||||||2018-06-01 02:16:40.78022|2018-06-01 02:16:40.78022
NCT00653081|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|July 2006||2006-07-31|January 2007|2007-01-31|December 2008|Anticipated|2008-12-31|September 2007|Actual|2007-09-30||Interventional|||Supervised Exercises Compared With Radial Extracorporal Shock Wave Therapy (rESWT) in Patients With SIS|Supervised Exercises Compared With Radial Extracorporal Shock Wave Therapy (rESWT) in Patients With Subacromial Impingement Syndrome: A Single Blind Clinical Randomized Study|Unknown status|Active, not recruiting|Phase 3|104|Actual|Ullevaal University Hospital||2|||f||||t||||||||||2018-06-01 02:16:40.874735|2018-06-01 02:16:40.874735
NCT00653068|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2016-12-20||2017-02-13|2008-04-03|2008-04-04|Estimate|2016-12-20|2017-02-13|Actual||||2017-02-13|2017-03-20|Actual|December 2008||2008-12-31|February 2017|2017-02-28||||April 2015|Actual|2015-04-30||Interventional|||Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System|Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation|Active, not recruiting||Phase 3|70|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 02:16:40.99732|2018-06-01 02:16:40.99732
NCT00653055|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|August 2001||2001-08-31|April 2008|2008-04-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions|Randomized, 4-Way Replicate Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fasting Conditions|Completed||Phase 1|40|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:41.868788|2018-06-01 02:16:41.868788
NCT00651495|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2016-11-23|2008-04-01|2008-04-02|Estimate|||||||2016-11-23|2016-11-28|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Activating Seniors to Improve Chronic Disease Care|Activating Seniors to Improve Chronic Disease Care|Completed||N/A|116|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:17:02.782331|2018-06-01 02:17:02.782331
NCT00653042|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-05-18|2008-04-01|2008-04-04|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2004||2004-03-31|March 2010|2010-03-31|June 2005|Actual|2005-06-30|||||Interventional|||Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPA|A Pilot, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Nesiritide Infusion, Initiated Post-Induction of Anesthesia, in the Management of Coronary Artery Bypass Graft (CABG) Patients Requiring CardioPulmonary Bypass (CPB)|Completed||Phase 2|305|Actual|Scios, Inc.|||||||||||||||||||2018-06-01 02:16:41.977258|2018-06-01 02:16:41.977258
NCT00653029|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2016-05-01|2008-04-03|2008-04-04|Estimate|||||||2016-05-01|2016-05-03|Estimate|October 2006||2006-10-31|May 2016|2016-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||An fMRI Study of Attention and Effort After Concussion|An fMRI Study of Selective Attention, Working Memory, and Effort After Mild Traumatic Brain Injury|Terminated|||12|Actual|State University of New York - Upstate Medical University||||Difficulties with recruitment and MRI scanner became unavailable.|f||||f||||||None Retained|"~     No biospecimens~   "|||2018-06-01 02:16:42.056409|2018-06-01 02:16:42.056409
NCT00653016|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2010-03-25|2008-04-01|2008-04-04|Estimate|||||||2010-03-25|2010-03-26|Estimate|October 2002||2002-10-31|March 2010|2010-03-31|August 2003|Actual|2003-08-31|||||Interventional|||An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method|An Open Label Multicentre Study to Evaluate Patient Satisfaction and Preference for the EVRA Transdermal Contraceptive System Compared to Previously Used Contraceptive Method.|Completed||Phase 4|405|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 02:16:42.185324|2018-06-01 02:16:42.185324
NCT00653003|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-22|2008-04-03|2008-04-04|Estimate|||||||2017-09-22|2017-09-26|Actual|December 2003||2003-12-31|September 2017|2017-09-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Bioavailability Study of Leflunomide Tablets Under Fed Conditions|To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fed Conditions|Completed||Phase 1|62|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:42.238819|2018-06-01 02:16:42.238819
NCT00652977|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-04|2008-04-01|2008-04-04|Estimate|||||||2008-04-04|2008-04-07|Estimate|December 1999||1999-12-31|April 2008|2008-04-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Ritgens Maneuver for the Prevention of Anal Sphincter Tears at Delivery: A Randomized Controlled Trial|Modified Ritgens Maneuver for Perineal Protection at Delivery|Completed||N/A|1623|Actual|Lund University Hospital||2|||f||||f||||||||||2018-06-01 02:16:42.371867|2018-06-01 02:16:42.371867
NCT00652964|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2012-11-06|2008-04-03|2008-04-04|Estimate|||||||2012-11-06|2012-11-08|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||PHOX2B Mutation-Confirmed Congenital Central Hypoventilation Syndrome in A Chinese Family: Presentations From Newborn to Adulthood|PHOX2B Mutation-Confirmed Congenital Central Hypoventilation Syndrome in A Chinese Family: Presentations From Newborn to Adulthood|Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 02:16:42.498695|2018-06-01 02:16:42.498695
NCT00652951|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21||2011-11-17|2017-08-31|2008-04-01|2008-04-04|Estimate||||2011-11-17|2011-11-21|Estimate|2017-08-31|2017-09-06|Actual|April 1, 2008|Actual|2008-04-01|August 2017|2017-08-31|May 12, 2009|Actual|2009-05-12|May 12, 2009|Actual|2009-05-12||Interventional|||Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib|Non-inferiority of Co-administration of GSK Biologicals'Pneumococcal Conjugate Vaccine GSK1024850A With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib.|Completed||Phase 3|780|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:16:42.631391|2018-06-01 02:16:42.631391
NCT00652938|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2010-08-04||2017-04-20|2008-04-01|2008-04-04|Estimate|2010-08-04|2010-08-31|Estimate||||2017-04-20|2017-05-17|Actual|April 9, 2008||2008-04-09|April 2017|2017-04-30|January 8, 2010|Actual|2010-01-08|August 28, 2009|Actual|2009-08-28||Interventional|||Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine (580299) Co-administrated With a Commercially Available Vaccine in Healthy Female Adolescents|Completed||Phase 3|744|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:16:42.880839|2018-06-01 02:16:42.880839
NCT00652925|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-05-29|2008-04-03|2008-04-04|Estimate|||||||2008-05-29|2008-05-30|Estimate|October 2002||2002-10-31|April 2008|2008-04-30|April 2005|Actual|2005-04-30|April 2004|Actual|2004-04-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA|Randomized, Double-Blind, Multicenter, Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA|Completed||Phase 3|225|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 02:16:44.19573|2018-06-01 02:16:44.19573
NCT00652912|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|March 2004||2004-03-31|April 2008|2008-04-30|May 2004|Actual|2004-05-31|April 2004|Actual|2004-04-30||Interventional|||Bioavailability Study of Clonazepam ODT Under Fasting Conditions|Comparative, Randomized, Single-Dose, Bioavailability Study of Kali's Clonazepam ODT 1 mg With That of Klonopin Wafers 1 mg ODT in Healthy Adult Subjects Under Fasting Conditions.|Completed||Phase 1|32|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:44.47975|2018-06-01 02:16:44.47975
NCT00652899|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|2010-08-20||2017-12-03|2008-04-03|2008-04-04|Estimate|2010-08-20|2010-09-15|Estimate||||2017-12-03|2017-12-28|Actual|March 2008||2008-03-31|December 2017|2017-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer|MT2007-19R: WCC #53 Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer|Terminated||Phase 2|14|Actual|Masonic Cancer Center, University of Minnesota|"Endpoint for association of clinical benefit response with donor/recipient KIR ligand matching status is not evaluable due to 0 complete responders.~Correlative laboratory objectives are irrelevant due to ineffectiveness of study regimen."|2||Withdrawn due to toxicity|f||||t||||||||||2018-06-01 02:16:44.806039|2018-06-01 02:16:44.806039
NCT00652886|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|March 2005||2005-03-31|April 2008|2008-04-30|June 2005|Actual|2005-06-30|March 2005|Actual|2005-03-31||Interventional|||Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions|Compare the Relative Bioavailability of Oxandrolone 10mg Tablets With That of OXANDRIN 10 mg Tablets Following a Single Oral Dose(1*10 mg Tablet) in Healthy, Adult Subjects Under Fasting Conditions.|Completed||Phase 1|26|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:45.249237|2018-06-01 02:16:45.249237
NCT00652873|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-22|2008-04-01|2008-04-04|Estimate|||||||2017-09-22|2017-09-26|Actual|July 2001||2001-07-31|September 2017|2017-09-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Cabergoline 0.5 mg Tablets and Dostinex 0.5 mg Tablets Administered as 2 x 0.5 mg Tablets in Healthy Adult Females and Males Under Fed Conditions|Completed||Phase 1|24|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:45.340342|2018-06-01 02:16:45.340342
NCT00652860|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2011-05-13|2008-04-03|2008-04-04|Estimate|||||||2011-05-13|2011-05-16|Estimate|August 2001||2001-08-31|May 2011|2011-05-31||||November 2006|Actual|2006-11-30||Interventional|||Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery|Chemotherapy, Irradiation, and Surgery for Function-Preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and GM-CSF; Aerosol GM-CSF During Preoperative Irradiation and Postoperatively|Completed||Phase 2|39|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:16:45.413705|2018-06-01 02:16:45.413705
NCT00652847|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-03-09|2008-04-03|2008-04-04|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2005||2005-05-31|March 2017|2017-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)|Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia|Completed||Phase 4|1140|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:16:45.512959|2018-06-01 02:16:45.512959
NCT00652834|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2014-12-02||2016-02-05|2008-04-03|2008-04-04|Estimate|2016-02-05|2016-03-04|Estimate||||2016-02-05|2016-03-04|Estimate|April 2009||2009-04-30|December 2014|2014-12-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional||of 23 participants, 18 participants completed the study.|Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®|Gastrointestinal Mucosal Findings in Patients Receiving Mycophenolic Acid (MPA) as Demonstrated by Small Bowel Capsule Endoscopy (SBCE)|Completed||Phase 4|23|Actual|University of California, Los Angeles|We did not enroll asymptomatic patients and in the extension of the trial the number of patients re-examined were few and the data obtained from them are not enough to provide definitive information.|1|||f||||f||||||||||2018-06-01 02:16:45.583839|2018-06-01 02:16:45.583839
NCT00652821|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-22|2008-04-01|2008-04-04|Estimate|||||||2017-09-22|2017-09-26|Actual|May 2002||2002-05-31|September 2017|2017-09-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Bioavailability Study of Tramadol/APAP Tablets Under Fed Conditions|To Compare the Relative Bioavailability of the Kali's Tramadol APAP Tablets With Ortho-McNeil's Ultracet Tablets Under Fed Conditions.|Completed||Phase 1|22|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:45.767319|2018-06-01 02:16:45.767319
NCT00652808|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-07|2008-04-03|2008-04-04|Estimate|||||||2008-04-07|2008-04-10|Estimate|May 2004||2004-05-31|April 2008|2008-04-30|September 2004|Actual|2004-09-30|||||Interventional|||Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee|Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg QD and Naproxen 500 mg BID in Treating the Signs and Symptoms of Osteoarthritis of the Knee|Completed||Phase 3|265|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:16:45.854668|2018-06-01 02:16:45.854668
NCT00652795|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-04|Estimate|||||||2008-04-01|2008-04-04|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions|Randomized, 2-Way Crossover, Bioequivalence Study of Doxycycline 150 mg Tablet and Monodox 50 mg Capsule Administered as 1 x 150 mg Tablet or 3 x 50 mg Capsules in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|36|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:45.954452|2018-06-01 02:16:45.954452
NCT00652782|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-04|Estimate|||||||2008-04-01|2008-04-04|Estimate|December 2004||2004-12-31|April 2008|2008-04-30||||August 2005|Actual|2005-08-31||Interventional|||Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients|A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of The Effects of MK7418, Both as Monotherapy and in Combination With Furosemide, On Diuresis and Renal Function in Patients With Congestive Heart Failure (CHF) And Renal Impairment Treated With Oral Loop Diuretics Who Require Hospitalization For Fluid Overload|Completed||Phase 2|160|Actual|NovaCardia, Inc.||5|||f||||||||||||||2018-06-01 02:16:46.042503|2018-06-01 02:16:46.042503
NCT00652769|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-10-31|2008-04-03|2008-04-04|Estimate|||||||2017-10-31|2017-11-01|Actual|March 2008||2008-03-31|October 2017|2017-10-31|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Interventional|BOOST||A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)|A Randomized Controlled Trial of Endobronchial or Endoscopic Ultrasound as a First Test in the Diagnosis and Staging of Lung Cancer|Completed||Phase 3|168|Anticipated|University College London Hospitals||2|||f||||t||||||||||2018-06-01 02:16:46.167792|2018-06-01 02:16:46.167792
NCT00652756|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-04-05|2008-04-03|2008-04-04|Estimate|||||||2017-04-05|2017-04-06|Actual|August 2007||2007-08-31|April 2017|2017-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|iVent||Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation|Evaluation of the Versamed iVent in the Transport of Patients Receiving Mechanical Ventilation|Withdrawn||N/A|0|Actual|Tufts Medical Center||2||Unable to recruit adequately|f||||f||||||||||2018-06-01 02:16:46.325958|2018-06-01 02:16:46.325958
NCT00652743|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21||2012-07-23|2016-10-18|2008-04-01|2008-04-04|Estimate||||2012-07-23|2012-07-31|Estimate|2016-10-18|2016-10-19|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules|Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules|Completed||Phase 3|516|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:16:46.407837|2018-06-01 02:16:46.407837
NCT00652730|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-22|2008-04-01|2008-04-04|Estimate|||||||2017-09-22|2017-09-26|Actual|July 1998||1998-07-31|September 2017|2017-09-30|September 1998|Actual|1998-09-30|September 1998|Actual|1998-09-30||Interventional|||Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions|Comparative, Randomized, 3-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar)15 mg Buspirone HCl Tablets Following Administration of a 30 mg Dose in Healthy Adult Males Under Fed and Fasting Conditions|Completed||Phase 1|21|Actual|Par Pharmaceutical, Inc.||3|||f||||f||||||||||2018-06-01 02:16:46.545243|2018-06-01 02:16:46.545243
NCT00652717|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-19|2008-04-01|2008-04-04|Estimate|||||||2017-09-19|2017-09-20|Actual|February 1, 2005|Actual|2005-02-01|September 2017|2017-09-30|August 4, 2005|Actual|2005-08-04|February 15, 2005|Actual|2005-02-15||Interventional|||Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)|A Multicenter, Open Study To Evaluate The Efficacy Of Ezetimibe 10 Mg Added On Statin Therapy, In Reducing LDL Cholesterol To Target Levels In Patients After Acute Coronary Syndrome|Completed||Phase 4|280|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:16:46.665285|2018-06-01 02:16:46.665285
NCT00652704|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-22|2008-04-01|2008-04-04|Estimate|||||||2017-09-22|2017-09-26|Actual|July 1999||1999-07-31|September 2017|2017-09-30|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions|Randomized, Open-Label, 3-Way Crossover, Comparative Bioavailability Study of Par's and Oclassen's (Monodox) Doxycycline Monohydrate Capsules Administered as 1 x 100 mg Capsule in Healthy Adult Males Under Fasting and Fed Conditions|Completed||Phase 1|24|Actual|Par Pharmaceutical, Inc.||3|||f||||f||||||||||2018-06-01 02:16:46.747074|2018-06-01 02:16:46.747074
NCT00652691|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-03|||2018-03-05|2008-04-03|2008-04-04|Estimate|||||||2018-03-05|2018-03-06|Actual|August 1998|Actual|1998-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer|A Dose Seeking Trial of Topotecan Combined With High-Dose Cyclophosphamide and Carboplatin With Peripheral Blood Stem Cell Transplant for the Treatment of Relapsed Ovarian Cancer and Primary Peritoneal Cancer|Active, not recruiting||Phase 1|48|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:16:46.833847|2018-06-01 02:16:46.833847
NCT00652678|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-07-08|2008-04-01|2008-04-04|Estimate|||||||2011-07-08|2011-07-12|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|August 2012|Anticipated|2012-08-31|||||Observational|||Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients|Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients|Unknown status|Recruiting||45|Anticipated|State University of New York - Upstate Medical University|||||f||||f||||||Samples With DNA|"~     peripheral blood mononuclear cells~   "|||2018-06-01 02:16:46.896961|2018-06-01 02:16:46.896961
NCT00652665|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Bioavailability Study of Leflunomide Tablets Under Fasting Conditions|To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fasting Conditions|Completed||Phase 1|52|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:46.970549|2018-06-01 02:16:46.970549
NCT00652652|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-05-18|2008-04-01|2008-04-04|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2003||2003-03-31|March 2010|2010-03-31|January 2004|Actual|2004-01-31|||||Interventional|||Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS|Evaluation of Synergy Between Natrecor and Furosemide on Renal and Neurohormone Responses in Chronic Heart Failure: A Phase-IV Study|Completed||Phase 4|||Scios, Inc.|||||||||||||||||||2018-06-01 02:16:47.039662|2018-06-01 02:16:47.039662
NCT00652639|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-03|2008-04-04|Estimate|||||||2008-04-03|2008-04-04|Estimate|February 2004||2004-02-29|April 2008|2008-04-30|April 2004|Actual|2004-04-30|March 2004|Actual|2004-03-31||Interventional|||Bioavailability Study of Clonazepam Tablets Under Fasting Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Kali's Clonazepam Tablets 1 mg With That of Klonopin Tablets 1 mg in Healthy Adult Subjects Under Fasting Conditions.|Completed||Phase 1|32|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:47.093422|2018-06-01 02:16:47.093422
NCT00652626|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2013-08-02||2016-03-24|2008-04-01|2008-04-04|Estimate|2013-08-02|2013-10-17|Estimate||||2016-03-24|2016-04-22|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|RENAL|Safety population. The total number of participants in the study was 27; 18 continued treatment in the extension phase.|Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function|A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function|Completed||Phase 1|31|Actual|Celgene Corporation||5|||f||||f||||||||||2018-06-01 02:16:47.212599|2018-06-01 02:16:47.212599
NCT00652613|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-04-09|2008-04-03|2008-04-04|Estimate|||||||2008-04-09|2008-04-11|Estimate|August 2005||2005-08-31|April 2008|2008-04-30|August 2009|Anticipated|2009-08-31|March 2008|Anticipated|2008-03-31||Interventional|||Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase II Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) vs Intensity Modulated Radiotherapy (IMRT) for Squamous Cell Carcinoma of the Head and Neck (HNSCC)|Unknown status|Active, not recruiting|Phase 2|60|Actual|Tata Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:16:49.426653|2018-06-01 02:16:49.426653
NCT00652600|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2017-09-22|2008-04-01|2008-04-04|Estimate|||||||2017-09-22|2017-09-26|Actual|September 2005||2005-09-30|September 2017|2017-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Bioavailability Study of Propranolol Under Fed Conditions|Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|46|Actual|Par Pharmaceutical, Inc.||2|||f||||f||||||||||2018-06-01 02:16:49.505253|2018-06-01 02:16:49.505253
NCT00652587|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-03|Estimate|||||||2008-03-31|2008-04-03|Estimate|January 2002||2002-01-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Hepatectomy With or Without Transcatheter Arterial Chemoembolization for Stage IIIA Hepatocellular Carcinoma|A Randomized Controlled Trial of Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Hepatectomy Alone for Stage IIIA Hepatocellular Carcinoma|Completed||Phase 3|115|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:16:49.570995|2018-06-01 02:16:49.570995
NCT00652574|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2017-09-25|2008-03-31|2008-04-03|Estimate|||||||2017-09-25|2017-09-27|Actual|March 2008|Actual|2008-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Dasatinib in Resectable Malignant Pleural Mesothelioma|Phase I Trial of Induction Dasatinib Therapy in Patients With Resectable Malignant Pleural Mesothelioma|Active, not recruiting||Phase 1|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:16:49.636681|2018-06-01 02:16:49.636681
NCT00651001|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2009-08-03|2008-04-01|2008-04-02|Estimate|||||||2009-08-03|2009-08-06|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|June 2009||2009-06-30|January 2009|Actual|2009-01-31||Observational|||Metabolic Syndrome and Leptin Level Associated With Fructose Consumption in Spain|Prevalence of Cardiovascular Risk Factors in Minorca - Spain|Completed|||800|Anticipated|Hospital Mateo Orfila|||||f||||f||||||Samples Without DNA|"~     Serum and urine collections.~   "|||2018-06-01 02:17:11.37039|2018-06-01 02:17:11.37039
NCT00652561|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-03-17|2008-03-31|2008-04-03|Estimate|||||||2011-03-17|2011-03-18|Estimate|February 2005||2005-02-28|March 2011|2011-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer|An Open-Label, Non-Randomized, Multicenter, Three Stage, Phase 2 Study of S-1 as 2nd Line Therapy for Patients With Advanced Non-Small Cell Lung Cancer (Stage IIIB/Stage IV)|Completed||Phase 2|57|Actual|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-06-01 02:16:49.735396|2018-06-01 02:16:49.735396
NCT00652548|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2017-03-29|2008-04-02|2008-04-03|Estimate|||||||2017-03-29|2017-03-31|Actual|March 2008||2008-03-31|March 2017|2017-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Use of Ultrasound to Evaluate Clavicle Fractures in Pediatric Patients|Utility of Bedside Ultrasound to Diagnose Clavicle Fractures in the Pediatric Emergency Department|Completed|||100|Actual|University of Louisville|||||f||||f||||||||||2018-06-01 02:16:49.787096|2018-06-01 02:16:49.787096
NCT00652522|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2017-08-09|2008-03-31|2008-04-03|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2008|Actual|2008-01-31|August 2017|2017-08-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|AMICA||Atrial Fibrillation Management in Congestive Heart Failure With Ablation|Atrial Fibrillation Management in Congestive Heart Failure With Ablation|Completed||N/A|202|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 02:16:49.92434|2018-06-01 02:16:49.92434
NCT00652509|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-04-27|2008-03-31|2008-04-03|Estimate|||||||2017-04-27|2017-04-28|Actual|May 1, 2008|Actual|2008-05-01|April 2017|2017-04-30|July 1, 2011|Actual|2011-07-01|March 1, 2010|Actual|2010-03-01||Interventional|||Journey for Control of Diabetes Study (0431-111)|Journey for Control of Diabetes Study|Completed||N/A|621|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:16:50.023821|2018-06-01 02:16:50.023821
NCT00652496|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-03|Estimate|||||||2008-04-01|2008-04-03|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 2|249|Actual|Allergan||5|||f||||||||||||||2018-06-01 02:16:50.082737|2018-06-01 02:16:50.082737
NCT00652483|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-03|Estimate|||||||2008-04-01|2008-04-03|Estimate|May 2003||2003-05-31|April 2008|2008-04-30|September 2004|Actual|2004-09-30|December 2003|Actual|2003-12-31||Interventional|||Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|433|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:16:50.147442|2018-06-01 02:16:50.147442
NCT00652470|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-04-24|2008-03-31|2008-04-03|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2005||2005-09-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study Comparing Two Treatments for Infants With Hydrocephalus|International Infant Hydrocephalus Study: A Multicentre, Prospective Study|Active, not recruiting||Phase 2|182|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 02:16:50.235687|2018-06-01 02:16:50.235687
NCT00652457|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-03|Estimate|||||||2008-03-31|2008-04-03|Estimate||||March 2008|2008-03-31||||||||Interventional|||Study of Memantine to Treat Huntington's Disease|"A Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's Disease"|Unknown status|Recruiting|Phase 4|60||University of California, San Diego||1|||f||||t||||||||||2018-06-01 02:16:50.350663|2018-06-01 02:16:50.350663
NCT00652444|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2016-01-21|2008-03-31|2008-04-03|Estimate|||||||2016-01-21|2016-01-22|Estimate|September 2003||2003-09-30|January 2016|2016-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)|Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 4|120|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:16:50.419573|2018-06-01 02:16:50.419573
NCT00652431|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2016-11-14|2008-04-02|2008-04-03|Estimate|||||||2016-11-14|2016-11-15|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)|SCH 465981: Assessment of Bi-Directional Interaction Between Components of Vytorin® (Ezetimibe and Simvastatin) and Niaspan® (Niacin Extended-Release Tablets) in Healthy Subjects|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 02:16:50.477347|2018-06-01 02:16:50.477347
NCT00652418|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2013-10-10|2008-04-02|2008-04-03|Estimate|||||||2013-10-10|2013-10-14|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography|Evaluation of a Single Intravenous Injection of Magnevist (SH L 451 A) at 0.1 mmol/kg and 0.2 mmol/kg in Contrast-enhanced 3D-Magnetic Resonance Angiography in Patients With Arterial Disease in the Abdominal to Leg Regions in the Ability of Detecting of Vessel Abnormalities|Completed||Phase 2|12|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:16:50.535261|2018-06-01 02:16:50.535261
NCT00652405|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2010-08-10|2008-03-31|2008-04-03|Estimate|||||||2010-08-10|2010-08-11|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|AR22||Effect of Alcohol on Cephalic Phase Reflex and Gene Expression|Effect of Moderate Alcohol Consumption on Cephalic Phase Reflex and Gene Expression of Adipose Tissue in Postmenopausal Women|Completed||N/A|24|Actual|TNO||2|||f||||t||||||||||2018-06-01 02:16:50.598732|2018-06-01 02:16:50.598732
NCT00652392|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-01-21|2008-04-02|2008-04-03|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2003||2003-04-30|January 2011|2011-01-31|June 2004|Actual|2004-06-30|||||Interventional|||Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM|A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active-controlled Study of Symbicort pMDI Administered Once Daily in Adults and Adolescents With Asthma - STEM|Completed||Phase 3|750|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:16:50.663878|2018-06-01 02:16:50.663878
NCT00652379|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2012-01-25|2008-03-31|2008-04-03|Estimate|||||||2012-01-25|2012-01-26|Estimate|June 2008||2008-06-30|January 2012|2012-01-31|May 2011|Actual|2011-05-31|November 2009|Actual|2009-11-30||Interventional|||Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients|Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics|Completed||N/A|18|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:16:51.615282|2018-06-01 02:16:51.615282
NCT00650988|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2012-12-21|2008-04-01|2008-04-02|Estimate|||||||2012-12-21|2012-12-24|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Cryotherapy for Barrett's Esophagus and Early Esophageal Cancers|A Pilot Study of Cryotherapy for Barrett's Esophagus With High-Grade Dysplasia and Early Esophageal Cancers|Completed||Early Phase 1|37|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:17:11.451777|2018-06-01 02:17:11.451777
NCT00652366|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2014-12-08||2015-01-27|2008-04-01|2008-04-03|Estimate|2015-01-27|2015-02-11|Estimate||||2015-01-27|2015-02-11|Estimate|May 2008||2008-05-31|January 2015|2015-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Safety analysis population (SAP): all participants who received at least 1 dose of the trial medication and had at least 1 safety follow-up, whether withdrawn prematurely or not.|A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|A Randomized, Open-label, Dose-escalation to Rash Study to Assess the Effect of Tarceva in Combination With Gemcitabine on Overall Survival in Patients With Metastatic Pancreatic Cancer.|Completed||Phase 2|467|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:16:51.768485|2018-06-01 02:16:51.768485
NCT00652353|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2013-03-18|2008-03-31|2008-04-03|Estimate|||||||2013-03-18|2013-03-19|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Mnemonic for the Ottawa Ankle Rule|Efficacy of a Mnemonic to Improve Knowledge of the Ottawa Ankle and Foot Rules Among Medical Students and Residents; a Randomized Controlled Trial.|Completed||N/A|191|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-06-01 02:16:53.287401|2018-06-01 02:16:53.287401
NCT00652340|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2012-03-13||2012-03-13|2008-04-02|2008-04-03|Estimate|2012-03-13|2012-04-09|Estimate||||2012-03-13|2012-04-09|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|June 2010|Actual|2010-06-30||Interventional|TP2001-201||APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer|APRiCOT-L (Apricoxib in Combination Oncology Treatment - Lung) A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients|Completed||Phase 2|120|Actual|Tragara Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 02:16:53.470789|2018-06-01 02:16:53.470789
NCT00652327|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2010-05-12||2015-06-23|2008-04-02|2008-04-03|Estimate|2010-05-12|2010-06-10|Estimate||||2015-06-23|2015-07-16|Estimate|December 2005||2005-12-31|June 2015|2015-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)|A Multicenter, Randomized, Open-labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety and Tolerability of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Ongoing Statin in the Treatment of Hypercholesterolemia.|Completed||Phase 4|83|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:16:53.823412|2018-06-01 02:16:53.823412
NCT00652314|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2015-12-04||2016-02-05|2008-03-28|2008-04-03|Estimate|2016-02-05|2016-03-07|Estimate||||2016-02-05|2016-03-07|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|Control||Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin|Evaluation of an Absorbable Surgical Hemostatic Agent: Thrombi-Gel® Versus Gelfoam-Thrombin|Completed||Phase 4|97|Actual|Vascular Solutions, Inc||2|||f||||f||||||||No||2018-06-01 02:16:54.037134|2018-06-01 02:16:54.037134
NCT00652301|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-03-07|2008-03-31|2008-04-03|Estimate|||||||2017-03-07|2017-03-10|Actual|July 2003||2003-07-31|March 2017|2017-03-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled,4-Period, Crossover Study to Evaluate the Effects of Ezetimibe and Simvastatin, Coadministered and Alone, on Intestinal Absorption of Cholesterol|Completed||Phase 3|40|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 02:16:54.508718|2018-06-01 02:16:54.508718
NCT00652288|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2016-08-30|2008-03-31|2008-04-03|Estimate|||||||2016-08-30|2016-09-01|Estimate|April 2007||2007-04-30|August 2016|2016-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|PK/PD||Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs|Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs Given as a Bolus by Continuous Subcutaneous Insulin Infusion (CSII) and in MDI Basal-Bolus Therapy in Pediatric Subjects With Type 1 Diabetes (TID)|Completed||Phase 1|36|Actual|Yale University||4|||f||||f||||||||||2018-06-01 02:16:54.580771|2018-06-01 02:16:54.580771
NCT00652275|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-05-06|2008-04-02|2008-04-03|Estimate|||||||2008-05-06|2008-05-07|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine|Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali.|Unknown status|Recruiting|Phase 2|378|Anticipated|African Malaria Network Trust||2|||f||||t||||||||||2018-06-01 02:16:54.651139|2018-06-01 02:16:54.651139
NCT00652262|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-12-18|2008-04-01|2008-04-03|Estimate|||||||2014-12-18|2014-12-23|Estimate|March 2004||2004-03-31|December 2014|2014-12-31|November 2004|Actual|2004-11-30|||||Interventional|||BAY38-9456 - Supportive Trial for Spinal Injury|An Open, Multi-centre, Flexible Dose Uptitration Study to Investigate the Efficacy and Safety of Vardenafil 10 mg and 20 mg in Males With Spinal Cord Injury Suffering From Erectile Dysfunction|Completed||Phase 3|32|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:16:54.74343|2018-06-01 02:16:54.74343
NCT00652249|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2012-06-04|2008-03-31|2008-04-03|Estimate|||||||2012-06-04|2012-06-05|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Diagnosing Malfunctioning Hydrocephalic Shunt Valves With a Flow Sensor|A Flow Monitor for Pediatric Hydrocephalic Shunts - Study of Flow Sensor With the Shunt Valve|Withdrawn|||0|Actual|Transonic Systems Inc.|||1|Due to lack of enrollment.|f||||f||||||||||2018-06-01 02:16:54.875765|2018-06-01 02:16:54.875765
NCT00652236|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-03-31|2008-03-31|2008-04-03|Estimate|||||||2008-03-31|2008-04-03|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Observational|||Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain|Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain. Three-Year Follow up of a Randomized Trial|Terminated|||174|Actual|Klinik Valens|||2|Study was terminated according the study protocol end of 2007|f||||f||||||||||2018-06-01 02:16:54.936685|2018-06-01 02:16:54.936685
NCT00652223|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-04|2008-04-01|2008-04-03|Estimate|||||||2008-04-04|2008-04-09|Estimate|March 2005||2005-03-31|April 2008|2008-04-30|November 2005|Actual|2005-11-30|||||Interventional|||Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy|Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (AllQbG10) in Subjects With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy|Completed||Phase 1/Phase 2|21|Actual|Cytos Biotechnology AG||1|||f||||f||||||||||2018-06-01 02:16:55.003836|2018-06-01 02:16:55.003836
NCT00652210|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-12-08|2008-03-31|2008-04-03|Estimate|||||||2015-12-08|2015-12-10|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|MPM||Use of Multiphoton Microscopy in the Diagnosis of Cancer|Use of Multiphoton Microscopy in the Diagnosis of Cancer|Completed||Phase 1|344|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 02:16:55.122351|2018-06-01 02:16:55.122351
NCT00652184|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-10-03|2008-04-02|2008-04-03|Estimate|||||||2008-10-03|2008-10-07|Estimate|March 2008||2008-03-31|October 2008|2008-10-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|||Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)|Phase 2/3 Multi-Center, Double-Blind, Controlled Trial Comparing Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir, and Combination Topical ARYS-01 Cream /Oral Valaciclovir for Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older|Unknown status|Active, not recruiting|Phase 2|300|Anticipated|aRigen Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 02:16:55.269097|2018-06-01 02:16:55.269097
NCT00652171|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-03|2008-04-02|2008-04-03|Estimate|||||||2008-04-03|2008-04-09|Estimate|January 2004||2004-01-31|April 2008|2008-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Efficacy and Safety of Antidepressant Augmentation With Lamotrigine|Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression|Completed||Phase 3|34|Actual|Institute of Social Security of the Civil Servants of Minas Gerais||2|||f||||t||||||||||2018-06-01 02:16:55.372998|2018-06-01 02:16:55.372998
NCT00652158|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2013-09-20|2008-03-31|2008-04-03|Estimate|||||||2013-09-20|2013-09-23|Estimate|April 2006||2006-04-30|September 2013|2013-09-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies|A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies|Terminated||Phase 1|44|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:16:55.521995|2018-06-01 02:16:55.521995
NCT00652145|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2014-12-01||2015-05-04|2008-04-01|2008-04-03|Estimate|2015-05-04|2015-05-05|Estimate||||2015-05-04|2015-05-05|Estimate|September 2008||2008-09-30|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|DEAR||Dose Escalation and Remission (DEAR)|Test Treat Strategy to Prevent Ulcerative Colitis Relapse|Completed||Phase 4|119|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 02:16:55.605057|2018-06-01 02:16:55.605057
NCT00652132|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2018-05-24|2008-04-02|2008-04-03|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 15, 2007|Actual|2007-12-15|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|September 4, 2017|Actual|2017-09-04||Interventional|SIOPEL6||Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer|A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma|Completed||Phase 3|116|Actual|University of Birmingham||2|||f||||t||||||||||2018-06-01 02:16:56.210073|2018-06-01 02:16:56.210073
NCT00652119|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-08-25|2008-03-31|2008-04-03|Estimate|||||||2017-08-25|2017-08-28|Actual|February 2008|Actual|2008-02-29|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin|Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Treatment of Women With Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin|Active, not recruiting||N/A|46|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:16:56.307522|2018-06-01 02:16:56.307522
NCT00652106|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-03|Estimate|||||||2008-04-01|2008-04-03|Estimate|June 2003||2003-06-30|April 2008|2008-04-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|432|Actual|Allergan||3|||f||||||||||||||2018-06-01 02:16:56.396783|2018-06-01 02:16:56.396783
NCT00652093|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2012-07-10||2016-02-24|2008-03-31|2008-04-03|Estimate|2016-02-24|2016-03-25|Estimate||||2016-02-24|2016-03-25|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|August 2011|Actual|2011-08-31|November 2010|Actual|2010-11-30||Interventional|LUSTORII||Lumbar Stenosis Outcomes Research II|Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial|Terminated||Phase 4|24|Actual|University of Rochester|This study terminated early (leading to small number of subjects analyzed) due to US Food and Drug Administration (FDA) removing active control (Darvocet) from the U.S. market.|6||Removal of Darvocet from US market|f||||t||||||||||2018-06-01 02:16:56.499702|2018-06-01 02:16:56.499702
NCT00652080|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2012-07-24|2008-04-02|2008-04-03|Estimate|||||||2012-07-24|2012-07-25|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)||Completed||Phase 1/Phase 2|35|Actual|Berg, LLC||1|||f||||t||||||||||2018-06-01 02:16:57.175298|2018-06-01 02:16:57.175298
NCT00652067|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-04-02|2008-04-02|2008-04-03|Estimate|||||||2008-04-02|2008-04-03|Estimate|May 2006||2006-05-31|March 2008|2008-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Clofazamine for the Treatment of Mycobacterium Avium Intracellulare(MAI)|IND for One Patient to Receive Clofazamine for Treatment of MAI|Completed|||1|Actual|Yale University|||1||f||||f||||||||||2018-06-01 02:16:57.23846|2018-06-01 02:16:57.23846
NCT00652054|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-03-17|2008-03-31|2008-04-03|Estimate|||||||2011-03-17|2011-03-18|Estimate|June 2005||2005-06-30|March 2011|2011-03-31|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer|An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase 2 Study of S-1 as 2nd Line Therapy for Patients With Metastatic Pancreatic Cancer Who Have Previously Received 1st Line Treatment With a Gemcitabine Regimen|Completed||Phase 2|39|Actual|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-06-01 02:16:57.282846|2018-06-01 02:16:57.282846
NCT00652041|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-09-16|2008-03-31|2008-04-03|Estimate|||||||2011-09-16|2011-09-19|Estimate|January 2007||2007-01-31|September 2011|2011-09-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|TaCyDexVMP7||Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma|Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma|Completed||Phase 4|40|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-06-01 02:16:57.341636|2018-06-01 02:16:57.341636
NCT00652028|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2015-03-11|2011-09-06|2017-03-16|2008-04-02|2008-04-03|Estimate|2015-08-07|2015-08-14|Estimate|2011-09-06|2011-09-12|Estimate|2017-03-16|2017-04-13|Actual|November 2008||2008-11-30|August 2015|2015-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Safety Population: Participants who received any amount of study drug were included in the Safety Population|Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects|A Phase II, Open-Label, Multicenter, Escalating Dose, Study to Determine Pharmacokinetic and Pharmacodynamic Profile of Dexmedetomidine in Pediatric Subjects Ages ≥ 2 Through < 17 Years Old|Completed||Phase 2|69|Actual|Hospira, now a wholly owned subsidiary of Pfizer||4|||f||||t||||||||||2018-06-01 02:16:57.505231|2018-06-01 02:16:57.505231
NCT00652015|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-09-22|2008-04-02|2008-04-03|Estimate|||||||2015-09-22|2015-09-23|Estimate|May 2008||2008-05-31|September 2015|2015-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Molecular and Cellular Mechanisms of the In-stent-thrombosis|Molecular and Cellular Mechanisms of the In-stent-thrombosis. Is it Possible to Predict a In-stent-thrombosis Using Biomarkers?|Withdrawn|||0|Actual|RWTH Aachen University|||2|Recruitment numbers could not at all been achieved in an acceptable period of time|f||||f||||||Samples Without DNA|"~     1 sample of approximately 30 mL blood will be taken from each patient of both study group.~      CD39 and CD73 activity as well as EPC-number and function will be analyzed.~   "|||2018-06-01 02:16:58.354337|2018-06-01 02:16:58.354337
NCT00652002|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-01-21|2008-04-02|2008-04-03|Estimate|||||||2011-01-21|2011-01-24|Estimate|July 2002||2002-07-31|January 2011|2011-01-31|January 2004|Actual|2004-01-31|||||Interventional|||Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5|A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5|Completed||Phase 3|450|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:16:58.410324|2018-06-01 02:16:58.410324
NCT00651989|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-02|2008-04-02|2008-04-03|Estimate|||||||2008-04-02|2008-04-03|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Observational|||Agreement Between Spectral Domain and Time Domain Optical Coherence Tomography (OCT)|Agreement in Foveal Thickness Measurements Between Spectralis® and Stratus® Optical Coherence Tomography|Unknown status|Not yet recruiting||40|Anticipated|G. d'Annunzio University|||1||f||||t||||||||||2018-06-01 02:16:58.47895|2018-06-01 02:16:58.47895
NCT00651976|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2017-07-18|2008-04-02|2008-04-03|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2008||2008-03-31|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery|Pre-Surgical Trial of Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer (Spore)|Suspended||N/A|200|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:16:58.551372|2018-06-01 02:16:58.551372
NCT00651963|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-03-09|2008-03-31|2008-04-03|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2004||2004-09-30|March 2017|2017-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED)|Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia|Completed||Phase 4|80|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:16:58.644758|2018-06-01 02:16:58.644758
NCT00651950|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2012-06-04|2008-03-31|2008-04-03|Estimate|||||||2012-06-04|2012-06-05|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Bench Study of Transcutaneous Hydrocephalic Shunt Flow Sensor Alignment Accuracy and Repeatability|A Flow Monitor for Pediatric Hydrocephalic Shunts - Bench Study of Sensor Alignment Accuracy and Repeatability|Withdrawn|||0|Actual|Transonic Systems Inc.|||1|Withdrawn due to lack of enrollment.|f||||f||||||||||2018-06-01 02:16:58.699603|2018-06-01 02:16:58.699603
NCT00651937|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2016-01-21|2008-03-31|2008-04-03|Estimate|||||||2016-01-21|2016-01-25|Estimate|March 2008||2008-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden|Randomized Phase II Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden in High Risk Patients With Multiple Myeloma or Amyloidosis|Completed||Phase 2|80|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:16:59.085827|2018-06-01 02:16:59.085827
NCT00651924|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2014-09-17||2015-04-06|2008-04-02|2008-04-03|Estimate|2014-10-15|2014-10-21|Estimate||||2015-04-06|2015-04-28|Estimate|December 2008||2008-12-31|June 2014|2014-06-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional||Phase 2: two individuals completed all 10 sessions of treatment, however, we have baseline measures on 6 individuals (1 dropped after 5 sessions, 2 dropped after 1 session, 1 dropped after 2 sessions and 1 dropped after 4 sessions).|Piloting IVR (Interactive Voice Response) for Chronic Pain Treatment|Piloting Interactive Voice Response Modules for Chronic Pain Treatment|Completed||N/A|27|Actual|VA Office of Research and Development|Difficulty recruiting for phase 2 lead to a small number of subjects analyzed.|2|||f||||f||||||||||2018-06-01 02:16:59.18218|2018-06-01 02:16:59.18218
NCT00651911|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-03-31|2008-03-31|2008-04-03|Estimate|||||||2008-03-31|2008-04-03|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|July 2004|Actual|2004-07-31|||||Interventional|||Fasturtec TLS Treatment / Prophylysis|A Multicenter Open Label Study of the Efficacy and Safety of Rasburicase in the Treatment of Prophylysis for Tumor Lysis Syndrome|Completed||Phase 4|45|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:16:59.388676|2018-06-01 02:16:59.388676
NCT00651898|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2016-02-27|2008-04-02|2008-04-03|Estimate|||||||2016-02-27|2016-03-01|Estimate|August 2006||2006-08-31|February 2016|2016-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Circulating-water Garment With Forced-air Warming and Circulating-water Mattress During Abdominal Surgery|Comparison of a Circulating-water Garment With a Combination of Forced-air Warming and Circulating-water Mattress Warming During Major Abdominal Surgery|Completed|||50|Actual|The Cleveland Clinic|||2||f||||f||||||||No||2018-06-01 02:16:59.445502|2018-06-01 02:16:59.445502
NCT00651885|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-05-13|2008-03-31|2008-04-03|Estimate|||||||2011-05-13|2011-05-16|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure|A Randomized, Single-Center, Placebo Controlled Study To Assess the Safety of UT-15C (Treprostinil Diethanolamine) Sustained Release (SR) in Patients Undergoing an Infra-Popliteal Endovascular Intervention for the Treatment of Critical Limb Ischemia|Completed||Phase 2|20|Anticipated|Ochsner Health System||2|||f||||f||||||||||2018-06-01 02:16:59.506621|2018-06-01 02:16:59.506621
NCT00651872|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-03-05|2008-04-02|2008-04-03|Estimate|||||||2014-03-05|2014-03-06|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Development and Validation of a PTSD-Related Functional Impairment Scale|Development and Validation of a PTSD-Related Functional Impairment Scale|Completed|||740|Actual|Boston VA Research Institute, Inc.|||1||f||||f||||||||||2018-06-01 02:16:59.574162|2018-06-01 02:16:59.574162
NCT00651859|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-03|Estimate|||||||2008-04-01|2008-04-03|Estimate|November 2002||2002-11-30|April 2008|2008-04-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 2|111|Actual|Allergan||3|||f||||||||||||||2018-06-01 02:16:59.700631|2018-06-01 02:16:59.700631
NCT00156468|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-05-11|2005-09-08|2005-09-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|October 2003||2003-10-31|May 2011|2011-05-31|September 2005||2005-09-30|||||Interventional|||Office-Based Asthma Screening Intervention|Office-Based Asthma Screening Intervention|Completed||N/A|365||University of Rochester|||||f||||||||||||||2018-06-01 04:42:04.331512|2018-06-01 04:42:04.331512
NCT00651846|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-12-29|2008-04-02|2008-04-03|Estimate|||||||2014-12-29|2014-12-30|Estimate|June 2003||2003-06-30|December 2014|2014-12-31|February 2005|Actual|2005-02-28|||||Interventional|||Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women|Single Center, Double Blind, Randomized, Crossover Study to Investigate the Impact of the Oral Contraceptive Yasmin (30 µg EE / 3 mg DRSP) Compared to Microgynon (30 µg / 150 LNG) on Hemostasis Parameters in 40 Female Volunteers|Completed||Phase 4|43|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:16:59.770398|2018-06-01 02:16:59.770398
NCT00651833|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-03-17|2008-03-31|2008-04-03|Estimate|||||||2011-03-17|2011-03-18|Estimate|February 2005||2005-02-28|March 2011|2011-03-31|July 2007|Actual|2007-07-31|October 2006|Actual|2006-10-31||Interventional|||Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer|An Open-Label, Non-Randomized, Multicenter, Three-Stage, Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy for Patients With Advanced Non-Small Cell Lung Cancer (Stage IIIB/Stage IV)|Completed||Phase 2|60|Actual|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-06-01 02:16:59.835806|2018-06-01 02:16:59.835806
NCT00651820|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2010-06-04||2011-06-07|2008-04-02|2008-04-03|Estimate|2011-01-07|2011-01-26|Estimate||||2011-06-07|2011-06-09|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Effect of Collagenase on Healing and Scarring|A Randomized, Double-blind, Paired-Comparison of the Effect of Collagenase Santyl® Ointment on Healing and Scarring Characteristics of 600μm Dermatome Wounds|Completed||Phase 4|28|Actual|Healthpoint||2|||f||||f||||||||||2018-06-01 02:16:59.898493|2018-06-01 02:16:59.898493
NCT00651807|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-02-03|2008-03-31|2008-04-03|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2008||2008-03-31|February 2015|2015-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)|Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy and Safety of Org 3236 Tablets in Men With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia (BPH)|Terminated||Phase 2|16|Actual|Merck Sharp & Dohme Corp.||2||Business Reasons|f||||f||||||||||2018-06-01 02:17:00.065041|2018-06-01 02:17:00.065041
NCT00651794|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2015-12-08||2017-09-19|2008-03-31|2008-04-03|Estimate|2017-09-19|2017-10-19|Actual||||2017-09-19|2017-10-19|Actual|June 2007||2007-06-30|September 2017|2017-09-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Improving Teamwork for Neonatal Resuscitation|Improving Teamwork for Neonatal Resuscitation|Completed||N/A|100|Actual|The University of Texas Health Science Center, Houston|Questions remain about whether similar training will be effective for other types of caregivers. Generalizability might be limited if other sites were not able to re-create the team training content.|3|||f||||f||||||||||2018-06-01 02:17:00.140048|2018-06-01 02:17:00.140048
NCT00651781|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2013-02-27|2008-04-02|2008-04-03|Estimate|||||||2013-02-27|2013-02-28|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia|A Phase I/II National, Open-label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).|Completed||Phase 1/Phase 2|40|Actual|PETHEMA Foundation||1|||f||||t||||||||||2018-06-01 02:17:00.449313|2018-06-01 02:17:00.449313
NCT00651768|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-01-21|2008-04-02|2008-04-03|Estimate|||||||2011-01-21|2011-01-24|Estimate|August 2003||2003-08-31|January 2011|2011-01-31|January 2005|Actual|2005-01-31|||||Interventional|||Titratable Dosing in Moderate to Severe Asthmatics|A 52 wk Randomized, Doubleblind, Single Dummy, Parallel Group Multicenter Phase 3 Study Comparing the Long Term Safety of Symbicort pMDI 4x160/4.5mcg Bid to SymbicortpMDI 2x160/4.5mcg Bid & Budesonide HFA pMDI 4x160mcg Bid in Adult and Adolescent Subjects With Asthma|Completed||Phase 3|570|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:17:00.541993|2018-06-01 02:17:00.541993
NCT00651755|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2013-02-08||2013-06-28|2008-03-31|2008-04-03|Estimate|2013-06-28|2013-07-02|Estimate||||2013-06-28|2013-07-02|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients|Evaluation of Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Patients With Non-Hodgkin's Lymphoma|Completed||N/A|23|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:17:00.626384|2018-06-01 02:17:00.626384
NCT00651742|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31||2013-06-04|2013-06-04|2008-04-02|2008-04-03|Estimate||||2013-06-04|2013-06-12|Estimate|2013-06-04|2013-06-12|Estimate|February 2006||2006-02-28|June 2013|2013-06-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer|An Open-Label, Non-Randomized, Multicenter, Two-Stage, Phase 2 Study of S-1 in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|28|Actual|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-06-01 02:17:00.884768|2018-06-01 02:17:00.884768
NCT00651729|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-05-23|2008-04-01|2008-04-03|Estimate|||||||2008-05-23|2008-05-28|Estimate|April 2003||2003-04-30|May 2008|2008-05-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity||Completed||Phase 2|279|Actual|Allergan||1|||f||||||||||||||2018-06-01 02:17:00.940197|2018-06-01 02:17:00.940197
NCT00651716|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-02|||2017-06-26|2008-04-02|2008-04-03|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2006||2006-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant|Regulatory T Cells at Engraftment as Predictors of Acute Graft-Versus-Host Disease Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation|Suspended|||200|Anticipated|Vanderbilt-Ingram Cancer Center|||1|Funding unavailable|f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:17:01.126175|2018-06-01 02:17:01.126175
NCT00651703|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2010-11-11|2008-04-01|2008-04-03|Estimate|||||||2010-11-11|2010-11-15|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients|Safety, Tolerability, and Immunogenicity of CYT004-MelQbG10 Vaccine With or Without Immunostimulating Adjuvant in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma|Completed||Phase 2|21|Actual|Cytos Biotechnology AG||4|||f||||f||||||||||2018-06-01 02:17:01.221587|2018-06-01 02:17:01.221587
NCT00651690|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-05-23|2008-04-02|2008-04-03|Estimate|||||||2008-05-23|2008-05-28|Estimate|March 2004||2004-03-31|May 2008|2008-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment||Completed||Phase 2|62|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:17:01.288656|2018-06-01 02:17:01.288656
NCT00651677|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-04-18|2008-04-02|2008-04-03|Estimate|||||||2011-04-18|2011-04-19|Estimate|April 2011||2011-04-30|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||"Hand Assisted Versus Pure Laparoscopic Assisted Proctectomy for Rectal Cancer"|"A Multicenter Prospective Randomized Study Comparing Hand Assisted Versus Pure Laparoscopic Assisted Proctectomy for Rectal Cancer"|Unknown status|Recruiting|N/A|128|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:17:01.358984|2018-06-01 02:17:01.358984
NCT00651664|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2013-11-15|2008-04-02|2008-04-03|Estimate|||||||2013-11-15|2013-11-18|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies|A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies|Completed||Phase 1|59|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:17:01.434216|2018-06-01 02:17:01.434216
NCT00651651|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2011-01-21|2008-04-02|2008-04-03|Estimate|||||||2011-01-21|2011-01-24|Estimate|August 2002||2002-08-31|January 2011|2011-01-31|September 2003|Actual|2003-09-30|||||Interventional|||Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5|A 12 Week Randomized, Double-blind, Double-Dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Children (at Least 6years of Age) and Adults With Asthma-SPRUCE 80/4.5|Completed||Phase 3|450|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:17:01.492279|2018-06-01 02:17:01.492279
NCT00651638|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-06-18|2008-04-01|2008-04-03|Estimate|||||||2008-06-18|2008-06-19|Estimate|March 2008||2008-03-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype|A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype|Completed||Phase 1|17|Actual|ArQule|||||f||||f||||||||||2018-06-01 02:17:01.546703|2018-06-01 02:17:01.546703
NCT00651625|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2013-06-05||2016-02-02|2008-03-31|2008-04-03|Estimate|2016-02-02|2016-03-02|Estimate||||2016-02-02|2016-03-02|Estimate|November 2004||2004-11-30|February 2016|2016-02-29|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|RPD||Reciprocating Medical Devices - a Study of a New Safety Device|Randomized Controlled Trial of the Reciprocating Procedure Device Versus the Conventional Syringe in Syringe-and-Needle Procedures|Completed||N/A|437|Actual|University of New Mexico|no adverse events|2|||f||||t||||||||No||2018-06-01 02:17:01.668622|2018-06-01 02:17:01.668622
NCT00651612|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-04-01|2008-04-01|2008-04-03|Estimate|||||||2008-04-01|2008-04-03|Estimate|November 2005||2005-11-30|April 2008|2008-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients||Completed||Phase 3|604|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:17:02.068576|2018-06-01 02:17:02.068576
NCT00651599|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-12-30|2008-04-02|2008-04-03|Estimate|||||||2014-12-30|2014-12-31|Estimate|July 2004||2004-07-31|December 2014|2014-12-31|May 2005|Actual|2005-05-31|||||Interventional|||Treatment of Vasomotor Symptoms in Korean Post Menopausal Women|A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq(drospirenon2mg and Estradiol 1mg) in Postmenopausal Korean Women With Vasomotor Symptoms Over 3, 28 Day Treatment Cycle|Completed||Phase 3|90|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:17:02.157568|2018-06-01 02:17:02.157568
NCT00651586|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2008-07-25|2008-04-01|2008-04-03|Estimate|||||||2008-07-25|2008-07-29|Estimate|October 2003||2003-10-31|July 2008|2008-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers||Completed||Phase 2|129|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:17:02.269256|2018-06-01 02:17:02.269256
NCT00651573|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2018-04-05|2008-03-31|2008-04-03|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2007||2007-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2014|Actual|2014-08-31||Interventional|||Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery|Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery|Active, not recruiting||N/A|717|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 02:17:02.385246|2018-06-01 02:17:02.385246
NCT00651560|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-03-28|2008-03-31|2008-04-03|Estimate|||||||2017-03-28|2017-03-29|Actual|November 1, 2005|Actual|2005-11-01|March 2017|2017-03-31|December 23, 2005|Actual|2005-12-23|December 23, 2005|Actual|2005-12-23||Interventional|||Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)|Vytorin As Strategy To Reduce Dislipidemia In Adults|Completed||Phase 3|167|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:17:02.465985|2018-06-01 02:17:02.465985
NCT00651547|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2009-03-27|2008-04-01|2008-04-03|Estimate|||||||2009-03-27|2009-03-30|Estimate|July 2002||2002-07-31|March 2009|2009-03-31|October 2003|Actual|2003-10-31|||||Interventional|||Symbicort in Asthmatic Children - SEEDLING|A 12 Week Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial of Symbicort TM (40/4.5 Mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Asthmatic Children Aged Six to Eleven Years - SEEDLING 40/4.5|Completed||Phase 3|405|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:17:02.534214|2018-06-01 02:17:02.534214
NCT00651534|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2016-04-28|2008-03-28|2008-04-02|Estimate|||||||2016-04-28|2016-05-02|Estimate|February 2008||2008-02-29|April 2016|2016-04-30||||||||Interventional|||To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females|An Open-label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400 mg Ronacaleret (a Calcium-sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females.|Completed||Phase 1|32||GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:17:02.593189|2018-06-01 02:17:02.593189
NCT00651521|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2013-12-24|2008-04-01|2008-04-02|Estimate|||||||2013-12-24|2013-12-25|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|||||Observational|||Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients|Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients|Unknown status|Recruiting||1000|Anticipated|Chang Gung Memorial Hospital|||6||f||||t||||||||||2018-06-01 02:17:02.642488|2018-06-01 02:17:02.642488
NCT00651508|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26||2010-09-10|2016-04-19|2008-03-28|2008-04-02|Estimate||||2010-09-10|2010-09-14|Estimate|2016-04-19|2016-05-17|Estimate|April 2008||2008-04-30|April 2016|2016-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|Open Label, Multi-center, Phase 2 Study of KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Previously Treated With First-Line Chemotherapy|Completed||Phase 2|1|Actual|Bristol-Myers Squibb||1|||t||||||||||||||2018-06-01 02:17:02.714018|2018-06-01 02:17:02.714018
NCT00651482|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2014-06-30||2017-03-13|2008-03-28|2008-04-02|Estimate|2014-06-30|2014-07-29|Estimate||||2017-03-13|2017-04-11|Actual|August 2008||2008-08-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)|Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)|Terminated||Phase 2|10|Actual|Stanford University||1||slow accrual|f||||t||||||||||2018-06-01 02:17:02.863516|2018-06-01 02:17:02.863516
NCT00651469|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2014-12-29|2008-04-01|2008-04-02|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2003||2003-01-31|December 2014|2014-12-31|July 2004|Actual|2004-07-31|||||Interventional|||Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety & Efficacy of Oral Contraceptive Prep., Containing Drospirenone 3 mg/Ethinyl Estradiol 20 Mcg for 6 Treatment Cycles in Women With Moderate Acne Vulgaris.|Completed||Phase 3|534|Actual|Bayer||2|||t||||||||||||||2018-06-01 02:17:03.269589|2018-06-01 02:17:03.269589
NCT00651456|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-29|||2016-09-01|2008-04-01|2008-04-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|February 2008||2008-02-29|September 2016|2016-09-30|September 2016|Actual|2016-09-30|January 2015|Actual|2015-01-31||Interventional|MAPS||Mesothelioma Avastin Plus Pemetrexed-cisplatin Study|A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)|Completed||Phase 2/Phase 3|448|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||Undecided||2018-06-01 02:17:03.396463|2018-06-01 02:17:03.396463
NCT00651443|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-01-06|2008-04-01|2008-04-02|Estimate|||||||2011-01-06|2011-01-07|Estimate|August 2008||2008-08-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma|A Phase I, Open Label Study to Evaluate the Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma|Terminated||Phase 1|20|Anticipated|Biogen||1||"A company's strategic decision to focus on areas whereit believes it can be competitive and~   decided to exit Oncology"|f||||f||||||||||2018-06-01 02:17:03.555071|2018-06-01 02:17:03.555071
NCT00651430|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2010-06-10|2008-04-01|2008-04-02|Estimate|||||||2010-06-10|2010-06-11|Estimate|March 2008||2008-03-31|December 2007|2007-12-31|May 2010|Actual|2010-05-31|May 2008|Actual|2008-05-31||Observational|||Physical Functioning Following Total Hip Arthroplasty|Step Execution, Stability, Quality of Life, Fear of Falling and Their Association Following Total Hip Arthroplasty|Completed|||30|Anticipated|Soroka University Medical Center|||1||f||||f||||||None Retained|"~     no biospecimens are to be retained~   "|||2018-06-01 02:17:03.637368|2018-06-01 02:17:03.637368
NCT00651417|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-06-21|2008-04-01|2008-04-02|Estimate|||||||2011-06-21|2011-06-23|Estimate|April 2005||2005-04-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue|A Phase II, Pilot, Randomized, Double-blind Study Comparing the Effectiveness Organic Germanium to Placebo in Decreasing the Severity of Fatigue in Patients Undergoing Radiation Therapy for Prostae and Bbreast Cancers|Unknown status|Recruiting|Phase 2|101|Anticipated|Arizona Oncology Services||2|||f||||t||||||||||2018-06-01 02:17:03.691136|2018-06-01 02:17:03.691136
NCT00651404|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-04-07|2008-04-01|2008-04-02|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2004||2004-01-31|April 2015|2015-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)|A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 mg In Subjects With Primary Hypercholesterolemia And Coronary Heart Disease.|Completed||Phase 3|137|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:17:03.758958|2018-06-01 02:17:03.758958
NCT00651391|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-05-10|2008-03-31|2008-04-02|Estimate|||||||2017-05-10|2017-05-11|Actual|October 1, 2003|Actual|2003-10-01|May 2017|2017-05-31|September 1, 2004|Actual|2004-09-01|September 1, 2004|Actual|2004-09-01||Interventional|||Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Ezetimibe Plus Simvastatin Compared With Simvastatin Alone on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (The EFFECTS Trial)|Terminated||Phase 3|28|Actual|Merck Sharp & Dohme Corp.||3||Slow enrollment|f||||f||||||||||2018-06-01 02:17:03.812159|2018-06-01 02:17:03.812159
NCT00651378|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-05-10|2008-04-01|2008-04-02|Estimate|||||||2017-05-10|2017-05-11|Actual|September 1, 2004|Actual|2004-09-01|May 2017|2017-05-31|June 1, 2005|Actual|2005-06-01|June 1, 2005|Actual|2005-06-01||Interventional|||Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)|"An Open-Label, Randomized, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of Switching to Rosuvastatin 10 mg Daily Versus Atorvastatin 10 mg Daily With Ezetimibe 10 mg Daily Versus Doubling the Dose of Atorvastatin to 20 mg Daily in Subjects With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease or Diabetes Mellitus Who Have Not Achieved Study Target LDL-C Goal While Dosing With Atorvastatin 10 mg Daily"|Terminated||Phase 4|87|Actual|Merck Sharp & Dohme Corp.||3||Slow enrollment [HIGH SCREEN FAILURE RATE]|f||||f||||||||||2018-06-01 02:17:03.887845|2018-06-01 02:17:03.887845
NCT00651365|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2013-03-07|2008-04-01|2008-04-02|Estimate|||||||2013-03-07|2013-03-08|Estimate|February 2008||2008-02-29|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of the Selective Met Inhibitor JNJ-38877605 in Subjects With Advanced or Refractory Solid Tumors|Terminated||Phase 1|14|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1||Early termination due to increase in serum creatinine levels and minimal PD activity.|f||||t||||||||||2018-06-01 02:17:04.847931|2018-06-01 02:17:04.847931
NCT00651352|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2014-11-20|2008-03-31|2008-04-02|Estimate|||||||2014-11-20|2014-11-24|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges|A Single Dose Bioequivalence Study of 2mg and 4mg Nicotine Lozenges|Completed||Phase 1|32|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 02:17:04.910397|2018-06-01 02:17:04.910397
NCT00651339|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2010-04-12|2008-04-01|2008-04-02|Estimate|||||||2010-04-12|2010-04-13|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Observational|||The Effect of Botox Injection on Postural Stability of Cerebral Palsy (CP) Children||Terminated|||20|Anticipated|Soroka University Medical Center|||1|recruiting or enrolling participants has halted prematurely and will not resume|f||||t||||||||||2018-06-01 02:17:04.975037|2018-06-01 02:17:04.975037
NCT00651326|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2012-12-17|2008-04-01|2008-04-02|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|||||Interventional|||Androgen Suppression Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With High-Risk Localized Prostate Cancer|A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate (DART)|Terminated||Phase 3|48|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 02:17:05.040505|2018-06-01 02:17:05.040505
NCT00651313|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2011-06-07||2012-02-16|2008-04-01|2008-04-02|Estimate|2011-06-07|2011-07-06|Estimate||||2012-02-16|2012-02-17|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|Lidocaine 04||Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)|A Phase II, Double-Blind, Crossover Study to Assess the Efficacy and Safety of 10% (150mg) Lidocaine Vaginal Gel Administered to Women With Recurrent Dysmenorrhea|Completed||Phase 2|81|Actual|Juniper Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:17:05.154074|2018-06-01 02:17:05.154074
NCT00651300|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2009-06-08|2008-03-31|2008-04-02|Estimate|||||||2009-06-08|2009-06-11|Estimate|April 2003||2003-04-30|June 2009|2009-06-30|March 2004|Actual|2004-03-31|||||Interventional|||A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery|A Multicentre, Double-Blind, Placebo-Controlled Study of the Recovery Benefits Following Treatment With a Cox-2 Regimen in Patients Undergoing Elective Laparoscopic Intra-Peritoneal Abdominal Surgery|Terminated||Phase 3|91|Actual|Pfizer||2||See Detailed Description field.|f||||f||||||||||2018-06-01 02:17:05.396327|2018-06-01 02:17:05.396327
NCT00651287|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-04-07|2008-03-31|2008-04-02|Estimate|||||||2008-04-07|2008-04-10|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|June 2004|Actual|2004-06-30|||||Interventional|||A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension|A 12-Week Open-Label, Uncontrolled Multicenter Study to Assess the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Subjects With Mild to Moderate Hypertension|Completed||Phase 4|200|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:05.572387|2018-06-01 02:17:05.572387
NCT00651274|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-05-10|2008-04-01|2008-04-02|Estimate|||||||2017-05-10|2017-05-11|Actual|April 1, 2003|Actual|2003-04-01|May 2017|2017-05-31|August 1, 2004|Actual|2004-08-01|August 1, 2004|Actual|2004-08-01||Interventional|||Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)|A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Simvastatin 20 Mg In Subjects With Primary Hypercholesterolemia And Coronary Heart Disease|Completed||Phase 4|144|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:17:05.661265|2018-06-01 02:17:05.661265
NCT00651261|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2016-12-12||2018-04-06|2008-04-01|2008-04-02|Estimate|2016-12-12|2017-02-06|Estimate||||2018-04-06|2018-05-08|Actual|April 2008||2008-04-30|April 2018|2018-04-30||||July 2016|Actual|2016-07-31||Interventional|||Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 3|717|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 02:17:05.921136|2018-06-01 02:17:05.921136
NCT00651248|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-02|Estimate|||||||2008-03-31|2008-04-02|Estimate|September 2006||2006-09-30|March 2008|2008-03-31|August 2007|Actual|2007-08-31|||||Observational|||Evaluation of Salivary Flow and Buffer Capacity Associated to Aged People's Oral Health|Evaluation of Salivary Flow and Buffer Capacity Associated to Aged People's Oral Health|Completed|||68|Actual|Academia Cearense de Odontologia|||||f||||t||||||||||2018-06-01 02:17:08.356785|2018-06-01 02:17:08.356785
NCT00651235|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2010-06-08|2008-04-01|2008-04-02|Estimate|||||||2010-06-08|2010-06-09|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|February 2011|Anticipated|2011-02-28||Interventional|MFS||A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome|A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome|Unknown status|Recruiting|Phase 2|44|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 02:17:08.421442|2018-06-01 02:17:08.421442
NCT00651222|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-02|Estimate|||||||2008-03-31|2008-04-02|Estimate||||March 2008|2008-03-31||||||||Observational|||Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy|Influence of Androgen Suppression Therapy for Prostate Cancer on the Timing and Onset of Fatal Myocardial Infarctions in Men Undergoing Prostate Brachytherapy|Completed|||||Prostate Cancer Foundation of Chicago|||1||f||||f||||||||||2018-06-01 02:17:08.502175|2018-06-01 02:17:08.502175
NCT00651209|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2014-03-06|2008-03-28|2008-04-02|Estimate|||||||2014-03-06|2014-03-07|Estimate|February 2008||2008-02-29|March 2014|2014-03-31||||December 2011|Actual|2011-12-31||Interventional|||A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)|A Single-arm, Multinational, Two Year Study Evaluating the Efficacy and Safety of lead-in Telbivudine for 24 Weeks With or Without Tenofovir Treatment Intensification in Adult Patients With HBeAg-positive Chronic Hepatitis B.|Completed||Phase 4|105|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:17:08.557496|2018-06-01 02:17:08.557496
NCT00651196|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2013-03-14|2008-04-01|2008-04-02|Estimate|||||||2013-03-14|2013-03-18|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|DMB||Bone Health in Type 1 Diabetes|Pilot Study - Type 1 Diabetes and Bone Health|Completed|||60|Anticipated|Creighton University|||2||f||||f||||||Samples Without DNA|"~     Transilial bone specimens are retained for measurements~   "|||2018-06-01 02:17:08.638715|2018-06-01 02:17:08.638715
NCT00651183|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2009-12-14||2014-05-09|2008-04-01|2008-04-02|Estimate|2010-02-11|2010-03-03|Estimate||||2014-05-09|2014-05-20|Estimate||||May 2014|2014-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational||Safety set (SAF)|Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment|Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment|Completed|||286|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 02:17:08.762619|2018-06-01 02:17:08.762619
NCT00651170|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2016-09-23|2008-03-28|2008-04-02|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2008||2008-03-31|September 2016|2016-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|Echoalr||Diffusion of Local Anesthetic After Median Nerve Block|Can Ultrasound Predict Success of Median Nerve Block? Relationship Between Diffusion of Local Anesthetic and Effectiveness of a Nerve Block|Completed|||103|Actual|Hopital Foch|||||f||||f||||||||No||2018-06-01 02:17:09.207712|2018-06-01 02:17:09.207712
NCT00651157|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|2013-08-05||2014-03-21|2008-04-01|2008-04-02|Estimate|2013-08-05|2013-10-16|Estimate||||2014-03-21|2014-04-22|Estimate|April 2008||2008-04-30|February 2014|2014-02-28|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|||Viral Therapy in Treating Patients With Metastatic Melanoma|A Phase II Trial of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (Reolysin®) in Patients With Metastatic Melanoma|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:17:09.359993|2018-06-01 02:17:09.359993
NCT00651144|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-04-15|2008-03-31|2008-04-02|Estimate|||||||2015-04-15|2015-04-16|Estimate|March 2003||2003-03-31|April 2015|2015-04-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)|SCH 058235: Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Rosuvastatin in Healthy Hypercholesterolemic Subjects|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:17:09.641481|2018-06-01 02:17:09.641481
NCT00651131|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-08-28|2008-03-31|2008-04-02|Estimate|||||||2017-08-28|2017-08-30|Actual|June 1, 2004|Actual|2004-06-01|August 2017|2017-08-31|March 1, 2005|Actual|2005-03-01|March 1, 2005|Actual|2005-03-01||Interventional|PSW||Cubicin(R) for Complicated Post-surgical Wound Infections|Cubicin(R) for Complicated Post-surgical Wound Infections|Terminated||Phase 4|69|Actual|Cubist Pharmaceuticals LLC||||terminated due to slow enrollment|f||||f||||||||||2018-06-01 02:17:09.76156|2018-06-01 02:17:09.76156
NCT00651118|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2012-05-10|2011-06-23|2012-08-27|2008-03-28|2008-04-02|Estimate|2012-08-27|2012-09-26|Estimate|2011-07-12|2011-07-14|Estimate|2012-08-27|2012-09-26|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies|Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis|Completed||Phase 3|832|Actual|Meda Pharmaceuticals||4|||f||||f||||||||||2018-06-01 02:17:09.858212|2018-06-01 02:17:09.858212
NCT00651105|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2016-11-16|2008-04-01|2008-04-02|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2008||2008-02-29|November 2016|2016-11-30||||May 2009|Actual|2009-05-31||Interventional|||Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects|A Double-blind, Placebo-controlled, Randomized, Cross-over Study to Evaluate the GLP-1-mediated and Non-GLP-1-mediated Effects of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects|Completed||Phase 3|63|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:17:10.497808|2018-06-01 02:17:10.497808
NCT00651092|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-04-01|2008-04-01|2008-04-02|Estimate|||||||2008-04-01|2008-04-02|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|January 2010|Anticipated|2010-01-31|May 2008|Anticipated|2008-05-31||Interventional|||Inferior Submucosal Turbinectomy Versus Blunt Turbinectomy for Inferior Turbinate Hypertrophy|to Compare Two Well Popularized Methods of Inferior Nasal Turbinectomy|Unknown status|Not yet recruiting|N/A|50|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-06-01 02:17:10.586742|2018-06-01 02:17:10.586742
NCT00651079|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31||2010-10-14|2010-10-14|2008-03-31|2008-04-02|Estimate||||2010-10-14|2010-10-19|Estimate|2010-10-14|2010-10-19|Estimate|February 2008||2008-02-29|October 2010|2010-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||GSK1247303 First Time in Human Study|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1247303 in Healthy Male and Female Subjects|Terminated||Phase 1|58|Anticipated|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:17:10.661613|2018-06-01 02:17:10.661613
NCT00651066|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2013-07-16|2008-04-01|2008-04-02|Estimate|||||||2013-07-16|2013-07-17|Estimate|June 2010||2010-06-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam|Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in Vietnam : A Phase II Trial|Completed||Phase 2|47|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 02:17:10.72428|2018-06-01 02:17:10.72428
NCT00651053|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2016-02-02|2008-03-30|2008-04-02|Estimate|||||||2016-02-02|2016-02-03|Estimate|May 2005||2005-05-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|||||Interventional|||Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis|Validation of Endoscopic Ultrasound Criteria for Diagnosis of Chronic Pancreatitis Using Dual Secretin and Cholecystokinin Pancreatic Function Testing as Reference Standard|Completed||N/A|70|Actual|The Cleveland Clinic|||||||||f||||||||||2018-06-01 02:17:10.815487|2018-06-01 02:17:10.815487
NCT00651040|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2015-10-29||2016-04-06|2008-04-01|2008-04-02|Estimate|2016-04-06|2016-05-12|Estimate||||2016-04-06|2016-05-12|Estimate|May 2008||2008-05-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Prometheus||Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM|A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis.|Completed||Phase 3|31|Actual|Institute of Rheumatology, Prague||2|||f||||f||||||||||2018-06-01 02:17:10.886318|2018-06-01 02:17:10.886318
NCT00651027|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2014-01-02|2008-03-31|2008-04-02|Estimate|||||||2014-01-02|2014-01-03|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554|An Open Label Study, To Evaluate The Pharmacokinetics, Safety And Toleration Of A Single Oral Dose Of Pf-00868554 In Subjects With Hepatic Impairment To Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:11.139702|2018-06-01 02:17:11.139702
NCT00651014|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-04-15|2008-04-01|2008-04-02|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2004||2004-01-31|April 2015|2015-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease and/or Type II Diabetes|Terminated||Phase 4|82|Actual|Merck Sharp & Dohme Corp.||2||"slow subject recruitment and lack of medical and scientific merit due to change in new standard~   of therapy during that same period."|f||||t||||||||||2018-06-01 02:17:11.280482|2018-06-01 02:17:11.280482
NCT00650975|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-01-19|2008-03-31|2008-04-02|Estimate|||||||2011-01-19|2011-01-20|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|January 2010|Actual|2010-01-31|||||Interventional|TAAMI||ThromboAblation in Acute Myocardial Infarction|ThromboAblation in Acute Myocardial Infarction|Terminated||Phase 2/Phase 3|78|Actual|KCRI||2||Slow enrollment rate.|f||||t||||||||||2018-06-01 02:17:11.52551|2018-06-01 02:17:11.52551
NCT00650962|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2012-01-02|2008-04-01|2008-04-02|Estimate|||||||2012-01-02|2012-01-05|Estimate|February 2008||2008-02-29|December 2011|2011-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|CPR||Pre-shock Cardiopulmonary Resuscitation to Patients With Out-of-hospital Resuscitation, A Randomised Clinical Trial|Does Longer Pre-shock Cardiopulmonary Resuscitation Improve the Outcome of Patients With Out-of-hospital Cardiac Arrest? A Randomized Control Trial.|Completed||N/A|1666|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 02:17:11.601478|2018-06-01 02:17:11.601478
NCT00650949|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27||2013-04-25|2013-04-25|2008-03-31|2008-04-02|Estimate||||2013-04-25|2013-05-03|Estimate|2013-04-25|2013-05-03|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma|A Phase Ib/II Study of CYT997 in Combination With Carboplatin in Relapsed Glioblastoma Multiforme|Terminated||Phase 1/Phase 2|20|Actual|Gilead Sciences||1||Strategic|f||||t||||||||||2018-06-01 02:17:11.674815|2018-06-01 02:17:11.674815
NCT00650936|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-01-30|2008-03-31|2008-04-02|Estimate|||||||2015-01-30|2015-02-03|Estimate|August 2007||2007-08-31|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder - Post Approval Study||Unknown status|Active, not recruiting|N/A|1000|Anticipated|St. Jude Medical||1|||f||||f||||||||||2018-06-01 02:17:11.774|2018-06-01 02:17:11.774
NCT00650923|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-01|||2014-05-29|2008-04-01|2008-04-02|Estimate|||||||2014-05-29|2014-05-30|Estimate|July 2008||2008-07-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma|Phase I Trial of Aflibercept (VEGF Trap) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Glioma|Completed||Phase 1|61|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:17:11.892924|2018-06-01 02:17:11.892924
NCT00650910|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2017-11-13|2008-03-28|2008-04-02|Estimate|||||||2017-11-13|2017-11-17|Actual|April 23, 2008|Actual|2008-04-23|November 2017|2017-11-30|July 10, 2009|Actual|2009-07-10|July 10, 2009|Actual|2009-07-10||Interventional|||Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer|An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally Administered Digoxin in Subjects With Metastatic ErbB2 Positive Breast Cancer|Completed||Phase 1|17|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:17:11.980522|2018-06-01 02:17:11.980522
NCT00650897|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-30|2008-03-30|2008-04-02|Estimate|||||||2008-03-30|2008-04-02|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|October 2009|Anticipated|2009-10-31|June 2009|Anticipated|2009-06-30||Interventional|EFDID||Efficacy Study of Escitalopram for Depression in Patients With Diabetes|Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:17:12.062535|2018-06-01 02:17:12.062535
NCT00650884|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2012-04-27|2008-03-31|2008-04-02|Estimate|||||||2012-04-27|2012-04-30|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Plantar Fasciitis Treated With Dynamic Splinting|Plantar Fasciopathy Treated With Dynamic Splinting: A Randomized, Controlled, Cross-Over Study|Completed||N/A|66|Anticipated|Dynasplint Systems, Inc.||3|||f||||t||||||||||2018-06-01 02:17:12.131003|2018-06-01 02:17:12.131003
NCT00650871|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-08-07|2008-03-31|2008-04-02|Estimate|||||||2017-08-07|2017-08-08|Actual|July 30, 2004|Actual|2004-07-30|August 2017|2017-08-31|August 30, 2005|Actual|2005-08-30|August 30, 2005|Actual|2005-08-30||Interventional|||A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia|Completed||Phase 2|48|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:17:12.200068|2018-06-01 02:17:12.200068
NCT00650858|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2009-03-12||2017-11-08|2008-04-01|2008-04-02|Estimate|2012-06-13|2012-07-17|Estimate||||2017-11-08|2017-12-11|Actual|February 2004||2004-02-29|November 2017|2017-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|CLEAR IVH||Clinical Trial on Treatment of Intraventricular Hemorrhage|Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (IVH)|Completed||Phase 2|52|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-06-01 02:17:12.307443|2018-06-01 02:17:12.307443
NCT00650845|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2015-03-11||2015-05-21|2008-04-01|2008-04-02|Estimate|2015-05-21|2015-06-09|Estimate||||2015-05-21|2015-06-09|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|RESCUE||Renal Safety Evaluation After Dotarem®-Enhanced MRI|Renal Safety Evaluation After Dotarem®-Enhanced MRI Compared With Non-enhanced MRI in Patients at High Risk of Developing Contrast Medium Induced Nephropathy|Completed||Phase 4|135|Actual|Guerbet||2|||f||||t||||||||||2018-06-01 02:17:13.068998|2018-06-01 02:17:13.068998
NCT00650832|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28||2011-06-02|2011-06-02|2008-03-28|2008-04-02|Estimate||||2011-06-02|2011-06-15|Estimate|2011-06-02|2011-06-15|Estimate|October 2003||2003-10-31|June 2011|2011-06-30|July 2007|Actual|2007-07-31|February 2005|Actual|2005-02-28||Interventional|||TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.|A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Subjects, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.|Completed||Phase 2|334|Actual|Tibotec Pharmaceuticals, Ireland|||||||||||||||||||2018-06-01 02:17:13.497703|2018-06-01 02:17:13.497703
NCT00650819|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-05-10|2008-03-31|2008-04-02|Estimate|||||||2017-05-10|2017-05-11|Actual|June 1, 2004|Actual|2004-06-01|May 2017|2017-05-31|February 1, 2005|Actual|2005-02-01|February 1, 2005|Actual|2005-02-01||Interventional|||Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)|A Multicenter, Double-blind, Randomized, Active-controlled Parallel Groups Study Comparing The Efficacy and Safety of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg Vs Simvastatin Or Ezetimibe Alone in Subjects With Primary Hypercholesterolemia|Completed||Phase 3|240|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 02:17:13.563372|2018-06-01 02:17:13.563372
NCT00650806|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2013-04-01|2009-07-23|2013-04-01|2008-03-31|2008-04-02|Estimate|2013-04-01|2013-05-24|Estimate|2009-07-23|2009-08-10|Estimate|2013-04-01|2013-05-24|Estimate|May 2008||2008-05-31|April 2013|2013-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects|Completed||Phase 2|376|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-06-01 02:17:13.675251|2018-06-01 02:17:13.675251
NCT00650793|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-06-06|2008-04-01|2008-04-02|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|February 2006|Actual|2006-02-28|||||Interventional|||A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia|A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS� Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia - Open Label Phase|Completed||Phase 3|473|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:17:14.299181|2018-06-01 02:17:14.299181
NCT00650780|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-04-01|2008-04-01|2008-04-02|Estimate|||||||2008-04-01|2008-04-02|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|Gc||Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment|Vitamin D Binding Protein (Gc) Allele Variation Effects Response to Vitamin D Treatment|Completed|||29|Actual|Creighton University|||1||f||||f||||||||||2018-06-01 02:17:14.346116|2018-06-01 02:17:14.346116
NCT00650767|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2016-07-21|2009-12-09|2016-09-20|2008-03-31|2008-04-02|Estimate|2016-09-20|2016-11-07|Estimate|2009-12-09|2009-12-11|Estimate|2016-09-20|2016-11-07|Estimate|March 2008||2008-03-31|September 2016|2016-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Baseline Demographics represent the Intent-to-Treat (ITT) population, which is all patients who were randomized to a treatment group.|A Study of ARRY-438162 in Patients With Rheumatoid Arthritis||Completed||Phase 2|201|Actual|Array BioPharma||4|||f||||t||||||||||2018-06-01 02:17:14.537456|2018-06-01 02:17:14.537456
NCT00650754|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-09-28|2008-04-01|2008-04-02|Estimate|||||||2015-09-28|2015-09-30|Estimate|March 2008||2008-03-31|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|DHEAFert||Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility|A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Normal Hysterosalpingogram and Normal Semen Analysis and Evidence of Premature Ovarian Aging (POA).|Terminated||Phase 2/Phase 3|35|Actual|Center for Human Reproduction||2||Failure to recruit designed nuimebrt of subjects|f||||f||||||||||2018-06-01 02:17:18.251498|2018-06-01 02:17:18.251498
NCT00650741|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-30|2008-03-30|2008-04-02|Estimate|||||||2008-03-30|2008-04-02|Estimate|February 2008||2008-02-29|March 2008|2008-03-31||||||||Observational|||Evaluation of a New Non-Invasive Device for Detection of Endothelial Dysfunction|Evaluation of a New Non-Invasive Device for Detection of Endothelial Dysfunction|Unknown status|Enrolling by invitation||30|Anticipated|Lavi Cardiatec|||3||f||||f||||||||||2018-06-01 02:17:18.584737|2018-06-01 02:17:18.584737
NCT00650728|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2011-06-22|2008-04-01|2008-04-02|Estimate|||||||2011-06-22|2011-06-27|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Esophagus Imaging for Radiofrequency Ablation of Atrial Fibrillation|Esophagus Imaging for Radiofrequency Ablation of Atrial Fibrillation: Comparison of Two Methods|Completed||N/A|||Luzerner Kantonsspital|||||f||||t||||||||||2018-06-01 02:17:18.812896|2018-06-01 02:17:18.812896
NCT00650715|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-02|Estimate|||||||2008-03-31|2008-04-02|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Effects of Whole-Body Vibration Exercise on Serum IGF-1 in Fibromyalgia|Effect of Acute and Chronic Whole-Body Vibration Exercise on Serum Insulin-Like Growth Factor-1 Levels in Women With Fibromyalgia|Completed||N/A|24|Actual|Institut Nacional d'Educacio Fisica de Catalunya||2|||f||||||||||||||2018-06-01 02:17:18.928518|2018-06-01 02:17:18.928518
NCT00650702|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27||2011-02-23|2013-09-16|2008-04-01|2008-04-02|Estimate||||2011-02-23|2011-03-02|Estimate|2013-09-16|2013-09-19|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|CORE||Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Phase II, Randomized, Masked, Parallel-Group Study of Safety and Preliminary Efficacy of the Punctum Plug Delivery System in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|36|Actual|Mati Therapeutics Inc.||3|||f||||f||||||||||2018-06-01 02:17:19.004435|2018-06-01 02:17:19.004435
NCT00650689|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2015-07-03|2008-04-01|2008-04-02|Estimate|||||||2015-07-03|2015-07-07|Estimate|May 2003||2003-05-31|July 2015|2015-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)|A Multicenter, Randomized, Parallel Groups, Placebo-controlled Study Comparing the Efficacy, Safety, and Tolerability of the Daily Coadministration of Ezetimibe 10 mg With Atorvastatin 10 mg in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease for Whom Diet and Exercise Have Failed.|Completed||Phase 3|122|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:17:19.075085|2018-06-01 02:17:19.075085
NCT00650676|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2010-09-19|2008-04-01|2008-04-02|Estimate|||||||2010-09-19|2010-09-21|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|March 2009|Actual|2009-03-31||Observational|||The Effect of Somatosensory Cue on Postural Stability in Blinded Persons|The Effect of Somatosensory Cue on Postural Stability in Blinded Persons|Completed|||60|Anticipated|Soroka University Medical Center|||1||f||||t||||||||||2018-06-01 02:17:19.145268|2018-06-01 02:17:19.145268
NCT00650663|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2017-05-10|2008-03-31|2008-04-02|Estimate|||||||2017-05-10|2017-05-11|Actual|October 1, 2003|Actual|2003-10-01|May 2017|2017-05-31|September 1, 2004|Actual|2004-09-01|September 1, 2004|Actual|2004-09-01||Interventional|||Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)|A Multicenter, Double-Blind, Randomized Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of Ezetimibe Coadministered With Simvastatin Versus Simvastatin Monotherapy in African-American Subjects With Primary Hypercholesterolemia|Completed||Phase 4|247|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:17:19.267505|2018-06-01 02:17:19.267505
NCT00650650|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2009-04-20|2008-03-28|2008-04-02|Estimate|||||||2009-04-20|2009-04-21|Estimate|March 2008||2008-03-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Comparison of Ultrasound Versus Radiography for Diagnosis of Nasal Fractures|Comparison of Ultrasound Versus Radiography for Diagnosis of Nasal Fractures|Completed|||80|Anticipated|Klinikum der Universitaet Muenchen, Grosshadern|||||f||||f||||||||||2018-06-01 02:17:19.329914|2018-06-01 02:17:19.329914
NCT00650637|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2011-06-03|2008-04-01|2008-04-02|Estimate|||||||2011-06-03|2011-06-08|Estimate|January 2003||2003-01-31|June 2011|2011-06-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea|A Randomized, Open-Label, Third-Party Blinded Study for the Prophylaxis and Treatment of Nelfinavir-associated Diarrhea|Terminated||Phase 3|17|Actual|Pfizer||2||"The study was prematurely discontinued due to administrative reasons on August 18, 2003. There~   were no safety concerns that led to the decision to terminate."|f||||t||||||||||2018-06-01 02:17:19.374929|2018-06-01 02:17:19.374929
NCT00650624|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-04-07|2008-03-31|2008-04-02|Estimate|||||||2008-04-07|2008-04-10|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|January 2004|Actual|2004-01-31|||||Interventional|||A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)|A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg QD Versus Placebo In Patients With OA Of The Knee|Completed||Phase 2|416|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:17:19.465147|2018-06-01 02:17:19.465147
NCT00650611|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-03-31|2008-04-02|Estimate|||||||2008-04-07|2008-04-10|Estimate|December 2003||2003-12-31|April 2008|2008-04-30|March 2005|Actual|2005-03-31|||||Interventional|||A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders|A 27-Week Open-Label Trial To Characterize The Safety And Tolerability Of Orally Administered Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed), Schizophrenia Or Schizoaffective Disorder|Completed||Phase 2|63|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:17:19.562023|2018-06-01 02:17:19.562023
NCT00650598|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-10-06|2008-04-01|2008-04-02|Estimate|||||||2008-10-06|2008-10-08|Estimate|March 2004||2004-03-31|October 2008|2008-10-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy for Anterior Cruciate Ligament (ACL) Reconstruction|A Multicentre, Double-Blind, Double-Dummy, Randomised Study of the Analgesic Efficacy and Safety of Valdecoxib Compared to Diclofenac Sodium in Patients Undergoing Knee Arthroscopy Procedure for Anterior Cruciate Ligament Reconstruction|Completed||Phase 4|328|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:17:19.657437|2018-06-01 02:17:19.657437
NCT00650585|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|2009-07-27||2013-06-05|2008-04-01|2008-04-02|Estimate|2009-10-14|2009-10-21|Estimate||||2013-06-05|2013-06-13|Estimate|May 2004||2004-05-31|June 2013|2013-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||An Effectiveness Trial of Project ALERT|Promising Programs for Substance Abuse Prevention: Replication and Evaluation Initiative|Completed||N/A|8338|Actual|Pacific Institute for Research and Evaluation||2|||f||||f||||||||||2018-06-01 02:17:19.765009|2018-06-01 02:17:19.765009
NCT00650572|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2013-03-06|2008-03-31|2008-04-02|Estimate|||||||2013-03-06|2013-03-07|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of ARRY-380 in Patients With Advanced HER2+ Cancer||Completed||Phase 1|50|Actual|Array BioPharma||1|||f||||f||||||||||2018-06-01 02:17:20.049678|2018-06-01 02:17:20.049678
NCT00650559|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-03-28|2008-03-28|2008-04-01|Estimate|||||||2008-03-28|2008-04-01|Estimate|June 2004||2004-06-30|March 2008|2008-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|TE||Thorax Enlarging Surgery: a Novel Surgical Approach to Emphysema|Chest Wall Enlargement by Widening Sternotomy in Patients With Severe Emphysema: a Feasibility Trial.|Terminated||N/A|4|Actual|Katholieke Universiteit Leuven||1||post-surgical complications in the last 2 patients|f||||f||||||||||2018-06-01 02:17:20.113565|2018-06-01 02:17:20.113565
NCT00650546|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2015-08-31||2017-03-13|2008-03-28|2008-04-01|Estimate|2016-04-07|2016-05-12|Estimate||||2017-03-13|2017-04-11|Actual|August 2006||2006-08-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|NAFLD|eight adult patients with known type 2 DM and biopsy -proven NAFLD were treated with 5-10 subcutaneous exenatide for 28 weeks|Role of Exenatide in NASH-a Pilot Study|Role of Exenatide in Treatment of NASH-a Pilot Study|Completed||Phase 2/Phase 3|8|Actual|Indiana University|As a case series our findings are limited by a control group and a small number of subjects enrolled. These limitations are tempered by the single expert hepatologist and the stringent definitions for histological improvement, ((primary end point)..|1|||f||||f||||||||||2018-06-01 02:17:20.183147|2018-06-01 02:17:20.183147
NCT00650533|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Food Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg|Single-Dose Food In Vivo Bioequivalence Study of Glimepiride Tablets (1 mg; Mylan) to Amaryl® Tablets (1 mg; Aventis) in Healthy Volunteers|Completed||Phase 1|40|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:20.363317|2018-06-01 02:17:20.363317
NCT00650520|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2007||2007-05-31|March 2008|2008-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets|Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions|Completed||Phase 1|119|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:20.622303|2018-06-01 02:17:20.622303
NCT00650507|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2013-08-25|2008-03-27|2008-04-01|Estimate|||||||2013-08-25|2013-08-27|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical and Genomic Responses to Open Heart Surgery|Clinical and Genomic Responses to Open Heart Surgery: A Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning|Completed||Phase 3|300|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 02:17:20.693447|2018-06-01 02:17:20.693447
NCT00650494|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-11|2008-03-31|2008-04-01|Estimate|||||||2009-11-11|2009-11-13|Estimate|August 2005||2005-08-31|November 2009|2009-11-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg|Single-Dose Food in Vivo Bioequivalence Study of Valacyclovir Hydrochloride Tablets (1000 mg; Mylan) to Valtrex® Tablets (1000 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|66|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:20.7794|2018-06-01 02:17:20.7794
NCT00650481|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Fasting Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (5 mg; Mylan) and Ditropan XL® Tablets (5 mg; ALZA) in Healthy Volunteers|Completed||Phase 1|60|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:20.856018|2018-06-01 02:17:20.856018
NCT00650468|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2011-11-15|2008-03-28|2008-04-01|Estimate|||||||2011-11-15|2011-11-17|Estimate|November 1999||1999-11-30|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients|A Prospective, Randomized, Multi-Center Double-Blind Study of Early Corticosteroid Cessation vs. Long Term Corticosteroid Therapy With Prograf and CellCept in Primary Renal Transplant Patients|Completed||Phase 4|397|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 02:17:20.945912|2018-06-01 02:17:20.945912
NCT00154050|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-11|2005-09-09|2005-09-12|Estimate|||||||2006-09-11|2006-09-12|Estimate|May 2004||2004-05-31|September 2006|2006-09-30|July 2006||2006-07-31|||||Interventional|||High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty||Completed||N/A|22||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:42:26.164667|2018-06-01 04:42:26.164667
NCT00650455|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-07-18|2008-03-28|2008-04-01|Estimate|||||||2008-07-18|2008-07-21|Estimate|February 2003||2003-02-28|July 2008|2008-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients|Clinical Protocol for a Multicenter, Double-Blind, Randomized, Placebo Controlled, Comparison of the Efficacy and Safety of Bextra® (Valdecoxib) 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe RA Population|Completed||Phase 4|489|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:21.079502|2018-06-01 02:17:21.079502
NCT00650442|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System|Evaluation of the Adhesion Quality and Primary Dermal Irritation Potential of an Alternate Second Generation Estradiol Transdermal Systems in Normal Healthy Female Volunteers|Completed||Phase 1|39|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:21.318147|2018-06-01 02:17:21.318147
NCT00650429|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-03-28|2008-04-01|Estimate|||||||2008-04-07|2008-04-10|Estimate|October 2003||2003-10-31|April 2008|2008-04-30|May 2005|Actual|2005-05-31|||||Interventional|||A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder|Ziprasidone Intramuscular/Oral In The Treatment Of Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder: A Six-Week Open Administration Study|Completed||Phase 4|28|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:17:21.384516|2018-06-01 02:17:21.384516
NCT00650416|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Carvedilol Tablets (12.5 mg; Mylan) to Coreg® Tablets (12.5 mg; GSK) in Healthy Volunteers|Completed||Phase 1|50|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:21.463119|2018-06-01 02:17:21.463119
NCT00650403|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2006||2006-12-31|March 2008|2008-03-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Food Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg|Single-Dose Fed Bioequivalence Study of Paroxetine Hydrochloride Tablets (40 mg; Mylan) and Paxil® Tablets (40 mg; GSK) in Healthy Adult Volunteers|Completed||Phase 1|66|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:21.52472|2018-06-01 02:17:21.52472
NCT00650390|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-03-28|2008-03-28|2008-04-01|Estimate|||||||2008-03-28|2008-04-01|Estimate||||March 2008|2008-03-31||||||||Expanded Access|PROWD||Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab|Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab|Approved for marketing|||||Abbott|||||f||||||||||||||2018-06-01 02:17:21.584127|2018-06-01 02:17:21.584127
NCT00650377|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2004||2004-10-31|March 2008|2008-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Finasteride Tablets (5 mg; Mylan) to Proscar® Tablets (5 mg; Merck) in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:21.642488|2018-06-01 02:17:21.642488
NCT00650364|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2002||2002-08-31|March 2008|2008-03-31|September 2002|Actual|2002-09-30|August 2002|Actual|2002-08-31||Interventional|||Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Midodrine HCl Tablets (5 mg; Mylan) and ProAmatine® Tablets (5 mg; Roberts) in Healthy Volunteers|Completed||Phase 1|38|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:21.713283|2018-06-01 02:17:21.713283
NCT00650351|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg|Single-Dose Food In Vivo Bioequivalence Study of Ciprofloxacin Extended-Release Tablets (1000 mg; Mylan) and Cipro® XR Tablets (1000 mg; Bayer) in Healthy Volunteers|Completed||Phase 1|35|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:21.786468|2018-06-01 02:17:21.786468
NCT00650338|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-11-01|2008-03-31|2008-04-01|Estimate|||||||2011-11-01|2011-11-03|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension|A Randomized, Double-masked, Placebo- and Active- Controlled, Parallel-group, Multi-center, Dose-response Trial of DE-104 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 2|165|Anticipated|Santen Inc.||5|||f||||||||||||||2018-06-01 02:17:21.84496|2018-06-01 02:17:21.84496
NCT00650325|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Sertraline Hydrochloride Tablets (100 mg; Mylan) and Zoloft® Tablets (100 mg; Pfizer) in Healthy Volunteers|Completed||Phase 1|49|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:21.993522|2018-06-01 02:17:21.993522
NCT00650312|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|November 2002|Actual|2002-11-30|October 2002|Actual|2002-10-31||Interventional|||Fasting Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR Tablets (500 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|50|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.055734|2018-06-01 02:17:22.055734
NCT00650299|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Fed Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg|Single-Dose Food In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (3 mg; Mylan) to Xanax XR® Tablets (3 mg; Pharmacia & Upjohn) in Healthy Volunteers|Completed||Phase 1|21|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.119933|2018-06-01 02:17:22.119933
NCT00642486|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2010-05-25|2008-03-24|2008-03-25|Estimate|||||||2010-05-25|2010-05-27|Estimate|February 2008||2008-02-29|March 2008|2008-03-31|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|HomePAP||Portable Monitoring for Diagnosis and Management of Sleep Apnea|Portable Monitoring in the Diagnosis and Management of Obstructive Sleep Apnea|Completed||N/A|373|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-06-01 02:19:08.578297|2018-06-01 02:19:08.578297
NCT00650286|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2002||2002-09-30|March 2008|2008-03-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Food Study of Modafinil Tablets 200 mg to Provigil® Tablets 200 mg|Single-Dose Food In Vivo Bioequivalence Study of Modafinil Tablets (200 mg; Mylan) to Provigil® Tablets (200 mg; Cephalon) in Healthy Volunteers|Completed||Phase 1|20|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.180842|2018-06-01 02:17:22.180842
NCT00650273|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Azithromycin Tablets (600 mg; Mylan) to Zithromax® Tablets (600 mg; Pfizer) in Healthy Volunteers|Completed||Phase 1|54|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.243076|2018-06-01 02:17:22.243076
NCT00650260|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2010-08-05||2012-09-25|2008-03-31|2008-04-01|Estimate|2012-09-25|2012-10-29|Estimate||||2012-09-25|2012-10-29|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Intraoperative Warming Comparison of Devices|Intraoperative Warming : Comparison of Performance of the Dynatherm Medical vitalHEAT™ Temperature Management System (vH2) and the Arizant Bair Hugger System|Completed||N/A|42|Actual|University of South Florida||2|||f||||f||||||||||2018-06-01 02:17:22.309945|2018-06-01 02:17:22.309945
NCT00650247|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-30|2008-03-31|2008-04-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2004||2004-11-30|November 2009|2009-11-30|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Sumatriptan Succinate Tablets (100 mg; Mylan) to Imitrex® Tablets (100 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|57|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.536176|2018-06-01 02:17:22.536176
NCT00650234|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR Tablets (500 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|47|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.594701|2018-06-01 02:17:22.594701
NCT00650221|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects|A Two-Way Crossover, Open-Label, Single-Dose, Fasting, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|43|Actual|Mylan Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:17:22.653726|2018-06-01 02:17:22.653726
NCT00650208|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2004||2004-07-31|March 2008|2008-03-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Fasting Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Lamotrigine Tablets (25 mg; Mylan) to Lamictal® Tablets (25 mg; GSK) in Healthy Volunteers|Completed||Phase 1|27|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.840575|2018-06-01 02:17:22.840575
NCT00650195|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|||Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (10 mg; Mylan) and Zaroloxyn® Tablets (10 mg; Celltech) in Healthy Volunteers|Completed||Phase 1|56|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:22.904941|2018-06-01 02:17:22.904941
NCT00650182|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2011-05-18|2008-03-28|2008-04-01|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2003||2003-01-31|April 2010|2010-04-30|July 2003|Actual|2003-07-31|||||Interventional|||A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant|Safety Evaluation of D-TRANS Fentanyl With Naltrexone HCL in Opioid Tolerant Patients (ALZA C-2002-022)|Completed||Phase 2|406|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 02:17:22.974354|2018-06-01 02:17:22.974354
NCT00650169|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg|Single-Dose Food In Vivo Bioequivalence Study of Clopidogrel Bisulfate Tablets (75 mg; Mylan) to Plavix® Tablets (75 mg; Bristol-Myers Squibb/Sanofi) in Healthy Volunteers|Completed||Phase 1|47|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:23.039526|2018-06-01 02:17:23.039526
NCT00650156|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2017-11-16|2008-03-28|2008-04-01|Estimate|||||||2017-11-16|2017-11-20|Actual|June 2007||2007-06-30|September 2010|2010-09-30||||October 2007|Actual|2007-10-31||Interventional|||Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis|A Randomized, Parallel-group, Open-Label, Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis.|Completed||Phase 1|24|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 02:17:23.099524|2018-06-01 02:17:23.099524
NCT00650143|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-07-07|2008-03-31|2008-04-01|Estimate|||||||2011-07-07|2011-07-08|Estimate|March 2008||2008-03-31|July 2011|2011-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|SITAGRAMI||Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction|Safety and Efficacy of Sitagliptin Plus Granulocyte-colony Stimulating Factor in Patients Suffering From Acute Myocardial Infarction|Unknown status|Recruiting|Phase 2/Phase 3|174|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 02:17:23.167633|2018-06-01 02:17:23.167633
NCT00650130|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2013-11-01|2008-03-31|2008-04-01|Estimate|||||||2013-11-01|2013-11-04|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|December 2008|Actual|2008-12-31||Observational|||Whole Blood-plasma-oral Fluid Ratios of Psychoactive Drugs and Medicines|DRUID Sub-study: Substance Concentration Ratio/Impairment|Completed|||300|Actual|National Institute for Health and Welfare, Finland|||1||f||||f||||||Samples With DNA|"~     Blood samples and oral fluid are collected for the study. However no DNA detection is done at~     any stage. The laboratory where samples are analysed do not analyse DNA. DNA is not relevant~     to this study.~   "|||2018-06-01 02:17:23.247955|2018-06-01 02:17:23.247955
NCT00646269|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2013-07-31|2008-03-25|2008-03-28|Estimate|||||||2013-07-31|2013-08-01|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|ETNA3||Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease|Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease|Completed||Phase 3|640|Actual|University Hospital, Bordeaux||4|||f||||t||||||||||2018-06-01 02:18:05.924259|2018-06-01 02:18:05.924259
NCT00650117|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2006||2006-10-31|March 2008|2008-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System|Single-Dose In Vivo Bioequivalence and Wear Study of Fentanyl Transdermal System (25 µg/h; Mylan) and Fentanyl Transdermal System With Overlay (25 µg/h; Mylan) in Healthy Volunteers|Completed||Phase 1|12|Actual|Mylan Pharmaceuticals||6|||f||||||||||||||2018-06-01 02:17:23.304621|2018-06-01 02:17:23.304621
NCT00650104|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2010-02-24||2013-05-02|2008-03-31|2008-04-01|Estimate|2010-04-02|2010-04-21|Estimate||||2013-05-02|2013-05-06|Estimate|May 2002||2002-05-31|April 2013|2013-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164|101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164|Completed||Phase 3|76|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:17:23.476225|2018-06-01 02:17:23.476225
NCT00650091|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2014-07-31||2015-05-27|2008-03-28|2008-04-01|Estimate|2015-05-27|2015-06-02|Estimate||||2015-05-27|2015-06-02|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|PANTHER-IPF||Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF|Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF|Completed||Phase 3|264|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:17:24.140238|2018-06-01 02:17:24.140238
NCT00650078|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2012-11-01|2011-03-15|2013-04-23|2008-03-31|2008-04-01|Estimate|2012-11-15|2012-12-13|Estimate|2011-03-15|2011-03-25|Estimate|2013-04-23|2013-04-30|Estimate|March 2008||2008-03-31|April 2013|2013-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|CAPRA-2||Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis|A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients With Rheumatoid Arthritis|Completed||Phase 3|350|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||f||||||||||2018-06-01 02:17:24.679504|2018-06-01 02:17:24.679504
NCT00650065|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Cetirizine HCl Tablets (10 mg; Mylan) and Zyrtec® Tablets (10 mg; Pfizer) in Healthy Volunteers|Completed||Phase 1|26|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:25.107272|2018-06-01 02:17:25.107272
NCT00650052|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2003||2003-11-30|March 2008|2008-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Zonisamide Capsules (100 mg; Mylan) to Zonegran® Capsules (100 mg; Elan) in Healthy Volunteers|Completed||Phase 1|107|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:25.178851|2018-06-01 02:17:25.178851
NCT00650039|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-06-03|2008-03-28|2008-04-01|Estimate|||||||2008-06-03|2008-06-04|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|February 2005|Actual|2005-02-28|||||Interventional|||Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction|A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg QD And Valdecoxib 20 Mg BID Compared To Placebo Over Multiple Days For Management Of Acute Postsurgical Pain In Patients Undergoing Anterior Cruciate Ligament Reconstruction|Completed||Phase 3|488|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:25.281203|2018-06-01 02:17:25.281203
NCT00650026|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-04-10|2008-03-27|2008-04-01|Estimate|||||||2008-04-10|2008-04-14|Estimate||||April 2008|2008-04-30||||||||Expanded Access|ReAct||Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis|Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis|Approved for marketing|||||Abbott|||||f||||||||||||||2018-06-01 02:17:25.427046|2018-06-01 02:17:25.427046
NCT00650013|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2002||2002-07-31|March 2008|2008-03-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Midodrine HCl Tablets (5 mg; Mylan) and ProAmatine® Tablets (5 mg; Roberts) in Healthy Volunteers|Completed||Phase 1|23|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:25.477902|2018-06-01 02:17:25.477902
NCT00650000|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Fasting Study of Modafinil Tablets 200 mg and Provigil® Tablets 200 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Modafinil Tablets (200 mg; Mylan) and Provigil® Tablets (200 mg; Cephalon) in Healthy Volunteers|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:25.535322|2018-06-01 02:17:25.535322
NCT00649987|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Fed Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg|Single-Dose Fed Bioequivalence Study of Albuterol Sulfate Extended-Release Tablets (8 mg; Mylan) and VoSpire® ER Tablets (8 mg; Pliva) in Healthy Volunteers|Completed||Phase 1|21|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:25.590652|2018-06-01 02:17:25.590652
NCT00649974|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|May 2005||2005-05-31|November 2009|2009-11-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Fasting Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Valacyclovir Hydrochloride Tablets (1000 mg; Mylan) to Valtrex® Tablets (1000 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:25.650378|2018-06-01 02:17:25.650378
NCT00649961|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2014-01-13||2017-01-18|2008-03-31|2008-04-01|Estimate|2014-01-13|2014-02-28|Estimate||||2017-01-18|2017-03-03|Actual|May 2010||2010-05-31|January 2011|2011-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|MIND|less than 31 weeks gestation|Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study|Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study|Completed||Phase 2|18|Actual|Imperial College London|||||f||||f||||||||||2018-06-01 02:17:26.64117|2018-06-01 02:17:26.64117
NCT00649948|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|June 2004|Actual|2004-06-30|May 2004|Actual|2004-05-31||Interventional|||Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mg|Single-Dose Food In Vivo Bioequivalence Study Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR (500 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|27|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:26.848305|2018-06-01 02:17:26.848305
NCT00649935|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2005||2005-05-31|March 2008|2008-03-31|June 2005|Actual|2005-06-30|May 2005|Actual|2005-05-31||Interventional|||Fed Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg|Single-Dose Fed In Vivo Bioequivalence Study of Azithromycin Tablets (600 mg; Mylan) to Zithromax® Tablets (600 mg; Pfizer) in Healthy Volunteers|Completed||Phase 1|54|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:26.908424|2018-06-01 02:17:26.908424
NCT00649922|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|February 2005|Actual|2005-02-28|December 2004|Actual|2004-12-31||Interventional|||Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis|Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis|Completed||Phase 4|226|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:17:26.96735|2018-06-01 02:17:26.96735
NCT00649909|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2017-08-09|2008-03-31|2008-04-01|Estimate|||||||2017-08-09|2017-08-10|Actual|November 2008||2008-11-30|August 2017|2017-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients|Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients|Completed|||18|Actual|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 02:17:27.024589|2018-06-01 02:17:27.024589
NCT00649896|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day|Comparative Evaluation of the Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System (0.025 mg/Day; Mylan) and Climara® Transdermal System (0.025 mg/Day; Berlex) in Healthy Postmenopausal Female Volunteers|Completed||Phase 1|76|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:27.08019|2018-06-01 02:17:27.08019
NCT00649883|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2017-04-05|2008-03-27|2008-04-01|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2008||2008-01-31|April 2017|2017-04-30|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months|A Phase II, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Investigational Vaccine and Active Influenza Vaccine in Healthy Children Aged 6 to <60 Months|Completed||Phase 2|360|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:17:27.145681|2018-06-01 02:17:27.145681
NCT00649870|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|May 2005||2005-05-31|November 2009|2009-11-30|June 2005|Actual|2005-06-30|May 2005|Actual|2005-05-31||Interventional|||Food Study of Valacyclovir Hydrochloride Tablets 1000 mg to Valtrex® Tablets 1000 mg|Single-Dose Food In Vivo Bioequivalence Study of Valacyclovir Hydrochloride Tablets (1000 mg; Mylan) to Valtrex® Tablets (1000 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|26|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:27.330923|2018-06-01 02:17:27.330923
NCT00649857|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg|Single-Dose Food In Vivo Bioequivalence Study of Cetirizine HCl Tablets (10 mg; Mylan) and Zyrtec® (10 mg; Pfizer) in Healthy Volunteers|Completed||Phase 1|18|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:27.410013|2018-06-01 02:17:27.410013
NCT00649844|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2009-09-24|2008-03-31|2008-04-01|Estimate|||||||2009-09-24|2009-09-25|Estimate|January 2003||2003-01-31|September 2009|2009-09-30|September 2004|Actual|2004-09-30|||||Interventional|MOZART||A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs|Double Blind, Double-Dummy Multicenter, Parallel Group Comparison Of The Efficacy And The Tolerability Of Ziprasidone Vs. Clozapine In Schizophrenic Patients Who Are Refractory And/Or Intolerant To Antipsychotic Therapy|Completed||Phase 3|147|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:17:27.48759|2018-06-01 02:17:27.48759
NCT00649831|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-10-20|2008-03-27|2008-04-01|Estimate|||||||2008-10-20|2008-10-21|Estimate|October 2002||2002-10-31|October 2008|2008-10-31|June 2003|Actual|2003-06-30|||||Interventional|||A Multicentre, Randomised, Open-Label Study To Compare The Efficacy And Safety Of Azithromycin For 5 Days With Those Of Amoxicillin-Clavulanic Acid In Patients With Chronic Bronchitis|Azithromycin (Zithromax®) 5 Days Versus Amoxicillin-Clavulanic Acid (Augmentin®): Multicentre, Randomised, Open-Label Study To Compare The Clinical Efficacy And Safety Of Azithromycin With Those Of Amoxicillin-Clavulanic Acid In Patients Presenting With An Exacerbation Of Chronic Bronchitis|Completed||Phase 3|250|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 02:17:27.603935|2018-06-01 02:17:27.603935
NCT00649818|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Lorazepam Tablets (2 mg; Mylan) and Ativan Tablets (2 mg; Wyeth) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:27.722708|2018-06-01 02:17:27.722708
NCT00649805|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fasting Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg;Mylan) and Verelan® PM Extended-Release Capsules (300 mg; Schwarz) Sprinkled on Applesauce in Healthy Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:27.78393|2018-06-01 02:17:27.78393
NCT00649610|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-03-28|2008-04-01|Estimate|||||||2008-04-07|2008-04-10|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|May 2003|Actual|2003-05-31|||||Interventional|||Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain|Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily vs. Diclofenac 75 mg Twice Daily in Subjects With Acute Low Back Pain|Completed||Phase 4|340|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:17:29.300921|2018-06-01 02:17:29.300921
NCT00649792|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2012-01-25||2012-02-24|2008-03-28|2008-04-01|Estimate|2012-01-25|2012-02-27|Estimate||||2012-02-24|2012-02-28|Estimate|August 2007||2007-08-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial|Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial|Completed||Phase 3|214|Actual|Acorda Therapeutics|||||f||||t||||||||||2018-06-01 02:17:27.874507|2018-06-01 02:17:27.874507
NCT00649779|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg|Single-Dose Fasting Bioequivalence Study of Albuterol Sulfate Extended-Release Tablets (8 mg; Mylan) and VoSpire® ER Tablets (8 mg; Pliva) in Healthy Volunteers|Completed||Phase 1|21|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:28.322105|2018-06-01 02:17:28.322105
NCT00649766|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-03-28|2008-03-28|2008-04-01|Estimate|||||||2008-03-28|2008-04-01|Estimate|June 2006||2006-06-30|March 2008|2008-03-31|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Tailored Messages to Increase Eye Examination Behavior|Tailored Messages to Increase Eye Examination Behavior|Unknown status|Active, not recruiting|N/A|330|Actual|National Eye Institute (NEI)||2|||f||||f||||||||||2018-06-01 02:17:28.396212|2018-06-01 02:17:28.396212
NCT00649753|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2009-07-22|2008-03-31|2008-04-01|Estimate|||||||2009-07-22|2009-07-23|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Algometer||Algometer and Category II Pelvic Blocking and Cranial Protocol|An Investigation of Algometer Readings for DeJarnette Category II Indicators After Category II Blocking and Cranial Protocol|Completed||N/A|40|Anticipated|Logan College of Chiropractic||4|||f||||||||||||||2018-06-01 02:17:28.496852|2018-06-01 02:17:28.496852
NCT00649740|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg|Single-Dose Fasting Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:28.565059|2018-06-01 02:17:28.565059
NCT00649727|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2002||2002-07-31|March 2008|2008-03-31|August 2002|Actual|2002-08-31|July 2002|Actual|2002-07-31||Interventional|||Fed Study of Oxybutynin Chloride Extended-Release Tablets 10 mg and Ditropan XL® Tablets 10 mg|Single-Dose Food In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (10 mg; Mylan) and Ditropan XL® Tablets(10 mg; ALZA) in Healthy Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:28.641716|2018-06-01 02:17:28.641716
NCT00649714|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Zonisamide Capsules (100 mg; Mylan) to Zonegran® Capsules (100 mg; Elan) in Healthy Volunteers|Completed||Phase 1|110|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:28.717346|2018-06-01 02:17:28.717346
NCT00649701|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-06-19|2008-03-31|2008-04-01|Estimate|||||||2008-06-19|2008-06-20|Estimate|April 2008||2008-04-30|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|5Part||Novel Internet-Based Interventions to Reduce Sexual Risk Among Men Who Have Sex With Men|Phase 1 Online Intervention to Reduce Sexual Risk Among Men Who Have Sex With Men|Unknown status|Active, not recruiting|Phase 1|3097|Actual|Public Health Solutions||5|||f||||t||||||||||2018-06-01 02:17:28.788385|2018-06-01 02:17:28.788385
NCT00649688|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets (100/50 mg; Mylan) and Lopressor HCT® Tablets (100/50 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:28.883192|2018-06-01 02:17:28.883192
NCT00649675|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg|Single-Dose Food In Vivo Bioequivalence Study of Meloxicam Tablets (15 mg; Mylan) and Mobic® Tablets (15 mg; Boehringer Ingelheim) in Healthy Volunteers|Completed||Phase 1|27|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:28.959974|2018-06-01 02:17:28.959974
NCT00649662|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ciprofloxacin Extended-Release Tablets (1000 mg; Mylan) and Cipro® XR Tablets (1000 mg; Bayer) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.031494|2018-06-01 02:17:29.031494
NCT00649649|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Food Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg|Single-Dose Food In Vivo Bioequivalence Study of Quinapril Hydrochloride Tablets (40 mg; Mylan) and Accupril® Tablets (40 mg; Parke-Davis) in Healthy Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.103721|2018-06-01 02:17:29.103721
NCT00649636|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Fasting Study of Fluoxetine Capsules 40 mg and Prozac Pulvules 40 mg|Single-Dose Fasting Bioequivalence Study of Fluoxetine Capsules (40 mg; Mylan) and Prozac Pulvules (40 mg; Dista) in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.174157|2018-06-01 02:17:29.174157
NCT00649623|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.2338|2018-06-01 02:17:29.2338
NCT00649597|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|56|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.416878|2018-06-01 02:17:29.416878
NCT00649584|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2014-12-17|2008-03-27|2008-04-01|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies|A Phase I Dose Escalation Study of Weekly SGN-35 Monotherapy and in Combination With Gemcitabine in Patients With Relapsed/Refractory CD30-positive Hematologic Malignancies|Terminated||Phase 1|44|Actual|Seattle Genetics, Inc.||1||Sponsor decision not to enroll cohorts of combined SGN-35 and gemcitabine therapy.|f||||f||||||||||2018-06-01 02:17:29.47605|2018-06-01 02:17:29.47605
NCT00649571|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Fasting Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Doxycycline Monohydrate Tablets (100 mg; Mylan) and Adoxa Tablets (100 mg; Par) in Healthy Volunteers|Completed||Phase 1|35|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.560605|2018-06-01 02:17:29.560605
NCT00649558|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|February 2003||2003-02-28|March 2008|2008-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Pioglitazone HCl Tablets (45 mg; Mylan) and Actos® Tablets (45 mg; Takeda) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.700368|2018-06-01 02:17:29.700368
NCT00649545|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate||||March 2008|2008-03-31||||||||Expanded Access|CanAct||Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis|A Multi-Center Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Active Rheumatoid Arthritis|Approved for marketing|||||Abbott|||||f||||||||||||||2018-06-01 02:17:29.808694|2018-06-01 02:17:29.808694
NCT00649532|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ondansetron Tablets (24 mg; Mylan) and Zofran® Tablets (24 mg; GSK) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:29.918909|2018-06-01 02:17:29.918909
NCT00649519|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|54|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:30.029106|2018-06-01 02:17:30.029106
NCT00649506|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2003||2003-09-30|March 2008|2008-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mg|Single-Dose Food In Relative Bioavailability Study of Mylan Nitrofurantoin Macrocrystals 100 mg Capsules and Procter & Gamble Macrodantin® 100 mg Capsules in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:30.106374|2018-06-01 02:17:30.106374
NCT00649493|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|May 2003||2003-05-31|November 2009|2009-11-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg|Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Tablets (20 mg; Mylan) and Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers|Completed||Phase 1|72|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:30.257983|2018-06-01 02:17:30.257983
NCT00649480|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2007||2007-01-31|December 2006|2006-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Fed Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg|Single-Dose Fed Bioequivalence Study of Balsalazide Disodium Capsules (750 mg; Mylan) and Colazal® Capsules (750 mg; Salix) in Healthy Volunteers|Completed||Phase 1|60|Actual|Mylan Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:17:30.552646|2018-06-01 02:17:30.552646
NCT00649467|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Applesauce Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg|Single-Dose Fasting Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers Dosed With Applesauce|Completed||Phase 1|35|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:30.660951|2018-06-01 02:17:30.660951
NCT00649454|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|June 2005||2005-06-30|March 2008|2008-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Fasting Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Glipizide and Metformin HCl Tablets (5 mg/500 mg; Mylan) to Metaglip® Tablets (5 mg/500 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:30.740848|2018-06-01 02:17:30.740848
NCT00649441|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Quinapril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Accuretic™ Tablets (20 mg/25 mg; Parke-Davis) in Healthy Volunteers|Completed||Phase 1|60|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:30.84424|2018-06-01 02:17:30.84424
NCT00104078|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-22|||2007-12-19|2005-02-22|2005-02-23|Estimate|||||||2007-12-19|2007-12-28|Estimate|February 2005||2005-02-28|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Study Evaluating MYO-029 in Adult Muscular Dystrophy||Completed||Phase 1/Phase 2|108||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:58:17.223293|2018-06-01 04:58:17.223293
NCT00649415|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-03-28|2008-04-01|Estimate|||||||2008-04-07|2008-04-10|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|July 2003|Actual|2003-07-31|||||Interventional|||A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea|A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg BID, PRN In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea|Completed||Phase 4|154|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:17:31.671189|2018-06-01 02:17:31.671189
NCT00649402|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg|Single-Dose Food in Vivo Bioequivalence Study of Amlodipine and Benazepril HCl Capsules (10 mg/20 mg; Mylan) to Lotrel® Capsules (10 mg/20 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|64|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:31.899905|2018-06-01 02:17:31.899905
NCT00649389|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2010-08-09|2010-04-07|2010-08-31|2008-03-31|2008-04-01|Estimate|2010-08-09|2010-09-01|Estimate|2010-04-07|2010-04-09|Estimate|2010-08-31|2010-09-08|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension|A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension|Completed||Phase 3|2500|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-06-01 02:17:32.066603|2018-06-01 02:17:32.066603
NCT00649376|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra® Tablets (180 mg; Aventis) in Healthy Adult Volunteers|Completed||Phase 1|68|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:33.583551|2018-06-01 02:17:33.583551
NCT00649363|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ondansetron Orally Disintegrating Tablets (8 mg; Mylan) to Zofran ODT® Tablets (8 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:33.674441|2018-06-01 02:17:33.674441
NCT00649350|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Food Study Metformin Hydrochloride ER Tablets 750 mg and Glucophage XR 750 mg|Single-Dose Food In Vivo Bioequivalence Study Metformin Hydrochloride ER Tablets (750 mg; Mylan) and Glucophage XR (750 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:33.799625|2018-06-01 02:17:33.799625
NCT00649337|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-27|2008-03-27|2008-04-01|Estimate|||||||2008-03-27|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|January 2010|Anticipated|2010-01-31|July 2008|Anticipated|2008-07-31||Interventional|||Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Mammography, Including Cost Comparisons|Earlier Breast Cancer Detection Using Automated Whole Breast Ultrasound With Screening Mammography, Including Cost Comparisons|Unknown status|Recruiting|N/A|4650|Anticipated|SonoCine, Inc.||1|||f||||t||||||||||2018-06-01 02:17:33.868412|2018-06-01 02:17:33.868412
NCT00649324|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Fasting Study of Hydrochlorothiazide Tablets 50 mg to Hydrochlorothiazide Tablets 50 mg|Single-Dose Fasting In-Vivo Bioequivalence Study of Hydrochlorothiazide Tablets (50 mg; Mylan) to Hydrochlorothiazide Tablets (50 mg; Ivax) in Healthy Volunteers|Completed||Early Phase 1|40|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:33.989396|2018-06-01 02:17:33.989396
NCT00649311|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2009-11-30|2008-03-27|2008-04-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|April 2003||2003-04-30|November 2009|2009-11-30|September 2003|Actual|2003-09-30|||||Interventional|||A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension|Clinical Protocol For A Double-Blind, Randomized, Active- Controlled Comparison Study Of The Antihypertensive Effect Of Eplerenone Versus Losartan In Patients With Mild To Moderate Hypertension|Terminated||Phase 2|248|Actual|Pfizer||2||Poor enrollment; termination not due to safety reasons.|f||||f||||||||||2018-06-01 02:17:34.058637|2018-06-01 02:17:34.058637
NCT00649298|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2015-06-23|2008-03-31|2008-04-01|Estimate|||||||2015-06-23|2015-06-24|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|ACTIVE||A Clinical Trial of IntensiVE Dialysis|ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease.|Completed||Phase 4|200|Actual|The George Institute||2|||f||||t||||||||||2018-06-01 02:17:34.152139|2018-06-01 02:17:34.152139
NCT00649285|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Food Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg and Macrobid® Capsules 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Nitrofurantoin Monohydrate/Macrocrystals Capsules (100 mg; Mylan) and Macrobid® Capsules (100 mg; Procter & Gamble) in Healthy Volunteers|Completed||Phase 1|71|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:34.286551|2018-06-01 02:17:34.286551
NCT00649272|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg|Single-Dose Fasting Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (15 mg; Mylan)and Ditropan XL® Tablets (15 mg; ALZA) in Healthy Volunteers|Completed||Phase 1|80|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:34.383278|2018-06-01 02:17:34.383278
NCT00648583|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Food Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg|Single-Dose Food In Vivo Bioequivalence Study of Ondansetron Tablets (24 mg; Mylan) and Zofran® Tablets (24 mg; GSK) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:39.977816|2018-06-01 02:17:39.977816
NCT00649259|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg|Single-Dose Food In Vivo Bioequivalence Study of Oxybutynin Chloride ER Tablets (10 mg; Mylan) and Ditropan XL® Tablets (10 mg; ALZA) in Healthy Volunteers|Completed||Phase 1|39|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:34.478245|2018-06-01 02:17:34.478245
NCT00649246|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2018-03-26|2008-03-28|2008-04-01|Estimate|||||||2018-03-26|2018-03-27|Actual|July 1997||1997-07-31|March 2018|2018-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|PANDA||Prospective Assessment in Newborns for Diabetes Autoimmunity|1. Prospective Studies in Infants of the Immunopathogenesis of Type 1 Diabetes 2. Consortium for Identification of Environmental Triggers of Type 1 Diabetes: MCG/UF Clinical Center 3. Identification of Serum Protein Markers for Type 1 Diabetes Using Mass-Spectrometry Techniques 4. Validation of Microarray-Based Biomarkers for Type 1 Diabetes 5. Development of Microarray-Based Biomarkers for Type 1 Diabetes 6. Proteomic Changes/Progression of Human Type 1 Diabetes 7. Identification and Validation of Serum Biomarkers for T1D|Completed|||25055|Actual|Augusta University|||3||f||||t||||||Samples With DNA|"~     whole blood, DNA, serum, RNA, urine~   "|||2018-06-01 02:17:34.561555|2018-06-01 02:17:34.561555
NCT00649233|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg|Single-Dose Food In Vivo Bioequivalence Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets (100/50 mg; Mylan) to Lopressor HCT® Tablets (100/50 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:34.628526|2018-06-01 02:17:34.628526
NCT00649220|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2011-08-09||2011-09-22|2008-03-27|2008-04-01|Estimate|2011-08-09|2011-09-13|Estimate||||2011-09-22|2011-09-26|Estimate|July 2008||2008-07-31|September 2011|2011-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|MemAP||Memantine and Antipsychotics Use|Prospective, Single-arm, Multi-centre, Open-label Study to Investigate the Potential to Reduce Concomitant Antipsychotics Use in Patients With Moderate to Severe Dementia of Alzheimer's Type (DAT) Treated With Memantine|Terminated||Phase 4|19|Actual|Merz Pharmaceuticals GmbH|Early termination due to too slow enrollment lead to a small sample size, limiting the ability for confirmatory analysis. All analysis of the primary efficacy endpoint were treated as exploratory.|1||Study terminated due to too slow enrollment|f||||f||||||||||2018-06-01 02:17:34.703506|2018-06-01 02:17:34.703506
NCT00649207|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2017-11-17|2008-03-28|2008-04-01|Estimate|||||||2017-11-17|2017-11-21|Actual|March 2008||2008-03-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases|A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases|Completed||Phase 1|80|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 02:17:34.925464|2018-06-01 02:17:34.925464
NCT00649194|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg|Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Delayed-Release Tablets (20 mg; Mylan) to Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers|Completed||Phase 1|72|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.012054|2018-06-01 02:17:35.012054
NCT00649181|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (5 mg; Mylan) and Zaroloxyn® Tablets (5 mg; Celltech) in Healthy Volunteers|Completed||Phase 1|52|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.186894|2018-06-01 02:17:35.186894
NCT00649168|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|April 2007||2007-04-30|March 2008|2008-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg|Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg Bromocriptine Mesylate Capsules Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions|Completed||Phase 1|120|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.255132|2018-06-01 02:17:35.255132
NCT00649155|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Ciprofloxacin Extended-Release Tablets (500 mg; Mylan) and Cipro® XR Tablets (500 mg; Bayer) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.330853|2018-06-01 02:17:35.330853
NCT00649142|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2009-01-20|2008-03-31|2008-04-01|Estimate|||||||2009-01-20|2009-01-22|Estimate|January 2007||2007-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Predisposing Factors for Chronic Postherniotomy Pain|Prospective Study of Predisposing Factors for Chronic Postherniotomy Pain|Completed||N/A|455|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:17:35.404075|2018-06-01 02:17:35.404075
NCT00649129|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2002||2002-07-31|March 2008|2008-03-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride ER Tablets (10 mg; Mylan) and Ditropan XL® Tablets (10 mg; ALZA) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.493208|2018-06-01 02:17:35.493208
NCT00649116|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Metoprolol Tartrate Tablets (100 mg; Mylan) and Lopressor® (100 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|20|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.577768|2018-06-01 02:17:35.577768
NCT00647517|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-03-31|2008-03-28|2008-03-31|Estimate|||||||2010-03-31|2010-04-01|Estimate|March 2008||2008-03-31|January 2008|2008-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|CS07102||Tramadol/Acetaminophen(Ultracet) AS add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis|Chung Shan Medical University Hospital, Taiwan|Completed||Phase 4|60|Actual|Chung Shan Medical University||2|||f||||f||||||||||2018-06-01 02:17:49.68421|2018-06-01 02:17:49.68421
NCT00649103|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Fasting Study of Quinapril Hydrochloride Tablets 40 mg and Accupril® Tablets 40 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Quinapril Hydrochloride Tablets (40 mg; Mylan) and Accupril® Tablets (40 mg; Parke-Davis) in Healthy Volunteers|Completed||Phase 1|60|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.68052|2018-06-01 02:17:35.68052
NCT00649090|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-09-25|2008-03-27|2008-04-01|Estimate|||||||2008-09-25|2008-09-29|Estimate|March 2005||2005-03-31|September 2008|2008-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer|A Phase 4, Open-Label Exemestane Adjuvant Safety Surveillance Program: Adjuvant Exemestane (Aromasin) Treatment Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer (IES Inclusion Criteria)|Completed||Phase 4|1549|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:17:35.751073|2018-06-01 02:17:35.751073
NCT00649077|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Meloxicam Tablets (15 mg; Mylan) and Mobic® Tablets (15 mg; Boehringer Ingelheim) in Healthy Volunteers|Completed||Phase 1|30|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:35.876239|2018-06-01 02:17:35.876239
NCT00649064|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-03-28|2008-04-01|Estimate|||||||2008-04-07|2008-04-10|Estimate|December 2003||2003-12-31|April 2008|2008-04-30|September 2004|Actual|2004-09-30|||||Interventional|||A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs|A Multi-Center Study To Examine The Clinical Effects Of Cross Titration Of Antipsychotics With Ziprasidone In Subjects With Schizophrenia Or Schizoaffective Disorder|Completed||Phase 4|46|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:17:35.946054|2018-06-01 02:17:35.946054
NCT00649051|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (2.5 mg; Mylan) and Zaroloxyn® Tablets (2.5 mg; Celltech) in Healthy Volunteers|Completed||Phase 1|52|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:36.234505|2018-06-01 02:17:36.234505
NCT00649038|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg|Single-Dose Food in Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:36.313299|2018-06-01 02:17:36.313299
NCT00649025|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28||2010-08-24|2010-08-24|2008-03-31|2008-04-01|Estimate||||2010-08-24|2010-08-27|Estimate|2010-08-24|2010-08-27|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults|A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10ug Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (250ug Twice Daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients With Moderate to Severe Asthma|Completed||Phase 3|438|Actual|SkyePharma AG||3|||f||||t||||||||||2018-06-01 02:17:36.415664|2018-06-01 02:17:36.415664
NCT00649012|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|March 2003||2003-03-31|March 2008|2008-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg|Single-Dose Food In Vivo Bioequivalence Study of Pioglitazone HCl Tablets (45 mg; Mylan) to Actos® Tablets (45 mg; Takeda) in Healthy Volunteers|Completed||Phase 1|40|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:36.708465|2018-06-01 02:17:36.708465
NCT00648999|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2013-03-14|2008-03-31|2008-04-01|Estimate|||||||2013-03-14|2013-03-15|Estimate|November 2003||2003-11-30|January 2013|2013-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients|Phase IV, Non Randomized Study in ARV Experienced Patients Under Switch Therapy With Kaletra|Completed||Phase 4|207|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 02:17:36.794343|2018-06-01 02:17:36.794343
NCT00648986|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2014-06-30|2008-03-27|2008-04-01|Estimate|||||||2014-06-30|2014-07-02|Estimate|August 2005||2005-08-31|June 2014|2014-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails|Single Center, Open-Label, Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails|Completed||Phase 4|20|Actual|Columbia University||1|||f||||f||||||||||2018-06-01 02:17:36.890967|2018-06-01 02:17:36.890967
NCT00648973|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2011-08-19|2008-03-27|2008-04-01|Estimate|||||||2011-08-19|2011-08-22|Estimate|November 2006||2006-11-30|August 2011|2011-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses|Evaluation of Nasal Congestion Clinical Efficacy for Diphenhydramine 25 mg and Diphenhydramine 50 mg in Seasonal Allergic Rhinitis: a Randomized, Double-blind, Placebo and Pseudoephedrine Controlled Study|Completed||Phase 4|1021|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-06-01 02:17:36.967279|2018-06-01 02:17:36.967279
NCT00648960|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting State|Single Dose Crossover Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Healthy Male and Female Volunteers / Fasting State|Completed||Phase 1|64|Actual|Mylan Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:17:37.076073|2018-06-01 02:17:37.076073
NCT00648947|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Clopidogrel Bisulfate Tablets (75 mg; Mylan) to Plavix® Tablets (75 mg; Bristol-Myers Squibb/Sanofi) in Healthy Volunteers|Completed||Phase 1|46|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:37.148581|2018-06-01 02:17:37.148581
NCT00648934|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg|Single-Dose Fed Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:37.222577|2018-06-01 02:17:37.222577
NCT00648921|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Olanzapine Tablets (5 mg; Mylan) and Zyprexa® Tablets (5 mg; Eli Lilly) in Healthy Volunteers|Completed||Phase 1|30|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:37.298448|2018-06-01 02:17:37.298448
NCT00648908|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2012-01-25||2012-02-24|2008-03-28|2008-04-01|Estimate|2012-02-24|2012-02-27|Estimate||||2012-02-24|2012-02-27|Estimate|June 2006||2006-06-30|January 2012|2012-01-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial|Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial|Completed||Phase 3|269|Actual|Acorda Therapeutics|||||f||||t||||||||||2018-06-01 02:17:37.416016|2018-06-01 02:17:37.416016
NCT00648895|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2010-07-21||2010-08-30|2008-03-28|2008-04-01|Estimate|2010-08-30|2010-09-20|Estimate||||2010-08-30|2010-09-20|Estimate|November 2007||2007-11-30|August 2010|2010-08-31||||July 2009|Actual|2009-07-31||Interventional|||A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients|Effect of Nebivolol on Forearm Vasodilation, Nitric Oxide Bioavailability, and Oxidative Stress in Patients With Stage 1/2 Hypertension|Completed||Phase 3|12|Actual|Forest Laboratories|The study was terminated early because of difficulties with enrollment. Only 12 of 30 planned patients were enrolled.|2|||f||||f||||||||||2018-06-01 02:17:37.838345|2018-06-01 02:17:37.838345
NCT00648882|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|March 2007||2007-03-31|March 2008|2008-03-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Fasting Study of Levothyroxine Sodium Tablets 300 Mcg to Synthroid® Tablets 300 Mcg|Single-Dose Fasting Bioequivalence Study of Levothyroxine Sodium Tablets (300 Mcg; Mylan) to Synthroid® Tablets (300 Mcg; Abbott)|Completed||Phase 1|33|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:38.166855|2018-06-01 02:17:38.166855
NCT00648869|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2009-10-25|2008-03-31|2008-04-01|Estimate|||||||2009-10-25|2009-10-27|Estimate|June 2008||2008-06-30|March 2008|2008-03-31|November 2008|Anticipated|2008-11-30|October 2008|Anticipated|2008-10-31||Interventional|||Open-label Crossover Metformin Gum Versus Tablet in Healthy Volunteers|Open-label,Randomized, Crossover Study Comparing Metformin Gum and Immediate Release Tablet in Healthy Volunteers|Withdrawn||N/A|12|Anticipated|Hadassah Medical Organization||||Drug was not sent|f||||t||||||||||2018-06-01 02:17:38.230332|2018-06-01 02:17:38.230332
NCT00648856|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Food Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Sertraline Hydrochloride Tablets (100 mg; Mylan) and Zoloft® Tablets (100 mg; Pfizer) in Healthy Volunteers|Completed||Phase 1|21|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:38.296189|2018-06-01 02:17:38.296189
NCT00648843|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Food Study of Oxybutynin Chloride Extended-Release Tablets 5 mg and Ditropan XL® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-Release Tablets (5 mg; Mylan) and Ditropan XL® Tablets (5 mg; ALZA) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:38.368606|2018-06-01 02:17:38.368606
NCT00648830|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Comparative Bioavailability Study of Clarithromycin 250 mg Tablets|Randomized Single Dose Crossover Replicate Comparative Bioavailability Study of Clarithromycin 250 mg Tablets in Healthy Male and Female Volunteers Under Fasted Conditions|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:17:38.436624|2018-06-01 02:17:38.436624
NCT00648817|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers|A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV-1 Seronegative Healthy Adult Males|Completed||Phase 4|8|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 02:17:38.505998|2018-06-01 02:17:38.505998
NCT00648804|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Food Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg|Single-Dose Food In Vivo Bioequivalence Study of Ondansetron Orally Disintegrating Tablets (8 mg; Mylan) to Zofran ODT® Tablets (8 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:38.57636|2018-06-01 02:17:38.57636
NCT00648791|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2004||2004-09-30|March 2008|2008-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Finasteride Tablets (5 mg; Mylan) and Proscar Tablets (5 mg; Merck) in Healthy Male Volunteers|Completed||Phase 1|29|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:38.705932|2018-06-01 02:17:38.705932
NCT00648778|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Loxapine Succinate Capsules (25 mg; Mylan) and Loxitane® Capsules (25 mg; Watson) in Healthy Volunteers|Completed||Phase 1|53|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:38.775646|2018-06-01 02:17:38.775646
NCT00325611|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2006-05-12|2006-05-12|2006-05-15|Estimate|||||||2006-05-12|2006-05-15|Estimate|April 2002||2002-04-30|May 2006|2006-05-31|July 2004||2004-07-31|||||Interventional|||Multidisciplinary Inpatient Palliative Care Intervention|A Multi-Site Replication of an Inpatient Palliative Care Program|Completed||N/A|550||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:00:16.835996|2018-06-01 04:00:16.835996
NCT00648765|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg|Single-Dose Food In Vivo Bioequivalence Study of Anagrelide Hydrochloride Capsules (1 mg; Mylan) to Agrylin® Capsules (1 mg; Shire US) in Healthy Volunteers|Completed||Phase 1|22|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:38.843789|2018-06-01 02:17:38.843789
NCT00648739|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28||2017-01-27|2017-01-27|2008-03-31|2008-04-01|Estimate||||2017-01-27|2017-01-30|Estimate|2017-01-27|2017-01-30|Estimate|June 2008||2008-06-30|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM|A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma|Completed||Phase 1/Phase 2|26|Actual|Alexion Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:17:38.916054|2018-06-01 02:17:38.916054
NCT00648726|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-03-27|2008-03-27|2008-04-01|Estimate|||||||2008-03-27|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|August 2003|Actual|2003-08-31|||||Interventional|||An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia|An Open, Prospective, Randomized, Multi-Center Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin vs. Cefuroxime Monotherapy or Plus Oral Erythromycin for the Treatment of Chinese Hospitalized Patients With Community- Acquired Pneumonia|Completed||Phase 3|139|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:39.000561|2018-06-01 02:17:39.000561
NCT00648713|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Fed Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® 250 mg|Single-Dose Food In Vivo Bioequivalence Study of Terbinafine Hydrochloride Tablets (250 mg; Mylan) and Lamisil® (250 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:39.081354|2018-06-01 02:17:39.081354
NCT00648700|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2005||2005-08-31|March 2008|2008-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg|Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (300 μg; Mylan) to Levothroid® Tablets (300 μg; Llyod) in Healthy Volunteers.|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:39.155988|2018-06-01 02:17:39.155988
NCT00648687|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2010-07-21|2008-03-31|2008-04-01|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2008||2008-03-31|September 2009|2009-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|ROP||Pain Response During Examination for Retinopathy of Prematurity|Evaluation of the Pain Response During Examination for Retinopathy of Prematurity in Very Low Birth Weight Infants|Completed||N/A|100|Anticipated|National Bioethics Commission of Brazil||2|||f||||f||||||||||2018-06-01 02:17:39.239514|2018-06-01 02:17:39.239514
NCT00648674|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2015-08-18|2008-03-28|2008-04-01|Estimate|||||||2015-08-18|2015-08-19|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers|A Prospective, Single-Site Study to Identify and Characterize the Molecular Mechanisms of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers|Withdrawn||Phase 4|0|Actual|Organogenesis||1|||f||||f||||||||||2018-06-01 02:17:39.313574|2018-06-01 02:17:39.313574
NCT00648661|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2004||2004-09-30|March 2008|2008-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg|Single-Dose Food In Vivo Bioequivalence Study of Escitalopram Oxalate Tablets (20 mg; Mylan) to Lexapro® Tablets (20 mg; Forest) in Healthy Volunteers|Completed||Phase 1|35|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:39.373364|2018-06-01 02:17:39.373364
NCT00648648|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2015-02-03|2008-03-28|2008-04-01|Estimate|||||||2015-02-03|2015-02-04|Estimate|February 2008||2008-02-29|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)|A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|203|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-06-01 02:17:39.441091|2018-06-01 02:17:39.441091
NCT00648635|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2017-09-26|2008-03-27|2008-04-01|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2008|Actual|2008-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations|A Pilot Study for Prospective Discovery of Possible Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations in Patients Undergoing Treatment for Locally Recurrent Rectal Adenocarcinoma|Recruiting|||164|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:17:39.549039|2018-06-01 02:17:39.549039
NCT00648622|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|April 2004||2004-04-30|March 2008|2008-03-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg|Single-Dose Food In Vivo Bioequivalence Study of Carvedilol Tablets (12.5 mg; Mylan) to Coreg® Tablets (12.5 mg; GSK) in Healthy Volunteers|Completed||Phase 1|50|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:39.654333|2018-06-01 02:17:39.654333
NCT00648609|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-06-16|2008-03-27|2008-04-01|Estimate|||||||2011-06-16|2011-06-20|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Community Based Self Management of COPD Facilitated by a Palliative Care Team:Impact on Health Care Utilization and QOL|Community Based Self Management of COPD Facilitated by a Palliative Care Team:Impact on Health Care Utilization and QOL|Completed|||23|Actual|Essentia Health|||2||f||||f||||||||||2018-06-01 02:17:39.74228|2018-06-01 02:17:39.74228
NCT00648596|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2015-04-21|2008-03-31|2008-04-01|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2003||2003-05-31|April 2015|2015-04-30|May 2004|Actual|2004-05-31|||||Interventional|||A Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion|An International, Multicentre, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfunction Treated With Sildenafil Citrate|Completed||Phase 4|780|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:17:39.81983|2018-06-01 02:17:39.81983
NCT00648570|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg|The Objective of This Study Was to Investigate the Bioequivalence of Mylan's Escitalopram Oxalate 20 mg Tablets to Forest's Lexapro® 20 mg Tablets Following a Single, Oral 20 mg (1 x 20 mg) Dose Administered Under Fasting Conditions.|Completed||Phase 1|37|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.049688|2018-06-01 02:17:40.049688
NCT00648557|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (200 mg; Mylan) to Synthroid Tablets (200 mg; Abbott) in Healthy Volunteers|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.116324|2018-06-01 02:17:40.116324
NCT00648544|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects|A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Non-Smoking Male and Female Subjects|Completed||Phase 1|44|Actual|Mylan Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:17:40.17899|2018-06-01 02:17:40.17899
NCT00648531|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Balsalazide Disodium Capsules (750 mg; Mylan) and Colazal® Capsules (750 mg; Salix) in Healthy Volunteers|Completed||Phase 1|80|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.245327|2018-06-01 02:17:40.245327
NCT00648518|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Fasting Study of Metformin Hydrochloride ER Tablets 750 mg and Glucophage® XR Tablets 750 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Metformin Hydrochloride ER Tablets (750 mg; Mylan) and Glucophage® XR Tablets (750 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.310773|2018-06-01 02:17:40.310773
NCT00648505|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|June 2005||2005-06-30|March 2008|2008-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Food Study of Glipizide and Metformin HCl Tablets 5 mg/500 mg to Metaglip® Tablets 5 mg/500 mg|Single-Dose Food In Vivo Bioequivalence Study of Glipizide and Metformin HCl Tablets (5 mg/500 mg; Mylan) to Metaglip® Tablets (5 mg/500 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.367044|2018-06-01 02:17:40.367044
NCT00648492|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg|Single-Dose Food In Vivo Bioequivalence Study Metformin Hydrochloride ER Tablets (500 mg; Mylan) and Glucophage® XR (500 mg; Bristol-Myers Squibb) in Healthy Volunteers|Completed||Phase 1|18|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.428613|2018-06-01 02:17:40.428613
NCT00648479|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2011-12-25|2008-03-31|2008-04-01|Estimate|||||||2011-12-25|2011-12-28|Estimate||||December 2011|2011-12-31||||||||Interventional|||New Method for Distal Interlocking of Cannulated Intramedullary Nails|New Method for Distal Interlocking of Cannulated Intramedullary Nails|Terminated||Phase 1/Phase 2|10|Anticipated|Hadassah Medical Organization||2||the company does not want to proceed yet with the study|f||||||||||||||2018-06-01 02:17:40.59248|2018-06-01 02:17:40.59248
NCT00648466|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-30|2008-03-31|2008-04-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2004||2004-11-30|November 2009|2009-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Sumatriptan Succinate Tablets (100 mg; Mylan) to Imitrex® Tablets (100 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|55|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.646328|2018-06-01 02:17:40.646328
NCT00648453|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-01|2008-03-31|2008-04-01|Estimate|||||||2008-04-01|2008-04-03|Estimate|December 2002||2002-12-31|April 2008|2008-04-30|April 2004|Actual|2004-04-30|||||Interventional|||Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function|Effect of Plavix Treatment on NO Production Measured by Laser Doppler Method Referring to Endothelial Function in Patients With Severe Coronary Heart Disease|Completed||Phase 4|39|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:17:40.713534|2018-06-01 02:17:40.713534
NCT00648440|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Midodrine HCl Tablets (5 mg; Mylan) and ProAmatine® Tablets (5 mg; Roberts) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.782609|2018-06-01 02:17:40.782609
NCT00648427|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|May 2005|Actual|2005-05-31|April 2005|Actual|2005-04-30||Interventional|||Fasting Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Paroxetine Hydrochloride Controlled-Release Tablets (25 mg; Mylan) to Paxil CR™ Tablets (25 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|75|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:40.877635|2018-06-01 02:17:40.877635
NCT00648414|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2006||2006-10-31|March 2008|2008-03-31||||October 2006|Actual|2006-10-31||Interventional|||Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr|Investigational Study of the Effect of Clinical Procedures on Drug Delivery of the Fentanyl Transdermal System (25 µg/hr; Mylan) and Duragesic® (25 µg/hr; Janssen) in Healthy Volunteers|Terminated||Phase 1|12|Actual|Mylan Pharmaceuticals||6||due to multiple subjects reporting pain and burning at the phlebotomy sites after 38hr|f||||||||||||||2018-06-01 02:17:40.974596|2018-06-01 02:17:40.974596
NCT00051857|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2018-05-22|2003-01-16|2003-01-17|Estimate|||||||2018-05-22|2018-05-23|Actual|January 16, 2003||2003-01-16|May 9, 2018|2018-05-09||||||||Observational|||MRI Study of Musculoskeletal Function|Virtual Functional Anatomy (VFA)|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:20.877998|2018-06-01 05:29:20.877998
NCT00648401|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fed Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) and Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:41.053212|2018-06-01 02:17:41.053212
NCT00648388|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Cilostazol Tablets (100 mg; Mylan) and Pletal® Tablets(100 mg; Otsuka) in Healthy Volunteers|Completed||Phase 1|44|Actual|Mylan Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:17:41.209653|2018-06-01 02:17:41.209653
NCT00648375|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2012-06-27|2008-03-28|2008-04-01|Estimate|||||||2012-06-27|2012-06-28|Estimate|December 2003||2003-12-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder|Efficacy of Propanolol for Treatment of Posttraumatic Stress Disorder|Terminated||Phase 4|12|Actual|Weill Medical College of Cornell University||2||inadequate recruitment|f||||f||||||||||2018-06-01 02:17:41.298477|2018-06-01 02:17:41.298477
NCT00648362|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Glimepiride Tablets (1 mg; Mylan) to Amaryl® Tablets (1 mg; Aventis) in Healthy Volunteers|Completed||Phase 1|40|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:41.404159|2018-06-01 02:17:41.404159
NCT00648349|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2003||2003-05-31|March 2008|2008-03-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Rabeprazole Sodium Delayed-Release Tablets (20 mg; Mylan) to Aciphex® Delayed-Release Tablets (20 mg; Eisia) in Healthy Volunteers|Completed||Phase 1|72|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:41.544852|2018-06-01 02:17:41.544852
NCT00648336|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2003||2003-11-30|March 2008|2008-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Mercaptopurine (50 mg; Mylan) and Purinethol® Tablets (50 mg; Gate) in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:41.657212|2018-06-01 02:17:41.657212
NCT00648323|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-04-02|2008-03-27|2008-04-01|Estimate|||||||2008-04-02|2008-04-07|Estimate|November 2003||2003-11-30|March 2008|2008-03-31|January 2005|Actual|2005-01-31|||||Interventional|||Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement|A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia|Completed||Phase 4|80|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:17:41.770402|2018-06-01 02:17:41.770402
NCT00648310|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-03-27|2008-03-27|2008-04-01|Estimate|||||||2008-03-27|2008-04-01|Estimate|January 2004||2004-01-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|||||Interventional|||Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity|Is There A Synergic Effect Of Topical Oestrogens When Associated To Antimuscarinics In The Treatment Of Symptomatic Detrusor Overactivity|Completed||Phase 2/Phase 3|||Università degli Studi dell'Insubria||2|||f||||f||||||||||2018-06-01 02:17:41.864431|2018-06-01 02:17:41.864431
NCT00648297|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2006||2006-08-31|March 2008|2008-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg|Single-Dose Fed Bioequivalence Study of Nadolol/Bendroflumethiazide Tablets (80 mg/5 mg; Mylan) and Corzide® Tablets (80 mg/5 mg; King) in Healthy Volunteers|Completed||Phase 1|42|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:41.929693|2018-06-01 02:17:41.929693
NCT00648284|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-10-13|2008-03-31|2008-04-01|Estimate|||||||2008-10-13|2008-10-15|Estimate|March 2004||2004-03-31|October 2008|2008-10-31||||||||Observational|||Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects|An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece|Completed|||1100||GlaxoSmithKline|||||f||||||||||||||2018-06-01 02:17:42.001941|2018-06-01 02:17:42.001941
NCT00648271|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg|Single-Dose Food In Vivo Bioequivalence Study of Metoprolol Tartrate Tablets (25 mg; Mylan) and Lopressor® (50 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|19|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:42.091912|2018-06-01 02:17:42.091912
NCT00648258|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-03-28|2008-04-01|Estimate|||||||2008-04-07|2008-04-10|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|April 2004|Actual|2004-04-30|||||Interventional|||A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg Once Daily And Naproxen 500mg Twice Daily In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan|A Double-Blind, Double Dummy, Randomized Comparison Study Of The Efficacy And Safety Of Valdecoxib 10mg QD And Naproxen 500mg BID In Treating The Signs And Symptoms Of Osteoarthritis Of The Knee Or Hip In Taiwan|Completed||Phase 3|130|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:17:42.22552|2018-06-01 02:17:42.22552
NCT00648245|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2011-02-09|2008-03-28|2008-04-01|Estimate|||||||2011-02-09|2011-02-10|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|BREATH-1||Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD|A Phase 2a, Double Blind, Placebo Controlled, Multicenter, Dose Escalation Study to Evaluate the Safety and Efficacy of BIO 11006 Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|172|Anticipated|BioMarck Pharmaceuticals, Ltd.||5|||f||||t||||||||||2018-06-01 02:17:42.359838|2018-06-01 02:17:42.359838
NCT00648232|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2013-12-11|2008-03-28|2008-04-01|Estimate|||||||2013-12-11|2013-12-12|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||HIV Counseling and Testing and Linkage to Care in Uganda|HIV Counseling and Testing and Linkage to Care in Uganda|Completed||N/A|3415|Actual|University of California, Los Angeles||6|||f||||t||||||||||2018-06-01 02:17:42.53379|2018-06-01 02:17:42.53379
NCT00648219|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-23|2008-03-31|2008-04-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg|Single-Dose Fed In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:42.598491|2018-06-01 02:17:42.598491
NCT00648206|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2013-11-01|2008-03-31|2008-04-01|Estimate|||||||2013-11-01|2013-11-04|Estimate|September 2008||2008-09-30|November 2013|2013-11-30|October 2011|Actual|2011-10-31|September 2008|Actual|2008-09-30||Observational|||Testing Alcohol Only Samples for Drugs and Drugs Only Samples for Alcohol|Retrospective Study of Unrequested Analytical Data in DUID-cases From a 2 Week Period|Completed|||250|Actual|National Institute for Health and Welfare, Finland|||2||f||||f||||||Samples With DNA|"~     Whole blood samples are collected for the study. However no DNA detection is done at any~     point in the study. The laboratory where the samples are analysed does not analyse DNA. DNA~     is not relevant for this study~   "|||2018-06-01 02:17:42.660428|2018-06-01 02:17:42.660428
NCT00648193|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|December 2006||2006-12-31|March 2008|2008-03-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg|Single-Dose Fasting Bioequivalence Study of Paroxetine Hydrochloride Tablets (40 mg; Mylan) and Paxil® Tablets (40 mg; GSK) in Healthy Adult Volunteers|Completed||Early Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:42.750085|2018-06-01 02:17:42.750085
NCT00648180|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Food Study of Doxycycline Monohydrate Tablets 100 mg and Adoxa Tablets 100 mg|Single-Dose Food In Vivo Bioequivalence Study of Doxycycline Monohydrate Tablets (100 mg; Mylan) and Adoxa Tablets (100 mg; Par) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:42.811378|2018-06-01 02:17:42.811378
NCT00648167|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2014-10-04||2017-03-03|2008-03-31|2008-04-01|Estimate|2014-10-04|2014-10-09|Estimate||||2017-03-03|2017-04-04|Actual|March 2008||2008-03-31|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||Intent-to-Treat|A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)|A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)|Completed||Phase 2|55|Actual|Keryx Biopharmaceuticals||1|||f||||t||||||||No||2018-06-01 02:17:42.877291|2018-06-01 02:17:42.877291
NCT00648154|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-30|2008-03-31|2008-04-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg|Single-Dose Fed Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:43.065249|2018-06-01 02:17:43.065249
NCT00648141|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-04-07|2008-03-28|2008-04-01|Estimate|||||||2008-04-07|2008-04-10|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|January 2005|Actual|2005-01-31|||||Interventional|||Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis|A 12-Week Symptomatic Effect Evaluation to Compare Celecoxib 200 mg QD, Celecoxib 200 mg BID and Diclofenac 75 mg SR BID in Patients With Ankylosing Spondylitis|Completed||Phase 3|458|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:43.251059|2018-06-01 02:17:43.251059
NCT00648128|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-31|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|March 2003||2003-03-31|February 2003|2003-02-28|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fed State|Single Dose Crossover Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Healthy Male and Female Volunteers / Fed State|Completed||Phase 1|44|Actual|Mylan Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:17:43.394802|2018-06-01 02:17:43.394802
NCT00648115|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2015-02-09||2017-11-14|2008-03-27|2008-04-01|Estimate|2015-09-28|2015-10-30|Estimate||||2017-11-14|2017-12-18|Actual|June 1, 2009|Actual|2009-06-01|November 2017|2017-11-30|September 29, 2017|Actual|2017-09-29|October 1, 2014|Actual|2014-10-01||Interventional|||Evaluating Vocational Materials for Incarcerated Veterans With Mental Illness or Substance Abuse|Evaluating Vocational Materials for Incarcerated Veterans With Mental Illness|Completed||N/A|111|Actual|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-06-01 02:17:43.471879|2018-06-01 02:17:43.471879
NCT00648102|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2010-07-23|2008-03-31|2008-04-01|Estimate|||||||2010-07-23|2010-07-26|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|CDX1307-02||Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer|A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted hCG-β Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder and Ovarian Cancer|Completed||Phase 1|36|Anticipated|Celldex Therapeutics|||||f||||f||||||||||2018-06-01 02:17:43.749249|2018-06-01 02:17:43.749249
NCT00648089|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-01-28|2008-03-31|2008-04-01|Estimate|||||||2011-01-28|2011-01-31|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|EPOMI||EPOMI Study: ErythroPOietin in Myocardial Infarction|ErythroPOietin in Myocardial Infarction|Completed||Phase 2|110|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-06-01 02:17:43.809593|2018-06-01 02:17:43.809593
NCT00648076|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-09-24|2008-03-31|2008-04-01|Estimate|||||||2009-09-24|2009-09-25|Estimate|December 2004||2004-12-31|September 2009|2009-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg|Single-Dose Food In Vivo Bioequivalence Study of Divalproex Sodium Extended-Release Tablets (500 mg; Mylan) to Depakote ER® Tablets (500 mg; Abbott) in Healthy, Adult Male Volunteers|Completed||Phase 1|40|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:43.866551|2018-06-01 02:17:43.866551
NCT00648063|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-30|2008-03-31|2008-04-01|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg|Single-Dose Fasting Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:43.921905|2018-06-01 02:17:43.921905
NCT00646074|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2012-03-05|2008-03-27|2008-03-28|Estimate|||||||2012-03-05|2012-03-07|Estimate|July 2006||2006-07-31|March 2012|2012-03-31|August 2008|Actual|2008-08-31|March 2008|Actual|2008-03-31||Interventional|||Self- Care TALK Study - Promoting Alzheimer's Disease (AD) Spousal Caregiver Health|Self Care TALK to Promote AD Spousal Caregiver Health|Completed||N/A|46|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 02:18:07.269612|2018-06-01 02:18:07.269612
NCT00648050|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|March 2006||2006-03-31|March 2008|2008-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fasting Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) to Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers Dosed in the Evening|Completed||Phase 1|72|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:44.001282|2018-06-01 02:17:44.001282
NCT00648037|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2015-10-20||2015-12-29|2008-03-31|2008-04-01|Estimate|2015-12-29|2016-02-01|Estimate||||2015-12-29|2016-02-01|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT|Pilot Trial of Rituximab (Rituxan) for the Prevention of EBV-LPD Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT|Completed||N/A|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:17:44.082191|2018-06-01 02:17:44.082191
NCT00648024|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Anagrelide Hydrochloride Capsules (1 mg; Mylan) to Agrylin® Capsules (1 mg; Shire US) in Healthy Volunteers|Completed||Phase 1|47|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:44.244788|2018-06-01 02:17:44.244788
NCT00648011|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|September 2003|Actual|2003-09-30|August 2003|Actual|2003-08-31||Interventional|||Food Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg|Single-Dose Food In Vivo Bioequivalence Study of Quinapril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Accuretic™ Tablets (20 mg/25 mg; Parke-Davis) in Healthy Volunteers|Completed||Phase 1|44|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:45.23654|2018-06-01 02:17:45.23654
NCT00647998|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2016-11-03||2017-05-01|2008-03-31|2008-04-01|Estimate|2016-11-03|2017-01-02|Estimate||||2017-05-01|2017-06-05|Actual|January 2008||2008-01-31|May 2017|2017-05-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|DISC||The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial|Phase 2 Dose Finding Trial of Prophylactic Darbepoetin Alfa to Improve Outcomes From Ischemic Complications of Surgery|Completed||Phase 2|18|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-06-01 02:17:45.3188|2018-06-01 02:17:45.3188
NCT00647985|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2003||2003-11-30|March 2008|2008-03-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg|Single-Dose Food In Vivo Bioequivalence Study of Fexofenadine Tablets (180 mg; Mylan) and Allegra® Tablets (180 mg; Aventis) in Healthy Adult Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:45.538615|2018-06-01 02:17:45.538615
NCT00647972|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-11-19|2008-03-31|2008-04-01|Estimate|||||||2009-11-19|2009-11-23|Estimate|May 2003||2003-05-31|November 2009|2009-11-30||||May 2003|Actual|2003-05-31||Interventional|||Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Olanzapine Tablets (20 mg; Mylan) and Zyprexa® Tablets (20 mg; Eli Lilly) in Healthy Volunteers|Terminated||Phase 1|32|Actual|Mylan Pharmaceuticals||2||"during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to~   5 mg due to safety concerns."|f||||||||||||||2018-06-01 02:17:45.607073|2018-06-01 02:17:45.607073
NCT00647959|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|March 2006||2006-03-31|March 2008|2008-03-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mg|Single-Dose Fasting Bioequivalence Study of Doxycycline Monohydrate Tablets (150 mg; Mylan) and Adoxa Tablets (150 mg; Par) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:45.685175|2018-06-01 02:17:45.685175
NCT00647946|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-06-27|2008-03-27|2008-04-01|Estimate|||||||2008-06-27|2008-06-30|Estimate|February 2003||2003-02-28|June 2008|2008-06-30|February 2006|Actual|2006-02-28|October 2004|Actual|2004-10-31||Interventional|RAVE||Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue|A Phase II, Open-Label, Multicentre, Randomised, Comparator Study of Substitution With Tenofovir or Abacavir in HIV-1 Infected Individuals, With a Viral Load < 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of Their Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 2|100|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 02:17:45.753868|2018-06-01 02:17:45.753868
NCT00647933|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2015-06-26|2008-03-31|2008-04-01|Estimate|||||||2015-06-26|2015-06-29|Estimate|June 2000||2000-06-30|June 2015|2015-06-30|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)|An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 After a Single Subcutaneous Dose in Healthy Female Volunteers Whose Pituitary Function is Suppressed by Lyndiol®.|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:17:45.984958|2018-06-01 02:17:45.984958
NCT00647920|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-03-28|2008-03-28|2008-04-01|Estimate|||||||2008-03-28|2008-04-01|Estimate|July 2003||2003-07-31|March 2008|2008-03-31||||April 2005|Actual|2005-04-30||Interventional|||Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate|Study of the Human Anti-TNF-Antibody Adalimumab|Completed||Phase 3|47|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:17:46.094825|2018-06-01 02:17:46.094825
NCT00647907|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-05-12|2008-03-27|2008-04-01|Estimate|||||||2011-05-12|2011-05-16|Estimate|April 2003||2003-04-30|May 2011|2011-05-31|May 2004|Actual|2004-05-31|||||Interventional|||A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections|An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection|Completed||Phase 4|7|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:17:46.177939|2018-06-01 02:17:46.177939
NCT00647894|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (1 mg; Mylan) to Xanax XR Tablets (1 mg; Pharmacia & Upjohn) in Healthy Volunteers|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:46.281426|2018-06-01 02:17:46.281426
NCT00647881|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg|Single-Dose Food In Vivo Bioequivalence Study of Paroxetine Hydrochloride Controlled-Release Tablets (25 mg; Mylan) to Paxil CR™ Tablets (25 mg; GlaxoSmithKline) in Healthy Volunteers|Completed||Phase 1|75|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:46.363624|2018-06-01 02:17:46.363624
NCT00647868|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2018-03-29|2008-03-31|2008-04-01|Estimate|||||||2018-03-29|2018-03-30|Actual|May 2008||2008-05-31|March 2018|2018-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers|A Multiple Dose, Pharmacokinetic Study Comparing Different Regimens of Testosterone Given as Intranasal NASOBOL® in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers|Completed||Phase 1|32|Actual|Acerus Pharmaceuticals Corporation||3|||f||||f||||||||||2018-06-01 02:17:46.447156|2018-06-01 02:17:46.447156
NCT00647855|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2003||2003-05-31|March 2008|2008-03-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg|Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (300 μg; Mylan) to Synthroid® Tablets (300 μg; Abbott) in Healthy Volunteers.|Completed||Phase 1|30|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:46.56263|2018-06-01 02:17:46.56263
NCT00647842|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System|Single-Dose In Vivo Bioequivalence and Wear Study of Fentanyl Transdermal System (25 µg/h; Mylan) and Fentanyl Transdermal System With Overlay (25 µg/h; Mylan) in Healthy Volunteers|Completed||Phase 1|120|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:46.642733|2018-06-01 02:17:46.642733
NCT00647829|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-04-23|2008-03-27|2008-04-01|Estimate|||||||2008-04-23|2008-04-24|Estimate|February 2003||2003-02-28|April 2008|2008-04-30|December 2003|Actual|2003-12-31|||||Interventional|||A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat|Clinical Protocol For A Double-Blind, Randomized, Placebo-Controlled Comparison Of The Efficacy, Safety, And Tolerability Of Bextra® (Valdecoxib) 20 Mg Twice Daily, Bextra® 40 Mg Once Daily, And Placebo In The Symptomatic Treatment Of Subjects With Pharyngitis|Completed||Phase 3|197|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:46.722903|2018-06-01 02:17:46.722903
NCT00647816|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg|Single-Dose Fasting Bioequivalence Study of Propranolol Hydrochloride Extended-Release Capsules (160 mg; Mylan) and Inderal® LA Capsules (160 mg; Wyeth) in Healthy Volunteers|Completed||Phase 1|100|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:46.801414|2018-06-01 02:17:46.801414
NCT00647790|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2015-08-12|2008-03-31|2008-04-01|Estimate|||||||2015-08-12|2015-08-13|Estimate|November 2006||2006-11-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer|PET Using Hormone Receptor Ligands in Breast Cancer|Completed|||79|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     Serum blood sample postimaging, Serum Estradiol (female only)~   "|||2018-06-01 02:17:46.867366|2018-06-01 02:17:46.867366
NCT00647777|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg|Single-Dose Food In Vivo Bioequivalence Study of Olanzapine Tablets (5 mg; Mylan) and Zyprexa® Tablets (5 mg; Eli Lilly) in Healthy Volunteers|Completed||Phase 1|32|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:46.928673|2018-06-01 02:17:46.928673
NCT00647764|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2012-05-15|2008-03-31|2008-04-01|Estimate|||||||2012-05-15|2012-05-17|Estimate|March 2008||2008-03-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas|Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas|Completed||Phase 1|32|Actual|Esanex Inc.||1|||f||||f||||||||||2018-06-01 02:17:47.00963|2018-06-01 02:17:47.00963
NCT00647751|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Food Study of Lamotrigine Tablets 25 mg to Lamictal® Tablets 25 mg|Single-Dose Food In Vivo Bioequivalence Study of Lamotrigine Tablets (25 mg; Mylan) to Lamictal® Tablets (25 mg; GSK) in Healthy Volunteers|Completed||Phase 1|28|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:47.077159|2018-06-01 02:17:47.077159
NCT00647738|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State|Single Dose Crossover Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting State|Completed||Phase 1|27|Actual|Mylan Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:17:47.224315|2018-06-01 02:17:47.224315
NCT00647725|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2009-09-30|2008-03-31|2008-04-01|Estimate|||||||2009-09-30|2009-10-01|Estimate|January 2003||2003-01-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|LALP||Labor Analgesia in the Latent Phrase|Labor Analgesia in the Latent Phrase of the First-stage of Spontaneous Delivery|Completed||N/A|15000|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 02:17:47.291166|2018-06-01 02:17:47.291166
NCT00647712|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2009-09-24|2008-03-31|2008-04-01|Estimate|||||||2009-09-24|2009-09-25|Estimate|December 2004||2004-12-31|September 2009|2009-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Divalproex Sodium Extended-Release Tablets (500 mg; Mylan) to Depakote ER® Tablets (500 mg; Abbott) in Healthy, Adult Male Volunteers|Completed||Phase 1|38|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:47.378084|2018-06-01 02:17:47.378084
NCT00647699|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|2016-05-02|2012-05-18|2017-12-04|2008-03-31|2008-04-01|Estimate|2016-06-14|2016-07-07|Estimate|2012-05-18|2012-05-30|Estimate|2017-12-04|2017-12-06|Actual|December 2007||2007-12-31|December 2017|2017-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|CXL||Corneal Collagen Cross-linking for Progressive Keratoconus|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus|Completed||Phase 3|147|Actual|Avedro, Inc.||2|||f||||f||||||||||2018-06-01 02:17:47.45818|2018-06-01 02:17:47.45818
NCT00647686|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|June 2006||2006-06-30|March 2008|2008-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System With Askina Derm Overlay|Single-Dose In Vivo Bioequivalence and Wear Study of Fentanyl Transdermal System (25 µg/h; Mylan) and Fentanyl Transdermal System With Overlay (25 µg/h; Mylan) in Healthy Volunteers|Completed||Phase 1|80|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:47.854629|2018-06-01 02:17:47.854629
NCT00647673|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg|Single-Dose Fasting Bioequivalence Study of Verapamil HCl Extended-Release Capsules (300 mg; Mylan) to Verelan® PM Extended-Release Capsules (300 mg; Schwarz) in Healthy Volunteers Dosed in the Evening|Completed||Phase 1|24|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:47.931071|2018-06-01 02:17:47.931071
NCT00647660|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg|Single-Dose Fasting Bioequivalence Study of Nadolol/Bendroflumethiazide Tablets (80 mg/5 mg; Mylan) to Corzide® Tablets (80 mg/5 mg; King) in Healthy Volunteers|Completed||Phase 1|66|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:48.026665|2018-06-01 02:17:48.026665
NCT00647647|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Terbinafine Hydrochloride Tablets (250 mg; Mylan) to Lamisil® Tablets (250 mg; Novartis) in Healthy Volunteers|Completed||Phase 1|36|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:48.100247|2018-06-01 02:17:48.100247
NCT00647634|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg|Single-Dose Fasting In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (3 mg; Mylan) to Xanax XR® Tablets (3 mg; Pharmacia & Upjohn) in Healthy Volunteers|Completed||Phase 1|21|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:48.178074|2018-06-01 02:17:48.178074
NCT00647621|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|October 2005||2005-10-31|February 2008|2008-02-29|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Steady-State Study of Extended Phenytoin Sodium Capsules 100 mg and Dilantin® Kapseals® 100 mg|Steady-State Bioequivalence Study of Extended Phenytoin Sodium Capsules (100 mg; Mylan) and Dilantin® Kapseals® (100 mg; Pfizer) in Healthy Adult Volunteers|Completed||Phase 1|72|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:48.252324|2018-06-01 02:17:48.252324
NCT00647608|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-30|||2008-03-31|2008-03-31|2008-04-01|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg|Single-Dose Fed Bioequivalence Study of Propranolol Hydrochloride Extended-Release Capsules (160 mg; Mylan) and Inderal® LA Capsules (160 mg; Wyeth) in Healthy Volunteers|Completed||Phase 1|98|Actual|Mylan Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:17:48.321157|2018-06-01 02:17:48.321157
NCT00647595|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2015-04-21|2008-03-27|2008-03-31|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome|Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome|Completed||Phase 3|100|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 02:17:48.39379|2018-06-01 02:17:48.39379
NCT00647582|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2018-03-20|2008-03-28|2008-03-31|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2002||2002-10-31|April 2016|2016-04-30|December 21, 2013|Actual|2013-12-21|June 2005|Actual|2005-06-30||Interventional|||Radiation Therapy During and After Lumpectomy in Treating Women With Stage I or Stage II Breast Cancer|Phase II Study of Intra-operative Electron Irradiation and External Beam Irradiation After Lumpectomy in Patients With Stage T1N0M0 or T2N0M0 Breast Cancer|Completed||Phase 2|80|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:17:48.47466|2018-06-01 02:17:48.47466
NCT00647569|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2013-09-06|2008-03-28|2008-03-31|Estimate|||||||2013-09-06|2013-09-09|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|VRAM||Trial of Collagen Mesh for Prevention of Ventral Hernia After Surgery for Advanced Pelvic Cancer|Randomized Controlled Trial of Collagen Mesh for Prevention of Ventral Hernia in Patients With Vertical Rectus Abdominis Musculocutaneus Flap for Advanced Pelvic Malignancy|Completed||Phase 3|59|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:17:48.545161|2018-06-01 02:17:48.545161
NCT00647556|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2011-01-28||2012-09-21|2008-03-26|2008-03-31|Estimate|2011-01-28|2011-02-24|Estimate||||2012-09-21|2012-10-02|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage|A Comparative Study of Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream, for the Treatment of Photodamage|Completed||Phase 3|30|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 02:17:48.667787|2018-06-01 02:17:48.667787
NCT00647543|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-04-28|2008-03-26|2008-03-31|Estimate|||||||2008-04-28|2008-05-05|Estimate|August 2003||2003-08-31|April 2008|2008-04-30|April 2004|Actual|2004-04-30|||||Interventional|||Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand|A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, And 40 Mg|Completed||Phase 4|242|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:17:49.47996|2018-06-01 02:17:49.47996
NCT00647530|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2017-08-01|2008-03-28|2008-03-31|Estimate|||||||2017-08-01|2017-08-02|Actual|May 15, 2008|Actual|2008-05-15|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FOxTROT||Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery|FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer|Active, not recruiting||Phase 2/Phase 3|1053|Actual|University of Birmingham||3|||f||||t||||||||||2018-06-01 02:17:49.567275|2018-06-01 02:17:49.567275
NCT00647504|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-09-09|2008-03-28|2008-03-31|Estimate|||||||2011-09-09|2011-09-12|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Observational|NIVUS||Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis|Nordic IVUS Study: Prospective Clinical Observational Registry Study Including Consecutive Patients With Clinical Signs or Symptoms Due to In-stent Restenosis (ISR) or Definite (ARC Criteria) Stent Thrombosis (ST)|Completed|||450|Anticipated|University of Tampere|||4||f||||t||||||||||2018-06-01 02:17:49.754485|2018-06-01 02:17:49.754485
NCT00647491|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2008-03-27|2008-03-27|2008-03-31|Estimate|||||||2008-03-27|2008-03-31|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis||Completed||Phase 2/Phase 3|352|Actual|Abbott||4|||f||||f||||||||||2018-06-01 02:17:49.833309|2018-06-01 02:17:49.833309
NCT00647478|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2018-04-27|2008-03-28|2008-03-31|Estimate|||||||2018-04-27|2018-05-01|Actual|October 2007||2007-10-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|October 2010|Actual|2010-10-31||Observational|SIGAL||System-IGF-1 Pathway and Alzheimer's Disease|A Multicenter Study to Assess Differences Between Circulating Levels of IGF-I and IGFBP-3 in Patients With Sporadic Late-onset Alzheimer's Disease and Control Elderly Subjects.|Completed|||693|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||Samples With DNA|"~     Blood for plasma levels and polymorphisms in IGF1 system components~   "|||2018-06-01 02:17:49.961105|2018-06-01 02:17:49.961105
NCT00647465|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-28|2008-03-28|2008-03-31|Estimate|||||||2008-03-28|2008-03-31|Estimate|October 2005||2005-10-31|November 2005|2005-11-30|March 2008|Actual|2008-03-31|May 2006|Actual|2006-05-31||Interventional|GP-INFA||Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer|Randomized Double-Blind Placebo Controlled Study Evaluating the Effect of Sublingual Administration of IFNa on the Immune Response to Influenza Vaccination in Subjects Aged 75 or More.|Terminated||Phase 3|140|Actual|Assistance Publique - Hôpitaux de Paris||2||End of the study|f||||t||||||||||2018-06-01 02:17:50.039846|2018-06-01 02:17:50.039846
NCT00647452|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-11-07|2008-03-28|2008-03-31|Estimate|||||||2011-11-07|2011-11-08|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Very Low Density Lipoprotein (VLDL) Triglyceride Metabolism in Exercise|Very Low Density Lipoprotein (VLDL) Triglyceride Metabolism in Exercise|Completed||N/A|16|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:17:50.132893|2018-06-01 02:17:50.132893
NCT00647439|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2018-05-24|2008-03-28|2008-03-31|Estimate|||||||2018-05-24|2018-05-25|Actual|March 27, 2008||2008-03-27|November 29, 2017|2017-11-29||||||||Observational|||Genetics and Markers of Degenerative and Inflammatory Eye Diseases|Epigenetics, Molecular Genetics, and Biomarkers of Degenerative and Inflammatory Ocular Diseases|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:17:50.194727|2018-06-01 02:17:50.194727
NCT00647426|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2016-09-23|2008-03-28|2008-03-31|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|December 2012|Actual|2012-12-31|August 2011|Actual|2011-08-31||Interventional|||Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Phase II Study of Sorafenib in Combination With Carboplatin and Docetaxel in the First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 2|7|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||f||||||||||2018-06-01 02:17:50.270832|2018-06-01 02:17:50.270832
NCT00647413|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-28|2008-03-28|2008-03-31|Estimate|||||||2008-03-28|2008-03-31|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|GESA||Prevent Exposure to Tobacco Smoke at Home [Gesunde Atemluft zu Hause]|Cancer Prevention by Reducing Exposure to Environmental Tobacco Smoke at Home|Unknown status|Not yet recruiting|N/A|6000|Anticipated|University Medicine Greifswald||2|||f||||f||||||||||2018-06-01 02:17:50.349063|2018-06-01 02:17:50.349063
NCT00647400|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2009-12-04||2011-04-01|2008-03-27|2008-03-31|Estimate|2009-12-04|2010-01-11|Estimate||||2011-04-01|2011-04-08|Estimate|April 2006||2006-04-30|April 2011|2011-04-30|April 2010|Actual|2010-04-30|September 2007|Actual|2007-09-30||Interventional|||Adalimumab in Adult Japanese Subjects With Psoriasis|A Multicenter Open-Label Continuation Study of the Long-term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2/Phase 3|147|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:17:50.450022|2018-06-01 02:17:50.450022
NCT00647387|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2018-05-01|2008-03-28|2008-03-31|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2008||2008-03-31|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|December 2018|Anticipated|2018-12-31||Interventional|VPA||Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study||Recruiting||N/A|100|Anticipated|St. Jude Medical||1|||f||||t||||||||||2018-06-01 02:17:51.1769|2018-06-01 02:17:51.1769
NCT00647374|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-03-01|2008-03-26|2008-03-31|Estimate|||||||2010-03-01|2010-03-02|Estimate|May 2008||2008-05-31|February 2010|2010-02-28||||||||Observational|||Assessment of Cortical Plasticity Following Short Term Limb Immobility|Assessment of Cortical Plasticity Following Short Term Limb Immobility|Suspended|||||Hadassah Medical Organization|||1||f||||||||||||||2018-06-01 02:17:51.396396|2018-06-01 02:17:51.396396
NCT00647361|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-07-18|2008-03-28|2008-03-31|Estimate|||||||2011-07-18|2011-07-19|Estimate|March 2008||2008-03-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects on Cardiac Performance|Short Term Effects of Neurally Adjusted Ventilatory Assist and Pressure Support Ventilation on Cardiac Performance|Completed||Phase 1|15|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 02:17:51.45298|2018-06-01 02:17:51.45298
NCT00647348|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2012-11-26|2008-03-28|2008-03-31|Estimate|||||||2012-11-26|2012-11-27|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|MS-STAT||Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis|A Phase II Randomised, Placebo-controlled Clinical Trial of Simvastatin in Patients With Secondary Progressive Multiple Sclerosis.|Completed||Phase 2|140|Actual|Imperial College London||2|||f||||t||||||||||2018-06-01 02:17:51.528429|2018-06-01 02:17:51.528429
NCT00647335|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2013-05-08|2008-03-28|2008-03-31|Estimate|||||||2013-05-08|2013-05-13|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Genetics of Polycystic Ovary Syndrome|Population Genetics of Polycystic Ovary Syndrome|Completed|||189|Actual|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-06-01 02:17:51.603671|2018-06-01 02:17:51.603671
NCT00647322|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-31|Estimate|||||||2008-03-26|2008-03-31|Estimate|September 2008||2008-09-30|March 2008|2008-03-31||||September 2010|Anticipated|2010-09-30||Interventional|||The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy|The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy|Unknown status|Not yet recruiting|Phase 4|64|Anticipated|Institute of Child Health||2|||f||||||||||||||2018-06-01 02:17:51.664574|2018-06-01 02:17:51.664574
NCT00647309|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2012-06-11|2008-03-28|2008-03-31|Estimate|||||||2012-06-11|2012-06-12|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|February 2013|Anticipated|2013-02-28||Observational|||Troponin Elevation in the Elderly Patient With Hip Fracture|Correlation Between Troponin Level and Rehabilitation Outcome in Elderly Patient With Hip Fracture|Unknown status|Recruiting||100|Anticipated|Sheba Medical Center|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 02:17:51.751238|2018-06-01 02:17:51.751238
NCT00647296|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26||2011-01-25|2017-12-13|2008-03-28|2008-03-31|Estimate||||2011-02-01|2011-02-08|Estimate|2017-12-13|2017-12-15|Actual|March 2008||2008-03-31|December 2017|2017-12-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|CL201||Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)|A 2-Part, Randomized, Double-Blind, Safety and Tolerability Study Evaluating KNS-760704 in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|102|Actual|Knopp Biosciences||4|||f||||f||||||||||2018-06-01 02:17:51.833404|2018-06-01 02:17:51.833404
NCT00647283|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-04-19|2008-03-28|2008-03-31|Estimate|||||||2011-04-19|2011-04-20|Estimate|November 2005||2005-11-30|April 2011|2011-04-30|December 2012|Anticipated|2012-12-31|September 2010|Actual|2010-09-30||Interventional|||Assessment Of the Safety and Benefit of Prospective Immunosuppressive Drug Withdrawal in Liver Transplantation and Prediction of Operational Tolerance|ASSESSMENT OF THE SAFETY AND BENEFIT OF PROSPECTIVE IMMUNOSUPPRESSIVE DRUG WITHDRAWAL IN LIVER TRANSPLANTATION AND PREDICTION OF OPERATIONAL TOLERANCE|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Hospital Clinic of Barcelona||1|||f||||t||||||||||2018-06-01 02:17:51.958409|2018-06-01 02:17:51.958409
NCT00647270|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|2010-04-14||2011-04-07|2008-03-28|2008-03-31|Estimate|2010-04-14|2010-05-10|Estimate||||2011-04-07|2011-04-11|Estimate|December 2007||2007-12-31|April 2011|2011-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing|A Multi-center, Randomized, Double-blind,Placebo-controlled Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing|Completed||Phase 3|420|Actual|Abbott|Abbott identified Investigator non-compliance with the protocol requirements at one site and made the decision to exclude the data from this site from all efficacy analyses. Sample size was too small to demonstrate superiority and non-inferiority.|3|||f||||f||||||||||2018-06-01 02:17:52.073161|2018-06-01 02:17:52.073161
NCT00647257|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-03-31|2008-03-26|2008-03-31|Estimate|||||||2010-03-31|2010-04-01|Estimate|April 2008||2008-04-30|March 2010|2010-03-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||The Effect of Losartan on Atrial Fibrillation (AF) Burden and Pacemaker Dependence in Patients With Sick Sinus Syndrome|The Effect of Losartan on Atrial Fibrillation and Pacemaker Dependence in Sick Sinus Syndrome (SSS) Patients Receiving Physiological Pacemaker - A Prospective, Randomized, Multicenter Study in Taiwan|Unknown status|Recruiting|N/A|220|Anticipated|Chung Shan Medical University||2|||f||||t||||||||||2018-06-01 02:17:52.985876|2018-06-01 02:17:52.985876
NCT00647244|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-12-17|2008-03-28|2008-03-31|Estimate|||||||2010-12-17|2010-12-20|Estimate|June 2008||2008-06-30|December 2010|2010-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|SWAP||Efficacy and Safety of Switching From Retrovir to Tenofovir or Abacavir in HIV-infected Patients|Efficacy and Safety of Switching From AZT to Tenofovir|Completed||Phase 4|40|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:17:53.10004|2018-06-01 02:17:53.10004
NCT00647231|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26||2015-03-17|2015-05-12|2008-03-28|2008-03-31|Estimate||||2015-05-12|2015-06-04|Estimate|2015-05-12|2015-06-04|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||HKT-500-US12 In Adult Patients With OA Knee Pain|Protocol HKT-500-US12: A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee|Completed||Phase 2|300|Actual|Hisamitsu Pharmaceutical Co., Inc.||2|||f||||t||||||||||2018-06-01 02:17:53.178916|2018-06-01 02:17:53.178916
NCT00647218|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2017-02-21|2008-03-28|2008-03-31|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2000||2000-02-29|February 2017|2017-02-28|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer|A Pilot Study of Neoadjuvant Paclitaxel and Concurrent Radiation With Correlative Molecular Studies in Stage II/III Breast Cancer|Completed||N/A|38|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:17:53.282097|2018-06-01 02:17:53.282097
NCT00647205|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-08-08|2008-03-26|2008-03-31|Estimate|||||||2011-08-08|2011-08-09|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|||Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT|Evaluation of 2 Interferon γ Assays (QuantiFERON TB Gold In-Tube® and T-SPOT.TB®) in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT|Completed||Phase 4|240|Anticipated|French National Agency for Research on AIDS and Viral Hepatitis||6|||f||||f||||||||||2018-06-01 02:17:53.368433|2018-06-01 02:17:53.368433
NCT00647192|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2012-02-09|2008-03-28|2008-03-31|Estimate|||||||2012-02-09|2012-02-10|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|EPLERAF||EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion|EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion|Terminated||Phase 2|38|Actual|University Hospital, Saarland||2||Inclusion rate too low. Recruitment of further study centers too costly.|f||||t||||||||||2018-06-01 02:17:53.462279|2018-06-01 02:17:53.462279
NCT00647179|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2017-12-22|2008-03-28|2008-03-31|Estimate|||||||2017-12-22|2017-12-26|Actual|February 2008||2008-02-29|December 2017|2017-12-31|December 7, 2016|Actual|2016-12-07|December 7, 2016|Actual|2016-12-07||Observational|||Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment|Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment|Completed|||27|Actual|University of Aarhus|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, muscle samples, fat samples~   "|||2018-06-01 02:17:53.54142|2018-06-01 02:17:53.54142
NCT00647166|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2015-10-06|2008-03-26|2008-03-31|Estimate|||||||2015-10-06|2015-10-07|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|CHUSPAN2||Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)|Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors|Completed||Phase 3|114|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:17:53.601066|2018-06-01 02:17:53.601066
NCT00647153|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-28|||2017-11-02|2008-03-28|2008-03-31|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2006||2006-05-31|November 2017|2017-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer|Pre-Surgical Detection of Colorectal Carcinomas Using 123Iodine-Labeled cT84.66 Diabody Antibody Fragments to Carcinoembryonic Antigen (CEA)|Completed||Phase 1|1|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:17:53.691614|2018-06-01 02:17:53.691614
NCT00647140|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-07-06|2008-03-28|2008-03-31|Estimate|||||||2010-07-06|2010-07-07|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|DOPMET||Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer|Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer.|Terminated||Phase 2|29|Actual|Assistance Publique - Hôpitaux de Paris||1||Insuffisent recruitment|f||||f||||||||||2018-06-01 02:17:53.779753|2018-06-01 02:17:53.779753
NCT00647127|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2012-09-13|2008-03-28|2008-03-31|Estimate|||||||2012-09-13|2012-09-14|Estimate|February 2008||2008-02-29|September 2012|2012-09-30|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain|Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain|Completed||Phase 3|22|Actual|University of Aarhus||3|||f||||t||||||||||2018-06-01 02:17:53.910088|2018-06-01 02:17:53.910088
NCT00647114|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2015-03-12|2008-03-28|2008-03-31|Estimate|||||||2015-03-12|2015-03-13|Estimate|August 2007||2007-08-31|March 2015|2015-03-31|April 2009|Actual|2009-04-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)|A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V930/V932 in Patients With Cancer Expressing HER-2 and/or CEA|Completed||Phase 1|41|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:17:54.086446|2018-06-01 02:17:54.086446
NCT00647101|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-28|2008-03-28|2008-03-31|Estimate|||||||2008-03-28|2008-03-31|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|February 2005|Actual|2005-02-28|||||Interventional|||A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma|Open Multicenter Study on the Efficacy of Xalatan at 3 Months as First-Line Therapy in Naive Patients With Ocular Hypertension (OH) or Open Angle Glaucoma (OAG), Based on Initial Intraocular Pressure (IOP): 20 mmHg Less Than or Equal to IOP Less Than 24 mmHg, IOP Greater Than or Equal to 24 mmHg|Completed||Phase 4|600|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:17:54.214304|2018-06-01 02:17:54.214304
NCT00647088|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2017-02-27|2008-03-26|2008-03-31|Estimate|||||||2017-02-27|2017-03-01|Actual|March 2008||2008-03-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|GENERAC||Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications|Genetic of Aortic Valve Stenosis - Clinical and Therapeutic Implications|Unknown status|Recruiting||2200|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||Samples With DNA|"~     blood samples DNA Tissue valve~   "|No||2018-06-01 02:17:54.744162|2018-06-01 02:17:54.744162
NCT00647075|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-12-14|2008-03-28|2008-03-31|Estimate|||||||2010-12-14|2010-12-15|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|YUNZHI-BC||Yunzhi as Dietary Supplement in Breast Cancer|A Randomized, Parallel, Double-blind, Placebo-controlled, Pilot Clinical Study on the Effects of Yunzhi as Dietary Supplement in 60 Adult Patients Undergoing Adjuvant/Neoadjuvant Chemotherapy for Breast Cancer.|Unknown status|Recruiting|Phase 4|60|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:17:54.812562|2018-06-01 02:17:54.812562
NCT00647049|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-11-16|2008-03-28|2008-03-31|Estimate|||||||2009-11-16|2009-11-17|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Freiburg ZNS-NHL Study|Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation|Unknown status|Recruiting|Phase 2|78|Anticipated|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 02:17:54.882007|2018-06-01 02:17:54.882007
NCT00647036|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-28|2008-03-28|2008-03-31|Estimate|||||||2008-03-28|2008-03-31|Estimate|July 2008||2008-07-31|March 2008|2008-03-31||||July 2010|Anticipated|2010-07-31||Interventional|||Microbial Invasion During Parenteral Nutrition in Surgical Infants Receiving Glutamine|Microbial Invasion During Parenteral Nutrition in Surgical Infants Receiving Glutamine.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Institute of Child Health||2|||f||||f||||||||||2018-06-01 02:17:55.10881|2018-06-01 02:17:55.10881
NCT00647023|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-31|Estimate|||||||2008-03-26|2008-03-31|Estimate|February 2004||2004-02-29|March 2008|2008-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)||Terminated||N/A|66|Actual|Hvidovre University Hospital||1|||f||||f||||||||||2018-06-01 02:17:55.286251|2018-06-01 02:17:55.286251
NCT00646997|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-06-27|2008-03-28|2008-03-31|Estimate|||||||2008-06-27|2008-06-30|Estimate|March 2008||2008-03-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Impact of Left Atrial Function on Postoperative Atrial Fibrillation|Impact Of Velocity Vector Imaging, Tissue Doppler Imaging, Conventional Echocardiography And P Wave Dispertion In Evaluating Post-Operative Atrial Fibrillation After Coronary Bypass Graft Surgery|Completed|||80|Anticipated|Florence Nightingale Hospital, Istanbul|||2||f||||t||||||||||2018-06-01 02:17:55.354726|2018-06-01 02:17:55.354726
NCT00646984|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-28|2008-03-28|2008-03-31|Estimate|||||||2008-03-28|2008-03-31|Estimate|January 2002||2002-01-31|March 2008|2008-03-31|April 2006|Actual|2006-04-30|April 2005|Actual|2005-04-30||Interventional|||Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy|Comparison of Strategies of Interruption/Reinitiation of Antiretroviral Therapy in Response to Immunologic/Virologic Changes in HIV-Infected Patients With Lipodystrophy.|Completed||Phase 4|147|Actual|Hospital Clinic of Barcelona||3|||f||||t||||||||||2018-06-01 02:17:55.427847|2018-06-01 02:17:55.427847
NCT00646971|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2010-07-09|2008-03-28|2008-03-31|Estimate|||||||2010-07-09|2010-07-12|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|SOREVAS||Oxidative Stress and Endothelial Dysfunction in Obstructive Sleep Apnea|Exhaled Markers of Oxidative Stress and Endothelium-dependent Vascular Relaxation in Obstructive Sleep Apnea. Effect of Continuous Positive Airway Pressure Therapy.|Terminated||N/A|11|Actual|Assistance Publique - Hôpitaux de Paris||2||Insuffisent recrutment|f||||f||||||||||2018-06-01 02:17:55.515789|2018-06-01 02:17:55.515789
NCT00646620|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-04-03|2008-03-27|2008-03-28|Estimate|||||||2009-04-03|2009-04-06|Estimate|April 2003||2003-04-30|April 2009|2009-04-30|September 2003|Actual|2003-09-30|||||Interventional|||Symbicort Onset of Action 1|A Randomized, Multicenter, Placebo and Active-Controlled, Single-Dose, 4-Period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.|Completed||Phase 3|48|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:18:01.36625|2018-06-01 02:18:01.36625
NCT00646958|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2009-03-24||2014-02-26|2008-03-28|2008-03-31|Estimate|2009-06-25|2009-06-26|Estimate||||2014-02-26|2014-03-27|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||The intent-to-treat (ITT) population included those patients who were randomized and took at least one (1) dose of study medication.|Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections|A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection|Completed||Phase 2|150|Actual|Melinta Therapeutics, Inc.|This was an unblinded study, which raises the possibility of bias.|3|||f||||f||||||||||2018-06-01 02:17:55.615863|2018-06-01 02:17:55.615863
NCT00646945|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2009-01-09|2008-03-28|2008-03-31|Estimate|||||||2009-01-09|2009-01-12|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology|International, Randomized, Controled, Double-Blind Study Assessing Efficacy of Kalinox® 170 Bar During the Realization of Invasive Gestures in Adult Oncology|Completed||Phase 4|286|Anticipated|Air Liquide Santé International||2|||f||||f||||||||||2018-06-01 02:17:55.959131|2018-06-01 02:17:55.959131
NCT00646932|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-31|Estimate|||||||2008-03-26|2008-03-31|Estimate|November 2005||2005-11-30|March 2008|2008-03-31||||February 2007|Actual|2007-02-28||Interventional|||Paricalcitol Injection Phase II Trial|A Phase 2, Open-Label, Multicenter, Multi-Dose Study to Evaluate the Pharmacokinetics and Tolerability of Paricalcitol Injection in Chronic Kidney Disease Stage 5 Subjects With Secondary Hyperparathyroidism Undergoing Hemodialysis|Completed||Phase 2|25|Actual|Abbott||4|||f||||f||||||||||2018-06-01 02:17:56.035412|2018-06-01 02:17:56.035412
NCT00646919|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-31|Estimate|||||||2008-03-26|2008-03-31|Estimate||||March 2008|2008-03-31||||||||Observational|||Preoperative Nasal Swabs From Pediatric Patients|Double-Blind Prospective Study Concerning the Connection Between Positive Nasal Culture for Staphyloccoci in Pediatric Patients Undergoing Any Elective Surgery in the Out-Patient Clinic in the Hillel Yaffe Medical Center, Over a Period of One Year|Unknown status|Not yet recruiting||||Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-06-01 02:17:56.151797|2018-06-01 02:17:56.151797
NCT00646906|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2013-05-14|2008-03-26|2008-03-31|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 2004||2004-05-31|December 2011|2011-12-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Mechanisms of Action of Acetaminophen|A Randomized, Double-Blind, Crossover Study to Evaluate the Mechanism of Action of Acetaminophen|Completed||Phase 4|12|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 02:17:56.241769|2018-06-01 02:17:56.241769
NCT00646893|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-02-21|2008-03-28|2008-03-31|Estimate|||||||2010-02-21|2010-02-23|Estimate|June 2008||2008-06-30|February 2010|2010-02-28|April 2011|Anticipated|2011-04-30|January 2011|Anticipated|2011-01-31||Interventional|||Preimplantation Genetic Diagnosis for the Indication of Advanced Reproductive Age|Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART|Suspended||Phase 4|1200|Anticipated|Reprogenetics||2||lack of appropriate funding|f||||t||||||||||2018-06-01 02:17:56.351866|2018-06-01 02:17:56.351866
NCT00646880|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-28|2008-03-28|2008-03-31|Estimate|||||||2008-03-28|2008-03-31|Estimate|March 2003||2003-03-31|March 2008|2008-03-31|August 2003|Actual|2003-08-31|||||Interventional|||A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring|Double-Blind Crossover Comparative Ambulatory Urodynamic Monitoring (AUM) Study of Tolterodine PR and Propiverine in Korean Patients With Overactive Bladder (OAB)|Completed||Phase 3|41|Actual|Pfizer||2|||f||||||||||||||2018-06-01 02:17:56.461957|2018-06-01 02:17:56.461957
NCT00646867|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-05-19|2008-03-28|2008-03-31|Estimate|||||||2008-05-19|2008-05-22|Estimate|February 2008||2008-02-29|May 2008|2008-05-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Effect of Tetrix on Alleviation of Burning,Itching Associated With Lesions of Contact Dermatitis|An Open Label Study of the Therapeutic Effects of Tetrix Cream in Allergic Contact and Irritant Contact Dermatitis|Completed||N/A|44|Actual|Coria Laboratories, Ltd.||2|||f||||f||||||||||2018-06-01 02:17:56.559444|2018-06-01 02:17:56.559444
NCT00646854|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2015-01-08|2008-03-26|2008-03-31|Estimate|||||||2015-01-08|2015-01-09|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|December 2016|Anticipated|2016-12-31|April 2015|Anticipated|2015-04-30||Interventional|ACT-1||Alemtuzumab and CHOP in T-cell Lymphoma|A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas|Unknown status|Active, not recruiting|Phase 3|308|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:17:56.666811|2018-06-01 02:17:56.666811
NCT00646841|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-08-07|2008-03-26|2008-03-31|Estimate|||||||2008-08-07|2008-08-11|Estimate|February 2003||2003-02-28|August 2008|2008-08-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients|The Effects of Doxazosin Gastrointestinal Therapeutic System (GITS) on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensives on Drug Therapy|Completed||Phase 4|89|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:17:56.815794|2018-06-01 02:17:56.815794
NCT00646828|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2012-01-18|2008-03-26|2008-03-31|Estimate|||||||2012-01-18|2012-01-19|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|PHACARV||Cardiovascular Evaluation of Adult PHA 1 Patients|Cardiovascular Evaluation of a Rare Condition With Hyperaldosteronism Without Hypertension: PHA 1|Completed|||98|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-06-01 02:17:56.89006|2018-06-01 02:17:56.89006
NCT00646815|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2009-10-21|2008-03-28|2008-03-31|Estimate|||||||2009-10-21|2009-10-22|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency|Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency|Completed||N/A|24|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:17:56.960017|2018-06-01 02:17:56.960017
NCT00646802|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2016-08-18|2008-03-26|2008-03-31|Estimate|||||||2016-08-18|2016-08-19|Estimate|June 2008||2008-06-30|August 2016|2016-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PROMISE||Vaginal PROgesterone as Maintenance Treatment After an epISode of prEterm Labor (PROMISE Study)|Vaginal Progesterone as a Maintenance Treatment in Women With Previous Preterm Labor. Randomized, Double Blinded, Placebo-controlled Trial|Completed||Phase 4|265|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 02:17:57.047617|2018-06-01 02:17:57.047617
NCT00646789|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2015-05-29|2008-03-26|2008-03-31|Estimate|||||||2015-05-29|2015-06-01|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)|A Multicenter, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 02:17:57.227845|2018-06-01 02:17:57.227845
NCT00646776|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2010-09-03||2013-01-23|2008-03-26|2008-03-31|Estimate|2010-12-09|2011-01-05|Estimate||||2013-01-23|2013-01-31|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Drug Interaction Study|Study to Evaluate the Exposure of Rifabutin Administered in an Alternate Regimen in Combination With Atazanavir and Ritonavir Healthy Subjects|Completed||Phase 1|85|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:17:57.332557|2018-06-01 02:17:57.332557
NCT00646763|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|2012-03-14||2013-11-26|2008-03-27|2008-03-28|Estimate|2012-04-13|2012-05-11|Estimate||||2013-11-26|2013-12-20|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|February 2011|Actual|2011-02-28|September 2009|Actual|2009-09-30||Interventional|||A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation|A Phase II Single Institution Randomized Study Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplant|Terminated||Phase 2|35|Actual|Emory University||2||Accrual goal met|f||||t||||||||||2018-06-01 02:17:58.309832|2018-06-01 02:17:58.309832
NCT00646750|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2016-02-12|2008-03-25|2008-03-28|Estimate|||||||2016-02-12|2016-02-15|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|June 2012|Actual|2012-06-30|February 2010|Actual|2010-02-28||Interventional|Z-BEAM LDGGB||Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom|Autologous Transplantation of Haematopoietic Stem Cells With Conditioning Including Zevalin + BEAM to Patients Suffering From Refractory Large B-cell Diffuse Lymphom|Completed||Phase 2|31|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||||2018-06-01 02:17:59.385991|2018-06-01 02:17:59.385991
NCT00646737|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2017-02-21|2008-03-27|2008-03-28|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2008||2008-05-31|February 2017|2017-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant|Phase IV Study of Enteric-coated Mycophenolate Sodium in Combination With Tacrolimus in Renal Transplant Patient|Completed||Phase 4|18|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:17:59.75754|2018-06-01 02:17:59.75754
NCT00646724|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2011-06-15|2008-03-25|2008-03-28|Estimate|||||||2011-06-15|2011-06-16|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|January 2014|Anticipated|2014-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients|Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Fuzhou General Hospital||1|||f||||t||||||||||2018-06-01 02:18:00.103717|2018-06-01 02:18:00.103717
NCT00646711|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-28|Estimate|||||||2008-03-25|2008-03-28|Estimate|February 2003||2003-02-28|March 2008|2008-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Pediatric Switch Study for Children and Adolescent Patients With Epilepsy|A 14 Day Randomized, Open-Label, Cross-Over, Single Center, Outpatient Study of Depakote Delayed-Release or Depakote Sprinkle vs. Divalproex Sodium Extended-Release in Child and Adolescent Patients With Epilepsy|Completed||Phase 2|16|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:18:00.182014|2018-06-01 02:18:00.182014
NCT00646698|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-03-27|2008-03-27|2008-03-28|Estimate|||||||2008-03-27|2008-03-28|Estimate|April 2006||2006-04-30|March 2008|2008-03-31|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Observational|||Body Composition and Very-Low-Density-Lipoprotein-Triglycerides (VLDL-TG) Kinetics|Impact of Body Composition on Very-Low-Density-Lipoprotein-Triglycerides Kinetics|Completed|||30|Actual|University of Aarhus|||3||f||||f||||||||||2018-06-01 02:18:00.419209|2018-06-01 02:18:00.419209
NCT00646685|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2014-07-24|2008-03-27|2008-03-28|Estimate|||||||2014-07-24|2014-07-25|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Duct-to-duct vs Roux-en-y Hepaticojejunostomy for Biliary Reconstruction in Adult Living Donor Liver Transplantation|Prospective Randomized Trial for Comparison of Duct-to-duct and Roux-en-y Hepaticojejunostomy for Biliary Reconstruction in Adult Living Donor Liver Transplantation|Unknown status|Enrolling by invitation|Phase 4|80|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:18:00.516059|2018-06-01 02:18:00.516059
NCT00646672|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2017-06-30|2008-03-26|2008-03-28|Estimate|||||||2017-06-30|2017-07-02|Actual|March 17, 2008||2008-03-17|April 16, 2010|2010-04-16|April 16, 2010||2010-04-16|||||Observational|||Aneurysms and Carotid Artery Block in Newborns|Assessment of Cerebral Circulation and Perfusion in Adults After Neonatal Carotid Occlusion|Completed|||6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:18:00.621063|2018-06-01 02:18:00.621063
NCT00646659|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2013-01-07|2008-03-27|2008-03-28|Estimate|||||||2013-01-07|2013-01-08|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|April 2011|Actual|2011-04-30|May 2010|Actual|2010-05-31||Interventional|||Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery|Randomized Phase II Feasibility Study of Cetuximab Combined With 4 Cycles of TPF Followed by Platinum Based Chemo-radiation Strategies|Terminated||Phase 2|47|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||Recruitment was suspended prematurely for safety concerns and closed after IDMC review|f||||||||||||||2018-06-01 02:18:00.694627|2018-06-01 02:18:00.694627
NCT00646646|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|2013-06-27|2012-05-24|2017-04-18|2008-03-27|2008-03-28|Estimate|2014-04-08|2014-05-08|Estimate|2012-05-31|2012-06-06|Estimate|2017-04-18|2017-05-19|Actual|April 2007||2007-04-30|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|Eye Movement||The Effect of Sedation on Eye Movements|The Effect of Sedation on Eye Movements|Completed||N/A|65|Actual|University of Alabama at Birmingham||4|||f||||f||||||||||2018-06-01 02:18:00.822301|2018-06-01 02:18:00.822301
NCT00646633|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2016-07-05|2008-03-25|2008-03-28|Estimate|||||||2016-07-05|2016-07-07|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Interventional|||Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors|Improving Fatigue: A Pilot Study of Acupuncture and Patient Education for Breast Cancer Survivors|Completed||N/A|12|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:18:01.189906|2018-06-01 02:18:01.189906
NCT00646061|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2009-09-20|2008-03-25|2008-03-28|Estimate|||||||2009-09-20|2009-09-22|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pain Control in Renal Colic||Completed||Phase 1|||Seoul National University Hospital||2|||f||||||||||||||2018-06-01 02:18:07.330099|2018-06-01 02:18:07.330099
NCT00646607|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2014-11-25|2008-03-25|2008-03-28|Estimate|||||||2014-11-25|2014-11-26|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|November 2014|Actual|2014-11-30|April 2013|Actual|2013-04-30||Interventional|TOSCA||FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer|A Randomized Trial Investigating the Role of FOLFOX-4 Regimen Duration (3 Versus 6 Months) and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer|Completed||Phase 3|3756|Actual|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||2|||f||||t||||||||||2018-06-01 02:18:01.502411|2018-06-01 02:18:01.502411
NCT00646594|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-03-26|2008-03-27|2008-03-28|Estimate|||||||2009-03-26|2009-03-27|Estimate|November 2003||2003-11-30|March 2009|2009-03-31|January 2005|Actual|2005-01-31|||||Interventional|||Atlantis Symbicort|A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.|Completed||Phase 3|1200|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:18:01.818719|2018-06-01 02:18:01.818719
NCT00646581|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2012-08-17||2013-02-12|2008-03-27|2008-03-28|Estimate|2012-12-17|2013-01-29|Estimate||||2013-02-12|2013-02-15|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Single Dose Intranasal Insulin On Cognitive Function|Effect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia|Completed||Phase 4|30|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 02:18:01.972402|2018-06-01 02:18:01.972402
NCT00646568|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2011-06-22|2008-03-25|2008-03-28|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Human Chorionic Gonadotropin (hCG) Test: A Novel Method to Evaluate the Ovarian Reserve|hCG Stimulating Test of the Thecal Cells to Evaluate the Ovarian Reserve|Completed||N/A|60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:18:02.383436|2018-06-01 02:18:02.383436
NCT00646555|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2017-06-30|2008-03-27|2008-03-28|Estimate|||||||2017-06-30|2017-07-02|Actual|November 20, 2003||2003-11-20|April 10, 2012|2012-04-10|April 10, 2012||2012-04-10|||||Observational|||Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis|Evaluation of Angiogenesis Parameters and Tumor Markers in Inflammatory Breast Cancer Specimens|Completed|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:18:02.491579|2018-06-01 02:18:02.491579
NCT00646542|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24||2013-01-02|2013-01-03|2008-03-26|2008-03-28|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-03|2013-01-09|Estimate|March 2005||2005-03-31|January 2013|2013-01-31||||October 2010|Actual|2010-10-31||Interventional|||Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency|A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency|Completed||Phase 3|525|Actual|Novartis||2|||f||||t||||||||||2018-06-01 02:18:02.549425|2018-06-01 02:18:02.549425
NCT00646529|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-03-27|2008-03-27|2008-03-28|Estimate|||||||2009-03-27|2009-03-30|Estimate|July 2002||2002-07-31|March 2009|2009-03-31|October 2003|Actual|2003-10-31|||||Interventional|||Long-Term Safety of Symbicort in Asthmatic Children - SAPLING|A Six Month, Randomized, Open-Label, Safety Study of Symbicort (160/4.5mcg) Compared to Pulmicort Turbuhaler in Asthmatic Children Aged Six to Eleven Years - SAPLING|Completed||Phase 3|175|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:18:02.618574|2018-06-01 02:18:02.618574
NCT00646516|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-01-21|2008-03-27|2008-03-28|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2003||2003-10-31|January 2011|2011-01-31|February 2005|Actual|2005-02-28|||||Interventional|||Gemini Symbicort pMDI|A Rand, Doubleblind, Activecontrolled, Parallel-grp,Singledummy, Multicenter,12 wk Study to Assess the Effic.&Safety of Symbicort pMDI 2x160/4.5mcg QD Compared to Symb. pMDI 2x80/4.5mcg QD, Symb. pMDI 2x80/4.5mcg Bid and to Budesonide pMDI 2x160 Mcg QD in Asthmatic Sub's12yrs and Over|Completed||Phase 3|615|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:18:03.639849|2018-06-01 02:18:03.639849
NCT00646503|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2017-06-21|2008-03-27|2008-03-28|Estimate|||||||2017-06-21|2017-06-22|Actual|March 2008||2008-03-31|June 2017|2017-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B|A Single Arm, Multicenter, Open-label, 52-week, the Omnibus Extension Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B and Are HBV DNA PCR Negative at the End of Year 4 Treatment|Completed||Phase 4|150|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:18:03.736515|2018-06-01 02:18:03.736515
NCT00646490|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2013-02-27|2008-03-25|2008-03-28|Estimate|||||||2013-02-27|2013-02-28|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Pleural Fluid and Serum Procalcitonin in Patients With Parapneumonic Pleural Effusion|Diagnostic and Prognostic Values of Pleural Fluid Procalcitonin in Parapneumonic Pleural Effusion|Completed|||150|Actual|Chang Gung Memorial Hospital|||2||f||||f||||||Samples Without DNA|"~     serum,pleural fluid~   "|||2018-06-01 02:18:03.806064|2018-06-01 02:18:03.806064
NCT00646477|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-28|Estimate|||||||2008-03-25|2008-03-28|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|||ISIS 1 Therapeutic Effectiveness|Therapeutic Efficacy Evaluation of the CPAP/autoCPAP Sandman in the Treatment of New Patients With Obstructive Sleep Apnoea Syndrome|Unknown status|Recruiting|Phase 3|24|Anticipated|Tyco Healthcare Group||4|||f||||f||||||||||2018-06-01 02:18:03.872923|2018-06-01 02:18:03.872923
NCT00646464|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2018-02-28|2008-03-27|2008-03-28|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2008|Actual|2008-02-29|August 2009|2009-08-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Observational|CPT||New Continuous Performance Tests (CPT) for the Diagnosis of Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)|New Computerized Continuous Performance Test (CPT) for Diagnosing Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)|Completed|||500|Actual|Hadassah Medical Organization|||2||f||||f||||||||||2018-06-01 02:18:03.967946|2018-06-01 02:18:03.967946
NCT00646451|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2015-11-04|2008-03-26|2008-03-28|Estimate|||||||2015-11-04|2015-11-06|Estimate|June 2006||2006-06-30|November 2015|2015-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pregabalin in the Treatment of Essential Tremor|A 17 Week, Investigator-initiated, Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Trial of Pregabalin in Essential Tremor|Completed||Phase 4|20|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:18:04.039812|2018-06-01 02:18:04.039812
NCT00646438|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2009-02-03|2008-03-27|2008-03-28|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2009||2009-03-31|March 2008|2008-03-31|December 2012|Anticipated|2012-12-31|February 2012|Anticipated|2012-02-29||Interventional|USCDP||United States Coronary Artery Bypass Surgery (CABG) Diabetes Project (USCDP) Pilot Study|United States CABG Diabetes Project (USCDP) Pilot Study|Unknown status|Not yet recruiting|N/A|120|Anticipated|Providence Heart & Vascular Institute||2|||f||||f||||||||||2018-06-01 02:18:04.128564|2018-06-01 02:18:04.128564
NCT00646425|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-08-17|2008-03-26|2008-03-28|Estimate|||||||2010-08-17|2010-08-19|Estimate|May 2008||2008-05-31|August 2010|2010-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|BSX-003||The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis|Randomized, Double-Masked, Placebo-controlled Evaluation of the Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis Who Undergo Tapering of Concomitant Immunosuppressive Medications|Terminated||Phase 2|5|Actual|Cerimon Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:18:04.208734|2018-06-01 02:18:04.208734
NCT00646412|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2015-09-08|2008-03-25|2008-03-28|Estimate|||||||2015-09-08|2015-09-09|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|A-PART||A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group|A Prospective, Randomised, Controlled, Single-blind Phase I-II Clinical Trial on the Safety of A-Part® Gel as Adhesion Prophylaxis After Major Abdominal Surgery Versus a Non-treated Group|Completed||Phase 1/Phase 2|60|Actual|Aesculap AG||2|||f||||f||||||||||2018-06-01 02:18:04.399066|2018-06-01 02:18:04.399066
NCT00646399|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2011-08-22||2011-10-20|2008-03-26|2008-03-28|Estimate|2011-10-20|2011-10-24|Estimate||||2011-10-20|2011-10-24|Estimate|March 2009||2009-03-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis|A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis|Completed||Phase 2/Phase 3|1579|Actual|Biosynexus Incorporated||2|||f||||t||||||||||2018-06-01 02:18:04.525699|2018-06-01 02:18:04.525699
NCT00646386|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-28|Estimate|||||||2008-03-26|2008-03-28|Estimate|March 2003||2003-03-31|March 2008|2008-03-31||||April 2004|Actual|2004-04-30||Interventional|||Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis|Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis|Completed||Phase 2|315|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:04.981272|2018-06-01 02:18:04.981272
NCT00646373|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2011-04-19|2008-03-27|2008-03-28|Estimate|||||||2011-04-19|2011-04-20|Estimate|December 2006||2006-12-31|December 2006|2006-12-31||||December 2006|Actual|2006-12-31||Interventional|||Effect of Decreased Pump Prime Volume on Blood Transfusions and Postoperative Complications of Patients Undergoing High Risk Cardiac Surgical Procedures|Effect of Decreased Pump Prime Volume on Blood Transfusions and Postoperative Complications of Patients Undergoing High Risk Cardiac Surgical Procedures: A Pilot Study|Terminated||N/A|50|Actual|University Health Network, Toronto||||"Protocol was comparing to standard of practice, which has changed over the course of slow~   recruitment and no longer can be used as a comparator."|f||||||||||||||2018-06-01 02:18:05.048489|2018-06-01 02:18:05.048489
NCT00646360|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2018-03-20|2008-03-25|2008-03-28|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2005||2005-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2007|Actual|2007-07-31||Interventional|||Effects of Prenatal DHA Supplements on Infant Development|Effects of Prenatal DHA Supplements on Infant Development|Active, not recruiting||Phase 3|1094|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:18:05.099622|2018-06-01 02:18:05.099622
NCT00646347|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2009-02-04|2008-03-27|2008-03-28|Estimate|||||||2009-02-04|2009-02-05|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|January 2009|Anticipated|2009-01-31||Interventional|NHOP||A Pilot Study of Neuro Hand Orthosis Program In Stroke Upper Limb Rehabilitation|A Pilot Study of Neuro Hand Orthosis Program: A Promising Restorative Therapy Treatment for the Severe Paralytic Arm in Subacute Stroke Rehabilitation|Unknown status|Recruiting|N/A|30|Anticipated|St Luke's Hospital, Singapore||2|||f||||t||||||||||2018-06-01 02:18:05.176617|2018-06-01 02:18:05.176617
NCT00646334|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2015-05-27|2008-03-25|2008-03-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2006||2006-06-30|May 2015|2015-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Optilene||Comparative Study of AESCULAP Optilene® Mesh Elastic Versus Ethicon Ultrapro® Mesh in Incisional Hernia Repair|A Randomised, Multi-center, Prospective, Observer and Patient Blind Study to Evaluate AESCULAP Optilene® Mesh Elastic Versus Ethicon Ultrapro® Mesh in Incisional Hernia Repair|Completed||N/A|80|Actual|Aesculap AG||2|||f||||f||||||||||2018-06-01 02:18:05.261125|2018-06-01 02:18:05.261125
NCT00646321|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-01-21|2008-03-27|2008-03-28|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2003||2003-04-30|January 2011|2011-01-31|August 2004|Actual|2004-08-31|||||Interventional|||Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT|A 12 Week, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study of SYMBICORT pMDI Administered Once Daily in Children and Adolescents 6 to 15 Years of Age With Asthma - SPROUT|Completed||Phase 3|540|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:18:05.352332|2018-06-01 02:18:05.352332
NCT00646308|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2011-04-22|2008-03-27|2008-03-28|Estimate|||||||2011-04-22|2011-04-26|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Observational|||Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas|Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas|Terminated|||60|Anticipated|Columbia University|||2|Poor enrollment|f||||f||||||None Retained|"~     Serum samples~   "|||2018-06-01 02:18:05.415163|2018-06-01 02:18:05.415163
NCT00646295|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-06-18|2008-03-27|2008-03-28|Estimate|||||||2008-06-18|2008-06-19|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||Pascal Pascal Dynamic Contour Tonometer (DCT) Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on CT Scan|Pascal Dynamic Contour Tonometer Intraocular Pressure and Ocular Pulse Amplitude in Patients With Thyroid Related Orbitopathy: A Comparison to Goldmann Tonometer and to Muscles Characteristics on Orbital CT Scan|Unknown status|Recruiting|N/A|30|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:18:05.569771|2018-06-01 02:18:05.569771
NCT00646282|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|2015-01-14||2015-01-14|2008-03-27|2008-03-28|Estimate|2015-01-14|2015-01-26|Estimate||||2015-01-14|2015-01-26|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|PAD||Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients|Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney|Terminated||Phase 4|12|Actual|Emory University|Due to slow enrollment and primary investigator leaving institution, the study was terminated. Subjects were notified and those on active drug returned to their physicians to be treated according to standard of care.|2||slow enrollment and discontinued once original principal investigator left Emory|f||||f||||||||||2018-06-01 02:18:05.690838|2018-06-01 02:18:05.690838
NCT00646256|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-28|Estimate|||||||2008-03-25|2008-03-28|Estimate|February 2006||2006-02-28|March 2008|2008-03-31||||December 2008|Anticipated|2008-12-31||Interventional|COGPIP||Cognitive Determinants of Psychoeducation and Information in Psychoses|Psychoeducation in Patients With Schizophrenia: Neuropsychological Performance and Cognitive Training as Determinants of Outcome|Unknown status|Recruiting|N/A|120|Anticipated|German Research Foundation||2|||f||||f||||||||||2018-06-01 02:18:06.077843|2018-06-01 02:18:06.077843
NCT00646243|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-27|2008-03-27|2008-03-28|Estimate|||||||2008-03-27|2008-03-28|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|March 2009|Anticipated|2009-03-31|||||Observational|IMPROVE||Echo Assessment of Intraventricular Dyssynchrony|Italian Multicenter PROject on Echo Assessment of Left VEntricular (IMPROVE) Dyssynchrony Study|Unknown status|Not yet recruiting||336|Anticipated|Italian Society of Cardiology|||2||f||||f||||||||||2018-06-01 02:18:06.161941|2018-06-01 02:18:06.161941
NCT00646230|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2016-12-20|2008-03-27|2008-03-28|Estimate|||||||2016-12-20|2016-12-22|Estimate|December 2006||2006-12-31|December 2016|2016-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|IV Fenretinide||N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma|A Phase I Study of Intravenous (Emulsion) Fenretinide in Children With Recurrent or Resistant Neuroblastoma|Completed||Phase 1|17|Actual|Children's Hospital Los Angeles||1|||f||||t||||||||||2018-06-01 02:18:06.274227|2018-06-01 02:18:06.274227
NCT00646217|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2016-11-23|2008-03-27|2008-03-28|Estimate|||||||2016-11-23|2016-11-28|Estimate|July 2005||2005-07-31|November 2016|2016-11-30|February 2010|Actual|2010-02-28|March 2008|Actual|2008-03-31||Interventional|||Self Care TALK Study - Promoting Stroke Caregiver Health|Promoting Stroke Caregiver Health Vis Self Care TALK: Education and Support Telephone Partnerships With Nurses|Completed||N/A|39|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 02:18:06.378908|2018-06-01 02:18:06.378908
NCT00646204|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2009-04-30|2008-03-26|2008-03-28|Estimate|||||||2009-04-30|2009-05-01|Estimate|April 2006||2006-04-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease|A 16 WEEK, INVESTIGATOR-INITIATED, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NAMENDA® (MEMANTINE HCL) FOR NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE|Completed||Phase 4|40|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:18:06.451322|2018-06-01 02:18:06.451322
NCT00646191|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-28|Estimate|||||||2008-03-26|2008-03-28|Estimate|March 2003||2003-03-31|March 2008|2008-03-31||||June 2004|Actual|2004-06-30||Interventional|||Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Multicenter Extension Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|137|Actual|Abbott||3|||f||||f||||||||||2018-06-01 02:18:06.549965|2018-06-01 02:18:06.549965
NCT00646178|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-28|Estimate|||||||2008-03-26|2008-03-28|Estimate|June 2003||2003-06-30|March 2008|2008-03-31||||March 2004|Actual|2004-03-31||Interventional|||Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy|Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy|Completed||Phase 3|102|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:06.63122|2018-06-01 02:18:06.63122
NCT00646165|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-03-30|2008-03-27|2008-03-28|Estimate|||||||2010-03-30|2010-03-31|Estimate|July 2008||2008-07-31|March 2010|2010-03-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|||Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia|Phase 1, Multicentre, Open-label, Dose Finding Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia|Terminated||Phase 1|1|Actual|Mundipharma Research Limited||||Poor recruitment and change in development strategy|f||||||||||||||2018-06-01 02:18:06.701639|2018-06-01 02:18:06.701639
NCT00646152|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2017-10-05|2008-03-27|2008-03-28|Estimate|||||||2017-10-05|2017-10-06|Actual|March 24, 2008||2008-03-24|July 1, 2014|2014-07-01|December 16, 2009|Actual|2009-12-16|December 16, 2009|Actual|2009-12-16||Interventional|||Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study|A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC|Completed||Phase 1|57|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:18:06.755664|2018-06-01 02:18:06.755664
NCT00646139|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-03-01|2008-03-27|2008-03-28|Estimate|||||||2011-03-01|2011-03-02|Estimate|October 2007||2007-10-31|March 2011|2011-03-31|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|||KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment|A Combined Rising Single-Dose (RSD) and Rising Multiple-Dose (RMD) Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of KX2-391 in Patients With Advanced Malignancies That Are Refractory to Conventional Therapies|Completed||Phase 1|7|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 02:18:06.820261|2018-06-01 02:18:06.820261
NCT00646126|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-27|2008-03-27|2008-03-28|Estimate|||||||2008-03-27|2008-03-28|Estimate|August 2005||2005-08-31|August 2005|2005-08-31||||||||Interventional|||Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission|Validation of the Use of Istope-Based Molecular Techniques for Malaria Control|Completed||Phase 3|||Tropical Medicine Research Institute||2|||f||||t||||||||||2018-06-01 02:18:06.895774|2018-06-01 02:18:06.895774
NCT00646113|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2017-08-21|2008-03-25|2008-03-28|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2008||2008-03-31|August 2017|2017-08-31||||August 2014|Actual|2014-08-31||Interventional|||Study Evaluating OsseoSpeed™ Narrow Implant in the Upper and Lower Anterior Jaw|An Open, Prospective, Single Arm, Multi-centre Study Evaluating Osseospeed™ Implant 3 mm Diameter Replacing a Central or Lateral Mandibular Incisor or Lateral Maxillary Incisor. A 5-year Follow-up Study.|Completed||N/A|72|Actual|Dentsply Sirona Implants||1|||f||||f||||||||||2018-06-01 02:18:06.967363|2018-06-01 02:18:06.967363
NCT00646100|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2012-06-05|2008-03-27|2008-03-28|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|TACEHCC||Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Completed||Phase 4|164|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:18:07.032214|2018-06-01 02:18:07.032214
NCT00646087|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2011-06-03|2008-03-27|2008-03-28|Estimate|||||||2011-06-03|2011-06-06|Estimate|March 2008||2008-03-31|June 2011|2011-06-30||||||||Interventional|||Ketamine Frequency Treatment for Major Depressive Disorder|Ketamine Frequency Treatment for Major Depressive Disorder|Withdrawn||Phase 4|0|Actual|Essentia Health||2||Pilot study determined that this study would not be feasible.|f||||f||||||||||2018-06-01 02:18:07.182239|2018-06-01 02:18:07.182239
NCT00646048|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2010-06-29||2011-01-26|2008-03-27|2008-03-28|Estimate|2010-12-16|2011-01-19|Estimate||||2011-01-26|2011-01-28|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|March 2010|Actual|2010-03-31|November 2004|Actual|2004-11-30||Interventional|AAA IDE||A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms|A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms|Completed||Phase 1|43|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 02:18:07.421415|2018-06-01 02:18:07.421415
NCT00646035|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-28|Estimate|||||||2008-03-26|2008-03-28|Estimate|January 2002||2002-01-31|March 2008|2008-03-31||||November 2002|Actual|2002-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis|A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis|Completed||Phase 3|75|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:07.773087|2018-06-01 02:18:07.773087
NCT00646022|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2018-04-24|2008-03-26|2008-03-28|Estimate|||||||2018-04-24|2018-04-25|Actual|March 24, 2008||2008-03-24|April 12, 2018|2018-04-12||||||||Observational|||Natural History of Familial Carcinoid Tumor|Natural History of Familial Carcinoid Tumor|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:18:07.877074|2018-06-01 02:18:07.877074
NCT00646009|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-01-21|2008-03-26|2008-03-28|Estimate|||||||2011-01-21|2011-01-24|Estimate|March 2003||2003-03-31|January 2011|2011-01-31|August 2003|Actual|2003-08-31|||||Interventional|||Symbicort Onset of Action 2|A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.|Completed||Phase 3|48|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:18:07.960095|2018-06-01 02:18:07.960095
NCT00645996|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-26|2008-03-26|2008-03-28|Estimate|||||||2008-03-26|2008-03-28|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|October 2009|Anticipated|2009-10-31|July 2009|Anticipated|2009-07-31||Interventional|||The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants||Unknown status|Recruiting|N/A|100|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 02:18:08.058865|2018-06-01 02:18:08.058865
NCT00645983|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2009-12-01|2008-03-26|2008-03-28|Estimate|||||||2009-12-01|2009-12-02|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Chamomile Therapy for Generalized Anxiety|Chamomile Therapy for Generalized Anxiety Disorder|Completed||Phase 4|61|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:18:08.156181|2018-06-01 02:18:08.156181
NCT00645970|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2014-12-08||2015-05-14|2008-03-25|2008-03-28|Estimate|2014-12-16|2014-12-30|Estimate||||2015-05-14|2015-05-15|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma|Pain, Psychiatric Disorders, and Disability Among Veterans With and Without Polytrauma|Completed|||359|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 02:18:08.267836|2018-06-01 02:18:08.267836
NCT00645957|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2013-11-19|2008-03-25|2008-03-28|Estimate|||||||2013-11-19|2013-11-21|Estimate|February 2008||2008-02-29|November 2013|2013-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|redrubber||A Comparison of Redrubber Versus Penrose Drains|A Comparison of Redrubber Versus Penrose Drains in the Management of Odontogenic (Dental) Infections|Completed||N/A|50|Actual|Emory University||2|||f||||f||||||||||2018-06-01 02:18:08.474819|2018-06-01 02:18:08.474819
NCT00645944|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|2015-05-05|2012-07-17|2015-06-22|2008-03-27|2008-03-28|Estimate|2015-06-22|2015-07-16|Estimate|2012-07-17|2012-08-01|Estimate|2015-06-22|2015-07-16|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Of the remaining 39 randomized, 19 were randomized to placebo and 20 to eszopiclone 3mg. Two participants in the placebo arm and 1 participant in the eszopiclone arm withdrew before receiving study medication|Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia|Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia|Completed||N/A|39|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:18:08.553068|2018-06-01 02:18:08.553068
NCT00645931|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2009-12-29|2008-03-27|2008-03-28|Estimate|||||||2009-12-29|2009-12-30|Estimate|June 2004||2004-06-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||Psychological Effects of Bone Marrow Transplants in Children|Proposal for a Bone Marrow Transplant Pre, Post, and Long Term Psychological Evaluation Study.|Completed|||40|Anticipated|Spectrum Health Hospitals|||||f||||f||||||||||2018-06-01 02:18:08.792871|2018-06-01 02:18:08.792871
NCT00645918|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2011-06-15|2008-03-26|2008-03-28|Estimate|||||||2011-06-15|2011-06-16|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|GRAVITAS||GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety|GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety|Completed||N/A|2800|Actual|Accumetrics, Inc.||3|||f||||t||||||||||2018-06-01 02:18:08.870749|2018-06-01 02:18:08.870749
NCT00645905|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-28|Estimate|||||||2008-03-26|2008-03-28|Estimate|June 2003||2003-06-30|March 2008|2008-03-31||||March 2005|Actual|2005-03-31||Interventional|||Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|148|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:18:09.130741|2018-06-01 02:18:09.130741
NCT00645892|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-28|Estimate|||||||2008-03-25|2008-03-28|Estimate|November 2003||2003-11-30|March 2008|2008-03-31||||September 2004|Actual|2004-09-30||Interventional|||Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|32|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:18:09.204147|2018-06-01 02:18:09.204147
NCT00645879|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2015-01-17|2008-03-27|2008-03-28|Estimate|||||||2015-01-17|2015-01-21|Estimate|July 2008||2008-07-31|January 2015|2015-01-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Anaplerotic Therapy in Propionic Acidemia|Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia.|Completed||Phase 1|3|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 02:18:09.274794|2018-06-01 02:18:09.274794
NCT00645866|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2011-05-13|2008-03-27|2008-03-28|Estimate|||||||2011-05-13|2011-05-16|Estimate|April 2003||2003-04-30|May 2011|2011-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer|A Neo-Adjuvant Study of Sequential Epirubicin and Docetaxel in Combination With Capecitabine in Patients With Locally Advanced Breast Cancer|Completed||Phase 2|47|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:18:09.366022|2018-06-01 02:18:09.366022
NCT00645853|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2011-06-30||2012-03-20|2008-03-25|2008-03-28|Estimate|2012-02-02|2012-03-06|Estimate||||2012-03-20|2012-03-23|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Long-term Safety in Atrial Fibrillation Patients|Long-term Treatment With the Oral Direct Thrombin Inhibitor AZD0837, Compared to Vitamin-K Antagonists, as Stroke Prevention in Patients With Non-valvular Atrial Fibrillation and One or More Risk Factors for Stroke and Systemic Embolic Events. A 5-year Follow-up Study|Completed||Phase 2|523|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:18:09.476177|2018-06-01 02:18:09.476177
NCT00645840|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2012-06-12|2008-03-27|2008-03-28|Estimate|||||||2012-06-12|2012-06-14|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes|An Exploratory, Open Label Study of Anti-inflammatory Therapy With Anakinra in Children With Newly Diagnosed Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|15|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 02:18:10.160179|2018-06-01 02:18:10.160179
NCT00645827|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|2014-09-03||2014-09-12|2008-03-27|2008-03-28|Estimate|2014-09-12|2014-09-15|Estimate||||2014-09-12|2014-09-15|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|IICE||Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients|Use of an Insulin Infusion Conversion Equation (IICE) to Improve Inpatient Glycemic Control: A Randomized Controlled Trial|Completed||N/A|78|Actual|Emory University||2|||f||||f||||||||||2018-06-01 02:18:10.241577|2018-06-01 02:18:10.241577
NCT00645814|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2008-03-26|2008-03-26|2008-03-28|Estimate|||||||2008-03-26|2008-03-28|Estimate|March 2003||2003-03-31|March 2008|2008-03-31||||September 2003|Actual|2003-09-30||Interventional|||Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|148|Actual|Abbott||3|||f||||f||||||||||2018-06-01 02:18:10.456857|2018-06-01 02:18:10.456857
NCT00645801|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2012-09-04|2008-03-25|2008-03-28|Estimate|||||||2012-09-04|2012-09-06|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Amitiza® Plus GoLYTELY® Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation|Amitiza® (Lubiprostone) Plus GoLYTELY® (Polyethylene Glycol-electrolyte Solution) vs. Placebo Plus GoLYTELY® (Polyethylene Glycol-electrolyte Solution) for Outpatient Colonoscopy Preparation: A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 4|158|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-06-01 02:18:10.519948|2018-06-01 02:18:10.519948
NCT00645788|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|2012-01-21||2014-05-30|2008-03-27|2008-03-28|Estimate|2012-05-30|2012-07-03|Estimate||||2014-05-30|2014-06-09|Estimate|May 2008||2008-05-31|May 2014|2014-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis|Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Inhaled Ciprofloxacin Compared to Placebo in Subjects With Cystic Fibrosis|Completed||Phase 2|288|Actual|Bayer||4|||f||||t||||||||||2018-06-01 02:18:10.663422|2018-06-01 02:18:10.663422
NCT00645775|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-28|Estimate|||||||2008-03-25|2008-03-28|Estimate|November 2006||2006-11-30|August 2006|2006-08-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome|The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.|Completed||N/A|102|Actual|Gateway Health Alliance||1|||f||||t||||||||||2018-06-01 02:18:11.552758|2018-06-01 02:18:11.552758
NCT00645762|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2013-03-15||2013-06-20|2008-03-25|2008-03-28|Estimate|2013-06-20|2013-07-29|Estimate||||2013-06-20|2013-07-29|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|BREATHE I||Balloon REmodeling Antrostomy THErapy Study|Balloon REmodeling Antrostomy THErapy Study (BREATHE I)|Completed||Phase 2|71|Actual|Entellus Medical, Inc.||1|||f||||f||||||||||2018-06-01 02:18:11.648516|2018-06-01 02:18:11.648516
NCT00645749|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2018-01-22|2008-03-25|2008-03-28|Estimate|||||||2018-01-22|2018-01-24|Actual|July 2008||2008-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|April 2016|Actual|2016-04-30||Interventional|HINT||Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis|Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis|Active, not recruiting||Phase 1|17|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:18:11.830539|2018-06-01 02:18:11.830539
NCT00645736|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2011-11-21|2008-03-25|2008-03-28|Estimate|||||||2011-11-21|2011-11-22|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Observational|CHARM||CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study|Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy|Completed|||788|Actual|Gilead Sciences|||1||f||||f||||||||||2018-06-01 02:18:11.902219|2018-06-01 02:18:11.902219
NCT00645723|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2009-08-03|2008-03-25|2008-03-28|Estimate|||||||2009-08-03|2009-08-06|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii|Phase 3b Randomized Double Blind Controled Placebo Comparative Trial of Intravenous Colistin vs Intravenous Colistin Plus Nebulized Colistin in Patients With Ventilator-associated Pneumonia (VAP) Due Multiresistant Acinetobacter Baumanii|Unknown status|Recruiting|Phase 3|67|Anticipated|Hospitales Universitarios Virgen del Rocío||2|||f||||t||||||||||2018-06-01 02:18:11.974693|2018-06-01 02:18:11.974693
NCT00645710|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2018-02-16|2008-03-27|2008-03-28|Estimate|||||||2018-02-16|2018-02-20|Estimate|February 11, 2005||2005-02-11|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery|A Phase I/II Trial of Radioimmunotherapy (Y-90 cT84.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver|Completed||Phase 1/Phase 2|16|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:18:12.049264|2018-06-01 02:18:12.049264
NCT00645697|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-28|Estimate|||||||2008-03-25|2008-03-28|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|AVA-ION||Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization|Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization: Multicenter Collaborative Study|Completed|||100|Actual|Rafic Hariri University Hospital|||||f||||f||||||||||2018-06-01 02:18:12.137051|2018-06-01 02:18:12.137051
NCT00638521|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2013-12-10|2008-03-18|2008-03-19|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|August 2012|Actual|2012-08-31||Observational|||Immune-cell Membrane Trafficking|Trauma and Sepsis Induced Changes in Immune-cell Membrane Receptor Trafficking|Completed|||213|Actual|University of Washington|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 02:20:15.061189|2018-06-01 02:20:15.061189
NCT00645684|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-28|Estimate|||||||2008-03-25|2008-03-28|Estimate|April 1998||1998-04-30|March 2008|2008-03-31|May 2002|Actual|2002-05-31|September 2001|Actual|2001-09-30||Interventional|||Clinical Use of an Absorbable Coated Suture Material in Surgery (Safil)|Clinical Use of an Absorbable Coated Suture Material in Surgery (Safil) One Layer Running(A) vs. Two-Layer Suture Technique (B)|Completed||Phase 4|210|Actual|Aesculap AG||2|||f||||f||||||||||2018-06-01 02:18:12.192404|2018-06-01 02:18:12.192404
NCT00645671|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2010-06-28||2015-03-04|2008-03-25|2008-03-28|Estimate|2010-09-01|2010-09-23|Estimate||||2015-03-04|2015-03-24|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery|A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery|Completed||Phase 3|400|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:18:12.274792|2018-06-01 02:18:12.274792
NCT00645658|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2012-05-03|2008-03-27|2008-03-28|Estimate|||||||2012-05-03|2012-05-07|Estimate|August 2007||2007-08-31|May 2012|2012-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Testosterone Replacement Therapy in Advanced Chronic Kidney Disease|Testosterone Replacement Therapy in Advanced Chronic Kidney Disease|Completed||N/A|17|Actual|Stanford University|||||f||||||||||||||2018-06-01 02:18:12.579161|2018-06-01 02:18:12.579161
NCT00645645|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-27|||2018-05-22|2008-03-27|2008-03-28|Estimate|||||||2018-05-22|2018-05-23|Actual|October 2, 1998||1998-10-02|September 11, 2017|2017-09-11||||||||Observational|||A Study of the Genetic Analysis of Brain Disorders|Genetic Analysis of Brain Disorders|Recruiting|||6000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:18:12.657587|2018-06-01 02:18:12.657587
NCT00645632|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2011-05-13|2008-03-26|2008-03-27|Estimate|||||||2011-05-13|2011-05-16|Estimate|November 1990||1990-11-30|May 2011|2011-05-31|January 2008|Actual|2008-01-31|January 1995|Actual|1995-01-31||Interventional|||Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma|Treatment of Newly Diagnosed Untreated Osteosarcoma: A Pilot Study of a New Chemotherapeutic Regimen Including Ifosfamide|Completed||N/A|60|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 02:18:12.732402|2018-06-01 02:18:12.732402
NCT00645619|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|November 2007||2007-11-30|March 2008|2008-03-31|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Observational|||Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children|Use of a Novel Protein (sTREM-1) to Differentiate Pure Viral Lung Infection From Viral With co-Existing Bacterial Lung Infection|Unknown status|Recruiting||60|Anticipated|University of Texas Southwestern Medical Center|||4||f||||f||||||Samples Without DNA|"~     Bronchoalveolar lavage fluid and Serum.~   "|||2018-06-01 02:18:12.794633|2018-06-01 02:18:12.794633
NCT00645606|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2017-07-27|2008-03-26|2008-03-27|Estimate|||||||2017-07-27|2017-08-01|Actual|December 2007||2007-12-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|February 2014|Actual|2014-02-28||Interventional|LLC2007SA||Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia|Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO|Completed||Phase 3|542|Actual|University Hospital, Tours||2|||f||||t|f|f|||f|||No||2018-06-01 02:18:12.855685|2018-06-01 02:18:12.855685
NCT00645593|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2014-07-16||2016-04-14|2008-03-24|2008-03-27|Estimate|2014-10-22|2014-10-27|Estimate||||2016-04-14|2016-05-23|Estimate|March 2008||2008-03-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Interventional||Although 89 patients were enrolled, only 88 patients were analyzed. 1 patient was randomized to arm A, was treated, and developed grade 4 neutropenia but was found to be ineligible upon histology review and was removed from the study.|Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer|Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma|Completed||Phase 2|89|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-06-01 02:18:12.954542|2018-06-01 02:18:12.954542
NCT00645580|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-23|||2009-02-18|2008-03-26|2008-03-27|Estimate|||||||2009-02-18|2009-02-19|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function|Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function|Unknown status|Active, not recruiting|N/A|15|Anticipated|Sha’ar Menashe Mental Health Center||1|||f||||f||||||||||2018-06-01 02:18:13.539634|2018-06-01 02:18:13.539634
NCT00645567|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2015-02-27||2017-04-05|2008-03-19|2008-03-27|Estimate|2017-04-05|2017-04-07|Actual||||2017-04-05|2017-04-07|Actual|January 2010||2010-01-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Observational||One individual was enrolled in the study but withdrew due to an adverse event (hand injury UNRELATED to the study).|Biomechanics of Wheelchair Transfers|Evaluation of Transfer Technologies to Preserve Shoulder Function in SCI|Completed|||10|Actual|VA Office of Research and Development|PI has left facility. This study did not yield usable results due to staffing, contracting issues. Although 10 individuals signed ICs, 4 actually actively participated in the study and verifiable data is not available for any of the participants.||5||f||||f||||||||No||2018-06-01 02:18:13.626137|2018-06-01 02:18:13.626137
NCT00645554|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2011-05-18|2008-03-24|2008-03-27|Estimate|||||||2011-05-18|2011-05-19|Estimate||||March 2010|2010-03-31|September 2004|Actual|2004-09-30|||||Interventional|||A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers|A Bioequivalent Study to Compare Galantamine Oral Solution With Marketed Galantamine Capsule After Single Oral Administration of 10 mg.|Completed||Phase 1|2|Actual|Xian-Janssen Pharmaceutical Ltd.|||||f||||||||||||||2018-06-01 02:18:13.794529|2018-06-01 02:18:13.794529
NCT00645541|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2012-08-01|2008-03-25|2008-03-27|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Axillary Reverse Mapping for Invasive Carcinoma of the Breast|Axillary Reverse Mapping for Invasive Carcinoma of the Breast|Completed||Phase 1|35|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:18:13.83967|2018-06-01 02:18:13.83967
NCT00645203|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-03-20|2008-03-20|2008-03-27|Estimate|||||||2008-03-20|2008-03-27|Estimate|July 2002||2002-07-31|March 2008|2008-03-31||||April 2003|Actual|2003-04-30||Interventional|||Safety and Efficacy Study of Cefdinir Oral Suspension, in Pediatric Subjects to Treat Acute Otitis Media|An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media|Completed||Phase 2/Phase 3|447|Actual|Abbott||1|||f||||||||||||||2018-06-01 02:18:18.973824|2018-06-01 02:18:18.973824
NCT00645528|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2014-12-10||2015-05-06|2008-03-21|2008-03-27|Estimate|2015-05-06|2015-05-08|Estimate||||2015-05-06|2015-05-08|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional||Subjects were eligible to participate if they (a) were referred to the group by their primary care provider; (b) had uncontrolled diabetes (hemoglobin A1c (A1c) >= 8.0%) not treated with insulin; (c) brought a glucose log to the first visit and (d) signed a consent form.|Do Group Insulin Education Visits Reduce Barriers to Insulin Initiation?|Do Group Insulin Education Visits Reduce Barriers to Insulin Initiation?|Completed||N/A|39|Actual|VA Office of Research and Development|This was a pilot study. Limitations include the small sample size and lack of a control group.|1|||f||||f||||||||||2018-06-01 02:18:13.929085|2018-06-01 02:18:13.929085
NCT00645515|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-04-25|2008-03-20|2008-03-27|Estimate|||||||2008-04-25|2008-05-05|Estimate|June 2003||2003-06-30|April 2008|2008-04-30|December 2003|Actual|2003-12-31|||||Interventional|||A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia|Ziprasidone Versus Risperidone In The Treatment Of Chronic Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study|Terminated||Phase 3|240|Anticipated|Pfizer||2||"This study was terminated on November 20, 2003 because of poor recruitment. This study was not~   terminated due to safety/efficacy."|f||||f||||||||||2018-06-01 02:18:14.300796|2018-06-01 02:18:14.300796
NCT00645502|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2010-04-22|2008-03-26|2008-03-27|Estimate|||||||2010-04-22|2010-04-26|Estimate|June 2003||2003-06-30|April 2010|2010-04-30|July 2003|Actual|2003-07-31|||||Interventional|||Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.|A Bioequivalence Study Comparing a Single Oral Intake of a 4mg Orally-disintegrating Tablet With a 4mg Conventional Risperdal Tablet in Patients With Schizophrenia|Completed||Phase 1|40|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:18:14.411736|2018-06-01 02:18:14.411736
NCT00645489|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2010-01-04|2008-03-26|2008-03-27|Estimate|||||||2010-01-04|2010-01-06|Estimate|March 2008||2008-03-31|December 2008|2008-12-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||A Family Intervention for Improving Self-Care of Patients With Heart Failure|A Family Intervention for Improving Self-Care of Patients With Heart Failure|Completed||Early Phase 1|40|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:18:14.504051|2018-06-01 02:18:14.504051
NCT00645463|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2009-09-16|2008-03-21|2008-03-27|Estimate|||||||2009-09-16|2009-09-17|Estimate|March 2007||2007-03-31|March 2008|2008-03-31|June 2007|Actual|2007-06-30|||||Interventional|||Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics|A Phase 1, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Modified Release Diltiazem On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects|Completed||Phase 1|28|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:14.589154|2018-06-01 02:18:14.589154
NCT00645450|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2013-11-19|2008-03-19|2008-03-27|Estimate|||||||2013-11-19|2013-11-20|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||PTSD Symptom Reduction by Propranolol Given After Trauma Memory Activation|PTSD Symptom Reduction by Propranolol Given After Memory Activation|Terminated||Phase 4|9|Actual|VA Office of Research and Development||2||Difficulty recruiting subjects and unable to replace study physician who changed jobs|f||||t||||||||||2018-06-01 02:18:14.670353|2018-06-01 02:18:14.670353
NCT00645437|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2011-06-06|2008-03-26|2008-03-27|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2004||2004-10-31|April 2010|2010-04-30|April 2006|Actual|2006-04-30|||||Interventional|||A Study to Evaluate the Pharmacokinetics and Safety of Levofloxacin in Patients With Varying Degrees of Renal Function.|An Open-Label Randomized Multiple-Dose Study to Evaluate Levofloxacin Steady-State Pharmacokinetics and Safety in Subjects With Varying Degrees of Renal Function|Completed||Phase 1|59|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:18:14.758487|2018-06-01 02:18:14.758487
NCT00645424|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-04-28|2008-03-24|2008-03-27|Estimate|||||||2008-04-28|2008-05-05|Estimate|December 2003||2003-12-31|April 2008|2008-04-30|October 2004|Actual|2004-10-31|||||Interventional|||A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol|A Randomized, 12-Week, Open Labeled Study To Evaluate The Efficacy And Safety Of Once Daily Atorvastatin In Diabetes Mellitus Type 2 With Hyperlipidemia|Completed||Phase 4|155|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:18:14.8237|2018-06-01 02:18:14.8237
NCT00645411|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2012-11-21|2011-03-25|2015-10-20|2008-03-21|2008-03-27|Estimate|2013-01-15|2013-01-16|Estimate|2011-03-25|2011-04-04|Estimate|2015-10-20|2015-11-23|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|||Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents|A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Children and Adolescents|Completed||Phase 2/Phase 3|3604|Actual|Novartis||4|||f||||t||||||||||2018-06-01 02:18:15.007261|2018-06-01 02:18:15.007261
NCT00645398|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-04-23|2008-03-25|2008-03-27|Estimate|||||||2008-04-23|2008-04-25|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|June 2005|Actual|2005-06-30|||||Interventional|||A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia|A 13-Week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of Pregabalin (BID) in Patients With Fibromyalgia|Completed||Phase 3|751|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 02:18:16.098466|2018-06-01 02:18:16.098466
NCT00645385|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2009-08-26|2008-03-25|2008-03-27|Estimate|||||||2009-08-26|2009-08-28|Estimate|June 2007||2007-06-30|August 2009|2009-08-31|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|Gliadel-MRS||Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.|Treatment Of Newly Diagnosed, High-Grade, Malignant Glioma With Polifeprosan 20 Containing Carmustine Implant (Gliadel® Wafer) Using MR Spectroscopy Data As A Primary Indicator Of Therapeutic Response.|Terminated||N/A|15|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 02:18:16.309247|2018-06-01 02:18:16.309247
NCT00645372|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2015-04-21|2008-03-24|2008-03-27|Estimate|||||||2015-04-21|2015-04-22|Estimate|July 2004||2004-07-31|April 2015|2015-04-30|May 2005|Actual|2005-05-31|||||Interventional|||A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients|A Six Week, Multicenter, Double Blind, Double-Dummy, Parallel, Comparative Study To Compare The Efficacy, Safety And Tolerability Of Ziprasidone With Risperidone In The Treatment Of Chinese Subjects With Acute Exacerbation Of Schizophrenia|Completed||Phase 3|242|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:16.378139|2018-06-01 02:18:16.378139
NCT00645359|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2014-10-03||2017-03-16|2008-03-26|2008-03-27|Estimate|2014-10-03|2014-10-08|Estimate||||2017-03-16|2017-04-14|Actual|November 2006||2006-11-30|March 2017|2017-03-31|April 2014|Actual|2014-04-30|July 2011|Actual|2011-07-31||Observational|dMRI||Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma|Pilot Study of Diffusion MRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B Cell Lymphoma|Terminated|||9|Actual|University of Michigan Cancer Center|This study was not completed due to insufficient resources to evaluate the pilot phase of the study, secondary to shifting research priorities.||1|Insufficient resources to evaluate pilot, second to shift in research priorities|f||||t||||||||||2018-06-01 02:18:16.463905|2018-06-01 02:18:16.463905
NCT00645346|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2011-12-07|2008-03-21|2008-03-27|Estimate|||||||2011-12-07|2011-12-08|Estimate|February 2008||2008-02-29|December 2011|2011-12-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age|A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age|Completed||Phase 1|130|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:18:16.578823|2018-06-01 02:18:16.578823
NCT00645333|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2013-08-09||2014-02-24|2008-03-26|2008-03-27|Estimate|2014-02-24|2014-04-04|Estimate||||2014-02-24|2014-04-04|Estimate|March 2008||2008-03-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|January 2010|Actual|2010-01-31||Interventional|||Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer|Phase I/II Trial of MK-0752 Followed by Docetaxel in Locally Advanced or Metastatic Breast Cancer: A Study by the Stem Cell Clinical Consortium|Completed||Phase 1/Phase 2|30|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 02:18:17.622767|2018-06-01 02:18:17.622767
NCT00645320|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-04-07|2008-03-21|2008-03-27|Estimate|||||||2008-04-07|2008-04-10|Estimate|August 2003||2003-08-31|April 2008|2008-04-30|August 2004|Actual|2004-08-31|||||Interventional|||A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study|An Open Label, Extension Study To Assess The Efficacy And Tolerability Of Oral Ziprasidone In Patients Successfully Completing A Previous Study With Ziprasidone|Completed||Phase 4|75|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:18:17.940443|2018-06-01 02:18:17.940443
NCT00645307|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2011-06-06|2008-03-26|2008-03-27|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|August 2006|Actual|2006-08-31|||||Interventional|||A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS® Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia - Open Label Phase|Completed||Phase 3|235|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:18:18.028675|2018-06-01 02:18:18.028675
NCT00645294|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-03-21|2008-03-21|2008-03-27|Estimate|||||||2008-03-21|2008-03-27|Estimate|February 2003||2003-02-28|March 2008|2008-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV|A Phase 1-2 Open-Label Study of the Pharmacokinetics and Safety of a Single Dose of Adefovir Dipivoxil in Children and Adolescents (Aged 2-17) With Chronic Hepatitis B|Completed||Phase 1/Phase 2|47|Actual|Gilead Sciences||3|||f||||f||||||||||2018-06-01 02:18:18.084928|2018-06-01 02:18:18.084928
NCT00645281|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-27|Estimate|||||||2008-03-25|2008-03-27|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|January 2005|Actual|2005-01-31|||||Interventional|||A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.|Symptom Specific Effectiveness of Tolterodine ER 4 mg in Patients With Symptoms of Overactive Bladder (OAB) in a Primary Care Setting. A Phase IV, Open-Label, Single-Arm, Non-Randomized, Trial in Adult Patients With OAB.|Completed||Phase 4|896|Actual|Pfizer||1|||f||||||||||||||2018-06-01 02:18:18.279765|2018-06-01 02:18:18.279765
NCT00645268|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-03-20|2008-03-20|2008-03-27|Estimate|||||||2008-03-20|2008-03-27|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|January 2004|Actual|2004-01-31|||||Interventional|||A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes|A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes|Completed||Phase 4|300|Anticipated|Pfizer||3|||f||||f||||||||||2018-06-01 02:18:18.504366|2018-06-01 02:18:18.504366
NCT00645255|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-24|2008-03-24|2008-03-27|Estimate|||||||2008-03-24|2008-03-27|Estimate|September 1998||1998-09-30|March 2008|2008-03-31||||January 2003|Actual|2003-01-31||Interventional|||Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Examine the Longer-Term Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Obese Subjects|Terminated||Phase 3|466|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:18:18.637027|2018-06-01 02:18:18.637027
NCT00645242|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-25|2008-03-25|2008-03-27|Estimate|||||||2008-03-25|2008-03-27|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|March 2003|Actual|2003-03-31|||||Interventional|||A Study Of Diflucan In Children With Ringworm Of The Scalp|An Open Label, Multicenter Trial Of Diflucan (Fluconazole) For 6 Weeks Given Once Daily To Pediatric Patients With Tinea Capitis|Completed||Phase 3|185|Anticipated|Pfizer||1|||f||||f||||||||||2018-06-01 02:18:18.729396|2018-06-01 02:18:18.729396
NCT00645229|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-04-07|2008-03-25|2008-03-27|Estimate|||||||2008-04-07|2008-04-10|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|March 2005|Actual|2005-03-31|||||Interventional|||A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder|Efficacy And Safety Of Ziprasidone In Acute Exacerbation Of Schizophrenia Or Schizoaffective Disorder, Including Patients With A Diagnosis Of Recent Onset|Terminated||Phase 3|1|Actual|Pfizer||1||Please see Detailed Description for termination reason.|f||||f||||||||||2018-06-01 02:18:18.831625|2018-06-01 02:18:18.831625
NCT00645216|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2009-08-06|2008-03-21|2008-03-27|Estimate|||||||2009-08-06|2009-08-10|Estimate|June 2007||2007-06-30|March 2008|2008-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety|A Phase 1, Open Label, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Grapefruit Juice On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects|Completed||Phase 1|28|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:18.907872|2018-06-01 02:18:18.907872
NCT00645190|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2011-05-18|2008-03-24|2008-03-27|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2004||2004-03-31|March 2010|2010-03-31|February 2005|Actual|2005-02-28|||||Interventional|||A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease|A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation.|Completed||Phase 3|215|Actual|Xian-Janssen Pharmaceutical Ltd.|||||f||||||||||||||2018-06-01 02:18:19.160574|2018-06-01 02:18:19.160574
NCT00645177|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24||2011-08-23|2013-01-23|2008-03-26|2008-03-27|Estimate||||2011-08-23|2011-08-25|Estimate|2013-01-23|2013-01-29|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 2|10|Actual|AbbVie||2|||f||||||||||||||2018-06-01 02:18:19.226451|2018-06-01 02:18:19.226451
NCT00645164|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2008-10-08||2010-06-01|2008-03-24|2008-03-27|Estimate|2009-03-04|2009-04-06|Estimate||||2010-06-01|2010-06-08|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment|Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment|Completed||Phase 1|59|Actual|Healthpoint|Interpretation of frequency distribution of skin irritation scores was based on long term experience with this type of testing.|1|||f||||f||||||||||2018-06-01 02:18:19.317723|2018-06-01 02:18:19.317723
NCT00645151|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-04-08|2008-03-25|2008-03-27|Estimate|||||||2008-04-08|2008-04-10|Estimate|April 2004||2004-04-30|April 2008|2008-04-30|February 2005|Actual|2005-02-28|||||Interventional|LA ATGOAL||A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol|A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study)|Completed||Phase 4|512|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:18:19.494837|2018-06-01 02:18:19.494837
NCT00645138|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-08-04|2008-03-25|2008-03-27|Estimate|||||||2011-08-04|2011-08-05|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of Paravertebral Block With General Anesthesia in Patients Undergoing Breast Cancer Surgery|A Comparison of Ultrasound-assisted Paravertebral Block and General Anesthesia for Outpatient Breast Cancer Surgery, a Prospective Randomized Trial|Completed||Phase 3|40|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:18:19.622383|2018-06-01 02:18:19.622383
NCT00645125|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|January 2003||2003-01-31|March 2008|2008-03-31||||February 2003|Actual|2003-02-28||Interventional|||A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications|A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications|Completed||Phase 4|154|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:19.725243|2018-06-01 02:18:19.725243
NCT00645112|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2008-03-22|2008-03-22|2008-03-27|Estimate|||||||2008-03-22|2008-03-27|Estimate|November 2003||2003-11-30|March 2008|2008-03-31||||January 2004|Actual|2004-01-31||Interventional|||A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media|A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media|Completed||Phase 4|357|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:19.805824|2018-06-01 02:18:19.805824
NCT00645099|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2010-04-07||2014-04-24|2008-03-24|2008-03-27|Estimate|2010-07-01|2010-07-29|Estimate||||2014-04-24|2014-05-08|Estimate|October 2007||2007-10-31|April 2014|2014-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia|A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia|Completed||Phase 3|462|Actual|Janssen-Cilag International NV|Open-label design|2|||f||||f||||||||||2018-06-01 02:18:19.971993|2018-06-01 02:18:19.971993
NCT00645086|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|December 2002||2002-12-31|March 2008|2008-03-31||||April 2004|Actual|2004-04-30||Interventional|||Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis|A Phase III Comparative Efficacy Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Subjects With Acute Bacterial Exacerbation of Chronic Bronchitis.|Completed||Phase 3|465|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:20.794169|2018-06-01 02:18:20.794169
NCT00645073|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2008-03-22|2008-03-22|2008-03-27|Estimate|||||||2008-03-22|2008-03-27|Estimate|November 2003||2003-11-30|March 2008|2008-03-31||||March 2004|Actual|2004-03-31||Interventional|||Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis|A Phase IV Comparative Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis|Completed||Phase 4|271|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:21.086129|2018-06-01 02:18:21.086129
NCT00645060|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2018-05-04|2008-03-26|2008-03-27|Estimate|||||||2018-05-04|2018-05-07|Actual|October 9, 2006||2006-10-09|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors|A Phase I Study of Yttrium-90 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced Malignancies|Active, not recruiting||Phase 1|18|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:18:21.203877|2018-06-01 02:18:21.203877
NCT00645047|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2015-07-07||2017-03-02|2008-03-19|2008-03-27|Estimate|2017-03-02|2017-04-14|Actual||||2017-03-02|2017-04-14|Actual|February 2009||2009-02-28|November 2016|2016-11-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|VTOPS||Veterans Telemedicine Outreach for PTSD Services|Veterans Telemedicine Outreach for PTSD Services|Completed||N/A|207|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-06-01 02:18:21.318676|2018-06-01 02:18:21.318676
NCT00645034|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2017-03-07|2008-03-26|2008-03-27|Estimate|||||||2017-03-07|2017-03-10|Actual|November 2002||2002-11-30|March 2017|2017-03-31|July 2003|Actual|2003-07-31|||||Interventional|||A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin|A Double-blind, Placebo-controlled, Randomized, 2-way Crossover Study to Investigate the Hemodynamic Effects of a Single Dose of Sildenafil (100mg) in Subjects With Benign Prostatic Hyperplasia Being Treated With Doxazosin|Completed||Phase 2|20|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:21.589792|2018-06-01 02:18:21.589792
NCT00645021|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21||2009-08-26|2009-08-26|2008-03-21|2008-03-27|Estimate||||2009-08-11|2009-08-13|Estimate|2009-08-26|2009-08-27|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug|A Phase 1, Open-Label, Parallel Group, Multiple-Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of CP-945,598 Administered To Subjects With Impaired And Normal Hepatic Function|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:18:21.65222|2018-06-01 02:18:21.65222
NCT00645008|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2017-02-02|2008-03-25|2008-03-27|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 2008|Actual|2008-04-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||Identification of Dominate Stressors in the Intensive Care Unit (ICU)|Stressors Associated With Cardiac Surgery Intensive Care Treatment|Completed|||160|Actual|Weill Medical College of Cornell University|||||f||||f|f|f||||||No|Will not be shared|2018-06-01 02:18:21.725809|2018-06-01 02:18:21.725809
NCT00644995|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|2013-07-01||2017-10-11|2008-03-25|2008-03-27|Estimate|2014-07-23|2014-07-24|Estimate||||2017-10-11|2017-10-13|Actual|November 2008||2008-11-30|October 2017|2017-10-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Effectiveness of The Step Up Wellness Program for People With Depression|Step Up Wellness Program for Depression, Physical Inactivity, and Smoking|Completed||N/A|52|Actual|Kaiser Permanente|"This was a pilot feasibility trial and was not powered to detect statistically significant outcomes.~Point prevalent abstinence outcomes imputed missing values as smokers."|2|||f||||f||||||||||2018-06-01 02:18:21.785027|2018-06-01 02:18:21.785027
NCT00644982|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-04-07|2008-03-26|2008-03-27|Estimate|||||||2008-04-07|2008-04-10|Estimate|October 2002||2002-10-31|April 2008|2008-04-30|September 2003|Actual|2003-09-30|||||Interventional|||A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression|A Multicenter Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder|Completed||Phase 4|163|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:22.036745|2018-06-01 02:18:22.036745
NCT00644969|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2011-03-23||2011-03-23|2008-03-21|2008-03-27|Estimate|2011-03-23|2011-04-15|Estimate||||2011-03-23|2011-04-15|Estimate|May 2008||2008-05-31|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder|A Phase 3B 12-Week, Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Varenicline Tartrate (CP-526,555) 1 mg BID for Smoking Cessation in Subjects With Schizophrenia and Schizoaffective Disorder.|Completed||Phase 3|128|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:18:22.238057|2018-06-01 02:18:22.238057
NCT00644956|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|November 2003|Actual|2003-11-30|||||Interventional|||A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil|A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra (Sildenafil Citrate) And Cialis (Tadalafil)|Completed||Phase 4|56|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:22.994716|2018-06-01 02:18:22.994716
NCT00644943|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-03-21|2008-03-21|2008-03-27|Estimate|||||||2008-03-21|2008-03-27|Estimate|February 2003||2003-02-28|March 2008|2008-03-31||||April 2003|Actual|2003-04-30||Interventional|||A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media|A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media|Completed||Phase 4|425|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:23.090967|2018-06-01 02:18:23.090967
NCT00644930|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|September 2005|Actual|2005-09-30||Interventional|NPPV||Non-Invasive Positive Pressure Ventilation and Adult Respiratory Distress Syndrome (ARDS)|The Efficacy of Non-Invasive Positive Pressure Ventilation in ARDS: A Controlled Cohort Study|Completed||N/A|20|Actual|Eskisehir Osmangazi University||2|||f||||t||||||||||2018-06-01 02:18:23.211291|2018-06-01 02:18:23.211291
NCT00644917|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2013-10-09||2013-12-11|2008-03-24|2008-03-27|Estimate|2013-12-11|2014-01-13|Estimate||||2013-12-11|2014-01-13|Estimate|February 2008||2008-02-29|December 2013|2013-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment|Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment|Completed||Phase 1|38|Actual|Healthpoint||3|||f||||f||||||||||2018-06-01 02:18:23.297103|2018-06-01 02:18:23.297103
NCT00644904|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-27|2008-03-26|2008-03-27|Estimate|||||||2008-03-27|2008-03-28|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|VitD4MS||Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis|A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis|Completed||Phase 1/Phase 2|49|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 02:18:23.46137|2018-06-01 02:18:23.46137
NCT00644891|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|January 2003||2003-01-31|March 2008|2008-03-31||||January 2003|Actual|2003-01-31||Interventional|||Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications|A Comparative, Multi-Center, Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications|Completed||Phase 4|158|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:23.557548|2018-06-01 02:18:23.557548
NCT00644878|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2016-11-16|2008-03-26|2008-03-27|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|MACS0254||Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib|A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib|Completed||Phase 4|18|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:18:23.655447|2018-06-01 02:18:23.655447
NCT00644852|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2014-05-22|2008-03-24|2008-03-27|Estimate|||||||2014-05-22|2014-05-23|Estimate|January 2007||2007-01-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone|Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone|Completed|||342|Actual|Johnson & Johnson Taiwan Ltd|||1||f||||||||||||||2018-06-01 02:18:23.755596|2018-06-01 02:18:23.755596
NCT00021970|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-02-29|2001-08-09|2001-08-10|Estimate|||||||2016-02-29|2016-03-01|Estimate|April 2001||2001-04-30|February 2016|2016-02-29|March 2005||2005-03-31|||||Observational|||Modifying Oxidative Damage in WAVE - Ancillary to WAVE||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:36:43.274644|2018-06-01 05:36:43.274644
NCT00644839|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21||2009-08-11|2009-08-11|2008-03-21|2008-03-27|Estimate||||2009-08-11|2009-08-13|Estimate|2009-08-11|2009-08-13|Estimate|April 2008||2008-04-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug|A Phase 1, Open-Label, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Omeprazole On The Single Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects|Completed||Phase 1|28|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:18:23.816345|2018-06-01 02:18:23.816345
NCT00644826|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-26|||2010-06-01|2008-03-26|2008-03-27|Estimate|||||||2010-06-01|2010-06-03|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Growing Old at Home|Growing Old at Home - Effectiveness and Cost-effectiveness of Preventive Home Visits to Reduce Nursing Home Admissions in the Elderly|Completed||N/A|336|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-06-01 02:18:23.907881|2018-06-01 02:18:23.907881
NCT00644813|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2017-12-18|2008-03-24|2008-03-27|Estimate|||||||2017-12-18|2017-12-19|Actual|March 2008||2008-03-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Observational|||Clinical Outcomes Following Glenoid Neck Fracture as Correlated With Quantitative Assessment of Osseous Injury|Clinical Outcomes Following Glenoid Neck Fracture as Correlated With Quantitative Assessment of Osseous Injury|Active, not recruiting|||75|Anticipated|Boston Medical Center|||1||f||||t||||||||||2018-06-01 02:18:23.990447|2018-06-01 02:18:23.990447
NCT00644800|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-04-07|2008-03-20|2008-03-27|Estimate|||||||2008-04-07|2008-04-10|Estimate|July 2003||2003-07-31|April 2008|2008-04-30|May 2004|Actual|2004-05-31|||||Interventional|||A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis|An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis|Completed||Phase 4|89|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:18:24.053993|2018-06-01 02:18:24.053993
NCT00644787|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2013-04-01||2013-06-06|2008-03-24|2008-03-27|Estimate|2013-04-01|2013-05-21|Estimate||||2013-06-06|2013-06-13|Estimate|December 2007||2007-12-31|June 2013|2013-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Out of a total of 156 participants, Baseline characteristics were available for only 155 participants who were included in Full Analysis Set (FAS) population. FAS population included all participants who applied at least 1 study drug patch and had 1 VAS assessment performed after application of the study drug.|A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain|A Phase II/III Study of JNS020QD in Cancer Pain Patients - A Dose-Finding, Double-Blind Study of JNS020QD Compared With JNS005 in Patients Previously Untreated With Opioid Analgesics|Completed||Phase 2/Phase 3|156|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 02:18:24.19382|2018-06-01 02:18:24.19382
NCT00644774|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|January 2003||2003-01-31|March 2008|2008-03-31||||January 2003|Actual|2003-01-31||Interventional|||A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications|A Comparative, Multi-Center, Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications|Completed||Phase 4|157|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:25.556407|2018-06-01 02:18:25.556407
NCT00644761|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-04-07|2008-03-21|2008-03-27|Estimate|||||||2008-04-07|2008-04-10|Estimate|February 2004||2004-02-29|April 2008|2008-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients|A Multi-Center Phase 2, Open-Label Study to Evaluate the Pharmacokinetics of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil 10 mg to Patients Post-Liver Transplantation|Completed||Phase 2|16|Actual|Gilead Sciences||1|||f||||f||||||||||2018-06-01 02:18:25.651498|2018-06-01 02:18:25.651498
NCT00644748|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-10-09|2008-03-25|2008-03-27|Estimate|||||||2008-10-09|2008-10-10|Estimate|May 2003||2003-05-31|October 2008|2008-10-31|August 2004|Actual|2004-08-31|||||Interventional|||A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy|An Open, Multicenter Study on the Efficacy, Safety and Tolerability of Gabapentin, Titrated for Reaching an Effect for the Treatment of the Painful Diabetic Neuropathy|Completed||Phase 4|95|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:18:25.743528|2018-06-01 02:18:25.743528
NCT00644735|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-25|2008-03-21|2008-03-27|Estimate|||||||2009-03-25|2009-03-26|Estimate|December 2002||2002-12-31|March 2009|2009-03-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed|Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed.|Completed||Phase 4|750|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:18:25.830779|2018-06-01 02:18:25.830779
NCT00644722|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2009-01-27|2008-03-24|2008-03-27|Estimate|||||||2009-01-27|2009-01-29|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|LAMETA||Out-of-Hospital Intubation With Metal Single Use Laryngoscope Blades|Out-of-Hospital Intubation in Emergency Conditions With Either Metal Single Use or Reusable Laryngoscope Blades : Impact on Intubation Difficulties|Completed||Phase 4|800|Anticipated|Henri Mondor University Hospital||2|||f||||t||||||||||2018-06-01 02:18:25.899195|2018-06-01 02:18:25.899195
NCT00644709|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-27|2008-03-25|2008-03-27|Estimate|||||||2008-03-27|2008-03-28|Estimate|September 2003||2003-09-30|March 2008|2008-03-31|March 2005|Actual|2005-03-31|||||Interventional|||A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)|A Multicenter, Open-Label Extension Study Of High-Risk Hyperlipidemic Patients Treated With An Atorvastatin Starting Dose Adapted To Their Baseline LDL-C Level|Completed||Phase 4|196|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:18:25.97599|2018-06-01 02:18:25.97599
NCT00644696|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2017-07-03|2008-03-26|2008-03-27|Estimate|||||||2017-07-03|2017-07-06|Actual|April 2008||2008-04-30|July 2017|2017-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma|A Phase One Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma|Completed||Phase 1|18|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 02:18:26.059193|2018-06-01 02:18:26.059193
NCT00644683|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2014-06-05|2008-03-26|2008-03-27|Estimate|||||||2014-06-05|2014-06-06|Estimate|September 2007||2007-09-30|June 2014|2014-06-30|September 2013|Actual|2013-09-30|March 2012|Actual|2012-03-31||Observational|||A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy|A Pilot Observational Study to Assess Changes in Biochemical Parameters of Ovarian Reserve With Chemotherapy|Completed|||28|Actual|University of Michigan Cancer Center|||||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:18:26.131729|2018-06-01 02:18:26.131729
NCT00644670|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-26|2008-03-24|2008-03-27|Estimate|||||||2008-03-26|2008-03-28|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|March 2004|Actual|2004-03-31|||||Interventional|||A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol|A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving LDL Cholesterol Targets With Atorvastatin Starting Doses Of 10 Mg, 20 Mg And 40 Mg.|Completed||Phase 4|232|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:26.18421|2018-06-01 02:18:26.18421
NCT00644657|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2011-01-06||2011-09-07|2008-03-26|2008-03-27|Estimate|2011-09-07|2011-10-07|Estimate||||2011-09-07|2011-10-07|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization|The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization|Completed||N/A|27|Actual|University of Oklahoma|Limited to primarily Male VA population.||||f||||f||||||||||2018-06-01 02:18:26.272053|2018-06-01 02:18:26.272053
NCT00644644|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2017-04-07|2008-03-25|2008-03-27|Estimate|||||||2017-04-07|2017-04-11|Actual|March 2008||2008-03-31|April 2017|2017-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|TATRC||Validation of the NTX Wireless Patient Monitoring System|A Validation of the NTX Wireless Patient Monitoring System in Combination With Novel Computer Interface to Generate Proactive Medical Responses to Patient Specific Events|Completed|||1303|Actual|Vanderbilt University Medical Center|||2||f||||t||||||||||2018-06-01 02:18:26.497146|2018-06-01 02:18:26.497146
NCT00644631|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|April 2004|Actual|2004-04-30|||||Interventional|||A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate|A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) In The United States|Completed||Phase 4|300|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:26.57408|2018-06-01 02:18:26.57408
NCT00644618|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-24|2008-03-24|2008-03-27|Estimate|||||||2008-03-24|2008-03-27|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy|Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy Versus Gemcitabine Alone in Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 3|120|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-06-01 02:18:26.684282|2018-06-01 02:18:26.684282
NCT00644605|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2015-04-21|2008-03-20|2008-03-27|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2002||2002-10-31|April 2015|2015-04-30|November 2003|Actual|2003-11-30|||||Interventional|||A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension|A Multinational, Multi-centre, Randomised, Double-blind, Double-dummy, Placebo-controlled Study to Assess the Efficacy and Safety of 20, 40, and 80mg TID Sildenafil in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over|Completed||Phase 3|275|Anticipated|Pfizer||4|||f||||f||||||||||2018-06-01 02:18:26.748795|2018-06-01 02:18:26.748795
NCT00644592|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2012-03-12||2012-05-24|2008-03-25|2008-03-27|Estimate|2012-05-23|2012-05-24|Estimate||||2012-05-24|2012-06-01|Estimate|March 2008||2008-03-31|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||LXRA Gene Polymorphisms and Response to Fenofibrate|LXRA Gene Polymorphisms and Response to Fenofibrate|Terminated||N/A|11|Actual|University of Florida||2||supply issues with the formulation of fenofibrate that was used.|f||||f||||||||||2018-06-01 02:18:26.919551|2018-06-01 02:18:26.919551
NCT00644579|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|February 2009|Anticipated|2009-02-28|December 2008|Anticipated|2008-12-31||Interventional|||bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients|bLAC - A Phase II Double-Blind, Placebo Controlled, Clinical Proof of Concept Trial of the Efficacy of 8 Weeks Treatment of Cutaneous Warts With bLAC in Immune Suppressed, Kidney Transplanted Patients|Unknown status|Recruiting|Phase 2|120|Anticipated|NatImmune A/S||3|||f||||f||||||||||2018-06-01 02:18:27.167797|2018-06-01 02:18:27.167797
NCT00644566|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2010-11-04|2008-03-25|2008-03-27|Estimate|||||||2010-11-04|2010-11-05|Estimate|August 2006||2006-08-31|November 2010|2010-11-30|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|shared care||Pilot Study of Shared Care of ADHD in a Pediatric Clinic:Colocation of a Psychologist as an ADHD Care Manager|Pilot Study of Shared Care of ADHD in a Pediatric Clinic:Colocation of a Psychologist as an ADHD Care Manager|Unknown status|Recruiting|N/A|140|Anticipated|Weill Medical College of Cornell University||2|||f||||||||||||||2018-06-01 02:18:27.24352|2018-06-01 02:18:27.24352
NCT00644553|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2008-03-26|2008-03-26|2008-03-27|Estimate|||||||2008-03-26|2008-03-27|Estimate|May 2003||2003-05-31|March 2008|2008-03-31||||March 2004|Actual|2004-03-31||Interventional|||Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis|A Phase IIIB/IV Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets vs. Amoxicillin-Clavulanate for the Treatment of Subjects With Acute Bacterial Sinusitis|Completed||Phase 3|437|Actual|Abbott||2|||f||||||||||||||2018-06-01 02:18:27.322998|2018-06-01 02:18:27.322998
NCT00644540|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2016-11-30|2008-03-25|2008-03-27|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2007||2007-11-30|January 2014|2014-01-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study|A Phase II, Observer-Blind, Parallel Groups, Single Center, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine in the Previous V70P2 Study.|Completed||Phase 2|89|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:18:27.464209|2018-06-01 02:18:27.464209
NCT00644527|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-11-17|2008-03-25|2008-03-26|Estimate|||||||2008-11-17|2008-11-18|Estimate|March 2008||2008-03-31|November 2008|2008-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Receptive Music Therapy for the Treatment of Depression|"Rezeptive Musiktherapie Bei Depression - Eine Randomisierte, Placebokontrollierte Studie / Receptive Music Therapy in Depression: A Randomized Placebo-Controlled Trial"|Completed||N/A|203|Actual|Heidelberg University||4|||f||||t||||||||||2018-06-01 02:18:27.532344|2018-06-01 02:18:27.532344
NCT00319176|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2013-02-06|2006-04-26|2006-04-27|Estimate|||||||2013-02-06|2013-02-08|Estimate|April 2004||2004-04-30|February 2013|2013-02-28|December 2007|Actual|2007-12-31|||||Observational|||Evaluation of Pre-dose and Post-dose Anti-factor Xa Levels With Enoxaparin Use During Pregnancy||Completed|||15|Anticipated|University of California, Irvine|||||f||||||||||||||2018-06-01 04:02:24.163856|2018-06-01 04:02:24.163856
NCT00644514|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2013-07-15|2008-03-24|2008-03-26|Estimate|||||||2013-07-15|2013-07-16|Estimate|September 2007||2007-09-30|July 2013|2013-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Genetics of Asthma - Bronchoscopy Studies|The Genetics of Environmental Asthma: LPS Inhalation and Bronchoscopy in Normal Subjects and Subjects With Mild Atopic Asthma|Terminated||Phase 1|17|Actual|Duke University||1||grant funding no longer available|f||||f||||||||||2018-06-01 02:18:27.759771|2018-06-01 02:18:27.759771
NCT00644501|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2013-07-10|2008-03-23|2008-03-26|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes|Open Label Study to Evaluate Long Term Treatment Effect of DiaPep277® in Patients Who Have Completed Studies 461* (Phase II) or 901** (Pase III)|Completed||Phase 3|43|Actual|Andromeda Biotech Ltd.||1|||f||||t||||||||||2018-06-01 02:18:27.838075|2018-06-01 02:18:27.838075
NCT00644488|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2011-01-24|2008-03-20|2008-03-26|Estimate|||||||2011-01-24|2011-01-25|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer|A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer|Completed||Phase 1|7|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 02:18:27.917814|2018-06-01 02:18:27.917814
NCT00644475|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|March 2009|Anticipated|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension|Randomized, Controlled, Parallel Arm, PROBE Study to Evaluate Different Effects of Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Pavia||2|||f||||f||||||||||2018-06-01 02:18:27.997492|2018-06-01 02:18:27.997492
NCT00644462|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2009-01-10|2008-03-25|2008-03-26|Estimate|||||||2009-01-10|2009-01-13|Estimate|June 2009||2009-06-30|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording|Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording|Unknown status|Not yet recruiting||50|Anticipated|KarmelSonix Ltd.|||2||f||||f||||||||||2018-06-01 02:18:28.120875|2018-06-01 02:18:28.120875
NCT00644449|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-05-12|2008-03-19|2008-03-26|Estimate|||||||2011-05-12|2011-05-16|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|March 2004|Actual|2004-03-31|||||Interventional|||A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (AECB)|Completed||Phase 3|551|Actual|Pfizer||2|||f||||||||||||||2018-06-01 02:18:28.212296|2018-06-01 02:18:28.212296
NCT00644436|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-03-26|2008-03-25|2008-03-26|Estimate|||||||2008-03-26|2008-03-28|Estimate|November 2007||2007-11-30|March 2008|2008-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study to Determine if Tetrix Cream is Removed From the Hands by Gentle Washing With Soap and Water|A Study of the Substantivity of Tetrix Cream|Completed||N/A|10|Actual|Coria Laboratories, Ltd.||2|||f||||f||||||||||2018-06-01 02:18:28.439015|2018-06-01 02:18:28.439015
NCT00644423|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2017-07-26|2008-03-25|2008-03-26|Estimate|||||||2017-07-26|2017-07-28|Actual|September 2008||2008-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)|Omega-3 Fatty Acids and PTSD|Active, not recruiting||N/A|18|Actual|Durham VA Medical Center||2|||f||||f||||||||||2018-06-01 02:18:28.515988|2018-06-01 02:18:28.515988
NCT00644410|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2015-03-16|2008-03-25|2008-03-26|Estimate|||||||2015-03-16|2015-03-17|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Autologous Mesenchymal Stromal Cell Therapy in Heart Failure|A Single Centre, Randomised Controlled Study of the Effect of NOGA-guided Direct Intramyocardial Injection of Mesenchymal Stromal Cells on the Development of New Myocardium and Blood Vessels in Patients With Heart Failure|Completed||Phase 1/Phase 2|59|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:18:28.595139|2018-06-01 02:18:28.595139
NCT00644397|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2018-05-08|2008-03-25|2008-03-26|Estimate|||||||2018-05-08|2018-05-14|Actual|May 2006||2006-05-31|March 2017|2017-03-31|May 2027|Anticipated|2027-05-31|October 2017|Actual|2017-10-31||Observational|||Plate Fixation of Distal Femur Fractures: A Protocol for a Study of Two Plate Options|Plate Fixation of Distal Femur Fractures: a Protocol for a Randomized, Prospective Study of Two Plate Options|Active, not recruiting|||80|Actual|MetroHealth Medical Center|||2||f||||f||||||||||2018-06-01 02:18:28.67775|2018-06-01 02:18:28.67775
NCT00644384|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2011-05-13|2008-03-25|2008-03-26|Estimate|||||||2011-05-13|2011-05-16|Estimate|February 2003||2003-02-28|May 2011|2011-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer|Chemoprevention Trial of Acitretin Versus Placebo in Patients at High Risk for Basal Cell Carcinoma or Squamous Cell Carcinoma|Completed||N/A|130|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:18:28.745867|2018-06-01 02:18:28.745867
NCT00644371|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2017-03-23|2008-03-25|2008-03-26|Estimate|||||||2017-03-23|2017-03-27|Actual|November 2007||2007-11-30|March 2017|2017-03-31|February 4, 2013|Actual|2013-02-04|February 21, 2011|Actual|2011-02-21||Interventional|Z-RIC-Allo||Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)|Allogeneic Transplantation of Haematopoietic Stem Cells Following Non-myeloablative Conditioning With Melphalan, Fludarabine, Thiotepa, Rituximab and Ibritumomab Tiuxetan (Zevalin) in Patients With Aggressive Non-Hodgkin's B-cell Lymphoma|Completed||Phase 2|20|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||||2018-06-01 02:18:28.81917|2018-06-01 02:18:28.81917
NCT00644358|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2017-08-22||2017-08-22|2008-03-25|2008-03-26|Estimate|2017-08-22|2017-09-25|Actual||||2017-08-22|2017-09-25|Actual|December 31, 2007|Actual|2007-12-31|August 2017|2017-08-31|May 31, 2009|Actual|2009-05-31|May 31, 2009|Actual|2009-05-31||Interventional||Safety population consisted of enrolled participants who took at least 1 dose of study drug and had at least 1 post-baseline safety measurement.|A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)|A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder|Completed||Phase 3|616|Actual|Forest Laboratories||1|||f||||f||||||||||2018-06-01 02:18:28.937436|2018-06-01 02:18:28.937436
NCT00644345|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-23|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|May 2009|Anticipated|2009-05-31|January 2009|Anticipated|2009-01-31||Observational|||T-Wave Alternans (TWA) Reproducibility in CAD Patients|Reproducibility of T Wave Alternans Testing in Patients With Ischemic Heart Disease.|Unknown status|Not yet recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 02:18:29.370055|2018-06-01 02:18:29.370055
NCT00644332|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2012-05-29||2012-05-29|2008-03-24|2008-03-26|Estimate|2012-05-29|2012-07-02|Estimate||||2012-05-29|2012-07-02|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)|An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women's Ischemia Symptom Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)|Completed||Phase 4|172|Actual|Gilead Sciences|The study was terminated early at 86% of targeted enrollment (172 of approximately 200 subjects).||||f||||f||||||||||2018-06-01 02:18:29.452349|2018-06-01 02:18:29.452349
NCT00644319|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2009-07-07|2008-03-25|2008-03-26|Estimate|||||||2009-07-07|2009-07-08|Estimate|March 2007||2007-03-31|July 2009|2009-07-31||||September 2009|Anticipated|2009-09-30||Interventional|||Ibuprofen or Morphine in Treating Pain in Patients Undergoing Pleurodesis for Malignant Pleural Effusion|A 2 x 2 Factorial Trial to Assess Whether Non-Steroidal Anti-Inflammatory Analgesics and Small Bore Chest Tubes Are Less Painful Than Opiate Analgesics and a Large Bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion [TIME1]|Unknown status|Recruiting|Phase 2|320|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:18:29.746323|2018-06-01 02:18:29.746323
NCT00644306|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-03-20|2008-03-20|2008-03-26|Estimate|||||||2008-03-20|2008-03-26|Estimate|April 2002||2002-04-30|March 2008|2008-03-31|May 2007|Actual|2007-05-31|||||Interventional|IFM 01/01||Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma|Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma|Terminated||Phase 3|232|Actual|Central Hospital, Nancy, France||2||survival advantage demonstrated|f||||t||||||||||2018-06-01 02:18:29.813559|2018-06-01 02:18:29.813559
NCT00644293|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-06-03|2008-03-19|2008-03-26|Estimate|||||||2011-06-03|2011-06-08|Estimate|January 2003||2003-01-31|June 2011|2011-06-30|April 2004|Actual|2004-04-30|||||Interventional|||A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Three-Day Azithromycin for the Treatment of Group A β-Hemolytic Streptococcal Pharyngitis/Tonsillitis in Adolescents and Adults|Completed||Phase 3|598|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:29.893022|2018-06-01 02:18:29.893022
NCT00644280|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2013-05-29||2013-07-25|2008-03-24|2008-03-26|Estimate|2013-05-29|2013-07-26|Estimate||||2013-07-25|2013-07-31|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery|"Evaluation of Safety and Efficacy of Ranibizumab in Glaucoma Patients Treated With Filtration Tubes"|Terminated||N/A|11|Actual|University of California, San Francisco|IOP reduction may be attributable to cataract surgery instead of or in addition to ranibizumab use. Further studies, with larger sample size and longer follow-up, are needed to evaluate safety and potential efficacy of intravitreal ranibizumab.|2||low recruitment|f||||t||||||||||2018-06-01 02:18:30.174922|2018-06-01 02:18:30.174922
NCT00644267|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2010-09-30|2008-03-24|2008-03-26|Estimate|||||||2010-09-30|2010-10-01|Estimate|April 2008||2008-04-30|September 2010|2010-09-30|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|AHRQ||Using a Telemedicine System to Promote Patient Care Among Underserved Individuals|Using a Telemedicine System to Promote Patient Care Among Underserved Individuals|Unknown status|Active, not recruiting|N/A|242|Actual|Temple University||2|||f||||t||||||||||2018-06-01 02:18:30.395239|2018-06-01 02:18:30.395239
NCT00644254|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2009-07-06|2008-03-20|2008-03-26|Estimate|||||||2009-07-06|2009-07-07|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Observational|ECLNI DPAC||The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma|The Prognostic Impact of Extracapsular Lymph Node Involvement (ECLNI) in Ductal Pancreatic Adenocarcinoma (DPAC).|Completed|||145|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-06-01 02:18:30.46794|2018-06-01 02:18:30.46794
NCT00644241|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2015-10-19|2008-03-25|2008-03-26|Estimate|||||||2015-10-19|2015-10-21|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SCT||Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus|Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|10|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||f||||||||||2018-06-01 02:18:30.568696|2018-06-01 02:18:30.568696
NCT00644228|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|2017-04-20||2017-06-06|2008-03-22|2008-03-26|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|April 2008||2008-04-30|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|July 2016|Actual|2016-07-31||Interventional||Includes all eligible and analyzable patients.|Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma|A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients With Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant|Active, not recruiting||Phase 3|525|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 02:18:30.830026|2018-06-01 02:18:30.830026
NCT00644215|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-06-16|2008-03-25|2008-03-26|Estimate|||||||2008-06-16|2008-06-17|Estimate|June 2007||2007-06-30|June 2008|2008-06-30||||February 2009|Anticipated|2009-02-28||Interventional|||Comparison of Subconjunctival 5-Fluorouracil (FU) Injection and Mitomycin C for Treatment of Early Bleb Failure|Comparison of Subconjunctival 5-FU Injection and Mitomycin C for Treatment of Early Bleb Failure, a Randomized Clinical Trial|Unknown status|Recruiting|N/A|40|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:18:32.39371|2018-06-01 02:18:32.39371
NCT00644202|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-03-20|2008-03-20|2008-03-26|Estimate|||||||2008-03-20|2008-03-26|Estimate|May 2006||2006-05-31|March 2008|2008-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Pilot Weight Control Intervention at HPHC|A Pilot Weight Control Intervention at Harvard Pilgrim Health Care (HPHC)|Completed||N/A|101|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 02:18:32.461537|2018-06-01 02:18:32.461537
NCT00644189|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2017-02-02||2017-03-26|2008-03-24|2008-03-26|Estimate|2017-03-26|2017-05-08|Actual||||2017-03-26|2017-05-08|Actual|June 2008||2008-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2013|Actual|2013-12-31||Interventional||Phase I participants|Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma|A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma|Terminated||Phase 1/Phase 2|50|Actual|Massachusetts General Hospital||1||discontinuation of the drug formulation used in the study|f||||t||||||||||2018-06-01 02:18:32.53112|2018-06-01 02:18:32.53112
NCT00644176|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-06-03|2008-03-19|2008-03-26|Estimate|||||||2011-06-03|2011-06-08|Estimate|November 2004||2004-11-30|June 2011|2011-06-30|April 2005|Actual|2005-04-30|||||Interventional|||A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery|A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin in Serum, Bronchial Washings and Lung Tissue Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Resection|Completed||Phase 2|66|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:32.916768|2018-06-01 02:18:32.916768
NCT00644163|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2014-01-23|2008-03-24|2008-03-26|Estimate|||||||2014-01-23|2014-01-27|Estimate|November 2003||2003-11-30|February 2009|2009-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effectiveness of a Risk Reduction Program in Preventing the Transmission of HIV and Sexually Transmitted Diseases in African-American Couples|NIMH Multisite HIV/STD Prevention Trial for African American Couples|Completed||N/A|1070|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:18:33.02479|2018-06-01 02:18:33.02479
NCT00644150|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2013-12-11|2008-03-24|2008-03-26|Estimate|||||||2013-12-11|2013-12-13|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effectiveness of HIV/Sexually Transmitted Infection Training for Physicians in China|Project Ai Shi Zi: Integrating HIV/STI Prevention and Treatment in China|Completed||N/A|1373|Actual|University of California, Los Angeles||6|||f||||t||||||||||2018-06-01 02:18:34.034826|2018-06-01 02:18:34.034826
NCT00644137|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2015-07-07|2008-03-25|2008-03-26|Estimate|||||||2015-07-07|2015-07-08|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||GABA (Gamma Amino Butyric Acid) Medication for Tobacco|Pregabalin Given to Tobacco Users to Study Addiction|Completed||Early Phase 1|24|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:18:34.132089|2018-06-01 02:18:34.132089
NCT00644124|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2016-05-05|2008-03-21|2008-03-26|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 2008||2008-03-31|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma|A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non Hodgkin's B-cell Lymphoma|Completed||Phase 1|25|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:18:34.263705|2018-06-01 02:18:34.263705
NCT00644111|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2013-02-11|2008-03-25|2008-03-26|Estimate|||||||2013-02-11|2013-02-13|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Post-operative Epidural Analgesia After Minimally Invasive Lumbar Decompression and Fusion|Post-operative Epidural Analgesia After Minimally Invasive Lumbar Decompression and Fusion|Completed||N/A|32|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 02:18:34.356613|2018-06-01 02:18:34.356613
NCT00644098|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2015-09-30|2008-03-25|2008-03-26|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2008||2008-09-30|September 2015|2015-09-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Effect of a Soluble Fibre Blend and Medium Chain Triglycerides on Body Composition and Cardiometabolic Risk Factors|The Effect and Dose-response of Soluble Fibre Blend and Medium Chain Triglycerides (MCT) on Body Composition and Cardiometabolic Risk Factors in Overweight and Obese Adults: a Double-blind, Placebo-controlled Study.|Completed||Phase 2|138|Actual|Canadian Center for Functional Medicine||2|||f||||||||||||||2018-06-01 02:18:34.48783|2018-06-01 02:18:34.48783
NCT00644085|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-03-26|2008-03-25|2008-03-26|Estimate|||||||2008-03-26|2008-03-28|Estimate|April 2000||2000-04-30|March 2008|2008-03-31|December 2007|Actual|2007-12-31|||||Interventional|||Does Low-Dose Aspirin Improve Outcome in In Vitro Fertilisation/Intra Cytoplasmatic Sperm Injection (IVF/ICSI)?|Does Low-Dose Aspirin Improve Outcome in IVF/ICSI? A Prospective, Randomized, Double Blind Placebo Controlled Trial|Completed||Phase 3|201|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:18:34.695231|2018-06-01 02:18:34.695231
NCT00644072|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2017-06-30|2008-03-25|2008-03-26|Estimate|||||||2017-06-30|2017-07-02|Actual|March 7, 2008||2008-03-07|June 16, 2011|2011-06-16|June 16, 2011|Actual|2011-06-16|June 30, 2009|Actual|2009-06-30||Interventional|||SNX-5422 to Treat Solid Tumor Cancers and Lymphomas|Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas|Completed||Phase 1|33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:18:34.770403|2018-06-01 02:18:34.770403
NCT00644059|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2011-10-06||2015-08-31|2008-03-25|2008-03-26|Estimate|2014-10-13|2014-10-15|Estimate||||2015-08-31|2015-09-18|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines|A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months|Completed||Phase 3|4902|Actual|Novartis||3|||f||||t||||||||||2018-06-01 02:18:35.91073|2018-06-01 02:18:35.91073
NCT00644046|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2012-09-05|2008-03-25|2008-03-26|Estimate|||||||2012-09-05|2012-09-06|Estimate|July 2007||2007-07-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Chronic Kidney Disease Prevention of An-Lo District, Keelung|Chronic Kidney Disease Prevention of An-Lo District, Keelung.|Completed||Phase 4|1500|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:18:40.079754|2018-06-01 02:18:40.079754
NCT00644033|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2011-06-13|2008-03-24|2008-03-26|Estimate|||||||2011-06-13|2011-06-14|Estimate|June 2001||2001-06-30|June 2011|2011-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine||Completed||Phase 3|579|Actual|Endo Pharmaceuticals||3|||f||||||||||||||2018-06-01 02:18:40.216052|2018-06-01 02:18:40.216052
NCT00644020|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-23|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Observational|||Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients|A Randomized, Double Blind, Placebo Controled, Multicenter Phase ⅡStudy to Evaluate the Safety and Efficacy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients|Unknown status|Recruiting||100|Anticipated|Shenzhen Kangzhe Pharmaceutical Co., Ltd.|||4||f||||t||||||Samples With DNA|"~     collection of blood sample before the operation and ahead of the third and the sixth period.~      collection of the tumor tissue during the operation~   "|||2018-06-01 02:18:40.373294|2018-06-01 02:18:40.373294
NCT00643656|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2009-01-09|2008-03-20|2008-03-26|Estimate|||||||2009-01-09|2009-01-12|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Use of 50% Nitrous Oxide / 50% Oxygen Premix During Liver Biopsy of Focal Lesion|Study of the Efficiency of Kalinox 170 Bar During Liver Biospy of Focal Lesion|Completed||Phase 4|94|Anticipated|Air Liquide Santé International||2|||f||||f||||||||||2018-06-01 02:18:48.005243|2018-06-01 02:18:48.005243
NCT00644007|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-23|||2013-04-16|2008-03-25|2008-03-26|Estimate|||||||2013-04-16|2013-04-18|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension|A Double Blind, Randomized, Placebo-controlled, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction Taking Antihypertensive Medication|Completed||Phase 3|109|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||||2018-06-01 02:18:40.515364|2018-06-01 02:18:40.515364
NCT00643994|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2016-07-14|2008-03-20|2008-03-26|Estimate|||||||2016-07-14|2016-07-18|Estimate|December 2007||2007-12-31|July 2016|2016-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Homogenous Dose Distribution|Active, not recruiting||Phase 2|298|Anticipated|Accuray Incorporated||1|||f||||t||||||||||2018-06-01 02:18:40.609323|2018-06-01 02:18:40.609323
NCT00643981|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2011-04-27|2008-03-25|2008-03-26|Estimate|||||||2011-04-27|2011-04-28|Estimate|February 2008||2008-02-29|December 2008|2008-12-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|CI||Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia|Phase I Study to See if a of A Combination Stem Cell Therapy is Safe and Feasible for the Treatment of Severe Coronary Ischemia|Completed||Phase 1|10|Anticipated|TCA Cellular Therapy|||||f||||||||||||||2018-06-01 02:18:40.731456|2018-06-01 02:18:40.731456
NCT00643968|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-06-27|2008-03-25|2008-03-26|Estimate|||||||2008-06-27|2008-06-30|Estimate|March 2003||2003-03-31|June 2008|2008-06-30|September 2005|Actual|2005-09-30|June 2005|Actual|2005-06-30||Interventional|COOL||Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial|Randomized Multicenter Open-Label, Pilot Trial to Evaluate the Efficacy and Safety of Switching HIV-1 Stable Infected Patients Under HAART to a New Once Daily Triple Therapy Combination Including EFV+3TC+TDF Versus a Dual QD Therapy Containing EFV+TDF|Completed||Phase 4|140|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 02:18:40.78949|2018-06-01 02:18:40.78949
NCT00643955|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|March 2008||2008-03-31|March 2008|2008-03-31||||||||Observational|||Neuromuscular Characteristics of Individuals With Down Syndrome (DS)|Neuromuscular Characteristics of Individuals With Down Syndrome|Unknown status|Recruiting||15|Anticipated|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 02:18:40.868132|2018-06-01 02:18:40.868132
NCT00643942|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2015-05-08|2008-03-24|2008-03-26|Estimate|||||||2015-05-08|2015-05-12|Estimate|June 2007||2007-06-30|March 2008|2008-03-31||||January 2008|Actual|2008-01-31||Observational|||Staining in a Healthy, Non-Dry Eye Population||Completed|||120||Alcon Research|||1||f||||f||||||||||2018-06-01 02:18:41.05095|2018-06-01 02:18:41.05095
NCT00643929|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2017-03-21|2008-03-18|2008-03-26|Estimate|||||||2017-03-21|2017-03-23|Actual|February 2007||2007-02-28|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|LENS||LENS - Long-term Eltrombopag Observational Study|LENS - Long-term Eltrombopag Observational Study - A Long Term Observational Ocular Safety Follow-up Study in Adults Who Have Received Study Medication (SB-497115-GR / Eltrombopag Olamine or Placebo) in a Phase II or III Clinical Study Evaluating Eltrombopag|Completed|||164|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 02:18:41.128385|2018-06-01 02:18:41.128385
NCT00643916|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2009-09-24||2014-01-21|2008-03-25|2008-03-26|Estimate|2009-12-04|2010-01-08|Estimate||||2014-01-21|2014-02-14|Estimate|December 2004||2004-12-31|January 2014|2014-01-31|October 2007|Actual|2007-10-31|March 2006|Actual|2006-03-31||Interventional|||Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age|Safety and Immunogenicity of a Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine (TetraMenD) In Toddlers 9 to 18 Months of Age|Completed||Phase 2|378|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 02:18:41.391822|2018-06-01 02:18:41.391822
NCT00643903|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2012-01-18|2008-03-24|2008-03-26|Estimate|||||||2012-01-18|2012-01-20|Estimate|April 2004||2004-04-30|January 2012|2012-01-31|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional|||Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project)|The Balance Project - RCT of an HIV Treatment Side Effects Coping Intervention|Completed||N/A|250|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:18:42.468152|2018-06-01 02:18:42.468152
NCT00643890|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2012-02-20|2008-03-24|2008-03-26|Estimate|||||||2012-02-20|2012-02-22|Estimate|August 2008||2008-08-31|February 2012|2012-02-29||||December 2010|Actual|2010-12-31||Interventional|||Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease|Phase 2 Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to Subthalamic Nuclei in Subjects With Advanced Parkinson's Disease|Terminated||Phase 2|44|Anticipated|Neurologix, Inc.||||Due to financial reasons|f||||t||||||||||2018-06-01 02:18:42.558518|2018-06-01 02:18:42.558518
NCT00643877|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2009-03-24|2008-03-25|2008-03-26|Estimate|||||||2009-03-24|2009-03-25|Estimate|December 2008||2008-12-31|March 2009|2009-03-31|December 2014|Anticipated|2014-12-31|December 2009|Anticipated|2009-12-31||Interventional|PHRAC||Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer|A Prospective,Multi-Center,Randomized Control Trial of Preoperative Hepatic and Regional Arterial Chemotherapy(PHRAC) Using Oxaliplatin, Fluorodeoxyuridine(FUDR) and Mitomycin C(MMC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer|Unknown status|Recruiting|Phase 3|600|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 02:18:42.637681|2018-06-01 02:18:42.637681
NCT00643864|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2012-02-09|2008-03-25|2008-03-26|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Mirror-Box Training in Adults With Chronic Hemiparesis Secondary to Stroke|Mirror-Box Training in Adults With Chronic Hemiparesis Secondary to Stroke: A Descriptive Case Series and Pilot Study|Terminated||N/A|3|Actual|Carolinas Healthcare System||||lack of enrollment|f||||t||||||||||2018-06-01 02:18:42.772957|2018-06-01 02:18:42.772957
NCT00643851|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2016-09-30||2017-01-05|2008-03-20|2008-03-26|Estimate|2017-01-05|2017-02-23|Actual||||2017-01-05|2017-02-23|Actual|June 2008||2008-06-30|January 2017|2017-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||All randomized participants who received at least 1 dose of study medication|An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets|A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 3|994|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:18:42.912825|2018-06-01 02:18:42.912825
NCT00643838|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2009-01-09|2008-03-20|2008-03-26|Estimate|||||||2009-01-09|2009-01-12|Estimate|December 2007||2007-12-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Use of 50% Nitrous Oxide / 50% Oxygen Premix in Primary Care Dental Centers|Sedation Faisability by Inhalation of Kalinox 170 Bar During Therapeutic Cares in Primary Care Dental Centers|Completed||Phase 3|480|Anticipated|Air Liquide Santé International||1|||f||||f||||||||||2018-06-01 02:18:44.048674|2018-06-01 02:18:44.048674
NCT00643825|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2010-07-22|2008-03-25|2008-03-26|Estimate|||||||2010-07-22|2010-07-23|Estimate|January 2008||2008-01-31|July 2010|2010-07-31|January 2012|Anticipated|2012-01-31|January 2011|Anticipated|2011-01-31||Interventional|PATSGO||"Prolonged Adjuvant Temozolomide vs Stop & Go in Glioblastoma Patients"|"Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or Stop and Go in Glioblastoma Patients: The PATSGO Study"|Unknown status|Recruiting|Phase 2|64|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-06-01 02:18:44.120588|2018-06-01 02:18:44.120588
NCT00643812|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Improving Firearm Storage in Alaska Native Villages|Improving Firearm Storage in Alaska Native Villages|Completed||N/A|266|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:18:44.270246|2018-06-01 02:18:44.270246
NCT00643799|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-04-22|2008-03-18|2008-03-26|Estimate|||||||2008-04-22|2008-04-24|Estimate|March 2004||2004-03-31|April 2008|2008-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|CLOAK||Safety and Efficacy of Celecoxib Versus Naproxen in the 6-Month Treatment of Knee Osteoarthritis|A Randomized, Multicenter, Double-Blind, Double-Dummy Study Comparing the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Naproxen 500 mg Twice Daily in the 6-Month Treatment of Subjects With Osteoarthritis of the Knee|Completed||Phase 4|586|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:18:44.376883|2018-06-01 02:18:44.376883
NCT00643786|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2014-06-23|2008-03-25|2008-03-26|Estimate|||||||2014-06-23|2014-06-24|Estimate|February 2004||2004-02-29|June 2014|2014-06-30|June 2008|Actual|2008-06-30|May 2007|Actual|2007-05-31||Interventional|||Interest of Re-oxygenation After Inhalation of 50% Nitrous Oxide / 50% Oxygen Premix in Dental Cares|Validation of a Kalinox's Administration Protocol for Dental Cares : Interest of Re-oxygenation and Pollution Control|Terminated||Phase 3|128|Actual|Air Liquide Santé International||2|||f||||f||||||||||2018-06-01 02:18:44.527747|2018-06-01 02:18:44.527747
NCT00643773|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2011-08-25|2008-03-25|2008-03-26|Estimate|||||||2011-08-25|2011-08-26|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||The Effect of Leucine on Body Composition and Muscle Characteristics in Elderly, Type 2 Diabetes Patients|The Influence of Leucine Supplementation on Body Composition and Muscle Characteristics in Elderly, Type 2 Diabetes Patients.|Completed||Phase 2/Phase 3|60|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 02:18:44.596602|2018-06-01 02:18:44.596602
NCT00643760|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2011-04-21|2010-05-14|2013-07-15|2008-03-19|2008-03-26|Estimate|2011-04-21|2011-05-11|Estimate|2010-05-14|2010-05-18|Estimate|2013-07-15|2013-07-22|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)|Study PXN110448: A Dose-response Study of XP13512, Compared With Concurrent Placebo Control and LYRICA(Pregabalin), in Subjects With Neuropathic Pain Associated Withdiabetic Peripheral Neuropathy (DPN)|Completed||Phase 2|421|Actual|XenoPort, Inc.||5|||f||||f||||||||||2018-06-01 02:18:44.697592|2018-06-01 02:18:44.697592
NCT00643747|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2015-12-04|2008-03-25|2008-03-26|Estimate|||||||2015-12-04|2015-12-07|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety Study of RPE65 Gene Therapy to Treat Leber Congenital Amaurosis|An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (AAV2/2-hRPE65p-hRPE65) for Gene Therapy of Severe Early-onset Retinal Degeneration|Completed||Phase 1/Phase 2|12|Actual|University College, London||1|||f||||t||||||||||2018-06-01 02:18:46.919557|2018-06-01 02:18:46.919557
NCT00643734|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-19|2008-03-19|2008-03-26|Estimate|||||||2008-03-19|2008-03-26|Estimate|April 2003||2003-04-30|March 2008|2008-03-31|April 2004|Actual|2004-04-30|||||Interventional|||A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults|Completed||Phase 3|468|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:47.056791|2018-06-01 02:18:47.056791
NCT00643721|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|April 2008|Anticipated|2008-04-30|April 2008|Anticipated|2008-04-30||Observational|||Body Water Content Sensor|Body Water Content Sensor|Unknown status|Active, not recruiting||12|Anticipated|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 02:18:47.250753|2018-06-01 02:18:47.250753
NCT00643708|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Ovarian Laser Treatment in Women With Polycystic Ovarian Syndrome: A Randomized Study on the Laser Dose|Transvaginal Ultrasound-Guided Ovarian Interstitial Laser Treatment in Anovulatory Women With Polycystic Ovarian Syndrome: A Randomized Prospective Study on the Effect of Laser Dose Used on the Outcome|Completed|||56|Actual|Shen-Zhen City Maternity and Child Healthcare Hospital|||4||f||||t||||||||||2018-06-01 02:18:47.309795|2018-06-01 02:18:47.309795
NCT00643695|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2016-03-28|2008-03-20|2008-03-26|Estimate|||||||2016-03-28|2016-03-29|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C|Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C|Completed||N/A|14|Actual|Portland VA Medical Center||2|||f||||f||||||||||2018-06-01 02:18:47.383101|2018-06-01 02:18:47.383101
NCT00643682|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2012-07-09||2012-08-29|2008-03-20|2008-03-26|Estimate|2012-08-29|2012-10-01|Estimate||||2012-08-29|2012-10-01|Estimate|February 2006||2006-02-28|August 2012|2012-08-31|October 2009|Actual|2009-10-31|June 2008|Actual|2008-06-30||Interventional|||Improving Bowel Preparation for Colonoscopy With a Simple Educational Card|Improving Bowel Preparation for Colonoscopy With a Simple Educational Card|Completed||N/A|2000|Actual|Boston Medical Center||2|||f||||f||||||||||2018-06-01 02:18:47.635625|2018-06-01 02:18:47.635625
NCT00643669|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24||2012-11-27|2012-11-27|2008-03-24|2008-03-26|Estimate||||2012-11-27|2012-11-29|Estimate|2012-11-27|2012-11-29|Estimate|February 2008||2008-02-29|November 2012|2012-11-30||||April 2008|Actual|2008-04-30||Interventional|||24 Hour IOP Lowering Efficacy of AL-3789||Completed||Phase 2|25|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:18:47.930687|2018-06-01 02:18:47.930687
NCT00021957|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-02-17|2001-08-09|2001-08-10|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2001||2001-04-30|May 2005|2005-05-31|March 2005|Actual|2005-03-31|||||Observational|||ESCAPE Mechanistic Substudies - Ancillary to ESCAPE||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:36:43.344882|2018-06-01 05:36:43.344882
NCT00643643|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2010-11-09|2008-03-19|2008-03-26|Estimate|||||||2010-11-09|2010-11-10|Estimate|October 2002||2002-10-31|November 2010|2010-11-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus|A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.|Completed||Phase 2|41|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-06-01 02:18:48.13124|2018-06-01 02:18:48.13124
NCT00643630|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-05-19|2008-03-25|2008-03-26|Estimate|||||||2008-05-19|2008-05-22|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Evaluation of Tetrix Cream as a Protective Barrier Against Injurious Materials|A Study to Determine the Skin Barrier Effect of Tetrix Cream|Completed||N/A|36|Actual|Coria Laboratories, Ltd.||2|||f||||f||||||||||2018-06-01 02:18:48.296495|2018-06-01 02:18:48.296495
NCT00643617|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2016-07-14|2008-03-20|2008-03-26|Estimate|||||||2016-07-14|2016-07-18|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry|Active, not recruiting||Phase 2|253|Anticipated|Accuray Incorporated||1|||f||||t||||||||||2018-06-01 02:18:48.362447|2018-06-01 02:18:48.362447
NCT00643604|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2013-03-28||2013-06-19|2008-03-25|2008-03-26|Estimate|2013-06-19|2013-06-21|Estimate||||2013-06-19|2013-06-21|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|January 2010|Actual|2010-01-31||Interventional|||Rapid Switch From Flolan to Remodulin in the Outpatient Clinic|Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension in the Outpatient Clinic: Safety, Efficacy and Treatment Satisfaction|Terminated||Phase 4|7|Actual|United Therapeutics|The main limitations of this study are the small sample size, open-label design and relatively short duration of follow-up.|1||"Due to availability of eligible subjects at center and enrollment competition with other~   studies."|f||||f||||||||||2018-06-01 02:18:48.5412|2018-06-01 02:18:48.5412
NCT00643591|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2015-04-09|2008-03-25|2008-03-26|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Observational|||Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma|Pilot Study on the Determination of Therapy Resistant Areas Within the Tumor in Patients With High-grade Glioma by Repeated 18F-FDG-PET-CT Scans|Terminated|||10|Actual|Maastricht Radiation Oncology|||1|Patient compliance was low.|f||||t||||||Samples Without DNA|"~     EDTA blood, serum~   "|||2018-06-01 02:18:49.062378|2018-06-01 02:18:49.062378
NCT00643578|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2011-08-05||2011-11-29|2008-03-20|2008-03-26|Estimate|2011-11-08|2011-11-18|Estimate||||2011-11-29|2011-12-05|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay|A Pilot Study to Evaluate the Dose-response of Inhaled Formoterol to Inhibit Airway Responsiveness to Methacholine in Patients With Mild Asthma|Completed||N/A|37|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 02:18:49.129826|2018-06-01 02:18:49.129826
NCT00643565|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2015-12-07||2018-03-15|2008-03-25|2008-03-26|Estimate|2016-01-15|2016-02-12|Estimate||||2018-03-15|2018-03-19|Actual|July 29, 2008|Actual|2008-07-29|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|May 31, 2015|Actual|2015-05-31||Interventional||Intent-to-treat (ITT) population included all participants randomized to the treatment group in the study.|A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.|An Open-label, Multi-center, Randomized Study of the Safety and Effect on Event-free Survival of Bevacizumab in Combination With Standard Chemotherapy in Childhood and Adolescent Patients With Metastatic Rhabdomyosarcoma and Non-rhabdomyosarcoma Soft Tissue Sarcoma|Active, not recruiting||Phase 2|154|Actual|Hoffmann-La Roche|Reported results represent the interim results up to approximately 6.75 years (data cut-off date 31 May 2015).|2|||f||||||||||||||2018-06-01 02:18:49.550669|2018-06-01 02:18:49.550669
NCT00643552|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate||||March 2008|2008-03-31||||||||Observational|||Muscle Strength, Physical Work Capacity and Functional Performance in Individuals With Down Syndrome|Muscle Strength, Physical Work Capacity and Functional Performance in Individuals With Down Syndrome|Completed|||18|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:18:50.433425|2018-06-01 02:18:50.433425
NCT00643539|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-19|2008-03-19|2008-03-26|Estimate|||||||2008-03-19|2008-03-26|Estimate|December 2002||2002-12-31|March 2008|2008-03-31|July 2003|Actual|2003-07-31|||||Interventional|||Multicenter, Open, Randomized Comparative Trial To Compare The Efficacy Of Azithromycin Versus Amoxicillin In Children With Strep Throat|Multicenter, Open, Randomized Comparative Trial To Compare Bacteriological And Clinical Efficacy Of Azithromycin Versus Amoxicillin In Children With Streptococcus Tonsillitis|Completed||Phase 4|360|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:50.597835|2018-06-01 02:18:50.597835
NCT00643526|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2015-04-09|2008-03-24|2008-03-26|Estimate|||||||2015-04-09|2015-04-10|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector|An Open-Label, Randomized, Validation Study to Establish That the Design, Functionality, and Ergonomic Features of the Autoinjector Conform to Defined User Needs and Intended Use for Self-Administration by Subjects With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Psoriasis|Completed||Early Phase 1|68|Actual|Centocor, Inc.||2|||f||||f||||||||||2018-06-01 02:18:50.804257|2018-06-01 02:18:50.804257
NCT00643513|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2009-04-21|2008-03-20|2008-03-26|Estimate|||||||2009-04-21|2009-04-22|Estimate|June 2007||2007-06-30|April 2009|2009-04-30|January 2009|Actual|2009-01-31|||||Observational|||Quality Of Life While Receiving Faslodex|Quality Of Life And Symptoms In Postmenopausal Women With Hormone Receptor Positive Disseminated Breast Cancer While Receiving Faslodex.|Completed|||120|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 02:18:50.875605|2018-06-01 02:18:50.875605
NCT00643500|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2013-11-14|2008-03-25|2008-03-26|Estimate|||||||2013-11-14|2013-11-15|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy|Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy|Completed||Phase 4|342|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:18:50.950744|2018-06-01 02:18:50.950744
NCT00643305|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2013-05-02|2008-03-25|2008-03-26|Estimate|||||||2013-05-02|2013-05-03|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||HIV Prevention With the Mentally Ill|HIV Prevention With the Mentally Ill: Motivation-Skills|Completed||Phase 2|53|Actual|Boston Medical Center||2|||f||||t||||||||||2018-06-01 02:18:52.831136|2018-06-01 02:18:52.831136
NCT00643487|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2016-05-03||2018-04-20|2008-03-25|2008-03-26|Estimate|2016-05-03|2016-05-18|Estimate||||2018-04-20|2018-04-24|Actual|February 2006||2006-02-28|April 2018|2018-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||In Vivo Arthroscopic Behavior of the Infrapatellar Plica of the Knee|In Vivo Arthroscopic Behavior of the Infrapatellar Plica of the Knee|Completed|||8|Actual|State University of New York - Upstate Medical University|It is difficult technically to place percutaneously an 18 gauge spinal needle in the central body of the fat pad in an awake patient who is lightly sedated. We were fortunate to achieve complete films in 2 patients, and partial films in 3 others.||1||f||||f||||||||||2018-06-01 02:18:51.033449|2018-06-01 02:18:51.033449
NCT00643474|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2016-03-01|2008-03-25|2008-03-26|Estimate|||||||2016-03-01|2016-03-03|Estimate|March 2008||2008-03-31|May 2010|2010-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)|PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)|Completed||N/A|1000|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:18:51.162665|2018-06-01 02:18:51.162665
NCT00643461|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2013-04-16|2008-03-25|2008-03-26|Estimate|||||||2013-04-16|2013-04-18|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Observational|||Clinical Evaluation of Three Dental Adhesive Systems in Class V Restorations|Clinical Evaluation of Three Dental Adhesive Systems in Class V Restorations|Completed|||46|Actual|3M|||3||f||||f||||||||||2018-06-01 02:18:51.41983|2018-06-01 02:18:51.41983
NCT00643448|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2011-01-24||2011-12-21|2008-03-20|2008-03-26|Estimate|2011-12-21|2012-01-26|Estimate||||2011-12-21|2012-01-26|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Explorative Study of AZD1305 in Atrial Fibrillation Patients|A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship Between QTcF Interval at First Dose (Loading Dose) and at Steady State After Treatment With AZD1305 Extended-release Tablets or Placebo When Given to Patients With Documented AF|Completed||Phase 2|65|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:18:51.520983|2018-06-01 02:18:51.520983
NCT00643435|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-25|2008-03-25|2008-03-26|Estimate|||||||2008-03-25|2008-03-26|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|March 2008|Actual|2008-03-31|June 2007|Actual|2007-06-30||Interventional|SEE-IT||Self-Efficacy Enhancing Interviewing Techniques Study|Self-Efficacy Enhancing Interviewing Techniques Study|Completed||N/A|64|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 02:18:51.82773|2018-06-01 02:18:51.82773
NCT00643422|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-22|||2008-07-21|2008-03-25|2008-03-26|Estimate|||||||2008-07-21|2008-07-22|Estimate||||July 2008|2008-07-31||||||||Observational|||Reproducibility of Cirrus Optical Coherence Tomography Measurements|Reproducibility of Retinal Thickness and Volume Measurements Determined With the Cirrus Spectral Domain OCT|Completed|||16|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||1||f||||||||||||||2018-06-01 02:18:51.893334|2018-06-01 02:18:51.893334
NCT00643409|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-05-10|2008-03-19|2008-03-26|Estimate|||||||2011-05-10|2011-05-11|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|February 2004|Actual|2004-02-29|||||Interventional|||A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Acute Bacterial Maxillary Sinusitis in Adults Undergoing Diagnostic Sinus Aspiration|Completed||Phase 3|541|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:52.044151|2018-06-01 02:18:52.044151
NCT00643396|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2016-02-24|2008-03-25|2008-03-26|Estimate|||||||2016-02-24|2016-02-26|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer|Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|30|Actual|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 02:18:52.241986|2018-06-01 02:18:52.241986
NCT00643383|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20||2010-01-12|2012-04-30|2008-03-25|2008-03-26|Estimate||||2010-01-12|2010-01-14|Estimate|2012-04-30|2012-05-01|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain||Completed||Phase 3|277|Actual|Labopharm Inc.||2|||f||||||||||||||2018-06-01 02:18:52.302575|2018-06-01 02:18:52.302575
NCT00643370|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2016-02-12|2008-03-25|2008-03-26|Estimate|||||||2016-02-12|2016-02-17|Estimate|April 2008||2008-04-30|August 2011|2011-08-31||||January 2011|Actual|2011-01-31||Observational|||Quantifying Lung Tumor Movement Under Deep Inspiration Breath Holds|Quantifying Lung Tumor Movement Under Dep Inspiration Breath Holds|Completed|||8|Actual|AHS Cancer Control Alberta|||1||f||||||||||||||2018-06-01 02:18:52.407855|2018-06-01 02:18:52.407855
NCT00643357|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2012-01-18|2008-03-25|2008-03-26|Estimate|||||||2012-01-18|2012-01-19|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|Burns||Study of the Efficacy and Safety of Kalinox® 170 Bar for the Performance of Care Procedures in Children With Burns|Study of the Efficacy and Safety of KALINOX® 170 Bar for the Performance of Care Procedures in Children With Burns|Withdrawn||Phase 3|0|Actual|Air Liquide Santé International||2||No patient recruited due to current guidelines for the pain related to burn|f||||f||||||||||2018-06-01 02:18:52.486065|2018-06-01 02:18:52.486065
NCT00643344|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2014-10-25|2008-03-24|2008-03-26|Estimate|||||||2014-10-25|2014-10-28|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|CALMM||Craving and Lifestyle Management Through Mindfulness Pilot Study|Craving and Lifestyle Management Through Mindfulness Pilot Study|Completed||N/A|15|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:18:52.550146|2018-06-01 02:18:52.550146
NCT00643331|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2015-06-02|2008-03-24|2008-03-26|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2001||2001-02-28|March 2008|2008-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||The Effect of Exercise in Postmenopausal Women With Low Bone Density|The Effect of Exercise in Postmenopausal Women With Low Bone Density|Completed||Phase 2|38|Actual|University of Melbourne||2|||f||||f||||||||||2018-06-01 02:18:52.62598|2018-06-01 02:18:52.62598
NCT00643318|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2017-06-26|2008-03-20|2008-03-26|Estimate|||||||2017-06-26|2017-06-27|Actual|April 2006||2006-04-30|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer|A Prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|40|Actual|Accuray Incorporated||1|||f||||f||||||||||2018-06-01 02:18:52.715483|2018-06-01 02:18:52.715483
NCT00643292|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-05-16|2008-03-19|2008-03-26|Estimate|||||||2011-05-16|2011-05-17|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|May 2004|Actual|2004-05-31|||||Interventional|||A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Amoxicillin/Clavulanate Potassium (Augmentin ES-600 Trademark) for the Treatment of Acute Otitis Media in Children Undergoing Diagnostic Tympanocentesis|Completed||Phase 3|902|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:52.917195|2018-06-01 02:18:52.917195
NCT00643279|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2013-01-31|2008-03-24|2008-03-26|Estimate|||||||2013-01-31|2013-02-01|Estimate|March 2003||2003-03-31|January 2013|2013-01-31||||June 2005|Actual|2005-06-30||Interventional|||Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)|Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)|Unknown status|Active, not recruiting|Phase 2|274|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||t||||||||||2018-06-01 02:18:53.111467|2018-06-01 02:18:53.111467
NCT00643266|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2016-12-21|2008-03-24|2008-03-26|Estimate|||||||2016-12-21|2016-12-22|Estimate|February 2008||2008-02-29|December 2016|2016-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment|Memory Interventions for Older Adults|Completed||N/A|91|Actual|Baycrest||2|||f||||f||||||||||2018-06-01 02:18:53.342811|2018-06-01 02:18:53.342811
NCT00643253|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2013-07-09|2008-03-24|2008-03-26|Estimate|||||||2013-07-09|2013-07-11|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Interventional|PAIRINGS||Provider Approaches to Improved Rates of Infant Nutrition and Growth Study|Provider Approaches to Improved Rates of Infant Nutrition and Growth Study|Completed||Phase 3|299|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-06-01 02:18:53.414204|2018-06-01 02:18:53.414204
NCT00643240|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|||2017-11-27|2008-03-25|2008-03-26|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2008||2008-01-31|November 2017|2017-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia|Phase I Open Label, Single Arm Escalation Trial to Evaluate the Biodistribution and Safety of BU-12 in Patients With Advanced Leukemia|Terminated||Phase 1|1|Actual|Masonic Cancer Center, University of Minnesota||1||Due to slow accrual|f||||t||||||||||2018-06-01 02:18:53.511182|2018-06-01 02:18:53.511182
NCT00643227|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-19|2008-03-19|2008-03-26|Estimate|||||||2008-03-19|2008-03-26|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|March 2004|Actual|2004-03-31|||||Interventional|||A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Clarithromycin Extended Release for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults|Completed||Phase 3|504|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:53.617686|2018-06-01 02:18:53.617686
NCT00643214|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2008-05-19|2008-03-25|2008-03-26|Estimate|||||||2008-05-19|2008-05-22|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis|A Study to Determine if Tetrix Cream Impedes the Resolution of Experimentally Induced Allergic Contact Dermatitis|Completed||N/A|12|Actual|Coria Laboratories, Ltd.||2|||f||||f||||||||||2018-06-01 02:18:53.880407|2018-06-01 02:18:53.880407
NCT00643201|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2014-03-04||2014-04-17|2008-03-20|2008-03-26|Estimate|2014-03-04|2014-04-10|Estimate||||2014-04-17|2014-04-21|Estimate|July 2008||2008-07-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Randomized Participants|Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism|A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism|Completed||Phase 3|5614|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 02:18:54.128228|2018-06-01 02:18:54.128228
NCT00643188|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2017-05-17|2008-03-20|2008-03-26|Estimate|||||||2017-05-17|2017-05-18|Actual|January 2008|Actual|2008-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|CASTLE-AF||Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF|Catheter Ablation Versus Standard Conventional Treatment in Patients With Left Ventricular Dysfunction and Atrial Fibrillation|Completed||Phase 4|398|Actual|Biotronik SE & Co. KG||2|||f||||t||||||||Undecided|It is planned to publish results of this investigation in peer-reviewed journals (online: open-access), but it is not yet decided to annex individual participant data (IPD).|2018-06-01 02:18:58.372555|2018-06-01 02:18:58.372555
NCT00643175|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2009-12-29|2008-03-25|2008-03-26|Estimate|||||||2009-12-29|2009-12-30|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Effectiveness of Automated Inpatient Endocrinology Consultation for Osteoporotic Hip Fracture||Terminated|||20|Anticipated|State University of New York - Upstate Medical University|||1|Dr. Grose has left this practice, this study is terminated|f||||||||||||||2018-06-01 02:18:58.484989|2018-06-01 02:18:58.484989
NCT00643162|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2012-03-26|2008-03-20|2008-03-26|Estimate|||||||2012-03-26|2012-03-27|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Depression in Older Adults|Combination Lexapro and Massage for Treatment in Depression in Older Subjects|Completed||N/A|17|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-06-01 02:18:58.542456|2018-06-01 02:18:58.542456
NCT00643149|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-05-16|2008-03-19|2008-03-26|Estimate|||||||2011-05-16|2011-05-17|Estimate|May 2003||2003-05-31|May 2011|2011-05-31|March 2004|Actual|2004-03-31|||||Interventional|||A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of Azithromycin SR Versus Amoxicillin For The Treatment Of Strep Throat In Children|A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial Of Azithromycin SR Versus Amoxicillin For The Treatment Of Group A Β-Hemolytic Streptococcal Pharyngitis/Tonsillitis In Children|Completed||Phase 3|693|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:18:58.638965|2018-06-01 02:18:58.638965
NCT00643136|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-04-23|2008-03-19|2008-03-26|Estimate|||||||2008-04-23|2008-04-24|Estimate|November 2002||2002-11-30|April 2008|2008-04-30|June 2004|Actual|2004-06-30|||||Interventional|||A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures|Pregabalin BID Add-on Trial: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Single-Center Sleep EEG Study in Patients With Partial Seizures and Sleep Disturbance Part B: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Pregabalin Add-on Treatment|Completed||Phase 3|17|Actual|Pfizer||2|||f||||||||||||||2018-06-01 02:18:58.855588|2018-06-01 02:18:58.855588
NCT00643123|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|2018-01-24||2018-03-16|2008-03-25|2008-03-26|Estimate|2018-03-16|2018-04-13|Actual||||2018-03-16|2018-04-13|Actual|September 2007||2007-09-30|March 2018|2018-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Allopurinol Add-on Treatment for Refractory Mania|A Double-Blind, Placebo Controlled Augmentation Study With Allopurinol for Treatment Resistant Mania|Completed||Phase 4|40|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-06-01 02:18:58.938895|2018-06-01 02:18:58.938895
NCT00643110|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2015-03-24|2008-03-25|2008-03-26|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Milk as Treatment for Hypoglycemia|Milk as Treatment for Hypoglycemia|Withdrawn||N/A|0|Actual|Creighton University||||Not funded|f||||f||||||||||2018-06-01 02:18:59.469686|2018-06-01 02:18:59.469686
NCT00643097|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-25|2014-01-06||2016-12-02|2008-03-25|2008-03-26|Estimate|2014-01-06|2014-02-17|Estimate||||2016-12-02|2017-02-01|Estimate|September 2007||2007-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|January 2012|Actual|2012-01-31||Interventional|ACTIVATe||Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII|Completed||Phase 2|40|Actual|Duke University||3|||f||||t||||||||||2018-06-01 02:18:59.551748|2018-06-01 02:18:59.551748
NCT00643084|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2008-03-24|2008-03-24|2008-03-26|Estimate|||||||2008-03-24|2008-03-26|Estimate|May 2008||2008-05-31|March 2008|2008-03-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Bowel Prep vs Non-Bowel Prep for Laparoscopic Colorectal Surgery|A Randomized Controlled Trial of Bowel-Prepped vs Non-Bowel-Prepped Laparoscopic Colorectal Surgery|Unknown status|Not yet recruiting|N/A|120|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 02:19:00.107947|2018-06-01 02:19:00.107947
NCT00643071|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2014-08-25|2008-03-20|2008-03-26|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients|Tacrolimus (FK506) P-III, Open-label Study in Severe Refractory Ulcerative Colitis Patients or Patients Who Attended and Received Placebo in F506-CL-1107 Study|Completed||Phase 3|32|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 02:19:00.186618|2018-06-01 02:19:00.186618
NCT00643058|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|||2013-07-15|2008-03-24|2008-03-26|Estimate|||||||2013-07-15|2013-07-16|Estimate|April 2003||2003-04-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Nitric Oxide, LPS and the Pathogenesis of Asthma Phase II|Nitric Oxide, LPS and the Pathogenesis of Asthma - Phase II|Terminated||Phase 1|70|Actual|Duke University||1||Funding period completed.|f||||f||||||||||2018-06-01 02:19:00.267376|2018-06-01 02:19:00.267376
NCT00643045|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-03-24|2008-03-24|2008-03-25|Estimate|||||||2008-03-24|2008-03-25|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|July 2007|Actual|2007-07-31|January 2006|Actual|2006-01-31||Interventional|||Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|A Phase III, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of a Low (50 100 mg/Day) and High (150 200 mg/Day) Dose Range of Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|Completed||Phase 3|269|Actual|Newron Pharmaceuticals SPA||3|||f||||t||||||||||2018-06-01 02:19:00.352784|2018-06-01 02:19:00.352784
NCT00643032|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-19|2008-03-19|2008-03-25|Estimate|||||||2008-03-19|2008-03-25|Estimate|March 2008||2008-03-31|March 2008|2008-03-31||||January 2010|Anticipated|2010-01-31||Interventional|||Preoperative Anxiety and Postoperative Pain in Children|Comparison of 2 Methods to Reduce Postoperative Pain in Children and a Comparison of 3 Methods of Preoperative Education Intervention to Reduce Anxiety in Children and Their Family|Unknown status|Not yet recruiting|Phase 4|250|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-06-01 02:19:00.449485|2018-06-01 02:19:00.449485
NCT00643019|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2015-04-14|2008-03-24|2008-03-25|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 1993||1993-01-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|January 1994|Actual|1994-01-31||Interventional|SAFE||Project Sexual Awareness for Everyone (SAFE)|Preventing Recurrent Sexually Transmitted Infections in Minority Women|Completed||Phase 3|800|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-06-01 02:19:00.530598|2018-06-01 02:19:00.530598
NCT00643006|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2012-05-03||2012-09-28|2008-03-19|2008-03-25|Estimate|2012-09-28|2012-10-30|Estimate||||2012-09-28|2012-10-30|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Physical Exercise and Its Impact on Signs of Inflammation in Fibromyalgia|Physical Exercise and Its Impact on Signs of Inflammation in Women With Fibromyalgia|Completed||N/A|67|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 02:19:00.614203|2018-06-01 02:19:00.614203
NCT00642993|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2016-09-06|2009-04-23|2016-09-06|2008-03-21|2008-03-25|Estimate|2016-09-06|2016-10-27|Estimate|2009-09-30|2009-10-01|Estimate|2016-09-06|2016-10-27|Estimate|June 2008||2008-06-30|August 2016|2016-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)|A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects|Completed||Phase 2|401|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:19:00.863748|2018-06-01 02:19:00.863748
NCT00642980|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2014-01-22|2008-03-24|2008-03-25|Estimate|||||||2014-01-22|2014-01-23|Estimate|April 2006||2006-04-30|January 2008|2008-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PREMEVA||Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis|Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy|Completed||Phase 4|3105|Actual|University Hospital, Lille||3|||f||||t||||||||||2018-06-01 02:19:01.243162|2018-06-01 02:19:01.243162
NCT00642967|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2016-02-01|2008-03-19|2008-03-25|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis|A Single Arm, Open Label, French Multi-centre Study to Assess the Maintenance of Hemoglobin Levels With Once Monthly Subcutaneous Administration of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease Not on Dialysis|Completed||Phase 3|127|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:19:01.33776|2018-06-01 02:19:01.33776
NCT00642954|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2016-02-25|2008-03-21|2008-03-25|Estimate|||||||2016-02-25|2016-02-26|Estimate|February 2008||2008-02-29|February 2016|2016-02-29|August 2013|Actual|2013-08-31|September 2012|Actual|2012-09-30||Interventional|||Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)|A Phase I Study of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 02:19:01.496585|2018-06-01 02:19:01.496585
NCT00642941|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19||2016-11-02|2017-04-03|2008-03-19|2008-03-25|Estimate||||2016-11-02|2016-11-03|Estimate|2017-04-03|2017-04-04|Actual|December 18, 2007|Actual|2007-12-18|April 2017|2017-04-30|February 19, 2014|Actual|2014-02-19|February 19, 2014|Actual|2014-02-19||Interventional|||A Study of R1507 in Participants With Recurrent or Refractory Sarcoma|A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.|Completed||Phase 2|317|Actual|Hoffmann-La Roche||12|||f||||||||||||||2018-06-01 02:19:01.577138|2018-06-01 02:19:01.577138
NCT00642928|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2012-06-08|2008-03-21|2008-03-25|Estimate|||||||2012-06-08|2012-06-11|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients|Randomized, Dose-finding Study of BF 2.649 5, 10 20 and 40 mg/d in Comparison to Placebo in Excessive Daytime Sleepiness in Parkinson's Disease Patients (PD)|Completed||Phase 2|108|Actual|Bioprojet||5|||f||||t||||||||||2018-06-01 02:19:01.732217|2018-06-01 02:19:01.732217
NCT00642915|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-08-22|2008-03-24|2008-03-25|Estimate|||||||2008-08-22|2008-08-25|Estimate|June 2003||2003-06-30|August 2008|2008-08-31|July 2004|Actual|2004-07-31|||||Interventional|||Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)|A 24 Week, Open-Label, Single Arm, Multi-Center Clinical Study to Document the Benefits of the Combination of Lantus and Amaryl in Ethnic Japanese Type 2 Diabetic Patients Living Outside of Japan (in US or Brazil), Who Failed Good Metabolic Control With Oral Antidiabetic Drugs (OADs)|Completed||Phase 4|100|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:19:01.808414|2018-06-01 02:19:01.808414
NCT00642902|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2016-04-15||2016-04-15|2008-03-24|2008-03-25|Estimate|2016-04-15|2016-05-24|Estimate||||2016-04-15|2016-05-24|Estimate|April 2008||2008-04-30|April 2016|2016-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|ATAMS|Intent-to-treat (ITT) population included all randomized participants.|A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)|A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course|Terminated||Phase 2|255|Actual|EMD Serono|Sponsor voluntarily decided to prematurely terminate this trial due to an increase in multiple sclerosis (MS) disease activity observed in atacicept arms as compared to placebo during a routine independent data monitoring committee (IDMC) review.|4||"Sponsor voluntarily decided to terminate trial due to increased MS disease activity in~   atacicept arms as compared to placebo during a routine IDMC review."|f||||t||||||||||2018-06-01 02:19:01.90065|2018-06-01 02:19:01.90065
NCT00642889|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-03-21|2008-03-21|2008-03-25|Estimate|||||||2008-03-21|2008-03-25|Estimate|June 2005||2005-06-30|March 2008|2008-03-31|July 2007|Actual|2007-07-31|January 2007|Actual|2007-01-31||Interventional|||Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)|A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE TREATED WITH A STABLE DOSE OF A SINGLE DOPAMINE AGONIST.|Completed||Phase 3|227|Actual|Newron Pharmaceuticals SPA||3|||f||||t||||||||||2018-06-01 02:19:02.430953|2018-06-01 02:19:02.430953
NCT00642876|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2013-07-31|2008-03-24|2008-03-25|Estimate|||||||2013-07-31|2013-08-02|Estimate|October 2002||2002-10-31|February 2013|2013-02-28|May 2013|Actual|2013-05-31|July 2006|Actual|2006-07-31||Interventional|||PRESTIGE® Cervical Disc Study|Investigation of the PRESTIGE® Cervical Disc Device at a Single Level for Symptomatic Cervical Disc Disease|Completed||N/A|541|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 02:19:02.515506|2018-06-01 02:19:02.515506
NCT00642863|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2014-10-28|2008-03-21|2008-03-25|Estimate|||||||2014-10-28|2014-10-29|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Brain and Behavior Depending on Timing of Iron Deficiency in Human Infants|Brain and Behavior Depending on Timing of Iron Deficiency in Human Infants|Completed||N/A|1614|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||7|||f||||t||||||||||2018-06-01 02:19:02.668262|2018-06-01 02:19:02.668262
NCT00642850|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2016-05-17||2016-05-17|2008-03-19|2008-03-25|Estimate|2016-05-17|2016-06-23|Estimate||||2016-05-17|2016-06-23|Estimate|November 2007||2007-11-30|May 2016|2016-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||The safety population was defined as all participants enrolled into the study.|STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients|A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia|Completed||Phase 3|188|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:19:02.783305|2018-06-01 02:19:02.783305
NCT00642837|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2014-04-24|2008-03-21|2008-03-25|Estimate|||||||2014-04-24|2014-04-28|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets|Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets ; Multicenter, Open-label, Prospective, Observational Study|Completed|||982|Actual|Janssen Korea, Ltd., Korea|||9||f||||||||||||||2018-06-01 02:19:03.087105|2018-06-01 02:19:03.087105
NCT00642824|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2016-11-01|2008-03-19|2008-03-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.|Local Substudy Associated to the International Study MO19390 to Determine the BRCA1 Gene mRNA Expression as a Predictive Marker of Response to Chemotherapy|Terminated||Phase 2|3|Actual|Hoffmann-La Roche||1||Terminated due to low enrollment. No statistical analyses were performed.|f||||||||||||||2018-06-01 02:19:03.224767|2018-06-01 02:19:03.224767
NCT00642811|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2011-01-27||2011-08-30|2008-03-19|2008-03-25|Estimate|2011-08-30|2011-10-04|Estimate||||2011-08-30|2011-10-04|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|RESPOND||A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders|A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders [RESPOND]|Completed||Phase 2|98|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:19:03.415355|2018-06-01 02:19:03.415355
NCT00642798|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2015-02-02|2008-03-21|2008-03-25|Estimate|||||||2015-02-02|2015-02-03|Estimate|March 2008||2008-03-31|February 2015|2015-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)|An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:19:04.031467|2018-06-01 02:19:04.031467
NCT00642785|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-05-30|2008-03-24|2008-03-25|Estimate|||||||2008-05-30|2008-06-03|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections|A Research Study Examining the Effectiveness of Distant Activation of ACE Pigments Associated With Recurrent Human Herpes Simplex Virus-Induced Skin Lesions.|Completed|||500|Anticipated|Institute of Progressive Medicine|||4||f||||t||||||||||2018-06-01 02:19:04.094904|2018-06-01 02:19:04.094904
NCT00642772|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2014-06-05||2015-04-06|2008-03-24|2008-03-25|Estimate|2014-06-05|2014-07-08|Estimate||||2015-04-06|2015-04-28|Estimate|March 2008||2008-03-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Group Physical Therapy for Knee Osteoarthritis|Pilot Study of Group Physical Therapy for Knee Osteoarthritis|Completed||N/A|24|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 02:19:04.159248|2018-06-01 02:19:04.159248
NCT00642759|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2016-10-18||2017-02-23|2008-03-21|2008-03-25|Estimate|2016-10-18|2016-12-12|Estimate||||2017-02-23|2017-04-07|Actual|April 2008||2008-04-30|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Trial of Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|36|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 02:19:04.317133|2018-06-01 02:19:04.317133
NCT00642746|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-24|2014-02-12||2014-09-24|2008-03-24|2008-03-25|Estimate|2014-09-24|2014-09-26|Estimate||||2014-09-24|2014-09-26|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||11 patients included for all baseline measures except for age, categorical because the age is missing for the 1 patient who eventually was ineligible.|Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)|Phase II Study of Erlotinib (Tarceva) Alternating With Chemotherapy for Second-line Treatment of Metastatic Colorectal Cancer With Molecular Correlates for p53 Pathway|Terminated||Phase 2|16|Actual|OHSU Knight Cancer Institute|Study terminated before target enrollment was reached due to excessive toxicities and limited enrollment.|2||Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.|f||||t||||||||||2018-06-01 02:19:04.527698|2018-06-01 02:19:04.527698
NCT00642733|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2016-08-22|2008-03-19|2008-03-25|Estimate|||||||2016-08-22|2016-08-24|Estimate|August 2007||2007-08-31|August 2016|2016-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer|An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|Terminated||Phase 4|6|Actual|Hoffmann-La Roche||1||poor recruitment|f||||||||||||||2018-06-01 02:19:04.805305|2018-06-01 02:19:04.805305
NCT00642720|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-03-24|2008-03-24|2008-03-25|Estimate|||||||2008-03-24|2008-03-25|Estimate|October 2006||2006-10-31|March 2008|2008-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|mec-2005-290||Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients|The Effects of Weekly Administration of 40 mg Pegvisomant or Placebo on Quality of Life and Insulin Sensitivity in Acromegalic Patients With Normal IGF-I Concentrations During Long-Term Treatment With Long-Acting Somatostatin Analogs|Completed||Phase 4|20|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-06-01 02:19:04.875569|2018-06-01 02:19:04.875569
NCT00642707|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2013-04-12||2015-12-14|2008-03-21|2008-03-25|Estimate|2013-04-12|2013-05-31|Estimate||||2015-12-14|2016-01-14|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection|A Phase 2a, Randomized, Double-blind, Placebo Controlled Study of PRO 140 by Subcutaneous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection|Completed||Phase 2|44|Actual|CytoDyn, Inc.||4|||f||||f||||||||||2018-06-01 02:19:04.966549|2018-06-01 02:19:04.966549
NCT00642694|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2012-03-29||2012-10-24|2008-03-24|2008-03-25|Estimate|2012-10-24|2012-10-26|Estimate||||2012-10-24|2012-10-26|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TAKEDA||Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon|Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon|Terminated||Phase 3|29|Actual|University of Texas Southwestern Medical Center||2||Enrollment discontinued based on mutually agreed upon decision by PI and funding sponsor|f||||f||||||||||2018-06-01 02:19:05.573194|2018-06-01 02:19:05.573194
NCT00642681|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2014-12-01|2008-03-24|2008-03-25|Estimate|||||||2014-12-01|2014-12-03|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Observational|||Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge|Evaluation of the Effect of Symptomatic Upper Respiratory Infections on Pharmacological Characteristics of Technosphere®/Insulin in Subjects With Diabetes Mellitus After a Meal Challenge|Completed|||20|Actual|Mannkind Corporation|||1||f||||||||||||||2018-06-01 02:19:05.927227|2018-06-01 02:19:05.927227
NCT00642668|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2016-06-09||2017-06-13|2008-03-19|2008-03-25|Estimate|2016-06-09|2016-07-22|Estimate||||2017-06-13|2017-07-05|Actual|June 30, 2008|Actual|2008-06-30|May 2017|2017-05-31|December 31, 2009|Actual|2009-12-31|December 31, 2009|Actual|2009-12-31||Interventional||The safety population included all participants who received at least one dose of active drug.|A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia|Subcutaneous Treatment of Anemia in Patients With a GFR Below 45 ml/Min/1.73m2 Through Injections With Mircera as Low Frequent as Once Monthly (STABILO)|Completed||Phase 4|35|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-06-01 02:19:06.01956|2018-06-01 02:19:06.01956
NCT00642655|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-24|2008-03-24|2008-03-25|Estimate|||||||2008-03-24|2008-03-25|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation|A Phase I/II Trial to Investigate the Safety and Efficacy of Rituximab and IVIG as Agents to Desensitize Highly-HLA Sensitized Dialysis Patients Awaiting Kidney Transplantation|Completed||Phase 1/Phase 2|20|Actual|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-06-01 02:19:06.343941|2018-06-01 02:19:06.343941
NCT00642642|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2012-02-09||2013-07-19|2008-03-19|2008-03-25|Estimate|2013-07-19|2013-08-21|Estimate||||2013-07-19|2013-08-21|Estimate|November 2007||2007-11-30|July 2013|2013-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring|A Phase II/III Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of Isolagen Therapy in the Treatment of Moderate to Sever Facial Acne Scarring|Completed||Phase 2/Phase 3|122|Actual|Fibrocell Technologies, Inc.||2|||f||||f||||||||||2018-06-01 02:19:06.413484|2018-06-01 02:19:06.413484
NCT00642629|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2014-02-03|2008-03-24|2008-03-25|Estimate|||||||2014-02-03|2014-02-04|Estimate|December 2005||2005-12-31|February 2014|2014-02-28||||||||Interventional|||A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes||Completed||Phase 2|35|Anticipated|Synta Pharmaceuticals Corp.||2|||f||||f||||||||||2018-06-01 02:19:06.660216|2018-06-01 02:19:06.660216
NCT00642616|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2015-11-23|2009-06-09|2017-04-12|2008-03-24|2008-03-25|Estimate|2016-02-12|2016-02-15|Estimate|2009-11-18|2009-11-20|Estimate|2017-04-12|2017-04-14|Actual|March 2009||2009-03-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Subjects who received at least one dose of study medication|Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease|A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up|Terminated||Phase 3|34|Actual|Mannkind Corporation|- Early termination of trial leading to small numbers of subjects analyzed|4||Terminated upon recommendation of the Data Safety Monitoring Board (DSMB)|f||||t||||||||||2018-06-01 02:19:06.740823|2018-06-01 02:19:06.740823
NCT00642603|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2010-06-10||2018-02-28|2008-03-19|2008-03-25|Estimate|2011-05-31|2011-06-23|Estimate||||2018-02-28|2018-03-29|Actual|May 2008||2008-05-31|February 2018|2018-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer|A Randomized, Open Label Study of the Effect of First Line Treatment With Xeloda in Combination With Avastin and Either Short Course Irinotecan or Short Course Oxaliplatin on Progression-free Survival in Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|41|Actual|Hoffmann-La Roche|This study was terminated early because interim data from a predecessor study invalidated the scientific rationale that provided justification for the conduct of this study. Efficacy analyses were not performed.|2|||f||||||||||||||2018-06-01 02:19:07.283758|2018-06-01 02:19:07.283758
NCT00642590|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2016-03-30|2008-03-21|2008-03-25|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|November 2017|Anticipated|2017-11-30|December 2016|Anticipated|2016-12-31||Observational|||Lifestyle and Fertility Study on Antioxidant Status, Diet and Early Pregnancy|Antioxidant Status, Diet and Early Pregnancy|Unknown status|Active, not recruiting||266|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum, urine~   "|||2018-06-01 02:19:07.776633|2018-06-01 02:19:07.776633
NCT00642577|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2013-10-07|2008-03-19|2008-03-25|Estimate|||||||2013-10-07|2013-10-08|Estimate|July 2007||2007-07-31|October 2013|2013-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.|A Randomized, Open Label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Irinotecan + 5-fluorouracil/Folinic Acid, and Irinotecan + 5-fluorouracil/Folinic Acid Alone, on Progression-free Survival in Chinese Patients With Metastatic Colorectal Cancer.|Completed||Phase 3|214|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:19:07.855836|2018-06-01 02:19:07.855836
NCT00642564|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2014-05-22|2008-03-21|2008-03-25|Estimate|||||||2014-05-22|2014-05-23|Estimate|February 2008||2008-02-29|May 2014|2014-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Study on Migraine and Headache in Epileptic Patients|MIGRAINE AND HEADACHE IN EPILEPTIC PATIENTS|Completed|||955|Actual|Johnson & Johnson Taiwan Ltd|||1||f||||||||||||||2018-06-01 02:19:07.950909|2018-06-01 02:19:07.950909
NCT00642551|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2012-06-11|2008-03-19|2008-03-25|Estimate|||||||2012-06-11|2012-06-12|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Beneficial Effects of Long Term Menaquinone-7|Clinical Trial on Beneficial Effects of Long Term Menaquinone-7 (Vitamin K2) Intake by Postmenopausal Women|Completed||N/A|240|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 02:19:08.043004|2018-06-01 02:19:08.043004
NCT00642538|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2012-06-12|2008-03-21|2008-03-25|Estimate|||||||2012-06-12|2012-06-14|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus|A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|20|Actual|Mannkind Corporation||5|||f||||||||||||||2018-06-01 02:19:08.114044|2018-06-01 02:19:08.114044
NCT00642525|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-19|2008-03-19|2008-03-25|Estimate|||||||2008-03-19|2008-03-25|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Detection of Anastomotic Leakage After Esophageal Surgery|Radiologic vs. Endoscopic Evaluation of the Conduit After Esophageal Resection: a Prospective, Blinded, Intraindividual Controlled Diagnostic Study.|Completed||N/A|55|Actual|Heidelberg University||1|||f||||f||||||||||2018-06-01 02:19:08.184501|2018-06-01 02:19:08.184501
NCT00642512|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-03-31|2008-03-21|2008-03-25|Estimate|||||||2008-03-31|2008-04-03|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Efficacy Study of Oral Dronabinol Alone and in Combination With Ondansetron Versus Ondansetron Alone in Subjects With Delayed Chemotherapy-Induced Nausea and Vomiting|Completed||Phase 3|64|Actual|Solvay Pharmaceuticals||4|||f||||f||||||||||2018-06-01 02:19:08.250668|2018-06-01 02:19:08.250668
NCT00642499|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-04-01|2008-03-24|2008-03-25|Estimate|||||||2008-04-01|2008-04-02|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting|A Double-Blind, Randomized, Parallel-Group, Pilot Study of Oral Dronabinol Versus Placebo in the Treatment or Prevention of Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting|Completed||Phase 2|103|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:19:08.482601|2018-06-01 02:19:08.482601
NCT00642473|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2016-03-09||2016-04-14|2008-03-19|2008-03-25|Estimate|2016-04-14|2016-05-23|Estimate||||2016-04-14|2016-05-23|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|MATER|All enrolled participants|A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash|A Phase II Trial Assessing Metronidazol Actavis 1% Topical Cream in the Prevention and Treatment of Erlotinib Associated Rash|Completed||Phase 2|34|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:19:08.654856|2018-06-01 02:19:08.654856
NCT00642460|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2011-09-16||2016-06-24|2008-03-19|2008-03-25|Estimate|2011-09-16|2011-10-26|Estimate||||2016-06-24|2016-07-25|Estimate|May 2008||2008-05-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|September 2009|Actual|2009-09-30||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)|A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab|Completed||Phase 3|112|Actual|Hoffmann-La Roche|"This study consists of 3 parts:~Part I: a 12 week double-blind placebo controlled study is complete. Part II: a 92 week single arm open-label extension study- CSR completed Dec. 2011.~Part III: a 3 year open label continuation study is ongoing."|2|||f||||||||||||||2018-06-01 02:19:09.205663|2018-06-01 02:19:09.205663
NCT00642447|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-24|2008-03-24|2008-03-25|Estimate|||||||2008-03-24|2008-03-25|Estimate|April 2007||2007-04-30|March 2008|2008-03-31||||||||Interventional|||Helium:Oxygen Noninvasive Positive Pressure Ventilation in Patients Exposed to Sulfur Mustard|Helium:Oxygen Versus Air:Oxygen Nonivasive Positive Pressure Ventilation in Patients Exposed to Sulfur Mustard|Completed||Phase 2/Phase 3|23||Baqiyatallah Medical Sciences University||1|||f||||||||||||||2018-06-01 02:19:11.331534|2018-06-01 02:19:11.331534
NCT00642434|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2011-08-24|2008-03-24|2008-03-25|Estimate|||||||2011-08-24|2011-08-25|Estimate|January 2004||2004-01-31|August 2011|2011-08-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Comparison of Blood Pressure Medications on Metabolism|Carvedilol vs.Metoprolol: A Comparison of Effects on Endothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients With Type 2 Diabetes and Hypertension|Completed||Phase 4|21|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 02:19:11.381994|2018-06-01 02:19:11.381994
NCT00642421|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2010-02-07|2008-03-21|2008-03-25|Estimate|||||||2010-02-07|2010-02-09|Estimate|February 2008||2008-02-29|February 2010|2010-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients|Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2l-OCT-01 PR, Administered Intra Muscularly Every 4, 5 or 6 Weeks in Acromegalic Patients|Terminated||Phase 3|40|Anticipated|Ambrilia Biopharma, Inc.||2||Commercial reasons|f||||f||||||||||2018-06-01 02:19:11.463741|2018-06-01 02:19:11.463741
NCT00642408|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2010-09-12|2008-03-21|2008-03-25|Estimate|||||||2010-09-12|2010-09-14|Estimate|June 2003||2003-06-30|September 2010|2010-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso|Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso|Completed||Phase 4|1370|Actual|Institute of Tropical Medicine, Belgium||2|||f||||t||||||||||2018-06-01 02:19:12.626823|2018-06-01 02:19:12.626823
NCT00642395|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2017-05-10|2008-03-24|2008-03-25|Estimate|||||||2017-05-10|2017-05-12|Actual|July 2007||2007-07-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|October 2008|Actual|2008-10-31||Interventional|||Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)|Velcade®-Melphalan Association as Conditioning Regimen Before Autologous Stem-cell Transplantation in Multiple Myeloma Patients Under 65 Years|Completed||Phase 2|61|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-06-01 02:19:12.96042|2018-06-01 02:19:12.96042
NCT00642382|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2017-01-30||2017-07-18|2008-03-19|2008-03-25|Estimate|2017-07-18|2017-08-17|Actual||||2017-07-18|2017-08-17|Actual|April 2008||2008-04-30|July 2017|2017-07-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional||Zero patients were analyzed for this study due to the study being closed 2 months after it started. Baseline data were not collected|Safety and Effectiveness of Agilus (Hyaluronic Acid) for Ankle Osteoarthritis|Randomized, Double Blind,Saline-Controlled, Multi-Center, Prospective Study to Evaluate the Safety and Effectiveness of Carticept's Agilus Device for the Treatment of Ankle Osteoarthritis|Terminated||N/A|17|Actual|Cartiva, Inc.||2||For safety concerns|f||||f||||||||No||2018-06-01 02:19:13.381698|2018-06-01 02:19:13.381698
NCT00642369|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2009-12-14||2014-03-21|2008-03-24|2008-03-25|Estimate|2014-03-21|2014-04-17|Estimate||||2014-03-21|2014-04-17|Estimate|March 2008||2008-03-31|March 2014|2014-03-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia|Study of Evaluating Quetiapine in Improving Sleep Quality of Schizophrenia|Completed||N/A|60|Actual|Guang Dong Provincial Mental Health Institute|the present study lasted for only 4 weeks. it might be too short to investigate the effect of quetiapine fumarate and haloperidol on sleep and clinical parameters.|2|||f||||f||||||||||2018-06-01 02:19:14.13269|2018-06-01 02:19:14.13269
NCT00642356|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2010-12-14||2011-02-16|2008-03-24|2008-03-25|Estimate|2010-12-14|2011-01-11|Estimate||||2011-02-16|2011-02-18|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off|An 8-week, Prospective, Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center Comparison Study of the Effects of Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off|Terminated||Phase 4|14|Actual|Novartis||2||slow enrollment|f||||||||||||||2018-06-01 02:19:15.236335|2018-06-01 02:19:15.236335
NCT00642343|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2010-06-14|2008-03-24|2008-03-25|Estimate|||||||2010-06-14|2010-06-15|Estimate|March 2008||2008-03-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Balance in Children With Cochlear Implants|Balance in Children With Cochlear Implants|Completed||Early Phase 1|66|Actual|University of Oklahoma||4|||f||||f||||||||||2018-06-01 02:19:16.265177|2018-06-01 02:19:16.265177
NCT00642330|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-24|2008-03-24|2008-03-25|Estimate|||||||2008-03-24|2008-03-25|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|March 2007|Actual|2007-03-31||Interventional|||Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants|Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus|Completed||Phase 4|62|Actual|Hopital La Rabta||2|||f||||t||||||||||2018-06-01 02:19:16.396243|2018-06-01 02:19:16.396243
NCT00642317|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2012-07-31|2008-03-19|2008-03-25|Estimate|||||||2012-07-31|2012-08-01|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Asian Youth and Tobacco Control Survey|Asian Youth and Tobacco Control Survey|Completed|||617|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:19:16.503739|2018-06-01 02:19:16.503739
NCT00642304|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2016-09-16||2018-02-27|2008-03-19|2008-03-25|Estimate|2016-09-16|2016-11-07|Estimate||||2018-02-27|2018-03-26|Estimate|March 27, 2008|Actual|2008-03-27|February 2018|2018-02-28|December 9, 2009|Actual|2009-12-09|December 9, 2009|Actual|2009-12-09||Interventional||Safety population included all participants who received at least one dose trial medication and underwent a safety follow-up, whether withdrawn prematurely or not.|A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.|A Single Arm Open Label Study to Assess Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneously C.E.R.A. for the Maintenance of Hemoglobin Levels in Patients With Chronic Renal Anemia Not on Dialysis|Completed||Phase 3|22|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-06-01 02:19:16.595992|2018-06-01 02:19:16.595992
NCT00642291|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-04-07|2008-03-24|2008-03-25|Estimate|||||||2008-04-07|2008-04-10|Estimate|November 2002||2002-11-30|April 2008|2008-04-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects|An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects|Completed||Phase 2|16|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 02:19:16.821128|2018-06-01 02:19:16.821128
NCT00642278|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2013-04-01|2009-07-23|2013-07-15|2008-03-24|2008-03-25|Estimate|2013-04-01|2013-05-17|Estimate|2009-07-23|2009-08-10|Estimate|2013-07-15|2013-07-19|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm|Completed||Phase 2|451|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||7|||f||||f||||||||||2018-06-01 02:19:16.946878|2018-06-01 02:19:16.946878
NCT00642265|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2014-12-04|2008-03-24|2008-03-25|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Treatment of Clavicular Fractures|The Treatment of Displaced, Midshaft Clavicular Fractures: Operative vs Conservative. A Prospected, Randomized Study|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:19:18.400088|2018-06-01 02:19:18.400088
NCT00642252|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-03-23|2008-03-24|2008-03-25|Estimate|||||||2015-03-23|2015-03-25|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Development and Validation of a Multi-Mineral Fluoride Mouthrinse|Development and Validation of a Multi-Mineral Fluoride Mouthrinse|Completed||Phase 1|30|Actual|Indiana Nanotech, LLC||2|||f||||f||||||||||2018-06-01 02:19:18.497068|2018-06-01 02:19:18.497068
NCT00642239|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2008-05-13|2008-03-24|2008-03-25|Estimate|||||||2008-05-13|2008-05-14|Estimate|April 2008||2008-04-30|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma|A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma|Unknown status|Recruiting|Phase 4|48|Anticipated|Shandong Luye Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:19:18.565223|2018-06-01 02:19:18.565223
NCT00642226|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2014-01-03|2008-03-19|2008-03-24|Estimate|||||||2014-01-03|2014-01-06|Estimate|November 2006||2006-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)|A Randomized Study Comparing Combined Vitrectomy and Triamcinolone to Laser Grid in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)|Terminated||Phase 3|34|Actual|Helse Stavanger HF||2||"Due to recruiting problems and the introduction of new treatment strategies (ranibizumab and~   dexamethasone implant)."|f||||f||||||||||2018-06-01 02:19:18.662678|2018-06-01 02:19:18.662678
NCT00642213|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2017-05-11|2008-03-19|2008-03-24|Estimate|||||||2017-05-11|2017-05-12|Actual|July 1993||1993-07-31|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|GCNKSS||A Comparison of Hemorrhagic and Ischemic Strokes Among Blacks and Whites|A Comparison of Hemorrhagic and Ischemic Strokes Among Blacks and Whites: A Population-Based Study in Cincinnati, Ohio|Active, not recruiting|||1200|Actual|University of Cincinnati|||2||f||||f||||||Samples With DNA|"~     We have collected blood and/or buccal samples from an interviewed cohort during years~     1999,2005, and 2010.~   "|Yes|we have a website: www.gcnkss.com where de-identified data can be requested via an approval process|2018-06-01 02:19:18.730607|2018-06-01 02:19:18.730607
NCT00642200|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-05-20|2008-03-21|2008-03-24|Estimate|||||||2008-05-20|2008-05-22|Estimate|January 1997||1997-01-31|May 2008|2008-05-31|April 2007|Actual|2007-04-30|February 2002|Actual|2002-02-28||Interventional|||Recurrent Inguinal Hernia Treatment - Lichtenstein Versus Laparoscopic Totally Extraperitoneal Preperitoneal Hernioplasty|Lichtenstein Hernioplasty Versus Totally Extraperitoneal Laparoscopic Hernioplasty in Treatment of Recurrent Inguinal Hernia - A Prospective Randomized Trial|Completed||N/A|100|Actual|North Karelia Central Hospital||2|||f||||f||||||||||2018-06-01 02:19:18.790329|2018-06-01 02:19:18.790329
NCT00642187|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-01-21|2008-03-18|2008-03-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|July 2002||2002-07-31|January 2011|2011-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||New Version Pulmicort Turbuhaler USA Adults|A Placebo-controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated With Inhaled Steroids.|Completed||Phase 3|525|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:19:18.843149|2018-06-01 02:19:18.843149
NCT00642174|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2010-01-18||2010-02-19|2008-03-21|2008-03-24|Estimate|2010-01-18|2010-02-12|Estimate||||2010-02-19|2010-02-23|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|OPTIMUS-3||Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)|A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.|Completed||Phase 2|35|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:19:18.917228|2018-06-01 02:19:18.917228
NCT00642161|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-01-21|2008-03-18|2008-03-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|November 2002||2002-11-30|January 2011|2011-01-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||New Version Pulmicort Turbuhaler USA Children|A Placebo-controlled Comparison of the Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Children and Adolescents.|Completed||Phase 3|430|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:19:19.467087|2018-06-01 02:19:19.467087
NCT00642148|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17||2010-02-05|2017-08-17|2008-03-21|2008-03-24|Estimate||||2010-02-05|2010-02-10|Estimate|2017-08-17|2017-08-18|Actual|February 14, 2008|Actual|2008-02-14|August 2017|2017-08-31|July 27, 2009|Actual|2009-07-27|July 27, 2009|Actual|2009-07-27||Interventional|||A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week, Randomised, Double-blind, Placebo-controlled Study to Assess the Anti-inflammatory Activity, Efficacy and Safety of GW856553 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|306|Actual|GlaxoSmithKline||3|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:19:19.532913|2018-06-01 02:19:19.532913
NCT00642135|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-09|2008-03-21|2008-03-24|Estimate|||||||2008-04-09|2008-04-10|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|June 2008|Anticipated|2008-06-30|February 2008|Anticipated|2008-02-29||Interventional|||CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment|Efficacy and Tolerance of Ophthalmic Insert Mydriasert® Versus Reference Treatment (Phenylephrine and Tropicamide Eyedrops) in Premature Newborns, Neonates and Infants Justifying a Mydriasis for a Bilateral Diagnosis Fundus|Terminated||Phase 3|80|Actual|Assistance Publique - Hôpitaux de Paris||2||The total number of patients has been reached.|f||||t||||||||||2018-06-01 02:19:19.766432|2018-06-01 02:19:19.766432
NCT00642122|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-01-21|2008-03-18|2008-03-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2003||2003-04-30|January 2011|2011-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Adults With Moderate to Severe Asthma|A Randomized, Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of Pulmicort Respules at 0.5mg QD, 1.0mg QD, 1.0mg Bid, 2.0mg Bid and Pulmicort Turbuhaler at 4.00mcg Bid on Adolescents (12 Yrs of Age and Older) With Adults With Moderate to Severe Asthma.|Completed||Phase 3|900|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:19:19.863689|2018-06-01 02:19:19.863689
NCT00642109|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-07-25|2008-03-21|2008-03-24|Estimate|||||||2015-07-25|2015-07-28|Estimate|January 2006||2006-01-31|July 2015|2015-07-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||A Comparison of the Retropubic (TVT) With the Transobturator Sling Operation in the Treatment of Female Stress Urinary Incontinence or Stress Dominated Mixed Urinary Incontinence|A Prospective Randomized Clinical Trial: Comparison of the Retropubic (TVT) With the Transobturator (outside-in T.O.T. Monarc or Inside-out TVT-O) Sling Operation in the Treatment of Female Stress Urinary Incontinence or Stress Dominated Mixed Urinary Incontinence|Terminated||N/A|160|Actual|University of Zurich||3||higher incidence of pain related sexual dysfunction in the TO arm|f||||f||||||||||2018-06-01 02:19:19.950958|2018-06-01 02:19:19.950958
NCT00642096|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-24|2008-03-18|2008-03-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|June 2003||2003-06-30|March 2009|2009-03-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Factorial Study of Metoprolol Succinate TOPROL-XL (324A)|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Factorial Study of Metoprolol Succinate Extended Release Tablets (TOPROL-XL) Hydrochlorothiazide and Their Combination in Patients With Essential Hypertension.|Completed||Phase 3|1900|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:19:20.009374|2018-06-01 02:19:20.009374
NCT00642083|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2011-12-14|2008-03-19|2008-03-24|Estimate|||||||2011-12-14|2011-12-15|Estimate||||December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|SHARE||Stenting of Haemodialysis Acces Trial|Stenting of Haemodialysis Acces Re-stenosis Trial (SHARE Trial)|Terminated||Phase 2|20|Anticipated|Rijnstate Hospital||1||slow inclusion|f||||||||||||||2018-06-01 02:19:20.09497|2018-06-01 02:19:20.09497
NCT00642070|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2014-06-03|2008-03-18|2008-03-24|Estimate|||||||2014-06-03|2014-06-05|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Host Response to Urinary Tract Infection in Women|Host Response to Urinary Tract Infection in Women|Completed|||326|Actual|University of Washington|||1||f||||f||||||Samples With DNA|"~     whole blood,serum, urine~   "|||2018-06-01 02:19:20.16867|2018-06-01 02:19:20.16867
NCT00642057|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2016-09-26|2008-03-21|2008-03-24|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 1989||1989-06-30|September 2016|2016-09-30|February 2013|Actual|2013-02-28|December 2009|Actual|2009-12-31||Expanded Access|TBZ||Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements|Compassionate Use of Tetrabenazine in the Treatment of Hyperkinesias|Available|||||Baylor College of Medicine||||Commercial availability of Xenazine|||||||||||||||2018-06-01 02:19:20.234295|2018-06-01 02:19:20.234295
NCT00642044|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-22|2008-03-21|2008-03-24|Estimate|||||||2008-04-22|2008-04-23|Estimate|February 2007||2007-02-28|March 2008|2008-03-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Corneal Collagen Crosslinking With Riboflavin for Keratoconus Treatment: A Brazilian Study|Corneal Collagen Crosslinking With Riboflavin for Keratoconus Treatment: A Brazilian Study|Unknown status|Recruiting|N/A|100|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-06-01 02:19:20.316136|2018-06-01 02:19:20.316136
NCT00642031|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2016-08-06|2008-03-18|2008-03-24|Estimate|||||||2016-08-06|2016-08-09|Estimate|August 2006||2006-08-31|August 2016|2016-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies|A Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies|Completed||Phase 1|20|Actual|Prescient Therapeutics, Ltd.||1|||f||||f||||||||||2018-06-01 02:19:20.408739|2018-06-01 02:19:20.408739
NCT00642018|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28||2012-05-24|2012-05-24|2008-03-19|2008-03-24|Estimate||||2012-05-24|2012-06-01|Estimate|2012-05-24|2012-06-01|Estimate|March 2008||2008-03-31|May 2012|2012-05-31|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Interventional|||A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer|A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Hormone Refractory Prostate Cancer|Completed||Phase 2|150|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:19:20.498545|2018-06-01 02:19:20.498545
NCT00642005|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2014-03-10|2008-03-17|2008-03-24|Estimate|||||||2014-03-10|2014-03-11|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Humidification in Laparoscopic Colonic Surgery|Humidification in Laparoscopic Colonic Surgery - A Double Blinded, Randomised Controlled Trial.|Completed||N/A|82|Actual|University of Auckland, New Zealand||2|||f||||f||||||||||2018-06-01 02:19:20.593298|2018-06-01 02:19:20.593298
NCT00641992|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-17|2008-03-17|2008-03-24|Estimate|||||||2008-03-17|2008-03-24|Estimate|May 1999||1999-05-31|March 2008|2008-03-31|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Observational|||Prognosis of Failure Treatment of Amebic Liver Abscess|Prognosis Factors of the Response After Medical Treatment of Amebic Liver Abscess|Completed|||40|Actual|Universidad Autonoma de San Luis Potosí|||2||f||||f||||||||||2018-06-01 02:19:20.663103|2018-06-01 02:19:20.663103
NCT00641979|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-01-21|2008-03-21|2008-03-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2002||2002-04-30|January 2011|2011-01-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||New Nasal Applicator / New Formulation - User Study|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Functionality of a New Nasal Device With Reformulated Rhinocort Aqua (Budesonide) Versus the Current Product and Versus Placebo in Subjects With Seasonal Allergic Rhinitis (SAR).|Completed||Phase 2|200|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:19:20.715161|2018-06-01 02:19:20.715161
NCT00641953|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-06-13|2008-03-21|2008-03-24|Estimate|||||||2008-06-13|2008-06-17|Estimate|August 2007||2007-08-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||IMX-150 Cream for Diabetic Neuropathy|A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of Pain in Diabetic Peripheral Neuropathy of the Feet|Completed||Phase 2|155|Actual|Procris Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:19:20.779597|2018-06-01 02:19:20.779597
NCT00641940|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-17|2008-03-17|2008-03-24|Estimate|||||||2008-03-17|2008-03-24|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|GT||Girls in Transition Study: Helping Girls Enter the Teenage Years|Girls in Transition Study: Helping Girls Enter the Teenage Years|Unknown status|Active, not recruiting|Phase 1|32|Actual|Swarthmore College||2|||f||||||||||||||2018-06-01 02:19:20.901032|2018-06-01 02:19:20.901032
NCT00641927|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-03-18|2008-03-18|2008-03-24|Estimate|||||||2008-03-18|2008-03-24|Estimate|April 2002||2002-04-30|March 2008|2008-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Antidepressant Therapy for Bipolar II Major Depression|Acute Antidepressant Therapy in Bipolar II Major Depression|Completed||Phase 4|90|Actual|Stanley Medical Research Institute||2|||f||||t||||||||||2018-06-01 02:19:21.036528|2018-06-01 02:19:21.036528
NCT00641914|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-24|2008-03-21|2008-03-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 1996||1996-10-31|March 2009|2009-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|START||Inhaled Steroid Treatment as Regular Therapy in Early Asthma|Inhaled Steroid Treatment As Regular Therapy in Early Asthma. A Study on the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort Turbuhaler ® ) in Newly Diagnosed Asthma.|Completed||Phase 4|6800|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:19:21.131167|2018-06-01 02:19:21.131167
NCT00641901|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2013-02-27|2008-03-17|2008-03-24|Estimate|||||||2013-02-27|2013-03-01|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|TRIUMPH||A Study to Evaluate Associations Between Gingivitis and Pregnancy Outcomes|A Study of Oral Health Care Education and Therapy to Reduce Gingivitis During Pregnancy|Completed|||120|Actual|University of Alabama at Birmingham|||1||f||||f||||||Samples Without DNA|"~     Samples of venous blood and gingivial crevicular fluid (GCF)will be collected at baseline and~     at week-8.~      GCF samples will be harvested from two non-adjacent oral sites, flash-frozen in liquid~     nitrogen and stored at -70 degrees F. until batched testing. GCF samples will be analyzed for~     TNFalpha, IL1beta and IL 6 by Lumidex methodology.~      Blood samples will be analyzed for Serum Inflammatory markers, C-Reative Protein and~     inflammatory cytokines.~   "|||2018-06-01 02:19:21.201497|2018-06-01 02:19:21.201497
NCT00641888|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2017-07-06|2008-03-21|2008-03-24|Estimate|||||||2017-07-06|2017-07-11|Actual|March 2008|Actual|2008-03-31|July 2017|2017-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Impact of Antiretroviral Therapy on Cardiac Biomarkers|Impact of Antiretroviral Therapy on Biomarkers of Inflammation Associated With Cardiovascular Risk|Completed|||40|Actual|University of California, Davis|||2||f||||f||||||||||2018-06-01 02:19:21.2754|2018-06-01 02:19:21.2754
NCT00641875|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-04-23|2008-03-21|2008-03-24|Estimate|||||||2015-04-23|2015-04-27|Estimate|December 2005||2005-12-31|April 2015|2015-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||The Effect of Nocturnal Haemodialysis on Arterial Stiffness|The Effect of Nocturnal Haemodialysis on Arterial Stiffness|Completed|||30|Actual|Melbourne Health|||||f||||f||||||||||2018-06-01 02:19:21.330606|2018-06-01 02:19:21.330606
NCT00641862|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|2016-08-22||2016-08-22|2008-03-21|2008-03-24|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|April 2019|Anticipated|2019-04-30|January 2011|Actual|2011-01-31||Interventional|B12||Randomized Trial of Vitamin B12 in Pregnant Indian Women|Randomized Trial of Vitamin B12 in Pregnant Indian Women|Active, not recruiting||Phase 3|366|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-06-01 02:19:21.391352|2018-06-01 02:19:21.391352
NCT00641849|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2016-10-03|2008-03-18|2008-03-24|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2008||2008-07-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|Compliance||Physical Activity and Dietary Behaviors of Adults 18 to 80 Years of Age|Physical Activity and Dietary Behaviors of Adults 18 to 80 Years of Age|Terminated||N/A|54|Actual|University of Missouri-Columbia||2||Terminated by PI r/t lack of funding and retirement of study personel.|f||||f||||||||No||2018-06-01 02:19:21.580427|2018-06-01 02:19:21.580427
NCT00641836|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-03-18|2008-03-18|2008-03-24|Estimate|||||||2008-03-18|2008-03-24|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|||||Interventional|||Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension|One-Year Follow-Up of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension|Completed||N/A|98|Actual|Zhejiang University|||||f||||||||||||||2018-06-01 02:19:21.682584|2018-06-01 02:19:21.682584
NCT00641823|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2013-03-21|2008-03-21|2008-03-24|Estimate|||||||2013-03-21|2013-03-22|Estimate|March 2008||2008-03-31|March 2013|2013-03-31||||March 2015|Anticipated|2015-03-31||Observational|||Objective Functional Outcome Measures in Orthopedic Surgery Using Advanced Tracking Technologies|Objective Functional Outcome Measures in Orthopedic Surgery Using Advanced Tracking Technologies|Unknown status|Recruiting||60|Anticipated|Hadassah Medical Organization|||3||f||||||||||||||2018-06-01 02:19:21.748011|2018-06-01 02:19:21.748011
NCT00641810|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2013-12-29|2008-03-18|2008-03-24|Estimate|||||||2013-12-29|2013-12-31|Estimate|March 2008||2008-03-31|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effect of Caffeine Reduction on Snoring and Quality of Life|The Effect of Caffeine Reduction on Snoring and Quality of Life|Completed||N/A|30|Anticipated|University of Vermont||1|||f||||f||||||||||2018-06-01 02:19:21.811624|2018-06-01 02:19:21.811624
NCT00641472|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-24|2008-03-21|2008-03-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 2002||2002-10-31|March 2009|2009-03-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children|An Evaluation of the Effectiveness of Pulmicort Respules (Budesonide Inhalation Suspension) Versus SINGULAIR (Montelukast Sodium) in Children 2-8 Years Old With Asthma Requiring Controller Therapy.|Completed||Phase 4|380|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:19:31.004824|2018-06-01 02:19:31.004824
NCT00641797|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2017-09-19||2018-03-05|2008-03-21|2008-03-24|Estimate|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|November 2006||2006-11-30|March 2018|2018-03-31|November 2013|Actual|2013-11-30|December 2010|Actual|2010-12-31||Interventional||To be included in the study, patients had to be at least 18 years of age, presenting to the ED weekdays during business hours, and have a positive DH test.|Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients|A Randomized Trial to Evaluate Resolution of Symptoms Using Vestibular Rehab Versus Conventional Therapy in Patients Presenting to the Emergency Department (ED) With Diagnosis of Benign Paroxysmal Positional Vertigo (BPPV)|Completed||N/A|26|Actual|Lehigh Valley Hospital||2|||f||||t||||||||No|No plan to share IPD, just publish the study's results.|2018-06-01 02:19:21.88113|2018-06-01 02:19:21.88113
NCT00641784|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2009-09-17|2008-03-21|2008-03-24|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2008||2008-03-31|September 2009|2009-09-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Tocolytics Trial: Intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population|A Randomized Trial of Oral Nifedipine Versus Intravenous Magnesium Sulfate in the Acute Management of Preterm Labor in Women With Singleton Gestations, Intact Fetal Membranes, and Positive Vaginal Fetal Fibronectin|Terminated||Phase 3|200|Anticipated|MemorialCare||2|||f||||f||||||||||2018-06-01 02:19:22.08643|2018-06-01 02:19:22.08643
NCT00641771|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2014-12-24|2008-03-18|2008-03-24|Estimate|||||||2014-12-24|2014-12-25|Estimate|May 2004||2004-05-31|December 2014|2014-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter 4-Week Study to Assess the Effect of Alendronate 70 mg and Vitamin D3 2800 IU Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women|Completed||Phase 1|56|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:19:22.157682|2018-06-01 02:19:22.157682
NCT00641758|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2010-02-09|2008-03-17|2008-03-24|Estimate|||||||2010-02-09|2010-02-10|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pycnogenol and Endothelial Function in Coronary Artery Disease|A Double-blind, Randomized, Placebo-controlled, Cross - Over Design, Single Center Study to Evaluate the Effects of Treatment With Pycnogenol® on Endothelial Function in Subjects With Stable Coronary Artery Disease (Pycno2007-003)|Completed||N/A|25|Anticipated|University of Zurich||2|||f||||f||||||||||2018-06-01 02:19:22.230141|2018-06-01 02:19:22.230141
NCT00641745|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2011-09-01||2015-06-16|2008-03-21|2008-03-24|Estimate|2011-09-01|2011-10-06|Estimate||||2015-06-16|2015-06-22|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia|Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial|Completed||Phase 3|629|Actual|Sunovion||2|||f||||t||||||||||2018-06-01 02:19:22.35694|2018-06-01 02:19:22.35694
NCT00641732|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18||2016-03-13|2016-03-13|2008-03-18|2008-03-24|Estimate||||2016-03-13|2016-04-13|Estimate|2016-03-13|2016-04-13|Estimate|October 2007||2007-10-31|March 2016|2016-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement|A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement|Completed||Phase 2|1045|Actual|Takeda||7|||f||||t||||||||||2018-06-01 02:19:22.825655|2018-06-01 02:19:22.825655
NCT00641719|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2011-03-03||2011-03-03|2008-03-21|2008-03-24|Estimate|2011-03-03|2011-03-31|Estimate||||2011-03-03|2011-03-31|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Long-term Study for the Treatment of Painful Diabetic Neuropathy|A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain - Extension Phase|Completed||Phase 3|258|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:19:22.981296|2018-06-01 02:19:22.981296
NCT00641706|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|2013-03-06||2014-04-28|2008-03-21|2008-03-24|Estimate|2013-05-16|2013-07-10|Estimate||||2014-04-28|2014-05-14|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme|Phase II Study of Vorinostat (SAHA) in Combination With Bortezomib (PS-341) in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 02:19:23.986801|2018-06-01 02:19:23.986801
NCT00641693|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-01-21|2008-03-18|2008-03-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2004||2004-04-30|January 2011|2011-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Assess the Efficacy and Safety of Rhinocort Aqua|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT AQUA (Budesonide) Nasal Spray 16mg, 32mg and 64mg Per Day Versus Placebo in Paediatric Subjects Ages 2-5 Years Old With Allergic Rhinitis.|Completed||Phase 2|650|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:19:24.633547|2018-06-01 02:19:24.633547
NCT00641680|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-01-21|2008-03-21|2008-03-24|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2003||2003-04-30|January 2011|2011-01-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Rhinocort Aqua Versus Placebo and Fluticasone Propionate|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IIIb Study to Assess the Efficacy, Safety & Product Attributes of Rhinocort Aqua(Budesonide) Versus Placebo and FluticasonePropionate as an Active Comparator in Patients 12yrs Age &Older With SeasonalAllergicRhinitis|Completed||Phase 3|750|Anticipated|AstraZeneca||3|||f||||||||||||||2018-06-01 02:19:24.717562|2018-06-01 02:19:24.717562
NCT00641667|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|2013-03-21||2013-05-31|2008-03-17|2008-03-24|Estimate|2013-03-21|2013-05-08|Estimate||||2013-05-31|2013-06-07|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain|A Phase III Study of JNS020QD in Cancer Pain Patients - Evaluation of the Efficacy and Safety of JNS020QD Switched From Opioid Analgesics|Completed||Phase 3|66|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-06-01 02:19:24.811235|2018-06-01 02:19:24.811235
NCT00641654|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2012-08-29|2008-03-21|2008-03-24|Estimate|||||||2012-08-29|2012-08-30|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|RelapC||Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin|An Open-label Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 Weeks Pegylated Interferon Alfa-2a 40 kD (PEGASYS) Combination Therapy With Ribavirin (Copegus) in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After a Minimum of 12 Weeks and a Maximum of 24 Weeks of Therapy With Pegylated Interferon and Ribavirin|Terminated||Phase 4|75|Actual|Göteborg University||3||Recruitment problems in Denmark and Norway|f||||f||||||||||2018-06-01 02:19:25.164142|2018-06-01 02:19:25.164142
NCT00641641|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2012-04-11||2017-08-30|2008-03-18|2008-03-24|Estimate|2013-05-23|2013-05-27|Estimate||||2017-08-30|2017-08-31|Actual|March 2008||2008-03-31|August 2017|2017-08-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|PINT||The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection|An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection|Completed||N/A|16|Actual|Kirby Institute|Limited cohort (n=16) of exclusively male participants treated with a licensed regimen of combination antiretroviral therapy with the primary focus being a detailed examination of virus decay characteristics|1|||f||||t||||||||||2018-06-01 02:19:25.235617|2018-06-01 02:19:25.235617
NCT00641628|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-03-19|2008-03-19|2008-03-24|Estimate|||||||2008-03-19|2008-03-24|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Nipple Areola Complex Conservation|Subcutaneous Mastectomy With Conservation of the Nipple Areola Complex: Broadening the Indications|Completed|||||Technische Universität München|||1||f||||f||||||Samples Without DNA|"~     Breast Carcinoma Tissue~   "|||2018-06-01 02:19:25.371629|2018-06-01 02:19:25.371629
NCT00641615|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-05-11|2008-03-17|2008-03-24|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2007||2007-05-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer|Phase I Study of Peptide Vaccine and S-1 Plus CPT-11 Chemotherapy in Patients With Unresectable Recurrent or Metastatic Colorectal Cancer|Completed||Phase 1|18|Actual|Tokyo Women's Medical University||1|||f||||t||||||||||2018-06-01 02:19:25.474743|2018-06-01 02:19:25.474743
NCT00641602|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-25|2008-03-21|2008-03-24|Estimate|||||||2009-03-25|2009-03-26|Estimate|December 2002||2002-12-31|March 2009|2009-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis|A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis.|Completed||Phase 4|1000|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:19:25.540561|2018-06-01 02:19:25.540561
NCT00641589|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2011-05-17|2008-03-17|2008-03-24|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|November 2006|Actual|2006-11-30|||||Interventional|||A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease|An Open-Label, Randomized Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Subjects With Chronic Kidney Disease|Completed||Phase 1|40|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:19:25.679206|2018-06-01 02:19:25.679206
NCT00641576|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2013-07-18|2008-03-21|2008-03-24|Estimate|||||||2013-07-18|2013-07-22|Estimate|April 2005||2005-04-30|July 2013|2013-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|ACE-2005||Evaluation of the ACE Dental Implant|A Study to Evaluate the Morse Taper Lock and Connection of the ACE Implant Internal-Connection and Its Effect of the Biological Gap|Completed|||23|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 02:19:25.758206|2018-06-01 02:19:25.758206
NCT00641563|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2009-04-27||2011-10-13|2008-03-21|2008-03-24|Estimate|2011-10-13|2011-11-22|Estimate||||2011-10-13|2011-11-22|Estimate|March 2004||2004-03-31|October 2011|2011-10-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Effects of Two Different Sedation Regimes on Auditory Evoked Potentials and Electroencephalogram (EEG)|The Effects of Dexmedetomidine/Remifentanil and Midazolam/Remifentanil on Auditory-evoked Potentials and Electroencephalogram at Light-to-moderate Sedation Levels in Healthy Subjects|Completed||N/A|10|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:19:25.839369|2018-06-01 02:19:25.839369
NCT00641550|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2011-12-12|2008-03-17|2008-03-24|Estimate|||||||2011-12-12|2011-12-13|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|December 2011|Anticipated|2011-12-31|April 2009|Actual|2009-04-30||Interventional|||Exercise and Pregnancy: Randomized Clinical Trial|Effects of Physical Exercise During Pregnancy on the Maternal and Perinatal Outcomes: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|188|Anticipated|Universidade Estadual da Paraiba||3|||f||||f||||||||||2018-06-01 02:19:26.089189|2018-06-01 02:19:26.089189
NCT00641537|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2013-09-30||2014-01-10|2008-03-21|2008-03-24|Estimate|2013-09-30|2013-12-02|Estimate||||2014-01-10|2014-02-07|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Intention-to-treat (ITT) population included all participants who were randomized in the study.|CLARITY Extension Study|A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)|Completed||Phase 3|867|Actual|EMD Serono||5|||f||||||||||||||2018-06-01 02:19:26.397155|2018-06-01 02:19:26.397155
NCT00641524|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2016-05-12|2008-03-17|2008-03-24|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease|Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease|Completed||N/A|45|Actual|University of Western Ontario, Canada||1|||f||||f||||||||||2018-06-01 02:19:30.020776|2018-06-01 02:19:30.020776
NCT00641511|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-06-08|2008-03-21|2008-03-24|Estimate|||||||2011-06-08|2011-06-09|Estimate|June 2008||2008-06-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)|Pharmacogenetic Clinical Trial of Nepicastat for PTSD|Completed||Phase 2|30|Anticipated|Michael Debakey Veterans Affairs Medical Center||2|||f||||t||||||||||2018-06-01 02:19:30.087955|2018-06-01 02:19:30.087955
NCT00641498|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-03-27|2008-03-17|2008-03-24|Estimate|||||||2015-03-27|2015-03-30|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|December 2009|Actual|2009-12-31||Interventional|||Effectiveness of Standard Emergency Department Psychiatric Treatment Associated With Treatment Delivery by a Suicide Prevention Center|Effectiveness of Standard Emergency Department Psychiatric Treatment Compared With Effectiveness of Standard Emergency Department Psychiatric Treatment Associated With Treatment Delivery by a Suicide Prevention Center.|Completed||N/A|607|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 02:19:30.163456|2018-06-01 02:19:30.163456
NCT00641459|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2014-05-22|2008-03-17|2008-03-24|Estimate|||||||2014-05-22|2014-05-23|Estimate|September 2007||2007-09-30|May 2014|2014-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||A Study on Behavioral and Psychological Symptoms of Dementia|Behavioral and Psychological Symptoms of Dementia (BPSD) in Taiwan - An Observational Study|Completed|||359|Actual|Johnson & Johnson Taiwan Ltd|||1||f||||||||||||||2018-06-01 02:19:31.065025|2018-06-01 02:19:31.065025
NCT00641446|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-24|2008-03-21|2008-03-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 2001||2001-10-31|March 2009|2009-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Varicella Vaccination With Pulmicort|Rates of Seroconversion Following Varicella Vaccination of Asthmatic Children Between the Ages of One and Eight Years Treated With Pulmicort Respules® Versus Non-Steroidal Conventional Asthma Therapy|Completed||Phase 4|250|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:19:31.120804|2018-06-01 02:19:31.120804
NCT00641433|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-03-18|2008-03-18|2008-03-24|Estimate|||||||2008-03-18|2008-03-24|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails|Topical Collagen-Silver Versus Standard Care Following Phenol Ablation of Ingrown Nails: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|80|Anticipated|Rosalind Franklin University of Medicine and Science||2|||f||||f||||||||||2018-06-01 02:19:31.181464|2018-06-01 02:19:31.181464
NCT00641420|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-21|2008-03-21|2008-03-24|Estimate|||||||2008-03-21|2008-03-24|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|September 2008|Anticipated|2008-09-30|August 2008|Anticipated|2008-08-31||Interventional|||Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin|Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin|Unknown status|Active, not recruiting|N/A|15|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-06-01 02:19:31.281342|2018-06-01 02:19:31.281342
NCT00641407|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-28|2008-03-21|2008-03-24|Estimate|||||||2008-03-28|2008-03-31|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes|Bedtime Insulin Glargine or Bedtime Neutral Protamine Lispro Combined With Sulfonylurea and Metformin in Type 2 Diabetes. A Randomized, Controlled Trial|Completed||Phase 4|100|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-06-01 02:19:31.357399|2018-06-01 02:19:31.357399
NCT00641394|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2018-04-23|2008-03-21|2008-03-24|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2008||2008-04-30|April 2018|2018-04-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||The Effect of Psychotherapy on Stress Biochemistry: An RCT of Psychotherapy and Emotional Freedom Techniques (EFT)|The Effect of Psychotherapy on Stress Biochemistry: A Randomized Blind Controlled Trial of Psychotherapy and Emotional Freedom Techniques (EFT)|Completed||N/A|83|Actual|Soul Medicine Institute||3|||f||||t||||||||||2018-06-01 02:19:31.435119|2018-06-01 02:19:31.435119
NCT00641381|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2018-02-16|2008-03-21|2008-03-24|Estimate|||||||2018-02-16|2018-02-20|Estimate|May 10, 2000|Actual|2000-05-10|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma|High Dose Chemotherapy and Combination Anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|25|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:19:31.583661|2018-06-01 02:19:31.583661
NCT00641368|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-17|2008-03-17|2008-03-24|Estimate|||||||2008-03-17|2008-03-24|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|R4Power||R4Power: An Online Resilience Program for Adolescents|R4Power: An Online Resilience Program for Adolescents|Unknown status|Recruiting|Phase 1|200|Anticipated|Swarthmore College||2|||f||||||||||||||2018-06-01 02:19:31.763805|2018-06-01 02:19:31.763805
NCT00641355|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-21|2008-03-21|2008-03-24|Estimate|||||||2008-03-21|2008-03-24|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|September 2012|Anticipated|2012-09-30|||||Observational|||Acute Phase Proteins as Early Markers in Sepsis|Acute Phase Proteins as Early Markers in Sepsis|Unknown status|Not yet recruiting||15|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 02:19:31.850879|2018-06-01 02:19:31.850879
NCT00641342|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2014-02-06|2008-03-21|2008-03-24|Estimate|||||||2014-02-06|2014-02-07|Estimate|March 2007||2007-03-31|March 2008|2008-03-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Prevention of Parastomal Hernia by Primary Mesh Insertion|Prevention of Parastomal Hernia by Primary Mesh Insertion: a Randomized Double-blinded Controlled Multi-centre Study.|Terminated||Phase 2/Phase 3|198|Anticipated|University Hospital, Gentofte, Copenhagen||3||"Lack of recruitment from different study sites and due to structural changes in the included~   centers"|f||||f||||||||||2018-06-01 02:19:31.925829|2018-06-01 02:19:31.925829
NCT00641329|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2010-04-08|2008-03-19|2008-03-24|Estimate|||||||2010-04-08|2010-04-09|Estimate|February 2008||2008-02-29|March 2009|2009-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD|Phase III Evaluation of the Safety and Efficacy of CLONICEL (Clonidine HCl Sustained Release) as Add-on to Psychostimulant Medication vs. Psychostimulant Medication Alone in Children and Adolescents With ADHD|Completed||Phase 3|198|Actual|Addrenex Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:19:32.020226|2018-06-01 02:19:32.020226
NCT00641316|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2013-02-27|2008-03-21|2008-03-24|Estimate|||||||2013-02-27|2013-03-01|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|April 2010|Actual|2010-04-30||Interventional|FMD-007||An Assessment of Bone Augmentation in Post-Extraction Sockets|A Prospective Study of Bone Augmentation Techniques in Extraction Sockets and Implant Surface Textures|Completed||N/A|102|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-06-01 02:19:32.144635|2018-06-01 02:19:32.144635
NCT00641303|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-21|||2012-01-26|2008-03-21|2008-03-24|Estimate|||||||2012-01-26|2012-01-31|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer|A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors|Completed||Phase 2|51|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 02:19:32.23336|2018-06-01 02:19:32.23336
NCT00641290|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-04|2008-03-21|2008-03-24|Estimate|||||||2008-04-04|2008-04-15|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Observational|||Vigileo FloTrac vs Pulmonary Artery Catheter|Cardiac Output and Central Venous Oxygen Saturation Monitoring Using the Vigileo FloTrac Sensor Versus Conventional Thermodilution Method Using the Pulmonary Artery Catheter: A Prospective Study|Unknown status|Not yet recruiting||60|Anticipated|Hospital Sultanah Aminah Johor Bahru|||||f||||t||||||||||2018-06-01 02:19:32.315108|2018-06-01 02:19:32.315108
NCT00641277|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2013-02-27|2008-03-21|2008-03-24|Estimate|||||||2013-02-27|2013-03-01|Estimate|March 2004||2004-03-31|February 2013|2013-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|Maximus||Longitudinal Efficacy of Dental Implants in Anterior Areas|A Study to Evaluate the Efficacy of the 3mm Maximus Dental Implant in Areas of Limited Tooth-to-tooth Spacing|Completed|||15|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 02:19:32.378045|2018-06-01 02:19:32.378045
NCT00641264|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-06-10|2008-03-18|2008-03-24|Estimate|||||||2009-06-10|2009-06-11|Estimate|May 2001||2001-05-31|June 2009|2009-06-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Quality of Life Validation in Laryngitis|Laryngopharyngeal Reflux Health Related Quality of Life (LPR-HRQL) Questionnaire Development and Psychometric Testing in Patients Receiving Omeprazole 20 mg Bid as Treatment for Laryngopharyngeal Reflux.|Completed||Phase 4|90|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:19:32.443394|2018-06-01 02:19:32.443394
NCT00641251|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2017-11-27|2008-03-17|2008-03-24|Estimate|||||||2017-11-27|2017-11-29|Actual|February 2008||2008-02-29|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DSS||DSS: Diabetes Surgery Study - Intensive Medical Management of Type 2 Diabetes, With and Without Gastric Bypass Surgery|Global Randomized Prospective Study of Intensive Medical Management of Type 2 Diabetes, With and Without Gastric Bypass Surgery|Completed||N/A|120|Actual|Medtronic - MITG||2|||f||||t||||||||||2018-06-01 02:19:32.497109|2018-06-01 02:19:32.497109
NCT00641238|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-05-12|2008-03-21|2008-03-24|Estimate|||||||2015-05-12|2015-05-14|Estimate|March 2004||2004-03-31|May 2015|2015-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Outcome of Patients With Lung Masses Who Are Treated With Radiofrequency Ablation (RFA)|Clinical Follow-up of Patients Treated With Radiofrequency Ablation of Lung Masses.|Completed|||20|Actual|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 02:19:32.558157|2018-06-01 02:19:32.558157
NCT00641225|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2013-02-21|2008-03-21|2008-03-24|Estimate|||||||2013-02-21|2013-02-22|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis|An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Subjects With Rheumatoid Arthritis|Completed||Phase 1|62|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:19:32.614948|2018-06-01 02:19:32.614948
NCT00641212|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-24|2008-03-21|2008-03-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2000||2000-01-31|March 2009|2009-03-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Children, Perennial Allergic Rhinitis (PAR), l-t Growth|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis.|Completed||Phase 4|209|Anticipated|AstraZeneca||2|||||||||||||||||2018-06-01 02:19:32.712356|2018-06-01 02:19:32.712356
NCT00641199|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2010-01-14|2008-03-21|2008-03-24|Estimate|||||||2010-01-14|2010-01-15|Estimate|March 2008||2008-03-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Probiotics for Prevention of Antibiotic-associated Diarrhea|The Effect of Jarro-Dophilus EPS Probiotics on the Prevention of Diarrhea, Quality of Life and Symptoms in Adults Receiving Antibiotic Therapy.|Completed||N/A|204|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 02:19:32.833713|2018-06-01 02:19:32.833713
NCT00641186|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-04-30|2008-03-21|2008-03-24|Estimate|||||||2009-04-30|2009-05-01|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|Xyrem||Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)|A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease|Completed||N/A|30|Anticipated|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 02:19:32.912079|2018-06-01 02:19:32.912079
NCT00641173|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-06-25|2008-03-21|2008-03-24|Estimate|||||||2015-06-25|2015-06-26|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Early Intervention for Post Traumatic Stress Disorder (PTSD)|Early Intervention for PTSD in Iraqi Veterans|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Withdrawn by funding source|f||||t||||||||||2018-06-01 02:19:33.000745|2018-06-01 02:19:33.000745
NCT00641160|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2008-09-24|2008-03-19|2008-03-24|Estimate|||||||2008-09-24|2008-09-26|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies|A Phase 1 Study of the Safety, Pharmacokinetics, and Biological Activity of Metronomic Dosing With Orally Administered Vinorelbine Tablets in Subjects With Non-Hematologic Malignancies For Which There Are No Currently Accepted Therapies|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|Metronome Therapeutics||3|||f||||f||||||||||2018-06-01 02:19:33.092312|2018-06-01 02:19:33.092312
NCT00641147|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|2017-07-13||2017-09-27|2008-03-21|2008-03-24|Estimate|2017-09-27|2017-09-29|Actual||||2017-09-27|2017-09-29|Actual|October 2010||2010-10-31|September 2017|2017-09-30|November 30, 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Curcumin in Treating Patients With Familial Adenomatous Polyposis|Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||No||2018-06-01 02:19:33.204673|2018-06-01 02:19:33.204673
NCT00641134|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-02-05|2008-03-18|2008-03-24|Estimate|||||||2009-02-05|2009-02-06|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|November 2010|Anticipated|2010-11-30|November 2009|Anticipated|2009-11-30||Interventional|CR-AGE-EXTRA||Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active Follow-up CR-AGE-EXTRA Trial|Cardiac Rehabilitation in Advanced aGE: EXercise TRaining and Active Follow-up, a Randomised Controlled Trial. CR-AGE EXTRA Trial|Unknown status|Recruiting|N/A|80|Anticipated|University of Florence||2|||f||||f||||||||||2018-06-01 02:19:33.861498|2018-06-01 02:19:33.861498
NCT00641121|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2018-01-11|2008-03-20|2008-03-21|Estimate|||||||2018-01-11|2018-01-12|Actual|November 2005||2005-11-30|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Bethaherpesviruses in Children Who Are Immune Suppressed|Bethaherpesviruses in Children Who Are Immune Suppressed|Completed|||80|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-06-01 02:19:33.937094|2018-06-01 02:19:33.937094
NCT00641108|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2012-07-26|2008-03-19|2008-03-21|Estimate|||||||2012-07-26|2012-07-30|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Cognitive Behavioral Therapy on Brain Serotonin Activity in People With Depression|Effect of Psychotherapy on Brain Serotonin Activity|Completed||Phase 2/Phase 3|30|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:19:33.980671|2018-06-01 02:19:33.980671
NCT00641095|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2013-08-09|2008-03-20|2008-03-21|Estimate|||||||2013-08-09|2013-08-12|Estimate|December 2006||2006-12-31|November 2008|2008-11-30||||September 2010|Anticipated|2010-09-30||Interventional|||Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma|Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma|Unknown status|Recruiting|Phase 3|550|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:19:34.070036|2018-06-01 02:19:34.070036
NCT00641082|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2012-04-24|2008-03-17|2008-03-21|Estimate|||||||2012-04-24|2012-04-25|Estimate|February 2008||2008-02-29|April 2012|2012-04-30||||March 2012|Actual|2012-03-31||Interventional|||A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function|A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function|Completed||Phase 4|43|Actual|Bukwang Pharmaceutical||2|||f||||||||||||||2018-06-01 02:19:34.373175|2018-06-01 02:19:34.373175
NCT00641069|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-07-14|2008-03-18|2008-03-21|Estimate|||||||2009-07-14|2009-07-15|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Automated Chest Compression in Cardiac Arrest|Effect on Hemodynamics of Automated Band Chest Compression Device in Cardiac Arrest Resuscitation|Completed|||30|Anticipated|Beaujon Hospital|||||f||||f||||||||||2018-06-01 02:19:34.454061|2018-06-01 02:19:34.454061
NCT00641056|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|2012-02-14|2010-08-13|2015-05-21|2008-03-20|2008-03-21|Estimate|2012-05-31|2012-07-04|Estimate|2010-08-13|2010-08-18|Estimate|2015-05-21|2015-06-15|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)|Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea|Completed||Phase 3|467|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:19:34.555709|2018-06-01 02:19:34.555709
NCT00641043|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2011-05-13||2014-01-22|2008-03-20|2008-03-21|Estimate|2011-05-13|2011-06-07|Estimate||||2014-01-22|2014-02-17|Estimate|March 2008||2008-03-31|January 2014|2014-01-31||||June 2009|Actual|2009-06-30||Interventional|||Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone|A Randomised, Double-blind, Placebo Controlled, Parallel Group 24 Week Study to Assess the Efficacy and Safety of BI 1356 (5 mg) in Combination With 30 mg Pioglitazone (Both Administered Orally Once Daily), Compared to 30 mg Pioglitazone Plus Placebo in Drug Naive or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control.|Completed||Phase 3|389|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:19:35.211023|2018-06-01 02:19:35.211023
NCT00641030|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2012-07-16|2008-03-20|2008-03-21|Estimate|||||||2012-07-16|2012-07-17|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes|A Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation|Completed||Phase 1|20|Actual|City of Hope Medical Center|||||f||||t||||||||||2018-06-01 02:19:35.784393|2018-06-01 02:19:35.784393
NCT00641017|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2013-02-22|2008-03-19|2008-03-21|Estimate|||||||2013-02-22|2013-02-25|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine|A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age|Completed||Phase 1|87|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||t||||||||||2018-06-01 02:19:35.853176|2018-06-01 02:19:35.853176
NCT00641004|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-08-23|2008-03-20|2008-03-21|Estimate|||||||2011-08-23|2011-08-24|Estimate|April 2008||2008-04-30|December 2009|2009-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy|Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy|Completed||Phase 4|30|Anticipated|Otsuka Pharmaceutical, Inc., Philippines||2|||f||||f||||||||||2018-06-01 02:19:35.922642|2018-06-01 02:19:35.922642
NCT00640991|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2010-06-15|2008-03-18|2008-03-21|Estimate|||||||2010-06-15|2010-06-16|Estimate|April 2008||2008-04-30|June 2009|2009-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|RECREATE Pilot||REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)|An International Multicentre Randomized Controlled Trial of Intensive Insulin Therapy Targeting Normoglycemia In Acute Myocardial Infarction: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) Pilot Study|Completed||Phase 3|500|Anticipated|Population Health Research Institute||2|||f||||t||||||||||2018-06-01 02:19:35.979763|2018-06-01 02:19:35.979763
NCT00640978|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|2011-07-22||2012-06-18|2008-03-17|2008-03-21|Estimate|2011-08-23|2011-09-27|Estimate||||2012-06-18|2012-06-25|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer|Phase II Study of Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer|Terminated||Phase 2|16|Actual|M.D. Anderson Cancer Center||1||Significant Adverse Effects - Futility|f||||f||||||||||2018-06-01 02:19:36.056505|2018-06-01 02:19:36.056505
NCT00640965|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2009-05-04|2008-03-17|2008-03-21|Estimate|||||||2009-05-04|2009-05-05|Estimate|July 2008||2008-07-31|May 2009|2009-05-31|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Interventional|||DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Two-Arm, Multi-Center Phase II Trial to Assess the Safety, Tolerability, and Efficacy of DP-VPA (up to 900 mg) Once Daily for 10 Weeks in Adult Subjects With Migraine|Withdrawn||Phase 2|40|Anticipated|D-Pharm Ltd.||2||STUDY WAS NOT STARTED|f||||f||||||||||2018-06-01 02:19:36.332627|2018-06-01 02:19:36.332627
NCT00640952|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2015-11-10|2008-03-20|2008-03-21|Estimate|||||||2015-11-10|2015-11-13|Estimate|August 2006||2006-08-31|November 2015|2015-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease|Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease|Withdrawn||N/A|0|Actual|Baylor College of Medicine||||PI left site|f||||f||||||||||2018-06-01 02:19:36.41432|2018-06-01 02:19:36.41432
NCT00640939|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-08-05|2008-03-18|2008-03-21|Estimate|||||||2008-08-05|2008-08-06|Estimate|December 2007||2007-12-31|August 2008|2008-08-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Pain Due to Mild to Moderate Tendonitis or Bursitis|Completed||Phase 2/Phase 3|308|Actual|Cerimon Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:19:36.49044|2018-06-01 02:19:36.49044
NCT00575679|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2018-02-12|2007-12-14|2007-12-18|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2008|Actual|2008-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BADS||Behavior and Driving Safety Study|Behavior and Driving Safety Study|Active, not recruiting||N/A|800|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-06-01 02:39:39.224343|2018-06-01 02:39:39.224343
NCT00640926|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2010-01-08||2016-04-07|2008-03-20|2008-03-21|Estimate|2010-01-08|2010-02-04|Estimate||||2016-04-07|2016-05-12|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia|A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of RX-1741 in the Treatment of Adult Patients With Mild to Moderate Severity of Community-Acquired Pneumonia (CAP)|Completed||Phase 2|158|Actual|Melinta Therapeutics, Inc.|The yield of typical bacterial pathogens, most importantly S. pneumoniae, was quite low. The presence of atypical pathogens was assessed only by paired serologies, not by culture or polymerase chain reaction (PCR).|3|||f||||f||||||||||2018-06-01 02:19:36.568772|2018-06-01 02:19:36.568772
NCT00640913|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2008-03-19|2008-03-19|2008-03-21|Estimate|||||||2008-03-19|2008-03-21|Estimate|February 2008||2008-02-29|March 2008|2008-03-31|November 2009|Anticipated|2009-11-30|April 2009|Anticipated|2009-04-30||Observational|ELSOR||Early Reversal of Defunctioning Stoma Trial|Early Reversal of Defunctioning Stoma Trial|Unknown status|Recruiting||20|Anticipated|Rectal Cancer Trial on Defunctioning Stoma Study Group|||1||f||||t||||||Samples Without DNA|"~     Analysis of serum C-Reactive Protein (CRP) and Procalcitonin (PCT).~   "|||2018-06-01 02:19:36.943941|2018-06-01 02:19:36.943941
NCT00640900|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-03-31|2008-03-18|2008-03-21|Estimate|||||||2008-03-31|2008-04-01|Estimate|July 2007||2007-07-31|March 2008|2008-03-31|July 2010|Anticipated|2010-07-31|July 2009|Anticipated|2009-07-31||Interventional|FAB||Food, Activity and Behavior Trial|A Multi-Site Randomized Trial of a Commercial Weight Loss Program|Unknown status|Active, not recruiting|N/A|440|Anticipated|Jenny Craig, Inc.||3|||f||||t||||||||||2018-06-01 02:19:37.029614|2018-06-01 02:19:37.029614
NCT00640887|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2011-06-17|2008-03-17|2008-03-21|Estimate|||||||2011-06-17|2011-06-20|Estimate|February 2009||2009-02-28|June 2011|2011-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa|Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial|Completed||Phase 2|48|Anticipated|French National Agency for Research on AIDS and Viral Hepatitis||3|||f||||t||||||||||2018-06-01 02:19:37.10736|2018-06-01 02:19:37.10736
NCT00640874|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2012-04-22|2008-03-17|2008-03-21|Estimate|||||||2012-04-22|2012-04-24|Estimate||||April 2012|2012-04-30||||||||Observational|PIPET C||A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza|A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza.|Withdrawn|||0|Actual|Kirby Institute|||1||f||||f||||||||||2018-06-01 02:19:37.185339|2018-06-01 02:19:37.185339
NCT00640861|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2017-08-28|2008-03-20|2008-03-21|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2008||2008-08-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer|MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines for Breast Adenocarcinomas|Active, not recruiting||N/A|45|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:19:37.255751|2018-06-01 02:19:37.255751
NCT00640848|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2016-02-11|2008-03-18|2008-03-21|Estimate|||||||2016-02-11|2016-02-12|Estimate|May 2006||2006-05-31|February 2016|2016-02-29|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|Insomnia||Almorexant in Primary Insomnia|Multi-center, Multiple-stage, Double-blind, Randomized, Placebo-controlled, Two-way Crossover, Single-dose Study to Investigate the Effects of ACT-078573 on Sleep Measured by Polysomnography in Patients With Primary Insomnia|Completed||Phase 1|161|Actual|Midnight Pharma, LLC||5|||f||||t||||||||||2018-06-01 02:19:37.344652|2018-06-01 02:19:37.344652
NCT00640835|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|2010-09-30|2010-09-30|2012-11-06|2008-03-14|2008-03-21|Estimate|2010-09-30|2010-10-26|Estimate|2010-09-30|2010-10-26|Estimate|2012-11-06|2012-11-12|Estimate|February 2008||2008-02-29|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Tolerability of Buprenorphine/Naloxone Film Strips|A Phase 2 Multi-Center Open-label Study to Assess the Safety and Tolerability of a Buprenorphine/Naloxone Film Strip Administered by the Sublingual and Buccal Routes|Completed||Phase 2|382|Actual|Indivior Inc.||2|||f||||f||||||||||2018-06-01 02:19:37.473176|2018-06-01 02:19:37.473176
NCT00640822|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2010-11-23||2015-04-07|2008-03-20|2008-03-21|Estimate|2010-11-23|2010-12-21|Estimate||||2015-04-07|2015-04-29|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds|A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intertriginous Areas|Completed||Phase 3|782|Actual|LEO Pharma||3|||f||||f||||||||||2018-06-01 02:19:37.853677|2018-06-01 02:19:37.853677
NCT00640809|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-02|2008-03-17|2008-03-21|Estimate|||||||2008-04-02|2008-04-07|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|April 2004|Actual|2004-04-30|||||Interventional|||Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole|Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD)|Completed||Phase 4|408|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:19:38.12759|2018-06-01 02:19:38.12759
NCT00640796|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2014-04-23|2008-03-20|2008-03-21|Estimate|||||||2014-04-23|2014-04-24|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors|Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors|Completed||Phase 1|22|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 02:19:38.211686|2018-06-01 02:19:38.211686
NCT00640783|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-03-19|2008-03-19|2008-03-21|Estimate|||||||2008-03-19|2008-03-21|Estimate|June 2001||2001-06-30|March 2008|2008-03-31|January 2004|Actual|2004-01-31|October 2003|Actual|2003-10-31||Interventional|||Mediterranean Diet and the Metabolic Syndrome|Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome|Completed||N/A|180|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-06-01 02:19:38.28498|2018-06-01 02:19:38.28498
NCT00640770|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2011-03-14|2008-03-18|2008-03-21|Estimate|||||||2011-03-14|2011-03-15|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|ACHILLES||Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease|A Prospective, Randomized, Multicenter Comparison of Balloon Angioplasty and the Cypher Selecttm + Coronary and Infrapopliteal Stent in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease|Completed||Phase 4|200|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 02:19:38.349157|2018-06-01 02:19:38.349157
NCT00640757|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2015-12-17|2008-03-18|2008-03-21|Estimate|||||||2015-12-17|2015-12-18|Estimate|July 2006||2006-07-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome|Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome|Completed||Phase 2|56|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 02:19:38.413834|2018-06-01 02:19:38.413834
NCT00640744|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2010-12-02|2008-03-20|2008-03-21|Estimate|||||||2010-12-02|2010-12-07|Estimate|February 2006||2006-02-28|December 2010|2010-12-31|February 2010|Anticipated|2010-02-28|November 2009|Anticipated|2009-11-30||Interventional|DCAT||Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions|Phase 3 Study of Atorvastatin Effects on Carotid Atherosclerosis|Unknown status|Recruiting|Phase 4|12|Anticipated|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 02:19:38.485952|2018-06-01 02:19:38.485952
NCT00640731|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-20|2008-03-20|2008-03-21|Estimate|||||||2008-03-20|2008-03-21|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|SONIC I||Safety and Efficacy Study of OmniWave Endovascular System to Treat Deep Vein Thrombosis|Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study|Unknown status|Enrolling by invitation|Phase 4|50|Anticipated|OmniSonics Medical Technologies, Inc.|||||f||||t||||||||||2018-06-01 02:19:38.596588|2018-06-01 02:19:38.596588
NCT00640718|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2016-07-17|2008-03-20|2008-03-21|Estimate|||||||2016-07-17|2016-07-19|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|May 2010|Anticipated|2010-05-31|March 2009|Anticipated|2009-03-31||Observational|||Evaluation of EverOn™ System in Medical / Surgical Ward|Evaluation of EarlySense EverOn™ System in Medical / Surgical Ward|Withdrawn|||0|Actual|EarlySense Ltd.|||||f||||t||||||||||2018-06-01 02:19:38.708027|2018-06-01 02:19:38.708027
NCT00640705|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-09-03|2008-03-18|2008-03-21|Estimate|||||||2008-09-03|2008-09-04|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|October 2008|Anticipated|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Diclofenac Sodium Patch for the Topical Treatment of Pain Due to Mild to Moderate Ankle Sprain.|Terminated||Phase 2/Phase 3|170|Actual|Cerimon Pharmaceuticals||2||Sponsor decision|f||||f||||||||||2018-06-01 02:19:38.756122|2018-06-01 02:19:38.756122
NCT00640692|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-09-18|2008-03-20|2008-03-21|Estimate|||||||2009-09-18|2009-09-21|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|April 2011|Anticipated|2011-04-30|September 2009|Anticipated|2009-09-30||Observational|||Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial|Kinase Genotyping of Gastrointestinal Stromal Tumors (GIST) From Patients Enrolled in the A6181112 Phase IIIb Trial at Participating U.S. and Ex-U.S. Medical Centers|Terminated|||120|Anticipated|Oregon Health and Science University|||2|Insufficient enrollment|f||||f||||||Samples With DNA|"~     Genomic DNA from tumor samples~   "|||2018-06-01 02:19:38.828726|2018-06-01 02:19:38.828726
NCT00640679|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2016-07-26|2008-03-20|2008-03-21|Estimate|||||||2016-07-26|2016-07-27|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ISAR-CAUTION||Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation|Prospective, Randomized, Double-Blind Trial of Abrupt and Tapered Interruption of Long-term Clopidogrel Therapy After Implantation of a Drug-Eluting Stent|Terminated||Phase 4|782|Actual|Deutsches Herzzentrum Muenchen||2||Due to slow enrollment the study was stopped prematurely.|f||||t||||||||||2018-06-01 02:19:38.894694|2018-06-01 02:19:38.894694
NCT00640666|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2015-05-09|2008-03-14|2008-03-21|Estimate|||||||2015-05-09|2015-05-12|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2013|Actual|2013-03-31||Interventional|CICK||Changes in Cancer-related Cytokines After Participation in a Physical Activity Behavior Change Intervention (CICK Study)|Changes in Cancer-related Cytokines After Participation in a Physical Activity Behavior Change Intervention (CICK Study)|Completed||N/A|30|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:19:38.99786|2018-06-01 02:19:38.99786
NCT00640653|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2015-09-23||2017-11-15|2008-03-19|2008-03-21|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|September 2001||2001-09-30|November 2017|2017-11-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional||Sociodemographic Characteristics and Self-Reported Sexual Behaviors at Baseline of Participating African American Students in Grades 6 and 7 by Intervention Arm|Efficacy of an Abstinence-Only HIV Risk-Reduction Intervention for Young African-American Adolescents|HIV/Sexually Transmitted Disease (STD) Prevention Interventions for Black Adolescents|Completed||N/A|662|Actual|University of Pennsylvania|The data were based on self-reports, which can be inaccurate because of poor memory or socially desirability bias. The results may be limited to African American grade 6 and 7 students willing to take part in a health program on weekends.|5|||f||||f||||||||||2018-06-01 02:19:39.101174|2018-06-01 02:19:39.101174
NCT00640640|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2008-03-20|2008-03-20|2008-03-21|Estimate|||||||2008-03-20|2008-03-21|Estimate|August 2007||2007-08-31|March 2008|2008-03-31|February 2009|Anticipated|2009-02-28|December 2008|Anticipated|2008-12-31||Interventional|AMD||The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)|The Effect of Intravitreal Bevacizumab & Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration|Unknown status|Recruiting|N/A|60|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:19:39.908128|2018-06-01 02:19:39.908128
NCT00640627|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-02|2008-03-20|2008-03-21|Estimate|||||||2008-04-02|2008-04-07|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|September 2004|Actual|2004-09-30|||||Interventional|||Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen|A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen|Completed||Phase 4|380|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:19:40.009673|2018-06-01 02:19:40.009673
NCT00640614|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2013-02-21||2015-11-18|2008-03-20|2008-03-21|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|April 2008||2008-04-30|November 2015|2015-11-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy|Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol|Completed||Phase 3|235|Actual|Allerderm||2|||f||||f||||||||||2018-06-01 02:19:40.146305|2018-06-01 02:19:40.146305
NCT00640445|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2015-09-21|2008-03-18|2008-03-21|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|M2C||Military to Civilian: Trial of an Intervention to Promote Postdeployment Reintegration|Military to Civilian: RCT of an Intervention to Promote Postdeployment Reintegration|Completed||Phase 2/Phase 3|1292|Actual|Minneapolis Veterans Affairs Medical Center||3|||f||||f||||||||||2018-06-01 02:19:43.100676|2018-06-01 02:19:43.100676
NCT00640601|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|2011-06-21||2012-06-22|2008-03-20|2008-03-21|Estimate|2012-06-21|2012-06-22|Estimate||||2012-06-22|2012-06-25|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SPECTRUM||Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia|A Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia|Completed||Phase 3|331|Actual|AstraZeneca|The open-label design and lack of a placebo group constitute potential limitations. In addition, the small sample size of some of the subgroups may limit conclusions drawn from subgroup analyses.||||f||||f||||||||||2018-06-01 02:19:40.627341|2018-06-01 02:19:40.627341
NCT00640588|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2017-03-24|2008-03-20|2008-03-21|Estimate|||||||2017-03-24|2017-03-28|Actual|March 2008||2008-03-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|EBEREST||Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine|Prospective Exploratory Study to Describe in CHB naïve and Non-naïve Patients, Hepatitis B Virus (HBV) Kinetics During the First 24 Weeks of Treatment With Telbivudine|Completed||Phase 3|30|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:19:40.922296|2018-06-01 02:19:40.922296
NCT00640575|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2011-07-03|2008-03-16|2008-03-21|Estimate|||||||2011-07-03|2011-07-06|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Subacromial Ultrasound-guided or Systemic Steroid Injection for Rotator Cuff Disease, a Randomized Double Blinded Study|Subacromial Ultrasound-guided or Systemic Steroid Injection for Rotator Cuff Disease, a Randomized Double Blinded Study|Completed||N/A|106|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 02:19:41.001106|2018-06-01 02:19:41.001106
NCT00640562|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|2011-03-29||2012-05-17|2008-03-17|2008-03-21|Estimate|2012-05-17|2012-06-19|Estimate||||2012-05-17|2012-06-19|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|ExAttitude||Quetiapine Extended Release Depression Symptoms|Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study|Completed||Phase 3|216|Actual|AstraZeneca|Multicentre, randomized, open-label, flexible dose, parallel group, non inferiority|2|||f||||f||||||||||2018-06-01 02:19:41.076878|2018-06-01 02:19:41.076878
NCT00640549|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-03-28|2008-03-20|2008-03-21|Estimate|||||||2008-03-28|2008-04-01|Estimate|March 2003||2003-03-31|March 2008|2008-03-31|October 2004|Actual|2004-10-31|||||Interventional|ALPIN||Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus|Impact of Atorvastatin on the Distribution, Composition, and Metabolism of LDL and HDL Subfractions: A Double-Blind Placebo-Controlled Phase IV Study With Patients Suffering From Combined Hyperlipidemia and Diabetes. Atorvastatin and LDL Profile in NIDDM (ALPIN Study)|Terminated||Phase 4|41|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:19:41.473978|2018-06-01 02:19:41.473978
NCT00640536|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-11-28|2008-03-20|2008-03-21|Estimate|||||||2008-11-28|2008-12-01|Estimate|June 2006||2006-06-30|November 2008|2008-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Right Ventricular Function in Obstructive Sleep Apnea|The Evaluation of Subclinical Right Ventricular Dysfunction in Obstructive Sleep Apnea Patients Without Systemic and Pulmonary Arterial Hypertension Using Velocity Vector Imaging|Completed|||53|Actual|Florence Nightingale Hospital, Istanbul|||2||f||||t||||||||||2018-06-01 02:19:41.634325|2018-06-01 02:19:41.634325
NCT00640523|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17||2012-01-18|2012-01-18|2008-03-20|2008-03-21|Estimate||||2012-01-18|2012-01-23|Estimate|2012-01-18|2012-01-23|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)|Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|23|Actual|BioCryst Pharmaceuticals|||||f||||t||||||||||2018-06-01 02:19:41.723116|2018-06-01 02:19:41.723116
NCT00640510|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2009-07-16||2009-08-26|2008-03-18|2008-03-21|Estimate|2009-07-16|2009-08-26|Estimate||||2009-08-26|2009-09-02|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia|A Placebo-Controlled, Double-Blind Confirmatory Study of Rapid-Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia|Completed||Phase 3|34|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:19:41.831231|2018-06-01 02:19:41.831231
NCT00640497|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-04-28|2008-03-18|2008-03-21|Estimate|||||||2009-04-28|2009-04-29|Estimate|January 2010||2010-01-31|April 2009|2009-04-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease|A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins for the Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease|Withdrawn||Phase 1/Phase 2|12|Anticipated|Henogen||1||Unavailability of investigational product|f||||t||||||||||2018-06-01 02:19:42.428753|2018-06-01 02:19:42.428753
NCT00640484|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18||2010-08-18|2010-08-24|2008-03-18|2008-03-21|Estimate||||2010-08-18|2010-08-20|Estimate|2010-08-24|2010-08-27|Estimate|April 2008||2008-04-30|August 2010|2010-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD|Evaluation of the Effect of 2 Weeks Treatment With CHF 4226 pMDI 2µg and 4µg, Given Once Daily in the Morning, on 24-Hour FEV1 in Patients With COPD|Completed||Phase 2|57|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-06-01 02:19:42.540463|2018-06-01 02:19:42.540463
NCT00640471|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-20|||2013-07-16|2008-03-20|2008-03-21|Estimate|||||||2013-07-16|2013-07-17|Estimate|May 2008||2008-05-31|November 2012|2012-11-30|January 2013|Actual|2013-01-31|March 2011|Actual|2011-03-31||Interventional|||Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer|A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination With Cetuximab (Erbitux®) Versus Placebo in Combination With Cetuximab (Erbitux®) in Patients With K-RAS Wild Type Tumors Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma|Completed||Phase 3|750|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 02:19:42.781638|2018-06-01 02:19:42.781638
NCT00640458|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-04|2008-03-20|2008-03-21|Estimate|||||||2008-04-04|2008-04-08|Estimate|April 2004||2004-04-30|April 2008|2008-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-Menopausal Women With Female Sexual Arousal Disorder|A Double Blind, Placebo Controlled 2-Way Cross-Over Study to Assess the Clitoral Engorgement Response as Measured by Non-Contrast Magnetic Resonance Imaging (MRI) in Women With Female Sexual Arousal Disorder (FSAD) When Administered a Single Dose of Sildenafil (100mg) Followed by Audio/Visual Sexual Stimulation|Completed||Phase 2|20|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:19:42.979989|2018-06-01 02:19:42.979989
NCT00640432|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-02|2008-03-20|2008-03-21|Estimate|||||||2008-04-02|2008-04-07|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|October 2004|Actual|2004-10-31|||||Interventional|||Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain|A Multicenter, Randomized, Double-Blind, Double-Dummy Study Of The Safety, Tolerability And Efficacy Of Celecoxib 200 Mg Twice A Day (With A 400 Mg Attack Dose) Versus Sodium Diclofenac 75 Mg Twice A Day In Subjects With Acute Low Back Pain|Completed||Phase 4|244|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:19:43.223944|2018-06-01 02:19:43.223944
NCT00640419|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18||2011-08-18|2013-01-10|2008-03-18|2008-03-21|Estimate||||2011-08-18|2011-08-23|Estimate|2013-01-10|2013-01-18|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of 0.7 mg/kg/Day and 1.4 mg/kg/Day of ABT-089 in the Treatment of Children With Attention Deficit-Hyperactivity Disorder (ADHD)|Completed||Phase 2|121|Actual|AbbVie||3|||f||||t||||||||||2018-06-01 02:19:43.335499|2018-06-01 02:19:43.335499
NCT00640406|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-07-20|2008-03-20|2008-03-21|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2008||2008-04-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|December 2011|Actual|2011-12-31||Interventional|RADAR||Comparison of Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting|A Randomized, Multi-centre, Prospective Study Comparing Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting in Patients With Hemodynamically Relevant Atherosclerotic Renal Artery Stenosis|Completed||Phase 3|86|Actual|Biotronik AG||2|||f||||t||||||||||2018-06-01 02:19:43.421681|2018-06-01 02:19:43.421681
NCT00640393|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2010-08-27||2011-09-01|2008-03-20|2008-03-21|Estimate|2010-11-16|2010-12-14|Estimate||||2011-09-01|2011-09-09|Estimate|April 2008||2008-04-30|September 2011|2011-09-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy of Combining nbUVB to Etanercept in Patients|A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris|Completed||Phase 4|99|Actual|Innovaderm Research Inc.||3|||f||||f||||||||||2018-06-01 02:19:43.547434|2018-06-01 02:19:43.547434
NCT00640380|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-04-07|2008-03-20|2008-03-21|Estimate|||||||2008-04-07|2008-04-11|Estimate|May 2008||2008-05-31|April 2008|2008-04-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||A Comparison Between Neurostimulation and Loss of Resistance for Cervical Paravertebral Blocks|A Comparison Between Neurostimulation and Loss of Resistance for Cervical Paravertebral Blocks|Unknown status|Not yet recruiting|N/A|90|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-06-01 02:19:44.302792|2018-06-01 02:19:44.302792
NCT00640367|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2014-04-24|2008-03-18|2008-03-21|Estimate|||||||2014-04-24|2014-04-25|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|July 2012|Actual|2012-07-31|February 2009|Actual|2009-02-28||Interventional|SYNTHESIS EXP||Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke|Synthesis Expansion: A Randomized Controlled Trial on Intra-Arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke|Completed||Phase 3|350|Actual|Niguarda Hospital||2|||f||||t||||||||||2018-06-01 02:19:44.419673|2018-06-01 02:19:44.419673
NCT00640354|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-03-18|2008-03-18|2008-03-21|Estimate|||||||2008-03-18|2008-03-21|Estimate|December 2006||2006-12-31|March 2008|2008-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Time to Defibrillation Using Automated External Defibrillators by Pediatric Residents in Simulated Cardiac Arrests|Defibrillation by Automated External Defibrillators Versus Manual Defibrillators in Simulated Pediatric In-Hospital Cardiac Arrests: A Prospective Randomized Controlled Trial of Pediatric Residents|Completed||N/A|60|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:19:44.505824|2018-06-01 02:19:44.505824
NCT00640341|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2011-02-03||2011-12-07|2008-03-20|2008-03-21|Estimate|2011-03-03|2011-03-31|Estimate||||2011-12-07|2011-12-12|Estimate|February 2008||2008-02-29|December 2011|2011-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparative Performance of PureVision, Acuvue Oasys and O2Optix|Product Performance of Bausch & Lomb PureVision® Contact Lens When Compared to Johnson & Johnson Acuvue Oasys Contact Lens and the Ciba Vision O2Optix Contact Lens Worn Daily.|Completed||Phase 4|510|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 02:19:44.588283|2018-06-01 02:19:44.588283
NCT00640328|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2012-11-01||2017-03-13|2008-03-18|2008-03-21|Estimate|2012-12-03|2012-12-04|Estimate||||2017-03-13|2017-04-11|Actual|May 2008||2008-05-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|May 2010|Actual|2010-05-31||Interventional|OMS115102||Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients|A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients|Completed||Phase 2|38|Actual|GlaxoSmithKline||6|||f||||t||||||||||2018-06-01 02:19:44.945802|2018-06-01 02:19:44.945802
NCT00640315|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2013-11-07||2016-11-04|2008-03-20|2008-03-21|Estimate|2014-01-27|2014-02-28|Estimate||||2016-11-04|2016-12-28|Estimate|August 2008||2008-08-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.|Proof of Concept Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics, Gas Exchange and Lung Function Parameters of a Single-dose of BAY63-2521 IR-tablet in Patients With COPD Associated Pulmonary Hypertension in an Non-randomized, Non-blinded Design|Completed||Phase 1|23|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:19:48.29096|2018-06-01 02:19:48.29096
NCT00640302|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-16|||2012-04-22|2008-03-16|2008-03-21|Estimate|||||||2012-04-22|2012-04-24|Estimate||||April 2012|2012-04-30||||||||Observational|PIPET A||A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza|A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza Infection|Withdrawn|||0|Actual|Kirby Institute|||1||f||||f||||||Samples With DNA|"~     Patients will be asked to provide a blood sample and an appropriate respiratory tract sample.~     As a minimum, we will collect a combined nose and throat sample.~      A further respiratory tract swab will be collected on day 5 (range 5-10) and stored for~     future use. Index case follow-up will include an assessment and respiratory tract specimen~     and blood sample 14 days after informed consent. A final assessment for outcomes (including a~     blood sample) will occur approximately one month after enrolment.~   "|||2018-06-01 02:19:49.383061|2018-06-01 02:19:49.383061
NCT00640289|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2015-02-09|2008-03-17|2008-03-21|Estimate|||||||2015-02-09|2015-02-11|Estimate|January 2000||2000-01-31|March 2008|2008-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Clinical Trial of Factor XIII (FXIII) Concentrate|Clinical Research Study of Factor XIII Concentrate From Human Plasma Fibrogammin P in Patients With Factor XIII Deficiency|Completed||N/A|73|Actual|Children’s Hospital of Orange County||1|||f||||f||||||||||2018-06-01 02:19:49.445331|2018-06-01 02:19:49.445331
NCT00640276|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2012-03-28|2008-03-20|2008-03-21|Estimate|||||||2012-03-28|2012-03-30|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|ProPit||Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome|A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome|Completed||Phase 4|187|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-06-01 02:19:49.512678|2018-06-01 02:19:49.512678
NCT00640263|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2014-04-11|2008-03-20|2008-03-21|Estimate|||||||2014-04-11|2014-04-14|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|May 2013|Actual|2013-05-31||Interventional|||Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding|A Randomised Controlled Trial Comparing the Efficacy of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir (LPV/r) Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding|Completed||Phase 3|1500|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 02:19:49.584223|2018-06-01 02:19:49.584223
NCT00640250|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2013-02-21||2018-04-06|2008-03-18|2008-03-21|Estimate|2018-04-06|2018-04-09|Actual||||2018-04-06|2018-04-09|Actual|April 2008||2008-04-30|April 2018|2018-04-30|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional||The analysis included all enrolled subjects but it should be noted that subject 5-D220 was not sensitive to either allergen and thus was not included in either population of sensitive subjects; the subject was included in the population of all enrolled subjects.|Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response|Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study|Completed||Phase 2|48|Actual|Allerderm|There were no limitations or caveats which led to unreadable or uninterpretable data.|1|||f||||f||||||||||2018-06-01 02:19:49.783244|2018-06-01 02:19:49.783244
NCT00640237|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-16|||2008-03-20|2008-03-20|2008-03-21|Estimate|||||||2008-03-20|2008-03-21|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|August 2008|Anticipated|2008-08-31|July 2008|Anticipated|2008-07-31||Interventional|||Interventional Trial of Vitamin D Deficiency in the Patients of General Departments|Vitamin D Deficiency in the Elder Patients of General Departments and Its Treatment During the Hospitalization|Unknown status|Recruiting|Phase 3|300|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-06-01 02:19:50.396037|2018-06-01 02:19:50.396037
NCT00640224|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2017-07-27||2017-10-16|2008-03-18|2008-03-21|Estimate|2017-10-16|2017-11-17|Actual||||2017-10-16|2017-11-17|Actual|March 2005||2005-03-31|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study|Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives|Completed||Phase 4|65|Actual|University of Pittsburgh|The potential unblinding due to the rapid regulation of withdrawal bleeding which may have influenced the dropout rates;the short duration of treatment in contrast to clinical practice where treatment may be for several years.|4|||f||||f||||||||||2018-06-01 02:19:50.503779|2018-06-01 02:19:50.503779
NCT00640211|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2012-04-22|2008-03-17|2008-03-21|Estimate|||||||2012-04-22|2012-04-24|Estimate||||April 2012|2012-04-30||||||||Observational|PIPET B||A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B|A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B|Withdrawn|||0|Actual|Kirby Institute|||1||f||||f||||||||||2018-06-01 02:19:51.245724|2018-06-01 02:19:51.245724
NCT00640198|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2008-03-20|2008-03-20|2008-03-21|Estimate|||||||2008-03-20|2008-03-21|Estimate|March 2005||2005-03-31|March 2008|2008-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Memantine and Intensive Speech-Language Therapy in Aphasia|A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.|Completed||Phase 4|28|Actual|Gabinete Berthier y Martínez||2|||f||||f||||||||||2018-06-01 02:19:51.311118|2018-06-01 02:19:51.311118
NCT00640185|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18||2011-08-18|2013-01-10|2008-03-18|2008-03-21|Estimate||||2011-08-18|2011-08-23|Estimate|2013-01-10|2013-01-18|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety, Tolerability and Efficacy of 40 mg QD and 80 mg QD ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)|Completed||Phase 2|160|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 02:19:51.395749|2018-06-01 02:19:51.395749
NCT00640172|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2016-03-23|2008-03-14|2008-03-21|Estimate|||||||2016-03-23|2016-03-24|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Anemia in the Elderly|Anemia in the Elderly|Completed|||343|Actual|Stanford University|||5||f||||f||||||Samples With DNA|"~     blood, urine and bone marrow~   "|No||2018-06-01 02:19:51.485297|2018-06-01 02:19:51.485297
NCT00640159|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2009-03-12|2008-03-20|2008-03-21|Estimate|||||||2009-03-12|2009-03-16|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease|Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease.|Completed||Phase 4|55|Anticipated|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 02:19:51.563697|2018-06-01 02:19:51.563697
NCT00640146|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2011-07-17|2008-03-18|2008-03-21|Estimate|||||||2011-07-17|2011-07-19|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Phase 2 Study of Once-Daily Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures|Completed||Phase 2|33|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 02:19:51.673768|2018-06-01 02:19:51.673768
NCT00640133|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2017-08-03|2008-03-20|2008-03-21|Estimate|||||||2017-08-03|2017-08-04|Actual|March 2008||2008-03-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2017|Actual|2017-02-28||Interventional|||Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder|Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder|Active, not recruiting||Phase 2|27|Actual|Butler Hospital||2|||f||||t||||||||||2018-06-01 02:19:51.747096|2018-06-01 02:19:51.747096
NCT00640120|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-15|||2011-06-08|2008-03-17|2008-03-21|Estimate|||||||2011-06-08|2011-06-09|Estimate|July 2008||2008-07-31|March 2008|2008-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Wheeze Detection in Children During Dynamic Bronchial Situations Measured by WIM-PC™ Recording|Wheeze Detection in Children During Dynamic Bronchial Situations Measured by WIM-PC™ Recording|Completed|||40|Anticipated|KarmelSonix Ltd.|||2||f||||f||||||||||2018-06-01 02:19:51.833762|2018-06-01 02:19:51.833762
NCT00640107|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2017-11-14|2008-03-19|2008-03-20|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2006||2006-10-31|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||The Purpose of This Study is to Evaluate New Commercially Available MRI and Ultrasound Software and/or Hardware|Evaluation and Optimization of Ultrasound and/or MRI Hardware and Software in Existing SUNY Ultrasound and/or MRI Units and Newly Installed Commercially Available Units|Recruiting|||30|Anticipated|State University of New York - Upstate Medical University|||||f||||f||||||||No||2018-06-01 02:19:51.889237|2018-06-01 02:19:51.889237
NCT00640094|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2016-07-22|2008-03-19|2008-03-20|Estimate|||||||2016-07-22|2016-07-25|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|March 2016|Actual|2016-03-31||Interventional|MARIA||The Melatonin Adjunct in the Acute myocaRdial Infarction Treated With Angioplasty|Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Melatonin as an Adjunct in Patients With Acute myocaRdial Infarction Undergoing Primary Angioplasty|Terminated||Phase 2|272|Actual|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||2|||f||||t||||||||||2018-06-01 02:19:51.950113|2018-06-01 02:19:51.950113
NCT00640081|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2016-03-22|2008-03-19|2008-03-20|Estimate|||||||2016-03-22|2016-03-23|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|June 2010|Actual|2010-06-30||Interventional|||Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer|A Two-arm Phase II Randomised Trial of Intermittent Chemotherapy Plus Continuous Cetuximab and of Intermittent Chemotherapy Plus Intermittent Cetuximab in First Line Treatment of Patients With K-ras-normal (Wild-type) Metastatic Colorectal Cancer|Completed||Phase 2|169|Actual|Medical Research Council||2|||f||||t||||||||Yes|Publication|2018-06-01 02:19:52.117961|2018-06-01 02:19:52.117961
NCT00640068|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2014-04-02|2008-03-19|2008-03-20|Estimate|||||||2014-04-02|2014-04-03|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ACIC||Advanced Cardiovascular Imaging Consortium|Advanced Cardiovascular Imaging Consortium: A Collaborative Quality Improvement Project|Completed|||42926|Actual|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 02:19:52.269068|2018-06-01 02:19:52.269068
NCT00640055|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2014-07-29|2008-03-18|2008-03-20|Estimate|||||||2014-07-29|2014-07-31|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|VA||Verbal Autopsy to Assess Early Neonatal Death and Stillbirth|Using Verbal Autopsy to Determine Cause of Stillbirths and Early Neonatal Deaths Within the NICHD Global Network|Completed||Phase 4|200|Anticipated|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-06-01 02:19:52.45471|2018-06-01 02:19:52.45471
NCT00640042|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2009-11-30||2012-06-06|2008-03-19|2008-03-20|Estimate|2010-01-20|2010-02-15|Estimate||||2012-06-06|2012-06-11|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|ACCESS 2008||Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza|AVINZA Control of Chronic Pain, Effectiveness and Safety Study (ACCESS 2008) A Multi-Center Study to Evaluate the Effectiveness and Tolerability of AVINZA for Chronic Moderate-Severe Pain: A Focus on Risk Minimization Assessment, Intervention and Outcomes|Completed||Phase 4|1570|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:19:52.609486|2018-06-01 02:19:52.609486
NCT00640029|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2015-03-06|2008-03-19|2008-03-20|Estimate|||||||2015-03-06|2015-03-10|Estimate|February 2008||2008-02-29|March 2015|2015-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|EVA||Evaluation of the Prosthetic Disc Replacement|Medico-economic Evaluation of the Prosthetic Replacement of the Lumbar and Cervical Intervertebral Disc|Terminated||N/A|301|Actual|Assistance Publique - Hôpitaux de Paris||5||Insuffisent recruitment|f||||t||||||||||2018-06-01 02:19:53.666062|2018-06-01 02:19:53.666062
NCT00640016|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2016-06-03||2016-12-07|2008-03-19|2008-03-20|Estimate|2016-12-07|2017-01-31|Estimate||||2016-12-07|2017-01-31|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Analysis population included all participants who were enrolled.|A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma|A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354|Terminated||Phase 2|14|Actual|MedImmune LLC|Study was prematurely terminated due to low recruitment rate, delay due to temporary halt and potential for expiry date of study drug. It was not considered possible to draw meaningful conclusions from the small dataset.|4||The study was terminated prematurely by the sponsor due to slow recruitment.|f||||f||||||||||2018-06-01 02:19:53.794658|2018-06-01 02:19:53.794658
NCT00640003|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2017-12-18|2008-03-19|2008-03-20|Estimate|||||||2017-12-18|2017-12-20|Actual|April 2007||2007-04-30|December 2017|2017-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Baclofen Treatment of Ataxia Telangiectasia||Completed||Early Phase 1|10|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:19:54.741906|2018-06-01 02:19:54.741906
NCT00639990|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-12|2008-03-12|2008-03-20|Estimate|||||||2008-03-12|2008-03-20|Estimate|June 2007||2007-06-30|March 2008|2008-03-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Respiratory Mechanics in Brain Injured Patients|Effects of PEEP in Brain Injury Patients|Unknown status|Recruiting|N/A|40|Anticipated|Università degli Studi dell'Insubria||4|||f||||f||||||||||2018-06-01 02:19:54.807092|2018-06-01 02:19:54.807092
NCT00639977|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-03-19|2008-03-19|2008-03-20|Estimate|||||||2008-03-19|2008-03-20|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Acupuncture on Intraocular Pressure|Effect of Acupuncture on Intraocular Pressure|Completed||Phase 1/Phase 2|50|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-06-01 02:19:54.892255|2018-06-01 02:19:54.892255
NCT00639964|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2016-05-31|2008-03-19|2008-03-20|Estimate|||||||2016-05-31|2016-06-01|Estimate|January 2008||2008-01-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|January 2012|Actual|2012-01-31||Interventional|DIAMANT||Exploration of the Lipid Metabolism During the Diabetic Pregnancies|Exploration of the Lipid Metabolism During the Diabetic Pregnancies and Research for New Biological Predictors to Nutritional Interventions|Completed||N/A|186|Actual|University Hospital, Lille||3|||f||||t||||||||||2018-06-01 02:19:54.962655|2018-06-01 02:19:54.962655
NCT00639782|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-16|||2017-09-24|2008-03-19|2008-03-20|Estimate|||||||2017-09-24|2017-09-26|Actual|July 2003||2003-07-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|PROSE||Prospective Randomized On-X Versus SJM Evaluation Trial|Thromboembolic Related Complications in a Randomized Trial of Previous and Current Generation Mechanical Valve Prostheses|Recruiting||N/A|1000|Anticipated|On-X Life Technologies, Inc.||2|||f||||t||||||||||2018-06-01 02:19:56.296983|2018-06-01 02:19:56.296983
NCT00639951|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2016-07-18|2008-03-19|2008-03-20|Estimate|||||||2016-07-18|2016-07-20|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation|Multicentric, Randomized,Controlled and Comparative Study to Evaluate the Efficacy of Two Treatment Schemes With Antivipmyn ® for the Treatment of Snake Bite Envenomation|Terminated||Phase 4|10|Actual|Instituto Bioclon S.A. de C.V.||2||Administrative reasons|f||||f||||||||Undecided|Not yet decided|2018-06-01 02:19:55.121917|2018-06-01 02:19:55.121917
NCT00639938|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2008-04-01|2008-03-18|2008-03-20|Estimate|||||||2008-04-01|2008-04-02|Estimate|July 2004||2004-07-31|March 2008|2008-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda|A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV Transmission in Uganda|Completed||Phase 3|722|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 02:19:55.242829|2018-06-01 02:19:55.242829
NCT00639925|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2013-03-13|2008-03-19|2008-03-20|Estimate|||||||2013-03-13|2013-03-14|Estimate|March 2007||2007-03-31|March 2013|2013-03-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer|Phase I Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1|5|Actual|Fukushima Medical University||1|||f||||t||||||||||2018-06-01 02:19:55.352733|2018-06-01 02:19:55.352733
NCT00639912|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2010-11-29|2008-03-19|2008-03-20|Estimate|||||||2010-11-29|2010-11-30|Estimate|June 2007||2007-06-30|March 2008|2008-03-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|CINIMA||Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction.|Randomized Trial on the Effects of Hydration With Sodium Chloride Versus Sodium Bicarbonate to Prevent Contrast Induced Nephropathy, in Patients Undergoing Primary Coronary Interventions for Acute ST Elevation Myocardial Infarction.|Completed||Phase 4|599|Actual|Arcispedale Santa Maria Nuova-IRCCS||4|||f||||f||||||||||2018-06-01 02:19:55.441551|2018-06-01 02:19:55.441551
NCT00639899|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2008-03-19|2008-03-19|2008-03-20|Estimate|||||||2008-03-19|2008-03-20|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The Effect of Spermatic Vein Embolization on Prostatic Hypertrophy|Selective Retrograde Venography and Sclerotherapy of Internal Spermatic Veins and Associated Venous Bypasses and Retro-Peritoneal Collateral in Patients With Varicocele and Hypertrophy of Prostate|Completed||N/A|35|Actual|Maaynei Hayesha Medical Center|||||f||||f||||||||||2018-06-01 02:19:55.538894|2018-06-01 02:19:55.538894
NCT00639873|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2013-08-22|2008-03-14|2008-03-20|Estimate|||||||2013-08-22|2013-08-23|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Artemisinin Resistance in Bangladesh|Artemisinin Resistance in Bangladesh|Completed||N/A|126|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-06-01 02:19:55.614359|2018-06-01 02:19:55.614359
NCT00639860|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|2015-12-11||2016-03-01|2008-03-14|2008-03-20|Estimate|2016-03-01|2016-03-31|Estimate||||2016-03-01|2016-03-31|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|OSSIX||Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia|Clinical and Histological Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia|Completed||Phase 1/Phase 2|10|Actual|University of Michigan||1|||f||||f||||||||No||2018-06-01 02:19:55.704182|2018-06-01 02:19:55.704182
NCT00639847|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2008-03-21|2008-03-19|2008-03-20|Estimate|||||||2008-03-21|2008-03-24|Estimate|October 1998||1998-10-31|March 2008|2008-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||This Study Compared an in Home Asthma Management Program Provided by Nurses or Respiratory Therapist|A Randomized Controlled Study to Evaluate the Role of an In Home Asthma Disease Management Program Provided by Respiratory Therapists in Improving Outcomes and Reducing the Cost of the Care|Completed||N/A|159|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||f||||||||||2018-06-01 02:19:55.903776|2018-06-01 02:19:55.903776
NCT00639834|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2013-05-21|2008-03-19|2008-03-20|Estimate|||||||2013-05-21|2013-05-22|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MDX1342-01||Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Phase 1, Multicenter, Single-dose, Dose-escalation, Safety and Tolerability Study of MDX-1342 (Anti-CD19 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis|Completed||Phase 1|26|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 02:19:55.976304|2018-06-01 02:19:55.976304
NCT00639821|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2012-10-19|2008-03-19|2008-03-20|Estimate|||||||2012-10-19|2012-10-22|Estimate|July 2004||2004-07-31|October 2012|2012-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Mucosal Gene Expression Defects in IBD|Mucosal Gene Expression Defects in Patients With Inflammatory Bowel Disease Before and After First Infliximab Therapy|Completed|||73|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||Samples Without DNA|"~     Ileal/colonic mucosal biopsies from patiens with inflammatory bowel disease refractory to~     corticosteroids and/or immunosuppression and from 12 control individuals~   "|||2018-06-01 02:19:56.090382|2018-06-01 02:19:56.090382
NCT00639808|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2008-03-19|2008-03-19|2008-03-20|Estimate|||||||2008-03-19|2008-03-20|Estimate|August 2006||2006-08-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis|Multicenter, Randomized, Double-Blind, Placebo Controlled, Crossover Single Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Effect on Gastric Emptying of TZP-101 IV Infusion in Diabetic Gastroparesis Patients|Completed||Phase 1|10|Actual|Tranzyme, Inc.||2|||f||||f||||||||||2018-06-01 02:19:56.150344|2018-06-01 02:19:56.150344
NCT00639795|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2013-07-02|2008-03-19|2008-03-20|Estimate|||||||2013-07-02|2013-07-03|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|VATS_IM||Study of the Effect of Regional Nerve Blocks on Pain and Inflammation After Video Assisted Thorascopic Lung Surgery|Prospective Randomized Trial Evaluating the Effects of Paravertebral Nerve Blocks on Postoperative Pain and the Perioperative Inflammatory Response Following Video Assisted Thorascopic Surgery|Terminated||N/A|60|Anticipated|Memorial Medical Center||2||inadequate sample population|f||||t||||||||||2018-06-01 02:19:56.226644|2018-06-01 02:19:56.226644
NCT00639769|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2010-10-11||2012-09-07|2008-03-19|2008-03-20|Estimate|2011-11-02|2011-12-07|Estimate||||2012-09-07|2012-09-14|Estimate|February 2002||2002-02-28|September 2012|2012-09-30|July 2008|Actual|2008-07-31|May 2007|Actual|2007-05-31||Interventional|||Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck|Completed||Phase 2|41|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:19:56.394498|2018-06-01 02:19:56.394498
NCT00639756|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2008-10-10|2008-03-19|2008-03-20|Estimate|||||||2008-10-10|2008-10-13|Estimate|June 2008||2008-06-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||The Effect of Allopurinol on Insulin Resistance and Blood Pressure|Phase 2 Study to Determine if Allopurinol Blocks Features of Metabolic Syndrome Induced by Fructose Ingestion|Completed||Phase 2|60|Anticipated|Hospital Mateo Orfila||2|||f||||f||||||||||2018-06-01 02:19:56.726152|2018-06-01 02:19:56.726152
NCT00639743|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2015-03-26|2008-03-19|2008-03-20|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|July 2012|Actual|2012-07-31||Interventional|PEITHO||PEITHO Pulmonary Embolism Thrombolysis Study|Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients|Unknown status|Active, not recruiting|Phase 3|1005|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:19:56.808039|2018-06-01 02:19:56.808039
NCT00639730|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2010-05-26|2008-03-14|2008-03-20|Estimate|||||||2010-05-26|2010-05-27|Estimate|May 2006||2006-05-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Use of the Atkins Diet for Children With Sturge Weber Syndrome|Use of the Atkins Diet for Children With Sturge Weber Syndrome|Completed||Phase 1|5|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 02:19:56.904948|2018-06-01 02:19:56.904948
NCT00639717|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2014-09-19||2017-07-03|2008-03-19|2008-03-20|Estimate|2014-09-19|2014-09-25|Estimate||||2017-07-03|2017-08-01|Actual|March 2009||2009-03-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|January 2012|Actual|2012-01-31||Interventional|||Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant|Addition of Etanercept and Extracorporeal Photopheresis to Standard GVHD Prophylaxis in Patients Undergoing Reduced Intensity Unrelated Donor Hematopoietic Stem Cell Transplant|Completed||Phase 2|48|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 02:19:56.996258|2018-06-01 02:19:56.996258
NCT00639704|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2015-05-13|2008-03-19|2008-03-20|Estimate|||||||2015-05-13|2015-05-14|Estimate|January 1996||1996-01-31|May 2015|2015-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Improve Nuclear Medicine Heart Imaging, Compare MRI Results With Single Photon Emission Computed Tomography Imaging|Evaluation of EM-IntraSPECT Reconstruction Algorithm by Comparison of Transmission Images Reconstructed From SPECT Projections Alone With MRI Studies|Completed|||6|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:19:57.266024|2018-06-01 02:19:57.266024
NCT00639691|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2016-09-28|2008-03-19|2008-03-20|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy|A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy|Completed||Phase 4|48|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:19:57.322803|2018-06-01 02:19:57.322803
NCT00639678|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2013-09-05|2009-10-14|2014-02-13|2008-03-19|2008-03-20|Estimate|2014-01-09|2014-02-07|Estimate|2009-10-14|2009-10-16|Estimate|2014-02-13|2014-03-13|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects|A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects|Completed||Phase 3|322|Actual|GlaxoSmithKline||4|||f||||t||||||||||2018-06-01 02:19:57.455456|2018-06-01 02:19:57.455456
NCT00639665|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2015-03-30|2008-03-19|2008-03-20|Estimate|||||||2015-03-30|2015-03-31|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Cocoa, Polyphenols, and the Kidney in Healthy Subjects and in Subjects With Hypertension and Diabetes Mellitus|Cocoa, Polyphenols, and the Kidney in Healthy Subjects and in Subjects With Hypertension and Diabetes Mellitus|Completed|||228|Actual|Brigham and Women's Hospital|||||f||||f||||||Samples With DNA|"~     Whole red blood cells will be retained for DNA analysis. Subjects may opt-out of genetic~     testing.~   "|||2018-06-01 02:19:59.047431|2018-06-01 02:19:59.047431
NCT00639652|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-03-14|2008-03-14|2008-03-20|Estimate|||||||2008-03-14|2008-03-20|Estimate|December 2007||2007-12-31|March 2008|2008-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970|Observational Study: Recurrence Rate and Esthetic Outcome After Excision of Basal Cell Carcinomas Excluded From Trial NCT00515970|Unknown status|Enrolling by invitation||800|Anticipated|University Hospital Tuebingen|||2||f||||f||||||Samples Without DNA|"~     Paraffinized histology blocks and sections.~   "|||2018-06-01 02:19:59.20276|2018-06-01 02:19:59.20276
NCT00639639|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2018-05-15|2008-03-19|2008-03-20|Estimate|||||||2018-05-15|2018-05-17|Actual|January 2006||2006-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ATTAC||Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia|Active, not recruiting||Phase 1|16|Anticipated|Duke University||4|||f||||t||||||||||2018-06-01 02:19:59.280747|2018-06-01 02:19:59.280747
NCT00639626|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|2015-05-15||2018-03-14|2008-03-19|2008-03-20|Estimate|2018-03-14|2018-04-12|Actual||||2018-03-14|2018-04-12|Actual|August 2008||2008-08-31|March 2018|2018-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.|Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)|Use of Levemir® Improves Metabolic and Clinical Status in CFRD|Terminated||Phase 2/Phase 3|6|Actual|Nationwide Children's Hospital||1||PI left the institution|f||||f||||||||||2018-06-01 02:19:59.372611|2018-06-01 02:19:59.372611
NCT00639613|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2015-06-25|2008-03-12|2008-03-20|Estimate|||||||2015-06-25|2015-06-26|Estimate|March 2008||2008-03-31|June 2015|2015-06-30||||June 2015|Actual|2015-06-30||Observational|T2DM-PC1-2||The Role of Small Intestinal Endocrine Cells in Type 2 Diabetic Hyperglucagonemia|Exspression of Prohormone Convertase 1 and 2 in Small Intestinal Endocrine Mucosa Cells in Patients With Type 2 Diabetes|Completed|||20|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||t||||||Samples With DNA|"~     Buffy coat~   "|||2018-06-01 02:19:59.515504|2018-06-01 02:19:59.515504
NCT00639600|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2010-05-28|2008-03-19|2008-03-20|Estimate|||||||2010-05-28|2010-05-31|Estimate|June 2008||2008-06-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|GRAGIL1||Transplantation of Pancreatic Islets in Patients With Type 1 Diabetes Mellitus and Functional Kidney Graft|Transplantation d'îlots pancréatiques allogéniques Adultes Pour le Traitement du diabète insulinodépendant. Etude GRAGIL 1|Terminated||Phase 1/Phase 2|21|Anticipated|University Hospital, Grenoble||||a new study has began recently|f||||t||||||||||2018-06-01 02:19:59.589263|2018-06-01 02:19:59.589263
NCT00639587|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2009-09-03|2008-03-14|2008-03-20|Estimate|||||||2009-09-03|2009-09-04|Estimate|August 2002||2002-08-31|September 2009|2009-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis|A Double-blind, Parallel, Active Comparator Controlled, Randomized Trial; Comparison of the Efficacy and Safety in Children With Perennial Allergic Rhinitis of Cetirizine Tablets Versus Ketotifen Dry Syrup|Completed||Phase 3|149|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:19:59.667313|2018-06-01 02:19:59.667313
NCT00639574|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2010-03-26|2008-03-19|2008-03-20|Estimate|||||||2010-03-26|2010-03-29|Estimate|March 2008||2008-03-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|November 2008|Actual|2008-11-30||Interventional|||Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi|Interest of Néfopam in the Treatment of Pain During the Intense Ureteral Calculi Uncomplicated in Adults in Emergencies Unit.|Completed||Phase 4|52|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 02:19:59.720165|2018-06-01 02:19:59.720165
NCT00639561|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2009-02-16|2008-03-19|2008-03-20|Estimate|||||||2009-02-16|2009-02-17|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|AlimIntest||Calibrated Diets and Human Intestinal Microflora|Effect of Controlled Diets on Structural and Functional Dynamic of the Human Intestinal Microflora|Completed||N/A|20|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-06-01 02:19:59.841959|2018-06-01 02:19:59.841959
NCT00639548|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-12|2008-03-12|2008-03-20|Estimate|||||||2008-03-12|2008-03-20|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|September 2007|Actual|2007-09-30|July 2006|Actual|2006-07-31||Observational|||ERPS, BIS and Entropy for Neuromonitoring in ICU Patients|Auditory Event-Related Potentials, BIS-Index and Entropy for the Discrimination of Different Levels of Sedation in the ICU Patients|Completed|||20|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 02:19:59.920255|2018-06-01 02:19:59.920255
NCT00639535|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2015-05-20|2008-03-19|2008-03-20|Estimate|||||||2015-05-20|2015-05-21|Estimate|January 2002||2002-01-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Study Comparing the PET Scan and MRI in Identifying Breast Malignancies in Women With Breast Abnormalities|Comparative Study of the Diagnostic Accuracy of Scintimammography (Fluorine 18-FDG PET Scintigraphic Imaging) and Magnetic Resonance Imaging in Identifying Malignant Breast Lesions, In Subjects With Breast Abnormalities|Completed|||56|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:19:59.99578|2018-06-01 02:19:59.99578
NCT00639522|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2009-04-14|2008-03-19|2008-03-20|Estimate|||||||2009-04-14|2009-04-15|Estimate|May 2008||2008-05-31|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma|A Phase I Clinical Trial to Investigate the Maximum Tolerated Dose and Pharmacokinetics of Liposomal Paclitaxel With/Without Capecitabine in Chinese Cancer Patients With Advanced Gastric Carcinoma.|Unknown status|Recruiting|Phase 1|18|Anticipated|Nanjing Sike Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 02:20:00.086896|2018-06-01 02:20:00.086896
NCT00639509|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|2013-09-25||2014-05-07|2008-03-19|2008-03-20|Estimate|2013-09-25|2013-12-03|Estimate||||2014-05-07|2014-05-23|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||IMC-A12 in Treating Patients With Advanced Liver Cancer|A Phase 2 Study of IMC-A12 (NSC742460) in Hepatocellular Carcinoma|Completed||Phase 2|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:20:00.191456|2018-06-01 02:20:00.191456
NCT00639496|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2015-03-04|2008-03-19|2008-03-20|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2000||2000-03-31|March 2008|2008-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|IFIGENIA||Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)|Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 3|184|Actual|Zambon SpA||2|||f||||t||||||||||2018-06-01 02:20:00.491654|2018-06-01 02:20:00.491654
NCT00639483|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2009-03-12|2008-03-13|2008-03-20|Estimate|||||||2009-03-12|2009-03-16|Estimate|March 2003||2003-03-31|March 2009|2009-03-31|January 2004|Actual|2004-01-31|||||Interventional|||Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia|A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia|Completed||Phase 2|270|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:20:00.58723|2018-06-01 02:20:00.58723
NCT00639470|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-08-12|2008-03-12|2008-03-20|Estimate|||||||2008-08-12|2008-08-13|Estimate|August 2005||2005-08-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|March 2007|Actual|2007-03-31||Interventional|||Parents Reading Comprehension of Their Child's Post-Operative Medicine Fact Sheets|Parents Reading Comprehension of Their Child's Post-Operative Medicine Fact|Completed||N/A|23|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:20:00.69351|2018-06-01 02:20:00.69351
NCT00639457|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2013-05-02||2013-09-16|2008-03-18|2008-03-20|Estimate|2013-07-30|2013-09-12|Estimate||||2013-09-16|2013-10-23|Estimate|January 2005||2005-01-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Exercise and Pioglitazone for HIV-Metabolic Syndromes|Exercise and Pioglitazone for HIV-Metabolic Syndromes|Completed||N/A|44|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|No intervention and exercise training only control groups were not included. Intracellular mechanisms were not explored. Relatively small number of participants taking a variety of anti-HIV medication regimens.|2|||f||||f||||||||||2018-06-01 02:20:00.769383|2018-06-01 02:20:00.769383
NCT00639444|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2013-12-09|2008-03-19|2008-03-20|Estimate|||||||2013-12-09|2013-12-10|Estimate|September 2004||2004-09-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|December 2007|Actual|2007-12-31||Interventional|CELIPREV||Risk of Celiac Disease and Age at Gluten Introduction|Infant Nutrition and Development of Celiac Disease in Genetically At-risk Babies: a Dietary Intervention Study at Weaning|Completed||N/A|703|Actual|Università Politecnica delle Marche||2|||f||||f||||||||||2018-06-01 02:20:01.232371|2018-06-01 02:20:01.232371
NCT00639067|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2014-05-15|2008-03-12|2008-03-19|Estimate|||||||2014-05-15|2014-05-16|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|||Breath Test for Early Detection of Lung Cancer|Breath Test Assay for the Adjunctive Detection of Lung Cancer|Completed|||215|Actual|Menssana Research, Inc.|||4||f||||f||||||||||2018-06-01 02:20:05.97468|2018-06-01 02:20:05.97468
NCT00639431|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2014-08-11|2008-03-19|2008-03-20|Estimate|||||||2014-08-11|2014-08-12|Estimate|December 2007||2007-12-31|August 2014|2014-08-31|August 2014|Anticipated|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study to Assess the Efficacy of Direct Observation and Mental Visualization of Foot Movements to Treat Bilateral Lower Limb Phantom Limb Pain|Study to Assess the Efficacy of Direct Observation and Mental Visualization of Foot Movements to Treat Bilateral Lower Limb Phantom Limb Pain|Unknown status|Recruiting|N/A|42|Anticipated|Walter Reed Army Medical Center||6|||f||||f||||||||||2018-06-01 02:20:01.305571|2018-06-01 02:20:01.305571
NCT00639418|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2014-01-10||2014-09-12|2008-03-19|2008-03-20|Estimate|2014-09-12|2014-09-15|Estimate||||2014-09-12|2014-09-15|Estimate|August 2007||2007-08-31|September 2014|2014-09-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Observational|||A Study to Describe Pediatric Influenza Vaccine Coverage|An Observational Study to Describe Pediatric Influenza Vaccine Coverage Among Pediatricians in the United States|Completed|||147494|Actual|MedImmune LLC|||4||f||||f||||||||||2018-06-01 02:20:01.682727|2018-06-01 02:20:01.682727
NCT00639405|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2011-04-26|2008-03-19|2008-03-20|Estimate|||||||2011-04-26|2011-04-27|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas|Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism|Terminated|||12|Actual|State University of New York - Upstate Medical University|||1|Subject population not available.|f||||f||||||||||2018-06-01 02:20:02.55027|2018-06-01 02:20:02.55027
NCT00639392|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2011-11-10|2008-03-19|2008-03-20|Estimate|||||||2011-11-10|2011-11-11|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Phase 1 Study of Zoledronic Acid in Sickle Cell Disease|Phase 1 Study of Zoledronic Acid in Sickle Cell Disease|Withdrawn||Phase 1/Phase 2|0|Actual|Virginia Commonwealth University||2||Ended early due to inability to identify eligible subjects|f||||t||||||||||2018-06-01 02:20:02.613231|2018-06-01 02:20:02.613231
NCT00639379|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2010-06-18||2015-05-05|2008-03-19|2008-03-20|Estimate|2010-06-18|2010-07-19|Estimate||||2015-05-05|2015-05-21|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Comparison of Two Toric Contact Lenses on Current Toric Wearers|A Multi-Center, Subject Masked, Randomized, Two Week Crossover Design, Investigation of the Acuvue Cypress Toric Silicone Hydrogel Lens Compared to the Bausch & Lomb SofLens66® Toric Hydrophilic Lens|Completed||N/A|89|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 02:20:02.722619|2018-06-01 02:20:02.722619
NCT00639366|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-19|||2013-08-06|2008-03-19|2008-03-20|Estimate|||||||2013-08-06|2013-08-07|Estimate|February 2007||2007-02-28|December 2008|2008-12-31|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Interventional|||Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast Cancer|Prospective Randomised Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated With Trastuzumab (Herceptin®) for Metastatic Breast Cancer|Completed||Phase 3|390|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:20:03.014334|2018-06-01 02:20:03.014334
NCT00639353|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2014-10-28|2008-03-14|2008-03-20|Estimate|||||||2014-10-28|2014-10-29|Estimate|February 2008||2008-02-29|October 2014|2014-10-31||||June 2008|Actual|2008-06-30||Interventional|||Silicone Hydrogel Contact Lenses on Low Astigmatism in Japan|The Clinical Performance of the Silicone Hydrogel Contact Lens on Low to Moderate Astigmatism in Japan|Terminated||N/A|102|Actual|Johnson & Johnson Vision Care, Inc.||2||"English to Japanese translation issues caused enrollment of incorrect and unqualified subjects;~   error applied to all subjects enrolled prior to termination."|f||||f||||||||||2018-06-01 02:20:03.135971|2018-06-01 02:20:03.135971
NCT00639340|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2010-02-22|2008-03-14|2008-03-20|Estimate|||||||2010-02-22|2010-02-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:20:03.217131|2018-06-01 02:20:03.217131
NCT00639327|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2011-06-27|2008-03-19|2008-03-20|Estimate|||||||2011-06-27|2011-06-28|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer|Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer|Completed||Phase 2/Phase 3|300|Anticipated|Japan Clinical Cancer Research Organization||2|||f||||t||||||||||2018-06-01 02:20:03.26746|2018-06-01 02:20:03.26746
NCT00639314|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2011-06-23|2008-03-19|2008-03-20|Estimate|||||||2011-06-23|2011-06-27|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|March 2011|Actual|2011-03-31|May 2009|Actual|2009-05-31||Interventional|||Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy|Randomized Controlled Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy|Completed||N/A|130|Anticipated|Wakayama Medical University||2|||f||||t||||||||||2018-06-01 02:20:03.438065|2018-06-01 02:20:03.438065
NCT00639301|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2018-04-17|2008-03-19|2008-03-20|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2008|Actual|2008-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life|Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life|Active, not recruiting|||473|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:20:03.524696|2018-06-01 02:20:03.524696
NCT00639288|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2016-03-18|2008-03-19|2008-03-20|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Modification of Cognitive Processing Therapy (CPT-C) for PTSD and Alcohol Dependence|Modification of Cognitive Processing Therapy (CPT-C) for Posttraumatic Stress Disorder (PTSD) and Alcohol Dependence (AD)|Completed||Phase 2/Phase 3|9|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:20:03.60515|2018-06-01 02:20:03.60515
NCT00639275|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2013-01-08|2008-03-19|2008-03-20|Estimate|||||||2013-01-08|2013-01-10|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|SCPDig||Deep Brain Stimulation and Digestive Symptomatology|Effects of Subthalamic Nucleus Deep Brain Stimulation on Gastrointestinal Symptoms and Motility in Parkinson's Disease.|Completed|||14|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 02:20:03.666561|2018-06-01 02:20:03.666561
NCT00639262|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2016-10-19|2008-03-19|2008-03-20|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors|Phase I Study of the Combination of Sorafenib and Radiation Therapy -/+ Temozolomide for the Treatment of Patients With Brain Metastases and Primary Brain Tumors|Completed||Phase 1|35|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 02:20:03.717076|2018-06-01 02:20:03.717076
NCT00639249|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2009-07-28|2008-03-14|2008-03-20|Estimate|||||||2009-07-28|2009-07-29|Estimate|February 2008||2008-02-29|July 2009|2009-07-31||||June 2009|Actual|2009-06-30||Interventional|||Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke|A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Phase IIa Study of Safety and Motor Function Restoration in Subjects Treated With SA4503 Following Acute Ischemic Stroke|Completed||Phase 2|60|Actual|M's Science Corporation||3|||f||||t||||||||||2018-06-01 02:20:03.922494|2018-06-01 02:20:03.922494
NCT00639236|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-03-19|2008-03-19|2008-03-20|Estimate|||||||2008-03-19|2008-03-20|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|November 2006|Actual|2006-11-30|September 2004|Actual|2004-09-30||Interventional|||Effectiveness and Safety of Inhaling Hypertonic Saline in Patients With Chronic Obstructive Pulmonary Disease|Effectiveness and Safety of Inhaling Hypertonic Saline in the Functional Exercise Capacity of Patients With Chronic Obstructive Pulmonary Disease: a Randomized Trial|Completed||Phase 4|68|Actual|Federal University of São Paulo|||||f||||t||||||||||2018-06-01 02:20:04.016609|2018-06-01 02:20:04.016609
NCT00639223|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|2009-12-09||2009-12-09|2008-03-19|2008-03-20|Estimate|2009-12-09|2010-01-18|Estimate||||2009-12-09|2010-01-18|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Safety of Red Yeast Rice for High Cholesterol in Individuals With Statin Intolerance|Red Yeast Rice vs. Pravastatin: A Double-Blind Randomized Comparative Study of Myopathic Symptoms|Completed||Phase 2|43|Actual|University of Pennsylvania|Small sample size precluded definitive conclusions.|2|||f||||t||||||||||2018-06-01 02:20:04.089697|2018-06-01 02:20:04.089697
NCT00639210|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2008-03-19|2008-03-19|2008-03-20|Estimate|||||||2008-03-19|2008-03-20|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|BREX||BREAST CANCER AND EXERCISE|BREAST CANCER AND EXERCISE BREX: A Multicenter Phase III Open Randomised Trial of the Efficacy of Exercise in the Prevention of Long-Term Adverse Effects of Adjuvant Treatments and Breast Cancer Recurrences in Women With Primary Breast Cancer.|Completed||Phase 3|573|Actual|Finnish Breast Cancer Group||2|||f||||t||||||||||2018-06-01 02:20:04.336987|2018-06-01 02:20:04.336987
NCT00639197|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-04-10|2008-03-14|2008-03-20|Estimate|||||||2008-04-10|2008-04-11|Estimate|March 2008||2008-03-31|March 2008|2008-03-31||||June 2008|Anticipated|2008-06-30||Interventional|UGIST||UGIST: Ultrasound Guided Internal Jugular Short-Term Central Venous Catheters Tunneling|UGIST Pilot Trial: Ultrasound Guided Internal Jugular Short-Term Central Venous Catheters Tunneling. Does it Reduce the Technical Difficulty and Mechanical Complications?|Unknown status|Recruiting|N/A|20|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 02:20:04.40845|2018-06-01 02:20:04.40845
NCT00639184|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2014-07-29|2008-03-18|2008-03-20|Estimate|||||||2014-07-29|2014-07-31|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|BRAIN-HIT||BRAIN - Home Intervention Trial|Brain Research to Ameliorate Impaired Neurodevelopment (BRAIN): Home-based Intervention A Multicenter Trial of the Global Network for Women's and Children's Health Research|Completed||Phase 4|240|Anticipated|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-06-01 02:20:04.481689|2018-06-01 02:20:04.481689
NCT00639171|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2017-10-10|2008-03-19|2008-03-20|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2005||2005-11-30|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Evaluate the Use of the Magnetic Resonance Spectroscopy in Determining if the Breast Tumor is Benign or Malignant|Clinical Implementation and Evaluation of MR Spectroscopy for Breast Cancer Detection|Completed|||13|Actual|State University of New York - Upstate Medical University|||2||f||||f||||||||No||2018-06-01 02:20:04.611765|2018-06-01 02:20:04.611765
NCT00639158|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|2009-10-02||2011-06-09|2008-03-14|2008-03-20|Estimate|2009-10-02|2009-11-05|Estimate||||2011-06-09|2011-06-13|Estimate|February 2008||2008-02-29|June 2011|2011-06-30||||October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 in Combination With Atorvastatin and Ezetimibe to Atorvastatin in Combination With Ezetimibe in Subjects With Combined (Atherogenic) Dyslipidemia|Completed||Phase 3|543|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:20:04.732627|2018-06-01 02:20:04.732627
NCT00639145|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2013-08-13|2008-03-19|2008-03-20|Estimate|||||||2013-08-13|2013-08-14|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|MEP Project||Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol|Maternal Events and Pregnancy Outcomes in a Cohort of Human Immunodeficiency Virus‐Infected Women Receiving Antiretroviral Therapy in Sub‐ Saharan Africa|Completed|||600|Actual|Elizabeth Glaser Pediatric AIDS Foundation|||||f||||f||||||||||2018-06-01 02:20:05.396942|2018-06-01 02:20:05.396942
NCT00639132|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2018-02-05|2008-03-11|2008-03-19|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2012||2012-01-31|February 2018|2018-02-28|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Observational|NH-US||The Natural History of Metachromatic Leukodystrophy|The Natural History of Metachromatic Leukodystrophy|Active, not recruiting|||10|Anticipated|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     blood, CSF and urine~   "|||2018-06-01 02:20:05.465008|2018-06-01 02:20:05.465008
NCT00639119|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-03-18|2008-03-18|2008-03-19|Estimate|||||||2008-03-18|2008-03-19|Estimate|August 2007||2007-08-31|February 2008|2008-02-29||||August 2008|Anticipated|2008-08-31||Interventional|||Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type|Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type|Unknown status|Enrolling by invitation|Phase 2|16|Anticipated|University of Turku|||||f||||f||||||||||2018-06-01 02:20:05.528522|2018-06-01 02:20:05.528522
NCT00639106|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2018-04-03|2008-03-12|2008-03-19|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2008|Actual|2008-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial|The Use of Alloderm in Two-Stage, Tissue Expander/Implant Reconstruction: A Single-Blinded, Randomized, Controlled Trial|Active, not recruiting||Phase 3|98|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:20:05.597055|2018-06-01 02:20:05.597055
NCT00639093|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2009-07-30||2012-06-25|2008-03-12|2008-03-19|Estimate|2009-07-30|2009-07-31|Estimate||||2012-06-25|2012-07-02|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||A Virtual Arm to Stop Smoking|A Virtual Arm to Stop Smoking. A Comparative Study|Completed||N/A|91|Actual|Universite du Quebec en Outaouais||2|||f||||f||||||||||2018-06-01 02:20:05.701328|2018-06-01 02:20:05.701328
NCT00639080|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2011-07-21|2008-03-12|2008-03-19|Estimate|||||||2011-07-21|2011-07-22|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients|Necessity for Lipid Lowering Therapy in Type 2 Diabetes Patients|Completed|||25|Actual|Endocrine Research Society|||1||f||||f||||||||||2018-06-01 02:20:05.900903|2018-06-01 02:20:05.900903
NCT00639054|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2016-01-06|2008-03-12|2008-03-19|Estimate|||||||2016-01-06|2016-01-07|Estimate|March 2008||2008-03-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|MM-FISH/DNA||The Molecular Characterization of Multiple Myeloma at Relapse|The Molecular Characterization of Multiple Myeloma at Relapse|Completed|||134|Actual|Rigshospitalet, Denmark|||3||f||||f||||||Samples With DNA|"~     Peripheral whole blood Bone marrow~   "|||2018-06-01 02:20:06.180755|2018-06-01 02:20:06.180755
NCT00639041|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2011-09-21|2008-03-12|2008-03-19|Estimate|||||||2011-09-21|2011-09-22|Estimate|April 2006||2006-04-30|February 2008|2008-02-29|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Changes in Blood Lipids After Long-term Consumption of n-3 LC-PUFA-Enriched Dairy Products|Changes in Blood Lipids After Long Time Consumption of n-3 LC-PUFA-enriched Dairy Products in Hypertriglyceridemic Patients: a Randomized, Double-blind, Cross-over Study|Completed||N/A|51|Actual|University of Jena||2|||f||||t||||||||||2018-06-01 02:20:06.274377|2018-06-01 02:20:06.274377
NCT00639028|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2014-01-22|2008-03-18|2008-03-19|Estimate|||||||2014-01-22|2014-01-23|Estimate|November 2007||2007-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|TALOS||Comparative Study of Two Radiological Modalities, Ultrasonography Versus Stress Radiography, in the Urgent Care and Prognosis of Lateral Ankle Sprain (TALOS)|Comparative Study of Two Radiological Modalities, Ultrasonography Versus Stress Radiography, in the Urgent Care and Prognosis of Lateral Ankle Sprains.|Completed||N/A|390|Anticipated|University Hospital, Grenoble||3|||f||||t||||||||||2018-06-01 02:20:06.346176|2018-06-01 02:20:06.346176
NCT00639015|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2017-10-24|2008-03-12|2008-03-19|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2007||2007-11-30|October 2017|2017-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Phenylephrine in Septic Shock|Phenylephrine Versus Norepinephrine in Septic Shock: Effects on Systemic and Regional Hemodynamics. A Randomized, Controlled, Trial|Completed||Phase 2|32|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-06-01 02:20:06.433931|2018-06-01 02:20:06.433931
NCT00639002|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2011-12-16|2010-06-18|2018-01-15|2008-03-12|2008-03-19|Estimate|2011-12-16|2012-01-23|Estimate|2010-06-18|2010-06-22|Estimate|2018-01-15|2018-02-13|Actual|March 2008||2008-03-31|January 2018|2018-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma|A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|13|Actual|Incyte Corporation||1|||f||||f||||||||||2018-06-01 02:20:06.535494|2018-06-01 02:20:06.535494
NCT00638989|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2017-03-22||2017-03-22|2008-03-18|2008-03-19|Estimate|2017-03-22|2017-05-04|Actual||||2017-03-22|2017-05-04|Actual|April 11, 2008|Actual|2008-04-11|March 2017|2017-03-31|June 7, 2008|Actual|2008-06-07|June 7, 2008|Actual|2008-06-07||Interventional||Analysis population included all enrolled participants.|A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354|An Open-Label, Parallel-Group, Bioavailability Study to Assess the Pharmacokinetics of CAT-354 Following Subcutaneous and Intravenous Administration|Completed||Phase 1|30|Actual|MedImmune LLC||3|||f||||f||||||||||2018-06-01 02:20:06.959849|2018-06-01 02:20:06.959849
NCT00638976|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2010-05-27|2008-03-18|2008-03-19|Estimate|||||||2010-05-27|2010-05-28|Estimate|November 2007||2007-11-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|INSTANT||INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial|INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial|Completed||Phase 3|91|Actual|Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS||2|||f||||t||||||||||2018-06-01 02:20:07.393802|2018-06-01 02:20:07.393802
NCT00638963|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2011-06-23||2017-05-18|2008-03-18|2008-03-19|Estimate|2011-06-23|2011-07-22|Estimate||||2017-05-18|2017-06-14|Actual|October 2, 2008|Actual|2008-10-02|May 2017|2017-05-31|June 30, 2010|Actual|2010-06-30|June 30, 2010|Actual|2010-06-30||Interventional|STOP||Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)|Temozolomide in Metastatic Breast Cancer Patients at High Risk of Brain Recurrence: Impact on the Incidence of Brain Metastases (STOP)|Terminated||Phase 2|6|Actual|Merck Sharp & Dohme Corp.|The primary outcome measure and the survival analyses could not be analyzed due to the low enrollment.|2||Terminated due to poor accrual|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:20:07.454978|2018-06-01 02:20:07.454978
NCT00638950|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2011-09-21|2008-03-12|2008-03-19|Estimate|||||||2011-09-21|2011-09-22|Estimate|September 2004||2004-09-30|February 2008|2008-02-29|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Long-term Moderate Intervention With n-3 LC-PUFA-supplemented Dairy Products in Patients With Rheumatoid Arthritis|Long-term Moderate Intervention With n-3 LC-PUFA-supplemented Dairy Products: Effects on Pathophysiological Biomarkers in Rheumatoid Arthritis|Completed||N/A|45|Actual|University of Jena||2|||f||||t||||||||||2018-06-01 02:20:08.838835|2018-06-01 02:20:08.838835
NCT00638937|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|2014-08-28||2015-06-22|2008-03-18|2008-03-19|Estimate|2015-06-22|2015-07-14|Estimate||||2015-06-22|2015-07-14|Estimate|February 2008||2008-02-29|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy|A Phase 2 Study of AZD0530 in Patients With Advanced, Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Combination Chemotherapy|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:20:08.940775|2018-06-01 02:20:08.940775
NCT00638924|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2012-05-06||2012-06-13|2008-03-12|2008-03-19|Estimate|2012-06-13|2012-07-17|Estimate||||2012-06-13|2012-07-17|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Physiologic Variables in Healthy Women in Shuttle Walk Test|Analysis of Physiologic Variables in Healthy Women in Shuttle Walk Test|Completed|||40|Actual|University of Campinas, Brazil|Small number of subjects, only females were analyzed making generalization impossible.||1||f||||f||||||||||2018-06-01 02:20:09.166789|2018-06-01 02:20:09.166789
NCT00638911|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2012-05-18|2008-03-18|2008-03-19|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2004||2004-09-30|May 2012|2012-05-31||||October 2009|Actual|2009-10-31||Observational|||Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension|PMS Assessing the Safety and Efficacy of Telmisartan in Patients With Mild-to-moderate Essential Hypertension|Completed|||33247|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 02:20:09.423052|2018-06-01 02:20:09.423052
NCT00638898|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-18|||2018-05-04|2008-03-18|2008-03-19|Estimate|||||||2018-05-04|2018-05-07|Actual|December 11, 2006||2006-12-11|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor|Pilot Study of High-Dose Chemotherapy With Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors|Active, not recruiting||Phase 1|25|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:20:09.506873|2018-06-01 02:20:09.506873
NCT00638885|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2015-01-08||2015-01-08|2008-03-18|2008-03-19|Estimate|2015-01-08|2015-01-15|Estimate||||2015-01-08|2015-01-15|Estimate|April 2010||2010-04-30|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational||Vietnam veteran twins with and without PTSD.|Memory and the Hippocampus in Twins|Memory and the Hippocampus in Vietnam Twins With PTSD|Completed|||142|Actual|VA Office of Research and Development|||1||f||||t||||||Samples With DNA|"~     blood for genetic testing, blood samples and urine and saliva collections~   "|||2018-06-01 02:20:09.632915|2018-06-01 02:20:09.632915
NCT00638872|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2012-09-10|2008-03-18|2008-03-19|Estimate|||||||2012-09-10|2012-09-11|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers|Diabetic Foot Ulcers and Use of PDRN (Polydeoxyribonucleotide -Placentex Mastelli) as a Treatment for Wound Healing.|Completed||Phase 4|215|Actual|University of Messina||2|||f||||t||||||||||2018-06-01 02:20:09.79052|2018-06-01 02:20:09.79052
NCT00638859|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2009-10-01|2008-03-18|2008-03-19|Estimate|||||||2009-10-01|2009-10-02|Estimate|March 2004||2004-03-31|October 2009|2009-10-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia|Evaluation of the Safety, Pharmacokinetics, Efficacy, and Acceptability of HMR3647 20 mg/kg qd for 5-7 Days With Community-Acquired Pneumonia (CAP) in Children (Multicenter, Open Label, Noncomparative Study)|Completed||Phase 3|56|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:09.890575|2018-06-01 02:20:09.890575
NCT00638846|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2010-06-18||2015-05-05|2008-03-10|2008-03-19|Estimate|2010-06-18|2010-07-19|Estimate||||2015-05-05|2015-05-21|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Performance of Two Silicone Hydrogel Toric Contact Lenses|Multi-Center Evaluation Of Two Silicone Hydrogel Toric Contact Lenses|Completed||N/A|276|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 02:20:09.99391|2018-06-01 02:20:09.99391
NCT00638833|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2012-06-07|2008-03-18|2008-03-19|Estimate|||||||2012-06-07|2012-06-08|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Memantine-MS||Memantine Therapy for Multiple Sclerosis|Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis|Terminated||Phase 2|20|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2||Unexpected side-effects: reversible and mild to moderate neurological impairment|f||||f||||||||||2018-06-01 02:20:10.28811|2018-06-01 02:20:10.28811
NCT00638820|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2009-08-26||2017-12-03|2008-03-18|2008-03-19|Estimate|2010-01-18|2010-02-03|Estimate||||2017-12-03|2017-12-28|Actual|September 2007||2007-09-30|December 2017|2017-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Reduced Intensity AlloTransplant For Osteopetrosis|Reduced Intensity Allogeneic Transplantation For Severe Osteopetrosis Incorporating A Second Cd34 Selected Graft|Terminated||Phase 2|3|Actual|Masonic Cancer Center, University of Minnesota|Only 3 participants were treated in this study; all died by Day 100. Data for both treatment arms were combined due to low number. (Arm 1 utilized mobilized peripheral blood or marrow (related or unrelated). Arm 2 received cord blood transplants).|1||Excess toxicity|f||||t||||||||||2018-06-01 02:20:10.629373|2018-06-01 02:20:10.629373
NCT00638807|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2009-03-12|2008-03-12|2008-03-19|Estimate|||||||2009-03-12|2009-03-13|Estimate|December 2003||2003-12-31|March 2009|2009-03-31|July 2004|Actual|2004-07-31|||||Interventional|||Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen|A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen|Completed||Phase 4|388|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:20:10.843859|2018-06-01 02:20:10.843859
NCT00638794|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2013-01-22|2008-03-18|2008-03-19|Estimate|||||||2013-01-22|2013-01-23|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Observational|ADAPT-DES||Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents|Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents|Completed|||8575|Actual|Cardiovascular Research Foundation, New York|||2||f||||f||||||||||2018-06-01 02:20:10.979795|2018-06-01 02:20:10.979795
NCT00638781|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-12|2008-03-12|2008-03-19|Estimate|||||||2008-03-12|2008-03-19|Estimate|March 2001||2001-03-31|March 2008|2008-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Desmoteplase in Acute Ischemic Stroke (DIAS)|Multicentre, Multinational, Double-Blind, Placebo-Controlled, Randomised Phase II Trial of Desmoteplase (INN) in the Indication of Acute Ischaemic Stroke|Completed||Phase 2|104|Actual|PAION Deutschland GmbH||4|||f||||t||||||||||2018-06-01 02:20:11.081841|2018-06-01 02:20:11.081841
NCT00638768|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-12|2008-03-12|2008-03-19|Estimate|||||||2008-03-12|2008-03-19|Estimate|February 2006||2006-02-28|March 2008|2008-03-31||||||||Interventional|||Effectiveness of Physiotherapy for Osteoporotic Spinal Fracture|Effectiveness of Physiotherapy for Vertebral Osteoporotic Fracture: a Randomised Controlled Pilot Trial|Completed||Phase 2|20|Actual|University of Melbourne||2|||f||||f||||||||||2018-06-01 02:20:11.174741|2018-06-01 02:20:11.174741
NCT00638755|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13||2010-08-17|2010-08-17|2008-03-18|2008-03-19|Estimate||||2010-08-17|2010-08-19|Estimate|2010-08-17|2010-08-19|Estimate|February 2008||2008-02-29|August 2010|2010-08-31|July 2008||2008-07-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Nasal Carbon Dioxide (CO2) on Nasal Congestion in Subjects With Perennial Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Effect of Nasal Carbon Dioxide on Nasal Congestion Via Acoustic Rhinometry in Subjects With Perennial Allergic Rhinitis|Completed||Phase 2|20|Actual|Capnia, Inc.||4|||f||||f||||||||||2018-06-01 02:20:11.26877|2018-06-01 02:20:11.26877
NCT00638742|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-12-29|2008-03-12|2008-03-19|Estimate|||||||2010-12-29|2010-12-31|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.|A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost 0.005%.|Completed||Phase 1|47|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:20:11.354412|2018-06-01 02:20:11.354412
NCT00638729|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-18|2008-03-18|2008-03-19|Estimate|||||||2008-03-18|2008-03-19|Estimate|August 2005||2005-08-31|February 2008|2008-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Clonidine Versus Midazolam for Premedication|Effects of Clonidine and Midazolam Premedication on Bispectral Index and Recovery After Elective Surgery|Completed||N/A|60|Actual|University of Schleswig-Holstein||3|||f||||f||||||||||2018-06-01 02:20:11.450086|2018-06-01 02:20:11.450086
NCT00638534|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2009-10-01|2008-03-18|2008-03-19|Estimate|||||||2009-10-01|2009-10-02|Estimate|February 2004||2004-02-29|October 2009|2009-10-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media|Evaluation of the Safety, Efficacy, Pharmacokinetics, and Acceptability of HMR3647 20 mg/kg qd for 5 Days With Acute Otitis Media (AOM) in Children (Multicenter, Open Label, Non Comparative Study)|Completed||Phase 3|56|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:14.992311|2018-06-01 02:20:14.992311
NCT00638716|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2017-05-02||2017-05-02|2008-03-18|2008-03-19|Estimate|2017-05-02|2017-06-02|Actual||||2017-05-02|2017-06-02|Actual|February 2008||2008-02-29|May 2017|2017-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|DM200-101|Safety Population|A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy|A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy|Completed||Phase 2|122|Actual|ConjuChem||3|||f||||t||||||||||2018-06-01 02:20:11.58084|2018-06-01 02:20:11.58084
NCT00638703|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12||2013-05-07|2013-05-07|2008-03-18|2008-03-19|Estimate||||2013-05-07|2013-05-15|Estimate|2013-05-07|2013-05-15|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|PHOENIX||Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients|A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria|Completed||Phase 2/Phase 3|43|Actual|OxThera||2|||f||||f||||||||||2018-06-01 02:20:11.954431|2018-06-01 02:20:11.954431
NCT00638690|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|2011-08-23||2014-04-10|2008-03-13|2008-03-19|Estimate|2013-04-05|2013-05-16|Estimate||||2014-04-10|2014-04-30|Estimate|May 2008||2008-05-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|August 2010|Actual|2010-08-31||Interventional|||Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy|Completed||Phase 3|1195|Actual|Cougar Biotechnology, Inc.||2|||f||||t||||||||||2018-06-01 02:20:12.185733|2018-06-01 02:20:12.185733
NCT00638677|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2013-01-07|2008-03-12|2008-03-19|Estimate|||||||2013-01-07|2013-01-08|Estimate|June 2004||2004-06-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier|Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier|Completed||Phase 4|106|Actual|University of Turku||3|||f||||t||||||||||2018-06-01 02:20:14.10487|2018-06-01 02:20:14.10487
NCT00638664|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2015-05-20|2008-03-18|2008-03-19|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 1995||1995-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Evaluation of the MRI in Measuring the Cardiac Chambers and Thoracic Great Vessels|Optimized MRI Evaluation of Maximal Temporal and Spatial Measurability of the Cardiac Chambers and Thoracic Great Vessels. A Comparison of MR Acquisition Pulse Sequences.|Completed|||31|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:20:14.190154|2018-06-01 02:20:14.190154
NCT00638651|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2014-08-20||2018-02-22|2008-03-12|2008-03-19|Estimate|2014-08-20|2014-09-01|Estimate||||2018-02-22|2018-03-22|Actual|February 2008||2008-02-29|February 2018|2018-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal|Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal|Completed||Phase 1|3|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 02:20:14.243823|2018-06-01 02:20:14.243823
NCT00638638|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2009-09-16|2008-03-11|2008-03-19|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 2005||2005-01-31|September 2009|2009-09-30|January 2010|Anticipated|2010-01-31|August 2009|Anticipated|2009-08-31||Interventional|MISTRAL||Myocardial Infarction With ST-Elevation|Myocardial Infarction With ST-elevation Treated by Primary Percutaneous Intervention Facilitated by Early Reopro Administration in Alsace.|Unknown status|Active, not recruiting|Phase 3|292|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 02:20:14.41241|2018-06-01 02:20:14.41241
NCT00638625|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2015-05-12|2008-03-12|2008-03-19|Estimate|||||||2015-05-12|2015-05-14|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Correlation of X-ray and Pathology With Needle Biopsy of Lung Tumors|Pilot Study of Radiologic-Pathologic Correlation in Lung Tumors Based on Core Needle Biopsy|Withdrawn|||0|Actual|State University of New York - Upstate Medical University||||Due to specimen collection difficulties; this study has been terminated|f||||f||||||||||2018-06-01 02:20:14.509187|2018-06-01 02:20:14.509187
NCT00638612|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2015-10-28|2008-03-13|2008-03-19|Estimate|||||||2015-10-28|2015-10-29|Estimate|August 2008||2008-08-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|May 2013|Actual|2013-05-31||Interventional|PaTK01||AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)|AdV-tk + Valacyclovir Therapy in Combination With Surgery and Chemoradiation for Pancreas Cancer|Completed||Phase 1|27|Actual|Advantagene, Inc.||2|||f||||t||||||||||2018-06-01 02:20:14.580253|2018-06-01 02:20:14.580253
NCT00638599|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-07-14|2008-03-12|2008-03-19|Estimate|||||||2009-07-14|2009-07-15|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|LMATBBC||Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer|Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube for Airway Management in Modified Radical Mastectomy on Breast Cancer|Completed||Phase 4|200|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 02:20:14.677351|2018-06-01 02:20:14.677351
NCT00638586|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-12|2008-03-12|2008-03-19|Estimate|||||||2008-03-12|2008-03-19|Estimate|April 2008||2008-04-30|March 2008|2008-03-31||||||||Observational|||Comparison of Patients Undergoing Radial or Femoral Arterial Access for Percutaneous Catheterization-Nursing Aspects||Unknown status|Not yet recruiting||160|Anticipated|Hillel Yaffe Medical Center|||2||f||||||||||||||2018-06-01 02:20:14.755445|2018-06-01 02:20:14.755445
NCT00638573|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-01-12|2008-03-12|2008-03-19|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|July 2006||2006-07-31|||||Observational|||The Incretin Effect in Patients With Chronic Pancreatitis|The Incretin Effect in Patients With Chronic Pancreatitis With and Without Secondary Diabetes Mellitus|Completed|||32|Actual|University Hospital, Gentofte, Copenhagen|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 02:20:14.802811|2018-06-01 02:20:14.802811
NCT00638560|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-01-19|2008-03-12|2008-03-19|Estimate|||||||2010-01-19|2010-01-20|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Changes of Biomarkers in Response to Training and Antioxidant Treatment|Effects of Training and Antioxidant Treatment on Circulating Markers of Oxidative Stress and Skeletal Muscle mRNA Expression|Completed||Phase 1|40|Actual|University of Leipzig||2|||f||||f||||||||||2018-06-01 02:20:14.856289|2018-06-01 02:20:14.856289
NCT00638547|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2017-12-03|2008-03-18|2008-03-19|Estimate|||||||2017-12-03|2017-12-05|Actual|January 2, 2008|Actual|2008-01-02|December 2017|2017-12-31|November 10, 2018|Anticipated|2018-11-10|February 18, 2017|Actual|2017-02-18||Interventional|||Intrathecal Enzyme Replacement for Hurler Syndrome|Intrathecal Enzyme Replacement Therapy For Patients With Mucopolysaccharidosis Type I (Hurler Syndrome)|Active, not recruiting||Phase 1|26|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:20:14.928164|2018-06-01 02:20:14.928164
NCT00638508|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-18|2008-03-18|2008-03-19|Estimate|||||||2008-03-18|2008-03-19|Estimate|June 2007||2007-06-30|March 2008|2008-03-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management|The Analgesic Efficacy of Continuous Infusion of Ketorolac and Ropivacaine at the Wound Site Using ON-Q Pump for Postoperative Pain Management|Unknown status|Recruiting|N/A|70|Anticipated|Maimonides Medical Center||2|||f||||t||||||||||2018-06-01 02:20:15.109058|2018-06-01 02:20:15.109058
NCT00638495|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-01-28|2008-03-18|2008-03-19|Estimate|||||||2010-01-28|2010-02-01|Estimate|March 2008||2008-03-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease —|Phase II Study of TRK-820 Soft Capsules — Intractable Pruritus in Patients With Chronic Liver Disease —|Completed||Phase 2|120|Anticipated|Toray Industries, Inc||2|||f||||f||||||||||2018-06-01 02:20:15.20517|2018-06-01 02:20:15.20517
NCT00638482|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-17|2008-03-17|2008-03-19|Estimate|||||||2008-03-17|2008-03-19|Estimate|July 2003||2003-07-31|July 2003|2003-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|DESY||Dose-Dependent Effect of Thiazide in Dent's Disease Hypercalciuria|Pharmacodynamic Evaluation of the ANTICALCIURIC Effect of Hydrochlorothiazide in Dent's Disease|Terminated||Phase 2/Phase 3|10|Actual|Assistance Publique - Hôpitaux de Paris||1||terminated|f||||f||||||||||2018-06-01 02:20:15.273738|2018-06-01 02:20:15.273738
NCT00638469|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2013-10-31|2008-03-18|2008-03-19|Estimate|||||||2013-10-31|2013-11-01|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis|Prospective, Randomized Half-side Study on the Efficacy of UVB-311nm Phototherapy in Patients With Psoriasis After Partial Remission to Treatment With Adalimumab|Unknown status|Recruiting|N/A|10|Anticipated|Medical University of Graz||1|||f||||f||||||||||2018-06-01 02:20:15.349118|2018-06-01 02:20:15.349118
NCT00638456|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2009-09-09|2008-03-18|2008-03-19|Estimate|||||||2009-09-09|2009-09-10|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis|Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis, a Randomized Clinical Trial|Completed||Phase 2|33|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 02:20:15.545278|2018-06-01 02:20:15.545278
NCT00638443|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2012-07-09||2016-05-11|2008-03-12|2008-03-19|Estimate|2016-05-11|2016-06-20|Estimate||||2016-05-11|2016-06-20|Estimate|March 2008||2008-03-31|May 2016|2016-05-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|LUSTOR||Lumbar Stenosis Outcomes Research (LUSTOR)|Lumbar Stenosis Outcomes Research (LUSTOR)- A Randomized, Double-blind, Cross-over Trial of Pregabalin vs. Diphenhydramine in Patients With Lumbar Spinal Stenosis and Neuropathic Low Back Pain|Completed||Phase 4|29|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 02:20:15.646164|2018-06-01 02:20:15.646164
NCT00638430|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-12|2008-03-12|2008-03-19|Estimate|||||||2008-03-12|2008-03-19|Estimate|March 2007||2007-03-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Observational|||The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test|The Effect of Myopic Optical Defocus on the Humphrey Matrix 30-2 Test|Completed|||40|Actual|Samsung Medical Center|||2||f||||f||||||||||2018-06-01 02:20:15.968109|2018-06-01 02:20:15.968109
NCT00638417|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2018-03-09|2008-03-18|2008-03-19|Estimate|||||||2018-03-09|2018-03-12|Actual|January 2006|Actual|2006-01-31|March 2018|2018-03-31|November 2007|Actual|2007-11-30|March 2006|Actual|2006-03-31||Interventional|||Treatment and Rehabilitation of Patients With Hip Arthroplasty to Regain Walk and Work Efficiency and Quality of Life|Treatment and Rehabilitation of Patients With Hip Arthroplasty to Regain Walk and Work Efficiency and Quality of Life|Completed||N/A|24|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 02:20:16.108574|2018-06-01 02:20:16.108574
NCT00638404|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-02-01|2008-03-12|2008-03-19|Estimate|||||||2010-02-01|2010-02-02|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Severity Postoperative Pain Prediction|Predicting Severity of Postoperative Pain After Surgery|Terminated|||300|Actual|Wake Forest University Health Sciences|||2|"Further evaluation determined it was not feasible to enroll the post-partum tubal ligation~   group at our facility"|f||||t||||||||||2018-06-01 02:20:16.189348|2018-06-01 02:20:16.189348
NCT00638391|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-13|||2008-03-19|2008-03-18|2008-03-19|Estimate|||||||2008-03-19|2008-03-20|Estimate|May 2005||2005-05-31|March 2008|2008-03-31|March 2007|Actual|2007-03-31|||||Observational|Ax-003||Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer|Postmenopausal Women With Early Hormone-Receptor Positive Breast Cancer/no Metastasis|Completed|||1600|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:20:16.275726|2018-06-01 02:20:16.275726
NCT00638378|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2011-12-15|2010-06-17|2018-01-15|2008-03-12|2008-03-19|Estimate|2011-12-15|2012-01-20|Estimate|2010-06-17|2010-06-22|Estimate|2018-01-15|2018-02-12|Actual|February 2008||2008-02-29|January 2018|2018-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer|A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer|Terminated||Phase 2|22|Actual|Incyte Corporation||1||"According to the protocol, the sponsor terminated the study after it was determined that less~   than 2 of the first 22 patients showed a PSA50 response."|f||||f||||||||||2018-06-01 02:20:16.378267|2018-06-01 02:20:16.378267
NCT00638365|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2011-07-12||2014-06-04|2008-03-12|2008-03-19|Estimate|2011-07-12|2011-08-08|Estimate||||2014-06-04|2014-06-09|Estimate|March 2008||2008-03-31|June 2014|2014-06-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa|A Phase I/II Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa|Completed||Phase 1/Phase 2|27|Actual|Humanigen, Inc.||2|||f||||t||||||||||2018-06-01 02:20:16.704327|2018-06-01 02:20:16.704327
NCT00638352|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2016-07-15|2008-03-12|2008-03-19|Estimate|||||||2016-07-15|2016-07-18|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Observational|||False/Negative Rate of Lung Percutaneous Needle Biopsy|Determination of the False Negative Rate of Percutaneous Needle Biopsies That Include Core Tissue Samples|Completed|||5|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||No||2018-06-01 02:20:17.131286|2018-06-01 02:20:17.131286
NCT00638339|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2018-05-25|2008-03-18|2008-03-19|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2006|Actual|2006-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Observational|||Effects Of Invasive And Noninvasive Mechanical Ventilation On Sleep In The Intensive Care Unit (ICU)|Effects Of Invasive And Noninvasive Mechanical Ventilation On Sleep In The Icu|Active, not recruiting|||20|Anticipated|Tufts Medical Center|||2||f||||f||||||||No||2018-06-01 02:20:17.19318|2018-06-01 02:20:17.19318
NCT00638326|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2010-03-20|2008-03-11|2008-03-19|Estimate|||||||2010-03-20|2010-03-23|Estimate|March 2008||2008-03-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|DOSER||Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity|150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention|Terminated||Phase 3|500|Anticipated|University of Pecs||3||Greater differences between randomized patients than previously anticipated|f||||t||||||||||2018-06-01 02:20:17.260625|2018-06-01 02:20:17.260625
NCT00638313|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2009-07-30|2008-03-12|2008-03-19|Estimate|||||||2009-07-30|2009-07-31|Estimate|August 2007||2007-08-31|March 2008|2008-03-31|February 2008|Actual|2008-02-29|||||Interventional|||Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects|A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Subcutaneous Doses Of PF-04603629 In Type 2 Diabetic Adult Subjects|Completed||Phase 1|71|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:20:17.328935|2018-06-01 02:20:17.328935
NCT00638300|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-07-11|2008-03-18|2008-03-19|Estimate|||||||2010-07-11|2010-07-13|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD)|Removal of Ligand-bound Iron During Intravenous Iron Administration in Hemodialysis by Large Pore Dialyzers|Completed||N/A|25|Actual|Soroka University Medical Center||6|||f||||f||||||||||2018-06-01 02:20:17.398922|2018-06-01 02:20:17.398922
NCT00638287|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2008-10-03|2008-03-18|2008-03-19|Estimate|||||||2008-10-03|2008-10-06|Estimate|November 2007||2007-11-30|September 2008|2008-09-30|January 2011|Anticipated|2011-01-31|||||Observational|||Inter-Assay Growth Hormone and IGF-I Variability|Inter-Assay Growth Hormone and IGF-I Variability|Withdrawn|||171|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||Samples With DNA|"~     1. Group I Growth Hormone Deficiency (GHD): subjects with pituitary disease undergoing~          testing for GH deficiency: GHRH-ARG Test, collect total of 84 cc whole blood.~        2. Group II Acromegaly: subjects with suspicion for (or diagnosis of) acromegaly undergoing~          OGTT Test, collect total of 48 cc whole blood.~        3. Group III Normal Controls: subjects without evidence of pituitary dysfunction undergoing~          OGTT Test, collect total of 136 cc whole blood.~   "|||2018-06-01 02:20:17.472649|2018-06-01 02:20:17.472649
NCT00638274|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2017-11-06|2008-03-12|2008-03-19|Estimate|||||||2017-11-06|2017-11-08|Actual|July 2005||2005-07-31|February 2017|2017-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Comparison of Loss of Resistance Techniques|Comparison of Loss of Resistance Technique With Air Versus Saline to Identify Epidural Space for Combined Spinal Epidural Labor Analgesia|Completed||N/A|350|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-06-01 02:20:17.521181|2018-06-01 02:20:17.521181
NCT00638261|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2012-03-15|2008-03-18|2008-03-19|Estimate|||||||2012-03-15|2012-03-16|Estimate|March 2008||2008-03-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Primary UVB-311nm and Adalimumab in Psoriasis Patients|Adalimumab in Primary Combination With UVB-311nm Half-side Phototherapy in Patients With Psoriasis|Completed||N/A|4|Actual|Medical University of Graz||1|||f||||f||||||||||2018-06-01 02:20:17.64824|2018-06-01 02:20:17.64824
NCT00638248|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-12|2008-03-12|2008-03-19|Estimate|||||||2008-03-12|2008-03-19|Estimate|March 2003||2003-03-31|March 2008|2008-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|DEDAS||Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)|International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase I/II Trial of Desmoteplase in the Indication of Acute Ischemic Stroke|Completed||Phase 1/Phase 2|38|Actual|PAION Deutschland GmbH||3|||f||||t||||||||||2018-06-01 02:20:17.720789|2018-06-01 02:20:17.720789
NCT00638235|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2016-09-06||2016-09-06|2008-03-18|2008-03-19|Estimate|2016-09-06|2016-10-28|Estimate||||2016-09-06|2016-10-28|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|September 2012|Actual|2012-09-30|February 2011|Actual|2011-02-28||Observational|PROPEL||Pelvic Floor Repair Systems for Prolapse Repair|A Prospective, Multi-Center Study to Assess the AMS Pelvic Floor Repair System Devices for Prolapse Repair|Completed|||725|Actual|ASTORA Women's Health|"Ph- II ended before all subjects reached 24M visit b/c the next generation of Perigee was already under trial, Ph-III/IV~Ph-VI ended after 12M visit because the next generation of study device was already under clinical evaluation in Phase VII"||9||f||||f||||||||No||2018-06-01 02:20:17.921541|2018-06-01 02:20:17.921541
NCT00638222|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2014-07-08||2014-11-05|2008-03-18|2008-03-19|Estimate|2014-11-05|2014-11-13|Estimate||||2014-11-05|2014-11-13|Estimate|May 2008||2008-05-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease|Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease|Terminated||N/A|6|Actual|University of Toledo Health Science Campus|Early termination due to poor enrollment leading to small number of subjects to be analyzed.|1||Poor enrollment|f||||t||||||||||2018-06-01 02:20:21.995828|2018-06-01 02:20:21.995828
NCT00638209|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2008-03-18|2008-03-18|2008-03-19|Estimate|||||||2008-03-18|2008-03-19|Estimate|February 2008||2008-02-29|March 2008|2008-03-31||||May 2010|Anticipated|2010-05-31||Interventional|||Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2|Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Typ 2|Unknown status|Recruiting|N/A|42|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 02:20:22.426724|2018-06-01 02:20:22.426724
NCT00638196|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2015-08-07|2008-03-17|2008-03-18|Estimate|||||||2015-08-07|2015-08-11|Estimate|March 2008||2008-03-31|August 2015|2015-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PLACATE-MS||Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS|Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis|Terminated||Phase 1|9|Actual|University of Rochester||1||funding stopped due to slow enrollment.|f||||t||||||||||2018-06-01 02:20:22.497426|2018-06-01 02:20:22.497426
NCT00638183|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2010-01-19||2014-06-18|2008-03-17|2008-03-18|Estimate|2010-03-23|2010-04-05|Estimate||||2014-06-18|2014-06-19|Estimate|April 2005||2005-04-30|June 2014|2014-06-30||||January 2009|Actual|2009-01-31||Observational||"Number of participants in this summary is Number of patients eligible for efficacy analysis~Throughout this report, the discrepancy between the total number of participants and the numbers analyzed for a certain parameter is due to missing data."|Special Survey Long-term Treatment With Tiotropium on COPD|Special Survey Long-term Treatment|Completed|||385|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:20:22.621305|2018-06-01 02:20:22.621305
NCT00638170|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2009-02-13|2008-03-10|2008-03-18|Estimate|||||||2009-02-13|2009-02-16|Estimate|May 2001||2001-05-31|January 2008|2008-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Cranberry Juice in the Prevention of Urinary Tract Infections in Children|The Efficacy of Cranberry Juice in the Prevention of Urinary Tract Infections in Children - Randomized, Placebo Controlled Multi-Center Study|Completed||N/A|262|Anticipated|University of Oulu||2|||f||||f||||||||||2018-06-01 02:20:23.032877|2018-06-01 02:20:23.032877
NCT00638157|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2013-03-04||2018-01-07|2008-03-17|2008-03-18|Estimate|2013-04-15|2013-05-22|Estimate||||2018-01-07|2018-01-31|Actual|February 13, 2009|Actual|2009-02-13|January 2018|2018-01-31|November 9, 2011|Actual|2011-11-09|November 9, 2011|Actual|2011-11-09||Interventional||Intent-to-Treat (ITT) Population used. Includes all randomized subjects.|Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)|A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis|Terminated||Phase 4|24|Actual|Cubist Pharmaceuticals LLC|As the study was terminated prematurely, conclusions that can be drawn from the efficacy results are limited.|2||commitment completed|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:20:23.349567|2018-06-01 02:20:23.349567
NCT00638144|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2015-09-29|2008-03-10|2008-03-18|Estimate|||||||2015-09-29|2015-09-30|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C|Prevention of Graft Reinfection After Liver Transplantation for HCV Related End-stage Liver Disease . Study of Humoral Anti-HCV Response|Unknown status|Recruiting||300|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-06-01 02:20:24.246478|2018-06-01 02:20:24.246478
NCT00638131|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-06-14|2008-03-17|2008-03-18|Estimate|||||||2010-06-14|2010-06-15|Estimate|January 2009||2009-01-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|March 2010|Anticipated|2010-03-31||Interventional|||Bosentan Use in Patients With Diabetic Nephropathy|Effect of Bosentan on Systemic and Renal Inflammatory Markers in Patients With Diabetic Nephropathy on Angiotensin II Receptor Blockers|Terminated||Phase 3|1|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2||problem of recruitment|f||||f||||||||||2018-06-01 02:20:24.419987|2018-06-01 02:20:24.419987
NCT00638118|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2011-01-10|2008-03-17|2008-03-18|Estimate|||||||2011-01-10|2011-01-11|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|May 2003|Actual|2003-05-31|||||Interventional|||Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen|A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen|Completed||Phase 4|48|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:24.519697|2018-06-01 02:20:24.519697
NCT00638092|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2015-05-15|2008-03-14|2008-03-18|Estimate|||||||2015-05-15|2015-05-18|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|I2S2||A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years|A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants With Follow-up at 2 Years|Completed||Phase 4|1275|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 02:20:24.658296|2018-06-01 02:20:24.658296
NCT00638079|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2016-04-18|2008-03-11|2008-03-18|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2006||2006-06-30|August 2015|2015-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Evaluating the Effect of Food on Absorption of Megace ES|Single-center, Randomized, Open-label, 2-way Crossover Bioavailability Study, Evaluating the Effect of Food on Megace ES (Megestrol Acetate 625 mg/5 mL Oral Suspension) Following a 625 mg Dose in Healthy Subjects|Completed||Phase 1|24|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:20:24.829494|2018-06-01 02:20:24.829494
NCT00638066|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2008-03-17|2008-03-17|2008-03-18|Estimate|||||||2008-03-17|2008-03-18|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|April 2008|Anticipated|2008-04-30|April 2008|Anticipated|2008-04-30||Interventional|||Botulinum Toxin Injection for Treatment of Vaginismus|Comparison of Efficacy of 250 Units Versus 500 Units of Botulinum Toxin in the Treatment of Refractory Vaginismus|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:20:24.926203|2018-06-01 02:20:24.926203
NCT00638053|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-27|2008-03-11|2008-03-18|Estimate|||||||2008-03-27|2008-04-01|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|November 2003|Actual|2003-11-30|||||Interventional|GHD||A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury|Head Trauma With Traumatic Brain Injury (TBI): A Multicenter, Phase IV Study to Evaluate the Effects of Genotropin in Adult Patients With Growth Hormone Deficiency (GHD) Caused by Trauma and/or Head Injury|Terminated||Phase 4|100|Anticipated|Pfizer||1||See reason for termination in detailed description.|f||||f||||||||||2018-06-01 02:20:25.048945|2018-06-01 02:20:25.048945
NCT00638040|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2014-07-09|2008-03-17|2008-03-18|Estimate|||||||2014-07-09|2014-07-11|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression|The Gene Expression Studies of Tumor Microenvironments and Their Roles in Tumor Progression|Withdrawn|||0|Actual|Duke University|||1|the study has stopped due to no recruitment|f||||t||||||||||2018-06-01 02:20:25.134654|2018-06-01 02:20:25.134654
NCT00638027|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2013-01-31||2015-11-06|2008-03-10|2008-03-18|Estimate|2015-11-06|2015-12-07|Estimate||||2015-11-06|2015-12-07|Estimate|July 2006||2006-07-31|November 2015|2015-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Memantine for Spasticity in MS Patients|Memantine for Spasticity in MS Patients|Completed||Phase 4|21|Actual|University of Rochester|Small exploratory study that may have been hindered due to lack of adequate power.|2|||f||||f||||||||||2018-06-01 02:20:25.231592|2018-06-01 02:20:25.231592
NCT00638014|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2011-02-23||2011-04-05|2008-03-17|2008-03-18|Estimate|2011-04-05|2011-05-02|Estimate||||2011-04-05|2011-05-02|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|TALON||Rapid Sternal Closure System (TALON)|A Randomized, Controlled, Phase 4 Study of Sternal Plating (Rapid Sternal Closure System, KLS Martin L.P.) in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Complications.|Completed||Phase 4|51|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:20:25.530172|2018-06-01 02:20:25.530172
NCT00638001|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2014-07-10|2008-03-17|2008-03-18|Estimate|||||||2014-07-10|2014-07-11|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy||Completed||Phase 4|70|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||t||||||||||2018-06-01 02:20:25.825334|2018-06-01 02:20:25.825334
NCT00637988|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-01-20|2008-03-11|2008-03-18|Estimate|||||||2011-01-20|2011-01-21|Estimate|April 2002||2002-04-30|January 2011|2011-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Barrett's Esophagus - 315 - 3 Way Cross Over|A Multicenter, Open-label, Four-way Crossover Study of the Effects of Esomeprazole, Aspirin and Rofecoxib on Prostaglandin (PGE2) Production, Cyclooxygenase-2 Enzyme Activity and PCNA Expression in Patients With Barrett's Esophagus|Completed||Phase 4|32|Anticipated|AstraZeneca||4|||f||||||||||||||2018-06-01 02:20:25.903316|2018-06-01 02:20:25.903316
NCT00637975|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2011-02-01|2008-03-17|2008-03-18|Estimate|||||||2011-02-01|2011-02-02|Estimate|September 2007||2007-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain|Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain|Completed||Phase 2|80|Anticipated|Associazione Progetto Oncologia UMAN.A||2|||f||||t||||||||||2018-06-01 02:20:26.040383|2018-06-01 02:20:26.040383
NCT00637962|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-02-10|2008-03-11|2008-03-18|Estimate|||||||2011-02-10|2011-02-11|Estimate|September 2007||2007-09-30|February 2011|2011-02-28|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|SG06RS02||Reactogenicity and Immunogenicity of Vaginal CNgp140|Phase I Clinical Trial in Healthy Female Volunteers of Reactogenicity and Immunogenicity of Nine Vaginal Immunisations With HIV CN54gp140 Glycoprotein|Terminated||Phase 1|23|Actual|St George's, University of London||2||IMP expired prior to completion of recruitment|f||||f||||||||||2018-06-01 02:20:26.145671|2018-06-01 02:20:26.145671
NCT00637949|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-17|2008-03-17|2008-03-18|Estimate|||||||2008-03-17|2008-03-18|Estimate|December 2000||2000-12-31|March 2008|2008-03-31|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Safety of Lumiracoxib in Patients With Osteoarthritis|A 6-Week Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Clinical Saftey Study to Evaluate Incidence of Predefined Gastrointestinal Adverse Events and Peripheral Edema in Subjects With Primary Osteoarthritis Treated With COX189 400 mg o-do Using Rofecoxib 25 mg o.d. as a Comparator|Completed||Phase 3|309|Actual|Novartis||2|||||||||||||||||2018-06-01 02:20:26.235492|2018-06-01 02:20:26.235492
NCT00637936|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2009-01-09|2008-03-10|2008-03-18|Estimate|||||||2009-01-09|2009-01-12|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Respiratory Effects of Perioperative Oxygen During General Anaesthesia|Perioperative Oxygen Fraction - Effects on the PaO2/FiO2-Index During Laparotomy|Completed||Phase 4|35|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 02:20:26.2994|2018-06-01 02:20:26.2994
NCT00637923|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2013-11-18||2014-01-09|2008-03-11|2008-03-18|Estimate|2013-11-18|2014-01-06|Estimate||||2014-01-09|2014-02-10|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|STEALTHC-3||Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients|Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C|Completed||Phase 2|112|Actual|Romark Laboratories L.C.||2|||f||||t||||||||||2018-06-01 02:20:26.393404|2018-06-01 02:20:26.393404
NCT00637910|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2012-02-23|2008-03-12|2008-03-18|Estimate|||||||2012-02-23|2012-02-24|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|February 2013|Anticipated|2013-02-28|February 2012|Anticipated|2012-02-29||Interventional|TAILOR||Tarceva Italian Lung Optimization tRial|Optimization of Erlotinib for the Treatment of Patients With Advanced Non Small Cell Lung Cancer: an Italian Randomized Trial|Unknown status|Recruiting|Phase 3|850|Anticipated|Fatebenefratelli and Ophthalmic Hospital||2|||f||||t||||||||||2018-06-01 02:20:27.011389|2018-06-01 02:20:27.011389
NCT00637897|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2017-05-25|2008-03-17|2008-03-18|Estimate|||||||2017-05-25|2017-05-30|Actual|March 2008||2008-03-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|November 2011|Actual|2011-11-30||Interventional|||Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer|Feasibility of Dose Titrating Paricalcitol (Zemplar) in Women Receiving Taxanes or Ixabepilone for Metastatic Breast Cancer|Completed||Phase 1|24|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-06-01 02:20:27.3848|2018-06-01 02:20:27.3848
NCT00637884|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2011-01-10|2008-03-17|2008-03-18|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2003||2003-11-30|January 2011|2011-01-31|February 2004|Actual|2004-02-29|||||Interventional|||A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms|Completed||Phase 4|70|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:27.464142|2018-06-01 02:20:27.464142
NCT00637871|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2011-01-21|2008-03-17|2008-03-18|Estimate|||||||2011-01-21|2011-01-24|Estimate|November 2002||2002-11-30|January 2011|2011-01-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Casodex - Nolvadex Combination|Randomised, Double-blind, Placebo Controlled, Parallel-group, Multicentre Phase II Study to Assess Dose Response Relationship of Nolvadex (Oral Tablet) in Prophylactic Treatment of Gynaecomastia and Breast Pain Associated With CASODEX 150 mg (Oral Tablet), and to Assess the Tumour Control…..|Completed||Phase 2|||AstraZeneca||2|||||||||||||||||2018-06-01 02:20:27.521801|2018-06-01 02:20:27.521801
NCT00637858|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2013-01-06|2008-03-17|2008-03-18|Estimate|||||||2013-01-06|2013-01-08|Estimate|October 2008||2008-10-31|July 2009|2009-07-31|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Different Doses of Tomato Lycopene on Blood Pressure in Pre-hypertensive Otherwise Healthy Subjects|Effect of Different Doses of Tomato Lycopene on the Blood Pressure in Prehypertensives and Grade I Never Treated Otherwise Healthy Subjects|Terminated||N/A|130|Actual|Soroka University Medical Center||5||difficulty to enroll more subjects|f||||f||||||||||2018-06-01 02:20:27.592975|2018-06-01 02:20:27.592975
NCT00637845|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-01-20|2008-03-11|2008-03-18|Estimate|||||||2011-01-20|2011-01-21|Estimate|June 2002||2002-06-30|January 2011|2011-01-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)|A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy|Completed||Phase 4|248|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:20:27.664558|2018-06-01 02:20:27.664558
NCT00637832|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2009-10-06|2008-03-14|2008-03-18|Estimate|||||||2009-10-06|2009-10-07|Estimate|April 2008||2008-04-30|July 2009|2009-07-31||||March 2010|Anticipated|2010-03-31||Interventional|||Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma|Short Chemo Radiotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab Tiuxetan (ZevalinTM) as Therapy for First and Second Relapse in Follicular Lymphoma|Unknown status|Recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:20:27.739142|2018-06-01 02:20:27.739142
NCT00637819|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-27|2008-03-17|2008-03-18|Estimate|||||||2008-03-27|2008-03-28|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|July 2004|Actual|2004-07-31|||||Interventional|||Leflunomide in Systemic Lupus Erythematosus|A Randomized, Double-Blind, Placebo Controlled Clinical Trial of Leflunomide in Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|27|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:27.820879|2018-06-01 02:20:27.820879
NCT00637806|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2016-01-29||2016-03-31|2008-03-11|2008-03-18|Estimate|2016-03-31|2016-05-02|Estimate||||2016-03-31|2016-05-02|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional||All subjects who received at least 1 dose of study medication and who had at least 1 on-therapy safety assessment|Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension|A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects With Cancer of Multiple Types|Terminated||Phase 3|4|Actual|Par Pharmaceutical, Inc.||3||Difficulty finding the required patient population|f||||f||||||||||2018-06-01 02:20:27.972895|2018-06-01 02:20:27.972895
NCT00637793|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2009-01-28|2008-03-11|2008-03-18|Estimate|||||||2009-01-28|2009-01-29|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|November 2008|Actual|2008-11-30|||||Interventional|||Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome|A Double-Blind, Placebo-Controlled, Cross Over Study Using a Latin Square Design to Evaluate the Safety, Tolerability, and Efficacy of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjogren's Syndrome|Completed||Phase 2|24|Anticipated|TorreyPines Therapeutics||4|||f||||f||||||||||2018-06-01 02:20:28.548928|2018-06-01 02:20:28.548928
NCT00637780|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2016-09-20||2017-01-03|2008-03-11|2008-03-18|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|June 2010||2010-06-30|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||The only 2 participants who were enrolled and completed the study at study termination were included in all analyses.|Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis|An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis|Terminated||Phase 4|2|Actual|Pfizer|The study was terminated prematurely and only 2 participants were enrolled and completed the study.|1||"Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns~   contributed to the termination of the study"|f||||f||||||||||2018-06-01 02:20:28.66535|2018-06-01 02:20:28.66535
NCT00637767|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2009-07-07|2008-03-14|2008-03-18|Estimate|||||||2009-07-07|2009-07-08|Estimate|December 2007||2007-12-31|July 2009|2009-07-31||||December 2010|Anticipated|2010-12-31||Interventional|||High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant|A Randomised Phase II Clinical Trial Using Targeted Radiotherapy Delivered by an Yttrium-90 Radio-Labelled Anti-CD66 Monoclonal Antibody With High Dose Melphalan Compared to Melphalan Alone, Prior to Autologous Stem Cell Transplantation for Multiple Myeloma|Unknown status|Recruiting|Phase 2|90|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:20:28.96599|2018-06-01 02:20:28.96599
NCT00637754|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2015-06-10|2008-03-11|2008-03-18|Estimate|||||||2015-06-10|2015-06-11|Estimate|September 2006||2006-09-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Safety of Sports for Patients With Implantable Cardioverter-Defibrillators|Safety of Sports for Patients With Implantable Cardioverter-Defibrillators: A Multi-Center Registry|Completed|||400|Actual|Yale University|||||f||||t||||||||||2018-06-01 02:20:29.110233|2018-06-01 02:20:29.110233
NCT00637741|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2010-11-30|2008-03-17|2008-03-18|Estimate|||||||2010-11-30|2010-12-01|Estimate|March 2008||2008-03-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|September 2009|Actual|2009-09-30||Interventional|||DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions|Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions|Completed||Phase 4|100|Actual|Flanders Medical Research Program||1|||f||||f||||||||||2018-06-01 02:20:29.323913|2018-06-01 02:20:29.323913
NCT00637728|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2016-01-29||2016-05-18|2008-03-11|2008-03-18|Estimate|2016-01-29|2016-02-29|Estimate||||2016-05-18|2016-06-23|Estimate|June 2006||2006-06-30|May 2016|2016-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional||All subjects who received at least 1 dose of study medication and who had at least 1 on-therapy safety assessment|Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients|A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects With Lung or Pancreatic Cancer|Terminated||Phase 3|5|Actual|Par Pharmaceutical, Inc.||2||Difficulty finding the required patient population|f||||f||||||||||2018-06-01 02:20:29.413507|2018-06-01 02:20:29.413507
NCT00637715|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-04-01|2008-03-17|2008-03-18|Estimate|||||||2008-04-01|2008-04-03|Estimate|October 2003||2003-10-31|April 2008|2008-04-30|December 2004|Actual|2004-12-31|||||Interventional|||Once Daily Given Alfuzosin in the Treatment of BPH|Evaluation of the Effect of 10 mg Alfuzosin (Alfetim Uno®) o. d. in Patients Presenting Low-Urinary Tract Symptoms|Completed||Phase 4|60|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:20:30.02002|2018-06-01 02:20:30.02002
NCT00637702|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2013-02-15|2008-03-12|2008-03-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of ARRY-334543 in Patients With Advanced Cancer||Completed||Phase 1|31|Actual|Array BioPharma||1|||f||||||||||||||2018-06-01 02:20:30.08639|2018-06-01 02:20:30.08639
NCT00637689|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2017-11-22|2008-03-17|2008-03-18|Estimate|||||||2017-11-22|2017-11-27|Actual|September 2007||2007-09-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2014|Actual|2014-05-31||Observational|||Improving Outcomes Assessment in Chronic GVHD|Improving Outcomes Assessment in Chronic GVHD|Active, not recruiting|||601|Actual|Fred Hutchinson Cancer Research Center|||||f||||f||||||Samples With DNA|"~     Some centers are collecting serum, plasma, cells and urine.~   "|||2018-06-01 02:20:30.158252|2018-06-01 02:20:30.158252
NCT00637676|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-09-22|2008-03-17|2008-03-18|Estimate|||||||2011-09-22|2011-09-23|Estimate|July 2008||2008-07-31|March 2008|2008-03-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Tunneled Pleural Catheter in Partially Entrapped Lung|Randomized Trial of Tunneled Pleural Catheter Versus Standard Chest Tube in Management of Malignant Pleural Effusion in Patients With Partial Entrapment of the Lung|Completed||Phase 2|50|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-06-01 02:20:30.241693|2018-06-01 02:20:30.241693
NCT00637663|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2015-03-04|2008-03-11|2008-03-18|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2008||2008-02-29|March 2015|2015-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA|Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA|Completed||Phase 4|72|Actual|Pusan National University Hospital||2|||f||||t||||||||||2018-06-01 02:20:30.377915|2018-06-01 02:20:30.377915
NCT00567983|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2008-09-23|2007-12-04|2007-12-05|Estimate|||||||2008-09-23|2008-09-25|Estimate|December 2007||2007-12-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Topical Cyclosporine and Disease Progression|Topical Cyclosporine and Disease Progression|Completed||Phase 4|80|Anticipated|Innovative Medical||2|||f||||||||||||||2018-06-01 02:41:56.362981|2018-06-01 02:41:56.362981
NCT00637650|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2009-02-09|2008-03-12|2008-03-18|Estimate|||||||2009-02-09|2009-02-10|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Management of Fragments During Ureteroscopy|"Should we Strive for Absolute Stone Freedom While Performing Holmium Laser Lithotripsy for Ureteral Stones? A Randomized Controlled Trial."|Completed||N/A|||The Chaim Sheba Medical Center||2|||f||||||||||||||2018-06-01 02:20:30.497221|2018-06-01 02:20:30.497221
NCT00637637|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-14|||2013-08-09|2008-03-14|2008-03-18|Estimate|||||||2013-08-09|2013-08-12|Estimate|September 2007||2007-09-30|December 2008|2008-12-31||||June 2009|Anticipated|2009-06-30||Interventional|||External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases|Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study|Unknown status|Recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:20:30.59532|2018-06-01 02:20:30.59532
NCT00637624|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-08-08|2008-03-17|2008-03-18|Estimate|||||||2011-08-08|2011-08-09|Estimate|March 2008||2008-03-31|August 2011|2011-08-31|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|NAC-PNP||N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy|A Randomized Double-blind Study of N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy in Patients Treated for (Non)Small Cell Lung Cancer and Malignant Mesothelioma|Unknown status|Recruiting|N/A|50|Anticipated|Rijnstate Hospital||2|||f||||||||||||||2018-06-01 02:20:30.733949|2018-06-01 02:20:30.733949
NCT00637611|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2011-01-11|2008-03-11|2008-03-18|Estimate|||||||2011-01-11|2011-01-12|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|April 2003|Actual|2003-04-30|||||Interventional|||Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit|Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit (Study I)|Completed||Phase 4|1010|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:30.827308|2018-06-01 02:20:30.827308
NCT00637598|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2017-04-11|2008-03-17|2008-03-18|Estimate|||||||2017-04-11|2017-04-13|Actual|November 2004||2004-11-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Early Detection of Breast Cancer Using Tomosynthesis Imaging|Early Detection of Breast Cancer Using Tomosynthesis Imaging|Completed||N/A|385|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:20:30.883053|2018-06-01 02:20:30.883053
NCT00637585|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2011-01-10|2008-03-11|2008-03-18|Estimate|||||||2011-01-10|2011-01-11|Estimate|December 2002||2002-12-31|January 2011|2011-01-31|July 2003|Actual|2003-07-31|||||Interventional|||Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine|A Comparison of Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine|Completed||Phase 4|42|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:30.956582|2018-06-01 02:20:30.956582
NCT00637572|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2016-01-29||2017-09-07|2008-03-11|2008-03-18|Estimate|2016-03-18|2016-04-20|Estimate||||2017-09-07|2017-10-05|Actual|December 2004||2004-12-31|September 2017|2017-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional||Analysis based on Intend to Treat (ITT) population; all randomized subjects who were dispensed medication and had at least one post-randomization visit.|Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss|A Randomized, Open-labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace)|Completed||Phase 2|63|Actual|Endo Pharmaceuticals||2|||f||||f||||||||No||2018-06-01 02:20:31.031082|2018-06-01 02:20:31.031082
NCT00637559|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-01-24|2008-03-11|2008-03-18|Estimate|||||||2011-01-24|2011-01-25|Estimate|March 2002||2002-03-31|January 2011|2011-01-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Barrett's Esophagus - 315 - 3 Way Cross-Over|A Multicenter, Double-blind, Three-way Crossover Intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients|Completed||Phase 4|50|Anticipated|AstraZeneca||3|||f||||||||||||||2018-06-01 02:20:31.876379|2018-06-01 02:20:31.876379
NCT00637546|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2010-01-13|2008-03-11|2008-03-18|Estimate|||||||2010-01-13|2010-01-14|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||Gait and Balance of Diabetes Type 2 Patients|Efficacy of a Specific Physiotherapy Group Treatment on Gait and Balance in Patients With Diabetic Neuropathy|Completed||Phase 2/Phase 3|71|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-06-01 02:20:31.961332|2018-06-01 02:20:31.961332
NCT00637533|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-01-18|2008-03-17|2008-03-18|Estimate|||||||2011-01-18|2011-01-19|Estimate|May 2004||2004-05-31|January 2011|2011-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.|A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.|Completed||N/A|10|Actual|Stanford University||2|||f||||||||||||||2018-06-01 02:20:32.046284|2018-06-01 02:20:32.046284
NCT00637520|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2017-07-10|2008-03-17|2008-03-18|Estimate|||||||2017-07-10|2017-07-11|Actual|July 2007||2007-07-31|September 2016|2016-09-30|April 13, 2017|Actual|2017-04-13|March 29, 2013|Actual|2013-03-29||Observational|||Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study|Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study|Terminated|||29|Actual|Duke University|||3||f||||f||||||Samples With DNA|"~     Frozen tissue, serum, whole blood, urine~   "|||2018-06-01 02:20:32.138596|2018-06-01 02:20:32.138596
NCT00637507|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2016-11-18|2008-03-11|2008-03-18|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|HFO-TGI-2||Study of a Novel Technique of Mechanical Ventilation in Patients With Severe Acute Respiratory Failure|Phase II/Phase III Study of the Effect of Combined High-frequency Oscillation and Tracheal Gas Insufflation on the Survival to Hospital Discharge of Patients With Severe Acute Respiratory Distress Syndrome|Completed||Phase 2/Phase 3|124|Actual|University of Athens||2|||f||||t||||||||||2018-06-01 02:20:32.232126|2018-06-01 02:20:32.232126
NCT00637494|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2016-12-23||2017-05-04|2008-03-12|2008-03-18|Estimate|2016-12-23|2017-02-16|Actual||||2017-05-04|2017-06-05|Actual|March 2008||2008-03-31|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features|A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features|Terminated||Phase 3|292|Actual|Corcept Therapeutics||2||DRC recommended stopping study as it had missed its primary endpoint|f||||t||||||||No||2018-06-01 02:20:32.35769|2018-06-01 02:20:32.35769
NCT00637481|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-17|||2016-12-28|2008-03-17|2008-03-18|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2008||2008-03-31|December 2016|2016-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer|A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer|Completed||Phase 1|66|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 02:20:32.720041|2018-06-01 02:20:32.720041
NCT00637468|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-17|2008-03-17|2008-03-18|Estimate|||||||2008-03-17|2008-03-18|Estimate|September 2002||2002-09-30|March 2008|2008-03-31||||||||Interventional|EAGLE||EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye|Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie|Terminated||Phase 3|84|Actual|University Hospital Freiburg||2||"Due to results of conditional power analysis performed at the first interim analysis and due to~   observed spectrum of adverse events."|f||||t||||||||||2018-06-01 02:20:32.806444|2018-06-01 02:20:32.806444
NCT00637455|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2011-01-10|2008-03-17|2008-03-18|Estimate|||||||2011-01-10|2011-01-11|Estimate|September 2003||2003-09-30|January 2011|2011-01-31|January 2005|Actual|2005-01-31|||||Interventional|||Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel|Single Center, Randomized,Double-Blind,Crossover Study Comparing the Effects of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel|Completed||Phase 4|72|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:32.918882|2018-06-01 02:20:32.918882
NCT00637442|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2010-11-08|2008-03-11|2008-03-18|Estimate|||||||2010-11-08|2010-11-09|Estimate|February 2008||2008-02-29|July 2010|2010-07-31||||December 2010|Anticipated|2010-12-31||Interventional|CASL-AD-01||Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)|Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)|Unknown status|Active, not recruiting|N/A|30|Anticipated|University Hospital, Bonn||1|||f||||f||||||||||2018-06-01 02:20:32.978051|2018-06-01 02:20:32.978051
NCT00637429|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-04-01|2008-03-11|2008-03-18|Estimate|||||||2008-04-01|2008-04-02|Estimate|November 2007||2007-11-30|March 2008|2008-03-31||||||||Observational|||HIV-HBV Co-Infection and Liver Disease|Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) co-Infection and Liver Disease|Unknown status|Recruiting||70|Anticipated|Bayside Health|||1||f||||f||||||Samples Without DNA|"~     serum samples~   "|||2018-06-01 02:20:33.04678|2018-06-01 02:20:33.04678
NCT00637416|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2016-10-05||2016-11-29|2008-03-10|2008-03-18|Estimate|2016-11-29|2017-01-23|Estimate||||2016-11-29|2017-01-23|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness|The Effect of Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness|Terminated||Phase 4|9|Actual|University of Kansas Medical Center||2||Enrollment challenges|f||||f||||||||||2018-06-01 02:20:33.12388|2018-06-01 02:20:33.12388
NCT00637403|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2016-10-13|2008-03-17|2008-03-18|Estimate|||||||2016-10-13|2016-10-17|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension|An Open-Label, Single-Dose Study to Assess the Effect of Renal Impairment on the Pharmacokinetic Characteristics, Safety, and Tolerability of Megestrol Acetate|Terminated||Phase 1|7|Actual|Par Pharmaceutical, Inc.||5||Difficulty finding the required subject population|f||||f||||||||||2018-06-01 02:20:33.359802|2018-06-01 02:20:33.359802
NCT00637390|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2016-12-01|2008-03-17|2008-03-18|Estimate|||||||2016-12-01|2016-12-02|Estimate|March 2008||2008-03-31|December 2016|2016-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.|A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.|Terminated||Phase 1|3|Actual|University of Michigan Cancer Center||1||"Genzyme will no longer supply the study drug for this trial as it does not believe the study~   will not fully enroll within an appropriate time frame."|f||||t||||||||||2018-06-01 02:20:33.437317|2018-06-01 02:20:33.437317
NCT00637377|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2011-12-16||2014-11-28|2008-03-17|2008-03-18|Estimate|2011-12-16|2012-01-23|Estimate||||2014-11-28|2014-12-12|Estimate|April 2008||2008-04-30|November 2014|2014-11-30|August 2011|Actual|2011-08-31|September 2010|Actual|2010-09-30||Interventional|VIEW 2||Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)|A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)|Completed||Phase 3|1240|Actual|Bayer|The conditional sequence of hypothesis testing had to stop after testing the first superiority hypothesis. Therefore, all further statistical tests are exploratory tests.|4|||f||||t||||||||||2018-06-01 02:20:33.620198|2018-06-01 02:20:33.620198
NCT00637364|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2009-01-12|2008-03-12|2008-03-18|Estimate|||||||2009-01-12|2009-01-13|Estimate|March 2008||2008-03-31|January 2009|2009-01-31||||July 2010|Anticipated|2010-07-31||Interventional|HIFU Pancreas||High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain|An Open Label, Non-Randomized, Single-Center, Therapeutic Trial Examining the Feasibility, Safety, and Efficacy of FEP-BY02, a High Intensity Focused Ultrasound Tumor Treatment Device, in Patients With Pancreatic Cancer Pain|Suspended||Phase 1/Phase 2|5|Anticipated|CMED HIFU Development Corporation||||Sponsor is not proceeding with USA human trial at this time|f||||t||||||||||2018-06-01 02:20:37.083371|2018-06-01 02:20:37.083371
NCT00637351|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2014-01-09|2008-03-17|2008-03-18|Estimate|||||||2014-01-09|2014-01-13|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||A Study in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic Assays|A Study to Collect Blood and Urine Samples in Elderly Subjects With Pneumonia to Support the Development of Bacteriological Diagnostic Assays|Completed|||21|Actual|GlaxoSmithKline|||2||f||||||||||Samples With DNA|"~     whole blood, urine samples~   "|||2018-06-01 02:20:37.152822|2018-06-01 02:20:37.152822
NCT00637338|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2009-07-30|2008-03-10|2008-03-17|Estimate|||||||2009-07-30|2009-07-31|Estimate|April 2008||2008-04-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Placebo-Controlled, Sequential Parallel Group, Multiple Dose Escalation Trial To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of 4, Once-Weekly Subcutaneous Doses Of PF-04603629 To Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 1|42|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:20:37.226265|2018-06-01 02:20:37.226265
NCT00637325|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-03-10|2008-03-10|2008-03-17|Estimate|||||||2008-03-10|2008-03-17|Estimate|November 2007||2007-11-30|March 2008|2008-03-31|April 2011|Anticipated|2011-04-30|May 2009|Anticipated|2009-05-31||Interventional|TOP||Trastuzumab Optimization Trial in Breast Cancer|TOP Trial. A Randomised Phase III Clinical Trial of Trastuzumab (Herceptin) Optimization in Patients With Locally Advanced and/or Metastatic Breast Cancer Overexpressing HER2 After a First Line Chemotherapy Plus Trastuzumab.|Unknown status|Recruiting|Phase 3|500|Anticipated|Regione Lombardia||2|||f||||||||||||||2018-06-01 02:20:37.317455|2018-06-01 02:20:37.317455
NCT00637312|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2014-02-12||2014-02-12|2008-03-14|2008-03-17|Estimate|2014-02-12|2014-03-27|Estimate||||2014-02-12|2014-03-27|Estimate|March 2008||2008-03-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|July 2011|Actual|2011-07-31||Interventional|||Advent™ Cervical Disc Versus ACDF for Treatment of One Level Degenerative Disc Disease (IDE Study)|Clinical Trial Comparing the Blackstone Advent™ Cervical Disc to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of One Level Degenerative Disc Disease|Terminated||N/A|108|Actual|Orthofix Inc.|The study was suspended for a high rate of adverse events in the treatment group. Enrollment was stopped and patients were followed for 36 months in the Advent group. Approval is not being pursued and thus no analysis has been completed.|2||Greater-than-anticipated rate of revisions|f||||t||||||||||2018-06-01 02:20:37.447764|2018-06-01 02:20:37.447764
NCT00637299|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2009-01-05||2011-10-16|2008-03-14|2008-03-17|Estimate|2009-04-17|2009-04-20|Estimate||||2011-10-16|2011-10-24|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|||Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial|Osteopathic Treatment May Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease|Completed||Early Phase 1|20|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||||2018-06-01 02:20:37.805361|2018-06-01 02:20:37.805361
NCT00637286|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2009-04-03|2008-03-10|2008-03-17|Estimate|||||||2009-04-03|2009-04-06|Estimate|July 2004||2004-07-31|April 2009|2009-04-30|May 2005|Actual|2005-05-31|||||Interventional|||ZAP, US. Zomig for Appropriate for Primary Care|A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated.|Completed||Phase 4|120|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:20:38.05601|2018-06-01 02:20:38.05601
NCT00637273|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2012-02-14|2011-06-17|2015-03-19|2008-03-10|2008-03-17|Estimate|2012-05-15|2012-06-19|Estimate|2011-06-17|2011-06-27|Estimate|2015-03-19|2015-04-07|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)|A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin|Completed||Phase 3|514|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:20:38.142658|2018-06-01 02:20:38.142658
NCT00637260|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2015-09-01|2008-03-10|2008-03-17|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2007||2007-12-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Motor Cortex Stimulation for Parkinson's Disease|Motor Cortex Stimulation for Parkinson's Disease. A Prospective Double Blind Randomized Study With Cross-over|Completed||N/A|13|Actual|Catholic University, Italy||2|||f||||t||||||||||2018-06-01 02:20:39.012375|2018-06-01 02:20:39.012375
NCT00637247|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2010-09-17||2018-01-11|2008-03-10|2008-03-17|Estimate|2010-11-29|2010-11-30|Estimate||||2018-01-11|2018-01-16|Actual|April 2008||2008-04-30|January 2018|2018-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer|A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)|Completed||Phase 2|142|Actual|AmpliMed Corporation||2|||f||||t||||||||||2018-06-01 02:20:39.120048|2018-06-01 02:20:39.120048
NCT00637234|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2008-07-23|2008-03-10|2008-03-17|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2004||2004-07-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|OXC-SCZ||Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia|Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia|Completed||Phase 2/Phase 3|54|Actual|University of Cologne||2|||f||||t||||||||||2018-06-01 02:20:39.704394|2018-06-01 02:20:39.704394
NCT00637221|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2012-04-26|2008-03-10|2008-03-17|Estimate|||||||2012-04-26|2012-04-27|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome|An Open Label Exploratory Study to Investigate the Safety and Effects of NPL-2009 ( 50 mg - 150 mg Single Dose) on Prepulse Inhibition Tests and Continuous Performance Tasks, in Adults With Fragile X Syndrome|Completed||Phase 1/Phase 2|12|Actual|Neuropharm|||||f||||t||||||||||2018-06-01 02:20:39.803076|2018-06-01 02:20:39.803076
NCT00637208|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2008-03-14|2008-03-14|2008-03-17|Estimate|||||||2008-03-14|2008-03-17|Estimate|November 2007||2007-11-30|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Sclerotherapy of Internal Spermatic Veins in Patients With Varicocele and Localized Prostate Cancer|Selective Retrograde Venography and Sclerotherapy of Internal Spermatic Veins and Associated Venous Bypasses and Retro-Peritoneal Collateral in Patients With Bilateral Varicocele and Localized Prostate Cancer|Completed||N/A|10|Actual|Maaynei Hayesha Medical Center||2|||f||||f||||||||||2018-06-01 02:20:39.867781|2018-06-01 02:20:39.867781
NCT00637195|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2009-11-12||2016-10-11|2008-03-10|2008-03-17|Estimate|2009-11-12|2009-12-18|Estimate||||2016-10-11|2016-11-23|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)|Evaluation of the Immunogenicity and Safety of a Commercially Available Vaccine When Co-administered With GlaxoSmithKline Biologicals' HPV Vaccine (580299) in Healthy Female Subjects.|Completed||Phase 3|152|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:20:39.959308|2018-06-01 02:20:39.959308
NCT00637182|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-03-10|2008-03-10|2008-03-17|Estimate|||||||2008-03-10|2008-03-17|Estimate|January 2001||2001-01-31|March 2008|2008-03-31|October 2002|Actual|2002-10-31|June 2002|Actual|2002-06-30||Interventional|||Gynecomastia Extension Study|An OptioExtension of Trial 1033US/0006 to Assess Safety, Tolerability, Efficacy of Anastrozole (ZD1033, Arimidex™) in Treatment of Gynecomastia in Pubertal Boys Given Placebo and to Conduct a Long-Term Safety Follow-Up of Non-Responding Subjects Given Anastrozole in the Previous Trial|Completed||Phase 3|||AstraZeneca|||||||||f||||||||||2018-06-01 02:20:40.464223|2018-06-01 02:20:40.464223
NCT00637169|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2018-03-20|2008-03-10|2008-03-17|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2006||2006-12-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|COT||Canadian Oxygen Trial (COT)|Efficacy and Safety of Targeting Lower Arterial Oxygen Saturations to Reduce Oxygen Toxicity and Oxidative Stress in Very Preterm Infants: The Canadian Oxygen Trial (COT)|Completed||Phase 3|1201|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 02:20:40.519493|2018-06-01 02:20:40.519493
NCT00637156|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2016-08-02|2011-12-07|2018-04-03|2008-03-10|2008-03-17|Estimate|2016-09-27|2016-11-18|Estimate|2011-12-07|2011-12-22|Estimate|2018-04-03|2018-05-01|Actual|June 2006||2006-06-30|October 2017|2017-10-31|February 1, 2018|Actual|2018-02-01|January 2011|Actual|2011-01-31||Interventional|||Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels|A Prospective, Randomized, Controlled, Multicenter Pivotal Clinical Trial of the Artificial Cervical Disc-LP at Two Levels for Symptomatic Cervical Disc Disease|Completed||N/A|397|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 02:20:40.693052|2018-06-01 02:20:40.693052
NCT00637143|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2017-02-15|2008-03-14|2008-03-17|Estimate|||||||2017-02-15|2017-02-16|Actual|April 1999||1999-04-30|February 2017|2017-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)|Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure|Completed||Phase 4|107|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:20:43.06574|2018-06-01 02:20:43.06574
NCT00637130|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29||2012-12-03|2012-12-04|2008-03-10|2008-03-17|Estimate||||2012-12-03|2012-12-05|Estimate|2012-12-04|2012-12-06|Estimate|October 2007||2007-10-31|December 2012|2012-12-31||||January 2008|Actual|2008-01-31||Interventional|||Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost|Safety and IOP Lowering Efficacy of Low Dose Travoprost Ophthalmic Solutions Dosed BID Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|138|Actual|Alcon Research||5|||f||||f||||||||||2018-06-01 02:20:43.184162|2018-06-01 02:20:43.184162
NCT00637117|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2017-06-09|2008-03-14|2008-03-17|Estimate|||||||2017-06-09|2017-06-12|Actual|July 2008||2008-07-31|June 2017|2017-06-30|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.|A Phase I/II Study of Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.|Withdrawn||Phase 1/Phase 2|0|Actual|Baylor Research Institute||||The study never opened and not sure if it ever will.|f||||t||||||||||2018-06-01 02:20:43.246295|2018-06-01 02:20:43.246295
NCT00637104|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2010-02-08|2008-03-14|2008-03-17|Estimate|||||||2010-02-08|2010-02-09|Estimate|July 2008||2008-07-31|February 2010|2010-02-28|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|MARTIN||European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent|A European Multicenter, Randomized, Single Blind Study of the MAR-Tyn Cobalt Chromium TiN-Coated Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions|Unknown status|Recruiting|Phase 2/Phase 3|160|Anticipated|International Biomedical Systems S.p.A.||2|||f||||t||||||||||2018-06-01 02:20:43.296075|2018-06-01 02:20:43.296075
NCT00637091|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2014-07-17|2008-03-10|2008-03-17|Estimate|||||||2014-07-17|2014-07-18|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Interventional|||Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions|A Phase II Trial of Cetuximab Plus Irinotecan as a 2nd-line Treatment in Patients With Metastatic Colorectal Cancer After Failure to Irinotecan That Express Wild-type KRAS With and Without Detectable EGFR Expression|Completed||Phase 2|40|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 02:20:43.490263|2018-06-01 02:20:43.490263
NCT00637078|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2012-06-13|2008-03-14|2008-03-17|Estimate|||||||2012-06-13|2012-06-14|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|STITCH2||STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia)|Evaluation of a Primary Treatment Algorithm Using Combination Therapy for the Management of Patients With Hypertension and Hypercholesterolemia|Completed||Phase 4|1000|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-06-01 02:20:43.557267|2018-06-01 02:20:43.557267
NCT00637065|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2008-03-10|2008-03-10|2008-03-17|Estimate|||||||2008-03-10|2008-03-17|Estimate|April 2008||2008-04-30|March 2008|2008-03-31|August 2010|Anticipated|2010-08-31|April 2010|Anticipated|2010-04-30||Interventional|B-PHIT||Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study|Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study.|Unknown status|Not yet recruiting|Phase 4|48|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 02:20:43.628112|2018-06-01 02:20:43.628112
NCT00637052|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22||2012-01-13|2012-09-19|2008-03-14|2008-03-17|Estimate||||2012-01-13|2012-01-19|Estimate|2012-09-19|2012-09-26|Estimate|February 2008||2008-02-29|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia||Completed||Phase 1/Phase 2|36|Actual|Array BioPharma||1|||f||||||||||||||2018-06-01 02:20:43.741817|2018-06-01 02:20:43.741817
NCT00637039|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2013-03-11|2008-03-10|2008-03-17|Estimate|||||||2013-03-11|2013-03-12|Estimate|February 2008||2008-02-29|March 2013|2013-03-31|December 2012|Actual|2012-12-31|June 2009|Actual|2009-06-30||Interventional|||Study of AZD8931 in Patients With Advanced Solid Malignancies|A Phase 1, Open-label, Multiple-dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies|Completed||Phase 1|41|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:20:43.855091|2018-06-01 02:20:43.855091
NCT00637026|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2009-04-22|2008-03-14|2008-03-17|Estimate|||||||2009-04-22|2009-04-23|Estimate|July 2003||2003-07-31|April 2009|2009-04-30|February 2005|Actual|2005-02-28|||||Interventional|||Ph II Early BC Pre-Surgical Biologic Study|A PreSurgical Study to Evaluate Molecular Alterations That Occur in Human Breast Cancer Tissue and Normal Skin After Short Term Exposure to ZD1839 (IRESSA) and to Correlate These Alterations With Pharmacokinetic Parameters.|Completed||Phase 2|65|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:20:43.936292|2018-06-01 02:20:43.936292
NCT00637013|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2017-11-14|2008-03-10|2008-03-17|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2008|Actual|2008-06-30|November 2017|2017-11-30|January 2027|Anticipated|2027-01-31|January 2017|Actual|2017-01-31||Interventional|||Operative Versus Non-operative Management of Subacromial Impingement|The Effectiveness and Cost-effectiveness of Operative Versus Non-operative Management of Subacromial Impingement|Active, not recruiting||N/A|100|Anticipated|Central Finland Hospital District||2|||f||||t||||||||Undecided||2018-06-01 02:20:44.027715|2018-06-01 02:20:44.027715
NCT00637000|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2010-09-30|2010-09-30|2017-04-24|2008-03-10|2008-03-17|Estimate|2014-04-09|2014-05-09|Estimate|2014-04-09|2014-05-09|Estimate|2017-04-24|2017-06-05|Actual|March 2008||2008-03-31|April 2017|2017-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone|Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone|Completed||Phase 2|38|Actual|Indivior Inc.||2|||f||||f||||||||||2018-06-01 02:20:44.273459|2018-06-01 02:20:44.273459
NCT00636987|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2016-10-14||2017-04-26|2008-03-10|2008-03-17|Estimate|2017-04-26|2017-06-02|Actual||||2017-04-26|2017-06-02|Actual|April 2007||2007-04-30|September 2015|2015-09-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra|Post-Approval Study Protocol of the St. Jude Medical Biocor and Biocor Supra Valves|Completed||N/A|297|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 02:20:46.277837|2018-06-01 02:20:46.277837
NCT00636974|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-10-22|2008-03-14|2008-03-17|Estimate|||||||2013-10-22|2013-10-23|Estimate|January 2006||2006-01-31|October 2013|2013-10-31|July 2008|Actual|2008-07-31|||||Interventional|||A Randomised Comparison on the Dose Requirement Between, Levobupivacaine, Ropivacaine and Bupivacaine in Intrathecal Anaesthesia|Minimum Local Anaesthetic Dose for Intrathecal Anaesthesia: a Randomised Comparison Between Levobupivacaine, Ropivacaine and Bupivacaine|Completed||N/A|75|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:20:46.78124|2018-06-01 02:20:46.78124
NCT00636961|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2011-07-29||2011-07-29|2008-03-10|2008-03-17|Estimate|2011-07-29|2011-08-30|Estimate||||2011-07-29|2011-08-30|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)|An Exploratory, Double Blind, Randomized, Placebo-controlled, 2-way Cross-over Study to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With COPD|Completed||Phase 2|27|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:20:47.393848|2018-06-01 02:20:47.393848
NCT00636948|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-03-10|2008-03-10|2008-03-17|Estimate|||||||2008-03-10|2008-03-17|Estimate|December 1999||1999-12-31|March 2008|2008-03-31||||June 2005|Actual|2005-06-30||Observational|RECTODES||Rectal Cancer Trial On Defunctioning Stoma|Rectal Cancer Trial On Defunctioning Stoma|Completed|||234|Actual|Rectal Cancer Trial on Defunctioning Stoma Study Group|||||f||||t||||||||||2018-06-01 02:20:48.284156|2018-06-01 02:20:48.284156
NCT00636935|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-06-23|2008-03-14|2008-03-17|Estimate|||||||2017-06-23|2017-06-27|Actual|February 2008||2008-02-29|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)|Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of >70 at Presentation.|Withdrawn||Phase 4|0|Actual|George Washington University||3||No patient completed protocol|f||||f||||||||No||2018-06-01 02:20:48.365375|2018-06-01 02:20:48.365375
NCT00636922|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2013-02-12|2008-03-10|2008-03-17|Estimate|||||||2013-02-12|2013-02-15|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|January 2014|Anticipated|2014-01-31|July 2013|Anticipated|2013-07-31||Interventional|||Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia|A Phase I Dose Finding Study of Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia (AML) Unfit for Intensive Induction Chemotherapy|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Bayside Health||1|||f||||f||||||||||2018-06-01 02:20:48.749681|2018-06-01 02:20:48.749681
NCT00636909|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2017-04-05|2008-03-10|2008-03-17|Estimate|||||||2017-04-05|2017-04-06|Actual|July 1999||1999-07-31|April 2017|2017-04-30||||March 2006|Actual|2006-03-31||Interventional|MINI HEME||Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders|Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders|Completed||Phase 2|25|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-06-01 02:20:48.845778|2018-06-01 02:20:48.845778
NCT00636896|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2008-03-10|2008-03-10|2008-03-17|Estimate|||||||2008-03-10|2008-03-17|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effects of Modafinil on Olanzapine Weight Gain|A Comparison of the Effects of Modafinil on Olanzapine Associated Eating Behaviors in Normal Human Subjects|Completed||N/A|50|Actual|Neuropsychiatric Research Institute, Fargo, North Dakota||2|||f||||f||||||||||2018-06-01 02:20:48.961594|2018-06-01 02:20:48.961594
NCT00636883|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-08|||2014-01-19|2008-03-08|2008-03-17|Estimate|||||||2014-01-19|2014-01-22|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|GEMOX-T||Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer|Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer|Terminated||Phase 2|9|Actual|National Guard Health Affairs||||slow accrual rate|f||||t||||||||||2018-06-01 02:20:49.271822|2018-06-01 02:20:49.271822
NCT00636870|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2011-01-10|2008-03-14|2008-03-17|Estimate|||||||2011-01-10|2011-01-11|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|January 2004|Actual|2004-01-31|||||Interventional|||Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine|A Randomized, Double-blind, Repeat-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Desloratadine (Clarinex®) Compared to Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine.|Completed||Phase 4|220|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:20:49.381116|2018-06-01 02:20:49.381116
NCT00636857|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2013-06-11|2008-03-10|2008-03-17|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Postoperative Hyponatremia - Are There Gender Differences?|Postoperative Hyponatremia - Are There Gender Differences?|Unknown status|Recruiting|N/A|60|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-06-01 02:20:49.535294|2018-06-01 02:20:49.535294
NCT00636844|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2013-03-11|2008-03-14|2008-03-17|Estimate|||||||2013-03-11|2013-03-13|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Observational|||Detection of Chemotherapy Induced Cardiotoxicity|Detection of Chemotherapy Induced Cardiotoxicity|Completed|||36|Actual|George Washington University|||1||f||||f||||||Samples With DNA|"~     Blood sample for analysis of mRNA and oxidative stress markers~   "|||2018-06-01 02:20:49.771434|2018-06-01 02:20:49.771434
NCT00636831|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2012-02-06|2008-03-10|2008-03-17|Estimate|||||||2012-02-06|2012-02-07|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|RCT-herniation||Prophylactic Antibiotic Use in Hernioplasty|Prophylactic Antibiotic Use in Inguinal Hernioplasty: A Placebo-controlled, Double-blind Trial|Completed||Phase 3|400|Actual|Nihon University||2|||f||||||||||||||2018-06-01 02:20:49.864535|2018-06-01 02:20:49.864535
NCT00636818|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2009-09-18||2010-10-20|2008-03-07|2008-03-14|Estimate|2009-11-20|2009-12-23|Estimate||||2010-10-20|2010-11-04|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)|An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity Disorder|Completed||Phase 2|45|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:20:49.969088|2018-06-01 02:20:49.969088
NCT00636805|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2014-01-09||2014-03-04|2008-03-13|2008-03-14|Estimate|2014-03-04|2014-04-01|Estimate||||2014-03-04|2014-04-01|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab|A Phase II Single Arm Trial of Palonosetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan in Combination With Bevacizumab|Terminated||Phase 2|63|Actual|Duke University||1||Study was halted early after 63 subjects were enrolled due to slow accrual.|f||||f||||||||||2018-06-01 02:20:50.512945|2018-06-01 02:20:50.512945
NCT00636792|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2011-05-31||2012-01-11|2008-03-13|2008-03-14|Estimate|2011-05-31|2011-06-22|Estimate||||2012-01-11|2012-01-13|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|VERTICAL||A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma|A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma|Completed||Phase 2|73|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 02:20:50.821326|2018-06-01 02:20:50.821326
NCT00636779|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2011-06-12|2008-03-09|2008-03-14|Estimate|||||||2011-06-12|2011-06-14|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|BraveNet||BraveNet Integrative Medicine Descriptive Study|BraveNet Multi-Center Integrative Medicine Survey|Completed|||4340|Actual|Duke University|||1||f||||f||||||||||2018-06-01 02:20:51.096319|2018-06-01 02:20:51.096319
NCT00636766|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2012-11-01|2008-03-11|2008-03-14|Estimate|||||||2012-11-01|2012-11-02|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|||Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque|Atherosclerotic Plaque Texture-Experimental and Clinical Study on the Diagnostic and Therapeutic Strategies of Atherosclerotic Plaque Vulnerability|Completed||N/A|300|Actual|Aristotle University Of Thessaloniki||1|||f||||||||||||||2018-06-01 02:20:51.172464|2018-06-01 02:20:51.172464
NCT00636753|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2010-07-29|2008-03-13|2008-03-14|Estimate|||||||2010-07-29|2010-07-30|Estimate|September 2008||2008-09-30|July 2010|2010-07-31||||July 2009|Anticipated|2009-07-31||Observational|||Antipsychotics and Metabolic Syndrome||Suspended|||60|Anticipated|Glostrup University Hospital, Copenhagen|||2|this study has not finding place|f||||t||||||None Retained|"~     whole blood, serum/plasma~   "|||2018-06-01 02:20:51.260742|2018-06-01 02:20:51.260742
NCT00636740|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2009-02-19|2008-03-07|2008-03-14|Estimate|||||||2009-02-19|2009-02-20|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients|A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets To Intravenous Zometa 4mg in Male Bisphosphonate-Naive Hormone Refractory Prostate Cancer Patients|Completed||Phase 2|30|Actual|Merrion Pharmaceuticals, LLC||3|||f||||f||||||||||2018-06-01 02:20:51.326055|2018-06-01 02:20:51.326055
NCT00636727|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2013-11-19|2008-03-11|2008-03-14|Estimate|||||||2013-11-19|2013-11-21|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|TMJ||A Comparison of Arthrocentesis, Arthroscopy and Arthroplasty in the Treatment of Temporomandibular Joint Dysfunction|A Comparison of Arthrocentesis, Arthroscopy and Arthroplasty in the Treatment of Temporomandibular Joint Dysfunction|Completed||N/A|100|Actual|Emory University||3|||f||||f||||||||||2018-06-01 02:20:51.411078|2018-06-01 02:20:51.411078
NCT00636714|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2017-01-03|2008-03-07|2008-03-14|Estimate|||||||2017-01-03|2017-01-05|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Comparison of 2 Methods to Achieve Tight Glucose Control in Cardiovascular ICU Patients|Randomized Controlled Trial of Nurse-directed vs Nomogram-directed Intensive Glucose Control in the CVICU|Completed||Phase 4|40|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 02:20:51.496032|2018-06-01 02:20:51.496032
NCT00636701|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2014-11-20||2015-04-15|2008-03-13|2008-03-14|Estimate|2015-04-15|2015-05-01|Estimate||||2015-04-15|2015-05-01|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Improving Rehabilitation by Magnetic Brain Stimulation|Improving Rehabilitation by Magnetic Brain Stimulation: Improving Motor Recovery After Stroke|Completed||Phase 1|4|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:20:51.570512|2018-06-01 02:20:51.570512
NCT00636688|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-04-17|2008-03-07|2008-03-14|Estimate|||||||2008-04-17|2008-04-18|Estimate|October 2000||2000-10-31|March 2008|2008-03-31|October 2003|Actual|2003-10-31|April 2003|Actual|2003-04-30||Interventional|||Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: a Randomized Controlled Trial|Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: a Randomized Controlled Trial.|Completed||N/A|110|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-06-01 02:20:51.782322|2018-06-01 02:20:51.782322
NCT00636675|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2017-07-19|2008-03-09|2008-03-14|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2009||2009-09-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CONNECT||CONNECT for Quality: A Study to Reduce Falls in Nursing Homes|Outcomes of Nursing Management Practice in Nursing Homes|Completed||N/A|1350|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:20:51.849187|2018-06-01 02:20:51.849187
NCT00636662|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2009-01-08|2008-03-13|2008-03-14|Estimate|||||||2009-01-08|2009-01-12|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|FLUA+B||FLU A+B Nasal Swab Clinical Study|Evaluation of the RAMP FLU A+B Test Versus Viral Culture Using Clinical Nasal Swab Samples From Patients With Suspected Influenza Infections|Completed|||800|Actual|Response Biomedical Corp.|||1||f||||f||||||Samples With DNA|"~     mucous~   "|||2018-06-01 02:20:51.933425|2018-06-01 02:20:51.933425
NCT00636649|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-03|2012-12-07||2016-05-23|2008-03-13|2008-03-14|Estimate|2013-03-25|2013-05-06|Estimate||||2016-05-23|2016-06-29|Estimate|October 2008||2008-10-31|May 2016|2016-05-31|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|||Escitalopram Treatment of Night Eating Syndrome|Escitalopram Treatment of Night Eating Syndrome: a Randomized Controlled Trial|Completed||N/A|40|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:20:52.004473|2018-06-01 02:20:52.004473
NCT00303394|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2007-03-02|2006-03-14|2006-03-16|Estimate|||||||2007-03-02|2007-03-05|Estimate|April 2004||2004-04-30|March 2007|2007-03-31|March 2006||2006-03-31|||||Interventional|||Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist|Phase 2 Study of IL-1Ra in Patients With Type 2 Diabetes|Completed||Phase 2|72||University of Zurich|||||f||||||||||||||2018-06-01 04:07:03.821047|2018-06-01 04:07:03.821047
NCT00636636|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2011-10-13||2012-02-21|2008-03-13|2008-03-14|Estimate|2011-12-09|2012-01-13|Estimate||||2012-02-21|2012-02-22|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy of Gabapentin in Postherpetic Neuralgia|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia|Completed||Phase 3|452|Actual|Depomed||2|||f||||f||||||||||2018-06-01 02:20:52.515314|2018-06-01 02:20:52.515314
NCT00636623|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-03-07|2008-03-07|2008-03-14|Estimate|||||||2008-03-07|2008-03-14|Estimate|November 2006||2006-11-30|March 2008|2008-03-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|FM||Comparison of Exercise and Massage in Fibromyalgia|Comparison of Pilates Exercises and Connective Tissue Massage in Females With Fibromyalgia|Completed||N/A|36|Actual|Pamukkale University||2|||f||||f||||||||||2018-06-01 02:20:52.904975|2018-06-01 02:20:52.904975
NCT00636610|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2012-02-14||2017-05-15|2008-03-11|2008-03-14|Estimate|2012-06-01|2012-07-03|Estimate||||2017-05-15|2017-06-08|Actual|May 2008|Actual|2008-05-31|May 2017|2017-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer|A Randomized, Placebo-Controlled Phase II Study of Vismodegib (GDC-0449, Systemic Hedgehog Antagonist) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer|Completed||Phase 2|199|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 02:20:53.070487|2018-06-01 02:20:53.070487
NCT00636597|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2011-10-19|2008-03-07|2008-03-14|Estimate|||||||2011-10-19|2011-10-20|Estimate|April 2007||2007-04-30|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Prospective Evaluation of Same Day Bidirectional Endoscopy for Occult Bleeding|Prospective Evaluation of Same Day Bidirectional Endoscopy for Occult Bleeding|Terminated|||200|Anticipated|VA Office of Research and Development|||1|Not able to find enough eligible patients (200) in last 4 years.|f||||f||||||||||2018-06-01 02:20:54.018741|2018-06-01 02:20:54.018741
NCT00636584|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-03-07|2008-03-07|2008-03-14|Estimate|||||||2008-03-07|2008-03-14|Estimate|February 2008||2008-02-29|March 2008|2008-03-31|March 2008|Anticipated|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Clinical Study Investigating the Effect of Sodium Nitroprusside Infusion on Thyroidal Function|Does Sodium Nitroprusside Infusion Affect Thyroidal Function in Patients Undergoing Coronary Artery Bypass Grafting, a Prospective Randomized Clinical Trial.|Unknown status|Recruiting|Phase 4|106|Anticipated|Kavaklıdere Umut Hospital||2|||f||||f||||||||||2018-06-01 02:20:54.073465|2018-06-01 02:20:54.073465
NCT00636571|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-10-25|2008-03-13|2008-03-14|Estimate|||||||2013-10-25|2013-10-28|Estimate|March 2006||2006-03-31|October 2013|2013-10-31|March 2008|Actual|2008-03-31|September 2007|Actual|2007-09-30||Interventional|||Feasibility of Exercise With Post-Op Lung Cancer Patients|Determining the Feasibility of Post-Operative Training for Patients Diagnosed With Non-Small Cell Lung Cancer|Completed||N/A|21|Actual|Duke University|||||f||||f||||||||||2018-06-01 02:20:54.177675|2018-06-01 02:20:54.177675
NCT00636558|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2018-01-10|2008-03-13|2008-03-14|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2008||2008-03-31|January 2018|2018-01-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|PSX-X04||Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)|A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours (PSX-X04)|Completed||Phase 1|8|Actual|Viralytics||1|||f||||t||||||||||2018-06-01 02:20:54.238216|2018-06-01 02:20:54.238216
NCT00636545|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2012-04-04|2008-03-13|2008-03-14|Estimate|||||||2012-04-04|2012-04-06|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|March 2010|Actual|2010-03-31|March 2008|Actual|2008-03-31||Interventional|||Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors|A Safety, Pharmacokinetic, and Pharmacodynamic Assessment of Genasense Administered as a 2-hour Intravenous Infusion to Subjects With Solid Tumors|Completed||Phase 1|25|Actual|Genta Incorporated||3|||f||||f||||||||||2018-06-01 02:20:54.311912|2018-06-01 02:20:54.311912
NCT00636519|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2011-02-22|2008-03-13|2008-03-14|Estimate|||||||2011-02-22|2011-02-23|Estimate|February 2008||2008-02-29|February 2011|2011-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle|Botulism Antitoxin Effects on Paralysis Induced by Type A and Type B Botulinum Neurotoxins in the Extensor Digitorum Brevis Muscle|Completed||Phase 1|36|Actual|Cangene Corporation||2|||f||||f||||||||||2018-06-01 02:20:54.481589|2018-06-01 02:20:54.481589
NCT00636506|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-11|2008-03-11|2008-03-14|Estimate|||||||2008-03-11|2008-03-14|Estimate|August 2005||2005-08-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|February 2006|Actual|2006-02-28||Interventional|||Evaluate Improvement of Erectile Dysfunction After Placement of the AMS IPP 2005 Inflatable Penile Prosthesis|A Multi-Center Study to Assess the AMS IPP 2005 Inflatable Penile Prosthesis Cylinders, Pump and Reservoir.|Completed||Phase 2|70|Actual|American Medical Systems|||||f||||||||||||||2018-06-01 02:20:54.748813|2018-06-01 02:20:54.748813
NCT00636493|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2012-12-11|2008-03-13|2008-03-14|Estimate|||||||2012-12-11|2012-12-12|Estimate|October 2002||2002-10-31|December 2012|2012-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)|A Pilot Study of a Sustained-Release Fluocinolone Implant for Treatment of Retinal Vein Occlusion|Completed||Early Phase 1|30|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:20:54.885655|2018-06-01 02:20:54.885655
NCT00636480|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11||2013-02-19|2016-01-07|2008-03-13|2008-03-14|Estimate||||2013-02-19|2013-02-22|Estimate|2016-01-07|2016-02-05|Estimate|October 2007||2007-10-31|January 2016|2016-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Preoperative Skin Preparation Evaluation|Preoperative Skin Preparation Evaluation of One Test Product With a Positive and a Negative Control|Completed||Phase 3|60|Actual|CareFusion||3|||f||||f||||||||||2018-06-01 02:20:55.010605|2018-06-01 02:20:55.010605
NCT00636467|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2012-09-25|2008-03-11|2008-03-14|Estimate|||||||2012-09-25|2012-09-26|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|GAS2PLUS||Axillary Sentinel Lymph Node Detection in Breast Cancers > 2 cm|Evaluation of the Technique of Axillary Sentinel Lymph Node (SLN) Detection in Breast Cancers > 2 cm|Completed||Phase 2|249|Actual|Centre Leon Berard||1|||f||||f||||||||||2018-06-01 02:20:55.134233|2018-06-01 02:20:55.134233
NCT00636454|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2013-09-25|2008-03-12|2008-03-14|Estimate|||||||2013-09-25|2013-09-27|Estimate|May 2008||2008-05-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effectiveness of a Training Program in Improving Coping Skills in People With Arthritis Pain|Coping Skills Training for Arthritis: An Effectiveness Trial|Completed||Phase 2/Phase 3|257|Actual|Stony Brook University||2|||f||||f||||||||||2018-06-01 02:20:55.282828|2018-06-01 02:20:55.282828
NCT00303199|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2012-07-18|2006-03-14|2006-03-15|Estimate|||||||2012-07-18|2012-07-19|Estimate|January 2006||2006-01-31|July 2012|2012-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study of ZIO-101 in Multiple Myeloma|A Phase I/II Trial of ZIO-101 in Advanced Multiple Myeloma|Completed||Phase 1/Phase 2|35|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 04:07:06.495325|2018-06-01 04:07:06.495325
NCT00636441|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|2014-05-07||2015-11-16|2008-03-13|2008-03-14|Estimate|2014-10-06|2014-10-07|Estimate||||2015-11-16|2015-12-11|Estimate|April 2008||2008-04-30|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||All patients who signed a consent form are included in the baseline analysis.|Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer|A Randomized Phase II Trial Evaluating the Performance of Genomic Expression Profiles to Direct the Use of Preoperative Chemotherapy for Early Stage Breast Cancer|Terminated||Phase 2|56|Actual|Duke University||2||Study terminated due to reproducibility issues with genomics prediction model|f||||f||||||||||2018-06-01 02:20:55.404727|2018-06-01 02:20:55.404727
NCT00636428|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-04-08|2008-03-13|2008-03-14|Estimate|||||||2008-04-08|2008-04-11|Estimate|March 2007||2007-03-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Clinical Trial of Oral Midazolam in Pediatric Endoscopy|Clinical Trial of Oral Midazolam in Pediatric Endoscopy|Completed||Phase 4|50|Actual|Tabriz University||2|||f||||t||||||||||2018-06-01 02:20:56.411652|2018-06-01 02:20:56.411652
NCT00636415|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-11|2008-03-11|2008-03-14|Estimate|||||||2008-03-11|2008-03-14|Estimate|June 2004||2004-06-30|March 2008|2008-03-31|December 2006|Actual|2006-12-31|July 2005|Actual|2005-07-31||Interventional|||Intra-Articular Morphine Versus Bupivacaine on Knee Motion in Patients With Osteoarthritis|Intra-Articular Morphine Versus Bupivacaine on Knee Motion in Patients With Osteoarthritis: Randomized and Double-Blind Clinical Trial|Completed||N/A|30|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 02:20:57.441265|2018-06-01 02:20:57.441265
NCT00636402|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-12-10|2008-03-07|2008-03-14|Estimate|||||||2008-12-10|2008-12-11|Estimate|March 2008||2008-03-31|December 2008|2008-12-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Study of Efficacy and Adverse Effects: Vessel Sealing System Tonsillectomy Versus Cold Knife Tonsillectomy|Vessel Sealing System Tonsillectomy vs Cold Knife Tonsillectomy: A Randomized, Paired Control Study of Efficacy and Adverse Effects|Unknown status|Enrolling by invitation|N/A|20|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-06-01 02:20:57.504919|2018-06-01 02:20:57.504919
NCT00636389|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2011-03-07||2017-04-04|2008-03-11|2008-03-14|Estimate|2011-07-18|2011-08-11|Estimate||||2017-04-04|2017-05-10|Actual|February 2008||2008-02-29|April 2017|2017-04-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers|Urea, Phosphate and b2-Microglobulin Removal and Ease of Use: Comparing the Polyflux HD-C4 With the Polyflux 210H|Completed||N/A|12|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 02:20:57.625125|2018-06-01 02:20:57.625125
NCT00636376|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-10-20|2008-03-13|2008-03-14|Estimate|||||||2008-10-20|2008-10-21|Estimate|January 2002||2002-01-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effects of Head Elevation on Intracranial Pressure in Children|Effect of Head Elevation on Intracranial Pressure and Cerebral Venous Outflow in Children|Completed||N/A|18|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-06-01 02:20:57.816071|2018-06-01 02:20:57.816071
NCT00636363|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2011-02-03||2015-03-04|2008-03-07|2008-03-14|Estimate|2011-03-11|2011-04-08|Estimate||||2015-03-04|2015-03-24|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution||Completed||N/A|541|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 02:20:57.900566|2018-06-01 02:20:57.900566
NCT00636350|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2017-10-11|2008-03-13|2008-03-14|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2007||2007-09-30|September 2009|2009-09-30|June 30, 2010|Actual|2010-06-30|June 30, 2010|Actual|2010-06-30||Interventional|||Bioavailability of Pepper Carotenoids in Humans||Completed||Phase 1|5|Anticipated|Tufts University|||||f||||f||||||||||2018-06-01 02:20:58.360615|2018-06-01 02:20:58.360615
NCT00636337|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2013-02-15|2008-03-13|2008-03-14|Estimate|||||||2013-02-15|2013-02-18|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|June 2010|Actual|2010-06-30||Interventional|TRICCS||Inattention in Childhood Cancer Survivors|TRICCS: Targeting Inattention in Childhood Cancer Survivors|Completed||N/A|23|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:20:58.436217|2018-06-01 02:20:58.436217
NCT00636324|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2009-02-09|2008-03-13|2008-03-14|Estimate|||||||2009-02-09|2009-02-10|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|March 2008|Actual|2008-03-31||Interventional|L-CPAP||Level of Continuous Positive Airway Pressure (CPAP) in Preterm Infants After Extubation (L-CPAP Study)|Nasal Continuous Positive Airway Pressure in Preterm Infants After Extubation: Comparison of Different Levels of Pressure|Terminated||Phase 2|23|Actual|McMaster University||2||Difficulties in recruitment - will require longer time to achieve sample size|f||||t||||||||||2018-06-01 02:20:58.515246|2018-06-01 02:20:58.515246
NCT00636311|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2010-09-01|2008-03-11|2008-03-14|Estimate|||||||2010-09-01|2010-09-02|Estimate|February 2008||2008-02-29|September 2010|2010-09-30|February 2010|Actual|2010-02-28|April 2008|Actual|2008-04-30||Interventional|||A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma|IGEV +/- Bortezomib (Velcade) as Induction Before High Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma After First Line Treatment: a Randomized Phase II Trial. On Behalf of Intergruppo Italiano Linfomi|Completed||Phase 2|13|Actual|Istituto Clinico Humanitas||2|||f||||f||||||||||2018-06-01 02:20:58.655949|2018-06-01 02:20:58.655949
NCT00636298|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2013-11-18|2008-03-11|2008-03-14|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2008||2008-10-31|November 2013|2013-11-30|March 2012|Anticipated|2012-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy|Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy|Withdrawn||Phase 2|0|Actual|Emory University||1||lack of funding|f||||t||||||||||2018-06-01 02:20:58.752525|2018-06-01 02:20:58.752525
NCT00636285|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-10-08|2008-03-07|2008-03-14|Estimate|||||||2008-10-08|2008-10-09|Estimate|April 2001||2001-04-30|October 2008|2008-10-31|November 2001|Actual|2001-11-30|September 2001|Actual|2001-09-30||Interventional|||Safety and Pharmacokinetics Study in Adults for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants|Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetics Study in Adults of BSYX-A110, a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for the Prevention of S. Epidermidis Infection in Low Birth Weight Infants|Completed||Phase 1|8|Actual|Biosynexus Incorporated||3|||f||||f||||||||||2018-06-01 02:20:58.869992|2018-06-01 02:20:58.869992
NCT00636272|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-08-14|2008-03-07|2008-03-14|Estimate|||||||2008-08-14|2008-08-18|Estimate|March 2008||2008-03-31|August 2008|2008-08-31||||||||Observational|LSR||Longitudinal Surveillance Registry|Longitudinal Surveillance Registry|Terminated|||2500|Anticipated|Boston Scientific Corporation|||||f||||t||||||||||2018-06-01 02:20:58.988861|2018-06-01 02:20:58.988861
NCT00636259|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-06-10|2008-03-07|2008-03-14|Estimate|||||||2008-06-10|2008-06-11|Estimate||||June 2008|2008-06-30||||||||Expanded Access|||Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer|A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer|No longer available|||||AstraZeneca|||||||||||||||||||2018-06-01 02:20:59.057676|2018-06-01 02:20:59.057676
NCT00636246|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-04-03|2008-03-07|2008-03-14|Estimate|||||||2008-04-03|2008-04-04|Estimate|June 2004||2004-06-30|April 2008|2008-04-30|August 2005|Actual|2005-08-31|||||Interventional|||A Comparison of Sertraline-Reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.|Sertraline/[S,S]-Reboxetine Combination Versus Sertraline And [S,S]-Reboxetine Monotherapy In Major Depressive Disorder (MDD) In A Double-Blind, Placebo-Controlled, Eight Week Study.|Completed||Phase 2|510|Actual|Pfizer||8|||f||||f||||||||||2018-06-01 02:20:59.146547|2018-06-01 02:20:59.146547
NCT00636233|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2018-04-17|2008-03-09|2008-03-14|Estimate|||||||2018-04-17|2018-04-18|Actual|May 1993||1993-05-31|April 2018|2018-04-30|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Observational|||Genetics of Spina Bifida and Anencephaly|The Hereditary Basis of Neural Tube Defects|Active, not recruiting|||10000|Anticipated|Duke University|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum, saliva, cord blood, fetal tissue, cultured fetal cells~   "|No||2018-06-01 02:20:59.283607|2018-06-01 02:20:59.283607
NCT00636220|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|2009-01-08||2015-07-27|2008-03-11|2008-03-14|Estimate|2010-01-20|2010-02-15|Estimate||||2015-07-27|2015-08-17|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|HIVOF||Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid|Evaluation of the DPP HIV Test With Reader and the HIV 1/2 Stat-Pak Test Using Oral Fluids|Completed|||101|Actual|Chembio Diagnostic Systems, Inc.|||1||f||||t||||||Samples Without DNA|"~     oral fluid samples and venous blood~   "|||2018-06-01 02:20:59.365128|2018-06-01 02:20:59.365128
NCT00636207|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2012-12-20||2017-03-09|2008-03-07|2008-03-14|Estimate|2012-12-20|2013-01-28|Estimate||||2017-03-09|2017-04-06|Actual|August 2007||2007-08-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)|A Sequential, 3-Part, Double-Blind, Randomized, Placebo-Controlled, Single-Rising-Dose and Rising-Multiple-Dose Study in Healthy Subjects and Mild or Moderate Asthmatic Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled MK-0476|Completed||Phase 1|46|Actual|Merck Sharp & Dohme Corp.||6|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:20:59.551981|2018-06-01 02:20:59.551981
NCT00636194|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2010-12-14||2011-12-07|2008-03-07|2008-03-14|Estimate|2011-01-19|2011-02-15|Estimate||||2011-12-07|2011-12-13|Estimate|February 2008||2008-02-29|December 2011|2011-12-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon OptiFree Replenish Multipurpose Solution|Product Performance of Bausch & Lomb Multi-Purpose Solution Compared to Alcon Opti-Free Replenish Multi-Purpose Solution When Used With Silicone Hydrogel Contact Lenses Worn on a Daily Wear Basis|Completed||N/A|361|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:21:00.424397|2018-06-01 02:21:00.424397
NCT00636181|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-06-09|2008-03-13|2008-03-14|Estimate|||||||2009-06-09|2009-06-10|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Positive Pressure Treatment of Obstructive Sleep Apnea|Positive Airway Pressure Initiation: Impact of Therapy Mode and Titration Process on Adherence and Outcomes|Completed||N/A|150|Anticipated|Philips Respironics||3|||f||||f||||||||||2018-06-01 02:21:00.730244|2018-06-01 02:21:00.730244
NCT00636168|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2014-07-25||2017-10-04|2008-03-07|2008-03-14|Estimate|2014-08-18|2014-08-19|Estimate||||2017-10-04|2017-11-06|Actual|June 30, 2008|Actual|2008-06-30|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|July 26, 2013|Actual|2013-07-26||Interventional||All participants randomized to a study arm (Intent to treat population) were analyzed in the arm to which they were allocated by randomization.|Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma|Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group|Active, not recruiting||Phase 3|1211|Actual|Bristol-Myers Squibb||2|||f||||t|t|||||||||2018-06-01 02:21:00.887016|2018-06-01 02:21:00.887016
NCT00636155|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2012-05-29||2012-11-26|2008-03-13|2008-03-14|Estimate|2012-07-16|2012-08-22|Estimate||||2012-11-26|2012-11-28|Estimate|February 2008||2008-02-29|November 2012|2012-11-30|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|||EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of EL625 in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Terminated||Phase 2|20|Actual|Duke University||1||funding|f||||f||||||||||2018-06-01 02:21:02.578597|2018-06-01 02:21:02.578597
NCT00636142|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-13|2008-03-13|2008-03-14|Estimate|||||||2008-03-13|2008-03-14|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity|A Prospective Trial of Anti-TNF-Alpha Chimeric Monoclonal Antibody (Infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity|Completed||Phase 4|9|Actual|Medical University of Graz||2|||f||||t||||||||||2018-06-01 02:21:02.877906|2018-06-01 02:21:02.877906
NCT00636129|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2011-09-16|2008-03-13|2008-03-14|Estimate|||||||2011-09-16|2011-09-19|Estimate|December 2006||2006-12-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Biochemical and Physiological Changes Associated With Differing Durations of Relaxation Response Training|Biochemical and Physiological Changes Associated With Differing Durations of Relaxation Response Training|Completed|||30|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Whole blood Serum Plasma~   "|||2018-06-01 02:21:02.965976|2018-06-01 02:21:02.965976
NCT00636116|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2012-01-09|2008-03-11|2008-03-14|Estimate|||||||2012-01-09|2012-01-10|Estimate|May 2008||2008-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.|A Comparison of Anavip® and CroFab® in the Treatment of Patients With Crotalinae Envenomation: A Randomized, Prospective, Blinded, Controlled, Comparative, Multicenter Study|Completed||Phase 3|121|Actual|Instituto Bioclon S.A. de C.V.||3|||f||||f||||||||||2018-06-01 02:21:03.043506|2018-06-01 02:21:03.043506
NCT00636103|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-11|2008-03-11|2008-03-14|Estimate|||||||2008-03-11|2008-03-14|Estimate|July 2002||2002-07-31|March 2008|2008-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Efficacy Study of Herbal Formula CUF2 to Treat Childhood Asthma|A Randomized Double-Blind Placebo-Controlled Study of the Effect of Traditional Chinese Medicines in the Treatment of Childhood Asthma|Completed||Phase 1/Phase 2|90|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 02:21:03.231849|2018-06-01 02:21:03.231849
NCT00298571|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2012-06-14|2006-02-28|2006-03-02|Estimate|||||||2012-06-14|2012-06-15|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|October 2007|Actual|2007-10-31|||||Interventional|||Cesarean Delivery and Post-operative Pain Management With Local Anesthesia||Completed||Phase 2/Phase 3|100|Anticipated|University of South Florida|||||f||||||||||||||2018-06-01 04:08:15.257688|2018-06-01 04:08:15.257688
NCT00636090|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2013-12-03|2008-03-13|2008-03-14|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Observational|||Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001|Molecular, Genetic, and Genomic Assessments of MTOR Inhibition in Metastatic Hormone-Refractory Prostate Cancer Tissue From Patients Treated With RAD001|Completed|||35|Actual|Duke University|||||f||||f||||||Samples With DNA|"~     This study involves the retention of tissue sample from tumor biopsies as well as blood~     samples.~   "|||2018-06-01 02:21:03.379355|2018-06-01 02:21:03.379355
NCT00636077|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2011-03-07||2017-04-04|2008-03-11|2008-03-14|Estimate|2011-06-06|2011-07-01|Estimate||||2017-04-04|2017-05-10|Actual|February 2008||2008-02-29|April 2017|2017-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparative Effects Of Dialysate Flow Rate And Membrane Packing On The Performance Of Dialyzers Used For Hemodialysis|Effect Of Dialysate Flow Rate On Mass Transfer Coefficient - Area (KoA) In Dialyzers With Different Membrane Packing Densities|Completed||N/A|12|Actual|Baxter Healthcare Corporation||4|||f||||f||||||||||2018-06-01 02:21:03.473272|2018-06-01 02:21:03.473272
NCT00636064|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-10-09|2008-03-07|2008-03-14|Estimate|||||||2008-10-09|2008-10-10|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|January 2004|Actual|2004-01-31|||||Interventional|||A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery|A Double-Blind Multicenter Study of the Safety and Efficacy of Parecoxib Sodium/Valdecoxib and Placebo/Valdecoxib Compared to Placebo for Treatment of Post-Surgical Pain in Patients Who Have Coronary Bypass Graft Via Median Sternotomy|Completed||Phase 3|1671|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 02:21:03.890958|2018-06-01 02:21:03.890958
NCT00636051|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2009-06-08|2008-03-13|2008-03-14|Estimate|||||||2009-06-08|2009-06-09|Estimate|February 2005||2005-02-28|June 2009|2009-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Evidence-Based Practice (EBP) Awareness Project: Peer-to-Peer Dissemination|Evidence-Based Practice (EBP) Awareness Project: Peer-to-Peer Dissemination|Completed|||91|Actual|State University of New York - Upstate Medical University|||2||f||||f||||||||||2018-06-01 02:21:04.348763|2018-06-01 02:21:04.348763
NCT00636038|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-03-13|2008-03-13|2008-03-14|Estimate|||||||2008-03-13|2008-03-14|Estimate|January 2008||2008-01-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Bioavailability of Yellow Maize Carotenoids in Humans||Completed||Phase 1|8|Actual|Tufts University|||||f||||f||||||||||2018-06-01 02:21:04.40614|2018-06-01 02:21:04.40614
NCT00636025|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2015-02-24|2008-03-13|2008-03-14|Estimate|||||||2015-02-24|2015-02-26|Estimate|July 2008||2008-07-31|February 2015|2015-02-28|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Observational|||Cellulite and Magnetic Resonance Imaging|Anatomy of Subcutaneous Structures in Areas With and Without Cellulite Depressions by Magnetic Resonance Imaging|Completed|||30|Actual|Brazilan Center for Studies in Dermatology|||1||f||||f||||||None Retained|"~     None retained~   "|||2018-06-01 02:21:04.472728|2018-06-01 02:21:04.472728
NCT00636012|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2012-07-09|2008-03-11|2008-03-14|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|GSW||Stimulation of Gastric Slow Waves With Acupuncture at St36 and Pe6 - a Randomized Single-blind Controlled Trial|Stimulation of Gastric Slow Waves by Acupuncture of St36 and Pe6 - a Randomized Single-blind Controlled Trial|Completed||N/A|65|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 02:21:04.519151|2018-06-01 02:21:04.519151
NCT00635999|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2012-05-23||2018-01-24|2008-03-12|2008-03-14|Estimate|2018-01-24|2018-01-25|Actual||||2018-01-24|2018-01-25|Actual|October 1991||1991-10-31|January 2018|2018-01-31|October 1998|Actual|1998-10-31|October 1998|Actual|1998-10-31||Interventional|||A Comparison Between Cognitive, Behavioral, and Cognitive-Behavioral Therapy for Generalized Anxiety Disorder|Desensitization and Cognitive Therapy in General Anxiety|Completed||N/A|76|Actual|Penn State University||3|||f||||f||||||||No|Summary data has been shared.|2018-06-01 02:21:04.621996|2018-06-01 02:21:04.621996
NCT00635986|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-03-11|2008-03-11|2008-03-14|Estimate|||||||2008-03-11|2008-03-14|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|November 2006|Actual|2006-11-30|June 2005|Actual|2005-06-30||Interventional|FTN||Analgesic Effect and Plasma Concentration of Epidural Versus Intravenous Fentanyl|Analgesic Effect and Plasma Concentration of Epidural Versus Intravenous Fentanyl|Completed||N/A|30|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 02:21:04.949636|2018-06-01 02:21:04.949636
NCT00635973|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2009-04-21|2008-03-13|2008-03-14|Estimate|||||||2009-04-21|2009-04-22|Estimate|February 2000||2000-02-29|April 2009|2009-04-30|October 2003|Actual|2003-10-31|||||Interventional|||Open-Label Extension of Other SZ1839 (Iressa) Trials|Multi-Centre, Open-Label Extension Trial of Treatment With ZD1839 (Iressa) in Patients Who Have Been Treated in Other ZD1839 Clinical Trials and May Benefit From Continued Monotherapy ZD 1839.|Completed||Phase 3|100|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:21:05.008124|2018-06-01 02:21:05.008124
NCT00635960|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2010-05-25|2008-03-13|2008-03-14|Estimate|||||||2010-05-25|2010-05-27|Estimate|March 2007||2007-03-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|July 2009|Actual|2009-07-31||Interventional|||Growth Hormone in Amyotrophic Lateral Sclerosis|Efficacy, Safety and Tolerability of Growth Hormone in Patients With Amyotrophic Lateral Sclerosis as add-on Therapy to Riluzole|Completed||Phase 2|40|Anticipated|Federico II University||2|||f||||t||||||||||2018-06-01 02:21:05.071066|2018-06-01 02:21:05.071066
NCT00635947|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-03-13|2008-03-13|2008-03-14|Estimate|||||||2008-03-13|2008-03-14|Estimate|July 1998||1998-07-31|March 2008|2008-03-31|January 2005|Actual|2005-01-31|July 1999|Actual|1999-07-31||Interventional|||Study of Maternal Hydration on the Increase of Amniotic Fluid Index|Randomized Trial of Maternal Hydration on the Increase of Amniotic Fluid Index|Completed||Phase 4|99|Actual|UPECLIN HC FM Botucatu Unesp||3|||f||||t||||||||||2018-06-01 02:21:05.163587|2018-06-01 02:21:05.163587
NCT00635934|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2012-04-24|2008-03-13|2008-03-14|Estimate|||||||2012-04-24|2012-04-25|Estimate|December 2005||2005-12-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Interventional|||A-MAV™ Anterior Motion Segment Replacement|A Prospective, Non-Randomized Pilot Clinical Investigation of the A-MAV™ Anterior Motion Segment Replacement in Patients With Lumbar Degenerative Disc Disease|Completed||Phase 1|53|Actual|Medtronic Spinal and Biologics||1|||f||||t||||||||||2018-06-01 02:21:05.256109|2018-06-01 02:21:05.256109
NCT00635921|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2008-03-11|2008-03-11|2008-03-14|Estimate|||||||2008-03-11|2008-03-14|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Ziprasidone in the Treatment of Borderline Personality Disorder|Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study|Completed||Phase 2|60|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-06-01 02:21:05.330199|2018-06-01 02:21:05.330199
NCT00635271|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-08|||2018-05-11|2008-03-08|2008-03-13|Estimate|||||||2018-05-11|2018-05-14|Actual|February 29, 2008||2008-02-29|November 28, 2012|2012-11-28|November 28, 2012||2012-11-28|||||Observational|||Biomarkers in Exhaled Breath From Asthmatic Patients|Identification of Biomarkers in Exhaled Breath Condensates From Asthmatic Patients|Terminated|||19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:21:18.816972|2018-06-01 02:21:18.816972
NCT00635895|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2008-03-07|2008-03-07|2008-03-14|Estimate|||||||2008-03-07|2008-03-14|Estimate|June 2006||2006-06-30|March 2008|2008-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|FM||Comparison of Lymph Drainage and Connective Tissue Massage in Fibromyalgia Patients|Comparison of Manual Lymph Drainage Therapy and Connective Tissue Massage in Females With Fibromyalgia: A Randomized Controlled Trial|Completed||N/A|50|Actual|Pamukkale University||2|||f||||f||||||||||2018-06-01 02:21:05.414229|2018-06-01 02:21:05.414229
NCT00635882|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|2010-10-22|2009-07-08|2017-03-15|2008-03-07|2008-03-14|Estimate|2011-01-12|2011-02-09|Estimate|2009-09-30|2009-10-01|Estimate|2017-03-15|2017-04-12|Actual|February 2008||2008-02-29|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)|A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma|Completed||Phase 2|93|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:21:05.527498|2018-06-01 02:21:05.527498
NCT00635869|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2008-03-13|2008-03-13|2008-03-14|Estimate|||||||2008-03-13|2008-03-14|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Advancing Research and Clinical Practice Through Close Collaboration (ARCC): A Pilot Test of an Intervention to Improve Evidence-Based Care and Patient Outcomes|Advancing Research and Clinical Practice Through Close Collaboration (ARCC): A Pilot Test of an Intervention to Improve Evidence-Based Care and Patient Outcomes|Completed|||29|Actual|State University of New York - Upstate Medical University|||3||f||||f||||||||||2018-06-01 02:21:06.357697|2018-06-01 02:21:06.357697
NCT00635856|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2009-04-22|2008-03-13|2008-03-14|Estimate|||||||2009-04-22|2009-04-23|Estimate|May 2001||2001-05-31|April 2009|2009-04-30|February 2003|Actual|2003-02-28|||||Interventional|||Open Label Trial to Assess Iressa in Prostate Cancer Patients|Phase II, Open-Label Trial to Assess the Activity of ZD1839 (IRESSA TM) in Patients With Recurrent Prostate Cancer Who Have Rising Serum PSA Levels Despite Serum Testosterone < 50mg/dl|Completed||Phase 2|100|Anticipated|AstraZeneca|||||t||||f||||||||||2018-06-01 02:21:06.424088|2018-06-01 02:21:06.424088
NCT00635843|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2013-08-01|2008-03-13|2008-03-14|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2003||2003-04-30|October 2011|2011-10-31|November 2010|Actual|2010-11-30|October 2006|Actual|2006-10-31||Interventional|||MAVERICK™ Total Disc Replacement- Pivotal Study|"A Prospective, Randomized Controlled Clinical Investigation of MAVERICK™ Total Disc Replacement in Patients With Degenerative Disc Disease"|Completed||Phase 3|577|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 02:21:06.491365|2018-06-01 02:21:06.491365
NCT00635830|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2009-03-17||2015-10-08|2008-03-07|2008-03-14|Estimate|2009-07-10|2009-08-20|Estimate||||2015-10-08|2015-10-09|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)|An Open-Label, Single-Dose, Safety and Tolerability Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 02:21:06.5878|2018-06-01 02:21:06.5878
NCT00635817|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2011-01-20||2011-10-25|2008-03-13|2008-03-14|Estimate|2011-01-20|2011-02-09|Estimate||||2011-10-25|2011-11-02|Estimate|June 2008||2008-06-30|October 2011|2011-10-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty|A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious Puberty|Completed||Phase 3|84|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:21:06.955499|2018-06-01 02:21:06.955499
NCT00635804|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2016-02-18||2017-02-28|2008-03-07|2008-03-14|Estimate|2016-03-31|2016-05-04|Estimate||||2017-02-28|2017-03-29|Actual|February 2008||2008-02-29|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)|A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Rising Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy Male Subjects and Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-3281 in Hepatitis C Infected Male Patients|Completed||Phase 1|60|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-06-01 02:21:07.742575|2018-06-01 02:21:07.742575
NCT00635791|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2013-06-18|2008-03-13|2008-03-14|Estimate|||||||2013-06-18|2013-06-20|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Phase I Study of Vorinostat and Sorafenib in Advanced Cancer|A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-type Specific Expanded Cohorts at the Recommended Phase 2 Dose|Completed||Phase 1|36|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-06-01 02:21:09.030328|2018-06-01 02:21:09.030328
NCT00635778|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2016-04-07|2008-03-07|2008-03-14|Estimate|||||||2016-04-07|2016-04-08|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Infusion of MK-0646 in Subjects With Advanced Solid Tumors (MK-0646-002)(COMPLETED)|An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers|Completed||Phase 1|50|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 02:21:09.103409|2018-06-01 02:21:09.103409
NCT00635765|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2009-06-03|2008-03-13|2008-03-14|Estimate|||||||2009-06-03|2009-06-04|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients|Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients|Completed||Phase 3|63|Anticipated|Ambrilia Biopharma, Inc.|||||f||||f||||||||||2018-06-01 02:21:09.175402|2018-06-01 02:21:09.175402
NCT00635752|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2015-04-22|2008-03-13|2008-03-14|Estimate|||||||2015-04-22|2015-04-23|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|February 2011|Actual|2011-02-28||Interventional|||Trauma-focused Cognitive-behavioural Therapy(TF-CBT) for Children: A Study of Process and Outcome.|Trauma-focused Cognitive-behavioural Therapy for Children: A Study of Process and Outcome.|Completed||N/A|156|Actual|Norwegian Center for Violence and Traumatic Stress Studies||2|||f||||f||||||||||2018-06-01 02:21:09.254328|2018-06-01 02:21:09.254328
NCT00635739|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2012-05-30|2008-03-13|2008-03-14|Estimate|||||||2012-05-30|2012-06-01|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Whey Protein Supplementation and Resistance Exercise on Muscle Parameters in Older Adults|Efficacy of Whey Protein Supplementation on Resistance Exercise-Induced Changes in Muscle Strength, Fat Free Mass, and Function in Mobility-Limited Older Adults|Completed||N/A|80|Anticipated|Tufts University||2|||f||||f||||||||||2018-06-01 02:21:09.348937|2018-06-01 02:21:09.348937
NCT00635726|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2015-10-07|2008-03-13|2008-03-14|Estimate|||||||2015-10-07|2015-10-08|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer|Sequential High Dose MVAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin), Followed by Gemcitabine Plus Cisplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer|Terminated||Phase 2|41|Actual|Hellenic Oncology Research Group||1||Due to poor accrual|f||||f||||||||||2018-06-01 02:21:09.435599|2018-06-01 02:21:09.435599
NCT00635713|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2009-04-09|2008-03-13|2008-03-14|Estimate|||||||2009-04-09|2009-04-10|Estimate|May 1997||1997-05-31|April 2009|2009-04-30|September 2004|Actual|2004-09-30|||||Interventional|||Second Line Breast Cancer Trial|A Double-Blind, Randomized, Multi-Center Trial Comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long Acting ICI 182,780) With 1mg Arimidex (Anastrazole) in Postmenopausal Women With Advanced Breast Cancer.|Completed||Phase 3|588|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:21:09.645229|2018-06-01 02:21:09.645229
NCT00635700|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2016-09-06||2016-09-06|2008-03-13|2008-03-14|Estimate|2016-09-06|2016-10-27|Estimate||||2016-09-06|2016-10-27|Estimate|March 2008||2008-03-31|September 2016|2016-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ZIP|Of 51 patients randomized, 27 were assigned to placebo and 24 to ziprasidone. One case allocated to ziprasidone was never dispensed study medication and was removed from analysis per protocol, leaving 23.|Ziprasidone in the Psychosis Prodrome|Ziprasidone vs Placebo in the Prevention of Psychosis Among Symptomatic Adolescents and Young Adults at Prodromal Risk|Completed||Phase 2|66|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:21:09.910928|2018-06-01 02:21:09.910928
NCT00635687|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2013-03-04|2008-03-13|2008-03-14|Estimate|||||||2013-03-04|2013-03-05|Estimate|March 2008||2008-03-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|PROME||Transient Elastography and Variceal Bleeding|Can Liver Stiffness Values Predict Early Rebleeding in Variceal Rupture|Terminated||N/A|29|Actual|University Hospital, Rouen||1||lack of recruitment|f||||f||||||||||2018-06-01 02:21:10.721999|2018-06-01 02:21:10.721999
NCT00635674|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-13|2008-03-13|2008-03-14|Estimate|||||||2008-03-13|2008-03-14|Estimate|February 2007||2007-02-28|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome|Effects of CPAP on Cardiovascular Risk Profile in Patients With Severe Obstructive Sleep Apnea and Metabolic Syndrome|Completed||N/A|32|Actual|Pavol Jozef Safarik University||2|||f||||f||||||||||2018-06-01 02:21:10.793155|2018-06-01 02:21:10.793155
NCT00635661|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2011-08-09||2012-01-31|2008-03-07|2008-03-14|Estimate|2012-01-31|2012-03-02|Estimate||||2012-01-31|2012-03-02|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Assessment of the Stroke Rehabilitation Assessment of Movement as a Clinical Tool|A Comparison of the Stroke Rehabilitation Assessment of Movement, the Functional Independence Measure and the Stroke Impact Scale|Completed|||34|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:21:10.867511|2018-06-01 02:21:10.867511
NCT00635648|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2012-04-26||2017-02-21|2008-03-07|2008-03-14|Estimate|2012-04-26|2012-05-28|Estimate||||2017-02-21|2017-03-24|Actual|January 2008||2008-01-31|February 2017|2017-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)|A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults|Completed||Phase 3|63|Actual|Merck Sharp & Dohme Corp.|This was an open-label non-comparative study with a relatively small sample size.|1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:21:11.019404|2018-06-01 02:21:11.019404
NCT00635635|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-09|||2010-05-25|2008-03-13|2008-03-14|Estimate|||||||2010-05-25|2010-05-26|Estimate|October 2007||2007-10-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Guided Imagery for Military Sexual Trauma-Related Posttraumatic Stress Disorder (PTSD)|Guided Imagery for Military Sexual Trauma-Related PTSD|Completed||N/A|40|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:21:11.180716|2018-06-01 02:21:11.180716
NCT00635622|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2009-07-09|2008-03-11|2008-03-14|Estimate|||||||2009-07-09|2009-07-10|Estimate|April 2008||2008-04-30|March 2009|2009-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis|A Phase IIa Study of the Colonization Efficiency, Safety and Acceptability of LACTIN-V Administered Vaginally to Women With Bacterial Vaginosis|Completed||Phase 2|40|Anticipated|Osel, Inc.||2|||f||||t||||||||||2018-06-01 02:21:11.308332|2018-06-01 02:21:11.308332
NCT00635609|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2009-09-23||2012-04-18|2008-03-13|2008-03-14|Estimate|2009-11-23|2009-12-30|Estimate||||2012-04-18|2012-04-20|Estimate|March 2008||2008-03-31|April 2012|2012-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate|Randomized, Open-label Study to Evaluate the Efficacy and Safety of Doryx Tablets Compared to Doxycycline Hyclate in the Treatment of Acne Vulgaris.|Completed||Phase 4|93|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 02:21:11.44308|2018-06-01 02:21:11.44308
NCT00635596|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2015-01-12|2008-03-07|2008-03-14|Estimate|||||||2015-01-12|2015-01-13|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|MT110-101||Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer|An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE) MT110 in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment|Completed||Phase 1|65|Actual|Amgen Research (Munich) GmbH||1|||f||||t||||||||||2018-06-01 02:21:11.793351|2018-06-01 02:21:11.793351
NCT00542074|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2007-10-29|2007-10-09|2007-10-10|Estimate|||||||2007-10-29|2007-10-31|Estimate|June 2003||2003-06-30|October 2007|2007-10-31|August 2005|Actual|2005-08-31|||||Interventional|||Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence|Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence|Completed||N/A|223|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:51:34.334972|2018-06-01 02:51:34.334972
NCT00635583|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2018-05-03|2008-03-12|2008-03-13|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2008|Actual|2008-03-31|May 2018|2018-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|B3||The Effect of Dairy on Bone Mass and Body Composition in 4th-8th Grade Boys and Girls|Influence of Dairy on Bone Accrual and Bone Size and Fat and Lean Mass in Early Pubertal Overweight vs. Healthy-weight Boys and Girls|Completed||N/A|47|Actual|Purdue University||2|||f||||f||||||||||2018-06-01 02:21:11.875963|2018-06-01 02:21:11.875963
NCT00635570|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2012-10-05||2013-06-24|2008-03-12|2008-03-13|Estimate|2012-11-05|2012-11-07|Estimate||||2013-06-24|2013-07-02|Estimate|July 2008||2008-07-31|June 2013|2013-06-30|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|ACCEPT||Acceptability of the NuvaRing Among Students|Acceptability of the NuvaRing Among College and Graduate Students|Completed||Phase 4|273|Actual|University of Chicago|This study is an randomized controlled trial offering internal but not necessarily external validity. Thus, we do not know whether these findings would be replicable in other populations.|2|||f||||f||||||||||2018-06-01 02:21:11.964645|2018-06-01 02:21:11.964645
NCT00635557|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2011-03-24|2008-03-06|2008-03-13|Estimate|||||||2011-03-24|2011-03-25|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|August 2011|Anticipated|2011-08-31|October 2010|Actual|2010-10-31||Interventional|||Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme|Dose Finding Phase 1 Study of the Treatment of Recurrent/Relapsed Glioblastoma Multiforme With MPC-6827 in Combination With Carboplatin|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Myrexis Inc.|||||f||||f||||||||||2018-06-01 02:21:12.708598|2018-06-01 02:21:12.708598
NCT00635544|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2009-01-27|2008-03-06|2008-03-13|Estimate|||||||2009-01-27|2009-01-28|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|HELENA-COMS||Cross-Over Multicentre Study in Adolescents|Healthy Life Style in Europe by Nutrition in Adolescence: Cross-Over Multicentre Study|Completed||N/A|80|Anticipated|Federico II University||2|||f||||t||||||||||2018-06-01 02:21:12.811114|2018-06-01 02:21:12.811114
NCT00635531|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-04-07|2008-03-05|2008-03-13|Estimate|||||||2008-04-07|2008-04-10|Estimate|April 2004||2004-04-30|April 2008|2008-04-30|September 2004|Actual|2004-09-30|||||Interventional|||A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder|Terminated||Phase 4|16|Actual|Pfizer||2||Please see Detailed Description for termination reason.|f||||t||||||||||2018-06-01 02:21:12.900746|2018-06-01 02:21:12.900746
NCT00635518|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2011-06-22|2008-03-05|2008-03-13|Estimate|||||||2011-06-22|2011-06-23|Estimate|March 2008||2008-03-31|May 2011|2011-05-31||||||||Interventional|||Randomized Controlled Trial of Dietary Advice in Primary Care to Promote Healthy Feeding of Infants|Randomized Controlled Trial of Dietary Advice in Primary Care to Promote Healthy Feeding of Infants|Withdrawn||N/A|329|Anticipated|Federal University of Health Science of Porto Alegre||1||Funding was canceled and no resources are available.|f||||f||||||||||2018-06-01 02:21:13.185764|2018-06-01 02:21:13.185764
NCT00635505|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07||2013-07-10|2013-07-11|2008-03-12|2008-03-13|Estimate||||2013-07-11|2013-07-15|Estimate|2013-07-11|2013-07-15|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients|Randomized, Placebo-Controlled, Parallel, Multi-Center, 12-Week Study to Evaluate the Efficacy and Safety of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Adult and Adolescent Asthmatic Patients|Terminated||Phase 3|300|Actual|Amphastar Pharmaceuticals, Inc.||3||IND voluntarily withdrawn, without prejudice|f||||f||||||||||2018-06-01 02:21:13.28321|2018-06-01 02:21:13.28321
NCT00635492|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2013-07-31||2015-03-20|2008-03-12|2008-03-13|Estimate|2014-06-06|2014-07-09|Estimate||||2015-03-20|2015-04-09|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational||Analysis population description: all patients who provided consent to release information and who fulfill the study entry criteria were included in the analyses. Patients were assigned to the exenatide BID or insulin cohort based on their initial injectable treatment started at baseline.|CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy|CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months|Completed|||2515|Actual|AstraZeneca|"Serious adverse events (SAEs) and adverse events (AEs) were not collected as part of this observational study~Factors associated with treatment choice : this analysis was done on baseline lock( april 2009) where all others are from final lock."||2||f||||f||||||||||2018-06-01 02:21:13.530811|2018-06-01 02:21:13.530811
NCT00635479|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2014-01-01||2017-11-08|2008-03-12|2008-03-13|Estimate|2014-01-01|2014-02-14|Estimate||||2017-11-08|2017-12-11|Actual|March 2008||2008-03-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Role of Vacuum Assisted Closure (VAC) Device in Postoperative Management of Pelvic and Acetabular Fractures|Role of Vacuum Assisted Closure (VAC) Device in Postoperative Management of Pelvic and Acetabular Fractures|Completed||N/A|115|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-06-01 02:21:14.80261|2018-06-01 02:21:14.80261
NCT00635466|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2011-06-15|2008-03-12|2008-03-13|Estimate|||||||2011-06-15|2011-06-16|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|Lap RC||Phase II Trial to Evaluate Laparoscopic Surgery for Stage 0/I Rectal Carcinoma|Phase II Trial to Evaluate Laparoscopic Surgery for Stage 0/I Rectal Carcinoma|Unknown status|Active, not recruiting|Phase 2|495|Actual|Japan Society of Laparoscopic Colorectal Surgery||1|||f||||t||||||||||2018-06-01 02:21:15.157065|2018-06-01 02:21:15.157065
NCT00635453|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2012-07-17|2008-03-12|2008-03-13|Estimate|||||||2012-07-17|2012-07-18|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|February 2010|Actual|2010-02-28||Interventional|||"Impact of the Ten Steps for Healthy Feeding of Children Younger Than Two Years in Health Centers"|"Impact of the Ten Steps for Healthy Feeding of Children Younger Than Two Years in Health Centers"|Completed||N/A|474|Actual|Federal University of Health Science of Porto Alegre||1|||f||||f||||||||||2018-06-01 02:21:15.276443|2018-06-01 02:21:15.276443
NCT00635440|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-12|2008-03-12|2008-03-13|Estimate|||||||2008-03-12|2008-03-13|Estimate|December 2005||2005-12-31|March 2008|2008-03-31||||||||Interventional|||Randomized, Controlled Study to Investigate the Effect of Neuromuscular Electrical Stimulation (NMES) on Muscle Metabolism of Abdominal Surgical Patients|The Effect of Neuromuscular Electrical Stimulation on Muscle Metabolism of Major Abdominal Surgical Patients|Completed||N/A|26|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:21:15.370246|2018-06-01 02:21:15.370246
NCT00281411|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2018-02-14|2006-01-20|2006-01-24|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2001||2001-03-31|November 2016|2016-11-30|March 2009|Actual|2009-03-31|||||Observational|||Follow-up of Endovascular Aneurysm Treatment - The FEAT Trial|Follow-up Study of Endovascular Abdominal Aortic Aneurysm Treatment|Completed|||46|Actual|UMC Utrecht|||||f||||||||||||||2018-06-01 04:12:45.208747|2018-06-01 04:12:45.208747
NCT00635427|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2013-12-11||2015-05-15|2008-03-12|2008-03-13|Estimate|2013-12-11|2014-01-28|Estimate||||2015-05-15|2015-05-18|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Two participants who did not have type 1 Gaucher disease were withdrawn from the ITT study as per SAP definition and removed from the long-term efficacy analyses in this study, needed to support the interpretation of the long-term efficacy results. Therefore, 93 of 95 (97.9%) participants were included in the HGT-GCB-044 ITT population.|An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease|An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease|Completed||Phase 3|95|Actual|Shire||3|||f||||f||||||||||2018-06-01 02:21:15.559322|2018-06-01 02:21:15.559322
NCT00635414|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2011-01-24|2008-03-06|2008-03-13|Estimate|||||||2011-01-24|2011-01-25|Estimate|August 2002||2002-08-31|January 2011|2011-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously|An Open, Randomized, Two-way Crossover Study Comparing the Effect of 40mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD).|Completed||Phase 4|60|Anticipated|AstraZeneca||2|||||||||||||||||2018-06-01 02:21:16.642527|2018-06-01 02:21:16.642527
NCT00635401|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-04-07|2008-03-05|2008-03-13|Estimate|||||||2008-04-07|2008-04-10|Estimate|May 2004||2004-05-31|April 2008|2008-04-30|August 2004|Actual|2004-08-31|||||Interventional|||A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking|A Multicenter, Open-Label Study Exploring the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking|Completed||Phase 2|30|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:21:16.862432|2018-06-01 02:21:16.862432
NCT00635388|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2009-10-15|2008-03-12|2008-03-13|Estimate|||||||2009-10-15|2009-10-16|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study of the Effects of Probiotics in Children Grades 1-3|A Double-blind, Randomized, Placebo-controlled Study of the Effects of Probiotics in Children Grades 1-3|Completed||N/A|360|Actual|Procter and Gamble||3|||f||||f||||||||||2018-06-01 02:21:16.944492|2018-06-01 02:21:16.944492
NCT00635375|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2009-01-09|2008-03-12|2008-03-13|Estimate|||||||2009-01-09|2009-01-13|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparative Study of Phototherapy for Hyperbilirubinemia|A Comparative Study Between BiliSoft Blue LED Fiberoptic Blanket Phototherapy, Giraffe Spot PT Phototherapy, Natus Blue LED Bank Light Phototherapy, and BiliSoft + Giraffe Spot PT Combination Therapy|Completed||N/A|82|Anticipated|GE Healthcare||4|||f||||f||||||||||2018-06-01 02:21:17.032093|2018-06-01 02:21:17.032093
NCT00635362|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2013-02-22||2013-04-01|2008-03-12|2008-03-13|Estimate|2013-04-01|2013-05-13|Estimate||||2013-04-01|2013-05-13|Estimate|May 2007||2007-05-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|January 2011|Actual|2011-01-31||Interventional|||Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion|Immediate Post-placental Insertion of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean Delivery vs. 4-8 Week Post-delivery Interval Insertion: A Randomized Controlled Trial|Terminated||N/A|42|Actual|University of Chicago||2||Low recruitment|f||||f||||||||||2018-06-01 02:21:17.14446|2018-06-01 02:21:17.14446
NCT00635349|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2013-05-02||2013-07-16|2008-03-06|2008-03-13|Estimate|2013-05-02|2013-06-24|Estimate||||2013-07-16|2013-07-22|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Comparative Study of Tramadol Hydrochloride Plus Acetaminophen Tablets Maintenance Versus Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Maintenance in Participants With Knee Osteoarthritis|A Comparison of Tramadol/Acetaminophen Tablets Maintenance Versus NSAID Maintenance After Tramadol/Acetaminophen and NSAID Combination Therapy in Knee Osteoarthritis Patients: Multicenter, Randomized, Open Comparative Study|Completed||Phase 4|143|Actual|Janssen Korea, Ltd., Korea|There was no wash-out period after Day 28 to show drug efficacy in participants whose pain was already relieved and results were not meet the objective by setting inappropriate non-inferiority limit by applying WOMAC total score in hypothesis.|2|||f||||f||||||||||2018-06-01 02:21:17.83816|2018-06-01 02:21:17.83816
NCT00635336|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2010-10-20|2008-03-12|2008-03-13|Estimate|||||||2010-10-20|2010-10-21|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|February 2010|Actual|2010-02-28|February 2007|Actual|2007-02-28||Interventional|||Novel Peptide Vaccination for Patients With Advanced Bladder Cancer|Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer|Completed||Phase 1|20|Anticipated|Iwate Medical University|||||f||||t||||||||||2018-06-01 02:21:18.335297|2018-06-01 02:21:18.335297
NCT00635323|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-04-02|2008-03-05|2008-03-13|Estimate|||||||2008-04-02|2008-04-07|Estimate|November 2002||2002-11-30|April 2008|2008-04-30|May 2005|Actual|2005-05-31|||||Interventional|||Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma|A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable Hepatocellular Carcinoma|Completed||Phase 2|73|Anticipated|Pfizer||1|||f||||f||||||||||2018-06-01 02:21:18.447615|2018-06-01 02:21:18.447615
NCT00635310|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2012-12-19|2008-03-05|2008-03-13|Estimate|||||||2012-12-19|2012-12-20|Estimate|January 2005||2005-01-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin|Safety Profiles of Percutaneous Liver Biopsy in Hemodialysis Patients With Chronic Hepatitis C Pre-treated With 1-Deamino-8- D-Arginine Vasopressin|Unknown status|Recruiting|N/A|3520|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 02:21:18.55062|2018-06-01 02:21:18.55062
NCT00635297|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2010-03-02|2008-03-05|2008-03-13|Estimate|||||||2010-03-02|2010-03-03|Estimate|April 2008||2008-04-30|January 2008|2008-01-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Percutaneous Vertebroplasty: Prophylactic Treatment of Adjacent Vertebra|Percutaneous Vertebroplasty.Study of Refracture Rates After Prophylactic Vertebroplasty of Adjacent Vertebrae|Suspended||N/A|100|Anticipated|Ullevaal University Hospital||2||Problems with patient recruitement|f||||t||||||||||2018-06-01 02:21:18.674005|2018-06-01 02:21:18.674005
NCT00635284|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2016-10-25|2008-03-12|2008-03-13|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2007||2007-12-31|October 2016|2016-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies|A Phase I Trial of ABI-009 (Nab-rapamycin) Administered Weekly in Patients With Advanced Non-hematologic Malignancies|Completed||Phase 1|27|Actual|Celgene Corporation||1|||f||||f||||||||||2018-06-01 02:21:18.741554|2018-06-01 02:21:18.741554
NCT00635258|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-03-06|2008-03-06|2008-03-13|Estimate|||||||2008-03-06|2008-03-13|Estimate|January 2004||2004-01-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|GnRH-Ovodon||Administration of GnRH Antagonist to Oocyte Donation Recipients|Administration of GnRH Antagonist to Oocyte Donation Recipients During Endometrial Preparation.|Completed|||100|Actual|Centro Ginecologia y Obstetricia.|||2||f||||t||||||||||2018-06-01 02:21:18.871448|2018-06-01 02:21:18.871448
NCT00635245|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2015-03-10|2008-03-12|2008-03-13|Estimate|||||||2015-03-10|2015-03-11|Estimate||||March 2015|2015-03-31||||||||Interventional|||CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery|A Phase 1 Pharmacodynamic Study Of CP-751,871 As Neoadjuvant Treatment For Early Breast Cancer|Withdrawn||Phase 1|0|Actual|Pfizer|||||f||||||||||||||2018-06-01 02:21:18.963433|2018-06-01 02:21:18.963433
NCT00635232|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2011-08-09||2011-09-12|2008-03-12|2008-03-13|Estimate|2011-08-10|2011-09-13|Estimate||||2011-09-12|2011-09-16|Estimate|March 2008||2008-03-31|September 2011|2011-09-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension|A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension|Completed||Phase 2|261|Actual|Ligand Pharmaceuticals|The 800mg dose level was discontinued from further enrollment per protocol amendment due to findings from another PS433540 trial that suggested clinical benefit beyond 500mg was expected to be limited.|5|||f||||f||||||||||2018-06-01 02:21:19.045598|2018-06-01 02:21:19.045598
NCT00635219|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2013-10-28||2013-12-23|2008-03-05|2008-03-13|Estimate|2013-12-23|2014-02-11|Estimate||||2013-12-23|2014-02-11|Estimate|February 2008||2008-02-29|December 2013|2013-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Full-analysis set (FAS) - all patients in the all-patients-treated set (APTS) who had at least one valid postbaseline assessment of the primary efficacy variable|Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder|A Randomised, Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Evaluating the Efficacy and Safety of Three Dosages of [Vortioxetine] Lu AA21004, in Acute Treatment of Major Depressive Disorder|Completed||Phase 3|766|Actual|H. Lundbeck A/S||5|||f||||f||||||||||2018-06-01 02:21:19.579146|2018-06-01 02:21:19.579146
NCT00635206|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2009-07-13|2008-03-12|2008-03-13|Estimate|||||||2009-07-13|2009-07-14|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|BIPAP||Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter|Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter|Completed||Phase 3|51|Actual|Clayton Sleep Insititute||2|||f||||t||||||||||2018-06-01 02:21:20.493727|2018-06-01 02:21:20.493727
NCT00635193|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05||2012-05-04|2013-01-10|2008-03-12|2008-03-13|Estimate||||2012-05-10|2012-05-14|Estimate|2013-01-10|2013-01-18|Estimate|July 2007||2007-07-31|January 2013|2013-01-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)|A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer That Have Relapsed After Prior Therapy With a Platinum/Taxane-Based Chemotherapy|Completed||Phase 1/Phase 2|138|Actual|AbbVie||5|||f||||f||||||||||2018-06-01 02:21:20.58666|2018-06-01 02:21:20.58666
NCT00635180|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2011-07-03|2008-03-12|2008-03-13|Estimate|||||||2011-07-03|2011-07-06|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|March 2007|Actual|2007-03-31||Interventional|||Intraocular Pressure (IOP) and Isometric Exercise|Changes in Intraocular Pressure and Pulsatile Ocular Blood Flow Measured Continuously During Isometric Exercise|Completed||N/A|9|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-06-01 02:21:20.713038|2018-06-01 02:21:20.713038
NCT00635167|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-04-09|2008-03-12|2008-03-13|Estimate|||||||2008-04-09|2008-04-10|Estimate|January 2008||2008-01-31|April 2008|2008-04-30|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Interventional|||Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)|Contrast Enhanced Transrectal Ultrasound (TRUS) to Assess Prostatic Vascularity as a Measure of Treatment Response and Early Prediction of Treatment Failure After XRT|Unknown status|Recruiting|N/A|14|Anticipated|Thomas Jefferson University|||||f||||t||||||||||2018-06-01 02:21:20.761553|2018-06-01 02:21:20.761553
NCT00635154|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2010-11-09||2010-12-17|2008-03-12|2008-03-13|Estimate|2010-11-09|2010-12-09|Estimate||||2010-12-17|2010-12-30|Estimate|December 2002||2002-12-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|December 2009|Actual|2009-12-31||Interventional|||Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma|A Phase II Study of Anakinra (IL-1 Receptor Antagonist) in Patients With Smoldering/Indolent Multiple Myeloma|Completed||Phase 2|55|Actual|Mayo Clinic||1|||f||||||||||||||2018-06-01 02:21:20.835475|2018-06-01 02:21:20.835475
NCT00635141|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2013-08-30|2008-03-04|2008-03-13|Estimate|||||||2013-08-30|2013-09-02|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of Hypertonic Saline on the Lung Clearance Index in Patients With Cystic Fibrosis|The Effect of Inhaled Hypertonic Saline (7%) Versus Normal Saline (0.9%) on the Lung Clearance Index in Patients With Cystic Fibrosis|Completed||Phase 3|20|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 02:21:22.050078|2018-06-01 02:21:22.050078
NCT00635128|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2017-02-21|2009-05-20|2017-04-12|2008-03-06|2008-03-13|Estimate|2017-04-12|2017-07-05|Actual|2009-09-28|2009-09-30|Estimate|2017-04-12|2017-07-05|Actual|February 1, 2008|Actual|2008-02-01|April 2017|2017-04-30|July 8, 2008|Actual|2008-07-08|July 8, 2008|Actual|2008-07-08||Interventional|||Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine|Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting.|Completed||Phase 4|415|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:21:22.161751|2018-06-01 02:21:22.161751
NCT00635115|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2008-03-12|2008-03-12|2008-03-13|Estimate|||||||2008-03-12|2008-03-13|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|VEPRO||The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia|The VEPRO Trial: A Cross-Over Randomised Controlled Trial Comparing 2 Corrective Lenses for Patients With Presbyopia|Completed||N/A|127|Actual|Santéclair||2|||f||||f||||||||||2018-06-01 02:21:22.914349|2018-06-01 02:21:22.914349
NCT00633425|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-03-26|2008-03-11|2008-03-12|Estimate|||||||2008-03-26|2008-03-28|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|October 2003|Actual|2003-10-31|||||Interventional|||Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride||Completed||Phase 4|43|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:21:59.203953|2018-06-01 02:21:59.203953
NCT00635102|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2016-01-06||2016-12-14|2008-03-12|2008-03-13|Estimate|2016-12-14|2016-12-16|Estimate||||2016-12-14|2016-12-16|Estimate|October 1997||1997-10-31|December 2016|2016-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||57 individuals signed consent forms, of the 57 individuals 27 were alcohol dependent and 30 were healthy subjects. Of the alcohol dependent subjects 20 completed, 3 completed part of the study and 4 withdrew from the study. Of the healthy subjects, 22 completed, 4 completed part of the study and 4 withdrew from the study.|Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects|Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects|Completed||N/A|57|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:21:23.133764|2018-06-01 02:21:23.133764
NCT00635089|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2016-03-23|2013-08-16|2017-02-02|2008-03-06|2008-03-13|Estimate|2017-02-02|2017-03-23|Actual|2013-08-16|2013-08-26|Estimate|2017-02-02|2017-03-23|Actual|July 2008||2008-07-31|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis|An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002|Completed||Phase 3|190|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 02:21:24.513421|2018-06-01 02:21:24.513421
NCT00635076|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-04-07|2008-03-05|2008-03-13|Estimate|||||||2008-04-07|2008-04-10|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|September 2004|Actual|2004-09-30|||||Interventional|||A Study to Assess the Long-Term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder|Terminated||Phase 4|3|Actual|Pfizer||2||Please see Detailed Description for the termination reason.|f||||t||||||||||2018-06-01 02:21:25.075034|2018-06-01 02:21:25.075034
NCT00635063|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-06-05|2008-03-12|2008-03-13|Estimate|||||||2008-06-05|2008-06-06|Estimate|February 2008||2008-02-29|June 2008|2008-06-30||||||||Interventional|||A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects|A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects With Malignancies|Terminated||Phase 3|150|Anticipated|Sosei||2||"Termination is due to a combination of a device defect potentially impacting the quality of the~   AD 923 IMP and a major change in corporate strategy."|f||||f||||||||||2018-06-01 02:21:25.152056|2018-06-01 02:21:25.152056
NCT00635050|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2016-03-31||2016-06-15|2008-03-12|2008-03-13|Estimate|2016-05-10|2016-06-15|Estimate||||2016-06-15|2016-07-14|Estimate|March 2008||2008-03-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional||women with locally advanced invasive breast cancer|Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin|Phase II Trial of Primary Systemic Therapy for Locally Advanced Breast Cancer Using Sequential Doxil, Paclitaxel, and Cyclophosphamide With Concurrent Avastin|Completed||Phase 2|32|Actual|University of Alabama at Birmingham|pilot study|1|||f||||t||||||||No||2018-06-01 02:21:25.248415|2018-06-01 02:21:25.248415
NCT00635037|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-03-12|2008-03-12|2008-03-13|Estimate|||||||2008-03-12|2008-03-13|Estimate|June 2004||2004-06-30|March 2008|2008-03-31|November 2006|Actual|2006-11-30|February 2005|Actual|2005-02-28||Interventional|ACP||Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine|Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine on Pain Relief of Patients With Myofascial Pain: Randomized Clinical Study|Completed||N/A|30|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 02:21:25.430845|2018-06-01 02:21:25.430845
NCT00635024|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2010-08-27||2016-12-20|2008-03-12|2008-03-13|Estimate|2010-10-01|2010-10-18|Estimate||||2016-12-20|2017-02-10|Actual|May 2008||2008-05-31|August 2011|2011-08-31|November 2010|Actual|2010-11-30|July 2008|Actual|2008-07-31||Interventional|||Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma|A Phase II Trial of Thymoglobulin and Melphalan in Patients With Relapsed Multiple Myeloma|Terminated||Phase 2|1|Actual|Mayo Clinic|After 1 patient was recruited, this trial temporarily closed to allow the first dose of Anti-thymocyte Globulin to be split over two days. Before the modification was written, it was decided to permanently close this study due to competing trials.|1||Due to competing trials, this study is permanenlty closed to patient acrrual.|f||||||||||||||2018-06-01 02:21:25.595072|2018-06-01 02:21:25.595072
NCT00635011|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2018-02-25|2008-03-12|2008-03-13|Estimate|||||||2018-02-25|2018-02-27|Actual|February 2008||2008-02-29|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2011|Actual|2011-12-31||Interventional|||Pre- and Postoperative Cognitive Behavior Therapy for Patients Accepted for Bariatric Surgery|Pre- and Postoperative Cognitive Behavior Therapy for Patients Accepted for Bariatric Surgery|Completed||N/A|100|Anticipated|Helse Fonna|||||f||||t||||||||||2018-06-01 02:21:25.842141|2018-06-01 02:21:25.842141
NCT00634998|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2012-09-06|2008-03-05|2008-03-13|Estimate|||||||2012-09-06|2012-09-10|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy|Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy|Completed||Phase 1|10|Actual|Washington State University||2|||f||||f||||||||||2018-06-01 02:21:25.911737|2018-06-01 02:21:25.911737
NCT00634985|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2011-04-22|2008-03-06|2008-03-13|Estimate|||||||2011-04-22|2011-04-26|Estimate|November 2002||2002-11-30|April 2011|2011-04-30|December 2003|Actual|2003-12-31|||||Interventional|||Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs|A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS|Completed||Phase 4|120|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:21:25.986674|2018-06-01 02:21:25.986674
NCT00634972|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-03-12|2008-03-12|2008-03-13|Estimate|||||||2008-03-12|2008-03-13|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|ROP||Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity|Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity|Unknown status|Enrolling by invitation|Phase 4|200|Anticipated|University of South Alabama||2|||f||||f||||||||||2018-06-01 02:21:26.067405|2018-06-01 02:21:26.067405
NCT00634959|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2010-11-09|2008-03-05|2008-03-13|Estimate|||||||2010-11-09|2010-11-10|Estimate|July 2003||2003-07-31|November 2010|2010-11-30|December 2003|Actual|2003-12-31|||||Interventional|||Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus|An Investigation Into The Effects Of Food And Dose Regimen On Viral Load Response In HIV Infected Patients On Short-Term Monotherapy With UK-427,857 (Maraviroc)|Completed||Phase 2|37|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-06-01 02:21:26.156654|2018-06-01 02:21:26.156654
NCT00634946|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2011-03-29|2008-03-12|2008-03-13|Estimate|||||||2011-03-29|2011-03-31|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|August 2010|Actual|2010-08-31|November 2009|Actual|2009-11-30||Interventional|||SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation|A Multicenter, Randomized, Double-blind Recommended Dose-finding Study of SI-6603 in Patients With Lumbar Disc Herniation (Phase II/III Study)|Completed||Phase 2/Phase 3|195|Actual|Seikagaku Corporation||4|||f||||||||||||||2018-06-01 02:21:26.253008|2018-06-01 02:21:26.253008
NCT00634933|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2012-12-27|2012-07-17|2013-02-06|2008-03-12|2008-03-13|Estimate|2013-02-06|2013-03-11|Estimate|2012-07-17|2012-07-25|Estimate|2013-02-06|2013-03-11|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|February 2010|Actual|2010-02-28||Interventional|||Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis|A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate|Terminated||Phase 2|222|Actual|Pfizer|As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.|3||"The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No~   safety reasons contributed to the termination of the study."|f||||f||||||||||2018-06-01 02:21:26.450342|2018-06-01 02:21:26.450342
NCT00634920|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2014-05-06||2014-08-12|2008-03-12|2008-03-13|Estimate|2014-08-12|2014-08-13|Estimate||||2014-08-12|2014-08-13|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients|A Controlled Randomized Open-label Multicenter Study Evaluating if Early Conversion to Everolimus (Certican) From Cyclosporine (Neoral) in de Novo Renal Transplant Recipients Can Improve Long-term Renal Function and Slow Down the Progression of Chronic Allograft Nephropathy|Completed||Phase 4|204|Actual|Novartis||2|||f||||t||||||||||2018-06-01 02:21:28.193907|2018-06-01 02:21:28.193907
NCT00634907|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2013-04-23||2017-04-25|2008-03-06|2008-03-13|Estimate|2017-04-25|2017-06-08|Actual||||2017-04-25|2017-06-08|Actual|September 2006||2006-09-30|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)|Prospective CYP2C9 And VKORC1 Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)For Anticoagulation|Completed||N/A|263|Actual|University of Utah|Limited by the fact that INR was used to adjust dose at the third dose, which may not have allowed enough time for steady-state concentrations of warfarin to be achieved, nor for the genotype-based dosing to be adequately studied.|2|||f||||t||||||||No||2018-06-01 02:21:29.373658|2018-06-01 02:21:29.373658
NCT00634894|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2016-04-19|2008-03-06|2008-03-13|Estimate|||||||2016-04-19|2016-04-20|Estimate|March 2008||2008-03-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II, Double-Blinded, Randomized Evaluation of Femara (Letrozole) Versus Placebo for Adjuvant Treatment After Completion of First-Line Chemotherapy for Patients With Optimally Debulked and Chemoresponsive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2||Study halted with no registration, the drug company sponsor withdrew support.|f||||t||||||||||2018-06-01 02:21:29.645461|2018-06-01 02:21:29.645461
NCT00634881|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2018-05-09|2008-03-12|2008-03-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 2003||2003-11-30|May 2018|2018-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia|Consolidation Therapy With Alemtuzumab (MabCampath®) in Patients With Chronic Lymphocytic Leukemia Who Are in Complete or Partial 2nd Remission After Cytoreduction With Fludarabine or Fludarabine Plus Cyclophosphamide or Fludarabine Plus Cyclophosphamide Plus Rituximab or Bendamustine or Bendamustine Plus Rituximab - a Phase I/II Study|Completed||Phase 1/Phase 2|13|Actual|German CLL Study Group||2|||f||||f||||||||No||2018-06-01 02:21:29.809158|2018-06-01 02:21:29.809158
NCT00634868|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2011-06-09|2008-03-12|2008-03-13|Estimate|||||||2011-06-09|2011-06-10|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Wounds Utilizing Light||Terminated||N/A|30|Anticipated|QRay Ltd.||2||Slow patients recruitment|f||||t||||||||||2018-06-01 02:21:29.896747|2018-06-01 02:21:29.896747
NCT00634855|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-03-12|2008-03-12|2008-03-13|Estimate|||||||2008-03-12|2008-03-13|Estimate|March 2008||2008-03-31|March 2008|2008-03-31||||||||Observational|||Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR|Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR|Unknown status|Not yet recruiting||30|Anticipated|Medical University of South Carolina|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:21:29.956443|2018-06-01 02:21:29.956443
NCT00634842|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2009-10-23||2017-01-30|2008-03-06|2008-03-13|Estimate|2009-11-17|2009-12-22|Estimate||||2017-01-30|2017-03-10|Actual|February 2008||2008-02-29|January 2017|2017-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|TITRATE™||Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily|Effect of Two Different Fasting Blood Glucose Titration Targets in Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily in Combination With 1-3 Oral Agents|Completed||Phase 4|244|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 02:21:30.031173|2018-06-01 02:21:30.031173
NCT00634829|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07||2013-07-10|2013-07-11|2008-03-12|2008-03-13|Estimate||||2013-07-11|2013-07-15|Estimate|2013-07-11|2013-07-15|Estimate|February 2008||2008-02-29|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction|Randomized, Double-Blind, Controlled, Single-Dose, Three-Treatment, Cross-Over Study of The Protective Effects Of Albuterol-HFA In Preventing Exercise-Induced Bronchoconstriction In Adolescent And Adult Asthmatic Patients|Terminated||Phase 3|24|Actual|Amphastar Pharmaceuticals, Inc.||3||IND voluntarily withdrawn, without prejudice|f||||f||||||||||2018-06-01 02:21:30.614071|2018-06-01 02:21:30.614071
NCT00634816|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2013-05-29|2008-03-12|2008-03-13|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2003||2003-04-30|May 2013|2013-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers|Cross-sectional Study of Bone Mineral Density in Adult Survivors of Solid Pediatric Cancers|Completed|||38|Actual|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 02:21:30.710457|2018-06-01 02:21:30.710457
NCT00634803|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2014-09-29|2008-03-06|2008-03-13|Estimate|||||||2014-09-29|2014-09-30|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|POD||Clinical Trial of Integrated Treatment for Pain and Opioid Dependence|Clinical Trial of Integrated Treatment for Pain and Opioid Dependence|Unknown status|Recruiting|Phase 1/Phase 2|91|Anticipated|Yale University||3|||f||||f||||||||||2018-06-01 02:21:30.7812|2018-06-01 02:21:30.7812
NCT00634790|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-04-07|2008-03-05|2008-03-13|Estimate|||||||2008-04-07|2008-04-10|Estimate|May 2004||2004-05-31|April 2008|2008-04-30|October 2004|Actual|2004-10-31|||||Interventional|||A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks|An Open-Label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks|Terminated||Phase 4|49|Actual|Pfizer||1||Please see Detailed Description for termination reason.|f||||t||||||||||2018-06-01 02:21:30.879626|2018-06-01 02:21:30.879626
NCT00634777|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2011-07-19|2008-03-12|2008-03-13|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|pet||Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma|Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma|Unknown status|Recruiting|N/A|239|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-06-01 02:21:31.013373|2018-06-01 02:21:31.013373
NCT00634764|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2018-05-15|2008-03-12|2008-03-13|Estimate|||||||2018-05-15|2018-05-18|Actual|November 2006|Actual|2006-11-30|May 2018|2018-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Predictors of Maternal Weight Gain and Neonatal Body Composition|Resting Metabolic Rate, Insulin Resistance, and Attitude Towards Weight Gain During Pregnancy to Predict Maternal Weight Gain and Neonatal Body Composition.|Terminated|||3|Actual|Medical University of South Carolina|||1||f||||f||||||||||2018-06-01 02:21:31.145526|2018-06-01 02:21:31.145526
NCT00634751|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2017-06-12||2017-07-07|2008-03-12|2008-03-13|Estimate|2017-07-07|2017-08-08|Actual||||2017-07-07|2017-08-08|Actual|February 2008||2008-02-29|July 2017|2017-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||Participants with histologically or cytologically confirmed adenocarcinoma of the pancreas or biliary tract were enrolled.|CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma|"A Phase I/II STudy of Oxaliplatin, Oral Capecitabine and Sorafenib in Patients With Advanced Pancreatic and Biliary Carcinoma"|Completed||Phase 1/Phase 2|48|Actual|University of Wisconsin, Madison||4|||f||||t||||||||||2018-06-01 02:21:31.260773|2018-06-01 02:21:31.260773
NCT00634738|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2011-06-25|2008-03-12|2008-03-13|Estimate|||||||2011-06-25|2011-06-28|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||The Treatment of the Median Nerve for the Elimination of the Symptoms Associated With the Carpal Tunnel Syndrome|Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study|Completed||Phase 1/Phase 2|60|Anticipated|Guy Hains Chiropractor||1|||f||||f||||||||||2018-06-01 02:21:32.309353|2018-06-01 02:21:32.309353
NCT00634725|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|||2015-12-10|2008-03-12|2008-03-13|Estimate|||||||2015-12-10|2015-12-11|Estimate|February 2008||2008-02-29|November 2012|2012-11-30|September 2014|Actual|2014-09-30|February 2013|Actual|2013-02-28||Interventional|||Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery|Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study|Completed||Phase 3|820|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||4|||f||||t||||||||||2018-06-01 02:21:32.379169|2018-06-01 02:21:32.379169
NCT00634712|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2011-01-24|2008-03-12|2008-03-13|Estimate|||||||2011-01-24|2011-01-25|Estimate|June 1999||1999-06-30|January 2011|2011-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)|Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function|Completed||Phase 3|734|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:21:32.689933|2018-06-01 02:21:32.689933
NCT00634699|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2011-06-25|2008-03-12|2008-03-13|Estimate|||||||2011-06-25|2011-06-28|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||The Treatment of Carpal Tunnel Syndrome Using Thumb Pressure Along the Median Nerve|Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome: a Preliminary Study.|Completed||Phase 1/Phase 2|60|Anticipated|Guy Hains Chiropractor||1|||f||||t||||||||||2018-06-01 02:21:32.75168|2018-06-01 02:21:32.75168
NCT00634686|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|||2009-01-29|2008-03-11|2008-03-13|Estimate|||||||2009-01-29|2009-02-02|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Effects of Omega-3 Fatty Acids on Bone and Frailty|Effects of Omega-3 Fatty Acids on Bone and Frailty|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|National Institute on Aging (NIA)||2|||f||||f||||||||||2018-06-01 02:21:32.821856|2018-06-01 02:21:32.821856
NCT00634673|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2008-03-12|2008-03-12|2008-03-13|Estimate|||||||2008-03-12|2008-03-13|Estimate|June 2006||2006-06-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Postprandial Fatty Acids and FABP2 in Type 2 Diabetes Mellitus (DM)|FABP2 Ala54Thr Genotype Influences the Postprandial Serum Fatty Acids Profile in Type 2 Diabetic Patients|Completed||N/A|26|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-06-01 02:21:32.902221|2018-06-01 02:21:32.902221
NCT00634660|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2017-01-30|2008-03-06|2008-03-13|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 2008||2008-05-31|January 2017|2017-01-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria|A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Subcutaneous Doses of rAvPAL-PEG in Subjects With Phenylketonuria|Completed||Phase 1|25|Actual|BioMarin Pharmaceutical||7|||f||||t|t|f||||||No||2018-06-01 02:21:32.971593|2018-06-01 02:21:32.971593
NCT00634647|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2013-02-27||2015-09-30|2008-03-12|2008-03-13|Estimate|2013-02-27|2013-04-10|Estimate||||2015-09-30|2015-10-02|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|April 2013|Actual|2013-04-30|August 2011|Actual|2011-08-31||Interventional|||Satraplatin and Prednisone to Treat Prostate Cancer|A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)|Completed||Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 02:21:33.072448|2018-06-01 02:21:33.072448
NCT00634634|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2017-11-15|2008-03-12|2008-03-13|Estimate|||||||2017-11-15|2017-11-17|Actual|August 11, 2008|Actual|2008-08-11|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer|Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|54|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 02:21:33.384214|2018-06-01 02:21:33.384214
NCT00634621|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2014-07-09||2014-08-12|2008-03-12|2008-03-13|Estimate|2014-08-12|2014-08-25|Estimate||||2014-08-12|2014-08-25|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer|A Post-authorization, Observational Study to Assess the Impact of Blue Light Cystoscopy After Administration of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer.|Completed|||283|Actual|GE Healthcare|||||f||||f||||||||||2018-06-01 02:21:33.486765|2018-06-01 02:21:33.486765
NCT00634608|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2016-09-29|2008-03-05|2008-03-13|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2008||2008-02-29|September 2016|2016-09-30|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow|Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow|Completed||N/A|224|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 02:21:33.665907|2018-06-01 02:21:33.665907
NCT00634595|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2010-07-26|2008-03-05|2008-03-13|Estimate|||||||2010-07-26|2010-07-28|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Trial of E10A in Head and Neck Cancer|A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer|Unknown status|Recruiting|Phase 2|116|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:21:33.740764|2018-06-01 02:21:33.740764
NCT00634582|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-12|2013-11-22||2017-07-27|2008-03-12|2008-03-13|Estimate|2013-11-22|2014-01-10|Estimate||||2017-07-27|2017-08-25|Actual|January 2009||2009-01-31|November 2013|2013-11-30|June 2015|Actual|2015-06-30|January 2013|Actual|2013-01-31||Interventional|||Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases|Phase II Trial of Zemplar (19-nor-1 a,25-Dihydroxyvitamin D2, Paricalcitol Capsule) on Bony Remodeling in Advanced Androgen-Insensitive Prostate Cancer|Terminated||Phase 2|2|Actual|Wake Forest University Health Sciences||||slow accrual|f||||t|t|f||||||||2018-06-01 02:21:33.828311|2018-06-01 02:21:33.828311
NCT00634569|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2015-05-20||2016-12-07|2008-03-12|2008-03-13|Estimate|2016-10-14|2016-12-08|Estimate||||2016-12-07|2017-02-02|Estimate|May 2008||2008-05-31|December 2016|2016-12-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects|Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases.|Completed||Phase 4|24|Actual|Grifols Biologicals Inc.||1|||f||||f||||||||||2018-06-01 02:21:33.988986|2018-06-01 02:21:33.988986
NCT00634556|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2018-02-08|2008-03-12|2008-03-13|Estimate|||||||2018-02-08|2018-02-12|Actual|February 2006||2006-02-28|February 2018|2018-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|TSfMRI||Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)|Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)|Completed||Phase 1|49|Actual|Washington University School of Medicine||2|||f||||f|t|f||||||No|Vital signs IPD are shared at: Siddiqi SH, Creech ML, Black KJ. Orthostatic stability with intravenous levodopa. PeerJ. 2015 Aug 27;3:e1198. doi: 10.7717/peerj.1198. eCollection 2015. PubMed ID: 26336641 There is no plan to share other IPD.|2018-06-01 02:21:34.306192|2018-06-01 02:21:34.306192
NCT00634543|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2013-04-30||2013-07-26|2008-03-06|2008-03-13|Estimate|2013-04-30|2013-07-16|Estimate||||2013-07-26|2013-08-12|Estimate|December 2006||2006-12-31|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Full analysis set (FAS) included all randomly assigned participants who met the eligibility criteria and had at least 1 post-baseline efficacy assessment data.|A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy|Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study|Completed||Phase 4|162|Actual|Janssen Korea, Ltd., Korea|The study was a non-inferiority study to demonstrate that tramadol/acetaminophen did not have poorer ffectiveness as compared to gabapentin. However this could not be demonstrated because of error in the minimum significant difference set-up.|2|||f||||f||||||||||2018-06-01 02:21:34.586643|2018-06-01 02:21:34.586643
NCT00634530|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-10|||2009-02-03|2008-03-12|2008-03-13|Estimate|||||||2009-02-03|2009-02-04|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Impact of a Nutritional Intervention Program for Weight Control During Pregnancy|Impact of a Nutritional Intervention Program for Weight Control During Pregnancy|Completed||N/A|318|Actual|Federal University of Health Science of Porto Alegre||1|||f||||f||||||||||2018-06-01 02:21:34.994111|2018-06-01 02:21:34.994111
NCT00634517|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07||2013-07-10|2013-07-11|2008-03-12|2008-03-13|Estimate||||2013-07-11|2013-07-15|Estimate|2013-07-11|2013-07-15|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma|A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, 4-Week Study to Evaluate the Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Patients With Asthma in Pediatric Patients With Asthma|Terminated||Phase 3|48|Actual|Amphastar Pharmaceuticals, Inc.||2||IND voluntarily withdrawn, without prejudice|f||||f||||||||||2018-06-01 02:21:35.060574|2018-06-01 02:21:35.060574
NCT00634504|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2014-06-04||2014-06-04|2008-03-06|2008-03-13|Estimate|2014-06-04|2014-07-03|Estimate||||2014-06-04|2014-07-03|Estimate|May 2008||2008-05-31|June 2014|2014-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|LVPK|Safety population|Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze|An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, With or Without Voraxaze Treatment|Completed||Phase 1|20|Actual|BTG International Inc.||2|||f||||f||||||||||2018-06-01 02:21:35.215446|2018-06-01 02:21:35.215446
NCT00634491|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-03-04|2008-03-04|2008-03-13|Estimate|||||||2008-03-04|2008-03-13|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Comparison Between Effect of Acetazolamide and NaHco3 in Prevention of Contrast Nephropathy|Effect of Acetazolamide in Prevention of Contrast Nephropathy|Completed||Phase 2|240|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-06-01 02:21:35.568075|2018-06-01 02:21:35.568075
NCT00634478|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2015-08-21|2008-03-06|2008-03-13|Estimate|||||||2015-08-21|2015-08-24|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Interventional|||Pre-lemniscal Radiation Deep Brain Stimulation for ET|Pre-lemniscal Radiation Deep Brain Stimulation for ET|Terminated||Phase 2/Phase 3|10|Actual|Medical College of Wisconsin||2||Difficulty in recruitment. Funding issues.|f||||f||||||||||2018-06-01 02:21:35.652442|2018-06-01 02:21:35.652442
NCT00634465|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2015-05-22|2008-03-04|2008-03-13|Estimate|||||||2015-05-22|2015-05-25|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||A Biomechanical Assessment of the AST Stabilimax BAR Using Radiostereometric Analysis (RSA)|A Biomechanical Assessment of the AST Stabilimax BAR Using Radiostereometric Analysis (RSA)|Withdrawn|||0|Actual|State University of New York - Upstate Medical University|||1|low enrollment|f||||f||||||||||2018-06-01 02:21:35.732381|2018-06-01 02:21:35.732381
NCT00634452|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2012-12-05|2008-03-07|2008-03-13|Estimate|||||||2012-12-05|2012-12-06|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|MDX1401-01||Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma|A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma|Completed||Phase 1|22|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:21:35.790656|2018-06-01 02:21:35.790656
NCT00634439|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-09-14|2008-03-12|2008-03-13|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Safety Study of Atomoxetine and Cerebrovascular Outcomes|Atomoxetine and Cerebrovascular Outcomes in Adults|Completed|||72000|Anticipated|Eli Lilly and Company|||3||f||||f||||||||||2018-06-01 02:21:35.866965|2018-06-01 02:21:35.866965
NCT00634426|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2015-05-19|2008-03-12|2008-03-13|Estimate|||||||2015-05-19|2015-05-21|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|MESCC||Surgical Versus Nonoperative Treatment of Metastatic Epidural Spinal Cord Compression|Surgical Versus Nonoperative Treatment of Metastatic Epidural Spinal Cord Compression. Quality of Life and Cost-effectiveness Outcomes|Completed|||163|Actual|AOSpine North America Research Network|||3||f||||f||||||||||2018-06-01 02:21:35.957781|2018-06-01 02:21:35.957781
NCT00634413|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2009-02-27|2008-03-07|2008-03-13|Estimate|||||||2009-02-27|2009-03-02|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD|A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 on Markers of Pulmonary Inflammation in Subjects With Moderate to Severe COPD|Completed||Phase 2|91|Actual|Pulmagen Therapeutics||2|||f||||f||||||||||2018-06-01 02:21:36.064955|2018-06-01 02:21:36.064955
NCT00634400|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2011-01-24|2008-03-12|2008-03-13|Estimate|||||||2011-01-24|2011-01-25|Estimate|March 1999||1999-03-31|January 2011|2011-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)|Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function|Completed||Phase 3|6268|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:21:36.144087|2018-06-01 02:21:36.144087
NCT00634387|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2011-07-03|2008-03-12|2008-03-13|Estimate|||||||2011-07-03|2011-07-06|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effects of Anthocyans on Cardiovascular and Sympathetic Function|Effects of Anthocyans on Cardiovascular and Sympathetic Function|Completed||N/A|27|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 02:21:36.213317|2018-06-01 02:21:36.213317
NCT00634374|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-04-11|2008-03-06|2008-03-13|Estimate|||||||2008-04-11|2008-04-14|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Administration of a Bitter-Tasting Medication: Comparison Between the Rx Medibottle and the Oral Syringe|Efficacy of the Rx Medibottle Compared to the Oral Syringe in Delivering Infant-Acceptable Liquid Medication Completely and Accurately: a Controlled Clinical Trial|Completed||N/A|81|Actual|Bronx-Lebanon Hospital Center Health Care System||2|||f||||f||||||||||2018-06-01 02:21:36.271881|2018-06-01 02:21:36.271881
NCT00634361|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2014-05-21|2008-03-06|2008-03-13|Estimate|||||||2014-05-21|2014-05-22|Estimate|September 2001||2001-09-30|May 2014|2014-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Ethyl-EPA Treatment of Prodromal Patients|Ethyl-EPA Treatment of Prodromal Patients|Completed||Phase 2/Phase 3|7|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:21:36.336743|2018-06-01 02:21:36.336743
NCT00634348|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2017-03-07|2008-03-05|2008-03-13|Estimate|||||||2017-03-07|2017-03-10|Actual|April 2004||2004-04-30|March 2017|2017-03-31|March 2005|Actual|2005-03-31|||||Interventional|||A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients|A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care|Completed||Phase 4|256|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:21:36.423541|2018-06-01 02:21:36.423541
NCT00634335|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-12-29|2008-03-04|2008-03-13|Estimate|||||||2008-12-29|2008-12-30|Estimate|March 2008||2008-03-31|February 2008|2008-02-29|June 2009|Anticipated|2009-06-30|March 2009|Anticipated|2009-03-31||Observational|||Echocardiographic Characteristics of High Endurance Israeli Athletes|Echocardiographic Characteristics of High Endurance Israeli Athletes|Unknown status|Recruiting||81|Anticipated|Soroka University Medical Center|||1||f||||t||||||||||2018-06-01 02:21:36.525372|2018-06-01 02:21:36.525372
NCT00634322|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2012-11-30|2011-07-28|2014-09-09|2008-03-06|2008-03-13|Estimate|2014-09-09|2014-09-15|Estimate|2011-07-28|2011-08-01|Estimate|2014-09-09|2014-09-15|Estimate|October 2008||2008-10-31|September 2014|2014-09-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma|Randomized, Blinded, Placebo-Controlled Trial of High Dose Methotrexate With Leucovorin Rescue (HDMTX-LV) With or Without Glucarpidase in Osteosarcoma|Terminated||Phase 2|7|Actual|BTG International Inc.|No efficacy endpoints were reported due to early termination (insufficient enrollment).|3||Lack of enrollment|f||||f||||||||||2018-06-01 02:21:36.584918|2018-06-01 02:21:36.584918
NCT00634309|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2011-01-24|2008-03-12|2008-03-13|Estimate|||||||2011-01-24|2011-01-25|Estimate|June 1999||1999-06-30|January 2011|2011-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)|Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Depressed Left Ventricular Systolic Function|Completed||Phase 3|597|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:21:36.955153|2018-06-01 02:21:36.955153
NCT00634296|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2008-03-06|2008-03-06|2008-03-13|Estimate|||||||2008-03-06|2008-03-13|Estimate|March 2005||2005-03-31|March 2008|2008-03-31|March 2010|Anticipated|2010-03-31|March 2008|Anticipated|2008-03-31||Interventional|||The Effects of the Inspiratory Muscle Plus Aerobic Training Compare to Aerobic Training Alone in Heart Failure Patients.|The Effects of the Inspiratory Muscle Training Plus Aerobic Training Compare to Aerobic Training Alone in Heart Failure Patients With Inspiratory Muscle Weakness.|Unknown status|Recruiting|N/A|30|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f||||||||||2018-06-01 02:21:37.01809|2018-06-01 02:21:37.01809
NCT00634283|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2009-08-06|2008-03-06|2008-03-13|Estimate|||||||2009-08-06|2009-08-07|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects|Physiologic Monitoring of Antidepressant Medication Effects in Normal Healthy Subjects II|Completed||Phase 4|7|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-06-01 02:21:37.09542|2018-06-01 02:21:37.09542
NCT00634270|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2015-07-03||2017-10-12|2008-03-12|2008-03-13|Estimate|2016-12-21|2017-02-14|Actual||||2017-10-12|2017-11-17|Actual|April 2008||2008-04-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|Protocol 102|Of the 49 patients enrolled in Stratum 1; 46 were evaluable. Of the 13 enrolled in Stratum 2; 12 were evaluable. This information is also listed in the Analysis Population Descriptions and Additional Description.|A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas|A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas|Completed||Phase 2|58|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 02:21:37.224314|2018-06-01 02:21:37.224314
NCT00634257|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2018-01-24|2008-03-04|2008-03-12|Estimate|||||||2018-01-24|2018-01-26|Actual|February 22, 2008|Actual|2008-02-22|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||Spirituality/Religiosity in Patients and Caregivers|A Preliminary Study of Spirituality/Religiosity, Symptom Distress and Quality of Life Among Palliative Care Patients and Their Primary Caregivers|Active, not recruiting|||193|Actual|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 02:21:37.858692|2018-06-01 02:21:37.858692
NCT00634244|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2015-06-10||2015-07-02|2008-03-11|2008-03-12|Estimate|2015-07-02|2015-07-07|Estimate||||2015-07-02|2015-07-07|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional||Eligible and treated patients|Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)|Completed||Phase 2|92|Actual|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-06-01 02:21:37.968658|2018-06-01 02:21:37.968658
NCT00634231|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2018-04-26|2008-03-05|2008-03-12|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2010||2010-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2015|Actual|2015-12-31||Interventional|||A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors|A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors|Active, not recruiting||Phase 1|12|Anticipated|Advantagene, Inc.||1|||f||||t||||||||||2018-06-01 02:21:38.845782|2018-06-01 02:21:38.845782
NCT00634218|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2012-06-25|2008-03-11|2008-03-12|Estimate|||||||2012-06-25|2012-06-27|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Reaching and Treating Lesbian, Gay, Bisexual, and Transgender (LGBT) Cigarette Smokers|REaching and Treating LGBT Smokers: The Internet|Completed||Phase 2/Phase 3|363|Actual|University of California, San Francisco||4|||f||||t||||||||||2018-06-01 02:21:38.915803|2018-06-01 02:21:38.915803
NCT00634205|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2015-02-11|2008-03-05|2008-03-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2006||2006-07-31|February 2015|2015-02-28|June 2010|Actual|2010-06-30|March 2009|Actual|2009-03-31||Interventional|||Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma|A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma|Completed||Phase 2|45|Actual|European Lung Cancer Working Party||1|||f||||t||||||||||2018-06-01 02:21:38.970797|2018-06-01 02:21:38.970797
NCT00634192|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2017-02-22|2008-03-11|2008-03-12|Estimate|||||||2017-02-22|2017-02-24|Actual|February 2008||2008-02-29|February 2017|2017-02-28|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|||Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin|A Multicenter, Open Label, 2 Period Cross-over Study to Evaluate the PK of a 8 Week Continuous Treatment With 1x300mg/d and 2x300mg/d Tobramycin Inhaled With a 'Soft Mist' Nebulizer in Cystic Fibrosis (CF) Subjects|Completed||Phase 3|50|Anticipated|Novartis||2|||f||||||||||||||2018-06-01 02:21:39.050869|2018-06-01 02:21:39.050869
NCT00634179|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2016-02-17||2016-09-21|2008-03-11|2008-03-12|Estimate|2016-02-17|2016-03-15|Estimate||||2016-09-21|2016-10-27|Estimate|February 2008||2008-02-29|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||A total of 37 patients were enrolled on this study. However, not all patients participated in both phases of this study. For phase I, 19 patients were enrolled, and for phase II, 30 patients were enrolled.|A Phase I/II Trial of VR-CHOP in Lymphoma Patients|A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas|Completed||Phase 1/Phase 2|37|Actual|Emory University||1|||f||||t||||||||||2018-06-01 02:21:39.12906|2018-06-01 02:21:39.12906
NCT00634166|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2014-09-22||2016-03-15|2008-03-11|2008-03-12|Estimate|2014-09-26|2014-09-29|Estimate||||2016-03-15|2016-04-14|Estimate|September 2007||2007-09-30|April 2013|2013-04-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional||The full analysis set (FAS) consisted of all subjects in the safety analysis set who had at least 1 graft assessment after Day 1. Subjects who had no graft assessments after Day 1 were excluded from the FAS population.|Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group|Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group|Terminated||Phase 4|220|Actual|Mylan Bertek Pharmaceuticals|The study was terminated on 17 June 2013 due to the recommendation and request by the FDA to design a superiority clinical study to satisfy the sponsor’s post marketing study commitment for SS5%.|2||"FDA request as study could not serve as the confirmatory trial as required under Subpart H~   approval."|f||||f||||||||||2018-06-01 02:21:39.534009|2018-06-01 02:21:39.534009
NCT00634153|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2018-02-15|2008-03-11|2008-03-12|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2004||2004-01-31|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Observational|||The Surgical Gastrointestinal Diseases Registry Protocol|The Surgical Gastrointestinal Diseases Registry Protocol|Completed|||750|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:21:39.883736|2018-06-01 02:21:39.883736
NCT00634140|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2015-03-27|2008-03-10|2008-03-12|Estimate|||||||2015-03-27|2015-03-30|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||The Influence of Ezetimibe on Gallbladder Function|Te Influence of Ezetimibe on Gallbladder Function|Withdrawn||N/A|0|Actual|Indiana University||2||Study was never initiated due to lack of funding support.|f||||t||||||||||2018-06-01 02:21:39.988667|2018-06-01 02:21:39.988667
NCT00634114|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2010-05-18||2010-05-18|2008-03-05|2008-03-12|Estimate|2010-05-18|2010-06-17|Estimate||||2010-05-18|2010-06-17|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|May 2009|Actual|2009-05-31|||||Interventional|||Reflux Esophagitis Phase III Study (Maintenance Treatment)|A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg Once Daily Oral Administration With Omeprazole 10 mg and Esomeprazole 10 mg Once Daily Oral Administration in Maintenance Treatment in Patients With Healed Reflux Esophagitis|Completed||Phase 3|540|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:21:40.141137|2018-06-01 02:21:40.141137
NCT00634101|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28||2017-06-15|2017-06-15|2008-03-11|2008-03-12|Estimate||||2017-06-15|2017-06-20|Actual|2017-06-15|2017-06-20|Actual|January 1, 2008|Actual|2008-01-01|June 2017|2017-06-30|March 1, 2008|Actual|2008-03-01|March 1, 2008|Actual|2008-03-01||Interventional|||A Comparison of Two Daily Disposable Contact Lenses|The Comparative Clinical Performance of Narafilcon A and the FOCUS DAILIES AquaComfort Plus Lens|Terminated||N/A|129|Actual|Johnson & Johnson Vision Care, Inc.||2||Study was resurrected as NCT00727558 (CR-0808)|f||||f|f|t|f|f|t|||||2018-06-01 02:21:40.604429|2018-06-01 02:21:40.604429
NCT00634088|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2011-04-01||2016-02-09|2008-03-11|2008-03-12|Estimate|2011-04-01|2011-05-03|Estimate||||2016-02-09|2016-03-10|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|Parallel Phase I Study of Ixabepilone Plus Lapatinib and Ixabepilone Plus Lapatinib Plus Capecitabine in Subjects With HER2 Positive Locally Advanced or Metastatic Breast Cancer|Terminated||Phase 1|13|Actual|R-Pharm||4||Slow Accrual|f||||f||||||||||2018-06-01 02:21:40.762831|2018-06-01 02:21:40.762831
NCT00634075|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-08-12|2008-03-11|2008-03-12|Estimate|||||||2009-08-12|2009-08-13|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Clinical Assessment of Fish Oil-based Lipid Emulsion Infusions in Critical Patients With Severe Sepsis|Clinical Assessment of Fish Oil-based Lipid Emulsion Infusions in Critical Patients With Severe Sepsis|Completed||Phase 4|100|Anticipated|Li Shin Hospital||2|||f||||t||||||||||2018-06-01 02:21:41.935493|2018-06-01 02:21:41.935493
NCT00634062|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-03-11|2008-03-11|2008-03-12|Estimate|||||||2008-03-11|2008-03-12|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder|Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder|Completed||Phase 4|28|Actual|Mclean Hospital||2|||f||||t||||||||||2018-06-01 02:21:42.035081|2018-06-01 02:21:42.035081
NCT00634049|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2015-12-02||2017-12-07|2008-03-11|2008-03-12|Estimate|2016-01-08|2016-01-11|Estimate||||2017-12-07|2018-01-02|Actual|April 22, 2008|Actual|2008-04-22|December 2017|2017-12-31|May 5, 2016|Actual|2016-05-05|January 3, 2014|Actual|2014-01-03||Interventional|VITAL|Intent to Treat Population (ITT)|Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi|Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi|Completed||Phase 3|149|Actual|Astellas Pharma Inc|Enrollment in the clinical study was suspended in January 2009 pending further characterization of newly identified impurities. After successful study completion resumption of enrollment started in April 2011 for the 9766-CL-0103/WSA-CS-003 study.|1|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 02:21:42.150121|2018-06-01 02:21:42.150121
NCT00634036|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2016-03-18||2017-06-19|2008-03-11|2008-03-12|Estimate|2017-06-19|2017-07-19|Actual||||2017-06-19|2017-07-19|Actual|October 2009||2009-10-31|June 2017|2017-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|GLITZ Asthma||Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics|A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics|Completed||Phase 2|23|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:21:44.033115|2018-06-01 02:21:44.033115
NCT00634023|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2009-03-10|2008-03-05|2008-03-12|Estimate|||||||2009-03-10|2009-03-11|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|RANGE||Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD|A Cross-Sectional, Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With Gastroesophageal Reflux Disease (GERD) RANGE: Retrospective ANalysis of GErd|Completed|||500|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:21:44.973876|2018-06-01 02:21:44.973876
NCT00634010|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2016-01-28||2016-04-05|2008-03-05|2008-03-12|Estimate|2016-04-05|2016-05-09|Estimate||||2016-04-05|2016-05-09|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain|Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain|Terminated||Phase 3|36|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||t||||||||||2018-06-01 02:21:45.073029|2018-06-01 02:21:45.073029
NCT00633997|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04||2016-04-25|2016-04-25|2008-03-11|2008-03-12|Estimate||||2016-04-25|2016-05-24|Estimate|2016-04-25|2016-05-24|Estimate|February 2008||2008-02-29|April 2016|2016-04-30||||December 2008|Actual|2008-12-31||Interventional|||Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes|An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes|Terminated||Phase 1/Phase 2|22|Actual|Novartis||2||"After analysis of the existing data, it was determined that additional skin biopsy samples~   would not be required to determine study outcome."|f||||f||||||||||2018-06-01 02:21:45.497171|2018-06-01 02:21:45.497171
NCT00633984|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2014-01-02||2014-04-14|2008-03-04|2008-03-12|Estimate|2014-04-14|2014-05-14|Estimate||||2014-04-14|2014-05-14|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||D-Cycloserine Enhancement of Exposure in Social Phobia|D-Cycloserine Enhancement of Exposure in Social Phobia|Completed||Phase 4|169|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:21:45.576104|2018-06-01 02:21:45.576104
NCT00633971|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2011-04-21|2008-03-11|2008-03-12|Estimate|||||||2011-04-21|2011-04-22|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|June 2010|Actual|2010-06-30||Interventional|||Treatment Trial for Post-Thrombotic Syndrome|A Randomized Trial to Determine the Impact of Lymphedema Therapy on Quality of Life and Disease Severity in Patients With Post-Thrombotic Syndrome|Unknown status|Active, not recruiting|Phase 3|44|Anticipated|University of Vermont||2|||f||||f||||||||||2018-06-01 02:21:45.789692|2018-06-01 02:21:45.789692
NCT00633789|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05||2015-09-23|2015-09-23|2008-03-11|2008-03-12|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|June 2008||2008-06-30|September 2015|2015-09-30|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|||Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types|A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors|Completed||Phase 2|597|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:21:53.352208|2018-06-01 02:21:53.352208
NCT00633958|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2018-04-05|2008-03-05|2008-03-12|Estimate|||||||2018-04-05|2018-04-09|Actual|March 2008||2008-03-31|April 2018|2018-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|FLT||A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors|A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors|Terminated||N/A|2|Actual|Dana-Farber Cancer Institute||1||Large phase II opened to accue same patients|f||||f||||||||||2018-06-01 02:21:45.864419|2018-06-01 02:21:45.864419
NCT00633945|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2011-02-18|2008-03-04|2008-03-12|Estimate|||||||2011-02-18|2011-02-21|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)|Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus|Completed||N/A|6|Anticipated|University of Pennsylvania|||||f||||t||||||||||2018-06-01 02:21:45.930276|2018-06-01 02:21:45.930276
NCT00633932|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2009-12-10||2010-12-02|2008-03-05|2008-03-12|Estimate|2010-03-26|2010-04-08|Estimate||||2010-12-02|2010-12-20|Estimate|December 2007||2007-12-31|December 2010|2010-12-31|December 2008|Actual|2008-12-31|||||Interventional|||Reflux Esophagitis Phase III Study (Initial Treatment)|A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of Esomeprazole 20 mg and 40 mg Once Daily Oral Administration With Omeprazole 20 mg Once Daily Oral Administration in Patients With Reflux Esophagitis|Completed||Phase 3|602|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:21:46.023187|2018-06-01 02:21:46.023187
NCT00633919|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2010-11-11||2011-06-07|2008-03-11|2008-03-12|Estimate|2011-01-27|2011-02-21|Estimate||||2011-06-07|2011-06-08|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Efficacy of SLITone in House Dust Mite Allergic Patients|A Randomised, Double-blind, Placebo-controlled Trial Assessing the Efficacy of SLITone in House Dust Mite Allergic Patients|Completed||Phase 2/Phase 3|124|Actual|ALK-Abelló A/S|Retrospectively, trial design (medication use did not reflect the asthma status of subjects), and subject number (low power) and characteristics (mild, well-controlled asthma; low medication use needed) were not optimal for this trial purpose.|2|||f||||f||||||||||2018-06-01 02:21:46.49179|2018-06-01 02:21:46.49179
NCT00633906|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2013-11-18|2008-03-11|2008-03-12|Estimate|||||||2013-11-18|2013-11-19|Estimate|April 2002||2002-04-30|June 2008|2008-06-30|October 2005|Actual|2005-10-31|August 2004|Actual|2004-08-31||Interventional|HORIZONS||HORIZONS HIV Intervention|Reducing HIV Risk in Female Teens: A Tailored Approach|Completed||N/A|715|Actual|Emory University||2|||f||||f||||||||||2018-06-01 02:21:46.827235|2018-06-01 02:21:46.827235
NCT00633893|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2013-08-19||2013-10-30|2008-03-05|2008-03-12|Estimate|2013-08-19|2013-10-25|Estimate||||2013-10-30|2013-11-25|Estimate|May 2008||2008-05-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||All randomized participants regardless of whether treatment was actually received were included; intent to treat (ITT) principle.|Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism|A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism|Completed||Phase 3|2711|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 02:21:47.021771|2018-06-01 02:21:47.021771
NCT00633880|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2014-03-18|2012-01-25|2014-04-22|2008-03-11|2008-03-12|Estimate|2014-04-22|2014-05-20|Estimate|2012-01-25|2012-01-30|Estimate|2014-04-22|2014-05-20|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|NOH302||Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)|Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH|Completed||Phase 3|181|Actual|Chelsea Therapeutics||2|||f||||t||||||||||2018-06-01 02:21:50.77593|2018-06-01 02:21:50.77593
NCT00633867|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2010-02-25||2011-07-29|2008-03-11|2008-03-12|Estimate|2010-02-25|2010-03-25|Estimate||||2011-07-29|2011-08-02|Estimate|February 2008||2008-02-29|March 2008|2008-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Randomised Controlled Trial of Intubation With the McGrath Series 5 Video Laryngoscope vs the Macintosh Laryngoscope|Randomised Controlled Trial of Intubation With the McGrath Series 5 Video Laryngoscope vs the Macintosh Laryngoscope|Completed||N/A|120|Actual|NHS Grampian||2|||f||||t||||||||||2018-06-01 02:21:52.084142|2018-06-01 02:21:52.084142
NCT00633854|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-03-04|2008-03-04|2008-03-12|Estimate|||||||2008-03-04|2008-03-12|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||High-Frequency-Ultrasound Annular Arrays for Ophthalmic Imaging|High-Frequency-Ultrasound Annular Arrays for Small Animal and Ophthalmic Imaging|Unknown status|Enrolling by invitation||30|Anticipated|Weill Medical College of Cornell University|||1||f||||t||||||||||2018-06-01 02:21:52.584289|2018-06-01 02:21:52.584289
NCT00633841|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2010-10-18|2008-03-05|2008-03-12|Estimate|||||||2010-10-18|2010-10-19|Estimate|February 2008||2008-02-29|October 2010|2010-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease|Randomized, Controlled, Parallel Group, Patient-Blinded, Single-Center Phase I Pilot Study to Assess Tolerability and Safety of Repeated s.c. Administration of a Single-Dose of AFFITOPE AD02 Applied With or Without Adjuvant to Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|24|Actual|Affiris AG||2|||f||||t||||||||||2018-06-01 02:21:52.681969|2018-06-01 02:21:52.681969
NCT00633828|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2017-09-28|2008-03-11|2008-03-12|Estimate|||||||2017-09-28|2017-09-29|Actual|August 1999||1999-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Influence of External Factors on Skeletal Growth in Youth|Determinants for Peak Bone Mass, Skeletal Architecture, Fractures, Adipositas and Cardiovascular Risk Factors During Growth and Adulthood|Active, not recruiting||N/A|500|Actual|Region Skane||2|||f||||f||||||||||2018-06-01 02:21:53.007415|2018-06-01 02:21:53.007415
NCT00633815|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2017-05-09|2008-03-04|2008-03-12|Estimate|||||||2017-05-09|2017-05-10|Actual|January 2008||2008-01-31|May 2017|2017-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Upright Versus Supine Exercise Testing in Fontan-palliated Patients|Study of Upright Versus Supine Exercise Testing in Fontan-palliated Patients, Compared With Healthy Controls, to Evaluate for Postural Effects on Exercise Parameters|Completed|||45|Actual|University of Michigan|||2||f||||f|f|f||||||||2018-06-01 02:21:53.098688|2018-06-01 02:21:53.098688
NCT00633802|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-03-11|2008-03-11|2008-03-12|Estimate|||||||2008-03-11|2008-03-12|Estimate|April 2004||2004-04-30|March 2008|2008-03-31||||April 2009|Anticipated|2009-04-30||Interventional|||Low-Dose Risperidone Treatment for Subjects Suffering From Borderline Personality Disorder||Unknown status|Recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-06-01 02:21:53.218525|2018-06-01 02:21:53.218525
NCT00633776|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2016-08-02|2008-03-11|2008-03-12|Estimate|||||||2016-08-02|2016-08-04|Estimate|March 2008||2008-03-31|August 2016|2016-08-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)|Perforomist Versus Foradil Evaluated by Inspiratory Capacity and HRCT|Withdrawn||Phase 4|0|Actual|University of California, Los Angeles||2||Sponsor withdrew funding prior to study initiation|f||||f||||||||||2018-06-01 02:21:53.495852|2018-06-01 02:21:53.495852
NCT00633763|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-05-27|2008-03-11|2008-03-12|Estimate|||||||2009-05-27|2009-05-29|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus|PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus|Completed|||30|Anticipated|University of California, Irvine|||2||f||||f||||||||||2018-06-01 02:21:53.62213|2018-06-01 02:21:53.62213
NCT00633750|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-11|2012-05-01||2012-08-02|2008-03-11|2008-03-12|Estimate|2012-08-02|2012-09-05|Estimate||||2012-08-02|2012-09-05|Estimate|August 2002||2002-08-31|July 2012|2012-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery|Phase II Trial of OSI-774 (Tarceva), a Human Epidermal Growth Factor (HER) (erbB, Also Known as Epidermal Growth Factor Receptor, EGFR) Tyrosine Kinase Inhibitor, in Treatment-Naïve Operable Breast Cancer|Completed||Phase 2|50|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:21:53.726185|2018-06-01 02:21:53.726185
NCT00633737|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2013-12-19|2008-03-04|2008-03-12|Estimate|||||||2013-12-19|2013-12-23|Estimate|March 2008||2008-03-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||The Effects of Stress Reduction on Surgical Wound Healing|The Effects of Stress Reduction on Surgical Wound Healing: A Randomised Controlled Trial|Completed||N/A|70|Actual|University of Auckland, New Zealand||2|||f||||f||||||||||2018-06-01 02:21:54.278525|2018-06-01 02:21:54.278525
NCT00633724|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2013-08-13|2008-03-03|2008-03-12|Estimate|||||||2013-08-13|2013-08-15|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer|Phase I Study of Multiple-vaccine Therapy Including Antiangiogenic Vaccine Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Unresectable or Recurrent Non-small Cell Lung Cancer|Completed||Phase 1|9|Anticipated|Fukushima Medical University||1|||f||||t||||||||||2018-06-01 02:21:54.358818|2018-06-01 02:21:54.358818
NCT00633711|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2011-06-15|2008-03-04|2008-03-12|Estimate|||||||2011-06-15|2011-06-16|Estimate|March 2007||2007-03-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Obstructive Sleep Apnea Treatment by Fixed CPAP and by Auto-CPAP (Somnosmart2)|Differential Effects of Chronic Treatment of OSAS by CPAP and SOMNOsmart2 on Norepinephrine and Blood Pressure|Completed||Phase 4|17|Actual|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||f||||||||||2018-06-01 02:21:54.451237|2018-06-01 02:21:54.451237
NCT00633698|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2009-08-03|2008-03-05|2008-03-12|Estimate|||||||2009-08-03|2009-08-04|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|NICOLa||Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)|Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 02:21:54.631778|2018-06-01 02:21:54.631778
NCT00633685|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2010-05-24|2008-03-11|2008-03-12|Estimate|||||||2010-05-24|2010-05-25|Estimate|March 2010||2010-03-31|February 2010|2010-02-28|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure|Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure|Unknown status|Recruiting|Phase 4|300|Anticipated|TEMPVA Research Group, Inc.||2|||f||||f||||||||||2018-06-01 02:21:54.850301|2018-06-01 02:21:54.850301
NCT00633672|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2011-01-24|2008-03-11|2008-03-12|Estimate|||||||2011-01-24|2011-01-25|Estimate|February 2001||2001-02-28|January 2011|2011-01-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued|A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued|Completed||Phase 3|400|Anticipated|AstraZeneca||3|||||||||||||||||2018-06-01 02:21:55.052038|2018-06-01 02:21:55.052038
NCT00633659|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2013-08-15|2008-03-04|2008-03-12|Estimate|||||||2013-08-15|2013-08-19|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia|A Phase II Study of Hemospan® Versus Voluven® to Evaluate Vascular Resistance and Forearm Blood Flow, and to Assess Local Skin Blood Flow and Tissue Oxygenation in the Ischemic Foot of Patients With Chronic Critical Limb Ischemia|Completed||Phase 2|6|Actual|Sangart||2|||f||||f||||||||||2018-06-01 02:21:55.119234|2018-06-01 02:21:55.119234
NCT00633646|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-04-24|2008-03-11|2008-03-12|Estimate|||||||2008-04-24|2008-04-28|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Effect of Protein-Restricted Diet on Nitrogen Balance and Residual Renal Function in Peritoneal Dialysis (PD) Patients|Effect of Protein-Restricted Diet on Nitrogen Balance and Residual Renal Function in PD Patients|Completed||N/A|94|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||||2018-06-01 02:21:55.214871|2018-06-01 02:21:55.214871
NCT00633633|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2018-03-13|2008-03-05|2008-03-12|Estimate|||||||2018-03-13|2018-03-15|Actual|February 2008|Actual|2008-02-29|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Lifestyle Intervention for Heart Failure|Take Heart: Exercise & Diet Intervention for Heart Failure in Cancer Survivors|Active, not recruiting||N/A|85|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-06-01 02:21:55.329057|2018-06-01 02:21:55.329057
NCT00633620|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-03-11|2008-03-11|2008-03-12|Estimate|||||||2008-03-11|2008-03-12|Estimate|March 2007||2007-03-31|March 2008|2008-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|BECOP-2||Narrow Band Versus Conventional Endoscopic Imaging for Screening Colonoscopy|Narrow Band Versus Conventional Endoscopic Imaging for Screening Colonoscopy in a Private Practice Setting - A Large Prospective Randomized Trial|Completed||N/A|1250|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 02:21:55.430458|2018-06-01 02:21:55.430458
NCT00633607|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2018-02-15|2008-03-11|2008-03-12|Estimate|||||||2018-02-15|2018-02-16|Estimate|April 2012||2012-04-30|February 2018|2018-02-28|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Observational|||Hereditary Colorectal and Associated Tumor Registry Study|Hereditary Colorectal and Associated Tumor Registry Study|Completed|||114|Actual|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Serum, plasma, and extracted DNA are stored for potential future studies.~   "|||2018-06-01 02:21:55.511122|2018-06-01 02:21:55.511122
NCT00633594|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2016-08-19||2016-12-06|2008-03-04|2008-03-12|Estimate|2016-12-06|2017-01-31|Estimate||||2016-12-06|2017-01-31|Estimate|June 2008||2008-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|April 2015|Actual|2015-04-30||Interventional||Based on efficacy evaluable population, all participants that received any study therapy. Participants were stratified based on phase of study (Phase I vs Phase II) and previous treatment status prior to study start (Previously Untreated vs Previously Treated (relapsed or refractory))|Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma|Phase I/II Study Evaluating Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients With Mantle Cell Lymphoma|Completed||Phase 1/Phase 2|39|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||No||2018-06-01 02:21:55.618018|2018-06-01 02:21:55.618018
NCT00633581|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2009-04-08|2008-03-05|2008-03-12|Estimate|||||||2009-04-08|2009-04-10|Estimate|March 2008||2008-03-31|April 2009|2009-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy of Vitamin C Injection on Fatigue in Workers After Work|Efficacy of High Dose Vitamin C Parenteral Supplement on Amelioration of Fatigue in Company Workers After Work: A Double-Blind, Randomized Controlled Trial|Completed||Phase 2/Phase 3|150|Actual|DongGuk University||2|||f||||f||||||||||2018-06-01 02:21:56.75541|2018-06-01 02:21:56.75541
NCT00633568|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2015-02-11|2008-03-11|2008-03-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|January 2007||2007-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Randomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung Cancer|A Phase III Randomised Study Comparing Concomitant Radiochemotherapy With Cisplatin and Docetaxel as Induction Versus Consolidation Treatment in Patients With Locally Advanced Unresectable Non-small Cell Lung Cancer.|Terminated||Phase 3|125|Actual|European Lung Cancer Working Party||2||Slow recruitment|f||||t||||||||||2018-06-01 02:21:56.847269|2018-06-01 02:21:56.847269
NCT00633555|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2018-05-23|2008-03-11|2008-03-12|Estimate|||||||2018-05-23|2018-05-25|Actual|July 2006||2006-07-31|May 2018|2018-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|LR||A Comparison of the Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Women Who Are or Who Are Predicted to be Low Responders|A Randomized Controlled Trial of Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Predicted Low Responders|Completed|||54|Actual|UConn Health|||||f||||f||||||||||2018-06-01 02:21:56.978708|2018-06-01 02:21:56.978708
NCT00633542|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-03-04|2008-03-04|2008-03-12|Estimate|||||||2008-03-04|2008-03-12|Estimate|June 2003||2003-06-30|March 2008|2008-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)|Thalidomide-Dexamethasone vs Alpha-Interferon-Dexamethasone as Maintenance Therapy After Thalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin Combination for|Completed||Phase 3|103|Actual|Università Politecnica delle Marche||2|||f||||f||||||||||2018-06-01 02:21:57.180038|2018-06-01 02:21:57.180038
NCT00633529|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2013-10-21|2008-03-03|2008-03-12|Estimate|||||||2013-10-21|2013-10-22|Estimate|November 2007||2007-11-30|October 2013|2013-10-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC|Open-Label Phase 1b Study of Erlotinib Plus Bevacizumab and IMO-2055 in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Chemotherapy for Advanced or Metastatic Disease|Completed||Phase 1|36|Actual|EMD Serono||1|||f||||f||||||||||2018-06-01 02:21:57.264719|2018-06-01 02:21:57.264719
NCT00633516|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2017-02-08|2008-03-04|2008-03-12|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2008||2008-07-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions|A Pilot Study to Evaluate the Correlation Between Modified Two Layer Diffuse Optical Spectroscopy With the Clinical and Histological Examinations of Pigmented Skin Lesions Based on Physiological Parameters|Completed|||37|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:21:57.3674|2018-06-01 02:21:57.3674
NCT00633503|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2012-11-11|2008-03-11|2008-03-12|Estimate|||||||2012-11-11|2012-11-14|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||Monitoring of Tissue Transfer Flaps by Modulated Imaging (MI) Spectroscopy|Monitoring of Tissue Transfer Flaps by Modulated Imaging (MI) Spectroscopy|Unknown status|Recruiting||200|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:21:57.446476|2018-06-01 02:21:57.446476
NCT00633490|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2008-07-21|2008-03-11|2008-03-12|Estimate|||||||2008-07-21|2008-07-22|Estimate|July 2007||2007-07-31|March 2008|2008-03-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Study of Apatinib as an Inhibitor of Tumor Angiogenesis|Phase 1 Study of Apatinib as an Inhibitor of Angiogenesis|Unknown status|Recruiting|Phase 1|18|Anticipated|Fudan University||1|||f||||f||||||||||2018-06-01 02:21:57.516773|2018-06-01 02:21:57.516773
NCT00633477|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2012-12-05||2013-01-10|2008-03-04|2008-03-12|Estimate|2012-12-05|2013-01-09|Estimate||||2013-01-10|2013-01-18|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis-Induced Cardiovascular and Respiratory Failure|Terminated||Phase 3|18|Actual|Takeda||2||Business Decision; No Safety Or Efficacy Concerns.|f||||t||||||||||2018-06-01 02:21:57.620095|2018-06-01 02:21:57.620095
NCT00633464|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|2012-03-30||2016-02-09|2008-03-11|2008-03-12|Estimate|2012-03-30|2012-04-24|Estimate||||2016-02-09|2016-03-10|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|||Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer|Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative (ER, PR, Her2 Negative) Locally Advanced Non-resectable and/or Metastatic Breast Cancer|Completed||Phase 2|79|Actual|R-Pharm||2|||f||||f||||||||||2018-06-01 02:21:58.247617|2018-06-01 02:21:58.247617
NCT00633451|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2013-03-26|2008-03-04|2008-03-12|Estimate|||||||2013-03-26|2013-03-28|Estimate|February 2008||2008-02-29|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Randomized Clinical Trial of Rehabilitation for Subacromial Impingement Syndrome|Randomized Clinical Trial of Rehabilitation for Subacromial Impingement Syndrome: A Comparison of Manual Therapy + Exercise to Exercise Only|Completed||N/A|109|Actual|Proaxis Therapy||2|||f||||f||||||||||2018-06-01 02:21:58.997587|2018-06-01 02:21:58.997587
NCT00633438|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-03-12|2008-03-04|2008-03-12|Estimate|||||||2009-03-12|2009-03-13|Estimate|January 2004||2004-01-31|March 2009|2009-03-31|June 2004|Actual|2004-06-30|||||Interventional|||Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery|A Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery|Completed||Phase 4|204|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:21:59.096853|2018-06-01 02:21:59.096853
NCT00633412|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2009-06-09|2008-03-11|2008-03-12|Estimate|||||||2009-06-09|2009-06-11|Estimate|February 2001||2001-02-28|June 2009|2009-06-30|March 2003|Actual|2003-03-31|||||Interventional|||A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only||Completed||Phase 3|400|Anticipated|AstraZeneca||3|||f||||||||||||||2018-06-01 02:21:59.25672|2018-06-01 02:21:59.25672
NCT00633399|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2014-06-24||2014-06-24|2008-03-11|2008-03-12|Estimate|2014-06-24|2014-07-03|Estimate||||2014-06-24|2014-07-03|Estimate|July 2008||2008-07-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs|A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.|Completed||Phase 2|458|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:21:59.32415|2018-06-01 02:21:59.32415
NCT00633386|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-03-12|2008-03-11|2008-03-12|Estimate|||||||2009-03-12|2009-03-13|Estimate|February 2003||2003-02-28|March 2009|2009-03-31|August 2003|Actual|2003-08-31|||||Interventional|||Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery|A Double-Blind, Placebo-Controlled, Randomized, Comparison Study of the Efficacy of Celebrex 400 mg Single Dose Pre and Celebrex 200 mg Post Ambulatory Arthroscopic Knee Surgery for Total Analgesic Use After Surgery|Completed||Phase 4|200|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:21:59.55443|2018-06-01 02:21:59.55443
NCT00633373|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2012-09-13|2008-03-05|2008-03-12|Estimate|||||||2012-09-13|2012-09-17|Estimate||||September 2012|2012-09-30||||||||Expanded Access|||Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients|An Open-label Treatment Use Protocol of Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients|No longer available|||||APT Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 02:21:59.624472|2018-06-01 02:21:59.624472
NCT00633360|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2016-06-24||2017-01-30|2008-03-11|2008-03-12|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|February 2008||2008-02-29|January 2017|2017-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Oral Contraceptive Pill for Premenstrual Worsening of Depression|The Oral Contraceptive Pill for Premenstrual Worsening of Depression.|Completed||N/A|32|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:21:59.690023|2018-06-01 02:21:59.690023
NCT00633347|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2013-02-14|2008-03-10|2008-03-12|Estimate|||||||2013-02-14|2013-02-15|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation||Completed||Phase 4|570|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 02:21:59.971254|2018-06-01 02:21:59.971254
NCT00633334|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2017-11-07|2008-03-11|2008-03-12|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2003||2003-09-30|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 7, 2017|Actual|2017-02-07||Observational|||Development of Early Detection Signs for Gastrointestinal Cancer|Investigation of the Immune Response to Gastrointestinal Tumors and Development of Novel Biomarkers for the Presence of Gastrointestinal Cancer|Active, not recruiting|||1500|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     peripheral blood portions of tumor tumor draining lymph nodes~   "|||2018-06-01 02:22:00.151463|2018-06-01 02:22:00.151463
NCT00633321|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2011-06-07|2008-03-11|2008-03-12|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation|Completed||Phase 2|522|Anticipated|Celtic Pharma Development Services||3|||f||||f||||||||||2018-06-01 02:22:00.228467|2018-06-01 02:22:00.228467
NCT00633308|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2016-02-29|2008-03-11|2008-03-12|Estimate|||||||2016-02-29|2016-03-01|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|February 2011|Anticipated|2011-02-28|January 2010|Anticipated|2010-01-31||Interventional|hemodialysis||Phosphorus and Calcium Removal During Long Hemodialysis Treatment Sessions|Phosphorus and Calcium Removal During Long Hemodialysis Treatment Sessions|Withdrawn||Phase 2|0|Actual|Indiana University||1||No coordinator available to work on study.|f||||f||||||||||2018-06-01 02:22:00.344724|2018-06-01 02:22:00.344724
NCT00633295|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2017-06-21|2008-03-04|2008-03-12|Estimate|||||||2017-06-21|2017-06-22|Actual|June 2008||2008-06-30|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor|An Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor|Completed||Phase 2|9|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:22:00.4055|2018-06-01 02:22:00.4055
NCT00633282|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2012-06-03|2008-03-10|2008-03-12|Estimate|||||||2012-06-03|2012-06-05|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease|Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus|Completed||Phase 2|184|Actual|Fudan University||3|||f||||t||||||||||2018-06-01 02:22:00.478095|2018-06-01 02:22:00.478095
NCT00633269|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2009-01-13|2008-03-05|2008-03-12|Estimate|||||||2009-01-13|2009-01-14|Estimate|April 2008||2008-04-30|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours|Open, Non-Randomized, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]-AZD2281 (KU-0059436) in Patients With Advanced or Metastatic Solid Tumours Refractory to Standard Treatments|Completed||Phase 1|6|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:22:00.571676|2018-06-01 02:22:00.571676
NCT00633256|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2012-03-14||2012-03-14|2008-03-10|2008-03-11|Estimate|2012-03-14|2012-04-11|Estimate||||2012-03-14|2012-04-11|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers|The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers.|Completed||N/A|20|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:22:00.666071|2018-06-01 02:22:00.666071
NCT00632372|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29||2016-05-18|2016-06-09|2008-03-07|2008-03-10|Estimate||||2016-05-18|2016-06-03|Estimate|2016-06-09|2016-06-13|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|September 2011|Actual|2011-09-30||Interventional|zLAP||Cardiac Resynchronization Therapy (CRT) Based Heart Failure Monitoring Study|CRT-D Based Heart Failure Monitoring Study|Completed||Phase 2|8|Actual|St. Jude Medical||1|||f||||t||||||||No||2018-06-01 02:22:25.078963|2018-06-01 02:22:25.078963
NCT00633243|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2012-10-19||2013-01-01|2008-02-29|2008-03-11|Estimate|2012-10-19|2012-11-20|Estimate||||2013-01-01|2013-01-03|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effective Treatment of Hepatitis C in Substance Users|Effective Treatment of Hepatitis C in Substance Users|Completed||N/A|21|Actual|Yale University|This trial contains a small sample size of patients with considerable comorbidity and is drawn from one specialized treatment setting. Our conclusions will need empiric testing within carefully conducted RCTs.|2|||f||||f||||||||||2018-06-01 02:22:01.007966|2018-06-01 02:22:01.007966
NCT00633230|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2015-06-24|2008-03-03|2008-03-11|Estimate|||||||2015-06-24|2015-06-25|Estimate||||June 2015|2015-06-30||||||||Interventional|||Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C|Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C|Withdrawn||Phase 1|0|Actual|University of Virginia||2||No funding secured|f||||f||||||||||2018-06-01 02:22:01.220091|2018-06-01 02:22:01.220091
NCT00633217|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2009-10-22||2016-10-26|2008-03-10|2008-03-11|Estimate|2009-10-22|2009-11-26|Estimate||||2016-10-26|2016-12-08|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)|A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg Twice-daily With Fluticasone Propionate/Salmeterol DISKUS 250/50mcg Twice-daily in Subjects With COPD|Completed||Phase 4|247|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:22:01.309124|2018-06-01 02:22:01.309124
NCT00633204|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2011-06-22|2008-03-04|2008-03-11|Estimate|||||||2011-06-22|2011-06-23|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|November 2011|Anticipated|2011-11-30|November 2011|Anticipated|2011-11-30||Interventional|||Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer|Phase II Study of Bladder Cancer Using Novel Tumor Antigens for Prevention of the Recurrence for Bladder Cancer After TUR-Bt|Unknown status|Active, not recruiting|Phase 2|150|Anticipated|Iwate Medical University|||||f||||t||||||||||2018-06-01 02:22:01.663516|2018-06-01 02:22:01.663516
NCT00633191|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2016-08-31|2008-03-10|2008-03-11|Estimate|||||||2016-08-31|2016-09-01|Estimate|November 2003||2003-11-30|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PseudIgY||Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis|Post Marketing Study of Anti-pseudomonas IgY in Prevention of Recurrence of Pseudomonas Aeruginosa Infections Infections in Cystic Fibrosis (CF) Patients|Completed||Phase 1/Phase 2|14|Actual|Immunsystem AB||1|||f||||t||||||||No||2018-06-01 02:22:01.754838|2018-06-01 02:22:01.754838
NCT00633178|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2015-08-31|2008-03-07|2008-03-11|Estimate|||||||2015-08-31|2015-09-02|Estimate|January 2005||2005-01-31|December 2011|2011-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effectiveness of Group Interpersonal Psychotherapy in Treating Women With Prenatal Depression|Therapy for Prenatal Depression: Maternal & Fetal Effects|Completed||N/A|116|Actual|New York State Psychiatric Institute||3|||f||||t||||||||||2018-06-01 02:22:01.876316|2018-06-01 02:22:01.876316
NCT00633165|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2010-02-24|2008-03-10|2008-03-11|Estimate|||||||2010-02-24|2010-02-26|Estimate|August 2007||2007-08-31|February 2010|2010-02-28|June 2010|Anticipated|2010-06-30|October 2008|Actual|2008-10-31||Interventional|SMI-BRS-202||Brostallicin Clinical Trial for Myxoid Liposarcoma|A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|Systems Medicine LLC|||||f||||f||||||||||2018-06-01 02:22:01.957559|2018-06-01 02:22:01.957559
NCT00633152|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2012-07-25||2017-02-02|2008-03-03|2008-03-11|Estimate|2012-07-31|2012-08-31|Estimate||||2017-02-02|2017-03-14|Actual|February 2008||2008-02-29|February 2017|2017-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections|A Phase 2, Multicenter, Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Intramuscular Ceftaroline Versus Intravenous Linezolid in Adult Subjects With Complicated Skin and Skin Structure Infections|Completed||Phase 2|150|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 02:22:02.027207|2018-06-01 02:22:02.027207
NCT00633139|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2010-10-06||2015-07-14|2008-02-29|2008-03-11|Estimate|2012-05-14|2012-06-15|Estimate||||2015-07-14|2015-08-05|Estimate|August 2007||2007-08-31|February 2014|2014-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)|A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose, Dose Escalation Study of the Safety, Pharmacokinetics, Efficacy and Long Term Safety of HGT-1111 (Recombinant Human Arylsulfatase A [rhASA, Metazym]) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)|Completed||Phase 1/Phase 2|13|Actual|Shire||3|||f||||t||||||||||2018-06-01 02:22:02.301736|2018-06-01 02:22:02.301736
NCT00633126|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2012-03-28||2017-02-02|2008-03-10|2008-03-11|Estimate|2013-02-11|2013-02-12|Estimate||||2017-02-02|2017-03-14|Actual|March 2008||2008-03-31|February 2017|2017-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age|Pharmacokinetics of a Single Dose of Ceftaroline in Subjects 12 to 17 Years of Age Receiving Antibiotic Therapy|Completed||Phase 1|9|Actual|Forest Laboratories||1|||f||||f||||||||||2018-06-01 02:22:02.711397|2018-06-01 02:22:02.711397
NCT00633113|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2013-04-25|2008-03-04|2008-03-11|Estimate|||||||2013-04-25|2013-04-29|Estimate|November 2007||2007-11-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|MIKRO||Minimally Invasive Knee Replacement Outcomes (MIKRO) Study|A Randomized, Prospective, Blinded Clinical Trial Comparing Two Total Knee Replacement Techniques|Completed||N/A|131|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 02:22:02.996183|2018-06-01 02:22:02.996183
NCT00633087|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2013-11-15||2013-11-15|2008-03-10|2008-03-11|Estimate|2013-11-15|2014-01-07|Estimate||||2013-11-15|2014-01-07|Estimate|November 2006||2006-11-30|November 2013|2013-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|2-Deoxyglucose||A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer|A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|12|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||f||||||||||2018-06-01 02:22:03.12228|2018-06-01 02:22:03.12228
NCT00633074|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2012-04-26|2009-05-20|2016-11-03|2008-03-10|2008-03-11|Estimate|2012-04-26|2012-05-28|Estimate|2009-09-28|2009-09-30|Estimate|2016-11-03|2016-12-16|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations|Non-inferiority Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A Using Different Formulations.|Completed||Phase 2|720|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:22:03.328299|2018-06-01 02:22:03.328299
NCT00633061|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2013-02-06|2008-02-29|2008-03-11|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|DVT||Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer|Phase II Study on the Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer|Completed||Phase 2|136|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 02:22:03.796019|2018-06-01 02:22:03.796019
NCT00633048|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2009-02-16|2008-03-10|2008-03-11|Estimate|||||||2009-02-16|2009-02-17|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study Evaluating the Safety and Tolerability of NSA-789|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects|Completed||Phase 1|64|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:22:03.861929|2018-06-01 02:22:03.861929
NCT00633035|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2013-10-12|2008-03-10|2008-03-11|Estimate|||||||2013-10-12|2013-10-16|Estimate|September 2007||2007-09-30|October 2013|2013-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit|Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit|Completed||Phase 4|60|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:22:03.926436|2018-06-01 02:22:03.926436
NCT00633022|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13||2012-03-22|2017-01-31|2008-03-04|2008-03-11|Estimate||||2012-04-03|2012-04-05|Estimate|2017-01-31|2017-02-02|Estimate|June 2008||2008-06-30|January 2017|2017-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging|A Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Two Regimens of GW856553, Over a Period of 3 Month, on In-vivo Macrophage Activity, as Assessed by FDG-PET/CT Imaging, in the Carotid Arteries and Aorta of Subjects With Established Atherosclerosis|Completed||Phase 2|102|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:22:04.009794|2018-06-01 02:22:04.009794
NCT00633009|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2012-07-19||2013-10-28|2008-03-10|2008-03-11|Estimate|2012-12-04|2012-12-06|Estimate||||2013-10-28|2013-11-20|Estimate|August 2008||2008-08-31|October 2013|2013-10-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen|A Blinded, Placebo Controlled Study Evaluating Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen (LtSTA)|Completed||Phase 2|50|Actual|Nielsen BioSciences, Inc.||3|||f||||f||||||||||2018-06-01 02:22:05.042129|2018-06-01 02:22:05.042129
NCT00632996|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2015-12-18|2008-03-10|2008-03-11|Estimate|||||||2015-12-18|2015-12-21|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Exercise and Manual Therapy for Shoulder Subacromial Impingement Syndrome|Effectiveness of Rehabilitation for Subacromial Impingement Syndrome|Completed||Phase 2|162|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-06-01 02:22:05.302495|2018-06-01 02:22:05.302495
NCT00632970|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2014-03-04||2017-06-23|2008-03-10|2008-03-11|Estimate|2017-06-23|2017-06-26|Actual||||2017-06-23|2017-06-26|Actual|February 2008||2008-02-29|June 2017|2017-06-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals|A Multi-Center Comparison of Raltegravir to Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV-Infected Individuals Naive to Antiretroviral Therapy|Terminated||Phase 4|6|Actual|George Washington University||2||no patients completed|f||||t||||||||No|Findings not relevant|2018-06-01 02:22:05.380211|2018-06-01 02:22:05.380211
NCT00632957|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2011-04-11|2008-03-10|2008-03-11|Estimate|||||||2011-04-11|2011-04-12|Estimate|September 2004||2004-09-30|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Oral Infections: Dietary Regulation of Local and Systemic Inflammatory Responses|Center for the Biologic Basis of Oral/Systemic Diseases Project 5: Oral Infections: Dietary Regulation of Local and Systemic Inflammatory Responses.|Completed||N/A|126|Actual|University of Kentucky||2|||f||||f||||||||||2018-06-01 02:22:05.673114|2018-06-01 02:22:05.673114
NCT00632944|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2015-06-04|2008-03-10|2008-03-11|Estimate|||||||2015-06-04|2015-06-08|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Effects of Nursing Rounds on Patients Fall Rates|Effects of Nursing Rounds on Patients Fall Rates, Satisfaction, and Call Light Use in an In-patient Medical Surgical Unit|Completed|||300|Anticipated|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:22:05.740637|2018-06-01 02:22:05.740637
NCT00632931|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2010-01-18||2015-07-08|2008-02-29|2008-03-11|Estimate|2010-01-22|2010-02-15|Estimate||||2015-07-08|2015-07-30|Estimate|July 2007||2007-07-31|July 2015|2015-07-31|April 2009|Actual|2009-04-30|May 2008|Actual|2008-05-31||Interventional|||A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)|A Randomized, Partially-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Effects of a Single Dose of Vorinostat on the QTc Interval in Patients With Advanced Cancer|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:22:05.917128|2018-06-01 02:22:05.917128
NCT00632918|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2008-12-25|2008-03-10|2008-03-11|Estimate|||||||2008-12-25|2008-12-29|Estimate|October 2007||2007-10-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|||||Observational|DSCT||Effects of Heart Rates and Variability of Heart Rates on Image Quality of Dual-Source CT Coronary Angiography|A Retrospective Study of Effects of Heart Rates and Variability of Heart Rates on Image Quality of Dual-Source CT Coronary Angiography With Regard to Motion Artifact.|Completed|||149|Actual|Far Eastern Memorial Hospital|||||f||||t||||||None Retained|"~     No biospecimens~   "|||2018-06-01 02:22:06.514968|2018-06-01 02:22:06.514968
NCT00632905|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-09-27|2008-03-04|2008-03-11|Estimate|||||||2017-09-27|2017-09-28|Actual|September 2007||2007-09-30|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|BHOS||Bone Health Observational Study|A Prospective Study to Evaluate the Incidence of Skeletal Related Events In Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT).|Completed|||599|Actual|CMX Research|||3||f||||f||||||||Undecided||2018-06-01 02:22:06.609102|2018-06-01 02:22:06.609102
NCT00632892|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2008-03-10|2008-03-10|2008-03-11|Estimate|||||||2008-03-10|2008-03-11|Estimate|December 2007||2007-12-31|February 2008|2008-02-29||||January 2008|Actual|2008-01-31||Observational|||The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity|The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity|Completed|||80||Far Eastern Memorial Hospital|||||f||||t||||||Samples Without DNA|"~     The urine samples are collected just before and 30 minutes after IVP.The samples are~     immediately frozen at -80'C until analyzed.~   "|||2018-06-01 02:22:06.745568|2018-06-01 02:22:06.745568
NCT00632879|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2008-07-07|2008-03-03|2008-03-11|Estimate|||||||2008-07-07|2008-07-09|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|March 2008|Anticipated|2008-03-31|||||Observational|||The Study of Metabolic Syndrome in Hemodialysis Patients|The Study of Metabolic Syndrome in Hemodialysis Patients|Unknown status|Recruiting||300|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||Samples With DNA|"~     Blood samples are collected for analysis~   "|||2018-06-01 02:22:06.795051|2018-06-01 02:22:06.795051
NCT00632866|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2012-07-01|2008-02-29|2008-03-11|Estimate|||||||2012-07-01|2012-07-03|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|JOQUER||Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome|Randomized, Double-blind, Placebo-controlled Trial of Hydroxychloroquine in Primary Sjögren's Syndrome|Completed||Phase 3|120|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:22:06.856962|2018-06-01 02:22:06.856962
NCT00632853|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-08|||2018-05-04|2008-03-08|2008-03-11|Estimate|||||||2018-05-04|2018-05-08|Actual|March 2008||2008-03-31|May 2018|2018-05-31||||June 2023|Anticipated|2023-06-30||Interventional|||Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide|Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide|Recruiting||Phase 3|729|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 02:22:07.357476|2018-06-01 02:22:07.357476
NCT00632840|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-02-29|2008-02-29|2008-03-11|Estimate|||||||2008-02-29|2008-03-11|Estimate|June 2001||2001-06-30|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2002|Actual|2002-12-31||Interventional|||Pharmacological Regulation of Fat Transport in Metabolic Syndrome|Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate With the Metabolic Syndrome|Completed||Phase 4|11|Actual|The University of Western Australia||3|||f||||f||||||||||2018-06-01 02:22:10.049168|2018-06-01 02:22:10.049168
NCT00632827|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2014-10-03|2008-03-10|2008-03-11|Estimate|||||||2014-10-03|2014-10-06|Estimate|June 2008||2008-06-30|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)|Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak) for In-vivo Purging and Post-Transplant Therapy: A Multicenter Phase II Clinical Trial|Unknown status|Active, not recruiting|Phase 2|21|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:22:10.118447|2018-06-01 02:22:10.118447
NCT00632814|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2011-01-14||2015-06-04|2008-03-10|2008-03-11|Estimate|2011-01-14|2011-02-08|Estimate||||2015-06-04|2015-07-01|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Russian Kogenate Pediatric Study|A Prospective Study to Evaluate the Effect of rFVIII-FS in Different Prophylactic Regimens on Bleeding Events Frequency and Development of Arthropathy in Previously Treated and Minimally Treated Hemophilia A Pediatric Population.|Completed||Phase 4|32|Actual|Bayer|Protocol deviations were not excluded: e.g. a previously untreated patient developed the transitory inhibitor; change to a higher group did not always occur according protocol; there was temporary lack of smaller vial sizes at the centers.|3|||f||||f||||||||||2018-06-01 02:22:10.215065|2018-06-01 02:22:10.215065
NCT00632801|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2014-12-07|2008-03-10|2008-03-11|Estimate|||||||2014-12-07|2014-12-09|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Does Chewing Gum After Elective Laparoscopic Colectomy Surgery Decrease Ileus?|Does Chewing Gum After Elective Laparoscopic Colectomy Surgery Decrease Ileus?|Terminated||N/A|3|Actual|State University of New York - Upstate Medical University||1||Change in procedure nd medication used instead of gum|f||||f||||||||||2018-06-01 02:22:10.926364|2018-06-01 02:22:10.926364
NCT00632788|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2008-03-03|2008-03-03|2008-03-11|Estimate|||||||2008-03-03|2008-03-11|Estimate|April 2006||2006-04-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Observational|||The Influence of Acute Myocardial Infarction Checklist on the Door-to-Balloon Time|The Influence of Acute Myocardial Infarction Checklist on the Door-to-Balloon Time in Patients Suffering From Acute ST-Elevation Myocardial Infarction|Completed|||213|Actual|Far Eastern Memorial Hospital|||2||f||||f||||||||||2018-06-01 02:22:10.994531|2018-06-01 02:22:10.994531
NCT00632775|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2013-08-23|2008-03-03|2008-03-11|Estimate|||||||2013-08-23|2013-08-26|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Hospitalized Children|Randomized, Double Blind, Controlled Trial of 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Hospitalized Children|Completed||Phase 3|110|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 02:22:11.063081|2018-06-01 02:22:11.063081
NCT00632762|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2011-04-07|2008-03-10|2008-03-11|Estimate|||||||2011-04-07|2011-04-08|Estimate|November 2007||2007-11-30|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|AMANDYSK||Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)|Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.|Completed||Phase 4|80|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 02:22:11.139979|2018-06-01 02:22:11.139979
NCT00632749|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2015-03-27|2014-04-30|2015-08-31|2008-03-04|2008-03-11|Estimate|2015-05-07|2015-05-25|Estimate|2014-04-30|2014-05-16|Estimate|2015-08-31|2015-09-14|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||68 participants were randomised, and 64 were treated with the study treatment hence the number of participants differs from the number of participants that started in the participant flow.|BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment|An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Efficacy and Pharmacokinetics of BI 811283 in Combination With Cytarabine in Patients With Previously Untreated Acute Myeloid Leukaemia Ineligible for Intensive Treatment|Completed||Phase 2|68|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:22:11.437121|2018-06-01 02:22:11.437121
NCT00632736|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2010-12-02||2017-03-21|2008-03-10|2008-03-11|Estimate|2010-12-02|2010-12-24|Estimate||||2017-03-21|2017-03-23|Actual|February 2004||2004-02-29|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease|An Open-Label Extension Study With REQUIP (Ropinirole) CR for Subjects From Studies 101468/165, 101468/168 and 101468/169|Completed||Phase 3|419|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:22:18.022403|2018-06-01 02:22:18.022403
NCT00632723|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2009-04-21|2008-03-04|2008-03-11|Estimate|||||||2009-04-21|2009-04-22|Estimate|April 2001||2001-04-30|April 2009|2009-04-30|October 2005|Actual|2005-10-31|||||Interventional|||IRESSA™ (Gefitinib) in Breast Cancer Patients|A Phase II Trial to Assess the Efficacy of IRESSA™ (Gefitinib) 500 mg/Day in Patients With Breast Cancer Who Have Failed Tamoxifen or Have an Oestrogen Receptor Negative Tumour and Would be Considered for Systemic Therapy|Completed||Phase 2|54|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:22:18.601861|2018-06-01 02:22:18.601861
NCT00632710|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-03-04|2008-03-04|2008-03-11|Estimate|||||||2008-03-04|2008-03-11|Estimate|July 2004||2004-07-31|March 2008|2008-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Assessment of the Effectiveness of Low-Level Laser Therapy on the Hands of Patients With Rheumatoid Arthritis|Assessment of the Effectiveness of Low-Level Laser Therapy on the Hands of Patients With Rheumatoid Arthritis: a Randomized Double-Blind Controlled Trial|Completed||N/A|82|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 02:22:18.731328|2018-06-01 02:22:18.731328
NCT00632697|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2008-03-10|2008-03-10|2008-03-11|Estimate|||||||2008-03-10|2008-03-11|Estimate|October 2001||2001-10-31|March 2008|2008-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|LETS1||Pentoxifylline and Endometriosis|Combined Laparoscopic Surgery and Pentoxifylline Therapy for Treatment of Endometriosis-Associated Infertility: A Preliminary Study|Completed||Phase 3|104|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:22:18.801697|2018-06-01 02:22:18.801697
NCT00632684|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2011-11-22|2008-03-07|2008-03-11|Estimate|||||||2011-11-22|2011-11-23|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effectiveness of an Adaptive Treatment Model for At-risk Family Caregivers|Adaptive Intervention for At-risk Family Caregivers|Completed||N/A|65|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 02:22:18.863187|2018-06-01 02:22:18.863187
NCT00632671|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2013-12-31|2008-03-10|2008-03-11|Estimate|||||||2013-12-31|2014-01-01|Estimate|March 2005||2005-03-31|December 2013|2013-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|COLOMBES||COLOMBES Project:Constitution of a Population-based Cohort of Obese Subjects With Longitudinal Long-term Follow-up|Constitution of a Population-based Cohort of Obese Subjects With Longitudinal Long-term Follow-up.|Active, not recruiting|||311|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     plasma, serum, DNA, RNA, cell blood, for persons undergoing bariatric surgery (specific~     consentment): samples of liver and adipocytes~   "|||2018-06-01 02:22:18.925568|2018-06-01 02:22:18.925568
NCT00632658|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2009-01-27|2008-03-04|2008-03-11|Estimate|||||||2009-01-27|2009-01-28|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|July 2010|Anticipated|2010-07-31|July 2009|Anticipated|2009-07-31||Observational|cGVHD||Development and Validation of a Symptom Scale for Children With Chronic Graft-Versus-Host Disease|Development and Validation of a Symptoms Scale for Children With Chronic Graft-Versus-Host Disease|Unknown status|Recruiting||24|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||f||||||||||2018-06-01 02:22:18.98265|2018-06-01 02:22:18.98265
NCT00632645|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2018-01-18|2008-03-10|2008-03-11|Estimate|||||||2018-01-18|2018-01-19|Actual|April 2009|Actual|2009-04-30|January 2018|2018-01-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|NEUROHD||Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride|Neuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study.|Completed||Phase 3|180|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-06-01 02:22:19.04497|2018-06-01 02:22:19.04497
NCT00632632|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2015-06-10||2015-07-29|2008-03-10|2008-03-11|Estimate|2015-07-29|2015-08-27|Estimate||||2015-07-29|2015-08-27|Estimate|January 2005||2005-01-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|VR-DCS||Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)|Combined Exposure Therapy and D-Cycloserine vs. Placebo for Posttraumatic Stress Disorder|Completed||N/A|25|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 02:22:19.13044|2018-06-01 02:22:19.13044
NCT00632619|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|2012-08-29||2013-04-12|2008-03-07|2008-03-11|Estimate|2013-04-12|2013-05-21|Estimate||||2013-04-12|2013-05-21|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood|A Novel Multimodal Intervention for Children With ADHD and Impaired Mood|Completed||N/A|68|Actual|Florida International University|relatively small sample size, the lack of a gold standard measurement for mood dysregulation in children, run at a specialty mental health research center and therapy subjects had more contact with study staff which may have impacted results.|2|||f||||t||||||||||2018-06-01 02:22:19.380438|2018-06-01 02:22:19.380438
NCT00632606|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2012-12-21|2008-03-10|2008-03-11|Estimate|||||||2012-12-21|2012-12-25|Estimate|August 2008||2008-08-31|December 2012|2012-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|MagHead||MgSO4 vs Metoclopramide for Headache in Pregnant Women|Magnesium Sulfate vs Metoclopramide for Headache in Pregnant Women|Withdrawn||Phase 2/Phase 3|0|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-06-01 02:22:20.1044|2018-06-01 02:22:20.1044
NCT00632593|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-03-07|2008-03-07|2008-03-10|Estimate|||||||2008-03-07|2008-03-10|Estimate|March 2005||2005-03-31|February 2008|2008-02-29|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Interventional|||Trial Comparing Early Complications of Two Techniques in the Laparoscopic Gastric Bypass|Prospective Randomized Trial Comparing Early Complications of Hand-Sewn Versus Circular Stapled Gastro-Jejunal Anastomosis in Laparoscopic Gastric Bypass|Completed||N/A|102|Actual|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-06-01 02:22:20.184628|2018-06-01 02:22:20.184628
NCT00632580|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2009-03-17|2008-02-28|2008-03-10|Estimate|||||||2009-03-17|2009-03-18|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||Intra- Versus Extraarticular Injection of Ropivacaine in Total Knee Arthroplasty|Intraartikulær Versus ekstraartikulær Bolus Injektion Med Ropivacain Ved Total knæalloplastik: et Prospektivt, Randomiseret, Dobbeltblindet, Kontrolleret Studie|Unknown status|Recruiting|Phase 4|60|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 02:22:20.247736|2018-06-01 02:22:20.247736
NCT00632567|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2016-12-14|2008-03-07|2008-03-10|Estimate|||||||2016-12-14|2016-12-15|Estimate|March 2008||2008-03-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|EPIC||EPIC :Anal Incontinence After Delivery. Secondary Prevention With Caesarean Section.|Anal Incontinence After Delivery. Secondary Prevention With Caesarean Section.|Completed||N/A|554|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-06-01 02:22:20.328627|2018-06-01 02:22:20.328627
NCT00267072|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2018-01-05|2005-12-19|2005-12-20|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2001||2001-06-30|January 2018|2018-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Ovarian Screening Study|The University of Louisville Ovarian Screening Study|Completed|||5000|Anticipated|University of Louisville|||||f||||t||||||||||2018-06-01 04:16:17.02936|2018-06-01 04:16:17.02936
NCT00632554|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2014-09-18|2008-02-28|2008-03-10|Estimate|||||||2014-09-18|2014-09-19|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia|Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia|Completed||Phase 4|50|Anticipated|Hamamatsu University||2|||f||||f||||||||||2018-06-01 02:22:20.439467|2018-06-01 02:22:20.439467
NCT00632541|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2015-12-02||2018-02-13|2008-03-07|2008-03-10|Estimate|2015-12-02|2016-01-07|Estimate||||2018-02-13|2018-02-14|Actual|October 2007||2007-10-31|February 2018|2018-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer|A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109|Terminated||Phase 2|18|Actual|Hoosier Cancer Research Network|The study was terminated early due to a poor safety profile as well as the lack of significant efficacy of this combination over bevacizumab alone in the short followup period where it was evaluated. Therefore, secondary objectives were not analyzed.|1||Significant Toxicities Experienced|f||||t||||||||||2018-06-01 02:22:20.663594|2018-06-01 02:22:20.663594
NCT00632528|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2012-01-09|2008-03-07|2008-03-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|March 2008||2008-03-31|February 2008|2008-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|KINOPA||MEOPA to Improve Physical Therapy Results After Multilevel Surgery|"Evaluation of the Efficacy of MEOPA Used to Obtain Better ROM Immediately After Multilevel Surgery in Children With Spastic Diplegia, Quadriplegia or Hemiplegia."|Completed||Phase 3|64|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:22:21.036223|2018-06-01 02:22:21.036223
NCT00632515|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2018-02-06|2008-03-07|2008-03-10|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2008|Actual|2008-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Screening for Familial Colorectal Cancer (CRC) Patients|Screening and Risk Communication for First Degree Relatives of Colorectal Cancer Patients|Active, not recruiting|||325|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 02:22:21.136664|2018-06-01 02:22:21.136664
NCT00632502|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2014-10-14||2017-03-10|2008-02-29|2008-03-10|Estimate|2014-11-14|2014-11-18|Estimate||||2017-03-10|2017-04-10|Actual|May 2008||2008-05-31|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||All randomized participants who received study drug|Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)|Safety of SCH 527123 in Subjects With Neutrophilic Asthma|Completed||Phase 2|37|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:22:21.24304|2018-06-01 02:22:21.24304
NCT00632489|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2015-05-18||2015-06-04|2008-03-07|2008-03-10|Estimate|2015-06-04|2015-06-08|Estimate||||2015-06-04|2015-06-08|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|July 2011|Actual|2011-07-31|January 2009|Actual|2009-01-31||Interventional|||LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients|A Phase I Study of LBH589 in Combination With Capecitabine ± Lapatinib|Completed||Phase 1|20|Actual|SCRI Development Innovations, LLC||3|||f||||f||||||||||2018-06-01 02:22:21.633273|2018-06-01 02:22:21.633273
NCT00632476|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2013-08-31|2008-03-05|2008-03-10|Estimate|||||||2013-08-31|2013-09-04|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluating the Effects of Supplemental Vitamin C on Infant Lung Function in Pregnant Smoking Women|In-Utero Smoke, Vitamin C, and Newborn Lung Function|Completed||N/A|282|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 02:22:21.941284|2018-06-01 02:22:21.941284
NCT00632463|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2013-02-22||2013-03-12|2008-03-07|2008-03-10|Estimate|2013-03-12|2013-04-24|Estimate||||2013-03-12|2013-04-24|Estimate|February 2008||2008-02-29|March 2013|2013-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness|RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness|Completed||Phase 2|21|Actual|ADMA Biologics, Inc.|Unfortunately enrollment in this study was suspended early due to slow accrual rates.|3|||f||||t||||||||||2018-06-01 02:22:22.056587|2018-06-01 02:22:22.056587
NCT00632450|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2010-03-25|2008-03-07|2008-03-10|Estimate|||||||2010-03-25|2010-03-29|Estimate|December 2007||2007-12-31|March 2010|2010-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|EnSite RT CPM||EnSite Real-Time Cardiac Performance Measurements (RT CPM) Study|EnSite Real-Time Cardiac Performance Measurements Study, a Non-significant Risk Study|Completed|||21|Actual|St. Jude Medical|||1||f||||f||||||||||2018-06-01 02:22:22.948537|2018-06-01 02:22:22.948537
NCT00632437|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2012-07-27|2008-03-03|2008-03-10|Estimate|||||||2012-07-27|2012-07-30|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Intraoperative Optical Imaging of Brain Function|Intraoperative Optical Imaging of Brain Function|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1|Terminated due to poor enrollment.|f||||f||||||||||2018-06-01 02:22:23.117068|2018-06-01 02:22:23.117068
NCT00632424|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2010-09-15||2016-02-09|2008-03-07|2008-03-10|Estimate|2010-11-04|2010-12-02|Estimate||||2016-02-09|2016-03-10|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase 1 Trial of Oral Ixabepilone|A Phase 1 Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects With Advanced Cancer|Terminated||Phase 1|23|Actual|R-Pharm|The MTD of oral ixabepilone at the scheduled doses used in this study was not determined due to early study discontinuation.|1||Business Objectives Changed|f||||f||||||||||2018-06-01 02:22:23.376722|2018-06-01 02:22:23.376722
NCT00632411|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2016-09-28||2018-02-14|2008-03-06|2008-03-10|Estimate|2017-04-21|2017-05-24|Actual||||2018-02-14|2018-03-14|Actual|April 2008||2008-04-30|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|AFIII||Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)|Efficacy of a Smoking Quit Line in the Military|Completed||N/A|1298|Actual|University of Tennessee||2|||f||||t||||||||||2018-06-01 02:22:24.32355|2018-06-01 02:22:24.32355
NCT00632398|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2015-12-12|2008-03-07|2008-03-10|Estimate|||||||2015-12-12|2015-12-15|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Multimedia Training for Family Caregivers in Use of Touch and Massage in Supportive Cancer Care|Couples and Cancer: Building Partner Efficacy in Caring|Completed||Phase 2|228|Actual|Collinge and Associates, Inc.||2|||f||||f||||||||||2018-06-01 02:22:24.729115|2018-06-01 02:22:24.729115
NCT00632385|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2011-04-22|2008-03-03|2008-03-10|Estimate|||||||2011-04-22|2011-04-26|Estimate|January 2003||2003-01-31|April 2011|2011-04-30|August 2003|Actual|2003-08-31|||||Interventional|||Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy|An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy|Completed||Phase 4|127|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:22:24.946645|2018-06-01 02:22:24.946645
NCT00632359|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2015-10-13|2008-03-07|2008-03-10|Estimate|||||||2015-10-13|2015-10-15|Estimate|February 2008||2008-02-29|October 2015|2015-10-31||||October 2015|Actual|2015-10-31||Interventional|||Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease|A Study of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy - RV-CLL-PI-0270|Completed||Phase 2|36|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 02:22:25.173089|2018-06-01 02:22:25.173089
NCT00632346|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2008-03-07|2008-03-07|2008-03-10|Estimate|||||||2008-03-07|2008-03-10|Estimate|September 2007||2007-09-30|February 2008|2008-02-29|February 2008|Anticipated|2008-02-29|February 2008|Anticipated|2008-02-29||Observational|||Relationship of Adverse Childhood Experiences to Overweight and Obesity|Relationship of Adverse Childhood Experiences (Childhood Abuse, Neglect, and Household Dysfunction) to the Severity of Overweight and Obesity in Young Adults in a Military Dependent Population.|Unknown status|Active, not recruiting||200|Actual|Brooke Army Medical Center|||1||f||||t||||||||||2018-06-01 02:22:25.434839|2018-06-01 02:22:25.434839
NCT00632333|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2011-07-20|2008-03-07|2008-03-10|Estimate|||||||2011-07-20|2011-07-21|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|March 2012|Anticipated|2012-03-31|December 2011|Anticipated|2011-12-31||Interventional|||Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer|Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer|Unknown status|Recruiting|Phase 1|9|Anticipated|Teikyo University||1|||f||||t||||||||||2018-06-01 02:22:25.521464|2018-06-01 02:22:25.521464
NCT00632320|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-02|||2008-03-07|2008-03-07|2008-03-10|Estimate|||||||2008-03-07|2008-03-10|Estimate|October 2004||2004-10-31|March 2008|2008-03-31|August 2005|Actual|2005-08-31|December 2004|Actual|2004-12-31||Observational|||Continuous Positive Airway Pressure and Oxygen Concentration on Measurement of Rapid Shallow Breathing Index|Effect of Continuous Positive Airway Pressure and Oxygen Concentration on Measurement of Rapid Shallow Breathing Index|Completed|||98|Actual|Taipei Veterans General Hospital, Taiwan|||1||f||||f||||||||||2018-06-01 02:22:25.774145|2018-06-01 02:22:25.774145
NCT00632307|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2018-03-05|2008-03-07|2008-03-10|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2006||2006-07-31|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Observational|||Breath Analysis by Ion Mobility Spectrometry|Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry|Recruiting|||1000|Anticipated|Lung Clinic Hemer|||8||f||||f||||||Samples Without DNA|"~     breath, pleural fluid (only in patients with therapeutic pleurocentesis)~   "|||2018-06-01 02:22:25.856085|2018-06-01 02:22:25.856085
NCT00632294|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2012-07-31|2008-03-07|2008-03-10|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Retrospective Study of the Biomechanical Properties of Large Allografts|Retrieved Allograft Study: Retrospective Study of the Biomechanical Properties of Large Allografts|Terminated|||2|Actual|M.D. Anderson Cancer Center|||1|Low accrual.|f||||f||||||Samples With DNA|"~     A leftover sample of the removed allograft bone will be collected and used to learn about the~     properties (such as bone strength, bone density, and new bone formation) of the removed~     transplant tissue.~   "|||2018-06-01 02:22:26.116009|2018-06-01 02:22:26.116009
NCT00632281|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2011-12-01||2012-01-17|2008-03-07|2008-03-10|Estimate|2012-01-17|2012-02-20|Estimate||||2012-01-17|2012-02-20|Estimate|January 2006||2006-01-31|June 2010|2010-06-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) for Lung Tumors|Stereotactic Body Radiation Therapy for Tumors in the Thorax|Completed||N/A|38|Actual|University of Florida|||||f||||f||||||||||2018-06-01 02:22:26.229143|2018-06-01 02:22:26.229143
NCT00632268|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2013-08-19|2008-03-07|2008-03-10|Estimate|||||||2013-08-19|2013-08-21|Estimate|February 2008||2008-02-29|August 2013|2013-08-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer|Phase II Study of Low-dose RAD001(Everolimus) Plus Cisplatin and HDFL (Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin) Chemotherapy for First-line Treatment of Unresectable, Recurrent or Metastatic Gastric Cancer|Completed||Phase 2|40|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 02:22:26.493851|2018-06-01 02:22:26.493851
NCT00632255|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2015-06-02|2008-03-07|2008-03-10|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment|Compliance to Long Term Imatinib Therapy in Newly Diagnosed Patients With Chronic Myeloid Leukaemia.|Completed|||88|Actual|Imperial College London|||1||f||||f||||||||||2018-06-01 02:22:26.645424|2018-06-01 02:22:26.645424
NCT00632242|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2009-01-08|2008-03-03|2008-03-10|Estimate|||||||2009-01-08|2009-01-09|Estimate|January 2008||2008-01-31|March 2008|2008-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders|A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders|Completed||Phase 2|28|Anticipated|Archemix Corp.||5|||f||||f||||||||||2018-06-01 02:22:26.722584|2018-06-01 02:22:26.722584
NCT00632229|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2013-10-23||2013-12-19|2008-02-29|2008-03-10|Estimate|2013-12-19|2014-02-06|Estimate||||2013-12-19|2014-02-06|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder|Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder|Completed||Phase 2|34|Actual|University of South Florida|"Modest sample and analyses were potentially underpowered to detect between-group differences on OCD measures.~It was not possible to determine response from participants' current medication.~Little racial/ethnic and socioeconomic variability"|2|||f||||f||||||||||2018-06-01 02:22:26.807552|2018-06-01 02:22:26.807552
NCT00632216|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2008-03-10|2008-03-07|2008-03-10|Estimate|||||||2008-03-10|2008-03-11|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|May 2006|Actual|2006-05-31|||||Interventional|ROSPA-CTx||A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis|Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis|Completed||Phase 4|464|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:22:27.349506|2018-06-01 02:22:27.349506
NCT00632008|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2010-01-25|2008-02-29|2008-03-10|Estimate|||||||2010-01-25|2010-01-26|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers|A Randomised, Double-blind, Placebo-controlled Study to Determine the Efficacy of Soluble Beta-1,3/1,6-glucan in Chronic Foot Ulcers in Diabetes|Completed||Phase 3|122|Actual|Biotec Pharmacon ASA||2|||f||||f||||||||||2018-06-01 02:22:30.605025|2018-06-01 02:22:30.605025
NCT00632203|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2011-12-22||2017-05-15|2008-02-29|2008-03-10|Estimate|2012-02-23|2012-03-26|Estimate||||2017-05-15|2017-06-07|Actual|March 4, 2008|Actual|2008-03-04|May 2017|2017-05-31|January 7, 2011|Actual|2011-01-07|January 6, 2011|Actual|2011-01-06||Interventional|||Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)|A Randomized Phase 2 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients|Terminated||Phase 2|53|Actual|Merck Sharp & Dohme Corp.|The interpretation of the study results should be taken with caution because of the small sample size due to early termination.|2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:22:27.423251|2018-06-01 02:22:27.423251
NCT00632190|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2010-01-27|2008-03-07|2008-03-10|Estimate|||||||2010-01-27|2010-01-28|Estimate|January 2000||2000-01-31|January 2009|2009-01-31||||March 2003|Actual|2003-03-31||Interventional|||Spectroscopy in Diagnosing Dysplasia and Neoplasia in the Cervix in Women Undergoing Colposcopy|Measurement of Fluorescence EEM of Cervical Intraepithelial Neoplasia|Completed||N/A|1800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:22:27.828272|2018-06-01 02:22:27.828272
NCT00632164|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2008-02-29|2008-02-29|2008-03-10|Estimate|||||||2008-02-29|2008-03-10|Estimate|January 2005||2005-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Sympathetic and Parasympathetic Responses to Specific Chiropractic Adjustments|Sympathetic and Parasympathetic Responses to Specific Chiropractic Adjustments of Subluxation of the Cervical and Thoracic Spine|Completed|||40|Actual|Sherman College of Straight Chiropractic|||2||f||||f||||||||||2018-06-01 02:22:27.896902|2018-06-01 02:22:27.896902
NCT00632138|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2013-08-06|2008-03-07|2008-03-10|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2005||2005-01-31|December 2008|2008-12-31|July 2011|Actual|2011-07-31|December 2008|Actual|2008-12-31||Interventional|||Pelvic Floor Muscle Training and Biofeedback or Standard Therapy in Men Who Have Undergone Radical Prostatectomy or Transurethral Resection of the Prostate|MAPS (Men After Prostate Surgery) : Conservative Treatment for Men With Urinary Incontinence After Prostate Surgery; Multicentre Randomised Controlled Trial of Pelvic Floor Muscle Training and Biofeedback [MAPS]|Completed||Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:22:27.951778|2018-06-01 02:22:27.951778
NCT00632125|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2017-04-03||2017-07-10|2008-03-07|2008-03-10|Estimate|2017-07-10|2017-07-11|Actual||||2017-07-10|2017-07-11|Actual|July 2008||2008-07-31|July 2017|2017-07-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|EPO-PASS||Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.|Post-authorization Safety Study to Prospectively Monitor the Incidence of Relevant Drug-related Adverse Events and EPO-related Lack of Efficacy Among CKD Subjects Receiving HX575 Recombinant Human Erythropoietin Alfa i.v.|Completed||Phase 4|1695|Actual|Sandoz||1|||f||||t||||||||Undecided||2018-06-01 02:22:28.142606|2018-06-01 02:22:28.142606
NCT00632112|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2009-06-03|2008-02-29|2008-03-10|Estimate|||||||2009-06-03|2009-06-05|Estimate|March 2008||2008-03-31|June 2009|2009-06-30||||July 2009|Anticipated|2009-07-31||Observational|||A Real Life Evaluation of the Performance of a Large Volume Nebulizer|A Real Life Evaluation of the Performance of a Large Volume Nebulizer|Unknown status|Recruiting||50|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-06-01 02:22:29.20956|2018-06-01 02:22:29.20956
NCT00632099|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2014-04-09||2014-04-09|2008-03-06|2008-03-10|Estimate|2014-04-09|2014-05-12|Estimate||||2014-04-09|2014-05-12|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PROG||Progesterone Treatment for Cocaine-dependent Women: A Pilot Study|Progesterone Treatment for Cocaine-dependent Women: A Pilot Study|Completed||Phase 2/Phase 3|21|Actual|New York State Psychiatric Institute|Given the limited sample size, it was not possible to adequately determine whether OM-PROG may be an effective treatment for cocaine-dependence in women, but it was well tolerated.|2|||f||||t||||||||||2018-06-01 02:22:29.332786|2018-06-01 02:22:29.332786
NCT00632086|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2008-03-07|2008-03-07|2008-03-10|Estimate|||||||2008-03-07|2008-03-10|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy Volunteers|A Phase 1, Open-Label, Randomized, 3-Way Crossover Study to Evaluate the Relative Bioavailability of a Single Oral Dose of Aspirin Administered as PA32540 (Aspirin/Omeprazole) or as the Aspirin Component of PA32540 or as Ecotrin® 325 mg in Healthy Volunteers|Completed||Phase 1|36|Anticipated|POZEN||3|||f||||f||||||||||2018-06-01 02:22:29.612333|2018-06-01 02:22:29.612333
NCT00632073|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2015-02-20|2008-03-07|2008-03-10|Estimate|||||||2015-02-20|2015-02-23|Estimate|March 2008||2008-03-31|February 2015|2015-02-28|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)|Effect of Vicriviroc on HIV RNA Levels in Cerebrospinal Fluid|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:22:29.679115|2018-06-01 02:22:29.679115
NCT00632060|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2008-03-07|2008-03-07|2008-03-10|Estimate|||||||2008-03-07|2008-03-10|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Manual and Manipulative Therapy for Low Back Pain|The Efficacy of Manual and Manipulative Therapy for Low Back Pain in Military Active Duty Personnel: A Feasibility Study|Unknown status|Recruiting|N/A|100|Anticipated|Samueli Institute for Information Biology||2|||f||||||||||||||2018-06-01 02:22:29.763904|2018-06-01 02:22:29.763904
NCT00632047|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2013-08-23|2008-03-07|2008-03-10|Estimate|||||||2013-08-23|2013-08-26|Estimate|May 1998||1998-05-31|July 2009|2009-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Early Detection of Breast Cancer and Cervical Cancer in Women in India|Early Detection of Common Cancers in Women in India|Unknown status|Recruiting|Phase 2|151538|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:22:29.869939|2018-06-01 02:22:29.869939
NCT00632034|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2016-02-19|2008-02-29|2008-03-10|Estimate|||||||2016-02-19|2016-02-22|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|STIF||Stem Cells and Tibial Fractures|A Phase I Safety Study Following the Infusion of Expanded Autologous Progeny of an Adult CD34+ Stem Cell Subset to Patients With Recent Tibial Fractures|Completed||Phase 1|9|Actual|Imperial College London||1|||f||||t||||||||||2018-06-01 02:22:29.928389|2018-06-01 02:22:29.928389
NCT00632021|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2017-06-01||2017-08-02|2008-03-06|2008-03-10|Estimate|2017-06-01|2017-08-01|Actual||||2017-08-02|2017-09-01|Actual|May 2008||2008-05-31|August 2017|2017-08-31|March 2012|Actual|2012-03-31|September 2009|Actual|2009-09-30||Interventional|PILL-CVD||Pharmacist Intervention to Decrease Medication Errors in Heart Disease Patients (The PILL-CVD Study)|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Completed||N/A|862|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 02:22:30.013206|2018-06-01 02:22:30.013206
NCT00631995|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2018-02-05|2008-02-29|2008-03-10|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2008||2008-04-30|February 2018|2018-02-28|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers|Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) in Toddlers|Completed||Phase 1|360|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 02:22:30.787266|2018-06-01 02:22:30.787266
NCT00631982|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2008-03-07|2008-03-07|2008-03-10|Estimate|||||||2008-03-07|2008-03-10|Estimate|April 2008||2008-04-30|March 2008|2008-03-31||||October 2009|Anticipated|2009-10-31||Interventional|||Invitro Maturation of Oocytes for Patients With Polycystic Ovaries|In Vitro Maturation of Oocytes for Patients With Polycystic Ovaries|Unknown status|Not yet recruiting|N/A|30|Anticipated|Assaf-Harofeh Medical Center||1|||f||||||||||||||2018-06-01 02:22:30.879197|2018-06-01 02:22:30.879197
NCT00631969|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2010-10-05|2010-02-08|2014-12-08|2008-02-29|2008-03-10|Estimate|2010-12-21|2011-01-21|Estimate|2010-02-08|2010-02-10|Estimate|2014-12-08|2014-12-30|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction|Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-dose, Double-blind, Randomized Multi-center Trial - POTENT I|Completed||Phase 3|362|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:22:31.015819|2018-06-01 02:22:31.015819
NCT00631956|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2016-04-05|2008-03-03|2008-03-10|Estimate|||||||2016-04-05|2016-04-07|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||SAPPHIRe III in Taiwan－Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families|Progression Evaluation and Cardiovascular Outcomes of Hypertensive Families－A Follow-up Genetic Study of Taiwan SAPPHIRe Cohort|Unknown status|Active, not recruiting||1038|Actual|National Health Research Institutes, Taiwan|||||f||||f||||||Samples With DNA|"~     Plasma, serum, urine, and buffy coat~   "|Undecided||2018-06-01 02:22:32.236141|2018-06-01 02:22:32.236141
NCT00631943|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2011-04-22|2008-03-03|2008-03-10|Estimate|||||||2011-04-22|2011-04-26|Estimate|November 2004||2004-11-30|April 2011|2011-04-30|March 2005|Actual|2005-03-31|||||Interventional|||A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain|An Open Label, Non-comparative, Multicentre Study to Evaluate the Efficacy and Tolerability of Pregabalin in Peripheral Neuropathic Pain|Completed||Phase 3|112|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:22:32.301124|2018-06-01 02:22:32.301124
NCT00631917|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2011-01-05||2011-06-30|2008-03-07|2008-03-10|Estimate|2011-05-18|2011-06-21|Estimate||||2011-06-30|2011-07-12|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension|A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension|Completed||Phase 4|774|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:22:32.429131|2018-06-01 02:22:32.429131
NCT00631904|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2011-08-31|2008-03-07|2008-03-10|Estimate|||||||2011-08-31|2011-09-02|Estimate|January 2005||2005-01-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Observational|||St. Mary's Duluth Clinic (SMDC) Pacemaker Magnetic Resonance Imaging (MRI) Study|SMDC Pacemaker-MRI Cohort Study|Completed|||150|Actual|Essentia Health|||1||f||||f||||||||||2018-06-01 02:22:32.960233|2018-06-01 02:22:32.960233
NCT00631878|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2008-02-29|2008-02-29|2008-03-10|Estimate|||||||2008-02-29|2008-03-10|Estimate|November 2001||2001-11-30|February 2008|2008-02-29|August 2003|Actual|2003-08-31|May 2003|Actual|2003-05-31||Interventional|N002||Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110|Phase I/II Randomized, Double Blind, Placebo Controlled, Dose Escalation, Safety and Pharmacokinetics Study in VLBW Neonates, a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for the Prevention of S. Epidermidis Infection|Completed||Phase 1/Phase 2|53|Actual|Biosynexus Incorporated||5|||f||||t||||||||||2018-06-01 02:22:33.031837|2018-06-01 02:22:33.031837
NCT00631865|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2016-07-18|2008-03-07|2008-03-10|Estimate|||||||2016-07-18|2016-07-20|Estimate|February 2009||2009-02-28|February 2009|2009-02-28|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin|Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin|Completed||Phase 3|300|Actual|Royan Institute||1|||f||||t||||||||||2018-06-01 02:22:33.103915|2018-06-01 02:22:33.103915
NCT00631852|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2018-04-16|2008-02-29|2008-03-10|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2008||2008-02-29|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|March 9, 2017|Actual|2017-03-09||Interventional|||A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer|A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer|Active, not recruiting||Phase 2|20|Anticipated|Southern Illinois University||1|||f||||t||||||||||2018-06-01 02:22:33.183777|2018-06-01 02:22:33.183777
NCT00631839|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-02|||2008-10-06|2008-03-02|2008-03-10|Estimate|||||||2008-10-06|2008-10-07|Estimate|January 2002||2002-01-31|October 2008|2008-10-31|October 2008|Anticipated|2008-10-31|January 2006|Actual|2006-01-31||Observational|||Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury|Prospect Study to Evaluate Clinical, Dosimetrical, Functional, Biological and Genetic Factors in Predicting Chemo-Radiotherapy Induced Lung and Esophagus Injury|Unknown status|Active, not recruiting||140|Actual|Shanghai Cancer Hospital, China|||1||f||||t||||||Samples With DNA|"~     Patients' blood samples will be retained for the purpose of cytokine and MnSOD assay and DNA~     detection. The samples will be left till the study ends. Paitents will have their vein blood~     drawn from left arm 6am every Monday during RT. All above is stated in informed consent form.~   "|||2018-06-01 02:22:33.248591|2018-06-01 02:22:33.248591
NCT00631826|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2012-04-04|2008-03-07|2008-03-10|Estimate|||||||2012-04-04|2012-04-05|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Shoulder Rotational Flexibility and Throwing Arm Injuries of Baseball Pitchers|Shoulder Internal/External Rotational Flexibility is Related to Throwing Arm Injuries in Professional Baseball Players|Completed|||40|Actual|University of Florida|||||f||||f||||||||||2018-06-01 02:22:33.308286|2018-06-01 02:22:33.308286
NCT00631813|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2008-05-28|2008-03-07|2008-03-10|Estimate|||||||2008-05-28|2008-05-29|Estimate|November 1995||1995-11-30|February 2008|2008-02-29|April 1997|Actual|1997-04-30|April 1997|Actual|1997-04-30||Interventional|||Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation|A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation|Completed||Phase 2|253|Actual|Movetis||4|||f||||f||||||||||2018-06-01 02:22:33.352559|2018-06-01 02:22:33.352559
NCT00631800|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2008-02-29|2008-02-29|2008-03-10|Estimate|||||||2008-02-29|2008-03-10|Estimate|May 2003||2003-05-31|February 2008|2008-02-29|November 2004|Actual|2004-11-30|March 2004|Actual|2004-03-31||Interventional|N003||Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110|Phase II Randomized, Double Blind, Placebo Controlled, Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110, for the Prevention of Staphylococcal Infection|Completed||Phase 2|88|Actual|Biosynexus Incorporated||3|||f||||t||||||||||2018-06-01 02:22:33.410508|2018-06-01 02:22:33.410508
NCT00631787|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2018-03-31|2008-03-07|2008-03-10|Estimate|||||||2018-03-31|2018-04-03|Actual|February 29, 2008||2008-02-29|December 7, 2015|2015-12-07|December 7, 2015||2015-12-07|||||Observational|||Evaluation of Toxicity From Stem Cell Transplant|Evaluation of Systemic Toxicity Associated With Allogeneic Peripheral Blood Stem Cell Infusion|Completed|||61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:22:33.490201|2018-06-01 02:22:33.490201
NCT00631774|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-02|||2011-12-05|2008-03-07|2008-03-10|Estimate|||||||2011-12-05|2011-12-06|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study to Evaluate the Postprandial Metabolic Response After Use of Glucerna SR in Obese Type 2 Diabetes|An Open Label, Randomized, and Parallel Study to Evaluate the Postprandial Metabolic Response After 24-Week Use of Glucerna SR in Obese Asian Subjects With Type 2 Diabetes|Completed||N/A|60|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-06-01 02:22:33.539677|2018-06-01 02:22:33.539677
NCT00631761|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-08-18|2008-03-07|2008-03-10|Estimate|||||||2008-08-18|2008-08-19|Estimate|May 2008||2008-05-31|August 2008|2008-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Standardized Criteria to Judge Diagnostic Urethrocystoscopy Skills|Standardized Criteria to Judge Diagnostic Urethrocystoscopy Skills|Completed||N/A|36|Anticipated|University of Cincinnati||2|||f||||f||||||||||2018-06-01 02:22:33.734298|2018-06-01 02:22:33.734298
NCT00631748|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2011-12-16||2014-03-03|2008-03-07|2008-03-10|Estimate|2013-12-26|2014-02-12|Estimate||||2014-03-03|2014-03-31|Estimate|February 2008||2008-02-29|March 2014|2014-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|AZC||Quetiapine for the Reduction of Cocaine Use|A Double-Blind, Placebo-Controlled Trial of the Efficacy of Quetiapine for the Reduction of Cocaine Use|Completed||N/A|60|Actual|Seattle Institute for Biomedical and Clinical Research|1) High number of drop-outs (68%) means that analyses are limited by a lack of power. 2) More males than females included-may reflect differences in cocaine drug usage between the sexes.|2|||f||||t||||||||||2018-06-01 02:22:33.814539|2018-06-01 02:22:33.814539
NCT00631735|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2009-06-16|2008-03-07|2008-03-10|Estimate|||||||2009-06-16|2009-06-17|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Perceptions of Touch in People With Cancer|Perceptions of Touch in People With Cancer|Completed|||12|Anticipated|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:22:34.072921|2018-06-01 02:22:34.072921
NCT00631722|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2012-08-21|2008-02-29|2008-03-10|Estimate|||||||2012-08-21|2012-08-22|Estimate|May 2007||2007-05-31|February 2008|2008-02-29|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of Schizophrenia||Completed||N/A|80|Actual|Peking University||2|||f||||f||||||||||2018-06-01 02:22:34.138593|2018-06-01 02:22:34.138593
NCT00631709|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2018-04-24|2008-03-03|2008-03-10|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2008||2008-03-31|April 2018|2018-04-30|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|REMOTE-IPG||REmote MOnitoring Transmission Evaluation of IPGs|REmote MOnitoring Transmission Evaluation of IPGs|Completed||Phase 4|120|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-06-01 02:22:34.207165|2018-06-01 02:22:34.207165
NCT00631696|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2012-09-24||2012-09-24|2008-03-07|2008-03-10|Estimate|2012-09-24|2012-10-24|Estimate||||2012-09-24|2012-10-24|Estimate|February 2008||2008-02-29|September 2012|2012-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Evaluation Of Sperm Production With Healthy Male Volunteers Receiving Lyrica Or Placebo|Prospective Randomized Double-Blind Study Of Sperm Production In Healthy Volunteers Receiving Pregabalin Or Placebo|Completed||Phase 4|222|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:22:34.346552|2018-06-01 02:22:34.346552
NCT00631683|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2009-05-14|2008-03-07|2008-03-10|Estimate|||||||2009-05-14|2009-05-15|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|February 2008|Anticipated|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Assessment of Hemodynamic Changes During Weaning From Mechanical Ventilation With Flo-Trac Vigileo (TM) Monitor.|Use of Flo-Trac/Vigileo (TM) for Hemodynamic Monitoring During Discontinuation From Mechanical Ventilation|Withdrawn|||80|Anticipated|The University of Texas Health Science Center, Houston|||1|Terms for legal agreements between institution and Sponsor could not be made.|f||||f||||||||||2018-06-01 02:22:34.819055|2018-06-01 02:22:34.819055
NCT00631670|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2011-11-28||2012-02-01|2008-03-07|2008-03-10|Estimate|2012-01-17|2012-01-25|Estimate||||2012-02-01|2012-02-03|Estimate|October 2005||2005-10-31|June 2010|2010-06-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) for Tumors Near the Spinal Cord|Stereotactic Body Radiation Therapy for Tumors Near the Spinal Cord|Completed||N/A|21|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 02:22:34.895831|2018-06-01 02:22:34.895831
NCT00631657|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2014-05-15|2009-12-03|2015-07-21|2008-02-29|2008-03-10|Estimate|2014-07-03|2014-08-01|Estimate|2009-12-03|2009-12-07|Estimate|2015-07-21|2015-07-28|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||The Baseline Analysis Population consists of all participants who received study drug. Two participants in the esmertazapine 4.5 mg group and one participant in the placebo group did not receive study drug.|A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)|A 6-Month, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Outpatient Trial, Investigating the Efficacy and Safety of Org 50081 in Adult Patients With Chronic Primary Insomnia|Completed||Phase 3|460|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:22:35.203098|2018-06-01 02:22:35.203098
NCT00631644|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-07|||2017-10-05|2008-03-07|2008-03-10|Estimate|||||||2017-10-05|2017-10-06|Actual|March 5, 2008||2008-03-05|September 8, 2015|2015-09-08|September 8, 2015||2015-09-08|||||Observational|||Eating Behavior in Adolescents|Eating Behavior in Adolescents|Completed|||301|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:22:35.6039|2018-06-01 02:22:35.6039
NCT00631631|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2014-05-13|2008-02-29|2008-03-10|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma|Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE) for High-risk Osteosarcoma|Completed|||205|Actual|Millennium Pharmaceuticals, Inc.|||1||f||||f||||||||||2018-06-01 02:22:35.666899|2018-06-01 02:22:35.666899
NCT00631618|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2014-02-22|2008-03-07|2008-03-10|Estimate|||||||2014-02-22|2014-02-25|Estimate|September 2007||2007-09-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Clinical Trial of Sutent to Treat Metastatic Melanoma|A Phase II Trial of Sutent in Metastatic Melanoma Patients With KIT Aberrations.|Completed||Phase 2|12|Actual|California Pacific Medical Center Research Institute||1|||f||||||||||||||2018-06-01 02:22:35.736219|2018-06-01 02:22:35.736219
NCT00631605|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|||2009-03-01|2008-03-07|2008-03-10|Estimate|||||||2009-03-01|2009-03-03|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Studies of Neuroendocrine and Energy Metabolism in Patients With Eating Disorders|Studies of Neuroendocrine and Energy Metabolism in Patients With Eating Disorders|Completed|||112|Actual|National Taiwan University Hospital|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:22:35.803178|2018-06-01 02:22:35.803178
NCT00631592|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2017-02-01|2008-03-05|2008-03-07|Estimate|||||||2017-02-01|2017-02-03|Estimate|February 2008||2008-02-29|October 2010|2010-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study|GSK1349572 Repeat Dose Escalation Study|Completed||Phase 1|44|Actual|ViiV Healthcare||1|||f||||f||||||||No||2018-06-01 02:22:35.860236|2018-06-01 02:22:35.860236
NCT00631579|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-10-01|2008-03-06|2008-03-07|Estimate|||||||2009-10-01|2009-10-02|Estimate|April 2003||2003-04-30|October 2009|2009-10-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma|Open-label, Multicenter Study of Repeated Doses of SR29142 (Rasburicase) as a Uricolytic Therapy for Hyperuricemia in Adult Patients With Leukemia or Lymphoma.|Completed||Phase 2|50|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:22:35.94467|2018-06-01 02:22:35.94467
NCT00631566|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2017-06-13|2008-03-06|2008-03-07|Estimate|||||||2017-06-13|2017-06-14|Actual|May 2007||2007-05-31|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|May 2017|Actual|2017-05-31||Interventional|MRSA||Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons|Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons|Active, not recruiting||N/A|550|Anticipated|Uniformed Services University of the Health Sciences||2|||f||||t||||||||||2018-06-01 02:22:35.996556|2018-06-01 02:22:35.996556
NCT00631553|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-08-06|2008-03-06|2008-03-07|Estimate|||||||2008-08-06|2008-08-07|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound|Assessment of Changes in Renal Cortical and Medullary Blood Flow by Contrast Ultrasound|Unknown status|Recruiting|N/A|20|Anticipated|University of Virginia|||||f||||f||||||||||2018-06-01 02:22:36.212721|2018-06-01 02:22:36.212721
NCT00631540|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2011-02-11||2013-11-21|2008-03-06|2008-03-07|Estimate|2011-04-20|2011-05-19|Estimate||||2013-11-21|2013-12-16|Estimate|February 2008||2008-02-29|November 2013|2013-11-30|May 2012|Actual|2012-05-31|May 2010|Actual|2010-05-31||Interventional|||REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent||Completed||N/A|100|Actual|Cook Group Incorporated||1|||f||||t||||||||||2018-06-01 02:22:36.306177|2018-06-01 02:22:36.306177
NCT00631527|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2015-01-28|2008-02-27|2008-03-07|Estimate|||||||2015-01-28|2015-01-29|Estimate|February 2008||2008-02-29|January 2015|2015-01-31||||January 2015|Actual|2015-01-31||Interventional|||Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer|Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer|Completed||Phase 1|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:22:36.643229|2018-06-01 02:22:36.643229
NCT00631514|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-03-07|2008-03-06|2008-03-07|Estimate|||||||2008-03-07|2008-03-10|Estimate|January 2005||2005-01-31|February 2008|2008-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)|Relevance of the Interaction Between Antihypertensive and Antirheumatic Drugs in a Family Practice|Completed||Phase 4|88|Actual|University Hospital of Split||3|||f||||f||||||||||2018-06-01 02:22:36.792236|2018-06-01 02:22:36.792236
NCT00631501|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-02-27|2008-02-27|2008-03-07|Estimate|||||||2008-02-27|2008-03-07|Estimate||||February 2008|2008-02-29||||||||Interventional|||Doxycycline for Lateral Epicondylalgia - RCT||Unknown status|Recruiting|N/A|34|Anticipated|Kaunas University of Medicine||2|||f||||||||||||||2018-06-01 02:22:36.915445|2018-06-01 02:22:36.915445
NCT00631488|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2011-10-07||2016-12-30|2008-02-27|2008-03-07|Estimate|2012-01-14|2012-02-17|Estimate||||2016-12-30|2017-01-02|Estimate|February 2008||2008-02-29|December 2016|2016-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)|A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK0893 in Combination With Sitagliptin or in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 2|146|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 02:22:37.000675|2018-06-01 02:22:37.000675
NCT00631475|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2012-06-19||2015-09-09|2008-02-28|2008-03-07|Estimate|2012-06-19|2012-08-03|Estimate||||2015-09-09|2015-09-28|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|BUILD OL||Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443|Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)|Completed||Phase 3|128|Actual|Actelion||1|||f||||f||||||||||2018-06-01 02:22:37.36298|2018-06-01 02:22:37.36298
NCT00631462|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2009-10-22|2008-03-06|2008-03-07|Estimate|||||||2009-10-22|2009-10-26|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis|A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis|Completed||Phase 1|59|Actual|TargeGen||1|||f||||f||||||||||2018-06-01 02:22:38.75103|2018-06-01 02:22:38.75103
NCT00631449|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2013-11-12||2015-10-30|2008-03-06|2008-03-07|Estimate|2013-11-12|2013-12-30|Estimate||||2015-10-30|2015-11-03|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||Raltegravir Intensification in HIV-infected Patients|Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response|Completed||Phase 4|30|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:22:38.840048|2018-06-01 02:22:38.840048
NCT00536185|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2011-08-03|2007-09-25|2007-09-27|Estimate|||||||2011-08-03|2011-08-04|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Heart & Health Study|Variation in the ALOX5 Gene and Response to Omega-3 Fatty Acid Supplements|Completed||N/A|166|Anticipated|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 02:53:33.434168|2018-06-01 02:53:33.434168
NCT00631436|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2011-07-20|2008-03-06|2008-03-07|Estimate|||||||2011-07-20|2011-07-21|Estimate|April 2008||2008-04-30|February 2008|2008-02-29|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Observational|||The Effects of Explosive Blast as Compared to Post-Traumatic Stress Disorder on Brain Function and Structure|The Effects of Explosive Blast as Compared to Post-Traumatic Stress Disorder on Brain Function and Structure|Unknown status|Recruiting||180|Anticipated|Minnesota Veterans Medical Research and Education Foundation|||4||f||||t||||||Samples With DNA|"~     Whole blood samples and isolated DNA and serum~   "|||2018-06-01 02:22:39.080171|2018-06-01 02:22:39.080171
NCT00631423|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2015-04-14|2008-02-27|2008-03-07|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2007||2007-07-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Observational|||Evaluation of Patients With Vena Cava Inferior Thrombosis|Clinical Course and Prognosis of Patients With Vena Cava Inferior Thrombosis|Completed|||120|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-06-01 02:22:39.953547|2018-06-01 02:22:39.953547
NCT00631410|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2010-07-21||2011-03-11|2008-02-27|2008-03-07|Estimate|2010-07-21|2010-08-17|Estimate||||2011-03-11|2011-03-16|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|||Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer|Phase I Study Of Sunitinib In Combination With Oxaliplatin, L-Leucovorin, And 5-Fluorouracil In Patients With Metastatic Colorectal Cancer|Completed||Phase 1|12|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:22:40.064663|2018-06-01 02:22:40.064663
NCT00631397|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2012-06-14|2008-02-27|2008-03-07|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||A Preliminary Study of Bone Density in Neonates|A Preliminary Study of Bone Density Measurements in Neonates Using the Sunlight Omnisense 7000P Ultrasound Bone Sonometer|Completed|||40|Actual|University of South Florida|||1||f||||t||||||Samples Without DNA|"~     Measuring proteins in the blood plasma~   "|||2018-06-01 02:22:40.794972|2018-06-01 02:22:40.794972
NCT00631384|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2018-04-18|2008-03-06|2008-03-07|Estimate|||||||2018-04-18|2018-04-20|Actual|March 2003||2003-03-31|April 2018|2018-04-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|CVCT||Experimental Design of Couple Counseling and Testing in Antenatal Clinics in Dar es Salaam, Tanzania|Experimental Design of Couple Counseling and Testing in Antenatal Clinics in Dar es Salaam, Tanzania|Completed||N/A|1521|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-06-01 02:22:40.890149|2018-06-01 02:22:40.890149
NCT00631371|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2013-04-18||2016-03-25|2008-02-28|2008-03-07|Estimate|2013-04-18|2013-06-04|Estimate||||2016-03-25|2016-04-27|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2012|Actual|2012-04-30||Interventional|INTORACT||Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects|Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma|Completed||Phase 3|791|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:22:41.105246|2018-06-01 02:22:41.105246
NCT00631358|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2010-02-17||2010-03-29|2008-02-29|2008-03-07|Estimate|2010-03-29|2010-04-12|Estimate||||2010-03-29|2010-04-12|Estimate|February 2008||2008-02-29|March 2010|2010-03-31||||February 2009|Actual|2009-02-28||Interventional|||Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention||Completed||Phase 4|97|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:22:42.652132|2018-06-01 02:22:42.652132
NCT00631345|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2018-04-03|2008-03-05|2008-03-07|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2007||2007-08-31|April 2018|2018-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|HELP PD||Healthy Living Partnership to Prevent Diabetes|Translating Research Into the Prevention of Diabetes Mellitus (TRIP DM)|Completed||N/A|301|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-06-01 02:22:42.944696|2018-06-01 02:22:42.944696
NCT00631332|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-11-02|2008-02-28|2008-03-07|Estimate|||||||2017-11-02|2017-11-06|Actual|July 1999||1999-07-31|June 2017|2017-06-30|June 2008|Actual|2008-06-30|September 2007|Actual|2007-09-30||Observational|WHISCA||Women's Health Initiative Study of Cognitive Aging|Effects of Hormone Replacement Therapy on Cognitive Aging: Women's Health Initiative Study of Cognitive Aging (WHISCA)|Completed|||2303|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||Yes|WHISCA will follow guidelines, methods and processes as set forth in the WHI 2015-2020 Data Sharing Plan. Accompanying the limited data sets, substantial electronic documentation will be provided in a standard format that is readable on a variety of platforms. Documentation will include data collection forms, a description of study protocol and procedures, description of all variable re-coding and a list of major study publications. These data will be available to users only under a data-sharing agreement that provides for: a commitment to using the data only for research purposes and not to identify any individual participant; a commitment to securing the data using appropriate computer technology; and a commitment to destroying or returning the data after analyses are completed. Data will be made available for timely release no later than the acceptance for publication of the main findings from the final dataset.|2018-06-01 02:22:43.050732|2018-06-01 02:22:43.050732
NCT00631319|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2012-03-20|2008-02-28|2008-03-07|Estimate|||||||2012-03-20|2012-03-21|Estimate|February 2008||2008-02-29|March 2012|2012-03-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|OA Pain||A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic OA Pain|A Phase III, Flexible Dose Titration Followed by a Randomized Double-Blind Study of Controlled Release OROS Hydromorphone HCL Compared to Placebo in Patients With Chronic OA Pain|Completed||Phase 3|200|Actual|Mallinckrodt|||||f||||f||||||||||2018-06-01 02:22:43.10992|2018-06-01 02:22:43.10992
NCT00631306|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2011-08-10|2008-03-06|2008-03-07|Estimate|||||||2011-08-10|2011-08-12|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|||Effects of Cranberry Juice on Risk Factors for Cardiovascular Disease|Effects of Cranberry Juice on Risk Factors for Cardiovascular Disease|Completed|||60|Anticipated|Mayo Clinic|||2||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-06-01 02:22:43.168046|2018-06-01 02:22:43.168046
NCT00631293|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-04-06|2008-02-27|2008-03-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|March 2008||2008-03-31|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of the Effect of Lactisole on the Intestinal Glucose Uptake|Study on the Effect of Lactisole on the Intestinal Glucose Uptake|Completed||Phase 1/Phase 2|10|Anticipated|University Ghent||2|||f||||f||||||||||2018-06-01 02:22:43.324005|2018-06-01 02:22:43.324005
NCT00631280|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2015-03-03|2008-02-28|2008-03-07|Estimate|||||||2015-03-03|2015-03-05|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD|Response Variability in Children With ADHD|Completed||N/A|70|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-06-01 02:22:43.402956|2018-06-01 02:22:43.402956
NCT00631267|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2014-11-05|2008-02-27|2008-03-07|Estimate|||||||2014-11-05|2014-11-06|Estimate|July 2008||2008-07-31|November 2014|2014-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|CoNCReTe||CoNCReTe-trial: Colles Fractures, Determining the Norm in Closed Reduction Techniques|Colles Fractures, Determining the Norm in Closed Reduction Techniques|Terminated||N/A|98|Actual|Rijnstate Hospital||2||Due to poor patient accrual|f||||f||||||||||2018-06-01 02:22:43.469996|2018-06-01 02:22:43.469996
NCT00631254|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-05-07|2008-02-27|2008-03-07|Estimate|||||||2008-05-07|2008-05-12|Estimate|October 2003||2003-10-31|November 2007|2007-11-30|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||CysLT1-r Expression Following Allergen Exposure in Asthma and Allergic Rhinitis|Modulation of the CysLT1-r Expression Following Allergen Exposure in Non Asthmatic Subjects With Allergic Rhinitis and Mild Allergic Asthmatic Subjects Using the Induced Sputum Technique.|Unknown status|Recruiting|N/A|30|Anticipated|Laval University||2|||f||||f||||||||||2018-06-01 02:22:43.548167|2018-06-01 02:22:43.548167
NCT00631241|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2016-04-28|2008-02-27|2008-03-07|Estimate|||||||2016-04-28|2016-05-02|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer|Histopathologic Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer Undergoing Radical Hysterectomy or Radical Trachelectomy and Pelvic Lymph Node Dissection: A Feasibility Study|Completed||N/A|20|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:22:43.642322|2018-06-01 02:22:43.642322
NCT00631228|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2012-08-13|2008-03-06|2008-03-07|Estimate|||||||2012-08-13|2012-08-14|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|April 2010|Actual|2010-04-30||Observational|XIENCE V India||XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study|XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study|Completed|||1000|Actual|Abbott Vascular|||1||f||||t||||||||||2018-06-01 02:22:43.720073|2018-06-01 02:22:43.720073
NCT00631215|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-03-06|2008-03-06|2008-03-07|Estimate|||||||2008-03-06|2008-03-07|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|October 2009|Anticipated|2009-10-31|June 2009|Anticipated|2009-06-30||Interventional|||Effects of Hyperbaric Oxygen Therapy on Cognitive Function on Autistic Spectrum Disordered Children|Effects of Hyperbaric Oxygen Therapy on Cognitive Function on Autistic Spectrum Disordered Children|Unknown status|Recruiting|N/A|40|Anticipated|Pediatric Partners of Ponte Vedra||1|||f||||f||||||||||2018-06-01 02:22:43.835254|2018-06-01 02:22:43.835254
NCT00631202|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2010-05-26|2008-02-28|2008-03-07|Estimate|||||||2010-05-26|2010-05-27|Estimate|February 2008||2008-02-29|May 2010|2010-05-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia|Single-Center, Open-Label, Sequential Trial to Test the Efficacy, Safety and Tolerability of Epoetin Alfa in Patients With Friedreich's Ataxia|Completed||Phase 2|10|Anticipated|Federico II University||1|||f||||f||||||||||2018-06-01 02:22:43.908172|2018-06-01 02:22:43.908172
NCT00631189|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2010-03-11||2013-11-25|2008-02-28|2008-03-07|Estimate|2010-08-24|2010-09-17|Estimate||||2013-11-25|2013-11-26|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|CAP-Chol||Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients|Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Subjects With Type IIa and IIb Hypercholesterolaemia|Completed||Phase 4|668|Actual|AstraZeneca|As the recruitment target was not reached at the date initially planned, and in view of the recruitment difficulties, AstraZeneca decided not to extend the patient recruitment period and to perform only a descriptive analysis of the data.|2|||f||||f||||||||||2018-06-01 02:22:44.026491|2018-06-01 02:22:44.026491
NCT00631176|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2010-01-07|2008-02-28|2008-03-07|Estimate|||||||2010-01-07|2010-01-08|Estimate|June 2007||2007-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|JIT||"Just-In-Time Training in Pediatric Airway Management"|"Effectiveness of Just-In-Time Training With/Without a High Fidelity Simulation on Patient Safety in Airway Management in Pediatric Intensive Care Unit"|Completed||N/A|13|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 02:22:44.97761|2018-06-01 02:22:44.97761
NCT00631163|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2016-11-15|2008-03-06|2008-03-07|Estimate|||||||2016-11-15|2016-11-16|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis|A Multi-Center, Open-label, Non Comparative, Phase II Trial on Efficacy and Safety of ICL670 Given for 1 Year With Dose Adjustments Based on Serum Ferritin in Patients With Chronic Anemia and Transfusional Hemosiderosis Including an Additional 1 Year Extension.|Completed||Phase 2|114|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:22:45.061692|2018-06-01 02:22:45.061692
NCT00631150|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-11-14|2008-03-06|2008-03-07|Estimate|||||||2013-11-14|2013-11-15|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy|A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy|Completed||Phase 4|35|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:22:45.194529|2018-06-01 02:22:45.194529
NCT00631137|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2008-09-29|2008-03-06|2008-03-07|Estimate|||||||2008-09-29|2008-09-30|Estimate|January 2008||2008-01-31|March 2008|2008-03-31||||September 2008|Anticipated|2008-09-30||Interventional|||Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men Receiving Glucocorticoids for Newly Diagnosed High-Grade Glioma|A Randomized, Controlled Comparative Trial to Determine if Testosterone Gel Prevents Steroid Related Weakness in Brain Cancer Patients|Terminated||N/A|60|Anticipated|National Cancer Institute (NCI)||||Study terminated due to low accrual.|f||||||||||||||2018-06-01 02:22:45.258959|2018-06-01 02:22:45.258959
NCT00631124|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2014-11-28|2008-03-06|2008-03-07|Estimate|||||||2014-11-28|2014-12-02|Estimate|February 2008||2008-02-29|November 2014|2014-11-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||A Study to Evaluate Inhibition of Ovulation of Two Oral Estrogen/Progestogen Regimens in Healthy, Young Females Over a Period of 3 Treatment Cycles|A Double-blind, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Oral Estradiol / Drospirenone Regimens in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles|Completed||Phase 2|103|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:22:45.333833|2018-06-01 02:22:45.333833
NCT00631111|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28||2009-07-10|2009-07-10|2008-02-28|2008-03-07|Estimate||||2009-07-10|2009-08-10|Estimate|2009-07-10|2009-08-10|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain|Ibuprofen 400 mg Effervescent Tablet Dental Pain Study II|Completed||Phase 3|270|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-06-01 02:22:45.434833|2018-06-01 02:22:45.434833
NCT00631098|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2009-01-20|2008-03-06|2008-03-07|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2004||2004-03-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CARE||Cannulation for Resuscitation|The Feasibility of Cannulating External Jugular Vein Compared With Cubital Vein (by Paramedics and Emergency Department Interns)|Completed||Phase 4|60|Anticipated|Kuopio University Hospital||1|||f||||f||||||||||2018-06-01 02:22:45.50732|2018-06-01 02:22:45.50732
NCT00631085|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2011-04-14|2008-03-06|2008-03-07|Estimate|||||||2011-04-14|2011-04-18|Estimate|May 2008||2008-05-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|GammaTox||Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adults|Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Normal Adults|Completed||Phase 1|18|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 02:22:45.568342|2018-06-01 02:22:45.568342
NCT00631072|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-06-07|2008-02-28|2008-03-07|Estimate|||||||2017-06-07|2017-06-09|Actual|February 2008||2008-02-29|June 2017|2017-06-30|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|||In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer|A Phase I Trial of in Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer|Completed||Phase 1|9|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 02:22:45.633193|2018-06-01 02:22:45.633193
NCT00631059|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2010-10-11|2008-02-27|2008-03-07|Estimate|||||||2010-10-11|2010-10-13|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|June 2010|Actual|2010-06-30|||||Interventional|||Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients|Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients|Terminated||N/A|40|Anticipated|University of California, Irvine||||Haluted due to slow accrual|f||||t||||||||||2018-06-01 02:22:45.717494|2018-06-01 02:22:45.717494
NCT00631046|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2009-07-14|2008-03-06|2008-03-07|Estimate|||||||2009-07-14|2009-07-15|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|EFiON||Essential Fatty Acids During Complementary Feeding|The Importance of Increasing Intake of Essential Fatty Acids During Complementary Feeding on Infant Growth and Body Composition, Intestinal Health, Immune Function and Risk Markers for Later Metabolic Complications.|Completed||N/A|150|Anticipated|University of Copenhagen||2|||f||||||||||||||2018-06-01 02:22:45.773682|2018-06-01 02:22:45.773682
NCT00631033|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2014-11-05|2008-02-27|2008-03-07|Estimate|||||||2014-11-05|2014-11-06|Estimate|July 2008||2008-07-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||DZX Mediated Insulin Suppression in Obese Men|Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III|Completed||Phase 2|51|Actual|Rijnstate Hospital||3|||f||||||||||||||2018-06-01 02:22:45.836511|2018-06-01 02:22:45.836511
NCT00631020|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2014-12-02||2015-04-18|2008-03-06|2008-03-07|Estimate|2015-04-18|2015-04-22|Estimate||||2015-04-18|2015-04-22|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||"Youth Smoking Cessation: Therapy +/- The Patch"|Determining the Efficacy of Cognitive-behavioral Motivational Enhancement +/- Nicotine Replacement Therapy for Adolescents|Completed||N/A|34|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-06-01 02:22:45.894964|2018-06-01 02:22:45.894964
NCT00631007|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2010-08-18||2010-08-18|2008-03-06|2008-03-07|Estimate|2010-08-18|2010-09-13|Estimate||||2010-08-18|2010-09-13|Estimate|February 2008||2008-02-29|August 2010|2010-08-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator|A Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of INT131 Besylate Compared to Pioglitazone in Subjects With Type 2 Diabetes|Completed||Phase 2|367|Actual|InteKrin Therapeutics, Inc.||6|||f||||f||||||||||2018-06-01 02:22:46.094274|2018-06-01 02:22:46.094274
NCT00630994|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|2012-01-09||2015-11-25|2008-03-06|2008-03-07|Estimate|2012-03-05|2012-04-02|Estimate||||2015-11-25|2015-12-30|Estimate|March 2008||2008-03-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|August 2009|Actual|2009-08-31||Interventional|||Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis|Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis|Terminated||Phase 2|4|Actual|Mayo Clinic|Study terminated early. Most analyses were not performed.|||Stopped due to slow accrual|f||||t||||||||||2018-06-01 02:22:46.969342|2018-06-01 02:22:46.969342
NCT00630981|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2009-04-16|2008-03-06|2008-03-07|Estimate|||||||2009-04-16|2009-04-20|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|July 2009|Anticipated|2009-07-31|April 2009|Actual|2009-04-30||Observational|||Psychotherapy and Pharmacotherapy in Dissociative Disorders|The Interest of a Specific Combined Treatment (Psychotherapy and Pharmacotherapy) in Patients With Dissociative Disorders|Unknown status|Active, not recruiting||30|Actual|Espace Hogan|||1||f||||t||||||||||2018-06-01 02:22:47.238914|2018-06-01 02:22:47.238914
NCT00630968|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-11-14|2008-03-06|2008-03-07|Estimate|||||||2013-11-14|2013-11-15|Estimate|August 2000||2000-08-31|September 2009|2009-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy|Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy|Completed||Phase 4|1541|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:22:47.346339|2018-06-01 02:22:47.346339
NCT00630955|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2013-08-19||2018-05-22|2008-02-27|2008-03-07|Estimate|2014-01-17|2014-03-05|Estimate||||2018-05-22|2018-05-24|Actual|June 2006||2006-06-30|May 2018|2018-05-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Family History Study of Alcohol Consumption Using Memantine|NMDA Antagonist Efficacy in Reducing Human Alcohol Consumption: Impact of Family History|Completed||Phase 2|111|Actual|Yale University||3|||f||||t||||||||||2018-06-01 02:22:47.423318|2018-06-01 02:22:47.423318
NCT00630942|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2010-12-03|2008-02-27|2008-03-07|Estimate|||||||2010-12-03|2010-12-07|Estimate|February 2003||2003-02-28|December 2010|2010-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Minocycline in Primary Sclerosing Cholangitis (PSC)|Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC)|Completed||Phase 1|16|Actual|Mayo Clinic||1|||||||f||||||||||2018-06-01 02:22:47.796274|2018-06-01 02:22:47.796274
NCT00630929|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-09-10|2008-02-28|2008-03-07|Estimate|||||||2008-09-10|2008-09-12|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|February 2004|Actual|2004-02-29|||||Interventional|||Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)|A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee|Completed||Phase 4|388|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:22:47.88082|2018-06-01 02:22:47.88082
NCT00630916|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2011-07-08||2011-09-20|2008-02-28|2008-03-07|Estimate|2011-08-15|2011-09-20|Estimate||||2011-09-20|2011-09-22|Estimate|November 2003||2003-11-30|September 2011|2011-09-30|December 2007|Actual|2007-12-31|December 2005|Actual|2005-12-31||Interventional|||Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve|Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve|Completed||N/A|756|Actual|Sorin Group USA, Inc.||1|||f||||t||||||||||2018-06-01 02:22:48.056787|2018-06-01 02:22:48.056787
NCT00630903|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-03-06|2008-03-06|2008-03-07|Estimate|||||||2008-03-06|2008-03-07|Estimate|January 2000||2000-01-31|February 2008|2008-02-29||||January 2003|Anticipated|2003-01-31||Interventional|MF99||PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides|Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa.|Terminated||Phase 4|54|Actual|Madrilenian Group of Cutaneous Lymphomas||2||Insufficient accrual|f||||f||||||||||2018-06-01 02:22:48.353968|2018-06-01 02:22:48.353968
NCT00630890|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2015-09-09|2008-03-06|2008-03-07|Estimate|||||||2015-09-09|2015-09-11|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)|Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)|Terminated||Phase 1|11|Actual|University of California, San Francisco||1||investigator left UCSF and study was closed prematurely in 2008. No results to report.|f||||f||||||||||2018-06-01 02:22:48.474153|2018-06-01 02:22:48.474153
NCT00630877|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|2009-06-11||2009-09-09|2008-02-29|2008-03-07|Estimate|2009-09-09|2009-10-09|Estimate||||2009-09-09|2009-10-09|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin|A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan® Plus Acetylsalicylic Acid (ASA), Niaspan® Plus ASA Placebo or Niaspan® Placebo Plus ASA Placebo Daily for Six Weeks|Completed||Phase 3|276|Actual|Abbott||3|||f||||f||||||||||2018-06-01 02:22:48.590917|2018-06-01 02:22:48.590917
NCT00630864|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2012-11-16|2010-10-12|2013-01-09|2008-03-05|2008-03-07|Estimate|2012-11-16|2012-12-17|Estimate|2011-06-03|2011-06-16|Estimate|2013-01-09|2013-01-18|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis|The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis|Completed||Phase 2|21|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:22:49.247359|2018-06-01 02:22:49.247359
NCT00630851|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2015-03-04|2008-02-27|2008-03-07|Estimate|||||||2015-03-04|2015-03-05|Estimate|October 2002||2002-10-31|March 2015|2015-03-31|October 2004|Actual|2004-10-31|||||Interventional|||A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes|A Six-month, Multicenter, Double-blind, Parallel, Placebo-controlled Study of the Effect on Global/Behavioural/ADL Functions and Tolerability of Aricept in Patients Wtih Severe Alzheimer's Disease Living in an Assisted Care Facility|Completed||Phase 3|249|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:22:50.238934|2018-06-01 02:22:50.238934
NCT00630838|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2015-04-01||2016-06-07|2008-02-28|2008-03-07|Estimate|2016-06-07|2016-07-19|Estimate||||2016-06-07|2016-07-19|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)|Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)|Completed||Phase 2|62|Actual|University of Michigan|The secondary outcome measure was defined before beginning the study as the measure of the expression of MUC-2 and MUC-3 expressed proteins in the stools of study patients. However, stool samples were not collected and this analysis was not done.|2|||f||||t||||||||||2018-06-01 02:22:50.452797|2018-06-01 02:22:50.452797
NCT00630825|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2014-10-03|2009-12-09|2014-12-08|2008-02-28|2008-03-07|Estimate|2014-12-08|2014-12-10|Estimate|2009-12-09|2009-12-11|Estimate|2014-12-08|2014-12-10|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|EGO|Participants who received at least one dose of LY2189265 or Placebo.|A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus|The Effect of Dose Titration of LY2189265 in Overweight and Obese Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|262|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 02:22:50.876006|2018-06-01 02:22:50.876006
NCT00630812|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27||2012-08-06|2012-08-06|2008-02-27|2008-03-07|Estimate||||2012-08-06|2012-08-15|Estimate|2012-08-06|2012-08-15|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|||Long Term Administration of Inhaled Mannitol in Cystic Fibrosis|Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study|Completed||Phase 3|318|Actual|Pharmaxis||2|||f||||t||||||||||2018-06-01 02:22:53.227418|2018-06-01 02:22:53.227418
NCT00630799|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27||2010-08-30|2010-09-07|2008-02-27|2008-03-07|Estimate||||2010-09-07|2010-09-09|Estimate|2010-09-07|2010-09-09|Estimate|May 2008||2008-05-31|September 2010|2010-09-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients|Efficacy and Safety of a New Leuprolide Acetate 17 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients|Terminated||Phase 3|20|Actual|GP-Pharm||1|||f||||f||||||||||2018-06-01 02:22:53.442356|2018-06-01 02:22:53.442356
NCT00630786|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2010-08-06||2014-02-05|2008-02-28|2008-03-07|Estimate|2014-02-05|2014-02-06|Estimate||||2014-02-05|2014-02-06|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|November 2010|Actual|2010-11-30|May 2009|Actual|2009-05-31||Interventional|||Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study|A Phase 1b/2 Trial of AMG 655 in Combination With Panitumumab in Subjects With Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|53|Actual|Amgen||1|||f||||f||||||||||2018-06-01 02:22:53.6197|2018-06-01 02:22:53.6197
NCT00630773|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-12-02|2008-02-28|2008-03-07|Estimate|||||||2008-12-02|2008-12-03|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|PUCK||Q-CPR Compression Sensor Size Qualification in Children|Feasibility of CPR Adjuncts in Children: Q-CPR Compression Sensor Size Qualification|Completed|||150|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 02:22:54.20862|2018-06-01 02:22:54.20862
NCT00630760|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2014-05-19|2008-03-06|2008-03-07|Estimate|||||||2014-05-19|2014-05-21|Estimate|February 2008||2008-02-29|May 2014|2014-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Oral NRX 194204 in Patients With Refractory Malignancies|A Multiple-Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients With Refractory Malignancies|Terminated||Phase 1|24|Actual|University of Southern California||1||Sponsor withdrew study. Accrual not completed|f||||f||||||||||2018-06-01 02:22:55.643763|2018-06-01 02:22:55.643763
NCT00630565|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-06|||2017-12-03|2008-03-06|2008-03-07|Estimate|||||||2017-12-03|2017-12-05|Actual|July 26, 2006|Actual|2006-07-26|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia|Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)|Recruiting||Phase 2/Phase 3|60|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 02:22:58.385746|2018-06-01 02:22:58.385746
NCT00630747|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2012-02-27||2015-07-16|2008-03-06|2008-03-07|Estimate|2014-01-31|2014-03-17|Estimate||||2015-07-16|2015-08-07|Estimate|September 2004||2004-09-30|May 2014|2014-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase|An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy|Completed||Phase 2/Phase 3|94|Actual|Shire|This study design was open-label, and the lack of a concurrently followed placebo group limits the strength of the observations, because the progression of the disease is variable and has not been well described.|1|||f||||t||||||||||2018-06-01 02:22:55.860941|2018-06-01 02:22:55.860941
NCT00630734|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2011-09-12||2014-05-20|2008-03-06|2008-03-07|Estimate|2012-10-15|2012-11-15|Estimate||||2014-05-20|2014-05-22|Estimate|February 2008||2008-02-29|May 2014|2014-05-31|September 2010|Actual|2010-09-30|October 2009|Actual|2009-10-31||Interventional|||Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin|Genetic Predictors of Pharmacokinetic Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin: the Role of SLCO1B1 Polymorphisms.|Completed||Phase 4|32|Actual|University of Colorado, Denver|The study included only heterozygous carriers of the SLCO1B1 *15 and *17 haplotypes. Pravastatin urine concentrations were not measured; therefore the impact of darunavir/ritonavir on pravastatin renal clearance was not assessed in this population.|3|||f||||t||||||||||2018-06-01 02:22:56.644809|2018-06-01 02:22:56.644809
NCT00630721|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2013-04-02|2008-03-06|2008-03-07|Estimate|||||||2013-04-02|2013-04-04|Estimate|September 2007||2007-09-30|April 2013|2013-04-30|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|||Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells|Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells|Completed||Phase 1|56|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 02:22:57.306734|2018-06-01 02:22:57.306734
NCT00630708|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2016-04-02|2008-03-06|2008-03-07|Estimate|||||||2016-04-02|2016-04-05|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|SDBRAS||Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency|Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency|Terminated||N/A|309|Anticipated|Nanfang Hospital of Southern Medical University||3||Significant differences observed between groups.|f||||t||||||||||2018-06-01 02:22:57.371381|2018-06-01 02:22:57.371381
NCT00630695|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2012-01-13|2008-02-27|2008-03-07|Estimate|||||||2012-01-13|2012-01-16|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer|Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer|Completed||Phase 3|148|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-06-01 02:22:57.442101|2018-06-01 02:22:57.442101
NCT00630682|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2013-05-30|2008-03-06|2008-03-07|Estimate|||||||2013-05-30|2013-06-03|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|August 2011|Actual|2011-08-31|March 2009|Actual|2009-03-31||Interventional|1D||A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence|A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence|Completed||Phase 2|60|Actual|California Pacific Medical Center Research Institute||2|||f||||t||||||||||2018-06-01 02:22:57.516788|2018-06-01 02:22:57.516788
NCT00630669|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-03-06|2008-03-06|2008-03-07|Estimate|||||||2008-03-06|2008-03-07|Estimate|December 1997||1997-12-31|May 2001|2001-05-31|May 2001|Actual|2001-05-31|May 2000|Actual|2000-05-31||Interventional|||Comparison Between Two Endoscopic Treatments of Bleeding Internal Hemorrhoids:Band Ligation and Electrocoagulation Probe|Randomized Study Of Endoscopic Band Ligation Versus Bipolar Probe Electrocoagulation Of Bleeding Internal Hemorrhoids|Completed||N/A|45|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:22:57.592952|2018-06-01 02:22:57.592952
NCT00630656|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28||2011-08-11|2011-08-18|2008-02-28|2008-03-07|Estimate||||2011-08-11|2011-08-15|Estimate|2011-08-18|2011-08-23|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis|A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis|Completed||Phase 2|190|Actual|Agennix||2|||f||||t||||||||||2018-06-01 02:22:57.771432|2018-06-01 02:22:57.771432
NCT00630643|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-03-06|2008-03-06|2008-03-07|Estimate|||||||2008-03-06|2008-03-07|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||NI-0401 in Active Crohn's Disease|A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn´s Disease|Completed||Phase 1/Phase 2|40|Actual|NovImmune SA||2|||f||||t||||||||||2018-06-01 02:22:57.887842|2018-06-01 02:22:57.887842
NCT00630630|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-11-25|2008-03-06|2008-03-07|Estimate|||||||2013-11-25|2013-11-26|Estimate|November 2002||2002-11-30|September 2009|2009-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy|A Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Adult Female Subjects (18 to 40 Years of Age) With C1 Catamenial Epilepsy|Completed||Phase 4|3|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 02:22:57.948319|2018-06-01 02:22:57.948319
NCT00630617|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-02-28|2008-02-28|2008-03-07|Estimate|||||||2008-02-28|2008-03-07|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Childhood Obesity Prevention|Project FAMILIA Giya Marianas: Childhood Obesity Prevention Program|Completed||N/A|900|Actual|Western Michigan University|||||f||||t||||||||||2018-06-01 02:22:58.068322|2018-06-01 02:22:58.068322
NCT00630604|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-03-06|2008-03-06|2008-03-07|Estimate|||||||2008-03-06|2008-03-07|Estimate||||February 2008|2008-02-29||||||||Observational|US||Quantitative Ultrasonography (US) Evaluation on Femoral Condyle Cartilage|Quantitative Evaluation by Ultrasonography for Severity of Knee Osteoarthritis|Completed|||||Kaohsiung Medical University|||||f||||||||||||||2018-06-01 02:22:58.184265|2018-06-01 02:22:58.184265
NCT00630591|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-02-01|2008-02-28|2008-03-07|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||DAMES: Daughters And MothErS Against Breast Cancer|DAMES: Daughters And MothErS Against Breast Cancer|Completed||N/A|482|Actual|Duke University||3|||f||||t||||||||||2018-06-01 02:22:58.231735|2018-06-01 02:22:58.231735
NCT00630578|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2011-04-06|2008-03-06|2008-03-07|Estimate|||||||2011-04-06|2011-04-07|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Improving Effectiveness: Treatment Outcome Research|Improving Effectiveness: Treatment Outcome Research|Completed||N/A|50|Anticipated|Center for Trauma Recovery, St Louis||2|||f||||f||||||||||2018-06-01 02:22:58.312532|2018-06-01 02:22:58.312532
NCT00630552|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28||2015-04-06|2016-10-26|2008-02-28|2008-03-07|Estimate||||2015-04-06|2015-04-27|Estimate|2016-10-26|2016-10-27|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|April 2012|Actual|2012-04-30|January 2010|Actual|2010-01-31||Interventional|||QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer|A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|138|Actual|NantCell, Inc.||3|||f||||||||||||||2018-06-01 02:22:58.518176|2018-06-01 02:22:58.518176
NCT00630539|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2013-03-19||2013-05-21|2008-03-06|2008-03-07|Estimate|2013-05-21|2013-06-28|Estimate||||2013-05-21|2013-06-28|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women|Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A Phase II Dose Ranging, 12-Week, Randomized , Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 5 mg, 15 mg and 30 mg Daily Doses With Placebo|Completed||Phase 2|126|Actual|Shionogi Inc.||4|||f||||||||||||||2018-06-01 02:22:58.684445|2018-06-01 02:22:58.684445
NCT00630526|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-04-29|2008-02-28|2008-03-07|Estimate|||||||2008-04-29|2008-05-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:22:59.551403|2018-06-01 02:22:59.551403
NCT00630513|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2011-08-17|2008-02-27|2008-03-07|Estimate|||||||2011-08-17|2011-08-18|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|TEA||T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam|A Prospective, Double-blind, Multi Center, Randomized Clinical Study to Compare the Efficacy and Safety of Ertapenem 3 Days Versus Ampicillin-Sulbactam 3 Days in the Treatment of Localized Community Acquired Intra-abdominal Infection (IAI). (T.E.A. Study Three Days Ertapenem vs Three Days Ampicillin- Sulbactam)|Completed||Phase 4|142|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 02:22:59.590615|2018-06-01 02:22:59.590615
NCT00630500|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2015-07-27|2008-03-06|2008-03-07|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|MEMPDD||Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)|A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies|Completed||Phase 2|75|Actual|Helse Stavanger HF||2|||f||||t||||||||||2018-06-01 02:22:59.683912|2018-06-01 02:22:59.683912
NCT00630487|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2010-08-03||2013-02-26|2008-02-28|2008-03-07|Estimate|2011-01-05|2011-01-27|Estimate||||2013-02-26|2013-03-04|Estimate|May 2008||2008-05-31|February 2013|2013-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|IGHD||Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency|Prospective, Randomized, Double Blind Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Adult Patients With Isolated Growth Hormone Deficiency (PRO ISO-GHD Study)|Terminated||Phase 3|9|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:22:59.801976|2018-06-01 02:22:59.801976
NCT00630474|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2009-12-21|2008-03-06|2008-03-07|Estimate|||||||2009-12-21|2009-12-23|Estimate|January 2004||2004-01-31|December 2009|2009-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Nasal Decongestion and Obstructive Sleep Apnea|Does Nasal Decongestion Improve Obstructive Sleep Apnea ?|Completed||Phase 4|12|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 02:23:00.139151|2018-06-01 02:23:00.139151
NCT00630461|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2012-10-05|2008-03-06|2008-03-07|Estimate|||||||2012-10-05|2012-10-08|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma|Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma|Terminated||Phase 1|4|Actual|University of North Carolina, Chapel Hill||||Data collected under different protocol; funding exhuasted|f||||f||||||||||2018-06-01 02:23:00.235037|2018-06-01 02:23:00.235037
NCT00630448|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2017-05-23|2008-02-27|2008-03-07|Estimate|||||||2017-05-23|2017-05-25|Actual|November 2008||2008-11-30|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)|Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)|Withdrawn|||0|Actual|Weill Medical College of Cornell University|||2|Prinicipal Investigator initiated study closure.|f||||t||||||Samples With DNA|"~     Blood~   "|No||2018-06-01 02:23:00.302037|2018-06-01 02:23:00.302037
NCT00630435|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2009-02-03|2008-03-06|2008-03-07|Estimate|||||||2009-02-03|2009-02-04|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of 3 New Formulations of Premarin® /MPA 0.625 mg/2.5 mg Compared With Reference Formulation of Premarin®/MPA in Healthy Postmenopausal Women|Completed||Phase 1|76|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-06-01 02:23:00.395222|2018-06-01 02:23:00.395222
NCT00630422|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-03-06|2008-03-06|2008-03-07|Estimate|||||||2008-03-06|2008-03-07|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Observational|||Functional Abilities in Rett Syndrome|Functional Abilities in Rett Syndrome|Completed|||64|Actual|Faculdades Metropolitanas Unidas|||1||f||||f||||||||||2018-06-01 02:23:00.476729|2018-06-01 02:23:00.476729
NCT00630409|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2016-01-14||2017-01-21|2008-03-06|2008-03-07|Estimate|2017-01-21|2017-03-10|Actual||||2017-01-21|2017-03-10|Actual|September 2004||2004-09-30|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma|Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma|Completed||Phase 2|5|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:23:00.555946|2018-06-01 02:23:00.555946
NCT00630396|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2011-08-01||2011-12-09|2008-03-06|2008-03-07|Estimate|2011-12-09|2012-01-13|Estimate||||2011-12-09|2012-01-13|Estimate|May 2008||2008-05-31|December 2011|2011-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|MINOS||Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke|Minocycline to Improve Neurologic Outcome in Stroke (MINOS)|Completed||Phase 1/Phase 2|60|Actual|Augusta University|"Some statistical tests could not be performed due to small sample size in the 4.5 and 6mg/kg dose tiers.~The modified continual reassessment method (CRM) failed to identify the maximum tolerated dose of intravenous minocycline."||||f||||t||||||||||2018-06-01 02:23:00.848151|2018-06-01 02:23:00.848151
NCT00630383|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2012-06-13|2008-02-27|2008-03-07|Estimate|||||||2012-06-13|2012-06-14|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|WIRMS-1||Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.|Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.|Withdrawn||Phase 2|0|Actual|University of Nottingham||2||superceded by another similar study|f||||t||||||||||2018-06-01 02:23:01.191757|2018-06-01 02:23:01.191757
NCT00630370|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2009-06-16|2008-03-06|2008-03-07|Estimate|||||||2009-06-16|2009-06-17|Estimate|February 2008||2008-02-29|December 2008|2008-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome|A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-Controlled, 58 Day, Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome|Terminated||Phase 2|6|Actual|Procter and Gamble||4|||f||||f||||||||||2018-06-01 02:23:01.306478|2018-06-01 02:23:01.306478
NCT00630357|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-11-14|2008-03-06|2008-03-07|Estimate|||||||2013-11-14|2013-11-15|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy|A Phase IV, Open-label, Multi-center Trial to Evaluate the Safety and Efficacy of Keppra® After Conversion to Mono-therapy in Adult Subjects With Partial Epilepsy|Completed||Phase 4|14|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:23:01.456299|2018-06-01 02:23:01.456299
NCT00630344|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2014-01-20||2017-11-06|2008-02-28|2008-03-07|Estimate|2014-01-20|2014-03-03|Estimate||||2017-11-06|2017-12-08|Actual|February 2008||2008-02-29|November 2017|2017-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||RAD001 and Bicalutamide for Androgen Independent Prostate Cancer|A Phase II Trial of RAD001 and Bicalutamide for Androgen Independent Prostate Cancer|Completed||Phase 2|36|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-06-01 02:23:01.559706|2018-06-01 02:23:01.559706
NCT00630331|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2012-11-21|2011-03-16|2013-01-15|2008-03-06|2008-03-07|Estimate|2013-01-15|2013-01-16|Estimate|2011-03-16|2011-03-28|Estimate|2013-01-15|2013-01-16|Estimate|October 2007||2007-10-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects|A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects|Completed||Phase 3|11404|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:23:02.078119|2018-06-01 02:23:02.078119
NCT00630318|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-01-11|2008-03-06|2008-03-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2008||2008-03-31|January 2017|2017-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Testing New Method of Analyzing MR Images|Imaging Protocol Design for Anti-Angiogenesis Tracking With MRI|Terminated||Phase 1|12|Actual|Indiana University||||Unable to accrue enough subjects to analyze data.|f||||f||||||||||2018-06-01 02:23:03.404899|2018-06-01 02:23:03.404899
NCT00630305|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2014-03-26||2017-01-11|2008-02-28|2008-03-07|Estimate|2017-01-11|2017-03-03|Actual||||2017-01-11|2017-03-03|Actual|January 2008||2008-01-31|January 2017|2017-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||All participants who were enrolled and randomized to a trial arm.|Endothelial Bleb Response With Toric Lenses|Evaluation of the Short-Term Corneal Endothelial Response to Wear of Toric Soft Contact Lenses in Asian Eyes|Completed||N/A|37|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||f||||||||||2018-06-01 02:23:03.554491|2018-06-01 02:23:03.554491
NCT00630292|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2010-02-03||2010-05-10|2008-03-06|2008-03-07|Estimate|2010-04-14|2010-05-05|Estimate||||2010-05-10|2010-05-18|Estimate|March 2008||2008-03-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors|Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors|Terminated||N/A|6|Actual|University of North Carolina, Chapel Hill|The software used to perform breast vessel analysis failed to detect any vessels in the breast due to the limited spatial resolution possible for breast imaging with the 1.5T Magnetic Resonance Imaging System used in the study.|1||Existing vessel analysis software could not be applied to breast MRI data.|f||||f||||||||||2018-06-01 02:23:04.360781|2018-06-01 02:23:04.360781
NCT00630279|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2009-08-04|2008-02-26|2008-03-06|Estimate|||||||2009-08-04|2009-08-06|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis|A Multi-center, Single-blind, Parallel-design, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate Oral Recombinant Microbial Lipase Efficacy in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis|Terminated||Phase 2|56|Actual|Solvay Pharmaceuticals||4||This trial discontinued March 7,2009 due to high screen failure rate.|f||||f||||||||||2018-06-01 02:23:04.51555|2018-06-01 02:23:04.51555
NCT00630266|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2009-06-16|2008-03-05|2008-03-06|Estimate|||||||2009-06-16|2009-06-18|Estimate|January 2008||2008-01-31|June 2009|2009-06-30||||December 2009|Anticipated|2009-12-31||Interventional|MVR + CorCap||Confirmation Trial of the Acorn CorCap Cardiac Support Device (CSD) at the Same Time as Mitral Valve Repair|Clinical Evaluation of Acorn CorCap Cardiac Support Device Concomitant to MVR - A Confirmatory Trial|Unknown status|Recruiting|Phase 2|50|Anticipated|Acorn Cardiovascular, Inc.|||||f||||f||||||||||2018-06-01 02:23:04.770631|2018-06-01 02:23:04.770631
NCT00630253|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2017-12-03|2008-03-05|2008-03-06|Estimate|||||||2017-12-03|2017-12-05|Actual|February 17, 2000|Actual|2000-02-17|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia|A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia|Recruiting||Phase 1/Phase 2|45|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:23:04.929171|2018-06-01 02:23:04.929171
NCT00630240|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-08-30|2008-03-05|2008-03-06|Estimate|||||||2009-08-30|2009-09-01|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation by Transcatheter Arterial Chemoembolization|Investigation the Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation in Patients With Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization|Completed|||53|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 02:23:05.049061|2018-06-01 02:23:05.049061
NCT00630227|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2011-10-21|2008-03-05|2008-03-06|Estimate|||||||2011-10-21|2011-10-24|Estimate|February 2008||2008-02-29|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study|Phase 2 Study of the 20 mL Biologic Lung Volume Reduction (BLVR) System in Patients With Homogeneous or Upper Lobe Predominant Emphysema|Completed||Phase 2|33|Actual|Aeris Therapeutics||1|||f||||f||||||||||2018-06-01 02:23:05.128475|2018-06-01 02:23:05.128475
NCT00630214|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-05|2008-03-05|2008-03-06|Estimate|||||||2008-03-05|2008-03-06|Estimate|May 2004||2004-05-31|February 2008|2008-02-29|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection|Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients|Completed||Phase 2|200|Actual|Asan Medical Center||4|||f||||t||||||||||2018-06-01 02:23:05.265032|2018-06-01 02:23:05.265032
NCT00630201|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26||2011-01-05|2017-06-12|2008-03-05|2008-03-06|Estimate||||2012-10-23|2012-10-30|Estimate|2017-06-12|2017-06-14|Actual|October 2007||2007-10-31|June 2017|2017-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|PRO-807||Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence|An Open-Label, Multi-Center Extension Study Of Probuphine in Patients With Opioid Dependence|Completed||Phase 3|62|Actual|Braeburn Pharmaceuticals||1|||f||||t||||||||||2018-06-01 02:23:05.365042|2018-06-01 02:23:05.365042
NCT00630188|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2008-03-05|2008-03-05|2008-03-06|Estimate|||||||2008-03-05|2008-03-06|Estimate|March 2005||2005-03-31|February 2008|2008-02-29|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial|Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial|Completed||N/A|128|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:23:05.463461|2018-06-01 02:23:05.463461
NCT00630175|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-05-15|2008-03-05|2008-03-06|Estimate|||||||2009-05-15|2009-05-18|Estimate|September 2003||2003-09-30|May 2009|2009-05-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia|Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia. A Double-Blind, Randomized, Placebo-Controlled,Three Way Cross-Over Study|Completed||Phase 3|113|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:23:05.727626|2018-06-01 02:23:05.727626
NCT00630162|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-02-02|2008-03-05|2008-03-06|Estimate|||||||2009-02-02|2009-02-03|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|July 2008|Actual|2008-07-31|||||Observational|||Intestinal Protozoal Infections and Sexual Transmitted Diseases Among Targeted Cohorts|Survey of Intestinal Protozoal Infections and Sexual Transmitted Diseases Among Targeted Cohorts|Completed|||400|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-06-01 02:23:06.006062|2018-06-01 02:23:06.006062
NCT00630149|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2012-02-14|2008-02-25|2008-03-06|Estimate|||||||2012-02-14|2012-02-16|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy|Open-Label Single-Arm Phase 2 Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy|Completed||Phase 2|35|Actual|Sun Yat-sen University||1|||f||||||||||||||2018-06-01 02:23:06.14635|2018-06-01 02:23:06.14635
NCT00630136|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2010-03-23|2008-02-27|2008-03-06|Estimate|||||||2010-03-23|2010-03-24|Estimate|February 2008||2008-02-29|October 2008|2008-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Effectiveness of the Consent Process|Effectiveness of the Consent Process Used for Outpatient Endoscopy|Completed|||20|Actual|Children's Mercy Hospital Kansas City|||1||f||||f||||||||||2018-06-01 02:23:06.228435|2018-06-01 02:23:06.228435
NCT00630123|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2015-12-14|2008-03-05|2008-03-06|Estimate|||||||2015-12-14|2015-12-16|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation(TMS) on Brain Derived Neurotrophic Factor (BDNF) in Depressed Patients.|Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) on Serum Levels of Brain Derived Neurotrophic Factor in Depressed Patients.|Completed|||36|Actual|Queen's University|||2||f||||f||||||Samples Without DNA|"~     serum frozen~   "|||2018-06-01 02:23:06.315437|2018-06-01 02:23:06.315437
NCT00630110|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2011-08-15|2008-03-05|2008-03-06|Estimate|||||||2011-08-15|2011-08-16|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer|Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|172|Actual|Nereus Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 02:23:06.372636|2018-06-01 02:23:06.372636
NCT00630097|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2011-06-21|2008-02-27|2008-03-06|Estimate|||||||2011-06-21|2011-06-22|Estimate|December 2009||2009-12-31|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||A Dose Ranging Study of Modafinil for Methamphetamine Dependence|A Dose Ranging Study of Modafinil for Methamphetamine Dependence|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|California Pacific Medical Center Research Institute|||||f||||t||||||||||2018-06-01 02:23:06.53305|2018-06-01 02:23:06.53305
NCT00630084|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2015-09-03|2008-03-05|2008-03-06|Estimate|||||||2015-09-03|2015-09-04|Estimate|August 2006||2006-08-31|September 2015|2015-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma|The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma|Completed||Phase 4|120|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:23:06.696602|2018-06-01 02:23:06.696602
NCT00630071|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2012-10-15|2008-02-26|2008-03-06|Estimate|||||||2012-10-15|2012-10-16|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|August 2008|Actual|2008-08-31|||||Observational|||Diagnostic Value of Procalcitonin in Patients With Acute Appendicitis|A Prospective Study Investigating the Diagnostic Value of Procalcitonin in Patients With Acute Appendicitis|Completed|||103|Actual|Ruhr University of Bochum|||||f||||t||||||Samples With DNA|"~     1.5 ml whole blood~   "|||2018-06-01 02:23:06.788636|2018-06-01 02:23:06.788636
NCT00630058|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|2012-12-12||2014-04-16|2008-02-26|2008-03-06|Estimate|2012-12-12|2013-01-18|Estimate||||2014-04-16|2014-05-02|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C|A Phase I, Open-Label, Two-Arm Study of MP-424 in Combination With Peginterferon Alfa 2b and Ribavirin in Patients With Genotype 1b Hepatitis C|Completed||Phase 1|20|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 02:23:06.880513|2018-06-01 02:23:06.880513
NCT00629382|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-12-01|2008-03-05|2008-03-06|Estimate|||||||2008-12-01|2008-12-02|Estimate|December 2004||2004-12-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|EUPHAS||Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis|Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico|Completed||Phase 4|70|Actual|St. Bortolo Hospital||2|||f||||f||||||||||2018-06-01 02:23:13.091745|2018-06-01 02:23:13.091745
NCT00630045|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-03-05|2008-03-05|2008-03-06|Estimate|||||||2008-03-05|2008-03-06|Estimate|January 2008||2008-01-31|February 2008|2008-02-29|June 2015|Anticipated|2015-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis|A Phase III Study of Surgery in Combination With Neoadjuvant Chemotherapy of Oxaliplatin Plus Capecitabine in Colorectal Cancer With Respectable Liver Metastasis|Unknown status|Recruiting|Phase 3|392|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-06-01 02:23:07.372633|2018-06-01 02:23:07.372633
NCT00630032|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2017-08-04|2008-03-05|2008-03-06|Estimate|||||||2017-08-04|2017-08-07|Actual|September 2007|Actual|2007-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|June 2017|Actual|2017-06-30||Interventional|TavIx||Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer|Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.|Active, not recruiting||Phase 3|762|Actual|UNICANCER||2|||f||||t||||||||||2018-06-01 02:23:07.534153|2018-06-01 02:23:07.534153
NCT00630019|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2009-02-04|2008-03-05|2008-03-06|Estimate|||||||2009-02-04|2009-02-06|Estimate|February 2008||2008-02-29|February 2009|2009-02-28||||October 2008|Actual|2008-10-31||Interventional|||Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator||Completed||Phase 4|96|Anticipated|Santen Inc.||2|||f||||f||||||||||2018-06-01 02:23:07.747646|2018-06-01 02:23:07.747646
NCT00630006|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-03-05|2008-03-05|2008-03-06|Estimate|||||||2008-03-05|2008-03-06|Estimate|January 2007||2007-01-31|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Genetic Polymorphisms of Interleukin-10 and TNF-α on Outcome of HCV-Related Chronic Liver Disease||Unknown status|Recruiting|N/A|||Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-06-01 02:23:07.861709|2018-06-01 02:23:07.861709
NCT00629993|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2011-02-28|2008-03-05|2008-03-06|Estimate|||||||2011-02-28|2011-03-01|Estimate|January 2004||2004-01-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2006|Actual|2006-08-31||Interventional|||Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities|Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities|Terminated||Phase 4|282|Actual|Columbia University||1||Principal Investigator left the institution|f||||t||||||||||2018-06-01 02:23:07.943081|2018-06-01 02:23:07.943081
NCT00629980|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27||2009-03-24|2011-09-20|2008-03-05|2008-03-06|Estimate||||2009-11-13|2009-11-17|Estimate|2011-09-20|2011-09-26|Estimate|February 2008||2008-02-29|September 2011|2011-09-30||||September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis|A Multi-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone in Subjects With Blepharitis|Completed||Phase 4|60|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:23:08.041507|2018-06-01 02:23:08.041507
NCT00629967|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-02-26|2008-02-26|2008-03-06|Estimate|||||||2008-02-26|2008-03-06|Estimate|April 2005||2005-04-30|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients|A Randomized, Open Labeled, Active-Controlled Trial of 24-Week Versus 48-Week Courses of Peg-Interferon Alpha Plus Ribavirin for Genotype-1 Infected Chronic Hepatitis C Patients|Completed||Phase 4|200|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:23:08.122144|2018-06-01 02:23:08.122144
NCT00629954|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2013-09-25|2008-03-05|2008-03-06|Estimate|||||||2013-09-25|2013-09-26|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|November 2016|Anticipated|2016-11-30|November 2014|Anticipated|2014-11-30||Observational|AHS||Abuja Heart Study: Prospective Epidemiological Investigation of Cardiovascular Diseases|Abuja Heart Study (AHS) is a Multi-site Prospective Epidemiological Investigation of Cardiovascular Disease (CVD) .|Unknown status|Recruiting||10000|Anticipated|Healthsystem Plus|||1||f||||t||||||||||2018-06-01 02:23:08.224646|2018-06-01 02:23:08.224646
NCT00629941|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27||2009-03-24|2011-09-20|2008-03-05|2008-03-06|Estimate||||2009-11-13|2009-11-17|Estimate|2011-09-20|2011-09-26|Estimate|March 2008||2008-03-31|September 2011|2011-09-30||||August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis|A Multi-Center, Open-Label Study Evaluating the Cytokine and Eyelid Margin Bacterial Load Levels of Subjects Diagnosed With Chronic Blepharitis Following Dosing With AzaSite® (Azithromycin Ophthalmic Solution) 1%|Completed||Phase 4|25|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 02:23:08.310947|2018-06-01 02:23:08.310947
NCT00629928|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2011-01-24|2008-02-27|2008-03-06|Estimate|||||||2011-01-24|2011-01-25|Estimate|February 2001||2001-02-28|January 2011|2011-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Ulcer Prevention II|A Comparative Efficacy and Safety of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric and Duodenal Ulcers Associated With Daily NSAID Use in Patients at Risk|Completed||Phase 3|800|Anticipated|AstraZeneca||3|||||||||||||||||2018-06-01 02:23:08.376901|2018-06-01 02:23:08.376901
NCT00629915|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2018-05-04|2008-03-04|2008-03-06|Estimate|||||||2018-05-04|2018-05-07|Actual|October 2006||2006-10-31|May 2018|2018-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Role of Cerebral Hemodynamics in Moyamoya Disease|The Role of Cerebral Hemodynamics in Moyamoya Disease|Completed|||56|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 02:23:08.449692|2018-06-01 02:23:08.449692
NCT00629902|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2008-05-09|2008-03-05|2008-03-06|Estimate|||||||2008-05-09|2008-05-12|Estimate|February 2008||2008-02-29|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Heart Valve Prosthesis-Patient Mismatch|Impact of Prosthesis-Patient Mismatch on Clinical Outcomes After Mitral Valve Replacement|Completed|||100|Anticipated|Florence Nightingale Hospital, Istanbul|||2||f||||t||||||||||2018-06-01 02:23:08.520396|2018-06-01 02:23:08.520396
NCT00629889|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2013-05-21|2008-03-05|2008-03-06|Estimate|||||||2013-05-21|2013-05-22|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors|Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study.|Completed||Phase 2|52|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-06-01 02:23:08.585074|2018-06-01 02:23:08.585074
NCT00629369|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-07|2008-03-05|2008-03-06|Estimate|||||||2008-03-07|2008-03-13|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Duration of Second Stage of Labor Wearing a Dental Occlusion Device|Duration of Second Stage of Labor Wearing a Dental Occlusion Device: a Randomized Controlled Trial|Completed||N/A|64|Actual|Mercy Medical Center||2|||f||||t||||||||||2018-06-01 02:23:13.178644|2018-06-01 02:23:13.178644
NCT00629876|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2011-11-29|2008-03-05|2008-03-06|Estimate|||||||2011-11-29|2011-12-01|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.|A Phase 1, Multicenter, Open-Label Dose Escalation Study Evaluating the Safety and Tolerability of Multiple Hematide Injections in Subjects With Refractory Non-Small Cell Lung Cancer, Breast Cancer, or Prostate Cancer Who Are Anemic and Receiving Cytotoxic Chemotherapy|Terminated||Phase 1|2|Actual|Takeda||1||"Due to the uncertain regulatory landscape for erythropoiesis-stimulating agents in oncology~   indications."|f||||f||||||||||2018-06-01 02:23:08.675868|2018-06-01 02:23:08.675868
NCT00629863|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2013-08-06|2008-03-05|2008-03-06|Estimate|||||||2013-08-06|2013-08-07|Estimate|September 2004||2004-09-30|January 2009|2009-01-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Endoscopic Ultrasound in Diagnosing Cancer in Patients With Localized Stomach Cancer or Esophageal Cancer|Cancer of the Oesophagus or Gastricus: New Assessment of the Technology of Endosonography COGNATE|Completed||N/A|700|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:23:08.759461|2018-06-01 02:23:08.759461
NCT00629850|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2011-07-19||2011-08-17|2008-02-25|2008-03-06|Estimate|2011-08-17|2011-08-18|Estimate||||2011-08-17|2011-08-18|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Respiratory Resistance Training on Sleep Quality in Persons With Spinal Cord Injury|Concurrent Respiratory Resistance Training and Changes in Respiratory Muscle Strength and Sleep Quality in Persons With Spinal Cord Injury|Terminated||Phase 1|1|Actual|Texas State University, San Marcos|Unable to recruit subjects for the study|2||unable to recruit participants.|f||||f||||||||||2018-06-01 02:23:08.852697|2018-06-01 02:23:08.852697
NCT00629837|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2014-11-17|2008-02-27|2008-03-06|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2005||2005-09-30|November 2014|2014-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980|A Randomized, Double-blind, Cross-over Study to Determine the Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 in Previously Treated Patients With Severe Hemophilia A|Completed||Phase 1|27|Actual|Bayer||4|||f||||f||||||||||2018-06-01 02:23:09.074187|2018-06-01 02:23:09.074187
NCT00629824|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2010-09-06|2008-03-05|2008-03-06|Estimate|||||||2010-09-06|2010-09-08|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C|Efficacy and Safety of Pegylated Interferon Plus Ribavirin Combination Therapy in Treating Older Patients With Chronic Hepatitis C|Completed||Phase 4|250|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t||||||||||2018-06-01 02:23:09.183408|2018-06-01 02:23:09.183408
NCT00629811|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-02-26|2008-02-26|2008-03-06|Estimate|||||||2008-02-26|2008-03-06|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women|A Double-Blind, Placebo-Controlled, Randomised Dose Ranging Trial to Investigate the Efficacy of Two Different Dosing Regimens of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers.|Completed||Phase 2|78|Actual|Renovo|||||f||||f||||||||||2018-06-01 02:23:09.273687|2018-06-01 02:23:09.273687
NCT00629798|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2018-02-23|2008-02-26|2008-03-06|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2008|Actual|2008-02-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)|A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|52|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:23:09.331343|2018-06-01 02:23:09.331343
NCT00629785|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-02-26|2008-02-26|2008-03-06|Estimate|||||||2008-02-26|2008-03-06|Estimate||||March 2007|2007-03-31||||||||Observational|||The Analysis of BMI, Asthma Prevalence, and Lung Functions of Schoolchildren in Southern Taiwan||Completed|||||Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-06-01 02:23:09.394794|2018-06-01 02:23:09.394794
NCT00629772|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2010-04-14||2011-09-01|2008-03-05|2008-03-06|Estimate|2010-08-16|2010-09-02|Estimate||||2011-09-01|2011-09-09|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy of Infliximab in Palmoplantar Psoriasis|A Double-Blind Study on the Safety and Efficacy of Infliximab in Palmoplantar Psoriasis|Completed||Phase 3|24|Actual|Innovaderm Research Inc.|The lack of validated scales to specifically assess severity of palmoplantar psoriasis. The study was powered to detect a difference of 55 percentage points.|2|||f||||f||||||||||2018-06-01 02:23:09.606769|2018-06-01 02:23:09.606769
NCT00629759|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2013-01-03|2008-02-26|2008-03-06|Estimate|||||||2013-01-03|2013-01-04|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma|Phase 1 Clinical Study for Evaluating the Safety and Efficacy of a Transdermal Injection of JX-594 (Thymidine Kinase (-)/GM-CSF(+) Vaccinia Virus) Within the Tumor of Patients With Hepatic Carcinoma|Completed||Phase 1|14|Actual|Jennerex Biotherapeutics||4|||f||||t||||||||||2018-06-01 02:23:10.072261|2018-06-01 02:23:10.072261
NCT00629746|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2010-09-06|2008-03-05|2008-03-06|Estimate|||||||2010-09-06|2010-09-08|Estimate|June 2006||2006-06-30|May 2010|2010-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Intraoperative Electromyographic Monitoring of the Recurrent Laryngeal Nerve in Thyroid Surgery|Intraoperative Electromyographic Monitoring of the Recurrent Laryngeal Nerve in Thyroid Surgery|Unknown status|Recruiting|N/A|1000|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||t||||||||||2018-06-01 02:23:10.155249|2018-06-01 02:23:10.155249
NCT00629733|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2011-06-07|2008-02-26|2008-03-06|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers||Completed||Phase 1|12|Anticipated|Rovi Pharmaceuticals Laboratories||1|||f||||f||||||||||2018-06-01 02:23:10.235807|2018-06-01 02:23:10.235807
NCT00629720|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-12-11|2008-02-26|2008-03-06|Estimate|||||||2009-12-11|2009-12-15|Estimate|July 2006||2006-07-31|December 2009|2009-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|ALFACHIP||Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology|Four-week, Open-label, Multicenter, Randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety, Tolerability and the Effects on Leak Point Pressure of Two Oral Doses of Alfuzosin (0.1 mg/kg/Day; 0.2 mg/kg/Day) in Children and Adolescents 2 to 16 Years-of-age With Elevated Detrusor Leak-point Pressure of Neuropathic Etiology|Completed||Phase 3|29|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:23:10.361802|2018-06-01 02:23:10.361802
NCT00629707|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|2012-06-18||2012-09-12|2008-03-04|2008-03-06|Estimate|2012-08-09|2012-09-12|Estimate||||2012-09-12|2012-09-18|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Cerebral Edema in Pediatric Diabetic Ketoacidosis|Cerebral Edema in Pediatric Diabetic Ketoacidosis|Completed||N/A|20|Actual|University of California, Davis|Study terminated after enrollment of 20 subjects. Review of data from these subjects showed minimal difference between groups and substantial variability suggesting that a larger sample would be very unlikely to show significant differences.|2|||f||||t||||||||||2018-06-01 02:23:10.444967|2018-06-01 02:23:10.444967
NCT00629694|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2012-01-20|2008-02-27|2008-03-06|Estimate|||||||2012-01-20|2012-01-23|Estimate|September 2007||2007-09-30|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Adenoidectomy, Myringotomy and Tubes' Insertion vs Adenoidectomy and Myringotomy Alone in Children With Otitis Media With Effusion and Adenoid Hypertrophy|Adenoidectomy, Myringotomy and Tubes' Insertion vs Adenoidectomy and Myringotomy Alone in Children With Otitis Media With Effusion and Adenoid Hypertrophy|Completed||Phase 2|52|Actual|Aghia Sophia Children's Hospital of Athens||2|||f||||||||||||||2018-06-01 02:23:10.764679|2018-06-01 02:23:10.764679
NCT00629681|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2011-04-22|2008-02-26|2008-03-06|Estimate|||||||2011-04-22|2011-04-26|Estimate|November 2004||2004-11-30|April 2011|2011-04-30|February 2006|Actual|2006-02-28|||||Interventional|||A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia|Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia|Completed||Phase 4|217|Actual|Pfizer||1|||f||||||||||||||2018-06-01 02:23:10.862235|2018-06-01 02:23:10.862235
NCT00629668|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-03-05|2008-03-05|2008-03-06|Estimate|||||||2008-03-05|2008-03-06|Estimate|January 2007||2007-01-31|July 2007|2007-07-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Genetic Polymorphisms of TNF-α Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease||Unknown status|Recruiting|N/A|||Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-06-01 02:23:11.039171|2018-06-01 02:23:11.039171
NCT00629655|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2009-06-04|2008-03-05|2008-03-06|Estimate|||||||2009-06-04|2009-06-05|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||A Spinal Functional Magnetic Resonance Imagine (fMRI) Study of Resting-State, Motor Task and Acupoint Stimulation|A Spinal fMRI Study of Resting-State, Motor Task and Acupoint Stimulation|Completed|||22|Actual|China Rehabilitation Research Center|||2||f||||t||||||||||2018-06-01 02:23:11.119456|2018-06-01 02:23:11.119456
NCT00629642|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2017-08-31|2008-02-27|2008-03-06|Estimate|||||||2017-08-31|2017-09-01|Actual|March 14, 2008|Actual|2008-03-14|August 2017|2017-08-31|January 28, 2011|Actual|2011-01-28|January 28, 2011|Actual|2011-01-28||Interventional|SONIC||Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis|A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity|Completed||Phase 4|249|Actual|Astellas Pharma Inc||4|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 02:23:11.226227|2018-06-01 02:23:11.226227
NCT00629629|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2008-03-05|2008-03-05|2008-03-06|Estimate|||||||2008-03-05|2008-03-06|Estimate|October 2001||2001-10-31|March 2008|2008-03-31|June 2003|Actual|2003-06-30|October 2002|Actual|2002-10-31||Interventional|||Impacts of the 10 Steps for Healthy Feeding in Infants: a Randomized Field Trial|Impacts of the 10 Steps for Healthy Feeding in Infants: a Randomized Field Trial|Completed||N/A|500|Actual|Federal University of Health Science of Porto Alegre||1|||f||||f||||||||||2018-06-01 02:23:11.413585|2018-06-01 02:23:11.413585
NCT00629616|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2014-08-05|2008-03-05|2008-03-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|August 2007||2007-08-31|August 2014|2014-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|NIMFEA||Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer|A Randomized Multicenter Phase II Study Identifying Hormone Sensitivity Profiles and Evaluating the Efficacy of Anastrozole and Fulvestrant in the Neo-adjuvant Treatment of Operable Breast Cancer in Postmenopausal Women.|Unknown status|Active, not recruiting|Phase 2|116|Actual|UNICANCER||2|||f||||t||||||||||2018-06-01 02:23:11.499263|2018-06-01 02:23:11.499263
NCT00629603|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2013-04-17|2008-03-05|2008-03-06|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease|Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease|Completed||N/A|600|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||||2018-06-01 02:23:11.59593|2018-06-01 02:23:11.59593
NCT00629590|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21||2009-03-24|2011-09-20|2008-03-05|2008-03-06|Estimate||||2009-11-13|2009-11-17|Estimate|2011-09-20|2011-09-26|Estimate|March 2008||2008-03-31|September 2011|2011-09-30||||July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis|A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Two Weeks in Subjects With Posterior Blepharitis|Completed||Phase 4|20|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:23:11.665578|2018-06-01 02:23:11.665578
NCT00629577|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-05|||2017-01-30|2008-03-05|2008-03-06|Estimate|||||||2017-01-30|2017-02-01|Estimate|September 2006||2006-09-30|November 2010|2010-11-30|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional|SAGE||Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples|Ex Vivo Gene Expression Profiling of Cervical Cancer Progression in Biopsies And Tissue Samples From Patients With Cervical Lesions|Terminated||Phase 1|50|Anticipated|British Columbia Cancer Agency||||no funding|f||||f||||||||||2018-06-01 02:23:11.738328|2018-06-01 02:23:11.738328
NCT00629005|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2013-01-28|2008-02-26|2008-03-05|Estimate|||||||2013-01-28|2013-01-29|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Strength Training and Stroke|Should We Train Strength or Skill in Post-Stroke Rehabilitation?|Completed||Phase 1/Phase 2|20|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:23:17.751512|2018-06-01 02:23:17.751512
NCT00629564|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2011-01-24|2008-02-27|2008-03-06|Estimate|||||||2011-01-24|2011-01-25|Estimate|September 2002||2002-09-30|January 2011|2011-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)|An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)|Completed||Phase 4|60|Actual|AstraZeneca||2|||||||||||||||||2018-06-01 02:23:11.804619|2018-06-01 02:23:11.804619
NCT00629551|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26||2016-04-26|2016-04-26|2008-03-05|2008-03-06|Estimate||||2016-04-26|2016-05-26|Estimate|2016-04-26|2016-05-26|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|COMPASS||An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder|An Eight-week, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Saredutant (100 mg and 30 mg) Once Daily in Combination With Paroxetine 20 mg Once Daily Compared to Saredutant Placebo in Combination With Paroxetine 20 mg Once Daily in Patients With Major Depressive Disorder|Completed||Phase 3|825|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 02:23:11.87865|2018-06-01 02:23:11.87865
NCT00629538|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2010-12-28|2008-02-25|2008-03-06|Estimate|||||||2010-12-28|2010-12-30|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Therapeutic Thoracentesis for Patients With Congestive Heart Failure and Large Pleural Effusion|Effect of Therapeutic Thoracentesis on Cardiopulmonary Function in Patients With Congestive Heart Failure Complicated With Large to Massive Pleural Effusion|Completed||N/A|20|Anticipated|Taipei Medical University Hospital|||||f||||t||||||||||2018-06-01 02:23:11.967407|2018-06-01 02:23:11.967407
NCT00629525|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|2013-01-04||2015-02-12|2008-02-27|2008-03-06|Estimate|2013-01-04|2013-02-07|Estimate||||2015-02-12|2015-03-03|Estimate|August 2005||2005-08-31|February 2015|2015-02-28|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer|A Single Arm, Two Center, Phase II Study of RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer|Completed||Phase 2|35|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:23:12.125802|2018-06-01 02:23:12.125802
NCT00629512|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2009-03-12|2008-03-05|2008-03-06|Estimate|||||||2009-03-12|2009-03-13|Estimate|March 2001||2001-03-31|March 2009|2009-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Prevention of Gastric Ulcers|A Comparative Efficacy and Safety Study of Nexium (Esomeprazole Magnesium) Delayed-Release Capsules (40mg qd and 20mg qd) Versus Placebo for the Prevention of Gastric Ulcers Associated With Daily NSAID Use in Patients at Risk|Completed||Phase 3|504|Anticipated|AstraZeneca||3|||||||||||||||||2018-06-01 02:23:12.344558|2018-06-01 02:23:12.344558
NCT00629499|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2012-08-22||2013-08-29|2008-02-26|2008-03-06|Estimate|2012-11-19|2012-12-20|Estimate||||2013-08-29|2013-09-09|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|September 2010|Actual|2010-09-30|October 2008|Actual|2008-10-31||Interventional|||Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer|Phase II Trial of Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer (With Trastuzumab in HER2 Positive Patients)|Completed||Phase 2|63|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:23:12.427347|2018-06-01 02:23:12.427347
NCT00629486|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2013-04-17|2008-03-05|2008-03-06|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma|Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma|Completed||N/A|300|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||||2018-06-01 02:23:12.591979|2018-06-01 02:23:12.591979
NCT00629473|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2017-11-20|2008-03-05|2008-03-06|Estimate|||||||2017-11-20|2017-11-22|Actual|July 2007||2007-07-31|November 2017|2017-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies|A Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies|Completed||Phase 1|86|Actual|Celgene||2|||f||||f||||||||Undecided||2018-06-01 02:23:12.66588|2018-06-01 02:23:12.66588
NCT00629460|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2012-10-16|2008-03-04|2008-03-06|Estimate|||||||2012-10-16|2012-10-17|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|April 2012|Actual|2012-04-30|August 2010|Actual|2010-08-31||Observational|||A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors|A Pilot Study of PET-CT in the Assessment of Pulmonary Nodules in Children With Malignant Solid Tumors|Completed|||27|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 02:23:12.774361|2018-06-01 02:23:12.774361
NCT00629447|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-01-04|2008-03-05|2008-03-06|Estimate|||||||2013-01-04|2013-01-07|Estimate|February 2004||2004-02-29|January 2013|2013-01-31|October 2009|Actual|2009-10-31|March 2007|Actual|2007-03-31||Interventional|||Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients|A Pilot Trial of Innohep (Tinzaparin) Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients|Completed||N/A|40|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:23:12.832315|2018-06-01 02:23:12.832315
NCT00629434|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-04|2008-03-04|2008-03-06|Estimate|||||||2008-03-04|2008-03-06|Estimate|June 2001||2001-06-30|February 2008|2008-02-29|August 2008|Anticipated|2008-08-31|June 2008|Anticipated|2008-06-30||Interventional|||A Comparison of Diabetes Group Education as Administered Through Telemedicine Versus as Administered in Person|A Comparison of Diabetes Group Education as Administered Through Telemedicine Versus as Administered in Person|Unknown status|Active, not recruiting|N/A|68|Actual|State University of New York - Upstate Medical University||2|||f||||f||||||||||2018-06-01 02:23:12.897017|2018-06-01 02:23:12.897017
NCT00629421|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2017-08-20|2008-03-05|2008-03-06|Estimate|||||||2017-08-20|2017-08-22|Actual|January 1, 2001|Actual|2001-01-01|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study|Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study|Completed|||1200|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-06-01 02:23:12.963453|2018-06-01 02:23:12.963453
NCT00629395|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-05-31|2008-03-05|2008-03-06|Estimate|||||||2013-05-31|2013-06-03|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Computerized Cognitive Training for Childhood Cancer Survivors|Computerized Cognitive Training for Childhood Cancer Survivors: A Pilot Study|Terminated||N/A|9|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:23:13.029769|2018-06-01 02:23:13.029769
NCT00628823|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2016-05-14|2008-02-24|2008-03-05|Estimate|||||||2016-05-14|2016-05-17|Estimate|March 2003||2003-03-31|May 2016|2016-05-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|TMCD||Treatment of Mild Enteropathy Celiac Disease|Treatment of Mild Enteropathy Celiac Disease|Completed||N/A|73|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-06-01 02:23:20.659591|2018-06-01 02:23:20.659591
NCT00629356|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2015-03-31|2008-03-05|2008-03-06|Estimate|||||||2015-03-31|2015-04-03|Estimate|July 2007||2007-07-31|May 2010|2010-05-31|July 2008|Anticipated|2008-07-31|||||Observational|||Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection|Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection|Withdrawn|||0|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||||The study had been revised and made a new application.|f||||f||||||||||2018-06-01 02:23:14.194195|2018-06-01 02:23:14.194195
NCT00629343|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2012-11-07|2008-03-05|2008-03-06|Estimate|||||||2012-11-07|2012-11-08|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|August 2014|Anticipated|2014-08-31|October 2012|Actual|2012-10-31||Interventional|||Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide|A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma|Unknown status|Active, not recruiting|Phase 1|28|Actual|Columbia University||1|||f||||t||||||||||2018-06-01 02:23:14.266487|2018-06-01 02:23:14.266487
NCT00629330|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2015-10-12|2008-03-05|2008-03-06|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2004||2004-01-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|March 2008|Actual|2008-03-31||Interventional|||Dissemination of Prostate Cancer Screening to PCP's in African American Communities|Dissemination of Prostate Cancer Screening to Primary Care Physicians in African American Communities|Terminated||Phase 4|86|Actual|Columbia University||1||Principal Investigator left the institution.|f||||t||||||||||2018-06-01 02:23:14.338727|2018-06-01 02:23:14.338727
NCT00629317|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2009-03-13|2008-03-04|2008-03-06|Estimate|||||||2009-03-13|2009-03-16|Estimate|February 2008||2008-02-29|March 2009|2009-03-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Trial of Methyl Aminolevulinate Plus Aktilite in Facial Photodamage|A Randomized, Double-Blind, Placebo-Controlled Trial of Methyl Aminolevulinate + Aktilite in Patients With Facial Photodamage|Completed||Phase 3|49|Actual|Universidad de Antioquia||2|||f||||f||||||||||2018-06-01 02:23:14.400271|2018-06-01 02:23:14.400271
NCT00629304|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2012-02-08|2008-03-04|2008-03-05|Estimate|||||||2012-02-08|2012-02-09|Estimate|September 2007||2007-09-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|TELEDIAB-1||Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients|Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients With Chronic Failure of Intensive Insulin Therapy and Conventional Care. The TELEDIAB-1 STUDY|Completed||Phase 3|180|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||3|||f||||f||||||||||2018-06-01 02:23:14.488436|2018-06-01 02:23:14.488436
NCT00629291|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2010-05-09|2008-02-25|2008-03-05|Estimate|||||||2010-05-09|2010-05-11|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||MRI Evaluation of Iron Overload in the Heart, Liver and Pancreas in Patients Receiving Multiple Blood Transfusions.|Evaluation of Iron Overload in the Heart, Liver and Pancreas: Patients With Sickle β Thalassemia and Sickle Cell Anemia.|Completed|||60|Anticipated|Sheba Medical Center|||2||f||||f||||||None Retained|"~     No biosepcimens retained~   "|||2018-06-01 02:23:14.591745|2018-06-01 02:23:14.591745
NCT00629278|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2013-08-06|2008-03-04|2008-03-05|Estimate|||||||2013-08-06|2013-08-07|Estimate|December 2007||2007-12-31|July 2009|2009-07-31||||December 2010|Anticipated|2010-12-31||Interventional|||Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer|SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS|Unknown status|Recruiting|Phase 3|2500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:23:14.755467|2018-06-01 02:23:14.755467
NCT00629265|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2013-08-28||2014-10-29|2008-03-04|2008-03-05|Estimate|2014-10-29|2014-10-31|Estimate||||2014-10-29|2014-10-31|Estimate|March 2008||2008-03-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|April 2012|Actual|2012-04-30||Interventional|||Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients|Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients|Completed||N/A|170|Actual|Boston Medical Center|Because of funding limitations research assistants could not be hired at most sites, and so 170 (instead of 240) subjects were enrolled. However, the results suggest additional patients would not have changed the outcome.|2|||f||||t||||||||||2018-06-01 02:23:14.891295|2018-06-01 02:23:14.891295
NCT00629252|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2012-09-14|2008-02-26|2008-03-05|Estimate|||||||2012-09-14|2012-09-17|Estimate|February 2008||2008-02-29|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients||Terminated||N/A|14|Actual|University of Zurich||3||Not enough subjects have been recruited in the expected period.|f||||f||||||||||2018-06-01 02:23:15.287128|2018-06-01 02:23:15.287128
NCT00629239|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2010-11-04||2010-11-04|2008-02-25|2008-03-05|Estimate|2010-11-04|2010-12-06|Estimate||||2010-11-04|2010-12-06|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|TOP||Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A 4-week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|65|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:23:15.389875|2018-06-01 02:23:15.389875
NCT00629226|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-01|||2011-09-29|2008-03-01|2008-03-05|Estimate|||||||2011-09-29|2011-09-30|Estimate|October 2007||2007-10-31|September 2011|2011-09-30||||December 2010|Actual|2010-12-31||Interventional|||Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer|Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer|Completed||Phase 1|46|Anticipated|National Institutes of Health Clinical Center (CC)||2|||||||||||||||||2018-06-01 02:23:15.776831|2018-06-01 02:23:15.776831
NCT00629213|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-03-05|2008-03-04|2008-03-05|Estimate|||||||2008-03-05|2008-03-07|Estimate||||March 2008|2008-03-31||||||||Interventional|||Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial|Metabolic Syndrome and Its Single Traits as Risk Factors of Diabetes in People With Impaired Glucose Tolerance: The STOP-NIDDM Trial|Completed||Phase 3|1429||GWT-TUD GmbH||2|||f||||t||||||||||2018-06-01 02:23:15.862544|2018-06-01 02:23:15.862544
NCT00629200|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2011-11-21|2008-02-25|2008-03-05|Estimate|||||||2011-11-21|2011-11-23|Estimate|September 2006||2006-09-30|November 2011|2011-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies|Completed||Phase 1|33|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:23:16.014598|2018-06-01 02:23:16.014598
NCT00629187|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2012-04-26|2008-02-26|2008-03-05|Estimate|||||||2012-04-26|2012-04-27|Estimate|April 2004||2004-04-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|CN-306||Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy|Phase I Dose Escalation Study of Temozolomide With Autologous Stem Cell Rescue for Patients With Relapsed/Refractory CNS Malignancy Including Isolated Metastatic Disease|Terminated||Phase 1|2|Actual|Tufts Medical Center||1||The study was stopped due to lack of adequate enrollment.|f||||f||||||||||2018-06-01 02:23:16.10553|2018-06-01 02:23:16.10553
NCT00629174|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-11|2008-03-04|2008-03-05|Estimate|||||||2008-03-11|2008-03-12|Estimate|June 2006||2006-06-30|March 2008|2008-03-31||||December 2008|Anticipated|2008-12-31||Interventional|BBF||Prevention of the Age-Related Cognitive Impairment by Exercise and Mental Activity - Berlin Bleibt Fit|Randomized, Controlled Study About the Effects of an Exercise Program and Mental Activity on the Age-Associated Impairment of Cognitive Function|Unknown status|Recruiting|Phase 3|252|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-06-01 02:23:16.188765|2018-06-01 02:23:16.188765
NCT00629161|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2010-05-26|2008-02-25|2008-03-05|Estimate|||||||2010-05-26|2010-05-28|Estimate|November 2008||2008-11-30|September 2009|2009-09-30||||August 2010|Anticipated|2010-08-31||Interventional|||Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease||Unknown status|Recruiting|Phase 2/Phase 3|144|Anticipated|Fudan University||2|||f||||||||||||||2018-06-01 02:23:16.287876|2018-06-01 02:23:16.287876
NCT00629148|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2011-07-06|2008-02-26|2008-03-05|Estimate|||||||2011-07-06|2011-07-07|Estimate|August 2007||2007-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|August 2009|Actual|2009-08-31||Interventional|||Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)|Randomized Multicenter Phase II Study of Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine as First Line Chemotherapy for Patients With Metastatic Breast Cancer|Completed||Phase 2|60|Actual|Fudan University||2|||f||||f||||||||||2018-06-01 02:23:16.413156|2018-06-01 02:23:16.413156
NCT00629135|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2011-06-21|2008-03-04|2008-03-05|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2005||2005-11-30|May 2010|2010-05-31|August 2012|Anticipated|2012-08-31|February 2012|Anticipated|2012-02-29||Interventional|MEMO||Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses|Single Centre, Prospective, Comparative, Open-label, Randomised Study to Evaluate the Efficacy and Tolerability of the Combination of Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses|Unknown status|Recruiting|Phase 3|180|Anticipated|Hannover Medical School||2|||f||||t||||||||||2018-06-01 02:23:16.498192|2018-06-01 02:23:16.498192
NCT00629122|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2015-07-09||2017-11-02|2008-02-25|2008-03-05|Estimate|2017-11-02|2017-12-11|Actual||||2017-11-02|2017-12-11|Actual|February 2008||2008-02-29|November 2017|2017-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation|Pharmacokinetic Evaluation of Sublingual Versus Oral Tacrolimus Administration in Patients Awaiting Kidney Transplantation|Completed||Phase 4|5|Actual|Weill Medical College of Cornell University|Small sample size; variable absorption profile; poor vascular access in some subjects; possible enteral absorption of sublingual drug; unable to assess genotype polymorphisms due to the small number of subjects.|2|||f||||f||||||||||2018-06-01 02:23:16.612999|2018-06-01 02:23:16.612999
NCT00629096|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2014-12-04|2008-03-04|2008-03-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy|Effects of Intracoronary Infusion of Bone Marrow-derived Progenitor Cells on Myocardial Regeneration in Patients With Non-ischemic Dilated Cardiomyopathy.|Completed||Phase 2|27|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||1|||f||||f||||||||||2018-06-01 02:23:16.931719|2018-06-01 02:23:16.931719
NCT00629083|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26||2015-02-06|2017-07-03|2008-02-26|2008-03-05|Estimate||||2015-02-06|2015-02-25|Estimate|2017-07-03|2017-07-06|Actual|April 2008||2008-04-30|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Bulking Agents for the Treatment of Stress Urinary Incontinence in Females|A Single-Masked, Randomized, Multi-Center, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Bulkamid® and Contigen® as Bulking Agents for the Treatment of Stress Urinary Incontinence in Females|Completed||N/A|345|Actual|Contura||2|||f||||t||||||||||2018-06-01 02:23:17.015791|2018-06-01 02:23:17.015791
NCT00629070|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2018-05-14|2008-02-25|2008-03-05|Estimate|||||||2018-05-14|2018-05-17|Actual|January 2009|Actual|2009-01-31|May 2018|2018-05-31|December 13, 2010|Actual|2010-12-13|December 13, 2010|Actual|2010-12-13||Interventional|||Quadriceps Muscle Plasticity in Children With Cerebral Palsy|In Vivo Assessment of Quadriceps Muscle Plasticity in Children With Cerebral Palsy|Completed||N/A|16|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 02:23:17.132704|2018-06-01 02:23:17.132704
NCT00629057|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2013-05-06|2008-02-25|2008-03-05|Estimate|||||||2013-05-06|2013-05-08|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|BNIT-PR-001||A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer|An Open-Label, Phase I Dose Escalation Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer|Completed||Phase 1|24|Actual|Bavarian Nordic, Inc.||3|||f||||f||||||||||2018-06-01 02:23:17.217353|2018-06-01 02:23:17.217353
NCT00629044|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2011-03-25|2008-02-25|2008-03-05|Estimate|||||||2011-03-25|2011-03-28|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|January 2011|Actual|2011-01-31|November 2009|Actual|2009-11-30||Interventional|||Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD|Etude du Polymorphysme génétique de la cholestérol 24S Hydroxylase et Des Teneurs en 24S hydroxycholestérol Chez Des Patients Atteints de Glaucome ou de dégénérescence Maculaire liée à l'âge.|Completed||N/A|320|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||t||||||||||2018-06-01 02:23:17.299261|2018-06-01 02:23:17.299261
NCT00629031|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-09-11|2008-02-25|2008-03-05|Estimate|||||||2008-09-11|2008-09-12|Estimate|February 2008||2008-02-29|September 2008|2008-09-30|August 2008|Actual|2008-08-31|February 2008|Actual|2008-02-29||Interventional|||An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis|An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL)|Completed||Phase 3|329|Actual|Banaras Hindu University||2|||f||||f||||||||||2018-06-01 02:23:17.361717|2018-06-01 02:23:17.361717
NCT00629018|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2013-04-09||2015-04-23|2008-02-25|2008-03-05|Estimate|2015-04-23|2015-05-12|Estimate||||2015-04-23|2015-05-12|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy|The Effects of Autologous Intracoronary Stem Cell Transplantation In Patients With End-Stage Dilated Cardiomyopathy|Completed||Phase 2|110|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-06-01 02:23:17.434808|2018-06-01 02:23:17.434808
NCT00628992|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2015-03-26|2008-02-25|2008-03-05|Estimate|||||||2015-03-26|2015-03-27|Estimate|February 2008||2008-02-29|March 2015|2015-03-31|September 2011|Actual|2011-09-30|November 2008|Actual|2008-11-30||Interventional|||Early Rehabilitation of COPD Patients in ICU|Effects of Early Rehabilitation in Chronic Obstructive Pulmonary Disease Patients Under Mechanical Ventilation for Acute Respiratory Failure in Intensive Care Unit.|Terminated||N/A|5|Actual|University Hospital, Strasbourg, France||4|||f||||||||||||||2018-06-01 02:23:17.833971|2018-06-01 02:23:17.833971
NCT00628979|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2009-07-01|2008-02-26|2008-03-05|Estimate|||||||2009-07-01|2009-07-03|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|March 2008|Actual|2008-03-31||Interventional|||Addressing Help-Seeking Barriers in Developing an Intensive Treatment for Veterans With Panic Disorder|Addressing Help-Seeking Barriers in Developing an Intensive Treatment for Veterans With Panic Disorder|Completed||N/A|23|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 02:23:17.917015|2018-06-01 02:23:17.917015
NCT00628966|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2011-11-10|2008-02-29|2008-03-05|Estimate|||||||2011-11-10|2011-11-11|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|VEST/PREDICTS||Evaluating the Effectiveness of the LifeVest Defibrillator and Improving Methods for Determining the Use of Implantable Cardioverter Defibrillators|Vest Prevention of Early Sudden Death and PREDiction of ICD Therapies|Unknown status|Active, not recruiting|Phase 3|2400|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 02:23:18.008451|2018-06-01 02:23:18.008451
NCT00628953|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-03-12|2008-03-04|2008-03-05|Estimate|||||||2009-03-12|2009-03-13|Estimate|October 2002||2002-10-31|March 2009|2009-03-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Adult Asthmatics and Acid Reflux|A Randomized, Double-Blind, Parallel Group Multicenter Efficacy and Safety Phase IIB Pilot Study of Esomeprazole 40mg Bid Versus Placebo Bid in Adult Asthmatics Treated for 4 Months|Completed||Phase 2|1400|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:23:18.179289|2018-06-01 02:23:18.179289
NCT00628940|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2018-05-15|2008-02-26|2008-03-05|Estimate|||||||2018-05-15|2018-05-18|Actual|January 12, 2010|Actual|2010-01-12|May 2018|2018-05-31|March 22, 2018|Actual|2018-03-22|March 14, 2017|Actual|2017-03-14||Interventional|||PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?|PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?|Completed||Phase 1|90|Actual|University Ghent||1|||f||||f||||||||||2018-06-01 02:23:18.254449|2018-06-01 02:23:18.254449
NCT00628927|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-03|2013-05-03||2015-12-01|2008-03-03|2008-03-05|Estimate|2013-07-22|2013-08-30|Estimate||||2015-12-01|2015-12-30|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Observational||Stimulant dependent participants were starting treatment, and participating in the CTN0031 study. Normal controls were recruited from the community.|An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.|An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association With Treatment Outcomes in Methamphetamine and Cocaine Abusers|Completed|||217|Actual|University of Cincinnati|||2||f||||t||||||Samples With DNA|"~     Blood sample for the oxidative stress/damage analysis~   "|||2018-06-01 02:23:18.329274|2018-06-01 02:23:18.329274
NCT00628914|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2010-08-19|2008-02-25|2008-03-05|Estimate|||||||2010-08-19|2010-08-20|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|February 2010|Anticipated|2010-02-28|November 2009|Anticipated|2009-11-30||Interventional|||Brain Mechanisms and Targeting Insomnia in Major Depression|Brain Mechanisms and Targeting Insomnia in Major Depression|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|University of California, Los Angeles||3|||f||||f||||||||||2018-06-01 02:23:18.603037|2018-06-01 02:23:18.603037
NCT00628901|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2011-06-13||2012-07-02|2008-03-04|2008-03-05|Estimate|2011-07-25|2011-08-22|Estimate||||2012-07-02|2012-07-11|Estimate|January 2006||2006-01-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Interventional|||A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)|A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE)|Completed||Phase 4|60|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-06-01 02:23:18.747986|2018-06-01 02:23:18.747986
NCT00628888|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2014-12-18|2008-02-29|2008-03-05|Estimate|||||||2014-12-18|2014-12-19|Estimate|July 2006||2006-07-31|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Waitlist-Controlled Trial of the Unified Protocol for the Treatment of Emotional Disorders in Adolescents|Treatment of Emotional Disorders in Adolescence|Completed||N/A|51|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 02:23:19.706715|2018-06-01 02:23:19.706715
NCT00628875|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2010-04-12|2008-02-26|2008-03-05|Estimate|||||||2010-04-12|2010-04-14|Estimate|January 2007||2007-01-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Observational|Vent Detection||Feasibility of Ventilation Detection Via Standard Defibrillator Pads in Mechanically Ventilated Pediatric Patients|"Feasibility of Ventilation Detection Using Thoracic Impedence Acquired Via Standard Defibrillator Electrode Pads in Mechanically Ventilated Pediatric Patients"|Completed|||28|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 02:23:19.780805|2018-06-01 02:23:19.780805
NCT00628862|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2010-03-19||2012-09-25|2008-02-25|2008-03-05|Estimate|2012-09-25|2012-10-25|Estimate||||2012-09-25|2012-10-25|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|OCEAN||Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU|A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-national, Phase III, Efficacy and Safety Study of Inhaled Formoterol 4.5 μg and 9 μg Twice Daily in Japanese and European Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|613|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:23:19.847057|2018-06-01 02:23:19.847057
NCT00628849|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2013-11-19|2008-02-26|2008-03-05|Estimate|||||||2013-11-19|2013-11-21|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|Mand||Champy Versus AO for Mandible Fractures|A Comparison of 2mm Plates and Screws With Larger Plates Ans Screws in the Treatment of Mandibular Fractures|Completed|||126|Actual|Emory University|||3||f||||f||||||||||2018-06-01 02:23:20.48085|2018-06-01 02:23:20.48085
NCT00628836|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2015-06-01|2008-02-25|2008-03-05|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2001||2001-06-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Treatment of Shoulder Subluxation in Chronic Stroke Patients|BION Implantable Microstimulation System|Completed||Phase 1|30|Actual|University of Southern California||2|||f||||f||||||||||2018-06-01 02:23:20.568972|2018-06-01 02:23:20.568972
NCT00628810|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2016-05-27|2008-03-04|2008-03-05|Estimate|||||||2016-05-27|2016-05-30|Estimate|January 2007||2007-01-31|May 2016|2016-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer|Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study|Completed||Phase 2|86|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||f||||||||||2018-06-01 02:23:20.772152|2018-06-01 02:23:20.772152
NCT00628797|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2017-05-29|2008-02-26|2008-03-05|Estimate|||||||2017-05-29|2017-05-31|Actual|February 2008||2008-02-29|May 2017|2017-05-31|November 2013|Actual|2013-11-30|July 2010|Actual|2010-07-31||Interventional|||Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis|Multizenter-Studie Zur UVA-1 Therapie für Die Hautbeteiligung Bei Systemischer Sklerodermie|Terminated||Phase 1/Phase 2|9|Actual|University of Cologne||2||lack of recruitement|f||||f||||||||||2018-06-01 02:23:21.031843|2018-06-01 02:23:21.031843
NCT00628784|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-07-22|2008-02-25|2008-03-05|Estimate|||||||2008-07-22|2008-07-24|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|March 2012|Anticipated|2012-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer|Endoesophageal Cryotherapy: A New Technique For Ablating Barrett's Esophagus And Early Stage Esophageal Cancer|Unknown status|Recruiting|Phase 4|100|Anticipated|Walter Reed Army Medical Center||4|||f||||t||||||||||2018-06-01 02:23:21.138173|2018-06-01 02:23:21.138173
NCT00628771|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2016-07-25|2008-02-29|2008-03-05|Estimate|||||||2016-07-25|2016-07-27|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women|Integrating Prenatal Care to Reduce HIV/STDs Among Teens: A Translational Study|Completed||Phase 4|1233|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:23:21.295763|2018-06-01 02:23:21.295763
NCT00628758|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2009-09-18||2012-07-06|2008-02-25|2008-03-05|Estimate|2012-07-06|2012-08-14|Estimate||||2012-07-06|2012-08-14|Estimate|December 2005||2005-12-31|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|PASSION||A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma|A Comparison of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5mg, 1 Inhalation Two Times a Day (b.i.d.) Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults a -26-week, Randomized, Open-label, Parallel-group, Multicentre Study|Completed||Phase 3|430|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:23:21.406369|2018-06-01 02:23:21.406369
NCT00628745|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2018-05-14|2008-03-04|2008-03-05|Estimate|||||||2018-05-14|2018-05-15|Actual|July 27, 2007|Actual|2007-07-27|May 2018|2018-05-31|June 16, 2021|Anticipated|2021-06-16|June 16, 2021|Anticipated|2021-06-16||Observational|THAOS||Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)|Transthyretin-associated Amyloidosis Outcomes Survey (Thaos): A Global, Multi-center, Longitudinal, Observational Survey Of Patients With Documented Transthyretin (Ttr) Mutations Or Wild-type Ttr Amyloidosis|Recruiting|||1|Anticipated|Pfizer|||1||f||||f|t|f||||Samples With DNA|"~     whole blood~   "|||2018-06-01 02:23:21.694803|2018-06-01 02:23:21.694803
NCT00628732|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2009-01-27|2008-02-25|2008-03-05|Estimate|||||||2009-01-27|2009-01-28|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors|A Pharmacokinetic and Phase II Study of Oral Cyclophosphamide and Oral Topotecan in Children With Recurrent and or Refractory Solid Tumors|Completed||Phase 2|36|Anticipated|Children's Medical Center Dallas||1|||f||||f||||||||||2018-06-01 02:23:21.934157|2018-06-01 02:23:21.934157
NCT00628719|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2009-04-02|2008-02-25|2008-03-05|Estimate|||||||2009-04-02|2009-04-03|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|||Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis|A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis|Completed||Phase 3|400|Anticipated|Banaras Hindu University||2|||f||||f||||||||||2018-06-01 02:23:21.99563|2018-06-01 02:23:21.99563
NCT00628706|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2009-02-17|2008-02-24|2008-03-05|Estimate|||||||2009-02-17|2009-02-18|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|FIX||Investigating the Acute Effects of THC on Functional Brain Systems|Investigating the Acute Effects of THC on Functional Brain Systems|Completed||Phase 1|12|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-06-01 02:23:22.061072|2018-06-01 02:23:22.061072
NCT00628693|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2016-01-26|2008-02-26|2008-03-05|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2006||2006-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Observational|Q-CPR||Quantitative Measurement of Cardiopulmonary Resuscitation (CPR) During In Hospital Cardiac Arrest|Quantitative Measurement of Cardiopulmonary Resuscitation During In Hospital Cardiac Arrest|Completed|||89|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 02:23:22.128998|2018-06-01 02:23:22.128998
NCT00628680|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-03-04|2008-03-04|2008-03-05|Estimate|||||||2008-03-04|2008-03-05|Estimate|July 2006||2006-07-31|February 2008|2008-02-29||||July 2008|Actual|2008-07-31||Interventional|||A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis|Pivotal/Phase III Multicentered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 Solution (Zuragen), and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis|Unknown status|Active, not recruiting|Phase 3|415|Actual|Ash Access Technology||2|||f||||f||||||||||2018-06-01 02:23:22.203915|2018-06-01 02:23:22.203915
NCT00628667|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2011-01-24|2008-03-04|2008-03-05|Estimate|||||||2011-01-24|2011-01-25|Estimate|February 2002||2002-02-28|January 2011|2011-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux|A Multicenter, Double -Blind, Placebo-controlled Study to Evaluate the Effects of Esomeprazole 40mg Bid on the Signs and Symptoms of Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux|Completed||Phase 4|120|Anticipated|AstraZeneca||2|||||||||||||||||2018-06-01 02:23:22.369847|2018-06-01 02:23:22.369847
NCT00628654|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-04|||2018-03-01|2008-03-04|2008-03-05|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2005||2005-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants|Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer|Recruiting|||700|Anticipated|University of California, Davis|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 02:23:22.503747|2018-06-01 02:23:22.503747
NCT00628628|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2013-05-31||2013-05-31|2008-02-25|2008-03-05|Estimate|2013-05-31|2013-08-01|Estimate||||2013-05-31|2013-08-01|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Rasburicase in Patients at Risk for Tumor Lysis Syndrome|Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome|Completed||Phase 2|82|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:23:22.576481|2018-06-01 02:23:22.576481
NCT00628615|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-12-15|2008-03-04|2008-03-05|Estimate|||||||2008-12-15|2008-12-16|Estimate|April 2008||2008-04-30|December 2008|2008-12-31|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Observational|||Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase|Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase|Unknown status|Active, not recruiting||50|Anticipated|Maastricht University Medical Center|||2||f||||f||||||||||2018-06-01 02:23:22.793363|2018-06-01 02:23:22.793363
NCT00628602|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2015-06-01|2008-02-25|2008-03-05|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||BION Active Seating for Pressure Ulcer Prevention|BION Active Seating for Pressure Ulcer Prevention|Completed||Phase 1|3|Actual|University of Southern California||2|||f||||f||||||||||2018-06-01 02:23:22.858799|2018-06-01 02:23:22.858799
NCT00628589|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2017-02-04||2017-06-28|2008-02-25|2008-03-05|Estimate|2017-05-30|2017-06-29|Actual||||2017-06-28|2017-07-26|Actual|February 2008||2008-02-29|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Safety Population|Staccato Loxapine in Agitated Patients With Schizophrenia|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Schizophrenic Patients With Agitation|Completed||Phase 3|344|Actual|Alexza Pharmaceuticals, Inc.|Because of the need to provide informed consent, the types of patients enrolled in the study may not have been representative of the most severely agitated patients who present for emergency care.|3|||f||||f|t|f||||||No|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 02:23:22.931755|2018-06-01 02:23:22.931755
NCT00628576|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-02-26|2008-02-26|2008-03-05|Estimate|||||||2008-02-26|2008-03-05|Estimate|October 1993||1993-10-31|February 2008|2008-02-29|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities|Deep Venous Thrombosis. Long-Term Results After Treatment With Either Low-Molecular -Weight Heparin or Unfractionated Heparin. Examinations of the Venous System.|Completed||Phase 3|99|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-06-01 02:23:23.33475|2018-06-01 02:23:23.33475
NCT00628563|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2016-02-26|2008-02-26|2008-03-05|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|REALL||REALL: A Retrospective Observational Study to Compare the Effectiveness and Cost-Effectiveness Between Different Step-3 Asthma Treatment Strategies|REALL STUDY: A Retrospective Observational Study to Compare the Effectiveness and Cost-effectiveness Between Different Step-3 Asthma Treatment Strategies in Real Life Patients in Primary Care|Completed|||50000|Actual|University of Aberdeen|||1||f||||t||||||||||2018-06-01 02:23:23.428012|2018-06-01 02:23:23.428012
NCT00628550|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2010-06-24|2008-03-04|2008-03-05|Estimate|||||||2010-06-24|2010-06-28|Estimate|April 2008||2008-04-30|June 2010|2010-06-30|December 2011|Anticipated|2011-12-31|April 2011|Anticipated|2011-04-30||Interventional|Vasopressin||Trial of Vasopressin and Epinephrine to Epinephrine Only for In-Hospital Pediatric Cardiopulmonary Resuscitation|A Prospective, Randomized, Controlled Trial of Combination Vasopressin and Epinephrine to Epinephrine Only for In-Intensive Care Unit Pediatric Cardiopulmonary Resuscitation|Unknown status|Recruiting|Phase 1|130|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 02:23:23.519422|2018-06-01 02:23:23.519422
NCT00628537|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2015-06-01|2008-02-25|2008-03-05|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2004||2004-04-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Prevention of Post-Stroke Hand/Wrist Flexion Deformity|BION Implantable Microstimulator|Completed||Phase 1|30|Actual|University of Southern California||3|||f||||f||||||||||2018-06-01 02:23:23.642499|2018-06-01 02:23:23.642499
NCT00628524|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2013-12-06|2008-02-25|2008-03-05|Estimate|||||||2013-12-06|2013-12-09|Estimate|February 2008||2008-02-29|December 2013|2013-12-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|HCS||Homburg Cream & Sugar Study|Prospective Investigation of the Influence of Triglyceride Tolerance on Cardiovascular Outcomes in Patients With Coronary Artery Disease|Completed|||514|Actual|University Hospital, Saarland|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:23:23.759064|2018-06-01 02:23:23.759064
NCT00628511|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2016-02-08|2008-02-25|2008-03-05|Estimate|||||||2016-02-08|2016-02-09|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Observational|||Validation of Portable Monitoring Device for Diagnosing Sleep Apnea|A Validation Study of A New Diagnostic Device for Screening of Obstructive Sleep Apnea in High Risk Patient Population|Completed|||175|Actual|Chinese University of Hong Kong|||1||f||||f||||||||||2018-06-01 02:23:23.843198|2018-06-01 02:23:23.843198
NCT00628498|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2017-11-02||2017-11-02|2008-03-04|2008-03-05|Estimate|2017-11-02|2017-11-30|Actual||||2017-11-02|2017-11-30|Actual|December 2007||2007-12-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|Treatment IND|Safety Population|Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study|Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study|Completed||Phase 3|1206|Actual|Jazz Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:23:24.00626|2018-06-01 02:23:24.00626
NCT00628485|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2015-06-01|2008-02-25|2008-03-05|Estimate|||||||2015-06-01|2015-06-03|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||BION Treatment of Dysphagia After Radical Head-Neck Surgery|BION Stimulation to Improve Swallowing Function After Radical Head-neck Surgery and Follow-up Chemoradiation Therapy|Completed||Phase 1|4|Actual|University of Southern California||3|||f||||f||||||||||2018-06-01 02:23:24.724414|2018-06-01 02:23:24.724414
NCT00628472|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-04|2008-03-04|2008-03-05|Estimate|||||||2008-03-04|2008-03-05|Estimate|January 2007||2007-01-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort|Novel Technique for Botulinum Toxin Injection to Minimize Patient Discomfort|Completed||N/A|21|Actual|Henry Ford Health System|||||f||||f||||||||||2018-06-01 02:23:24.850383|2018-06-01 02:23:24.850383
NCT00534105|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2013-07-02||2013-07-02|2007-09-21|2007-09-24|Estimate|2013-07-02|2013-09-11|Estimate||||2013-07-02|2013-09-11|Estimate|September 2007||2007-09-30|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Lipid Metabolism in Gestational Diabetes|Study of Lipid Metabolism in Gestational Diabetes|Completed|||106|Actual|Baystate Medical Center|||2||f||||f||||||||||2018-06-01 02:54:08.59559|2018-06-01 02:54:08.59559
NCT00628459|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-03-04|2008-03-04|2008-03-05|Estimate|||||||2008-03-04|2008-03-05|Estimate|August 2006||2006-08-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Interventional|||Effect of Iron Versus Multiple Micronutrient Supplementation on Anemia in Preschool Children of Malaria-Endemic Area||Completed||N/A|297|Actual|Centre National de la Recherche Scientifique et Technologique||3|||f||||f||||||||||2018-06-01 02:23:24.967026|2018-06-01 02:23:24.967026
NCT00628446|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2012-02-27||2015-07-27|2008-02-26|2008-03-05|Estimate|2013-03-30|2013-05-16|Estimate||||2015-07-27|2015-08-14|Estimate|September 2007||2007-09-30|July 2015|2015-07-31|December 2009|Actual|2009-12-31|November 2008|Actual|2008-11-30||Observational|||Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury|Prevalence and Risk of Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury(SCI): A Pilot Study|Completed|||45|Actual|Carolinas Healthcare System|||||f||||t||||||||||2018-06-01 02:23:25.116309|2018-06-01 02:23:25.116309
NCT00628433|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2011-06-11|2008-02-25|2008-03-05|Estimate|||||||2011-06-11|2011-06-14|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis|A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis|Completed||Phase 1/Phase 2|27|Actual|Harbor Therapeutics||5|||f||||f||||||||||2018-06-01 02:23:25.473057|2018-06-01 02:23:25.473057
NCT00628420|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2011-06-27|2008-02-24|2008-03-05|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2005||2005-01-31|February 2008|2008-02-29|October 2007|Actual|2007-10-31|November 2006|Actual|2006-11-30||Interventional|ACP-104||Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics|A Randomized, Double Blind, Placebo Controlled, Single Oral Dose Study to Demonstrate the Safety, Tolerability, and Pharmacokinetics of ACP-104 (N-desmethylclozapine) in Schizophrenia, or Other Psychotic Disorders.|Completed||Phase 1|45|Actual|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-06-01 02:23:25.776771|2018-06-01 02:23:25.776771
NCT00628407|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2010-11-18||2011-03-09|2008-03-04|2008-03-05|Estimate|2011-02-02|2011-03-01|Estimate||||2011-03-09|2011-03-11|Estimate|January 2007||2007-01-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Observational|SWP||Effects of Sternal Wall Pressure in Children|Effect of Gentle Sternal Chest Wall Pressure on Intrathoracic Pressure During Mechanical Ventilation in Children.|Completed|||13|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 02:23:26.137973|2018-06-01 02:23:26.137973
NCT00628394|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2012-06-21|2008-02-24|2008-03-05|Estimate|||||||2012-06-21|2012-06-22|Estimate|September 2003||2003-09-30|June 2012|2012-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation|Cognitive Treatments in Schizophrenia|Completed||Phase 4|119|Actual|University of Texas Southwestern Medical Center||4|||f||||f||||||||||2018-06-01 02:23:26.666182|2018-06-01 02:23:26.666182
NCT00628381|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2010-09-02|2008-02-26|2008-03-05|Estimate|||||||2010-09-02|2010-09-03|Estimate|January 2011||2011-01-31|September 2010|2010-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||L-citrulline Supplementation During Sepsis|Arginine and Nitric Oxide (NO) Metabolism in Sepsis; L-citrulline Enteral Supplementation for the Normalisation of the Arginine-NO Metabolism|Unknown status|Not yet recruiting|Phase 3|48|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 02:23:26.839046|2018-06-01 02:23:26.839046
NCT00628368|ClinicalTrials.gov processed this data on May 31, 2018|2008-03-01|||2009-12-13|2008-03-01|2008-03-05|Estimate|||||||2009-12-13|2009-12-15|Estimate|November 2005||2005-11-30|July 2009|2009-07-31||||September 2009|Anticipated|2009-09-30||Interventional|||Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer|Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of the EGFR in Response to Treatment With Neoadjuvant Chemoradiotherapy in Patients With Cancer of the Esophagus or Rectum|Unknown status|Recruiting|N/A|160|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:23:27.070526|2018-06-01 02:23:27.070526
NCT00628355|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2010-09-15||2014-05-23|2008-02-25|2008-03-05|Estimate|2014-03-24|2014-04-25|Estimate||||2014-05-23|2014-06-06|Estimate|February 2008||2008-02-29|May 2014|2014-05-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional|||Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment|Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial.|Terminated||Phase 4|30|Actual|University of Sao Paulo|Early termination leading to small numbers of subjects analyzed.|2||Lidocaine injection group showed significant improvement in pain|f||||t||||||||||2018-06-01 02:23:27.199779|2018-06-01 02:23:27.199779
NCT00628342|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-03-11|2008-02-26|2008-03-05|Estimate|||||||2009-03-11|2009-03-12|Estimate|April 2003||2003-04-30|March 2009|2009-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 4|600|Anticipated|AstraZeneca||3|||f||||||||||||||2018-06-01 02:23:27.753265|2018-06-01 02:23:27.753265
NCT00628329|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2012-05-03|2008-02-26|2008-03-05|Estimate|||||||2012-05-03|2012-05-07|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Vitamin A, Its Receptors and Asthma|Vitamin A, Its Receptors and Asthma: Vitamin A Levels in Serum and Expression and Responsiveness of Vitamin A Receptors in Circulating Mononuclear Cells of Asthmatics|Withdrawn|||0|Actual|University of Kansas Medical Center|||2||f||||f||||||Samples With DNA|"~     Serum without DNA, cells with DNA~   "|||2018-06-01 02:23:27.896093|2018-06-01 02:23:27.896093
NCT00628316|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2011-03-21|2008-02-25|2008-03-05|Estimate|||||||2011-03-21|2011-03-22|Estimate|January 2008||2008-01-31|February 2008|2008-02-29|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Effects of Caffeine in Tinnitus|Effects of Caffeine Consumption on Tinnitus Perception|Completed||N/A|50|Anticipated|Faculdade de Medicina de Valenca|||||f||||f||||||||||2018-06-01 02:23:28.00268|2018-06-01 02:23:28.00268
NCT00628303|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2012-07-30|2008-03-04|2008-03-05|Estimate|||||||2012-07-30|2012-08-01|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|December 2011|Anticipated|2011-12-31|February 2011|Anticipated|2011-02-28||Interventional|||A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Motavizumab Prophylaxis on Reduction of the Incidence of Serious Early Childhood Wheezing in Preterm Infants|Withdrawn||Phase 3|0|Actual|MedImmune LLC||2||Study never officially opened for enrollment|f||||||||||||||2018-06-01 02:23:28.081076|2018-06-01 02:23:28.081076
NCT00628290|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-03-17|2008-02-26|2008-03-05|Estimate|||||||2008-03-17|2008-03-18|Estimate|October 2002||2002-10-31|January 2008|2008-01-31|March 2008|Actual|2008-03-31|November 2004|Actual|2004-11-30||Interventional|CBD-CT1||Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis|Evaluation of the Antipsychotic Efficacy of the Phytocannabinoid Cannabidiol in Treating Acute Schizophrenic Psychosis. A Double-Blind, Controlled Clinical Trial|Completed||Phase 2|42|Anticipated|University of Cologne||2|||f||||f||||||||||2018-06-01 02:23:28.234844|2018-06-01 02:23:28.234844
NCT00628277|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2008-02-26|2008-02-26|2008-03-05|Estimate|||||||2008-02-26|2008-03-05|Estimate|October 2002||2002-10-31|February 2008|2008-02-29|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Methods of Weight Loss in Overweight Coronary Patients|Methods of Weight Loss in Overweight Coronary Patients|Completed||Phase 3|74|Actual|University of Vermont||2|||f||||t||||||||||2018-06-01 02:23:28.33779|2018-06-01 02:23:28.33779
NCT00628264|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2009-05-29|2008-02-25|2008-03-05|Estimate|||||||2009-05-29|2009-06-01|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery|Terminated||Phase 2|75|Anticipated|Action Pharma A/S||2||The study was terminated due to a considerably lower recruitment rate than anticipated|f||||t||||||||||2018-06-01 02:23:28.434192|2018-06-01 02:23:28.434192
NCT00628251|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2015-01-14|2013-07-22|2018-02-27|2008-03-04|2008-03-05|Estimate|2016-04-27|2016-06-03|Estimate|2013-07-22|2013-07-24|Estimate|2018-02-27|2018-03-01|Actual|July 30, 2008|Actual|2008-07-30|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|September 15, 2009|Actual|2009-09-15||Interventional|ICEBERG 3||Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer|A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy|Active, not recruiting||Phase 2|97|Actual|AstraZeneca|The AEs reported include all events up to the OS data cut-off. After the PFS data cut-off, AEs were only collected for the olaparib and cross-over groups. The safety profile of these 2 groups at OS was consistent with that at the time of PFS.|3|||t||||t||||||||||2018-06-01 02:23:28.688404|2018-06-01 02:23:28.688404
NCT00628238|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2010-09-08|2008-02-26|2008-03-05|Estimate|||||||2010-09-08|2010-09-10|Estimate|February 2008||2008-02-29|September 2010|2010-09-30|July 2011|Anticipated|2011-07-31|February 2011|Anticipated|2011-02-28||Interventional|||Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)|A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)|Unknown status|Recruiting|Phase 2|80|Anticipated|Chronic Lymphocytic Leukemia Research Consortium||2|||t||||t||||||||||2018-06-01 02:23:30.085008|2018-06-01 02:23:30.085008
NCT00628225|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-10-16|2008-02-25|2008-03-04|Estimate|||||||2008-10-16|2008-10-17|Estimate|March 2000||2000-03-31|February 2008|2008-02-29|December 2003|Actual|2003-12-31|December 2002|Actual|2002-12-31||Interventional|SMOCC||Smoking Cessation in Patients With COPD (SMOCC) in General Practice|Smoking Cessation in Patients With COPD (SMOCC) in General Practice|Completed||Phase 4|667|Actual|Radboud University||3|||f||||t||||||||||2018-06-01 02:23:30.22788|2018-06-01 02:23:30.22788
NCT00628212|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|2013-04-12||2013-04-12|2008-02-24|2008-03-04|Estimate|2013-04-12|2013-05-31|Estimate||||2013-04-12|2013-05-31|Estimate|January 2008||2008-01-31|April 2013|2013-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes|A Phase II, Double-Blind, Placebo-Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus -Confirmative Study-|Completed||Phase 2|324|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||f||||||||||2018-06-01 02:23:30.445294|2018-06-01 02:23:30.445294
NCT00628199|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2009-02-20|2008-02-22|2008-03-04|Estimate|||||||2009-02-20|2009-02-24|Estimate|September 2007||2007-09-30|February 2009|2009-02-28||||January 2010|Anticipated|2010-01-31||Observational|||Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability|Derivation of Primary Donor Cell Lines for Human Cell Reprogramming|Unknown status|Enrolling by invitation||60|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 02:23:31.607718|2018-06-01 02:23:31.607718
NCT00628186|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2010-01-15|2008-03-03|2008-03-04|Estimate|||||||2010-01-15|2010-01-18|Estimate|April 2005||2005-04-30|January 2010|2010-01-31|February 2008|Actual|2008-02-29|August 2007|Actual|2007-08-31||Interventional|||Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy|Prospective, Randomized, and Controlled Trial That Lost Stent Versus External Stent of Pancreaticojejunostomy After Pancreaticoduodenectomy|Completed||N/A|100|Actual|Wakayama Medical University||1|||f||||t||||||||||2018-06-01 02:23:31.692233|2018-06-01 02:23:31.692233
NCT00628173|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-10-16|2008-02-25|2008-03-04|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2005||2005-01-31|February 2008|2008-02-29|December 2007||2007-12-31|May 2007||2007-05-31||Interventional|||Results of Different Location of Ahmed Glaucoma Valve Implantation in Refractory Glaucoma, Superior Versus Inferior||Completed||N/A|106|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 02:23:31.829766|2018-06-01 02:23:31.829766
NCT00628160|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2016-02-23|2008-03-03|2008-03-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Terlipressin in Septic Shock in Cirrhosis|Effects on Survival of Terlipressin Administration in Cirrhotic Patients With Severe Sepsis or Septic Shock. A Randomized, Open Labelled Controlled Trial|Completed||Phase 2/Phase 3|72|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||Yes|We are currently writing the manuscript|2018-06-01 02:23:33.025868|2018-06-01 02:23:33.025868
NCT00628147|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2017-01-17||2017-01-17|2008-03-03|2008-03-04|Estimate|2017-01-17|2017-03-08|Actual||||2017-01-17|2017-03-08|Actual|January 2006||2006-01-31|January 2017|2017-01-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Clinical Evaluation of Narrow Band Imaging Colonoscope|Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates|Completed||Phase 4|284|Actual|VA Palo Alto Health Care System||2|||f||||t||||||||No||2018-06-01 02:23:33.613519|2018-06-01 02:23:33.613519
NCT00628134|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2013-06-19||2017-07-24|2008-02-22|2008-03-04|Estimate|2013-09-03|2013-11-07|Estimate||||2017-07-24|2017-08-24|Actual|March 2008||2008-03-31|July 2017|2017-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Cystic fibrosis subjects|Self-dispersing Liquids as Aerosol Drug Carriers|Self-dispersing Liquids as Aerosol Drug Carriers|Completed||N/A|8|Actual|University of Pittsburgh|Our aerosol delivery method resulted in more peripheral distribution than was anticipated. The more peripheral deposition pattern likely affected the location and quantity of deposited calfactant available to cause transport.|2|||f||||t||||||||Yes||2018-06-01 02:23:33.993552|2018-06-01 02:23:33.993552
NCT00628121|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2008-02-25|2008-02-25|2008-03-04|Estimate|||||||2008-02-25|2008-03-04|Estimate|April 2006||2006-04-30|February 2008|2008-02-29|February 2007|Actual|2007-02-28|||||Interventional|||Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer|Clinical Pharmacological Study of NS75A for Healthy Adult Women|Completed||N/A|31|Actual|Nippon Kayaku Co.,Ltd.||3|||f||||f||||||||||2018-06-01 02:23:34.205995|2018-06-01 02:23:34.205995
NCT00628108|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2009-09-09||2015-02-18|2008-02-22|2008-03-04|Estimate|2009-09-09|2009-10-14|Estimate||||2015-02-18|2015-03-06|Estimate|March 2008||2008-03-31|February 2015|2015-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|BALL||Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria.|Completed||Phase 3|69|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 02:23:34.350611|2018-06-01 02:23:34.350611
NCT00628095|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25||2009-04-13|2009-10-07|2008-02-25|2008-03-04|Estimate||||2009-10-07|2009-10-12|Estimate|2009-10-07|2009-10-12|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CE-224,535, An Antagonist Of The P2x7 Receptor, In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate|Completed||Phase 2/Phase 3|100|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:23:35.277279|2018-06-01 02:23:35.277279
NCT00628082|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2008-02-24|2008-02-24|2008-03-04|Estimate|||||||2008-02-24|2008-03-04|Estimate|March 2006||2006-03-31|February 2008|2008-02-29|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Observational|||Energetic Abnormalities in Heart Failure With Preserved Ejection Fraction|Energetic Abnormalities in Heart Failure With Preserved Ejection Fraction|Unknown status|Recruiting||50|Anticipated|University Hospital Birmingham|||2||f||||f||||||||||2018-06-01 02:23:35.470927|2018-06-01 02:23:35.470927
NCT00628069|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2012-09-04|2008-02-25|2008-03-04|Estimate|||||||2012-09-04|2012-09-05|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||The Effect of Bench-model Training in Cognitive Learning in the Operating Room|The Effect of Bench-model Training in Cognitive Learning in the Operating Room|Completed|||30|Actual|The Physicians' Services Incorporated Foundation|||2||f||||||||||||||2018-06-01 02:23:35.819373|2018-06-01 02:23:35.819373
NCT00628056|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2008-02-24|2008-02-24|2008-03-04|Estimate|||||||2008-02-24|2008-03-04|Estimate|October 2006||2006-10-31|February 2008|2008-02-29|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|DDCM||Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes|Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes|Unknown status|Recruiting|Phase 1/Phase 2|75|Anticipated|University Hospital Birmingham||2|||f||||f||||||||||2018-06-01 02:23:35.90974|2018-06-01 02:23:35.90974
NCT00628043|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2009-09-17|2008-03-03|2008-03-04|Estimate|||||||2009-09-17|2009-09-18|Estimate|May 2008||2008-05-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients|A Phase Ⅲ Randomized Double-Blind Placebo-Controlled Study of Epoetin Beta for the Treatment of Chemotherapy-Induced Anemia (CIA) in Cancer Patients|Completed||Phase 3|160|Anticipated|Chugai Pharmaceutical||2|||f||||||||||||||2018-06-01 02:23:36.029613|2018-06-01 02:23:36.029613
NCT00628030|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2014-01-06||2015-01-09|2008-03-03|2008-03-04|Estimate|2015-01-05|2015-01-09|Estimate||||2015-01-09|2015-01-19|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|NOURISH|Families completed baseline, post, and six-month follow-up assessments. Although baseline and outcome data for parents and children were collected, only parents participated in the intervention: NOURISH (n = 92; 44 parents/caregivers, 48 children). Wellness Group (n = 92; 47 parents/caregivers, 45 children).|NOURISH: Nourishing Our Understanding of Role Modeling to Improve Support and Health|Parent Skills Training to Enhance Weight Loss in Overweight Children|Completed||N/A|184|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 02:23:36.139358|2018-06-01 02:23:36.139358
NCT00628017|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2008-02-24|2008-02-24|2008-03-04|Estimate|||||||2008-02-24|2008-03-04|Estimate|January 2003||2003-01-31|February 2008|2008-02-29|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Preliminary Study of Fish Oil and Dementia|The Effects of Omega-3 Fatty Acids Monotherapy in Alzheimer's Disease and Mild Cognitive Impairment: a Preliminary Randomized Double-Blind Placebo-Controlled Study|Completed||N/A|46|Actual|Taipei City Psychiatric Center, Taiwan||2|||f||||f||||||||||2018-06-01 02:23:36.433439|2018-06-01 02:23:36.433439
NCT00628004|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-04-25|2008-03-03|2008-03-04|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2008||2008-05-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Safety Evaluation of Biatain Ibu in Painful Chronic Venous Leg Ulcers|An Open Label Extension Study (to Study DK143WS) Evaluating the Safety and Long-term Safety Follow-up of Biatain Ibu in Painful Chronic Venous Leg Ulcers|Completed||N/A|93|Actual|Coloplast A/S||3|||f||||f|f|f||||||||2018-06-01 02:23:36.645039|2018-06-01 02:23:36.645039
NCT00627991|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2016-04-12|2008-02-22|2008-03-04|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2007||2007-08-31|April 2016|2016-04-30||||||||Interventional|||Blood Pressure Lowering in Acute Stroke Trial (BLAST)|The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Effects on Cerebral Blood Flow.|Withdrawn||N/A|0|Actual|Stanford University|||||f||||||||||||||2018-06-01 02:23:37.04197|2018-06-01 02:23:37.04197
NCT00627978|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2017-02-02||2017-06-13|2008-03-03|2008-03-04|Estimate|2017-06-13|2017-07-13|Actual||||2017-06-13|2017-07-13|Actual|November 2007||2007-11-30|June 2017|2017-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons|Phase II Study of Ixabepilone in Patients With Metastatic Breast Cancer and a Prospective Evaluation of Its Effects on the Ultrastructure of Neurons|Completed||Phase 2|15|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-06-01 02:23:37.161531|2018-06-01 02:23:37.161531
NCT00627965|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2008-02-24|2008-02-24|2008-03-04|Estimate|||||||2008-02-24|2008-03-04|Estimate|March 2003||2003-03-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|||||Interventional|||Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness|Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness|Completed||Phase 4|62|Actual|Altitude Physiology Expeditions||2|||f||||f||||||||||2018-06-01 02:23:37.636863|2018-06-01 02:23:37.636863
NCT00627770|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-01-28|2008-02-22|2008-03-03|Estimate|||||||2009-01-28|2009-01-29|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Lower Leg Edema Evaluation After Total Knee Arthroplasty Using Bioimpedance|Validation of a Procedure Using Bioimpedance to Measure the Edema of Lower Leg of Patients After Total Knee Surgery|Completed||N/A|34|Actual|Haute Ecole Cantonale Vaudoise de Santé|||||f||||f||||||||||2018-06-01 02:23:42.140557|2018-06-01 02:23:42.140557
NCT00627952|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2013-01-18|2008-02-24|2008-03-04|Estimate|||||||2013-01-18|2013-01-21|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Evaluate the Effects of Manidipine Versus Amlodipine and the Combination of Manidipine Plus Delapril Versus Amlodipine Plus Delapril on Intraglomerular Pressure in Hypertensive Patients|Double Blind, Randomized, Parallel Group, Multicentre Study to Evaluate the Effects of Manidipine 20 MG Vs. Amlodipine 10 MG and the Combination of Manidipine 10 MG Plus Delapril 30 MG Vs. Amlodipine 5 MG Plus Delapril 30 MG on Intraglomerular Pressure in Hypertensive Patients|Completed||Phase 3|100|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-06-01 02:23:37.725694|2018-06-01 02:23:37.725694
NCT00627926|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2011-06-22||2014-07-16|2008-02-22|2008-03-04|Estimate|2011-06-22|2011-07-21|Estimate||||2014-07-16|2014-08-08|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||The full analysis (FA) set included all randomized subjects who received at least 1 dose of any study drug.|A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)|A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C|Completed||Phase 3|1095|Actual|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-06-01 02:23:37.913122|2018-06-01 02:23:37.913122
NCT00627913|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|||2017-11-21|2008-02-25|2008-03-04|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2008||2008-02-29|November 2017|2017-11-30|November 11, 2010|Actual|2010-11-11|November 11, 2010|Actual|2010-11-11||Interventional|||Retrobulbar Injection of Anesthesia Versus Healon 5 in the Management of Intraoperative Floppy Iris Syndrome|Retrobulbar Injection of Anesthesia Versus Injection of Healon 5 Viscoelastic Into the Anterior Chamber in the Management of Intraoperative Floppy Iris Syndrome|Terminated||N/A|6|Actual|Penn State University||2||Study terminated due to insufficient subject participation|f||||t||||||||||2018-06-01 02:23:39.898319|2018-06-01 02:23:39.898319
NCT00627900|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2008-02-24|2008-02-24|2008-03-04|Estimate|||||||2008-02-24|2008-03-04|Estimate|April 2003||2003-04-30|February 2008|2008-02-29||||September 2008|Anticipated|2008-09-30||Interventional|GERSHWIN||Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents|Model Project for the Reduction of Coronary Restenosis|Completed||Phase 4|958|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 02:23:40.245109|2018-06-01 02:23:40.245109
NCT00627887|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2012-06-20|2008-02-25|2008-03-04|Estimate|||||||2012-06-20|2012-06-22|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression|Randomised Controlled Trial of Electroconvulsive Therapy (ECT) With Pharmacotherapy or Pharmacotherapy Alone in Relapse Prevention of Depression|Completed||Phase 4|56|Actual|Örebro County Council||2|||f||||f||||||||||2018-06-01 02:23:40.650288|2018-06-01 02:23:40.650288
NCT00627874|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2009-02-20|2008-02-24|2008-03-04|Estimate|||||||2009-02-20|2009-02-24|Estimate|April 2010||2010-04-30|February 2009|2009-02-28|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|PLS||Trial of Myopia Prevention Using +3D Lenses|A Randomised, Controlled Trial of Prevention of Juvenile-Onset Myopia in Chinese Children|Unknown status|Not yet recruiting|N/A|1200|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-06-01 02:23:40.903806|2018-06-01 02:23:40.903806
NCT00627861|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|2011-08-19||2015-10-26|2008-02-24|2008-03-04|Estimate|2011-08-19|2011-09-28|Estimate||||2015-10-26|2015-11-24|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Combined Renin Inhibition/Beta-blockade|Renin System Responses to Combined Renin Inhibition and Beta Adrenergic Blockade|Terminated||N/A|1|Actual|The Rogosin Institute||1||The renin laboratory used in the study is no longer available.|f||||f||||||||||2018-06-01 02:23:41.04396|2018-06-01 02:23:41.04396
NCT00627848|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2011-10-27|2008-02-22|2008-03-03|Estimate|||||||2011-10-27|2011-10-28|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ADFRMI||Rivastigmine in Mild Alzheimer's Disease, FMRI Study|Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease|Completed||N/A|20|Actual|Kuopio University Hospital|||||f||||f||||||||||2018-06-01 02:23:41.508785|2018-06-01 02:23:41.508785
NCT00627835|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2016-07-18|2008-02-22|2008-03-03|Estimate|||||||2016-07-18|2016-07-20|Estimate||||November 2010|2010-11-30||||||||Interventional|||Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)|A Phase I Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)|Withdrawn||Phase 1|0|Actual|British Columbia Cancer Agency||5||Site decided not to open this study|f||||f||||||||||2018-06-01 02:23:41.603341|2018-06-01 02:23:41.603341
NCT00627822|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-02-22|2008-02-22|2008-03-03|Estimate|||||||2008-02-22|2008-03-03|Estimate|March 2005||2005-03-31|February 2008|2008-02-29|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Medical Education in a Private Hospital|Patient and Companion Perspectives on Medical Education in a Non-Teaching Private Hospital|Completed|||209|Actual|Instituto do Cerebro de Brasilia|||3||f||||f||||||||||2018-06-01 02:23:41.721542|2018-06-01 02:23:41.721542
NCT00627809|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2009-06-22|2008-02-22|2008-03-03|Estimate|||||||2009-06-22|2009-06-23|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction|Phase 4 Study of Application of Intracoronary Low Dose Streptokinase Complementary to Standard Percutaneous Coronary Intervention in Patients With ST Elevation Acute Myocardial Infarction: Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction|Completed||Phase 4|53|Actual|Istanbul University||2|||f||||f||||||||||2018-06-01 02:23:41.800655|2018-06-01 02:23:41.800655
NCT00627796|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-02-22|2008-02-22|2008-03-03|Estimate|||||||2008-02-22|2008-03-03|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|ATG1line||Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly|A Multicenter, Open, Prospective, Observational Study to Investigate the Effect of Lanreotide Autogel 120 mg on Control of GH and IGF-I Excess and Tumor Shrinkage in Newly Diagnosed Patients With Acromegaly|Completed||Phase 4|27|Actual|Federico II University||1|||f||||f||||||||||2018-06-01 02:23:41.908083|2018-06-01 02:23:41.908083
NCT00627783|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-02-29|2008-02-29|2008-03-03|Estimate|||||||2008-02-29|2008-03-03|Estimate|December 2000||2000-12-31|February 2008|2008-02-29|July 2005||2005-07-31|July 2005||2005-07-31||Interventional|DYNAMIT||Do You Need to Assess Myocardial Ischemia in Type 2 Diabetes|Randomized Strategy Trial Comparing Detection of Silent Ischemia With no Detection of Silent Ischemia in Asymptomatic Patients With Type 2 Diabetes Mellitus. Effects on Cardiovascular Events.|Terminated||N/A|642|Actual|Hospices Civils de Lyon||2||Poor recruiting status|f||||f||||||||||2018-06-01 02:23:42.075509|2018-06-01 02:23:42.075509
NCT00627757|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2010-07-29|2008-02-29|2008-03-03|Estimate|||||||2010-07-29|2010-07-30|Estimate|February 2008||2008-02-29|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|February 2010|Anticipated|2010-02-28||Observational|AMMS1||Antipsychotic Medicine and Metabolic Syndrome|Changes in Enteroendocrine and Neuroendocrine Axes in Patients With Weight Gain After Treatment With Antipsychotics|Unknown status|Recruiting||100|Anticipated|Glostrup University Hospital, Copenhagen|||2||f||||t||||||Samples Without DNA|"~     whole blood, serum, plasma~   "|||2018-06-01 02:23:42.222622|2018-06-01 02:23:42.222622
NCT00627744|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2015-12-10|2008-02-22|2008-03-03|Estimate|||||||2015-12-10|2015-12-11|Estimate|May 2008||2008-05-31|December 2015|2015-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|BEGAMI||Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction|Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes.|Completed||Phase 4|85|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 02:23:42.362682|2018-06-01 02:23:42.362682
NCT00627731|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2011-09-05|2008-02-29|2008-03-03|Estimate|||||||2011-09-05|2011-09-07|Estimate|June 2007||2007-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients|Phase 4, Randomized Study of Oral Glucocorticosteroid Administration in the Treatment of Acute Severe Asthma Exacerbation in Hospitalized Patients|Completed||Phase 4|50|Actual|Hamamatsu University||2|||f||||f||||||||||2018-06-01 02:23:42.44676|2018-06-01 02:23:42.44676
NCT00627718|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-02-29|2008-02-29|2008-03-03|Estimate|||||||2008-02-29|2008-03-03|Estimate|April 2008||2008-04-30|February 2008|2008-02-29|July 2009|Anticipated|2009-07-31|April 2009|Anticipated|2009-04-30||Interventional|||Assessment of Macular Edema Using HRT Technique|Assessment of Macular Edema Using HRT Technique|Unknown status|Not yet recruiting|N/A|50|Anticipated|McGill University Health Center||1|||f||||f||||||||||2018-06-01 02:23:42.523398|2018-06-01 02:23:42.523398
NCT00627705|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2016-08-12||2017-04-10|2008-02-29|2008-03-03|Estimate|2017-04-10|2017-05-18|Actual||||2017-04-10|2017-05-18|Actual|February 2008||2008-02-29|April 2017|2017-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of N-Acetyl Cysteine in Children With Autism|Double-blind , Randomized, Placebo Controlled Study of N-Acetyl Cysteine in Autism.|Completed||Phase 2|43|Actual|Stanford University|The sample size was relatively small and the age range was narrow, which limits the generalizability of the findings. Most subjects were taking psychotropic medications and were receiving behavioral interventions.|2|||f||||t||||||||Yes||2018-06-01 02:23:42.61619|2018-06-01 02:23:42.61619
NCT00627692|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2008-05-28|2008-02-29|2008-03-03|Estimate|||||||2008-05-28|2008-05-29|Estimate|February 1999||1999-02-28|January 2008|2008-01-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility|A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Oral Once-Daily Prucalopride (R108512) Solution in Constipated Elderly Subjects Living in a Nursing Facility|Completed||Phase 2|100|Actual|Movetis||5|||f||||f||||||||||2018-06-01 02:23:43.170303|2018-06-01 02:23:43.170303
NCT00627679|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2013-08-19||2013-12-09|2008-02-29|2008-03-03|Estimate|2013-08-19|2013-10-23|Estimate||||2013-12-09|2014-01-09|Estimate|December 2005||2005-12-31|December 2013|2013-12-31|May 2006|Actual|2006-05-31|December 2005|Actual|2005-12-31||Interventional|UDB P101||Safety and Blood Level Study of Unit Dose Budesonide|A Randomized, Double Blind, Active Controlled, Single Dose, 4 Arm, 4 Period Crossover, Phase 1 Study Investigating the Tolerability and Pharmacokinetics of MAP0010|Completed||Phase 1|16|Actual|Allergan||4|||f||||f||||||||||2018-06-01 02:23:43.251379|2018-06-01 02:23:43.251379
NCT00627666|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2013-03-25|2008-02-29|2008-03-03|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 2003||2003-01-31|July 2009|2009-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer|Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning For Patients With Hematological Malignancies|Completed||Phase 2|52|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:23:43.60271|2018-06-01 02:23:43.60271
NCT00627653|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2009-02-18|2008-02-28|2008-03-03|Estimate|||||||2009-02-18|2009-02-19|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|PPAR||Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function|PET (Positron Emission Tomography) Detection of the Effects of Aging on the Human Heart (Aim #2 Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function)|Unknown status|Active, not recruiting|N/A|60|Anticipated|National Institute on Aging (NIA)||1|||f||||f||||||||||2018-06-01 02:23:43.728666|2018-06-01 02:23:43.728666
NCT00627640|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2013-03-27|2008-02-29|2008-03-03|Estimate|||||||2013-03-27|2013-03-29|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|SETTLE||Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa|A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine|Completed||Phase 3|549|Actual|Newron Pharmaceuticals SPA||2|||f||||||||||||||2018-06-01 02:23:43.830898|2018-06-01 02:23:43.830898
NCT00627627|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2010-02-01|2008-02-21|2008-03-03|Estimate|||||||2010-02-01|2010-02-03|Estimate|April 2008||2008-04-30|February 2010|2010-02-28||||February 2010|Anticipated|2010-02-28||Interventional|||A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer|A Phase 2, Open-Label, Single-Arm, Multicenter, Multinational Study to Evaluate the Antitumor Activity and Safety of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90(HSP90), in Patients With Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive(HER2+) Breast Cancer That Has Progressed Despite Prior Her2=Targeted Therapy|Withdrawn||Phase 1/Phase 2|56|Anticipated|MedImmune LLC||1||Redirect focus of the indication|f||||t||||||||||2018-06-01 02:23:44.073813|2018-06-01 02:23:44.073813
NCT00627614|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2015-06-01|2008-02-29|2008-03-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2006||2006-03-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer|Identification and Differentiation of Breast Masses by Vibro-Acoustography|Completed||N/A|147|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:23:44.155522|2018-06-01 02:23:44.155522
NCT00525551|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-09-10|2007-09-04|2007-09-06|Estimate|||||||2013-09-10|2013-09-11|Estimate|September 2007||2007-09-30|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy of Acetylcysteine in Patients Undergoing Surgery for Otosclerosis|Acetylcystein Vid Stapedotomi|Completed||Phase 4|152|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-06-01 02:57:08.473985|2018-06-01 02:57:08.473985
NCT00627588|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2013-05-09|2008-02-22|2008-03-03|Estimate|||||||2013-05-09|2013-05-13|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's Disease|A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin®, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.|Completed||Phase 1/Phase 2|15|Actual|Oxford BioMedica||2|||f||||t||||||||||2018-06-01 02:23:44.255494|2018-06-01 02:23:44.255494
NCT00627575|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-08-02|2008-02-20|2008-03-03|Estimate|||||||2017-08-02|2017-08-04|Actual|February 4, 2008|Actual|2008-02-04|August 2017|2017-08-31|September 12, 2008|Actual|2008-09-12|September 12, 2008|Actual|2008-09-12||Interventional|||AED/Statin Interaction Study|An Open-label, Two-cohort Study to Assess the Effect of Lamotrigine and Phenytoin on the Pharmacokinetics of Atorvastatin in Healthy Subjects|Completed||Phase 1|119|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:23:44.346876|2018-06-01 02:23:44.346876
NCT00627562|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2016-03-15|2008-02-29|2008-03-03|Estimate|||||||2016-03-15|2016-03-17|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|June 2014|Actual|2014-06-30||Interventional|||A Pilot Study of the Use of the DaVinci Robotic System for Otorhinolaryngology-Head and Neck Surgery|A Pilot Study of the Use of the DaVinci Robotic System for Otorhinolaryngology-Head and Neck Surgery|Unknown status|Active, not recruiting|N/A|71|Actual|Montefiore Medical Center||1|||f||||t||||||||||2018-06-01 02:23:44.465705|2018-06-01 02:23:44.465705
NCT00627549|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-02-29|2008-02-29|2008-03-03|Estimate|||||||2008-02-29|2008-03-03|Estimate||||February 2008|2008-02-29||||||||Interventional|||Avaulta Versus Anterior Repair|The Use of Avaulta Plus for Anterior Repair. A Multicenter Randomised Prospective Controlled Study|Unknown status|Not yet recruiting|N/A|||Zealand University Hospital||2|||f||||||||||||||2018-06-01 02:23:44.568752|2018-06-01 02:23:44.568752
NCT00627536|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-03-03|2008-02-22|2008-03-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions|A Double-Blind, Placebo-Controlled, Randomised Dose-Ranging Trial to Investigate the Efficacy of Avotermin (Juvista) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers|Completed||Phase 2|39|Actual|Renovo||8|||f||||f||||||||||2018-06-01 02:23:44.636611|2018-06-01 02:23:44.636611
NCT00627523|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2014-09-10||2014-10-27|2008-02-22|2008-03-03|Estimate|2014-09-10|2014-09-18|Estimate||||2014-10-27|2014-11-04|Estimate|February 2008||2008-02-29|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EGN||Genotropin Treatment In Very Young Children Born Small For Gestational Age|A Two Year Multicentre, Randomized Two Arm Study Of Genotropin Treatment In Very Young Children Born Small For Gestational Age: Early Growth And Neurodevelopment(Egn)|Completed||Phase 3|43|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:23:44.753041|2018-06-01 02:23:44.753041
NCT00627510|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-02-22|2008-02-22|2008-03-03|Estimate|||||||2008-02-22|2008-03-03|Estimate|June 2005||2005-06-30|February 2008|2008-02-29|December 2007|Actual|2007-12-31|July 2005|Actual|2005-07-31||Observational|||Routine Plasma Level Determination to Compare Actual vs Expected Plasma Levels at Psychiatric Inpatient Admission|Routine Plasma Level Determination to Compare Actual vs Expected Plasma Levels at Psychiatric Inpatient Admission for Determination of Compliance and/or Speed of Drug Metabolism|Completed|||161|Actual|Medical University Innsbruck|||1||f||||t||||||||||2018-06-01 02:23:45.270359|2018-06-01 02:23:45.270359
NCT00627497|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2011-11-29||2012-04-24|2008-02-21|2008-03-03|Estimate|2012-03-20|2012-04-24|Estimate||||2012-04-24|2012-04-27|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion|A Prospective, Randomized, Controlled Pivotal Clinical Investigation of DIAM™ Spinal Stabilization System in Patients With Degenerative Lumbar Spinal Stenosis.|Terminated||Phase 3|32|Actual|Medtronic Spinal and Biologics|Studies terminated before full cohort of participants were enrolled. Data and adverse events presented are through 24 months of follow-up.|4||slow patient recruitment|f||||t||||||||||2018-06-01 02:23:45.366828|2018-06-01 02:23:45.366828
NCT00627484|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-12-07|2008-02-28|2008-03-03|Estimate|||||||2017-12-07|2017-12-11|Actual|March 1, 2005|Actual|2005-03-01|December 2017|2017-12-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2017|Actual|2017-09-01||Observational|||Changes in Insulin Sensitivity After Weight Loss|Changes in Insulin Sensitivity After Weight Loss Induced by Diet or Bariatric Surgery|Active, not recruiting|||110|Anticipated|Columbia University|||5||f||||t||||||Samples With DNA|"~     The researchers may want to retain your blood and/or tissue sample(s) so that additional~     research studies can be done now or in the future.~   "|Undecided||2018-06-01 02:23:46.512295|2018-06-01 02:23:46.512295
NCT00627471|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2010-06-01|2008-02-29|2008-03-03|Estimate|||||||2010-06-01|2010-06-02|Estimate|January 2008||2008-01-31|June 2010|2010-06-30||||March 2009|Actual|2009-03-31||Interventional|Malbec||Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)|A 24 Weeks, Randomized, 2 Arms, Controlled, Multi-centre, National, Open-labeled, Parallel Study in Insulin naïve Patients With Type 2 Diabetes to Compare a Lantus Titration Algorithm vs. Physician's Standard Practice|Terminated||Phase 4|9|Actual|Sanofi||2||Low recruitment in spite of strategies implemented|f||||t||||||||||2018-06-01 02:23:46.625937|2018-06-01 02:23:46.625937
NCT00627458|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2017-04-07|2009-05-20|2017-04-07|2008-02-20|2008-03-03|Estimate|2017-04-07|2017-06-26|Actual|2009-09-29|2009-09-30|Estimate|2017-04-07|2017-06-26|Actual|February 1, 2008||2008-02-01|March 2017|2017-03-31|August 18, 2008|Actual|2008-08-18|August 18, 2008|Actual|2008-08-18||Interventional|||Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine|Immunogenicity and Reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine When Given as a Booster Dose|Completed||Phase 2|403|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:23:46.795129|2018-06-01 02:23:46.795129
NCT00627445|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2010-03-11||2014-10-14|2008-02-29|2008-03-03|Estimate|2010-03-11|2010-03-31|Estimate||||2014-10-14|2014-10-22|Estimate|February 2008||2008-02-29|October 2014|2014-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Insulin Aspart 30 Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes|Completed||Phase 3|441|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 02:23:47.768629|2018-06-01 02:23:47.768629
NCT00525538|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate|August 2006||2006-08-31|August 2007|2007-08-31||||||||Interventional|||Evaluation Conformal Radiotherapy for Gynecologic Cancer||Completed||N/A|||Istanbul University|||||f||||f||||||||||2018-06-01 02:57:08.556676|2018-06-01 02:57:08.556676
NCT00627432|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2010-10-06|2008-02-29|2008-03-03|Estimate|||||||2010-10-06|2010-10-07|Estimate|July 2004||2004-07-31|July 2009|2009-07-31||||March 2009|Anticipated|2009-03-31||Interventional|||Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer|Phase 2 Randomized Study Evaluating the Efficacy of Gemcitabine With or Without Oxaliplatin in Patients With Advanced Urothelial Cancer That Cannot be Treated With Cisplatin-based Chemotherapy|Suspended||Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:23:48.247563|2018-06-01 02:23:48.247563
NCT00627419|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21||2012-12-06|2012-12-06|2008-02-21|2008-03-03|Estimate||||2012-12-06|2012-12-10|Estimate|2012-12-06|2012-12-10|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma|A Phase 2, Open-Label, Single-Arm, Multicenter Study Evaluating the Safety and Antitumor Activity of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90 (HSP90), in Patients With Metastatic Melanoma|Terminated||Phase 2|1|Actual|Infinity Pharmaceuticals, Inc.||1||Study closed & recruitment will not recommence|f||||f||||||||||2018-06-01 02:23:48.303063|2018-06-01 02:23:48.303063
NCT00627406|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2013-09-25||2013-09-25|2008-02-29|2008-03-03|Estimate|2013-09-25|2013-11-27|Estimate||||2013-09-25|2013-11-27|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles|A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl)|Completed||Phase 4|384|Actual|Regionshospitalet Viborg, Skive||4|||f||||f||||||||||2018-06-01 02:23:48.373978|2018-06-01 02:23:48.373978
NCT00627393|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2014-12-02||2015-04-16|2008-02-28|2008-03-03|Estimate|2014-12-19|2014-12-23|Estimate||||2015-04-16|2015-04-17|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|RING|All randomized subjects.|Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)|High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes)|Completed||Phase 3|114|Actual|New England Research Institutes||3|||f||||t||||||||||2018-06-01 02:23:48.65186|2018-06-01 02:23:48.65186
NCT00627380|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2010-07-23|2008-02-28|2008-03-03|Estimate|||||||2010-07-23|2010-07-26|Estimate|November 2005||2005-11-30|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Yoga for the Management of HIV-Metabolic Syndromes|Yoga for the Management of HIV-Metabolic Syndromes|Completed||Phase 4|60|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:23:50.311356|2018-06-01 02:23:50.311356
NCT00627367|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2018-02-07||2018-04-04|2008-02-29|2008-03-03|Estimate|2018-04-04|2018-04-05|Actual||||2018-04-04|2018-04-05|Actual|December 2007|Actual|2007-12-31|April 2018|2018-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||The difference between the number of participants who enrolled and completed the study and the number of participants analyzed is due to missing outcome data. There were 4 missing data from the Protocolized group, and 2 missing data from the Nonprotocolized group, for a total of 6 patients. These 6 patients were excluded from the analysis.|Protocolized vs Nonprotocolized Treatment of Adult ED Patients With Acute Severe Pain|A Randomized Controlled Trial Comparing Protocolized Versus Non-protocolized Treatment of Adult ED Patients With Acute Severe Pain|Completed||Phase 3|224|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 02:23:50.505232|2018-06-01 02:23:50.505232
NCT00627354|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2011-05-13|2008-02-29|2008-03-03|Estimate|||||||2011-05-13|2011-05-16|Estimate|September 2006||2006-09-30|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|Phase 2 Randomized Study Evaluating 3 Chemotherapy Regimens as Second-line Treatment in Patients With Hormone-refractory Metastatic Prostate Cancer|Completed||Phase 2|90|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:23:50.930543|2018-06-01 02:23:50.930543
NCT00627341|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2012-05-10|2008-02-28|2008-03-03|Estimate|||||||2012-05-10|2012-05-11|Estimate|December 2007||2007-12-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa|Addressing Fear of Food in Anorexia Nervosa|Completed||Phase 1/Phase 2|34|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 02:23:51.01474|2018-06-01 02:23:51.01474
NCT00627328|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-02-22|2008-02-22|2008-03-03|Estimate|||||||2008-02-22|2008-03-03|Estimate|July 2000||2000-07-31|February 2008|2008-02-29|September 2004|Actual|2004-09-30|||||Observational|||The Atrial High Rate Episodes in Pacemaker Patients|The Atrial High Rate Episodes (A-HIRATE) in Pacemaker Patients|Completed|||427|Actual|Medtronic Cardiac Rhythm and Heart Failure|||2||f||||f||||||||||2018-06-01 02:23:51.11113|2018-06-01 02:23:51.11113
NCT00627315|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-12-07|2008-02-28|2008-03-03|Estimate|||||||2017-12-07|2017-12-11|Actual|March 2015||2015-03-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Prospective Study of Hormone Levels After Bariatric Surgery|Prospective Study of Hormone Levels and Appetite After Bariatric Surgery|Recruiting|||240|Anticipated|Columbia University|||1||f||||t||||||Samples With DNA|"~     blood samples~   "|Undecided||2018-06-01 02:23:51.230341|2018-06-01 02:23:51.230341
NCT00627302|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-11-20|2008-02-29|2008-03-03|Estimate|||||||2008-11-20|2008-11-24|Estimate|February 2008||2008-02-29|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision||Completed||Phase 4|40|Actual|Bp Consulting, Inc||2|||f||||||||||||||2018-06-01 02:23:51.311379|2018-06-01 02:23:51.311379
NCT00627289|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2014-04-04|2008-02-22|2008-03-03|Estimate|||||||2014-04-04|2014-04-07|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Selective Neurectomy and Mesh Removal for Chronic Postherniotomy Pain|The Effect of Selective Neurectomy and Mesh Removal on Chronic Postherniotomy Pain|Completed|||21|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-06-01 02:23:51.376866|2018-06-01 02:23:51.376866
NCT00627276|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-29|||2017-04-25|2008-02-29|2008-03-03|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2007||2007-12-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|||Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia|Omega-3 Fatty Acids and Prevention of DCIS and/or ADH: A Translational Approach|Completed||N/A|16|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 02:23:51.452944|2018-06-01 02:23:51.452944
NCT00627263|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2018-01-12|2008-02-28|2008-03-03|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2008|Actual|2008-01-31|January 2018|2018-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RISTA||Stress Reduction to Reduce Risk for Arrhythmia in ICD Patients (The RISTA Study)|Reducing Vulnerability to ICD Shock Treated Ventricular Arrhythmias|Completed||N/A|314|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:23:51.558444|2018-06-01 02:23:51.558444
NCT00627250|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2010-03-23|2008-02-28|2008-02-29|Estimate|||||||2010-03-23|2010-03-24|Estimate|March 2003||2003-03-31|February 2008|2008-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability|Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||N/A|76|Actual|Carolinas Healthcare System||2|||f||||t||||||||||2018-06-01 02:23:51.649454|2018-06-01 02:23:51.649454
NCT00627237|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2013-09-23|2008-02-28|2008-02-29|Estimate|||||||2013-09-23|2013-09-24|Estimate|January 2008||2008-01-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|STEP||"Improving Executive Functioning After Traumatic Brain Injury (TBI): A Trial of the Short Term Executive Plus Program"|Short-Term Executive Plus (STEP): A Randomized Controlled Trial of Short Term Intensive Cognitive Rehabilitation.|Completed||N/A|101|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 02:23:51.741201|2018-06-01 02:23:51.741201
NCT00627211|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2017-09-14|2008-02-28|2008-02-29|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2008||2008-02-29|September 2017|2017-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Carbon Dioxide Versus Air Insufflation in Oesophago-gastro-duodenoscopy (OGD)|A Double-blinded, Randomized Trial Comparing Carbondioxide(CO2)and Air Insufflation in Oesophago-gastro-duodenoscopy (OGD)|Completed||N/A|107|Actual|Norwegian Department of Health and Social Affairs||2|||f||||f||||||||||2018-06-01 02:23:51.954407|2018-06-01 02:23:51.954407
NCT00627185|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2015-03-05|2008-02-28|2008-02-29|Estimate|||||||2015-03-05|2015-03-09|Estimate|September 2003||2003-09-30|August 2010|2010-08-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|DTC||Dental Tobacco Control.Net:Improving Practice|Dental Tobacco Control.Net:Improving Practice|Completed||Early Phase 1|190|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 02:23:52.025195|2018-06-01 02:23:52.025195
NCT00627172|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-08-08|2008-02-20|2008-02-29|Estimate|||||||2008-08-08|2008-08-11|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|||||Observational|PECTUS||Combined Use of Coronary MDCTA, Coronary Doppler Ultrasonography and PET Perfusion in Diagnosing Coronary Artery Disease|Combined Use of Coronary MDCTA, Coronary Doppler Ultrasonography and PET Perfusion in Diagnosis of Coronary Artery Disease|Completed|||107|Actual|University of Turku|||||f||||f||||||Samples With DNA|"~     serum~   "|||2018-06-01 02:23:52.107909|2018-06-01 02:23:52.107909
NCT00627159|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-02-20|2008-02-20|2008-02-29|Estimate|||||||2008-02-20|2008-02-29|Estimate|May 2007||2007-05-31|February 2008|2008-02-29|June 2008|Anticipated|2008-06-30|April 2008|Anticipated|2008-04-30||Interventional|ICA-CHAMP||ICA-CHAMP: Indo-Central Asian Cardiovascular Health Assessment and Management Program|ICA-CHAMP: Indo-Central Asian Cardiovascular Health Assessment and Management Program|Unknown status|Active, not recruiting|N/A|375|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 02:23:52.163828|2018-06-01 02:23:52.163828
NCT00627146|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2008-09-25|2008-02-22|2008-02-29|Estimate|||||||2008-09-25|2008-09-29|Estimate|June 2000||2000-06-30|September 2008|2008-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients|Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients|Completed||Phase 2|80|Actual|AZ-VUB||2|||f||||f||||||||||2018-06-01 02:23:52.247822|2018-06-01 02:23:52.247822
NCT00627133|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-10-23|2008-02-28|2008-02-29|Estimate|||||||2008-10-23|2008-10-24|Estimate|February 2008||2008-02-29|February 2008|2008-02-29||||July 2008|Anticipated|2008-07-31||Interventional|||Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study|A Pilot Study Examining the Efficacy of Keppra in Acute Alcohol Related Seizure Control in the Emergency Department Setting|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Medical University of South Carolina||1|||f||||f||||||||||2018-06-01 02:23:52.351352|2018-06-01 02:23:52.351352
NCT00627120|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2009-01-08|2008-02-20|2008-02-29|Estimate|||||||2009-01-08|2009-01-09|Estimate|February 2008||2008-02-29|January 2009|2009-01-31||||September 2008|Actual|2008-09-30||Interventional|||Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy Subjects|A Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety and Pharmacokinetics of VGX-1027 in Healthy Subjects|Completed||Phase 1|48|Anticipated|VGX Pharmaceuticals, LLC||6|||f||||f||||||||||2018-06-01 02:23:52.42796|2018-06-01 02:23:52.42796
NCT00627107|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2010-11-27|2008-02-21|2008-02-29|Estimate|||||||2010-11-27|2010-11-30|Estimate|February 2008||2008-02-29|November 2010|2010-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|RW||A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit|Study of the ReWalk Motorized Exoskeleton Suit That Enables Individuals With Lower Limbs Impairment to Walk and to Perform Other Basic Mobility Functions.|Completed||N/A|6|Anticipated|ReWalk Robotics, Inc.||1|||f||||t||||||||||2018-06-01 02:23:52.504837|2018-06-01 02:23:52.504837
NCT00627094|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2015-09-03||2017-08-17|2008-02-20|2008-02-29|Estimate|2016-12-14|2017-02-07|Estimate||||2017-08-17|2017-09-15|Actual|March 2008||2008-03-31|August 2017|2017-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers|A Randomised, Controlled and Double-blind Clinical Investigation on the Effectiveness and Safety of a Foam Dressing Biatain Ibu Non-adhesive vs. Biatain Non-adhesive, in Painful Chronic Venous Leg Ulcers|Completed||N/A|120|Actual|Coloplast A/S||2|||f||||f||||||||No||2018-06-01 02:23:52.600612|2018-06-01 02:23:52.600612
NCT00627081|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2016-09-22|2008-02-20|2008-02-29|Estimate|||||||2016-09-22|2016-09-23|Estimate|February 2008||2008-02-29|September 2016|2016-09-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|Drone-APDT||Effect of Thoracic Epidural Analgesia on Intravenous Closed-Loop Anesthesia|Intravenous Opioid-sparing Effect of Thoracic Epidural Administration of Chirocaine (5 mg/ml) During Thoracotomy|Completed||Phase 4|40|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 02:23:52.972362|2018-06-01 02:23:52.972362
NCT00627068|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2011-09-16|2008-02-28|2008-02-29|Estimate|||||||2011-09-16|2011-09-20|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function|The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function|Completed|||60|Actual|University of California, San Francisco|||4||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 02:23:53.059962|2018-06-01 02:23:53.059962
NCT00627055|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2011-02-03|2008-02-28|2008-02-29|Estimate|||||||2011-02-03|2011-02-07|Estimate|May 2008||2008-05-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens|The HIV Second-line Therapy AntiRetroviral Study in Patients Who Failed NNRTI-based Regimens|Completed||Phase 4|200|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-06-01 02:23:53.133225|2018-06-01 02:23:53.133225
NCT00627042|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|2014-05-16|2010-08-25|2014-09-29|2008-02-28|2008-02-29|Estimate|2014-07-01|2014-07-03|Estimate|2010-08-25|2010-08-27|Estimate|2014-09-29|2014-10-08|Estimate|February 2008||2008-02-29|September 2014|2014-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Participants who received at least 1 dose of ramucirumab.|Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy|An Open Label, Multicenter, Phase 2 Study Evaluating the Safety and Efficacy of IMC-1121B as First Line Monotherapy in Patients With Unresectable Hepatocellular Cancer|Completed||Phase 2|42|Actual|Eli Lilly and Company|The duration of response results should be interpreted with caution since the sample size for this analysis was very small (2 participants).|1|||f||||f||||||||||2018-06-01 02:23:53.252948|2018-06-01 02:23:53.252948
NCT00627029|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2015-09-29|2008-02-28|2008-02-29|Estimate|||||||2015-09-29|2015-10-01|Estimate|September 2000||2000-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|August 2015|Actual|2015-08-31||Interventional|Coca||Evaluation of Programs of Coordinated Care and Disease Management|Evaluation of Programs of Coordinated Care and Disease Management|Unknown status|Active, not recruiting|N/A|18277|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-06-01 02:23:53.639992|2018-06-01 02:23:53.639992
NCT00627016|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2010-03-18||2011-04-25|2008-02-28|2008-02-29|Estimate|2010-04-15|2010-05-06|Estimate||||2011-04-25|2011-04-28|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn|A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|305|Actual|Takeda||2|||f||||f||||||||||2018-06-01 02:23:53.838078|2018-06-01 02:23:53.838078
NCT00627003|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2011-04-22|2008-02-19|2008-02-29|Estimate|||||||2011-04-22|2011-04-25|Estimate|November 2002||2002-11-30|April 2011|2011-04-30|May 2003|Actual|2003-05-31|||||Interventional|||A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS|A Double-blind, Randomized, Placebo-controlled Multicenter Efficacy Study for the Treatment of Patients With Restless Legs Syndrome (RLS)|Completed||Phase 3|43|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:23:54.441223|2018-06-01 02:23:54.441223
NCT00626990|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-07-26|2008-02-28|2008-02-29|Estimate|||||||2017-07-26|2017-07-27|Actual|December 2007|Actual|2007-12-31|July 2017|2017-07-31|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31||Interventional|CATNON||Phase III Trial of Anaplastic Glioma Without 1p/19q LOH|Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.|Active, not recruiting||Phase 3|751|Actual|European Organisation for Research and Treatment of Cancer - EORTC||4|||f||||t||||||||||2018-06-01 02:23:54.55635|2018-06-01 02:23:54.55635
NCT00626977|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2015-07-07|2008-02-28|2008-02-29|Estimate|||||||2015-07-07|2015-07-08|Estimate|May 2000||2000-05-31|February 2008|2008-02-29|December 2001|Actual|2001-12-31|May 2000|Actual|2000-05-31||Observational|LA||Labor Analgesia With Ropivacaine and Clonidine|Labor Analgesia With Ropivacaine Added to Clonidine. A Randomized Clinical Trial|Completed|||32|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||t||||||||||2018-06-01 02:23:54.839339|2018-06-01 02:23:54.839339
NCT00626964|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-05-11|2008-02-28|2008-02-29|Estimate|||||||2017-05-11|2017-05-12|Actual|February 2008||2008-02-29|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|SphCor||Prevention of Coronary Heart Disease in Morbidly Obese Patients|Prevention of Coronary Heart Disease in Morbidly Obese Patients. Lifestyle Intervention, Low Energy Diet or Bariatric Surgery.|Active, not recruiting|||200|Actual|The Hospital of Vestfold|||1||f||||f||||||Samples With DNA|"~     Blood samples to biobank.~   "|No||2018-06-01 02:23:54.91418|2018-06-01 02:23:54.91418
NCT00626951|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2008-06-25|2008-02-20|2008-02-29|Estimate|||||||2008-06-25|2008-07-03|Estimate|December 2007||2007-12-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Supreme||Crossover Study With the ProSeal and Supreme Laryngeal Mask Airway|The Supreme Laryngeal Mask Airway. A Randomized, Crossover Study With the ProSeal Laryngeal Mask Airway in Paralyzed, Anesthetized Patients|Completed||N/A|94|Actual|Medical University Innsbruck||2|||f||||f||||||||||2018-06-01 02:23:54.990802|2018-06-01 02:23:54.990802
NCT00626938|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2012-11-05|2008-02-28|2008-02-29|Estimate|||||||2012-11-05|2012-11-07|Estimate|March 2005||2005-03-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Role of Proteomics in Diagnosing Sarcoidosis|Proteomics as a Tool for Biomarker Detection in Sarcoidosis|Completed|||1000|Actual|Maastricht University Medical Center|||2||f||||f||||||Samples With DNA|"~     Blood will be collected from all participants, but all samples will be stored anonymously.~   "|||2018-06-01 02:23:55.073344|2018-06-01 02:23:55.073344
NCT00626925|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2016-04-08||2018-02-07|2008-02-21|2008-02-29|Estimate|2016-08-02|2016-08-03|Estimate||||2018-02-07|2018-03-08|Actual|February 2008||2008-02-29|February 2018|2018-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||In the Total topiramate and Placebo group e included all subjects enrolled who were randomized into the study based.|Topiramate Treatment of Problem Drinkers|Topiramate Treatment of Problem Drinkers|Completed||Phase 4|200|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 02:23:55.184|2018-06-01 02:23:55.184
NCT00626912|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2016-08-03|2008-02-21|2008-02-29|Estimate|||||||2016-08-03|2016-08-05|Estimate|June 2007||2007-06-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|PRET||PRET: Patients Prone to Recurrence After Endovascular Treatment|PRET: Patients Prone to Recurrence After Endovascular Treatment. A Randomized Trial Comparing Platinum and Hydrogel-coated Coils|Completed||Phase 4|447|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-06-01 02:23:55.878015|2018-06-01 02:23:55.878015
NCT00626899|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2010-01-13|2008-02-20|2008-02-29|Estimate|||||||2010-01-13|2010-01-14|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Observational|||Comparison Performance Vigileo vs. Continuous CCO (Vigilance) in Patients With Induced Therapeutic Hypothermia|Comparison of the Performance of a New Pulse-contour Analysis Cardiac Output Measurement (Vigileo) With the Traditional Method in Patients With Induced Therapeutic Hypothermia After Cardiac Arrest|Completed|||8|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 02:23:56.011613|2018-06-01 02:23:56.011613
NCT00626886|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2013-04-29|2008-02-20|2008-02-29|Estimate|||||||2013-04-29|2013-04-30|Estimate|January 2008||2008-01-31|April 2013|2013-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy|A Phase II, Randomized, Single Dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx® Bupivacaine Implant in Men After Open Mesh Herniorrhaphy|Completed||Phase 2|53|Actual|Innocoll||2|||f||||f||||||||||2018-06-01 02:23:56.06482|2018-06-01 02:23:56.06482
NCT00626873|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2017-04-14|2008-02-28|2008-02-29|Estimate|||||||2017-04-14|2017-04-18|Actual|January 2007||2007-01-31|October 2008|2008-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary|Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer|Completed||Phase 1|67|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f|t|f||||||||2018-06-01 02:23:56.1508|2018-06-01 02:23:56.1508
NCT00626860|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2017-03-24|2008-02-21|2008-02-29|Estimate|||||||2017-03-24|2017-03-28|Actual|July 2000||2000-07-31|March 2017|2017-03-31|September 10, 2008|Actual|2008-09-10|January 2002|Actual|2002-01-31||Interventional|||The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma|The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma|Completed||Phase 1/Phase 2|20|Anticipated|Beth Israel Deaconess Medical Center|||||f||||t||||||||||2018-06-01 02:23:56.311138|2018-06-01 02:23:56.311138
NCT00626847|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2016-11-17|2008-02-28|2008-02-29|Estimate|||||||2016-11-17|2016-11-21|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||How Does Your Genetic Make-up (Profile) Influence Your Glaucoma?|Nuclear Genetic and Mitochondrial Influences in Glaucoma|Completed|||97|Actual|Wills Eye|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|Yes|Two manuscripts have been written and published.|2018-06-01 02:23:56.374858|2018-06-01 02:23:56.374858
NCT00626834|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2017-01-11|2008-02-28|2008-02-29|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2008||2008-02-29|August 2016|2016-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Vigabatrin Ph 1 Cocaine Interaction Study|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study|Completed||Phase 1|24|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||t||||||||No||2018-06-01 02:23:56.43556|2018-06-01 02:23:56.43556
NCT00626821|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2011-10-06||2012-02-09|2008-02-21|2008-02-29|Estimate|2012-02-09|2012-03-12|Estimate||||2012-02-09|2012-03-12|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Coloplast DialogueStudy|An Open Label, Non-comparative, Multi-national Post-Market Study to Document Real Life Experience on SenSura With Focus on Skin Condition and Quality of Life|Completed||Phase 4|3017|Actual|Coloplast A/S||1|||f||||f||||||||||2018-06-01 02:23:56.515751|2018-06-01 02:23:56.515751
NCT00626808|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2014-07-21||2014-07-21|2008-02-20|2008-02-29|Estimate|2014-07-21|2014-08-12|Estimate||||2014-07-21|2014-08-12|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children|A Post Marketing Evaluation of the Effectiveness of the Risk Minimization Plan For Use of FluMist Among Children Less Than 5 Years of Age|Completed|||321697|Actual|MedImmune LLC|||4||f||||f||||||||||2018-06-01 02:23:56.706727|2018-06-01 02:23:56.706727
NCT00626795|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2013-11-22|2008-02-21|2008-02-29|Estimate|||||||2013-11-22|2013-11-25|Estimate|February 2008||2008-02-29|November 2013|2013-11-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)|Efficacy, Safety and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)|Completed||Phase 2|682|Actual|LEO Pharma||3|||f||||t||||||||||2018-06-01 02:23:57.312657|2018-06-01 02:23:57.312657
NCT00626782|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2015-02-11||2018-02-23|2008-02-20|2008-02-29|Estimate|2015-03-12|2015-03-13|Estimate||||2018-02-23|2018-03-22|Actual|January 2008||2008-01-31|February 2018|2018-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Lucentis Versus Mitomycin C During Glaucoma Surgery|Lucentis Versus Mitomycin C as Adjunctive Agent During Trabeculectomy Surgery|Completed||Phase 2/Phase 3|24|Actual|Wills Eye|Small sample size. Different surgical techniques among multiple surgeons.|2|||f||||f||||||||No||2018-06-01 02:23:57.407479|2018-06-01 02:23:57.407479
NCT00626769|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2009-05-18|2008-02-28|2008-02-29|Estimate|||||||2009-05-18|2009-05-19|Estimate|July 2005||2005-07-31|May 2009|2009-05-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Observational|||Third Year Evaluation on Genistein Efficacy and Safety|Safety Profile and Bone Efficacy of the Phytoestrogen Genistein in a Cohort of Osteopenic, Postmenopausal Women After Three Years of Treatment: a Follow-up Study|Completed|||138|Actual|University of Messina|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, urine.~   "|||2018-06-01 02:23:57.699537|2018-06-01 02:23:57.699537
NCT00626756|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2008-02-28|2008-02-28|2008-02-29|Estimate|||||||2008-02-28|2008-02-29|Estimate|January 2008||2008-01-31|February 2008|2008-02-29||||December 2008|Anticipated|2008-12-31||Interventional|LIGA||Lithium Dilution Method in Guiding Fluid Therapy in Critically Ill Patients|LIGA Trial-Lithium Dilution Method in Guiding Fluid Therapy in Critically Ill Patients|Unknown status|Recruiting|N/A|15|Anticipated|ASQA a.s.||2|||f||||f||||||||||2018-06-01 02:23:57.785358|2018-06-01 02:23:57.785358
NCT00626743|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2014-03-13||2014-03-13|2008-02-28|2008-02-29|Estimate|2014-03-13|2014-04-21|Estimate||||2014-03-13|2014-04-21|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|July 2011|Actual|2011-07-31|May 2009|Actual|2009-05-31||Interventional|||Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine|Clinical Trial to Investigate the Influence of SK3530 on the Blood Pressure of Patients With Hypertension Taking Amlodipine|Completed||Phase 1|13|Actual|SK Chemicals Co.,Ltd.||2|||f||||||||||||||2018-06-01 02:23:57.871334|2018-06-01 02:23:57.871334
NCT00626730|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2014-07-16|2008-02-28|2008-02-29|Estimate|||||||2014-07-16|2014-07-18|Estimate|December 2007||2007-12-31|July 2014|2014-07-31||||February 2013|Actual|2013-02-28||Interventional|||Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma|Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study|Completed||Phase 2|78|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 02:23:58.078962|2018-06-01 02:23:58.078962
NCT00626717|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2013-01-16|2008-02-28|2008-02-29|Estimate|||||||2013-01-16|2013-01-17|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CCL||Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus|Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus|Completed||Phase 2/Phase 3|30|Actual|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 02:23:58.143164|2018-06-01 02:23:58.143164
NCT00626704|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14||2015-03-24|2015-05-07|2008-02-21|2008-02-29|Estimate||||2015-03-24|2015-04-14|Estimate|2015-05-07|2015-05-25|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|March 2011|Actual|2011-03-31|August 2009|Actual|2009-08-31||Interventional|||Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma|A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma|Completed||Phase 1/Phase 2|134|Actual|Amgen||2|||f||||f||||||||||2018-06-01 02:23:58.204089|2018-06-01 02:23:58.204089
NCT00626691|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2009-02-18|2008-02-28|2008-02-29|Estimate|||||||2009-02-18|2009-02-19|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effects of Walnuts on Antioxidant Capacity and Nutritional Status in Humans|The Effects of Walnuts on Antioxidant Capacity and Nutritional Status in Humans|Completed||N/A|24|Actual|Tufts University|||||f||||t||||||||||2018-06-01 02:23:58.270684|2018-06-01 02:23:58.270684
NCT00626678|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2010-11-26|2008-02-28|2008-02-29|Estimate|||||||2010-11-26|2010-11-30|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2008|Actual|2008-09-30||Interventional|||Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone|A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Adjuvant Azathioprine Therapy in New Cases of Pemphigus Vulgaris Receiving Prednisone|Completed||Phase 2|48|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:23:58.328215|2018-06-01 02:23:58.328215
NCT00626665|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2013-03-21|2008-02-28|2008-02-29|Estimate|||||||2013-03-21|2013-03-22|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma|Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma|Completed||Phase 3|25|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||1|||f||||f||||||||||2018-06-01 02:23:58.4157|2018-06-01 02:23:58.4157
NCT00626652|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2010-01-07|2008-02-20|2008-02-29|Estimate|||||||2010-01-07|2010-01-08|Estimate|March 2008||2008-03-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|RESTORATION||Study of K201 Injection on Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Effects of K201 Injection, 2 mg/mL on the Restoration of Sinus Rhythm in Subjects Who Are in Atrial Fibrillation|Completed||Phase 2|153|Actual|Sequel Pharmaceuticals, Inc||1|||f||||f||||||||||2018-06-01 02:23:58.488573|2018-06-01 02:23:58.488573
NCT00626639|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2014-01-24||2017-05-29|2008-02-21|2008-02-29|Estimate|2014-01-24|2014-03-06|Estimate||||2017-05-29|2017-06-21|Actual|July 2005||2005-07-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|May 2007|Actual|2007-05-31||Interventional|||A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy|A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy With Concurrent Chemotherapy|Completed||Phase 1/Phase 2|5|Actual|Swedish Orphan Biovitrum|Pharmacokinetic, pharmacodynamic, safety and efficacy endpoints were not evaluable due to the limited number of subjects enrolled.|2|||f||||t||||||||||2018-06-01 02:23:58.562334|2018-06-01 02:23:58.562334
NCT00626626|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2014-05-07||2018-03-23|2008-02-20|2008-02-29|Estimate|2018-03-23|2018-04-25|Actual||||2018-03-23|2018-04-25|Actual|May 2007||2007-05-31|March 2018|2018-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation|Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation|Terminated||Phase 1/Phase 2|8|Actual|Milton S. Hershey Medical Center||2||Investigator decision|f||||t||||||||No||2018-06-01 02:23:58.842532|2018-06-01 02:23:58.842532
NCT00626613|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-29|2008-02-28|2008-02-29|Estimate|||||||2008-02-29|2008-03-05|Estimate||||February 2008|2008-02-29||||||||Interventional|||The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)|Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN)|Unknown status|Active, not recruiting|Phase 4|||Jinan Mental Hospital|||||f||||||||||||||2018-06-01 02:23:59.192933|2018-06-01 02:23:59.192933
NCT00626600|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2012-10-25|2008-02-28|2008-02-29|Estimate|||||||2012-10-25|2012-10-26|Estimate|May 2008||2008-05-31|October 2012|2012-10-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion|An Open, Multi-centre, Non-comparative Observational Study to Assess the Safety and Tolerability of Oxycodone Injection 50 mg/mL as a Subcutaneous Infusion in Patients With Severe Cancer Pain.|Terminated||Phase 3|33|Actual|Mundipharma Research Limited||||Lack of recruitment|f||||||||||||||2018-06-01 02:23:59.27055|2018-06-01 02:23:59.27055
NCT00626587|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2008-02-28|2008-02-28|2008-02-29|Estimate|||||||2008-02-28|2008-02-29|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||EBUS-Guided TBNA Increases the Diagnostic Yield of Peripheral Pulmonary Lesions|Endobronchial Ultrasonography-Guided Transbronchial Needle Aspiration Increases the Diagnostic Yield of Peripheral Pulmonary Lesions : A Randomized Trial|Completed||N/A|182|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 02:23:59.372555|2018-06-01 02:23:59.372555
NCT00626574|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2011-09-08||2012-09-25|2008-02-28|2008-02-29|Estimate|2012-09-25|2012-10-29|Estimate||||2012-09-25|2012-10-29|Estimate|July 2007||2007-07-31|September 2012|2012-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|EPO||Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa|A Double Blinded, Placebo Controlled, Pilot Study to Evaluate the Safety of Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa|Terminated||Phase 4|3|Actual|University of South Florida|In late October 2008, we received a letter from the sponsor requesting that we terminate any further work on this study.|2||"This study is terminated as a result of data from a study that showed increased mortality in~   stroke patients."|f||||t||||||||||2018-06-01 02:23:59.460933|2018-06-01 02:23:59.460933
NCT00626561|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2014-06-05||2014-06-05|2008-02-20|2008-02-29|Estimate|2014-06-05|2014-07-07|Estimate||||2014-06-05|2014-07-07|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||One participant not treated.|Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix|A Phase II Evaluation of Bevacizumab and Paclitaxel in Patients With Recurrent Small Cell, Large Cell, and Neuroendocrine Tumors of the Cervix and Uterus|Terminated||Phase 2|4|Actual|M.D. Anderson Cancer Center||1||Due to slow accrual.|f||||f||||||||||2018-06-01 02:23:59.712873|2018-06-01 02:23:59.712873
NCT00626548|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2012-04-26||2012-08-29|2008-02-21|2008-02-29|Estimate|2012-04-26|2012-06-01|Estimate||||2012-08-29|2012-09-03|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|ENTHUSE M0||A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer|A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients|Terminated||Phase 3|2577|Actual|AstraZeneca||2||"early efficacy review by the Independent Data Monitoring Committee indicated it was unlikely to~   meet its primary efficacy endpoints"|f||||t||||||||||2018-06-01 02:24:00.00576|2018-06-01 02:24:00.00576
NCT00626535|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2009-03-11|2008-02-21|2008-02-29|Estimate|||||||2009-03-11|2009-03-12|Estimate|March 2003||2003-03-31|March 2009|2009-03-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)|A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)|Completed||Phase 3|500|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 02:24:01.23159|2018-06-01 02:24:01.23159
NCT00626522|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2016-06-28||2016-09-27|2008-02-28|2008-02-29|Estimate|2016-06-28|2016-08-08|Estimate||||2016-09-27|2016-11-16|Estimate|February 2008||2008-02-29|September 2016|2016-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Aclidinium/Formoterol Fixed Combination Dose Finding Study|A Randomised, 4-week, Placebo-controlled, Double-blind, 6 Arm Parallel Group, Dose-finding Clinical Trial, to Assess the Efficacy, Safety and Pharmacokinetics of Three Different Doses of Formoterol Combined With the Inhaled Anticholinergic Aclidinium Bromide, Aclidinium Bromide Monotherapy and Formoterol Monotherapy All Administrated Once Daily by Inhalation Via Almirall Inhaler in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease.|Completed||Phase 2|808|Actual|AstraZeneca||6|||f||||f||||||||||2018-06-01 02:24:01.29963|2018-06-01 02:24:01.29963
NCT00626509|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2013-08-09|2008-02-28|2008-02-29|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2008||2008-02-29|June 2009|2009-06-30||||January 2011|Anticipated|2011-01-31||Interventional|||Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer|Sunitinib Either Before or After Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma|Unknown status|Recruiting|Phase 2|110|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:24:02.779709|2018-06-01 02:24:02.779709
NCT00626496|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2018-04-20|2008-02-20|2008-02-29|Estimate|||||||2018-04-20|2018-04-23|Actual|April 2004|Actual|2004-04-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Family Study of Lymphoproliferative Disorders|Genetic Epidemiology of Lymphoproliferative Disorders|Recruiting|||2000|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     We will collect blood samples from patients and their relatives for DNA and cytogenetic~     studies. A one time blood draw of 50 cc will be done.~   "|||2018-06-01 02:24:02.878038|2018-06-01 02:24:02.878038
NCT00626483|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2018-05-15|2008-02-28|2008-02-29|Estimate|||||||2018-05-15|2018-05-17|Actual|March 2007||2007-03-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|REGULATe||Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia|REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme|Active, not recruiting||Phase 1|18|Anticipated|Duke University||1|||f||||t||||||||||2018-06-01 02:24:02.974408|2018-06-01 02:24:02.974408
NCT00626470|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2017-09-28|2008-02-28|2008-02-29|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2008|Actual|2008-12-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|TSP||Prospective Trial on Trochanteric Femur Fractures Treated With or Without a Trochanter Support Plate|A Prospective Randomised Study of Unstable Trochanteric Femur Fractures Treated With Dynamic Hip Screw With and Without a Trochanter Support Plate|Completed||N/A|100|Actual|St. Olavs Hospital||2|||f||||f|f|f||||||||2018-06-01 02:24:03.076548|2018-06-01 02:24:03.076548
NCT00626457|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2015-06-30|2008-02-28|2008-02-29|Estimate|||||||2015-06-30|2015-07-01|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Promoting Healthy Weight With 'Stability Skills First'|Promoting Healthy Weight With 'Stability Skills First' (Fresh Start Weight Loss Study)|Completed||N/A|267|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 02:24:03.163993|2018-06-01 02:24:03.163993
NCT00626444|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2014-11-24||2016-10-19|2008-02-28|2008-02-29|Estimate|2014-12-03|2014-12-10|Estimate||||2016-10-19|2016-11-29|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)|Phase II Trial of High Dose Intravenous Vitamin C in Patients With Refractory Non-Hodgkin Lymphoma|Terminated||Phase 2|2|Actual|Thomas Jefferson University|Study was terminated due to poor accrual. No reportable data has been collected for any of the specified outcome measures.|1||Slow accrual|f||||t||||||||||2018-06-01 02:24:03.251316|2018-06-01 02:24:03.251316
NCT00626431|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2010-08-20||2011-07-15|2008-02-20|2008-02-29|Estimate|2010-10-07|2010-11-01|Estimate||||2011-07-15|2011-07-19|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||A Study of Leuprolide to Treat Prostate Cancer|A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma|Completed||Phase 3|310|Actual|Abbott|Treatment with Formulation B was prematurely discontinued as testosterone was not adequately suppressed to <= 50 ng/dL or escapes from suppression occurred. Subjects who had not received dose 2 of Formulation B were discontinued after Week 24.|2|||f||||f||||||||||2018-06-01 02:24:03.615744|2018-06-01 02:24:03.615744
NCT00626418|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2011-09-29|2008-02-28|2008-02-29|Estimate|||||||2011-09-29|2011-10-03|Estimate|February 2008||2008-02-29|September 2011|2011-09-30||||October 2008|Actual|2008-10-31||Interventional|||The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome|A Single-blind, Placebo Controlled Sleep Laboratory Study of the Acute Effects of Aplindore in Restless Legs Syndrome|Completed||Phase 2|24|Anticipated|Ligand Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:24:04.467142|2018-06-01 02:24:04.467142
NCT00626405|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|2017-02-01||2018-04-30|2008-02-28|2008-02-29|Estimate|2018-04-30|2018-05-01|Actual||||2018-04-30|2018-05-01|Actual|August 2008||2008-08-31|April 2018|2018-04-30|November 2012|Actual|2012-11-30|July 2010|Actual|2010-07-31||Interventional||All eligible patients who began treatment|Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Trial of Temozolomide (TMZ) and Bevacizumab or ABI-007 (ABX)/Carboplatin (CBDCA) and Bevacizumab in Patients With Unresectable Stage IV Malignant Melanoma|Completed||Phase 2|95|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 02:24:04.616294|2018-06-01 02:24:04.616294
NCT00626067|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2016-11-08|2008-02-19|2008-02-29|Estimate|||||||2016-11-08|2016-11-10|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of Patient Use and Perception of the Travatan Dosing Aid|Pilot Study of Patient Acceptance and Impact of the New Travatan™ Compliance Monitoring Dispenser (Travatan™ Dosing Aid)|Completed||Phase 4|45|Actual|Wills Eye||3|||f||||f||||||||Yes|A Manuscript has been accepted and published in Patient Preference and Adherence.|2018-06-01 02:24:10.070947|2018-06-01 02:24:10.070947
NCT00626392|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2009-04-16||2009-08-26|2008-02-21|2008-02-29|Estimate|2009-07-15|2009-08-25|Estimate||||2009-08-26|2009-09-02|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|ASA EFFECTS||Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia|Multicenter, Randomized, Double-Blind, Parallel, Acetylsalicylic Acid (ASA) Run-In Study to Evaluate the EFFECTS of Acetylsalicylic Acid on Niaspan®-Induced Flushing in Subjects With Dyslipidemia|Completed||Phase 3|277|Actual|Abbott||6|||f||||f||||||||||2018-06-01 02:24:05.611669|2018-06-01 02:24:05.611669
NCT00626379|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2015-02-27|2008-02-27|2008-02-29|Estimate|||||||2015-02-27|2015-03-02|Estimate|November 2007||2007-11-30|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|August 2010|Actual|2010-08-31||Observational|CHAS||Examining How Heart Disease Risk Factors Affect Healthy Aging (The Chicago Healthy Aging Study [CHAS])|Low CV Risk, Ages 25-44 & CV/Non-CV Outcomes, Ages 65+|Unknown status|Active, not recruiting||1395|Actual|Northwestern University|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, white cells, and urine~   "|||2018-06-01 02:24:06.047617|2018-06-01 02:24:06.047617
NCT00626366|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-02-20|2008-02-20|2008-02-29|Estimate|||||||2008-02-20|2008-02-29|Estimate|March 2008||2008-03-31|February 2008|2008-02-29|June 2008|Anticipated|2008-06-30|April 2008|Anticipated|2008-04-30||Interventional|||Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison|Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison|Unknown status|Not yet recruiting|N/A|8|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-06-01 02:24:06.102561|2018-06-01 02:24:06.102561
NCT00626353|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2014-03-17|2008-02-28|2008-02-29|Estimate|||||||2014-03-17|2014-03-18|Estimate|July 2007||2007-07-31|March 2014|2014-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Interdisciplinary Home Rehabilitation of Patients With Stroke. A Randomised Controlled Intervention Trial.|Interdisciplinary Home Rehabilitation of Patients With Stroke. A Randomised Controlled Intervention Trial.|Completed||N/A|71|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-06-01 02:24:06.172101|2018-06-01 02:24:06.172101
NCT00626340|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2017-03-17||2017-05-25|2008-02-28|2008-02-29|Estimate|2017-05-25|2017-06-01|Actual||||2017-05-25|2017-06-01|Actual|July 1999||1999-07-31|May 2017|2017-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||As far as we know, data was never analyzed for this study. We only know that 18 participants completed.|Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder|Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen|Completed||Phase 4|18|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 02:24:06.342865|2018-06-01 02:24:06.342865
NCT00626327|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2013-02-12|2011-02-18|2013-04-12|2008-02-28|2008-02-29|Estimate|2013-02-12|2013-03-15|Estimate|2011-02-18|2011-02-25|Estimate|2013-04-12|2013-04-19|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers|A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers|Completed||Phase 3|1630|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:24:06.558749|2018-06-01 02:24:06.558749
NCT00626314|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2008-02-28|2008-02-28|2008-02-29|Estimate|||||||2008-02-28|2008-02-29|Estimate|March 2008||2008-03-31|February 2008|2008-02-29|August 2010|Anticipated|2010-08-31|March 2010|Anticipated|2010-03-31||Interventional|CAuSMIc II||Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Trial to Assess the Efficacy, Safety and Tolerability of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Myocardium, Using an Endomyocardial Delivery System|Unknown status|Not yet recruiting|Phase 2|165|Anticipated|Mytogen, Inc.||2|||f||||||||||||||2018-06-01 02:24:07.412902|2018-06-01 02:24:07.412902
NCT00626301|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2015-03-25|2008-02-28|2008-02-29|Estimate|||||||2015-03-25|2015-03-26|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Lopinavir/Ritonavir Monotherapy in Children|Simplifying Antiretroviral Treatment in Virally Suppressed Children by Switching From Double Boosted Protease Inhibitors to Lopinavir/Ritonavir Monotherapy|Completed||Phase 4|40|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-06-01 02:24:07.482331|2018-06-01 02:24:07.482331
NCT00626288|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2013-07-25|2008-02-21|2008-02-29|Estimate|||||||2013-07-25|2013-07-26|Estimate|December 2007||2007-12-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|IBS-02/07||Mesalazine Therapy in Patients With Irritable Bowel Syndrome|A Randomised Controlled Multicenter Trial Assessing the Efficacy and Safety of Mesalazine Therapy in Patients With Irritable Bowel Syndrome.|Completed||Phase 3|187|Actual|SOFAR S.p.A.||2|||f||||f||||||||||2018-06-01 02:24:07.565197|2018-06-01 02:24:07.565197
NCT00626275|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|2015-04-27||2015-06-04|2008-02-28|2008-02-29|Estimate|2015-06-04|2015-07-01|Estimate||||2015-06-04|2015-07-01|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||All participants who received at least 1 dose of study drug|Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis|A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Subjects With Rheumatoid Arthritis|Completed||Phase 2|46|Actual|Cubist Pharmaceuticals LLC||5|||f||||f||||||||||2018-06-01 02:24:07.690976|2018-06-01 02:24:07.690976
NCT00626262|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2011-01-21|2008-02-21|2008-02-29|Estimate|||||||2011-01-21|2011-01-24|Estimate|July 2002||2002-07-31|January 2011|2011-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv|An Open, Randomised Two Way Crossover Study Comparing the Effects of 20mg of Esomeprazole Administered Orally and Intravenously as a 3 Minute Injection on Basal and Pentagastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)|Completed||Phase 4|60|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:24:08.445838|2018-06-01 02:24:08.445838
NCT00626249|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2013-12-13|2008-02-28|2008-02-29|Estimate|||||||2013-12-13|2013-12-17|Estimate|August 2007||2007-08-31|December 2013|2013-12-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function|A Phase 1b, Single-Dose, Open Label, Parallel Design, Controlled Pharmacology Trial of Fumaryl Diketopiperazine Administered as Technosphere Inhalation Power in Subjects With Either Mild or Moderate Chronic Kidney Disease vs. Matched Subjects Without Chronic Kidney Disease|Completed||Phase 1|36|Actual|Mannkind Corporation||2|||f||||||||||||||2018-06-01 02:24:08.620373|2018-06-01 02:24:08.620373
NCT00626236|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20||2013-01-18|2013-01-18|2008-02-28|2008-02-29|Estimate||||2013-01-18|2013-01-28|Estimate|2013-01-18|2013-01-28|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems|A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems|Completed||Phase 2|78|Actual|Supernus Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-06-01 02:24:08.693913|2018-06-01 02:24:08.693913
NCT00626223|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-02-28|2008-02-28|2008-02-29|Estimate|||||||2008-02-28|2008-02-29|Estimate|January 1998||1998-01-31|February 2008|2008-02-29|July 2007|Actual|2007-07-31|July 2001|Actual|2001-07-31||Interventional|||5-Methyltetrahydrofolate Survival and Inflammation in ESRD Patients|5-Methyltetrahydrofolate Survival and Inflammation in ESRD Patients|Completed||N/A|341|Actual|St. Orsola Hospital||2|||f||||f||||||||||2018-06-01 02:24:08.795611|2018-06-01 02:24:08.795611
NCT00626210|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2014-06-12||2018-01-03|2008-02-20|2008-02-29|Estimate|2014-10-28|2014-10-30|Estimate||||2018-01-03|2018-01-29|Actual|February 2008||2008-02-29|January 2018|2018-01-31|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional|||Modafinil Treatment for Sleep/Wake Disturbances in Older Adults|Modafinil Treatment for Sleep/Wake Disturbances in Older Adults|Terminated||Phase 4|2|Actual|VA Palo Alto Health Care System|Early termination leading to small numbers of subjects analyzed|1|||f||||f||||||||||2018-06-01 02:24:08.877762|2018-06-01 02:24:08.877762
NCT00626197|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20||2016-03-17|2017-05-09|2008-02-21|2008-02-29|Estimate||||2016-03-17|2016-04-15|Estimate|2017-05-09|2017-05-10|Actual|February 2008|Actual|2008-02-29|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2009|Actual|2009-10-31||Interventional|BELONG||A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)|A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus|Completed||Phase 3|381|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 02:24:09.043309|2018-06-01 02:24:09.043309
NCT00626184|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2009-08-17|2008-02-21|2008-02-29|Estimate|||||||2009-08-17|2009-08-18|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease|A Phase 1, Two Stage, Single Dose, Single-Blind, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease|Completed||Phase 1|28|Actual|Alvine Pharmaceuticals Inc.||2|||f||||f||||||||||2018-06-01 02:24:09.120314|2018-06-01 02:24:09.120314
NCT00626171|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2013-04-23|2008-02-20|2008-02-29|Estimate|||||||2013-04-23|2013-04-24|Estimate|August 2008||2008-08-31|April 2013|2013-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Role of Cigarette Smoking in Regulating Allergen-induced Early and Late Responses in Mild Asthmatics|A Study Evaluating the Role of Cigarette Smoking in Regulating Allergen-induced Early and Late Responses in Mild Asthmatics.|Completed||Early Phase 1|25|Actual|McMaster University||1|||f||||f||||||||||2018-06-01 02:24:09.190478|2018-06-01 02:24:09.190478
NCT00626158|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2012-04-03|2008-02-28|2008-02-29|Estimate|||||||2012-04-03|2012-04-04|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers|A Phase I Study, With Expanded Cohort, of Biweekly Fixed-dose Rate Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic and Biliary Carcinomas|Completed||Phase 1|45|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 02:24:09.252792|2018-06-01 02:24:09.252792
NCT00626145|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-02-28|2008-02-28|2008-02-29|Estimate|||||||2008-02-28|2008-02-29|Estimate|March 2003||2003-03-31|February 2008|2008-02-29|March 2008|Anticipated|2008-03-31|March 2008|Anticipated|2008-03-31||Interventional|||Long Term Follow-up of Autologous Bone Marrow Mononuclear Cells Therapy in STEMI|Long Term Functional Evaluation After Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells in Patients With ST-Elevation Myocardial Infarction|Unknown status|Active, not recruiting|Phase 1/Phase 2|37|Actual|Xijing Hospital||2|||f||||t||||||||||2018-06-01 02:24:09.326851|2018-06-01 02:24:09.326851
NCT00626132|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2015-12-17|2008-02-19|2008-02-29|Estimate|||||||2015-12-17|2015-12-18|Estimate|May 2007||2007-05-31|December 2015|2015-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Standardized Eucommia Extract in the Treatment of Hypertension|Evaluation of the Safety and Efficacy of a Standardized Eucommia Extract in the Treatment of Hypertension|Completed||Phase 2|30|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 02:24:09.40913|2018-06-01 02:24:09.40913
NCT00626119|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2012-06-19|2008-02-28|2008-02-29|Estimate|||||||2012-06-19|2012-06-21|Estimate|June 2001||2001-06-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Vibro-Acoustography Imaging in Finding Breast Microcalcifications and Lesions in Women|In Vivo Breast Imaging by Vibro-acoustography|Completed|||34|Actual|Mayo Clinic|||2||f||||t||||||||||2018-06-01 02:24:09.498838|2018-06-01 02:24:09.498838
NCT00626106|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21||2015-01-16|2016-10-26|2008-02-21|2008-02-29|Estimate||||2015-01-16|2015-01-28|Estimate|2016-10-26|2016-10-27|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|||QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer|An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|156|Actual|NantCell, Inc.||3|||f||||||||||||||2018-06-01 02:24:09.575259|2018-06-01 02:24:09.575259
NCT00626093|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2011-07-21||2013-01-18|2008-02-28|2008-02-29|Estimate|2012-12-11|2013-01-21|Estimate||||2013-01-18|2013-01-24|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||'Effect of CRT on Defibrillation Threshold Estimates' Study|Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates|Completed||Phase 4|77|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 02:24:09.724146|2018-06-01 02:24:09.724146
NCT00626080|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2011-12-29|2008-02-20|2008-02-29|Estimate|||||||2011-12-29|2011-12-30|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|INcEREBRO||Insulin Detemir Action in Cerebro|Effects of INsulin dEtemiR and Neutral protaminE Hagedorn (NPH) Insulin on BRain glucOse Metabolism: a Study in Persons With Type 1 Diabetes|Completed||N/A|40|Anticipated|VU University Medical Center|||||f||||f||||||||||2018-06-01 02:24:09.885281|2018-06-01 02:24:09.885281
NCT00623792|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2016-03-15|2008-02-25|2008-02-26|Estimate|||||||2016-03-15|2016-03-17|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PREP||Study on Impact of Lifestyle Change and Weight Loss Before Bariatric Surgery|Preoperative Lifestyle Intervention in Bariatric Surgery|Completed||N/A|300|Actual|Duquesne University||2|||f||||f||||||||||2018-06-01 02:24:46.901566|2018-06-01 02:24:46.901566
NCT00626054|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2016-04-12|2008-02-20|2008-02-29|Estimate|||||||2016-04-12|2016-04-13|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|PEG||Comparison of Two Methods of Administration of a PEG Solution|Comparison of Two Methods of Administration of a PEG Solution During Bowel Preparation for Colonoscopy in Hospitalized Patients|Completed||Phase 4|400|Actual|Rabin Medical Center||2|||f||||t||||||||||2018-06-01 02:24:10.139442|2018-06-01 02:24:10.139442
NCT00626041|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2010-01-25|2008-02-28|2008-02-29|Estimate|||||||2010-01-25|2010-01-27|Estimate|February 2008||2008-02-29|January 2010|2010-01-31|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|U-CHAMP||U-CHAMP: Urban Cardiovascular Health Assessment and Management Program|U-CHAMP: Urban Cardiovascular Health Assessment and Management Program|Unknown status|Recruiting|N/A|110|Anticipated|University of Calgary||1|||f||||f||||||||||2018-06-01 02:24:10.214049|2018-06-01 02:24:10.214049
NCT00626028|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2009-09-21||2016-09-08|2008-02-28|2008-02-29|Estimate|2010-08-23|2010-09-16|Estimate||||2016-09-08|2016-10-21|Estimate|September 2004||2004-09-30|September 2016|2016-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing|Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing|Completed||Phase 3|136|Actual|Mallinckrodt|Although the first and last treatments were randomly assigned, the second treatment was always the iNO/O2 combination. Without randomization of all 3 treatments, we cannot exclude an interaction of time with treatment.|3|||f||||f||||||||||2018-06-01 02:24:10.304057|2018-06-01 02:24:10.304057
NCT00626015|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2016-01-20|2008-02-28|2008-02-29|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2007||2007-03-31|January 2016|2016-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ZAP IT||Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery|Zenapax®-Activated Peptide ImmunoTherapy [ZAP IT]|Completed||Phase 1|16|Actual|Duke University||3|||f||||t||||||||||2018-06-01 02:24:10.647902|2018-06-01 02:24:10.647902
NCT00626002|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22||2012-10-05|2013-01-28|2008-02-22|2008-02-29|Estimate||||2012-10-05|2012-10-10|Estimate|2013-01-28|2013-01-30|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Open Label Continuation Study in Moderate to Severe Psoriasis|A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Plaque Psoriasis in Subjects Who Completed a Preceding Psoriasis Study With ABT-874|Completed||Phase 3|2301|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 02:24:10.82136|2018-06-01 02:24:10.82136
NCT00625989|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2015-04-14||2018-03-15|2008-02-20|2008-02-29|Estimate|2015-04-30|2015-05-15|Estimate||||2018-03-15|2018-05-21|Actual|February 2008||2008-02-29|April 2015|2015-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics|The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics|Completed||Early Phase 1|12|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 02:24:11.094956|2018-06-01 02:24:11.094956
NCT00625976|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2014-09-18|2008-02-28|2008-02-29|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2008||2008-05-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|December 2012|Actual|2012-12-31||Interventional|||Graded Exposure (GEXP) in Vivo Versus Physiotherapy in Complex Regional Pain Syndrome Type I (CRPS-I)|The Effectivity of Graded Exposure in Vivo Versus Standardized Physiotherapy in Complex Regional Pain Syndrome Type I (CRPS-I) Patients With Pain Related Fear: a Randomized Clinical Trial|Completed||N/A|46|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 02:24:11.274944|2018-06-01 02:24:11.274944
NCT00625963|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2013-07-29|2008-02-20|2008-02-29|Estimate|||||||2013-07-29|2013-07-30|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|July 2011|Actual|2011-07-31|June 2008|Actual|2008-06-30||Observational|||The Study Of CT Scans and Echo Parameters in Patients With PAH|The Study of CT Scan and Echocardiogram Parameters in Patients With Pulmonary Hypertension With Regards to Hemodynamics, Sleep Studies, and Various Laboratory Markers.|Completed|||71|Actual|Northwell Health|||1||f||||f||||||||||2018-06-01 02:24:11.345645|2018-06-01 02:24:11.345645
NCT00625950|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2009-01-09|2008-02-28|2008-02-29|Estimate|||||||2009-01-09|2009-01-12|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Endometriosis Patients Undergoing Quinagolide Treatment|Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.|Completed||Phase 4|5|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-06-01 02:24:11.412121|2018-06-01 02:24:11.412121
NCT00625937|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-28|||2011-02-25|2008-02-28|2008-02-29|Estimate|||||||2011-02-25|2011-02-28|Estimate|November 2006||2006-11-30|February 2011|2011-02-28||||November 2010|Anticipated|2010-11-30||Interventional|||Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer|Unknown status|Recruiting|Phase 2|46|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:24:11.466414|2018-06-01 02:24:11.466414
NCT00625924|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2014-01-14|2008-02-20|2008-02-29|Estimate|||||||2014-01-14|2014-01-16|Estimate|February 2008||2008-02-29|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Sensory Morbidity Following Breast Surgery|Sensory Morbidity Following Breast Surgery|Completed|||290|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 02:24:11.54085|2018-06-01 02:24:11.54085
NCT00625911|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2008-02-28|2008-02-28|2008-02-29|Estimate|||||||2008-02-28|2008-02-29|Estimate|September 2001||2001-09-30|February 2008|2008-02-29|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Ketamine Improves Post-Thoracotomy Analgesia|Ketamine Improves Post-Thoracotomy Analgesia|Completed||N/A|44|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-06-01 02:24:11.623853|2018-06-01 02:24:11.623853
NCT00625898|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2014-07-07|2008-02-28|2008-02-29|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2013|Actual|2013-06-30||Interventional|BETH||BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab|A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab|Terminated||Phase 3|3509|Actual|NSABP Foundation Inc||4|||f||||t||||||||||2018-06-01 02:24:11.809689|2018-06-01 02:24:11.809689
NCT00625885|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2017-11-28|2008-02-19|2008-02-28|Estimate|||||||2017-11-28|2017-11-30|Actual|February 2007||2007-02-28|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Observational|MARS||Multicenter ACL Revision Study (MARS)|Multicenter ACL Revision Study (MARS)|Active, not recruiting|||1250|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||No||2018-06-01 02:24:12.865234|2018-06-01 02:24:12.865234
NCT00625872|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2012-01-27||2012-01-27|2008-02-19|2008-02-28|Estimate|2012-01-27|2012-02-29|Estimate||||2012-01-27|2012-02-29|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|SGA-POWER||Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy|Neuromuscular Changes In Small For Gestational Age (SGA) Children During Somatropin Therapy - A Prospective Randomized, Controlled, Open-Label Multicenter Trial|Terminated||Phase 3|23|Actual|Pfizer|The study was prematurely discontinued, therefore not all data was powered.|2||"The study terminated on 19-Jan-2011 due to insufficient recruitment of patients. No safety~   reasons contributed to the termination of the study."|f||||f||||||||||2018-06-01 02:24:13.021839|2018-06-01 02:24:13.021839
NCT00625859|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2017-08-23|2008-02-27|2008-02-28|Estimate|||||||2017-08-23|2017-08-24|Actual|January 16, 2008|Actual|2008-01-16|August 2017|2017-08-31|April 10, 2008|Actual|2008-04-10|April 10, 2008|Actual|2008-04-10||Interventional|||A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects|A Double-blind, Randomized, 6-sequence, 3-period, Crossover Drug Drug Interaction Study to Evaluate the Pharmacokinetics of Wellbutrin SR and GSK189075 When Co-administered or Administered Alone in Healthy Male Volunteers|Completed||Phase 1|27|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 02:24:14.06826|2018-06-01 02:24:14.06826
NCT00625846|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2018-05-08|2008-02-27|2008-02-28|Estimate|||||||2018-05-08|2018-05-09|Actual|February 22, 2008|Actual|2008-02-22|May 2018|2018-05-31||||January 17, 2019|Anticipated|2019-01-17||Interventional|||Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer|A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer|Active, not recruiting||Phase 2|188|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 02:24:14.16069|2018-06-01 02:24:14.16069
NCT00625833|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2009-02-16|2008-02-19|2008-02-28|Estimate|||||||2009-02-16|2009-02-18|Estimate|December 2007||2007-12-31|February 2009|2009-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.|A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.|Terminated||Phase 2|330|Anticipated|Pfizer||2||Study was terminated for futility following the planned interim analysis.|f||||f||||||||||2018-06-01 02:24:14.256281|2018-06-01 02:24:14.256281
NCT00625820|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2015-08-04||2016-08-22|2008-02-19|2008-02-28|Estimate|2016-08-22|2016-10-18|Estimate||||2016-08-22|2016-10-18|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria|Safety and Efficacy of Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria: An Open-Label Pilot Study|Completed||Phase 2|17|Actual|University of Michigan|It was a small single center non-randomized pilot study & was not powered to detect significant changes in albuminuria.|1|||f||||f||||||||No||2018-06-01 02:24:15.41694|2018-06-01 02:24:15.41694
NCT00625807|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|||2009-12-03|2008-02-26|2008-02-28|Estimate|||||||2009-12-03|2009-12-04|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of Two Behavioral Treatments for Stress Reduction|Exploratory Analysis of RR and MBSR for Stress Reduction|Completed||Early Phase 1|70|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:24:15.580309|2018-06-01 02:24:15.580309
NCT00625794|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-27|2008-02-27|2008-02-28|Estimate|||||||2008-02-27|2008-02-28|Estimate|September 2005||2005-09-30|May 2007|2007-05-31|July 2007|Actual|2007-07-31|May 2007|Actual|2007-05-31||Interventional|||Nicotine Replacement and Counseling In Adolescents|A Randomized Trial of the Nicotine Nasal Spray in Adolescent Smokers|Completed||Phase 4|40|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:24:15.666138|2018-06-01 02:24:15.666138
NCT00625781|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2016-05-10|2008-02-27|2008-02-28|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2008||2008-02-29|May 2016|2016-05-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|TIP||Treatment of Impaired Glucose Tolerance in Pregnancy|Randomized Controlled, Multicenter Study Evaluating Treatment of Glucose Intolerance in Pregnancy|Completed||N/A|72|Actual|Region Örebro County||2|||f||||f||||||||||2018-06-01 02:24:15.738057|2018-06-01 02:24:15.738057
NCT00625768|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2009-08-24|2008-02-27|2008-02-28|Estimate|||||||2009-08-24|2009-08-25|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma|A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma|Completed||Phase 1|13|Actual|Antisoma Research|||||f||||t||||||||||2018-06-01 02:24:15.815495|2018-06-01 02:24:15.815495
NCT00625755|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-03-24|2008-02-27|2008-02-28|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2002||2002-12-31|March 2017|2017-03-31|February 2008|Actual|2008-02-29|June 2005|Actual|2005-06-30||Interventional|||A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma|A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma|Completed||Phase 1/Phase 2|40|Actual|Beth Israel Deaconess Medical Center|||||f||||t||||||||||2018-06-01 02:24:15.998448|2018-06-01 02:24:15.998448
NCT00625742|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2015-12-04||2016-01-08|2008-02-19|2008-02-28|Estimate|2016-01-08|2016-02-12|Estimate||||2016-01-08|2016-02-12|Estimate|February 2008||2008-02-29|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Multimodal Treatment Strategy for Cancer Cachexia|An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia|Terminated||N/A|15|Actual|M.D. Anderson Cancer Center|The sample size of the available data is too small to detect any significant differences.|1||Low Accrual|f||||f||||||||||2018-06-01 02:24:16.098647|2018-06-01 02:24:16.098647
NCT00625729|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2010-07-02||2017-12-03|2008-02-26|2008-02-28|Estimate|2010-07-02|2010-07-30|Estimate||||2017-12-03|2017-12-28|Actual|January 2008||2008-01-31|December 2017|2017-12-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia|MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis|Terminated||Phase 1/Phase 2|6|Actual|Masonic Cancer Center, University of Minnesota|Study was terminated early due to lack of NK expansion and failure to meet primary outcome.|1||No patients exhibited natural killer cell expansion (primary endpoint).|f||||t||||||||||2018-06-01 02:24:16.327457|2018-06-01 02:24:16.327457
NCT00625703|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2009-01-21|2008-02-27|2008-02-28|Estimate|||||||2009-01-21|2009-01-23|Estimate|May 2008||2008-05-31|December 2008|2008-12-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Pharmacokinetics of Linezolid in Children With Cystic Fibrosis|Pharmacokinetics of Linezolid in Children With Cystic Fibrosis|Unknown status|Recruiting|Phase 2|14|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-06-01 02:24:16.578039|2018-06-01 02:24:16.578039
NCT00625690|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2017-09-02|2008-02-27|2008-02-28|Estimate|||||||2017-09-02|2017-09-07|Actual|May 2005||2005-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||CT Scans in Screening for Lung Cancer in Current and Former Smokers|Development of a Lung Cancer-Screening Program at the University of Nebraska Medical Center: A Feasibility Study|Active, not recruiting|||100|Actual|University of Nebraska|||||f||||t||||||Samples Without DNA|"~     Collection of blood sample: At the time of the initial CT scan, every subject will be asked~     to donate a small blood sample, approximately 10 ml in a yellow EDTA tube (less than 1~     tablespoon) from their arm by standard blood drawing techniques, for storage for use in~     future studies. The blood sample will be number coded, and serum from the blood sample will~     be stored frozen and held at UNMC for future studies. All studies will be proposed in future~     IRB submissions.~   "|||2018-06-01 02:24:16.682636|2018-06-01 02:24:16.682636
NCT00625677|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2010-09-01|2008-02-27|2008-02-28|Estimate|||||||2010-09-01|2010-09-02|Estimate|February 2008||2008-02-29|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|Sched2||Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life|A Phase IV, Randomized Study to Evaluate the Immune Response of UK Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life|Completed||Phase 4|130|Anticipated|Public Health England||2|||f||||f||||||||||2018-06-01 02:24:16.750003|2018-06-01 02:24:16.750003
NCT00625664|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19||2016-04-06|2016-04-06|2008-02-19|2008-02-28|Estimate||||2016-04-06|2016-05-05|Estimate|2016-04-06|2016-05-05|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|CILAB||Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer|Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer|Completed||Phase 3|337|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:24:16.864122|2018-06-01 02:24:16.864122
NCT00625651|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14||2014-01-15|2014-03-28|2008-02-20|2008-02-28|Estimate||||2014-01-15|2014-02-12|Estimate|2014-03-28|2014-04-25|Estimate|October 2007||2007-10-31|March 2014|2014-03-31|September 2011|Actual|2011-09-30|August 2010|Actual|2010-08-31||Interventional|||Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer|A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|202|Actual|Amgen||3|||f||||||||||||||2018-06-01 02:24:17.326548|2018-06-01 02:24:17.326548
NCT00625638|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2017-09-28|2008-02-19|2008-02-28|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2008|Actual|2008-01-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Interactive Voice Response System in Advanced Cancer Patients|Symptom Assessment in Advanced Cancer Patients Using an Interactive Voice Response (IVR) System|Active, not recruiting||N/A|136|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:24:17.522539|2018-06-01 02:24:17.522539
NCT00625625|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2013-09-16|2008-02-27|2008-02-28|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2004||2004-03-31|February 2008|2008-02-29||||November 2007|Anticipated|2007-11-30||Interventional|||Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer|Ultrastaging of Early Cancer of the Large Bowel Using Intraoperative Lymphatic Mapping, Sentinel Node Analysis and Blood Testing|Unknown status|Active, not recruiting|Phase 2|225|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:24:17.605633|2018-06-01 02:24:17.605633
NCT00625612|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12||2011-03-24|2015-10-08|2008-02-27|2008-02-28|Estimate||||2011-03-30|2011-04-07|Estimate|2015-10-08|2015-11-02|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease|A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease and FEV1 Greater Than or Equal to 75% Predicted But Less Than or Equal to 110% Predicted|Completed||Phase 3|466|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:24:17.70049|2018-06-01 02:24:17.70049
NCT00625599|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-28|2008-02-19|2008-02-28|Estimate|||||||2008-02-28|2008-02-29|Estimate|January 2008||2008-01-31|January 2008|2008-01-31||||April 2008|Anticipated|2008-04-30||Observational|||Fractures in the Elderly Population of El Salvador at Hospital Zacamil: Exploring Knowledge, Causes, Risk Factors, and Outcomes|Fractures in the Elderly Population of El Salvador at Hospital Zacamil: Exploring Knowledge, Causes, Risk Factors, and Outcomes|Unknown status|Recruiting||400|Anticipated|Edward Via Virginia College of Osteopathic Medicine|||2||f||||t||||||||||2018-06-01 02:24:17.91131|2018-06-01 02:24:17.91131
NCT00625586|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2012-08-20||2012-11-20|2008-02-26|2008-02-28|Estimate|2012-11-20|2012-12-19|Estimate||||2012-11-20|2012-12-19|Estimate|March 2008||2008-03-31|November 2012|2012-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer|A Phase 2 Evaluation of the Monoclonal Antibody, RAV12, in Combination With Standard Gemcitabine in the Treatment of Patients With Metastatic Pancreatic Cancer Who Have Not Been Previously Treated for Metastatic Disease|Terminated||Phase 2|2|Actual|MacroGenics|Only 2 patients enrolled in the trial. Both were evaluable for safety and only one was evaluable for efficacy. No statistical analyses were performed.|1||Corporate decision|f||||f||||||||||2018-06-01 02:24:18.252406|2018-06-01 02:24:18.252406
NCT00625573|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2009-09-17|2008-02-27|2008-02-28|Estimate|||||||2009-09-17|2009-09-18|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|ABX067||Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)|Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)|Completed||Phase 2|29|Anticipated|Mt. Sinai Medical Center, Miami|||||f||||t||||||||||2018-06-01 02:24:18.552163|2018-06-01 02:24:18.552163
NCT00625560|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2012-05-07|2008-02-19|2008-02-28|Estimate|||||||2012-05-07|2012-05-08|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|||Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA|Randomized, Open-Labelled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B With Detectable HBV DNA|Completed||Phase 4|72|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 02:24:18.694419|2018-06-01 02:24:18.694419
NCT00259259|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-01-20|2005-11-28|2005-11-29|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||Functional Lipids and Appetite Regulation|The Effect of Functional Lipids on Appetite Regulation in Man|Completed||N/A|22||University of Copenhagen|||||f||||||||||||||2018-06-01 04:19:09.355459|2018-06-01 04:19:09.355459
NCT00625547|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-10-28|2008-02-27|2008-02-28|Estimate|||||||2008-10-28|2008-10-29|Estimate|January 2003||2003-01-31|October 2008|2008-10-31|December 2004|Actual|2004-12-31|||||Interventional|||A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS|A Double-Blind, Randomized, Active-Controlled Multicenter Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)|Completed||Phase 3|361|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:24:18.802047|2018-06-01 02:24:18.802047
NCT00625534|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-04-10|2008-02-19|2008-02-28|Estimate|||||||2008-04-10|2008-04-15|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|GENINGHERNIA||Functional Outcome After Groin Hernia Mesh Repair: Open Versus Laparoscopy|Chronic Significant Pain and Functional Outcome After Laparoscopic Versus Open Groin Hernia Mesh Repair: Design of a Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|260|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 02:24:18.943964|2018-06-01 02:24:18.943964
NCT00625521|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-02-28|2008-02-27|2008-02-28|Estimate|||||||2008-02-28|2008-02-29|Estimate|November 2006||2006-11-30|February 2008|2008-02-29|July 2007|Actual|2007-07-31|||||Interventional|||Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions|Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study|Completed||Phase 2|32|Actual|Astion Pharma A/S||2|||f||||f||||||||||2018-06-01 02:24:19.029532|2018-06-01 02:24:19.029532
NCT00625495|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2011-01-21|2008-02-20|2008-02-28|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2002||2002-09-30|January 2011|2011-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)|An Open, Randomised Two Way Crossover Study Comparing the Effects of 40mg of Esomeprazole Adminstered Orally and Intravenously as a 3 Minute Injection on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)|Completed||Phase 4|60|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:24:19.090779|2018-06-01 02:24:19.090779
NCT00625482|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2013-10-22|2008-02-27|2008-02-28|Estimate|||||||2013-10-22|2013-10-23|Estimate|February 2008||2008-02-29|October 2013|2013-10-31||||||||Interventional|||Sex-Differential Health Interventions In Low-Birth-Weight Infants|Sex-Differential Health Interventions In Low-Birth-Weight Infants|Unknown status|Active, not recruiting|N/A|||Bandim Health Project||4|||f||||||||||||||2018-06-01 02:24:19.169164|2018-06-01 02:24:19.169164
NCT00625469|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2018-03-02|2008-02-19|2008-02-28|Estimate|||||||2018-03-02|2018-03-06|Actual|October 2007|Actual|2007-10-31|March 2018|2018-03-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan|Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study|Withdrawn||Phase 4|0|Actual|University of California, Los Angeles||3||competing studies did not allow enrollment|f||||t|t|||||||||2018-06-01 02:24:19.244453|2018-06-01 02:24:19.244453
NCT00625456|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2015-11-30|2008-02-27|2008-02-28|Estimate|||||||2015-11-30|2015-12-03|Estimate|June 2008||2008-06-30|March 2012|2012-03-31|June 2014|Actual|2014-06-30|April 2010|Actual|2010-04-30||Interventional|||Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors|A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors|Completed||Phase 1|23|Actual|SillaJen, Inc.||1|||f||||t||||||||||2018-06-01 02:24:19.325053|2018-06-01 02:24:19.325053
NCT00625443|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2017-12-04|2013-05-21|2018-03-09|2008-02-27|2008-02-28|Estimate|2018-03-09|2018-03-16|Actual|2013-05-21|2013-05-29|Estimate|2018-03-09|2018-03-16|Actual|May 2007||2007-05-31|March 2018|2018-03-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional||Full analysis set (FAS) included all participants who completed 501-CL-003 and received study drug in 501-CL-004, except baseline values and ITP-directed medications taken during the 2-week period before the first dose of avatrombopag in 501-CL-004. Data was summarized using the observed case (OC) method.|Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003|A Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) Who Completed 28 Days of Study Treatment in Protocol 501-CL-003|Completed||Phase 2|53|Actual|Eisai Inc.||3|||f||||f||||||||||2018-06-01 02:24:19.447051|2018-06-01 02:24:19.447051
NCT00625430|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2011-07-08|2008-02-27|2008-02-28|Estimate|||||||2011-07-08|2011-07-11|Estimate|March 2008||2008-03-31|July 2011|2011-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|FP253-GDEPT||A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer|A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate|Unknown status|Recruiting|Phase 1|18|Anticipated|Biotech Equity Partners Pty Ltd||1|||f||||t||||||||||2018-06-01 02:24:20.36315|2018-06-01 02:24:20.36315
NCT00625417|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2018-04-27|2008-02-27|2008-02-28|Estimate|||||||2018-04-27|2018-05-01|Actual|August 2006||2006-08-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors|Breast Tumor Detection Using Optical Spectroscopy|Recruiting||N/A|180|Anticipated|Vanderbilt University||1|||f||||||||||||Undecided||2018-06-01 02:24:20.456218|2018-06-01 02:24:20.456218
NCT00625404|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2013-12-09||2018-03-31|2008-02-26|2008-02-28|Estimate|2014-03-11|2014-04-16|Estimate||||2018-03-31|2018-05-01|Actual|May 2009||2009-05-31|March 2018|2018-03-31|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|||FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women|Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women|Completed||Phase 3|2120|Actual|FHI 360||2|||f||||t||||||||||2018-06-01 02:24:20.601786|2018-06-01 02:24:20.601786
NCT00625391|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2012-12-05||2014-08-01|2008-02-26|2008-02-28|Estimate|2014-08-01|2014-08-18|Estimate||||2014-08-01|2014-08-18|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|GTP-TC-Bone||Green Tea and Tai Chi for Bone Health|GTP and Tai Chi for Bone Health: a Pilot Study|Completed||Phase 1/Phase 2|171|Actual|Texas Tech University Health Sciences Center|Limitation of this study included: (1) the number of subjects in each group at the baseline was not equal. (2) The amount of dietary calcium intake for each subject was not available.|4|||f||||f||||||||||2018-06-01 02:24:21.528303|2018-06-01 02:24:21.528303
NCT00625378|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2018-05-15|2008-02-20|2008-02-28|Estimate|||||||2018-05-15|2018-05-16|Actual|December 21, 2007|Actual|2007-12-21|May 2018|2018-05-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|STEP||Sorafenib Long Term Extension Program|Sorafenib Long Term Extension Program (STEP)|Recruiting||Phase 3|1000|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-06-01 02:24:21.830756|2018-06-01 02:24:21.830756
NCT00625365|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2010-12-17||2015-12-31|2008-02-27|2008-02-28|Estimate|2010-12-17|2011-01-14|Estimate||||2015-12-31|2016-02-02|Estimate|February 2008||2008-02-29|August 2011|2011-08-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice|CARES (Contrast EchocArdiography REgistry for Safety Surveillance): A Prospective, Phase IV, Open-Label, Nonrandomized, Multicenter, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice|Completed||Phase 4|1060|Actual|Lantheus Medical Imaging||1|||f||||f||||||||||2018-06-01 02:24:22.079014|2018-06-01 02:24:22.079014
NCT00625352|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-28|Estimate|||||||2008-02-19|2008-02-28|Estimate|February 2008||2008-02-29|February 2008|2008-02-29||||December 2009|Anticipated|2009-12-31||Interventional|||Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma|Prospective Phase II Trial of a Combination of Gemcitabine and UFT as First-Line Treatment in Elderly Patients With Advanced Non-Small Cell Carcinoma|Unknown status|Recruiting|Phase 2|48|Anticipated|Ulsan University Hospital|||||f||||f||||||||||2018-06-01 02:24:22.260546|2018-06-01 02:24:22.260546
NCT00625339|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2012-05-07|2008-02-27|2008-02-28|Estimate|||||||2012-05-07|2012-05-08|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA|Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA|Completed||Phase 4|72|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 02:24:22.344571|2018-06-01 02:24:22.344571
NCT00625326|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20||2010-12-01|2011-04-19|2008-02-27|2008-02-28|Estimate||||2010-12-01|2010-12-03|Estimate|2011-04-19|2011-04-27|Estimate|January 2008||2008-01-31|April 2011|2011-04-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Study of Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis|A Phase II Study of the Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis|Completed||Phase 2|321|Actual|Deltanoid Pharmaceuticals||5|||f||||f||||||||||2018-06-01 02:24:22.415531|2018-06-01 02:24:22.415531
NCT00625313|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2015-08-17|2008-02-27|2008-02-28|Estimate|||||||2015-08-17|2015-08-19|Estimate|March 2004||2004-03-31|August 2015|2015-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|HMY||Clinical Study of a UV-Absorbing Acrylic Posterior Chamber Intraocular Lens|A Prospective, Multi-center, Single-phase, Non-randomized, Open-label Study to Assess the Safety and Efficacy of the HMY Model YA-60BB Intraocular Lens (IOL) for the Correction of Aphakia Following Phacoemulsification Cataract Extraction|Completed||N/A|617|Actual|Hoya Surgical Optics, Inc.||1|||f||||f||||||||||2018-06-01 02:24:22.525452|2018-06-01 02:24:22.525452
NCT00625300|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2009-10-19|2008-02-27|2008-02-28|Estimate|||||||2009-10-19|2009-10-20|Estimate|April 2008||2008-04-30|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|r-TMS||Repetitive Transcranial Stimulation (r-TMS) Treatment for Patients With Parkinson's Disease|Efficacy and Safety Study:The Influence of Repetitive Transcranial Stimulation (r-TMS) Treatment on Motor and Cognitive Measurements in Patients With Parkinson's Disease|Completed||Phase 2|20|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 02:24:22.605577|2018-06-01 02:24:22.605577
NCT00625274|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-02-27|2008-02-27|2008-02-28|Estimate|||||||2008-02-27|2008-02-28|Estimate|June 2004||2004-06-30|February 2008|2008-02-29|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients||Completed||Phase 4|100|Anticipated|AstraZeneca||3|||f||||||||||||||2018-06-01 02:24:22.674408|2018-06-01 02:24:22.674408
NCT00625261|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-28|Estimate|||||||2008-02-19|2008-02-28|Estimate|October 2003||2003-10-31|August 2007|2007-08-31|October 2011|Anticipated|2011-10-31|February 2008|Actual|2008-02-29||Interventional|||Effectiveness of Early Parent-Based Language Intervention|Effectiveness of a Parent-Based Language Intervention Group Program for Two-Year-Old Children With Language Delay|Unknown status|Active, not recruiting|Phase 3|150|Actual|Heidelberg University||2|||f||||t||||||||||2018-06-01 02:24:22.746854|2018-06-01 02:24:22.746854
NCT00625248|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2013-06-20|2008-02-19|2008-02-28|Estimate|||||||2013-06-20|2013-06-24|Estimate|February 2008||2008-02-29|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Observational|||Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy|A Prospective Evaluation of Bleeding Risk of Anticoagulant and Antiplatelet Therapy for Interventional Techniques|Completed|||12000|Actual|Pain Management Center of Paducah|||3||f||||t||||||||||2018-06-01 02:24:22.820316|2018-06-01 02:24:22.820316
NCT00625235|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-28|Estimate|||||||2008-02-19|2008-02-28|Estimate|July 2003||2003-07-31|June 2003|2003-06-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A High Protein Diet and Weight Maintenance|The Use of a High Protein Diet in Achieving Long-Term Weight Loss and Improved Cardiovascular Risk Factors|Completed||N/A|180||University of Melbourne||2|||f||||f||||||||||2018-06-01 02:24:22.89972|2018-06-01 02:24:22.89972
NCT00625222|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2010-01-27|2008-02-27|2008-02-28|Estimate|||||||2010-01-27|2010-01-28|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) As A Tool For Prospective Responder Identification Before Vagus Nerve Stimulation (VNS) Implantation||Unknown status|Recruiting|N/A|70|Anticipated|University of Luebeck||1|||f||||t||||||||||2018-06-01 02:24:22.978511|2018-06-01 02:24:22.978511
NCT00625209|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2017-06-10|2008-02-19|2008-02-28|Estimate|||||||2017-06-10|2017-06-14|Actual|March 2008||2008-03-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|June 2015|Actual|2015-06-30||Interventional|APROCCHS||Activated Protein C and Corticosteroids for Human Septic Shock|Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock|Completed||Phase 3|1241|Actual|University of Versailles||4|||f||||t||||||||||2018-06-01 02:24:23.07777|2018-06-01 02:24:23.07777
NCT00625196|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2017-08-16|2008-02-27|2008-02-28|Estimate|||||||2017-08-16|2017-08-21|Actual|February 27, 2008|Actual|2008-02-27|August 2017|2017-08-31|May 6, 2008|Actual|2008-05-06|May 6, 2008|Actual|2008-05-06||Interventional|||Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects|A Randomised, Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Pharmacodynamics and Pharmacokinetics of GW685698X and GW642444M When Administered Separately and in Combination as a Single Dose From a Novel Dry Powder Device in Healthy Japanese Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:24:23.180556|2018-06-01 02:24:23.180556
NCT00625183|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-26|2014-09-19||2017-10-13|2008-02-26|2008-02-28|Estimate|2014-09-19|2014-09-26|Estimate||||2017-10-13|2017-11-17|Actual|March 2008||2008-03-31|October 2017|2017-10-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional||All treated and eligible patients|Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma|A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma|Terminated||Phase 2|5|Actual|Roswell Park Cancer Institute|Due to the study's early termination, as a result of low accrual, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.|1||Withdrawn due to poor/low accrual|f||||||||||||||2018-06-01 02:24:23.405306|2018-06-01 02:24:23.405306
NCT00625170|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-28|Estimate|||||||2008-02-19|2008-02-28|Estimate|May 2004||2004-05-31|March 2004|2004-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans|Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans|Completed||N/A|11|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-06-01 02:24:23.614162|2018-06-01 02:24:23.614162
NCT00625157|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-02-28|2008-02-20|2008-02-28|Estimate|||||||2008-02-28|2008-02-29|Estimate||||February 2008|2008-02-29||||||||Interventional|||Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)|Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study (2)|Completed||Phase 2|||Astion Pharma A/S||2|||f||||f||||||||||2018-06-01 02:24:23.690623|2018-06-01 02:24:23.690623
NCT00625131|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2014-10-28||2014-11-12|2008-02-19|2008-02-28|Estimate|2014-11-12|2014-11-20|Estimate||||2014-11-12|2014-11-20|Estimate|May 2008||2008-05-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Nicotine Patch Pretreatment for Smoking Cessation in PTSD|Nicotine Patch Pre-treatment for Smoking Cessation in PTSD|Completed||Early Phase 1|87|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 02:24:23.766167|2018-06-01 02:24:23.766167
NCT00625118|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2010-11-02|2008-02-27|2008-02-28|Estimate|||||||2010-11-02|2010-11-04|Estimate|December 2007||2007-12-31|January 2009|2009-01-31||||||||Observational|DIPS||A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years|A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five Years|Completed|||500|Anticipated|Public Health England|||1||f||||f||||||||||2018-06-01 02:24:24.163104|2018-06-01 02:24:24.163104
NCT00625105|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2014-11-05|2008-02-27|2008-02-28|Estimate|||||||2014-11-05|2014-11-07|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|HRVB||Using Heart Rate Variability Biofeedback to Improve Attention and Memory in PTSD+ Combat Veterans|Using Heart Rate Variability Biofeedback to Improve Attention and Memory in PTSD+ Combat Veterans|Unknown status|Active, not recruiting|N/A|30|Anticipated|William Jennings Bryan Dorn VA Medical Center||2|||f||||t||||||||||2018-06-01 02:24:24.245752|2018-06-01 02:24:24.245752
NCT00625092|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2017-11-27|2008-02-27|2008-02-28|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2007||2007-10-31|November 2017|2017-11-30|September 2011|Actual|2011-09-30|January 2010|Actual|2010-01-31||Interventional|||Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies|Phase I Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies|Completed||Phase 1|17|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:24:24.315743|2018-06-01 02:24:24.315743
NCT00625079|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2018-04-27|2008-02-19|2008-02-28|Estimate|||||||2018-04-27|2018-05-01|Actual|February 2007|Actual|2007-02-28|March 2018|2018-03-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil|Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study|Withdrawn||Phase 4|0|Actual|University of California, Los Angeles||3||inclusion/exclusion criteria limited enrollment|f||||t||||||||||2018-06-01 02:24:24.414159|2018-06-01 02:24:24.414159
NCT00625066|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2017-10-15|2008-02-27|2008-02-28|Estimate|||||||2017-10-15|2017-10-17|Actual|January 2003||2003-01-31|October 2017|2017-10-31|October 2025|Anticipated|2025-10-31|January 2011|Actual|2011-01-31||Observational|||Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy|Tennessee Colorectal Polyp Study|Active, not recruiting|||8108|Actual|Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 02:24:24.50943|2018-06-01 02:24:24.50943
NCT00625053|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-04-10|2008-02-19|2008-02-28|Estimate|||||||2008-04-10|2008-04-15|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|GINCISHERNIA||Functional Outcome After Incisional Hernia Repair: Open Versus Laparoscopic Repair|Abdominal Midline Incisional Hernia Repair and Functional Outcome: Randomized Controlled Trial to Compare Open and Laparoscopic Surgical|Unknown status|Recruiting|Phase 4|60|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 02:24:24.614577|2018-06-01 02:24:24.614577
NCT00625040|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2014-10-08|2008-02-26|2008-02-28|Estimate|||||||2014-10-08|2014-10-09|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Incretin Physiology and Beta-cell Function Before and After Weight-loss|Incretin Physiology and Beta-cell Function Before and After Weight-loss - Effects of Long-term Weight Loss Following Laparoscopic Adjustable Gastric Banding|Terminated|||10|Actual|Glostrup University Hospital, Copenhagen|||1|Not enough patients in the follow-up period|f||||t||||||Samples With DNA|"~     p-glucose, p-glucagon, p-GLP1, p-GIP, p-cpeptid, p-insulin, p-paracetamol, buffy coat, urine,~     whole blood sampels~   "|||2018-06-01 02:24:24.737147|2018-06-01 02:24:24.737147
NCT00625027|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2013-07-31|2008-02-19|2008-02-28|Estimate|||||||2013-07-31|2013-08-02|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||The Effect of Telehealth Ontario on Non-urgent Emergency Department Use at The Hospital for Sick Children|The Effect of Telehealth Ontario on Non-urgent Emergency Department Use at The Hospital for Sick Children|Completed|||115|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-06-01 02:24:24.840722|2018-06-01 02:24:24.840722
NCT00625014|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-28|Estimate|||||||2008-02-19|2008-02-28|Estimate|March 2005||2005-03-31|February 2008|2008-02-29|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans|Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans|Completed||N/A|8|Actual|Leiden University Medical Center||1|||f||||f||||||||||2018-06-01 02:24:24.936539|2018-06-01 02:24:24.936539
NCT00625001|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-28|Estimate|||||||2008-02-19|2008-02-28|Estimate|November 1994||1994-11-30|February 2008|2008-02-29|June 2010|Anticipated|2010-06-30|October 1996|Actual|1996-10-31||Observational|||Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome|Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome|Unknown status|Active, not recruiting||54|Actual|University of Aarhus|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 02:24:25.017683|2018-06-01 02:24:25.017683
NCT00624988|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-10-16|2008-02-19|2008-02-28|Estimate|||||||2008-10-16|2008-10-17|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|SCI||The Effect of Vibration Therapy on the Bone Density of the Tiba in Patients With Spinal Cord Injury|The Effect of Vibration Therapy on the Bone Density of the Tiba in Patients With Spinal Cord Injury|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Logan College of Chiropractic||1|||f||||t||||||||||2018-06-01 02:24:25.072651|2018-06-01 02:24:25.072651
NCT00624975|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2012-07-30|2008-02-27|2008-02-28|Estimate|||||||2012-07-30|2012-08-01|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants|A Multi-site, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Trehalose-reformulated Peru-15 (Choleragarde)Vaccine Given Simultaneously With Measles Vaccine in Healthy Indian and Bangladeshi Infants|Terminated||Phase 2|74|Actual|International Vaccine Institute||2||one of site was not able to get an approval from the national regulatory authority.|f||||t||||||||||2018-06-01 02:24:25.14559|2018-06-01 02:24:25.14559
NCT00624962|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2014-12-10|2008-02-27|2008-02-28|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2006||2006-03-31|November 2010|2010-11-30|January 2008|Anticipated|2008-01-31|January 2008|Anticipated|2008-01-31||Interventional|||Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors|Pilot Study of Early Enteral Tube Feedings in Children Receiving Chemotherapy for Newly Diagnosed AML/MDS and High Risk Solid Tumors|Withdrawn||N/A|0|Actual|Vanderbilt University||1||no participants enrolled|f||||t||||||||||2018-06-01 02:24:25.226023|2018-06-01 02:24:25.226023
NCT00624949|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-27|2008-02-27|2008-02-28|Estimate|||||||2008-02-27|2008-02-28|Estimate|August 2003||2003-08-31|February 2008|2008-02-29|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Aortic Dimensions in Turner Syndrome|Aortic Dimensions, 24hour Ambulatory Blood Pressure and Sympathovagal Tone in Turner Syndrome. In Relation to Aortic Dilatation and Dissection.|Unknown status|Active, not recruiting||102|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 02:24:25.305865|2018-06-01 02:24:25.305865
NCT00624936|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-27|||2017-08-21|2008-02-27|2008-02-28|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2008|Actual|2008-04-30|August 2017|2017-08-31|June 2014|Actual|2014-06-30|December 2009|Actual|2009-12-31||Interventional|||Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes|Phase I Study of Vidaza and Velcade (Bortezomib) in Acute Myeloid Leukemia|Completed||Phase 1|23|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:24:25.356004|2018-06-01 02:24:25.356004
NCT00624923|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2016-08-29||2017-11-08|2008-02-27|2008-02-28|Estimate|2017-11-08|2017-12-12|Actual||||2017-11-08|2017-12-12|Actual|September 2008|Actual|2008-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|January 2015|Actual|2015-01-31||Interventional|TINSAL-CVD||Targeting Inflammation Using Salsalate in CardioVascular Disease|Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)|Active, not recruiting||Phase 2/Phase 3|340|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-06-01 02:24:25.440677|2018-06-01 02:24:25.440677
NCT00624910|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2012-03-22|2008-02-27|2008-02-28|Estimate|||||||2012-03-22|2012-03-23|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety of A Collagen Bupivacaine Implant in Women Following Abdominal Hysterectomy|A Phase II, Single Dose, Blinded, Prospective Study to Investigate the Efficacy and Safety of the CollaRx® Bupivacaine Implant in Women Following Abdominal Hysterectomy or Other Nonlaparoscopic Benign Gynecological Procedure|Completed||Phase 2|54|Actual|Innocoll||3|||f||||f||||||||||2018-06-01 02:24:25.803068|2018-06-01 02:24:25.803068
NCT00624884|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-06-27|2008-02-19|2008-02-28|Estimate|||||||2008-06-27|2008-06-30|Estimate|March 2008||2008-03-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Observational|||Velocity Vector Imaging in Patients With Moderate-to-Severe Aortic Regurgitation|Velocity Vector Imaging in Patients With Moderate-to-Severe Aortic Regurgitation|Completed|||50|Anticipated|Florence Nightingale Hospital, Istanbul|||2||f||||t||||||||||2018-06-01 02:24:25.876159|2018-06-01 02:24:25.876159
NCT00624871|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2008-02-27|2008-02-27|2008-02-28|Estimate|||||||2008-02-27|2008-02-28|Estimate|April 2004||2004-04-30|February 2008|2008-02-29|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Ascorbic Acid and Ibuprofen in Infants With Hypoxic Ischemic Encephalopathy|Ascorbic Acid Combined With Ibuprofen in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial.|Completed||N/A|60|Actual|Al-Azhar University||2|||f||||t||||||||||2018-06-01 02:24:25.940792|2018-06-01 02:24:25.940792
NCT00624858|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19||2012-10-23|2012-10-23|2008-02-26|2008-02-27|Estimate||||2012-10-23|2012-10-30|Estimate|2012-10-23|2012-10-30|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression|An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) in Overweight or Obese Subjects With Major Depression|Completed||Phase 2|25|Anticipated|Orexigen Therapeutics, Inc||1|||f||||f||||||||||2018-06-01 02:24:26.009723|2018-06-01 02:24:26.009723
NCT00624845|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19||2011-06-17|2011-06-17|2008-02-26|2008-02-27|Estimate||||2011-06-17|2011-06-27|Estimate|2011-06-17|2011-06-27|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|C07-004||Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy|Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP|Completed||Phase 2/Phase 3|200|Anticipated|Omeros Corporation||2|||f||||f||||||||||2018-06-01 02:24:26.071047|2018-06-01 02:24:26.071047
NCT00624832|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|2011-01-21||2011-04-12|2008-02-26|2008-02-27|Estimate|2011-01-21|2011-02-14|Estimate||||2011-04-12|2011-04-19|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels|A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy of Xolair in an Allergen Bronchoprovocation Study in Asthmatic Populations Defined by Serum IgE Concentrations|Completed||Phase 4|60|Actual|Novartis||4|||f||||f||||||||||2018-06-01 02:24:26.164656|2018-06-01 02:24:26.164656
NCT00624819|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15||2012-07-24|2016-10-18|2008-02-25|2008-02-27|Estimate||||2012-07-24|2012-08-02|Estimate|2016-10-18|2016-10-19|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine|Long-term Follow-up Study to Assess Antibody Persistence in Children Previously Vaccinated With Four Doses of Pneumococcal Conjugate Vaccine in Primary Vaccination Study (105553) and Booster Vaccination Study (107046)|Completed||Phase 3|524|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:24:26.584124|2018-06-01 02:24:26.584124
NCT00624806|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2014-07-25||2015-04-06|2008-02-25|2008-02-27|Estimate|2014-11-26|2014-12-05|Estimate||||2015-04-06|2015-04-28|Estimate|February 2008||2008-02-29|July 2014|2014-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Developing a Home Telehealth Program to Manage Pressure Ulcers in SCI/D|Developing a Home Telehealth Program to Manage Pressure Ulcers in SCI/D|Completed||N/A|18|Actual|VA Office of Research and Development|The study duration was short and the sample was small. Because we only studied subjects who received the DMP, it is unknown how many would have had skin breakdown in a comparable period without the DMP.|2|||f||||f||||||||||2018-06-01 02:24:26.697157|2018-06-01 02:24:26.697157
NCT00624793|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2012-06-21|2008-02-19|2008-02-27|Estimate|||||||2012-06-21|2012-06-22|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|AcuN||Acupuncture for Nausea in HIV|Acupuncture for Chronic Nausea in HIV: A Randomized Clinical Trial|Completed||Phase 2|159|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-06-01 02:24:28.533457|2018-06-01 02:24:28.533457
NCT00624780|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2013-03-05||2013-03-05|2008-02-15|2008-02-27|Estimate|2013-03-05|2013-04-19|Estimate||||2013-03-05|2013-04-19|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder|Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder|Completed||Phase 4|615|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 02:24:28.716547|2018-06-01 02:24:28.716547
NCT00624767|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-05-16|2008-02-26|2008-02-27|Estimate|||||||2008-05-16|2008-05-20|Estimate|March 2008||2008-03-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients|A Phase 2, Randomized, Crossover Study to Evaluate the Effect of Intranasal Insulin and NovoLog on Postprandial Glycemic Control in Type 2 Diabetic Patients|Completed||Phase 2|18|Actual|Nastech Pharmaceutical Company, Inc.||2|||f||||f||||||||||2018-06-01 02:24:31.294955|2018-06-01 02:24:31.294955
NCT00624754|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2013-05-03|2008-02-25|2008-02-27|Estimate|||||||2013-05-03|2013-05-06|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Alloforb||Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT|recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients|Completed||Phase 2|32|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:24:31.382109|2018-06-01 02:24:31.382109
NCT00624741|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2012-06-20|2008-02-15|2008-02-27|Estimate|||||||2012-06-20|2012-06-22|Estimate||||June 2012|2012-06-30||||||||Expanded Access|||Compassionate Use Study of Pergolide in Patients With Parkinson's Disease|Compassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's Disease|No longer available|||||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 02:24:31.472192|2018-06-01 02:24:31.472192
NCT00624728|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2012-05-03|2008-02-15|2008-02-27|Estimate|||||||2012-05-03|2012-05-04|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|GLIO-TEP||Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)|Assessment of 18Fluoro-thymidine PET-CT for the Volume Definition of High-grade Gliomas (GLIO-TEP) : Correlation With Histopathology|Completed||Phase 1/Phase 2|21|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-06-01 02:24:31.523683|2018-06-01 02:24:31.523683
NCT00624715|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2017-11-28|2008-02-26|2008-02-27|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2007||2007-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Cannabinoid Receptor Function & Alcoholism|Cannabinoid Receptor Function & Alcoholism: Effects of Δ-9-THC|Active, not recruiting||Phase 1|36|Anticipated|Yale University||2|||f||||||||||||||2018-06-01 02:24:31.595285|2018-06-01 02:24:31.595285
NCT00624702|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2010-08-26|2008-02-25|2008-02-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|February 2008||2008-02-29|August 2010|2010-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma|A Multi-center, Randomized, Single-dose, Double-blind, 4-way Cross-over Study to Evaluate Tolerability Following Treatment With Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma|Completed||Phase 1|98|Actual|Novartis||4|||f||||f||||||||||2018-06-01 02:24:31.755327|2018-06-01 02:24:31.755327
NCT00624689|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2016-10-28|2008-02-26|2008-02-27|Estimate|||||||2016-10-28|2016-10-31|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|March 2013|Actual|2013-03-31||Interventional|TUMME||Effects of Milk Fat Globule Membrane (MFGM) - Enriched Formula With Reduced Energy and Protein Content on Growth and Development|Double-blinded Interventional Study on the Effects of MFGM-enriched Formula With Reduced Energy and Protein Content on Growth and Development|Active, not recruiting||N/A|240|Anticipated|Umeå University||3|||f||||f||||||||||2018-06-01 02:24:31.834332|2018-06-01 02:24:31.834332
NCT00624676|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2011-09-18|2008-02-26|2008-02-27|Estimate|||||||2011-09-18|2011-09-20|Estimate|January 2006||2006-01-31|September 2011|2011-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne Vulgaris|Randomized Study Comparing the Efficacy and Tolerance of a Lipophilic Hydroxy Acid Derivative of Salicylic Acid and 5% Benzoyl Peroxide in the Treatment of Facial Acne Vulgaris|Completed||N/A|80|Actual|Cosmetique Active International||2|||f||||f||||||||||2018-06-01 02:24:31.89938|2018-06-01 02:24:31.89938
NCT00624663|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2014-03-26|2008-02-15|2008-02-27|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2009||2009-01-31|February 2008|2008-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|RIVA-1||A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers|A Double-Blind, Placebo-controlled Crossover Study to Assess the Pharmacokinetic Profile and the Physiological and Behavioral Effects of Repeat Rivastigmine (Exelon®) Administration in Young Healthy Male Volunteers|Completed||N/A|15|Actual|Tel-Aviv Sourasky Medical Center||3|||f||||t||||||||||2018-06-01 02:24:31.98436|2018-06-01 02:24:31.98436
NCT00624650|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2011-05-27|2008-02-26|2008-02-27|Estimate|||||||2011-05-27|2011-05-30|Estimate|February 2008||2008-02-29|July 2010|2010-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|HEAL||Hemodynamics and Extravascular Lung Water in Acute Lung Injury|Hemodynamics and Extravascular Lung Water in Acute Lung Injury: A Prospective Randomized Controlled Multicentered Trial of Goal Directed Treatment of EVLW Versus Standard Management for the Treatment of Acute Lung Injury|Completed||Phase 2|72|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:24:32.06999|2018-06-01 02:24:32.06999
NCT00624637|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2008-02-25|2008-02-25|2008-02-27|Estimate|||||||2008-02-25|2008-02-27|Estimate|January 2008||2008-01-31|February 2008|2008-02-29|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|aromatherapy||Does Massage With or Without Aromatherapy Reduce Infant's Distress?|Does Massage With or Without Aromatherapy Reduce Infant's Distress After Craniofacial Surgery? A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|110|Anticipated|Erasmus Medical Center||3|||f||||f||||||||||2018-06-01 02:24:32.219725|2018-06-01 02:24:32.219725
NCT00624624|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2014-11-05|2008-02-25|2008-02-27|Estimate|||||||2014-11-05|2014-11-06|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism|Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism|Completed|||24|Actual|Rijnstate Hospital|||4||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:24:32.340411|2018-06-01 02:24:32.340411
NCT00624611|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2011-04-12|2008-02-26|2008-02-27|Estimate|||||||2011-04-12|2011-04-14|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Effect of Washing Red Blood Cells on Post Heart Surgery Blood Loss|Post Cardiac Surgery Blood Loss: Effect of Washing Residual Cardiopulmonary Bypass Circuit Blood Red Cells Prior to Re-infusion. A Proof of Concept Study|Completed||Phase 3|9|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 02:24:32.404947|2018-06-01 02:24:32.404947
NCT00624598|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-09-15|2008-02-26|2008-02-27|Estimate|||||||2008-09-15|2008-09-17|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|WCPC||The Short-Term Effect of a Technology Driven Weight Control (SMART) Program for Obese Adults|Phase I Study of Integrating RMR Technology and Email Counseling in a PCP Office.|Completed||N/A|110|Actual|Colorado Center for Chronic Care Innovations, Inc.||2|||f||||f||||||||||2018-06-01 02:24:32.474456|2018-06-01 02:24:32.474456
NCT00624585|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2012-05-23||2013-11-21|2008-02-25|2008-02-27|Estimate|2012-05-23|2012-06-25|Estimate||||2013-11-21|2013-12-16|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts|A Pilot Study of Oral Dasatinib in Subjects With MDS and Excess Marrow Blasts|Completed||N/A|18|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 02:24:32.548803|2018-06-01 02:24:32.548803
NCT00624572|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2008-02-25|2008-02-25|2008-02-27|Estimate|||||||2008-02-25|2008-02-27|Estimate|October 2007||2007-10-31|February 2008|2008-02-29|February 2009|Anticipated|2009-02-28|November 2008|Anticipated|2008-11-30||Interventional|||Efficacy of Chlorexidine as Intracanal Medicament in Primary Teeth|Efficacy of 1% Chlorexidine Gel as Intracanal Medicament in Primary Molar Teeth - a Clinical and Microbiological Study|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Universidade Federal do Ceara|||||f||||||||||||||2018-06-01 02:24:32.985629|2018-06-01 02:24:32.985629
NCT00624559|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2011-08-17||2012-01-04|2008-02-15|2008-02-27|Estimate|2011-11-16|2011-12-21|Estimate||||2012-01-04|2012-01-06|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure|COX-2 Regulation of Renal Sodium Handling in Blood Pressure Maintenance|Completed||Phase 4|12|Actual|University of Delaware||4|||f||||t||||||||||2018-06-01 02:24:33.059741|2018-06-01 02:24:33.059741
NCT00624546|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2015-10-23|2008-02-26|2008-02-27|Estimate|||||||2015-10-23|2015-10-26|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD|Effect of Antireflux Therapy on the Expression of Genes Known to be Important in Inflammation, Metaplasia and Neoplasia in Patients With GERD|Terminated|||24|Actual|University of Rochester|||2|Expected recruitment numbers have not been achieved.|f||||t||||||Samples With DNA|"~     Esophageal mucosal biopsies~   "|||2018-06-01 02:24:33.365359|2018-06-01 02:24:33.365359
NCT00624533|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-26|2008-02-26|2008-02-27|Estimate|||||||2008-02-26|2008-02-27|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|October 2006|Actual|2006-10-31|March 2006|Actual|2006-03-31||Interventional|GDS||Efficiency of GDS Method for Lumbar Stabilization for Non-Specific Low Back Pain in Primary Care|Evaluation of the Efficiency of Physiotherapeutic Treatment of Non-Specific Low Back Pain in Primary Care Centers Through GDS Techniques for Articular and Muscular Chains|Completed||Phase 2|160|Actual|Carlos III Health Institute||2|||f||||t||||||||||2018-06-01 02:24:33.505876|2018-06-01 02:24:33.505876
NCT00624520|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2014-11-19||2014-12-15|2008-02-15|2008-02-27|Estimate|2014-12-15|2014-12-22|Estimate||||2014-12-15|2014-12-22|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|May 2012|Actual|2012-05-31||Interventional||Subjects randomized , including drop-outs before commencement of intervention.|Mental Stress Reduction in Defibrillator Patients|Effectiveness of Mental Stress Reduction in Defibrillator Patients|Terminated||Phase 3|129|Actual|VA Office of Research and Development|Early termination of study after 12 month study extension and interim data analysis, due to high drop-out rate and exhaustion of population pool, 9 subjects short of revised target enrollment.|2||"Exhaustion of subject population pool, greater than expected drop-out rates . Data analysis~   approved by DMC for study completions"|f||||t||||||||||2018-06-01 02:24:33.602032|2018-06-01 02:24:33.602032
NCT00624494|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2011-01-04|2008-02-26|2008-02-27|Estimate|||||||2011-01-04|2011-01-06|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|OPCAB||Single Transpulmonary Thermodilution and Continuous Monitoring of Central Venous Oxygen Saturation During Off-pump Coronary Surgery|Single Transpulmonary Thermodilution and Continuous Monitoring of Central Venous Oxygen Saturation During Off-pump Coronary Surgery|Completed||N/A|40|Actual|Northern State Medical University||2|||f||||f||||||||||2018-06-01 02:24:34.225217|2018-06-01 02:24:34.225217
NCT00624481|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-03-11|2008-02-26|2008-02-27|Estimate|||||||2008-03-11|2008-03-13|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD|A Phase 2, 24-Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study To Evaluate The Effect Of Teriparatide Nasal Spray On Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density|Withdrawn||Phase 2|350|Anticipated|Nastech Pharmaceutical Company, Inc.||5|||f||||f||||||||||2018-06-01 02:24:34.303154|2018-06-01 02:24:34.303154
NCT00624468|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2016-01-19||2016-01-19|2008-02-25|2008-02-27|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|January 2011|Actual|2011-01-31|September 2009|Actual|2009-09-30||Interventional||Intent-to-treat (ITT) population included all randomized participants.|Atacicept in Subjects With Optic Neuritis|A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course|Terminated||Phase 2|34|Actual|EMD Serono|The Sponsor voluntarily terminated this trial after observing increased Multiple Sclerosis (MS) disease activity in trial 28063 (ATAMS).|2||"EMD Serono voluntarily decided to terminate this trial after observing increased MS disease~   activity in trial 28063 ATAMS [Please refer to ATAMS]"|f||||t||||||||||2018-06-01 02:24:34.411759|2018-06-01 02:24:34.411759
NCT00624455|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2009-08-17|2008-02-26|2008-02-27|Estimate|||||||2009-08-17|2009-08-18|Estimate|July 2007||2007-07-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||How Does Gabapentin Affects Post-operative Tonsillectomy Pain?|Does a Single Preoperative Dose of Gabapentin Reduce Postoperative Tonsillectomy Pain and Subsequent Morphine Requirement in Children?|Completed||Phase 3|28|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 02:24:35.289596|2018-06-01 02:24:35.289596
NCT00624442|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-02-28||2017-01-06|2008-02-19|2008-02-27|Estimate|2010-07-16|2010-08-16|Estimate||||2017-01-06|2017-02-23|Actual|April 2007||2007-04-30|January 2017|2017-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study of CK-1827452 Infusion in Stable Heart Failure|A Phase II, Multi Center, Double-Blind, Randomized, Placebo Controlled, Dose-Escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CK-1827452 in Patients With Stable Heart Failure|Completed||Phase 2|45|Actual|Cytokinetics|Other Adverse Event table shows treatment emergent adverse events that occurred in two or more patients. Total for Other Adverse Events is the number of patients affected by an adverse event where an adverse event occurred in two or more patients.|5|||f||||||||||||||2018-06-01 02:24:35.402626|2018-06-01 02:24:35.402626
NCT00624429|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2009-09-17|2008-02-25|2008-02-27|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2008||2008-03-31|February 2009|2009-02-28|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|||A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children|A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children|Unknown status|Recruiting|Phase 4|20|Anticipated|Phoenix Children's Hospital|||||f||||f||||||||||2018-06-01 02:24:36.194211|2018-06-01 02:24:36.194211
NCT00624416|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2011-02-10||2015-12-17|2008-02-15|2008-02-27|Estimate|2012-05-21|2012-06-22|Estimate||||2015-12-17|2015-12-21|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas|A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas|Completed||Phase 1/Phase 2|10|Actual|Pennington Biomedical Research Center|The single case that did not have an increase in lipoma volume showed variability which may have been because of a small lipoma making accurate measurement difficult.|1|||f||||f||||||||||2018-06-01 02:24:36.287065|2018-06-01 02:24:36.287065
NCT00624403|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2015-03-09|2008-02-26|2008-02-27|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|I-Gel||Comparison of Two Type of Laryngeal Mask : I-Gel & LMA ProSeal|LMA ProSeal & I-Gel : a Prospective Controlled Trial|Completed||N/A|700|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 02:24:36.442594|2018-06-01 02:24:36.442594
NCT00624390|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15||2016-12-13|2016-12-13|2008-02-15|2008-02-27|Estimate||||2016-12-13|2016-12-14|Estimate|2016-12-13|2016-12-14|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Sepraspray™ Laparoscopic Myomectomy Study|A Randomized, Masked Patient, Independent Reviewer, Multi-Center Pilot Study to Evaluate the Feasibility of Sepraspray™ Adhesion Barrier in Laparoscopic Myomectomy|Completed||N/A|41|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:24:36.519677|2018-06-01 02:24:36.519677
NCT00624377|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2012-02-23||2014-02-27|2008-02-26|2008-02-27|Estimate|2012-04-16|2012-05-15|Estimate||||2014-02-27|2014-03-28|Estimate|December 2007||2007-12-31|February 2014|2014-02-28||||March 2010|Actual|2010-03-31||Observational|||Safety and Effectiveness of Spiriva in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice|Safety and Effectiveness of Spiriva® in COPD (Chronic Obstructive Pulmonary Disease) Patients Under the Real Condition of Usual Practice|Completed|||2031|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 02:24:36.62657|2018-06-01 02:24:36.62657
NCT00624364|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2017-01-05|2008-02-15|2008-02-27|Estimate|||||||2017-01-05|2017-01-06|Estimate|May 2004||2004-05-31|January 2017|2017-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes|Comparison of Efficacy and Safety of Biphasic Insulin Aspart Plus Metformin to Biphasic Insulin Aspart Monotherapy in Subjects With Type 2 Diabetes|Completed||Phase 4|140|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:24:36.923868|2018-06-01 02:24:36.923868
NCT00624351|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15||2010-11-22|2011-09-02|2008-02-15|2008-02-27|Estimate||||2010-11-22|2010-11-29|Estimate|2011-09-02|2011-09-12|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease|A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease|Completed||Phase 2|227|Actual|UCB Pharma||6|||f||||t||||||||||2018-06-01 02:24:37.060204|2018-06-01 02:24:37.060204
NCT00624338|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2016-01-19||2016-03-11|2008-02-15|2008-02-27|Estimate|2016-03-11|2016-03-14|Estimate||||2016-03-11|2016-03-14|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|APRIL-SLE|Intent-to-treat (ITT) population included all the randomized participants, regardless of whether they received treatment.|Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)|A Randomised, Double-blind, Placebo Controlled, Multicentre Prospective Dose-finding Phase II/III Study With Atacicept Given Subcutaneously to Subjects Having Recently Experienced a Flare of Systemic Lupus Erythematosus (SLE)|Completed||Phase 2/Phase 3|461|Actual|EMD Serono|Atacicept 150 mg group was discontinued on 2 February 2011 based on the recommendation from the Independent Data Monitoring Committee.|3|||f||||||||||||||2018-06-01 02:24:37.240862|2018-06-01 02:24:37.240862
NCT00624325|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2011-03-10|2008-02-25|2008-02-27|Estimate|||||||2011-03-10|2011-03-11|Estimate|July 2007||2007-07-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|SCIN-C||Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders|Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders|Completed||Phase 2/Phase 3|30|Actual|Foundation for Liver Research||3|||f||||t||||||||||2018-06-01 02:24:38.365838|2018-06-01 02:24:38.365838
NCT00624312|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2013-09-30|2008-02-26|2008-02-27|Estimate|||||||2013-09-30|2013-10-01|Estimate|February 2008||2008-02-29|September 2013|2013-09-30|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations|A Prospective, Randomized, Double-Blinded Control Study of Procrit Versus Placebo to Determine Efficacy in Pre-Operative Patients Undergoing Major Surgical Oncology Operations|Withdrawn||Phase 2|0|Actual|University of Louisville||2|||f||||t||||||||||2018-06-01 02:24:38.457728|2018-06-01 02:24:38.457728
NCT00624299|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2015-03-17|2008-02-25|2008-02-27|Estimate|||||||2015-03-17|2015-03-18|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|May 2010|Anticipated|2010-05-31|March 2010|Anticipated|2010-03-31||Interventional|||Botox Clinical Trial|Botulinum Toxin: an Adjunct in Limb Reconstruction - Can it Reduce Pain and Joint Complications in the Lengthening Phase?|Withdrawn||Phase 4|0|Actual|Sheffield Children's NHS Foundation Trust||2||"A similar study had already been conducted, therefore pursuing this trial would have been~   unethical"|f||||f||||||||||2018-06-01 02:24:38.534298|2018-06-01 02:24:38.534298
NCT00624286|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2011-07-22||2011-07-22|2008-02-15|2008-02-27|Estimate|2011-07-22|2011-08-18|Estimate||||2011-07-22|2011-08-18|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|416|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:24:38.634792|2018-06-01 02:24:38.634792
NCT00624273|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2009-01-06|2008-02-19|2008-02-27|Estimate|||||||2009-01-06|2009-01-07|Estimate|February 2004||2004-02-29|July 2003|2003-07-31|February 2007|Actual|2007-02-28|November 2004|Actual|2004-11-30||Interventional|Sildenafil||Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis|Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis|Completed||Phase 2|17|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-06-01 02:24:39.014686|2018-06-01 02:24:39.014686
NCT00624260|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2016-03-17|2008-02-25|2008-02-27|Estimate|||||||2016-03-17|2016-03-18|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ITEP||Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study|Impact of PET Scan on the Curative Strategy of Colo-rectal Cancers : A Randomized Study|Completed||N/A|240|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:24:39.087814|2018-06-01 02:24:39.087814
NCT00624247|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2014-10-16|2008-02-26|2008-02-27|Estimate|||||||2014-10-16|2014-10-17|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|SWAB||Early Versus Delayed Routine HIV Testing in Connecticut Jails|Early Versus Delayed Routine HIV Testing in Connecticut Jails|Completed||Early Phase 1|621|Actual|Yale University||3|||f||||f||||||||||2018-06-01 02:24:39.169|2018-06-01 02:24:39.169
NCT00624234|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-25|2016-08-05||2017-04-11|2008-02-25|2008-02-27|Estimate|2017-02-23|2017-04-10|Actual||||2017-04-11|2017-04-13|Actual|February 2006|Actual|2006-02-28|April 2017|2017-04-30|January 2017|Actual|2017-01-31|March 2013|Actual|2013-03-31||Interventional||Participants both with and without NF1 were determined by researcher-administered assessments as having Reading Difficulties or typically developing reading skills.|Neurobiology and Treatment of Reading Disability in NF-1|Neurobiology and Treatment of Reading Disability in Neurofibromatosis Type 1 (NF-1)|Completed||N/A|184|Actual|Vanderbilt University|Small sample size; Different group sizes; Random assignment to treatment group (along with small sample size) produced some asymmetry of pretest score by treatment group, such that the NF-Tutoring Program 2 started with a higher group mean score.|6|||f||||f||||||||Yes|De-identified behavioral data (Woodcock Johnson-III NU scores) may be shared with other researchers upon request. De-identified T1 structural neuroimaging scans will be shared with other researchers through a neuroimaging data warehouse or consortium.|2018-06-01 02:24:39.245329|2018-06-01 02:24:39.245329
NCT00624221|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2010-02-02||2016-03-28|2008-02-19|2008-02-27|Estimate|2010-03-02|2010-03-12|Estimate||||2016-03-28|2016-04-27|Estimate|January 2006||2006-01-31|October 2010|2010-10-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty|A Prospective, Randomized, Single Center Study Evaluating Use of Surgeon- and Eye Bank-prepared Donor Tissue for Descemet's Stripping and Endothelial Keratoplasty, a Type of Cornea Transplant|Completed||N/A|40|Actual|Cornea Research Foundation of America||2|||f||||f||||||||||2018-06-01 02:24:39.528618|2018-06-01 02:24:39.528618
NCT00624208|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2017-11-07|2008-02-26|2008-02-27|Estimate|||||||2017-11-07|2017-11-09|Actual|February 2008||2008-02-29|November 2017|2017-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats|The Effects of Droperidol and Ondansetron on Dispersion of Myocardial Repolarization in Children|Completed||N/A|80|Actual|University of British Columbia||4|||f||||f||||||||||2018-06-01 02:24:39.687075|2018-06-01 02:24:39.687075
NCT00624195|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2013-12-09||2014-03-21|2008-02-26|2008-02-27|Estimate|2014-03-21|2014-04-23|Estimate||||2014-03-21|2014-04-23|Estimate|March 2007||2007-03-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Clinical Trial of CNS-targeted HAART (CIT2)|HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART|Completed||Phase 2/Phase 3|59|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 02:24:39.774267|2018-06-01 02:24:39.774267
NCT00624182|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2015-06-22|2008-02-19|2008-02-26|Estimate|||||||2015-06-22|2015-06-23|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer|Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer|Suspended||Phase 1|9|Anticipated|Akita University Hospital||1|||f||||t||||||||||2018-06-01 02:24:39.991161|2018-06-01 02:24:39.991161
NCT00624169|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2010-05-26|2008-02-15|2008-02-26|Estimate|||||||2010-05-26|2010-05-27|Estimate|November 2007||2007-11-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|PULP||Peptic Ulcer Perforation Study|Peptic Ulcer Perforation Study - an Optimized Perioperative Course for Patients Surgically Treated for Peptic Ulcer Perforation|Completed||N/A|200|Anticipated|Copenhagen University Hospital at Herlev|||||f||||f||||||||||2018-06-01 02:24:40.194552|2018-06-01 02:24:40.194552
NCT00624156|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2015-10-28|2008-02-25|2008-02-26|Estimate|||||||2015-10-28|2015-10-30|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Expressive Writing and Adjustment to Metastatic Breast Cancer|Expressive Writing and Adjustment to Metastatic Breast Cancer|Completed|||98|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:24:40.273195|2018-06-01 02:24:40.273195
NCT00624143|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-26|Estimate|||||||2008-02-19|2008-02-26|Estimate|February 2008||2008-02-29|January 2008|2008-01-31||||December 2009|Anticipated|2009-12-31||Interventional|||Antifungal Prophylaxis in Pediatric Acute Leukemia|Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial.|Unknown status|Recruiting|Phase 3|100|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 02:24:40.351768|2018-06-01 02:24:40.351768
NCT00624130|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2014-12-30|2008-02-25|2008-02-26|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2004||2004-03-31|December 2014|2014-12-31|June 2005|Actual|2005-06-30|||||Interventional|||Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers|Open, Randomized, Parallel Multi-center Comparison of Cycle Control and Safety of the Oral Contraceptive Yasmin 20 in a 24-day Regimen vs. Mercilon for 7 Cycles in 440 Healthy Female Volunteers|Completed||Phase 3|453|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:24:40.43078|2018-06-01 02:24:40.43078
NCT00624117|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2010-05-25|2008-02-25|2008-02-26|Estimate|||||||2010-05-25|2010-05-27|Estimate|May 2006||2006-05-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional|||Progressive Exercise After Operation of Rotator Cuff Rupture and Anterior Labrum Rupture|Progressive Exercise After Operation of Rotator Cuff Rupture and Anterior Labrum Rupture: Randomized Controlled Trial|Completed||N/A|100|Actual|Jyväskylä Central Hospital||1|||f||||f||||||||||2018-06-01 02:24:40.521152|2018-06-01 02:24:40.521152
NCT00624104|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2011-11-04|2008-02-25|2008-02-26|Estimate|||||||2011-11-04|2011-11-07|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||VLDL-triglyceride Under Acute Hyperinsulinaemia|VLDL-triglyceride Under Acute Hyperinsulinaemia|Completed|||16|Actual|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     specimen of muscle specimen of adipose tissue~   "|||2018-06-01 02:24:40.601317|2018-06-01 02:24:40.601317
NCT00624091|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-02|||2008-02-18|2008-02-18|2008-02-26|Estimate|||||||2008-02-18|2008-02-26|Estimate|September 2007||2007-09-30|February 2008|2008-02-29|September 2010|Anticipated|2010-09-30|November 2007|Anticipated|2007-11-30||Interventional|ENDOVAL||Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study (ENDOVAL)|Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis|Unknown status|Recruiting|Phase 4|216|Anticipated|Instituto de Ciencias del Corazon||2|||f||||t||||||||||2018-06-01 02:24:40.731476|2018-06-01 02:24:40.731476
NCT00624078|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-02-19|2008-02-25|2008-02-26|Estimate|||||||2011-02-19|2011-02-23|Estimate|May 2005||2005-05-31|February 2011|2011-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation|Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation|Completed||Phase 2/Phase 3|1426|Actual|Instituto Bioclon S.A. de C.V.||1|||f||||f||||||||||2018-06-01 02:24:40.8202|2018-06-01 02:24:40.8202
NCT00624065|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2009-06-11||2016-11-04|2008-02-14|2008-02-26|Estimate|2009-06-11|2009-08-03|Estimate||||2016-11-04|2016-12-28|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure|COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects With Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either Carvedilol CR + Lisinopril or Lisinopril Monotherapy|Completed||Phase 3|348|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:24:40.967765|2018-06-01 02:24:40.967765
NCT00624052|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2009-12-28||2014-05-13|2008-02-25|2008-02-26|Estimate|2010-02-25|2010-03-25|Estimate||||2014-05-13|2014-05-20|Estimate|March 2008||2008-03-31|May 2014|2014-05-31||||June 2009|Actual|2009-06-30||Interventional|||26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension|An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension|Completed||Phase 3|838|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:24:41.600712|2018-06-01 02:24:41.600712
NCT00624039|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2008-02-18|2008-02-18|2008-02-26|Estimate|||||||2008-02-18|2008-02-26|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|March 2008|Anticipated|2008-03-31|March 2008|Anticipated|2008-03-31||Interventional|||The Effect of Cataract Extraction on the Contractility of Ciliary Muscle|The Effect of Cataract Extraction on the Contractility of Ciliary Muscle|Unknown status|Enrolling by invitation|N/A|15|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-06-01 02:24:42.263073|2018-06-01 02:24:42.263073
NCT00624026|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-10-31|2008-02-14|2008-02-26|Estimate|||||||2011-10-31|2011-11-01|Estimate|November 2007||2007-11-30|October 2011|2011-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Memantine - Communication Study|Prospective, Single-arm, Multicenter, Open-label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment|Completed||Phase 3|107|Actual|Merz Pharmaceuticals GmbH||1|||f||||f||||||||||2018-06-01 02:24:42.327575|2018-06-01 02:24:42.327575
NCT00624013|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2017-04-13||2017-11-09|2008-02-15|2008-02-26|Estimate|2017-11-09|2017-12-12|Actual||||2017-11-09|2017-12-12|Actual|September 2006||2006-09-30|November 2017|2017-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Treatment of Diabetes and Depression in Hispanics and African Americans and Its Effect on A1c and Quality of Life.|Effect of Pharmacological Treatment of Depression on A1C and Quality of Life in Underserved Hispanics and African Americans With Diabetes: A Randomized, Placebo Controlled Trial.|Completed||Phase 4|89|Actual|Charles Drew University of Medicine and Science||2|||f||||t|t|f|||t|||No||2018-06-01 02:24:42.388832|2018-06-01 02:24:42.388832
NCT00624000|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-11-04|2008-02-25|2008-02-26|Estimate|||||||2011-11-04|2011-11-08|Estimate|March 2004||2004-03-31|November 2011|2011-11-30|December 2008|Actual|2008-12-31|September 2007|Actual|2007-09-30||Interventional|||IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion|IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion|Completed||N/A|7|Actual|University of North Carolina, Chapel Hill||2|||f||||||||||||||2018-06-01 02:24:42.786485|2018-06-01 02:24:42.786485
NCT00623987|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-03-24|2008-02-19|2008-02-26|Estimate|||||||2008-03-24|2008-03-25|Estimate|June 1999||1999-06-30|March 2008|2008-03-31|January 2008|Actual|2008-01-31|June 2006|Actual|2006-06-30||Interventional|Exten-DACUS||Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants|Absence of Residual Vein Thrombosis After an Episode of Unprovoked Deep Vein Thrombosis: Short-Term Anticoagulation is Safe.|Completed||Phase 4|500|Actual|Azienda Ospedaliera Universitaria Policlinico||2|||f||||t||||||||||2018-06-01 02:24:42.859838|2018-06-01 02:24:42.859838
NCT00623974|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2010-08-13||2012-12-04|2008-02-14|2008-02-26|Estimate|2010-08-13|2010-09-13|Estimate||||2012-12-04|2012-12-06|Estimate|May 2008||2008-05-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia|A Phase II Study of Short-Term Use of Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia|Terminated||Phase 2|7|Actual|M.D. Anderson Cancer Center||4||Terminated due to slow accrual.|f||||t||||||||||2018-06-01 02:24:42.943463|2018-06-01 02:24:42.943463
NCT00623961|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2015-01-12|2008-02-25|2008-02-26|Estimate|||||||2015-01-12|2015-01-13|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Validation Study of Neuropathic Pain|Validation Study of Positive Phenomena in Neuropathic Pain|Completed|||7|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 02:24:43.182225|2018-06-01 02:24:43.182225
NCT00623948|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2015-05-21|2008-02-14|2008-02-26|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Implanted Gluteal Stimulation System for Pressure Sore Prevention|Implanted Gluteal Stimulation System for Pressure Sore Prevention|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1||Suitable implanted technolgy was not available|f||||f||||||||||2018-06-01 02:24:43.255909|2018-06-01 02:24:43.255909
NCT00623935|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2014-06-17||2016-03-10|2008-02-25|2008-02-26|Estimate|2014-06-17|2014-07-17|Estimate||||2016-03-10|2016-04-08|Estimate|March 2007||2007-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|June 2013|Actual|2013-06-30||Interventional|||Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia|Hematopoietic Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia|Completed||Phase 2|56|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-06-01 02:24:43.33037|2018-06-01 02:24:43.33037
NCT00623922|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2015-04-07|2008-02-24|2008-02-26|Estimate|||||||2015-04-07|2015-04-08|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Patient Education in Rheumatic Diseases|The Effect of Patient Education on Coping and Well Being in Patients With Arthritis.|Completed||N/A|141|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 02:24:43.537654|2018-06-01 02:24:43.537654
NCT00623909|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2017-02-03|2008-02-25|2008-02-26|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 2008||2008-01-31|February 2017|2017-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study|Laser Therapy in the Treatment of Post Thoracotomy Pain; A Pilot Study.|Withdrawn||N/A|0|Actual|Weill Medical College of Cornell University||1||Principal Investigator left the institution|f||||f||||||||No|Not Applicable, study terminated prior to enrollment and closed|2018-06-01 02:24:43.602844|2018-06-01 02:24:43.602844
NCT00623896|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-17|||2008-02-25|2008-02-25|2008-02-26|Estimate|||||||2008-02-25|2008-02-26|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|August 2008|Anticipated|2008-08-31|May 2008|Anticipated|2008-05-31||Observational|Nehb-STEMI||3 Nehb Precordial Leads Anterior, Dorsalis and Inferior Allow Accurate Diagnostics of Different Heart Conditions|Nehb 3-Lead Bipolar Leads for Rapid Diagnosis & Treatment of STEMI|Unknown status|Recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 02:24:43.667724|2018-06-01 02:24:43.667724
NCT00623883|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2008-02-15|2008-02-15|2008-02-26|Estimate|||||||2008-02-15|2008-02-26|Estimate|January 1999||1999-01-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Colonoscopic Removal of Aberrant Crypt Foci: a Prospective, Randomized, Blinded Trial|Colonoscopic Biomarkers for Cancer Risk Assessment and Prevention|Completed||N/A|98|Actual|National Naval Medical Center||2|||f||||t||||||||||2018-06-01 02:24:43.727411|2018-06-01 02:24:43.727411
NCT00623870|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2016-11-01|2008-02-18|2008-02-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2008||2008-05-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.|An Open Label Study to Investigate the Maximum Tolerated Dose of RO5045337 in Patients With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL / SCLL)|Completed||Phase 1|116|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:24:43.790261|2018-06-01 02:24:43.790261
NCT00623857|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2014-11-14|2008-02-14|2008-02-26|Estimate|||||||2014-11-14|2014-11-17|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|MACH||Micronutrients and Child Health Study|Effects of Supplementation With Zinc and Other Micronutrients on the Health and Development of African Children|Completed||Phase 3|612|Actual|Wageningen University||4|||f||||t||||||||||2018-06-01 02:24:44.798173|2018-06-01 02:24:44.798173
NCT00623844|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2015-03-30|2008-02-25|2008-02-26|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|PAKT||Prevention Through Activity in Kindergarten Trial|Prevention Through Acitivity in Kindergarten Trial|Completed||Phase 2/Phase 3|718|Actual|University of Wuerzburg||2|||f||||f||||||||||2018-06-01 02:24:44.892253|2018-06-01 02:24:44.892253
NCT00623831|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2016-09-21||2016-11-10|2008-02-24|2008-02-26|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional||All Enrolled Subjects|A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen|A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.|Completed||Phase 1|17|Actual|Ludwig Institute for Cancer Research||2|||f||||f||||||||Yes|Data have been published|2018-06-01 02:24:44.996552|2018-06-01 02:24:44.996552
NCT00623818|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2018-03-27|2008-02-24|2008-02-26|Estimate|||||||2018-03-27|2018-03-29|Actual|February 14, 2008||2008-02-14|January 24, 2018|2018-01-24||||||||Observational|||Mirror Therapy for Phantom Limb Pain|fMRI Investigation of Cortical Reorganization and Phantom Limb Pain Following Amputation|Completed|||45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:24:46.474532|2018-06-01 02:24:46.474532
NCT00623805|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|2014-06-06||2014-07-16|2008-02-18|2008-02-26|Estimate|2014-07-16|2014-08-08|Estimate||||2014-07-16|2014-08-08|Estimate|March 2008||2008-03-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Intent-to-treat population: All randomized participants with a least 1 post-randomization efficacy assessment.|A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer|A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma|Completed||Phase 3|123|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:24:46.563745|2018-06-01 02:24:46.563745
NCT00623779|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2011-06-30||2012-03-20|2008-02-15|2008-02-26|Estimate|2011-06-30|2011-07-28|Estimate||||2012-03-20|2012-03-23|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)|A Controlled, Randomized, Parallel , Multi-centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA Therapy|Completed||Phase 2|128|Actual|AstraZeneca|||||f||||t||||||||||2018-06-01 02:24:47.011201|2018-06-01 02:24:47.011201
NCT00623766|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2013-12-17|2011-01-29|2014-05-27|2008-02-19|2008-02-26|Estimate|2014-05-27|2014-06-09|Estimate|2011-07-18|2011-07-20|Estimate|2014-05-27|2014-06-09|Estimate|July 2008||2008-07-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|September 2009|Actual|2009-09-30||Interventional|||Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases|A Multi-Center Phase II Study to Evaluate Tumor Response to Ipilimumab (BMS-734016) Monotherapy in Subjects With Melanoma Brain Metastases|Completed||Phase 2|99|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:24:47.724588|2018-06-01 02:24:47.724588
NCT00623753|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2017-04-24|2008-02-25|2008-02-26|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2007||2007-05-31|September 2011|2011-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults|Evaluate Tolerability and Safety of Multi-Envelope, Prime-boost HIV Vaccine (DVP) in Healthy Adults|Terminated||Phase 1|3|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 02:24:48.571872|2018-06-01 02:24:48.571872
NCT00623740|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2016-08-12|2008-02-25|2008-02-26|Estimate|||||||2016-08-12|2016-08-15|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PREMILOC||PREMILOC Trial to Prevent Bronchopulmonary Dysplasia in Very Preterm Neonates|Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial|Completed||Phase 3|523|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:24:48.654752|2018-06-01 02:24:48.654752
NCT00623727|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2011-06-10||2013-07-08|2008-02-25|2008-02-26|Estimate|2011-07-22|2011-08-17|Estimate||||2013-07-08|2013-07-15|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A|Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A|Terminated||Phase 2|143|Actual|Bayer|The recruitment and double-blind study phase were prematurely terminated after a scheduled interim analysis confirmed overt failure regarding the primary endpoint as judged by the independent Data and Safety Monitoring Board.|2|||f||||t||||||||||2018-06-01 02:24:48.790647|2018-06-01 02:24:48.790647
NCT00623714|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2010-05-24||2015-04-15|2008-02-25|2008-02-26|Estimate|2010-05-24|2010-06-22|Estimate||||2015-04-15|2015-05-05|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Induced Sputum Study (0000-065)|A Randomized, Placebo-Controlled, Crossover Study to Assess the Effects of Inhaled Fluticasone on Markers of Inflammation After Allergen Challenge in Patients With Allergic Asthma|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:24:49.419619|2018-06-01 02:24:49.419619
NCT00623701|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2013-11-07|2008-02-25|2008-02-26|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2008||2008-03-31|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|ALLEGRA6||Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation|A Multicentre, Multinational, Placebo-controlled, Double-blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen|Completed||Phase 3|126|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 02:24:49.599441|2018-06-01 02:24:49.599441
NCT00623688|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2015-01-13|2008-02-15|2008-02-26|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2008||2008-02-29|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital|Effectiveness and Costs of Albuterol Delivered by MDI With Spacer Versus Nebulizer in Children Hospitalized With Moderate and Severe Asthma Exacerbations|Completed||N/A|11|Actual|Akron Children's Hospital||2|||f||||t||||||||||2018-06-01 02:24:49.671604|2018-06-01 02:24:49.671604
NCT00623675|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-17|||2009-07-06|2008-02-25|2008-02-26|Estimate|||||||2009-07-06|2009-07-07|Estimate|February 2008||2008-02-29|July 2009|2009-07-31||||||||Interventional|||Heavy Metal Urine Analysis in 20 Healthy Persons Taking Mineralox|Heavy Metal Urine Analysis in 20 Healthy Persons Taking Mineralox|Suspended||Phase 4|20|Anticipated|CreoMed, Inc.||1|||f||||f||||||||||2018-06-01 02:24:49.748547|2018-06-01 02:24:49.748547
NCT00623662|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2018-04-02|2008-02-25|2008-02-26|Estimate|||||||2018-04-02|2018-04-03|Actual|February 2008||2008-02-29|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Preoperative Glucose Infusion: a Novel Strategy to Improve Liver Function After Liver Resection|Metabolic Preconditioning Using Intravenous Dextrose: a Novel Strategy to Improve Hepatic Function After Liver Resection|Recruiting||N/A|50|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-06-01 02:24:49.809926|2018-06-01 02:24:49.809926
NCT00623649|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2014-04-02|2008-02-25|2008-02-26|Estimate|||||||2014-04-02|2014-04-04|Estimate|November 2007||2007-11-30|February 2014|2014-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection|A Phase 1B, Multicentre, Randomized, Double-Blinded, and PLacebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and PK of Multiple Ascending Doses of VCH-916 in the Treatment Naive or Experienced Subjects With Chronic Hep C-Infection.|Completed||Phase 1|42|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-06-01 02:24:49.891782|2018-06-01 02:24:49.891782
NCT00623636|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2013-08-19||2013-12-09|2008-02-25|2008-02-26|Estimate|2013-08-19|2013-10-29|Estimate||||2013-12-09|2014-01-09|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|FREEDOM301|mITT population was defined as all randomized subjects who reported a qualifying migraine and received at least one dose of study treatment, and had at least one post-treatment efficacy evaluation.|Phase 3 Study of MAP0004 in Adult Migraineurs|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Study of MAP0004 in Adult Migraineurs for a Single Migraine Followed by Open Label Extension.|Completed||Phase 3|902|Actual|Allergan||2|||f||||t||||||||||2018-06-01 02:24:49.978475|2018-06-01 02:24:49.978475
NCT00622453|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2018-02-13|2008-02-13|2008-02-25|Estimate|||||||2018-02-13|2018-02-14|Actual|September 1996||1996-09-30|February 2018|2018-02-28|February 2015|Actual|2015-02-28|January 2006|Actual|2006-01-31||Observational|DM1||Arrhythmias in Myotonic Muscular Dystrophy|A Registry of Arrhythmias in Myotonic Muscular Dystrophy|Completed|||448|Actual|Indiana University|||1||f||||t||||||||||2018-06-01 02:25:14.278121|2018-06-01 02:25:14.278121
NCT00623623|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15||2014-04-30|2014-04-30|2008-02-25|2008-02-26|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|March 2008||2008-03-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction|STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms|Completed||Phase 3|1891|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:24:50.522167|2018-06-01 02:24:50.522167
NCT00623610|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-19|2008-02-19|2008-02-26|Estimate|||||||2008-02-19|2008-02-26|Estimate|September 2000||2000-09-30|February 2008|2008-02-29|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes|Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes|Completed||Phase 1/Phase 2|36|Actual|AZ-VUB|||||f||||f||||||||||2018-06-01 02:24:50.919566|2018-06-01 02:24:50.919566
NCT00623597|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|2015-12-10||2016-02-04|2008-02-18|2008-02-26|Estimate|2015-12-10|2016-01-14|Estimate||||2016-02-04|2016-03-07|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||The Safety Analysis Population (SAP) comprised all participants who received at least one dose of study medication. The SAP was used for all efficacy and safety analyses|A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.|A Phase I/II Study of Invirase® Boosted With Ritonavir in HIV Infected Infants and Children 4 Months to Less Than 6 Years Old|Completed||Phase 2|18|Actual|Hoffmann-La Roche||1|||f||||f||||||||Yes||2018-06-01 02:24:51.043671|2018-06-01 02:24:51.043671
NCT00623584|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2010-12-07|2008-02-25|2008-02-26|Estimate|||||||2010-12-07|2010-12-08|Estimate|April 2011||2011-04-30|December 2010|2010-12-31|October 2012|Anticipated|2012-10-31|April 2012|Anticipated|2012-04-30||Interventional|SFM||Comparison of Corneal Grafts Cultured in Serum-free Versus Corneal Grafts Cultured in Serum Supplemented Culture Media|In Vitro and Clinical Comparison of Corneal Grafts Cultured in Serum Free Medium or Standard Serum Supplemented Medium in Patients With Degeneration of the Corneal Endothelium|Unknown status|Not yet recruiting|N/A|60|Anticipated|Klinikum Chemnitz gGmbH||2|||f||||t||||||||||2018-06-01 02:24:51.914561|2018-06-01 02:24:51.914561
NCT00623571|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2008-02-25|2008-02-25|2008-02-26|Estimate|||||||2008-02-25|2008-02-26|Estimate|April 2004||2004-04-30|January 2004|2004-01-31|October 2005|Actual|2005-10-31|April 2005|Actual|2005-04-30||Interventional|||Hospitalization at Home of Elderly Patients With Heart Failure|"Acute Exacerbation of Chronic Heart Failure: Hospital at Home Versus Inpatient Care for Elderly Patients. A Randomized, Controlled Trial."|Completed||N/A|101|Actual|Azienda Ospedaliera San Giovanni Battista||2|||f||||f||||||||||2018-06-01 02:24:52.008569|2018-06-01 02:24:52.008569
NCT00623558|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-17|||2013-12-03|2008-02-17|2008-02-26|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|August 2013|Actual|2013-08-31|November 2012|Actual|2012-11-30||Interventional|||Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)|A Randomized, Multicenter, Open Phase II Study of Cetuximab With Docetaxel, Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Completed||Phase 2|92|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-06-01 02:24:52.061281|2018-06-01 02:24:52.061281
NCT00623545|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2013-07-22||2015-01-05|2008-02-25|2008-02-26|Estimate|2015-01-05|2015-01-09|Estimate||||2015-01-05|2015-01-09|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Bioenergetic Alterations After Exenatide Administration|Bioenergetic Alterations After Exenatide Administration|Completed||Phase 4|28|Actual|University of Wisconsin, Madison|study was limited by the number of subjects who did not complete the study as a result of nausea. The nausea was short-lived and mild in all subjects that completed the study.|1|||f||||f||||||||||2018-06-01 02:24:52.124722|2018-06-01 02:24:52.124722
NCT00623532|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2009-05-18|2008-02-15|2008-02-26|Estimate|||||||2009-05-18|2009-05-19|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|February 2008|Actual|2008-02-29|||||Interventional|||Intervention Study of Mind-Body Physical Activity in Frail Institutionalized Elderly|A Randomized Interventional Study of a Cognition-Action Physical Activity and Adapted Tai-Chi in Frail Institutionalized Elderly|Completed||N/A|160|Actual|Association de Recherche Gerontologique||3|||f||||t||||||||||2018-06-01 02:24:52.270164|2018-06-01 02:24:52.270164
NCT00623519|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-03-06|2008-02-25|2008-02-26|Estimate|||||||2009-03-06|2009-03-09|Estimate|June 2004||2004-06-30|March 2009|2009-03-31|February 2009|Actual|2009-02-28|||||Observational|||Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole|Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole.|Completed|||165|Actual|AstraZeneca|||1||f||||||||||||||2018-06-01 02:24:52.434285|2018-06-01 02:24:52.434285
NCT00623506|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2013-03-05||2013-05-13|2008-02-25|2008-02-26|Estimate|2013-05-13|2013-06-20|Estimate||||2013-05-13|2013-06-20|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|August 2009|Actual|2009-08-31||Interventional|||Adjunctive Pregnenolone in Veterans With Mild TBI|Adjunctive Pregnenolone in Veterans With Mild TBI|Completed||N/A|30|Actual|Durham VA Medical Center||2|||f||||||||||||||2018-06-01 02:24:52.521531|2018-06-01 02:24:52.521531
NCT00623493|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-24|||2018-04-04|2008-02-24|2008-02-26|Estimate|||||||2018-04-04|2018-04-05|Actual|February 7, 2008||2008-02-07|August 17, 2017|2017-08-17||||||||Observational|||Detecting Risk of Suicide in a Pediatric Emergency Department|Detecting Risk of Suicide in a Pediatric Emergency Department|Completed|||524|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:24:52.887275|2018-06-01 02:24:52.887275
NCT00623480|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2013-05-02|2012-09-18|2014-11-05|2008-02-25|2008-02-26|Estimate|2013-07-08|2013-08-07|Estimate|2012-09-18|2012-09-25|Estimate|2014-11-05|2014-11-17|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|September 2011|Actual|2011-09-30||Interventional|SPINART||Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment|Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment|Completed||Phase 3|84|Actual|Bayer||2|||f||||t||||||||||2018-06-01 02:24:52.991347|2018-06-01 02:24:52.991347
NCT00623467|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|2011-06-20||2014-01-16|2008-02-25|2008-02-26|Estimate|2011-09-01|2011-10-06|Estimate||||2014-01-16|2014-02-10|Estimate|December 2007||2007-12-31|January 2014|2014-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging|A Multicenter, Open-label, Phase 3 Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients Referred for Contrast-enhanced MRI of the Central Nervous System (CNS).|Completed||Phase 3|343|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:24:53.502534|2018-06-01 02:24:53.502534
NCT00623454|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-08-25|2008-02-14|2008-02-26|Estimate|||||||2011-08-25|2011-08-29|Estimate|March 2007||2007-03-31|August 2011|2011-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Non Cardiac Chest Pain and Benign Palpitations|A Randomized Controlled Trial of Cognitive Behavioural Therapy for Non-cardiac Chest Pain and Palpitations.|Completed||Phase 4|40|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 02:24:54.780973|2018-06-01 02:24:54.780973
NCT00623441|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|2009-09-01||2015-10-26|2008-02-25|2008-02-26|Estimate|2011-11-14|2011-12-16|Estimate||||2015-10-26|2015-11-23|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|February 2009|Actual|2009-02-28|November 2007|Actual|2007-11-30||Observational|eFive||E-Five Registry: A World-Wide Registry With The Endeavor Zotarolimus Eluting Coronary Stent|E-Five Registry: To Evaluate the 'Real World' Clinical Performance of the Medtronic Endeavor ABT-578 Eluting Coronary Stent System; A Prospective, Multicenter Registry|Completed|||8314|Actual|Medtronic Cardiovascular|Data collection in this large global registry was limited to MACE (major adverse cardiac events) defined as the composite endpoint of death, myocardial infarction (Q- and non-Q-wave), emergent cardiac bypass surgery and TLR.||||f||||t||||||||||2018-06-01 02:24:54.89621|2018-06-01 02:24:54.89621
NCT00623428|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|2013-05-02||2013-07-15|2008-02-18|2008-02-26|Estimate|2013-05-02|2013-06-24|Estimate||||2013-07-15|2013-07-22|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response|A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response|Completed||Phase 3|235|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:24:55.13769|2018-06-01 02:24:55.13769
NCT00623415|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2018-03-19|2008-02-15|2008-02-26|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2007||2007-12-31|December 2017|2017-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|FLORIMS||Flupirtine as Oral Treatment in Multiple Sclerosis|Multicentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-β1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis|Terminated||Phase 2|30|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:24:56.343195|2018-06-01 02:24:56.343195
NCT00623402|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2011-01-11|2008-02-14|2008-02-26|Estimate|||||||2011-01-11|2011-01-12|Estimate|January 2008||2008-01-31|February 2008|2008-02-29||||October 2009|Actual|2009-10-31||Interventional|SoraPeg||Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma|Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma: a Prospective Non-randomized, Multicenter Phase II Study|Completed||Phase 2|55|Anticipated|University of Schleswig-Holstein||1|||f||||t||||||||||2018-06-01 02:24:56.505369|2018-06-01 02:24:56.505369
NCT00623389|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2018-01-23|2008-02-15|2008-02-26|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2005||2005-05-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|LE-IST||Evaluation of an Advanced Lower Extremity Neuroprostheses|Evaluation of Advanced Lower Extremity Neuroprostheses|Recruiting||N/A|10|Anticipated|Case Western Reserve University||1|||f||||t||||||||||2018-06-01 02:24:56.681412|2018-06-01 02:24:56.681412
NCT00623376|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-25|2008-02-25|2008-02-26|Estimate|||||||2008-02-25|2008-02-26|Estimate|July 2007||2007-07-31|June 2007|2007-06-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons|Randomized Double Blind Cross Over Study Assessing the Effect of Cannabiniods on Spasticity in Spinal Cord Injured Persons :A Pilot Study|Completed||Phase 2|||University of Manitoba||2|||f||||||||||||||2018-06-01 02:24:56.90545|2018-06-01 02:24:56.90545
NCT00623363|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02||2011-04-04|2015-11-06|2008-02-19|2008-02-26|Estimate||||2011-04-04|2011-04-12|Estimate|2015-11-06|2015-12-07|Estimate|April 2007||2007-04-30|November 2015|2015-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease||Completed||Phase 2|27|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 02:24:57.13819|2018-06-01 02:24:57.13819
NCT00623350|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2011-05-11|2008-02-25|2008-02-26|Estimate|||||||2011-05-11|2011-05-12|Estimate|December 2007||2007-12-31|May 2011|2011-05-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Stroke DOC Arizona TIME - Stroke Team Remote Evaluation Using a Digital Observation Camera|Stroke Team Remote Evaluation Using a Digital Observation Camera Arizona - The Initial Mayo Clinic Experience|Completed||N/A|60|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:24:57.220959|2018-06-01 02:24:57.220959
NCT00623337|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2017-08-23|2008-02-15|2008-02-26|Estimate|||||||2017-08-23|2017-08-24|Actual|January 2009||2009-01-31|February 2010|2010-02-28|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|Newhints||Ghana Newborn Home Visits Neonatal Mortality Trial|Cluster Randomised Trial to Evaluate the Impact of Routine Home Visits to Provide a Package of Essential Newborn Care Interventions in the Third Trimester of Pregnancy and the 1st Week of Life on Neonatal Mortality in Rural Ghana|Completed||Phase 3|15000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 02:24:57.325644|2018-06-01 02:24:57.325644
NCT00623324|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-09-29|2008-02-24|2008-02-26|Estimate|||||||2011-09-29|2011-10-03|Estimate|January 2008||2008-01-31|September 2011|2011-09-30||||July 2008|Actual|2008-07-31||Interventional|||The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease|A Phase II, Dose Ranging, Randomized, Double Blind, Placebo-controlled, Multi-center, Pilot Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of Aplindore in Patients With Early Stage Parkinson's Disease|Completed||Phase 2|40|Anticipated|Ligand Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:24:57.408594|2018-06-01 02:24:57.408594
NCT00623298|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-25|2008-02-25|2008-02-26|Estimate|||||||2008-02-25|2008-02-26|Estimate|January 2005||2005-01-31|February 2008|2008-02-29|March 2006|Actual|2006-03-31|||||Interventional|||Narrative Exposure Therapy Versus Group Interpersonal Psychotherapy|Narrative Exposure Therapy Versus Group Interpersonal Psychotherapy -A Controlled Clinical Trial With Orphaned Survivors of the Rwandan Genocide|Terminated||Phase 2|26|Actual|University of Konstanz||3|||f||||f||||||||||2018-06-01 02:24:57.484861|2018-06-01 02:24:57.484861
NCT00623285|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-03-14|2008-02-14|2008-02-26|Estimate|||||||2011-03-14|2011-03-16|Estimate|April 2008||2008-04-30|March 2011|2011-03-31|June 2011|Anticipated|2011-06-30|March 2011|Anticipated|2011-03-31||Interventional|||The Effects of Peri-operative Pregabalin Administration on Post-operative Analgesia in Patients Undergoing Coronary Bypass Grafting|The Effects of Peri-operative Pregabalin Administration on Post-operative Analgesia in Patients Undergoing Coronary Bypass Grafting|Unknown status|Recruiting|Phase 3|40|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-06-01 02:24:57.555414|2018-06-01 02:24:57.555414
NCT00623272|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2015-08-21|2008-02-25|2008-02-26|Estimate|||||||2015-08-21|2015-08-24|Estimate|November 2008||2008-11-30|June 2008|2008-06-30|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Left Ventricular Function Assessment After Acute Myocardial Infarction: Comparison Between Bi-, Three-dimensional and Cardiac Magnetic Resonance|Left Ventricular Function Assessment After Acute Myocardial Infarction: Comparison Between bi-, Three-dimensional and Cardiac Magnetic Resonance|Completed||N/A|120|Actual|Assistance Publique Hopitaux De Marseille|||||f||||t||||||||||2018-06-01 02:24:57.667432|2018-06-01 02:24:57.667432
NCT00623259|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2010-05-19|2008-02-19|2008-02-26|Estimate|||||||2010-05-19|2010-05-20|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects|Phase I Vaccination Study Testing the Safety and Reactogenicity of a Recombinant MVA HIV Multiantigen Vaccine (MVA-mBN120B) in HIV-infected Subjects With CD4 Count > 350/µL|Completed||Phase 1|15|Anticipated|Bavarian Nordic||1|||||||t||||||||||2018-06-01 02:24:57.776656|2018-06-01 02:24:57.776656
NCT00623246|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2016-09-28|2008-02-21|2008-02-25|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2007||2007-12-31|December 2014|2014-12-31|November 2015|Actual|2015-11-30|November 2012|Actual|2012-11-30||Interventional|BREATHE||Evaluating Behavioral Treatments to Improve Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in People With Obstructive Sleep Apnea (The BREATHE Study)|Motivating Adherence to CPAP in Obstructive Sleep Apnea|Completed||N/A|306|Actual|National Jewish Health||3|||f||||t||||||||||2018-06-01 02:24:57.881367|2018-06-01 02:24:57.881367
NCT00623233|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2011-12-02||2011-12-02|2008-02-13|2008-02-25|Estimate|2011-12-02|2012-01-09|Estimate||||2011-12-02|2012-01-09|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer|A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes|Completed||Phase 2|52|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:24:57.972477|2018-06-01 02:24:57.972477
NCT00623220|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2013-10-28|2008-02-13|2008-02-25|Estimate|||||||2013-10-28|2013-10-30|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Inhaled Nitrous Oxide for Pain Relief During Eye Exam in the Pre-term Infant|A Randomized Controlled Trial on the Effectiveness of Inhaled Nitrous Oxide for Pain Relief During ROP Screening Exam in the Pre-term Infant|Completed||Phase 3|40|Actual|McGill University Health Center||2|||f||||f||||||||||2018-06-01 02:24:58.312139|2018-06-01 02:24:58.312139
NCT00623207|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2015-07-24|2008-02-22|2008-02-25|Estimate|||||||2015-07-24|2015-07-27|Estimate|December 2007||2007-12-31|July 2015|2015-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Use of Atropine in Tredmill Stress Testing|Safety and Feasibility of Atropine Added During Treadmill Stress Testing in Patients With Chronotropic Incompetence or Poor Exercise Capacity.|Completed||Phase 3|103|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-06-01 02:24:58.374693|2018-06-01 02:24:58.374693
NCT00623194|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2010-09-05||2016-10-17|2008-02-14|2008-02-25|Estimate|2011-01-23|2011-01-24|Estimate||||2016-10-17|2016-11-28|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689|A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 Years With Type 1 Diabetes on a Basal-Bolus Regimen With Insulin Aspart as Bolus Insulin|Completed||Phase 3|146|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 02:24:58.460405|2018-06-01 02:24:58.460405
NCT00623181|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2011-07-14|2010-03-31|2016-04-12|2008-02-22|2008-02-25|Estimate|2011-07-14|2011-08-11|Estimate|2010-03-31|2010-04-02|Estimate|2016-04-12|2016-04-14|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults|Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age|Completed||Phase 2|110|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:24:59.949469|2018-06-01 02:24:59.949469
NCT00623168|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2018-05-02|2008-02-13|2008-02-25|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2008|Actual|2008-02-29|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Ribavirin for Hemorrhagic Fever With Renal Syndrome|A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in the 121st Combat Support Hospital (Seoul, Korea)|Enrolling by invitation||Phase 2|50|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 02:25:00.321962|2018-06-01 02:25:00.321962
NCT00623155|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-22|2008-02-22|2008-02-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|July 2002||2002-07-31|September 2002|2002-09-30|January 2004|Actual|2004-01-31|July 2003|Actual|2003-07-31||Interventional|||Seasonal Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine in Children in Mali|Evaluation of a Malaria Transmission Target Strategy Based on the Periodic Treatment With Sulfadoxine-Pyrimethamine vs. Early Case Management|Completed||N/A|262|Actual|University of Bamako||2|||f||||f||||||||||2018-06-01 02:25:00.49934|2018-06-01 02:25:00.49934
NCT00623142|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-22|2008-02-22|2008-02-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery|The Effects of Hyperbaric Oxygen Preconditioning On Cardiovascular Protection & Ischemic Reperfusion Injury|Completed||Phase 1/Phase 2|81|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 02:25:00.596108|2018-06-01 02:25:00.596108
NCT00623129|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2016-04-18|2008-02-22|2008-02-25|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2006||2006-02-28|August 2011|2011-08-31||||November 2010|Actual|2010-11-30||Interventional|||Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer|Electroacupuncture for Xerostomia in Head and Neck Patients|Terminated||N/A|30|Anticipated|Mayo Clinic||||Slow accrual; did not meet accrual goal|f||||t||||||||||2018-06-01 02:25:00.700271|2018-06-01 02:25:00.700271
NCT00623116|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2008-02-13|2008-02-13|2008-02-25|Estimate|||||||2008-02-13|2008-02-25|Estimate|December 2007||2007-12-31|January 2008|2008-01-31|December 2025|Anticipated|2025-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland|Kallmann Syndrome in Finland|Enrolling by invitation||N/A|50|Anticipated|Hospital for Children and Adolescents, Finland|||||f||||f||||||||||2018-06-01 02:25:00.824642|2018-06-01 02:25:00.824642
NCT00622440|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2014-07-17||2014-08-11|2008-02-22|2008-02-25|Estimate|2014-07-17|2014-08-12|Estimate||||2014-08-11|2014-08-15|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AIJP||Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream|Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream|Completed||Phase 2|70|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:25:14.368816|2018-06-01 02:25:14.368816
NCT00623103|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2011-10-19||2011-10-19|2008-02-22|2008-02-25|Estimate|2011-10-19|2011-11-28|Estimate||||2011-10-19|2011-11-28|Estimate|January 2008||2008-01-31|October 2011|2011-10-31||||November 2010|Actual|2010-11-30||Interventional|||Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)|A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)|Completed||Phase 3|583|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:25:00.98999|2018-06-01 02:25:00.98999
NCT00623090|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2012-12-11|2008-02-22|2008-02-25|Estimate|||||||2012-12-11|2012-12-13|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|PCSEd||Internet-Based Education for Prostate Cancer Screening|Internet-Based Education for Prostate Cancer Screening|Completed||Phase 3|1893|Actual|Georgetown University||3|||f||||f||||||||||2018-06-01 02:25:02.281679|2018-06-01 02:25:02.281679
NCT00623077|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2017-12-03|2008-02-22|2008-02-25|Estimate|||||||2017-12-03|2017-12-05|Actual|August 2005||2005-08-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|July 2012|Actual|2012-07-31||Interventional|||MT2004-30: Tomotherapy for Solid Tumors|Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors|Terminated||Phase 1|23|Actual|Masonic Cancer Center, University of Minnesota||1||Replaced by another study|f||||t||||||||||2018-06-01 02:25:02.379898|2018-06-01 02:25:02.379898
NCT00623064|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2014-06-30|2008-02-22|2008-02-25|Estimate|||||||2014-06-30|2014-07-01|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer|Phase I Study of Cisplatin, Gemcitabine and Lapatinib as First Line Treatment in Advanced/Metastatic Urothelial Cancer|Completed||Phase 1|18|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 02:25:02.518141|2018-06-01 02:25:02.518141
NCT00623051|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2013-07-16|2008-02-22|2008-02-25|Estimate|||||||2013-07-16|2013-07-17|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ORANGE FARM 2||Evaluation of the Extension at Community Level of Safe Male Circumcision (ANRS 12126 ORANGE FARM 2)|Evaluation of the Extension at Community Level of Safe Male Circumcision (ANRS 12126 ORANGE FARM 2)|Completed||N/A|27000|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-06-01 02:25:02.586201|2018-06-01 02:25:02.586201
NCT00623038|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-04-21|2008-02-14|2008-02-25|Estimate|||||||2011-04-21|2011-04-22|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|TEST-APGAR||Trial to Evaluate a Specified Type of APGAR|Trial to Evaluate a Specified Type of APGAR|Completed|||1855|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 02:25:02.659455|2018-06-01 02:25:02.659455
NCT00623025|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-07-28|2008-02-14|2008-02-25|Estimate|||||||2011-07-28|2011-08-01|Estimate|January 2009||2009-01-31|July 2011|2011-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Creon in HIV Patients With Steatorrhea|Double-blind, Cross-over, Randomized, Placebo-controlled, Multi-center Study to Investigate the Effect of Creon®25 000 on the Coefficient of Fat Absorption of HIV-infected Patients|Terminated||Phase 3|34|Actual|Abbott||2||Discontinued prematurely due to low enrollment|f||||f||||||||||2018-06-01 02:25:02.715358|2018-06-01 02:25:02.715358
NCT00623012|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2016-10-06||2016-12-09|2008-02-13|2008-02-25|Estimate|2016-12-09|2017-02-03|Estimate||||2016-12-09|2017-02-03|Estimate|February 2008||2008-02-29|December 2016|2016-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Rapamycin for Prevention of Chronic Graft-Versus-Host Disease|Rapamycin for Prevention of Chronic Graft-Versus-Host Disease|Terminated||Phase 1/Phase 2|2|Actual|Yale University|Only 2 patients were enrolled. Early termination of trial, so patients were not followed long enough to see improvement.|1||Low accrual|f||||f||||||||||2018-06-01 02:25:02.795479|2018-06-01 02:25:02.795479
NCT00622999|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-03-10|2008-02-14|2008-02-25|Estimate|||||||2011-03-10|2011-03-11|Estimate|January 2003||2003-01-31|March 2011|2011-03-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Observational|||Effects of Malnutrition on Colon Cancer Patients With Abdominal Surgery|Effects of Malnutrition on Colon Cancer Patients With Abdominal Surgery|Completed|||186|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-06-01 02:25:02.950282|2018-06-01 02:25:02.950282
NCT00622986|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-22|2008-02-22|2008-02-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|CCCCC||China Cimicifuga Trial of Climacteric Complaint Control|A Multicentered RCT Study of the Efficacy and Safety of an Extract of Cimicifuga Foetida L. for the Treatment of Climacteric Symptoms of Chinese Women|Unknown status|Recruiting|Phase 4|288|Anticipated|Shandong Luye Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 02:25:03.04425|2018-06-01 02:25:03.04425
NCT00622973|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2011-10-07|2008-02-22|2008-02-25|Estimate|||||||2011-10-07|2011-10-12|Estimate|September 2007||2007-09-30|October 2011|2011-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases|Noninvasive Detection of Clinically Occult Lymph Node Metastases in Prostate and Bladder Cancer Evaluated by USPIO-Enhanced MRI and Diffusion-Weighted MRI: A Histopathological Correlation|Completed||Phase 3|130|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 02:25:03.271492|2018-06-01 02:25:03.271492
NCT00622960|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2008-02-22|2008-02-22|2008-02-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|April 2004||2004-04-30|February 2008|2008-02-29|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effect of High Monounsaturated Fat Diet on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes|Comparison of High Monounsaturated Fat and High Carbohydrate Diets on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes|Completed||Phase 1|124|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 02:25:03.371814|2018-06-01 02:25:03.371814
NCT00622947|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2010-06-25|2008-02-22|2008-02-25|Estimate|||||||2010-06-25|2010-06-28|Estimate|February 2008||2008-02-29|June 2010|2010-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Antidepressant Effect of Right Temporal Low Frequency rTMS Compared to Sham|The Antidepressant Effect of Right Temporal Kow Frequency rTMS Compared to Sham. A Clinical Controlled, Randomized, Blinded Study.|Terminated||Phase 2/Phase 3|10|Actual|University of Aarhus||2||to few included patients|f||||f||||||||||2018-06-01 02:25:03.444112|2018-06-01 02:25:03.444112
NCT00622427|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2012-06-05||2013-04-02|2008-02-22|2008-02-25|Estimate|2013-04-02|2013-05-24|Estimate||||2013-04-02|2013-05-24|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia|Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia|Completed||Phase 4|32|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:25:14.955898|2018-06-01 02:25:14.955898
NCT00622934|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2010-11-17|2008-02-21|2008-02-25|Estimate|||||||2010-11-17|2010-11-18|Estimate|July 2007||2007-07-31|November 2010|2010-11-30|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|EPREX||Relationship Between Erythropoietin Administration and Stress Responses in Trauma Patients|Relationship Between Clinical Recovery and Oxidative Stress and Inflammation Following Usage of Erythropoietin in Admitted Traumatic Patient In Intensive Care Unit|Unknown status|Recruiting|Phase 2|20|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:25:03.520154|2018-06-01 02:25:03.520154
NCT00622921|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2012-01-26|2008-02-13|2008-02-25|Estimate|||||||2012-01-26|2012-01-31|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|February 2012|Anticipated|2012-02-29|February 2012|Anticipated|2012-02-29||Interventional|||Couples-based Behavioral Psychotherapy for Male Patients With Posttraumatic Stress Disorder and Alcohol Dependence|Couples-based Behavioral Psychotherapy for Male Patients With Posttraumatic Stress Disorder and Alcohol Dependence|Withdrawn||Phase 2/Phase 3|0|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:25:03.603487|2018-06-01 02:25:03.603487
NCT00622908|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2009-06-29||2015-03-04|2008-02-14|2008-02-25|Estimate|2009-08-12|2009-08-13|Estimate||||2015-03-04|2015-03-24|Estimate|December 2004||2004-12-31|March 2015|2015-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis|Completed||Phase 2|270|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:25:03.681255|2018-06-01 02:25:03.681255
NCT00622895|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2017-03-07|2008-02-22|2008-02-25|Estimate|||||||2017-03-07|2017-03-08|Actual|September 2006||2006-09-30|March 2017|2017-03-31||||March 2018|Anticipated|2018-03-31||Interventional|||Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis|Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis|Recruiting||Phase 1/Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 02:25:04.049999|2018-06-01 02:25:04.049999
NCT00622882|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2014-01-06|2008-02-22|2008-02-25|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia|Early Infectious Disease Consultation for Better Outcomes From Staphylococcus Aureus Bacteremia|Unknown status|Recruiting|N/A|200|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 02:25:04.209711|2018-06-01 02:25:04.209711
NCT00622869|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2013-04-02||2013-05-17|2008-02-22|2008-02-25|Estimate|2013-04-02|2013-05-20|Estimate||||2013-05-17|2013-05-27|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|RAD||Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients|A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients|Completed||Phase 3|719|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:25:04.36715|2018-06-01 02:25:04.36715
NCT00622856|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2018-05-09|2008-02-13|2008-02-25|Estimate|||||||2018-05-09|2018-05-15|Actual|February 2008|Actual|2008-02-29|May 2018|2018-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Cost-efficacy of Psychological Intervention for Strengthening Parental Authority Among Parents of Diabetic Adolescents With Poor Glycemic Control|The Cost-efficacy of Psychological Intervention for Strengthening Parental Authority Among Parents of Diabetic Adolescents With Poor Glycemic Control|Completed||N/A|55|Actual|Rabin Medical Center||3|||f||||f||||||||||2018-06-01 02:25:06.715311|2018-06-01 02:25:06.715311
NCT00622843|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2014-10-07|2008-02-22|2008-02-25|Estimate|||||||2014-10-07|2014-10-09|Estimate|December 2002||2002-12-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting|An Open-Label, Phase III, Randomized Study of Pneumococcal Conjugate Vaccination in HIV, in Comparison to Polysaccharide Vaccine Boosting in Previously Vaccinated Patients|Completed||Phase 3|275|Actual|Uniformed Services University of the Health Sciences||3|||f||||t||||||||||2018-06-01 02:25:06.803753|2018-06-01 02:25:06.803753
NCT00622830|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2016-11-02|2008-02-22|2008-02-25|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-|Phase I Study of SB-480848 (Darapladib) -A Double Blind, Randomised, Placebo-controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-480848 in Healthy Japanese Male Subjects-|Completed||Phase 1|18|Anticipated|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:25:06.895708|2018-06-01 02:25:06.895708
NCT00622817|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-25|2008-02-22|2008-02-25|Estimate|||||||2008-02-25|2008-02-26|Estimate|October 2004||2004-10-31|February 2002|2002-02-28|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||The Influence of Inhaled Adrenalin Versus Decongestant as a Local Nasal Treatment in Bronchiolitis|Double Blinded Controled Study:Treatment With Adrenaline Inhalation Versus Nasal Decongestant Drops for Bronchiolitis|Completed||N/A|65|Actual|Schneider Children's Medical Center, Israel||2|||f||||f||||||||||2018-06-01 02:25:06.983687|2018-06-01 02:25:06.983687
NCT00622804|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2009-07-31|2008-02-22|2008-02-25|Estimate|||||||2009-07-31|2009-08-03|Estimate|July 2007||2007-07-31|July 2009|2009-07-31||||July 2009|Anticipated|2009-07-31||Interventional|||Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy|Phase III Study on Comparison for Bile Reflux and Gastric Stasis in Patients With Gastric Cancer After Distal Gastrectomy|Withdrawn||Phase 3|90|Anticipated|The Catholic University of Korea||3||It was very difficult to enroll patients in this study.|f||||f||||||||||2018-06-01 02:25:07.057482|2018-06-01 02:25:07.057482
NCT00622791|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2008-02-13|2008-02-13|2008-02-25|Estimate|||||||2008-02-13|2008-02-25|Estimate||||February 2008|2008-02-29||||||||Observational|||Propofol Pharmacokinetics and Pharmacodynamics During Cardiopulmonary Bypass|Effects of Cardiopulmonary Bypass on Plasma Propofol Concentrations and Bis Values During Coronary Surgery|Completed|||20|Actual|University of Sao Paulo|||2||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 02:25:07.257138|2018-06-01 02:25:07.257138
NCT00622778|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2012-04-10|2008-02-13|2008-02-25|Estimate|||||||2012-04-10|2012-04-11|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Observational|MHI||Immunemodulation in Patients With Minor Head Injury|Diagnostic Algorithm in Minor Head Injury|Completed|||130|Actual|Medical University of Vienna|||1||f||||f||||||Samples Without DNA|"~     Serum from peripheral blood~   "|||2018-06-01 02:25:07.3729|2018-06-01 02:25:07.3729
NCT00622765|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21||2011-06-03|2014-04-24|2008-02-14|2008-02-25|Estimate||||2009-12-23|2009-12-25|Estimate|2014-04-24|2014-05-13|Estimate|November 2007||2007-11-30|April 2014|2014-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects|Completed||Phase 2|321|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||t||||||||||2018-06-01 02:25:07.484749|2018-06-01 02:25:07.484749
NCT00622752|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2008-06-16|2008-02-13|2008-02-25|Estimate|||||||2008-06-16|2008-06-17|Estimate|February 2008||2008-02-29|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes|A Double-Blind, Randomized, Placebo- and NRT -Controlled Phase II Study to Assess the Effects of EVT 302 Alone and in Combination With NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes|Completed||Phase 2|90|Anticipated|Evotec Neurosciences GmbH||4|||f||||f||||||||||2018-06-01 02:25:07.591406|2018-06-01 02:25:07.591406
NCT00622739|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2014-03-12||2014-06-25|2008-02-22|2008-02-25|Estimate|2014-06-25|2014-07-21|Estimate||||2014-06-25|2014-07-21|Estimate|February 2007||2007-02-28|June 2014|2014-06-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Ziprasidone in Pediatric Bipolar Disorder|Ziprasidone in Pediatric Bipolar Disorder: a 6-week, Open-label Comparison of Rapid vs. Slow Dose Titration|Completed||Phase 4|28|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 02:25:07.673526|2018-06-01 02:25:07.673526
NCT00622726|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2013-05-08||2017-05-08|2008-02-22|2008-02-25|Estimate|2014-05-08|2014-06-09|Estimate||||2017-05-08|2017-06-06|Actual|March 2008|Actual|2008-03-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2010|Actual|2010-08-31||Interventional|BEAT-ROP||Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity|Intravitreal Bevacizumab (AvastinTM) Injections Versus Conventional Laser Surgery for Vision-threatening Retinopathy of Prematurity: a Prospective, Randomized, Non-blinded, Controlled, Multi-center, Clinical Trial|Active, not recruiting||Phase 2|150|Actual|The University of Texas Health Science Center, Houston|"Limitations:~number of patients is too small to determine efficacy of bevacizumab in posterior zone II ROP.~number of patients is too small to determine safety of bevacizumab systemically."|2|||f||||t||||||||||2018-06-01 02:25:07.973919|2018-06-01 02:25:07.973919
NCT00622713|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2010-12-10||2011-06-27|2008-02-22|2008-02-25|Estimate|2011-06-27|2011-07-26|Estimate||||2011-06-27|2011-07-26|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|EXTRA||A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)|A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26)|Completed||Phase 4|228|Actual|Novartis|||||f||||||||||||||2018-06-01 02:25:08.475712|2018-06-01 02:25:08.475712
NCT00622700|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2014-11-07|2013-12-16|2017-01-20|2008-02-22|2008-02-25|Estimate|2014-12-17|2014-12-19|Estimate|2013-12-16|2014-01-17|Estimate|2017-01-20|2017-03-13|Actual|February 2008||2008-02-29|January 2017|2017-01-31|February 2016|Actual|2016-02-29|December 2012|Actual|2012-12-31||Interventional|TOPIC|Randomized population: all randomized participants according to the treatment group to which they were assigned in the core treatment period.|Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis|An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period|Completed||Phase 3|618|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 02:25:09.146049|2018-06-01 02:25:09.146049
NCT00622687|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-22|2008-02-22|2008-02-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|September 1997||1997-09-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2003|Actual|2003-12-31||Interventional|ILODOSE||Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis|Comparision Between Maximally Tolerated Intravenous Iloprost Doses Versus Low-Dosed Iloprost for a 21-Day Treatment Course|Terminated||Phase 2|50|Actual|Charite University, Berlin, Germany||2||sufficient number to reach the primary endpoint and as planned|f||||f||||||||||2018-06-01 02:25:11.190358|2018-06-01 02:25:11.190358
NCT00622674|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2017-11-29|2008-02-22|2008-02-25|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2005||2005-11-30|April 2010|2010-04-30|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors|Phase I Study of Bortezomib (Velcade) and Cetuximab (Erbitux) for Patients With Solid Tumors Expressing EGFR|Completed||Phase 1|37|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:25:11.384441|2018-06-01 02:25:11.384441
NCT00622661|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2012-01-04|2008-02-14|2008-02-25|Estimate|||||||2012-01-04|2012-01-05|Estimate|June 2006||2006-06-30|January 2012|2012-01-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|CARB||Carbohydrates and Related Biomarkers|A Feeding Study to Examine the Effect of Glycemic Load and Obesity on Cancer Biomarkers|Completed||N/A|89|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 02:25:11.486387|2018-06-01 02:25:11.486387
NCT00622648|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2010-12-27|2008-02-22|2008-02-25|Estimate|||||||2010-12-27|2010-12-28|Estimate|January 2008||2008-01-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|LIFENOX||Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin|International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings|Completed||Phase 4|8329|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:25:11.580566|2018-06-01 02:25:11.580566
NCT00622635|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2011-07-22||2011-07-22|2008-02-22|2008-02-25|Estimate|2011-07-22|2011-08-18|Estimate||||2011-07-22|2011-08-18|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, 3-period, 14-day Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol (300 µg Once Daily [od]) in Patients With Moderate-to-severe COPD, Using Open-label Salmeterol (50 µg Twice Daily [Bis in Die, Bid]) as Active Control|Completed||Phase 3|68|Actual|Novartis||6|||f||||||||||||||2018-06-01 02:25:11.704544|2018-06-01 02:25:11.704544
NCT00622414|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2014-02-21|2008-02-22|2008-02-25|Estimate|||||||2014-02-21|2014-02-24|Estimate|April 2008||2008-04-30|October 2011|2011-10-31||||February 2010|Actual|2010-02-28||Interventional|||Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors|A Phase I Study of VEGF Trap (NSC# 724770, IND# 100137) in Children With Refractory Solid Tumors|Completed||Phase 1|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:25:15.231967|2018-06-01 02:25:15.231967
NCT00622622|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2009-02-17|2008-02-13|2008-02-25|Estimate|||||||2009-02-17|2009-02-18|Estimate|November 2006||2006-11-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|December 2006|Actual|2006-12-31||Interventional|||Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer|Phase I Study of Gemcitabine With Antiangiogenic Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 Derived From VEGFR2 in Patients With Unresectable, Locally Advanced, Recurrent or Metastatic Pancreatic Cancer|Completed||Phase 1|21|Actual|Wakayama Medical University||1|||f||||t||||||||||2018-06-01 02:25:12.369916|2018-06-01 02:25:12.369916
NCT00622609|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2017-07-19|2008-02-13|2008-02-25|Estimate|||||||2017-07-19|2017-07-21|Actual|August 1, 2007|Actual|2007-08-01|July 2017|2017-07-31|April 9, 2009|Actual|2009-04-09|April 9, 2009|Actual|2009-04-09||Interventional|||Anti-MAG First Administration to Human|A Single-blind, Single Dose, Placebo Controlled, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of GSK249320 in Healthy Volunteers|Completed||Phase 1|46|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:25:12.457522|2018-06-01 02:25:12.457522
NCT00622596|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2016-08-23|2008-02-22|2008-02-25|Estimate|||||||2016-08-23|2016-08-24|Estimate|October 2003||2003-10-31|August 2016|2016-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Project BEST||Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance|Prospective Cohort of Opiate Dependent Patients on Buprenorphine/Naloxone for Maintenance|Completed||N/A|200|Actual|Yale University||1|||f||||t||||||||No||2018-06-01 02:25:12.556102|2018-06-01 02:25:12.556102
NCT00622583|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2018-01-02|2008-02-14|2008-02-25|Estimate|||||||2018-01-02|2018-01-03|Actual|September 1, 2007|Actual|2007-09-01|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|IHMR||International Hernia Mesh Registry|A Two-Year Follow-up, Post-Implantation, Multi-center, International Hernia Mesh Registry|Recruiting|||3500|Anticipated|Ethicon, Inc.|||1||f||||f||||||||||2018-06-01 02:25:12.646757|2018-06-01 02:25:12.646757
NCT00622570|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-22|2008-02-22|2008-02-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|May 2002||2002-05-31|July 2007|2007-07-31|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension|Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension.|Terminated||Phase 3|44|Actual|Hospital Universitari Son Dureta||2||Slowly recruitment rate. Intermediate analysis|f||||f||||||||||2018-06-01 02:25:12.813243|2018-06-01 02:25:12.813243
NCT00622557|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2013-12-11|2008-02-22|2008-02-25|Estimate|||||||2013-12-11|2013-12-12|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|SOCRATES||General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)|General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)|Unknown status|Recruiting||200000|Anticipated|University Hospitals Cleveland Medical Center|||1||f||||f||||||||||2018-06-01 02:25:12.934308|2018-06-01 02:25:12.934308
NCT00622544|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2013-12-12|2008-02-22|2008-02-25|Estimate|||||||2013-12-12|2013-12-16|Estimate|July 2007||2007-07-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|MA||A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome|A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome|Completed|||44|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||Samples Without DNA|"~     Each urine sample will be assayed for albumin, total protein and creatinine. The following~     definitions will be used:~        -  Microalbuminuria: urine albumin:creatinine ratio (ACR) > 30 mcg/mg, on 3 consecutive~          measurements spaced one month apart~        -  Overt proteinuria: urine protein:creatinine ratio (UPC) > 0.2 mg/mg, on 3 consecutive~          measurements spaced one month apart~   "|||2018-06-01 02:25:13.047586|2018-06-01 02:25:13.047586
NCT00622531|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2015-11-16|2008-02-22|2008-02-25|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|USE-BNP||Serial BNP Testing for Heart Failure Management|Utilizing, Studying, Evaluating BNP for Monitoring in Patients With Heart Failure (USE-BNP)|Terminated|||108|Actual|Siemens Healthcare Diagnostics Inc|||2|Study terminated due to insufficient enrollment|f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 02:25:13.130963|2018-06-01 02:25:13.130963
NCT00622518|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2010-09-28||2010-11-04|2008-02-22|2008-02-25|Estimate|2010-11-04|2010-12-02|Estimate||||2010-11-04|2010-12-02|Estimate|February 2008||2008-02-29|November 2010|2010-11-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Ear Drops for Children With Otitis Media|Ear Drops for Children With Otitis Media|Completed||N/A|119|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:25:13.458493|2018-06-01 02:25:13.458493
NCT00622505|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2016-11-16|2008-02-22|2008-02-25|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|Z-MARK||Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients|Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma|Completed||Phase 4|159|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:25:13.802184|2018-06-01 02:25:13.802184
NCT00622492|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2008-02-22|2008-02-22|2008-02-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|January 2008||2008-01-31|February 2008|2008-02-29|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Observational|ECMO||Circulatory Changes During Venovenous (VV)- and Venoarterial (VA) Extracorporeal Membrane Oxygenation (ECMO)|ECMO in Newborn Infants: Circulatory Changes in Relation to Venovenous and Venoarterial Bypass. Implications for Peripheral Organ Circulation|Unknown status|Recruiting||30|Anticipated|Radboud University|||2||f||||||||||Samples Without DNA|"~     whole blood, urine~   "|||2018-06-01 02:25:13.935787|2018-06-01 02:25:13.935787
NCT00622479|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2014-12-17|2008-02-13|2008-02-25|Estimate|||||||2014-12-17|2014-12-18|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.|Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients With Advanced Renal Cell Carcinoma|Terminated||Phase 1|12|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:25:14.100477|2018-06-01 02:25:14.100477
NCT00622466|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-22|||2015-05-29|2008-02-22|2008-02-25|Estimate|||||||2015-05-29|2015-06-01|Estimate|October 2007||2007-10-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer|Unknown status|Active, not recruiting|Phase 2|41|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 02:25:14.19076|2018-06-01 02:25:14.19076
NCT00622401|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2016-01-20||2017-10-12|2008-02-14|2008-02-25|Estimate|2016-02-16|2016-03-16|Estimate||||2017-10-12|2017-11-14|Actual|December 2009||2009-12-31|October 2017|2017-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Females >18yo with metastatic breast cancer|Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12|Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12|Terminated||Phase 1/Phase 2|8|Actual|Dana-Farber Cancer Institute|In the conduct of the study, it became apparent that the setting of advanced breast cancer with malignant effusions/ascites for vaccine generation was a difficult setting for evaluation of an immune based therapy.|3|||f||||t||||||||||2018-06-01 02:25:15.340043|2018-06-01 02:25:15.340043
NCT00622388|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2011-08-04||2015-07-02|2008-02-13|2008-02-25|Estimate|2011-08-04|2011-09-08|Estimate||||2015-07-02|2015-07-24|Estimate|December 2007||2007-12-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|May 2010|Actual|2010-05-31||Interventional|||Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant|An Open-label, Single-arm. Multi-center Phase 2 Trial With Ofatumumab in Patients With Relapsed/Progressive Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Transplant or Relapse/Progression After Autologous Transplant|Completed||Phase 2|81|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-06-01 02:25:15.59811|2018-06-01 02:25:15.59811
NCT00622375|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2009-12-21|2008-02-22|2008-02-25|Estimate|||||||2009-12-21|2009-12-23|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers|A Phase I, Single- And Multiple-Dose, Relative Bioavailability and Pharmacokinetic Study of Encapsulated Mesalamine Granules Administered Orally to Healthy Volunteers|Completed||Phase 1|24|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 02:25:16.153365|2018-06-01 02:25:16.153365
NCT00622362|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2018-02-21|2008-02-13|2008-02-25|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2008|Actual|2008-01-31|February 2018|2018-02-28|March 24, 2014||2014-03-24|February 2009|Actual|2009-02-28||Interventional|||Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract|Depigmented and Polymerised Allergenic Extract of Dermatophagoides Pteronyssinus as Antiasthmatic Treatment for Children With Slight Allergic Asthma to Mites|Suspended||Phase 2|90|Anticipated|Laboratorios Leti, S.L.||3||Lack of recruitment|f||||f||||||||||2018-06-01 02:25:16.227962|2018-06-01 02:25:16.227962
NCT00622349|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2013-01-29|2008-02-14|2008-02-25|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2004||2004-02-29|January 2013|2013-01-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer|A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer|Completed||Phase 3|707|Actual|European Lung Cancer Working Party||3|||f||||t||||||||||2018-06-01 02:25:16.307879|2018-06-01 02:25:16.307879
NCT00622336|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2014-12-18||2017-07-14|2008-02-22|2008-02-25|Estimate|2014-12-18|2014-12-30|Estimate||||2017-07-14|2017-08-15|Actual|December 2003||2003-12-31|July 2017|2017-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma|Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 Monotherapy for Subjects With Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010|Completed||Phase 3|330|Actual|Celgene||1|||f||||f||||||||||2018-06-01 02:25:16.432311|2018-06-01 02:25:16.432311
NCT00622323|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2016-10-25|2008-02-14|2008-02-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients|Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients|Completed|||41|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:25:17.281193|2018-06-01 02:25:17.281193
NCT00622310|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2018-05-24|2008-02-21|2008-02-25|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 2007||2007-09-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|January 2011|Actual|2011-01-31||Interventional|||Energy Expenditure & Activity During & After Exercise-Induced Weight Loss|Energy Expenditure & Activity During & After Exercise-Induced Weight Loss|Active, not recruiting||N/A|40|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 02:25:17.362443|2018-06-01 02:25:17.362443
NCT00622284|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2011-11-30||2013-12-11|2008-02-22|2008-02-25|Estimate|2012-01-17|2012-02-20|Estimate||||2013-12-11|2014-01-29|Estimate|February 2008||2008-02-29|December 2013|2013-12-31||||December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes|A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy|Completed||Phase 3|1560|Actual|Boehringer Ingelheim|With the exception of HbA1c<6.5% and HbA1c<7.0% at Week52, all other endpoints are presented in the Week52 repeated analysis within the final clinical trial report, where discrepancies between interim and final results are also explained.|2|||f||||||||||||||2018-06-01 02:25:17.519766|2018-06-01 02:25:17.519766
NCT00622271|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-11-16|2008-02-14|2008-02-25|Estimate|||||||2011-11-16|2011-11-17|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Intervention Groups for Adolescents With Type 1 Diabetes Mellitus|Adjustment and Self-Management Intervention Groups for Adolescents With Type 1 Diabetes Mellitus and Their Parents.|Completed||N/A|30|Actual|Children's Hospital and Health System Foundation, Wisconsin||1|||f||||f||||||||||2018-06-01 02:25:19.445527|2018-06-01 02:25:19.445527
NCT00622258|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2014-09-24|2008-02-12|2008-02-22|Estimate|||||||2014-09-24|2014-09-26|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 1|13|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:25:19.745841|2018-06-01 02:25:19.745841
NCT00622245|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2010-09-24|2008-02-12|2008-02-22|Estimate|||||||2010-09-24|2010-09-27|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|November 2009|Actual|2009-11-30|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression|Randomised, Double-blind, Parallel-group, Placebo-controlled, and Active Referenced Study of Lu AA34893 to Evaluate the Efficacy and Safety of Three Doses Lu AA34893 in the Treatment of Depression in Patients With Bipolar I or II Disorder|Terminated||Phase 2|166|Actual|H. Lundbeck A/S||5||Human metabolite not yet covered sufficiently by nonclinical data|f||||f||||||||||2018-06-01 02:25:19.937117|2018-06-01 02:25:19.937117
NCT00622232|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2011-06-07|2008-02-21|2008-02-22|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|June 2023|Anticipated|2023-06-30|January 2009|Actual|2009-01-31||Interventional|Rollover||A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial|A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-infusing Subjects Who Completed Participation in the VRX496-USA-05-002 Trial With Autologous T Cells Transduced With VRX496|Active, not recruiting||Phase 2|40|Anticipated|VIRxSYS Corporation|||||f||||t||||||||||2018-06-01 02:25:20.189684|2018-06-01 02:25:20.189684
NCT00622219|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2017-06-19|2008-02-11|2008-02-22|Estimate|||||||2017-06-19|2017-06-21|Actual|March 2008||2008-03-31|June 2017|2017-06-30|August 31, 2013|Actual|2013-08-31|August 31, 2013|Actual|2013-08-31||Interventional|||Mentored Clinical Career Award in Adolescent Substance Abuse|Mentored Clinical Career Award in Adolescent Substance Abuse|Completed||N/A|96|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 02:25:20.296404|2018-06-01 02:25:20.296404
NCT00622206|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2012-04-03|2008-02-21|2008-02-22|Estimate|||||||2012-04-03|2012-04-05|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Pharmacokinetics of Low Dose Ritonavir|Pharmacokinetics of Low Dose Ritonavir in Thai Patients on a Saquinavir 1500 mg Based HAART Regimen|Completed||Phase 1/Phase 2|20|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-06-01 02:25:20.462629|2018-06-01 02:25:20.462629
NCT00622193|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12||2011-06-08|2017-04-12|2008-02-12|2008-02-22|Estimate||||2011-06-08|2011-06-23|Estimate|2017-04-12|2017-04-14|Actual|March 2008||2008-03-31|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC|Completed||Phase 2|228|Actual|Helsinn Therapeutics (U.S.), Inc||3|||f||||t||||||||||2018-06-01 02:25:20.610299|2018-06-01 02:25:20.610299
NCT00622180|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2009-01-21|2008-02-11|2008-02-22|Estimate|||||||2009-01-21|2009-01-23|Estimate|January 2008||2008-01-31|February 2008|2008-02-29|April 2009|Anticipated|2009-04-30|January 2009|Anticipated|2009-01-31||Interventional|||The Efficacy of Hand NBUVB Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands|The Efficacy of Hand-Foot Narrow-Band UVB Versus Focal 308-nm Treatment in Inducing Repigmentation of Vitiligo After Minigrafting on the Dorsal Hands|Unknown status|Active, not recruiting|N/A|25|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:25:20.82268|2018-06-01 02:25:20.82268
NCT00622167|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2011-07-28||2012-01-03|2008-02-21|2008-02-22|Estimate|2012-01-03|2012-02-03|Estimate||||2012-01-03|2012-02-03|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|April 2008|Actual|2008-04-30||Interventional|||Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease|Comparison of Dual Source Computed Tomography (DSCT) With Integrated Backscatter Intravascular Ultrasound (IB-IVUS) and Contrast Angiography in the Assessment of Coronary Artery Disease|Terminated||N/A|24|Actual|Massachusetts General Hospital|Study terminated after imaging 4 subjects due to slow enrollment. Results will not be analyzed.|1||Subject recruitment was slow, so enrollment has been closed.|f||||f||||||||||2018-06-01 02:25:21.133632|2018-06-01 02:25:21.133632
NCT00622141|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2015-03-24|2008-02-21|2008-02-22|Estimate|||||||2015-03-24|2015-03-26|Estimate||||March 2015|2015-03-31||||||||Interventional|||Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®|Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir® in Thai Healthy Volunteers|Withdrawn||Phase 1/Phase 2|0|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2||"The study was never started because the sponsor decided not to manufacture the investigational~   product."|f||||f||||||||||2018-06-01 02:25:21.495009|2018-06-01 02:25:21.495009
NCT00622128|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2010-10-14|2008-02-21|2008-02-22|Estimate|||||||2010-10-14|2010-10-18|Estimate|June 2009||2009-06-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|PAVeD||Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients|Completed||Phase 3|10|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 02:25:21.692186|2018-06-01 02:25:21.692186
NCT00622115|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2011-03-14|2008-02-21|2008-02-22|Estimate|||||||2011-03-14|2011-03-15|Estimate|July 2007||2007-07-31|March 2011|2011-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)|A Phase I, Pharmacokinetic and Tolerability Study of Intravenous Unfractionated Heparin After Subcutaneous Enoxaparin 1mg/kg Bid Repeated Administration in Healthy Subjects|Completed||Phase 1|72|Actual|Sanofi||3|||f||||||||||||||2018-06-01 02:25:21.783097|2018-06-01 02:25:21.783097
NCT00622102|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2009-12-01|2008-02-21|2008-02-22|Estimate|||||||2009-12-01|2009-12-02|Estimate|December 2007||2007-12-31|December 2009|2009-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Testing Strategies to Improving Warfarin Adherence|Testing Strategies to Improving Warfarin Adherence|Completed||N/A|101|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:25:21.927922|2018-06-01 02:25:21.927922
NCT00622089|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-05-22|2008-02-12|2008-02-22|Estimate|||||||2008-05-22|2008-05-28|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients|An Open Label Follow-On Study of Safety and Pharmacodynamic Effects of 24 Weeks of Treatment With DIO-902 in Combination With Metformin and Atorvastatin in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-503)|Terminated||Phase 2/Phase 3|150|Anticipated|DiObex||3||Program terminated|f||||f||||||||||2018-06-01 02:25:22.003805|2018-06-01 02:25:22.003805
NCT00622076|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2008-02-13|2008-02-13|2008-02-22|Estimate|||||||2008-02-13|2008-02-22|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Postoperative Catheterization After Anterior Colporrhaphy|Randomised Controled Multicenter Trial Regarding the Appropriate Length of Postoperative Catheterization After Anterior Colporrhaphy for Repair of Cystocele|Unknown status|Recruiting|N/A|230|Anticipated|Atrium Medical Center||2|||f||||t||||||||||2018-06-01 02:25:22.303778|2018-06-01 02:25:22.303778
NCT00622063|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12||2013-02-21|2013-02-22|2008-02-12|2008-02-22|Estimate||||2013-02-22|2013-02-28|Estimate|2013-02-22|2013-02-28|Estimate|December 2006||2006-12-31|February 2013|2013-02-28||||September 2008|Actual|2008-09-30||Interventional|||An Extension Study for Patients Previously Treated With ARQ 501|An Extension Study for Patients Previously Treated With ARQ 501|Completed||Phase 1/Phase 2|1|Actual|ArQule|||||f||||f||||||||||2018-06-01 02:25:22.397405|2018-06-01 02:25:22.397405
NCT00622050|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-10-15|2008-02-12|2008-02-22|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2008||2008-01-31|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|TView||The Relationship of TV Viewing to Energy Balance in Adults|The Effects of Limiting TV Viewing on Diet, Exercise, and Sleep in Overweight and Obese Adults|Completed||N/A|44|Anticipated|University of Vermont||2|||f||||||||||||||2018-06-01 02:25:22.554014|2018-06-01 02:25:22.554014
NCT00622037|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2010-02-02|2008-02-21|2008-02-22|Estimate|||||||2010-02-02|2010-02-03|Estimate|February 2008||2008-02-29|February 2010|2010-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality||Completed||Phase 4|70|Anticipated|Bp Consulting, Inc||2|||f||||||||||||||2018-06-01 02:25:22.658753|2018-06-01 02:25:22.658753
NCT00622024|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2013-02-22|2008-02-21|2008-02-22|Estimate|||||||2013-02-22|2013-02-25|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Perioperative Depression and Postoperative Arrhythmia in Elective Coronary Bypass Graft Surgery|Perioperative Depression and Postoperative Arrhythmia in Elective Coronary Bypass Graft Surgery|Completed|||120|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 02:25:22.79566|2018-06-01 02:25:22.79566
NCT00622011|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-02-11|2008-02-11|2008-02-22|Estimate|||||||2008-02-11|2008-02-22|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|||Risperidone and Zotepine in the Treatment of Delirium|Risperidone and Zotepine in the Treatment of Delirium|Unknown status|Recruiting|Phase 4|60|Anticipated|Changhua Christian Hospital||2|||f||||f||||||||||2018-06-01 02:25:22.867283|2018-06-01 02:25:22.867283
NCT00621998|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2008-02-13|2008-02-13|2008-02-22|Estimate|||||||2008-02-13|2008-02-22|Estimate|July 2000||2000-07-31|February 2000|2000-02-29|June 2004|Actual|2004-06-30|December 2003|Actual|2003-12-31||Interventional|||Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia|A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia|Completed||Phase 4|60|Actual|Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan||2|||f||||t||||||||||2018-06-01 02:25:22.997611|2018-06-01 02:25:22.997611
NCT00621985|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2010-09-17||2011-01-26|2008-02-11|2008-02-22|Estimate|2011-01-26|2011-02-23|Estimate||||2011-01-26|2011-02-23|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Dexamethasone Treatment of Congenital Adrenal Hyperplasia|Dexamethasone Treatment of Congenital Adrenal Hyperplasia|Completed||Phase 2|5|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-06-01 02:25:23.13538|2018-06-01 02:25:23.13538
NCT00621972|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Observational|||AV Fistula Salvage in Advanced CKD Using Sodium Bicarbonate Prophylaxis|A Prospective Observational Study on the Use of Iodinated Contrast for AV Fistula Salvage in Stage 4/5 CKD Using Bicarbonate Prophylaxis|Unknown status|Recruiting||25|Anticipated|Maine Medical Center|||1||f||||f||||||||||2018-06-01 02:25:23.628626|2018-06-01 02:25:23.628626
NCT00621959|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2009-06-18||2015-01-06|2008-02-21|2008-02-22|Estimate|2009-06-18|2009-08-06|Estimate||||2015-01-06|2015-01-15|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine 5 mg Once Daily Given for 2 Weeks in Subjects 18 yr of Age and Older With Seasonal Allergic Rhinitis|Completed||Phase 4|596|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 02:25:23.756676|2018-06-01 02:25:23.756676
NCT00621946|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2013-05-24||2014-01-02|2008-02-21|2008-02-22|Estimate|2013-11-08|2013-12-27|Estimate||||2014-01-02|2014-02-04|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||One participant had no post-baseline data, leaving 25 evaluable participants in the intent-to-treat sample that was used in the analysis.|Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder|Escitalopram in the Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 4|26|Actual|University of Texas Southwestern Medical Center|A limitation of this proof-of-concept study was the small sample size.|2|||f||||||||||||||2018-06-01 02:25:25.094706|2018-06-01 02:25:25.094706
NCT00621933|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2011-10-17||2012-07-16|2008-02-21|2008-02-22|Estimate|2012-07-16|2012-07-18|Estimate||||2012-07-16|2012-07-18|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Observational|||Surveillance of Ocular Surface Flora (SURFACE)||Completed|||399|Actual|Allergan|||1||f||||f||||||Samples Without DNA|"~     Culture Swabs of the conjunctiva and eyelids~   "|||2018-06-01 02:25:25.485764|2018-06-01 02:25:25.485764
NCT00621920|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2012-02-08|2008-02-21|2008-02-22|Estimate|||||||2012-02-08|2012-02-10|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy Study of Bowel Preparation Before Colonoscopy|Efficacy Study of Bowel Preparation Before Colonoscopy|Completed||Phase 2|72|Actual|C.B. Fleet Company, Inc.|||||f||||f||||||||||2018-06-01 02:25:25.697046|2018-06-01 02:25:25.697046
NCT00621907|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2010-09-15|2008-02-21|2008-02-22|Estimate|||||||2010-09-15|2010-09-16|Estimate|March 2008||2008-03-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|LEVOBU||Study : LEVOBUPIVACAINE Versus Placebo|Levobupivacïne Into Post-analgesia : Randomized Monocentric Study Against Placebo|Completed||Phase 3|140|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t||||||||||2018-06-01 02:25:25.755482|2018-06-01 02:25:25.755482
NCT00621894|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12||2012-07-26|2018-01-16|2008-02-21|2008-02-22|Estimate||||2012-07-26|2012-08-03|Estimate|2018-01-16|2018-01-18|Actual|March 1, 2008|Actual|2008-03-01|January 2018|2018-01-31|May 1, 2009|Actual|2009-05-01|May 1, 2009|Actual|2009-05-01||Interventional|||Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation|A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension|Completed||Phase 2|23|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:25:25.922878|2018-06-01 02:25:25.922878
NCT00621881|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2011-06-16|2008-02-21|2008-02-22|Estimate|||||||2011-06-16|2011-06-17|Estimate|January 2008||2008-01-31|June 2011|2011-06-30||||April 2008|Actual|2008-04-30||Interventional|||A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects|A Phase 1, Repeated-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Naproxcinod 750 mg Bid Administered to Patients With Impaired Hepatic Function Compared to Matching Healthy Subjects|Completed||Phase 1|24|Anticipated|NicOx||1|||f||||t||||||||||2018-06-01 02:25:26.101511|2018-06-01 02:25:26.101511
NCT00621868|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2016-01-18|2008-02-13|2008-02-22|Estimate|||||||2016-01-18|2016-01-20|Estimate|February 2008||2008-02-29|January 2016|2016-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase 2 Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|A Phase 2, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|361|Actual|Astellas Pharma Inc||5|||f||||f||||||||Undecided||2018-06-01 02:25:26.169493|2018-06-01 02:25:26.169493
NCT00621855|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2010-11-18||2014-02-10|2008-02-21|2008-02-22|Estimate|2011-01-17|2011-02-11|Estimate||||2014-02-10|2014-03-12|Estimate|March 2008||2008-03-31|February 2014|2014-02-28||||October 2009|Actual|2009-10-31||Interventional|||RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome|RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)|Completed||Phase 2|1878|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-06-01 02:25:26.342829|2018-06-01 02:25:26.342829
NCT00621842|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2011-08-09||2014-12-08|2008-02-21|2008-02-22|Estimate|2011-09-15|2011-10-25|Estimate||||2014-12-08|2014-12-30|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|Geri-BD SAD||Lamotrigine for Symptoms of Geriatric Bipolar Depression|Open-label, Prospective Trial of Lamotrigine for Symptoms of Geriatric Bipolar Depression|Completed||Phase 3|57|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-06-01 02:25:28.124578|2018-06-01 02:25:28.124578
NCT00621829|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2017-05-11|2008-02-21|2008-02-22|Estimate|||||||2017-05-11|2017-05-15|Actual|February 2008||2008-02-29|May 2017|2017-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms|Pilot Study of Supplemental Eicosapentanoic Acid (EPA)-Enriched Omega-3 Polyunsaturated Fatty Acids (n3-PUFA) in a Subset of Moderate to Severe Asthmatics With Polymorphisms of the Arachidonate 5-lipoxygenase (ALOX5) Gene|Completed||N/A|30|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 02:25:28.485224|2018-06-01 02:25:28.485224
NCT00621816|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2011-12-02|2008-02-20|2008-02-22|Estimate|||||||2011-12-02|2011-12-06|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Pharmacodynamics of Sodium Nitroprusside During Prolonged Infusion in Pediatric Subjects|Completed||Phase 2|45|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 02:25:28.637205|2018-06-01 02:25:28.637205
NCT00621803|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|March 2003||2003-03-31|February 2008|2008-02-29|October 2005|Anticipated|2005-10-31|October 2004|Anticipated|2004-10-31||Interventional|||Lcr35 / ICU / P. Aeruginosa|Prevention of Gastric Colonisation by Antibiotic Resistant Pseudomonas Aeruginosa Strains Using Oral Probiotic in ICU-Patients|Terminated||N/A|400|Actual|University Hospital, Clermont-Ferrand||||Recruiting or enrolling participants has halted and will not resume|f||||||||||||||2018-06-01 02:25:28.744721|2018-06-01 02:25:28.744721
NCT00621790|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2015-10-13|2008-02-21|2008-02-22|Estimate|||||||2015-10-13|2015-10-14|Estimate|February 2008||2008-02-29|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|FENO HSR||Fenoldopam and Acute Renal Failure|Efficacy of Fenoldopam in Reducing the Need for Renal Replacement Therapy After Cardiac Surgery. A Randomized Controlled Study.|Completed||Phase 3|667|Actual|Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-06-01 02:25:28.803339|2018-06-01 02:25:28.803339
NCT00621777|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2015-05-01||2017-11-27|2008-02-21|2008-02-22|Estimate|2015-05-19|2015-05-21|Estimate||||2017-11-27|2017-12-21|Actual|February 2008||2008-02-29|November 2017|2017-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SCRP||A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder|Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking|Completed||Phase 4|247|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:25:28.914142|2018-06-01 02:25:28.914142
NCT00621764|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2014-09-09||2014-09-23|2008-02-21|2008-02-22|Estimate|2014-09-22|2014-09-25|Estimate||||2014-09-23|2014-10-02|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|December 2009|Actual|2009-12-31||Interventional|||Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children|A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children|Completed||Phase 2|300|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 02:25:29.40934|2018-06-01 02:25:29.40934
NCT00621751|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2014-08-11|2008-02-21|2008-02-22|Estimate|||||||2014-08-11|2014-08-13|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression|Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression: A 42-Day, Single-Site, Forced-Titration, Parallel Group, Randomized, Double-Blind, Placebo Controlled Trial|Completed||N/A|74|Actual|Carolinas Healthcare System||2|||f||||t||||||||||2018-06-01 02:25:30.439443|2018-06-01 02:25:30.439443
NCT00621738|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2010-02-09|2008-02-21|2008-02-22|Estimate|||||||2010-02-09|2010-02-10|Estimate|December 2007||2007-12-31|February 2010|2010-02-28||||December 2009|Actual|2009-12-31||Observational|||Effect of Mental Stress on Platelet Function in Healthy Subject|Effect of Mental Stress on Platelet Function in Healthy Subject|Completed|||45|Anticipated|University of Zurich|||||f||||||||||||||2018-06-01 02:25:30.510704|2018-06-01 02:25:30.510704
NCT00621725|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2014-07-14|2008-02-13|2008-02-22|Estimate|||||||2014-07-14|2014-07-15|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|July 2010|Actual|2010-07-31||Interventional|||Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours|A Phase I, Open Label Study of the Pharmacokinetics and Safety of Cediranib (RECENTINTM, AZD2171) Following Single and Multiple Oral Doses in Patients With Advanced Solid Tumours With Various Degrees of Hepatic Dysfunction|Completed||Phase 1|36|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:25:30.560719|2018-06-01 02:25:30.560719
NCT00621712|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2017-04-19|2008-02-21|2008-02-22|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2007||2007-10-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Assessment of a New Catheter Surface Coating With Antimicrobial Properties|Clinical Assessment of a New Catheter Surface Coating With Antimicrobial Properties: Efficacy and Effect of Intensive Catheter and Exit Site Care Education|Completed||N/A|90|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 02:25:30.709223|2018-06-01 02:25:30.709223
NCT00621699|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-02-12|2008-02-12|2008-02-22|Estimate|||||||2008-02-12|2008-02-22|Estimate|September 2007||2007-09-30|February 2008|2008-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects|Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects|Completed||Phase 1|24|Actual|University Medicine Greifswald||3|||f||||f||||||||||2018-06-01 02:25:30.783201|2018-06-01 02:25:30.783201
NCT00619658|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2016-01-27|2008-02-08|2008-02-21|Estimate|||||||2016-01-27|2016-01-28|Estimate|February 2008||2008-02-29|January 2016|2016-01-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|SMART||The Feasibility of Simplified Telephone Follow-up After Medical Abortion|The Feasibility of Simplified Telephone Follow-up After Medical Abortion|Completed||N/A|139|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:26:19.686013|2018-06-01 02:26:19.686013
NCT00621686|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|2016-11-07||2018-04-06|2008-02-21|2008-02-22|Estimate|2016-11-07|2017-01-04|Estimate||||2018-04-06|2018-05-08|Actual|September 2008|Actual|2008-09-30|April 2018|2018-04-30|February 19, 2014|Actual|2014-02-19|October 2010|Actual|2010-10-31||Interventional|||Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme|Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme|Completed||Phase 2|54|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 02:25:30.907357|2018-06-01 02:25:30.907357
NCT00621673|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2014-12-17|2008-02-21|2008-02-22|Estimate|||||||2014-12-17|2014-12-18|Estimate|May 2006||2006-05-31|December 2014|2014-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A|Assessment of the Risk of Inhibitor Formation in Subjects With Severe Hemophilia A When Switched From a Replacement Therapy With a rFVIII Produced by a Chinese Hamster Ovary (CHO) Cell Line to a rFVIII Produced by a Baby Hamster Kidney (BHK) Cell Line (Kogenate® FS).|Terminated||Phase 4|1|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:25:31.66313|2018-06-01 02:25:31.66313
NCT00621660|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Acupuncture Versus Sham for Radiotherapy-Induced Emesis|Acupuncture Compared To Sham With a Placebo-Needle in Radiotherapy-Induced Nausea - a Randomised Controlled Study|Completed||N/A|237|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-06-01 02:25:31.73515|2018-06-01 02:25:31.73515
NCT00621647|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-03-24|2008-02-11|2008-02-22|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2002||2002-09-30|March 2009|2009-03-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Seroquel- Agitation Associated With Dementia|A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia.|Completed||Phase 3|333|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:25:31.803997|2018-06-01 02:25:31.803997
NCT00621634|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|February 2008||2008-02-29|September 2007|2007-09-30||||June 2011|Anticipated|2011-06-30||Interventional|||Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia|Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy of Omega-3 Supplementation With Docosahexaenoic Acid (DHA) on Tardive Dyskinesia|Unknown status|Recruiting|Phase 2|40|Anticipated|Université de Montréal||2|||f||||t||||||||||2018-06-01 02:25:31.866139|2018-06-01 02:25:31.866139
NCT00621621|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2014-07-22||2015-04-06|2008-02-21|2008-02-22|Estimate|2015-04-06|2015-04-23|Estimate||||2015-04-06|2015-04-23|Estimate|December 2006||2006-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PS-010|A total of 105 subjects gave actual consent in the study. Of the 105 consented 75 went on to have an ablation procedure performed. Data from 675 subjects were taken from published data that met inclusion criteria with publication search approved by the FDA.|CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)|CryoCath Freezor CryoAblation Catheter System (CRYOFACTS)|Completed||Phase 4|105|Actual|Medtronic Atrial Fibrillation Solutions|Slow enrollment in the trial showed limited the amount of available data. Detailed subject data from the published literature was not available.|2|||f||||f||||||||||2018-06-01 02:25:32.086083|2018-06-01 02:25:32.086083
NCT00621608|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2013-05-07|2008-02-12|2008-02-22|Estimate|||||||2013-05-07|2013-05-09|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|HBOT||Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers|A Prospective, Double-blind, Randomized, Controlled Clinical Trial Comparing Standard Wound Care With Adjunctive Hyperbaric Oxygen Therapy (HBOT) to Standard Wound Care Only for the Treatment of Chronic, Non-healing Ulcers of the Lower Limb in Patients With Diabetes Mellitus.|Completed||Phase 4|107|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-06-01 02:25:32.308662|2018-06-01 02:25:32.308662
NCT00621595|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2015-09-09|2008-02-21|2008-02-22|Estimate|||||||2015-09-09|2015-09-11|Estimate|November 2000||2000-11-30|September 2015|2015-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||The Effects of Breakfast on Brain Function|The Effects of Breakfast on Cognitive Functioning|Completed||N/A|166|Actual|Arkansas Children's Hospital Research Institute||1|||f||||f||||||||||2018-06-01 02:25:32.383113|2018-06-01 02:25:32.383113
NCT00621582|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|2010-02-09||2014-10-14|2008-02-21|2008-02-22|Estimate|2010-05-19|2010-06-15|Estimate||||2014-10-14|2014-10-23|Estimate|May 2006||2006-05-31|October 2014|2014-10-31||||February 2008|Actual|2008-02-29||Observational|||Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities|Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities|Completed|||4918|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:25:32.448913|2018-06-01 02:25:32.448913
NCT00621569|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2013-03-15|2008-02-21|2008-02-22|Estimate|||||||2013-03-15|2013-03-18|Estimate|January 2005||2005-01-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|July 2008|Actual|2008-07-31||Interventional|ADAPT||ADAPT-Altering Diet for African American Populations to Treat Hypertension|A Culturally Appropriate Intervention in Hypertensive African-Americans Based on the DASH Diet—The ADAPT Hypertension Study = Altering Diet for African American Populations to Treat Hypertension|Completed||N/A|122|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:25:32.682418|2018-06-01 02:25:32.682418
NCT00621556|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2009-01-27|2008-02-12|2008-02-22|Estimate|||||||2009-01-27|2009-01-29|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas|RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas|Terminated||Phase 1|2|Actual|Massachusetts General Hospital||1||Poor patient enrollment due to logistical issues|f||||f||||||||||2018-06-01 02:25:32.763302|2018-06-01 02:25:32.763302
NCT00621543|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2011-04-04||2011-07-12|2008-02-21|2008-02-22|Estimate|2011-06-10|2011-07-08|Estimate||||2011-07-12|2011-07-14|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||Insertion of an Intrauterine Device (IUD) After Medical Abortion|Insertion of an IUD After Medical Abortion|Completed||N/A|120|Actual|Boston University|21 women did not return for the 3 months follow-up. Some of the 21 women were contacted earlier 3 months, and none had had an expulsion. 2 women were ineligible at the first visit.|1|||f||||f||||||||||2018-06-01 02:25:32.831298|2018-06-01 02:25:32.831298
NCT00621530|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2015-06-01||2017-11-03|2008-02-11|2008-02-22|Estimate|2017-06-28|2017-07-27|Actual||||2017-11-03|2017-11-07|Actual|March 2008||2008-03-31|August 2017|2017-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement|Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity After Total Hip Arthroplasty|Terminated||Phase 2|62|Actual|Wake Forest University Health Sciences|The trial was terminated because the study drug became unavailable.|2||Terminated due to discontinuation of Acular PF (investigational medication)|f||||t||||||||No||2018-06-01 02:25:33.014457|2018-06-01 02:25:33.014457
NCT00621517|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2012-03-04||2012-04-04|2008-02-21|2008-02-22|Estimate|2012-04-04|2012-04-05|Estimate||||2012-04-04|2012-04-05|Estimate|February 2008||2008-02-29|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Bupropion and Restless Legs Syndrome|Bupropion and Restless Legs Syndrome|Completed||Phase 2/Phase 3|60|Actual|East Tennessee State University|Possible Type II error as we were unable to recruit our target of 100 participants.|2|||f||||f||||||||||2018-06-01 02:25:33.418172|2018-06-01 02:25:33.418172
NCT00621504|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2010-10-12||2017-02-02|2008-02-20|2008-02-22|Estimate|2010-10-12|2010-11-10|Estimate||||2017-02-02|2017-03-14|Actual|January 2008||2008-01-31|February 2017|2017-02-28|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|CAP||Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia|Completed||Phase 3|606|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 02:25:33.712965|2018-06-01 02:25:33.712965
NCT00621491|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2012-10-25|2008-02-11|2008-02-22|Estimate|||||||2012-10-25|2012-10-26|Estimate|February 2004||2004-02-29|January 2008|2008-01-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation|Randomized Controlled Clinical Trial for Prevention of Thromboembolic Complications After Permanent Transvenous Leads Implantation in High-risk Patients|Completed||N/A|101|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-06-01 02:25:34.375639|2018-06-01 02:25:34.375639
NCT00621478|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2012-12-14|2008-02-20|2008-02-22|Estimate|||||||2012-12-14|2012-12-18|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)|Use Of Lorazepam For The Treatment Of Pediatric Status Epilepticus: A Randomized, Double-Blinded Trial Of Lorazepam And Diazepam|Completed||Phase 2/Phase 3|259|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 02:25:34.535293|2018-06-01 02:25:34.535293
NCT00621465|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2011-12-28|2008-02-20|2008-02-22|Estimate|||||||2011-12-28|2011-12-30|Estimate|April 2002||2002-04-30|December 2011|2011-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Critical Time Intervention in the Transition From Hospital to Community in People With Severe Mental Illness|CTI in the Transition From Hospital to Community|Completed||N/A|150|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 02:25:34.65274|2018-06-01 02:25:34.65274
NCT00621452|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2014-08-04|2008-02-21|2008-02-22|Estimate|||||||2014-08-04|2014-08-06|Estimate|August 2007||2007-08-31|August 2014|2014-08-31||||January 2014|Actual|2014-01-31||Interventional|||Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma|A Pilot Study to Evaluate the Safety and Feasibility of Cellular Immunotherapy Using Genetically Modified Autologous CD20-Specific T Cells For Patients With Relapsed or Refractory Mantle Cell and Indolent B Cell Lymphomas|Completed||Phase 1|12|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 02:25:34.730354|2018-06-01 02:25:34.730354
NCT00621439|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2013-11-28|2008-02-11|2008-02-22|Estimate|||||||2013-11-28|2013-12-02|Estimate|March 2007||2007-03-31|November 2013|2013-11-30||||June 2008|Actual|2008-06-30||Interventional|||Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye|Exploratory Trial of Interferon Alpha-2b in Neoadjuvant Treatment of Ocular Melanoma|Withdrawn||N/A|0|Actual|Emory University||2||no funding- study never began|f||||f||||||||||2018-06-01 02:25:34.819488|2018-06-01 02:25:34.819488
NCT00621426|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2015-03-11|2008-02-21|2008-02-22|Estimate|||||||2015-03-11|2015-03-12|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||T-Wave Alternans in Dialysis Patients|T-Wave Alternans in Dialysis Patients|Completed|||40|Actual|Northwestern University|||1||f||||f||||||||||2018-06-01 02:25:34.885793|2018-06-01 02:25:34.885793
NCT00621413|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|February 2007||2007-02-28|February 2008|2008-02-29||||||||Observational|||Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer|Dosimetric and Morbidity Outcomes of Cs-131 Brachytherapy in Combination With External Beam Radiation Therapy in Subjects With Intermediate to High Risk Adenocarcinoma of the Prostate: An Observational Study|Unknown status|Enrolling by invitation||100|Anticipated|IsoRay Medical, Inc.|||||f||||f||||||||||2018-06-01 02:25:35.003697|2018-06-01 02:25:35.003697
NCT00621400|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2011-05-09|2008-02-21|2008-02-22|Estimate|||||||2011-05-09|2011-05-10|Estimate|January 2008||2008-01-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis|A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination With Melphalan and Dexamethasone in Subjects With Newly-diagnosed Light-chain (AL)-Amyloidosis|Completed||Phase 1/Phase 2|27|Actual|Nantes University Hospital|||||f||||f||||||||||2018-06-01 02:25:35.096566|2018-06-01 02:25:35.096566
NCT00621387|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-02-11|2008-02-11|2008-02-22|Estimate|||||||2008-02-11|2008-02-22|Estimate|November 1993||1993-11-30|November 2007|2007-11-30|June 1998|Actual|1998-06-30|||||Interventional|||Study of Long-Term Antibiotic Treatment in Reactive Arthritis|Double-Blind, Placebo-Controlled Study of Three-Month Treatment With the Combination of Ofloxacin and Roxithromycin in Recent-Onset Reactive Arthritis|Completed||N/A|56|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:25:35.221048|2018-06-01 02:25:35.221048
NCT00621374|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2013-01-14|2008-02-21|2008-02-22|Estimate|||||||2013-01-14|2013-01-16|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Management of Pain in Persons With Multiple Sclerosis|Pilot Study of CBT and Self-hypnosis Training for Pain in Persons With Multiple Sclerosis|Completed||N/A|22|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:25:35.322149|2018-06-01 02:25:35.322149
NCT00621361|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2012-12-13|2008-02-12|2008-02-22|Estimate|||||||2012-12-13|2012-12-17|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|February 2012|Actual|2012-02-29|August 2009|Actual|2009-08-31||Interventional|||Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients|A Phase I, Multi-Centre, Open-Label, Dose Selection Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Etoposide and Cisplatin (EP) as First Line Therapy for Lung Cancer Patients With Extensive Stage or Metastatic Disease for Whom EP Would be a Standard Therapy|Completed||Phase 1|62|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:25:35.408487|2018-06-01 02:25:35.408487
NCT00619073|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2012-01-10||2018-04-30|2008-02-06|2008-02-20|Estimate|2012-10-06|2012-11-06|Estimate||||2018-04-30|2018-05-31|Estimate|April 2008||2008-04-30|April 2018|2018-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PACT||PACT (Platelet Activity After Clopidogrel Termination)|PACT (Platelet Activity After Clopidogrel Termination)|Completed||N/A|15|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 02:26:33.07001|2018-06-01 02:26:33.07001
NCT00621348|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2011-07-12||2011-08-08|2008-02-12|2008-02-22|Estimate|2011-07-12|2011-08-05|Estimate||||2011-08-08|2011-08-10|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Maintenance Intravenous Fluids in Children|A RCT to Evaluate the Effect of Normal Saline in 5% Dextrose at Maintenance Rate, N/5 Saline in 5% Dextrose at 2/3 Maintenance Rate and N/5 Saline in 5% Dextrose at Maintenance Rate on Incidence of Hyponatremia in Hospitalized Children.|Completed||Phase 3|167|Actual|All India Institute of Medical Sciences, New Delhi||3|||f||||f||||||||||2018-06-01 02:25:35.498498|2018-06-01 02:25:35.498498
NCT00621335|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2013-02-22|2008-02-13|2008-02-22|Estimate|||||||2013-02-22|2013-02-25|Estimate|March 2007||2007-03-31|February 2013|2013-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|CICOM1010||A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt|A 12- Week Investigator Masked, Parallel Comparison of Tolerability of Combigan and Cosopt in the Treatment of Open Angle Glaucoma or Ocular Hypertension|Completed|||64|Actual|DBYAN Medicine Professional Corporation|||||f||||t||||||||||2018-06-01 02:25:35.838708|2018-06-01 02:25:35.838708
NCT00621322|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2016-12-08|2009-09-03|2016-12-08|2008-02-21|2008-02-22|Estimate|2016-12-08|2017-02-03|Estimate|2009-09-03|2009-09-04|Estimate|2016-12-08|2017-02-03|Estimate|April 2008||2008-04-30|October 2016|2016-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults|Dose Range Study Evaluating Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccines (692342) When Administered to Healthy Adults Aged 18 to 45 Years.|Completed||Phase 2|181|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 02:25:35.983964|2018-06-01 02:25:35.983964
NCT00621309|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2009-11-12|2008-02-21|2008-02-22|Estimate|||||||2009-11-12|2009-11-16|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions|Phase I Clinical Trial to Evaluate the Efficacy of Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|University of Washington||3|||f||||f||||||||||2018-06-01 02:25:38.722679|2018-06-01 02:25:38.722679
NCT00621296|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2012-09-19||2014-04-16|2008-02-12|2008-02-22|Estimate|2012-09-19|2012-10-19|Estimate||||2014-04-16|2014-05-02|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C|Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C|Completed||Phase 2|15|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 02:25:38.860583|2018-06-01 02:25:38.860583
NCT00621283|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2009-01-27|2008-02-12|2008-02-22|Estimate|||||||2009-01-27|2009-01-29|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population|RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population|Terminated||Phase 1|0|Actual|Massachusetts General Hospital||1||Poor patient enrollment due to logistical issues|f||||f||||||||||2018-06-01 02:25:39.068098|2018-06-01 02:25:39.068098
NCT00621270|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2011-10-20|2008-02-21|2008-02-22|Estimate|||||||2011-10-20|2011-10-24|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety|A 6-Week Randomised Double-Blind, Placebo-Controlled Study of BCI-540 80 mg q.d. and 80 mg t.i.d. in the Treatment of Adults With Major Depressive Disorder and Concomitant Anxiety|Completed||Phase 2|115|Actual|BrainCells Inc.||3|||f||||f||||||||||2018-06-01 02:25:39.145382|2018-06-01 02:25:39.145382
NCT00621257|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2016-12-27||2017-02-18|2008-02-11|2008-02-22|Estimate|2016-12-27|2017-02-17|Actual||||2017-02-18|2017-03-22|Actual|January 2008||2008-01-31|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vitamin D Levels in Children With IBD|Optimization of Vitamin D Stores and Its Impact on the Bone Health and Disease Outcomes of Children and Adolescents With IBD.|Terminated||N/A|134|Actual|Boston Children’s Hospital||5||Maintenance phase outcome unattenable|f||||t||||||||No||2018-06-01 02:25:39.279234|2018-06-01 02:25:39.279234
NCT00621244|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2016-10-24|2012-05-01|2017-07-17|2008-02-21|2008-02-22|Estimate|2017-07-17|2017-08-17|Actual|2012-05-01|2012-05-03|Estimate|2017-07-17|2017-08-17|Actual|March 1, 2003|Actual|2003-03-01|July 2017|2017-07-31|December 3, 2009|Actual|2009-12-03|December 3, 2009|Actual|2009-12-03||Interventional|||A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies|A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies|Completed||Phase 1/Phase 2|175|Actual|Novartis||4|||f|||||t|f||||||||2018-06-01 02:25:40.017388|2018-06-01 02:25:40.017388
NCT00621231|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|September 2007||2007-09-30|May 2007|2007-05-31|April 2008||2008-04-30|December 2007|Actual|2007-12-31||Interventional|ProF||The Protein (Meat) and Function Study|Effect of Normal Versus High Amounts of Protein Intake on Physiological Functions and Proteomics in Healthy Men|Completed||N/A|||University of Copenhagen||2|||f||||f||||||||||2018-06-01 02:25:49.601811|2018-06-01 02:25:49.601811
NCT00621218|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-12-17|2008-02-21|2008-02-22|Estimate|||||||2008-12-17|2008-12-18|Estimate|February 2008||2008-02-29|December 2008|2008-12-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea|A Pilot Study to Compare Tretinoin Gel, 0.05% to Tretinoin Gel Vehicle When Dosed Once or Twice Daily in Female Subjects With Classical Rosacea|Completed||Phase 2|36|Actual|Coria Laboratories, Ltd.||2|||f||||f||||||||||2018-06-01 02:25:49.660492|2018-06-01 02:25:49.660492
NCT00621205|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2012-04-16|2008-02-11|2008-02-22|Estimate|||||||2012-04-16|2012-04-17|Estimate|October 2003||2003-10-31|April 2012|2012-04-30|December 2005|Actual|2005-12-31|December 2004|Actual|2004-12-31||Interventional|Genobin||Gene Expression in Obesity and Insulin Resistance|Gene Expression in Adipose Tissue of Genes Involved in Obesity, Insulin Resistance and Lipid Metabolism Before and After Weight Loss or an Intensive Exercise Period|Completed||N/A|75|Actual|University of Eastern Finland|||||f||||f||||||||||2018-06-01 02:25:49.730217|2018-06-01 02:25:49.730217
NCT00621192|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2011-10-20||2015-03-30|2008-02-20|2008-02-22|Estimate|2011-10-20|2011-11-29|Estimate||||2015-03-30|2015-04-17|Estimate|June 2008||2008-06-30|March 2015|2015-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections|Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 Days) With Suspected or Complicated Intra-abdominal Infections|Completed||Phase 1/Phase 2|200|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||t||||||||||2018-06-01 02:25:49.810765|2018-06-01 02:25:49.810765
NCT00617162|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-08-27|2008-02-14|2008-02-15|Estimate|||||||2015-08-27|2015-08-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:27:11.413201|2018-06-01 02:27:11.413201
NCT00621179|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2008-02-13|2008-02-13|2008-02-22|Estimate|||||||2008-02-13|2008-02-22|Estimate|March 2003||2003-03-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|IntegrinIVF||Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF|Do Endometrial Implantation Markers Predict in Vitro Fertilization-Embryo Transfer Cycle Outcomes in Endometriosis Patients Pretreated With Leuprolide Acetate in Depot Suspension?|Completed||Phase 4|37|Actual|Colorado Center for Reproductive Medicine||4|||f||||t||||||||||2018-06-01 02:25:50.508832|2018-06-01 02:25:50.508832
NCT00621166|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2012-04-03|2008-02-21|2008-02-22|Estimate|||||||2012-04-03|2012-04-05|Estimate|June 2008||2008-06-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women|The Pharmacokinetics and Safety of Generic Lopinavir/Ritonavir (200/50 mg Tablets) 400/100 mg q12h in Thai HIV-infected Pregnant Women|Completed||Phase 2|20|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-06-01 02:25:50.605199|2018-06-01 02:25:50.605199
NCT00621153|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2010-02-24||2010-02-24|2008-02-12|2008-02-22|Estimate|2010-02-24|2010-03-23|Estimate||||2010-02-24|2010-03-23|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|CAESAR||Candesartan Effect in Second Stage Arterial Hypertension|Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults|Completed||Phase 4|214|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:25:50.832957|2018-06-01 02:25:50.832957
NCT00621140|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2011-05-13||2014-01-22|2008-02-13|2008-02-22|Estimate|2011-05-13|2011-06-07|Estimate||||2014-01-22|2014-02-17|Estimate|February 2008||2008-02-29|January 2014|2014-01-31||||May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control|A Randomised, Double-blind, Placebo-controled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or Previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycemic Control|Completed||Phase 3|503|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:25:51.129031|2018-06-01 02:25:51.129031
NCT00621114|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2017-04-19|2008-02-21|2008-02-22|Estimate|||||||2017-04-19|2017-04-20|Actual|August 2007||2007-08-31|January 2010|2010-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ABBA||Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application|Ex Vivo Microbiological Assessment of an Anti-biofilm Catheter in Acute Dialysis Application|Completed||N/A|69|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 02:25:51.821073|2018-06-01 02:25:51.821073
NCT00621101|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-02-12|2008-02-12|2008-02-22|Estimate|||||||2008-02-12|2008-02-22|Estimate|April 2007||2007-04-30|February 2008|2008-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects|Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects|Completed||Phase 1|24|Actual|University Medicine Greifswald||3|||f||||f||||||||||2018-06-01 02:25:51.896347|2018-06-01 02:25:51.896347
NCT00621088|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2010-09-12|2008-02-11|2008-02-22|Estimate|||||||2010-09-12|2010-09-14|Estimate|February 2008||2008-02-29|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Interventional|||A Prospective Randomised Multicenter Study Comparing the Sliding Hip Screw and the Intertan Nail in Trochanteric and Subtrochanteric Femoral Fractures|A Prospective Randomised Multicenter Study Comparing the Sliding Hip Screw and the Intertan Nail in Trochanteric and Subtrochanteric Femoral Fractures|Completed||N/A|500|Anticipated|Haukeland University Hospital||1|||f||||||||||||||2018-06-01 02:25:51.99074|2018-06-01 02:25:51.99074
NCT00621075|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2010-03-08|2008-02-21|2008-02-22|Estimate|||||||2010-03-08|2010-03-09|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans|Correlation of Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans|Completed|||50|Actual|Northwell Health|||1||f||||f||||||||||2018-06-01 02:25:52.054408|2018-06-01 02:25:52.054408
NCT00621062|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2014-01-31|2008-02-12|2008-02-22|Estimate|||||||2014-01-31|2014-02-03|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|RAFPELS||Prospective Randomized Trial Comparing the New Endovenous Procedures Versus Conventional Surgery for Varicose Veins Due to Great Saphenous Vein Incompetence|Randomized Prospective Trial of Varicose Vein Surgery|Completed||N/A|540|Actual|Uppsala University||4|||f||||t||||||||||2018-06-01 02:25:52.129735|2018-06-01 02:25:52.129735
NCT00621049|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-04-24||2015-05-13|2008-02-21|2008-02-22|Estimate|2015-04-24|2015-05-14|Estimate||||2015-05-13|2015-06-08|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional||All patients on-study|Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC|Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Patients With Resected Non-Small Cell Lung Cancer|Completed||Phase 2|112|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 02:25:52.24136|2018-06-01 02:25:52.24136
NCT00621036|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-21|||2010-04-01|2008-02-21|2008-02-22|Estimate|||||||2010-04-01|2010-04-02|Estimate|November 2007||2007-11-30|August 2008|2008-08-31||||June 2009|Anticipated|2009-06-30||Interventional|||Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma|A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With CNS Lymphoma|Unknown status|Recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 02:25:52.660809|2018-06-01 02:25:52.660809
NCT00621023|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-12-21||2013-01-30|2008-02-21|2008-02-22|Estimate|2012-12-21|2013-01-28|Estimate||||2013-01-30|2013-02-04|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome|A Pilot Phase II Study of Decitabine, Arsenic Trioxide and Ascorbic Acid for Patients With Myelodysplastic Syndrome|Completed||Phase 2|7|Actual|Duke University|Enrollment stopped early, which lead to a small number of subjects analyzed. The subjects who were enrolled did complete the entire protocol and their data was analyzed.|1|||f||||t||||||||||2018-06-01 02:25:52.745246|2018-06-01 02:25:52.745246
NCT00621010|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-07-07|2008-02-11|2008-02-22|Estimate|||||||2008-07-07|2008-07-09|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|CTS||Safety Study of CTS21166 to Treat Alzheimer Disease|A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males|Completed||Phase 1|56|Actual|CoMentis||1|||f||||t||||||||||2018-06-01 02:25:53.385415|2018-06-01 02:25:53.385415
NCT00620997|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|Dogma||Proparacaine vs Placebo for Corneal Injuries|Challenging the Dogma: Topical Proparacaine is Safe and Effective for the Emergency Department Management of Acute Traumatic Corneal Injuries|Completed||Phase 1|43|Actual|London Health Sciences Centre||2|||f||||f||||||||||2018-06-01 02:25:53.460423|2018-06-01 02:25:53.460423
NCT00620984|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2015-05-29|2008-02-21|2008-02-22|Estimate|||||||2015-05-29|2015-06-02|Estimate|August 2006||2006-08-31|May 2015|2015-05-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Observational|||Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis|Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis: A Large Prospective Study|Completed|||557|Actual|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-06-01 02:25:53.530207|2018-06-01 02:25:53.530207
NCT00620971|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2014-06-24|2008-02-11|2008-02-22|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC|Sequential Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus Cisplatin/Docetaxel/Bevacizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|Completed||Phase 2|77|Actual|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 02:25:53.593359|2018-06-01 02:25:53.593359
NCT00620958|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-07-31|2008-02-20|2008-02-22|Estimate|||||||2017-07-31|2017-08-02|Actual|August 2008||2008-08-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cognitive Behavioral Therapy With Parental Involvement for Treating Children With Anxiety Disorders|Parent Mediation of Child Anxiety CBT Outcome|Completed||N/A|341|Actual|Florida International University||3|||f||||t||||||||||2018-06-01 02:25:53.830258|2018-06-01 02:25:53.830258
NCT00620945|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2017-10-20||2017-11-20|2008-02-11|2008-02-22|Estimate|2017-10-20|2017-11-20|Actual||||2017-11-20|2017-12-19|Actual|June 2006||2006-06-30|November 2017|2017-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||Patients undergoing open heart surgery and who are less than 18 years of age.|Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass|Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass in Infants and Children With Congenital Heart Disease and to Assist Steady State Alfa-blockade in the Intensive Care Phase|Terminated||N/A|87|Actual|The Cleveland Clinic|Due to a change in leadership the protocol of cardiopulmonary bypass was changed on 9/22/2008. The high flow low pressure perfusion is no longer used. As a result phenoxybenzamine was no longer able to be studied and the study was closed early.|1||New protocol now being used for cardiopulmonary bypass|f||||t||||||||||2018-06-01 02:25:54.038967|2018-06-01 02:25:54.038967
NCT00620932|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2013-10-25|2008-02-21|2008-02-22|Estimate|||||||2013-10-25|2013-10-28|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Exercise Training Among Men With Prostate Cancer|Feasibility of Endurance Exercise Training on Cardiovascular Risk Factors Following Radical Prostatectomy Among Men With Localized Prostate Cancer; A Community-Based Intervention|Withdrawn||N/A|0|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:25:54.400407|2018-06-01 02:25:54.400407
NCT00620919|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2009-01-27|2008-02-12|2008-02-22|Estimate|||||||2009-01-27|2009-01-29|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis|RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis|Terminated||Phase 1|0|Actual|Massachusetts General Hospital||1||Poor patient enrollment due to logistical issues.|f||||f||||||||||2018-06-01 02:25:54.481037|2018-06-01 02:25:54.481037
NCT00620906|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2013-05-01|2008-02-21|2008-02-22|Estimate|||||||2013-05-01|2013-05-03|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Motion Capture Analysis of Sacroiliac Joint Motion After Manipulation|Motion Capture Analysis of Sacroiliac Joint Motion After Manipulation|Completed||N/A|20|Actual|Logan College of Chiropractic||1|||f||||f||||||||||2018-06-01 02:25:54.576444|2018-06-01 02:25:54.576444
NCT00620893|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2009-09-17|2008-02-20|2008-02-22|Estimate|||||||2009-09-17|2009-09-21|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).||Completed||Phase 4|100|Anticipated|Bp Consulting, Inc||2|||f||||||||||||||2018-06-01 02:25:54.681234|2018-06-01 02:25:54.681234
NCT00620880|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-11-19|2008-02-11|2008-02-22|Estimate|||||||2008-11-19|2008-11-20|Estimate|September 2005||2005-09-30|November 2008|2008-11-30|September 2006|Actual|2006-09-30|||||Observational|||IVN-CAT-001A Performance of CAST With Different Allergens in Patients With Cat Dander Allergy|Performance of CAST With Different Allergens in Patients With Cat Dander Allergy|Completed|||||University of Zurich|||||f||||f||||||||||2018-06-01 02:25:54.797498|2018-06-01 02:25:54.797498
NCT00620867|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-11-05|2008-02-12|2008-02-22|Estimate|||||||2008-11-05|2008-11-06|Estimate|October 2002||2002-10-31|November 2008|2008-11-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)|A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee|Completed||Phase 4|393|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:25:54.886364|2018-06-01 02:25:54.886364
NCT00620854|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2009-04-22||2012-01-30|2008-02-12|2008-02-22|Estimate|2009-08-14|2009-09-24|Estimate||||2012-01-30|2012-02-01|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women||Completed||Phase 2|24|Actual|Tarsa Therapeutics, Inc.||3|||f||||f||||||||||2018-06-01 02:25:55.053677|2018-06-01 02:25:55.053677
NCT00620841|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-13|||2008-02-21|2008-02-21|2008-02-22|Estimate|||||||2008-02-21|2008-02-22|Estimate|May 2007||2007-05-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|DDI-TAC||Gene Polymorphisms in Tacrolimus Drug Interactions|Gene Polymorphisms in Tacrolimus Drug Interactions in Renal Transplant Patients|Completed|||40|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||Samples With DNA|"~     DNA samples~   "|||2018-06-01 02:25:55.65047|2018-06-01 02:25:55.65047
NCT00257790|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-07-03|2005-11-22|2005-11-23|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2001||2001-09-30|November 2005|2005-11-30|March 2005||2005-03-31|||||Interventional|||The Tobramycin Study|Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber|Completed||Phase 4|210||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:19:25.675682|2018-06-01 04:19:25.675682
NCT00620828|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2010-06-17||2015-06-02|2008-02-12|2008-02-22|Estimate|2013-03-19|2013-05-03|Estimate||||2015-06-02|2015-06-03|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty|The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Trial|Completed||Phase 4|67|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:25:55.788134|2018-06-01 02:25:55.788134
NCT00620815|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|2011-07-04||2016-03-03|2008-02-21|2008-02-22|Estimate|2012-09-17|2012-09-19|Estimate||||2016-03-03|2016-03-28|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above|A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (Containing Both Interpandemic Strains and H5N1) in Adults Aged 18 Years and Above|Completed||Phase 2|601|Actual|Novartis||6|||f||||f||||||||||2018-06-01 02:25:56.253882|2018-06-01 02:25:56.253882
NCT00620802|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2008-08-22|2008-02-21|2008-02-22|Estimate|||||||2008-08-22|2008-08-26|Estimate|November 2007||2007-11-30|August 2008|2008-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pharmacodynamics of CGT 2168 Compared With Plavix®|A Phase I, Open-Label, Randomized, Multiple-Dose, Two-Way Crossover Study of the Pharmacodynamics of CGT 2168 Compared With Plavix®|Completed||Phase 1|60|Actual|Cogentus Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:25:57.355413|2018-06-01 02:25:57.355413
NCT00620789|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2013-05-30|2008-02-12|2008-02-22|Estimate|||||||2013-05-30|2013-05-31|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Behavioral Insomnia Therapy For Those With Insomnia and Depression|Behavioral Insomnia Therapy For Those With Insomnia and Depression|Unknown status|Recruiting|N/A|477|Anticipated|Ryerson University||3|||f||||f||||||||||2018-06-01 02:25:57.453743|2018-06-01 02:25:57.453743
NCT00620776|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2016-10-31||2016-12-23|2008-02-07|2008-02-21|Estimate|2016-12-23|2017-02-16|Actual||||2016-12-23|2017-02-16|Actual|October 2006||2006-10-31|December 2016|2016-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||26 out of 29 patients who consented to receive combined treatment received at least one session of CBT. 35 out of 40 patients who consented to received medication only received at least one dose of medication.|Combined Treatment for Generalized Anxiety Disorder (GAD)|Combined Treatment for Generalized Anxiety Disorder (GAD)|Completed||Phase 2|69|Actual|University of Pennsylvania|Only one-third of those approached to add on CBT were interested in this option. Strict exclusion criteria reduces the generalizability of the study results. Possible that other forms of CBT treatment may produce different results.|2|||f||||t||||||||No||2018-06-01 02:25:57.598807|2018-06-01 02:25:57.598807
NCT00620763|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2008-12-31||2011-08-04|2008-02-08|2008-02-21|Estimate|2009-06-17|2009-08-03|Estimate||||2011-08-04|2011-08-10|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Calcium Retention as Influenced by Dietary Components That Induce an Acid Load|Calcium Retention in Postmenopausal Women as Influenced by Beef and Other Dietary Components That Induce an Acid Load|Completed||N/A|22|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||||2018-06-01 02:25:58.536826|2018-06-01 02:25:58.536826
NCT00620750|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2011-06-09||2011-08-22|2008-02-11|2008-02-21|Estimate|2011-08-22|2011-09-27|Estimate||||2011-08-22|2011-09-27|Estimate|July 2007||2007-07-31|August 2011|2011-08-31|February 2010|Actual|2010-02-28|November 2008|Actual|2008-11-30||Interventional|||Extended-release Naltrexone for Alcohol Dependence in Primary Care|Extended-release Naltrexone (Vivitrol) for the Treatment of Alcohol Dependence in Urban Primary Care: a Feasibility Study|Completed||Phase 4|72|Actual|New York University School of Medicine|There was no formal control arm. Drinking and satisfaction outcomes were self-reported, these outcomes and Adverse Event data were not available for those lost to follow-up. The drinking Timeline Follow-Back is subject to recall and response biases.|1|||f||||f||||||||||2018-06-01 02:25:58.728571|2018-06-01 02:25:58.728571
NCT00620737|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2012-02-08|2008-02-20|2008-02-21|Estimate|||||||2012-02-08|2012-02-10|Estimate|February 2008||2008-02-29|February 2012|2012-02-29||||December 2008|Anticipated|2008-12-31||Interventional|||Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars||Withdrawn||Phase 2|0|Actual|Fibrocell Technologies, Inc.||2||Company Decision|f||||f||||||||||2018-06-01 02:25:58.915927|2018-06-01 02:25:58.915927
NCT00620724|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2014-07-09|2008-02-08|2008-02-21|Estimate|||||||2014-07-09|2014-07-10|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa|Maintenance Oral Nifedipine for Management of Symptomatic Placenta Previa : A Randomized Clinical Trial|Completed||Phase 2|109|Actual|University Hospital, Rouen||2|||f||||||||||||||2018-06-01 02:25:59.031243|2018-06-01 02:25:59.031243
NCT00620711|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2014-05-28||2014-07-30|2008-02-07|2008-02-21|Estimate|2014-07-30|2014-07-31|Estimate||||2014-07-30|2014-07-31|Estimate|February 2008||2008-02-29|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Preterm infants with HIE|Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy|"IRB# 070984 Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy"|Completed||Phase 1|4|Actual|Vanderbilt University||1|||f||||t||||||||||2018-06-01 02:25:59.10493|2018-06-01 02:25:59.10493
NCT00620698|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-09|2014-07-18||2014-09-13|2008-02-20|2008-02-21|Estimate|2014-09-03|2014-09-10|Estimate||||2014-09-13|2014-09-25|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|||Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials|Electrical Impedance Myography as an Outcome Measure in ALS Clinical Trials|Completed|||89|Actual|Beth Israel Deaconess Medical Center|||1||f||||f||||||||||2018-06-01 02:25:59.260911|2018-06-01 02:25:59.260911
NCT00620685|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10||2009-04-06|2011-05-16|2008-02-07|2008-02-21|Estimate||||2009-10-07|2009-10-12|Estimate|2011-05-16|2011-05-19|Estimate|March 2008||2008-03-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate|A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate|Completed||Phase 2|27|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:25:59.413433|2018-06-01 02:25:59.413433
NCT00620672|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2016-05-30|2008-02-20|2008-02-21|Estimate|||||||2016-05-30|2016-06-01|Estimate|May 2004||2004-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2011|Actual|2011-12-31||Interventional|||N-3 Fatty Acid Requirements for Human Development|To Compare Measures of Central Nervous System Maturity of Visual Acuity, Language, Mental and Motor Skill Development in Term Infants Following Maternal Supplementation Wit the n-3 Fatty Acid Docosahexaenoic Acid (DHA) During Gestation.|Completed||Phase 1|270|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 02:25:59.495524|2018-06-01 02:25:59.495524
NCT00620659|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2010-10-13||2015-04-27|2008-02-11|2008-02-21|Estimate|2011-01-27|2011-02-23|Estimate||||2015-04-27|2015-05-13|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015)|Phase IIa, Randomized, Double-blind, Placebo-controlled, 3-period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate Safety & Efficacy of MK0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using nCPAP Therapy.|Terminated||Phase 2|125|Actual|Merck Sharp & Dohme Corp.||6|||f||||||||||||||2018-06-01 02:25:59.611082|2018-06-01 02:25:59.611082
NCT00620646|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2009-02-11|2008-02-10|2008-02-21|Estimate|||||||2009-02-11|2009-02-12|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|4C-DES||The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol|The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol in Clopidogrel Non-Responders After Drug-Eluting Stent Implantation|Completed||N/A|80|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 02:26:00.623229|2018-06-01 02:26:00.623229
NCT00620633|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2018-02-23|2008-02-20|2008-02-21|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2008|Actual|2008-02-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation|A Phase I Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation|Active, not recruiting||Phase 1|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:26:00.74398|2018-06-01 02:26:00.74398
NCT00620620|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2017-03-13|2008-02-19|2008-02-21|Estimate|||||||2017-03-13|2017-03-14|Actual|February 2008||2008-02-29|July 2013|2013-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Staccato Zaleplon Single Dose Pharmacokinetics|Safety, Tolerability, and Pharmacokinetics of a Single Dose of Staccato® Zaleplon for Inhalation in Healthy Volunteers|Completed||Phase 1|40|Actual|Alexza Pharmaceuticals, Inc.||5|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 02:26:00.812762|2018-06-01 02:26:00.812762
NCT00620607|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2015-08-25|2008-02-07|2008-02-21|Estimate|||||||2015-08-25|2015-08-26|Estimate|May 2007||2007-05-31|April 2009|2009-04-30|September 2010|Anticipated|2010-09-30|May 2010|Anticipated|2010-05-31||Interventional|||huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas|A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas|Withdrawn||Phase 2|0|Actual|ImmunoGen, Inc.||||Lack of accrual|f||||||||||||||2018-06-01 02:26:00.897132|2018-06-01 02:26:00.897132
NCT00620594|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2017-02-13|2008-02-20|2008-02-21|Estimate|||||||2017-02-13|2017-02-14|Actual|December 21, 2006|Actual|2006-12-21|February 2017|2017-02-28|January 8, 2013|Actual|2013-01-08|January 8, 2013|Actual|2013-01-08||Interventional|||A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer|A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer|Completed||Phase 1|183|Actual|Novartis||4|||f||||||||||||||2018-06-01 02:26:00.948273|2018-06-01 02:26:00.948273
NCT00620581|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-02-07|2008-02-07|2008-02-21|Estimate|||||||2008-02-07|2008-02-21|Estimate||||November 2005|2005-11-30||||||||Interventional|PMDD||Luteal Phase Administration of Paroxetine for the Treatment of PMDD|Luteal Phase Administration of Paroxetine for the Treatment of PMDD: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women|Completed||Phase 3|||McMaster University||1|||f||||||||||||||2018-06-01 02:26:01.053982|2018-06-01 02:26:01.053982
NCT00620568|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2009-08-03|2008-02-08|2008-02-21|Estimate|||||||2009-08-03|2009-08-04|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating Multiple Ascending Dose in Schizophrenia Patients|An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder|Terminated||Phase 1|32|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-06-01 02:26:01.121509|2018-06-01 02:26:01.121509
NCT00620555|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2011-11-14||2012-01-24|2008-02-11|2008-02-21|Estimate|2011-11-14|2011-12-20|Estimate||||2012-01-24|2012-01-26|Estimate|May 2008||2008-05-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures|A 52 Weeks, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Gabapentin As Adjunctive Therapy In Pediatric Patients Who Have Completed The 12 Weeks Treatment In Study A9451162 (NCT00603473)|Completed||Phase 3|65|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:26:01.195741|2018-06-01 02:26:01.195741
NCT00620542|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2012-05-22||2012-07-11|2008-02-20|2008-02-21|Estimate|2012-05-22|2012-06-25|Estimate||||2012-07-11|2012-07-16|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SATURN||CRESTOR Athero Imaging Head to Head IVUS Study|Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)|Completed||Phase 3|2333|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 02:26:02.73534|2018-06-01 02:26:02.73534
NCT00620529|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2010-01-31|2008-02-20|2008-02-21|Estimate|||||||2010-01-31|2010-02-02|Estimate|February 2008||2008-02-29|January 2010|2010-01-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|fops||The Effects of Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat in the Polycystic Ovary Syndrome|A Clinical Trial to Measure the Effect of DHA-enriched Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat Content in the Polycystic Ovary Syndrome|Completed||Phase 4|40|Anticipated|Keogh Institute for Medical Research||2|||f||||t||||||||||2018-06-01 02:26:05.693629|2018-06-01 02:26:05.693629
NCT00620516|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2013-11-18|2008-02-11|2008-02-21|Estimate|||||||2013-11-18|2013-11-19|Estimate|March 2004||2004-03-31|November 2013|2013-11-30||||December 2007|Actual|2007-12-31||Observational|||Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD Patients|Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study|Completed|||3008|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:26:05.859775|2018-06-01 02:26:05.859775
NCT00620503|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2010-02-08|2008-02-20|2008-02-21|Estimate|||||||2010-02-08|2010-02-10|Estimate|February 2008||2008-02-29|February 2010|2010-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|PK||Proellex® Pharmacokinetic Bridging Study II|Proellex® Pharmacokinetic Bridging Study II|Completed||Phase 1|12|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-06-01 02:26:06.000402|2018-06-01 02:26:06.000402
NCT00620490|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-06-25|2008-02-20|2008-02-21|Estimate|||||||2010-06-25|2010-06-28|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Paravertebral Analgesia Associated With Intravenous Morphine PCA After Thoracotomy|Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia : Paravertebral Analgesia With a Catheter Associated With Intravenous Morphine Patient-controlled-analgesia (Pca)|Completed||Phase 3|60|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 02:26:06.071376|2018-06-01 02:26:06.071376
NCT00620477|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2014-12-04|2008-02-20|2008-02-21|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Evaluation of Arthroscopic Reconstruction of the Anterior Cruciate Ligament by One Night Hospital Stay or by Day Surgery: a Randomised, Prospective Clinical Trial|Evaluation of Arthroscopic Reconstruction of the Anterior Cruciate Ligament by One Night Hospital Stay or by Day Surgery: a Randomised, Prospective Clinical Trial|Unknown status|Recruiting|Phase 4|75|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:26:06.144517|2018-06-01 02:26:06.144517
NCT00620464|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2010-02-17||2015-08-11|2008-02-11|2008-02-21|Estimate|2010-04-28|2010-05-17|Estimate||||2015-08-11|2015-08-13|Estimate|May 2005||2005-05-31|August 2015|2015-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)|A Randomized, Double-Blind, Parallel Group, Bioequivalence Study of IMPLANON and Radiopaque IMPLANON|Completed||Phase 3|108|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:26:06.233139|2018-06-01 02:26:06.233139
NCT00620451|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07||2017-09-11|2017-09-15|2008-02-11|2008-02-21|Estimate||||2017-09-15|2017-09-20|Actual|2017-09-15|2017-09-20|Actual|February 2008|Actual|2008-02-29|September 2017|2017-09-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease|A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With Larazotide Acetate (AT-1001)|Completed||Phase 2|105|Actual|Innovate Biopharmaceuticals||3|||f||||f|t|f||||||||2018-06-01 02:26:06.60806|2018-06-01 02:26:06.60806
NCT00620438|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-12-03|2008-02-19|2008-02-21|Estimate|||||||2010-12-03|2010-12-06|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients|Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|Makerere University||3|||f||||f||||||||||2018-06-01 02:26:06.828081|2018-06-01 02:26:06.828081
NCT00620425|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2010-11-01||2012-07-16|2008-02-20|2008-02-21|Estimate|2012-07-16|2012-07-17|Estimate||||2012-07-16|2012-07-17|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study on the Effects of Repeat Doses of Intraject® Sumatriptan on Local Site Signs|A Single-Center, Open-label, Single-Arm Study to Evaluate the Effects of Repeat Doses of Subcutaneously Delivered Sumatriptan Via the Intraject System of Local Injection Site Signs in Healthy Adult Subjects.|Completed||Phase 1|18|Actual|Zogenix, Inc.|||||f||||t||||||||||2018-06-01 02:26:06.958149|2018-06-01 02:26:06.958149
NCT00620412|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2011-01-16|2008-02-11|2008-02-21|Estimate|||||||2011-01-16|2011-01-19|Estimate|September 2007||2007-09-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Probiotics to Enhance Immunogenicity of Influenza Vaccine in Healthy Adults|Lactobacillus GG to Enhance the Immunogenicity of Influenza Vaccine in Healthy Adults - Proof of Concept Study|Completed||Phase 1|52|Anticipated|Tufts Medical Center||2|||f||||t||||||||||2018-06-01 02:26:07.147965|2018-06-01 02:26:07.147965
NCT00620399|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-02-20|2008-02-20|2008-02-21|Estimate|||||||2008-02-20|2008-02-21|Estimate|May 1996||1996-05-31|February 2008|2008-02-29|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Study on the Use of a Brace Following Low Back Surgery|Lumbar Fusion With and Without Postoperative Bracing: A Randomized Prospective Study|Completed||Phase 3|||Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 02:26:07.227818|2018-06-01 02:26:07.227818
NCT00620386|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2008-02-08|2008-02-08|2008-02-21|Estimate|||||||2008-02-08|2008-02-21|Estimate|October 2006||2006-10-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|||Endotracheal Intubation Using Bonfils Fibrescope Without Neuromuscular Blockade|Comparing Intubating Conditions and Hemodynamic Changes Between Macintosh Laryngoscopy and Bonfils Fibrescope During Endotracheal Intubation Without Neuromuscular Blockade|Completed||Phase 2/Phase 3|80|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:26:07.355254|2018-06-01 02:26:07.355254
NCT00620373|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-08-15||2014-07-30|2008-02-20|2008-02-21|Estimate|2013-11-07|2013-12-30|Estimate||||2014-07-30|2014-08-01|Estimate|August 2005||2005-08-31|July 2014|2014-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts|Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool in Women With Mammographically Dense Breasts and Increased Risk of Breast Cancer|Completed||N/A|969|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:26:07.477015|2018-06-01 02:26:07.477015
NCT00620360|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2012-02-23|2008-02-08|2008-02-21|Estimate|||||||2012-02-23|2012-02-24|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Acute Effect of Fructose on Lipid Metabolism and Gender Differences|Acute Effect of Fructose on Lipid Metabolism and Gender Differences|Completed||N/A|18|Actual|University of Lausanne||1|||f||||f||||||||||2018-06-01 02:26:07.844079|2018-06-01 02:26:07.844079
NCT00620347|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-06-17|2008-02-20|2008-02-21|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Interventional|||Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer|A Phase II Study of Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer.|Completed||Phase 2|25|Actual|National Cancer Center, Korea||1|||f||||t||||||||||2018-06-01 02:26:07.914177|2018-06-01 02:26:07.914177
NCT00620334|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-08-09|2008-02-20|2008-02-21|Estimate|||||||2010-08-09|2010-08-10|Estimate|February 2007||2007-02-28|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Predicting the Diagnosis of Asthma|Predicting the Diagnosis of Asthma Based on History|Completed|||50|Anticipated|University of South Florida|||2||f||||f||||||||||2018-06-01 02:26:08.024322|2018-06-01 02:26:08.024322
NCT00620321|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04||2010-10-25|2010-10-25|2008-02-11|2008-02-21|Estimate||||2010-10-25|2010-10-27|Estimate|2010-10-25|2010-10-27|Estimate|March 2008||2008-03-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open-Label Phase 2 Trial of LY2181308 Sodium Administered in Combination With Idarubicin and Cytarabine to Patients With Refractory or Relapsed Acute Myeloid Leukemia|Completed||Phase 2|24|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:26:08.110687|2018-06-01 02:26:08.110687
NCT00620308|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-10|||2012-09-07|2008-02-10|2008-02-21|Estimate|||||||2012-09-07|2012-09-10|Estimate|June 2008||2008-06-30|August 2012|2012-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|CD-NP||CD-NP in Subjects With Stable Chronic Heart Failure|A Human Physiologic Study to Evaluate the Renal and Neurohumoral Effects of a Novel Chimeric Natriuretic Peptide, CD-NP, in Subjects With Stable Chronic Heart Failure|Completed||Phase 1|19|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 02:26:08.185037|2018-06-01 02:26:08.185037
NCT00620295|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2017-11-27|2008-02-20|2008-02-21|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2007||2007-03-31|November 2017|2017-11-30|October 2009|Actual|2009-10-31|February 2009|Actual|2009-02-28||Interventional|||Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors|Phase I Study of Bortezomib and Gemcitabine in Elderly Patients With Solid Tumors (X05227)|Completed||Phase 1|17|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:26:08.251624|2018-06-01 02:26:08.251624
NCT00620282|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2011-05-19||2017-01-25|2008-02-20|2008-02-21|Estimate|2011-05-19|2011-06-15|Estimate||||2017-01-25|2017-03-08|Actual|February 2008||2008-02-29|January 2017|2017-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus|The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm|Completed||Phase 3|49|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 02:26:08.384664|2018-06-01 02:26:08.384664
NCT00620269|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2011-11-04|2008-02-20|2008-02-21|Estimate|||||||2011-11-04|2011-11-07|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III|A Randomized Phase II Study of Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy According to EGFR Mutation Status in Patients With Unresectable Stage III NSCLC|Unknown status|Recruiting|Phase 2|212|Anticipated|National Cancer Center, Korea||4|||f||||t||||||||||2018-06-01 02:26:09.400731|2018-06-01 02:26:09.400731
NCT00620256|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11||2012-12-03|2012-12-03|2008-02-11|2008-02-21|Estimate||||2012-12-03|2012-12-05|Estimate|2012-12-03|2012-12-05|Estimate|November 2007||2007-11-30|December 2012|2012-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Adjunctive Study of AL-37807 Ophthalmic Suspension|Comparison of Safety and Efficacy of Al-37807 Ophthalmic Suspension vs. Timolol Gel Forming Solution and Vehicle, All Dosed Concomitantly With Xalatan in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|129|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 02:26:09.487812|2018-06-01 02:26:09.487812
NCT00620243|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-01-06|2008-02-19|2008-02-21|Estimate|||||||2012-01-06|2012-01-09|Estimate|June 2004||2004-06-30|January 2012|2012-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.|Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.|Completed||Early Phase 1|9|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||f||||||||||2018-06-01 02:26:09.581184|2018-06-01 02:26:09.581184
NCT00620230|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-09-24|2008-02-07|2008-02-21|Estimate|||||||2010-09-24|2010-09-27|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects|A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Profile and Pharmacodynamic Effect of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects|Completed||Phase 1|46|Actual|Novartis||2|||||||f||||||||||2018-06-01 02:26:09.709695|2018-06-01 02:26:09.709695
NCT00620217|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2009-11-27|2008-02-07|2008-02-21|Estimate|||||||2009-11-27|2009-12-01|Estimate|December 2004||2004-12-31|November 2009|2009-11-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|VIF-CAD||Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial|"Therapeutic Angiogenesis Using Human VEGF-A165/bFGF Plasmid Injected Percutaneously Into the Ischemic Myocardium of No-option Coronary Artery Disease Patients; Double-blind Placebo Controlled Study"|Completed||Phase 2|52|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||t||||||||||2018-06-01 02:26:09.79516|2018-06-01 02:26:09.79516
NCT00620204|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-10|||2009-04-02|2008-02-10|2008-02-21|Estimate|||||||2009-04-02|2009-04-06|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|ESAVA||Efficacy Study of Atorvastatin to Treat Variant Angina|Efficacy Study of Atorvastatin to Treat Variant Angina|Unknown status|Recruiting|Phase 4|136|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 02:26:09.891776|2018-06-01 02:26:09.891776
NCT00620191|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2013-03-13|2008-02-19|2008-02-21|Estimate|||||||2013-03-13|2013-03-14|Estimate|February 2008||2008-02-29|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|MCI||Metformin in Amnestic Mild Cognitive Impairment|Metformin in the Prevention of Alzheimer's Disease|Completed||Phase 2|80|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 02:26:09.970369|2018-06-01 02:26:09.970369
NCT00620178|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2010-12-01|2008-02-08|2008-02-21|Estimate|||||||2010-12-01|2010-12-02|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|Real Life||Atacand (Candesartan) Real Life Study|"A REtrospective Study on the Effects of cAndesartan vs. Losartan on Blood Pressure, Health Care Consumption and cardiovascuLar Events In a Real-liFe GP sEtting in Sweden"|Completed|||14000|Anticipated|AstraZeneca|||2||f||||||||||||||2018-06-01 02:26:10.062314|2018-06-01 02:26:10.062314
NCT00620165|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2009-04-16|2008-02-20|2008-02-21|Estimate|||||||2009-04-16|2009-04-17|Estimate|January 2005||2005-01-31|April 2009|2009-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy of Levetiracetam in Essential Tremor|Efficacy of Levetiracetam in Patients With Essential Tremor|Completed||Phase 1/Phase 2|10|Actual|Southern California Institute for Research and Education||2|||f||||f||||||||||2018-06-01 02:26:10.128246|2018-06-01 02:26:10.128246
NCT00620152|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2010-08-20|2008-02-19|2008-02-21|Estimate|||||||2010-08-20|2010-08-24|Estimate|April 2008||2008-04-30|August 2010|2010-08-31||||||||Interventional|||Nutrition Study for School Age Children|Randomized Trial of Telephone Interventions for Pediatric Obesity in School Age Children|Completed||N/A|40|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-06-01 02:26:10.221418|2018-06-01 02:26:10.221418
NCT00620139|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-10-23|2008-02-19|2008-02-21|Estimate|||||||2013-10-23|2013-10-24|Estimate|March 2005||2005-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma|Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma|Completed|||17|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||Samples Without DNA|"~     Urine Blood Tissue~   "|||2018-06-01 02:26:10.282065|2018-06-01 02:26:10.282065
NCT00620126|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2011-08-13||2012-10-10|2008-02-20|2008-02-21|Estimate|2012-10-10|2012-10-11|Estimate||||2012-10-10|2012-10-11|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|UCHAT||The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis|The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis|Completed||Phase 3|47|Actual|University of Maryland|"Insufficient sample size to detect moderate differences in outcomes between arms~Differences between groups at baseline may have resulted in no overall difference between arms at one year~Higher rate of attrition than expected"|2|||f||||f||||||||||2018-06-01 02:26:10.349688|2018-06-01 02:26:10.349688
NCT00620113|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2017-01-23||2017-01-23|2008-02-11|2008-02-21|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|December 2007||2007-12-31|January 2017|2017-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||Safety Population: All randomized participants receiving at least one dose of correct study medication. One participant received both 25 mg and 50 mg doses during the study and was excluded from all analyses.|Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Dose-Finding Study of MK-0822 in the Treatment of Involutional Osteoporosis|Completed||Phase 2|287|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||No||2018-06-01 02:26:10.628339|2018-06-01 02:26:10.628339
NCT00620100|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2009-05-29|2008-02-20|2008-02-21|Estimate|||||||2009-05-29|2009-06-03|Estimate|September 2004||2004-09-30|May 2009|2009-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent|A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel (Taxotere®) + Anthracycline (Epirubicin or Doxorubicin) x 4 Cycles Followed by Docetaxel (T) Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed > or = 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®-Based Chemotherapy|Terminated||Phase 2|2|Actual|Sanofi||||the study was early terminated due to lack of recruitment.|f||||||||||||||2018-06-01 02:26:11.31761|2018-06-01 02:26:11.31761
NCT00620087|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-10-06|2008-02-20|2008-02-21|Estimate|||||||2016-10-06|2016-10-10|Estimate|August 2003||2003-08-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Molecular Breast Imaging in Women With Atypia and LCIS|Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ|Completed||N/A|66|Actual|Mayo Clinic||2|||f||||f||||||||Undecided||2018-06-01 02:26:11.374143|2018-06-01 02:26:11.374143
NCT00620074|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2010-01-21||2010-01-21|2008-02-20|2008-02-21|Estimate|2010-01-21|2010-02-15|Estimate||||2010-01-21|2010-02-15|Estimate|August 2008||2008-08-31|January 2010|2010-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)|Phase IV Open-Label Pilot Study to Evaluate the Combination of Voriconazole and Anidulafungin for the Treatment of Subjects With Proven or Probable Invasive Aspergillosis Who Are Intolerant of Polyene Treatment|Terminated||Phase 4|6|Actual|Pfizer|Due to low enrollment and early termination of the study, data was insufficient for descriptive or inferential analysis as planned; no significant treatment-related safety results were identified in the subjects treated with combination therapy.|2||See Detailed Description|f||||t||||||||||2018-06-01 02:26:11.458171|2018-06-01 02:26:11.458171
NCT00620061|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11||2011-03-04|2013-02-01|2008-02-20|2008-02-21|Estimate||||2013-02-01|2013-02-05|Estimate|2013-02-01|2013-02-05|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone|A Multi-center, Open-labeled Study of the Long-term Safety and Efficacy of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction|Completed||Phase 3|440|Actual|Sucampo Pharma Americas, LLC||1|||f||||||||||||||2018-06-01 02:26:11.648645|2018-06-01 02:26:11.648645
NCT00620048|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2015-03-30|2008-02-07|2008-02-21|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2008||2008-03-31|November 2011|2011-11-30||||January 2011|Actual|2011-01-31||Interventional|||Stem Cell Study for Subjects With Congestive Heart Failure|Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40%|Terminated||Phase 1|4|Actual|Losordo, Douglas, M.D.||2||Study terminated due to lack of funding.|f||||f||||||||||2018-06-01 02:26:11.841314|2018-06-01 02:26:11.841314
NCT00620035|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2011-09-22||2015-08-26|2008-02-11|2008-02-21|Estimate|2011-09-22|2011-10-31|Estimate||||2015-08-26|2015-08-27|Estimate|March 2007||2007-03-31|August 2015|2015-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)|An Open-Label, Non-Controlled Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator|Completed||Phase 3|301|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:26:11.92979|2018-06-01 02:26:11.92979
NCT00620022|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2011-07-22||2011-07-22|2008-02-20|2008-02-21|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Phase III Randomized, Double-blind, Placebo-controlled, 2-period Crossover, Multicenter Study to Assess the Effect of Indacaterol (300 μg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|90|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:26:12.228066|2018-06-01 02:26:12.228066
NCT00620009|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-02-11|2008-02-11|2008-02-21|Estimate|||||||2008-02-11|2008-02-21|Estimate|June 2002||2002-06-30|February 2008|2008-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|EMPATHY||The Measurement of Empathy and Its Efficacy in Psychotherapy|The Measurement of Empathy and Its Efficacy in Psychotherapy|Completed||N/A|16|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 02:26:12.508565|2018-06-01 02:26:12.508565
NCT00619996|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2009-02-25|2008-02-20|2008-02-21|Estimate|||||||2009-02-25|2009-02-26|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|P1||Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer|Phase II Study of Sorafenib (Bay 43-9006) and Docetaxel in Metastatic Prostate Cancer|Completed||Phase 2|43|Anticipated|Italian Trial in Medical Oncology||1|||f||||t||||||||||2018-06-01 02:26:12.588154|2018-06-01 02:26:12.588154
NCT00619632|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2015-01-13|2008-02-20|2008-02-21|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2008||2008-02-29|January 2015|2015-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|BINGO||Boosting Breastfeeding in Low-Income, Multi-ethnic Women: A Primary Care Based RCT|Boosting Breastfeeding in Low-Income, Multi-ethnic Women: A Primary Care Based RCT|Completed||N/A|666|Actual|Albert Einstein College of Medicine, Inc.||4|||f||||t||||||||||2018-06-01 02:26:20.005504|2018-06-01 02:26:20.005504
NCT00619983|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2017-07-11||2017-11-03|2008-02-08|2008-02-21|Estimate|2017-07-11|2017-08-10|Actual||||2017-11-03|2017-11-07|Actual|February 2008||2008-02-29|September 2017|2017-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy|Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy|Terminated||Phase 4|22|Actual|Wake Forest University Health Sciences|We recruited only a small proportion of the planned enrollment in the period of grant funding, leading to early termination of the study. Also, the failure of the electronic diaries and loss of primary outcome data prevented the planned analysis.|4||Study terminated due to low enrollment|f||||t|t|f||||||No|Raw IPD will not be shared|2018-06-01 02:26:12.700507|2018-06-01 02:26:12.700507
NCT00619970|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2016-09-27||2017-02-15|2008-02-07|2008-02-21|Estimate|2017-02-15|2017-02-16|Actual||||2017-02-15|2017-02-16|Actual|February 2007||2007-02-28|February 2017|2017-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|CAP&SIBO||Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?|Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?|Completed||N/A|115|Actual|Children's Hospital Los Angeles||3|||f||||t||||||||||2018-06-01 02:26:13.1762|2018-06-01 02:26:13.1762
NCT00619957|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2011-05-23||2011-09-20|2008-02-11|2008-02-21|Estimate|2011-09-20|2011-10-28|Estimate||||2011-09-20|2011-10-28|Estimate|June 2002||2002-06-30|September 2011|2011-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis|Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study|Completed||Phase 3|285|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 02:26:13.482637|2018-06-01 02:26:13.482637
NCT00619944|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-12-03|2008-02-19|2008-02-21|Estimate|||||||2010-12-03|2010-12-06|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir|Lumefantrine Pharmacokinetics When Administered as a Fixed Dose Combination With Artemether in HIV Positive Patients on Lopinavir/Ritonavir|Completed||Phase 4|32|Anticipated|Makerere University||2|||f||||f||||||||||2018-06-01 02:26:14.887132|2018-06-01 02:26:14.887132
NCT00619931|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-12-29|2008-02-11|2008-02-21|Estimate|||||||2008-12-29|2008-12-30|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers||Completed|||50|Anticipated|Arena Pharmaceuticals|||5||f||||f||||||||||2018-06-01 02:26:14.950721|2018-06-01 02:26:14.950721
NCT00619918|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2013-07-29||2013-07-29|2008-02-08|2008-02-21|Estimate|2013-07-29|2013-10-10|Estimate||||2013-07-29|2013-10-10|Estimate|February 2008||2008-02-29|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Nebulized Hypertonic Saline for Bronchiolitis|Nebulized Hypertonic Saline for Treatment of Viral Bronchiolitis|Completed||Phase 2/Phase 3|447|Actual|Children's Hospital Los Angeles|"Albuterol administered before each study treatment~Did not reach subject accrual goals~Number of patients recruited from inpatient unit too small to analyze separately"|2|||f||||t||||||||||2018-06-01 02:26:15.010751|2018-06-01 02:26:15.010751
NCT00619905|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2008-02-08|2008-02-08|2008-02-21|Estimate|||||||2008-02-08|2008-02-21|Estimate|December 2003||2003-12-31|February 2008|2008-02-29|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate|A Randomized, Double-Blind, Placebo-Controlled, Cohort Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 (Anti-Interleukin-1Beta Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis (RA) Despite Ongoing Treatment With Methotrexate (MTX) 15 mg or More Weekly for at Least 3 Months.|Completed||Phase 1/Phase 2|53|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:26:15.232672|2018-06-01 02:26:15.232672
NCT00619892|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2015-07-27||2015-12-15|2008-02-20|2008-02-21|Estimate|2015-12-15|2016-01-21|Estimate||||2015-12-15|2016-01-21|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients|An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder|Completed||Phase 4|26|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 02:26:16.297122|2018-06-01 02:26:16.297122
NCT00619879|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2011-03-29|2008-02-07|2008-02-21|Estimate|||||||2011-03-29|2011-03-30|Estimate|March 2007||2007-03-31|March 2011|2011-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies|Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies|Recruiting||Phase 3|200|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 02:26:16.582147|2018-06-01 02:26:16.582147
NCT00619866|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24||2012-02-07|2013-01-02|2008-02-20|2008-02-21|Estimate||||2012-02-07|2012-02-09|Estimate|2013-01-02|2013-01-08|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||An Efficacy and Safety Study of NBI-56418 in Endometriosis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis|Completed||Phase 2|155|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 02:26:16.668198|2018-06-01 02:26:16.668198
NCT00619853|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-10|||2008-02-20|2008-02-20|2008-02-21|Estimate|||||||2008-02-20|2008-02-21|Estimate|June 2007||2007-06-30|February 2008|2008-02-29|October 2007||2007-10-31|||||Interventional|CIMT||The Influence of MCIMT (Modified Constrained Induced Movement Therapy), Bilateral Intensive Treatment, and NDT Approach on the UL Function in Children With Hemiplegic Cerebral Palsy||Completed||Phase 2|||Sheba Medical Center|||||f||||f||||||||||2018-06-01 02:26:16.834332|2018-06-01 02:26:16.834332
NCT00619840|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-02-11|2008-02-11|2008-02-21|Estimate|||||||2008-02-11|2008-02-21|Estimate|November 2004||2004-11-30|February 2008|2008-02-29||||May 2006|Actual|2006-05-31||Interventional|EMMA||Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD|Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD|Completed||Phase 3|363|Actual|Medice Arzneimittel Pütter GmbH & Co KG||2|||f||||f||||||||||2018-06-01 02:26:16.951418|2018-06-01 02:26:16.951418
NCT00619645|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2017-01-13||2018-01-05|2008-02-20|2008-02-21|Estimate|2017-03-27|2017-05-08|Actual||||2018-01-05|2018-01-10|Actual|June 2007||2007-06-30|January 2018|2018-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers|Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan|Completed||Phase 2|8|Actual|University of California, Davis|This study was closed after only enrolling 8 patients and results were never published.|1|||f||||t||||||||||2018-06-01 02:26:19.777444|2018-06-01 02:26:19.777444
NCT00619827|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2016-01-25||2016-04-18|2008-02-20|2008-02-21|Estimate|2016-04-18|2016-05-23|Estimate||||2016-04-18|2016-05-23|Estimate|September 2007||2007-09-30|April 2016|2016-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||The Intent-to-treat (ITT) population included all randomised subjects who received at least one dose of the investigational product.|Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract|A Randomised, Double-blind, in Parallel Groups Placebo-controlled, Mono-centre, Phase I Study to Assess After Allergen Challenge in an Allergen Exposition Chamber the Effect and Its Time Course of Sublingual Immunotherapy (SLIT) Administered as 300IR Allergen-based Tablets Once Daily to Adults Suffering From Grass Pollen Rhinoconjunctivitis|Completed||Phase 1|89|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-06-01 02:26:17.04432|2018-06-01 02:26:17.04432
NCT00619814|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2008-02-20|2008-02-20|2008-02-21|Estimate|||||||2008-02-20|2008-02-21|Estimate|September 2003||2003-09-30|February 2008|2008-02-29|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|DCBE||Is Barium Enema an Adequate Diagnostic Test for Patients With Positive FOBT?|Is Barium Enema an Adequate Diagnostic Test for Patients With Positive FOBT?|Completed||N/A|50|Actual|VA Caribbean Healthcare System||1|||f||||t||||||||||2018-06-01 02:26:17.272866|2018-06-01 02:26:17.272866
NCT00619801|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2009-07-28||2015-02-18|2008-02-11|2008-02-21|Estimate|2009-07-28|2009-09-04|Estimate||||2015-02-18|2015-03-06|Estimate|March 2008||2008-03-31|February 2015|2015-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PAL||Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin|A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin|Completed||Phase 3|173|Actual|UCB Pharma||2|||f||||||||||||||2018-06-01 02:26:17.369302|2018-06-01 02:26:17.369302
NCT00619788|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-07-02|2008-02-07|2008-02-21|Estimate|||||||2010-07-02|2010-07-05|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|October 2009|Actual|2009-10-31|November 2008|Actual|2008-11-30||Interventional|MASCOT||FeMoropopliteal AngioSculpt™ SCoring BallOon CaTheter Study|Prospective, Multicenter, Non-randomized Clinical Trial Investigating the Safety and Efficacy of the AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for the Treatment of Femoropopliteal Stenotic Disease.|Completed||Phase 2/Phase 3|50|Anticipated|Flanders Medical Research Program||1|||f||||f||||||||||2018-06-01 02:26:17.876439|2018-06-01 02:26:17.876439
NCT00619775|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-12-05|2008-02-07|2008-02-21|Estimate|||||||2008-12-05|2008-12-09|Estimate|April 2004||2004-04-30|December 2008|2008-12-31|October 2005|Actual|2005-10-31|||||Interventional|CREATE||Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial|Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial|Completed||Phase 3|419|Actual|ev3|||||f||||t||||||||||2018-06-01 02:26:17.949912|2018-06-01 02:26:17.949912
NCT00619762|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2012-12-19||2016-10-04|2008-02-11|2008-02-21|Estimate|2013-04-07|2013-05-15|Estimate||||2016-10-04|2016-11-08|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||Immediate Postmastectomy Breast Reconstruction (Strattice Breast)|A Multicenter, Prospective, Open-Label Study to Assess the Clinical Outcomes of LTM Use in Two-Stage Breast Reconstruction Immediately Post Mastectomy|Completed|||17|Actual|LifeCell|Small number of subjects and breasts analyzed.||||f||||f||||||Samples Without DNA|"~     Tissue sample~   "|||2018-06-01 02:26:18.06171|2018-06-01 02:26:18.06171
NCT00619749|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2016-07-07|2008-02-20|2008-02-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|March 2008||2008-03-31|July 2016|2016-07-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Polyphenols and Endothelial Function|Polyphenols Rich Fruit Juice Effects on Endothelial Function and Exercise Capacity|Terminated||Phase 3|50|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 02:26:18.349128|2018-06-01 02:26:18.349128
NCT00619736|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2009-01-28|2008-02-08|2008-02-21|Estimate|||||||2009-01-28|2009-01-30|Estimate|March 2008||2008-03-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study Evaluating the Safety, Tolerability and Pharmacokinetics of NSA-789 in Healthy Japanese Male Subjects|Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of NSA-789 Administered Orally to Healthy Japanese Male Subjects|Completed||Phase 1|56|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:26:18.414399|2018-06-01 02:26:18.414399
NCT00619723|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2017-04-03|2013-04-22|2018-01-23|2008-02-20|2008-02-21|Estimate|2018-01-23|2018-01-24|Actual|2013-04-29|2013-05-07|Estimate|2018-01-23|2018-01-24|Actual|April 2008||2008-04-30|January 2018|2018-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Citicoline for Bipolar 1 Disorder and Cocaine Dependence|A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence.|Completed||Phase 4|130|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:26:18.540966|2018-06-01 02:26:18.540966
NCT00619710|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2017-08-31|2008-02-20|2008-02-21|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2001||2001-02-28|August 2017|2017-08-31|April 2004|Actual|2004-04-30|December 2003|Actual|2003-12-31||Interventional|||Complicated Skin and Skin Structure Infections|A Multicenter, Randomized, Double Blind, Comparative Trial of Intravenous MERREM (Meropenem, ICI 194,660) vs PRIMAXIN I.V. (Imipenem-cilastatin) in the Treatment of Hospitalised Subjects With Complicated Skin and Skin Structure Infections.|Completed||Phase 3|1000|Anticipated|Pfizer||2|||f||||||||||||||2018-06-01 02:26:18.979036|2018-06-01 02:26:18.979036
NCT00619697|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2017-01-05|2008-02-11|2008-02-21|Estimate|||||||2017-01-05|2017-01-06|Estimate|December 2003||2003-12-31|January 2017|2017-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|EUROMIX||Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes|Comparison of Efficacy and Safety of Biphasic Insulin Aspart 30 Plus Metformin With Insulin Glargine Plus Glimepiride in Type 2 Diabetes|Completed||Phase 4|260|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:26:19.176876|2018-06-01 02:26:19.176876
NCT00619684|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|2017-03-07||2017-04-19|2008-02-20|2008-02-21|Estimate|2017-03-07|2017-04-18|Actual||||2017-04-19|2017-05-18|Actual|February 2008||2008-02-29|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant|A Phase II Study of Lenalidomide Following Allogeneic Stem Cell Transplant for Multiple Myeloma Patients Who Relapse or Have Disease Progression|Completed||Phase 2|18|Actual|Fred Hutchinson Cancer Research Center||1|||f||||||||||||||2018-06-01 02:26:19.344444|2018-06-01 02:26:19.344444
NCT00619671|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2013-01-15|2008-02-08|2008-02-21|Estimate|||||||2013-01-15|2013-01-16|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Pilot Trial of Rituxan in Refractory Myasthenia Gravis|Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.|Completed||Phase 1/Phase 2|10|Anticipated|University of Vermont|||||f||||t||||||||||2018-06-01 02:26:19.610587|2018-06-01 02:26:19.610587
NCT00619619|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2010-11-10||2011-02-18|2008-02-08|2008-02-21|Estimate|2011-01-21|2011-02-21|Estimate||||2011-02-18|2011-02-23|Estimate|February 2008||2008-02-29|February 2011|2011-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder|Final Report: Multicenter, Open-Label, Safety, Tolerability, And Pharmacokinetic Study To Evaluate Single Ascending Doses And Subsequent Short-Term Administration Of Fixed Doses Of DVS SR Tablets In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder|Completed||Phase 2|59|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:26:20.217052|2018-06-01 02:26:20.217052
NCT00619606|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-02-20|2008-02-20|2008-02-21|Estimate|||||||2008-02-20|2008-02-21|Estimate|November 2006||2006-11-30|February 2008|2008-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||To Determine the Efficacy of the TwinGuard in Oxygen Delivery During and Post Endoscopic Procedure|A Randomised, Parallel, Open Label Study to Determine the Efficacy of a New Oral-Nasal Oxygenating Device (TwinGuard) Compared to Standard Bite Block Plus Nasal Cannulae|Completed||Phase 2|150|Actual|Trawax Pty Limited|||||f||||t||||||||||2018-06-01 02:26:22.229795|2018-06-01 02:26:22.229795
NCT00619593|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2015-01-09|2008-02-20|2008-02-21|Estimate|||||||2015-01-09|2015-01-12|Estimate|February 2008||2008-02-29|January 2015|2015-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|SPIRIT-ICD||Survival of Patients With Primary Prophylactic ICD Indication|Survival of Patients With Primary Prophylactic ICD Indication, Provided With Intensified Care After 1st ICD Therapy|Completed||Phase 4|504|Actual|Biotronik SE & Co. KG||2|||f||||f||||||||||2018-06-01 02:26:22.327444|2018-06-01 02:26:22.327444
NCT00619580|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2014-12-05|2008-02-20|2008-02-21|Estimate|||||||2014-12-05|2014-12-08|Estimate|February 2008||2008-02-29|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Ampicillin-sulbactam Resistant E.Coli at UPMC|Ampicillin-sulbactam Resistant E.Coli at UPMC|Withdrawn|||0|Actual|University of Pittsburgh|||1||f||||t||||||||||2018-06-01 02:26:22.542991|2018-06-01 02:26:22.542991
NCT00619567|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2013-12-09|2008-02-20|2008-02-21|Estimate|||||||2013-12-09|2013-12-10|Estimate|September 2007||2007-09-30|December 2013|2013-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Cognitive Stimulation Program in AIDS|Pilot Study of an Internet-Based Cognitive Stimulation Program in AIDS|Completed||Phase 1|60|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:26:22.602309|2018-06-01 02:26:22.602309
NCT00619554|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-02-20|2008-02-20|2008-02-21|Estimate|||||||2008-02-20|2008-02-21|Estimate|July 2007||2007-07-31|February 2008|2008-02-29||||August 2007|Actual|2007-08-31||Observational|||A Study on the Intraject Instructions for Use|Zogenix Intraject Instructions for Use Pilot Study|Completed|||19|Actual|Zogenix, Inc.|||||f||||f||||||||||2018-06-01 02:26:22.67854|2018-06-01 02:26:22.67854
NCT00619541|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2009-02-25|2008-02-20|2008-02-21|Estimate|||||||2009-02-25|2009-02-26|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|November 2007|Actual|2007-11-30||Interventional|P2||Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)|Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.|Completed||Phase 2|46|Anticipated|Italian Trial in Medical Oncology||1|||f||||t||||||||||2018-06-01 02:26:22.720426|2018-06-01 02:26:22.720426
NCT00619528|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2016-10-07|2008-02-08|2008-02-21|Estimate|||||||2016-10-07|2016-10-10|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|February 2021|Anticipated|2021-02-28|February 2018|Anticipated|2018-02-28||Interventional|||HLA-Identical Sibling Renal Transplant Tolerance|HLA-Identical Sibling Renal Transplant Tolerance With Donor Hematopoietic Stem Cells and Campath-1H|Active, not recruiting||N/A|230|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 02:26:22.827991|2018-06-01 02:26:22.827991
NCT00619515|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-20|||2013-02-27|2008-02-20|2008-02-21|Estimate|||||||2013-02-27|2013-03-01|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer|Prospective Evaluation of Cyberknife Stereotactic Radiosurgery for Low and Low/Intermediate Risk Prostate Cancer|Completed||N/A|73|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:26:22.899653|2018-06-01 02:26:22.899653
NCT00619502|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2014-02-22||2016-04-08|2008-02-11|2008-02-21|Estimate|2014-02-22|2014-04-03|Estimate||||2016-04-08|2016-05-13|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants|Immunogenicity and Safety Study of a Booster Dose of DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series at 2, 3 and 4 Months of Age in Healthy Turkish Infants|Completed||Phase 3|254|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:26:22.988463|2018-06-01 02:26:22.988463
NCT00619489|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2014-06-19||2014-06-19|2008-02-20|2008-02-21|Estimate|2014-06-19|2014-07-18|Estimate||||2014-06-19|2014-07-18|Estimate|December 2007||2007-12-31|June 2014|2014-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||"The Safety Analysis Set defined as all enrolled participants who received at least 1 dose of study drug. Patients were analyzed based on the lowest dose they received.~Baseline is the time closest to, but before, the start of study drug administration; for participants who rolled over from Study C13002 Baseline data are from the C13002 dataset."|Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease|Phase 2, Multiple Dose, Open-Label Study to Determine the Long Term Safety of MLN0002 in Patients With Ulcerative Colitis and Crohn's Disease|Completed||Phase 2|72|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:26:23.473988|2018-06-01 02:26:23.473988
NCT00619476|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2011-04-26|2010-08-12|2013-07-15|2008-02-07|2008-02-21|Estimate|2011-04-26|2011-05-20|Estimate|2011-03-31|2011-04-07|Estimate|2013-07-15|2013-07-22|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)|Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)|Completed||Phase 2|376|Actual|XenoPort, Inc.||4|||f||||f||||||||||2018-06-01 02:26:24.300104|2018-06-01 02:26:24.300104
NCT00619463|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2013-09-23|2008-02-20|2008-02-21|Estimate|||||||2013-09-23|2013-09-24|Estimate|August 2007||2007-08-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Aerobic Exercise on Cognition, Mood and Fatigue Following TBI|Effects of Aerobic Exercise on Cognition, Mood and Fatigue Following TBI|Completed||N/A|154|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 02:26:25.685257|2018-06-01 02:26:25.685257
NCT00619450|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2017-01-31|2008-02-19|2008-02-21|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 2007|Actual|2007-08-31|January 2017|2017-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|DynaC-Arm||Siemens 3-D C-Arm CT of the Heart Chambers|Three Dimensional C-Arm Computed Tomography of the Heart Chambers|Completed|||16|Actual|The Cleveland Clinic|||||f||||f|f|f|||t|||No||2018-06-01 02:26:25.773009|2018-06-01 02:26:25.773009
NCT00619424|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2017-11-13|2008-02-20|2008-02-21|Estimate|||||||2017-11-13|2017-11-17|Actual|November 15, 2007|Actual|2007-11-15|November 2017|2017-11-30|September 4, 2009|Actual|2009-09-04|September 4, 2009|Actual|2009-09-04||Interventional|||A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors|A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors|Completed||Phase 1|58|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:26:25.927396|2018-06-01 02:26:25.927396
NCT00619411|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2012-03-08|2008-02-11|2008-02-21|Estimate|||||||2012-03-08|2012-03-09|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Interpersonal Psychotherapy for Depressed Adolescents and Parents|An Open Clinical Trial of Interpersonal Psychotherapy for Depressed Adolescence and Parents|Completed||Phase 1|10|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-06-01 02:26:26.018448|2018-06-01 02:26:26.018448
NCT00619398|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2016-02-23|2008-02-07|2008-02-21|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients and a Pharmacokinetics Study|Completed||Phase 3|172|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 02:26:26.131585|2018-06-01 02:26:26.131585
NCT00619385|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2014-06-27||2014-08-05|2008-02-20|2008-02-21|Estimate|2014-06-27|2014-07-28|Estimate||||2014-08-05|2014-08-08|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|PK||A Safety and Pharmacokinetic Study of Proellex®|A Safety and Pharmacokinetic Study of 100 mg, 150 mg and 200 mg of Proellex® Taken for Seven Days by Healthy Adult Female Subjects|Completed||Phase 1|25|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-06-01 02:26:26.262366|2018-06-01 02:26:26.262366
NCT00619372|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-10|||2009-02-03|2008-02-20|2008-02-21|Estimate|||||||2009-02-03|2009-02-04|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|June 2008|Anticipated|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Oral OKT3 in Combination With Beta-D-Glucosylceramide|Administration of Anti-CD3 (OKT3) in Combination With Beta-D-Glucosylceramide|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Hadassah Medical Organization||6|||f||||t||||||||||2018-06-01 02:26:26.78691|2018-06-01 02:26:26.78691
NCT00619359|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2010-01-19||2017-02-14|2008-02-11|2008-02-21|Estimate|2010-01-19|2010-02-12|Estimate||||2017-02-14|2017-03-21|Actual|February 2008||2008-02-29|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|EASE||Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)|A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intravenous MK-0517 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Cisplatin Chemotherapy|Completed||Phase 3|2322|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:26:26.924498|2018-06-01 02:26:26.924498
NCT00619346|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2013-03-06|2008-02-19|2008-02-20|Estimate|||||||2013-03-06|2013-03-07|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects|Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects|Terminated||Phase 1|100|Actual|Immtech Pharmaceuticals, Inc||2||FDA Full Clinical Hold due to safety concerns, as of 12/21/07|f||||f||||||||||2018-06-01 02:26:27.836068|2018-06-01 02:26:27.836068
NCT00619333|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2010-01-11|2008-02-06|2008-02-20|Estimate|||||||2010-01-11|2010-01-12|Estimate|March 2007||2007-03-31|January 2010|2010-01-31||||March 2010|Anticipated|2010-03-31||Interventional|||Inactive FSH in Galactosemia|The Role of Inactive Follicle Stimulating Hormone in Ovarian Dysfunction in Galactosemia|Unknown status|Active, not recruiting|N/A|25|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 02:26:27.905148|2018-06-01 02:26:27.905148
NCT00619320|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2013-02-11|2008-02-19|2008-02-20|Estimate|||||||2013-02-11|2013-02-12|Estimate|December 2008||2008-12-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women|Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women|Completed||Phase 2/Phase 3|380|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 02:26:27.983923|2018-06-01 02:26:27.983923
NCT00619307|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2010-05-11||2014-01-26|2008-02-08|2008-02-20|Estimate|2010-06-30|2010-07-26|Estimate||||2014-01-26|2014-02-27|Estimate|July 2007||2007-07-31|January 2014|2014-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|TRANSFER||Transition to Rebif New Formulation|A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen When Necessary (PRN) or as Prophylaxis|Completed||Phase 3|117|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 02:26:28.11483|2018-06-01 02:26:28.11483
NCT00619294|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2013-09-25|2008-02-08|2008-02-20|Estimate|||||||2013-09-25|2013-09-26|Estimate|August 2006||2006-08-31|September 2013|2013-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Endothelial Dysfunction and Coronary Artery Spasm|Digital Tonometry for Measurement of Peripheral Artery Reactive Hyperemia as Non-invasive Test for Diagnosis of Coronary Artery Spasm|Completed|||158|Actual|Kumamoto University|||||f||||f||||||||||2018-06-01 02:26:28.468169|2018-06-01 02:26:28.468169
NCT00619281|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2009-11-23|2008-02-08|2008-02-20|Estimate|||||||2009-11-23|2009-11-25|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||How Much Cardiac Output is Enough?|Prospective, Observational Study in Cardiac Surgery: How Much Cardiac Output is Enough?|Completed|||600|Anticipated|Klinikum Ludwigshafen|||1||f||||f||||||||||2018-06-01 02:26:28.525054|2018-06-01 02:26:28.525054
NCT00619268|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2013-02-14|2008-02-08|2008-02-20|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|TORAVA||Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma|Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel® (Temsirolimus) and Avastin® (Bevacizumab) Versus Sutent® (Sunitinib) and Versus a Combination of Avastin® (Bevacizumab) and Roféron® (Interferon Alpha-2a) in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma.|Completed||Phase 2|160|Anticipated|Centre Leon Berard||3|||f||||t||||||||||2018-06-01 02:26:28.598003|2018-06-01 02:26:28.598003
NCT00524992|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-01|||2018-04-04|2007-09-01|2007-09-05|Estimate|||||||2018-04-04|2018-04-05|Actual|August 29, 2007||2007-08-29|December 24, 2014|2014-12-24|December 24, 2014||2014-12-24|||||Observational|||Evaluation of Albuminuria HIV-Infected Patients|Prospective Evaluation of Albuminuria in HIV Positive Patients|Completed|||252|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:57:18.601852|2018-06-01 02:57:18.601852
NCT00619255|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2017-07-03||2018-02-16|2008-02-06|2008-02-20|Estimate|2017-07-03|2017-11-07|Actual||||2018-02-16|2018-02-19|Actual|March 1, 2008|Actual|2008-03-01|February 2018|2018-02-28|June 1, 2014|Actual|2014-06-01|October 31, 2010|Actual|2010-10-31||Interventional|ATRSCC||Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial|Maternal Child Health Bureau Adolescent Trauma Recovery and Stress Disorders Collaborative Care (ATRSCC) Model Program Trial|Completed||N/A|120|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:26:28.782118|2018-06-01 02:26:28.782118
NCT00619242|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2009-09-23||2014-02-10|2008-02-19|2008-02-20|Estimate|2013-08-14|2013-10-21|Estimate||||2014-02-10|2014-03-12|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Barrett's||The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer|A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia|Terminated||N/A|3|Actual|University of Chicago||1||Low accrual|f||||t||||||||||2018-06-01 02:26:29.242078|2018-06-01 02:26:29.242078
NCT00619229|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|2011-01-27||2014-10-17|2008-02-08|2008-02-20|Estimate|2011-03-10|2011-04-11|Estimate||||2014-10-17|2014-10-27|Estimate|July 2006||2006-07-31|November 2011|2011-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Alprostadil in Maculopathy Study (AIMS)|Confirmatory, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Dry Age-related Macular Degeneration.|Terminated||Phase 3|37|Actual|UCB Pharma||2||Interim Analysis: Optimization of study design required.|f||||t||||||||||2018-06-01 02:26:29.373155|2018-06-01 02:26:29.373155
NCT00619216|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2011-06-01|2008-02-19|2008-02-20|Estimate|||||||2011-06-01|2011-06-03|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Myfortic Conversion Trial in OLT Recipients With GI Intolerance|A Three-Month, Open-Label, Two Cohort Study to Investigate the Safety and Tolerability of Myfortic in Combination With Neoral (Cyclosporin) or Prograf (Tacrolimus) in Liver Transplant Recipients With GI Intolerance|Completed|||31|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 02:26:29.941042|2018-06-01 02:26:29.941042
NCT00619203|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2012-07-09|2008-02-19|2008-02-20|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|GLYIP||Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis|Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis - A Prospective, Randomized, and Double-Blind Clinical Study Using a Two-by-Two Factorial Design|Completed||Phase 3|466|Actual|University of Malawi College of Medicine||4|||f||||f||||||||||2018-06-01 02:26:30.007531|2018-06-01 02:26:30.007531
NCT00619190|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2013-09-16||2014-02-07|2008-02-07|2008-02-20|Estimate|2014-02-07|2014-03-26|Estimate||||2014-02-07|2014-03-26|Estimate|January 2006||2006-01-31|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PAIRS||Study of Aripiprazole to Treat Children and Adolescents With Autism|An Open Label Study of Aripiprazole in Children and Adolescents With Autism Spectrum Disorders|Completed||Phase 2|30|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:26:30.108803|2018-06-01 02:26:30.108803
NCT00619177|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2009-05-22||2015-01-30|2008-02-19|2008-02-20|Estimate|2009-11-10|2009-11-18|Estimate||||2015-01-30|2015-02-16|Estimate|March 2007||2007-03-31|January 2015|2015-01-31||||May 2008|Actual|2008-05-31||Observational||Treated set|Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of Life|Assessing the Impact of MOVALIS on Health Related Quality of Life|Completed|||3569|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:26:30.467382|2018-06-01 02:26:30.467382
NCT00619164|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2013-05-09|2008-02-08|2008-02-20|Estimate|||||||2013-05-09|2013-05-13|Estimate|November 2007||2007-11-30|February 2010|2010-02-28||||September 2009|Actual|2009-09-30||Interventional|||A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome|A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome|Completed||Phase 2|240|Actual|Eisai Inc.||4|||f||||||||||||||2018-06-01 02:26:31.410385|2018-06-01 02:26:31.410385
NCT00619151|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2011-06-07||2011-11-07|2008-02-19|2008-02-20|Estimate|2011-09-20|2011-11-03|Estimate||||2011-11-07|2011-11-16|Estimate|December 2007||2007-12-31|September 2011|2011-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||CarboMedics Top Hat vs St. Jude Medical Regent Valve Comparing Sizing and Hemodynamics|A Randomized Study to Compare Sizing, Implant Techniques, & Hemodynamic Performance Between the CarboMedics Supra-annular Top Hat Valve and the St. Jude Medical Regent Valve in the Aortic Position.|Terminated||N/A|2|Actual|Sorin Group USA, Inc.|Early termination due to low enrollment resulted in only 2 patients. Insufficient data for analysis.|2||Study stopped due to lack of elegible patient enrollment|f||||f||||||||||2018-06-01 02:26:31.627597|2018-06-01 02:26:31.627597
NCT00619138|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2016-01-25|2008-02-08|2008-02-20|Estimate|||||||2016-01-25|2016-01-26|Estimate|March 2008||2008-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2012|Actual|2012-05-31||Interventional|TSPPA||Treatment of Social Phobia and Panic Disorder in Adults|A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults|Completed||Phase 3|174|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 02:26:31.856751|2018-06-01 02:26:31.856751
NCT00619125|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2017-06-16|2008-02-07|2008-02-20|Estimate|||||||2017-06-16|2017-06-20|Actual|April 2008||2008-04-30|October 2011|2011-10-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Observational|||Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stress, and Bloating in IBS Diarrhea and Constipation Symptoms Using a Palm Pilot|A Proposal to Evaluate Time-specific Relationships Between Variables of Pain, Stress, and Bloating in the Onset of IBS Diarrhea and Constipation Symptoms Using Ecological Momentary Assessment (EMA)|Completed|||85|Actual|University of North Carolina, Chapel Hill|||4||f||||f||||||||||2018-06-01 02:26:31.928856|2018-06-01 02:26:31.928856
NCT00619112|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2013-06-17||2018-01-05|2008-02-19|2008-02-20|Estimate|2013-08-22|2013-10-29|Estimate||||2018-01-05|2018-01-31|Actual|October 2007||2007-10-31|January 2018|2018-01-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Temozolomide in Treating Patients With Recurrent High-Grade Glioma|Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma|Completed||Phase 2|60|Actual|University of California, San Francisco|The trial reached enrollment. There were no unexpected toxicities.|1|||f||||t||||||||||2018-06-01 02:26:32.010817|2018-06-01 02:26:32.010817
NCT00619099|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2013-07-14||2013-09-18|2008-02-19|2008-02-20|Estimate|2013-07-14|2013-09-18|Estimate||||2013-09-18|2013-10-24|Estimate|May 2008||2008-05-31|September 2013|2013-09-30||||March 2012|Actual|2012-03-31||Interventional||Modified Intent to Treat (mITT) Population|A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)|Randomized Open-label Phase 2 Study of Low Dose Dacogen® for Injection (Decitabine) in Patients With Low or Intermediate 1 Risk Myelodysplastic Syndromes|Completed||Phase 2|67|Actual|Eisai Inc.||2|||f||||f||||||||||2018-06-01 02:26:32.298823|2018-06-01 02:26:32.298823
NCT00619060|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2013-11-27||2016-03-09|2008-02-19|2008-02-20|Estimate|2016-03-09|2016-03-10|Estimate||||2016-03-09|2016-03-10|Estimate|August 2007||2007-08-31|September 2014|2014-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers|A Phase I Study of Topical Myristyl Nicotinate Cream on Human Skin in Healthy Volunteers|Completed||Phase 1|22|Actual|University of Arizona||2|||f||||t||||||||||2018-06-01 02:26:33.2829|2018-06-01 02:26:33.2829
NCT00619047|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-11-18|2008-02-19|2008-02-20|Estimate|||||||2009-11-18|2009-11-20|Estimate|January 2002||2002-01-31|November 2009|2009-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||The Role of Impact Activity in Peripubertal Bone Accrual|The Role of Impact Activity in Peripubertal Bone Accrual|Completed|||131|Actual|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 02:26:33.484189|2018-06-01 02:26:33.484189
NCT00619034|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2010-12-28|2008-02-19|2008-02-20|Estimate|||||||2010-12-28|2010-12-29|Estimate|September 2007||2007-09-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|XAVOT||Pharmacological Intervention in Diabetic Retinopathy|Pharmacological Intervention Against Diabetic Retinal Flow Disturbances.|Completed||N/A|87|Actual|University of Aarhus||3|||f||||t||||||||||2018-06-01 02:26:33.541285|2018-06-01 02:26:33.541285
NCT00619021|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2017-11-27|2008-02-19|2008-02-20|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2003||2003-01-31|November 2017|2017-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer|A Phase I Study Evaluating Bronchial Artery Infusion (BAI) of Gemcitabine in Recurrent or Progressive Non-Small Cell Lung Cancer|Terminated||Phase 1|4|Actual|Masonic Cancer Center, University of Minnesota||4||Funding and study drugs unavailable|f||||t||||||||||2018-06-01 02:26:33.713853|2018-06-01 02:26:33.713853
NCT00619008|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2008-10-02|2008-02-15|2008-02-20|Estimate|||||||2008-10-02|2008-10-03|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|BALANCE||Energy Balance Weight Regulation Study|Energy and Appetite Regulation by High and Low CHO Diets|Completed||Phase 2|35|Actual|National Center for Complementary and Integrative Health (NCCIH)||3|||f||||t||||||||||2018-06-01 02:26:33.814934|2018-06-01 02:26:33.814934
NCT00618995|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2008-12-05||2015-08-25|2008-02-08|2008-02-20|Estimate|2009-02-04|2009-02-05|Estimate||||2015-08-25|2015-09-07|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 Diabetes|Completed||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 02:26:33.916161|2018-06-01 02:26:33.916161
NCT00618982|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2010-04-30||2015-11-23|2008-02-19|2008-02-20|Estimate|2010-04-30|2010-05-27|Estimate||||2015-11-23|2015-12-24|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|January 2011|Actual|2011-01-31|April 2009|Actual|2009-04-30||Interventional|||Sorafenib Dose Escalation in Renal Cell Carcinoma|A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma.|Completed||Phase 2|83|Actual|Bayer||1|||f||||t||||||||||2018-06-01 02:26:34.305958|2018-06-01 02:26:34.305958
NCT00618969|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2016-03-01|2008-02-08|2008-02-20|Estimate|||||||2016-03-01|2016-03-03|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2013|Actual|2013-12-31||Interventional|||Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors|A Phase II Study of Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors for Treatment of Hematologic Malignancies and Hematopoietic Failure States|Completed||Phase 2|2|Actual|University of Arizona||1|||f||||t||||||||||2018-06-01 02:26:34.769053|2018-06-01 02:26:34.769053
NCT00618956|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2009-07-29||2009-11-10|2008-02-19|2008-02-20|Estimate|2009-07-29|2009-09-03|Estimate||||2009-11-10|2009-11-20|Estimate|October 2007||2007-10-31|November 2009|2009-11-30||||July 2008|Actual|2008-07-31||Interventional|||A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Milnacipran 100 And 200 MG Daily in Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure|Completed||Phase 3|321|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 02:26:34.847591|2018-06-01 02:26:34.847591
NCT00618943|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2011-12-07|2008-02-15|2008-02-20|Estimate|||||||2011-12-07|2011-12-08|Estimate|April 2008||2008-04-30|December 2011|2011-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders|Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders|Completed||Phase 3|60|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 02:26:35.382843|2018-06-01 02:26:35.382843
NCT00618930|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-04-14|2008-02-19|2008-02-20|Estimate|||||||2009-04-14|2009-04-15|Estimate|February 2008||2008-02-29|April 2009|2009-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Moviprep® Versus Fleet Phospho-Soda® (Golden Standard): A Study That Compared Two Laxatives on Patients Undergoing Colo-Rectal Cleansing Prior to an Abdominal Operation|Moviprep® Versus Fleet Phospho-Soda® (Golden Standard): A Study That Compared Two Laxatives on Patients Undergoing Colo-Rectal Cleansing Prior to an Abdominal Operation.|Completed||Phase 4|40|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:26:35.450603|2018-06-01 02:26:35.450603
NCT00618917|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2018-04-25|2008-02-06|2008-02-20|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2005||2005-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|MnSOD||MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)|Chemotherapy (Paclitaxel and Carboplatin)and Thoracic Radiotherapy With Swallowed Manganese Superoxide Dismutase (MnSOD) Plasmid Liposome Protection in Patients With Locally Advanced Stage III Non-Small Cell Lung Cancer: A Phase I-II Study|Suspended||Phase 1/Phase 2|45|Anticipated|University of Pittsburgh||1||MnSOD currently being manufactured|f||||t||||||||||2018-06-01 02:26:35.520386|2018-06-01 02:26:35.520386
NCT00618904|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2013-07-08|2008-02-19|2008-02-20|Estimate|||||||2013-07-08|2013-07-09|Estimate|December 2005||2005-12-31|July 2013|2013-07-31|September 2007|Actual|2007-09-30|February 2007|Actual|2007-02-28||Interventional|||Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating|Clinical Efficacy of Probiotic Bacteria in Subjects With Irritable Bowel Syndrome (IBS), Functional Diarrhea, or Functional Bloating|Completed||N/A|56|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:26:35.59543|2018-06-01 02:26:35.59543
NCT00524979|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2008-05-15|2007-09-04|2007-09-05|Estimate|||||||2008-05-15|2008-05-16|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|||||Observational|||Digital Voice Analysis in Patients With Schizophrenia|Digital Voice Analysis in Patients With Schizophrenia|Completed|||60|Actual|BeerYaakov Mental Health Center|||3||f||||t||||||||||2018-06-01 02:57:18.661851|2018-06-01 02:57:18.661851
NCT00618878|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2008-10-16|2008-02-08|2008-02-20|Estimate|||||||2008-10-16|2008-10-17|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Electroacupuncture and Laser Therapy on Neck Pain|The Effects of Electroacupuncture and Laser Therapy on Chronic Neck Pain, A Pilot Study|Unknown status|Recruiting|N/A|20|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 02:26:35.67473|2018-06-01 02:26:35.67473
NCT00618865|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2008-02-08|2008-02-08|2008-02-20|Estimate|||||||2008-02-08|2008-02-20|Estimate|June 2004||2004-06-30|February 2008|2008-02-29|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy|Omega-3 Polyunsaturated Fatty Acids in Women With Major Depressive Disorders During Pregnancy|Completed||N/A|36|Actual|National Science Council, Taiwan||2|||f||||f||||||||||2018-06-01 02:26:35.753621|2018-06-01 02:26:35.753621
NCT00618852|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-02-19|2008-02-19|2008-02-20|Estimate|||||||2008-02-19|2008-02-20|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|June 2009|Anticipated|2009-06-30|December 2008|Anticipated|2008-12-31||Interventional|||Using Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates|A Randomized Controlled Trial of Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates|Unknown status|Recruiting|Phase 3|64|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 02:26:35.80829|2018-06-01 02:26:35.80829
NCT00618839|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2009-05-08||2012-08-08|2008-02-19|2008-02-20|Estimate|2012-08-08|2012-09-10|Estimate||||2012-08-08|2012-09-10|Estimate|July 2006||2006-07-31|August 2012|2012-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects|Open-Label, Controlled, Randomized, Comparative, Dose Escalation Study Of The Safety, Human Immunology, And Efficacy Of StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects In Patients Undergoing Sequential Skin Reconstruction Procedures|Completed||Phase 1/Phase 2|15|Actual|Stratatech, a Mallinckrodt Company||1|||f||||t||||||||||2018-06-01 02:26:35.985912|2018-06-01 02:26:35.985912
NCT00618826|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2016-01-12||2017-03-03|2008-02-07|2008-02-20|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|November 2006||2006-11-30|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer|A Phase II Trial of Biweekly Gemcitabine, Paclitaxel, and Avastin as Frontline Therapy for Metastatic Breast Cancer|Completed||Phase 2|14|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||f||||||||||2018-06-01 02:26:36.351984|2018-06-01 02:26:36.351984
NCT00618813|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2013-12-17||2014-09-11|2008-02-19|2008-02-20|Estimate|2013-12-17|2014-02-10|Estimate||||2014-09-11|2014-09-25|Estimate|March 2008||2008-03-31|September 2014|2014-09-30||||March 2010|Actual|2010-03-31||Interventional|||Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors|A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents With an Interval Compression Schedule in Newly Diagnosed Patients With Localized Ewing Sarcoma Family of Tumors|Completed||N/A|35|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 02:26:36.724358|2018-06-01 02:26:36.724358
NCT00618800|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2011-09-16|2008-02-07|2008-02-20|Estimate|||||||2011-09-16|2011-09-19|Estimate|August 2004||2004-08-31|September 2011|2011-09-30|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Preventing Falls Through Enhanced Pharmaceutical Care|Preventing Falls Through Enhanced Pharmaceutical Care|Completed||N/A|200|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:26:37.008456|2018-06-01 02:26:37.008456
NCT00618787|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2009-07-29||2010-04-09|2008-02-06|2008-02-20|Estimate|2010-04-05|2010-04-07|Estimate||||2010-04-09|2010-04-15|Estimate|February 2008||2008-02-29|April 2010|2010-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Prospective Randomized Double Blind Clinical Trial of Polyhexamethylene Biguanide Impregnated Foam Dressing|Prospective Randomized Double Blind Clinical Trial of Polyhexamethylene Biguanide Impregnated Foam Dressing|Completed||Phase 2|45|Actual|Tyco Healthcare Group||2|||f||||||||||||||2018-06-01 02:26:37.105493|2018-06-01 02:26:37.105493
NCT00618774|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2009-12-28||2014-06-17|2008-02-19|2008-02-20|Estimate|2010-02-18|2010-03-03|Estimate||||2014-06-17|2014-06-27|Estimate|January 2008||2008-01-31|April 2014|2014-04-30||||October 2009|Actual|2009-10-31||Interventional|||An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination|An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination|Completed||Phase 3|259|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:26:37.349835|2018-06-01 02:26:37.349835
NCT00618761|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2012-06-14|2008-02-06|2008-02-20|Estimate|||||||2012-06-14|2012-06-15|Estimate|October 2004||2004-10-31|January 2008|2008-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Insulin Secretory Capacity in Insulin-independent Pancreas-Kidney Recipients Compared to Controls|Insulin Secretory Capacity in Insulin-independent Pancreas-Kidney Recipients Compared to Non-Diabetic Kidney Recipients, Insulin Independent Recipients of Beta-cell Grafts and Healthy Controls.|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Gasthuisberg||4|||f||||t||||||||||2018-06-01 02:26:37.6912|2018-06-01 02:26:37.6912
NCT00618748|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2011-05-24||2011-07-25|2008-02-08|2008-02-20|Estimate|2011-05-24|2011-06-27|Estimate||||2011-07-25|2011-07-27|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed|Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed|Completed||Phase 3|101|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:26:37.781294|2018-06-01 02:26:37.781294
NCT00618735|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2016-12-27|2008-02-08|2008-02-20|Estimate|||||||2016-12-27|2016-12-29|Estimate|February 2008||2008-02-29|December 2016|2016-12-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB021 Administered Once or Twice Daily to Subjects With Advanced Solid Tumors|Completed||Phase 1|68|Actual|Biogen||2|||f||||t||||||||||2018-06-01 02:26:38.590984|2018-06-01 02:26:38.590984
NCT00618722|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2015-05-28||2015-06-17|2008-02-08|2008-02-20|Estimate|2015-05-28|2015-06-15|Estimate||||2015-06-17|2015-07-14|Estimate|August 2007||2007-08-31|June 2015|2015-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ATX-101|Safety analysis set|Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat|Phase 1-2, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) for the Reduction of Subcutaneous Fat in the Submental Area|Completed||Phase 1/Phase 2|85|Actual|Kythera Biopharmaceuticals||4|||f||||f||||||||||2018-06-01 02:26:38.697345|2018-06-01 02:26:38.697345
NCT00257595|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2013-05-03|2005-11-22|2005-11-23|Estimate|||||||2013-05-03|2013-05-06|Estimate|August 2005||2005-08-31|May 2013|2013-05-31||||||||Interventional|||Perennial Allergic Rhinitis In Pediatric Subjects|Long-term Study of Cetirizine Dry Syrup in Children. Suffering From Perennial Allergic Rhinitis.|Completed||Phase 3|30||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:19:29.064176|2018-06-01 04:19:29.064176
NCT00618709|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2014-05-28|2008-02-19|2008-02-20|Estimate|||||||2014-05-28|2014-05-30|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Dose-Escalation Safety and Pharmacokinetic Study of ATX-101|Phase 1, Open-Label, Dose-Escalation Safety and Pharmacokinetic Study of ATX-101 (Sodium Deoxycholate for Injection) Following Subcutaneous Injections in the Submental Area|Completed||Phase 1|24|Actual|Kythera Biopharmaceuticals||4|||f||||f||||||||||2018-06-01 02:26:39.643574|2018-06-01 02:26:39.643574
NCT00618696|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2017-11-27|2008-02-19|2008-02-20|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2005||2005-07-31|November 2017|2017-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia|MT2005-13R - Phase I Open Label, Single Arm, Dose Escalation Trial to Evaluate the Biodistribution and Safety of AHN-12 in Patients With Advanced Leukemia|Terminated||Phase 1|4|Actual|Masonic Cancer Center, University of Minnesota||1||Replaced with another study|f||||t||||||||||2018-06-01 02:26:39.732199|2018-06-01 02:26:39.732199
NCT00618683|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2018-04-10|2008-02-19|2008-02-20|Estimate|||||||2018-04-10|2018-04-11|Actual|March 2004||2004-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|AVNRT||AV Nodal Reentrant Tachycardia Study|Localization of the Anterograde and Retrograde Components of the Reentrant Circuit of AV Nodal Reentrant Tachycardia|Recruiting||N/A|100|Anticipated|University of Oklahoma||1|||f||||f||||||||||2018-06-01 02:26:39.837706|2018-06-01 02:26:39.837706
NCT00618670|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2018-03-30|2008-02-15|2008-02-20|Estimate|||||||2018-03-30|2018-04-02|Actual|September 2006||2006-09-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Home-based vs. Supervised Exercise for People With Claudication|Home-based vs. Supervised Exercise for Claudicants|Completed||N/A|135|Actual|University of Oklahoma||3|||f||||t||||||||||2018-06-01 02:26:39.934725|2018-06-01 02:26:39.934725
NCT00618657|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2018-01-11|2008-02-19|2008-02-20|Estimate|||||||2018-01-11|2018-01-16|Actual|February 2008||2008-02-29|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting|A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting|Active, not recruiting||Phase 2|132|Actual|University of California, Irvine||2|||f||||t||||||||||2018-06-01 02:26:40.020337|2018-06-01 02:26:40.020337
NCT00618644|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2012-09-25|2008-02-19|2008-02-20|Estimate|||||||2012-09-25|2012-09-27|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Ranibizumab for Neovascularization in Sickle Cell Retinopathy|A Phase I Study to Evaluate the Ocular and Non Ocular Safety of Ranibizumab in Treating Neovascularization Secondary to Sickle Cell Retinopathy|Withdrawn||N/A|0|Actual|Kresge Eye Institute||1||Withdrawn due to lack of eligible participants|f||||f||||||||||2018-06-01 02:26:40.135298|2018-06-01 02:26:40.135298
NCT00618631|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-17|||2018-04-04|2008-02-17|2008-02-20|Estimate|||||||2018-04-04|2018-04-05|Actual|January 17, 2008||2008-01-17|January 8, 2015|2015-01-08|January 8, 2015|Actual|2015-01-08|||||Interventional|||Effects of Smoking on Opioid Receptor Binding: A PET Study|Effects of Smoking on Opioid Receptor Binding Using [(11)C]Carfentanil: An Imaging PET Study|Completed||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:26:40.224939|2018-06-01 02:26:40.224939
NCT00618618|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2015-05-28|2014-05-30|2015-06-17|2008-02-08|2008-02-20|Estimate|2015-05-28|2015-06-15|Estimate|2014-05-30|2014-06-17|Estimate|2015-06-17|2015-07-14|Estimate|April 2008||2008-04-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||Safety/Modified Intent-to-Treat (mITT) subset included all randomized participants who received at least 1 dose of study material and who had at least 1 post-baseline observation|Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat|Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 2|73|Actual|Kythera Biopharmaceuticals||6|||f||||f||||||||||2018-06-01 02:26:40.326676|2018-06-01 02:26:40.326676
NCT00618605|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-18|||2016-10-31|2008-02-18|2008-02-20|Estimate|||||||2016-10-31|2016-11-02|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|October 2015|Actual|2015-10-31|July 2011|Actual|2011-07-31||Interventional|||Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults|A Phase 1 Randomized, Double-Blind, Placebo Controlled Dose Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenovirus Serotype 26 HIV-1 Vaccine (Ad26.ENVA.01) in Healthy, HIV-1 Uninfected Adults|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 02:26:41.481035|2018-06-01 02:26:41.481035
NCT00618592|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2010-07-21|2008-02-08|2008-02-20|Estimate|||||||2010-07-21|2010-07-22|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|Preop||Does Pre-operative Carbohydrate Loading Reduce Insulin Resistance and Improve Outcomes in Elective Surgical Patients?|Does Pre-operative Carbohydrate Loading Reduce Insulin Resistance and Improve Outcomes in Elective Surgical Patients?|Completed||N/A|60|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-06-01 02:26:41.5532|2018-06-01 02:26:41.5532
NCT00618579|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2014-04-04|2008-02-19|2008-02-20|Estimate|||||||2014-04-04|2014-04-07|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin|A Randomised, Controlled Study Investigating the Safety and Anticoagulant Activity of Administration of Low-molecular-weight Heparin in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402 and the Safety and Anticoagulant Activity of Administration of TB-402 in Healthy Male Subjects Treated With Warfarin|Completed||Phase 1|15|Actual|ThromboGenics||4|||f||||f||||||||||2018-06-01 02:26:41.633793|2018-06-01 02:26:41.633793
NCT00618566|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2012-10-15|2008-02-08|2008-02-20|Estimate|||||||2012-10-15|2012-10-17|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|CBT-WPD||Group Therapy Program for Women With Physical Disabilities|A Peer Implemented Cognitive Behavioral Group Therapy Intervention for Use With Women With Physical Disabilities With Secondary Depression|Completed||N/A|82|Actual|Oregon Health and Science University||1|||f||||t||||||||||2018-06-01 02:26:41.711288|2018-06-01 02:26:41.711288
NCT00618553|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2017-08-03|2008-02-08|2008-02-20|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2008|Actual|2008-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting|The Efficacy of Pulmonary Rehabilitation in Improving Surgical Eligibility for Lung Resection|Active, not recruiting||Phase 2|75|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:26:41.780625|2018-06-01 02:26:41.780625
NCT00618540|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|2015-04-22||2017-12-03|2008-02-19|2008-02-20|Estimate|2015-10-02|2015-11-03|Estimate||||2017-12-03|2017-12-28|Actual|January 2007||2007-01-31|December 2017|2017-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis|Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis|Terminated||Phase 2|1|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||t||||||||||2018-06-01 02:26:41.847167|2018-06-01 02:26:41.847167
NCT00618527|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2012-11-14|2008-02-19|2008-02-20|Estimate|||||||2012-11-14|2012-11-15|Estimate|August 2006||2006-08-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Combination Therapy Using Cellcept and Rebif in RRMS|Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis|Completed||Early Phase 1|31|Actual|Ohio State University||2|||f||||t||||||||||2018-06-01 02:26:42.019452|2018-06-01 02:26:42.019452
NCT00618514|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2010-01-26||2015-03-20|2008-02-19|2008-02-20|Estimate|2015-03-20|2015-03-23|Estimate||||2015-03-20|2015-03-23|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|BRILLIANT|Reporting per limb treated (versus per subject)|The BRILLIANT Study|Comparative Evaluation of the FDA-Cleared Bright Tip Laser Fiber Versus Commercially Available Bare Laser Fiber (the Control) in the Treatment of Reflux in the Greater Saphenous Vein (GSV) Using Endovenous Laser Therapy|Terminated||N/A|93|Actual|Vascular Solutions, Inc|Due to budgetary constraints, enrollment in the BRILLIANT trial was ended after 90 subjects (110 limbs) were enrolled in the study. This study had an insufficient sample size to perform the planned formal statistical hypothesis testing.|2||Sponsor decision|f||||f||||||||||2018-06-01 02:26:42.091634|2018-06-01 02:26:42.091634
NCT00618501|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2013-03-25|2008-02-19|2008-02-20|Estimate|||||||2013-03-25|2013-03-26|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:26:43.448645|2018-06-01 02:26:43.448645
NCT00618488|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2008-02-19|2008-02-19|2008-02-20|Estimate|||||||2008-02-19|2008-02-20|Estimate|February 2007||2007-02-28|February 2008|2008-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy of Yogurt Containing BB12 in Subjects With GI Symptoms|Clinical Efficacy of Yogurt Containing Bifidobacterium Lactis (BB12) in Subjects With Functional Gastrointestinal Symptoms|Completed||N/A|63|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:26:43.527348|2018-06-01 02:26:43.527348
NCT00618475|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2017-09-14|2008-02-15|2008-02-20|Estimate|||||||2017-09-14|2017-09-15|Actual|August 2008||2008-08-31|September 2017|2017-09-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis||Completed||N/A|65|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f|f|f||||||||2018-06-01 02:26:43.60023|2018-06-01 02:26:43.60023
NCT00618462|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2011-12-23|2008-02-15|2008-02-20|Estimate|||||||2011-12-23|2011-12-29|Estimate|August 2004||2004-08-31|December 2011|2011-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Cognitive Behavioral Treatments for Pathological Gambling|Cognitive Behavioral Treatments for Pathological Gambling|Completed||Phase 2|210|Actual|UConn Health||3|||f||||t||||||||||2018-06-01 02:26:43.740487|2018-06-01 02:26:43.740487
NCT00618449|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2011-01-27||2012-04-10|2008-02-06|2008-02-20|Estimate|2012-04-10|2012-05-08|Estimate||||2012-04-10|2012-05-08|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger|Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger|Completed||Phase 4|1139|Actual|University of California, San Francisco|Prevalence of infection in communities was less than predicted, as was return of infection post-treatment, thus hypothesis could not be evaluated.|2|||f||||f||||||||||2018-06-01 02:26:43.848578|2018-06-01 02:26:43.848578
NCT00618436|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2013-08-29||2014-03-07|2008-02-19|2008-02-20|Estimate|2014-03-07|2014-04-07|Estimate||||2014-03-07|2014-04-07|Estimate|August 2007||2007-08-31|March 2014|2014-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Keppra|One patient was enrolled at 17 years of age. His age was unknown at the time of admission to the hospital after his trauma, and based on body size/habitus he appeared to be a young adult. It was later discovered that he was only 17, but turning 18 in 3 days. The PI decided to allow his participation in the study at the parents request.|Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention|Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit|Completed||Phase 4|52|Actual|University of Cincinnati||2|||f||||t||||||||||2018-06-01 02:26:44.206772|2018-06-01 02:26:44.206772
NCT00618423|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2013-04-12|2008-02-06|2008-02-20|Estimate|||||||2013-04-12|2013-04-15|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|KetaDol||The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery|The Effect of Perioperative Intravenous Low-dose Ketamine on Acute and Chronic Neuropathic Pain After Major Back Surgery. A Randomised, Placebo-controlled, Double-blind Study|Completed||Phase 2|160|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 02:26:44.495642|2018-06-01 02:26:44.495642
NCT00618410|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2013-08-28||2013-12-09|2008-02-19|2008-02-20|Estimate|2013-12-09|2014-01-27|Estimate||||2013-12-09|2014-01-27|Estimate|February 2008||2008-02-29|December 2013|2013-12-31|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|||Intranasal CO2 for Allergic Rhinitis|Intranasal CO2 for Allergic Rhinitis|Completed||N/A|13|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:26:44.602796|2018-06-01 02:26:44.602796
NCT00618397|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2016-10-24|2008-02-06|2008-02-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2006||2006-06-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pharmacokinetics of Low Dose Ketamine Infusion|Phase I Trial to Determine Steady State Pharmacokinetics and Sedative Effects of Low Dose Ketamine Infusion|Terminated||Phase 1|5|Actual|University of Texas Southwestern Medical Center||1||Poor recruitement|f||||f||||||||||2018-06-01 02:26:44.857297|2018-06-01 02:26:44.857297
NCT00618384|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2012-06-06|2008-02-08|2008-02-20|Estimate|||||||2012-06-06|2012-06-07|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|SOCRATES||TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)|Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)|Terminated||Phase 2|43|Actual|Heinrich-Heine University, Duesseldorf||1|||f||||f||||||||||2018-06-01 02:26:44.940043|2018-06-01 02:26:44.940043
NCT00618371|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-29|2011-09-12||2016-12-06|2008-02-06|2008-02-20|Estimate|2016-10-11|2016-12-06|Estimate||||2016-12-06|2017-02-01|Estimate|October 2007||2007-10-31|December 2016|2016-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia|Investigating the Source of HIV-1 Viremia in Patients on Antiretroviral Therapy Through Intensification With MK-0518|Completed||N/A|10|Actual|University of Pittsburgh||1|||f||||t||||||||No|Data were analyzed and there is no plan to make individual participant data available|2018-06-01 02:26:45.029424|2018-06-01 02:26:45.029424
NCT00618358|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2015-03-26|2008-02-19|2008-02-20|Estimate|||||||2015-03-26|2015-03-27|Estimate|March 2007||2007-03-31|January 2010|2010-01-31||||||||Interventional|VSS||Vascular Sealant Study|A Prospective, Randomized, Multi-Center, Two Arm Study to Evaluate the Safety and Effectiveness of the Vascular Sealant System Compared With Gelfoam/Thrombin for Control of Anastomosis Suture Line Bleeding in Patients Undergoing Vascular Reconstructive Surgery With PTFE Grafts|Terminated||Phase 1|||Georgetown University||2||Sponsor - Confluent Surgical terminated study re: surgical techniques Letter dated 4/31/2008|f||||t||||||||||2018-06-01 02:26:45.210043|2018-06-01 02:26:45.210043
NCT00618345|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-19|||2011-05-13|2008-02-19|2008-02-20|Estimate|||||||2011-05-13|2011-05-16|Estimate|March 2005||2005-03-31|May 2011|2011-05-31|August 2008|Actual|2008-08-31|October 2006|Actual|2006-10-31||Interventional|||Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Trial of RAD001 in Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|35|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:26:45.269907|2018-06-01 02:26:45.269907
NCT00618332|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2013-11-21||2014-01-21|2008-02-19|2008-02-20|Estimate|2013-11-21|2014-01-10|Estimate||||2014-01-21|2014-02-14|Estimate|April 2008||2008-04-30|January 2014|2014-01-31|July 2010|Actual|2010-07-31|July 2008|Actual|2008-07-31||Interventional|||Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?|Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex?|Completed||N/A|40|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:26:45.351687|2018-06-01 02:26:45.351687
NCT00618319|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08||2015-09-17|2015-09-17|2008-02-08|2008-02-20|Estimate||||2015-09-17|2015-10-02|Estimate|2015-09-17|2015-10-02|Estimate|February 2008||2008-02-29|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)|An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment|Completed||Phase 2|20|Actual|Biogen||1|||f||||f||||||||||2018-06-01 02:26:45.74817|2018-06-01 02:26:45.74817
NCT00618293|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2012-01-03|2008-02-08|2008-02-20|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|July 2011|Actual|2011-07-31|July 2010|Anticipated|2010-07-31||Interventional|HAVAS||Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis|Phase 2 Study in Evaluation of the Efficacy and Safety of Haemate HS in This Clinical Setting (Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis)|Withdrawn||Phase 2|0|Actual|Heinrich-Heine University, Duesseldorf||2||No patient met the criteria for inclusion in the study.|f||||f||||||||||2018-06-01 02:26:45.822408|2018-06-01 02:26:45.822408
NCT00618280|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2012-03-01|2008-02-08|2008-02-20|Estimate|||||||2012-03-01|2012-03-02|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|NIKOGEN||Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail|Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail|Completed||Phase 1/Phase 2|101|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-06-01 02:26:45.911864|2018-06-01 02:26:45.911864
NCT00618267|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2010-03-04|2008-02-08|2008-02-20|Estimate|||||||2010-03-04|2010-03-05|Estimate|March 2008||2008-03-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|Cylex||"ATP Expression in Lymphocytes of MS Patients by Means of ImmuKnow® Assay."|"Single Center, Pilot Study to Measure ATP Expression in Lymphocytes of MS Patients Undergoing Various Therapies by Means of Using the ImmuKnow® Test"|Completed|||100|Actual|Biogen|||||f||||t||||||Samples Without DNA|"~     About 1 ½ teaspoons of blood will be drawn.~   "|||2018-06-01 02:26:46.00641|2018-06-01 02:26:46.00641
NCT00618254|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2018-01-19|2008-02-18|2008-02-19|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2005||2005-03-31|January 2018|2018-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions|Completed||N/A|32|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:26:46.07255|2018-06-01 02:26:46.07255
NCT00618241|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2011-06-06|2008-02-18|2008-02-19|Estimate|||||||2011-06-06|2011-06-07|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|GRANOLA||Pharmacokinetic Study on Raltegravir and Lamotrigine|The Influence of Raltegravir (MK-0518) on the Pharmacokinetics of Single-dose Lamotrigine in Healthy Male Subjects (GRANOLA)|Completed||Phase 1|24|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 02:26:46.144568|2018-06-01 02:26:46.144568
NCT00618228|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2018-01-19|2008-02-18|2008-02-19|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2004||2004-01-31|January 2018|2018-01-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Bioequivalency Study of Balsalazide Capsules Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Randomized Crossover Bioequivalency Study of 750 mg Balsalazide Capsules Under Fasting Conditions|Completed||N/A|52|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:26:46.238995|2018-06-01 02:26:46.238995
NCT00618215|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-18|2008-02-18|2008-02-19|Estimate|||||||2008-02-18|2008-02-19|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||A Cluster Randomized Controlled Trial in Primary Oral Care|Impact of Multifaceted Peer Group Education to Improve Routine Oral Examinations in Primary Care A Cluster-Randomised Controlled Trial|Completed||Early Phase 1|1161|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 02:26:46.308424|2018-06-01 02:26:46.308424
NCT00618202|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2018-01-19|2008-02-18|2008-02-19|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2005||2005-05-31|January 2018|2018-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions|Completed||N/A|52|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:26:46.385346|2018-06-01 02:26:46.385346
NCT00618176|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-03-21|2008-02-15|2008-02-18|Estimate|||||||2008-03-21|2008-03-24|Estimate|January 2005||2005-01-31|March 2008|2008-03-31||||September 2006|Actual|2006-09-30||Interventional|||Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort||Completed||Phase 4|198|Actual|Peking Union Medical College||3|||f||||||||||||||2018-06-01 02:26:46.446493|2018-06-01 02:26:46.446493
NCT00618163|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-02-15|2008-02-18|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2005||2005-03-31|January 2018|2018-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 15 mg Meloxicam Tablets Under Fasting Conditions|Completed||N/A|47|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:26:46.520971|2018-06-01 02:26:46.520971
NCT00618150|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2017-01-16|2008-02-05|2008-02-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 1996||1996-09-30|January 2017|2017-01-31||||December 1999|Actual|1999-12-31||Interventional|||Patient Education in Gastroesophageal Reflux Disease|Patient Education in Gastroesophageal Reflux Disease|Completed||N/A|211|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-06-01 02:26:46.584514|2018-06-01 02:26:46.584514
NCT00618137|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2012-08-23|2008-02-05|2008-02-18|Estimate|||||||2012-08-23|2012-08-24|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Inert Dusts and Pathology of Chronic Obstructive Pulmonary Disease|Longitudinal Assessment of Clinical and Molecular Pathology of Chronic Obstructive Lung Disease and the Possible Influence of Inert Dusts in Working Volunteers of the Greater Vienna Area|Completed|||160|Actual|Medical University of Vienna|||||f||||t||||||Samples With DNA|"~     Transbronchial lung biopsies Blood serum~   "|||2018-06-01 02:26:46.667291|2018-06-01 02:26:46.667291
NCT00618124|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2010-04-29|2008-02-05|2008-02-18|Estimate|||||||2010-04-29|2010-05-03|Estimate|May 2005||2005-05-31|April 2010|2010-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together|A Phase 1 Safety And Pharmacokinetic Study Of SU011248 And Capecitabine In Patients With Advanced Solid Tumors|Completed||Phase 1|77|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:26:46.732397|2018-06-01 02:26:46.732397
NCT00618111|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2018-01-19|2008-02-15|2008-02-18|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2005||2005-03-31|January 2018|2018-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions|A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions|Completed||N/A|32|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:26:46.821308|2018-06-01 02:26:46.821308
NCT00618098|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05||2015-07-07|2016-10-17|2008-02-15|2008-02-18|Estimate||||2016-10-17|2016-10-18|Estimate|2016-10-17|2016-10-18|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures|A Randomized, Open-label, Efficacy and Safety Study of Octaplex and Fresh Frozen Plasma (FFP) in Patients Under Vitamin K Antagonist Therapy With the Need for Urgent Surgery or Invasive Procedures|Completed||Phase 3|200|Actual|Octapharma||2|||f||||t||||||||||2018-06-01 02:26:46.87803|2018-06-01 02:26:46.87803
NCT00618085|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2009-05-01|2008-02-05|2008-02-18|Estimate|||||||2009-05-01|2009-05-04|Estimate|February 2008||2008-02-29|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Motor Imagery Practice in Neurological Rehabilitation|An Integrated Motor Imagery Program in Rehabilitation - a RCT|Completed||Phase 2|50|Anticipated|Nuffield Orthopaedic Centre NHS Trust||2|||f||||f||||||||||2018-06-01 02:26:46.958288|2018-06-01 02:26:46.958288
NCT00618072|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2014-01-30||2014-03-27|2008-02-05|2008-02-18|Estimate|2014-03-27|2014-03-28|Estimate||||2014-03-27|2014-03-28|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|EMPOWIR||EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance|EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrome W)|Completed||Phase 2|46|Actual|New York Medical College|Widespread media coverage of cardiovascular risks of rosiglitazone led to an unanticipated high drop out rate of subjects just prior to their randomization; 22 of 68 eligible subjects did not undergo randomization due to concerns about the drug.|3|||f||||t||||||||||2018-06-01 02:26:47.053107|2018-06-01 02:26:47.053107
NCT00618059|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-02-15|2008-02-18|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2004||2004-08-31|January 2018|2018-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Sequence Crossover Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fed Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:26:47.841463|2018-06-01 02:26:47.841463
NCT00618046|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2018-01-19|2008-02-15|2008-02-18|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2004||2004-11-30|January 2018|2018-01-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:26:47.918153|2018-06-01 02:26:47.918153
NCT00618033|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2011-06-08|2008-02-15|2008-02-18|Estimate|||||||2011-06-08|2011-06-09|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Dextrose||Comparison of Different Glucose Concentrations in Dialysate of Hemodialysis Patients|Short-Term Study of Physiologic Dialysate Glucose Concentration in Chronic Hemodialysis Patients|Completed||N/A|30|Actual|Renal Research Institute||2|||f||||f||||||||||2018-06-01 02:26:47.98911|2018-06-01 02:26:47.98911
NCT00618020|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-07-17|2008-02-05|2008-02-18|Estimate|||||||2008-07-17|2008-07-18|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries|A Feasibility Study to Evaluate the Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusion in Coronary Arteries|Completed||N/A|10|Actual|Ovalum|||||f||||t||||||||||2018-06-01 02:26:48.087351|2018-06-01 02:26:48.087351
NCT00618007|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05||2009-03-20|2011-06-09|2008-02-15|2008-02-18|Estimate||||2009-09-24|2009-09-28|Estimate|2011-06-09|2011-06-27|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of PF-00734200 in Subjects With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of 12-Week Administration Of PF-00734200 To Subjects With Type 2 Diabetes Mellitus And Insufficient Glycemic Control On Metformin Treatment|Completed||Phase 2|289|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:26:48.189501|2018-06-01 02:26:48.189501
NCT00524238|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2008-02-07|2007-08-31|2007-09-03|Estimate|||||||2008-02-07|2008-02-12|Estimate|March 2004||2004-03-31|February 2008|2008-02-29|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Metabolic Changes in Hypothyroid Patients|Impact of Hypothyroidism on Glucose, Lipid, and Amino Acid Turnover|Completed||N/A|22|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:57:31.44547|2018-06-01 02:57:31.44547
NCT00617994|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21||2010-06-28|2018-01-15|2008-02-06|2008-02-18|Estimate||||2010-06-28|2010-07-01|Estimate|2018-01-15|2018-01-17|Actual|August 2007||2007-08-31|January 2018|2018-01-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis|An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of INCB018424 When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).|Completed||Phase 2|25|Actual|Incyte Corporation||3|||f||||f||||||||||2018-06-01 02:26:48.384004|2018-06-01 02:26:48.384004
NCT00617981|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2017-02-03||2017-03-24|2008-02-15|2008-02-18|Estimate|2017-02-03|2017-03-24|Actual||||2017-03-24|2017-04-25|Actual|May 2008|Actual|2008-05-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|January 2013|Actual|2013-01-31||Interventional|||Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)|A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma|Completed||Phase 3|701|Actual|Celsion||2|||f||||t||||||||||2018-06-01 02:26:48.499074|2018-06-01 02:26:48.499074
NCT00617968|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-09-01|2008-02-06|2008-02-18|Estimate|||||||2009-09-01|2009-09-02|Estimate|October 2003||2003-10-31|September 2009|2009-09-30|June 2005|Actual|2005-06-30|||||Interventional|||GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer|A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-positive Breast Tumor.|Completed||Phase 2|5|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:26:49.272825|2018-06-01 02:26:49.272825
NCT00617955|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2016-04-18|2008-02-15|2008-02-18|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2007||2007-09-30|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Effects of Aprotinin During Cardiac Surgery/Long Term Death Rates|Systemic Effects of Aprotinin During Cardiac Surgery/ Long Term Death Rates|Completed|||462|Actual|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 02:26:49.328347|2018-06-01 02:26:49.328347
NCT00617942|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2015-11-14||2018-01-17|2008-02-15|2008-02-18|Estimate|2017-07-24|2017-08-22|Actual||||2018-01-17|2018-01-19|Actual|February 2008||2008-02-29|January 2018|2018-01-31|December 2015|Actual|2015-12-31|August 2012|Actual|2012-08-31||Interventional|||Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer|BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer|Completed||Phase 2|60|Actual|Brown University||4|||f||||t||||||||||2018-06-01 02:26:49.411043|2018-06-01 02:26:49.411043
NCT00617929|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2016-09-28||2017-12-03|2008-02-15|2008-02-18|Estimate|2016-11-22|2017-01-20|Estimate||||2017-12-03|2017-12-28|Actual|January 2008||2008-01-31|December 2017|2017-12-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant|Conditioning for Graft Failure After Hematopoietic Stem Cell Transplantation|Terminated||Phase 2|12|Actual|Masonic Cancer Center, University of Minnesota||1||Replaced by another protocol|f||||t||||||||||2018-06-01 02:26:50.173487|2018-06-01 02:26:50.173487
NCT00617916|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-06-02|2008-02-15|2008-02-18|Estimate|||||||2009-06-02|2009-06-04|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers|Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers|Completed|||256|Actual|HyperMed|||||f||||f||||||||||2018-06-01 02:26:50.480631|2018-06-01 02:26:50.480631
NCT00617903|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2013-05-02||2013-12-26|2008-02-15|2008-02-18|Estimate|2013-05-02|2013-07-04|Estimate||||2013-12-26|2014-01-31|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea|A 12-week Exploratory, Multicenter, Double-blind, Vehicle-controlled Study to Investigate the Efficacy and Safety of Topical Azelaic Acid 15% Foam Twice Daily in Patients With Papulopustular Rosacea|Completed||Phase 2|83|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:26:50.60679|2018-06-01 02:26:50.60679
NCT00617890|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2015-11-09||2017-05-15|2008-02-06|2008-02-18|Estimate|2015-11-09|2015-12-11|Estimate||||2017-05-15|2017-06-07|Actual|February 1, 2008|Actual|2008-02-01|May 2017|2017-05-31|August 31, 2013|Actual|2013-08-31|August 31, 2011|Actual|2011-08-31||Interventional||Three participants did not receive study treatment but are included in the baseline population.|A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)|A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy|Terminated||Phase 2|219|Actual|Merck Sharp & Dohme Corp.|The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.|4||The study was prematurely terminated for strategic reasons, not for a safety concern.|f||||f||||||||||2018-06-01 02:26:51.442951|2018-06-01 02:26:51.442951
NCT00617877|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2009-07-21|2008-02-05|2008-02-18|Estimate|||||||2009-07-21|2009-07-22|Estimate|March 2005||2005-03-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Antihypertensive Response to Losartan and Genetic Polymorphisms|Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide|Completed||N/A|800|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 02:26:52.573952|2018-06-01 02:26:52.573952
NCT00617864|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2012-02-20|2008-02-15|2008-02-18|Estimate|||||||2012-02-20|2012-02-22|Estimate|September 2007||2007-09-30|February 2012|2012-02-29||||||||Interventional|||The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome|The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome.|Withdrawn||N/A|0|Actual|Yale University||2||"The syndrome of hyperstimulation is so rare that after one year no patients were eligible.The~   study was withdrawn and never started."|f||||t||||||||||2018-06-01 02:26:52.647089|2018-06-01 02:26:52.647089
NCT00617851|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2010-02-03|2009-08-06|2012-05-03|2008-02-15|2008-02-18|Estimate|2010-05-27|2010-06-24|Estimate|2009-08-06|2009-08-10|Estimate|2012-05-03|2012-05-08|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old|A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Consistency of Three Consecutive Lots of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs in Healthy Subjects Aged 18 to 49 Years|Completed||Phase 3|1507|Actual|Novartis||5|||f||||||||||||||2018-06-01 02:26:52.748346|2018-06-01 02:26:52.748346
NCT00616837|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2015-12-16|2008-02-14|2008-02-15|Estimate|||||||2015-12-16|2015-12-17|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2012|Actual|2012-10-31||Interventional|||Remote Orthopedic Outpatient Consultation by Help of Telemedicine|Remote Orthopedic Outpatient Consultation by Help of Telemedicine|Completed||N/A|400|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 02:27:19.236341|2018-06-01 02:27:19.236341
NCT00617838|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2013-08-22|2008-02-15|2008-02-18|Estimate|||||||2013-08-22|2013-08-23|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Celiac Disease Prevention|Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization|Unknown status|Active, not recruiting|N/A|168|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 02:26:53.464466|2018-06-01 02:26:53.464466
NCT00617825|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2011-08-04|2008-02-15|2008-02-18|Estimate|||||||2011-08-04|2011-08-05|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|Cryo||Feasibility Study of Cryotherapy for Chronic Venous Disorders|Cryotherapy for Chronic Venous Disorders|Completed||N/A|60|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 02:26:53.537458|2018-06-01 02:26:53.537458
NCT00617812|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-06-24|2008-02-15|2008-02-18|Estimate|||||||2009-06-24|2009-06-25|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine|An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants.|Completed||Phase 4|160|Actual|Shantha Biotechnics Limited||1|||f||||f||||||||||2018-06-01 02:26:53.625999|2018-06-01 02:26:53.625999
NCT00617799|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|||2018-03-29|2008-02-15|2008-02-18|Estimate|||||||2018-03-29|2018-04-02|Actual|October 2007||2007-10-31|March 2018|2018-03-31|April 16, 2010|Actual|2010-04-16|February 18, 2009|Actual|2009-02-18||Observational|||Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma|Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2|Completed|||15|Actual|University of Nebraska|||||f||||||||||Samples With DNA|"~     Blood samples will be collected prior to, at mid-course and at the end of the course of IL-2~     therapy.~   "|||2018-06-01 02:26:53.732471|2018-06-01 02:26:53.732471
NCT00617786|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2011-11-22|2008-02-15|2008-02-18|Estimate|||||||2011-11-22|2011-11-23|Estimate|October 2008||2008-10-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||CPT Testing for Sacral Neuromodulation Outcomes|Current Perception Threshold Testing for Sacral Neuuromodulation Outcomes|Completed||N/A|13|Actual|William Beaumont Hospitals|||||f||||f||||||||||2018-06-01 02:26:53.812967|2018-06-01 02:26:53.812967
NCT00617773|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2013-05-15||2013-11-01|2008-02-15|2008-02-18|Estimate|2013-11-01|2013-11-26|Estimate||||2013-11-01|2013-11-26|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||The baseline descriptive analyses were performed for the safety population. Lewis Y antigen expression and blood type were also analyzed for this population.|Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A PHASE II TRIAL OF Hu3S193 THERAPY FOR PATIENTS WITH PLATINUM REFRACTORY OR PLATINUM RESISTANT EPITHELIAL OVARIAN, PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCER|Completed||Phase 2|31|Actual|Recepta Biopharma||1|||f||||f||||||||||2018-06-01 02:26:53.912762|2018-06-01 02:26:53.912762
NCT00617760|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2015-05-20|2008-02-06|2008-02-18|Estimate|||||||2015-05-20|2015-05-21|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)|Open-label, Randomized, 3-arm, Phase 3B Clinical Study to Investigate the Safety and Immunogenicity of a Concomitant Administration of Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate (MenC-TT) Vaccine and 7-valent Pneumococcal CRM197-conjugate Vaccine (PCV7) in Toddlers Previously Immunized During Infancy With PCV7|Completed||Phase 3|330|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 02:26:54.533533|2018-06-01 02:26:54.533533
NCT00617747|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-04-03|2008-02-06|2008-02-18|Estimate|||||||2009-04-03|2009-04-06|Estimate|September 2002||2002-09-30|April 2009|2009-04-30|June 2003|Actual|2003-06-30|||||Interventional|||Efficacy and Tolerability of Zolmitriptan Nasal Spray|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG) Nasal Spray in the Acute Treatment of Adult Subjects With Migraine.|Completed||Phase 3|2114|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:26:54.65841|2018-06-01 02:26:54.65841
NCT00617734|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2018-03-17|2010-09-10|2018-03-17|2008-02-15|2008-02-18|Estimate|2018-03-17|2018-04-17|Actual|2010-09-10|2010-09-14|Estimate|2018-03-17|2018-04-17|Actual|March 2008||2008-03-31|March 2018|2018-03-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional||Randomized participants who received at least 1 dose of study drug.|Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck|A Randomized Phase 2 Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy|Completed||Phase 2|97|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:26:54.745641|2018-06-01 02:26:54.745641
NCT00617721|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2016-06-16|2008-02-05|2008-02-18|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2008||2008-06-30|June 2016|2016-06-30||||||||Observational|||Markers of Defective Membrane Remodelling in Scott-like Syndromes|Defect in Cell Stimulation and Unexplained hemorrhagesMarkers Related to Membrane Remodelling in the Prognosis Scott-like Syndormes|Terminated|||29|Actual|University Hospital, Strasbourg, France|||2||f||||f||||||Samples With DNA|"~     plasma, white cells, DNA (when the family is informative)~   "|||2018-06-01 02:26:55.441607|2018-06-01 02:26:55.441607
NCT00617708|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2013-10-07||2014-07-25|2008-02-15|2008-02-18|Estimate|2013-10-07|2013-12-05|Estimate||||2014-07-25|2014-07-31|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|February 2014|Actual|2014-02-28|September 2011|Actual|2011-09-30||Interventional||Eligible patients who began protocol therapy|S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients With Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|134|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 02:26:55.625989|2018-06-01 02:26:55.625989
NCT00617695|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-04-03|2008-02-06|2008-02-18|Estimate|||||||2009-04-03|2009-04-06|Estimate|September 2003||2003-09-30|April 2009|2009-04-30|October 2004|Actual|2004-10-31|||||Interventional|||Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study With Single-Blind, Placebo-Challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the Treatment of Acute Migraine Headache in Adolescents.|Completed||Phase 3|247|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:26:57.210936|2018-06-01 02:26:57.210936
NCT00617682|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2008-02-14|2008-02-14|2008-02-18|Estimate|||||||2008-02-14|2008-02-18|Estimate|October 2000||2000-10-31|February 2008|2008-02-29|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Maternal Immunization To Prevent Infant Otitis Media|Maternal Immunization To Prevent Infant Otitis Media|Completed||Phase 1/Phase 2|153|Actual|National Institute on Deafness and Other Communication Disorders (NIDCD)||2|||f||||t||||||||||2018-06-01 02:26:57.268298|2018-06-01 02:26:57.268298
NCT00617669|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2012-04-26||2012-09-04|2008-02-06|2008-02-18|Estimate|2012-04-26|2012-05-31|Estimate||||2012-09-04|2012-09-10|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|ENTHUSE M1C||A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer|A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 (Zibotentan) in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-resistant Prostate Cancer|Completed||Phase 3|1494|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:26:57.41609|2018-06-01 02:26:57.41609
NCT00617656|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2015-07-03|2008-02-06|2008-02-18|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2008||2008-02-29|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|BREC||Multicenter, Predictive, Prospective, Phase III, Open, Randomized, Pharmacogenomic Study in Patients With Advanced Lung Carcinoma|Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer|Terminated||Phase 3|400|Actual|Spanish Lung Cancer Group||4||"No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental~   arm over the control arm- would not be confirmed."|f||||t||||||||||2018-06-01 02:26:59.606238|2018-06-01 02:26:59.606238
NCT00617643|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2010-12-03|2008-02-15|2008-02-18|Estimate|||||||2010-12-03|2010-12-06|Estimate|May 2008||2008-05-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|June 2009|Actual|2009-06-30||Interventional|||Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis|Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy|Completed||Phase 4|18|Anticipated|Makerere University||2|||f||||t||||||||||2018-06-01 02:26:59.743358|2018-06-01 02:26:59.743358
NCT00617630|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2017-03-21|2008-02-05|2008-02-18|Estimate|||||||2017-03-21|2017-03-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:26:59.873125|2018-06-01 02:26:59.873125
NCT00617617|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2012-09-21|2008-02-05|2008-02-18|Estimate|||||||2012-09-21|2012-09-24|Estimate|February 2002||2002-02-28|February 2010|2010-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Specific Role of Isoflavones in Reducing Prostate Cancer Risk|The Specific Role of Isoflavones in Reducing Prostate Cancer Risk|Completed||Phase 2|52|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 02:26:59.984655|2018-06-01 02:26:59.984655
NCT00617604|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2016-01-05|2010-09-29|2016-01-05|2008-02-06|2008-02-18|Estimate|2016-01-05|2016-02-04|Estimate|2010-09-29|2010-10-01|Estimate|2016-01-05|2016-02-04|Estimate|December 2007||2007-12-31|January 2016|2016-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||All randomized patients who took at least 1 dose of study drug (Safety Analysis Set).|A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients|Efficacy and Safety of Alefacept in Combination With Tacrolimus, Mycophenolate Mofetil and Steroids in de Novo Kidney Transplantation - a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study|Completed||Phase 2|218|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 02:27:00.129714|2018-06-01 02:27:00.129714
NCT00617591|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2013-10-25||2013-12-16|2008-02-05|2008-02-18|Estimate|2013-10-25|2013-12-17|Estimate||||2013-12-16|2014-01-17|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||All participants|Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)|Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®), Low Frequency Dexamethasone and Revlimid® (Dd-R) in Newly Diagnosed Multiple Myeloma|Completed||Phase 2|57|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 02:27:01.465957|2018-06-01 02:27:01.465957
NCT00617578|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2013-12-18|2008-02-15|2008-02-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|FavoriteATP||Fast VT Episodes Are Terminated by ATP One Shot|Fast VT Episodes Are Terminated by ATP One Shot|Completed||Phase 4|194|Actual|Biotronik SE & Co. KG||2|||f||||f||||||||||2018-06-01 02:27:02.052944|2018-06-01 02:27:02.052944
NCT00617565|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2017-02-22|2008-02-06|2008-02-18|Estimate|||||||2017-02-22|2017-02-24|Actual|July 8, 2003|Actual|2003-07-08|February 2017|2017-02-28|November 26, 2003|Actual|2003-11-26|November 26, 2003|Actual|2003-11-26||Interventional|||Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes|A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficacy and Safety Profile of Biphasic Insulin Aspart 30 (BIAsp 30) and Biphasic Human Insulin 30/70 (BHI 30/70) in Chinese Type 1 and 2 Diabetics|Completed||Phase 3|219|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:27:02.23399|2018-06-01 02:27:02.23399
NCT00617552|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06||2012-12-05|2012-12-05|2008-02-06|2008-02-18|Estimate||||2012-12-05|2012-12-07|Estimate|2012-12-05|2012-12-07|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess Efficacy and Safety of TZP-101 When Administered as 30 Minute i.v. Infusion for POI to Subjects Undergoing Major Open Abdominal Surgery|Completed||Phase 2|267|Actual|Tranzyme, Inc.||8|||f||||t||||||||||2018-06-01 02:27:02.380338|2018-06-01 02:27:02.380338
NCT00617539|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-15|2017-12-11||2018-03-23|2008-02-15|2008-02-18|Estimate|2018-03-23|2018-04-20|Actual||||2018-03-23|2018-04-20|Actual|February 2005||2005-02-28|March 2018|2018-03-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases|A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation|Completed||Phase 2|30|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 02:27:02.629482|2018-06-01 02:27:02.629482
NCT00617526|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06||2013-10-29|2013-12-20|2008-02-15|2008-02-18|Estimate||||2013-10-29|2013-11-21|Estimate|2013-12-20|2014-01-28|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Naïve HIV POC Monotherapy Trial|A Multicenter Phase 2a, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Determine the Antiviral Activity, Pharmacokinetics, Tolerability and Safety of RDEA806 in HIV-1 Positive, Antiretroviral naïve Subjects|Completed||Phase 2|48|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-06-01 02:27:02.986973|2018-06-01 02:27:02.986973
NCT00617513|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2008-05-28|2008-02-15|2008-02-18|Estimate|||||||2008-05-28|2008-05-29|Estimate|March 1995||1995-03-31|February 2008|2008-02-29|March 1996|Actual|1996-03-31|March 1996|Actual|1996-03-31||Interventional|||Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation|A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation|Completed||Phase 2|174|Actual|Movetis||4|||f||||f||||||||||2018-06-01 02:27:03.125668|2018-06-01 02:27:03.125668
NCT00617500|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2009-09-18|2008-02-15|2008-02-18|Estimate|||||||2009-09-18|2009-09-22|Estimate|July 2008||2008-07-31|September 2009|2009-09-30|November 2009|Anticipated|2009-11-30|December 2008|Anticipated|2008-12-31||Interventional|||Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement|Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement|Unknown status|Active, not recruiting|Phase 4|278|Anticipated|Sociedade Hospital Samaritano||4|||f||||t||||||||||2018-06-01 02:27:03.273065|2018-06-01 02:27:03.273065
NCT00617487|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2018-03-06|2008-02-15|2008-02-18|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2007||2007-12-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|March 2018|Anticipated|2018-03-31||Observational|||Pulmonary Arterial Hypertension in Systemic Sclerosis|Stress Echocardiography in the Early Identification of Pulmonary Arterial Hypertension in Systemic Sclerosis|Active, not recruiting|||200|Anticipated|IRCCS Policlinico S. Matteo|||||f||||t||||||||||2018-06-01 02:27:03.392062|2018-06-01 02:27:03.392062
NCT00617474|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2008-03-27|2008-02-15|2008-02-18|Estimate|||||||2008-03-27|2008-03-28|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|March 2009|Anticipated|2009-03-31|September 2008|Anticipated|2008-09-30||Interventional|||The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group|The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group|Unknown status|Not yet recruiting|Phase 1|50|Anticipated|Labbafinejhad Hospital||2|||f||||||||||||||2018-06-01 02:27:03.480363|2018-06-01 02:27:03.480363
NCT00617461|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2011-04-26|2010-08-12|2013-07-15|2008-02-15|2008-02-18|Estimate|2011-04-26|2011-05-20|Estimate|2010-08-12|2010-08-17|Estimate|2013-07-15|2013-07-22|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment|Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.|Completed||Phase 2|96|Actual|XenoPort, Inc.||2|||f||||f||||||||||2018-06-01 02:27:03.603472|2018-06-01 02:27:03.603472
NCT00617448|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-15|2008-02-15|2008-02-18|Estimate|||||||2008-02-15|2008-02-18|Estimate|May 2005||2005-05-31|February 2008|2008-02-29|June 2007|Actual|2007-06-30|June 2006|Actual|2006-06-30||Interventional|LDHLA||Ligasure Versus Diathermy Haemorrhoidectomy Under Local Anesthesia|Ligasure™ Versus Diathermy Haemorrhoidectomy Under Spinal or Local Anaesthesia With Ropivacaine. A Randomized Study With One Year Follow-up|Completed||N/A|81|Actual|Hospital de Viladecans||4|||f||||t||||||||||2018-06-01 02:27:04.625039|2018-06-01 02:27:04.625039
NCT00617435|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2009-03-13|2008-02-05|2008-02-18|Estimate|||||||2009-03-13|2009-03-16|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|Trans-Insulin||Impact of Trans Fatty Acids From Natural and Industrial Origin in the Induction of Insulin Resistance Development||Completed||N/A|66|Anticipated|Institut National de la Recherche Agronomique||3|||f||||||||||||||2018-06-01 02:27:04.741196|2018-06-01 02:27:04.741196
NCT00617409|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2016-09-12||2018-03-27|2008-02-05|2008-02-18|Estimate|2016-09-12|2016-11-01|Estimate||||2018-03-27|2018-04-25|Actual|October 2, 2007|Actual|2007-10-02|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 21, 2015|Actual|2015-09-21||Interventional||All participants.|To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid|A Randomized Phase II Trial Using Dendritic Cells Transduced With an Adenoviral Vector Containing the p53 Gene to Immunize Patients With Extensive Stage Small Cell Lung Cancer in Combination With Chemotherapy With or Without All Trans Retinoic Acid|Active, not recruiting||Phase 2|69|Actual|H. Lee Moffitt Cancer Center and Research Institute|Protocol V.10.1, 04/11/2012: Arm A was closed due to lack of feasibility; Arm B was closed at the end of the first stage due to lack of efficacy.|3|||f||||t||||||||||2018-06-01 02:27:04.861004|2018-06-01 02:27:04.861004
NCT00617396|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2013-07-12||2017-09-13|2008-02-14|2008-02-18|Estimate|2014-02-04|2014-03-21|Estimate||||2017-09-13|2017-09-15|Actual|February 2008||2008-02-29|February 2014|2014-02-28|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional||Subjects who received the investigational medication were analyzed. 4 subjects did not meet the study inclusion/exclusion criteria and were not analyzed.|Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder|An Open Label Study of Seroquel SR® (Quetiapine) for the Treatment of Refractory and Treatment Resistant Functional Bowel Disorders|Completed||N/A|25|Actual|University of North Carolina, Chapel Hill|"Uncontrolled open label study and is vulnerable to biases favoring a treatment response.~Sample size is small."|1|||f||||f||||||||||2018-06-01 02:27:05.68763|2018-06-01 02:27:05.68763
NCT00617383|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2017-03-30|2008-02-05|2008-02-18|Estimate|||||||2017-03-30|2017-04-04|Actual|February 2008||2008-02-29|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ARMS||AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS|Determine if the Presence of Characteristic MS-like Lesion(s) on Baseline MRI Predisposes to CIS/MS in Female MZ Twins Discordant for CIS/MS.|Completed|||3|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||Samples Without DNA|"~     blood for serum and peripheral mononuclear cells; optional CSF - cerebrospinal fluid at entry~     and exit from trail~   "|||2018-06-01 02:27:05.924239|2018-06-01 02:27:05.924239
NCT00617370|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2015-12-21|2008-02-15|2008-02-18|Estimate|||||||2015-12-21|2015-12-23|Estimate|November 2004||2004-11-30|December 2015|2015-12-31|June 2008|Actual|2008-06-30|July 2005|Actual|2005-07-31||Interventional|||Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility|Pilot Study of Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in High-Risk Breast Cancer: Feasibility|Completed||N/A|38|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:27:05.978971|2018-06-01 02:27:05.978971
NCT00617357|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2012-08-16||2015-10-29|2008-02-06|2008-02-18|Estimate|2015-10-29|2015-12-01|Estimate||||2015-10-29|2015-12-01|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|RICH|83 subjects enrolled, of which 80 subjects were implanted. The ITT population is defined as subjects enrolled and implanted (n=80).|Repair of Infected or Contaminated Hernias|A Multicenter, Prospective, Observational Evaluation of Repair of Infected or Contaminated Hernias (RICH) Using LTM|Completed||N/A|83|Actual|LifeCell||1|||f||||f||||||||||2018-06-01 02:27:06.145155|2018-06-01 02:27:06.145155
NCT00617344|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06||2011-02-15|2016-04-12|2008-02-06|2008-02-18|Estimate||||2011-02-15|2011-02-18|Estimate|2016-04-12|2016-05-10|Estimate|April 2008||2008-04-30|September 2014|2014-09-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US|Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US|Completed||Phase 2|260|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 02:27:06.598026|2018-06-01 02:27:06.598026
NCT00617331|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14||2011-07-20|2011-07-20|2008-02-14|2008-02-18|Estimate||||2011-07-20|2011-07-22|Estimate|2011-07-20|2011-07-22|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||H9 Priming Study in Healthy Adults|A Randomized, Double-Blind, Clinical Trial Evaluating the Immunogenicity of an Inactivated Influenza A/H9N2 Vaccine Among Healthy Adults With and Without Prior Exposure to Influenza A/H2N2|Completed||Phase 2|121|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 02:27:06.791928|2018-06-01 02:27:06.791928
NCT00617318|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2008-02-15|2008-02-15|2008-02-18|Estimate|||||||2008-02-15|2008-02-18|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Pomegranate Products for Prevention of Common Cold|Pomegranate Products for Prevention of Common Cold and Influenza-Like Symptoms: A Double- Blind, Placebo-Controlled Randomized Clinical Trial|Completed||Phase 3|461|Actual|Texas Heart Institute||2|||f||||t||||||||||2018-06-01 02:27:06.896638|2018-06-01 02:27:06.896638
NCT00617305|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2012-05-11||2012-06-22|2008-02-15|2008-02-18|Estimate|2012-06-22|2012-07-30|Estimate||||2012-06-22|2012-07-30|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|ATHENA-1||Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)|An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to a Phosphodiesterase Type-5 Inhibitor|Completed||Phase 4|38|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 02:27:07.05591|2018-06-01 02:27:07.05591
NCT00617292|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-12-08|2008-02-05|2008-02-18|Estimate|||||||2008-12-08|2008-12-09|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Observational|||Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers|Long-Term Outcome in Offspring and Mothers of Dexamethasone-Treated Pregnancies at Risk for Classical Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency|Unknown status|Recruiting||233|Anticipated|Office of Rare Diseases (ORD)|||3||f||||t||||||||||2018-06-01 02:27:08.692252|2018-06-01 02:27:08.692252
NCT00617279|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2011-02-07||2011-12-08|2008-02-05|2008-02-18|Estimate|2011-12-08|2012-01-12|Estimate||||2011-12-08|2012-01-12|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|PRODIGY||GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft|Comparison of Primary Patency Between GORE PROPATEN Vascular Graft and Disadvantaged Autologous Vein Graft For Below-Knee Arterial Bypass (PRODIGY Study)|Terminated||Phase 4|31|Actual|W.L.Gore & Associates|The study was terminated prior to completion of enrollment. The primary patency and secondary endpoints were not calculated due to the paucity of data.|2||Study terminated due to low enrollment|f||||f||||||||||2018-06-01 02:27:08.795003|2018-06-01 02:27:08.795003
NCT00617266|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-02-14|2008-02-14|2008-02-15|Estimate|||||||2008-02-14|2008-02-15|Estimate|August 2007||2007-08-31|February 2008|2008-02-29|February 2009|Anticipated|2009-02-28|April 2008|Anticipated|2008-04-30||Interventional|||Tobacco Control Among Business Process Outsourcing (BPO) Employees|Tobacco Control Among Business Process Outsourcing (BPO) Employees|Unknown status|Recruiting|Phase 3|800|Anticipated|Tata Memorial Hospital||4|||f||||t||||||||||2018-06-01 02:27:09.529843|2018-06-01 02:27:09.529843
NCT00617253|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2017-02-28|2008-02-04|2008-02-15|Estimate|||||||2017-02-28|2017-03-01|Actual|July 12, 2007|Actual|2007-07-12|February 2017|2017-02-28|June 30, 2008|Actual|2008-06-30|June 30, 2008|Actual|2008-06-30||Interventional|||Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients|An Open Label, Dose Escalation Safety and Tolerability Trial of the Combination of s.c. Recombinant Human IL-21 (rIL-21) and Sunitinib (Phase 1) Followed by an Open Label Stratified Randomized 2-arm Trial of rIL-21 Plus Sunitinib Versus Sunitinib Alone (Phase 2a) in Subjects With Stage IV Renal Cell Carcinoma|Completed||Phase 2|9|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 02:27:09.645708|2018-06-01 02:27:09.645708
NCT00617240|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2013-09-02||2014-02-07|2008-02-14|2008-02-15|Estimate|2014-02-07|2014-03-11|Estimate||||2014-02-07|2014-03-11|Estimate|January 2007||2007-01-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PREVENT||Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth|Metformin Mitigation of Atypical Antipsychotic-Induced Metabolic Dysregulation in Adolescent Youth|Completed||Phase 2|9|Actual|University of North Carolina, Chapel Hill|Small number of subjects analyzed and recruited, however, based on preliminary data, a larger, multi-site trial was developed.|2|||f||||f||||||||||2018-06-01 02:27:09.763025|2018-06-01 02:27:09.763025
NCT00617227|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2010-02-09|2008-02-04|2008-02-15|Estimate|||||||2010-02-09|2010-02-10|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|May 2008|Actual|2008-05-31||Observational|||Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin|Measurement of Serum Vancomycin in Patients Receiving Enteral ( Oral/Intracolonic) Vancomycin.|Completed|||100|Anticipated|Maimonides Medical Center|||||f||||t||||||||||2018-06-01 02:27:10.15657|2018-06-01 02:27:10.15657
NCT00617214|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2010-12-08|2008-02-14|2008-02-15|Estimate|||||||2010-12-08|2010-12-10|Estimate|January 2008||2008-01-31|October 2008|2008-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|CARE I||Schizophrenic Patients Taking Part in Integrated Care Program|Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Non-interventional Study|Terminated|||20|Actual|AstraZeneca|||1|"Difficulty finding eligible sites/patients:current situation in health policy cause negative~   effects on existing/planned contracts for integrated care programs"|f||||f||||||||||2018-06-01 02:27:10.250499|2018-06-01 02:27:10.250499
NCT00617201|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2012-11-13||2017-08-01|2008-02-14|2008-02-15|Estimate|2012-11-13|2012-12-11|Estimate||||2017-08-01|2017-08-31|Actual|July 2007||2007-07-31|August 2017|2017-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial|Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial|Completed||Phase 2|50|Actual|University of Kentucky||2|||f||||t||||||||||2018-06-01 02:27:10.351937|2018-06-01 02:27:10.351937
NCT00617188|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2009-06-12||2017-12-03|2008-02-14|2008-02-15|Estimate|2010-03-16|2010-03-17|Estimate||||2017-12-03|2017-12-28|Actual|June 2007||2007-06-30|December 2017|2017-12-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer|Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma|Completed||Phase 2|26|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:27:10.594492|2018-06-01 02:27:10.594492
NCT00617175|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2012-08-30||2016-03-23|2008-02-14|2008-02-15|Estimate|2013-01-21|2013-02-25|Estimate||||2016-03-23|2016-03-24|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|ADVANCEIII||Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III|ADVANCE III: Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III|Completed||Phase 4|1902|Actual|Medtronic Bakken Research Center||2|||f||||t||||||||||2018-06-01 02:27:10.799031|2018-06-01 02:27:10.799031
NCT00617149|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2009-09-17|2008-02-14|2008-02-15|Estimate|||||||2009-09-17|2009-09-18|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Regular Exercise in Prevention of Excessive Weight Gain in Pregnancy|Effect of Regular Exercise in Prevention of Excessive Weight Gain in Pregnancy. A Single Blind Randomized Controlled Trial|Completed||Phase 1|105|Actual|Norwegian School of Sport Sciences|||||f||||f||||||||||2018-06-01 02:27:11.452379|2018-06-01 02:27:11.452379
NCT00617136|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2014-12-16|2008-02-14|2008-02-15|Estimate|||||||2014-12-16|2014-12-17|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|HOT||Perioperative Temperature Management|Perioperative Temperature Management: A Big Small Problem|Completed||N/A|70|Actual|VU University Medical Center||3|||f||||f||||||||||2018-06-01 02:27:11.523607|2018-06-01 02:27:11.523607
NCT00617123|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2014-05-09||2017-03-31|2008-02-04|2008-02-15|Estimate|2014-07-11|2014-07-14|Estimate||||2017-03-31|2017-05-05|Actual|July 1, 2008|Actual|2008-07-01|March 2017|2017-03-31|October 1, 2010|Actual|2010-10-01|October 1, 2010|Actual|2010-10-01||Interventional||Participants who were included in the analysis of ocular safety.|Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Ocular Safety of SCH 530348 in Subjects Participating in the Schering-Plough P04737 Study (TRA^SM-Secondary Prevention Ocular Safety Study)|Completed||Phase 3|258|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:27:11.605136|2018-06-01 02:27:11.605136
NCT00617110|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2015-06-01|2008-02-14|2008-02-15|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|FLAIR||Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies|Effects of Diesel Exhaust Particles on Influenza-induced Nasal Inflammation in Allergic Rhinitics and Non-allergic Individuals|Completed||N/A|54|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-06-01 02:27:12.022621|2018-06-01 02:27:12.022621
NCT00617097|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2014-06-09||2017-08-17|2008-02-04|2008-02-15|Estimate|2014-09-10|2014-09-15|Estimate||||2017-08-17|2017-09-15|Actual|January 2008||2008-01-31|August 2017|2017-08-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Paracervical Block in First Trimester Surgical Abortions|Paracervical Block With Ketorolac and Lidocaine in First Trimester Surgical Abortions|Completed||Phase 2/Phase 3|50|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:27:12.158439|2018-06-01 02:27:12.158439
NCT00617084|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2010-11-22||2014-05-27|2008-02-14|2008-02-15|Estimate|2011-04-19|2011-05-17|Estimate||||2014-05-27|2014-06-06|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|May 2010|Actual|2010-05-31||Interventional|RESOLUTE-AC||Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent|RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention|Completed||Phase 4|2292|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-06-01 02:27:12.888601|2018-06-01 02:27:12.888601
NCT00617071|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2013-12-17|2008-02-14|2008-02-15|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 2007||2007-01-31|July 2009|2009-07-31||||December 2010|Anticipated|2010-12-31||Interventional|||Personalized Screening Plans to Increase Colorectal Cancer Screening in Healthy Participants|Tailored Navigation in CRC Screening|Unknown status|Recruiting|Phase 3|900|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:27:13.966448|2018-06-01 02:27:13.966448
NCT00617058|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2012-10-29||2012-11-28|2008-02-14|2008-02-15|Estimate|2012-11-28|2012-12-31|Estimate||||2012-11-28|2012-12-31|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|ZAC||Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine|Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine|Terminated||Phase 2|1|Actual|University of North Carolina, Chapel Hill|In terms of study limitations, this research study was only able to enroll a single study participant before the trial was terminated prematurely due to study start-up for a larger, multisite effort examining similar outcome measures.|3||Terminated in lieu of similar,competing large, multi-site study.|f||||t||||||||||2018-06-01 02:27:14.055498|2018-06-01 02:27:14.055498
NCT00617045|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2016-06-15|2008-02-14|2008-02-15|Estimate|||||||2016-06-15|2016-06-17|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|DuloxPPD||Duloxetine for the Treatment of Postpartum Depression|Duloxetine in the Treatment of Postpartum-onset and Non-Postpartum Onset Major Depressive Disorder|Withdrawn||N/A|0|Actual|Yale University||1||poor patient recruitment|f||||f||||||||No||2018-06-01 02:27:14.368004|2018-06-01 02:27:14.368004
NCT00617032|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-05|2008-02-05|2008-02-15|Estimate|||||||2008-02-05|2008-02-15|Estimate|February 2004||2004-02-29|February 2008|2008-02-29|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94|A Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis|Completed||Phase 1|15|Actual|Targeted Genetics Corporation||3|||f||||t||||||||||2018-06-01 02:27:14.438559|2018-06-01 02:27:14.438559
NCT00617019|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2013-11-11|2008-02-14|2008-02-15|Estimate|||||||2013-11-11|2013-11-13|Estimate|September 2006||2006-09-30|November 2013|2013-11-30||||January 2008|Actual|2008-01-31||Observational|||Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)|A Cross-sectional, Retrospective Screening and Case-control Study Examining the Frequency of, and Risk Factors Associated With, Impulse Control Disorders in Parkinson's Disease Patients Treated With MIRAPEX® (Pramipexole) and Other Anti-parkinson Agents (DOMINION Study)|Completed|||3234|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 02:27:14.518847|2018-06-01 02:27:14.518847
NCT00617006|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-14|2008-02-14|2008-02-15|Estimate|||||||2008-02-14|2008-02-15|Estimate|July 2007||2007-07-31|February 2008|2008-02-29|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Observational|||Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice|Before and After Study Evaluating Deployment of the Sprixx GJ Personal Hand Hygiene Device in the Intra-Operative Environment|Completed|||114|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||f||||||Samples Without DNA|"~     Environmental Bacterial Samples of Workspace~   "|||2018-06-01 02:27:14.622942|2018-06-01 02:27:14.622942
NCT00616993|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2011-06-29|2008-02-04|2008-02-15|Estimate|||||||2011-06-29|2011-07-01|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)||Completed||Phase 3|120|Anticipated|Sirion Therapeutics, Inc.||2|||f||||||||||||||2018-06-01 02:27:14.677246|2018-06-01 02:27:14.677246
NCT00616473|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2014-12-01|2008-02-04|2008-02-15|Estimate|||||||2014-12-01|2014-12-04|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Quality End-of-Life Care in Nursing Homes|The Impact of Quality End-of-Life Care in Nursing Homes|Completed|||8500|Anticipated|University of Nebraska|||2||f||||f||||||||||2018-06-01 02:27:25.515314|2018-06-01 02:27:25.515314
NCT00616980|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2011-07-21|2008-02-04|2008-02-15|Estimate|||||||2011-07-21|2011-07-25|Estimate|December 2007||2007-12-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|ACT34-CLI||Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia|Injection of Autologous CD34-Positive Cells for Improved Symptomatic Relief and Ischemic Wound Healing in Subjects With Moderate or High-Risk Critical Limb Ischemia|Completed||Phase 1/Phase 2|28|Actual|Losordo, Douglas, M.D.||3|||f||||t||||||||||2018-06-01 02:27:14.733244|2018-06-01 02:27:14.733244
NCT00616967|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2014-04-08||2014-06-16|2008-02-14|2008-02-15|Estimate|2014-06-16|2014-07-16|Estimate||||2014-06-16|2014-07-16|Estimate|May 2008||2008-05-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|June 2012|Actual|2012-06-30||Interventional||"The information for the primary populations for analysis are included (Placebo and Vorinostat arms). The initial run-in phase of 6 participants was conducted to confirm safety and dosing for the combination of vorinostat with chemotherapy only, and these data are not a part of our primary study analyses."|Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer|A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in HER2-negative Primary Operable Breast Cancer|Completed||Phase 2|68|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|A proportion of women received additional preoperative chemotherapy after study treatment,complicating the evaluation of primary endpoint and role of FDG-PET in predicting response. Limited matched samples for Ki67 analysis.|2|||f||||f||||||||||2018-06-01 02:27:15.878984|2018-06-01 02:27:15.878984
NCT00616954|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2015-04-19|2008-02-05|2008-02-15|Estimate|||||||2015-04-19|2015-04-21|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT|An Investigator Initiated, Prospective, Randomized, Controlled Study in Order to Evaluate the Effect of Anti-thymocyte Globulin (Fresenius ATG) on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical Allogeneic Hematopoietic Stem-cell Transplantation|Terminated||Phase 3|50|Anticipated|Hadassah Medical Organization||2||low recruitment|f||||||||||||||2018-06-01 02:27:16.37577|2018-06-01 02:27:16.37577
NCT00616941|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2012-04-16|2008-02-14|2008-02-15|Estimate|||||||2012-04-16|2012-04-18|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission|A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) With or Without Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission|Completed||Phase 1|26|Anticipated|Ludwig Institute for Cancer Research||3|||f||||t||||||||||2018-06-01 02:27:16.459795|2018-06-01 02:27:16.459795
NCT00616928|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2013-12-19|2009-05-20|2016-10-11|2008-02-05|2008-02-15|Estimate|2013-12-19|2014-02-07|Estimate|2009-09-28|2009-09-30|Estimate|2016-10-11|2016-11-23|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|||Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years|A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged ≥18 Years|Completed||Phase 3|4561|Actual|GlaxoSmithKline||10|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:27:16.717248|2018-06-01 02:27:16.717248
NCT00616915|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2015-12-14|2008-02-14|2008-02-15|Estimate|||||||2015-12-14|2015-12-16|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|||Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?|Does Sleep Quality Change After Switch From Wellbutrin SR to Wellbutrin XL in Patients With Major Depressive Disorder?|Completed||Phase 1|20|Actual|Queen's University||1|||f||||f||||||||||2018-06-01 02:27:18.157186|2018-06-01 02:27:18.157186
NCT00616902|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2010-05-21||2012-01-18|2008-02-05|2008-02-15|Estimate|2010-07-07|2010-08-04|Estimate||||2012-01-18|2012-01-20|Estimate|January 2009||2009-01-31|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PRIMO II||The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5|Clinical Study Protocol M10-221 The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5|Terminated||Phase 3|12|Actual|Abbott|This study was prematurely terminated due to low enrollment. Only 12 subjects were randomized at 10 investigative sites with none of the subjects completing the study.|2||This study was prematurely terminated due to low enrollment|f||||t||||||||||2018-06-01 02:27:18.344601|2018-06-01 02:27:18.344601
NCT00616889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-12-14|2008-02-04|2008-02-15|Estimate|||||||2015-12-14|2015-12-16|Estimate|May 2006||2006-05-31|December 2015|2015-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder|Effects of Seroquel on Sleep Architecture in Patients With Bipolar Depression or Major Depressive Disorder - An Open Label Study|Completed|||15|Actual|Queen's University|||1||f||||f||||||||||2018-06-01 02:27:18.88166|2018-06-01 02:27:18.88166
NCT00616876|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-14|2008-02-14|2008-02-15|Estimate|||||||2008-02-14|2008-02-15|Estimate|February 2005||2005-02-28|February 2008|2008-02-29|January 2007|Actual|2007-01-31|August 2006|Actual|2006-08-31||Interventional|||Lactulose Supplementation in Premature Infants|The Effects of Lactulose Supplementation to Enteral Feedings in Premature Infants - A Pilot Study|Completed||Phase 2|28|Actual|Bnai Zion Medical Center||2|||f||||f||||||||||2018-06-01 02:27:18.965722|2018-06-01 02:27:18.965722
NCT00616863|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2018-01-19|2008-02-14|2008-02-15|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2004||2004-07-31|January 2018|2018-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Oxcarbazapine 600 mg Tablets Under Fed Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:27:19.074908|2018-06-01 02:27:19.074908
NCT00616850|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2014-05-20|2008-02-04|2008-02-15|Estimate|||||||2014-05-20|2014-05-22|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion|Treatment of Postoperative Pain After Total Knee Arthroplasty Using Intravenous Lidocaine Infusion in Combination With Patient Controlled Analgesia Versus Continuous Femoral Block Catheter in Combination With Patient Controlled Analgesia: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study.|Withdrawn||N/A|0|Actual|Loma Linda University||3||Orthopedic surgeon that does our knee surgeries moved to a different location|f||||f||||||||||2018-06-01 02:27:19.140646|2018-06-01 02:27:19.140646
NCT00616824|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2017-03-30|2008-02-14|2008-02-15|Estimate|||||||2017-03-30|2017-04-04|Actual|September 2007||2007-09-30|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Use of an Acellular Dermal Matrix in a Two-Staged Breast Reconstruction|The Use of an Acellular Dermal Matrix in a Two-Staged Breast Reconstruction The Use of an Acellular Dermal Matrix in a Two-Staged Breast Reconstruction After Mastectomy: A Double-Blinded, Randomized Trial|Terminated||Phase 4|36|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-06-01 02:27:19.310375|2018-06-01 02:27:19.310375
NCT00616811|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04||2013-01-02|2013-01-02|2008-02-04|2008-02-15|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-02|2013-01-04|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency|A Multi-center, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With Vildagliptin (50 mg qd) Versus Sitagliptin (25 mg qd) in Patients With Type 2 Diabetes and Severe Renal Insufficiency|Completed||Phase 3|148|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:27:19.399422|2018-06-01 02:27:19.399422
NCT00616798|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04||2013-08-20|2014-06-23|2008-02-13|2008-02-15|Estimate||||2013-08-20|2013-08-28|Estimate|2014-06-23|2014-06-24|Estimate|March 2008||2008-03-31|June 2014|2014-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.|Randomized, Double-blind, Placebo-controlled add-on Trial of the Safety and Efficacy of RO4917838 in Outpatients on Select Atypical Antipsychotics With Prominent Negative or Disorganized Thought Symptoms|Completed||Phase 2|323|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 02:27:19.675438|2018-06-01 02:27:19.675438
NCT00616785|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2009-02-06|2008-02-14|2008-02-15|Estimate|||||||2009-02-06|2009-02-09|Estimate|June 2007||2007-06-30|September 2008|2008-09-30||||November 2010|Anticipated|2010-11-30||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Phase II Trial Irinotecan and Cisplatin Induction Chemotherapy Followed by Radiotherapy Concurrently With Etoposide/Cisplatin in Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|41|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:27:19.902939|2018-06-01 02:27:19.902939
NCT00616772|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2013-09-13||2013-12-03|2008-02-14|2008-02-15|Estimate|2013-12-03|2014-01-20|Estimate||||2013-12-03|2014-01-20|Estimate|February 2008||2008-02-29|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|FIRST|All randomized participants who received at least 1 dose of study drug.|Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood|Evaluation of Choline Fenofibrate (ABT-335) on Carotid Intima-Media Thickness (cIMT) in Subjects With Type IIb Dyslipidemia With Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial|Completed||Phase 3|682|Actual|AbbVie||2|||f||||t||||||||||2018-06-01 02:27:20.03933|2018-06-01 02:27:20.03933
NCT00616759|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2010-11-30||2017-10-23|2008-02-14|2008-02-15|Estimate|2012-12-30|2013-02-04|Estimate||||2017-10-23|2017-10-25|Actual|September 2006||2006-09-30|October 2017|2017-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Effect on Cognition of Terminating ECT Induced Seizures With Propofol|The Effect on Cognition of Terminating ECT Induced Seizures With Propofol|Completed||N/A|20|Actual|Loma Linda University||2|||f||||f||||||||||2018-06-01 02:27:20.931708|2018-06-01 02:27:20.931708
NCT00616746|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2014-07-07|2008-02-04|2008-02-15|Estimate|||||||2014-07-07|2014-07-08|Estimate|January 2007||2007-01-31|July 2014|2014-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans|Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans|Completed||Early Phase 1|18|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:27:21.811528|2018-06-01 02:27:21.811528
NCT00616733|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2011-03-09|2008-02-04|2008-02-15|Estimate|||||||2011-03-09|2011-03-10|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients|An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis|Completed||Phase 1|25|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-06-01 02:27:22.095207|2018-06-01 02:27:22.095207
NCT00616720|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-05-13|2008-02-14|2008-02-15|Estimate|||||||2011-05-13|2011-05-16|Estimate|August 2001||2001-08-31|May 2011|2011-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma|Randomized Phase II Trial of Dendritic Cell-Based Idiotype Vaccination With Adjuvant Cytokines for Plateau Phase and Post-Transplant Multiple Myeloma|Completed||Phase 2|15|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 02:27:22.166824|2018-06-01 02:27:22.166824
NCT00616707|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2017-05-25|2008-02-14|2008-02-15|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2006||2006-08-31|May 2017|2017-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|IM||Analysis of Microalbuminuria and Markers of Inflammation and Oxidative Stress in Adolescents of Different Ethnic Backgrounds|Analysis of Microalbuminuria and Markers of Inflammation and Oxidative Stress in Adolescents of Different Ethnic Backgrounds|Completed|||68|Actual|University of California, Davis|||||f||||f||||||Samples Without DNA|"~     Aliquots from the citrate vial & Serum seperator vial are being retained~   "|||2018-06-01 02:27:22.239341|2018-06-01 02:27:22.239341
NCT00616694|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-20|2008-02-14|2008-02-15|Estimate|||||||2008-02-20|2008-02-21|Estimate|July 2002||2002-07-31|February 2008|2008-02-29|December 2004|Actual|2004-12-31|||||Interventional|ACTIVATE||Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy|A Randomized Multicenter Parallel Group Study to Determine if Knowledge of Baseline Vertebral Fracture Prevalence (as Determined by Hologic IVA) and Bone Turnover Marker Determinations Improves Persistence With Actonel 5mg Daily Therapy in Subjects Receiving Chronic Glucocorticoid Therapy|Completed||Phase 4|248|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:27:22.376678|2018-06-01 02:27:22.376678
NCT00616681|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2018-01-19|2008-02-14|2008-02-15|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2004||2004-06-30|January 2018|2018-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Bioequivalency Study of 600 mg Oxcarbazepine Tablets Under Fasting Conditions|A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fasting Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:27:22.454065|2018-06-01 02:27:22.454065
NCT00616668|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-02-14|2008-02-14|2008-02-15|Estimate|||||||2008-02-14|2008-02-15|Estimate|January 2003||2003-01-31|February 2008|2008-02-29|December 2005|Actual|2005-12-31|||||Interventional|||Early Postoperative Fitting of the Air- Limb Prosthesis for Transtibial Amputees|Early Postoperative Fitting of the Air- Limb Prosthesis for Transtibial Amputees|Completed||Phase 2|20|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 02:27:22.507281|2018-06-01 02:27:22.507281
NCT00616655|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2015-06-02|2009-12-16|2016-03-10|2008-02-14|2008-02-15|Estimate|2015-07-27|2015-08-21|Estimate|2009-12-16|2009-12-18|Estimate|2016-03-10|2016-04-08|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||ITT Population|Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects|A Double Blind, Randomized, Placebo Controlled, Multicenter Study Examining the Efficacy and Safety of SEP-225441 in Subjects With Generalized Anxiety Disorder.|Completed||Phase 2|456|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 02:27:22.628001|2018-06-01 02:27:22.628001
NCT00616642|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2013-03-04||2013-03-04|2008-02-14|2008-02-15|Estimate|2013-03-04|2013-04-15|Estimate||||2013-03-04|2013-04-15|Estimate|October 2006||2006-10-31|March 2013|2013-03-31||||November 2010|Actual|2010-11-30||Interventional|||Rosiglitazone in Treating Patients With Pituitary Tumors|Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors|Terminated||Phase 2|1|Actual|Jonsson Comprehensive Cancer Center|Recruitment was the main limitation. Patients were available but were not interested in the study due to possible side effects of the study drug.|2||low patient recruitment|f||||t||||||||||2018-06-01 02:27:23.683499|2018-06-01 02:27:23.683499
NCT00616629|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2011-01-24||2011-08-17|2008-02-05|2008-02-15|Estimate|2011-08-17|2011-09-22|Estimate||||2011-08-17|2011-09-22|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Cardiac Electrophysiological Study|A Multi-centre, Double-blind, Randomised, Placebo-controlled, Singledose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of AZD1305 in Patients Undergoing an Invasive Electrophysiological Procedure|Completed||Phase 2|55|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:27:23.988317|2018-06-01 02:27:23.988317
NCT00616616|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2016-10-24|2008-02-14|2008-02-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|SIL||Single Incision Laparoscopy|Single Incision Laparoscopy|Completed||N/A|24|Actual|University of California, San Diego||1|||f||||f||||||||||2018-06-01 02:27:24.454917|2018-06-01 02:27:24.454917
NCT00616603|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2013-05-17||2014-06-10|2008-02-04|2008-02-15|Estimate|2014-06-10|2014-06-11|Estimate||||2014-06-10|2014-06-11|Estimate|August 2007||2007-08-31|June 2014|2014-06-30|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks|The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks|Terminated||N/A|43|Actual|Loma Linda University|PI left the institution and data analysis cannot be summarized due to poor data integrity.|3||PI is no longer here.|f||||f||||||||||2018-06-01 02:27:24.519356|2018-06-01 02:27:24.519356
NCT00616590|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2014-06-15|2008-02-14|2008-02-15|Estimate|||||||2014-06-15|2014-06-17|Estimate|July 2007||2007-07-31|June 2014|2014-06-30||||July 2012|Anticipated|2012-07-31||Observational|||Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer|Assessment of Insomnia in Patients With Head and Neck Cancer During Treatment|Withdrawn|||0|Actual|Vanderbilt University|||||f||||||||||||||2018-06-01 02:27:24.78992|2018-06-01 02:27:24.78992
NCT00616577|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2015-04-02||2016-12-14|2008-02-04|2008-02-15|Estimate|2015-04-02|2015-04-08|Estimate||||2016-12-14|2017-02-07|Estimate|October 2007||2007-10-31|December 2016|2016-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||PI left institution and records cannot be located|Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine|Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine: A Prospective, Randomized, Double-blinded, Controlled Study|Terminated||N/A|26|Actual|Loma Linda University||3||PI is no longer here.|f||||f||||||||||2018-06-01 02:27:24.868747|2018-06-01 02:27:24.868747
NCT00616564|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2012-05-02|2008-02-14|2008-02-15|Estimate|||||||2012-05-02|2012-05-03|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma|Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma|Completed||Phase 2|36|Actual|Mt. Sinai Medical Center, Miami|||||f||||t||||||||||2018-06-01 02:27:25.02672|2018-06-01 02:27:25.02672
NCT00616551|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-10-07|2008-02-04|2008-02-15|Estimate|||||||2008-10-07|2008-10-08|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients|Open Label, Randomized Study Comparing the Biological Efficacy & Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients|Completed||Phase 3|65|Actual|Ambrilia Biopharma, Inc.||2|||f||||f||||||||||2018-06-01 02:27:25.088758|2018-06-01 02:27:25.088758
NCT00616538|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-05|2008-02-05|2008-02-15|Estimate|||||||2008-02-05|2008-02-15|Estimate|December 2006||2006-12-31|February 2008|2008-02-29||||April 2007|Actual|2007-04-30||Interventional|||Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis|Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing Effect of Epiceram™ Device vs Standard of Care Therapy of Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) in Treatment of Atopic Dermatitis in Pediatric Subjects|Completed||Phase 4|121|Actual|Ceragenix Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:27:25.231904|2018-06-01 02:27:25.231904
NCT00616512|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2011-06-22|2008-02-04|2008-02-15|Estimate|||||||2011-06-22|2011-06-23|Estimate|April 2008||2008-04-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Randomized Controlled Trial of a Water Protocol for Clients With Thin Liquid Dysphagia|A Randomized Controlled Trial of a Water Protocol for Clients With Thin Liquid Dysphagia: a Pilot Project|Completed||Phase 1|40|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-06-01 02:27:25.304263|2018-06-01 02:27:25.304263
NCT00616499|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2009-02-06|2008-02-14|2008-02-15|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2006||2006-11-30|September 2008|2008-09-30||||November 2010|Anticipated|2010-11-30||Interventional|||Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer|A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:27:25.369356|2018-06-01 02:27:25.369356
NCT00616486|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2015-12-14|2008-02-04|2008-02-15|Estimate|||||||2015-12-14|2015-12-16|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|November 2012|Actual|2012-11-30|May 2010|Actual|2010-05-31||Interventional|||rTMS in Treatment of Obsessive Compulsive Disorder (OCD)|A Multicentre, Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy, Safety, and Clinical Outcomes of Low Frequency, Repetitive Transcranial Magnetic Stimulation (Over Supplementary Motor Area (SMA) Applied Bilaterally and Simultaneously) Versus Sham (Placebo rTMS) Treatment for 6 Weeks, When Added to a Stable Pharmacotherapy in Subjects With Obsessive Compulsive Disorder (OCD).|Completed||N/A|24|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:27:25.441235|2018-06-01 02:27:25.441235
NCT00616447|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2015-12-14|2008-02-04|2008-02-15|Estimate|||||||2015-12-14|2015-12-16|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||rTMS Treatment in Patients With General Anxiety Disorder|A 12-week, Double-blind, Randomized, Placebo-controlled Multicentered Study Evaluating Efficacy and Safety of High-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment in Patients With Generalized Anxiety Disorder (GAD)|Completed||N/A|30|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:27:25.71222|2018-06-01 02:27:25.71222
NCT00616434|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2014-07-23||2014-07-23|2008-02-05|2008-02-15|Estimate|2014-07-23|2014-08-13|Estimate||||2014-07-23|2014-08-13|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Avonex® in Subjects With Moderate to Severe Ulcerative Colitis|Completed||Phase 2|123|Actual|Biogen||2|||f||||f||||||||||2018-06-01 02:27:25.806829|2018-06-01 02:27:25.806829
NCT00616421|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2011-02-28|2010-08-27|2016-01-19|2008-02-14|2008-02-15|Estimate|2011-05-10|2011-06-09|Estimate|2010-08-27|2010-08-31|Estimate|2016-01-19|2016-02-15|Estimate|March 2008||2008-03-31|January 2016|2016-01-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children|A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age|Completed||Phase 3|2907|Actual|Novartis||3|||f||||t||||||||||2018-06-01 02:27:26.114563|2018-06-01 02:27:26.114563
NCT00616408|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-05|2008-02-05|2008-02-15|Estimate|||||||2008-02-05|2008-02-15|Estimate|January 1997||1997-01-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Prediction of Tumor Shrinkage in Acromegaly|Predictive Value of 3 Months Results on 12 Months Tumor Shrinkage After First-Line Octreotide-LAR Therapy in Patients With Acromegaly|Completed|||61|Actual|Federico II University|||1||f||||f||||||||||2018-06-01 02:27:27.219181|2018-06-01 02:27:27.219181
NCT00616395|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2018-02-06|2008-02-14|2008-02-15|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2002|Actual|2002-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Observational|Beginnings||Study of Early Infant Diet on Growth and Development|Effects of Diet on Metabolism, Body Composition, Brain Function in Infants/Children|Active, not recruiting|||600|Anticipated|Arkansas Children's Hospital Research Institute|||1||f||||f||||||Samples Without DNA|"~     Plasma, urine, and stool may be collected from some study participants.~   "|||2018-06-01 02:27:27.569562|2018-06-01 02:27:27.569562
NCT00616382|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-13|||2008-02-14|2008-02-14|2008-02-15|Estimate|||||||2008-02-14|2008-02-15|Estimate|March 2008||2008-03-31|January 2008|2008-01-31||||March 2010|Anticipated|2010-03-31||Interventional|||Treating the Resistant Patent Ductus Arteriosus (PDA)|New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates|Unknown status|Not yet recruiting|Phase 2|68|Anticipated|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-06-01 02:27:27.836008|2018-06-01 02:27:27.836008
NCT00616369|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2016-01-07|2008-02-14|2008-02-15|Estimate|||||||2016-01-07|2016-01-11|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|Genotype||Identification of Genetic Markers for Cardiopulmonary Diseases (Genotype)|Identification of Genetic Markers for Cardiopulmonary Diseases|Completed|||255|Actual|University of Alabama at Birmingham|||2||f||||f||||||Samples With DNA|"~     The following genetic tests will be performed on these specimens:~      Endothelin1, Endothelin receptors A&B, Prostaglandin, Prostaglandin receptors,~     CytochromeP450, NPR, A, B and C, Transforming Growth Factor (B), Pai-1 HindIII, Toll-like~     receptor4, Pai-1 4g5g, Xho-1, P22, Tissue Plasminogin Activators, Urokinase Plasminogen~     Activators, Fibrinogen, Nitric Oxide Synthase, BMPRs, SMADs, VEGFs, FGFs, Rho Kinase,~     Elastins, Angiopoietin, PDE5, Serotonin receptor, Angiotensin, Alk 1, and Cell Culture (DNA~     immortalization)~      There is a possibility that other genetic testing could arise as the study progresses. In~     this case, the IRB would be notified prior to testing.~   "|||2018-06-01 02:27:28.202245|2018-06-01 02:27:28.202245
NCT00616356|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2011-11-07|2008-02-14|2008-02-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2007||2007-12-31|November 2011|2011-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults|Characterization of T Cell Responses Following Yellow Fever Virus Vaccination in Healthy Adults|Completed|||8|Anticipated|Rockefeller University|||||f||||f||||||||||2018-06-01 02:27:28.458034|2018-06-01 02:27:28.458034
NCT00616343|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2014-06-12||2014-07-16|2008-02-13|2008-02-15|Estimate|2014-07-16|2014-07-17|Estimate||||2014-07-16|2014-07-17|Estimate|June 2003||2003-06-30|July 2014|2014-07-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional||•<=18 years Male/Female Hx essential tremor|Zonisamide in the Treatment of Essential Tremor|Pilot Study of Zonisamide in the Treatment of Essential Tremor|Terminated||N/A|9|Actual|Loma Linda University|PI has left the institution and we are unable to accurately assess the data from the remaining records.|1||Principal Investigator left the study site on December 28, 2012.|f||||t||||||||||2018-06-01 02:27:28.667954|2018-06-01 02:27:28.667954
NCT00616330|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04||2010-11-02|2012-02-29|2008-02-13|2008-02-15|Estimate||||2011-01-14|2011-01-21|Estimate|2012-02-29|2012-03-05|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Vaginal Infection Study||Completed||Phase 3|1443|Actual|Lumara Health, Inc.||3|||f||||||||||||||2018-06-01 02:27:29.24319|2018-06-01 02:27:29.24319
NCT00616317|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2018-03-01|2008-02-14|2008-02-15|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2006||2006-09-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|APS||Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study|Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study|Recruiting|||50|Anticipated|University of California, Davis|||||f||||f||||||||||2018-06-01 02:27:29.981051|2018-06-01 02:27:29.981051
NCT00616304|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2013-06-24|2008-02-04|2008-02-15|Estimate|||||||2013-06-24|2013-06-26|Estimate|February 2008||2008-02-29|June 2013|2013-06-30||||March 2009|Actual|2009-03-31||Interventional|ARGISM||Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria|Safety and Preliminary Efficacy, Pharmacokinetics, Pharmacodynamics of L-arginine in Severe Falciparum Malaria|Suspended||Phase 2|8|Actual|Menzies School of Health Research||2||Local circumstances & difficulties in site access has prevented continuation|f||||t||||||||||2018-06-01 02:27:30.244566|2018-06-01 02:27:30.244566
NCT00616291|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2012-11-05|2008-02-14|2008-02-15|Estimate|||||||2012-11-05|2012-11-06|Estimate|April 2006||2006-04-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer|Immunotherapy of Patients With Androgen-Independent Prostate Carcinoma Using NY-ESO-1/LAGE1 Peptide Vaccine (SPORE #: 11-01-30-14)|Completed||Phase 1|14|Actual|Baylor College of Medicine||3|||f||||||||||||||2018-06-01 02:27:30.689238|2018-06-01 02:27:30.689238
NCT00616278|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2017-05-25|2008-02-14|2008-02-15|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2005||2005-10-31|May 2017|2017-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|NCGS||National Cooperative Growth Study in CKD|National Cooperative Growth Study of Nutropin AQ, Nutropin, Protropin, and Nutropin Depot in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End-Stage Renal Disease (ESRD)|Completed|||27|Actual|University of California, Davis|||||f||||t||||||||||2018-06-01 02:27:30.996268|2018-06-01 02:27:30.996268
NCT00616265|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2012-02-28|2008-02-14|2008-02-15|Estimate|||||||2012-02-28|2012-02-29|Estimate|June 2008||2008-06-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Effect of Continuous Positive Airway Pressure (CPAP) Treatment in the Control of Refractory Hypertension|Effect of CPAP Treatment in the Control of Refractory Hypertension|Completed||N/A|210|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||t||||||||||2018-06-01 02:27:31.204522|2018-06-01 02:27:31.204522
NCT00616252|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2010-12-03|2008-02-04|2008-02-15|Estimate|||||||2010-12-03|2010-12-06|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|September 2009|Actual|2009-09-30|November 2008|Actual|2008-11-30||Observational|||Antiretroviral Drug Levels During and After Pregnancy|Comparison of the Pharmacokinetics of Antiretroviral Agents in HIV Infected Ugandan Women During and After Pregnancy|Completed|||16|Actual|Makerere University|||||f||||f||||||Samples With DNA|"~     Human plasma Red cell pellets~   "|||2018-06-01 02:27:31.313391|2018-06-01 02:27:31.313391
NCT00616239|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2013-08-26||2014-01-09|2008-02-14|2008-02-15|Estimate|2013-11-08|2013-12-30|Estimate||||2014-01-09|2014-02-07|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women|The Efficacy of Salicylic Acid Peels Combined With 4% Hydroquinone Cream Versus 4% Hydroquinone Cream Alone in the Treatment of Hispanic Women With Moderate to Severe Melasma|Completed||Phase 4|20|Actual|University of Texas Southwestern Medical Center|Two subjects did not complete the study were unable to come in for visits because of scheduling difficulties and had no adverse effects at the time of discontinuation.|2|||f||||f||||||||||2018-06-01 02:27:31.400865|2018-06-01 02:27:31.400865
NCT00616226|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-02-27|2008-02-14|2008-02-15|Estimate|||||||2015-02-27|2015-03-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:27:31.636586|2018-06-01 02:27:31.636586
NCT00616213|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2011-05-31|2008-02-14|2008-02-15|Estimate|||||||2011-05-31|2011-06-01|Estimate|February 2008||2008-02-29|May 2011|2011-05-31|June 2009|Actual|2009-06-30|September 2008|Actual|2008-09-30||Interventional|||PR104 and G-CSF in Treating Patients With Solid Tumors|A Phase I, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given With Prophylactic G-CSF in Subjects With Solid Tumors|Completed||Phase 1|5|Actual|Proacta, Incorporated|||||f||||||||||||||2018-06-01 02:27:31.677926|2018-06-01 02:27:31.677926
NCT00616200|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2010-06-29||2017-09-13|2008-02-14|2008-02-15|Estimate|2011-10-05|2011-11-11|Estimate||||2017-09-13|2017-10-16|Actual|August 2009||2009-08-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)|The Effect of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome: A Prospective Pilot Study|Completed||N/A|17|Actual|University of North Carolina, Chapel Hill|Low N, lack of standard control group and specific overweight/obese female predominant population.|1|||f||||f||||||||||2018-06-01 02:27:31.77941|2018-06-01 02:27:31.77941
NCT00616187|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2018-03-19|2008-02-14|2008-02-15|Estimate|||||||2018-03-19|2018-03-20|Actual|October 2003||2003-10-31|December 2017|2017-12-31||||June 2007|Actual|2007-06-30||Interventional|||Atorvastatin in Relapsing-Remitting Multiple Sclerosis|Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|41|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:27:31.966567|2018-06-01 02:27:31.966567
NCT00616174|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2014-03-14|2008-02-05|2008-02-15|Estimate|||||||2014-03-14|2014-03-17|Estimate|February 2008||2008-02-29|March 2014|2014-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Does Warming Mothers During Cesarean Delivery Help Keep Babies Warm When Delivered?|The Effect of Maternal Warming During Cesarean Delivery on Neonatal Temperature|Completed||N/A|70|Actual|University of British Columbia||1|||f||||t||||||||||2018-06-01 02:27:32.042414|2018-06-01 02:27:32.042414
NCT00616161|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2008-02-05|2008-02-05|2008-02-15|Estimate|||||||2008-02-05|2008-02-15|Estimate|August 2006||2006-08-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|HORIZON-HF||A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function|A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function|Completed||Phase 2|120|Actual|sigma-tau i.f.r. S.p.A.||4|||f||||t||||||||||2018-06-01 02:27:32.114003|2018-06-01 02:27:32.114003
NCT00616148|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04||2013-06-17|2013-12-26|2008-02-04|2008-02-15|Estimate||||2013-12-02|2013-12-27|Estimate|2013-12-26|2014-01-31|Estimate|August 2007||2007-08-31|December 2013|2013-12-31|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy of YKP3089 in Patients With Photosensitive Epilepsy|Pharmacodynamic Evaluation of YKP3089 in Epilepsy Patients With a Photo-induced Paroxysmal EEG-Response: Proof of Principle|Completed||Phase 2|11|Actual|SK Life Science||2|||f||||t||||||||||2018-06-01 02:27:32.238027|2018-06-01 02:27:32.238027
NCT00616135|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2011-05-13|2008-02-05|2008-02-15|Estimate|||||||2011-05-13|2011-05-17|Estimate|June 2008||2008-06-30|May 2011|2011-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|RESTORE-2||Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy|A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study.|Completed||Phase 4|71|Anticipated|Cytori Therapeutics|||||f||||f||||||||||2018-06-01 02:27:32.314046|2018-06-01 02:27:32.314046
NCT00616122|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|2012-12-18||2017-08-30|2008-02-14|2008-02-15|Estimate|2013-01-09|2013-02-12|Estimate||||2017-08-30|2017-09-28|Actual|March 2006||2006-03-31|August 2017|2017-08-31|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Interventional|||Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer|Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|32|Actual|University of California, San Francisco|Based on published literature indicating significant toxicity and low response rate for combination sunitinib in the treatment of advanced breast cancer, the PI and Breast Oncology Site Committee closed enrollment after accrual of 32 participants.|1|||f||||t||||||||||2018-06-01 02:27:32.399289|2018-06-01 02:27:32.399289
NCT00616109|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2013-02-07||2014-03-13|2008-02-14|2008-02-15|Estimate|2014-03-13|2014-04-21|Estimate||||2014-03-13|2014-04-21|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Interventional||Lung cancer patients who are greater than or equal to 18 years old, who have had a response or maintained stable disease after undergoing no more that 4 cycles with platinum with etoposide chemotherapy|Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC|Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|16|Actual|University of Michigan Cancer Center|The trial was to be terminated at stage 1 if less than, or equal to, 8 patients were progression free at 4 months. The PFS rate did not reach the threshold required for study continuation and, therefore, the study was discontinued early.|1|||f||||t||||||||||2018-06-01 02:27:32.568653|2018-06-01 02:27:32.568653
NCT00616096|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2010-01-27|2008-02-05|2008-02-15|Estimate|||||||2010-01-27|2010-01-28|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels|Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels|Completed||N/A|10|Actual|University of Luebeck||1|||f||||f||||||||||2018-06-01 02:27:32.783878|2018-06-01 02:27:32.783878
NCT00616083|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2009-08-19|2008-02-14|2008-02-15|Estimate|||||||2009-08-19|2009-08-20|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|PeaPod||Percent Body Fat in Breast Fed Infants|Developing Normative Body Composition Data in Early Infancy|Completed|||190|Actual|Arkansas Children's Hospital Research Institute|||1||f||||f||||||||||2018-06-01 02:27:32.851936|2018-06-01 02:27:32.851936
NCT00616070|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2011-06-29|2008-02-04|2008-02-15|Estimate|||||||2011-06-29|2011-06-30|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)||Completed||Phase 3|120|Anticipated|Sirion Therapeutics, Inc.||2|||f||||||||||||||2018-06-01 02:27:32.909023|2018-06-01 02:27:32.909023
NCT00616057|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2012-07-04|2008-02-04|2008-02-15|Estimate|||||||2012-07-04|2012-07-06|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|FRUCTOB||Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome|Evaluation of Fructans Supplementation on Parameters of Metabolic Syndrome|Completed||N/A|34|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-06-01 02:27:33.069463|2018-06-01 02:27:33.069463
NCT00616044|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-02-14|2008-02-14|2008-02-15|Estimate|||||||2008-02-14|2008-02-15|Estimate|March 2008||2008-03-31|January 2008|2008-01-31|January 2009|Anticipated|2009-01-31|February 2008|Anticipated|2008-02-29||Interventional|Spinocath||Continuous Spinal Anesthesia Versus Combined Spinal Epidural Block|Continuous Spinal Anesthesia Versus Combined Spinal Epidural Block for Major Orthopedic Surgeries. Study Prospective and Randomized.|Unknown status|Not yet recruiting|N/A|240|Anticipated|Sao Jose do Rio Preto Medical School||2|||f||||f||||||||||2018-06-01 02:27:33.142857|2018-06-01 02:27:33.142857
NCT00616031|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-14|||2013-08-09|2008-02-14|2008-02-15|Estimate|||||||2013-08-09|2013-08-12|Estimate|January 2008||2008-01-31|July 2009|2009-07-31||||December 2011|Anticipated|2011-12-31||Interventional|||Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:27:33.229345|2018-06-01 02:27:33.229345
NCT00616018|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2011-03-03||2012-07-10|2008-02-04|2008-02-14|Estimate|2012-07-10|2012-07-12|Estimate||||2012-07-10|2012-07-12|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|Non-Drinker||Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days|Acetaminophen Adduct Formation in Alcohol Abstaining Subjects Administered Therapeutic Doses of Acetaminophen for Ten Consecutive Days|Completed||Phase 4|35|Actual|Denver Health and Hospital Authority|One limitation is that this study did not include a placebo group. The study was limited to healthy volunteers. The ingestion of each dose and use of other medications was self-reported.|1|||f||||t||||||||||2018-06-01 02:27:33.300025|2018-06-01 02:27:33.300025
NCT00616005|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-03|||2014-08-14|2008-02-13|2008-02-14|Estimate|||||||2014-08-14|2014-08-18|Estimate|November 2005||2005-11-30|August 2010|2010-08-31|June 2009|Actual|2009-06-30|July 2007|Actual|2007-07-31||Interventional|||Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide|Phase II Treatment of Adults With Primary Malignant Glioma With Irinotecan Plus Temozolomide|Completed||Phase 2|41|Anticipated|Duke University||2|||f||||t||||||||||2018-06-01 02:27:33.452073|2018-06-01 02:27:33.452073
NCT00615992|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2009-06-30||2016-01-13|2008-02-13|2008-02-14|Estimate|2009-11-17|2009-12-24|Estimate||||2016-01-13|2016-02-08|Estimate|April 2007||2007-04-30|January 2016|2016-01-31||||April 2008|Actual|2008-04-30||Observational|||Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines|Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines|Completed|||754|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:27:33.535693|2018-06-01 02:27:33.535693
NCT00615979|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-01-26|2008-02-13|2008-02-14|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2002|Actual|2002-10-31|January 2017|2017-01-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Observational|||Far Forward Battlefield Telemedicine: Evaluation of Handheld Ultrasound|Far Forward Battlefield Telemedicine:Ultrasound Guidance System (UGS)|Completed|||120|Actual|The Cleveland Clinic|||1||f||||f|f|t|f|f|t|||No||2018-06-01 02:27:33.783797|2018-06-01 02:27:33.783797
NCT00615966|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01||2011-06-07|2011-06-24|2008-02-01|2008-02-14|Estimate||||2011-06-07|2011-06-21|Estimate|2011-06-24|2011-06-29|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|February 2010|Actual|2010-02-28|January 2009|Actual|2009-01-31||Interventional|||Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients|A Phase 2, Two-Part Study of the Safety and Tolerability of Diannexin in Kidney Transplant Recipients|Completed||Phase 2|58|Actual|Alavita Pharmaceuticals Inc||3|||f||||t||||||||||2018-06-01 02:27:33.84158|2018-06-01 02:27:33.84158
NCT00615940|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01||2014-01-28|2014-01-28|2008-02-01|2008-02-14|Estimate||||2014-01-28|2014-02-28|Estimate|2014-01-28|2014-02-28|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer|A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer|Completed||Phase 2|132|Actual|Wilex||2|||f||||f||||||||||2018-06-01 02:27:34.821342|2018-06-01 02:27:34.821342
NCT00615927|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-03|2012-12-31||2013-03-13|2008-02-13|2008-02-14|Estimate|2013-03-13|2013-03-15|Estimate||||2013-03-13|2013-03-15|Estimate|February 2006||2006-02-28|December 2012|2012-12-31|June 2012|Actual|2012-06-30|April 2009|Actual|2009-04-30||Interventional|||Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)|Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma|Completed||Phase 2|64|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:27:34.978438|2018-06-01 02:27:34.978438
NCT00615914|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-09-08||2014-06-10|2008-02-13|2008-02-14|Estimate|2010-10-26|2010-11-23|Estimate||||2014-06-10|2014-07-11|Estimate|February 2004||2004-02-29|June 2014|2014-06-30||||March 2009|Actual|2009-03-31||Observational||Data set for safety analysis - The number of patients enrolled was 1645. The number of case report forms which were collected was 1581. Moreover the number of patients analyzed as safety analysis was 1553 because 28 patients were excluded due to protocol violations.|Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole|Pramipexole Special Survey on Long-Term Use|Completed|||1645|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:27:35.420048|2018-06-01 02:27:35.420048
NCT00615901|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2015-12-23||2017-01-11|2008-02-13|2008-02-14|Estimate|2017-01-11|2017-03-03|Actual||||2017-01-11|2017-03-03|Actual|January 2008||2008-01-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer|Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer|Completed||N/A|38|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:27:37.00865|2018-06-01 02:27:37.00865
NCT00615888|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2010-01-13|2008-02-01|2008-02-14|Estimate|||||||2010-01-13|2010-01-14|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Fast Track Management in Elective Open Infrarenal Aortic Aneurysm Repair|Prospective Randomized Controlled Trial to Evaluate Fast Track Recovery in Elective Open Infrarenal Aortic Aneurysm Repair|Completed||N/A|100|Actual|University of Ulm||2|||f||||t||||||||||2018-06-01 02:27:37.159733|2018-06-01 02:27:37.159733
NCT00615875|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2008-02-01|2008-02-01|2008-02-14|Estimate|||||||2008-02-01|2008-02-14|Estimate|March 2008||2008-03-31|January 2008|2008-01-31|June 2008|Anticipated|2008-06-30|May 2008|Anticipated|2008-05-31||Interventional|NAPS||Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial|Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial|Unknown status|Not yet recruiting|Phase 4|24|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 02:27:37.230517|2018-06-01 02:27:37.230517
NCT00615862|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2012-02-21|2008-02-13|2008-02-14|Estimate|||||||2012-02-21|2012-02-22|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis|Relationship Between Alcohol Use Disorders and Cortisol Levels in Patients With Sepsis|Completed|||40|Anticipated|Virginia Commonwealth University|||1||f||||f||||||Samples Without DNA|"~     1. Diagnosis of alcohol use disorders will be made through the use of a validated~          questionnaire.~        2. Blood collected as part of routine patient care (and that is destined to be discarded)~          will be evaluated for a number of immune markers. Cortisol levels measured as part of~          routine care will be recorded.~        3. Delirium will be assessed through the use of a validated instrument.~   "|||2018-06-01 02:27:37.41971|2018-06-01 02:27:37.41971
NCT00615849|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2011-09-28|2008-02-01|2008-02-14|Estimate|||||||2011-09-28|2011-09-30|Estimate|November 2006||2006-11-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy of the Additional Mechanical Pleurodesis for Surgical Management of Primary Spontaneous Pneumothorax|Phase III Study of Evaluation of the Efficacy of Additional Mechanical Pleurodesis After Thoracoscopic Wedge Resection for the Management of Primary Spontaneous Pneumothorax|Completed||Phase 3|1440|Actual|Seoul National University Bundang Hospital|||||f||||t||||||||||2018-06-01 02:27:37.524637|2018-06-01 02:27:37.524637
NCT00615836|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2015-06-23|2010-10-04|2015-11-11|2008-02-04|2008-02-14|Estimate|2015-11-11|2015-12-15|Estimate|2010-10-04|2010-10-05|Estimate|2015-11-11|2015-12-15|Estimate|December 2007||2007-12-31|November 2015|2015-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Demographic data provided for the Efficacy Analysis Dataset, which consisted of the intent-to-treat population from CS29 (all randomized patients who received at least 1 dose of study drug and provided at least 1 primary efficacy measure during Part I) who were on active treatment (i.e., placebo participants are not included).|"An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (Melt) Formulation of Desmopressin for the Treatment of Nocturia in Adults"|"A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving (Melt) Formulation of Desmopressin for the Treatment of Nocturia in Adults"|Completed||Phase 3|554|Actual|Ferring Pharmaceuticals||4|||f||||t||||||||||2018-06-01 02:27:37.685557|2018-06-01 02:27:37.685557
NCT00615823|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2012-02-22|2008-02-13|2008-02-14|Estimate|||||||2012-02-22|2012-02-23|Estimate|February 2007||2007-02-28|February 2012|2012-02-29|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|APATH||Atorvastatin in Pulmonary Hypertension|Clinical Effect and Tolerability of Atorvastatin Versus Placebo in Patients With Pulmonary Hypertension: Double-blinded, Randomised, Prospective Phase II Study for 6 Months With Adjusted Doses of Atorvastatin|Completed||Phase 2|220|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-06-01 02:27:39.232045|2018-06-01 02:27:39.232045
NCT00615810|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2010-07-30|2008-02-13|2008-02-14|Estimate|||||||2010-07-30|2010-08-02|Estimate|March 2008||2008-03-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|ROCKET I||ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial|A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching From a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raised Cholesterol|Completed||Phase 4|159|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 02:27:39.393593|2018-06-01 02:27:39.393593
NCT00615797|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2014-12-03|2008-02-13|2008-02-14|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2002||2002-05-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea|Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea|Completed||N/A|20|Actual|University of Cape Town||2|||f||||f||||||||||2018-06-01 02:27:39.480877|2018-06-01 02:27:39.480877
NCT00615784|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2016-09-23|2008-02-01|2008-02-14|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2008||2008-01-31|September 2016|2016-09-30||||October 2013|Actual|2013-10-31||Interventional|UPCC 04407||Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia|A Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia|Active, not recruiting||Phase 2|25|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||f||||||||||2018-06-01 02:27:39.571354|2018-06-01 02:27:39.571354
NCT00615771|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2016-11-23|2008-02-01|2008-02-14|Estimate|||||||2016-11-23|2016-11-28|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Day of Embryo Transfer for Patients Undergoing In Vitro Fertilization|Embryo Transfer on Day 2 vs. Day 3 After Oocyte Retrieval in Patients Who Plan to Replace All Embryos After an In Vitro Fertilization Cycle|Completed||N/A|242|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 02:27:39.637854|2018-06-01 02:27:39.637854
NCT00615758|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2009-12-14|2008-02-01|2008-02-14|Estimate|||||||2009-12-14|2009-12-15|Estimate|October 2006||2006-10-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV|ERLOTINIB, A TYROSINE KINASE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AS FIRST LINE TREATMENT, IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC). A PHASE II STUDY|Completed||Phase 2|50|Anticipated|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-06-01 02:27:39.701777|2018-06-01 02:27:39.701777
NCT00615745|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2011-11-18|2008-02-13|2008-02-14|Estimate|||||||2011-11-18|2011-11-21|Estimate|April 2008||2008-04-30|November 2011|2011-11-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|ONCE||ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla|A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla (Efavirenz/Emtricitabine/Tenofovir DF) on an Empty Stomach|Completed||Phase 4|115|Actual|Gilead Sciences||1|||f||||f||||||||||2018-06-01 02:27:39.78957|2018-06-01 02:27:39.78957
NCT00615732|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2012-07-09|2008-02-01|2008-02-14|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Interventional|QENA||Qigong and Exercise for Neck Pain in Adults (QENA)|Prospective, Randomized Controlled Trial on the Effectiveness of Qigong and Exercise Therapy in Patients With Chronic Neck Pain|Completed||N/A|123|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-06-01 02:27:39.871125|2018-06-01 02:27:39.871125
NCT00615719|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2011-08-15||2011-12-07|2008-02-01|2008-02-14|Estimate|2011-12-07|2011-12-08|Estimate||||2011-12-07|2011-12-08|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|EDCCTA||Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation|Utility of 64-slice Multidetector CT Coronary Angiography in the Evaluation of Low to Intermediate Risk ED Patients|Terminated|||35|Actual|Virginia Commonwealth University|Early termination leading to small numbers of subjects analyzed||1|Enrollment rate was too slow.|f||||f||||||||||2018-06-01 02:27:39.96986|2018-06-01 02:27:39.96986
NCT00615706|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-09-22|2008-02-04|2008-02-14|Estimate|||||||2008-09-22|2008-09-23|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|ABI/BALA||Study to Evaluate the Impact of Obesity on Airway Inflammation and Mechanics in Asthmatics||Completed|||300|Anticipated|Emory University|||2||f||||f||||||Samples With DNA|"~     Serum, urine, DNA, exhaled breath condensate. For substudy participants, bronchoalveolar~     lavage samples.~   "|||2018-06-01 02:27:40.114214|2018-06-01 02:27:40.114214
NCT00615693|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2017-02-21|2008-02-13|2008-02-14|Estimate|||||||2017-02-21|2017-02-23|Actual|July 2008||2008-07-31|February 2017|2017-02-28||||October 2009|Actual|2009-10-31||Interventional|||Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis|A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis|Completed||Phase 2|13|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:27:40.18376|2018-06-01 02:27:40.18376
NCT00615667|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2016-04-19|2008-02-01|2008-02-14|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)||Completed||Phase 3|61|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-06-01 02:27:40.289077|2018-06-01 02:27:40.289077
NCT00615654|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2008-10-17|2008-02-13|2008-02-14|Estimate|||||||2008-10-17|2008-10-20|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|February 2007|Actual|2007-02-28||Interventional|||Aquatic Physical Therapy in Fibromyalgia|A Randomized Clinical Trial of Aquatic Physiotherapy Program on Functional Capacity in Patients With Fibromyalgia.|Completed||Phase 3|40|Actual|Sao Camilo University Center||1|||f||||t||||||||||2018-06-01 02:27:40.363732|2018-06-01 02:27:40.363732
NCT00615641|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2010-02-12|2008-02-13|2008-02-14|Estimate|||||||2010-02-12|2010-02-17|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Diet, Exercise and Body Fat in 3-5 Year Olds|Relationship of Dietary Factors and Physical Activity to Body Fat in 3-5 Year Old Children|Completed|||65|Anticipated|Arkansas Children's Hospital Research Institute|||3||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-06-01 02:27:40.435896|2018-06-01 02:27:40.435896
NCT00615628|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2013-05-29|2008-02-13|2008-02-14|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2002||2002-04-30|May 2013|2013-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18:|Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: Examination of Osteosarcoma Tissue Samples From Two Family Members for Loss of Heterozygosity in the Chromosome 18 Region, Genetically Linked With Paget's Disease of Bone|Terminated|||8|Actual|State University of New York - Upstate Medical University|||1|low enrollment low enrollment|f||||f||||||Samples With DNA|"~     Once a specimen is obtained DNA will be isolated for paraffin-embedded tissue and peripheral~     blood. Osteosarcoma samples from paraffin embedded, formalin-fixed post-surgical tissue~     samples will be obtained for the proband and father. Matched normal spamples will be obtained~     from these individuals as adjacent normal tissue from the post-surgical specimens~   "|||2018-06-01 02:27:40.504394|2018-06-01 02:27:40.504394
NCT00615615|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2013-09-16|2008-02-01|2008-02-14|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 1999||1999-09-30|September 2009|2009-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures|Evaluation of the Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures: A 28-Week Double-Blind, Placebo-Controlled Multi-center Trial|Completed||Phase 3|216|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:27:40.564638|2018-06-01 02:27:40.564638
NCT00615433|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2010-11-08||2015-05-19|2008-02-13|2008-02-14|Estimate|2011-01-17|2011-02-14|Estimate||||2015-05-19|2015-06-12|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia|A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia.|Completed||Phase 3|478|Actual|Sunovion||4|||f||||t||||||||||2018-06-01 02:27:43.090153|2018-06-01 02:27:43.090153
NCT00615602|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2015-03-03|2008-02-01|2008-02-14|Estimate|||||||2015-03-03|2015-03-04|Estimate|October 2004||2004-10-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer|A Multicenter Randomized Phase III Study Comparing 6 Versus 12 Months of Trastuzumab in Combination With Dose Dense Docetaxel Following FE75C as Adjuvant Treatment of Women With Axillary Lymph Node Positive Breast Cancer Over-expressing HER2|Completed||Phase 3|489|Actual|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 02:27:40.630397|2018-06-01 02:27:40.630397
NCT00615589|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2014-12-03||2016-03-03|2008-02-13|2008-02-14|Estimate|2014-12-03|2014-12-11|Estimate||||2016-03-03|2016-04-04|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen|Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen|Terminated||Phase 2|22|Actual|University of Michigan Cancer Center||1||Low accrual|f||||t||||||||||2018-06-01 02:27:40.828067|2018-06-01 02:27:40.828067
NCT00615576|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2017-08-04|2008-02-01|2008-02-14|Estimate|||||||2017-08-04|2017-08-08|Actual|March 26, 2008|Actual|2008-03-26|August 2017|2017-08-31|July 24, 2008|Actual|2008-07-24|July 24, 2008|Actual|2008-07-24||Interventional|||Repeat Dose Study in Male Healthy Volunteer Smokers|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SB-656933 Following 14 Days Repeat Dosing in Healthy Male Smokers|Completed||Phase 1|13|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:27:41.063145|2018-06-01 02:27:41.063145
NCT00615563|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2013-11-20|2008-02-13|2008-02-14|Estimate|||||||2013-11-20|2013-11-21|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|January 2008||2008-01-31|January 2008|Actual|2008-01-31||Observational|||Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)|Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)|Completed|||246|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-06-01 02:27:41.13861|2018-06-01 02:27:41.13861
NCT00615550|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2012-02-24||2012-02-27|2008-02-01|2008-02-14|Estimate|2012-02-27|2012-03-13|Estimate||||2012-02-27|2012-03-13|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||PREGNANT Short Cervix Trial|The Effect of Vaginal Progesterone Administration in the Prevention of Preterm Birth in Women With a Short Cervix [Vaginal Progesterone Bioadhesive Gel (Prochieve)® Extending Gestation A New Therapy for Short Cervix - Trial (PREGNANT Short Cervix - Trial)]|Completed||Phase 3|465|Actual|Juniper Pharmaceuticals, Inc.|Trial not powered for subgroup analysis.|2|||f||||t||||||||||2018-06-01 02:27:41.341947|2018-06-01 02:27:41.341947
NCT00615537|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-03|||2011-04-04|2008-02-13|2008-02-14|Estimate|||||||2011-04-04|2011-04-05|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses|Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses|Completed||N/A|20|Anticipated|BioTex, Inc.|||||f||||t||||||||||2018-06-01 02:27:42.058343|2018-06-01 02:27:42.058343
NCT00615524|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2018-01-10|2008-02-01|2008-02-14|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2008||2008-04-30|January 2018|2018-01-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Compare the Efficacy and Tolerability of Pazopanib Administered in Combination With Exemestane Versus Exemestane Plus Placebo in Postmenopausal Subjects With Advanced or Metastatic Hormone Receptor Positive Breast Cancer|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||||Cancelled Before Enrollment|f||||||||||||||2018-06-01 02:27:42.130136|2018-06-01 02:27:42.130136
NCT00615511|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2015-12-18|2008-02-13|2008-02-14|Estimate|||||||2015-12-18|2015-12-21|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy of Pregnenolone in Patients With Schizophrenia|Efficacy of Pregnenolone in Patients With Schizophrenia|Completed||Phase 2|100|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:27:42.206758|2018-06-01 02:27:42.206758
NCT00615498|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2013-07-30|2008-02-04|2008-02-14|Estimate|||||||2013-07-30|2013-07-31|Estimate|July 2006||2006-07-31|July 2013|2013-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Study to Evaluate the Effects of Weight Loss on Airway Inflammation and Mechanics in Subjects With Asthma (Asthma-Bariatric Surgery Study)|Study to Evaluate the Effects of Weight Loss on Airway Inflammation and Mechanics in Subjects With Asthma|Completed|||80|Anticipated|Emory University|||2||f||||f||||||Samples With DNA|"~     Blood and exhaled breath condensate samples will obtained at all time points (baseline, 1~     month, 6 months, and 1 year.~   "|||2018-06-01 02:27:42.280919|2018-06-01 02:27:42.280919
NCT00615485|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2013-05-29|2008-02-13|2008-02-14|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2006||2006-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Longitudinal Study of Bone Mineral Density in Survivors of Solid Pediatric Cancers|Longitudinal Study of Bone Mineral Density in Survivors of Solid Pediatric Cancers|Completed|||38|Actual|State University of New York - Upstate Medical University|||||f||||f||||||Samples Without DNA|"~     bone specific alkaline phosphatase n-telopeptide~   "|||2018-06-01 02:27:42.348595|2018-06-01 02:27:42.348595
NCT00615472|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2015-06-02||2015-06-19|2008-02-01|2008-02-14|Estimate|2015-06-19|2015-07-13|Estimate||||2015-06-19|2015-07-13|Estimate|October 2003||2003-10-31|June 2015|2015-06-30|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional||Patients had neuropsychometric analysis before and after procedure.|Intravenous Versus Inhalational Anesthesia in Parkinson's Disease|Intravenous General Anesthesia Versus Inhalational General Anesthesia in Parkinson's Disease|Terminated||N/A|58|Actual|Columbia University||2||Lack of funding|f||||f||||||||||2018-06-01 02:27:42.411005|2018-06-01 02:27:42.411005
NCT00615459|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2011-07-22||2011-07-22|2008-02-01|2008-02-14|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control|A Phase III, Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, 3-period Incomplete Block, Multidose Crossover Study to Determine the Effect on Lung Function of Indacaterol (150 and 300 μg o.d.) in Patients With Moderate to Severe COPD, Using Tiotropium (18 μg o.d.) as an Active Control|Completed||Phase 3|169|Actual|Novartis||4|||f||||f||||||||||2018-06-01 02:27:42.644283|2018-06-01 02:27:42.644283
NCT00615446|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2010-04-29|2008-02-01|2008-02-14|Estimate|||||||2010-04-29|2010-04-30|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors|A Phase 1 Study Of SU011248 And Gemcitabine In Patients With Advanced Solid Tumors|Completed||Phase 1|44|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:27:42.915305|2018-06-01 02:27:42.915305
NCT00615420|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2012-05-22|2008-02-13|2008-02-14|Estimate|||||||2012-05-22|2012-05-24|Estimate|July 2008||2008-07-31|May 2012|2012-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer|A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer|Completed||Phase 3|106|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-06-01 02:27:43.712106|2018-06-01 02:27:43.712106
NCT00615407|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2013-11-14|2008-02-04|2008-02-14|Estimate|||||||2013-11-14|2013-11-18|Estimate|January 2007||2007-01-31|November 2013|2013-11-30||||||||Observational|AIM Asthma||A Pilot Evaluation of the Impact of Alcohol Use on Airway Inflammation and Mechanics in Asthmatics||Withdrawn|||0|Actual|Emory University|||2|Dr. Holguin is relocating.|f||||f||||||Samples With DNA|"~     Blood, urine, and exhaled breath condensate~   "|||2018-06-01 02:27:43.795569|2018-06-01 02:27:43.795569
NCT00615394|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2008-02-01|2008-02-01|2008-02-14|Estimate|||||||2008-02-01|2008-02-14|Estimate|April 2004||2004-04-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|STEMDILCARD||Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy|Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy in Dilated Cardiomyopathy - Technique and Early Results|Completed||Phase 1/Phase 2|6|Actual|Instituto de Cardiologia do Rio Grande do Sul|||||f||||t||||||||||2018-06-01 02:27:43.851593|2018-06-01 02:27:43.851593
NCT00615381|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2015-04-21|2008-02-01|2008-02-14|Estimate|||||||2015-04-21|2015-04-23|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Supraphysiologic Insulin to Improve Outcomes After Surgical Treatment of Unruptured Cerebral Aneurysms|Clinical Trial of Euglycemia Maintenance With Supraphysiologic Insulin vs Conventional Intensive Insulin Therapy to Improve Outcomes (Neurologic, Neuropsychiatric, and Biomarkers) After Surgical Treatment of Unruptured Cerebral Aneurysms|Withdrawn||N/A|0|Actual|Northwestern University||2||Study was not initiated and has been withdrawn due to lack of appropriate cases|f||||f||||||||||2018-06-01 02:27:43.917278|2018-06-01 02:27:43.917278
NCT00615368|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2015-08-20|2008-02-01|2008-02-14|Estimate|||||||2015-08-20|2015-08-24|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Treatment With Erythropoietin and Cognition During Hypoglycaemia|The Effect of Intravenous Erythropoietin Treatment on Cognition During Hypoglycemia in Patients With Type 1 Diabetes.|Completed||N/A|11|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-06-01 02:27:44.004415|2018-06-01 02:27:44.004415
NCT00615355|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-02|||2017-01-11|2008-02-02|2008-02-14|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2008||2008-02-29|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Epidermal Cell Transplantation in Vitiligo Skin With and Without Narrow-band Ultraviolet B (UVB) Treatment|Efficacy of Narrow-band UVB Treatment After Transplantation of Harvested Epidermal Cells in Vitiligo|Completed||N/A|11|Actual|Medical University of Graz||2|||f||||f||||||||||2018-06-01 02:27:44.107185|2018-06-01 02:27:44.107185
NCT00615342|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-02-17|2008-02-13|2008-02-14|Estimate|||||||2015-02-17|2015-02-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:27:44.194873|2018-06-01 02:27:44.194873
NCT00615329|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2014-11-24|2008-02-13|2008-02-14|Estimate|||||||2014-11-24|2014-11-25|Estimate|April 2003||2003-04-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Huntsman Biopsy Study|The Huntsman Cancer Institute - The Use of Microarray Analysis in Characterizing Mesenchymal Tissue Tumors: Differentiation of Normal, Benign, and Malignant Conditions|Terminated|||142|Actual|State University of New York - Upstate Medical University|||1|Huntmans Cancer Institute terminated study|f||||f||||||Samples With DNA|"~     cDNA microarrays facilitate the systematic and comprehensive analysis of transcriptional~     alterations occurring in diseased tissues.~   "|||2018-06-01 02:27:44.236397|2018-06-01 02:27:44.236397
NCT00615316|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-02-13|2008-02-13|2008-02-14|Estimate|||||||2008-02-13|2008-02-14|Estimate|December 2006||2006-12-31|February 2008|2008-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Guaraná for Radiation Related Fatigue in Breast Cancer Patients|"Guaraná (Paullinia Cupana) for Radiation Related Fatigue in Breast Cancer Patients: Results Of A Pilot Double Blind Randomized Study"|Completed||Phase 2|36|Actual|Faculdade de Medicina do ABC||2|||f||||t||||||||||2018-06-01 02:27:44.305854|2018-06-01 02:27:44.305854
NCT00615303|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2013-02-21|2008-02-01|2008-02-14|Estimate|||||||2013-02-21|2013-02-22|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effectiveness of Simethicone In Improving Visibility During Colonoscopy|The Effectiveness of Simethicone In Improving Visibility During Colonoscopy: A Randomized, Placebo-controlled Study|Completed||Phase 4|194|Actual|Ramathibodi Hospital||2|||f||||f||||||||||2018-06-01 02:27:44.37723|2018-06-01 02:27:44.37723
NCT00615290|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-02-03||2014-08-06|2008-02-13|2008-02-14|Estimate|2010-02-03|2010-02-23|Estimate||||2014-08-06|2014-08-08|Estimate|June 2007||2007-06-30|August 2014|2014-08-31||||May 2009|Actual|2009-05-31||Observational||All enrolled patients|Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy|Pharmaco-epidemiological Description of the Patient Population Treated With Aptivus Under Market Conditions, Safety & Efficacy|Completed|||42|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:27:44.465793|2018-06-01 02:27:44.465793
NCT00615277|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2008-02-13|2008-02-13|2008-02-14|Estimate|||||||2008-02-13|2008-02-14|Estimate|October 2006||2006-10-31|February 2008|2008-02-29||||January 2007|Actual|2007-01-31||Interventional|||The Effect of Long-Chain Polyunsaturated Fatty Acids on Cognitive Performance and Mood|The Effect of Long-Chain Polyunsaturated Fatty Acids on Cognitive Performance and Mood of Healthy Young Adults|Completed||N/A|82|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 02:27:44.698688|2018-06-01 02:27:44.698688
NCT00615264|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2015-11-16||2016-05-25|2008-02-13|2008-02-14|Estimate|2016-05-25|2016-06-06|Estimate||||2016-05-25|2016-06-06|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|DIA-AID||Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients|A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277® in Newly Diagnosed Type 1 Diabetes Patients|Completed||Phase 3|457|Actual|Andromeda Biotech Ltd.||2|||f||||t||||||||||2018-06-01 02:27:44.780476|2018-06-01 02:27:44.780476
NCT00615251|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04||2011-06-08|2013-08-30|2008-02-04|2008-02-14|Estimate||||2011-06-08|2011-06-22|Estimate|2013-08-30|2013-09-13|Estimate|February 2008||2008-02-29|August 2013|2013-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization|A Phase 3, Single-Blind, Randomized Study to Compare DR-2011 to a Progesterone Gel for Luteal Phase Supplementation for In Vitro Fertilization|Completed||Phase 3|1297|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 02:27:45.247486|2018-06-01 02:27:45.247486
NCT00615238|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-12|||2017-09-26|2008-02-12|2008-02-14|Estimate|||||||2017-09-26|2017-09-28|Actual|April 2000||2000-04-30|March 2010|2010-03-31|May 2004|Actual|2004-05-31|March 2004|Actual|2004-03-31||Interventional|CHANGE||Physical Activity in the Treatment of Obesity|Physical Activity in the Treatment of Obesity: A Randomized Trial|Completed||N/A|177|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||f||||||||||2018-06-01 02:27:45.352249|2018-06-01 02:27:45.352249
NCT00615225|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-02-13|2008-02-13|2008-02-14|Estimate|||||||2008-02-13|2008-02-14|Estimate|January 2000||2000-01-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Observational|||Brain Death: Inflammatory Response, Apoptosis, and Endotoxin Tolerance|Observational Study on the Systemic Inflammatory Response During Brain Death.|Completed|||||Delafontaine Hospital|||3||f||||f||||||||||2018-06-01 02:27:45.431991|2018-06-01 02:27:45.431991
NCT00615212|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2017-09-08|2008-02-01|2008-02-14|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2, 2008|Actual|2008-01-02|September 2017|2017-09-30|February 15, 2008|Actual|2008-02-15|February 15, 2008|Actual|2008-02-15||Interventional|||Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects|A Single Center, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK376501 on Hepatic Cytochrome P450 Activity in Healthy Adult Subjects|Completed||Phase 1|23|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-06-01 02:27:45.509781|2018-06-01 02:27:45.509781
NCT00615199|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2012-11-28|2011-03-24|2013-01-18|2008-02-01|2008-02-14|Estimate|2012-11-28|2012-12-31|Estimate|2011-03-24|2011-04-01|Estimate|2013-01-18|2013-01-25|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Safety And Efficacy Of CP-690,550 In Subjects With Moderate To Severe Crohn's Disease.|Completed||Phase 2|139|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:27:45.694252|2018-06-01 02:27:45.694252
NCT00615186|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2011-02-08|2008-02-01|2008-02-14|Estimate|||||||2011-02-08|2011-02-10|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|Glass-Art||Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy|A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Terminated||Phase 3|9|Actual|Bradmer Pharmaceuticals Inc.||2||Due to delay in site initiation and funding considerations|f||||t||||||||||2018-06-01 02:27:46.83956|2018-06-01 02:27:46.83956
NCT00615173|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2008-10-27|2008-02-01|2008-02-14|Estimate|||||||2008-10-27|2008-10-29|Estimate|July 2006||2006-07-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis||Completed||Phase 3|81|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:27:46.921139|2018-06-01 02:27:46.921139
NCT00615160|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-01-11|2008-02-01|2008-02-14|Estimate|||||||2011-01-11|2011-01-12|Estimate|December 2006||2006-12-31|December 2007|2007-12-31||||September 2008|Actual|2008-09-30||Interventional|||PTK/ZK in Disseminated Malignant Melanoma|Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma|Suspended||Phase 1/Phase 2|30|Anticipated|University of Schleswig-Holstein||2||Substance was withdrawn from further development.|f||||t||||||||||2018-06-01 02:27:47.018583|2018-06-01 02:27:47.018583
NCT00615147|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2012-01-06|2008-02-13|2008-02-14|Estimate|||||||2012-01-06|2012-01-09|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population|Accuracy of the D-Dimer Assay for the Exclusion of Pulmonary Embolism in a High Risk Oncologic Population: A Correlation With Ct Pulmonary Angiogram in the Urgent Care Setting|Completed|||213|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:27:47.116874|2018-06-01 02:27:47.116874
NCT00615134|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2015-01-19|2008-02-13|2008-02-14|Estimate|||||||2015-01-19|2015-01-27|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.|A Randomized, Open-label Study Evaluating the Antiviral Activity and Safety of 3 Month Fuzeon Induction With an Optimized Background Antiretroviral Regimen Versus OB Alone, in Fuzeon-naive HIV-1 Infected Patients With Virological Failure.|Completed||Phase 2|29|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:27:47.206495|2018-06-01 02:27:47.206495
NCT00615121|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-03|||2016-01-21|2008-02-03|2008-02-14|Estimate|||||||2016-01-21|2016-01-25|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Genetics of Peripheral Artery Genomics|Genetics of Peripheral Artery Disease|Completed|||122|Actual|Duke University|||2||f||||f||||||Samples With DNA|"~     Peripheral artery samples collected from patients are stored in -80celcius refrigerator for~     future analysis.~   "|||2018-06-01 02:27:47.301132|2018-06-01 02:27:47.301132
NCT00615108|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2009-12-16||2014-02-28|2008-02-13|2008-02-14|Estimate|2009-12-16|2010-01-26|Estimate||||2014-02-28|2014-04-07|Estimate|December 2006||2006-12-31|February 2014|2014-02-28||||December 2008|Actual|2008-12-31||Observational|||Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters|Safety and Effectiveness of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertension Patients|Completed|||3148|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:27:47.439787|2018-06-01 02:27:47.439787
NCT00615095|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2011-04-19|2008-02-01|2008-02-14|Estimate|||||||2011-04-19|2011-04-20|Estimate|February 1997||1997-02-28|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Differential Risks for Melanoma: p16 and DNA Repair|Differential Risks for Melanoma: p16 and DNA Repair|Completed|||323|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:27:47.700256|2018-06-01 02:27:47.700256
NCT00615082|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2011-09-06|2008-02-01|2008-02-14|Estimate|||||||2011-09-06|2011-09-08|Estimate|February 2007||2007-02-28|September 2011|2011-09-30|March 2011|Actual|2011-03-31|May 2009|Actual|2009-05-31||Interventional|Balance||The Balance Study Balancing Life and Reducing Stress For Those Providing Elder Care|Stress Reduction for Caregivers: A Randomized Controlled Pilot Study|Completed||N/A|78|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-06-01 02:27:47.784499|2018-06-01 02:27:47.784499
NCT00615069|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-03-26||2015-03-23|2008-02-01|2008-02-14|Estimate|2009-05-18|2009-07-09|Estimate||||2015-03-23|2015-04-14|Estimate|May 2006||2006-05-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|March 2008|Actual|2008-03-31||Interventional|||Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms|A Clinical Study Evaluating the Use of the GORE EXCLUDER® AAA Endoprosthesis - 31mm In the Primary Treatment of Infrarenal Abdominal Aortic Aneurysms|Completed||Phase 2|35|Actual|W.L.Gore & Associates||1|||f||||f||||||||||2018-06-01 02:27:47.862894|2018-06-01 02:27:47.862894
NCT00615056|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2012-03-28||2013-04-12|2008-02-01|2008-02-14|Estimate|2012-03-28|2012-04-20|Estimate||||2013-04-12|2013-04-19|Estimate|March 2008||2008-03-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|||A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen|A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen|Completed||Phase 2|171|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:27:48.140215|2018-06-01 02:27:48.140215
NCT00615043|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2010-12-20|2008-02-01|2008-02-14|Estimate|||||||2010-12-20|2010-12-22|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|||Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure|A Multi Center Study to Obtain Bladder Tissue Specimens From Subjects Undergoing Transurethral Resection of Bladder Tumor (TURBT) or Other Transurethral Biopsy Procedures|Completed|||6|Actual|Tengion|||1||f||||f||||||Samples Without DNA|"~     Tissue~   "|||2018-06-01 02:27:51.298308|2018-06-01 02:27:51.298308
NCT00615030|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2011-07-22||2011-07-22|2008-02-13|2008-02-14|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Randomized, Double Blind, Double Dummy, Placebo Controlled, Multicenter, 4 Treatments, 3 Period Incomplete Block Crossover Study to Assess the Efficacy and Safety of Indacaterol 300 µg o.d. Dosed in the Evening in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Salmeterol 50 µg b.i.d. as Active Control|Completed||Phase 3|96|Actual|Novartis||12|||f||||f||||||||||2018-06-01 02:27:51.400786|2018-06-01 02:27:51.400786
NCT00615017|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2012-11-30||2013-07-19|2008-02-01|2008-02-14|Estimate|2013-07-19|2013-08-22|Estimate||||2013-07-19|2013-08-22|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||AZD9773 Dose Escalation Study|A Placebo-controlled, Double-blind, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients With Severe Sepsis|Completed||Phase 2|70|Actual|AstraZeneca||6|||f||||t||||||||||2018-06-01 02:27:51.964524|2018-06-01 02:27:51.964524
NCT00615004|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2008-02-13|2008-02-13|2008-02-14|Estimate|||||||2008-02-13|2008-02-14|Estimate|January 1997||1997-01-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|CVAcro||Cardiovascular Outcome After Surgery or Somatostatin Analogues|An Observational, Retrospective, Comparative Study to Investigate Differential Outcome on Cardiomyopathy Following Control of Acromegaly After Surgery or Somatostatin Analogues Given as First-Line Therapy|Completed|||215|Actual|Federico II University|||2||f||||f||||||Samples Without DNA|"~     Sera from most patients on a yearly bases are stored in our freezed at minus 80° for eventual~     further studies. No experimental parameters are included in the current study.~   "|||2018-06-01 02:27:54.249283|2018-06-01 02:27:54.249283
NCT00614991|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2015-03-24||2016-01-27|2008-02-13|2008-02-14|Estimate|2016-01-27|2016-01-29|Estimate||||2016-01-27|2016-01-29|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||An Interaction Study to Assess Drug Levels in Healthy Adult Subjects|Steady-State Plasma Amprenavir (APV) and Raltegravir (RTG) Pharmacokinetics After Fosamprenavir (FPV) and Raltegravir (RTG) Are Each Administered Alone Versus in Combination With or Without Ritonavir (RTV) Boosting in Healthy Adult Subjects|Completed||N/A|44|Actual|Garden State Infectious Disease Associates, PA|Data for primary outcomes are not available per intervention . Values reported as means are uncertain measure type (data no longer available).|6|||f||||f||||||||||2018-06-01 02:27:54.410694|2018-06-01 02:27:54.410694
NCT00614978|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2012-09-18|2008-02-13|2008-02-14|Estimate|||||||2012-09-18|2012-09-19|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|LAPTEM||Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer|Phase 1 Study of the Combination of Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer|Completed||Phase 1|18|Actual|Jules Bordet Institute||1|||f||||f||||||||||2018-06-01 02:27:55.088625|2018-06-01 02:27:55.088625
NCT00614965|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2011-05-20|2008-02-01|2008-02-14|Estimate|||||||2011-05-20|2011-05-23|Estimate|November 2006||2006-11-30|May 2011|2011-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV|A Multicenter Randomized Phase II Study of the Combination of Irinotecan/Cisplatin Versus Pemetrexed/Cisplatin as Second-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|124|Anticipated|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 02:27:55.204461|2018-06-01 02:27:55.204461
NCT00614952|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2016-04-19|2008-02-13|2008-02-14|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|Telesleep||Cost/Effectiveness Analysis of the Respiratory Poligraphy at Home|Diagnostic Validity Study and Cost Analysis of Domiciliary Respiratory|Completed||N/A|320|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||||2018-06-01 02:27:55.308175|2018-06-01 02:27:55.308175
NCT00614939|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-06-07||2011-05-16|2008-02-12|2008-02-13|Estimate|2010-06-07|2010-07-07|Estimate||||2011-05-16|2011-05-19|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment|A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin Compared With Placebo in Adult Patients With Type 2 Diabetes and Renal Impairment (Moderate, Severe, and End-Stage) With an Additional 40-week, Randomized, Double-blind, Placebo-controlled Long-term Observational Period.|Completed||Phase 3|572|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:27:55.512105|2018-06-01 02:27:55.512105
NCT00614926|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-01-12||2012-02-17|2008-01-31|2008-02-13|Estimate|2011-06-27|2011-07-25|Estimate||||2012-02-17|2012-02-20|Estimate|June 2006||2006-06-30|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Modafinil for Treatment of Fatigue in ALS Patients|Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study|Completed||Phase 4|32|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 02:27:56.380818|2018-06-01 02:27:56.380818
NCT00614913|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-06-29||2012-07-16|2008-02-12|2008-02-13|Estimate|2012-07-16|2012-08-20|Estimate||||2012-07-16|2012-08-20|Estimate|May 1998||1998-05-31|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Proton Beam Therapy for Treatment of Hepatocellular Carcinoma|Phase I/II Study of Proton Beam Therapy for Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|76|Actual|Loma Linda University|||||f||||t||||||||||2018-06-01 02:27:56.620679|2018-06-01 02:27:56.620679
NCT00614900|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-09-17|2008-01-31|2008-02-13|Estimate|||||||2012-09-17|2012-09-18|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Prevalence of Pulmonary Hypertension in COPD Patients|Prevalence and Influence of Pulmonary Hypertension in COPD Patients|Completed|||117|Actual|University of Aarhus|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 02:27:56.902775|2018-06-01 02:27:56.902775
NCT00614887|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-02-12|2008-02-12|2008-02-13|Estimate|||||||2008-02-12|2008-02-13|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|November 2006|Actual|2006-11-30||Observational|SAHENDO||Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage|Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage|Completed|||46|Actual|Kuopio University Hospital|||2||f||||t||||||Samples Without DNA|"~     serum and plasma samples~   "|||2018-06-01 02:27:56.963436|2018-06-01 02:27:56.963436
NCT00614874|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2011-06-17||2011-09-01|2008-02-12|2008-02-13|Estimate|2011-09-01|2011-09-02|Estimate||||2011-09-01|2011-09-02|Estimate|December 2008||2008-12-31|September 2011|2011-09-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||The Use of Rosiglitazone to Treat Asthma|The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity|Completed||Phase 2|16|Actual|Creighton University|Small sample size. Lack of placebo control arm.|1|||f||||f||||||||||2018-06-01 02:27:57.038727|2018-06-01 02:27:57.038727
NCT00614861|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2014-05-22|2008-01-31|2008-02-13|Estimate|||||||2014-05-22|2014-05-23|Estimate|September 2007||2007-09-30|May 2014|2014-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Pain Satisfaction Survey|A Clinical Survey on Satisfaction of Pain Management in Patients With Non-cancer Pain in Taiwan|Completed|||2929|Actual|Johnson & Johnson Taiwan Ltd|||1||f||||||||||||||2018-06-01 02:27:57.253453|2018-06-01 02:27:57.253453
NCT00614848|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2011-04-08|2008-01-30|2008-02-13|Estimate|||||||2011-04-08|2011-04-11|Estimate|June 2003||2003-06-30|April 2011|2011-04-30|July 2009|Actual|2009-07-31|January 2005|Actual|2005-01-31||Interventional|ENDEAVOR II||The ENDEAVOR II Clinical Trial: The Medtronic Endeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions|Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions|Completed||N/A|1200|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-06-01 02:27:57.322539|2018-06-01 02:27:57.322539
NCT00614835|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2015-12-21|2008-02-12|2008-02-13|Estimate|||||||2015-12-21|2015-12-22|Estimate|August 2001||2001-08-31|December 2015|2015-12-31|January 2012|Actual|2012-01-31|February 2006|Actual|2006-02-28||Interventional|||Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus|A Pilot Study of Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus|Completed||N/A|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:27:57.388783|2018-06-01 02:27:57.388783
NCT00614822|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2017-10-19|2008-02-11|2008-02-13|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2007||2007-11-30|October 2017|2017-10-31|August 22, 2016|Actual|2016-08-22|August 22, 2016|Actual|2016-08-22||Interventional|H3E-US-X072||Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer|A Phase II Trial of Carboplatin, Bevacizumab and Pemetrexed in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|51|Actual|Christiana Care Health Services||1|||f||||t||||||||||2018-06-01 02:27:57.51391|2018-06-01 02:27:57.51391
NCT00614809|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-02-13|2008-02-12|2008-02-13|Estimate|||||||2008-02-13|2008-02-22|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|December 2010|Anticipated|2010-12-31|March 2010|Anticipated|2010-03-31||Interventional|||Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer|A Phase II Study of Gefitinib in Benefited Patients With Asymptomatic Brain Metastasis Advanced Non-Small Cell Lung Cancer by Chemotherapy|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|Guangdong Provincial People's Hospital||1|||f||||t||||||||||2018-06-01 02:27:57.593842|2018-06-01 02:27:57.593842
NCT00614796|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-03-23|2008-02-12|2008-02-13|Estimate|||||||2012-03-23|2012-03-26|Estimate|November 2006||2006-11-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|August 2009|Actual|2009-08-31||Interventional|COACH||A Structured Lifestyle Intervention on Daily Physical Activity Level in COPD|A Study Evaluating the Effects of a Structured Lifestyle Intervention on Daily Physical Activity Level of COPD Patients in the First, Second and Third Echelon.|Completed||N/A|155|Actual|Groningen Research Institute for Asthma and COPD||2|||f||||f||||||||||2018-06-01 02:27:57.666584|2018-06-01 02:27:57.666584
NCT00614783|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2012-12-03|2008-02-12|2008-02-13|Estimate|||||||2012-12-03|2012-12-04|Estimate|May 2007||2007-05-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|SEED||Screening for Early Evidence of Diabetes|A Prospective, Multi-Center, Paired Data, Cohort Screening Trial Comparing SCOUT to the Fasting Plasma Glucose Test in Subjects at Risk for Diabetes|Completed|||3478|Actual|VeraLight, Inc.|||||f||||f||||||||||2018-06-01 02:27:57.754181|2018-06-01 02:27:57.754181
NCT00614770|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2010-06-16|2008-01-31|2008-02-13|Estimate|||||||2010-06-16|2010-06-17|Estimate|February 2008||2008-02-29|June 2010|2010-06-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Narrow Band Imaging Colon Polyp Study|A Multicenter, Prospective, Randomized Controlled Trial for the Detection of Colon Polyps and Predicting Histology|Completed||N/A|630|Actual|Kansas City Veteran Affairs Medical Center||3|||f||||f||||||||||2018-06-01 02:27:57.822445|2018-06-01 02:27:57.822445
NCT00614757|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-10-25|2008-01-31|2008-02-13|Estimate|||||||2012-10-25|2012-10-26|Estimate|May 2005||2005-05-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|IR||Insulin Resistance Study|The Prevalence of Insulin Resistance and the Potential Modulation of Insulin Resistance by N-acetylcysteine (NAC) in Patients Chronically Infected by the Hepatitis C Virus|Suspended||N/A|121|Actual|Midwest Biomedical Research Foundation||2|||f||||t||||||||||2018-06-01 02:27:57.915742|2018-06-01 02:27:57.915742
NCT00614744|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2017-06-30||2017-06-30|2008-02-11|2008-02-13|Estimate|2017-06-30|2017-08-07|Actual||||2017-06-30|2017-08-07|Actual|April 2008||2008-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Late Hypothermia for Hypoxic-Ischemic Encephalopathy|Evaluation of Systemic Hypothermia Initiated After 6 Hours of Age in Infants ≥36 Weeks Gestation With Hypoxic-Ischemic Encephalopathy: A Bayesian Evaluation. A Protocol for the NICHD Neonatal Research Network|Completed||Phase 2/Phase 3|168|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 02:27:58.009128|2018-06-01 02:27:58.009128
NCT00614731|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2017-01-10|2008-02-11|2008-02-13|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2007||2007-12-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route|Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route|Completed||Phase 1|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 02:27:58.432218|2018-06-01 02:27:58.432218
NCT00614718|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2008-02-12|2008-02-12|2008-02-13|Estimate|||||||2008-02-12|2008-02-13|Estimate|January 1993||1993-01-31|January 2008|2008-01-31|January 2007|Actual|2007-01-31|January 2004|Actual|2004-01-31||Observational|||Failure of Chronically Implanted Defibrillator Leads -Incidence and Management|Failure of Chronically Implanted Defibrillator Leads -Incidence and Management A Retrospective Multicenter Study|Completed|||1317|Actual|University Hospital, Basel, Switzerland|||3||f||||f||||||||||2018-06-01 02:27:58.525876|2018-06-01 02:27:58.525876
NCT00614705|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31||2009-04-06|2011-05-09|2008-02-12|2008-02-13|Estimate||||2009-10-21|2009-10-23|Estimate|2011-05-09|2011-05-16|Estimate|April 2008||2008-04-30|May 2011|2011-05-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia|A Four Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2A Study Of PH-797804 In The Treatment Of Post-Herpetic Neuralgia|Completed||Phase 2|80|Actual|Pfizer||2|||f||||||||||||||2018-06-01 02:27:58.596287|2018-06-01 02:27:58.596287
NCT00614679|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2008-02-11|2008-02-11|2008-02-13|Estimate|||||||2008-02-11|2008-02-13|Estimate|October 2006||2006-10-31|February 2008|2008-02-29||||December 2008|Anticipated|2008-12-31||Interventional|||A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia|A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia|Unknown status|Recruiting|Phase 1|20|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||f||||||||||2018-06-01 02:27:58.696958|2018-06-01 02:27:58.696958
NCT00614666|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2013-02-12|2008-02-12|2008-02-13|Estimate|||||||2013-02-12|2013-02-15|Estimate|September 2007||2007-09-30|August 2009|2009-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment|Phase I/II Evaluation of the Safety, Pharmacokinetics, and Preliminary Effectiveness of Nikkomycin Z in the Treatment of Patients With Uncomplicated Coccidioides Pneumonia|Terminated||Phase 1/Phase 2|6|Actual|University of Arizona||4||Recruitment challenges and lack of funding caused an early end to this study|f||||t||||||||||2018-06-01 02:27:58.771818|2018-06-01 02:27:58.771818
NCT00614653|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2016-07-29|2008-01-31|2008-02-13|Estimate|||||||2016-07-29|2016-08-01|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer|Phase I Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer|Completed||Phase 1|17|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:27:58.857322|2018-06-01 02:27:58.857322
NCT00614640|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2013-09-04|2008-02-11|2008-02-13|Estimate|||||||2013-09-04|2013-09-05|Estimate||||September 2013|2013-09-30||||November 2013|Anticipated|2013-11-30||Interventional|||Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults|A Phase I/II Study of the Safety, Tolerability, and Immunogenicity of a Topical Therapeutic DNA Dendritic Cell Vaccine (DermaVir Patch) in Children, Adolescents, and Young Adults With HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)|Withdrawn||Phase 1/Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 02:27:58.947254|2018-06-01 02:27:58.947254
NCT00614614|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2012-06-15|2011-11-22|2016-10-06|2008-01-31|2008-02-13|Estimate|2012-06-15|2012-07-20|Estimate|2011-11-22|2011-11-23|Estimate|2016-10-06|2016-11-09|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|||Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014|Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Meningococcal Vaccine 134612 Given at 12-15 Months of Age or at 15-18 Months of Age (Co-administered With Infanrix®) in Primed Healthy Toddlers.|Completed||Phase 3|1558|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:27:59.076877|2018-06-01 02:27:59.076877
NCT00614601|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31||2014-05-28|2015-05-29|2008-01-31|2008-02-13|Estimate||||2014-05-28|2014-06-02|Estimate|2015-05-29|2015-06-26|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|May 2010|Actual|2010-05-31||Interventional|||Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer|A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer|Terminated||Phase 2|9|Actual|NewLink Genetics Corporation||2||Sponsor proceeded with a phase III study for same indication.|f||||t||||||||||2018-06-01 02:28:01.210152|2018-06-01 02:28:01.210152
NCT00614588|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2016-07-18|2008-01-31|2008-02-13|Estimate|||||||2016-07-18|2016-07-20|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Temperature Measurement in Post-Anesthesia Care Units|Accuracy of Temperature Measurement in Post-Anesthesia Care Units|Completed|||50|Actual|The Cleveland Clinic|||1||f||||f||||||||||2018-06-01 02:28:01.319351|2018-06-01 02:28:01.319351
NCT00614575|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2011-02-23||2014-08-01|2008-02-12|2008-02-13|Estimate|2011-06-21|2011-07-19|Estimate||||2014-08-01|2014-08-06|Estimate|January 2007||2007-01-31|August 2014|2014-08-31||||August 2009|Actual|2009-08-31||Observational|||Survey on PD Patients With Depressive Symptoms|BI_Sifrol Tablets Special Drug Use Surveillance(Survey on the Safety and Efficacy in Parkinson's Disease Patients With Depressive Symptoms)|Completed|||1089|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 02:28:01.460114|2018-06-01 02:28:01.460114
NCT00614562|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-02-02|2008-02-12|2008-02-13|Estimate|||||||2011-02-02|2011-02-03|Estimate|January 2008||2008-01-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|June 2009|Actual|2009-06-30||Interventional|||Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)|Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)|Completed||Phase 1|15|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 02:28:02.264934|2018-06-01 02:28:02.264934
NCT00614549|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2012-05-25|2008-01-30|2008-02-13|Estimate|||||||2012-05-25|2012-05-28|Estimate|March 2007||2007-03-31|May 2012|2012-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.|Long-term Evaluation of the Efficacy and Safety of Levetiracetam in Routine Clinical Practice in the Czech and Slovak Republics, Hungary, and Romania - Non-interventional Study|Completed|||2569|Actual|UCB Pharma|||1||f||||f||||||||||2018-06-01 02:28:02.385364|2018-06-01 02:28:02.385364
NCT00614536|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2014-04-24|2008-01-31|2008-02-13|Estimate|||||||2014-04-24|2014-04-28|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period|Observational Study: Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period|Completed|||1142|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-06-01 02:28:02.469481|2018-06-01 02:28:02.469481
NCT00614523|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2012-01-20||2016-04-05|2008-01-31|2008-02-13|Estimate|2013-08-09|2013-08-13|Estimate||||2016-04-05|2016-05-09|Estimate|July 2008||2008-07-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|July 2012|Actual|2012-07-31||Interventional|||Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 2|250|Actual|Amgen||2|||f||||t||||||||||2018-06-01 02:28:02.582717|2018-06-01 02:28:02.582717
NCT00614510|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2015-07-28|2008-02-12|2008-02-13|Estimate|||||||2015-07-28|2015-07-30|Estimate|August 2006||2006-08-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||SynCardia CardioWest TAH-t Postmarket Surveillance Study|The SynCardia CardioWest Temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study|Completed|||196|Actual|SynCardia Systems. LLC|||||f||||t||||||||||2018-06-01 02:28:04.801522|2018-06-01 02:28:04.801522
NCT00614484|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2013-07-16||2014-04-28|2008-01-29|2008-02-13|Estimate|2014-04-28|2014-05-22|Estimate||||2014-04-28|2014-05-22|Estimate|August 1999||1999-08-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||28 subjects were enrolled and received the study treatment. All 28 were followed for treatment outcomes.|Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer|Phase I/II Study of Combined Chemotherapy and High Dose, Accelerated Proton Radiation for the Treatment of Locally Advanced Non-Small Cell Lung Carcinoma|Terminated||Phase 1/Phase 2|28|Actual|Loma Linda University|Slow enrollment over a long time period limits the conclusions that can be drawn.|1||Low participant enrollment rates. Significant comparative data not obtained.|f||||t||||||||||2018-06-01 02:28:04.935495|2018-06-01 02:28:04.935495
NCT00614471|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2016-11-01|2008-02-11|2008-02-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2007||2007-08-31|November 2016|2016-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.|A Randomized, Open Label Study of the Effect of Peginterferon Alfa-2a (40KD) (PEGASYS®) Plus Entecavir (Baraclude®) Combination Therapy on Quantitative Changes in HBeAg in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B|Completed||Phase 4|219|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 02:28:05.16166|2018-06-01 02:28:05.16166
NCT00614458|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2011-04-15||2011-10-24|2008-02-12|2008-02-13|Estimate|2011-10-24|2011-10-25|Estimate||||2011-10-24|2011-10-25|Estimate|April 2007||2007-04-30|September 2011|2011-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection|10493 - MK-0518 Intensification and HDAC Inhibition in Depletion of Resting CD4+ T Cell HIV Infection|Terminated||Phase 2|6|Actual|University of North Carolina, Chapel Hill||1||Due to insufficient funds|f||||t||||||||||2018-06-01 02:28:05.333379|2018-06-01 02:28:05.333379
NCT00614445|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2011-08-01||2011-08-04|2008-01-30|2008-02-13|Estimate|2011-08-04|2011-09-05|Estimate||||2011-08-04|2011-09-05|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy|A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy|Completed||Phase 3|280|Actual|Duchesnay Inc.||2|||f||||f||||||||||2018-06-01 02:28:05.659759|2018-06-01 02:28:05.659759
NCT00614432|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2010-12-16|2008-02-12|2008-02-13|Estimate|||||||2010-12-16|2010-12-20|Estimate|January 2008||2008-01-31|December 2010|2010-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women|Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women|Completed|||30|Anticipated|University of Hawaii|||2||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 02:28:05.998952|2018-06-01 02:28:05.998952
NCT00614419|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-02-12|2008-02-12|2008-02-13|Estimate|||||||2008-02-12|2008-02-13|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Prospective Randomized Trial Comparing Lichtenstein's Repair of Inguinal Hernia With Polypropylene Mesh Versus Surgisis|Prospective Randomized, Double-Blind, Controlled Trial Comparing Lichtenstein's Repair of Inguinal Hernia With Polypropylene Mesh Versus Surgisis ES Soft Tissue Graft|Completed||Phase 4|70|Actual|St. Orsola Hospital||2|||f||||f||||||||||2018-06-01 02:28:06.077519|2018-06-01 02:28:06.077519
NCT00614406|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2011-07-15||2012-12-11|2008-01-31|2008-02-13|Estimate|2012-06-01|2012-07-04|Estimate||||2012-12-11|2012-12-13|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle|The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle.|Completed||N/A|11|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 02:28:06.182031|2018-06-01 02:28:06.182031
NCT00614393|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2016-11-01||2017-01-10|2008-02-11|2008-02-13|Estimate|2016-11-01|2016-12-28|Estimate||||2017-01-10|2017-02-24|Actual|December 2007||2007-12-31|January 2017|2017-01-31|March 2012|Actual|2012-03-31|June 2010|Actual|2010-06-30||Interventional||The Baseline Analysis Population was the All Participants As Treated (APAT) population and consisted of all participants who received at least one dose of study drug.|Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)|A Phase II/III Study of Dalotuzumab (MK-0646) Treatment in Combination With Cetuximab and Irinotecan for Patients With Metastatic Colorectal Cancer|Completed||Phase 2|558|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 02:28:06.459702|2018-06-01 02:28:06.459702
NCT00614380|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2009-12-14||2013-12-16|2008-02-12|2008-02-13|Estimate|2009-12-14|2010-01-18|Estimate||||2013-12-16|2014-02-13|Estimate|January 2008||2008-01-31|December 2013|2013-12-31||||March 2009|Actual|2009-03-31||Interventional|||Open Label Study Telmisartan and Amlodipine in Hypertension|An Open Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Combination of Telmisartan 40mg + Amlodipine 5mg or the Combination of Telmisartan 80mg + Amlodipine 5mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.|Completed||Phase 3|976|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:28:08.677816|2018-06-01 02:28:08.677816
NCT00614367|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2008-02-11|2008-02-11|2008-02-13|Estimate|||||||2008-02-11|2008-02-13|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|June 2008|Anticipated|2008-06-30|March 2008|Anticipated|2008-03-31||Observational|||Chromosomal Analysis of Single Cells in Human Embryos|Chromosomal Analysis of Single Cells in Human Embryos|Unknown status|Active, not recruiting||30|Actual|Katholieke Universiteit Leuven|||||f||||f||||||Samples With DNA|"~     Single blastomeres of human embryos~   "|||2018-06-01 02:28:10.149868|2018-06-01 02:28:10.149868
NCT00614354|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2013-10-23|2008-02-12|2008-02-13|Estimate|||||||2013-10-23|2013-10-24|Estimate|October 2008||2008-10-31|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.|Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.|Completed||Phase 2|66|Actual|Molecular Targeting Technologies, Inc.||1|||f||||f||||||||||2018-06-01 02:28:10.253472|2018-06-01 02:28:10.253472
NCT00614341|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2008-02-12|2008-02-12|2008-02-13|Estimate|||||||2008-02-12|2008-02-13|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|DPN||Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study|A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study|Completed||Phase 4|23|Actual|MedRelief||1|||f||||f||||||||||2018-06-01 02:28:10.404036|2018-06-01 02:28:10.404036
NCT00614328|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-05-05|2008-02-12|2008-02-13|Estimate|||||||2011-05-05|2011-05-06|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Combination of Naltrexone and Baclofen for Alcohol Dependence:A Pilot Study.|Feasibility and Tolerability of a Combination of Naltrexone and Baclofen for Alcohol Dependence: A Pilot Study.|Completed||Phase 1|40|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-06-01 02:28:10.571074|2018-06-01 02:28:10.571074
NCT00614315|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2009-02-20||2017-01-14|2008-02-11|2008-02-13|Estimate|2010-09-17|2010-10-06|Estimate||||2017-01-14|2017-02-28|Actual|December 2007||2007-12-31|January 2017|2017-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|FLAIR DS||FLAIR™ Delivery System Study|A Prospective Observational Study of the FLAIR™ Endovascular Stent Graft Optimized Delivery System|Completed||N/A|30|Actual|C. R. Bard||1|||f||||f||||||||||2018-06-01 02:28:10.71058|2018-06-01 02:28:10.71058
NCT00614302|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-10-01|2008-02-12|2008-02-13|Estimate|||||||2009-10-01|2009-10-02|Estimate|June 2007||2007-06-30|October 2009|2009-10-31||||October 2008|Actual|2008-10-31||Observational|||Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population|Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Patient Population|Completed|||428|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:28:10.976222|2018-06-01 02:28:10.976222
NCT00614289|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2010-03-04|2008-02-12|2008-02-13|Estimate|||||||2010-03-04|2010-03-08|Estimate|August 2006||2006-08-31|October 2008|2008-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Novel Topical Treatment of Hand Dermatitis (Eczema)|Phase 1 Study to Demonstrate Efficacy of Epikeia Coatings in a Human Clinical Trial|Completed||Phase 1|30|Actual|Biomedical Development Corporation|||||f||||f||||||||||2018-06-01 02:28:11.060554|2018-06-01 02:28:11.060554
NCT00614276|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2015-01-07|2008-01-30|2008-02-13|Estimate|||||||2015-01-07|2015-01-09|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Female Sexual Dysfunction Intervention|TENDRILS: A Multimedia Intervention for Women's Sexual Dysfunction After Cancer|Completed|||91|Actual|M.D. Anderson Cancer Center|||3||f||||t||||||||||2018-06-01 02:28:11.148951|2018-06-01 02:28:11.148951
NCT00614263|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2017-06-09|2008-01-31|2008-02-13|Estimate|||||||2017-06-09|2017-06-12|Actual|March 2006||2006-03-31|June 2017|2017-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||A Study to Examine Levels of Sedation During Outpatient Colonoscopies|A Prospective, Blinded Study Examining Sedation Levels During Outpatient Colonoscopies|Completed|||100|Actual|Baylor Research Institute|||2||f||||f||||||||||2018-06-01 02:28:11.227361|2018-06-01 02:28:11.227361
NCT00614250|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-07-17|2008-01-31|2008-02-13|Estimate|||||||2009-07-17|2009-07-20|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea|A Double-blind, Randomized, Placebo-controlled, Study of the Safety and Activity of Four Escalating Single Doses of AVE0657 in Patients Suffering From Obstructive Sleep Apnea Hypopnea Syndrome|Completed||Phase 2|38|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 02:28:11.294709|2018-06-01 02:28:11.294709
NCT00614224|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2015-05-27|2008-01-31|2008-02-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Structural Neuroplasticity Associated With Aerobic Treadmill Training in Geriatric Chronic Stroke Survivors|Structural Neuroplasticity Associated With Aerobic Treadmill Training in Geriatric Chronic Stroke Survivors|Completed||N/A|38|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 02:28:11.369177|2018-06-01 02:28:11.369177
NCT00614211|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2018-01-31|2008-02-12|2008-02-13|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2008||2008-01-31|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|LACC||Laparoscopic Approach to Cervical Cancer|A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer|Active, not recruiting||N/A|636|Actual|Queensland Centre for Gynaecological Cancer||2|||f||||t||||||||No||2018-06-01 02:28:11.437055|2018-06-01 02:28:11.437055
NCT00614198|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-05-17||2010-08-31|2008-01-31|2008-02-13|Estimate|2010-08-31|2010-10-01|Estimate||||2010-08-31|2010-10-01|Estimate|April 2006||2006-04-30|May 2010|2010-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ScanBrit||ScanBrit Dietary Intervention in Autism|The ScanBrit Randomised Controlled Study of Gluten- and Casein-free Dietary Intervention for Children With Autism Spectrum Disorders|Completed||Phase 2|72|Actual|Center for Autisme, Denmark|Single-blind trial, no placebo condition, analysis based on per protocol (not intention to treat), socio-economic status not recorded, independent screening for underlying somatic conditions potentially associated with results not undertaken|2|||f||||f||||||||||2018-06-01 02:28:11.682233|2018-06-01 02:28:11.682233
NCT00614172|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-18|2008-01-29|2008-02-13|Estimate|||||||2017-05-18|2017-05-22|Actual|February 2004||2004-02-29|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Proton Therapy for Early Stage Breast Cancer|Phase II Trial of Lumpectomy and Partial Breast Proton Therapy for Early Stage Breast Cancer|Active, not recruiting||Phase 2|150|Anticipated|Loma Linda University||1|||f||||t||||||||||2018-06-01 02:28:12.141317|2018-06-01 02:28:12.141317
NCT00614159|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-06-30|2008-02-12|2008-02-13|Estimate|||||||2009-06-30|2009-07-02|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Ketamine Compared to Propofol for Pediatric GI Endoscopy||Completed|||34|Anticipated|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-06-01 02:28:12.298496|2018-06-01 02:28:12.298496
NCT00614146|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2017-05-05|2008-01-31|2008-02-13|Estimate|||||||2017-05-05|2017-05-08|Actual|April 2003||2003-04-30|April 2017|2017-04-30|April 2009|Actual|2009-04-30|January 2008|Actual|2008-01-31||Interventional|RELIEF||Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure|Therapeutic Impact of Albumin Dialysis With the Molecular Adsorbents Recirculating System (MARS®) in Severely Decompensated Chronic Liver Disease|Completed||N/A|59|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-06-01 02:28:12.430742|2018-06-01 02:28:12.430742
NCT00614133|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2008-01-30|2008-01-30|2008-02-13|Estimate|||||||2008-01-30|2008-02-13|Estimate|June 2004||2004-06-30|January 2008|2008-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Intravenous Nutrition and Epidural Analgesia on Protein Loss After Surgery|Hypocaloric Isonitrogenous Nutrition and Epidural Analgesia: a Novel Strategy to Induce Anabolism After Surgery|Completed||N/A|22|Actual|McGill University Health Center||2|||f||||f||||||||||2018-06-01 02:28:12.581661|2018-06-01 02:28:12.581661
NCT00614120|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2010-02-23|2009-11-09|2017-01-25|2008-02-12|2008-02-13|Estimate|2010-02-23|2010-03-12|Estimate|2009-11-09|2009-11-11|Estimate|2017-01-25|2017-03-08|Actual|January 2008||2008-01-31|January 2017|2017-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes|Completed||Phase 3|929|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 02:28:12.719207|2018-06-01 02:28:12.719207
NCT00614107|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2008-02-12|2008-02-12|2008-02-13|Estimate|||||||2008-02-12|2008-02-13|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Observational|A-Fib||Organization in Acute Atrial Fibrillation Post Open Heart Surgery|Organization in Acute Atrial Fibrillation Post Open Heart Surgery|Unknown status|Enrolling by invitation||75|Actual|State University of New York - Upstate Medical University|||||f||||f||||||Samples With DNA|"~     Tissue sample for the right and left sid eof the heart.~   "|||2018-06-01 02:28:13.769687|2018-06-01 02:28:13.769687
NCT00614094|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-07-08|2008-01-31|2008-02-13|Estimate|||||||2008-07-08|2008-07-09|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Maternal Hypoglycemia and Placental Pathology|Maternal Hypoglycemia During One Hour Glucose Tolerance Test as a Risk for Decreased Placental Weight and Placental Pathology|Completed|||350|Anticipated|Oklahoma State University Center for Health Sciences|||||f||||t||||||||||2018-06-01 02:28:13.948448|2018-06-01 02:28:13.948448
NCT00614081|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2013-05-21|2008-01-30|2008-02-13|Estimate|||||||2013-05-21|2013-05-22|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|IREN||GFR Measurement With Contrast-enhanced Dynamic MRI|Measurement of Glomerular Filtration Rate With Contrast-enhanced Dynamic MR Imaging in Renal Transplant Recipients: Evaluation of the Agreement With the Cr51 -EDTA Method and of Reproducibility|Completed||N/A|71|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-06-01 02:28:14.019039|2018-06-01 02:28:14.019039
NCT00614068|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2015-04-03|2008-02-11|2008-02-13|Estimate|||||||2015-04-03|2015-04-06|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Effectiveness of Trauma-Focused Cognitive Behavioral Therapy in Treating Children With Post-Traumatic Stress Disorder|Creating a Collaborative Field Research Organization|Completed||N/A|40|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 02:28:14.111593|2018-06-01 02:28:14.111593
NCT00614055|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2015-10-16|2009-11-09|2017-02-09|2008-01-30|2008-02-13|Estimate|2015-10-16|2015-11-17|Estimate|2009-11-09|2009-11-11|Estimate|2017-02-09|2017-03-20|Actual|January 2008||2008-01-31|February 2017|2017-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes|A 16 Week Randomised, Open Labelled, 3 Armed, Parallel Group, Treat-to-target Trial Comparing Once Daily Injection of SIAC 30 (B), SIAC 45 (B) and Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment|Completed||Phase 2|178|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 02:28:14.261066|2018-06-01 02:28:14.261066
NCT00614042|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-06-26|2008-01-31|2008-02-13|Estimate|||||||2017-06-26|2017-06-28|Actual|January 2008||2008-01-31|June 2017|2017-06-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma|A Phase 1/1b Study of TRU-016 in Patients With Previously Treated Chronic Lymphocytic Leukemia or Select Subtypes of Non-Hodgkin's Lymphoma|Completed||Phase 1|96|Actual|Aptevo Therapeutics||1|||f||||t||||||||||2018-06-01 02:28:14.928208|2018-06-01 02:28:14.928208
NCT00614029|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2009-11-23|2008-02-12|2008-02-13|Estimate|||||||2009-11-23|2009-11-25|Estimate|December 2006||2006-12-31|November 2009|2009-11-30||||December 2006|Actual|2006-12-31||Interventional|||A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System|A Randomized, Open-Label, Single-Dose, Four-way Crossover Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System Versus IMITREX STATdose at Three Injection Sites in Healthy Adults|Completed||Phase 1|54|Actual|Zogenix, Inc.||6|||f||||t||||||||||2018-06-01 02:28:15.011721|2018-06-01 02:28:15.011721
NCT00614016|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2008-08-01|2008-02-11|2008-02-13|Estimate|||||||2008-08-01|2008-08-05|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers|A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers|Completed||Phase 1|40|Actual|HemaQuest Pharmaceuticals Inc.||1|||f||||f||||||||||2018-06-01 02:28:15.10182|2018-06-01 02:28:15.10182
NCT00614003|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2015-05-21|2008-01-30|2008-02-13|Estimate|||||||2015-05-21|2015-05-25|Estimate|April 2007||2007-04-30|May 2015|2015-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of an Intervention Designed to Enhance the Quality of Decision Support Provided to Patients Making Decisions About End-of-life Place of Care|Efficacy of a Training Intervention on the Quality of Case Coordinators and Nurses' Decision Support for Patients Deciding About the Place of Care at the End Of-Life: A Randomized Control Trial|Completed||Phase 2|90|Actual|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-06-01 02:28:15.167166|2018-06-01 02:28:15.167166
NCT00613977|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-09-19|2008-02-12|2008-02-13|Estimate|||||||2011-09-19|2011-09-20|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Observational|||Comparison of Two Fetal Lung Maturity Tests|Pilot Study-A Cost and Time Savings Comparison of Lamellar Body Count and FLM II|Withdrawn|||10|Anticipated|Oklahoma State University Center for Health Sciences||||Withdrawn|f||||t||||||None Retained|"~     Amniotic fluid for fetal lung maturity test~   "|||2018-06-01 02:28:15.247791|2018-06-01 02:28:15.247791
NCT00613964|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-07-20|2008-01-31|2008-02-13|Estimate|||||||2011-07-20|2011-07-22|Estimate|May 2009||2009-05-31|February 2009|2009-02-28|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure|The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure|Terminated||Phase 4|200|Anticipated|Nara Medical University||2|||f||||t||||||||||2018-06-01 02:28:15.347198|2018-06-01 02:28:15.347198
NCT00613951|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2015-10-16|2009-11-09|2017-02-09|2008-01-30|2008-02-13|Estimate|2015-11-27|2015-12-01|Estimate|2009-11-09|2009-11-11|Estimate|2017-02-09|2017-03-20|Actual|January 2008||2008-01-31|February 2017|2017-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes|A 16 Week Randomised, Open Labelled, 3-armed, Parallel Group, Treat-to-target Trial Comparing Twice Daily (BID) Injections of SIAC 30 (B), SIAC 45 (B) and NovoMix®30, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment|Completed||Phase 2|182|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 02:28:15.475451|2018-06-01 02:28:15.475451
NCT00613938|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2009-10-02||2014-04-24|2008-01-31|2008-02-13|Estimate|2010-04-05|2010-04-23|Estimate||||2014-04-24|2014-05-09|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy|Completed||Phase 3|901|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-06-01 02:28:16.113578|2018-06-01 02:28:16.113578
NCT00613925|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2012-06-04||2014-04-07|2008-01-31|2008-02-13|Estimate|2014-04-07|2014-05-12|Estimate||||2014-04-07|2014-05-12|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2009|Actual|2009-01-31||Interventional|||Endometrial Biopsy Instrument Comparison Study|Comparison of Pain Experienced by Patients Undergoing Endometrial Biopsy by Pipelle and Explora Curette|Completed||N/A|73|Actual|Oregon Health and Science University|Providers not blinded|2|||f||||f||||||||||2018-06-01 02:28:16.658703|2018-06-01 02:28:16.658703
NCT00613912|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-11-18|2008-01-31|2008-02-13|Estimate|||||||2011-11-18|2011-11-21|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Observational|||Advanced MRI in Major Depression|Advanced MRI at 3T for the Evaluation of Ambulant Patients With Major Depression|Completed|||49|Actual|University of Aarhus|||1||f||||t||||||||||2018-06-01 02:28:17.13106|2018-06-01 02:28:17.13106
NCT00613899|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2016-02-03|2008-02-12|2008-02-13|Estimate|||||||2016-02-03|2016-02-04|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|October 2008|Actual|2008-10-31|March 2008|Actual|2008-03-31||Interventional|||Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)|Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)|Completed||Phase 4|40|Actual|Fondazione Salvatore Maugeri||1|||f||||f||||||||||2018-06-01 02:28:17.424772|2018-06-01 02:28:17.424772
NCT00613886|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-06-26|2008-02-12|2008-02-13|Estimate|||||||2013-06-26|2013-06-27|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|NPH||Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus|Factors Predicting Response to Shunting in Normal Pressure Hydrocephalus|Terminated||N/A|16|Actual|University of California, Irvine||1||"Funding was withdrawn by Codman as expected number of patient subjects enrolled did not meet~   expected numbers."|f||||f||||||||||2018-06-01 02:28:17.722765|2018-06-01 02:28:17.722765
NCT00613873|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-01-14|2008-01-31|2008-02-13|Estimate|||||||2009-01-14|2009-01-15|Estimate|July 2003||2003-07-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Use of Screening Colonoscopy Among Minority Women and Men|A Model Program for Increasing Use of Screening Colonoscopy Among Minority Women and Men|Completed|||611|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:28:18.014721|2018-06-01 02:28:18.014721
NCT00613860|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-04-26|2008-02-12|2008-02-13|Estimate|||||||2011-04-26|2011-04-27|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Sequential Endoscopic Lung Volume Reduction|Sequential Endoscopic Lung Volume Reduction in Patients With Heterogeneous Lung Emphysema|Unknown status|Recruiting|Phase 3|30|Anticipated|Heidelberg University|||||f||||t||||||||||2018-06-01 02:28:18.266089|2018-06-01 02:28:18.266089
NCT00613847|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2015-12-23|2008-01-31|2008-02-13|Estimate|||||||2015-12-23|2015-12-24|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab|Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab|Completed||Phase 1|17|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:28:18.823429|2018-06-01 02:28:18.823429
NCT00613834|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-02-09|2008-02-12|2008-02-13|Estimate|||||||2012-02-09|2012-02-13|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Intrauterine Lidocaine Infusion for Essure Sterilization Procedures|Intrauterine Lidocaine Infusion for Pain Management During Outpatient Essure Transcervical Tubal Sterilization Procedures|Completed||N/A|58|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 02:28:19.164569|2018-06-01 02:28:19.164569
NCT00613821|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2017-04-29||2017-07-28|2008-02-12|2008-02-13|Estimate|2017-07-28|2017-07-31|Actual||||2017-07-28|2017-07-31|Actual|September 2007||2007-09-30|July 2017|2017-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Lidocaine and Pain Management in First Trimester Abortions|A Comparison of Intrauterine Lidocaine Infusion and Paracervical Block for Pain Management in First Trimester Abortions|Completed||N/A|80|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:28:19.530833|2018-06-01 02:28:19.530833
NCT00613808|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2012-01-24|2008-01-30|2008-02-13|Estimate|||||||2012-01-24|2012-01-25|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers|An Investigation of Topical Application of Gaseous Nitric Oxide on Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremities|Terminated||Phase 2|6|Actual|Nitric BioTherapeutics, Inc||2|||f||||t||||||||||2018-06-01 02:28:20.436856|2018-06-01 02:28:20.436856
NCT00613795|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2010-03-17|2008-02-12|2008-02-13|Estimate|||||||2010-03-17|2010-03-18|Estimate|August 2004||2004-08-31|March 2010|2010-03-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia|Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia: A Prospective, Randomized, Placebo-controlled, Double-blind Study|Completed||Phase 3|125|Anticipated|Creighton University||2|||f||||f||||||||||2018-06-01 02:28:20.745502|2018-06-01 02:28:20.745502
NCT00613782|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2014-06-30|2008-02-12|2008-02-13|Estimate|||||||2014-06-30|2014-07-01|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Reandron in Diabetic Men Witn Low Testosterone Level|Testosterone Replacement Therapy in Men With Type 2 Diabetes Mellitus and Low Testosterone Levels|Completed||Phase 2/Phase 3|88|Actual|Austin Health||2|||f||||t||||||||||2018-06-01 02:28:21.045653|2018-06-01 02:28:21.045653
NCT00613769|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-09-27|2008-01-31|2008-02-13|Estimate|||||||2012-09-27|2012-09-28|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery|A Prospective, Randomized, Blind, Multicenter Trial Comparing Orally Administered Trimethoprim-sulfamethoxazole With Intravenously Administered Cefuroxime and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery|Completed||Phase 4|1073|Actual|Halmstad County Hospital||2|||f||||t||||||||||2018-06-01 02:28:21.326715|2018-06-01 02:28:21.326715
NCT00257569|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2013-05-03|2005-11-22|2005-11-23|Estimate|||||||2013-05-03|2013-05-06|Estimate|August 2005||2005-08-31|May 2013|2013-05-31||||||||Interventional|||Study Of Atopic Dermatitis In Pediatrics|Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Atopic Dermatitis-|Completed||Phase 3|278||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:19:29.198664|2018-06-01 04:19:29.198664
NCT00613756|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2013-11-12|2008-02-12|2008-02-13|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2004||2004-02-29|November 2013|2013-11-30||||September 2008|Actual|2008-09-30||Observational|||Special Survey on PD Patients With Renal Dysfunction|Post Marketing Surveillance of BI-Sifrol® (Pramipexole). Special Survey on Patients With Parkinson's Disease and Renal Dysfunction|Completed|||107|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:28:21.80995|2018-06-01 02:28:21.80995
NCT00613743|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2010-01-12|2008-02-12|2008-02-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|December 2007||2007-12-31|January 2008|2008-01-31|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Interventional|||Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis|Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis|Completed||N/A|30|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-06-01 02:28:22.347352|2018-06-01 02:28:22.347352
NCT00613730|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-08-06||2013-11-15|2008-01-31|2008-02-13|Estimate|2013-11-15|2014-01-06|Estimate||||2013-11-15|2014-01-06|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|APPRISE 1||Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint|Phase II, Multi-center, Open-label, Single-Arm Study Using Gemcitabine and Panitumumab in the First-line Treatment of Subjects With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas|Terminated||Phase 2|3|Actual|Amgen||1||"APPRISE closure prompted by SWOG S0205 not meeting primary endpoint-improving OS. APPRISE~   enrollment closure due to similar design;no unexpected safety data"|f||||||||||||||2018-06-01 02:28:22.674495|2018-06-01 02:28:22.674495
NCT00613717|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|||2014-10-28|2008-02-11|2008-02-13|Estimate|||||||2014-10-28|2014-10-29|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Healthy Infant Development Project|Timing, Duration and Severity of Infant Iron Deficiency: Developmental Impacts|Completed||N/A|2371|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||4|||f||||t||||||||||2018-06-01 02:28:23.495605|2018-06-01 02:28:23.495605
NCT00613691|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2013-10-17|2008-02-12|2008-02-13|Estimate|||||||2013-10-17|2013-10-21|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma|A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma|Completed||Phase 1|36|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-06-01 02:28:23.830871|2018-06-01 02:28:23.830871
NCT00613678|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2015-08-03|2008-02-12|2008-02-13|Estimate|||||||2015-08-03|2015-08-05|Estimate|July 2006||2006-07-31|August 2015|2015-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Exercise Plus Activity Strategy Training for Osteoarthritis|Exercise Plus Activity Strategy Training for Older Adults With Osteoarthritis|Completed||N/A|54|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 02:28:24.13931|2018-06-01 02:28:24.13931
NCT00613665|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2013-06-10|2008-02-12|2008-02-13|Estimate|||||||2013-06-10|2013-06-11|Estimate|February 2001||2001-02-28|June 2013|2013-06-30|April 2002|Actual|2002-04-30|December 2001|Actual|2001-12-31||Interventional|||Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults|Phase I, Randomized, Controlled, Single-blind, Dose-Ranging and Schedule-Finding Study of the Safety, Tolerability, and Immunogenicity of Chiron Helicobacter Pylori Vaccine in Healthy, Helicobacter Pylori-negative Adults|Completed||Phase 1|113|Actual|Novartis||7|||f||||||||||||||2018-06-01 02:28:24.467637|2018-06-01 02:28:24.467637
NCT00613652|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-07-20|2008-01-31|2008-02-13|Estimate|||||||2009-07-20|2009-07-21|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies|Completed||Phase 1|30|Anticipated|AstraZeneca|||||f||||t||||||||||2018-06-01 02:28:24.78754|2018-06-01 02:28:24.78754
NCT00613626|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2015-08-31||2015-10-19|2008-01-31|2008-02-13|Estimate|2015-10-19|2015-11-18|Estimate||||2015-10-19|2015-11-18|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Subjects 18 years of age or older at time of consent, ECOG Performance Status of 0-1 14 days prior to registration, and histological or cytological proof of chemotherapy naive extensive small cell cancers or neuroendocrine cancers that are high grade or poorly differentiated.|Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer|A Randomized Double Blind Phase II Trial of Cisplatin Plus Etoposide With/Without Concurrent ZD6474 in Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Hoosier Oncology Group LUN06-113|Completed||Phase 2|74|Actual|Hoosier Cancer Research Network|The primary object analysis was under powered. The sample size calculation determined 34 subjects per arm, however the actual primary objective analysis was based on 31 subjects per arm.|3|||f||||t||||||||||2018-06-01 02:28:25.027663|2018-06-01 02:28:25.027663
NCT00613613|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2014-12-01|2008-02-12|2008-02-13|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|FPI||Fenofibrate and Pharmacogenetic Impact in Dyslipidemia|The Impact of Genetic Determinants of Fenofibrate's Pharmacogenetics on Lipid Response|Completed||Phase 4|56|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 02:28:26.267828|2018-06-01 02:28:26.267828
NCT00613600|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2011-12-01|2008-02-12|2008-02-13|Estimate|||||||2011-12-01|2011-12-02|Estimate|February 2008||2008-02-29|December 2011|2011-12-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Safety and Effectiveness Study of a Fiber Supplement for Weight Loss|Safety and Efficacy of Glucomannan for Weight Loss|Completed||Phase 2|50|Anticipated|Rush University Medical Center||2|||f||||t||||||||||2018-06-01 02:28:26.822573|2018-06-01 02:28:26.822573
NCT00613587|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2012-10-08|2008-01-30|2008-02-13|Estimate|||||||2012-10-08|2012-10-10|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Roflumilast In-Vitro Basophil Release|Effect of Roflumilast In-Vitro on Basophil Histamine, Leukotriene, IL-4 and IL13-release.|Completed|||15|Actual|Creighton University|||||f||||f||||||Samples Without DNA|"~     Polymorphal Blood Mononuclar Cells will be stimulated to release various cytokines. The~     supernatant of the stimulations will be stored for batched analysis.~   "|||2018-06-01 02:28:26.982756|2018-06-01 02:28:26.982756
NCT00613574|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2009-10-29||2014-03-12|2008-02-12|2008-02-13|Estimate|2009-12-15|2010-01-18|Estimate||||2014-03-12|2014-04-10|Estimate||||March 2014|2014-03-31|October 2007||2007-10-31|||||Observational|||RUSSE / Russian Spiriva® Safety & Efficacy Study|RUSSE / Russian Spiriva® Safety & Efficacy Study|Completed|||407|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:28:27.084707|2018-06-01 02:28:27.084707
NCT00613561|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-05-26|2008-02-12|2008-02-13|Estimate|||||||2009-05-26|2009-05-27|Estimate|December 2007||2007-12-31|May 2009|2009-05-31|December 2017|Anticipated|2017-12-31|December 2012|Anticipated|2012-12-31||Interventional|SIDS||Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases|Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases|Unknown status|Recruiting|Phase 2|25|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 02:28:27.30221|2018-06-01 02:28:27.30221
NCT00613548|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-11-10|2008-02-12|2008-02-13|Estimate|||||||2008-11-10|2008-11-11|Estimate|February 2008||2008-02-29|November 2008|2008-11-30|June 2015|Anticipated|2015-06-30|June 2010|Anticipated|2010-06-30||Interventional|MoMIC||Moderate Mitral Regurgitation in CABG Patients|Moderate Mitral Regurgitation in CABG Patients|Unknown status|Recruiting|N/A|550|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:28:27.387827|2018-06-01 02:28:27.387827
NCT00613535|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2015-05-18|2008-02-12|2008-02-13|Estimate|||||||2015-05-18|2015-05-19|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MILE||Knee Articular Cartilage Debridement in Conjunction With Partial Meniscectomy|Magnetic Resonance Imaging and Clinical Outcomes After Three Different Treatments for Articular Cartilage Lesions Concomitant With Partial Meniscectomy|Terminated||Phase 4|165|Actual|Smith & Nephew, Inc.||3||"The correlation coefficient at the interim analysis with results for all three groups pooled,~   did not reach the level of statistical significance of (p<0.05)."|f||||f||||||||||2018-06-01 02:28:27.479208|2018-06-01 02:28:27.479208
NCT00613522|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2015-03-04|2008-01-30|2008-02-13|Estimate|||||||2015-03-04|2015-03-05|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|AVSAS||Role of Obstructive Sleep Apnea in Stroke Appearance|Role of Nocturnal Respiratory Disorders on Ischemic Stroke Occurrence|Completed|||289|Actual|University Hospital, Bordeaux|||2||f||||f||||||||||2018-06-01 02:28:27.589347|2018-06-01 02:28:27.589347
NCT00613509|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2010-09-14||2016-04-12|2008-01-30|2008-02-13|Estimate|2010-11-22|2010-12-17|Estimate||||2016-04-12|2016-04-14|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma|Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma|Terminated||Phase 2|23|Actual|Sanofi||2||"No safety concerns, the study was terminated due to slow enrollment. All enrolled patients were~   followed per protocol."|f||||t||||||||||2018-06-01 02:28:27.838617|2018-06-01 02:28:27.838617
NCT00613496|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-05-28|2008-02-12|2008-02-13|Estimate|||||||2009-05-28|2009-05-29|Estimate|May 2009||2009-05-31|May 2009|2009-05-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|CREATIVE-AF||Irbesartan and Adhesion Molecules in AF|Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation|Unknown status|Recruiting|Phase 4|60|Anticipated|University of Magdeburg||2|||f||||t||||||||||2018-06-01 02:28:30.261999|2018-06-01 02:28:30.261999
NCT00613470|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2013-12-16|2008-01-30|2008-02-13|Estimate|||||||2013-12-16|2013-12-18|Estimate|March 2005||2005-03-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PGRN-SSRI||Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram|Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram|Completed||Phase 1|927|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:28:30.368228|2018-06-01 02:28:30.368228
NCT00613457|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2015-01-13|2008-01-31|2008-02-13|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2000||2000-09-30|January 2015|2015-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|AIEOP LLA 2000||Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia|AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia|Completed||Phase 3|2039|Actual|Associazione Italiana Ematologia Oncologia Pediatrica||7|||f||||t||||||||||2018-06-01 02:28:30.521295|2018-06-01 02:28:30.521295
NCT00613444|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2015-04-30|2008-01-30|2008-02-13|Estimate|||||||2015-04-30|2015-05-04|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|March 2010|Actual|2010-03-31|February 2008|Actual|2008-02-29||Interventional|||Photodynamic Therapy in the Treatment of Acne|Photodynamic Therapy in the Treatment of Acne Vulgaris Using Non-Coherent Red Light (Derm 590)|Withdrawn||N/A|0|Actual|University of Michigan||1||Study was never started due to logistical issues.|f||||f||||||||||2018-06-01 02:28:30.725337|2018-06-01 02:28:30.725337
NCT00613431|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-12-19|2008-02-12|2008-02-13|Estimate|||||||2008-12-19|2008-12-22|Estimate|January 2008||2008-01-31|December 2008|2008-12-31||||August 2008|Actual|2008-08-31||Interventional|||Effects of CS-8080 in Healthy Volunteers|A Randomized, Placebo-Controlled, Single Ascending Dose Study To Assess The Safety, Tolerability and Pharmacokinetics Of CS-8080 In Healthy Volunteers|Completed||Phase 1|72|Anticipated|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 02:28:31.679922|2018-06-01 02:28:31.679922
NCT00613418|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2012-09-27|2008-01-31|2008-02-13|Estimate|||||||2012-09-27|2012-09-28|Estimate||||September 2012|2012-09-30||||||||Interventional|I-WIN||Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac Artery|Comparative Study of Safety and Efficacy of the SUPERA® Wire Interwoven Self-expanding Nitinol Stent and Currently Approved Stents for Patients With Iliac Lesions|Withdrawn||Phase 2/Phase 3|0|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 02:28:31.766614|2018-06-01 02:28:31.766614
NCT00613405|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-11|2011-06-15||2013-04-23|2008-02-11|2008-02-13|Estimate|2012-04-09|2012-05-04|Estimate||||2013-04-23|2013-04-30|Estimate|January 2008||2008-01-31|April 2013|2013-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Stress and Marijuana Cue-elicited Craving and Reactivity|Stress and Marijuana Cue-elicited Craving and Reactivity|Completed||N/A|87|Actual|Medical University of South Carolina|A control group of non-marijuana dependent individuals was not included, which may have provided further insight into the interactions of stress and cues both in the presence and absence of addiction.|2|||f||||f||||||||||2018-06-01 02:28:31.843115|2018-06-01 02:28:31.843115
NCT00613392|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2016-01-25|2008-02-11|2008-02-13|Estimate|||||||2016-01-25|2016-01-26|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Antioxidant Supplementation in Trauma Patients|Antioxidant Supplementation in Trauma Patients|Terminated||Phase 3|18|Actual|Boston Medical Center||2||Supplement expired and unable to obtain more from company manufacturing|f||||f||||||||||2018-06-01 02:28:32.075944|2018-06-01 02:28:32.075944
NCT00613379|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2013-04-12||2016-06-16|2008-02-12|2008-02-13|Estimate|2013-04-12|2013-05-31|Estimate||||2016-06-16|2016-07-15|Estimate|December 2007||2007-12-31|June 2016|2016-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||PRO 140 by IV Administration in Adults With HIV-1 Infection|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of PRO 140 by Intravenous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection|Completed||Phase 2|30|Actual|CytoDyn, Inc.||3|||f||||f||||||||||2018-06-01 02:28:32.159356|2018-06-01 02:28:32.159356
NCT00257179|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2006-03-13|2005-11-21|2005-11-22|Estimate|||||||2006-03-13|2006-03-14|Estimate|June 2005||2005-06-30|June 2005|2005-06-30||||||||Observational|||The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor||Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:19:35.123866|2018-06-01 04:19:35.123866
NCT00613366|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2012-06-01||2013-02-04|2008-01-31|2008-02-13|Estimate|2013-02-04|2013-03-15|Estimate||||2013-02-04|2013-03-15|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Misoprostol With Intrauterine Device Insertion|Effect of Prophylactic Misoprostol Prior to Intrauterine Device Insertion|Completed||N/A|40|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 02:28:32.767375|2018-06-01 02:28:32.767375
NCT00613353|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2008-11-12|2008-02-12|2008-02-13|Estimate|||||||2008-11-12|2008-11-13|Estimate|January 2008||2008-01-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Sedentary Behavior in Overweight Women|Sedentary Behavior in Overweight Women|Completed|||38|Anticipated|University of Mississippi Medical Center|||1||f||||t||||||||||2018-06-01 02:28:33.134998|2018-06-01 02:28:33.134998
NCT00613340|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-08-05|2008-02-12|2008-02-13|Estimate|||||||2009-08-05|2009-08-07|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||The Specificity of Cervical Facet Medial Branch Blocks|Randomized Study Comparing the Accuracy and Specificity of Cervical Facet Medial Branch Blocks With 0.25 ml and 0.5 ml of Local Anesthetic|Completed||N/A|20|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:28:33.212607|2018-06-01 02:28:33.212607
NCT00613327|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2013-07-09||2013-10-24|2008-01-31|2008-02-13|Estimate|2013-07-09|2013-09-16|Estimate||||2013-10-24|2013-11-19|Estimate|September 2007||2007-09-30|October 2013|2013-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional||Intent-to-treat (ITT) population included all participants who received study drug at least once and had data for efficacy evaluation (goal achievement in treatment) available.|An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants|The Efficacy of Oxybutynin Chloride OROS in Patient-Reported Outcomes With Dose Escalation in Korean Overactive Bladder Patients|Completed||Phase 4|345|Actual|Janssen Korea, Ltd., Korea||1|||f||||f||||||||||2018-06-01 02:28:33.354923|2018-06-01 02:28:33.354923
NCT00613314|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-02-08||2014-04-30|2008-02-12|2008-02-13|Estimate|2010-02-08|2010-03-05|Estimate||||2014-04-30|2014-05-26|Estimate|June 2007||2007-06-30|April 2014|2014-04-30||||April 2008|Actual|2008-04-30||Observational||The figure was based on the ITT (intention to treat) population which was reported in the PMS report. The total ITT population is 14, 161.|Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen|Clinical EvaluatioN of TElmisartan-based Antihypertensive Regimen (CENTER)|Completed|||15268|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:28:34.067309|2018-06-01 02:28:34.067309
NCT00613301|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-09-08||2014-05-28|2008-02-12|2008-02-13|Estimate|2010-10-26|2010-11-23|Estimate||||2014-05-28|2014-06-06|Estimate|February 2004||2004-02-29|May 2014|2014-05-31||||September 2009|Actual|2009-09-30||Observational||Data Set for Safety Analysis|Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa|Pramipexole Special Survey on Patients Without Concomitant Use of L-Dopa|Completed|||416|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:28:34.468987|2018-06-01 02:28:34.468987
NCT00613288|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-10-21|2008-02-12|2008-02-13|Estimate|||||||2009-10-21|2009-10-22|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism|Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism|Completed||N/A|12|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-06-01 02:28:34.954821|2018-06-01 02:28:34.954821
NCT00613275|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2016-06-14|2008-02-11|2008-02-13|Estimate|||||||2016-06-14|2016-06-15|Estimate|July 2005||2005-07-31|June 2016|2016-06-30|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Interventional|||Patient Navigation in the Safety Net:CONNECTeDD|Patient Navigation in the Safety Net:CONNECTeDD|Completed||Phase 4|4038|Actual|Boston Medical Center|||||f||||t||||||||||2018-06-01 02:28:35.025815|2018-06-01 02:28:35.025815
NCT00613262|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-04-06|2008-01-31|2008-02-13|Estimate|||||||2012-04-06|2012-04-09|Estimate|April 2012||2012-04-30|February 2009|2009-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|NBI||A Prospective, Single Blinded Study for Predicting Colon Polyp Histology With Narrow Band Imaging|A Prospective, Single Blinded Study for Predicting Colon Polyp Histology With Narrow Band Imaging|Unknown status|Recruiting|N/A|200|Anticipated|Midwest Biomedical Research Foundation|||||f||||t||||||||||2018-06-01 02:28:35.105035|2018-06-01 02:28:35.105035
NCT00613249|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2009-03-26|2008-01-31|2008-02-13|Estimate|||||||2009-03-26|2009-03-27|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Phase I Pharmacokinetics and Safety Study of Two Dapivirine Intravaginal Gels|A Double-Blind, Randomized, Placebo-Controlled Phase I Study to Compare the Pharmacokinetics of Intravaginal Dapivirine Gel 4750, 0.05%, 2.5g and Dapivirine Gel 4789, 0.05%, 2.5g Formulations and to Assess the Safety as Compared to the Intravaginal HEC-Based Universal Placebo Gel, 2.5g in Healthy HIV-Negative Women.|Completed||Phase 1|36|Actual|International Partnership for Microbicides, Inc.||3|||f||||f||||||||||2018-06-01 02:28:35.192512|2018-06-01 02:28:35.192512
NCT00613223|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2013-02-19|2008-02-11|2008-02-12|Estimate|||||||2013-02-19|2013-02-20|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|||Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas|Phase I Dose Escalation of Vandetanib (Zactima, ZD6474) in Combination With Etoposide for Malignant Gliomas|Completed||Phase 1|49|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:28:35.283782|2018-06-01 02:28:35.283782
NCT00613210|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-02-11|2008-02-11|2008-02-12|Estimate|||||||2008-02-11|2008-02-12|Estimate|January 2008||2008-01-31|January 2008|2008-01-31||||June 2008|Anticipated|2008-06-30||Observational|||Sonographic Prediction of Preterm Delivery Between 24-34 Weeks of Gestation|Sonographic Prediction of Preterm Delivery Between 24-34 Weeks of Gestation|Unknown status|Active, not recruiting||150|Anticipated|Soroka University Medical Center|||3||f||||||||||None Retained|"~     sonographic measurments~   "|||2018-06-01 02:28:35.386283|2018-06-01 02:28:35.386283
NCT00613197|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2013-04-03|2008-02-11|2008-02-12|Estimate|||||||2013-04-03|2013-04-04|Estimate|January 2003||2003-01-31|April 2013|2013-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|EPIC-1||EPANOVA in Crohn's Disease, Study 1|A One Year, Multi-center, Randomised, Double-blind Placebo-controlled Parallel-groups Assessment of the Tolerability, Safety and Efficacy of Epanova Soft Gelatin Capsules 4g/Day for Maintenance of Remission of Crohn's Disease.|Completed||Phase 3|384|Actual|Tillotts Pharma AG||2|||f||||t||||||||||2018-06-01 02:28:35.453141|2018-06-01 02:28:35.453141
NCT00613184|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2008-02-11|2008-02-11|2008-02-12|Estimate|||||||2008-02-11|2008-02-12|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|January 2008|Anticipated|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses|Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses|Unknown status|Active, not recruiting|N/A|150|Anticipated|Kern Medical Center||4|||f||||f||||||||||2018-06-01 02:28:35.535866|2018-06-01 02:28:35.535866
NCT00613171|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-03-17|2008-01-29|2008-02-12|Estimate|||||||2017-03-17|2017-03-21|Actual|January 2008||2008-01-31|March 2017|2017-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Patients With Systemic Sclerosis|A Multi-centre, Open-label, Proof of Concept (PoC) Study to Evaluate the Efficacy and Tolerability of STI571 for the Treatment of Fibrosis in Patients With Systemic Sclerosis|Completed||Phase 2|27|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:28:35.630249|2018-06-01 02:28:35.630249
NCT00613158|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2016-07-28|2008-02-08|2008-02-12|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|February 2010|Actual|2010-02-28|August 2007|Actual|2007-08-31||Observational|||Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk|Atherosclerosis Risk Refinement - a Multi-marker Approach Using Microarrays|Completed|||120|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||3||f||||t||||||||||2018-06-01 02:28:35.72507|2018-06-01 02:28:35.72507
NCT00613145|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2013-01-31|2008-01-29|2008-02-12|Estimate|||||||2013-01-31|2013-02-04|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors|A Phase I Pharmacokinetic and Safety Study of Sorafenib + Capecitabine in Advanced Solid Tumors|Completed||Phase 1|32|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 02:28:35.797691|2018-06-01 02:28:35.797691
NCT00613132|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2013-02-19|2008-02-11|2008-02-12|Estimate|||||||2013-02-19|2013-02-20|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|August 2008|Actual|2008-08-31||Interventional|||Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG|Phase I Dose Escalation of Gleevec in Combination With RAD001 Plus Hydroxyurea for Patients With Recurrent Malignant Glioma|Completed||Phase 1|78|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:28:35.894392|2018-06-01 02:28:35.894392
NCT00613119|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-10|||2018-05-24|2008-02-10|2008-02-12|Estimate|||||||2018-05-24|2018-05-25|Actual|January 31, 2008||2008-01-31|July 13, 2017|2017-07-13|July 13, 2017||2017-07-13|||||Observational|||PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Neurological Disorders|Completed|||108|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:28:36.001568|2018-06-01 02:28:36.001568
NCT00613106|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2011-05-23||2013-04-23|2008-01-29|2008-02-12|Estimate|2011-05-23|2011-06-17|Estimate||||2013-04-23|2013-04-30|Estimate|September 2007||2007-09-30|April 2013|2013-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|HZ-CA-304||Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)|Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)|Completed||Phase 3|179|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||t||||||||||2018-06-01 02:28:36.117202|2018-06-01 02:28:36.117202
NCT00613093|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2014-07-08|2008-02-11|2008-02-12|Estimate|||||||2014-07-08|2014-07-09|Estimate|October 2002||2002-10-31|November 2012|2012-11-30|August 2008|Actual|2008-08-31|March 2006|Actual|2006-03-31||Interventional|||Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma|Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma|Completed||Phase 2|67|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:28:36.469858|2018-06-01 02:28:36.469858
NCT00613080|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-09|2013-04-12||2016-12-30|2008-02-09|2008-02-12|Estimate|2013-06-06|2013-06-10|Estimate||||2016-12-30|2017-02-17|Actual|April 2008||2008-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|January 2010|Actual|2010-01-31||Interventional||All eligible patients.|Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer|A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer|Completed||Phase 2|79|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 02:28:36.63492|2018-06-01 02:28:36.63492
NCT00613067|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2010-06-29|2008-01-29|2008-02-12|Estimate|||||||2010-06-29|2010-06-30|Estimate|December 2007||2007-12-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|N1||ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder|The Amplitude Change of the Auditory Evoked N1 Component as a Predictor of Response to Escitalopram Treatment in Patients With Generalized Anxiety Disorder|Completed||N/A|35|Anticipated|Inje University||1|||f||||f||||||||||2018-06-01 02:28:37.379993|2018-06-01 02:28:37.379993
NCT00613054|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2012-12-04|2008-02-11|2008-02-12|Estimate|||||||2012-12-04|2012-12-05|Estimate|November 2007||2007-11-30|December 2012|2012-12-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma|Phase I Study of Zactima (ZD6474) Plus Imatinib Mesylate and Hydroxyurea for Patients With Recurrent Malignant Glioma|Completed||Phase 1|27|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:28:37.476039|2018-06-01 02:28:37.476039
NCT00613041|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2017-09-05|2008-01-29|2008-02-12|Estimate|||||||2017-09-05|2017-09-06|Actual|April 2003||2003-04-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||3-D Reconstruction of CT Scan Images in the Evaluation of Non-Specific Pulmonary Nodules|Pilot Study: 3-D Reconstruction of CT Scan Images in the Evaluation of Non-Specific Pulmonary Nodules|Active, not recruiting|||19|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:28:37.567527|2018-06-01 02:28:37.567527
NCT00613028|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2012-12-31||2013-07-10|2008-02-11|2008-02-12|Estimate|2012-12-31|2013-02-04|Estimate||||2013-07-10|2013-07-16|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|January 2011|Actual|2011-01-31|October 2009|Actual|2009-10-31||Interventional|||Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan|Phase II Study of Bevacizumab Plus Either Temozolomide or Etoposide for (GBM) Patients Who Have Failed Bevacizumab Plus Irinotecan|Completed||Phase 2|23|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:28:37.667955|2018-06-01 02:28:37.667955
NCT00613015|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2013-05-23||2016-02-08|2008-02-08|2008-02-12|Estimate|2013-10-16|2013-11-08|Estimate||||2016-02-08|2016-03-08|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Stress and Medication Effects on Cocaine Cue Reactivity|Interdisciplinary Medication Development for Multiple Risk Factors in Relapse.|Completed||Phase 2|109|Actual|Medical University of South Carolina||6|||f||||t||||||||||2018-06-01 02:28:37.986692|2018-06-01 02:28:37.986692
NCT00612833|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2013-09-09|2008-01-29|2008-02-12|Estimate|||||||2013-09-09|2013-09-10|Estimate|January 2009||2009-01-31|September 2013|2013-09-30||||||||Interventional|||A Randomized Controlled Trial of Three Vasectomy Techniques|A Randomized Controlled Trial of Three Vasectomy Techniques|Terminated||N/A|||FHI 360||3||FHI 360 participation in the study was terminated due to lack of funding|f||||t||||||||||2018-06-01 02:28:40.435995|2018-06-01 02:28:40.435995
NCT00613002|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30||2013-01-04|2013-01-04|2008-01-30|2008-02-12|Estimate||||2013-01-04|2013-01-10|Estimate|2013-01-04|2013-01-10|Estimate|December 2006||2006-12-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|BLOOM||Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women|Completed||Phase 3|597|Actual|BioSante Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:28:38.453116|2018-06-01 02:28:38.453116
NCT00612989|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2014-07-15|2008-02-11|2008-02-12|Estimate|||||||2014-07-15|2014-07-16|Estimate|February 2005||2005-02-28|January 2009|2009-01-31|July 2008|Actual|2008-07-31|August 2007|Actual|2007-08-31||Interventional|||Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM|Phase I Trial of a 5-day Regimen of Temodar Plus O6-Benzylguanine (O6-BG) in the Treatment of Patients With Recurrent / Progressive Glioblastoma Multiforme|Completed||Phase 1|42|Anticipated|Duke University||3|||f||||t||||||||||2018-06-01 02:28:38.606795|2018-06-01 02:28:38.606795
NCT00612976|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2008-02-11|2008-02-11|2008-02-12|Estimate|||||||2008-02-11|2008-02-12|Estimate|February 2006||2006-02-28|January 2008|2008-01-31||||September 2006|Actual|2006-09-30||Observational|SYMBIOSE||Symbicort in Chronic Obstruktive Pulmonary Disease|Symbicort in Chronic Obstruktive Pulmonary Disease|Completed|||18014|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:28:38.676899|2018-06-01 02:28:38.676899
NCT00612963|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2010-03-04|2008-02-11|2008-02-12|Estimate|||||||2010-03-04|2010-03-08|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Novel Rinse to Treat in Oral Candidiasis in Cancer Patients|"Novel Rinse to Treat Oral Candidiasis in Cancer Patients Evaluate Iocide Oral Rinse in Any Patient With Thrush, Including But Not Limited to Patients Currently Receiving or Post Radiation Therapy for Head and Neck Cancer or Patients Positive for HIV/AIDS or Transplant Patients"|Completed|||23|Actual|Biomedical Development Corporation|||||f||||f||||||||||2018-06-01 02:28:38.724751|2018-06-01 02:28:38.724751
NCT00612950|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-02-11|2008-02-11|2008-02-12|Estimate|||||||2008-02-11|2008-02-12|Estimate|October 2006||2006-10-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|February 2007|Actual|2007-02-28||Interventional|||Beta-Cell Function After Near-Normalisation of Blood Glucose|Four Weeks of Near Normalisation of Blood Glucose Improves the Insulin Response to GLP-1 and GIP in Patients With Type 2 Diabetes|Completed||N/A|8|Actual|Hvidovre University Hospital||3|||f||||f||||||||||2018-06-01 02:28:38.780167|2018-06-01 02:28:38.780167
NCT00612937|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-10|||2018-04-04|2008-02-10|2008-02-12|Estimate|||||||2018-04-04|2018-04-05|Actual|February 4, 2008||2008-02-04|June 19, 2015|2015-06-19|June 19, 2015||2015-06-19|||||Observational|||Streptococcal Infection and Respiratory Distress in Newborns|Respiratory Distress of the Newborn and Its Relationship to Group B Streptococcal Colonization|Completed|||13180|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:28:38.858382|2018-06-01 02:28:38.858382
NCT00612924|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2016-02-10|2014-12-10|2017-10-12|2008-02-11|2008-02-12|Estimate|2016-02-10|2016-03-09|Estimate|2014-12-10|2014-12-31|Estimate|2017-10-12|2017-10-16|Actual|April 2009||2009-04-30|October 2017|2017-10-31|July 13, 2017|Actual|2017-07-13|July 2013|Actual|2013-07-31||Interventional|||The Vascutek AnacondaTM Stent Graft System Phase II IDE Study|The Anaconda Endovascular Graft US FDA Phase II Clinical Study|Completed||N/A|195|Actual|Terumo CVS||1|||f||||t||||||||||2018-06-01 02:28:38.933215|2018-06-01 02:28:38.933215
NCT00612911|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-01-29|2008-01-29|2008-02-12|Estimate|||||||2008-01-29|2008-02-12|Estimate|February 2005||2005-02-28|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Observational|||Cell Therapy in Dilated Cardiomyopathy: Observational Study|Cell Therapy in Dilated Cardiomyopathy: A Safety and Feasibility Study Using Autologous Bone Marrow Mononuclear Cells|Terminated|||24|Actual|Ministry of Health, Brazil|||1|finish study as protocol|f||||f||||||||||2018-06-01 02:28:39.578318|2018-06-01 02:28:39.578318
NCT00612898|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2012-01-19|2008-02-11|2008-02-12|Estimate|||||||2012-01-19|2012-01-23|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection|A Phase 2b/3, Randomized, Double Blind, Dose Confirming Study of the Safety, Efficacy and Tolerability of Apricitabine Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V/I Mutation in Reverse Transcriptase|Terminated||Phase 2/Phase 3|239|Actual|Avexa||2||Sponsor decision|f||||t||||||||||2018-06-01 02:28:39.673047|2018-06-01 02:28:39.673047
NCT00612885|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2013-10-31|2008-02-11|2008-02-12|Estimate|||||||2013-10-31|2013-11-01|Estimate|March 2004||2004-03-31|October 2013|2013-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study|Post Marketing Surveillance to Assess the Safety and Efficacy of Mobic® (Meloxicam) Intramuscular Injection (7.5mg ~ 15mg, q.d.) up to 3 Days (in Case of Need for Prolonged Treatment, Switch to Mobic® Capsule Therapy Was Possible) in Korean Patients With Osteoarthritis and Rheumatoid Arthritis (KFDA Regulatory Requirement PMS)|Completed|||425|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:28:39.898094|2018-06-01 02:28:39.898094
NCT00612872|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2010-09-20|2008-01-29|2008-02-12|Estimate|||||||2010-09-20|2010-09-21|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|CLINDE||Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects|Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects|Terminated||Phase 1|46|Actual|Institute for Neurodegenerative Disorders||1||Results did not show reason to continue with study.|f||||f||||||||||2018-06-01 02:28:39.965897|2018-06-01 02:28:39.965897
NCT00612859|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2013-11-25|2008-01-29|2008-02-12|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)|A Multicenter, Randomized, Double-Blind, PBO-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Levetiracetam Versus PBO for the Treatment of Social Anxiety Disorder (Generalized Type)|Completed||Phase 2|217|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:28:40.085014|2018-06-01 02:28:40.085014
NCT00612846|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2008-01-29|2008-01-29|2008-02-12|Estimate|||||||2008-01-29|2008-02-12|Estimate|March 2000||2000-03-31|January 2008|2008-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study Investigating the Best Method of Treatment of Bile Duct Stones in Higher Risk Patients|A Randomised Clinical Trial to Compare Endoscopic Sphincterotomy and Subsequent Laparoscopic Cholecystectomy With Primary Laparoscopic Bile Duct Exploration During Cholecystectomy in Higher Risk Patients With Choledocholithiasis|Terminated||N/A|91|Actual|North Bristol NHS Trust||2||Terminated early due to slow recruitment|f||||t||||||||||2018-06-01 02:28:40.347028|2018-06-01 02:28:40.347028
NCT00612820|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29||2010-10-13|2016-11-02|2008-01-29|2008-02-12|Estimate||||2010-10-13|2010-11-15|Estimate|2016-11-02|2016-11-03|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)|An 8 Day, Randomised, Double Blind, 3-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Fluticasone Propionate in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|55|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:28:40.565878|2018-06-01 02:28:40.565878
NCT00612807|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2011-02-16||2013-06-17|2008-02-11|2008-02-12|Estimate|2011-03-29|2011-04-26|Estimate||||2013-06-17|2013-06-24|Estimate|July 2006||2006-07-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Treatment of Mood and Marriage Study (TOMMS)|Adapting Marital Therapy in Older Adults With Depression|Completed||Phase 1/Phase 2|42|Actual|Duke University|Small sample size limits power to detect differences. Some participants reported difficulty understanding how to complete the questions, which may introduce additional variability into the data.|2|||f||||t||||||||||2018-06-01 02:28:40.727723|2018-06-01 02:28:40.727723
NCT00612794|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2015-02-23|2008-01-30|2008-02-12|Estimate|||||||2015-02-23|2015-02-24|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes|Multiple-Dose Study to Examine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2148568 Long-Acting Release in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|30|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:28:41.08756|2018-06-01 02:28:41.08756
NCT00612781|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2008-01-29|2008-01-29|2008-02-12|Estimate|||||||2008-01-29|2008-02-12|Estimate|December 2005||2005-12-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|February 2007|Actual|2007-02-28||Interventional|YeWhi||Yellow Versus White Study|Influence of Blue-Light-Filter IOLs on Color Perception and Contrast Acuity. A Randomized, Double-Masked Study With Intraindividual Comparison.|Completed||Phase 4|24|Actual|Hospital Hietzing||2|||f||||f||||||||||2018-06-01 02:28:41.206017|2018-06-01 02:28:41.206017
NCT00612768|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2013-02-26||2018-04-06|2008-01-30|2008-02-12|Estimate|2018-04-06|2018-04-09|Actual||||2018-04-06|2018-04-09|Actual|January 2008||2008-01-31|April 2018|2018-04-30|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations|Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations|Completed||Phase 2|50|Actual|Allerderm||1|||f||||f||||||||||2018-06-01 02:28:41.330551|2018-06-01 02:28:41.330551
NCT00612755|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2008-01-29|2008-01-29|2008-02-12|Estimate|||||||2008-01-29|2008-02-12|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4|Open, Randomized, Multicenter Phase IV Study to Evaluate Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Patients Genotype 1 and/or 4|Completed||Phase 4|43|Actual|Hospital Clinico Universitario San Cecilio||2|||f||||f||||||||||2018-06-01 02:28:41.701938|2018-06-01 02:28:41.701938
NCT00612742|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2013-01-04|2008-01-30|2008-02-12|Estimate|||||||2013-01-04|2013-01-08|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|BLOOM||Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women|Completed||Phase 3|3656|Actual|BioSante Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:28:41.826245|2018-06-01 02:28:41.826245
NCT00612729|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2010-08-16|2008-01-29|2008-02-12|Estimate|||||||2010-08-16|2010-08-17|Estimate|May 2008||2008-05-31|December 2008|2008-12-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.|Influence of Light-filters in IOLs on Color Perception and Contrast Acuity. A Randomized, Double-masked Study With Intraindividual Comparison.|Completed||Phase 4|32|Actual|Hospital Hietzing|||||f||||f||||||||||2018-06-01 02:28:42.149857|2018-06-01 02:28:42.149857
NCT00612716|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-09|||2018-01-03|2008-02-09|2008-02-12|Estimate|||||||2018-01-03|2018-01-05|Actual|October 6, 1999|Actual|1999-10-06|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia|Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia|Recruiting||Phase 2|15|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:28:42.244488|2018-06-01 02:28:42.244488
NCT00612703|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2012-07-20|2008-01-30|2008-02-12|Estimate|||||||2012-07-20|2012-07-23|Estimate|February 2008||2008-02-29|July 2012|2012-07-31||||September 2010|Actual|2010-09-30||Interventional|||A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|32|Actual|ArQule|||||f||||f||||||||||2018-06-01 02:28:42.371467|2018-06-01 02:28:42.371467
NCT00612690|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2013-08-16||2014-05-15|2008-02-08|2008-02-12|Estimate|2014-05-15|2014-06-04|Estimate||||2014-05-15|2014-06-04|Estimate|June 2005||2005-06-30|May 2014|2014-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Total number of students, teachers, parents, and service providers (in the Links to Learn condition only) who were consented to participate in the study (Note: Service providers in the Services as Usual condition were not research participants).|School-Based Mental Health Services for Urban Children|Mental Health Services & Predictors of Learning in Urban Schools|Completed||N/A|482|Actual|University of Illinois at Chicago|This study was conducted in high poverty urban communities and therefore there were many impediments to recruitment and retention such as school closings and family migration.|2|||f||||f||||||||||2018-06-01 02:28:42.455003|2018-06-01 02:28:42.455003
NCT00612677|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2011-02-21||2017-02-20|2008-01-29|2008-02-12|Estimate|2011-03-24|2011-04-20|Estimate||||2017-02-20|2017-03-23|Actual|June 2007||2007-06-30|December 2013|2013-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem|Phase II Combination of Pemetrexed and Oxaliplatin in Patients With Recurrent Non-Small Cell Lung Cancer After Failure to Platinum Based Adjuvant Chemotherapy|Terminated||Phase 2|1|Actual|H. Lee Moffitt Cancer Center and Research Institute|Terminated due to slow accrual. Study closed before treatment started.|1||slow accrual - the 1 patient accrued did not go on treatment|f||||f||||||||||2018-06-01 02:28:42.903513|2018-06-01 02:28:42.903513
NCT00612664|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30||2011-06-21|2015-09-23|2008-01-30|2008-02-12|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|March 2008||2008-03-31|September 2015|2015-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase II, 2nd Line Melanoma - RAND Monotherapy|A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma|Completed||Phase 2|158|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 02:28:43.128944|2018-06-01 02:28:43.128944
NCT00612651|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2013-02-15|2008-02-11|2008-02-12|Estimate|||||||2013-02-15|2013-02-20|Estimate|October 2005||2005-10-31|February 2013|2013-02-28|June 2011|Actual|2011-06-30|January 2009|Actual|2009-01-31||Interventional|||PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas|A Phase I Trial of the Addition of the Farnesyl Transferase Inhibitor, SCH 66336, to Temodar for Patients With Grade 3 and 4 Malignant Gliomas|Completed||Phase 1|37|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:28:43.261649|2018-06-01 02:28:43.261649
NCT00612638|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2013-06-18|2008-02-11|2008-02-12|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|January 2007|Actual|2007-01-31||Interventional|||Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas|Phase I Trail of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) Plus Irinotecan (CPT-11) (NSC 616348) in the Treatment of Patients With Recurrent / Progressive Cerebral Anaplastic Gliomas|Completed||Phase 1|96|Anticipated|Duke University||2|||f||||t||||||||||2018-06-01 02:28:43.34939|2018-06-01 02:28:43.34939
NCT00612625|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-02-11|2008-02-11|2008-02-12|Estimate|||||||2008-02-11|2008-02-12|Estimate|February 2004||2004-02-29|January 2008|2008-01-31|December 2004|Actual|2004-12-31|July 2004|Actual|2004-07-31||Interventional|||Near Normalisation of BG Improves the Potentiating Effect of GLP-1|Near Normalisation of Blood Glucose Improves the Potentiating Effect of GLP-1 on Glucose Induced Insulin Secretion in Patients With Type 2 Diabetes|Completed||N/A|9|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 02:28:43.435904|2018-06-01 02:28:43.435904
NCT00612612|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2013-09-27|2008-02-08|2008-02-11|Estimate|||||||2013-09-27|2013-09-30|Estimate|January 2008||2008-01-31|September 2013|2013-09-30||||July 2013|Actual|2013-07-31||Interventional|||Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia|A Phase 1 Study of Obatoclax Mesylate (GX15-070MS) in Combination With Fludarabine-Based Chemoimmunotherapy in Previously Treated Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Terminated||Phase 1|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:28:43.520308|2018-06-01 02:28:43.520308
NCT00612599|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2017-01-05|2008-01-29|2008-02-11|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2003||2003-09-30|January 2017|2017-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes|Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Non-obese and Obese With Type 2 Diabetes Mellitus|Completed||Phase 3|75|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:28:43.593483|2018-06-01 02:28:43.593483
NCT00612586|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28||2010-10-25|2012-02-17|2008-01-28|2008-02-11|Estimate||||2010-10-25|2010-10-27|Estimate|2012-02-17|2012-02-22|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|November 2011|Actual|2011-11-30|January 2010|Actual|2010-01-31||Interventional|||Phase 2 Study of Enzastaurin With 5 FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer|A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5 FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer.|Completed||Phase 2|150|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:28:43.689667|2018-06-01 02:28:43.689667
NCT00612573|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2011-02-14||2013-04-15|2008-01-25|2008-02-11|Estimate|2011-03-18|2011-04-19|Estimate||||2013-04-15|2013-04-22|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Treatment of Moderate to Severe Facial Acne Vulgaris|Phase 2 Study Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 3 Doses of Doxycycline as Compared to Placebo in the Treatment of Moderate to Severe Facial Acne Vulgaris|Completed||Phase 2|257|Actual|Warner Chilcott||4|||f||||f||||||||||2018-06-01 02:28:43.808047|2018-06-01 02:28:43.808047
NCT00612560|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2017-07-17||2017-09-11|2008-02-07|2008-02-11|Estimate|2017-07-17|2017-08-16|Actual||||2017-09-11|2017-10-12|Actual|November 2007||2007-11-30|September 2017|2017-09-30|April 2014|Actual|2014-04-30|January 2011|Actual|2011-01-31||Interventional|FABrC|All treated and eligible patients|Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics|Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis|Completed||N/A|28|Actual|Roswell Park Cancer Institute||4|||f||||t||||||||||2018-06-01 02:28:44.279333|2018-06-01 02:28:44.279333
NCT00612547|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2009-02-25|2008-01-28|2008-02-11|Estimate|||||||2009-02-25|2009-02-26|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||ACT for the Home Management in Malagasy Children|Assessment of the Use of Fixed Doses of Artesunate Plus Amodiaquine Combination for the Home Management of Presumed Malaria in Malagasy Children|Completed|||1200|Actual|National Malaria Control Programme, Madagascar|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:28:45.846013|2018-06-01 02:28:45.846013
NCT00612534|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2013-10-18||2014-01-22|2008-01-29|2008-02-11|Estimate|2014-01-22|2014-02-17|Estimate||||2014-01-22|2014-02-17|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ARX-F01||A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement|A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement|Completed||Phase 2|94|Actual|AcelRx Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 02:28:45.938863|2018-06-01 02:28:45.938863
NCT00612521|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-08-28|2008-02-07|2008-02-11|Estimate|||||||2012-08-28|2012-08-29|Estimate|August 2007||2007-08-31|August 2012|2012-08-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis|Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis|Terminated||Phase 3|200|Actual|Ottawa Heart Institute Research Corporation||2||At half the sample size, the results were negative with no benefit demonstrated with adenosine.|f||||f||||||||||2018-06-01 02:28:46.358442|2018-06-01 02:28:46.358442
NCT00612508|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2010-12-16||2012-10-09|2008-01-29|2008-02-11|Estimate|2012-10-09|2012-11-08|Estimate||||2012-10-09|2012-11-08|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Hormonal Contraception and Vaginal Health|The Effects of Oral vs. Intravaginal Hormonal Contraception on Vaginal Health|Completed||N/A|14|Actual|Oregon Health and Science University|Did not fully recruit; small number of subject|2|||f||||f||||||||||2018-06-01 02:28:46.443508|2018-06-01 02:28:46.443508
NCT00612495|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-02-08|2008-02-08|2008-02-11|Estimate|||||||2008-02-08|2008-02-11|Estimate|January 2001||2001-01-31|January 2008|2008-01-31|March 2005|Actual|2005-03-31|||||Interventional|||Endometrial Cancer - LOHP Alone and With 5FU|Parallel Randomised Open Phase II Study of Oxaliplatin (L-OHP) Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Locally Advanced or Metastatic Endometrial Cancer Previously Treated With Cisplatin or Arboplatin|Completed||Phase 2|31|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:28:46.848658|2018-06-01 02:28:46.848658
NCT00612482|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2011-03-11|2008-01-29|2008-02-11|Estimate|||||||2011-03-11|2011-03-14|Estimate|December 2006||2006-12-31|March 2011|2011-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education|Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education: A High School Pilot Study|Completed||Phase 1|225|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 02:28:46.919878|2018-06-01 02:28:46.919878
NCT00612469|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2008-01-29|2008-01-29|2008-02-11|Estimate|||||||2008-01-29|2008-02-11|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Interventional|||The Use of Antimicrobial Agents in the Inhibition of Mutans Streptococci in Children With Dental Caries|Sodium Fluoride, Chlorhexidine and Vancomycin Effect in the Inhibition of Mutans Streptococci in Children With Dental Caries: a Randomized, Double-Blind Clinical Trial|Completed||N/A|69|Actual|Universidade Federal do Ceara||4|||f||||f||||||||||2018-06-01 02:28:46.989137|2018-06-01 02:28:46.989137
NCT00612456|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2017-09-05|2010-02-05|2017-10-18|2008-02-08|2008-02-11|Estimate|2017-09-05|2017-09-28|Actual|2010-02-05|2010-02-10|Estimate|2017-10-18|2017-11-20|Actual|March 5, 2008|Actual|2008-03-05|September 2017|2017-09-30|June 17, 2009|Actual|2009-06-17|January 1, 2009|Actual|2009-01-01||Interventional|||To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD|A Double-masked, Randomized, Parallel-group Study to Investigate the Pharmacodynamics, Safety, and Systemic Pharmacokinetics of Pazopanib Drops, Administered for 28 Days to Adult Subjects With Neovascular Age-related Macular Degeneration.|Completed||Phase 2|70|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 02:28:47.14497|2018-06-01 02:28:47.14497
NCT00612443|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2009-01-20|2008-01-25|2008-02-11|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Healing Touch and Health-Related Quality of Life in Women With Breast Cancer Receiving Radiation Therapy|Healing Touch and Health-Related Quality of Life in Women With Breast Cancer in Women With Breast Cancer Receiving Radiation Therapy|Completed||Phase 2/Phase 3|40|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-06-01 02:28:48.063791|2018-06-01 02:28:48.063791
NCT00612430|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2013-05-28||2013-07-30|2008-02-08|2008-02-11|Estimate|2013-05-28|2013-07-26|Estimate||||2013-07-30|2013-08-12|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2008|Actual|2008-09-30||Interventional|||Ph II Bevacizumab + Etoposide for Pts w Recurrent MG|Phase II Trial of Bevacizumab Plus Etoposide for Patients With Recurrent Malignant Glioma|Completed||Phase 2|59|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:28:48.298317|2018-06-01 02:28:48.298317
NCT00612417|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2014-04-04|2008-02-08|2008-02-11|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402|A Randomised, Double-blind and Placebo-controlled Study Investigating the Pharmacodynamic Effects of Administration of Recombinant Human Factor VIII in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402|Completed||Phase 1|12|Actual|ThromboGenics||2|||f||||f||||||||||2018-06-01 02:28:48.842806|2018-06-01 02:28:48.842806
NCT00612404|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-02-08|2008-02-08|2008-02-11|Estimate|||||||2008-02-08|2008-02-11|Estimate|September 2005||2005-09-30|January 2008|2008-01-31||||December 2005|Actual|2005-12-31||Observational|||Symptoms and Endoscopic Results in Consideration of Pretreatment|Symptoms and Endoscopic Results in Consideration of Pretreatment|Completed|||16255|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:28:48.940556|2018-06-01 02:28:48.940556
NCT00612391|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2018-01-31|2008-02-08|2008-02-11|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 2007||2007-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|HURA||Lateral Mini Approach vs Anterior Approach for Plating of Proximal Humerus Fracture|A Randomized Clinical Trail Comparing a Lateral Minimally Invasive Approach and the Traditional Anterior Approach for Plating of Proximal Humerus Fractures|Active, not recruiting||N/A|79|Actual|Université de Montréal||2|||f||||f||||||||||2018-06-01 02:28:48.996151|2018-06-01 02:28:48.996151
NCT00612378|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2014-06-23|2008-02-08|2008-02-11|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2007||2007-09-30|June 2014|2014-06-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||A Multi-center Acute Efficacy Trial of GFX For Reduction of Glabellar Furrowing|A Multi-center Acute Efficacy Trial of GFX For Reduction of Glabellar Furrowing|Completed||N/A|94|Actual|Advanced Cosmetic Intervention||1|||f||||t||||||||||2018-06-01 02:28:49.065359|2018-06-01 02:28:49.065359
NCT00612365|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2016-07-28|2008-02-07|2008-02-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|June 2013|Actual|2013-06-30|August 2012|Actual|2012-08-31||Observational|MESA ABD||Association Between Abdominal Body Composition, Inflammation, and Risk for Cardiovascular Disease (The MESA ABD Study)|Abdominal Body Composition, Inflammation, and Cardiovascular Disease|Completed|||1975|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||1||f||||f||||||||||2018-06-01 02:28:49.143089|2018-06-01 02:28:49.143089
NCT00612352|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2017-01-03||2017-01-03|2008-01-25|2008-02-11|Estimate|2017-01-03|2017-02-24|Actual||||2017-01-03|2017-02-24|Actual|March 2001||2001-03-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism|Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism|Completed||N/A|180|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:28:49.312684|2018-06-01 02:28:49.312684
NCT00612339|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2012-08-09||2013-05-20|2008-02-08|2008-02-11|Estimate|2012-08-09|2012-09-10|Estimate||||2013-05-20|2013-05-27|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas|Avastin in Combination With Temozolomide for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas|Completed||Phase 2|41|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:28:50.653295|2018-06-01 02:28:50.653295
NCT00612326|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2015-12-16|2008-01-28|2008-02-11|Estimate|||||||2015-12-16|2015-12-18|Estimate|June 2004||2004-06-30|December 2015|2015-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging|Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging|Completed|||26|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:28:50.870345|2018-06-01 02:28:50.870345
NCT00612313|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2014-07-03||2015-12-03|2008-02-07|2008-02-11|Estimate|2014-12-16|2014-12-17|Estimate||||2015-12-03|2016-01-07|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|January 2014|Actual|2014-01-31|February 2013|Actual|2013-02-28||Interventional|||Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse|Pediatric MDD: Sequential Treatment With Fluoxetine and Relapse Prevention|Completed||N/A|144|Actual|University of Texas Southwestern Medical Center|"Primary outcomes based on data through 30 weeks.~Participants were not blinded to treatment assignment."|2|||f||||t||||||||||2018-06-01 02:28:50.973517|2018-06-01 02:28:50.973517
NCT00612300|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2010-02-16|2008-01-28|2008-02-11|Estimate|||||||2010-02-16|2010-02-17|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|GTS||Gait Training for Persons With Stroke|The Lokomat Gait Orthosis Compared to Categorized Gait Training by Physical Therapists in Patients Early Post Stroke|Completed||Early Phase 1|16|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:28:51.423593|2018-06-01 02:28:51.423593
NCT00612287|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2009-04-06|2008-02-06|2008-02-11|Estimate|||||||2009-04-06|2009-04-07|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|August 2009|Anticipated|2009-08-31|May 2009|Anticipated|2009-05-31||Interventional|||Sublingual Buprenorphine for Chronic Pain|Sublingual Buprenorphine for Chronic Pain in Patients at Risk for Drug Abuse|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|National Institute on Drug Abuse (NIDA)||1|||f||||f||||||||||2018-06-01 02:28:51.51295|2018-06-01 02:28:51.51295
NCT00612274|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2016-11-29|2008-02-08|2008-02-11|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation|Pilot Study of Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute Graft Versus Host Disease in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation|Completed||Early Phase 1|26|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:28:51.588844|2018-06-01 02:28:51.588844
NCT00612261|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2008-01-25|2008-01-25|2008-02-11|Estimate|||||||2008-01-25|2008-02-11|Estimate|October 2006||2006-10-31|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion|Arteriovenous Crossing Sheathotomy Versus Intravitreal Triamcinolone Acetonide Injection for Treatment of Macular Edema Associated With Branch Retinal Vein Occlusion|Completed||N/A|40|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 02:28:51.664116|2018-06-01 02:28:51.664116
NCT00612248|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2008-01-29|2008-01-29|2008-02-11|Estimate|||||||2008-01-29|2008-02-11|Estimate|July 2005||2005-07-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Functional Splint for Osteoarthritis of the Trapeziometacarpal Joint|Assessment of the Effectiveness of a Functional Splint for Osteoarthritis of the Trapeziometacarpal Joint on the Dominant Hand: A Randomized Controlled Study|Completed||Phase 2|40|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 02:28:51.983756|2018-06-01 02:28:51.983756
NCT00612235|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2010-03-15|2008-01-29|2008-02-11|Estimate|||||||2010-03-15|2010-03-16|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Observational|||Premenstrual Dysphoric Disorder and Antiepileptic Drugs|Comparison of Different Antiepileptic Drug Monotherapies for the Occurrence of Premenstrual Dysphoric Disorder Among Women With Epilepsy|Unknown status|Recruiting||100|Anticipated|Beth Israel Deaconess Medical Center|||5||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:28:52.056544|2018-06-01 02:28:52.056544
NCT00612222|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2012-03-13||2015-10-06|2008-02-08|2008-02-11|Estimate|2012-03-13|2012-04-19|Estimate||||2015-10-06|2015-10-28|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization|Terminated||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)|Early termination leading to small numbers of subjects analyzed.|1||The study was terminated due to low accrual.|f||||t||||||||||2018-06-01 02:28:52.176262|2018-06-01 02:28:52.176262
NCT00612209|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2012-07-20|2008-01-29|2008-02-11|Estimate|||||||2012-07-20|2012-07-23|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|ARQ 197||A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|51|Actual|ArQule||1|||f||||f||||||||||2018-06-01 02:28:52.434478|2018-06-01 02:28:52.434478
NCT00612196|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2014-04-04|2008-02-08|2008-02-11|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers|A Randomised, Phase I, Single Dose, Placebo-Controlled, Dose Escalation Study of TB-402, A Monocloncal Antibody Directed Against FACTOR VIII, Administered Intravenously in Healthy Male Volunteers.|Completed||Phase 1|56|Actual|ThromboGenics||10|||f||||f||||||||||2018-06-01 02:28:52.505806|2018-06-01 02:28:52.505806
NCT00612183|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2010-07-21|2008-01-28|2008-02-11|Estimate|||||||2010-07-21|2010-07-22|Estimate|December 2007||2007-12-31|May 2010|2010-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma|Phase II Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (Multicenter, Open-label Study)|Completed||Phase 2|56|Anticipated|SymBio Pharmaceuticals|||||f||||t||||||||||2018-06-01 02:28:52.581646|2018-06-01 02:28:52.581646
NCT00612170|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2011-04-06|2008-01-29|2008-02-11|Estimate|||||||2011-04-06|2011-04-07|Estimate|December 2007||2007-12-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.|A 14-week, Randomized, Double-blind, Placebo-controlled, Multi-center Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily (O.D.) in Patients With Fibromyalgia|Completed||Phase 3|1129|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 02:28:52.71159|2018-06-01 02:28:52.71159
NCT00612157|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2009-02-25|2008-02-08|2008-02-11|Estimate|||||||2009-02-25|2009-02-26|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|June 2008|Actual|2008-06-30||Interventional|CPAPASAP||Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Effect of Eszoplicone on Initial Continuous Positive Airway Pressure (CPAP) Compliance|Completed||Phase 4|154|Anticipated|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 02:28:53.168474|2018-06-01 02:28:53.168474
NCT00612144|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2013-03-26|2008-01-28|2008-02-11|Estimate|||||||2013-03-26|2013-03-28|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Comparing Efficacy and Safety of Amaryl M and Metformin Uptitraion to Type 2 DM|A Multicenter, Randomized, Parallel-group, Open Study to Compare the Efficacy and Safety of Early Combination Therapy With Amaryl M to Metformin Uptitration in Type 2 DM Patients Inadequately Controlled on Metformin HCL|Completed||Phase 4|192|Anticipated|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:28:53.263627|2018-06-01 02:28:53.263627
NCT00612131|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2012-10-15|2008-01-28|2008-02-11|Estimate|||||||2012-10-15|2012-10-17|Estimate|November 2007||2007-11-30|September 2007|2007-09-30||||January 2008|Actual|2008-01-31||Observational|||Medical Residents Performance: Effect of Simulation-Based Training|Medical Residents Performance in Maximum Barrier Precautions During Central Venous Catheter Placement: Effect of Simulation-Based Training|Completed|||47|Anticipated|St. Luke's-Roosevelt Hospital Center|||||f||||f||||||||||2018-06-01 02:28:53.34198|2018-06-01 02:28:53.34198
NCT00612118|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29||2009-07-22|2012-05-31|2008-02-08|2008-02-11|Estimate||||2009-07-22|2009-08-10|Estimate|2012-05-31|2012-06-05|Estimate|February 2008||2008-02-29|February 2011|2011-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis|A Randomised, Double Blind, 2-way Crossover Trial of 8 Days Repeat Dosing With Intranasal GSK256066 and Azelastine Hydrochloride in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|70|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:28:53.459115|2018-06-01 02:28:53.459115
NCT00612105|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2011-07-08||2018-04-06|2008-01-25|2008-02-11|Estimate|2011-12-09|2012-01-11|Estimate||||2018-04-06|2018-05-08|Actual|October 2007||2007-10-31|April 2018|2018-04-30|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated With Post-Herpetic Neuralgia|Completed||Phase 2|187|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 02:28:53.599655|2018-06-01 02:28:53.599655
NCT00612092|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-08-26|2008-01-28|2008-02-11|Estimate|||||||2008-08-26|2008-08-27|Estimate|May 2008||2008-05-31|August 2008|2008-08-31|February 2009|Anticipated|2009-02-28|January 2009|Anticipated|2009-01-31||Interventional|PROTECTION-III||Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A Sequential Scan Protocol|Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A Sequential Scan Protocol|Unknown status|Recruiting|Phase 4|400|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:28:54.770254|2018-06-01 02:28:54.770254
NCT00612079|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2012-09-14|2008-02-08|2008-02-11|Estimate|||||||2012-09-14|2012-09-17|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers||Completed||N/A|30|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 02:28:54.839678|2018-06-01 02:28:54.839678
NCT00612066|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2013-01-11||2016-01-19|2008-02-08|2008-02-11|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|April 2007||2007-04-30|January 2016|2016-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)|An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease|Terminated||Phase 2|2|Actual|Jonsson Comprehensive Cancer Center|Recruitment was a major limitation. Patients were available but were not interested in the study due to possible side effects of the study drug.|1||Low accrual and funding term ended|f||||t||||||||||2018-06-01 02:28:54.919033|2018-06-01 02:28:54.919033
NCT00612053|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2010-06-28|2008-01-29|2008-02-11|Estimate|||||||2010-06-28|2010-06-29|Estimate|May 2008||2008-05-31|February 2010|2010-02-28|December 2015|Anticipated|2015-12-31|December 2009|Anticipated|2009-12-31||Observational|RITMO||Italian Registry on Unprotected Left Main|Italian Registry on Treatment for Unprotected Left Main Disease (Registro Italiano Sul Trattamento Del Tronco coMune Non protettO)|Unknown status|Recruiting||1200|Anticipated|University of Turin, Italy|||||f||||t||||||||||2018-06-01 02:28:55.145065|2018-06-01 02:28:55.145065
NCT00612040|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2015-10-16|2009-11-09|2017-01-18|2008-01-29|2008-02-11|Estimate|2015-10-16|2015-11-16|Estimate|2009-11-09|2009-11-11|Estimate|2017-01-18|2017-03-03|Actual|January 2008||2008-01-31|January 2017|2017-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes|A 16 Week Randomised, Open Labelled, 3-armed, Treat-to-target, Parallel Group Trial Comparing SIBA (D) Once Daily + NovoRapid®, SIBA (E) Once Daily + NovoRapid® and Insulin Glargine Once Daily + NovoRapid®, All in a Basal/Bolus Regimen in Subjects With Type 1 Diabetes|Completed||Phase 2|178|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 02:28:55.366085|2018-06-01 02:28:55.366085
NCT00612027|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2008-02-08|2008-02-08|2008-02-11|Estimate|||||||2008-02-08|2008-02-11|Estimate|January 2006||2006-01-31|January 2008|2008-01-31||||March 2006|Actual|2006-03-31||Observational|||Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions|Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions|Completed|||29586|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:28:56.106125|2018-06-01 02:28:56.106125
NCT00612014|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28||2012-12-05|2012-12-05|2008-02-08|2008-02-11|Estimate||||2012-12-05|2012-12-07|Estimate|2012-12-05|2012-12-07|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus|Completed||Phase 2|78|Actual|Tranzyme, Inc.||6|||f||||t||||||||||2018-06-01 02:28:56.229619|2018-06-01 02:28:56.229619
NCT00612001|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2015-10-01|2008-02-08|2008-02-11|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2006||2006-05-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|January 2011|Actual|2011-01-31||Interventional|||Vaccine Therapy in Treating Patients With Malignant Glioma|Phase I Study of Glioma-Associated Antigen (GAA) Peptide-pulsed Dendritic Cell Vaccination in Malignant Glioma Patients|Completed||Phase 1|8|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:28:56.402411|2018-06-01 02:28:56.402411
NCT00611988|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-12-09|2008-01-25|2008-02-11|Estimate|||||||2013-12-09|2013-12-10|Estimate|August 2006||2006-08-31|December 2013|2013-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Self-Managed Walking Improves Function|Self-Managed Walking Improves Function in Patients With Diabetes Mellitus and Peripheral Arterial Disease|Completed||Phase 2|145|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 02:28:56.500808|2018-06-01 02:28:56.500808
NCT00611975|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2012-06-27|2008-02-06|2008-02-11|Estimate|||||||2012-06-27|2012-06-28|Estimate|October 2005||2005-10-31|June 2012|2012-06-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning|Effect of Serotonin Reuptake Inhibitors on Gonadal Steroid Hormones|Completed||Phase 4|80|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:28:56.648818|2018-06-01 02:28:56.648818
NCT00611962|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-01-28|2008-01-28|2008-02-11|Estimate|||||||2008-01-28|2008-02-11|Estimate|December 2000||2000-12-31|January 2008|2008-01-31|March 2004|Actual|2004-03-31|||||Interventional|||Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin|Phase II Study of Combined Oxaliplatin and Paclitaxel for Metastatic Germ Cell Tumors|Completed||Phase 2|27|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:28:56.81222|2018-06-01 02:28:56.81222
NCT00611949|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2015-12-17|2008-01-29|2008-02-11|Estimate|||||||2015-12-17|2015-12-18|Estimate|May 2002||2002-05-31|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison of 2 Vials of Components of a Synthetic Geranium Oil|EPT 101: New Geranium Oil Formulation for the Treatment of Neuropathy Pain|Completed||N/A|64|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 02:28:56.895591|2018-06-01 02:28:56.895591
NCT00611936|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2012-07-24|2008-02-08|2008-02-11|Estimate|||||||2012-07-24|2012-07-25|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|September 2009|Actual|2009-09-30|August 2007|Actual|2007-08-31||Interventional|||Effects of Atomoxetine Treatment in Humans|Effects of Atomoxetine Treatment in Humans|Completed||Phase 1/Phase 2|10|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:28:57.007188|2018-06-01 02:28:57.007188
NCT00611923|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2012-06-27|2008-02-06|2008-02-11|Estimate|||||||2012-06-27|2012-06-28|Estimate|February 2005||2005-02-28|June 2012|2012-06-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder|Androgen Hormones in PMDD|Completed||Phase 4|25|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:28:57.12351|2018-06-01 02:28:57.12351
NCT00611910|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2011-05-12|2008-01-29|2008-02-11|Estimate|||||||2011-05-12|2011-05-13|Estimate|November 2007||2007-11-30|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|ISAR-CABG||Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions|Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts.|Completed||Phase 4|610|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:28:57.235865|2018-06-01 02:28:57.235865
NCT00611897|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2013-01-10||2015-05-07|2008-01-29|2008-02-11|Estimate|2015-05-07|2015-05-08|Estimate||||2015-05-07|2015-05-08|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||N-acetylcysteine and NMDA Antagonist Interactions|N-acetylcysteine and NMDA Antagonist Interactions|Completed||Phase 1/Phase 2|16|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:28:57.419654|2018-06-01 02:28:57.419654
NCT00611884|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2015-10-16|2009-11-09|2017-01-19|2008-02-08|2008-02-11|Estimate|2015-10-16|2015-11-16|Estimate|2009-11-09|2009-11-11|Estimate|2017-01-19|2017-03-03|Actual|January 2008||2008-01-31|January 2017|2017-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes|A 16 Week Randomised, Open-labelled, Four-armed, Treat-to-target, Parallel-group Trial Comparing SIBA D Once Daily, SIBA E Once Daily, SIBA D Monday, Wednesday and Friday and Insulin Glargine Once Daily, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment|Completed||Phase 2|245|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 02:28:58.140732|2018-06-01 02:28:58.140732
NCT00611871|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2016-10-31|2008-02-08|2008-02-11|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||The Use of Propranolol to Block Memory Reconsolidation in PTSD|The Use of Propranolol to Block Memory Reconsolidation in Post Traumatic Stress Disorders (PTSD)|Terminated||Phase 2|12|Actual|Wayne State University||3||Low enrollment, grant term expired|f||||f||||||||No||2018-06-01 02:28:59.35356|2018-06-01 02:28:59.35356
NCT00611858|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2017-02-06|2008-02-08|2008-02-11|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 2008||2008-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Interventional|||Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer|Phase II Study of Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer|Terminated||Phase 2|13|Actual|Dana-Farber Cancer Institute||||Slow accrual|f||||t||||||||||2018-06-01 02:28:59.482253|2018-06-01 02:28:59.482253
NCT00611845|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2014-06-20|2008-02-08|2008-02-11|Estimate|||||||2014-06-20|2014-06-23|Estimate||||June 2014|2014-06-30||||||||Expanded Access|||Aprotinin US Special Access Protocol|Aprotinin US Special Access Protocol: An Open Label, Non-Comparative Treatment Protocol for the Use of Aprotinin in Patients Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass Who Are at Increased Risk of Blood Loss and Transfusion|No longer available|||||Bayer|||||||||f||||||||||2018-06-01 02:28:59.565767|2018-06-01 02:28:59.565767
NCT00611832|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2014-03-27|2008-02-06|2008-02-11|Estimate|||||||2014-03-27|2014-03-31|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2011|Actual|2011-12-31||Interventional|ParentMedia||Evaluation of a Video-Based Media Series to Promote Effective Parenting|Evaluation of a Video-Based Media Series to Promote Effective Parenting|Completed||N/A|318|Actual|Oregon Research Institute||3|||f||||f||||||||||2018-06-01 02:28:59.664772|2018-06-01 02:28:59.664772
NCT00611819|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2008-01-25|2008-01-25|2008-02-11|Estimate|||||||2008-01-25|2008-02-11|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|December 2008|Anticipated|2008-12-31|April 2008|Anticipated|2008-04-30||Interventional|||Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV|Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients.|Unknown status|Active, not recruiting|Phase 4|59|Actual|University of Valencia||2|||f||||f||||||||||2018-06-01 02:28:59.752333|2018-06-01 02:28:59.752333
NCT00611806|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2014-07-31||2014-07-31|2008-02-07|2008-02-11|Estimate|2014-07-31|2014-08-19|Estimate||||2014-07-31|2014-08-19|Estimate|December 2007||2007-12-31|July 2014|2014-07-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia|A Placebo-Controlled Trial of Folate With B12 in Schizophrenia Patients With Residual Symptoms|Completed||Phase 4|140|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:28:59.857866|2018-06-01 02:28:59.857866
NCT00611793|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2009-01-22|2008-02-08|2008-02-11|Estimate|||||||2009-01-22|2009-01-23|Estimate|October 2004||2004-10-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies|A Phase I Trial of PTK787/ZK222584 in Combination With Bevacizumab (Avastin) in Patients With Refractory and/or Advanced Malignancies|Completed||Phase 1|50|Anticipated|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:29:00.27336|2018-06-01 02:29:00.27336
NCT00611780|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-08-26|2008-01-28|2008-02-11|Estimate|||||||2008-08-26|2008-08-27|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|PROTECTION-II||Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol|Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol|Unknown status|Recruiting|Phase 4|400|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:29:00.335065|2018-06-01 02:29:00.335065
NCT00611767|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2016-11-17||2017-01-24|2008-02-08|2008-02-11|Estimate|2017-01-24|2017-03-17|Actual||||2017-01-24|2017-03-17|Actual|November 2005||2005-11-30|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence|Gamma-Aminobutyric Acid (GABA) Mechanisms Underlying the Vulnerability to Alcohol Dependence|Completed||N/A|73|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:29:00.471513|2018-06-01 02:29:00.471513
NCT00611754|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-01-28|2008-01-28|2008-02-11|Estimate|||||||2008-01-28|2008-02-11|Estimate|May 2000||2000-05-31|January 2008|2008-01-31|February 2003|Actual|2003-02-28|||||Interventional|||Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase II Study of Oxaliplatin in Combination With 5-Fluorouracil (5-FU) in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|15|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:29:03.768486|2018-06-01 02:29:03.768486
NCT00611741|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2016-02-06|2008-02-08|2008-02-11|Estimate|||||||2016-02-06|2016-02-09|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|MRS||The Effect of Plasma Osmolality on Brain Glutamate|The Role of Cortical Glutamate and GABA in Brains Osmotic Regulation: A Pilot Study in Healthy Volunteers and in Patients With Schizophrenia|Completed||Phase 1|30|Actual|Yale University||1|||f||||t||||||||||2018-06-01 02:29:03.927104|2018-06-01 02:29:03.927104
NCT00611728|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2014-07-18|2008-02-08|2008-02-11|Estimate|||||||2014-07-18|2014-07-21|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Ph I SU011248 + Irinotecan in Treatment of Pts w MG|A Phase I Study of SU011248 Plus Irinotecan in the Treatment of Patients With Malignant Glioma|Completed||Phase 1|25|Actual|Duke University|||||f||||f||||||||||2018-06-01 02:29:04.006478|2018-06-01 02:29:04.006478
NCT00611715|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|2012-03-12||2012-08-03|2008-02-08|2008-02-11|Estimate|2012-06-07|2012-07-13|Estimate||||2012-08-03|2012-08-09|Estimate|November 2003||2003-11-30|August 2012|2012-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.|A Phase II Trial of Letrozole Plus OSI-774 (Tarceva) in Post-menopausal Women With ER and/or PR-Positive Metastatic Breast Cancer|Terminated||Phase 2|48|Actual|Vanderbilt-Ingram Cancer Center|The total number of worst-grade toxicities will not match the total number of participants, as patients can have multiple events or no events.|2||low accrual|f||||t||||||||||2018-06-01 02:29:04.120386|2018-06-01 02:29:04.120386
NCT00611702|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2015-05-13|2008-02-07|2008-02-11|Estimate|||||||2015-05-13|2015-05-14|Estimate|June 2008||2008-06-30|May 2015|2015-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Genomics of Chronic Renal Allograft Rejection (The GoCAR Study)|Genomics of Chronic Renal Allograft Rejection|Completed|||588|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     Blood from both kidney donor and recipient and transplant kidney biopsy samples~   "|||2018-06-01 02:29:04.561609|2018-06-01 02:29:04.561609
NCT00611689|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2013-01-31|2008-01-28|2008-02-11|Estimate|||||||2013-01-31|2013-02-04|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|April 2011|Actual|2011-04-30|January 2008|Actual|2008-01-31||Interventional|||Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors|A Phase I Study to Determine the Safety of Imatinib in Combination With PTK787/ZK222584 in Patients With Refractory and/or Advanced Solid Tumors|Completed||Phase 1|45|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:29:04.636348|2018-06-01 02:29:04.636348
NCT00611676|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2008-01-25|2008-01-25|2008-02-11|Estimate|||||||2008-01-25|2008-02-11|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain|A Single-Blind Placebo Run-In Study of Venlafaxine for Activity-Limiting Osteoarthritis Pain|Completed||Phase 4|18|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:29:04.712445|2018-06-01 02:29:04.712445
NCT00611663|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2016-07-05|2008-02-08|2008-02-11|Estimate|||||||2016-07-05|2016-07-06|Estimate|May 2008||2008-05-31|December 2015|2015-12-31|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|VACCILUP||Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus|"VACCILUP A Multicenter, Randomized Double-blind Trial Comparing Two Pneumococcal Vaccination Strategies in Patients With Systemic Lupus Erythematosus"|Completed||Phase 2/Phase 3|47|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:29:04.807957|2018-06-01 02:29:04.807957
NCT00611650|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-08|||2012-03-07|2008-02-08|2008-02-11|Estimate|||||||2012-03-07|2012-03-09|Estimate|October 2006||2006-10-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia|Phase II Trial of Polyphenon E in Current and Former Smokers With Bronchial Dysplasia|Terminated||Phase 2|23|Actual|British Columbia Cancer Agency||2||Slow recruitment|f||||t||||||||||2018-06-01 02:29:04.92561|2018-06-01 02:29:04.92561
NCT00611637|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2012-11-08|2008-02-08|2008-02-11|Estimate|||||||2012-11-08|2012-11-12|Estimate|August 2005||2005-08-31|November 2012|2012-11-30|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|CMV-BMT||CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease|A Pilot Clinical Trial of CMV pp65 Specific T Cell Adoptive Immunotherapy in Patients Who Have Undergone Allogeneic Stem Cell Transplantation for Malignant Disease|Terminated||Phase 1|2|Actual|Duke University||1||low accrual|f||||f||||||||||2018-06-01 02:29:05.067879|2018-06-01 02:29:05.067879
NCT00611624|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2016-07-25||2017-04-10|2008-01-29|2008-02-11|Estimate|2017-04-10|2017-05-16|Actual||||2017-04-10|2017-05-16|Actual|May 2006||2006-05-31|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Mammosite||Mammosite Breast Brachytherapy Optimization in the Treatment of Breast Carcinoma|A Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I and II Breast Carcinoma|Completed||N/A|28|Actual|Yale University||1|||f||||t||||||||||2018-06-01 02:29:05.174155|2018-06-01 02:29:05.174155
NCT00611611|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2011-04-27|2008-01-28|2008-02-11|Estimate|||||||2011-04-27|2011-04-28|Estimate|October 2007||2007-10-31|April 2011|2011-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||BLYS and IFN in SLE|BLyS and IFN Responses to Antigen Challenge in Human SLE|Completed|||39|Actual|University of Alabama at Birmingham|||2||f||||f||||||||||2018-06-01 02:29:05.541714|2018-06-01 02:29:05.541714
NCT00611598|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2017-10-04|2008-02-08|2008-02-11|Estimate|||||||2017-10-04|2017-10-05|Actual|February 2003||2003-02-28|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||DNA Repair and Genetic Susceptibility to Lung Cancer|DNA Repair and Genetic Susceptibility to Lung Cancer|Active, not recruiting|||218|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     -  30 ml. Blood in heparinized, green top tubes.~        -  Fresh tumor or normal tissue, when available.~        -  Tissue or cells from routine bronchoscopy, when available.~   "|||2018-06-01 02:29:05.6194|2018-06-01 02:29:05.6194
NCT00611585|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2017-09-07|2008-02-08|2008-02-11|Estimate|||||||2017-09-07|2017-09-11|Actual|September 2006||2006-09-30|September 2017|2017-09-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|BHR||A Safety and Efficacy Study of the Birmingham Hip Resurfacing System|Birmingham Hip Resurfacing System (BHR) Post Approval Study: A Prospective, Multi-Centered Study of the Birmingham Hip Resurfacing System|Active, not recruiting||N/A|359|Actual|Smith & Nephew, Inc.||1|||f||||f||||||||||2018-06-01 02:29:05.724727|2018-06-01 02:29:05.724727
NCT00611572|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2017-06-08|2008-01-29|2008-02-11|Estimate|||||||2017-06-08|2017-06-09|Actual|January 2007||2007-01-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||GABA-glutamate Interactions and Psychosis|Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction|Active, not recruiting||Phase 1|15|Anticipated|Yale University||2|||f||||f||||||||||2018-06-01 02:29:05.811603|2018-06-01 02:29:05.811603
NCT00611559|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2009-06-22||2017-05-03|2008-01-29|2008-02-11|Estimate|2009-06-22|2009-08-10|Estimate||||2017-05-03|2017-05-31|Actual|February 14, 2008||2008-02-14|October 2016|2016-10-31|June 25, 2008|Actual|2008-06-25|June 25, 2008|Actual|2008-06-25||Interventional|||Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children|Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children|Completed||Phase 4|283|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:29:05.948398|2018-06-01 02:29:05.948398
NCT00611546|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-01-28|2008-01-28|2008-02-11|Estimate|||||||2008-01-28|2008-02-11|Estimate|April 2003||2003-04-30|January 2008|2008-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Perenteral Nutrition and Oxidative Stress in Preterm Infants|Study of the Oxidant-Antioxidant Effects of Parenteral Nutrition in Preterm Neonates|Completed||N/A|80|Actual|Mansoura University||2|||f||||f||||||||||2018-06-01 02:29:06.74234|2018-06-01 02:29:06.74234
NCT00611533|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2017-01-10||2017-03-20|2008-02-08|2008-02-11|Estimate|2017-01-10|2017-03-03|Actual||||2017-03-20|2017-04-17|Actual|May 2004||2004-05-31|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||Participants who had at least one post randomization visit.|Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women|A Controlled Trial of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women|Completed||N/A|16|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 02:29:06.8333|2018-06-01 02:29:06.8333
NCT00611520|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2011-01-27|2008-02-08|2008-02-11|Estimate|||||||2011-01-27|2011-01-28|Estimate|September 2005||2005-09-30|January 2011|2011-01-31||||December 2005|Actual|2005-12-31||Observational|SYMBOL||Symbicort in Chronic Obstructive Pulmonary Disease|Symbicort in Chronic Obstructive Pulmonary Disease|Completed|||64730|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:29:07.126475|2018-06-01 02:29:07.126475
NCT00611507|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-03-24|2008-01-28|2008-02-11|Estimate|||||||2008-03-24|2008-03-25|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|April 2004|Actual|2004-04-30|||||Interventional|||A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer|A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer|Completed||Phase 2|21|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:29:07.174616|2018-06-01 02:29:07.174616
NCT00611494|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2009-02-16|2008-01-29|2008-02-11|Estimate|||||||2009-02-16|2009-02-17|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|MOTOR-MPA||Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors|A Single Centre, Prospective, Open-Label, Parallel Group, Randomized Study to Compare the Gastrointestinal Tolerability of Mycophenolate Mofetil (MMF, CellCept) and Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic) in Maintenance Transplant Patients Treated With Calcineurin Inhibitors|Unknown status|Recruiting|Phase 4|400|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:29:07.229956|2018-06-01 02:29:07.229956
NCT00611481|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2011-10-10|2008-02-06|2008-02-11|Estimate|||||||2011-10-10|2011-10-12|Estimate|October 2008||2008-10-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Study of Tai Chi Exercise and Balance in Persons With Parkinson's Disease|Phase II Study of Tai Chi Exercise in Relation to Balance in Persons With Parkinson's Disease|Completed||Phase 2|195|Actual|Oregon Research Institute||3|||f||||t||||||||||2018-06-01 02:29:07.304827|2018-06-01 02:29:07.304827
NCT00611468|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2010-07-01||2011-08-18|2008-01-29|2008-02-11|Estimate|2011-06-21|2011-07-19|Estimate||||2011-08-18|2011-08-22|Estimate|June 2006||2006-06-30|August 2011|2011-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors|A Phase I, Dosage-finding and Pharmacokinetic Study of Intravenous Topotecan and Oral Erlotinib in Adults With Refractory Solid Tumors|Completed||Phase 1|29|Actual|Accelerated Community Oncology Research Network||1|||f||||f||||||||||2018-06-01 02:29:07.493282|2018-06-01 02:29:07.493282
NCT00611455|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2011-09-21||2017-11-02|2008-01-29|2008-02-11|Estimate|2011-09-21|2011-10-28|Estimate||||2017-11-02|2017-11-06|Actual|January 1, 2008||2008-01-01|November 2017|2017-11-30|July 15, 2013|Actual|2013-07-15|June 8, 2009|Actual|2009-06-08||Interventional|||Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy|A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Adult Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy|Terminated||Phase 3|265|Actual|GlaxoSmithKline||2||"Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical~   development of autoimmune indications on the subcutaneous delivery."|f||||f||||||||||2018-06-01 02:29:08.292048|2018-06-01 02:29:08.292048
NCT00611260|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-05-25|2008-01-25|2008-02-08|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2007||2007-04-30|May 2017|2017-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Improvement in Clinical Outcomes in Heart Failure Patients With ICDs That Practice Meditation|Does Meditation Improve Outcomes in Patients With Heart Failure Who Received Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy Defibrillators?|Completed||N/A|27|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 02:29:13.657554|2018-06-01 02:29:13.657554
NCT00611442|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2012-07-24||2012-10-03|2008-01-29|2008-02-11|Estimate|2012-10-03|2012-11-01|Estimate||||2012-10-03|2012-11-01|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy|Single Dose Lubiprostone Along With Split-dose PEG Solution Without Dietary Restrictions for Bowel Cleansing Prior to Colonoscopy, a Randomized, Double-blind, Placebo Controlled Trial|Completed||N/A|191|Actual|Brooke Army Medical Center|This study may be limited by the recruitment of outpatients as the only study participants. The study results might have also been affected by limiting the indication for colonoscopy to colorectal cancer screening.|2|||f||||t||||||||||2018-06-01 02:29:11.352869|2018-06-01 02:29:11.352869
NCT00611429|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2014-12-01|2008-02-06|2008-02-11|Estimate|||||||2014-12-01|2014-12-02|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|||An Educational and Supportive Counseling Program for Increasing Antiretroviral Use and Adherence in People With HIV|Preparing Patients to Start Antiretroviral Therapy: A Randomized Controlled Trial|Completed||N/A|219|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:29:11.593802|2018-06-01 02:29:11.593802
NCT00611416|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2009-02-06|2008-02-07|2008-02-08|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|February 2006|Actual|2006-02-28|||||Interventional|||The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism|The Role of Tea Catechins and Caffeine in Relation to Energy Metabolism in Man|Completed||N/A|15|Actual|University of Copenhagen||5|||f||||f||||||||||2018-06-01 02:29:11.735637|2018-06-01 02:29:11.735637
NCT00611403|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2011-11-17||2011-11-17|2008-02-07|2008-02-08|Estimate|2011-11-17|2011-12-20|Estimate||||2011-11-17|2011-12-20|Estimate|December 2007||2007-12-31|November 2011|2011-11-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients|Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients|Completed||Phase 2|137|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:29:11.828502|2018-06-01 02:29:11.828502
NCT00611390|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-06-13|2008-02-07|2008-02-08|Estimate|||||||2008-06-13|2008-06-17|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Treatment of Acute Tracheitis and Laryngitis With Essential Oils of Aromatic Plants|Treatment of Acute Tracheitis and Laryngitis With Essential Oils of Some Aromatic Medical Plants.|Completed||Phase 1/Phase 2|29|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-06-01 02:29:12.105737|2018-06-01 02:29:12.105737
NCT00611377|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-01-28|2008-01-28|2008-02-08|Estimate|||||||2008-01-28|2008-02-08|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|March 2008|Anticipated|2008-03-31|February 2008|Anticipated|2008-02-29||Observational|delricu||Study on the Incidence of Delirium in a Respiratory Weaning Centre|Delirium in Patients Admitted to a Respiratory Weaning Centre: Analysis of Incidence and Risk Factor|Unknown status|Recruiting||200|Anticipated|Fondazione Salvatore Maugeri|||1||f||||f||||||||||2018-06-01 02:29:12.178495|2018-06-01 02:29:12.178495
NCT00611364|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2008-10-17|2008-02-07|2008-02-08|Estimate|||||||2008-10-17|2008-10-20|Estimate|March 2004||2004-03-31|January 2008|2008-01-31|December 2005|Actual|2005-12-31|September 2004|Actual|2004-09-30||Interventional|||Physical Therapy for Hypertensive Elderly|Physical Therapy for Hipertensive Elderly: Effects in the Physical Activity and Exercise Adherence|Completed||Phase 4|30|Actual|Universidade Federal de Goias||2|||f||||t||||||||||2018-06-01 02:29:12.252931|2018-06-01 02:29:12.252931
NCT00611351|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2018-03-05||2018-03-05|2008-02-07|2008-02-08|Estimate|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|June 2005||2005-06-30|March 2018|2018-03-31|September 2008|Actual|2008-09-30|February 2008|Actual|2008-02-29||Interventional|||Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation With a Conditioning Regimen of Targeted Busulfan, Cyclophosphamide, and Thymoglobulin|Completed||Phase 2|5|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:29:12.329105|2018-06-01 02:29:12.329105
NCT00611338|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2009-12-11|2008-01-25|2008-02-08|Estimate|||||||2009-12-11|2009-12-15|Estimate|July 2006||2006-07-31|December 2009|2009-12-31|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Efficacy of Group Intervention to Reduce Stress Symptoms|Efficacy of Group Intervention to Reduce Stress Symptoms|Unknown status|Recruiting|Phase 3|290|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 02:29:12.664243|2018-06-01 02:29:12.664243
NCT00611325|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2013-12-18||2014-02-07|2008-02-07|2008-02-08|Estimate|2013-12-18|2014-02-04|Estimate||||2014-02-07|2014-03-12|Estimate|May 2008||2008-05-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|September 2009|Actual|2009-09-30||Interventional|||Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma|Phase II Trial of Avastin Plus Bortezomib for Patients With Recurrent Malignant Glioma|Completed||Phase 2|56|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:29:12.770234|2018-06-01 02:29:12.770234
NCT00611312|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2012-10-02|2008-01-28|2008-02-08|Estimate|||||||2012-10-02|2012-10-03|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease|Effects of Intense Cognitive Training on Standardized Measures of Cognition in Those With Very Mild Alzheimer's Disease|Completed||Phase 2|25|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 02:29:13.343314|2018-06-01 02:29:13.343314
NCT00611299|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-03-17|2008-02-07|2008-02-08|Estimate|||||||2008-03-17|2008-03-18|Estimate|April 2003||2003-04-30|December 2002|2002-12-31|November 2003||2003-11-30|||||Interventional|||Dose-Response Study of Probiotic Bacteria BB-12 and CRL-431 in Healthy Young Adults|Dose-Response Study of Probiotic Bacteria Bifidobacterium Animalis Subsp. Lactis BB-12 and Lactobacillus Paracasei Subsp. Paracasei CRL-341 in Healthy Young Adults|Completed||Phase 1|71||University of Copenhagen|||||f||||||||||||||2018-06-01 02:29:13.414179|2018-06-01 02:29:13.414179
NCT00611286|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-10-06|2008-02-07|2008-02-08|Estimate|||||||2012-10-06|2012-10-10|Estimate|December 2006||2006-12-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|December 2010|Actual|2010-12-31||Interventional|PRODIGY||Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention|PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY|Completed||Phase 4|1700|Anticipated|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-06-01 02:29:13.486939|2018-06-01 02:29:13.486939
NCT00611273|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2014-06-23|2008-02-07|2008-02-08|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2007||2007-09-30|June 2014|2014-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing|A Multi-center Long Term Efficacy Trial of the GFX For Reduction of Glabellar Furrowing|Completed||Phase 4|260|Actual|Advanced Cosmetic Intervention||1|||f||||f||||||||||2018-06-01 02:29:13.582213|2018-06-01 02:29:13.582213
NCT00611247|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2014-04-29||2014-07-07|2008-01-25|2008-02-08|Estimate|2014-07-07|2014-07-09|Estimate||||2014-07-07|2014-07-09|Estimate|December 2007||2007-12-31|July 2014|2014-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia|Phase II Study of Two Distinct Tailored Temozolomide Regimens for Patients With Acute Myeloid Leukemia Age > 60 Years and Poor Risk/Refractory Disease|Completed||Phase 2|42|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 02:29:13.741932|2018-06-01 02:29:13.741932
NCT00611221|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2011-04-26|2008-02-07|2008-02-08|Estimate|||||||2011-04-26|2011-04-27|Estimate|January 2008||2008-01-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Massage Therapy Study: Massage Therapy and Labour Outcomes|Massage Therapy and Labour Outcomes; A Randomized Controlled Trial|Completed||Phase 3|77|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 02:29:14.227969|2018-06-01 02:29:14.227969
NCT00611208|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2016-11-28|2008-01-25|2008-02-08|Estimate|||||||2016-11-28|2016-11-29|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|February 2015|Actual|2015-02-28||Interventional|||A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)|A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma|Completed||Phase 2|32|Actual|Angimmune LLC||1|||f||||t||||||||||2018-06-01 02:29:14.314544|2018-06-01 02:29:14.314544
NCT00611195|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2015-10-29|2008-02-07|2008-02-08|Estimate|||||||2015-10-29|2015-10-30|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Remifentanil and Laryngeal Reflex Responses in Pediatric Patients With URI|Impact of Remifentanil Administration on Laryngeal Reflex Responses in Pediatric Patients With Upper Respiratory Anesthetized With Propofol|Completed||Phase 4|62|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 02:29:14.399576|2018-06-01 02:29:14.399576
NCT00611182|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2013-11-15|2008-02-07|2008-02-08|Estimate|||||||2013-11-15|2013-11-18|Estimate|January 2008||2008-01-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Dyspnea in Patients With Pulmonary Fibrosis|Dyspnea in Patients With Pulmonary Fibrosis|Completed|||60|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-06-01 02:29:14.476722|2018-06-01 02:29:14.476722
NCT00611169|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2008-02-07|2008-02-07|2008-02-08|Estimate|||||||2008-02-07|2008-02-08|Estimate|January 2006||2006-01-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|February 2007|Actual|2007-02-28||Interventional|||The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction|The Effects of Facilitated Percutaeous Coronary Intervention Compared to Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction|Completed||Phase 4|40|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 02:29:14.556234|2018-06-01 02:29:14.556234
NCT00611156|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-02-07|2008-02-07|2008-02-08|Estimate|||||||2008-02-07|2008-02-08|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Examination of the Effects of Four Different Spices on Energy Metabolism|Bioactive Food Ingredients and Energy Metabolism: The Effects of Ginger, Black Pepper, Horseradish and Mustard on Meal-Induced Thermogenesis and Fat Oxidation|Completed||N/A|22|Actual|University of Copenhagen||5|||f||||f||||||||||2018-06-01 02:29:14.662447|2018-06-01 02:29:14.662447
NCT00611143|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2008-01-27|2008-01-27|2008-02-08|Estimate|||||||2008-01-27|2008-02-08|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Atorvastatin for Prevention of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery|The Effects of Atorvastatin on the Occurrence of Postoperative Atrial Fibrillation After Off-Pump Coronary Artery Bypass Grafting Surgery|Completed||N/A|124|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 02:29:14.853653|2018-06-01 02:29:14.853653
NCT00611130|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2012-04-13|2012-04-13|2016-03-14|2008-01-28|2008-02-08|Estimate|2012-05-10|2012-06-12|Estimate|2012-05-10|2012-06-12|Estimate|2016-03-14|2016-04-13|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|October 2012|Actual|2012-10-31|May 2009|Actual|2009-05-31||Interventional|||Vigabatrin for Treatment of Cocaine Dependence|Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study|Completed||Phase 2|186|Actual|Catalyst Pharmaceuticals, Inc.|Lack of subject medication compliance, site-to-site variability in medication compliance possibly indicative of differing site capabilities to attract subjects sufficiently motivated to stop using cocaine.|2|||f||||f||||||||No||2018-06-01 02:29:14.968761|2018-06-01 02:29:14.968761
NCT00611117|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2016-01-22|2008-02-07|2008-02-08|Estimate|||||||2016-01-22|2016-01-25|Estimate|May 2007||2007-05-31|January 2016|2016-01-31|June 2020|Anticipated|2020-06-30|March 2009|Actual|2009-03-31||Interventional|||Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet|Mechanisms of the Effect of Physical Activity on the Adaptation to a High-Fat Diet|Active, not recruiting||N/A|24|Anticipated|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-06-01 02:29:15.363213|2018-06-01 02:29:15.363213
NCT00611104|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2018-02-05|2008-02-07|2008-02-08|Estimate|||||||2018-02-05|2018-02-07|Actual|May 2008||2008-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women|Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract|Active, not recruiting|||25|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:29:15.444753|2018-06-01 02:29:15.444753
NCT00611091|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-09-12|2008-02-07|2008-02-08|Estimate|||||||2013-09-12|2013-09-16|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|June 2012|Actual|2012-06-30||Interventional|||Improving Posthospital Medication Management of Older Adults Through Health IT|Improving Posthospital Medication Management of Older Adults Through Health IT|Completed||N/A|5077|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 02:29:15.513779|2018-06-01 02:29:15.513779
NCT00611078|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2011-01-19|2008-02-07|2008-02-08|Estimate|||||||2011-01-19|2011-01-20|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study|Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study|Completed|||56|Actual|Memorial Sloan Kettering Cancer Center|||||f||||f||||||Samples With DNA|"~     blood, adipose tissue~   "|||2018-06-01 02:29:15.599112|2018-06-01 02:29:15.599112
NCT00611065|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-12|||2009-02-12|2008-01-25|2008-02-08|Estimate|||||||2009-02-12|2009-02-16|Estimate|June 2007||2007-06-30|February 2009|2009-02-28||||June 2009|Anticipated|2009-06-30||Interventional|||Imaging of Prostate Cancer Using Two-Dimensional MR Spectroscopy and Diffusion Tensor Imaging|Imaging of Prostate Cancer Using Two-Dimensional MR Spectroscopy and Diffusion Tensor Imaging|Withdrawn||N/A|60|Anticipated|University of California, Irvine||||There is no funding to proceed.|f||||f||||||||||2018-06-01 02:29:15.669003|2018-06-01 02:29:15.669003
NCT00609648|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2013-02-15|2008-01-24|2008-02-07|Estimate|||||||2013-02-15|2013-02-20|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CARL||Computer Assisted Relaxation Learning for Dental Offices|Distance Psychology for Treating Dental Fear in Rural Communities|Completed||N/A|84|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:29:41.050305|2018-06-01 02:29:41.050305
NCT00611052|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2016-04-19|2008-02-07|2008-02-08|Estimate|||||||2016-04-19|2016-04-20|Estimate|March 2008||2008-03-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CWSA-Fin||Prevention of Adolescent Major Depression|"Adolescents Coping With Stress: Prevention of Adolescent Major Depression in School Health Care"|Terminated||N/A|65|Actual|National Institute for Health and Welfare, Finland||3||"Unsuccessful recruitment, failed training of the group leaders leading into lack of study~   groups"|f||||f||||||||||2018-06-01 02:29:15.749906|2018-06-01 02:29:15.749906
NCT00611039|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2009-10-05|2008-02-07|2008-02-08|Estimate|||||||2009-10-05|2009-10-06|Estimate|February 2008||2008-02-29|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|DRV900100QD||Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy|Clinical Pilot, Open, Comparative and Randomized Trial to Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy|Completed||Phase 4|30|Anticipated|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 02:29:15.829182|2018-06-01 02:29:15.829182
NCT00611026|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2010-10-12||2011-01-28|2008-01-28|2008-02-08|Estimate|2010-12-13|2011-01-12|Estimate||||2011-01-28|2011-02-02|Estimate|February 2008||2008-02-29|January 2011|2011-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.|12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder.|Completed||Phase 3|2417|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:29:16.093207|2018-06-01 02:29:16.093207
NCT00611013|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-12|||2013-06-19|2008-01-25|2008-02-08|Estimate|||||||2013-06-19|2013-06-21|Estimate|June 2002||2002-06-30|June 2013|2013-06-30||||July 2012|Anticipated|2012-07-31||Interventional|||Magnetic Resonance Imaging and Spectroscopy at High Field|Magnetic Resonance Imaging and Spectroscopy at High Field|Withdrawn||N/A|0|Actual|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:29:18.744628|2018-06-01 02:29:18.744628
NCT00611000|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2009-02-14|2008-02-07|2008-02-08|Estimate|||||||2009-02-14|2009-02-17|Estimate|June 2003||2003-06-30|February 2008|2008-02-29||||January 2006|Actual|2006-01-31||Interventional|||Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia|Effect of Folate on Colonic and Blood Cells|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:29:18.806252|2018-06-01 02:29:18.806252
NCT00610987|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2015-02-12||2015-05-28|2008-02-07|2008-02-08|Estimate|2015-05-28|2015-06-12|Estimate||||2015-05-28|2015-06-12|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Antibiotic Prophylaxis in Orthopaedic Traumatology|Antibiotic Prophylaxis in Orthopaedic Traumatology: A Prospective, Randomized Trial of Duration of Administration|Completed||N/A|178|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-06-01 02:29:19.672118|2018-06-01 02:29:19.672118
NCT00610974|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2014-09-24|2008-02-07|2008-02-08|Estimate|||||||2014-09-24|2014-09-25|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Enhancing Walking in People With Incomplete Spinal Cord Injury: a Pilot Study|Enhancing Walking in People With Incomplete Spinal Cord Injury by Improving Swing Phase Activity: a Pilot Study|Completed||N/A|15|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 02:29:20.014348|2018-06-01 02:29:20.014348
NCT00610961|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2011-09-26|2008-02-07|2008-02-08|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Observational|BK||Induction Related BK Viremia in Renal Transplant Patients|The Induction Agent Effect on BK Viremia in Renal and Pancreas Transplant Patients|Completed|||60|Actual|University of Florida|||2||f||||f||||||||||2018-06-01 02:29:20.160908|2018-06-01 02:29:20.160908
NCT00610948|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2017-05-01|2008-02-07|2008-02-08|Estimate|||||||2017-05-01|2017-05-04|Actual|March 2008||2008-03-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|May 2013|Actual|2013-05-31||Interventional|||Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment|A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies|Completed||Phase 1|74|Actual|UNC Lineberger Comprehensive Cancer Center||3|||f||||t||||||||||2018-06-01 02:29:20.266366|2018-06-01 02:29:20.266366
NCT00610935|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25||2011-12-21|2014-12-15|2008-02-07|2008-02-08|Estimate||||2011-12-21|2011-12-26|Estimate|2014-12-15|2015-01-06|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza.|Terminated||Phase 3|82|Actual|BioCryst Pharmaceuticals||2||This study was terminated for administrative reasons.|f||||t||||||||||2018-06-01 02:29:20.427854|2018-06-01 02:29:20.427854
NCT00610922|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-02-07|2008-02-07|2008-02-08|Estimate|||||||2008-02-07|2008-02-08|Estimate|May 2005||2005-05-31|January 2008|2008-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Docosaexahenoic Acid and Gross Motor Milestones in Infants|RCT of Supplemented Docosahexaenoic Acid and Gross Motor Development Milestones in Healthy Infants.|Completed||N/A|1160|Actual|University of Milan||2|||f||||f||||||||||2018-06-01 02:29:20.742173|2018-06-01 02:29:20.742173
NCT00610909|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2013-06-19|2008-01-28|2008-02-08|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 2002||2002-01-31|January 2008|2008-01-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)|Single-Site, Double-Blind, Flexible-Dose, Placebo-Controlled Study of the Efficacy, Tolerability, & Safety of Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)|Completed||Phase 4|60|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:29:20.884201|2018-06-01 02:29:20.884201
NCT00610896|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2011-08-31|2008-02-06|2008-02-08|Estimate|||||||2011-08-31|2011-09-02|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Observational|||CRM and Fusion Beats: Effects of Progressive Fusion on Intra-left Ventricular Mechanical Function|CRM and Fusion Beats: Effects of Progressive Fusion on Intra-left Ventricular Mechanical Function|Completed|||25|Actual|Essentia Health|||1||f||||f||||||||||2018-06-01 02:29:21.078713|2018-06-01 02:29:21.078713
NCT00610883|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-21||2015-12-21|2008-02-07|2008-02-08|Estimate|2015-12-21|2016-01-25|Estimate||||2015-12-21|2016-01-25|Estimate|May 1990||1990-05-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma|LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma|Completed||Phase 2|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:29:21.174713|2018-06-01 02:29:21.174713
NCT00610870|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2011-03-02|2008-02-07|2008-02-08|Estimate|||||||2011-03-02|2011-03-03|Estimate|July 2007||2007-07-31|March 2011|2011-03-31|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|||Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention|Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction|Completed||N/A|173|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-06-01 02:29:21.327949|2018-06-01 02:29:21.327949
NCT00610857|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2016-03-21||2017-06-20|2008-01-28|2008-02-08|Estimate|2016-08-22|2016-10-17|Estimate||||2017-06-20|2017-06-22|Actual|November 2006||2006-11-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Patients with stage IV melanoma (cutaneous, uveal, or mucosal) and measurable disease, most who had previously received therapy|Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma|Safety and Efficacy of Combination Biotherapy With High-dose Interferon Alfa-2b and Anti-CTLA4 Monoclonal Antibody for Recurrent Inoperable Stage III or Stage IV Melanoma|Completed||Phase 2|37|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:29:21.437626|2018-06-01 02:29:21.437626
NCT00610844|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-02-15|2008-01-28|2008-02-08|Estimate|||||||2008-02-15|2008-02-20|Estimate|April 2004||2004-04-30|November 2007|2007-11-30||||May 2006|Actual|2006-05-31||Interventional|||Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors|Evaluation of Effectiveness of Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors|Completed||Phase 2|9|Actual|University Hospital Tuebingen||1|||f||||||||||||||2018-06-01 02:29:21.639829|2018-06-01 02:29:21.639829
NCT00610831|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-12|||2018-01-29|2008-01-25|2008-02-08|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2007||2007-05-31|January 2018|2018-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)|Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)|Withdrawn||N/A|0|Actual|University of California, Irvine||1||Funding Issues|f||||f||||||||||2018-06-01 02:29:21.724358|2018-06-01 02:29:21.724358
NCT00610818|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-01-28|2008-01-28|2008-02-08|Estimate|||||||2008-01-28|2008-02-08|Estimate|July 2007||2007-07-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|Palifermin||Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation|Effect of Palifermin Therapy on Benign and Malignant Skin Tumors in Patients Undergoing High-Dose Chemotherapy With Autologous Stem Cell Transplantation|Terminated|||7|Actual|McGill University Health Center|||1|We did not see any effect of Palifermin on benign or malignant tumor growth|f||||f||||||||||2018-06-01 02:29:21.831935|2018-06-01 02:29:21.831935
NCT00610805|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2016-01-14|2008-02-07|2008-02-08|Estimate|||||||2016-01-14|2016-01-15|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Cardiology Prevention in Systemic Lupus Erythematosus (SLE)|Cardiology Prevention Trial in Systemic Lupus Erythematosus|Withdrawn||N/A|0|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:29:22.012211|2018-06-01 02:29:22.012211
NCT00610792|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2009-07-13|2008-01-28|2008-02-08|Estimate|||||||2009-07-13|2009-07-14|Estimate|July 2006||2006-07-31|July 2009|2009-07-31||||September 2009|Anticipated|2009-09-30||Interventional|||Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens|An Open Label, Phase 2 Study of Biweekly VELCADE and Intermittent CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens|Withdrawn||Phase 2|91|Anticipated|Millennium Pharmaceuticals, Inc.||1||Study never submitted to IND. Study is being sponsored by Johnson and Johnson in the EU only.|f||||t||||||||||2018-06-01 02:29:22.129209|2018-06-01 02:29:22.129209
NCT00610779|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-06-13|2008-02-07|2008-02-08|Estimate|||||||2008-06-13|2008-06-17|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Treatment of Acute Rhino-Sinusitis With Essential Oils of Aromatic Plants|Treatment of Acute Rhino-Sinusitis With Essential Oils of Some Aromatic Medical Plants.|Completed||Phase 1/Phase 2|14|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-06-01 02:29:22.214434|2018-06-01 02:29:22.214434
NCT00610766|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-03-14|2008-01-28|2008-02-08|Estimate|||||||2008-03-14|2008-03-17|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Observational|PROTECTION-I||International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily Practice|International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily Practice|Completed|||1965|Actual|Deutsches Herzzentrum Muenchen|||1||f||||t||||||||||2018-06-01 02:29:22.379569|2018-06-01 02:29:22.379569
NCT00610753|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-02-07|2008-01-25|2008-02-08|Estimate|||||||2013-02-07|2013-02-11|Estimate|July 2006||2006-07-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa|Family Therapy in the Treatment of Adolescent Anorexia Nervosa|Completed||Phase 3|164|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 02:29:22.488325|2018-06-01 02:29:22.488325
NCT00610740|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|2010-05-19||2017-12-03|2008-02-07|2008-02-08|Estimate|2010-05-19|2010-06-17|Estimate||||2017-12-03|2017-12-28|Actual|July 2006||2006-07-31|December 2017|2017-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer|WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer|Completed||Phase 2|18|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:29:22.594184|2018-06-01 02:29:22.594184
NCT00610727|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2009-04-27|2008-01-28|2008-02-08|Estimate|||||||2009-04-27|2009-04-29|Estimate|August 2004||2004-08-31|September 2008|2008-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Staccato Prochlorperazine Single Dose PK|Tolerability, Safety and Pharmacokinetics of a Single Dose of Staccato™ Prochlorperazine for Inhalation in Normal, Healthy Volunteers|Completed||Phase 1|32|Actual|Alexza Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-06-01 02:29:22.901744|2018-06-01 02:29:22.901744
NCT00610714|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2011-05-03||2012-12-14|2008-01-25|2008-02-08|Estimate|2011-08-16|2011-09-20|Estimate||||2012-12-14|2012-12-18|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|January 2012|Actual|2012-01-31|August 2009|Actual|2009-08-31||Interventional|OVERT-1||AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer|A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy|Completed||Phase 2|211|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:29:23.107283|2018-06-01 02:29:23.107283
NCT00610532|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2012-12-06||2013-05-13|2008-01-28|2008-02-08|Estimate|2013-05-13|2013-05-14|Estimate||||2013-05-13|2013-05-14|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy|Evaluating Transporter Protein Inhibitors in Patients With Epilepsy|Terminated||Phase 4|8|Actual|Ohio State University|problems with measurement led to uninterpretable data|2||Investigators decided not to continue|f||||f||||||||||2018-06-01 02:29:27.736362|2018-06-01 02:29:27.736362
NCT00610701|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2014-04-10||2017-06-22|2008-02-07|2008-02-08|Estimate|2014-09-03|2014-09-10|Estimate||||2017-06-22|2017-07-24|Actual|March 2006||2006-03-31|June 2017|2017-06-30|February 2014|Actual|2014-02-28|August 2012|Actual|2012-08-31||Interventional||initially based on power analysis for anticipated quad strength data, final numbers based on those completing study in each group|Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures|Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures|Terminated||N/A|35|Actual|University of Missouri-Columbia||2||Extremely low enrollment and very little follow-up for meaningful data|f||||f||||||||No||2018-06-01 02:29:24.012363|2018-06-01 02:29:24.012363
NCT00610688|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2012-05-15||2013-06-05|2008-01-28|2008-02-08|Estimate|2013-06-05|2013-06-07|Estimate||||2013-06-05|2013-06-07|Estimate|January 2008||2008-01-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Interventional|||Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants|High Prevalence of Rickets and Subclinical Maternal and Childhood Vitamin D Deficiency in the Middle East: a Randomized Controlled Trial of Prenatal Vitamin D Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants|Completed||Phase 3|192|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-06-01 02:29:24.298378|2018-06-01 02:29:24.298378
NCT00610675|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2014-06-25||2015-07-13|2008-01-28|2008-02-08|Estimate|2014-07-29|2014-07-30|Estimate||||2015-07-13|2015-07-28|Estimate|December 2006||2006-12-31|July 2015|2015-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Participants treated with Esmirtazapine in Follow up trial P05708|Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)|Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002.|Completed||Phase 3|346|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:29:24.771179|2018-06-01 02:29:24.771179
NCT00610662|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-07|||2014-07-17|2008-02-07|2008-02-08|Estimate|||||||2014-07-17|2014-07-21|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia in Patients With An Abnormal Pap Smear|A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia Using a Second Generation Device|Withdrawn|||0|Actual|British Columbia Cancer Agency||||Study modified and has been running as CDR0000581286 instead.|f||||f||||||||||2018-06-01 02:29:25.039134|2018-06-01 02:29:25.039134
NCT00610649|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2014-05-27|2009-04-17|2015-05-11|2008-01-28|2008-02-08|Estimate|2014-06-30|2014-07-02|Estimate|2009-09-30|2009-10-02|Estimate|2015-05-11|2015-06-04|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)|Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder (Protocol No. P174001)|Completed||Phase 2|54|Actual|Merck Sharp & Dohme Corp.||11|||f||||f||||||||||2018-06-01 02:29:25.156975|2018-06-01 02:29:25.156975
NCT00610636|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2012-12-06|2008-01-28|2008-02-08|Estimate|||||||2012-12-06|2012-12-10|Estimate|January 2002||2002-01-31|December 2012|2012-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment Outcomes of Hepatic Metastasis After FOLFOX-4 Therapy|Oncologic Outcomes of Surgical Versus Non-surgical Methods for the Treatment of Resectable Colorectal Liver-confined Metastases Converted From Initially Non-resectable Metastases by FOLFOX-4 Neoadjuvant Chemotherapy: A Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|200|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 02:29:26.377248|2018-06-01 02:29:26.377248
NCT00610623|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-01-28|2008-01-28|2008-02-08|Estimate|||||||2008-01-28|2008-02-08|Estimate|April 2003||2003-04-30|January 2008|2008-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia|Proof of Concept Study to Investigate the Impact of Azithromycin Administered iv Versus Placebo on the Prevention of Pneumonia in Ventilated Patients Colonized by Pseudomonas Aeruginosa|Terminated||Phase 2|92|Actual|Anbics Management-Services Ag||2||The sponsor decided to stop the study prematurely because of financial issues|f||||t||||||||||2018-06-01 02:29:26.517377|2018-06-01 02:29:26.517377
NCT00610610|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2013-06-19|2008-02-07|2008-02-08|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 2002||2002-01-31|January 2008|2008-01-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome|Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome: A Randomized, Double Blind, Parallel Group, Flexible Dose, Placebo Controlled Trial.|Completed||Phase 4|120|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:29:26.63862|2018-06-01 02:29:26.63862
NCT00610597|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-01-28|2008-01-28|2008-02-08|Estimate|||||||2008-01-28|2008-02-08|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Observational|||Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease|Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease|Completed|||49|Actual|Erasme University Hospital|||2||f||||f||||||Samples Without DNA|"~     plasma and peripheral blood mononuclear cell culture medium.~   "|||2018-06-01 02:29:26.772648|2018-06-01 02:29:26.772648
NCT00610584|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2012-10-22|2008-01-28|2008-02-08|Estimate|||||||2012-10-22|2012-10-23|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ACUSAR||Acupuncture for Seasonal Allergic Rhinitis|Acupuncture for Seasonal Allergic Rhinitis (ACUSAR) - A Randomised Controlled Trial|Completed||N/A|422|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-06-01 02:29:26.975319|2018-06-01 02:29:26.975319
NCT00610571|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2013-10-23|2008-02-07|2008-02-08|Estimate|||||||2013-10-23|2013-10-25|Estimate|April 2004||2004-04-30|October 2013|2013-10-31|April 2012|Actual|2012-04-30|September 2009|Actual|2009-09-30||Interventional|||Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas|Phase I Trial of Oral Topotecan Plus Temodar in the Treatment of Patients With Malignant Gliomas|Completed||Phase 1|62|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:29:27.307511|2018-06-01 02:29:27.307511
NCT00610558|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-12|||2013-06-19|2008-01-25|2008-02-08|Estimate|||||||2013-06-19|2013-06-21|Estimate|July 2003||2003-07-31|June 2013|2013-06-30|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional|||Neocortical Epilepsies - Do They Progress?|Neocortical Epilepsies - Do They Progress?|Completed||N/A|43|Actual|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:29:27.569823|2018-06-01 02:29:27.569823
NCT00610545|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2009-02-13|2008-02-07|2008-02-08|Estimate|||||||2009-02-13|2009-02-16|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|APVS||Atorvastatin in Perioperative Vascular Surgery - Pilot Study|Atorvastatin 80mg Versus Atorvastatin 20mg in Perioperative Vascular Surgery to Evaluate Cardiovascular Outcomes|Completed||Phase 4|100|Anticipated|University of Campinas, Brazil||2|||f||||t||||||||||2018-06-01 02:29:27.642808|2018-06-01 02:29:27.642808
NCT00610519|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-06-13|2008-02-07|2008-02-08|Estimate|||||||2008-06-13|2008-06-17|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Treatment of Acute Pharyngo-Tonsillitis With Essential Oils of Aromatic Plants|Treatment of Acute Pharyngo-Tonsillitis With Essential Oils of Some Aromatic Medical Plants.|Completed||Phase 1/Phase 2|33|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-06-01 02:29:28.000706|2018-06-01 02:29:28.000706
NCT00610506|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2013-05-30|2008-02-07|2008-02-08|Estimate|||||||2013-05-30|2013-05-31|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features|A Pilot Study -- An Open-Label, Rater-blinded, Flexible-dose, 8-week Trial of Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features.|Completed||Phase 3|15|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:29:28.167258|2018-06-01 02:29:28.167258
NCT00610493|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-12-06|2008-01-25|2008-02-08|Estimate|||||||2017-12-06|2017-12-08|Actual|January 25, 2008|Actual|2008-01-25|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Bevacizumab and Temsirolimus in Patients With Advanced Malignancy|A Phase I Trial of Bevacizumab and Temsirolimus in Patients With Advanced Malignancy|Completed||Phase 1|193|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:29:28.30673|2018-06-01 02:29:28.30673
NCT00610480|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2009-07-13|2008-02-07|2008-02-08|Estimate|||||||2009-07-13|2009-07-14|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Tear Film Stability After Instillation Of OTC Artificial Drops|Effects of Systane® Versus Optive™ and Soothe™ Lubricating Eye Drops in Maintaining Tear Film Stability at Determined Time Points|Completed||N/A|20|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 02:29:28.477267|2018-06-01 02:29:28.477267
NCT00610467|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-12|||2016-12-06|2008-01-25|2008-02-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|October 2006||2006-10-31|December 2016|2016-12-31||||October 2016|Actual|2016-10-31||Interventional|||Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis|Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis|Terminated||N/A|120|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:29:28.591351|2018-06-01 02:29:28.591351
NCT00610454|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2013-12-05|2008-01-27|2008-02-08|Estimate|||||||2013-12-05|2013-12-06|Estimate|June 2004||2004-06-30|September 2009|2009-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures|Trial Evaluating the Safety and Tolerability of Levetiracetam Intravenous 15-minute Infusion, Administered in b.i.d. Regimen as an Adjunctive Antiepileptic Treatment in Subjects From 16 to 65 Years Suffering From Partial Onset Seizures|Completed||Phase 2|25|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:29:28.705059|2018-06-01 02:29:28.705059
NCT00610441|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2014-05-30|2009-05-14|2015-05-13|2008-01-28|2008-02-08|Estimate|2014-08-28|2014-08-29|Estimate|2009-09-30|2009-10-01|Estimate|2015-05-13|2015-06-08|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)|A Double Blind, Placebo Controlled, Randomized, Two Period 4-Arm Trial to Investigate the Dose-Related Efficacy and Safety of Org 26576 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|67|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:29:28.842784|2018-06-01 02:29:28.842784
NCT00610428|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|2017-02-07||2017-06-17|2008-01-28|2008-02-08|Estimate|2017-06-17|2018-01-25|Actual||||2017-06-17|2018-01-25|Actual|March 2005||2005-03-31|January 2008|2008-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional||Safety Population|Staccato Prochlorperazine in Migraine (in Clinic)|A Multi-center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache|Completed||Phase 2|75|Actual|Alexza Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 02:29:30.304288|2018-06-01 02:29:30.304288
NCT00610415|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2016-06-29|2008-01-25|2008-02-08|Estimate|||||||2016-06-29|2016-07-01|Estimate|December 2007||2007-12-31|June 2016|2016-06-30||||October 2012|Actual|2012-10-31||Observational|||Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study|Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study|Completed|||40|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     Tissue samples~   "|||2018-06-01 02:29:30.601727|2018-06-01 02:29:30.601727
NCT00610402|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-02-08|2008-01-25|2008-02-08|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2007||2007-07-31|February 2017|2017-02-28|June 2008|Actual|2008-06-30|July 2007|Actual|2007-07-31||Observational|||Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)|Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)|Completed|||57|Actual|University of California, Irvine|||1||f||||f||||||Samples Without DNA|"~     blood sample tear drop sample~   "|||2018-06-01 02:29:30.663824|2018-06-01 02:29:30.663824
NCT00610389|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2010-05-07|2008-01-28|2008-02-08|Estimate|||||||2010-05-07|2010-05-10|Estimate|February 2008||2008-02-29|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|April 2010|Anticipated|2010-04-30||Interventional|||Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors|Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors|Unknown status|Recruiting|Phase 2|27|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-06-01 02:29:30.727589|2018-06-01 02:29:30.727589
NCT00610376|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-27|||2015-09-21|2008-02-07|2008-02-08|Estimate|||||||2015-09-21|2015-09-22|Estimate|September 2000||2000-09-30|January 2008|2008-01-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|JHS||Jerusalem Handwashing Study|A Controlled Trial to Assess the Effect of a Health Promotion Intervention on Hygiene Behavior and Illness Absenteeism in Jerusalem Preschools|Completed||Phase 3|1029|Actual|Hebrew University of Jerusalem||3|||f||||f||||||||||2018-06-01 02:29:30.796352|2018-06-01 02:29:30.796352
NCT00610363|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2017-03-20|2010-11-23|2017-03-20|2008-01-24|2008-02-07|Estimate|2017-03-20|2017-05-02|Actual|2010-11-23|2010-11-29|Estimate|2017-03-20|2017-05-02|Actual|November 2007||2007-11-30|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Baseline population included full analysis set (FAS) comprising of all randomized participants who received any study medication and was based on treatment allocated by Interactive voice response system (IVRS) at randomization (as randomized).|Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy|Completed||Phase 2|83|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:29:30.907162|2018-06-01 02:29:30.907162
NCT00610350|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-02-06|2008-02-06|2008-02-07|Estimate|||||||2008-02-06|2008-02-07|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Levosimendan and Myocardial Protection|Levosimendan Pre-Treatment in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-Blind, Single Center, Prospective, Randomized, Placebo-Controlled Trial|Completed||Phase 4|100|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-06-01 02:29:31.434214|2018-06-01 02:29:31.434214
NCT00610337|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2014-01-16|2008-02-06|2008-02-07|Estimate|||||||2014-01-16|2014-01-17|Estimate||||February 2010|2010-02-28||||||||Interventional|||Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury|A Phase IIb, Double-Blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Safety and Efficacy of Intraoperative Epidural Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury|Withdrawn||Phase 2|0|Actual|BioAxone BioSciences, Inc.||6||Due to a change of sponsor|f||||t||||||||||2018-06-01 02:29:31.542664|2018-06-01 02:29:31.542664
NCT00610324|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-01-24|2008-01-24|2008-02-07|Estimate|||||||2008-01-24|2008-02-07|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients|Effect of Oral Decontamination Using Chlorhexidine or Potassium Permanganate in ICU Patients: an Open-Labelled Randomized Controlled Trial|Completed||Phase 4|512|Actual|King Edward Memorial Hospital||2|||f||||f||||||||||2018-06-01 02:29:31.633572|2018-06-01 02:29:31.633572
NCT00610311|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2012-03-14||2015-10-06|2008-02-06|2008-02-07|Estimate|2012-03-14|2012-04-10|Estimate||||2015-10-06|2015-10-28|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes and ALVAC Virus Immunization|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|Early termination leading to a small number of subjects analyzed.|1||The study was terminated due to low accrual.|f||||t||||||||||2018-06-01 02:29:31.766652|2018-06-01 02:29:31.766652
NCT00610298|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-09-12|2008-02-06|2008-02-07|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2001||2001-10-31|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Whole Body Vibration in Elderly Patients Requiring Rehabilitation: A Pilot Study|Effects of Whole Body Vibration in Elderly Patients Requiring Rehabilitation: A Pilot Study|Withdrawn||N/A|0|Actual|Ohio State University||2||Another institution conducted and published this study.No subjects enrolled.|f||||f||||||||||2018-06-01 02:29:32.035576|2018-06-01 02:29:32.035576
NCT00610285|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2015-12-17|2008-02-06|2008-02-07|Estimate|||||||2015-12-17|2015-12-18|Estimate|October 2005||2005-10-31|December 2015|2015-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases|A Feasibility Study of Image Guided Noninvasive Single Fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases|Completed|||9|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:29:32.110981|2018-06-01 02:29:32.110981
NCT00610272|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-08-06|2008-02-06|2008-02-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|bone mets||Optimization of Radiotherapy in Treatment of Painful Bone Metastasis|Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis|Completed||Phase 3|650|Actual|International Atomic Energy Agency||4|||f||||t||||||||||2018-06-01 02:29:32.189427|2018-06-01 02:29:32.189427
NCT00610259|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2009-09-17|2008-01-24|2008-02-07|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia|Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia - An Assessors-blinded, Randomized Controlled Effectiveness Trial|Completed||Phase 2/Phase 3|40|Anticipated|Nagoya City University||2|||f||||f||||||||||2018-06-01 02:29:32.300414|2018-06-01 02:29:32.300414
NCT00610246|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2011-10-19|2008-02-06|2008-02-07|Estimate|||||||2011-10-19|2011-10-21|Estimate|May 2007||2007-05-31|October 2011|2011-10-31||||December 2010|Actual|2010-12-31||Interventional|||A Study of Radiation With Sorafenib in Advanced Cancer|A Phase I Dose Escalation Study of Concurrent Low Dose Radiation With Sorafenib in Three Anatomically-based Independent Cohorts (Thorax, Abdomen, Pelvis)|Completed||Phase 1|36|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 02:29:32.372671|2018-06-01 02:29:32.372671
NCT00610233|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2014-09-18|2008-02-06|2008-02-07|Estimate|||||||2014-09-18|2014-09-19|Estimate|June 2005||2005-06-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Deep Brain Stimulation on Lower Urinary Tract Function|Effect of Deep Brain Stimulation (DBS) on Lower Urinary Tract (LUT) Function|Completed||N/A|45|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:29:32.463539|2018-06-01 02:29:32.463539
NCT00610220|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2017-10-06|2008-01-24|2008-02-07|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2007||2007-01-31|May 2014|2014-05-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Cast Versus Splint in Children With Acceptably Angulated Wrist Fractures|Cast Versus Splint in Children With Minimally Angulated Fractures of the Distal Radius: a Randomized Controlled Trial.|Completed||Phase 4|96|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 02:29:32.548763|2018-06-01 02:29:32.548763
NCT00610207|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2011-04-25||2015-12-29|2008-02-06|2008-02-07|Estimate|2011-07-21|2011-08-17|Estimate||||2015-12-29|2016-02-02|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|SurgiSIS AFP||Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft|Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft (SurgiSIS AFP)|Terminated||N/A|21|Actual|Cook Group Incorporated|Early termination did lead to small patient numbers.|1||Study stopped early due to staffing changes at the site.|f||||f||||||||||2018-06-01 02:29:32.640358|2018-06-01 02:29:32.640358
NCT00610194|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2014-12-30|2008-01-24|2008-02-07|Estimate|||||||2014-12-30|2015-01-01|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|August 2012|Actual|2012-08-31|November 2010|Actual|2010-11-30||Interventional|||Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients|A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients|Completed||Phase 1|69|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:29:32.866299|2018-06-01 02:29:32.866299
NCT00610181|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2015-06-29|2008-01-24|2008-02-07|Estimate|||||||2015-06-29|2015-07-01|Estimate|January 2008||2008-01-31|June 2015|2015-06-30||||June 2015|Actual|2015-06-30||Observational|||Magnetic Resonance Imaging in Patients With Breast Cancer|Magnetic Resonance Imaging (MRI) for Preoperative Staging of Patients With Invasive Lobular Carcinoma of the Breast|Completed|||96|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:29:32.955048|2018-06-01 02:29:32.955048
NCT00610168|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2017-02-09|2010-12-07|2017-02-09|2008-01-25|2008-02-07|Estimate|2017-02-09|2017-03-30|Actual|2010-12-07|2010-12-10|Estimate|2017-02-09|2017-03-30|Actual|January 2008||2008-01-31|February 2017|2017-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.|Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting.|Completed||Phase 4|82|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:29:33.057974|2018-06-01 02:29:33.057974
NCT00610155|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2012-12-20||2013-09-19|2008-01-24|2008-02-07|Estimate|2013-09-19|2013-11-28|Estimate||||2013-09-19|2013-11-28|Estimate|September 2008||2008-09-30|September 2013|2013-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients|A Methodology Study To Assess The Feasibility Of Using Functional Magnetic Resonance Imaging (fRMI) To Quantify The Effects Of Analgesic Drugs In Post-Traumatic Neuropathic Pain Subjects|Completed||N/A|18|Actual|Pfizer|Results for primary outcome, BOLD activation signals(whole brain) was not available to reported, as DMAa, DMAc, TH and VIS were captured as COPE images only, which could not be included in basic results format.|3|||f||||f||||||||||2018-06-01 02:29:33.542818|2018-06-01 02:29:33.542818
NCT00610142|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2014-06-10|2008-01-24|2008-02-07|Estimate|||||||2014-06-10|2014-06-11|Estimate|December 2007||2007-12-31|June 2014|2014-06-30|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|OCT-AD||Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis|Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis|Completed||Phase 2|20|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 02:29:34.351008|2018-06-01 02:29:34.351008
NCT00610129|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2015-10-19||2015-10-19|2008-02-06|2008-02-07|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)|A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)|Completed||Phase 2|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:29:34.461361|2018-06-01 02:29:34.461361
NCT00610116|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2017-02-17|2008-02-06|2008-02-07|Estimate|||||||2017-02-17|2017-02-23|Actual|September 2006||2006-09-30|February 2017|2017-02-28|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|ERACE||Electronic Repositioning With Acuity and Easytrak Leads|Electronic Repositioning With Acuity and Easytrak Leads|Completed||N/A|400|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 02:29:34.679789|2018-06-01 02:29:34.679789
NCT00610103|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2017-02-28|2008-01-23|2008-02-07|Estimate|||||||2017-02-28|2017-03-03|Actual|November 2007||2007-11-30|February 2017|2017-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy|A Phase 2 Clinical Study of KW-6500 (Apomorphine Hydrochloride) in Patients With Parkinson's Disease|Completed||Phase 2|16|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||||2018-06-01 02:29:34.763419|2018-06-01 02:29:34.763419
NCT00610090|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2015-08-23|2008-01-24|2008-02-07|Estimate|||||||2015-08-23|2015-08-25|Estimate|May 2007||2007-05-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|UNITE||Safety Study for the Treatment of Abdominal Aortic Aneurysms|A Phase II, Single-arm, Prospective Study of the Safety of the UniFit Aorto-uni-iliac Endoluminal Stent Graft for the Repair of Abdominal Aortic Aneurysms|Terminated||Phase 2|71|Actual|Duke Vascular, Inc.||1|||f||||t||||||||||2018-06-01 02:29:34.84152|2018-06-01 02:29:34.84152
NCT00610077|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-02-06|2008-02-06|2008-02-07|Estimate|||||||2008-02-06|2008-02-07|Estimate|December 2004||2004-12-31|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Letrozole vs. Clomiphene Citrate in Patients With Anovulatory Infertility|An Open, Randomized, Parallel-Group, Multicentric, Comparative Study of Letrozole With Clomiphene Citrate for Induction of Ovulation in Anovulatory Infertility.|Completed||Phase 3|55|Actual|Sun Pharmaceutical Industries Limited||2|||f||||f||||||||||2018-06-01 02:29:34.947346|2018-06-01 02:29:34.947346
NCT00610064|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2010-02-04|2008-02-06|2008-02-07|Estimate|||||||2010-02-04|2010-02-05|Estimate|October 2005||2005-10-31|February 2010|2010-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Brain Effects of Sacral Neuromodulation|Brain Effects of Sacral Neuromodulation in Patients With Refractory Lower Urinary Tract Dysfunction|Completed||N/A|30|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:29:35.05059|2018-06-01 02:29:35.05059
NCT00610051|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-01-30|2008-02-06|2008-02-07|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Alprostadil Continuous Intravenous Infusion in Bridging Cardiac Transplant in Severe Heart Failure Patients|Phase 3 Study of Alprostadil Continuous Intravenous Infusion in Bridging Cardiac Transplant in Severe Heart Failure Patients|Suspended||Phase 3|500|Anticipated|Biopeutics Co., Ltd||2||DD issue|f||||t|t|f||||||No||2018-06-01 02:29:35.17007|2018-06-01 02:29:35.17007
NCT00610038|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2012-11-16|2008-02-06|2008-02-07|Estimate|||||||2012-11-16|2012-11-19|Estimate|July 2006||2006-07-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|August 2010|Actual|2010-08-31||Interventional|GLIDKIR6-2||Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus|Sulfonylureas in Neonatal Diabetes Mellitus With Mutations of 2 Type of Subunits Kir6.2 and SUR1 of the Pancreatic Beta-cell ATP-sensitive K+ Channel.|Completed||Phase 2|19|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 02:29:35.260146|2018-06-01 02:29:35.260146
NCT00610025|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-02-11|2008-02-06|2008-02-07|Estimate|||||||2013-02-11|2013-02-12|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Minimally Invasive Trocar Placement in Obesity Surgery|Transgastric Peritoneoscopy for Evaluation of the Abdominal Wall to Direct Laparoscopic Trocar Placement|Completed||N/A|60|Actual|Ohio State University||6|||f||||f||||||||||2018-06-01 02:29:35.339162|2018-06-01 02:29:35.339162
NCT00610012|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-08-24|2008-02-06|2008-02-07|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2007|Actual|2007-12-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|RCC-Registry||Tumor Registry of Advanced Renal Cell Carcinoma|Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy|Active, not recruiting|||1500|Actual|iOMEDICO AG|||||f||||f||||||||No||2018-06-01 02:29:35.404064|2018-06-01 02:29:35.404064
NCT00609986|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2013-06-05||2013-08-21|2008-02-06|2008-02-07|Estimate|2013-06-05|2013-08-07|Estimate||||2013-08-21|2013-09-06|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||The intent-to-treat anaylsis consisted only of the 93 participants that underwent a renal transplant.|IV Insulin Protocol in Diabetes and Renal Transplantation|Intravenous Insulin Protocol in Diabetes and Renal Transplantation Study|Completed||N/A|104|Actual|Medical University of South Carolina|A limitation of the trial was that the majority of the patients enrolled in the study were African American, and therefore the findings cannot be extended to groups of other ethnic groups.|2|||f||||t||||||||||2018-06-01 02:29:35.574863|2018-06-01 02:29:35.574863
NCT00609973|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2012-11-12||2013-03-21|2008-02-06|2008-02-07|Estimate|2013-03-21|2013-05-03|Estimate||||2013-03-21|2013-05-03|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease|Double-blind, Placebo Controlled, Randomized, Multicentre, Pilot Study on the Safety and Efficacy of Ciprofloxacin for Prophylactic Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease Patients|Completed||Phase 2|33|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 02:29:35.948266|2018-06-01 02:29:35.948266
NCT00609960|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-02-06|2008-02-06|2008-02-07|Estimate|||||||2008-02-06|2008-02-07|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Clowns as Treatment for Preoperative Anxiety in Children: A Randomized Controlled Trial|Clowns as Treatment for Preoperative Anxietyin Children- a Randomized Controlled Trial|Completed||N/A|65|Actual|Sheba Medical Center||3|||f||||f||||||||||2018-06-01 02:29:36.15795|2018-06-01 02:29:36.15795
NCT00609947|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2013-06-05||2015-01-26|2008-01-25|2008-02-07|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-26|2015-02-09|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|September 2013|Actual|2013-09-30|March 2012|Actual|2012-03-31||Interventional|ENDEAVORSVS||Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.|A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries|Completed||N/A|241|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-06-01 02:29:36.242546|2018-06-01 02:29:36.242546
NCT00609934|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2015-07-22|2008-02-06|2008-02-07|Estimate|||||||2015-07-22|2015-07-23|Estimate|December 2007||2007-12-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone|A Phase I/II Study of Sorafenib and Palliative Radiotherapy in Patients With Advanced Renal Cell Carcinoma and Symptomatic Bony Metastases|Completed||Phase 1/Phase 2|12|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 02:29:36.475908|2018-06-01 02:29:36.475908
NCT00609921|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-09-06|2008-01-25|2008-02-07|Estimate|||||||2012-09-06|2012-09-07|Estimate|January 2008||2008-01-31|September 2012|2012-09-30||||September 2011|Actual|2011-09-30||Interventional|||A Phase 1 Study of ARQ 197 in Patients With Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors|Completed||Phase 1|42|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 02:29:36.555989|2018-06-01 02:29:36.555989
NCT00609908|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2015-06-25|2008-02-06|2008-02-07|Estimate|||||||2015-06-25|2015-06-26|Estimate|December 2007||2007-12-31|June 2015|2015-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Technique of Skin Stretching for Acute Burn Treatment and Scar Reconstruction|The Technique of Skin Stretching for Acute Burn Treatment and Scar Reconstruction: Clinical Applications and Working Mechanisms.|Completed||Phase 3|30|Actual|Association of Dutch Burn Centres||4|||f||||f||||||||||2018-06-01 02:29:36.610206|2018-06-01 02:29:36.610206
NCT00609895|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-03-26|2008-02-06|2008-02-07|Estimate|||||||2008-03-26|2008-03-28|Estimate|January 2004||2004-01-31|March 2008|2008-03-31|August 2004|Actual|2004-08-31|||||Interventional|||The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing|The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning Dosing|Completed||Phase 4|22|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:29:36.675733|2018-06-01 02:29:36.675733
NCT00609882|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2013-02-05|2008-02-06|2008-02-07|Estimate|||||||2013-02-05|2013-02-06|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|HHFNC||Comparison of Humidified High Flow Nasal Cannula to Nasal CPAP in Neonates|Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates|Completed||N/A|420|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 02:29:36.739|2018-06-01 02:29:36.739
NCT00609869|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2014-08-20||2015-09-01|2008-02-06|2008-02-07|Estimate|2014-08-20|2014-09-01|Estimate||||2015-09-01|2015-09-17|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|February 2014|Actual|2014-02-28||Interventional||All enrolled participants|Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab|A Phase II Study of Lenalidomide (REVLIMID®) in Combination With Rituximab for Patients With CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab|Completed||Phase 2|29|Actual|H. Lee Moffitt Cancer Center and Research Institute|The 4 Mantle Cell participants were not evaluated for Outcome Measures due to their low enrollment.|1|||f||||f||||||||||2018-06-01 02:29:36.840392|2018-06-01 02:29:36.840392
NCT00609856|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-01-24|2008-01-24|2008-02-07|Estimate|||||||2008-01-24|2008-02-07|Estimate|April 2004||2004-04-30|January 2008|2008-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes|Differences in Metabolic and Cardiovascular Effects of Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes|Completed||Phase 4|36|Actual|Skane University Hospital||2|||f||||f||||||||||2018-06-01 02:29:38.068917|2018-06-01 02:29:38.068917
NCT00609843|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2015-12-04|2008-01-24|2008-02-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pilot Studie of Lipiodol Demarcation of the Tumour in Bladder Cancer|Lipiodol Demarcation of the Bladder Tumour in Adaptive Image-guided Radiotherapy: A Pilot Study. (Danish: Lipiodol Til Markering af blæretumoren i Forbindelse Med Adaptiv Billedvejledt strålebehandling: Et Pilotstudie.)|Completed||N/A|5|Actual|University of Aarhus||1|||f||||t||||||||||2018-06-01 02:29:38.140548|2018-06-01 02:29:38.140548
NCT00609830|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2015-06-12|2008-01-24|2008-02-07|Estimate|||||||2015-06-12|2015-06-16|Estimate|July 2001||2001-07-31|January 2008|2008-01-31|February 2006|Actual|2006-02-28|||||Interventional|||GIOP Prevention Among People With Rheumatoid Arthritis|Osteoporosis Prevention Among People With Rheumatoid Arthritis Receiving Oral Glucocorticoid Therapy|Completed||N/A|273|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-06-01 02:29:38.282881|2018-06-01 02:29:38.282881
NCT00609817|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2013-06-21|2008-01-24|2008-02-07|Estimate|||||||2013-06-21|2013-06-25|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma|An Open-Label Phase 1/2 Study of the Safety and Efficacy of GCS-100 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1|9|Actual|La Jolla Pharmaceutical Company||1||Lack of funding|f||||t||||||||||2018-06-01 02:29:38.369151|2018-06-01 02:29:38.369151
NCT00609804|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2015-04-24||2016-03-10|2008-01-24|2008-02-07|Estimate|2015-05-13|2015-06-02|Estimate||||2016-03-10|2016-04-08|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|May 2012|Actual|2012-05-31||Interventional|||Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib|Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib|Completed||Phase 2|53|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 02:29:38.519553|2018-06-01 02:29:38.519553
NCT00609791|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2018-03-01|2008-02-06|2008-02-07|Estimate|||||||2018-03-01|2018-03-02|Actual|January 25, 2008||2008-01-25|March 2018|2018-03-31|August 20, 2018|Anticipated|2018-08-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer|Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics|Active, not recruiting||Phase 2|40|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:29:39.212022|2018-06-01 02:29:39.212022
NCT00609778|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-10-04|2008-02-06|2008-02-07|Estimate|||||||2012-10-04|2012-10-05|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|LINC||A Comparison of Conventional Adult Out-of-hospital Cardiopulmonary Resuscitation Against a Concept With Mechanical Chest Compressions and Simultaneous Defibrillation - LINC Study|A Comparison of Conventional Adult Out-of-hospital Cardiopulmonary Resuscitation Against a Concept With Mechanical Chest Compressions and Simultaneous Defibrillation|Completed||N/A|2500|Actual|Jolife AB||2|||f||||t||||||||||2018-06-01 02:29:39.304036|2018-06-01 02:29:39.304036
NCT00609765|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2011-02-21||2017-02-20|2008-02-06|2008-02-07|Estimate|2011-02-21|2011-03-22|Estimate||||2017-02-20|2017-03-23|Actual|August 2007||2007-08-31|March 2011|2011-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors|Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors|Terminated||Phase 2|1|Actual|H. Lee Moffitt Cancer Center and Research Institute|This trial only enrolled one patient and was closed because of development of a new chemotherapy standard of care for treatment of this cancer which we felt rendered the trial obsolete. The trial was open for only 7 months.|1||Development of new chemotherapy standard of care for treatment rendered the trial obsolete.|f||||t||||||||||2018-06-01 02:29:39.406511|2018-06-01 02:29:39.406511
NCT00609752|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-12-29|2008-01-24|2008-02-07|Estimate|||||||2008-12-29|2008-12-30|Estimate|February 2008||2008-02-29|December 2008|2008-12-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease|Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease|Unknown status|Recruiting|Phase 4|80|Anticipated|University Hospital Birmingham||2|||f||||t||||||||||2018-06-01 02:29:39.590216|2018-06-01 02:29:39.590216
NCT00609739|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2011-11-22||2017-12-03|2008-02-06|2008-02-07|Estimate|2012-01-31|2012-03-02|Estimate||||2017-12-03|2017-12-28|Actual|June 1999||1999-06-30|December 2017|2017-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation|Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation|Terminated||Phase 1/Phase 2|1|Actual|Masonic Cancer Center, University of Minnesota|Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.|1||Low accrual|f||||t||||||||||2018-06-01 02:29:39.70078|2018-06-01 02:29:39.70078
NCT00609726|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2016-01-21|2008-02-06|2008-02-07|Estimate|||||||2016-01-21|2016-01-25|Estimate|December 2015||2015-12-31|January 2015|2015-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Prospective Evaluation of Idiopathic Pancreatitis: Role of Endoscopic Ultrasonography|Prospective Evaluation of Idiopathic Pancreatitis: Role of Endoscopic Ultrasonography|Completed|||199|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 02:29:39.970731|2018-06-01 02:29:39.970731
NCT00609713|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-02-15|2008-01-25|2008-02-07|Estimate|||||||2013-02-15|2013-02-18|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Bone Health of Obese Adolescents During Weight Loss|Bone Health of Obese Adolescents During Weight Loss|Completed||N/A|91|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 02:29:40.029687|2018-06-01 02:29:40.029687
NCT00609700|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2011-10-14|2008-02-06|2008-02-07|Estimate|||||||2011-10-14|2011-10-17|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Observational|VoLTRAB||Balanced Volume Replacement Therapy With Ringer's Acetate Solution in Burn Injury|Balanced Volume Replacement Therapy With Ringer's Acetate Solution in Burn Injury|Completed|||82|Actual|Klinikum St. Georg gGmbH|||2||f||||f||||||||||2018-06-01 02:29:40.114862|2018-06-01 02:29:40.114862
NCT00609687|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-04-09|2008-02-06|2008-02-07|Estimate|||||||2013-04-09|2013-04-11|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis|Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis|Completed||N/A|150|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:29:40.187507|2018-06-01 02:29:40.187507
NCT00609674|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2009-06-22||2016-11-02|2008-01-25|2008-02-07|Estimate|2009-11-18|2009-12-23|Estimate||||2016-11-02|2016-12-16|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR)|Completed||Phase 4|315|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:29:40.306756|2018-06-01 02:29:40.306756
NCT00609661|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2012-10-05|2008-02-06|2008-02-07|Estimate|||||||2012-10-05|2012-10-08|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|June 2010|Anticipated|2010-06-30|February 2010|Anticipated|2010-02-28||Observational|||Adult Stem Cell Response to Burn Injury|Comparison of Burn Severity and Patient Outcomes to the Subsets of Mesenchymal Stem Cells Identified in the Blood of Burn Victims|Withdrawn|||0|Actual|Ohio State University|||2|Assay for stem cell analysis not available|f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 02:29:40.988537|2018-06-01 02:29:40.988537
NCT00609635|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2009-04-03|2008-01-25|2008-02-07|Estimate|||||||2009-04-03|2009-04-06|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly|The Association Between Cytokine Genotype Polymorphisms and Severity of RSV-Induced Illness in the Elderly|Completed|||300|Anticipated|West Penn Allegheny Health System|||||f||||f||||||Samples With DNA|"~     A buccal brushing (cells collected from the inside of the cheek) will be collected and stored~     for DNA analysis.~   "|||2018-06-01 02:29:41.127749|2018-06-01 02:29:41.127749
NCT00609622|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2012-07-06||2012-09-10|2008-01-25|2008-02-07|Estimate|2012-09-10|2012-10-11|Estimate||||2012-09-10|2012-10-11|Estimate|April 2008||2008-04-30|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer|A Randomized, Phase 2B Study Of Sunitinib Plus Oxaliplatin, 5-Fluorouracil And Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX As First-Line Treatment In Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|191|Actual|Pfizer|Due to early study termination, not all data was analyzable.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:29:41.319005|2018-06-01 02:29:41.319005
NCT00609609|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2016-02-09|2008-01-23|2008-02-07|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Photopheresis for the Treatment of Acute Graft Versus Host Disease|A Randomized Phase II Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination With Corticosteroids for the Initial Treatment of Acute Graft-Versus-Host Disease (GVHD)|Completed||Phase 2|81|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:29:42.858851|2018-06-01 02:29:42.858851
NCT00609596|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-08-02|2008-02-06|2008-02-07|Estimate|||||||2017-08-02|2017-08-04|Actual|February 26, 2008|Actual|2008-02-26|August 2017|2017-08-31|April 23, 2008|Actual|2008-04-23|April 23, 2008|Actual|2008-04-23||Interventional|||A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.|An Open Label, Randomized, Repeat Dose, 3 Period Crossover Study to Determine the Bioequivalence of 3 Different Formulations of Tamsulosin at Steady State in Healthy Male Volunteers|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:29:42.93826|2018-06-01 02:29:42.93826
NCT00609570|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2008-10-27|2008-02-06|2008-02-07|Estimate|||||||2008-10-27|2008-10-28|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Nutritional Supplements on Blood Pressure 2008|Effects of Nutritional Supplements on Blood Pressure and Heart Rate Variability|Unknown status|Recruiting|Phase 1|60|Anticipated|Logan College of Chiropractic||3|||f||||f||||||||||2018-06-01 02:29:43.056634|2018-06-01 02:29:43.056634
NCT00609557|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-01-24|2008-01-24|2008-02-07|Estimate|||||||2008-01-24|2008-02-07|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain|A Single-Blind Placebo Run-in Study of Duloxetine for Activity-Limiting Osteoarthritis Pain|Completed||Phase 4|25|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:29:43.21988|2018-06-01 02:29:43.21988
NCT00609544|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-04-17|2008-01-24|2008-02-07|Estimate|||||||2011-04-17|2011-04-19|Estimate||||April 2011|2011-04-30||||||||Interventional|||Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia|A Multi-Center, Double-Blind, Placebo-Controlled Safety and Preliminary Efficacy Study of IL-1 Trap (Rilonacept) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia|Withdrawn||Phase 2|0|Actual|Regeneron Pharmaceuticals||2||Unable to enroll patients|f||||f||||||||||2018-06-01 02:29:43.315231|2018-06-01 02:29:43.315231
NCT00609531|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2012-10-05|2008-02-06|2008-02-07|Estimate|||||||2012-10-05|2012-10-08|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders|Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders|Completed||Phase 1|12|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 02:29:43.424145|2018-06-01 02:29:43.424145
NCT00609518|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2010-10-15||2010-12-10|2008-01-23|2008-02-07|Estimate|2010-10-15|2010-11-15|Estimate||||2010-12-10|2010-12-28|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Interventional|||A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer|Pemetrexed With Simplified Folate and Dexamethasone Supplementation Versus Pemetrexed With Standard Supplementation as Second-line Chemotherapy for Patients With Non-squamous Non-small Cell Lung Cancer|Completed||Phase 2|111|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:29:43.541487|2018-06-01 02:29:43.541487
NCT00609505|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-02-21|2008-02-06|2008-02-07|Estimate|||||||2012-02-21|2012-02-22|Estimate|August 2008||2008-08-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Telemedicine vs. Face-to-Face Cancer Genetic Counseling|Telemedicine vs. Face-to-Face Cancer Genetic Counseling in Rural Oncology Clinics|Completed||N/A|130|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:29:44.212161|2018-06-01 02:29:44.212161
NCT00609492|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2016-11-28|2009-09-09|2017-03-01|2008-01-25|2008-02-07|Estimate|2017-03-01|2017-04-12|Actual|2009-09-09|2009-09-10|Estimate|2017-03-01|2017-04-12|Actual|January 2008||2008-01-31|March 2017|2017-03-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.|Safety, Reactogenicity and Immunogenicity Following Booster Dose of GSK Biologicals´ Pneumococcal Conjugate Vaccine When Co-administered With a Booster Dose of Infanrix-IPV/Hib in Preterm Born Children at 16-18 Months of Age|Completed||Phase 3|245|Actual|GlaxoSmithKline|None reported.|3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:29:44.369074|2018-06-01 02:29:44.369074
NCT00609479|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2010-04-09|2008-02-06|2008-02-07|Estimate|||||||2010-04-09|2010-04-12|Estimate|January 2008||2008-01-31|April 2010|2010-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Comparison of Two Methods for Treatment of Colles´s Fracture|Comparison of External and Internal Fixationmethods for Distal Radius Fracture - a Randomized Study.|Completed||N/A|60|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:29:45.550484|2018-06-01 02:29:45.550484
NCT00609050|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2016-02-18|2008-02-01|2008-02-06|Estimate|||||||2016-02-18|2016-02-19|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Exercise Training Study for Patients With Cystic Fibrosis|Self-Regulated Exercise in CF: A Randomized Trial|Completed||N/A|38|Actual|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-06-01 02:29:49.835426|2018-06-01 02:29:49.835426
NCT00609466|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2009-09-16||2011-11-10|2008-01-24|2008-02-07|Estimate|2009-10-22|2009-11-25|Estimate||||2011-11-10|2011-11-16|Estimate|September 2007||2007-09-30|November 2011|2011-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy|A Randomized, Double-blind, Parallel-group, Multi-center, Active- and Placebo-controlled Trial to Evaluate the Analgesic Efficacy and Safety of Multiple Doses of CG5503 IR for Postoperative Pain Following Bunionectomy|Completed||Phase 3|291|Actual|Grünenthal GmbH|Lortab (hydrocodone/acetaminophen) was allowed as rescue medication.|3|||f||||f||||||||||2018-06-01 02:29:45.630648|2018-06-01 02:29:45.630648
NCT00609453|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2012-10-05|2008-02-06|2008-02-07|Estimate|||||||2012-10-05|2012-10-08|Estimate|October 2006||2006-10-31|October 2012|2012-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Brain Imaging of Psychotherapy for Depression|"Brain Imaging of Psychotherapy for Depression (Includes, Reward System Recovery Following Behavioral Activation Therapy in Depression)"|Completed||N/A|27|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 02:29:46.170539|2018-06-01 02:29:46.170539
NCT00609440|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2008-10-17|2008-01-25|2008-02-07|Estimate|||||||2008-10-17|2008-10-20|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|August 2006|Actual|2006-08-31||Interventional|||Morquio's Syndrome: a Case Study|Morquio's Syndrome: a Case Study|Terminated||Phase 4|1|Actual|Clínica de Hidroterapia e Recuperacao Funcional||1||terminated|f||||f||||||||||2018-06-01 02:29:46.255757|2018-06-01 02:29:46.255757
NCT00609427|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2010-06-01|2008-02-06|2008-02-07|Estimate|||||||2010-06-01|2010-06-02|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study|Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study|Completed||Phase 1|30|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-06-01 02:29:46.31602|2018-06-01 02:29:46.31602
NCT00609414|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2011-04-15|2008-01-24|2008-02-07|Estimate|||||||2011-04-15|2011-04-18|Estimate|January 2005||2005-01-31|April 2011|2011-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Albumin Use in Burn Patients|Albumin Use in Burn Patients|Completed|||460|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 02:29:46.387996|2018-06-01 02:29:46.387996
NCT00609401|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-02-25|2008-01-24|2008-02-07|Estimate|||||||2009-02-25|2009-02-26|Estimate|November 2006||2006-11-30|February 2009|2009-02-28|May 2008|Actual|2008-05-31|May 2007|Actual|2007-05-31||Interventional|ROSORC||Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)|A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma|Completed||Phase 2|90|Actual|Italian Trial in Medical Oncology||2|||f||||t||||||||||2018-06-01 02:29:46.468738|2018-06-01 02:29:46.468738
NCT00609388|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2010-12-07|2008-02-06|2008-02-07|Estimate|||||||2010-12-07|2010-12-08|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|TAC-Infusion||Tacrolimus During the Implantation and the Effect on Ischemia-reperfusion Injury in Liver Transplantation|Evaluation of Tacrolimus (Prograf®) Intraportal Infusion During the Implantation and the Protective Effect on Ischemia-reperfusion Injury in Orthotopic Liver Transplant Recipients - Single Center Study|Completed||Phase 4|26|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:29:46.552941|2018-06-01 02:29:46.552941
NCT00609375|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-02-06|2008-02-06|2008-02-07|Estimate|||||||2008-02-06|2008-02-07|Estimate|September 2006||2006-09-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|CEFPK/PD||Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen|Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen in Adult Critically Ill Patients With Gram Negative Bacilli Bacteremia|Completed||Phase 4|30|Actual|Javeriana University||2|||f||||t||||||||||2018-06-01 02:29:46.639109|2018-06-01 02:29:46.639109
NCT00609362|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2011-02-17||2011-03-29|2008-02-06|2008-02-07|Estimate|2011-03-29|2011-04-27|Estimate||||2011-03-29|2011-04-27|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells|The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells|Completed||Phase 2|57|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:29:46.737997|2018-06-01 02:29:46.737997
NCT00609349|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2012-01-11|2008-02-06|2008-02-07|Estimate|||||||2012-01-11|2012-01-12|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Early Recognition of Pulmonary Arterial Hypertension|The Early Recognition of Pulmonary Arterial Hypertension|Completed||N/A|52|Actual|Medical University of Graz||1|||f||||f||||||||||2018-06-01 02:29:47.049568|2018-06-01 02:29:47.049568
NCT00609336|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|2017-03-21||2017-06-13|2008-02-06|2008-02-07|Estimate|2017-06-13|2017-07-13|Actual||||2017-06-13|2017-07-13|Actual|January 2008||2008-01-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|November 2014|Actual|2014-11-30||Interventional||All eligible patients|Perioperative Therapy for Resectable Pancreatic Cancer|A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients With Locally Advanced, Resectable Pancreatic Adenocarcinoma|Completed||Phase 2|35|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:29:47.158688|2018-06-01 02:29:47.158688
NCT00609323|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18||2012-03-22|2012-03-22|2008-01-24|2008-02-07|Estimate||||2012-03-22|2012-03-29|Estimate|2012-03-22|2012-03-29|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)|A Randomized, Double-Blind, Crossover Study Comparing Pliaglis™ (Lidocaine and Tetracaine) Cream 7%/7% to Placebo Cream When Applied for 60 Minutes in the Treatment of Patients With Postherpetic Neuralgia|Completed||Phase 2|23|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 02:29:47.534402|2018-06-01 02:29:47.534402
NCT00609310|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2012-02-02|2008-02-06|2008-02-07|Estimate|||||||2012-02-02|2012-02-03|Estimate|May 2015||2015-05-31|February 2012|2012-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Dietary Bioflavonoid Supplementation for the Prevention of Neoplasia Recurrence|Dietary Supplementation With Bioflavonoids for the Prevention of the Recurrence of Neoplasia in Patients With Resected Colorectal Carcinoma|Suspended||Phase 2|382|Anticipated|Technische Universität Dresden||1|||f||||f||||||||||2018-06-01 02:29:47.613866|2018-06-01 02:29:47.613866
NCT00609297|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-06|||2012-10-23|2008-02-06|2008-02-07|Estimate|||||||2012-10-23|2012-10-24|Estimate|July 2007||2007-07-31|October 2012|2012-10-31|May 2011|Actual|2011-05-31|March 2008|Actual|2008-03-31||Observational|||Pain Control in Hospice Patients With Cancer-Related Pain|Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol Stage 2, Part A|Completed|||22|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||||||2018-06-01 02:29:47.691651|2018-06-01 02:29:47.691651
NCT00609284|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2018-02-15|2008-02-06|2008-02-07|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2008||2008-02-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|2007-01||Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux|Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux|Active, not recruiting||Phase 3|406|Actual|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||||2018-06-01 02:29:47.784737|2018-06-01 02:29:47.784737
NCT00609271|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2013-12-31|2008-01-24|2008-02-07|Estimate|||||||2013-12-31|2014-01-03|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|MACRO||Study of Macronutrients and Heart Disease Risk|Macronutrient Composition of Diet and Risk Factors for Cardiovascular Disease|Completed||N/A|148|Actual|Tulane University Health Sciences Center||2|||f||||t||||||||||2018-06-01 02:29:47.866765|2018-06-01 02:29:47.866765
NCT00609245|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2016-05-05||2017-05-18|2008-02-05|2008-02-06|Estimate|2017-05-18|2017-06-14|Actual||||2017-05-18|2017-06-14|Actual|December 2007||2007-12-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Valproic Acid Concentration on Photic Response|Effect of Small Changes in Plasma Valproic Acid Concentration on the Photoparoxysmal Response|Completed||Phase 4|13|Actual|Vanderbilt University Medical Center||1|||f||||t|t|f|||f|||No||2018-06-01 02:29:47.957001|2018-06-01 02:29:47.957001
NCT00609219|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-02|||2012-10-05|2008-02-02|2008-02-06|Estimate|||||||2012-10-05|2012-10-10|Estimate|August 2001||2001-08-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|October 2007|Actual|2007-10-31||Interventional|NPC||T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC|Administration of EBV-Specific T-Lymphocytes to Patients With EBV-Positive Nasopharyngeal Carcinoma|Completed||Phase 1|25|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:29:48.169158|2018-06-01 02:29:48.169158
NCT00609193|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2015-12-03|2008-01-23|2008-02-06|Estimate|||||||2015-12-03|2015-12-07|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Functional and Neurochemical Brain Changes in First-episode Bipolar Mania|Functional and Neurochemical Brain Changes in First-episode Bipolar Mania Following Successful Treatment With Lithium or Quetiapine|Completed|||81|Actual|University of Cincinnati|||2||f||||f||||||||||2018-06-01 02:29:48.236572|2018-06-01 02:29:48.236572
NCT00609180|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2016-04-12|2008-01-31|2008-02-06|Estimate|||||||2016-04-12|2016-04-13|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|EDEN-Omega||Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)|Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) and Prospective, Randomized, Blinded, Placebo-Controlled, Multi-Center Trial of Omega-3 Fatty Acid, Gamma-Linolenic Acid, and Anti-Oxidant Supplementation in the Management of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)|Terminated||Phase 3|272|Actual|National Heart, Lung, and Blood Institute (NHLBI)||4||"The Omega arm of this study was stopped for futility. The EDEN arm continues to recruit~   patients as a separate independent study."|f||||t||||||||||2018-06-01 02:29:48.308653|2018-06-01 02:29:48.308653
NCT00609167|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-11-05||2011-05-13|2008-02-02|2008-02-06|Estimate|2010-11-05|2010-12-07|Estimate||||2011-05-13|2011-05-17|Estimate|December 2006||2006-12-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|January 2009|Actual|2009-01-31||Interventional|||Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Trial of Cyclophosphamide, Bortezomib and Dexamethasone (CYBOR-D) in Patients With Newly Diagnosed Active Multiple Myeloma|Completed||Phase 2|63|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:29:48.553899|2018-06-01 02:29:48.553899
NCT00609154|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|November 2007||2007-11-30|January 2008|2008-01-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates|Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates|Unknown status|Recruiting|Phase 1|16|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-06-01 02:29:49.168533|2018-06-01 02:29:49.168533
NCT00609141|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-02|||2014-06-18|2008-02-02|2008-02-06|Estimate|||||||2014-06-18|2014-06-19|Estimate|January 2008||2008-01-31|June 2014|2014-06-30||||September 2009|Actual|2009-09-30||Interventional|||IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor|A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors|Completed||Phase 1|34|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:29:49.269879|2018-06-01 02:29:49.269879
NCT00609128|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-10-30|2008-02-05|2008-02-06|Estimate|||||||2008-10-30|2008-11-03|Estimate|September 2000||2000-09-30|October 2008|2008-10-31|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Allergic Eye Disease Tear Mediators|Expression of Inflammatory Mediators in Allergic Conjunctivitis|Unknown status|Recruiting|N/A|40|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 02:29:49.362259|2018-06-01 02:29:49.362259
NCT00609115|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2014-01-16|2008-01-23|2008-02-06|Estimate|||||||2014-01-16|2014-01-20|Estimate|September 2007||2007-09-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|AMES||Sub-Acute Stroke Rehabilitation With AMES|Sub-Acute Stroke Rehabilitation With Assisted Movement With Enhanced Sensation|Unknown status|Active, not recruiting|Phase 2/Phase 3|132|Anticipated|AMES Technology||3|||f||||t||||||||||2018-06-01 02:29:49.507189|2018-06-01 02:29:49.507189
NCT00609102|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2014-12-22|2008-01-23|2008-02-06|Estimate|||||||2014-12-22|2014-12-24|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Antioxidant Treatment of Type 2 Diabetes||Completed||Early Phase 1|44|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||||||||||||2018-06-01 02:29:49.610442|2018-06-01 02:29:49.610442
NCT00609089|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2012-08-13|2008-01-29|2008-02-06|Estimate|||||||2012-08-13|2012-08-14|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|June 2013|Anticipated|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction|A Stage 1 Study of Community Reinforcement and Family Training for Treatment Drug Abuse Treatment Retention/HIV Risk Reduction|Unknown status|Active, not recruiting|Phase 1/Phase 2|104|Anticipated|University of Cincinnati||2|||f||||f||||||||||2018-06-01 02:29:49.67388|2018-06-01 02:29:49.67388
NCT00609063|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-01-05|2008-01-25|2008-02-06|Estimate|||||||2012-01-05|2012-01-09|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|STOMP||The Effect of Statin Medications on Muscle Performance (The STOMP Study)|The Effect of Statins on Skeletal Muscle Function|Completed||N/A|420|Actual|Hartford Hospital||2|||f||||t||||||||||2018-06-01 02:29:49.752611|2018-06-01 02:29:49.752611
NCT00609037|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2015-12-10|2008-02-05|2008-02-06|Estimate|||||||2015-12-10|2015-12-14|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Wound Repair and Body Contouring Surgery After Gastric Bypass|A Pilot/Feasibility Study on Wound Repair and Body Contouring Surgery After Gastric By-pass|Completed|||34|Actual|Vanderbilt University|||2||f||||f||||||||||2018-06-01 02:29:49.89829|2018-06-01 02:29:49.89829
NCT00609011|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2010-08-19|2008-01-23|2008-02-06|Estimate|||||||2010-08-19|2010-08-23|Estimate|March 2008||2008-03-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma|Dose Finding Phase 1 Study of the Treatment of Metastatic Melanoma With MPC-6827 in Combination With Temozolomide|Completed||Phase 1/Phase 2|22|Actual|Myrexis Inc.|||||f||||f||||||||||2018-06-01 02:29:49.959369|2018-06-01 02:29:49.959369
NCT00608998|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2011-03-28|2008-02-05|2008-02-06|Estimate|||||||2011-03-28|2011-03-29|Estimate|July 2007||2007-07-31|January 2008|2008-01-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Observational|Pre-HD||Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression|Vascular Risk Factors and Coronary Calcifications in Chronic Renal Failure Patients: Identification of Specific Factors Linked to Renal Failure Progression|Unknown status|Recruiting||120|Anticipated|University Hospital, Montpellier|||||f||||t||||||Samples With DNA|"~     whole blood white cells serum plasma urine~   "|||2018-06-01 02:29:50.024486|2018-06-01 02:29:50.024486
NCT00608985|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2012-12-21||2016-02-11|2008-01-23|2008-02-06|Estimate|2013-02-06|2013-02-07|Estimate||||2016-02-11|2016-03-14|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|RESTORA 1||Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia|Multi-center, Double-blind, Randomized, Placebo-controlled, Active Reference, Parallel-group Polysomnography Study to Assess the Efficacy and Safety of a 16-day Oral Administration of ACT-078573 in Adult Subjects With Chronic Primary Insomnia|Completed||Phase 3|709|Actual|Midnight Pharma, LLC||4|||f||||f||||||||||2018-06-01 02:29:50.187692|2018-06-01 02:29:50.187692
NCT00608972|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2015-11-05|2008-02-05|2008-02-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2008||2008-05-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer|A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer|Completed||Phase 2|31|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 02:29:51.184912|2018-06-01 02:29:51.184912
NCT00608959|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2009-06-30||2010-01-22|2008-01-23|2008-02-06|Estimate|2009-12-16|2010-01-25|Estimate||||2010-01-22|2010-01-26|Estimate|May 2008||2008-05-31|January 2010|2010-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects|A Single- Center, Open-Label, Study of the Persistence of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects|Completed||Phase 3|30|Actual|Mallinckrodt|FDA reviewer noted that there were multiple endpoints that required multiplicity adjustments to control for the overall type I error rate.Based on feedback the 72 hour endpoint was selected for Part 2 as the primary efficacy endpoint.|2|||f||||f||||||||||2018-06-01 02:29:51.275275|2018-06-01 02:29:51.275275
NCT00608946|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|March 2004||2004-03-31|January 2008|2008-01-31||||August 2007|Actual|2007-08-31||Interventional|||Treatment With Copper in Patients With Mild Alzheimer´s Dementia||Completed||Phase 2|68|Actual|University Hospital, Saarland||2|||f||||t||||||||||2018-06-01 02:29:52.521105|2018-06-01 02:29:52.521105
NCT00608933|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2017-09-05|2008-01-30|2008-02-06|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2008|Actual|2008-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine|CAM USE and Cancer|Active, not recruiting||Phase 3|1360|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 02:29:52.597959|2018-06-01 02:29:52.597959
NCT00608920|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2013-05-22|2008-02-05|2008-02-06|Estimate|||||||2013-05-22|2013-05-24|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|SPECT||Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping|SPECT Lymph Node Mapping to Define Nodal Clinical Target Volume in Patients With Prostate Cancer|Completed||N/A|15|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:29:52.721667|2018-06-01 02:29:52.721667
NCT00608907|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2011-03-29||2012-01-26|2008-01-23|2008-02-06|Estimate|2011-07-11|2011-07-13|Estimate||||2012-01-26|2012-01-30|Estimate|September 2007||2007-09-30|January 2012|2012-01-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)|An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)|Completed||Phase 1|61|Actual|Millennium Pharmaceuticals, Inc.||3|||f||||||||||||||2018-06-01 02:29:52.83726|2018-06-01 02:29:52.83726
NCT00608894|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2014-12-18|2008-01-23|2008-02-06|Estimate|||||||2014-12-18|2014-12-23|Estimate|December 2007||2007-12-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis|A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis|Completed||Phase 2|60|Actual|Veloxis Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:29:53.570183|2018-06-01 02:29:53.570183
NCT00608881|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2015-12-07||2016-02-29|2008-02-04|2008-02-06|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|2CARE||Coenzyme Q10 in Huntington's Disease (HD)|Coenzyme Q10 in Huntington's Disease (HD)|Terminated||Phase 3|609|Actual|Massachusetts General Hospital|An interim analysis for futility revealed a conditional power of < 5% for the primary analysis, and the trial was halted in July, 2014. Only data collected prior to this time were included in the final analyses.|2||Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.|f||||t||||||||||2018-06-01 02:29:53.790766|2018-06-01 02:29:53.790766
NCT00608868|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2010-02-08||2012-08-29|2008-02-05|2008-02-06|Estimate|2012-08-29|2012-09-28|Estimate||||2012-08-29|2012-09-28|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|SELINE||SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients|A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients|Completed||Phase 4|156|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:29:55.191474|2018-06-01 02:29:55.191474
NCT00256659|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2008-03-31|2005-11-17|2005-11-21|Estimate|||||||2008-03-31|2008-04-03|Estimate|September 1998||1998-09-30|March 2008|2008-03-31|April 1999||1999-04-30|||||Interventional|||Hospital Outcomes: Intervention in Moderately III Patients|Hospital Outcomes: Intervention in Moderately III Patients|Completed||N/A|444||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:19:50.274431|2018-06-01 04:19:50.274431
NCT00608855|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2017-01-11|2008-02-01|2008-02-06|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2003||2003-11-30|January 2017|2017-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases|Percutaneous US and CT-guided Cryoablation of Painful Metastases Involving Bone: A Feasibility Study|Completed||N/A|60|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 02:29:55.56934|2018-06-01 02:29:55.56934
NCT00608842|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2015-12-08|2014-05-30|2015-12-08|2008-02-05|2008-02-06|Estimate|2015-12-08|2016-01-14|Estimate|2014-05-30|2014-06-17|Estimate|2015-12-08|2016-01-14|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|January 2010|Actual|2010-01-31|August 2008|Actual|2008-08-31||Interventional||Modified intent-to-treat (MITT) population included all randomized participants who had received at least 1 dose of study material and who had at least 1 postbaseline observation.|Phase 2 Study for the Treatment of Superficial Lipomas|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas|Completed||Phase 2|62|Actual|Kythera Biopharmaceuticals||4|||f||||f||||||||||2018-06-01 02:29:55.69121|2018-06-01 02:29:55.69121
NCT00608829|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-08-18||2015-03-04|2008-02-05|2008-02-06|Estimate|2010-08-18|2010-09-15|Estimate||||2015-03-04|2015-03-05|Estimate|February 2007||2007-02-28|March 2015|2015-03-31|September 2014|Actual|2014-09-30|August 2009|Actual|2009-08-31||Interventional|||GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta|Evaluation of the GORE TAG® Thoracic Endoprosthesis - 45 mm for the Primary Treatment of Aneurysms of the Descending Thoracic Aorta|Completed||Phase 2|23|Actual|W.L.Gore & Associates|Enrollment into this trial was completed prematurely with 23 enrolled subjects. The 45mm TAG Device was approved based on the data collected and a descriptive statistical analysis. Follow up of enrolled subjects continued for 5 years.|1|||f||||f||||||||||2018-06-01 02:29:56.338643|2018-06-01 02:29:56.338643
NCT00608816|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2014-12-10|2008-01-23|2008-02-06|Estimate|||||||2014-12-10|2014-12-11|Estimate||||December 2014|2014-12-31||||||||Interventional|||Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q4|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 4|Withdrawn||N/A|0|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:29:56.616431|2018-06-01 02:29:56.616431
NCT00608803|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2009-09-16|2008-02-05|2008-02-06|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors|A Phase I Study of ZIO-201-T in Combination With Doxorubicin in Subjects With Advanced, Refractory Solid Tumors for Which no Standard Therapy Exists and for Whom Treatment With Doxorubicin is Considered Medically Acceptable|Completed||Phase 1|30|Anticipated|Ziopharm||1|||f||||f||||||||||2018-06-01 02:29:56.69821|2018-06-01 02:29:56.69821
NCT00608790|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-07-23|2008-01-31|2008-02-06|Estimate|||||||2012-07-23|2012-07-24|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||Rapid Diagnosis of Pulmonary Tuberculosis|Diagnostic Yield of Induced Sputum for Rapid Diagnosis of Pulmonary Tuberculosis|Unknown status|Recruiting|N/A|600|Anticipated|University of Cape Town||1|||f||||f||||||||||2018-06-01 02:29:56.767423|2018-06-01 02:29:56.767423
NCT00608777|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2012-03-05||2012-08-07|2008-01-23|2008-02-06|Estimate|2012-03-05|2012-04-03|Estimate||||2012-08-07|2012-08-10|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)|Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Mild Breakthrough in Moderate to Severe Plaque Psoriasis Patients Receiving Efalizumab ( Raptiva).|Terminated||Phase 4|6|Actual|Derm Research, PLLC|Study terminated due to withdrawal of Raptiva from the market. Study specifically designed to address a side effect associated with the administration of Raptiva. Therefore no data analysis completed for this study and no measuremnet of outcomes.|||Withdrawal of marketing autorization of efalizumab by the EMEA.|f||||f||||||||||2018-06-01 02:29:56.842461|2018-06-01 02:29:56.842461
NCT00608764|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2018-01-16|2008-01-28|2008-02-06|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2007||2007-11-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|COPDGene||Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD)|Genetic Epidemiology of Chronic Obstructive Pulmonary Disease|Recruiting|||10500|Anticipated|Brigham and Women's Hospital|||4||f||||f||||||Samples With DNA|"~     Genomic DNA, serum, and plasma will be collected and stored.~   "|Yes|COPDGene phenotypic and genotypic data are available through dbGaP.|2018-06-01 02:29:57.030302|2018-06-01 02:29:57.030302
NCT00608751|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2013-05-22|2008-01-22|2008-02-06|Estimate|||||||2013-05-22|2013-05-24|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|IMRT||A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy|A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy in the Definitive Treatment of Head-and-Neck Cancer|Terminated||Early Phase 1|5|Actual|Washington University School of Medicine||1||Lack of accrual and software issues|f||||f||||||||||2018-06-01 02:29:57.150788|2018-06-01 02:29:57.150788
NCT00608738|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2012-07-09|2008-02-05|2008-02-06|Estimate|||||||2012-07-09|2012-07-10|Estimate|July 2001||2001-07-31|July 2012|2012-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment|Developing a Nested Whole-Person-Care Guide: Screening and Evaluation Steps (American Cancer Society) ACS|Completed||N/A|750|Anticipated|Northwestern University|||||f||||||||||||||2018-06-01 02:29:57.226992|2018-06-01 02:29:57.226992
NCT00608725|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2018-03-26|2008-02-05|2008-02-06|Estimate|||||||2018-03-26|2018-03-27|Actual|December 1996||1996-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pathophysiology of Orthostatic Intolerance|Pathophysiology of Orthostatic Intolerance|Recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 02:29:57.31316|2018-06-01 02:29:57.31316
NCT00608712|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2011-01-21|2008-01-23|2008-02-06|Estimate|||||||2011-01-21|2011-01-24|Estimate|November 2005||2005-11-30|January 2011|2011-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)|Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)|Completed||Phase 4|140|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:29:57.432743|2018-06-01 02:29:57.432743
NCT00608699|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2012-04-26|2008-02-05|2008-02-06|Estimate|||||||2012-04-26|2012-04-30|Estimate|December 2007||2007-12-31|April 2012|2012-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers|A Study to Evaluate the Ability of the HM74A Agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:29:57.483652|2018-06-01 02:29:57.483652
NCT00608686|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-26|||2008-12-18|2008-01-28|2008-02-06|Estimate|||||||2008-12-18|2008-12-19|Estimate|May 2004||2004-05-31|December 2008|2008-12-31|March 2009|Anticipated|2009-03-31|January 2009|Anticipated|2009-01-31||Interventional|||Neurosteroids and Acute Alcohol Intoxication in Humans|Neurosteroids and Acute Alcohol Intoxication in Humans|Unknown status|Active, not recruiting|Phase 1|92|Anticipated|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||t||||||||||2018-06-01 02:29:57.593043|2018-06-01 02:29:57.593043
NCT00608673|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-02-06|2008-01-23|2008-02-06|Estimate|||||||2008-02-06|2008-02-15|Estimate|April 2006||2006-04-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus|Pimecrolimus 1% Cream vs. Betamethasone Valerate 0.1% Cream in the Treatment of Facial Discoid Lupus Erythematosus: a Double-Blind Randomized, Pilot Study.|Completed||N/A|10|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:29:57.677318|2018-06-01 02:29:57.677318
NCT00608660|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2009-09-15|2008-01-24|2008-02-06|Estimate|||||||2009-09-15|2009-09-17|Estimate|October 2006||2006-10-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Randomized Controlled Trial of Acupuncture to Treat Bell's Palsy According to Different Stages|Studying of Acupuncture for Bell's Palsy According to Different Stages|Completed||N/A|900|Actual|Chengdu University of Traditional Chinese Medicine||5|||f||||t||||||||||2018-06-01 02:29:57.784317|2018-06-01 02:29:57.784317
NCT00608647|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2015-05-18|2008-02-05|2008-02-06|Estimate|||||||2015-05-18|2015-05-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:29:57.874204|2018-06-01 02:29:57.874204
NCT00608634|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|2011-04-15||2015-03-27|2008-02-05|2008-02-06|Estimate|2015-03-27|2015-04-01|Estimate||||2015-03-27|2015-04-01|Estimate|May 2004||2004-05-31|March 2014|2014-03-31|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses|Phase 2a Randomized, Placebo-Controlled, Double-Blind Trial of Topical Perillyl Alcohol in Sun Damaged Skin|Completed||Phase 2|89|Actual|University of Arizona||3|||f||||t||||||||||2018-06-01 02:29:57.930551|2018-06-01 02:29:57.930551
NCT00608621|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|ANA06103||Influence of Physostigmine on Patient-Controlled Analgesia (PCA) in Postoperative Intensive Care Patients|Influence of Physostigmine on Patient-Controlled Analgesia (PCA) in Postoperative Intensive Care Patients, Considering Pain Score, Opioid Consumption, Hemodynamics and Cognitive Function|Completed|||60|Actual|Klinikum Ludwigshafen|||2||f||||f||||||||||2018-06-01 02:29:58.299564|2018-06-01 02:29:58.299564
NCT00608595|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2013-03-02|2008-02-02|2008-02-06|Estimate|||||||2013-03-02|2013-03-05|Estimate|July 2002||2002-07-31|March 2013|2013-03-31|April 2008|Actual|2008-04-30|May 2004|Actual|2004-05-31||Interventional|||Celecoxib in Treating Patients With Early-Stage Rectal Cancer|Pilot COX-2 Activity in Early Stage Rectal Cancer -Short Term Administration of Celecoxib (SPORE)|Terminated||N/A|10|Actual|Vanderbilt-Ingram Cancer Center||1||low accrual|f||||t||||||||||2018-06-01 02:29:58.370466|2018-06-01 02:29:58.370466
NCT00608582|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2016-09-22||2016-12-01|2008-01-24|2008-02-06|Estimate|2016-12-01|2017-01-31|Estimate||||2016-12-01|2017-01-31|Estimate|July 2002||2002-07-31|December 2016|2016-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Number of participants randomized to each treatment arm|Transcranial Magnetic Stimulation to Improve Speech in Aphasia|Transcranial Magnetic Stimulation to Improve Speech|Completed||Phase 1|63|Actual|Boston University||2|||f||||f||||||||No||2018-06-01 02:29:58.508518|2018-06-01 02:29:58.508518
NCT00608569|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|2013-09-05||2013-11-14|2008-01-23|2008-02-06|Estimate|2013-11-14|2013-11-15|Estimate||||2013-11-14|2013-11-15|Estimate|March 2009||2009-03-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Five hundred twenty nine subjects including participants and partners entered the study. Among the 529 subjects, 259 were participants, which include two participants with eligibility violations. Only the 257 eligible participants were included in the analysis.|Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults|International Trial of Modified Directly Observed Therapy Versus Self-Administered Therapy for Participants With First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen|Completed||N/A|529|Actual|AIDS Clinical Trials Group||2|||f||||||||||||||2018-06-01 02:29:58.988597|2018-06-01 02:29:58.988597
NCT00608556|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2017-06-30|2008-02-04|2008-02-06|Estimate|||||||2017-06-30|2017-07-02|Actual|January 25, 2008||2008-01-25|October 31, 2011|2011-10-31|October 31, 2011||2011-10-31|||||Observational|||Dyskinesia, Heterotaxy and Congenital Heart Disease|Ciliary Dysfunction as an Underlying Etiology Linking Primary Ciliary Dyskinesia With Heterotaxy and Complex Congenital Heart Disease|Completed|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:29:59.710318|2018-06-01 02:29:59.710318
NCT00608543|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2011-11-15||2012-10-24|2008-02-05|2008-02-06|Estimate|2012-10-24|2012-10-26|Estimate||||2012-10-24|2012-10-26|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression|Aripiprazole Augmentation of SSRI Antidepressant Therapy in Treatment Refractory Depression: Assessment of Symptom Reduction, Psychosocial Function, and Cognitive Function|Completed||Phase 4|17|Actual|University of Texas Southwestern Medical Center|Note that because this is an augmentation trial, reported AEs are due to combined treatment with escitalopram, citalopram, or sertraline AND aripiprazole.|1|||f||||f||||||||||2018-06-01 02:29:59.799034|2018-06-01 02:29:59.799034
NCT00608530|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2015-02-18||2018-01-18|2008-02-05|2008-02-06|Estimate|2015-03-04|2015-03-19|Estimate||||2018-01-18|2018-02-16|Estimate|March 2008||2008-03-31|January 2018|2018-01-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|TELE|ln Study 1 (Psychologist-delivered treatment) all eligible individuals who were enrolled and randomized to treatment were analyzed. In Study 2 (Nurse-delivered treatment) all participants who were randomized and attended at least 1 treatment session were analyzed.|Telehealth Outreach for Chronic Back Pain|Telehealth Outreach for Chronic Back Pain|Completed||N/A|127|Actual|VA Office of Research and Development|The small sample size and attrition limits the strength of the evidence.|4|||f||||t||||||||||2018-06-01 02:30:00.089708|2018-06-01 02:30:00.089708
NCT00608517|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2010-10-11||2014-05-12|2008-01-31|2008-02-06|Estimate|2010-10-11|2010-11-10|Estimate||||2014-05-12|2014-05-20|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|May 2011|Actual|2011-05-31|March 2008|Actual|2008-03-31||Interventional|||Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil|The Treatment of Hematologic Malignancies With Single or Double Umbilical Cord Blood Unit Transplantation Followed by Graft-versus-Host Prophylaxis With Tacrolimus and Mycophenolate Mofetil|Terminated||N/A|6|Actual|Vanderbilt-Ingram Cancer Center||3||slow accrual|f||||t||||||||||2018-06-01 02:30:00.464967|2018-06-01 02:30:00.464967
NCT00608504|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2012-06-01|2008-01-31|2008-02-06|Estimate|||||||2012-06-01|2012-06-05|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|DSC||Effects of Environmental Factors on Opiate Drug Choice in Opioid Dependent Individuals.|Biobehavioral Study of Opioid Drug Seeking Behavior: Study 3|Completed|||16|Anticipated|Wayne State University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:30:00.943455|2018-06-01 02:30:00.943455
NCT00608491|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2013-02-18||2013-05-15|2008-01-25|2008-02-06|Estimate|2013-05-15|2013-06-24|Estimate||||2013-05-15|2013-06-24|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|CARRESS||Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)|CARdiorenal REScue Study in Acute Decompensated Heart Failure: CARRESS|Completed||Phase 3|188|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:30:01.050753|2018-06-01 02:30:01.050753
NCT00608465|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2017-03-16||2017-07-13|2008-02-05|2008-02-06|Estimate|2017-03-16|2017-05-01|Actual||||2017-07-13|2017-08-11|Actual|May 2006|Actual|2006-05-31|July 2017|2017-07-31|May 2011|Actual|2011-05-31|May 2009|Actual|2009-05-31||Interventional|||Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity|Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity|Terminated||Phase 4|4|Actual|Vanderbilt University Medical Center||2||Lack of enrollment|f||||t||||||||||2018-06-01 02:30:03.819999|2018-06-01 02:30:03.819999
NCT00608452|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2009-11-12|2008-01-23|2008-02-06|Estimate|||||||2009-11-12|2009-11-13|Estimate|July 1995||1995-07-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers|A Prospective Study of The Prevalence and Significance of Paraneoplastic Autoantibodies in Small Cell Lung Cancer and Cancer of The Breast, Ovary, Hodgkin's Disease, Neuroblastoma and Other Cancers|Completed|||121|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||t||||||Samples Without DNA|"~     blood samples for autoantibody determinations and HLA typing~   "|||2018-06-01 02:30:04.081186|2018-06-01 02:30:04.081186
NCT00608439|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2012-11-09|2008-01-28|2008-02-06|Estimate|||||||2012-11-09|2012-11-12|Estimate|September 2007||2007-09-30|November 2012|2012-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|CAST||Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy|Centella Asiatica Triterpene Extract for Diabetic Neuropathy -- a Pilot Study|Completed||Phase 2|43|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:30:04.245213|2018-06-01 02:30:04.245213
NCT00608426|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2014-06-06||2015-04-06|2008-02-05|2008-02-06|Estimate|2014-12-22|2015-01-09|Estimate||||2015-04-06|2015-04-24|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||Proactive Tobacco Treatment for Veterans|Proactive Tobacco Treatment for Diverse Veteran Smokers|Completed||N/A|6400|Actual|VA Office of Research and Development|Smoking abstinence rates were not biochemically verified|2|||f||||t||||||||||2018-06-01 02:30:04.420431|2018-06-01 02:30:04.420431
NCT00608400|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2012-03-01|2008-01-23|2008-02-06|Estimate|||||||2012-03-01|2012-03-02|Estimate|December 2008||2008-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Dietary Conjugated Linoleic Acid (CLA) on Parathyroid Hormone in Men|Does Dietary Cis-9, Trans-11 Conjugated Linoleic Acid Reduce Parathyroid Hormone in Men?|Completed||Phase 1|55|Actual|McGill University||3|||f||||f||||||||||2018-06-01 02:30:05.522068|2018-06-01 02:30:05.522068
NCT00608387|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2014-06-03|2008-01-31|2008-02-06|Estimate|||||||2014-06-03|2014-06-04|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluating a Web-Based Cardiovascular Disease Risk Factor Reduction Program Among American Indians|Web-based, Patient-centered Approach to CVD Risk-factor Management and Reduction|Completed||N/A|149|Actual|Black Hills Center for American Indian Health||2|||f||||t||||||||||2018-06-01 02:30:05.627878|2018-06-01 02:30:05.627878
NCT00608374|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-08-23|2008-01-26|2008-02-06|Estimate|||||||2013-08-23|2013-08-26|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|January 2013|Actual|2013-01-31|December 2009|Actual|2009-12-31||Interventional|||Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma|A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes|Completed||Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:30:05.765972|2018-06-01 02:30:05.765972
NCT00608361|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2015-06-30|2008-01-30|2008-02-06|Estimate|||||||2015-06-30|2015-07-02|Estimate|October 2008||2008-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery|Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction|Completed||Phase 1|80|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 02:30:05.906454|2018-06-01 02:30:05.906454
NCT00608348|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2015-06-09|2008-01-29|2008-02-06|Estimate|||||||2015-06-09|2015-06-10|Estimate|April 2002||2002-04-30|June 2015|2015-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Sympathetic Nerve Activity During Hypoglycemia and Exercise|Sympathetic Nerve Activity During Hypoglycemia and Exercise|Completed||N/A|36|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:30:06.046224|2018-06-01 02:30:06.046224
NCT00608335|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2013-03-12|2008-01-23|2008-02-06|Estimate|||||||2013-03-12|2013-03-13|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug|A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis|Completed||Phase 1|84|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:30:06.152512|2018-06-01 02:30:06.152512
NCT00608322|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2013-04-16||2013-06-03|2008-01-23|2008-02-06|Estimate|2013-06-03|2013-07-11|Estimate||||2013-06-03|2013-07-11|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Randomized Trial of Inhaled Nitric Oxide to Augment Tissue Perfusion in Sepsis|Randomized Double-blind Placebo-controlled Trial of Inhaled Nitric Oxide for the Treatment of Microcirculatory Dysfunction and Organ Failure in Sepsis|Completed||Phase 3|49|Actual|National Institute of General Medical Sciences (NIGMS)||2|||f||||t||||||||||2018-06-01 02:30:06.279368|2018-06-01 02:30:06.279368
NCT00608296|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2014-12-22|2008-02-05|2008-02-06|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Functional and Neurochemical Brain Changes Bipolar Depression|Functional and Neurochemical Brain Changes Following Successful Treatment of Early Course Bipolar Depression|Completed|||120|Anticipated|University of Cincinnati|||2||f||||f||||||||||2018-06-01 02:30:06.57495|2018-06-01 02:30:06.57495
NCT00608283|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2017-03-23|2008-02-05|2008-02-06|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2007||2007-08-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Live Kidney Donor Study|Live Kidney Donor Study (RELIVE-01)|Completed|||8951|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 02:30:06.683126|2018-06-01 02:30:06.683126
NCT00608244|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2014-06-10||2015-08-14|2008-01-23|2008-02-06|Estimate|2015-08-14|2015-08-28|Estimate||||2015-08-14|2015-08-28|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients|A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day|Completed||Phase 2|59|Actual|Veloxis Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:30:06.91488|2018-06-01 02:30:06.91488
NCT00608231|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2014-06-30|2008-01-25|2008-02-06|Estimate|||||||2014-06-30|2014-07-01|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation|Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation|Withdrawn||Phase 2/Phase 3|0|Actual|Vanderbilt University||8||Intraoperative recording could not be maintained for required period|f||||t||||||||||2018-06-01 02:30:07.263299|2018-06-01 02:30:07.263299
NCT00608218|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2016-12-02|2008-01-23|2008-02-06|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|ARTIST||Efficacy of Ciclesonide During the Cold Season in Patients Older Than 12 Years With Persistent Asthma|Ciclesonide for the Therapy of Asthma During the Cold Season.|Completed|||2100|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:30:07.411334|2018-06-01 02:30:07.411334
NCT00608205|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2013-07-11||2016-09-09|2008-01-31|2008-02-06|Estimate|2013-07-11|2013-09-19|Estimate||||2016-09-09|2016-10-21|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|September 2012|Actual|2012-09-30||Interventional|||Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer|A Phase III Randomized Trial Comparing Single Agent Cisplatin With the Combination of 5-Fluorouracil and Cisplatin, Concurrent With Radiation Therapy in Stage III and IV Squamous Cell Head and Neck Cancer|Completed||Phase 3|69|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:30:07.848666|2018-06-01 02:30:07.848666
NCT00608192|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2013-01-15|2008-01-31|2008-02-06|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||HIV and Hepatitis Care Coordination in Methadone Treatment|HIV and Hepatitis Care Coordination in Methadone Treatment|Completed||N/A|489|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:30:08.956676|2018-06-01 02:30:08.956676
NCT00608179|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2014-12-10|2008-01-25|2008-02-06|Estimate|||||||2014-12-10|2014-12-11|Estimate|August 2002||2002-08-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|September 2004|Actual|2004-09-30||Interventional|||Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia|Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia|Completed||N/A|32|Actual|Vanderbilt University||4|||f||||t||||||||||2018-06-01 02:30:09.079279|2018-06-01 02:30:09.079279
NCT00608153|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Observational|CoCa||Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide|Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide|Completed|||1773|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:30:09.148646|2018-06-01 02:30:09.148646
NCT00608140|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2013-04-29||2018-03-09|2008-01-24|2008-02-06|Estimate|2013-07-16|2013-07-18|Estimate||||2018-03-09|2018-04-04|Actual|March 2008||2008-03-31|July 2013|2013-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|SMMART-HF||Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure|Surgery Versus Medical Treatment Alone for Patients With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure: SMMART-HF|Terminated||Phase 3|2|Actual|Duke University||3||Unable to recruit sufficient numbers of patients.|f||||t||||||||||2018-06-01 02:30:09.240941|2018-06-01 02:30:09.240941
NCT00608127|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-05-21|2008-02-05|2008-02-06|Estimate|||||||2008-05-21|2008-05-23|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|August 2008|Anticipated|2008-08-31|May 2008|Anticipated|2008-05-31||Interventional|||Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients|A Single - Arm Open - Label Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients|Unknown status|Active, not recruiting|N/A|10|Anticipated|Verto LTD||1|||f||||f||||||||||2018-06-01 02:30:09.657779|2018-06-01 02:30:09.657779
NCT00608101|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2014-12-10|2008-02-05|2008-02-06|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 1|Withdrawn||N/A|0|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:30:09.735792|2018-06-01 02:30:09.735792
NCT00608088|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-01-24|2008-01-24|2008-02-06|Estimate|||||||2008-01-24|2008-02-06|Estimate|March 2003||2003-03-31|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Evaluation of a Community Health Nurse/Peer Counselor Program to Help Low-Income Women Breastfeed Longer|Support for Low-Income Breastfeeding: Cost and Outcomes|Completed||Phase 3|328|Actual|National Institute of Nursing Research (NINR)||2|||f||||t||||||||||2018-06-01 02:30:09.796402|2018-06-01 02:30:09.796402
NCT00608075|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2016-10-05|2008-01-23|2008-02-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2015|Actual|2015-07-31||Interventional|LAMBS/LADS||Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder|Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder|Active, not recruiting||Phase 4|260|Anticipated|University of Cincinnati||2|||f||||f||||||||||2018-06-01 02:30:09.862585|2018-06-01 02:30:09.862585
NCT00608062|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2017-10-26|2008-01-31|2008-02-06|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2007||2007-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2013|Actual|2013-06-30||Interventional|SHAPE||Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women|Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency|Active, not recruiting||N/A|92|Actual|University of Colorado, Denver||8|||f||||f||||||||||2018-06-01 02:30:09.942304|2018-06-01 02:30:09.942304
NCT00608049|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2016-07-05|2008-01-23|2008-02-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|February 2008||2008-02-29|July 2016|2016-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes|Optimal Macronutrient Intake - Carbohydrate|Completed||N/A|189|Actual|Brigham and Women's Hospital||8|||f||||t||||||||||2018-06-01 02:30:10.048649|2018-06-01 02:30:10.048649
NCT00608036|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2015-12-07|2008-01-28|2008-02-06|Estimate|||||||2015-12-07|2015-12-09|Estimate|May 2008||2008-05-31|December 2015|2015-12-31|May 2012|Actual|2012-05-31|December 2010|Actual|2010-12-31||Observational|||Evaluating the Relationship Between Physical Activity, Diet, Weight, and the Neighborhood Environment for Adolescents|Ecological Analysis of Activity, Eating, and Weight in Adolescents|Completed|||954|Actual|University of California, San Diego|||||f||||f||||||||||2018-06-01 02:30:10.133073|2018-06-01 02:30:10.133073
NCT00608023|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2013-11-27||2014-03-27|2008-01-23|2008-02-06|Estimate|2013-11-27|2014-01-15|Estimate||||2014-03-27|2014-04-17|Estimate|August 2007||2007-08-31|March 2014|2014-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy|A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Subjects With Excess Abdominal Fat Accumulation|Completed||Phase 3|263|Actual|Theratechnologies||3|||f||||||||||||||2018-06-01 02:30:11.364715|2018-06-01 02:30:11.364715
NCT00608010|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|October 2006||2006-10-31|January 2008|2008-01-31||||January 2007|Actual|2007-01-31||Interventional|||Day 3 Embryo Cryopreservation: Metabolic and Viability Analysis|Day 3 Embryo Cryopreservation: Metabolic and Viability Analysis|Completed||N/A|186|Actual|V.K.V. American Hospital, Istanbul||2|||f||||||||||||||2018-06-01 02:30:11.960563|2018-06-01 02:30:11.960563
NCT00607997|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2017-03-27||2017-05-25|2008-01-23|2008-02-06|Estimate|2017-05-25|2017-06-28|Actual||||2017-05-25|2017-06-28|Actual|May 15, 2008|Actual|2008-05-15|May 2017|2017-05-31|November 23, 2009|Actual|2009-11-23|November 2009|Actual|2009-11-30||Interventional|||Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia|A Phase 2, Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Voreloxin (Vosaroxin) Injection in Patients Equal to or Greater Than 60 Years of Age With Previously Untreated Acute Myeloid Leukemia|Completed||Phase 2|113|Actual|Sunesis Pharmaceuticals|Due to the limited sample size in this study, further study is needed to confirm these results. No statistical testings were performed to compare any of the treatment groups. No p-values or odds ratios were reported.|1|||f||||f||||||||Yes|De-identified data of individual participants experiencing Serious Adverse Events|2018-06-01 02:30:12.294509|2018-06-01 02:30:12.294509
NCT00607984|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|June 2006||2006-06-30|January 2008|2008-01-31||||December 2010|Anticipated|2010-12-31||Interventional|||Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors|High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors|Unknown status|Recruiting|N/A|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-06-01 02:30:15.478169|2018-06-01 02:30:15.478169
NCT00607971|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-07-04|2008-01-23|2008-02-06|Estimate|||||||2008-07-04|2008-07-08|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|Terminated||Phase 3|939|Actual|Alizyme||1||Terminated due to insufficient efficacy over placebo in Study ATL1251/038/CL.|f||||t||||||||||2018-06-01 02:30:15.592403|2018-06-01 02:30:15.592403
NCT00607958|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2009-07-14|2008-02-05|2008-02-06|Estimate|||||||2009-07-14|2009-07-15|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours|Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours|Completed||Phase 4|15|Anticipated|Germans Trias i Pujol Hospital||1|||f||||f||||||||||2018-06-01 02:30:15.913757|2018-06-01 02:30:15.913757
NCT00607945|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2014-03-19|2008-01-24|2008-02-06|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|FACT||Dietary Fatty Acids as Complementary Therapy in Type 2 Diabetes Mellitus|Dietary Fatty Acids as Complementary Therapy in Type 2 Diabetes Mellitus|Completed||Phase 1|48|Actual|Ohio State University||3|||f||||t||||||||||2018-06-01 02:30:16.020695|2018-06-01 02:30:16.020695
NCT00607932|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2016-04-26|2008-02-02|2008-02-06|Estimate|||||||2016-04-26|2016-04-27|Estimate|March 2005||2005-03-31|April 2016|2016-04-30|November 2010|Actual|2010-11-30|January 2007|Actual|2007-01-31||Interventional|||Brassica Vegetables or Indole-3-Carbinol in Treating Patients With PSA Recurrence After Surgery for Prostate Cancer|Effects of Bassica or Indole-3-Carbinol on Prostatectomy Patients With PSA Recurrence|Completed||N/A|66|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-06-01 02:30:16.146451|2018-06-01 02:30:16.146451
NCT00607919|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2011-11-11||2011-11-11|2008-01-23|2008-02-06|Estimate|2011-11-11|2011-12-15|Estimate||||2011-11-11|2011-12-15|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia|A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia|Completed||Phase 4|209|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:30:16.28588|2018-06-01 02:30:16.28588
NCT00607906|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2017-09-01|2008-01-23|2008-02-06|Estimate|||||||2017-09-01|2017-09-06|Actual|November 16, 2007|Actual|2007-11-16|September 2017|2017-09-30|March 10, 2008|Actual|2008-03-10|March 10, 2008|Actual|2008-03-10||Interventional|||First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050|A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered SB756050 in Healthy Volunteers and in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|36|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:30:17.6193|2018-06-01 02:30:17.6193
NCT00607893|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|2017-04-06||2017-08-17|2008-01-25|2008-02-06|Estimate|2017-08-17|2017-09-15|Actual||||2017-08-17|2017-09-15|Actual|September 2006||2006-09-30|August 2017|2017-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SASS||Efficacy of Continuous Positive Airway Pressure in Reducing Oxidative Stress in Individuals With Sleep Apnea|Oxidative Stress in Sleep Apnea and Cardiac Disease|Completed||N/A|153|Actual|Case Western Reserve University||2|||f||||t||||||||Undecided||2018-06-01 02:30:17.787253|2018-06-01 02:30:17.787253
NCT00607880|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2014-04-09||2014-04-09|2008-02-01|2008-02-06|Estimate|2014-04-09|2014-05-09|Estimate||||2014-04-09|2014-05-09|Estimate|June 2004||2004-06-30|April 2014|2014-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||All 100 patients accrued to participate in this study were included in the baseline population analysis.|Study Comparing Two Types of Ports in Patients With Cancer Receiving Intravenous Chemotherapy|A Prospective Randomized Study of the Vortex® Implantable Access Port Versus the BardPort™ Implantable Port in Cancer Patients Receiving Adjuvant Intravenous Chemotherapy|Completed||Phase 2|100|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:30:18.603168|2018-06-01 02:30:18.603168
NCT00607867|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2014-11-17||2014-12-10|2008-02-05|2008-02-06|Estimate|2014-12-10|2014-12-12|Estimate||||2014-12-10|2014-12-12|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|LoBAG Diet|Subjects with type 2 diabetes being treated with metformin|LoBAG30 Diet in Patients on Metformin|Metabolic Response to a LoBAG30 Diet in Diabetic Patients on Metformin|Terminated||N/A|20|Actual|VA Office of Research and Development|Funding ended with only 14 subjects studied. With a parallel arm design, we were not able to draw any conclusions from the study. Funds were unavailable for a more sophisticated statistical analysis.|2||The funding ended before the study was completed.|f||||f||||||||||2018-06-01 02:30:18.916604|2018-06-01 02:30:18.916604
NCT00607854|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2016-10-04|2008-02-05|2008-02-06|Estimate|||||||2016-10-04|2016-10-05|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|November 2011|Actual|2011-11-30|February 2011|Actual|2011-02-28||Interventional|ZEVALLO||Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)|Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.|Completed||Phase 2|31|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-06-01 02:30:19.285463|2018-06-01 02:30:19.285463
NCT00607841|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2010-01-14|2008-01-23|2008-02-06|Estimate|||||||2010-01-14|2010-01-18|Estimate|December 2007||2007-12-31|January 2010|2010-01-31||||November 2009|Actual|2009-11-30||Interventional|||A Study of Ispinesib in Metastatic Breast Cancer|A Phase I/II Non-Randomized, Open-Label, Dose-Finding Study of Ispinesib (SB-715992) Followed By a Fixed-Dose Study in Chemotherapy-Naïve Patients With Metastatic Breast Cancer (MBC).|Completed||Phase 1/Phase 2|100|Anticipated|Cytokinetics||1|||f||||f||||||||||2018-06-01 02:30:19.419755|2018-06-01 02:30:19.419755
NCT00607828|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|||2017-09-23|2008-02-01|2008-02-06|Estimate|||||||2017-09-23|2017-09-26|Actual|November 2007||2007-11-30|August 2017|2017-08-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer|Feasibility of Hypofractionated Stereotactic Radiotherapy in Patients With Hepatocellular Carcinoma|Completed||Phase 1|9|Actual|University of Nebraska|||||f||||t||||||||||2018-06-01 02:30:19.534216|2018-06-01 02:30:19.534216
NCT00607815|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2015-02-27||2017-08-04|2008-02-05|2008-02-06|Estimate|2015-07-16|2015-07-20|Estimate||||2017-08-04|2017-09-05|Actual|June 15, 2009|Actual|2009-06-15|August 2017|2017-08-31|December 27, 2017|Anticipated|2017-12-27|February 1, 2015|Actual|2015-02-01||Interventional|||A Comparison of Cognitive Processing Therapy (CPT) Versus Present Centered Therapy (PCT) for Veterans|A Comparison of CPT vs PCT for Veterans|Active, not recruiting||N/A|79|Actual|VA Office of Research and Development|Significant amounts of missing data from patients not attending assessment. Drop out rate from treatment was higher than other clinical trials of CPT and PCT in civilian samples, but in keeping with other studies of Veterans.|2|||f||||f|f|f|||f|||Undecided||2018-06-01 02:30:19.621021|2018-06-01 02:30:19.621021
NCT00607802|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|||2017-01-17|2008-01-30|2008-02-06|Estimate|||||||2017-01-17|2017-01-19|Estimate||||June 2013|2013-06-30||||||||Interventional|||Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer|White Cell Transfer as Cancer Therapy|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 02:30:20.138738|2018-06-01 02:30:20.138738
NCT00607789|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2011-03-08||2017-07-20|2008-02-05|2008-02-06|Estimate|2012-10-12|2012-11-14|Estimate||||2017-07-20|2017-08-21|Actual|October 2006||2006-10-31|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression|A 12-Week, Double-Blind, Placebo-Controlled, Trial of Duloxetine Versus Placebo in the Treatment of Binge Eating Disorder and Comorbid Depressive Disorder.|Completed||Phase 4|40|Actual|University of Cincinnati||2|||f||||t||||||||||2018-06-01 02:30:20.248457|2018-06-01 02:30:20.248457
NCT00607776|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Artificial Tears Study in Mild to Moderate Dry Eye Patients|Artificial Tears Study in Mild to Moderate Dry Eye Patients|Completed||Phase 2|110|Actual|Abbott Medical Optics||2|||f||||t||||||||||2018-06-01 02:30:20.823588|2018-06-01 02:30:20.823588
NCT00607763|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2014-08-19|2008-01-23|2008-02-06|Estimate|||||||2014-08-19|2014-08-20|Estimate|October 2007||2007-10-31|August 2014|2014-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug|A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Infants And Toddlers (≥4 Months TO < 24 Months Of Age) With Esophageal Candidiasis Or Other Invasive Candidiasis|Completed||Phase 1|9|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:30:20.959173|2018-06-01 02:30:20.959173
NCT00607750|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2010-10-26|2008-01-23|2008-02-06|Estimate|||||||2010-10-26|2010-10-28|Estimate|May 2008||2008-05-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF|A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab or Bevacizumab)|Completed||Phase 2|60|Actual|CoMentis||2|||f||||f||||||||||2018-06-01 02:30:21.064999|2018-06-01 02:30:21.064999
NCT00607737|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2012-08-31|2008-02-05|2008-02-06|Estimate|||||||2012-08-31|2012-09-03|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Interventional|APPLY||Applications Site Reactions After Injection of Insulin Detemir and Saline in Subjects With Diabetes|Doubleblind, Randomised, Single Centre Investigator Sponsored Study of Applications Site Reactions After Deep and Superficial Subcutaneous and Intradermal Injection of Insulin Detemir and Saline in Subjects With Diabetes Mellitus|Completed||Phase 4|40|Actual|Steno Diabetes Center||2|||f||||f||||||||||2018-06-01 02:30:21.16007|2018-06-01 02:30:21.16007
NCT00607529|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2010-06-03|2008-02-04|2008-02-05|Estimate|||||||2010-06-03|2010-06-04|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device|Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device|Completed|||99|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     blood~   "|||2018-06-01 02:30:29.097352|2018-06-01 02:30:29.097352
NCT00607724|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2015-07-22||2015-09-08|2008-01-31|2008-02-06|Estimate|2015-09-08|2015-10-08|Estimate||||2015-09-08|2015-10-08|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||Safety-evaluable population included all participants who received any amount of GDC-0449.|GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists|Completed||Phase 1|68|Actual|Genentech, Inc.||7|||f||||||||||||||2018-06-01 02:30:21.394138|2018-06-01 02:30:21.394138
NCT00607711|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2008-04-30|2008-01-24|2008-02-06|Estimate|||||||2008-04-30|2008-05-05|Estimate|March 2008||2008-03-31|January 2008|2008-01-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Study of Oral Palifosfamide Tris in Solid Tumors|A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors|Suspended||Phase 1|20|Anticipated|Ziopharm||1||IND was withdrawn|f||||f||||||||||2018-06-01 02:30:24.327071|2018-06-01 02:30:24.327071
NCT00607685|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2010-05-11|2008-01-23|2008-02-06|Estimate|||||||2010-05-11|2010-05-12|Estimate|February 2008||2008-02-29|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy|Prospective Case-controlled Study Comparing 5-Fluorouracil vs 5-Fluorouracil With Viscoelastic (Hyaluronic Acid) Formulation for the Prevention of Subconjunctival Scarring Post-trabeculectomy|Completed||Phase 4|50|Anticipated|Singapore National Eye Centre||2|||f||||f||||||||||2018-06-01 02:30:24.404668|2018-06-01 02:30:24.404668
NCT00607672|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|2012-08-02||2012-09-07|2008-02-05|2008-02-06|Estimate|2012-09-07|2012-10-10|Estimate||||2012-09-07|2012-10-10|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||The RAS, Fibrinolysis and Cardiopulmonary Bypass|The RAS, Fibrinolysis and Cardiopulmonary Bypass|Completed||Phase 4|111|Actual|Vanderbilt University|We cannot exclude the possibility that our results may have been different if we studied a homogenous surgery population.|3|||f||||f||||||||||2018-06-01 02:30:24.717933|2018-06-01 02:30:24.717933
NCT00607659|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2016-04-12|2008-01-23|2008-02-06|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Immunopathogenesis of Chlamydia|Immunopathogenesis of Chlamydia Trachomatis Infection|Completed|||29|Actual|Arkansas Children's Hospital Research Institute|||2||f||||f||||||Samples With DNA|"~     Endocervical or vaginal swabs, rectal swabs, blood (whole and serum),urine~   "|||2018-06-01 02:30:25.984281|2018-06-01 02:30:25.984281
NCT00607646|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2018-01-09|2008-02-05|2008-02-06|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2010||2010-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 3|Recruiting||Early Phase 1|56|Anticipated|University of Maryland||4|||f||||t||||||||||2018-06-01 02:30:26.270976|2018-06-01 02:30:26.270976
NCT00607633|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-02-05|2008-02-05|2008-02-06|Estimate|||||||2008-02-05|2008-02-06|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|||||Observational|CandLE||Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH|Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy|Completed|||686|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:30:26.46525|2018-06-01 02:30:26.46525
NCT00607620|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|2017-10-26||2018-03-02|2008-01-29|2008-02-06|Estimate|2018-03-02|2018-03-07|Actual||||2018-03-02|2018-03-07|Actual|September 2008||2008-09-30|March 2018|2018-03-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|DO-SBIS||Disseminating Organizational SBI Services at Trauma Centers|Disseminating Organizational SBI Services (DO-SBIS) at Trauma Centers|Completed||N/A|878|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:30:26.675834|2018-06-01 02:30:26.675834
NCT00607607|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2012-01-19|2008-01-23|2008-02-06|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|||A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer|A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Recurrent or Resistant Epithelial Ovarian Cancer or Advanced Endometrial Cancer|Completed||Phase 2|44|Actual|CASI Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:30:27.45095|2018-06-01 02:30:27.45095
NCT00607594|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-01|2014-06-19||2014-06-19|2008-02-01|2008-02-06|Estimate|2014-06-19|2014-07-18|Estimate||||2014-06-19|2014-07-18|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|April 2012|Actual|2012-04-30|March 2010|Actual|2010-03-31||Interventional|||Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer|A Phase 2 Study of AZD0530 in Patients With Metastatic or Locally Advanced Gastric Carcinoma|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:30:27.553373|2018-06-01 02:30:27.553373
NCT00607581|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2012-02-09|2008-01-22|2008-02-05|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis|An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis|Completed||Phase 2|21|Actual|IRCCS Policlinico S. Matteo||1|||f||||f||||||||||2018-06-01 02:30:27.931237|2018-06-01 02:30:27.931237
NCT00607568|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2011-12-09|2008-02-04|2008-02-05|Estimate|||||||2011-12-09|2011-12-12|Estimate|June 2006||2006-06-30|December 2011|2011-12-31|September 2009|Actual|2009-09-30|August 2007|Actual|2007-08-31||Interventional|||Atomoxetine Effects in Humans|Atomoxetine Effects in Humans|Completed||Phase 1/Phase 2|10|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:30:28.316875|2018-06-01 02:30:28.316875
NCT00607555|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2009-10-30|2008-02-04|2008-02-05|Estimate|||||||2009-10-30|2009-11-02|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||A Study on the Effects of Feeding and Feeding Methods on Breathing Pattern in Very Low Birth Weight Preterm Infants|Observational Study on the Effects of Enteral Feeding and Feeding Methods on Respiratory Pattern as Assessed by Diaphragm Electrical Activity (EAdi) in Very Low Birth Weight Preterm Infants|Completed|||10|Anticipated|Sunnybrook Health Sciences Centre|||1||f||||f||||||||||2018-06-01 02:30:28.542551|2018-06-01 02:30:28.542551
NCT00607542|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2011-12-02|2008-02-04|2008-02-05|Estimate|||||||2011-12-02|2011-12-06|Estimate|November 2008||2008-11-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Best PK/PD||Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity|Pediatric Pharmacokinetic and Pharmacodynamic Study of Oral Baclofen for the Treatment of Spasticity Associated With Cerebral Palsy|Completed||Phase 1/Phase 2|61|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||t||||||||||2018-06-01 02:30:28.875862|2018-06-01 02:30:28.875862
NCT00607516|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2009-06-23|2008-01-22|2008-02-05|Estimate|||||||2009-06-23|2009-06-24|Estimate|March 2006||2006-03-31|February 2007|2007-02-28|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|HEMI-RSADEXA||Radiostereometric Analysis of Acetabular Wear and Periprosthetic Bone Mineral Density Changes in Hemiarthroplasties|Radiostereometric Analysis of Acetabular Wear and Periprosthetic Bone Mineral Density Changes in Cemented and Uncemented Hemiarthroplasties for Femoral Neck Fractures|Unknown status|Active, not recruiting|N/A|22|Actual|Ullevaal University Hospital||2|||f||||f||||||||||2018-06-01 02:30:29.208662|2018-06-01 02:30:29.208662
NCT00607503|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2016-09-02|2008-02-04|2008-02-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|February 2008||2008-02-29|September 2016|2016-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes|A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes|Completed||Phase 1|9|Actual|Jaeb Center for Health Research||1|||f||||t||||||||||2018-06-01 02:30:29.357845|2018-06-01 02:30:29.357845
NCT00607490|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2016-05-20|2008-02-04|2008-02-05|Estimate|||||||2016-05-20|2016-05-23|Estimate|September 2000||2000-09-30|January 2008|2008-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Randomized Clinical Trial for Women With Vulvodynia|Cognitive-behavioral Therapy for Vulvodynia: a Clinical Trial|Completed||N/A|50|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-06-01 02:30:29.522536|2018-06-01 02:30:29.522536
NCT00607477|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2010-11-22||2014-06-03|2008-01-22|2008-02-05|Estimate|2011-01-19|2011-02-16|Estimate||||2014-06-03|2014-06-10|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension|A Pilot Study of the Treatment of VEGF-Signaling Pathway Inhibitor-Induced Hypertension With Direct Vasodilators, Minoxidil and Hydralazine|Terminated||N/A|2|Actual|University of Chicago|This study enrolled only 2 subjects and due to poor accrual, enrollment was stopped early. Due to the limited number of subjects available results cannot be assessed.|2||Study has been terminated due to poor accrual.|f||||f||||||||||2018-06-01 02:30:29.66309|2018-06-01 02:30:29.66309
NCT00607464|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2016-04-21|2008-01-22|2008-02-05|Estimate|||||||2016-04-21|2016-04-25|Estimate|September 2004||2004-09-30|April 2016|2016-04-30|October 2012|Actual|2012-10-31|March 2010|Actual|2010-03-31||Interventional|HeLP||Multicentre Randomised Controlled Trial of HELP (Heat Loss Prevention) in the Delivery Room|Multicentre Randomised Controlled Trial of HELP (Heat Loss Prevention) in the Delivery Room|Terminated||N/A|804|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 02:30:30.087444|2018-06-01 02:30:30.087444
NCT00607451|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2018-03-27|2008-02-04|2008-02-05|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2008||2008-03-31|March 2018|2018-03-31|August 27, 2016|Actual|2016-08-27|August 27, 2016|Actual|2016-08-27||Interventional|||Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia|A Double-blind, Placebo Controlled, Crossover, Ascending Single Dose Safety Tolerability, Pharmacokinetic and Pharmacodynamic Study of Neu-120 in Patients With Advanced Phase Idiopathic Parkinson's Disease With Levodopa Induced Dyskinesia|Terminated||Phase 1/Phase 2|8|Actual|Neurim Pharmaceuticals Ltd.||4|||f||||t||||||||||2018-06-01 02:30:30.20044|2018-06-01 02:30:30.20044
NCT00607438|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2012-05-09|2008-02-04|2008-02-05|Estimate|||||||2012-05-09|2012-05-11|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer|A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer|Terminated||Phase 2|16|Actual|Veeda Oncology||||Low accrual|f||||f||||||||||2018-06-01 02:30:30.354623|2018-06-01 02:30:30.354623
NCT00607425|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-07-15|2008-02-04|2008-02-05|Estimate|||||||2008-07-15|2008-07-17|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|SPIT-LC||Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening|Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening|Terminated|||40|Actual|Scottsdale Healthcare|||2|Change in isolation method|f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-06-01 02:30:30.423725|2018-06-01 02:30:30.423725
NCT00607412|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-05-10|2008-01-22|2008-02-05|Estimate|||||||2011-05-10|2011-05-11|Estimate|August 2007||2007-08-31|June 2009|2009-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Alcohol Use Disorders (AUDs) and Post-traumatic Stress Disorder (PTSD) Treatment for Victims of Partner Violence|AUDs and PTSD Treatment for Victims of Partner Violence|Completed||Phase 2|50|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-06-01 02:30:30.507134|2018-06-01 02:30:30.507134
NCT00607399|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-07-22|2008-01-23|2008-02-05|Estimate|||||||2008-07-22|2008-07-24|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Interventional|||Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors|A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, Ona Twice Daily, Interrupted Schedule in Patients With Advanced Cancer|Terminated||Phase 1|46|Anticipated|SGX Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:30:30.645225|2018-06-01 02:30:30.645225
NCT00607386|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2013-09-03||2015-10-06|2008-01-22|2008-02-05|Estimate|2013-09-03|2013-11-07|Estimate||||2015-10-06|2015-10-28|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Safety population was defined as all enrolled participants who received at least one study dose (or any portion of a dose) of idursulfase.|Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy|A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy|Completed||Phase 4|28|Actual|Shire||1|||f||||f||||||||||2018-06-01 02:30:30.7858|2018-06-01 02:30:30.7858
NCT00607373|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2013-02-15|2010-10-02|2016-08-01|2008-02-04|2008-02-05|Estimate|2013-02-15|2013-03-21|Estimate|2010-10-02|2010-10-05|Estimate|2016-08-01|2016-09-09|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|RADICHOL 1||Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects|Completed||Phase 3|51|Actual|Kastle Therapeutics, LLC||2|||f||||t||||||||||2018-06-01 02:30:31.409386|2018-06-01 02:30:31.409386
NCT00607360|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2017-01-09|2008-02-04|2008-02-05|Estimate|||||||2017-01-09|2017-01-10|Estimate|August 2004||2004-08-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Integration of the Therapeutic Workplace in Drug Court|Integration of the Therapeutic Workplace in Drug Court|Completed||Phase 1|59|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 02:30:32.831464|2018-06-01 02:30:32.831464
NCT00607347|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-09-16|2008-01-24|2008-02-05|Estimate|||||||2011-09-16|2011-09-20|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers|Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers|Completed||N/A|24|Anticipated|University of Florida||1|||f||||t||||||||||2018-06-01 02:30:32.924304|2018-06-01 02:30:32.924304
NCT00607334|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-01-22|2008-01-22|2008-02-05|Estimate|||||||2008-01-22|2008-02-05|Estimate|July 2003||2003-07-31|October 2007|2007-10-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Experimental Word Learning in Children With and Without Language Impairment|Experimental Word Learning in Children With Normal Development and Children With Language Impairment|Completed||N/A|51|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 02:30:33.071066|2018-06-01 02:30:33.071066
NCT00607321|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2011-08-01||2017-04-18|2008-02-04|2008-02-05|Estimate|2011-08-01|2011-08-31|Estimate||||2017-04-18|2017-05-18|Actual|February 2008||2008-02-29|April 2017|2017-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|BRANCH||Bare Metal Bifurcation Stent Clinical Trial in Humans|The Medtronic Bare Metal Bifurcation Stent Clinical Trial in Humans|Completed||N/A|60|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-06-01 02:30:33.172406|2018-06-01 02:30:33.172406
NCT00607308|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2010-12-06|2008-01-22|2008-02-05|Estimate|||||||2010-12-06|2010-12-07|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease|A Phase 1, Randomized, Placebo-Controlled, Double Blind, Dose-Escalation, Multicenter Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease|Completed||Phase 1|20|Actual|Pfizer||6|||f||||t||||||||||2018-06-01 02:30:33.568731|2018-06-01 02:30:33.568731
NCT00607295|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2010-07-23|2008-02-04|2008-02-05|Estimate|||||||2010-07-23|2010-07-27|Estimate|December 2007||2007-12-31|July 2010|2010-07-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients|Prospective Randomized Study on Efficacy and Safety of Clino-san® in the Management of Vaginal Dryness in Breast Cancer Patients|Completed||Phase 3|98|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:30:33.780845|2018-06-01 02:30:33.780845
NCT00607282|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2012-09-02|2008-02-04|2008-02-05|Estimate|||||||2012-09-02|2012-09-05|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer|Efficacy of Udenafil in Treatment of Erectile Dysfunction After Radical Resection for Sigmoid Colon and Rectal Cancer : a Randomized Controlled Trial|Completed||Phase 2|46|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:30:33.958232|2018-06-01 02:30:33.958232
NCT00607269|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2013-04-19||2013-07-30|2008-02-04|2008-02-05|Estimate|2013-07-30|2013-08-01|Estimate||||2013-07-30|2013-08-01|Estimate|April 2005||2005-04-30|July 2013|2013-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|VIPS||Voucher-Based Incentives in a Prevention Setting|Voucher-Based Incentives in a Prevention Setting|Completed||Phase 2/Phase 3|131|Actual|Friends Research Institute, Inc.||2|||f||||f||||||||||2018-06-01 02:30:34.119131|2018-06-01 02:30:34.119131
NCT00607256|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2011-02-15|2008-01-23|2008-02-05|Estimate|||||||2011-02-15|2011-02-17|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia|A Multi-center, Long-term, Open-label Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia|Terminated||Phase 3|500|Anticipated|Pfizer||1|||f||||t||||||||||2018-06-01 02:30:34.73111|2018-06-01 02:30:34.73111
NCT00607243|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|2011-08-02||2013-07-07|2008-02-04|2008-02-05|Estimate|2013-07-07|2013-07-09|Estimate||||2013-07-07|2013-07-09|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy of CJ-50300 in Healthy Volunteers|Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers|Completed||Phase 2/Phase 3|123|Actual|Seoul National University Hospital|the study was limited to vaccinia-naïve adults, thus yielding no data concerning the efﬁcacy of CJ-50300 in non-naïve adults or in children.|2|||f||||t||||||||||2018-06-01 02:30:35.040466|2018-06-01 02:30:35.040466
NCT00607230|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2013-11-04|2008-02-04|2008-02-05|Estimate|||||||2013-11-04|2013-11-05|Estimate|November 2007||2007-11-30|November 2013|2013-11-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics|Determination of Dosing and Frequency of BCG Administration Necessary to Alter T-Lymphocyte Profiles in Type I Diabetics|Completed||Phase 1|25|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:30:35.455276|2018-06-01 02:30:35.455276
NCT00607217|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2009-01-20|2008-02-04|2008-02-05|Estimate|||||||2009-01-20|2009-01-22|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases|Controlled Trial of Serologic and Clinical Efficacy of Influenza Vaccine in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris|Completed||Phase 2/Phase 3|360|Anticipated|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-06-01 02:30:35.60599|2018-06-01 02:30:35.60599
NCT00607204|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2013-07-30|2008-02-04|2008-02-05|Estimate|||||||2013-07-30|2013-07-31|Estimate|October 2005||2005-10-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Examining the Biological Factors That Affect Sleep Duration|Neurobiology of Individual Differences in Sleep Duration|Completed|||119|Actual|Brigham and Women's Hospital|||||f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-06-01 02:30:35.725964|2018-06-01 02:30:35.725964
NCT00607191|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2017-05-05|2008-01-22|2008-02-05|Estimate|||||||2017-05-05|2017-05-09|Actual|January 2008||2008-01-31|May 2017|2017-05-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Observational|||Clubfoot DNA Repository|Clubfoot DNA Repository|Completed|||379|Actual|Texas Scottish Rite Hospital for Children|||||f||||t||||||Samples With DNA|"~     Each of the study participants (affected and non-affected individuals) will be asked to~     provide DNA from a blood sample. A 10cc sample of blood will be removed on 1 or 2 occasions~     by drawing blood from the arm or by finger stick by research staff. If the participant is a~     child who will be undergoing surgery, the blood sample will be collected at that time to~     eliminate additional stick. If collecting a blood sample is not possible we can also obtain~     DNA by collecting a saliva sample. This second technique does not give us as much DNA as we~     would get from blood. Therefore, if we get saliva samples, we might require more than one~     saliva sample over the course of the study.~   "|Undecided||2018-06-01 02:30:35.851395|2018-06-01 02:30:35.851395
NCT00607178|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2009-01-20|2008-02-04|2008-02-05|Estimate|||||||2009-01-20|2009-01-22|Estimate|January 2008||2008-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|IVCAD||The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases|Randomized, Single-Blind, Placebo-Controlled Study of Influenza Vaccine in Preventing Cardiovascular Events in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris|Completed||Phase 2/Phase 3|300|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:30:35.91605|2018-06-01 02:30:35.91605
NCT00607152|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2014-05-07|2008-01-22|2008-02-05|Estimate|||||||2014-05-07|2014-05-08|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Rasburicase (Fasturtec) Registration Trial|A Multi-center, Randomized, Open-label, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Patients With Hematological Malignancies|Terminated||Phase 3|10|Actual|Sanofi||2||the patient enrollment is too difficult|f||||f||||||||||2018-06-01 02:30:36.053942|2018-06-01 02:30:36.053942
NCT00607139|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2016-09-02|2008-01-22|2008-02-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|December 2006||2006-12-31|September 2016|2016-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors|Evaluation of Counter-regulatory Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors in Children With T1DM|Completed|||28|Actual|Jaeb Center for Health Research|||||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:30:36.154143|2018-06-01 02:30:36.154143
NCT00607126|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2015-12-30|2012-06-14|2016-07-01|2008-02-04|2008-02-05|Estimate|2016-07-01|2016-08-15|Estimate|2013-01-15|2013-01-25|Estimate|2016-07-01|2016-08-15|Estimate|July 2006||2006-07-31|July 2016|2016-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Locomotor Training in Persons With Multiple Sclerosis|Robotic Locomotor Training in Persons With Multiple Sclerosis|Completed||Phase 1/Phase 2|38|Actual|University of California, Los Angeles|This was a small study and the number of subjects enrolled may not have been sufficient to show an effect.|2|||f||||f||||||||No||2018-06-01 02:30:36.282791|2018-06-01 02:30:36.282791
NCT00607113|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2012-12-31||2013-05-14|2008-01-22|2008-02-05|Estimate|2013-03-26|2013-05-08|Estimate||||2013-05-14|2013-07-18|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma|Exploratory Study of Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (AVF3961s) (CRAD001C2481)|Completed||Phase 2|41|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 02:30:36.916304|2018-06-01 02:30:36.916304
NCT00607100|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-04|||2008-11-11|2008-02-04|2008-02-05|Estimate|||||||2008-11-11|2008-11-13|Estimate|December 2007||2007-12-31|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|March 2008|Anticipated|2008-03-31||Observational|||High-Resolution Optical Coherence Tomography for Detection of Retinal Nerve Fiber Layer Loss in Band Atrophy of the Optic Nerve|High-Resolution Optical Coherence Tomography for Detection of Retinal Nerve Fiber Layer Loss in Band Atrophy of the Optic Nerve|Unknown status|Active, not recruiting||30|Anticipated|University of Sao Paulo|||2||f||||t||||||||||2018-06-01 02:30:37.336045|2018-06-01 02:30:37.336045
NCT00607087|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2010-06-30||2010-08-26|2008-01-23|2008-02-05|Estimate|2010-06-30|2010-07-30|Estimate||||2010-08-26|2010-08-31|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PUMP||Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus|Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus|Completed||Phase 4|289|Actual|Sanofi||3|||f||||||||||||||2018-06-01 02:30:37.475164|2018-06-01 02:30:37.475164
NCT00607074|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-02-04|2008-02-04|2008-02-05|Estimate|||||||2008-02-04|2008-02-05|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|December 2006|Actual|2006-12-31|April 2004|Actual|2004-04-30||Interventional|||Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh|Effects of Anti-Giardia and Antihelmintic Treatment on Infant Nutritional and Biochemical Status and Intestinal Permeability in Rural Bangladesh|Completed||N/A|410|Actual|University of Cambridge||1|||f||||f||||||||||2018-06-01 02:30:39.933907|2018-06-01 02:30:39.933907
NCT00607061|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2013-09-27|2008-02-04|2008-02-05|Estimate|||||||2013-09-27|2013-09-30|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|glutathione||Synthesis of Glutathione From Low Birth Weight Newborn Babies|Synthesis of Glutathione in Erythrocytes From Low Birth Weight Newborn Babies : Effect of Cysteine in Vitro|Terminated||N/A|35|Actual|Nantes University Hospital||3|||f||||f||||||||||2018-06-01 02:30:40.034667|2018-06-01 02:30:40.034667
NCT00607048|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2012-05-03||2017-02-22|2008-01-22|2008-02-05|Estimate|2012-09-25|2012-10-31|Estimate||||2017-02-22|2017-03-27|Actual|November 2007||2007-11-30|February 2017|2017-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors|A Phase 1 Study Of CP- 870,893 In Combination With Paclitaxel And Carboplatin In Patients With Metastatic Solid Tumors|Completed||Phase 1|34|Actual|Hoffmann-La Roche||2|||f||||f||||||||||2018-06-01 02:30:40.178392|2018-06-01 02:30:40.178392
NCT00607035|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-11-19|2008-02-04|2008-02-05|Estimate|||||||2008-11-19|2008-11-20|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)|The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)|Completed||Phase 4|220|Actual|Jichi Medical University||2|||f||||t||||||||||2018-06-01 02:30:41.826631|2018-06-01 02:30:41.826631
NCT00607022|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2017-05-25|2008-02-04|2008-02-05|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2007||2007-12-31|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Randomized Prospective Clinical Trial Comparing Single Tooth Implant 3 Loading Protocols|the Effects of 3 Loading Protocols on Dental Implant Stability in Healed Ridges|Completed||Phase 4|40|Actual|University of Iowa||3|||f||||t||||||||Undecided|Primary data belongs to DENTSPLY-Sirona, the sponsor|2018-06-01 02:30:41.920696|2018-06-01 02:30:41.920696
NCT00607009|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-02-04|2008-02-04|2008-02-05|Estimate|||||||2008-02-04|2008-02-05|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Project ALIVE (A Lifestyle Intervention Via Email)|Email-Based Diet and Activity Promotion in Worksites|Completed||N/A|797|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 02:30:42.043022|2018-06-01 02:30:42.043022
NCT00606996|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2013-04-17|2008-01-22|2008-02-05|Estimate|||||||2013-04-17|2013-04-18|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Group Therapy for Women Prisoners With Comorbid Substance Use and Depression|Group IPT for Women Prisoners With Comorbid Substance Use and Depression|Completed||Phase 2|38|Actual|Brown University||2|||f||||||||||||||2018-06-01 02:30:42.12066|2018-06-01 02:30:42.12066
NCT00606983|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2011-07-18|2008-02-04|2008-02-05|Estimate|||||||2011-07-18|2011-07-20|Estimate|May 2007||2007-05-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Prevention of Acute Voiding Difficulty After Radical Proctectomy|Prevention of Acute Voiding Difficulty After Radical Proctectomy for Rectal Cancer With Tamsulosin|Completed||Phase 3|100|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:30:42.230253|2018-06-01 02:30:42.230253
NCT00606970|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2013-05-05|2008-02-04|2008-02-05|Estimate|||||||2013-05-05|2013-05-07|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|||Safety Assessment of Lactobacillus Fermented Extract in Cancer Patients Undergoing Chemotherapy|Assessment of the Safety of Dietary Supplement Lactobacillus Fermented Extract in Cancer Patients Undergoing Chemotherapy|Withdrawn||Early Phase 1|0|Actual|New Hope Medical Center||2||FDA sent letter to IRB stating it should be done under new drug application|f||||f||||||||||2018-06-01 02:30:42.335067|2018-06-01 02:30:42.335067
NCT00606957|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2011-10-12|2008-02-04|2008-02-05|Estimate|||||||2011-10-12|2011-10-13|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Effect of Vitamin D Repletion on Insulin Resistance|The Effect of Vitamin D Repletion on Insulin Resistance|Completed||N/A|10|Anticipated|Rockefeller University|||||f||||||||||||||2018-06-01 02:30:42.418347|2018-06-01 02:30:42.418347
NCT00606944|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2012-07-19||2012-07-19|2008-02-04|2008-02-05|Estimate|2012-07-19|2012-08-21|Estimate||||2012-07-19|2012-08-21|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|October 2009|Actual|2009-10-31||Interventional|||Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection|Randomized Controlled Trial of Fast-Track Rehabilitation After Elective Colorectal and Small Bowel Resection|Completed||N/A|200|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:30:42.620644|2018-06-01 02:30:42.620644
NCT00606931|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2009-03-27||2009-05-20|2008-02-04|2008-02-05|Estimate|2009-05-20|2009-07-07|Estimate||||2009-05-20|2009-07-07|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|PEM-BX||Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities|Pilot Clinical Study to Evaluate High Resolution PET Imaging- Guidance for Sampling of Breast Abnormalities in Patients With Known or Suspected Breast Cancer|Completed||N/A|22|Actual|Naviscan PET Systems||1|||f||||t||||||||||2018-06-01 02:30:42.959914|2018-06-01 02:30:42.959914
NCT00606918|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2011-05-11|2008-02-04|2008-02-05|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|ATLIS||Validation of a New Device to Measure Neuromuscular Disease Progression|Validation of a New Device to Measure Neuromuscular Disease Progression|Completed|||120|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 02:30:43.185243|2018-06-01 02:30:43.185243
NCT00606905|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2010-08-03||2012-10-03|2008-02-04|2008-02-05|Estimate|2010-08-03|2010-08-30|Estimate||||2012-10-03|2012-10-08|Estimate|November 1999||1999-11-30|August 2010|2010-08-31|January 2010|Actual|2010-01-31|March 2009|Actual|2009-03-31||Interventional|||Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage|Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial|Completed||N/A|82|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:30:43.262651|2018-06-01 02:30:43.262651
NCT00606892|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2012-03-14||2014-09-09|2008-02-04|2008-02-05|Estimate|2014-09-09|2014-09-25|Estimate||||2014-09-09|2014-09-25|Estimate|August 2007||2007-08-31|September 2014|2014-09-30|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional||37 subjects signed consent. 17 subjects received the first treatment. Five subjects dropped out due to non-compliance with study procedures prior to study completion, and therefore were not included in the analysis. The 12 subjects who completed both interventions were included in the analysis.|Varenicline and Nicotine Interactions in Humans (VA)|Varenicline Attenuates Some of the Subjective and Physiological Effects of Intravenous Nicotine in Humans.|Completed||N/A|37|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:30:43.581141|2018-06-01 02:30:43.581141
NCT00606879|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2008-07-22|2008-01-22|2008-02-05|Estimate|||||||2008-07-22|2008-07-24|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Interventional|||Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors|A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer|Terminated||Phase 1|46|Anticipated|SGX Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:30:44.104181|2018-06-01 02:30:44.104181
NCT00606866|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2014-03-26|2008-02-04|2008-02-05|Estimate|||||||2014-03-26|2014-03-27|Estimate|July 2004||2004-07-31|March 2014|2014-03-31|June 2008|Actual|2008-06-30|January 2007|Actual|2007-01-31||Interventional|MRI||MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma|Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma|Completed||Phase 3|57|Actual|University of Chicago||3|||f||||t||||||||||2018-06-01 02:30:44.201227|2018-06-01 02:30:44.201227
NCT00606853|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2011-11-17|2008-02-04|2008-02-05|Estimate|||||||2011-11-17|2011-11-21|Estimate|October 2003||2003-10-31|November 2011|2011-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Enhanced and Attendance-based Prize CM in Community Settings|Enhanced and Attendance-based Prize CM in Community Settings|Completed||Phase 2|443|Actual|UConn Health||4|||f||||f||||||||||2018-06-01 02:30:44.351197|2018-06-01 02:30:44.351197
NCT00606840|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2012-04-12|2008-02-04|2008-02-05|Estimate|||||||2012-04-12|2012-04-13|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Weight Gain Prevention|Study to Prevent Weight Gain|Completed||N/A|52|Actual|The Miriam Hospital||2|||f||||||||||||||2018-06-01 02:30:44.465204|2018-06-01 02:30:44.465204
NCT00606827|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2012-05-06|2008-01-22|2008-02-05|Estimate|||||||2012-05-06|2012-05-08|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|March 2006|Actual|2006-03-31|||||Interventional|||Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy|Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy in Patients Undergoing Coronary Angiography|Completed||Phase 4|500|Actual|Ospedale Misericordia e Dolce||2|||f||||t||||||||||2018-06-01 02:30:44.569077|2018-06-01 02:30:44.569077
NCT00606814|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2012-03-02|2008-02-04|2008-02-05|Estimate|||||||2012-03-02|2012-03-06|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors|A Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|60|Actual|Infinity Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 02:30:44.657327|2018-06-01 02:30:44.657327
NCT00606801|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2012-02-08||2013-06-24|2008-02-04|2008-02-05|Estimate|2013-06-24|2013-07-31|Estimate||||2013-06-24|2013-07-31|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Galantamine Effects on Cognitive Function in Abstinent Cocaine Users|Galantamine Effects on Cognitive Function in Abstinent Cocaine Users|Completed||N/A|34|Actual|Yale University|Relatively low medication dose and short duration of treatment. Multiple cognitive tests and outcome measures increase probability of Type 1 errors. Absence of non-addicted controls limits determination of a unique effect in abstinent users.|2|||f||||t||||||||||2018-06-01 02:30:44.821931|2018-06-01 02:30:44.821931
NCT00606788|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-02-12|2008-01-22|2008-02-05|Estimate|||||||2008-02-12|2008-02-18|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|February 2007|Anticipated|2007-02-28|January 2007|Anticipated|2007-01-31||Interventional|||Therapy Study of Automated Protocolized vs. Physician-Directed Non-Protocolized Weaning|Comparison of Computer-Driven Protocolized Weaning With Physician-Directed Weaning in Surgical Intensive Care Unit (ICU) Patients|Suspended||N/A|60|Actual|University of Luebeck||2||"Interim analysis indicated that sample size of study patients had to be highly increased to~   obtain significant outcomes."|f||||f||||||||||2018-06-01 02:30:45.542145|2018-06-01 02:30:45.542145
NCT00606775|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-02-04|2008-02-04|2008-02-05|Estimate|||||||2008-02-04|2008-02-05|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|December 2012|Anticipated|2012-12-31|December 2008|Anticipated|2008-12-31||Interventional|||The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy|Carvedilol for the Prevention of Minor Cardiac Damage and Cardiac Function in Duchenne Muscular Dystrophy|Unknown status|Recruiting|Phase 4|60|Anticipated|Suzuka Hospital||2|||f||||t||||||||||2018-06-01 02:30:45.66909|2018-06-01 02:30:45.66909
NCT00606762|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-02-04|2008-02-04|2008-02-05|Estimate|||||||2008-02-04|2008-02-05|Estimate|October 2006||2006-10-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Comparison Between Low Pressure Versus High Pressure Laparoscopic Cholecystectomy|A Prospective Randomized, Controlled Study Comparing Low Pressure Versus High Pressure Pneumoperitoneum During Laparoscopic Cholecystectomy.|Completed||N/A|26|Actual|Sterling Hospital||1|||f||||f||||||||||2018-06-01 02:30:45.834933|2018-06-01 02:30:45.834933
NCT00606749|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-06-18|2008-02-04|2008-02-05|Estimate|||||||2008-06-18|2008-06-19|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Use of KC706 for the Treatment of Pemphigus Vulgaris|A Phase 2 Open-Label Uncontrolled Pilot Study of KC706 in Patients With Stable, Active Pemphigus Vulgaris|Completed||Phase 2|20|Anticipated|Kemia, Inc|||||f||||f||||||||||2018-06-01 02:30:45.933434|2018-06-01 02:30:45.933434
NCT00606736|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2015-07-02|2008-02-01|2008-02-04|Estimate|||||||2015-07-02|2015-07-03|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Relativity Study Between Idiopathic Ventricular Arrhythmia and Sex Hormone Levels in Different Stages of Menstrual Cycle|Relativity Study Between Idiopathic Ventricular Arrhythmia and Sex Hormone Levels in Different Stages of Menstrual Cycle|Withdrawn|||0|Actual|Harbin Medical University|||2|it's difficult to recruit enough participants eligible for this study|f||||t||||||Samples With DNA|"~     whole blood, serum~   "|||2018-06-01 02:30:46.022098|2018-06-01 02:30:46.022098
NCT00606723|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2017-11-13|2008-02-01|2008-02-04|Estimate|||||||2017-11-13|2017-11-14|Actual|April 2010||2010-04-30|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML|Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML; Multi Center Therapy Concept|Active, not recruiting||Phase 3|154|Actual|Hannover Clinical Trial Center GmbH||1|||f||||t||||||||||2018-06-01 02:30:46.10875|2018-06-01 02:30:46.10875
NCT00606710|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-11-21|2008-01-22|2008-02-04|Estimate|||||||2008-11-21|2008-11-24|Estimate|February 2008||2008-02-29|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|Cogent-4||Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following|Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following|Completed|||450|Anticipated|Guidant Corporation|||||f||||f||||||||||2018-06-01 02:30:46.240808|2018-06-01 02:30:46.240808
NCT00606697|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22||2009-07-22|2017-07-06|2008-02-01|2008-02-04|Estimate||||2009-07-22|2009-08-10|Estimate|2017-07-06|2017-07-11|Actual|December 19, 2007|Actual|2007-12-19|July 2017|2017-07-31|May 7, 2008|Actual|2008-05-07|May 7, 2008|Actual|2008-05-07||Interventional|||A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia|Vestipitant and Vofopitant 2 Day PSG Study for Insomnia|Completed||Phase 2|51|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:30:46.333265|2018-06-01 02:30:46.333265
NCT00606684|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2013-06-12|2012-03-01|2016-11-04|2008-02-01|2008-02-04|Estimate|2013-07-11|2013-09-17|Estimate|2012-03-01|2012-03-05|Estimate|2016-11-04|2016-12-16|Estimate|February 2008||2008-02-29|November 2016|2016-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Study B2C111045, A Dose-Finding Study of GW642444 Versus Placebo in Patients With COPD|Completed||Phase 2|602|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:30:46.562592|2018-06-01 02:30:46.562592
NCT00606671|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-02-01|2008-02-01|2008-02-04|Estimate|||||||2008-02-01|2008-02-04|Estimate|February 2004||2004-02-29|January 2008|2008-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Metabolic Disturbances in Polycystic Ovary Syndrome (PCOS)|Insulin Resistance in Polycystic Ovary Syndrome (PCOS)|Completed|||65|Actual|Hvidovre University Hospital|||8||f||||t||||||Samples With DNA|"~     Fat and muscle biopsies~   "|||2018-06-01 02:30:47.645615|2018-06-01 02:30:47.645615
NCT00606658|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2012-09-18|2008-01-21|2008-02-04|Estimate|||||||2012-09-18|2012-09-20|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Usefulness of Shirodhara for Insomnia|Usefulness of Shirodhara (Oil Dripping Treatment in Ayurveda) for Insomnia - A Case Series|Completed||Early Phase 1|10|Actual|Southern California University of Health Sciences||1|||f||||f||||||||||2018-06-01 02:30:47.859112|2018-06-01 02:30:47.859112
NCT00606645|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2014-04-18|2008-01-21|2008-02-04|Estimate|||||||2014-04-18|2014-04-21|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma|A Phase 1 Study of Every Other Week XmAb®2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma|Completed||Phase 1|23|Actual|Xencor, Inc.||1|||f||||f||||||||||2018-06-01 02:30:48.04499|2018-06-01 02:30:48.04499
NCT00606632|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|2011-06-07||2014-03-17|2008-01-21|2008-02-04|Estimate|2014-03-17|2014-04-14|Estimate||||2014-03-17|2014-04-14|Estimate|March 2008||2008-03-31|March 2014|2014-03-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody|A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)|Completed||Phase 3|226|Actual|Wilex||1|||f||||f||||||||||2018-06-01 02:30:48.180066|2018-06-01 02:30:48.180066
NCT00606619|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2010-05-27|2008-02-01|2008-02-04|Estimate|||||||2010-05-27|2010-05-28|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effects of Early Oral Feeding After Resection of Gastric Cancer|Phase III Clinical Trial for Effect Early Oral Feeding on Recovery After Resection of Gastric Cancer|Completed||Phase 3|58|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-06-01 02:30:48.477877|2018-06-01 02:30:48.477877
NCT00606606|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2015-03-27|2008-02-01|2008-02-04|Estimate|||||||2015-03-27|2015-03-30|Estimate|July 2000||2000-07-31|March 2015|2015-03-31|June 2006|Actual|2006-06-30|February 2005|Actual|2005-02-28||Interventional|||Reducing Adverse Drug Events in the Nursing Home|Reducing Adverse Drug Events in the Nursing Home|Withdrawn||N/A|0|Actual|University of Massachusetts, Worcester||2||"This is not a human subject's study. Protocol registered in error. This protocol studied~   nursing homes as a unit."|f||||f||||||||||2018-06-01 02:30:48.5606|2018-06-01 02:30:48.5606
NCT00606593|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2012-12-21|2010-02-11|2016-02-11|2008-01-22|2008-02-04|Estimate|2013-02-06|2013-03-11|Estimate|2010-02-11|2010-02-15|Estimate|2016-02-11|2016-03-14|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia|Multicenter, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Dose-finding Study to Evaluate the Efficacy and Safety of Oral Administration of ACT-078573 in Elderly Subjects With Chronic Primary Insomnia|Completed||Phase 2|112|Actual|Midnight Pharma, LLC||10|||f||||f||||||||||2018-06-01 02:30:48.655291|2018-06-01 02:30:48.655291
NCT00606580|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|2014-05-12||2014-06-11|2008-01-31|2008-02-04|Estimate|2014-06-11|2014-07-14|Estimate||||2014-06-11|2014-07-14|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)|A Pivotal, Randomized, Double-blind, Vehicle-controlled Study to Evaluate WR 279,396 and Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)|Completed||Phase 3|375|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-06-01 02:30:49.344742|2018-06-01 02:30:49.344742
NCT00606567|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2014-07-11|2008-02-01|2008-02-04|Estimate|||||||2014-07-11|2014-07-14|Estimate|December 2006||2006-12-31|December 2012|2012-12-31|May 2010|Actual|2010-05-31|December 2008|Actual|2008-12-31||Interventional|Medusa SAK||A Randomized Trial of Remote Monitoring of Implantable Cardioverter Defibrillators Versus Quarterly Device Interrogations in Clinic|A Randomized Trial of Remote Monitoring of Implantable Cardioverter Defibrillators Versus Quarterly Device Interrogations in Clinic|Completed||N/A|151|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:30:50.430699|2018-06-01 02:30:50.430699
NCT00606554|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2011-02-07||2017-11-09|2008-01-22|2008-02-04|Estimate|2011-07-22|2011-08-17|Estimate||||2017-11-09|2017-12-11|Actual|January 2008||2008-01-31|November 2017|2017-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Clinical Trial of a Computer-driven Weaning System for Patients Requiring Mechanical Ventilation|A Randomized Controlled Trial of Computer-Driven Weaning Compared With Standard of Care Weaning in Medical Patients Requiring Mechanical Ventilation|Terminated||N/A|33|Actual|Boston Medical Center|This trial was terminated early due to slow recruitment. It did not reach the target N of 220.|2||Slow recruitment of subjects|f||||f|f|t|f|f|t|||||2018-06-01 02:30:50.526788|2018-06-01 02:30:50.526788
NCT00606541|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2014-07-31|2008-02-01|2008-02-04|Estimate|||||||2014-07-31|2014-08-01|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional|||An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)|An Open Label, Double-blind Discontinuation Study of Quetiapine (Extended Release) XR in Social Anxiety Disorder|Terminated||Early Phase 1|55|Actual|Duke University||2||The study was terminated by the sponsor due to budgetary issues|f||||t||||||||||2018-06-01 02:30:50.923869|2018-06-01 02:30:50.923869
NCT00606528|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2013-07-24|2008-01-21|2008-02-04|Estimate|||||||2013-07-24|2013-07-25|Estimate|February 2008||2008-02-29|July 2013|2013-07-31||||July 2013|Actual|2013-07-31||Observational|||FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy|FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy|Completed|||54|Actual|University Health Network, Toronto|||2||f||||f||||||Samples With DNA|"~     Whole Blood Plasma Liver tissue from biopsy~   "|||2018-06-01 02:30:51.039866|2018-06-01 02:30:51.039866
NCT00606515|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2009-02-09|2008-01-31|2008-02-04|Estimate|||||||2009-02-09|2009-02-10|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|LPS-PK-H||Pharmacokinetics Study of Liposomal Paclitaxel in Humans|A Clinical Trial to Compare the Pharmacokinetics of Two Formulations of Taxane, Paclitaxel Injection and Liposomal Paclitaxel, in Humans|Completed||Phase 4|16|Anticipated|Shandong Luye Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:30:51.142759|2018-06-01 02:30:51.142759
NCT00606502|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2010-12-22||2015-06-02|2008-02-01|2008-02-04|Estimate|2010-12-22|2011-01-20|Estimate||||2015-06-02|2015-06-30|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|August 2011|Actual|2011-08-31|May 2010|Actual|2010-05-31||Interventional|||Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment|A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment|Completed||Phase 2|201|Actual|Spectrum Pharmaceuticals, Inc|The date of the CRF database cut-off for patients (no further case report form or query data entry) was 24 Jun 2010. As of the CRF data cut-off date, 3 patients, remained on therapy.|2|||f||||||||||||||2018-06-01 02:30:51.30612|2018-06-01 02:30:51.30612
NCT00606489|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2011-04-04||2011-07-18|2008-02-01|2008-02-04|Estimate|2011-07-18|2011-08-11|Estimate||||2011-07-18|2011-08-11|Estimate|November 2007||2007-11-30|July 2011|2011-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients|A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Ibuprofen Injection (IVIb) for Treatment of Fever and Pain in Burn Patients|Completed||Phase 3|61|Actual|Cumberland Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:30:52.124336|2018-06-01 02:30:52.124336
NCT00605436|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-01-30|2008-01-30|2008-01-31|Estimate|||||||2008-01-30|2008-01-31|Estimate|October 2006||2006-10-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Yoga for the Treatment of Metabolic Syndrome|Restorative Yoga for Therapy of the Metabolic Syndrome: A Pilot Trial|Completed||Phase 1|26|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:31:09.112817|2018-06-01 02:31:09.112817
NCT00606476|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11||2013-10-30|2013-10-30|2008-01-22|2008-02-04|Estimate||||2013-10-30|2013-11-25|Estimate|2013-10-30|2013-11-25|Estimate|December 2006||2006-12-31|August 2012|2012-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease|A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102|Terminated||Phase 2|194|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||3|||f||||t||||||||||2018-06-01 02:30:52.612643|2018-06-01 02:30:52.612643
NCT00606463|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2017-04-21|2008-02-01|2008-02-04|Estimate|||||||2017-04-21|2017-04-25|Actual|February 2008||2008-02-29|April 2017|2017-04-30|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Gen2 Isthmus-Dependent Atrial Flutter Ablation Study|Gen2 Cardiac Ablation System Isthmus-Dependent Atrial Flutter Study|Completed||N/A|30|Actual|St. Jude Medical||1|||f||||f||t|t|f||||No||2018-06-01 02:30:52.785765|2018-06-01 02:30:52.785765
NCT00606450|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2017-09-18|2008-02-01|2008-02-04|Estimate|||||||2017-09-18|2017-09-19|Actual|April 1, 2006|Actual|2006-04-01|September 2017|2017-09-30|May 1, 2007|Actual|2007-05-01|February 1, 2007|Actual|2007-02-01||Interventional|PSOR-003||Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Comparison Study of CC-10004 in Subjects With Moderate-to-Severe Plaque-Type Psoriasis|Completed||Phase 2|260|Actual|Celgene||3|||f||||t||||||||||2018-06-01 02:30:52.911825|2018-06-01 02:30:52.911825
NCT00606437|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2014-05-15|2008-01-22|2008-02-04|Estimate|||||||2014-05-15|2014-05-16|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants|Total Body Irradiation With Fludarabine Conditioning Followed by Transplantation With Combined Umbilical Cord Blood Grafts|Completed||Phase 1|40|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:30:53.108051|2018-06-01 02:30:53.108051
NCT00606424|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2009-01-29|2008-02-01|2008-02-04|Estimate|||||||2009-01-29|2009-02-02|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|HX4||An Exploratory, Open Label, Single Center Study of [F-18]HX4|An Exploratory, Open Label, Single Center Study of [F-18]HX4|Completed||Early Phase 1|10|Anticipated|Siemens Molecular Imaging|||||f||||f||||||||||2018-06-01 02:30:53.218041|2018-06-01 02:30:53.218041
NCT00606411|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2018-03-20|2008-02-01|2008-02-04|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2008||2008-01-31|March 2018|2018-03-31||||June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder|Recruiting||Early Phase 1|40|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:30:53.297154|2018-06-01 02:30:53.297154
NCT00606398|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2014-01-24|2008-02-01|2008-02-04|Estimate|||||||2014-01-24|2014-01-27|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2007|Actual|2007-12-31||Interventional|CRC||Combined Resection of Colorectal Metastases|Combined Resection of Intra- and Extra-Hepatic Metastases From Colorectal Cancer: A Phase II Trial|Completed||Phase 2|56|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 02:30:53.477212|2018-06-01 02:30:53.477212
NCT00606385|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2016-10-27|2008-02-01|2008-02-04|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2007||2007-12-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|HCC||Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC|Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for Patients With Hepatocellular Carcinoma|Enrolling by invitation||N/A|84|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-06-01 02:30:53.574015|2018-06-01 02:30:53.574015
NCT00606372|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2008-01-22|2008-01-22|2008-02-04|Estimate|||||||2008-01-22|2008-02-04|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|December 2009|Anticipated|2009-12-31|December 2008|Actual|2008-12-31||Observational|PRAGUE 6+||On-Pump vs. Off-Pump CABG in High-Risk Patients (EuroSCORE 6+)|Aortocoronary Bypasses in High-Risk Patients (EuroSCORE 6+) With or Without Use of the Cardio-Pulmonary Bypass.|Unknown status|Enrolling by invitation||220|Anticipated|Charles University, Czech Republic|||2||f||||t||||||||||2018-06-01 02:30:53.701089|2018-06-01 02:30:53.701089
NCT00606359|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2014-01-10|2008-01-31|2008-02-01|Estimate|||||||2014-01-10|2014-01-14|Estimate|November 2007||2007-11-30|January 2014|2014-01-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects|Immunogenicity of the Inactivated Split-Virion Influenza Vaccine Administered by the Intradermal Route in Renal Transplant Subjects|Completed||Phase 2|62|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:30:53.810363|2018-06-01 02:30:53.810363
NCT00606346|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2018-05-30|2008-01-21|2008-02-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 17, 2007|Actual|2007-05-17|May 2018|2018-05-31|June 30, 2038|Anticipated|2038-06-30|June 30, 2038|Anticipated|2038-06-30||Observational|DEVELOP||A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease|A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease|Active, not recruiting|||4954|Actual|Janssen Biotech, Inc.|||2||f||||t||f||||||||2018-06-01 02:30:53.916176|2018-06-01 02:30:53.916176
NCT00606333|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2012-10-24|2008-01-31|2008-02-01|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2008||2008-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|May 2009|Actual|2009-05-31||Interventional|NEVO RES-I||Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions|A Randomized, Multi-Center, Single-Blind Comparison of the Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Versus the TAXUS Liberte Paclitaxel-eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|Terminated||N/A|394|Actual|Cordis Corporation||2||"The NEVO™ stent will not be commercialized. Cordis have decided to close the study after 3~   years. This decision took the absence of safety signals into account."|f||||t||||||||||2018-06-01 02:30:54.13744|2018-06-01 02:30:54.13744
NCT00606320|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|2013-11-28||2014-01-16|2008-01-31|2008-02-01|Estimate|2014-01-16|2014-02-12|Estimate||||2014-01-16|2014-02-12|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||"Full Analysis Population(FAS)：Excluding the following subjects from the randomized subjects:~3 subjects with GCP violation~1 subject whose post dose efficacy were not available"|A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|Completed||Phase 3|59|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 02:30:54.440689|2018-06-01 02:30:54.440689
NCT00606307|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2013-05-23|2008-01-21|2008-02-01|Estimate|||||||2013-05-23|2013-05-24|Estimate|December 2007||2007-12-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases|A Phase IIA Study of the Histone-deacetylase Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases|Completed||Phase 2|29|Actual|Italfarmaco||1|||f||||f||||||||||2018-06-01 02:30:54.720573|2018-06-01 02:30:54.720573
NCT00606294|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2018-03-05|2008-01-21|2008-02-01|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2004|Actual|2004-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients|A Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients|Active, not recruiting||N/A|216|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-06-01 02:30:54.807453|2018-06-01 02:30:54.807453
NCT00606281|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|2013-11-28||2014-01-16|2008-01-31|2008-02-01|Estimate|2014-01-16|2014-02-12|Estimate||||2014-01-16|2014-02-12|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||"Full Analysis Population(FAS)：~Excluding the following subjects from the randomized subjects:~2 subjects who did not take the study medication (Aripipirazole:1, Placebo:1)~8 subjects with GCP violation (Aripipirazole:5, Placebo:3)~1 subject whose post dose efficacy were not available (Placebo:1)"|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|Completed||Phase 3|258|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:30:54.958419|2018-06-01 02:30:54.958419
NCT00606268|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2014-08-19|2008-01-31|2008-02-01|Estimate|||||||2014-08-19|2014-08-21|Estimate|November 2007||2007-11-30|August 2014|2014-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant|A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin as an Antifungal Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplant|Completed||Phase 1|42|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:30:55.443306|2018-06-01 02:30:55.443306
NCT00606255|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2008-01-31|2008-01-31|2008-02-01|Estimate|||||||2008-01-31|2008-02-01|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Observational|CAT||Compliance of Antihypertensive Treatment Study (CAT Study)|Compliance of Antihypertensive Treatment Study|Unknown status|Active, not recruiting||1062|Anticipated|The Catholic University of Korea|||3||f||||t||||||||||2018-06-01 02:30:55.548468|2018-06-01 02:30:55.548468
NCT00606242|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2014-03-06|2008-01-21|2008-02-01|Estimate|||||||2014-03-06|2014-03-10|Estimate|January 2000||2000-01-31|March 2014|2014-03-31|December 2007|Actual|2007-12-31|December 2002|Actual|2002-12-31||Interventional|FluSAL||Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma|A Randomized Double Blind Study of the Dose Response Effects of Fluticasone Propionate on Hypertonic-saline Induced Bronchoconstriction in Asthmatic Subjects|Completed||Phase 4|44|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:30:55.609198|2018-06-01 02:30:55.609198
NCT00606229|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|2013-12-19||2014-02-11|2008-01-31|2008-02-01|Estimate|2014-02-11|2014-03-13|Estimate||||2014-02-11|2014-03-13|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Results obtained from the LOCF dataset of 40 subjects of the Full Analysis Set (FAS) (excluding 1 subject whose post-dose data of efficacy endpoint were not available from the 41 treated subjects)|A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|Completed||Phase 3|41|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 02:30:55.707267|2018-06-01 02:30:55.707267
NCT00606216|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2015-12-09|2008-01-31|2008-02-01|Estimate|||||||2015-12-09|2015-12-10|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy|Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy|Completed|||66|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 02:30:55.905977|2018-06-01 02:30:55.905977
NCT00606203|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2008-10-15|2008-01-31|2008-02-01|Estimate|||||||2008-10-15|2008-10-17|Estimate|September 2007||2007-09-30|October 2008|2008-10-31|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke?||Unknown status|Recruiting|N/A|120|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-06-01 02:30:55.986731|2018-06-01 02:30:55.986731
NCT00606190|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-02-15|2008-01-31|2008-02-01|Estimate|||||||2017-02-15|2017-02-17|Actual|June 2003||2003-06-30|February 2017|2017-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Prospective Randomized Study of Brain Protection During Aortic Arch Replacement|Prospective Randomized Study of Brain Protection During Aortic Arch Replacement|Completed||N/A|123|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-06-01 02:30:56.081294|2018-06-01 02:30:56.081294
NCT00606177|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|2013-11-28||2014-01-16|2008-01-31|2008-02-01|Estimate|2014-01-16|2014-02-12|Estimate||||2014-01-16|2014-02-12|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||"Full Analysis Population(FAS)：Excluding 3 subject with GCP violation from the randomized subjects.~(Aripiprazole:1, Placebo:2)"|A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode|Completed||Phase 3|99|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:30:56.284495|2018-06-01 02:30:56.284495
NCT00523887|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2010-04-26|2007-08-30|2007-09-03|Estimate|||||||2010-04-26|2010-04-28|Estimate|August 2005||2005-08-31|April 2010|2010-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Fentanyl for Treatment Pain Caused by Radiotherapy|Post-Marketing Surveillance of Durogesic for Treatment Pain Caused by Radiotherapy|Completed||Phase 4|163|Actual|Johnson & Johnson Taiwan Ltd|||||f||||||||||||||2018-06-01 02:57:39.534253|2018-06-01 02:57:39.534253
NCT00606164|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2008-01-21|2008-01-21|2008-02-01|Estimate|||||||2008-01-21|2008-02-01|Estimate|April 2008||2008-04-30|January 2008|2008-01-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Mild to Moderate Alzheimer's Disease|Unknown status|Not yet recruiting|Phase 2|9|Anticipated|Blanchette Rockefeller Neurosciences Insitute||3|||f||||f||||||||||2018-06-01 02:30:56.725274|2018-06-01 02:30:56.725274
NCT00606151|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2009-03-25|2008-01-31|2008-02-01|Estimate|||||||2009-03-25|2009-03-26|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||PeriOperative Bridging - Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents|Short-Term Outcomes of Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents|Terminated|||60|Anticipated|The Cleveland Clinic||||subject enrollment goals not met|f||||f||||||||||2018-06-01 02:30:56.851222|2018-06-01 02:30:56.851222
NCT00606138|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2012-12-07||2014-11-04|2008-01-31|2008-02-01|Estimate|2014-11-04|2014-11-06|Estimate||||2014-11-04|2014-11-06|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging|Investigation of Ranibizumab for the Treatment of Persistent Diabetic Neovascularization as Assessed by Super Wide-Field Angiography (Optos)|Completed||Phase 1/Phase 2|8|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 02:30:56.928372|2018-06-01 02:30:56.928372
NCT00606125|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2014-06-20|2008-01-31|2008-02-01|Estimate|||||||2014-06-20|2014-06-23|Estimate|May 2007||2007-05-31|June 2014|2014-06-30|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors|Phase I Study With Sorafenib in Combination With Carboplatin and Paclitaxel to Evaluate the Safety and Pharmacokinetics of This Combination in Patients With Solid Tumors|Completed||Phase 1|16|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:30:57.236072|2018-06-01 02:30:57.236072
NCT00606112|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2009-04-14|2008-01-21|2008-02-01|Estimate|||||||2009-04-14|2009-04-15|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|June 2008|Actual|2008-06-30||Interventional|||A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers|A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese Type 2 Diabetics|Completed||Phase 1|28|Actual|Genaera Corporation||4|||f||||f||||||||||2018-06-01 02:30:57.30903|2018-06-01 02:30:57.30903
NCT00606099|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2012-05-01|2008-01-31|2008-02-01|Estimate|||||||2012-05-01|2012-05-02|Estimate|November 2007||2007-11-30|May 2012|2012-05-31||||November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B|A 26 Week Randomized, Open Label, Multi-center Study of the Efficacy and Safety of Telbivudine 600 mg Once Daily Versus Adefovir Dipivoxil 10mg Once Daily in Subjects With Compensated Chronic Hepatitis B and Sub-optimal Response to at Least 48 Weeks of Adefovir Dipivoxil 10 mg|Withdrawn||Phase 4|0|Actual|Novartis||2||study was cancelled|f||||||||||||||2018-06-01 02:30:57.378794|2018-06-01 02:30:57.378794
NCT00606086|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2014-05-05||2014-06-17|2008-01-30|2008-02-01|Estimate|2014-05-05|2014-06-03|Estimate||||2014-06-17|2014-06-27|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection|A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone, and GI-5005 Salvage of Standard of Care Failures, in Patients With Genotype 1 Chronic Hepatitis C Infection|Completed||Phase 2|140|Actual|GlobeImmune||2|||f||||t||||||||||2018-06-01 02:30:57.479682|2018-06-01 02:30:57.479682
NCT00606073|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2008-01-21|2008-01-21|2008-02-01|Estimate|||||||2008-01-21|2008-02-01|Estimate|February 2008||2008-02-29|January 2008|2008-01-31||||August 2009|Anticipated|2009-08-31||Interventional|||The Influence of Different Concentrations of Glucose in Culture Media on Fertilization and Embryo Quality|The Influence of Different Concentrations of Glucose in Culture Media(i.e: ISM1 vs. IVF) on Fertilization and Embryo Quality|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||4|||f||||t||||||||||2018-06-01 02:30:58.816143|2018-06-01 02:30:58.816143
NCT00606060|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2010-04-12|2008-01-31|2008-02-01|Estimate|||||||2010-04-12|2010-04-13|Estimate|July 2004||2004-07-31|April 2010|2010-04-30|May 2005|Actual|2005-05-31|||||Interventional|||BAY14-2222 Continuous Infusion in Surgeries|Safety and Efficacy of Continuous Infusion of Recombinant Factor VIII - Sucrose-formulated (BAY 14 2222) Concentrate in Patients With Hemophilia A Undergoing Major Elective Surgery.|Completed||Phase 3|15|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:30:58.87701|2018-06-01 02:30:58.87701
NCT00606047|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2018-04-13|2008-01-31|2008-02-01|Estimate|||||||2018-04-13|2018-04-17|Actual|August 1, 2007|Actual|2007-08-01|April 2018|2018-04-30|February 13, 2017|Actual|2017-02-13|February 2017|Actual|2017-02-28||Observational|||Prevalence of Femoroacetabular Impingement in Asymptomatic Patients|Prevalence of Femoroacetabular Impingement in Asymptomatic Patients|Completed|||200|Actual|Ottawa Hospital Research Institute|||1||f||||f|f|f||||||||2018-06-01 02:30:58.959782|2018-06-01 02:30:58.959782
NCT00606034|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|2012-07-26||2014-01-07|2008-01-31|2008-02-01|Estimate|2013-11-08|2013-12-30|Estimate||||2014-01-07|2014-02-06|Estimate|December 2007||2007-12-31|January 2014|2014-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod|A Prospective Trial of U500 Regular Insulin by Continuous Subcutaneous Insulin Infusion in Patients With Type 2 Diabetes and Severe Insulin Resistance Who Have Failed Previous Insulin Regimens|Completed||Phase 4|21|Actual|Mountain Diabetes and Endocrine Center|Small sample size. Also an uncontrolled pilot study.|1|||f||||f||||||||||2018-06-01 02:30:59.041738|2018-06-01 02:30:59.041738
NCT00606021|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2011-10-03||2011-11-21|2008-01-31|2008-02-01|Estimate|2011-11-21|2011-12-26|Estimate||||2011-11-21|2011-12-26|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 2|106|Actual|Eli Lilly and Company|Due to a mistake in the randomization parameters form, the randomization was actually implemented in the ratio of 1:1 instead of the planned ratio of 2:1.|2|||f||||||||||||||2018-06-01 02:30:59.387339|2018-06-01 02:30:59.387339
NCT00606008|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|2012-10-02||2012-11-13|2008-01-31|2008-02-01|Estimate|2012-10-02|2012-10-31|Estimate||||2012-11-13|2012-11-19|Estimate|March 2007||2007-03-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma|A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme|Completed||Phase 2|30|Actual|H. Lee Moffitt Cancer Center and Research Institute|No definitive conclusions can be made regarding outcome differences between bevacizumab vs. bevacizumab-naive study patients, due to not enough patients who received bevacizumab prior to study enrollment (2 AA, 3 GB).|1|||f||||t||||||||||2018-06-01 02:31:00.207329|2018-06-01 02:31:00.207329
NCT00605995|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2017-01-12|2008-01-31|2008-02-01|Estimate|||||||2017-01-12|2017-03-24|Actual|February 2008||2008-02-29|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ASSIST||Add-on Simvastatin in Schizophrenia Trial|Add-on Simvastatin in Schizophrenia Trial|Terminated||N/A|15|Actual|New York State Psychiatric Institute||2||"Enrollment was slower than anticipated by the investigators and the funding research~   foundation."|f||||f||||||||||2018-06-01 02:31:00.709814|2018-06-01 02:31:00.709814
NCT00605982|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2017-11-01|2008-01-21|2008-02-01|Estimate|||||||2017-11-01|2017-11-06|Actual|October 10, 2006||2006-10-10|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Breast MRI as a Preoperative Tool for DCIS|Breast MRI as a Preoperative Tool for DCIS|Active, not recruiting||N/A|115|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:31:00.837654|2018-06-01 02:31:00.837654
NCT00605969|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2017-04-03|2008-01-31|2008-02-01|Estimate|||||||2017-04-03|2017-04-05|Actual|May 2007||2007-05-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Dynamic Imaging of the Hip for Pre-operative Planning|Hip Reconstruction and Modeling for Surgical Pre-Operative Planning|Completed||N/A|30|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 02:31:00.948162|2018-06-01 02:31:00.948162
NCT00605956|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|||2008-07-31|2008-01-31|2008-02-01|Estimate|||||||2008-07-31|2008-08-04|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers|An Evaluation of the Photoallergy Potential of NatrOVA Creme Rinse - 1% in Healthy Volunteers|Completed||Phase 1|65|Anticipated|ParaPRO LLC||3|||f||||f||||||||||2018-06-01 02:31:01.14393|2018-06-01 02:31:01.14393
NCT00605943|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2017-06-30|2008-01-23|2008-01-31|Estimate|||||||2017-06-30|2017-07-02|Actual|January 16, 2008||2008-01-16|August 4, 2009|2009-08-04|August 4, 2009|Actual|2009-08-04|August 4, 2009|Actual|2009-08-04||Observational|||Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab|Pilot Study for the Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab Avastin or Ranibizumab Lucentis|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:31:01.248197|2018-06-01 02:31:01.248197
NCT00605930|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-04-06|2008-01-18|2008-01-31|Estimate|||||||2017-04-06|2017-04-10|Actual|April 2004||2004-04-30|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.|Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.|Completed||N/A|20|Actual|University of Louisville||2|||f||||f||||||||||2018-06-01 02:31:01.316329|2018-06-01 02:31:01.316329
NCT00605917|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2012-08-20||2012-08-20|2008-01-30|2008-01-31|Estimate|2012-08-20|2012-09-21|Estimate||||2012-08-20|2012-09-21|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Special Investigation Of J Zoloft For Panic Disorder Patients|Special Investigation Of J Zoloft For Panic Disorder Patients|Completed|||997|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:31:01.45908|2018-06-01 02:31:01.45908
NCT00605904|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-30|2011-09-21||2012-05-23|2008-01-30|2008-01-31|Estimate|2012-05-23|2012-07-03|Estimate||||2012-05-23|2012-07-03|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics|Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics|Completed||Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 02:31:02.071271|2018-06-01 02:31:02.071271
NCT00605891|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2017-04-07|2008-01-18|2008-01-31|Estimate|||||||2017-04-07|2017-04-11|Actual|October 2006||2006-10-31|April 2017|2017-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Dose Finding Study of CHF 4226 for Treating Patients With COPD|A Randomized, Controlled,14-Treatment Day, Multicenter Study to Determine the Optimal Efficacious and Safe Dose of CHF 4226 in a Metered Dose Inhaler in Treating Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|278|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||f||||||||||2018-06-01 02:31:02.626038|2018-06-01 02:31:02.626038
NCT00605878|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2018-03-27|2008-01-26|2008-01-31|Estimate|||||||2018-03-27|2018-03-29|Actual|January 22, 2008||2008-01-22|February 2, 2018|2018-02-02||||||||Observational|||Studies of Skin Microbes in Healthy People and in People With Skin Conditions|Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients|Recruiting|||530|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:31:02.791934|2018-06-01 02:31:02.791934
NCT00605865|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2012-08-28||2012-08-28|2008-01-30|2008-01-31|Estimate|2012-08-28|2012-10-01|Estimate||||2012-08-28|2012-10-01|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Drug Use Investigation of Jzoloft.|Drug Use Investigation of Jzoloft.|Completed|||2272|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:31:02.905854|2018-06-01 02:31:02.905854
NCT00605852|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2017-08-16|2008-01-18|2008-01-31|Estimate|||||||2017-08-16|2017-08-21|Actual|October 29, 2007|Actual|2007-10-29|August 2017|2017-08-31|May 3, 2008|Actual|2008-05-03|May 3, 2008|Actual|2008-05-03||Interventional|||Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects|A Double-blind, Placebo-controlled, Randomized Cross-over Single Dose Escalation Study and a Double-blind, Placebo-controlled, Randomised Parallel Group 7-days Once Daily Repeat Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral H1/H3 Dual Antagonist Compound in Healthy Male Subjects|Completed||Phase 1|29|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:31:03.729232|2018-06-01 02:31:03.729232
NCT00605839|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2012-09-12||2017-09-11|2008-01-30|2008-01-31|Estimate|2013-09-17|2013-11-20|Estimate||||2017-09-11|2017-10-11|Actual|January 2008||2008-01-31|September 2017|2017-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Mobile Communication Technology for Adolescents With Diabetes|Adapting Mobile Communication Technology to Improve the Management of Adolescents With Diabetes|Completed||N/A|105|Actual|Indiana University|This was a small pilot study to generate results for further work.|3|||f||||f||||||||||2018-06-01 02:31:03.879301|2018-06-01 02:31:03.879301
NCT00605826|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2011-07-13|2008-01-30|2008-01-31|Estimate|||||||2011-07-13|2011-07-15|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|December 2009|Actual|2009-12-31||Interventional|||A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence|A Randomized, Subject and Evaluator Blinded, Sham Controlled, Multicenter Study to Evaluate Efficacy and Safety of NASHA/Dx for the Treatment of Fecal Incontinence|Unknown status|Active, not recruiting|N/A|200|Anticipated|Q-Med Scandinavia, Inc.||2|||f||||f||||||||||2018-06-01 02:31:04.180717|2018-06-01 02:31:04.180717
NCT00605813|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2012-08-09||2012-08-09|2008-01-30|2008-01-31|Estimate|2012-08-09|2012-09-10|Estimate||||2012-08-09|2012-09-10|Estimate|September 2007||2007-09-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Special Investigation Of Long Term Use Of Sertraline.|Special Investigation Of Long Term Use Of J ZOLOFT.|Completed|||542|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:31:04.299319|2018-06-01 02:31:04.299319
NCT00605800|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2009-03-18|2008-01-30|2008-01-31|Estimate|||||||2009-03-18|2009-03-19|Estimate|March 2006||2006-03-31|March 2009|2009-03-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Observational|||Bone Marrow Derived Adult Liver Stem Cell Recruitment After Major Liver Resections: Correlation With Liver Regeneration and Hepatic Function|Bone Marrow Derived Adult Liver Stem Cell Recruitment After Major Liver Resections: Correlation With Liver Regeneration and Hepatic Function|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center|||2|Study was closed due to logistical issues.|f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:31:04.600131|2018-06-01 02:31:04.600131
NCT00605787|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-17|2008-01-17|2008-01-31|Estimate|||||||2008-01-17|2008-01-31|Estimate|January 2002||2002-01-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|June 2003|Actual|2003-06-30||Interventional|TODDY||TTA in Treatment of Diabetes and Dyslipidemia|TTA in Treatment of Diabetes and Dyslipidemia|Completed||Phase 2|16|Actual|Haukeland University Hospital||1|||f||||t||||||||||2018-06-01 02:31:04.674809|2018-06-01 02:31:04.674809
NCT00605774|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2014-12-10|2008-01-18|2008-01-31|Estimate|||||||2014-12-10|2014-12-11|Estimate||||December 2014|2014-12-31||||||||Interventional|||Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q5|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 5|Withdrawn||N/A|0|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:31:04.75328|2018-06-01 02:31:04.75328
NCT00605761|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2012-03-15|2008-01-18|2008-01-31|Estimate|||||||2012-03-15|2012-03-19|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||SD Cystic Fibrosis Study|An Open Label Dose Ascending, Single Dose Study to Investigate the Pharmacokinetics of SB-656933 in Subjects With Cystic Fibrosis.|Completed||Phase 1|9|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:31:04.817737|2018-06-01 02:31:04.817737
NCT00605748|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2008-08-26|2008-01-18|2008-01-31|Estimate|||||||2008-08-26|2008-08-27|Estimate|December 2007||2007-12-31|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|PAVAV||Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins|PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins|Unknown status|Recruiting|Phase 4|212|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:31:04.906074|2018-06-01 02:31:04.906074
NCT00605735|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18||2010-09-10|2015-09-23|2008-01-18|2008-01-31|Estimate||||2010-09-13|2010-09-15|Estimate|2015-09-23|2015-10-12|Estimate|March 2008||2008-03-31|September 2015|2015-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||PoC in Rheumatoid Arthritis With Methotrexate|A Randomized, Parallel Group, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects With Rheumatoid Arthritis Having an Inadequate Response to Methotrexate|Completed||Phase 2|121|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 02:31:05.001748|2018-06-01 02:31:05.001748
NCT00605722|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2014-06-12||2014-06-12|2008-01-18|2008-01-31|Estimate|2014-06-12|2014-07-14|Estimate||||2014-06-12|2014-07-14|Estimate|March 2008||2008-03-31|June 2014|2014-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.|A Single Arm, Open Label Study of First Line Treatment With Tarceva Plus Avastin on Progression-free Survival in Patients With Advanced or Metastatic Liver Cancer|Completed||Phase 2|51|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:31:05.146428|2018-06-01 02:31:05.146428
NCT00605709|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2012-07-24|2008-01-18|2008-01-31|Estimate|||||||2012-07-24|2012-07-25|Estimate|March 2008||2008-03-31|July 2012|2012-07-31||||July 2008|Anticipated|2008-07-31||Interventional|||Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma||Withdrawn||Phase 2|0|Actual|Berg, LLC||4|||f||||t||||||||||2018-06-01 02:31:05.426599|2018-06-01 02:31:05.426599
NCT00605696|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2013-04-16||2018-04-04|2008-01-18|2008-01-31|Estimate|2017-04-06|2017-04-10|Actual||||2018-04-04|2018-05-07|Actual|April 2008||2008-04-30|April 2018|2018-04-30|September 2013|Actual|2013-09-30|December 2011|Actual|2011-12-31||Interventional|||Early Insulin and Development of ARDS|Early Insulin Therapy and Development of Acute Respiratory Distress Syndrome|Completed||Phase 2|18|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||Undecided||2018-06-01 02:31:05.590089|2018-06-01 02:31:05.590089
NCT00605683|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-10-28|2008-01-18|2008-01-31|Estimate|||||||2013-10-28|2013-10-29|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|MOTION||MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist|A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist|Completed||Phase 3|679|Actual|Newron Pharmaceuticals SPA||3|||f||||||||||||||2018-06-01 02:31:05.892851|2018-06-01 02:31:05.892851
NCT00605670|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2013-11-13|2008-01-30|2008-01-31|Estimate|||||||2013-11-13|2013-11-14|Estimate|June 2005||2005-06-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery|Measuring Patient Satisfaction and Quality of Life Following Body Image Altering Surgery: Development and Validation of a Patient-Reported Outcomes Instrument|Completed|||722|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:31:06.175054|2018-06-01 02:31:06.175054
NCT00605657|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2013-02-14||2013-02-14|2008-01-23|2008-01-31|Estimate|2013-02-14|2013-03-21|Estimate||||2013-02-14|2013-03-21|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)|Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)|Completed||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 02:31:06.274026|2018-06-01 02:31:06.274026
NCT00605644|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18||2009-03-02|2011-07-22|2008-01-18|2008-01-31|Estimate||||2009-09-28|2009-09-30|Estimate|2011-07-22|2011-07-28|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain|Completed||Phase 2|120|Actual|Valeant Pharmaceuticals International, Inc.||5|||f||||f||||||||||2018-06-01 02:31:06.509418|2018-06-01 02:31:06.509418
NCT00605631|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-04-04|2008-01-29|2008-01-31|Estimate|||||||2017-04-04|2017-04-05|Actual|May 2005|Actual|2005-05-31|April 2017|2017-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study|The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study|Completed||N/A|105|Actual|Boston Scientific Corporation||3|||f||||t||||||||No||2018-06-01 02:31:06.601185|2018-06-01 02:31:06.601185
NCT00605618|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2011-01-24|2008-01-18|2008-01-31|Estimate|||||||2011-01-24|2011-01-25|Estimate|March 2008||2008-03-31|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors|A Phase I/II Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1/Phase 2|8|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:31:06.701109|2018-06-01 02:31:06.701109
NCT00605605|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2008-01-30|2008-01-30|2008-01-31|Estimate|||||||2008-01-30|2008-01-31|Estimate|March 2005||2005-03-31|January 2008|2008-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Vascular Endothelial Protection Effects of Dextromethorphan|Anti-Inflammation & Vascular Endothelial Protection Effects of Dextromethorphan on Heavy Smoker|Completed||Phase 4|40|Actual|National Cheng-Kung University Hospital||1|||f||||f||||||||||2018-06-01 02:31:06.771678|2018-06-01 02:31:06.771678
NCT00605592|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2009-02-16|2008-01-30|2008-01-31|Estimate|||||||2009-02-16|2009-02-18|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||UVA Islet Cell Transplantation in Patients With Type I Diabetes|UVA Islet Cell Transplantation in Patients With Type I Diabetes|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|University of Virginia||1|||f||||t||||||||||2018-06-01 02:31:06.853068|2018-06-01 02:31:06.853068
NCT00605566|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2016-03-14|2008-01-18|2008-01-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors|Tailored-dose Sorafenib Plus Metronomic Cyclophosphamide in Advanced Neuroendocrine Tumors (NET): a Phase II Clinical Trial Based on Individual Pharmacodynamic Assessment|Completed||Phase 2|22|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 02:31:06.927549|2018-06-01 02:31:06.927549
NCT00605553|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15||2009-12-03|2017-08-03|2008-01-30|2008-01-31|Estimate||||2009-12-03|2009-12-07|Estimate|2017-08-03|2017-08-08|Actual|April 2008||2008-04-30|August 2017|2017-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study to Evaluate SYN115 in Parkinson's Disease|A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease|Completed||Phase 2|30|Actual|Biotie Therapies Inc.||2|||f||||f||||||||||2018-06-01 02:31:07.012117|2018-06-01 02:31:07.012117
NCT00605540|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2009-06-22||2014-09-02|2008-01-18|2008-01-31|Estimate|2014-09-02|2014-09-03|Estimate||||2014-09-02|2014-09-03|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|March 2010|Actual|2010-03-31||Observational|||Chronic Obstructive Pulmonary Disease Markers and Prognosis|Three-years Follow-up of Diagnostic and Prognostic Markers in Chronic Obstructive Pulmonary Disease|Completed|||133|Actual|UPECLIN HC FM Botucatu Unesp|We excluded patients with comorbidities; therefore, many patients seen in clinical practice may not have been well represented in our study.||1||f||||t||||||||||2018-06-01 02:31:07.110265|2018-06-01 02:31:07.110265
NCT00605527|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2015-10-30|2008-01-18|2008-01-31|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|PALI||Understanding the Role of Genes and Biomarkers in the Blood Clotting Process in Children With Acute Lung Injury|Targeted Genomic Analysis of Coagulation Pathways in Acute Lung Injury|Unknown status|Recruiting||450|Anticipated|University of California, San Francisco|||||f||||f||||||Samples With DNA|"~     Blood and plasma samples will be analyzed~   "|||2018-06-01 02:31:07.324528|2018-06-01 02:31:07.324528
NCT00605514|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2017-06-30|2008-01-29|2008-01-31|Estimate|||||||2017-06-30|2017-07-02|Actual|January 25, 2008||2008-01-25|June 21, 2010|2010-06-21|June 21, 2010|Actual|2010-06-21|June 21, 2010|Actual|2010-06-21||Interventional|||Ebola and Marburg Virus Vaccines|VRC 206: A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults|Completed||Phase 1|20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:31:07.413635|2018-06-01 02:31:07.413635
NCT00605488|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-04-07|2008-01-30|2008-01-31|Estimate|||||||2017-04-07|2017-04-10|Actual|April 25, 2006||2006-04-25|April 2017|2017-04-30|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer|Pilot Study Investigating the Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer|Completed||N/A|20|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:31:07.484905|2018-06-01 02:31:07.484905
NCT00605475|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2011-09-01||2012-01-10|2008-01-30|2008-01-31|Estimate|2012-01-10|2012-02-13|Estimate||||2012-01-10|2012-02-13|Estimate|December 2007||2007-12-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes|A Multi Center, Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered Intravenously to Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|231|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:31:07.592255|2018-06-01 02:31:07.592255
NCT00605449|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18||2010-10-14|2010-10-14|2008-01-18|2008-01-31|Estimate||||2010-10-14|2010-10-19|Estimate|2010-10-14|2010-10-19|Estimate|January 2008||2008-01-31|October 2010|2010-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Drug Interaction Study Between Simvastatin and GSK376501|Phase I, Randomized, Open-Label, 3 Period Crossover Drug Interaction Study Between Simvastatin and GSK376501 in Healthy Subjects|Completed||Phase 1|39|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:31:09.019754|2018-06-01 02:31:09.019754
NCT00523874|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2007-08-31|2007-08-31|2007-09-03|Estimate|||||||2007-08-31|2007-09-03|Estimate|January 2001||2001-01-31|January 2001|2001-01-31|May 2007|Actual|2007-05-31|||||Observational|||Recurrence of Acute Alcoholic Pancreatitis|Recurrence of Acute Alcoholic Pancreatitis|Completed|||120|Actual|University of Tampere|||||f||||f||||||||||2018-06-01 02:57:39.595434|2018-06-01 02:57:39.595434
NCT00605423|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2013-09-20||2014-03-10|2008-01-30|2008-01-31|Estimate|2014-03-10|2014-04-07|Estimate||||2014-03-10|2014-04-07|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|MAP||The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot|A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur™ in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis™|Completed||Phase 2|6|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 02:31:09.223871|2018-06-01 02:31:09.223871
NCT00605410|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2009-01-06|2008-01-30|2008-01-31|Estimate|||||||2009-01-06|2009-01-07|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness|Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness|Completed||Phase 4|12|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 02:31:09.543693|2018-06-01 02:31:09.543693
NCT00605397|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2015-12-23|2008-01-30|2008-01-31|Estimate|||||||2015-12-23|2015-12-28|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Cu-64 HER2+||PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer|Pilot Trial of PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer|Completed||Phase 1|11|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:31:09.62299|2018-06-01 02:31:09.62299
NCT00605384|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2010-07-13||2010-11-15|2008-01-30|2008-01-31|Estimate|2010-07-13|2010-08-10|Estimate||||2010-11-15|2010-11-23|Estimate|August 2008||2008-08-31|November 2010|2010-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection|A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Versus Adefovir Added to Continuing Lamivudine in Adults With Lamivudine- Resistant Chronic Hepatitis B Virus Infection|Terminated||Phase 3|4|Actual|Bristol-Myers Squibb|Following review of business priorities, BMS decided to terminate this study at an early stage. This was a strategic decision, not based on clinical or safety concerns. Due to limited data, no conclusions on safety and efficacy can be made.|2||Business Objectives Have Changed|f||||f||||||||||2018-06-01 02:31:09.727027|2018-06-01 02:31:09.727027
NCT00605371|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2017-09-08|2008-01-18|2008-01-31|Estimate|||||||2017-09-08|2017-09-11|Actual|January 15, 2008|Actual|2008-01-15|September 2017|2017-09-30|March 6, 2008|Actual|2008-03-06|March 6, 2008|Actual|2008-03-06||Interventional|||Bioequivalence and Food Effect of 250mg of Lamotrigine XR|A Pivotal, Single-Dose, Randomised, Parallel-Group, Open-Label Study to Demonstrate Bioequivalence of 250mg Lamotrigine XR Relative to 200mg + 50mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 250mg Lamotrigine XR in Healthy Male and Female Volunteers|Completed||Phase 1|209|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:31:10.128079|2018-06-01 02:31:10.128079
NCT00605358|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2016-04-26||2017-01-12|2008-01-18|2008-01-31|Estimate|2017-01-12|2017-03-03|Actual||||2017-01-12|2017-03-03|Actual|August 2007||2007-08-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|OpenDoor||Increasing Use of Mental Health Services|Increasing Use of Mental Health Services by Community Dwelling Adults With Depression|Completed||N/A|161|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||Undecided||2018-06-01 02:31:10.272743|2018-06-01 02:31:10.272743
NCT00605345|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2016-04-19||2016-08-17|2008-01-18|2008-01-31|Estimate|2016-06-24|2016-08-05|Estimate||||2016-08-17|2016-09-23|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.|An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera Versus Darboepoetin Alfa for the Maintenance of Haemoglobin Levels in Renal Transplant Recipients With Chronic Renal Anaemia.|Completed||Phase 3|71|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:31:10.906419|2018-06-01 02:31:10.906419
NCT00605332|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2012-08-03|2008-01-30|2008-01-31|Estimate|||||||2012-08-03|2012-08-06|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|Retrieve||Crux Biomedical IVC Filter - Evaluation of the Crux Inferior Vena Cava Filter System (Retrieve)|"Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System - (Retrieve)"|Completed||Phase 2|88|Actual|Crux Biomedical||1|||f||||t||||||||||2018-06-01 02:31:11.304069|2018-06-01 02:31:11.304069
NCT00605319|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2017-03-17||2018-03-12|2008-01-30|2008-01-31|Estimate|2018-03-12|2018-04-10|Actual||||2018-03-12|2018-04-10|Actual|January 2010||2010-01-31|March 2018|2018-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Toviaz||An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia|An Open Label Study to Measure the Efficacy of Fesoterodine (Toviaz) on Continued Detrusor Overactivity in Patients That Have Undergone Treatment for Bladder Outlet Obstruction|Completed||Phase 4|17|Actual|Weill Medical College of Cornell University|Small Sample size and the nonrandomized and nonblinded administration of the drug.|1|||f||||f||||||||No|No plan to share data|2018-06-01 02:31:11.376873|2018-06-01 02:31:11.376873
NCT00605306|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2013-03-11||2013-03-11|2008-01-30|2008-01-31|Estimate|2013-03-11|2013-04-22|Estimate||||2013-03-11|2013-04-22|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Tolerability of 14-days Treatment With an Inhaled Dose of QMF149 (500/800) in Mild to Moderate Asthmatic Patients|Completed||Phase 2|28|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:31:11.744949|2018-06-01 02:31:11.744949
NCT00605293|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2016-04-08||2016-04-08|2008-01-18|2008-01-31|Estimate|2016-04-08|2016-05-13|Estimate||||2016-04-08|2016-05-13|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Intent-to-treat (ITT) population included all participants who received at least one dose of C.E.R.A. or epoetin alfa after Week 0, and for whom, data for at least one follow-up variable was available.|A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia|An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. Versus Epoetin Alfa for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Anaemia|Completed||Phase 3|101|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:31:13.270987|2018-06-01 02:31:13.270987
NCT00605280|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2010-11-18||2012-07-05|2008-01-30|2008-01-31|Estimate|2011-03-03|2011-03-30|Estimate||||2012-07-05|2012-07-16|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|November 2009|Actual|2009-11-30||Interventional|||A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.|A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.|Completed||Phase 2/Phase 3|317|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:31:13.814285|2018-06-01 02:31:13.814285
NCT00605267|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2010-11-26||2012-08-03|2008-01-30|2008-01-31|Estimate|2012-08-03|2012-09-06|Estimate||||2012-08-03|2012-09-06|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment|Multi-centre, Randomised, Double-blind, Parallel-group Study to Compare Efficacy and Safety Between Anastrozole (ZD1033) and Tamoxifen in Pre- and Post-operative Administration Under Goserelin Acetate Treatment for Premenopausal Breast Cancer Patients|Completed||Phase 3|197|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:31:15.411689|2018-06-01 02:31:15.411689
NCT00605254|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-26|||2018-04-19|2008-01-26|2008-01-31|Estimate|||||||2018-04-19|2018-04-20|Actual|January 24, 2008||2008-01-24|September 4, 2014|2014-09-04|September 4, 2014||2014-09-04|||||Observational|||PET Imaging of P-glycoprotein Function Using [11C]dLop|Brain and Whole Body Imaging of P-Glycoprotein Function Using [11C]dLop|Completed|||58|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:31:16.152406|2018-06-01 02:31:16.152406
NCT00605241|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2017-07-19|2008-01-18|2008-01-31|Estimate|||||||2017-07-19|2017-07-21|Actual|February 25, 2008|Actual|2008-02-25|July 2017|2017-07-31|March 20, 2009|Actual|2009-03-20|March 20, 2009|Actual|2009-03-20||Interventional|||A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward|A Randomized, Double-bind, Placebo Controlled, Two-way Cross-over Study to Assess the Effects of a Single Dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward|Completed||Phase 1|29|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:31:16.249435|2018-06-01 02:31:16.249435
NCT00605228|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-29|2008-01-29|2008-01-30|Estimate|||||||2008-01-29|2008-01-30|Estimate|May 2007||2007-05-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|NORMO||A Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation|A Randomised, Multicentre, Single-Blind, Phase IV Study, of the Efficacy, Safety, and Acceptability of Moviprep® Versus Colopeg® in Colonoscopy Preparation.|Completed||Phase 4|400|Actual|Norgine||2|||f||||f||||||||||2018-06-01 02:31:16.374214|2018-06-01 02:31:16.374214
NCT00605215|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08||2013-08-16|2013-08-16|2008-01-17|2008-01-30|Estimate||||2013-08-16|2013-08-26|Estimate|2013-08-16|2013-08-26|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|BRAVO||BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)|A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With RRMS to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design.|Completed||Phase 3|1331|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 02:31:16.523466|2018-06-01 02:31:16.523466
NCT00605202|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2009-08-13||2009-12-10|2008-01-29|2008-01-30|Estimate|2009-12-07|2009-12-09|Estimate||||2009-12-10|2009-12-15|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effect of Licorice and Hydrochlorothiazide on Plasma Potassium|Effect of Licorice and Hydrochlorothiazide on Plasma Potassium|Completed||Phase 4|10|Actual|University of Oulu||2|||f||||f||||||||||2018-06-01 02:31:16.858348|2018-06-01 02:31:16.858348
NCT00605189|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-10-10|2008-01-29|2008-01-30|Estimate|||||||2013-10-10|2013-10-14|Estimate|July 2007||2007-07-31|October 2013|2013-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Trial Examining Cellular Energetics Related to Various Wound Treatment Therapies|A Randomized, Controlled Trial Examining Cellular Energetics Related To Various Wound Treatment Therapies|Terminated||N/A|26|Actual|KCI USA, Inc.||2||Study no longer met business objectives|f||||f||||||||||2018-06-01 02:31:17.045699|2018-06-01 02:31:17.045699
NCT00605176|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2010-04-15||2010-06-22|2008-01-28|2008-01-30|Estimate|2010-05-25|2010-06-22|Estimate||||2010-06-22|2010-06-29|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)|A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Four Weeks of Treatment With Imiquimod Creams for Actinic Keratoses|Completed||Phase 3|479|Actual|Graceway Pharmaceuticals, LLC||3|||f||||f||||||||||2018-06-01 02:31:17.187858|2018-06-01 02:31:17.187858
NCT00605163|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-03-26|2008-01-17|2008-01-30|Estimate|||||||2008-03-26|2008-03-28|Estimate|August 2006||2006-08-31|March 2008|2008-03-31||||August 2010|Anticipated|2010-08-31||Observational|PostCEPT||A Longitudinal Observational Follow-up of the PRECEPT Study Cohort|A Longitudinal Observational Follow-up of the PRECEPT Study Cohort|Unknown status|Enrolling by invitation||530|Anticipated|The Parkinson Study Group|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:31:17.698506|2018-06-01 02:31:17.698506
NCT00605150|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2013-08-23||2017-07-31|2008-01-16|2008-01-30|Estimate|2015-02-03|2015-02-16|Estimate||||2017-07-31|2017-08-29|Actual|January 2008||2008-01-31|July 2017|2017-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC|A Humanitarian Device Exemption (HDE) Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma|Completed|||11|Actual|Carolinas Healthcare System|||1||f||||t||||||||||2018-06-01 02:31:17.854199|2018-06-01 02:31:17.854199
NCT00605137|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-02-22|2008-01-23|2008-01-30|Estimate|||||||2017-02-22|2017-02-24|Actual|May 21, 2004|Actual|2004-05-21|February 2017|2017-02-28|April 23, 2005|Actual|2005-04-23|April 23, 2005|Actual|2005-04-23||Interventional|||Safety of Insulin Detemir in Children With Type 1 Diabetes|Safety of Insulin Detemir and Insulin NPH in Children With Type 1 Diabetes Mellitus|Completed||Phase 3|83|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:31:18.017474|2018-06-01 02:31:18.017474
NCT00605124|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2013-03-04|2008-01-16|2008-01-30|Estimate|||||||2013-03-04|2013-03-05|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Progressive Exercise After Total Knee Arthroplasty (TKA)|Progressive Exercise After Total Knee Arthroplasty: A Randomised Controlled Trial|Completed||N/A|120|Actual|Jyväskylä Central Hospital||2|||f||||f||||||||||2018-06-01 02:31:18.101453|2018-06-01 02:31:18.101453
NCT00605111|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2017-01-10|2008-01-18|2008-01-30|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2003||2003-12-31|January 2017|2017-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes|Efficacy and Safety of Initiation of Biphasic Insulin Aspart 30 Treatment in Subjects With Type 2 Diabetes Mellitus Failing OAD Therapy|Completed||Phase 4|193|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:31:18.207564|2018-06-01 02:31:18.207564
NCT00605098|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2013-10-25|2008-01-17|2008-01-30|Estimate|||||||2013-10-25|2013-10-28|Estimate|February 2008||2008-02-29|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy|Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy in HIV-infected Women|Completed||Phase 4|60|Actual|Oswaldo Cruz Foundation||2|||f||||f||||||||||2018-06-01 02:31:18.323059|2018-06-01 02:31:18.323059
NCT00605085|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2012-06-01||2012-10-19|2008-01-16|2008-01-30|Estimate|2012-10-19|2012-11-20|Estimate||||2012-10-19|2012-11-20|Estimate|October 2005||2005-10-31|October 2012|2012-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Safety and Tolerability of the Japanese Encephalitis Vaccine IC51|Safety and Tolerability of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Placebo Controlled Phase 3 Study|Completed||Phase 3|2675|Actual|Valneva Austria GmbH||2|||f||||||||||||||2018-06-01 02:31:18.415695|2018-06-01 02:31:18.415695
NCT00605072|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2012-12-04||2013-01-14|2008-01-17|2008-01-30|Estimate|2013-01-14|2013-02-15|Estimate||||2013-01-14|2013-02-15|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|AVEC||The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial|The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)|Completed||Phase 2|53|Actual|University of Southern California|The main limitation is the small sample size. The validity of TCD measurements as an index of cerebral blood flow is based on the assumption that cerebral vessel diameters are constant but we didn't have brain imaging to validate this assumption.|3|||f||||f||||||||||2018-06-01 02:31:18.658049|2018-06-01 02:31:18.658049
NCT00605059|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2010-10-05|2008-01-28|2008-01-30|Estimate|||||||2010-10-05|2010-10-06|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|AV94||Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Terminated||Phase 1|3|Actual|Institute for Neurodegenerative Disorders||1||Scans showed no visual difference between affected subjects & healthy volunteers|f||||f||||||||||2018-06-01 02:31:18.978369|2018-06-01 02:31:18.978369
NCT00605046|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2010-10-05|2008-01-28|2008-01-30|Estimate|||||||2010-10-05|2010-10-06|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|AV151||Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects|Evaluation of [123I] AV151 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease (AD) in Comparison to Healthy Subjects|Terminated||Phase 1|1|Actual|Institute for Neurodegenerative Disorders||1||Scans showed no visual difference between affected subjects & healthy volunteers|f||||f||||||||||2018-06-01 02:31:19.136153|2018-06-01 02:31:19.136153
NCT00605033|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2010-05-27||2016-09-09|2008-01-17|2008-01-30|Estimate|2010-05-27|2010-06-30|Estimate||||2016-09-09|2016-10-21|Estimate|March 2008||2008-03-31|September 2016|2016-09-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)|A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects|Completed||Phase 4|241|Actual|Indivior Inc.||2|||f||||f||||||||||2018-06-01 02:31:19.228644|2018-06-01 02:31:19.228644
NCT00605020|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-06-26|2008-01-17|2008-01-30|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2, 2003|Actual|2003-12-02|June 2017|2017-06-30|March 3, 2005|Actual|2005-03-03|March 3, 2005|Actual|2005-03-03||Interventional|PreFER||Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus|Completed||Phase 3|719|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:31:19.461356|2018-06-01 02:31:19.461356
NCT00605007|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2013-11-20|2008-01-29|2008-01-30|Estimate|||||||2013-11-20|2013-11-21|Estimate|February 2006||2006-02-28|April 2010|2010-04-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|||Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD|The Impact of Corticosteroid-induced Hyperglycemia on Clinical Outcome (Length of Stay, Disposition, APACHE Score, Need for Ventilatory Support and ICU Admission, Mortality) in Patients With COPD Exacerbation|Completed|||450|Actual|Emory University|||||f||||f||||||||||2018-06-01 02:31:19.748278|2018-06-01 02:31:19.748278
NCT00604994|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-13|||2013-08-18|2008-01-29|2008-01-30|Estimate|||||||2013-08-18|2013-08-20|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Observational|LEGS||Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer|Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer|Completed|||761|Actual|Queensland Centre for Gynaecological Cancer|||2||f||||f||||||||||2018-06-01 02:31:19.814425|2018-06-01 02:31:19.814425
NCT00604981|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-29|2008-01-29|2008-01-30|Estimate|||||||2008-01-29|2008-01-30|Estimate|May 2005||2005-05-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Multisystemic Therapy (MST) for Obesity in African American Youth|Adapting Multisystemic Therapy to Improve Food Choices and Health Outcomes in Obese African American Youth|Completed||N/A|49|Actual|Wayne State University||2|||f||||f||||||||||2018-06-01 02:31:19.909458|2018-06-01 02:31:19.909458
NCT00604968|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|2011-01-27||2017-05-15|2008-01-29|2008-01-30|Estimate|2011-04-04|2011-05-02|Estimate||||2017-05-15|2017-06-07|Actual|February 7, 2007|Actual|2007-02-07|May 2017|2017-05-31|October 16, 2009|Actual|2009-10-16|October 16, 2009|Actual|2009-10-16||Interventional|||Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)|Caelyx(R) in Breast Cancer in the Elderly. Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer.|Terminated||Phase 4|25|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:31:20.00029|2018-06-01 02:31:20.00029
NCT00604773|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2010-08-30|2008-01-17|2008-01-30|Estimate|||||||2010-08-30|2010-08-31|Estimate|February 2008||2008-02-29|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Incidence of Delirium in Critically Ill Patients in a Dutch University Hospital|Incidence of Delirium in Critically Ill Patients in a Dutch University Hospital|Completed|||700|Anticipated|Radboud University|||2||f||||f||||||Samples With DNA|"~     blood, urine~   "|||2018-06-01 02:31:24.672433|2018-06-01 02:31:24.672433
NCT00604955|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2014-10-02|2008-01-29|2008-01-30|Estimate|||||||2014-10-02|2014-10-03|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|January 2010|Actual|2010-01-31|December 2008|Actual|2008-12-31||Interventional|||Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis|A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis|Completed||Phase 4|2000|Actual|PATH||1|||f||||t||||||||||2018-06-01 02:31:20.323855|2018-06-01 02:31:20.323855
NCT00604942|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2009-07-31|2008-01-29|2008-01-30|Estimate|||||||2009-07-31|2009-08-03|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|vMII||vMII for Measurement of Oesophageal Bolus Transport and Reflux|Volume Sensitive Multichannel Intraluminal Impedance (vMII) for the Measurement of Oesophageal Bolus Transport and Reflux|Terminated||N/A|140|Anticipated|Guy's and St Thomas' NHS Foundation Trust||4||prototype catheter never delivered|f||||f||||||||||2018-06-01 02:31:20.438615|2018-06-01 02:31:20.438615
NCT00604929|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2015-04-13|2008-01-29|2008-01-30|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2008||2008-08-31|April 2015|2015-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Nutrition on Muscle Protein Synthesis|The Effect of Carbohydrate and Protein Intake on Muscle Protein Synthesis During Endurance Exercise|Completed||N/A|12|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 02:31:20.538273|2018-06-01 02:31:20.538273
NCT00604916|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-01-16|2008-01-16|2008-01-30|Estimate|||||||2008-01-16|2008-01-30|Estimate|March 2007||2007-03-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|VAP||Oral Care Protocol for Preventing Ventilator- Associated Pneumonia|The Effectiveness of an Oral Care Protocol in Preventing Ventilator- Associated Pneumonia for Intensive Care Unit Patient|Completed||Early Phase 1|53|Actual|Mackay Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:31:20.610659|2018-06-01 02:31:20.610659
NCT00604903|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-02-16|2008-01-29|2008-01-30|Estimate|||||||2017-02-16|2017-02-17|Actual|August 23, 2006|Actual|2006-08-23|February 2012|2012-02-29|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|PAPIRUSII||Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal|Remon CHF Medical Device Clinical Investigation PAPIRUS II: Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal|Completed||N/A|42|Actual|Boston Scientific Corporation||1|||f||||f|f|f||||||No||2018-06-01 02:31:20.673686|2018-06-01 02:31:20.673686
NCT00604890|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2012-07-24|2008-01-17|2008-01-30|Estimate|||||||2012-07-24|2012-07-25|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma|Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma|Completed||Phase 2|186|Actual|Berg, LLC||4|||f||||t||||||||||2018-06-01 02:31:20.747213|2018-06-01 02:31:20.747213
NCT00604877|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-17|2008-01-17|2008-01-30|Estimate|||||||2008-01-17|2008-01-30|Estimate|August 2003||2003-08-31|January 2008|2008-01-31|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Effects of Exercise on Endothelial Function in Stroke Patients|Effects of Exercise on Endothelial Function in Stroke Patients|Unknown status|Active, not recruiting|N/A|140|Actual|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 02:31:20.822942|2018-06-01 02:31:20.822942
NCT00604864|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-29|2008-01-29|2008-01-30|Estimate|||||||2008-01-29|2008-01-30|Estimate|February 2004||2004-02-29|January 2008|2008-01-31|November 2005|Actual|2005-11-30|February 2005|Actual|2005-02-28||Interventional|Infliximab||Effect of Anti TNFa Upon Deep Endometriosis Associated Pain|Anti TNFa Treatment for Deep Endometriosis Associated Pain : a Randomised Placebo Controlled Trial.|Completed||Phase 2|20|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-06-01 02:31:20.900156|2018-06-01 02:31:20.900156
NCT00604838|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-29|2008-01-29|2008-01-30|Estimate|||||||2008-01-29|2008-01-30|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Pivotal Study of the Al-Sense Study Protocol|Pivotal Study of the Al-ASense Study Protocol|Completed||Phase 1/Phase 2|330|Actual|Western Galilee Hospital-Nahariya||1|||f||||t||||||||||2018-06-01 02:31:20.968371|2018-06-01 02:31:20.968371
NCT00604825|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2017-09-06|2009-07-22|2017-09-06|2008-01-17|2008-01-30|Estimate|2017-09-06|2017-10-03|Actual|2009-07-22|2009-08-10|Estimate|2017-09-06|2017-10-03|Actual|July 17, 2007|Actual|2007-07-17|September 2017|2017-09-30|July 23, 2008|Actual|2008-07-23|July 23, 2008|Actual|2008-07-23||Interventional|||Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)|A Parallel-group, Double-blind, Randomized, Placebo-controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Two Doses of GSK232802 Administered Orally as Monotherapy for 12 Weeks in Healthy Postmenopausal Women With Moderate to Extremely Severe Vasomotor Symptoms|Completed||Phase 2|356|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 02:31:21.122692|2018-06-01 02:31:21.122692
NCT00604812|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2009-06-03||2017-05-11|2008-01-17|2008-01-30|Estimate|2009-07-27|2009-09-02|Estimate||||2017-05-11|2017-06-06|Actual|December 17, 2007|Actual|2007-12-17|May 2017|2017-05-31|September 17, 2010|Actual|2010-09-17|September 17, 2010|Actual|2010-09-17||Interventional|||Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.|Pharmacokinetic data presented are preliminary data.|6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:31:23.730292|2018-06-01 02:31:23.730292
NCT00604799|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-07-16|2008-01-28|2008-01-30|Estimate|||||||2012-07-16|2012-07-17|Estimate|July 2003||2003-07-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2006|Actual|2006-06-30||Interventional|VALOR||VALOR: The Talent Thoracic Stent Graft System Clinical Study|Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms|Completed||Phase 2/Phase 3|379|Actual|Medtronic Endovascular||4|||f||||t||||||||||2018-06-01 02:31:24.268299|2018-06-01 02:31:24.268299
NCT00604786|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-12-04||2017-04-04|2008-01-16|2008-01-30|Estimate|2017-03-30|2017-04-04|Actual||||2017-04-04|2017-05-10|Actual|July 2007||2007-07-31|April 2017|2017-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Effect of Omalizumab on Responses to Cat Allergen Challenge|Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge|Completed||N/A|18|Actual|Johns Hopkins University|2 subject in active group did not finish the study, small sample size|2|||f||||t||||||||||2018-06-01 02:31:24.38869|2018-06-01 02:31:24.38869
NCT00604591|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|||2016-06-14|2008-01-19|2008-01-30|Estimate|||||||2016-06-14|2016-06-16|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|August 2015|Actual|2015-08-31||Interventional|||Effects of Tolcapone on Frontotemporal Dementia|Investigation of the Dopamine System in Frontotemporal Dementia|Active, not recruiting||Phase 2|28|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-06-01 02:31:28.169364|2018-06-01 02:31:28.169364
NCT00604760|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-12-05|2008-01-29|2008-01-30|Estimate|||||||2008-12-05|2008-12-08|Estimate|December 2007||2007-12-31|December 2008|2008-12-31||||February 2009|Anticipated|2009-02-28||Interventional|||Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia|A Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|Memory Pharmaceuticals||4|||f||||f||||||||||2018-06-01 02:31:24.738363|2018-06-01 02:31:24.738363
NCT00604747|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-29|2008-01-29|2008-01-30|Estimate|||||||2008-01-29|2008-01-30|Estimate|August 2006||2006-08-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Practice Structure on Motor Learning in Post-Stroke Patients|The Effects of Practice Structure on Motor Learning in Post-Stroke Patients|Completed||N/A|34|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-06-01 02:31:24.871007|2018-06-01 02:31:24.871007
NCT00604734|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-23|||2016-01-08|2008-01-29|2008-01-30|Estimate|||||||2016-01-08|2016-01-11|Estimate|October 2004||2004-10-31|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|October 2007|Actual|2007-10-31||Interventional|||A Prospective Clinical Study On A Total Hip Resurfacing System|A Prospective Clinical Study On A Total Hip Resurfacing System|Unknown status|Active, not recruiting|N/A|280|Actual|Zimmer Biomet||1|||f||||f||||||||||2018-06-01 02:31:24.962731|2018-06-01 02:31:24.962731
NCT00604721|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2012-06-22||2014-05-12|2008-01-17|2008-01-30|Estimate|2012-08-03|2012-09-06|Estimate||||2014-05-12|2014-05-28|Estimate|November 2007||2007-11-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer|A Phase 2 Study of AZD6244 in Advanced or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)|The study was stopped at the interim analysis due to lack of radiographic response.|1|||f||||||||||||||2018-06-01 02:31:25.068963|2018-06-01 02:31:25.068963
NCT00604708|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2012-05-24||2016-05-03|2008-01-16|2008-01-30|Estimate|2012-10-31|2012-11-29|Estimate||||2016-05-03|2016-06-02|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Immunogenicity Study of the Japanese Encephalitis Vaccine IC51|Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of IC51 vs. JE-VAX as Vaccines for Japanese Encephalitis in Healthy Subjects|Completed||Phase 3|867|Actual|Valneva Austria GmbH||2|||f||||t||||||||||2018-06-01 02:31:26.279095|2018-06-01 02:31:26.279095
NCT00604695|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2012-05-15||2012-08-06|2008-01-17|2008-01-30|Estimate|2012-08-06|2012-09-07|Estimate||||2012-08-06|2012-09-07|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|ICE T-TIMI 49||A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks|A Randomized Trial Evaluating Low-Dose IntraCoronary AdjunctivE Tenecteplase During Primary PCI for ST-Elevation Myocardial Infarction (ICE T)|Completed||Phase 2|40|Actual|Brigham and Women's Hospital|This pilot study was not adequately powered to exclude a modest increase in bleeding events. Study drug could not be administered to 4 patients and 7 patients were excluded for not meeting the inclusion criteria of TIMI Flow Grade 0/1 at enrollment.|2|||f||||t||||||||||2018-06-01 02:31:26.603522|2018-06-01 02:31:26.603522
NCT00604682|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-09-18|2008-01-17|2008-01-30|Estimate|||||||2017-09-18|2017-09-19|Actual|January 1, 2005|Actual|2005-01-01|September 2017|2017-09-30|December 1, 2005|Actual|2005-12-01|October 1, 2005|Actual|2005-10-01||Interventional|PSOR-001||Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis|Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis|Completed||Phase 2|19|Actual|Celgene||1|||f||||f||||||||||2018-06-01 02:31:27.017219|2018-06-01 02:31:27.017219
NCT00604669|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2008-12-08||2013-11-20|2008-01-29|2008-01-30|Estimate|2010-03-15|2010-04-07|Estimate||||2013-11-20|2013-12-13|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients|Total Parenteral Nutrition(TPN)-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients|Completed|||170|Actual|Emory University|||||f||||t||||||||||2018-06-01 02:31:27.219204|2018-06-01 02:31:27.219204
NCT00604656|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-02-28|2008-01-17|2008-01-30|Estimate|||||||2017-02-28|2017-03-01|Actual|May 5, 2003|Actual|2003-05-05|February 2017|2017-02-28|January 29, 2004|Actual|2004-01-29|January 29, 2004|Actual|2004-01-29||Interventional|||Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes|A Six Months, Multi-centre, Open, Randomised, Parallel Safety and Efficacy Comparison of NovoRapid® Produced by the Current Process and Insulin Aspart With the Same Formulation as NovoRapid®, Produced by the NN2000 Process in Subjects With Type 1 Diabetes on a Basal/Bolus Regimen|Completed||Phase 3|241|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:31:27.39535|2018-06-01 02:31:27.39535
NCT00604643|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-07-31|2008-01-16|2008-01-30|Estimate|||||||2015-07-31|2015-08-03|Estimate|October 2002||2002-10-31|July 2015|2015-07-31|April 2012|Anticipated|2012-04-30|July 2008|Actual|2008-07-31||Expanded Access|||Talent Aortic Cuff Stent Graft System Compassionate Use Registry|Compassionate Use of the TALENT Aortic Cuff in the Treatment of Patients Previously Treated With the AneuRx Stent Graft System With Sub-Optimal Stent Graft Outcomes|No longer available|||||Medtronic Endovascular|||||f||||f||||||||||2018-06-01 02:31:27.544243|2018-06-01 02:31:27.544243
NCT00604630|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-10-21|2008-01-29|2008-01-30|Estimate|||||||2008-10-21|2008-10-22|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|ESS||Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke|German Multicenter EPO Stroke Trial (Phase II/III)|Completed||Phase 2/Phase 3|522|Actual|Max-Planck-Institute of Experimental Medicine||2|||f||||t||||||||||2018-06-01 02:31:27.720441|2018-06-01 02:31:27.720441
NCT00604617|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2010-08-02|2008-01-17|2008-01-30|Estimate|||||||2010-08-02|2010-08-03|Estimate|August 2007||2007-08-31|August 2010|2010-08-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Observational|||Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children|The Utility of Interferon-Gamma Release Assays in TB-HIV Co-infected Children|Unknown status|Recruiting||800|Anticipated|Case Western Reserve University|||||f||||f||||||||||2018-06-01 02:31:27.91917|2018-06-01 02:31:27.91917
NCT00604604|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2015-06-02|2008-01-17|2008-01-30|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2004||2004-08-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Postpartum Depression Prevention Trial|An RCT to Evaluate the Effectiveness of Peer (Mother-to-Mother) Support for the Prevention of Postpartum Depression|Completed||N/A|702|Actual|University of Toronto||2|||f||||t||||||||||2018-06-01 02:31:28.052366|2018-06-01 02:31:28.052366
NCT00604578|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2017-06-30|2008-01-19|2008-01-30|Estimate|||||||2017-06-30|2017-07-02|Actual|January 4, 2008||2008-01-04|October 30, 2009|2009-10-30|October 30, 2009|Anticipated|2009-10-30|October 30, 2009|Anticipated|2009-10-30||Interventional|||Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma|A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Allergic Asthma|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:31:28.2511|2018-06-01 02:31:28.2511
NCT00604565|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2015-03-11||2015-08-05|2008-01-29|2008-01-30|Estimate|2015-08-05|2015-08-31|Estimate||||2015-08-05|2015-08-31|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients|A Prospective, Randomized, Open-label, Multi-center, Controlled Clinical Trial of the Safety and Efficacy of Physiological Iron Maintenance in End Stage Renal Disease (ESRD) Subjects by Delivery of Soluble Ferric Pyrophosphate (SFP) Via Hemodialysate|Terminated||N/A|11|Actual|Charles Drew University of Medicine and Science|Study suspended after 1st 11 subjects enrolled. Study design changed significantly upon re-initiation, so 1st 11 subjects analyzed for safety only; no efficacy. Efficacy analysis from study after re-initiation is found under protocol NIH-FP-01 PRIME.|2||major planned changes to study design|f||||f||||||||||2018-06-01 02:31:28.386412|2018-06-01 02:31:28.386412
NCT00604552|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-02-21||2018-02-12|2008-01-16|2008-01-30|Estimate|2013-06-24|2013-07-30|Estimate||||2018-02-12|2018-03-12|Actual|July 2003||2003-07-31|January 2013|2013-01-31|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||AneuRx Post Market Study in the Treatment of AAA|AneuRx Post Market Surveillance Registry|Terminated||N/A|349|Actual|Medtronic Endovascular|Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.|2||Mutual agreement between FDA closed the 522 postmarket surveillance Registry.|f||||f||||||||||2018-06-01 02:31:28.910012|2018-06-01 02:31:28.910012
NCT00604539|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2011-12-16|2008-01-29|2008-01-30|Estimate|||||||2011-12-16|2011-12-19|Estimate|February 2008||2008-02-29|December 2011|2011-12-31||||November 2009|Actual|2009-11-30||Interventional|||Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee|Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee|Completed||Phase 3|70|Anticipated|Bioiberica||2|||f||||f||||||||||2018-06-01 02:31:29.160735|2018-06-01 02:31:29.160735
NCT00604526|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2016-01-04|2008-01-28|2008-01-30|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy|Pilot Study of High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy|Completed||Phase 1|42|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:31:29.275573|2018-06-01 02:31:29.275573
NCT00604513|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-07-10|2008-01-17|2008-01-30|Estimate|||||||2012-07-10|2012-07-12|Estimate|September 2006||2006-09-30|July 2012|2012-07-31|May 2007|Actual|2007-05-31|||||Interventional|RSA||Ready. Set. ACTION! A Theater-Based Obesity Prevention Program for Children|A Theater-Based Obesity Prevention Program for Children|Completed||N/A|181|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 02:31:29.356336|2018-06-01 02:31:29.356336
NCT00604500|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-21|2010-07-15||2017-03-15|2008-01-21|2008-01-30|Estimate|2011-03-11|2011-04-12|Estimate||||2017-03-15|2017-04-12|Actual|March 2008||2008-03-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)|An Open-Label, Multi-Center, Patient Handling Study of Mometasone Furoate/Formoterol Fumarate MDI With an Integrated Dose Counter in Adolescent and Adult Subjects and Adult With Asthma or COPD|Completed||Phase 3|272|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:31:29.461098|2018-06-01 02:31:29.461098
NCT00604487|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2016-02-18|2008-01-29|2008-01-30|Estimate|||||||2016-02-18|2016-02-22|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Induction of Labor in Patients With Unfavorable Cervical Conditions||Completed||N/A|300|Actual|Hillel Yaffe Medical Center||3|||f||||f||||||||||2018-06-01 02:31:29.792495|2018-06-01 02:31:29.792495
NCT00604474|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2012-02-02|2008-01-17|2008-01-30|Estimate|||||||2012-02-02|2012-02-06|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants|Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants|Withdrawn||N/A|0|Actual|University of California, San Francisco||1||Not sufficient enrollment|f||||f||||||||||2018-06-01 02:31:29.870573|2018-06-01 02:31:29.870573
NCT00604461|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2011-11-17||2017-02-20|2008-01-29|2008-01-30|Estimate|2011-11-17|2011-12-26|Estimate||||2017-02-20|2017-03-23|Actual|October 2007||2007-10-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)|Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)|Terminated||Phase 1/Phase 2|13|Actual|H. Lee Moffitt Cancer Center and Research Institute|This trial was closed early due to slow patient accrual. The planned accrual had been 44.|1||Slow Accrual|f||||t||||||||||2018-06-01 02:31:29.958806|2018-06-01 02:31:29.958806
NCT00604448|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2012-06-14|2008-01-17|2008-01-30|Estimate|||||||2012-06-14|2012-06-15|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional|||The Effect of Eating Pulses for 8 Weeks on Satiety and Metabolic Syndrome Risk Factors in Overweight Individuals|The Effect of Frequent Consumption of Pulses for Eight Weeks on Blood Lipids and on Glycemic and Satiety Hormones Response in Overweight and Obese Subjects|Completed||N/A|44|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 02:31:30.163147|2018-06-01 02:31:30.163147
NCT00604435|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2010-01-18|2008-01-29|2008-01-30|Estimate|||||||2010-01-18|2010-01-20|Estimate|February 2008||2008-02-29|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Neoadjuvant Endostatin and Chemotherapy for Breast Cancer|Phase II Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-line Therapy in Patients With Breast Cancer|Completed||Phase 2|69|Actual|Xijing Hospital||2|||f||||t||||||||||2018-06-01 02:31:30.261061|2018-06-01 02:31:30.261061
NCT00604422|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2010-03-10|2008-01-29|2008-01-30|Estimate|||||||2010-03-10|2010-03-11|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Observational|||Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis|Completed|||97|Actual|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 02:31:30.331843|2018-06-01 02:31:30.331843
NCT00604409|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2015-09-03|2008-01-29|2008-01-30|Estimate|||||||2015-09-03|2015-09-07|Estimate|April 2006||2006-04-30|September 2015|2015-09-30|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer|Phase I Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer|Completed||Phase 1|34|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-06-01 02:31:30.400942|2018-06-01 02:31:30.400942
NCT00604396|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-01-26|2008-01-17|2008-01-30|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2003||2003-03-31|January 2017|2017-01-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes|Safety and Efficacy of Insulin Detemir Combined With OAD Versus Insulin NPH Combined With OAD in Type 2 Mellitus|Completed||Phase 3|477|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:31:30.585173|2018-06-01 02:31:30.585173
NCT00604383|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2015-12-22||2016-08-25|2008-01-17|2008-01-30|Estimate|2015-12-22|2016-01-28|Estimate||||2016-08-25|2016-10-06|Estimate|March 2001||2001-03-31|August 2016|2016-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional||All randomized participants.|Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study|Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.|Completed||Phase 3|685|Actual|Chromaderm, Inc.||2|||f||||f||||||||||2018-06-01 02:31:30.811511|2018-06-01 02:31:30.811511
NCT00604370|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2012-02-09|2008-01-29|2008-01-30|Estimate|||||||2012-02-09|2012-02-10|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|December 2011|Actual|2011-12-31|February 2010|Actual|2010-02-28||Observational|||Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge|VTE Prophylaxis Across the Continuum of Care: High Risk Patients at Hospital Discharge|Completed|||2500|Actual|Brigham and Women's Hospital|||2||f||||f||||||||||2018-06-01 02:31:32.16452|2018-06-01 02:31:32.16452
NCT00604357|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2014-12-15|2008-01-17|2008-01-30|Estimate|||||||2014-12-15|2014-12-16|Estimate|December 2008||2008-12-31|December 2014|2014-12-31|August 2012|Actual|2012-08-31|July 2011|Actual|2011-07-31||Interventional|PATRON07||CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment|A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients With Impaired Renal Function. (PATRON-Study)|Completed||Phase 3|27|Actual|University of Regensburg||1|||f||||f||||||||||2018-06-01 02:31:32.230926|2018-06-01 02:31:32.230926
NCT00604344|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-01-26|2008-01-17|2008-01-30|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2003||2003-04-30|January 2017|2017-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes|A 48-week, Randomised, Multi-centre, Openlabelled, Parallel-group Trial to Compare the Efficacy and the Safety of NN304 (Insulin Detemir) and NPH Human Insulin in Subjects With Insulin Requiring Diabetes Mellitus on a Basal-bolus Regimen|Completed||Phase 3|401|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:31:32.306147|2018-06-01 02:31:32.306147
NCT00604331|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2010-12-07|2008-01-17|2008-01-30|Estimate|||||||2010-12-07|2010-12-09|Estimate|August 2008||2008-08-31|December 2010|2010-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation|Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation|Completed||Phase 2|8|Actual|Herzzentrum Goettingen||1|||f||||f||||||||||2018-06-01 02:31:32.3751|2018-06-01 02:31:32.3751
NCT00604318|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2013-01-09|2008-01-29|2008-01-30|Estimate|||||||2013-01-09|2013-01-10|Estimate|February 2008||2008-02-29|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer|Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer?|Completed||Phase 4|56|Actual|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-06-01 02:31:32.528407|2018-06-01 02:31:32.528407
NCT00604305|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2012-06-10|2008-01-29|2008-01-30|Estimate|||||||2012-06-10|2012-06-12|Estimate|March 2008||2008-03-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Comperative Trial Between an Accommodative Iol and Monofocal Iol|A Randomized Single Blind Comparative Study of the Acuity's C-Well Accommodating Intra Occular Lens (AIOL) Against Alcon's Acrysof|Withdrawn||N/A|0|Actual|Shaare Zedek Medical Center||2||Company could not supply the accommodating intraocular lenses for the study|f||||f||||||||||2018-06-01 02:31:32.607742|2018-06-01 02:31:32.607742
NCT00604292|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-29|||2010-03-10|2008-01-29|2008-01-30|Estimate|||||||2010-03-10|2010-03-11|Estimate|June 2007||2007-06-30|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Evaluation of the PillCam Colon Capsule Endoscopy (PCCE) Preparation and Procedure|Evaluation of the PillCam Colon Capsule Endoscopy Preparation and Procedure|Completed|||50|Actual|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 02:31:32.688985|2018-06-01 02:31:32.688985
NCT00604279|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2013-02-21||2013-06-04|2008-01-17|2008-01-30|Estimate|2013-06-04|2013-07-10|Estimate||||2013-06-04|2013-07-10|Estimate|January 2008||2008-01-31|June 2013|2013-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia|A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects With Schizophrenia|Completed||Phase 3|452|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-06-01 02:31:32.775329|2018-06-01 02:31:32.775329
NCT00604266|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-05-01|2008-01-29|2008-01-30|Estimate|||||||2017-05-01|2017-05-04|Actual|August 2007||2007-08-31|May 2017|2017-05-31|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Observational|PET/MRCP||Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study|Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study.|Withdrawn|||0|Actual|University of Toronto|||1||f||||f||||||||||2018-06-01 02:31:33.200655|2018-06-01 02:31:33.200655
NCT00604253|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-01-26|2008-01-17|2008-01-30|Estimate|||||||2017-01-26|2017-01-27|Estimate|December 2003||2003-12-31|January 2017|2017-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone|Comparison of Efficacy and the Safety of Insulin Detemir and Insulin NPH as add-on to Current OHA Therapy in Subjects With type2 Diabetes Mellitus|Completed||Phase 3|362|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:31:33.263832|2018-06-01 02:31:33.263832
NCT00604240|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2017-05-09|2008-01-29|2008-01-30|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2007||2007-11-30|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Telephone Follow-up From an Intensive Care Nursery|Telephone Follow-up From an Intensive Care Nursery: What do Parents Actually Remember?|Completed|||175|Actual|Christiana Care Health Services|||1||f||||f||||||||||2018-06-01 02:31:33.342019|2018-06-01 02:31:33.342019
NCT00604227|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-29|2008-01-29|2008-01-30|Estimate|||||||2008-01-29|2008-01-30|Estimate|July 2005||2005-07-31|November 2007|2007-11-30|August 2005|Actual|2005-08-31|||||Interventional|||Pulmonary Function at High-Altitude|Interstitial Pulmonary Edema After Rapid Ascent to High Altitude (Margherita Hut, 4559 m)|Completed||N/A|34|Actual|Heidelberg University||1|||f||||f||||||||||2018-06-01 02:31:33.40782|2018-06-01 02:31:33.40782
NCT00604214|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2012-08-20||2012-08-20|2008-01-24|2008-01-30|Estimate|2012-08-20|2012-09-18|Estimate||||2012-08-20|2012-09-18|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock|Completed||Phase 3|1696|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:31:33.542543|2018-06-01 02:31:33.542543
NCT00604201|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2018-05-08|2008-01-17|2008-01-30|Estimate|||||||2018-05-08|2018-05-09|Actual|January 7, 2008||2008-01-07|April 30, 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome|Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy|Recruiting||Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:31:35.407019|2018-06-01 02:31:35.407019
NCT00604188|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2010-12-07||2017-06-02|2008-01-17|2008-01-30|Estimate|2011-04-06|2011-05-06|Estimate||||2017-06-02|2017-07-02|Actual|February 22, 2008|Actual|2008-02-22|June 2017|2017-06-30|December 10, 2009|Actual|2009-12-10|December 10, 2009|Actual|2009-12-10||Interventional|||A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)|A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users|Completed||Phase 4|188|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:31:35.531195|2018-06-01 02:31:35.531195
NCT00604175|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2013-07-15|2012-12-11|2015-08-11|2008-01-17|2008-01-30|Estimate|2013-08-06|2013-10-17|Estimate|2012-12-28|2013-01-01|Estimate|2015-08-11|2015-09-07|Estimate|February 2008||2008-02-29|August 2015|2015-08-31|November 2012|Actual|2012-11-30|January 2012|Actual|2012-01-31||Interventional||All participants, except 4: one was found to be ineligible after enrollment (Stratum A) and 3 failed to start intervention (2 in Stratum A, 1 in Stratum C).|Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women|A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females|Completed||Phase 2|319|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 02:31:36.174471|2018-06-01 02:31:36.174471
NCT00604162|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2010-07-07||2012-06-10|2008-01-29|2008-01-30|Estimate|2011-01-23|2011-02-18|Estimate||||2012-06-10|2012-06-13|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|MA-53||PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon|Evaluation of PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon|Completed||Phase 3|332|Actual|Given Imaging Ltd.||1|||f||||f||||||||||2018-06-01 02:31:37.447037|2018-06-01 02:31:37.447037
NCT00604149|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2015-06-24|2008-01-28|2008-01-30|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|CARTAGENE||Cardiac AResT And GENEtic|Etude Multicentrique en Population de la susceptibilité génétique à Faire Une Mort Subite|Completed|||2332|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||f||||||Samples With DNA|"~     whole blood to obtain DNA~   "|||2018-06-01 02:31:37.785437|2018-06-01 02:31:37.785437
NCT00604136|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2015-08-19|2008-01-29|2008-01-30|Estimate|||||||2015-08-19|2015-08-20|Estimate|July 2008||2008-07-31|August 2015|2015-08-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy|Treatment of Metastatic Melanoma Patients With Tumor Infiltrating Lymphocytes and IL-2 Following a Regimen of Non-myeloablative Lymphocyte Depleting Chemotherapy|Unknown status|Recruiting|Phase 2|20|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 02:31:37.842837|2018-06-01 02:31:37.842837
NCT00604123|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08||2011-08-12|2015-04-07|2008-01-16|2008-01-30|Estimate||||2011-08-12|2011-08-17|Estimate|2015-04-07|2015-04-29|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adult Men or Women Allergic to Mountain Cedar Pollen|Completed||Phase 2|74|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||t||||||||||2018-06-01 02:31:37.910965|2018-06-01 02:31:37.910965
NCT00604110|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-01-29|2008-01-29|2008-01-30|Estimate|||||||2008-01-29|2008-01-30|Estimate|February 2008||2008-02-29|January 2008|2008-01-31|October 2008|Anticipated|2008-10-31|September 2008|Anticipated|2008-09-30||Interventional|||Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%|Interest in Biventricular Epicardial Pacing Post Cardiac Surgery in Patients With Left Ventricular Ejection Fractions Less Than 45%|Unknown status|Enrolling by invitation|Phase 3|12|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 02:31:38.00161|2018-06-01 02:31:38.00161
NCT00604097|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2012-12-13|2008-01-16|2008-01-29|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 2004||2004-09-30|December 2012|2012-12-31|August 2008|Actual|2008-08-31|May 2007|Actual|2007-05-31||Interventional|||Preventing Youth Suicide in Primary Care: A Family Model|Preventing Youth Suicide in Primary Care: A Family Model|Completed||Phase 3|66|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-06-01 02:31:38.073024|2018-06-01 02:31:38.073024
NCT00604084|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2009-03-09|2008-01-16|2008-01-29|Estimate|||||||2009-03-09|2009-03-10|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|VSEEP||Veron Scabies Education and Eradication Program|Veron Scabies Education and Eradication Program|Completed||N/A|1057|Actual|Edward Via Virginia College of Osteopathic Medicine||2|||f||||t||||||||||2018-06-01 02:31:38.146553|2018-06-01 02:31:38.146553
NCT00604071|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2015-04-13|2008-01-16|2008-01-29|Estimate|||||||2015-04-13|2015-04-14|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Observational|HMP||Sensitivity of the Home Macular Perimeter (HMP)|Sensitivity of the Home Macular Perimeter (HMP) in the Detection of Visual Field Abnormalities in Patients With Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD)- PILOT Study|Completed|||99|Actual|Notal Vision Ltd|||1||f||||t||||||||||2018-06-01 02:31:38.252469|2018-06-01 02:31:38.252469
NCT00604058|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2014-01-20|2008-01-28|2008-01-29|Estimate|||||||2014-01-20|2014-01-22|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly|Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine Administered Intradermally vs Full Doses of Inactivated Poliomyelitis Vaccine Administered Intramuscularly in Healthy Philippines Infants|Completed||Phase 2|236|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:31:38.331083|2018-06-01 02:31:38.331083
NCT00604045|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2013-12-13||2014-02-11|2008-01-28|2008-01-29|Estimate|2014-02-11|2014-03-28|Estimate||||2014-02-11|2014-03-28|Estimate|May 2009||2009-05-31|January 2008|2008-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||DoD PTSD November 13 - Information Processing Modification in the Treatment of PTSD|Information Processing Modification in the Treatment of PTSD|Completed||N/A|25|Actual|San Diego State University||2|||f||||t||||||||||2018-06-01 02:31:38.437142|2018-06-01 02:31:38.437142
NCT00604032|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-03-26|2008-01-28|2008-01-29|Estimate|||||||2008-03-26|2008-03-28|Estimate|January 2008||2008-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05%|Clinical Evaluation of the Phototoxic Potential of Atralin (Tretinoin) Gel, 0.05%|Completed||Phase 1|60|Actual|Coria Laboratories, Ltd.||1|||f||||f||||||||||2018-06-01 02:31:38.61119|2018-06-01 02:31:38.61119
NCT00604019|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2011-07-20||2013-02-26|2008-01-28|2008-01-29|Estimate|2012-11-08|2012-12-07|Estimate||||2013-02-26|2013-03-04|Estimate|March 2003||2003-03-31|February 2013|2013-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock|Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock|Completed||Phase 3|252|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-06-01 02:31:38.664774|2018-06-01 02:31:38.664774
NCT00604006|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2015-06-02|2008-01-28|2008-01-29|Estimate|||||||2015-06-02|2015-06-04|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)|SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)|Completed||Phase 3|20|Actual|Monash University||2|||f||||f||||||||||2018-06-01 02:31:38.870611|2018-06-01 02:31:38.870611
NCT00603993|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2009-10-16||2011-06-17|2008-01-28|2008-01-29|Estimate|2010-01-15|2010-02-04|Estimate||||2011-06-17|2011-06-21|Estimate|March 2006||2006-03-31|June 2011|2011-06-30||||November 2006|Actual|2006-11-30||Interventional|||Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|A Non-Randomized, Open-Label, Roll-Over Study With Self Injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|Completed||Phase 3|88|Actual|Abbott|Due to the small population, statistical tests were not performed.|1|||f||||f||||||||||2018-06-01 02:31:38.99843|2018-06-01 02:31:38.99843
NCT00603980|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2009-03-20|2008-01-28|2008-01-29|Estimate|||||||2009-03-20|2009-03-24|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Abuse Liability of Staccato Alprazolam|Abuse Liability Study of Staccato® Alprazolam for Inhalation in Subjects With Histories of Sedative Abuse|Completed||Phase 1|14|Anticipated|Alexza Pharmaceuticals, Inc.||7|||f||||f||||||||||2018-06-01 02:31:39.852924|2018-06-01 02:31:39.852924
NCT00603967|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2013-05-22|2008-01-28|2008-01-29|Estimate|||||||2013-05-22|2013-05-24|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Aromatase Inhibitors on Bones and Genes|Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms|Completed||N/A|151|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:31:40.048481|2018-06-01 02:31:40.048481
NCT00603954|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2015-01-26|2008-01-28|2008-01-29|Estimate|||||||2015-01-26|2015-01-27|Estimate|December 2007||2007-12-31|January 2015|2015-01-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings|Allogeneic Hematopoietic Cell Transplantation With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings|Completed||Phase 2|97|Actual|University Hospital of Liege||2|||f||||f||||||||||2018-06-01 02:31:40.251222|2018-06-01 02:31:40.251222
NCT00603941|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15||2013-02-01|2013-02-06|2008-01-28|2008-01-29|Estimate||||2013-02-01|2013-02-05|Estimate|2013-02-06|2013-02-08|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy|A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer|Completed||Phase 1/Phase 2|19|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 02:31:40.510575|2018-06-01 02:31:40.510575
NCT00603928|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-11-19|2008-01-28|2008-01-29|Estimate|||||||2008-11-19|2008-11-20|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Placebo Interventions in General Practice|Placebo Interventions in General Practice|Completed|||600|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 02:31:40.61666|2018-06-01 02:31:40.61666
NCT00603915|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2011-05-06||2011-10-06|2008-01-28|2008-01-29|Estimate|2011-07-14|2011-08-10|Estimate||||2011-10-06|2011-10-10|Estimate|June 2006||2006-06-30|October 2011|2011-10-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer|Phase II Trial of Gemcitabine and Cisplatin/Carboplatin (GC) Plus Erlotinib in Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer|Completed||Phase 2|20|Actual|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 02:31:40.749456|2018-06-01 02:31:40.749456
NCT00603902|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2013-01-04|2012-07-26|2013-01-04|2008-01-16|2008-01-29|Estimate|2013-01-04|2013-02-07|Estimate|2012-08-06|2012-08-14|Estimate|2013-01-04|2013-02-07|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management|A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients|Completed||Phase 3|4008|Actual|Arena Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:31:40.934065|2018-06-01 02:31:40.934065
NCT00603889|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2011-06-21||2012-01-18|2008-01-28|2008-01-29|Estimate|2012-01-18|2012-02-23|Estimate||||2012-01-18|2012-02-23|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Development of a Skin Test for the Na-ASP-2 Hookworm Antigen|Development of a Skin Test to Detect Immediate-type Hypersensitivity to the Experimental Na-ASP-2 Hookworm Antigen|Completed||N/A|12|Actual|Albert B. Sabin Vaccine Institute||1|||f||||f||||||||||2018-06-01 02:31:41.633378|2018-06-01 02:31:41.633378
NCT00603876|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2013-05-20|2008-01-28|2008-01-29|Estimate|||||||2013-05-20|2013-05-22|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Almonds Added to Chronic Statin Therapy|Efficacy of Almonds Added to Chronic Statin Therapy|Completed||Phase 4|50|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 02:31:41.915196|2018-06-01 02:31:41.915196
NCT00603863|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2014-01-22|2008-01-16|2008-01-29|Estimate|||||||2014-01-22|2014-01-23|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer|A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.|Completed||Phase 1/Phase 2|80|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-06-01 02:31:42.256454|2018-06-01 02:31:42.256454
NCT00603850|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2015-04-13|2008-01-16|2008-01-29|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|HMP||Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP)|Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP) in Intermediate Age Related Macular Degeneration Patients|Completed|||25|Actual|Notal Vision Ltd|||1||f||||t||||||||||2018-06-01 02:31:42.532261|2018-06-01 02:31:42.532261
NCT00603837|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2009-07-24||2009-10-12|2008-01-28|2008-01-29|Estimate|2009-07-24|2009-09-02|Estimate||||2009-10-12|2009-10-16|Estimate|May 2007||2007-05-31|October 2009|2009-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Warming Mattress Versus Polyethylene Wrapping to Prevent Hypothermia in Preterm Newborns.|Thermal Defense of Extremely Low Gestational Age Newborns (ELGANs) During Resuscitation: Exothermic Mattresses vs. Polyethylene Wrap|Completed||N/A|36|Actual|University of Oklahoma|Technical difficulties with the polyethylene wrap were the main limitations (variation of use, heat loss during pulse oximeter adjustment).|2|||f||||t||||||||||2018-06-01 02:31:42.637663|2018-06-01 02:31:42.637663
NCT00603824|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2016-09-12|2008-01-16|2008-01-29|Estimate|||||||2016-09-12|2016-09-13|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)|Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia|Withdrawn||Phase 4|0|Actual|Methodist Healthcare||2||PI relocated|f||||f||||||||||2018-06-01 02:31:43.060616|2018-06-01 02:31:43.060616
NCT00603811|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2014-09-22|2008-01-28|2008-01-29|Estimate|||||||2014-09-22|2014-09-23|Estimate|September 2007||2007-09-30|September 2014|2014-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults|A Multicenter, Double-blind, Randomized, Escalating Dose-ranging Study to Investigate the Safety and Immunogenicity of the VAX102 Influenza Vaccine in Healthy Adults|Completed||Phase 1|60|Actual|VaxInnate Corporation||2|||f||||t||||||||||2018-06-01 02:31:43.153847|2018-06-01 02:31:43.153847
NCT00603798|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2010-04-15||2010-06-22|2008-01-16|2008-01-29|Estimate|2010-05-25|2010-06-22|Estimate||||2010-06-22|2010-06-29|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)|A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment With Imiquimod Creams for Actinic Keratoses|Completed||Phase 3|490|Actual|Graceway Pharmaceuticals, LLC||3|||f||||f||||||||||2018-06-01 02:31:43.276592|2018-06-01 02:31:43.276592
NCT00603785|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2014-06-10|2008-01-28|2008-01-29|Estimate|||||||2014-06-10|2014-06-12|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|April 2008|Anticipated|2008-04-30|April 2008|Anticipated|2008-04-30||Interventional|||Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis|Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||2||Insufficient funds available|f||||f||||||||||2018-06-01 02:31:43.853908|2018-06-01 02:31:43.853908
NCT00603772|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-05-05|2008-01-16|2008-01-29|Estimate|||||||2008-05-05|2008-05-06|Estimate|January 2008||2008-01-31|February 2008|2008-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Clinical Evaluation of the Photoallergy Potential of Atralin Gel|Clinical Evaluation of the Photoallergy Potential of Atralin Gel (Tretinoin Gel 0.05%)|Completed||Phase 1|40|Anticipated|Coria Laboratories, Ltd.||1|||f||||f||||||||||2018-06-01 02:31:43.943412|2018-06-01 02:31:43.943412
NCT00603759|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-01-16|2008-01-16|2008-01-29|Estimate|||||||2008-01-16|2008-01-29|Estimate|April 2006||2006-04-30|January 2008|2008-01-31|August 2009|Anticipated|2009-08-31|August 2007|Actual|2007-08-31||Interventional|||COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma|the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head & Neck Carcinoma, Phase III Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 3|122|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:31:44.016332|2018-06-01 02:31:44.016332
NCT00603746|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-06-12|2010-10-13|2017-08-17|2008-01-17|2008-01-29|Estimate|2013-06-13|2013-08-19|Estimate|2011-02-07|2011-02-10|Estimate|2017-08-17|2017-09-15|Actual|December 1, 2007||2007-12-01|August 2017|2017-08-31|September 20, 2008|Actual|2008-09-20|September 1, 2008|Actual|2008-09-01||Interventional|||A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.|A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent an|Completed||Phase 2|627|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:31:44.190916|2018-06-01 02:31:44.190916
NCT00603577|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17||2016-04-06|2016-04-06|2008-01-28|2008-01-29|Estimate||||2016-04-06|2016-05-05|Estimate|2016-04-06|2016-05-05|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|XENON||Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens|A Multi-center, Randomized, Double Blind, Placebo Controlled Phase III Study to Assess the Efficacy of Xaliproden in Patients With Oxaliplatin-induced Peripheral Sensory Neuropathy (PSN) Following Adjuvant Chemotherapy for Colon Cancer|Terminated||Phase 3|102|Actual|Sanofi||2||development of product discontinued|f||||t||||||||||2018-06-01 02:31:48.443162|2018-06-01 02:31:48.443162
NCT00603733|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2015-03-04||2016-04-21|2008-01-28|2008-01-29|Estimate|2016-04-21|2016-04-22|Estimate||||2016-04-21|2016-04-22|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|CAMMP|Baseline characteristics were reported for the Per Protocol population who participated in the Active phase and in the maintenance phase of this study.|Canadian Active & Maintenance Modified Pentasa Study|A Multicentre, Randomised, Double-blind, Non-inferiority Trial Comparing the Efficacy and Safety of a New Modified Oral Extended Release Pentasa® (Mesalamine) 500 mg Tablet to the Currently Marketed Pentasa® (Mesalamine) 500 mg Tablet in Subjects With Active Mild to Moderate Ulcerative Colitis Treated With 4 g/Day for 8 Weeks and in Maintenance of Remission of Ulcerative Colitis in Subjects Treated With 2 g/Day for 24 Weeks|Completed||Phase 3|288|Actual|Ferring Pharmaceuticals|Study was amended to modify sample size as subject enrolment was lower than anticipated. A data lock was imposed, pending completion of the Maintenance Phase by 12 subjects to report all Active Phase efficacy data & all available safety data.|2|||f||||f||||||||||2018-06-01 02:31:46.498295|2018-06-01 02:31:46.498295
NCT00603720|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2016-01-24|2008-01-16|2008-01-29|Estimate|||||||2016-01-24|2016-01-26|Estimate|September 2005||2005-09-30|January 2016|2016-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling|PET Detection of the Effects of Aging on the Human Heart. Aim#1-Impact of Aging on Myocardial Remodeling: Role of Nitric Oxide|Completed||N/A|59|Actual|Washington University School of Medicine||5|||f||||f||||||||Undecided||2018-06-01 02:31:46.930789|2018-06-01 02:31:46.930789
NCT00603707|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-08-28|2008-01-28|2008-01-29|Estimate|||||||2008-08-28|2008-08-29|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|WholeGut||Assessment of Whole Gut Transit Time Using the SmartPill Capsule|Assessment of Whole Gut Transit Time Using the SmartPill Capsule: a Multi-Center Study|Completed|||178|Actual|The SmartPill Corporation|||2||f||||f||||||||||2018-06-01 02:31:47.070211|2018-06-01 02:31:47.070211
NCT00603694|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2016-06-21|2008-01-16|2008-01-29|Estimate|||||||2016-06-21|2016-06-23|Estimate|September 2007||2007-09-30|June 2016|2016-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Hippocampal Radiation Exposure and Memory|Hippocampal Radiation Exposure and Memory: A Pilot Study|Completed|||1|Actual|University Health Network, Toronto|||3||f||||t||||||||||2018-06-01 02:31:47.162921|2018-06-01 02:31:47.162921
NCT00603681|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-10-06|2008-01-28|2008-01-29|Estimate|||||||2008-10-06|2008-10-07|Estimate|January 2008||2008-01-31|October 2008|2008-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PEGorion||Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation|Non-Inferiority Study; Comparison of Polyethylene Glycol Solution With and Without Electrolytes for Treatment of Chronic Constipation in Elderly Institutionalised Patients: a Double-Blind, Randomised, Parallel-Group, Multicentre Study|Completed||Phase 4|67|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 02:31:47.234834|2018-06-01 02:31:47.234834
NCT00603668|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2013-03-25|2008-01-16|2008-01-29|Estimate|||||||2013-03-25|2013-03-27|Estimate|August 2008||2008-08-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL|A Phase I/II Study of Immunotherapy With Milatuzumab (hLL1) in Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 1/Phase 2|19|Actual|Immunomedics, Inc.||1|||f||||f||||||||||2018-06-01 02:31:47.348097|2018-06-01 02:31:47.348097
NCT00603655|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-12-30|2008-01-28|2008-01-29|Estimate|||||||2008-12-30|2008-12-31|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Effect of Glycemic Load on Body Composition|Assessment of Glycemic Load on Body Composition Among Overweight and Obese Adults During 12 Month Period|Terminated||Early Phase 1|29|Actual|Universidad Autonoma de Baja California||2||Higher drop out than expected. Lower Statistical Power.|f||||t||||||||||2018-06-01 02:31:47.455013|2018-06-01 02:31:47.455013
NCT00603642|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2010-11-18||2011-02-04|2008-01-17|2008-01-29|Estimate|2010-11-18|2010-12-10|Estimate||||2011-02-04|2011-02-11|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura|A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura|Completed||Phase 3|34|Actual|Amgen||2|||f||||||||||||||2018-06-01 02:31:47.583077|2018-06-01 02:31:47.583077
NCT00603629|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2011-09-20|2008-01-28|2008-01-29|Estimate|||||||2011-09-20|2011-09-21|Estimate|January 2008||2008-01-31|September 2011|2011-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|MAST-X||Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues|A Pilot Study Determining Mechanisms of Acute Asthma Exacerbations Through Detailed Molecular Analysis of Airway Secretions and Tissues|Completed|||23|Actual|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     whole blood, DNA, RNA, sputum, nasopharyngeal swab~   "|||2018-06-01 02:31:47.94564|2018-06-01 02:31:47.94564
NCT00603616|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2018-04-30|2008-01-28|2008-01-29|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2008||2008-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Induction of Clinical Response Using Rifaximin in Crohn's Disease|A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease|Active, not recruiting||Phase 2|36|Actual|University of Washington||2|||f||||f||f||||||No||2018-06-01 02:31:48.011647|2018-06-01 02:31:48.011647
NCT00603603|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2016-06-20|2008-01-28|2008-01-29|Estimate|||||||2016-06-20|2016-06-22|Estimate|February 2008||2008-02-29|June 2016|2016-06-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|Peri-Op||Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity|Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious Morbidity|Completed||N/A|606|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-06-01 02:31:48.104981|2018-06-01 02:31:48.104981
NCT00603590|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|2009-04-13||2009-09-22|2008-01-28|2008-01-29|Estimate|2009-05-02|2009-06-23|Estimate||||2009-09-22|2009-10-02|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|Polypill||Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease|Phase II Study of Heart Polypill in Primary Prevention of Cardiovascular Disease - Safety and Efficacy|Completed||Phase 2|475|Actual|Tehran University of Medical Sciences|Incomplete follow up Because of differences in systolic blood pressure at baseline, final analysis will take account of baseline differences|2|||f||||t||||||||||2018-06-01 02:31:48.191086|2018-06-01 02:31:48.191086
NCT00603564|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2009-09-11||2009-10-26|2008-01-28|2008-01-29|Estimate|2009-10-26|2009-12-02|Estimate||||2009-10-26|2009-12-02|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|CAPOVeRSO||Helmet Continuous Positive Airway Pressure Versus Oxygen Venturi in Acute Respiratory Failure in CAP: CAPOVeRSO|A Comparison of CPAP Delivered by Helmet and O2 Therapy With Venturi Mask for the Treatment of Acute Respiratory Failure in Community-acquired Pneumonia|Terminated||N/A|47|Actual|University of Milan|Limitations of our study are mainly related to the early reaching of the end-point of the CPAP group. We were not able to evaluate the safety of the CPAP application and to address conclusions on its efficacy on outcomes.|2||"The study was prematurely interrupted because patients randomized to CPAP reached the endpoint~   quicker than anticipated in the protocol"|f||||t||||||||||2018-06-01 02:31:48.522766|2018-06-01 02:31:48.522766
NCT00603551|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2008-07-18|2008-01-28|2008-01-29|Estimate|||||||2008-07-18|2008-07-21|Estimate|November 2006||2006-11-30|July 2008|2008-07-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Observational|||Screening of Bone Mineral Density in Women Who Have Received Chemotherapy|Screening of Bone Mineral Density in Women Who Have Received Chemotherapy|Unknown status|Recruiting||100|Anticipated|Medical University of South Carolina|||1||f||||f||||||||||2018-06-01 02:31:48.749962|2018-06-01 02:31:48.749962
NCT00603538|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2013-01-18||2013-03-05|2008-01-17|2008-01-29|Estimate|2013-03-05|2013-04-11|Estimate||||2013-03-05|2013-04-11|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer|Phase 1, Dose Escalation Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|19|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 02:31:48.834643|2018-06-01 02:31:48.834643
NCT00603525|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2011-10-20||2014-05-22|2008-01-16|2008-01-29|Estimate|2011-10-20|2011-11-28|Estimate||||2014-05-22|2014-06-09|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|March 2011|Actual|2011-03-31||Interventional|||Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy|A Double-blind, Randomized, Placebo Controlled, Parallel Group, Multi-center, Phase III Trial of Ofatumumab Investigating Clinical Efficacy in Patients With Active Rheumatoid Arthritis Who Have Previously Had an Inadequate Response to One or More TNF Antagonist Therapies|Terminated||Phase 3|169|Actual|GlaxoSmithKline||2||"Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical~   development of autoimmune indications on the subcutaneous delivery."|f||||f||||||||||2018-06-01 02:31:49.710131|2018-06-01 02:31:49.710131
NCT00603512|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2012-11-14|2009-04-06|2012-12-16|2008-01-17|2008-01-29|Estimate|2012-12-16|2013-01-25|Estimate|2009-10-21|2009-10-23|Estimate|2012-12-16|2013-01-25|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone|Completed||Phase 2|140|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 02:31:54.212553|2018-06-01 02:31:54.212553
NCT00603499|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-01-16|2008-01-16|2008-01-29|Estimate|||||||2008-01-16|2008-01-29|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||Magnesium and Metabolic Syndrome|Hypomagnesemia as a Risk Factor for Development of Metabolic Syndrome|Completed||Phase 4|85|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-06-01 02:31:56.466261|2018-06-01 02:31:56.466261
NCT00603486|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-07-22|2008-01-16|2008-01-29|Estimate|||||||2008-07-22|2008-07-23|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|July 2008|Anticipated|2008-07-31|May 2008|Actual|2008-05-31||Observational|||SuperSTAT Noninvasive Blood Pressure Monitor Evaluation|SuperSTAT Noninvasive Blood Pressure Monitor Evaluation|Unknown status|Active, not recruiting||20|Anticipated|GE Healthcare|||||f||||f||||||||||2018-06-01 02:31:56.533099|2018-06-01 02:31:56.533099
NCT00603473|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2010-12-06||2011-01-24|2008-01-16|2008-01-29|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|January 2008||2008-01-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Phase III Open-Label Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures|An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Patients With Partial Seizures When Other Antiepileptics Do Not Provide Satisfactory Effects|Completed||Phase 3|92|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:31:56.603876|2018-06-01 02:31:56.603876
NCT00603460|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2017-04-28|2008-01-16|2008-01-29|Estimate|||||||2017-04-28|2017-05-02|Actual|January 2012||2012-01-31|April 2017|2017-04-30|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|||DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer|A Phase-I/II Randomized Trial of Maintenance Vaccination Combined With Metronomic Cyclophosphamide w/wo Adoptive Transfer of CD3/CD28-CoStimulated T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer Previously Vaccinated DCVax-L|Withdrawn||Phase 1/Phase 2|0|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:31:56.804383|2018-06-01 02:31:56.804383
NCT00603447|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|2015-05-15||2017-04-28|2008-01-28|2008-01-29|Estimate|2015-05-15|2015-06-03|Estimate||||2017-04-28|2017-05-30|Actual|May 2008||2008-05-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|May 2013|Actual|2013-05-31||Interventional|||Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma|Phase 1b Multicenter Dose Escalation Study of Carfilzomib With Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma|Completed||Phase 1|84|Actual|Amgen||1|||f||||f||||||||||2018-06-01 02:31:56.949055|2018-06-01 02:31:56.949055
NCT00603434|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2017-01-11|2008-01-28|2008-01-29|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)|Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)|Completed||Phase 1|16|Anticipated|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 02:31:59.429011|2018-06-01 02:31:59.429011
NCT00603421|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2016-02-24|2008-01-28|2008-01-29|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2009||2009-02-28|February 2016|2016-02-29|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients|Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients|Completed||N/A|318|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-06-01 02:31:59.518063|2018-06-01 02:31:59.518063
NCT00603408|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2016-07-08||2016-07-08|2008-01-28|2008-01-29|Estimate|2016-07-08|2016-08-19|Estimate||||2016-07-08|2016-08-19|Estimate|December 2007||2007-12-31|July 2016|2016-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer|Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters|Terminated||Phase 2|5|Actual|Washington University School of Medicine||1||Study was discontinued due to lack of accrual.|f||||f||||||||||2018-06-01 02:31:59.634004|2018-06-01 02:31:59.634004
NCT00603395|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-23|||2014-05-15|2008-01-16|2008-01-29|Estimate|||||||2014-05-15|2014-05-16|Estimate|September 2004||2004-09-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|September 2012|Actual|2012-09-30||Interventional|||A Prospective Clinical Study On A Total Hip Resurfacing System|A Prospective Clinical Study On A Total Hip Resurfacing System|Completed||N/A|298|Actual|St. Anna Ziekenhuis, Geldrop, Netherlands||1|||f||||f||||||||||2018-06-01 02:31:59.962846|2018-06-01 02:31:59.962846
NCT00603382|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-06-06|2009-11-30|2018-03-19|2008-01-28|2008-01-29|Estimate|2013-08-15|2013-08-19|Estimate|2009-11-30|2009-12-02|Estimate|2018-03-19|2018-04-18|Actual|December 1, 2007||2007-12-01|March 2018|2018-03-31|October 2, 2008|Actual|2008-10-02|October 1, 2008|Actual|2008-10-01||Interventional|||A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.|A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Administered Once Daily and Fluticasone Propionate Inhalation Powder 100mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy|Completed||Phase 2|599|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:32:00.16795|2018-06-01 02:32:00.16795
NCT00603369|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2009-02-05|2008-01-28|2008-01-29|Estimate|||||||2009-02-05|2009-02-06|Estimate|September 1999||1999-09-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|Project STAR||HIV, Abuse, and Psychiatric Disorders Among Youth|HIV, Abuse, and Psychiatric Disorders Among Youth|Completed||Phase 1|212|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-06-01 02:32:02.71493|2018-06-01 02:32:02.71493
NCT00603356|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-09-26|2008-01-28|2008-01-29|Estimate|||||||2011-09-26|2011-09-27|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Phase I Study of OSI-930 and Erlotinib in Cancer Tumors|A Phase 1 Dose Escalation Study of Daily Oral OSI-930 and Erlotinib (Tarceva) in Patients With Advanced Solid Tumors|Completed||Phase 1|60|Anticipated|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:32:02.913609|2018-06-01 02:32:02.913609
NCT00603343|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-01-16|2008-01-16|2008-01-29|Estimate|||||||2008-01-16|2008-01-29|Estimate|June 2004||2004-06-30|January 2008|2008-01-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence|Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial|Completed||Phase 3|303|Actual|APOGEPHA Arzneimittel GmbH||2|||f||||t||||||||||2018-06-01 02:32:02.996396|2018-06-01 02:32:02.996396
NCT00603330|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2018-05-02|2008-01-28|2008-01-29|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2008||2008-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function|Infusion of Mesenchymal Stem Cells as Treatment for Steroid-Resistant Grade II to IV Acute GVHD or Poor Graft Function: a Multicenter Phase II Study|Recruiting||Phase 2|100|Anticipated|University Hospital of Liege||3|||f||||f||||||||||2018-06-01 02:32:03.10236|2018-06-01 02:32:03.10236
NCT00603317|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2010-07-09|2008-01-16|2008-01-29|Estimate|||||||2010-07-09|2010-07-12|Estimate|March 2008||2008-03-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|INWARA||Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid|Pharmacodynamic Drug Interaction Between Warfarin and Amoxicillin-clavulanic Acid|Completed||Phase 4|13|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:32:03.253822|2018-06-01 02:32:03.253822
NCT00603304|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-04-26||2012-09-12|2008-01-28|2008-01-29|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|February 2008||2008-02-29|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|CAMUS||Complementary and Alternative Medicine for Urological Symptoms(CAMUS)|Complementary and Alternative Medicine for Urological Symptoms (CAMUS)|Completed||Phase 3|369|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 02:32:03.401992|2018-06-01 02:32:03.401992
NCT00603291|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2013-01-04|2012-07-26|2013-01-04|2008-01-17|2008-01-29|Estimate|2013-01-04|2013-02-07|Estimate|2012-08-06|2012-08-14|Estimate|2013-01-04|2013-02-07|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus|A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients With Type 2 Diabetes Mellitus Managed With Oral Hypoglycemic Agent(s)|Completed||Phase 3|604|Actual|Arena Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:32:04.217163|2018-06-01 02:32:04.217163
NCT00603278|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-06-06|2009-11-30|2016-11-04|2008-01-28|2008-01-29|Estimate|2013-06-06|2013-08-12|Estimate|2009-11-30|2009-12-02|Estimate|2016-11-04|2016-12-28|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.|A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma Symptomatic on Low-Dose ICS Therapy|Completed||Phase 2|622|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:32:04.941286|2018-06-01 02:32:04.941286
NCT00603265|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2015-04-21||2015-06-04|2008-01-17|2008-01-29|Estimate|2015-06-04|2015-07-01|Estimate||||2015-06-04|2015-07-01|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||All participants who were randomized and treated with study medication.|Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|A Phase 2a, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100 mg BID in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|Completed||Phase 2|226|Actual|Cubist Pharmaceuticals LLC||3|||f||||f||||||||||2018-06-01 02:32:07.477551|2018-06-01 02:32:07.477551
NCT00603252|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2017-03-13|2008-01-28|2008-01-29|Estimate|||||||2017-03-13|2017-03-14|Actual|January 2008||2008-01-31|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults|Evaluate the Effect of Risk Factors That Influence the Immunogenicity of GSK Biologicals' Twinrix Compared to Hepatitis A and Hepatitis B Vaccines Given Separately and to Show the Non-inferiority Between the Vaccines in Adults|Completed||Phase 4|213|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:32:08.329785|2018-06-01 02:32:08.329785
NCT00603239|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|2010-07-20||2015-03-19|2008-01-28|2008-01-29|Estimate|2010-08-12|2010-09-02|Estimate||||2015-03-19|2015-04-07|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin|Completed||Phase 3|165|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:32:08.503839|2018-06-01 02:32:08.503839
NCT00603226|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2008-01-16|2008-01-16|2008-01-29|Estimate|||||||2008-01-16|2008-01-29|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Observational|||Slow Coronary Artery Flow: Influence on Morbidity and Mortality|Slow Coronary Artery Flow: Influence on Morbidity and Mortality|Unknown status|Recruiting||50|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-06-01 02:32:09.370696|2018-06-01 02:32:09.370696
NCT00603213|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2013-05-21|2008-01-28|2008-01-29|Estimate|||||||2013-05-21|2013-05-22|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|February 2011|Actual|2011-02-28|October 2010|Actual|2010-10-31||Observational|Optivol||Correlation of Intrathoracic Impedance Measures With Blood Plasma Volume in Congestive Heart Failure|Correlation of Intrathoracic Impedance Measure With Blood Plasma Volume in Congestive Heart Failure|Completed|||25|Actual|Medical University of South Carolina|||||f||||f||||||Samples Without DNA|"~     15 mls of blood will be drawn to assay for plasma analytes including but not limited to MMPs,~     TIMPs and collagen propeptides.~   "|||2018-06-01 02:32:09.489112|2018-06-01 02:32:09.489112
NCT00603200|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2010-11-04|2008-01-26|2008-01-28|Estimate|||||||2010-11-04|2010-11-05|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|December 2009|Anticipated|2009-12-31|June 2008|Anticipated|2008-06-30||Observational|||Effect of Large Volume Paracentesis on Fatigue in Cirrhosis|The Effect of Large Volume Paracentesis on Fatigue in Cirrhosis|Unknown status|Recruiting||10|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 02:32:09.626946|2018-06-01 02:32:09.626946
NCT00603187|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2011-01-10||2011-05-10|2008-01-26|2008-01-28|Estimate|2011-05-10|2011-06-09|Estimate||||2011-05-10|2011-06-09|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|ACY-7||ACY-7 Oral Administration of Acyline|Oral Administration of the GnRH Antagonist Acyline in Normal Men Part II: Multiple-dose Pharmacokinetics (Acyline-7/MER 104-02)|Completed||Phase 1/Phase 2|4|Actual|University of Washington|||||f||||f||||||||||2018-06-01 02:32:09.767815|2018-06-01 02:32:09.767815
NCT00603174|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2012-09-18|2008-01-15|2008-01-28|Estimate|||||||2012-09-18|2012-09-19|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|NAVA||Use of Neurally Adjusted Ventilatory Assist in Infants Respiratory Failure|Use of Neurally Adjusted Ventilatory Assist in Infants With Acute Respiratory Failure: a Case Study on Servo I|Completed||N/A|10|Actual|St. Justine's Hospital||1|||f||||f||||||||||2018-06-01 02:32:10.172815|2018-06-01 02:32:10.172815
NCT00603148|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2013-12-16|2008-01-26|2008-01-28|Estimate|||||||2013-12-16|2013-12-17|Estimate|September 2006||2006-09-30|December 2013|2013-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications|The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications in Patients Undergoing Invasive Procedures in the Hybrid Cardiac Catheterization/Cardiac Surgery Suite|Completed|||475|Anticipated|Vanderbilt University|||||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 02:32:10.253211|2018-06-01 02:32:10.253211
NCT00603135|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-03-09|2008-01-26|2008-01-28|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|March 2010|Anticipated|2010-03-31|July 2009|Anticipated|2009-07-31||Interventional|Keppra||Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus|Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus|Withdrawn||Phase 2|0|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-06-01 02:32:10.411789|2018-06-01 02:32:10.411789
NCT00603122|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2014-05-18|2008-01-26|2008-01-28|Estimate|||||||2014-05-18|2014-05-20|Estimate|March 2005||2005-03-31|May 2014|2014-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Acclimatization Mechanisms During Ascent to 7500m|Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology|Completed||N/A|37|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 02:32:10.535047|2018-06-01 02:32:10.535047
NCT00603109|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-01-03|2008-01-26|2008-01-28|Estimate|||||||2011-01-03|2011-01-04|Estimate|August 2007||2007-08-31|January 2011|2011-01-31|August 2008|Anticipated|2008-08-31|June 2008|Anticipated|2008-06-30||Interventional|PWS||Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome|Effect of Rimonabant, a Cannabinoid Receptor 1 Antagonist on Weight Gain and Body Composition in Adults With Prader Willi Syndrome.|Unknown status|Recruiting|Phase 3|18|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 02:32:10.872793|2018-06-01 02:32:10.872793
NCT00603096|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2008-01-15|2008-01-15|2008-01-28|Estimate|||||||2008-01-15|2008-01-28|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|NIV-OHS||Use of Polysomnography for Non-Invasive Ventilation Settings' Optimization|Interest of Using Nocturnal Polysomnography for Non-Invasive Ventilation (NIV) Settings' Optimization in Obesity-Hypoventilation Syndrome (OHS)|Unknown status|Recruiting|N/A|45|Anticipated|Tyco Healthcare Group||2|||f||||f||||||||||2018-06-01 02:32:11.001045|2018-06-01 02:32:11.001045
NCT00603083|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2011-12-08|2008-01-26|2008-01-28|Estimate|||||||2011-12-08|2011-12-09|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Postoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia|Postoperative Pain Treatment in Total Hip Arthroplasty A Randomized Double-blinded Placebo-controlled Study to Assess the Effect of Local Analgesia|Completed||Phase 4|60|Actual|Vejle Hospital||2|||f||||t||||||||||2018-06-01 02:32:11.124944|2018-06-01 02:32:11.124944
NCT00603070|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2012-02-17|2008-01-26|2008-01-28|Estimate|||||||2012-02-17|2012-02-20|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Electronic Prescribing and Electronic Transmission of Discharge Medication Lists|Electronic Prescribing and Electronic Transmission of Discharge Medication Lists to Improve Ambulatory Medication Safety|Completed|||130|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-06-01 02:32:11.324503|2018-06-01 02:32:11.324503
NCT00603057|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-10-10|2008-01-15|2008-01-28|Estimate|||||||2017-10-10|2017-10-12|Actual|May 2007||2007-05-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2013|Actual|2013-09-30||Observational|||Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer|Using Functional Image and Circulating Molecular Markers to Predict Tumor Response and Lung Toxicity in Treatment of Lung Cancer|Active, not recruiting|||140|Anticipated|University of Michigan Cancer Center|||1||f||||t||||||||||2018-06-01 02:32:11.432324|2018-06-01 02:32:11.432324
NCT00603044|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2015-04-13||2015-04-29|2008-01-26|2008-01-28|Estimate|2015-04-29|2015-05-04|Estimate||||2015-04-29|2015-05-04|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome|Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome|Completed||Phase 4|24|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:32:11.53035|2018-06-01 02:32:11.53035
NCT00603031|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-01-20|2008-01-26|2008-01-28|Estimate|||||||2011-01-20|2011-01-21|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus|Effect of GLP-1 and GIP on the Maximal Insulin Secretory Capacity in Type-1 Diabetes Mellitus|Completed||N/A|9|Actual|Hvidovre University Hospital||3|||f||||f||||||||||2018-06-01 02:32:11.964973|2018-06-01 02:32:11.964973
NCT00603018|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2016-01-25||2016-08-02|2008-01-26|2008-01-28|Estimate|2016-08-02|2016-09-23|Estimate||||2016-08-02|2016-09-23|Estimate|June 2007||2007-06-30|August 2016|2016-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||PET Imaging Study of Recovered Anorexics|PET Imaging of Dopaminergic Transmission and Serotonin Markers in Anorexia Nervosa|Completed||N/A|23|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:32:12.06243|2018-06-01 02:32:12.06243
NCT00603005|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2010-02-23|2008-01-26|2008-01-28|Estimate|||||||2010-02-23|2010-02-24|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Adherence Improvement in Glaucoma Patients|Adherence Improvement in Glaucoma Patients|Completed||N/A|802|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-06-01 02:32:12.242289|2018-06-01 02:32:12.242289
NCT00602992|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2016-06-21|2008-01-26|2008-01-28|Estimate|||||||2016-06-21|2016-06-23|Estimate|August 2006||2006-08-31|June 2016|2016-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Exploring the Role of 3T MRI in Gamma Knife Radiosurgery|Exploring the Role of 3T MRI in Gamma Knife Radiosurgery: A Pilot Study|Completed|||45|Actual|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 02:32:12.362136|2018-06-01 02:32:12.362136
NCT00602979|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2017-02-17||2017-04-10|2008-01-15|2008-01-28|Estimate|2017-04-10|2017-05-19|Actual||||2017-04-10|2017-05-19|Actual|April 2008||2008-04-30|April 2017|2017-04-30|July 2011|Actual|2011-07-31|September 2009|Actual|2009-09-30||Interventional|||Comparison Study in Adult Surgical Patients of 5 Airway Devices|Prospective, Randomized Comparison of Intubating Conditions With Airtraq Optical, Storz DCI Video, McGRATH Video, GlideScope Video, & Macintosh Laryngoscope in Randomly Selected Elective Adult Surgical Patients|Completed||N/A|240|Actual|Weill Medical College of Cornell University||5|||f||||f||||||||No||2018-06-01 02:32:12.423449|2018-06-01 02:32:12.423449
NCT00602966|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-10-26|2008-01-26|2008-01-28|Estimate|||||||2011-10-26|2011-10-28|Estimate|July 2006||2006-07-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Observational|||Oocyte Cryopreservation: Slow Cooling Versus Vitrification Techniques on Oocyte Survival|Oocyte Cryopreservation: Comparison of Slow Cooling Versus Vitrification Techniques on Oocyte Survival, Fertilization, and Embryo Development|Completed|||14|Actual|UConn Health|||2||f||||f||||||||||2018-06-01 02:32:12.823064|2018-06-01 02:32:12.823064
NCT00602953|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2017-08-17||2017-11-29|2008-01-15|2008-01-28|Estimate|2017-11-29|2017-12-26|Actual||||2017-11-29|2017-12-26|Actual|September 2007||2007-09-30|November 2017|2017-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Role of Pancreatic Triglyceride Content in Beta-cell Function|Role of Pancreatic Triglyceride Content in Beta-cell Function|Completed|||101|Actual|University of Texas Southwestern Medical Center|||5||f||||t||||||||||2018-06-01 02:32:12.899089|2018-06-01 02:32:12.899089
NCT00602940|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2010-05-20|2008-01-26|2008-01-28|Estimate|||||||2010-05-20|2010-05-21|Estimate|January 2006||2006-01-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Acupuncture for Polycystic Ovarian Syndrome|The Influence of Acupuncture on Ovulation and Reproductive Hormones|Unknown status|Active, not recruiting|N/A|78|Anticipated|University of Virginia||2|||f||||f||||||||||2018-06-01 02:32:13.417744|2018-06-01 02:32:13.417744
NCT00602927|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2010-10-06||2011-05-06|2008-01-26|2008-01-28|Estimate|2011-04-01|2011-05-02|Estimate||||2011-05-06|2011-05-10|Estimate|November 2007||2007-11-30|May 2011|2011-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effects of Varenicline on Brain Activity During Nicotine Abstinence|Neural Substrates of Varenicline's (Chantix®) Efficacy for Smoking Cessation|Completed||N/A|38|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:32:13.510684|2018-06-01 02:32:13.510684
NCT00602914|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-30|||2013-05-08|2008-01-15|2008-01-28|Estimate|||||||2013-05-08|2013-05-10|Estimate|March 2008||2008-03-31|April 2008|2008-04-30|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|MicronJet||A Pilot Study to Assess the Safety, PK and PD of Insulin Injected Via MicronJet or Conventional Needle|An Open Label Study in Healthy Volunteers and Diabetes Mellitus Type II Subjects to Determine the Safety, Pharmacokinetics and Pharmacodynamics Profile of Insulin Injected by the MicronJet Device|Completed||Early Phase 1|23|Actual|NanoPass Technologies Ltd||2|||f||||f||||||||||2018-06-01 02:32:13.77057|2018-06-01 02:32:13.77057
NCT00602901|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2017-04-05|2008-01-25|2008-01-28|Estimate|||||||2017-04-05|2017-04-06|Actual|July 2004||2004-07-31|April 2017|2017-04-30|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|HRSA4||Elderly Back Pain: Comparing Chiropractic to Medical Care|Elderly Back Pain: Comparing Chiropractic to Medical Care|Completed||Phase 2|240|Actual|Palmer College of Chiropractic||3|||f||||f||||||||||2018-06-01 02:32:13.850788|2018-06-01 02:32:13.850788
NCT00602862|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-11-29|2008-01-15|2008-01-28|Estimate|||||||2013-11-29|2013-12-02|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250|The Effect of Sorafenib (Nexavar®) on 111-Indium Labeled Chimeric Monoclonal Antibody G250 or 111-Indium Labeled Bevacizumab (Avastin®) Uptake in Patients With Clear Cell RCC (ccRCC)|Completed||N/A|26|Actual|Radboud University||3|||f||||t||||||||||2018-06-01 02:32:13.960039|2018-06-01 02:32:13.960039
NCT00602849|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2003||2003-06-30|January 2018|2018-01-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Bioequivalency Study of Sertraline Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fasting Conditions|Completed||N/A|38|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:14.03966|2018-06-01 02:32:14.03966
NCT00602836|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-12|2012-03-15||2017-09-12|2008-01-25|2008-01-28|Estimate|2012-03-15|2012-04-11|Estimate||||2017-09-12|2017-10-13|Actual|February 2008|Actual|2008-02-29|September 2017|2017-09-30|September 12, 2017|Actual|2017-09-12|December 2010|Actual|2010-12-31||Interventional|||Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab Followed by Consolidation With Lenalidomide for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Completed||Phase 2|45|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:32:14.240353|2018-06-01 02:32:14.240353
NCT00602823|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2008-01-25|2008-01-25|2008-01-28|Estimate|||||||2008-01-25|2008-01-28|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|May 2006||2006-05-31|||||Observational|||Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)|Ex Vivo Monocyte and Lymphocyte Stimulation Tests and Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva)|Completed|||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 02:32:14.568477|2018-06-01 02:32:14.568477
NCT00602797|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2018-01-30||2018-04-17|2008-01-15|2008-01-28|Estimate|2018-04-17|2018-05-17|Actual||||2018-04-17|2018-05-17|Actual|December 2007||2007-12-31|April 2018|2018-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study of Weekly Vinorelbine and Paclitaxel in Elderly Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|20|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:32:14.662961|2018-06-01 02:32:14.662961
NCT00602784|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2012-10-18|2008-01-15|2008-01-28|Estimate|||||||2012-10-18|2012-10-19|Estimate|November 2002||2002-11-30|October 2012|2012-10-31|September 2004|Actual|2004-09-30|May 2004|Actual|2004-05-31||Interventional|||Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine|Double Blind, Randomized, Multicenter, Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine Together With Polyarginine, HCV Peptide Vaccine Alone, or Polyarginine Alone, in Patients With Chronic HCV Having Not Responded to or Relapsed From Primary Standard HCV Therapy|Completed||Phase 2|66|Actual|Valneva Austria GmbH||5|||f||||f||||||||||2018-06-01 02:32:14.978983|2018-06-01 02:32:14.978983
NCT00602771|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|2013-01-08||2014-10-01|2008-01-24|2008-01-28|Estimate|2014-04-22|2014-05-26|Estimate||||2014-10-01|2014-10-09|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia|A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML)|Completed||Phase 2|84|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 02:32:15.062802|2018-06-01 02:32:15.062802
NCT00602758|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2016-05-19|2008-01-25|2008-01-28|Estimate|||||||2016-05-19|2016-05-20|Estimate|December 2004||2004-12-31|May 2016|2016-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV|ART Adherence: Enhanced Counseling and Observed Therapy|Completed||N/A|252|Actual|University of Missouri, Kansas City||3|||f||||f||||||||||2018-06-01 02:32:15.337968|2018-06-01 02:32:15.337968
NCT00602745|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16||2016-04-27|2016-04-27|2008-01-16|2008-01-28|Estimate||||2016-04-27|2016-05-26|Estimate|2016-04-27|2016-05-26|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|S-1 Pancreas||S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen|A Multicenter, Open-Label, Randomized Study Comparing Efficacy and Safety of S-1 as Single Agent Versus 5-FU Bolus for the Treatment of Patients With Metastatic Pancreatic Cancer Previously Treated With a Gemcitabine-Based Regimen|Terminated||Phase 3|61|Actual|Sanofi||2||"Following the termination of development and commercialization agreement for S-1 with Taiho~   Pharmaceutical"|f||||t||||||||||2018-06-01 02:32:15.447984|2018-06-01 02:32:15.447984
NCT00602732|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2014-03-27|2008-01-22|2008-01-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|September 2005||2005-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Interpersonal Treatment Program to Prevent Depression and Post-Traumatic Stress Disorder in Low-Income Pregnant Women With Partner Abuse|Intervention for Low-income Pregnant Women With Partner Abuse|Completed||Phase 1|60|Actual|Butler Hospital||2|||f||||t||||||||||2018-06-01 02:32:15.548958|2018-06-01 02:32:15.548958
NCT00602719|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2004||2004-03-31|January 2018|2018-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zolpidem Tartrate Tablets 10 MG Under Fed Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:15.662905|2018-06-01 02:32:15.662905
NCT00602706|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-05-13|2008-01-24|2008-01-28|Estimate|||||||2011-05-13|2011-05-16|Estimate|January 2000||2000-01-31|May 2011|2011-05-31|July 2010|Actual|2010-07-31|June 2003|Actual|2003-06-30||Interventional|||Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant|A Phase I/II Dose Escalation Study Assessing the Toxicity and Efficacy of 153-Samarium-EDTMP in Place of TBI in the Conditioning Regimen for PBSCT for Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|76|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 02:32:15.752998|2018-06-01 02:32:15.752998
NCT00602693|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2017-11-29|2008-01-18|2008-01-28|Estimate|||||||2017-11-29|2017-12-02|Actual|July 23, 2007|Actual|2007-07-23|November 2017|2017-11-30|April 16, 2015|Actual|2015-04-16|September 25, 2014|Actual|2014-09-25||Interventional|||T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer|Phase I Study of Infusion of Umbilical Cord Blood (UCB) Derived CD25+CD4+ T-Regulatory (Treg) Cells After Nonmyeloablative Cord Blood Transplantation|Completed||Phase 1|41|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 02:32:15.842608|2018-06-01 02:32:15.842608
NCT00602680|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2009-07-17|2008-01-16|2008-01-28|Estimate|||||||2009-07-17|2009-07-20|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease|A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease|Terminated||Phase 2|1|Actual|Sanofi||5||Insufficient expected benefit risk|f||||t||||||||||2018-06-01 02:32:15.963308|2018-06-01 02:32:15.963308
NCT00602667|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2017-05-22|2008-01-24|2008-01-28|Estimate|||||||2017-05-22|2017-05-23|Actual|December 17, 2007|Actual|2007-12-17|May 2017|2017-05-31|April 30, 2023|Anticipated|2023-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma|Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma|Active, not recruiting||Phase 2|293|Actual|St. Jude Children's Research Hospital||3|||f||||f|t|f||||||||2018-06-01 02:32:16.043699|2018-06-01 02:32:16.043699
NCT00602641|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2015-05-05||2018-05-24|2008-01-25|2008-01-28|Estimate|2015-06-09|2015-06-29|Estimate||||2018-05-24|2018-05-25|Actual|February 29, 2008|Actual|2008-02-29|March 2018|2018-03-31||||January 18, 2014|Actual|2014-01-18||Interventional|||Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma|An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy|Active, not recruiting||Phase 3|306|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 02:32:16.239899|2018-06-01 02:32:16.239899
NCT00602628|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2013-06-25|2008-01-24|2008-01-28|Estimate|||||||2013-06-25|2013-06-26|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|||Radiation Therapy Planning Techniques in Reducing Damage to Normal Tissue in Women Undergoing Breast-Conserving Surgery for Ductal Carcinoma of the Breast|WILL MULTIFUNCTIONAL MAGNETIC RESONANCE TECHNIQUES, DETAILED HISTOPATHOLOGICAL ANALYSIS AND PRONE TREATMENT POSITION IMPROVE ACCURACY OF TARGET VOLUME LOCALISATION & DEFINITION AND REDUCE EXPOSURE OF NORMAL TISSUES IN BREAST RADIOTHERAPY?|Completed||N/A|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:32:17.629302|2018-06-01 02:32:17.629302
NCT00602615|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2003||2003-09-30|January 2018|2018-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Bioequivalency Study of Torsemide Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fed Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:17.69141|2018-06-01 02:32:17.69141
NCT00602602|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2017-01-24|2008-01-22|2008-01-28|Estimate|||||||2017-01-24|2017-01-25|Estimate|March 2007||2007-03-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer|A Phase II Study of Gemcitabine, Oxaliplatin and Bevacizumab Followed by 5-Fluorouracil, Oxaliplatin, Bevacizumab and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer|Active, not recruiting||Phase 2|99|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||||||||||||2018-06-01 02:32:17.74019|2018-06-01 02:32:17.74019
NCT00602589|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2016-12-21|2008-01-25|2008-01-28|Estimate|||||||2016-12-21|2016-12-22|Estimate|October 2002||2002-10-31|April 2010|2010-04-30|November 2002|Actual|2002-11-30|||||Interventional|||A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects|An Open-label, Randomized, 3-way Crossover Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects|Completed||Phase 1|72|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:32:17.799762|2018-06-01 02:32:17.799762
NCT00602576|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2009-08-12|2008-01-25|2008-01-28|Estimate|||||||2009-08-12|2009-08-13|Estimate|January 2005||2005-01-31|August 2009|2009-08-31||||March 2008|Anticipated|2008-03-31||Interventional|||Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma|RANDOMIZED PHASE II STUDY COMPARING TWO SCHEDULES OF TEMOZOLOMIDE IN COMBINATION WITH BAY43-9006 IN PATIENTS WITH ADVANCED MELANOMA|Unknown status|Active, not recruiting|Phase 2|167|Anticipated|National Cancer Institute (NCI)||2|||||||||||||||||2018-06-01 02:32:17.850925|2018-06-01 02:32:17.850925
NCT00602563|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2016-12-06|2008-01-25|2008-01-28|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2007||2007-12-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Attention Training for Generalized Anxiety Disorder|Attention Training for Generalized Anxiety Disorder (Attention Training and Relaxation for GAD: Testing the Efficacy of Home-Delivery)|Completed||N/A|193|Actual|San Diego State University||4|||f||||t||||||||||2018-06-01 02:32:18.308802|2018-06-01 02:32:18.308802
NCT00602550|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2003||2003-06-30|January 2018|2018-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Bioequivalency Study of Zidovudine Under Fasting Conditions|A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fasting Conditions|Completed||N/A|52|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:18.584497|2018-06-01 02:32:18.584497
NCT00602537|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2016-11-10||2017-04-21|2008-01-15|2008-01-28|Estimate|2017-04-21|2017-04-25|Actual||||2017-04-21|2017-04-25|Actual|December 2007||2007-12-31|April 2017|2017-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Antidepressant Therapy in Treating Bipolar Type II Major Depression|Treatment of Bipolar Type II Major Depression|Completed||Phase 4|140|Actual|University of Pennsylvania||2|||f||||t||||||||No||2018-06-01 02:32:18.877793|2018-06-01 02:32:18.877793
NCT00602524|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2004||2004-08-31|January 2018|2018-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Sequence Crossover Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:19.555487|2018-06-01 02:32:19.555487
NCT00602511|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-02-08|2008-01-15|2008-01-28|Estimate|||||||2011-02-08|2011-02-09|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma|Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma|Completed||Phase 3|300|Anticipated|Nordic Myeloma Study Group||2|||f||||f||||||||||2018-06-01 02:32:19.611482|2018-06-01 02:32:19.611482
NCT00602498|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2003||2003-03-31|January 2018|2018-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions|A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 500 mg Clarithromycin Tablets Under Fed Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:19.710607|2018-06-01 02:32:19.710607
NCT00248326|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2016-01-04|2005-11-02|2005-11-03|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2005||2005-01-31|January 2016|2016-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||The Genetic Basis of Atrial Fibrillation (AF)|The Genetic Basis of Atrial Fibrillation|Completed|||50|Actual|University of Pittsburgh|||2||f||||t||||||||||2018-06-01 04:21:56.515361|2018-06-01 04:21:56.515361
NCT00602485|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2009-09-17|2008-01-25|2008-01-28|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Effect of Action Control Based Intervention on Adherence After Cardiac Rehabilitaiton|The Effect of Action Control Based Interventions on Adherence to Prescribed Exercise and Diet Regimens for Patients Completing a Cardiac Rehabilitation Program Intervetnion on|Completed||Phase 1|80|Anticipated|Summa Health System|||||f||||f||||||||||2018-06-01 02:32:19.767345|2018-06-01 02:32:19.767345
NCT00602472|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2011-05-13||2014-02-27|2008-01-25|2008-01-28|Estimate|2011-05-13|2011-06-15|Estimate||||2014-02-27|2014-03-28|Estimate|February 2008||2008-02-29|February 2014|2014-02-28||||May 2009|Actual|2009-05-31||Interventional|||BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg) Administered Orally Once Daily Over 24 Weeks, With an Open-label Extension to One Year (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite a Therapy of Metformin in Combination With a Sulphonylurea|Completed||Phase 3|1058|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:32:19.847265|2018-06-01 02:32:19.847265
NCT00602459|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2016-12-19||2017-12-01|2008-01-23|2008-01-28|Estimate|2017-02-15|2017-04-04|Actual||||2017-12-01|2017-12-05|Actual|January 15, 2008|Actual|2008-01-15|October 2017|2017-10-31||||December 1, 2014|Actual|2014-12-01||Interventional||400 participants were evaluable for analysis. (18 participants were excluded from the analysis.)|Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia|A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 2|418|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 02:32:22.043923|2018-06-01 02:32:22.043923
NCT00602446|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2010-03-16||2017-12-03|2008-01-24|2008-01-28|Estimate|2010-03-16|2010-03-30|Estimate||||2017-12-03|2017-12-28|Actual|August 2007||2007-08-31|December 2017|2017-12-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant|Open-Label Single-Arm Pilot Study of Deferasirox (Exjade®) in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload|Terminated||Phase 2|4|Actual|Masonic Cancer Center, University of Minnesota||1||Due to slow accrual of patients|f||||t||||||||||2018-06-01 02:32:24.961579|2018-06-01 02:32:24.961579
NCT00602433|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2011-04-14|2008-01-24|2008-01-28|Estimate|||||||2011-04-14|2011-04-15|Estimate|December 2007||2007-12-31|April 2011|2011-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib|Evaluation of Hormonal Changes in Women on Erlotinib Therapy|Completed|||10|Actual|Northwestern University|||1||f||||f||||||Samples Without DNA|"~     blood will be tested for different sex hormones as well as glucose metabolism~   "|||2018-06-01 02:32:25.113297|2018-06-01 02:32:25.113297
NCT00602420|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2014-06-24||2015-10-13|2008-01-22|2008-01-28|Estimate|2015-05-08|2015-05-12|Estimate||||2015-10-13|2015-11-09|Estimate|June 2008||2008-06-30|October 2015|2015-10-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional||At least 145 evaluable patients in each treatment group, thus 290 evaluable patients in total, required for an 80% power analysis.|Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)|Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial|Completed||Phase 3|510|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 02:32:25.202704|2018-06-01 02:32:25.202704
NCT00602407|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2004||2004-02-29|January 2018|2018-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions|A Single Dose, Randomized, Two-Period, Two-Treatment, Crossover Bioequivalency Study of Cilostazol 50 mg Tablets Under Fasting Conditions|Completed||N/A|36|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:25.692607|2018-06-01 02:32:25.692607
NCT00602394|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2003||2003-05-31|January 2018|2018-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:25.742692|2018-06-01 02:32:25.742692
NCT00602381|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2002||2002-11-30|January 2018|2018-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions|A Single Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalency Study of 450 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:25.87934|2018-06-01 02:32:25.87934
NCT00602368|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2017-01-30|2008-01-25|2008-01-28|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2010||2010-12-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Digital Colposcopy in Finding Cervical Intraepithelial Neoplasia|Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia: A Pilot Study|Completed||N/A|114|Actual|British Columbia Cancer Agency|||||f||||f||||||||||2018-06-01 02:32:25.940125|2018-06-01 02:32:25.940125
NCT00602355|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2016-06-01||2016-07-29|2008-01-23|2008-01-28|Estimate|2016-07-29|2016-09-21|Estimate||||2016-07-29|2016-09-21|Estimate|February 2008||2008-02-29|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effectiveness of Sertraline Alone and Interpersonal Psychotherapy Alone in Treating Women With Postpartum Depression|Placebo Controlled Trial of Sertraline and Interpersonal Psycho-Therapy for Postpartum Depression|Completed||Phase 2|162|Actual|Women and Infants Hospital of Rhode Island||3|||f||||t||||||||||2018-06-01 02:32:26.027139|2018-06-01 02:32:26.027139
NCT00602342|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2004||2004-03-31|January 2018|2018-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fasting Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:26.692622|2018-06-01 02:32:26.692622
NCT00602329|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|||2009-07-07|2008-01-19|2008-01-28|Estimate|||||||2009-07-07|2009-07-08|Estimate|February 2006||2006-02-28|July 2009|2009-07-31||||December 2009|Anticipated|2009-12-31||Interventional|||MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer|A Phase II Study Assessing Tumor Blood Flow as Measured by Dynamic Contrast Enhanced MRI in Patients With Metastatic Colorectal Cancer Receiving FOLFOX Alone Versus Patients Randomized to Receive FOLFOX Plus Bevacizumab at 5mg/kg or 10mg/kg.|Unknown status|Recruiting|Phase 2|120|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 02:32:26.750394|2018-06-01 02:32:26.750394
NCT00602316|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-16|||2013-08-23|2008-01-16|2008-01-28|Estimate|||||||2013-08-23|2013-08-26|Estimate|November 2007||2007-11-30|June 2009|2009-06-30||||September 2009|Anticipated|2009-09-30||Interventional|||Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer|Using Magnetic Resonance Techniques to Improve the Characterisation and Localisation of Breast Cancer. A Pilot Observational Study Testing the Accuracy of Multifunctional Magnetic Resonance Techniques in Predicting the Presence, Distribution and Nature of Breast Lesions in Women With Known Breast Cancer|Unknown status|Recruiting|N/A|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:32:26.828641|2018-06-01 02:32:26.828641
NCT00602303|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2003||2003-09-30|January 2018|2018-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Bioequivalency Study of Torsemide Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fasting Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:27.052147|2018-06-01 02:32:27.052147
NCT00602290|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2014-06-08||2017-12-12|2008-01-23|2008-01-28|Estimate|2014-08-28|2014-09-01|Estimate||||2017-12-12|2018-01-11|Actual|February 2008||2008-02-29|December 2017|2017-12-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression|The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients|Completed||Phase 4|181|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-06-01 02:32:27.117969|2018-06-01 02:32:27.117969
NCT00602277|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|||2016-08-05|2008-01-25|2008-01-28|Estimate|||||||2016-08-05|2016-08-08|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy|A Phase 1 Study of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) (NSC 729968) in Patients With Ovarian, Primary Peritoneal and Fallopian Tube Carcinoma|Completed||Phase 1|70|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:32:27.411316|2018-06-01 02:32:27.411316
NCT00602264|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2008-01-25|2008-01-25|2008-01-28|Estimate|||||||2008-01-25|2008-01-28|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|May 2007|Actual|2007-05-31|||||Observational|||Adipokines and Ghrelin Concentrations in Different Stages of Anorexia Nervosa|Adipocytokine and Ghrelin Concentrations in Different Stages of Anorexia Nervosa|Completed|||41|Actual|Istanbul University|||4||f||||f||||||||||2018-06-01 02:32:27.485861|2018-06-01 02:32:27.485861
NCT00602251|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2004||2004-03-31|January 2018|2018-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Bioequivalency Study of Terbinafine Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 250 mg Terbinafine Hydrochloride Tablets Under Fed Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:27.543392|2018-06-01 02:32:27.543392
NCT00602225|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2017-03-04||2018-02-08|2008-01-23|2008-01-28|Estimate|2017-08-07|2017-09-08|Actual||||2018-02-08|2018-03-09|Actual|December 2007||2007-12-31|February 2018|2018-02-28|April 2015|Actual|2015-04-30|March 2010|Actual|2010-03-31||Interventional|||Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Dose Escalation Study of Clofarabine in Combination With Cytarabine (Ara-C) and G-CSF Priming for Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients|Completed||Phase 1/Phase 2|50|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:32:27.622974|2018-06-01 02:32:27.622974
NCT00602212|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2011-09-08|2008-01-25|2008-01-28|Estimate|||||||2011-09-08|2011-09-09|Estimate|February 2008||2008-02-29|January 2008|2008-01-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|INTREPID||Virtual Reality as Anxiety Management Tool for Generalized Anxiety Disorder|The Potential of Virtual Reality as Anxiety Management Tool: a Randomised Controlled Study in a Sample of Patients Affected by Generalized Anxiety Disorder|Completed||N/A|24|Actual|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-06-01 02:32:27.979157|2018-06-01 02:32:27.979157
NCT00602199|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2011-05-13|2008-01-12|2008-01-28|Estimate|||||||2011-05-13|2011-05-16|Estimate|November 2004||2004-11-30|May 2011|2011-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||ABT-510 in Treating Patients With Metastatic Melanoma|A Phase II Study of Anti-angiogenesis Therapy for Metastatic Melanoma Using ABT-510|Completed||Phase 2|42|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 02:32:28.064345|2018-06-01 02:32:28.064345
NCT00602186|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2008-01-26|2008-01-25|2008-01-28|Estimate|||||||2008-01-26|2008-01-29|Estimate|July 2005||2005-07-31|January 2008|2008-01-31|March 2008|Anticipated|2008-03-31|March 2007|Anticipated|2007-03-31||Interventional|||Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction|Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction|Unknown status|Active, not recruiting|Phase 1/Phase 2|80|Actual|Tabriz University||2|||f||||t||||||||||2018-06-01 02:32:28.120746|2018-06-01 02:32:28.120746
NCT00602173|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2003||2003-05-31|January 2018|2018-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions|A Single Dose, Randomized, Three-Period, Three-Treatment, Crossover Bioequivalency Study of Cilostazol 100 mg Tablets Under Fasting Conditions|Completed||N/A|32|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:28.184591|2018-06-01 02:32:28.184591
NCT00602160|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2010-11-03|2008-01-15|2008-01-28|Estimate|||||||2010-11-03|2010-11-04|Estimate|December 2007||2007-12-31|November 2010|2010-11-30|June 2012|Anticipated|2012-06-30|May 2012|Anticipated|2012-05-31||Interventional|FAHF-2||Therapeutic Effect of Chinese Herbal Medicine on Food Allergy|Investigation of the Efficacy of the Food Allergy Herbal Formula (FAHF-2TM) in Patients With Food Allergy - Phase II Trial|Unknown status|Recruiting|Phase 2|68|Anticipated|Li, Xiu-Min, M.D.||2|||f||||t||||||||||2018-06-01 02:32:28.282308|2018-06-01 02:32:28.282308
NCT00602147|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2013-03-12|2008-01-22|2008-01-28|Estimate|||||||2013-03-12|2013-03-14|Estimate|July 2007||2007-07-31|March 2013|2013-03-31|April 2010|Actual|2010-04-30|January 2009|Actual|2009-01-31||Observational|||Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan|Genetic Analysis of Toxicity Associated With High-Dose Melphalan|Terminated|||95|Actual|Vanderbilt-Ingram Cancer Center|||2|The original PI on this study left VICC, thus study was closed.|f||||f||||||Samples With DNA|"~     Blood sample or cheek cells will be collected.~   "|||2018-06-01 02:32:28.368383|2018-06-01 02:32:28.368383
NCT00601952|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2013-12-13||2013-12-13|2008-01-15|2008-01-28|Estimate|2013-12-13|2014-02-04|Estimate||||2013-12-13|2014-02-04|Estimate|July 2012||2012-07-31|July 2009|2009-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Information Processing Modification in PTSD (Oct. 18)|Information Processing Modification in PTSD|Completed||N/A|37|Actual|San Diego State University||2|||f||||t||||||||||2018-06-01 02:32:30.16177|2018-06-01 02:32:30.16177
NCT00602134|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2002||2002-11-30|January 2018|2018-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions|A Pharmacokinetic Study to Assess the Single-Dose Bioequivalence of a Potential Generic Formulation of a 6-Mercaptopurine 50 mg Tablet Compared to a Marketed 6-Mercaptopurine 50 mg Tablet, Purinethol®, When Administered to Healthy Male Subjects, in the Fasted State|Completed||N/A|54|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:28.453101|2018-06-01 02:32:28.453101
NCT00602108|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2011-08-09|2008-01-23|2008-01-28|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2005||2005-01-31|August 2011|2011-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Radiation Therapy in Treating Women Undergoing Lumpectomy for Stage I or Stage IIA Breast Cancer|Phase II Study of Intra-operative Electron Irradiation and Hypofractionated External Beam Irradiation After Lumpectomy in Patients With Stage T1N0M0 or T2N0M0 Breast Cancer|Completed||Phase 2|50|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:32:28.510835|2018-06-01 02:32:28.510835
NCT00602095|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-01-15|2008-01-15|2008-01-28|Estimate|||||||2008-01-15|2008-01-28|Estimate|December 2004||2004-12-31|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|LI||Labour Induction With Misoprostol, Dinoprostone and Bard Catheter|A Randomised Comparison Between Intravaginal Dinoprostone Intravaginal Misoprostol and Transcervical Balloon Catheter for Labour Induction|Completed||Phase 3|592|Actual|Karolinska University Hospital||3|||f||||t||||||||||2018-06-01 02:32:28.563399|2018-06-01 02:32:28.563399
NCT00602082|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-08-06|2008-01-25|2008-01-28|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors|A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors|Completed||Phase 2|84|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:32:28.625918|2018-06-01 02:32:28.625918
NCT00602069|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|||2013-06-21|2008-01-18|2008-01-28|Estimate|||||||2013-06-21|2013-06-24|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Cognitive Behavioral Therapy for Treating Recently Abused Women With Post-Traumatic Stress Disorder|Treatment of PTSD in Recently Battered Women Living in Shelters|Completed||Phase 1|60|Actual|The University of Akron||2|||f||||t||||||||||2018-06-01 02:32:28.868091|2018-06-01 02:32:28.868091
NCT00602056|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-13|||2008-01-13|2008-01-13|2008-01-28|Estimate|||||||2008-01-13|2008-01-28|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Low Cost Interventions to Improve Adherence to Childhood Immunization Schedule|A Randomized Controlled Trial of Low Cost Interventions to Improve Adherence to Childhood Immunization Schedule in a Low Literacy Population in Pakistan|Completed||N/A|1506|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-06-01 02:32:28.954677|2018-06-01 02:32:28.954677
NCT00602043|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|2014-12-16||2018-04-30|2008-01-23|2008-01-28|Estimate|2014-12-16|2014-12-25|Estimate||||2018-04-30|2018-05-01|Actual|September 2008||2008-09-30|April 2018|2018-04-30|September 2014|Actual|2014-09-30|August 2011|Actual|2011-08-31||Interventional|||F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer|A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer|Completed||N/A|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:32:29.043053|2018-06-01 02:32:29.043053
NCT00602030|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-04-18|2008-01-25|2008-01-28|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 2007||2007-12-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|February 2010|Actual|2010-02-28||Interventional|||Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLC|A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease|Completed||Phase 1/Phase 2|132|Actual|Syndax Pharmaceuticals||3|||f||||t||||||||||2018-06-01 02:32:29.242041|2018-06-01 02:32:29.242041
NCT00602017|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2004||2004-04-30|January 2018|2018-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 10 mg Amlodipine Besylate Tablets Under Fasting Conditions|Completed||N/A|40|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:29.372138|2018-06-01 02:32:29.372138
NCT00602004|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2015-05-08|2008-01-15|2008-01-28|Estimate|||||||2015-05-08|2015-05-12|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan|Early and Late Cardiac Effects of Arteriovenous Fistula Creation for Haemodialysis in End-stage Renal Failure and Their Possible Attenuation|Completed||N/A|52|Anticipated|Melbourne Health|||||f||||t||||||||||2018-06-01 02:32:29.508585|2018-06-01 02:32:29.508585
NCT00601991|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2013-03-29|2008-01-22|2008-01-28|Estimate|||||||2013-03-29|2013-04-02|Estimate|March 2007||2007-03-31|March 2013|2013-03-31|October 2009|Actual|2009-10-31|March 2009|Anticipated|2009-03-31||Interventional|||A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia|A Multi-Center Phase 2 Study of Vascular Endothelial Growth Factor (VEGF) Trap as a Single Agent in Acute Myeloid Leukemia|Withdrawn||Phase 2|0|Actual|Vanderbilt-Ingram Cancer Center||||Another study was opened.|f||||t||||||||||2018-06-01 02:32:29.572738|2018-06-01 02:32:29.572738
NCT00601978|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2012-04-27|2008-01-15|2008-01-28|Estimate|||||||2012-04-27|2012-04-30|Estimate|August 2008||2008-08-31|April 2012|2012-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off|A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event-Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease and End-of-Dose Wearing Off|Withdrawn||Phase 4|0|Actual|Novartis||2||Business decision brand strategy; no patients enrolled|f||||t||||||||||2018-06-01 02:32:29.638362|2018-06-01 02:32:29.638362
NCT00601965|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2014-09-03||2016-07-14|2008-01-15|2008-01-28|Estimate|2016-07-14|2016-08-25|Estimate||||2016-07-14|2016-08-25|Estimate|October 2007||2007-10-31|July 2016|2016-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||please see Wetherell et al. (2013), Antidepressant Medication Augmented with Cognitive-Behavioral Therapy for Generalized Anxiety Disorder in Older Adults, American Journal of Psychiatry, 170:782-9.|Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults|CBT Augmentation of SSRI Treatment for Geriatric GAD|Completed||N/A|73|Actual|Veterans Medical Research Foundation||4|||f||||t||||||||No||2018-06-01 02:32:29.719172|2018-06-01 02:32:29.719172
NCT00601939|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2017-07-29|2008-01-15|2008-01-28|Estimate|||||||2017-07-29|2017-08-01|Actual|March 2008||2008-03-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships|Group Interventions for Abused, Suicidal Black Women|Recruiting||Phase 4|190|Anticipated|Emory University||2|||f||||t||||||||||2018-06-01 02:32:30.372314|2018-06-01 02:32:30.372314
NCT00601926|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2014-06-20||2015-05-18|2008-01-22|2008-01-28|Estimate|2015-02-09|2015-02-18|Estimate||||2015-05-18|2015-06-15|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|May 2013|Actual|2013-05-31|August 2011|Actual|2011-08-31||Interventional|||Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase II Trial Of Avastin (Bevacizumab) In Patients With Metastatic Papillary Renal Cell Carcinoma|Terminated||Phase 2|5|Actual|Ohio State University Comprehensive Cancer Center|This trial closed early due to poor patient accrual. Attempts to open this trial at other sites were not successful.|1||Poor patient accrual. Attempts to open at other sites unsuccessful.|f||||t||||||||||2018-06-01 02:32:30.46917|2018-06-01 02:32:30.46917
NCT00601913|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2017-07-31|2008-01-24|2008-01-28|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2008|Actual|2008-03-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery|CCCWFU 60307 - Pilot Study to Evaluate the Anti-tumor Effect of Erlotnib Administered Befor Surgery in Operable Patients With Squamous Cell Carcinoma of the Head and Neck (HNSCC)|Completed||Early Phase 1|24|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||Undecided||2018-06-01 02:32:30.684181|2018-06-01 02:32:30.684181
NCT00601900|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2016-05-16||2017-09-19|2008-01-24|2008-01-28|Estimate|2016-07-13|2016-08-23|Estimate||||2017-09-19|2017-10-20|Actual|May 2008||2008-05-31|September 2017|2017-09-30||||June 2014|Actual|2014-06-30||Interventional|||Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer|Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer|Active, not recruiting||Phase 3|394|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 02:32:30.880281|2018-06-01 02:32:30.880281
NCT00601887|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2005||2005-03-31|January 2018|2018-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Bioequivalency Study of Meloxicam Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 15 mg Meloxicam Tablets Under Fed Conditions|Completed||N/A|48|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:32.363949|2018-06-01 02:32:32.363949
NCT00601874|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2003||2003-09-30|January 2018|2018-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions|A Single Dose, Two-Treatment, Two-Period, Two Sequence Crossover Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:32.4147|2018-06-01 02:32:32.4147
NCT00601861|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2017-02-28|2008-01-15|2008-01-28|Estimate|||||||2017-02-28|2017-03-01|Actual|February 13, 2008|Actual|2008-02-13|February 2017|2017-02-28|June 25, 2008|Actual|2008-06-25|June 25, 2008|Actual|2008-06-25||Interventional|||Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer|A Single Arm, Single-centre, Open-label, Exploratory Trial of Recombinant Interleukin-21 Administered Subcutaneously for 4 Weeks as Neo-adjuvant Treatment Prior to Sentinel Lymph Node/Complete Lymph Node Dissection Followed by 8 Weeks of Adjuvant Treatment in Subjects With Stage III Malignant Melanoma|Terminated||Phase 2|1|Actual|Novo Nordisk A/S||1||See termination reason in detailed description|f||||f||||||||||2018-06-01 02:32:32.460669|2018-06-01 02:32:32.460669
NCT00601848|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2016-09-23|2008-01-25|2008-01-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2004||2004-11-30|September 2016|2016-09-30||||July 2012|Actual|2012-07-31||Interventional|||Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura|A Phase II Study of Pleural Photodynamic Therapy for Patients With Non-small Cell Lung Cancer and Pleural Spread|Active, not recruiting||Phase 2|9|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 02:32:32.524449|2018-06-01 02:32:32.524449
NCT00601835|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2009-11-16||2016-04-12|2008-01-25|2008-01-28|Estimate|2011-01-21|2011-02-18|Estimate||||2016-04-12|2016-04-14|Estimate|May 2004||2004-05-31|April 2016|2016-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td|Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age|Completed||Phase 4|3651|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:32:32.599251|2018-06-01 02:32:32.599251
NCT00601822|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2012-04-09|2008-01-16|2008-01-28|Estimate|||||||2012-04-09|2012-04-10|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa|Cognitive Remediation Therapy for Anorexia Nervosa|Completed||Phase 1|46|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 02:32:33.263606|2018-06-01 02:32:33.263606
NCT00601809|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-25|2008-01-25|2008-01-28|Estimate|||||||2008-01-25|2008-01-28|Estimate|September 2003||2003-09-30|January 2008|2008-01-31|November 2006|Actual|2006-11-30|||||Interventional|GUSBOCA||(Gastrografin Use in Small Bowel Obstruction Caused by Adherences)|Gastrografin Use in Small Bowel Obstruction Caused by Adherences|Completed||Phase 4|76|Actual|University of Bologna||2|||f||||f||||||||||2018-06-01 02:32:33.331654|2018-06-01 02:32:33.331654
NCT00601796|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-19|2013-02-27||2013-05-15|2008-01-24|2008-01-28|Estimate|2013-04-09|2013-05-15|Estimate||||2013-05-15|2013-05-24|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||24 participants were accrued at a single center from 10/2006 to 6/2008. There were 14 participants with evaluable peripheral blood mononuclear cells (PBMCs).|Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer|Combination Immunotherapy for Lung Cancer|Completed||Phase 2|24|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 02:32:33.466876|2018-06-01 02:32:33.466876
NCT00601770|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2014-02-10|2008-01-15|2008-01-28|Estimate|||||||2014-02-10|2014-02-11|Estimate|February 2006||2006-02-28|February 2014|2014-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Virological Response Study of the HCV Vaccine IC41|Open-label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV|Completed||Phase 2|71|Actual|Valneva Austria GmbH||1|||f||||f||||||||||2018-06-01 02:32:33.76427|2018-06-01 02:32:33.76427
NCT00601757|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|||2014-01-29|2008-01-22|2008-01-28|Estimate|||||||2014-01-29|2014-01-31|Estimate|January 2006||2006-01-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Depression Prevention for Pregnant Women on Public Assistance|Depression Intervention for Financially Disadvantaged Pregnant Women.|Completed||Phase 2|207|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-06-01 02:32:33.83569|2018-06-01 02:32:33.83569
NCT00601744|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2013-01-09|2008-01-15|2008-01-28|Estimate|||||||2013-01-09|2013-01-10|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Social-Psychological Aspects of Orbital Exenteration|Social-Psychological Aspects of Survivorship in Cancer Patients After Orbital Exenteration: Issues Stemming From Alterations of Normal Facial Appearance|Completed|||33|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 02:32:33.92248|2018-06-01 02:32:33.92248
NCT00601731|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2011-10-28|2011-07-20|2014-10-14|2008-01-25|2008-01-28|Estimate|2012-09-17|2012-09-19|Estimate|2011-07-20|2011-07-25|Estimate|2014-10-14|2014-10-24|Estimate|February 2008||2008-02-29|October 2014|2014-10-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months|A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months Who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infants|Completed||Phase 2|382|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:32:34.049014|2018-06-01 02:32:34.049014
NCT00601718|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|2017-04-17||2017-04-17|2008-01-24|2008-01-28|Estimate|2017-04-17|2017-05-25|Actual||||2017-04-17|2017-05-25|Actual|December 2007||2007-12-31|April 2017|2017-04-30||||June 2010|Actual|2010-06-30||Interventional|||Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma|A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma|Completed||Phase 1/Phase 2|29|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 02:32:35.088455|2018-06-01 02:32:35.088455
NCT00601705|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2016-02-04|2008-01-23|2008-01-28|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2008||2008-01-31|February 2016|2016-02-29||||June 2012|Actual|2012-06-30||Interventional|||Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach|A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia|Unknown status|Active, not recruiting|Phase 2|61|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:32:35.305834|2018-06-01 02:32:35.305834
NCT00601692|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2013-03-21|2008-01-17|2008-01-28|Estimate|||||||2013-03-21|2013-03-22|Estimate|April 2003||2003-04-30|March 2013|2013-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer|A Phase I Trial of Irinotecan, Radiation Therapy and Escalating Doses of Docetaxel With Cisplatin in Locally Advanced Esophageal Cancer|Completed||Phase 1|27|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:32:35.512314|2018-06-01 02:32:35.512314
NCT00601679|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2015-10-13|2008-01-15|2008-01-28|Estimate|||||||2015-10-13|2015-10-14|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|EXIMPROVECHF||Improvement of Patients With Chronic Heart Failure Using NT-proBNP|Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study|Unknown status|Active, not recruiting|Phase 4|400|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 02:32:35.588846|2018-06-01 02:32:35.588846
NCT00601666|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2004||2004-03-31|January 2018|2018-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zolpidem Tartrate Tablets 10 MG Under Fasting Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:35.658341|2018-06-01 02:32:35.658341
NCT00601653|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2012-07-20|2008-01-23|2008-01-28|Estimate|||||||2012-07-20|2012-07-23|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder|CBT and Dieting: Effects on Psychopathology and Weight in BED|Completed||N/A|50|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:32:35.716853|2018-06-01 02:32:35.716853
NCT00601640|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-22|2011-04-15||2017-02-02|2008-01-25|2008-01-28|Estimate|2017-02-02|2017-03-23|Actual||||2017-02-02|2017-03-23|Actual|January 2007||2007-01-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|February 2010|Actual|2010-02-28||Interventional|||Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin|Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm|Completed||Phase 2|184|Actual|University of Arizona||3|||f||||t||||||||||2018-06-01 02:32:35.79569|2018-06-01 02:32:35.79569
NCT00601627|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-18|2017-02-21||2017-02-21|2008-01-24|2008-01-28|Estimate|2017-02-21|2017-04-05|Actual||||2017-02-21|2017-04-05|Actual|June 2009||2009-06-30|February 2017|2017-02-28|May 2013|Actual|2013-05-31|July 2011|Actual|2011-07-31||Interventional||All patients were included in this analysis.|Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery|Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 2|52|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:32:36.16417|2018-06-01 02:32:36.16417
NCT00601614|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-24|||2014-03-06|2008-01-24|2008-01-28|Estimate|||||||2014-03-06|2014-03-10|Estimate|January 2008||2008-01-31|March 2014|2014-03-31||||January 2010|Anticipated|2010-01-31||Interventional|||Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery|Phase I Study of ZD6474 and Temozolomide in Patients With Advanced Cancer|Withdrawn||Phase 1|0|Actual|Mayo Clinic||||no enrollment|f||||||||||||||2018-06-01 02:32:37.936076|2018-06-01 02:32:37.936076
NCT00601601|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-03-07|2008-01-25|2008-01-28|Estimate|||||||2012-03-07|2012-03-09|Estimate|December 2004||2004-12-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|April 2009|Actual|2009-04-30||Observational|||Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix|Genomics Approach to Id Novel Targets & Markers for Early Detection And Intervention In Cancer (Cervical)|Completed|||80|Actual|British Columbia Cancer Agency|||||f||||||||||||||2018-06-01 02:32:38.001402|2018-06-01 02:32:38.001402
NCT00601588|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2003||2003-06-30|January 2018|2018-01-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Bioequivalency Study of Sertraline Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Sertraline Tablets 100 mg Under Fed Conditions|Completed||N/A|43|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:38.06809|2018-06-01 02:32:38.06809
NCT00601575|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2002||2002-10-31|January 2018|2018-01-31|November 2002|Actual|2002-11-30|October 2002|Actual|2002-10-31||Interventional|||Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions|A Single Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalency Study of 450 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions|Completed||N/A|30|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:38.126394|2018-06-01 02:32:38.126394
NCT00601562|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2003||2003-06-30|January 2018|2018-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Bioequivalency Study of Zidovudine Under Fed Conditions|A Single Dose, Two Treatment, Two Period, Two Sequence, Crossover Bioequivalency Study of 300 mg Zidovudine Tablets Under Fed Conditions|Completed||N/A|52|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:38.184689|2018-06-01 02:32:38.184689
NCT00601549|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2012-12-05|2008-01-25|2008-01-28|Estimate|||||||2012-12-05|2012-12-06|Estimate|January 2000||2000-01-31|December 2012|2012-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT)|A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT)|Unknown status|Recruiting|Phase 3|600|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 02:32:38.263321|2018-06-01 02:32:38.263321
NCT00601536|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-15|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2003||2003-04-30|January 2018|2018-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fasting Conditions.|Completed||N/A|29|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:38.368269|2018-06-01 02:32:38.368269
NCT00601523|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2011-06-06||2014-06-03|2008-01-25|2008-01-28|Estimate|2011-07-27|2011-08-25|Estimate||||2014-06-03|2014-06-09|Estimate|January 2008||2008-01-31|March 2014|2014-03-31||||June 2010|Actual|2010-06-30||Interventional||Treated Set, all patients randomized and received treatment|Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).|Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).|Completed||Phase 3|511|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:32:38.492172|2018-06-01 02:32:38.492172
NCT00601510|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-03-18|2008-01-25|2008-01-28|Estimate|||||||2013-03-18|2013-03-19|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer|A Phase I Study of Capecitabine, Cisplatin and Imatinib in Patients With Unresectable or Metastatic Gastric Cancer.|Completed||Phase 1|38|Actual|Technische Universität München||1|||f||||||||||||||2018-06-01 02:32:39.376312|2018-06-01 02:32:39.376312
NCT00601497|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-12|||2008-01-25|2008-01-25|2008-01-28|Estimate|||||||2008-01-25|2008-01-28|Estimate|December 2004||2004-12-31|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effects of Electrical Stimulation on Osteoarthritis of the Knee|Effects of Electrical Stimulation on Osteoarthritis of the Knee|Completed||N/A|39|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 02:32:39.473452|2018-06-01 02:32:39.473452
NCT00601484|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15||2010-12-21|2011-01-04|2008-01-15|2008-01-28|Estimate||||2011-01-04|2011-01-07|Estimate|2011-01-04|2011-01-07|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis|A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of PF-04383119 For The Treatment Of Pain Associated With Interstitial Cystitis|Completed||Phase 2|65|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:32:39.55206|2018-06-01 02:32:39.55206
NCT00601471|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2010-06-23|2008-01-14|2008-01-28|Estimate|||||||2010-06-23|2010-06-24|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation, Ankle Range of Motion, and Functional Outcome Scores in Individuals With Chronic Ankle Instability|Effects of Proximal and Distal Tibiofibular Joint Manipulation on Lower Extremity Muscle Activation, Ankle Range of Motion, and Functional Outcome Scores in Individuals With Chronic Ankle Instability|Completed||N/A|61|Actual|University of Virginia||3|||f||||f||||||||||2018-06-01 02:32:39.65736|2018-06-01 02:32:39.65736
NCT00601458|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2009-12-23||2015-03-23|2008-01-25|2008-01-28|Estimate|2010-03-23|2010-04-08|Estimate||||2015-03-23|2015-04-10|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Bunionectomy Study (0000-063)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Pregabalin and Naproxen Sodium on Postoperative Pain After Bunionectomy|Completed||Phase 1|100|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 02:32:39.777093|2018-06-01 02:32:39.777093
NCT00601445|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2008-05-28|2008-01-15|2008-01-28|Estimate|||||||2008-05-28|2008-05-30|Estimate|September 1999||1999-09-30|May 2008|2008-05-31|March 2004|Actual|2004-03-31|||||Interventional|||Homeostatic Sleep Regulation in Older Persons|Homeostatic Sleep Regulation in Older Persons|Completed||N/A|58|Anticipated|National Institute on Aging (NIA)|||||f||||f||||||||||2018-06-01 02:32:40.278575|2018-06-01 02:32:40.278575
NCT00601432|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2016-12-21|2008-01-25|2008-01-28|Estimate|||||||2016-12-21|2016-12-22|Estimate|October 2002||2002-10-31|April 2010|2010-04-30|December 2002|Actual|2002-12-31|||||Interventional|||A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation|An Open-label, Randomized, 2-way Crossover Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation|Completed||Phase 1|24|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 02:32:40.341792|2018-06-01 02:32:40.341792
NCT00601419|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2013-12-17||2013-12-17|2008-01-25|2008-01-28|Estimate|2013-12-17|2014-02-06|Estimate||||2013-12-17|2014-02-06|Estimate|March 2007||2007-03-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Drug Use Investigation of Somatropin for GHD-ADULTS.|Drug Use Investigation of GENOTROPIN for GHD-ADULTS.|Completed|||230|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:32:40.429716|2018-06-01 02:32:40.429716
NCT00601406|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2013-08-23|2008-01-25|2008-01-28|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2006||2006-03-31|April 2008|2008-04-30||||February 2008|Anticipated|2008-02-29||Interventional|||Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer|Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER)|Unknown status|Recruiting|N/A|2200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:32:40.779818|2018-06-01 02:32:40.779818
NCT00601393|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2012-01-25|2008-01-23|2008-01-28|Estimate|||||||2012-01-25|2012-01-30|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effectiveness of Internet-Based Cognitive Behavioral Therapy for Treating Mothers With Depression|Interactive Internet Intervention for Depressed Mothers|Completed||N/A|70|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-06-01 02:32:40.902145|2018-06-01 02:32:40.902145
NCT00601367|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2014-04-22||2014-05-20|2008-01-25|2008-01-28|Estimate|2014-05-20|2014-06-20|Estimate||||2014-05-20|2014-06-20|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder|A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD|Completed||Phase 3|480|Actual|Sprout Pharmaceuticals, Inc||1|||f||||t||||||||||2018-06-01 02:32:40.982805|2018-06-01 02:32:40.982805
NCT00601354|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-06-18||2013-06-26|2008-01-16|2008-01-28|Estimate|2013-06-26|2013-09-09|Estimate||||2013-06-26|2013-09-09|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder|Comparing Orlistat/Alli to Orlistat/Alli Plus Guided Self-help Group Therapy in Overweight Binge Eaters|Completed||N/A|17|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 02:32:41.2624|2018-06-01 02:32:41.2624
NCT00601341|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2010-06-23|2008-01-25|2008-01-28|Estimate|||||||2010-06-23|2010-06-24|Estimate|May 2005||2005-05-31|June 2010|2010-06-30|November 2009|Actual|2009-11-30|May 2009|Anticipated|2009-05-31||Interventional|||Effects of Lumbosacral Joint Mobilization/Manipulation on Lower Extremity Muscle Neuromuscular Response|Effects of Lumbosacral Joint Mobilization/Manipulation on Lower Extremity Muscle Neuromuscular Response|Terminated||N/A|106|Actual|University of Virginia||3||Anticipated that results would not be conclusive|f||||f||||||||||2018-06-01 02:32:41.469826|2018-06-01 02:32:41.469826
NCT00601328|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2003||2003-07-31|January 2018|2018-01-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Calcitriol Tablets, 0.25 mg, Under Fasting Conditions|Completed||N/A|36|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:41.529894|2018-06-01 02:32:41.529894
NCT00601315|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2003||2003-04-30|January 2018|2018-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions|A Single Dose, Two-Treatment, Two-Period, Two-Sequence Crossover Bioequivalency Study of 250 mg Clarithromycin Tablets Under Fasting Conditions|Completed||N/A|40|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:41.666585|2018-06-01 02:32:41.666585
NCT00601302|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2004||2004-04-30|January 2018|2018-01-31|May 2004|Actual|2004-05-31|April 2004|Actual|2004-04-30||Interventional|||Bioequivalency Study of Amlodipine Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 10 mg Amlodipine Besylate Tablets Under Fed Conditions|Completed||N/A|40|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:41.718486|2018-06-01 02:32:41.718486
NCT00601289|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-25|||2012-07-27|2008-01-25|2008-01-28|Estimate|||||||2012-07-27|2012-07-31|Estimate|December 2009||2009-12-31|July 2012|2012-07-31||||October 2010|Actual|2010-10-31||Interventional|||Temozolomide in Treating Patients With Invasive Pituitary Tumors|An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||||funding term ended|f||||t||||||||||2018-06-01 02:32:41.783994|2018-06-01 02:32:41.783994
NCT00601276|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2009-07-10|2008-01-15|2008-01-28|Estimate|||||||2009-07-10|2009-07-13|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PCNET||Comparison of Two Pharmacological Treatments of Pedophilia|Comparative Controlled Clinical Trial of Two Pharmacological Treatments of Pedophilia|Terminated||Phase 3|48|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-06-01 02:32:41.850551|2018-06-01 02:32:41.850551
NCT00601263|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-18|2008-01-15|2008-01-28|Estimate|||||||2018-01-18|2018-01-23|Actual|October 2006||2006-10-31|February 2012|2012-02-29|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Safety Study of Chinese Herbal Therapy to Treat Asthma|Center for Chinese Herbal Therapy for Asthma. Project #2-Clinical Effect of a Chinese Herbal Therapy in Human Asthma-Phase I|Completed||Phase 1|35|Actual|Icahn School of Medicine at Mount Sinai||6|||f||||f||||||||||2018-06-01 02:32:41.92545|2018-06-01 02:32:41.92545
NCT00601250|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2011-05-13||2013-12-11|2008-01-15|2008-01-28|Estimate|2011-05-13|2011-06-07|Estimate||||2013-12-11|2014-01-28|Estimate|January 2008||2008-01-31|December 2013|2013-12-31||||May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 1356 (One Dose, e.g. 5 mg), Administered Orally Once Daily Over 24 Weeks, With an Open Label Extension to 80 Weeks (Placebo Patients Switched to BI 1356), in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy|Completed||Phase 3|701|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:32:42.034972|2018-06-01 02:32:42.034972
NCT00601237|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2015-04-01|2008-01-25|2008-01-28|Estimate|||||||2015-04-01|2015-04-03|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effectiveness of a Cell Phone-Based Program for Abstinence and HIV Risk Prevention|Text Messaging for Abstinence and HIV Risk Prevention: The 411 on Safe Text|Completed||N/A|103|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-06-01 02:32:42.685364|2018-06-01 02:32:42.685364
NCT00601224|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2013-03-28|2008-01-15|2008-01-28|Estimate|||||||2013-03-28|2013-03-29|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia|Social Cognition and Interaction Training for Schizophrenia|Completed||Phase 1|66|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 02:32:42.760551|2018-06-01 02:32:42.760551
NCT00601211|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-01-19|2008-01-25|2008-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2003||2003-09-30|January 2018|2018-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions|A Single Dose, Two-Treatment, Two-Period, Two Sequence Crossover Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fed Conditions|Completed||N/A|28|Actual|West-Ward Pharmaceutical|||||f||||f||||||||||2018-06-01 02:32:42.838196|2018-06-01 02:32:42.838196
NCT00601198|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2010-03-22|2008-01-24|2008-01-25|Estimate|||||||2010-03-22|2010-03-23|Estimate|October 2006||2006-10-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer|Phase II Study of the Efficacy of Amifostine (Ethyol) in Reducing the Incidence and Severity of Oxaliplatin-Induced Neuropathy in Patients With Colorectal Cancer|Terminated||Phase 2|97|Anticipated|University of Cincinnati||1||Funding support withdrawn|f||||f||||||||||2018-06-01 02:32:42.896854|2018-06-01 02:32:42.896854
NCT00601185|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2018-02-26|2008-01-14|2008-01-25|Estimate|||||||2018-02-26|2018-02-27|Actual|February 14, 2006|Actual|2006-02-14|February 2018|2018-02-28|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Observational|||Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo.|Confocal Reflectance Microscopy of Shave-Biopsy Sites on Skin in Vivo|Completed|||116|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:32:42.969743|2018-06-01 02:32:42.969743
NCT00601172|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2017-09-07|2010-03-17|2017-12-18|2008-01-24|2008-01-25|Estimate|2017-12-18|2018-01-17|Actual|2010-03-17|2010-03-19|Estimate|2017-12-18|2018-01-17|Actual|March 10, 2008|Actual|2008-03-10|November 2017|2017-11-30|April 13, 2009|Actual|2009-04-13|April 13, 2009|Actual|2009-04-13||Interventional||For Age, only 352 participants were analyzed in the Placebo group.|A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.|A Study of Single Dose Intravenous Casopitant in Combination With Ondansetron and Dexamethasone for the Prevention of Oxaliplatin Induced Nausea and Vomiting.|Completed||Phase 3|710|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:32:43.123806|2018-06-01 02:32:43.123806
NCT00601159|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-07-01|2008-01-14|2008-01-25|Estimate|||||||2011-07-01|2011-07-04|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC|Phase Ⅱ Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC|Completed||Phase 2|70|Actual|Fudan University||1|||f||||f||||||||||2018-06-01 02:32:44.470352|2018-06-01 02:32:44.470352
NCT00601146|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2016-01-19||2017-07-25|2008-01-15|2008-01-25|Estimate|2016-01-19|2016-02-17|Estimate||||2017-07-25|2017-08-24|Actual|November 2006||2006-11-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2010|Actual|2010-12-31||Observational|||Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease|Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease|Active, not recruiting|||39|Actual|Dana-Farber Cancer Institute|||||f||||f||||||||No||2018-06-01 02:32:44.580154|2018-06-01 02:32:44.580154
NCT00601133|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2013-01-09|2008-01-24|2008-01-25|Estimate|||||||2013-01-09|2013-01-10|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Function and Balance for Inpatient Rehabilitation|Quantitative and Clinical Description of Postural Instability in Patient Who Underwent Acute Inpatient Rehabilitation and at Follow-Up|Completed|||24|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:32:44.730861|2018-06-01 02:32:44.730861
NCT00601120|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2013-02-26|2008-01-15|2008-01-25|Estimate|||||||2013-02-26|2013-02-27|Estimate|June 2007||2007-06-30|February 2013|2013-02-28||||June 2010|Anticipated|2010-06-30||Interventional|||RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma|Pilot Feasibility Protocol of RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma|Withdrawn||N/A|0|Actual|Dana-Farber Cancer Institute||||This protocol was never officially opened and no patients were recruited.|f||||t||||||||||2018-06-01 02:32:44.812677|2018-06-01 02:32:44.812677
NCT00601107|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|2014-04-02|2010-04-28|2014-04-02|2008-01-24|2008-01-25|Estimate|2014-04-02|2014-05-05|Estimate|2010-05-04|2010-05-06|Estimate|2014-04-02|2014-05-05|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional||Safety Set included all randomized participants who received at least 1 dose of study medication.|A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis|A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in the Treatment of Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|111|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 02:32:44.915117|2018-06-01 02:32:44.915117
NCT00601094|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2018-04-26|2008-01-24|2008-01-25|Estimate|||||||2018-04-26|2018-04-30|Actual|February 26, 2009|Actual|2009-02-26|October 2017|2017-10-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase I Trial of CCL21 Gene Modified Dendritic Cells In Non-Small Cell Lung Cancer|Completed||Phase 1|17|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:32:45.456152|2018-06-01 02:32:45.456152
NCT00601081|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2017-05-09|2008-01-15|2008-01-25|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2007||2007-11-30|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Human Milk Fortifier and Cytokine Profile|Alterations in the Cytokine Profile of Premature Infants After Human Milk Fortifier|Completed|||24|Actual|Christiana Care Health Services|||1||f||||f||||||Samples With DNA|"~     Blood and stool~   "|||2018-06-01 02:32:45.532588|2018-06-01 02:32:45.532588
NCT00601068|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2013-01-03|2008-01-24|2008-01-25|Estimate|||||||2013-01-03|2013-01-04|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis|Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis of the Jaws (BON)|Completed|||35|Actual|University of Florida|||1||f||||t||||||Samples With DNA|"~     biopsy tissue submitted from bone biopsies~   "|||2018-06-01 02:32:45.588108|2018-06-01 02:32:45.588108
NCT00601055|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2016-07-13|2008-01-14|2008-01-25|Estimate|||||||2016-07-13|2016-07-15|Estimate|February 2008||2008-02-29|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Problem-Solving Therapy for People With Major Depression and Chronic Obstructive Pulmonary Disease|Treating Older Patients With Major Depression and Severe COPD|Completed||N/A|101|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||Undecided||2018-06-01 02:32:45.6537|2018-06-01 02:32:45.6537
NCT00599105|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2010-11-17|2008-01-22|2008-01-23|Estimate|||||||2010-11-17|2010-11-19|Estimate|November 2000||2000-11-30|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Angiogenesis in Early Breast Cancer for Prognosis Prediction|Angiogenesis in Early Breast Cancer for Prognosis Prediction|Completed||N/A|700|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:33:18.552112|2018-06-01 02:33:18.552112
NCT00601042|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2013-12-10|2008-01-24|2008-01-25|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|2SRT||Serbian Smoking Reduction/Cessation Trial (2SRT)|"Randomized, Placebo-controlled, Double-blind, Phase IV Trial to Assess the Efficacy of a Traditional Swedish Smokeless Tobacco Product (Snus) to Reduce or Replace Cigarette Smoking Among Adult Smokers in Serbia"|Completed||Phase 4|319|Actual|Swedish Match AB||2|||f||||t||||||||||2018-06-01 02:32:45.718108|2018-06-01 02:32:45.718108
NCT00601029|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2012-04-18|2008-01-24|2008-01-25|Estimate|||||||2012-04-18|2012-04-20|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Observational|||Rhabdomyolysis in Basic Training|Rhabdomyolysis in Basic Training|Completed|||499|Actual|Martin Army Community Hospital|||2||f||||f||||||Samples With DNA|"~     Serum and stored blood~   "|||2018-06-01 02:32:45.784252|2018-06-01 02:32:45.784252
NCT00601016|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-24|2008-01-24|2008-01-25|Estimate|||||||2008-01-24|2008-01-25|Estimate|March 2005||2005-03-31|January 2008|2008-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy|A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy|Completed||Phase 2|18|Actual|St. Justine's Hospital|||||f||||f||||||||||2018-06-01 02:32:45.841412|2018-06-01 02:32:45.841412
NCT00601003|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-04-25|2008-01-24|2008-01-25|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2008||2008-02-29|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma|A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.|Recruiting||Phase 2|100|Anticipated|Spectrum Health Hospitals||1|||f||||t||||||||||2018-06-01 02:32:45.902549|2018-06-01 02:32:45.902549
NCT00600990|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2017-01-19|2008-01-15|2008-01-25|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2004||2004-12-31|January 2017|2017-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients|Phase II Multicenter, Dose Ranging Study on the Safety and Antiemetic Efficacy of One Day Intraveous Dosing of GW597599 Administered With Ondansetron HCL in a Female Subjects Undergoing Surgical Procedures of High Emetogenic Risk|Completed||Phase 2|624|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:32:46.126095|2018-06-01 02:32:46.126095
NCT00600977|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2008-06-25|2008-01-24|2008-01-25|Estimate|||||||2008-06-25|2008-06-26|Estimate|March 2002||2002-03-31|June 2008|2008-06-30|October 2006|Actual|2006-10-31|||||Interventional|||Liposomal Anthracyclin in the Treatment of Elderly ALL|A Multicentric Phase II-III Randomized Study Safety of Intraveinous Liposomal Pegylated Doxorubicin Versus Continuous Infusion of Doxorubicin During Induction Treatment of Acute Lymphoblastic Leukemia in Patients|Completed||Phase 2|60|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||||2018-06-01 02:32:46.275278|2018-06-01 02:32:46.275278
NCT00600964|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2014-05-09|2008-01-24|2008-01-25|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2004||2004-09-30|May 2014|2014-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Phase I/II Study of GX15-070MS in Untreated CLL|A Multi-Center, Open-Label, Phase I/II Study of Single-Agent GX15-070MS Administered Every 2 to 3 Weeks to Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 1|26|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 02:32:46.343545|2018-06-01 02:32:46.343545
NCT00600951|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2014-10-31|2008-01-15|2008-01-25|Estimate|||||||2014-10-31|2014-11-04|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease|A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 3 to 5 Chronic Kidney Disease Undergoing MRI With the Injection of MultiHance|Completed|||366|Actual|Bracco Diagnostics, Inc|||2||f||||f||||||Samples Without DNA|"~     fixed tissue samples~   "|||2018-06-01 02:32:46.417716|2018-06-01 02:32:46.417716
NCT00600938|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2014-02-21||2014-08-13|2008-01-14|2008-01-25|Estimate|2014-08-13|2014-08-27|Estimate||||2014-08-13|2014-08-27|Estimate|November 2007||2007-11-30|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CORDELIA|Per Protocol Set (PPS): randomized patients who received at least 6 months of study drug, had a T2* value assessed at least 150 days after randomization, and had no major protocol deviations. A total of 25 patients (7 in the deferasirox arm and 18 in the DFO arm) were excluded from PPS|Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload|A Multicenter, Randomized, Open-label Phase II Trial Evaluating Deferasirox Compared With Deferoxamine in Patients With Cardiac Iron Overload Due to Chronic Blood Transfusions|Completed||Phase 2|197|Actual|Novartis||4|||f||||t||||||||||2018-06-01 02:32:46.507669|2018-06-01 02:32:46.507669
NCT00600925|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2012-03-22|2008-01-24|2008-01-25|Estimate|||||||2012-03-22|2012-03-23|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|March 2009|Actual|2009-03-31||Interventional|||A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection|A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in General Surgical Subjects at Higher Risk for Surgical Wound Infection|Completed||Phase 3|600|Actual|Innocoll||2|||f||||t||||||||||2018-06-01 02:32:47.769512|2018-06-01 02:32:47.769512
NCT00600912|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2009-12-02|2008-01-14|2008-01-25|Estimate|||||||2009-12-02|2009-12-03|Estimate|December 2006||2006-12-31|December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Influence of of a Lipid Emulsion on Inflammatory Response and Hepatic Function|Inflammatory Response and Hepatic Function in Patients Requiring Parenteral Nutrition: Comparison of a Lipid Emulsion Based ob Soybean Oil, Medium-Chain Triglycerides, Olive Oil and Fish Oil Versus a Lipid Emulsion Based on Olive and Soybean Oil|Completed||Phase 4|42|Actual|Klinikum Ludwigshafen||2|||f||||f||||||||||2018-06-01 02:32:47.893828|2018-06-01 02:32:47.893828
NCT00600899|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2009-01-28|2008-01-24|2008-01-25|Estimate|||||||2009-01-28|2009-01-29|Estimate|September 2008||2008-09-30|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Home Infusors for Analgesia After Foot Surgery|Use of Home Pumps for Analgesia After Ambulatory Foot Surgery - Comparison of Two Infusion Rates - a Randomized, Double-Blind Study|Unknown status|Enrolling by invitation|Phase 4|40|Anticipated|Frederiksberg University Hospital||2|||f||||t||||||||||2018-06-01 02:32:47.97235|2018-06-01 02:32:47.97235
NCT00600886|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2014-12-19|2014-11-04|2017-06-05|2008-01-24|2008-01-25|Estimate|2015-01-28|2015-01-30|Estimate|2014-11-04|2014-11-18|Estimate|2017-06-05|2017-07-02|Actual|February 11, 2008|Actual|2008-02-11|June 2017|2017-06-30|March 11, 2016|Actual|2016-03-11|March 11, 2016|Actual|2016-03-11||Interventional||Full Analysis Set: All patients who were randomized into the study. Patients were analyzed according to the treatment they were assigned to at randomization.|Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly|A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly|Completed||Phase 3|358|Actual|Novartis||2|||f||||t||||||||||2018-06-01 02:32:48.178995|2018-06-01 02:32:48.178995
NCT00600873|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-05|||2010-09-10|2008-01-15|2008-01-25|Estimate|||||||2010-09-10|2010-09-13|Estimate|August 2007||2007-08-31|September 2010|2010-09-30|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||R(+)PPX High Dose Treatment of ALS|Pharmacokinetics and Nitrative-Oxidative Stress Pharmacodynamics in Amyotrophic Lateral Sclerosis Subjects Taking Daily High-Dose R(+) Pramipexole Dihydrochloride for Six Months|Completed||Phase 1/Phase 2|10|Actual|Bennett, James P., Jr., M.D., Ph.D.||1|||t||||t||||||||||2018-06-01 02:32:50.475226|2018-06-01 02:32:50.475226
NCT00600860|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2016-11-23|2008-01-24|2008-01-25|Estimate|||||||2016-11-23|2016-11-28|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|EUMDS||A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes|A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (MDS), Including Acute Myeloid Leukaemia With 20-30 Percent Marrow Blasts (Former RAEB-t), and Chronic Myelomonocytic Leukaemia (CMML)|Recruiting|||4000|Anticipated|Radboud University|||1||f||||f||||||Samples With DNA|"~     Blood and Bone marrow~   "|No|The study results (aggregated data) will be published in an academic journal and presented at scientific meetings. A study newsletter will be produced regularly and will be available to read on the EUMDS website.|2018-06-01 02:32:50.537628|2018-06-01 02:32:50.537628
NCT00600847|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2008-01-15|2008-01-15|2008-01-25|Estimate|||||||2008-01-15|2008-01-25|Estimate|November 2006||2006-11-30|January 2008|2008-01-31||||November 2007|Actual|2007-11-30||Interventional|AUDACU||A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria Lesions|An Exploratory Phase IV, Randomised, Double-Blind, Placebo Controlled Crossover Study to Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Experimentally Induced Urticaria Lesions|Completed||Phase 4|33|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-06-01 02:32:50.64063|2018-06-01 02:32:50.64063
NCT00600834|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2014-10-31|2008-01-15|2008-01-25|Estimate|||||||2014-10-31|2014-11-04|Estimate|February 2008||2008-02-29|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease|A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 3 to 5 Chronic Kidney Disease Undergoing MRI With the Injection of ProHance|Completed|||172|Actual|Bracco Diagnostics, Inc|||2||f||||f||||||None Retained|"~     Fixed tissue samples~   "|||2018-06-01 02:32:50.705797|2018-06-01 02:32:50.705797
NCT00600821|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2012-04-20|2010-02-11|2013-10-16|2008-01-13|2008-01-25|Estimate|2012-04-21|2012-05-22|Estimate|2010-02-11|2010-02-15|Estimate|2013-10-16|2013-11-08|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional||Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.|A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.|Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer|Completed||Phase 2|118|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:32:50.804616|2018-06-01 02:32:50.804616
NCT00600808|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2008-01-15|2008-01-15|2008-01-25|Estimate|||||||2008-01-15|2008-01-25|Estimate|June 2003||2003-06-30|July 2007|2007-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Sustained Release Formulation of Somatropin (rDNA Origin)for Injection|A Phase II/IIIa, Assessor Blinded (Partially Blinded), Randomised, Active-Controlled, Multicentre, Parallel-Group Study of the Safety, Efficacy and pk/pd of LB03002 Administered Weekly in Children With Growth Failure Due to GH Deficiency.|Completed||Phase 2/Phase 3|51|Actual|BioPartners GmbH|||||f||||t||||||||||2018-06-01 02:32:53.602169|2018-06-01 02:32:53.602169
NCT00600795|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2017-03-30|2008-01-14|2008-01-25|Estimate|||||||2017-03-30|2017-04-04|Actual|January 2008||2008-01-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus|Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus|Completed|||21|Actual|Vanderbilt University Medical Center|||1||f||||t||||||Samples Without DNA|"~     CSF~   "|||2018-06-01 02:32:53.680967|2018-06-01 02:32:53.680967
NCT00600782|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15||2009-09-03|2009-09-03|2008-01-24|2008-01-25|Estimate||||2009-09-03|2009-09-04|Estimate|2009-09-03|2009-09-04|Estimate|February 2008||2008-02-29|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region|Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.|Completed||Phase 2|45|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 02:32:53.7875|2018-06-01 02:32:53.7875
NCT00600769|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-05-19|2008-01-14|2008-01-25|Estimate|||||||2017-05-19|2017-05-23|Actual|January 1991|Actual|1991-01-31|May 2017|2017-05-31|May 18, 2017|Actual|2017-05-18|November 2006|Actual|2006-11-30||Interventional|||Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)|Open Study of Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)|Completed||Phase 4|210|Actual|The University of Texas Health Science Center at Tyler||1|||f||||f||||||||No||2018-06-01 02:32:53.889007|2018-06-01 02:32:53.889007
NCT00600756|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2010-10-20||2012-10-02|2008-01-15|2008-01-25|Estimate|2012-08-13|2012-09-12|Estimate||||2012-10-02|2012-10-05|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|RECOVER||Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone|A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting|Completed||Phase 3|798|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:32:54.036774|2018-06-01 02:32:54.036774
NCT00600743|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2011-02-21||2017-04-26|2008-01-24|2008-01-25|Estimate|2017-04-26|2017-04-28|Actual||||2017-04-26|2017-04-28|Actual|January 2008||2008-01-31|April 2017|2017-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|GSK||Effect of a CCK-1R Agonist on Food Intake in Humans|Effect of a CCK-1R Agonist on Food Intake in Humans|Terminated||Phase 2|40|Actual|St. Luke's-Roosevelt Hospital Center|"No adverse events - Some subjects reported a sick feeling that was significantly different between drug and control, in the condition where they were instructed to binge eat. This is a subtle feeling without any other symptoms. It is not adverse."|8||Drug expired before was completed.|f||||f||||||||||2018-06-01 02:32:55.658688|2018-06-01 02:32:55.658688
NCT00600730|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2015-06-09|2008-01-24|2008-01-25|Estimate|||||||2015-06-09|2015-06-10|Estimate||||June 2015|2015-06-30||||||||Interventional|||The Effects of Antecedent Hypoglycemia or Exercise on the Response of the Brain to Subsequent Hypoglycemia|The Effects of Antecedent Hypoglycemia or Exercise on the Response of the Brain to Subsequent Hypoglycemia|Withdrawn||N/A|0|Actual|Vanderbilt University||2||Funding not available. Could not start this study.|f||||f||||||||||2018-06-01 02:32:56.659625|2018-06-01 02:32:56.659625
NCT00600717|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2017-07-18|2008-01-24|2008-01-25|Estimate|||||||2017-07-18|2017-07-21|Actual|November 1, 2006|Actual|2006-11-01|July 2017|2017-07-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|HFOs||Clinical Applications of High-Frequency Oscillations|Localizing Functional Brain Cortices and Epileptogenic Zones With HFOs|Enrolling by invitation|||120|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f|f|f||||||Undecided||2018-06-01 02:32:56.918895|2018-06-01 02:32:56.918895
NCT00600704|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2011-03-04||2011-05-09|2008-01-24|2008-01-25|Estimate|2011-05-09|2011-06-07|Estimate||||2011-05-09|2011-06-07|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|November 2008|Actual|2008-11-30||Interventional|||Impact of Fluid Restriction Policy in Reducing the Use of Red Cells in Cardiac Surgery|Impact of Fluid Restriction Policy Added to Intra-Operative Cell Salvage in Reducing the Use of Red Cells in Cardiac Surgery|Completed||N/A|192|Actual|Larissa University Hospital||2|||f||||f||||||||||2018-06-01 02:32:57.035044|2018-06-01 02:32:57.035044
NCT00600691|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2014-01-29|2008-01-24|2008-01-25|Estimate|||||||2014-01-29|2014-01-31|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy|The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy|Terminated||Phase 2|29|Actual|University of British Columbia||1||Did not achieve enrollment goal and decided to terminate early|f||||f||||||||||2018-06-01 02:32:57.30973|2018-06-01 02:32:57.30973
NCT00600678|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-05-14|2008-01-15|2008-01-25|Estimate|||||||2008-05-14|2008-05-15|Estimate|November 2007||2007-11-30|May 2008|2008-05-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Gastric Emptying Study After Administration of a High Caloric Sip Feed|Characterisation of Gastric Emptying of a High Caloric Sip Feed Using the Paracetamol Absorption Method: Intraindividual Comparison of Paracetamol Pharmacokinetics After Oral co-Administration With Sip-Feed and After Intravenous Administration in Healthy Volunteers of Both Genders in an Open, Single Centre Study|Completed||N/A|12|Actual|Fresenius Kabi||1|||f||||f||||||||||2018-06-01 02:32:57.39645|2018-06-01 02:32:57.39645
NCT00600665|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2015-05-26|2008-01-14|2008-01-25|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2007||2007-02-28|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease|Computerized PAINRelieveIt for Adult Sickle Cell Disease|Completed||N/A|279|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 02:32:57.47587|2018-06-01 02:32:57.47587
NCT00600652|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2008-01-24|2008-01-24|2008-01-25|Estimate|||||||2008-01-24|2008-01-25|Estimate|December 2006||2006-12-31|January 2008|2008-01-31||||December 2010|Actual|2010-12-31||Observational|||FCM Analysis GR in Steroid-Treatment Patients|Flow Cytometric Analysis of Glucocorticoid Receptor Using Monoclonal Antibody and Fluoresceinated Ligand Probes in Glucocorticoid-Resistant and -Sensitive Patients|Unknown status|Enrolling by invitation||150|Anticipated|Changhai Hospital|||3||f||||t||||||Samples With DNA|"~     introcellular and exocellular proteins in peripheral blood mononuclear cells of subjects~   "|||2018-06-01 02:32:57.601455|2018-06-01 02:32:57.601455
NCT00600639|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2012-07-16|2008-01-24|2008-01-25|Estimate|||||||2012-07-16|2012-07-17|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Non-Invasive Mechanical Ventilation in Elderly Patients|Non-Invasive Mechanical Ventilation in Elderly Patients Affected by Acute Hypercapnic Respiratory Failure:A Randomized Control Study vs Standard Medical Therapy A Multicentric Randomized Controlled Trial|Terminated||Phase 4|82|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-06-01 02:32:57.676982|2018-06-01 02:32:57.676982
NCT00600626|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-01-05|2008-01-14|2008-01-25|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2004||2004-01-31|January 2017|2017-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes|Comparison of Basal Bolus Treatment With Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes Mellitus|Completed||Phase 3|394|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:32:57.782941|2018-06-01 02:32:57.782941
NCT00600613|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2015-04-07||2015-04-17|2008-01-14|2008-01-25|Estimate|2015-04-07|2015-04-17|Estimate||||2015-04-17|2015-05-07|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy|A Pilot Study to Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy|Completed||N/A|6|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:32:57.935876|2018-06-01 02:32:57.935876
NCT00600600|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-05-19|2008-01-14|2008-01-25|Estimate|||||||2017-05-19|2017-05-23|Actual|April 2002||2002-04-30|May 2017|2017-05-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Tigecycline for Treatment of Rapidly Growing Mycobacteria|Use of Tigecycline for Treatment of Serious Infection Due to Rapidly Growing Mycobacteria (Especially M.Abscessus)|Completed||Phase 2|8|Actual|The University of Texas Health Science Center at Tyler||1|||f||||f||||||||No||2018-06-01 02:32:58.095978|2018-06-01 02:32:58.095978
NCT00600587|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2013-06-23|2008-01-14|2008-01-25|Estimate|||||||2013-06-23|2013-06-25|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)|Phase Ⅱ Study of Induction Erlotinib Therapy in Stage III A(N2) Non-small Cell Lung Cancer Proceeding to Mediastinoscopy/PET and Thoracotomy/Radiotherapy|Completed||Phase 2|24|Actual|Guangdong Provincial People's Hospital||2|||f||||t||||||||||2018-06-01 02:32:58.173665|2018-06-01 02:32:58.173665
NCT00600574|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2014-12-01|2008-01-14|2008-01-25|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Ai Chi Versus Stretching in Fibromyalgia Management|A Randomized Controlled Trial Comparing the Efficay and Tolerability of Ai Chi Versus Stretching in Fibromyalgia Management: a Six Months Study|Completed||Phase 4|94|Actual|Universidad de Granada||2|||f||||f||||||||||2018-06-01 02:32:58.251089|2018-06-01 02:32:58.251089
NCT00600561|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-14|2008-01-14|2008-01-25|Estimate|||||||2008-01-14|2008-01-25|Estimate|June 2005||2005-06-30|January 2008|2008-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|MBSR||Mindfulness Meditation Training in HIV|Biobehavioral Effects of Mindfulness-Based Stress Reduction in HIV|Completed||Phase 2|50|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:32:58.317912|2018-06-01 02:32:58.317912
NCT00600548|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2010-04-14|2008-01-14|2008-01-25|Estimate|||||||2010-04-14|2010-04-15|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)|Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control|Completed||Phase 2|180|Actual|Hospital Universitário Professor Edgard Santos||4|||f||||t||||||||||2018-06-01 02:32:58.384435|2018-06-01 02:32:58.384435
NCT00600535|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2013-04-16|2008-01-14|2008-01-25|Estimate|||||||2013-04-16|2013-04-17|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer|A Pharmacokinetics Study to Assess the Oral Administration of CB7630 (Abiraterone Acetate) Capsule Formulation and Tablet Formulation in Patients With Prostate Cancer|Completed||Phase 1|31|Actual|Cougar Biotechnology, Inc.||2|||f||||f||||||||||2018-06-01 02:32:58.546734|2018-06-01 02:32:58.546734
NCT00600522|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-14|2008-01-14|2008-01-25|Estimate|||||||2008-01-14|2008-01-25|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Observational|||Alternative Surgical Policy for Central Liver Tumors|Ultrasound-Guided Conservative Heopatecomy for Tumors Invading the Middle Hepatic Vein at the Caval Confluence as Alternative to Mesohepatectomy and Trisectionectomy|Completed|||15|Actual|University of Milan|||1||f||||f||||||||||2018-06-01 02:32:58.639594|2018-06-01 02:32:58.639594
NCT00600509|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2013-09-16|2008-01-14|2008-01-25|Estimate|||||||2013-09-16|2013-09-17|Estimate|January 2001||2001-01-31|September 2009|2009-09-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method|Bridging Study of L059(Levetiracetam) in Patients With Epilepsy by Double Blind Method|Completed||Phase 2|216|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:32:58.707988|2018-06-01 02:32:58.707988
NCT00600496|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2018-05-18|2008-01-24|2008-01-25|Estimate|||||||2018-05-18|2018-05-21|Actual|December 14, 2007|Actual|2007-12-14|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 20, 2010|Actual|2010-08-20||Interventional|||A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)|A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|140|Actual|AstraZeneca||4|||f||||t||||||||||2018-06-01 02:32:58.759734|2018-06-01 02:32:58.759734
NCT00600483|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2012-03-22|2008-01-24|2008-01-25|Estimate|||||||2012-03-22|2012-03-23|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection|A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection|Completed||Phase 3|1502|Actual|Innocoll||2|||f||||t||||||||||2018-06-01 02:32:58.848123|2018-06-01 02:32:58.848123
NCT00600470|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2015-05-29|2008-01-14|2008-01-25|Estimate|||||||2015-05-29|2015-06-01|Estimate|September 2000||2000-09-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SKIP||Effectiveness of Collaborative Services in Primary Care for Treating Children With Behavior Disorders|Collaborative Mental Health Services for Behavior Disorders in Primary Care|Completed||Phase 1/Phase 2|858|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:32:59.026909|2018-06-01 02:32:59.026909
NCT00600457|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-23|||2008-12-15|2008-01-23|2008-01-25|Estimate|||||||2008-12-15|2008-12-16|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Observational|||Modified Polyurethane Film Dressing For Skin Graft Donor Sites|Modified Polyurethane Film Dressing For Skin Graft Donor Sites|Completed|||30|Actual|Klinik Bogenhausen|||1||f||||f||||||||||2018-06-01 02:32:59.105569|2018-06-01 02:32:59.105569
NCT00600444|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2010-01-26|2008-01-24|2008-01-25|Estimate|||||||2010-01-26|2010-01-27|Estimate|February 2008||2008-02-29|May 2008|2008-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PORTAS2||PORTAS 2, Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port|Randomized Controlled Trial Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port|Completed||N/A|100|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-06-01 02:32:59.173276|2018-06-01 02:32:59.173276
NCT00600431|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-24|2008-01-24|2008-01-25|Estimate|||||||2008-01-24|2008-01-25|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Melanocytic Nevi in Children Under Chemotherapy|Melanocytic-Nevi-Counts During Chemotherapy of Children With Malignancies.|Completed|||32|Actual|Medical University of Graz|||2||f||||f||||||||||2018-06-01 02:32:59.25225|2018-06-01 02:32:59.25225
NCT00600418|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2013-09-03|2008-01-15|2008-01-25|Estimate|||||||2013-09-03|2013-09-04|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Observational|||Identifying Toddlers and Their Parents Who Are Suffering From Posttraumatic Distress Following War and Terror|Identifying Posttraumatic Distress Among Toddlers and Their Parents Following Ongoing Exposure to Terrorism or War|Completed|||500|Actual|Herzog Hospital|||||f||||t||||||||||2018-06-01 02:32:59.315442|2018-06-01 02:32:59.315442
NCT00600405|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-14|2008-01-14|2008-01-25|Estimate|||||||2008-01-14|2008-01-25|Estimate|August 2006||2006-08-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients|The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients|Completed||N/A|81|Actual|Maine Medical Center||2|||f||||f||||||||||2018-06-01 02:32:59.39088|2018-06-01 02:32:59.39088
NCT00600392|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2016-01-15|2008-01-24|2008-01-25|Estimate|||||||2016-01-15|2016-01-20|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|October 2008|Actual|2008-10-31||Observational|Medusa PH||DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)|Transcriptomal Analysis of Peripheral Blood and Skeletal Muscle in Patients Undergoing CRT Using Oligonucleotide Arrays|Completed|||30|Actual|Duke University|||1||f||||f||||||Samples With DNA|"~     Serum TNF alpha, IL-1, IL6, CRP, uric acid, albumin, BNP, IGF-1 and growth hormone at~     baseline and at 6 months.~      50 ml of blood will be collected at baseline and at 6 months. It will be divided into~     aliquots as follows; 10 ml in Pax-gene tubes for mRNA extraction, 20 ml for various other~     biomarkers, 10 ml for proteomics and 10 ml will be stored for any future use.~      Approximately a 5x5 - 7x7mm muscle biopsy will be obtained from the mid thigh region of each~     subject at baseline and at six months~   "|||2018-06-01 02:32:59.496729|2018-06-01 02:32:59.496729
NCT00600379|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2011-06-15|2008-01-24|2008-01-25|Estimate|||||||2011-06-15|2011-06-16|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Virtual Reality Training Program for Ambulatory Patients With Chronic Gait Deficits After Stroke|A Randomized Controlled Trial of a Virtual Reality Training Program for Ambulatory Patients With Mild-to-moderate Chronic Gait Deficits After Stroke|Completed||Phase 2|48|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 02:32:59.561339|2018-06-01 02:32:59.561339
NCT00600366|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-01-05|2008-01-14|2008-01-25|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2004||2004-03-31|January 2017|2017-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes|Efficacy and Safety of Biphasic Insulin Aspart 30 in Insulin Naive Type 2 Diabetic Patients With Secondary OHA Failure|Completed||Phase 4|71|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:32:59.634054|2018-06-01 02:32:59.634054
NCT00600353|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2013-03-27||2017-01-18|2008-01-14|2008-01-25|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|October 2007||2007-10-31|January 2017|2017-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||2 patients excluded from analysis|Multi-day Doses in Prevention of Nausea and Emesis|Combined Use of Multi-Day Doses of Palonosetron and Aprepitant With Low Doses Dexamethasone in Prevention of Nausea and Emesis Among Patients With Multiple Myeloma and Lymphoma Undergoing Autologous Stem Cell Transplant: A Pilot Study|Completed||Phase 2|20|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 02:32:59.736727|2018-06-01 02:32:59.736727
NCT00600340|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2016-02-17|2008-01-24|2008-01-25|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab|A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of HER2-negative Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 3|560|Actual|Central European Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 02:33:00.107913|2018-06-01 02:33:00.107913
NCT00600327|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-14|2008-01-14|2008-01-24|Estimate|||||||2008-01-14|2008-01-24|Estimate|December 2001||2001-12-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|March 2005|Actual|2005-03-31||Interventional|CABERNET||Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™|Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™|Completed||Phase 3|488|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 02:33:00.243269|2018-06-01 02:33:00.243269
NCT00600314|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2010-10-07|2008-01-11|2008-01-24|Estimate|||||||2010-10-07|2010-10-11|Estimate|April 2005||2005-04-30|October 2010|2010-10-31|April 2012|Anticipated|2012-04-30|||||Observational|||Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease|Measurements of Resting Energy Expenditure in Patients With or at Risk of Developing Graft Versus Host Disease|Unknown status|Recruiting||60|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-06-01 02:33:00.328627|2018-06-01 02:33:00.328627
NCT00600301|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate||||January 2008|2008-01-31||||||||Interventional|||Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study||Unknown status|Recruiting|Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 02:33:00.384056|2018-06-01 02:33:00.384056
NCT00600288|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11||2011-03-24|2014-12-21|2008-01-23|2008-01-24|Estimate||||2011-03-30|2011-04-07|Estimate|2014-12-21|2015-01-09|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)|A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% and Placebo in Subjects With Dry Eye Disease|Completed||Phase 3|261|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:33:00.436328|2018-06-01 02:33:00.436328
NCT00600275|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11||2012-05-01|2012-11-26|2008-01-23|2008-01-24|Estimate||||2012-05-01|2012-05-03|Estimate|2012-11-26|2012-11-27|Estimate|December 2007||2007-12-31|November 2012|2012-11-30||||March 2010|Actual|2010-03-31||Interventional|||A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer|A Phase I/II, Multi-center, Open-label Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer|Completed||Phase 1/Phase 2|57|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:33:00.505857|2018-06-01 02:33:00.505857
NCT00600262|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|December 2005||2005-12-31|January 2008|2008-01-31|June 2006||2006-06-30|||||Interventional|||Intravitreal Bevacizumab for Diabetic Retinopathy|Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.|Completed||Phase 2/Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 02:33:00.572804|2018-06-01 02:33:00.572804
NCT00600249|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2014-03-19|2008-01-14|2008-01-24|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||"Assessment of the Efficacy of a Neoadjuvant Combination: Chemotherapy-targeted Therapy in Breast Cancer."|"Phase II Pilot Study Evaluating the Neoadjuvant Combination Taxotere (Docetaxel) and Erbitux (Cetuximab) in Operable and Triple Negative Breast Cancer Patients. TENEO Study."|Completed||Phase 2|35|Anticipated|Centre Jean Perrin|||||f||||f||||||||||2018-06-01 02:33:00.631509|2018-06-01 02:33:00.631509
NCT00600236|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population|HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population|Completed||Phase 3|300|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 02:33:00.771418|2018-06-01 02:33:00.771418
NCT00600223|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2010-10-08|2008-01-11|2008-01-24|Estimate|||||||2010-10-08|2010-10-11|Estimate|October 2005||2005-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches|Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Reconstruction Approaches|Completed|||5|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:33:00.829249|2018-06-01 02:33:00.829249
NCT00600210|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-08-22|2008-01-23|2008-01-24|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2008||2008-01-31|August 2017|2017-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer|AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer|Withdrawn||Phase 2|0|Actual|Leo W. Jenkins Cancer Center||1||low patient accrual|f||||t||||||||||2018-06-01 02:33:00.910404|2018-06-01 02:33:00.910404
NCT00596284|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2015-08-12|2008-01-04|2008-01-16|Estimate|||||||2015-08-12|2015-08-13|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Cognitive Behavior Therapy for Treating Anxiety in People With Dementia|Cognitive Behavior Therapy for Anxiety in Dementia|Completed||Phase 1|34|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 02:34:08.228753|2018-06-01 02:34:08.228753
NCT00600197|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-13|||2009-11-17|2008-01-13|2008-01-24|Estimate|||||||2009-11-17|2009-11-18|Estimate|July 2008||2008-07-31|November 2009|2009-11-30|September 2012|Anticipated|2012-09-30|April 2010|Anticipated|2010-04-30||Interventional|||Biopsychosocial Education and Chronic Low Back Pain|The Effectiveness of Biopsychosocial Education on Quality of Life and Disability of Individuals Suffering From Chronic Low Back Pain|Unknown status|Active, not recruiting|N/A|170|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:33:01.014231|2018-06-01 02:33:01.014231
NCT00600184|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2016-12-07|2008-01-23|2008-01-24|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|November 2009|Actual|2009-11-30||Interventional|AMES||Clinic-Based AMES Treatment of Stroke|Clinic-Based Assisted Movement and Enhanced Sensation Treatment of Stroke|Terminated||Phase 1/Phase 2|2|Actual|AMES Technology||1||Funding unavailable at this time for this particular study.|f||||t||||||||||2018-06-01 02:33:01.08723|2018-06-01 02:33:01.08723
NCT00600171|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2013-06-06|2009-07-22|2016-11-04|2008-01-23|2008-01-24|Estimate|2013-06-06|2013-08-12|Estimate|2009-07-22|2009-08-10|Estimate|2016-11-04|2016-12-16|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.|A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma|Completed||Phase 2|614|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:33:01.275098|2018-06-01 02:33:01.275098
NCT00600158|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|April 2005||2005-04-30|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy|Effects of Intravenous Local Anesthetic on Bowel Function After Colectomy|Completed||Phase 3|45|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 02:33:02.386284|2018-06-01 02:33:02.386284
NCT00600145|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2011-04-26|2008-01-10|2008-01-24|Estimate|||||||2011-04-26|2011-04-27|Estimate|September 2007||2007-09-30|April 2011|2011-04-30|July 2010|Anticipated|2010-07-31|December 2009|Anticipated|2009-12-31||Interventional|||Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward|Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward|Withdrawn||N/A|0|Actual|University of Virginia||2||PI decision|f||||t||||||||||2018-06-01 02:33:02.451739|2018-06-01 02:33:02.451739
NCT00600119|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2014-10-13|2013-01-28|2015-05-28|2008-01-11|2008-01-24|Estimate|2015-05-28|2015-06-12|Estimate|2013-01-28|2013-01-29|Estimate|2015-05-28|2015-06-12|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional||Baseline characteristics are summarized based on the MITT analysis population, which consisted of all randomized patients who received at least 1 dose of double-blind study treatment, had a baseline value and Visit 6 evaluable data (where Visit 6 was the Week 1 visit during the double-blind study treatment period).|A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients With Opioid-Induced Constipation (OIC)|Completed||Phase 2|207|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:33:02.555509|2018-06-01 02:33:02.555509
NCT00600106|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2015-08-20||2017-12-18|2008-01-23|2008-01-24|Estimate|2017-12-18|2017-12-19|Actual||||2017-12-18|2017-12-19|Actual|December 1999||1999-12-31|December 2017|2017-12-31|March 2010|Actual|2010-03-31|May 2003|Actual|2003-05-31||Interventional|||Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study|WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis|Completed||N/A|37|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||No||2018-06-01 02:33:03.498666|2018-06-01 02:33:03.498666
NCT00600093|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-13|||2011-07-24|2008-01-13|2008-01-24|Estimate|||||||2011-07-24|2011-07-26|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine|Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine|Terminated||Phase 2|20|Anticipated|Rabin Medical Center||1||PI leaving the institute for a fellowship.|f||||f||||||||||2018-06-01 02:33:05.200776|2018-06-01 02:33:05.200776
NCT00600080|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-10-20||2015-05-05|2008-01-23|2008-01-24|Estimate|2012-07-23|2012-08-23|Estimate||||2015-05-05|2015-05-21|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||Subjects are those who were enrolled and randomized to a study arm. Sixty subjects were enrolled and sixty subjects completed.|A Comparison of Two Daily Disposable Contact Lenses|The Comparative Clinical Performance of the Etafilcon A Lens and the DAILIES AquaComfort Plus Lens|Completed||N/A|60|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 02:33:05.30364|2018-06-01 02:33:05.30364
NCT00600067|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2012-07-31|2009-11-18|2012-09-05|2008-01-23|2008-01-24|Estimate|2012-07-31|2012-09-03|Estimate|2009-11-18|2009-11-19|Estimate|2012-09-05|2012-09-10|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults|A Randomized, Double Blind Multicenter Study to Evaluate the Long-term Safety and Efficacy of VI-0521 Relative to Placebo in Providing and Maintaining Glycemic Control in Type 2 Diabetic Adults|Completed||Phase 2|130|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-06-01 02:33:05.51767|2018-06-01 02:33:05.51767
NCT00600054|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2011-07-04|2008-01-23|2008-01-24|Estimate|||||||2011-07-04|2011-07-06|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma|Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma|Completed||Phase 2|44|Actual|YM BioSciences||1|||f||||t||||||||||2018-06-01 02:33:05.796462|2018-06-01 02:33:05.796462
NCT00600041|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-03-22|2008-01-23|2008-01-24|Estimate|||||||2009-03-22|2009-03-24|Estimate|May 2005||2005-05-31|February 2008|2008-02-29|November 2006|Actual|2006-11-30|January 2006|Actual|2006-01-31||Interventional|HIPPO||Placebo-Controlled Crossover Study for the Investigation of the Effect of Pantoprazole on Cardiac Contractility|Heart Issues of PantoPrazOle (HIPPO)|Completed||Phase 1|20|Actual|Herzzentrum Goettingen||2|||f||||f||||||||||2018-06-01 02:33:06.034877|2018-06-01 02:33:06.034877
NCT00600028|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2013-04-04||2017-04-06|2008-01-23|2008-01-24|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|December 2007||2007-12-31|April 2017|2017-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide|Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide|Completed||Phase 3|25|Actual|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-06-01 02:33:06.162982|2018-06-01 02:33:06.162982
NCT00600015|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-08-22||2012-08-22|2008-01-23|2008-01-24|Estimate|2012-08-22|2012-09-21|Estimate||||2012-08-22|2012-09-21|Estimate|February 2008||2008-02-29|August 2012|2012-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)|A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|166|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 02:33:06.505116|2018-06-01 02:33:06.505116
NCT00600002|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-17|||2018-02-05|2008-01-23|2008-01-24|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2004||2004-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma|A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1|30|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 02:33:06.823204|2018-06-01 02:33:06.823204
NCT00599989|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-07-08|2008-01-11|2008-01-24|Estimate|||||||2009-07-08|2009-07-09|Estimate|January 2005||2005-01-31|July 2009|2009-07-31||||January 2010|Anticipated|2010-01-31||Interventional|||Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer|Accelerated Partial Breast Irradiation|Unknown status|Active, not recruiting|N/A|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:33:06.886266|2018-06-01 02:33:06.886266
NCT00599976|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|PABA CHF||Comparison of Pulmonary Vein Isolation Versus AV Nodal Ablation With Biventricular Pacing for Patients With Atrial Fibrillation With Congestive Heart Failure (PABA CHF)|Randomized Controlled Trial of Pulmonary Vein Antrum Isolation vs. AV Node Ablation With Bi-Ventricular Pacing for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure (PABA CHF)|Completed||N/A|81|Actual|Azienda Policlinico Umberto I|||||f||||f||||||||||2018-06-01 02:33:06.950619|2018-06-01 02:33:06.950619
NCT00599963|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2015-07-31|2008-01-14|2008-01-24|Estimate|||||||2015-07-31|2015-08-03|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|||Paricalcitol for the Treatment of Immunoglobulin A Nephropathy|Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study|Withdrawn||Phase 3|0|Actual|Chinese University of Hong Kong||2||Funding problem.|f||||t||||||||||2018-06-01 02:33:06.999265|2018-06-01 02:33:06.999265
NCT00599950|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|January 2007|Actual|2007-01-31||Interventional|||Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C|Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C.|Completed||Phase 4|10|Actual|Asociación para Evitar la Ceguera en México||2|||f||||t||||||||||2018-06-01 02:33:07.065208|2018-06-01 02:33:07.065208
NCT00599937|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|January 1993||1993-01-31|December 2007|2007-12-31|December 1998|Actual|1998-12-31|December 1998|Actual|1998-12-31||Interventional|||APL93: Timing of CxT and Role of Maintenance|Assessment of the Optimal Timing of Chemotherapy With or After ATRA and the Role of Maintenance|Completed||Phase 3|576|Actual|Groupe d'etude et de travail sur les leucemies aigues promyelocytaires||7|||f||||f||||||||||2018-06-01 02:33:07.127627|2018-06-01 02:33:07.127627
NCT00599924|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2009-11-04||2015-06-22|2008-01-11|2008-01-24|Estimate|2009-11-04|2009-12-09|Estimate||||2015-06-22|2015-07-15|Estimate|September 2005||2005-09-30|June 2015|2015-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors|Phase I Study Of SU011248 In Combination With Oxaliplatin, Leucovorin, And 5-Fluorouracil In Patients With Advanced Solid Malignancies|Completed||Phase 1|53|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:33:07.377043|2018-06-01 02:33:07.377043
NCT00599911|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2016-11-07|2008-01-11|2008-01-24|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Dose-finding Study With Lu AA24530 in Major Depressive Disorder|Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced, Dose-finding Study of Lu AA24530 in Major Depressive Disorder|Completed||Phase 2|652|Actual|H. Lundbeck A/S||5|||f||||f||||||||||2018-06-01 02:33:08.941806|2018-06-01 02:33:08.941806
NCT00599898|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2012-03-12|2008-01-13|2008-01-24|Estimate|||||||2012-03-12|2012-03-13|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Nifedipine Compared to Atosiban for Treating Preterm Labor|Nifedipine Compared to Atosiban for Treating Preterm Labor. A Randomized Controlled Trial.|Completed||Phase 4|145|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-06-01 02:33:09.174958|2018-06-01 02:33:09.174958
NCT00599885|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2015-09-02|2008-01-23|2008-01-24|Estimate|||||||2015-09-02|2015-09-03|Estimate|September 2007||2007-09-30|September 2015|2015-09-30||||July 2008|Actual|2008-07-31||Interventional|||Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes||Completed||Phase 4|72|Actual|Korea University Anam Hospital||2|||f||||||||||||||2018-06-01 02:33:09.247277|2018-06-01 02:33:09.247277
NCT00599872|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-07-07||2015-01-06|2008-01-23|2008-01-24|Estimate|2015-01-06|2015-01-14|Estimate||||2015-01-06|2015-01-14|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies|Parallel, Randomized, Double-Blind, Placebo-Controlled Trial in Adults for the Sublingual-Oral Immunotherapy (SLIT) of Allergic Rhinoconjunctivitis With or Without Asthma Caused By Ragweed Pollen|Completed||Phase 3|430|Actual|Greer Laboratories||2|||f||||f||||||||||2018-06-01 02:33:09.330836|2018-06-01 02:33:09.330836
NCT00599859|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2009-09-18|2008-01-23|2008-01-24|Estimate|||||||2009-09-18|2009-09-21|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|ELM||Effects of Lactose on Fecal Microflora|Differential Biologic Impact of Lactose Consumption in Lactase Persistent and Non-persistent Populations: Evaluation of Microflora and Insulin/Glycemic Response|Completed||N/A|57|Actual|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||t||||||||||2018-06-01 02:33:09.706587|2018-06-01 02:33:09.706587
NCT00599846|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-13|||2010-02-26|2008-01-23|2008-01-24|Estimate|||||||2010-02-26|2010-03-02|Estimate|December 2007||2007-12-31|February 2010|2010-02-28||||December 2009|Actual|2009-12-31||Observational|||The Natural History of Geographic Atrophy Progression (GAP) Study||Terminated|||1000|Anticipated|Alcon Research|||||f||||f||||||||||2018-06-01 02:33:09.795794|2018-06-01 02:33:09.795794
NCT00599092|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-07-08|2008-01-11|2008-01-23|Estimate|||||||2009-07-08|2009-07-09|Estimate|January 1997||1997-01-31|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Pituitary Tumor Surveillance: Pathogenic Correlation|Pituitary Tumor Surveillance: Pathogenetic Correlation|Unknown status|Recruiting||1250|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 02:33:18.616104|2018-06-01 02:33:18.616104
NCT00599833|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2013-06-25|2008-01-11|2008-01-24|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery|Locally Advanced Pancreatic Cancer: Phase II Study of Cetuximab and 3-D Conformal Image Guided Radiotherapy (PACER)|Completed||Phase 2|44|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:33:09.87206|2018-06-01 02:33:09.87206
NCT00599820|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|May 2006||2006-05-31|||||Interventional|||Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks|OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab|Unknown status|Active, not recruiting|Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 02:33:09.935105|2018-06-01 02:33:09.935105
NCT00599807|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2014-10-27|2008-01-23|2008-01-24|Estimate|||||||2014-10-27|2014-10-28|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients|Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial|Completed||Phase 4|273|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 02:33:10.005797|2018-06-01 02:33:10.005797
NCT00599794|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Observational|||A Simple Clinical Tool to Help Assess Patient Volume (Fluid) Status|A Simple Clinical Tool to Help Assess Patient Volume (Fluid) Status|Completed|||84|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 02:33:10.105728|2018-06-01 02:33:10.105728
NCT00599781|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|March 1992||1992-03-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|July 2006|Actual|2006-07-31||Interventional|||Gene Therapy for ADA-SCID|Treatment of ADA-SCID by Gene Therapy on Somatic Cells|Completed||Phase 1/Phase 2|8|Actual|IRCCS San Raffaele||1|||f||||f||||||||||2018-06-01 02:33:10.161449|2018-06-01 02:33:10.161449
NCT00599768|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11||2009-11-19|2009-11-19|2008-01-23|2008-01-24|Estimate||||2009-11-19|2009-11-23|Estimate|2009-11-19|2009-11-23|Estimate|March 2008||2008-03-31|November 2009|2009-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.|Development and Validation for Taiwan Version ID Pain Questionnaire (ID Pain-T) and DN4 Questionnaire.|Completed|||325|Actual|Pfizer|||||f||||f||||||||||2018-06-01 02:33:10.232012|2018-06-01 02:33:10.232012
NCT00599755|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2012-04-10||2017-12-15|2008-01-11|2008-01-24|Estimate|2012-05-22|2012-06-27|Estimate||||2017-12-15|2018-01-16|Actual|January 1, 2009|Actual|2009-01-01|December 2017|2017-12-31|April 13, 2011|Actual|2011-04-13|June 10, 2010|Actual|2010-06-10||Interventional|||Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)|A Multicenter Phase Ib Trial to Measure [18F]-Fluorodeoxyglucose Uptake by Positron Emission Tomography in Stage IIIB and IV Non-Small Cell Lung Cancer Before and After Chemotherapy With Gemcitabine and Cisplatin or Carboplatin|Completed||Phase 1|68|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:33:10.408775|2018-06-01 02:33:10.408775
NCT00599742|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|December 2007||2007-12-31|January 2008|2008-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Comorbidity Between Balance and Childhood Anxiety|Comorbidity Between Balance and Childhood Anxiety: Treatment of Anxiety by Training of Balance|Unknown status|Recruiting|N/A|64|Anticipated|Lev-Hasharon Mental Healtlh Center||2|||f||||t||||||||||2018-06-01 02:33:10.63457|2018-06-01 02:33:10.63457
NCT00599729|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2008-01-23|2008-01-23|2008-01-24|Estimate|||||||2008-01-23|2008-01-24|Estimate|January 2008||2008-01-31|December 2007|2007-12-31||||July 2008|Anticipated|2008-07-31||Observational|||Measurement of Gait Spatio-Temporal Characteristics in Knee Osteoarthritis Patients||Unknown status|Recruiting||30|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-06-01 02:33:10.722012|2018-06-01 02:33:10.722012
NCT00599716|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-01-08|2008-01-11|2008-01-24|Estimate|||||||2009-01-08|2009-01-09|Estimate|December 2006||2006-12-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome|A Phase 3, Multicenter, Randomized, Double-Masked Study of Safety and Efficacy of Vismed® in Dry Eye Syndrome|Completed||Phase 3|300|Anticipated|Lantibio||2|||f||||f||||||||||2018-06-01 02:33:10.790284|2018-06-01 02:33:10.790284
NCT00599703|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-07-07|2008-01-11|2008-01-24|Estimate|||||||2009-07-07|2009-07-08|Estimate|May 2005||2005-05-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Language Function in Patients With Brain Tumors|Reorganization of Language Function in Patients With Brain Tumors|Completed|||7|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:33:10.871534|2018-06-01 02:33:10.871534
NCT00599690|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-28|2008-01-23|2008-01-24|Estimate|||||||2008-01-28|2008-01-29|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|January 2006|Actual|2006-01-31||Interventional|||Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma.|Epi-LASIK : A Confocal Microscopy Analysis of the Corneal Epithelium and Anterior Stroma.|Completed||N/A|10|Actual|Asociación para Evitar la Ceguera en México||1|||f||||t||||||||||2018-06-01 02:33:10.99225|2018-06-01 02:33:10.99225
NCT00599677|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2011-11-08|2008-01-23|2008-01-24|Estimate|||||||2011-11-08|2011-11-09|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Randomized Controlled Trial of Acupuncture for Functional Dyspepsia|Randomized Controlled Trial of Acupuncture for Functional Dyspepsia|Completed||N/A|720|Actual|Chengdu University of Traditional Chinese Medicine||6|||f||||t||||||||||2018-06-01 02:33:11.058634|2018-06-01 02:33:11.058634
NCT00599664|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2010-04-28|2008-01-10|2008-01-24|Estimate|||||||2010-04-28|2010-04-30|Estimate|December 2007||2007-12-31|April 2010|2010-04-30|September 2008|Actual|2008-09-30|||||Interventional|||Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones|Double-Blind, Placebo-Controlled, Two-Center, Pharmacokinetic Study Evaluating the Systemic Absorption and Safety of OMS201 in Subjects Undergoing Ureteroscopic Treatment of Unilateral Ureteral- or Renal Collecting System-Located Stones|Completed||Phase 1|11|Actual|Omeros Corporation||2|||f||||f||||||||||2018-06-01 02:33:11.132665|2018-06-01 02:33:11.132665
NCT00599651|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-29|||2010-05-06|2008-01-23|2008-01-24|Estimate|||||||2010-05-06|2010-05-07|Estimate|June 2005||2005-06-30|May 2010|2010-05-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)|Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)|Terminated||N/A|380|Anticipated|University of Virginia||2||Study was closed due to extremely low enrollment|f||||f||||||||||2018-06-01 02:33:11.201831|2018-06-01 02:33:11.201831
NCT00599638|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04||2009-04-06|2009-10-07|2008-01-11|2008-01-24|Estimate||||2009-10-07|2009-10-12|Estimate|2009-10-07|2009-10-12|Estimate|March 2008||2008-03-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia|A Two Week Double-Blind Placebo-Controlled Crossover Study To Compare The Efficacy And Safety Of A Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Patients With Post-Herpetic Neuralgia|Completed||Phase 2|130|Anticipated|Pfizer||3|||f||||||||||||||2018-06-01 02:33:11.297943|2018-06-01 02:33:11.297943
NCT00599625|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-03-04|2008-01-11|2008-01-24|Estimate|||||||2011-03-04|2011-03-08|Estimate|October 2004||2004-10-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study|Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|University of Virginia||1|||f||||f||||||||||2018-06-01 02:33:11.418622|2018-06-01 02:33:11.418622
NCT00599612|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-08-03|2008-01-11|2008-01-24|Estimate|||||||2017-08-03|2017-08-04|Actual|January 17, 2008|Actual|2008-01-17|August 2017|2017-08-31|February 18, 2008|Actual|2008-02-18|February 18, 2008|Actual|2008-02-18||Interventional|||To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males|An Open Label Study to Determine the Safety, Tolerability, Excretion Balance and Pharmacokinetics of [14C]GW856553, Administered as a Single Dose of an Oral Solution to Healthy Adult Male Subjects|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:33:11.51934|2018-06-01 02:33:11.51934
NCT00599599|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-03-04|2008-01-23|2008-01-24|Estimate|||||||2009-03-04|2009-03-05|Estimate|April 2005||2005-04-30|March 2009|2009-03-31|February 2010|Anticipated|2010-02-28|February 2009|Anticipated|2009-02-28||Interventional|PEACH||Stress-Reducing Interventions in HIV+ Patients: Pilot|Pilot Intervention for PTSD, Nonadherence, and HIV Risk|Unknown status|Active, not recruiting|N/A|70|Anticipated|Kent State University||2|||f||||t||||||||||2018-06-01 02:33:11.609999|2018-06-01 02:33:11.609999
NCT00599586|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2010-06-27|2008-01-14|2008-01-24|Estimate|||||||2010-06-27|2010-06-29|Estimate|November 2007||2007-11-30|June 2010|2010-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Randomized Controlled Trial of Treating Migraine With Acupuncture|Randomized Controlled Trial of Treating Migraine With Acupuncture|Completed||N/A|480|Actual|Chengdu University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-06-01 02:33:11.684521|2018-06-01 02:33:11.684521
NCT00599573|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2010-04-12|2008-01-23|2008-01-24|Estimate|||||||2010-04-12|2010-04-14|Estimate|October 2007||2007-10-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Pharmacotherapy for HIV+ Stimulant Dependent Individuals|Pharmacotherapy for HIV+ Stimulant Dependent Individuals|Unknown status|Recruiting|N/A|12|Anticipated|University of Virginia||1|||f||||t||||||||||2018-06-01 02:33:11.765512|2018-06-01 02:33:11.765512
NCT00599560|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2016-03-28|2008-01-22|2008-01-23|Estimate|||||||2016-03-28|2016-03-29|Estimate|April 1998||1998-04-30|January 2008|2008-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Vasopressin and V2 Receptor in Meniere's Disease|Vasopressin and V2 Receptor in Meniere's Disease|Completed||N/A|135|Actual|Osaka University||2|||f||||f||||||||||2018-06-01 02:33:11.860978|2018-06-01 02:33:11.860978
NCT00599547|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2016-01-13|2008-01-22|2008-01-23|Estimate|||||||2016-01-13|2016-01-14|Estimate|November 2002||2002-11-30|January 2016|2016-01-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients|Allogeneic Stem Cell Transplantation After Dose-reduced Intensity Conditioning Regimen for Patients With Myelofibrosis With Myeloid Metaplasia (MMM): A Phase II-study|Completed||Phase 2|106|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-06-01 02:33:11.942879|2018-06-01 02:33:11.942879
NCT00599534|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-04-06|2008-01-22|2008-01-23|Estimate|||||||2017-04-06|2017-04-10|Actual|December 2007||2007-12-31|April 2017|2017-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Controlled Trial on Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome|A Randomized Double Blind Controlled Trial on the Effect of Treatment in Children With Obstructive Sleep Apnea Syndrome.|Withdrawn||Phase 2|0|Actual|University of Louisville||2||Principal Investigator has transferred to another Institution|f||||f||||||||||2018-06-01 02:33:12.01105|2018-06-01 02:33:12.01105
NCT00599521|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2010-04-16||2011-03-21|2008-01-11|2008-01-23|Estimate|2011-03-21|2011-04-19|Estimate||||2011-03-21|2011-04-19|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%|A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris|Completed||Phase 3|1067|Actual|Galderma||2|||f||||f||||||||||2018-06-01 02:33:12.094525|2018-06-01 02:33:12.094525
NCT00599508|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2016-10-07|2008-01-10|2008-01-23|Estimate|||||||2016-10-07|2016-10-10|Estimate|June 2006||2006-06-30|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Nutritional Supplementation in Cognitive Aging|Nutritional Supplementation in Cognitive Aging|Completed||N/A|120|Actual|University of Cincinnati||5|||f||||f||||||||||2018-06-01 02:33:12.395373|2018-06-01 02:33:12.395373
NCT00599495|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2015-11-30|2008-01-22|2008-01-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2002||2002-11-30|November 2015|2015-11-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT|Allogeneic Stem Cell Transplantation From Unrelated Donors After Dose-reduced Intensity Conditioning Regimen for Patients With Multiple Myeloma and Relapse After Autologous Stem Cell Transplantation: A Phase II-study|Completed||Phase 2|50|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-06-01 02:33:12.470583|2018-06-01 02:33:12.470583
NCT00599482|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-01-02|2008-01-11|2008-01-23|Estimate|||||||2009-01-02|2009-01-05|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|January 2009|Anticipated|2009-01-31|September 2008|Anticipated|2008-09-30||Interventional|||Far Infrared Radiation for Sickle Cell Pain Management|Phase 1 Study to Examine the Use of Far Infrared Radiation for Pain Management During Sickle Cell Crisis|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:33:12.63048|2018-06-01 02:33:12.63048
NCT00599469|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-08-14|2008-01-11|2008-01-23|Estimate|||||||2009-08-14|2009-08-17|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|April 2009|Anticipated|2009-04-30|March 2009|Anticipated|2009-03-31||Interventional|||Far Infrared Treatment for Alzheimer's Disease|Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.|Unknown status|Active, not recruiting|Phase 1|4|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:33:12.714832|2018-06-01 02:33:12.714832
NCT00599456|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-05-09|2008-01-22|2008-01-23|Estimate|||||||2017-05-09|2017-05-10|Actual|September 2007||2007-09-30|May 2017|2017-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.|A Placebo Controlled Double Blinded Prospective Study to Investigate the Usefulness of Omega 3 Fatty Acids in the Relief of Vasomotor Symptoms of Menopausal Women|Completed||N/A|100|Anticipated|Christiana Care Health Services||2|||f||||f||||||||||2018-06-01 02:33:12.783499|2018-06-01 02:33:12.783499
NCT00599443|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2008-06-27|2008-01-10|2008-01-23|Estimate|||||||2008-06-27|2008-06-30|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.|Completed||Phase 1|120|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:33:12.856482|2018-06-01 02:33:12.856482
NCT00599430|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-11|2008-01-11|2008-01-23|Estimate|||||||2008-01-11|2008-01-23|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Evaluation of Probiotics on Symptoms of Upper Respiratory Tract Infections|Probiotics and Effects on Illness-Related Symptoms for Pre-School Age Children|Completed||N/A|326|Actual|Danisco||3|||f||||f||||||||||2018-06-01 02:33:12.919844|2018-06-01 02:33:12.919844
NCT00599417|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-09-18|2008-01-11|2008-01-23|Estimate|||||||2009-09-18|2009-09-21|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||PulmonarOM (Bacterial Lysates) in Respiratory Tract Infections|Prospective, Pivotal Unicentre, Randomized Double-bind, Placebo-controlled Study, to Evaluate Efficacy and Safety of Bacterial Lysates (Pulmonarom) in the Prevention of Respiratory Tract Infections|Completed||Phase 4|80|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:33:12.993786|2018-06-01 02:33:12.993786
NCT00599404|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2008-04-23|2008-01-22|2008-01-23|Estimate|||||||2008-04-23|2008-04-30|Estimate|January 2008||2008-01-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400|An Open-Label, 2-Period Pharmacokinetic Study to Evaluate the Intra-Subject Variability in Esomeprazole Plasma Levels in Healthy Subjects Following Oral Administration of PN 400 Tablets|Completed||Phase 1|18|Actual|POZEN|||||f||||f||||||||||2018-06-01 02:33:13.062224|2018-06-01 02:33:13.062224
NCT00599391|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-01-02|2008-01-11|2008-01-23|Estimate|||||||2009-01-02|2009-01-05|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|February 2009|Anticipated|2009-02-28|October 2008|Anticipated|2008-10-31||Interventional|||Far Infrared Treatment for Kidney Diseases|Phase 1 Study to Examine the Use of Far Infrared Radiation for Renal Failure.|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:33:13.111425|2018-06-01 02:33:13.111425
NCT00599378|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2013-09-06|2008-01-10|2008-01-23|Estimate|||||||2013-09-06|2013-09-10|Estimate|September 2007||2007-09-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Implementation Intentions to Promote Colon Cancer Screening in Rural Primary Care Practice|Implementation Intentions to Promote Colon Cancer Screening in Rural Primary Care Practice|Completed||N/A|373|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 02:33:13.237721|2018-06-01 02:33:13.237721
NCT00599365|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-02-14|2008-01-22|2008-01-23|Estimate|||||||2008-02-14|2008-02-15|Estimate|December 2007||2007-12-31|November 2007|2007-11-30|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|CAMP||Impact of CAMP in an Ambulatory Renal Clinic|Impact of a Pharmacist's Collaborative Management, Adherence,and Medication Education Program (CAMP) in an Ambulatory Renal Clinic|Unknown status|Recruiting|N/A|100|Anticipated|San Francisco Veterans Affairs Medical Center||2|||f||||t||||||||||2018-06-01 02:33:13.309041|2018-06-01 02:33:13.309041
NCT00599352|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2013-05-28|2008-01-11|2008-01-23|Estimate|||||||2013-05-28|2013-05-30|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Hypovitaminosis D and an Inadequate PTH Response in Chronic Liver Disease Patients|Hypovitaminosis D and an Inadequate PTH Response in Chronic Liver Disease Patients|Terminated||N/A|14|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 02:33:13.394716|2018-06-01 02:33:13.394716
NCT00599339|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2015-04-10||2015-07-27|2008-01-10|2008-01-23|Estimate|2015-04-10|2015-04-29|Estimate||||2015-07-27|2015-08-17|Estimate|June 2006||2006-06-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|TRUST|Baseline Characterisitcs refer to the Enrolled Set [ES]. 2195 patients were enrolled in this study, of which 36 patients had no valid data consent. Data from these patients were not used for analysis.|Transdermal Rotigotine User Surveillance Study|A Naturalistic, Multisite, Observational Study of Rotigotine Transdermal Patch and Other Currently Prescribed Therapies in Patients With Idiopathic Parkinson's Disease|Completed|||2195|Actual|UCB Pharma|||5||f||||f||||||||||2018-06-01 02:33:13.546706|2018-06-01 02:33:13.546706
NCT00599326|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2013-08-21||2014-01-09|2008-01-10|2008-01-23|Estimate|2014-01-09|2014-02-10|Estimate||||2014-01-09|2014-02-10|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda|Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda|Completed||Phase 3|10|Actual|University of Texas Southwestern Medical Center|10 patients were enrolled, of which 8 were compliant with therapy and had evaluable data. Of the 2 patients dropped from the study, one patient was lost to follow-up after 2 months and another was noncompliant with medication dosing.|1|||f||||f||||||||||2018-06-01 02:33:15.680869|2018-06-01 02:33:15.680869
NCT00599313|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2016-01-20||2016-10-13|2008-01-22|2008-01-23|Estimate|2016-10-13|2016-12-08|Estimate||||2016-10-13|2016-12-08|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Total participants|Phase II Sunitinib Prog Met AIPC|Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-based Chemotherapy|Completed||Phase 2|36|Actual|US Oncology Research||1|||f||||f||||||||||2018-06-01 02:33:15.886575|2018-06-01 02:33:15.886575
NCT00599287|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2018-03-19|2008-01-22|2008-01-23|Estimate|||||||2018-03-19|2018-03-21|Actual|February 2008||2008-02-29|February 2008|2008-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients|Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients: a Randomized, Mono-blind Pilot Trial|Terminated||Phase 3|80|Anticipated|UMC Utrecht||4||"Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed~   consent."|f||||t||||||||||2018-06-01 02:33:16.300783|2018-06-01 02:33:16.300783
NCT00233025|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2007-08-22|2005-10-03|2005-10-05|Estimate|||||||2007-08-22|2007-08-23|Estimate|September 2005||2005-09-30|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Duloxetine Versus Placebo in the Treatment of FMS|Duloxetine 60/120mg Versus Placebo in the Treatment of Fibromyalgia Syndrome|Completed||Phase 3|320||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:25:51.731433|2018-06-01 04:25:51.731433
NCT00599274|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2010-01-26|2008-01-22|2008-01-23|Estimate|||||||2010-01-26|2010-01-27|Estimate|August 2002||2002-08-31|January 2010|2010-01-31|May 2003|Actual|2003-05-31|||||Observational|PROOF||Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis|A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS)|Completed|||136|Actual|Biogen|||2||f||||t||||||||||2018-06-01 02:33:16.412603|2018-06-01 02:33:16.412603
NCT00599261|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2013-01-08|2008-01-22|2008-01-23|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||MAKE IT CLEAN, Impact of Pocket Revision on the Rate of Infection and Other Complications in Patients Requiring Pocket Manipulation for Generator Replacement and/or Lead Replacement or Revision: A Prospective Randomized Study|Impact of Pocket Revision on the Rate of Infection and Other Complications in Patients Requiring Pocket Manipulation for Generator Replacement and/or Lead Replacement or Revision: A Prospective Randomized Study|Completed||Phase 4|265|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 02:33:16.519567|2018-06-01 02:33:16.519567
NCT00599248|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2016-05-23||2017-06-07|2008-01-22|2008-01-23|Estimate|2016-05-23|2016-06-30|Estimate||||2017-06-07|2017-07-07|Actual|January 2007||2007-01-31|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|TGC-03-01|Adults 18 or older with degenerative joint disease of the knee (confirmed by Kellgren and Lawrence criteria) refractory to existing drug therapies who were scheduled for total knee arthroplasty.|Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee|A Phase 1 Study to Determine the Safety and Biological Activity of Cell-Mediated Gene Therapy Using TissueGene-C in Patients With Degenerative Joint Disease Prior to Total Knee Arthroplasty|Completed||Phase 1|12|Actual|TissueGene, Inc.|This study was designed a a preliminary assessment of safety in a limited population (12 subjects: 9 active 3 placebo) therefore statistics are presented descriptively.|4|||f||||t||||||||No||2018-06-01 02:33:16.622551|2018-06-01 02:33:16.622551
NCT00599235|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2010-04-07|2008-01-10|2008-01-23|Estimate|||||||2010-04-07|2010-04-08|Estimate|March 2007||2007-03-31|January 2008|2008-01-31|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Sildenafil and Exercise Capacity in Hypertension|Effects of the Selective Phosphodiesterase Type 5 Inhibitor Sildenafil Citrate on Exercise Capacity and Vascular Function in Hypertensive Subjects|Completed||N/A|30|Actual|University of Edinburgh||2|||f||||||||||||||2018-06-01 02:33:17.012386|2018-06-01 02:33:17.012386
NCT00599222|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2011-11-21|2008-01-10|2008-01-23|Estimate|||||||2011-11-21|2011-11-22|Estimate|February 2008||2008-02-29|November 2011|2011-11-30|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study|A Prospective, Randomized, Controlled Study on Intravitreal Ranibizumab (Lucentis) Combined With Transpupillary Thermotherapy (TTT) for Neovascular Age-related Macular Degeneration (AMD)|Completed||Phase 3|100|Actual|St. Erik Eye Hospital||2|||f||||f||||||||||2018-06-01 02:33:17.101794|2018-06-01 02:33:17.101794
NCT00599209|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2011-08-02|2008-01-22|2008-01-23|Estimate|||||||2011-08-02|2011-08-04|Estimate|September 2004||2004-09-30|August 2011|2011-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Health Information Technology in the Nursing Home|Health Information Technology in the Nursing Home|Completed||N/A|23|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 02:33:17.181068|2018-06-01 02:33:17.181068
NCT00599196|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|2009-12-11||2014-09-24|2008-01-10|2008-01-23|Estimate|2009-12-11|2010-01-18|Estimate||||2014-09-24|2014-10-02|Estimate|August 2002||2002-08-31|September 2010|2010-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease|An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease|Completed||Phase 3|381|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:33:17.298489|2018-06-01 02:33:17.298489
NCT00599183|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2013-07-29|2008-01-22|2008-01-23|Estimate|||||||2013-07-29|2013-07-31|Estimate|August 2006||2006-08-31|July 2013|2013-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Diffusion Tensor (Magnetic Resonance) Imaging and Tractography in Herniation of the Cervical Spine|Diffusion Tensor (Magnetic Resonance) Imaging and Tractography in Herniation of the Cervical Spine: An Investigator-Initiated Pilot Study|Completed||N/A|12|Actual|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-06-01 02:33:17.943085|2018-06-01 02:33:17.943085
NCT00599170|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2018-03-30|2008-01-22|2008-01-23|Estimate|||||||2018-03-30|2018-04-02|Actual|January 10, 2008|Actual|2008-01-10|March 2018|2018-03-31|January 10, 2020|Anticipated|2020-01-10|January 10, 2019|Anticipated|2019-01-10||Interventional|||Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma|Rituximab Plus CHOP Given Every Two Weeks With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 2|52|Actual|University of Southern California||1|||f||||t|t|f|||f|||||2018-06-01 02:33:18.118777|2018-06-01 02:33:18.118777
NCT00599144|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2008-01-22|2008-01-22|2008-01-23|Estimate|||||||2008-01-22|2008-01-23|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effectiveness of Bupivacaine After Laparoscopic Cholecystectomy|Effectiveness for Postoperative Pain After Laparoscopic Cholecystectomy of 0,5% Bupivacaine-Soaked Tabotamp Placed in the Gallbladder Bed|Completed||N/A|45|Actual|Santa Maria alla Gruccia Hospital||3|||f||||t||||||||||2018-06-01 02:33:18.205653|2018-06-01 02:33:18.205653
NCT00599131|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2014-04-16||2015-11-04|2008-01-22|2008-01-23|Estimate|2014-05-19|2014-06-16|Estimate||||2015-11-04|2015-12-03|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|October 2010|Actual|2010-10-31|July 2008|Actual|2008-07-31||Interventional|||Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)|A Phase II Organ Preservation Trial Using Cetuximab and Radiation Therapy in Advanced Laryngeal Cancer Patients Who Have Responded to One Cycle of Induction Chemotherapy With Taxotere, Cisplatin, 5-Fluorouracil (TPF), and Cetuximab|Terminated||Phase 2|4|Actual|University of Michigan Cancer Center|The study was discontinued prematurely due to an early stopping rule.|1||The study was discontinued prematurely due to early stopping rules.|f||||t||||||||||2018-06-01 02:33:18.304513|2018-06-01 02:33:18.304513
NCT00599118|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2017-07-21|2008-01-11|2008-01-23|Estimate|||||||2017-07-21|2017-07-25|Actual|August 2005|Actual|2005-08-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation|Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation|Active, not recruiting|||1300|Anticipated|The Cleveland Clinic|||2||f||||t|f|f||||Samples With DNA|"~     plasma, serum, buffy coat, DNA~   "|No||2018-06-01 02:33:18.494114|2018-06-01 02:33:18.494114
NCT00599079|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-05-19|2008-01-11|2008-01-23|Estimate|||||||2017-05-19|2017-05-23|Actual|February 1993|Actual|1993-02-28|May 2017|2017-05-31|May 18, 2017|Actual|2017-05-18|May 2008|Actual|2008-05-31||Interventional|||Azithromycin in the Treatment of M. Avium Complex Lung Disease|Open, Noncomparative Trial of Azithromycin in the Treatment of M.Avium Complex (MAC) Lung Disease|Completed||Phase 4|66|Actual|The University of Texas Health Science Center at Tyler||1|||f||||f||||||||No||2018-06-01 02:33:18.677297|2018-06-01 02:33:18.677297
NCT00599066|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-04-12|2008-01-22|2008-01-23|Estimate|||||||2017-04-12|2017-04-14|Actual|September 2007||2007-09-30|April 2017|2017-04-30|April 2009|Actual|2009-04-30|June 2008|Actual|2008-06-30||Observational|||Intraoperative M-Entropy Measurements|Same-patient Reproducibility of Intraoperative M-Entropy Measurements|Completed|||24|Actual|University of Oklahoma|||1||f||||t||||||||No||2018-06-01 02:33:18.739007|2018-06-01 02:33:18.739007
NCT00599053|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2012-05-30||2017-04-17|2008-01-22|2008-01-23|Estimate|2012-11-28|2012-12-31|Estimate||||2017-04-17|2017-05-17|Actual|May 2007||2007-05-31|April 2017|2017-04-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates|Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates|Terminated||Phase 1/Phase 2|7|Actual|University of Alabama at Birmingham|Early termination due to small number enrolled.|2||"Enrollment was terminated early due to a change in practice on the obstetrical side that~   included administering azithromycin to women with preterm labor."|f||||t||||||||||2018-06-01 02:33:18.805655|2018-06-01 02:33:18.805655
NCT00599040|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2013-03-15|2008-01-22|2008-01-23|Estimate|||||||2013-03-15|2013-03-18|Estimate|September 2005||2005-09-30|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|DINE||The DINE Study-Diet Intervention to Negate Diabetes Study (Improving Weight Loss Outcomes for African Americans)|The DINE Study-Diet Intervention to Negate Diabetes Study (Improving Weight Loss Outcomes for African Americans)|Completed||Phase 4|113|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-06-01 02:33:19.057835|2018-06-01 02:33:19.057835
NCT00599027|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2010-04-08||2017-03-15|2008-01-22|2008-01-23|Estimate|2010-04-08|2010-04-30|Estimate||||2017-03-15|2017-04-12|Actual|May 2008||2008-05-31|March 2017|2017-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma|An Exploratory Study of Mometasone Furoate Nasal Spray in Patients With Moderate-severe Persistent Allergic Rhinitis and Intermittent Asthma: Effects on the Quality of Life Evaluated With the Rhinasthma Questionnaire|Completed||Phase 3|51|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:33:19.117192|2018-06-01 02:33:19.117192
NCT00599014|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2013-11-13||2015-10-04|2008-01-22|2008-01-23|Estimate|2013-11-13|2014-01-01|Estimate||||2015-10-04|2015-11-02|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|TACC||Heart Failure Study: The Atlanta Cardiomyopathy Consortium|The Atlanta Cardiomyopathy Consortium|Completed|||335|Actual|Emory University|Long baseline visit with several questionnaires to be completed made more difficult for the patients to be enrolled. Adverse Events data was not collected as part of this observational registry.||||f||||f||||||Samples With DNA|"~     Blood for DNA/RNA/Proteomics analysis and Urine for proteomic analysis~   "|||2018-06-01 02:33:20.446867|2018-06-01 02:33:20.446867
NCT00599001|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2018-02-27|2008-01-22|2008-01-23|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2008||2008-01-31|February 2018|2018-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males|A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Male Volunteers|Completed||Phase 1|26|Actual|Dynavax Technologies Corporation||2|||f||||f||||||||Undecided|No Change to status of this study.|2018-06-01 02:33:20.629947|2018-06-01 02:33:20.629947
NCT00598988|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2009-01-08|2008-01-10|2008-01-23|Estimate|||||||2009-01-08|2009-01-09|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|AIM||Acupuncture for Infectious Mononucleosis Trial|Acupuncture for Infectious Mononucleosis Trial|Completed||Phase 2/Phase 3|36|Anticipated|University of Alberta||2|||f||||t||||||||||2018-06-01 02:33:20.712626|2018-06-01 02:33:20.712626
NCT00598975|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11||2014-08-12|2014-08-12|2008-01-22|2008-01-23|Estimate||||2014-08-12|2014-08-15|Estimate|2014-08-12|2014-08-15|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients|A Multicenter, Open-Label, Phase 2 Study to Determine the Dose, Safety and Efficacy of NKTR 102 (PEG-Irinotecan) in Combination With Cetuximab in Patients With Solid Tumors Refractory to Standard Treatment and to Evaluate the Safety and Efficacy of NKTR 102 or Irinotecan in Combination With Cetuximab in Second Line, Irinotecan and Cetuximab Naïve, Colorectal Cancer Patients With Metastatic or Locally Advanced Disease|Completed||Phase 2|18|Actual|Nektar Therapeutics||1|||f||||f||||||||||2018-06-01 02:33:20.81497|2018-06-01 02:33:20.81497
NCT00598962|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-05-19|2008-01-11|2008-01-23|Estimate|||||||2017-05-19|2017-05-23|Actual|December 1994|Actual|1994-12-31|May 2017|2017-05-31|May 18, 2017|Actual|2017-05-18|November 2006|Actual|2006-11-30||Interventional|||Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease|Open, Noncomparative Trial of Multidrug Regimens Containing Azithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease|Completed||Phase 4|58|Actual|The University of Texas Health Science Center at Tyler||1|||f||||f||||||||No||2018-06-01 02:33:20.889897|2018-06-01 02:33:20.889897
NCT00598949|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2010-12-14|2008-01-11|2008-01-23|Estimate|||||||2010-12-14|2010-12-15|Estimate|January 2003||2003-01-31|December 2010|2010-12-31||||December 2015|Anticipated|2015-12-31||Observational|||Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma|Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma|Unknown status|Recruiting||600|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||Samples With DNA|"~     cell lines are established for future genetic analysis~   "|||2018-06-01 02:33:20.959527|2018-06-01 02:33:20.959527
NCT00598936|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2011-09-01|2008-01-22|2008-01-23|Estimate|||||||2011-09-01|2011-09-05|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients|A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients|Terminated|||21|Actual|University of California, Irvine|||1|Investigator considered the device with no clinical utility.|f||||t||||||||||2018-06-01 02:33:21.802474|2018-06-01 02:33:21.802474
NCT00598923|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-06-26|2008-01-22|2008-01-23|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2004||2004-11-30|June 2017|2017-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|PEPTO||Preventing Epilepsy After Traumatic Brain Injury With Topiramate|Preventing Epilepsy After Traumatic Brain Injury: A Pilot, Single-center Randomized Trial of Topiramate to Prevent Seizures After Moderate to Severe TBI|Terminated||Early Phase 1|6|Actual|University of Pennsylvania||3||End of funding and low enrollment|f||||f||||||||||2018-06-01 02:33:21.92605|2018-06-01 02:33:21.92605
NCT00598910|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2009-03-27|2008-01-11|2008-01-23|Estimate|||||||2009-03-27|2009-03-30|Estimate|August 2007||2007-08-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||Effect of Omacor on Triglycerides in HIV Infected Subjects|A Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Investigate the Effect of Omacor (n-3 PUFA) on Lipid Parameters in HIV Infected Subjects Treated With HAART|Terminated||Phase 4|51|Actual|Solvay Pharmaceuticals||2||The study was discontinued prematurely on December 18 2008 due to slow recruitment|f||||f||||||||||2018-06-01 02:33:22.028568|2018-06-01 02:33:22.028568
NCT00598897|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-05-19|2008-01-11|2008-01-23|Estimate|||||||2017-05-19|2017-05-23|Actual|August 1995|Actual|1995-08-31|May 2017|2017-05-31|May 18, 2017|Actual|2017-05-18|August 7, 2002|Actual|2002-08-07||Interventional|||Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease|Open, Noncomparative Trial of Multidrug Regimens Containing Clarithromycin and Rifabutin Administered Three Times Per Week for the Treatment of M. Avium Complex (MAC) Lung Disease|Completed||Phase 4|89|Actual|The University of Texas Health Science Center at Tyler||1|||f||||f||||||||No|No plan to share.|2018-06-01 02:33:22.110398|2018-06-01 02:33:22.110398
NCT00598884|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2013-06-21|2008-01-11|2008-01-23|Estimate|||||||2013-06-21|2013-06-24|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effectiveness of an Internet-Based Self-Management Program in Treating Prolonged Grief Disorder|Internet-Based Self-Management Intervention for Prolonged Grief|Completed||Phase 1|135|Actual|Boston University||2|||f||||t||||||||||2018-06-01 02:33:22.183195|2018-06-01 02:33:22.183195
NCT00598871|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-02-22||2015-06-10|2008-01-11|2008-01-23|Estimate|2010-03-23|2010-04-13|Estimate||||2015-06-10|2015-07-08|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds|A Randomized, Double-Mask, Placebo-Controlled, Dose Response, Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Diabetic Patients' Corneal Wounds Resulting From Epithelial Debridement During Vitrectomy|Terminated||Phase 2|12|Actual|ReGenTree, LLC||2||slow recruitment|f||||f||||||||||2018-06-01 02:33:22.260852|2018-06-01 02:33:22.260852
NCT00598858|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2016-12-06|2008-01-10|2008-01-23|Estimate|||||||2016-12-06|2016-12-08|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|2007-5904||Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate|Phase II Study to Determine the Effects of Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate in Patients Who Are Scheduled for Radical Prostatectomy With Genomic Correlates of Pathological Response|Withdrawn||Phase 2|0|Actual|University of California, Irvine||1||Halted due to zero accrual and lack of funding|f||||t||||||||||2018-06-01 02:33:22.572879|2018-06-01 02:33:22.572879
NCT00598845|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-12-22|2008-01-22|2008-01-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|April 2001||2001-04-30|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|MoMaTEC||Molecular Markers in Treatment in Endometrial Cancer|Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.|Unknown status|Recruiting||1000|Anticipated|University of Bergen|||1||f||||f||||||Samples With DNA|"~     Tumor specimens from endometrial carcinoma, from curettage and hysterectomy specimens,~     formalin-fixed and paraffin-embedded and fresh frozen, stored at minus 80 °C, corresponding~     blood samples with normal DNA~   "|||2018-06-01 02:33:22.706153|2018-06-01 02:33:22.706153
NCT00598832|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2010-04-16||2011-03-21|2008-01-11|2008-01-23|Estimate|2011-03-21|2011-04-19|Estimate||||2011-03-21|2011-04-19|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%|A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris|Completed||Phase 3|1075|Actual|Galderma||2|||f||||f||||||||||2018-06-01 02:33:22.855542|2018-06-01 02:33:22.855542
NCT00598819|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-01-15||2011-08-15|2008-01-22|2008-01-23|Estimate|2010-06-04|2010-07-07|Estimate||||2011-08-15|2011-08-17|Estimate|October 2007||2007-10-31|August 2011|2011-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Prospective Study of a New Device for Monitoring Cerebral Oxygenation on Healthy Volunteers|A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Healthy Volunteers|Completed||Phase 1|14|Actual|University of California, Irvine|No Adverse Events (AE's) or Serious Adverse Events (SAE's) were reported in this study.|1|||f||||t||||||||||2018-06-01 02:33:23.480997|2018-06-01 02:33:23.480997
NCT00598806|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2017-07-14|2013-12-18|2017-10-10|2008-01-22|2008-01-23|Estimate|2017-07-14|2017-08-15|Actual|2015-05-26|2015-06-19|Estimate|2017-10-10|2017-11-13|Actual|August 2007|Actual|2007-08-31|October 2017|2017-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Safety Population|Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-612)|Completed||Phase 3|812|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 02:33:23.821389|2018-06-01 02:33:23.821389
NCT00598793|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2017-01-06|2008-01-11|2008-01-23|Estimate|||||||2017-01-06|2017-01-09|Estimate|November 2002||2002-11-30|January 2017|2017-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|INITIATE||Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy|Biphasic Insulin Aspart 70/30 + Metformin Compared to Insulin Glargine + Metformin in Type 2 Diabetes Failing OAD Therapy|Completed||Phase 3|242|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:33:25.114003|2018-06-01 02:33:25.114003
NCT00598780|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|||2012-05-25|2008-01-22|2008-01-23|Estimate|||||||2012-05-25|2012-05-28|Estimate|September 2007||2007-09-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study|Long-term Evaluation of Safety and Treatment Satisfaction With Levocetirizine in Routine Clinical Practice in the Czech and Slovak Republics - Non-interventional Study|Completed|||7870|Actual|UCB Pharma|||1||f||||f||||||||||2018-06-01 02:33:25.256951|2018-06-01 02:33:25.256951
NCT00598767|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-01-10|2008-01-21|2008-01-22|Estimate|||||||2017-01-10|2017-01-12|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Three Dimensional Imaging and Wireless Technologies to Enhance Medical Care in Space|Multimodality 3D Imaging and Wireless Technologies To Enhance Medical Care in Space|Terminated|||3|Actual|The Cleveland Clinic||||funding issues|f||||f||||||||No||2018-06-01 02:33:25.370325|2018-06-01 02:33:25.370325
NCT00598754|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-01-10|2008-01-21|2008-01-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2001||2001-06-30|January 2008|2008-01-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Diagnostic Three Dimensional Echocardiography Study Protocol|Diagnostic Two and Three Dimensional Echocardiography Study Protocol|Withdrawn|||0|Actual|The Cleveland Clinic||||Funding issues|f||||f||||||||No||2018-06-01 02:33:25.442604|2018-06-01 02:33:25.442604
NCT00598741|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2014-04-09|2008-01-21|2008-01-22|Estimate|||||||2014-04-09|2014-04-10|Estimate|July 2004||2004-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors|Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors|Completed||N/A|61|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:33:25.519113|2018-06-01 02:33:25.519113
NCT00598728|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2016-04-26|2008-01-21|2008-01-22|Estimate|||||||2016-04-26|2016-04-27|Estimate|May 2005||2005-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Quality of Life Among Survivors of Hodgkin Lymphoma|A Global Assessment of Medical Morbidities and Quality of Life Among Survivors of Hodgkin Lymphoma|Completed|||255|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:33:25.603675|2018-06-01 02:33:25.603675
NCT00598715|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2010-12-16|2008-01-21|2008-01-22|Estimate|||||||2010-12-16|2010-12-17|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|DESIRE-2||Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents|Randomized Trial of Paclitaxel- vs Sirolimus-eluting Stents for Treatment of Coronary Restenosis in Sirolimus-eluting Stents|Completed||Phase 4|450|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:33:25.691993|2018-06-01 02:33:25.691993
NCT00598702|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2009-09-25|2009-04-03|2017-04-04|2008-01-16|2008-01-22|Estimate|2010-12-09|2011-01-06|Estimate|2010-12-09|2011-01-06|Estimate|2017-04-04|2017-05-10|Actual|January 2008||2008-01-31|April 2017|2017-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients|A Phase III Multi-Center, Open-Label, Prospective, Repeated Dose, Multi-Day Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients.|Completed||Phase 3|100|Actual|Mallinckrodt|The original protocol required 50 subjects that completed 5 days of treatment. With protocol amendment 2, the criteria for enrollment/completion was reduced to 1 day of treatment. Subjects were required to have a minimum of 3 IV APAP doses per day.|1|||f||||f||||||||||2018-06-01 02:33:25.856475|2018-06-01 02:33:25.856475
NCT00598689|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2015-01-27||2016-02-10|2008-01-21|2008-01-22|Estimate|2016-02-10|2016-03-07|Estimate||||2016-02-10|2016-03-07|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Consented subjects with a best corrected visual acuity of 20/40 or better in each eye.|GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients|Efficacy, Tolerability and Comfort of GenTeal and GenTeal Gel, (0.3% Hypromellose) in the Pre- and Post- Operative Treatment of Patients Undergoing LASIK Surgery|Completed||Phase 4|80|Actual|Augusta University||2|||f||||t||||||||||2018-06-01 02:33:26.943402|2018-06-01 02:33:26.943402
NCT00598676|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2010-03-12|2008-01-21|2008-01-22|Estimate|||||||2010-03-12|2010-03-15|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|ISAR-TEST-4||3 Limus Agent Eluting Stents With Different Polymer Coating|Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting STents (ISAR-TEST 4): Prospective, Randomized Trial of 3-limus Agent-eluting Stents With Different Polymer Coatings|Completed||Phase 4|2600|Actual|Deutsches Herzzentrum Muenchen||3|||f||||t||||||||||2018-06-01 02:33:27.202967|2018-06-01 02:33:27.202967
NCT00598663|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2010-09-17|2008-01-21|2008-01-22|Estimate|||||||2010-09-17|2010-09-20|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SWITCH||SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c|Randomized, Cross Over, Controlled, Multi-centric Study to Assess Whether Type 1 Diabetic Patients in Sub-optimal Glycemic Control Can Improve Using the Continuous Glucose Values of the MiniMed Paradigm REAL-Time Insulin Pump System Versus the MiniMed Paradigm Insulin Pump|Completed||Phase 4|154|Actual|Medtronic||2|||f||||f||||||||||2018-06-01 02:33:27.274393|2018-06-01 02:33:27.274393
NCT00598650|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2014-08-08||2014-08-29|2008-01-10|2008-01-22|Estimate|2014-08-29|2014-09-03|Estimate||||2014-08-29|2014-09-03|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies|A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies|Completed||Phase 2|160|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 02:33:27.353728|2018-06-01 02:33:27.353728
NCT00598637|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2013-07-01|2008-01-21|2008-01-22|Estimate|||||||2013-07-01|2013-07-02|Estimate|December 2007||2007-12-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|LEFT-MAIN-2||Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease|Prospective Randomized Trial of Everolimus- and Zotarolimus-eluting Stents for Treatment of Unprotected Left Main Coronary Artery Disease: ISAR-LEFT-MAIN-2|Completed||Phase 4|650|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:33:27.651638|2018-06-01 02:33:27.651638
NCT00598624|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2009-08-10|2008-01-21|2008-01-22|Estimate|||||||2009-08-10|2009-08-11|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|AlloTreo||Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)|Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies|Unknown status|Recruiting|Phase 2|175|Anticipated|IRCCS San Raffaele||1|||f||||f||||||||||2018-06-01 02:33:27.761982|2018-06-01 02:33:27.761982
NCT00598611|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2012-05-30|2008-01-10|2008-01-22|Estimate|||||||2012-05-30|2012-05-31|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|AUD2OCU||Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)|An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)|Completed||Phase 3|29|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:33:27.89599|2018-06-01 02:33:27.89599
NCT00598598|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-01-10|2008-01-21|2008-01-22|Estimate|||||||2017-01-10|2017-01-12|Estimate|October 2003||2003-10-31|January 2008|2008-01-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Echocardiographic Assessment of Cardiovascular Changes in Long Term Space Flight|Echocardiographic Assessment of Cardiovascular Adaptation and Counter Measures n Microgravity|Terminated|||1|Actual|The Cleveland Clinic||||funding issues|f||||f||||||||No||2018-06-01 02:33:27.972957|2018-06-01 02:33:27.972957
NCT00598585|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2017-04-14||2017-05-25|2008-01-21|2008-01-22|Estimate|2017-05-25|2017-06-27|Actual||||2017-05-25|2017-06-27|Actual|July 2002||2002-07-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS|Phase 4 Study of the Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic Fatigue Syndrome.|Completed||Phase 4|12|Actual|Charles Drew University of Medicine and Science|small number of subjects enrolled in trial|2|||f||||t||||||||No||2018-06-01 02:33:28.082109|2018-06-01 02:33:28.082109
NCT00598572|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2018-01-11|2008-01-21|2008-01-22|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2008||2008-07-31|January 2018|2018-01-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|DFO In ICH||Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage|Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage|Completed||Phase 1|20|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||No||2018-06-01 02:33:28.398108|2018-06-01 02:33:28.398108
NCT00598559|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2009-09-25|2009-04-03|2016-09-08|2008-01-21|2008-01-22|Estimate|2010-11-11|2010-12-10|Estimate|2010-11-11|2010-12-10|Estimate|2016-09-08|2016-10-21|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients|A Phase III, Multi-Center, Open-Label, Prospective, Repeated Dose, Randomized, Controlled, Multi-Day Study of the Safety and Efficacy of Intravenous Acetaminophen in Adult Inpatients|Completed||Phase 3|213|Actual|Mallinckrodt|No separate efficacy analyses were performed for the fever because only 1 subject in each active group had fever as an indication, and no subject had both pain and fever as indications for treatment with IV acetaminophen.|3|||f||||f||||||||||2018-06-01 02:33:28.496638|2018-06-01 02:33:28.496638
NCT00598546|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2009-07-09|2008-01-21|2008-01-22|Estimate|||||||2009-07-09|2009-07-10|Estimate|September 2004||2004-09-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Quality of Life Among Long-Term Survivors of Resected Gastric Cancer|Quality of Life Among Long-Term Survivors of Resected Gastric Cancer|Completed|||212|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||t||||||||||2018-06-01 02:33:28.990136|2018-06-01 02:33:28.990136
NCT00598533|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2012-01-03|2008-01-21|2008-01-22|Estimate|||||||2012-01-03|2012-01-05|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|ISAR-TEST-5||Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis|Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis|Completed||Phase 4|3002|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 02:33:29.119663|2018-06-01 02:33:29.119663
NCT00598507|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2013-09-12||2013-11-15|2008-01-21|2008-01-22|Estimate|2013-09-12|2013-11-15|Estimate||||2013-11-15|2013-12-11|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Participants treated with at least one dose of sagopilone.|Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma|Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma|Completed||Phase 2|35|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 02:33:29.231393|2018-06-01 02:33:29.231393
NCT00598494|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-01-26|2008-01-21|2008-01-22|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2007||2007-02-28|January 2017|2017-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Effect of Bedrest With and Without Exercise on the Heart|Effect of Bedrest With and Without Exercise on Cardiac Atrophy: Synergistic Supplemental Testing With the Cleveland Clinic Bedrest Study|Terminated|||6|Actual|The Cleveland Clinic||||Main bedrest study moved to Texas. No enrollment at Cleveland Clinic.|f||||f|f|f||||||No||2018-06-01 02:33:29.593232|2018-06-01 02:33:29.593232
NCT00598481|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2017-05-31|2008-01-21|2008-01-22|Estimate|||||||2017-05-31|2017-06-02|Actual|October 2, 2002|Actual|2002-10-02|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|July 10, 2011|Actual|2011-07-10||Interventional|Gene-ADA||ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID|ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID|Active, not recruiting||Phase 2|18|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:33:29.721107|2018-06-01 02:33:29.721107
NCT00598455|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-05-02|2008-01-21|2008-01-22|Estimate|||||||2017-05-02|2017-05-04|Actual|February 2008||2008-02-29|May 2017|2017-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Tuberous Sclerosis Complex Natural History Study: Renal Manifestations|Tuberous Sclerosis Complex Natural History Study: Renal Manifestations|Completed|||450|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 02:33:29.809236|2018-06-01 02:33:29.809236
NCT00598442|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2012-04-26|2010-09-27|2013-02-06|2008-01-18|2008-01-21|Estimate|2012-06-22|2012-07-30|Estimate|2010-09-27|2010-09-29|Estimate|2013-02-06|2013-02-12|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|PEARL 2||Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis|AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment|Completed||Phase 3|493|Actual|Affymax||3|||f||||t||||||||||2018-06-01 02:33:29.935746|2018-06-01 02:33:29.935746
NCT00598429|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2016-12-08|2008-01-10|2008-01-21|Estimate|||||||2016-12-08|2016-12-09|Estimate|May 2008||2008-05-31|July 2015|2015-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|IPGE1||Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure|Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network|Withdrawn||Phase 2|0|Actual|NICHD Neonatal Research Network||3||Withdrawn due to lack of recruitment|f||||t||||||||||2018-06-01 02:33:32.011253|2018-06-01 02:33:32.011253
NCT00598416|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2014-11-03|2008-01-18|2008-01-21|Estimate|||||||2014-11-03|2014-11-04|Estimate|September 2006||2006-09-30|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Psychoeducation for Hepatitis and Alcohol Behaviors|Psychoeducation for HCV and Alcohol Behaviors|Completed||N/A|556|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||1|||f||||t||||||||||2018-06-01 02:33:32.247756|2018-06-01 02:33:32.247756
NCT00595543|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2009-03-17|2008-01-15|2008-01-16|Estimate|||||||2009-03-17|2009-03-19|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%||Completed||Phase 4|166|Anticipated|Bp Consulting, Inc||3|||f||||||||||||||2018-06-01 02:34:16.663146|2018-06-01 02:34:16.663146
NCT00598403|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2010-06-28|2008-01-09|2008-01-21|Estimate|||||||2010-06-28|2010-06-29|Estimate|November 2007||2007-11-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis|Multicentre, Prospective, Comparative, Randomized, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of Cefditoren Pivoxil vs. Ciprofloxacin in Uncomplicated Acute Cystitis|Completed||Phase 3|611|Actual|Tedec-Meiji Farma, S.A.||2|||f||||f||||||||||2018-06-01 02:33:32.390577|2018-06-01 02:33:32.390577
NCT00598390|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2018-05-12|2008-01-10|2008-01-21|Estimate|||||||2018-05-12|2018-05-15|Actual|January 8, 2008||2008-01-08|January 22, 2013|2013-01-22|January 22, 2013|Actual|2013-01-22|January 22, 2013|Actual|2013-01-22||Interventional|||PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP|PET Test/Retest Brain Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP|Completed||Phase 1/Phase 2|19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:33:32.542919|2018-06-01 02:33:32.542919
NCT00598377|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2009-02-17|2008-01-18|2008-01-21|Estimate|||||||2009-02-17|2009-02-19|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease|Assessment of Adrenal Functions in Patients With Autosomal Dominant Polycystic Kidney Disease|Completed||N/A|49|Actual|Istanbul University||2|||f||||f||||||||||2018-06-01 02:33:32.636084|2018-06-01 02:33:32.636084
NCT00598364|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2014-12-05|2008-01-10|2008-01-21|Estimate|||||||2014-12-05|2014-12-08|Estimate|February 2007||2007-02-28|December 2014|2014-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31|13 Years|Observational [Patient Registry]|||Molecular Markers in Thyroid Cancer|Molecular Markers in the Diagnostic and Prognostic Evaluation of Thyroid Cancer|Completed|||847|Actual|OHSU Knight Cancer Institute|||1||f||||f||||||||||2018-06-01 02:33:32.713516|2018-06-01 02:33:32.713516
NCT00598351|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2018-04-03|2008-01-10|2008-01-21|Estimate|||||||2018-04-03|2018-04-04|Actual|January 9, 2008||2008-01-09|March 23, 2018|2018-03-23||||||||Observational|||Natural History Study of Patients With Neurofibromatosis Type 2|A Prospective Natural History Study of Patients With Neurofibromatosis Type 2 (NF2)|Active, not recruiting|||169|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:33:32.823803|2018-06-01 02:33:32.823803
NCT00598338|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2008-05-28|2008-01-18|2008-01-21|Estimate|||||||2008-05-28|2008-05-29|Estimate|April 1999||1999-04-30|January 2008|2008-01-31|February 2000|Actual|2000-02-29|February 2000|Actual|2000-02-29||Interventional|||Efficacy and Safety Study of Prucalopride for the Re-Treatment of Chronic Constipation|A Two-Period, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of re-Treatment of Prucalopride on Efficacy and Safety in Subjects With Chronic Constipation.|Completed||Phase 3|516|Actual|Movetis||2|||f||||f||||||||||2018-06-01 02:33:32.955614|2018-06-01 02:33:32.955614
NCT00598325|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-05-08|2008-01-18|2008-01-21|Estimate|||||||2012-05-08|2012-05-09|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Antibody and Safety Study of 6 Doses of NicVAX in Smokers|Phase 2 Single Center, Open-label Study to Assess Immunogenicity and Safety of 6 Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®)in Smokers|Completed||Phase 1/Phase 2|74|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-06-01 02:33:33.063519|2018-06-01 02:33:33.063519
NCT00598312|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10||2009-07-10|2010-09-02|2008-01-10|2008-01-21|Estimate||||2010-02-09|2010-03-04|Estimate|2010-09-02|2010-09-08|Estimate|April 2007||2007-04-30|September 2010|2010-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer|A Phase 3, Open-Label, Multi-Center, Safety And Efficacy Study of Oakwood Laboratories' Leuprolide Acetate For Injectable Suspension 22.5 mg In Patients With Prostate Cancer|Completed||Phase 3|201|Actual|Oakwood Laboratories, LLC|||||f||||f||||||||||2018-06-01 02:33:33.219027|2018-06-01 02:33:33.219027
NCT00598299|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2008-11-02|2008-01-18|2008-01-21|Estimate|||||||2008-11-02|2008-11-04|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|April 2008|Actual|2008-04-30|||||Observational|||Comparison of the Effects on Promoting Corneal Epithelial Wound Healing Between Human Auto-Serum and Cord Blood Serum|Department of Ophthalmology, National Taiwan University Hospital|Completed|||100|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-06-01 02:33:33.474379|2018-06-01 02:33:33.474379
NCT00598286|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2017-10-26|2008-01-10|2008-01-21|Estimate|||||||2017-10-26|2017-10-27|Actual|January 2008||2008-01-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2|Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2|Completed||Phase 1|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:33:33.55081|2018-06-01 02:33:33.55081
NCT00598273|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2012-04-26|2010-09-27|2013-02-06|2008-01-18|2008-01-21|Estimate|2012-06-22|2012-07-30|Estimate|2010-09-27|2010-09-29|Estimate|2013-02-06|2013-02-12|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|February 2010|Actual|2010-02-28|March 2009|Actual|2009-03-31||Interventional|PEARL 1||Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis|AFX01-11: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment|Completed||Phase 3|490|Actual|Affymax||3|||f||||t||||||||||2018-06-01 02:33:33.697846|2018-06-01 02:33:33.697846
NCT00598260|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2011-05-09|2008-01-18|2008-01-21|Estimate|||||||2011-05-09|2011-05-10|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Active Management Of Risk In Pregnancy At Term to Reduce Rate of Cesarean Deliveries|Active Management Of Risk In Pregnancy At Term - a Prospective Study|Terminated||N/A|222|Actual|Albert Einstein Healthcare Network||2|||f||||t||||||||||2018-06-01 02:33:36.327758|2018-06-01 02:33:36.327758
NCT00598247|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2014-02-05|2008-01-10|2008-01-21|Estimate|||||||2014-02-05|2014-02-06|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|July 2011|Actual|2011-07-31|September 2008|Actual|2008-09-30||Interventional|||A Pilot Study of PPX in Women With Metastatic Colorectal Cancer|A Pilot Study of PPX (Paclitaxel Poliglumex, CT-2103) in Women With Metastatic Colorectal Cancer|Completed||Phase 1|15|Actual|University of Southern California||1|||f||||f||||||||||2018-06-01 02:33:36.411221|2018-06-01 02:33:36.411221
NCT00598234|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2010-06-20|2008-01-10|2008-01-21|Estimate|||||||2010-06-20|2010-06-22|Estimate|September 2006||2006-09-30|June 2010|2010-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty|Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty|Completed||Phase 4|120|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 02:33:36.510349|2018-06-01 02:33:36.510349
NCT00598026|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-02-23|2008-01-17|2008-01-18|Estimate|||||||2012-02-23|2012-02-24|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|EVATEL||"Evaluation of the  Tele-follow-up  for the Follow-up of Implantable Defibrillators"|"Evaluation of the  Tele-follow-up  for the Follow-up of Implantable Defibrillators"|Completed||N/A|1501|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 02:33:38.691617|2018-06-01 02:33:38.691617
NCT00598208|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2017-06-02|2008-01-10|2008-01-21|Estimate|||||||2017-06-02|2017-06-05|Actual|May 19, 2003|Actual|2003-05-19|June 2017|2017-06-30|March 15, 2004|Actual|2004-03-15|March 15, 2004|Actual|2004-03-15||Interventional|||A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)|A Phase 2, Open Label, Randomized Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or ICSI.|Completed||Phase 2|325|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:33:36.625435|2018-06-01 02:33:36.625435
NCT00598195|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-02-26|2008-01-18|2008-01-21|Estimate|||||||2013-02-26|2013-02-27|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|||Ketamine Pharmacokinetics in Children Having Heart Surgery|Ketamine Pharmacokinetics in Children Undergoing Cardiac Surgery|Completed||N/A|18|Actual|Arkansas Children's Hospital Research Institute||1|||f||||f||||||||||2018-06-01 02:33:36.712376|2018-06-01 02:33:36.712376
NCT00598182|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-05-16|2008-01-17|2008-01-18|Estimate|||||||2012-05-16|2012-05-17|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|September 2009|Actual|2009-09-30|||||Observational|||Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study|From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD|Completed|||64|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 02:33:36.814934|2018-06-01 02:33:36.814934
NCT00598169|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2018-02-23|2008-01-09|2008-01-18|Estimate|||||||2018-02-23|2018-02-27|Actual|November 2007||2007-11-30|February 2018|2018-02-28|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma|Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma|Completed||Phase 1|23|Actual|AIDS Malignancy Consortium||2|||f||||f||||||||||2018-06-01 02:33:36.879167|2018-06-01 02:33:36.879167
NCT00598156|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2013-04-19|2008-01-17|2008-01-18|Estimate|||||||2013-04-19|2013-04-22|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|October 2009|Actual|2009-10-31||Interventional|ACT||Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva|Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.|Completed||Phase 3|249|Actual|Lund University Hospital||2|||f||||t||||||||||2018-06-01 02:33:37.119584|2018-06-01 02:33:37.119584
NCT00598143|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2015-05-27|2008-01-09|2008-01-18|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2005||2005-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Biomarkers of Molecular Risk in Smokers|Biomarkers of Molecular Risk in Smokers|Completed|||45|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Saliva Samples~   "|||2018-06-01 02:33:37.237201|2018-06-01 02:33:37.237201
NCT00598130|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-23|||2009-11-05|2008-01-17|2008-01-18|Estimate|||||||2009-11-05|2009-11-06|Estimate|February 2008||2008-02-29|November 2009|2009-11-30|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|Fleece||Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy|A Prospective, Randomized, Single-Blind, Standard Care Controlled, Multi-Center, Phase II Study Evaluating the Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy|Completed||Phase 2|30|Anticipated|OMRIX Biopharmaceuticals||2|||f||||t||||||||||2018-06-01 02:33:37.384194|2018-06-01 02:33:37.384194
NCT00598117|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2013-06-26|2008-01-09|2008-01-18|Estimate|||||||2013-06-26|2013-06-27|Estimate|August 2003||2003-08-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Quality Of Life Outcomes Following Treatment for Esophageal Cancer|Quality Of Life Outcomes Following Treatment for Esophageal Cancer|Completed|||409|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||||||2018-06-01 02:33:37.511689|2018-06-01 02:33:37.511689
NCT00598104|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2016-03-02|2008-01-09|2008-01-18|Estimate|||||||2016-03-02|2016-03-04|Estimate|January 2008||2008-01-31|March 2016|2016-03-31||||December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma|A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal|Withdrawn||Phase 1/Phase 2|0|Actual|Novartis||2||"Due to the lack of enrolment and complexity of design, this study in asthma was terminated. No~   subjects have been dosed for this study."|||||f||||||||||2018-06-01 02:33:37.625556|2018-06-01 02:33:37.625556
NCT00598091|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-09-04|2008-01-10|2008-01-18|Estimate|||||||2015-09-04|2015-09-07|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|May 2012|Actual|2012-05-31|June 2010|Actual|2010-06-30||Interventional|Gem/Dsat||A Phase I/Expansion Study of Dasatinib|A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer|Terminated||Phase 1|30|Actual|Duke University||2||Low accrual, unable to meet endpoint in timely manner|f||||t||||||||||2018-06-01 02:33:37.73987|2018-06-01 02:33:37.73987
NCT00598078|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2011-09-13||2011-12-15|2008-01-09|2008-01-18|Estimate|2011-12-15|2012-01-23|Estimate||||2011-12-15|2012-01-23|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor|Multiple-dose, Double-blind, Placebo-controlled, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Sodium Oxybate (Xyrem) in Subjects With Moderate to Severe Essential Tremor|Completed||Phase 2|19|Actual|Jazz Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:33:37.883089|2018-06-01 02:33:37.883089
NCT00598065|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2009-12-02|2008-01-09|2008-01-18|Estimate|||||||2009-12-02|2009-12-03|Estimate|March 2004||2004-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules|The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules|Completed||N/A|26|Actual|Memorial Sloan Kettering Cancer Center|||||f||||t||||||||||2018-06-01 02:33:38.268903|2018-06-01 02:33:38.268903
NCT00598052|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-03-30|2008-01-17|2008-01-18|Estimate|||||||2008-03-30|2008-04-01|Estimate|December 2007||2007-12-31|January 2008|2008-01-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy|Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy- a Double-Blind Placebo-Controlled Study|Unknown status|Recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-06-01 02:33:38.372534|2018-06-01 02:33:38.372534
NCT00598013|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-01-17|2008-01-17|2008-01-18|Estimate|||||||2008-01-17|2008-01-18|Estimate|November 2004||2004-11-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes|A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes|Completed||N/A|83|Actual|Yonsei University||2|||f||||t||||||||||2018-06-01 02:33:38.822163|2018-06-01 02:33:38.822163
NCT00598000|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2015-04-22|2008-01-09|2008-01-18|Estimate|||||||2015-04-22|2015-04-23|Estimate|February 2005||2005-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Quality of Life and Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) Anatomic Lung Resection Versus Thoracotomy and Anatomic Lung Resection|Quality of Life and Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) Anatomic Lung Resection Versus Thoracotomy and Anatomic Lung Resection|Completed|||216|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:33:38.965032|2018-06-01 02:33:38.965032
NCT00597987|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-09-12|2008-01-17|2008-01-18|Estimate|||||||2012-09-12|2012-09-13|Estimate|September 2004||2004-09-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||BRCA1 Haploinsufficiency and Gene Expression|BRCA1 Haploinsufficiency and Gene Expression|Completed|||120|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Blood samples from cases will be collected from patients who have previously undergone~     genetic counseling through the Clinical Genetics Service at MSKCC and tested positive for a~     germline mutation in BRCA1. Blood samples from controls will be obtained from two sources.~      First from specimens already collected under IRB Protocol #99-030, entitled Collection of~     Tissue, Blood, and Cells to be Used for Studying the Causes, Prevention, Diagnosis, and~     Treatment of Breast Cancer (T. King, PI). Controls will also be collected from patients who~     have previously undergone genetic counseling through the Clinical Genetics Service at MSKCC~     and tested negative for germline mutations in BRCA1. Isolation of total RNA from blood will~     be performed using the PAXgene™ Blood RNA System. This study will use lymphocyte RNA samples~     from 50 individuals with BRCA1 mutations and 50 age-matched controls. Gene expression~     profiling will be performed in the Genomics Core Laboratory of MSKCC.~   "|||2018-06-01 02:33:39.05869|2018-06-01 02:33:39.05869
NCT00597974|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2015-06-02|2008-01-09|2008-01-18|Estimate|||||||2015-06-02|2015-06-04|Estimate|September 2003||2003-09-30|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|CAS||Neurological Outcome With Carotid Artery Stenting|Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty|Completed|||108|Actual|Columbia University|||2||f||||f||||||Samples With DNA|"~     plasma serum DNA (obtained via buccal samples using a buccal cell collection swab)~   "|||2018-06-01 02:33:39.165691|2018-06-01 02:33:39.165691
NCT00597961|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2017-09-05|2008-01-17|2008-01-18|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2003||2003-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Health Communication in Families|Health Communication in Families|Active, not recruiting|||42|Actual|Memorial Sloan Kettering Cancer Center|||||f||||t||||||||||2018-06-01 02:33:39.353642|2018-06-01 02:33:39.353642
NCT00597948|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-02-23|2008-01-09|2008-01-18|Estimate|||||||2012-02-23|2012-02-27|Estimate|April 2007||2007-04-30|February 2012|2012-02-29|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|HLID||Healthy Lifestyles for People With Intellectual Disabilities|Efficacy of a Health Intervention for People With Intellectual Disabilities|Completed||N/A|131|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-06-01 02:33:39.496612|2018-06-01 02:33:39.496612
NCT00597935|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2018-04-30|2008-01-09|2008-01-18|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2008||2008-02-29|April 2018|2018-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|OPTIMAL||Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial|Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial: A Randomized Trial of Sacrospinous Ligament Fixation (SSLF) Versus Uterosacral Ligament Suspension (ULS) With and Without Perioperative Behavioral Therapy/Pelvic Muscle Training|Completed||Phase 3|439|Actual|NICHD Pelvic Floor Disorders Network||4|||f||||t||||||||||2018-06-01 02:33:39.665308|2018-06-01 02:33:39.665308
NCT00597922|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2014-06-26|2008-01-09|2008-01-18|Estimate|||||||2014-06-26|2014-06-30|Estimate|September 2007||2007-09-30|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|VIRGO||Examining Heart Attacks in Young Women|Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction (AMI) Patients (VIRGO)|Completed|||2985|Actual|Yale University|||2||f||||f||||||Samples With DNA|"~     Blood specimens for biomarker analysis and storage for future genetic studies~   "|||2018-06-01 02:33:39.894547|2018-06-01 02:33:39.894547
NCT00597909|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2016-02-03||2016-03-01|2008-01-17|2008-01-18|Estimate|2016-03-01|2016-03-31|Estimate||||2016-03-01|2016-03-31|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy|Terminated||Phase 2|1|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|One participant was enrolled but did not receive drug or was randomized.|3||Study was terminated due to lack of enrollment and business decisions.|f||||t||||||||||2018-06-01 02:33:40.203128|2018-06-01 02:33:40.203128
NCT00597896|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2013-01-04||2015-06-10|2008-01-17|2008-01-18|Estimate|2015-06-10|2015-06-12|Estimate||||2015-06-10|2015-06-12|Estimate|October 2005||2005-10-31|June 2015|2015-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Cognitive Enhancement in Bipolar Disorder|Cognitive Enhancement in Bipolar Disorder|Completed||Phase 4|50|Actual|Northwell Health||2|||f||||f||||||||||2018-06-01 02:33:40.574933|2018-06-01 02:33:40.574933
NCT00597883|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2015-02-04|2008-01-09|2008-01-18|Estimate|||||||2015-02-04|2015-02-05|Estimate|March 2003||2003-03-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|CEA||Neuropsychometric Outcome After Carotid Endarterectomy|Neurologic and Neuropsychometric Outcome in Patients Undergoing Carotid Endarterectomy|Completed|||585|Actual|Columbia University|||||f||||f||||||Samples With DNA|"~     serum plasma DNA (via buccal samples will be obtained using a buccal cell collection swab)~   "|||2018-06-01 02:33:41.155144|2018-06-01 02:33:41.155144
NCT00597870|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-10-11|2008-01-17|2008-01-18|Estimate|||||||2017-10-11|2017-10-12|Actual|May 2002||2002-05-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions|Physician-Sponsored IDE for the Talent Endoluminal Stent Graft System for the Treatment of Thoracic Lesions|Active, not recruiting||N/A|304|Actual|Los Angeles Biomedical Research Institute||1|||f||||t||||||||||2018-06-01 02:33:41.254089|2018-06-01 02:33:41.254089
NCT00597857|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2009-01-27|2008-01-10|2008-01-18|Estimate|||||||2009-01-27|2009-01-28|Estimate|June 2005||2005-06-30|January 2009|2009-01-31|November 2009|Anticipated|2009-11-30|August 2009|Anticipated|2009-08-31||Interventional|||Prevention of Posttraumatic Stress Disorder (PTSD) With Early Hydrocortisone Treatment: Pilot|Prevention of PTSD With Early Hydrocortisone Treatment: Pilot|Unknown status|Recruiting|N/A|65|Anticipated|Kent State University||2|||f||||t||||||||||2018-06-01 02:33:41.345294|2018-06-01 02:33:41.345294
NCT00597844|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2013-09-04|2008-01-17|2008-01-18|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2005||2005-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Improving Functional Outcomes in Patients With Unilateral Vocal Cord Paralysis: Assessment of Adaptation Using Functional Magnetic Resonance Imaging|Improving Functional Outcomes in Patients With Unilateral Vocal Cord Paralysis: Assessment of Adaptation Using Functional Magnetic Resonance Imaging|Completed||N/A|20|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:33:41.499412|2018-06-01 02:33:41.499412
NCT00597831|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2010-10-25|2008-01-09|2008-01-18|Estimate|||||||2010-10-25|2010-10-26|Estimate|January 2008||2008-01-31|October 2010|2010-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Regulation of Intracerebral Pressure During Electroconvulsive Therapy|Regulation of Intracerebral Pressure During Electroconvulsive Therapy. Does Systemic Bloodpressure Reflect the Intracranial Pressure?|Completed|||16|Anticipated|Rijnstate Hospital|||1||f||||f||||||||||2018-06-01 02:33:41.624749|2018-06-01 02:33:41.624749
NCT00597818|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2010-06-02|2008-01-17|2008-01-18|Estimate|||||||2010-06-02|2010-06-03|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury|A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone for the Prevention of NSAID-induced Gastroduodenal Injury in Patients With Osteoarthritis and/or Rheumatoid Arthritis Patients|Completed||Phase 2|120|Anticipated|Sucampo Pharma Americas, LLC||4|||f||||f||||||||||2018-06-01 02:33:41.917679|2018-06-01 02:33:41.917679
NCT00597805|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2018-02-12|2008-01-09|2008-01-18|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2005|Actual|2005-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Quality of Life in Patients Undergoing Total Pelvic Exenteration|A Prospective Study of Quality of Life in Patients Undergoing Pelvic Exenteration|Recruiting|||136|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:33:42.032656|2018-06-01 02:33:42.032656
NCT00597792|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-05-29|2008-01-09|2008-01-18|Estimate|||||||2008-05-29|2008-05-30|Estimate|August 2004||2004-08-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Registry Study of the NDO Surgical Plicator for the Treatment of GERD|Registry Study of the NDO Surgical Plicator for the Treatment of GERD|Terminated||N/A|131|Actual|NDO Surgical, Inc.||1||Sponsoring company ceased business operations|f||||f||||||||||2018-06-01 02:33:42.150096|2018-06-01 02:33:42.150096
NCT00597779|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2014-08-14|2008-01-17|2008-01-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|February 2007||2007-02-28|August 2014|2014-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|EMvsIM||Randomized Comparison of 2 Fixation Techniques for Unstable Intertrochanteric Hip Fractures|Extramedullary vs. Intramedullary Devices in the Treatment of Unstable Intertrochanteric Hip Fractures|Completed||Phase 3|200|Actual|McGill University Health Center||2|||f||||f||||||||||2018-06-01 02:33:42.251719|2018-06-01 02:33:42.251719
NCT00597766|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2017-09-15||2017-11-11|2008-01-17|2008-01-18|Estimate|2017-11-11|2017-12-13|Actual||||2017-11-11|2017-12-13|Actual|December 2007||2007-12-31|November 2017|2017-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||The number of participants was determined on a power analysis. The goal was 31 subjects per group.|Subacromial Corticosteroid Injection for Hemiplegic Shoulder Pain|Clinical Trials in Stroke Rehabilitation|Completed||Phase 2|28|Actual|MetroHealth Medical Center|The study was powered to detect differnces between high-dose and placebo, and standard-dose and placebo. The trial was altered due to ethical concerns for placebo injection due to apparent effectiveness in the literature. Low dose was substituted.|3|||f||||f||f||||||No||2018-06-01 02:33:42.468022|2018-06-01 02:33:42.468022
NCT00597753|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2012-04-26|2010-08-16|2013-02-06|2008-01-17|2008-01-18|Estimate|2012-06-22|2012-07-30|Estimate|2010-08-16|2010-08-19|Estimate|2013-02-06|2013-02-12|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|EMERALD 1||Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis|AFX01-12: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin Alfa|Completed||Phase 3|803|Actual|Affymax||2|||f||||t||||||||||2018-06-01 02:33:43.355453|2018-06-01 02:33:43.355453
NCT00597740|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2013-12-02|2008-01-17|2008-01-18|Estimate|||||||2013-12-02|2013-12-03|Estimate|December 2007||2007-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|September 2010|Actual|2010-09-30||Observational|SPIN||Propofol Sedation Study|"Clinical Utility of Propofol Sedations Without and With a Formal ICU Sedation Protocol in Intubated Neurotrauma Patients"|Completed|||57|Actual|Scottsdale Healthcare|||||f||||f||||||||||2018-06-01 02:33:44.824007|2018-06-01 02:33:44.824007
NCT00597727|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2017-02-07||2018-02-27|2008-01-15|2008-01-18|Estimate|2017-04-07|2017-05-18|Actual||||2018-02-27|2018-03-27|Actual|January 2008||2008-01-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SLB||A Study of Sublingual Immunotherapy in Peanut-allergic Children|A Double-blinded, Placebo-controlled Study of Peanut Sublingual Immunotherapy in Children - DBPC Peanut SLIT|Completed||Phase 2|60|Actual|University of North Carolina, Chapel Hill|The initial 27 subjects in the study were unblinded in 12/2009 due to concerns for study drug integrity. These subjects were offered reentry into the study on open label drug. 18 accepted and are presented as the Early Unblinded Peanut SLIT cohort.|5|||f||||t||||||||No||2018-06-01 02:33:44.999704|2018-06-01 02:33:44.999704
NCT00597714|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|2014-02-05||2014-05-02|2008-01-14|2008-01-18|Estimate|2014-05-02|2014-06-02|Estimate||||2014-05-02|2014-06-02|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional||Participants who proceeded to therapy and transplant.|Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant|Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplantation|Completed||Phase 2|264|Actual|Duke University||3|||f||||t||||||||||2018-06-01 02:33:45.613371|2018-06-01 02:33:45.613371
NCT00597701|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2011-06-29||2011-07-25|2008-01-17|2008-01-18|Estimate|2011-06-29|2011-07-26|Estimate||||2011-07-25|2011-07-27|Estimate|April 2003||2003-04-30|July 2011|2011-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Treating Alcohol Withdrawal With Oral Baclofen|Treating Alcohol Withdrawal With Oral Baclofen: a Randomized, Double Blind, Placebo Controlled Trial|Completed||N/A|79|Actual|Essentia Health||2|||f||||f||||||||||2018-06-01 02:33:46.190328|2018-06-01 02:33:46.190328
NCT00597688|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2011-03-22|2008-01-10|2008-01-18|Estimate|||||||2011-03-22|2011-03-23|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Role of Oral Chlorhexidine Gel in Prevention of Ventilator Associated Pneumonia|Oral Mucosal Decontamination With Chlorhexidine for Prevention of Ventilator Associated Pneumonia in Children - A Randomized Controlled Trial|Completed||Phase 3|86|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 02:33:46.442437|2018-06-01 02:33:46.442437
NCT00597675|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2017-01-25|2012-09-14|2018-02-27|2008-01-15|2008-01-18|Estimate|2017-03-22|2017-05-03|Actual|2012-09-28|2012-10-05|Estimate|2018-02-27|2018-03-27|Actual|March 2007||2007-03-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PMIT||Oral Immunotherapy for Peanut Allergy (PMIT)|Oral Immunotherapy for Peanut Allergy (2nd Generation PMIT Collaboration With Arkansas Children's)|Completed||Phase 2|10|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-06-01 02:33:46.540718|2018-06-01 02:33:46.540718
NCT00597662|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-06-09|2008-01-17|2008-01-18|Estimate|||||||2008-06-09|2008-06-10|Estimate|January 2008||2008-01-31|June 2008|2008-06-30||||April 2008|Actual|2008-04-30||Interventional|||Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis|Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis|Completed||Phase 1|30|Anticipated|University Hospital Tuebingen||2|||f||||||||||||||2018-06-01 02:33:46.936921|2018-06-01 02:33:46.936921
NCT00597649|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2009-06-29|2008-01-17|2008-01-18|Estimate|||||||2009-06-29|2009-06-30|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|An Open-Label 52-Week Safety Study of Bicifadine SR in Adult Outpatients With Chronic Peripheral Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|Terminated||Phase 2|250|Anticipated|XTL Biopharmaceuticals||2||The 001 trial did not show benefit versus placebo|f||||f||||||||||2018-06-01 02:33:47.011164|2018-06-01 02:33:47.011164
NCT00597636|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2017-07-12|2008-01-17|2008-01-18|Estimate|||||||2017-07-12|2017-07-13|Actual|June 2005||2005-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Genetic Susceptibility to Lung Cancer in Never Smokers|Genetic Susceptibility to Lung Cancer in Never Smokers|Active, not recruiting|||238|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:33:47.100874|2018-06-01 02:33:47.100874
NCT00597623|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-15|||2012-07-25|2008-01-15|2008-01-18|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|DORA||Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis|Randomized Double Blind Placebo-controlled Trial of the Efficacy of an Anti-TNF Alpha Agent (Adalimumab, Humira®) in Patients With Incapacitating Hand Osteoarthritis Refractory to Usual Treatment|Completed||Phase 3|84|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:33:47.172655|2018-06-01 02:33:47.172655
NCT00597610|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-09-26|2008-01-09|2008-01-18|Estimate|||||||2012-09-26|2012-09-27|Estimate|November 2003||2003-11-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluating The Response to Pre-Operative Chemotherapy and/or Radiation Therapy For Rectal Cancer Using Three-Dimension Transrectal Ultrasound|Evaluating The Response to Pre-Operative Chemotherapy and/or Radiation Therapy For Rectal Cancer Using Three-Dimension Transrectal Ultrasound (3-D TRUS) - A Pilot Project|Completed||N/A|84|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:33:47.283618|2018-06-01 02:33:47.283618
NCT00597597|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-12-31|2008-01-09|2008-01-18|Estimate|||||||2012-12-31|2013-01-03|Estimate|April 2007||2007-04-30|December 2012|2012-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer|A Phase II Open-Label Trial to Evaluate the Efficacy and Toxicity of Tarceva (Erlotinib) in Women With Metastatic, Hormone Receptor Negative and Her2-Negative Breast Cancer|Terminated||Phase 2|11|Actual|Rush University Medical Center||1||not enough patients enrolled|f||||t||||||||||2018-06-01 02:33:47.368216|2018-06-01 02:33:47.368216
NCT00597584|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2012-04-26|2010-08-16|2013-03-06|2008-01-17|2008-01-18|Estimate|2012-06-22|2012-07-30|Estimate|2010-08-16|2010-08-19|Estimate|2013-03-06|2013-03-08|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|EMERALD 2||Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis|AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin|Completed||Phase 3|823|Actual|Affymax||2|||f||||t||||||||||2018-06-01 02:33:47.511869|2018-06-01 02:33:47.511869
NCT00597571|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2015-04-27|2008-01-09|2008-01-18|Estimate|||||||2015-04-27|2015-04-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:33:49.286455|2018-06-01 02:33:49.286455
NCT00597558|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-06|2016-04-07||2018-02-27|2008-01-15|2008-01-18|Estimate|2016-04-08|2016-05-16|Estimate||||2018-02-27|2018-03-26|Estimate|February 2003||2003-02-28|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|EggOIT||Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)|Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)|Completed||N/A|13|Actual|University of North Carolina, Chapel Hill|Endpoints were based on reaching certain lab criteria and thus the time on treatment varied from 24-60 months.|1|||f||||t||||||||No||2018-06-01 02:33:49.356829|2018-06-01 02:33:49.356829
NCT00597545|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2015-06-02||2015-06-19|2008-01-09|2008-01-18|Estimate|2015-06-19|2015-07-13|Estimate||||2015-06-19|2015-07-13|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Raised CBF During CEA on Cognition in DM Patients|Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients|Terminated||N/A|10|Actual|Columbia University||2||Half of DM patients had EEG changes and therefore were excluded.|f||||f||||||||||2018-06-01 02:33:49.599399|2018-06-01 02:33:49.599399
NCT00597532|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-04-12|2008-01-10|2008-01-18|Estimate|||||||2016-04-12|2016-04-13|Estimate|August 2002||2002-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study|Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study|Completed||N/A|140|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:33:49.794351|2018-06-01 02:33:49.794351
NCT00596674|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2012-04-24|2008-01-08|2008-01-17|Estimate|||||||2012-04-24|2012-04-25|Estimate|July 2003||2003-07-31|April 2012|2012-04-30|May 2008|Actual|2008-05-31|January 2007|Actual|2007-01-31||Interventional|||Health Promotion for Women With Fibromyalgia|Health Promotion for Women With Fibromyalgia|Completed||N/A|177|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-06-01 02:34:03.909797|2018-06-01 02:34:03.909797
NCT00597519|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2016-01-14||2016-01-14|2008-01-10|2008-01-18|Estimate|2016-01-14|2016-02-12|Estimate||||2016-01-14|2016-02-12|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy|A Myeloablative Conditioning Regimen Consisting of Cyclophosphamide, Fludarabine and Total Body Irradiation Followed by the Transplantation of Unrelated Donor Double Unit Umbilical Cord Blood Grafts for Patients With Hematological Malignancy.|Completed||Phase 2|28|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:33:49.910721|2018-06-01 02:33:49.910721
NCT00597506|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-07-10||2012-12-21|2008-01-17|2008-01-18|Estimate|2012-08-14|2012-08-16|Estimate||||2012-12-21|2012-12-27|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|BEV/EV||Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus|Expanded Cohort of Patients With Refractory Metastatic Colorectal Cancer (MCRC) Treated With Bevacizumab and Everolimus|Completed||Phase 2|50|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:33:50.084011|2018-06-01 02:33:50.084011
NCT00597493|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2013-05-03||2013-05-03|2008-01-17|2008-01-18|Estimate|2013-05-03|2013-06-24|Estimate||||2013-05-03|2013-06-24|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|December 2010|Actual|2010-12-31|February 2009|Actual|2009-02-28||Interventional|||Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM|Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme|Completed||Phase 2|32|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:33:50.407134|2018-06-01 02:33:50.407134
NCT00597480|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2015-04-20|2008-01-17|2008-01-18|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2008||2008-01-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|SGA||Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)|Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH) by Comparison of Two Regimens of rhGH Administration to SGA Children. Pharmacogenetics of Metabolic Responses to rhGH|Terminated||Phase 4|10|Actual|Assistance Publique - Hôpitaux de Paris||2||no more inclusions|f||||t||||||||||2018-06-01 02:33:50.692487|2018-06-01 02:33:50.692487
NCT00597467|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-12-19|2008-01-09|2008-01-18|Estimate|||||||2008-12-19|2008-12-22|Estimate|March 2006||2006-03-31|December 2008|2008-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Soft Contact Lens Use With 7 Day Extended Wear|An Open-Labeled, Multi-Center, Randomized Investigation of the VISA (Comfilcon A) Silicone Hydrogel Soft (Hydrophilic) Contact Lens for Use in a 7 Day Extended Wear Regimen|Completed||Phase 3|455|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-06-01 02:33:50.765624|2018-06-01 02:33:50.765624
NCT00597454|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|||2012-07-25|2008-01-10|2008-01-18|Estimate|||||||2012-07-25|2012-07-26|Estimate|July 2004||2004-07-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||An Access Delivery Model That Eliminates Barriers to Breast Cancer Care Delivery|An Access Delivery Model That Eliminates Barriers to Breast Cancer Care Delivery With Emphasis on the Coordination of Care Within and Between an Outpatient Screening Facility and a Diagnostic and Treatment Center|Completed||N/A|150|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:33:50.85651|2018-06-01 02:33:50.85651
NCT00597441|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2012-11-13|2008-01-10|2008-01-18|Estimate|||||||2012-11-13|2012-11-15|Estimate|November 2005||2005-11-30|November 2012|2012-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation|Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation|Terminated||Phase 1|6|Actual|Duke University||1||accrual of evaluable subjects too low|f||||t||||||||||2018-06-01 02:33:50.98694|2018-06-01 02:33:50.98694
NCT00597428|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2013-11-22|2010-06-02|2015-11-02|2008-01-17|2008-01-18|Estimate|2015-11-02|2015-12-07|Estimate|2013-02-01|2013-02-05|Estimate|2015-11-02|2015-12-07|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|OPAL|Baseline analysis based on ITT population, which included 212 placebo-treated subjects and 223 lubiprostone-treated subjects.|Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone|A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)|Completed||Phase 3|437|Actual|Sucampo Pharma Americas, LLC|Post-study, it was determined that lubiprostone efficacy was dose-dependently decreased with concomitant methadone use (30% higher morphine equivalent daily dose (MEDD) than parallel pivotal study NCT00595946).|2|||f||||f||||||||||2018-06-01 02:33:51.144474|2018-06-01 02:33:51.144474
NCT00597415|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-01-09|2008-01-09|2008-01-18|Estimate|||||||2008-01-09|2008-01-18|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|March 2008|Anticipated|2008-03-31|February 2008|Anticipated|2008-02-29||Interventional|||Efficacy of Celecoxib 200mg in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee|A Double-Blind, Placebo-Controlled, Randomized, Crossover Pilot Study of the Efficacy of Celecoxib 200 mg QD in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee.|Unknown status|Recruiting|Phase 2|30|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 02:33:51.675642|2018-06-01 02:33:51.675642
NCT00597402|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-10|2012-12-12||2014-04-22|2008-01-17|2008-01-18|Estimate|2012-12-12|2013-01-18|Estimate||||2014-04-22|2014-05-07|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|August 2011|Actual|2011-08-31||Interventional|||Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas|Avastin in Combination With Radiation and Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma Multiformes and Gliosarcomas|Completed||Phase 2|125|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:33:51.832275|2018-06-01 02:33:51.832275
NCT00597389|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-01-17|2008-01-17|2008-01-18|Estimate|||||||2008-01-17|2008-01-18|Estimate|February 2004||2004-02-29|January 2008|2008-01-31|February 2006|Actual|2006-02-28|November 2005|Actual|2005-11-30||Interventional|||Propranolol Administration and Prevention of Child PTSD in Child Trauma Victims|The Efficacy of Early Propranolol Administration at Preventing/Reducing PTSD Symptoms in Child Trauma Victims: Pilot.|Completed||N/A|29|Actual|Kent State University||2|||f||||t||||||||||2018-06-01 02:33:52.318556|2018-06-01 02:33:52.318556
NCT00597376|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2013-01-25||2013-05-20|2008-01-09|2008-01-18|Estimate|2013-05-20|2013-05-23|Estimate||||2013-05-20|2013-05-23|Estimate|November 2007||2007-11-30|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints|A Six-month, Double-blind, Placebo-controlled, Single Site Study of Cerefolin NAC on Blood Homocysteine, Oxidative Stress, and Beta-amyloid Biomarkers That May Potentiate Inflammation and Neuronal Damage in Older Individuals With Memory Complaints Who Have Not Been Clinically Diagnosed With Mild Cognitive Impairment, Vascular Dementia, or Alzheimer's Disease|Completed||N/A|104|Actual|Rush University Medical Center|No limitations or caveats to report.|2|||f||||f||||||||||2018-06-01 02:33:52.414915|2018-06-01 02:33:52.414915
NCT00597363|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-01-17|2008-01-17|2008-01-18|Estimate|||||||2008-01-17|2008-01-18|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|September 2007|Actual|2007-09-30||Interventional|||Neptune Pad ® Compared to Conventional Manual Compression|Neptune Pad ® Compared to Conventional Manual Compression for Access Site Management After Peripheral Percutaneous Transluminal Procedures|Completed||N/A|201|Actual|Vienna General Hospital||2|||f||||t||||||||||2018-06-01 02:33:52.822097|2018-06-01 02:33:52.822097
NCT00597350|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2015-12-17|2008-01-17|2008-01-18|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Observational|Fenugreek||Effect of Fenugreek on Blood Sugar and Insulin in Diabetic Humans|Pilot Study of the Effect of Fenugreek on Blood Sugar and Insulin in Diabetic Humans|Completed|||8|Actual|Pennington Biomedical Research Center|||1||f||||f||||||Samples Without DNA|"~     Whole blood drawn for glucose and insulin levels.~   "|||2018-06-01 02:33:52.960055|2018-06-01 02:33:52.960055
NCT00597337|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-12-17|2008-01-17|2008-01-18|Estimate|||||||2008-12-17|2008-12-18|Estimate|November 2007||2007-11-30|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effectiveness of the FearNot!v.2.0 Software in Reducing Bullying Victimisation Among Primary School Children|Using a Virtual Learning Environment to Reduce Bullying: Evaluation of the FearNot!v.2.0 Intervention in Primary Schools in England and Germany|Completed||N/A|1129|Actual|University of Warwick||2|||f||||f||||||||||2018-06-01 02:33:53.059371|2018-06-01 02:33:53.059371
NCT00597324|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-10-26|2008-01-09|2008-01-18|Estimate|||||||2011-10-26|2011-10-27|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|June 2009|Actual|2009-06-30||Interventional|RADAR||Predictive Value of Allen's Test Result in Elective Patients Undergoing Coronary Catheterization Through Radial Approach|Should Intervention Through RADial Approach be Denied to Patients With Negative Allen's Test Results?|Completed||Phase 3|203|Actual|Università degli Studi di Ferrara||3|||f||||t||||||||||2018-06-01 02:33:53.151815|2018-06-01 02:33:53.151815
NCT00597311|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-01-09|2008-01-09|2008-01-18|Estimate|||||||2008-01-09|2008-01-18|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer|Preoperative Chemoradiation Versus Short Term Radiation Alone With Delayed Surgery for Stage II and III Resectable Rectal Cancer|Unknown status|Recruiting|Phase 3|150|Anticipated|Kaunas University of Medicine||2|||f||||f||||||||||2018-06-01 02:33:53.234474|2018-06-01 02:33:53.234474
NCT00597298|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2009-02-03|2008-01-09|2008-01-18|Estimate|||||||2009-02-03|2009-02-04|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|DIATRACS||Diaphragm Training Post-Cardiac Surgery|Randomized Controlled Trial on the Diaphragm Training With Threshold for Patient With Post-Cardiac Surgery Diaphragmatic Paralysis|Completed||N/A|48|Actual|Ospedali Riuniti Trieste||2|||f||||f||||||||||2018-06-01 02:33:53.342559|2018-06-01 02:33:53.342559
NCT00597285|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2018-05-23|2008-01-09|2008-01-18|Estimate|||||||2018-05-23|2018-05-24|Actual|January 3, 2008||2008-01-03|November 1, 2013|2013-11-01|November 1, 2013||2013-11-01|||||Observational|||Relationship of HHV-6B Virus to Seizures and Brain Injury|HHV6B in Epilepsy Imaging and CSF Studies|Terminated|||33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:33:53.420405|2018-06-01 02:33:53.420405
NCT00597272|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2015-10-20||2016-08-10|2008-01-17|2008-01-18|Estimate|2016-06-29|2016-08-10|Estimate||||2016-08-10|2016-09-20|Estimate|December 2007||2007-12-31|August 2016|2016-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma|Pilot Trials With a KLH Conjugated Bivalent GangliosideVaccine Mixed With Immunological Adjuvants QS-DG or OPT-821in Patients With Disease Free AJCC Stage III or IV|Completed||N/A|34|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:33:53.512329|2018-06-01 02:33:53.512329
NCT00597259|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2010-06-28|2008-01-17|2008-01-18|Estimate|||||||2010-06-28|2010-06-29|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B|Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B|Unknown status|Recruiting|Phase 4|294|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 02:33:54.197694|2018-06-01 02:33:54.197694
NCT00597246|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2017-09-22|2008-01-17|2008-01-18|Estimate|||||||2017-09-22|2017-09-25|Actual|May 13, 2003|Actual|2003-05-13|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Imaging Brain Tumors With FACBC and Methionine|Imaging Brain Tumors With FACBC and Methionine|Active, not recruiting||N/A|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:33:54.322311|2018-06-01 02:33:54.322311
NCT00597233|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2016-12-20|2008-01-09|2008-01-18|Estimate|||||||2016-12-20|2016-12-22|Estimate|October 2002||2002-10-31|December 2016|2016-12-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Human Insulin NPH and Insulin Aspart in Type 1 Diabetes|Comparative Evaluation of Human NPH Insulin + Insulin Aspart and Human NPH Insulin + Human Soluble Insulin in Type 1 Diabetes Mellitus|Completed||Phase 4|91|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:33:54.414819|2018-06-01 02:33:54.414819
NCT00597220|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2011-06-21|2008-01-16|2008-01-17|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2008||2008-01-31|June 2011|2011-06-30|August 2011|Anticipated|2011-08-31|July 2011|Anticipated|2011-07-31||Interventional|FORWARD||Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation|Randomized, Prospective, Placebo-controlled, Multi-center Study to Test the Efficacy of n-3 PUFA for the Maintenance of Normal Sinus Rhythm in Patients With Persistent Atrial Fibrillation|Unknown status|Active, not recruiting|Phase 3|1600|Anticipated|Fundacion GESICA||2|||f||||t||||||||||2018-06-01 02:33:54.508244|2018-06-01 02:33:54.508244
NCT00597207|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2014-03-08||2017-09-21|2008-01-16|2008-01-17|Estimate|2014-03-08|2014-04-14|Estimate||||2017-09-21|2017-09-26|Actual|January 2008||2008-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|February 2011|Actual|2011-02-28||Interventional|CIRC||Circulation Improving Resuscitation Care (CIRC)|A Randomized Controlled Study Comparing Autopulse To Manual CPR In A CPR-First Protocol For Out-Of-Hospital Cardiac Arrest|Completed||N/A|4231|Actual|Zoll Medical Corporation||2|||f||||t||||||||||2018-06-01 02:33:54.613468|2018-06-01 02:33:54.613468
NCT00597194|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate|October 2002||2002-10-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Day Case Inguinal Hernia Repair in Children. Is Laparoscopic Approach Justified?|Day Case Inguinal Hernia Repair in Children. Is Laparoscopic Approach Justified?|Completed||N/A|89|Actual|Hospital for Children and Adolescents, Finland||2|||f||||f||||||||||2018-06-01 02:33:54.981406|2018-06-01 02:33:54.981406
NCT00597181|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2010-09-16|2008-01-16|2008-01-17|Estimate|||||||2010-09-16|2010-09-17|Estimate|November 2007||2007-11-30|September 2010|2010-09-30|August 2010|Actual|2010-08-31|January 2009|Actual|2009-01-31||Interventional|Optonol||A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy|A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open-Angle Glaucoma|Terminated||Phase 4|40|Anticipated|Indiana University||2||Patient population limited|f||||f||||||||||2018-06-01 02:33:55.061275|2018-06-01 02:33:55.061275
NCT00597168|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2010-06-08|2008-01-16|2008-01-17|Estimate|||||||2010-06-08|2010-06-09|Estimate|October 2007||2007-10-31|June 2010|2010-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|Quality||Quality of Life in Schizophrenic Patients|QUALITY: A Non-interventional Study Evaluating Quality Of Life in Schizophrenic Patients Treated With Atypical Antipsychotics, in the Ambulatory Setting. A 9-month, Observational, Multicentric Prospective Study.|Completed|||124|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:33:55.147249|2018-06-01 02:33:55.147249
NCT00597142|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2014-11-20|2008-01-09|2008-01-17|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2004||2004-01-31|November 2014|2014-11-30|October 2009|Actual|2009-10-31|July 2005|Actual|2005-07-31||Interventional|RENAISSANCE||A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.|A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.|Completed||Phase 4|100|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-06-01 02:33:55.304534|2018-06-01 02:33:55.304534
NCT00597129|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-08|2008-01-08|2008-01-17|Estimate|||||||2008-01-08|2008-01-17|Estimate|August 2004||2004-08-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy Study of 90Y-hPAM4 at Different Doses|A Phase I, Dose-Escalating Study to Investigate the Safety, Tolerability, Pharmacokinetics and Dosimetry of a Single Dose of 90YHumanized PAM4 IgG in Patients With Locally Advanced/Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|21|Actual|Immunomedics, Inc.||1|||f||||f||||||||||2018-06-01 02:33:55.42103|2018-06-01 02:33:55.42103
NCT00597116|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|2011-04-27||2016-08-29|2008-01-16|2008-01-17|Estimate|2012-09-14|2012-10-15|Estimate||||2016-08-29|2016-10-10|Estimate|December 2007||2007-12-31|August 2016|2016-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma|A Randomized Phase II Trial To Evaluate The Efficacy And Safety Of Vandetanib (ZD6474, ZACTIMA ™) Versus Vinorelbine In Patients With Inoperable Or Relapsed Malignant Mesothelioma.|Terminated||Phase 2|25|Actual|Sanofi|Early termination leading to small number of subjects analyzed.|2||Recruitment stopped according to early stopping rule (by protocol)|f||||f||||||||||2018-06-01 02:33:55.631507|2018-06-01 02:33:55.631507
NCT00597103|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-08|2008-01-08|2008-01-17|Estimate|||||||2008-01-08|2008-01-17|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Comparison of Dialysis Therapies on Cognitive Function|Comparison of Dialysis Therapies on Cognitive Function|Unknown status|Recruiting||100|Anticipated|Satellite Healthcare|||3||f||||f||||||||||2018-06-01 02:33:56.177165|2018-06-01 02:33:56.177165
NCT00597090|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2011-01-19|2008-01-16|2008-01-17|Estimate|||||||2011-01-19|2011-01-20|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections|The Role of Genetic Polymorphisms in Innate Immune Response Genes in Susceptibility to Infections|Completed|||319|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||Samples With DNA|"~     We will genotype the genes of innate immune receptors to identify genetic polymorphisms~     associated with higher frequency of invasive infections or susceptibility to lymphoma. All~     specimens will be processed in the Infectious Diseases Laboratory at MSKCC. RNA will be~     extracted from peripheral blood mononuclear cells (PBMCs). Genotyping will be done from~     genomic DNA or from cDNA generated from RNA by RT-PCR. Cell lines will be created from PBMCs~     and will be analyzed in functional assays for responses to bacterial and fungal products~     (cytokine secretion, upregulation of cell surface molecules). All patient samples including~     genomic DNA, RNA, cDNA and cell lines will be banked in the Infectious Disease laboratory at~     MSKCC.~   "|||2018-06-01 02:33:56.296449|2018-06-01 02:33:56.296449
NCT00597077|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-02-01|2008-01-16|2008-01-17|Estimate|||||||2008-02-01|2008-02-08|Estimate|April 2001||2001-04-30|January 2008|2008-01-31|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Atrial Fibrillation and Congestive Heart Failure Trial|Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial|Completed||Phase 4|1376|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-06-01 02:33:56.373334|2018-06-01 02:33:56.373334
NCT00597064|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate|July 2006||2006-07-31|November 2007|2007-11-30|March 2008|Anticipated|2008-03-31|March 2008|Anticipated|2008-03-31||Interventional|APITA||Inflammatory, Functional and Image Composite Measure to Define Asthma Control|Inflammatory, Functional and Image Composite Measure to Define Asthma Control|Unknown status|Recruiting|Phase 4|70|Anticipated|Federal University of São Paulo|||||f||||t||||||||||2018-06-01 02:33:56.468765|2018-06-01 02:33:56.468765
NCT00597051|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|ARD-0403-001||Study of 3 Doses of ARD-0403 in Testosterone Deficient Men|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Centre Study of the Pharmacokinetics and Tolerability of 3 Different Doses of ARD-0403 in Testosterone Deficient Men|Completed||Phase 2|42|Actual|Ardana Bioscience Ltd|||||f||||f||||||||||2018-06-01 02:33:56.562945|2018-06-01 02:33:56.562945
NCT00597038|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2012-05-22||2013-11-21|2008-01-16|2008-01-17|Estimate|2012-05-22|2012-06-26|Estimate||||2013-11-21|2013-12-16|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Phase I/II Study of Dasatinib and Dacarbazine|A Phase I/II Study of Dasatinib and Dacarbazine in Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|50|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-06-01 02:33:56.638673|2018-06-01 02:33:56.638673
NCT00597025|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-08|2008-01-08|2008-01-17|Estimate|||||||2008-01-08|2008-01-17|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin|Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin|Unknown status|Recruiting|N/A|375|Anticipated|Satellite Healthcare||5|||f||||f||||||||||2018-06-01 02:33:56.971192|2018-06-01 02:33:56.971192
NCT00226252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2013-03-11|2005-09-22|2005-09-26|Estimate|||||||2013-03-11|2013-03-12|Estimate|December 2003||2003-12-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|March 2008|Actual|2008-03-31||Interventional|||Manual Wheelchair Propulsion Training|Manual Wheelchair Propulsion Training|Completed||N/A|28|Actual|VA Pittsburgh Healthcare System||3|||f||||f||||||||||2018-06-01 04:27:14.769814|2018-06-01 04:27:14.769814
NCT00597012|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2013-08-02||2017-01-30|2008-01-16|2008-01-17|Estimate|2013-12-19|2014-01-27|Estimate||||2017-01-30|2017-03-10|Actual|May 2008||2008-05-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|February 2012|Actual|2012-02-29||Interventional||Analysis was completed on the 330 active participants in the study at 6 months.|Comparing Knee Cartilage Surgery Versus Standard Physical Therapy in Treating People With a Meniscal Tear and Osteoarthritis|Partial Meniscectomy Versus Nonoperative Management in Meniscal Tear With OA: A Randomized Controlled Trial (MeTeOR)|Active, not recruiting||N/A|351|Actual|Brigham and Women's Hospital|Surgical randomized controlled trials present methodological challenges, including crossover from one group to the other.|2|||f||||t||||||||No||2018-06-01 02:33:57.064723|2018-06-01 02:33:57.064723
NCT00596999|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2012-04-09|2008-01-16|2008-01-17|Estimate|||||||2012-04-09|2012-04-10|Estimate|May 2007||2007-05-31|November 2007|2007-11-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|HPDSC||A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders|A Single-Arm Study to Assess the Safety of Transplantation With Umbilical Cord Blood Augmented With Human Placental-Derived Stem Cells From Partially Matched Related Donors in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders|Unknown status|Enrolling by invitation||6|Anticipated|Celgene|||1||f||||t||||||||||2018-06-01 02:33:57.505403|2018-06-01 02:33:57.505403
NCT00596986|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2009-07-31|2008-01-08|2008-01-17|Estimate|||||||2009-07-31|2009-08-03|Estimate|October 2008||2008-10-31|July 2009|2009-07-31||||September 2009|Anticipated|2009-09-30||Interventional|GETTY||Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression|Impact of Therapeutical Strategies on Emotional Processing in Depression: Neurofunctional and Clinical Issues in the Context of Affective Bias|Unknown status|Active, not recruiting|N/A|30|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-06-01 02:33:57.561749|2018-06-01 02:33:57.561749
NCT00596973|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2014-11-14|2008-01-08|2008-01-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients|Phase IV Study of Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients|Withdrawn||Phase 4|0|Actual|Medtronic - MITG||1||Business Reasons|f||||t||||||||||2018-06-01 02:33:57.625668|2018-06-01 02:33:57.625668
NCT00596960|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2014-11-12||2014-11-26|2008-01-08|2008-01-17|Estimate|2014-11-26|2014-11-28|Estimate||||2014-11-26|2014-11-28|Estimate|November 2008||2008-11-30|November 2014|2014-11-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients|Motivating Chronic Hepatitis C Patients to Reduce Alcohol Use|Completed||N/A|139|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 02:33:57.81406|2018-06-01 02:33:57.81406
NCT00596947|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2011-02-18||2017-03-29|2008-01-08|2008-01-17|Estimate|2011-02-18|2011-03-21|Estimate||||2017-03-29|2017-05-15|Actual|October 2005||2005-10-31|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant|Randomized, Prospective Single-center Study Comparing a Rapid Discontinuation of Corticosteroids (Steroid Withdrawal) With Corticosteroid Therapy in Kidney Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy|Terminated||Phase 4|18|Actual|University of Pennsylvania|The trial was terminated early due to low enrollment. Therefore no results beyond basic results section are reported due to uninterpretable data.|2||due to low study enrollment|f||||f||||||||||2018-06-01 02:33:58.202552|2018-06-01 02:33:58.202552
NCT00596934|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2016-08-22||2017-10-19|2008-01-16|2008-01-17|Estimate|2016-10-17|2016-12-09|Estimate||||2017-10-19|2017-11-24|Actual|February 2006||2006-02-28|October 2017|2017-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)|Nonalcoholic Steatohepatitis: is Leptin an Etiological Factor (Phase 2).|Completed||Phase 2|9|Actual|University of Michigan|This is a non-blinded, non-placebo controlled proof of concept trial. Out of the 9 patients, there were 7 completers.|1|||f||||f||||||||Undecided||2018-06-01 02:33:58.770227|2018-06-01 02:33:58.770227
NCT00596921|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate||||January 2008|2008-01-31||||||||Observational|||Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure|Bedside Ultrasound Measurement of the Inferior Vena Cava Correlates to Central Venous Pressure|Unknown status|Not yet recruiting||100|Anticipated|Brooke Army Medical Center|||||f||||f||||||||||2018-06-01 02:33:59.207351|2018-06-01 02:33:59.207351
NCT00596908|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2009-05-28|2008-01-16|2008-01-17|Estimate|||||||2009-05-28|2009-05-29|Estimate|December 2007||2007-12-31|May 2009|2009-05-31|March 2009|Actual|2009-03-31|||||Observational|AIM||123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor|123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor (AIM)|Completed|||54|Actual|Alseres Pharmaceuticals, Inc|||2||f||||f||||||Samples Without DNA|"~     2 blood draws and 2 urine collections per subject.~   "|||2018-06-01 02:33:59.265532|2018-06-01 02:33:59.265532
NCT00596895|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2011-09-16|2008-01-16|2008-01-17|Estimate|||||||2011-09-16|2011-09-20|Estimate|November 2003||2003-11-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer|Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy.|Completed||Phase 2|20|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 02:33:59.325542|2018-06-01 02:33:59.325542
NCT00596882|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2009-12-01|2008-01-16|2008-01-17|Estimate|||||||2009-12-01|2009-12-02|Estimate|February 2008||2008-02-29|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study|Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study|Completed||Phase 4|100|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 02:33:59.398545|2018-06-01 02:33:59.398545
NCT00596856|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2013-03-15|2008-01-16|2008-01-17|Estimate|||||||2013-03-15|2013-03-18|Estimate|April 2011||2011-04-30|March 2013|2013-03-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|PORRT||Development and Dissemination of Oral Health Risk Assessment and Referral Guidelines|Development and Dissemination of Oral Health Risk Assessment and Referral Guidelines - PORRT|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||3||"Published study provided evidence that intervention would provide little effect; study not~   approved by provider community."|f||||f||||||||||2018-06-01 02:33:59.5926|2018-06-01 02:33:59.5926
NCT00596843|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2017-02-28|2008-01-07|2008-01-17|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2003||2003-09-30|November 2008|2008-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Chronic Hepatitis Intervention Project for Drug Users|Chronic Hepatitis Intervention Project for Drug Users|Completed||Phase 3|851|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 02:33:59.698849|2018-06-01 02:33:59.698849
NCT00596830|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2013-09-25|2011-04-22|2013-12-11|2008-01-08|2008-01-17|Estimate|2013-09-25|2013-12-03|Estimate|2011-06-17|2011-06-28|Estimate|2013-12-11|2014-01-13|Estimate|April 2008||2008-04-30|December 2013|2013-12-31|September 2012|Actual|2012-09-30|March 2011|Actual|2011-03-31||Interventional|||Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology|Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer|Terminated||Phase 3|681|Actual|Pfizer|The study was terminated early due to futility. CP-751,871 will not undergo further development in the indication of advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 02:33:59.847837|2018-06-01 02:33:59.847837
NCT00596817|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2013-10-28||2014-02-13|2008-01-08|2008-01-17|Estimate|2014-02-13|2014-03-31|Estimate||||2014-02-13|2014-03-31|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional||"The total number of patients under Baseline Measures is not 1035 as automatically calculated, but 639 as stated in the Open-label Period (APTS) column and 396 in the “Double-blind Period (FAS)”.~The Total column of each Baseline Measure is Double-blind Period (FAS)."|Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes|A Double-blind, Randomised, Placebo-controlled, Multicentre, Relapse-prevention Study With Two Doses of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder|Completed||Phase 3|639|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-06-01 02:34:01.329581|2018-06-01 02:34:01.329581
NCT00596804|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2012-02-02|2008-01-16|2008-01-17|Estimate|||||||2012-02-02|2012-02-06|Estimate|March 2004||2004-03-31|February 2012|2012-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma|A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|39|Actual|Immunomedics, Inc.|||||f||||f||||||||||2018-06-01 02:34:01.902346|2018-06-01 02:34:01.902346
NCT00596791|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2009-01-09|2008-01-16|2008-01-17|Estimate|||||||2009-01-09|2009-01-12|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops|Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops|Completed||Phase 3|150|Anticipated|Santen Oy||1|||f||||f||||||||||2018-06-01 02:34:01.970256|2018-06-01 02:34:01.970256
NCT00596778|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate|February 2004||2004-02-29|January 2008|2008-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery|Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery|Terminated||N/A|31|Actual|University of Sao Paulo||1||terminated|f||||f||||||||||2018-06-01 02:34:02.026508|2018-06-01 02:34:02.026508
NCT00596765|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2016-05-24|2008-01-08|2008-01-17|Estimate|||||||2016-05-24|2016-05-25|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Neuropsychological Cognitive Behavioral Therapy for Patients With Acquired Brain Injury|Phase 2 Study of Neuropsychological Therapy for Patients With Acquired Brain Injury Focusing on the Role of Psychosocial Adjustment Using a Cognitive Behavioral Approach|Completed||N/A|62|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-06-01 02:34:02.199087|2018-06-01 02:34:02.199087
NCT00596752|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-05-05||2018-03-08|2008-01-16|2008-01-17|Estimate|2014-07-21|2014-08-12|Estimate||||2018-03-08|2018-04-04|Estimate|March 2004||2004-03-31|March 2018|2018-03-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|ESPECIAL|Baseline Characteristics refer to the Safety Set including all randomized subjects who received at least one dose of trial medication. Subjects were analyzed according to the actual treatment received. 4 PBO subjects were treated with Alprostadil, 3 Alprostadil subjects were treated with PBO.1 PBO subject withdrew prior to start of study treatment.|Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV|Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)|Completed||Phase 4|840|Actual|UCB Pharma||2|||f||||t||||||||||2018-06-01 02:34:02.346464|2018-06-01 02:34:02.346464
NCT00596739|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2016-08-15|2008-01-16|2008-01-17|Estimate|||||||2016-08-15|2016-08-17|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||A Study of the Pre- and Post-operative Semen Analyses and Reproductive Hormone Levels of Men Undergoing Weight-reduction Surgery|Weight Loss Surgery and Male Fertility|Completed|||60|Anticipated|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     Blood and Sperm~   "|||2018-06-01 02:34:03.289127|2018-06-01 02:34:03.289127
NCT00596726|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2010-05-25|2008-01-16|2008-01-17|Estimate|||||||2010-05-25|2010-05-27|Estimate|August 2006||2006-08-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|RECOVER I||RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study|RECOVER I: IMPELLA® RECOVER® LP/LD 5.0 Support System: A Clinical Safety & Feasibility Study|Completed||Phase 2|17|Actual|Abiomed Inc.|||||f||||f||||||||||2018-06-01 02:34:03.385797|2018-06-01 02:34:03.385797
NCT00596713|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2012-07-11|2008-01-16|2008-01-17|Estimate|||||||2012-07-11|2012-07-12|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Epidemiology of Sleep Disturbances Among the Adult Population of the Sao Paulo City|Epidemiology of Sleep Disturbances Among the Adult Population of the Sao Paulo City|Completed|||1100|Actual|Associação Fundo de Incentivo à Pesquisa|||1||f||||t||||||||||2018-06-01 02:34:03.473485|2018-06-01 02:34:03.473485
NCT00596700|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2014-04-28|2008-01-16|2008-01-17|Estimate|||||||2014-04-28|2014-04-29|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study|Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study|Completed||Phase 3|100|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-06-01 02:34:03.55533|2018-06-01 02:34:03.55533
NCT00596687|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2013-07-09||2014-02-07|2008-01-16|2008-01-17|Estimate|2014-02-07|2014-03-12|Estimate||||2014-02-07|2014-03-12|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|December 2009|Actual|2009-12-31||Interventional|RABBIT 2-SX||Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery|RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)|Completed||Phase 4|234|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:34:03.647498|2018-06-01 02:34:03.647498
NCT00596661|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2008-10-10|2008-01-16|2008-01-17|Estimate|||||||2008-10-10|2008-10-15|Estimate|May 2004||2004-05-31|October 2008|2008-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||The TRIMAXX Coronary Stent Trial|A Prospective, Multi-Center, Non-Randomized, Single-Arm Trial to Evaluate the Safety and Feasibility of the TriMaxx Coronary Stent in de Novo Coronary Artery Lesions.|Completed||Phase 1|100|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 02:34:04.001492|2018-06-01 02:34:04.001492
NCT00596648|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2013-09-17|2008-01-08|2008-01-17|Estimate|||||||2013-09-17|2013-09-19|Estimate|December 2007||2007-12-31|September 2013|2013-09-30||||August 2012|Actual|2012-08-31||Interventional|||A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer|A Phase 1b/2 Study of XL184 With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|92|Actual|Exelixis||3|||f||||||||||||||2018-06-01 02:34:04.115213|2018-06-01 02:34:04.115213
NCT00596635|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2010-06-30||2013-03-19|2008-01-08|2008-01-17|Estimate|2010-09-01|2010-09-23|Estimate||||2013-03-19|2013-03-29|Estimate|January 2007||2007-01-31|March 2013|2013-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|PACS||Cranberry for UTI Prevention in Residents of Long Term Care Facilities|Cranberry for UTI Prevention in Residents of Long Term Care Facilities|Completed||N/A|56|Actual|Yale University|The inability to follow all participants for the full six months reflects the vulnerability of the population.|3|||f||||f||||||||||2018-06-01 02:34:04.267061|2018-06-01 02:34:04.267061
NCT00596622|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2016-07-08||2016-08-23|2008-01-08|2008-01-17|Estimate|2016-08-23|2016-10-17|Estimate||||2016-08-23|2016-10-17|Estimate|August 2007||2007-08-31|August 2016|2016-08-31|November 2012|Actual|2012-11-30|January 2012|Actual|2012-01-31||Interventional|||FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder|Dysfunctional Cortico-Limbic Activity and Connectivity in Bipolar Disorder Before and After Lithium Treatment: An fMRI Study|Completed||Phase 4|46|Actual|Indiana University|Small number of subjects|3|||f||||f||||||||No||2018-06-01 02:34:04.557347|2018-06-01 02:34:04.557347
NCT00596609|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2009-09-14|2008-01-16|2008-01-17|Estimate|||||||2009-09-14|2009-09-16|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|EIM||Intrathecal Morphine on Transcranial Electric Motor-Evoked Potentials|Effects of Intrathecal Morphine on Transcranial Electric Motor-Evoked Potentials in Patients Undergoing Posterior Spine Fusion|Completed|||36|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||||||2018-06-01 02:34:04.801831|2018-06-01 02:34:04.801831
NCT00596596|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-05-28|2008-01-16|2008-01-17|Estimate|||||||2008-05-28|2008-05-29|Estimate|September 1996||1996-09-30|January 2008|2008-01-31|June 1997|Actual|1997-06-30|June 1997|Actual|1997-06-30||Interventional|||Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation|A Double-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Efficacy and Safety of Prucalopride (R093877) in Subjects With Chronic Idiopathic Constipation|Completed||Phase 2|313|Actual|Movetis||5|||f||||f||||||||||2018-06-01 02:34:04.87559|2018-06-01 02:34:04.87559
NCT00596583|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2009-02-27|2008-01-09|2008-01-17|Estimate|||||||2009-02-27|2009-03-02|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery|AQNA-DY001: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery|Completed||Phase 3|300|Anticipated|Aqumen Biopharmaceuticals, N.A.||2|||f||||f||||||||||2018-06-01 02:34:04.944358|2018-06-01 02:34:04.944358
NCT00596570|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2010-06-29|2008-01-08|2008-01-17|Estimate|||||||2010-06-29|2010-06-30|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|February 2010|Actual|2010-02-28|||||Observational|AFCAS||Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting|Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: A Multicenter, Prospective Registry|Completed|||996|Actual|University of Turku|||1||f||||f||||||Samples Without DNA|"~     Anticoagulation samples~   "|||2018-06-01 02:34:05.175489|2018-06-01 02:34:05.175489
NCT00596557|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2011-07-28|2008-01-16|2008-01-17|Estimate|||||||2011-07-28|2011-07-29|Estimate|February 2008||2008-02-29|July 2011|2011-07-31|July 2011|Actual|2011-07-31|February 2009|Actual|2009-02-28||Interventional|CRAD001AILO2||Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up|Phase IV: Effect of Everolimus and CNI Minimalization on Renal Function.|Completed||Phase 4|20|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-06-01 02:34:05.29618|2018-06-01 02:34:05.29618
NCT00596544|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2015-11-25|2008-01-08|2008-01-17|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2004||2004-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Sexual Functioning After Primary Treatment of Ovarian Cancer|Sexual Functioning After Primary Treatment of Ovarian Cancer|Terminated|||18|Actual|Memorial Sloan Kettering Cancer Center|||2|Lack of accrual|f||||||||||||||2018-06-01 02:34:05.398462|2018-06-01 02:34:05.398462
NCT00596531|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2016-11-07|2008-01-08|2008-01-17|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Clinical Trial of Acamprosate for Tinnitus|Clinical Trial of Acamprosate for Tinnitus|Completed||Phase 1|154|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:34:05.468123|2018-06-01 02:34:05.468123
NCT00596518|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2017-03-07|2008-01-08|2008-01-17|Estimate|||||||2017-03-07|2017-03-10|Actual|October 2007||2007-10-31|March 2017|2017-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function|A Phase 1, Open-Label Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PF-00734200 Administered To Subjects With Various Degrees Of Renal Impairment And Normal Renal Function|Completed||Phase 1|30|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:34:05.565524|2018-06-01 02:34:05.565524
NCT00596505|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate|April 2007||2007-04-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy|Intravitreal Bevacizumab (Avastin) Pretreatment for Reducing Intraoperative and Postoperative Preretinal Hemorrhage in Primary Diabetic Vitrectomy With Silicone Oil Infusion|Completed|||41|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-06-01 02:34:05.628418|2018-06-01 02:34:05.628418
NCT00596492|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-09|||2009-02-27|2008-01-09|2008-01-17|Estimate|||||||2009-02-27|2009-03-02|Estimate|May 2008||2008-05-31|February 2009|2009-02-28|December 2008|Anticipated|2008-12-31|September 2008|Anticipated|2008-09-30||Interventional|AQNA-DY002||DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery|AQNA-DY002: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery|Terminated||Phase 3|200|Anticipated|Aqumen Biopharmaceuticals, N.A.||2||Terminated due to reasons unrelated to safety|f||||f||||||||||2018-06-01 02:34:05.769092|2018-06-01 02:34:05.769092
NCT00596479|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2015-06-15|2008-01-16|2008-01-17|Estimate|||||||2015-06-15|2015-06-16|Estimate|November 2004||2004-11-30|June 2015|2015-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Filgrastim for the Promotion of Collateral Growth in Patients With CAD|Subcutaneous Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease|Completed||N/A|50|Anticipated|University Hospital Inselspital, Berne|||||f||||||||||||||2018-06-01 02:34:05.866449|2018-06-01 02:34:05.866449
NCT00596466|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2012-06-22||2012-08-10|2008-01-08|2008-01-17|Estimate|2012-08-10|2012-09-11|Estimate||||2012-08-10|2012-09-11|Estimate|April 2008||2008-04-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures|An Open-Label Multicenter Extension Study To Determine Long Term Safety And Efficacy Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures|Completed||Phase 3|75|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:34:05.961584|2018-06-01 02:34:05.961584
NCT00596453|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2016-08-16||2016-11-28|2008-01-16|2008-01-17|Estimate|2016-11-28|2017-01-23|Estimate||||2016-11-28|2017-01-23|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability|Impact of Antibiotic Treatment on PSA Variability|Terminated||Phase 4|31|Actual|Johns Hopkins University||2||Unable to recruit enough patients|f||||f||||||||||2018-06-01 02:34:06.224732|2018-06-01 02:34:06.224732
NCT00596440|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2015-05-27||2015-08-20|2008-01-16|2008-01-17|Estimate|2015-05-27|2015-06-11|Estimate||||2015-08-20|2015-08-28|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Observational|TM||Assessment of a Teachable Moment for Smoking Cessation|Assessment of a Teachable Moment for Smoking Cessation|Completed|||234|Actual|University of Pennsylvania|||2||f||||f||||||||||2018-06-01 02:34:06.521413|2018-06-01 02:34:06.521413
NCT00596427|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2012-04-19||2012-10-10|2008-01-16|2008-01-17|Estimate|2012-10-10|2012-10-12|Estimate||||2012-10-10|2012-10-12|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Mechanisms of Glucose Lowering Effect of Colesevelam HCl|Effects of Colesevelam HCl on Hepatic Insulin Sensitivity, Gluconeogenesis, Glucose Absorption and Lipid Synthesis in Subjects With Type 2 Diabetes Mellitus|Completed||N/A|60|Actual|KineMed||2|||f||||f||||||||||2018-06-01 02:34:06.790472|2018-06-01 02:34:06.790472
NCT00596414|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate|May 2003||2003-05-31|December 2007|2007-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial|Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial|Completed||Phase 4|180|Actual|Erasme University Hospital||3|||f||||t||||||||||2018-06-01 02:34:07.285473|2018-06-01 02:34:07.285473
NCT00596401|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2017-10-04|2008-01-16|2008-01-17|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2007||2007-09-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer|The Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer and the Medical Care Cost in Iijima Town|Active, not recruiting|||3000|Actual|Showa Inan General Hospital|||3||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:34:07.34818|2018-06-01 02:34:07.34818
NCT00596388|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2013-05-14|2008-01-07|2008-01-17|Estimate|||||||2013-05-14|2013-05-15|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|HMP||Usage of the Home Macular Perimeter (HMP)|Usage of the Home Macular Perimeter (HMP) in Intermediate Age Related Macular Degeneration Patients Pilot Study|Completed|||20|Actual|Notal Vision Ltd|||1||f||||f||||||||||2018-06-01 02:34:07.397044|2018-06-01 02:34:07.397044
NCT00596375|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2008-01-16|2008-01-16|2008-01-17|Estimate|||||||2008-01-16|2008-01-17|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Lidocaine Lubricant in Pediatric Urethral Catheterization|Lidocaine Lubricant Use as an Anesthetic Agent in Emergency Room Urethral Catheterization|Completed||N/A|47|Actual|Children's Healthcare of Atlanta||3|||f||||f||||||||||2018-06-01 02:34:07.459806|2018-06-01 02:34:07.459806
NCT00596362|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|2015-03-31||2016-05-16|2008-01-08|2008-01-17|Estimate|2015-03-31|2015-04-14|Estimate||||2016-05-16|2016-06-17|Estimate|April 2007||2007-04-30|May 2016|2016-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Treatment With Intravitreal Avastin for Large Uveal Melanomas|Neoadjuvant Treatment With Intravitreal Avastin for Large Uveal Melanomas|Completed||N/A|1|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:34:07.666403|2018-06-01 02:34:07.666403
NCT00596349|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2009-02-25|2008-01-08|2008-01-17|Estimate|||||||2009-02-25|2009-02-26|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Women Surviving Ovarian Cancer|Quality of Life in Women Surviving Ovarian Cancer|Completed|||62|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 02:34:07.820463|2018-06-01 02:34:07.820463
NCT00596336|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-08|||2017-04-11|2008-01-08|2008-01-17|Estimate|||||||2017-04-11|2017-04-12|Actual|October 2007||2007-10-31|April 2017|2017-04-30|March 15, 2017|Actual|2017-03-15|December 2011|Actual|2011-12-31||Interventional|CLLIFVAC||Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients|A Randomized Phase II Trial to Determine Whether the Application of Imiquimod Cream to the Vaccination Site Can Improve the Immune Responsiveness to Influenza Vaccination in Patients With Untreated Chronic Lymphocytic Leukemia|Terminated||Phase 2|24|Actual|The Royal Bournemouth Hospital||3||Recruitment issues|f||||f||||||||||2018-06-01 02:34:07.894763|2018-06-01 02:34:07.894763
NCT00596323|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2009-12-01|2008-01-15|2008-01-16|Estimate|||||||2009-12-01|2009-12-02|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Implantable Antenna Sensors for Continuous Glucose Monitoring|Implantable Antenna Sensors for Continuous Glucose Monitoring|Completed|||10|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 02:34:07.985281|2018-06-01 02:34:07.985281
NCT00596310|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2018-01-10|2008-01-07|2008-01-16|Estimate|||||||2018-01-10|2018-01-11|Actual|November 2004|Actual|2004-11-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2016|Actual|2016-12-31||Interventional|||Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning|Early Detection of Lung Cancer in a High-Risk Population Defined by Pulmonary Function Testing, Biomarkers, and Computerized Tomography Scanning|Active, not recruiting||N/A|1000|Anticipated|University of Kentucky||1|||f||||f||||||||||2018-06-01 02:34:08.057979|2018-06-01 02:34:08.057979
NCT00596297|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-10-02|2008-01-15|2008-01-16|Estimate|||||||2008-10-02|2008-10-03|Estimate|November 2007||2007-11-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|IBEVI||Preoperative Bevacizumab for Vitreous Hemorrhage|Intra-Operative and Postoperative Intraocular Bleeding After Pars Plana Vitrectomy for Vitreous Hemorrhage in Diabetic Patients Previously Treated With Intravitreal Bevacizumab|Completed||Phase 1/Phase 2|16|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 02:34:08.128532|2018-06-01 02:34:08.128532
NCT00596271|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-11-12||2014-04-09|2008-01-15|2008-01-16|Estimate|2014-04-09|2014-05-13|Estimate||||2014-04-09|2014-05-13|Estimate|September 2005||2005-09-30|April 2014|2014-04-30|August 2008|Actual|2008-08-31|July 2006|Actual|2006-07-31||Interventional|||Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440|Safety and Immunogenicity of Concomitant Vaccination With IC51 and HARVIX® 1440 in Healthy Subjects. A Single-blind Randomized, Controlled Phase 3 Study|Completed||Phase 3|192|Actual|Valneva Austria GmbH||3|||f||||f||||||||||2018-06-01 02:34:08.300918|2018-06-01 02:34:08.300918
NCT00596258|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2009-05-21|2008-01-04|2008-01-16|Estimate|||||||2009-05-21|2009-05-22|Estimate|November 2007||2007-11-30|May 2009|2009-05-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|TG-003||A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)|A Two-Stage Phase 2 Study Of Dose-Intense 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-Hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix|Completed||Phase 2|11|Actual|Tigris Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:34:08.558106|2018-06-01 02:34:08.558106
NCT00596245|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2015-04-14|2008-01-15|2008-01-16|Estimate|||||||2015-04-14|2015-04-16|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets|Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets Administered Two Hours Apart on Chromosomal Aberrations in Peripheral Blood Lymphocytes|Completed||Phase 1|42|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-06-01 02:34:08.639175|2018-06-01 02:34:08.639175
NCT00596232|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2016-04-28|2008-01-15|2008-01-16|Estimate|||||||2016-04-28|2016-05-02|Estimate|April 2003||2003-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|Mucinase||Investigating Mucinase Activity in Airway Disease|Investigating Mucinase Activity in Airway Disease|Completed|||211|Actual|University of California, San Francisco|||3||f||||f||||||Samples Without DNA|"~     Sputum~   "|||2018-06-01 02:34:08.706702|2018-06-01 02:34:08.706702
NCT00596219|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2015-12-21|2008-01-15|2008-01-16|Estimate|||||||2015-12-21|2015-12-23|Estimate|December 2003||2003-12-31|December 2015|2015-12-31|October 2010|Actual|2010-10-31|October 2006|Actual|2006-10-31||Interventional|||Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma|Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma|Completed||N/A|12|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:34:08.776955|2018-06-01 02:34:08.776955
NCT00596206|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2010-10-11|2008-01-04|2008-01-16|Estimate|||||||2010-10-11|2010-10-13|Estimate|December 2007||2007-12-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|LEADER||Leflunomide EfficAcy Response Related to Dosing Regimen in Early Rheumatoid Arthritis|Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients|Completed||Phase 3|124|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:34:09.820678|2018-06-01 02:34:09.820678
NCT00596193|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-03-07|2008-01-15|2008-01-16|Estimate|||||||2012-03-07|2012-03-08|Estimate|May 2001||2001-05-31|March 2012|2012-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Neuropeptide Y (NPY) Regulation of Nociceptors|NPY Regulation of Nociceptors in Clinical Inflammation|Completed|||11|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||f||||||||||2018-06-01 02:34:09.897062|2018-06-01 02:34:09.897062
NCT00596180|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-04-16|2008-01-04|2008-01-16|Estimate|||||||2017-04-16|2017-04-18|Actual|January 2007||2007-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Carbon Monoxide Poisoning|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Carbon Monoxide Poisoning|Recruiting|||40|Anticipated|Louisiana State University Health Sciences Center in New Orleans|||1||f||||f||||||||No||2018-06-01 02:34:09.956518|2018-06-01 02:34:09.956518
NCT00596167|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2013-04-03||2016-02-24|2008-01-15|2008-01-16|Estimate|2016-02-24|2016-03-25|Estimate||||2016-02-24|2016-03-25|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||Intradialytic Drug Removal by Short-daily Hemodialysis|Intradialytic Drug Removal by Short-daily Hemodialysis|Completed||N/A|6|Actual|Indiana University|Overall limitation is the relatively small sample size.|1|||f||||t||||||||No||2018-06-01 02:34:10.046521|2018-06-01 02:34:10.046521
NCT00596154|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2018-04-17|2008-01-07|2008-01-16|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2004|Actual|2004-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PCNSL||Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma|Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)|Active, not recruiting||Phase 2|33|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:34:10.192458|2018-06-01 02:34:10.192458
NCT00596141|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-05|||2013-05-06|2008-01-15|2008-01-16|Estimate|||||||2013-05-06|2013-05-08|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pilot Study to Evaluate the Use of OroScience Topical Oral Wound Emulsion in Post Operative Wound Healing|Pilot Study to Evaluate the Use of OroScience Topical Oral Wound Emulsion in Post Operative Wound Healing|Completed||N/A|17|Actual|OroScience, Inc.||2|||f||||f||||||||||2018-06-01 02:34:10.266463|2018-06-01 02:34:10.266463
NCT00596128|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-06-04|2008-01-15|2008-01-16|Estimate|||||||2008-06-04|2008-06-05|Estimate|December 2006||2006-12-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Standard Operating Procedures in Daily Clinical Routine|Does Implementation of a Standard Operating Procedure for Blood Sugar Control Into Daily Clinical Routine Improve Care of Patients|Completed||N/A|800|Actual|University of Schleswig-Holstein||2|||f||||t||||||||||2018-06-01 02:34:10.341731|2018-06-01 02:34:10.341731
NCT00596115|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-05|||2012-07-24|2008-01-15|2008-01-16|Estimate|||||||2012-07-24|2012-07-25|Estimate||||July 2012|2012-07-31||||||||Expanded Access|||Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day|Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day|Temporarily not available|||||Bennett, James P., Jr., M.D., Ph.D.|||||||||||||||||||2018-06-01 02:34:10.50427|2018-06-01 02:34:10.50427
NCT00596102|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-11-14||2014-06-27|2008-01-15|2008-01-16|Estimate|2014-06-27|2014-07-30|Estimate||||2014-06-27|2014-07-30|Estimate|October 2005||2005-10-31|June 2014|2014-06-30||||March 2011|Actual|2011-03-31||Observational|||Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51|Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51. An Uncontrolled Phase 3 Follow-up Study|Completed|||3258|Actual|Valneva Austria GmbH|||||f||||||||||||||2018-06-01 02:34:10.577308|2018-06-01 02:34:10.577308
NCT00596089|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2015-10-01|2008-01-15|2008-01-16|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2007||2007-10-31|January 2008|2008-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Use of Jumping Mechanography as a Method to Assess Musculoskeletal Status in Older Adults|Use of Jumping Mechanography as a Method to Assess Musculoskeletal Status in Older Adults: A Pilot Study|Completed|||80|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||||||2018-06-01 02:34:11.070238|2018-06-01 02:34:11.070238
NCT00596076|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-05|||2010-08-13|2008-01-15|2008-01-16|Estimate|||||||2010-08-13|2010-08-16|Estimate|February 2008||2008-02-29|August 2010|2010-08-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||Back School Efficacy on Low Back Pain and Quality of Life of Workers. COPCORD STUDY (Stage II)|The Efficacy of Back School on Low Back Pain and Quality of Life of Workers of a Pharmaceutics Company in Tehran Suburb. COPCORD Study (Stage II)|Completed||Phase 3|30|Anticipated|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 02:34:11.122261|2018-06-01 02:34:11.122261
NCT00596063|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-12-26|2008-01-15|2008-01-16|Estimate|||||||2012-12-26|2012-12-27|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.|A Randomized, Single Center, Double Blind, Two Period, Crossover Glucose Clamp Study to Test for Bioequivalence Between Two Recombinant Human Soluble Insulins- Wockhardts Insulin Human Regular for Injection and Novolin R in Healthy Subjects|Completed||Phase 1|25|Actual|Wockhardt||2|||f||||f||||||||||2018-06-01 02:34:11.185069|2018-06-01 02:34:11.185069
NCT00596050|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2017-05-08|2008-01-15|2008-01-16|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2006||2006-08-31|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions|Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions|Completed||Phase 4|50|Actual|Drexel University||2|||f||||f||||||||No||2018-06-01 02:34:11.25334|2018-06-01 02:34:11.25334
NCT00596037|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-10-04|2008-01-15|2008-01-16|Estimate|||||||2012-10-04|2012-10-05|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|September 2008|Actual|2008-09-30||Interventional|||Treatment of Adults With Growth Hormone Deficiency|A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency|Completed||Phase 3|136|Actual|LG Life Sciences||2|||f||||t||||||||||2018-06-01 02:34:11.327139|2018-06-01 02:34:11.327139
NCT00596024|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-01-04|2008-01-04|2008-01-16|Estimate|||||||2008-01-04|2008-01-16|Estimate|December 2007||2007-12-31|January 2008|2008-01-31||||December 2008|Anticipated|2008-12-31||Interventional|LAD||Lutein and Alzheimer's Disease Study|Lutein and Oxidative Stress in Alzheimer's Disease - A Pilot Study|Unknown status|Recruiting|Phase 2|16|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-06-01 02:34:11.389419|2018-06-01 02:34:11.389419
NCT00596011|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2014-08-15||2018-02-26|2008-01-07|2008-01-16|Estimate|2014-09-02|2014-09-03|Estimate||||2018-02-26|2018-03-26|Estimate|November 14, 2007|Actual|2007-11-14|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|March 25, 2014|Actual|2014-03-25||Interventional||All participants|Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia|Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia (HGPIN) or Atypical Small Acinar Proliferation (ASAP)|Active, not recruiting||Phase 2|97|Actual|H. Lee Moffitt Cancer Center and Research Institute|Primary Endpoint: Progression to PCa. Recent evidence demonstrates ASAP is a stronger diagnostic predictor associated with PCa compared to HGPIN. Due to this evidence and recruitment challenges, we revised inclusion criteria to include men with ASAP.|2|||f||||f||||||||||2018-06-01 02:34:11.580209|2018-06-01 02:34:11.580209
NCT00595998|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-06|||2009-01-27|2008-01-06|2008-01-16|Estimate|||||||2009-01-27|2009-01-28|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Observational|HMP||Sensitivity and Specificity of the Home Macular Perimeter (HMP)|Sensitivity and Specificity of the Home Macular Perimeter|Completed|||42|Actual|Notal Vision Ltd|||2||f||||t||||||||||2018-06-01 02:34:12.011468|2018-06-01 02:34:12.011468
NCT00595985|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2009-07-06|2008-01-15|2008-01-16|Estimate|||||||2009-07-06|2009-07-07|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer|Phase II Trial of Sorafenib as Second Line Therapy in Patients With Advanced or Metastatic Gastric Cancer|Terminated||Phase 2|5|Actual|Fudan University||1||low response rate, no evidence of PFS or OS improved.|f||||f||||||||||2018-06-01 02:34:12.07876|2018-06-01 02:34:12.07876
NCT00595972|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2011-06-27|2008-01-15|2008-01-16|Estimate|||||||2011-06-27|2011-06-28|Estimate|November 2007||2007-11-30|September 2010|2010-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer|Phase II Trial of Epirubicin Cisplatin and FU Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer|Completed||Phase 2|25|Actual|Fudan University||1|||f||||f||||||||||2018-06-01 02:34:12.160642|2018-06-01 02:34:12.160642
NCT00595959|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2009-02-23||2011-06-13|2008-01-04|2008-01-16|Estimate|2009-04-30|2009-06-19|Estimate||||2011-06-13|2011-07-12|Estimate|November 2006||2006-11-30|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2007|Actual|2007-04-30||Interventional|CELLO||CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings|CLiRpath® Excimer Laser System to Enlarge Lumen Openings|Completed||Phase 3|65|Actual|Spectranetics Corporation|Non-randomized study|1|||f||||t||||||||||2018-06-01 02:34:12.255817|2018-06-01 02:34:12.255817
NCT00595946|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-11-22|2010-06-02|2015-12-21|2008-01-15|2008-01-16|Estimate|2015-12-21|2016-02-03|Estimate|2013-02-01|2013-02-05|Estimate|2015-12-21|2016-02-03|Estimate|August 2007||2007-08-31|December 2015|2015-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|OPAL|Baseline analysis based on ITT population, which included 217 placebo-treated subjects and 221 lubiprostone-treated subjects.|Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone|A Multi-center, Randomized, Double-Blinded Study of the Efficacy and Safety of Lubiprostone in Patients With Opioid-induced Bowel Dysfunction (OBD)|Completed||Phase 3|439|Actual|Sucampo Pharma Americas, LLC||2|||f||||f||||||||||2018-06-01 02:34:12.582813|2018-06-01 02:34:12.582813
NCT00595933|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-05-26|2008-01-02|2008-01-16|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparing Over-the-counter Dry Mouth Remedies After Radiation|A Comparative Trial of Over-the-counter Dry Mouth Remedies for Dry Mouth After Radiation to the Head and Neck|Completed||Phase 1|28|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 02:34:13.11738|2018-06-01 02:34:13.11738
NCT00595335|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|2014-03-26||2015-12-30|2008-01-15|2008-01-16|Estimate|2014-05-05|2014-06-03|Estimate||||2015-12-30|2016-01-01|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|||Trial of Rituximab for Graves' Ophthalmopathy|Phase 2/3 Study of Rituximab for Graves' Ophthalmopathy|Completed||Phase 2/Phase 3|25|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:34:19.763817|2018-06-01 02:34:19.763817
NCT00595920|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2014-01-13||2016-02-16|2008-01-04|2008-01-16|Estimate|2016-02-16|2016-03-15|Estimate||||2016-02-16|2016-03-15|Estimate|November 2007||2007-11-30|February 2014|2014-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|OLTERMS|Randomized and received at least one dose.|Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis|An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00|Terminated||Phase 2|116|Actual|Opexa Therapeutics, Inc.||1||Financial Constraints|f||||t||||||||||2018-06-01 02:34:13.235994|2018-06-01 02:34:13.235994
NCT00595907|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-01-07|2008-01-07|2008-01-16|Estimate|||||||2008-01-07|2008-01-16|Estimate|October 2004||2004-10-31|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis|Observational Study of Production of IFN-Gamma by Peripheral Lymphocytes in Response to Specific Antigens Before and After Treatment for Tuberculosis|Completed|||89|Actual|University Hospital, Geneva|||||f||||t||||||Samples Without DNA|"~     Peripheral blood lymphocytes cultured over-night; ELISPOT for detection of interferon-gamma~     production~   "|||2018-06-01 02:34:13.437637|2018-06-01 02:34:13.437637
NCT00595894|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2013-06-18|2008-01-07|2008-01-16|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2004||2004-07-31|March 2011|2011-03-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Observational|||Rheumatoid Arthritis Comorbidity: Bone Health in Men and African Americans|RA Comorbidity: Bone Health in Men and African Americans|Completed|||1745|Actual|University of Nebraska|||2||f||||t||||||Samples With DNA|"~     Baseline sera and DNA collected~   "|||2018-06-01 02:34:13.496487|2018-06-01 02:34:13.496487
NCT00595881|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2011-07-13||2012-12-27|2008-01-07|2008-01-16|Estimate|2012-12-11|2012-12-27|Estimate||||2012-12-27|2012-12-31|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections|Emergency Bedside Ultrasound for the Evaluation of Soft Tissue Infections in the Pediatric Emergency Department|Completed|||420|Actual|Children's Hospital of Philadelphia|"Potential misclassification of lesions based on reference standard. Biased lesion outcome, as ultrasound results were not incorporated into patient care.~Single institution"||1||f||||f||||||||||2018-06-01 02:34:13.568492|2018-06-01 02:34:13.568492
NCT00595868|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2011-09-07||2011-11-22|2008-01-15|2008-01-16|Estimate|2011-10-20|2011-11-22|Estimate||||2011-11-22|2011-12-02|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy of Varenicline in Ambivalent Smokers|Efficacy of Varenicline in Ambivalent Smokers|Completed||Phase 2|220|Actual|University of Vermont Medical Center||2|||f||||f||||||||||2018-06-01 02:34:13.743833|2018-06-01 02:34:13.743833
NCT00595855|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-01-07|2008-01-07|2008-01-16|Estimate|||||||2008-01-07|2008-01-16|Estimate|October 1997||1997-10-31|January 2008|2008-01-31|December 2006|Actual|2006-12-31|January 2007|Actual|2007-01-31||Interventional|||A Comparison Between Deep Sclerectomy and Trabeculectomy|Deep Sclerectomy Versus Trabeculectomy. A 7 Year Prospective Randomised Clinical Trial|Completed||N/A|70|Actual|University of Parma||2|||f||||f||||||||||2018-06-01 02:34:14.033076|2018-06-01 02:34:14.033076
NCT00595842|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-03-07|2008-01-15|2008-01-16|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Artificial Root-End Barriers|Clinical Success of Artificial Root-End Barriers With Mineral Trioxide Aggregate in Teeth With Immature Apices|Completed|||10|Actual|The University of Texas Health Science Center at San Antonio|||1||f||||f||||||||||2018-06-01 02:34:14.106005|2018-06-01 02:34:14.106005
NCT00595829|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2015-08-19|2008-01-07|2008-01-16|Estimate|||||||2015-08-19|2015-08-21|Estimate|December 2007||2007-12-31|August 2015|2015-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Phase 1 Study of XL019 in Adults With Polycythemia Vera|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera|Terminated||Phase 1|3|Actual|Exelixis||1|||f||||||||||||||2018-06-01 02:34:14.168587|2018-06-01 02:34:14.168587
NCT00595816|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-01-04|2008-01-04|2008-01-16|Estimate|||||||2008-01-04|2008-01-16|Estimate|July 2007||2007-07-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|VASTE||Injury Prevention Among Conscripts|Prevention of Musculoskeletal Injuries in Finnish Conscripts. A Cluster Randomized Controlled Trial.|Completed||N/A|800|Anticipated|UKK Institute||1|||f||||t||||||||||2018-06-01 02:34:14.242246|2018-06-01 02:34:14.242246
NCT00595790|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-12-05||2014-04-09|2008-01-04|2008-01-16|Estimate|2014-02-07|2014-03-26|Estimate||||2014-04-09|2014-04-29|Estimate|September 2005||2005-09-30|April 2014|2014-04-30|November 2007|Actual|2007-11-30|February 2006|Actual|2006-02-28||Interventional|||Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51|Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis|Completed||Phase 3|374|Actual|Valneva Austria GmbH||3|||f||||f||||||||||2018-06-01 02:34:14.365967|2018-06-01 02:34:14.365967
NCT00595777|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-09-25|2008-01-15|2008-01-16|Estimate|||||||2012-09-25|2012-09-26|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|EPAT©||Edinburgh Pain Assessment Tool (EPAT©) Study|Does the Institutionalisation of Pain Assessment Using the EPAT© Package Reduce the Pain in Cancer In-patients More Than Usual Care; a Cluster Randomised Trial.|Completed||N/A|1928|Actual|University of Edinburgh||2|||f||||t||||||||||2018-06-01 02:34:14.62383|2018-06-01 02:34:14.62383
NCT00595764|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|2013-07-18||2014-09-30|2008-01-15|2008-01-16|Estimate|2014-09-30|2014-10-06|Estimate||||2014-09-30|2014-10-06|Estimate|August 2005||2005-08-31|September 2014|2014-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Counseling for Primary Care Office-based Buprenorphine|Counseling for Primary Care Office-based Buprenorphine|Completed||Phase 4|141|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:34:14.719958|2018-06-01 02:34:14.719958
NCT00595751|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-07-29|2008-01-15|2008-01-16|Estimate|||||||2008-07-29|2008-07-30|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|NEBA||NeuroLex EEG-Based ADHD Assessment Aid, Pivotal Study|Best Estimate Diagnosis Used to Evaluate EEG in Association With ADHD in a Multi-Site, Clinical Sample of Children and Adolescents|Completed|||300|Anticipated|Lexicor Medical Technology, LLC|||||f||||f||||||||||2018-06-01 02:34:14.983867|2018-06-01 02:34:14.983867
NCT00595738|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2011-07-19|2008-01-07|2008-01-16|Estimate|||||||2011-07-19|2011-07-20|Estimate|December 2007||2007-12-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Observational|||Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Heart Failure|Use of Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Patients With Advanced Heart Failure|Completed|||30|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples Without DNA|"~     We will be banking serum collected from peripheral blood draws, and blood draws from a~     pulmonary artery catheter and arterial line.~   "|||2018-06-01 02:34:15.047853|2018-06-01 02:34:15.047853
NCT00595725|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2011-09-07|2008-01-15|2008-01-16|Estimate|||||||2011-09-07|2011-09-08|Estimate|February 2003||2003-02-28|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma|Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma|Completed||N/A|151|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:34:15.103159|2018-06-01 02:34:15.103159
NCT00595712|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-05|||2010-05-22|2008-01-05|2008-01-16|Estimate|||||||2010-05-22|2010-05-25|Estimate|September 2007||2007-09-30|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2008|Actual|2008-02-29||Interventional|||Results of Opening-wedge High Tibial Osteotomy Using Iliac Crest Allograft Compared to Iliac Crest Autograft||Completed||Phase 3|40|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:34:15.246365|2018-06-01 02:34:15.246365
NCT00595699|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03||2010-05-25|2011-07-14|2008-01-15|2008-01-16|Estimate||||2011-06-21|2011-06-29|Estimate|2011-07-14|2011-07-18|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy|Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy. A Double-blind, Placebo-controlled Study.|Completed||Phase 4|8|Actual|Conrad, Erich J., M.D.||2|||f||||f||||||||||2018-06-01 02:34:15.306176|2018-06-01 02:34:15.306176
NCT00595686|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-05-15|2008-01-07|2008-01-16|Estimate|||||||2012-05-15|2012-05-17|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies|A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies|Completed||Phase 1|25|Actual|Esanex Inc.||1|||f||||f||||||||||2018-06-01 02:34:15.381595|2018-06-01 02:34:15.381595
NCT00595673|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-07-01|2008-01-07|2008-01-16|Estimate|||||||2008-07-01|2008-07-03|Estimate|July 2002||2002-07-31|July 2008|2008-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007||Completed||Phase 3|428|Actual|Point Biomedical|||||f||||t||||||||||2018-06-01 02:34:15.454776|2018-06-01 02:34:15.454776
NCT00595660|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-01-15|2008-01-15|2008-01-16|Estimate|||||||2008-01-15|2008-01-16|Estimate|February 2008||2008-02-29|January 2008|2008-01-31||||February 2010|Anticipated|2010-02-28||Interventional|||Best Needle Size for FNA of Palpable Breast Mass:Randomised Controlled Study|Best Needle Size for FNA of Palpable Breast Mass:Randomised Controlled Study|Unknown status|Not yet recruiting|N/A|250|Anticipated|Kashani Social Security Hospital||4|||f||||f||||||||||2018-06-01 02:34:15.557989|2018-06-01 02:34:15.557989
NCT00595647|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2015-04-19|2008-01-15|2008-01-16|Estimate|||||||2015-04-19|2015-04-21|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BASKET-SAVAGE||Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions|BAsel Stent Kosten Effektivitäts Trial - SAphenous Venous Graft Angioplasty Using Glycoprotein IIb/IIIa Receptor Inhibitors and Drug-Eluting Stents|Terminated||Phase 4|162|Actual|University Hospital, Basel, Switzerland||2||insufficient enrollment|f||||t||||||||||2018-06-01 02:34:15.640233|2018-06-01 02:34:15.640233
NCT00595634|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2014-03-31|2008-01-04|2008-01-16|Estimate|||||||2014-03-31|2014-04-01|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|INTUIT||INTUIT Hip Fracture Outcome Study|Intramedullary Nailing for Treatment of Unstable InterTrochanteric (INTUIT) Hip Fracture Outcome Study.|Terminated|||92|Actual|Smith & Nephew, Inc.||||Could not power primary endpoint due to lost to follow-up rate|f||||f||||||||||2018-06-01 02:34:15.774403|2018-06-01 02:34:15.774403
NCT00595621|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2015-05-01|2008-01-15|2008-01-16|Estimate|||||||2015-05-01|2015-05-05|Estimate|February 2006||2006-02-28|May 2015|2015-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis|Multi-Channel Gastric Electrical Stimulation for the Treatment of Gastroparesis|Completed||N/A|22|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 02:34:15.85723|2018-06-01 02:34:15.85723
NCT00595608|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-01-15|2008-01-15|2008-01-16|Estimate|||||||2008-01-15|2008-01-16|Estimate|February 2008||2008-02-29|December 2007|2007-12-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Sterimar vs Saline Sprays in Nasal Surgical Aftercare - a Blinded, Randomised Trial|Sterimar vs Saline Sprays in Nasal Surgical Aftercare - a Blinded, Randomised Trial|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|NHS Grampian||2|||f||||t||||||||||2018-06-01 02:34:15.959823|2018-06-01 02:34:15.959823
NCT00595595|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-09-14|2008-01-15|2008-01-16|Estimate|||||||2012-09-14|2012-09-17|Estimate|February 2007||2007-02-28|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Development of a Model to Evaluate Regenerative Endodontic Techniques Using Extract Human Teeth|Development of a Model to Evaluate Regenerative Endodontic Techniques|Completed|||1080|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||Samples With DNA|"~     extracted teeth 10ml of blood for DNA banking~   "|||2018-06-01 02:34:16.043722|2018-06-01 02:34:16.043722
NCT00595582|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2011-10-11||2012-05-25|2008-01-15|2008-01-16|Estimate|2012-05-25|2012-05-28|Estimate||||2012-05-25|2012-05-28|Estimate|May 2005||2005-05-31|May 2012|2012-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine|Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine|Terminated||N/A|10|Actual|Louisiana State University Health Sciences Center Shreveport|2 patients withdrew due to Dyspepsia (intolerance to supplement).|1||For various reasons.|f||||f||||||||||2018-06-01 02:34:16.129648|2018-06-01 02:34:16.129648
NCT00595569|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2008-01-15|2008-01-15|2008-01-16|Estimate|||||||2008-01-15|2008-01-16|Estimate|April 2002||2002-04-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Flexible, Intensive Insulin Therapy in Patients With Type 1 Diabetes|Flexible, Intensive Insulin Management in Patients With Type 1 Diabetes and Changes in Metabolic Control, Quality of Life, Locus of Control and Diabetes Knowledge|Completed|||45|Actual|University of Lausanne Hospitals|||1||f||||f||||||||||2018-06-01 02:34:16.286723|2018-06-01 02:34:16.286723
NCT00595556|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-06|2010-05-15||2010-09-28|2008-01-06|2008-01-16|Estimate|2010-09-28|2010-10-15|Estimate||||2010-09-28|2010-10-15|Estimate|July 2006||2006-07-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Zonisamide vs. Placebo in the Treatment of Alcohol Dependence|Zonisamide vs. Placebo in the Treatment of Alcohol Dependence|Completed||Phase 4|40|Actual|UConn Health|The small sample size and the short duration of treatment are limitations. High rates of retention in the treatment and adherence to the medication regimen are strengths. The concomitant psychotherapy may have caused a ceiling effect on medication.|2|||f||||f||||||||||2018-06-01 02:34:16.370095|2018-06-01 02:34:16.370095
NCT00595530|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2015-07-27||2016-02-29|2008-01-07|2008-01-16|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Unfortunately, there was a lack of interest for enrollment and this study never reached a reportable effect size. It was closed for this reason.|Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain|Use of Low-Dose Ketamine Infusion in Acute Painful Episodes of Sickle Cell Disease: A Pilot Study|Terminated||Phase 2|3|Actual|Connecticut Children's Medical Center||1||Lack of enrollment and patient interest in study|f||||t||||||||No|There is no plan to share data as the low enrollment makes the results of this study non-generalizable.|2018-06-01 02:34:16.757964|2018-06-01 02:34:16.757964
NCT00595517|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2010-08-04||2012-08-20|2008-01-15|2008-01-16|Estimate|2012-08-20|2012-09-14|Estimate||||2012-08-20|2012-09-14|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer|A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use|Completed||Phase 3|395|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:34:16.966328|2018-06-01 02:34:16.966328
NCT00595504|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2012-04-26||2012-08-14|2008-01-15|2008-01-16|Estimate|2012-08-14|2012-09-13|Estimate||||2012-08-14|2012-09-13|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia|Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia|Completed||Phase 4|25|Actual|Massachusetts General Hospital|The limitations of this study include the relatively small sample size and short intervention period (8 weeks).|2|||f||||t||||||||||2018-06-01 02:34:17.186462|2018-06-01 02:34:17.186462
NCT00595491|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2017-09-14|2008-01-15|2008-01-16|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2008||2008-01-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation|Inflammatory Cellular Trafficking in Asthma in Response to Segmental Allergen Challenge|Recruiting||Phase 1|313|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:34:17.452875|2018-06-01 02:34:17.452875
NCT00595478|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2017-10-30||2018-03-01|2008-01-15|2008-01-16|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-01|2018-03-29|Actual|August 2007||2007-08-31|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Family Based Contingency Management for Adolescent Alcohol Abuse|Family Based Contingency Management for Adolescent Alcohol Abuse|Completed||N/A|75|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||No||2018-06-01 02:34:17.535791|2018-06-01 02:34:17.535791
NCT00595465|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2012-06-01||2014-05-05|2008-01-15|2008-01-16|Estimate|2012-10-19|2012-11-20|Estimate||||2014-05-05|2014-05-16|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51|Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.|Completed||Phase 3|389|Actual|Valneva Austria GmbH||3|||f||||f||||||||||2018-06-01 02:34:17.883312|2018-06-01 02:34:17.883312
NCT00595439|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-06-30|2008-01-05|2008-01-16|Estimate|||||||2017-06-30|2017-07-02|Actual|December 21, 2007||2007-12-21|October 5, 2009|2009-10-05||||October 5, 2009|Actual|2009-10-05||Observational|||Association Between Focal Dystonia and Complex Regional Pain Syndrome|The Association Between Focal Dystonia (FD) and Complex Regional Pain Syndrome (CRPS)|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:34:18.283295|2018-06-01 02:34:18.283295
NCT00595426|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07||2010-05-26|2013-03-19|2008-01-07|2008-01-16|Estimate||||2010-05-26|2010-05-28|Estimate|2013-03-19|2013-03-25|Estimate|May 2008||2008-05-31|May 2010|2010-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PEARL||A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery|A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty|Completed||Phase 2|685|Actual|Astellas Pharma Inc||5|||f||||t||||||||||2018-06-01 02:34:18.364798|2018-06-01 02:34:18.364798
NCT00595413|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2016-01-19||2016-01-19|2008-01-15|2008-01-16|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|September 2007||2007-09-30|January 2016|2016-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|AUGUST II|Intention-to-treat (ITT) population included all randomized participants who received at least 1 study treatment dose.|Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)|A Randomised, Double-blind, Placebo Controlled, Multi-centre Phase II Study of Atacicept in Anti-TNFα-naïve Patients With Moderate to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate|Completed||Phase 2|311|Actual|EMD Serono||4|||f||||f||||||||||2018-06-01 02:34:18.576134|2018-06-01 02:34:18.576134
NCT00595387|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2015-04-28|2008-01-04|2008-01-16|Estimate|||||||2015-04-28|2015-04-29|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|January 2013|Actual|2013-01-31|September 2011|Actual|2011-09-30||Interventional|||Effectiveness of Cognitive Behavioral Therapy for Treating Depression in People With Bipolar I Disorder|Cognitive-Behavior Therapy for Bipolar Disorder|Completed||N/A|54|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:34:19.149545|2018-06-01 02:34:19.149545
NCT00595374|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2017-02-22|2008-01-07|2008-01-16|Estimate|||||||2017-02-22|2017-02-24|Actual|December 2, 2003|Actual|2003-12-02|February 2017|2017-02-28|October 7, 2004|Actual|2004-10-07|October 7, 2004|Actual|2004-10-07||Interventional|||Efficacy and Safety of Insulin Detemir in Type 1 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart to Insulin NPH Plus Insulin Aspart in Adults With Type 1 Diabetes Mellitus|Completed||Phase 3|114|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:34:19.248772|2018-06-01 02:34:19.248772
NCT00595361|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2014-07-16||2017-05-15|2008-01-07|2008-01-16|Estimate|2014-07-16|2014-08-08|Estimate||||2017-05-15|2017-06-08|Actual|January 2008||2008-01-31|May 2017|2017-05-31|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|SECS||How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment|The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma|Completed||N/A|30|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 02:34:19.366132|2018-06-01 02:34:19.366132
NCT00595348|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-06|||2011-05-09|2008-01-15|2008-01-16|Estimate|||||||2011-05-09|2011-05-11|Estimate|November 2007||2007-11-30|May 2011|2011-05-31|May 2017|Anticipated|2017-05-31|May 2012|Anticipated|2012-05-31||Observational|KOHBRA||Korean Hereditary Breast Cancer Study|Korean Hereditary Breast Cancer Study|Unknown status|Recruiting||2250|Anticipated|Korean Breast Cancer Study Group|||||f||||t||||||Samples With DNA|"~     DNA, Serum, plasma, Whole blood~   "|||2018-06-01 02:34:19.659512|2018-06-01 02:34:19.659512
NCT00595322|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2017-05-22|2008-01-07|2008-01-16|Estimate|||||||2017-05-22|2017-05-23|Actual|December 2005|Actual|2005-12-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma|Safety of Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma: A Pilot Study|Completed||N/A|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:34:20.210594|2018-06-01 02:34:20.210594
NCT00595309|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2012-05-24||2014-05-05|2008-01-04|2008-01-16|Estimate|2012-05-24|2012-06-27|Estimate||||2014-05-05|2014-05-16|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51|Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 on Long Term Immunogenicity. An Uncontrolled, Open-label Phase 3 Study.|Completed||Phase 3|198|Actual|Valneva Austria GmbH||1|||f||||f||||||||||2018-06-01 02:34:20.283393|2018-06-01 02:34:20.283393
NCT00595296|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2016-01-11|2008-01-04|2008-01-16|Estimate|||||||2016-01-11|2016-01-12|Estimate|December 2007||2007-12-31|January 2016|2016-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study|GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study|Terminated|||461|Actual|Janssen Diagnostics, LLC|||1|GeneSearch™ BLN Assay has been voluntarily withdrawn from the US market.|f||||f||||||Samples With DNA|"~     Samples of the lymph node tissue homogenate and RNA extract are collected if the subject~     gives permission via the informed consent form.~   "|||2018-06-01 02:34:20.500806|2018-06-01 02:34:20.500806
NCT00595283|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2013-03-20|2008-01-04|2008-01-16|Estimate|||||||2013-03-20|2013-03-22|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Effectiveness of Parent-Child Interaction and Emotion Development Therapy in Treating Preschool Children With Depression|Early Intervention in Depression: Dyadic Emotion Development Therapy for Preschool Children|Completed||N/A|38|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 02:34:20.593692|2018-06-01 02:34:20.593692
NCT00595270|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-12-05||2014-02-05|2008-01-04|2008-01-16|Estimate|2014-02-05|2014-03-07|Estimate||||2014-02-05|2014-03-07|Estimate|October 2005||2005-10-31|February 2014|2014-02-28|April 2009|Actual|2009-04-30|September 2007|Actual|2007-09-30||Interventional|||Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51|Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51|Completed||Phase 3|349|Actual|Valneva Austria GmbH||1|||f||||f||||||||||2018-06-01 02:34:20.670357|2018-06-01 02:34:20.670357
NCT00595257|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-03-08|2008-01-15|2008-01-16|Estimate|||||||2012-03-08|2012-03-09|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Feasability Study of Autologous Bone Marrow Aspirate Concentrate for Treatment of CLI|Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Non Reconstructable Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease|Completed||Phase 1/Phase 2|60|Actual|Harvest Technologies||2|||f||||f||||||||||2018-06-01 02:34:20.976589|2018-06-01 02:34:20.976589
NCT00595244|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-07-01|2008-01-07|2008-01-16|Estimate|||||||2008-07-01|2008-07-03|Estimate|July 2002||2002-07-31|July 2008|2008-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease|CSP 127-006 A Phase 3 Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive Technology Using PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Arter Disease|Completed||Phase 3|456|Actual|Point Biomedical|||||f||||t||||||||||2018-06-01 02:34:21.045059|2018-06-01 02:34:21.045059
NCT00595231|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07||2009-12-03|2018-01-03|2008-01-15|2008-01-16|Estimate||||2009-12-03|2009-12-07|Estimate|2018-01-03|2018-01-05|Actual|March 2008||2008-03-31|February 2014|2014-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)|A Multi-Center,Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients With Moderate to Severe Generalized Anxiety Disorder|Completed||Phase 2|239|Actual|Biotie Therapies Inc.||2|||f||||f||||||||||2018-06-01 02:34:22.068988|2018-06-01 02:34:22.068988
NCT00595218|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-07-21|2008-01-04|2008-01-16|Estimate|||||||2017-07-21|2017-07-25|Actual|April 2006||2006-04-30|July 2017|2017-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Patient Preference Survey for Radiation Oncologists|How Can Radiation Oncologists Better Serve Their Patients? A Randomized Study to Determine Whether Radiation Oncologists Can Improve Patient Satisfaction by Attempting to Meet Their Patients' Preferences|Completed||N/A|500|Actual|University of Pittsburgh||2|||f||||||||||||||2018-06-01 02:34:22.145072|2018-06-01 02:34:22.145072
NCT00595205|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2012-03-15|2008-01-04|2008-01-16|Estimate|||||||2012-03-15|2012-03-19|Estimate|January 2008||2008-01-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Intussusception Surveillance After Rotarix Introduction in Mexico|Post-Authorization Safety Study (PASS) of Post-Marketing Surveillance for Intussusception Following Rotarix™ Introduction Into the Instituto Mexicano Del Seguro Social (IMSS) in Mexico|Completed|||786|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 02:34:22.222252|2018-06-01 02:34:22.222252
NCT00595179|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2012-04-04|2008-01-05|2008-01-16|Estimate|||||||2012-04-04|2012-04-06|Estimate|December 2007||2007-12-31|April 2012|2012-04-30|January 2012|Actual|2012-01-31|||||Observational|||Intraperative Assessment of Renal Perfusion Using Infrared Imaging|Intraoperative Assessment of Renal Perfusion Using Infrared Imaging|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:34:22.290012|2018-06-01 02:34:22.290012
NCT00595166|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2016-04-04|2008-01-15|2008-01-16|Estimate|||||||2016-04-04|2016-04-06|Estimate|June 2007||2007-06-30|April 2016|2016-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Using a Sheathed Speculum to Visualize and Access the Cervix in Women With Excessive Vaginal Tissue|Using a Sheathed Speculum to Visualize and Access the Cervix in Women With Excessive Vaginal Tissue|Terminated|||38|Actual|University of South Florida|||1|Design changed to observational, not RCT. PI left USF; study closed.|f||||f||||||||||2018-06-01 02:34:22.34098|2018-06-01 02:34:22.34098
NCT00595153|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2013-09-25||2013-12-05|2008-01-15|2008-01-16|Estimate|2013-12-05|2014-01-20|Estimate||||2013-12-05|2014-01-20|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|MAST||Study of the Mechanisms of Asthma|Determining Mechanisms of Asthma Through Detailed Analysis of Airway Secretions and Tissues|Completed||Phase 1|127|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-06-01 02:34:22.409941|2018-06-01 02:34:22.409941
NCT00595140|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-03-31|2008-01-07|2008-01-16|Estimate|||||||2008-03-31|2008-04-01|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Acute Application of Pegvisomant and Octreotide in Acromegaly|The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment|Completed||Phase 4|10|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-06-01 02:34:22.749774|2018-06-01 02:34:22.749774
NCT00595127|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2015-12-22||2016-06-29|2008-01-15|2008-01-16|Estimate|2016-06-29|2016-08-10|Estimate||||2016-06-29|2016-08-10|Estimate|June 2001||2001-06-30|June 2016|2016-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine|A Pilot Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine|Completed||N/A|21|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:34:22.874322|2018-06-01 02:34:22.874322
NCT00595114|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2016-05-23||2016-09-04|2008-01-07|2008-01-16|Estimate|2016-05-26|2016-07-06|Estimate||||2016-09-04|2016-10-19|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease|Ancillary Study of Oxidative Stress and Anti-Inflammatory Lipids in Airway Disease in the MIA (ACRN) and LEUKO (CCRN) Trials|Completed|||43|Actual|Brigham and Women's Hospital|||6||f||||t||||||Samples With DNA|"~     Blood and sputum samples with DNA~   "|||2018-06-01 02:34:23.121873|2018-06-01 02:34:23.121873
NCT00595101|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04||2013-11-20|2013-11-20|2008-01-15|2008-01-16|Estimate||||2013-11-20|2013-12-13|Estimate|2013-11-20|2013-12-13|Estimate|December 2007||2007-12-31|November 2013|2013-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.|A Phase 2, 28-Day Parallel-Group, Double-Masked, Dose Finding Study Comparing The Safety And Efficacy Of PF-03187207 To Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.|Completed||Phase 2|128|Actual|Bausch & Lomb Incorporated||4|||f||||f||||||||||2018-06-01 02:34:23.475841|2018-06-01 02:34:23.475841
NCT00595088|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2013-06-16||2014-07-16|2008-01-07|2008-01-16|Estimate|2013-06-16|2013-08-21|Estimate||||2014-07-16|2014-07-24|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|January 2013|Actual|2013-01-31||Interventional|||Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer|Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer|Unknown status|Active, not recruiting|Phase 2|47|Actual|BioCancell Ltd.||1|||f||||f||||||||||2018-06-01 02:34:23.5987|2018-06-01 02:34:23.5987
NCT00595075|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2010-07-22||2012-10-24|2008-01-15|2008-01-16|Estimate|2012-09-12|2012-10-12|Estimate||||2012-10-24|2012-10-30|Estimate|December 2007||2007-12-31|October 2012|2012-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Ramelteon for a Nap Prior to a Night Shift|Effects of Ramelteon on Sleep and Neurobehavioral Performance in a Simulated Night Shift Preceded by a Sleep Opportunity|Completed||N/A|11|Actual|Brigham and Women's Hospital|Circadian phase was not measured.|2|||f||||f||||||||||2018-06-01 02:34:23.810613|2018-06-01 02:34:23.810613
NCT00595062|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2015-12-21|2008-01-15|2008-01-16|Estimate|||||||2015-12-21|2015-12-22|Estimate|October 2002||2002-10-31|December 2015|2015-12-31|July 2013|Actual|2013-07-31|January 2006|Actual|2006-01-31||Interventional|||Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study|Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study|Completed||N/A|51|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:34:24.124033|2018-06-01 02:34:24.124033
NCT00595049|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2015-04-28|2008-01-07|2008-01-16|Estimate|||||||2015-04-28|2015-04-30|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|December 2008|Actual|2008-12-31||Interventional|||Pulmonary Artery Remodelling With Bosentan|Open Label, Non Comparative Study to Investigate the Effect of Bosentan on Pulmonary Artery Remodelling in Pulmonary Arterial Hypertension (PAH).|Completed||Phase 4|11|Actual|Actelion||1|||f||||||||||||||2018-06-01 02:34:24.294745|2018-06-01 02:34:24.294745
NCT00595023|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2016-01-11|2008-01-04|2008-01-16|Estimate|||||||2016-01-11|2016-01-12|Estimate|December 2007||2007-12-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||GeneSearch Breast Lymph Node (BLN) Assay Timing Study|GeneSearch Breast Lymph Node (BLN) Assay Timing Study|Terminated|||233|Actual|Janssen Diagnostics, LLC|||1|GeneSearch™ BLN Assay has been voluntarily withdrawn from the US market.|f||||f||||||||||2018-06-01 02:34:24.382903|2018-06-01 02:34:24.382903
NCT00595010|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2016-06-08|2008-01-04|2008-01-16|Estimate|||||||2016-06-08|2016-06-09|Estimate|September 2007||2007-09-30|June 2016|2016-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effectiveness of a Multi-Component Evidence-Based Parent Training Program in Reducing Child Maltreatment|Developing Multi-Component Evidence Based Practice in Child Abuse Service Systems|Completed||Phase 1|26|Actual|University of Oklahoma||1|||f||||t||||||||No||2018-06-01 02:34:24.463325|2018-06-01 02:34:24.463325
NCT00594997|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2015-07-29|2008-01-15|2008-01-16|Estimate|||||||2015-07-29|2015-07-31|Estimate|April 2004||2004-04-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|March 2008|Actual|2008-03-31||Interventional|||A School-Based Intervention to Reduce Lyme Disease|A School-Based Intervention to Reduce Lyme Disease|Unknown status|Active, not recruiting|N/A|4101|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:34:24.538547|2018-06-01 02:34:24.538547
NCT00594984|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07||2015-09-23|2015-10-12|2008-01-15|2008-01-16|Estimate||||2015-09-23|2015-10-09|Estimate|2015-10-12|2015-11-04|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase I/II Combination With Irinotecan- Erbitux|A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs Placebo in Combination With Erbitux and Irinotecan K-Ras Wildtype Subjects With Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|38|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 02:34:24.628321|2018-06-01 02:34:24.628321
NCT00594971|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2011-01-10|2008-01-15|2008-01-16|Estimate|||||||2011-01-10|2011-01-11|Estimate|April 2008||2008-04-30|January 2011|2011-01-31|November 2010|Anticipated|2010-11-30|October 2009|Anticipated|2009-10-31||Interventional|||A Shared Care Approach for Seriously Ill Cancer Patients Between General Practice, Discharge Department and a Specialist Palliative Care Team|A Shared Care Approach for Seriously Ill Cancer Patients Between General Practice, Discharge Department and a Specialist Palliative Care Team|Withdrawn||N/A|270|Anticipated|University of Aarhus||3||"Recruitment problems has forced us to change the design of this study from a clinical trial to~   a comparative study of 3 different groups of patients."|f||||t||||||||||2018-06-01 02:34:24.736287|2018-06-01 02:34:24.736287
NCT00594958|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-12-05||2016-03-29|2008-01-15|2008-01-16|Estimate|2013-12-05|2014-01-23|Estimate||||2016-03-29|2016-05-04|Estimate|September 2006||2006-09-30|March 2016|2016-03-31|September 2007|Actual|2007-09-30|April 2007|Actual|2007-04-30||Interventional||Safety population, i.e. subjects who received at least one vaccination|Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51|Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.|Completed||Phase 3|639|Actual|Valneva Austria GmbH||3|||f||||f||||||||||2018-06-01 02:34:24.834128|2018-06-01 02:34:24.834128
NCT00594945|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2013-06-26||2014-05-29|2008-01-07|2008-01-16|Estimate|2014-05-29|2014-07-01|Estimate||||2014-05-29|2014-07-01|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional||There were 9 subjects total and 2 subjects were enrolled in both Cohorts.|Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures|A Phase 2a, Open-label,Proof -Of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures|Completed||Phase 2|45|Actual|Jazz Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:34:25.205024|2018-06-01 02:34:25.205024
NCT00594932|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2012-12-26|2008-01-04|2008-01-16|Estimate|||||||2012-12-26|2012-12-27|Estimate|November 2006||2006-11-30|December 2012|2012-12-31|April 2009|Actual|2009-04-30|July 2008|Actual|2008-07-31||Interventional|||Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis|Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis|Completed||N/A|27|Actual|Oklahoma Medical Research Foundation||3|||f||||f||||||||||2018-06-01 02:34:25.572222|2018-06-01 02:34:25.572222
NCT00594919|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2009-02-03|2008-01-15|2008-01-16|Estimate|||||||2009-02-03|2009-02-04|Estimate|October 2007||2007-10-31|February 2009|2009-02-28||||||||Observational|||Neutrophil Gelatinase-Associated Lipocalin: Biomarker of Acute Kidney Injury After Cardiac Surgery|Neutrophil Gelatinase-Associated Lipocalin(NGAL): Early Biomarker of Acute Kidney Injury After Cardiac Surgery|Unknown status|Recruiting||150|Anticipated|Hospital de Base|||2||f||||f||||||||||2018-06-01 02:34:25.665814|2018-06-01 02:34:25.665814
NCT00594906|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2012-10-24||2014-12-03|2008-01-07|2008-01-16|Estimate|2013-03-14|2013-04-24|Estimate||||2014-12-03|2014-12-19|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Use of Teriparatide to Accelerate Fracture Healing|Use of Teriparatide to Accelerate Fracture Healing|Terminated||N/A|10|Actual|University of Rochester|Early termination leading to small numbers of subjects analyzed.|2||The study was terminated due to poor enrollment.|f||||f||||||||||2018-06-01 02:34:25.7362|2018-06-01 02:34:25.7362
NCT00594893|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-08-29|2008-01-07|2008-01-16|Estimate|||||||2012-08-29|2012-08-31|Estimate|June 2006||2006-06-30|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study Comparing Mini-Incision Versus 2-Incision Approach for Total Hip Replacement|A Prospective Randomized Trial of Mini Incision and 2-Incision Total Hip Arthroplasty|Completed||N/A|72|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 02:34:25.983183|2018-06-01 02:34:25.983183
NCT00594880|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-01-24||2015-01-28|2008-01-15|2008-01-16|Estimate|2015-01-28|2015-02-10|Estimate||||2015-01-28|2015-02-10|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection|Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection|Completed||Phase 2|23|Actual|The Wistar Institute|"The follwing limitations of this study should be noted:~Small number of participants enrolled~Lack of a control arm interrupting ART without immunotherapy"|2|||f||||t||||||||||2018-06-01 02:34:26.084025|2018-06-01 02:34:26.084025
NCT00594867|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-01-04|2008-01-04|2008-01-16|Estimate|||||||2008-01-04|2008-01-16|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|December 2007|Actual|2007-12-31||Interventional|||The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers|Does Acetaminophen Potentiate the Gastroduodenal Mucosal Injury of Aspirin? A Prospective, Randomized, Pilot Study.|Completed||Phase 4|94|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-06-01 02:34:26.598495|2018-06-01 02:34:26.598495
NCT00594854|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-05-28||2010-08-27|2008-01-15|2008-01-16|Estimate|2010-08-27|2010-09-22|Estimate||||2010-08-27|2010-09-22|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec|6-Month, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study of Gastric Ulcer Incidence With PN400 (Esomeprazole/Naproxen) Versus Diclofenac/Misoprostol in Subjects at High Risk for Developing NSAID-Associated Ulcers|Terminated||Phase 3|20|Actual|POZEN|Early termination due to small number of subjects.|2||POZEN agreed with FDA to stop study due to low and inadequate enrollment|f||||t||||||||||2018-06-01 02:34:26.694042|2018-06-01 02:34:26.694042
NCT00594841|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2016-12-06|2008-01-15|2008-01-16|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ACJoint||Non-operative Versus Operative Treatment of Acute Acromioclavicular Joint Dislocation|A Multicenter Randomized Clinical Trial of Non-operative Versus Operative Treatment of Acute Acromioclavicular Joint Dislocation|Completed||N/A|83|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-06-01 02:34:26.983701|2018-06-01 02:34:26.983701
NCT00594828|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-01-07|2008-01-07|2008-01-16|Estimate|||||||2008-01-07|2008-01-16|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|April 2008|Anticipated|2008-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Patient Self Testing of Warfarin Therapy|Randomized Controlled Trial of Patient Self-Testing of Warfarin Therapy Using an Internet Based Expert System|Unknown status|Active, not recruiting|Phase 4|163|Actual|University College Cork||2|||f||||f||||||||||2018-06-01 02:34:27.069906|2018-06-01 02:34:27.069906
NCT00594815|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2017-02-13||2017-04-03|2008-01-15|2008-01-16|Estimate|2017-04-03|2017-04-06|Actual||||2017-04-03|2017-04-06|Actual|August 28, 2002||2002-08-28|April 2017|2017-04-30|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Interventional|||Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|Completed||N/A|52|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||f||||||||||2018-06-01 02:34:27.167084|2018-06-01 02:34:27.167084
NCT00594802|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2010-08-05|2008-01-15|2008-01-16|Estimate|||||||2010-08-05|2010-08-09|Estimate|August 2006||2006-08-31|July 2008|2008-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|chackos||Systemic Reactions to Allergen Immunotherapy Amd Skin Testing|Systemic Reactions to Allergen Immunotherapy Amd Skin Testing|Completed|||100|Anticipated|University of South Florida|||1||f||||f||||||||||2018-06-01 02:34:27.40309|2018-06-01 02:34:27.40309
NCT00594789|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2017-10-24|2008-01-15|2008-01-16|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2008||2008-06-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|March 2011|Actual|2011-03-31||Interventional|||Closing The Post Fracture Care Gap In Manitoba|Closing The Post Fracture Care Gap In Manitoba|Active, not recruiting||N/A|4264|Actual|University of Manitoba||3|||f||||f||||||||||2018-06-01 02:34:27.480987|2018-06-01 02:34:27.480987
NCT00594776|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2016-02-08|2008-01-07|2008-01-16|Estimate|||||||2016-02-08|2016-02-09|Estimate|November 2006||2006-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Vascular CT Assessment of Structural Autograft and Allograft Healing|Vascular CT Assessment of Structural Autograft and Allograft Healing|Completed|||8|Actual|University of Rochester|||1||f||||f||||||||||2018-06-01 02:34:27.575361|2018-06-01 02:34:27.575361
NCT00594763|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2008-01-31|2008-01-15|2008-01-16|Estimate|||||||2008-01-31|2008-02-01|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|April 2008|Anticipated|2008-04-30|April 2008|Anticipated|2008-04-30||Observational|||Venous Thrombosis in Turner Syndrome|The Risk of Venous Thrombosis in Women With Turner Syndrome|Unknown status|Active, not recruiting||60|Anticipated|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:34:27.644386|2018-06-01 02:34:27.644386
NCT00594750|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2016-06-01|2008-01-15|2008-01-16|Estimate|||||||2016-06-01|2016-06-02|Estimate|May 2006||2006-05-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|MECA||Mechanisms of Exacerbation of Asthma|Mechanisms of Exacerbation of Asthma|Recruiting|||115|Anticipated|University of California, San Francisco|||1||f||||f||||||Samples Without DNA|"~     Sputum, whole blood~   "|||2018-06-01 02:34:27.71061|2018-06-01 02:34:27.71061
NCT00594737|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-06-01|2008-01-07|2008-01-16|Estimate|||||||2012-06-01|2012-06-04|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia|An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia|Completed||Phase 3|17|Actual|Rotman Research Institute at Baycrest|||||f||||t||||||||||2018-06-01 02:34:27.792244|2018-06-01 02:34:27.792244
NCT00594724|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2014-06-11|2008-01-15|2008-01-16|Estimate|||||||2014-06-11|2014-06-12|Estimate|November 2002||2002-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging|Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging|Completed||N/A|99|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:34:27.894721|2018-06-01 02:34:27.894721
NCT00594711|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2011-10-28|2008-01-15|2008-01-16|Estimate|||||||2011-10-28|2011-10-31|Estimate|January 2000||2000-01-31|October 2011|2011-10-31|December 2008|Actual|2008-12-31|||||Observational|||Monoamine Transporter Function and Autonomic Regulation During Psychodynamic Psychotherapy||Completed|||26|Actual|Kuopio University Hospital|||2||f||||t||||||Samples With DNA|"~     DNA, creatine, B-vitamin,BP from blood samples.~   "|||2018-06-01 02:34:27.980394|2018-06-01 02:34:27.980394
NCT00594698|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-07-01|2008-01-04|2008-01-16|Estimate|||||||2008-07-01|2008-07-03|Estimate|February 2002||2002-02-28|January 2008|2008-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Familiarization and Safety Study of PB127 Ultrasound Contrast Agent|A Familiarization and Safety Study of Myocardial Perfusion Contrast Echocardiography With PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Artery Disease|Completed||Phase 2/Phase 3|150|Actual|Point Biomedical|||||f||||t||||||||||2018-06-01 02:34:28.060564|2018-06-01 02:34:28.060564
NCT00594685|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2009-10-01||2013-03-11|2008-01-07|2008-01-16|Estimate|2010-02-22|2010-03-09|Estimate||||2013-03-11|2013-03-13|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|HOT||Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)|HIT Observational Thromboembolism Study (A TMH CTN Study)|Terminated|||10|Actual|New England Research Institutes|Early termination of study due to low enrollment. Due to the early termination, the central laboratory tests necessary for analyzing outcomes 11, 12, and 13 were not performed.||1|Low accrual rate|f||||t||||||Samples With DNA|"~     Serum, plasma, and packed cells will be retained at Day 1 and Day 35 (+/- 7 days)~   "|||2018-06-01 02:34:28.178561|2018-06-01 02:34:28.178561
NCT00594672|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2018-05-17|2008-01-04|2008-01-16|Estimate|||||||2018-05-17|2018-05-18|Actual|January 3, 2008||2008-01-03|February 14, 2018|2018-02-14||||||||Observational|||Age-Related Eye Disease Study (AREDS) Follow-Up|Age-Related Eye Disease Study (AREDS) and AREDS2 Follow-Up|Enrolling by invitation|||111|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:34:28.576388|2018-06-01 02:34:28.576388
NCT00594659|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2013-04-16||2013-12-03|2008-01-15|2008-01-16|Estimate|2013-12-03|2013-12-04|Estimate||||2013-12-03|2013-12-04|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Development and Efficacy Test of Computerized Treatment for Marijuana Dependence|Development and Efficacy Test of Computerized Treatment for Marijuana Dependence|Completed||N/A|75|Actual|Dartmouth-Hitchcock Medical Center||3|||f||||f||||||||||2018-06-01 02:34:28.652327|2018-06-01 02:34:28.652327
NCT00594646|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|2015-08-10||2015-08-10|2008-01-07|2008-01-16|Estimate|2015-08-10|2015-09-10|Estimate||||2015-08-10|2015-09-10|Estimate|February 2008||2008-02-29|August 2015|2015-08-31|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|||HIV Non Occupational Post-Exposure Prophylaxis (PEP)|A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1|Completed||Phase 4|100|Actual|Fenway Community Health|"Limitations of the current study included:~Reliance on self-reports to measure adherence~Study population almost exclusively male (reflecting the demographics of people who call Fenway Health's hotline after an acute sexual exposure)"|1|||f||||f||||||||||2018-06-01 02:34:28.971999|2018-06-01 02:34:28.971999
NCT00594633|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2016-01-13|2008-01-07|2008-01-16|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2004||2004-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors|Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors|Completed||Phase 1|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:34:29.172497|2018-06-01 02:34:29.172497
NCT00594620|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2011-05-10|2008-01-14|2008-01-15|Estimate|||||||2011-05-10|2011-05-11|Estimate|August 2004||2004-08-31|May 2011|2011-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy|A Prospective Trial of Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy|Completed||Phase 2|11|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 02:34:29.245749|2018-06-01 02:34:29.245749
NCT00594607|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2011-07-03|2008-01-14|2008-01-15|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2004||2004-09-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Nephral 400 ST Dialysis Membrane on Coagulation in Hemodialysis|A Comparing Study of Nephral 400 ST and Fx8 Dialysis Membranes on Coagulation During Hemodialysis|Completed||N/A|12|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 02:34:29.309817|2018-06-01 02:34:29.309817
NCT00594425|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2013-03-14||2013-08-07|2008-01-14|2008-01-15|Estimate|2013-08-07|2013-08-08|Estimate||||2013-08-07|2013-08-08|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne||Completed||Phase 2|150|Actual|Photocure||3|||f||||f||||||||||2018-06-01 02:34:36.611999|2018-06-01 02:34:36.611999
NCT00594594|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2009-07-06|2008-01-14|2008-01-15|Estimate|||||||2009-07-06|2009-07-07|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury|A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled Trial for Efficacy in the Use of Adjuntive Probiotic Therapy in Reducing Urinary Tract Infections in Those Individual With Spinal Cord Injury|Terminated||Phase 1|2|Actual|Lawson Health Research Institute||1||Unable to recruit enough patients to continue on with the study.|f||||t||||||||||2018-06-01 02:34:29.376556|2018-06-01 02:34:29.376556
NCT00594581|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2008-01-02|2008-01-02|2008-01-15|Estimate|||||||2008-01-02|2008-01-15|Estimate|October 2003||2003-10-31|January 2008|2008-01-31|March 2005|Actual|2005-03-31|||||Interventional|||Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males|A Single-Site, Double-Blind, Phase II Trial to Investigate the Safety, Toleration, Systemic Exposure and Anti-Scarring Potential of Different Applications of Intradermal Juvista (Avotermin) in Male Subjects Aged 18-45 Years|Completed||Phase 2|71|Actual|Renovo||2|||f||||f||||||||||2018-06-01 02:34:29.443408|2018-06-01 02:34:29.443408
NCT00594568|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-11|2013-11-06|2011-08-09|2015-03-13|2008-01-11|2008-01-15|Estimate|2014-09-22|2014-09-25|Estimate|2011-08-09|2011-08-15|Estimate|2015-03-13|2015-03-17|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of LY450139 on the Long Term Progression of Alzheimer's Disease|Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo|Completed||Phase 3|1537|Actual|Eli Lilly and Company|Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.|3|||f||||t||||||||||2018-06-01 02:34:29.643459|2018-06-01 02:34:29.643459
NCT00594555|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-10-29|2008-01-14|2008-01-15|Estimate|||||||2008-10-29|2008-10-31|Estimate|November 2007||2007-11-30|October 2008|2008-10-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia|A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Acute Myeloid Leukemia|Withdrawn||Phase 2|20|Anticipated|University of Cincinnati||1||"Principal Investigator resigned position with the University of Cincinnati, closing study at~   this site will reopen study in new position"|f||||f||||||||||2018-06-01 02:34:34.249672|2018-06-01 02:34:34.249672
NCT00594542|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-01-03|2008-01-03|2008-01-15|Estimate|||||||2008-01-03|2008-01-15|Estimate|June 2007||2007-06-30|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of the Total Dose and Efficacy of Two Lidocaine Concentrations Needed for Cutaneous Surgery Local Anesthesia|A Randomized, Double Blind Comparison of the Total Dose of 1.0% Lidocaine With 1:100,000 Epinephrine Versus 0.5% Lidocaine With 1:200,000 Epinephrine Needed to Achieve Effective Anesthesia During Mohs Micrographic Surgery|Completed||N/A|149|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:34:35.183931|2018-06-01 02:34:35.183931
NCT00594529|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2011-06-22|2008-01-14|2008-01-15|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|May 2013|Anticipated|2013-05-31|May 2010|Actual|2010-05-31||Interventional|||Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers||Unknown status|Recruiting|Phase 2|27|Anticipated|Kyoto University||1|||f||||||||||||||2018-06-01 02:34:35.276796|2018-06-01 02:34:35.276796
NCT00594516|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2009-04-28||2015-03-26|2008-01-03|2008-01-15|Estimate|2010-07-01|2010-07-26|Estimate||||2015-03-26|2015-04-15|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain|A Randomized, Double-Blind, 2-Period, Crossover Study to Establish the Dose Equivalence and Direct Conversion Between Immediate Release (IR) and Extended-Release (ER) CG5503 in Subjects With Moderate-to-Severe, Chronic Low Back Pain|Completed||Phase 3|117|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 02:34:35.374437|2018-06-01 02:34:35.374437
NCT00594503|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2017-04-16|2008-01-14|2008-01-15|Estimate|||||||2017-04-16|2017-04-18|Actual|January 2007||2007-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Traumatic Brain Injury|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Traumatic Brain Injury|Recruiting||Phase 1|45|Anticipated|Louisiana State University Health Sciences Center in New Orleans||1|||f||||f||||||||No||2018-06-01 02:34:35.632941|2018-06-01 02:34:35.632941
NCT00594490|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2012-11-11|2008-01-14|2008-01-15|Estimate|||||||2012-11-11|2012-11-14|Estimate|January 2001||2001-01-31|November 2012|2012-11-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||Evaluating the Effectiveness and Outcomes of Silicone Breast Prosthetics|Adjunct Study for Silicone Gel-Filled Mammary Prosthesis|Active, not recruiting|||20|Actual|University of California, Irvine|||1||f||||t||||||||||2018-06-01 02:34:35.72233|2018-06-01 02:34:35.72233
NCT00594477|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-08-08|2008-01-14|2008-01-15|Estimate|||||||2017-08-08|2017-08-10|Actual|January 4, 2008|Actual|2008-01-04|August 2017|2017-08-31|August 8, 2016|Actual|2016-08-08|August 8, 2016|Actual|2016-08-08||Interventional|IMRT||Intensity Modulated Radiotherapy for Breast Cancer|Intensity Modulated Radiation Therapy for Breast Cancer: A Phase I Feasibility Study|Completed||Phase 1|100|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-06-01 02:34:35.795273|2018-06-01 02:34:35.795273
NCT00594464|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-05-11||2014-09-24|2008-01-03|2008-01-15|Estimate|2009-05-11|2009-07-03|Estimate||||2014-09-24|2014-10-02|Estimate|September 2007||2007-09-30|December 2010|2010-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|NEUPOS||A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery|An Explorative, Multicenter, Open-label Pilot Trial With Neupro® (Rotigotine Transdermal Patch) Once Daily Treatment Administered Perioperatively in Patients With Idiopathic Parkinson's Disease|Completed||Phase 4|14|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:34:36.000812|2018-06-01 02:34:36.000812
NCT00594451|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-06-18|2008-01-03|2008-01-15|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|January 2013|Actual|2013-01-31|April 2010|Actual|2010-04-30||Observational|||Gene-Environment Interactions in Rheumatoid Arthritis Autoimmunity Disease Severity|Gene-Environment Interactions in RA Autoimmunity Disease Severity|Completed|||800|Actual|University of Nebraska|||2||f||||t||||||Samples With DNA|"~     All subjects will provide baseline serum and DNA.~   "|||2018-06-01 02:34:36.365402|2018-06-01 02:34:36.365402
NCT00594438|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-11-23|2008-01-02|2008-01-15|Estimate|||||||2013-11-23|2013-11-26|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|RIA||Randomized, Prospective Comparison of Two Femoral Reaming Systems|Randomized, Prospective Comparison of Two Femoral Reaming Systems|Completed||N/A|20|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:34:36.467823|2018-06-01 02:34:36.467823
NCT00594412|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2017-06-30|2008-01-03|2008-01-15|Estimate|||||||2017-06-30|2017-07-02|Actual|December 20, 2007||2007-12-20|June 15, 2011|2011-06-15|June 15, 2011|Actual|2011-06-15|July 1, 2010|Actual|2010-07-01||Interventional|||MRI to Measure Liver Fat Content|Validation of (1)H-Magnetic Resonance Spectroscopy for Quantification of Hepatic Triglyceride Content|Completed||N/A|53|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:34:37.715912|2018-06-01 02:34:37.715912
NCT00594399|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2014-10-01||2015-04-06|2008-01-14|2008-01-15|Estimate|2015-01-08|2015-01-09|Estimate||||2015-04-06|2015-04-27|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional||The average age of the sample was 67 year with a range of 60 to 89. Participant were in a normal usual walking speed for their ages but were at the 10th percentile in norms for six-minute walk distance indicating poor aerobic capacity for their age.|Enhancing Fitness in Older Pre-diabetic Veterans|Enhancing Fitness in Older Overweight Vets With Impaired Fasting Glucose|Completed||Phase 2/Phase 3|302|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:34:37.924907|2018-06-01 02:34:37.924907
NCT00594386|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|2009-11-16||2014-09-24|2008-01-14|2008-01-15|Estimate|2009-11-16|2009-12-18|Estimate||||2014-09-24|2014-10-02|Estimate|August 2002||2002-08-31|September 2010|2010-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|SP715||An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease|An Open-Label Extension to the Double-Blind SP650 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease.|Completed||Phase 3|258|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:34:39.479166|2018-06-01 02:34:39.479166
NCT00594373|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2013-09-23|2008-01-02|2008-01-15|Estimate|||||||2013-09-23|2013-09-24|Estimate||||September 2013|2013-09-30|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women|Effect of Repeated Applications of Tenofovir Gel on Mucosal Mediators of Immunity and Intrinsic Antimicrobial Activity of Cervicovaginal Secretions in Women at Low Risk for HIV-1 Infection|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 02:34:40.14667|2018-06-01 02:34:40.14667
NCT00594360|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-03|2008-01-03|2008-01-15|Estimate|||||||2008-01-03|2008-01-15|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|EoP||Evaluation of Effect of Exercise on Prescription - a Psychological Perspective|Exercise on Prescription: Effects and Comparison of Psychological Parameters Physical Activity, Physical Fitness, and Health Physical Between Participants in a Danish Version of Exercise on Prescription.|Unknown status|Active, not recruiting|Phase 2/Phase 3|200|Anticipated|University of Southern Denmark||1|||f||||t||||||||||2018-06-01 02:34:40.227303|2018-06-01 02:34:40.227303
NCT00594347|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-06-16|2008-01-14|2008-01-15|Estimate|||||||2015-06-16|2015-06-18|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|April 2009|Actual|2009-04-30|March 2008|Actual|2008-03-31||Interventional|||Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar|Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal Vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed With Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) in Thailand.|Completed||Phase 3|339|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:34:40.303768|2018-06-01 02:34:40.303768
NCT00594334|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2009-02-25|2008-01-14|2008-01-15|Estimate|||||||2009-02-25|2009-02-26|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|January 2011|Anticipated|2011-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Effect of Actonel on Periodontal Health of Postmenopausal Women|Effect of Actonel on Periodontal Health of Postmenopausal Women|Unknown status|Recruiting|Phase 4|240|Anticipated|University Hospitals Cleveland Medical Center||1|||t||||f||||||||||2018-06-01 02:34:40.402093|2018-06-01 02:34:40.402093
NCT00594321|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-08-31|2008-01-14|2008-01-15|Estimate|||||||2012-08-31|2012-09-03|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|EFFECTS||Evaluation of Fracture Fixation With Energy and Cement in Tumors of the Spine|Evaluation of Fracture Fixation With Energy and Cement in Tumors of the Spine|Withdrawn||N/A|0|Actual|University of California, Davis||2||Sponsor closed the trial before it began|f||||t||||||||||2018-06-01 02:34:40.48829|2018-06-01 02:34:40.48829
NCT00594308|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2011-08-05||2014-09-26|2008-01-04|2008-01-15|Estimate|2012-03-16|2012-03-20|Estimate||||2014-09-26|2014-10-06|Estimate|October 2007||2007-10-31|September 2014|2014-09-30||||October 2008|Actual|2008-10-31||Interventional|||In-Vivo Activated T-Cell Depletion to Prevent GVHD|In-Vivo Activated T-Cell Depletion to Prevent GVHD|Terminated||N/A|10|Actual|Indiana University|Four patients experienced grade 3-4 GVHD and this study was stopped.|||Treatment ineffective|f||||t||||||||||2018-06-01 02:34:40.570276|2018-06-01 02:34:40.570276
NCT00594295|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2015-10-01|2008-01-03|2008-01-15|Estimate|||||||2015-10-01|2015-10-05|Estimate|June 2007||2007-06-30|April 2010|2010-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Follow-up of Bone Quality in Long-Term Bone Marrow Transplant Survivors|Follow-up of Bone Quality in Long-Term Bone Marrow Transplant Survivors|Completed|||15|Anticipated|University of Wisconsin, Madison|||||f||||f||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-06-01 02:34:40.755043|2018-06-01 02:34:40.755043
NCT00594282|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-09-10|2008-01-14|2008-01-15|Estimate|||||||2008-09-10|2008-09-12|Estimate|September 2005||2005-09-30|September 2008|2008-09-30||||July 2007|Actual|2007-07-31||Interventional|||Use of a Radiolucent Pad to Reduce Mammography Among African Americans|Use of a Radiolucent Pad to Reduce Mammography Among African Americans|Completed||N/A|300|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 02:34:40.811067|2018-06-01 02:34:40.811067
NCT00594269|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2011-02-22|2008-01-03|2008-01-15|Estimate|||||||2011-02-22|2011-02-23|Estimate|August 2008||2008-08-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|DESEP||Dementia Antipsychotics And Antidepressants Discontinuation Study|Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT.|Completed||Phase 4|149|Actual|Sykehuset Innlandet HF||1|||f||||t||||||||||2018-06-01 02:34:40.894378|2018-06-01 02:34:40.894378
NCT00594256|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2011-06-06||2016-01-05|2008-01-14|2008-01-15|Estimate|2016-01-05|2016-02-08|Estimate||||2016-01-05|2016-02-08|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Sodium Oxybate in Schizophrenia With Insomnia|Open Label, Pilot Study of Adjunctive Xyrem (Sodium Oxybate) for the Treatment of Schizophrenia and Associated Sleep Disturbances|Completed||Phase 2|8|Actual|Nathan Kline Institute for Psychiatric Research|Open Label Small sample|1|||f||||f||||||||||2018-06-01 02:34:41.02092|2018-06-01 02:34:41.02092
NCT00594243|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-14|2008-01-14|2008-01-15|Estimate|||||||2008-01-14|2008-01-15|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Feasibility of Mindfulness Meditation for Adults 65+ With Chronic Low Back Pain||Completed||Phase 2/Phase 3|37|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 02:34:41.21311|2018-06-01 02:34:41.21311
NCT00594230|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-08-22||2015-10-08|2008-01-02|2008-01-15|Estimate|2012-11-19|2012-12-19|Estimate||||2015-10-08|2015-11-13|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||LBH589 in Refractory Myelodysplastic Syndromes (MDS)|A Phase II Trial of LBH589 in Refractory Myelodysplastic Syndromes (MDS) Patients|Terminated||Phase 2|26|Actual|SCRI Development Innovations, LLC|Results of a planned interim analysis demonstrated that the regimen did not demonstrate sufficient evidence of efficacy necessary to justify further enrollment. Per protocol, the results of this analysis led to early termination of the study.|2||"Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and~   led to early termination of the study."|f||||f||||||||||2018-06-01 02:34:41.369712|2018-06-01 02:34:41.369712
NCT00594217|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2018-01-18|2008-01-04|2008-01-15|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2007||2007-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CRM001||Determining How Quickly Progesterone Slows LH Pulse Frequency|Determining the Rapidity With Which Exogenous P Suppresses Daytime LH (GnRH) Pulse Frequency in Women During the Follicular Phase of the Menstrual Cycle|Recruiting||Phase 1|72|Anticipated|University of Virginia||2|||f||||t|t|f||||||Undecided|We do not have current plans to share IPD|2018-06-01 02:34:41.683074|2018-06-01 02:34:41.683074
NCT00594204|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2010-05-27||2010-07-14|2008-01-14|2008-01-15|Estimate|2010-05-27|2010-07-05|Estimate||||2010-07-14|2010-07-20|Estimate|April 2008||2008-04-30|July 2010|2010-07-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Assessment of Safety and Efficacy of Varenicline in Patients That Wish to Stop Smoking|A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study With Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate (CP-526,555-18) 1 Mg Bid For Smoking Cessation (Protocol A3051080)|Completed||Phase 4|593|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:34:41.802632|2018-06-01 02:34:41.802632
NCT00594191|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-03|2008-01-03|2008-01-15|Estimate|||||||2008-01-03|2008-01-15|Estimate|March 2004||2004-03-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension|Phase IV-II Randomized, Multicenter, Placebo-Controlled Double-Blind Clinical Trial Evaluating the Effects of Continuous Simvastatin Administration on Hepatic and Systemic Hemodynamics in Patients With Cirrhosis.|Completed||Phase 2|59|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 02:34:42.255286|2018-06-01 02:34:42.255286
NCT00594178|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2010-10-01||2010-12-13|2008-01-03|2008-01-15|Estimate|2010-12-13|2011-01-13|Estimate||||2010-12-13|2011-01-13|Estimate|October 2003||2003-10-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|July 2008|Actual|2008-07-31||Interventional|||Palliative Strategies in Spinal Cord Injury (SCI)|Palliative Strategies in Spinal Cord Injury (SCI)|Completed||N/A|17|Actual|University of Arkansas|This was a pilot study to determine if a passive exercise bicycle would suppress the H-reflex after a spinal cord injury. We were not able to collect stable H-reflex data. However, the Dual-Energy X-ray Absortiometry (DEXA) scan data was useable.|1|||f||||f||||||||||2018-06-01 02:34:42.336805|2018-06-01 02:34:42.336805
NCT00594165|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|2009-11-06||2014-09-24|2008-01-03|2008-01-15|Estimate|2010-02-02|2010-02-25|Estimate||||2014-09-24|2014-10-02|Estimate|June 2002||2002-06-30|September 2010|2010-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|SP512OL||An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.|An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.|Completed||Phase 3|217|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:34:42.542801|2018-06-01 02:34:42.542801
NCT00594152|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-14|2008-01-14|2008-01-15|Estimate|||||||2008-01-14|2008-01-15|Estimate|January 1993||1993-01-31|January 2008|2008-01-31|January 1995|Actual|1995-01-31|||||Interventional|||Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)|Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)|Completed||Phase 3|71|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-06-01 02:34:43.079346|2018-06-01 02:34:43.079346
NCT00594139|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2015-11-02|2008-01-03|2008-01-15|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2008||2008-01-31|November 2015|2015-11-30||||||||Interventional|||Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence|An Open Label Multi-center Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence|Withdrawn||Phase 2|0|Actual|Tengion||1||Reprioritization of study programs|f||||t||||||||||2018-06-01 02:34:43.160972|2018-06-01 02:34:43.160972
NCT00594126|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2015-12-22|2008-01-03|2008-01-15|Estimate|||||||2015-12-22|2015-12-24|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma|A Phase 1 Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Refractory or Relapsed Multiple Myeloma|Completed||Phase 1|20|Actual|Geron Corporation||1|||f||||f||||||||||2018-06-01 02:34:43.224896|2018-06-01 02:34:43.224896
NCT00594113|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2012-06-18|2008-01-14|2008-01-15|Estimate|||||||2012-06-18|2012-06-20|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|May 2010|Actual|2010-05-31||Interventional|||"Touch 2 Screen Multi-media Colorectal Cancer Screening Intervention"|Tailored Touch-Screens for Colorectal Cancer Prevention in Urban Core Clinics|Completed||N/A|470|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 02:34:43.31187|2018-06-01 02:34:43.31187
NCT00594100|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-03-19||2013-12-02|2008-01-02|2008-01-15|Estimate|2009-03-19|2009-05-05|Estimate||||2013-12-02|2013-12-27|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|EMPiRE||GORE Embolic Protection With Reverse Flow|The Embolic Protection With Reverse Flow Study of the GORE Neuro Protection System in Carotid Stenting of Subjects At High Risk for Carotid Endarterectomy|Completed||Phase 3|245|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-06-01 02:34:43.392356|2018-06-01 02:34:43.392356
NCT00594087|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-12-31|2008-01-14|2008-01-15|Estimate|||||||2008-12-31|2009-01-05|Estimate|December 2006||2006-12-31|December 2008|2008-12-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)|Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime Fatigue|Completed||N/A|30|Actual|University of Vermont||2|||f||||t||||||||||2018-06-01 02:34:43.656812|2018-06-01 02:34:43.656812
NCT00594074|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2013-07-23|2008-01-04|2008-01-15|Estimate|||||||2013-07-23|2013-07-25|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Alcohol in the Treatment of Obesity|Alcohol in the Treatment of Obesity|Terminated||N/A|18|Actual|Duke University||2||Unable to recruit subjects|f||||f||||||||||2018-06-01 02:34:43.73795|2018-06-01 02:34:43.73795
NCT00594061|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2017-10-26||2018-05-22|2008-01-03|2008-01-15|Estimate|2018-05-22|2018-05-23|Actual||||2018-05-22|2018-05-23|Actual|December 2007||2007-12-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Iowa/Nucleus 10/10 mm and Nucleus Freedom Feasibility Study|Iowa/Nucleus 10/10 mm and Nucleus Freedom Cochlear Implants Implanted Bilaterally in Children Ages 12-24 Months|Completed||N/A|9|Actual|University of Iowa||1|||f||||t||||||||||2018-06-01 02:34:43.80729|2018-06-01 02:34:43.80729
NCT00594048|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2011-10-25|2008-01-14|2008-01-15|Estimate|||||||2011-10-25|2011-10-26|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of Device-guided Breathing Exercises on Blood Pressure in Patients With Hypertension|The Effects of Device-guided Breathing Exercises on Blood Pressure in Patients With Hypertension. A Randomized, Single-blind, Controlled Trial|Completed||N/A|30|Anticipated|Medical Research Foundation, The Netherlands||2|||f||||f||||||||||2018-06-01 02:34:44.054974|2018-06-01 02:34:44.054974
NCT00594035|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2009-10-30||2017-08-07|2008-01-02|2008-01-15|Estimate|2009-10-30|2009-12-03|Estimate||||2017-08-07|2017-09-07|Actual|September 2005||2005-09-30|August 2017|2017-08-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Study to Evaluate Safety and Effectiveness of Spinal Sealant|A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery|Completed||N/A|158|Actual|Integra LifeSciences Corporation||2|||f||||t||||||||||2018-06-01 02:34:44.153675|2018-06-01 02:34:44.153675
NCT00594022|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2016-07-13||2016-07-13|2008-01-14|2008-01-15|Estimate|2016-07-13|2016-08-23|Estimate||||2016-07-13|2016-08-23|Estimate|October 2007||2007-10-31|July 2016|2016-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|VSOM||Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness|The Effect of Vestibular Stimulation on Transient Insomnia Induced by a Five-hour Phase Advance of Sleep Time|Completed||N/A|349|Actual|Philips Respironics||2|||f||||f||||||||||2018-06-01 02:34:44.48667|2018-06-01 02:34:44.48667
NCT00594009|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2015-09-08|2008-01-02|2008-01-15|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|VVCCO2R||Venovenous CO2 Removal in Patients With COPD and Acute Respiratory Failure|Safety and Efficacy of Venovenous Carbon Dioxide Removal in Patients With Chronic Obstructive Pulmonary Disease and Acute Respiratory Failure|Terminated||N/A|2|Actual|The University of Texas Medical Branch, Galveston||1||due to loss of key personnel due to illness and sabbatical of thePI|f||||f||||||||||2018-06-01 02:34:44.86184|2018-06-01 02:34:44.86184
NCT00593996|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2015-10-01|2008-01-03|2008-01-15|Estimate|||||||2015-10-01|2015-10-05|Estimate|July 2006||2006-07-31|May 2010|2010-05-31||||May 2010|Actual|2010-05-31||Interventional|||Evaluation of Potential Vitamin D Effects on Muscle: a Pilot Study|Evaluation of Potential Vitamin D Effects on Muscle: a Pilot Study|Completed||N/A|50|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 02:34:44.937229|2018-06-01 02:34:44.937229
NCT00593983|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2012-05-08|2008-01-02|2008-01-15|Estimate|||||||2012-05-08|2012-05-09|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials (the ACT2 Project)|Peer-Driven Intervention to Enroll Minorities/Women in HIV/AIDS Clinical Trials|Completed||Phase 2|540|Actual|New York University||2|||f||||f||||||||||2018-06-01 02:34:45.044858|2018-06-01 02:34:45.044858
NCT00593970|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2016-04-22|2008-01-14|2008-01-15|Estimate|||||||2016-04-22|2016-04-25|Estimate|November 2007||2007-11-30|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Influenza Vaccine in Pregnancy Part 2|Knowledge Possessed by Pregnant Women Regarding Influenza Vaccination During Pregnancy|Completed|||100|Actual|St. Michael's Hospital, Toronto|||1||f||||f||||||||||2018-06-01 02:34:45.122675|2018-06-01 02:34:45.122675
NCT00593957|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2013-03-08||2014-03-26|2008-01-04|2008-01-15|Estimate|2014-03-26|2014-04-23|Estimate||||2014-03-26|2014-04-23|Estimate|August 2004||2004-08-31|July 2013|2013-07-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Trial of Dextromethorphan in Rett Syndrome|Trial of Dextromethorphan in Rett Syndrome|Terminated||Phase 2|38|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|The trial was terminated due to the FDA requiring a placebo controlled trial instead of the ongoing open label trial. As recruitment was delayed,the total number of participants was also less than anticipated.|3||Study changed to a placebo controlled trial of dextromethorphan|f||||t||||||||||2018-06-01 02:34:45.219675|2018-06-01 02:34:45.219675
NCT00593944|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-05-21|2008-01-14|2008-01-15|Estimate|||||||2013-05-21|2013-05-22|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|MDX1342-02||Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase 1, Open-Label, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients With CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 1|15|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:34:45.669702|2018-06-01 02:34:45.669702
NCT00593931|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2017-05-25|2008-01-03|2008-01-15|Estimate|||||||2017-05-25|2017-05-30|Actual|May 1999||1999-05-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Development Of New Techniques For Functional Magnetic Resonance Imaging Of The Brain|Development Of New Techniques For Functional Magnetic Resonance Imaging Of The Brain|Terminated||N/A|215|Actual|University of California, Davis||1||Principal Investigator is deceased|f||||f||||||||||2018-06-01 02:34:45.785934|2018-06-01 02:34:45.785934
NCT00593918|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2009-06-19||2015-09-30|2008-01-14|2008-01-15|Estimate|2010-04-13|2010-05-13|Estimate||||2015-09-30|2015-10-20|Estimate|November 2003||2003-11-30|September 2015|2015-09-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Observational|IIRI||Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children|Innate Immunity and RSV Infection in Children|Completed|||91|Actual|University of Wisconsin, Madison|Subject withdraw before blood draw on second visit and small numbers recruited lead to small numbers of subjects analyzed.||2||f||||t||||||Samples With DNA|"~     Nasal samples Supernatant from Peripheral mononuclear cell stimulation cultures DNA~   "|||2018-06-01 02:34:45.861461|2018-06-01 02:34:45.861461
NCT00593905|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2012-01-20|2008-01-03|2008-01-15|Estimate|||||||2012-01-20|2012-01-24|Estimate|July 2005||2005-07-31|January 2012|2012-01-31|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Observational|||Pharmacogenomics in Pulmonary Arterial Hypertension|Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin Receptor Antagonists and Several Gene Polymorphisms in Several Key Disease-Specific and Therapy Specific Genes|Unknown status|Recruiting||1300|Anticipated|West Penn Allegheny Health System|||2||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 02:34:46.118313|2018-06-01 02:34:46.118313
NCT00593892|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-10-27|2008-01-03|2008-01-15|Estimate|||||||2013-10-27|2013-10-29|Estimate|May 2007||2007-05-31|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|Cytokine||Inflammatory Cytokine Variations in Traumatic Injury Responses|Cytokine Liberation From Secondary Surgery in the Setting of the Second Hit Syndrome|Completed|||90|Actual|University of Alabama at Birmingham|||1||f||||f||||||||||2018-06-01 02:34:46.25583|2018-06-01 02:34:46.25583
NCT00593879|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2008-01-02|2008-01-02|2008-01-15|Estimate|||||||2008-01-02|2008-01-15|Estimate|February 2005||2005-02-28|January 2008|2008-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder|A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of Mecamylamine 5.0 to 10 mg, in the Treatment of Major Depressive Disorder With Subjects Who Are Partial or Non- Responders to Citalopram Therapy.|Completed||Phase 2|450|Actual|Targacept Inc.||2|||f||||f||||||||||2018-06-01 02:34:46.318325|2018-06-01 02:34:46.318325
NCT00593866|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2014-08-12||2015-08-28|2008-01-14|2008-01-15|Estimate|2014-08-12|2014-08-27|Estimate||||2015-08-28|2015-09-11|Estimate|June 2006||2006-06-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|May 2012|Actual|2012-05-31||Interventional|||Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer|A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer|Completed||Phase 1/Phase 2|50|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 02:34:46.39125|2018-06-01 02:34:46.39125
NCT00593853|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2014-06-03|2008-01-14|2008-01-15|Estimate|||||||2014-06-03|2014-06-04|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy Study of Methylphenidate Hydrochloride to Reduce Fatigue in Prostate Cancer Patients Receiving Hormone Therapy|A Phase II, Randomized, Double-blind, Placebo Controlled Trial of Methylphenidate Hydrochloride for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH-Agonist Therapy|Terminated||Phase 2|33|Actual|University Health Network, Toronto||2||Slow Accrual|f||||t||||||||||2018-06-01 02:34:46.668943|2018-06-01 02:34:46.668943
NCT00593840|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2016-06-09||2018-05-02|2008-01-14|2008-01-15|Estimate|2017-04-27|2017-06-02|Actual||||2018-05-02|2018-05-04|Actual|April 2007||2007-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|February 2014|Actual|2014-02-28||Interventional|||Phase II Trial Evaluating Elimination of Radiation Therapy|Phase II Trial Evaluating Elimination of Radiation Therapy To Pathological N0 Neck(s) With Intensity Modulated Postoperative Radiation Therapy|Active, not recruiting||Phase 2|73|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:34:46.892856|2018-06-01 02:34:46.892856
NCT00593827|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2012-03-14||2016-02-09|2008-01-04|2008-01-15|Estimate|2012-04-25|2012-05-25|Estimate||||2016-02-09|2016-03-10|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer|Phase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients|Completed||Phase 2|176|Actual|R-Pharm||2|||f||||f||||||||||2018-06-01 02:34:47.315781|2018-06-01 02:34:47.315781
NCT00593814|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-04-20||2017-12-08|2008-01-03|2008-01-15|Estimate|2010-07-13|2010-08-23|Estimate||||2017-12-08|2018-01-08|Actual|June 2005||2005-06-30|December 2017|2017-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||GORE EXCLUDER® Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms|A Clinical Evaluation of the GORE EXCLUDER® Bifurcated Endoprosthesis - Low Permeability in the Primary Treatment of Infrarenal Abdominal Aortic Aneurysms|Completed||Phase 4|139|Actual|W.L.Gore & Associates|||||f||||f||||||||||2018-06-01 02:34:49.064299|2018-06-01 02:34:49.064299
NCT00593801|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-01-04|2008-01-04|2008-01-15|Estimate|||||||2008-01-04|2008-01-15|Estimate|May 1998||1998-05-31|January 2008|2008-01-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|EPO||Erythropoietin Treatment in Extremely Low Birth Weight Infants|Multicentre, Blinded, Randomised, Controlled Study on the Efficacy and Safety of Early or Late Epoetin Beta Treatment in Premature Infants (500- 999g Birth Weight)for Prevention or Treatment of Anaemia of Prematurity|Completed||N/A|219|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-06-01 02:34:49.240979|2018-06-01 02:34:49.240979
NCT00593788|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-14|2008-01-14|2008-01-15|Estimate|||||||2008-01-14|2008-01-15|Estimate|March 2003||2003-03-31|January 2008|2008-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Observational|||The Gaps-in-Noise Test: Gap Detection Thresholds in Normal-Hearing Young Adults|The Gaps-in-Noise Test: Gap Detection Thresholds in Normal-Hearing Young Adults|Completed|||100|Actual|University of Sao Paulo|||1||f||||f||||||||||2018-06-01 02:34:49.316076|2018-06-01 02:34:49.316076
NCT00593775|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-04-28|2008-01-14|2008-01-15|Estimate|||||||2017-04-28|2017-05-02|Actual|February 2006||2006-02-28|April 2017|2017-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Laser Assisted Hatching in Thawing Cycles: a Prospective Randomized Controlled Study|The Effect of Laser Assisted Hatching in Thawing Cycles: a Prospective Randomized Controlled Study|Completed||N/A|647|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 02:34:49.371227|2018-06-01 02:34:49.371227
NCT00593762|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2010-03-15|2008-01-14|2008-01-15|Estimate|||||||2010-03-15|2010-03-16|Estimate|May 2005||2005-05-31|January 2008|2008-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures|Investigation of Laboratory Resistance to Aspirin and Clopidogrel and Its Clinical Relevance in Patients With Peripheral Arterial Occlusive Disease Requiring Interventional Procedures|Suspended|||200|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-06-01 02:34:49.52633|2018-06-01 02:34:49.52633
NCT00593749|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-06-28|2008-01-14|2008-01-15|Estimate|||||||2013-06-28|2013-07-01|Estimate|September 2007||2007-09-30|January 2008|2008-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|HCSI||Healthy Corner Store Initiative|Healthy Corner Store Initiative|Completed||N/A|2000|Anticipated|Temple University||2|||f||||f||||||||||2018-06-01 02:34:49.610171|2018-06-01 02:34:49.610171
NCT00593736|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2009-07-31||2012-02-27|2008-01-02|2008-01-15|Estimate|2010-02-05|2010-03-09|Estimate||||2012-02-27|2012-02-28|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals With Delayed Sleep Phase Syndrome (DSPS)|Completed||Phase 2|132|Actual|Takeda||4|||f||||f||||||||||2018-06-01 02:34:49.868894|2018-06-01 02:34:49.868894
NCT00593723|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2016-04-03|2008-01-02|2008-01-15|Estimate|||||||2016-04-03|2016-04-05|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|IMRT||IMRT Tomotherapy for Esophagus Cancer|IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients|Completed||Phase 1|26|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:34:52.655655|2018-06-01 02:34:52.655655
NCT00593710|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2012-07-11|2008-01-03|2008-01-15|Estimate|||||||2012-07-11|2012-07-12|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|October 2010|Actual|2010-10-31||Interventional|||Losartan Versus Atenolol for the Treatment of Marfan Syndrome|A Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan Syndrome|Completed||Phase 2|17|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 02:34:52.716807|2018-06-01 02:34:52.716807
NCT00593697|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2015-03-05|2008-01-14|2008-01-15|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SOLD||The Synergism Or Long Duration (SOLD) Study|A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer|Completed||Phase 3|2168|Actual|Finnish Breast Cancer Group||2|||f||||t||||||||||2018-06-01 02:34:52.782382|2018-06-01 02:34:52.782382
NCT00593684|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2012-02-16||2017-06-09|2008-01-14|2008-01-15|Estimate|2015-03-24|2015-04-07|Estimate||||2017-06-09|2017-06-14|Actual|April 2006||2006-04-30|June 2017|2017-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Safety Evaluation of Silver Alginate (Algidex™) Dressing in Very Low Birth Weight (VLBW) Infants||Completed||N/A|50|Actual|Baylor Research Institute||2|||f||||||||||||||2018-06-01 02:34:52.938347|2018-06-01 02:34:52.938347
NCT00593671|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-01-14|2008-01-14|2008-01-15|Estimate|||||||2008-01-14|2008-01-15|Estimate|June 2002||2002-06-30|January 2008|2008-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Preimplantation Genetic Screening in Women Over 35 Year|Preimplantation Genetic Screening for Aneuploidy in Embryos After in Vitro Fertilization in Women Over 35: a Prospective Controlled Randomized Study.|Completed||N/A|100|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 02:34:53.283994|2018-06-01 02:34:53.283994
NCT00593658|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2015-03-06|2008-01-03|2008-01-15|Estimate|||||||2015-03-06|2015-03-09|Estimate|June 2004||2004-06-30|January 2008|2008-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome|Open Label Single Arm Pilot Study of Pentoxifylline in Advanced Hepatopulmonary Syndrome|Terminated||Phase 1|9|Actual|University of Alabama at Birmingham||1||Poor tolerability of drug and side effects|f||||t||||||||||2018-06-01 02:34:53.360445|2018-06-01 02:34:53.360445
NCT00593645|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2014-07-18||2014-09-05|2008-01-14|2008-01-15|Estimate|2014-09-05|2014-09-12|Estimate||||2014-09-05|2014-09-12|Estimate|November 2007||2007-11-30|September 2014|2014-09-30|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation|A Non-Myeloablative Conditioning Regimen for Allogeneic Transplantation With Clofarabine, Cytarabine, and Thymoglobulin for Myelodysplastic Syndrome and Acute Myeloid Leukemia|Terminated||Phase 2|7|Actual|Washington University School of Medicine|Enrollment was halted after 3 of the first 7 patients expired on days 15/26/32. Predefined early stopping rules were defined that if three deaths occurred in the first 11 patients then it was unlikely to achieve a low treatment-related mortality.|1||toxicities were worse than expected|f||||t||||||||||2018-06-01 02:34:53.470486|2018-06-01 02:34:53.470486
NCT00593632|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2017-03-07|2008-01-14|2008-01-15|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2008|Actual|2008-01-31|March 2017|2017-03-31|July 2013|Actual|2013-07-31|July 2011|Actual|2011-07-31||Interventional|||A Controlled Trial of High Dietary Fiber Intake on Serum Lipids|A Controlled Trial of High Dietary Fiber Intake on Serum Lipids|Completed||N/A|50|Actual|The Cleveland Clinic||1|||f||||f|f|f||||||No||2018-06-01 02:34:53.911173|2018-06-01 02:34:53.911173
NCT00593619|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2009-03-02|2008-01-14|2008-01-15|Estimate|||||||2009-03-02|2009-03-03|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Trial Comparing the Safety of Two Different Intravenous Iron Formulations|A Randomized Double-Blind Safety Comparison of Intravenous Iron Dextran Versus Iron Sucrose in an Adult Non-Hemodialysis Outpatient Population: A Pilot Study|Suspended||Phase 4|200|Anticipated|London Health Sciences Centre||2||Interim Analysis and review by Data Safety Monitoring Board|f||||t||||||||||2018-06-01 02:34:54.035842|2018-06-01 02:34:54.035842
NCT00593606|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2008-12-17||2014-09-24|2008-01-14|2008-01-15|Estimate|2009-04-01|2009-05-27|Estimate||||2014-09-24|2014-10-02|Estimate|July 2007||2007-07-31|October 2011|2011-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine|A Phase 3b, Open-Label, Multicenter Trial to Assess the Safety and Tolerability of Switching Korean Subjects From Ropinirole to the Rotigotine Transdermal System and Its Effect on Symptoms in Idiopathic Parkinson's Disease|Completed||Phase 3|124|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:34:54.202269|2018-06-01 02:34:54.202269
NCT00593593|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-10-13|2008-01-14|2008-01-15|Estimate|||||||2008-10-13|2008-10-15|Estimate|December 2004||2004-12-31|October 2008|2008-10-31||||||||Observational|||Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia|A Pharmacovigilance Study to Evaluate Safety of AVODART (Dutasteride) Administration 0,5 mg Once Daily, for 52 Weeks, in Subjects With Benign Prostate Hyperplasia|Completed|||1000||GlaxoSmithKline|||||f||||||||||||||2018-06-01 02:34:55.530276|2018-06-01 02:34:55.530276
NCT00593580|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2011-06-27|2008-01-14|2008-01-15|Estimate|||||||2011-06-27|2011-06-29|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|FOSAVANCE||Bone Health in Gynecologic Cancers-does FOSAVANCE Help?|The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies.|Completed||Phase 2|60|Anticipated|British Columbia Cancer Agency||2|||f||||t||||||||||2018-06-01 02:34:55.600149|2018-06-01 02:34:55.600149
NCT00593567|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2012-03-22|2008-01-14|2008-01-15|Estimate|||||||2012-03-22|2012-03-23|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer|A Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge Compared to Levofloxacin in Diabetic Patients With a Mild Infection of a Lower Extremity Skin Ulcer|Completed||Phase 2|70|Actual|Innocoll||2|||f||||f||||||||||2018-06-01 02:34:55.720694|2018-06-01 02:34:55.720694
NCT00593554|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2018-03-12||2018-03-12|2008-01-14|2008-01-15|Estimate|2018-03-12|2018-04-10|Actual||||2018-03-12|2018-04-10|Actual|August 7, 2007|Actual|2007-08-07|March 2018|2018-03-31|July 28, 2017|Actual|2017-07-28|August 27, 2016|Actual|2016-08-27||Interventional|||Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies|A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies|Terminated||Phase 2|9|Actual|Indiana University||2||Slow accrual|f||||t|t|f||||||||2018-06-01 02:34:55.841127|2018-06-01 02:34:55.841127
NCT00593541|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2017-05-24|2008-01-03|2008-01-15|Estimate|||||||2017-05-24|2017-05-30|Actual|May 1999||1999-05-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|CVMRI||Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging|Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging|Terminated|||42|Actual|University of California, Davis||||Principal Investigator is deceased|f||||f||||||||||2018-06-01 02:34:56.516872|2018-06-01 02:34:56.516872
NCT00523120|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2016-04-18|2007-08-28|2007-08-30|Estimate|||||||2016-04-18|2016-04-20|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Topical Voltaren in Otitis Externa|Topical Voltaren as an Alternative Treatment for Otitis Externa|Terminated||Phase 2|20|Actual|Sieff Medical Center||2|||f||||f||||||||||2018-06-01 02:57:50.564682|2018-06-01 02:57:50.564682
NCT00593528|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2015-04-08|2008-01-14|2008-01-15|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||PTFE Covered Stents Versus Naked Stents in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)|Randomized Study With Medico-economic Evaluation Comparing the Use of PTFE Covered Stents vs Naked Stent in the TIPS (Transjugular Intra-hepatic Porto-systemic Shunt)|Completed||N/A|138|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-06-01 02:34:56.607978|2018-06-01 02:34:56.607978
NCT00593515|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-03|2008-01-03|2008-01-15|Estimate|||||||2008-01-03|2008-01-15|Estimate|March 2000||2000-03-31|January 2008|2008-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Effects of Parental Behavior on Child Anxiety Regulation|Effects of Parental Behavior on Child Anxiety Regulation|Completed||Phase 2|40|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:34:56.731959|2018-06-01 02:34:56.731959
NCT00593502|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2009-06-18|2008-01-14|2008-01-15|Estimate|||||||2009-06-18|2009-06-19|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ETOPOM||Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age|A Double-Blind, Randomized, Placebo-Controlled Study of Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age|Completed||Phase 4|409|Actual|Hospital District of Southwestern Finland||2|||f||||t||||||||||2018-06-01 02:34:56.839799|2018-06-01 02:34:56.839799
NCT00593489|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2009-07-06|2008-01-04|2008-01-15|Estimate|||||||2009-07-06|2009-07-07|Estimate|July 2006||2006-07-31|July 2009|2009-07-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|AIM@GP||Advancing Insulin Prescribing in General Practice|Advancing INSIGHT Methods in General Practice|Unknown status|Active, not recruiting|N/A|240|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 02:34:56.933739|2018-06-01 02:34:56.933739
NCT00593476|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-06-28|2008-01-14|2008-01-15|Estimate|||||||2013-06-28|2013-07-01|Estimate|March 2007||2007-03-31|January 2008|2008-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|NS||Pilot Study to Assess Pre-packaged, Portion-controlled Meal Plan on Weight Loss|A Pilot Study to Assess the Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control|Completed||N/A|50|Actual|Temple University||2|||f||||f||||||||||2018-06-01 02:34:57.032413|2018-06-01 02:34:57.032413
NCT00593463|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2011-03-10|2008-01-04|2008-01-15|Estimate|||||||2011-03-10|2011-03-11|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|OMDD1||Drug Discrimination in Methadone-Maintained Humans Study 1|Drug Discrimination in Methadone-Maintained Humans Study 1|Completed||Phase 1|40|Anticipated|University of Arkansas||1|||f||||t||||||||||2018-06-01 02:34:57.106335|2018-06-01 02:34:57.106335
NCT00593450|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2012-06-18||2017-07-20|2008-01-03|2008-01-15|Estimate|2012-08-21|2012-08-30|Estimate||||2017-07-20|2017-08-21|Actual|February 2008|Actual|2008-02-29|July 2017|2017-07-31|April 2015|Actual|2015-04-30|December 2010|Actual|2010-12-31||Interventional|||Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial|Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial (CATT)|Completed||Phase 3|1208|Actual|University of Pennsylvania||4|||f||||t|t|f||||||Yes|Available at https://hyperprod.cceb.med.upenn.edu/catt/catt_index.php|2018-06-01 02:34:57.249755|2018-06-01 02:34:57.249755
NCT00593437|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2015-10-01|2008-01-14|2008-01-15|Estimate|||||||2015-10-01|2015-10-05|Estimate|February 2006||2006-02-28|April 2010|2010-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|Wildwood||T-score Comparability Between GE Lunar Prodigy and Norland Excel Densitometers|T-score Comparability Between GE Lunar Prodigy and Norland Excel Densitometers|Completed|||35|Anticipated|University of Wisconsin, Madison|||3||f||||f||||||||||2018-06-01 02:34:58.553978|2018-06-01 02:34:58.553978
NCT00593424|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2011-09-01|2008-01-14|2008-01-15|Estimate|||||||2011-09-01|2011-09-02|Estimate|August 2002||2002-08-31|September 2011|2011-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins|Effect of Changing the Diet to Low Fat/High Carbohydrate or High Monounsaturated Fat/Low Carbohydrate on Fasting and Post Fat Load Lipoproteins of Diabetics With Moderate Hypertriglyceridemia|Completed||N/A|15|Actual|University of Arkansas||2|||f||||f||||||||||2018-06-01 02:34:58.6056|2018-06-01 02:34:58.6056
NCT00593411|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2011-04-01|2008-01-14|2008-01-15|Estimate|||||||2011-04-01|2011-04-04|Estimate|June 2005||2005-06-30|April 2011|2011-04-30|June 2015|Anticipated|2015-06-30|||||Observational|MDAnalyze||Neurological Surgery & Affiliated Services De-Identified Clinical Outcomes Database|Neurological Surgery & Affiliated Services De-Identified Clinical Outcomes Database|Unknown status|Recruiting||10000|Anticipated|University of California, Irvine|||||f||||t||||||||||2018-06-01 02:34:58.752928|2018-06-01 02:34:58.752928
NCT00593398|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2010-12-12|2008-01-03|2008-01-15|Estimate|||||||2010-12-12|2010-12-14|Estimate|September 2008||2008-09-30|December 2010|2010-12-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Observational|||Malarial Immunity in Pregnant Cameroonian Women|Malarial Immunity in Pregnant Cameroonian Women|Unknown status|Recruiting||1376|Anticipated|University of Hawaii|||||f||||f||||||Samples With DNA|"~     Serum samples and biopsies of placental tissue~   "|||2018-06-01 02:34:58.856753|2018-06-01 02:34:58.856753
NCT00593385|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2018-02-12|2012-08-02|2018-04-13|2008-01-14|2008-01-15|Estimate|2018-04-13|2018-05-17|Actual|2012-08-02|2012-08-07|Estimate|2018-04-13|2018-05-17|Actual|October 2007||2007-10-31|April 2018|2018-04-30|May 2014|Actual|2014-05-31|August 2011|Actual|2011-08-31||Interventional|iCARUS|ITT population was assessed for baseline measures: this includes subjects who signed the written informed consent, enrolled in the study and met the study entry criteria.|Atrium iCAST Iliac Stent Pivotal Study|Atrium iCAST Iliac Stent Pivotal Study|Completed||N/A|165|Actual|Atrium Medical Corporation||1|||f||||t||||||||Undecided||2018-06-01 02:34:58.97158|2018-06-01 02:34:58.97158
NCT00593372|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2010-04-27||2016-11-17|2008-01-02|2008-01-15|Estimate|2010-07-16|2010-07-20|Estimate||||2016-11-17|2017-01-09|Estimate|August 2003||2003-08-31|November 2016|2016-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Treatment of Language and Memory in Patients With Alzheimer's Disease|Treatment of Language and Memory in Patients With Alzheimer's Disease: A Comparison Between Drug Therapy and Drug Therapy Plus Behavioral Intervention|Completed||Phase 1|11|Actual|University of Arkansas|Recruitment of participants was the major limitation of the trial. Alzheimer's patients at facility were asked to participate in so many studies, that participation in this one was challenging.|2|||f||||f||||||||||2018-06-01 02:34:59.832085|2018-06-01 02:34:59.832085
NCT00593359|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2016-02-19|2008-01-02|2008-01-15|Estimate|||||||2016-02-19|2016-02-23|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Intraocular Pressure During Spine Surgery|The Effect of Lactated Ringer's Solution Versus Albumin and the Alpha-2 Agonist Brimonidine Versus Placebo on Intraocular Pressure During Prone Spine Surgery|Completed|||60|Actual|The Cleveland Clinic|||4||f||||f||||||||||2018-06-01 02:35:00.065633|2018-06-01 02:35:00.065633
NCT00593346|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2015-04-13||2015-06-01|2008-01-02|2008-01-15|Estimate|2015-05-07|2015-05-29|Estimate||||2015-06-01|2015-06-29|Estimate|March 2004||2004-03-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Evaluation of Accelerated Partial Breast Brachytherapy|Evaluation of Accelerated Partial Breast Brachytherapy as the Sole Method of Radiation Therapy for Stage 0, 1 and II Lymph Node Negative Breast Carcinoma|Completed||N/A|151|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:35:00.153618|2018-06-01 02:35:00.153618
NCT00593333|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2013-09-05||2017-06-01|2008-01-02|2008-01-15|Estimate|2013-09-05|2013-11-11|Estimate||||2017-06-01|2017-06-05|Actual|June 2003||2003-06-30|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|TROCHNAIL||Intramedullary Nailing of the Femur:Trochanteric vs Piriformis Starting Portals|Intramedullary Nailing of the Femur: A Comparison of the Trochanteric and Piriformis Starting Portals|Completed||N/A|110|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:35:00.45745|2018-06-01 02:35:00.45745
NCT00593320|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2015-02-18||2015-02-18|2008-01-02|2008-01-15|Estimate|2015-02-18|2015-03-04|Estimate||||2015-02-18|2015-03-04|Estimate|September 2007||2007-09-30|February 2015|2015-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|SRS||Stereotactic Radiosurgery (SRS) for Spine Metastases|Stereotactic Radiosurgery (SRS) for One or Two Localized Spine Metastases|Terminated||N/A|2|Actual|Washington University School of Medicine||2||Due to low accrual|f||||f||||||||||2018-06-01 02:35:00.726613|2018-06-01 02:35:00.726613
NCT00593307|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-06-28|2008-01-14|2008-01-15|Estimate|||||||2013-06-28|2013-07-01|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|Breakfast||The Breakfast Study|The Effects of Low and High Glycemic Index Foods and Protein on Glycemic Response and Hunger|Completed||N/A|24|Actual|Temple University||4|||f||||f||||||||||2018-06-01 02:35:00.9971|2018-06-01 02:35:00.9971
NCT00593294|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|||2008-01-14|2008-01-14|2008-01-15|Estimate|||||||2008-01-14|2008-01-15|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Oral Contraceptive and Cardiovascular Risk in PCOS|Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women|Completed||Phase 4|150|Actual|Federico II University||3|||f||||f||||||||||2018-06-01 02:35:01.063732|2018-06-01 02:35:01.063732
NCT00593281|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-01-11|2008-01-11|2008-01-14|Estimate|||||||2008-01-11|2008-01-14|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|INFUSE||INFUSE Morphine Study|INcreased Flow Utilizing Subcutaneously Enabled Morphine (INFUSE-Morphine) With and Without Human Recombinant Hyaluronidase (HYLENEX) and Intravenously|Completed||Phase 3|13|Actual|Halozyme Therapeutics||3|||f||||f||||||||||2018-06-01 02:35:01.139499|2018-06-01 02:35:01.139499
NCT00593268|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2017-03-13|2008-01-02|2008-01-14|Estimate|||||||2017-03-13|2017-03-15|Actual|June 2004||2004-06-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|November 2015|Actual|2015-11-30||Observational|||Evaluation of Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage|Biological Markers of Vasospasm in Cerebral Spinal Fluid and Blood in Patients With Subarachnoid Hemorrhage|Active, not recruiting|||150|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     cerebrospinal fluid and blood~   "|Undecided||2018-06-01 02:35:01.215007|2018-06-01 02:35:01.215007
NCT00593255|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2016-12-21|2008-01-02|2008-01-14|Estimate|||||||2016-12-21|2016-12-22|Estimate|July 2004||2004-07-31|December 2016|2016-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes|A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficiency and Safety Profile of Insulin Aspart (NovoRapid®) and Human Soluble Insulin (Novolin® R) as Meal Related Insulin in a Three Times Daily Regimen With One Injection of Novolin® N at Bedtime in Chinese Type 1 and 2 Diabetics|Completed||Phase 4|220|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:35:01.342539|2018-06-01 02:35:01.342539
NCT00593242|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2017-03-20|2008-01-02|2008-01-14|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2008||2008-01-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy|Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy Study 1. Phase I Study of Feasibility and Safety.|Completed||Phase 1|52|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:35:01.418142|2018-06-01 02:35:01.418142
NCT00593229|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2013-06-18|2008-01-11|2008-01-14|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2007||2007-01-31|June 2013|2013-06-30||||October 2011|Actual|2011-10-31||Observational|||International Registry and Biorepository for TMA(Thrombotic Microangiopathy)|An Observational Study of All Forms of Thrombotic Microangiopathy in Pediatric Patients|Terminated|||6|Actual|Northwell Health|||4|study stopped at this site, as investigator left the institution|f||||f||||||Samples With DNA|"~     Serum, plasma, urine, and DNA~   "|||2018-06-01 02:35:01.479933|2018-06-01 02:35:01.479933
NCT00593216|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2011-06-21|2008-01-02|2008-01-14|Estimate|||||||2011-06-21|2011-06-23|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Diagnosis Of Vertigo With New Imaging|New Diagnosis Of Vestibular Vertigo With Functional MRI|Completed|||4|Actual|Boston University|||2||f||||f||||||||||2018-06-01 02:35:01.542638|2018-06-01 02:35:01.542638
NCT00593203|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2018-03-01|2008-01-02|2008-01-14|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2003||2003-05-31|March 2018|2018-03-31|December 2028|Anticipated|2028-12-31|December 2028|Anticipated|2028-12-31||Observational|||Brain Tissue Specimen Collection|Molecular Neurosurgical Tissue Bank|Enrolling by invitation|||2500|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     Brain Tissue, blood and cerebral spinal fluid~   "|No||2018-06-01 02:35:01.612359|2018-06-01 02:35:01.612359
NCT00593190|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2008-01-11|2008-01-11|2008-01-14|Estimate|||||||2008-01-11|2008-01-14|Estimate|January 2008||2008-01-31|January 2008|2008-01-31||||December 2008|Anticipated|2008-12-31||Interventional|||Intracameral Gas SF6 (Sulfur Hexafluoride) Injection for Acute Hydrops in Keratoconus||Unknown status|Recruiting|N/A|10|Anticipated|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-06-01 02:35:01.666967|2018-06-01 02:35:01.666967
NCT00593177|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-08-18|2008-01-11|2008-01-14|Estimate|||||||2008-08-18|2008-08-19|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis|A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of 0.10% or 0.05% PTH (1-34) Gel Versus Placebo Gel in the Treatment of Mild to Moderate Plaque Psoriasis.|Completed||Phase 2|61|Actual|Manhattan Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:35:02.808487|2018-06-01 02:35:02.808487
NCT00593164|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-08-23|2008-01-11|2008-01-14|Estimate|||||||2017-08-23|2017-08-25|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients With Intravenous Infusion of Magnesium Sulfate|Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients With Intravenous Infusion of Magnesium Sulfate|Withdrawn||Phase 2|0|Actual|Life Recovery Systems||2||Funding for study is currently unavailable.|f||||t|f|f||||||||2018-06-01 02:35:02.917292|2018-06-01 02:35:02.917292
NCT00593151|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2012-02-01|2008-01-02|2008-01-14|Estimate|||||||2012-02-01|2012-02-03|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|PLUS||Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C|An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics, and Viral Kinetics of Two Doses of LocteronTM (Poly ActiveTM - Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C|Completed||Phase 1/Phase 2|32|Actual|Biolex Therapeutics, Inc.||3|||f||||t||||||||||2018-06-01 02:35:03.073129|2018-06-01 02:35:03.073129
NCT00593138|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2013-10-21|2008-01-11|2008-01-14|Estimate|||||||2013-10-21|2013-10-22|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate|A Randomized Open-label Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate (20 mg, 30 mg, and 40 mg) as Measured With C-11 Altropane in Healthy Adult Volunteers|Completed||Phase 1/Phase 2|23|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 02:35:03.163907|2018-06-01 02:35:03.163907
NCT00593125|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2017-01-11|2007-12-31|2008-01-14|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2007||2007-01-31|September 2016|2016-09-30|August 2008|Actual|2008-08-31|August 2007|Actual|2007-08-31||Interventional|Keppra||Levetiracetam (Keppra) Tolerability in Cocaine Abusing Methadone-maintained Patients.|Levetiracetam (Keppra) Tolerability and Efficacy in Cocaine Abusing Methadone-maintained Patients.|Completed||Phase 2|15|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||f||||||||||2018-06-01 02:35:03.25151|2018-06-01 02:35:03.25151
NCT00593112|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-01-07||2012-08-22|2008-01-11|2008-01-14|Estimate|2011-04-06|2011-05-05|Estimate||||2012-08-22|2012-08-31|Estimate|November 2006||2006-11-30|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate|A Pilot Study of Proton Magnetic Spectroscopy in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) Before and After Treatment With Osmotic-controlled Release Oral Delivery System (OROS) Methylphenidate|Completed||Phase 4|39|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:35:03.360953|2018-06-01 02:35:03.360953
NCT00593099|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-01-10|2007-12-28|2008-01-14|Estimate|||||||2017-01-10|2017-01-11|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder|A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder|Completed||Phase 1/Phase 2|5|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 02:35:03.743032|2018-06-01 02:35:03.743032
NCT00593086|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-02-25|2008-01-11|2008-01-14|Estimate|||||||2013-02-25|2013-02-27|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|||Virtual Reality in Burn Pain Management|The Use of Virtual Reality Video Games to Control Procedural Pain During Burn Wound Care|Completed||N/A|26|Actual|United States Army Institute of Surgical Research||2|||f||||f||||||||||2018-06-01 02:35:03.846669|2018-06-01 02:35:03.846669
NCT00593073|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2008-09-10|2007-12-31|2008-01-14|Estimate|||||||2008-09-10|2008-09-12|Estimate|July 2005||2005-07-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Use of Novel Tailored Reminders in Rural Primary Care|Use of Novel Tailored Reminders in Rural Primary Care|Completed||N/A|707|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 02:35:03.938808|2018-06-01 02:35:03.938808
NCT00593060|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2011-12-01|2007-12-28|2008-01-14|Estimate|||||||2011-12-01|2011-12-02|Estimate|October 2007||2007-10-31|December 2011|2011-12-31|October 2010|Actual|2010-10-31|October 2009|Actual|2009-10-31||Interventional|||Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer|A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer|Completed||Phase 1|30|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 02:35:04.011979|2018-06-01 02:35:04.011979
NCT00593047|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-11-27|2008-01-11|2008-01-14|Estimate|||||||2008-11-27|2008-12-01|Estimate|November 2007||2007-11-30|May 2008|2008-05-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin|A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Statin Treatment in Patients With Dyslipidemia|Completed||Phase 2|180|Anticipated|Karo Bio AB||4|||f||||t||||||||||2018-06-01 02:35:04.122548|2018-06-01 02:35:04.122548
NCT00593034|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2011-03-07|2008-01-03|2008-01-14|Estimate|||||||2011-03-07|2011-03-08|Estimate|February 2007||2007-02-28|March 2011|2011-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Medical Office Intervention for Adolescent Drug Use - Attention Study Supplement|Medical Office Intervention for Adolescent Drug Use - Research Supplement for Under-represented Minorities|Completed|||42|Actual|Boston Children’s Hospital|||1||f||||t||||||||||2018-06-01 02:35:04.235786|2018-06-01 02:35:04.235786
NCT00593021|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2013-08-07|2007-12-28|2008-01-14|Estimate|||||||2013-08-07|2013-08-09|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Diagnostic Evaluation of Obscure Gastrointestinal Bleeding|Diagnostic Evaluation of Obscure Gastrointestinal Bleeding|Withdrawn|||0|Actual|Brigham and Women's Hospital||||Lack of funding|f||||f||||||||||2018-06-01 02:35:04.362062|2018-06-01 02:35:04.362062
NCT00593008|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2011-12-01|2008-01-11|2008-01-14|Estimate|||||||2011-12-01|2011-12-02|Estimate|October 2007||2007-10-31|December 2011|2011-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer|A Phase 1 Study of Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer|Terminated||Phase 1|5|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 02:35:04.476217|2018-06-01 02:35:04.476217
NCT00592995|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28||2014-01-10|2014-01-10|2008-01-11|2008-01-14|Estimate||||2014-01-10|2014-02-10|Estimate|2014-01-10|2014-02-10|Estimate|December 2007||2007-12-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PRECREST||Creatine Safety and Tolerability in Premanifest HD: PRECREST|Creatine Safety and Tolerability in Premanifest HD: PRECREST|Completed||Phase 2|64|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:35:04.571371|2018-06-01 02:35:04.571371
NCT00592982|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2013-10-24|2007-12-27|2008-01-14|Estimate|||||||2013-10-24|2013-10-25|Estimate|October 2006||2006-10-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging|Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging|Completed|||25|Actual|University of Arkansas|||||f||||f||||||||||2018-06-01 02:35:04.683332|2018-06-01 02:35:04.683332
NCT00592969|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2017-02-22|2008-01-02|2008-01-14|Estimate|||||||2017-02-22|2017-02-24|Actual|December 3, 2003|Actual|2003-12-03|February 2017|2017-02-28|November 2, 2004|Actual|2004-11-02|November 2, 2004|Actual|2004-11-02||Interventional|||Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes|Evaluation of Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart or Insulin NPH in Subjects With Type 2 Diabetes|Completed||Phase 4|164|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:35:04.753013|2018-06-01 02:35:04.753013
NCT00592943|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-02-15||2013-10-21|2008-01-11|2008-01-14|Estimate|2011-05-11|2011-06-10|Estimate||||2013-10-21|2013-11-13|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|May 2010|Actual|2010-05-31|May 2008|Actual|2008-05-31||Interventional|||PET Study Examining the Dopaminergic Activity of Armodafinil in Adults|A PET Study Examining the Dopaminergic Activity of Armodafinil in Adults|Completed||Phase 1/Phase 2|12|Actual|Massachusetts General Hospital|Extracellular dopamine could compete with [11C] altropane, causing an overestimation of DAT occupancy. Time between scans and menstrual cycle could be sources of variability. Brain pathology although unlikely in normal subjects, is possible.|2|||f||||f||||||||||2018-06-01 02:35:04.837986|2018-06-01 02:35:04.837986
NCT00592930|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-01-11|2008-01-11|2008-01-14|Estimate|||||||2008-01-11|2008-01-14|Estimate|June 2000||2000-06-30|January 2008|2008-01-31|December 2004||2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Olanzapine in the Treatment of Anorexia Nervosa|Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa|Completed||Phase 4|20||Northwell Health||2|||f||||f||||||||||2018-06-01 02:35:05.118349|2018-06-01 02:35:05.118349
NCT00592917|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2008-01-11|2008-01-11|2008-01-14|Estimate|||||||2008-01-11|2008-01-14|Estimate|August 2002||2002-08-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|OSTPRE-FPS||OSTPRE-Fracture Prevention Study|OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study|Completed||Phase 4|3432|Actual|Kuopio University Hospital||4|||f||||f||||||||||2018-06-01 02:35:05.214213|2018-06-01 02:35:05.214213
NCT00592904|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2012-10-23|2012-08-23|2015-12-17|2008-01-11|2008-01-14|Estimate|2013-02-06|2013-02-08|Estimate|2012-08-23|2012-08-30|Estimate|2015-12-17|2016-01-21|Estimate|January 2008||2008-01-31|November 2015|2015-11-30|July 2011|Actual|2011-07-31|November 2009|Actual|2009-11-30||Interventional|||Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)|A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)|Completed||Phase 2/Phase 3|262|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 02:35:05.456218|2018-06-01 02:35:05.456218
NCT00592891|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2015-01-01|2008-01-02|2008-01-14|Estimate|||||||2015-01-01|2015-01-05|Estimate|April 2002||2002-04-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Oxygen Toxicity of HBOT in Chronic Brain Injury|Oxygen Toxicity Effects Using Los-Pressure Hyperbaric Oxygen Therapy in the Treatment of Chronic Brain Injury|Unknown status|Recruiting|Phase 1|45|Anticipated|Louisiana State University Health Sciences Center in New Orleans||1|||f||||f||||||||||2018-06-01 02:35:06.456603|2018-06-01 02:35:06.456603
NCT00592865|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2017-03-30|2008-01-11|2008-01-14|Estimate|||||||2017-03-30|2017-04-04|Actual|October 2003||2003-10-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Risk Factors for Adult-Onset Brain Tumors|Genetic Epidemiology of Adult Brain Tumors|Terminated|||850|Actual|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     Mouthwash and salvia samples. Toenail samples are also collected.~   "|No||2018-06-01 02:35:06.54288|2018-06-01 02:35:06.54288
NCT00592852|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-07-28||2012-11-13|2008-01-11|2008-01-14|Estimate|2012-02-02|2012-03-06|Estimate||||2012-11-13|2012-11-20|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder|A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder|Terminated||Phase 4|13|Actual|Massachusetts General Hospital||1||Slow subject recruitment.|f||||f||||||||||2018-06-01 02:35:06.622466|2018-06-01 02:35:06.622466
NCT00592839|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-02-04||2013-07-12|2008-01-11|2008-01-14|Estimate|2010-03-05|2010-03-17|Estimate||||2013-07-12|2013-07-19|Estimate|December 2007||2007-12-31|July 2013|2013-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women|A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of SCE-B on Nocturnal Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 4|157|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 02:35:06.852157|2018-06-01 02:35:06.852157
NCT00592826|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2015-04-13|2008-01-11|2008-01-14|Estimate|||||||2015-04-13|2015-04-14|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||HMP (Home Macular Perimeter) -Usability Trial|Phase III Study of the Usability of the HMP Device|Completed|||25|Actual|Notal Vision Ltd|||||f||||t||||||||||2018-06-01 02:35:07.286372|2018-06-01 02:35:07.286372
NCT00592813|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2013-04-22|2008-01-11|2008-01-14|Estimate|||||||2013-04-22|2013-04-23|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy of a Post-Rehabilitation Exercise Intervention|Efficacy of a Post-Rehabilitation Exercise Intervention|Completed||N/A|232|Actual|Boston University||2|||f||||t||||||||||2018-06-01 02:35:07.34744|2018-06-01 02:35:07.34744
NCT00592800|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2009-09-14|2008-01-11|2008-01-14|Estimate|||||||2009-09-14|2009-09-16|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Understanding Probability in Children|Evaluation of the Understanding of Probability in Children|Terminated|||165|Actual|Children's Hospital of Philadelphia|||3|Lack of study funding & resources|f||||f||||||||||2018-06-01 02:35:07.420053|2018-06-01 02:35:07.420053
NCT00592774|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2012-10-23|2012-08-23|2013-02-07|2008-01-03|2008-01-14|Estimate|2013-02-07|2013-02-15|Estimate|2012-08-23|2012-08-30|Estimate|2013-02-07|2013-02-15|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Tolerability Titration Study To Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)|Completed||Phase 2|146|Actual|Eisai Inc.||5|||f||||||||||||||2018-06-01 02:35:07.515337|2018-06-01 02:35:07.515337
NCT00592761|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2010-01-25||2018-02-21|2007-12-27|2008-01-14|Estimate|2010-07-16|2010-07-20|Estimate||||2018-02-21|2018-03-20|Actual|July 2003||2003-07-31|February 2018|2018-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Dysphagia Using the Mendelsohn Maneuver|Treatment of Dysphagia Using the Mendelsohn Maneuver|Completed||Phase 1/Phase 2|18|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:35:08.731391|2018-06-01 02:35:08.731391
NCT00592748|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-06-14|2008-01-11|2008-01-14|Estimate|||||||2017-06-14|2017-06-16|Actual|June 1999||1999-06-30|June 2017|2017-06-30|May 2015|Actual|2015-05-31|July 2007|Actual|2007-07-31||Interventional|||Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine|Randomized Study of Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine|Completed||Phase 1/Phase 2|381|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:35:08.966765|2018-06-01 02:35:08.966765
NCT00592735|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2016-06-05|2008-01-11|2008-01-14|Estimate|||||||2016-06-05|2016-06-07|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|BOS||Effects of Medical and Surgical Weight Loss on Metabolism|The Role of Adipocyte-derived Inflammatory Cytokines in the Pathogenesis of Diabetes, Dyslipidaemia, Atherosclerosis and Gastro-oesophageal Reflux Disease: the Effects of Medical and Surgical Weight Loss|Completed|||20|Actual|Garvan Institute of Medical Research|||1||f||||f||||||Samples With DNA|"~     serum, tissue~   "|||2018-06-01 02:35:09.081062|2018-06-01 02:35:09.081062
NCT00592722|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2009-07-02|2008-01-02|2008-01-14|Estimate|||||||2009-07-02|2009-07-03|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Observational|||A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients|A Multi-Centre Clinical Study in Chronic Spinal Cord Injury Patients|Completed|||60|Actual|China Spinal Cord Injury Network|||||f||||f||||||||||2018-06-01 02:35:09.154934|2018-06-01 02:35:09.154934
NCT00592709|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2017-03-30|2008-01-11|2008-01-14|Estimate|||||||2017-03-30|2017-04-04|Actual|May 2003||2003-05-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Observational|||Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry|Analysis of Brain Tumors Using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry|Completed|||84|Actual|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     Brain Tissue~   "|No||2018-06-01 02:35:09.211092|2018-06-01 02:35:09.211092
NCT00592696|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2014-03-27|2008-01-11|2008-01-14|Estimate|||||||2014-03-27|2014-03-31|Estimate|December 2006||2006-12-31|March 2014|2014-03-31|February 2010|Actual|2010-02-28|May 2008|Actual|2008-05-31||Observational|||TRIAD Project: Qualitative Study of Adolescent Depression and Smoking|TRIAD Project: Qualitative Study of Adolescent Depression and Smoking|Completed|||30|Actual|Drexel University|||1||f||||f||||||||||2018-06-01 02:35:09.285607|2018-06-01 02:35:09.285607
NCT00592683|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-07-15||2012-03-09|2007-12-28|2008-01-14|Estimate|2012-03-09|2012-04-06|Estimate||||2012-03-09|2012-04-06|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents|A Randomized Placebo Controlled Clinical Trial of Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents Ages 6-17 With Bipolar Spectrum Disorder|Terminated||Phase 4|20|Actual|Massachusetts General Hospital||2||Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.|f||||f||||||||||2018-06-01 02:35:09.37988|2018-06-01 02:35:09.37988
NCT00592670|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2014-12-10|2008-01-01|2008-01-14|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2005||2005-03-31|December 2014|2014-12-31|October 2008|Actual|2008-10-31|June 2007|Actual|2007-06-30||Interventional|||Hypoglycemia Associated Autonomic Failure in Type 1 DM|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6|Completed||N/A|48|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:35:09.878302|2018-06-01 02:35:09.878302
NCT00592657|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2008-07-25|2008-01-11|2008-01-14|Estimate|||||||2008-07-25|2008-07-28|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions|Incidence of Rhabdomyolysis Among Pediatric and Adolescent Patients Admitted for Jimsonweed (Datura Stramonium) Ingestions|Completed|||46|Actual|Akron Children's Hospital|||2||f||||f||||||||||2018-06-01 02:35:09.97467|2018-06-01 02:35:09.97467
NCT00592644|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2011-03-29|2007-12-31|2008-01-14|Estimate|||||||2011-03-29|2011-03-31|Estimate|March 2005||2005-03-31|March 2011|2011-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Laser Treatment Of Vascular Lesions On Vocal Cords|Laser Atraumatic Treatment Of Ectasias On Vocal Cords|Completed||Phase 2|7|Actual|Boston University||2|||f||||f||||||||||2018-06-01 02:35:10.037286|2018-06-01 02:35:10.037286
NCT00592631|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2015-11-12||2016-01-12|2008-01-11|2008-01-14|Estimate|2016-01-12|2016-02-10|Estimate||||2016-01-12|2016-02-10|Estimate|February 2005||2005-02-28|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Assessment Of The Effects Of Short and Long Term Use Of CPAP|Assessment of the Effects of Short and Long Term Use of Continuous Positive Airway Pressure on Airway Reactivity in Children and Adults With and Without Asthma|Terminated||N/A|27|Actual|Indiana University||2||Key investigator resigned|f||||f||||||||||2018-06-01 02:35:10.120991|2018-06-01 02:35:10.120991
NCT00592618|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2008-01-11|2008-01-11|2008-01-14|Estimate|||||||2008-01-11|2008-01-14|Estimate||||May 2007|2007-05-31||||||||Interventional|||Effect of NAC on Sleep Apnea||Unknown status|Not yet recruiting|N/A|||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 02:35:10.294297|2018-06-01 02:35:10.294297
NCT00592605|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-06-01|2008-01-11|2008-01-14|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2007||2007-05-31|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Thyroid Disease Serum Repository|Thyroid Disease Serum Repository|Completed|||1000|Actual|University of Arkansas|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:35:10.363026|2018-06-01 02:35:10.363026
NCT00592592|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-05-03|2007-12-28|2008-01-14|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2004||2004-10-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Proton RT for the Treatment of Pediatric Rhabdomyosarcoma|A Phase II Trial of Proton RT for the Treatment of Pediatric Rhabdomyosarcoma|Recruiting||Phase 2|110|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:35:10.42159|2018-06-01 02:35:10.42159
NCT00592579|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2009-02-25|2008-01-02|2008-01-14|Estimate|||||||2009-02-25|2009-02-26|Estimate|March 2001||2001-03-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma|Phase 2, Open-Label, Safety, and Efficacy Study of 2-Methoxyestradiol Administered to Patients With Plateau Phase or Relapsed Multiple Myeloma|Completed||Phase 2|60|Actual|CASI Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 02:35:10.516113|2018-06-01 02:35:10.516113
NCT00592566|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2008-01-11|2008-01-11|2008-01-14|Estimate|||||||2008-01-11|2008-01-14|Estimate|July 2003||2003-07-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis|An Open Randomized Controlled Trial of Desmopressin, and Dexamethasone as Adjunctive Therapy in Patients With Pulmonary Hemorrhage Associated With Leptospirosis|Terminated||Phase 2/Phase 3|64|Actual|Mahidol University||3||Numbe of eligible patients has been decreased over time.|f||||f||||||||||2018-06-01 02:35:10.603174|2018-06-01 02:35:10.603174
NCT00592553|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01||2011-07-11|2017-12-06|2008-01-01|2008-01-14|Estimate||||2011-07-11|2011-07-14|Estimate|2017-12-06|2017-12-08|Actual|February 2008|Actual|2008-02-29|December 2017|2017-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2b Study of PTC124 in Duchenne/Becker Muscular Dystrophy (DMD/BMD)|A Phase 2b Efficacy and Safety Study of PTC124 in Subjects With Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy and Becker Muscular Dystrophy|Completed||Phase 2|174|Actual|PTC Therapeutics||3|||f||||t||||||||No||2018-06-01 02:35:10.684628|2018-06-01 02:35:10.684628
NCT00592540|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-11-22|2008-01-02|2008-01-14|Estimate|||||||2016-11-22|2016-11-25|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Unrelated Donor BMT for Treatment of Patients With PGK Deficiency|Unrelated Donor Bone Marrow Transplantation for Definitive Treatment of Patients With Phosphoglycerate Kinase (PGK) Deficiency|Completed||N/A|2|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 02:35:10.890964|2018-06-01 02:35:10.890964
NCT00592527|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2017-01-26|2008-01-02|2008-01-14|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2004||2004-04-30|January 2017|2017-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes|Evaluation of Insulin Detemir in Combination With OADs in Type 2 Diabetes Mellitus|Completed||Phase 3|132|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:35:11.098719|2018-06-01 02:35:11.098719
NCT00592514|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2011-08-31|2008-01-11|2008-01-14|Estimate|||||||2011-08-31|2011-09-02|Estimate|July 2005||2005-07-31|August 2011|2011-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Thyroid Dysfunction in Head and Neck Surgery Patients|Thyroid Dysfunction in Head and Neck Surgery Patients Treated With Intraoperative Oral Administration With Povidone-iodine 10% Solution|Completed|||14|Actual|University of Arkansas|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:35:11.169304|2018-06-01 02:35:11.169304
NCT00592501|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-02-13|2007-12-28|2008-01-14|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2006||2006-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma|A Phase II Study of Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma|Active, not recruiting||Phase 2|25|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:35:11.23881|2018-06-01 02:35:11.23881
NCT00592488|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2011-03-17||2017-11-07|2008-01-11|2008-01-14|Estimate|2011-05-09|2011-06-08|Estimate||||2017-11-07|2017-12-08|Actual|August 2006||2006-08-31|November 2017|2017-11-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|ALC||Acetyl-L-Carnitine in the Treatment of Septic Shock|Prospective, Randomized, Placebo-controlled, Double-Blinded, Phase II Pilot Study of Acetyl-L-carnitine in the Treatment of Patients With Septic Shock|Completed||Phase 1/Phase 2|13|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 02:35:11.32977|2018-06-01 02:35:11.32977
NCT00592475|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2010-05-24||2014-04-30|2008-01-02|2008-01-14|Estimate|2010-09-08|2010-09-28|Estimate||||2014-04-30|2014-05-15|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients|A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic Patients|Completed||Phase 2|20|Actual|Cumberland Pharmaceuticals|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||f||||||||||2018-06-01 02:35:11.588661|2018-06-01 02:35:11.588661
NCT00592462|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2016-10-26|2008-01-11|2008-01-14|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2007||2007-12-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases|Whole Body MRI for Detection of Cancer Metastases|Completed|||32|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:35:12.357744|2018-06-01 02:35:12.357744
NCT00592449|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2014-03-10|2007-12-28|2008-01-14|Estimate|||||||2014-03-10|2014-03-11|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|SOAP||Sleep in Osteoarthritis Project|Sleep Disturbance, Central Pain Modulation, and Clinical Pain in Osteoarthritis (The SOAP Study)|Completed||Phase 2|190|Anticipated|Johns Hopkins University||6|||f||||t||||||||||2018-06-01 02:35:12.434951|2018-06-01 02:35:12.434951
NCT00592436|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2015-05-05|2007-12-28|2008-01-14|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2003||2003-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder|A Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder|Terminated|||663|Actual|Massachusetts General Hospital|||1|New protocol developed for recruitment of children for all child studies|f||||f||||||||||2018-06-01 02:35:12.548606|2018-06-01 02:35:12.548606
NCT00592423|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2009-09-14|2008-01-11|2008-01-14|Estimate|||||||2009-09-14|2009-09-16|Estimate|January 2005||2005-01-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||CPAP and Lateral Neck Rotation on Anesthetized Children|Effect of Neck Rotation and Continuous Positive Airway Pressure (CPAP) on Upper Airway Anatomy in Anesthetized Children - an MRI Study|Terminated||N/A|12|Actual|Children's Hospital of Philadelphia||1||Preliminary data was inconclusive to warrant keeping the study open.|f||||f||||||||||2018-06-01 02:35:12.631923|2018-06-01 02:35:12.631923
NCT00592410|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-08-04|2008-01-01|2008-01-14|Estimate|||||||2011-08-04|2011-08-05|Estimate|February 2007||2007-02-28|August 2011|2011-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||The Effects of Intensive Insulin on Somatic and Visceral Protein Turnover in Acute Kidney Injury (AKI)|The Effects of Intensive Insulin on Somatic and Visceral Protein Turnover in Acute Kidney Injury (AKI)|Withdrawn||Phase 2|0|Actual|Vanderbilt University||1||no enrollment|f||||f||||||||||2018-06-01 02:35:12.699331|2018-06-01 02:35:12.699331
NCT00592397|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2017-01-27|2008-01-02|2008-01-14|Estimate|||||||2017-01-27|2017-01-30|Estimate|March 2006||2006-03-31|January 2017|2017-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Prestudy: Lifestyle and Cardiovascular Disease|Prestudy: Lifestyle and Cardiovascular Disease|Completed||N/A|5|Actual|Norwegian University of Science and Technology||1|||f||||t||||||||No||2018-06-01 02:35:12.761031|2018-06-01 02:35:12.761031
NCT00592384|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|2014-06-11||2014-12-31|2008-01-01|2008-01-14|Estimate|2014-12-31|2015-01-01|Estimate||||2014-12-31|2015-01-01|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|PRISMS||Project to Improve Symptoms and Mood in People With Spinal Cord Injury|A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study|Completed||Phase 4|133|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:35:12.875037|2018-06-01 02:35:12.875037
NCT00592371|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2012-09-04|2007-12-27|2008-01-14|Estimate|||||||2012-09-04|2012-09-05|Estimate|March 2006||2006-03-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Head and Neck Cancer Screening and Serum Repository|Head and Neck Cancer Screening and Serum Repository|Completed|||300|Actual|University of Arkansas|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:35:13.322102|2018-06-01 02:35:13.322102
NCT00592358|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2012-03-09||2012-06-04|2008-01-11|2008-01-14|Estimate|2012-06-04|2012-07-04|Estimate||||2012-06-04|2012-07-04|Estimate|November 2007||2007-11-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder|Open-Label Study of Invega for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder|Terminated||Phase 4|17|Actual|Massachusetts General Hospital||1||Slow enrollment.|f||||f||||||||||2018-06-01 02:35:13.382006|2018-06-01 02:35:13.382006
NCT00592345|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-02-02|2007-12-28|2008-01-14|Estimate|||||||2017-02-02|2017-02-03|Estimate|May 1999||1999-05-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2005|Actual|2005-03-31||Interventional|||High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum|High-Dose Proton/Photon RT + Surgery of Sarcomas of the Thoracic, Lumbar Spine/Sacrum|Completed||Phase 1/Phase 2|50|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 02:35:13.563864|2018-06-01 02:35:13.563864
NCT00592332|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2014-12-10|2008-01-01|2008-01-14|Estimate|||||||2014-12-10|2014-12-11|Estimate|June 2005||2005-06-30|December 2014|2014-12-31|June 2009|Actual|2009-06-30|June 2007|Actual|2007-06-30||Interventional|||Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2|Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 2|Completed||N/A|56|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:35:13.623456|2018-06-01 02:35:13.623456
NCT00592319|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|2012-05-03||2012-08-24|2007-12-31|2008-01-14|Estimate|2012-07-23|2012-08-24|Estimate||||2012-08-24|2012-08-31|Estimate|May 2005||2005-05-31|August 2012|2012-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Celebrex (Celecoxib) Treatment of Laryngeal Papilloma|Voice-preserving Treatment of Laryngeal Papilloma|Terminated||Phase 2|10|Actual|Boston University|We failed to recruit a total of 30 cases, due to (1) This disease is relative less common in clinic; and (2) particularly, more and more of patients now had a serious concern in safety of Celebrex due to news and warnings to public in recent years.|2||03/01/2009,due to date close to termination of this funding/study period|f||||f||||||||||2018-06-01 02:35:13.71753|2018-06-01 02:35:13.71753
NCT00592306|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-03-02|2007-12-28|2008-01-14|Estimate|||||||2018-03-02|2018-03-06|Actual|January 2006|Actual|2006-01-31|March 2018|2018-03-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation|A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.|Completed||Phase 3|50|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 02:35:14.092133|2018-06-01 02:35:14.092133
NCT00592293|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-05-03|2007-12-28|2008-01-14|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2006||2006-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas|Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas|Active, not recruiting||N/A|70|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:35:14.199188|2018-06-01 02:35:14.199188
NCT00592280|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2010-04-16|2007-12-27|2008-01-14|Estimate|||||||2010-04-16|2010-04-19|Estimate|October 2007||2007-10-31|April 2010|2010-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation|Two-Layer Method Preservation and Resuscitation of the Cadaveric Pancreas Before Transplantation|Terminated||Phase 1|7|Actual|University of Nebraska||1||Logistic problems with adequately timely organ collection and transport|f||||t||||||||||2018-06-01 02:35:14.286036|2018-06-01 02:35:14.286036
NCT00592267|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-03-07|2007-12-28|2008-01-14|Estimate|||||||2018-03-07|2018-03-08|Actual|September 2001||2001-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder|A Screening Protocol for Children and Adolescents With Bipolar and Bipolar Spectrum Disorder|Recruiting|||1000|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-06-01 02:35:14.358164|2018-06-01 02:35:14.358164
NCT00592254|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-05-02|2007-12-28|2008-01-14|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2002||2002-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Screening Protocol for Adults With ADHD|A Screening Protocol for Adults With Attention Deficit Hyperactivity Disorder|Active, not recruiting|||3000|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-06-01 02:35:14.424338|2018-06-01 02:35:14.424338
NCT00592241|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-04-06|2007-12-30|2008-01-14|Estimate|||||||2008-04-06|2008-04-08|Estimate|November 2007||2007-11-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Self Operating of the ADI Insulin Pump By Intended Users - A Usability Study|Self Operating of the ADI Insulin Pump By Intended Users - A Usability Study|Completed||N/A|30|Anticipated|NiliMedix||1|||f||||t||||||||||2018-06-01 02:35:14.504911|2018-06-01 02:35:14.504911
NCT00592228|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2010-12-20|2007-12-28|2008-01-11|Estimate|||||||2010-12-20|2010-12-21|Estimate|January 2007||2007-01-31|December 2010|2010-12-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|DEFER-DES||Proper Fractional Flow Reserve Criteria for Intermediate Lesions in the Era of Drug-eluting Stent|Deferral of Angioplasty According to Fractional Flow Reserve vs. Routine Drug-eluting Stent Implantation in Intermediate Coronary Stenosis|Terminated||N/A|250|Anticipated|Seoul National University Hospital||2||due to slow enrollment|f||||t||||||||||2018-06-01 02:35:14.604384|2018-06-01 02:35:14.604384
NCT00592215|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2017-12-06|2008-01-10|2008-01-11|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2008|Actual|2008-03-31|December 2017|2017-12-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||Second Trimester Labor Induction|A Pilot Study of Mifepristone Followed by Misoprostol in Women Undergoing Second Trimester Abortion|Withdrawn||Phase 1|0|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 02:35:14.768536|2018-06-01 02:35:14.768536
NCT00592202|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2014-03-31|2007-12-27|2008-01-11|Estimate|||||||2014-03-31|2014-04-02|Estimate|December 2004||2004-12-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents|Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents|Completed||N/A|37|Actual|University of Illinois at Chicago||1|||f||||f||||||||||2018-06-01 02:35:14.846909|2018-06-01 02:35:14.846909
NCT00519883|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2014-08-21|2007-08-22|2007-08-23|Estimate|||||||2014-08-21|2014-08-25|Estimate|December 2007||2007-12-31|August 2014|2014-08-31||||July 2010|Actual|2010-07-31||Interventional|RAE||Randomized Anastrozole Exercise Trial|Randomized Anastrozole Exercise Trial (The RAE Study)|Unknown status|Active, not recruiting|Phase 3|72|Anticipated|British Columbia Cancer Agency||2|||f||||f||||||||||2018-06-01 02:58:42.341779|2018-06-01 02:58:42.341779
NCT00592189|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-06-23|2008-01-10|2008-01-11|Estimate|||||||2014-06-23|2014-06-24|Estimate|December 1999||1999-12-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Amnion||Study of Donated Amnion, Fetal Placental Membrane, as Skin Substitute for Burn Patients|Fetal Membrane as a New Coverage Material|Completed||Early Phase 1|1164|Actual|The University of Texas Medical Branch, Galveston||1|||f||||f||||||||||2018-06-01 02:35:14.939997|2018-06-01 02:35:14.939997
NCT00592176|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-05-21||2014-05-20|2007-12-31|2008-01-11|Estimate|2012-05-21|2012-06-25|Estimate||||2014-05-20|2014-06-04|Estimate|August 2007||2007-08-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect of Bevacizumab (Avastin) on Pterygium|The Effect of Bevacizumab (Avastin) on Pterygium|Completed||Phase 2|5|Actual|University of Alabama at Birmingham|Initially we aimed for 10 to 15 subjects but only enrolled 5 subjects.|1|||f||||f||||||||||2018-06-01 02:35:15.027681|2018-06-01 02:35:15.027681
NCT00592163|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2007-12-26|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas|Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Ziopharm||1|||f||||||||||||||2018-06-01 02:35:15.179726|2018-06-01 02:35:15.179726
NCT00592150|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2013-01-22|2007-12-27|2008-01-11|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|March 2008|Actual|2008-03-31||Interventional|||Effect of Gene Variants on Dopamine Receptor Natriuretic Responses|Effect of Gene Variants on Dopamine Receptor Natriuretic Responses (RMC033)|Unknown status|Active, not recruiting|Phase 1|44|Anticipated|University of Virginia||2|||f||||f||||||||||2018-06-01 02:35:15.250356|2018-06-01 02:35:15.250356
NCT00592137|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2010-01-12|2008-01-10|2008-01-11|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2004||2004-04-30|January 2010|2010-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Calcium, Dairy, and Body Fat in Adolescents|Calcium, Dairy, and Body Fat in Adolescents|Completed||N/A|43|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 02:35:15.32947|2018-06-01 02:35:15.32947
NCT00592124|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|2017-01-04||2017-03-06|2007-12-31|2008-01-11|Estimate|2017-01-04|2017-02-27|Actual||||2017-03-06|2017-04-04|Actual|June 2008||2008-06-30|January 2017|2017-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||The baseline population consists of evaluable enrolled participants.|Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women|Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir|Completed||Phase 2|168|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|For a full discussion of the difficulties of sampling and comparing findings in the varied and complex anatomic spaces in this study, please see the primary results publication, listed in the References section (PLoS One 2013;8(1):e55013.)|6|||f||||t||||||||||2018-06-01 02:35:15.449196|2018-06-01 02:35:15.449196
NCT00592111|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-12-21|2007-12-26|2008-01-11|Estimate|||||||2015-12-21|2015-12-23|Estimate|March 1996||1996-03-31|December 2015|2015-12-31|January 2008|Actual|2008-01-31|February 1999|Actual|1999-02-28||Interventional|||A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)|A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)|Completed||Phase 2|21|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 02:35:16.818757|2018-06-01 02:35:16.818757
NCT00592098|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-29|||2008-01-10|2008-01-10|2008-01-11|Estimate|||||||2008-01-10|2008-01-11|Estimate|August 2007||2007-08-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||2PX (Topical Strontium Chloride Hexahydrate) in Patients With Post-Amputation Stump Pain.|A Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of 2PX (Topical Strontium Chloride Hexahydrate) in Patients With Persistent, Moderate-to-Severe Lower Limb Post-Amputation Stump Pain.|Completed||Phase 2|22|Anticipated|SantoSolve AS||2|||f||||f||||||||||2018-06-01 02:35:16.911646|2018-06-01 02:35:16.911646
NCT00592085|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2016-07-18|2008-01-10|2008-01-11|Estimate|||||||2016-07-18|2016-07-20|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Combined Treatment for Tobacco and Alcohol Use|Combined Treatment for Tobacco and Alcohol Use|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2||No patients registered; study terminated.|f||||t||||||||||2018-06-01 02:35:16.975419|2018-06-01 02:35:16.975419
NCT00592072|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2013-02-04||2015-01-08|2007-12-26|2008-01-11|Estimate|2014-12-18|2015-01-05|Estimate||||2015-01-08|2015-01-22|Estimate|July 2005||2005-07-31|January 2015|2015-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||The baseline number of subjects reflects the number of subjects with baseline data|Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes|Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes|Completed||N/A|12|Actual|Yale University|No technical limitations were seen.|2|||f||||f||||||||||2018-06-01 02:35:17.059577|2018-06-01 02:35:17.059577
NCT00592059|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2007-12-31|2007-12-31|2008-01-11|Estimate|||||||2007-12-31|2008-01-11|Estimate|November 2007||2007-11-30|December 2007|2007-12-31|November 2012|Anticipated|2012-11-30|November 2009|Anticipated|2009-11-30||Observational|||Systemic Consolidation Therapy After Chemoradiation Therapy Following Operation for High Risk Early Stage Cervical Cancer|A Phase II Study of Systemic Consolidation Therapy With Paclitaxel Plus Carboplatin Following Radical Hysterectomy and Adjuvant Chemoradiation for High Risk Early Stage Cervical Cancer|Unknown status|Recruiting||77|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 02:35:17.560014|2018-06-01 02:35:17.560014
NCT00592046|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2008-01-10|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Phase I Trial of ZIO-101 in Hematologic Cancers|A Phase I Trial of ZIO-101 in Hematologic Cancers|Completed||Phase 1|12|Actual|Ziopharm||1|||f||||t||||||||||2018-06-01 02:35:17.621975|2018-06-01 02:35:17.621975
NCT00592033|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2012-03-21|2007-12-31|2008-01-11|Estimate|||||||2012-03-21|2012-03-22|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Oxygen in Normoxaemic COPD Patients Who Desaturate During Exercise|Effect of Ambulatory Oxygen in Normoxaemic COPD Patients Who Desaturate During Exercise. A Randomised Placebo Controlled Trial of Patients Who Participate in Pulmonary Rehabilitation|Completed||Phase 4|45|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 02:35:17.697806|2018-06-01 02:35:17.697806
NCT00592020|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2011-05-20|2007-12-31|2008-01-11|Estimate|||||||2011-05-20|2011-05-23|Estimate|January 2008||2008-01-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Short Transverse Versus Conventional Hockey Stick Incision in Kidney Transplantation|"Short Transverse Versus Conventional Hockey Stick Incision in Kidney Transplantation"|Completed||N/A|50|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:35:17.768325|2018-06-01 02:35:17.768325
NCT00592007|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2016-11-26||2017-05-03|2007-12-26|2008-01-11|Estimate|2017-05-03|2017-06-06|Actual||||2017-05-03|2017-06-06|Actual|September 2007||2007-09-30|May 2017|2017-05-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer|Phase II Trial Evaluating Addition of Fulvestrant to Erlotinib in Patients With Stage IIIB/IV NSCLC Who Are Stable on Erlotinib and Exhibit Positivity for Estrogen or Progesterone Receptor|Terminated||Phase 2|7|Actual|University of California, San Diego||1||Study was terminated due to slow subject accrual|f||||t||||||||||2018-06-01 02:35:17.851083|2018-06-01 02:35:17.851083
NCT00591994|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-03-06|2007-12-26|2008-01-11|Estimate|||||||2008-03-06|2008-03-07|Estimate|November 2006||2006-11-30|December 2007|2007-12-31||||December 2007|Actual|2007-12-31||Interventional|piribedil||Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography|Tinnitus Treatment With Piribedil Guided by Acoustic Otoemissions and Electrocochleography|Completed||N/A|100|Actual|Faculdade de Medicina de Valenca|||||f||||f||||||||||2018-06-01 02:35:18.085394|2018-06-01 02:35:18.085394
NCT00591981|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-07-22|2008-01-10|2008-01-11|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|TOGA||Thoracic OncoGeriatric Assessment (TOGA) Trials|Preoperative Oncogeriatric Assessment for Thoracic Malignancies|Completed|||14|Actual|University of Wisconsin, Madison|||1||f||||f||||||||||2018-06-01 02:35:18.152178|2018-06-01 02:35:18.152178
NCT00591968|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2009-05-06|2007-12-31|2008-01-11|Estimate|||||||2009-05-06|2009-05-07|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican Community|Telesonography Adaptation and Use to Improve the Standard of Patient Care Within a Dominican Community|Completed||N/A|106|Actual|Edward Via Virginia College of Osteopathic Medicine||2|||f||||f||||||||||2018-06-01 02:35:18.32701|2018-06-01 02:35:18.32701
NCT00591955|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-07-11|2007-12-26|2008-01-11|Estimate|||||||2013-07-11|2013-07-12|Estimate|January 2006||2006-01-31|July 2013|2013-07-31|September 2009|Actual|2009-09-30|October 2008|Actual|2008-10-31||Observational|||Infected Elders in the Emergency Department: Outcomes and Processes of Care|Infected Elders in the Emergency Department: Outcomes and Processes of Care|Completed|||213|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 02:35:18.439804|2018-06-01 02:35:18.439804
NCT00591942|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2013-01-18||2018-02-06|2007-12-26|2008-01-11|Estimate|2018-02-06|2018-03-08|Actual||||2018-02-06|2018-03-08|Actual|November 2004||2004-11-30|February 2018|2018-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Outcome Evaluation of Ceramic Crowns Using Two Different Dental Cements|Outcome Evaluation of All Ceramic Crowns and Fixed Partial Dentures Bonded With Two Different Dental Cements.|Completed||N/A|36|Actual|University of Iowa||2|||f||||f||||||||No|IPD data is tied to Hippa identifiers and therefore cannot be released|2018-06-01 02:35:18.529619|2018-06-01 02:35:18.529619
NCT00591929|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2013-03-11|2007-12-28|2008-01-11|Estimate|||||||2013-03-11|2013-03-12|Estimate|December 2006||2006-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Use of Continuous Passive Motion in the Post-Operative Treatment of Intra-articular Knee Fractures|Use of Continuous Passive Motion in the Post-Operative Treatment of Intra-articular Knee Fractures|Completed||N/A|40|Actual|Greenville Health System||2|||f||||f||||||||||2018-06-01 02:35:18.79068|2018-06-01 02:35:18.79068
NCT00591916|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-12-10|2008-01-10|2008-01-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|Donors||New Treatment for Donor Sites|New Treatment for Donor Sites|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||3||"Donor site material (scarlet red ) came back on the market, therefore new treatements for donor~   sites was not needed."|f||||f||||||||||2018-06-01 02:35:18.857376|2018-06-01 02:35:18.857376
NCT00591903|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-30|2007-12-28|2008-01-11|Estimate|||||||2017-06-30|2017-07-02|Actual|December 14, 2007||2007-12-14|September 23, 2011|2011-09-23|September 23, 2011||2011-09-23|||||Observational|||Pilot Study to Assess the Proteome in Human Atrial Tissue|Pilot Study to Assess the Proteome in Human Atrial Tissue|Completed|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:35:18.934676|2018-06-01 02:35:18.934676
NCT00591890|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2007-12-26|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|June 2008|Actual|2008-06-30||Interventional|||Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans|Phase IB Study to Evaluate the Biological Activity of Indibulin Using Positron-Emission Tomography (PET) Scans|Completed||Phase 1|20|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 02:35:18.990544|2018-06-01 02:35:18.990544
NCT00591877|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2012-10-25|2008-01-10|2008-01-11|Estimate|||||||2012-10-25|2012-10-26|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|January 2015|Anticipated|2015-01-31|May 2014|Anticipated|2014-05-31||Interventional|||A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients|A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients|Withdrawn||N/A|0|Actual|Midwest Biomedical Research Foundation||3||Unable to enroll elegible subjects. No subjects enrolled, study closed.|f||||f||||||||||2018-06-01 02:35:19.065463|2018-06-01 02:35:19.065463
NCT00591864|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-03-07||2014-06-06|2008-01-09|2008-01-11|Estimate|2014-06-06|2014-07-09|Estimate||||2014-06-06|2014-07-09|Estimate|September 2008||2008-09-30|June 2014|2014-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MBI||Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation|Comparison of Magnetic Resonance Imaging and Molecular Breast Imaging in Breast Diagnostic Evaluation|Completed||N/A|89|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 02:35:19.168094|2018-06-01 02:35:19.168094
NCT00591851|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2014-11-24||2014-11-24|2008-01-10|2008-01-11|Estimate|2014-11-24|2014-12-01|Estimate||||2014-11-24|2014-12-01|Estimate|December 2004||2004-12-31|November 2014|2014-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility|Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility|Completed||Phase 2|70|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:35:19.336595|2018-06-01 02:35:19.336595
NCT00591838|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2018-03-22|2007-12-31|2008-01-11|Estimate|||||||2018-03-22|2018-03-26|Estimate|September 21, 2006|Actual|2006-09-21|March 2018|2018-03-31|August 17, 2018|Anticipated|2018-08-17|August 17, 2018|Anticipated|2018-08-17||Interventional|SBRT||A Phase I/II Trial of Stereotactic Body Radiation Therapy|A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT) Dose Escalation in the Treatment of Patients With Inoperable Stage I/II Non-Small Cell Lung Cancer Arising Within the Zone of the Proximal Bronchial Tree|Active, not recruiting||Phase 1/Phase 2|74|Actual|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-06-01 02:35:19.559207|2018-06-01 02:35:19.559207
NCT00591825|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2015-10-29||2017-06-01|2008-01-10|2008-01-11|Estimate|2017-06-01|2017-06-05|Actual||||2017-06-01|2017-06-05|Actual|March 2006||2006-03-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||fMRI Study Examining Effects of D-cycloserine in Specific Phobia|An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia.|Completed||Phase 2|54|Actual|University of Kansas Medical Center||4|||f||||f||||||||No||2018-06-01 02:35:19.654241|2018-06-01 02:35:19.654241
NCT00591812|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-08-23|2007-12-26|2008-01-11|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2000||2000-04-30|August 2016|2016-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Evaluation of the Compress Distal Femoral Replacement System|Evaluation of the Compress Distal Femoral Replacement System|Completed||Phase 1|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:35:20.084082|2018-06-01 02:35:20.084082
NCT00591799|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26||2013-09-18|2013-09-20|2007-12-29|2008-01-11|Estimate||||2013-09-20|2013-09-27|Estimate|2013-09-20|2013-09-27|Estimate|April 2005||2005-04-30|September 2013|2013-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Jarvik 2000 Heart as a Bridge to Cardiac Transplantation - Pivotal Trial|Clinical Protocol for Evaluation of the Jarvik 2000 Heart Assist System|Completed||Phase 2/Phase 3|150|Actual|Jarvik Heart, Inc.||1|||f||||t||||||||||2018-06-01 02:35:20.13617|2018-06-01 02:35:20.13617
NCT00591786|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-06-14|2008-01-10|2008-01-11|Estimate|||||||2017-06-14|2017-06-16|Actual|December 5, 2005|Actual|2005-12-05|June 2017|2017-06-30|October 19, 2006|Actual|2006-10-19|August 31, 2006|Actual|2006-08-31||Interventional|||A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.209A)(P05957)(COMPLETED)|A Multi -Center, Randomized, Open -Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at 1-2 PTC After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part A: Japanese Subjects.|Completed||Phase 2|100|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:35:20.198067|2018-06-01 02:35:20.198067
NCT00591773|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2011-03-24||2011-03-24|2007-12-27|2008-01-11|Estimate|2011-03-24|2011-04-19|Estimate||||2011-03-24|2011-04-19|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension|Completed||Phase 3|551|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:35:20.284676|2018-06-01 02:35:20.284676
NCT00591760|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-03-23||2012-10-17|2007-12-27|2008-01-11|Estimate|2012-10-17|2012-11-19|Estimate||||2012-10-17|2012-11-19|Estimate|December 2004||2004-12-31|March 2009|2009-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial|Correction of Growth Hormone Deficiency in Patients With Chronic Heart Failure: a Randomized, Controlled, Single-blind Study|Completed||Phase 2|56|Actual|Federico II University||2|||f||||f||||||||||2018-06-01 02:35:21.092992|2018-06-01 02:35:21.092992
NCT00591747|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2015-05-26|2008-01-10|2008-01-11|Estimate|||||||2015-05-26|2015-05-28|Estimate|November 2005||2005-11-30|May 2015|2015-05-31|June 2011|Actual|2011-06-30|January 2009|Actual|2009-01-31||Interventional|||Strength Training for Older Breast Cancer Survivors|Strength Training for Older Breast Cancer Survivors|Completed||N/A|106|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 02:35:21.33037|2018-06-01 02:35:21.33037
NCT00591734|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2013-01-22||2013-01-22|2007-12-26|2008-01-11|Estimate|2013-01-22|2013-02-26|Estimate||||2013-01-22|2013-02-26|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||RAD001 Plus Bevacizumab in Metastatic Melanoma|A Phase II Trial of RAD001 Plus Bevacizumab in the Treatment of Patients With Metastatic Melanoma|Completed||Phase 2|57|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:35:21.397589|2018-06-01 02:35:21.397589
NCT00591721|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-08-19||2013-02-27|2007-12-26|2008-01-11|Estimate|2013-02-27|2013-02-28|Estimate||||2013-02-27|2013-02-28|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Teleconference Fatigue Management for People With Multiple Sclerosis|Effectiveness of a Teleconference Delivered Fatigue Management Program for People With Multiple Sclerosis|Completed||N/A|190|Actual|University of Illinois at Chicago|Use of self-report rather than objective measures of MS disability. Only the participants were blinded to their allocation status. Co-intervention was tracked, but there is no way to know whether other interventions contributed to the results.|2|||f||||f||||||||||2018-06-01 02:35:22.547715|2018-06-01 02:35:22.547715
NCT00591708|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-05-03|2008-01-10|2008-01-11|Estimate|||||||2018-05-03|2018-05-09|Actual|July 2004||2004-07-31|May 2018|2018-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Calcium Metabolism in Asian Adolescents|Calcium Metabolism in Asian Adolescents|Completed||N/A|34|Actual|Purdue University||2|||f||||t||||||||||2018-06-01 02:35:22.835254|2018-06-01 02:35:22.835254
NCT00591695|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-29|||2016-01-20|2007-12-29|2008-01-11|Estimate|||||||2016-01-20|2016-01-22|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|July 2018|Anticipated|2018-07-31|July 2015|Actual|2015-07-31||Interventional|ESCO||Enteral Stents for Colonic Obstruction|Prospective, Randomised European Multicentric Study, Comparing Enteral Stent Followed by Elective Surgery Versus Emergency Surgical Treatment in Malignant Colonic Obstruction|Active, not recruiting||Phase 4|144|Actual|European Association for Endoscopic Surgery||2|||f||||t||||||||||2018-06-01 02:35:22.936391|2018-06-01 02:35:22.936391
NCT00591682|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2008-03-24|2007-12-31|2008-01-11|Estimate|||||||2008-03-24|2008-03-26|Estimate|November 2007||2007-11-30|March 2008|2008-03-31|March 2009|Anticipated|2009-03-31|December 2008|Anticipated|2008-12-31||Interventional|||MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors|Phase I Dose Escalation Study to Determine the Safety and Pharmacokinetics of MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors|Suspended||Phase 1|27|Anticipated|Metastatix, Inc.||1|||f||||f||||||||||2018-06-01 02:35:23.028332|2018-06-01 02:35:23.028332
NCT00591669|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-04-25|2007-12-27|2008-01-11|Estimate|||||||2011-04-25|2011-04-26|Estimate|May 2006||2006-05-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography|Non-invasive Imaging of GI Inflammation Using Microbubble Contrast Enhanced Ultrasonography|Terminated||N/A|10|Actual|University of Virginia||2||Data storage damage plus unexpected loss of funding|f||||f||||||||||2018-06-01 02:35:23.103092|2018-06-01 02:35:23.103092
NCT00591656|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2007-12-31|2007-12-31|2008-01-11|Estimate|||||||2007-12-31|2008-01-11|Estimate|November 2007||2007-11-30|December 2007|2007-12-31|November 2012|Anticipated|2012-11-30|November 2009|Anticipated|2009-11-30||Observational|||Systemic Consolidation Therapy After Primary Chemoradiation Therapy for Locally Advanced Cervical Cancer|A Phase II Study of Systemic Consolidation Therapy With Paclitaxel Plus Carboplatin Following Primary Chemoradiation for Locally Advanced Cervical Cancer|Unknown status|Recruiting||69|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 02:35:23.292911|2018-06-01 02:35:23.292911
NCT00591643|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-12-23|2007-12-26|2008-01-11|Estimate|||||||2015-12-23|2015-12-28|Estimate|July 1977||1977-07-31|December 2015|2015-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)|Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)|Completed||Phase 1|93|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:35:23.359635|2018-06-01 02:35:23.359635
NCT00591630|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-11-06|2007-12-27|2008-01-11|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2007|Actual|2007-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation|Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab Maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas|Active, not recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-06-01 02:35:24.322421|2018-06-01 02:35:24.322421
NCT00591617|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2013-01-28|2007-12-28|2008-01-11|Estimate|||||||2013-01-28|2013-01-29|Estimate|September 2006||2006-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|OpBup||Optimizing Outcomes Using Suboxone for Opiate Dependence|Optimizing Outcomes Using Suboxone for Opiate Dependence|Completed||N/A|202|Actual|University of California, Los Angeles||4|||f||||t||||||||||2018-06-01 02:35:24.464245|2018-06-01 02:35:24.464245
NCT00591604|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-11-13|2008-01-10|2008-01-11|Estimate|||||||2012-11-13|2012-11-15|Estimate|February 2007||2007-02-28|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|VitaminD||High-Dose Vitamin D Deficiency in Burn Injury|Use of High-Dose Vitamin D to Treat Vitamin D Deficiency Following Severe Burn Injury in Children I: A Pilot Study|Withdrawn||Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||1||hurricane caused closure of hospital with PI not associated with Shriners Hospital for children|f||||f||||||||||2018-06-01 02:35:24.610217|2018-06-01 02:35:24.610217
NCT00591591|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-09-22||2011-03-10|2008-01-10|2008-01-11|Estimate|2011-02-15|2011-03-11|Estimate||||2011-03-10|2011-03-16|Estimate|August 2007||2007-08-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|NIRS-OSAS||Brain Oxygenation and Hemodynamics During Sleep in Obstructive Sleep Apnea Sufferers|Absolute Near-Infrared Brain Oximeter|Completed||Phase 3|309|Actual|ISS, Inc.||2|||f||||t||||||||||2018-06-01 02:35:24.717154|2018-06-01 02:35:24.717154
NCT00591578|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2011-03-24||2012-01-31|2007-12-27|2008-01-11|Estimate|2011-03-24|2011-04-19|Estimate||||2012-01-31|2012-02-02|Estimate|December 2007||2007-12-31|January 2012|2012-01-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension|A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension|Completed||Phase 3|984|Actual|Takeda|For the Non-Serious Adverse Event Table, the total number of participants affected is based on the AEs with ≥5% in each phase, calculated separately.|3|||f||||f||||||||||2018-06-01 02:35:25.278136|2018-06-01 02:35:25.278136
NCT00591565|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-09-06||2014-12-09|2008-01-10|2008-01-11|Estimate|2014-12-09|2014-12-18|Estimate||||2014-12-09|2014-12-18|Estimate|June 2006||2006-06-30|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants|An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants|Completed||N/A|13|Actual|State University of New York - Upstate Medical University|open label design without placebo control|1|||f||||||||||||||2018-06-01 02:35:26.964005|2018-06-01 02:35:26.964005
NCT00591552|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-01-10|2008-01-10|2008-01-11|Estimate|||||||2008-01-10|2008-01-11|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.|Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy. A Single Center Prospective Randomized Controlled Study.|Unknown status|Recruiting|N/A|50|Anticipated|Sentara Cardiovascular Research Institute||2|||f||||f||||||||||2018-06-01 02:35:27.59139|2018-06-01 02:35:27.59139
NCT00591539|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2012-07-27|2007-12-28|2008-01-11|Estimate|||||||2012-07-27|2012-07-31|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Carotid Artery Disease in Childhood Cancer Survivors|Carotid Artery Disease in Long-Term Survivors of Childhood Cancer|Terminated|||3|Actual|M.D. Anderson Cancer Center|||1|Slow Accrual.|f||||f||||||||||2018-06-01 02:35:27.925167|2018-06-01 02:35:27.925167
NCT00591526|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-01-11|2007-12-27|2008-01-11|Estimate|||||||2008-01-11|2008-01-14|Estimate|June 2000||2000-06-30|January 2008|2008-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)|A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed Acute Promyelocytic Leukemia (APL)|Completed||Phase 3|250|Actual|Groupe d'etude et de travail sur les leucemies aigues promyelocytaires||4|||f||||t||||||||||2018-06-01 02:35:28.095363|2018-06-01 02:35:28.095363
NCT00591513|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2015-07-14|2008-01-10|2008-01-11|Estimate|||||||2015-07-14|2015-07-15|Estimate|February 1998||1998-02-28|July 2015|2015-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Autologous Engineered Skin Substitutes for Closure of Skin Wounds|Autologous Engineered Skin Substitutes for Closure of Burn Wounds|Terminated||Phase 2/Phase 3|144|Actual|University of Cincinnati||3|||f||||||||||||||2018-06-01 02:35:28.224029|2018-06-01 02:35:28.224029
NCT00591500|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-05-01|2007-12-26|2008-01-11|Estimate|||||||2018-05-01|2018-05-02|Actual|November 1999|Actual|1999-11-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||A Model for Genetic Susceptibility: Melanoma|A Model for Genetic Susceptibility: Melanoma|Active, not recruiting|||4082|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     buccal swabs tissue~   "|||2018-06-01 02:35:28.317352|2018-06-01 02:35:28.317352
NCT00591487|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2008-01-10|2008-01-10|2008-01-11|Estimate|||||||2008-01-10|2008-01-11|Estimate|December 2007||2007-12-31|December 2007|2007-12-31||||December 2008|Anticipated|2008-12-31||Interventional|||Safety and Efficacy of Lidocaine Infiltration in Suction Assisted Lipectomy|Safety and Efficacy of Lidocaine Infiltration in Suction Assisted Lipectomy With Tumescent Technique. A Randomized, Double Blinded, Controlled Trial.|Unknown status|Enrolling by invitation|Phase 3|60|Anticipated|Hospital Militar de Santiago||2|||f||||f||||||||||2018-06-01 02:35:28.435803|2018-06-01 02:35:28.435803
NCT00591474|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2008-01-10|2008-01-10|2008-01-11|Estimate|||||||2008-01-10|2008-01-11|Estimate|December 2007||2007-12-31|December 2007|2007-12-31||||November 2008|Anticipated|2008-11-30||Interventional|||The Influence of Probiotics on Vancomycin-Resistant Enterococcus|The Influence of Probiotics on Vancomycin-Resistant Enterococcus|Unknown status|Recruiting|N/A|30|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:35:28.724259|2018-06-01 02:35:28.724259
NCT00591461|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2009-09-28|2008-01-10|2008-01-11|Estimate|||||||2009-09-28|2009-09-29|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Study of Endoscopic Barrett's Esophagus Diagnosis|A Prospective Study on the Interobserver Agreement of Endoscopic Barrett's Esophagus|Suspended|||200|Anticipated|Oregon Health and Science University|||1|Suspended to modify recruitment process|f||||f||||||Samples Without DNA|"~     Esophageal biopsies~   "|||2018-06-01 02:35:28.980773|2018-06-01 02:35:28.980773
NCT00591448|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-10-16|2008-01-10|2008-01-11|Estimate|||||||2012-10-16|2012-10-17|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study in the Use of Virtual Reality as an Adjunct to Pain Control in Burn Patients|Improvement of Pain Management in Burn Patients Using Virtual Reality in Conjunction With Standard Opioids and Sedatives|Completed||N/A|10|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 02:35:29.084478|2018-06-01 02:35:29.084478
NCT00591435|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2010-03-23|2007-12-28|2008-01-11|Estimate|||||||2010-03-23|2010-03-24|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Influence of Resident Training on Intra-operative Workflow|Resident Training Affects Intra-Operative Workflow and Costs|Completed|||600|Actual|University of Schleswig-Holstein|||3||f||||t||||||||||2018-06-01 02:35:29.193553|2018-06-01 02:35:29.193553
NCT00591422|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2007-12-26|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas|Phase I Study of Oral Darinaparsin (ZIO-101-C) in Advanced Solid Tumors and Non-Hodgkin's Lymphomas|Unknown status|Active, not recruiting|Phase 1|23|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 02:35:29.293197|2018-06-01 02:35:29.293197
NCT00591409|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-06-14|2008-01-10|2008-01-11|Estimate|||||||2017-06-14|2017-06-16|Actual|January 3, 2006|Actual|2006-01-03|June 2017|2017-06-30|December 18, 2006|Actual|2006-12-18|September 22, 2006|Actual|2006-09-22||Interventional|||A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part A: Japanese Subjects (19.4.208A)(P05956)|A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part A: Japanese Subjects|Completed||Phase 2|100|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-06-01 02:35:29.375399|2018-06-01 02:35:29.375399
NCT00591396|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2008-01-10|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Phase I Trial of ZIO-101 in Solid Tumors|A Phase I Trial of ZIO-101 in Solid Tumors: Protocol # SGL1002|Completed||Phase 1|40|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 02:35:29.582676|2018-06-01 02:35:29.582676
NCT00591383|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2007-12-26|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors|Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|10|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 02:35:29.663334|2018-06-01 02:35:29.663334
NCT00591370|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-01-08||2015-10-17|2008-01-10|2008-01-11|Estimate|2015-01-20|2015-01-22|Estimate||||2015-10-17|2015-11-18|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma|Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma|Completed||Phase 2|51|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:35:29.865635|2018-06-01 02:35:29.865635
NCT00591357|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2016-05-02|2008-01-10|2008-01-11|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2007||2007-10-31|May 2016|2016-05-31||||December 2013|Actual|2013-12-31||Interventional|loperamide||Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy|Study of the Efficacy of Loperamide in Treating Patients for Clostridium Difficile Colitis and Diarrheal Disease of Unknown Cause Associated With Prior Antibiotic Therapy.|Suspended||Phase 4|120|Anticipated|VA Medical Center, Houston||2||Lack of personnel to complete trial|f||||f||||||||||2018-06-01 02:35:30.409752|2018-06-01 02:35:30.409752
NCT00591344|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2014-12-23||2015-02-16|2008-01-10|2008-01-11|Estimate|2015-01-26|2015-02-09|Estimate||||2015-02-16|2015-03-05|Estimate|October 2007||2007-10-31|February 2015|2015-02-28|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||The Effect of Exercise on Individuals With Parkinson's Disease|The Effect of Exercise on Individuals With Parkinson's Disease|Completed||N/A|51|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 02:35:30.727651|2018-06-01 02:35:30.727651
NCT00591331|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2008-05-16|2008-01-10|2008-01-11|Estimate|||||||2008-05-16|2008-05-20|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Phototoxicity Potential of NatrOVA Creme Rinse - 1%|Phase 1 Evaluation of the Phototoxic Potential of NatrOVA Creme Rinse - 1% in Healthy Volunteers|Completed||Phase 1|37|Actual|ParaPRO LLC||3|||f||||f||||||||||2018-06-01 02:35:31.685943|2018-06-01 02:35:31.685943
NCT00591318|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2009-09-17|2007-12-26|2008-01-11|Estimate|||||||2009-09-17|2009-09-18|Estimate|August 2007||2007-08-31|September 2009|2009-09-30||||August 2010|Anticipated|2010-08-31||Interventional|||A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis|IV Ceftriaxone for Refractory Psychosis: a Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|28|Anticipated|Research Foundation for Mental Hygiene, Inc.||2|||f||||f||||||||||2018-06-01 02:35:31.928589|2018-06-01 02:35:31.928589
NCT00591305|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|2017-02-24||2017-05-16|2008-01-10|2008-01-11|Estimate|2017-05-16|2017-05-18|Actual||||2017-05-16|2017-05-18|Actual|September 2007||2007-09-30|May 2017|2017-05-31|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional||There was only one participant due to difficulty in recruitment which resulted in early termination of the trial.|New Therapy of Laryngeal Papilloma In Children|Voice Preserving Therapy of Laryngeal Papilloma In Children|Terminated||N/A|1|Actual|Boston University|There was only one participant due to difficulty in recruitment which resulted in early termination of the trial.|2||insufficient resource for recruitment|f||||t||||||||No|no such meaningful data available due to insufficient recruitment|2018-06-01 02:35:32.058359|2018-06-01 02:35:32.058359
NCT00591292|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2007-12-26|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Phase I Study in Advanced Solid Tumors|IBL1002:Phase I Study of Indibulin in Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|22|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 02:35:32.716835|2018-06-01 02:35:32.716835
NCT00591279|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-01-31|2007-12-26|2008-01-11|Estimate|||||||2017-01-31|2017-02-02|Estimate|February 1981|Actual|1981-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Cancer Control Following Polypectomy|Cancer Control Following Polypectomy|Completed|||110|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||Samples With DNA|"~     fecal occult blood~   "|||2018-06-01 02:35:32.887223|2018-06-01 02:35:32.887223
NCT00591266|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2011-03-24||2011-07-18|2007-12-27|2008-01-11|Estimate|2011-03-24|2011-04-19|Estimate||||2011-07-18|2011-07-22|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Amlodipine 5 mg in Subjects With Essential Hypertension|Completed||Phase 3|566|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:35:33.011628|2018-06-01 02:35:33.011628
NCT00591253|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2011-03-24||2011-03-24|2007-12-27|2008-01-11|Estimate|2011-03-24|2011-04-19|Estimate||||2011-03-24|2011-04-19|Estimate|October 2007||2007-10-31|March 2011|2011-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Black Subjects With Essential Hypertension|Completed||Phase 3|413|Actual|Takeda||3|||f||||f||||||||||2018-06-01 02:35:34.060122|2018-06-01 02:35:34.060122
NCT00591240|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2016-06-24||2016-06-24|2008-01-10|2008-01-11|Estimate|2016-06-24|2016-06-27|Estimate||||2016-06-24|2016-06-27|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational||Research subjects recruited from spinal cord injury unit.|A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection|A Biochip for Rapid Diagnosis of Complicated Urinary Tract Infection|Completed|||338|Actual|VA Office of Research and Development|The trial is non-interventional. Future studies will focused on developing advanced prototypes with the option of using the biosensor platform to direct patient care in comparison with standard microbiology.||2||f||||f||||||Samples With DNA|"~     urine~   "|No||2018-06-01 02:35:35.241794|2018-06-01 02:35:35.241794
NCT00591227|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2011-04-08||2011-04-08|2007-12-31|2008-01-11|Estimate|2011-04-08|2011-05-05|Estimate||||2011-04-08|2011-05-05|Estimate|May 2008||2008-05-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.|Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care|Completed||Phase 4|176|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 02:35:35.700727|2018-06-01 02:35:35.700727
NCT00591214|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-09-19||2014-04-15|2007-12-26|2008-01-11|Estimate|2012-09-19|2012-10-22|Estimate||||2014-04-15|2014-05-01|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and PK Study of MP-424 to Treat Chronic Hepatitis C|A Phase I, Open-Label, Single-Dose Study of MP-424 in Patients With Genotype 1b Hepatitis C|Completed||Phase 1|10|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 02:35:36.6061|2018-06-01 02:35:36.6061
NCT00591201|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2008-01-16|2008-01-10|2008-01-11|Estimate|||||||2008-01-16|2008-01-17|Estimate|June 2002||2002-06-30|December 2007|2007-12-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies|Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension.|Completed||Phase 2/Phase 3|26|Actual|Hospital General de Mexico||2|||f||||t||||||||||2018-06-01 02:35:37.195929|2018-06-01 02:35:37.195929
NCT00591188|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2009-04-30|2008-01-10|2008-01-11|Estimate|||||||2009-04-30|2009-05-01|Estimate|December 2006||2006-12-31|April 2009|2009-04-30||||May 2008|Actual|2008-05-31||Interventional|||Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens|Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens|Completed||Phase 2|49|Anticipated|Kidney Cancer Research Bureau||1|||f||||t||||||||||2018-06-01 02:35:37.349321|2018-06-01 02:35:37.349321
NCT00591175|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-10-03|2007-12-26|2008-01-11|Estimate|||||||2017-10-03|2017-10-04|Actual|December 2001||2001-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers|A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers|Active, not recruiting|||1072|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||f||||||Samples Without DNA|"~     Salvia~   "|||2018-06-01 02:35:37.474855|2018-06-01 02:35:37.474855
NCT00591162|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-06-05|2008-01-10|2008-01-11|Estimate|||||||2014-06-05|2014-06-06|Estimate|October 1992||1992-10-31|June 2014|2014-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Bone Disease in Severely Burned Children|Bone Disease in Severely Burned Children|Terminated||Phase 2/Phase 3|254|Actual|The University of Texas Medical Branch, Galveston||1||terminated due to PI lab/duties affected by natural disaster.|f||||f||||||||||2018-06-01 02:35:37.551938|2018-06-01 02:35:37.551938
NCT00591149|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2017-01-11||2017-05-16|2007-12-28|2008-01-11|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|June 2007||2007-06-30|May 2017|2017-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer|Phase II Trial Of Oxaliplatin With Docetaxel Followed By Epidermal Growth Factor Antibody (EGFR-AB) Cetuximab In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)|Terminated||Phase 2|16|Actual|University of Kansas Medical Center||1||Study was stopped due to termination of funding|f||||t||||||||||2018-06-01 02:35:37.827974|2018-06-01 02:35:37.827974
NCT00591136|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-07-18|2007-12-26|2008-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|April 2003||2003-04-30|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Phase I Study of Indibulin in Patients With Solid Tumors|Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors|Completed||Phase 1|47|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 02:35:38.219833|2018-06-01 02:35:38.219833
NCT00591123|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2015-10-30|2007-12-28|2008-01-11|Estimate|||||||2015-10-30|2015-11-03|Estimate|December 2007||2007-12-31|October 2015|2015-10-31||||June 2011|Actual|2011-06-30||Interventional|||Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia|A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia|Completed||Phase 2|38|Actual|Translational Oncology Research International||1|||f||||t||||||||||2018-06-01 02:35:38.278257|2018-06-01 02:35:38.278257
NCT00591110|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-06-26|2007-12-31|2008-01-11|Estimate|||||||2012-06-26|2012-06-28|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|inCharge||Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program|Project inCharge: Increasing the Rate of Comprehensive Eye Care Utilization by Older African Americans Through Community-Based Eye Health Education Program|Completed||N/A|177|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:35:38.423234|2018-06-01 02:35:38.423234
NCT00591097|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2013-12-17|2008-01-10|2008-01-11|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2006||2006-10-31|December 2013|2013-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Normal Reference Ranges for Urinary Metabolites and Supersaturation Indices in Pediatric Populations|Determining Normal Reference Ranges for Urinary Metabolites and Supersaturation Indices in the Pediatric Population|Completed|||300|Actual|University of Wisconsin, Madison|||1||f||||f||||||||||2018-06-01 02:35:38.526388|2018-06-01 02:35:38.526388
NCT00591084|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2010-08-30|2008-01-10|2008-01-11|Estimate|||||||2010-08-30|2010-09-01|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|September 2006|Actual|2006-09-30|June 2006|Actual|2006-06-30||Interventional|||Ginsenoside-Rd for Acute Ischemic Stroke|Efficacy and Safety of Ginsenoside-Rd for Acute Ischemic Stroke: A Randomized, Double-blind, Placebo-controlled, Phase Ⅱ, Multicenter Trial|Completed||Phase 2|199|Actual|Xijing Hospital||3|||f||||t||||||||||2018-06-01 02:35:38.591548|2018-06-01 02:35:38.591548
NCT00591071|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-02-13|2008-01-10|2008-01-11|Estimate|||||||2008-02-13|2008-02-14|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|INSUREA||Impact of 2 Blood Glucose Levels on Hospital Mortality in Patients Admitted in ICU|Multicentre Randomized Trial Assessing the Impact of Maintaining 2 Blood Glucose Levels on Hospital Mortality in Patients Admitted to the ICU (INSUREA STUDY)|Unknown status|Recruiting|Phase 3|440|Anticipated|Poissy-Saint Germain Hospital||2|||f||||t||||||||||2018-06-01 02:35:38.714634|2018-06-01 02:35:38.714634
NCT00591058|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2009-07-16|2007-12-27|2008-01-11|Estimate|||||||2009-07-16|2009-07-17|Estimate|February 2008||2008-02-29|July 2009|2009-07-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma|A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|TransMolecular||6|||f||||||||||||||2018-06-01 02:35:38.817184|2018-06-01 02:35:38.817184
NCT00591045|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2008-01-10|2008-01-10|2008-01-11|Estimate|||||||2008-01-10|2008-01-11|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer|A Randomized Phase II Multicenter Controlled Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer|Unknown status|Not yet recruiting|Phase 2|263|Anticipated|Peking University||2|||f||||t||||||||||2018-06-01 02:35:38.910071|2018-06-01 02:35:38.910071
NCT00591032|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-05-14|2007-12-26|2008-01-11|Estimate|||||||2018-05-14|2018-05-15|Actual|May 2007||2007-05-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2017|Actual|2017-11-30||Observational|AQUA FONTIS||Approach to a Quantitative Follow-up of Non-thyroidal Illness Syndrome|Development of Rational and Standardized Diagnostics and Staging for a Differentiated Risk Stratification of Non-thyroidal Illness Syndrome|Active, not recruiting|||590|Actual|Ruhr University of Bochum|||||f||||t||||||Samples Without DNA|"~     Kryobase with serum and urine samples~   "|Undecided||2018-06-01 02:35:39.001869|2018-06-01 02:35:39.001869
NCT00591019|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2011-02-28||2015-09-23|2008-01-10|2008-01-11|Estimate|2011-04-15|2011-05-09|Estimate||||2015-09-23|2015-10-08|Estimate|August 2006||2006-08-31|September 2015|2015-09-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Use of Modafinil in the Treatment of Tinnitus|Use of Modafinil in the Treatment of Tinnitus|Terminated||Phase 1|7|Actual|University of Arkansas|Study was terminated early due to lack of change in primary and secondary outcome measures.|2||Terminated early due to lack of change in primary and secondary outcome measures.|f||||f||||||||||2018-06-01 02:35:39.097912|2018-06-01 02:35:39.097912
NCT00591006|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-07-08||2015-08-12|2008-01-10|2008-01-11|Estimate|2015-08-12|2015-08-19|Estimate||||2015-08-12|2015-08-19|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes|Phenytoin as a Neuroprotective Agent Against Corticosteroid-induced Functional Imaging Changes|Completed||Phase 3|17|Actual|University of Texas Southwestern Medical Center|The sample size in this pilot study was modest; The duration of exposure to hydrocortisone was subacute;|1|||f||||f||||||||||2018-06-01 02:35:39.427829|2018-06-01 02:35:39.427829
NCT00590993|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-02-27|2007-12-26|2008-01-11|Estimate|||||||2013-02-27|2013-02-28|Estimate|December 2000||2000-12-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Magnetic Resonance Imaging and Spectroscopy of the Prostate|Magnetic Resonance Imaging and Spectroscopy of the Prostate|Completed|||1005|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||||||2018-06-01 02:35:40.006291|2018-06-01 02:35:40.006291
NCT00590980|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2017-09-18||2017-10-20|2007-12-28|2008-01-11|Estimate|2017-10-20|2017-11-17|Actual||||2017-10-20|2017-11-17|Actual|July 2008|Actual|2008-07-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|VERiTAS|Analysis population consists of all participants meeting all inclusion/exclusion criteria|Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)|The Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS) Study|Completed|||82|Actual|University of Illinois at Chicago|||1||f||||f||||||||||2018-06-01 02:35:40.12718|2018-06-01 02:35:40.12718
NCT00590967|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|2016-06-02||2016-07-18|2007-12-31|2008-01-11|Estimate|2016-07-18|2016-08-29|Estimate||||2016-07-18|2016-08-29|Estimate|May 2003||2003-05-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy|A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy With Concurrent Weekly Cisplatin in Patients With Stage I-IVA Cervical Cancer Who Have FDG PET Positive Pelvic or Para-Aortic Lymph Nodes|Terminated||Phase 2|69|Actual|Washington University School of Medicine||2||Due to low accrual|f||||f||||||||||2018-06-01 02:35:40.38287|2018-06-01 02:35:40.38287
NCT00590954|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-06-01|2007-12-26|2008-01-11|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2006|Actual|2006-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas|Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas|Active, not recruiting||Phase 2|31|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:35:41.093271|2018-06-01 02:35:41.093271
NCT00590941|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2013-05-14|2007-12-28|2008-01-11|Estimate|||||||2013-05-14|2013-05-16|Estimate|February 2005||2005-02-28|May 2013|2013-05-31|April 2011|Actual|2011-04-30|July 2008|Actual|2008-07-31||Interventional|||Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma|Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma|Completed||N/A|52|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:35:41.240464|2018-06-01 02:35:41.240464
NCT00590928|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2007-12-26|2007-12-26|2008-01-11|Estimate|||||||2007-12-26|2008-01-11|Estimate|July 2004||2004-07-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Gastric pH in Critically Ill Patients|Effect of Intravenous Esomeprazole Versus Ranitidine on Gastric pH in Critically Ill Patients - a Prospective, Randomized, Double-Blind Study.|Completed||Phase 4|75|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:35:41.379861|2018-06-01 02:35:41.379861
NCT00590915|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-04-11|2007-12-26|2008-01-11|Estimate|||||||2012-04-11|2012-04-12|Estimate||||April 2012|2012-04-30||||||||Expanded Access|EMTP||Erwinase Master Treatment Protocol|Erwinase Master Treatment Protocol|No longer available|||||Phoenix Children's Hospital|||||||||||||||||||2018-06-01 02:35:41.468323|2018-06-01 02:35:41.468323
NCT00590902|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-15||2015-12-15|2007-12-26|2008-01-11|Estimate|2015-12-15|2016-01-20|Estimate||||2015-12-15|2016-01-20|Estimate|March 2002||2002-03-31|December 2015|2015-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer|Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer|Completed||Phase 2|81|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:35:41.562753|2018-06-01 02:35:41.562753
NCT00590889|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-06-22||2015-11-18|2008-01-10|2008-01-11|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|July 1998||1998-07-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AVERT|1 subject age is missing|Artificial Valve Endocarditis Reduction Trial|Artificial Valve Endocarditis Reduction Trial|Terminated||N/A|807|Actual|St. Jude Medical|This study was terminated early. No final report was created.|2||"A post-PMA begun in 1998; enrollment halted in 2000 due to an anomaly in one study arm. The~   protocol required annual study visits after 2000."|f||||t||||||||||2018-06-01 02:35:41.830708|2018-06-01 02:35:41.830708
NCT00590876|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-10-26|2007-12-26|2008-01-11|Estimate|||||||2011-10-26|2011-10-27|Estimate|December 2008||2008-12-31|October 2011|2011-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus|The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function and Brain Fuel Utilization in Patients With Type 1 Diabetes and Hypoglycemia Unawareness|Completed|||36|Anticipated|Yale University|||3||f||||f||||||||||2018-06-01 02:35:42.100975|2018-06-01 02:35:42.100975
NCT00590863|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-11-28||2014-04-21|2007-12-28|2008-01-11|Estimate|2014-04-21|2014-04-23|Estimate||||2014-04-21|2014-04-23|Estimate|March 2008||2008-03-31|April 2009|2009-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|CO-MED|Sociodemographic Characteristics|Combining Medications to Enhance Depression Outcomes|Combining Medications to Enhance Depression Outcomes|Completed||Phase 4|665|Actual|National Institute of Mental Health (NIMH)|Detailed results avaiable. A. J. Rush et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes: a single-blind randomized study. American Journal of Psychiatry, 2011; 168:689-701.|3|||f||||t||||||||||2018-06-01 02:35:42.167371|2018-06-01 02:35:42.167371
NCT00590850|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-02-16|2007-12-28|2008-01-11|Estimate|||||||2018-02-16|2018-02-19|Actual|October 2003||2003-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Non-Operative Versus Operative Treatment for High-Energy Midshaft Clavicle Fractures|A Multicenter, Prospective, Randomized Trial of Non-Operative Versus Operative Treatment for High-Energy Midshaft Clavicle Fractures|Enrolling by invitation||N/A|480|Anticipated|Greenville Health System||3|||f||||f||||||||No||2018-06-01 02:35:42.500882|2018-06-01 02:35:42.500882
NCT00590837|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2014-04-01|2008-01-10|2008-01-11|Estimate|||||||2014-04-01|2014-04-02|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|LAM-SA 2007||Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old|Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old|Completed||Phase 3|459|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 02:35:42.573981|2018-06-01 02:35:42.573981
NCT00590824|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-09-20|2008-01-10|2008-01-11|Estimate|||||||2017-09-20|2017-09-25|Actual|December 2007||2007-12-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma|A Pilot Trial of HU14.18-IL2 (EMD273063) in Subjects With Completely Resectable Recurrent Stage III or Stage IV Melanoma|Active, not recruiting||Phase 2|23|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 02:35:42.780522|2018-06-01 02:35:42.780522
NCT00590811|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2010-08-31|2007-12-31|2008-01-11|Estimate|||||||2010-08-31|2010-09-01|Estimate|January 2008||2008-01-31|January 2010|2010-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Prevalence of Menstrual Cycle Related Pain Complains in Adolescents and Young Adults|Prevalence of Menstrual Cycle Related Pain Complains in Adolescents and Young Adults|Completed|||200|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-06-01 02:35:42.854159|2018-06-01 02:35:42.854159
NCT00590798|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-04-09|2008-01-10|2008-01-11|Estimate|||||||2013-04-09|2013-04-10|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|STRUT||Star-Close Early Ambulation Trial|Star-Close Early Ambulation Trial|Completed||N/A|58|Actual|Ohio State University||1|||f||||f||||||||||2018-06-01 02:35:42.920898|2018-06-01 02:35:42.920898
NCT00590785|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-08-24|2007-12-26|2008-01-11|Estimate|||||||2017-08-24|2017-08-25|Actual|August 13, 1996||1996-08-13|August 2017|2017-08-31|January 13, 2015|Actual|2015-01-13|June 10, 1997|Actual|1997-06-10||Interventional|||Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)|Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)|Completed||Phase 3|60|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 02:35:43.008065|2018-06-01 02:35:43.008065
NCT00219570|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-09|2005-09-13|2005-09-22|Estimate|||||||2011-05-09|2011-05-11|Estimate|January 2005||2005-01-31|May 2011|2011-05-31|June 2005|Actual|2005-06-30|||||Interventional|||Dalacin-T Gel Post Approval Study|Phase IV Clinical Study Of Clindamycin Phosphate Topical Gel In The Treatment Of Acne Vulgaris|Completed||Phase 4|134|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:28:27.910721|2018-06-01 04:28:27.910721
NCT00590772|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2009-07-21||2014-10-20|2008-01-10|2008-01-11|Estimate|2014-10-20|2014-10-21|Estimate||||2014-10-20|2014-10-21|Estimate|May 2003||2003-05-31|October 2014|2014-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Role of Montelukast in Rhinitis and Sleep|Phase 4- The Role of Montelukast on Perennial Rhinitis and Associated Sleep Disturbance and Daytime Somnolence|Completed||Phase 4|31|Actual|Penn State University||2|||f||||f||||||||||2018-06-01 02:35:43.1468|2018-06-01 02:35:43.1468
NCT00590759|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-06-10||2014-08-06|2008-01-10|2008-01-11|Estimate|2014-08-06|2014-08-07|Estimate||||2014-08-06|2014-08-07|Estimate|August 2005||2005-08-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms|A Clinical Evaluation of the GORE TAG Thoracic Endoprosthesis in the Primary Treatment of Descending Thoracic Aortic Aneurysms|Completed||N/A|150|Actual|W.L.Gore & Associates||1|||f||||f||||||||||2018-06-01 02:35:43.373524|2018-06-01 02:35:43.373524
NCT00590746|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-02-11|2007-12-26|2008-01-11|Estimate|||||||2014-02-11|2014-02-13|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|September 2009|Actual|2009-09-30|October 2008|Actual|2008-10-31||Observational|||Bedside Assessment of Fall Risk in Emergency Department Elders|Bedside Assessment of Fall Risk in Emergency Department Elders|Completed|||53|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 02:35:43.59947|2018-06-01 02:35:43.59947
NCT00590720|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2013-10-22||2014-02-04|2007-12-27|2008-01-11|Estimate|2014-02-04|2014-03-21|Estimate||||2014-02-04|2014-03-21|Estimate|March 2008||2008-03-31|February 2014|2014-02-28|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction|Terminated||Phase 2|11|Actual|MedImmune LLC||2||Study is replaced by MI-CP198 per CPM.|f||||t||||||||||2018-06-01 02:35:43.778235|2018-06-01 02:35:43.778235
NCT00590707|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-08-22|2007-12-28|2008-01-11|Estimate|||||||2017-08-22|2017-08-24|Actual|January 2005||2005-01-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|STRIDE||Post-Operative Delirium in Elderly Surgical Patients|A Strategy to Reduce the Incidence of Post-Operative Delirium in Elderly Patients|Completed||N/A|200|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 02:35:44.257836|2018-06-01 02:35:44.257836
NCT00590694|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-04-10|2008-01-10|2008-01-11|Estimate|||||||2012-04-10|2012-04-12|Estimate|October 2006||2006-10-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|DETAIL||Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments|Determining Optimal Treatment Algorithms for Macular Degeneration Pigment Epithelial Detachments Treated With Intraocular Lucentis|Completed||Phase 2/Phase 3|15|Actual|Pacific Eye Associates||2|||f||||f||||||||||2018-06-01 02:35:44.347186|2018-06-01 02:35:44.347186
NCT00590681|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-09-02|2007-12-26|2008-01-11|Estimate|||||||2015-09-02|2015-09-04|Estimate|February 2007||2007-02-28|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme|Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study|Completed||Phase 2|62|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 02:35:44.476692|2018-06-01 02:35:44.476692
NCT00590668|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-02-02|2007-12-26|2008-01-10|Estimate|||||||2017-02-02|2017-02-03|Estimate|May 2004|Actual|2004-05-31|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2008|Actual|2008-04-30||Observational|ROTEA||Safety Monitoring of Patients Having Pulmonary Vein Ablation|Pulmonary Vein Ablation for Atrial Fibrillation: Safety Monitoring by Transesphoageal Echo, Intracardiac Echo and Computed Tomography and Assessment of Predictors of Recurrence and of Hypercoagulable State|Completed|||42|Actual|The Cleveland Clinic|||||f||||f|f|f||||||No||2018-06-01 02:35:44.584117|2018-06-01 02:35:44.584117
NCT00590655|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-01-09|2008-01-09|2008-01-10|Estimate|||||||2008-01-09|2008-01-10|Estimate|August 2002||2002-08-31|December 2007|2007-12-31|May 2006|Actual|2006-05-31|||||Interventional|||Maintenance Programme After Weight Loss|Effect of Maintenance Programme on the Long Term Weight Reduction in Severely Obese Patients. A Randomized Controlled Trial|Completed||N/A|201|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:35:44.648994|2018-06-01 02:35:44.648994
NCT00590642|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2009-11-27|2007-12-28|2008-01-10|Estimate|||||||2009-11-27|2009-12-01|Estimate|April 2006||2006-04-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Augmentation in Tx-resistant OCD: an Open Label Trial|Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial|Completed|||30|Anticipated|Creighton University|||1||f||||f||||||||||2018-06-01 02:35:44.718721|2018-06-01 02:35:44.718721
NCT00590629|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-09-13|2008-01-09|2008-01-10|Estimate|||||||2011-09-13|2011-09-14|Estimate|June 2002||2002-06-30|December 2007|2007-12-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women||Completed||Phase 4|43|Actual|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-06-01 02:35:44.819636|2018-06-01 02:35:44.819636
NCT00590616|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2014-08-11|2008-01-09|2008-01-10|Estimate|||||||2014-08-11|2014-08-12|Estimate|February 2005||2005-02-28|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Utility of Clinical Examination in the Noninvasive Prediction of Aortic Atheroma - A Prospective Study|Utility of Clinical Examination in the Noninvasive Prediction of Aortic Atheroma - A Prospective Study|Completed|||125|Actual|Creighton University|||1||f||||f||||||||||2018-06-01 02:35:44.880091|2018-06-01 02:35:44.880091
NCT00590603|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-01-07|2008-01-09|2008-01-10|Estimate|||||||2014-01-07|2014-01-08|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AAV||Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Arsenic Trioxide (Trisenox), Ascorbic Acid and Bortezomib Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1|25|Actual|Duke University||1||Poor accrual - terminated during Phase I; Phase II never started.|f||||t||||||||||2018-06-01 02:35:44.936739|2018-06-01 02:35:44.936739
NCT00590590|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2010-06-30||2012-02-29|2008-01-09|2008-01-10|Estimate|2011-01-13|2011-02-09|Estimate||||2012-02-29|2012-03-02|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort||Completed||Phase 2|105|Actual|Lumara Health, Inc.|The study was discontinued following enrollment of 106 of the planned 140 participants due to slow recruitment.|3|||f||||||||||||||2018-06-01 02:35:45.01632|2018-06-01 02:35:45.01632
NCT00590395|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-06-27|2007-12-26|2008-01-10|Estimate|||||||2017-06-27|2017-06-29|Actual|July 2007||2007-07-31|June 2017|2017-06-30|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|||FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis|The Utility of FDG-PET and PET/CT in the Evaluation of Patients With Suspected Cholecystitis|Completed||N/A|20|Actual|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-06-01 02:35:48.664636|2018-06-01 02:35:48.664636
NCT00590577|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-08-21|2009-03-24|2014-05-21|2007-12-26|2008-01-10|Estimate|2009-10-02|2009-10-05|Estimate|2009-10-02|2009-10-05|Estimate|2014-05-21|2014-06-04|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia|Completed||Phase 3|652|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No information on long-term (ie, more than 13-week) treatment; not designed to detect differences between doses of paliperidone palmitate; not designed to demonstrate efficacy for specific subgroups, such as subjects from a particular country|4|||f||||||||||||||2018-06-01 02:35:45.524128|2018-06-01 02:35:45.524128
NCT00590564|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-12-14||2015-12-14|2008-01-09|2008-01-10|Estimate|2015-12-14|2016-01-15|Estimate||||2015-12-14|2016-01-15|Estimate|October 2002||2002-10-31|December 2015|2015-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study|SHO-SAIKO-TO for Patients With Chronic Hepatitis C Who Are Intolerant to or Have Contraindication to Interferon-Based Therapy: A Phase II Study|Completed||Phase 2|42|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:35:47.129094|2018-06-01 02:35:47.129094
NCT00590551|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2008-12-30|2007-12-31|2008-01-10|Estimate|||||||2008-12-30|2008-12-31|Estimate|December 2007||2007-12-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Slings and Their Effect on Skin Pressure|Slings and Repositioning Devices: Their Effects on Skin Pressure|Terminated||N/A|240|Anticipated|Christiana Care Health Services||1||unable to recruit patients for study|f||||f||||||||||2018-06-01 02:35:47.392378|2018-06-01 02:35:47.392378
NCT00590538|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2010-11-15||2011-06-29|2007-12-27|2008-01-10|Estimate|2011-06-29|2011-06-30|Estimate||||2011-06-29|2011-06-30|Estimate|February 2003||2003-02-28|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)|A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygous Cystic Fibrosis Patients|Terminated||Phase 1/Phase 2|9|Actual|Children's Hospital of Philadelphia|No analysis was completed on data collected; More clinically efficacious compounds have been identified which suggested that completion of this study might not be as critical as when initially proposed; therefore, the study was terminated by PI.|2||12/15/2008 Voluntarily placed on inactive status-requested by the PI|f||||t||||||||||2018-06-01 02:35:47.494366|2018-06-01 02:35:47.494366
NCT00590525|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2009-11-27|2008-01-09|2008-01-10|Estimate|||||||2009-11-27|2009-12-01|Estimate|October 2004||2004-10-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Inflammation as a Predictor in Cardioversion of Atrial Fibrillation|Inflammation as a Predictor in Cardioversion of Atrial Fibrillation|Completed|||45|Actual|Creighton University|||1||f||||f||||||||||2018-06-01 02:35:47.692489|2018-06-01 02:35:47.692489
NCT00590512|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2013-08-28|2008-01-09|2008-01-10|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 2005||2005-03-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Dietary Salt Intake and Vascular Function|Dietary Salt Intake and Vascular Function|Completed||Early Phase 1|133|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:35:47.769096|2018-06-01 02:35:47.769096
NCT00590499|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-01-29|2007-12-26|2008-01-10|Estimate|||||||2014-01-29|2014-01-31|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|||Agitation in Post Operative Neurosurgical Patients|A Prospective Survey of Emergent Agitation Following Craniotomy: Incidence, Risk Factors and Outcomes|Completed|||120|Actual|Capital Medical University|||2||f||||||||||||||2018-06-01 02:35:47.834738|2018-06-01 02:35:47.834738
NCT00590473|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-04-07|2007-12-26|2008-01-10|Estimate|||||||2017-04-07|2017-04-10|Actual|April 2007||2007-04-30|April 2017|2017-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Sacral Neuromodulation in Patients With IC|Sacral Neuromodulation: Bilateral Placement vs. Unilateral Placement in Patients With Interstitial Cystitis|Completed||N/A|32|Actual|Drexel University||2|||f||||f||||||||||2018-06-01 02:35:47.896421|2018-06-01 02:35:47.896421
NCT00590460|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-07-02||2018-04-26|2007-12-26|2008-01-10|Estimate|2012-07-02|2012-08-09|Estimate||||2018-04-26|2018-05-24|Actual|July 2001||2001-07-31|April 2018|2018-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Mafia||Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia|Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia|Terminated||Phase 1/Phase 2|5|Actual|Baylor College of Medicine||1||slow accrual|f||||t||||||||||2018-06-01 02:35:47.984223|2018-06-01 02:35:47.984223
NCT00590447|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2017-03-06|2007-12-28|2008-01-10|Estimate|||||||2017-03-06|2017-03-07|Actual|December 2006||2006-12-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|PTLD-1/3||Risk Stratified Sequential Treatment for CD20-positive PTLD|Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3)|Completed||Phase 2|152|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 02:35:48.25396|2018-06-01 02:35:48.25396
NCT00590434|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-10-25|2008-01-09|2008-01-10|Estimate|||||||2012-10-25|2012-10-26|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Yield and Safety of Colonoscopy in Patients Older Than 80 Years|The Yield and Safety of Screening and Surveillance Colonoscopy in Elderly Patients (> 80 Years)|Completed|||169|Actual|Midwest Biomedical Research Foundation|||2||f||||f||||||||||2018-06-01 02:35:48.35656|2018-06-01 02:35:48.35656
NCT00590421|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2008-10-16|2007-12-31|2008-01-10|Estimate|||||||2008-10-16|2008-10-17|Estimate|July 2004||2004-07-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|January 2007|Actual|2007-01-31||Observational|||Carotid Atherosclerotic Disease Following Childhood Scalp Irradiation|Carotid Atherosclerotic Disease Following Childhood Scalp Irradiation|Completed|||295|Actual|Assaf-Harofeh Medical Center|||2||f||||f||||||Samples Without DNA|"~     Blood samples, 10 ml, were procured for assessment of creatinine, total cholesterol, high~     density lipoproteins (HDL), triglycerides (TG), calculated low density lipoproteins (LDL) and~     homocysteine.~   "|||2018-06-01 02:35:48.429593|2018-06-01 02:35:48.429593
NCT00590408|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2009-11-27|2008-01-09|2008-01-10|Estimate|||||||2009-11-27|2009-12-01|Estimate|March 2006||2006-03-31|November 2009|2009-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of Coenzyme Q10 in the Treatment of Statin-Associated Myalgia||Terminated||Phase 4|10|Actual|Creighton University||2||Lack of recruitment|f||||||||||||||2018-06-01 02:35:48.577589|2018-06-01 02:35:48.577589
NCT00590382|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-01-28|2008-01-09|2008-01-10|Estimate|||||||2015-01-28|2015-01-29|Estimate||||August 2009|2009-08-31||||||||Expanded Access|||Emergency/Compassionate Use - Muscular VSD Occluder||Approved for marketing|||||St. Jude Medical|||||||||||||||||||2018-06-01 02:35:48.748005|2018-06-01 02:35:48.748005
NCT00590369|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-06-22||2012-03-30|2008-01-09|2008-01-10|Estimate|2012-03-30|2012-04-02|Estimate||||2012-03-30|2012-04-02|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Negative Pressure Wound Therapy: Are All Systems Alike?|Negative Pressure Wound Therapy: Are All Systems Alike?|Terminated||Phase 3|11|Actual|The Cleveland Clinic|small sample size; early termination; did not reach expected sample size. Single center|2||Recruitment challenges|f||||f||||||||||2018-06-01 02:35:48.809186|2018-06-01 02:35:48.809186
NCT00590356|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2016-12-06|2008-01-09|2008-01-10|Estimate|||||||2016-12-06|2016-12-08|Estimate|March 2007||2007-03-31|December 2016|2016-12-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|CLOSE||Star-Close Versus Angio-Seal for Femoral Artery Hemostasis|A Randomized Comparison of Percutaneous CLip-based Vascular Occluder (Star-Close) Versus Bio-absorble Hemostatic Device (Angio-SEal) for Femoral Artery Hemostasis After Percutaneous Coronary Intervention|Withdrawn||Phase 4|0|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 02:35:49.128923|2018-06-01 02:35:49.128923
NCT00590343|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-06-28|2008-01-09|2008-01-10|Estimate|||||||2011-06-28|2011-06-29|Estimate|November 2004||2004-11-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|PTK787||Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors|An Open-label Phase II Study Evaluating the Safety and Efficacy of PTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors That Have Evidence of Progressive Disease or an Increase in Disease Related Syndrome Symptoms.|Completed||Phase 2|23|Actual|Louisiana State University Health Sciences Center in New Orleans||1|||f||||t||||||||||2018-06-01 02:35:49.208843|2018-06-01 02:35:49.208843
NCT00590330|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2011-05-12|2007-12-26|2008-01-10|Estimate|||||||2011-05-12|2011-05-13|Estimate|October 2007||2007-10-31|May 2011|2011-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs|Microbial Community Composition and Dynamics in Lungs of Cystic Fibrosis Sibling Pairs|Completed|||55|Actual|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     sputum or throat culture~   "|||2018-06-01 02:35:49.280712|2018-06-01 02:35:49.280712
NCT00590317|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-09-17||2014-04-23|2008-01-09|2008-01-10|Estimate|2014-04-23|2014-05-19|Estimate||||2014-04-23|2014-05-19|Estimate|March 2005||2005-03-31|April 2014|2014-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department|Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department|Completed||Phase 2|64|Actual|Emory University|Small sample size due to limited enrollment. Fewer patient in the Odansetron group were discharged home suggesting a possibly sicker baseline group. Complete data sets were not available for all patients due to sedation and participation.|2|||f||||f||||||||||2018-06-01 02:35:49.348588|2018-06-01 02:35:49.348588
NCT00590304|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-09-11|2007-12-27|2008-01-10|Estimate|||||||2017-09-11|2017-09-12|Actual|October 2006||2006-10-31|September 2017|2017-09-30|July 2015|Actual|2015-07-31|December 2009|Actual|2009-12-31||Observational|ADRA||Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors|Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors|Completed|||116|Actual|Arkansas Children's Hospital Research Institute|||1||f||||f||||||Samples With DNA|"~     Optional buccal swab samples will be obtained from participants. This is done by touching the~     inside of the participant's cheek to collect a sample of the cells in his/her mouth with a~     cotton swab type applicator.~   "|No|There is no plan to share individual data.|2018-06-01 02:35:49.625004|2018-06-01 02:35:49.625004
NCT00590291|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-02-02|2007-12-27|2008-01-10|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 1995||1995-01-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|GeneQuest||Molecular Determinants of Coronaruy Artery Disease|Genetic Studies of Coronary Artery Disease and Arteriovenous Malformation (GeneQuest) Molecular Determinants of Coronary Artery Disease|Recruiting|||2980|Anticipated|The Cleveland Clinic|||2||f||||t||||||Samples With DNA|"~     For each participant, 10 ml of blood for lymphoblastoid cell line immortalization, 10-20 ml~     blood for DNA extraction, or two buccal swabs. If gene identified, blood samples from~     children to identify the children affected with this gene will be obtained. When available,~     biopsy tissues for extracting DNA, RNA, protein, or for cell biological studies will be~     obtained. Human genomic DNA will be prepared from peripheral blood lymphocytes, biopsy~     tissue, or cell lines derived from Epstein Barr virus transformed lymphocytes 15. DNA will be~     used for a variety of purposes including linkage analysis and mutational screening.~   "|||2018-06-01 02:35:49.694188|2018-06-01 02:35:49.694188
NCT00590278|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-01-23|2007-12-26|2008-01-10|Estimate|||||||2008-01-23|2008-01-25|Estimate|August 2002||2002-08-31|January 2008|2008-01-31||||||||Interventional|TOMUDEX||A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer|A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer|Completed||Phase 2|49|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:35:49.764181|2018-06-01 02:35:49.764181
NCT00590265|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-07-28|2007-12-26|2008-01-10|Estimate|||||||2014-07-28|2014-07-29|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|BPII-DEP-LT||Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression|Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety|Unknown status|Recruiting|N/A|50|Anticipated|Douglas Mental Health University Institute||2|||f||||t||||||||||2018-06-01 02:35:49.824197|2018-06-01 02:35:49.824197
NCT00590252|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2012-05-14|2007-12-28|2008-01-10|Estimate|||||||2012-05-14|2012-05-15|Estimate|July 2007||2007-07-31|May 2012|2012-05-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||Clinical Testing of New MR Pulse Sequences|Clinical Testing of New MR Pulse Sequences|Unknown status|Recruiting||500|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||None Retained|"~     There are no biospecimens~   "|||2018-06-01 02:35:49.918023|2018-06-01 02:35:49.918023
NCT00590239|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-24|2008-01-09|2008-01-10|Estimate|||||||2017-05-24|2017-05-30|Actual|May 2007||2007-05-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|BERN||Barrett's Esophagus Related Neoplasia (BERN) Project|Endoscopic Detection of Early Neoplasia in Patients With Barrett's Esophagus|Recruiting|||150|Anticipated|Midwest Biomedical Research Foundation|||||f||||f||||||||Yes|Participants individual participant data collected in the study will be available to other researchers upon request. Participants will be identified by participant number, age, race and gender. This information will be available at the end of the study and may be requested via email to april.higbee@va.gov.|2018-06-01 02:35:50.000229|2018-06-01 02:35:50.000229
NCT00589498|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2013-11-01|2008-01-07|2008-01-09|Estimate|||||||2013-11-01|2013-11-04|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Fat Gain and Cardiovascular Disease Mechanisms|Fat Gain and Cardiovascular Disease Mechanisms|Completed||Phase 3|69|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:36:00.627525|2018-06-01 02:36:00.627525
NCT00590226|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-11-12||2014-06-06|2008-01-09|2008-01-10|Estimate|2014-06-06|2014-06-11|Estimate||||2014-06-06|2014-06-11|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|DEAN||Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes|Comparative Trial Between Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Type 2 Diabetes|Completed||Phase 4|130|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:35:50.088|2018-06-01 02:35:50.088
NCT00590213|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2008-01-23|2007-12-28|2008-01-10|Estimate|||||||2008-01-23|2008-01-25|Estimate|June 2003||2003-06-30|January 2008|2008-01-31||||||||Interventional|COMART||Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX|An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients|Completed||Phase 4|125|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:35:50.384769|2018-06-01 02:35:50.384769
NCT00590200|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-01-25|2007-12-26|2008-01-10|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2001||2001-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|July 2007|Actual|2007-07-31||Observational|GATC||GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Disease|Molecular Determinants of Coronary Artery Disease|Active, not recruiting|||15000|Anticipated|The Cleveland Clinic|||||f||||t||||||Samples With DNA|"~     Approximately 70 mls of blood will be dispensed as follows (Approximately 80 mls if cell~     lines are drawn or if the patient is having a cardiac CT scan):~      4 x 10 mls EDTA Tube (DNA will be amplified in order to preserve quantity)~        1. x 10ml Lithium Heparin Tube (drawn on selected patient populations at CCF only- See~          Appendix E. for cell line protocol)~        2. x 5 mls Serum Tube~      1 x 7 mls Serum Tube~      1 x 2.7 mls Sodium Citrate Tube (CCF Only. See Appendix D)~      1 x 4.5 mls CTAD tube (platelet release inhibited)~      1 x 4.5 mls SCAT-1 tube (coagulation activation inhibited) (Blood may be dispensed in the~     above tubes in different quantities if functional studies are needed on a subset of samples)~   "|No||2018-06-01 02:35:50.466082|2018-06-01 02:35:50.466082
NCT00590187|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-23|||2011-11-07|2008-01-09|2008-01-10|Estimate|||||||2011-11-07|2011-11-09|Estimate|December 2007||2007-12-31|November 2011|2011-11-30||||November 2011|Anticipated|2011-11-30||Interventional|||Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients|A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes|Unknown status|Recruiting|Phase 2|300|Anticipated|Cyclacel Pharmaceuticals, Inc.||9|||f||||f||||||||||2018-06-01 02:35:50.533129|2018-06-01 02:35:50.533129
NCT00590174|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2014-03-19|2008-01-09|2008-01-10|Estimate|||||||2014-03-19|2014-03-20|Estimate|October 2007||2007-10-31|March 2014|2014-03-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|ZEST-LATE||Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation|Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events|Completed||Phase 4|1175|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 02:35:50.666633|2018-06-01 02:35:50.666633
NCT00590161|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-03-07||2013-08-05|2007-12-26|2008-01-10|Estimate|2013-08-05|2013-09-26|Estimate||||2013-08-05|2013-09-26|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Pentoxifylline in Patients With Nonalcoholic Steatohepatitis|Treatment Efficacy of Pentoxifylline in Patients With Nonalcoholic Steatohepatitis: A Double-blind Randomized Placebo Controlled Trial|Completed||Phase 2|55|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-06-01 02:35:50.778395|2018-06-01 02:35:50.778395
NCT00590148|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2013-07-29|2007-12-27|2008-01-10|Estimate|||||||2013-07-29|2013-07-30|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Assessing Function in Pediatric Patients With Sickle Cell Disease|Assessing Function in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain Using the FIM Instrument|Completed|||25|Actual|Connecticut Children's Medical Center|||||f||||f||||||||||2018-06-01 02:35:51.007868|2018-06-01 02:35:51.007868
NCT00590135|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2017-04-18||2017-07-25|2008-01-09|2008-01-10|Estimate|2017-07-25|2017-07-26|Actual||||2017-07-25|2017-07-26|Actual|August 2000|Actual|2000-08-31|July 2017|2017-07-31|April 26, 2010|Actual|2010-04-26|April 26, 2010|Actual|2010-04-26||Interventional|||The Effect of Lipitor on Aortic Stenosis|The Effect of Statin Therapy (Atorvastatin) on the Progression of Calcific Valvular Aortic Stenosis|Terminated||Phase 4|59|Actual|The Cleveland Clinic||1||Poor Reducibility - primary endpoint measure not obtainable|f||||f||||||||No||2018-06-01 02:35:51.093843|2018-06-01 02:35:51.093843
NCT00590122|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2009-03-12|2008-01-09|2008-01-10|Estimate|||||||2009-03-12|2009-03-16|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study|COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL|Completed||Phase 4|20|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:35:51.287955|2018-06-01 02:35:51.287955
NCT00590109|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-01-02|2008-01-09|2008-01-10|Estimate|||||||2018-01-02|2018-01-03|Actual|March 1997||1997-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer|Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer|Active, not recruiting|||5600|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 02:35:51.378345|2018-06-01 02:35:51.378345
NCT00590096|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2009-08-24|2007-12-27|2008-01-10|Estimate|||||||2009-08-24|2009-08-25|Estimate|January 1991||1991-01-31|January 2007|2007-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma|I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma|Completed|||1380|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 02:35:51.46758|2018-06-01 02:35:51.46758
NCT00590083|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-02-14|2007-12-26|2008-01-10|Estimate|||||||2014-02-14|2014-02-19|Estimate|July 2003||2003-07-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|LYPTAIST||Administration of Virus-Specific Cytotoxic T-Lymphocytes|Administration of Virus-Specific Cytotoxic T-Lymphocytes for the Prophylaxis and Therapy of Adenovirus Infection Post Allogeneic Stem Cell Transplant|Completed||Phase 1|14|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:35:51.529115|2018-06-01 02:35:51.529115
NCT00590070|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2012-03-25|2008-01-09|2008-01-10|Estimate|||||||2012-03-25|2012-03-27|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|REOPEN-AMI||THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction|Randomized Evaluation Of Intracoronary Nitroprusside vs Adenosine After Thrombus-aspiration During Primary PErcutaneous Coronary Intervention for the Prevention of No Reflow in Acute Myocardial Infarction|Completed||Phase 2/Phase 3|240|Actual|Catholic University of the Sacred Heart||3|||f||||t||||||||||2018-06-01 02:35:51.613342|2018-06-01 02:35:51.613342
NCT00590044|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2009-01-30||2013-11-12|2008-01-09|2008-01-10|Estimate|2009-03-17|2009-04-30|Estimate||||2013-11-12|2013-12-05|Estimate|December 2007||2007-12-31|November 2013|2013-11-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)|Basal Insulin in the Management of Patients With Diabetic Ketoacidosis|Completed||Phase 4|74|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:35:51.719255|2018-06-01 02:35:51.719255
NCT00590031|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-18||2015-12-18|2008-01-09|2008-01-10|Estimate|2015-12-18|2016-01-25|Estimate||||2015-12-18|2016-01-25|Estimate|November 2002||2002-11-30|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.|Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.|Completed||Phase 2|61|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:35:51.954397|2018-06-01 02:35:51.954397
NCT00590018|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2016-02-23||2016-04-20|2007-12-28|2008-01-10|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|February 2003||2003-02-28|April 2016|2016-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Corti||Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease|Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease|Completed||Phase 2|18|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 02:35:52.163527|2018-06-01 02:35:52.163527
NCT00590005|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-07-10||2014-01-14|2008-01-09|2008-01-10|Estimate|2013-11-22|2014-01-13|Estimate||||2014-01-14|2014-02-10|Estimate|January 2003||2003-01-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|SARP||Redox Determinants of Severe Asthma (a Substudy of the Severe Asthma Research Program)|Redox Determinants of Severe Asthma: A Substudy of the NHLBI Severe Asthma Research Program|Completed|||225|Actual|Emory University|||2||f||||t||||||||||2018-06-01 02:35:52.401434|2018-06-01 02:35:52.401434
NCT00589992|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-01-27|2007-12-26|2008-01-10|Estimate|||||||2012-01-27|2012-01-31|Estimate|October 2007||2007-10-31|January 2012|2012-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|IBAD-AFIB||Ibutilide Administration During Pulmonary Vein Ablation|Atrial Fibrillation Mechanism Analysis Through Ibutilide Administration During Pulmonary Vein Ablation.|Unknown status|Recruiting|N/A|50|Anticipated|Ball Memorial Hospital|||||f||||f||||||||||2018-06-01 02:35:52.628427|2018-06-01 02:35:52.628427
NCT00589979|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2009-12-22||2017-09-07|2008-01-09|2008-01-10|Estimate|2010-09-20|2010-09-22|Estimate||||2017-09-07|2017-10-05|Actual|March 2007||2007-03-31|September 2017|2017-09-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee|Efficacy and Safety of the Lidocaine 5% Patch When Used as Adjunct Treatment in Patients With Osteoarthritis of the Knee Receiving Sub-Optimal Pain Relief From Their Current Analgesic Regimen|Completed||Phase 2|169|Actual|Endo Pharmaceuticals|Due to operational issues, the modified intent-to-treat (MITT) population, consisting of all intent-to-treat (ITT) patients randomized on or after January 22, 2008, was added to the analysis plan; all efficacy data are presented for this population.|2|||f||||f||||||||||2018-06-01 02:35:52.760343|2018-06-01 02:35:52.760343
NCT00589966|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2013-02-28|2008-01-09|2008-01-10|Estimate|||||||2013-02-28|2013-03-01|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|CAAPS||Coping in African American Prostate Cancer Survivors|Coping Skills Training Groups to Enhance Recovery From Prostate Cancer in African American Men|Completed||N/A|62|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:35:54.0855|2018-06-01 02:35:54.0855
NCT00589953|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2013-07-29|2007-12-27|2008-01-10|Estimate|||||||2013-07-29|2013-07-30|Estimate|July 2007||2007-07-31|July 2013|2013-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study|High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study|Terminated||Phase 2|22|Actual|Atlantic Health System||2|||f||||t||||||||||2018-06-01 02:35:54.156421|2018-06-01 02:35:54.156421
NCT00589927|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2010-03-17|2007-12-31|2008-01-10|Estimate|||||||2010-03-17|2010-03-18|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|DECLARELONG||Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent|Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions|Completed||Phase 4|486|Anticipated|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 02:35:54.285853|2018-06-01 02:35:54.285853
NCT00589914|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-08-30||2014-06-11|2007-12-26|2008-01-10|Estimate|2011-08-30|2011-10-04|Estimate||||2014-06-11|2014-06-24|Estimate|March 2007||2007-03-31|June 2014|2014-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia|A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects With Schizophrenia|Completed||Phase 3|1221|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Of 1221 patients randomized, one patient was enrolled twice and assigned 2 patient numbers. Only the first patient number is included in the results reported for 1220 randomized patients.|2|||f||||f||||||||||2018-06-01 02:35:54.42304|2018-06-01 02:35:54.42304
NCT00589901|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-04-17|2008-01-09|2008-01-10|Estimate|||||||2008-04-17|2008-04-18|Estimate|August 2006||2006-08-31|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)|Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Fudan University||1|||f||||f||||||||||2018-06-01 02:35:55.20514|2018-06-01 02:35:55.20514
NCT00589888|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2014-03-24||2014-06-06|2008-01-09|2008-01-10|Estimate|2014-06-06|2014-07-09|Estimate||||2014-06-06|2014-07-09|Estimate|August 2006||2006-08-31|May 2014|2014-05-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional||obese, healthy subjects.|FFA-Induced Hypertension and Endothelial Dysfunction|Free Fatty Acids-Induced Hypertension and Endothelial Dysfunction in Obese Subjects|Completed||N/A|13|Actual|Emory University||5|||f||||t||||||||||2018-06-01 02:35:55.319277|2018-06-01 02:35:55.319277
NCT00589875|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27||2017-04-08|2017-04-08|2007-12-27|2008-01-10|Estimate||||2017-04-08|2017-04-11|Actual|2017-04-08|2017-04-11|Actual|March 2007||2007-03-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|BrTK02||Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)|A Phase 2a Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Glioma|Completed||Phase 2|52|Actual|Advantagene, Inc.||1|||f||||t||||||||||2018-06-01 02:35:55.581309|2018-06-01 02:35:55.581309
NCT00589862|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2015-11-27|2008-01-09|2008-01-10|Estimate|||||||2015-11-27|2015-11-30|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents||Withdrawn||Phase 4|0|Actual|Creighton University||1||Failure to secure adequate funding|f||||||||||||||2018-06-01 02:35:55.686564|2018-06-01 02:35:55.686564
NCT00589849|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-08-03||2011-09-02|2008-01-09|2008-01-10|Estimate|2011-09-02|2011-10-05|Estimate||||2011-09-02|2011-10-05|Estimate|May 2006||2006-05-31|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy|T-Wave Alternans in Acute Myocardial Infarction: An Evaluation of the Time of Testing on Its Prognostic Accuracy|Completed|||32|Actual|Creighton University|||1||f||||f||||||||||2018-06-01 02:35:55.763545|2018-06-01 02:35:55.763545
NCT00589836|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2017-04-20||2017-07-19|2008-01-09|2008-01-10|Estimate|2017-07-19|2018-02-05|Actual||||2017-07-19|2018-02-05|Actual|June 2005||2005-06-30|July 2017|2017-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|LVTorsion||Assessment of Left Ventricular Torsion by Echocardiography Study|Assessment of LV Torsion by Tissue Doppler Echocardiography|Completed|||20|Actual|The Cleveland Clinic|||1||f||||f|f|f||||||No||2018-06-01 02:35:55.922168|2018-06-01 02:35:55.922168
NCT00589823|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27||2010-01-20|2010-01-20|2007-12-27|2008-01-10|Estimate||||2010-01-20|2010-01-22|Estimate|2010-01-20|2010-01-22|Estimate|June 2007||2007-06-30|January 2010|2010-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids|A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Fentanyl Citrate Nasal Spray Compared to Immediate Release Morphine Sulphate in the Treatment of BTCP in Subjects Taking Regular Opioid Therapy|Completed||Phase 3|135|Actual|Archimedes Development Ltd||2|||f||||f||||||||||2018-06-01 02:35:56.069006|2018-06-01 02:35:56.069006
NCT00589810|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-03-22|2007-12-26|2008-01-10|Estimate|||||||2017-03-22|2017-03-24|Actual|August 2007|Actual|2007-08-31|March 2017|2017-03-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Observational|||Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal|Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation Proposal|Completed|||761|Actual|The Cleveland Clinic|||2||f||||f|f|f||||Samples With DNA|"~     DNA~   "|No||2018-06-01 02:35:56.162995|2018-06-01 02:35:56.162995
NCT00589797|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-02-23|2007-12-26|2008-01-10|Estimate|||||||2013-02-23|2013-02-26|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|July 2017|Anticipated|2017-07-31|December 2012|Actual|2012-12-31||Interventional|||Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease|Clinical Study to Evaluate the Safety and Effectiveness of the Aesculap Activ-L™ Artificial Disc in the Treatment of Degenerative Disc Disease|Unknown status|Active, not recruiting|Phase 3|414|Anticipated|Aesculap Implant Systems||2|||f||||f||||||||||2018-06-01 02:35:56.274441|2018-06-01 02:35:56.274441
NCT00589784|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-21||2015-12-21|2008-01-09|2008-01-10|Estimate|2015-12-21|2016-01-25|Estimate||||2015-12-21|2016-01-25|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma|Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma|Completed||Phase 2|50|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:35:56.42203|2018-06-01 02:35:56.42203
NCT00589771|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-10-14|2007-12-26|2008-01-10|Estimate|||||||2012-10-14|2012-10-16|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SB-IBS||Saccharomyces Boulardii in Irritable Bowel Syndrome|Clinical and Cytokine Response to Saccharomyces Boulardii Therapy in Diarrhea Dominant Irritable Bowel Syndrome|Completed||Phase 3|72|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 02:35:56.696808|2018-06-01 02:35:56.696808
NCT00589758|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-01-31|2007-12-27|2008-01-10|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2006|Actual|2006-07-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|TARVA||Tissue Doppler Assessment of Right Ventricular Performance in Acute Heeart Failure|Tissue Doppler Assessment of Right Ventricular Performance in Acute Heeart Failure|Completed|||75|Actual|The Cleveland Clinic|||1||f||||f|f|f||||Samples Without DNA|"~     Blood and Urine~   "|No||2018-06-01 02:35:56.772655|2018-06-01 02:35:56.772655
NCT00589745|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2018-01-09|2008-01-09|2008-01-10|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2003||2003-09-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis|Measurement of Transepithelial Nasal Potential Difference (NPD) for the Diagnosis of Cystic Fibrosis|Recruiting||N/A|25|Anticipated|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-06-01 02:35:56.841565|2018-06-01 02:35:56.841565
NCT00589732|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2012-08-07|2007-12-31|2008-01-10|Estimate|||||||2012-08-07|2012-08-08|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|VAL-SUPPRES||Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent|Valsartan for SUPpression of Plaque Volume and Restenosis After Drug-Eluting Stent (The VAL-SUPPRESS TRial)|Completed||Phase 4|220|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 02:35:56.910341|2018-06-01 02:35:56.910341
NCT00589719|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-08-25|2007-12-27|2008-01-10|Estimate|||||||2008-08-25|2008-08-26|Estimate|August 2005||2005-08-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|May 2006|Actual|2006-05-31||Observational|||Asthma in the Delta Region of Arkansas (ADRA): Prevalence and Morbidity|Asthma in the Delta Region of Arkansas (ADRA): Prevalence and Morbidity|Completed|||964|Actual|Arkansas Children's Hospital Research Institute|||1||f||||f||||||||||2018-06-01 02:35:57.079596|2018-06-01 02:35:57.079596
NCT00589706|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-08|2008-01-09|2008-01-10|Estimate|||||||2017-05-08|2017-05-09|Actual|January 1985||1985-01-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas|A Phase II Study o the Adjuvant Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFR-425) Monoclonal Antibody Radiolabeled With I-125 for High Grade Gliomas|Completed||Phase 2|11|Actual|Drexel University||1|||f||||t|t|f||||||No||2018-06-01 02:35:57.134998|2018-06-01 02:35:57.134998
NCT00589485|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-19|2008-01-03|2008-01-09|Estimate|||||||2017-06-19|2017-06-21|Actual|November 2006||2006-11-30|June 2017|2017-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement|Total Knee Replacement Using Simplex® or Cobalt™ Bone Cement|Withdrawn|||0|Actual|Zimmer Biomet|||2|Sponsor did not fund the study|f||||f||||||||||2018-06-01 02:36:00.733881|2018-06-01 02:36:00.733881
NCT00196235|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-09|2005-09-13|2005-09-20|Estimate|||||||2018-03-09|2018-03-12|Actual|January 1995||1995-01-31|September 2005|2005-09-30||||||||Observational|||Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Diabetes Mellitus|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Diabetes Mellitus|Completed|||650||Deutsches Herzzentrum Muenchen|||||f||||||||||||||2018-06-01 04:33:10.058853|2018-06-01 04:33:10.058853
NCT00589693|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-06-13||2012-12-24|2007-12-26|2008-01-10|Estimate|2012-06-13|2012-07-18|Estimate||||2012-12-24|2012-12-28|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia|A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects With Ventilator-Associated Pneumonia|Terminated||Phase 3|274|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|41 patients (21 doripenem, 20 imipenem-cilastatin) were enrolled at 5 sites that were found to be Good Clinical Practice non-compliant and were excluded from the primary efficacy and safety analyses.|2||Observed lower cure rates and higher mortality rates in one of the treatment groups.|f||||t||||||||||2018-06-01 02:35:57.263008|2018-06-01 02:35:57.263008
NCT00589680|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-01-09|2008-01-09|2008-01-10|Estimate|||||||2008-01-09|2008-01-10|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Observational|||Compliance With American Diabetes Association Treatment Guidelines for Adult Ketoacidosis|Compliance With American Diabetes Association Treatment Guidelines for Adult Ketoacidosis|Unknown status|Active, not recruiting||60|Anticipated|Marshall University|||2||f||||f||||||||||2018-06-01 02:35:58.143613|2018-06-01 02:35:58.143613
NCT00589667|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2014-01-23||2014-03-05|2008-01-09|2008-01-10|Estimate|2014-01-23|2014-03-05|Estimate||||2014-03-05|2014-04-02|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)|A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)|Completed||Phase 2|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:35:58.240752|2018-06-01 02:35:58.240752
NCT00589654|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-01-02|2008-01-09|2008-01-10|Estimate|||||||2018-01-02|2018-01-03|Actual|December 1997||1997-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Menstrual Cycle Maintenance and Quality of Life: A Prospective Study|Menstrual Cycle Maintenance and Quality of Life: A Prospective Study|Active, not recruiting|||810|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:35:58.467983|2018-06-01 02:35:58.467983
NCT00589641|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-31|||2014-07-09|2008-01-09|2008-01-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|July 2005||2005-07-31|June 2010|2010-06-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|CBT-RP||Relapse Prevention for Suicidal Dually Diagnosed Youths|Relapse Prevention for Suicidal Dually Diagnosed Youths|Completed||Phase 1|13|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:35:58.536231|2018-06-01 02:35:58.536231
NCT00589628|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2013-02-21||2013-08-22|2008-01-09|2008-01-10|Estimate|2013-08-22|2013-08-26|Estimate||||2013-08-22|2013-08-26|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis|Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis|Completed||Phase 4|13|Actual|Duke University|Study recruitment was difficult and slow. Optimal number not achieved in this descriptive study.|2|||f||||t||||||||||2018-06-01 02:35:58.621449|2018-06-01 02:35:58.621449
NCT00589615|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2008-01-09|2008-01-09|2008-01-10|Estimate|||||||2008-01-09|2008-01-10|Estimate|January 1996||1996-01-31|December 2007|2007-12-31||||||||Interventional|||Effectiveness of an Educational Program in the Prevention of Osteoporosis and Fractures|Effectiveness of an Educational Program in the Prevention of Osteoporosis and Fractures|Completed||N/A|2181|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:35:59.001961|2018-06-01 02:35:59.001961
NCT00589602|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|2016-09-20||2017-04-18|2008-01-01|2008-01-09|Estimate|2017-04-18|2017-05-30|Actual||||2017-04-18|2017-05-30|Actual|January 2004||2004-01-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|August 2009|Actual|2009-08-31||Interventional|||T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases|Phase II Feasibility Study of T-Cell Depletion in Allogeneic Unrelated Bone Marrow Transplantation (MUD ALLO BMT) Followed by Delayed T-Cell Infusions|Terminated||Phase 2|13|Actual|The Cleveland Clinic||1||slow accrual|f||||t||||||||No||2018-06-01 02:35:59.191901|2018-06-01 02:35:59.191901
NCT00589589|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2015-09-01|2008-01-08|2008-01-09|Estimate|||||||2015-09-01|2015-09-03|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|EndoTool||Computer Decision Support to Achieve Glycemic Control in the ICU|Computer Decision Support to Achieve Glycemic Control in the ICU|Completed||Phase 1|24|Actual|United States Army Institute of Surgical Research||1|||f||||f||||||||||2018-06-01 02:35:59.383982|2018-06-01 02:35:59.383982
NCT00589563|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-07-21||2014-09-03|2007-12-25|2008-01-09|Estimate|2014-07-21|2014-08-12|Estimate||||2014-09-03|2014-09-10|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer|A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation|Completed||Phase 2|32|Actual|City of Hope Medical Center||3|||f||||t||||||||||2018-06-01 02:35:59.475116|2018-06-01 02:35:59.475116
NCT00589550|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-05|2015-05-06||2015-06-04|2008-01-05|2008-01-09|Estimate|2015-06-04|2015-06-08|Estimate||||2015-06-04|2015-06-08|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase I Study Of Peginterferon Alfa-2b (PEG-INTRON) With Sorafenib (Nexavar) In Patients With Unresectable Or Metastatic Clear Cell Renal Carcinoma (RCC).|Terminated||Phase 1|1|Actual|Ohio State University Comprehensive Cancer Center|Trial was terminated due to low patient accrual|1||low accrual|f||||t||||||||||2018-06-01 02:36:00.107628|2018-06-01 02:36:00.107628
NCT00589537|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2013-08-06|2007-12-25|2008-01-09|Estimate|||||||2013-08-06|2013-08-07|Estimate|March 2008||2008-03-31|July 2009|2009-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle|Trial of Imaging and Schedule in Seminoma Testis|Unknown status|Recruiting|Phase 3|660|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:36:00.304577|2018-06-01 02:36:00.304577
NCT00589524|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-01-12|2008-01-07|2008-01-09|Estimate|||||||2012-01-12|2012-01-16|Estimate|November 2007||2007-11-30|January 2012|2012-01-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Comparison of Coronary CT With IVUS in Heart Transplant Population|Comparison of Non-invasive Coronary CT With IVUS for the Detection of Coronary Artery Vasculopathy in a Cardiac Transplant Population|Withdrawn||N/A|0|Actual|Mayo Clinic||||Difficult recruitment -|f||||f||||||||||2018-06-01 02:36:00.495171|2018-06-01 02:36:00.495171
NCT00589511|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-23|||2014-08-07|2008-01-08|2008-01-09|Estimate|||||||2014-08-07|2014-08-11|Estimate|October 2006||2006-10-31|August 2014|2014-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study||Completed|||69|Actual|Cochlear|||||f||||||||||||||2018-06-01 02:36:00.559328|2018-06-01 02:36:00.559328
NCT00589472|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-03-24||2017-09-18|2007-12-25|2008-01-09|Estimate|2017-09-18|2017-10-06|Actual||||2017-09-18|2017-10-06|Actual|November 2007||2007-11-30|September 2017|2017-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|TARGET||Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer|Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET)|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:36:00.864146|2018-06-01 02:36:00.864146
NCT00589459|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-01-08|2008-01-08|2008-01-09|Estimate|||||||2008-01-08|2008-01-09|Estimate|October 2001||2001-10-31|December 2007|2007-12-31|December 2008|Anticipated|2008-12-31|September 2005|Anticipated|2005-09-30||Observational|||Gender Differences in Prevalence of Undiagnosed Diabetes in ACS|A Pilot Study of Gender Differences in the Prevalence of Undiagnosed Diabetes in Acute Coronary Syndromes (ACS)|Unknown status|Active, not recruiting||103|Actual|Yale University|||2||f||||f||||||||||2018-06-01 02:36:01.225907|2018-06-01 02:36:01.225907
NCT00589446|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2009-06-28|2008-01-08|2008-01-09|Estimate|||||||2009-06-28|2009-06-30|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Investigation of Embryoscopy in Recurrent Pregnancy Loss|Investigation of Embryoscopy in Recurrent Pregnancy Loss|Completed||N/A|20|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:36:01.304211|2018-06-01 02:36:01.304211
NCT00589433|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2013-03-21|2008-01-08|2008-01-09|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31||||||||Observational|||Follow Up Study of Tear in the Rotator Culf|Follow Up Study of Tear in the Rotator Culf|Terminated|||50|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 02:36:01.393477|2018-06-01 02:36:01.393477
NCT00589420|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2009-07-07|2007-12-25|2008-01-09|Estimate|||||||2009-07-07|2009-07-08|Estimate|October 2006||2006-10-31|July 2009|2009-07-31||||December 2009|Anticipated|2009-12-31||Interventional|||Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy|A Phase II Study of Sorafenib in Combination With Docetaxel in Patients With Androgen-Independent Prostate Cancer|Unknown status|Recruiting|Phase 2|69|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:36:01.450017|2018-06-01 02:36:01.450017
NCT00589407|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-23|||2013-03-21|2007-12-23|2008-01-09|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31||||||||Observational|||Unilateral Blindness/ Unilateral Deafness-relation to Neck Pain|Unilateral Blindness/ Unilateral Deafness-relation to Neck Pain|Terminated|||300|Anticipated|Hadassah Medical Organization||||there is a problem in recruting the paricipents|f||||||||||||||2018-06-01 02:36:01.523841|2018-06-01 02:36:01.523841
NCT00589394|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2016-01-08|2008-01-08|2008-01-09|Estimate|||||||2016-01-08|2016-01-11|Estimate|July 2007||2007-07-31|January 2016|2016-01-31|January 2010|Actual|2010-01-31|December 2008|Actual|2008-12-31||Interventional|||Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine|Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine|Completed||Phase 1|100|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:36:01.576543|2018-06-01 02:36:01.576543
NCT00589381|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-03-07|2007-12-25|2008-01-09|Estimate|||||||2012-03-07|2012-03-08|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma|Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas|Completed||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 02:36:01.646211|2018-06-01 02:36:01.646211
NCT00589368|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2012-10-05|2007-12-24|2008-01-09|Estimate|||||||2012-10-05|2012-10-08|Estimate|May 2006||2006-05-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Transfer of Grasp Control Across Hands After Stroke|Interhemispheric Transfer of Grasp Control After Stroke|Completed|||58|Actual|New York University School of Medicine|||2||f||||f||||||||||2018-06-01 02:36:01.728357|2018-06-01 02:36:01.728357
NCT00589355|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2007-12-27|2007-12-27|2008-01-09|Estimate|||||||2007-12-27|2008-01-09|Estimate|January 2002||2002-01-31|December 2007|2007-12-31|October 2008|Anticipated|2008-10-31|June 2003|Actual|2003-06-30||Observational|||C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance|C-Reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance|Unknown status|Active, not recruiting||46|Actual|Yale University|||2||f||||f||||||||||2018-06-01 02:36:01.806664|2018-06-01 02:36:01.806664
NCT00589329|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2012-10-23|2008-01-08|2008-01-09|Estimate|||||||2012-10-23|2012-10-24|Estimate|December 2007||2007-12-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam|Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam|Terminated||N/A|50|Actual|MetroHealth Medical Center||2||published data suggest potential harm in other investigations.|f||||t||||||||||2018-06-01 02:36:01.863488|2018-06-01 02:36:01.863488
NCT00589316|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2018-05-14|2008-01-03|2008-01-09|Estimate|||||||2018-05-14|2018-05-15|Actual|October 5, 2007|Actual|2007-10-05|May 2018|2018-05-31|October 1, 2024|Anticipated|2024-10-01|October 1, 2016|Actual|2016-10-01||Interventional|||Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome|Hematopoietic Bone Marrow Transplantation for Patients With High-risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined With Immunosuppression Before and After Transplantation|Active, not recruiting||Phase 1|26|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 02:36:01.935628|2018-06-01 02:36:01.935628
NCT00589303|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-02-25||2013-02-25|2008-01-07|2008-01-09|Estimate|2013-02-25|2013-04-04|Estimate||||2013-02-25|2013-04-04|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PACIFIC||AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study|Pacing and AV Node Ablation Compared to Drug Therapy in Symptomatic Elderly Patients With Atrial Fibrillation Clinical Trial (PACIFIC) - Pilot Study|Terminated||Phase 3|27|Actual|Mayo Clinic|The study was terminated when about half of the subjects were enrolled due to lack of funding.|2||Lack of funding|f||||t||||||||||2018-06-01 02:36:02.040771|2018-06-01 02:36:02.040771
NCT00589290|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2011-10-28||2015-09-29|2007-12-25|2008-01-09|Estimate|2012-04-24|2012-05-30|Estimate||||2015-09-29|2015-09-30|Estimate|December 2007||2007-12-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|July 2013|Actual|2013-07-31||Interventional|||Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage|A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma|Completed||Phase 2|41|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 02:36:02.288277|2018-06-01 02:36:02.288277
NCT00589277|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2013-01-02||2013-01-02|2008-01-08|2008-01-09|Estimate|2013-01-02|2013-02-05|Estimate||||2013-01-02|2013-02-05|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Message Framing for Telephone Quitline Callers|Promoting Tobacco and Cancer Control: Message Framing for Telephone Quitline Callers|Completed||Phase 1/Phase 2|2032|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:36:02.681179|2018-06-01 02:36:02.681179
NCT00589264|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2014-09-08|2008-01-08|2008-01-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|July 2004||2004-07-31|September 2014|2014-09-30|June 2009|Actual|2009-06-30|May 2008|Actual|2008-05-31||Interventional|||Zinc and Biobehavioral Development in Early Childhood|Zinc and Biobehavioral Development in Early Childhood|Completed||N/A|251|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 02:36:02.872265|2018-06-01 02:36:02.872265
NCT00589251|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2016-01-08|2008-01-08|2008-01-09|Estimate|||||||2016-01-08|2016-01-11|Estimate|June 2008||2008-06-30|January 2016|2016-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Equivalency of Penicilloate Skin Test Reactivity Prepared by a Modified Alkaline Hydrolysis Technique|Equivalency of Penicilloate Skin Test Reactivity Prepared by a Modified Alkaline Hydrolysis Technique|Withdrawn||N/A|0|Actual|Mayo Clinic||1||Lack of funding|f||||f||||||||Undecided||2018-06-01 02:36:02.950499|2018-06-01 02:36:02.950499
NCT00589238|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-06-18|2008-01-05|2008-01-09|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2008||2008-01-31|June 2013|2013-06-30||||July 2012|Actual|2012-07-31||Interventional|||Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery|Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Compared to Weekly Paclitaxel Alone Followed in Both Arms by Doxorubicin and Cyclophosphamide for Operable or Locally Advanced Basal-like Subtype Breast Cancer Correlating BRCA-1 mRNA and Protein Expression With Carboplatin Response|Terminated||Phase 2|16|Actual|National Cancer Centre, Singapore||2|||f||||||||||||||2018-06-01 02:36:03.025673|2018-06-01 02:36:03.025673
NCT00589225|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2016-07-05|2007-12-28|2008-01-09|Estimate|||||||2016-07-05|2016-07-07|Estimate|December 2003||2003-12-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Primary Hyperoxaluria Mutation Genotyping|Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria|Completed|||902|Actual|Mayo Clinic|||1||f||||t||||||Samples With DNA|"~     DNA samples~   "|No||2018-06-01 02:36:03.096068|2018-06-01 02:36:03.096068
NCT00589212|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2008-06-09|2008-01-08|2008-01-09|Estimate|||||||2008-06-09|2008-06-11|Estimate|October 2003||2003-10-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||GliaSite 1-3 Mets Study|A Phase II Study Utilizing Focal Radiation in Patients With 1-3 Brain Metastases|Completed||Phase 2|50|Anticipated|Hologic, Inc.||1|||f||||t||||||||||2018-06-01 02:36:03.165225|2018-06-01 02:36:03.165225
NCT00589199|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-05-23|2007-12-21|2008-01-09|Estimate|||||||2012-05-23|2012-05-25|Estimate|December 1993||1993-12-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Functional Electrical Stimulation for Production of Artificial Cough|Functional Electrical Stimulation for Production of Artificial Cough|Completed||N/A|5|Actual|Case Western Reserve University||1|||f||||f||||||||||2018-06-01 02:36:03.22908|2018-06-01 02:36:03.22908
NCT00589186|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-12-17|2007-12-25|2008-01-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2007||2007-11-30|December 2008|2008-12-31||||December 2009|Anticipated|2009-12-31||Interventional|||Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer|Phase II Clinical Trial of Tumour Vaccination By Intradermal Delivery of Autologous Dendritic Cells Transduced With Adenoviral Vector (AD5F35) Expressing Latent Membrane Protein-1 (LMP-1) and Latent Membrane Protein-2 (LMP-2) Genes in Combination With Celecoxib in Patient With Metastatic Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:36:03.284815|2018-06-01 02:36:03.284815
NCT00589173|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2012-07-22|2008-01-08|2008-01-09|Estimate|||||||2012-07-22|2012-07-24|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||An Interactive Preventive Health Record (IPHR) to Promote Patient-Centered Preventive Care|An Interactive Preventive Health Record (IPHR) to Promote Patient-Centered Preventive Care|Completed||N/A|5500|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-06-01 02:36:03.354292|2018-06-01 02:36:03.354292
NCT00589147|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-05-25|2008-01-08|2008-01-09|Estimate|||||||2012-05-25|2012-05-28|Estimate|August 2003||2003-08-31|May 2012|2012-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Prospective, Randomized, Controlled Study Comparing Three Tibial Component Designs in Total Knee Arthoplasty|A Prospective, Randomized, Controlled Study Comparing Three Tibial Component Designs in Total Knee Arthoplasty|Completed||N/A|397|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 02:36:03.417781|2018-06-01 02:36:03.417781
NCT00589134|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2010-07-15|2008-01-02|2008-01-09|Estimate|||||||2010-07-15|2010-07-16|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration|The Effects of Estradiol and Progesterone on Arginine Vasopressin Regulation and Serum Sodium Concentration|Completed||N/A|26|Actual|Yale University||1|||f||||||||||||||2018-06-01 02:36:03.468261|2018-06-01 02:36:03.468261
NCT00589121|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-05|2016-08-25||2017-06-19|2008-01-05|2008-01-09|Estimate|2017-06-19|2017-07-17|Actual||||2017-06-19|2017-07-17|Actual|March 2008||2008-03-31|June 2017|2017-06-30||||December 2012|Actual|2012-12-31||Interventional||All eligible patients who started protocol treatment.|Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg|A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity|Active, not recruiting||Phase 2|98|Actual|Radiation Therapy Oncology Group|Due to unmet accrual goals for Cohort A, the decision was made to close this cohort and to increase the sample size of Cohort B. Due to the small sample size for Cohort A results were not reported.|2|||f||||t||||||||||2018-06-01 02:36:04.464387|2018-06-01 02:36:04.464387
NCT00589108|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-12-10||2012-12-10|2008-01-08|2008-01-09|Estimate|2012-12-10|2013-01-16|Estimate||||2012-12-10|2013-01-16|Estimate|January 2001||2001-01-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparison of A Mobile-Bearing Total Knee System With A Fixed-Bearing Total Knee System In Cemented Total Knee Arthroplasty|A Prospective, Randomized, Controlled Study Comparing A Mobile-Bearing Total Knee System With A Fixed-Bearing Total Knee System In Cemented Total Knee Arthroplasty|Completed||N/A|240|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 02:36:05.842341|2018-06-01 02:36:05.842341
NCT00589095|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2014-07-01|2008-01-08|2008-01-09|Estimate|||||||2014-07-01|2014-07-02|Estimate|November 2006||2006-11-30|July 2014|2014-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities|Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities|Terminated|||5|Anticipated|Yale University|||1||f||||f||||||||||2018-06-01 02:36:06.22323|2018-06-01 02:36:06.22323
NCT00589082|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2008-01-08|2008-01-08|2008-01-09|Estimate|||||||2008-01-08|2008-01-09|Estimate|October 2001||2001-10-31|December 2007|2007-12-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML|DaunoXome (Liposomal Daunorubicin) Plus Ara-C Versus Daunorubicin Plus Ara-C in Elderly AML Patients.A Randomized Phase III Study.|Completed||Phase 3|||Gruppo Italiano Malattie EMatologiche dell'Adulto||2|||f||||f||||||||||2018-06-01 02:36:06.281556|2018-06-01 02:36:06.281556
NCT00589069|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2015-05-15|2008-01-08|2008-01-09|Estimate|||||||2015-05-15|2015-05-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:36:06.341417|2018-06-01 02:36:06.341417
NCT00589056|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2016-09-23|2007-12-25|2008-01-09|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2007||2007-06-30|September 2016|2016-09-30||||March 2012|Actual|2012-03-31||Interventional|||Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase I/II Trial of Protease Inhibitor, Nelfinavir, Given With Concurrent Thoracic Chemoradiotherapy in Patients With Locally-Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|55|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 02:36:06.374403|2018-06-01 02:36:06.374403
NCT00589043|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2015-08-24|2008-01-08|2008-01-09|Estimate|||||||2015-08-24|2015-08-25|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|CTLM||Computed Tomography Laser Mammography Breast Imaging Device|Computed Tomography Laser Mammography Breast Imaging Device Model 1020|Unknown status|Not yet recruiting||600|Anticipated|Imaging Diagnostic Systems|||||f||||f||||||||||2018-06-01 02:36:06.445758|2018-06-01 02:36:06.445758
NCT00589030|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2017-02-13|2008-01-03|2008-01-09|Estimate|||||||2017-02-13|2017-02-15|Actual|April 2007||2007-04-30|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Expanded Access|||Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol|No longer available|||||City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:36:06.585566|2018-06-01 02:36:06.585566
NCT00588991|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-04-20|2007-12-25|2008-01-09|Estimate|||||||2018-04-20|2018-04-23|Actual|November 28, 2007|Actual|2007-11-28|April 2018|2018-04-30||||February 1, 2014|Actual|2014-02-01||Interventional|||Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders|A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders|Active, not recruiting||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:36:06.656234|2018-06-01 02:36:06.656234
NCT00588978|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-01-08|2008-01-08|2008-01-09|Estimate|||||||2008-01-08|2008-01-09|Estimate|August 2003||2003-08-31|December 2007|2007-12-31|December 2008|Anticipated|2008-12-31|February 2007|Actual|2007-02-28||Interventional|||Impact of Diet and/or Exercise-Induced Weight Loss on Cardiovascular Risk Factors|Longitudinal Impact of Diet and/or Exercise-Induced Weight Loss on Metabolic Markers of Cardiovascular Disease|Unknown status|Active, not recruiting|N/A|30|Anticipated|Yale University||3|||f||||f||||||||||2018-06-01 02:36:06.765914|2018-06-01 02:36:06.765914
NCT00588965|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-05-01||2013-07-29|2007-12-26|2008-01-09|Estimate|2013-07-29|2013-07-30|Estimate||||2013-07-29|2013-07-30|Estimate|August 2007||2007-08-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects|Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects|Completed||N/A|36|Actual|MetroHealth Medical Center||2|||f||||f||||||||||2018-06-01 02:36:06.871988|2018-06-01 02:36:06.871988
NCT00588952|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2017-01-10||2017-01-10|2008-01-08|2008-01-09|Estimate|2017-01-10|2017-03-03|Actual||||2017-01-10|2017-03-03|Actual|March 2001||2001-03-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||All available data was utilized in the analysis using mixed models|Ketamine/Placebo Family History Positive Study|NMDA Dysregulation in Individuals With a Family Vulnerability to Alcoholism|Completed||N/A|99|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:36:07.119423|2018-06-01 02:36:07.119423
NCT00588939|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2013-05-17|2008-01-08|2008-01-09|Estimate|||||||2013-05-17|2013-05-21|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Confocal Laser Microscopy in Non Erosive Reflux Disease|Confocal Laser Microscopy in Non Erosive Reflux Disease|Completed|||60|Actual|Mayo Clinic|||1||f||||t||||||Samples Without DNA|"~     esophageal biopsy~   "|||2018-06-01 02:36:07.487742|2018-06-01 02:36:07.487742
NCT00588926|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-30|||2007-12-30|2007-12-30|2008-01-09|Estimate|||||||2007-12-30|2008-01-09|Estimate||||December 2007|2007-12-31||||||||Interventional|||Changes of the Neuronal Activity in the Subthalamic Nucleus Under Remifentanil Sedation During Stereotactic Electrode Implantation||Unknown status|Active, not recruiting|N/A|20|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 02:36:07.559016|2018-06-01 02:36:07.559016
NCT00588913|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-07-09|2007-12-28|2008-01-09|Estimate|||||||2013-07-09|2013-07-10|Estimate|January 2006||2006-01-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases|Phase I/II Study of Adoptive Immunotherapy Comprising Pyrophosphomonoester Antigen-stimulated T Cells, IL-2, and Nitrogen-containing Bisphosphonates in Patients With Stage IV Renal Cell Carcinoma|Completed||Phase 1/Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:36:07.616275|2018-06-01 02:36:07.616275
NCT00588900|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-01-11||2017-03-08|2007-12-28|2008-01-09|Estimate|2017-01-11|2017-03-03|Actual||||2017-03-08|2017-04-05|Actual|March 2008||2008-03-31|March 2017|2017-03-31|November 2011|Actual|2011-11-30|May 2010|Actual|2010-05-31||Interventional|||Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab|A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab|Terminated||Phase 2|5|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:36:07.698978|2018-06-01 02:36:07.698978
NCT00588887|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-19|2008-01-03|2008-01-09|Estimate|||||||2017-06-19|2017-06-21|Actual|June 2005||2005-06-30|June 2017|2017-06-30|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Observational|||Total Knee Replacement With Duracon® and Vanguard™ Prostheses||Terminated|||150|Actual|Zimmer Biomet|||2||f||||f||||||||||2018-06-01 02:36:08.03501|2018-06-01 02:36:08.03501
NCT00588874|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2008-01-08|2008-01-08|2008-01-09|Estimate|||||||2008-01-08|2008-01-09|Estimate|October 2000||2000-10-31|December 2007|2007-12-31|December 2008|Anticipated|2008-12-31|July 2002|Actual|2002-07-31||Observational|||Age Related Changes in Calciotropic Hormones and Their Impact on Male Osteoporosis|Pilot Study to Assess the Skeletal Effects of Age-Related Changes in Calcium and Vitamin D Metabolism in Men|Unknown status|Active, not recruiting||24|Actual|Yale University|||1||f||||f||||||||||2018-06-01 02:36:08.098114|2018-06-01 02:36:08.098114
NCT00588861|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-06-14||2017-01-26|2008-01-02|2008-01-09|Estimate|2012-01-12|2012-01-26|Estimate||||2017-01-26|2017-01-27|Estimate|September 2002||2002-09-30|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Shell Using Simplex® or Palacos® Bone Cement|Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Acetabular Shell Using Simplex® or Palacos® Bone Cement|Terminated||N/A|400|Actual|Zimmer Biomet|Study was terminated prematurely after sponsor no longer distributed the products involved and follow-up failed to produce sufficient data to be analyzed.|2||Study was terminated due to insufficient data and lack of patient follow-up|f||||f||||||||||2018-06-01 02:36:08.18838|2018-06-01 02:36:08.18838
NCT00588848|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|2012-10-28||2018-03-25|2008-01-03|2008-01-09|Estimate|2013-04-22|2013-05-27|Estimate||||2018-03-25|2018-04-24|Actual|January 2008||2008-01-31|March 2018|2018-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||CPAP vs AutoCPAP for Treatment of Obstructive Sleep Apnea (OSA) in the Postoperative Setting|Postoperative Management of Obstructive Sleep Apnea With CPAP vs. an Autoadjusting CPAP Device: a Randomized Controlled Single Center Trial|Terminated||N/A|11|Actual|MetroHealth Medical Center|"Trial limitations include:~1. Insufficient enrollment to adequately analyze data"|2||Difficulty with enrollment|f||||f||||||||||2018-06-01 02:36:08.497997|2018-06-01 02:36:08.497997
NCT00588835|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2010-03-01|2008-01-08|2008-01-09|Estimate|||||||2010-03-01|2010-03-02|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|ACE||Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients|A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Cisplatin - Etoposide (CE) Treatment of Patients With Metastatic Lung Carcinoma (ACE).|Terminated||Phase 4|20|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 02:36:08.763622|2018-06-01 02:36:08.763622
NCT00588822|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-02-12||2014-04-03|2007-12-28|2008-01-09|Estimate|2014-04-03|2014-05-06|Estimate||||2014-04-03|2014-05-06|Estimate|January 2005||2005-01-31|April 2014|2014-04-30|February 2011|Actual|2011-02-28|January 2009|Actual|2009-01-31||Interventional|||Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance|A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)|Terminated||Phase 2|21|Actual|Mayo Clinic|The study was discontinued at the first stage to the high response rate and slow accrual.|1||Discontinuation due to the high response rate at the 1st stage and slow accrual.|f||||t||||||||||2018-06-01 02:36:08.895906|2018-06-01 02:36:08.895906
NCT00588809|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-07-06||2015-07-06|2007-12-25|2008-01-09|Estimate|2015-07-06|2015-08-05|Estimate||||2015-07-06|2015-08-05|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia|A Phase 2 Study of AZD6244 in Relapsed or Refractory AML|Completed||Phase 2|47|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:36:09.141262|2018-06-01 02:36:09.141262
NCT00588796|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2015-02-02|2008-01-08|2008-01-09|Estimate|||||||2015-02-02|2015-02-04|Estimate|February 2005||2005-02-28|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Study of Fibrinogen Metabolism During Severe Trauma and Burns|Alteration in Fibrinogen Metabolism in Patients With Severe Burns and Traumatic Injuries|Completed|||30|Actual|United States Army Institute of Surgical Research|||3||f||||f||||||||||2018-06-01 02:36:09.457421|2018-06-01 02:36:09.457421
NCT00588783|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-19|2008-01-07|2008-01-09|Estimate|||||||2017-06-19|2017-06-21|Actual|August 2006||2006-08-31|June 2017|2017-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||I-beam and Cruciate Tibial Components Used in Total Knee Replacement||Terminated|||100|Actual|Zimmer Biomet|||2||f||||f||||||||||2018-06-01 02:36:09.51824|2018-06-01 02:36:09.51824
NCT00588770|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2018-03-01|2007-12-28|2008-01-09|Estimate|||||||2018-03-01|2018-03-02|Actual|August 8, 2008|Actual|2008-08-08|February 2018|2018-02-28||||February 28, 2018|Anticipated|2018-02-28||Interventional|||Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer|Active, not recruiting||Phase 3|400|Anticipated|National Cancer Institute (NCI)||8|||f||||f||||||||||2018-06-01 02:36:09.696358|2018-06-01 02:36:09.696358
NCT00588757|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2008-01-08|2008-01-08|2008-01-09|Estimate|||||||2008-01-08|2008-01-09|Estimate|March 2008||2008-03-31|December 2007|2007-12-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Comparison Between Two Optional IVC Filters Regardind Ease of Use,Complications and Outcome|Prospective Comparison Between OptEase and Gunter-Tulip|Unknown status|Not yet recruiting|N/A|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 02:36:11.052417|2018-06-01 02:36:11.052417
NCT00588731|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-29|2016-08-04||2017-06-06|2008-01-08|2008-01-09|Estimate|2017-06-06|2017-06-08|Actual||||2017-06-06|2017-06-08|Actual|February 2009||2009-02-28|June 2017|2017-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||A total of 36 participants completed all aspects of the study. Higher T-scores represent better outcomes.|Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia|Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia|Completed||Phase 2|41|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:36:11.151321|2018-06-01 02:36:11.151321
NCT00588718|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2018-03-08|2008-01-03|2008-01-09|Estimate|||||||2018-03-08|2018-03-09|Actual|April 2007|Actual|2007-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|NEC||A Biologic Validation of Biomarkers of Progressive NEC & Sepsis|A Biologic Sample Study for the Validation of Biomarkers of Progressive NEC & Sepsis|Active, not recruiting|||740|Anticipated|Nationwide Children's Hospital|||2||f||||f||||||Samples With DNA|"~     Blood and Urine~   "|||2018-06-01 02:36:11.674025|2018-06-01 02:36:11.674025
NCT00588705|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2017-01-27|2008-01-07|2008-01-08|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2007||2007-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer|The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer|Completed|||27|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:36:11.759072|2018-06-01 02:36:11.759072
NCT00588692|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-01-30||2014-04-07|2008-01-07|2008-01-08|Estimate|2014-04-07|2014-05-06|Estimate||||2014-04-07|2014-05-06|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|SACAR|Only the participants who completed the trial were included in the baseline analysis.|Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure|Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure|Completed||N/A|60|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:11.88301|2018-06-01 02:36:11.88301
NCT00519870|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2007-08-22|2007-08-22|2007-08-23|Estimate|||||||2007-08-22|2007-08-23|Estimate|January 2005||2005-01-31|August 2007|2007-08-31|July 2005||2005-07-31|||||Interventional|||Losartan Therapy in Pulmonary Hypertension|Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension|Completed||Phase 3|||Baskent University||1|||f||||||||||||||2018-06-01 02:58:42.437412|2018-06-01 02:58:42.437412
NCT00588679|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2018-04-17|2007-12-24|2008-01-08|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2006||2006-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla|Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla|Active, not recruiting||N/A|265|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:12.555594|2018-06-01 02:36:12.555594
NCT00588666|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-16||2015-12-16|2008-01-07|2008-01-08|Estimate|2015-12-16|2016-01-22|Estimate||||2015-12-16|2016-01-22|Estimate|May 2006||2006-05-31|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma|Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma|Completed||Phase 2|51|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:12.647086|2018-06-01 02:36:12.647086
NCT00588653|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2008-01-07|2008-01-07|2008-01-08|Estimate|||||||2008-01-07|2008-01-08|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease|Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease|Completed||Phase 4|41|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:36:12.886018|2018-06-01 02:36:12.886018
NCT00588640|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2015-12-17||2016-06-29|2007-12-22|2008-01-08|Estimate|2016-06-29|2016-08-10|Estimate||||2016-06-29|2016-08-10|Estimate|October 2004||2004-10-31|June 2016|2016-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of D-Methadone in Patients With Chronic Pain|A Phase I/II Study of D-Methadone in Patients With Chronic Pain|Completed||Phase 1/Phase 2|10|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 02:36:12.970514|2018-06-01 02:36:12.970514
NCT00588627|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2010-03-08|2007-12-25|2008-01-08|Estimate|||||||2010-03-08|2010-03-10|Estimate|March 2006||2006-03-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Capsaicin Cough Threshold in Chronic Cough Due to Postnasal Drip|Capsaicin Cough Sensitivity, Airway Inflammation and Neurogenic Peptides in Chronic Cough Associated With Postnasal Drip|Completed|||25|Actual|Mayo Clinic|||2||f||||t||||||Samples Without DNA|"~     Mucus will be quantified and protease inhibitors will be added after collection. The specimen~     will be coded to deidentify. It will be transported to laboratory for storage and analysis.~     The mucus collected from the posterior nasopharynx will be frozen and assayed simultaneously.~     Substance P and Neurokinin A will be measured by ELISA at the end of the study period.~   "|||2018-06-01 02:36:13.150936|2018-06-01 02:36:13.150936
NCT00588614|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-05-29|2007-12-26|2008-01-08|Estimate|||||||2012-05-29|2012-05-30|Estimate|April 2006||2006-04-30|May 2012|2012-05-31|February 2011|Actual|2011-02-28|December 2007|Actual|2007-12-31||Observational|||High Risk Screening Breast MR Using a Rapid Imaging Exam|High Risk Screening Breast MR Using a Rapid Imaging Exam|Completed|||140|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 02:36:13.23382|2018-06-01 02:36:13.23382
NCT00588601|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-10-11|2007-12-21|2008-01-08|Estimate|||||||2016-10-11|2016-10-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:36:13.285964|2018-06-01 02:36:13.285964
NCT00588588|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2012-01-24|2007-12-22|2008-01-08|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Bronchoscopy vs. Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP)|Bronchoscopy Versus Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP): Randomized Clinical Trial|Withdrawn||Phase 3|0|Actual|Mayo Clinic||2||Due to inability to get support for the study|f||||f||||||||||2018-06-01 02:36:13.319305|2018-06-01 02:36:13.319305
NCT00588575|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2016-01-05|2008-01-07|2008-01-08|Estimate|||||||2016-01-05|2016-01-07|Estimate|October 2004||2004-10-31|September 2009|2009-09-30|October 2007|Actual|2007-10-31|May 2007|Actual|2007-05-31||Observational|||Ramanspectroscopy in Barrett's Esophagus|In-Vivo Raman Spectroscopy of Barrett's Esophagus|Completed|||119|Actual|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     esophageal biopsy~   "|||2018-06-01 02:36:13.382719|2018-06-01 02:36:13.382719
NCT00588562|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-08-03|2007-12-27|2008-01-08|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2003||2003-07-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|RKSC||Rare Kidney Stone Consortium Patient Registry|Rare Kidney Stone Consortium Registry for Hereditary Kidney Stone Diseases|Recruiting|||730|Anticipated|Mayo Clinic|||4||f||||t||||||||Yes|Using limited data set, data will be shared through the Data Monitoring and Coordinating Center of the Rare Diseases Clinical Research Network.|2018-06-01 02:36:13.437019|2018-06-01 02:36:13.437019
NCT00588549|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2009-03-18|2007-12-24|2008-01-08|Estimate|||||||2009-03-18|2009-03-19|Estimate|July 1998||1998-07-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Utility of PET In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases|Utility of Whole-Body 18-Fluorodeoxyglucose Positron Emission Tomography (PET) In the Pre-Operative Assessment of Patients With Hepatic Colorectal Metastases|Completed|||204|Actual|Memorial Sloan Kettering Cancer Center|||||f||||f||||||||||2018-06-01 02:36:13.54665|2018-06-01 02:36:13.54665
NCT00588536|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-04-16||2015-04-16|2008-01-07|2008-01-08|Estimate|2015-04-16|2015-05-04|Estimate||||2015-04-16|2015-05-04|Estimate|January 1995||1995-01-31|April 2015|2015-04-30|June 2009|Actual|2009-06-30|July 2008|Actual|2008-07-31||Interventional|||Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH|Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH)|Completed||Phase 2|5|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:13.618379|2018-06-01 02:36:13.618379
NCT00588523|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-02-23|2007-12-22|2008-01-08|Estimate|||||||2018-02-23|2018-02-26|Actual|September 2002|Actual|2002-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma|A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma|Active, not recruiting||Phase 2|60|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:13.898176|2018-06-01 02:36:13.898176
NCT00588510|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2011-09-01|2008-01-07|2008-01-08|Estimate|||||||2011-09-01|2011-09-02|Estimate|January 2000||2000-01-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction|Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction|Completed|||59|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||||||2018-06-01 02:36:13.981019|2018-06-01 02:36:13.981019
NCT00588497|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2011-05-20|2007-12-22|2008-01-08|Estimate|||||||2011-05-20|2011-05-23|Estimate|February 2004||2004-02-29|May 2011|2011-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||Characterization of the Essure System Tubal Sterilization Using Ultrasound and X-Ray|Characterization of the Essure System Tubal Sterilization Using Ultrasound and X-Ray|Completed|||25|Actual|Mayo Clinic|||1||f||||||||||||||2018-06-01 02:36:14.062101|2018-06-01 02:36:14.062101
NCT00588484|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2012-11-07|2008-01-07|2008-01-08|Estimate|||||||2012-11-07|2012-11-09|Estimate|December 2002||2002-12-31|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Ultrasound-based Intima-Media Thickness Measurements|Determination of the Precision and Clinical Utility of Ultrasound-based Intima-Media Thickness Measurements|Completed|||128|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 02:36:14.1298|2018-06-01 02:36:14.1298
NCT00588471|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2012-10-09||2012-10-09|2008-01-07|2008-01-08|Estimate|2012-10-09|2012-11-08|Estimate||||2012-10-09|2012-11-08|Estimate|November 2002||2002-11-30|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention|The Effect of Acute Statin Treatment on Inflammation and Peripheral Arterial Tone in Patients Undergoing Percutaneous Coronary Intervention.|Terminated||N/A|57|Actual|Mayo Clinic|The study was terminated early because not enough subjects could be recruited.|2||The study was terminated because not enough subjects could be recruited.|f||||f||||||||||2018-06-01 02:36:14.197837|2018-06-01 02:36:14.197837
NCT00588458|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-04-27|2007-12-26|2008-01-08|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|February 2009|Anticipated|2009-02-28|November 2008|Anticipated|2008-11-30||Interventional|||The Value of CT Cholangiography in Primary Sclerosing Cholangitis|Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis|Withdrawn||Phase 2|0|Actual|Mayo Clinic||1||"There is no participant enrolled in this study since developing this trial and other~   cholangiographic techniques are more available in our institute."|f||||t||||||||||2018-06-01 02:36:14.419452|2018-06-01 02:36:14.419452
NCT00588445|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-17||2015-12-17|2008-01-07|2008-01-08|Estimate|2015-12-17|2016-01-22|Estimate||||2015-12-17|2016-01-22|Estimate|June 2004||2004-06-30|December 2015|2015-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene|Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene in Patients With NSCLC|Completed||Phase 2|65|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:14.486943|2018-06-01 02:36:14.486943
NCT00588432|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2009-12-03|2008-01-07|2008-01-08|Estimate|||||||2009-12-03|2009-12-04|Estimate|April 2003||2003-04-30|December 2009|2009-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE)|Characterization of Skeletal Muscle Using Magnetic Resonance Elastography (MRE)|Completed|||300|Anticipated|Mayo Clinic|||4||f||||||||||||||2018-06-01 02:36:14.749163|2018-06-01 02:36:14.749163
NCT00588419|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2017-09-05|2007-12-24|2008-01-08|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2006||2006-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Quantification of Breast Sensation Following Postmastectomy Breast Reconstruction|Quantification of Breast Sensation Following Postmastectomy Breast Reconstruction|Active, not recruiting|||153|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:36:14.808075|2018-06-01 02:36:14.808075
NCT00588406|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-10-12||2015-12-15|2007-12-21|2008-01-08|Estimate|2015-12-15|2016-01-21|Estimate||||2015-12-15|2016-01-21|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.|Emergency Department (ED) Use of Nebulized Budesonide as an Adjunct to Standardized Therapy in Acutely Ill Adults With Refractory Asthma: a Randomized, Double-blinded, Placebo-controlled Trial|Completed||Phase 3|95|Actual|Northwell Health||2|||f||||f||||||||||2018-06-01 02:36:14.885281|2018-06-01 02:36:14.885281
NCT00588393|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2010-04-15|2008-01-07|2008-01-08|Estimate|||||||2010-04-15|2010-04-16|Estimate|September 2006||2006-09-30|April 2010|2010-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||FolateScan in Autoimmune Disease|Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases|Completed||Phase 2|75|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 02:36:15.178423|2018-06-01 02:36:15.178423
NCT00588380|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2011-04-04||2011-12-14|2007-12-22|2008-01-08|Estimate|2011-11-01|2011-12-06|Estimate||||2011-12-14|2011-12-19|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||GLP1R Polymorphisms and Response to GLP1|A Pilot Study Examining How Common Genetic Variation in GLP1R Alters Response to GLP1 Infusion|Completed||N/A|88|Actual|Mayo Clinic|This is a pilot study with limited power to detect / replicate effects. It will require independent replication of study results.|1|||f||||f||||||||||2018-06-01 02:36:15.255656|2018-06-01 02:36:15.255656
NCT00588367|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2015-04-14|2007-12-24|2008-01-08|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2006||2006-04-30|April 2015|2015-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||CT Pancreas Perfusion|CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study|Completed|||30|Actual|Mayo Clinic|||3||f||||f||||||||||2018-06-01 02:36:15.438296|2018-06-01 02:36:15.438296
NCT00588354|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-06-03||2011-12-06|2008-01-07|2008-01-08|Estimate|2011-12-06|2012-01-11|Estimate||||2011-12-06|2012-01-11|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Epidural Clonidine for Lumbosacral Radiculopathy|Pilot Study of Transforaminal Epidural Injection of Clonidine for the Treatment of Acute Lumbosacral Radiculopathy|Terminated||N/A|26|Actual|Mayo Clinic|Early termination leading to small numbers of subjects analyzed; did not measure analgesia during the expected analgesic peak of bolus administration, but 10 days after last injection; compared clonidine with an active control, rather than placebo.|2||Targeted enrollment was not reached.|f||||f||||||||||2018-06-01 02:36:15.538788|2018-06-01 02:36:15.538788
NCT00588341|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-22||2015-12-22|2008-01-07|2008-01-08|Estimate|2015-12-22|2016-02-01|Estimate||||2015-12-22|2016-02-01|Estimate|September 2005||2005-09-30|December 2015|2015-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection|Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection|Completed||Phase 2|24|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:15.93538|2018-06-01 02:36:15.93538
NCT00588328|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-12-23|2007-12-21|2008-01-08|Estimate|||||||2015-12-23|2015-12-24|Estimate|March 2000||2000-03-31|December 2015|2015-12-31|May 2010|Actual|2010-05-31|July 2008|Actual|2008-07-31||Interventional|||The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning|The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning|Completed||Phase 1|35|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:16.09454|2018-06-01 02:36:16.09454
NCT00588315|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2017-09-29|2007-12-24|2008-01-08|Estimate|||||||2017-09-29|2017-10-02|Actual|November 1999|Actual|1999-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin|In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin|Recruiting|||1500|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||||||2018-06-01 02:36:16.167049|2018-06-01 02:36:16.167049
NCT00588302|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2011-05-20|2007-12-22|2008-01-08|Estimate|||||||2011-05-20|2011-05-23|Estimate|June 2003||2003-06-30|May 2011|2011-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Moexipril for Primary Biliary Cirrhosis|Open-Label Pilot Investigation of Moexipril for the Treatment of Primary Biliary Cirrhosis (PBC)|Completed||Phase 2|20|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:36:16.248326|2018-06-01 02:36:16.248326
NCT00588289|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2013-10-08|2007-12-24|2008-01-08|Estimate|||||||2013-10-08|2013-10-09|Estimate|September 1999||1999-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA|CCG-LTFI: A Groupwide Protocol for Collecting Follow- up Data|Completed|||102|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:36:16.312732|2018-06-01 02:36:16.312732
NCT00588276|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2015-12-23|2007-12-22|2008-01-08|Estimate|||||||2015-12-23|2015-12-24|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors|Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors|Completed||Phase 1|15|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:16.368407|2018-06-01 02:36:16.368407
NCT00588263|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-02-14|2008-01-07|2008-01-08|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 2000||2000-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer|Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individual With Cancer|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center||||Data from MSK-IMPACT is sufficient for relevant analyses going forward|f||||f||||||Samples With DNA|"~     Blocks or extracted DNA from patients who have identified themselves as Jewish will be~     obtained and a determination will be made as to whether there is adequate material to proceed~     without exhausting the block or extracted DNA.~      Four unstained sections (research specimens) or paraffin curls will be cut from each block.~     In those cases where a block containing normal resection margin or any other biopsy of normal~     tissue are available, tissue will be cut from this block so as to preserve tumor tissue for~     later investigators. It is not necessary for sections to be reviewed to confirm that tumor is~     present in the section, since any germline DNA is adequate for this analysis.~   "|||2018-06-01 02:36:16.430489|2018-06-01 02:36:16.430489
NCT00588250|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2015-04-06|2007-12-22|2008-01-08|Estimate|||||||2015-04-06|2015-04-08|Estimate|May 2003||2003-05-31|April 2015|2015-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates|Prospective Randomized Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates|Terminated||N/A|150|Actual|Mayo Clinic||2||Implantation rate significantly lower in treatment group than Controls.|f||||f||||||||||2018-06-01 02:36:16.486398|2018-06-01 02:36:16.486398
NCT00588237|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2015-12-15||2015-12-15|2007-12-22|2008-01-08|Estimate|2015-12-15|2016-01-20|Estimate||||2015-12-15|2016-01-20|Estimate|August 2006||2006-08-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|A Phase II Study of Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|Completed||Phase 2|42|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:16.546724|2018-06-01 02:36:16.546724
NCT00588224|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2009-07-20|2008-01-07|2008-01-08|Estimate|||||||2009-07-20|2009-07-22|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|3DUSstomach||3D Ultrasound Validation for Measuring Stomach Volume|Validation and Application of 3-dimensional Ultrasound for Measurement of Gastric Volumes in Healthy Subjects|Completed|||36|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 02:36:16.832593|2018-06-01 02:36:16.832593
NCT00588211|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2017-10-03|2007-12-24|2008-01-08|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2001||2001-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Measurement of Cancer-Related Risk Perception in Smokers|Measurement of Cancer-Related Risk Perception in Smokers|Active, not recruiting|||1514|Actual|Memorial Sloan Kettering Cancer Center|||4||f||||||||||||||2018-06-01 02:36:16.904878|2018-06-01 02:36:16.904878
NCT00588198|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2009-10-01|2008-01-07|2008-01-08|Estimate|||||||2009-10-01|2009-10-02|Estimate|October 1991||1991-10-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma|Study of Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma|Completed|||754|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||Samples With DNA|"~     Bone marrow and blood~   "|||2018-06-01 02:36:16.9771|2018-06-01 02:36:16.9771
NCT00588185|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-03-22|2008-01-07|2008-01-08|Estimate|||||||2018-03-22|2018-03-23|Actual|February 2003|Actual|2003-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer|Recruiting||N/A|300|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:36:17.048938|2018-06-01 02:36:17.048938
NCT00588172|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2010-08-16|2007-12-22|2008-01-08|Estimate|||||||2010-08-16|2010-08-17|Estimate|June 2010||2010-06-30|August 2010|2010-08-31|June 2011|Anticipated|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Genetic Variation in OCT1 and Response to Metformin|Genetic Variation in OCT1 and Response to Metformin|Withdrawn||Phase 4|0|Actual|Mayo Clinic||2||No funding|f||||f||||||||||2018-06-01 02:36:17.120663|2018-06-01 02:36:17.120663
NCT00588159|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2010-12-28||2016-03-29|2008-01-07|2008-01-08|Estimate|2011-07-19|2011-08-12|Estimate||||2016-03-29|2016-05-04|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia|Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia: A Randomized, Double-blinded, Placebo-controlled Study|Completed||N/A|146|Actual|Mayo Clinic||2|||f||||t||||||||No||2018-06-01 02:36:17.184621|2018-06-01 02:36:17.184621
NCT00588146|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-12-20||2013-02-19|2007-12-26|2008-01-08|Estimate|2012-12-20|2013-01-28|Estimate||||2013-02-19|2013-02-22|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia|Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia|Terminated||Phase 2|10|Actual|Mayo Clinic|The study was terminated early because Schering-Plough discontinued supplying study drug.|2||Schering-Plough discontinued supplying study drug.|f||||t||||||||||2018-06-01 02:36:17.562939|2018-06-01 02:36:17.562939
NCT00588133|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2009-11-09|2008-01-07|2008-01-08|Estimate|||||||2009-11-09|2009-11-10|Estimate|January 2004||2004-01-31|November 2009|2009-11-30|August 2008|Actual|2008-08-31|December 2007|Actual|2007-12-31||Interventional|||A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery|A Preliminary Study of a New Tranexamic Acid Dosing Schedule for Cardiac Surgery|Completed||Phase 3|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:17.794432|2018-06-01 02:36:17.794432
NCT00588120|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-06-15|2007-12-26|2008-01-08|Estimate|||||||2017-06-15|2017-06-19|Actual|December 1998||1998-12-31|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria|Investigations Into the Genotype and Phenotype of Unclassified Hyperoxaluria: Enteric Oxalate Absorption Study|Active, not recruiting||Phase 1|125|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:36:17.875838|2018-06-01 02:36:17.875838
NCT00588107|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2014-12-30|2008-01-07|2008-01-08|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|PFH2||A Web Site and Print Materials Intervention for Smoking Intervention for Childhood and Young Adult Cancer Survivors|Partnership for Health: A Web-Based Smoking Intervention For Cancer Survivors|Completed||N/A|374|Actual|Dana-Farber Cancer Institute||2|||f||||f||||||||||2018-06-01 02:36:17.962382|2018-06-01 02:36:17.962382
NCT00588094|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-10-27||2015-10-27|2008-01-07|2008-01-08|Estimate|2015-10-27|2015-12-04|Estimate||||2015-10-27|2015-12-04|Estimate|October 2003||2003-10-31|October 2015|2015-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL|A Phase II Study of Dose Augmented Rituximab and Ice for Patients With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell Non-Hodgkin's Lymphoma Undergoing Second-Line Therapy Prior to Stem Cell Transplantation|Completed||Phase 2|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:36:18.06395|2018-06-01 02:36:18.06395
NCT00588081|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2016-08-09|2007-12-22|2008-01-08|Estimate|||||||2016-08-09|2016-08-10|Estimate|May 2001||2001-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function|Immediate Vaginal Reconstruction Following Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function|Completed||N/A|27|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:36:18.268212|2018-06-01 02:36:18.268212
NCT00588068|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2018-03-27|2008-01-07|2008-01-08|Estimate|||||||2018-03-27|2018-03-29|Actual|September 26, 2000|Actual|2000-09-26|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome|Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome|Recruiting|||1500|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||Samples With DNA|"~     Tumor, marrow and blood samples~   "|||2018-06-01 02:36:18.348192|2018-06-01 02:36:18.348192
NCT00588042|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-06-03|2007-12-21|2008-01-08|Estimate|||||||2014-06-03|2014-06-04|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|RemoteMIPH||Remote Myocardial Ischemic Preconditioning in Humans|Remote Myocardial Ischemic Preconditioning in Humans|Completed||N/A|156|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:18.430016|2018-06-01 02:36:18.430016
NCT00588029|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2017-10-03|2007-12-24|2008-01-08|Estimate|||||||2017-10-03|2017-10-04|Actual|July 1999||1999-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer|Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer|Active, not recruiting|||7000|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||Samples With DNA|"~     Blood, Cerebro-Spinal Fluid and Saliva~   "|||2018-06-01 02:36:18.502864|2018-06-01 02:36:18.502864
NCT00588016|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-04-12|2008-01-07|2008-01-08|Estimate|||||||2015-04-12|2015-04-14|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Concentration of Itraconazole Solution in Nasal Secretions|Concentration of Itraconazole Solution in Nasal Secretions|Completed||Phase 1|6|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:36:18.583897|2018-06-01 02:36:18.583897
NCT00588003|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2015-12-23|2007-12-22|2008-01-08|Estimate|||||||2015-12-23|2015-12-24|Estimate|March 2004||2004-03-31|December 2015|2015-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer|Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer|Completed||Phase 1|45|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:36:18.69243|2018-06-01 02:36:18.69243
NCT00587990|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|2015-01-30||2017-11-01|2008-01-03|2008-01-08|Estimate|2015-04-01|2015-04-02|Estimate||||2017-11-01|2017-12-06|Actual|November 2007||2007-11-30|November 2017|2017-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PROMETHEUS||Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)|A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Intramyocardial Injection of Autologous Human Mesenchymal Stem Cells (MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction (MI) Undergoing Cardiac Surgery for Coronary Artery Bypass Grafting (CABG)|Completed||Phase 1/Phase 2|9|Actual|University of Miami||3|||f||||t|t|f||||||||2018-06-01 02:36:18.790628|2018-06-01 02:36:18.790628
NCT00587977|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2012-11-07|2008-01-07|2008-01-08|Estimate|||||||2012-11-07|2012-11-09|Estimate|November 2004||2004-11-30|November 2012|2012-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|FAMRI||Aortic Distensibility|ECG-Gated Multidetector CT of Aortic Distensibility FAMRI|Completed|||67|Actual|Mayo Clinic|||3||f||||f||||||||||2018-06-01 02:36:19.23609|2018-06-01 02:36:19.23609
NCT00587964|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2015-12-14||2016-01-22|2008-01-07|2008-01-08|Estimate|2016-01-22|2016-02-22|Estimate||||2016-01-22|2016-02-22|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases|Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases|Completed||Phase 2|51|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:19.428641|2018-06-01 02:36:19.428641
NCT00587951|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2008-01-07|2008-01-07|2008-01-08|Estimate|||||||2008-01-07|2008-01-08|Estimate|December 2005||2005-12-31|November 2007|2007-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates|The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates|Completed|||50|Actual|Mayo Clinic|||1||f||||t||||||||||2018-06-01 02:36:19.613101|2018-06-01 02:36:19.613101
NCT00587938|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2007-12-26|2007-12-26|2008-01-08|Estimate|||||||2007-12-26|2008-01-08|Estimate|December 2003||2003-12-31|December 2007|2007-12-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Observational|||BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED|BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED: A Clinical Development Project|Completed|||200|Actual|Mayo Clinic|||2||f||||f||||||Samples Without DNA|"~     Original protocol specifies a single 10 ml of blood is collected and frozen from each study~     participant (N=200), to be available for research assays.~   "|||2018-06-01 02:36:19.677329|2018-06-01 02:36:19.677329
NCT00587925|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2009-02-25|2007-12-22|2008-01-08|Estimate|||||||2009-02-25|2009-02-26|Estimate|March 2005||2005-03-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer|A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer|Completed||N/A|7|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:19.755742|2018-06-01 02:36:19.755742
NCT00587912|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2011-04-20|2007-12-24|2008-01-08|Estimate|||||||2011-04-20|2011-04-21|Estimate|June 1997||1997-06-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||AIDS and Cancer Specimen Bank (ACSB)|AIDS and Cancer Specimen Bank (ACSB)|Completed|||65|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Blood, urine, other bodily fluids (eg, pleural fluid), and tumor tissue obtained from~     patients.~   "|||2018-06-01 02:36:19.825605|2018-06-01 02:36:19.825605
NCT00587899|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2011-04-12|2008-01-07|2008-01-08|Estimate|||||||2011-04-12|2011-04-14|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Prophylactic Pulmonary Vein Isolation Study|A Randomized, Single-blind Prophylactic Pulmonary Vein Isolation Procedure Utilizing Bipolar Radiofrequency Ablation in Patients Undergoing Mitral Valve Surgery|Terminated||N/A|41|Actual|Mayo Clinic||2||"enrollment has been lower than anticipated due to growth in the minimally invasive mitral valve~   repair practice."|f||||f||||||||||2018-06-01 02:36:19.88528|2018-06-01 02:36:19.88528
NCT00587886|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2018-01-12|2007-12-24|2008-01-08|Estimate|||||||2018-01-12|2018-01-17|Actual|September 25, 2001|Actual|2001-09-25|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Estrogen, Diet, Genetics and Endometrial Cancer|Estrogen, Diet, Genetics and Endometrial Cancer|Active, not recruiting|||1315|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Buccal specimen~   "|||2018-06-01 02:36:19.996529|2018-06-01 02:36:19.996529
NCT00587873|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2009-06-10|2008-01-07|2008-01-08|Estimate|||||||2009-06-10|2009-06-12|Estimate|March 1994||1994-03-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|December 2003|Actual|2003-12-31||Interventional|||Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)|Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)|Completed||Phase 2|18|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:20.062662|2018-06-01 02:36:20.062662
NCT00587860|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2009-10-26||2010-03-02|2008-01-07|2008-01-08|Estimate|2010-02-12|2010-03-01|Estimate||||2010-03-02|2010-03-09|Estimate|February 2006||2006-02-28|March 2010|2010-03-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome|A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome|Completed||Phase 2|70|Actual|Mayo Clinic|"A majority of the participants were local females with mild symptoms~The number of participants limits power of conclusions~We evaluated the efficacy of SJW in all subtypes of IBS not allowing specific conclusions regarding subtypes"|2|||f||||f||||||||||2018-06-01 02:36:20.13606|2018-06-01 02:36:20.13606
NCT00587847|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-05-29||2015-09-16|2008-01-07|2008-01-08|Estimate|2015-09-16|2015-10-15|Estimate||||2015-09-16|2015-10-15|Estimate|August 2005||2005-08-31|September 2015|2015-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||This was a pilot study with enrollment goal of 20 based on our patient population with potential to meet inclusion criteria. This goal was not met due to patient preferance for no further treatment which is standard of care.|Campath Maintenance in Chronic Lymphocytic Leukemia|Maintenance Alemtuzumab in Refractory Chronic Lymphocytic Leukemia|Terminated||N/A|12|Actual|Northwell Health|Trial was terminated early due to poor accrual.|1||Insufficient recruitment.|f||||f||||||||||2018-06-01 02:36:20.444109|2018-06-01 02:36:20.444109
NCT00587834|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-04-04|2010-01-22|2012-10-09|2007-12-21|2008-01-07|Estimate|2012-10-09|2012-11-08|Estimate|2010-01-22|2010-02-15|Estimate|2012-10-09|2012-11-08|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration|A Clinical Trial to Evaluate Gintuit (TM) (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen) as an Alternative to Tissue From the Palate to Enhance Oral Soft Tissue Regeneration and Wound Healing|Completed||Phase 3|96|Actual|Organogenesis|Secondary outcome measures were tested with a closed testing strategy; therefore pain was not tested (no p-value) because previous endpoint (site sensitivity) failed.|2|||f||||f||||||||||2018-06-01 02:36:21.560498|2018-06-01 02:36:21.560498
NCT00587821|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-12-18|2007-12-21|2008-01-07|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Peptide Profiles of Women Undergoing Breast Biopsy|Peptide Profiles of Women Undergoing Breast Biopsy|Completed|||571|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:36:21.904314|2018-06-01 02:36:21.904314
NCT00587808|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-02-06|2007-12-21|2008-01-07|Estimate|||||||2012-02-06|2012-02-07|Estimate|November 2007||2007-11-30|May 2011|2011-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|HFpEF||Mechanisms in Heart Failure With Normal EF|Invasive Characterization of the Mechanisms Underlying Exertional Intolerance and Increased Filling Pressures in Patients With Heart Failure and a Preserved EF|Completed|||14|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 02:36:22.020138|2018-06-01 02:36:22.020138
NCT00587795|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2017-04-25||2017-04-25|2007-12-21|2008-01-07|Estimate|2017-04-25|2017-08-02|Actual||||2017-04-25|2017-08-02|Actual|April 2006||2006-04-30|April 2017|2017-04-30|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace|Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace|Terminated||N/A|1|Actual|Mayo Clinic|Early termination due to inability to enroll subjects, and concern about subject compliance in the use of the Stabilair wrist brace. The one subject enrolled disliked the brace and quickly withdrew from the study.|2||Inability to enroll subjects|f||||f|f|f||||||No||2018-06-01 02:36:22.096806|2018-06-01 02:36:22.096806
NCT00587769|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-10-05||2013-04-16|2007-12-21|2008-01-07|Estimate|2010-11-29|2010-12-23|Estimate||||2013-04-16|2013-04-24|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|ChanBan||Chantix & Bupropion for Smoking Cessation|Combination Pharmacotherapy With Chantix & Bupropion for Smoking Cessation (ChanBan)|Completed||Phase 3|38|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:36:22.405762|2018-06-01 02:36:22.405762
NCT00587756|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2008-01-07|2008-01-04|2008-01-07|Estimate|||||||2008-01-07|2008-01-08|Estimate|September 2001||2001-09-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Observational|||Alternative to Two-Stage Hepatectomy|One-Stage Ultrasound-Guided Hepatectomy for Multiple Bilobar Colorectal Metastases: a Feasible and Effective Alternative to Two-Stage Hepatectomy|Completed|||19|Actual|University of Milan|||1||f||||f||||||||||2018-06-01 02:36:22.635738|2018-06-01 02:36:22.635738
NCT00587730|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-04-21|2008-01-04|2008-01-07|Estimate|||||||2015-04-21|2015-04-23|Estimate|July 2001||2001-07-31|April 2015|2015-04-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|Hawkeye||Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System|Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System|Terminated||Phase 2/Phase 3|608|Actual|Mayo Clinic||1||Recruiting or enrolling participants has halted prematurely and will not resume.|f||||f||||||||||2018-06-01 02:36:22.720828|2018-06-01 02:36:22.720828
NCT00587717|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-02-14|2008-01-04|2008-01-07|Estimate|||||||2011-02-14|2011-02-16|Estimate|September 2002||2002-09-30|February 2011|2011-02-28|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue|The Acute Effect of Inflammatory Markers of Atherosclerotic Plaque in Humans|Completed||N/A|35|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:22.791285|2018-06-01 02:36:22.791285
NCT00587704|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-02-22|2008-01-04|2008-01-07|Estimate|||||||2010-02-22|2010-02-23|Estimate|July 2007||2007-07-31|February 2010|2010-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PVB||Paravertebral Blocks: Pilot Study to Compare Nerve Stimulation vs. Anatomic Landmarks in Inguinal Hernia Repair|Paravertebral Blocks Techniques: A Pilot Study to Compare Nerve Stimulation vs. Anatomic Landmarks for Patients Undergoing Inguinal Hernia Repair|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||||||||||||2018-06-01 02:36:22.861842|2018-06-01 02:36:22.861842
NCT00587691|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-01-09|2007-12-21|2008-01-07|Estimate|||||||2017-01-09|2017-01-11|Estimate|July 2002||2002-07-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Interventional|DES||Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis|An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis|Completed||Phase 1/Phase 2|16|Actual|Opexa Therapeutics, Inc.||3|||f||||t||||||||No||2018-06-01 02:36:22.943845|2018-06-01 02:36:22.943845
NCT00587678|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-08-02||2017-07-20|2007-12-21|2008-01-07|Estimate|2012-01-03|2012-02-03|Estimate||||2017-07-20|2017-08-21|Actual|January 2006||2006-01-31|July 2017|2017-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comprehensive Magnetic Resonance of Peripheral Arterial Disease|Comprehensive Magnetic Resonance of Peripheral Arterial Disease|Completed||N/A|85|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 02:36:23.093166|2018-06-01 02:36:23.093166
NCT00587665|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-12|2007-12-21|2008-01-07|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2006||2006-08-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Low Dose Ketamine as an Adjunct to Fentanyl in Outpatient Tonsillectomy|A Prospective Study of Low Dose Ketamine as an Adjunct to Fentanyl in Pediatric Patients Following Outpatient Tonsillectomy and Adenoidectomy|Completed||N/A|122|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:23.752951|2018-06-01 02:36:23.752951
NCT00587652|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-01-05|2007-12-21|2008-01-07|Estimate|||||||2010-01-05|2010-01-06|Estimate|December 2002||2002-12-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Methylene Blue Chromoendoscopy in Barrett's Esophagus|A Prospective Trial of Methylene Blue Chromoendoscopy in Barrett's Esophagus|Completed|||100|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 02:36:23.820175|2018-06-01 02:36:23.820175
NCT00587639|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-07-20||2012-03-08|2008-01-04|2008-01-07|Estimate|2012-02-10|2012-03-09|Estimate||||2012-03-08|2012-03-12|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||An Evaluation of Safety and Feasibility Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression|An Evaluation of Safety and Feasibility Using rTMS in Adolescents With Depression|Completed||N/A|8|Actual|Mayo Clinic|Limitations of the study include its open design, and small number of total participants.|1|||f||||t||||||||||2018-06-01 02:36:23.93225|2018-06-01 02:36:23.93225
NCT00587626|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-06-24|2007-12-21|2008-01-07|Estimate|||||||2010-06-24|2010-06-25|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Proposal to Evaluate the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain|Proposal to Evaluate the Efficacy of the InterX 5000 in the Treatment of Chronic Neck and Shoulder Pain|Completed||Phase 2|80|Anticipated|McMaster University||2|||f||||||||||||||2018-06-01 02:36:24.201459|2018-06-01 02:36:24.201459
NCT00587613|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-03-10|2007-12-21|2008-01-07|Estimate|||||||2017-03-10|2017-03-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:36:24.298331|2018-06-01 02:36:24.298331
NCT00587600|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-11-20|2008-01-04|2008-01-07|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2002||2002-12-31|November 2017|2017-11-30|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|BIOBAR||Biomarkers in Phototherapy of Barrett's Esophagus|Biomarkers in Phototherapy of Barrett's Esophagus|Completed||Phase 2/Phase 3|208|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:36:24.337532|2018-06-01 02:36:24.337532
NCT00587587|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-06-07||2011-08-16|2007-12-21|2008-01-07|Estimate|2011-08-16|2011-08-19|Estimate||||2011-08-16|2011-08-19|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids|A Prospective, Randomized, Controlled Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids|Completed||Phase 1/Phase 2|30|Actual|Organogenesis||2|||f||||f||||||||||2018-06-01 02:36:24.449162|2018-06-01 02:36:24.449162
NCT00587574|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2008-01-04|2008-01-04|2008-01-07|Estimate|||||||2008-01-04|2008-01-07|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|||Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic HSCT|Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic Hematopoietic Stem Cell Transplantation and Immunomodulatory Consequences of Chronic Graft-Versus-Host Disease and Therapy|Unknown status|Recruiting||150|Anticipated|Medical University of Vienna|||2||f||||f||||||Samples With DNA|"~     peripheral blood mononuclear cells as cell pellets and DNA, plasma and serum samples, tissue~     biopsy samples, urine~   "|||2018-06-01 02:36:25.017022|2018-06-01 02:36:25.017022
NCT00587561|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-05-01|2007-12-21|2008-01-07|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2008||2008-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of Social Cognition Training in Schizophrenia|Efficacy of Social Cognition Training in Schizophrenia|Active, not recruiting||N/A|75|Anticipated|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-06-01 02:36:25.143453|2018-06-01 02:36:25.143453
NCT00587548|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-09-27|2007-12-21|2008-01-07|Estimate|||||||2010-09-27|2010-09-29|Estimate|January 2006||2006-01-31|September 2010|2010-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Intraoperative Gamma Probe Localization of the Ureter|Intraoperative Gamma Probe Localization of the Ureter|Terminated||N/A|16|Actual|Mayo Clinic||||Decided not pursue the study|f||||t||||||||||2018-06-01 02:36:25.236673|2018-06-01 02:36:25.236673
NCT00587535|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-20|2007-12-21|2008-01-07|Estimate|||||||2016-01-20|2016-01-22|Estimate|August 2003||2003-08-31|January 2016|2016-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration|Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration|Completed|||18|Actual|Mayo Clinic|||2||f||||f||||||||No||2018-06-01 02:36:25.311283|2018-06-01 02:36:25.311283
NCT00587522|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-07|Estimate|||||||2007-12-21|2008-01-07|Estimate|August 2001||2001-08-31|December 2007|2007-12-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease|Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease|Completed||N/A|64|Actual|NDO Surgical, Inc.||1|||f||||f||||||||||2018-06-01 02:36:25.387771|2018-06-01 02:36:25.387771
NCT00587509|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-12-01|2007-12-21|2008-01-07|Estimate|||||||2011-12-01|2011-12-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:36:25.478285|2018-06-01 02:36:25.478285
NCT00587496|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-07|Estimate|||||||2007-12-21|2008-01-07|Estimate|April 2006||2006-04-30|December 2007|2007-12-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers|A 30-Day Double-Masked Study to Determine the Effect of Oral Valacyclovir or Oral Valacyclovir Plus Aspirin on the Shedding of Herpes Simplex Virus DNA in the Tears and Saliva of Volunteers Without Clinical Signs of Ocular Herpetic Disease|Unknown status|Recruiting|Phase 1|60|Anticipated|National Eye Institute (NEI)||3|||f||||t||||||||||2018-06-01 02:36:25.517283|2018-06-01 02:36:25.517283
NCT00587483|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-07-13||2011-08-09|2008-01-04|2008-01-07|Estimate|2011-07-13|2011-08-09|Estimate||||2011-08-09|2011-08-11|Estimate|November 2007||2007-11-30|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation|The Use of Amiodarone vs. Lidocaine and Placebo for the Prevention of Ventricular Fibrillation After Myocardial Reperfusion During Cardiopulmonary Bypass|Completed||N/A|342|Actual|Mayo Clinic|Included a heterogeneous group of operations which possibly make our results applicable to “real world” perioperative care; dosing of amiodarone was higher than in previous investigations, but the dose may not have been large enough.|3|||f||||f||||||||||2018-06-01 02:36:25.659368|2018-06-01 02:36:25.659368
NCT00587470|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-10-14|2008-01-04|2008-01-07|Estimate|||||||2010-10-14|2010-10-15|Estimate|August 1998||1998-08-31|October 2010|2010-10-31|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Angiotensin-II Blockade in Mitral Regurgitation|Angiotensin-II Blockade in Mitral Regurgitation|Completed||Phase 4|60|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:36:26.352334|2018-06-01 02:36:26.352334
NCT00587457|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2017-02-27||2017-06-12|2007-12-21|2008-01-07|Estimate|2017-02-27|2017-04-12|Actual||||2017-06-12|2017-07-06|Actual|March 7, 2007|Actual|2007-03-07|June 2017|2017-06-30|April 7, 2008|Actual|2008-04-07|April 7, 2008|Actual|2008-04-07||Interventional||Safety population included all participants who received any treatment of moxetumomab pasudotox.|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia|A Phase I, Multicenter, Dose-Escalation Study of CAT-8015 in Patients With Relapsed or Refactory Chronic Lymphocytic Leukemia (CLL) Prolymphocytic Leukemia (PLL), or Small Lymphocytic Leukemia (SLL)|Terminated||Phase 1|11|Actual|MedImmune LLC|The study was terminated early due to unavailability of investigational product.|3||The study is terminated early due to unavailability of investigational product.|f||||f||||||||||2018-06-01 02:36:26.461052|2018-06-01 02:36:26.461052
NCT00587444|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-10-14|2008-01-04|2008-01-07|Estimate|||||||2009-10-14|2009-10-15|Estimate|June 2001||2001-06-30|October 2009|2009-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|Heparin Dosing||Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass|Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass|Completed||Phase 3|270|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 02:36:27.258604|2018-06-01 02:36:27.258604
NCT00587431|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-01-21||2014-08-05|2008-01-04|2008-01-07|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|July 2003||2003-07-31|August 2014|2014-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer|Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer|Completed||Phase 2|102|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:36:27.354859|2018-06-01 02:36:27.354859
NCT00587418|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-08-30|2007-12-21|2008-01-07|Estimate|||||||2012-08-30|2012-09-03|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients|L-arginine Supplement for the Prevention of Calcineurin Inhibitor Nephrotoxicity|Completed||N/A|24|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:36:27.648224|2018-06-01 02:36:27.648224
NCT00587405|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-05|2008-01-04|2008-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|December 2007||2007-12-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Cyrotherapy vs. APC in GAVE|Prospective Randomized Study of Cryotherapy Versus Argon Plasma Coagulation Therapy for Treatment Of Watermelon Stomach|Completed||Phase 2/Phase 3|60|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:27.720667|2018-06-01 02:36:27.720667
NCT00587392|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-07|Estimate|||||||2007-12-21|2008-01-07|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|LTFU||Endoscopic Full-Thickness Plication for the Treatment of GERD: Long-Term Multicenter Results|Endoscopic Full-Thickness Plication for the Treatment of GERD: Long-Term Multicenter Results|Completed|||33|Actual|NDO Surgical, Inc.|||1||f||||f||||||||||2018-06-01 02:36:27.804821|2018-06-01 02:36:27.804821
NCT00587379|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-01-12|2008-01-04|2008-01-07|Estimate|||||||2012-01-12|2012-01-13|Estimate|June 2004||2004-06-30|January 2012|2012-01-31|May 2008|Anticipated|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Chronic Statin and Viagra Therapy in Persons With Endothelial Cell Dysfunction|The Effect of Chronic Statin Therapy on Peripheral Arterial Tone Response to Sildenafil Citrate (Viagra), and on Erectile Function in Men With Coronary Artery Endothelial Cell Dysfunction|Withdrawn||N/A|0|Actual|Mayo Clinic||2||Study closed per the request of PI due to lack of participant accrual|f||||f||||||||||2018-06-01 02:36:27.880952|2018-06-01 02:36:27.880952
NCT00587353|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-05-01|2007-12-21|2008-01-07|Estimate|||||||2012-05-01|2012-05-02|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Tobacco Use Intervention Among Radiation Oncology Patients|Tobacco Use Intervention Among Radiation Oncology Patients|Completed||Phase 2|26|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 02:36:27.942955|2018-06-01 02:36:27.942955
NCT00587340|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-09-16|2007-12-21|2008-01-07|Estimate|||||||2011-09-16|2011-09-19|Estimate|August 2006||2006-08-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Survey of Sleep Problems in Survivors of Breast Cancer|A Survey of Sleep Problems in Survivors of Breast Cancer|Completed|||256|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||f||||||||||2018-06-01 02:36:27.999037|2018-06-01 02:36:27.999037
NCT00587327|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-20|2007-12-21|2008-01-07|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2007||2007-11-30|June 2017|2017-06-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|OVANCON||Effect of Oxytocin and Vasopressin Antagonists on Uterine Contractions|A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Multi-centre Study Assessing the Effects of a Selective Oxytocin Antagonist (Barusiban) and a Mixed Oxytocin Antagonist - Vasopressin V1a Antagonist (Atosiban) Administered Intravenously on Luteal Phase Uterine Contractions in Oocyte Donors Supplemented With Vaginal Progesterone|Completed||Phase 2|125|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:36:28.069256|2018-06-01 02:36:28.069256
NCT00587314|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-02-08|2008-01-04|2008-01-07|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2004||2004-01-31|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Observational|ablation IN BE||The Effect of Ablation Therapy on Barrett's Esophagus|The Effect of Ablation Therapy on Barrett's Esophagus|Enrolling by invitation|||400|Anticipated|Mayo Clinic|||1||f||||f||||||Samples Without DNA|"~     Esophageal Biopsy~   "|||2018-06-01 02:36:28.13522|2018-06-01 02:36:28.13522
NCT00587301|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-09-27|2007-12-21|2008-01-07|Estimate|||||||2017-09-27|2017-09-29|Actual|June 2005||2005-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ALAGB||Lap-Band Surgery on Adolescents for Safety and Efficacy|A Prospective, Open-label Study to Evaluate the Safety and Efficacy of Lap-Band® Adjustable Gastric Band (LAGB®) Operations in the Treatment of Morbidly Obese Adolescents (Ages 14-17)|Active, not recruiting||N/A|120|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 02:36:28.218013|2018-06-01 02:36:28.218013
NCT00587288|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-04|2016-03-23|2013-08-16|2016-07-18|2008-01-04|2008-01-07|Estimate|2016-03-23|2016-04-26|Estimate|2013-08-16|2013-08-26|Estimate|2016-07-18|2016-08-17|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma|An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation|Completed||Phase 2|106|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 02:36:28.385647|2018-06-01 02:36:28.385647
NCT00587275|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21||2013-07-26|2014-06-02|2007-12-21|2008-01-07|Estimate||||2014-06-02|2014-06-18|Estimate|2014-06-02|2014-06-18|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI|A Double-Blind, Randomized, Placebo-Controlled Crossover Study to Assess the Efficacy of AST-120 in Patients With Gastroesophageal Reflux Disease (GERD) Who Continue to be Symptomatic on a Standard Dose of Proton Pump Inhibitor (PPI)|Terminated||Phase 2|4|Actual|Ocera Therapeutics||2||Terminated for lack of enrollment|f||||f||||||||||2018-06-01 02:36:28.835684|2018-06-01 02:36:28.835684
NCT00587262|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-12-30|2008-01-04|2008-01-07|Estimate|||||||2015-12-30|2016-01-01|Estimate|October 2006||2006-10-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Scalar Localization Cochlear Electrode Array Using 64 Slice CT|Scalar Localization of Cochlear Implant Electrode Array in Hearing Preservation Patients Using 64 Slice CT|Completed|||5|Actual|Mayo Clinic|||3||f||||f||||||||||2018-06-01 02:36:28.918098|2018-06-01 02:36:28.918098
NCT00587249|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-03|||2013-04-11|2008-01-03|2008-01-07|Estimate|||||||2013-04-11|2013-04-12|Estimate|July 2002||2002-07-31|March 2013|2013-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||ICC-1132 - Candidate Vaccine Against P Falciparum Malaria|Phase I Trial of ICC-1132, a Candidate Vaccine Against Plasmodium Falciparum Malaria Based on a Viral-like Particle Comprising Recombinant Hepatitis B Core Antigen and Circumsporozoite Epitopes, to Assess Vaccine Safety and Immunogenicity in Healthy Adult Volunteers|Completed||Phase 1|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 02:36:28.991824|2018-06-01 02:36:28.991824
NCT00587236|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-13|2007-12-21|2008-01-07|Estimate|||||||2016-01-13|2016-01-14|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis|A Blinded Comparison of Conventional Colonoscopy to Endoscopic AFI and NBI for Dysplasia Detection in Patients With Ulcerative Colitis and Sclerosing Cholangitis or Known Colorectal Dysplasia or Cancer- A Pilot Clinical Study|Completed|||65|Actual|Mayo Clinic|||2||f||||f||||||||||2018-06-01 02:36:29.067777|2018-06-01 02:36:29.067777
NCT00587223|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-03-29||2010-06-25|2007-12-21|2008-01-07|Estimate|2010-05-21|2010-06-22|Estimate||||2010-06-25|2010-06-29|Estimate|December 2007||2007-12-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)|A Prospective, Multicenter, Within Subject Controlled Study to Evaluate the Effect of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa|Terminated||Phase 3|1|Actual|Organogenesis|Study terminated early, the 1 enrolled subject subsequently discontinued study at Day 7.|2||Insufficient patient enrollment|f||||t||||||||||2018-06-01 02:36:29.155915|2018-06-01 02:36:29.155915
NCT00587210|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-20|2007-12-21|2008-01-07|Estimate|||||||2016-01-20|2016-01-22|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel|Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel|Completed|||34|Actual|Mayo Clinic|||1||f||||f||||||||No||2018-06-01 02:36:29.384313|2018-06-01 02:36:29.384313
NCT00587197|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-11-09|2008-01-04|2008-01-07|Estimate|||||||2009-11-09|2009-11-10|Estimate|January 2003||2003-01-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|October 2005|Actual|2005-10-31||Observational|||A Prospective Evaluation of Computerized Tomographic(CT) Scanning as a Screening Modality for Esophageal Varices|The Accuracy of Contrast Abdominal CT for the Detection of High-Grade Esophageal and Gastric Varices in Patients With Cirrhosis|Completed|||134|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 02:36:29.438354|2018-06-01 02:36:29.438354
NCT00587184|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-11-23|2008-01-04|2008-01-07|Estimate|||||||2015-11-23|2015-11-24|Estimate|July 2006||2006-07-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|||Confocal Microscopy in Barrett's Esophagus|The Use of Confocal Microscopy in Barrett's Esophagus|Completed|||92|Actual|Mayo Clinic|||1||f||||f||||||||||2018-06-01 02:36:29.48557|2018-06-01 02:36:29.48557
NCT00587171|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2011-04-22||2016-07-07|2007-12-21|2008-01-07|Estimate|2011-04-22|2011-05-18|Estimate||||2016-07-07|2016-07-13|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Interventional|ATS12||Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia|A Randomized Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia in Children 7 to <13 Years Old|Terminated||Phase 3|19|Actual|Jaeb Center for Health Research|The study was stopped prior to achieving the goal of 45 subjects enrolled due to slow recruitment, leaving only 19 subjects enrolled.|2||This study was stopped due to insufficient recruitment.|f||||t||||||||||2018-06-01 02:36:29.736565|2018-06-01 02:36:29.736565
NCT00587158|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-01-24||2013-05-09|2007-12-21|2008-01-07|Estimate|2013-03-29|2013-05-08|Estimate||||2013-05-09|2013-05-13|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Oral Paricalcitol in Kidney Transplant Recipients|Oral Paricalcitol in Kidney Transplant Recipients Receiving a Corticosteroid-free Immunosuppressive Regimen|Completed||N/A|100|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:36:30.499366|2018-06-01 02:36:30.499366
NCT00587145|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-07|Estimate|||||||2007-12-21|2008-01-07|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|May 2009|Anticipated|2009-05-31|March 2009|Anticipated|2009-03-31||Interventional|||Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer|Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|44|Anticipated|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 02:36:31.409373|2018-06-01 02:36:31.409373
NCT00587132|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-04-29||2013-06-19|2008-01-04|2008-01-07|Estimate|2013-04-29|2013-06-20|Estimate||||2013-06-19|2013-06-24|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma|Pilot Study Using Secretin and Iodinated Intravenous Contrast and 64-Channel CT in Patients at High Risk for Pancreatic Adenocarcinoma|Terminated||Phase 1/Phase 2|4|Actual|Mayo Clinic|The study was terminated early due to lack of funding.|4||Lack of funding|f||||f||||||||||2018-06-01 02:36:31.503601|2018-06-01 02:36:31.503601
NCT00587119|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-10-01|2008-01-04|2008-01-07|Estimate|||||||2010-10-01|2010-10-05|Estimate|December 2007||2007-12-31|October 2010|2010-10-31|July 2009|Anticipated|2009-07-31|July 2009|Actual|2009-07-31||Interventional|PBC||Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis|Open-Label Pilot Study Evaluating Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis.|Withdrawn||N/A|0|Actual|Mayo Clinic||1||Lack of enrollment|f||||f||||||||||2018-06-01 02:36:31.706982|2018-06-01 02:36:31.706982
NCT00587106|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-03-27|2007-12-21|2008-01-07|Estimate|||||||2009-03-27|2009-03-30|Estimate|April 1988||1988-04-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Studies of Neurological Paraneoplastic Syndromes|Studies of Neurological Paraneoplastic Syndromes|Completed|||51|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     blood and/or spinal fluid~   "|||2018-06-01 02:36:31.773693|2018-06-01 02:36:31.773693
NCT00587093|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-02-20|2007-12-21|2008-01-07|Estimate|||||||2018-02-20|2018-02-22|Actual|July 2001|Actual|2001-07-31|February 2018|2018-02-28|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Interventional|||A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer|Multicenter Trial on Utility and Impact of Computed Tomography and Serum CA-125 in Management of Newly Diagnosed Ovarian Cancer|Completed||N/A|669|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||f||||||||||2018-06-01 02:36:31.827851|2018-06-01 02:36:31.827851
NCT00587080|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-07|Estimate|||||||2007-12-21|2008-01-07|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Observational|||Stapled TransAnal Rectal Resection (STARR): Clinical and Radiological Outcome|Stapled TransAnal Rectal Resection (STARR): Correlation Between Clinical and Radiological Outcome|Completed|||24|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 02:36:31.896022|2018-06-01 02:36:31.896022
NCT00587067|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2017-05-09||2017-08-01|2008-01-04|2008-01-07|Estimate|2017-08-01|2017-08-04|Actual||||2017-08-01|2017-08-04|Actual|June 2003||2003-06-30|May 2016|2016-05-31|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|||A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy|A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy|Completed||Phase 2|34|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:31.947911|2018-06-01 02:36:31.947911
NCT00587054|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-12-22||2017-01-20|2007-12-21|2008-01-07|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|June 2001||2001-06-30|January 2017|2017-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders|Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (>18 Years) With Lymphohematopoietic Disorders|Completed||Phase 2|129|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:32.122605|2018-06-01 02:36:32.122605
NCT00587041|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-09-19||2012-04-28|2008-01-04|2008-01-07|Estimate|2012-04-28|2012-05-31|Estimate||||2012-04-28|2012-05-31|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Use of Oral Probiotics to Reduce Urinary Oxalate Excretion|Use of Oral Probiotics to Reduce Urinary Oxalate Excretion|Completed||Phase 1/Phase 2|40|Actual|Mayo Clinic|Small sample size, low oxalate levels in diet|3|||f||||t||||||||||2018-06-01 02:36:32.428219|2018-06-01 02:36:32.428219
NCT00587028|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-20|2008-01-04|2008-01-07|Estimate|||||||2016-01-20|2016-01-22|Estimate|February 2007||2007-02-28|January 2016|2016-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Cathartic-Free DECT Colonography for Detection of Colonic Polyps|Cathartic-Free Dual Energy Computerized Tomography (DECT) Colonography.|Terminated|||12|Actual|Mayo Clinic|||4|Administrative closed due to funding|f||||f||||||||No||2018-06-01 02:36:32.734653|2018-06-01 02:36:32.734653
NCT00587015|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-11-21|2007-12-21|2008-01-07|Estimate|||||||2011-11-21|2011-11-22|Estimate|August 2007||2007-08-31|November 2011|2011-11-30|October 2009|Actual|2009-10-31|March 2008|Actual|2008-03-31||Interventional|||A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)|Terminated||Phase 1|50|Anticipated|MedImmune LLC||1||"Due to a lack of IP supply and then terminated because they were combined into one new study~   with the new IP formulation."|f||||f||||||||||2018-06-01 02:36:32.803008|2018-06-01 02:36:32.803008
NCT00587002|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-04-13|2007-12-21|2008-01-07|Estimate|||||||2011-04-13|2011-04-15|Estimate|March 2007||2007-03-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Differences in Epicardial Plaque and Microvascular Function in Women With an Acute Myocardial Infarction|Differences in Epicardial Plaque and Microvascular Function in Women With an Acute Myocardial Infarction|Completed||N/A|65|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:36:32.865475|2018-06-01 02:36:32.865475
NCT00586989|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-05|2008-01-04|2008-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|December 2007||2007-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Observational|ETMI||Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus|Endoscopic Tri-Modal Imaging for the Detection of High-Grade Dysplasia and Early Adenocarcinoma in Patients With Barrett's Esophagus: A Randomized Crossover Multi-center Study|Completed|||60|Actual|Mayo Clinic|||1||f||||f||||||Samples Without DNA|"~     esophageal biopsies~   "|||2018-06-01 02:36:32.997949|2018-06-01 02:36:32.997949
NCT00586976|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-04-06|2008-01-04|2008-01-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery|A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery|Terminated||Phase 2/Phase 3|125|Actual|Mayo Clinic||2||Stopped by DSMB due to increased wound infection rate.|f||||t||||||||||2018-06-01 02:36:33.084272|2018-06-01 02:36:33.084272
NCT00586963|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-08-20|2007-12-21|2008-01-07|Estimate|||||||2010-08-20|2010-08-23|Estimate|January 2008||2008-01-31|August 2010|2010-08-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|EE||Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis|How Does Proton Pump Inhibitor Therapy Impact Quality of Life in Patients Newly Diagnosed With Erosive Reflux Esophagitis?|Completed|||65|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 02:36:33.151981|2018-06-01 02:36:33.151981
NCT00586950|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-09-12|2007-12-21|2008-01-07|Estimate|||||||2011-09-12|2011-09-13|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Observational|B-SAFE||123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients|Outcome Study on BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients|Completed|||1000|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||t||||||||||2018-06-01 02:36:33.217412|2018-06-01 02:36:33.217412
NCT00586937|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-01-02|2007-12-21|2008-01-07|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2005|Actual|2005-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Quality of Life in Lung Cancer Survivors|Quality of Life in Lung Cancer Survivors|Active, not recruiting|||193|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:36:33.274411|2018-06-01 02:36:33.274411
NCT00586924|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-08-06|2007-12-21|2008-01-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Phase I, Multicenter Dose Escalation Study in Patients With Leukemia|A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL)|Completed||Phase 1|50|Actual|MedImmune LLC||1|||f||||f||||||||||2018-06-01 02:36:33.378597|2018-06-01 02:36:33.378597
NCT00586911|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-04-06|2007-12-21|2008-01-07|Estimate|||||||2015-04-06|2015-04-08|Estimate|January 2003||2003-01-31|April 2015|2015-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Betaine in Patients With Nonalcoholic Steatohepatitis|A Randomized, Placebo-Controlled Trial of Betaine in Patients With Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 2|26|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:33.480217|2018-06-01 02:36:33.480217
NCT00586898|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-12-16||2016-02-24|2007-12-21|2008-01-07|Estimate|2016-02-24|2016-03-25|Estimate||||2016-02-24|2016-03-25|Estimate|July 2001||2001-07-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle|Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle|Completed||Phase 2|36|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:33.559641|2018-06-01 02:36:33.559641
NCT00586885|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-10-09|2007-12-21|2008-01-07|Estimate|||||||2012-10-09|2012-10-11|Estimate|February 2004||2004-02-29|October 2012|2012-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Effects of Alanine in Patients With Nonalcoholic Steatohepatitis|A Pilot Study: Therapeutic Effect of L-Alanine in Patients With Nonalcoholic Steatohepatitis|Completed||N/A|9|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:36:33.718654|2018-06-01 02:36:33.718654
NCT00586872|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-11-20|2007-12-21|2008-01-07|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2007||2007-10-31|November 2017|2017-11-30|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Observational|||Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus|Endoscopic Mucosal Resection in Barrett's Esophagus|Enrolling by invitation|||1800|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-06-01 02:36:33.788987|2018-06-01 02:36:33.788987
NCT00586859|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2008-05-29|2007-12-21|2008-01-07|Estimate|||||||2008-05-29|2008-05-30|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Multi-Center Study of the NDO Surgical Plicator Utilizing Multiple Implants for the Treatment of GERD|Multi-Center Study of the NDO Surgical Plicator Utilizing Multiple Implants|Terminated||N/A|41|Actual|NDO Surgical, Inc.||1||Sponsoring company ceased business operations.|f||||f||||||||||2018-06-01 02:36:33.883764|2018-06-01 02:36:33.883764
NCT00586846|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-12-15||2015-12-15|2007-12-21|2008-01-07|Estimate|2015-12-15|2016-01-20|Estimate||||2015-12-15|2016-01-20|Estimate|July 2003||2003-07-31|December 2015|2015-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma|Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma|Completed||Phase 2|40|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:36:33.963389|2018-06-01 02:36:33.963389
NCT00586833|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-10-13|2007-12-21|2008-01-07|Estimate|||||||2010-10-13|2010-10-14|Estimate|April 2007||2007-04-30|October 2010|2010-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Heart Failure and a Preserved Ejection Fraction|The Role of Vascular Dysfunction in Limiting Cardiovascular Reserve in Patients With Heart Failure and a Preserved Ejection Fraction|Completed|||51|Actual|Mayo Clinic|||3||f||||f||||||Samples With DNA|"~     Blood is drawn to evaluate BNP and cGMP pre and post exercise.~   "|||2018-06-01 02:36:34.196364|2018-06-01 02:36:34.196364
NCT00586820|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-04-21||2014-07-03|2008-01-04|2008-01-07|Estimate|2014-07-03|2014-07-04|Estimate||||2014-07-03|2014-07-04|Estimate|May 2005||2005-05-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|BQ-123|12 subjects were enrolled on the BQ-123 arm, but 1 subject was excluded due to unsuccessful PCI.|Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI|Role of Endothelin in Microvascular Dysfunction Following Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction|Completed||Phase 2|23|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:36:34.274597|2018-06-01 02:36:34.274597
NCT00586807|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-01-29|2007-12-21|2008-01-04|Estimate|||||||2009-01-29|2009-01-30|Estimate|June 2005||2005-06-30|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Metabolic Response to Infliximab in Pediatric Ulcerative Colitis|Metabolic Response to Infliximab in Pediatric Ulcerative Colitis|Terminated||N/A|10|Anticipated|Indiana University||1||poor enrollment|f||||t||||||||||2018-06-01 02:36:34.486812|2018-06-01 02:36:34.486812
NCT00586794|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-06-05|2007-12-21|2008-01-04|Estimate|||||||2012-06-05|2012-06-06|Estimate|December 2007||2007-12-31|October 2010|2010-10-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients|Therapy of Pulmonary Arterial Hypertension (PAH) - Treatment With Sildenafil in Eisenmenger Patients|Terminated||Phase 3|24|Actual|Competence Network for Congenital Heart Defects||2|||f||||f||||||||||2018-06-01 02:36:34.554681|2018-06-01 02:36:34.554681
NCT00586781|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-04|Estimate|||||||2007-12-21|2008-01-04|Estimate|September 2001||2001-09-30|December 2007|2007-12-31||||December 2006|Actual|2006-12-31||Interventional|||Study of the Scandinavian Total Ankle Replacement (STAR) for the Treatment of Bilateral Degenerative Ankle Disease|Investigational Device Exemption for the Scandinavian Total Ankle Replacement (STAR) - Bilateral Arm|Completed||Phase 3|21|Actual|Link America, Inc.||1|||f||||f||||||||||2018-06-01 02:36:34.653349|2018-06-01 02:36:34.653349
NCT00586755|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-07-16|2007-12-21|2008-01-04|Estimate|||||||2014-07-16|2014-07-18|Estimate|February 1998||1998-02-28|July 2014|2014-07-31|November 2008|Actual|2008-11-30|October 2007|Actual|2007-10-31||Interventional|||Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma|Intensive Induction Therapy Followed by Early High Dose Chemotherapy and Bone Marrow Transplantation for Mantle Cell Lymphoma|Completed||Phase 2|48|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:36:34.71955|2018-06-01 02:36:34.71955
NCT00586742|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-05-24|2008-01-03|2008-01-04|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2008||2008-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||SLAP Lesions; a Comparison of Conservative and Operative Treatment. A Prospective, Randomized Study|SLAP Lesions; a Comparison of Conservative and Operative Treatment. A Prospective, Randomized Study|Completed||N/A|118|Actual|Lovisenberg Diakonale Hospital||3|||f||||f||||||||||2018-06-01 02:36:34.776196|2018-06-01 02:36:34.776196
NCT00586729|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-08-09||2012-09-07|2007-12-21|2008-01-04|Estimate|2012-08-09|2012-09-10|Estimate||||2012-09-07|2012-09-14|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Vashe Wound Therapy Study|Pilot Study to Evaluate Effectiveness of Vashe™ Wound Therapy as an Antimicrobial Irrigant in Burn Wound Management|Completed||N/A|23|Actual|Maricopa Integrated Health System||2|||f||||f||||||||||2018-06-01 02:36:34.948571|2018-06-01 02:36:34.948571
NCT00586716|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-05-29||2016-11-17|2007-12-21|2008-01-04|Estimate|2016-04-28|2016-06-06|Estimate||||2016-11-17|2017-01-09|Estimate|November 2004||2004-11-30|April 2016|2016-04-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients|IVIG Treatment for Live-donor Renal Transplant Patients With a Positive Crossmatch and in Patients With High PRA|Terminated||N/A|22|Actual|Loma Linda University|A limitation to this study is early termination leading to small numbers of subjects analyzed.|2||Insufficient recruitment|f||||f||||||||No||2018-06-01 02:36:35.211883|2018-06-01 02:36:35.211883
NCT00586703|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-02-05||2014-06-06|2007-12-21|2008-01-04|Estimate|2014-02-05|2014-03-27|Estimate||||2014-06-06|2014-06-12|Estimate|April 2005||2005-04-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional||Participants who were eligible for study.|Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT|Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions (DLI) From 3-5/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)|Completed||Phase 1|21|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:36:35.385864|2018-06-01 02:36:35.385864
NCT00586690|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-02-05||2017-01-25|2007-12-21|2008-01-04|Estimate|2014-05-02|2014-06-02|Estimate||||2017-01-25|2017-02-08|Estimate|May 2005||2005-05-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional||Eligible adult patients were those who engrafted following a fludarabine based T cell depleted non-myeloablative allogeneic transplant regimen with alemtuzumab. Donors were the same HLA 6/6 matched family member used for the allogeneic transplantation.|Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT|Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions(DLI) From 6/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)|Completed||Phase 1|47|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:36:35.602579|2018-06-01 02:36:35.602579
NCT00586677|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-09-19|2007-12-21|2008-01-04|Estimate|||||||2014-09-19|2014-09-22|Estimate|May 2005||2005-05-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of Parenting Interventions to Decrease Family Risk for Child Maltreatment|Evaluation of Parenting Interventions to Decrease Family Risk for Child|Completed||N/A|123|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:36:36.078353|2018-06-01 02:36:36.078353
NCT00518414|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2015-09-24|2007-08-17|2007-08-20|Estimate|||||||2015-09-24|2015-09-28|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||The Evaluation of Cow Milk-Based Formulas|The Evaluation of Cow Milk-Based Formulas - Study A|Completed||N/A|136|Actual|Mead Johnson Nutrition||3|||f||||f||||||||||2018-06-01 02:59:07.760238|2018-06-01 02:59:07.760238
NCT00586664|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-10-08|2009-10-08|2013-02-04|2007-12-21|2008-01-04|Estimate|2012-02-22|2012-03-26|Estimate|2012-02-22|2012-03-26|Estimate|2013-02-04|2013-02-08|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis||Completed||Phase 3|130|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 02:36:36.218806|2018-06-01 02:36:36.218806
NCT00586651|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21||2013-08-22|2015-09-22|2007-12-21|2008-01-04|Estimate||||2013-08-22|2013-08-30|Estimate|2015-09-22|2015-10-08|Estimate|December 2007||2007-12-31|September 2015|2015-09-30|September 2010|Actual|2010-09-30|October 2009|Actual|2009-10-31||Interventional|||Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis|An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation|Completed||Phase 2|39|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 02:36:37.019035|2018-06-01 02:36:37.019035
NCT00586638|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-08-03|2007-12-21|2008-01-04|Estimate|||||||2015-08-03|2015-08-05|Estimate|December 2007||2007-12-31|August 2015|2015-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Training Cognitive Control Processes in Older Adults|Pilot Study Using a Video Game to Train Cognitive Control Processes in Healthy Older Adults|Completed||N/A|60|Actual|Columbia University||3|||f||||f||||||||||2018-06-01 02:36:37.087073|2018-06-01 02:36:37.087073
NCT00586625|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-10-08||2013-02-13|2007-12-21|2008-01-04|Estimate|2009-10-08|2009-11-11|Estimate||||2013-02-13|2013-02-15|Estimate|October 2007||2007-10-31|February 2013|2013-02-28||||May 2008|Actual|2008-05-31||Interventional|||Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers||Completed||Phase 3|861|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:36:37.184385|2018-06-01 02:36:37.184385
NCT00586612|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-12-17||2016-10-18|2007-12-21|2008-01-04|Estimate|2009-12-17|2010-01-22|Estimate||||2016-10-18|2016-11-29|Estimate|December 2007||2007-12-31|October 2016|2016-10-31|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Interventional|||Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants|Immunogenicity & Safety Study in Preterm & Full-term Infants of GSK Biologicals' Hib-MenC Vaccine, Menitorix™ Co-administered With Infanrix™ Penta & Prevenar™ at 2, 4, 6 Months & as a Booster With Infanrix™ IPV & Prevenar™ at 16-18 Months|Completed||Phase 3|313|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:36:37.545213|2018-06-01 02:36:37.545213
NCT00586599|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-04-01|2007-12-21|2008-01-04|Estimate|||||||2015-04-01|2015-04-03|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis|Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis|Completed||N/A|51|Actual|Indiana University||3|||f||||f||||||||||2018-06-01 02:36:38.310391|2018-06-01 02:36:38.310391
NCT00586586|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-08-07|2007-12-21|2008-01-04|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2, 2008||2008-01-02|August 2017|2017-08-31|March 21, 2014|Actual|2014-03-21|June 1, 2012|Actual|2012-06-01||Interventional|ATACA||Effectiveness Study of CBT for Anxiety in Children|Assessment and Treatment - Anxiety in Children and Adults (Child Part)|Completed||Phase 2|222|Actual|Haukeland University Hospital||3|||f||||t||||||||||2018-06-01 02:36:38.368352|2018-06-01 02:36:38.368352
NCT00586573|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-01-05||2012-05-02|2007-12-28|2008-01-04|Estimate|2012-05-02|2012-06-07|Estimate||||2012-05-02|2012-06-07|Estimate|March 2007||2007-03-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS|An Open-Label Pilot Study of Namenda (Memantine Hydrochloride) in Adult Subjects With Attention Deficit Hyperactivity Disorder (ADHD) and ADHD NOS|Completed||Phase 4|34|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 02:36:38.435686|2018-06-01 02:36:38.435686
NCT00586560|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-05-11|2008-01-03|2008-01-04|Estimate|||||||2012-05-11|2012-05-15|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|KTN10010||Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)|A Phase 1 Trial of Escalating Doses of Karenitecin Plus Cyclophosphamide Administered Intravenously Daily for 5 Consecutive Days in Pediatric Patients With Refractory or Recurrent Solid Tumors|Completed||Phase 1|15|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 02:36:38.578227|2018-06-01 02:36:38.578227
NCT00586547|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-12-02|2007-12-21|2008-01-04|Estimate|||||||2009-12-02|2009-12-03|Estimate|July 2000||2000-07-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation|A Phase I Trial Evaluating The Use of RFT5-dgA to Deplete Alloreactive Cells PriorTo Haploidentical Stem Cell Transplantation|Completed||Phase 1|24|Anticipated|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 02:36:38.659405|2018-06-01 02:36:38.659405
NCT00586534|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-03-17|2007-12-21|2008-01-04|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Developing Computer Based Treatments for Addiction|Developing Computer Based Treatments for Addiction|Completed||N/A|216|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:36:39.664144|2018-06-01 02:36:39.664144
NCT00586521|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-04-03||2014-10-27|2007-12-21|2008-01-04|Estimate|2009-11-09|2009-11-19|Estimate||||2014-10-27|2014-11-03|Estimate|February 2006||2006-02-28|October 2014|2014-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)|A Prospective Controlled Study on the Effect on Bleeding Events and Joint Function in Young Adults With Severe Hemophilia A After a 6 Month Prophylaxis Treatment Compared to on Demand Treatment|Completed||Phase 4|20|Actual|Bayer|The short observation period of 6 months may be responsible for the lack of statistical significance between treatments in the subject's overall assessment of disease-related quality of life; however, a positive trend was noted.|1|||f||||f||||||||||2018-06-01 02:36:39.771671|2018-06-01 02:36:39.771671
NCT00586508|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07||2014-01-07|2014-01-07|2007-12-21|2008-01-04|Estimate||||2014-01-07|2014-02-06|Estimate|2014-01-07|2014-02-06|Estimate|November 2007||2007-11-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Trial of Enzastaurin and Bevacizumab in Adults With Recurrent Malignant Gliomas|A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas|Completed||Phase 2|120|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:36:40.013324|2018-06-01 02:36:40.013324
NCT00586495|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-10-08||2013-11-19|2008-01-03|2008-01-04|Estimate|2010-01-12|2010-02-02|Estimate||||2013-11-19|2013-12-13|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Long-term Extension From RCC Phase II (11515)|Extension Study for BAY43-9006 in Japanese Patients With Renal Cell Carcinoma|Completed||Phase 2|95|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:36:40.130573|2018-06-01 02:36:40.130573
NCT00586482|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-11-26||2014-12-19|2007-12-21|2008-01-04|Estimate|2014-12-19|2014-12-22|Estimate||||2014-12-19|2014-12-22|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pilot Study: Preoperative Nicotine Lozenges|The Role of Nicotine Lozenges in Reducing Preoperative Exposure to Cigarette Smoke|Completed||Phase 4|46|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:36:40.741534|2018-06-01 02:36:40.741534
NCT00586469|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-01-14||2016-11-03|2007-12-21|2008-01-04|Estimate|2009-04-06|2009-05-28|Estimate||||2016-11-03|2016-12-16|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk|Observer-blind, Post-Marketing Study to Compare the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007-2008 Season) Made With New vs. Aged Bulk Material, in Adults Ranging in Age From 18 to 60 Years|Completed||Phase 4|1000|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:36:41.086559|2018-06-01 02:36:41.086559
NCT00586456|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-03-10|2007-12-21|2008-01-04|Estimate|||||||2017-03-10|2017-03-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:36:41.456606|2018-06-01 02:36:41.456606
NCT00586443|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-11-18|2007-12-21|2008-01-04|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2007||2007-11-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|BEP||BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)|A Phase I Study of Bevacizumab, Everolimus, and Panitumumab for Patients With Advanced Solid Tumors|Completed||Phase 1|56|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:36:41.565583|2018-06-01 02:36:41.565583
NCT00586430|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-04|Estimate|||||||2007-12-21|2008-01-04|Estimate|December 2005||2005-12-31|December 2007|2007-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The Impact of Lorazepam on Cognition in APOE e4 Carriers|The Impact of Lorazepam on Cognition in APOE e4 Carriers|Completed||N/A|36|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:36:41.654935|2018-06-01 02:36:41.654935
NCT00586417|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-12-02|2008-01-03|2008-01-04|Estimate|||||||2013-12-02|2013-12-03|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments|A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments.|Terminated||N/A|61|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:36:41.754243|2018-06-01 02:36:41.754243
NCT00586404|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-05-24|2007-12-21|2008-01-04|Estimate|||||||2017-05-24|2017-05-30|Actual|November 2007|Actual|2007-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|BEST||The Study of Barrett's Esophagus: What Are the Factors of Progression|Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project|Terminated|||1250|Actual|Midwest Biomedical Research Foundation|||1|lack of enrollment|f||||t||||||||||2018-06-01 02:36:41.82565|2018-06-01 02:36:41.82565
NCT00586391|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-01-21|2007-12-21|2008-01-04|Estimate|||||||2018-01-21|2018-01-23|Actual|February 2009||2009-02-28|January 2018|2018-01-31|July 2029|Anticipated|2029-07-31|July 2014|Actual|2014-07-31||Interventional|CRETI-NH||CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL|Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|14|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:36:41.935922|2018-06-01 02:36:41.935922
NCT00586378|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-03-01|2007-12-21|2008-01-04|Estimate|||||||2012-03-01|2012-03-02|Estimate|April 2006||2006-04-30|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Post-Ovatio||Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study|Ovatio DR and VR Implantable Cardioverter Defibrillators Post-approval Study|Completed||Phase 3|85|Actual|ELA Medical, Inc.|||||f||||f||||||||||2018-06-01 02:36:42.01725|2018-06-01 02:36:42.01725
NCT00586365|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2012-03-20|2008-01-03|2008-01-04|Estimate|||||||2012-03-20|2012-03-21|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|January 2010|Actual|2010-01-31||Interventional|Naproxen||Naproxen for the Prevention of HO After Complex Elbow Trauma|Effectiveness of Naproxen for the Prevention of Heterotopic Ossification After Complex Elbow Trauma: a Prospective Randomized Trial|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||Too difficult to satisfy all the inclusion criteria.|f||||f||||||||||2018-06-01 02:36:42.072719|2018-06-01 02:36:42.072719
NCT00586352|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-07-29|2007-12-21|2008-01-04|Estimate|||||||2016-07-29|2016-08-02|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease|Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease|Completed||N/A|31|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 02:36:42.149513|2018-06-01 02:36:42.149513
NCT00586339|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-02-16||2017-09-25|2007-12-21|2008-01-04|Estimate|2012-02-16|2012-03-22|Estimate||||2017-09-25|2017-10-26|Actual|January 17, 2008||2008-01-17|August 2016|2016-08-31|July 18, 2011|Actual|2011-07-18|July 18, 2011|Actual|2011-07-18||Interventional|||Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in HIV Infected Females|Evaluation of the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in Adult Human Immunodeficiency Virus (HIV) Infected Female Subjects|Completed||Phase 2|150|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:36:42.437492|2018-06-01 02:36:42.437492
NCT00586326|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-09-20||2012-11-02|2007-12-21|2008-01-04|Estimate|2012-09-20|2012-10-22|Estimate||||2012-11-02|2012-11-06|Estimate|August 2003||2003-08-31|November 2012|2012-11-30|April 2011|Actual|2011-04-30|January 2006|Actual|2006-01-31||Interventional|DCIS||MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ|MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS)|Completed||Phase 2|133|Actual|Hologic, Inc.||1|||f||||f||||||||||2018-06-01 02:36:47.448092|2018-06-01 02:36:47.448092
NCT00586313|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-03-17||2016-08-31|2008-01-03|2008-01-04|Estimate|2015-10-27|2015-11-30|Estimate||||2016-08-31|2016-10-17|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|NAFLD|13 females|Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)|Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)|Completed||N/A|21|Actual|Indiana University|The small sample size and low-risk population.|1|||f||||t||||||||No||2018-06-01 02:36:47.703728|2018-06-01 02:36:47.703728
NCT00586300|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2012-06-20|2007-12-28|2008-01-04|Estimate|||||||2012-06-20|2012-06-21|Estimate|June 2003||2003-06-30|June 2012|2012-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Community-Based Programs for Improving Physical Function in People With Early Knee Osteoarthritis|Multidimensional Intervention in Early Osteoarthritis (The Knee Study)|Completed||N/A|294|Actual|University of Arizona||3|||f||||f||||||||||2018-06-01 02:36:47.884333|2018-06-01 02:36:47.884333
NCT00586287|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-03-29|2007-12-21|2008-01-04|Estimate|||||||2012-03-29|2012-04-02|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon|Prospective Randomized Trial of a Clinical Algorithm to Predict the Loading Dose of Phenprocoumon|Completed||Phase 4|302|Actual|Cantonal Hospital of St. Gallen||3|||f||||f||||||||||2018-06-01 02:36:47.967255|2018-06-01 02:36:47.967255
NCT00586274|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-03-03|2007-12-21|2008-01-04|Estimate|||||||2014-03-03|2014-03-04|Estimate|March 2002||2002-03-31|March 2014|2014-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|RAFHAS||Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT|A Phase I Study Evaluating The Use Of Rft5-Dga To Deplete Alloreactive Cells For Patients With Fanconi Anemia After Haploidentical Stem Cell Transplantation|Terminated||Phase 1|1|Actual|Baylor College of Medicine||1||Poor accrual|f||||t||||||||||2018-06-01 02:36:48.065473|2018-06-01 02:36:48.065473
NCT00586261|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-11-13||2013-03-13|2007-12-21|2008-01-04|Estimate|2013-02-01|2013-03-07|Estimate||||2013-03-13|2013-03-15|Estimate|March 2006||2006-03-31|March 2013|2013-03-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|||Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function|Does Chronic Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function in Non-Diabetic Patients With Chronic Kidney Disease?|Terminated||N/A|36|Actual|Mayo Clinic|The study was stopped early due to low enrollment because of the specifics of the inclusion criteria.|2||Low enrollment because of the specifics of the inclusion criteria|f||||f||||||||||2018-06-01 02:36:48.153109|2018-06-01 02:36:48.153109
NCT00586248|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-04|Estimate|||||||2007-12-21|2008-01-04|Estimate|March 2006||2006-03-31|May 2007|2007-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||A Pilot Study on Pacemaker Interference From Peripheral Nerve Stimulator for Regional Anesthesia|A Pilot Study on Pacemaker Interference From Peripheral Nerve Stimulator for|Completed|||14|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:36:48.368512|2018-06-01 02:36:48.368512
NCT00586235|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-05-25|2007-12-21|2008-01-04|Estimate|||||||2012-05-25|2012-05-28|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization|Registration and Fusion of Real-Time Ultrasound With CT for Lesion Localization and Characterization|Completed|||80|Actual|Mayo Clinic|||1||f||||t||||||||||2018-06-01 02:36:48.522979|2018-06-01 02:36:48.522979
NCT00586222|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-01-24|2007-12-21|2008-01-04|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Omega 3 Fatty Acid Trial|Neurometabolic Effects of the Essential Polyunsaturated Fatty Acids in Early-Onset Bipolar Disorder: A Magnetic Resonance Spectroscopy Study|Completed||Phase 1|19|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 02:36:48.588403|2018-06-01 02:36:48.588403
NCT00586209|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-06-27|2008-01-03|2008-01-04|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2003||2003-01-31|June 2011|2011-06-30|November 2009|Actual|2009-11-30|January 2009|Actual|2009-01-31||Interventional|||L-Glutamine Therapy for Sickle Cell Anemia|A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia|Completed||Phase 2|15|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-06-01 02:36:48.654584|2018-06-01 02:36:48.654584
NCT00586196|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-02-28||2014-08-21|2007-12-21|2008-01-04|Estimate|2014-08-21|2014-08-22|Estimate||||2014-08-21|2014-08-22|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|SHARP||Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period|Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period|Completed||Phase 2|16|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-06-01 02:36:48.735724|2018-06-01 02:36:48.735724
NCT00586183|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-04|Estimate|||||||2007-12-21|2008-01-04|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome|Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome|Completed||N/A|1|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:36:48.962714|2018-06-01 02:36:48.962714
NCT00586170|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2016-03-09||2017-06-19|2007-12-21|2008-01-04|Estimate|2016-04-11|2016-05-16|Estimate||||2017-06-19|2017-06-21|Actual|November 2007||2007-11-30|June 2017|2017-06-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||A Double-Blind Study on Adjunctive Use of PEMF in the Treatment of 5th Metatarsal Non-Union Fractures|A Prospective, Randomized, Double-Blind Study on Adjunctive Use of Pulsed Electromagnetic Fields in the Treatment of 5th Metatarsal Non-Union Fractures: Effect on Clinical Outcome and Growth Factor Synthesis|Terminated||N/A|8|Actual|Zimmer Biomet||2||Slow enrollment|f||||f||||||||Undecided||2018-06-01 02:36:49.023854|2018-06-01 02:36:49.023854
NCT00586157|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-11-22||2012-11-09|2007-12-21|2008-01-04|Estimate|2011-01-03|2011-01-25|Estimate||||2012-11-09|2012-11-16|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Medication Patch to Treat Children Ages 6-12 With ADHD|Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 4|36|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:36:49.336182|2018-06-01 02:36:49.336182
NCT00586131|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-08-31|2008-01-03|2008-01-04|Estimate|||||||2017-08-31|2017-09-05|Actual|September 2003||2003-09-30|August 2017|2017-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Arterial pH and Total Body Nitrogen Balances in APD|Effect of Arterial pH on N-balances of Patients Undergoing Automated Peritoneal Dialysis|Completed||Phase 4|8|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-06-01 02:36:49.560862|2018-06-01 02:36:49.560862
NCT00586118|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2008-01-03|2008-01-03|2008-01-04|Estimate|||||||2008-01-03|2008-01-04|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Inhalative Sedation in ICU With Sevoflurane Via Anaesthetic Conserving Device Compared to Propofol||Completed|||120|Actual|Klinikum Ludwigshafen|||2||f||||f||||||||||2018-06-01 02:36:49.631606|2018-06-01 02:36:49.631606
NCT00585728|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-08-26|2007-12-21|2008-01-03|Estimate|||||||2011-08-26|2011-08-30|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||CT Virtual Proctoscopy for Staging and Volume Assessment for Rectal Cancer|CT Virtual Proctoscopy for Staging and Volume Assessment for Rectal Cancer|Completed||N/A|20|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:36:53.225547|2018-06-01 02:36:53.225547
NCT00586105|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-02-01||2014-03-25|2008-01-03|2008-01-04|Estimate|2010-09-10|2010-10-01|Estimate||||2014-03-25|2014-04-16|Estimate|December 2005||2005-12-31|March 2014|2014-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)|A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma|Completed||Phase 3|39|Actual|Bayer|The median for ´Overall Survival (OS)´ and the median for ´Overall Response Duration´ reported are the median of each distribution including the censored data. The correct estimates of these medians were not evaluable.|1|||f||||f||||||||||2018-06-01 02:36:49.717711|2018-06-01 02:36:49.717711
NCT00586092|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-04-04|2007-12-21|2008-01-04|Estimate|||||||2013-04-04|2013-04-08|Estimate|September 2005||2005-09-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors|A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid|Completed||Phase 1|45|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:36:50.088166|2018-06-01 02:36:50.088166
NCT00586079|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-03-17|2007-12-21|2008-01-04|Estimate|||||||2016-03-17|2016-03-18|Estimate|July 2007||2007-07-31|April 2015|2015-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Deep Brain Stimulation in Patients With Parkinson's Disease|The Effect of Deep Brain Stimulation on Movement-Related Cortical Potentials in Patients With Parkinson's Disease|Completed||N/A|20|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-06-01 02:36:50.20096|2018-06-01 02:36:50.20096
NCT00586066|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2017-03-24||2017-09-07|2007-12-21|2008-01-04|Estimate|2017-03-24|2017-05-05|Actual||||2017-09-07|2017-10-06|Actual|November 2005|Actual|2005-11-30|September 2017|2017-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||All randomized participants.|Memantine and Cognitive Dysfunction in Bipolar Disorder|Memantine and Cognitive Dysfunction in Bipolar Disorder|Completed||Phase 4|72|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:36:50.286258|2018-06-01 02:36:50.286258
NCT00586053|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-02-10|2008-01-03|2008-01-04|Estimate|||||||2010-02-10|2010-02-11|Estimate|August 2000||2000-08-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|||Unprepped CT Colonography|"CTC of the Unprepped Colon: Optimization & Validation"|Completed|||1255|Actual|Mayo Clinic|||3||f||||f||||||||||2018-06-01 02:36:50.566156|2018-06-01 02:36:50.566156
NCT00586040|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-04-09|2007-12-21|2008-01-04|Estimate|||||||2009-04-09|2009-04-10|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|PTB||Photochemical Tissue Bonding|Photochemical Tissue Bonding (PTB) for Excisional Wound Healing|Completed||Phase 2|40|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:36:50.640308|2018-06-01 02:36:50.640308
NCT00586027|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-11-23|2008-01-03|2008-01-04|Estimate|||||||2009-11-23|2009-11-25|Estimate|July 2008||2008-07-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Observational|||Is There a Correlation of Natriuretic Propeptide Type B With an Intraoperative Low Cardiac Output?|Prospective Observational Study in Patients Undergoing Cardiac Surgery: Part 2: Is There a Correlation of Natriuretic Propeptide Type B With an Intraoperative Low Cardiac Output?|Completed|||150|Anticipated|Klinikum Ludwigshafen|||1||f||||f||||||||||2018-06-01 02:36:50.70541|2018-06-01 02:36:50.70541
NCT00586014|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-07-07|2007-12-21|2008-01-04|Estimate|||||||2014-07-07|2014-07-08|Estimate|May 1997||1997-05-31|May 2013|2013-05-31|February 2008|Actual|2008-02-29|January 2006|Actual|2006-01-31||Interventional|||High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma|High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma|Completed||Phase 2|91|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:36:50.771468|2018-06-01 02:36:50.771468
NCT00586001|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-11-29|2007-12-21|2008-01-04|Estimate|||||||2011-11-29|2011-12-01|Estimate|September 2005||2005-09-30|March 2011|2011-03-31|November 2010|Actual|2010-11-30|November 2008|Actual|2008-11-30||Interventional|||A Unified Treatment for Anxiety Disorders|Phase 3 of The Development of A Unified Treatment for Anxiety Disorders|Completed||Phase 3|40|Actual|Boston University||2|||f||||f||||||||||2018-06-01 02:36:50.830551|2018-06-01 02:36:50.830551
NCT00585988|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-19|2007-12-21|2008-01-04|Estimate|||||||2017-06-19|2017-06-21|Actual|June 2007||2007-06-30|June 2017|2017-06-30|September 2010|Anticipated|2010-09-30|September 2009|Anticipated|2009-09-30||Interventional|||A Clinical Investigation of Recovery Following Hip Resurfacing or Total Hip Arthroplasty|Functional Recovery Following Hip Resurfacing or Total Hip Arthroplasty in Patients Matched By Age, Gender, and Activity Level|Withdrawn||N/A|0|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-06-01 02:36:50.911057|2018-06-01 02:36:50.911057
NCT00585975|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-11-07||2013-02-13|2007-12-21|2008-01-04|Estimate|2011-11-07|2011-12-09|Estimate||||2013-02-13|2013-02-15|Estimate|October 2007||2007-10-31|February 2013|2013-02-28||||July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety of Bromfenac Ophthalmic Solution||Completed||Phase 2|568|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:36:51.065234|2018-06-01 02:36:51.065234
NCT00585962|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2017-08-31|2007-12-27|2008-01-04|Estimate|||||||2017-08-31|2017-09-05|Actual|February 2004||2004-02-29|August 2017|2017-08-31||||March 2006|Actual|2006-03-31||Interventional|||Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate|A Phase II Study Using Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate|Completed||Phase 2|57|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 02:36:51.269444|2018-06-01 02:36:51.269444
NCT00585949|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-01-24|2007-12-21|2008-01-04|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2006||2006-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|AGE-PCI||Age and Endothelial Progenitor Cell Mobilization|"The Effects of Age on Endothelial Progenitor Cell Mobilization in Humans"|Active, not recruiting|||136|Anticipated|Emory University|||2||f||||f||||||||||2018-06-01 02:36:51.320455|2018-06-01 02:36:51.320455
NCT00585936|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-11-09|2007-12-21|2008-01-04|Estimate|||||||2011-11-09|2011-11-10|Estimate|September 2007||2007-09-30|November 2011|2011-11-30|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Observational|||Imaging Inflammation in Autoimmune Diabetes|Evaluation of Magnetic Nanoparticle Enhanced Imaging in Autoimmune Diabetes|Completed|||30|Anticipated|Joslin Diabetes Center|||4||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:36:51.379826|2018-06-01 02:36:51.379826
NCT00585923|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-11-11||2016-03-15|2007-12-21|2008-01-04|Estimate|2010-03-13|2010-03-26|Estimate||||2016-03-15|2016-04-14|Estimate|April 2002||2002-04-30|May 2012|2012-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Slotted Hole Versus Fixed Hole C-Tek|A Multi-Center Clinical Investigation of Slotted Hole Versus Fixed Hole C-Tek™ Anterior Cervical Plates|Terminated||N/A|115|Actual|Zimmer Biomet|Early termination of this study because the doctor involved in the study decided that he did not want to participate in the study any more. The site also did not have very good follow-up on all of their patients|2||Due to lack of follow-up information|f||||f||||||||Undecided||2018-06-01 02:36:51.441744|2018-06-01 02:36:51.441744
NCT00518076|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2007-08-17|2007-08-17|2007-08-20|Estimate|||||||2007-08-17|2007-08-20|Estimate|September 2006||2006-09-30|August 2007|2007-08-31||||||||Observational|||Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant||Unknown status|Recruiting||||University of Sao Paulo|||||f||||t||||||||||2018-06-01 02:59:20.844655|2018-06-01 02:59:20.844655
NCT00585910|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-09-22||2012-11-08|2008-01-03|2008-01-04|Estimate|2010-05-06|2010-05-10|Estimate||||2012-11-08|2012-11-14|Estimate|January 2004||2004-01-31|November 2012|2012-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD|Efficacy and Safety/Tolerability of OROS MPH (Concerta) Plus Atomoxetine (ATMX) in Children and Adolescents (Age 6-17) With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 4|94|Actual|Massachusetts General Hospital|"Open trial so may have been biased;~Small sample size which may have underestimated findings;~Used a priori definition of partial response. However, our definition of ATMX partial responders has not been validated."|1|||f||||f||||||||||2018-06-01 02:36:51.832492|2018-06-01 02:36:51.832492
NCT00585897|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-10-11|2008-01-03|2008-01-04|Estimate|||||||2015-10-11|2015-10-14|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effect of Discontinuation of Sugar Sweetened Beverages|Title: Effects of Discontinuation of Sugar Sweetened Beverages on Hemoglobin A1c, Fasting and Post Prandial Blood Glucose in Type 2 Diabetics|Completed||N/A|5|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:36:52.053471|2018-06-01 02:36:52.053471
NCT00585884|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-02-06|2007-12-26|2008-01-03|Estimate|||||||2013-02-06|2013-02-08|Estimate|January 2000||2000-01-31|February 2013|2013-02-28|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||Following the Use of Gel Prosethetics in Breast Reconstruction|Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Gel-filled Mammary Prostheses in Patients Who Are Undergoing Primary Breast Reconstruction or Revision|Active, not recruiting|||20|Actual|University of California, Irvine|||||f||||t||||||||||2018-06-01 02:36:52.187093|2018-06-01 02:36:52.187093
NCT00585871|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-29|||2013-12-09|2008-01-02|2008-01-03|Estimate|||||||2013-12-09|2013-12-11|Estimate|May 2006||2006-05-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Clonidine to Prevent Implantable Cardiovertor Defibrillator Firing|Clonidine to Prevent Implantable Cardiovertor Defibrillator Firing|Terminated||N/A|8|Actual|University of Iowa||2||could not recruit|f||||t||||||||||2018-06-01 02:36:52.308115|2018-06-01 02:36:52.308115
NCT00585858|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-05-10|2007-12-26|2008-01-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2006||2006-09-30|May 2016|2016-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant|Cytokine Kinetics Assay to Assess the Presence or Absence of Tolerance in Organ Transplant Recipients|Terminated|||15|Actual|University of Wisconsin, Madison|||3|PI leaving institution|f||||f||||||||No||2018-06-01 02:36:52.453423|2018-06-01 02:36:52.453423
NCT00585845|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2009-02-19|2007-12-22|2008-01-03|Estimate|||||||2009-02-19|2009-02-20|Estimate|December 2007||2007-12-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment|A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment|Terminated||Phase 1|17|Actual|Anza Therapeutics, Inc.||1|||f||||t||||||||||2018-06-01 02:36:52.531727|2018-06-01 02:36:52.531727
NCT00585832|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|||2016-07-15|2007-12-27|2008-01-03|Estimate|||||||2016-07-15|2016-07-18|Estimate|February 2008||2008-02-29|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|DASH-4-Teens||Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure|Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure|Completed||N/A|207|Actual|University of Cincinnati||2|||f||||t||||||||Undecided||2018-06-01 02:36:52.619834|2018-06-01 02:36:52.619834
NCT00585819|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-12-30|2007-12-21|2008-01-03|Estimate|||||||2011-12-30|2012-01-04|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study|Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||2||lack of interest|f||||t||||||||||2018-06-01 02:36:52.719702|2018-06-01 02:36:52.719702
NCT00585806|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-10-01|2008-01-02|2008-01-03|Estimate|||||||2015-10-01|2015-10-05|Estimate|December 2005||2005-12-31|February 2010|2010-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|DobStress||Assessment of Cardiac Functional Reserve in Heart Failure With Preserved Ejection Fraction (HF-PEF)|Assessment of Cardiac Functional Reserve in Heart Failure With Preserved Ejection Fraction (HF-PEF)|Completed|||19|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-06-01 02:36:52.799067|2018-06-01 02:36:52.799067
NCT00585793|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-09-29|2008-01-02|2008-01-03|Estimate|||||||2015-09-29|2015-10-01|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|RELATES||Relationship Between HIV-1 Subtype and ARV Response|Study of the Relationship Between HIV-1 Subtype and Antiretroviral (ARV) Response in Ugandan Children|Completed|||108|Actual|University of Wisconsin, Madison|||1||f||||f||||||Samples Without DNA|"~     Plasma obtained from participants~   "|||2018-06-01 02:36:52.872552|2018-06-01 02:36:52.872552
NCT00585780|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2018-01-08|2008-01-02|2008-01-03|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2009||2009-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Interventional|||Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse|Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse|Active, not recruiting||Phase 1/Phase 2|108|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:36:52.952248|2018-06-01 02:36:52.952248
NCT00585767|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-25|2008-01-02|2008-01-03|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2001||2001-04-30|May 2017|2017-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Functional, Dynamic, and Anatomic MR Urography|Functional, Dynamic, and Anatomic MR Urography|Withdrawn|||0|Actual|University of California, Davis|||2||f||||f||||||||||2018-06-01 02:36:53.037224|2018-06-01 02:36:53.037224
NCT00585754|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2016-11-28|2008-01-02|2008-01-03|Estimate|||||||2016-11-28|2016-11-30|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse|Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse|Completed||Phase 1|75|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:36:53.089247|2018-06-01 02:36:53.089247
NCT00585741|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-02-22|2007-12-21|2008-01-03|Estimate|||||||2012-02-22|2012-02-23|Estimate|December 2006||2006-12-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pilot Study of 18F-FLT PET|Pilot Study of 18F-FLT Pet Imaging in Cancer Patients|Terminated||N/A|15|Actual|University of Wisconsin, Madison||5|||f||||t||||||||||2018-06-01 02:36:53.148822|2018-06-01 02:36:53.148822
NCT00585715|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-06-17||2018-03-05|2007-12-26|2008-01-03|Estimate|2013-10-24|2013-12-16|Estimate||||2018-03-05|2018-03-30|Actual|October 2006||2006-10-31|March 2018|2018-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|IH062905||Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening|Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening|Completed||N/A|22|Actual|University of California, Irvine|Small sample size|2|||f||||t||||||||||2018-06-01 02:36:53.287081|2018-06-01 02:36:53.287081
NCT00585702|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2013-09-30|2008-01-02|2008-01-03|Estimate|||||||2013-09-30|2013-10-07|Estimate|August 2006||2006-08-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|AMUP||Antimanic Drug Use in Pregnancy|Antimanic Drug Use in Pregnancy|Completed|||201|Actual|University of Pittsburgh|||2||f||||f||||||||||2018-06-01 02:36:53.48086|2018-06-01 02:36:53.48086
NCT00585689|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2014-05-05||2015-11-03|2007-12-26|2008-01-03|Estimate|2014-05-05|2014-06-05|Estimate||||2015-11-03|2015-11-30|Estimate|December 2007||2007-12-31|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer|A Phase Two Trial of Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder|Completed||Phase 2|29|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 02:36:53.643788|2018-06-01 02:36:53.643788
NCT00585676|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-02|||2014-12-05|2008-01-02|2008-01-03|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2007||2007-11-30|December 2014|2014-12-31||||May 2011|Actual|2011-05-31||Observational|||Impact of Antenatal Betamethasone on Plasma Glucose Levels|Impact of Antenatal Betamethasone on Plasma Glucose Levels|Unknown status|Recruiting||45|Anticipated|University of California, Irvine|||3||f||||f||||||||||2018-06-01 02:36:53.88781|2018-06-01 02:36:53.88781
NCT00585650|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-05-12||2011-10-05|2007-12-26|2008-01-03|Estimate|2011-10-05|2011-11-08|Estimate||||2011-10-05|2011-11-08|Estimate|May 2007||2007-05-31|October 2011|2011-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet|Double-blind, Randomized, Placebo-controlled Study of Recombinant Human Tumor Necrosis Factor Receptor (p75) Fusion Protein Etanercept (Enbrel) in Patients With Moderate to Severe Plaque Psoriasis of the Hands and/or Feet|Completed||Phase 1/Phase 2|20|Actual|University of California, Irvine||2|||f||||t||||||||||2018-06-01 02:36:53.94666|2018-06-01 02:36:53.94666
NCT00585637|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|2015-03-03||2015-03-18|2008-01-02|2008-01-03|Estimate|2015-03-18|2015-04-01|Estimate||||2015-03-18|2015-04-01|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional||Participants were drawn from the Open Doors to Health, which is a colorectal cancer prevention study in 1554 subjects from 12 public-housing communities and community- and faith-based organizations in Boston.|Vitamin D for Chemoprevention|Defining Optimal Doses of Vitamin D for Chemoprevention in Blacks.|Completed||Phase 1|328|Actual|Dana-Farber Cancer Institute||4|||f||||t||||||||||2018-06-01 02:36:54.281346|2018-06-01 02:36:54.281346
NCT00585624|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-10-06|2007-12-26|2008-01-03|Estimate|||||||2015-10-06|2015-10-08|Estimate|April 2007||2007-04-30|October 2015|2015-10-31|October 2009|Actual|2009-10-31|||||Interventional|||Preoperative Nutritional Support in Esophagectomy or Pancreaticoduodenectomy|Preoperative Nutritional Support Reduces Postoperative Stay and Incidence of Complications in Patients Undergoing an Esophagectomy or Pancreaticoduodenectomy|Completed||N/A|344|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 02:36:54.753544|2018-06-01 02:36:54.753544
NCT00585611|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-10-01|2008-01-02|2008-01-03|Estimate|||||||2015-10-01|2015-10-05|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients|Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients|Terminated||N/A|1|Actual|University of Wisconsin, Madison||2||Unable to recruit into the study|f||||t||||||||||2018-06-01 02:36:54.810752|2018-06-01 02:36:54.810752
NCT00585598|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-10-06|2007-12-26|2008-01-03|Estimate|||||||2015-10-06|2015-10-08|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|July 2010|Actual|2010-07-31|||||Observational|||Evaluation of Supralaryngeal Airway Removal During Initial Resuscitation of the Trauma Patient|Evaluation of Supralaryngeal Airway Removal During Initial Resuscitation of the Trauma Patient|Completed|||50|Anticipated|University of Wisconsin, Madison|||1||f||||f||||||||||2018-06-01 02:36:54.869487|2018-06-01 02:36:54.869487
NCT00585585|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2011-03-08||2017-07-21|2007-12-28|2008-01-03|Estimate|2017-07-21|2017-07-25|Actual||||2017-07-21|2017-07-25|Actual|July 2007||2007-07-31|July 2017|2017-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features|A Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features|Terminated||Phase 2|1|Actual|University of Cincinnati||1||Lack of participants|f||||t||||||||||2018-06-01 02:36:54.924514|2018-06-01 02:36:54.924514
NCT00585572|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-03-30|2008-01-02|2008-01-03|Estimate|||||||2017-03-30|2017-03-31|Actual|March 2007||2007-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|WBDP||Wisconsin Brain Donor Program|University of Wisconsin-Madison: Wisconsin Brain Donor Program (WBDP)|Enrolling by invitation|||500|Anticipated|University of Wisconsin, Madison|||||f||||f||||||Samples Without DNA|"~     Brain tissue, blood, cerebrospinal fluid, spinal cord, peripheral nerves, and skeletal~     muscles, central/peripheral nervous tissue, as well as skeletal muscle tissue.~   "|||2018-06-01 02:36:55.046629|2018-06-01 02:36:55.046629
NCT00585559|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-03-20|2007-12-26|2008-01-03|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2007||2007-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm|Inhibition of Lipid Peroxidation and Cerebral Vasospasm by an Acetaminophen-Based Regimen in Patients With Aneurysmal Subarachnoid Hemorrhage|Enrolling by invitation||N/A|120|Anticipated|Vanderbilt University Medical Center||5|||f||||t||||||||No||2018-06-01 02:36:56.157847|2018-06-01 02:36:56.157847
NCT00585546|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2017-03-25||2017-05-16|2007-12-26|2008-01-03|Estimate|2017-05-16|2017-12-15|Actual||||2017-05-16|2017-12-15|Actual|July 2007||2007-07-31|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|HARPS||Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure|Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.|Terminated||Phase 1|18|Actual|University of Michigan|Because a new standard of care was developed during the start of the trial, the trial was stopped for futility in enrollment. The public should exercise great caution in drawing conclusions from such a small sample size.|1||No longer could obtain clenbuterol|f||||t|t|f||||||||2018-06-01 02:36:56.294159|2018-06-01 02:36:56.294159
NCT00585533|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2012-06-04||2013-07-23|2008-01-02|2008-01-03|Estimate|2012-10-19|2012-11-21|Estimate||||2013-07-23|2013-07-30|Estimate|June 2004||2004-06-30|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|40|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 02:36:56.592256|2018-06-01 02:36:56.592256
NCT00585520|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2014-02-10|2008-01-02|2008-01-03|Estimate|||||||2014-02-10|2014-02-12|Estimate|September 2007||2007-09-30|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues|Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues|Completed||Phase 1|60|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:36:57.835626|2018-06-01 02:36:57.835626
NCT00585507|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-02-09|2007-12-22|2008-01-03|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2004||2004-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of 500mg of Fulvestrant|A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer|Active, not recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 02:36:57.904556|2018-06-01 02:36:57.904556
NCT00585494|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-27|2008-11-07||2015-10-01|2007-12-27|2008-01-03|Estimate|2010-08-23|2010-09-17|Estimate||||2015-10-01|2015-10-26|Estimate|December 2007||2007-12-31|January 2011|2011-01-31|August 2010|Actual|2010-08-31|December 2008|Actual|2008-12-31||Observational|||Prevalence of Inpatient Hyperglycemia: Risks, Complications and Outcomes|Prevalence of Inpatient Hyperglycemia: Risks, Complications and Outcomes|Completed|||302|Actual|University of Wisconsin, Madison|||1||f||||f||||||||||2018-06-01 02:36:57.995078|2018-06-01 02:36:57.995078
NCT00585481|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2011-12-15|2008-01-02|2008-01-03|Estimate|||||||2011-12-15|2011-12-19|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children|Incidence of Severe Respiratory Syncytial Virus Infections in Preterm Brazilian Children - BREVI (Brazilian Respiratory Virus in Premature Infants) Study|Completed|||310|Actual|Abbott|||1||f||||f||||||Samples With DNA|"~     white cells and nasopharyngal aspirate~   "|||2018-06-01 02:36:58.141541|2018-06-01 02:36:58.141541
NCT00585468|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-09-10||2016-04-01|2007-12-21|2008-01-03|Estimate|2016-04-01|2016-05-06|Estimate||||2016-04-01|2016-05-06|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State|Pharmacokinetic Profile of Myfortic (Enteric Coated Mycophenolate Sodium) in a Rapid Steroid Withdrawal Protocol in Combination With Tacrolimus in Stable Renal Transplant Recipients in the Fed and Fasting State|Completed||Phase 4|21|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 02:36:58.248591|2018-06-01 02:36:58.248591
NCT00585455|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2009-07-22|2008-01-02|2008-01-03|Estimate|||||||2009-07-22|2009-07-23|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Vascular Effects of Sertraline in Heart Failure|Effects of Chronic Sertraline Hydrochloride Administration on Vascular Endothelial and Autonomic Function in Patients With Chronic Heart Failure|Terminated|||4|Actual|Yale University|||1|PI change in institution|f||||f||||||Samples Without DNA|"~     Plasma and serum~   "|||2018-06-01 02:36:58.680385|2018-06-01 02:36:58.680385
NCT00585442|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2016-05-25|2008-01-02|2008-01-03|Estimate|||||||2016-05-25|2016-05-27|Estimate|May 2007||2007-05-31|March 2016|2016-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effects of Vitamin D on Renin Expression in Hypertensive Patients|Effects of Calcitriol (1α, 25-[OH]2 Vitamin D3) on Renin Expression in Hypertensive Patients Without Vitamin D Deficiency|Terminated||Early Phase 1|12|Actual|University of Utah||2||Lack of quality data|f||||t||||||||||2018-06-01 02:36:58.760105|2018-06-01 02:36:58.760105
NCT00585429|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-05-10|2007-12-26|2008-01-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2006||2006-09-30|May 2016|2016-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Evaluation of Kidney Disease in Liver Transplant Recipients|Kidney Disease in Advanced Liver Disease Patients: A Study of Kidney Damage by a Urinary Cytokine/Chemokine Multiplex Assay|Withdrawn|||0|Actual|University of Wisconsin, Madison|||3|key personnel left institution|f||||f||||||||||2018-06-01 02:36:58.839818|2018-06-01 02:36:58.839818
NCT00585416|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-09-30|2007-12-21|2008-01-03|Estimate|||||||2015-09-30|2015-10-02|Estimate|June 2006||2006-06-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|November 2007|Actual|2007-11-30||Interventional|||Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer|A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001)|Terminated||Phase 2|23|Actual|University of Wisconsin, Madison||1||Further evaluation of phase I dosing|f||||t||||||||||2018-06-01 02:36:59.025903|2018-06-01 02:36:59.025903
NCT00585403|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2010-11-05|2007-12-26|2008-01-03|Estimate|||||||2010-11-05|2010-11-08|Estimate|September 2004||2004-09-30|November 2010|2010-11-30|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Observational|||Exercise Changes to Peripheral Blood Mononuclear Cells in Children|PBMC, Exercise and Children: Initial Mechanisms|Unknown status|Recruiting||160|Anticipated|University of California, Irvine|||1||f||||t||||||Samples With DNA|"~     Peripheral blood mononuclear cells, plasma, serum, mRNA~   "|||2018-06-01 02:36:59.101136|2018-06-01 02:36:59.101136
NCT00585390|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|||2011-08-01|2007-12-28|2008-01-03|Estimate|||||||2011-08-01|2011-08-02|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia|Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Essential Fatty Acid Deficiency Replacement in Early Schizophrenia|Completed||Phase 2/Phase 3|0|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 02:36:59.169376|2018-06-01 02:36:59.169376
NCT00585377|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-07-23||2015-08-21|2007-12-21|2008-01-03|Estimate|2015-08-21|2015-09-24|Estimate||||2015-08-21|2015-09-24|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer|AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer|Completed||Phase 2|50|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 02:36:59.350709|2018-06-01 02:36:59.350709
NCT00585208|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-05-08|2007-12-27|2008-01-03|Estimate|||||||2013-05-08|2013-05-10|Estimate|December 2007||2007-12-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance|A Randomized, Double-Blind, Placebo-Controlled Study of Add-On Ramelteon in Ambulatory Bipolar I Disorder With Clinically Significant Sleep Disturbance|Terminated||Phase 3|21|Actual|Lindner Center of HOPE||2||sponsor terminated study|f||||f||||||||||2018-06-01 02:37:01.820214|2018-06-01 02:37:01.820214
NCT00585364|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|||2016-02-12|2008-01-01|2008-01-03|Estimate|||||||2016-02-12|2016-02-15|Estimate|March 2005||2005-03-31|February 2016|2016-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|ABPA||Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA|SCCOR in Host Factors in Chronic Lung Diseases: Mechanisms of Immune Tolerance and Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients With Cystic Fibrosis|Completed|||79|Actual|University of Pittsburgh|||3||f||||f||||||Samples With DNA|"~     The CF subject's blood will be processed to establish a cell line (lymphocyte transformation)~     for a source of DNA for future genetic studies.~   "|No|This was an observational trial that involved no device or drug.|2018-06-01 02:36:59.59319|2018-06-01 02:36:59.59319
NCT00585351|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-08-16||2013-01-15|2007-12-26|2008-01-03|Estimate|2013-01-15|2013-01-16|Estimate||||2013-01-15|2013-01-16|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|AIRDOC||Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting|Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting (AIRDOC)|Completed||N/A|100|Actual|University of Iowa|Some procedural errors by the helicopter crew at the start of the trial, reliability of the stroke diagnosis from the outside hospital, and the possibility for a lower consent rate if a higher risk profile medication were used instead of Ranitidine.|4|||f||||t||||||||||2018-06-01 02:36:59.689038|2018-06-01 02:36:59.689038
NCT00585338|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-02-08|2007-12-26|2008-01-03|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2007||2007-12-31|February 2017|2017-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser|Completed||Phase 1|1|Actual|University of California, Irvine||1|||f||||f||||||||||2018-06-01 02:37:00.16483|2018-06-01 02:37:00.16483
NCT00585325|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2017-12-13||2018-03-05|2008-01-02|2008-01-03|Estimate|2018-03-05|2018-03-07|Actual||||2018-03-05|2018-03-07|Actual|October 2004||2004-10-31|March 2018|2018-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes|Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes.|Completed||N/A|15|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 02:37:00.248311|2018-06-01 02:37:00.248311
NCT00585312|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-01|2014-10-28||2014-10-28|2008-01-01|2008-01-03|Estimate|2014-10-28|2014-11-03|Estimate||||2014-10-28|2014-11-03|Estimate|September 2006||2006-09-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CHIP|The intent-to-treat (ITT) population (N: 106) consisted of all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether the participants received any study drug or received a different drug from that to which they were randomized.|Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)|A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis|Terminated||Phase 3|106|Actual|Pfizer|The study was early terminated and, due to the low number of participants, no efficacy analysis was performed. Only descriptive statistics was performed.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 02:37:00.479802|2018-06-01 02:37:00.479802
NCT00585299|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2014-06-16|2008-01-02|2008-01-03|Estimate|||||||2014-06-16|2014-06-17|Estimate|October 2006||2006-10-31|June 2014|2014-06-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD|Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD|Completed||N/A|4|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:37:00.937813|2018-06-01 02:37:00.937813
NCT00585286|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-06-17||2013-12-13|2007-12-26|2008-01-03|Estimate|2013-09-30|2013-12-02|Estimate||||2013-12-13|2014-01-15|Estimate|March 2007||2007-03-31|December 2013|2013-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Of 30 patients enrolled between two research centers, 15 subjects were enrolled at the UC Irvine General Clinical Research Center|Fractional Resurfacing Device for Treatment of Acne Scarring|Evaluation of a Novel Fractional Resurfacing Device for the Treatment of Acne Scarring|Completed||Phase 1/Phase 2|15|Actual|University of California, Irvine|There were no major limitations to this trial. The trial was completed without any technical problems or major complications.|1|||f||||t||||||||||2018-06-01 02:37:01.036649|2018-06-01 02:37:01.036649
NCT00585273|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-12-02|2007-12-29|2008-01-03|Estimate|||||||2015-12-02|2015-12-04|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Antipsychotics and Blood Vessel Function|Cardiovascular Complications of First-line, Second-generation Antipsychotics|Completed|||44|Actual|University of Iowa|||2||f||||f||||||||||2018-06-01 02:37:01.234979|2018-06-01 02:37:01.234979
NCT00585260|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-10-06|2007-12-26|2008-01-03|Estimate|||||||2015-10-06|2015-10-08|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|January 2011|Actual|2011-01-31|||||Interventional|||Mannitol Bronchoprovocation Challenge Ancillary Study/ACRN|Mannitol Bronchoprovocation Challenge Ancillary Study Protocol to Best Adjustment Strategy for Asthma Over Long Term|Completed||N/A|320|Anticipated|University of Wisconsin, Madison||3|||f||||f||||||||||2018-06-01 02:37:01.301717|2018-06-01 02:37:01.301717
NCT00585247|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2015-08-25||2018-03-06|2007-12-26|2008-01-03|Estimate|2018-03-06|2018-04-04|Actual||||2018-03-06|2018-04-04|Actual|November 2006||2006-11-30|March 2018|2018-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Aldara|27 subjects was enrolled to the study for 57 PWS sites (multiple sites per patient).|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks|Completed||N/A|27|Actual|University of California, Irvine|Effects were evaluated after a single treatment and duration of effect is unknown|2|||f||||t||||||||||2018-06-01 02:37:01.384452|2018-06-01 02:37:01.384452
NCT00585234|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-12-08|2007-12-21|2008-01-03|Estimate|||||||2014-12-08|2014-12-10|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Tools for the Objective Clinical Assessment of Pediatric Spinal Deformity|Tools for Objective Clinical Assessment of Pediatric Spinal Deformity and the Results of Surgical Intervention--Simultaneous Measurement of Sagittal and Coronal Balance and Symmetry With Digital Photography.|Withdrawn|||0|Actual|University of Utah|||1|Study has been withdrawn.|f||||f||||||||||2018-06-01 02:37:01.58986|2018-06-01 02:37:01.58986
NCT00585221|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-06-15||2016-12-20|2007-12-21|2008-01-03|Estimate|2012-10-19|2012-11-21|Estimate||||2016-12-20|2017-02-10|Actual|July 2007||2007-07-31|December 2016|2016-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients|A Phase II Study Combining Targeted Therapy With Immunotherapy Using Imatinib Plus Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients|Terminated||Phase 2|8|Actual|University of Utah||1||PI terminated at the recommendation of DSMC & IRB|f||||t||||||||||2018-06-01 02:37:01.663835|2018-06-01 02:37:01.663835
NCT00585195|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-29|||2018-01-29|2007-12-29|2008-01-03|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2006|Actual|2006-04-30|January 2018|2018-01-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|PROFILE 1001||A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer|Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer|Recruiting||Phase 1|600|Anticipated|Pfizer||1|||f||||f||||||||||2018-06-01 02:37:01.933314|2018-06-01 02:37:01.933314
NCT00585182|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-08-02||2018-03-09|2007-12-21|2008-01-03|Estimate|2011-08-02|2011-09-05|Estimate||||2018-03-09|2018-04-05|Actual|January 2007||2007-01-31|March 2018|2018-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT|Venous Thromboembolism Prevention in the Morbidly Obese Medically Ill Patient: A Pharmacological Analysis of the Predictability of Prophylactic Weight-Based Enoxaparin Dosing.|Completed||Phase 4|28|Actual|University of Utah|This study was limited by a relatively small sample size, lack of long-term clinical outcome data, and the use of only a single anti-Xa level, rather than repeat measures.|1|||f||||t||||||||||2018-06-01 02:37:02.060483|2018-06-01 02:37:02.060483
NCT00585169|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2013-01-29||2013-03-05|2008-01-02|2008-01-03|Estimate|2013-03-05|2013-04-08|Estimate||||2013-03-05|2013-04-08|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Memantine Treatment Study of Pathological Gambling|A Phase II Open-Label Multi-Center Trial of Memantine (Namenda(TM)) Treatment of Pathological Gambling|Completed||Phase 2|29|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:37:02.187869|2018-06-01 02:37:02.187869
NCT00585156|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2016-03-11|2008-01-02|2008-01-03|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Effects of Celecoxib on Bone Ingrowth|The Effects of Celecoxib on Bone Ingrowth in Porous Coated Titanium Ceramic Implants in Humans|Terminated||Early Phase 1|9|Actual|University of Utah||1||New clinical finding with Celebrex and cardiac concerns.|f||||f||||||||||2018-06-01 02:37:02.442273|2018-06-01 02:37:02.442273
NCT00585143|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2012-09-27|2008-01-02|2008-01-03|Estimate|||||||2012-09-27|2012-09-28|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly|Pharmacokinetics of ABT-335 and Rosuvastatin in Subjects With Normal Renal Function and Renal Impairment|Completed||Phase 1|37|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:37:02.519742|2018-06-01 02:37:02.519742
NCT00585117|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-02-22|2007-12-21|2008-01-03|Estimate|||||||2012-02-22|2012-02-24|Estimate|December 2006||2006-12-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients||Terminated||N/A|9|Actual|University of Wisconsin, Madison||5||change in imaging priorities|f||||t||||||||||2018-06-01 02:37:02.59404|2018-06-01 02:37:02.59404
NCT00585104|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-02-11||2013-05-14|2007-12-21|2008-01-03|Estimate|2010-05-17|2010-06-09|Estimate||||2013-05-14|2013-05-21|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Myocardial Hemodynamic Effects of Levosimendan|Myocardial Hemodynamic Effects of Levosimendan|Completed||Phase 2|10|Actual|University of Utah|Of the ten (10) patients enrolled, only 6 patients completed the study protocol for which we collected data. The data is insufficient to provide a formal summary for publication.|1|||f||||t||||||||||2018-06-01 02:37:02.679503|2018-06-01 02:37:02.679503
NCT00585091|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-06-12|2008-01-02|2008-01-03|Estimate|||||||2012-06-12|2012-06-13|Estimate|October 2003||2003-10-31|June 2012|2012-06-30|August 2008|Actual|2008-08-31|August 2007|Actual|2007-08-31||Interventional|||The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment|The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment|Completed||N/A|15|Actual|University of Utah||1|||f||||t||||||||||2018-06-01 02:37:02.872472|2018-06-01 02:37:02.872472
NCT00585078|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|2017-02-26||2017-02-26|2007-12-24|2008-01-03|Estimate|2017-02-26|2017-04-10|Actual||||2017-02-26|2017-04-10|Actual|May 2004|Actual|2004-05-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||The analysis dataset is comprised of enrolled patients.|Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma|Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|40|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-06-01 02:37:02.959737|2018-06-01 02:37:02.959737
NCT00585065|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-07|2008-01-02|2008-01-03|Estimate|||||||2016-01-07|2016-01-11|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||CRT Pilot Study for Children With Heart Failure|Cardiac Resynchronization Therapy for Children and Adolescents With Advanced Hearth Failure: A Pilot Study|Completed|||7|Actual|University of Utah|||1||f||||f||||||||||2018-06-01 02:37:03.25374|2018-06-01 02:37:03.25374
NCT00585052|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2017-10-10||2017-12-05|2007-12-21|2008-01-02|Estimate|2017-12-05|2018-01-05|Actual||||2017-12-05|2018-01-05|Actual|August 2003||2003-08-31|December 2017|2017-12-31|June 2013|Actual|2013-06-30|February 2010|Actual|2010-02-28||Interventional|||A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer|A Phase II Study of the Synergistic Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer|Terminated||Phase 2|11|Actual|University of Iowa|Trial closed early due to slow accrual, PI left the institution|1||Slow accrual, PI left the institution|f||||t|t|f|||f|||No||2018-06-01 02:37:03.373617|2018-06-01 02:37:03.373617
NCT00585039|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-03-17||2011-09-02|2007-12-20|2008-01-02|Estimate|2011-07-20|2011-08-16|Estimate||||2011-09-02|2011-09-09|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|Xopenex||Albuterol Versus Xopenex in Treatment of Acute Asthma in the Emergency Department (ED)|Comparison of Hospital Admission Rates and Plasma(s)-Albuterol Levels in Children Treated With Racemic Albuterol Versus Levalbuterol for Acute Asthma Exacerbations: A Randomized Double-Blind Clinical Trial|Completed||Phase 4|101|Actual|Phoenix Children's Hospital||1|||f||||t||||||||||2018-06-01 02:37:03.73525|2018-06-01 02:37:03.73525
NCT00585026|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-06-14|2007-12-21|2008-01-02|Estimate|||||||2011-06-14|2011-06-15|Estimate|October 2006||2006-10-31|December 2009|2009-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Randomized Clinical Trial of Bifocal Lenses Versus Computer-specific Progressive Addition Lenses|Randomized Clinical Trial of Bifocal Lenses Versus Computer-specific Progressive Addition Lenses on Symptoms and Performance on a Computer|Terminated||Phase 3|40|Anticipated|University of Alabama at Birmingham||||PI left UAB; protocol administratively terminated by UAB IRB.|f||||||||||||||2018-06-01 02:37:03.958017|2018-06-01 02:37:03.958017
NCT00585013|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-12-19||2015-11-03|2007-12-31|2008-01-02|Estimate|2015-11-03|2015-11-04|Estimate||||2015-11-03|2015-11-04|Estimate|January 2008||2008-01-31|November 2015|2015-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass|A Trial of Inhaled Nitric Oxide (NO) as an Anti-Inflammatory and Anti-Reperfusion Agent in the Treatment of Infants and Children Undergoing Cardiopulmonary Bypass for Repair of Congenital Heart Disease|Completed||Phase 1/Phase 2|17|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:37:04.043529|2018-06-01 02:37:04.043529
NCT00585000|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-06-05|2007-12-21|2008-01-02|Estimate|||||||2012-06-05|2012-06-06|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma|A Phase 1, Open Label, Single Arm Study To Establish The Safety Of Administering CP 675,206 As A One Hour Infusion In Patients With Surgically Incurable Stage III Or Stage IV Melanoma|Terminated||Phase 1|49|Actual|AstraZeneca||1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:37:04.386213|2018-06-01 02:37:04.386213
NCT00584987|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-07-08||2013-10-31|2007-12-31|2008-01-02|Estimate|2013-10-31|2013-12-17|Estimate||||2013-10-31|2013-12-17|Estimate|June 2007||2007-06-30|October 2013|2013-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Intranasal Steroids and Oxymetazoline in Allergic Rhinitis|A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa|Completed||Phase 4|64|Actual|University of Chicago||4|||f||||t||||||||||2018-06-01 02:37:04.457206|2018-06-01 02:37:04.457206
NCT00584974|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21||2009-12-16|2012-02-21|2007-12-21|2008-01-02|Estimate||||2009-12-16|2009-12-18|Estimate|2012-02-21|2012-02-23|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Safety, Efficacy and Tolerability Study of SEP-225289|A Double-Blind, Placebo-Controlled Study Examining The Safety, Efficacy, and Tolerability of SEP-225289 in Subjects With Major Depressive Disorder (Including Atypical and Melancholic Features)|Completed||Phase 2|523|Actual|Sunovion||4|||f||||f||||||||||2018-06-01 02:37:04.802233|2018-06-01 02:37:04.802233
NCT00584961|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-02-09|2007-12-21|2008-01-02|Estimate|||||||2010-02-09|2010-02-10|Estimate|May 2007||2007-05-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|BIMET||BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder|BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder|Completed|||553|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:37:05.056049|2018-06-01 02:37:05.056049
NCT00584948|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2014-06-27||2017-05-24|2007-12-22|2008-01-02|Estimate|2017-02-22|2017-04-10|Actual||||2017-05-24|2017-05-30|Actual|September 2007||2007-09-30|May 2017|2017-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome|Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine|Completed||N/A|94|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 02:37:05.162385|2018-06-01 02:37:05.162385
NCT00584935|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2011-02-15||2018-01-11|2007-12-31|2008-01-02|Estimate|2011-03-22|2011-04-21|Estimate||||2018-01-11|2018-02-07|Actual|January 2006||2006-01-31|January 2018|2018-01-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid|Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid|Completed||Phase 1/Phase 2|3|Actual|University of Alabama at Birmingham|Genentech closed trial before site was able to enroll 5 patients.|1|||f||||f||||||||||2018-06-01 02:37:05.554878|2018-06-01 02:37:05.554878
NCT00584922|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2011-03-02|2007-12-31|2008-01-02|Estimate|||||||2011-03-02|2011-03-03|Estimate|January 2007||2007-01-31|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation|Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation|Unknown status|Recruiting||200|Anticipated|University of Oklahoma|||1||f||||f||||||||||2018-06-01 02:37:05.750953|2018-06-01 02:37:05.750953
NCT00584909|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-09-21||2017-01-25|2007-12-26|2008-01-02|Estimate|2012-02-28|2012-03-29|Estimate||||2017-01-25|2017-01-27|Estimate|March 2006||2006-03-31|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus|A Phase II Study of Paclitaxel and Carboplatin in Patients With Intermediate-Risk Adenocarcinoma of the Endometrium|Terminated||Phase 2|13|Actual|University of Alabama at Birmingham|This study was terminated early due to slow accrual. 4 patients withdrew from the study due to side-effects from the treatment. All 9 patients were evaluable for toxicity and PFS.|1||low accrual|f||||t||||||||||2018-06-01 02:37:05.878511|2018-06-01 02:37:05.878511
NCT00584896|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-07-01|2007-12-20|2008-01-02|Estimate|||||||2008-07-01|2008-07-03|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|POINT II||Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease|A Phase 3 Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive Technology Using PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Artery Disease II|Terminated||Phase 3|1000|Anticipated|Point Biomedical||||Discontinued PB127 development program for business reasons|f||||t||||||||||2018-06-01 02:37:06.07978|2018-06-01 02:37:06.07978
NCT00584883|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2012-05-16|2007-12-26|2008-01-02|Estimate|||||||2012-05-16|2012-05-17|Estimate|August 2003||2003-08-31|May 2012|2012-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme|A Phase I Study of ABT 510 and Concurrent Temozolomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 1|24|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 02:37:06.217103|2018-06-01 02:37:06.217103
NCT00584870|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21||2009-10-01|2009-10-01|2007-12-21|2008-01-02|Estimate||||2009-10-01|2009-10-05|Estimate|2009-10-01|2009-10-05|Estimate|July 2007||2007-07-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||RN624 In Adult Patients With Chronic Low Back Pain|Phase II Randomized, Double-Blind, Placebo And Active Controlled, Multicenter, Parallel Group Proof Of Concept Study Of The Analgesic Effects Of RN624 In Adult Patients With Chronic Low Back Pain|Completed||Phase 2|225|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:37:06.314192|2018-06-01 02:37:06.314192
NCT00584857|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-09-23||2017-01-25|2007-12-26|2008-01-02|Estimate|2012-02-28|2012-03-29|Estimate||||2017-01-25|2017-01-27|Estimate|July 2004||2004-07-31|January 2017|2017-01-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer|A Phase II Study of Combination Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Advanced Stage or Recurrent Carcinoma of the Endometrium|Completed||Phase 2|30|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 02:37:06.440043|2018-06-01 02:37:06.440043
NCT00584844|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2016-12-28||2017-06-05|2007-12-20|2008-01-02|Estimate|2017-06-05|2017-07-02|Actual||||2017-06-05|2017-07-02|Actual|October 2004||2004-10-31|June 2017|2017-06-30|October 2013|Actual|2013-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine|A Longitudinal Phase 2 Study for the Continued Evaluation of the Safety and Immunogenicity of a Live Francisella Tularensis Vaccine, NDBR 101, Lot 4|Completed||Phase 2|484|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 02:37:06.618721|2018-06-01 02:37:06.618721
NCT00584831|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-09-24||2015-05-05|2007-12-31|2008-01-02|Estimate|2011-09-21|2011-11-01|Estimate||||2015-05-05|2015-05-21|Estimate|October 2007||2007-10-31|May 2015|2015-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effect of Eye Movement on Toric Lens Orientation and Visual Acuity|Development and Implementation of a Clinical Test to Investigate the Change in Vision With Soft Toric Contact Lenses During Eye Movements|Completed||N/A|40|Actual|Johnson & Johnson Vision Care, Inc.||19|||f||||f||||||||||2018-06-01 02:37:07.351015|2018-06-01 02:37:07.351015
NCT00584818|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-04-23|2007-12-20|2008-01-02|Estimate|||||||2008-04-23|2008-04-25|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease|A Phase 2 Dose-Finding Clinical Trial of CARDIOsphere® (PB127) in Normal Volunteers and in Patients With Known or Suspected Coronary Artery Disease|Completed||Phase 2|205|Actual|Point Biomedical|||||f||||f||||||||||2018-06-01 02:37:08.799149|2018-06-01 02:37:08.799149
NCT00584805|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-05-02|2007-12-31|2008-01-02|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2008|Actual|2008-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Interventional|EEE||Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine|A Multi-Site Phase 2 Open-Label, Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 in Healthy Adults At Risk for Exposure to Eastern Equine Encephalitis Virus|Active, not recruiting||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 02:37:08.895785|2018-06-01 02:37:08.895785
NCT00584792|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2007-12-22|2007-12-22|2008-01-02|Estimate|||||||2007-12-22|2008-01-02|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Diet, Genetic Variation and Prostate Cancer Among African Americans|Diet, Genetic Variation and Prostate Cancer Among African Americans|Completed|||102|Actual|University of California, Davis|||2||f||||t||||||Samples With DNA|"~     Serum collected for Ancestry Imformative Markers (AIMS) testing along with PSA and CRP.~   "|||2018-06-01 02:37:08.975057|2018-06-01 02:37:08.975057
NCT00584779|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-03-11|2007-12-21|2008-01-02|Estimate|||||||2009-03-11|2009-03-12|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis|An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis|Terminated||Phase 4|8|Actual|Pfizer||4||See detailed description for termination reason|f||||f||||||||||2018-06-01 02:37:09.032031|2018-06-01 02:37:09.032031
NCT00584766|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-05-28|2007-12-20|2008-01-02|Estimate|||||||2015-05-28|2015-05-29|Estimate|October 1987||1987-10-31|May 2015|2015-05-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer|Intensive Combination Chemotherapy With Autologous Bone Marrow Rescue for Metastatic Breast Cancer After Intitial Cytoreduction With Standard Agents: A Phase II Study|Completed||Phase 2|21|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 02:37:09.109213|2018-06-01 02:37:09.109213
NCT00584753|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-01-11|2007-12-26|2008-01-02|Estimate|||||||2013-01-11|2013-01-14|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Molecular Imaging of Breast Cancer With Breast PET/CT|Molecular Imaging of Breast Cancer With Breast PET/CT|Terminated||Phase 1|4|Actual|University of California, Davis||3||Low enrollment|f||||f||||||||||2018-06-01 02:37:09.212817|2018-06-01 02:37:09.212817
NCT00584740|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-01-28||2015-03-24|2007-12-21|2008-01-02|Estimate|2015-03-24|2015-03-31|Estimate||||2015-03-24|2015-03-31|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single iv Infusions of AIN457 10 mg/kg (Anti IL-17 Monoclonal Antibody) in Patients With Moderate to Severe Active Crohn's Disease|Terminated||Phase 2|59|Actual|Novartis||2||"The study was terminated prematurely after futility criterion was met at planned interim~   analysis of 41 patients."|f||||f||||||||||2018-06-01 02:37:09.369298|2018-06-01 02:37:09.369298
NCT00584727|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2008-12-05||2015-05-05|2007-12-31|2008-01-02|Estimate|2010-01-22|2010-02-10|Estimate||||2015-05-05|2015-05-21|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||In-office Evaluation of Two Toric Soft Contact Lenses and a Spherical Soft Contact Lens|Evaluation of Fit and Visual Acuity of the Cypress Toric Lens in Two Phases: Part A: A Non-Dispensing Comparison to SofLens66® Toric and Acuvue® 2|Completed||N/A|96|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||f||||||||||2018-06-01 02:37:09.781348|2018-06-01 02:37:09.781348
NCT00584714|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-07-01|2007-12-20|2008-01-02|Estimate|||||||2008-07-01|2008-07-03|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent|Long-Term Follow-Up of Selected Patients Enrolled in Phase 3 Clinical Trial 127-014 Using PB127 Ultrasound Imaging Agent|Terminated|||300|Anticipated|Point Biomedical||||Discontinued PB127 development program for business reasons|f||||f||||||||||2018-06-01 02:37:10.13724|2018-06-01 02:37:10.13724
NCT00584701|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2011-09-06||2012-06-18|2007-12-31|2008-01-02|Estimate|2012-06-18|2012-07-24|Estimate||||2012-06-18|2012-07-24|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|PG||Pharmacogenomics in Autism Treatment|Pharmacogenomics in Autism Treatment|Completed||Phase 2/Phase 3|49|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 02:37:10.239771|2018-06-01 02:37:10.239771
NCT00584688|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-06-14|2007-12-31|2008-01-02|Estimate|||||||2012-06-14|2012-06-18|Estimate|February 2007||2007-02-28|March 2009|2009-03-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study|A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study|Terminated||Phase 2|24|Actual|University of South Florida||||Lack of Enrollment|f||||t||||||||||2018-06-01 02:37:10.396243|2018-06-01 02:37:10.396243
NCT00518037|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2014-05-22|2007-08-15|2007-08-17|Estimate|||||||2014-05-22|2014-05-23|Estimate|June 2006||2006-06-30|May 2014|2014-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Quality of Life in Patients With Nonmelanoma Skin Cancer|Quality of Life in Patients With Nonmelanoma Skin Cancer|Completed|||112|Actual|Northwestern University|||1||f||||f||||||||||2018-06-01 02:59:20.973081|2018-06-01 02:59:20.973081
NCT00584675|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-06-18|2007-12-26|2008-01-02|Estimate|||||||2015-06-18|2015-06-19|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|February 2008|Anticipated|2008-02-29|January 2008|Anticipated|2008-01-31||Interventional|||Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers|Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers|Withdrawn||N/A|0|Actual|University of California, Davis||||Funding was never received so no patients were enrolled.|f||||f||||||||||2018-06-01 02:37:10.557177|2018-06-01 02:37:10.557177
NCT00584662|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-06-27|2007-12-31|2008-01-02|Estimate|||||||2012-06-27|2012-06-28|Estimate|January 2005||2005-01-31|July 2008|2008-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion|Oxymetazoline Hydrochloride in Combination With Nasal Glucocorticosteroid for Perennial Allergic and Non-allergic Rhinitis in Subjects With Persistent Nasal Congestion|Terminated||N/A|42|Actual|University of South Florida||1|||f||||f||||||||||2018-06-01 02:37:10.646346|2018-06-01 02:37:10.646346
NCT00584649|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-04-10|2007-12-31|2008-01-02|Estimate|||||||2018-04-10|2018-04-11|Actual|April 2004||2004-04-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|IST||Ablation of Inappropriate Sinus Tachycardia|Ablation of Inappropriate Sinus Tachycardia Syndrome by Targeting Cardiac Neural Input|Recruiting||N/A|25|Anticipated|University of Oklahoma||1|||f||||f||||||||||2018-06-01 02:37:10.74659|2018-06-01 02:37:10.74659
NCT00584636|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2011-09-02|2007-12-20|2008-01-02|Estimate|||||||2011-09-02|2011-09-05|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|Budesonide||Pulmicort Respules on Relapse Rates After Treatment in the ED|Nebulized Budesonide After Discharge From a Pediatric Emergency Department in Preventing Asthma Relapse: A Randomized, Double-Blind, Placebo Controlled Trial.|Withdrawn||Phase 4|0|Actual|Phoenix Children's Hospital||1||study halted prematurely before enrollment of first patient|f||||t||||||||||2018-06-01 02:37:10.843699|2018-06-01 02:37:10.843699
NCT00584623|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-26|2007-12-26|2008-01-02|Estimate|||||||2017-05-26|2017-05-31|Actual|March 2007||2007-03-31|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Simultaneous Fluoroscopic and Endoscopic Examination of the Oropharyngeal Phase of Deglutition|Simultaneous Fluoroscopic and Endoscopic Examination of the Oropharyngeal Phase of Deglutition|Withdrawn|||0|Actual|University of California, Davis||||Did not find interested patients.|f||||f||||||||||2018-06-01 02:37:10.920744|2018-06-01 02:37:10.920744
NCT00584610|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-01-15|2007-12-31|2008-01-02|Estimate|||||||2010-01-15|2010-01-18|Estimate|December 2007||2007-12-31|January 2010|2010-01-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots|The Effect of a Levonorgestrel-releasing Intrauterine Device Versus a Copper Containing Intrauterine Device on Coagulation Parameters|Unknown status|Recruiting|N/A|50|Anticipated|University of Vermont||2|||f||||t||||||||||2018-06-01 02:37:10.980595|2018-06-01 02:37:10.980595
NCT00584597|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-12-10|2007-12-31|2008-01-02|Estimate|||||||2010-12-10|2010-12-13|Estimate|October 2005||2005-10-31|December 2010|2010-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|TRAUMEEL||A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis|The Safety and Efficacy of the Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis|Completed||Phase 1|14|Actual|University of Oklahoma||4|||f||||t||||||||||2018-06-01 02:37:11.059357|2018-06-01 02:37:11.059357
NCT00584584|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-02-22|2007-12-21|2008-01-02|Estimate|||||||2017-02-22|2017-02-24|Actual|December 2007||2007-12-31|February 2017|2017-02-28||||August 2008|Actual|2008-08-31||Interventional|||An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever|A Proof of Concept Study of the Effects of QAX576 (an Interleukin-13 Monoclonal Antibody) on Allergic Inflammation Following Out of Allergy Season Repeated Nasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis Sensitive to Timothy Grass Pollen|Completed||Phase 2|36|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:37:11.149234|2018-06-01 02:37:11.149234
NCT00584571|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-03-10|2007-12-31|2008-01-02|Estimate|||||||2015-03-10|2015-03-11|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Randomized Controlled Trial of Treating Rectal Hypersensitivity - Comparing Escitalopram With Sensory Adaptation Training||Unknown status|Recruiting|Phase 2|60|Anticipated|Augusta University||2|||f||||f||||||||||2018-06-01 02:37:11.230691|2018-06-01 02:37:11.230691
NCT00584558|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-03-14||2017-05-03|2007-12-31|2008-01-02|Estimate|2017-05-03|2017-10-02|Actual||||2017-05-03|2017-10-02|Actual|February 2001||2001-02-28|May 2017|2017-05-31|June 8, 2016|Actual|2016-06-08|June 8, 2016|Actual|2016-06-08||Observational|||Long-Term Follow-Up of Patients Undergoing Catheter Ablation|Long-Term Follow-Up of Catheter Ablation|Completed|||2420|Actual|University of Oklahoma|||1||f||||f||||||||||2018-06-01 02:37:11.313406|2018-06-01 02:37:11.313406
NCT00584545|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-26|2007-12-26|2008-01-02|Estimate|||||||2017-05-26|2017-05-31|Actual|June 2007||2007-06-30|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Simultaneous Fluoroscopic and Manometric Measures of the Oropharyngeal Phase of Deglutition|Simultaneous Fluoroscopic and Manometric Measures of the Oropharyngeal Phase of Deglutition|Withdrawn|||0|Actual|University of California, Davis||||Study never got started.|f||||f||||||||||2018-06-01 02:37:11.476759|2018-06-01 02:37:11.476759
NCT00584532|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2007-12-22|2007-12-22|2008-01-02|Estimate|||||||2007-12-22|2008-01-02|Estimate|November 2003||2003-11-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2005|Actual|2005-12-31||Interventional|GCP||Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.|Effects of a Genistein Concentrated Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.|Completed||Phase 2/Phase 3|66|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 02:37:11.555393|2018-06-01 02:37:11.555393
NCT00584519|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-07-06|2007-12-21|2008-01-02|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|CRESSOB||Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight|Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight (CRESSOB)|Completed|||430|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:37:11.642112|2018-06-01 02:37:11.642112
NCT00584506|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2010-12-16|2007-12-26|2008-01-02|Estimate|||||||2010-12-16|2010-12-20|Estimate|November 2007||2007-11-30|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Computer Aided Evaluation of Orbital Volume|Computer Aided Evaluation of Orbital Volume|Completed|||250|Actual|University of California, Davis|||||f||||t||||||||||2018-06-01 02:37:11.72041|2018-06-01 02:37:11.72041
NCT00584493|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-12-11|2007-12-21|2008-01-02|Estimate|||||||2009-12-11|2009-12-14|Estimate|May 2008||2008-05-31|December 2009|2009-12-31||||||||Expanded Access|||Treatment Use Study for Advanced Melanoma.|Treatment Use Study of CP-675,206 for Advanced Melanoma|No longer available|||||Pfizer|||||||||f||||||||||2018-06-01 02:37:11.777027|2018-06-01 02:37:11.777027
NCT00584480|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2011-09-13||2012-08-01|2007-12-31|2008-01-02|Estimate|2012-03-19|2012-04-13|Estimate||||2012-08-01|2012-08-07|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|HBOT||Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism|Pilot Study of the Effect of Hyperbaric Oxygen Treatment on Behavioral and Biomarker Measures in Children With Autism|Completed||Phase 3|10|Actual|University of California, San Francisco|1) Small sample size 2) Lack of control group prevented an examination of whether changes in clinical measure of disease severity were due to HBOT or other factors.|1|||f||||t||||||||||2018-06-01 02:37:11.843476|2018-06-01 02:37:11.843476
NCT00584467|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-01-29|2007-12-26|2008-01-02|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2005||2005-01-31|January 2018|2018-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|GEM||Genetic and Inflammatory Markers in Cardiovascular Disease (GEM) Registry|Genetic and Inflammatory Markers in Cardiovascular Disease (GEM) Registry|Terminated|||21|Actual|University of California, Davis|||||f||||t|f|f||||Samples With DNA|"~     blood/serum~   "|||2018-06-01 02:37:11.989239|2018-06-01 02:37:11.989239
NCT00584454|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2016-11-22|2016-11-15|2017-01-18|2007-12-20|2008-01-02|Estimate|2017-01-18|2017-03-09|Actual|2016-11-15|2016-11-16|Estimate|2017-01-18|2017-03-09|Actual|February 2006||2006-02-28|January 2017|2017-01-31|June 2014|Actual|2014-06-30|July 2009|Actual|2009-07-31||Interventional|||Safety Evaluation of a Q-fever Vaccine, NDBR 105|Continued Evaluation of the Safety of Q Fever Vaccine, Phase I, Inactivated, Freeze Dried, NDBR 105, in Those at Risk of Exposure to Coxiella Burnetii, A Phase 2 Study|Completed||Phase 2|10|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||No||2018-06-01 02:37:12.046518|2018-06-01 02:37:12.046518
NCT00584441|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-02-11|2007-12-20|2008-01-02|Estimate|||||||2013-02-11|2013-02-13|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Menstrual Differences in Airway Inflammation in Asthma|Menstrual Differences in Airway Inflammation in Asthma|Completed|||6|Actual|The University of Texas Medical Branch, Galveston|||3||f||||f||||||Samples Without DNA|"~     Serum Eosinophil Cationic Protein (ECP) samples will be obtained. The 5ml blood samples for~     measuring ECP levels will be collected in silica gel-containing tubes. After centrifuging,~     the supernatant will be frozen and ECP levels will bemeasured using an ELISA kit~   "|||2018-06-01 02:37:12.260159|2018-06-01 02:37:12.260159
NCT00584428|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-05-26|2007-12-31|2008-01-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 1992||1992-06-30|May 2015|2015-05-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||High Dose Chemo With Autologous BMT for Treatment of Metastatic Breast Cancer|High Dose Chemotherapy With Autologous Bone Marrow Transplantation in the Treatment of Metastatic Breast Cancer|Completed||N/A|61|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 02:37:12.389801|2018-06-01 02:37:12.389801
NCT00584415|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2013-07-05||2014-07-01|2007-12-31|2008-01-02|Estimate|2014-07-01|2014-07-28|Estimate||||2014-07-01|2014-07-28|Estimate|February 2004||2004-02-29|July 2014|2014-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Navi-Star Thermo-Cool Catheter For Ablation of Atrial Fibrillation|Navi-Star Thermo-Cool Catheter For Ablation of Atrial Fibrillation|Completed||N/A|119|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 02:37:12.484102|2018-06-01 02:37:12.484102
NCT00584402|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-07-03||2017-07-10|2007-12-21|2008-01-02|Estimate|2017-07-10|2017-07-11|Actual||||2017-07-10|2017-07-11|Actual|April 2007||2007-04-30|July 2017|2017-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation|Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation|Completed||N/A|8|Actual|University of California, Davis||1|||f||||f||||||||No||2018-06-01 02:37:12.685758|2018-06-01 02:37:12.685758
NCT00584389|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2010-04-16|2007-12-31|2008-01-02|Estimate|||||||2010-04-16|2010-04-19|Estimate|July 2007||2007-07-31|April 2010|2010-04-30|May 2010|Anticipated|2010-05-31|April 2009|Anticipated|2009-04-30||Interventional|||The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition|The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition|Terminated||Phase 4|14|Actual|University of Surrey||2||Suspension of licence for rimonabant by European Medicines Agency|f||||f||||||||||2018-06-01 02:37:12.857532|2018-06-01 02:37:12.857532
NCT00584376|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-06-15|2007-12-20|2008-01-02|Estimate|||||||2012-06-15|2012-06-18|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pregabalin (Lyrica) for the Treatment of Essential Tremor|A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor|Completed||Phase 4|29|Actual|University of South Florida||2|||f||||t||||||||||2018-06-01 02:37:12.950478|2018-06-01 02:37:12.950478
NCT00584363|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2017-10-04|2007-12-24|2008-01-02|Estimate|||||||2017-10-04|2017-10-05|Actual|June 2004||2004-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|SPORE||Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection|Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)|Completed|||731|Actual|University of Alabama at Birmingham|||||f||||t||||||Samples With DNA|"~     Specimens are frozen and stored~   "|||2018-06-01 02:37:13.073399|2018-06-01 02:37:13.073399
NCT00584350|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-02-11|2007-12-20|2008-01-02|Estimate|||||||2015-02-11|2015-02-12|Estimate|November 2007||2007-11-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|NEPHRON||Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP|Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP|Unknown status|Recruiting|Phase 4|330|Anticipated|Université de Sherbrooke||3|||f||||t||||||||||2018-06-01 02:37:13.138667|2018-06-01 02:37:13.138667
NCT00584337|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2016-06-13|2007-12-31|2008-01-02|Estimate|||||||2016-06-13|2016-06-15|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|June 2010|Anticipated|2010-06-30|June 2009|Anticipated|2009-06-30||Observational|CTPRIME||Coronary CT Angiography as the Primary Initial Method of Evaluating Patients With Subacute Chest Pain (CT PRIME)|Coronary CT Angiography as the Primary Initial Method of Evaluating Patients With Subacute Chest Pain (CT PRIME)|Withdrawn|||0|Actual|William Beaumont Hospitals|||2|It was decided to not proceed with the study at this time.|f||||t||||||||||2018-06-01 02:37:13.227743|2018-06-01 02:37:13.227743
NCT00584324|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-12-18|2007-12-31|2008-01-02|Estimate|||||||2017-12-18|2017-12-20|Actual|March 2006||2006-03-31|December 2017|2017-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Depth of Anesthesia on Implicit Memory|The Effect of Depth of Anesthesia on Implicit Memory|Completed||N/A|70|Actual|University of Oklahoma||2|||f||||t||||||||No||2018-06-01 02:37:13.29336|2018-06-01 02:37:13.29336
NCT00584311|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-06-06|2007-12-31|2008-01-02|Estimate|||||||2008-06-06|2008-06-09|Estimate|June 2007||2007-06-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||MRI and Ultrasound Findings in Patients With Gout and Normal Plain Radiographs||Completed||N/A|33|Actual|University of South Florida||1|||f||||||||||||||2018-06-01 02:37:13.378044|2018-06-01 02:37:13.378044
NCT00584298|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-05-07|2007-12-21|2008-01-02|Estimate|||||||2009-05-07|2009-05-08|Estimate|January 2008||2008-01-31|May 2009|2009-05-31||||April 2009|Actual|2009-04-30||Interventional|||Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Women With Irritable Bowel Syndrome to Evaluate Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide.|Completed||Phase 1|50|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:37:13.441383|2018-06-01 02:37:13.441383
NCT00584285|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2008-01-02|Estimate|||||||2007-12-21|2008-01-02|Estimate|November 2007||2007-11-30|December 2007|2007-12-31||||December 2010|Anticipated|2010-12-31||Interventional|||Corneal Topographer Fluorescein Patterns|Objective and Subjective Correlation Between Clinical Fluoroscein Patterns and Theoretical Patterns Using the Medmont Corneal Topographer|Unknown status|Recruiting|N/A|0|Anticipated|University of Iowa||1|||f||||f||||||||||2018-06-01 02:37:13.526325|2018-06-01 02:37:13.526325
NCT00584272|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-06-19|2007-12-26|2008-01-02|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2007||2007-03-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Retrospective Study on the Outcome of Cleft Palate Repair: Comparing US Surgical and Ethicon Suture Materials|Retrospective Study on the Outcome of Cleft Palate Repair: Comparing US Surgical and Ethicon Suture Materials|Completed|||88|Actual|University of California, Davis|||||f||||f||||||||||2018-06-01 02:37:13.612578|2018-06-01 02:37:13.612578
NCT00584259|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2010-07-12|2007-12-26|2008-01-02|Estimate|||||||2010-07-12|2010-07-13|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux|Effect of Coffee on Gastro-Esophageal Disease in Patients With Symptoms of Reflux|Completed||N/A|7|Actual|University of California, Davis|||||f||||f||||||||||2018-06-01 02:37:13.671746|2018-06-01 02:37:13.671746
NCT00584246|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-04-18|2007-12-31|2008-01-02|Estimate|||||||2018-04-18|2018-04-20|Actual|November 2007||2007-11-30|April 2018|2018-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome|Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome|Withdrawn||Phase 4|0|Actual|University of South Florida||2||Study withdrawn due to budget (personnel) limitations.|f||||f||||||||||2018-06-01 02:37:13.738934|2018-06-01 02:37:13.738934
NCT00584233|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-05-24|2007-12-21|2008-01-02|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2004||2004-12-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Breast CT|Evaluation of Breast CT|Active, not recruiting||N/A|224|Actual|University of California, Davis||1|||f||||f||||||||||2018-06-01 02:37:13.813701|2018-06-01 02:37:13.813701
NCT00584220|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-08-21||2015-05-05|2007-12-31|2008-01-02|Estimate|2010-01-28|2010-02-19|Estimate||||2015-05-05|2015-05-21|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional||Baseline summary was conducted on enrolled subjects who completed the study.|Evaluation of Two Toric Soft Contact Lenses After Two Weeks of Wear|Evaluation of Fit and Visual Acuity of the Investigational Toric Lens in Two Phases: Part B: A Dispensing Cross-over Comparison to SofLens66 Toric|Completed||N/A|96|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-06-01 02:37:13.888124|2018-06-01 02:37:13.888124
NCT00584207|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-04-21|2007-12-21|2008-01-02|Estimate|||||||2009-04-21|2009-04-23|Estimate|March 2004||2004-03-31|April 2009|2009-04-30|July 2008|Actual|2008-07-31|March 2007|Actual|2007-03-31||Interventional|||Radiofrequency Ablation of Uterine Fibroids|Radiofrequency Ablation of Uterine Fibroids|Terminated||Early Phase 1|15|Actual|University of California, Davis||||Unsufficient referrals for recruitment|f||||f||||||||||2018-06-01 02:37:14.02613|2018-06-01 02:37:14.02613
NCT00584194|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-02-22|2017-02-02|2017-06-16|2007-12-31|2008-01-02|Estimate|2017-06-16|2017-07-14|Actual|2017-02-02|2017-02-03|Estimate|2017-06-16|2017-07-14|Actual|June 2004||2004-06-30|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|RVF|Baseline includes all subjects vaccinated and doesn't account for drop outs, deviations, and withdraws. Demographics weren't given in Final Clinical Study Report. Numbers are reliant on numbers of females and males receiving vaccination.|Safety and Immunogenicity Study of Rift Valley Fever Vaccine|Parts A&B: Evaluation of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200), A Phase 2 Study|Completed||Phase 2|278|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||No||2018-06-01 02:37:14.096741|2018-06-01 02:37:14.096741
NCT00584181|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-02-19|2007-12-20|2008-01-02|Estimate|||||||2018-02-19|2018-02-21|Estimate|August 2007||2007-08-31|February 2018|2018-02-28|January 7, 2018|Actual|2018-01-07|January 7, 2018|Actual|2018-01-07||Observational|||High-resolution Computed Tomography (HRCT) Evaluation of Airway Distensibility in Lung Transplant Recipients|High Resolution Computed Tomographic Evaluation of Airway Distensibility in Lung Transplant Recipients: A Pilot Study|Completed|||10|Actual|The University of Texas Medical Branch, Galveston|||1||f||||f||||||||||2018-06-01 02:37:14.388001|2018-06-01 02:37:14.388001
NCT00584168|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-02-01|2007-12-31|2008-01-02|Estimate|||||||2012-02-01|2012-02-02|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Using Dexamethasone After Uvulopalatopharyngoplasty|Decreasing Morbidity After Uvulopalatopharyngoplasty With the Use of Dexamethasone - A Randomized Double Blinded Placebo Controlled Trial|Completed||Phase 1|15|Actual|University of Oklahoma||2|||f||||f||||||||||2018-06-01 02:37:14.466412|2018-06-01 02:37:14.466412
NCT00584155|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-05-26|2007-12-31|2008-01-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2006||2006-07-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Protection From Cisplatin Ototoxicity by Lactated Ringers|Evaluation of Lactated Ringers for Protection From Cisplatin Ototoxicity.|Withdrawn||Phase 1|0|Actual|University of Oklahoma||2||PI left the university.|f||||f||||||||||2018-06-01 02:37:14.596902|2018-06-01 02:37:14.596902
NCT00584142|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-06-14|2007-12-31|2008-01-02|Estimate|||||||2012-06-14|2012-06-18|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Mindfulness-based Stress Reduction in Breast Cancer Recovery|Effects of MBSR in Early Stage Breast Cancer Recovery|Completed||N/A|84|Actual|University of South Florida||2|||f||||t||||||||||2018-06-01 02:37:14.693711|2018-06-01 02:37:14.693711
NCT00584129|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-03-12|2007-12-31|2008-01-02|Estimate|||||||2015-03-12|2015-03-17|Estimate|February 2006||2006-02-28|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Pre-treatment Exercises Versus Post-treatment Exercises for Dysphagia|Determining the Efficacy of Pre-treatment Swallowing Therapy as a Means to Improve Dysphagia Quality of Life When Compared to Post-Treatment Therapy.|Completed||N/A|52|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:37:14.76841|2018-06-01 02:37:14.76841
NCT00584116|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-05-25|2007-12-26|2008-01-02|Estimate|||||||2017-05-25|2017-05-30|Actual|March 2006||2006-03-31|May 2017|2017-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|BAV-SAVR||Balloon Aortic Valvuloplasty During Surgical Aortic Valve Replacement|Balloon Aortic Valvuloplasty During Surgical Aortic Valve Replacement|Completed|||2|Actual|University of California, Davis|||||f||||t||||||||||2018-06-01 02:37:14.849524|2018-06-01 02:37:14.849524
NCT00584103|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-05-03|2007-12-31|2008-01-02|Estimate|||||||2017-05-03|2017-05-08|Actual|January 2007||2007-01-31|May 2017|2017-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Evaluation of Upper Extremity Prosthesis|Evaluation of an Inexpensive Upper Extremity Prosthesis|Completed||N/A|1|Actual|University of Oklahoma||2|||f||||f||||||||No||2018-06-01 02:37:14.906551|2018-06-01 02:37:14.906551
NCT00584090|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-11-30|2007-12-31|2008-01-02|Estimate|||||||2012-11-30|2012-12-03|Estimate|November 2007||2007-11-30|October 2010|2010-10-31||||April 2011|Anticipated|2011-04-30||Interventional|||Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease||Withdrawn||Phase 4|0|Actual|University of South Florida||2||Study withdrawn with intent of persuing larger, multi-site study.|f||||f||||||||||2018-06-01 02:37:14.983116|2018-06-01 02:37:14.983116
NCT00584077|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2013-07-03||2015-08-24|2007-12-20|2008-01-02|Estimate|2015-08-24|2015-09-25|Estimate||||2015-08-24|2015-09-25|Estimate|April 2000||2000-04-30|July 2013|2013-07-31|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Observational|||Assessment of Cough Reflex in Lung Transplant Recipients|Assessment of Cough Reflex in Lung Transplant Recipients|Completed|||15|Actual|The University of Texas Medical Branch, Galveston|The limitations of this trial are that the results apply to lung transplant recipients||1||f||||f||||||||||2018-06-01 02:37:15.077495|2018-06-01 02:37:15.077495
NCT00584064|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2016-07-20|2007-12-31|2008-01-02|Estimate|||||||2016-07-20|2016-07-21|Estimate||||July 2016|2016-07-31||||||||Expanded Access|||Emergency/Compassionate Use PFO Occluder||Available|||||St. Jude Medical|||||||||||||||||||2018-06-01 02:37:15.229526|2018-06-01 02:37:15.229526
NCT00584051|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-02-10|2007-12-31|2008-01-02|Estimate|||||||2010-02-10|2010-02-11|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|October 2009|Actual|2009-10-31|January 2009|Anticipated|2009-01-31||Observational|||Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity|The Purpose of This Study is to Examine the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity|Terminated|||90|Anticipated|University of South Florida|||3|investigator closed study|f||||f||||||Samples With DNA|"~     CHEEK SWAB FOR DNA SAMPLES, BLOOD SAMPLES FOR IGE AND ANP LEVELS~   "|||2018-06-01 02:37:15.281378|2018-06-01 02:37:15.281378
NCT00584038|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-05-23|2007-12-31|2008-01-02|Estimate|||||||2013-05-23|2013-05-24|Estimate|January 2006||2006-01-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|December 2010|Actual|2010-12-31||Interventional|||Improving Adolescent Adherence to Hormonal Contraception|Improving Adolescent Adherence to Hormonal Contraception|Completed||N/A|1155|Actual|The University of Texas Medical Branch, Galveston||3|||f||||t||||||||||2018-06-01 02:37:15.344845|2018-06-01 02:37:15.344845
NCT00584025|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-03-22|2007-12-31|2008-01-02|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2007||2007-12-31|March 2018|2018-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease||Withdrawn||Phase 4|0|Actual|University of South Florida||2||Study withdrawn due to personnel limitations.|f||||f||||||||||2018-06-01 02:37:15.428925|2018-06-01 02:37:15.428925
NCT00584012|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-06-18|2007-12-21|2008-01-02|Estimate|||||||2009-06-18|2009-06-19|Estimate|April 2004||2004-04-30|June 2009|2009-06-30|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer|A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer|Terminated||Phase 1/Phase 2|96|Anticipated|University of Iowa||||Funding issues|f||||t||||||||||2018-06-01 02:37:15.525315|2018-06-01 02:37:15.525315
NCT00583999|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-05-25|2007-12-21|2008-01-02|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2006||2006-01-31|May 2017|2017-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|NASH||The Role of Leptin Receptors in NASH|Leptin, Soluble Leptin Receptor and Adiponectin in Non Alcoholic Steatohepatitis|Completed|||104|Actual|University of California, Davis|||1||f||||t||||||Samples With DNA|"~     Liver biopsy specimes, serum~   "|||2018-06-01 02:37:15.626679|2018-06-01 02:37:15.626679
NCT00583986|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-02-21|2007-12-21|2008-01-02|Estimate|||||||2012-02-21|2012-02-22|Estimate|September 2005||2005-09-30|February 2012|2012-02-29|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD|A Study to Determine the Reliability of a Top Mount Actuation Indicator When Used With Levalbuterol Tartrate HFA MDI in Adult and Pediatric Subjects With Asthma or Chronic Obstructive Pulmonary Disease|Completed||Phase 3|150|Actual|Sunovion||1|||f||||f||||||||||2018-06-01 02:37:15.72922|2018-06-01 02:37:15.72922
NCT00583973|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2017-06-19|2007-12-31|2008-01-02|Estimate|||||||2017-06-19|2017-06-21|Actual|January 2007||2007-01-31|June 2017|2017-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Effect of Parenteral Iron Therapy on Inflammatory Response and Oxidative Stress Chronic Hemodialysis|The Effect of Parenteral Iron Therapy on the Systemic Inflammatory Response and Oxidative Stress in Chronic Hemodialysis Patients|Completed|||11|Actual|University of California, Davis|||1||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 02:37:15.841044|2018-06-01 02:37:15.841044
NCT00583960|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-06-09|2007-12-26|2008-01-02|Estimate|||||||2015-06-09|2015-06-11|Estimate||||June 2015|2015-06-30||||||||Observational|||Office-based Radial Expansion Balloon Dilation of the Esophagus and Trachea|Office-based Radial Expansion Balloon Dilation of the Esophagus and Trachea|Withdrawn|||0|Actual|University of California, Davis||||PI chose not to proceed with study.|f||||f||||||||||2018-06-01 02:37:15.901687|2018-06-01 02:37:15.901687
NCT00583947|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-11-30||2012-02-21|2007-12-21|2008-01-02|Estimate|2010-01-19|2010-02-08|Estimate||||2012-02-21|2012-02-22|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects|A Cumulative Dose Safety and Tolerability Crossover Study of Arformoterol Tartrate Inhalation Solution and Levalbuterol Hydrochloride Inhalation Solution in Pediatric Subjects (Aged 2 to 11 Years of Age) With Asthma|Completed||Phase 2|53|Actual|Sunovion|Sample size was determined outside of statistical considerations. All data recorded at/after Visit 8 for 6 subjects, misdosed with ARF 7.5mcg instead of ARF 15mcg in open-label period, were excluded from the planned efficacy, PK and safety analyses.|2|||f||||f||||||||||2018-06-01 02:37:16.009239|2018-06-01 02:37:16.009239
NCT00583934|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-07-12|2007-12-21|2008-01-02|Estimate|||||||2010-07-12|2010-07-13|Estimate|September 2007||2007-09-30|July 2010|2010-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?|Is Screening for Esophageal Pathology in Asymptomatic Patients Post-Treatment for Head and Neck Cancer Beneficial?|Completed|||19|Actual|University of California, Davis|||1||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-06-01 02:37:17.051933|2018-06-01 02:37:17.051933
NCT00583921|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-07-10|2007-12-26|2008-01-02|Estimate|||||||2017-07-10|2017-07-13|Actual||||July 2017|2017-07-31||||||||Observational|VRR||Ventricular Rate Regularization for Improved Quality of Life in Patients With CHF and AF|Randomized Study of Ventricular Rate Regularization for Improved Quality of Life in Patients With Congestive Heart Failure and Atrial Fibrillation.|Withdrawn|||0|Actual|University of California, Davis||||no subjects enrolled|f||||t||||||||||2018-06-01 02:37:17.110163|2018-06-01 02:37:17.110163
NCT00583908|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2009-08-18||2015-05-05|2007-12-31|2008-01-02|Estimate|2009-08-18|2009-09-28|Estimate||||2015-05-05|2015-05-21|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Evaluation of Orientation and Visual Acuity of Four Toric Soft Contact Lenses When Head is Tilted at 90 Degrees|Clinical and Theoretical Evaluation of Factors Affecting Soft Toric Lens Performance: Part 3|Completed||N/A|14|Actual|Johnson & Johnson Vision Care, Inc.||12|||f||||f||||||||||2018-06-01 02:37:17.177618|2018-06-01 02:37:17.177618
NCT00583895|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-02-26|2007-12-31|2008-01-02|Estimate|||||||2010-02-26|2010-03-01|Estimate|December 2007||2007-12-31|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy Study of ImCOOH Cream in Patients Suffering From Moderate Atopic Dermatitis|Phase IIa, Randomized, Double-blind, Placebo-controlled, Intra-individual Left-right Limb Comparison Trial in 25 Patients With Moderate Atopic Dermatitis to Investigate the Efficacy, Local Irritation, Safety, Tolerability and Pharmacokinetics of Twice Daily Topical Applications With 10% ImCOOH Cream for 14 Days With an Additional Morning Application on Day 15.|Terminated||Phase 2|25|Anticipated|Valletta Health B.V.||2||Recruitment problems; insufficient number of new recruits|f||||f||||||||||2018-06-01 02:37:18.043749|2018-06-01 02:37:18.043749
NCT00583882|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2007-12-26|2007-12-26|2008-01-02|Estimate|||||||2007-12-26|2008-01-02|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Central Venous Catheter Replacement Strategies in Patients With Acute Burn Injury|A Prospective, Randomized Study to Evaluate the Risks Related to Central Venous Catheter Replacement Strategies in Patients With Acute Burn Injury|Unknown status|Recruiting|N/A|300|Anticipated|Shriners Hospitals for Children||3|||f||||f||||||||||2018-06-01 02:37:18.138342|2018-06-01 02:37:18.138342
NCT00583869|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-01-05|2007-12-21|2008-01-02|Estimate|||||||2014-01-05|2014-01-07|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|LYRICA||Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients|The Role of Pregabalin in the Treatment of Post-Operative Pain in Fracture Patients|Completed||Early Phase 1|86|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-06-01 02:37:18.240024|2018-06-01 02:37:18.240024
NCT00583856|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2010-12-16|2007-12-22|2008-01-02|Estimate|||||||2010-12-16|2010-12-20|Estimate|January 2007||2007-01-31|December 2010|2010-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Computer Modeling With Reconstruction of Maxillofacial Skeleton|Is Computer Modeling and Intra-Operative Navigation Helpful With Reconstruction of the Maxillofacial Skeleton?|Completed|||3|Actual|University of California, Davis|||||f||||f||||||||||2018-06-01 02:37:18.324767|2018-06-01 02:37:18.324767
NCT00583843|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2014-01-14|2007-12-20|2007-12-31|Estimate|||||||2014-01-14|2014-01-16|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|December 2011|Actual|2011-12-31|April 2009|Actual|2009-04-30||Observational|||Ultrasound Targeting for the Lumpectomy Cavity|Evaluation of Change in the Lumpectomy Cavity During Radiation Therapy by Weekly Ultrasound and by Daily Ultrasound During the Radiation Boost Dose|Completed|||20|Actual|University of Iowa|||1||f||||t||||||||||2018-06-01 02:37:18.414496|2018-06-01 02:37:18.414496
NCT00583830|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2011-03-30|2013-08-01|2007-12-20|2007-12-31|Estimate||||2011-04-11|2011-04-25|Estimate|2013-08-01|2013-08-08|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|NSCLC||A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer|A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab in Combination With Carboplatin and Paclitaxel as First Line Therapy in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|111|Actual|Human Genome Sciences Inc.||3|||f||||f||||||||||2018-06-01 02:37:18.51857|2018-06-01 02:37:18.51857
NCT00583817|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-04-12|2007-12-28|2007-12-31|Estimate|||||||2017-04-12|2017-04-14|Actual|May 2001||2001-05-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Endovascular Exclusion of Ascending and Thoracic Aortic Pathology|Endovascular Exclusion of Ascending and Thoracic Aortic Pathology|Recruiting||N/A|35|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-06-01 02:37:18.657505|2018-06-01 02:37:18.657505
NCT00583804|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-04-14|2007-12-20|2007-12-31|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 1989||1989-04-30|April 2015|2015-04-30|January 2019|Anticipated|2019-01-31|January 2015|Actual|2015-01-31||Interventional|||Implanted Myoelectric Control for Restoration of Hand Function in Spinal Cord Injury|Implanted Myoelectric Control for Restoration of Hand Function in Spinal Cord Injury|Active, not recruiting||N/A|50|Anticipated|MetroHealth Medical Center||1|||f||||f||||||||||2018-06-01 02:37:18.771076|2018-06-01 02:37:18.771076
NCT00583791|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-07-24|2007-12-21|2007-12-31|Estimate|||||||2009-07-24|2009-07-28|Estimate|July 2000||2000-07-31|December 2007|2007-12-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Closure of Muscular Ventricular Septal Defects With The AMPLATZER® Muscular VSD Occluder||Unknown status|Active, not recruiting|Phase 1|100|Actual|St. Jude Medical||1|||t||||t||||||||||2018-06-01 02:37:18.873695|2018-06-01 02:37:18.873695
NCT00583778|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-08-19|2007-12-20|2007-12-31|Estimate|||||||2010-08-19|2010-08-20|Estimate|August 2004||2004-08-31|December 2007|2007-12-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation|A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation|Completed||N/A|142|Actual|MetroHealth Medical Center||2|||f||||t||||||||||2018-06-01 02:37:18.967081|2018-06-01 02:37:18.967081
NCT00583765|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-06-02|2007-12-20|2007-12-31|Estimate|||||||2008-06-02|2008-06-04|Estimate|April 2005||2005-04-30|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration|Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration|Completed|||20|Actual|University of Alberta|||1||f||||t||||||||||2018-06-01 02:37:19.055594|2018-06-01 02:37:19.055594
NCT00583752|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-01-04|2007-12-20|2007-12-31|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2007||2007-12-31|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|APP21||Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21|Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy|Active, not recruiting||Phase 2|70|Anticipated|University of Iowa||2|||f||||t|t|f||||||No||2018-06-01 02:37:19.163441|2018-06-01 02:37:19.163441
NCT00583739|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-12-03|2007-12-20|2007-12-31|Estimate|||||||2008-12-03|2008-12-04|Estimate|August 2007||2007-08-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Yoga to Reduce Cancer Fatigue|Effect of a Yoga Intervention on Fatigue, Distress, and Quality of Life in Breast Cancer Patients: A Randomized Pilot Study|Completed||Phase 2|66|Anticipated|University of Iowa||2|||f||||t||||||||||2018-06-01 02:37:19.264215|2018-06-01 02:37:19.264215
NCT00583726|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-11-30|2007-12-20|2007-12-31|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2007||2007-12-31|December 2012|2012-12-31|November 2011|Actual|2011-11-30|August 2010|Actual|2010-08-31||Interventional|||The Women's Healthy Lifestyle Study|Motivational Interviewing for Weight Maintenance|Completed||N/A|40|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 02:37:19.372388|2018-06-01 02:37:19.372388
NCT00583713|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-09-17|2009-01-22|2010-10-29|2007-12-28|2007-12-31|Estimate|2010-10-08|2010-11-01|Estimate|2009-09-24|2009-09-28|Estimate|2010-10-29|2010-11-11|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters||Completed||Phase 1/Phase 2|18|Actual|Braintree Laboratories||3|||f||||f||||||||||2018-06-01 02:37:19.50418|2018-06-01 02:37:19.50418
NCT00583700|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-10-18||2012-12-18|2007-12-20|2007-12-31|Estimate|2012-12-18|2013-01-29|Estimate||||2012-12-18|2013-01-29|Estimate|February 2003||2003-02-28|October 2012|2012-10-31|June 2012|Actual|2012-06-30|May 2010|Actual|2010-05-31||Interventional|||Trental & Vitamin E for Radiation-Induced Fibrosis|Development of Radiation Fibrosis in Patients Treated With Pentoxyphylline and Vitamin E: a Prospective Randomized Study|Completed||Phase 2|54|Actual|University of Iowa|Small, single-institutional study. Smaller clinical trials are prone to imbalances in patient characteristics across treatment arms. t tests applied to small studies can be unduly influenced by data that contain outliers or are skewed.|2|||f||||t||||||||||2018-06-01 02:37:20.496726|2018-06-01 02:37:20.496726
NCT00583687|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-04-27|2007-12-20|2007-12-31|Estimate|||||||2009-04-27|2009-04-28|Estimate|December 2007||2007-12-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pulse Contour Analysis and Tissue Oxymetry in Changing Vascular Tone|Pulse Contour Analysis and Tissue Oxymetry in Changing Vascular Tone|Completed||N/A|30|Actual|University Hospital Inselspital, Berne|||||f||||||||||||||2018-06-01 02:37:21.011695|2018-06-01 02:37:21.011695
NCT00583674|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2014-02-07|2014-04-21|2007-12-20|2007-12-31|Estimate||||2014-02-07|2014-03-11|Estimate|2014-04-21|2014-05-07|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|June 2012|Actual|2012-06-30|March 2010|Actual|2010-03-31||Interventional|||Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma|A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma|Completed||Phase 2|171|Actual|Amgen||3|||f||||||||||||||2018-06-01 02:37:21.331932|2018-06-01 02:37:21.331932
NCT00583661|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-01-25||2013-03-13|2007-12-20|2007-12-31|Estimate|2013-03-13|2013-03-15|Estimate||||2013-03-13|2013-03-15|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device|A Prospective, Multi-center, Single Arm Study to Access the Safety and Probable Benefit of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device [EXCOR Pediatric]|Completed||N/A|48|Actual|Berlin Heart, Inc||1|||t||||t||||||||||2018-06-01 02:37:21.640683|2018-06-01 02:37:21.640683
NCT00583648|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2016-05-12|2007-12-20|2007-12-31|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 2008||2008-02-29|May 2016|2016-05-31|February 2009|Anticipated|2009-02-28|||||Interventional|||Does Implementing a Urinanylsis Protocol Based on Symptoms Decrease Length of Stay in the Emergency Department?|A Randomized Controlled Trial Showing the Effect of Patient Lenght of Stay in the Emergency Department Through Utilizing a Urinalysis Nursing Protocol.|Withdrawn||N/A|0|Actual|University of California, Los Angeles||2||lack of funding|f||||f||||||||||2018-06-01 02:37:22.097345|2018-06-01 02:37:22.097345
NCT00583635|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-10-03|2007-12-28|2007-12-31|Estimate|||||||2012-10-03|2012-10-05|Estimate|May 2004||2004-05-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Early Pregnancy Antioxidant Supplementation in the Prevention of Preeclampsia|Minimizing Early Pregnancy Oxidative Stress to Maximize Healthy Pregnancy Outcome: Reducing Preeclampsia and Reproductive Loss With Antioxidant-Rich Tablet Supplementation Initiated in the First Trimester|Completed|||684|Actual|University of Mississippi Medical Center|||4||f||||f||||||Samples Without DNA|"~     Blood to be analyzed for various markers, then discarded, none to be retained.~   "|||2018-06-01 02:37:22.173966|2018-06-01 02:37:22.173966
NCT00583622|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2013-02-26||2013-04-10|2007-12-20|2007-12-31|Estimate|2013-04-10|2013-05-21|Estimate||||2013-04-10|2013-05-21|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients|Bevacizumab Combined With High-Dose Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Patients With Advanced Epithelial Ovarian Cancer|Terminated||Phase 2|13|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-06-01 02:37:22.343807|2018-06-01 02:37:22.343807
NCT00583609|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2009-09-24|2009-09-24|2007-12-28|2007-12-31|Estimate||||2009-09-24|2009-09-28|Estimate|2009-09-24|2009-09-28|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children||Completed||Phase 4|20|Anticipated|Braintree Laboratories||1|||f||||f||||||||||2018-06-01 02:37:23.588754|2018-06-01 02:37:23.588754
NCT00583596|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-01-17||2015-01-28|2007-12-21|2007-12-31|Estimate|2014-07-17|2014-07-18|Estimate||||2015-01-28|2015-02-16|Estimate|October 1999||1999-10-31|January 2015|2015-01-31|February 2009|Actual|2009-02-28|April 2008|Actual|2008-04-30||Interventional|||Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder||Completed||N/A|436|Actual|St. Jude Medical||1|||t||||t||||||||||2018-06-01 02:37:23.678069|2018-06-01 02:37:23.678069
NCT00583583|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-01-28|2007-12-28|2007-12-31|Estimate|||||||2015-01-28|2015-01-29|Estimate||||January 2015|2015-01-31||||||||Expanded Access|||Emergency/Compassionate Use - AMPLATZER Duct Occluder||No longer available|||||St. Jude Medical|||||||||||||||||||2018-06-01 02:37:23.907387|2018-06-01 02:37:23.907387
NCT00583570|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-03-31|2007-12-20|2007-12-31|Estimate|||||||2009-03-31|2009-04-01|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Phosphorus Improvement Pilot Study|Phosphorus Improvement Pilot Study|Completed||N/A|279|Actual|MetroHealth Medical Center||1|||f||||f||||||||||2018-06-01 02:37:23.961881|2018-06-01 02:37:23.961881
NCT00582452|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-12-09|2007-12-21|2007-12-28|Estimate|||||||2009-12-09|2009-12-10|Estimate|November 2004||2004-11-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Attitudes Towards Prophylactic Colectomy in Hereditary Non-polyposis Colorectal Cancer (HNPCC) Patients|Attitudes Towards Prophylactic Colectomy in HNPCC Patients|Completed|||16|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:37:43.981422|2018-06-01 02:37:43.981422
NCT00583557|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-04-07||2013-08-01|2007-12-20|2007-12-31|Estimate|2011-06-03|2011-06-29|Estimate||||2013-08-01|2013-08-07|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01|A Multi-Center, Open-Label, Continuation Trial of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) Who Completed the Phase 2 Protocol LBRA01|Terminated||Phase 2|155|Actual|Human Genome Sciences Inc.||1||Sponsor decision - not related to safety|f||||t||||||||||2018-06-01 02:37:24.084261|2018-06-01 02:37:24.084261
NCT00583544|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-07-17|2007-12-28|2007-12-31|Estimate|||||||2008-07-17|2008-07-18|Estimate|January 2007||2007-01-31|July 2008|2008-07-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|SRD||A Safety and Tolerability Single Ascending Dose Study in Healthy Volunteers|A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.|Completed||Phase 1|72|Anticipated|Targacept Inc.||2|||f||||f||||||||||2018-06-01 02:37:24.703863|2018-06-01 02:37:24.703863
NCT00583531|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2013-07-26|2014-06-02|2007-12-20|2007-12-31|Estimate||||2014-06-02|2014-06-18|Estimate|2014-06-02|2014-06-18|Estimate|March 2007||2007-03-31|June 2014|2014-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis|A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis|Terminated||Phase 2|2|Actual|Ocera Therapeutics||1||Lack of enrollment|f||||f||||||||||2018-06-01 02:37:24.784804|2018-06-01 02:37:24.784804
NCT00583518|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-05-04|2007-12-20|2007-12-31|Estimate|||||||2012-05-04|2012-05-07|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)|Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis|Completed||Phase 4|129|Actual|Nycomed|||||f||||t||||||||||2018-06-01 02:37:24.884039|2018-06-01 02:37:24.884039
NCT00583505|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-10-21|2007-12-28|2007-12-31|Estimate|||||||2015-10-21|2015-10-23|Estimate||||October 2015|2015-10-31||||||||Expanded Access|||Emergency/Compassionate Use - Membranous VSD Occluder||No longer available|||||St. Jude Medical|||||||||||||||||||2018-06-01 02:37:24.955405|2018-06-01 02:37:24.955405
NCT00583492|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2015-04-13||2016-02-18|2007-12-20|2007-12-31|Estimate|2016-02-18|2016-03-17|Estimate||||2016-02-18|2016-03-17|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ReCAP||Randomized Trial of Suicide Gene Therapy and Prostate Cancer|A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile|Completed||Phase 2|44|Actual|Henry Ford Health System||2|||f||||t||||||||||2018-06-01 02:37:25.050626|2018-06-01 02:37:25.050626
NCT00583479|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-09-11|2007-12-20|2007-12-31|Estimate|||||||2012-09-11|2012-09-12|Estimate|June 2002||2002-06-30|September 2012|2012-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Prospective Study of Celiac Block Injection: 1 vs. 2|A Prospective Study of Celiac Block Technique: One Injection or Two?|Completed||Phase 4|100|Anticipated|Indiana University||2|||f||||f||||||||||2018-06-01 02:37:25.306255|2018-06-01 02:37:25.306255
NCT00583466|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-08-11||2017-09-11|2007-12-20|2007-12-31|Estimate|2017-09-11|2017-09-13|Actual||||2017-09-11|2017-09-13|Actual|May 2007|Actual|2007-05-31|September 2017|2017-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||No data on how participants were randomized, and no further baseline data (other than categorical age and sex) are available for this record. The PI has left the institution and has been contacted. Per the PI the data are no longer available and the study has not been published.|Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection|Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection|Completed||Phase 2|18|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-06-01 02:37:25.489107|2018-06-01 02:37:25.489107
NCT00583453|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-02-12||2017-02-12|2007-12-20|2007-12-31|Estimate|2017-02-12|2017-03-29|Actual||||2017-02-12|2017-03-29|Actual|October 2007||2007-10-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|December 2013|Actual|2013-12-31||Interventional|||Celecoxib as a Post-tonsillectomy Pain Medication|Perioperative Use of Celecoxib to Improve Pain Control in Patients Undergoing Tonsillectomy: a Randomized, Double Blind, Placebo-controlled Trial|Completed||Phase 2|18|Actual|University of Iowa|Small sample size Disproportionately female population|2|||f||||f||||||||Yes|Data will be uploaded through clinicaltrials.gov data tables|2018-06-01 02:37:25.694731|2018-06-01 02:37:25.694731
NCT00583440|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-01-28|2007-12-20|2007-12-31|Estimate|||||||2013-01-28|2013-01-30|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|TSFDD||12-step Facilitation for the Dually Diagnosed|12-step Facilitation for the Dually Diagnosed|Completed||Phase 1/Phase 2|121|Actual|University of New Mexico||2|||f||||f||||||||||2018-06-01 02:37:26.229434|2018-06-01 02:37:26.229434
NCT00583427|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-06-10|2007-12-28|2007-12-31|Estimate|||||||2015-06-10|2015-06-11|Estimate|December 2007||2007-12-31|June 2015|2015-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Sulodexide Treatment in Patients With Dense Deposit Disease|Sulodexide Treatment in Patients With Dense Deposit Disease|Withdrawn||Phase 1|0|Actual|University of Iowa||1||This study put on inactive status due to no identifiable subjects to enter the protocol.|f||||t||||||||||2018-06-01 02:37:26.329766|2018-06-01 02:37:26.329766
NCT00583414|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-12-12|2007-12-28|2007-12-31|Estimate|||||||2017-12-12|2017-12-14|Actual|September 1998|Actual|1998-09-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients|Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients|Completed||Phase 1|401|Actual|The Cleveland Clinic||1|||f||||t||||||||No||2018-06-01 02:37:26.409699|2018-06-01 02:37:26.409699
NCT00583401|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-02-16|2007-12-21|2007-12-31|Estimate|||||||2018-02-16|2018-02-20|Estimate||||February 2018|2018-02-28||||||||Expanded Access|||PFO ACCESS Registry|Patent Foramen Ovale Closure With the AMPLATZER PFO OCCLUDER in Patients With Recurrent Cryptogenic Stroke Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy|No longer available|||||St. Jude Medical|||||||||||||||||||2018-06-01 02:37:26.513618|2018-06-01 02:37:26.513618
NCT00583388|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-04-27|2007-12-28|2007-12-31|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||The Role of L-arginine in the Endothelial Dysfunction|The Efficacy of L-arginine in Preventing Early Morning Endothelial Dysfunction|Withdrawn|||0|Actual|Mayo Clinic|||1|PI is leaving the Institution, IRB will close the protocol.|f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 02:37:26.566223|2018-06-01 02:37:26.566223
NCT00583375|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-11-07||2018-03-06|2007-12-20|2007-12-31|Estimate|2018-01-26|2018-02-23|Actual||||2018-03-06|2018-04-02|Actual|April 2007||2007-04-30|March 2018|2018-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional||The safety population consisted of 414 patients, 272 randomized to Augment® Bone Graft and 142 randomized to autograft. The mITT population, submitted as the primary effectiveness analysis for the radiographic evaluation of bridging bone, consisted of 397 patients (414 patients in the Safety group minus 17 subjects excluded post-operatively).|Augment® Bone Graft (Formerly GEM OS™1 Bone Graft) Compared to Autologous Bone Graft in Foot and Ankle Fusions|A Prospective, Randomized, Controlled, Multi-Center, Pivotal Human Clinical Trial to Evaluate the Safety and Effectiveness of Augment® Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions|Completed||N/A|414|Actual|BioMimetic Therapeutics||2|||f||||t||||||||||2018-06-01 02:37:26.683218|2018-06-01 02:37:26.683218
NCT00583362|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2016-10-19||2017-08-22|2007-12-20|2007-12-31|Estimate|2017-03-20|2017-04-28|Actual||||2017-08-22|2017-09-20|Actual|May 1, 2005||2005-05-01|March 2017|2017-03-31|February 23, 2016|Actual|2016-02-23|February 1, 2016|Actual|2016-02-01||Interventional|||A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02|A Multi-Center, Open-Label, Continuation Trial LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 2 Protocol LBSL02|Completed||Phase 2|298|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-06-01 02:37:27.914722|2018-06-01 02:37:27.914722
NCT00583349|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-11-02|2007-12-20|2007-12-31|Estimate|||||||2012-11-02|2012-11-06|Estimate|December 2007||2007-12-31|November 2012|2012-11-30||||June 2013|Anticipated|2013-06-30||Interventional|Abraxane||Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer|A Combined Phase I & II Trial of Intravesicular Abraxane, a Nanoparticle Albumin-bound Paclitaxel, for Treatment-refractory Transitional Cell Carcinoma of the Urinary Bladder|Unknown status|Recruiting|Phase 1/Phase 2|47|Anticipated|Columbia University||1|||f||||t||||||||||2018-06-01 02:37:33.614133|2018-06-01 02:37:33.614133
NCT00583336|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-06-22|2007-12-28|2007-12-31|Estimate|||||||2015-06-22|2015-06-23|Estimate|September 2007||2007-09-30|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Physician Preference Study of ShuntCheck - Madsen|Physician Preference Study of the Utility of ShuntCheck to Detect Cerebrospinal Fluid (CSF) in Patients With Ventriculo-Peritoneal CSF Shunts|Unknown status|Recruiting|N/A|200|Anticipated|NeuroDx Development||1|||f||||f||||||||||2018-06-01 02:37:33.705795|2018-06-01 02:37:33.705795
NCT00583323|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2014-08-20|2007-12-20|2007-12-31|Estimate|||||||2014-08-20|2014-08-21|Estimate|February 2003||2003-02-28|August 2014|2014-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET|Diphenoxylate / Atropine to Decrease Bowel Activity During F-18 FDG PET|Completed||Phase 3|60|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:37:33.767456|2018-06-01 02:37:33.767456
NCT00583310|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-11-18|2007-12-20|2007-12-31|Estimate|||||||2013-11-18|2013-11-19|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|February 2010|Actual|2010-02-28||Interventional|||Telephone-Based Lifestyle Intervention to Reduce Blood Pressure in Prehypertensive Patients|Telephone-Based Lifestyle Intervention to Reduce Blood Pressure in Prehypertensive Patients|Terminated||Phase 2|125|Actual|New York University School of Medicine||2||PI left institution|f||||f||||||||||2018-06-01 02:37:33.815263|2018-06-01 02:37:33.815263
NCT00583297|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-02-21|2007-12-20|2007-12-31|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2007||2007-01-31|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Observational|ABCD||Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial|Identifying Genetic Markers That Predict Microvolt T-wave Alternans Status and Arrhythmia Risk in Patients With Ischemic Heart Disease|Completed|||400|Actual|CardioDx|||1||f||||t||||||Samples With DNA|"~     Whole blood and saliva.~   "|||2018-06-01 02:37:33.881506|2018-06-01 02:37:33.881506
NCT00583284|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-01-19|2007-12-20|2007-12-31|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2006|Actual|2006-11-30|January 2017|2017-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||The Use of CT to Identify Damaged Heart Muscle in Patients Undergoing Ventricular Tachycardia Ablation.|Utility of Delayed-Enhancement Multi-Detector Computed Tomography Imaging in Identifying Arrhymogenic Substrate in Patients Undergoing Catheter Ablation for Ventricular Tachycardia|Terminated|||4|Actual|The Cleveland Clinic||||key study staff left foundation|f||||f|f|f||||||No||2018-06-01 02:37:33.950633|2018-06-01 02:37:33.950633
NCT00583271|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2014-09-03|2007-12-20|2007-12-31|Estimate|||||||2014-09-03|2014-09-05|Estimate|June 2002||2002-06-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Prospective Study of EUS Guided Celiac Block|A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness|Completed|||127|Actual|Indiana University|||2||f||||f||||||||||2018-06-01 02:37:34.921646|2018-06-01 02:37:34.921646
NCT00583258|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-07-30|2007-12-20|2007-12-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|October 2007||2007-10-31|July 2015|2015-07-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones|A Randomized, Double-Blinded Placebo-Controlled Trial of Alfuzosin (Xatral)in the Management of Distal Ureteral Calculi|Withdrawn||N/A|0|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 02:37:35.029132|2018-06-01 02:37:35.029132
NCT00583245|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-03-07|2007-12-20|2007-12-31|Estimate|||||||2017-03-07|2017-03-10|Actual|December 2007||2007-12-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Improving Walking in Older Adults With Knee Osteoarthritis|Optimizing Mobility in Older Adults With Knee Osteoarthritis|Completed||N/A|27|Actual|University of Iowa||1|||f||||f||||||||||2018-06-01 02:37:35.096466|2018-06-01 02:37:35.096466
NCT00583232|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-03-14|2007-12-20|2007-12-31|Estimate|||||||2017-03-14|2017-03-16|Actual|February 2006||2006-02-28|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Protein and Energy Metabolism in Pediatric Crohn's Disease|Protein and Energy Metabolism in Pediatric Crohn's Disease|Completed||Phase 1|15|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 02:37:35.170512|2018-06-01 02:37:35.170512
NCT00583219|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-03-14||2014-03-14|2007-12-28|2007-12-31|Estimate|2014-03-14|2014-04-21|Estimate||||2014-03-14|2014-04-21|Estimate|March 2006||2006-03-31|March 2014|2014-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Botulin-A Toxin Instillations and Overactive Bladder|Botulin-A Toxin/Dimethyl Sulfoxide Bladder Instillations for Treatment of Voiding Dysfunction Secondary to Detrusor Hyperreflexia and Detrusor Instability in Women|Completed||Phase 1/Phase 2|25|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:37:35.279504|2018-06-01 02:37:35.279504
NCT00583206|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-02-24|2007-12-20|2007-12-31|Estimate|||||||2017-02-24|2017-02-28|Actual|December 2007||2007-12-31|February 2017|2017-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Muscle Atrophy in Sepsis|Biochemical Pathways to Skeletal Muscle Atrophy in Human Sepsis|Withdrawn|||0|Actual|University of Iowa|||||f||||f||||||Samples Without DNA|"~     Muscle RNA; blood~   "|||2018-06-01 02:37:35.7757|2018-06-01 02:37:35.7757
NCT00583193|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2007-12-20|2007-12-20|2007-12-31|Estimate|||||||2007-12-20|2007-12-31|Estimate|December 2005||2005-12-31|December 2007|2007-12-31|June 2008|Anticipated|2008-06-30|||||Interventional|||Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder|A Study of the Effectiveness and Tolerability of Duloxetine (Cymbalta) in the Treatment of PTSD.|Unknown status|Recruiting|Phase 3|20|Anticipated|New Mexico VA Healthcare System||1|||f||||t||||||||||2018-06-01 02:37:35.83995|2018-06-01 02:37:35.83995
NCT00583180|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-01-29|2007-12-20|2007-12-31|Estimate|||||||2008-01-29|2008-01-30|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|||||Observational|||Sensory Function After Wound Instillation of Capsaicin|Cutaneous Sensory Function After Wound Instillation of Capsaicin During Groin Hernia Repair|Completed|||42|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-06-01 02:37:35.93035|2018-06-01 02:37:35.93035
NCT00583167|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2014-05-27|2007-12-28|2007-12-31|Estimate|||||||2014-05-27|2014-05-28|Estimate|March 2006||2006-03-31|May 2014|2014-05-31|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Observational|||CNS (Central Nervous System) Viral Dynamics and Cellular Immunity During AIDS|CNS Viral Dynamics and Cellular Immunity During AIDS|Completed|||4|Actual|Vanderbilt University|||3||f||||t||||||Samples With DNA|"~     whole blood, plasma, CSF~   "|||2018-06-01 02:37:36.021223|2018-06-01 02:37:36.021223
NCT00583154|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2009-09-24|2009-09-24|2007-12-28|2007-12-31|Estimate||||2009-09-24|2009-09-28|Estimate|2009-09-24|2009-09-28|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults|A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults|Completed||Phase 2|60|Anticipated|Braintree Laboratories||4|||f||||f||||||||||2018-06-01 02:37:36.084136|2018-06-01 02:37:36.084136
NCT00583128|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2013-07-26|2014-06-02|2007-12-20|2007-12-31|Estimate||||2014-05-27|2014-05-30|Estimate|2014-06-02|2014-06-18|Estimate|August 2007||2007-08-31|June 2014|2014-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome|A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome|Completed||Phase 2|117|Actual|Ocera Therapeutics||2|||f||||f||||||||||2018-06-01 02:37:36.168658|2018-06-01 02:37:36.168658
NCT00583115|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2015-07-21||2015-09-28|2007-12-28|2007-12-31|Estimate|2015-09-28|2015-10-29|Estimate||||2015-09-28|2015-10-29|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Safety Study of Gleevec® in Children With Pulmonary Hypertension|A Phase II Study of Gleevec® (Imatinib Mesylate, NSC 716051 Formerly ST1571) in Children With Pulmonary Hypertension|Terminated||Phase 2|1|Actual|Indiana University||1||Unable to enroll subjects|f||||t||||||||||2018-06-01 02:37:36.266898|2018-06-01 02:37:36.266898
NCT00583102|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2017-10-10||2017-12-05|2007-12-20|2007-12-31|Estimate|2017-12-05|2018-01-05|Actual||||2017-12-05|2018-01-05|Actual|June 2001|Actual|2001-06-30|December 2017|2017-12-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML|A Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Patients With Refractory or Relapsed Acute Myeloid Leukemia|Terminated||Phase 1/Phase 2|23|Actual|University of Iowa|Trial terminated early due to slow accrual. PI left the institution.|1||Slow accrual, PI left institution|f||||t|t|f|||f|||No||2018-06-01 02:37:36.417872|2018-06-01 02:37:36.417872
NCT00583089|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-02-02|2007-12-28|2007-12-31|Estimate|||||||2017-02-02|2017-02-06|Estimate|March 2006||2006-03-31|February 2017|2017-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Decompensation Detection Study|Decompensation Detection Study|Completed|||699|Actual|Boston Scientific Corporation|||2||f||||f||||||||||2018-06-01 02:37:36.792978|2018-06-01 02:37:36.792978
NCT00583076|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2013-07-26|2014-06-02|2007-12-20|2007-12-31|Estimate||||2014-06-02|2014-06-18|Estimate|2014-06-02|2014-06-18|Estimate|February 2007||2007-02-28|June 2014|2014-06-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy of AST-120 in the Treatment of Pouchitis|A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Active Pouchitis|Completed||Phase 2|19|Actual|Ocera Therapeutics||1|||f||||t||||||||||2018-06-01 02:37:36.863542|2018-06-01 02:37:36.863542
NCT00583063|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-06-11|2007-12-20|2007-12-31|Estimate|||||||2013-06-11|2013-06-12|Estimate|October 2007||2007-10-31|March 2011|2011-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers|A Pharmacokinetic Interaction Study of Rapamycin (Sirolimus) and SU11248 (Sunitinib) in Patients With Advanced Solid Tumors|Completed||Early Phase 1|23|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 02:37:36.988765|2018-06-01 02:37:36.988765
NCT00583050|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-08-23|2007-12-20|2007-12-31|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2001||2001-02-28|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts|Endovascular Exclusion of Thoracoabdominal Aortic Aneurysms or Abdominal Aneurysms Utilizing Fenestrated/Branched Stent-Grafts|Recruiting||N/A|1440|Anticipated|The Cleveland Clinic||1|||f||||t||||||||No||2018-06-01 02:37:37.072924|2018-06-01 02:37:37.072924
NCT00583037|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-05-29|2007-12-28|2007-12-31|Estimate|||||||2009-05-29|2009-06-01|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||24-Hour NAVA Ventilation in Acute Respiratory Failure|FEASIBILITY OF 24 Hrs VENTILATION WITH NEURALLY ADJUSTED VENTILATORY ASSIST (NAVA) IN PATIENTS WITH ACUTE RESPIRATORY FAILURE|Completed||N/A|15|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-06-01 02:37:37.169348|2018-06-01 02:37:37.169348
NCT00583024|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-01-04|2007-12-20|2007-12-31|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2007||2007-12-31|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|APP22||Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer|Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer|Active, not recruiting||Phase 2|66|Anticipated|University of Iowa||1|||f||||t|t|f||||||No||2018-06-01 02:37:37.26133|2018-06-01 02:37:37.26133
NCT00583011|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-04-10|2007-12-27|2007-12-28|Estimate|||||||2017-04-10|2017-04-12|Actual|October 2007||2007-10-31|April 2017|2017-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Local Anesthesia and Pain Perception During an Amniocentesis|Local Anesthesia and Pain Perception During Amniocentesis: A Randomized Placebo-controlled Trial|Completed||N/A|70|Actual|University of Oklahoma||2|||f||||f||||||||||2018-06-01 02:37:37.347397|2018-06-01 02:37:37.347397
NCT00582998|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-09-18|2007-12-27|2007-12-28|Estimate|||||||2013-09-18|2013-09-20|Estimate|June 2001||2001-06-30|September 2013|2013-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|VAC-ST||Vacuum Assisted Closure as a Treatment for Soft Tissue Injuries|Vacuum Assisted Closure as a Treatment for Soft Tissue Injuries Sustained as a Result of Calcaneus, Tibial Plateau and Pilon Fractures|Completed||N/A|189|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:37:37.420617|2018-06-01 02:37:37.420617
NCT00582985|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-03-02|2007-12-19|2007-12-28|Estimate|||||||2012-03-02|2012-03-05|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer|An Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable|Completed||Phase 1|51|Actual|Tracon Pharmaceuticals Inc.|||||f||||f||||||||||2018-06-01 02:37:37.509951|2018-06-01 02:37:37.509951
NCT00582972|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-07-06||2013-02-14|2007-12-19|2007-12-28|Estimate|2012-12-12|2013-01-21|Estimate||||2013-02-14|2013-02-15|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Does Omeprazole Decrease Intestinal Calcium Absorption?|Does Omeprazole Decrease Intestinal Calcium Absorption?|Completed||Phase 4|23|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:37.597902|2018-06-01 02:37:37.597902
NCT00582959|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2014-02-05|2007-12-27|2007-12-28|Estimate|||||||2014-02-05|2014-02-06|Estimate|April 2004||2004-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Feasibility Study of Cone Beam Imaging for Radiation Therapy Treatment Verification|Feasibility Study of Cone Beam Imaging for Radiation Therapy Treatment Verification|Completed||N/A|19|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:37:37.752971|2018-06-01 02:37:37.752971
NCT00582946|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2013-10-29||2016-09-30|2007-12-19|2007-12-28|Estimate|2016-08-09|2016-10-03|Estimate||||2016-09-30|2016-11-04|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding|Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding|Completed||Phase 1|16|Actual|EarLens Corporation||1|||f||||t||||||||No|Please see publication for summary results.|2018-06-01 02:37:37.825059|2018-06-01 02:37:37.825059
NCT00582933|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-12-22||2015-12-22|2007-12-21|2007-12-28|Estimate|2015-12-22|2016-02-01|Estimate||||2015-12-22|2016-02-01|Estimate|May 2001||2001-05-31|December 2015|2015-12-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor|Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor For the Treatment of Lymphohematopoietic Disorders|Completed||Phase 2|96|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 02:37:38.004058|2018-06-01 02:37:38.004058
NCT00582920|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-12-23|2007-12-21|2007-12-28|Estimate|||||||2015-12-23|2015-12-24|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer|Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer|Completed||Phase 1|10|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:37:38.30293|2018-06-01 02:37:38.30293
NCT00582907|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-08-25||2013-02-05|2007-12-19|2007-12-28|Estimate|2012-10-29|2012-10-31|Estimate||||2013-02-05|2013-02-11|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Rilonacept for Treatment of Familial Mediterranean Fever (FMF)|Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF)|Completed||Phase 2|14|Actual|The Cleveland Clinic|"Small sample size - accounted for in study design and analysis plan.~Carry over/lag effect of rilonacept - sensitivity analysis of shifting course time frame showed similar results.~Heterogeneity of FMF mutations~Different age groups"|2|||f||||t||||||||||2018-06-01 02:37:38.405862|2018-06-01 02:37:38.405862
NCT00582894|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-01-10||2011-03-23|2007-12-27|2007-12-28|Estimate|2011-03-23|2011-04-22|Estimate||||2011-03-23|2011-04-22|Estimate|February 2005||2005-02-28|March 2011|2011-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases|Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases|Completed||N/A|17|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 02:37:39.09054|2018-06-01 02:37:39.09054
NCT00582881|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-08-07|2007-12-19|2007-12-28|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2007||2007-10-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus|Immune Response to Small Nuclear Ribonucleoprotein Autoantigens|Recruiting|||400|Anticipated|University of Miami|||||f||||f||||||Samples With DNA|"~     Serum, cells, DNA, urine~   "|||2018-06-01 02:37:39.309286|2018-06-01 02:37:39.309286
NCT00582868|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-10-01|2007-12-19|2007-12-28|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|May 2009|Actual|2009-05-31|||||Observational|||Use of Brain Oxygen Tension Level and Cleaved-tau Protein to Detect Vasospasm After SAH|Brain Oxygen Tension Level, Cerebral Perfusion and Cleaved-tau Protein for Detection of Cerebral Vasospasm and Independent Predictor of Poor Outcome After Aneurysmal Subarachnoid Hemorrhage|Terminated|||10|Actual|University of Wisconsin, Madison|||1|Insufficient subject enrollment|f||||t||||||Samples With DNA|"~     Cerebrospinal fluid Whole blood~   "|||2018-06-01 02:37:39.413128|2018-06-01 02:37:39.413128
NCT00582855|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-04-15|2007-12-21|2007-12-28|Estimate|||||||2016-04-15|2016-04-19|Estimate|December 2007||2007-12-31|April 2016|2016-04-30||||February 2009|Actual|2009-02-28||Interventional|||Effect of AQW051 in Patients With Memory Impairment|A 4-week, Parallel-group, Randomized, Double-blind, Placebo-controlled, Adaptive Proof of Concept Study of AQW051 at up to Three Dose Levels for the Treatment of Patients With Findings Consistent With Mild Alzheimer's Disease (AD) or Amnestic Mild Cognitive Impairment (Amnestic MCI)|Terminated||Phase 2|54|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:37:39.514786|2018-06-01 02:37:39.514786
NCT00582842|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-01|2007-12-21|2007-12-28|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2002|Actual|2002-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer|Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer|Active, not recruiting|||1800|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||||||2018-06-01 02:37:39.619199|2018-06-01 02:37:39.619199
NCT00582829|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2008-11-06|2007-12-21|2007-12-28|Estimate|||||||2008-11-06|2008-11-07|Estimate|June 2003||2003-06-30|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients|Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients|Completed|||213|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 02:37:39.716061|2018-06-01 02:37:39.716061
NCT00582816|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2016-11-02||2017-07-17|2007-12-27|2007-12-28|Estimate|2017-07-17|2017-07-19|Actual||||2017-07-17|2017-07-19|Actual|August 2008||2008-08-31|July 2017|2017-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors|Reduced Intensity Haploidentical Transplantation With NK Cell Infusion for Pediatric Acute Leukemia and High Risk Solid Tumors, BMT06407|Terminated||Phase 1/Phase 2|9|Actual|University of Wisconsin, Madison|This study involved a small patient cohort; blood samples were to be collected towards the secondary outcome measures. Unfortunately, participants whose blood samples were collected developed GVHD and the tests became uninterpretable.|1||toxicity|f||||t||||||||||2018-06-01 02:37:39.814954|2018-06-01 02:37:39.814954
NCT00582803|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-07-09|2007-12-27|2007-12-28|Estimate|||||||2009-07-09|2009-07-10|Estimate|May 2003||2003-05-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Adherence to Intensive Surveillance for Hereditary Breast Cancer|Adherence to Intensive Surveillance for Hereditary Breast Cancer|Completed|||85|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:37:40.094523|2018-06-01 02:37:40.094523
NCT00582790|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-09-30|2010-10-15|2013-03-18|2007-12-27|2007-12-28|Estimate|2013-03-18|2013-03-19|Estimate|2010-11-05|2010-11-29|Estimate|2013-03-18|2013-03-19|Estimate|August 2003||2003-08-31|March 2013|2013-03-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer|Phase II Study of Interleukin-2 in Combination With Zoledronic Acid in Patients With Untreated Metastatic Renal Cell Carcinoma|Terminated||Phase 2|12|Actual|University of Wisconsin, Madison||1||slow accrual|f||||t||||||||||2018-06-01 02:37:40.178576|2018-06-01 02:37:40.178576
NCT00582777|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-04-12|2007-12-27|2007-12-28|Estimate|||||||2012-04-12|2012-04-16|Estimate|November 2007||2007-11-30|April 2012|2012-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||African American Study of Kidney Disease and Hypertension ABPM Pilot Study|African American Study of Kidney Disease and Hypertension ABPM Pilot Study|Completed||Phase 2/Phase 3|180|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 02:37:40.372549|2018-06-01 02:37:40.372549
NCT00582764|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-07-07|2007-12-21|2007-12-28|Estimate|||||||2015-07-07|2015-07-08|Estimate|September 2005||2005-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Quantitative Dynamic Contrast Enhanced Breast MRI|Quantitative Dynamic Contrast Enhanced Breast MRI|Completed|||116|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:40.449565|2018-06-01 02:37:40.449565
NCT00582751|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-11-01|2007-12-21|2007-12-28|Estimate|||||||2010-11-01|2010-11-02|Estimate|November 2007||2007-11-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Volumetric Analysis in the Assessment of Therapy Response by CT|Volumetric Analysis in the Assessment of Therapy Response by CT|Completed|||26|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:37:40.508237|2018-06-01 02:37:40.508237
NCT00582738|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2012-01-10||2012-08-02|2007-12-21|2007-12-28|Estimate|2012-08-02|2012-09-06|Estimate||||2012-08-02|2012-09-06|Estimate|December 2007||2007-12-31|August 2012|2012-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|REVERT||Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection|A Randomized, Controlled, Open Label, Two Arms, Exploratory Study to Evaluate the Effect of Everolimus on Histologically Assessed Fibrosis Progression (Ishak-Knodell) in Liver Transplant Recipients With Recurrent Hepatitis C Viral Infection as Compared to Standard Treatment.|Terminated||Phase 2|43|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:37:40.658332|2018-06-01 02:37:40.658332
NCT00582725|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-05-23|2007-12-27|2007-12-28|Estimate|||||||2014-05-23|2014-05-26|Estimate|March 2002||2002-03-31|May 2014|2014-05-31|November 2010|Actual|2010-11-30|December 2005|Actual|2005-12-31||Interventional|||R-CHOP + GM-CSF for Previously Untreated LCL in Elderly|Phase II Trial of Rituximab-CHOP (R-CHOP) Plus GM-CSF for Previously Untreated Diffuse Large Cell Lymphoma in the Elderly|Completed||Phase 2|38|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:41.11106|2018-06-01 02:37:41.11106
NCT00582712|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2016-10-18||2016-10-18|2007-12-27|2007-12-28|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|April 2012|Actual|2012-04-30|May 2009|Actual|2009-05-31||Interventional||This study enrolled participants with Medullary Thyroid Cancer (MTC).|An Initial Study of Lithium in Patients With Medullary Thyroid Cancer|An Initial Study of Lithium in Patients With Medullary Thyroid Cancer|Terminated||Phase 2|5|Actual|University of Wisconsin, Madison||1||Budget/Funding|f||||t||||||||||2018-06-01 02:37:41.199198|2018-06-01 02:37:41.199198
NCT00582699|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-04-09|2007-12-21|2007-12-28|Estimate|||||||2014-04-09|2014-04-10|Estimate|November 2005||2005-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Depression, Cytokines and Pancreatic Cancer|Depression, Cytokines and Pancreatic Cancer|Completed|||80|Actual|Memorial Sloan Kettering Cancer Center|||4||f||||||||||||||2018-06-01 02:37:41.409916|2018-06-01 02:37:41.409916
NCT00582686|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-09-28|2007-12-27|2007-12-28|Estimate|||||||2013-09-28|2013-10-01|Estimate|May 2000||2000-05-31|September 2013|2013-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|CALCANEUS||Open Reduction Internal Fixation of Calcaneus Fractures With and Without Bone Graft|Prospective Comparison of Open Reduction Internal Fixation of Calcaneus Fractures With and Without Tricortical Iliac Crest Bone Grafting|Completed||N/A|49|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:37:41.487985|2018-06-01 02:37:41.487985
NCT00582673|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-05-13|2007-12-21|2007-12-28|Estimate|||||||2010-05-13|2010-05-14|Estimate|October 2007||2007-10-31|May 2010|2010-05-31||||May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa|A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa|Completed||Phase 2|31|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:37:41.57897|2018-06-01 02:37:41.57897
NCT00582660|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-02-02||2017-05-23|2007-12-27|2007-12-28|Estimate|2014-07-15|2014-08-07|Estimate||||2017-05-23|2017-06-15|Actual|December 2001||2001-12-31|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|UAB0040||Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib|Randomized, Placebo-Controlled, Phase 2B Evaluation of Cyclooxygenase-2 Activity in Surgically Resected Primary Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib|Completed||Phase 2|40|Actual|University of Alabama at Birmingham|The most prominent factor that limited enrollment was this period of time was at the point that the FDA released its finding about the possible cardiac risks associated with Rofecoxib (VIOXX).|2|||f||||t||||||||||2018-06-01 02:37:41.703869|2018-06-01 02:37:41.703869
NCT00582647|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-09-07|2007-12-27|2007-12-28|Estimate|||||||2017-09-07|2017-09-08|Actual|March 2000||2000-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract|Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites.|Active, not recruiting|||6000|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Tissue, Blood, Peritoneal, Pleural, Cyst, and Other gastrointestinal fluid~   "|||2018-06-01 02:37:41.93809|2018-06-01 02:37:41.93809
NCT00582634|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-09-30|2007-12-19|2007-12-28|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2004||2004-09-30|September 2015|2015-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer|Phase II Study of Adjuvant Cisplatin and Docetaxel in Non-small Cell Lung Cancer|Completed||Phase 2|4|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:41.993898|2018-06-01 02:37:41.993898
NCT00582621|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-04-24|2007-12-21|2007-12-28|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2000||2000-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders|Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders|Recruiting|||500|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Blood or alternatively, subjects may provide a saliva or buccal cell sample~   "|||2018-06-01 02:37:42.067854|2018-06-01 02:37:42.067854
NCT00582608|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2015-12-22||2017-01-10|2007-12-21|2007-12-28|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|October 2001||2001-10-31|January 2017|2017-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9|Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9|Terminated||N/A|12|Actual|Memorial Sloan Kettering Cancer Center|Technical problems led to unreliable and uninterpretable data. Therefore, there is no data to report under Outcome Measures. Due to lack of patients accrual.|1||Lack of accrual|f||||||||||||||2018-06-01 02:37:42.149528|2018-06-01 02:37:42.149528
NCT00582582|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-09-30|2007-12-27|2007-12-28|Estimate|||||||2015-09-30|2015-10-02|Estimate|April 2002||2002-04-30|April 2009|2009-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer|Phase II Evaluation of Docetaxel Randomized With Doxercalciferol or Placebo in Patients With Advanced Prostate Cancer|Terminated||Phase 2|70|Actual|University of Wisconsin, Madison||2||Lack of drug supply for doxercalciferol for this study|f||||t||||||||||2018-06-01 02:37:42.298112|2018-06-01 02:37:42.298112
NCT00582569|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-05-09|2007-12-21|2007-12-28|Estimate|||||||2013-05-09|2013-05-13|Estimate|February 2006||2006-02-28|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Breast MRI Spectroscopy, Department of Defense (DOD)|Breast MRI Spectroscopy, Department of Defense (DOD)|Completed|||146|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:37:42.382929|2018-06-01 02:37:42.382929
NCT00582556|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2014-02-24||2014-06-02|2007-12-27|2007-12-28|Estimate|2014-04-07|2014-05-12|Estimate||||2014-06-02|2014-06-09|Estimate|April 2003||2003-04-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2011|Actual|2011-03-31||Interventional|||Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy|Phase II Trial of Zometa on Bone Mineral Density on Patients With Stage D Prostate Cancer Undergoing Androgen Ablation Therapy|Completed||Phase 2|44|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-06-01 02:37:42.463086|2018-06-01 02:37:42.463086
NCT00582543|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-10-14|2007-12-21|2007-12-28|Estimate|||||||2011-10-14|2011-10-17|Estimate|October 2005||2005-10-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||MRI/MRSI in Risk Assessment of Prostate Cancer Patients|MRI/MRSI in Risk Assessment of Prostate Cancer Patients|Completed||N/A|357|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:37:43.021789|2018-06-01 02:37:43.021789
NCT00582530|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-06-12|2007-12-21|2007-12-28|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2004||2004-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Men Undergoing Radical Prostatectomy|Serum Protein Profiling to Characterize Patient Risk in Men Undergoing Radical Prostatectomy|Active, not recruiting|||1000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     Whole Blood~   "|||2018-06-01 02:37:43.086078|2018-06-01 02:37:43.086078
NCT00582517|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-09-18||2017-06-01|2007-12-20|2007-12-28|Estimate|2013-09-18|2013-11-25|Estimate||||2017-06-01|2017-06-05|Actual|August 2000||2000-08-31|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CKH||Compass Hinge Stabilization of Knee Dislocations: A Randomized Trial|Compass Hinge Stabilization of Knee Dislocations: A Randomized Trial|Completed||N/A|100|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:37:43.166217|2018-06-01 02:37:43.166217
NCT00582504|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-10-12|2007-12-27|2007-12-28|Estimate|||||||2017-10-12|2017-10-13|Actual|September 2007|Actual|2007-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|VEE TC-83||Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine|A Phase 2 Open-Label, Safety and Immunogenicity Study of a Single Dose of Venezuelan Equine Encephalomyelitis Vaccine, Live, Attenuated, Dried, TC-83, NDBR-102, as Primary Immunization in Healthy Adults At Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus|Enrolling by invitation||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 02:37:43.376217|2018-06-01 02:37:43.376217
NCT00582491|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2012-08-06||2012-09-06|2007-12-27|2007-12-28|Estimate|2012-08-06|2012-09-06|Estimate||||2012-09-06|2012-09-14|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Modafinil, Sleep, and Cognition in Cocaine Dependence|Modafinil, Sleep, and Cognition in Cocaine Dependence|Completed||N/A|44|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:37:43.533641|2018-06-01 02:37:43.533641
NCT00582478|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-10-03|2007-12-21|2007-12-28|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2001||2001-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients|Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients|Active, not recruiting|||650|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:43.855188|2018-06-01 02:37:43.855188
NCT00582465|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-10-25|2007-12-27|2007-12-28|Estimate|||||||2014-10-25|2014-10-28|Estimate|September 2003||2003-09-30|October 2014|2014-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|BMD||Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus|Bone Mineral Density of Children and Adolescents With Systemic Lupus Erythematosus|Unknown status|Active, not recruiting||425|Anticipated|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 02:37:43.923666|2018-06-01 02:37:43.923666
NCT00582439|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-09-28|2007-12-27|2007-12-28|Estimate|||||||2013-09-28|2013-10-01|Estimate|January 2007||2007-01-31|September 2013|2013-09-30|September 2009|Actual|2009-09-30|May 2007|Actual|2007-05-31||Interventional|RIA||The Use of RIA to Harvest Bone Graft for Treatment of Non-unions and Fractures|The Use of the Reamer-Irrigator-Aspirator (RIA) to Harvest Bone Graft for Treatment of Non-unions and Fractures|Completed||N/A|21|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 02:37:44.064561|2018-06-01 02:37:44.064561
NCT00582426|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-09-01||2015-04-13|2007-12-21|2007-12-28|Estimate|2012-02-22|2012-03-27|Estimate||||2015-04-13|2015-05-04|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|LARCID||Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea|LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea|Completed||Phase 3|139|Actual|Novartis|Limitations were the small number of patients who received irinotecan and small proportion of patients with grade III and IV diarrhea. It is not possible to generalize our results for these populations. Study wasn’t blinded or placebo-controlled.|2|||f||||||||||||||2018-06-01 02:37:44.164269|2018-06-01 02:37:44.164269
NCT00582413|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-10-15|2007-12-21|2007-12-28|Estimate|||||||2014-10-15|2014-10-16|Estimate|December 2004||2004-12-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Quality of Life and Development of Measures in Patients With Cancer of the Oral Cavity|Prospective Evaluation of Quality of Life and Development of Measures in Patients With Cancer of the Oral Cavity|Completed|||164|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:44.774534|2018-06-01 02:37:44.774534
NCT00582400|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2015-07-01||2016-02-18|2007-12-27|2007-12-28|Estimate|2016-02-18|2016-02-19|Estimate||||2016-02-18|2016-02-19|Estimate|September 2004||2004-09-30|January 2010|2010-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver|A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver|Terminated||Phase 2|9|Actual|The University of Texas Medical Branch, Galveston||1||"recruiting or enrolling participants has halted prematurely and will not resume; participants~   are no longer being examined or treated"|f||||f||||||||||2018-06-01 02:37:44.862811|2018-06-01 02:37:44.862811
NCT00582387|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-12-16|2007-12-19|2007-12-28|Estimate|||||||2015-12-16|2015-12-18|Estimate|March 2004||2004-03-31|December 2015|2015-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer|Pilot Study: Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer|Completed|||116|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     blood, urine and tissue~   "|||2018-06-01 02:37:45.051419|2018-06-01 02:37:45.051419
NCT00582374|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-03-24|2007-12-27|2007-12-28|Estimate|||||||2017-03-24|2017-03-28|Actual|March 2005||2005-03-31|March 2017|2017-03-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Observational|||Periodontal Disease and Preterm Birth|Periodontal Disease, Inflammatory Markers, and Preterm Birth|Withdrawn|||0|Actual|University of Oklahoma|||1|PI passed away unexpectedly|f||||f||||||None Retained|"~     Gingival crevicular fluid (GCF) and Vaginal Fluid~   "|||2018-06-01 02:37:45.120801|2018-06-01 02:37:45.120801
NCT00582361|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-07-27||2013-08-05|2007-12-27|2007-12-28|Estimate|2012-12-13|2013-01-24|Estimate||||2013-08-05|2013-08-14|Estimate|June 2001||2001-06-30|May 2012|2012-05-31|January 2010|Actual|2010-01-31|September 2008|Actual|2008-09-30||Interventional|VAC-OF||Vacuum Assisted Closure as a Treatment for Open Fractures|Vacuum Assisted Closure as a Treatment for Open Fractures|Completed||N/A|63|Actual|University of Alabama at Birmingham|None Noted.|2|||f||||f||||||||||2018-06-01 02:37:45.198914|2018-06-01 02:37:45.198914
NCT00582348|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-01-02|2007-12-21|2007-12-28|Estimate|||||||2018-01-02|2018-01-04|Actual|September 2005||2005-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Physical Activity and Inactivity in Lung Cancer Survivors|Physical Activity and Inactivity in Lung Cancer Survivors|Active, not recruiting|||188|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:37:45.455439|2018-06-01 02:37:45.455439
NCT00582335|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-01-02|2007-12-21|2007-12-28|Estimate|||||||2018-01-02|2018-01-03|Actual|February 1998||1998-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Identification of New Colorectal Cancer Genes|Identification of New Colorectal Cancer Genes|Active, not recruiting|||337|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Blood Tissue (tumor)~   "|||2018-06-01 02:37:45.524701|2018-06-01 02:37:45.524701
NCT00582322|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-07-17|2007-12-21|2007-12-28|Estimate|||||||2009-07-17|2009-07-20|Estimate|February 1992||1992-02-29|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Genetic Studies in Breast Cancer|Genetic Studies in Breast Cancer|Completed|||483|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     blood~   "|||2018-06-01 02:37:45.599596|2018-06-01 02:37:45.599596
NCT00582309|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2009-09-12||2015-05-26|2007-12-27|2007-12-28|Estimate|2009-12-18|2010-01-25|Estimate||||2015-05-26|2015-06-23|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparative Trial Between 3 Types of Insulin Infusion Protocols|Comparative Trial Between Computer-Guided Intravenous Infusion Protocol Versus a Standard Insulin Infusion Algorithm Versus a Simple Calculated Infusion Protocol in Medical and Surgical ICU|Completed||N/A|151|Actual|University of New Mexico|Limitations of trial. Variable length of stay the first 48 hours was analyzed as the sample size decreased after that.|3|||f||||f||||||||||2018-06-01 02:37:45.676593|2018-06-01 02:37:45.676593
NCT00582296|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-04-24|2007-12-21|2007-12-28|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2004|Actual|2004-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Multi-Organ Screening Recommendations in Patients With Lynch Syndrome|Adherence to Comprehensive, Multi-Organ Screening Recommendations in Patients With Lynch Syndrome|Recruiting|||2000|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:37:45.986559|2018-06-01 02:37:45.986559
NCT00582283|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-02-08|2007-12-19|2007-12-28|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2004||2004-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||NM404 as an Imaging Agent in Patients With NSCLC|NM404 as an Imaging Agent in Patients With Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||N/A|21|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:46.101943|2018-06-01 02:37:46.101943
NCT00582270|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2014-08-13|2007-12-21|2007-12-28|Estimate|||||||2014-08-13|2014-08-15|Estimate|February 2003||2003-02-28|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma|Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma|Completed|||56|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:37:46.162296|2018-06-01 02:37:46.162296
NCT00582257|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-11-06|2007-12-21|2007-12-28|Estimate|||||||2017-11-06|2017-11-08|Actual|December 2005||2005-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Early Onset and Familial Gastric Cancer Registry|Early Onset and Familial Gastric Cancer Registry|Active, not recruiting|||971|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Germline DNA and Tissue~   "|||2018-06-01 02:37:46.226136|2018-06-01 02:37:46.226136
NCT00582244|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2007-12-19|2007-12-19|2007-12-28|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|December 2010|Anticipated|2010-12-31|||||Interventional|EVA project||Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial|Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial|Unknown status|Not yet recruiting|Phase 3|325|Anticipated|The Netherlands Cancer Institute||4|||f||||f||||||||||2018-06-01 02:37:46.314991|2018-06-01 02:37:46.314991
NCT00582231|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-11-06|2007-12-21|2007-12-28|Estimate|||||||2017-11-06|2017-11-08|Actual|February 2007||2007-02-28|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Penile Injection Anxiety|Penile Injection Anxiety|Active, not recruiting|||126|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:46.381238|2018-06-01 02:37:46.381238
NCT00582218|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-01-13|2007-12-27|2007-12-28|Estimate|||||||2009-01-13|2009-01-14|Estimate|February 2003||2003-02-28|January 2009|2009-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Family Access to Care Study (FACS)|Family Access to Care Study (FACS)|Completed|||3200|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:37:46.447548|2018-06-01 02:37:46.447548
NCT00582205|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2017-04-12||2017-06-02|2007-12-27|2007-12-28|Estimate|2017-04-12|2017-05-18|Actual||||2017-06-02|2017-07-02|Actual|January 2006||2006-01-31|June 2017|2017-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma|Feasibility Trial of Intraperitoneal Chemotherapy in Stage IA, IB, IC, II, III, IV and Recurrent Platinum Sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma and Stage III and IV Uterine Cancer|Terminated||Phase 2|21|Actual|University of Oklahoma||1||Study completed per investigator.|f||||f||||||||||2018-06-01 02:37:46.521433|2018-06-01 02:37:46.521433
NCT00582192|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-04-30|2007-12-21|2007-12-28|Estimate|||||||2009-04-30|2009-05-01|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists'Communication Styles|Seeking Informed Consent to Phase I Cancer Clinical Trials: Identifying Oncologists' Communication Styles|Completed|||17|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:46.651323|2018-06-01 02:37:46.651323
NCT00582179|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-09-28|2007-12-27|2007-12-28|Estimate|||||||2013-09-28|2013-10-01|Estimate|September 2001||2001-09-30|September 2013|2013-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|VAC-DH||Vacuum Assisted Closure as a Treatment for Draining Hematomas|Vacuum Assisted Closure as a Treatment For Draining Hematomas (Vacuum Assisted Closure in the Management of Traumatic Extremity Wounds)|Completed||N/A|94|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:37:46.811115|2018-06-01 02:37:46.811115
NCT00582166|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-06-02|2007-12-27|2007-12-28|Estimate|||||||2014-06-02|2014-06-04|Estimate|September 2004||2004-09-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Zevalin(Ibritumomab Tiuxetan)+ Rituximab Maintenance|Ibritumomab Tiuxetan Plus Rituximab as Initial Therapy for Patients With High Tumor Burden, Indolent Histology Non-Hodgkin's Lymphoma|Completed||Phase 2|18|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:46.92682|2018-06-01 02:37:46.92682
NCT00582140|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-07-22|2007-12-19|2007-12-28|Estimate|||||||2015-07-22|2015-07-23|Estimate|March 2005||2005-03-31|July 2015|2015-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer|Phase I Study of a DNA-based Vaccine Targeting Prostatic Acid Phosphatase (PAP) in Patients With Stage D0 Prostate Cancer|Completed||Phase 1|22|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-06-01 02:37:47.080609|2018-06-01 02:37:47.080609
NCT00582127|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2010-12-22|2007-12-27|2007-12-28|Estimate|||||||2010-12-22|2010-12-24|Estimate|January 2008||2008-01-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Evaluation of the COGNISION(TM) System as an Event-related Potential (ERP) Collection System.|Evaluation of a Handheld Evoked Response Potentials (ERP) System as an Effective Method to Diagnose Alzheimer's Disease|Completed|||50|Anticipated|Neuronetrix, Inc.|||2||f||||f||||||||||2018-06-01 02:37:47.197054|2018-06-01 02:37:47.197054
NCT00582114|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2015-10-05||2015-12-14|2007-12-20|2007-12-28|Estimate|2015-12-14|2016-01-18|Estimate||||2015-12-14|2016-01-18|Estimate|August 2005||2005-08-31|December 2015|2015-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Hypertension in Hemodialysis Patients (Aim 3)|Hypertension in Hemodialysis Patients|Terminated||Phase 3|200|Actual|Indiana University||2||Stopped by data safety monitoring board|f||||t||||||||||2018-06-01 02:37:47.328024|2018-06-01 02:37:47.328024
NCT00582101|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-06-05|2007-12-27|2007-12-28|Estimate|||||||2012-06-05|2012-06-06|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Family-Based HIV Prevention for Latinos|Family-Based HIV Prevention for Latinos|Completed||Phase 1|80|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-06-01 02:37:48.54278|2018-06-01 02:37:48.54278
NCT00582088|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-05-08|2007-12-27|2007-12-28|Estimate|||||||2018-05-08|2018-05-14|Actual|March 2008|Actual|2008-03-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|VEE C-84||Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83|A Phase 2 Open-Label, Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205 When Used as a Booster After TC-83 Primary Immunization in Healthy Adults At-Risk for Exposure to Virulent Venezuelan Equine Encephalomyelitis Virus|Active, not recruiting||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-06-01 02:37:48.637782|2018-06-01 02:37:48.637782
NCT00582075|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2015-07-06||2017-02-06|2007-12-20|2007-12-28|Estimate|2015-08-17|2015-09-17|Estimate||||2017-02-06|2017-03-15|Actual|July 2002||2002-07-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|October 2008|Actual|2008-10-31||Interventional|RAD0102||Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases|Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases|Completed||Phase 2|25|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 02:37:48.763623|2018-06-01 02:37:48.763623
NCT00582062|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-04-03|2007-12-21|2007-12-28|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2006|Actual|2006-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Detection of Peritoneal Micrometastasis in Gastric and Pancreatic Cancer in Peritoneal Wash Samples|Detection of Peritoneal Micrometastasis in Gastric and Pancreatic Cancer in Peritoneal Wash Samples|Active, not recruiting|||144|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:37:49.104829|2018-06-01 02:37:49.104829
NCT00582049|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2008-07-03|2007-12-21|2007-12-28|Estimate|||||||2008-07-03|2008-07-04|Estimate|August 2003||2003-08-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Research on the Environment and Children's Health: Retinoblastoma|Research on the Environment and Children's Health: Retinoblastoma|Completed|||78|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:37:49.228833|2018-06-01 02:37:49.228833
NCT00582036|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-01-06||2011-03-23|2007-12-19|2007-12-28|Estimate|2011-03-23|2011-04-22|Estimate||||2011-03-23|2011-04-22|Estimate|February 2007||2007-02-28|March 2011|2011-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Glucose Control In Hematopoetic Stem Cell Transplant|Glucose Control In Hematopoetic Stem Cell Transplant|Terminated||N/A|11|Actual|University of Oklahoma|This study was terminated early due to lack of enrollment.|2||study terminated due to lack of enrollment|f||||f||||||||||2018-06-01 02:37:49.328199|2018-06-01 02:37:49.328199
NCT00582023|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-11-21|2007-12-27|2007-12-28|Estimate|||||||2013-11-21|2013-11-25|Estimate|September 2004||2004-09-30|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|CHAI||Role of Positive Affect in Adjustment to HIV|CHAI Study: Coping, HIV, and Affect Interview Study|Completed|||160|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 02:37:49.655604|2018-06-01 02:37:49.655604
NCT00582010|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2013-09-30|2010-10-12|2014-11-05|2007-12-27|2007-12-28|Estimate|2014-11-05|2014-11-06|Estimate|2010-11-15|2010-11-24|Estimate|2014-11-05|2014-11-06|Estimate|April 2008||2008-04-30|October 2014|2014-10-31|October 2012|Actual|2012-10-31|March 2009|Actual|2009-03-31||Interventional|||Study to Evaluate if Inhaled Nitric Oxide Improves Liver Function After Transplantation|Effects of Inhaled Nitric Oxide on Ischemia-Reperfusion Injury in Human Liver During Transplantation|Completed||Phase 2/Phase 3|80|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:37:49.726031|2018-06-01 02:37:49.726031
NCT00581997|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21||2012-05-02|2012-05-02|2007-12-21|2007-12-28|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|December 2007||2007-12-31|May 2012|2012-05-31||||April 2009|Actual|2009-04-30||Interventional|||QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis|A Randomized, Double-blinded, Placebo Controlled, Multiple-dose, Multi-center Pilot Study, to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous Doses of QAX576 in Patients With Pulmonary Fibrosis Secondary to System Sclerosis|Terminated||Phase 2|8|Actual|Novartis||2||"Concerns about risk of bronchoscopy procedure in the selected patient population and frequency~   of SAEs observed to date."|f||||f||||||||||2018-06-01 02:37:50.223351|2018-06-01 02:37:50.223351
NCT00581984|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-10-14|2007-12-21|2007-12-28|Estimate|||||||2013-10-14|2013-10-16|Estimate|September 1998||1998-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||McGhan Medical Silicone-Filled Breast Implant Adjunct Study|McGhan Medical Silicone-Filled Breast Implant Adjunct Study|Completed|||1016|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:37:50.387445|2018-06-01 02:37:50.387445
NCT00581971|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-05-30||2013-03-13|2007-12-20|2007-12-28|Estimate|2013-03-13|2013-04-25|Estimate||||2013-03-13|2013-04-25|Estimate|September 2002||2002-09-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|December 2007|Actual|2007-12-31||Interventional|RAD0201||Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer|Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck|Completed||Phase 1/Phase 2|30|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 02:37:50.509445|2018-06-01 02:37:50.509445
NCT00581958|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-03-13|2007-12-21|2007-12-28|Estimate|||||||2018-03-13|2018-03-14|Actual|November 2007|Actual|2007-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)|Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI)|Active, not recruiting|||198|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     Blood and Urine~   "|||2018-06-01 02:37:50.99027|2018-06-01 02:37:50.99027
NCT00581945|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-05-26||2011-06-28|2007-12-21|2007-12-28|Estimate|2011-05-26|2011-06-27|Estimate||||2011-06-28|2011-06-30|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-blind, Placebo Controlled, Exploratory Study to Assess the Safety and Efficacy of Multiple Doses of ACZ885 in Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||Phase 1/Phase 2|147|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:37:51.088672|2018-06-01 02:37:51.088672
NCT00581932|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-05-11|2007-12-19|2007-12-28|Estimate|||||||2017-05-11|2017-05-12|Actual|October 2001||2001-10-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine|Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine|Completed|||76|Actual|University of Iowa|||1||f||||f||||||Samples With DNA|"~     whole blood, saliva~   "|||2018-06-01 02:37:52.535506|2018-06-01 02:37:52.535506
NCT00581919|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2016-07-14||2016-11-21|2007-12-27|2007-12-28|Estimate|2016-07-14|2016-08-24|Estimate||||2016-11-21|2017-01-13|Estimate|February 2004||2004-02-29|November 2016|2016-11-30|July 2013|Actual|2013-07-31|December 2010|Actual|2010-12-31||Interventional|||Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma|Phase II Trial of Bortezomib, Low Dose Dexamethasone, and Doxorubicin With Acetyl-L-Carnitine for Neuroprotection in Patients With Previously Treated Multiple Myeloma|Completed||Phase 2|32|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:52.663685|2018-06-01 02:37:52.663685
NCT00581906|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-05-21|2007-12-21|2007-12-28|Estimate|||||||2018-05-21|2018-05-22|Actual|February 2006||2006-02-28|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors|Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors|Recruiting|||335|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:53.105514|2018-06-01 02:37:53.105514
NCT00581893|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-05-08|2007-12-27|2007-12-28|Estimate|||||||2017-05-08|2017-05-10|Actual|August 2005||2005-08-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phenytoin and Driving Safety|Phenytoin and Driving Safety|Completed||Phase 4|10|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 02:37:53.226084|2018-06-01 02:37:53.226084
NCT00581867|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2014-01-09||2015-07-10|2007-12-19|2007-12-28|Estimate|2015-07-10|2015-07-14|Estimate||||2015-07-10|2015-07-14|Estimate|October 2007||2007-10-31|July 2015|2015-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|MAIN|31 total participants were enrolled in the study. 29 completed the study and had, in a counterbalanced order, one-dose of intranasal insulin followed by fMRI and over 48 hours later a dose of intranasal saline followed by fMRI.|Memory and Insulin in Early Alzheimer's Disease|Intranasal Insulin and Memory in Early Alzheimer's Disease|Completed||Phase 1/Phase 2|31|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 02:37:53.64877|2018-06-01 02:37:53.64877
NCT00581854|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-12-02||2014-06-25|2007-12-27|2007-12-28|Estimate|2014-06-25|2014-07-21|Estimate||||2014-06-25|2014-07-21|Estimate|June 2000||2000-06-30|June 2014|2014-06-30|March 2010|Actual|2010-03-31|June 2006|Actual|2006-06-30||Interventional|||Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma|Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma|Completed||Phase 2|22|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 02:37:53.945038|2018-06-01 02:37:53.945038
NCT00581841|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-05-16|2007-12-27|2007-12-28|Estimate|||||||2013-05-16|2013-05-17|Estimate|November 2002||2002-11-30|May 2013|2013-05-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Observational|||Repeatability of X-Ray, MRI, and Gait Analysis|Repeatability of X-Ray, MRI, and Gait Analysis|Completed|||60|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-06-01 02:37:54.296603|2018-06-01 02:37:54.296603
NCT00581828|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-07-06||2012-09-13|2007-12-19|2007-12-28|Estimate|2012-09-13|2012-09-14|Estimate||||2012-09-13|2012-09-14|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Does Treatment of Hypovitaminosis D Increase Calcium Absorption?|Does Treatment of Hypovitaminosis D Increase Calcium Absorption?|Completed||Phase 4|19|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:54.423112|2018-06-01 02:37:54.423112
NCT00581815|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-12-23|2007-12-21|2007-12-28|Estimate|||||||2015-12-23|2015-12-28|Estimate|February 1997||1997-02-28|December 2015|2015-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Spectroscopy With Surface Coils and Decoupling|Spectroscopy With Surface Coils and Decoupling|Completed||Phase 1|582|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:37:54.923932|2018-06-01 02:37:54.923932
NCT00581802|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-05-02|2007-12-19|2007-12-28|Estimate|||||||2012-05-02|2012-05-04|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|||||Observational|||HIV Resistance and Treatment Strategies|Cohort Study to Understand Resistance and HIV Eradication (CURE): Observational Studies of Antiretroviral Drug Treatment Success and Failure|Completed|||89|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||5||f||||||||||Samples With DNA|"~     Plasma, white cells, and whole blood~   "|||2018-06-01 02:37:55.201808|2018-06-01 02:37:55.201808
NCT00581789|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-02-10|2007-12-19|2007-12-28|Estimate|||||||2012-02-10|2012-02-14|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|February 2010|Actual|2010-02-28||Interventional|||Erlotinib and Sunitinib in NSCLC|Phase I Study of Erlotinib and Sunitinib in Non-small Cell Lung Cancer|Completed||Phase 1|11|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:55.303739|2018-06-01 02:37:55.303739
NCT00581776|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-12-09||2016-05-12|2007-12-27|2007-12-28|Estimate|2011-01-20|2011-02-15|Estimate||||2016-05-12|2016-06-20|Estimate|May 2005||2005-05-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|November 2012|Actual|2012-11-30||Interventional|||Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma|Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma|Completed||Phase 2|30|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:37:55.414784|2018-06-01 02:37:55.414784
NCT00581763|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-06-11|2007-12-19|2007-12-28|Estimate|||||||2012-06-11|2012-06-13|Estimate|May 2001||2001-05-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|||||Observational|APL||Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies|Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies|Completed|||110|Actual|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 02:37:56.217338|2018-06-01 02:37:56.217338
NCT00581750|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2017-08-08|2007-12-21|2007-12-28|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2001||2001-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ|Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ|Active, not recruiting|||550|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||Samples Without DNA|"~     Tissue~   "|||2018-06-01 02:37:56.488856|2018-06-01 02:37:56.488856
NCT00581737|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-03-02|2007-12-21|2007-12-28|Estimate|||||||2012-03-02|2012-03-05|Estimate|July 2000||2000-07-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Cognitive Functioning and Quality of Life in CNS Lymphoma|Cognitive Functioning and Quality of Life in CNS Lymphoma|Completed|||50|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:37:57.140498|2018-06-01 02:37:57.140498
NCT00581724|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-01-25|2007-12-21|2007-12-28|Estimate|||||||2012-01-25|2012-01-26|Estimate|May 2007||2007-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Pain in Cancer Survivors|Pain in Cancer Survivors|Completed|||200|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:57.412699|2018-06-01 02:37:57.412699
NCT00581711|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-06-15|2007-12-19|2007-12-28|Estimate|||||||2012-06-15|2012-06-18|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|OMHIT||Improving Otitis Media Care With Clinical Decision Support|Improving Otitis Media Care With EHR-based Clinical Decision Support and Feedback|Completed||Phase 3|55779|Actual|Children's Hospital of Philadelphia||4|||f||||f||||||||||2018-06-01 02:37:57.776078|2018-06-01 02:37:57.776078
NCT00581698|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-09-14|2007-12-27|2007-12-28|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 1991||1991-01-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue|Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue|Completed|||876|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     tissue (lymph node)~   "|||2018-06-01 02:37:57.908694|2018-06-01 02:37:57.908694
NCT00581685|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-06-07|2007-12-27|2007-12-28|Estimate|||||||2012-06-07|2012-06-11|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Does Optimal Control of Pre-operative Chronic and Acute Pain Predict Improved Function After Orthopedic Surgery?|Does Optimal Pain Control With Pregabalin and Celecoxib Predict Improved Function After Total Hip Arthroplasty?|Completed||Phase 3|31|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-06-01 02:37:58.035048|2018-06-01 02:37:58.035048
NCT00581672|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2018-01-12|2007-12-27|2007-12-28|Estimate|||||||2018-01-12|2018-01-17|Actual|July 25, 2010|Actual|2010-07-25|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men|Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men|Active, not recruiting|||225|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:37:58.351179|2018-06-01 02:37:58.351179
NCT00581659|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-04-26|2007-12-19|2007-12-28|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2007|Actual|2007-11-30|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions|Evaluation of the Bausch & Lomb PureVision Under Nighttime Driving Conditions|Completed|||40|Actual|University of Iowa|||1||f||||f||||||||No|Individual data will not be shared|2018-06-01 02:37:58.579517|2018-06-01 02:37:58.579517
NCT00581646|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-07-07|2007-12-21|2007-12-28|Estimate|||||||2015-07-07|2015-07-08|Estimate|September 2006||2006-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance|Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance|Completed|||179|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||f||||||||||2018-06-01 02:37:58.644726|2018-06-01 02:37:58.644726
NCT00581633|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-03-26|2007-12-22|2007-12-27|Estimate|||||||2018-03-26|2018-03-27|Actual|February 2007||2007-02-28|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Acute Salt Handling in Orthostatic Intolerance|Acute Renal Salt Handling in Orthostatic Intolerance|Active, not recruiting||N/A|30|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 02:37:58.781858|2018-06-01 02:37:58.781858
NCT00581620|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2007-12-27|Estimate|||||||2007-12-21|2007-12-27|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Study Evaluating Prevenar Immunogenicity in High Risk Children|To Evaluate the Humoral Immune Response to a Conjugated Pneumococcus Vaccine 7-Valent (Prevenar®) in Children From High Risk Groups.|Completed||Phase 4|160|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-06-01 02:37:58.873997|2018-06-01 02:37:58.873997
NCT00581607|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2013-04-10|2007-12-26|2007-12-27|Estimate|||||||2013-04-10|2013-04-12|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|BOSAPAH||Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension|Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension|Completed||Phase 2/Phase 3|43|Actual|University of Cincinnati||2|||f||||t||||||||||2018-06-01 02:37:59.060583|2018-06-01 02:37:59.060583
NCT00581594|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-08-05|2007-12-20|2007-12-27|Estimate|||||||2010-08-05|2010-08-06|Estimate|January 2006||2006-01-31|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Traditional vs. Graft-augmented Posterior Colporrhaphy|Traditional vs. Graft-augmented Posterior Colporrhaphy: A Randomized Prospective Study|Terminated||N/A|128|Anticipated|University of California, Irvine||2||Could not meet recruitment, technology advancement.|f||||t||||||||||2018-06-01 02:37:59.187549|2018-06-01 02:37:59.187549
NCT00581581|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-01-24||2013-03-07|2007-12-26|2007-12-27|Estimate|2013-03-07|2013-03-08|Estimate||||2013-03-07|2013-03-08|Estimate|September 2007||2007-09-30|March 2013|2013-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||CoolCap Followup Study-Coordination of Participating Centers|Long-term Follow-up After Head Cooling for Neonatal Encephalopathy|Completed|||62|Actual|University of Rochester|||2||f||||f||||||||||2018-06-01 02:37:59.3176|2018-06-01 02:37:59.3176
NCT00581568|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-02-08|2007-12-26|2007-12-27|Estimate|||||||2017-02-08|2017-02-10|Actual|January 2004||2004-01-31|February 2017|2017-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|CSC||Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling|Completed||Phase 1|53|Actual|University of California, Irvine||1|||f||||f||||||||||2018-06-01 02:38:00.078947|2018-06-01 02:38:00.078947
NCT00581555|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-11-17||2012-03-28|2007-12-21|2007-12-27|Estimate|2012-03-28|2012-04-23|Estimate||||2012-03-28|2012-04-23|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy|A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy|Completed||Phase 4|120|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:38:00.229819|2018-06-01 02:38:00.229819
NCT00581542|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2015-04-15||2015-12-11|2007-12-26|2007-12-27|Estimate|2015-12-11|2016-01-18|Estimate||||2015-12-11|2016-01-18|Estimate|March 2007||2007-03-31|December 2015|2015-12-31|March 2012|Actual|2012-03-31|March 2009|Actual|2009-03-31||Interventional|||Moxifloxacin vs. Polytrim for Conjunctivitis|A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.|Completed||Phase 4|124|Actual|University of Rochester|No adverse events|2|||f||||f||||||||||2018-06-01 02:38:01.206957|2018-06-01 02:38:01.206957
NCT00581529|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-08-14||2017-09-28|2007-12-20|2007-12-27|Estimate|2014-08-14|2014-08-28|Estimate||||2017-09-28|2017-10-31|Actual|November 2004||2004-11-30|September 2017|2017-09-30|August 2014|Actual|2014-08-31|October 2010|Actual|2010-10-31||Interventional||34 for patients were enrolled and treated. 2 patients were excluded from all analysis due to fair baseline cosmesis. 2 additional patients underweant mastectomies and were therefore excluded from analysis (comsesis could not be assessed at 5 years). 30 patients were analyzed.|Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy|Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy in Early Stage Breast Cancer After Breast-Conserving Surgery|Terminated||Phase 2|34|Actual|University of Michigan Cancer Center|The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.|1||The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.|f||||t||||||||||2018-06-01 02:38:01.624134|2018-06-01 02:38:01.624134
NCT00581516|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2009-06-03|2007-12-19|2007-12-27|Estimate|||||||2009-06-03|2009-06-05|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Molecular Urine Tests for Prostate Cancer||Completed|||100|Actual|University of California, Irvine|||||f||||f||||||Samples Without DNA|"~     Blood and Urine~   "|||2018-06-01 02:38:02.222021|2018-06-01 02:38:02.222021
NCT00581503|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-02-12|2007-12-26|2007-12-27|Estimate|||||||2018-02-12|2018-02-14|Actual|March 2007||2007-03-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer|Optical Coherence Tomography for Early Detection and Staging of Endobronchial Lung and Pleural Cancer, Airway Injury, and Prostate Cancer|Withdrawn|||0|Actual|University of California, Irvine|||1|Not NIH defined clinical trial|f||||f||||||||||2018-06-01 02:38:02.373127|2018-06-01 02:38:02.373127
NCT00581490|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-03-30|2007-12-26|2007-12-27|Estimate|||||||2017-03-30|2017-04-04|Actual|August 2003||2003-08-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|PP||Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche|Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche|Completed|||52|Actual|Vanderbilt University Medical Center|||1||f||||t||||||Samples With DNA|"~     DNA sample from consented subjects and controls~   "|||2018-06-01 02:38:02.536764|2018-06-01 02:38:02.536764
NCT00581477|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-03-26|2007-12-22|2007-12-27|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2004||2004-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Orthostatic Hypotension|Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms|Enrolling by invitation||Phase 3|25|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 02:38:02.645564|2018-06-01 02:38:02.645564
NCT00581464|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-04-25|2007-12-26|2007-12-27|Estimate|||||||2017-04-25|2017-04-27|Actual|November 2009||2009-11-30|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|HABITS||Healthier Hearts and Brains in Treating Smoking: The HABITS Study|Healthier Hearts and Brains in Treating Smoking: The HABITS Study|Completed||N/A|79|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:38:02.749496|2018-06-01 02:38:02.749496
NCT00581451|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-07-08|2007-12-26|2007-12-27|Estimate|||||||2009-07-08|2009-07-10|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects|A 3-Part, Randomized, Multiple-Dose, Sequential Design Study of Bifeprunox in Healthy Subjects in Order to Establish a Titration Regimen With an Improved Tolerability Profile|Completed||Phase 1|144|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-06-01 02:38:02.876188|2018-06-01 02:38:02.876188
NCT00581438|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-26|2007-12-26|2007-12-27|Estimate|||||||2007-12-26|2007-12-27|Estimate|June 2007||2007-06-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Study Evaluating Approach to Treatment of Haemophilia A and B in Spain|Actual Approach to Treatment of Haemophilia A and B in Spain|Completed|||52|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 02:38:02.952331|2018-06-01 02:38:02.952331
NCT00581425|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-01-23|2007-12-26|2007-12-27|Estimate|||||||2013-01-23|2013-01-25|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)|Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp|Completed||Phase 4|49|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-06-01 02:38:03.052566|2018-06-01 02:38:03.052566
NCT00581412|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-01-07|2007-12-20|2007-12-27|Estimate|||||||2010-01-07|2010-01-11|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates|Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates|Completed|||60|Anticipated|University of California, Irvine|||||f||||t||||||||||2018-06-01 02:38:03.19975|2018-06-01 02:38:03.19975
NCT00581399|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-04-25||2011-10-27|2007-12-26|2007-12-27|Estimate|2011-10-27|2011-10-31|Estimate||||2011-10-27|2011-10-31|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|NO-NUMO||A Randomized Multicenter Clinical Study On the High Vacuum Body Cavity Drainage System Following Open Heart Surgery|A Prospective, Randomized, Multicenter Clinical Study on the High Vacuum Body Cavity Drainage Systems Following Open Heart Surgery|Completed||Phase 2|94|Actual|University of California, Irvine||2|||f||||t||||||||||2018-06-01 02:38:03.428221|2018-06-01 02:38:03.428221
NCT00581386|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-07-28||2016-08-11|2007-12-26|2007-12-27|Estimate|2010-02-10|2010-03-04|Estimate||||2016-08-11|2016-09-20|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Clinical Comparison of the Airway Devices|A Randomized Clinical Comparison Of The King Systems Disposable Laryngeal Tube Suction (LTS-D), The Esophageal Tracheal Combitube (ETC) And The Proseal Laryngeal Mask Airway (PLMA) In Adult Patients|Completed||N/A|218|Actual|The University of Texas Health Science Center, Houston||3|||f||||f||||||||Undecided||2018-06-01 02:38:03.654703|2018-06-01 02:38:03.654703
NCT00581373|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-03-26|2007-12-22|2007-12-27|Estimate|||||||2018-03-26|2018-03-27|Actual|August 2007||2007-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Water and the Gastropressor Response - Diurnal Variability|Water and the Gastropressor Response - Diurnal Variability (Specific Aim 1.3)|Active, not recruiting||N/A|20|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 02:38:04.081802|2018-06-01 02:38:04.081802
NCT00581360|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2016-01-14||2016-09-19|2007-12-26|2007-12-27|Estimate|2016-09-19|2016-11-07|Estimate||||2016-09-19|2016-11-07|Estimate|November 2007||2007-11-30|September 2016|2016-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck|Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Head and Neck Adenoid Cystic Carcinoma|Completed||Phase 2|10|Actual|University of Pittsburgh||1|||f||||t||||||||No||2018-06-01 02:38:04.166099|2018-06-01 02:38:04.166099
NCT00581347|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-08-12||2016-08-17|2007-12-26|2007-12-27|Estimate|2010-09-14|2010-10-01|Estimate||||2016-08-17|2016-09-23|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PCAIR||Primary Care and Adolescent Immunization for Rochester||Completed||N/A|7546|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-06-01 02:38:04.554|2018-06-01 02:38:04.554
NCT00581334|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2013-07-18|2007-12-26|2007-12-27|Estimate|||||||2013-07-18|2013-07-22|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Robotic-assisted Laparoscopic Sacrocolpopexy|Robotic-assisted Laparoscopic Sacrocolpopexy: A Feasibility Study|Completed||N/A|20|Actual|University of California, Irvine|||||f||||t||||||||||2018-06-01 02:38:04.854929|2018-06-01 02:38:04.854929
NCT00581321|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-01-24|2007-12-22|2007-12-27|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2006||2006-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Oral Water Ingestion in Heart Transplant Patients|Acute Hemodynamic Effects of Oral Water in a Stable Cardiac Transplant Population|Active, not recruiting||N/A|40|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 02:38:04.920483|2018-06-01 02:38:04.920483
NCT00581308|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-01-04||2018-02-15|2007-12-26|2007-12-27|Estimate|2012-01-04|2012-02-07|Estimate||||2018-02-15|2018-02-16|Estimate|August 2006||2006-08-31|February 2018|2018-02-28|October 2014|Actual|2014-10-31|October 2009|Actual|2009-10-31||Interventional|||Long-term Safety Study of the GORE® HELEX® Septal Occluder|GORE® HELEX® Septal Occluder Post-Approval Study|Completed||N/A|215|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-06-01 02:38:05.025687|2018-06-01 02:38:05.025687
NCT00581295|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-02-08|2007-12-26|2007-12-27|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2007||2007-03-31|February 2017|2017-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients|Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients|Completed|||93|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:38:05.513128|2018-06-01 02:38:05.513128
NCT00581282|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-10-14|2007-12-26|2007-12-27|Estimate|||||||2010-10-14|2010-10-15|Estimate|October 2006||2006-10-31|October 2010|2010-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Brain Imaging Studies of the Effects of Cocaine Abstinence|Brain Imaging Studies of the Effects of Cocaine Abstinence|Unknown status|Recruiting||30|Anticipated|University of California, Irvine|||2||f||||f||||||||||2018-06-01 02:38:05.58021|2018-06-01 02:38:05.58021
NCT00581269|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-11-01|2007-12-19|2007-12-27|Estimate|||||||2010-11-01|2010-11-03|Estimate|December 2007||2007-12-31|November 2010|2010-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Dietary Intervention and Exercise Training (DIET) in Moderate to Severe Chronic Kidney Disease|Dietary Intervention and Exercise Training (DIET) in Moderate to Severe Chronic Kidney Disease|Terminated||Phase 2|3|Actual|Vanderbilt University||3||the Fellow conducting the study left the institution in 2009|f||||f||||||||||2018-06-01 02:38:05.675571|2018-06-01 02:38:05.675571
NCT00581256|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2016-06-23||2017-09-28|2007-12-25|2007-12-27|Estimate|2016-10-07|2016-12-01|Estimate||||2017-09-28|2017-10-31|Actual|April 2006||2006-04-30|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer|A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer|Completed||Phase 1/Phase 2|54|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-06-01 02:38:05.763409|2018-06-01 02:38:05.763409
NCT00581243|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-07-20|2007-12-21|2007-12-27|Estimate|||||||2009-07-20|2009-07-21|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients|An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder|Terminated||Phase 1|32|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-06-01 02:38:06.114646|2018-06-01 02:38:06.114646
NCT00581230|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-04-12||2016-08-11|2007-12-20|2007-12-27|Estimate|2016-03-22|2016-04-25|Estimate||||2016-08-11|2016-09-20|Estimate|December 2007||2007-12-31|August 2016|2016-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|RAMP||Evaluation of the Rapid Airway Management Positioner|An Evaluation Of The Rapid Airway Management Positioner (RAMP) In Obese Patients Undergoing Gastric Bypass Or Laparoscopic Gastric Banding (Lap-Band) Surgery|Completed||N/A|51|Actual|The University of Texas Health Science Center, Houston|major limitations of the study was the lack of a blinded observer for the purpose of rating the laryngoscopic view & how easily, quickly & consistently this position can be achieved as well as to return the patient to a neutral position for surgery.|2|||f||||f||||||||Undecided||2018-06-01 02:38:06.289839|2018-06-01 02:38:06.289839
NCT00581217|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-05-11|2007-12-26|2007-12-27|Estimate|||||||2010-05-11|2010-05-13|Estimate|December 2007||2007-12-31|May 2010|2010-05-31|September 2010|Anticipated|2010-09-30|March 2010|Actual|2010-03-31||Observational|||A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings|A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings With Regards to Healing Time, Cosmesis, Infection Rate, and Patient's Perceived Pain: a Pilot Study.|Unknown status|Active, not recruiting||20|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:38:06.522381|2018-06-01 02:38:06.522381
NCT00581204|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-02-08|2007-12-26|2007-12-27|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2011||2011-12-31|February 2017|2017-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans|Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans|Completed|||8|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:38:06.583867|2018-06-01 02:38:06.583867
NCT00581191|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-08-03|2007-12-21|2007-12-27|Estimate|||||||2009-08-03|2009-08-04|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SLV-351 Administered Orally to Healthy Subjects|Terminated||Phase 1|72|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||9|||f||||f||||||||||2018-06-01 02:38:06.644452|2018-06-01 02:38:06.644452
NCT00581178|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-06-24|2007-12-19|2007-12-27|Estimate|||||||2013-06-24|2013-06-26|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation|Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation|Terminated|||16|Actual|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:38:06.709201|2018-06-01 02:38:06.709201
NCT00581165|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-26|2007-12-26|2007-12-27|Estimate|||||||2007-12-26|2007-12-27|Estimate|February 2006||2006-02-28|December 2007|2007-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept|Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept|Completed||Phase 4|500|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 02:38:06.774513|2018-06-01 02:38:06.774513
NCT00581152|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2007-12-19|2007-12-19|2007-12-27|Estimate|||||||2007-12-19|2007-12-27|Estimate|August 2007||2007-08-31|December 2007|2007-12-31|August 2010|Anticipated|2010-08-31|||||Observational|||The Role of TBX3 in Human ES Cell Differentiation|The Role of TBX3 in Human ES Cell Differentiation|Unknown status|Active, not recruiting||4|Anticipated|University of California, Irvine|||||f||||f||||||Samples With DNA|"~     NIH-approved cell lines will be available at the Sue and Bill Gross Stem Cell Research Core~     Facility at the University of California, Irvine. Non-NIH-approved cell lines will be~     obtained from Sue & Bill Gross Stem Cell Core at UC Irvine.~   "|||2018-06-01 02:38:06.93826|2018-06-01 02:38:06.93826
NCT00581139|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2008-10-27|2007-12-26|2007-12-27|Estimate|||||||2008-10-27|2008-10-28|Estimate|April 2003||2003-04-30|October 2008|2008-10-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|NIH||Psychological Influences on Postoperative Recovery|Psychological Influences on Postoperative Recovery|Unknown status|Recruiting|Phase 2|377|Anticipated|Yale University||4|||f||||t||||||||||2018-06-01 02:38:07.042882|2018-06-01 02:38:07.042882
NCT00581126|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-26|2007-12-26|2007-12-27|Estimate|||||||2007-12-26|2007-12-27|Estimate|December 2001||2001-12-31|December 2007|2007-12-31|July 2004|Actual|2004-07-31|||||Interventional|||Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B|Evaluation of Efficacy and Safety of Benefix®- Coagulation Factor ix, Recombinant, in Previously Treated Patients With Hemophilia b.|Completed||Phase 4|14|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:38:07.127798|2018-06-01 02:38:07.127798
NCT00581113|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-10-06||2015-05-15|2007-12-20|2007-12-27|Estimate|2011-01-27|2011-02-24|Estimate||||2015-05-15|2015-06-11|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Neural Stem Cell Preserving Brain Radiation Therapy & Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases|A Study of Neural Stem Cell (NSC) Preserving Whole Brain Radiation Therapy (WBRT) and Stereotactic Radiosurgery in Patients With 1-6 Brain Metastases|Terminated||Phase 3|8|Actual|Virginia Commonwealth University|Trial not completed. Insufficient data to analyze.|2||New research priorities|f||||t||||||||||2018-06-01 02:38:07.199488|2018-06-01 02:38:07.199488
NCT00581100|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-08-03||2013-02-20|2007-12-21|2007-12-27|Estimate|2010-08-03|2010-08-30|Estimate||||2013-02-20|2013-02-25|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis|Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis|Completed||Phase 4|136|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:38:07.485257|2018-06-01 02:38:07.485257
NCT00581087|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2015-01-13|2007-12-26|2007-12-27|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|DHEA-HTAP||Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults|Double-blind, Randomised, Placebo-controlled Phase III Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 02:38:08.139161|2018-06-01 02:38:08.139161
NCT00581074|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2011-07-25|2007-12-26|2007-12-27|Estimate|||||||2011-07-25|2011-07-27|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|GJW||Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults|Effects of Grapefruit or Grapefruit Juice on Anthropometry, Dietary Intakes, Appetite, and Metabolic Profile in Overweight and Obese Young and Middle-Aged Adults|Completed||N/A|90|Anticipated|Vanderbilt University||3|||f||||f||||||||||2018-06-01 02:38:08.240091|2018-06-01 02:38:08.240091
NCT00581061|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2010-03-11||2010-10-05|2007-12-26|2007-12-27|Estimate|2010-09-09|2010-09-30|Estimate||||2010-10-05|2010-10-07|Estimate|June 2008||2008-06-30|October 2010|2010-10-31|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional|||Study to Determine Effects of Vesicare on Return to Continence Post- Radical Prostatectomy|Vesicare™ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy|Terminated||N/A|13|Actual|University of California, Irvine||1||Study subjects were not compliant with study protocols.|f||||t||||||||||2018-06-01 02:38:08.35091|2018-06-01 02:38:08.35091
NCT00581048|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|2018-01-10||2018-03-02|2007-12-22|2007-12-27|Estimate|2018-01-10|2018-02-06|Actual||||2018-03-02|2018-03-29|Actual|December 2006||2006-12-31|March 2018|2018-03-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics|Oxidant Stress and Allergic Asthma|Completed||N/A|33|Actual|Vanderbilt University Medical Center||1|||f||||t||||||||||2018-06-01 02:38:08.589034|2018-06-01 02:38:08.589034
NCT00581035|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-26|2007-12-26|2007-12-27|Estimate|||||||2007-12-26|2007-12-27|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time|A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants|Completed||Phase 4|712|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 02:38:08.837026|2018-06-01 02:38:08.837026
NCT00581022|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2017-03-22|2007-12-22|2007-12-27|Estimate|||||||2017-03-22|2017-03-27|Actual|November 2006||2006-11-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Objective Sleep Disturbances in Orthostatic Intolerance|Assessment of Objective Sleep Disturbances in Orthostatic Intolerance|Completed|||100|Anticipated|Vanderbilt University Medical Center|||1||f||||f||||||||||2018-06-01 02:38:08.893432|2018-06-01 02:38:08.893432
NCT00581009|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2010-11-01|2007-12-26|2007-12-27|Estimate|||||||2010-11-01|2010-11-02|Estimate|March 2001||2001-03-31|November 2010|2010-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients|The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients|Unknown status|Recruiting|Phase 1/Phase 2|180|Anticipated|University of California, Irvine||3|||f||||f||||||||||2018-06-01 02:38:08.962119|2018-06-01 02:38:08.962119
NCT00580996|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-22|||2018-03-26|2007-12-22|2007-12-27|Estimate|||||||2018-03-26|2018-03-27|Actual|July 2006||2006-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Water and the Gastropressor Response - Tachyphylaxis|Water and the Gastropressor Response - Tachyphylaxis (Specific Aim 1.2)|Active, not recruiting||N/A|20|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 02:38:09.048008|2018-06-01 02:38:09.048008
NCT00580983|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2014-11-05||2016-07-28|2007-12-26|2007-12-27|Estimate|2014-11-13|2014-11-14|Estimate||||2016-07-28|2016-09-07|Estimate|August 2003||2003-08-31|July 2016|2016-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||90 patients were enrolled. Only 80 patients were treated and 7 patients did not complete the 12 month post-Radiation Therapy (RT) swallowing studies. Therefore only 73 participants were included in the baseline analysis.|Optimized Intensity Modulated Irradiation for Head and Neck Cancer|Optimized Intensity Modulated Irradiation for Head and Neck Cancer|Completed||N/A|90|Actual|University of Michigan Cancer Center|No modeling of observer-rated posttherapy dysphagia was performed because of the small number (four) of patients with greater than, or equal to, Grade 2 after 6 months.|1|||f||||t||||||||||2018-06-01 02:38:09.131664|2018-06-01 02:38:09.131664
NCT00580593|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-07-09|2007-12-20|2007-12-24|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS)|Pilot Placebo-Controlled Trial of Early Noninvasive Ventilation for ALS|Completed||Phase 1|60|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 02:38:18.004345|2018-06-01 02:38:18.004345
NCT00580970|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2016-06-03||2016-09-28|2007-12-20|2007-12-27|Estimate|2016-09-28|2016-11-18|Estimate||||2016-09-28|2016-11-18|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Between April 12, 2007 and May 30, 2013, 73 consecutive patients enrolled in the study. A total of 20 patients did not complete at least 6 months of Lovastatin treatment and were deemed ineligible for the purpose of assessing late rectal toxicity and additional patients were enrolled in order to achieve the accrual goal of 53 evaluable patients.|Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury|A Phase II Study to Prevent Radiation-Induced Rectal Injury With Lovastatin|Completed||Phase 2|73|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 02:38:09.419457|2018-06-01 02:38:09.419457
NCT00580957|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2015-05-29||2016-07-06|2007-12-20|2007-12-27|Estimate|2015-05-29|2015-06-17|Estimate||||2016-07-06|2016-08-05|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Autonomic Nervous System and the Metabolic Syndrome|The Autonomic Nervous System and the Metabolic Syndrome|Completed||N/A|56|Actual|Vanderbilt University||2|||f||||f||||||||Undecided||2018-06-01 02:38:09.729208|2018-06-01 02:38:09.729208
NCT00580944|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-02-08|2007-12-26|2007-12-27|Estimate|||||||2017-02-08|2017-02-10|Actual|April 2007||2007-04-30|February 2017|2017-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Combined Alexandrite and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks|Combined Alexandrite and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks|Withdrawn||Phase 1|0|Actual|University of California, Irvine||1||No participant enrolled|f||||f||||||||||2018-06-01 02:38:09.977048|2018-06-01 02:38:09.977048
NCT00580931|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-24|||2017-01-23|2007-12-26|2007-12-27|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 2008|Actual|2008-01-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety Study of Nicotinamide to Treat Alzheimer's Disease|Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease|Completed||Phase 1/Phase 2|50|Actual|University of California, Irvine||2|||f||||f||||||||||2018-06-01 02:38:10.067333|2018-06-01 02:38:10.067333
NCT00580918|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-10-14|2007-12-26|2007-12-27|Estimate|||||||2010-10-14|2010-10-15|Estimate|October 2003||2003-10-31|October 2010|2010-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients|Functional MRI Study of Attention in Normal Controls and Traumatic Brain Injured Patients|Unknown status|Recruiting||40|Anticipated|University of California, Irvine|||2||f||||f||||||||||2018-06-01 02:38:10.13499|2018-06-01 02:38:10.13499
NCT00580905|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2018-02-27|2007-12-20|2007-12-27|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2007||2007-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Role of Adenosine in the Release of VEGF and Cytokines|Role of Adenosine in the Release of VEGF and Cytokines|Terminated||Phase 1|8|Actual|Vanderbilt University Medical Center||2||Not enough volunteer recruited before funding could be secured.|f||||f||||||||||2018-06-01 02:38:10.306664|2018-06-01 02:38:10.306664
NCT00580892|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-08-23|2007-12-26|2007-12-27|Estimate|||||||2017-08-23|2017-08-25|Actual|July 2007||2007-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Optical Coherence Tomography of Airway and Pleural Disorders|Optical Coherence Tomography of Airway and Pleural Disorders|Withdrawn|||0|Actual|University of California, Irvine|||1|Not a clinical trial study|f||||f||||||||||2018-06-01 02:38:10.390362|2018-06-01 02:38:10.390362
NCT00580879|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-01-07|2007-12-21|2007-12-27|Estimate|||||||2010-01-07|2010-01-11|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Does Antenatal Fetal Head Circumference Predict Anal Sphincter Injury, a Prospective Study|Does Antenatal Fetal Head Circumference Predict Anal Sphincter Injury, a Prospective Study|Completed|||80|Anticipated|University of California, Irvine|||||f||||t||||||||||2018-06-01 02:38:10.46934|2018-06-01 02:38:10.46934
NCT00580866|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2015-11-10||2016-07-22|2007-12-19|2007-12-27|Estimate|2016-07-22|2016-09-07|Estimate||||2016-07-22|2016-09-07|Estimate|September 2006||2006-09-30|July 2016|2016-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|JAS||Progressive Splinting Status Post Elbow Fractures and Dislocations|Multi-Center Controlled Trial of Static Progressive Splinting Status Post Elbow Fractures and Dislocations|Terminated||N/A|17|Actual|Vanderbilt University||2||low accrual|f||||f||||||||||2018-06-01 02:38:10.579824|2018-06-01 02:38:10.579824
NCT00580853|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2016-10-21||2018-01-12|2007-12-26|2007-12-27|Estimate|2017-01-20|2017-03-10|Actual||||2018-01-12|2018-02-08|Actual|April 2007||2007-04-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior|The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior|Completed||Phase 2|62|Actual|Yale University||3|||f||||t||||||||No||2018-06-01 02:38:10.913819|2018-06-01 02:38:10.913819
NCT00580840|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2011-12-14||2014-08-26|2007-12-26|2007-12-27|Estimate|2012-03-16|2012-03-19|Estimate||||2014-08-26|2014-09-05|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|DoseFlex||Dosing Flexibility Study in Patients With Rheumatoid Arthritis|A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.|Completed||Phase 4|333|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 02:38:11.317348|2018-06-01 02:38:11.317348
NCT00580827|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2007-12-25|2007-12-25|2007-12-27|Estimate|||||||2007-12-25|2007-12-27|Estimate|September 2003||2003-09-30|December 2007|2007-12-31||||March 2004|Actual|2004-03-31||Interventional|||Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers|Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers|Completed||N/A|126|Actual|Yale University||4|||f||||t||||||||||2018-06-01 02:38:12.420827|2018-06-01 02:38:12.420827
NCT00580814|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2011-04-06|2007-12-26|2007-12-27|Estimate|||||||2011-04-06|2011-04-08|Estimate|February 2006||2006-02-28|April 2011|2011-04-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|Brookhaven||Brain Dopamine Function in Adults With ADHD|Brain Dopamine Function in Adults With ADHD|Completed||N/A|24|Actual|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:38:12.48401|2018-06-01 02:38:12.48401
NCT00580801|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2013-03-07||2013-08-27|2007-12-26|2007-12-27|Estimate|2013-06-05|2013-07-12|Estimate||||2013-08-27|2013-09-09|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 4 Hepatitis C Infection|Completed||Phase 2|24|Actual|Tibotec BVBA||3|||f||||f||||||||||2018-06-01 02:38:12.569845|2018-06-01 02:38:12.569845
NCT00580580|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-07-19|2007-12-18|2007-12-24|Estimate|||||||2012-07-19|2012-07-23|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|March 2014|Anticipated|2014-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Detection of Coronary Stenosis With Intravenous Microbubbles|The Detection of Coronary Stenosis With Intravenous Mircrobubbles and Contrast Pulse Sequence Low Mechanical Index Imaging|Withdrawn||N/A|0|Actual|University of Nebraska||3|||f||||f||||||||||2018-06-01 02:38:18.090391|2018-06-01 02:38:18.090391
NCT00580788|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-04-25||2016-02-09|2007-12-26|2007-12-27|Estimate|2016-02-09|2016-02-11|Estimate||||2016-02-09|2016-02-11|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study|Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone-related Protein(1-36): Effects on Bone Formation|Completed||Early Phase 1|14|Actual|University of Pittsburgh|Small number of subjects in each group Study limited to Caucasians Only one timepoint for follow-up was measure Study did not include saline infused controls|4|||f||||t||||||||No||2018-06-01 02:38:13.192398|2018-06-01 02:38:13.192398
NCT00580775|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-01-20|2007-12-19|2007-12-27|Estimate|||||||2015-01-20|2015-01-22|Estimate|September 2005||2005-09-30|January 2015|2015-01-31|December 2010|Actual|2010-12-31|July 2008|Actual|2008-07-31||Observational|KEEPS||Study of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death|Effects of Early Hormone Replacement Therapy on Risk Factors for Sudden Cardiac Death: Autonomic Function and Ventricular Repolarization Heterogeneity ( A KEEPS Ancillary Study)|Completed|||25|Actual|Yale University|||2||f||||f||||||||||2018-06-01 02:38:15.090828|2018-06-01 02:38:15.090828
NCT00580762|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-09-02|2007-12-18|2007-12-27|Estimate|||||||2016-09-02|2016-09-07|Estimate|October 2005||2005-10-31|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Bariatric Surgery for ESRD Patients vs Control|Obesity, End-Stage Renal Disease and Kidney Transplantation|Terminated||N/A|5|Actual|Yale University||2||Lack of enrollment|f||||t||||||||||2018-06-01 02:38:15.150709|2018-06-01 02:38:15.150709
NCT00580749|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-01-26|2007-12-26|2007-12-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SNAP||Study of Nutrition in Acute Pancreatitis|Feeding and Pancreatic Rest in Acute Pancreatitis|Terminated||N/A|23|Actual|University of Pittsburgh||2||not meeting enrollment criteria|f||||t||||||||||2018-06-01 02:38:15.296725|2018-06-01 02:38:15.296725
NCT00580736|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-02-08|2007-12-26|2007-12-27|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2004||2004-03-31|February 2017|2017-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Optical Clearing of the Skin in Conjunction With Laser Treatments|Optical Clearing of the Skin in Conjunction With Laser Treatments|Completed||Phase 1|35|Actual|University of California, Irvine||1|||f||||f||||||||||2018-06-01 02:38:15.371333|2018-06-01 02:38:15.371333
NCT00580723|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-03-18||2013-12-16|2007-12-21|2007-12-27|Estimate|2013-10-14|2013-12-10|Estimate||||2013-12-16|2014-01-17|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effects of PRK 124 Lotion in Acne Rosacea|Effects of PRK 124 (0.125%) Lotion in Acne Rosacea|Completed||Phase 1/Phase 2|24|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 02:38:15.464511|2018-06-01 02:38:15.464511
NCT00580710|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-01-12|2007-12-19|2007-12-27|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2001||2001-08-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Investigation Into the Effects Upon Brain Response to Change in Cirucating Glose Levels in Diabetes Mellitus|Investigation Into the Effects Upon Brain Response to Change in Cirucating Glose Levels in Diabetes Mellitus|Recruiting|||250|Anticipated|Yale University|||7||f||||t||||||||||2018-06-01 02:38:15.658836|2018-06-01 02:38:15.658836
NCT00580697|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2010-05-06|2007-12-19|2007-12-27|Estimate|||||||2010-05-06|2010-05-10|Estimate|January 2006||2006-01-31|May 2010|2010-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Prevalence of Lower Urinary Tract Symptoms in Women With Gynecologic Malignancy Planning to Undergo Surgical Management|Prevalence of Lower Urinary Tract Symptoms in Women With Gynecologic Malignancy Planning to Undergo Surgical Management|Unknown status|Active, not recruiting||100|Anticipated|University of California, Irvine|||||f||||t||||||||||2018-06-01 02:38:15.762315|2018-06-01 02:38:15.762315
NCT00580684|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2007-12-27|Estimate|||||||2007-12-21|2007-12-27|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children|Long-Term Efficacy of Pneumococcal Conjugate 7-Valent Vaccine Versus Plain Polisaccharide Pneumococcus Vacine in Reducing Pneumococcal Nasopharyngeal Carriage of Children.|Completed||Phase 4|101|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:38:15.818143|2018-06-01 02:38:15.818143
NCT00580671|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2013-03-25||2015-07-30|2007-12-26|2007-12-27|Estimate|2013-06-04|2013-06-05|Estimate||||2015-07-30|2015-08-20|Estimate|November 2007||2007-11-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional|||Treatment for Adolescent Marijuana Abuse|Behavioral Treatment of Adolescent Marijuana Use|Completed||N/A|153|Actual|Dartmouth-Hitchcock Medical Center||3|||f||||f||||||||||2018-06-01 02:38:15.895979|2018-06-01 02:38:15.895979
NCT00580658|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2016-05-11|2007-12-22|2007-12-27|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2006||2006-05-31|May 2016|2016-05-31|May 2020|Anticipated|2020-05-31|||||Expanded Access|Dystonia IRB||Humanitarian Device Exemption|Humanitarian Device Exemption for Medtronic Activa Dystonia Therapy|Approved for marketing|||||Vanderbilt University|||||||||||||||||||2018-06-01 02:38:16.234702|2018-06-01 02:38:16.234702
NCT00580645|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|2017-11-20||2018-01-08|2007-12-26|2007-12-27|Estimate|2018-01-08|2018-02-07|Actual||||2018-01-08|2018-02-07|Actual|April 2007|Actual|2007-04-30|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Do Treatments for Smoking Cessation Affect Alcohol Drinking?|Do Treatments for Smoking Cessation Affect Alcohol Drinking?|Completed||Phase 2|60|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:38:16.303616|2018-06-01 02:38:16.303616
NCT00580632|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2010-05-13|2007-12-26|2007-12-27|Estimate|||||||2010-05-13|2010-05-14|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Study Evaluating Workload, Clinical and Therapeutic Management of Psoriatic Arthritis|Workload, Clinical and Therapeutic Management of Psoriatic Arthritis|Completed|||300|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 02:38:16.677753|2018-06-01 02:38:16.677753
NCT00580619|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2017-01-16|2007-12-20|2007-12-27|Estimate|||||||2017-01-16|2017-01-18|Estimate|April 2007||2007-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|CFS&ANS||Autonomic Nervous System and Chronic Fatigue Syndrome|Autonomic Nervous System and Chronic Fatigue Syndrome|Completed||Phase 1|170|Actual|Vanderbilt University Medical Center||4|||f||||t||||||||No||2018-06-01 02:38:16.723946|2018-06-01 02:38:16.723946
NCT00580606|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2012-09-28|2011-08-26|2015-12-15|2007-12-21|2007-12-25|Estimate|2012-09-28|2012-10-30|Estimate|2011-08-26|2011-09-02|Estimate|2015-12-15|2016-01-22|Estimate|December 2007||2007-12-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2010|Actual|2010-12-31||Interventional|||A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial|Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Pilot Study With a Whole Peanut Extract|Completed||Phase 1/Phase 2|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Refer to the original results published in the Journal of Allergy and Clinical Immunology, Vol 135, Number 5, page 1247 for a full description of the limitations of the current study.|2|||f||||t||||||||||2018-06-01 02:38:16.952282|2018-06-01 02:38:16.952282
NCT00580567|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-06-03|2007-12-20|2007-12-24|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2007||2007-03-31|June 2013|2013-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Impulsivity in Pathological Gambling|Impulsivity in Pathological Gambling: A Cross Sectional Analysis on Tests of Impulsivity Between Pathological Gamblers and a Non-pathological Control Group.|Completed|||120|Actual|University of California, Los Angeles|||2||f||||f||||||||||2018-06-01 02:38:18.162421|2018-06-01 02:38:18.162421
NCT00580541|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-04-19|2007-12-21|2007-12-24|Estimate|||||||2012-04-19|2012-04-20|Estimate|August 2007||2007-08-31|December 2007|2007-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Liking on Fruit Intake||Completed||N/A|20|Actual|The Miriam Hospital|||||f||||f||||||||||2018-06-01 02:38:18.226537|2018-06-01 02:38:18.226537
NCT00580528|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2013-05-20|2007-12-17|2007-12-24|Estimate|||||||2013-05-20|2013-05-22|Estimate|August 2006||2006-08-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Reducing Blood Pressure in Prehypertensive Older Rural Women Also Known as Wellness for Women: DASHing Toward Health|Modifying Lifestyle in Prehypertensive Older Rural Women|Completed||N/A|289|Actual|University of Nebraska||3|||f||||f||||||||||2018-06-01 02:38:18.298557|2018-06-01 02:38:18.298557
NCT00580515|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-01-02|2007-12-20|2007-12-24|Estimate|||||||2018-01-02|2018-01-03|Actual|November 2005||2005-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Family Focused Grief Therapy in Palliative Care and Bereavement|Randomized Controlled Trial of Family Focused Grief Therapy in Palliative Care and Bereavement|Active, not recruiting||N/A|700|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 02:38:18.37212|2018-06-01 02:38:18.37212
NCT00580502|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|2014-12-29||2015-03-16|2007-12-21|2007-12-24|Estimate|2015-03-16|2015-03-23|Estimate||||2015-03-16|2015-03-23|Estimate|March 2004||2004-03-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|LBMI||Safety and Efficacy of Adjustable Gastric Band Operations for Patients With Body Mass Index (BMI) Between 30-40 kg/m2|A Prospective Study to Evaluate the Safety and Efficacy of LAP-BAND® Adjustable Gastric Band (LAGB®) Operations for Patients With BMI Between 30-40 kg/m2 With Co-morbidities|Completed||Phase 2/Phase 3|50|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 02:38:18.462125|2018-06-01 02:38:18.462125
NCT00580489|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2007-12-24|Estimate|||||||2007-12-21|2007-12-24|Estimate|August 2006||2006-08-31|December 2007|2007-12-31||||December 2008|Anticipated|2008-12-31||Interventional|||Lifeflight: Fentanyl Versus Morphine|Efficacy and Adverse Events of Morphine and Fentanyl in an Aeromedical Setting|Unknown status|Recruiting|N/A|200|Anticipated|MetroHealth Medical Center||2|||f||||f||||||||||2018-06-01 02:38:18.736159|2018-06-01 02:38:18.736159
NCT00580476|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-11-06|2007-12-19|2007-12-24|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2006||2006-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessing Depression in a Geriatric Cancer Population|Assessing Depression in a Geriatric Cancer Population|Active, not recruiting|||201|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||||||2018-06-01 02:38:18.819663|2018-06-01 02:38:18.819663
NCT00580463|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-03-18|2007-12-20|2007-12-24|Estimate|||||||2009-03-18|2009-03-19|Estimate|January 2000||2000-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors|Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors|Completed|||1128|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Blood Spinal fluid~   "|||2018-06-01 02:38:18.901684|2018-06-01 02:38:18.901684
NCT00580450|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2007-12-24|Estimate|||||||2007-12-21|2007-12-24|Estimate|December 2007||2007-12-31|November 2007|2007-11-30|December 2010|Anticipated|2010-12-31|December 2007|Actual|2007-12-31||Interventional|||Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies|Phase I/II Clinical Trial on Thymosin Alfa 1 of Allogeneic Hematopoietic Transplantation|Unknown status|Not yet recruiting|Phase 1/Phase 2|9|Anticipated|University Of Perugia||2|||f||||t||||||||||2018-06-01 02:38:18.956159|2018-06-01 02:38:18.956159
NCT00580437|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2011-08-02|2007-12-21|2007-12-24|Estimate|||||||2011-08-02|2011-08-03|Estimate|April 2003||2003-04-30|August 2011|2011-08-31|April 2012|Anticipated|2012-04-30|March 2012|Anticipated|2012-03-31||Interventional|||Pre-operative Evaluation of Kidney & Pancreas Transplant Patients|The Analysis of Data Collected During Angiography and Dobutamine Stress Contrast Echocardiograms in the Pre-Evaluation of Kidney and Pancreas Transplant Patients|Unknown status|Active, not recruiting|N/A|150|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:38:19.036373|2018-06-01 02:38:19.036373
NCT00580424|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-06-24|2007-12-18|2007-12-24|Estimate|||||||2010-06-24|2010-06-28|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|July 2009|Anticipated|2009-07-31|||||Interventional|||The Effect of the Mini-pill on Blood Factors in Women at Increased Risk for Forming Blood Clots|The Effect of Oral Norethindrone on Coagulation Parameters in Women at Increased Risk for Venous Thromboembolic Events|Terminated||N/A|20|Anticipated|University of Vermont|||||f||||t||||||||||2018-06-01 02:38:19.103598|2018-06-01 02:38:19.103598
NCT00580411|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-01-10|2007-12-19|2007-12-24|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2007||2007-03-31|October 2015|2015-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||A Timeline Study of Alcohol Use and Its Relationship to Insomnia|A Timeline Study of Alcohol Use and Its Relationship to Insomnia|Completed|||75|Actual|National Institute on Drug Abuse (NIDA)|||2||f||||f||||||||||2018-06-01 02:38:19.163167|2018-06-01 02:38:19.163167
NCT00580398|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2013-05-15||2014-11-20|2007-12-21|2007-12-24|Estimate|2014-11-20|2014-11-21|Estimate||||2014-11-20|2014-11-21|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Smoking Cessation Intervention for Thoracic Patients|A Pilot Smoking Cessation Study for Newly Diagnosed Lung Cancer Patients|Completed||Phase 1/Phase 2|49|Actual|Massachusetts General Hospital|The generalizability of the findings are limited by a single study site. The statistical power to detect differences was limited by the small sample size of this pilot study.|2|||f||||f||||||||||2018-06-01 02:38:19.242565|2018-06-01 02:38:19.242565
NCT00580385|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-09-05|2007-12-21|2007-12-24|Estimate|||||||2017-09-05|2017-09-06|Actual|August 1997||1997-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors|Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors|Recruiting||N/A|750|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:38:19.558463|2018-06-01 02:38:19.558463
NCT00580372|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2016-08-01||2016-08-01|2007-12-18|2007-12-24|Estimate|2016-08-01|2016-09-20|Estimate||||2016-08-01|2016-09-20|Estimate|August 2002||2002-08-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||"UARK 89-001 Phase II Study of Intensive TOTAL THERAPY For Untreated or Minimally Treated Patients With Multiple Myeloma"|"Phase II Study of Intensive TOTAL THERAPY for Untreated or Minimally Treated Patients With Multiple Myeloma"|Completed||Phase 2|231|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:38:19.686832|2018-06-01 02:38:19.686832
NCT00580359|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-26|2007-12-21|2007-12-24|Estimate|||||||2007-12-26|2008-01-08|Estimate|May 2007||2007-05-31|December 2007|2007-12-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||S-1 vs Capecitabine in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer|A Randomized Phase II Study of S-1 Versus Capecitabine as First-Line Chemotherapy in the Elderly and/or Poor Performance Status Patients With Recurrent or Metastatic Gastric Cancer|Unknown status|Recruiting|Phase 2|96|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 02:38:20.093195|2018-06-01 02:38:20.093195
NCT00580346|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-02-17|2007-12-21|2007-12-24|Estimate|||||||2009-02-17|2009-02-18|Estimate|August 2004||2004-08-31|January 2009|2009-01-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Dynamic Laryngotracheal Separation for Aspiration|Dynamic Laryngotracheal Separation for Aspiration. Prevention of Silent Aspiration Pneumonia During Swallowing by an Implanted Stimulator|Suspended||Phase 1|3|Anticipated|University Hospitals Cleveland Medical Center||1||Protocol currently reviewed for updating|f||||f||||||||||2018-06-01 02:38:20.177824|2018-06-01 02:38:20.177824
NCT00580333|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-04-02||2017-07-25|2007-12-20|2007-12-24|Estimate|2017-03-22|2017-03-31|Actual||||2017-07-25|2017-08-25|Actual|September 2007||2007-09-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|December 2010|Actual|2010-12-31||Interventional||stage 2 or 3 triple negative breast cancer|Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer|A Phase II Trial of Preoperative Cisplatin and Bevacizumab in Estrogen Receptor (ER) Negative, Progesterone (PR) Negative, Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer|Active, not recruiting||Phase 2|51|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 02:38:20.291768|2018-06-01 02:38:20.291768
NCT00580320|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-08-17|2007-12-18|2007-12-24|Estimate|||||||2016-08-17|2016-08-18|Estimate|September 2004||2004-09-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|October 2009|Actual|2009-10-31||Interventional|||Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma|Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma|Completed||Phase 1|17|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 02:38:20.488136|2018-06-01 02:38:20.488136
NCT00580307|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2016-09-29|2007-12-18|2007-12-24|Estimate|||||||2016-09-29|2016-09-30|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|RHINO||Rhinogenic Headache Improvement After Nasal Operation|Surgical Correction of Contact Point Headaches - Randomized Controlled Trial. [Rhinogenic Headache Improvement After Nasal Operation] Trial|Terminated||N/A|6|Actual|University of Missouri-Columbia||2||slow accrual|f||||f||||||||Undecided||2018-06-01 02:38:20.573024|2018-06-01 02:38:20.573024
NCT00580294|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2015-11-25||2016-01-04|2007-12-19|2007-12-24|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|November 2007||2007-11-30|January 2016|2016-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)|A Pilot Study of Rapid Opioid Rotation and Titration of Oxymorphone|Completed||N/A|12|Actual|Icahn School of Medicine at Mount Sinai|This was a pilot open-label study in a small number of participants. A larger randomized study with long-term follow-up and comparison to traditional protocols is necessary to affirm safety. (12 pts had 6 different chronic non-cancer pain diagnoses.)|1|||f||||f||||||||||2018-06-01 02:38:20.647972|2018-06-01 02:38:20.647972
NCT00580281|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-10-23|2007-12-19|2007-12-24|Estimate|||||||2013-10-23|2013-10-24|Estimate|November 2006||2006-11-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors|Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors.|Completed||N/A|33|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:38:20.878202|2018-06-01 02:38:20.878202
NCT00580268|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2014-08-11|2007-12-20|2007-12-24|Estimate|||||||2014-08-11|2014-08-12|Estimate|August 2005||2005-08-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|December 2010|Actual|2010-12-31||Observational|||Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity|Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity|Completed|||118|Actual|Massachusetts General Hospital|||1||f||||t||||||Samples With DNA|"~     serum, plasma, urine, whole blood, saliva, amniotic fluid, breast milk~   "|||2018-06-01 02:38:20.962102|2018-06-01 02:38:20.962102
NCT00580255|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-06-19|2007-12-20|2007-12-24|Estimate|||||||2017-06-19|2017-06-21|Actual|October 2006||2006-10-31|January 2013|2013-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Comparison Study of BNP and Thoracic Impedance Measurements on Arrhythmias|Does Elevated Brain Natriuretic Peptide (BNP) Reflect Changes in Thoracic Impedance Levels and Affect Occurrence of Atrial and Ventricular Arrhythmias?|Withdrawn|||0|Actual|University of California, Davis||||resources not available|f||||f||||||Samples Without DNA|"~     Teaspoon of blood drawn for testing of BNP levels.~   "|||2018-06-01 02:38:21.026298|2018-06-01 02:38:21.026298
NCT00580242|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2012-03-06|2007-12-21|2007-12-24|Estimate|||||||2012-03-06|2012-03-08|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia|A Phase I Dose Escalating Study of Bortezomib and Lenalidomide in Patients With Untreated or Previously Treated, Primary and Secondary Non 5q- Del Myelodysplasia|Completed||Phase 1|23|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 02:38:21.088973|2018-06-01 02:38:21.088973
NCT00580229|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-05-28||2016-08-10|2007-12-18|2007-12-24|Estimate|2016-08-10|2016-10-04|Estimate||||2016-08-10|2016-10-04|Estimate|December 2007||2007-12-31|May 2016|2016-05-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.|A Safety Analysis of Oral Prednisone as a Pre-Treatment for Rituximab in Rheumatoid Arthritis.|Completed||Phase 2/Phase 3|50|Actual|University of South Florida|An area of weakness to the study was the lack of direct comparison group.This was a single university study with two sites the cost,practicality of performing a noninferiority trial comparing these two pretreatment strategies was not feasible.|1|||f||||f||||||||No||2018-06-01 02:38:21.203714|2018-06-01 02:38:21.203714
NCT00580216|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21||2016-02-19|2016-02-19|2007-12-21|2007-12-24|Estimate||||2016-02-19|2016-03-21|Estimate|2016-02-19|2016-03-21|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|BOREALIS-AF||Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation|A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation|Terminated||Phase 3|3773|Actual|Sanofi||2||early discontinuation based on strategic sponsor decision not driven by any safety concern|f||||t||||||||||2018-06-01 02:38:21.458659|2018-06-01 02:38:21.458659
NCT00580203|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-11-06|2007-12-19|2007-12-24|Estimate|||||||2017-11-06|2017-11-08|Actual|February 2004||2004-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers|Collection of Tissue, Blood, and Other Specimens From Patients With Head and Neck Diseases to Study the Causes, Diagnosis, Prevention and Treatment of Cancers|Active, not recruiting|||1307|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Tissue and peripheral blood~   "|||2018-06-01 02:38:22.811112|2018-06-01 02:38:22.811112
NCT00580190|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-09-11|2007-12-20|2007-12-24|Estimate|||||||2009-09-11|2009-09-14|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|February 2008|Actual|2008-02-29|||||Interventional|||Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects|A Phase I, Randomized, Placebo Controlled, Parallel Group, Single Dose Study To Evaluate The Effects Of PF-00572778 And Alprazolam On A Naloxone Challenge In Healthy Adult Subjects|Terminated||Phase 1|47|Actual|Pfizer||3||"Date of termination was Feb. 7, 2008. Reasons of termination were due to elevation of liver~   function tests and long elimination half-life of the compound."|f||||f||||||||||2018-06-01 02:38:22.8904|2018-06-01 02:38:22.8904
NCT00580177|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2007-12-21|2007-12-21|2007-12-24|Estimate|||||||2007-12-21|2007-12-24|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|BOOP||PHS, Lichtenstein Mesh, and PerFixPlug for Primary Inguinal Hernia Repair - 3 Years Results|Prolene Hernia System, Lichtenstein Mesh, and Plug-and-Patch for Primary Inguinal Hernia Repair - Three Year Outcome of a Prospective Randomised Controlled Trial|Completed||Phase 4|472|Actual|Göteborg University||3|||f||||f||||||||||2018-06-01 02:38:22.980102|2018-06-01 02:38:22.980102
NCT00580164|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-12-29|2007-12-20|2007-12-24|Estimate|||||||2015-12-29|2015-12-30|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Observational|||The Role of Splinting in Fingertip Injuries|The Role of Splinting in Fingertip Injuries|Withdrawn|||0|Actual|Massachusetts General Hospital|||2|Very few subjects were enrolled. Therefore, the study was terminated.|f||||f||||||||||2018-06-01 02:38:23.088236|2018-06-01 02:38:23.088236
NCT00580151|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-02-08||2015-02-10|2007-12-21|2007-12-24|Estimate|2015-02-10|2015-02-23|Estimate||||2015-02-10|2015-02-23|Estimate|June 2004||2004-06-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|clonidine||The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children|The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children|Terminated||N/A|9|Actual|The University of Texas Medical Branch, Galveston|No Adverse Events Recorded.|2||Closed due to no response from PI to IRB|f||||f||||||||||2018-06-01 02:38:23.163251|2018-06-01 02:38:23.163251
NCT00580138|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-05-06||2017-01-04|2007-12-20|2007-12-24|Estimate|2010-05-06|2010-06-07|Estimate||||2017-01-04|2017-02-20|Actual|May 2005||2005-05-31|January 2017|2017-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Real-Time Internet Evaluation of Swallowing|Real-Time Internet Evaluation of Oropharyngeal Dysphagia|Completed|||30|Actual|University of Arkansas|||1||f||||f||||||||||2018-06-01 02:38:23.383546|2018-06-01 02:38:23.383546
NCT00580125|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2009-09-09|2012-04-16|2007-12-20|2007-12-24|Estimate||||2009-09-09|2009-09-11|Estimate|2012-04-16|2012-04-18|Estimate|November 2007||2007-11-30|January 2011|2011-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia|A Phase 2, Multicenter, Double-Blind, Randomized, Fixed Dose, Parallel Group, 3-Week Inpatient Treatment Study To Evaluate The Dose-Response Relationship, Safety, Efficacy, And Pharmacokinetics Of PF-00217830 Compared With Placebo, Using Aripiprazole As A Positive Control, In The Treatment Of Acute Exacerbation Of Schizophrenia|Completed||Phase 2|164|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 02:38:23.507468|2018-06-01 02:38:23.507468
NCT00580112|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2014-02-24|2007-12-20|2007-12-24|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2007||2007-06-30|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer|Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients With Triple Negative Profile (ER-, PR-, HER2-), HER2 Overexpressing Tumors and BRCA1 or BRCA2 Mutation Carriers|Completed||Phase 2|127|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 02:38:23.635564|2018-06-01 02:38:23.635564
NCT00580099|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-04-08|2007-12-18|2007-12-24|Estimate|||||||2011-04-08|2011-04-11|Estimate|September 2005||2005-09-30|April 2011|2011-04-30|March 2012|Anticipated|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Assisted Exercise in Prematurity; Effects and Mechanisms|Assisted Exercise in Prematurity; Effects and Mechanisms|Unknown status|Recruiting|N/A|100|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-06-01 02:38:23.835245|2018-06-01 02:38:23.835245
NCT00580086|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-12-23|2007-12-20|2007-12-24|Estimate|||||||2009-12-23|2009-12-24|Estimate|November 2006||2006-11-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Monitoring Response to Neoadjuvant Chemotherapy by the Use of Breast Proton MR Spectroscopy|Monitoring Response to Neoadjuvant Chemotherapy by the Use of Breast Proton MR Spectroscopy|Completed|||19|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||t||||||||||2018-06-01 02:38:23.929172|2018-06-01 02:38:23.929172
NCT00580073|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2016-12-05||2017-03-20|2007-12-21|2007-12-24|Estimate|2017-03-20|2017-05-01|Actual||||2017-03-20|2017-05-01|Actual|December 2007||2007-12-31|March 2017|2017-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum|A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum|Terminated||Phase 2|6|Actual|University of Wisconsin, Madison|Study closed due to withdrawal of funding.|1||Loss of funding|f||||t||||||||||2018-06-01 02:38:24.012988|2018-06-01 02:38:24.012988
NCT00580060|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2011-06-09|2007-12-21|2007-12-24|Estimate|||||||2011-06-09|2011-06-10|Estimate|December 2003||2003-12-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity|Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity|Completed||Early Phase 1|20|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:38:24.189333|2018-06-01 02:38:24.189333
NCT00579332|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-04-26|2007-12-21|2007-12-24|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2005||2005-01-31|April 2016|2016-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Effects of Brassica or Indole-3-carbinol on Prostatectomy Patients With PSA Recurrence|Effects of Brassica or Indole-3-Carbinol on Prostatectomy Patients With PSA Recurrenc|Completed||Phase 2/Phase 3|16|Actual|Vanderbilt University||3|||f||||t||||||||||2018-06-01 02:38:36.768674|2018-06-01 02:38:36.768674
NCT00580047|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2016-01-18||2018-03-15|2007-12-21|2007-12-24|Estimate|2018-03-15|2018-03-19|Actual||||2018-03-15|2018-03-19|Actual|December 2003||2003-12-31|March 2018|2018-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Men and women post kidney or kidney pancreas transplantation|Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants|Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplant|Completed||N/A|59|Actual|University of Nebraska|Small sample sizes and missing data.|3|||f||||t||||||||No||2018-06-01 02:38:24.264|2018-06-01 02:38:24.264
NCT00580034|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-02-05||2014-05-02|2007-12-21|2007-12-24|Estimate|2014-05-02|2014-06-03|Estimate||||2014-05-02|2014-06-03|Estimate|February 2003||2003-02-28|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Cohort of patients who actually received at least 1 donor lymphocyte infusion (DLI). DLI dosages thus ranged from 1×104 CD3+ cells/kg to 3.27 ×108 CD3+ cells/kg.|Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath|Allogeneic (Allo) Non-Myeloablative Stem Cell Transplantation (SCT) Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath-1H|Completed||Phase 2|176|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:38:24.618466|2018-06-01 02:38:24.618466
NCT00580021|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2016-01-27|2007-12-19|2007-12-24|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Clinical Outcomes in Hereditary Cancer|Clinical Outcomes in Hereditary Cancer|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Once potential subjects are identified, pathology records will be reviewed to establish which~     of the potential subjects have archived pathology material available at MSKCC. It is~     important to note that the material does not have to be tumor and, in fact, benign tissue,~     such as uninvolved lymph node, will be sought by preference. However, tumor tissue will be~     used if no benign tissue is available.~   "|||2018-06-01 02:38:24.845632|2018-06-01 02:38:24.845632
NCT00580008|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2016-04-19|2007-12-21|2007-12-24|Estimate|||||||2016-04-19|2016-04-21|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|ELUCIDATE)||Evaluation Using Computed Tomography Angiography (CTA) to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)|Evaluation Using CTA to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)|Completed|||178|Actual|William Beaumont Hospitals|||||f||||t||||||Samples With DNA|"~     Serum banking~   "|||2018-06-01 02:38:24.91737|2018-06-01 02:38:24.91737
NCT00579995|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-06-25|2007-12-21|2007-12-24|Estimate|||||||2010-06-25|2010-06-28|Estimate|May 2005||2005-05-31|June 2010|2010-06-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|PROTECt||A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate|A Prospective, Randomized Trial Comparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Cardiac Catheterization|Unknown status|Recruiting|N/A|140|Anticipated|University of Nebraska||2|||f||||f||||||||||2018-06-01 02:38:24.975804|2018-06-01 02:38:24.975804
NCT00579982|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-06-04||2016-11-02|2007-12-20|2007-12-24|Estimate|2009-06-12|2009-08-03|Estimate||||2016-11-02|2016-12-16|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder|An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects With a Mood Disorder|Completed||Phase 3|97|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:38:25.106414|2018-06-01 02:38:25.106414
NCT00579969|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-01-29|2007-12-21|2007-12-24|Estimate|||||||2010-01-29|2010-02-01|Estimate|December 2003||2003-12-31|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Comparison of Latanoprost Vs. Timolol|Comparison of the Effects of Latanoprost and Timolol on Aqueous Humor Dynamics in Ocular Hypertensive Patients|Completed||Phase 2|30|Anticipated|University of Nebraska||2|||f||||f||||||||||2018-06-01 02:38:25.554481|2018-06-01 02:38:25.554481
NCT00579956|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2008-06-03|2007-12-18|2007-12-24|Estimate|||||||2008-06-03|2008-06-04|Estimate|December 2007||2007-12-31|August 2007|2007-08-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|ATOM||A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis|A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis|Unknown status|Recruiting|N/A|750|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 02:38:25.629733|2018-06-01 02:38:25.629733
NCT00579943|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2008-06-03|2007-12-21|2007-12-24|Estimate|||||||2008-06-03|2008-06-04|Estimate|May 2001||2001-05-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Regulation of Cerebral Blood Flow in Very Low Birth Weight Infants|Development of Cerebral Autoregulation in Very Low Birth Weight Infants|Completed|||200|Anticipated|University of Arkansas|||1||f||||f||||||||||2018-06-01 02:38:25.728939|2018-06-01 02:38:25.728939
NCT00579930|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2016-02-24|2007-12-21|2007-12-24|Estimate|||||||2016-02-24|2016-02-25|Estimate|December 1993||1993-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Cytogenetic and Molecular Genetic Studies in Bone Sarcomas|Cytogenetic and Molecular Genetic Studies in Bone Sarcomas|Completed|||1|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Tumor Tissue~   "|||2018-06-01 02:38:25.80739|2018-06-01 02:38:25.80739
NCT00579917|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2009-01-05|2007-12-21|2007-12-24|Estimate|||||||2009-01-05|2009-01-07|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|BMT/SCT||Behavioral Intervention For BMT/SCT Survivors|Cognitive Behavioral Intervention for BMT/SCT Survivors: Looking Forward|Completed|||133|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:38:25.876485|2018-06-01 02:38:25.876485
NCT00579904|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2017-04-20|2007-12-21|2007-12-24|Estimate|||||||2017-04-20|2017-04-24|Actual|April 2006||2006-04-30|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effects of Walnuts, Walnut-Oil, Almonds and Fish Oils on Glucose Homeostasis in Polycystic Ovary Syndrome|Walnuts, Walnut-Oil, Glucose Homeostasis, PCOS|Completed||N/A|96|Actual|University of California, Davis||2|||f||||t||||||||No||2018-06-01 02:38:25.998912|2018-06-01 02:38:25.998912
NCT00579891|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-02-01|2007-12-20|2007-12-24|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 1989||1989-03-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Tissue and Serum Collection From Colorectal Cancer Patients|Tissue and Serum Collection From Colorectal Cancer Patients|Active, not recruiting|||1000|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     serum tissue~   "|||2018-06-01 02:38:26.292906|2018-06-01 02:38:26.292906
NCT00579878|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2014-01-02|2007-12-21|2007-12-24|Estimate|||||||2014-01-02|2014-01-03|Estimate|December 1999||1999-12-31|January 2014|2014-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis|Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations (Leflunomide-Hydroxychloroquine-Sulfasalazine or Methotrexate-Hydroxychloroquine-Sulfasalazine) in the Treatment of Rheumatoid Arthritis|Completed||Phase 3|70|Actual|University of Nebraska||3|||f||||t||||||||||2018-06-01 02:38:26.517798|2018-06-01 02:38:26.517798
NCT00579865|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-01-13|2007-12-20|2007-12-24|Estimate|||||||2010-01-13|2010-01-14|Estimate|May 2005||2005-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Quality Of Life in Patients With Malignant Biliary Obstruction|Impact of Biliary Drainage on Quality Of Life in Patients With Malignant Biliary Obstruction|Completed|||124|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:38:26.866782|2018-06-01 02:38:26.866782
NCT00579852|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-01-31|2007-12-20|2007-12-24|Estimate|||||||2008-01-31|2008-02-01|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Assess the Variability of Uni-Dimensional, Bi-Dimensional, and Volumetric CT Scan Measurement of Non-Small Cell Lung Cancer Tumors|A Prospective Trial to Assess the Variability of Uni-Dimensional, Bi-Dimensional, and Volumetric CT Scan Measurement of Non-Small Cell Lung Cancer Tumors|Completed|||37|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:38:27.157053|2018-06-01 02:38:27.157053
NCT00579839|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-01-19|2007-12-18|2007-12-24|Estimate|||||||2012-01-19|2012-01-20|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Trial of Immediate vs. Delayed Cord Clamping in the Preterm Neonate|A Randomized Controlled Trial of Immediate Versus Delayed Cord Clamping in the Preterm Neonate|Completed||N/A|200|Actual|University of Oklahoma||2|||f||||t||||||||||2018-06-01 02:38:27.288077|2018-06-01 02:38:27.288077
NCT00579826|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2016-07-19||2018-01-15|2007-12-18|2007-12-24|Estimate|2017-01-04|2017-02-23|Actual||||2018-01-15|2018-02-12|Actual|October 2006||2006-10-31|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||All enrolled subjects|Study of Breast Cancer Prevention by Letrozole in High Risk Women|Study of Breast Cancer Prevention by Letrozole in High Risk Women|Completed||Phase 2|55|Actual|University of Kansas Medical Center||2|||f||||t||||||||No|Global results will be published.|2018-06-01 02:38:27.363406|2018-06-01 02:38:27.363406
NCT00579813|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2011-02-22||2017-05-24|2007-12-20|2007-12-24|Estimate|2011-06-13|2011-07-12|Estimate||||2017-05-24|2017-06-15|Actual|April 2005||2005-04-30|May 2017|2017-05-31|January 2011|Actual|2011-01-31|January 2009|Actual|2009-01-31||Interventional|||Mechanisms Underlying Metabolic Syndrome in Obesity|Mechanisms Underlying Metabolic Syndrome in Obesity|Completed||Phase 4|70|Actual|University of Kentucky||2|||f||||f|t|f|||f|||Yes|Data from this study has been published. Individual (deidentified) data will be shared with other investigators upon request to Dr Kern.|2018-06-01 02:38:27.991482|2018-06-01 02:38:27.991482
NCT00579800|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2016-05-09|2007-12-21|2007-12-24|Estimate|||||||2016-05-09|2016-05-10|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation|Newer Breast MRI Sequences for the Evaluation of Breast Cancer -FIESTA, Vibrant-DE and IDEAL: Feasibility Evaluation|Completed||N/A|76|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:38:28.251154|2018-06-01 02:38:28.251154
NCT00579787|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2010-11-30|2007-12-19|2007-12-24|Estimate|||||||2010-11-30|2010-12-02|Estimate|January 2004||2004-01-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Prospective Study Assessing Emotional, Sexual and Quality of Life Concerns Of Women Undergoing Removal of the Cervix Versus Removal of the Uterus,Ovaries and Fallopian Tubes For Treatment Of Early Stage Cervical Cancer|A Prospective Study Assessing the Emotional, Sexual and Quality of Life Concerns Of Women Undergoing Radical Trachelectomy Versus Radical Hysterectomy For Treatment Of Early Stage Cervical Cancer|Completed|||72|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:38:28.311615|2018-06-01 02:38:28.311615
NCT00579774|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-04-08|2007-12-21|2007-12-24|Estimate|||||||2014-04-08|2014-04-09|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2009|Actual|2009-10-31||Interventional|||Effects of Glycoxidative Stress on Human Aging|Effects of Glycoxidative Stress on Human Aging|Completed||N/A|438|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 02:38:28.369284|2018-06-01 02:38:28.369284
NCT00579761|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2015-12-10|2007-12-21|2007-12-24|Estimate|||||||2015-12-10|2015-12-14|Estimate||||December 2015|2015-12-31||||||||Observational|||Retrospective Review of Management of Infective Endocarditis|A Retrospective Review of the Management of Infective Endocarditis in Patients at Virginia Commonwealth University Medical Center From 1996-2006|Withdrawn|||0|Actual|Virginia Commonwealth University||||Per PI on 12/9/15 - No patients were ever enrolled in this study|f||||f||||||||||2018-06-01 02:38:28.506867|2018-06-01 02:38:28.506867
NCT00579748|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2007-12-21|2007-12-21|2007-12-24|Estimate|||||||2007-12-21|2007-12-24|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|August 2008|Anticipated|2008-08-31|||||Observational|OCT||Optical Coherence Tomography of the Gastrointestinal Tract|Optical Coherence Tomography of the Gastrointestinal Tract|Unknown status|Active, not recruiting||4|Actual|University of California, Irvine|||1||f||||t||||||Samples Without DNA|"~     pinch biopsies blood~   "|||2018-06-01 02:38:28.58173|2018-06-01 02:38:28.58173
NCT00579735|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-03-03|2007-12-21|2007-12-24|Estimate|||||||2015-03-03|2015-03-04|Estimate|March 2005||2005-03-31|March 2015|2015-03-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Observational|||Histologic Diagnoses of Incidentally Detected Lesions on MRI|Histologic Diagnoses of Incidentally Detected Lesions on MRI|Withdrawn|||0|Actual|University of Arkansas||||No subjects were ever enrolled. This study was closed at the IRB.|f||||f||||||||||2018-06-01 02:38:28.65986|2018-06-01 02:38:28.65986
NCT00579709|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-07-25|2007-12-20|2007-12-24|Estimate|||||||2017-07-25|2017-07-28|Actual|July 2002||2002-07-31|July 2017|2017-07-31|June 2027|Anticipated|2027-06-30|December 2006|Actual|2006-12-31||Interventional|884||Thymus Transplantation With Immunosuppression|Thymus Transplantation With Immunosuppression, #884|Active, not recruiting||Phase 1|15|Actual|Duke University||1|||f||||t|t|f||||||||2018-06-01 02:38:28.732813|2018-06-01 02:38:28.732813
NCT00579696|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-12-16|2007-12-21|2007-12-24|Estimate|||||||2015-12-16|2015-12-18|Estimate|February 2007||2007-02-28|December 2015|2015-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||The Queens Library HealthLink Project|The Queens Library HealthLink Project|Completed|||2789|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:38:28.8343|2018-06-01 02:38:28.8343
NCT00579319|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-03-03|2007-12-21|2007-12-24|Estimate|||||||2015-03-03|2015-03-04|Estimate|April 2005||2005-04-30|March 2015|2015-03-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Observational|||Use of Breast MRI for Local Staging|Use of Breast MRI for Local Staging|Withdrawn|||0|Actual|University of Arkansas||||There were no subjects ever enrolled. Study was closed at the IRB.|f||||f||||||||||2018-06-01 02:38:36.838085|2018-06-01 02:38:36.838085
NCT00579683|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2016-02-03|2007-12-20|2007-12-24|Estimate|||||||2016-02-03|2016-02-04|Estimate|August 2004||2004-08-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer|A Prospective Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer|Completed|||228|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Tumor biopsy material will be processed to obtain RNA for analysis of EGFR sequence.~     Sequencing of additional candidate genes and other studies will follow if sufficient material~     is available.~   "|||2018-06-01 02:38:28.905096|2018-06-01 02:38:28.905096
NCT00579670|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-04-02||2010-09-16|2007-12-20|2007-12-24|Estimate|2010-04-27|2010-05-17|Estimate||||2010-09-16|2010-09-21|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|TRITON||Treatment of Schizophrenic Patients With Ziprasidone|Treatment of Schizophrenic Patients With Geodon; Capsules/Oral Suspension/Solution for Injection (Ziprasidone)|Completed|||450|Actual|Pfizer|Additional descriptive tables were identified as required after review of the originally planned study tables; many subjects included in the tables had received ziprasidone doses above those specified in the summary of product characteristics (SmPC).||||f||||f||||||||||2018-06-01 02:38:29.107573|2018-06-01 02:38:29.107573
NCT00579657|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-03-06|2007-12-21|2007-12-24|Estimate|||||||2016-03-06|2016-03-08|Estimate|August 2007||2007-08-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|March 2010|Actual|2010-03-31||Interventional|PROFIMET||Protein, Fiber, and Metabolic Syndrome - The PROFIMET Study|Effects of High Protein and High Cereal Fiber Diets on Insulin Sensitivity in Overweight and Obese Subjects With the Metabolic Syndrome - The PROFIMET Study|Completed||N/A|111|Actual|German Institute of Human Nutrition||4|||f||||f||||||||||2018-06-01 02:38:31.700386|2018-06-01 02:38:31.700386
NCT00579644|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2018-01-12|2007-12-21|2007-12-24|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2001||2001-01-31|January 2018|2018-01-31|May 31, 2006|Actual|2006-05-31|May 31, 2006|Actual|2006-05-31||Interventional|||Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone|Treatment of Early Rheumatoid Arthritis: Minocycline in Combination With Methotrexate Versus Methotrexate Alone|Completed||Phase 3|91|Actual|University of Nebraska||2|||f||||t|t|f|||t|||||2018-06-01 02:38:31.784433|2018-06-01 02:38:31.784433
NCT00579631|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2018-01-12|2007-12-20|2007-12-24|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2004||2004-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Adolescent Survivors of Cancer or Similar Illnesses|Health Behaviors in Adolescent Survivors of Cancer or Similar Illnesses|Active, not recruiting|||148|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:38:31.861431|2018-06-01 02:38:31.861431
NCT00579618|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-07-28|2007-12-21|2007-12-24|Estimate|||||||2017-07-28|2017-07-31|Actual|September 2006|Actual|2006-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging|Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging|Completed|||53|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Saliva or blood samples~   "|||2018-06-01 02:38:31.924479|2018-06-01 02:38:31.924479
NCT00579605|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2007-12-21|2007-12-21|2007-12-24|Estimate|||||||2007-12-21|2007-12-24|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Motivational Interviewing to Promote Sustained Breastfeeding|Motivational Interviewing to Promote Sustained Breastfeeding (Native American Women)|Completed||N/A|11|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:38:31.991342|2018-06-01 02:38:31.991342
NCT00579592|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2012-06-22|2007-12-21|2007-12-24|Estimate|||||||2012-06-22|2012-06-26|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation|A Pilot Study of Campath-1H Induction Therapy Combined With Rituximab®, Myfortic™ and a Short Course of Calcineurin Inhibitor Therapy to Allow for a Long Term Calcineurin Inhibitor Free Regimen After Renal Transplantation|Terminated||N/A|11|Actual|University of Wisconsin, Madison||1||Higher than expected rate of acute rejection|f||||t||||||||||2018-06-01 02:38:32.059994|2018-06-01 02:38:32.059994
NCT00579579|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-10-03|2007-12-20|2007-12-24|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2006||2006-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Functional Outcomes and Quality of Life in Patients Undergoing Surgery for Rectal Cancer|Functional Outcomes and Quality of Life in Patients Undergoing Surgery for Rectal Cancer|Active, not recruiting|||229|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||t||||||||||2018-06-01 02:38:33.103532|2018-06-01 02:38:33.103532
NCT00579566|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-09-18|2007-12-19|2007-12-24|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2002|Actual|2002-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma|Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma|Recruiting|||3000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||Samples With DNA|"~     Tissue, Blood~   "|||2018-06-01 02:38:33.181813|2018-06-01 02:38:33.181813
NCT00579553|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2014-05-20|2007-12-21|2007-12-24|Estimate|||||||2014-05-20|2014-05-21|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparing IM vs. Vaginal Progesterone for Pre-term Birth|Comparing Intramuscular Versus Vaginal Progesterone for Prevention of Preterm Birth.|Completed||N/A|264|Actual|University of Oklahoma||2|||f||||t||||||||||2018-06-01 02:38:33.275966|2018-06-01 02:38:33.275966
NCT00579540|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2017-05-25|2007-12-21|2007-12-24|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2007||2007-09-30|May 2017|2017-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|PCOS||Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels|CCRC: Prevention of Post-Prandial Hypoglycemia Using n-3/n-6 PUFA in PCOS|Completed||N/A|66|Actual|University of California, Davis||3|||f||||t||||||||||2018-06-01 02:38:33.355444|2018-06-01 02:38:33.355444
NCT00579527|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2015-12-10|2017-07-25|2007-12-20|2007-12-24|Estimate||||2012-10-15|2012-10-17|Estimate|2017-07-25|2017-07-28|Actual|March 2006||2006-03-31|July 2017|2017-07-31|June 2027|Anticipated|2027-06-30|December 2011|Actual|2011-12-31||Interventional|#950||Phase I/II Thymus Transplantation With Immunosuppression #950|Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950|Active, not recruiting||Phase 1/Phase 2|28|Actual|Duke University||3|||f||||t||||||||||2018-06-01 02:38:33.437467|2018-06-01 02:38:33.437467
NCT00579514|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-10-03|2007-12-21|2007-12-24|Estimate|||||||2017-10-03|2017-10-04|Actual|March 2000||2000-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients|Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients|Recruiting||N/A|2530|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:38:33.547559|2018-06-01 02:38:33.547559
NCT00579501|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2014-01-28|2013-02-14|2014-04-22|2007-12-20|2007-12-24|Estimate|2014-01-28|2014-03-11|Estimate|2013-02-14|2013-02-20|Estimate|2014-04-22|2014-05-07|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma|A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma|Completed||Phase 2|29|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||t||||||||||2018-06-01 02:38:33.723357|2018-06-01 02:38:33.723357
NCT00579488|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-08-25|2007-12-21|2007-12-24|Estimate|||||||2017-08-25|2017-08-28|Actual|July 1996||1996-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Clinical Significance of Germline BRCA Mutations|Clinical Significance of Germline BRCA Mutations|Recruiting|||20000|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Blood, Saliva, Buccal cell, Urine or Stool Tissue analysis and correlation of germline~     findings with somatic alterations within the tumor will be performed on a subset of~     individuals who have tumor tissue stored under protocol #06-107. Patients will be asked to~     fill out a baseline questionnaire on other medical, hormonal, and environmental risk factors.~   "|||2018-06-01 02:38:34.055225|2018-06-01 02:38:34.055225
NCT00579475|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2015-05-22|2007-12-21|2007-12-24|Estimate|||||||2015-05-22|2015-05-25|Estimate|November 2004||2004-11-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||The Effect of Mifepristone on Uterine Fibroids and Breast Tissue|The Effect of Preoperative Treatment With Mifepristone on Uterine Fibroids and Breast Tissue|Completed||Phase 1|30|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 02:38:34.135728|2018-06-01 02:38:34.135728
NCT00579462|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2010-11-30|2007-12-19|2007-12-24|Estimate|||||||2010-11-30|2010-12-01|Estimate|January 2003||2003-01-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer|Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer|Completed|||281|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 02:38:34.222162|2018-06-01 02:38:34.222162
NCT00579449|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2014-09-19|2007-12-20|2007-12-24|Estimate|||||||2014-09-19|2014-09-22|Estimate|March 2005||2005-03-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of a Home Visiting Program for First Time Parents|Evaluation of a Home Visiting Program for First Time Parents|Completed||N/A|343|Actual|Duke University||4|||f||||f||||||||||2018-06-01 02:38:34.296995|2018-06-01 02:38:34.296995
NCT00579436|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2018-02-13||2018-04-16|2007-12-20|2007-12-24|Estimate|2018-04-16|2018-05-16|Actual||||2018-04-16|2018-05-16|Actual|January 2007||2007-01-31|April 2018|2018-04-30|January 15, 2015|Actual|2015-01-15|March 27, 2013|Actual|2013-03-27||Interventional|||Effects of Fish Oils on Inflammation and Insulin Resistance|Effects of Fish Oils on Inflammation and Insulin Resistance|Completed||N/A|33|Actual|University of Kentucky|Study not being powered to identify a difference between groups|2|||f||||t||||||||||2018-06-01 02:38:34.396736|2018-06-01 02:38:34.396736
NCT00579423|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-03-17|2007-12-21|2007-12-24|Estimate|||||||2009-03-17|2009-03-18|Estimate|November 2000||2000-11-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|May 2003|Actual|2003-05-31||Interventional|||Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer|A Pilot Multivalent Conjugate Vaccine Trial for Patients With Biochemically Relapsed Prostate Cancer|Completed||Phase 2|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 02:38:34.768963|2018-06-01 02:38:34.768963
NCT00579410|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2011-03-21|2007-12-21|2007-12-24|Estimate|||||||2011-03-21|2011-03-22|Estimate|May 2004||2004-05-31|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule|Evaluation of Esophageal and Gastric Acid Levels in Patients Presenting With Upper Gastrointestinal Symptoms Using a Novel PH System|Completed|||85|Actual|Kansas City Veteran Affairs Medical Center|||3||f||||f||||||||||2018-06-01 02:38:34.837409|2018-06-01 02:38:34.837409
NCT00579397|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2009-05-26|2007-12-21|2007-12-24|Estimate|||||||2009-05-26|2009-05-27|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Markers of Inflammation in Hematopoietic Stem Cell Transplant|Markers of Inflammation in Hematopoietic Stem Cell Transplant|Completed|||30|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||Samples With DNA|"~     2.5 mL's of whole blood are obtained one time a week for the first 100 days of transplant~   "|||2018-06-01 02:38:34.912775|2018-06-01 02:38:34.912775
NCT00579384|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20||2011-08-12|2012-04-03|2007-12-20|2007-12-24|Estimate||||2011-08-12|2011-08-17|Estimate|2012-04-03|2012-04-05|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy|A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram Response in Patients With Photosensitive Epilepsy|Completed||Phase 2|12|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 02:38:34.97233|2018-06-01 02:38:34.97233
NCT00579371|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2010-06-25|2007-12-17|2007-12-24|Estimate|||||||2010-06-25|2010-06-28|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus|Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus|Unknown status|Enrolling by invitation|Phase 1/Phase 2|10|Anticipated|University of Nebraska||1|||f||||f||||||||||2018-06-01 02:38:35.040495|2018-06-01 02:38:35.040495
NCT00579358|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-11-05|2007-12-18|2007-12-24|Estimate|||||||2010-11-05|2010-11-08|Estimate|November 2007||2007-11-30|November 2010|2010-11-30|November 2010|Anticipated|2010-11-30|||||Observational|||Molecular Basis of Congenital Heart Defects|Molecular Basis of Congenital Heart Defects|Unknown status|Recruiting||150|Anticipated|University of California, Irvine|||||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 02:38:35.153773|2018-06-01 02:38:35.153773
NCT00579345|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-09-05||2016-11-30|2007-12-21|2007-12-24|Estimate|2011-09-05|2011-10-10|Estimate||||2016-11-30|2017-01-27|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup|A Phase III, Single-Blind, Multi-Center, Extension Study to Evaluate Safety and Tolerability of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adult and Elderly Subjects Who Participated in Study V58P4, With Subset Analyses of Immunogenicity and Evaluation of Concomitant Polysaccharide Pneumococcal Vaccine (Elderly).|Completed||Phase 3|1522|Actual|Novartis||4|||f||||f||||||||||2018-06-01 02:38:35.327154|2018-06-01 02:38:35.327154
NCT00579306|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2017-07-20|2007-12-20|2007-12-24|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2005|Actual|2005-06-30|July 2017|2017-07-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Observational|LIMITS||Levels of Inflammatory Markers in the Treatment of Stroke—An SPS3 Ancillary Study|Levels of Inflammatory Markers in the Treatment of Stroke|Completed|||1244|Actual|Columbia University|||1||f||||t|f|f||||Samples Without DNA|"~     blood serum (ancillary study)~   "|Undecided||2018-06-01 02:38:36.890564|2018-06-01 02:38:36.890564
NCT00579293|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-07-24|2007-12-20|2007-12-24|Estimate|||||||2008-07-24|2008-07-28|Estimate|August 2004||2004-08-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Development of a Computer Assisted Survivor Screening For Adult Survivors of Childhood Cancer|Development of a Computer Assisted Survivor Screening For Adult Survivors of Childhood Cancer|Completed|||100|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:38:37.102278|2018-06-01 02:38:37.102278
NCT00579280|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-01-13|2007-12-21|2007-12-24|Estimate|||||||2011-01-13|2011-01-17|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD|A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder.|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|University of South Florida||3|||f||||f||||||||||2018-06-01 02:38:37.160385|2018-06-01 02:38:37.160385
NCT00579267|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-02-13|2007-12-18|2007-12-24|Estimate|||||||2009-02-13|2009-02-16|Estimate|February 2004||2004-02-29|December 2007|2007-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)|Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)|Completed|||230|Actual|University of South Florida|||||f||||f||||||||||2018-06-01 02:38:37.245636|2018-06-01 02:38:37.245636
NCT00579254|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-05-01||2009-06-18|2007-12-20|2007-12-24|Estimate|2009-05-01|2009-06-19|Estimate||||2009-06-18|2009-06-25|Estimate|December 2007||2007-12-31|May 2009|2009-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|EXCEL||Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors|Real Life Experience With Caduet Evaluating Effectiveness, Safety and Tolerability in the Management of Cardiovascular Risk Factors (EXCEL Study)|Terminated|||112|Actual|Pfizer|The objectives for this terminated study could not be assessed due to limited data available. (Efficacy parameters were to include BP, heart rate, lipid profile, urine albumin.)|||See the termination reason in detailed description.|f||||f||||||||||2018-06-01 02:38:37.307953|2018-06-01 02:38:37.307953
NCT00579241|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-07-19|2007-12-21|2007-12-24|Estimate|||||||2012-07-19|2012-07-23|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|March 2010|Actual|2010-03-31||Interventional|||Detection of Ultrasound Contrast Signals in the Cerebral Circulation|Detection of Ultrasound Contrast Signals in the Cerebral Circulation During Stress Echocardiography|Withdrawn||N/A|0|Actual|University of Nebraska||1|||f||||f||||||||||2018-06-01 02:38:37.437622|2018-06-01 02:38:37.437622
NCT00579228|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-03-29|2007-12-21|2007-12-24|Estimate|||||||2018-03-29|2018-04-02|Actual|March 2007||2007-03-31|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Observational|||Vascular Risk Progression in Normal and Diabetic Control Subjects.|Vascular Risk Progression in Normal and Diabetes Control Subjects|Completed|||90|Actual|University of Nebraska|||3||f||||f|f|f||||||Undecided||2018-06-01 02:38:37.504226|2018-06-01 02:38:37.504226
NCT00579215|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2009-03-17|2007-12-20|2007-12-24|Estimate|||||||2009-03-17|2009-03-18|Estimate|November 2006||2006-11-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Lung Cancer Informational Study (LCIS)|Lung Cancer Informational Study (LCIS)|Completed||N/A|8|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:38:37.566426|2018-06-01 02:38:37.566426
NCT00579202|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-04-04|2007-12-19|2007-12-21|Estimate|||||||2017-04-04|2017-04-05|Actual|October 2007||2007-10-31|April 2017|2017-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Ease of Use Study for the Gambro Polyflux HD-C4 Small Dialyzer|The Gambro Polyflux HD-C4 Small Ease of Use Study|Completed|||24|Actual|Baxter Healthcare Corporation|||||f||||f||||||||||2018-06-01 02:38:37.644208|2018-06-01 02:38:37.644208
NCT00579189|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19||2012-11-28|2012-11-29|2007-12-20|2007-12-21|Estimate||||2012-11-28|2012-11-30|Estimate|2012-11-29|2012-12-03|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes|Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)|Completed||Phase 3|776|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:38:37.701138|2018-06-01 02:38:37.701138
NCT00579176|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-04-04|2007-12-20|2007-12-21|Estimate|||||||2017-04-04|2017-04-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:38:37.772314|2018-06-01 02:38:37.772314
NCT00579163|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-05-16|2007-12-20|2007-12-21|Estimate|||||||2018-05-16|2018-05-17|Actual|December 1994|Actual|1994-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers|Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers|Recruiting|||1000|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Blood, Saliva, Tumor Tissue, Normal Tissue~   "|||2018-06-01 02:38:37.82074|2018-06-01 02:38:37.82074
NCT00579150|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2016-05-24|2007-12-19|2007-12-21|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|Exenatide||Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy|Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy|Terminated|||7|Actual|AstraZeneca|||2||f||||t||||||||||2018-06-01 02:38:37.903462|2018-06-01 02:38:37.903462
NCT00579137|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2013-03-30||2013-06-28|2007-12-19|2007-12-21|Estimate|2013-06-28|2013-07-02|Estimate||||2013-06-28|2013-07-02|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|MASCI||Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders|CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders|Terminated||Phase 1/Phase 2|3|Actual|Baylor College of Medicine||1||slow accrual|f||||t||||||||||2018-06-01 02:38:38.152489|2018-06-01 02:38:38.152489
NCT00578591|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-07-06|2007-12-20|2007-12-21|Estimate|||||||2012-07-06|2012-07-09|Estimate|June 2007||2007-06-30|July 2012|2012-07-31||||||||Interventional|Rituximab GVHD||Rituximab for GVHD|CHIMERIC MONOCLONAL CD-20 ANTIBODY (RITUXIMAB) FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE (SR-AGVHD): A PILOT STUDY|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||1||No eligible patients were identified so the study was terminated.|f||||t||||||||||2018-06-01 02:38:49.563177|2018-06-01 02:38:49.563177
NCT00579124|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-04-11|2007-12-19|2007-12-21|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2005||2005-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CliniMACs||CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion|CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation With the CliniMACs Device for T and B Cell Depletion|Active, not recruiting||Phase 2|85|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-06-01 02:38:38.374114|2018-06-01 02:38:38.374114
NCT00579111|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-07-03||2016-03-29|2007-12-20|2007-12-21|Estimate|2012-07-03|2012-08-09|Estimate||||2016-03-29|2016-05-04|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|October 2010|Actual|2010-10-31|February 2009|Actual|2009-02-28||Interventional|||Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)|Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases|Terminated||Phase 1/Phase 2|4|Actual|Baylor College of Medicine||2||slow accrual|f||||t||||||||||2018-06-01 02:38:38.455393|2018-06-01 02:38:38.455393
NCT00579098|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-04-04||2014-03-21|2007-12-18|2007-12-21|Estimate|2014-03-21|2014-04-23|Estimate||||2014-03-21|2014-04-23|Estimate|December 2007||2007-12-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ATTAC||The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation|Atorvastatin for Prevention of Atrial Fibrillation Recurrence Following Pulmonary Veins Isolation: A Double-Blind, Placebo-Controlled, Randomized Pilot Trial|Completed||Phase 4|125|Actual|Mayo Clinic|The population was restricted to patients who did not have an indication for statin treatment. The lack of transtelephonic or prolonged Holter monitoring likely resulted in underestimation of the rate of asymptomatic episodes of AF.|2|||f||||f||||||||||2018-06-01 02:38:38.704112|2018-06-01 02:38:38.704112
NCT00579085|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2010-06-15|2007-12-20|2007-12-21|Estimate|||||||2010-06-15|2010-06-17|Estimate|September 2006||2006-09-30|June 2010|2010-06-30|November 2009|Actual|2009-11-30|September 2008|Actual|2008-09-30||Interventional|||Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS|Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS|Completed||Phase 2|40|Anticipated|Drexel University||2|||f||||t||||||||||2018-06-01 02:38:39.399464|2018-06-01 02:38:39.399464
NCT00579072|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-11-28|2007-12-20|2007-12-21|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2006||2006-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older|The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older|Recruiting|||220|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||||||2018-06-01 02:38:39.503244|2018-06-01 02:38:39.503244
NCT00579059|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2009-05-20||2017-06-19|2007-12-20|2007-12-21|Estimate|2009-05-20|2009-07-07|Estimate||||2017-06-19|2017-07-17|Actual|May 2004||2004-05-31|June 2017|2017-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Maxim® Knee Pop-Top® Tibia vs. Regular Maxim® Knee Tibia|A Randomized Data Collection of the Maxim® Knee System With Removable Molded Polyethylene Tibia and the Regular Maxim® Knee System|Terminated||N/A|31|Actual|Zimmer Biomet|Study was terminated after enrollment failed to produce sufficient data to be analyzed.|2||The study sponsor canceled the study.|f||||f||||||||||2018-06-01 02:38:39.602856|2018-06-01 02:38:39.602856
NCT00579046|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-10-29|2007-12-20|2007-12-21|Estimate|||||||2013-10-29|2013-10-30|Estimate|November 2008||2008-11-30|October 2013|2013-10-31|October 2009|Anticipated|2009-10-31|October 2009|Actual|2009-10-31||Interventional|ELAB||Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease|Erythropoietin Treatment of Anemia Complicating Chronic Obstructive Pulmonary Disease: Functional Impact During Exertion|Withdrawn||Phase 3|0|Actual|Assistance Publique - Hôpitaux de Paris||1||no patient recruiting|f||||t||||||||||2018-06-01 02:38:39.836926|2018-06-01 02:38:39.836926
NCT00579033|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-19|2007-12-19|2007-12-21|Estimate|||||||2007-12-19|2007-12-21|Estimate|May 2007||2007-05-31|March 2007|2007-03-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Somatosensory Processing in Focal Hand Dystonia|Tactile Operant Conditioning To Alleviate Focal Hand Dystonia Symptoms|Unknown status|Recruiting|N/A|24|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:38:39.906606|2018-06-01 02:38:39.906606
NCT00579020|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19||2012-12-03|2012-12-03|2007-12-19|2007-12-21|Estimate||||2012-12-03|2012-12-05|Estimate|2012-12-03|2012-12-05|Estimate|December 2007||2007-12-31|December 2012|2012-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates|An Evaluation of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates|Terminated||Phase 2|144|Actual|Alcon Research||3||Management decision|f||||f||||||||||2018-06-01 02:38:39.977456|2018-06-01 02:38:39.977456
NCT00579007|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-04-03|2007-12-20|2007-12-21|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2003|Actual|2003-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations|Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations|Active, not recruiting|||224|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||||||2018-06-01 02:38:40.050679|2018-06-01 02:38:40.050679
NCT00578994|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-06-15|2007-12-19|2007-12-21|Estimate|||||||2017-06-15|2017-06-16|Actual|March 2006||2006-03-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System|A Prospective, Non-randomized, Multicenter Study of the Oxford® Meniscal Unicompartmental Knee System|Active, not recruiting|||388|Actual|Zimmer Biomet|||1||f||||t||||||||Undecided||2018-06-01 02:38:40.13866|2018-06-01 02:38:40.13866
NCT00578981|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2016-02-01|2007-12-20|2007-12-21|Estimate|||||||2016-02-01|2016-02-02|Estimate|August 2007||2007-08-31|February 2016|2016-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women|Wiser Choices in Osteoporosis Trial: The OSTEOPOROSIS CHOICE Decision Aid to Support the Decision to Use or Not Use Bisphosphonates in Postmenopausal Women at Risk of Osteoporotic Fractures.|Completed||N/A|100|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:38:40.234434|2018-06-01 02:38:40.234434
NCT00578968|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-05-22||2012-05-22|2007-12-20|2007-12-21|Estimate|2012-05-22|2012-06-26|Estimate||||2012-05-22|2012-06-26|Estimate|October 2006||2006-10-31|May 2012|2012-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation|Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation|Completed||Phase 4|36|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 02:38:40.32845|2018-06-01 02:38:40.32845
NCT00578955|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19||2012-01-26|2012-01-27|2007-12-19|2007-12-21|Estimate||||2012-01-27|2012-01-31|Estimate|2012-01-27|2012-01-31|Estimate|December 2007||2007-12-31|January 2012|2012-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis|A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical and Anti-Microbial Efficacy and Safety of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone in the Treatment of Subjects With Blepharoconjunctivitis|Completed||Phase 3|417|Actual|InSite Vision||3|||f||||f||||||||||2018-06-01 02:38:41.202009|2018-06-01 02:38:41.202009
NCT00578942|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2014-04-25||2016-05-23|2007-12-19|2007-12-21|Estimate|2014-04-25|2014-05-23|Estimate||||2016-05-23|2016-06-24|Estimate|May 2005||2005-05-31|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||"Cohort of subjects who actually received at least 1 donor lymphocyte infusion (DLI).~DLI dosages thus ranged from 1×104 CD3+ cells/kg to 3.27 ×108 CD3+ cells/kg."|Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath|Allogeneic Non-myeloablative Stem Cell Transplantation Utilizing Matched Family Member Stem Cells Purged Using Campath-1H|Completed||Phase 2|48|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:38:41.297578|2018-06-01 02:38:41.297578
NCT00578929|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-01-14||2010-02-23|2007-12-19|2007-12-21|Estimate|2010-01-14|2010-02-09|Estimate||||2010-02-23|2010-03-02|Estimate|September 2007||2007-09-30|February 2010|2010-02-28||||November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients|Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients|Completed||Phase 3|2388|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 02:38:41.523679|2018-06-01 02:38:41.523679
NCT00578916|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2008-07-30|2007-12-19|2007-12-21|Estimate|||||||2008-07-30|2008-07-31|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects|Pharmacokinetics and Metabolism of [14C] BMS-690514 in Healthy Male Subjects|Completed||Phase 1|17|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:38:41.858067|2018-06-01 02:38:41.858067
NCT00578903|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2013-08-04||2016-03-24|2007-12-20|2007-12-21|Estimate|2013-08-04|2013-10-11|Estimate||||2016-03-24|2016-04-22|Estimate|February 2002||2002-02-28|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia|Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors (SAA MUD)|Terminated||Phase 2|22|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:38:41.953155|2018-06-01 02:38:41.953155
NCT00578890|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-09-14|2007-12-20|2007-12-21|Estimate|||||||2012-09-14|2012-09-17|Estimate|June 2008||2008-06-30|June 2011|2011-06-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|DIPIOS||a Randomized Controlled Trial Comparing Medical and Medical-surgical Treatment in Diabetic Foot Osteomyelitis|Comparison of Medical and Medical-surgical Management of Diabetic Foot Osteomyelitis|Withdrawn||Phase 4|0|Actual|Assistance Publique - Hôpitaux de Paris||1||not enough recruitment|f||||f||||||||||2018-06-01 02:38:42.201488|2018-06-01 02:38:42.201488
NCT00578877|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2016-01-07||2018-02-16|2007-12-19|2007-12-21|Estimate|2017-08-23|2017-08-24|Actual||||2018-02-16|2018-03-16|Actual|January 2008||2008-01-31|August 2017|2017-08-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional||treated population who answered the item|Contraceptive Effectiveness and Safety of the SILCS Diaphragm|Contraceptive Effectiveness and Safety Study of the SILCS Diaphragm: the Pivotal Study|Completed||Phase 2/Phase 3|450|Actual|CONRAD||2|||f||||t||||||||||2018-06-01 02:38:42.285238|2018-06-01 02:38:42.285238
NCT00578864|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-10-05||2015-06-25|2007-12-19|2007-12-21|Estimate|2012-10-05|2012-11-06|Estimate||||2015-06-25|2015-07-17|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|July 2009|Actual|2009-07-31||Interventional|PEPI||Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma|PEPI: Protracted Etoposide in a Phase II Upfront Window for Induction Therapy for High Risk Neuroblastoma|Completed||Phase 2|13|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 02:38:42.555505|2018-06-01 02:38:42.555505
NCT00578851|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-06-19|2007-12-19|2007-12-21|Estimate|||||||2017-06-19|2017-06-21|Actual|April 2006||2006-04-30|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Observational|||A Clinical Investigation of the C2a-Taper™ Acetabular System|Post Approval Study of the C2a-Taper™ Acetabular System|Completed|||28|Actual|Zimmer Biomet|||1||f||||f||||||||No||2018-06-01 02:38:42.91592|2018-06-01 02:38:42.91592
NCT00578838|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2016-05-06|2007-12-20|2007-12-21|Estimate|||||||2016-05-06|2016-05-09|Estimate|August 2006||2006-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Magnetic Resonance Study of Liver in Chemotherapy|Magnetic Resonance Study of Liver in Chemotherapy|Completed|||55|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||f||||||||||2018-06-01 02:38:43.156952|2018-06-01 02:38:43.156952
NCT00578825|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2013-08-21|2007-12-20|2007-12-21|Estimate|||||||2013-08-21|2013-08-22|Estimate||||August 2013|2013-08-31||||||||Interventional|||A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome|A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome|Unknown status|Not yet recruiting|N/A|340|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:38:43.217353|2018-06-01 02:38:43.217353
NCT00578812|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-11-29|2011-05-16|2015-06-08|2007-12-19|2007-12-21|Estimate|2013-01-09|2013-02-12|Estimate|2011-05-16|2011-05-19|Estimate|2015-06-08|2015-07-07|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|March 2010|Actual|2010-03-31||Interventional|||PCM Cervical Disc System|A Prospective, Randomized, Controlled Clinical Investigation Comparing PCM® Cervical Disc Arthroplasty to Anterior Cervical Discectomy and Fusion: 2 Year Results From the US IDE Clinical Trial|Completed||Phase 3|494|Actual|NuVasive||2|||f||||f||||||||||2018-06-01 02:38:43.337036|2018-06-01 02:38:43.337036
NCT00578799|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-07-01|2007-12-19|2007-12-21|Estimate|||||||2009-07-01|2009-07-02|Estimate|July 2008||2008-07-31|July 2009|2009-07-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Effects of Probiotics in Patients With Ulcerative Colitis|Effects of Probiotics in Patients With Ulcerative Colitis.|Terminated||Phase 1|40|Anticipated|University of California, Irvine||2||Low recruitment|f||||t||||||||||2018-06-01 02:38:44.550935|2018-06-01 02:38:44.550935
NCT00578617|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2011-07-20||2012-12-03|2007-12-20|2007-12-21|Estimate|2012-12-03|2013-01-04|Estimate||||2012-12-03|2013-01-04|Estimate|September 2006||2006-09-30|December 2012|2012-12-31|June 2010|Actual|2010-06-30|February 2009|Actual|2009-02-28||Interventional|CABANA||Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial|Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation - Pilot Trial|Completed||N/A|60|Actual|Mayo Clinic|Limited number enrolled. Study was designed to demonstrate feasibility for a pivotal trial, but small enrollment limits the final conclusions that can be drawn from a simple 'time to first atrial fibrillation recurrence.'|2|||f||||t||||||||||2018-06-01 02:38:49.124189|2018-06-01 02:38:49.124189
NCT00578786|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-04-12||2013-01-14|2007-12-19|2007-12-21|Estimate|2013-01-14|2013-01-15|Estimate||||2013-01-14|2013-01-15|Estimate|February 2004||2004-02-29|January 2013|2013-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)|A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)|Completed||Phase 3|383|Actual|Gilead Sciences|Analysis included those not enrolling in this study but received AMB in 1 of the 2 parent studies. At Year 3, almost half of those randomized to 2.5 mg were titrated to 5 mg and 10 mg; a third starting at 5 mg were titrated to 10 mg.|1|||f||||t||||||||||2018-06-01 02:38:44.873688|2018-06-01 02:38:44.873688
NCT00578773|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19||2012-11-28|2012-11-29|2007-12-20|2007-12-21|Estimate||||2012-11-29|2012-12-03|Estimate|2012-11-29|2012-12-03|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Phase II Study of an Otic Formulation in Treating Peri-Operative Tube Otorrhea|Safety and Efficacy of a Topical Otic Formulation in the Treatment of Peri-Operative Tube Otorrhea|Completed||Phase 2|303|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 02:38:47.030525|2018-06-01 02:38:47.030525
NCT00578760|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2007-12-19|2007-12-19|2007-12-21|Estimate|||||||2007-12-19|2007-12-21|Estimate|February 2008||2008-02-29|December 2007|2007-12-31|February 2010|Anticipated|2010-02-28|||||Interventional|||Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?|Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?|Unknown status|Not yet recruiting|N/A|110|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:38:47.095849|2018-06-01 02:38:47.095849
NCT00578747|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-09-02|2007-12-19|2007-12-21|Estimate|||||||2015-09-02|2015-09-04|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Do Skin Markings Reflect the Location of the Surgical Cavity During Daily Radiotherapy Treatment?|Development of Improved Target Volume Localization for Accelerated Partial Breast Irradiation- Stage I|Completed|||21|Actual|British Columbia Cancer Agency|||||f||||f||||||||||2018-06-01 02:38:47.323597|2018-06-01 02:38:47.323597
NCT00578734|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-04-02||2012-05-01|2007-12-20|2007-12-21|Estimate|2012-04-02|2012-04-27|Estimate||||2012-05-01|2012-05-03|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|KL4-AHRF-01||Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old|A Multicenter, Randomized, Masked, Placebo-Controlled Trial to Assess the Safety and Efficacy of Lucinactant in Acute Hypoxemic Respiratory Failure in Children Up to Two Years of Age|Completed||Phase 2|165|Actual|Windtree Therapeutics||2|||f||||t||||||||||2018-06-01 02:38:47.395898|2018-06-01 02:38:47.395898
NCT00578721|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-06-07|2007-12-19|2007-12-21|Estimate|||||||2017-06-07|2017-06-08|Actual|September 24, 2008||2008-09-24|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Trial of Aspirin and Arginine Restriction in Colorectal Cancer|Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Colorectal Cancer Patients|Active, not recruiting||Phase 2|24|Anticipated|University of California, Irvine||1|||f||||t||||||||No||2018-06-01 02:38:47.730402|2018-06-01 02:38:47.730402
NCT00578708|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2015-03-16|2007-12-20|2007-12-21|Estimate|||||||2015-03-16|2015-03-17|Estimate|September 2003||2003-09-30|March 2015|2015-03-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER||Completed||Phase 1|35|Actual|St. Jude Medical||1|||f||||t||||||||||2018-06-01 02:38:47.806583|2018-06-01 02:38:47.806583
NCT00578695|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19||2011-06-20|2011-06-20|2007-12-19|2007-12-21|Estimate||||2011-06-20|2011-06-28|Estimate|2011-06-20|2011-06-28|Estimate|January 2007||2007-01-31|November 2010|2010-11-30||||June 2010|Actual|2010-06-30||Interventional|||THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation|THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation|Completed||Phase 3|652|Actual|CardioKine Inc.||2|||f||||t||||||||||2018-06-01 02:38:47.959524|2018-06-01 02:38:47.959524
NCT00578682|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2011-11-22|2007-12-19|2007-12-21|Estimate|||||||2011-11-22|2011-11-23|Estimate|December 2007||2007-12-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557|A Phase I, Randomized, Double-Blind, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557, A Humanized Monoclonal Antibody With an Extended Half-Life Against Respiratory Syncytial Virus (RSV), in Healthy Adults|Completed||Phase 1|31|Actual|MedImmune LLC||4|||f||||||||||||||2018-06-01 02:38:48.654994|2018-06-01 02:38:48.654994
NCT00578669|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-08-26|2007-12-19|2007-12-21|Estimate|||||||2014-08-26|2014-08-27|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms|Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms|Completed||Phase 3|206|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-06-01 02:38:48.727629|2018-06-01 02:38:48.727629
NCT00578656|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-07-30|2007-12-19|2007-12-21|Estimate|||||||2012-07-30|2012-08-01|Estimate|June 2004||2004-06-30|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||An Interventional Study of Milk Allergy|The Impact of the Diet Containing Limited Amounts of Processed Milk Protein on the Natural History of IgE-Mediated Milk Hypersensitivity|Completed||Early Phase 1|220|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 02:38:48.811783|2018-06-01 02:38:48.811783
NCT00578643|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-08-29|2007-12-19|2007-12-21|Estimate|||||||2017-08-29|2017-08-31|Actual|March 2004||2004-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|MUNCHR||Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease|HLA Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease|Active, not recruiting||Phase 2|15|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:38:48.890882|2018-06-01 02:38:48.890882
NCT00578630|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-01-19|2007-12-20|2007-12-21|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2003||2003-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Bone Marrow Transplantation Patients|Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Oncology/Bone Marrow Transplantation Patients|Active, not recruiting|||128|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     peripheral blood and buccal swab~   "|||2018-06-01 02:38:49.032355|2018-06-01 02:38:49.032355
NCT00192985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-16|2005-09-16|2005-09-19|Estimate|||||||2005-09-16|2005-09-19|Estimate|May 2003||2003-05-31|September 2005|2005-09-30|September 2006||2006-09-30|||||Interventional|||Does a Nitrofurazone Coated Bladder Catheter Reduce the Number of Urinary Tract Infections in Trauma||Unknown status|Active, not recruiting|Phase 3|216||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:02.906815|2018-06-01 04:34:02.906815
NCT00578578|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2007-12-19|2007-12-19|2007-12-21|Estimate|||||||2007-12-19|2007-12-21|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|Omega-3||Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels|Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels|Terminated||Phase 4|53|Actual|The Cleveland Clinic||2||CRP is no longer SOC - enrollment halted and will analyze available data.|f||||t||||||||||2018-06-01 02:38:49.643373|2018-06-01 02:38:49.643373
NCT00578565|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2012-05-21||2012-09-25|2007-12-19|2007-12-21|Estimate|2012-08-27|2012-09-25|Estimate||||2012-09-25|2012-10-01|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Rituximab in Rheumatoid Arthritis Lung Disease|Rituximab for the Treatment of Rheumatoid Arthritis-Associated Interstitial Pneumonia: A Pilot Study|Completed||Phase 3|10|Actual|Mayo Clinic|Given the small number of patients, it could not be determined whether patients with nonspecific interstitial pneumonia (NSIP) or usual interstitial pneumonia (UIP) were more likely to respond. Further research is needed in less advanced disease.|1|||f||||f||||||||||2018-06-01 02:38:49.735831|2018-06-01 02:38:49.735831
NCT00578552|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-11-01||2011-04-15|2007-12-20|2007-12-21|Estimate|2010-11-01|2010-12-01|Estimate||||2011-04-15|2011-04-19|Estimate|October 2007||2007-10-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Gabapentin for Smoking Cessation|Gabapentin for Smoking Abstinence|Completed||Phase 2|80|Actual|Mayo Clinic|The original intent was to enroll a total of 120 subjects. However, due to the high study dropout rate, a review of the primary endpoint was performed after 80 subjects were enrolled and a decision was made to discontinue further enrollment.|3|||f||||f||||||||||2018-06-01 02:38:49.98219|2018-06-01 02:38:49.98219
NCT00578539|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2014-08-28||2016-03-24|2007-12-20|2007-12-21|Estimate|2014-08-28|2014-09-08|Estimate||||2016-03-24|2016-04-22|Estimate|October 2007||2007-10-31|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|REGALE|A total of 24 patients were enrolled on the study and all of them received the conditioning treatment and the transplant.|T-Reg Cell Kinetics, Stem Cell Transplant, REGALE|T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors|Terminated||N/A|24|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:38:50.534662|2018-06-01 02:38:50.534662
NCT00578526|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-01-18|2007-12-20|2007-12-21|Estimate|||||||2012-01-18|2012-01-19|Estimate|April 2008||2008-04-30|September 2011|2011-09-30||||||||Interventional|SPRUCE||SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial|A Randomized, Placebo-controlled Phase II Study to Compare the Efficacy and Safety of SU011248 Versus Placebo in Patients With Advanced Urothelial Transitional Cell Carcinoma Who Have Failed or Are Intolerant to Cisplatin-based Chemotherapy|Unknown status|Active, not recruiting|Phase 2|64|Anticipated|AHS Cancer Control Alberta||2|||f||||t||||||||||2018-06-01 02:38:50.76918|2018-06-01 02:38:50.76918
NCT00578513|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-06-19|2007-12-19|2007-12-21|Estimate|||||||2017-06-19|2017-06-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:38:50.866108|2018-06-01 02:38:50.866108
NCT00578500|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2007-12-19|2007-12-19|2007-12-21|Estimate|||||||2007-12-19|2007-12-21|Estimate|January 2000||2000-01-31|January 2002|2002-01-31|January 2010|Anticipated|2010-01-31|||||Interventional|HFPP||Fertility Preservation by Ovarian and Oocyte Cryopreservation|Study That Establishes the Potential of Fertility Preservation in Young Female Patients by Oocyte in Vitro Maturation and Cryopreservation and Ovarian Cortex Cryopreservation and Transplantation|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-06-01 02:38:50.906232|2018-06-01 02:38:50.906232
NCT00578487|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-06-19|2007-12-19|2007-12-21|Estimate|||||||2017-06-19|2017-06-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:38:51.005477|2018-06-01 02:38:51.005477
NCT00578474|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19||2012-11-28|2012-11-29|2007-12-20|2007-12-21|Estimate||||2012-11-28|2012-11-30|Estimate|2012-11-29|2012-12-03|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes|Safety and Efficacy of a Topical Otic Formulation in the Treatment of Acute Otitis Media With Otorrhea Through Tympanostomy Tubes (AOMT)|Completed||Phase 3|911|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:38:51.112316|2018-06-01 02:38:51.112316
NCT00578461|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2014-08-28||2016-03-24|2007-12-19|2007-12-21|Estimate|2014-08-28|2014-09-08|Estimate||||2016-03-24|2016-04-22|Estimate|October 2007||2007-10-31|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|REGKINE|A total of 26 patients were enrolled on the study and all of them received the conditioning treatment and the transplant.|T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE|T-Regulatory Cell Kinetics Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation|Terminated||N/A|26|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:38:51.199901|2018-06-01 02:38:51.199901
NCT00578448|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2013-10-28|2010-04-29|2013-12-16|2007-12-19|2007-12-21|Estimate|2013-10-28|2013-12-17|Estimate|2010-07-08|2010-07-12|Estimate|2013-12-16|2014-01-17|Estimate|March 2008||2008-03-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|March 2009|Actual|2009-03-31||Interventional||Participants treated with study drug after renal transplant.|Belatacept Pharmacokinetic Trial in Renal Transplantation|An Open-label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen|Completed||Phase 2|14|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:38:51.472788|2018-06-01 02:38:51.472788
NCT00578435|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2008-09-10|2007-12-20|2007-12-21|Estimate|||||||2008-09-10|2008-09-12|Estimate|January 1994||1994-01-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis|Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis|Completed||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:38:51.922359|2018-06-01 02:38:51.922359
NCT00578422|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-02-06|2007-12-20|2007-12-21|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2003|Actual|2003-12-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Clinical Implications of Peripheral Plaque Morphology|Clinical Implications of Peripheral Plaque Morphology|Completed|||143|Actual|The Cleveland Clinic|||2||f||||f|f|f||||||No||2018-06-01 02:38:51.990868|2018-06-01 02:38:51.990868
NCT00578266|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2017-03-23|2007-12-20|2007-12-21|Estimate|||||||2017-03-23|2017-03-24|Actual|February 2007||2007-02-28|March 2017|2017-03-31|August 16, 2016|Actual|2016-08-16|August 16, 2016|Actual|2016-08-16||Interventional|||Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia|Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors|Completed||Phase 1|8|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:38:55.639316|2018-06-01 02:38:55.639316
NCT00578409|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-12-16|2007-12-20|2007-12-21|Estimate|||||||2015-12-16|2015-12-18|Estimate|May 2004||2004-05-31|December 2015|2015-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data|Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data|Completed|||758|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     In a first analytical step, using only the clinical and pathological variables used in the~     original clinical mets castrate disease nomogram as inputs, supervised multivariate~     analytical techniques (SMA) were used to generate a new predictive model for patient~     survival. A similar approach will then be used to analyze a second group of approximately 223~     pts in the state of a rising PSA14 after surgery or radiation therapy treated on a sequential~     series of IRB approved trials testing conjugate vaccines also consented on IRB protocol~     90-40.~   "|||2018-06-01 02:38:52.063023|2018-06-01 02:38:52.063023
NCT00578396|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-05-04|2007-12-18|2007-12-21|Estimate|||||||2009-05-04|2009-05-05|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|January 2010|Anticipated|2010-01-31|May 2009|Anticipated|2009-05-31||Interventional|||Phase I Biomarker Study of Dietary Grape-Derived Low Dose Resveratrol for Colon Cancer Prevention|Phase I Biomarker Study of Dietary Grape-Derived Low Dose Resveratrol for Colon Cancer Prevention|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|University of California, Irvine||3|||f||||t||||||||||2018-06-01 02:38:52.113566|2018-06-01 02:38:52.113566
NCT00578383|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-10-09||2016-04-12|2007-12-18|2007-12-21|Estimate|2014-03-28|2014-04-30|Estimate||||2016-04-12|2016-05-16|Estimate|November 2007||2007-11-30|April 2016|2016-04-30|March 2013|Actual|2013-03-31|March 2011|Actual|2011-03-31||Interventional|LFMS|Enrolled participants are excluded from statistical results if they had baseline Hamilton Depression Rating scores under 17 or co-morbid disorders.|Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device|Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device|Completed||N/A|107|Actual|Mclean Hospital|A limitation of the current trial was that it was underpowered to detect moderate but clinically significant benefits of LFMS in diagnostic subgroups.|4|||f||||f||||||||||2018-06-01 02:38:52.216273|2018-06-01 02:38:52.216273
NCT00578370|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2008-11-04|2007-12-20|2007-12-21|Estimate|||||||2008-11-04|2008-11-05|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test|A Phase I, Single-Center, Randomized, Vehicle-Controlled Study, Double-Blind for the Study Preparations and Observer-Blind for the Comparators to Determine the Antipsoriatic Efficacy and Tolerability of Topical Formulations With Ciclosporin in a Psoriasis Plaque Test|Completed||Phase 1/Phase 2|25|Anticipated|ISDIN||5|||f||||f||||||||||2018-06-01 02:38:52.850183|2018-06-01 02:38:52.850183
NCT00578357|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-07-25|2007-12-20|2007-12-21|Estimate|||||||2011-07-25|2011-07-26|Estimate|December 2007||2007-12-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||A Personalized Feedback Intervention for Problem Gamblers|A Personalized Feedback Intervention for Problem Gamblers|Completed||N/A|209|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 02:38:52.937354|2018-06-01 02:38:52.937354
NCT00578344|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-04-22|2007-12-20|2007-12-21|Estimate|||||||2014-04-22|2014-04-23|Estimate|July 2005||2005-07-31|April 2014|2014-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SCALLOP||Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP|Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia|Terminated||N/A|8|Actual|Baylor College of Medicine||1||Terminated due to no new subject enrollment during the last 3 year period.|f||||t||||||||||2018-06-01 02:38:53.005543|2018-06-01 02:38:53.005543
NCT00578331|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2009-07-07||2017-09-29|2007-12-19|2007-12-21|Estimate|2010-01-08|2010-02-03|Estimate||||2017-09-29|2017-10-31|Actual|December 2006||2006-12-31|February 2010|2010-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety Study of Olopatadine Nasal Spray|Safety Study of Olopatadine Nasal Spray|Completed||Phase 3|890|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:38:53.117733|2018-06-01 02:38:53.117733
NCT00578318|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2013-01-28||2013-05-15|2007-12-19|2007-12-21|Estimate|2013-05-15|2013-05-17|Estimate||||2013-05-15|2013-05-17|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|AAKOMA||African American Knowledge Optimized for Mindfully Healthy Adolescents|Treatment Engagement in Psychiatric Clinical Research and Care for Depressed African American Adolescents|Completed||N/A|16|Actual|Georgetown University|We lost 3 participants prior to intervention completion of the intervention which impacted results.|2|||f||||t||||||||||2018-06-01 02:38:53.441934|2018-06-01 02:38:53.441934
NCT00578305|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2015-02-19||2015-03-26|2007-12-20|2007-12-21|Estimate|2015-03-26|2015-04-10|Estimate||||2015-03-26|2015-04-10|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|May 2013|Actual|2013-05-31|November 2009|Actual|2009-11-30||Interventional|SCORE|Safety population: All participants who received any part of an infusion of the study drug during the main study.|A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate|A Randomized, Placebo Controlled, Multicenter Clinical Study Investigating Efficacy of Rituximab in the Inhibition of Joint Structural Damage Assessed by Magnetic Resonance Imaging in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate|Completed||Phase 3|185|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 02:38:53.799552|2018-06-01 02:38:53.799552
NCT00578292|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2016-07-20|2007-12-20|2007-12-21|Estimate|||||||2016-07-20|2016-07-22|Estimate|February 2004||2004-02-29|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|THALLO||Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO|Pilot Study of Allogeneic Stem Cell Transplantation From Unrelated Donors for Patients With Severe Homozygous Beta 0/+ Thalassemia or Severe Variants of Beta 0/+ Thalassemia|Terminated||N/A|10|Actual|Baylor College of Medicine||1||"Over the course of this study stem cell transplant was determined to be standard of care for~   this disease and as such the study is no longer relevant."|f||||t||||||||||2018-06-01 02:38:55.388771|2018-06-01 02:38:55.388771
NCT00578279|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2010-09-23||2012-09-18|2007-12-19|2007-12-21|Estimate|2012-09-18|2012-10-19|Estimate||||2012-09-18|2012-10-19|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study|Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study|Completed||Phase 4|20|Actual|Indiana University||2|||f||||f||||||||||2018-06-01 02:38:55.488501|2018-06-01 02:38:55.488501
NCT00578240|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-08-21|2007-12-20|2007-12-21|Estimate|||||||2017-08-21|2017-08-22|Actual|April 1990||1990-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Molecular Studies and Clinical Correlations in Human Prostatic Disease|Molecular Studies and Clinical Correlations in Human Prostatic Disease|Active, not recruiting|||5290|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     Human tissue, body fluids, and blood Fresh tissue will be obtained from patients undergoing a~     biopsy or surgical procedure as part of their standard therapy or as part of an~     investigational research protocol. Previously stored pathology specimens may also be used.~     Peripheral blood, bone marrow, urine, and other bodily fluids and samples will also be~     obtained as needed.~   "|||2018-06-01 02:38:55.701842|2018-06-01 02:38:55.701842
NCT00578227|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2009-11-27||2016-10-11|2007-12-20|2007-12-21|Estimate|2009-12-03|2010-01-06|Estimate||||2016-10-11|2016-11-23|Estimate|December 2007||2007-12-31|October 2016|2016-10-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects|Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) Co-administered With a Commercially Available Vaccine in Healthy Female Adolescents|Completed||Phase 3|814|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:38:55.790218|2018-06-01 02:38:55.790218
NCT00578214|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2012-01-13||2012-02-08|2007-12-20|2007-12-21|Estimate|2012-02-08|2012-02-09|Estimate||||2012-02-08|2012-02-09|Estimate|March 2007||2007-03-31|February 2012|2012-02-29|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery|Randomized Controlled and Prospective Studies of Safety and Efficacy of Oral Midazolam for Perioperative Anxiolysis of Patients Undergoing Mohs Micrographic Surgery.|Completed||N/A|75|Actual|Mayo Clinic|The study was hindered by slow accrual and fell short of reaching the target number of patients.|3|||f||||t||||||||||2018-06-01 02:38:56.673361|2018-06-01 02:38:56.673361
NCT00578201|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|||2011-03-30|2007-12-20|2007-12-21|Estimate|||||||2011-03-30|2011-03-31|Estimate|November 2007||2007-11-30|May 2007|2007-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|FOLFOX||FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer|Phase II Trial of FOLFOX in Combination With Cetuximab and Concomitant Radiotherapy in the Treatment of Esophageal Cancer Stage III|Completed||Phase 2|80|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 02:38:57.34697|2018-06-01 02:38:57.34697
NCT00578188|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2016-04-12|2007-12-19|2007-12-21|Estimate|||||||2016-04-12|2016-04-13|Estimate|February 2006||2006-02-28|April 2016|2016-04-30|January 2008|Anticipated|2008-01-31|January 2008|Anticipated|2008-01-31||Observational|||Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract|Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract|Withdrawn|||0|Actual|Arkansas Children's Hospital Research Institute|||1|Study redesigned and re-submitted to UAMS IRB under different study title and IRB number.|f||||f||||||Samples With DNA|"~     Serum, whole blood, tissue~   "|||2018-06-01 02:38:57.425669|2018-06-01 02:38:57.425669
NCT00578175|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-20|2010-03-05||2016-10-11|2007-12-20|2007-12-21|Estimate|2010-08-02|2010-08-26|Estimate||||2016-10-11|2016-11-23|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age|Immunogenicity of GlaxoSmithKline Biologicals' MMRV Vaccine (208136) vs. ProQuad®, When Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children 12-14 Months of Age.|Completed||Phase 2|1851|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:38:57.552463|2018-06-01 02:38:57.552463
NCT00578162|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-01-06|2007-12-20|2007-12-21|Estimate|||||||2012-01-06|2012-01-09|Estimate|April 2005||2005-04-30|January 2012|2012-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||A Study of Survivorship Service Capacities Among Health Care Agencies in New York City|A Study of Survivorship Service Capacities Among Health Care Agencies in New York City|Completed|||||Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:38:58.995791|2018-06-01 02:38:58.995791
NCT00578149|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2007-12-19|2007-12-19|2007-12-21|Estimate|||||||2007-12-19|2007-12-21|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer|Bevacizumab and Carboplatin/Paclitaxel and Radiation in Stage III Non-Small Cell Lung Cancer|Completed||Phase 2|45|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 02:38:59.072428|2018-06-01 02:38:59.072428
NCT00578136|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2012-12-07||2014-07-30|2007-12-19|2007-12-20|Estimate|2014-07-30|2014-08-15|Estimate||||2014-07-30|2014-08-15|Estimate|November 2006||2006-11-30|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Interventional|||Analgesic Efficacy After Umbilical Hernia Repair in Children|A Randomized-Double Blinded Trial Comparing the Analgesic Efficacy and Side Effects of Rectus Sheath Block vs. Infiltration of Surgical Site for Post Operative Pain Control After Umbilical Hernia Repair Surgery|Completed||N/A|52|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 02:38:59.137604|2018-06-01 02:38:59.137604
NCT00578123|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-08-03|2007-12-19|2007-12-20|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2005||2005-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy|Prospective Assessment of Clinical and Quality of Life Outcomes After Open or Robotic-Assisted Laparoscopic Radical Prostatectomy|Active, not recruiting||N/A|959|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:38:59.453443|2018-06-01 02:38:59.453443
NCT00578110|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2010-04-01|2007-12-18|2007-12-20|Estimate|||||||2010-04-01|2010-04-02|Estimate|January 2008||2008-01-31|April 2010|2010-04-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|IGDM||Instrument for Glaucoma Early Detection and Monitoring|SBIR II Instrument for Glaucoma Early Detection and Monitoring|Unknown status|Recruiting|N/A|180|Anticipated|Synabridge Corporation||3|||f||||f||||||||||2018-06-01 02:38:59.542707|2018-06-01 02:38:59.542707
NCT00577902|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-02-08|2007-12-18|2007-12-20|Estimate|||||||2016-02-08|2016-02-09|Estimate|June 2005||2005-06-30|February 2016|2016-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation|Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation|Completed|||37|Actual|University of Arkansas|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be collected and nutritional risk evaluated, using the Patient-Generated~     Subjective Global Assessment tool (PG-SGA). The PG-SGA and blood tests will be performed~     before, at the end of XRT treatment and four to six weeks after treatment is completed.~   "|||2018-06-01 02:39:00.928246|2018-06-01 02:39:00.928246
NCT00578097|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2015-11-30|2007-12-18|2007-12-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder|A Phase II, International, Multi-centre, Prospective, Randomised, Parallel-group, Double-blind, Dose-ranging, Placebo-controlled, 12-week, Study to Assess the Efficacy and Safety of a One Injection Cycle With Either Botulinum Toxin Type-A (Dysport® 125, 250 or 500 Units) or Placebo Followed by an Optional 6-month Extension Phase in the Symptomatic Treatment of Micturition Urgency and Frequency in Continent Female Subjects Suffering From Idiopathic Overactive Bladder.|Terminated||Phase 2|81|Actual|Ipsen||4||The study was terminated early due to poor recruitment.|f||||f||||||||||2018-06-01 02:38:59.662172|2018-06-01 02:38:59.662172
NCT00578084|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-10-07|2007-12-19|2007-12-20|Estimate|||||||2013-10-07|2013-10-08|Estimate|June 2006||2006-06-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|||Lung Cancer Location: a Repository|Lung Cancer Location: A Prospective Repository|Terminated|||200|Anticipated|Indiana University|||4||f||||f||||||||||2018-06-01 02:38:59.804591|2018-06-01 02:38:59.804591
NCT00578071|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2012-04-10||2015-05-22|2007-12-18|2007-12-20|Estimate|2012-07-02|2012-08-07|Estimate||||2015-05-22|2015-07-02|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|June 2012|Actual|2012-06-30|July 2011|Actual|2011-07-31||Interventional|POXX||Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer|A Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin Chemotherapy With External Beam Radiation Therapy for the Treatment of Resectable, Locally Advanced/Unresectable or Metastatic Esophageal Cancer|Completed||Phase 1/Phase 2|29|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:38:59.877697|2018-06-01 02:38:59.877697
NCT00578058|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-08-02|2007-12-19|2007-12-20|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2004||2004-01-31|August 2011|2011-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Randomized Trial Of Tinnitus Retraining Therapy|Randomized Trial Of Tinnitus Retraining Therapy|Completed||Phase 2|180|Anticipated|University of Iowa||6|||f||||t||||||||||2018-06-01 02:39:00.096147|2018-06-01 02:39:00.096147
NCT00578045|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2015-10-23|2007-12-18|2007-12-20|Estimate|||||||2015-10-23|2015-10-26|Estimate|July 2006||2006-07-31|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies|UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies|Withdrawn||Phase 1|0|Actual|University of Arkansas||1||no accrual|f||||f||||||||||2018-06-01 02:39:00.181447|2018-06-01 02:39:00.181447
NCT00578032|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-10-17|2007-12-19|2007-12-20|Estimate|||||||2017-10-17|2017-10-19|Actual|December 2007||2007-12-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Reconstructive Surgery For Head And Neck Cancer Patients|Reconstructive Surgery For Head And Neck Cancer Patients: A Prospective Analysis Of Quality Of Life And Symptom Relief|Completed|||80|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:39:00.246397|2018-06-01 02:39:00.246397
NCT00578019|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2013-09-28|2007-12-19|2007-12-20|Estimate|||||||2013-09-28|2013-10-01|Estimate|December 1999||1999-12-31|September 2013|2013-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|LISS||Comparison Between LISS Plating and Intramedullary (IM) Nailing for Supracondylar Femur Fractures|Prospective Comparison Between Less Invasive Stabilization System (LISS) Plating and Intramedullary Nailing for the Treatment of Supracondylar Femur Fractures|Completed||N/A|80|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:39:00.327872|2018-06-01 02:39:00.327872
NCT00578006|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-01-09|2007-12-18|2007-12-20|Estimate|||||||2017-01-09|2017-01-10|Estimate|March 2004||2004-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Internet-based System for Cancer Patients to Self-report Toxicity|Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life|Completed||N/A|1007|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||f||||||||||2018-06-01 02:39:00.405239|2018-06-01 02:39:00.405239
NCT00577993|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-08-25|2007-12-18|2007-12-20|Estimate|||||||2017-08-25|2017-08-28|Actual|March 16, 1998|Actual|1998-03-16|August 2017|2017-08-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients|Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma|Completed||Phase 3|210|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-06-01 02:39:00.483535|2018-06-01 02:39:00.483535
NCT00577980|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2013-04-25|2007-12-17|2007-12-20|Estimate|||||||2013-04-25|2013-04-29|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Testosterone in Castration-Resistant Prostate Cancer|Testosterone Replacement Therapy in Castration-Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Zero accrual and failure to generate multicenter interest.|f||||f||||||||||2018-06-01 02:39:00.590684|2018-06-01 02:39:00.590684
NCT00577967|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2010-07-06|2007-12-19|2007-12-20|Estimate|||||||2010-07-06|2010-07-07|Estimate|October 2005||2005-10-31|July 2010|2010-07-31|March 2006|Anticipated|2006-03-31|||||Interventional|||Gabapentin - A Solution to Uremic Pruritus?|Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study|Unknown status|Not yet recruiting|N/A|80|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:39:00.674658|2018-06-01 02:39:00.674658
NCT00577954|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2017-09-20|2007-12-19|2007-12-20|Estimate|||||||2017-09-20|2017-09-21|Actual|October 2006||2006-10-31|December 2008|2008-12-31|June 2014|Actual|2014-06-30|March 2010|Actual|2010-03-31||Observational|MRI-Coma||Multimodal Resonance Imaging for Outcome Prediction on Coma Patients|Multimodal Magnetic Resonance (MRI) Development in Comatose Patients for an Algorithm in the Prediction of Consciousness Recovery|Completed|||417|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-06-01 02:39:00.751441|2018-06-01 02:39:00.751441
NCT00577928|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-08-07|2007-12-19|2007-12-20|Estimate|||||||2015-08-07|2015-08-10|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Value of Fecal Calprotectin|Correlation of Fecal Calprotectin Level With the Clinical, Endoscopic, Histologic and Radiologic Activity in Inflammatory Bowel diseaseThe Value of Fecal Calprotectin for the Diagnosis and Assessment of Inflammatory Bowel Disease|Completed|||171|Actual|Indiana University|||2||f||||f||||||||||2018-06-01 02:39:00.829612|2018-06-01 02:39:00.829612
NCT00577915|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-11-28|2007-12-19|2007-12-20|Estimate|||||||2016-11-28|2016-11-29|Estimate|May 2003||2003-05-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Breast MRI Spectroscopy|Breast MRI Spectroscopy|Completed||N/A|150|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:39:00.875722|2018-06-01 02:39:00.875722
NCT00577889|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2013-09-20||2014-07-23|2007-12-19|2007-12-20|Estimate|2013-09-20|2013-11-25|Estimate||||2014-07-23|2014-07-25|Estimate|March 2008||2008-03-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|January 2011|Actual|2011-01-31||Interventional||One patient in Arm I canceled prior to treatment and was not used in baseline summary.|Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer|A Phase II Trial of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 02:39:01.004336|2018-06-01 02:39:01.004336
NCT00577876|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-10-25|2007-12-19|2007-12-20|Estimate|||||||2011-10-25|2011-10-27|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Assessment of the Functional Significance of Accessory Pudendal Arteries|Assessment of the Functional Significance of Accessory Pudendal Arteries|Completed||N/A|38|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:39:01.63699|2018-06-01 02:39:01.63699
NCT00577863|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2009-05-05||2009-07-13|2007-12-18|2007-12-20|Estimate|2009-05-05|2009-06-24|Estimate||||2009-07-13|2009-07-22|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy|B3D-MC-GHDF: Community Experience of Subjects With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy|Completed||Phase 3|200|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 02:39:01.807818|2018-06-01 02:39:01.807818
NCT00577850|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-04-15|2007-12-19|2007-12-20|Estimate|||||||2013-04-15|2013-04-17|Estimate|November 2002||2002-11-30|April 2013|2013-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose|Study to Determine the Pharmacokinetics of a Single 14C-labeled Intravenous Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose to Postmenopausal Women With Osteopenia or Osteoporosis|Completed||Phase 1|32|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 02:39:03.005463|2018-06-01 02:39:03.005463
NCT00577837|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-04-15|2007-12-19|2007-12-20|Estimate|||||||2013-04-15|2013-04-17|Estimate|April 2004||2004-04-30|April 2013|2013-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD|Active-controlled, Double-blind, Randomized, Sequential Escalating Dose Study to Assess Safety, Pharmacokinetics and Efficacy of 100, 150, and 200 mg Oral Risedronate Administered Monthly in Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 2|370|Actual|Warner Chilcott||4|||f||||f||||||||||2018-06-01 02:39:03.108164|2018-06-01 02:39:03.108164
NCT00577824|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2009-11-23||2015-03-20|2007-12-18|2007-12-20|Estimate|2009-11-23|2009-12-31|Estimate||||2015-03-20|2015-04-09|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)|Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled|Completed||Phase 3|181|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:39:03.22736|2018-06-01 02:39:03.22736
NCT00577811|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-01-14|2007-12-19|2007-12-20|Estimate|||||||2009-01-14|2009-01-15|Estimate|February 2003||2003-02-28|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Evaluation of Enrollment, Dynamics of Care and Patient Outcomes in the NYS Medicaid HIV Special Needs Plans|Evaluation of Enrollment, Dynamics of Care and Patient Outcomes in the NYS Medicaid HIV Special Needs Plans|Completed|||628|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||||||2018-06-01 02:39:04.312344|2018-06-01 02:39:04.312344
NCT00577798|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2010-08-19|2007-12-19|2007-12-20|Estimate|||||||2010-08-19|2010-08-20|Estimate|November 2007||2007-11-30|August 2010|2010-08-31||||December 2012|Anticipated|2012-12-31||Interventional|||Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin|Cardiac MRI for Assessment of Cardiac Structure and Function Following Doxorubicin Based Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|Unknown status|Active, not recruiting|N/A|15|Anticipated|University of Nebraska|||||f||||f||||||||||2018-06-01 02:39:04.390937|2018-06-01 02:39:04.390937
NCT00577785|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-12-20|2007-12-19|2007-12-20|Estimate|||||||2010-12-20|2010-12-22|Estimate|August 2007||2007-08-31|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Study to Obtain Full Thickness Bladder Tissue From Subjects Undergoing Cystectomy Surgery|A Multi-Center Study to Obtain Full Thickness Bladder Tissue Specimen From Subjects Undergoing Cystectomy Surgery|Completed|||52|Actual|Tengion|||1||f||||f||||||Samples Without DNA|"~     Tissue~   "|||2018-06-01 02:39:04.477782|2018-06-01 02:39:04.477782
NCT00577772|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2012-08-30||2012-10-01|2007-12-19|2007-12-20|Estimate|2012-08-30|2012-10-01|Estimate||||2012-10-01|2012-10-05|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Transit Time and Bacterial Overgrowth Using SmartPill Capsule|An Exploratory Assessment of Small Bowel Transit Time and Small Bowel Bacterial Overgrowth Using the SmartPill Capsule|Terminated||N/A|17|Actual|Mayo Clinic|The study was terminated early because enrollment goals were not met.|2||Enrollment Goal Not Met|f||||f||||||||||2018-06-01 02:39:04.554725|2018-06-01 02:39:04.554725
NCT00577759|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2015-02-12|2007-12-17|2007-12-20|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|C2P2||Community and Clinician Partnership for Prevention|Community and Clinician Partnership for Prevention|Completed||N/A|9|Actual|Duke University||3|||f||||f||||||||||2018-06-01 02:39:04.817568|2018-06-01 02:39:04.817568
NCT00577746|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-09-03|2007-12-19|2007-12-20|Estimate|||||||2014-09-03|2014-09-05|Estimate|June 2006||2006-06-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|||Clinical Impact of EUS in Staging NSCLC|The Clinical Impact of Endoscopic Ultrasound (EUS) in Staging Non-small Cell Lung Cancer (NSCLC)|Completed|||110|Actual|Indiana University|||2||f||||f||||||||||2018-06-01 02:39:04.914026|2018-06-01 02:39:04.914026
NCT00577733|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2013-09-17|2007-12-19|2007-12-20|Estimate|||||||2013-09-17|2013-09-18|Estimate|January 2008||2008-01-31|December 2007|2007-12-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Observational|BOA||Study of the Physiology of the Asthma of the Obese Subjects. Breathing Obesity Asthma Study (BOA)|Pathophysiological Study of Obesity-related Asthma|Completed|||204|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-06-01 02:39:04.968595|2018-06-01 02:39:04.968595
NCT00577382|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2016-08-22||2016-10-16|2007-12-18|2007-12-20|Estimate|2016-10-16|2016-12-08|Estimate||||2016-10-16|2016-12-08|Estimate|August 2007||2007-08-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The analysis dataset is comprised of treated patients.|SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma|A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma|Completed||Phase 2|52|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 02:39:13.225723|2018-06-01 02:39:13.225723
NCT00577720|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-08-12||2011-12-06|2007-12-19|2007-12-20|Estimate|2011-12-06|2012-01-13|Estimate||||2011-12-06|2012-01-13|Estimate|July 2006||2006-07-31|November 2011|2011-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate|Study to Assess the Efficacy, Safety and Pharmacokinetics of Risedronate Upon Oral Administration of a 35 mg Delayed-Release, a 50 mg Delayed-Release or a 35 mg Immediate-Release Administered Weekly for 13 Weeks to Postmenopausal Women|Completed||Phase 2|181|Actual|Warner Chilcott||4|||f||||f||||||||||2018-06-01 02:39:05.051261|2018-06-01 02:39:05.051261
NCT00577707|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2015-10-19||2017-12-11|2007-12-18|2007-12-20|Estimate|2015-10-19|2015-11-20|Estimate||||2017-12-11|2018-01-10|Actual|November 2007||2007-11-30|December 2017|2017-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)|A Phase II Study of Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)|Completed||Phase 2|9|Actual|Memorial Sloan Kettering Cancer Center|Analysis was not done on the secondary outcomes because of lack of accrual|1|||f||||||||||||||2018-06-01 02:39:07.018284|2018-06-01 02:39:07.018284
NCT00577694|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-10-07|2007-12-19|2007-12-20|Estimate|||||||2015-10-07|2015-10-12|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|July 2010|Actual|2010-07-31||Interventional|||Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Nonrandomized Dose-escalation Study of Clofarabine in Combination With Gemtuzumab Ozogamicin for Relapsed/Refractory Acute Myeloid Leukemia (AML) for Patients Less Than 60 Years-old|Terminated||Phase 1|21|Actual|UNC Lineberger Comprehensive Cancer Center||1||funding unavailable|f||||t||||||||||2018-06-01 02:39:07.24328|2018-06-01 02:39:07.24328
NCT00577681|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2014-12-11|2007-12-17|2007-12-20|Estimate|||||||2014-12-11|2014-12-15|Estimate|January 2002||2002-01-31|December 2014|2014-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Understanding the Increased Risk of Cardiovascular Disease in People With HIV|Lipoproteins, HIV, and Antiretroviral Therapy in SMART|Completed|||5472|Actual|University of Minnesota - Clinical and Translational Science Institute|||3||f||||t||||||Samples Without DNA|"~     The plasma specimens will be collected using EDTA plasma tubes. For each specimen, four~     transport tubes (Sarstedt 2.0 mL Micro Tube), each containing 1 mL of plasma, will be~     prepared and labeled with preprinted bar coded labels. The preprinted bar coded labels~     specify the patient identification code (PID), visit and specimen type, and the protocol and~     vial ID. Specimens will be frozen at negative 70 degrees Celcius and shipped on dry ice to a~     central repository, Advanced Biomedical Laboratories, Cinnaminson, New Jersey, where they~     will be scanned and put into storage. Paperwork documenting the specimens will be processed~     by the SDMC, and electronic files will be sent to the central repository.~   "|||2018-06-01 02:39:07.343071|2018-06-01 02:39:07.343071
NCT00577668|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-05-02|2007-12-18|2007-12-20|Estimate|||||||2011-05-02|2011-05-03|Estimate|April 2007||2007-04-30|May 2011|2011-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)|UARK 2007-01, A Phase II Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) and Autologous Transplantation for Patients Relapsing or Progressing After Tandem Transplantation|Withdrawn||Phase 2|0|Actual|University of Arkansas||1||Poor accrual|f||||f||||||||||2018-06-01 02:39:07.422175|2018-06-01 02:39:07.422175
NCT00577655|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2009-07-21||2016-09-02|2007-12-19|2007-12-20|Estimate|2009-10-27|2009-12-03|Estimate||||2016-09-02|2016-10-25|Estimate|August 2007||2007-08-31|September 2016|2016-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Albuterol HFA MDI in Pediatric Participants With Asthma|Phase 3 Study to Evaluate the Chronic-dose Safety and Efficacy of Albuterol-HFA-MDI Relative to Placebo in Pediatric Asthmatics|Completed||Phase 3|103|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 02:39:07.550486|2018-06-01 02:39:07.550486
NCT00577642|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2014-06-23||2017-01-18|2007-12-18|2007-12-20|Estimate|2017-01-18|2017-03-10|Actual||||2017-01-18|2017-03-10|Actual|October 2007||2007-10-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates|A Phase II Study of Bone Marker Assessment of Multiple Myeloma Patients Treated With AminoBisphosphonates|Completed||Phase 2|29|Actual|Massachusetts General Hospital|Only 6 month biomarker data--but sufficient to change dosing regimen|1|||f||||f||||||||||2018-06-01 02:39:08.519994|2018-06-01 02:39:08.519994
NCT00577629|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-03-04||2017-04-19|2007-12-18|2007-12-20|Estimate|2013-03-04|2013-04-15|Estimate||||2017-04-19|2017-05-30|Actual|June 18, 2005|Actual|2005-06-18|April 2017|2017-04-30|November 3, 2016|Actual|2016-11-03|April 8, 2012|Actual|2012-04-08||Interventional|||Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma|Dose-Intensive Chemotherapy Combined With Monoclonal Antibody Therapy and Targeted Radioimmunotherapy for Untreated Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|39|Actual|Duke University||1|||f||||f|t|f|||f|||No||2018-06-01 02:39:08.767259|2018-06-01 02:39:08.767259
NCT00577616|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-10-22|2007-12-19|2007-12-20|Estimate|||||||2014-10-22|2014-10-23|Estimate|December 2007||2007-12-31|July 2013|2013-07-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|ECAR||Ruptured Aorta-iliac Aneurysms: Endo vs. Surgery|Randomized Study Comparing Endovascular Repair Versus Conventional Repair for Ruptured Aorta-iliac Aneurysms|Completed||N/A|107|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:39:09.112085|2018-06-01 02:39:09.112085
NCT00577603|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2013-04-24|2007-12-19|2007-12-20|Estimate|||||||2013-04-24|2013-04-25|Estimate|January 2006||2006-01-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluate and Compare the Rate of Para-Stomal Herniation After Permanent Stoma Formation|A Controlled, Randomized Study to Evaluate and Compare the Rate of Para-Stomal Herniation After Permanent Stoma Formation With and Without Reinforcement With a Collagen Mesh|Completed||N/A|40|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:39:09.28775|2018-06-01 02:39:09.28775
NCT00577590|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2018-02-07|2007-12-18|2007-12-20|Estimate|||||||2018-02-07|2018-02-09|Actual|October 2003||2003-10-31|February 2018|2018-02-28|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes|Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes|Completed||N/A|146|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 02:39:09.37557|2018-06-01 02:39:09.37557
NCT00577369|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-09-14|2007-12-19|2007-12-20|Estimate|||||||2009-09-14|2009-09-16|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Pilot Study to Measure Blood Levels of Desflurane in Children|A Pilot Study to Measure Blood Levels of Desflurane in Children|Completed||N/A|7|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-06-01 02:39:13.787054|2018-06-01 02:39:13.787054
NCT00577577|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2008-07-21|2007-12-19|2007-12-20|Estimate|||||||2008-07-21|2008-07-23|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1|A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Insmed Incorporated|||||f||||t||||||||||2018-06-01 02:39:09.50357|2018-06-01 02:39:09.50357
NCT00577564|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2012-09-11|2007-12-19|2007-12-20|Estimate|||||||2012-09-11|2012-09-12|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|December 2007|Actual|2007-12-31|||||Observational|||EUS-CPN: A Retrospective Review|Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN): A Retrospective Review of Safety|Completed|||||Indiana University|||||f||||f||||||||||2018-06-01 02:39:09.608036|2018-06-01 02:39:09.608036
NCT00577538|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2015-08-07|2007-12-19|2007-12-20|Estimate|||||||2015-08-07|2015-08-10|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Prevalence of Lymphoma in IBD|Prevalence and Risk Factor for Lymphoproliferative Disease in Patients With Inflammatory Bowel Disease|Completed|||7|Actual|Indiana University|||2||f||||f||||||||||2018-06-01 02:39:09.688472|2018-06-01 02:39:09.688472
NCT00577525|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-02-26|2007-12-19|2007-12-20|Estimate|||||||2014-02-26|2014-02-27|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|July 2010|Actual|2010-07-31||Observational|Nephrovir||Latent Viral Infection of Lymphoid Cells in Idiopathic Nephrotic Syndrome|Viral Infection of Lymphoid Cells Occuring at the First Manifestation of Idiopathic Nephrotic Syndrome|Completed|||401|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, red cells and DNA~   "|||2018-06-01 02:39:09.75518|2018-06-01 02:39:09.75518
NCT00577512|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2011-04-19||2017-10-17|2007-12-18|2007-12-20|Estimate|2011-04-19|2011-05-13|Estimate||||2017-10-17|2017-11-20|Actual|April 2007||2007-04-30|October 2017|2017-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE|2006-32: Phase II Study of Rapidly Recycled High Dose DTPACE (HD-DTPACE) for Untreated or Previously Treated, High-Risk Multiple Myeloma (MM)|Completed||Phase 2|4|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:39:09.83729|2018-06-01 02:39:09.83729
NCT00577499|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2015-03-03|2007-12-18|2007-12-20|Estimate|||||||2015-03-03|2015-03-04|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis|Effect of Lubiprostone on Nutritional Status and Pulmonary Function in Adults With Cystic Fibrosis|Terminated|||7|Actual|University of Arkansas|||1|Recruitment was suboptimal|f||||f||||||||||2018-06-01 02:39:10.006203|2018-06-01 02:39:10.006203
NCT00577473|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-05-24||2011-09-14|2007-12-19|2007-12-20|Estimate|2011-05-24|2011-06-22|Estimate||||2011-09-14|2011-09-16|Estimate|February 2001||2001-02-28|September 2011|2011-09-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|ASCEND I||Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)|A Double-blind, Randomized, 6 Week, Parallel-group Design Clinical Trial in Patients With Mildly to Moderately Active Ulcerative Colitis to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day|Completed||Phase 3|301|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 02:39:10.101006|2018-06-01 02:39:10.101006
NCT00577460|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2011-06-16||2014-05-07|2007-12-19|2007-12-20|Estimate|2011-06-16|2011-07-14|Estimate||||2014-05-07|2014-05-16|Estimate|December 2007||2007-12-31|April 2014|2014-04-30||||June 2010|Actual|2010-06-30||Interventional||Treated Set, all patients dispensed study drug and documented to have taken at least one dose|Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD|Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Advanced Parkinson's Disease (PD)|Completed||Phase 3|391|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:39:10.756438|2018-06-01 02:39:10.756438
NCT00577447|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2015-04-27|2007-12-19|2007-12-20|Estimate|||||||2015-04-27|2015-04-28|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Docosahexaenoic Acid in the Treatment of Autism|A Randomized, Double-Blind, Placebo-Controlled Trial of Docosahexaenoic Acid Supplementation in Children With Autism|Completed||N/A|48|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:39:12.334845|2018-06-01 02:39:12.334845
NCT00577434|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2015-03-11|2007-12-18|2007-12-20|Estimate|||||||2015-03-11|2015-03-12|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Observational|||Pharmacokinetics and Pharmacodynamics of Pentobarbital in Neonates, Infants, and Children Following Open Heart Surgery|The Pharmacokinetics and Pharmacodynamics of a Single Dose of Pentobarbital for Clinically Indicated Sedation for Neonates, Infants, and Children Recovering From Open Heart Surgery|Terminated|||37|Actual|Children's Hospital of Philadelphia||||Sluggish enrollment|f||||f||||||None Retained|"~     Blood~   "|||2018-06-01 02:39:12.408898|2018-06-01 02:39:12.408898
NCT00577421|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2011-09-27|2007-12-19|2007-12-20|Estimate|||||||2011-09-27|2011-09-28|Estimate|June 2003||2003-06-30|September 2011|2011-09-30|January 2006|Actual|2006-01-31|||||Interventional|||Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO|An Extension Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO|Completed||Phase 3|32|Actual|Warner Chilcott||1|||f||||f||||||||||2018-06-01 02:39:12.473266|2018-06-01 02:39:12.473266
NCT00577408|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2017-07-20||2017-08-24|2007-12-19|2007-12-20|Estimate|2017-08-24|2017-08-25|Actual||||2017-08-24|2017-08-25|Actual|September 2007||2007-09-30|August 2017|2017-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|Depot-BNT||Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone|Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial|Completed||Phase 3|60|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-06-01 02:39:12.553562|2018-06-01 02:39:12.553562
NCT00577395|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|2009-11-18||2013-04-15|2007-12-19|2007-12-20|Estimate|2009-11-18|2009-12-22|Estimate||||2013-04-15|2013-04-22|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Bone Microarchitecture in Osteopenic Postmenopausal Women|A 12-month, Multicenter, Double-blind, Randomized, Parallel Group Study Comparing 150 mg Once-a-month Risedronate and Placebo Using 3-dimensional Micro MRI (Magnetic Resonance Imaging).|Terminated||Phase 4|13|Actual|Warner Chilcott|NOTE: The study was terminated early (after 5 months), prior to acquiring any efficacy endpoints; consequently, NO subject efficacy analyses were performed|2|||f||||f||||||||||2018-06-01 02:39:12.880123|2018-06-01 02:39:12.880123
NCT00577356|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2010-09-13||2011-01-18|2007-12-18|2007-12-20|Estimate|2011-01-18|2011-01-20|Estimate||||2011-01-18|2011-01-20|Estimate|February 2008||2008-02-29|November 2010|2010-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer|Phase II Trial of Neoadjuvant Docetaxel and CG1940/CG8711 Followed by Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer|Terminated||Phase 2|6|Actual|Benaroya Research Institute|the trial was closed prior to planned accrual of 30 patients due to an external report from the randomized trial of docetaxel and CG1940/CG8711 resulting in a higher incidence of deaths compared to docetaxel alone in metastatic prostate cancer.|||Safety reasons, though no safety issues arose.|f||||t||||||||||2018-06-01 02:39:13.875695|2018-06-01 02:39:13.875695
NCT00577343|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2016-02-29|2007-12-19|2007-12-20|Estimate|||||||2016-02-29|2016-03-01|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Hospital Acquired and Community Acquired MRSA in GI Lab|Hospital Acquired and Community Acquired Methicillin Resistant Staph Aureus in the Outpatient Gastrointestinal Lab: A Prospective Study of Prevalence|Withdrawn|||0|Actual|Indiana University||||study lacked funding to recruit|f||||f||||||Samples Without DNA|"~     buccal swab for saliva~   "|||2018-06-01 02:39:14.00956|2018-06-01 02:39:14.00956
NCT00577330|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2007-12-19|2007-12-18|2007-12-20|Estimate|||||||2007-12-19|2007-12-28|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|January 2008|Anticipated|2008-01-31|||||Interventional|||Efficacy of Myalgesin™ to Support Joint Function in Patients With Knee Osteoarthritis|The Efficacy of Myalgesin™ for the Support of Joint Function in Patients With Osteoarthritis of the Knee — A Prospective Randomized Controlled Study|Unknown status|Active, not recruiting|Phase 3|110|Anticipated|ProThera, Inc.||2|||f||||f||||||||||2018-06-01 02:39:14.063008|2018-06-01 02:39:14.063008
NCT00577317|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2014-12-29|2007-12-19|2007-12-20|Estimate|||||||2014-12-29|2014-12-31|Estimate|December 2007||2007-12-31|December 2014|2014-12-31||||July 2009|Actual|2009-07-31||Interventional|||Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer|A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy|Terminated||Phase 3|2|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 02:39:14.130337|2018-06-01 02:39:14.130337
NCT00577304|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-02-03|2007-12-18|2007-12-20|Estimate|||||||2010-02-03|2010-02-05|Estimate|December 2007||2007-12-31|April 2008|2008-04-30|March 2008|Anticipated|2008-03-31|March 2008|Anticipated|2008-03-31||Interventional|||A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon|A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|MediQuest Therapeutics||2|||f||||f||||||||||2018-06-01 02:39:14.221923|2018-06-01 02:39:14.221923
NCT00577278|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-19|||2018-05-07|2007-12-19|2007-12-20|Estimate|||||||2018-05-07|2018-05-09|Actual|January 15, 2007||2007-01-15|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma|A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan|Active, not recruiting||Phase 2|54|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:39:14.34106|2018-06-01 02:39:14.34106
NCT00577265|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-01-27|2007-12-19|2007-12-20|Estimate|||||||2011-01-27|2011-01-28|Estimate|November 2004||2004-11-30|January 2011|2011-01-31||||||||Observational|INVOLVE||An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication|An Observational Study to Investigate How Patients Experience the Ability to Adjust Their Asthma Maintenance Medication According to Instructions Received From Their Physician (AMD).|Completed|||||AstraZeneca|||||f||||f||||||||||2018-06-01 02:39:14.468393|2018-06-01 02:39:14.468393
NCT00577252|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-11-23|2007-12-19|2007-12-20|Estimate|||||||2009-11-23|2009-11-24|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|April 2008|Actual|2008-04-30|||||Observational|||Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis|Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis|Completed|||40|Anticipated|Akron Children's Hospital|||1||f||||f||||||||||2018-06-01 02:39:14.525318|2018-06-01 02:39:14.525318
NCT00577226|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-05-04|2007-12-18|2007-12-20|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2005||2005-04-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Shilla Growth Permitting Spinal Instrumentation System for Treatment of Scoliosis in the Immature Spine|Use of the Shilla Growth Permitting Spinal Instrumentation System/Technique for the Treatment of Scoliosis in the Immature Spine|Terminated|||50|Actual|Arkansas Children's Hospital Research Institute|||1|IRB has requested additional information regarding IDE|f||||f||||||||||2018-06-01 02:39:14.694185|2018-06-01 02:39:14.694185
NCT00577213|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-10-25|2007-12-18|2007-12-20|Estimate|||||||2012-10-25|2012-10-26|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Diagnosis of Hemangiomas and Vascular Malformations|Diagnosis of Hemangiomas and Vascular Malformations Using Non-invasive Imaging Devices|Completed|||56|Actual|University of Arkansas|||||f||||t||||||||||2018-06-01 02:39:14.757494|2018-06-01 02:39:14.757494
NCT00577200|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-09-26|2007-12-19|2007-12-20|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2008||2008-01-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MACDrive||Safety of Driving After Minor Surgery With Monitored Anesthesia Care|The Safety of Driving in Patients After Minor Surgery With Monitored Anesthesia Care|Active, not recruiting||Phase 4|625|Anticipated|Rush University Medical Center||3|||f||||f||||||||||2018-06-01 02:39:14.824154|2018-06-01 02:39:14.824154
NCT00577187|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-06-11|2007-12-18|2007-12-20|Estimate|||||||2012-06-11|2012-06-12|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Placement of CS/LV Pacing Leads With EnSite NavX Guidance|Placement of Coronary Sinus/Left Ventricular Leads With EnSite NavX Guidance|Withdrawn||Early Phase 1|0|Actual|St. Jude Medical||||Lack of enrollment|f||||f||||||||||2018-06-01 02:39:14.92915|2018-06-01 02:39:14.92915
NCT00577174|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-04-27|2007-12-18|2007-12-20|Estimate|||||||2012-04-27|2012-04-30|Estimate|June 2007||2007-06-30|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|August 2011|Actual|2011-08-31||Observational|||Mitochondrial Function in Pediatric Obesity|Mitochondrial Function in Pediatric Obesity|Unknown status|Active, not recruiting||110|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, white blood cells~   "|||2018-06-01 02:39:14.986541|2018-06-01 02:39:14.986541
NCT00577161|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-09-19|2007-12-17|2007-12-19|Estimate|||||||2008-09-19|2008-09-22|Estimate|September 2007||2007-09-30|September 2008|2008-09-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL|Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) vs Fludarabine and Rituximab (F-R) for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|Terminated||Phase 3|300|Anticipated|CTI BioPharma||2||closed to enrollment|f||||t||||||||||2018-06-01 02:39:15.072345|2018-06-01 02:39:15.072345
NCT00577148|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18||2016-04-18|2016-04-18|2007-12-18|2007-12-19|Estimate||||2016-04-18|2016-05-18|Estimate|2016-04-18|2016-05-18|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes|A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).|Terminated||Phase 3|89|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 02:39:15.145285|2018-06-01 02:39:15.145285
NCT00577135|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-01-23||2018-02-05|2007-12-18|2007-12-19|Estimate|2013-04-17|2013-05-27|Estimate||||2018-02-05|2018-03-06|Actual|February 2008||2008-02-29|April 2013|2013-04-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)|Diuretic Optimal Strategy Evaluation in Acute Heart Failure (The DOSE-AHF Study)|Completed||Phase 3|308|Actual|Duke University||4|||f||||t||||||||||2018-06-01 02:39:15.355994|2018-06-01 02:39:15.355994
NCT00577122|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2014-09-16||2014-09-24|2007-12-18|2007-12-19|Estimate|2014-09-16|2014-09-23|Estimate||||2014-09-24|2014-10-03|Estimate|July 2007||2007-07-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer|MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial|Completed||Phase 2|30|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 02:39:17.201202|2018-06-01 02:39:17.201202
NCT00577109|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-08-23|2007-12-18|2007-12-19|Estimate|||||||2016-08-23|2016-08-24|Estimate||||August 2016|2016-08-31|June 2012|Actual|2012-06-30|||||Interventional|||A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.|An Open Label Study to Assess the Effect of FOLFIRI Plus Avastin and Cetuximab on Progression-free Survival in Patients With Previously Untreated Metastatic Colorectal Cancer.|Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche||1||Study was cancelled before patient enrollment|f||||||||||||||2018-06-01 02:39:17.736746|2018-06-01 02:39:17.736746
NCT00577096|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2011-03-17||2015-04-02|2007-12-18|2007-12-19|Estimate|2011-03-22|2011-04-21|Estimate||||2015-04-02|2015-04-06|Estimate|October 2001||2001-10-31|April 2015|2015-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Effects of Exercise in Combination With Epoetin Alfa|Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma|Completed||N/A|120|Actual|University of Arkansas|Patients with hemoglobin <8 g/dl received RBC transfusions according to the transplantation protocol. Analysis may have missed specific disease-related influences on hemoglobin. Randomization should have distributed disease risks equally for groups.|2|||f||||t||||||||||2018-06-01 02:39:17.836711|2018-06-01 02:39:17.836711
NCT00577083|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2015-07-27||2018-02-27|2007-12-18|2007-12-19|Estimate|2016-01-25|2016-02-22|Estimate||||2018-02-27|2018-03-26|Estimate|November 2006||2006-11-30|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates|Cap-fitted Colonoscopy: a Randomized, Tandem Colonoscopy Study of Adenoma Miss Rates|Completed||N/A|100|Actual|Indiana University||2|||f||||t||||||||No||2018-06-01 02:39:18.469722|2018-06-01 02:39:18.469722
NCT00577070|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2009-10-05|2007-12-18|2007-12-19|Estimate|||||||2009-10-05|2009-10-06|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression||Completed||Phase 2|40|Anticipated|BeerYaakov Mental Health Center||2|||f||||f||||||||||2018-06-01 02:39:18.725052|2018-06-01 02:39:18.725052
NCT00577057|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2013-08-21|2007-12-18|2007-12-19|Estimate|||||||2013-08-21|2013-08-22|Estimate|September 2006||2006-09-30|August 2013|2013-08-31|August 2013|Anticipated|2013-08-31|||||Interventional|||Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer|Randomized Trial to Evaluate the Therapeutic Gain by Changing the Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and the Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma|Unknown status|Not yet recruiting|N/A|798|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:39:18.790935|2018-06-01 02:39:18.790935
NCT00577044|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2008-12-15|2007-12-18|2007-12-19|Estimate|||||||2008-12-15|2008-12-17|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|December 2007|Anticipated|2007-12-31|||||Observational|||Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong|Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong: Natural History and Development of Liver Complications|Unknown status|Active, not recruiting||600|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:39:18.873176|2018-06-01 02:39:18.873176
NCT00577031|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2014-07-15||2015-07-21|2007-12-18|2007-12-19|Estimate|2015-07-21|2015-08-18|Estimate||||2015-07-21|2015-08-18|Estimate|February 2008||2008-02-29|July 2015|2015-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Safety population: all enrolled participants who received at least 1 dose of all study medications.|OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.|Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'|Completed||Phase 4|205|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:39:18.955421|2018-06-01 02:39:18.955421
NCT00577018|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-05-28|2007-12-18|2007-12-19|Estimate|||||||2008-05-28|2008-05-29|Estimate|August 1998||1998-08-31|December 2007|2007-12-31|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Efficacy and Safety Study of the Effect of Dose-Titration of Prucalopride for The Treatment of Chronic Constipation|A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dose-Titration on the Safety and Efficacy and R108512 Tablets in Subjects With Chronic Constipation|Completed||Phase 3|755|Actual|Movetis||3|||f||||f||||||||||2018-06-01 02:39:19.639978|2018-06-01 02:39:19.639978
NCT00576108|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2008-07-18|2007-12-17|2007-12-18|Estimate|||||||2008-07-18|2008-07-22|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)||Completed||Phase 2|48|Anticipated|Kalypsys, Inc.||2|||f||||f||||||||||2018-06-01 02:39:36.317715|2018-06-01 02:39:36.317715
NCT00577005|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2016-09-08||2018-01-12|2007-12-17|2007-12-19|Estimate|2017-04-20|2017-04-24|Actual||||2018-01-12|2018-01-17|Actual|July 2007||2007-07-31|January 2018|2018-01-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|Keppra-DB||Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients|Levetiracetam (Keppra) Treatment for Cocaine Dependence in Methadone-Maintained Patients|Completed||Phase 2|28|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:39:19.735617|2018-06-01 02:39:19.735617
NCT00576992|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-05-24|2007-12-18|2007-12-19|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2003||2003-01-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Demographics and Findings of Upper Endoscopy Patients|A Clinical Study of Demographics and Findings During Endoscopy in Patients With Abdominal Pain, Dyspepsia, GERD, and Associated Symptoms|Terminated|||1177|Actual|Midwest Biomedical Research Foundation|||1|Recruitment not being met|f||||f||||||||||2018-06-01 02:39:20.140364|2018-06-01 02:39:20.140364
NCT00576979|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2017-12-22|2007-12-18|2007-12-19|Estimate|||||||2017-12-22|2017-12-27|Actual|February 2, 2008||2008-02-02|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|Phase I-II Study of Escalating Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy in Combination With Etoposide (VP16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients With Poor Risk Acute Lymphocytic Leukemia (ALL) or Poor Risk Acute Myelogenous Leukemia (AML)|Active, not recruiting||Phase 1/Phase 2|87|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:39:20.226252|2018-06-01 02:39:20.226252
NCT00576953|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-11-11|2007-12-17|2007-12-19|Estimate|||||||2008-11-11|2008-11-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:39:20.350627|2018-06-01 02:39:20.350627
NCT00576940|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2007-12-18|2007-12-18|2007-12-19|Estimate|||||||2007-12-18|2007-12-19|Estimate|June 2004||2004-06-30|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|ImmuniEteral||Standard and Immunostimulating Enteral Nutrition in Surgical Patients|Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial|Completed||Phase 4|196|Actual|Jagiellonian University||2|||f||||f||||||||||2018-06-01 02:39:20.392223|2018-06-01 02:39:20.392223
NCT00576927|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2013-09-17||2014-08-12|2007-12-17|2007-12-19|Estimate|2014-08-12|2014-08-13|Estimate||||2014-08-12|2014-08-13|Estimate|October 2007||2007-10-31|August 2014|2014-08-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional||Subjects entered a clinical assessment phase (CAP) after consent, which eliminated 36 subjects. Then 43 subjects entered baseline which excluded 13 subjects. 30 subjects started sleep hygiene intervention, but only 23 subjects completed. 1 more subject withdrew during placebo. Then 22 started drug and those 22 completed randomization.|Improving Sleep in Nursing Homes|Improving Sleep in Nursing Homes|Completed||Phase 4|79|Actual|Emory University|Low power to detect statistically significant effects of the interventions on outcomes; Inability to examine predictors of responsiveness because of the small sample size and the large number of predictors of response.|2|||f||||t||||||||||2018-06-01 02:39:20.47822|2018-06-01 02:39:20.47822
NCT00576914|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-03-08|2007-12-18|2007-12-19|Estimate|||||||2010-03-08|2010-03-09|Estimate|June 2007||2007-06-30|March 2009|2009-03-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer|Adjuvant Vinorelbine Plus Cisplatin Versus Vinorelbine Plus Cisplatin Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer (Phase III Study, Randomized, Open, Multi-center)|Unknown status|Recruiting|Phase 3|1108|Anticipated|Chinese Academy of Sciences||2|||f||||t||||||||||2018-06-01 02:39:20.880364|2018-06-01 02:39:20.880364
NCT00576901|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2014-05-16||2014-07-17|2007-12-18|2007-12-19|Estimate|2014-07-17|2014-08-11|Estimate||||2014-07-17|2014-08-11|Estimate|November 2007||2007-11-30|July 2014|2014-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Intent-to-treat (ITT) population. The ITT population included all enrolled participants.|A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.|"An Open Label Study to Assess the Effect of Neoadjuvant Treatment With Docetaxel + Xeloda + Avastin on Pathological Response Rate in Inflammatory or Locally Advanced Breast Cancer"|Terminated||Phase 2|23|Actual|Hoffmann-La Roche||1||"The sample for statistical analysis of results could not be recruited within the specified~   timeframe upon retirement of the original principal investigator."|f||||||||||||||2018-06-01 02:39:20.981826|2018-06-01 02:39:20.981826
NCT00576888|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2018-04-16|2007-12-18|2007-12-19|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2007||2007-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|VAC||Registry for Vascular Anomalies Associated With Coagulopathy|International Registry for Vascular Anomalies Associated With Coagulopathy|Recruiting|||30|Anticipated|Medical College of Wisconsin|||1||f||||f||||||Samples With DNA|"~     Buccal swab, tissue biopsy if available~   "|||2018-06-01 02:39:21.150413|2018-06-01 02:39:21.150413
NCT00576875|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-02-20|2007-12-18|2007-12-19|Estimate|||||||2012-02-20|2012-02-22|Estimate|August 2006||2006-08-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Duke Conte Center for the Neuroscience of Depression in Late Life|Conte Centers for the Neuroscience of Depression|Completed|||795|Actual|Duke University|||2||f||||f||||||Samples With DNA|"~     Blood for DNA; Post-mortem brain tissue~   "|||2018-06-01 02:39:21.225261|2018-06-01 02:39:21.225261
NCT00576862|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-28|2007-12-17|2007-12-19|Estimate|||||||2007-12-28|2008-01-09|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|April 2004|Actual|2004-04-30|||||Interventional|||Extension to Study HMR1964A/3011 in Belgium|Multicenter,Open,Uncontrolled,Clinical Extension Trial in Subjects With Type I Diabetes Previously Participating in Study HMR1964A/3011 in Belgium|Completed||Phase 4|32|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:39:21.359263|2018-06-01 02:39:21.359263
NCT00576849|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2010-05-25|2007-12-18|2007-12-19|Estimate|||||||2010-05-25|2010-05-27|Estimate|December 2007||2007-12-31|January 2009|2009-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients|Phase 4 Study of a Total Balanced Volume Replacement Regimen in Elderly Cardiac Surgery Patients|Completed||Phase 4|50|Anticipated|Klinikum Ludwigshafen||2|||f||||t||||||||||2018-06-01 02:39:21.431481|2018-06-01 02:39:21.431481
NCT00576836|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17||2012-09-10|2018-05-02|2007-12-18|2007-12-19|Estimate||||2012-09-12|2012-09-14|Estimate|2018-05-02|2018-05-04|Actual|February 2006||2006-02-28|May 2018|2018-05-31|June 2027|Anticipated|2027-06-30|August 2010|Actual|2010-08-31||Interventional|||Thymus Transplantation Dose in DiGeorge #932|Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1|Active, not recruiting||Phase 2|28|Actual|Duke University||2|||f||||t|t|f||||||||2018-06-01 02:39:21.508589|2018-06-01 02:39:21.508589
NCT00576823|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2011-01-13|2010-03-08|2014-10-21|2007-12-18|2007-12-19|Estimate|2011-01-13|2011-02-08|Estimate|2010-03-08|2010-03-09|Estimate|2014-10-21|2014-10-29|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Interventional|Alfahydro||Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology|12-week, Multicenter, Open-label, Non-comparative Study to Investigate Pharmacodynamic and Safety of Alfuzosin 0.2 mg/kg/Day in the Treatment of Children and Adolescents 2 - 16 Years of Age With Hydronephrosis Associated With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension|Completed||Phase 3|25|Actual|Sanofi|This was an exploratory, open-label, non-comparative trial. Analyses were purely descriptive.|3|||f||||t||||||||||2018-06-01 02:39:21.612064|2018-06-01 02:39:21.612064
NCT00576810|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29||2014-04-30|2014-04-30|2007-12-18|2007-12-19|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|October 2007||2007-10-31|April 2014|2014-04-30||||January 2009|Actual|2009-01-31||Interventional|||Sodium Picosulphate vs. Placebo in Functional Constipation|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks Treatment With Sodium Picosulfate [Dulcolax®, Laxoberal®]Drops 10 mg Administered Orally, Once Daily, in Patients With Functional Constipation|Completed||Phase 3|367|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:39:22.488123|2018-06-01 02:39:22.488123
NCT00576797|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2016-02-01|2007-12-18|2007-12-19|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|VM||Genomic Tools for Studying the Ecology of the Human Vaginal Microflora|Genomic Tools for Studying the Ecology of the Human Vaginal Microflora|Completed|||396|Actual|Emory University|||||f||||f||||||Samples With DNA|"~     vaginal secretions~   "|||2018-06-01 02:39:22.874991|2018-06-01 02:39:22.874991
NCT00576784|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-17|2007-12-17|2007-12-19|Estimate|||||||2007-12-17|2007-12-19|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|PIOswitch||Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin|Multi Center, Open Label Study to Evaluate the Influence of Pioglitazone Treatment Over 6 Months on Metabolic Control in Type II Diabetic Patients Previously Treated With Insulin|Completed||Phase 4|100|Actual|IKFE Institute for Clinical Research and Development||1|||f||||f||||||||||2018-06-01 02:39:23.112141|2018-06-01 02:39:23.112141
NCT00576771|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2015-04-27|2007-12-18|2007-12-19|Estimate|||||||2015-04-27|2015-04-28|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Different Assisted Mechanical Ventilation in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilatory Assist (NAVA) and Controlled by Patient|Effects of Different Assisted Mechanical Ventilation in ALI/ARDS Patients: PSV, NAVA and Controlled by Patient|Completed||N/A|15|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 02:39:23.406725|2018-06-01 02:39:23.406725
NCT00576758|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2013-11-27||2014-08-15|2007-12-18|2007-12-19|Estimate|2014-02-13|2014-03-31|Estimate||||2014-08-15|2014-08-19|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|September 2011|Actual|2011-09-30||Interventional|||GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma|An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma|Completed||Phase 2|175|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:39:23.520177|2018-06-01 02:39:23.520177
NCT00576745|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-07-17|2007-12-18|2007-12-19|Estimate|||||||2012-07-17|2012-07-18|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||A Comparison Of The 3M TM S Surgical Skin Closure System To The Standard Vicryl Suture Closure of Sternotomy Incisions During Cardiac Surgery|Comparison Of The 3M Surgical Skin Closure System To The Standard Vicryl Suture Closure Of Sternotomy Incisions|Completed||Phase 1|36|Actual|American Heart Association||2|||f||||t||||||||||2018-06-01 02:39:24.387708|2018-06-01 02:39:24.387708
NCT00576732|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2010-09-02||2014-04-24|2007-12-17|2007-12-19|Estimate|2010-09-02|2010-09-28|Estimate||||2014-04-24|2014-05-09|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder|Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety|Completed||Phase 4|96|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 02:39:24.537471|2018-06-01 02:39:24.537471
NCT00576719|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2014-02-19|2007-12-17|2007-12-19|Estimate|||||||2014-02-19|2014-02-20|Estimate|March 2005||2005-03-31|February 2014|2014-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia|Intensive Treatment of Adolescent Panic and Agoraphobia|Completed||Phase 2|63|Actual|Boston University||3|||f||||t||||||||||2018-06-01 02:39:25.462206|2018-06-01 02:39:25.462206
NCT00576706|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2011-11-15|2007-12-18|2007-12-19|Estimate|||||||2011-11-15|2011-11-16|Estimate|December 2007||2007-12-31|November 2011|2011-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|PRESENT||PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity|A Phase III, Randomized, Double-dummy, Double Blind, Misoprostol-comparative Clinical Trial to Evaluate the Efficacy and Safety of Mucosta® Tablet in the Prevention of NSAID-induced Gastrointestinal Complications|Completed||Phase 3|396|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 02:39:25.640864|2018-06-01 02:39:25.640864
NCT00576693|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2014-05-06||2018-04-30|2007-12-17|2007-12-19|Estimate|2014-06-10|2014-07-11|Estimate||||2018-04-30|2018-05-30|Actual|October 2008||2008-10-31|April 2018|2018-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|SAMMPRIS||Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis|Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis|Completed||Phase 3|451|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 02:39:25.810942|2018-06-01 02:39:25.810942
NCT00576680|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2017-08-03|2007-12-18|2007-12-19|Estimate|||||||2017-08-03|2017-08-04|Actual|May 2008||2008-05-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors|Phase I/II Study of RAD001 in Combination With Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors|Active, not recruiting||Phase 1/Phase 2|12|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 02:39:26.898076|2018-06-01 02:39:26.898076
NCT00576095|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2014-03-12|2007-12-14|2007-12-18|Estimate|||||||2014-03-12|2014-03-14|Estimate|August 2005||2005-08-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Clinical and Biological Characteristics of Psychotic Depression|Hypothalamic-Pituitary-Adrenal (HPA)/ Dopamine Axis in Psychotic Depression|Completed|||73|Actual|Stanford University|||3||f||||f||||||Samples With DNA|"~     serum~   "|||2018-06-01 02:39:36.391673|2018-06-01 02:39:36.391673
NCT00576667|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18||2016-04-18|2016-04-18|2007-12-18|2007-12-19|Estimate||||2016-04-18|2016-05-18|Estimate|2016-04-18|2016-05-18|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes|A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Non-diabetic Patients With Nonalcoholic Steatohepatitis (NASH)|Terminated||Phase 3|165|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 02:39:26.990585|2018-06-01 02:39:26.990585
NCT00576654|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2018-04-12|2007-12-18|2007-12-19|Estimate|||||||2018-04-12|2018-04-13|Actual|December 5, 2007|Actual|2007-12-05|April 2018|2018-04-30||||August 1, 2018|Anticipated|2018-08-01||Interventional|||Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery|A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-06-01 02:39:27.111876|2018-06-01 02:39:27.111876
NCT00576641|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2014-10-29|2007-12-18|2007-12-19|Estimate|||||||2014-10-29|2014-10-30|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|April 2012|Actual|2012-04-30|January 2010|Actual|2010-01-31||Interventional|||Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma|A Phase l Trial of Tumor Associated Antigen Pulsed Dendritic Cell Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma|Completed||Phase 1|22|Actual|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-06-01 02:39:27.257139|2018-06-01 02:39:27.257139
NCT00576628|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2016-07-21||2016-10-07|2007-12-18|2007-12-19|Estimate|2016-10-07|2016-11-30|Estimate||||2016-10-07|2016-11-30|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||The intent-to-treat (ITT) population included all participants who received at least one dose of C.E.R.A. (Week 0) and for whom data for at least one follow-up variable were available.|A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.|A Single Arm Open Label Multicentre Study to Assess the Efficacy, Safety and Tolerability of Monthly Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Pre-dialysis Patients, Not Currently Treated With ESA|Completed||Phase 3|133|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:39:27.367055|2018-06-01 02:39:27.367055
NCT00576615|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-05-05|2007-12-18|2007-12-19|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2002||2002-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Propofol's Hypnotic and Memory Effects|CNS Targets of Propofol's Hypnotic and Memory Effects|Completed|||102|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:39:27.928507|2018-06-01 02:39:27.928507
NCT00576602|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-11-03|2007-12-18|2007-12-19|Estimate|||||||2016-11-03|2016-11-04|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant|A Randomized, Open Label Study to Evaluate the Effect of Subcutaneous Mircera, Versus no ESA Therapy, on Hemoglobin Levels in Chronic Kidney Disease Patients With Anemia After Kidney Transplant.|Terminated||Phase 4|1|Actual|Hoffmann-La Roche||2||poor recruitment|f||||||||||||||2018-06-01 02:39:28.00559|2018-06-01 02:39:28.00559
NCT00576589|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2010-01-14|2007-12-17|2007-12-19|Estimate|||||||2010-01-14|2010-01-18|Estimate|January 2008||2008-01-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|||||Interventional|||Study Of The Safety And Pharmacokinetics Of CE-326,597 In Patients With Asymptomatic Gallstones|A Phase 1, 2-Part, Randomized, Subject And Investigator Blinded, Placebo-Controlled, Cross-Over Trial To Evaluate The Safety, Tolerability And Pharmacokinetics Of CE-326,597 In Obese, Adult Subjects With Asymptomatic Cholelithiasis|Completed||Phase 1|41|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:39:28.09392|2018-06-01 02:39:28.09392
NCT00576576|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2012-11-28||2013-11-27|2007-12-18|2007-12-19|Estimate|2013-08-13|2013-10-18|Estimate||||2013-11-27|2013-12-24|Estimate|July 2007||2007-07-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Evaluation of Atorvastatin on Atherosclerosis Composition|The Evaluation of Atorvastatin on Wall Shear Stress, Atherosclerosis Composition, and Microvascular Function in Patients With Moderate Coronary Disease|Completed||N/A|27|Actual|Emory University|No adverse events to report.|1|||f||||t||||||||||2018-06-01 02:39:28.196842|2018-06-01 02:39:28.196842
NCT00576563|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-04-20|2007-12-18|2007-12-19|Estimate|||||||2016-04-20|2016-04-21|Estimate|March 2007||2007-03-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer|Rectal Cancer: Determination of the Predictive Value by Use of FDG-PET-CT Scans and Blood Proteins for the Prognosis of Patients With Rectal Cancer|Completed||N/A|103|Actual|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-06-01 02:39:28.360544|2018-06-01 02:39:28.360544
NCT00576550|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2008-10-10|2007-12-18|2007-12-19|Estimate|||||||2008-10-10|2008-10-13|Estimate|October 2007||2007-10-31|December 2007|2007-12-31|May 2008|Actual|2008-05-31|||||Interventional|||A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema|A Randomised Trial of a Moisturising Cream in Preventing Recurrence of Hand Eczema|Completed||Phase 4|53|Actual|ACO Hud Nordic AB||4|||f||||f||||||||||2018-06-01 02:39:28.427191|2018-06-01 02:39:28.427191
NCT00576537|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2013-02-18|2007-12-18|2007-12-19|Estimate|||||||2013-02-18|2013-02-20|Estimate|March 2001||2001-03-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors|Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System|Completed||Phase 2|50|Actual|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-06-01 02:39:29.513077|2018-06-01 02:39:29.513077
NCT00576524|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2012-12-12||2013-01-22|2007-12-17|2007-12-19|Estimate|2013-01-22|2013-02-26|Estimate||||2013-01-22|2013-02-26|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|ITD||Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During Dialysis|Application of Impedance Threshold Device Technologies to Treat and Prevent Intradialytic Hypotension in Children Undergoing Hemodialysis|Terminated||Phase 2|2|Actual|Children's Hospital of Philadelphia||2||Completion not feasible. THERE ARE NO RESULTS FROM THIS TRIAL|f||||f||||||||||2018-06-01 02:39:29.609158|2018-06-01 02:39:29.609158
NCT00576511|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-05-28|2007-12-18|2007-12-19|Estimate|||||||2008-05-28|2008-05-29|Estimate|December 1994||1994-12-31|December 2007|2007-12-31|February 1996|Actual|1996-02-29|February 1996|Actual|1996-02-29||Interventional|||Effect of Prucalopride in Patients With Severe Chronic Idiopathic Constipation|A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Severe Chronic Constipation|Completed||Phase 2|53|Actual|Movetis||2|||f||||f||||||||||2018-06-01 02:39:29.815632|2018-06-01 02:39:29.815632
NCT00576498|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2012-10-25|2007-12-18|2007-12-19|Estimate|||||||2012-10-25|2012-10-29|Estimate|October 2005||2005-10-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Novel Imaging Techniques in Barrett's Esophagus|Detection Of Intestinal Metaplasia And High Grade Dysplasia In Barrett's Esophagus Using Novel Imaging Techniques - A Randomized Controlled Trial.|Completed||N/A|130|Actual|Midwest Biomedical Research Foundation||2|||f||||f||||||||||2018-06-01 02:39:29.902402|2018-06-01 02:39:29.902402
NCT00576485|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2008-10-17|2007-12-18|2007-12-19|Estimate|||||||2008-10-17|2008-10-20|Estimate|February 2005||2005-02-28|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|IOLs||Spherical Aberration and Contrast Sensitivity in IOLs|Spherical Aberration and Contrast Sensitivity in Eyes Implanted With Aspheric and Spherical Intraocular Lenses: Clinical Comparative Study|Completed||Phase 4|25|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-06-01 02:39:30.000015|2018-06-01 02:39:30.000015
NCT00576472|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2011-10-28||2017-04-24|2007-12-17|2007-12-19|Estimate|2012-03-20|2012-04-16|Estimate||||2017-04-24|2017-05-30|Actual|January 2000||2000-01-31|February 2013|2013-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Learning Impairments Among Survivors of Childhood Cancer|Learning Impairments Among Survivors of Childhood Cancer|Completed||Phase 4|469|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 02:39:30.242763|2018-06-01 02:39:30.242763
NCT00576459|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-12-07|2007-12-18|2007-12-19|Estimate|||||||2011-12-07|2011-12-08|Estimate|March 2003||2003-03-31|July 2011|2011-07-31|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema|A Randomized, Controlled Pilot Study to Evaluate the Safety and Efficacy of Intravitreal Fluocinolone Acetonide (0.5mg and 2mg) Implants in Patients With Clinically Significant Diabetic Macular Edema|Completed||Phase 2|40|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 02:39:31.643109|2018-06-01 02:39:31.643109
NCT00576446|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2013-02-18|2007-12-18|2007-12-19|Estimate|||||||2013-02-18|2013-02-20|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|Gliadel Wafer||Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients|A Phase l Trial of Surgical Resection With Gliadel Wafer Placement Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate for Patients With Malignant Glioma|Completed||Phase 1|35|Actual|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-06-01 02:39:31.719109|2018-06-01 02:39:31.719109
NCT00576433|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2016-11-01|2007-12-18|2007-12-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.|An Open Label Study to Evaluate the Safety and Effect on Treatment Response of MabThera in Patients With Rheumatoid Arthritis Following Inadequate Response to One Prior Anti-TNF Inhibitor|Completed||Phase 4|60|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:39:31.791294|2018-06-01 02:39:31.791294
NCT00576420|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2012-09-13|2010-01-13|2012-10-26|2007-12-18|2007-12-19|Estimate|2012-10-26|2012-11-27|Estimate|2010-01-13|2010-01-18|Estimate|2012-10-26|2012-11-27|Estimate|December 2007||2007-12-31|October 2012|2012-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Fibrin Sealant Vascular Surgery Study|Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-apr for Hemostasis in Subjects Undergoing Vascular Surgery|Completed||Phase 2|101|Actual|Baxter Healthcare Corporation||3|||f||||f||||||||||2018-06-01 02:39:31.93921|2018-06-01 02:39:31.93921
NCT00576407|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17||2012-09-06|2017-08-10|2007-12-18|2007-12-19|Estimate||||2012-09-12|2012-09-14|Estimate|2017-08-10|2017-08-14|Actual|November 2001||2001-11-30|August 2017|2017-08-31|June 2027|Anticipated|2027-06-30|March 2008|Actual|2008-03-31||Interventional|||Thymus Transplantation in DiGeorge Syndrome #668|Phase II Study of Thymus Transplantation in Complete DiGeorge Syndrome #668|Active, not recruiting||Phase 2|26|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:39:33.319521|2018-06-01 02:39:33.319521
NCT00576394|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2015-06-22|2007-12-18|2007-12-19|Estimate|||||||2015-06-22|2015-06-23|Estimate|October 2006||2006-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients|Impact of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes Following Coronary Artery Bypass Graft Surgery in Diabetic Patients|Completed||Phase 1|108|Actual|American Heart Association||2|||f||||t||||||||||2018-06-01 02:39:33.418489|2018-06-01 02:39:33.418489
NCT00576381|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2012-12-13||2013-04-10|2007-12-17|2007-12-19|Estimate|2013-03-01|2013-04-11|Estimate||||2013-04-10|2013-04-18|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Dex||Understanding Dexmedetomidine in Neonates After Open Heart Surgery|The Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Neonates Following Open Heart Surgery|Completed||Phase 1|30|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-06-01 02:39:33.490729|2018-06-01 02:39:33.490729
NCT00576368|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-28|2007-12-17|2007-12-19|Estimate|||||||2007-12-28|2008-01-09|Estimate|June 2003||2003-06-30|December 2007|2007-12-31|April 2004|Actual|2004-04-30|||||Interventional|||An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice|An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice|Completed||Phase 4|4464|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:39:33.661959|2018-06-01 02:39:33.661959
NCT00576355|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2012-06-19|2007-12-17|2007-12-19|Estimate|||||||2012-06-19|2012-06-20|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Interpersonal and Social Rhythm Therapy for Adolescents With Bipolar Disorder|Adjunctive Psychotherapy for Teens With Bipolar Disorder|Completed||N/A|36|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:39:33.732406|2018-06-01 02:39:33.732406
NCT00576342|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17||2014-07-09|2014-07-09|2007-12-17|2007-12-19|Estimate||||2014-07-09|2014-07-11|Estimate|2014-07-09|2014-07-11|Estimate|December 2007||2007-12-31|July 2014|2014-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Patient Preference Study|A Single Dose Patient Preference Study Comparison in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|129|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:39:33.806385|2018-06-01 02:39:33.806385
NCT00576329|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2014-05-12|2007-12-17|2007-12-19|Estimate|||||||2014-05-12|2014-05-14|Estimate|November 2006||2006-11-30|May 2014|2014-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Topical 0.4% Ketorolac and Vitreoretinal Surgery|Topical 0.4% Ketorolac for the Inhibition of Miosis During Vitreoretinal Surgery: a Randomized, Placebo-controlled, Double-masked Study|Completed||Phase 2/Phase 3|76|Actual|Emory University||2|||f||||f||||||||||2018-06-01 02:39:33.877592|2018-06-01 02:39:33.877592
NCT00576316|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2009-11-19||2010-11-30|2007-12-18|2007-12-19|Estimate|2009-11-19|2009-12-29|Estimate||||2010-11-30|2010-12-16|Estimate|January 2008||2008-01-31|November 2010|2010-11-30|November 2008|Actual|2008-11-30|||||Interventional|SMARTER||Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia|Symbicort Maintenance And Reliever Therapy - Experience in Real Life Setting in Malaysia - SMARTER Study|Completed||Phase 4|201|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:39:33.972719|2018-06-01 02:39:33.972719
NCT00576303|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2016-04-20||2016-04-20|2007-12-18|2007-12-19|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|April 2008||2008-04-30|April 2016|2016-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.|A Single-arm, Open Label Multicenter Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of C.E.R.A. for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia|Completed||Phase 3|200|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:39:34.129506|2018-06-01 02:39:34.129506
NCT00576277|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-17|2007-12-17|2007-12-19|Estimate|||||||2007-12-17|2007-12-19|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|November 2007|Actual|2007-11-30|||||Interventional|||Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain|A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of AV411 to Assess Its Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in the Treatment of Neuropathic Pain|Completed||Phase 1/Phase 2|36|Anticipated|Avigen|||||f||||t||||||||||2018-06-01 02:39:34.498701|2018-06-01 02:39:34.498701
NCT00576264|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2011-06-24|2007-12-18|2007-12-19|Estimate|||||||2011-06-24|2011-06-27|Estimate|April 2007||2007-04-30|December 2007|2007-12-31|February 2012|Anticipated|2012-02-29|||||Observational|||Stem Cells Found in the Abdominal Cavity in Humans|Peritoneal Cavity Derived Stem Cells: A Pilot Study|Unknown status|Recruiting||50|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||Samples With DNA|"~     peritoneal fluid~   "|||2018-06-01 02:39:34.571627|2018-06-01 02:39:34.571627
NCT00576251|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2009-09-25||2010-02-23|2007-12-17|2007-12-19|Estimate|2009-12-09|2010-01-14|Estimate||||2010-02-23|2010-03-02|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|March 2008||2008-03-31|February 2008|Actual|2008-02-29||Interventional|||TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension||Completed||Phase 3|221|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:39:34.664545|2018-06-01 02:39:34.664545
NCT00576238|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|||2008-10-10|2007-12-18|2007-12-19|Estimate|||||||2008-10-10|2008-10-13|Estimate|January 2004||2004-01-31|October 2008|2008-10-31|February 2008|Actual|2008-02-29|||||Interventional|||Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser|A Multi Centre, Parallel, Randomised Study of the Skin Tolerance of Betamethasone Creams on Atopic Eczema and the Influence of Moisturiser Treatment on the Recurrence of Eczema|Completed||Phase 3|55|Actual|ACO Hud Nordic AB||4|||f||||f||||||||||2018-06-01 02:39:35.064315|2018-06-01 02:39:35.064315
NCT00576225|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2013-05-20|2007-12-17|2007-12-19|Estimate|||||||2013-05-20|2013-05-21|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL|Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol > 25 pg/mL|Unknown status|Active, not recruiting|Phase 3|450|Anticipated|CTI BioPharma||2|||f||||t||||||||||2018-06-01 02:39:35.18905|2018-06-01 02:39:35.18905
NCT00576212|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2009-07-29|2007-12-17|2007-12-19|Estimate|||||||2009-07-29|2009-07-30|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|||||Interventional|TOPFA||Impact of a Telephone-based Support Intervention on the Long-term Well-being of Women Undergoing Termination of Pregnancy for Fetal Anomaly|The Impact of a Telephone-based Support Intervention on the Long-term Well-being of Women Undergoing Termination of Pregnancy for Fetal Anomaly|Withdrawn||N/A|100|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||Study halted prematurely, prior to enrollment of first participant.|f||||f||||||||||2018-06-01 02:39:35.368191|2018-06-01 02:39:35.368191
NCT00576199|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-18|2014-08-18||2014-08-18|2007-12-18|2007-12-19|Estimate|2014-08-18|2014-08-29|Estimate||||2014-08-18|2014-08-29|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Intent-to-treat population: All participants who received study medication.|A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer|A Phase II Single Arm, Multi-centre Study of Bevacizumab (Avastin®) Pre- and Post-transarterial Chemoembolisation (TACE) Treatment for Localized Unresectable Hepatocellular Carcinoma (HCC)|Completed||Phase 2|30|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:39:35.453166|2018-06-01 02:39:35.453166
NCT00576186|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2016-06-21|2007-12-15|2007-12-18|Estimate|||||||2016-06-21|2016-06-23|Estimate|February 2005||2005-02-28|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Validation of the Gated Blood Pool SPECT: ERNA vs 3D Echo|Validation of the Gated Blood Pool SPECT: Comparison to ERNA and 3-dimensional Echocardiography.|Completed|||30|Actual|Yale University|||1||f||||f||||||||||2018-06-01 02:39:35.745064|2018-06-01 02:39:35.745064
NCT00576173|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2010-04-26|2007-12-14|2007-12-18|Estimate|||||||2010-04-26|2010-04-28|Estimate|December 2005||2005-12-31|April 2010|2010-04-30|February 2007|Actual|2007-02-28|||||Interventional|||An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients|An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients|Completed||Phase 4|60|Actual|Johnson & Johnson Taiwan Ltd|||||f||||||||||||||2018-06-01 02:39:35.834004|2018-06-01 02:39:35.834004
NCT00576160|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2015-05-13|2007-12-14|2007-12-18|Estimate|||||||2015-05-13|2015-05-15|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Improving Medication Adherence in Post-ACS Patients|Improving Med Adherence in Post-ACS Patients: Phase 1B Dose-Finding RCT|Terminated||Phase 1|22|Actual|Columbia University||2||"This was a dosing study to determine acceptability. Participants found protocol burdensome and~   so we terminated."|f||||t||||||||||2018-06-01 02:39:35.891897|2018-06-01 02:39:35.891897
NCT00576147|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2012-04-11||2018-02-28|2007-12-17|2007-12-18|Estimate|2013-12-19|2013-12-20|Estimate||||2018-02-28|2018-03-29|Actual|July 2006||2006-07-31|February 2018|2018-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection|A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection|Completed||N/A|431|Actual|InfraScan, Inc.||1|||f||||f||||||||||2018-06-01 02:39:35.968655|2018-06-01 02:39:35.968655
NCT00576134|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2015-01-22|2007-12-17|2007-12-18|Estimate|||||||2015-01-22|2015-01-26|Estimate|February 2008||2008-02-29|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement|Artificial Larynx : Intralaryngeal Prosthesis With Valve in Major Swallowing Troubles|Completed||Phase 1|10|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 02:39:36.146623|2018-06-01 02:39:36.146623
NCT00576121|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2016-06-22|2007-12-15|2007-12-18|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2008||2008-07-31|June 2016|2016-06-30|August 2012|Anticipated|2012-08-31|August 2011|Anticipated|2011-08-31||Observational|||Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction|Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction|Withdrawn|||0|Actual|Yale University|||3||f||||f||||||||||2018-06-01 02:39:36.239451|2018-06-01 02:39:36.239451
NCT00576082|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2018-03-21|2007-12-17|2007-12-18|Estimate|||||||2018-03-21|2018-03-22|Actual|March 2008|Actual|2008-03-31|September 2017|2017-09-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Borrelia Species in Cutaneous Lyme Borreliosis|DIVERSITY OF BORRELIA SPECIES INVOLVED IN CUTANEOUS MANIFESTATIONS OF LYME BORRELIOSIS IN FRANCE|Recruiting|||900|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||Samples With DNA|"~     Cutaneous biopsy specimen~   "|||2018-06-01 02:39:36.452677|2018-06-01 02:39:36.452677
NCT00576069|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2017-07-10|2007-12-17|2007-12-18|Estimate|||||||2017-07-10|2017-07-11|Actual|October 2007||2007-10-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma|Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers|Recruiting|||60|Anticipated|Gelb, Arthur F., M.D.|||1||f||||t||||||||Yes|see publications|2018-06-01 02:39:36.528107|2018-06-01 02:39:36.528107
NCT00576056|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2016-05-23||2016-12-28|2007-12-14|2007-12-18|Estimate|2016-11-01|2016-12-28|Estimate||||2016-12-28|2017-02-15|Actual|January 2008||2008-01-31|November 2016|2016-11-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC|Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Plus Oral Sorafenib (BAY 43-9006, Nexavar®) for Unresectable Hepatocellular Carcinoma (HCC)|Terminated||Phase 2|19|Actual|University of Pittsburgh||1||Bayer Healthcare is no supplying the study drug|f||||t||||||||No||2018-06-01 02:39:36.62987|2018-06-01 02:39:36.62987
NCT00576043|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-03-25|2007-12-17|2007-12-18|Estimate|||||||2008-03-25|2008-03-27|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|endosim||Effect of Virtual Endoscopy Simulator Training on Real Patient Endoscopy|Effect of Virtual Endoscopy Simulator Training on Real Patient Endoscopy: A Randomized, Controlled Trial|Completed||N/A|24|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:39:36.830452|2018-06-01 02:39:36.830452
NCT00576030|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2010-07-02|2007-12-17|2007-12-18|Estimate|||||||2010-07-02|2010-07-05|Estimate|January 2007||2007-01-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Action of Caffeinated and Decaffeinated Espresso on Autonomic Function|Short-term Autonomic Effects of Caffeinated and Decaffeinated Espresso in Young Healthy Individuals|Terminated||N/A|77|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-06-01 02:39:36.896999|2018-06-01 02:39:36.896999
NCT00576017|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2011-05-18|2007-12-14|2007-12-18|Estimate|||||||2011-05-18|2011-05-19|Estimate|October 2003||2003-10-31|April 2010|2010-04-30|March 2005|Actual|2005-03-31|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).|Randomised Study to Evaluate the Efficacy and Safety of Fentanyl-TTS Versus Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDs (Non-steroidal Anti-inflammatory Drugs).|Completed||Phase 4|19|Actual|Janssen-Cilag, S.A.|||||f||||||||||||||2018-06-01 02:39:36.964241|2018-06-01 02:39:36.964241
NCT00576004|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-17|2007-12-17|2007-12-18|Estimate|||||||2007-12-17|2007-12-18|Estimate|January 2002||2002-01-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Pelvic Organ Prolapse Repair With or Without Concomitant Burch Colposuspension in Patients With Urinary Incontinence|Pelvic Organ Prolapse Repair With or Without Concomitant Burch Colposuspension in Patients With Urinary Incontinence: A Randomised Surgical Trial|Completed||N/A|67|Actual|University Of Perugia||2|||f||||f||||||||||2018-06-01 02:39:37.018995|2018-06-01 02:39:37.018995
NCT00575991|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2012-03-12|2007-12-14|2007-12-18|Estimate|||||||2012-03-12|2012-03-13|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Conjugated Linoleic Acid on Body Fat in Overweight Children|Effect of CLA Supplementation on Body Fat Accretion Among Children Who Are Overweight or at Risk of Overweight|Completed||N/A|62|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 02:39:37.087836|2018-06-01 02:39:37.087836
NCT00575978|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2015-03-03|2007-12-14|2007-12-18|Estimate|||||||2015-03-03|2015-03-04|Estimate|June 2004||2004-06-30|March 2015|2015-03-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Hydralazine as Demethylating Agent in Breast Cancer|Hydralazine as Demethylating Agent in Breast Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of Arkansas||1||IRB request|f||||f||||||||||2018-06-01 02:39:37.156583|2018-06-01 02:39:37.156583
NCT00575965|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-16|2012-12-19||2015-11-11|2007-12-16|2007-12-18|Estimate|2015-11-11|2015-12-16|Estimate||||2015-11-11|2015-12-16|Estimate|November 2007||2007-11-30|November 2015|2015-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Simvastatin in Waldenstrom's Macroglobulinemia|Phase II Study of Simvastatin in Waldenstrom's Macroglobulinemia|Terminated||Phase 2|18|Actual|Dana-Farber Cancer Institute|Slow accrual led to early study termination.|1||Slow accrual led to early study termination.|f||||t||||||||||2018-06-01 02:39:37.228545|2018-06-01 02:39:37.228545
NCT00575952|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2017-08-23|2007-12-15|2007-12-18|Estimate|||||||2017-08-23|2017-08-24|Actual|January 17, 2008|Actual|2008-01-17|August 2017|2017-08-31|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Interventional|||Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer|A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure|Completed||Phase 1|27|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 02:39:37.368403|2018-06-01 02:39:37.368403
NCT00575939|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2014-12-18|2007-12-14|2007-12-18|Estimate|||||||2014-12-18|2014-12-19|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|July 2013|Actual|2013-07-31||Observational|||Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV|Assessment of the Use of a Metabolically-friendly Antiretroviral Regimen to Slow Down the Rate of Progression in Carotid Artery Intima-medial Thickness in Adults With HIV|Completed|||120|Actual|University Hospitals Cleveland Medical Center|||2||f||||f||||||Samples Without DNA|"~     Stored plasma and serum~   "|||2018-06-01 02:39:37.473309|2018-06-01 02:39:37.473309
NCT00575926|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-17|2007-12-17|2007-12-18|Estimate|||||||2007-12-17|2007-12-18|Estimate|September 2002||2002-09-30|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Lingzhi for Cancer Children|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Clinical Effects of Ganoderma Lucidum (Ling Zhi) in Children With Cancer|Completed||Phase 3|58|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 02:39:37.604809|2018-06-01 02:39:37.604809
NCT00575913|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-04-08|2007-12-17|2007-12-18|Estimate|||||||2008-04-08|2008-04-10|Estimate|September 2003||2003-09-30|April 2008|2008-04-30|March 2005|Actual|2005-03-31|||||Interventional|ALEX-XL||Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study|ALEX-XL: Alfuzosin XL-Lower Urinary Tract Symptoms Efficacy and Sexuality Study|Completed||Phase 4|118|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:39:37.697324|2018-06-01 02:39:37.697324
NCT00575900|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-16|||2007-12-16|2007-12-16|2007-12-18|Estimate|||||||2007-12-16|2007-12-18|Estimate|March 2005||2005-03-31|December 2007|2007-12-31|February 2006|Actual|2006-02-28|||||Interventional|||Low Carbohydrates in Obese Adolescents|Comparison Between Low Carbohydrate Low Fat, Low Carbohydrate High Fat and Balanced Low Fat Diets in the Treatment of Obesity in Adolescents- a Randomized Controlled Trail.|Completed||N/A|55|Actual|Rabin Medical Center||3|||f||||f||||||||||2018-06-01 02:39:37.765836|2018-06-01 02:39:37.765836
NCT00575887|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2013-11-03||2013-11-03|2007-12-17|2007-12-18|Estimate|2013-11-03|2013-12-20|Estimate||||2013-11-03|2013-12-20|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma|Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas|Completed||Phase 2|25|Actual|Marmara University||1|||f||||t||||||||||2018-06-01 02:39:37.850073|2018-06-01 02:39:37.850073
NCT00575874|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-02-06|2007-12-14|2007-12-18|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|RAISE||Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Dose and Active Comparator-Controlled Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes|Completed||Phase 2|150|Anticipated|Daiichi Sankyo, Inc.||5|||f||||f||||||||||2018-06-01 02:39:38.031459|2018-06-01 02:39:38.031459
NCT00575861|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2007-12-18|2007-12-17|2007-12-18|Estimate|||||||2007-12-18|2007-12-20|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Zileuton and Exhaled Nitric Oxide in Asthmatics|Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics|Completed||Phase 4|19|Actual|Gelb, Arthur F., M.D.||1|||f||||t||||||||||2018-06-01 02:39:38.148678|2018-06-01 02:39:38.148678
NCT00575848|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-11-25|2007-12-17|2007-12-18|Estimate|||||||2009-11-25|2009-11-26|Estimate|December 2007||2007-12-31|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of the Effects of Glycine on Symptoms and Memory in Patients With Schizophrenia|A Trial of the Effects of Glycine Loading on Clinical Symptoms and Logical Memory in Patients With Schizophrenia|Terminated||Phase 1|16|Anticipated|North Suffolk Mental Health Association||2||"Slow enrollment and due to personnel change there was no viable way to quantify glycine levels~   through imaging"|f||||f||||||||||2018-06-01 02:39:38.262007|2018-06-01 02:39:38.262007
NCT00575835|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-26|2007-12-17|2007-12-18|Estimate|||||||2007-12-26|2008-01-08|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Oral Vitamin D Supplementation in Elderly Women|Oral Vitamin D Supplementation in Elderly Women: Twice a Day or Three Times a Year? A Randomised Controlled Trial|Completed||N/A|40|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:39:38.363626|2018-06-01 02:39:38.363626
NCT00575822|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2008-07-15|2007-12-17|2007-12-18|Estimate|||||||2008-07-15|2008-07-16|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD|Endoscopic Full-Thickness Plication for the Treatment of Gastroesophageal Reflux Disease: A Randomized, Sham-Controlled Trial|Terminated||N/A|159|Actual|NDO Surgical, Inc.||2||Sponsoring company ceased business operations.|f||||f||||||||||2018-06-01 02:39:38.453839|2018-06-01 02:39:38.453839
NCT00575809|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2017-09-13|2007-12-17|2007-12-18|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2005||2005-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Incidence and Factors Associated With the Development and Severity of Oral Mucositis|Incidence and Factors Associated With the Development and Severity of Oral Mucositis in Patients Undergoing High-Dose Chemotherapy and Peripheral Blood Stem Cell Transplantation|Recruiting|||800|Anticipated|The University of Texas Health Science Center at San Antonio|||1||f||||f||||||||||2018-06-01 02:39:38.596393|2018-06-01 02:39:38.596393
NCT00575796|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-09-19|2007-12-14|2007-12-18|Estimate|||||||2017-09-19|2017-09-20|Actual|October 2007||2007-10-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)|Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)|Active, not recruiting||Phase 2|50|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||||2018-06-01 02:39:38.698531|2018-06-01 02:39:38.698531
NCT00575783|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2012-01-25|2007-12-17|2007-12-18|Estimate|||||||2012-01-25|2012-01-26|Estimate|August 2005||2005-08-31|January 2012|2012-01-31|August 2008|Actual|2008-08-31|||||Observational|||Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM|Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM|Completed|||51|Anticipated|Yale University|||3||f||||t||||||||||2018-06-01 02:39:38.795875|2018-06-01 02:39:38.795875
NCT00575757|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2016-08-17|2007-12-17|2007-12-18|Estimate|||||||2016-08-17|2016-08-18|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV|Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV|Completed|||12|Actual|Virginia Commonwealth University|||1||f||||t||||||Samples Without DNA|"~     sera, liver tissue~   "|||2018-06-01 02:39:38.867237|2018-06-01 02:39:38.867237
NCT00575744|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2016-10-26|2007-12-17|2007-12-18|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 1998||1998-12-31|October 2016|2016-10-31|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation|Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation|Completed||Phase 2|699|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:39:38.927942|2018-06-01 02:39:38.927942
NCT00575731|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-16|||2015-05-18|2007-12-16|2007-12-18|Estimate|||||||2015-05-18|2015-05-20|Estimate|July 2006||2006-07-31|May 2015|2015-05-31|May 2009|Actual|2009-05-31|April 2008|Actual|2008-04-30||Interventional|||Behavioral Strategies for Weight Management|Behavioral Strategies for Weight Management|Completed||N/A|40|Actual|Stanford University||2|||f||||||||||||||2018-06-01 02:39:39.014034|2018-06-01 02:39:39.014034
NCT00575718|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2018-01-02|2007-12-17|2007-12-18|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2002||2002-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Smoking Cessation Intervention for Cancer Patients|Presurgical Smoking Cessation Intervention for Cancer Patients: The Resolve Study|Active, not recruiting||N/A|204|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:39:39.078683|2018-06-01 02:39:39.078683
NCT00575692|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2014-05-27|2007-12-17|2007-12-18|Estimate|||||||2014-05-27|2014-05-28|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Magnetic Resonance Imaging in the Diagnosis of Pulmonary Hypertension|Magnetic Resonance Imaging in the Diagnosis of Pulmonary Hypertension|Completed|||240|Actual|Medical University of Graz|||2||f||||t||||||||||2018-06-01 02:39:39.161673|2018-06-01 02:39:39.161673
NCT00575666|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2012-04-27||2012-11-15|2007-12-14|2007-12-18|Estimate|2012-11-15|2012-12-17|Estimate||||2012-11-15|2012-12-17|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Intranasal Insulin Treatment in Patients With Schizophrenia|Intranasal Insulin Treatment in Patients With Schizophrenia|Completed||Phase 4|45|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 02:39:39.323976|2018-06-01 02:39:39.323976
NCT00575653|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2017-03-15|2007-12-17|2007-12-18|Estimate|||||||2017-03-15|2017-03-16|Actual|March 2005||2005-03-31|December 2007|2007-12-31|December 31, 2010|Actual|2010-12-31|December 31, 2009|Actual|2009-12-31||Observational|||Safety Study of GBS Following Menactra Meningococcal Vaccination|Risk of Guillain-Barré Syndrome Following Meningococcal Conjugate (MCV4) Vaccination|Completed|||6000000|Actual|Harvard Pilgrim Health Care|||2||f||||f||||||||||2018-06-01 02:39:39.735798|2018-06-01 02:39:39.735798
NCT00575640|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2015-03-03|2007-12-17|2007-12-18|Estimate|||||||2015-03-03|2015-03-04|Estimate|November 2004||2004-11-30|March 2015|2015-03-31||||May 2008|Actual|2008-05-31||Interventional|||Hydralazine as a Demethylating Agent in Rectal Cancer|Hydralazine as a Demethylating Agent in Rectal Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of Arkansas||1||No enrollment|f||||f||||||||||2018-06-01 02:39:39.808941|2018-06-01 02:39:39.808941
NCT00575627|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2008-06-03|2007-12-14|2007-12-18|Estimate|||||||2008-06-03|2008-06-04|Estimate|September 2007||2007-09-30|June 2008|2008-06-30|September 2010|Anticipated|2010-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels|Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin|Unknown status|Recruiting|Phase 4|150|Anticipated|University of Turin, Italy||2|||f||||t||||||||||2018-06-01 02:39:39.868842|2018-06-01 02:39:39.868842
NCT00575614|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-05-28|2007-12-17|2007-12-18|Estimate|||||||2008-05-28|2008-05-29|Estimate|April 1997||1997-04-30|December 2007|2007-12-31|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||Prucalopride in Patients With Chronic Idiopathic Constipation|Study to Evaluate the Effect of a 1 mg o.d. Dose of Prucalopride in Patients With Chronic Idiopathic Constipation|Completed||Phase 2|87|Actual|Movetis||2|||f||||f||||||||||2018-06-01 02:39:39.968107|2018-06-01 02:39:39.968107
NCT00575601|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2009-06-30|2007-12-15|2007-12-18|Estimate|||||||2009-06-30|2009-07-02|Estimate|August 2007||2007-08-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|||||Interventional|||Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients|Effects of Simvastatin on Biochemical Parameters and Outcome of IVF-ICSI in Pcos Patients : A Prospective Randomized Double Blind Placebo Controlled Trial|Completed||Phase 3|120|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:39:40.054921|2018-06-01 02:39:40.054921
NCT00575588|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2010-08-10||2012-03-20|2007-12-14|2007-12-18|Estimate|2010-08-10|2010-09-06|Estimate||||2012-03-20|2012-03-21|Estimate|December 2007||2007-12-31|March 2012|2012-03-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period|A 52-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone.|Completed||Phase 3|891|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:39:40.1445|2018-06-01 02:39:40.1445
NCT00575575|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2009-02-25|2007-12-17|2007-12-18|Estimate|||||||2009-02-25|2009-02-26|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Research on Suicidal Ideation of University Students in Harbin City and Cognitive Behavior Therapy|the Research on Suicidal Ideation of University Students in Harbin City and Intervention on Them|Completed||N/A|355|Actual|Harbin Medical University||1|||f||||t||||||||||2018-06-01 02:39:42.03747|2018-06-01 02:39:42.03747
NCT00575562|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-09-19|2007-12-14|2007-12-18|Estimate|||||||2017-09-19|2017-09-20|Actual|June 2007|Actual|2007-06-30|December 2007|2007-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer|Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer|Completed||Phase 1|42|Actual|Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 02:39:42.102012|2018-06-01 02:39:42.102012
NCT00575549|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2012-07-19|2007-12-14|2007-12-18|Estimate|||||||2012-07-19|2012-07-23|Estimate||||July 2012|2012-07-31||||||||Expanded Access|||Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo|Prospective Analysis and Comparison of Conventional Stress Echocardiograms and Real-Time Myocardial Contrast Stress Echocardiogram; for Bristol-Myers Squibb Medical Imaging: The Definity RT-P During DSE Database|Available|||||University of Nebraska|||||f||||||||||||||2018-06-01 02:39:42.157542|2018-06-01 02:39:42.157542
NCT00575536|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2018-04-27|2007-12-15|2007-12-18|Estimate|||||||2018-04-27|2018-05-01|Actual|January 2006||2006-01-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|Rhizotomy||Optical Stimulation in Peripheral Nerves for Select Rhizotomy Procedures|Optical Stimulation in Peripheral Nerves in Selective Rhizotomy Cases|Completed|||19|Actual|Vanderbilt University|||1||f||||f|f|||||Samples Without DNA|"~     abnormal spinal nerves that have been surgically removed~   "|No||2018-06-01 02:39:42.226911|2018-06-01 02:39:42.226911
NCT00575523|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-01-23|2007-12-17|2007-12-18|Estimate|||||||2008-01-23|2008-01-25|Estimate|October 2003||2003-10-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|||||Interventional|atropinePEI||Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy|Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy|Completed||Phase 4|31|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 02:39:42.301751|2018-06-01 02:39:42.301751
NCT00575510|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2014-05-19||2014-07-28|2007-12-17|2007-12-18|Estimate|2014-07-28|2014-08-15|Estimate||||2014-07-28|2014-08-15|Estimate|October 2005||2005-10-31|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Intervention to Improve Follow-up of Abnormal Pap Test|Intervention to Improve Follow-up of Abnormal Pap Test|Completed||N/A|341|Actual|The University of Texas Medical Branch, Galveston||3|||f||||t||||||||||2018-06-01 02:39:42.384272|2018-06-01 02:39:42.384272
NCT00575497|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2007-12-17|2007-12-17|2007-12-18|Estimate|||||||2007-12-17|2007-12-18|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|January 2010|Anticipated|2010-01-31|||||Interventional|MFD||More Frequent Dialysis (>3 Treatments Per Week)|Study of Clinical Outcomes of More Frequent Hemodialysis|Unknown status|Recruiting|Phase 4|300|Anticipated|Satellite Healthcare||7|||f||||f||||||||||2018-06-01 02:39:42.62848|2018-06-01 02:39:42.62848
NCT00575315|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2014-08-19|2007-12-17|2007-12-18|Estimate|||||||2014-08-19|2014-08-20|Estimate|July 2004||2004-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||HIV-HCV Coinfection: Impact of Immune Dysfunction|HIV-HCV Coinfection: Impact of Immune Dysfunction|Completed|||634|Actual|Virginia Commonwealth University|||||f||||t||||||Samples With DNA|"~     Sera~   "|||2018-06-01 02:39:44.255843|2018-06-01 02:39:44.255843
NCT00575484|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2014-01-22|2007-12-17|2007-12-18|Estimate|||||||2014-01-22|2014-01-24|Estimate|November 2007||2007-11-30|January 2014|2014-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction|Hypertonic Saline With Furosemide and a Normosodic Diet for the Treatment of Decompensated Congestive Heart Failure With Prerenal Physiology|Terminated||Phase 2|11|Actual|Barnes-Jewish Hospital||2|||f||||t||||||||||2018-06-01 02:39:42.811056|2018-06-01 02:39:42.811056
NCT00575471|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2009-02-27|2007-12-17|2007-12-18|Estimate|||||||2009-02-27|2009-03-02|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled 12-Week Dose-Response Study of Rivoglitazone (CS-011) in Patients With Type 2 Diabetes.|Completed||Phase 2|250|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-06-01 02:39:42.899411|2018-06-01 02:39:42.899411
NCT00575458|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2010-11-15|2007-12-14|2007-12-18|Estimate|||||||2010-11-15|2010-11-16|Estimate|June 2005||2005-06-30|November 2010|2010-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Splinting for Dupuytren's Contracture Release|Prospective Randomized Comparison of Dynamic Versus Static Splinting After Dupuytren's Contracture Release|Completed|||60|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 02:39:42.993459|2018-06-01 02:39:42.993459
NCT00575445|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2015-03-24|2007-12-14|2007-12-18|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2009|Actual|2009-12-31||Observational|||The Use of Exhaled Nitric Oxide in Conjunction With the Asthma Control Test to Determine Asthma Control in Pediatric Patients||Terminated|||100|Anticipated|Akron Children's Hospital|||1|Nitric Oxide analyzer not functioning properly|f||||f||||||||||2018-06-01 02:39:43.088101|2018-06-01 02:39:43.088101
NCT00575432|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2016-11-02|2007-12-17|2007-12-18|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2004||2004-11-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy|Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy in Renal Transplantation and Kidney Disease|Recruiting|||200|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||Undecided||2018-06-01 02:39:43.156401|2018-06-01 02:39:43.156401
NCT00575419|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2012-11-28|2007-12-14|2007-12-18|Estimate|||||||2012-11-28|2012-11-29|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|CIN-NAC||Safety Study Of N-Acetylcysteine For Prevention Of Contrast Induced Nephropathy In Patients w/Stage 3 Renal Failure|Dose Escalation Study Of I.V. And Intra-Aortic N-Acetylcysteine For The Prevention Of Contrast Induced Nephropathy In Patients With Stage 3 Renal Failure Undergoing Contrast Imaging Studies: A Phase I Trial|Unknown status|Recruiting|Phase 1|60|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:39:43.24992|2018-06-01 02:39:43.24992
NCT00575406|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2013-08-29|2007-12-17|2007-12-18|Estimate|||||||2013-08-29|2013-08-30|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|NHL-14||Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma|Multicentre Study to Determine the Cardiotoxicity of R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone) Compared to R-COMP (Rituximab, Cyclophosphamide, Liposomal Doxorubicin, Vincristin and Prednisolone) in Patients With Diffuse Large B-Cell Lymphoma (NHL-14)|Completed||Phase 2|94|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||f||||||||||2018-06-01 02:39:43.336489|2018-06-01 02:39:43.336489
NCT00575393|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2018-02-05|2007-12-15|2007-12-18|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2007|Actual|2007-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase I Dose Escalation Study of the PKC Inhibitor, Aurothiomalate (ATM) in Patients With Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1|27|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:39:43.446776|2018-06-01 02:39:43.446776
NCT00575380|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2009-06-09||2011-09-20|2007-12-14|2007-12-18|Estimate|2009-08-11|2009-09-16|Estimate||||2011-09-20|2011-09-22|Estimate|December 2007||2007-12-31|September 2011|2011-09-30||||June 2008|Actual|2008-06-30||Interventional|||Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery|A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery|Completed||Phase 4|116|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:39:43.546424|2018-06-01 02:39:43.546424
NCT00575367|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2009-08-10||2011-09-20|2007-12-14|2007-12-18|Estimate|2009-08-11|2009-09-17|Estimate||||2011-09-20|2011-09-22|Estimate|March 2008||2008-03-31|September 2011|2011-09-30||||October 2008|Actual|2008-10-31||Interventional|||Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers|A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration|Completed||Phase 4|37|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:39:43.85371|2018-06-01 02:39:43.85371
NCT00575354|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2008-04-18|2007-12-17|2007-12-18|Estimate|||||||2008-04-18|2008-04-21|Estimate|March 2007||2007-03-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|CSIABTEC||Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision|Anesthesia With Sevoflurane and Isoflurane for Excision Surgeries in Benign Breast Tumors|Completed||Phase 4|500|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 02:39:44.044942|2018-06-01 02:39:44.044942
NCT00575341|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2007-12-17|2007-12-17|2007-12-18|Estimate|||||||2007-12-17|2007-12-18|Estimate|October 2003||2003-10-31|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|DHEA2000||Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency|Dehydroepiandrosterone(DHEA) Substitution in Adolescent and Young Women With Central Adrenal Insufficiency. A Multicenter, Randomised Double Blind Trial|Completed||Phase 3|23|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-06-01 02:39:44.116559|2018-06-01 02:39:44.116559
NCT00575328|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14||2017-03-06|2017-03-06|2007-12-14|2007-12-18|Estimate||||2017-03-06|2017-03-08|Actual|2017-03-06|2017-03-08|Actual|November 2007||2007-11-30|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of Maca Root to Treat Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females|A Double-Blind, Placebo Controlled Study of Maca Root for the Treatment of Sexual Dysfunction Associated With the Treatment Regimen for Bipolar Disorder in Females|Completed||Phase 3|80|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:39:44.189488|2018-06-01 02:39:44.189488
NCT00575302|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2010-04-12|2007-12-17|2007-12-18|Estimate|||||||2010-04-12|2010-04-13|Estimate|December 2007||2007-12-31|April 2010|2010-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age|Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age|Withdrawn||Phase 4|400|Anticipated|Centre Hospitalier Chretien||2||"36 cases were included and the 4 centers and they are unable to increase their recruitment to~   obtain the 400 cases necessary to reach statistical significance."|f||||f||||||||||2018-06-01 02:39:44.406381|2018-06-01 02:39:44.406381
NCT00575276|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2012-03-07|2007-12-15|2007-12-18|Estimate|||||||2012-03-07|2012-03-08|Estimate|August 2006||2006-08-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Study of Pain Perception Between Males and Females Following Laparoscopic Cholecystectomy|Sex-Dependent Modulation of Clinical Outcomes Following Laparoscopic Cholecystectomy|Completed|||102|Actual|The University of Texas Health Science Center at San Antonio|||4||f||||f||||||Samples With DNA|"~     1 cm biopsies of the body and fundus of the excised gallbladder. Two 4ml blood samples~     collected for DNA analysis with future studies.~   "|||2018-06-01 02:39:44.50152|2018-06-01 02:39:44.50152
NCT00575263|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2015-09-21|2007-12-15|2007-12-18|Estimate|||||||2015-09-21|2015-09-22|Estimate|January 2006||2006-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Sodium Channel Expression in Human Teeth|Sodium Channel Expression in Human Teeth|Completed|||250|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||f||||||Samples Without DNA|"~     Extracted teeth including pulpal tissue~   "|||2018-06-01 02:39:44.6009|2018-06-01 02:39:44.6009
NCT00575250|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2007-12-17|2007-12-17|2007-12-18|Estimate|||||||2007-12-17|2007-12-18|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Education for Osteoporosis in Persons With Existing Fractures|Osteoporosis Education Clinic Study|Completed||N/A|152|Actual|University of Adelaide||2|||f||||f||||||||||2018-06-01 02:39:44.669798|2018-06-01 02:39:44.669798
NCT00575237|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2007-12-17|2007-12-17|2007-12-18|Estimate|||||||2007-12-17|2007-12-18|Estimate|February 2004||2004-02-29|December 2007|2007-12-31|February 2005|Actual|2005-02-28|||||Interventional|||A Simple Clinical Maneuver to Reduce Laparoscopy Induced Shoulder Pain|A Simple Clinical Maneuver to Reduce Laparoscopy Induced Shoulder Pain: A Randomized Clinical Trial|Completed||N/A|100|Actual|Phelps, Paul, M.D.||2|||f||||f||||||||||2018-06-01 02:39:44.761288|2018-06-01 02:39:44.761288
NCT00575224|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-15|||2009-11-23|2007-12-15|2007-12-18|Estimate|||||||2009-11-23|2009-11-25|Estimate|October 2004||2004-10-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9|Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9: a Phase IV, Randomized, Open-labeled, Multicenter Trial Comparing 24-week vs. 48-week Therapy|Completed||Phase 4|60|Actual|Pacific Health Foundation||2|||f||||f||||||||||2018-06-01 02:39:44.84968|2018-06-01 02:39:44.84968
NCT00575211|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2016-01-14|2007-12-17|2007-12-18|Estimate|||||||2016-01-14|2016-01-15|Estimate|January 2004||2004-01-31|January 2016|2016-01-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Observational|||Study Looking at the Recovery of New Onset Cardiomyopathy|Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy|Completed|||373|Actual|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     At time of enrollment, 30cc of blood will be obtained: 10cc for plasma banking for~     neurohormones and cytokine analysis, 10 cc for DNA banking and genotyping, 5 cc for~     evaluation of gene expression of inflammatory markers from circulating leukocytes and 5 cc~     for serum banking. Ten ccs of blood for cytokine analysis will also be collected at one month~     and six months after entry. A blood specimen for repeat analysis of serum mediator (5ccs in a~     red top tube) will be drawn at six months and sent to the University of Pittsburgh. All blood~     samples will be kept for 10 years. Access to the banked DNA will be limited to investigations~     at the University of Pittsburgh and each site of this multi-center trial. These samples will~     be available without any identifying information (name, social security number and medical~     record number). In addition, a Certificate of Confidentiality has been obtained from the NIH~     for further subject protection.~   "|||2018-06-01 02:39:44.951677|2018-06-01 02:39:44.951677
NCT00575198|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-06-19|2007-12-14|2007-12-18|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2007||2007-12-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|DARTT||Drainage Amount for Removal of Thoracostomy Tube|Non-inferiority Randomized Trial Evaluating Removal of Thoracostomy Tubes Independent of the Drainage Amount Versus Removal When the Drainage Amount Is Low|Completed||N/A|280|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 02:39:45.042482|2018-06-01 02:39:45.042482
NCT00575185|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2014-12-03||2017-02-16|2007-12-14|2007-12-18|Estimate|2015-03-13|2015-03-17|Estimate||||2017-02-16|2017-03-22|Actual|November 2007||2007-11-30|February 2017|2017-02-28|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|Mono6|College students infected with mono|Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection|Randomized, Placebo-Controlled, Double-Blind Study to Assess Clinical and Antiviral Activity of Valomaciclovir (EPB 348) in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection (Mono 6)|Completed||Phase 1/Phase 2|23|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 02:39:45.200167|2018-06-01 02:39:45.200167
NCT00575172|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|||2008-01-07|2007-12-17|2007-12-18|Estimate|||||||2008-01-07|2008-01-14|Estimate|March 2003||2003-03-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Observational|||Nippon Ultra-Rapid Insulin and Diabetic Complication Evaluation-Study (NICE-Study)|To Investigate Whether the Postprandial Blood Sugar Level as Achieved Using Ultrarapid-Acting Type Insulin Could Prevent Great Vessel Disorder in Japanese Type 2 Diabetic Patients.|Completed|||346|Actual|Osaka Saiseikai Nakatsu Hospital|||2||f||||t||||||||||2018-06-01 02:39:45.543267|2018-06-01 02:39:45.543267
NCT00575159|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2017-08-01|2012-03-29|2017-09-08|2007-12-14|2007-12-18|Estimate|2017-09-08|2017-10-09|Actual|2013-05-13|2013-05-21|Estimate|2017-09-08|2017-10-09|Actual|March 31, 2008|Actual|2008-03-31|August 2017|2017-08-31|December 18, 2008|Actual|2008-12-18|December 18, 2008|Actual|2008-12-18||Interventional|||A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus|A Double-blind, Randomized, Single Ascending Dose Escalation, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 Administered to Subjects With Type 1 Diabetes Mellitus|Completed||Phase 2|10|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:39:45.721859|2018-06-01 02:39:45.721859
NCT00574782|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2007-12-12|2007-12-12|2007-12-17|Estimate|||||||2007-12-12|2007-12-17|Estimate|September 2003||2003-09-30|December 2007|2007-12-31||||||||Observational|CHALLENGE||Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)|Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)|Completed|||2660|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:39:56.073977|2018-06-01 02:39:56.073977
NCT00575146|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-17|2013-06-18||2014-04-16|2007-12-17|2007-12-18|Estimate|2013-11-18|2013-12-13|Estimate||||2014-04-16|2014-05-02|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|ERGO||Ketogenic Diet for Recurrent Glioblastoma|Ketogenic Diet for Patients With Recurrent Glioblastoma|Completed||Phase 1|20|Actual|University Hospital Tuebingen|Because of the small number of patients efficacy cannot be concluded by the results of the study|1|||f||||f||||||||||2018-06-01 02:39:47.69432|2018-06-01 02:39:47.69432
NCT00575133|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2012-02-23|2007-12-17|2007-12-18|Estimate|||||||2012-02-23|2012-02-24|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|November 2027|Anticipated|2027-11-30|||||Observational|||Prospective Cohort Study in Patients With NAFLD|Multicentric, Prospective, Non-interventional, Long-term Cohort Study in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)|Recruiting|||150|Anticipated|University of Zurich|||||f||||f||||||Samples With DNA|"~     Liver biopsy~   "|||2018-06-01 02:39:47.985772|2018-06-01 02:39:47.985772
NCT00575120|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-10-02|2007-12-14|2007-12-18|Estimate|||||||2011-10-02|2011-10-04|Estimate|September 2007||2007-09-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|EFBOLD-MRI||Endothelial Function Assessed With BOLD-MRI|Assessment of Endothelial Function Using Blood Oxygen Level-Dependent MRI (BOLD-MRI)|Completed||N/A|15|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 02:39:48.131798|2018-06-01 02:39:48.131798
NCT00575107|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2011-08-03|2007-12-14|2007-12-18|Estimate|||||||2011-08-03|2011-08-04|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|LCT||A System for Lengthening Contraction Training of Muscle|A System for Lengthening Contraction Training of Muscle|Completed||N/A|36|Anticipated|University of Michigan||2|||f||||f||||||||||2018-06-01 02:39:48.220114|2018-06-01 02:39:48.220114
NCT00575094|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2009-03-31||2011-06-02|2007-12-13|2007-12-17|Estimate|2009-03-31|2009-05-27|Estimate||||2011-06-02|2011-06-03|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects|A Phase 3, Multicenter, Open-label Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects With Community-acquired Pneumonia|Completed||Phase 3|9|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:39:48.320117|2018-06-01 02:39:48.320117
NCT00575081|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2017-11-08|2007-12-13|2007-12-17|Estimate|||||||2017-11-08|2017-11-13|Actual|August 2006||2006-08-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|Brain Atlas||Physiological Brain Atlas Development|Physiological Brain Atlas Development|Recruiting|||5000|Anticipated|Vanderbilt University Medical Center|||1||f||||t||||||||Undecided||2018-06-01 02:39:48.513347|2018-06-01 02:39:48.513347
NCT00575068|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2012-06-07|2007-12-13|2007-12-17|Estimate|||||||2012-06-07|2012-06-08|Estimate|January 2002||2002-01-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|September 2002|Actual|2002-09-30||Interventional|||Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma|A Phase I/II Trial of Anti-CD80 Monoclonal Antibody (IDEC-114) Therapy for Patients With Relapsed or Refractory Follicular Lymphoma|Completed||Phase 1/Phase 2|42|Actual|Biogen||1|||f||||f||||||||||2018-06-01 02:39:48.611181|2018-06-01 02:39:48.611181
NCT00575055|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10||2013-09-27|2013-10-30|2007-12-13|2007-12-17|Estimate||||2013-09-27|2013-10-28|Estimate|2013-10-30|2013-11-25|Estimate|December 2007||2007-12-31|October 2013|2013-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.|Completed||Phase 3|1121|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||3|||f||||||||||||||2018-06-01 02:39:48.738675|2018-06-01 02:39:48.738675
NCT00575042|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2011-12-02||2018-02-07|2007-12-13|2007-12-17|Estimate|2011-12-02|2012-01-09|Estimate||||2018-02-07|2018-03-08|Actual|August 2007||2007-08-31|February 2018|2018-02-28|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||Use of Fenofibrate for Primary Biliary Cirrhosis|Pilot Study of Fenofibrate for Primary Biliary Cirrhosis|Completed||Phase 2|20|Actual|University of Florida|A major limitation is the uncontrolled nature of this study.|1|||f||||f|t|f||||||||2018-06-01 02:39:49.134278|2018-06-01 02:39:49.134278
NCT00575029|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2011-03-31||2011-07-27|2007-12-14|2007-12-17|Estimate|2011-07-27|2011-08-29|Estimate||||2011-07-27|2011-08-29|Estimate|April 2004||2004-04-30|July 2011|2011-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate|Evaluation of the Time Course of Adrenal Suppression and Adrenal Recovery After Ingestion of Megestrol Acetate|Completed||N/A|7|Actual|University of Arkansas|funding became an issue limiting the number of patients enrolled|1|||f||||f||||||||||2018-06-01 02:39:49.338712|2018-06-01 02:39:49.338712
NCT00575016|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2011-09-09|2011-03-31|2015-09-17|2007-12-13|2007-12-17|Estimate|2011-09-09|2011-10-17|Estimate|2011-03-31|2011-04-07|Estimate|2015-09-17|2015-10-02|Estimate|December 2007||2007-12-31|September 2015|2015-09-30|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder||Terminated||Phase 2|74|Actual|Allergan|Due to recruitment difficulties, study enrollment was stopped early.|4||The study was terminated early due to enrollment challenges.|f||||||||||||||2018-06-01 02:39:49.597796|2018-06-01 02:39:49.597796
NCT00575003|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-04-24|2007-12-14|2007-12-17|Estimate|||||||2009-04-24|2009-04-27|Estimate|December 2007||2007-12-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis|Double-Blind, Placebo-Controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis|Completed||Phase 2|64|Anticipated|Cytos Biotechnology AG||2|||f||||||||||||||2018-06-01 02:39:50.205542|2018-06-01 02:39:50.205542
NCT00574990|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2014-10-01||2015-05-22|2007-12-14|2007-12-17|Estimate|2015-05-22|2015-06-09|Estimate||||2015-05-22|2015-06-09|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|MED-COMM||Minimizing Harm From ADEs by Improving Nurse-Physician Communication|Minimizing Harm From ADEs by Improving Nurse-Physician Communication|Completed|||39|Actual|VA Office of Research and Development|||3||f||||f||||||||||2018-06-01 02:39:50.300425|2018-06-01 02:39:50.300425
NCT00574977|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2015-12-23|2007-12-14|2007-12-17|Estimate|||||||2015-12-23|2015-12-28|Estimate|May 2008||2008-05-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|January 2013|Actual|2013-01-31||Interventional|||Safety Study of Modified Vaccinia Virus to Cancer|A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection|Completed||Phase 1|26|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 02:39:50.648561|2018-06-01 02:39:50.648561
NCT00574964|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2016-10-25|2007-12-14|2007-12-17|Estimate|||||||2016-10-25|2016-10-27|Estimate|October 2005||2005-10-31|March 2010|2010-03-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|Temodar||Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme|Phase II Treatment of Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme Treated With Gliadel Wafers, Surgery and Limited Field Radiation Plus Concomitant Temozolomide Followed by Temozolomide|Terminated||Phase 2|50|Anticipated|University of Iowa||1||PI left the institution.|f||||t||||||||||2018-06-01 02:39:50.73857|2018-06-01 02:39:50.73857
NCT00574951|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2017-08-03||2017-12-12|2007-12-14|2007-12-17|Estimate|2017-12-12|2018-01-11|Actual||||2017-12-12|2018-01-11|Actual|December 2007||2007-12-31|May 2015|2015-05-31||||July 2013|Actual|2013-07-31||Interventional||Eligible and treated patients.|AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Terminated||Phase 2|23|Actual|Gynecologic Oncology Group||1||Study was stopped for severe toxicity causing concern for patients|f||||t||||||||||2018-06-01 02:39:50.841686|2018-06-01 02:39:50.841686
NCT00574925|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2007-12-17|2007-12-13|2007-12-17|Estimate|||||||2007-12-17|2007-12-18|Estimate|November 2003||2003-11-30|December 2007|2007-12-31|October 2007||2007-10-31|||||Interventional|||Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients|Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 4|||University of Zurich|||||f||||f||||||||||2018-06-01 02:39:51.21283|2018-06-01 02:39:51.21283
NCT00574912|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2014-12-18||2017-03-17|2007-12-13|2007-12-17|Estimate|2015-07-02|2015-08-03|Estimate||||2017-03-17|2017-04-17|Actual|March 2007||2007-03-31|March 2017|2017-03-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional||One participant may have received more than one intervention.|Characteristics of Glargine in Type 2 Diabetics|A Comparison of PK/PD Dose Response Characteristics of Glargine in Type 2 Diabetics|Completed||Phase 1|20|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 02:39:51.281397|2018-06-01 02:39:51.281397
NCT00574899|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2015-10-18|2007-12-14|2007-12-17|Estimate|||||||2015-10-18|2015-10-20|Estimate|May 2007||2007-05-31|October 2015|2015-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Prostate Biomarker Study|Multi-Institutional Inter-SPORE Prostate Biomarker Study|Completed|||32|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     tissue, serum, plasma, and lymphocytes~   "|||2018-06-01 02:39:51.513255|2018-06-01 02:39:51.513255
NCT00574886|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2018-01-13|2007-12-14|2007-12-17|Estimate|||||||2018-01-13|2018-01-17|Actual|July 2000||2000-07-31|January 2018|2018-01-31|April 2008|Actual|2008-04-30|March 2002|Actual|2002-03-31||Interventional|||Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy|Pilot Trial for Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy|Completed||N/A|2|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:39:51.598201|2018-06-01 02:39:51.598201
NCT00574873|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2012-10-04|2011-09-07|2016-08-22|2007-12-14|2007-12-17|Estimate|2012-10-04|2012-11-05|Estimate|2011-09-13|2011-09-21|Estimate|2016-08-22|2016-10-17|Estimate|February 2008||2008-02-29|August 2016|2016-08-31|May 2015|Actual|2015-05-31|August 2010|Actual|2010-08-31||Interventional||Intent-to-treat (ITT) population - included all participants who were randomized to test article.|Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML|A Phase 3 Randomized, Open-Label Study Of Bosutinib Versus Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia|Completed||Phase 3|502|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:39:51.719498|2018-06-01 02:39:51.719498
NCT00574860|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14||2013-09-09|2013-09-17|2007-12-14|2007-12-17|Estimate||||2013-09-17|2013-09-20|Estimate|2013-09-17|2013-09-20|Estimate|December 2007||2007-12-31|September 2013|2013-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer|A Phase 3, Multi-center, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of EN3285 for the Prevention or Delay to Onset of Severe Oral Mucositis in Patients With Head and Neck Cancer Receiving Chemoradiotherapy|Terminated||Phase 3|240|Actual|Endo Pharmaceuticals||3||Additional research|f||||t||||||||||2018-06-01 02:39:53.079548|2018-06-01 02:39:53.079548
NCT00574847|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2015-06-11||2015-07-08|2007-12-14|2007-12-17|Estimate|2015-07-08|2015-08-05|Estimate||||2015-07-08|2015-08-05|Estimate|September 2006||2006-09-30|July 2015|2015-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|REMIT||Responses of Myocardial Ischemia to Escitalopram Treatment|Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT Trial)|Completed||Phase 4|127|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:39:53.190806|2018-06-01 02:39:53.190806
NCT00574834|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2015-12-10||2017-02-09|2007-12-13|2007-12-17|Estimate|2015-12-10|2016-01-15|Estimate||||2017-02-09|2017-03-20|Actual|March 2007||2007-03-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes|Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis|Terminated||Early Phase 1|17|Actual|University of Maryland|Early termination leading to small numbers of subjects analyzed. No conclusions drawn.|3||Lack of funding|f||||t||||||||||2018-06-01 02:39:53.57252|2018-06-01 02:39:53.57252
NCT00574821|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-11-16|2007-12-14|2007-12-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)|Assessing the Utility of Magnetocardiography in Patients With Hypertrophic Cardiomyopathy|Withdrawn|||20|Anticipated|Cedars-Sinai Medical Center||||sponsor funding|f||||f||||||||||2018-06-01 02:39:54.02676|2018-06-01 02:39:54.02676
NCT00574808|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2014-10-03|2007-12-14|2007-12-17|Estimate|||||||2014-10-03|2014-10-06|Estimate|April 2007||2007-04-30|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|IDOCC||Improved Delivery of Cardiovascular Care Through Outreach Facilitation|Improved Delivery of Cardiovascular Preventive Care (IDOCC) Through Outreach Facilitation|Completed||Phase 1|194|Actual|Bruyere Research Institute||2|||f||||f||||||||||2018-06-01 02:39:54.158285|2018-06-01 02:39:54.158285
NCT00574795|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2010-03-26||2012-06-28|2007-12-13|2007-12-17|Estimate|2012-06-28|2012-08-08|Estimate||||2012-06-28|2012-08-08|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants|A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan|Completed||Phase 3|193|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 02:39:54.299712|2018-06-01 02:39:54.299712
NCT00574769|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-04-09|2007-12-14|2007-12-17|Estimate|||||||2017-04-09|2017-04-11|Actual|February 17, 2010|Actual|2010-02-17|April 2017|2017-04-30|February 17, 2017|Actual|2017-02-17|February 17, 2016|Actual|2016-02-17||Interventional|||Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer|Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer|Completed||Phase 1/Phase 2|27|Actual|University of Southern California||1|||f||||t|t|f||||||||2018-06-01 02:39:56.175839|2018-06-01 02:39:56.175839
NCT00574756|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2007-12-14|2007-12-14|2007-12-17|Estimate|||||||2007-12-14|2007-12-17|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction|The Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction|Unknown status|Recruiting|N/A|20|Anticipated|University of California, San Diego||2|||f||||||||||||||2018-06-01 02:39:56.278287|2018-06-01 02:39:56.278287
NCT00574743|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2011-11-01|2007-12-14|2007-12-17|Estimate|||||||2011-11-01|2011-11-02|Estimate|January 2002||2002-01-31|November 2011|2011-11-30||||April 2004|Actual|2004-04-30||Interventional|||Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients|A 12-month, Single-blind, Randomized, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of ERL080A Compared With MMF in de Novo Heart Recipients|Completed||Phase 4|162|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:39:56.356608|2018-06-01 02:39:56.356608
NCT00574730|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2018-01-22|2007-12-12|2007-12-17|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2001||2001-05-31|January 2018|2018-01-31|June 2012|Actual|2012-06-30|August 2005|Actual|2005-08-31||Interventional|||CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma|CHOP/Rituximab Followed by Maintenance Pegylated Interferon-Alpha (PEG Intron)With the Treatment of Patients With Anthracycline Naïve Indolent/Follicular Non-Hodgkin's Lymphoma|Completed||N/A|27|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:39:56.440564|2018-06-01 02:39:56.440564
NCT00574717|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2012-10-18|2007-12-13|2007-12-17|Estimate|||||||2012-10-18|2012-10-19|Estimate|December 2007||2007-12-31|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Enhancement of Emmetropization in Hyperopic Infants|Enhancement of Emmetropization in Hyperopic Infants|Terminated||Phase 1/Phase 2|6|Actual|Ohio State University||1||Lack of funding support for continued recruitment, enrollment, treatment|f||||f||||||||||2018-06-01 02:39:56.506594|2018-06-01 02:39:56.506594
NCT00574704|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2013-02-14||2013-06-04|2007-12-14|2007-12-17|Estimate|2013-06-04|2013-07-11|Estimate||||2013-06-04|2013-07-11|Estimate|September 2006||2006-09-30|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis|Double Blind Placebo Controlled Study to Assess Efficacy and Safety of a Combined Allergen Vaccine (CYT005-AllQbG10) and Its Single Components in Patients With House Dust Mite Allergy|Completed||Phase 2|40|Actual|Cytos Biotechnology AG||4|||f||||||||||||||2018-06-01 02:39:56.611521|2018-06-01 02:39:56.611521
NCT00574691|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2012-02-27|2007-12-14|2007-12-17|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|October 2007|Actual|2007-10-31|||||Interventional|ECLIPSE||ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis Trial) EU|ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis) Trial|Completed||Phase 1|93|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 02:39:57.089658|2018-06-01 02:39:57.089658
NCT00574678|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2016-02-02|2007-12-13|2007-12-17|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2006||2006-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ACT||Analyzing the Composition of Tears to Identify Cancer|ACT: Analyzing the Composition of Tears to Identify Cancer (Breast, Ovarian, Colon)|Completed||Phase 1/Phase 2|150|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:39:57.200609|2018-06-01 02:39:57.200609
NCT00574665|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2014-12-10|2007-12-13|2007-12-17|Estimate|||||||2014-12-10|2014-12-11|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 1|SCCOR in Hemostatic and Thrombotic Diseases Project 5 - Metabolic Causes of Thrombosis in Type 2 Diabetes|Completed||N/A|32|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 02:39:57.280372|2018-06-01 02:39:57.280372
NCT00574652|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2013-01-23|2007-12-14|2007-12-17|Estimate|||||||2013-01-23|2013-01-24|Estimate|March 2008||2008-03-31|January 2008|2008-01-31|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients|ANRS HC 21 VASCU IL-2, Evaluation of the Cellular Immune Response, Clinical Efficacy and Tolerance After IL-2 Therapy in HCV-related Vasculitis Patients, Resistant to Conventional Therapy.|Completed||Phase 1/Phase 2|10|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-06-01 02:39:57.359041|2018-06-01 02:39:57.359041
NCT00574639|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2017-02-09|2007-12-13|2007-12-17|Estimate|||||||2017-02-09|2017-02-10|Actual|July 2007||2007-07-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Alp Ex||Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2|Mechanisms of Hypoglycemia-Associated Autonomic Dysfunction. The Effect of Alprazolam on Exercise Induced Hypoglycemia.|Completed||Early Phase 1|14|Actual|University of Maryland||4|||f||||t||||||||||2018-06-01 02:39:57.452366|2018-06-01 02:39:57.452366
NCT00574626|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2018-01-13|2007-12-14|2007-12-17|Estimate|||||||2018-01-13|2018-01-17|Actual|December 1991||1991-12-31|January 2018|2018-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Randomized Trial Comparing Autologous PBSCT to BMT for Pts Receiving High-Dose Chemo & Transplant for Recurrent NHL|Randomized Trial Comparing Autologous Peripheral Blood Stem Cell Transplantation to Bone Marrow Transplantation for Patients Receiving High-Dose Chemotherapy and Transplantation for Recurrent Non-Hodgkin's Lymphoma|Completed||N/A|51|Actual|University of Nebraska||2|||f||||f||||||||||2018-06-01 02:39:57.53762|2018-06-01 02:39:57.53762
NCT00574613|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2013-02-08|2007-12-14|2007-12-17|Estimate|||||||2013-02-08|2013-02-11|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|September 2010|Actual|2010-09-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis|Phase II, Multicenter, Randomized, Double-blind, Intraindividually Placebo Controlled Clinical Trial, to Evaluate Efficacy and Safety of p144 Topical Administration for Skin Fibrosis in Patients With Systemic Sclerosis|Completed||Phase 2|56|Actual|ISDIN||2|||f||||f||||||||||2018-06-01 02:39:57.613688|2018-06-01 02:39:57.613688
NCT00574431|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2015-07-13|2007-12-14|2007-12-17|Estimate|||||||2015-07-13|2015-07-14|Estimate|February 2008||2008-02-29|March 2011|2011-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||ICU Nutrition Study Bern|Implementation of an Evidence-based Nutritional Management Protocol in Critically Ill Patients:Does Clinical Outcome Improve?|Completed||Phase 4|200|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:40:04.255182|2018-06-01 02:40:04.255182
NCT00574600|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2016-06-01|2007-12-13|2007-12-17|Estimate|||||||2016-06-01|2016-06-02|Estimate|November 2008||2008-11-30|June 2016|2016-06-30|January 2013|Actual|2013-01-31|October 2010|Actual|2010-10-31||Interventional|||Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults|A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 02:39:57.742302|2018-06-01 02:39:57.742302
NCT00574587|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2015-07-13|2007-12-14|2007-12-17|Estimate|||||||2015-07-13|2015-07-14|Estimate|December 2007||2007-12-31|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|May 2014|Actual|2014-05-31||Interventional|||Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis|Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel and Trastuzumab Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|54|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-06-01 02:39:57.85111|2018-06-01 02:39:57.85111
NCT00574574|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-07-10|2007-12-14|2007-12-17|Estimate|||||||2009-07-10|2009-07-14|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effects of Anthocyanin on Skin Health and Markers of Cardiovascular Disease Risk|Biological Effects of an Anthocyanin Rich Dietary Supplement on Skin Ageing and Markers of Inflammation in Post-Menopausal Women|Completed||N/A|62|Anticipated|University of East Anglia||2|||f||||f||||||||||2018-06-01 02:39:57.928569|2018-06-01 02:39:57.928569
NCT00574561|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-11-16|2007-12-14|2007-12-17|Estimate|||||||2009-11-16|2009-11-17|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Magnetocardiography (MCG) in Subjects Undergoing CT Angiography (CTA)|Magnetocardiography (MCG) in Subjects Undergoing CT Angiography (CTA)|Withdrawn|||300|Anticipated|Cedars-Sinai Medical Center||||sponsor funding|f||||f||||||||||2018-06-01 02:39:57.995645|2018-06-01 02:39:57.995645
NCT00574548|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2011-02-01||2011-07-18|2007-12-13|2007-12-17|Estimate|2011-04-15|2011-05-09|Estimate||||2011-07-18|2011-07-22|Estimate|November 2007||2007-11-30|July 2011|2011-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS|A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months Either as a 2-Dose Regimen or With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Adults 60 to 64 Years of Age Who Are Naive to 23vPS|Completed||Phase 3|720|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 02:39:58.411581|2018-06-01 02:39:58.411581
NCT00574535|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-11-17|2007-12-14|2007-12-17|Estimate|||||||2017-11-17|2017-11-21|Actual|January 1995||1995-01-31|November 2017|2017-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Reproductive Hormones And Pre-Clinical Cardiovascular Disease (CVD) In Women|Reproductive Hormones And Pre-Clinical CVD In Women|Completed|||269|Actual|Cedars-Sinai Medical Center|||||f||||t||||||||Yes||2018-06-01 02:40:03.326495|2018-06-01 02:40:03.326495
NCT00574522|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-14|2007-12-14|2007-12-17|Estimate|||||||2009-08-14|2009-08-17|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|November 2009|Anticipated|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Energy Specific Far Infrared Radiation Treatment for AIDS|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for HIV/AIDS|Unknown status|Active, not recruiting|Phase 1|3|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:03.395411|2018-06-01 02:40:03.395411
NCT00574509|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-05-01|2007-12-12|2007-12-17|Estimate|||||||2017-05-01|2017-05-04|Actual|March 1996||1996-03-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||BEAM+131I-Anti-B1 & Autologous Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma|BEAM + 131Iodine-Anti-B1 Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Recurrent Non-Hodgkin's Lymphoma|Completed||Phase 1|34|Actual|University of Nebraska||1|||f||||f||||||||||2018-06-01 02:40:03.474352|2018-06-01 02:40:03.474352
NCT00574496|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2018-05-02|2007-12-14|2007-12-17|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2007|Actual|2007-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma|An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma|Active, not recruiting||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:40:03.572505|2018-06-01 02:40:03.572505
NCT00574483|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2015-07-31|2007-12-13|2007-12-17|Estimate|||||||2015-07-31|2015-08-03|Estimate|November 2007||2007-11-30|January 2008|2008-01-31|January 2008|Anticipated|2008-01-31|January 2008|Anticipated|2008-01-31||Interventional|||Treatment of Advanced Renal Cell Carcinoma With Quinacrine|An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|Cleveland BioLabs||1||reevaluation of compound development|f||||f||||||||||2018-06-01 02:40:03.698842|2018-06-01 02:40:03.698842
NCT00574470|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-02-16|2007-12-14|2007-12-17|Estimate|||||||2017-02-16|2017-02-20|Actual|January 2006||2006-01-31|February 2017|2017-02-28|August 2008|Actual|2008-08-31|November 2007|Actual|2007-11-30||Interventional|||Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD|Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD|Completed||Phase 4|3|Actual|University of Iowa||1|||f||||t||||||||||2018-06-01 02:40:03.808882|2018-06-01 02:40:03.808882
NCT00574457|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2015-09-29|2007-12-12|2007-12-17|Estimate|||||||2015-09-29|2015-10-01|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MERC-CIMT||Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study|Improving Cardiovascular Risk Prediction Using Hand-Held Carotid Ultrasonography Study|Completed||Phase 4|355|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 02:40:03.894384|2018-06-01 02:40:03.894384
NCT00574444|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2016-09-29|2007-12-14|2007-12-17|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transvaginal Diagnostic Study in Women With Pelvic Pain|Laparoscopic Assisted Transvaginal Endoscopic Diagnostic Peritoneoscopy in Women With Pelvic Pain|Withdrawn||Phase 1|0|Actual|University of Missouri-Columbia||1||Investigator moved to another institution.|f||||f||||||||No||2018-06-01 02:40:04.010843|2018-06-01 02:40:04.010843
NCT00574418|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-01-02|2007-12-14|2007-12-17|Estimate|||||||2009-01-02|2009-01-05|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|September 2008|Anticipated|2008-09-30|March 2008|Anticipated|2008-03-31||Interventional|||Far Infrared Radiation Treatment for Uterine Fibroids|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Uterine Fibroids|Unknown status|Active, not recruiting|Phase 1|2|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:04.345989|2018-06-01 02:40:04.345989
NCT00574405|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2011-07-14||2017-09-11|2007-12-14|2007-12-17|Estimate|2011-07-14|2011-08-09|Estimate||||2017-09-11|2017-09-13|Actual|April 2005||2005-04-30|September 2017|2017-09-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|ktpump||Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy|Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy|Completed||N/A|24|Actual|Arkansas Children's Hospital Research Institute|Post hoc analysis demonstrated that the study design was weakened by an underestimation of the sample size per group needed to determine a statistically significant result for our primary outcome measure.|2|||f||||f||||||||||2018-06-01 02:40:04.454093|2018-06-01 02:40:04.454093
NCT00574392|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2015-12-17|2007-12-14|2007-12-17|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo|Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo|Completed|||50|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||f||||||||||2018-06-01 02:40:04.73298|2018-06-01 02:40:04.73298
NCT00574379|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-01-09|2007-12-14|2007-12-17|Estimate|||||||2009-01-09|2009-01-12|Estimate|December 2007||2007-12-31|January 2009|2009-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR|A Multi-Center Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in The Treatment of the Symptoms of Seasonal Allergic Rhino-Conjunctivitis With Allergy to Mountain Cedar Pollen|Completed||Phase 2|805|Actual|Faes Farma, S.A.||5|||f||||f||||||||||2018-06-01 02:40:04.814364|2018-06-01 02:40:04.814364
NCT00574366|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2016-05-06|2007-12-14|2007-12-17|Estimate|||||||2016-05-06|2016-05-10|Estimate|December 2005||2005-12-31|May 2016|2016-05-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer|A Phase I/II Trial of an Oral MTOR Protein Kinase Inhibitor (Everolimus, RAD001) in Combination With an Oral EGFR Tyrosine Kinase Inhibitor (Erlotinib, Tarceva™) In Patients With Metastatic Breast Cancer|Completed||Phase 1|14|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:40:04.915052|2018-06-01 02:40:04.915052
NCT00574353|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2017-10-24|2007-12-13|2007-12-17|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2007||2007-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients|A Feasibility Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients|Recruiting||Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:40:05.071541|2018-06-01 02:40:05.071541
NCT00574340|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2014-05-27||2017-02-09|2007-12-13|2007-12-17|Estimate|2014-08-22|2014-09-01|Estimate||||2017-02-09|2017-03-29|Actual|May 2007||2007-05-31|February 2017|2017-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4|SCCOR in Hemostatic and Thrombotic Diseases Project 5 - Metabolic Causes of Thrombosis in Type 2 Diabetes|Completed||Early Phase 1|20|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 02:40:05.190549|2018-06-01 02:40:05.190549
NCT00574327|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-05-24|2007-12-14|2007-12-17|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2006||2006-01-31|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Observational|||Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry|A Prospective Study To Define The Role Of Various Factors In Development And Progression Of Gastroesophageal Reflux Disease (GERD) And Barrett's Esophagus And The Creation Of A Registry.|Recruiting|||3000|Anticipated|Midwest Biomedical Research Foundation|||3||f||||f||||||Samples With DNA|"~     Serum samples from participating patients will be collected and frozen for measurements of~     insulin, glucose, lipid panel, CRP and adiponectin levels. Biopsies obtained from esophagus~     during endoscopy and blood samples will be frozen for future biomarker and cDNA microarray~     studies and histochemistry.~   "|||2018-06-01 02:40:05.391607|2018-06-01 02:40:05.391607
NCT00574314|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2017-11-17|2007-12-14|2007-12-17|Estimate|||||||2017-11-17|2017-11-21|Actual|July 2004||2004-07-31|November 2017|2017-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Women's Health Research Registry|Women's Health Research Registry|Terminated|||839|Actual|Cedars-Sinai Medical Center|||1|No more funding|f||||f||||||||Yes||2018-06-01 02:40:05.5207|2018-06-01 02:40:05.5207
NCT00574301|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2013-07-24|2007-12-14|2007-12-17|Estimate|||||||2013-07-24|2013-07-25|Estimate|March 2002||2002-03-31|July 2013|2013-07-31|October 2011|Actual|2011-10-31|October 2007|Actual|2007-10-31||Interventional|||Percutaneous Removal and Margin Ablation for Breast Cancer|Percutaneous Removal and Margin Ablation for Breast Cancer|Completed||Phase 1/Phase 2|32|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:40:05.596661|2018-06-01 02:40:05.596661
NCT00574288|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2016-10-21||2018-03-30|2007-12-14|2007-12-17|Estimate|2017-01-18|2017-03-09|Actual||||2018-03-30|2018-04-27|Actual|March 26, 2008|Actual|2008-03-26|March 2018|2018-03-31|April 3, 2017|Actual|2017-04-03|January 9, 2015|Actual|2015-01-09||Interventional|||Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma|Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - Open Label, Dose-escalation Followed by Open Label, Single-arm Study|Completed||Phase 2|104|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-06-01 02:40:05.752155|2018-06-01 02:40:05.752155
NCT00574275|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2012-08-17|2011-07-21|2016-05-04|2007-12-14|2007-12-17|Estimate|2012-09-24|2012-09-25|Estimate|2011-07-21|2011-07-25|Estimate|2016-05-04|2016-06-07|Estimate|December 2007||2007-12-31|May 2016|2016-05-31|November 2010|Actual|2010-11-30|October 2009|Actual|2009-10-31||Interventional|VANILLA||Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer|A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer|Terminated||Phase 3|546|Actual|Sanofi|"As the study was terminated due to futility, some changes were made to the planned analyses, and the analyses for the following outcome measures were not performed:~Objective Response Rate (ORR)~Clinical Benefit"|2||"Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to~   gemcitabine would be unable to demonstrate improved survival"|f||||t||||||||||2018-06-01 02:40:07.45|2018-06-01 02:40:07.45
NCT00574262|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2010-01-12|2007-12-14|2007-12-17|Estimate|||||||2010-01-12|2010-01-13|Estimate|October 2007||2007-10-31|November 2007|2007-11-30|April 2009|Anticipated|2009-04-30|||||Observational|QuASt||Quality Assessment in Acute Stroke Care|Quality of Acute Stroke Care Evaluated With a Clinical Pathway on a 16 Bed Stroke Unit - a Prospective Trial|Unknown status|Recruiting||400|Anticipated|University Hospital Muenster|||||f||||f||||||||||2018-06-01 02:40:08.792128|2018-06-01 02:40:08.792128
NCT00574249|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2009-10-29||2011-04-11|2007-12-12|2007-12-17|Estimate|2009-12-15|2010-01-18|Estimate||||2011-04-11|2011-04-13|Estimate|November 2007||2007-11-30|April 2011|2011-04-30||||October 2008|Actual|2008-10-31||Interventional|BELIEVE||Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment|A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)|Completed||Phase 3|730|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:40:08.889949|2018-06-01 02:40:08.889949
NCT00574236|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2018-03-21||2018-04-24|2007-12-13|2007-12-17|Estimate|2018-03-21|2018-04-20|Actual||||2018-04-24|2018-05-23|Actual|August 2006|Actual|2006-08-31|April 2018|2018-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer|A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer|Terminated||Phase 2|4|Actual|University of Wisconsin, Madison||1||no additional funding|f||||t||||||||||2018-06-01 02:40:09.911393|2018-06-01 02:40:09.911393
NCT00574223|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-04-24|2007-12-14|2007-12-17|Estimate|||||||2009-04-24|2009-04-27|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis|Double-Blind, Placebo-Controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immunotherapy Combining Allergen With CYT003-QbG10 (CYT005-AllQbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis Due to House Dust Mite Allergy|Completed||Phase 2|100|Anticipated|Cytos Biotechnology AG||2|||f||||||||||||||2018-06-01 02:40:10.247151|2018-06-01 02:40:10.247151
NCT00574210|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2009-01-09|2007-12-14|2007-12-17|Estimate|||||||2009-01-09|2009-01-12|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-Arm)|A Randomized, Double-Blind, Placebo-Controlled, 5-Arm Parallel Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Steady State Efficacy of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo Given Orally in the Treatment of the Symptoms of Seasonal Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Mode|Completed||Phase 2|502|Actual|Faes Farma, S.A.||5|||f||||t||||||||||2018-06-01 02:40:10.3295|2018-06-01 02:40:10.3295
NCT00574197|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2010-07-21|2007-12-14|2007-12-17|Estimate|||||||2010-07-21|2010-07-22|Estimate|June 2006||2006-06-30|August 2009|2009-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients|Assessment of Gastrointestinal Tolerability and Efficacy of Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients|Completed||Phase 4|11|Actual|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-06-01 02:40:10.688013|2018-06-01 02:40:10.688013
NCT00574184|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2017-10-27|2007-12-14|2007-12-17|Estimate|||||||2017-10-27|2017-10-31|Actual|August 2005||2005-08-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|PANPI||Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)|Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)|Completed|||10|Actual|University of California, Davis|||||f||||t|f|f||||||||2018-06-01 02:40:11.046406|2018-06-01 02:40:11.046406
NCT00574171|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2014-06-05||2016-02-19|2007-12-14|2007-12-17|Estimate|2015-06-19|2015-07-14|Estimate||||2016-02-19|2016-03-21|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma|A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)|Completed||Phase 2|29|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 02:40:11.754587|2018-06-01 02:40:11.754587
NCT00574158|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|||2014-09-25|2007-12-14|2007-12-17|Estimate|||||||2014-09-25|2014-09-29|Estimate|July 2005||2005-07-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Observational|||Pathogenesis and Genetics of Environmental Asthma Ozone Study|Project 2: Genetic Regulation of Ozone Induced Inflammation in Humans.|Completed|||170|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||f||||||Samples With DNA|"~     plasma, and ebc collected.~   "|||2018-06-01 02:40:12.080157|2018-06-01 02:40:12.080157
NCT00574145|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-14|2012-03-15||2012-08-04|2007-12-14|2007-12-17|Estimate|2012-08-04|2012-09-06|Estimate||||2012-08-04|2012-09-06|Estimate|February 2007||2007-02-28|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Healing Touch in Treating Fatigue in Women Undergoing Radiation Therapy for Breast Cancer|Examining the Effect of Healing Touch on Radiotherapy-induced Fatigue|Completed||N/A|44|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-06-01 02:40:12.164989|2018-06-01 02:40:12.164989
NCT00574132|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10||2013-09-27|2013-10-30|2007-12-13|2007-12-17|Estimate||||2013-09-27|2013-10-28|Estimate|2013-10-30|2013-11-25|Estimate|December 2007||2007-12-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.|Completed||Phase 3|1331|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||3|||f||||||||||||||2018-06-01 02:40:12.667728|2018-06-01 02:40:12.667728
NCT00574119|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2018-01-18|2007-12-14|2007-12-17|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2007||2007-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Aldosterone on Energy Starvation in Heart Failure|Effect of Aldosterone on Energy Starvation in Heart Failure|Active, not recruiting||Phase 4|20|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||No||2018-06-01 02:40:13.14734|2018-06-01 02:40:13.14734
NCT00574106|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-14|2007-12-12|2007-12-14|Estimate|||||||2009-08-14|2009-08-17|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|October 2009|Anticipated|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||A Study to Evaluate the Effect of Far Infrared Radiation for Cancer Treatment|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation for Cancer Treatment|Unknown status|Active, not recruiting|Phase 1|3|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:13.319017|2018-06-01 02:40:13.319017
NCT00574093|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2009-10-29|2007-12-13|2007-12-14|Estimate|||||||2009-10-29|2009-10-30|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|Luvi||Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD|12 Months Case Series Open Study to Assess the Safety and Efficacy of Intravitreal Injection of Lucentis (Ranibizumab 0.5 mg)Used in Combination With Visudyne (Verteporfin PDT) in Naive Subjects With Subfoveal CNV Secondary to AMD|Completed||Phase 2|15|Anticipated|Fondazione G.B. Bietti, IRCCS||1|||f||||t||||||||||2018-06-01 02:40:13.461616|2018-06-01 02:40:13.461616
NCT00574080|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2011-05-04||2017-10-17|2007-12-13|2007-12-14|Estimate|2011-06-01|2011-06-30|Estimate||||2017-10-17|2017-11-20|Actual|July 2006||2006-07-31|October 2017|2017-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide|UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients|Terminated||Phase 3|20|Actual|University of Arkansas|Early termination led to small numbers of subjects to be analyzed. Less than 10% of the target accrual were enrolled before termination of study.|2||low accrual|f||||f||||||||||2018-06-01 02:40:13.562639|2018-06-01 02:40:13.562639
NCT00574067|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2015-08-11||2016-03-11|2007-12-12|2007-12-14|Estimate|2016-03-11|2016-04-11|Estimate||||2016-03-11|2016-04-11|Estimate|September 2008||2008-09-30|March 2016|2016-03-31|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Interventional|||Buprenorphine for Prisoners|Buprenorphine for Prisoners|Completed||Phase 3|213|Actual|Friends Research Institute, Inc.||4|||f||||t||||||||||2018-06-01 02:40:14.12582|2018-06-01 02:40:14.12582
NCT00574054|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-14|2007-12-12|2007-12-14|Estimate|||||||2009-08-14|2009-08-17|Estimate|February 2008||2008-02-29|August 2009|2009-08-31|March 2009|Anticipated|2009-03-31|January 2009|Anticipated|2009-01-31||Interventional|||Far Infrared Radiation Treatment of Dementia and Other Mental Illness|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Dementia and Other Related Mental Illness.|Unknown status|Active, not recruiting|Phase 1|4|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:14.804523|2018-06-01 02:40:14.804523
NCT00574041|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2008-09-02|2007-12-13|2007-12-14|Estimate|||||||2008-09-02|2008-09-04|Estimate|June 2007||2007-06-30|September 2008|2008-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|TODAY||How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose|An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY)|Terminated||Phase 4|19|Actual|Biogen||2||Terminated due to poor recruitment|f||||f||||||||||2018-06-01 02:40:14.960316|2018-06-01 02:40:14.960316
NCT00574028|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2014-12-09|2007-12-13|2007-12-14|Estimate|||||||2014-12-09|2014-12-10|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Inflammatory Bowel Disease Research Registry|The University of California Irvine Medical Center Inflammatory Bowel Disease Research Registry|Completed|||138|Actual|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:40:15.077981|2018-06-01 02:40:15.077981
NCT00574015|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2014-03-21|2007-12-13|2007-12-14|Estimate|||||||2014-03-21|2014-03-24|Estimate|December 2007||2007-12-31|September 2010|2010-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache|The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache|Completed||Phase 4|18|Actual|Albany Medical College||2|||f||||f||||||||||2018-06-01 02:40:15.146307|2018-06-01 02:40:15.146307
NCT00574002|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-01-05|2007-12-12|2007-12-14|Estimate|||||||2017-01-05|2017-01-09|Estimate|December 2007||2007-12-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Observational|||Establishing Safe Drainage Limits for Pleural Chest Tube Removal.|Defining the Threshold for Safe Chest Tube Removal.|Withdrawn|||0|Actual|University of Missouri, Kansas City|||2|Low study enrollment; re-evaluating study protocol and study selection criteria.|f||||f||||||||||2018-06-01 02:40:15.398732|2018-06-01 02:40:15.398732
NCT00573989|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2018-02-28|2007-12-13|2007-12-14|Estimate|||||||2018-02-28|2018-03-01|Actual|March 2008|Actual|2008-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer|Phase I/II Clinical Trial of Combined Pre-Irradiation With Pemetrexed and Erlotinib Followed by Maintenance Erlotinib for Recurrent and Second Primary Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1/Phase 2|27|Actual|Wake Forest University Health Sciences||1||Drug Supply Issue|f||||t|t|f||||||||2018-06-01 02:40:15.557695|2018-06-01 02:40:15.557695
NCT00573976|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2010-11-02|2007-12-13|2007-12-14|Estimate|||||||2010-11-02|2010-11-04|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|||||Observational|||Study to Assess the Validity and Reliability of the Spinal Cord Independence Measure (SCIM III)|United States Multi-Center Study to Assess the Validity and Reliability of the Spinal Cord Independence Measure (SCIM III)|Completed|||660|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:40:15.693992|2018-06-01 02:40:15.693992
NCT00573963|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-07-29|2007-12-12|2007-12-14|Estimate|||||||2009-07-29|2009-07-30|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy of the Transversus Abdominus Plane (TAP) Block for Post-Cesarean Delivery Analgesia|Determination of the Efficay of the Transversus Abdominis Plane (TAP) Block as Part of a Multimodal Regimen for Post-cesarean Delivery Analgesia: a Double Blinded Placebo-controlled Study.|Completed||N/A|100|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 02:40:15.819784|2018-06-01 02:40:15.819784
NCT00573950|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2007-12-13|2007-12-13|2007-12-14|Estimate|||||||2007-12-13|2007-12-14|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness|Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study)|Unknown status|Recruiting|Phase 4|48|Anticipated|Korea University Anam Hospital||2|||f||||f||||||||||2018-06-01 02:40:16.148556|2018-06-01 02:40:16.148556
NCT00573937|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2010-10-04||2016-01-21|2007-12-13|2007-12-14|Estimate|2010-10-04|2010-11-04|Estimate||||2016-01-21|2016-02-19|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Methadone Versus Morphine for Cancer-Related Pain|Methadone Versus Morphine for Moderate to Severe Cancer-Related Pain: A Double-Blind Randomized Parallel Group Study|Terminated||Phase 2|1|Actual|Mayo Clinic|Due to slow accrual of subjects, the study was terminated after one subject started in the standard control group (morphine). No subject received investigational study drug (methadone). Therefore no data were analyzed.|2||Slow accrual.|f||||f||||||||||2018-06-01 02:40:16.284903|2018-06-01 02:40:16.284903
NCT00573924|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2011-02-04|2007-12-13|2007-12-14|Estimate|||||||2011-02-04|2011-02-08|Estimate|February 2006||2006-02-28|February 2011|2011-02-28|December 2007|Actual|2007-12-31|||||Interventional|||Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers|Prospective Randomized Comparison of the Effect of Frequent Oral Dosing Versus Constant IV Infusion of Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers|Completed||N/A|66|Actual|University of Southern California||2|||f||||f||||||||||2018-06-01 02:40:16.687157|2018-06-01 02:40:16.687157
NCT00573911|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2013-01-16|2007-12-13|2007-12-14|Estimate|||||||2013-01-16|2013-01-17|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus|Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus|Completed||Phase 1|16|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:40:17.065265|2018-06-01 02:40:17.065265
NCT00573898|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2011-02-17|2007-12-13|2007-12-14|Estimate|||||||2011-02-17|2011-02-18|Estimate|March 2008||2008-03-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|||||Observational|||Daptomycin Study - Collection of Pharmacokinetic Samples in Patients With Renal Failure|Pharmacokinetics of Daptomycin in Patients Receiving Continuous Veno-Venous Hemodiafiltration (CVVHDF)|Completed|||5|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     All of your biologic samples will be under the control of the principal investigator of this~     research project. To protect your confidentiality, all personal identifiers (i.e., name,~     social security number, and birth date) will be removed (de-identified) and replaced with a~     specific code number. The information linking these code numbers to the corresponding~     subjects' identities will be kept in a separate, secure location. The investigators on this~     study will keep the samples indefinitely. Samples will be kept in the investigator's~     laboratory located in Scaife Hall, room 812, 3500 Terrace Street. You may request to have~     your samples destroyed if you withdraw. The request must be in writing and samples collected~     and not already processed will be destroyed.~   "|||2018-06-01 02:40:17.219771|2018-06-01 02:40:17.219771
NCT00573885|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2012-03-07|2007-12-13|2007-12-14|Estimate|||||||2012-03-07|2012-03-09|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum|Phase II Trial of Polyphenon E in Former Smokers With Abnormal Sputa|Completed||Phase 2|53|Actual|British Columbia Cancer Agency||2|||f||||t||||||||||2018-06-01 02:40:17.44313|2018-06-01 02:40:17.44313
NCT00573872|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2017-08-08||2017-10-30|2007-12-13|2007-12-14|Estimate|2017-09-19|2017-10-20|Actual||||2017-10-30|2017-12-05|Actual|April 2005|Actual|2005-04-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|RAD0408||A Phase II Study of Spinal Radiosurgery|A Phase II Study of Spinal Radiosurgery|Completed||N/A|43|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 02:40:17.662053|2018-06-01 02:40:17.662053
NCT00573859|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2011-08-15||2011-09-23|2007-12-13|2007-12-14|Estimate|2011-09-23|2011-11-07|Estimate||||2011-09-23|2011-11-07|Estimate|September 2006||2006-09-30|September 2011|2011-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Reinforcing Mechanisms of Smoking in Adult ADHD|The Reinforcing Mechanisms of Smoking in Adult ADHD|Completed||Phase 1/Phase 2|27|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 02:40:18.189584|2018-06-01 02:40:18.189584
NCT00573846|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2015-01-26|2007-12-13|2007-12-14|Estimate|||||||2015-01-26|2015-01-28|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Phenotypic Characteristics of Inflammatory Bowel Disease in Southeast Asian Population - A Multi-centered US Study|Phenotypic Characteristics of Inflammatory Bowel Disease in Southeast Asian Population - A Multi-centered US Study|Withdrawn|||0|Actual|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:40:18.567462|2018-06-01 02:40:18.567462
NCT00573833|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2015-12-21||2017-09-19|2007-12-13|2007-12-14|Estimate|2017-09-19|2017-10-20|Actual||||2017-09-19|2017-10-20|Actual|November 2007||2007-11-30|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Internal Radiation Therapy in Treating Patients With Prostate Cancer|A Pilot Study of High Dose Rate Brachytherapy as Definitive Management for Intermediate Risk Prostate Cancer|Completed||N/A|23|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:40:18.678979|2018-06-01 02:40:18.678979
NCT00573820|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-14|2007-12-12|2007-12-14|Estimate|||||||2009-08-14|2009-08-17|Estimate|January 2006||2006-01-31|August 2009|2009-08-31|December 2008|Anticipated|2008-12-31|February 2008|Actual|2008-02-29||Interventional|||Far Infrared Radiation Treatment for Prostate Cancer|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer|Unknown status|Active, not recruiting|Phase 1|4|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:18.991714|2018-06-01 02:40:18.991714
NCT00573807|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-01-02|2007-12-12|2007-12-14|Estimate|||||||2009-01-02|2009-01-05|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|December 2008|Anticipated|2008-12-31|March 2008|Anticipated|2008-03-31||Interventional|||Energy Specific Far Infrared Radiation Treatment for Sciatica|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Sciatica.|Unknown status|Active, not recruiting|Phase 1|2|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:19.163807|2018-06-01 02:40:19.163807
NCT00573794|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2017-11-21||2018-01-23|2007-12-12|2007-12-14|Estimate|2017-11-21|2017-12-19|Actual||||2018-01-23|2018-02-20|Estimate|November 28, 2007|Actual|2007-11-28|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||ITT-1: All subjects who received ≥1 dose of study drug excluding 7 subjects at noncompliant sites.|Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis|A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Ulcerative Colitis|Completed||Phase 3|592|Actual|AbbVie|Efficacy data after Week 292 should be interpreted with caution because less than 10% of subjects were under observation beyond Week 292.|1|||f||||f||||||||||2018-06-01 02:40:19.422046|2018-06-01 02:40:19.422046
NCT00573781|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2012-04-16|2007-12-13|2007-12-14|Estimate|||||||2012-04-16|2012-04-17|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Sysdimet||Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism|Systems Biology Approach to Understand Dietary Modulation of Gene Expression and Metabolic Pathways in Subjects With Abnormal Glucose Metabolism (Sysdimet)|Completed||Phase 2|106|Actual|University of Eastern Finland||3|||f||||f||||||||||2018-06-01 02:40:20.666389|2018-06-01 02:40:20.666389
NCT00573417|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2009-08-11|2007-12-13|2007-12-14|Estimate|||||||2009-08-11|2009-08-12|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia|A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia|Completed||Phase 4|40|Actual|North Suffolk Mental Health Association||2|||f||||f||||||||||2018-06-01 02:40:28.210411|2018-06-01 02:40:28.210411
NCT00573768|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2010-07-28||2012-04-18|2007-12-13|2007-12-14|Estimate|2010-10-21|2010-11-18|Estimate||||2012-04-18|2012-04-20|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel in Patients With Acute Ankle Sprain|A Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Once or Twice Daily in Patients With Acute Ankle Sprain|Completed||Phase 2|271|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:40:20.881114|2018-06-01 02:40:20.881114
NCT00573755|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2014-02-10||2016-01-07|2007-12-13|2007-12-14|Estimate|2014-02-10|2014-03-26|Estimate||||2016-01-07|2016-02-05|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer|Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer|Terminated||Phase 2|4|Actual|Mayo Clinic||2||lack of participant accrual|f||||t||||||||||2018-06-01 02:40:21.38871|2018-06-01 02:40:21.38871
NCT00573742|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2010-08-18|2007-12-13|2007-12-14|Estimate|||||||2010-08-18|2010-08-19|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients|Non-interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or add-on Therapy.|Completed|||1940|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:40:21.80474|2018-06-01 02:40:21.80474
NCT00573729|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2017-02-08|2007-12-13|2007-12-14|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2007||2007-03-31|February 2017|2017-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks: Comparison of 577 nm Versus 595 nm Wavelengths|Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks: Comparison of 577 nm Versus 595 nm Wavelengths|Completed||Phase 1|56|Actual|University of California, Irvine||2|||f||||f||||||||||2018-06-01 02:40:21.881921|2018-06-01 02:40:21.881921
NCT00573716|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2011-08-03|2007-12-13|2007-12-14|Estimate|||||||2011-08-03|2011-08-04|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Observational|||Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents|A Comparison of Bone Mineral Density Changes During Treatment With Risperidone or Aripiprazole in Adolescents|Completed|||60|Anticipated|Creighton University|||3||f||||f||||||||||2018-06-01 02:40:21.975064|2018-06-01 02:40:21.975064
NCT00573703|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2013-04-05|2007-12-13|2007-12-14|Estimate|||||||2013-04-05|2013-04-08|Estimate|September 2007||2007-09-30|April 2013|2013-04-30||||December 2007|Actual|2007-12-31||Interventional|||Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence|A Comparison Between Laparoscopic Burch Colposuspension and Transobturatory Tape (TOT) for the Treatment of Female Urinary Stress Incontinence|Withdrawn||Phase 4|0|Actual|University Magna Graecia||2|||f||||t||||||||||2018-06-01 02:40:22.972865|2018-06-01 02:40:22.972865
NCT00573690|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2012-04-20|2007-12-13|2007-12-14|Estimate|||||||2012-04-20|2012-04-24|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|February 2011|Actual|2011-02-28|June 2009|Actual|2009-06-30||Interventional|||Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors|A Two Arm Phase I Trial of Sorafenib in Combination With Cisplatin/Etoposide or Carboplatin/Pemetrexed in Patients With Solid Tumors|Completed||Phase 1|31|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:40:23.062252|2018-06-01 02:40:23.062252
NCT00573664|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-07-29|2007-12-12|2007-12-14|Estimate|||||||2009-07-29|2009-07-30|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section|The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section: A Randomized Placebo-controlled Trial|Terminated||N/A|46|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||Interim analysis showed a significant reduction in the pain scores|f||||f||||||||||2018-06-01 02:40:23.203844|2018-06-01 02:40:23.203844
NCT00573651|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2018-03-04|2007-12-13|2007-12-14|Estimate|||||||2018-03-04|2018-03-06|Actual|November 2007||2007-11-30|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|CHASE||Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis|Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis|Active, not recruiting||Phase 4|43|Actual|University Hospitals Cleveland Medical Center||3|||f||||t||||||||||2018-06-01 02:40:23.282238|2018-06-01 02:40:23.282238
NCT00573638|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2008-08-07|2007-12-13|2007-12-14|Estimate|||||||2008-08-07|2008-08-08|Estimate|February 2005||2005-02-28|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|||||Interventional|Xal-Ease||Effects of Xal-Ease on Patient Compliance With Xalatan|The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops|Unknown status|Recruiting|N/A|50|Anticipated|Augusta University|||||f||||f||||||||||2018-06-01 02:40:23.39865|2018-06-01 02:40:23.39865
NCT00573612|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2012-04-05|2007-12-13|2007-12-14|Estimate|||||||2012-04-05|2012-04-06|Estimate|December 2007||2007-12-31|March 2011|2011-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Exercise-based Motivational Interviewing for Fibromyalgia|Exercise-based Motivational Interviewing for Fibromyalgia|Completed||N/A|200|Anticipated|Indiana University||2|||f||||f||||||||||2018-06-01 02:40:23.525732|2018-06-01 02:40:23.525732
NCT00573599|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2007-12-13|2007-12-13|2007-12-14|Estimate|||||||2007-12-13|2007-12-14|Estimate|February 2007||2007-02-28|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department|Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department|Completed||N/A|66|Actual|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-06-01 02:40:23.591621|2018-06-01 02:40:23.591621
NCT00573586|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2010-03-05|2007-12-13|2007-12-14|Estimate|||||||2010-03-05|2010-03-08|Estimate||||March 2010|2010-03-31|March 2009|Anticipated|2009-03-31|||||Interventional|||Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada|Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate® 500 (SB-500) System in Canada|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|SonaCare Medical|||||f||||f||||||||||2018-06-01 02:40:24.531853|2018-06-01 02:40:24.531853
NCT00573573|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-03-23|2007-12-12|2007-12-14|Estimate|||||||2009-03-23|2009-03-24|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|July 2009|Anticipated|2009-07-31|March 2009|Anticipated|2009-03-31||Interventional|||Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Hyperparathyroidism.|Unknown status|Active, not recruiting|Phase 1|2|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:24.606057|2018-06-01 02:40:24.606057
NCT00573560|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-06-21|2007-12-12|2007-12-14|Estimate|||||||2017-06-21|2017-06-22|Actual|December 2007||2007-12-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|January 2010|Actual|2010-01-31||Interventional|PARACHUTE||Safety Study of the Ventricular Partitioning Device (VPD) Implant System in Heart Failure Patients|A Feasibility Trial to Evaluate the VPD Implant System - Percutaneous Ventricular Restoration in Chronic Heart Failure Due to Ischemic Heart Disease|Completed||Phase 1|20|Actual|CardioKinetix, Inc|||||f||||t||||||||||2018-06-01 02:40:24.680303|2018-06-01 02:40:24.680303
NCT00573547|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2011-08-15|2007-12-12|2007-12-14|Estimate|||||||2011-08-15|2011-08-16|Estimate|February 2007||2007-02-28|August 2011|2011-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease|A 12-Week Open-Label Trial of Once-Weekly Fluoxetine for the Treatment of Depression in Patients With End-Stage Renal Disease|Withdrawn||Phase 4|0|Actual|Creighton University||||Principal Investigator decided not to initiate the study.|f||||f||||||||||2018-06-01 02:40:24.757252|2018-06-01 02:40:24.757252
NCT00573534|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2011-08-15||2017-01-03|2007-12-13|2007-12-14|Estimate|2011-10-24|2011-11-29|Estimate||||2017-01-03|2017-02-20|Actual|March 2008||2008-03-31|December 2016|2016-12-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse|Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence|Completed||Phase 4|8|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 02:40:24.844351|2018-06-01 02:40:24.844351
NCT00573521|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-06-09|2007-12-13|2007-12-14|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2007||2007-11-30|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms|Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms|Recruiting|||450|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 02:40:25.077449|2018-06-01 02:40:25.077449
NCT00573508|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2010-02-02||2010-09-07|2007-12-12|2007-12-14|Estimate|2010-09-07|2010-10-05|Estimate||||2010-09-07|2010-10-05|Estimate|August 2007||2007-08-31|September 2010|2010-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|VIBRANT||Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-center Study of VESIcare® (Solifenacin Succinate) in Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life VIBRANT: VESIcare® Investigation of BotheR And Quality of Life iN subjecTs With OAB|Completed||Phase 4|768|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||f||||||||||2018-06-01 02:40:25.312766|2018-06-01 02:40:25.312766
NCT00573495|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2016-09-27|2007-12-12|2007-12-14|Estimate|||||||2016-09-27|2016-09-29|Estimate|November 2007||2007-11-30|September 2016|2016-09-30|February 2013|Actual|2013-02-28|July 2011|Actual|2011-07-31||Interventional|||Multipeptide Vaccine for Advanced Breast Cancer|A Study of hTERT/Survivin Multi-peptide Vaccine With Daclizumab and Prevnar for Patients With Metastatic Breast Cancer|Completed||Phase 1|11|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 02:40:26.174753|2018-06-01 02:40:26.174753
NCT00573482|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2010-02-24|2007-12-13|2007-12-14|Estimate|||||||2010-02-24|2010-02-25|Estimate|September 2002||2002-09-30|February 2010|2010-02-28|February 2007|Actual|2007-02-28|||||Interventional|Cafeteria||A Cafeteria Based Study of Weight Gain Prevention|A Cafeteria Based Study of Weight Gain Prevention|Completed||N/A|106|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 02:40:26.26259|2018-06-01 02:40:26.26259
NCT00573469|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2009-03-18||2012-07-02|2007-12-13|2007-12-14|Estimate|2012-01-19|2012-02-24|Estimate||||2012-07-02|2012-07-12|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease|A Multicentre, Double-blind, Randomised, Parallel-group, Phase II Study to Assess Efficacy and Safety of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease|Completed||Phase 2|75|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:40:26.350358|2018-06-01 02:40:26.350358
NCT00573456|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-14|2007-12-12|2007-12-14|Estimate|||||||2009-08-14|2009-08-17|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|April 2009|Anticipated|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Far Infrared Radiation Treatment for Diabetes|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Diabetes|Unknown status|Active, not recruiting|Phase 1|2|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:26.862078|2018-06-01 02:40:26.862078
NCT00573443|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2011-07-18||2017-03-15|2007-12-13|2007-12-14|Estimate|2013-06-05|2013-07-10|Estimate||||2017-03-15|2017-04-12|Actual|December 2007||2007-12-31|March 2017|2017-03-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|STAR||Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)|Completed||Phase 3|326|Actual|Avanir Pharmaceuticals||3|||f||||t||||||||||2018-06-01 02:40:27.016237|2018-06-01 02:40:27.016237
NCT00573430|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2010-06-17||2011-08-19|2007-12-13|2007-12-14|Estimate|2011-06-21|2011-07-19|Estimate||||2011-08-19|2011-08-23|Estimate|December 2007||2007-12-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PCR||ARIA (Atacand Renoprotection In NephropAthy Pt.)|A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy|Completed||Phase 4|128|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:40:27.8625|2018-06-01 02:40:27.8625
NCT00573404|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2011-11-12|2007-12-13|2007-12-14|Estimate|||||||2011-11-12|2011-11-16|Estimate|July 2007||2007-07-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|September 2009|Actual|2009-09-30||Interventional|||Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors|A Phase I Study of Imatinib Mesylate and SU011248 for Patients With Gastrointestinal Stromal Tumors|Terminated||Phase 1|6|Actual|Vanderbilt-Ingram Cancer Center||1||slow accrual|f||||t||||||||||2018-06-01 02:40:28.282092|2018-06-01 02:40:28.282092
NCT00573391|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2011-04-15||2011-07-18|2007-12-13|2007-12-14|Estimate|2011-07-18|2011-08-12|Estimate||||2011-07-18|2011-08-12|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2|A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone|Terminated||Phase 3|5|Actual|University of Arkansas|early termination due to low accrual, no analyses|2||low accrual|f||||t||||||||||2018-06-01 02:40:28.364801|2018-06-01 02:40:28.364801
NCT00573378|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2016-06-23|2007-12-13|2007-12-14|Estimate|||||||2016-06-23|2016-06-24|Estimate|October 2007||2007-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|November 2015|Actual|2015-11-30||Interventional|||Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia|A Combination of Imatinib or Nilotinib Together With Pegylated Interferon-α2b in Chronic-Phase Chronic Myeloid Leukemia: A Phase II Pilot Study Targeting Both the Primitive and Differentiated CML Progenitor Populations|Withdrawn||Phase 2|0|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 02:40:28.648784|2018-06-01 02:40:28.648784
NCT00573365|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-08-01|2007-12-13|2007-12-14|Estimate|||||||2017-08-01|2017-08-02|Actual|March 2007||2007-03-31|August 2017|2017-08-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis|LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis: A Prospective, Randomized, Controlled Study|Completed||N/A|33|Actual|University of California, Irvine||2|||f||||t||||||||||2018-06-01 02:40:28.725072|2018-06-01 02:40:28.725072
NCT00573352|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-01-02|2007-12-12|2007-12-14|Estimate|||||||2009-01-02|2009-01-05|Estimate|September 2006||2006-09-30|January 2009|2009-01-31|December 2008|Anticipated|2008-12-31|February 2008|Actual|2008-02-29||Interventional|||Far Infrared Radiation Treatment for Osteoarthritis|Phase 1 Study to Determine the Efficacy of Using Energy Specific Far Infrared (FIR) Radiation for the Treatment of Arthritis and Other Related Diseases|Unknown status|Active, not recruiting|Phase 1|2|Anticipated|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:28.802059|2018-06-01 02:40:28.802059
NCT00573339|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2017-11-17|2007-12-13|2007-12-14|Estimate|||||||2017-11-17|2017-11-21|Actual|May 2007||2007-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing|Cardiac Magnetic Resonance Imaging Normal Reference Control Group Testing - Ancillary Study to Coronary Endothelial Function and Microvascular Disease in Women|Recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||None Retained|"~     BUN and Creatinine blood tests~   "|Yes||2018-06-01 02:40:28.910208|2018-06-01 02:40:28.910208
NCT00573326|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2009-09-02|2007-12-13|2007-12-14|Estimate|||||||2009-09-02|2009-09-03|Estimate|February 2009||2009-02-28|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement|Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study|Unknown status|Recruiting|Phase 2|30|Anticipated|Azienda Ospedaliera Universitaria Policlinico||1|||f||||t||||||||||2018-06-01 02:40:28.999876|2018-06-01 02:40:28.999876
NCT00573313|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2013-02-06||2017-05-24|2007-12-12|2007-12-14|Estimate|2013-06-07|2013-06-10|Estimate||||2017-05-24|2017-05-30|Actual|September 2005||2005-09-30|May 2017|2017-05-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional||294 patients were screened of whom 37 were selected for the SAMe v sugar pill trial. Of those excluded, 128 did not meet inclusion criteria, 105 met inclusion criteria but were excluded because of lack of reliable contact information, and 24 subjects declined to participate, leaving 37 subjects, 18 and 19 in each respective group at baseline.|Effects of SAMe in Patients With Alcoholic Liver Disease|Effects of SAMe in Patients With Alcoholic Liver Disease|Completed||Phase 3|94|Actual|University of California, Davis|Relatively small numbers of subjects analyzed with 13 each completers in the treatment and placebo groups. Within each group, violation of protocal by resumption of alcohol intake accounted for dropouts.|2|||f||||f||||||||||2018-06-01 02:40:29.103427|2018-06-01 02:40:29.103427
NCT00573300|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2009-08-11|2007-12-13|2007-12-14|Estimate|||||||2009-08-11|2009-08-12|Estimate|January 2006||2006-01-31|August 2009|2009-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study|Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative RT-PCR Study|Completed|||60|Anticipated|North Suffolk Mental Health Association|||2||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 02:40:29.412423|2018-06-01 02:40:29.412423
NCT00573287|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2013-01-16||2018-03-21|2007-12-12|2007-12-14|Estimate|2013-01-16|2013-02-18|Estimate||||2018-03-21|2018-03-23|Actual|June 2006||2006-06-30|March 2018|2018-03-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||First Episode Schizophrenia and Cannabis-Related Disorder Study|Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder|Completed||N/A|14|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 02:40:29.492946|2018-06-01 02:40:29.492946
NCT00573274|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-07-29|2007-12-12|2007-12-14|Estimate|||||||2009-07-29|2009-07-30|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Measuring Cardiac Output and Stroke Volume Using the Physioflow Impedance Device in Pregnant Patients|Pilot Study Measuring Cardiac Output and Stroke Volume Using Non-Invasive Thoracic Impedance With the Physioflow Impedance Device in Pregnant Patients Undergoing Cesarean Section Under Spinal Anesthesia|Completed|||20|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||1||f||||f||||||||||2018-06-01 02:40:29.788764|2018-06-01 02:40:29.788764
NCT00573261|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2012-12-21||2014-07-11|2007-12-12|2007-12-14|Estimate|2013-07-15|2013-07-18|Estimate||||2014-07-11|2014-07-21|Estimate|March 2006||2006-03-31|July 2013|2013-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|Pregabalin||A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy|Completed||Phase 4|40|Actual|Duke University|The study has a high dropout, which might have reduced the power of the analysis. One of the major reasons that many patients were not able to participate was an inability to commit to the relatively intense and frequent assessments.|2|||f||||f||||||||||2018-06-01 02:40:29.913352|2018-06-01 02:40:29.913352
NCT00573248|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2011-04-01||2011-09-01|2007-12-13|2007-12-14|Estimate|2011-08-02|2011-09-02|Estimate||||2011-09-01|2011-09-09|Estimate|August 2005||2005-08-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Nicotine and Behavior in Adult ADHD|Nicotine and Behavioral Regulation in Adult ADHD|Completed||N/A|78|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 02:40:30.358156|2018-06-01 02:40:30.358156
NCT00573235|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-06-08|2007-12-13|2007-12-14|Estimate|||||||2017-06-08|2017-06-09|Actual|October 2007||2007-10-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli|Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli|Active, not recruiting|||300|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     All samples provided to the investigators are deidentified by the honest broker and will be~     coded with numbers. The information linking these code numbers to the corresponding subjects'~     identities will be kept in a separate, secure location that only the honest broker has access~     to. The investigators on this study will keep the samples indefinitely. Samples will be kept~     in the investigator's laboratory located in Scaife Hall, room 812, 3500 Terrace Street. At no~     time with the research investigators have access to any patient identifers.~   "|||2018-06-01 02:40:30.654363|2018-06-01 02:40:30.654363
NCT00573222|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|||2010-11-30|2007-12-13|2007-12-14|Estimate|||||||2010-11-30|2010-12-01|Estimate|November 2007||2007-11-30|November 2010|2010-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma|Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma|Completed|||330|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:40:30.716542|2018-06-01 02:40:30.716542
NCT00573209|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-14|2007-12-12|2007-12-14|Estimate|||||||2009-08-14|2009-08-17|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|May 2009|Anticipated|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Energy Specific Far Infrared Radiation Treatment for Erectile Dysfunction|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Erectile Dysfunction.|Unknown status|Active, not recruiting|Phase 1|3|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:30.784059|2018-06-01 02:40:30.784059
NCT00573196|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-14|2007-12-12|2007-12-14|Estimate|||||||2009-08-14|2009-08-17|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|June 2008|Anticipated|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Far Infrared Radiation Treatment for Bipolar Condition|Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Bipolar Condition|Unknown status|Active, not recruiting|Phase 1|3|Actual|GAAD Medical Research Institute Inc.||1|||f||||t||||||||||2018-06-01 02:40:30.850753|2018-06-01 02:40:30.850753
NCT00573183|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2013-06-04||2016-10-24|2007-12-13|2007-12-14|Estimate|2013-12-09|2014-01-29|Estimate||||2016-10-24|2016-12-05|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|STAGE-12||Stimulant Abuser Groups to Engage in 12-Step|Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement|Completed||Phase 3|471|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:40:30.925331|2018-06-01 02:40:30.925331
NCT00573170|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2010-08-16||2010-11-30|2007-12-13|2007-12-14|Estimate|2010-11-30|2010-12-29|Estimate||||2010-11-30|2010-12-29|Estimate|February 2008||2008-02-29|November 2010|2010-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Migraine Pain, Studies 1 and 2 of 2|Completed||Phase 3|375|Actual|GlaxoSmithKline|Enrolled participants included all those entering the screening part of the study. Randomized participants included only those who completed screening and completed the 2-week butalbital wash-out, and were successfully randomized to study drug.|6|||f||||f||||||||||2018-06-01 02:40:31.602912|2018-06-01 02:40:31.602912
NCT00573157|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2016-02-22||2016-02-22|2007-12-13|2007-12-14|Estimate|2016-02-22|2016-03-23|Estimate||||2016-02-22|2016-03-23|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Baseline analysis population included all the participants randomized in the trial.|The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis|A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects With Lupus Nephritis in Combination With Mycophenolate Mofetil Therapy.|Terminated||Phase 2/Phase 3|6|Actual|EMD Serono|The study was terminated due to unanticipated safety issues.|2||The study was terminated due to unanticipated safety issues|f||||t||||||||||2018-06-01 02:40:32.838059|2018-06-01 02:40:32.838059
NCT00573144|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-13|2014-09-02||2014-09-02|2007-12-13|2007-12-14|Estimate|2014-09-02|2014-09-09|Estimate||||2014-09-02|2014-09-09|Estimate|September 2006||2006-09-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|Believe II|Baseline values are reported for subjects completing the study (28 in placebo group and 25 in nesiritide group).|Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction|Nesiritide Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction|Completed||Phase 2|59|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 02:40:33.167861|2018-06-01 02:40:33.167861
NCT00573131|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2014-04-17||2016-01-12|2007-12-11|2007-12-13|Estimate|2014-04-17|2014-05-16|Estimate||||2016-01-12|2016-02-09|Estimate|January 2008||2008-01-31|January 2016|2016-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer|A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer|Terminated||Phase 2|154|Actual|BTG International Inc.|Study prematurely terminated due to lack of efficacy in primary endpoint.|2||OncoGel did not show any impact on overall tumor response|f||||t||||||||||2018-06-01 02:40:33.424502|2018-06-01 02:40:33.424502
NCT00573118|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2007-12-12|2007-12-12|2007-12-13|Estimate|||||||2007-12-12|2007-12-13|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|January 2008|Anticipated|2008-01-31|||||Observational|||Severe Pregnancy Complications Are Associated With Elevated Factor VIII Plasma Activity|A Retrospective Analysis of Possible Association Between Severe Pregnancy Complications and Elevated Factor VIII Plasma Activity.|Unknown status|Active, not recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||||||2018-06-01 02:40:33.998979|2018-06-01 02:40:33.998979
NCT00573105|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2011-01-25|2007-12-11|2007-12-13|Estimate|||||||2011-01-25|2011-01-26|Estimate|February 2008||2008-02-29|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Laparoscopic Ventral Hernia Repair by Heavy Weight or Lighter Weight Mesh (COMPOSIX-trial)|Laparoscopic Ventral Hernia Repair by Heavy Weight or Lighter Weight Mesh (COMPOSIX-trial)|Terminated||N/A|110|Actual|University Hospital, Ghent||2||slow inclusion rate|f||||f||||||||||2018-06-01 02:40:34.067072|2018-06-01 02:40:34.067072
NCT00573092|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2016-11-07|2007-12-12|2007-12-13|Estimate|||||||2016-11-07|2016-11-09|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs|Genome-Wide Case-Only Study of Antihypertensive Drug-Gene Interactions|Withdrawn|||0|Actual|University of Washington|||1|Withdrawn|f||||f||||||||||2018-06-01 02:40:34.156302|2018-06-01 02:40:34.156302
NCT00573079|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2011-02-01|2007-12-12|2007-12-13|Estimate|||||||2011-02-01|2011-02-03|Estimate|December 2007||2007-12-31|February 2011|2011-02-28||||December 2010|Actual|2010-12-31||Observational|||Acute Kidney Injury in Premature Infants|Acute Kidney Injury in Premature Infants|Completed|||237|Actual|University of Alabama at Birmingham|||1||f||||f||||||||||2018-06-01 02:40:34.222182|2018-06-01 02:40:34.222182
NCT00573066|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2010-03-12||2013-02-28|2007-12-11|2007-12-13|Estimate|2013-02-28|2013-04-09|Estimate||||2013-02-28|2013-04-09|Estimate|May 2004||2004-05-31|February 2013|2013-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|InfantDex||Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery|The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery|Completed||Phase 1|56|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-06-01 02:40:34.315804|2018-06-01 02:40:34.315804
NCT00573053|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2011-04-18|2007-12-12|2007-12-13|Estimate|||||||2011-04-18|2011-04-19|Estimate|November 2007||2007-11-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effects of Targeting Lower Arterial Oxygen Saturations on the Development of Control of Breathing in Very Preterm Infants|Effects of Targeting Lower Arterial Oxygen Saturations on the Development of Control of Breathing in Very Preterm Infants|Completed||Phase 2/Phase 3|26|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-06-01 02:40:34.483488|2018-06-01 02:40:34.483488
NCT00573040|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2010-07-20|2007-12-12|2007-12-13|Estimate|||||||2010-07-20|2010-07-21|Estimate|August 2005||2005-08-31|July 2010|2010-07-31|June 2008|Actual|2008-06-30|||||Observational|BRONC MLD||Radiotherapy for NSCLC to a Individualized MLD|Radiotherapy for Stage I-III Non-small Cell Lung Cancer to an Individualized MLD|Completed|||180|Anticipated|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-06-01 02:40:34.555551|2018-06-01 02:40:34.555551
NCT00573027|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-11-14|2007-12-12|2007-12-13|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2005||2005-11-30|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Heart Disease of the Small Arteries in Women and Men|Coronary Microvascular Disease and Endothelial Function in Women and Men|Recruiting||N/A|634|Anticipated|Cedars-Sinai Medical Center||1|||f||||t||||||||Undecided||2018-06-01 02:40:34.618154|2018-06-01 02:40:34.618154
NCT00573014|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2017-08-29|2007-12-12|2007-12-13|Estimate|||||||2017-08-29|2017-08-30|Actual|October 1, 2006|Actual|2006-10-01|August 2017|2017-08-31|September 30, 2008|Actual|2008-09-30|July 1, 2008|Actual|2008-07-01||Observational|CSclearance||Cervical Spine Clearance in Obtunded Trauma Patients|Evaluating the Need for Magnetic Resonance Imaging of the Cervical Spine in Obtunded Trauma Patients|Completed|||197|Actual|MetroHealth Medical Center|||1||f||||f||||||||||2018-06-01 02:40:34.691289|2018-06-01 02:40:34.691289
NCT00573001|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2012-05-14|2007-12-12|2007-12-13|Estimate|||||||2012-05-14|2012-05-15|Estimate|July 2008||2008-07-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|DAYANA||Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)|Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde|Completed||Phase 3|120|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||4|||f||||t||||||||||2018-06-01 02:40:34.762946|2018-06-01 02:40:34.762946
NCT00572988|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2010-01-12|2007-12-12|2007-12-13|Estimate|||||||2010-01-12|2010-01-13|Estimate|May 2002||2002-05-31|January 2010|2010-01-31|January 2007|Actual|2007-01-31|||||Observational|||Symptom Management Intervention in Elderly Coronary Artery Bypass Patients|Symptom Management Intervention in Elderly CABG Patients|Completed|||232|Actual|University of Nebraska|||||f||||f||||||||||2018-06-01 02:40:34.851282|2018-06-01 02:40:34.851282
NCT00572975|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2008-09-26|2007-12-12|2007-12-13|Estimate|||||||2008-09-26|2008-09-30|Estimate|August 2006||2006-08-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|MBT||Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea|MALABSORPTION BLOOD TEST: Toward a Novel Approach to Quantify Steatorrhea|Completed||Phase 4|9|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-06-01 02:40:34.915521|2018-06-01 02:40:34.915521
NCT00572962|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2014-12-04|2007-12-11|2007-12-13|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Prospective Clinical Observational Cohort Study to Evaluate the Use of a Tissue Separating Mesh (Proceed®) in Laparoscopic Ventral Hernia Repair|Prospective Clinical Observational Cohort Study to Evaluate the Use of a Tissue Separating Mesh (Proceed®) in Laparoscopic Ventral Hernia Repair|Unknown status|Active, not recruiting|N/A|200|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 02:40:34.985145|2018-06-01 02:40:34.985145
NCT00572949|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-11-16|2007-12-12|2007-12-13|Estimate|||||||2009-11-16|2009-11-17|Estimate|October 2004||2004-10-31|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Magnetocardiography (MCG) in the Diagnosis of Chest Pain Syndrome|Magnetocardiography (MCG) in the Diagnosis of Chest Pain Syndrome|Withdrawn|||398|Anticipated|Cedars-Sinai Medical Center|||1|sponsor funding|f||||f||||||||||2018-06-01 02:40:35.052007|2018-06-01 02:40:35.052007
NCT00572936|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2017-10-24||2018-02-13|2007-12-11|2007-12-13|Estimate|2018-02-13|2018-02-14|Actual||||2018-02-13|2018-02-14|Actual|November 2005||2005-11-30|February 2018|2018-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Circadian Rhythms of Aqueous Humor Dynamics in Humans|Circadian Rhythms of Aqueous Humor Dynamics in Humans|Completed||Phase 2|30|Actual|University of Nebraska||1|||f||||f||||||||||2018-06-01 02:40:35.13413|2018-06-01 02:40:35.13413
NCT00572923|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-06-16|2007-12-12|2007-12-13|Estimate|||||||2009-06-16|2009-06-17|Estimate|August 2006||2006-08-31|June 2009|2009-06-30|February 2009|Actual|2009-02-28|||||Observational|BRONC 45 15||Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans|Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans|Completed|||52|Anticipated|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-06-01 02:40:35.547796|2018-06-01 02:40:35.547796
NCT00572910|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2011-07-20||2015-03-16|2007-12-11|2007-12-13|Estimate|2011-07-20|2011-08-15|Estimate||||2015-03-16|2015-04-03|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients With End-Stage Renal Disease on Chronic Hemodialysis|Completed||Phase 2|206|Actual|Merck Sharp & Dohme Corp.||6|||f||||||||||||||2018-06-01 02:40:35.662262|2018-06-01 02:40:35.662262
NCT00572897|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2014-11-21||2017-04-07|2007-12-12|2007-12-13|Estimate|2016-04-21|2016-05-02|Estimate||||2017-04-07|2017-05-15|Actual|August 2007||2007-08-31|April 2017|2017-04-30|June 15, 2015|Actual|2015-06-15|August 2011|Actual|2011-08-31||Interventional||Patients with myelofibrosis who received a stem cell transplant from either a sibling or unrelated donor.|Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis|Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis|Completed||Phase 2|66|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-06-01 02:40:37.382318|2018-06-01 02:40:37.382318
NCT00572884|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2007-12-11|2007-12-11|2007-12-13|Estimate|||||||2007-12-11|2007-12-13|Estimate|February 2006||2006-02-28|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Metabolism of the Insecticide Permethrin|CCRC:Identification and Development of Biological Markers of Human Exposure to the Insecticide Permethrin|Completed||N/A|6|Actual|University of California, Davis|||||f||||f||||||||||2018-06-01 02:40:38.165152|2018-06-01 02:40:38.165152
NCT00572871|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2016-09-30|2007-12-12|2007-12-13|Estimate|||||||2016-09-30|2016-10-04|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Hormonal and Bone Turnover Marker Response to an Acute Bout of Resistance or Plyometric Exercise|Hormonal and Bone Turnover Marker Response to an Acute Bout of Resistance or Plyometric Exercise|Completed|||12|Actual|University of Missouri-Columbia|||3||f||||f||||||Samples Without DNA|"~     serum plasma~   "|No||2018-06-01 02:40:38.276481|2018-06-01 02:40:38.276481
NCT00572858|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-11-17|2007-12-12|2007-12-13|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2005||2005-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women|Estrogen Deficiency and Cardiovascular Disease in Premenopausal Women|Recruiting|||75|Anticipated|Cedars-Sinai Medical Center|||1||f||||t||||||None Retained|"~     Blood Hormone draw for FSH, E2; Urine Pregnancy test; Fasting lipid (cholesterol) panel,~     fasting insulin and fasting blood glucose levels; Reproductive hormones (FSH, LH, E1, E2,~     bioE2, PO, freeT, SHBG, DHEA-S); Plasma levels of inflammatory and endothelial function~     markers including but not limited to hsCRP, serum amyloid, endothelin-1, and ELAM; Fasting~     Salivary Cortisol (stress hormone).~   "|Yes||2018-06-01 02:40:38.393141|2018-06-01 02:40:38.393141
NCT00572845|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2016-02-19|2007-12-11|2007-12-13|Estimate|||||||2016-02-19|2016-02-23|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation|Energy Costs of Spasticity in Spinal Cord Injury: A Pilot Investigation|Terminated||N/A|20|Actual|Virginia Commonwealth University||1||Unable to recruit enough participants.|f||||f||||||||||2018-06-01 02:40:38.52048|2018-06-01 02:40:38.52048
NCT00572832|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2009-09-03||2010-08-11|2007-12-12|2007-12-13|Estimate|2010-02-11|2010-02-25|Estimate||||2010-08-11|2010-08-17|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting|Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting|Completed||N/A|200|Actual|University of Pittsburgh|One participant in the Standard group did not respond to any of the vaccine HPV types. Eleven participants in the Alternate group either did not receive Dose 3 or were out of window, compared with only one participant in the Standard group.|2|||f||||t||||||||||2018-06-01 02:40:38.63072|2018-06-01 02:40:38.63072
NCT00572819|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-05-22|2007-12-12|2007-12-13|Estimate|||||||2009-05-22|2009-05-25|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Hysteroscopy After Pretreatment With Misoprostol and Estradiol Trial|Does Self-Administered Vaginal Misoprostol Result in Cervical Ripening in Postmenopausal Women After 14 Days Pre-Treatment With Estradiol?|Completed||Phase 3|100|Anticipated|Ullevaal University Hospital||2|||f||||t||||||||||2018-06-01 02:40:39.015656|2018-06-01 02:40:39.015656
NCT00572806|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-02-22|2007-12-12|2007-12-13|Estimate|||||||2017-02-22|2017-02-24|Actual|February 5, 2003|Actual|2003-02-05|February 2017|2017-02-28|February 2, 2004|Actual|2004-02-02|February 2, 2004|Actual|2004-02-02||Interventional|||Initiation of Insulin Aspart in Type 2 Diabetes|Evaluation of the Initiation of Insulin Treatment Using Insulin Aspart on Blood Glucose Profile in Type 2 Diabetes Mellitus|Completed||Phase 4|6|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:40:39.137382|2018-06-01 02:40:39.137382
NCT00572793|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-07-07|2007-12-12|2007-12-13|Estimate|||||||2015-07-07|2015-07-08|Estimate|November 2007||2007-11-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk|A Nested Case-Controlled Study Evaluating the Utility of Placental Protein 13 (PP13) In-vitro Diagnostic Kit as a Diagnostic Aiding Tool in Assessment of the Risk for Developing Preeclampsia Necessitating Delivery Before 37 Weeks (Early-preeclampsia) Based on First Trimester Blood Testing of Pregnant Women With Low and Unknown Risk|Completed|||431|Actual|University of Kansas Medical Center|||||f||||f||||||Samples Without DNA|"~     Maternal serum - placental protein 13 level~   "|||2018-06-01 02:40:39.227849|2018-06-01 02:40:39.227849
NCT00572780|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-08-07|2007-12-11|2007-12-13|Estimate|||||||2015-08-07|2015-08-10|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Can CT Enteroclysis Predict the Outcome of Crohn's Disease|Can CT Enteroclysis Predict the Response to Therapy and Outcome in Patient With Crohn's Disease|Completed|||125|Actual|Indiana University|||1||f||||f||||||||||2018-06-01 02:40:39.286954|2018-06-01 02:40:39.286954
NCT00572767|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2007-12-12|2007-12-12|2007-12-13|Estimate|||||||2007-12-12|2007-12-13|Estimate|January 2001||2001-01-31|December 2007|2007-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Evaluation of the Effect of Dextro-Amphetamin Added to Physiotherapy in Patients After Stroke|Evaluation of the Therapeutic Effect of Amphetamine in Association to Physiotherapy on Motor Recovery After Stroke: a Randomised, Double-Blinded, Placebo-Controlled Trial|Terminated||Phase 4|16|Actual|Reha Rheinfelden||2||Intended length of study ended|f||||f||||||||||2018-06-01 02:40:39.35771|2018-06-01 02:40:39.35771
NCT00572754|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2007-12-12|2007-12-12|2007-12-13|Estimate|||||||2007-12-12|2007-12-13|Estimate|November 2007||2007-11-30|December 2007|2007-12-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Phase II Trial to Evaluate the Safety and Efficacy of the Dry Circumcision Method|Phase II Trial to Evaluate the Safety and Efficacy of the Dry Circumcision|Unknown status|Recruiting|Phase 2|15|Anticipated|Progressus|||||f||||t||||||||||2018-06-01 02:40:39.428093|2018-06-01 02:40:39.428093
NCT00572741|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2016-05-03|2007-12-12|2007-12-13|Estimate|||||||2016-05-03|2016-05-05|Estimate|June 2008||2008-06-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Treating Oxidative Stress and the Metabolic Pathology of Autism|Treating Oxidative Stress and the Metabolic Pathology of Autism|Completed||N/A|39|Actual|Arkansas Children's Hospital Research Institute||2|||f||||t||||||||||2018-06-01 02:40:39.497361|2018-06-01 02:40:39.497361
NCT00572728|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2015-03-18||2016-12-28|2007-12-11|2007-12-13|Estimate|2015-12-10|2016-01-20|Estimate||||2016-12-28|2016-12-30|Estimate|December 2008||2008-12-31|December 2016|2016-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional||Registered|Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer|3'-Deoxy-3'-18F Fluorothymidine PET/CT in Predicting Response To Chemotherapy Before Surgery in Patients With Locally Advanced Breast Cancer|Completed||Phase 2|90|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:40:39.621096|2018-06-01 02:40:39.621096
NCT00572715|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-03-05|2007-12-12|2007-12-13|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2010||2010-01-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|||||Observational|||Acute Kidney Injury in Neonates|Acute Kidney Injury in Neonates|Withdrawn|||0|Actual|University of Alabama at Birmingham|||1|Investigator's decision:Did not open to enrollment|f||||f||||||||||2018-06-01 02:40:40.122333|2018-06-01 02:40:40.122333
NCT00572702|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-07-31|2007-12-12|2007-12-13|Estimate|||||||2009-07-31|2009-08-03|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Randomized,Multicentric Study to Treat Prolapse After Hysterectomy With Amreich Procedure or Total Prolift Procedure|Open, Randomized, Prospective, Comparative, Multicentric to Treat Prolapse of Vaginal Cuff After Hysterectomy With Amreich Procedure or Total Prolift Procedure|Unknown status|Recruiting|N/A|200|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||||2018-06-01 02:40:40.193436|2018-06-01 02:40:40.193436
NCT00572689|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2015-08-20|2007-12-12|2007-12-13|Estimate|||||||2015-08-20|2015-08-21|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes|Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes|Withdrawn||Phase 4|0|Actual|Georgetown University||2|||f||||t||||||||||2018-06-01 02:40:40.305948|2018-06-01 02:40:40.305948
NCT00572663|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2007-12-12|2007-12-12|2007-12-13|Estimate|||||||2007-12-12|2007-12-13|Estimate|January 2005||2005-01-31|December 2007|2007-12-31||||||||Interventional|||Optimalization of Nephroprotection Using N-Acetylcysteine|The Effect of N-Acetylcysteine on Proteinuria and Markers of Tubular Injury in Non-Diabetic Patientswith Chronic Kidney Disease-Placebo Controlled, Randomized,Open, Cross-Over Study|Completed||N/A|||Medical University of Gdansk|||||f||||||||||||||2018-06-01 02:40:40.438733|2018-06-01 02:40:40.438733
NCT00572650|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2012-04-30|2007-12-12|2007-12-13|Estimate|||||||2012-04-30|2012-05-02|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients|An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of LAF237 and Its Metabolites in Mild Renal Impaired Patients Compared to Age, Sex and Weight-matched Healthy Volunteers Following Daily Doses of 100 mg LAF237 for 14 Days|Completed||Phase 1|29|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:40:40.4997|2018-06-01 02:40:40.4997
NCT00572637|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2010-05-19|2007-12-12|2007-12-13|Estimate|||||||2010-05-19|2010-05-20|Estimate|November 2007||2007-11-30|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas|An Open-Label, Dose-escalation, Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, and Pharmacodynamics of the Proteosome Inhibitor CEP 18770 Given Intravenously as Single Agent in Patients With Advanced Solid Tumours or Non-Hodgkin's Lymphomas|Completed||Phase 1|55|Anticipated|Ethical Oncology Science|||||f||||f||||||||||2018-06-01 02:40:40.563782|2018-06-01 02:40:40.563782
NCT00572624|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2014-12-11||2017-05-08|2007-12-12|2007-12-13|Estimate|2017-05-08|2017-05-15|Actual||||2017-05-08|2017-05-15|Actual|June 2003||2003-06-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Participants who lost 5% of their total body weight following either the diet or gastric bypass surgery interventions|Effect of Weight Loss on Myocardial Metabolism and Cardiac Relaxation in Obese Adults|Effect of Weight Loss on Myocardial Oxygen Consumption and Left Ventricular Relaxation in Obese Adults|Completed||N/A|51|Actual|Washington University School of Medicine|While this study does show the strength of the relationships between myocardial FA metabolism and MVO2 and relaxation, it does not prove cause and effect, direction of the association, or the potential influence of unmeasured factors.|2|||f||||f||||||||No||2018-06-01 02:40:40.654319|2018-06-01 02:40:40.654319
NCT00572611|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2012-09-25|2007-12-12|2007-12-13|Estimate|||||||2012-09-25|2012-09-26|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Human Mass Balance Study With Bilastine|A Phase I Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Bilastine Following Oral Administration to Healthy Volunteers|Completed||Phase 1|6|Actual|Faes Farma, S.A.||1|||f||||f||||||||||2018-06-01 02:40:41.165387|2018-06-01 02:40:41.165387
NCT00572598|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2012-01-11|2007-12-11|2007-12-13|Estimate|||||||2012-01-11|2012-01-12|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Pilot Study of 18F Fluoropaclitaxel (FPAC)|Pilot Study of 18F Fluoropaclitaxel (FPAC) in Breast Cancer Patients and Normal Volunteers: Dosimetry and Imaging Feasibility|Completed||Early Phase 1|6|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 02:40:41.22729|2018-06-01 02:40:41.22729
NCT00572585|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2017-03-24|2007-12-12|2007-12-13|Estimate|||||||2017-03-24|2017-03-28|Actual|April 2010||2010-04-30|March 2017|2017-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis|A Randomized, Double Blind, Placebo Controlled, Parallel Group Design Study to Explore the Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis|Completed||Phase 2|60|Actual|Novartis||2|||f||||f||||||||No||2018-06-01 02:40:41.300716|2018-06-01 02:40:41.300716
NCT00571636|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2011-10-08|2007-12-11|2007-12-12|Estimate|||||||2011-10-08|2011-10-12|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Continuous Infusion of Fentanyl in Preterm on MV|Efficacy and Safety of Continuous Infusion of Fentanyl for Pain Control in Preterm Newborn on Mechanical Ventilation|Completed||Phase 3|128|Anticipated|St. Orsola Hospital||2|||f||||t||||||||||2018-06-01 02:40:58.766707|2018-06-01 02:40:58.766707
NCT00572572|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2015-12-17||2016-03-08|2007-12-12|2007-12-13|Estimate|2016-03-08|2016-04-06|Estimate||||2016-03-08|2016-04-06|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors|Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen|Completed||Phase 3|69|Actual|Hoosier Cancer Research Network||2|||f||||t||||||||||2018-06-01 02:40:41.410974|2018-06-01 02:40:41.410974
NCT00572559|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2010-06-08|2007-12-11|2007-12-13|Estimate|||||||2010-06-08|2010-06-09|Estimate|November 2002||2002-11-30|June 2010|2010-06-30|January 2005|Actual|2005-01-31|||||Interventional|||Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus|A Randomized, Open Label, Multi-Center Clinical Trial, Comparing Microbiologic Response To Linezolid And Vancomycin In Ventilator-Associated Pneumonia (VAP) Due To Methicillin Resistant Staphylococcus Aureus (MRSA)|Completed||Phase 4|149|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:40:42.976955|2018-06-01 02:40:42.976955
NCT00572533|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2012-10-15||2017-11-15|2007-12-11|2007-12-13|Estimate|2012-12-19|2012-12-20|Estimate||||2017-11-15|2017-12-13|Actual|April 2011||2011-04-30|November 2017|2017-11-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Intelligent Control Approach to Anemia Management|Intelligent Control Approach to Anemia Management (AIM 4)|Completed||N/A|62|Actual|University of Louisville|"Single-center design~Small sample size~Homogenous population~Only maintenance dosing phase tested"|2|||f||||f||||||||||2018-06-01 02:40:43.210958|2018-06-01 02:40:43.210958
NCT00572520|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2013-04-17|2007-12-11|2007-12-13|Estimate|||||||2013-04-17|2013-04-18|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effectiveness of Behavioral Treatments for Obesity and Major Depression in Women|Treating Co-morbid Obesity and Major Depressive Disorder|Completed||Phase 2|161|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 02:40:43.7255|2018-06-01 02:40:43.7255
NCT00572507|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-05-27|2007-12-12|2007-12-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|July 2009|Actual|2009-07-31|August 2008|Actual|2008-08-31||Interventional|ISSAAC||Multi-center Study to Evaluate the Safety and Efficacy of Aesculap MonoMax® for Abdominal Wall Closure|A Historically-controlled Single-arm Multi-center Prospective Trial to Evaluate the Safety and Efficacy of Aesculap MonoMax® Suture Material for Abdominal Wall Closure After Primary Median Laparotomy|Completed||N/A|150|Actual|Aesculap AG||1|||f||||f||||||||||2018-06-01 02:40:43.809403|2018-06-01 02:40:43.809403
NCT00572494|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2008-02-07|2007-12-12|2007-12-13|Estimate|||||||2008-02-07|2008-02-08|Estimate|July 2005||2005-07-31|February 2008|2008-02-29|January 2007|Actual|2007-01-31|||||Interventional|AMS-INSIGHT1||AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment|Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment|Completed||Phase 2|117|Actual|Flanders Medical Research Program||2|||f||||t||||||||||2018-06-01 02:40:43.896448|2018-06-01 02:40:43.896448
NCT00572481|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2017-08-30|2007-12-12|2007-12-13|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2007||2007-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ARM||Axillary Reverse Mapping|ARM: Axillary Reverse Mapping|Active, not recruiting||Phase 2|1000|Anticipated|University of Arkansas||2|||f||||f|f|f|||f|||No||2018-06-01 02:40:43.999318|2018-06-01 02:40:43.999318
NCT00572468|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2017-04-17||2017-06-13|2007-12-11|2007-12-13|Estimate|2017-06-13|2017-07-13|Actual||||2017-06-13|2017-07-13|Actual|December 2007||2007-12-31|June 2017|2017-06-30|April 30, 2017|Actual|2017-04-30|April 2013|Actual|2013-04-30||Interventional|||Statin Therapy Versus Placebo Prior to Prostatectomy|Pre-Operative Statin Therapy Versus Placebo in Human Prostate Cancer|Completed||N/A|42|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 02:40:44.100566|2018-06-01 02:40:44.100566
NCT00572455|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11||2011-02-17|2011-02-25|2007-12-11|2007-12-13|Estimate||||2011-02-17|2011-02-23|Estimate|2011-02-25|2011-03-11|Estimate|December 2007||2007-12-31|February 2011|2011-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.|A 2-Stage, Phase 2, Double-Masked, Randomized, Vehicle Controlled, Dose Response Trial Of PF-04217329 And The Marketed Formulation Of Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.|Completed||Phase 2|317|Actual|Pfizer||14|||f||||t||||||||||2018-06-01 02:40:44.330453|2018-06-01 02:40:44.330453
NCT00572442|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-11-16|2007-12-12|2007-12-13|Estimate|||||||2009-11-16|2009-11-17|Estimate|December 2007||2007-12-31|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Observational|||Magnetocardiography (MCG) in Asymptomatic Individuals - Pilot Trial|Magnetocardiography (MCG) in Asymptomatic Individuals - Pilot Trial|Withdrawn|||40|Anticipated|Cedars-Sinai Medical Center|||4|sponsor funding|f||||f||||||||||2018-06-01 02:40:44.463344|2018-06-01 02:40:44.463344
NCT00572429|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2012-12-17|2007-12-12|2007-12-13|Estimate|||||||2012-12-17|2012-12-19|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|HIV||Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART|Effects of Mixed Exercise Regime and L-Carnitine Supplementation on Kinetics of Triglyceride-rich Lipoproteins in HIV Patients on HAART|Withdrawn||N/A|0|Actual|University of California, Davis||1||no subjects enrolled,study never started|f||||f||||||||||2018-06-01 02:40:44.610677|2018-06-01 02:40:44.610677
NCT00572416|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2007-12-12|2007-12-12|2007-12-13|Estimate|||||||2007-12-12|2007-12-13|Estimate|April 2003||2003-04-30|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Fatigue in Breast Cancer: A Behavioral Sleep Intervention|Fatigue in Breast Cancer:A Behavioral Sleep Intervention|Completed||Phase 3|220|Actual|University of Nebraska||2|||f||||f||||||||||2018-06-01 02:40:44.685741|2018-06-01 02:40:44.685741
NCT00572403|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2011-03-04|2007-12-12|2007-12-13|Estimate|||||||2011-03-04|2011-03-08|Estimate|December 2007||2007-12-31|March 2011|2011-03-31|April 2008|Actual|2008-04-30|||||Observational|||Risk Factors Contributing to the Development of Microalbuminuria|Risk Factors Contributing to the Development of Microalbuminuria Over a 5 Year Period|Completed|||10|Actual|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 02:40:44.779609|2018-06-01 02:40:44.779609
NCT00572390|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2007-12-12|2007-12-12|2007-12-13|Estimate|||||||2007-12-12|2007-12-13|Estimate|January 2001||2001-01-31|December 2007|2007-12-31|February 2002|Actual|2002-02-28|||||Interventional|||Oestrogen Withdrawal in Hypopituitary Women|Oestrogen Withdrawal in Hypopituitary Women|Completed||N/A|38|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:40:44.838177|2018-06-01 02:40:44.838177
NCT00572377|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2008-06-19|2007-12-12|2007-12-13|Estimate|||||||2008-06-19|2008-06-20|Estimate|May 2007||2007-05-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder|Safety and Efficacy of Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder|Terminated||Phase 1|10|Anticipated|Cedars-Sinai Medical Center||2||"The investigator at Cedars stopped this study due to problems collecting payment from the~   sponsor."|f||||t||||||||||2018-06-01 02:40:44.902344|2018-06-01 02:40:44.902344
NCT00572364|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-08-19|2007-12-12|2007-12-13|Estimate|||||||2009-08-19|2009-08-20|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Open Label, Dose Escalation Phase I Study of AZD2281|A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies|Completed||Phase 1|18|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:40:44.984927|2018-06-01 02:40:44.984927
NCT00572351|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2017-11-14|2007-12-12|2007-12-13|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2006||2006-01-31|November 2017|2017-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels|The Effects of Red Wine and White Wine on Blood Estrogen and Progesterone Levels|Completed||N/A|44|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||Yes||2018-06-01 02:40:45.055597|2018-06-01 02:40:45.055597
NCT00572338|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-08-12|2007-12-12|2007-12-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2003||2003-08-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Therapeutic Research in Multiple Myeloma|UARK 91-004 Therapeutic Research in Multiple Myeloma|Completed|||6388|Actual|University of Arkansas|||1||f||||f||||||Samples With DNA|"~     -  A bone marrow aspirate and biopsy~        -  Blood~        -  Fine Needle aspirates~        -  Swabs of skin, throat, other sites~   "|||2018-06-01 02:40:45.116535|2018-06-01 02:40:45.116535
NCT00572325|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2010-07-20|2007-12-12|2007-12-13|Estimate|||||||2010-07-20|2010-07-21|Estimate|August 2006||2006-08-31|July 2010|2010-07-31|May 2009|Actual|2009-05-31|||||Observational|BRONC CONC MLD||Concurrent Chemo-radiation Form NSCLC to a Individualized MLD|Concurrent Chemo-radiotherapy for Stage III Non-small Cell Lung Cancer ta an Individualized MLD|Completed|||180|Actual|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-06-01 02:40:45.186632|2018-06-01 02:40:45.186632
NCT00572312|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2007-12-12|2007-12-12|2007-12-13|Estimate|||||||2007-12-12|2007-12-13|Estimate|February 2005||2005-02-28|December 2007|2007-12-31||||||||Interventional|||Optimalization of Nephroprotection Using Atorvastatin (Sortis)|Influence of Adding Atorvastatin to Dual Renin-Angiotensin-Aldosterone System Blockade on Proteinuria|Completed||N/A|||Medical University of Gdansk|||||f||||||||||||||2018-06-01 02:40:45.269116|2018-06-01 02:40:45.269116
NCT00572299|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2011-08-29|2007-12-12|2007-12-13|Estimate|||||||2011-08-29|2011-08-30|Estimate|January 2004||2004-01-31|August 2011|2011-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Glucocorticoids Promote Osteoclast Survival|Glucocorticoids Promote Osteoclast Survival|Terminated|||3|Actual|University of Arkansas|||2|Terminated due to recruitment problems|f||||f||||||Samples Without DNA|"~     bone biopsy specimens~   "|||2018-06-01 02:40:45.343839|2018-06-01 02:40:45.343839
NCT00572286|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|||2009-11-16|2007-12-12|2007-12-13|Estimate|||||||2009-11-16|2009-11-17|Estimate|October 2005||2005-10-31|November 2009|2009-11-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study|Evaluation of Non-invasive Methods for the Detection of Acute Rejection in Heart Transplant Patients: Use of Echocardiography and Magnetocardiography (MCG) -Pilot Study|Withdrawn|||20|Anticipated|Cedars-Sinai Medical Center|||1|sponsor funding|f||||f||||||||||2018-06-01 02:40:45.443583|2018-06-01 02:40:45.443583
NCT00572260|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-12|2011-03-29||2014-07-17|2007-12-12|2007-12-13|Estimate|2012-11-05|2012-12-03|Estimate||||2014-07-17|2014-07-25|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Pilot Study of Daptomycin for Antimicrobial Prophylaxis|A Pilot Study of Daptomycin for Antimicrobial Prophylaxis in Patients Undergoing Cardiac Valve Replacement and Coronary Artery Bypass Grafting (CABG) Who Are at Increased Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus (MRSA)|Terminated||Phase 4|11|Actual|Duke University|Premature termination of the study due to departure of the PI resulted in falling short of enrollment goal (enrolled - 11 enrolled/goal - 100) leading to uninterpretable data.|1||Study closed. PI left the institution.|f||||f||||||||||2018-06-01 02:40:45.560659|2018-06-01 02:40:45.560659
NCT00572247|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2012-03-05|2007-12-11|2007-12-13|Estimate|||||||2012-03-05|2012-03-07|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|||The Psychiatric Rehabilitation Approach to Weight Loss|The Intervention Involves Education on Nutrition and Physical Activity. Outcomes Evaluate Changes in BMI.|Completed||N/A|133|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 02:40:45.750968|2018-06-01 02:40:45.750968
NCT00572234|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2010-01-13|2007-12-11|2007-12-12|Estimate|||||||2010-01-13|2010-01-14|Estimate|June 2007||2007-06-30|January 2010|2010-01-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Bupropion in the Treatment of Methamphetamine Dependence|Bupropion in the Treatment of Methamphetamine Dependence|Unknown status|Recruiting|N/A|60|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-06-01 02:40:45.811622|2018-06-01 02:40:45.811622
NCT00572221|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2013-03-18|2007-12-11|2007-12-12|Estimate|||||||2013-03-18|2013-03-20|Estimate|February 2006||2006-02-28|March 2013|2013-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Improving the Quality of Care in Nursing Homes|Improving the Quality of Care in Nursing Homes|Completed||N/A|4316|Actual|Hebrew Rehabilitation Center, Boston||2|||f||||f||||||||||2018-06-01 02:40:45.890538|2018-06-01 02:40:45.890538
NCT00572208|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2009-02-12|2007-12-11|2007-12-12|Estimate|||||||2009-02-12|2009-02-13|Estimate|January 2008||2008-01-31|February 2009|2009-02-28|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Gabapentin for Postoperative Pain Management After Cardiac Surgery With Median Sternotomy|Gabapentin for Postoperative Pain Management After Cardiac Surgery With Median Sternotomy|Unknown status|Recruiting|N/A|64|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:40:45.964613|2018-06-01 02:40:45.964613
NCT00572195|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2017-10-11|2007-12-10|2007-12-12|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2006||2006-04-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||RNS® System LTT Study|RNS® System Long-term Treatment (LTT) Clinical Investigation|Active, not recruiting||Phase 4|230|Actual|NeuroPace||1|||f||||t||||||||||2018-06-01 02:40:46.060644|2018-06-01 02:40:46.060644
NCT00572182|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2012-03-02|2007-12-11|2007-12-12|Estimate|||||||2012-03-02|2012-03-06|Estimate|July 2008||2008-07-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer|A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies|Terminated||Phase 1|33|Actual|Pediatric Brain Tumor Consortium||||"This Phase I study was permanently closed to patient accrual on February 23, 2011, due to the~   discontinuation of support from MERCK."|f||||t||||||||||2018-06-01 02:40:46.174319|2018-06-01 02:40:46.174319
NCT00571805|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-04-08|2007-12-11|2007-12-12|Estimate|||||||2015-04-08|2015-04-09|Estimate|September 2007||2007-09-30|April 2015|2015-04-30||||||||Interventional|VarenSmoke||Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt|Placebo-controlled Study of Varenicline Effects on Nicotine Withdrawal Followed by a Test of Smoking Topography, Reward, and Reinforcement|Withdrawn||Phase 1/Phase 2|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 02:40:51.536972|2018-06-01 02:40:51.536972
NCT00572169|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2017-09-05|2007-12-11|2007-12-12|Estimate|||||||2017-09-05|2017-09-06|Actual|November 2006||2006-11-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy|A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance|Active, not recruiting||Phase 3|177|Actual|University of Arkansas||1|||f||||t||||||||||2018-06-01 02:40:46.271951|2018-06-01 02:40:46.271951
NCT00572156|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2015-08-06|2011-04-18|2015-11-10|2007-12-10|2007-12-12|Estimate|2015-11-10|2015-12-15|Estimate|2011-04-18|2011-04-27|Estimate|2015-11-10|2015-12-15|Estimate|December 2007||2007-12-31|November 2015|2015-11-30|March 2012|Actual|2012-03-31|April 2010|Actual|2010-04-30||Interventional||All Subjects|rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency|Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 rhIGF-1) Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency: A Six-year, Randomized, Multi-center, Open-label, Parallel-group, Active Treatment Controlled, Dose Selection Trial|Terminated||Phase 2|106|Actual|Ipsen|The study was prematurely terminated once the last subject had completed three years of treatment (compared to the six years planned in protocol Amendment) for strategic reasons.|4||The study was prematurely terminated due to strategic reasons.|f||||t||||||||||2018-06-01 02:40:46.48003|2018-06-01 02:40:46.48003
NCT00572143|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2016-01-26|2007-12-11|2007-12-12|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2007||2007-06-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|ONKOLINK||Follow-up After Surgery for Colon Cancer. General Practice vs. Surgical-based Follow-up?|Should the Surgeon or the General Practitioner (GP) Follow up Patients After Surgery for Colon Cancer? A Randomized Controlled Trial Focusing on Quality of Life, Cost-effectiveness and Serious Clinical Events.|Completed||N/A|180|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 02:40:47.8858|2018-06-01 02:40:47.8858
NCT00572130|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-06-09|2007-12-11|2007-12-12|Estimate|||||||2011-06-09|2011-06-10|Estimate|December 2007||2007-12-31|February 2010|2010-02-28|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||Phase II Study of Intravenous Rexin-G in Osteosarcoma|A Phase II Study of Intravenous Rexin-G in Recurrent or Metastatic Osteosarcoma|Completed||Phase 2|22|Actual|Epeius Biotechnologies||2|||f||||t||||||||||2018-06-01 02:40:47.949468|2018-06-01 02:40:47.949468
NCT00572117|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2016-08-17||2016-11-09|2007-12-10|2007-12-12|Estimate|2016-11-09|2017-01-09|Estimate||||2016-11-09|2017-01-09|Estimate|August 2007||2007-08-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder|Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder|Completed||Phase 4|12|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 02:40:48.323042|2018-06-01 02:40:48.323042
NCT00572104|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2016-10-06|2007-12-10|2007-12-12|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Plyometrics to Increase Bone Mass in Men With Osteopenia|Efficacy of Plyometrics to Increase Bone Mass in Men With Osteopenia|Completed||N/A|38|Actual|University of Missouri-Columbia||2|||f||||t||||||||No||2018-06-01 02:40:48.53744|2018-06-01 02:40:48.53744
NCT00572091|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2008-11-05|2007-12-10|2007-12-12|Estimate|||||||2008-11-05|2008-11-06|Estimate|February 2007||2007-02-28|November 2008|2008-11-30|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|PTOLEMY||Aachen Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device to Reduce Mitral Regurgitation|An Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device Used to Reduce Mitral Regurgitation|Completed||Phase 1/Phase 2|4|Actual|Viacor||1|||f||||t||||||||||2018-06-01 02:40:48.613215|2018-06-01 02:40:48.613215
NCT00572078|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2017-09-21|2007-12-10|2007-12-12|Estimate|||||||2017-09-21|2017-09-25|Actual|January 23, 2008|Actual|2008-01-23|September 2017|2017-09-30|September 14, 2014|Actual|2014-09-14|January 4, 2011|Actual|2011-01-04||Interventional|||Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors|Phase I Dose-Escalation Drug-Interaction Study of Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors|Completed||Phase 1|27|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 02:40:48.680493|2018-06-01 02:40:48.680493
NCT00572065|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2017-03-02|2007-12-11|2007-12-12|Estimate|||||||2017-03-02|2017-03-03|Actual|February 29, 2008|Actual|2008-02-29|March 2017|2017-03-31|February 8, 2010|Actual|2010-02-08|December 2009|Actual|2009-12-31||Interventional|||Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis|Prospective Pilot Trial of Arsenic Trioxide (Trisenox®) in Combination With Cytosine Arabinoside in Patients With Advanced or Transformed Myelofibrosis|Completed||Early Phase 1|21|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-06-01 02:40:48.749556|2018-06-01 02:40:48.749556
NCT00572052|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-01-18|2007-12-11|2007-12-12|Estimate|||||||2017-01-18|2017-01-19|Estimate|December 2002||2002-12-31|January 2017|2017-01-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Comparison of Glycemic Control Achieved With 2 Different Needles|Comparison of Glycemic Control Achieved With a 31 Gauge x 6 mm NovoFine® Needle vs. a BD 29 Gauge x 12.7 mm Ultra-Fine® Needle in Subjects With Diabetes Mellitus and a BMI Exceeding 30 kg/m2: An Open Label, Randomized, Two-Period Crossover Study|Completed||Phase 4|62|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:40:48.818834|2018-06-01 02:40:48.818834
NCT00572039|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2015-08-11||2015-09-14|2007-12-11|2007-12-12|Estimate|2015-09-14|2015-10-15|Estimate||||2015-09-14|2015-10-15|Estimate|August 2005||2005-08-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|IF-AMD||Improving Function in Age-Related Macular Degeneration|Improving Function in Age-Related Macular Degeneration|Completed||Phase 3|241|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 02:40:48.899059|2018-06-01 02:40:48.899059
NCT00572026|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2009-09-02|2007-12-10|2007-12-12|Estimate|||||||2009-09-02|2009-09-03|Estimate|July 2007||2007-07-31|September 2009|2009-09-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|||Enhancing ADHD Driving Performance With Stimulant Medication|Enhancing ADHD Driving Performance With Stimulant Medication|Unknown status|Recruiting|N/A|14|Anticipated|University of Virginia||2|||f||||f||||||||||2018-06-01 02:40:49.299595|2018-06-01 02:40:49.299595
NCT00572013|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2018-01-13|2007-12-11|2007-12-12|Estimate|||||||2018-01-13|2018-01-17|Actual|May 1998||1998-05-31|January 2018|2018-01-31|September 2009|Actual|2009-09-30|January 2001|Actual|2001-01-31||Interventional|||Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma|A Phase I/II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma|Completed||Phase 1/Phase 2|32|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:40:49.494239|2018-06-01 02:40:49.494239
NCT00572000|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2007-12-11|2007-12-11|2007-12-12|Estimate|||||||2007-12-11|2007-12-12|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|June 2008|Anticipated|2008-06-30|||||Interventional|HPV-022 PRI||Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule|Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule|Unknown status|Recruiting|N/A|222|Anticipated|National Institute for Control of Vaccine and Biologicals|||||f||||t||||||||||2018-06-01 02:40:49.576278|2018-06-01 02:40:49.576278
NCT00571987|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2015-07-29||2015-10-28|2007-12-11|2007-12-12|Estimate|2015-09-03|2015-10-06|Estimate||||2015-10-28|2015-11-24|Estimate|September 2004||2004-09-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|eRFA||Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation|Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation|Completed||Phase 1/Phase 2|107|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:40:49.65683|2018-06-01 02:40:49.65683
NCT00571974|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2012-05-11||2015-03-04|2007-12-10|2007-12-12|Estimate|2012-11-06|2012-11-13|Estimate||||2015-03-04|2015-03-24|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Treatment of Oral Premalignant Lesions With 5-ALA PDT|A Combined Phase I/II Single Site Study to Determine the Safety and Efficacy of Photodynamic Therapy (PDT) Utilizing 5-aminolevulinic Acid (5-ALA) and PDT in the Treatment of Premalignant Oral and/or Oropharynx Lesions.|Completed||Phase 1/Phase 2|29|Actual|University of Arkansas|Since all but one subject responded to treatment, no correlative analysis of response with change in expression of p53 or Ki-67 was undertaken.|2|||f||||f||||||||||2018-06-01 02:40:49.812153|2018-06-01 02:40:49.812153
NCT00571961|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2012-05-25||2012-10-19|2007-12-11|2007-12-12|Estimate|2012-10-19|2012-11-21|Estimate||||2012-10-19|2012-11-21|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)|Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)|Completed||N/A|12|Actual|Yale University||1|||f||||f||||||||||2018-06-01 02:40:50.115584|2018-06-01 02:40:50.115584
NCT00571948|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2009-05-01||2015-05-04|2007-12-11|2007-12-12|Estimate|2015-01-08|2015-01-09|Estimate||||2015-05-04|2015-05-21|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|March 2008|Actual|2008-03-31|July 2007|Actual|2007-07-31||Interventional|DINO||Modification in Complementary Food Composition to Improve the Status of Iron and Fatty Acids in Infants.|Dortmund Intervention Trial for Optimization of Infant Nutrition|Completed||N/A|132|Actual|Research Institute of Child Nutrition, Dortmund||2|||f||||f||||||||||2018-06-01 02:40:50.289976|2018-06-01 02:40:50.289976
NCT00571935|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2016-12-20|2007-12-11|2007-12-12|Estimate|||||||2016-12-20|2016-12-21|Estimate|August 2003||2003-08-31|December 2016|2016-12-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes|Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes Mellitus|Completed||Phase 4|61|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:40:50.539124|2018-06-01 02:40:50.539124
NCT00571922|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2016-02-05||2017-03-23|2007-12-11|2007-12-12|Estimate|2016-03-07|2016-04-06|Estimate||||2017-03-23|2017-03-24|Actual|July 2007||2007-07-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|AcampMet||A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction|A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence|Completed||Phase 1/Phase 2|72|Actual|New York University School of Medicine|Sadly, the PI of this study passed away on 4/20/2010. Data was not analyzed and is unavailable.|2|||f||||f||||||||||2018-06-01 02:40:50.627533|2018-06-01 02:40:50.627533
NCT00571909|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2017-10-18|2007-12-10|2007-12-12|Estimate|||||||2017-10-18|2017-10-20|Actual|May 2007||2007-05-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study|Evaluation and Treatment of Chronic Pain in Autosomal Dominant Polycystic Kidney Disease|Completed||N/A|18|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:40:50.842372|2018-06-01 02:40:50.842372
NCT00571896|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2012-01-03|2007-12-11|2007-12-12|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery|The Use of SennaS for Prevention of Post-operative Constipation After Urogynecologic Surgery: a Randomized Double Blinded Placebo Controlled Trial|Completed||Phase 2/Phase 3|72|Actual|Hartford Hospital||2|||f||||f||||||||||2018-06-01 02:40:50.920612|2018-06-01 02:40:50.920612
NCT00571883|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-12-11|2007-12-11|2007-12-12|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2007||2007-01-31|July 2009|2009-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Neck Surgery in Treating Patients With Early-Stage Oral Cancer|SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck|Unknown status|Active, not recruiting|N/A|652|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:40:51.017525|2018-06-01 02:40:51.017525
NCT00571870|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2009-08-20|2007-12-11|2007-12-12|Estimate|||||||2009-08-20|2009-08-21|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study|Study on the Effect of GnRH Antagonist on hCG Day on Outcomes of Controlled Ovarian Hyperstimulation With GnRH Antagonist Flexible Multiple-dose Protocols|Completed||N/A|80|Anticipated|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-06-01 02:40:51.148405|2018-06-01 02:40:51.148405
NCT00571844|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2014-07-11|2007-12-10|2007-12-12|Estimate|||||||2014-07-11|2014-07-14|Estimate|October 2003||2003-10-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2009|Actual|2009-07-31||Interventional|ENCORE||ENCORE: Exercise and Nutritional Interventions for Cardiovascular Health|Behavioral Treatment of High Blood Pressure|Completed||N/A|144|Actual|Duke University||3|||f||||t||||||||||2018-06-01 02:40:51.260378|2018-06-01 02:40:51.260378
NCT00571831|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2007-12-11|2007-12-11|2007-12-12|Estimate|||||||2007-12-11|2007-12-12|Estimate|February 2003||2003-02-28|December 2007|2007-12-31|March 2005|Actual|2005-03-31|||||Interventional|||The Effect of a Blue Light Filtering IOL|The Effect of a Blue Light Filtering Intraocular Lens on Blood Retinal Barrier After Cataract Surgery|Completed||N/A|50|Actual|Showa University||1|||f||||f||||||||||2018-06-01 02:40:51.356218|2018-06-01 02:40:51.356218
NCT00571818|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-05-26|2007-12-11|2007-12-12|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2000||2000-11-30|May 2015|2015-05-31|June 2010|Actual|2010-06-30|March 2008|Actual|2008-03-31||Interventional|||The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients|The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients|Completed||N/A|31|Actual|University of Nebraska||4|||f||||f||||||||||2018-06-01 02:40:51.443302|2018-06-01 02:40:51.443302
NCT00571792|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2007-12-11|2007-12-11|2007-12-12|Estimate|||||||2007-12-11|2007-12-12|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|September 2008|Anticipated|2008-09-30|||||Observational|||Evaluation of Airway Gene Expression in COPD and Controlled Populations|Evaluation of Airway Gene Expression in COPD and Controlled Populations|Unknown status|Recruiting||30|Anticipated|University of Nebraska|||3||f||||f||||||Samples With DNA|"~     Genetic testing involves identification of potential proteins and biomarkers produced from~     the DNA and RNA analysis. Included are MMP12 and MMP9, Nrf-2 gene, heme oxygenases,~     glutathione, sythesizing enzymes, thioredoxin reductase, NADPH dependent quinone reductase 1~     as well as certain p450 members.~   "|||2018-06-01 02:40:51.609989|2018-06-01 02:40:51.609989
NCT00571779|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-02-18|2007-12-10|2007-12-12|Estimate|||||||2011-02-18|2011-02-21|Estimate||||February 2011|2011-02-28||||||||Interventional|RESTORE SR IIB||AtriCure Minimally Invasive Surgical Ablation for Atrial Fibrillation/RESTORE IIB|Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation|Withdrawn||Phase 2|||AtriCure, Inc.|||||f||||||||||||||2018-06-01 02:40:51.771106|2018-06-01 02:40:51.771106
NCT00571766|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2009-09-09|2007-12-11|2007-12-12|Estimate|||||||2009-09-09|2009-09-10|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy|Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy|Completed||Phase 3|80|Anticipated|University of Modena and Reggio Emilia||2|||f||||t||||||||||2018-06-01 02:40:51.830467|2018-06-01 02:40:51.830467
NCT00571753|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2011-02-25|2007-12-11|2007-12-12|Estimate|||||||2011-02-25|2011-02-28|Estimate|June 2008||2008-06-30|February 2011|2011-02-28|February 2012|Anticipated|2012-02-29|December 2011|Anticipated|2011-12-31||Interventional|||Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)|A Double-blind, Multicentre, Parallel Group, Randomised, Controlled Trial to Evaluate the Possible Benefit of Isoniazid Dose Adjustment According to the Genotype for NAT2 (Arylamine N-acetyltransferase Type 2) in Patients With Pulmonary Tuberculosis|Terminated||Phase 3|900|Anticipated|University of Cologne||2||Enrolling participants has halted prematurely due to a low recruitment rate.|f||||t||||||||||2018-06-01 02:40:51.916972|2018-06-01 02:40:51.916972
NCT00571740|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2016-07-01|2007-12-11|2007-12-12|Estimate|||||||2016-07-01|2016-07-06|Estimate||||July 2016|2016-07-31||||||||Interventional|||Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer|Randomized Phase II Trial of Cetuximab/Bevacizumab (CB) as Palliative First-Line Therapy in Patients With Advanced Colorectal Cancer Followed by FOLFOX+CB vs. FOLFOX+B|Withdrawn||Phase 2|0|Actual|Alliance for Clinical Trials in Oncology||2||The study was not activated|f||||||||||||||2018-06-01 02:40:52.023792|2018-06-01 02:40:52.023792
NCT00571727|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2015-09-29|2007-12-10|2007-12-12|Estimate|||||||2015-09-29|2015-09-30|Estimate|January 1990||1990-01-31|September 2015|2015-09-30|December 2011|Actual|2011-12-31|October 2004|Actual|2004-10-31||Interventional|||Long-Term Treatment With rhIGF-1 in GHIS|A Study of the Long-Term Human Recombinant Insulin-Like Growth Factor-1 (rhIGF-1) Treatment in Children With Short Stature Due to Growth Hormone Insensitivity Syndrome (GHIS)|Completed||Phase 2/Phase 3|92|Actual|Ipsen||1|||f||||||||||||||2018-06-01 02:40:52.101777|2018-06-01 02:40:52.101777
NCT00571714|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2018-03-08|2007-12-11|2007-12-12|Estimate|||||||2018-03-08|2018-03-12|Actual|April 2008||2008-04-30|March 2018|2018-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients|Comparison of Standard Therapy,Peginterferon Alpha-2a + Ribavirin for 48 Weeks VS Peginterferon Alph-2a + Ribavirin + Betaine for 12 Weeks Followed by 36 Weeks Standard Therapy in Untreated Adults With Chronic Hepatitis C Genotype 1|Withdrawn||N/A|0|Actual|University of Nebraska||2||lack of enrollment|f||||t||||||||No|no patients enrolled to the study|2018-06-01 02:40:52.240954|2018-06-01 02:40:52.240954
NCT00571701|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2016-08-09||2017-03-31|2007-12-10|2007-12-12|Estimate|2016-12-29|2017-02-23|Actual||||2017-03-31|2017-05-15|Actual|February 2008||2008-02-29|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis|A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis|Completed||Phase 2|50|Actual|Northwell Health|Rare prevalence of moderate to severe recurrent respiratory papillomatosis (estimated at 1:1million) limited enrollment|2|||f||||t||||||||No||2018-06-01 02:40:52.367742|2018-06-01 02:40:52.367742
NCT00571688|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2015-07-29||2017-06-30|2007-12-11|2007-12-12|Estimate|2017-06-30|2017-07-31|Actual||||2017-06-30|2017-07-31|Actual|November 2007||2007-11-30|June 2017|2017-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|Consta||Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?|Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?|Completed||Phase 4|50|Actual|Vanderbilt University Medical Center|This was not a blinded study.|2|||f||||t|t|f|||f|||No||2018-06-01 02:40:52.961378|2018-06-01 02:40:52.961378
NCT00571675|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2010-11-08|2007-12-11|2007-12-12|Estimate|||||||2010-11-08|2010-11-09|Estimate|October 2007||2007-10-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)|Completed||Phase 2|220|Actual|Ascenta Therapeutics||2|||f||||f||||||||||2018-06-01 02:40:53.219016|2018-06-01 02:40:53.219016
NCT00571662|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2010-10-19||2018-01-22|2007-12-11|2007-12-12|Estimate|2010-10-19|2010-11-17|Estimate||||2018-01-22|2018-02-20|Estimate|December 2000||2000-12-31|January 2018|2018-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant|Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation|Completed||Phase 2|76|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:40:53.336448|2018-06-01 02:40:53.336448
NCT00571649|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|2012-02-16||2016-08-03|2007-12-11|2007-12-12|Estimate|2012-05-24|2012-06-27|Estimate||||2016-08-03|2016-09-15|Estimate|December 2007||2007-12-31|August 2016|2016-08-31|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|MAGELLAN||Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients|Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study|Completed||Phase 3|8101|Actual|Bayer|A heterogeneous population (with different acute medical illnesses and severity of illness) was included in the trial. VTE risk in acute medical illnesses is moderate [with no thromboprophylaxis] .|2|||f||||t||||||||||2018-06-01 02:40:53.82475|2018-06-01 02:40:53.82475
NCT00571623|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2014-07-08|2007-12-10|2007-12-12|Estimate|||||||2014-07-08|2014-07-09|Estimate|September 2007||2007-09-30|August 2008|2008-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|ACTION-ICP||Automated Chest Physiotherapy to Improve Outcomes in Neuro|Automated Chest Physiotherap to Improve Outcomes in Neurocritical Care: An Intracranial Pressure Study|Completed|||40|Anticipated|Duke University|||1||f||||f||||||||||2018-06-01 02:40:58.84544|2018-06-01 02:40:58.84544
NCT00571610|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2008-11-05|2007-12-10|2007-12-12|Estimate|||||||2008-11-05|2008-11-06|Estimate|April 2006||2006-04-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|PTOLEMY||Montreal Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device|A Single-Center, Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Implantable Device Used to Reduce Mitral Valve Regurgitation.|Completed||Phase 1|5|Actual|Viacor||1|||f||||t||||||||||2018-06-01 02:40:58.92209|2018-06-01 02:40:58.92209
NCT00571597|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2014-04-10|2007-12-10|2007-12-12|Estimate|||||||2014-04-10|2014-04-14|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Short Term Outcomes From Minimally Invasive Surgery for the Treatment of Atrial Fibrillation|Prospective Analysis of the Wolf Minimaze Procedure for Treatment of Atrial Fibrillation|Completed|||118|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 02:40:59.002218|2018-06-01 02:40:59.002218
NCT00571584|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2017-01-11|2007-12-11|2007-12-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2002||2002-11-30|January 2017|2017-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors|rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa|Completed||Phase 4|24|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:40:59.062645|2018-06-01 02:40:59.062645
NCT00571571|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2011-01-03|2007-12-11|2007-12-12|Estimate|||||||2011-01-03|2011-01-04|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|TFP-A||Application and Evaluation of Transference Focused Psychotherapy Modified for Adolescents|Application and Evaluation of Transference Focused Psychotherapy Modified for Adolescents|Unknown status|Recruiting|N/A|20|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 02:40:59.145344|2018-06-01 02:40:59.145344
NCT00571558|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2014-10-08|2007-12-11|2007-12-12|Estimate|||||||2014-10-08|2014-10-09|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia|Phase I Study of Photodynamic Therapy Using Pulsed Dye Laser and Oral Aminolevulinic Acid in Patients With Oral Leukoplakia|Terminated||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:40:59.230674|2018-06-01 02:40:59.230674
NCT00571545|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2017-02-02|2007-12-11|2007-12-12|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 2004||2004-04-30|February 2017|2017-02-28|October 2007|Actual|2007-10-31|||||Interventional|||The Effect of Exercise on Mood After Traumatic Brain Injury|The Effect of Exercise on Mood After Traumatic Brain Injury|Completed||N/A|78|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:40:59.308918|2018-06-01 02:40:59.308918
NCT00571519|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11||2013-02-01|2013-02-06|2007-12-11|2007-12-12|Estimate||||2013-02-01|2013-02-05|Estimate|2013-02-06|2013-02-08|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus|Terminated||Phase 3|94|Actual|Daiichi Sankyo, Inc.||8||DSPD focussing on Study 301 to confirm clinical profile before proceeding.|f||||t||||||||||2018-06-01 02:40:59.401389|2018-06-01 02:40:59.401389
NCT00571506|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2009-12-08|2007-12-11|2007-12-12|Estimate|||||||2009-12-08|2009-12-09|Estimate|May 2004||2004-05-31|December 2009|2009-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effect of Thiazolidinedione Treatment Vascular Risk Markers|A Pilot Study to Determine the Effects of Short-term Thiazolidinedione Treatment on Vascular Risk Markers in Type 2 Diabetes Patients|Completed||Phase 4|25|Actual|University of Arkansas||2|||f||||f||||||||||2018-06-01 02:40:59.523228|2018-06-01 02:40:59.523228
NCT00571493|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2015-08-11|2007-12-11|2007-12-12|Estimate|||||||2015-08-11|2015-08-13|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma|Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma|Completed||Phase 1/Phase 2|44|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 02:40:59.616813|2018-06-01 02:40:59.616813
NCT00571480|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2009-07-17|2007-12-11|2007-12-12|Estimate|||||||2009-07-17|2009-07-21|Estimate|February 2005||2005-02-28|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Use Ear Acupuncture as Treatment for Low Back Pain During Pregnancy|Acupuncture and Low Back Pain During Pregnancy|Completed||N/A|159|Actual|Yale University||3|||f||||f||||||||||2018-06-01 02:40:59.72623|2018-06-01 02:40:59.72623
NCT00571467|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2012-11-01|2007-12-10|2007-12-12|Estimate|||||||2012-11-01|2012-11-02|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP|An Open Label, Sequential, Dose Escalation, Repeat-dose Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRTX-100 in Adult Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Terminated||Phase 1|9|Actual|Protalex, Inc.||1||Terminated due to recruitment not meeting expectations.|f||||t||||||||||2018-06-01 02:40:59.961833|2018-06-01 02:40:59.961833
NCT00571454|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2009-10-28|2007-12-10|2007-12-12|Estimate|||||||2009-10-28|2009-10-30|Estimate|May 2007||2007-05-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Culturally Sensitive Depression Care Management for Latino Primary Care Patients|Culturally Sensitive Depression Care Management for Latino Primary Care Patients|Completed||Phase 2|38|Actual|Butler Hospital||2|||f||||t||||||||||2018-06-01 02:41:00.051898|2018-06-01 02:41:00.051898
NCT00571441|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2016-01-20|2007-12-10|2007-12-12|Estimate|||||||2016-01-20|2016-01-21|Estimate|December 2007||2007-12-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|EVOLVE||Estimating Volume Using LiDCO|Estimating Volume Using LiDCO Versus Other Measures of Volume|Completed|||34|Actual|Duke University|||1||f||||f||||||||||2018-06-01 02:41:00.123062|2018-06-01 02:41:00.123062
NCT00182130|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-09-10|2005-09-10|2005-09-16|Estimate|||||||2005-09-10|2005-09-16|Estimate|May 2002||2002-05-31|July 2005|2005-07-31|June 2007||2007-06-30|||||Interventional|||Quality Initiative in Rectal Cancer (QIRC) Trial|Quality Initiative in Rectal Cancer (QIRC) Trial|Unknown status|Active, not recruiting|N/A|691||McMaster University|||||f||||||||||||||2018-06-01 04:36:31.245531|2018-06-01 04:36:31.245531
NCT00571428|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2009-03-13||2012-02-21|2007-12-10|2007-12-12|Estimate|2009-05-12|2009-07-02|Estimate||||2012-02-21|2012-02-22|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD|Modified-blind, Randomized, Multicenter, Single Dose, Two-way Crossover Study of Arformoterol Tartrate Inhalation Solution 15 Micrograms Twice A Day Versus 30 Micrograms Once A Day in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|33|Actual|Sunovion|Single day/dose; small numbers of subjects; difference between arms (2mL vs 4mL per dose); Predefined +/-0.07L equivalence is arbitrarily lower than the clinically recognized 0.1L. Hence, clinical efficacy & safety conclusions are difficult to reach.|2|||f||||f||||||||||2018-06-01 02:41:00.236063|2018-06-01 02:41:00.236063
NCT00571415|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2016-05-27|2007-12-11|2007-12-12|Estimate|||||||2016-05-27|2016-06-01|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|May 2013|Actual|2013-05-31||Observational|||Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition|Image-guided Adaptive Radiotherapy for Cervix Cancer: Patient Image Acquisition|Terminated|||21|Actual|Virginia Commonwealth University|||1|Due to competing studies no further subjects could be recruited.|f||||f||||||||||2018-06-01 02:41:01.086704|2018-06-01 02:41:01.086704
NCT00571402|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2014-03-24|2007-12-11|2007-12-12|Estimate|||||||2014-03-24|2014-03-26|Estimate|July 2001||2001-07-31|March 2014|2014-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Evaluating the Effectiveness of Family-Focused Psychoeducation in Treating Adolescents With Bipolar Disorder|Family-Focused Psychoeducation for Bipolar Adolescents|Completed||Phase 1/Phase 2|58|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 02:41:01.158318|2018-06-01 02:41:01.158318
NCT00571389|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2017-05-30|2007-12-11|2007-12-12|Estimate|||||||2017-05-30|2017-05-31|Actual|November 2007||2007-11-30|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukopaks|A Study to Facilitate Development of an Ex-Vivo Device Platform for Circulating Tumor Cell and Immune Cell Harvesting, Banking, and Apoptosis-Viability Assay|Recruiting|||500|Anticipated|BioCytics, Inc.|||||f||||t||||||Samples With DNA|"~     Blood cells, tumor cells, immune cells, plasma, discarded tissue (inc. tissue obtained from~     biopsies, paracentesis, pleuracentesis), leukapheresis products~   "|||2018-06-01 02:41:01.257744|2018-06-01 02:41:01.257744
NCT00571376|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2017-02-17|2007-12-11|2007-12-12|Estimate|||||||2017-02-17|2017-02-23|Actual|January 2009|Actual|2009-01-31|February 2017|2017-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Evaluating the Impact on Quality and Costs of Regional Clinical Data Exchange Programs in New York State|Evaluating the Impact on Quality and Costs of Regional Clinical Data Exchange Programs in New York State|Completed|||218766|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||||2018-06-01 02:41:01.324675|2018-06-01 02:41:01.324675
NCT00571363|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2007-12-11|2007-12-11|2007-12-12|Estimate|||||||2007-12-11|2007-12-12|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||A Randomised Study Comparing Tissue Conservation in Conventional Versus Mohs' Surgery of Basal Cell Carcinoma|A Randomised Study Comparing Tissue Conservation in Conventional Versus Mohs' Surgery of Basal Cell Carcinoma|Completed||N/A|30|Actual|NHS Tayside||2|||f||||t||||||||||2018-06-01 02:41:01.405494|2018-06-01 02:41:01.405494
NCT00571350|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2007-12-10|2007-12-10|2007-12-12|Estimate|||||||2007-12-10|2007-12-12|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Anterior Vaginal Wall Reconstruction|Anterior Vaginal Wall Reconstruction: Anterior Colporrhaphy Reinforced With Tension Free Vaginal Tape Underneath Bladder Base|Unknown status|Enrolling by invitation|Phase 1/Phase 2|50|Actual|Hippocration General Hospital||1|||f||||f||||||||||2018-06-01 02:41:01.47533|2018-06-01 02:41:01.47533
NCT00571337|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2010-07-22|2007-12-11|2007-12-12|Estimate|||||||2010-07-22|2010-07-23|Estimate|December 2005||2005-12-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|STORI||Stop Infliximab in Patients With Crohn's Disease|Prospective Study of Predictive Factors of Sustained Remission of Crohn's Disease After Stopping Infliximab|Completed||Phase 3|126|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|||||f||||f||||||||||2018-06-01 02:41:01.556574|2018-06-01 02:41:01.556574
NCT00571324|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2016-07-29||2017-11-09|2007-12-11|2007-12-12|Estimate|2016-09-22|2016-11-09|Estimate||||2017-11-09|2017-12-11|Actual|August 2007||2007-08-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism|An Open Label Pilot Study of the Effects of the Glucagon-like Peptide-1 Receptor Antagonist, Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism|Completed||Phase 1/Phase 2|9|Actual|Children's Hospital of Philadelphia|Due to safety concerns subjects with symptomatic hypoglycemia were rescued with dextrose to maintain glucose levels >60mg/dL limiting detectable treatment effect.|2|||f||||f||||||||||2018-06-01 02:41:01.668963|2018-06-01 02:41:01.668963
NCT00571311|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-11|||2018-05-22|2007-12-11|2007-12-12|Estimate|||||||2018-05-22|2018-05-23|Actual|December 10, 2007||2007-12-10|March 12, 2018|2018-03-12|March 12, 2018||2018-03-12|||||Observational|||Parental Permission and Adolescent Assent and Decision-Making in Clinical Research|Parental Permission and Adolescent Assent and Decision Making in Clinical Research|Completed|||356|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:41:01.930616|2018-06-01 02:41:01.930616
NCT00571298|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2017-01-19|2007-12-10|2007-12-11|Estimate|||||||2017-01-19|2017-01-23|Estimate|November 2007||2007-11-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|November 2011|Actual|2011-11-30||Interventional|||Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma|A Phase I Trial of Extrapleural Pneumonectomy/Pleurectomy Decortication, Intrathoracic/Intraperitoneal Hyperthermic (IOHC) Cisplatin and Gemcitabine With Intravenous Amifostine and Sodium Thiosulfate Cytoprotection for Patients With Resectable Malignant Pleural Mesothelioma|Completed||Phase 1|141|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-06-01 02:41:01.995205|2018-06-01 02:41:01.995205
NCT00571285|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2017-01-23|2007-12-07|2007-12-11|Estimate|||||||2017-01-23|2017-01-24|Estimate|June 2007||2007-06-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|January 2011|Actual|2011-01-31||Interventional|VIDIP PILOT||Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease|Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease|Terminated||Phase 4|31|Actual|Emory University||2|||f||||f||||||||||2018-06-01 02:41:02.073973|2018-06-01 02:41:02.073973
NCT00570765|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2011-06-09||2018-03-09|2007-12-07|2007-12-11|Estimate|2011-06-09|2011-07-07|Estimate||||2018-03-09|2018-04-03|Actual|November 2007||2007-11-30|March 2018|2018-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of INT-747 as Monotherapy in Patients With PBC|A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis|Completed||Phase 2|59|Actual|Intercept Pharmaceuticals||3|||f||||t||||||||||2018-06-01 02:41:08.293186|2018-06-01 02:41:08.293186
NCT00571272|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2018-02-15|2007-12-07|2007-12-11|Estimate|||||||2018-02-15|2018-02-19|Actual|November 2007||2007-11-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|LOGIC||Evaluating the Genetic Causes and Progression of Cholestatic Liver Diseases (LOGIC)|Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis|Recruiting|||1150|Anticipated|Arbor Research Collaborative for Health|||5||f||||t||||||Samples With DNA|"~     Blood plasma and serum samples with DNA~   "|Yes|The data will be transferred to NIDDK at the end of the study.|2018-06-01 02:41:02.336775|2018-06-01 02:41:02.336775
NCT00571259|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-12-15|2007-12-10|2007-12-11|Estimate|||||||2011-12-15|2011-12-16|Estimate|September 2003||2003-09-30|December 2011|2011-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|ALLOCK||Prophylactic Antimicrobial Catheter Lock|Prophylactic Antimicrobial Catheter Lock in Hemodialysis Patients: A Randomized Controlled Clinical Trial|Completed||Phase 4|303|Actual|Satellite Healthcare||2|||f||||f||||||||||2018-06-01 02:41:02.533392|2018-06-01 02:41:02.533392
NCT00571246|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2012-08-30|2007-12-07|2007-12-11|Estimate|||||||2012-08-30|2012-08-31|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder|The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder|Withdrawn||Phase 3|0|Actual|Yale University|||||f||||t||||||||||2018-06-01 02:41:02.612117|2018-06-01 02:41:02.612117
NCT00571233|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2015-05-13|2007-12-07|2007-12-11|Estimate|||||||2015-05-13|2015-05-14|Estimate|February 2007||2007-02-28|May 2015|2015-05-31|January 2015|Actual|2015-01-31|December 2011|Actual|2011-12-31||Observational|BHFSVP||Biomarker Study for Heart Failure in Children With Single Ventricle Physiology|Identification of Biomarkers for Heart Failure in Children With Single Ventricle Physiology|Completed|||71|Actual|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 02:41:02.689153|2018-06-01 02:41:02.689153
NCT00571220|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2018-03-07|2007-12-07|2007-12-11|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2005|Actual|2005-09-30|March 2018|2018-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Mechanisms of Diabetes Control After Weight Loss Surgery|Mechanisms of Diabetes Control After Weight Loss Surgery|Completed|||20|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||2||f||||t||||||Samples Without DNA|"~     blood samples~   "|||2018-06-01 02:41:02.761419|2018-06-01 02:41:02.761419
NCT00571207|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-08-31|2007-12-10|2007-12-11|Estimate|||||||2011-08-31|2011-09-02|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|October 2010|Actual|2010-10-31|||||Observational|||Oral Fluid Screening Devices|Scientific Evaluation of Oral Fluid Screening Devices and Preceding Selection Procedures|Completed|||250|Anticipated|National Institute for Health and Welfare, Finland|||2||f||||f||||||Samples With DNA|"~     Oral fluid and whole blood are collected. However, no DNA testing will be carried out. The~     research focuses on drug and medicine concentrations in these matrices.~   "|||2018-06-01 02:41:02.830346|2018-06-01 02:41:02.830346
NCT00571194|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2011-02-15||2017-01-26|2007-12-10|2007-12-11|Estimate|2017-01-26|2017-03-15|Actual||||2017-01-26|2017-03-15|Actual|September 2007||2007-09-30|January 2017|2017-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients|A Single-dose Pilot Study to Evaluate the Pharmacokinetics of Pravastatin Given as an Oral Dose in Pediatric and Adolescent Subjects 12 Months to 16 Years of Age Receiving Continuous Cycling Peritoneal Dialysis|Terminated||Phase 1|7|Actual|Arkansas Children's Hospital Research Institute||1|||f||||f||||||||No|There is no plan to share the data|2018-06-01 02:41:03.007015|2018-06-01 02:41:03.007015
NCT00571181|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-09|||2016-09-22|2007-12-09|2007-12-11|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Automated Anesthesia During Bronchoscopy|Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison Between Manual Perfusion and Automated Perfusion During Rigid Bronchoscopy|Completed||Phase 4|66|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 02:41:03.311785|2018-06-01 02:41:03.311785
NCT00571168|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2010-01-11|2007-12-10|2007-12-11|Estimate|||||||2010-01-11|2010-01-12|Estimate|July 2005||2005-07-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|EmNa||Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy|Randomised, Placebo Controlled, Single-center, Double-blind Clinical Trial to Investigate Efficacy and Safety of Aprepitant Combined With Kevatril and Dexamethasone Versus Placebo Combined With Kevatril and Dexamethasone in Prevention of Acute and Delayed High-dose Chemotherapy-induced Nausea and Vomiting in Subjects With Multiple Myeloma Receiving an Autologous Peripheral Blood Stemcell Transplantation.|Unknown status|Recruiting|Phase 3|362|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-06-01 02:41:03.462619|2018-06-01 02:41:03.462619
NCT00571155|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2009-08-19|2007-12-10|2007-12-11|Estimate|||||||2009-08-19|2009-08-20|Estimate|December 2007||2007-12-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery|Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study)|Completed||Phase 4|30|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||||2018-06-01 02:41:03.630088|2018-06-01 02:41:03.630088
NCT00571142|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2007-12-07|2007-12-07|2007-12-11|Estimate|||||||2007-12-07|2007-12-11|Estimate|November 2007||2007-11-30|December 2007|2007-12-31|February 2008|Anticipated|2008-02-29|||||Interventional|||Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema|Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)|Unknown status|Recruiting|Phase 3|20|Anticipated|Asociación para Evitar la Ceguera en México||2|||f||||f||||||||||2018-06-01 02:41:03.723786|2018-06-01 02:41:03.723786
NCT00571129|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2018-04-26|2007-12-10|2007-12-11|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2004||2004-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2011|Actual|2011-12-31||Interventional|||Endoscopic Dacryocystorhinostomy Prospective Research|Recovery After Endoscopic Dacryocystorhinostomy|Active, not recruiting||N/A|80|Anticipated|Kuopio University Hospital||1|||f||||f||||||||||2018-06-01 02:41:03.795381|2018-06-01 02:41:03.795381
NCT00571116|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2016-12-31|2007-12-10|2007-12-11|Estimate|||||||2016-12-31|2017-01-04|Estimate|September 2006||2006-09-30|December 2016|2016-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy|Evaluation of Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy (Phase 1b)|Terminated||Phase 1/Phase 2|15|Actual|University of California, Irvine||1||Halted because of slow accrual and lack of study funding|f||||t||||||||No||2018-06-01 02:41:03.864006|2018-06-01 02:41:03.864006
NCT00571103|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2012-12-06||2017-04-24|2007-12-10|2007-12-11|Estimate|2017-04-24|2017-05-25|Actual||||2017-04-24|2017-05-25|Actual|October 2007||2007-10-31|April 2017|2017-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Acamprosate in the Treatment of Pathological Gambling|Open Label, Flexible Dose 12-Week Clinical Trial of the Safety and Efficacy of Acamprosate in the Treatment of Pathological Gambling|Completed||Phase 4|26|Actual|University of Iowa|The sample was relatively small, and there was no comparison group; therefore, our results could have resulted from the placebo effect. Another limitation is the relatively short length of the trial. Furthermore, there were few minority subjects.|1|||f||||f||||||||No|We do not plan to share individual participant data.|2018-06-01 02:41:04.020291|2018-06-01 02:41:04.020291
NCT00571090|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2014-03-28|2007-12-10|2007-12-11|Estimate|||||||2014-03-28|2014-03-31|Estimate|June 2003||2003-06-30|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Observational|||Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules|Evaluation of Thyroid Fine Needle Aspiration Biopsies: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules|Completed|||735|Actual|Istanbul Science University|||1||f||||f||||||||||2018-06-01 02:41:04.236379|2018-06-01 02:41:04.236379
NCT00571077|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2008-05-12|2007-12-10|2007-12-11|Estimate|||||||2008-05-12|2008-05-13|Estimate|January 2002||2002-01-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Observational|||Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study|Electrical Impedance Scanning of Thyroid Nodules Prior to Thyroid Surgery: a Prospective Study|Completed|||200|Anticipated|Hadassah Medical Organization|||1||f||||f||||||None Retained|"~     No biospecimens are retained~   "|||2018-06-01 02:41:04.311876|2018-06-01 02:41:04.311876
NCT00571064|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2018-02-07||2018-02-07|2007-12-10|2007-12-11|Estimate|2018-02-07|2018-03-12|Actual||||2018-02-07|2018-03-12|Actual|January 2008|Actual|2008-01-31|February 2018|2018-02-28|April 22, 2009|Actual|2009-04-22|December 2008|Actual|2008-12-31||Interventional||Safety population included all enrolled participants who took at least one dose of study medication.|The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility|A 12-Week, Multicenter, Open Label Study To Evaluate The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility|Completed||Phase 4|97|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 02:41:04.414921|2018-06-01 02:41:04.414921
NCT00571051|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2009-08-13|2007-12-07|2007-12-11|Estimate|||||||2009-08-13|2009-08-17|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||MEG Study of Mindfulness Based Stress Reduction|MEG Study of Mindfulness Based Stress Reduction|Unknown status|Recruiting|N/A|40|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||||||||||||2018-06-01 02:41:04.775334|2018-06-01 02:41:04.775334
NCT00571038|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2014-10-10||2015-04-06|2007-12-10|2007-12-11|Estimate|2014-12-01|2014-12-11|Estimate||||2015-04-06|2015-04-24|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|POWER||Working With Veterans Organizations to Improve Blood Pressure|Working With Veterans Organizations to Improve Blood Pressure|Completed||N/A|404|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:41:04.870249|2018-06-01 02:41:04.870249
NCT00571025|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2009-07-22|2007-12-07|2007-12-11|Estimate|||||||2009-07-22|2009-07-23|Estimate|August 2000||2000-08-31|July 2009|2009-07-31|April 2004|Actual|2004-04-30|||||Interventional|REVEAL I||Risk Evaluation and Education for Alzheimer's Disease|Genetic Risk Assessment and Counseling for Alzheimer's Disease|Completed||N/A|301|Actual|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 02:41:05.568553|2018-06-01 02:41:05.568553
NCT00571012|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2009-11-24|2007-12-10|2007-12-11|Estimate|||||||2009-11-24|2009-11-26|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Aqueous Outflow Facility Changes With Posture|Aqueous Outflow Facility Changes With Posture|Completed|||20|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-06-01 02:41:05.642952|2018-06-01 02:41:05.642952
NCT00570999|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2012-05-09|2007-12-10|2007-12-11|Estimate|||||||2012-05-09|2012-05-10|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|||||Interventional|KGF Haplo Allo||Palifermin After Haploidentical PBSCT|Randomised Placebo-Controlled Double-Blind Phase II Study Applying Palifermin to Improve T-cell Immune Reconstitution After Haploidentical Allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation|Withdrawn||Phase 2|0|Actual|European Group for Blood and Marrow Transplantation||2|||f||||t||||||||||2018-06-01 02:41:05.6928|2018-06-01 02:41:05.6928
NCT00570986|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07||2011-08-18|2013-02-06|2007-12-10|2007-12-11|Estimate||||2011-08-18|2011-08-23|Estimate|2013-02-06|2013-02-08|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|1465|Actual|AbbVie||3|||f||||t||||||||||2018-06-01 02:41:05.786267|2018-06-01 02:41:05.786267
NCT00570973|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-05-20|2007-12-10|2007-12-11|Estimate|||||||2011-05-20|2011-05-23|Estimate|November 2004||2004-11-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ENDOvsTIPS||Band Ligation Versus Transjugular Intrahepatic Portosystemic Stent Shunt (TIPS) in Cirrhotics With Recurrent Variceal Bleeding Non Responding to Medical Therapy|A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy|Completed||Phase 4|40|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 02:41:06.075582|2018-06-01 02:41:06.075582
NCT00570960|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2013-01-14||2014-12-01|2007-12-10|2007-12-11|Estimate|2014-12-01|2014-12-03|Estimate||||2014-12-01|2014-12-03|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis|Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis|Terminated||Phase 4|8|Actual|University of Virginia|The study was terminated early because the manufacturer of Dextran 70 ceased all production of the study drug approximately 10 months into the study. It was felt by the principle investigator that continuation of the study was impossible.|2||drug product became unavilable|f||||t||||||||||2018-06-01 02:41:06.183084|2018-06-01 02:41:06.183084
NCT00570947|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2012-04-25|2007-12-10|2007-12-11|Estimate|||||||2012-04-25|2012-04-26|Estimate|December 2007||2007-12-31|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||CPR Prescription Program|CPR Prescription Program|Completed||N/A|162|Actual|Lehigh Valley Hospital||1|||f||||t||||||||||2018-06-01 02:41:06.451465|2018-06-01 02:41:06.451465
NCT00570934|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2016-10-07|2007-12-10|2007-12-11|Estimate|||||||2016-10-07|2016-10-10|Estimate|March 1995||1995-03-31|October 2016|2016-10-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA|Effect of Supplementation With 2000 International Units (IU) Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis|Completed||Phase 3|24|Actual|University of Missouri-Columbia||4|||f||||f||||||||No||2018-06-01 02:41:06.530441|2018-06-01 02:41:06.530441
NCT00570921|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2014-12-18||2017-01-08|2007-12-07|2007-12-11|Estimate|2014-12-18|2014-12-31|Estimate||||2017-01-08|2017-02-23|Actual|April 2008||2008-04-30|January 2017|2017-01-31|January 2015|Actual|2015-01-31|February 2013|Actual|2013-02-28||Interventional|BRE-43|2 were not evaluable as described in participant flow and not included in demographic table.|Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure|A Phase II Study of Combined Fulvestrant (Faslodex) and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure|Completed||Phase 2|33|Actual|University of Kentucky|Potential toxicities of mammalian target of rapamycin (mTOR) inhibitors and our observation that a third of patients had no benefit from this strategy, we need to identify biomarkers that correlate with treatment benefit for better patient selection.|1|||f||||t||||||||||2018-06-01 02:41:06.643616|2018-06-01 02:41:06.643616
NCT00570908|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2014-07-22||2014-09-08|2007-12-10|2007-12-11|Estimate|2014-07-22|2014-08-12|Estimate||||2014-09-08|2014-09-18|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||12 patients were enrolled and started treatment|Brain Mets - Capecitabine Plus Sunitinib and WBRT|A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer|Terminated||Phase 2|12|Actual|Baylor Breast Care Center||1||Due to poor accrual this study is being closed to accrual|f||||t||||||||||2018-06-01 02:41:06.964638|2018-06-01 02:41:06.964638
NCT00570895|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2008-06-03|2007-12-07|2007-12-11|Estimate|||||||2008-06-03|2008-06-05|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Effect of Vitamin C on Iron Absorption|Effect of Ascorbic Acid on Iron Absorption From Ferrous Fumarate|Completed||N/A|22|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 02:41:07.171152|2018-06-01 02:41:07.171152
NCT00570882|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2014-09-22|2007-12-10|2007-12-11|Estimate|||||||2014-09-22|2014-09-25|Estimate|October 2007||2007-10-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)|A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma|Completed||Phase 2|76|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 02:41:07.244568|2018-06-01 02:41:07.244568
NCT00570869|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2012-04-25|2007-12-10|2007-12-11|Estimate|||||||2012-04-25|2012-04-26|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Training Mothers of Infants in Infant Cardiopulmonary Resuscitation (CPR)|Training Mothers of Infants in Infant Cardiopulmonary Resuscitation (CPR) Using a 22-Minute Instructional DVD and Infant Manikin|Completed||N/A|126|Actual|Lehigh Valley Hospital||1|||f||||t||||||||||2018-06-01 02:41:07.324442|2018-06-01 02:41:07.324442
NCT00570856|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2007-12-14|2007-12-10|2007-12-11|Estimate|||||||2007-12-14|2007-12-19|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|||Trial of Folic Acid Effect on Hcy and cIMT After Kidney Tx|Clinical Trial of Effectiveness of Folic Acid Therapy on Homocysteine Level and Carotid Intima-Media Thickness After Kidney Transplantation|Terminated||Phase 4|60|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:41:07.388672|2018-06-01 02:41:07.388672
NCT00570843|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2010-02-19|2007-12-10|2007-12-11|Estimate|||||||2010-02-19|2010-02-22|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses|Phase 4 Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses|Completed||Phase 4|50|Anticipated|Bp Consulting, Inc||2|||f||||||||||||||2018-06-01 02:41:07.551303|2018-06-01 02:41:07.551303
NCT00570830|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2014-08-29|2007-12-10|2007-12-11|Estimate|||||||2014-08-29|2014-09-03|Estimate|September 2006||2006-09-30|August 2008|2008-08-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional|||Retisert and Cataract Surgery in Patients With Severe Uveitis|Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients With Severe Uveitis|Completed||N/A|21|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:41:07.618175|2018-06-01 02:41:07.618175
NCT00570817|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-11-04|2007-12-10|2007-12-11|Estimate|||||||2011-11-04|2011-11-07|Estimate|June 2007||2007-06-30|January 2011|2011-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Prevention of Methotrexate Induced Nephrotoxicity and Prolonged Drug Elimination Time With 12 Hours Prehydration|Nephrotoxicity Induced by High-Dose Methotrexate Infusions to Children With Malignant Diseases|Completed||N/A|47|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 02:41:07.696841|2018-06-01 02:41:07.696841
NCT00570804|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2018-01-08|2007-12-07|2007-12-11|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2007|Actual|2007-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Combined Treatment for Tobacco and Alcohol Use in Puerto Rico|Oral Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use|Active, not recruiting||N/A|370|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:41:07.774625|2018-06-01 02:41:07.774625
NCT00570791|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2016-05-10|2007-12-10|2007-12-11|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2004||2004-02-29|May 2016|2016-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|CCT||Effect of Central Corneal Thickness On IOP Using Various Tonometers|The Effect of Central Corneal Thickness On Intraocular Pressure Measurements With the Goldman Applanation Tonometer, Ocular Blood Flow Pneumatonometer,Tono Pen,Pascal Dynamic Contour Tonometer, and Schiotz Tonometer|Completed|||166|Actual|University of Nebraska|||2||f||||f||||||||||2018-06-01 02:41:07.862389|2018-06-01 02:41:07.862389
NCT00570778|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2012-10-23|2012-05-08|2013-01-23|2007-12-10|2007-12-11|Estimate|2013-01-23|2013-02-28|Estimate|2012-05-08|2012-05-10|Estimate|2013-01-23|2013-02-28|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo Controlled, Multicentre Study to Determine the Effect of QVA149 on Lung Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|154|Actual|Novartis||4|||f||||||||||||||2018-06-01 02:41:07.950582|2018-06-01 02:41:07.950582
NCT00570752|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10||2012-03-24|2015-11-06|2007-12-10|2007-12-11|Estimate||||2015-09-23|2015-10-12|Estimate|2015-11-06|2015-12-07|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis|A 12-Week, Randomized, Semi Double-Blinded Study Evaluating the Effects of Daily Oral High-Dose Atorvastatin or BMS-582949 on Atherosclerotic Plaque Inflammation as Determined by FDG-PET in High Risk Atherosclerotic Patients|Completed||Phase 2|72|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 02:41:08.693946|2018-06-01 02:41:08.693946
NCT00570739|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2010-04-06||2010-07-19|2007-12-10|2007-12-11|Estimate|2010-07-12|2010-07-13|Estimate||||2010-07-19|2010-07-27|Estimate|November 2007||2007-11-30|July 2010|2010-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.|Effects of Metformin HCl in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, as Initial Therapy in Drug naïve Subjects With Type 2 Diabetes Mellitus, and the Effects of Colesevelam HCl on the Lipid Profile in Subjects With Pre Diabetes|Completed||Phase 3|502|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-06-01 02:41:10.079621|2018-06-01 02:41:10.079621
NCT00570726|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-09|||2014-10-14|2007-12-09|2007-12-11|Estimate|||||||2014-10-14|2014-10-15|Estimate|June 2000||2000-06-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Treatment of Failing Blebs With Ranibizumab|Effect of Needle Bleb Revision With Ranibizumab as a Primary Intervention in a Failing Bleb Following Trabeculectomy|Completed||Phase 1|6|Anticipated|The New York Eye & Ear Infirmary|||||f||||f||||||||||2018-06-01 02:41:13.893438|2018-06-01 02:41:13.893438
NCT00570713|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2011-12-08||2015-09-04|2007-12-07|2007-12-11|Estimate|2012-02-27|2012-03-27|Estimate||||2015-09-04|2015-09-09|Estimate|December 2007||2007-12-31|September 2015|2015-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer|A Phase 2 Randomized, Placebo-controlled, Double-blind Study of the Efficacy of MORAb-009 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.|Completed||Phase 2|155|Actual|Morphotek||2|||f||||t||||||||||2018-06-01 02:41:14.001321|2018-06-01 02:41:14.001321
NCT00570700|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2017-07-27||2018-05-24|2007-12-07|2007-12-11|Estimate|2018-05-24|2018-05-25|Actual||||2018-05-24|2018-05-25|Actual|July 2007||2007-07-31|May 2018|2018-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer|BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy|Completed||Phase 2|38|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 02:41:14.808795|2018-06-01 02:41:14.808795
NCT00570687|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2014-07-22|2009-06-09|2014-10-09|2007-12-10|2007-12-11|Estimate|2014-10-09|2014-10-16|Estimate|2009-10-23|2009-10-27|Estimate|2014-10-09|2014-10-16|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes||Completed||Phase 2|30|Actual|Mannkind Corporation||1|||f||||||||||||||2018-06-01 02:41:15.051714|2018-06-01 02:41:15.051714
NCT00570674|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2016-10-18||2017-10-10|2007-12-10|2007-12-11|Estimate|2016-10-18|2016-12-12|Estimate||||2017-10-10|2017-11-13|Actual|November 2007||2007-11-30|October 2017|2017-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||The analysis dataset is comprised of all treated patients.|Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck|A Phase I/II Trial of Abraxane in Combination With Carboplatin, Erbitux and Intensity Modulated Radiation Therapy (IMRT)for Treatment of Locally Advanced Squamous Cancer of the Head and Neck|Terminated||Phase 1/Phase 2|29|Actual|Dana-Farber Cancer Institute|The phase II portion planned to enroll 34 participants including the expansion cohort but the study did not continue beyond phase I given the importance of HPV status as a prognostic factor to guide treatment decisions.|5||"The study did not continue to phase II due to the importance of HPV status as a prognostic~   factor to guide treatment decisions."|f||||t||||||||No|No plans to share individual participant data. However, cumulative results will be posted here and also published.|2018-06-01 02:41:15.622263|2018-06-01 02:41:15.622263
NCT00570661|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2013-05-23|2007-12-10|2007-12-11|Estimate|||||||2013-05-23|2013-05-24|Estimate|August 2006||2006-08-31|January 2012|2012-01-31|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|SOJIA||Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)|Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)|Completed||Phase 2|17|Actual|Italfarmaco||1|||f||||f||||||||||2018-06-01 02:41:16.117083|2018-06-01 02:41:16.117083
NCT00570648|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2008-08-06|2007-12-07|2007-12-11|Estimate|||||||2008-08-06|2008-08-07|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|June 2008|Actual|2008-06-30|||||Interventional|||A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization|A Prospective Study of the Effect of Topical Sodium Hyaluronate Immediately Post-PKP on Time to Reepithelialization|Completed||N/A|50|Anticipated|University of Virginia||2|||f||||f||||||||||2018-06-01 02:41:16.192632|2018-06-01 02:41:16.192632
NCT00570635|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07||2013-05-30|2013-05-30|2007-12-07|2007-12-11|Estimate||||2013-05-30|2013-06-07|Estimate|2013-05-30|2013-06-07|Estimate|December 2007||2007-12-31|May 2013|2013-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib|A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib|Completed||Phase 2|16|Actual|Exelixis||2|||f||||t||||||||||2018-06-01 02:41:16.282431|2018-06-01 02:41:16.282431
NCT00570622|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2008-11-24|2007-12-10|2007-12-11|Estimate|||||||2008-11-24|2008-11-25|Estimate|December 2004||2004-12-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis|Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis|Completed||Phase 4|20|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 02:41:16.344198|2018-06-01 02:41:16.344198
NCT00570609|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2012-04-25|2007-12-10|2007-12-11|Estimate|||||||2012-04-25|2012-04-26|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||CPR Training in 7th Grade Students|CPR Training in 7th Grade Students|Completed||N/A|8|Actual|Lehigh Valley Hospital||1|||f||||t||||||||||2018-06-01 02:41:16.412691|2018-06-01 02:41:16.412691
NCT00514826|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2010-05-25|2007-08-09|2007-08-10|Estimate|||||||2010-05-25|2010-05-26|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study to Investigate Sleep Apnea Patients at Altitude|Study to Investigate Sleep Apnea Patients at Altitude|Completed||N/A|40|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 03:00:28.495641|2018-06-01 03:00:28.495641
NCT00570583|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2018-04-20|2007-12-07|2007-12-11|Estimate|||||||2018-04-20|2018-04-23|Actual|December 1995||1995-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|NCODE||Neurocognitive Outcomes of Depression in the Elderly|Clinical Studies of Mental Illness Not Involving Treatment Development, Efficacy, or Effectiveness Trials Phenotype-genotype Predictors of Cognitive Outcomes in Geriatric Depression|Active, not recruiting|||795|Anticipated|Duke University|||2||f||||f||||||Samples With DNA|"~     serum, white cells~   "|||2018-06-01 02:41:16.482614|2018-06-01 02:41:16.482614
NCT00570570|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2015-08-19|2007-12-10|2007-12-11|Estimate|||||||2015-08-19|2015-08-20|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|RenforcHémi||Muscular Strengthening for Paretic Knee Flexor and Extensor by Conventional Physiotherapy on Chronic Hemiplegic Stroke Patients|Muscular Strengthening for Paretic Knee Flexor and Extensor by Conventional Physiotherapy on Chronic Hemiplegic Stroke Patients|Completed||N/A|91|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 02:41:16.562755|2018-06-01 02:41:16.562755
NCT00570557|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2012-01-09|2007-12-10|2007-12-11|Estimate|||||||2012-01-09|2012-01-11|Estimate|September 2007||2007-09-30|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Development of a Web-Based Course to Maintain Skills in Nurses Trained to Screen for Dysphagia|Development of a Web-Based Course to Maintain Skills in Nurses Trained to Screen for Dysphagia|Completed||N/A|96|Actual|University Health Network, Toronto||2|||f||||||||||||||2018-06-01 02:41:16.651688|2018-06-01 02:41:16.651688
NCT00570544|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2008-08-13|2007-12-10|2007-12-11|Estimate|||||||2008-08-13|2008-08-14|Estimate|August 2004||2004-08-31|December 2007|2007-12-31|August 2005|Actual|2005-08-31|||||Observational|||Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema|Effectiveness of Tiotropium to Maintain Inspiratory Capacity Against Metronome Paced Hyperventilation Induced Dynamic Hyperinflation in COPD Patients With Lung CT Scored Emphysema|Completed|||29|Actual|Gelb, Arthur F., M.D.|||1||f||||t||||||||||2018-06-01 02:41:16.727541|2018-06-01 02:41:16.727541
NCT00570531|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2015-01-05||2016-04-19|2007-12-10|2007-12-11|Estimate|2015-01-05|2015-01-12|Estimate||||2016-04-19|2016-05-26|Estimate|June 2007||2007-06-30|April 2016|2016-04-30|June 2013|Actual|2013-06-30|October 2010|Actual|2010-10-31||Interventional|||Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma|Phase II Trial of Pre-Operative Chemoradiation Plus Bevacizumab, Followed by Surgery, and Post-Operative Adjuvant Bevacizumab for Patients With Loco-Regional Esophageal Carcinoma|Terminated||Phase 2|6|Actual|University of Michigan Cancer Center|The study was unable the accrue the required number of patients within a reasonable time and therefore the primary objective was not analyzed.|1||The study was unable the accrue the required number of patients within a reasonable time.|f||||t||||||||||2018-06-01 02:41:16.807685|2018-06-01 02:41:16.807685
NCT00570518|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-09-30|2007-12-10|2007-12-11|Estimate|||||||2011-09-30|2011-10-03|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|October 2011|Anticipated|2011-10-31|||||Observational|||Alcohol and Other Psychoactive Substances in Road Traffic - a Case-control Study|DRUID Work Package 2 - Epidemiology|Unknown status|Recruiting||4500|Anticipated|National Institute for Health and Welfare, Finland|||2||f||||f||||||Samples With DNA|"~     Whole blood and oral fluid are collected for the study. However, no DNA determinations are~     done at any point of the study. The laboratory where the samples are analysed does not~     analyse DNA. DNA is not relevant for this study.~   "|||2018-06-01 02:41:17.118652|2018-06-01 02:41:17.118652
NCT00570505|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|2012-07-23||2015-03-12|2007-12-10|2007-12-11|Estimate|2012-11-02|2012-12-03|Estimate||||2015-03-12|2015-03-17|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|November 2013|Actual|2013-11-30|October 2009|Actual|2009-10-31||Interventional|||Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2||Completed||N/A|151|Actual|Apollo Endosurgery, Inc.||1|||f||||t||||||||||2018-06-01 02:41:17.217952|2018-06-01 02:41:17.217952
NCT00570492|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2011-11-03||2017-08-17|2007-12-10|2007-12-11|Estimate|2012-01-05|2012-02-07|Estimate||||2017-08-17|2017-09-15|Actual|November 26, 2007||2007-11-26|August 2017|2017-08-31|March 17, 2011|Actual|2011-03-17|March 1, 2011|Actual|2011-03-01||Interventional|||Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent, Pediatric Subjects With Perennial Allergic Rhinitis|Completed||Phase 4|474|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:41:17.679422|2018-06-01 02:41:17.679422
NCT00570479|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-09|||2012-06-03|2007-12-10|2007-12-11|Estimate|||||||2012-06-03|2012-06-05|Estimate|September 2006||2006-09-30|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Prophylactic Anecortave Acetate in Patients With a Retisert Implant|Prevention of Steroid-induced Glaucoma Using Anecortave Acetate|Completed||Phase 1|12|Actual|Texas Retina Associates||4|||f||||f||||||||||2018-06-01 02:41:19.37366|2018-06-01 02:41:19.37366
NCT00570466|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2017-09-25|2007-12-07|2007-12-11|Estimate|||||||2017-09-25|2017-09-27|Actual|January 2008||2008-01-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|May 2009|Actual|2009-05-31||Interventional|||Computer Based Intervention for Type 2 Diabetes in Youth|Computer Based Intervention for Type 2 Diabetes in Youth: Phase 2|Completed||N/A|153|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 02:41:19.476257|2018-06-01 02:41:19.476257
NCT00570440|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2011-10-28|2007-12-10|2007-12-11|Estimate|||||||2011-10-28|2011-10-31|Estimate|August 2007||2007-08-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Continuous Use of COCs|Continuous Versus Cyclic Use of Combined Oral Contraceptive Pills|Completed||Phase 4|362|Anticipated|FHI 360||2|||f||||||||||||||2018-06-01 02:41:19.552316|2018-06-01 02:41:19.552316
NCT00570427|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2009-02-24|2007-12-07|2007-12-11|Estimate|||||||2009-02-24|2009-02-25|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Improving Depression Treatment for Older Minority Adults|Improving Depression Treatment for Older Minority Adults|Completed||N/A|30|Anticipated|National Institute on Aging (NIA)||1|||f||||t||||||||||2018-06-01 02:41:19.636676|2018-06-01 02:41:19.636676
NCT00570414|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-10|||2009-01-14|2007-12-10|2007-12-11|Estimate|||||||2009-01-14|2009-01-15|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Airway Management in Children Undergoing Adenotonsillectomies|Airway Management in Children Undergoing Adenotonsillectomies Under General Anesthesia; a Comparison of the Endotracheal Tube and the Laryngeal Mask Airway|Completed||N/A|128|Anticipated|Sykehuset Telemark||2|||f||||t||||||||||2018-06-01 02:41:19.717958|2018-06-01 02:41:19.717958
NCT00569491|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2008-09-24|2007-12-06|2007-12-07|Estimate|||||||2008-09-24|2008-09-25|Estimate|February 2004||2004-02-29|September 2008|2008-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|ARRIVE||TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program|TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program|Completed||Phase 4|2585|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 02:41:33.055223|2018-06-01 02:41:33.055223
NCT00570401|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2015-12-16||2015-12-16|2007-12-07|2007-12-10|Estimate|2015-12-16|2016-01-22|Estimate||||2015-12-16|2016-01-22|Estimate|June 2006||2006-06-30|December 2015|2015-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib|A Phase 2 Trial of Dasatinib in Patients With Lung Adenocarcinoma With Acquired Resistance to Erlotinib or Gefitinib|Completed||Phase 2|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:41:19.790377|2018-06-01 02:41:19.790377
NCT00570388|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2008-01-15|2007-12-07|2007-12-10|Estimate|||||||2008-01-15|2008-01-16|Estimate|March 2007||2007-03-31|January 2008|2008-01-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence|Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence|Unknown status|Recruiting|N/A|120|Anticipated|Institute of Addiction Medicine||2|||f||||f||||||||||2018-06-01 02:41:19.930135|2018-06-01 02:41:19.930135
NCT00570375|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2009-04-16|2007-12-07|2007-12-10|Estimate|||||||2009-04-16|2009-04-17|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|November 2012|Anticipated|2012-11-30|November 2009|Anticipated|2009-11-30||Interventional|||The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome|Phase II of Erlotinib an Epidermal Growth Factor Receptor Inhibitor in the Treatment of Myelodysplastic Syndrome|Withdrawn||Phase 2|35|Anticipated|University of Cincinnati||1||"Rami Komrokji, MD author of this protocol no longer is at the University of Cincinnati and this~   study has been withdrawn."|f||||f||||||||||2018-06-01 02:41:20.020178|2018-06-01 02:41:20.020178
NCT00570362|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2010-06-11||2010-07-14|2007-12-07|2007-12-10|Estimate|2010-07-14|2010-08-10|Estimate||||2010-07-14|2010-08-10|Estimate|March 2008||2008-03-31|December 2007|2007-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Systemic Glutathione Level in Normal Tension Glaucoma|Evaluation of Systemic Glutathione Level in Patients With Normal Tension Glaucoma|Completed|||49|Actual|The Catholic University of Korea|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:41:20.085824|2018-06-01 02:41:20.085824
NCT00570349|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2010-10-01||2016-05-12|2007-12-06|2007-12-10|Estimate|2010-11-30|2010-12-01|Estimate||||2016-05-12|2016-06-16|Estimate|July 2004||2004-07-31|May 2016|2016-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis|Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis|Completed||Phase 1/Phase 2|18|Actual|Mallinckrodt||3|||f||||t||||||||||2018-06-01 02:41:20.355154|2018-06-01 02:41:20.355154
NCT00570336|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06||2010-08-31|2010-09-14|2007-12-06|2007-12-10|Estimate||||2010-09-09|2010-09-13|Estimate|2010-09-14|2010-09-16|Estimate|December 2007||2007-12-31|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study of CTS-1027 in Hepatitis C Patients|A Dose Response Study of CTS-1027 in Hepatitis C Patients|Completed||Phase 2|87|Actual|Conatus Pharmaceuticals Inc.||5|||f||||t||||||||||2018-06-01 02:41:20.63594|2018-06-01 02:41:20.63594
NCT00570323|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06||2017-05-10|2017-10-24|2007-12-07|2007-12-10|Estimate||||2017-08-08|2017-08-11|Actual|2017-10-24|2017-10-26|Actual|December 2007|Actual|2007-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Interventional|PACT001||Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer|A Phase II Trial of Neoadjuvant Arimidex With or Without Faslodex in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|Active, not recruiting||Phase 2|72|Actual|Baylor Breast Care Center||2|||f||||t||||||||No||2018-06-01 02:41:20.738114|2018-06-01 02:41:20.738114
NCT00570310|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2010-01-13||2015-04-20|2007-12-07|2007-12-10|Estimate|2010-01-13|2010-02-05|Estimate||||2015-04-20|2015-05-07|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Neuropathic Pain Syndrome Patient Study (MK-0000-072)|A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug|Completed||Phase 1|104|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:41:20.819353|2018-06-01 02:41:20.819353
NCT00570297|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2017-01-31|2007-12-07|2007-12-10|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2007||2007-12-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Genetic Influences of Albuterol Response In Children With Bronchiolitis|Genetic Influences of Albuterol Response In Children With Bronchiolitis|Active, not recruiting|||55|Anticipated|Connecticut Children's Medical Center|||||f||||f|f|f||||||No||2018-06-01 02:41:21.199995|2018-06-01 02:41:21.199995
NCT00570284|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2016-08-17|2007-12-07|2007-12-10|Estimate|||||||2016-08-17|2016-08-18|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors|A Phase Ib Open-label, Multicenter Cross-over Study to Investigate the Effect of Food on the Rate and Extent of Oral LBH589 Absorption in Patients With Advanced Solid Tumors|Completed||Phase 1|36|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:41:21.264991|2018-06-01 02:41:21.264991
NCT00570271|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-07|2007-12-07|2007-12-10|Estimate|||||||2007-12-07|2007-12-10|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|February 2008|Anticipated|2008-02-29|||||Interventional|||Placebo Effects on Blood Pressure|Physiological Effects of Placebo Interventions to Increase or Decrease Blood Pressure|Unknown status|Recruiting|N/A|90|Anticipated|Charite University, Berlin, Germany||6|||f||||f||||||||||2018-06-01 02:41:21.338395|2018-06-01 02:41:21.338395
NCT00570258|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2018-01-04|2007-12-07|2007-12-10|Estimate|||||||2018-01-04|2018-01-05|Actual|September 2006||2006-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy|Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy|Active, not recruiting||Phase 2|130|Anticipated|University of Arkansas||2|||f||||f|t|f|||t|||||2018-06-01 02:41:21.415622|2018-06-01 02:41:21.415622
NCT00570245|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2016-10-18|2007-12-06|2007-12-10|Estimate|||||||2016-10-18|2016-10-19|Estimate|April 2005||2005-04-30|October 2016|2016-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy Study of Nitric Oxide in Patients Going Through Lung Transplantation|A Pilot, Single Center Prospective, With Parallel Groups, Controlled and Open to Evaluate the Efficacy of Nitric Oxide for Inhalation in Lung Donors and in the Prevention of Reperfusion Injury.|Completed||Phase 2|49|Actual|Mallinckrodt||3|||f||||t||||||||||2018-06-01 02:41:21.489382|2018-06-01 02:41:21.489382
NCT00182117|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-01-23|2005-09-09|2005-09-16|Estimate|||||||2006-01-23|2006-01-24|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|April 2006||2006-04-30|||||Observational|||Pilot Bleeding Study: Risk and Protective Factors Associated With Bleeding in the Hemodialysis Population|Pilot Bleeding Study|Unknown status|Recruiting||490||McMaster University|||||f||||||||||||||2018-06-01 04:36:31.310663|2018-06-01 04:36:31.310663
NCT00570232|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2015-03-24||2015-05-04|2007-12-07|2007-12-10|Estimate|2015-05-04|2015-05-21|Estimate||||2015-05-04|2015-05-21|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|UAB0718||UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer|Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer|Completed||Phase 2|31|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 02:41:21.563938|2018-06-01 02:41:21.563938
NCT00570219|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2008-10-16|2007-12-07|2007-12-10|Estimate|||||||2008-10-16|2008-10-17|Estimate|February 2005||2005-02-28|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Valproate on Benzodiazepine Withdrawal Severity|The Effect of Valproate Treatment on Withdrawal Severity in Benzodiazepine Dependent Opioid Maintenance Treatment Patients|Completed||N/A|30|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:41:21.862657|2018-06-01 02:41:21.862657
NCT00570206|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2009-12-21|2007-12-07|2007-12-10|Estimate|||||||2009-12-21|2009-12-23|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Interventional|ENCORE||An Evaluation of Motivational Interviewing to Increase Compliance in a Probation Setting|An Evaluation of Motivational Interviewing to Increase Compliance in a Probation Setting (Enhancing Communication and Officer Responsivity; ENCORE)|Completed||N/A|300|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||||||||||||2018-06-01 02:41:21.931403|2018-06-01 02:41:21.931403
NCT00570193|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2012-07-06|2007-12-07|2007-12-10|Estimate|||||||2012-07-06|2012-07-10|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PBS||Photodynamic and Pharmacologic Treatment of CNV|Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)|Completed||Phase 1/Phase 2|41|Actual|Mid-Atlantic Retina Consultations, Inc.||2|||f||||||||||||||2018-06-01 02:41:21.999759|2018-06-01 02:41:21.999759
NCT00570180|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2016-12-01|2007-12-07|2007-12-10|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma|An Open-label Phase II Study of the Efficacy of Combination Bortezomib-containing Regimens in the Treatment of Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma|Completed||Phase 2|36|Actual|University Health Network, Toronto||1|||f||||t||||||||Yes|Un-identified data will be submitted to the DSMB for review. Sites will be provided with the DSMB letter after a meeting has been held to review data.|2018-06-01 02:41:22.102498|2018-06-01 02:41:22.102498
NCT00570167|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-08-03|2007-12-07|2007-12-10|Estimate|||||||2009-08-03|2009-08-06|Estimate|November 2006||2006-11-30|August 2009|2009-08-31||||||||Interventional|||Comparison of Hip Resurfacing and Cementless Metal-on-metal Total Hip Arthroplasty|Comparison of Hip Resurfacing and Cementless Metal-on-metal Total Hip Arthroplasty - Prospective Randomized Clinival Trial|Completed||Phase 4|71|Anticipated|Helsinki University||2|||f||||f||||||||||2018-06-01 02:41:22.189309|2018-06-01 02:41:22.189309
NCT00570154|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2017-06-30|2007-12-07|2007-12-10|Estimate|||||||2017-06-30|2017-07-02|Actual|November 27, 2007||2007-11-27|October 19, 2009|2009-10-19||||October 19, 2009|Actual|2009-10-19||Observational|||Relation of White Blood Cell Function to Diabetes|Pilot Study of Monocyte Biology in Insulin Sensitive, Resistant and Diabetic Subjects|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:41:22.268201|2018-06-01 02:41:22.268201
NCT00570141|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2010-06-09||2011-06-07|2007-12-07|2007-12-10|Estimate|2010-07-14|2010-08-09|Estimate||||2011-06-07|2011-06-09|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||OASIS Wound Matrix (Oasis) Mechanism of Action|Case Study Documentation of Subjects With Either Diabetic Foot Ulcers or Venous Stasis Ulcers Being Treated With OASIS|Completed||Phase 4|13|Actual|Healthpoint||1|||f||||f||||||||||2018-06-01 02:41:22.33728|2018-06-01 02:41:22.33728
NCT00570128|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2009-08-04|2007-12-07|2007-12-10|Estimate|||||||2009-08-04|2009-08-06|Estimate|December 2007||2007-12-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome|A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome|Completed||Phase 2|150|Anticipated|Eisai Inc.||2|||f||||||||||||||2018-06-01 02:41:22.492851|2018-06-01 02:41:22.492851
NCT00570115|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2012-05-07|2007-12-07|2007-12-10|Estimate|||||||2012-05-07|2012-05-08|Estimate|June 2007||2007-06-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Observational|||Left Atrial Volume and Function Evaluation in Patients With Obstructive Sleep Apnea|Left Atrial Volume and Function in Patients With Obstructive Sleep Apnea Assessed by Real Time Three Dimensional Echocardiography|Completed|||106|Actual|Associação Fundo de Incentivo à Pesquisa|||1||f||||f||||||||||2018-06-01 02:41:22.600248|2018-06-01 02:41:22.600248
NCT00570102|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2012-11-27|2007-12-07|2007-12-10|Estimate|||||||2012-11-27|2012-11-28|Estimate|February 1995||1995-02-28|November 2012|2012-11-30|January 2008|Actual|2008-01-31|March 2004|Actual|2004-03-31||Interventional|MIP||Nutritional Prevention Pilot Trial for Type 1 Diabetes|Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study|Completed||Phase 2|230|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:41:22.666624|2018-06-01 02:41:22.666624
NCT00570089|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2011-07-19||2017-09-21|2007-12-07|2007-12-10|Estimate|2015-10-29|2015-12-03|Estimate||||2017-09-21|2017-10-23|Actual|April 2007||2007-04-30|September 2017|2017-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Microvascular Coronary Disease In Women: Impact Of Ranolazine|Microvascular Coronary Disease In Women: Impact Of Ranolazine|Completed||Phase 2|20|Actual|Cedars-Sinai Medical Center|This was a pilot study.|2|||f||||t||||||||Yes||2018-06-01 02:41:22.759178|2018-06-01 02:41:22.759178
NCT00570063|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2017-11-20|2009-03-20|2017-11-20|2007-12-07|2007-12-10|Estimate|2017-11-20|2017-12-20|Actual|2009-09-25|2009-09-30|Estimate|2017-11-20|2017-12-20|Actual|November 2007|Actual|2007-11-30|November 2017|2017-11-30|February 18, 2008|Actual|2008-02-18|February 18, 2008|Actual|2008-02-18||Interventional||The full analysis set (FAS) included all participants who were randomized to a treatment sequence and received at least 1 dose of study medication.|Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo|A Phase 2, Multicenter, Double-blind, Randomized, Fixed Dose, Parallel Group, 3-week Inpatient Treatment Study To Evaluate The Safety, Efficacy And Pharmacokinetics Of Pf-02545920 Compared With Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia|Terminated||Phase 2|35|Actual|Pfizer|Due to early termination of the study, PK parameters were not analyzed.|2|||f||||f||||||||||2018-06-01 02:41:23.099871|2018-06-01 02:41:23.099871
NCT00512577|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2007-08-13|2007-08-06|2007-08-07|Estimate|||||||2007-08-13|2007-08-14|Estimate|July 2007||2007-07-31|August 2007|2007-08-31||||||||Interventional|TAPS||Transfusion Alternatives Pre-Operatively in Sickle Cell Disease (TAPS)|Transfusion Alternatives Pre-Operatively in Sickle Cell Disease|Unknown status|Recruiting|Phase 3|400|Anticipated|NHS Blood and Transplant||2|||f||||t||||||||||2018-06-01 03:01:05.087632|2018-06-01 03:01:05.087632
NCT00570050|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2015-02-20|2007-12-07|2007-12-10|Estimate|||||||2015-02-20|2015-02-24|Estimate|June 2013||2013-06-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder|A Randomized, Double-blind, Placebo-controlled Cross-over Trial Evaluating the Effect of Intranasal Insulin on Depressive Symptoms in Individuals With Major Depressive Disorder Insufficiently Responsive to Antidepressant Therapy|Completed||Phase 3|35|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:41:24.233207|2018-06-01 02:41:24.233207
NCT00570037|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2010-10-06||2013-06-17|2007-12-07|2007-12-10|Estimate|2011-01-09|2011-02-01|Estimate||||2013-06-17|2013-06-24|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|Piiitch||Feasibility of Cocooning Immunization Strategy With Influenza Vaccine|Prevention of Influenza in Infants by Immunization of Their Contacts in the Household|Completed||N/A|544|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:41:24.32006|2018-06-01 02:41:24.32006
NCT00570024|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2017-11-17|2007-12-07|2007-12-10|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2006||2006-01-31|November 2017|2017-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effects of Traditional Acupuncture on Mechanisms of Coronary Heart Disease|The Effects of Traditional Acupuncture on Mechanisms of Coronary Heart Disease|Completed||N/A|145|Actual|Cedars-Sinai Medical Center||3|||f||||t||||||||||2018-06-01 02:41:24.531198|2018-06-01 02:41:24.531198
NCT00570011|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2007-12-10|2007-12-07|2007-12-10|Estimate|||||||2007-12-10|2007-12-11|Estimate|June 1997||1997-06-30|December 2007|2007-12-31|December 1998|Actual|1998-12-31|||||Interventional|||Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients|Efficacy of Two Different Dose Regimens of Somatropin in Growth Hormone Deficient Adult Patients|Completed||Phase 3|112|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:41:24.610238|2018-06-01 02:41:24.610238
NCT00569998|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-01-18|2007-12-07|2007-12-10|Estimate|||||||2017-01-18|2017-01-19|Estimate|August 2003||2003-08-31|January 2017|2017-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin|An Open-label, Multi-centre, Multi-national, Comparative, Randomised, Cross-over Trial Evaluating Preference as Well as Performance, Acceptance, Handling and Safety of NovoPen™ 4 (MS236) Versus NovoPen 3® in Insulin Treated Diabetic Patients|Completed||Phase 3|208|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:41:24.67996|2018-06-01 02:41:24.67996
NCT00569985|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2018-02-16|2007-12-07|2007-12-10|Estimate|||||||2018-02-16|2018-02-19|Actual|June 2007||2007-06-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma|A Pilot Study of Safety and Feasibility of Stem Cell Therapy for Aids Lymphoma Using Stem Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs|Active, not recruiting||Phase 1|10|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:41:24.758076|2018-06-01 02:41:24.758076
NCT00569972|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06||2009-12-10|2012-07-17|2007-12-06|2007-12-10|Estimate||||2009-12-10|2009-12-14|Estimate|2012-07-17|2012-07-25|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia|PD 0200390 Dose Ranging Trial: A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia|Completed||Phase 2|682|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 02:41:24.912366|2018-06-01 02:41:24.912366
NCT00569959|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2015-11-25|2007-12-07|2007-12-10|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2006||2006-11-30|December 2008|2008-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients|Assessment of Non-Fasting vs. Fasting Lipid Measures in Diabetes Patients|Completed||N/A|50|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-06-01 02:41:25.126784|2018-06-01 02:41:25.126784
NCT00569946|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2012-02-25||2014-07-16|2007-12-07|2007-12-10|Estimate|2012-02-25|2012-03-27|Estimate||||2014-07-16|2014-07-25|Estimate|December 2007||2007-12-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|February 2010|Actual|2010-02-28||Interventional|||Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)|Phase 2 Study Of AG-013736 As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer|Completed||Phase 2|64|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:41:25.231282|2018-06-01 02:41:25.231282
NCT00569933|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2015-05-21|2007-12-07|2007-12-10|Estimate|||||||2015-05-21|2015-05-22|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Audio Recording for Improved Surgical Outcome (ARISO)|Audio Recording for Improved Surgical Outcome|Completed||Phase 1|30|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 02:41:26.668111|2018-06-01 02:41:26.668111
NCT00569920|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|||2009-01-14|2007-12-07|2007-12-10|Estimate|||||||2009-01-14|2009-01-15|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Nausea and Pain Prophylaxis During Thyroid Surgery|Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo|Completed||N/A|120|Anticipated|Sykehuset Telemark||3|||f||||t||||||||||2018-06-01 02:41:26.74884|2018-06-01 02:41:26.74884
NCT00569907|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2015-11-25|2007-12-07|2007-12-10|Estimate|||||||2015-11-25|2015-11-26|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide|Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide|Completed|||18|Actual|HealthPartners Institute|||||f||||f||||||||||2018-06-01 02:41:26.830494|2018-06-01 02:41:26.830494
NCT00569894|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2012-03-06|2007-12-06|2007-12-10|Estimate|||||||2012-03-06|2012-03-08|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Post Marking Study to Evaluate the Safety of FluMist in Children|A Post Marketing Evaluation of the Safety of FluMist in Children 24-59 Months of Age in a Managed Care Setting|Completed|||29296|Actual|MedImmune LLC|||3||f||||f||||||||||2018-06-01 02:41:26.899018|2018-06-01 02:41:26.899018
NCT00569881|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2007-12-07|2007-12-07|2007-12-10|Estimate|||||||2007-12-07|2007-12-10|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Observational|||Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK|Effect of Gatifloxacin 0.3% and Moxifloxacin 0.5% on Epithelial Wound Healing After Photorefractive Keratectomy|Completed|||22|Actual|Donnenfeld, Eric, M.D.|||2||f||||t||||||||||2018-06-01 02:41:26.976336|2018-06-01 02:41:26.976336
NCT00569478|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2012-12-03|2007-12-06|2007-12-07|Estimate|||||||2012-12-03|2012-12-04|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|August 2009|Actual|2009-08-31||Interventional|ICD-rehab||The Effect of Rehabilitation for Patients Living With an Implantable Cardioverter Defibrillator|The Effect of Rehabilitation for Patients Living With an ICD|Completed||Phase 2|196|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:41:33.21369|2018-06-01 02:41:33.21369
NCT00569868|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-07|2011-04-14||2011-07-18|2007-12-07|2007-12-10|Estimate|2011-07-18|2011-08-12|Estimate||||2011-07-18|2011-08-12|Estimate|August 2005||2005-08-31|July 2011|2011-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma|UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma|Completed||N/A|11|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:41:27.055433|2018-06-01 02:41:27.055433
NCT00569855|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2011-01-12||2011-02-03|2007-12-07|2007-12-10|Estimate|2011-02-03|2011-03-01|Estimate||||2011-02-03|2011-03-01|Estimate|February 2001||2001-02-28|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery|Intravenous Phenoxybenzamine Use in Pediatric Patients Undergoing Open-Heart Surgery|Completed||Phase 2|785|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:41:27.277378|2018-06-01 02:41:27.277378
NCT00569842|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2014-09-10|2007-12-06|2007-12-07|Estimate|||||||2014-09-10|2014-09-11|Estimate|November 2007||2007-11-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|February 2010|Actual|2010-02-28||Observational|||Investigation of the Cylex® ImmuKnow® Assay|Investigation of the Cylex® ImmuKnow® Assay|Completed|||45|Actual|Indiana University|||1||f||||t||||||None Retained|"~     None to be retained.~   "|||2018-06-01 02:41:27.412144|2018-06-01 02:41:27.412144
NCT00569829|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-03-28|2007-12-05|2007-12-07|Estimate|||||||2012-03-28|2012-03-30|Estimate|January 2004||2004-01-31|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|KATES||Modular Cognitive Behavioral Therapy for the Treatment of Child Anxiety Disorders in Elementary School Settings|A Randomized, Controlled Trial of Modular CBT for Child Anxiety Disorders in Elementary School Settings|Completed||Phase 2|60|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:41:27.472469|2018-06-01 02:41:27.472469
NCT00569816|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2007-12-06|2007-12-06|2007-12-07|Estimate|||||||2007-12-06|2007-12-07|Estimate|January 2005||2005-01-31|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||Continuous Versus Repetitive Sevoflurane Administration for Preconditioning|A Comparison Between Continuous and Repetitive Sevoflurane Administration for Preconditioning During Coronary Artery Bypass Surgery|Completed||Phase 4|50|Actual|University of Schleswig-Holstein||3|||f||||f||||||||||2018-06-01 02:41:27.537272|2018-06-01 02:41:27.537272
NCT00569803|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2016-07-05||2016-08-16|2007-12-06|2007-12-07|Estimate|2016-07-05|2016-08-15|Estimate||||2016-08-16|2016-09-22|Estimate|December 2007||2007-12-31|August 2016|2016-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Subcutaneous Pharmacokinetics of Belatacept|Pharmacokinetics, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects|Completed||Phase 1|153|Actual|Bristol-Myers Squibb||8|||f||||f||||||||||2018-06-01 02:41:27.694805|2018-06-01 02:41:27.694805
NCT00569790|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-11-01|2007-12-05|2007-12-07|Estimate|||||||2012-11-01|2012-11-02|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer|Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer|Completed||Phase 2|53|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-06-01 02:41:29.117577|2018-06-01 02:41:29.117577
NCT00569777|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2010-10-04||2015-02-18|2007-12-06|2007-12-07|Estimate|2010-10-26|2010-11-23|Estimate||||2015-02-18|2015-03-06|Estimate|October 2007||2007-10-31|February 2015|2015-02-28|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers|A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers|Completed||Phase 3|310|Actual|Vistakon Pharmaceuticals||2|||f||||||||||||||2018-06-01 02:41:29.212903|2018-06-01 02:41:29.212903
NCT00569764|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2009-06-09|2007-12-06|2007-12-07|Estimate|||||||2009-06-09|2009-06-12|Estimate|December 2007||2007-12-31|June 2009|2009-06-30|October 2009|Anticipated|2009-10-31|||||Observational|||Effect on Metabolic Parameters of Abilify in SPR|The Effects of Metabolic Parameters of Aripiprazole in Patients With Schizophrenia|Unknown status|Recruiting||100|Anticipated|Seoul National Hospital|||1||f||||f||||||Samples Without DNA|"~     blood sampling~   "|||2018-06-01 02:41:29.789217|2018-06-01 02:41:29.789217
NCT00569751|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2008-09-25|2007-12-06|2007-12-07|Estimate|||||||2008-09-25|2008-09-29|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|July 2008|Actual|2008-07-31|November 2006|Actual|2006-11-30||Interventional|ARRIVE 2||TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program|TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program|Completed||Phase 4|5016|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 02:41:29.87813|2018-06-01 02:41:29.87813
NCT00569738|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2009-02-16|2007-12-06|2007-12-07|Estimate|||||||2009-02-16|2009-02-17|Estimate|December 2008||2008-12-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|||||Observational|||Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors|Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors|Unknown status|Recruiting||20|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 02:41:30.010936|2018-06-01 02:41:30.010936
NCT00569712|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2012-03-07|2007-12-06|2007-12-07|Estimate|||||||2012-03-07|2012-03-09|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol|A Pilot Comparative Study of the Genomic Molecular and Clinical Profiles of Patients With Lung Cancer, COPD, or Asthma Treated With Symbicort Turbuhaler|Completed||Phase 1|30|Actual|British Columbia Cancer Agency|||||f||||f||||||||||2018-06-01 02:41:30.086113|2018-06-01 02:41:30.086113
NCT00569699|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-11-01|2007-12-05|2007-12-07|Estimate|||||||2012-11-01|2012-11-02|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)|Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)|Completed||Phase 2|56|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-06-01 02:41:30.157808|2018-06-01 02:41:30.157808
NCT00569686|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2018-05-01|2007-12-06|2007-12-07|Estimate|||||||2018-05-01|2018-05-07|Actual|September 2007||2007-09-30|May 2018|2018-05-31|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Interventional|||Lovaza Therapy of Peripheral Arterial Disease|Lovaza Therapy of Peripheral Arterial Disease|Withdrawn||N/A|0|Actual|University of Virginia||2||No subject meeting criteria|f||||f||||||||||2018-06-01 02:41:30.231074|2018-06-01 02:41:30.231074
NCT00569075|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2017-05-09|2007-12-05|2007-12-06|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2006||2006-10-31|May 2017|2017-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Apoptic Biomarkers of Periodontal Disease|Apoptotic Biomarkers of Periodontal Disease|Completed|||60|Actual|University of Michigan|||2||f||||f||||||Samples Without DNA|"~     saliva and plaque~   "|||2018-06-01 02:41:41.275316|2018-06-01 02:41:41.275316
NCT00569673|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2014-05-27||2014-05-27|2007-12-06|2007-12-07|Estimate|2014-05-27|2014-06-26|Estimate||||2014-05-27|2014-06-26|Estimate|March 2008||2008-03-31|May 2014|2014-05-31||||January 2012|Actual|2012-01-31||Interventional||Total number eligible and evaluable|Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer|A Phase II Evaluation of Docetaxel (NSC #628503) Plus Trabectedin (Yondelis®), R279741, IND # 101018) With Growth Factor Support in the Third-Line Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 2|71|Actual|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 02:41:30.345365|2018-06-01 02:41:30.345365
NCT00569660|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2009-09-21||2012-08-01|2007-12-06|2007-12-07|Estimate|2011-03-03|2011-03-30|Estimate||||2012-08-01|2012-08-07|Estimate|June 2005||2005-06-30|August 2012|2012-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Ph II Study of Azacitidine in Myelofibrosis|Phase II Study of Azacitidine in Myelofibrosis|Completed||Phase 2|34|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:41:30.920423|2018-06-01 02:41:30.920423
NCT00569647|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-12-06|2007-12-06|2007-12-07|Estimate|||||||2007-12-06|2007-12-07|Estimate|November 2005||2005-11-30|November 2007|2007-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Preoperative Anxiety in Pediatric Reconstructive Burn Patients: The Role of Virtual Reality Hypnosis|Preoperative Anxiety in Pediatric Reconstructive Burn Patients: The Role of Virtual Reality Hypnosis|Completed||N/A|25|Actual|Shriners Hospitals for Children||2|||f||||t||||||||||2018-06-01 02:41:31.225482|2018-06-01 02:41:31.225482
NCT00569634|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2016-08-26|2007-12-06|2007-12-07|Estimate|||||||2016-08-26|2016-08-29|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|AVANTI||Agreement Between Venous and Arterial Blood Gas Measurements in the Intensive Care Unit|Agreement Between Venous and Arterial Blood Gas Measurements in the Intensive Care Unit|Completed||N/A|40|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-06-01 02:41:31.306503|2018-06-01 02:41:31.306503
NCT00569621|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-05|2007-12-05|2007-12-07|Estimate|||||||2007-12-05|2007-12-07|Estimate|March 2007||2007-03-31|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow|A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow|Completed||Phase 2|16|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 02:41:31.386402|2018-06-01 02:41:31.386402
NCT00569608|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2007-12-06|2007-12-06|2007-12-07|Estimate|||||||2007-12-06|2007-12-07|Estimate|January 2005||2005-01-31|June 2005|2005-06-30|October 2006|Actual|2006-10-31|||||Interventional|EDNEO||Early Hospital Discharge Program in Neonatology|Early Discharge Program From a Regional Reference Neonatal Intensive Care Unit|Completed||N/A|140|Actual|Fundacion Para La Investigacion Hospital La Fe||2|||f||||f||||||||||2018-06-01 02:41:31.482396|2018-06-01 02:41:31.482396
NCT00569595|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2011-06-06|2007-12-06|2007-12-07|Estimate|||||||2011-06-06|2011-06-07|Estimate|November 2008||2008-11-30|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Improving Health Habits in Impoverished Populations|Improving Health Habits in Impoverished Populations|Completed||Phase 3|100|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 02:41:31.601191|2018-06-01 02:41:31.601191
NCT00569582|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2012-04-04|2011-11-29|2013-08-12|2007-12-06|2007-12-07|Estimate|2012-04-25|2012-05-28|Estimate|2011-11-29|2011-12-02|Estimate|2013-08-12|2013-08-22|Estimate|December 2007||2007-12-31|August 2013|2013-08-31||||January 2011|Actual|2011-01-31||Interventional|SEISMIC||A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome|An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome|Completed||Phase 3|50|Actual|Corcept Therapeutics||1|||f||||t||||||||||2018-06-01 02:41:31.701189|2018-06-01 02:41:31.701189
NCT00569569|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-06|2007-12-06|2007-12-07|Estimate|||||||2007-12-06|2007-12-07|Estimate|February 2006||2006-02-28|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Retaane® in Age-Related Macular Degeneration|Retaane® in Age-Related Macular Degeneration|Completed||Phase 2/Phase 3|20|Actual|Rudolf Foundation Clinic||1|||f||||f||||||||||2018-06-01 02:41:32.130336|2018-06-01 02:41:32.130336
NCT00569556|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-06-11|2007-12-05|2007-12-07|Estimate|||||||2009-06-11|2009-06-15|Estimate|September 2006||2006-09-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Care Management on Diabetes Outcomes|Effect of Care Management on Diabetes Outcomes|Completed||N/A|550|Anticipated|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 02:41:32.195782|2018-06-01 02:41:32.195782
NCT00569543|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2013-05-14|2007-12-06|2007-12-07|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 2005||2005-05-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Undergoing Treatment for Newly Diagnosed Breast Cancer|Effects of Therapeutic Agents on Estrogens in the Breast|Completed|||27|Actual|University of Nebraska|||||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-06-01 02:41:32.278755|2018-06-01 02:41:32.278755
NCT00569530|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2016-02-29||2016-05-18|2007-12-06|2007-12-07|Estimate|2016-05-18|2016-06-28|Estimate||||2016-05-18|2016-06-28|Estimate|January 2008||2008-01-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TOLSURFPilot||Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide|Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide|Completed||Phase 3|85|Actual|University of California, San Francisco|More frequent dosing, with the resultant improvements in lung function, may allow for more rapid weaning from mechanical ventilation, leading to improved pulmonary outcomes, both short-term and long-term. Modifications to protocol being investigated.|2|||f||||f||||||||No||2018-06-01 02:41:32.373578|2018-06-01 02:41:32.373578
NCT00569517|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-03-19|2007-12-06|2007-12-07|Estimate|||||||2009-03-19|2009-03-20|Estimate|January 2008||2008-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Cognitive Behavioral Therapy for Obesity|The Effect of Brief Group Cognitive Behavioral Therapy on Decreasing Metabolic Syndrome Risk Factors in Obese Patients Treated With Atypical Antipsychotics|Completed||N/A|32|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:41:32.8357|2018-06-01 02:41:32.8357
NCT00569504|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2009-06-11|2007-12-06|2007-12-07|Estimate|||||||2009-06-11|2009-06-12|Estimate|December 2007||2007-12-31|June 2009|2009-06-30|September 2009|Anticipated|2009-09-30|||||Observational|||Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics|Prevalence of the Metabolic Syndrome in Patients With Schizophrenia Taking Antipsychotics|Unknown status|Recruiting||1000|Anticipated|Seoul National Hospital|||1||f||||f||||||Samples Without DNA|"~     blood sampling~   "|||2018-06-01 02:41:32.943012|2018-06-01 02:41:32.943012
NCT00569465|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2007-12-06|2007-12-06|2007-12-07|Estimate|||||||2007-12-06|2007-12-07|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|NACARGPAO||N-Acetylcysteine and Arginine Administration in Diabetic Patients|Effects of Arginine and N-Acetylcysteine Administration on Nitric Oxide Production and Arterial Blood Pressure in Hypertensive Diabetic Patients.|Terminated||Phase 4|24|Actual|University of Turin, Italy||2||End of the study|f||||f||||||||||2018-06-01 02:41:33.300776|2018-06-01 02:41:33.300776
NCT00569452|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2016-03-01|2007-12-06|2007-12-07|Estimate|||||||2016-03-01|2016-03-03|Estimate|January 2006||2006-01-31|June 2010|2010-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate|Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate|Completed||N/A|12|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:41:33.385204|2018-06-01 02:41:33.385204
NCT00569439|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2007-12-06|2007-12-06|2007-12-07|Estimate|||||||2007-12-06|2007-12-07|Estimate|November 2000||2000-11-30|June 2006|2006-06-30|June 2007|Actual|2007-06-30|||||Interventional|||A Study on the Effects of Dextrose Solutions on the Course of Labor|A Randomized Controlled Trial Comparing Normal Saline With and Without Dextrose on the Course of Labor in Nulliparas|Completed||Phase 2|301|Actual|MemorialCare||3|||f||||f||||||||||2018-06-01 02:41:33.457997|2018-06-01 02:41:33.457997
NCT00569426|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-01-18|2007-12-06|2007-12-07|Estimate|||||||2017-01-18|2017-01-19|Estimate|April 2005||2005-04-30|January 2017|2017-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Evaluating the Use of Two Different Needles in Subjects With Diabetes|An Open-label, Randomised, Multi-centre Cross-over Trial in Diabetes Patients Evaluating Preference, Injection Pressure, Pain Perception and Handling When Injections Are Performed With Two Different Needles i.e. NovoFine® 32 Gauge Tip x 6mm and NovoFine® 30 Gauge x 8mm Using a FlexPen® Disposable Insulin Injection Pen|Completed||Phase 4|119|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:41:33.658549|2018-06-01 02:41:33.658549
NCT00569413|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2010-06-09|2007-12-06|2007-12-07|Estimate|||||||2010-06-09|2010-06-10|Estimate|April 2011||2011-04-30|June 2010|2010-06-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Observational|||A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality|A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality|Suspended|||40|Anticipated|Hadassah Medical Organization|||2||f||||t||||||||||2018-06-01 02:41:33.743321|2018-06-01 02:41:33.743321
NCT00569400|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2017-02-23|2007-12-06|2007-12-07|Estimate|||||||2017-02-23|2017-02-27|Actual|May 1, 2003|Actual|2003-05-01|February 2017|2017-02-28|January 19, 2004|Actual|2004-01-19|January 19, 2004|Actual|2004-01-19||Interventional|||Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes|Comparison of Efficacy and Safety of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes Mellitus|Completed||Phase 3|241|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:41:33.841635|2018-06-01 02:41:33.841635
NCT00569387|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05||2014-08-28|2015-05-29|2007-12-05|2007-12-07|Estimate||||2014-08-28|2014-09-01|Estimate|2015-05-29|2015-06-26|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|March 2011|Actual|2011-03-31||Interventional|||Vaccine Study for Surgically Resected Pancreatic Cancer|A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer|Completed||Phase 2|73|Actual|NewLink Genetics Corporation||1|||f||||t||||||||||2018-06-01 02:41:33.945531|2018-06-01 02:41:33.945531
NCT00569374|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2009-11-06||2010-09-30|2007-12-05|2007-12-07|Estimate|2010-02-12|2010-03-22|Estimate||||2010-09-30|2010-10-05|Estimate|September 2007||2007-09-30|September 2010|2010-09-30||||September 2008|Actual|2008-09-30||Interventional|||Safety and Tolerability of Modafinil for Methamphetamine Dependence|Safety and Tolerability of Modafinil for Methamphetamine Dependence|Completed||Phase 2|8|Actual|University of Arkansas|||||f||||f||||||||||2018-06-01 02:41:34.074829|2018-06-01 02:41:34.074829
NCT00569361|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2009-06-08|2007-12-06|2007-12-07|Estimate|||||||2009-06-08|2009-06-09|Estimate|November 2004||2004-11-30|June 2009|2009-06-30|October 2005|Actual|2005-10-31|||||Interventional|||Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic Disease|Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic|Completed||N/A|80|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 02:41:34.398048|2018-06-01 02:41:34.398048
NCT00569335|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-11-01|2007-12-05|2007-12-07|Estimate|||||||2012-11-01|2012-11-02|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer|Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer|Completed||Phase 2|52|Actual|Taiho Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-06-01 02:41:34.584233|2018-06-01 02:41:34.584233
NCT00569322|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2015-11-25|2007-12-06|2007-12-07|Estimate|||||||2015-11-25|2015-11-26|Estimate|December 2003||2003-12-31|September 2007|2007-09-30|September 2004|Actual|2004-09-30|||||Observational|||Admission Glucose ICU Study|Evaluation of Admission Blood Glucose Levels in the Intensive Care Unit|Completed|||||HealthPartners Institute|||||f||||f||||||||||2018-06-01 02:41:34.701999|2018-06-01 02:41:34.701999
NCT00569309|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2017-06-08||2018-03-08|2007-12-06|2007-12-07|Estimate|2018-03-08|2018-03-12|Actual||||2018-03-08|2018-03-12|Actual|December 12, 2007|Actual|2007-12-12|March 2018|2018-03-31|July 29, 2011|Actual|2011-07-29|July 29, 2011|Actual|2011-07-29||Interventional|||Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma|Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation for High-Risk Lymphoma and Myeloma|Completed||N/A|30|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:41:34.886993|2018-06-01 02:41:34.886993
NCT00569296|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2015-03-24|2007-12-06|2007-12-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer|A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1|5|Actual|Roger Williams Medical Center||1||Funding ended|f||||t||||||||||2018-06-01 02:41:35.191591|2018-06-01 02:41:35.191591
NCT00569283|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2013-03-25|2007-12-06|2007-12-07|Estimate|||||||2013-03-25|2013-03-26|Estimate|May 2007||2007-05-31|January 2008|2008-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant|Donor Natural Killer Cell Infusion for the Prevention of Relapse or Graft Failure After HLA-Haploidentical Familial Donor Bone Marrow Transplantation-A Phase I Study|Completed||Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:41:35.338081|2018-06-01 02:41:35.338081
NCT00569270|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2011-08-20||2017-07-07|2007-12-06|2007-12-07|Estimate|2012-10-04|2012-10-05|Estimate||||2017-07-07|2017-08-08|Actual|October 2006||2006-10-31|July 2017|2017-07-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Dynamic Hyperinflation and Tiotropium|Simplified Detection of Dynamic Hyperinflation Using Metronome Paced Hyperventilation and the Effect of Tiotropium in Patients With COPD|Completed||Phase 4|30|Actual|Gelb, Arthur F., M.D.||2|||f||||t||||||||No|Please see published data|2018-06-01 02:41:35.52053|2018-06-01 02:41:35.52053
NCT00569257|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|||2011-12-12|2007-12-06|2007-12-07|Estimate|||||||2011-12-12|2011-12-13|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors|Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women With LHRH Receptor Positive Gynecological Tumors|Completed||Phase 2|85|Actual|AEterna Zentaris|||||f||||f||||||||||2018-06-01 02:41:36.069901|2018-06-01 02:41:36.069901
NCT00569244|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2014-10-28|2007-12-06|2007-12-07|Estimate|||||||2014-10-28|2014-10-29|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||SH T00186 in the Treatment of Primary Dysmenorrhea|A Multi-center, Open-label, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of an Extended Flexible Regimen of the Combined Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Beta-cyclodextrin Clathrate and 3 mg Drospirenone) Compared to the Conventional Regimen of SH T00186D in the Treatment of Primary Dysmenorrhea|Completed||Phase 3|223|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:41:36.163566|2018-06-01 02:41:36.163566
NCT00569231|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-06|2010-11-23||2010-12-29|2007-12-06|2007-12-07|Estimate|2010-12-29|2011-01-25|Estimate||||2010-12-29|2011-01-25|Estimate|February 2007||2007-02-28|December 2010|2010-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study With Candida Antigen for Treatment of Warts|A Phase 1 Study to Evaluate the Immunologic Mechanisms Underlying Wart Resolution After Intralesional Immunotherapy With Candida Antigen|Completed||Phase 1|18|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 02:41:36.308721|2018-06-01 02:41:36.308721
NCT00569192|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2013-08-19||2013-12-09|2007-12-05|2007-12-07|Estimate|2013-08-19|2013-10-23|Estimate||||2013-12-09|2014-01-09|Estimate|December 2007||2007-12-31|December 2013|2013-12-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Study Investigating the Safety and Efficacy Over 12 Weeks Treatment Period of MAP0010 in Asthmatic Infants and Children 12 Months to 8 Years of Age|Completed||Phase 3|360|Actual|Allergan||3|||f||||f||||||||||2018-06-01 02:41:36.511982|2018-06-01 02:41:36.511982
NCT00569179|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2015-08-28|2007-12-05|2007-12-07|Estimate|||||||2015-08-28|2015-08-31|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies|A PHASE I TRIAL OF ALLOREACTIVE NK CELLS INFUSION FOLLOWING TRANSPLANTATION OF HAPLOTYPE MISMATCHED, KIR MISMATCHED HIGHLY PURIFIED CD34 CELLS IN PATIENTS WITH ADVANCED OR REFRACTORY MYELOID MALIGNANCIES|Terminated||Phase 1|1|Actual|Indiana University||1||Slow accrual|f||||t||||||||||2018-06-01 02:41:36.895935|2018-06-01 02:41:36.895935
NCT00569166|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2011-09-13||2017-07-03|2007-12-05|2007-12-06|Estimate|2011-11-01|2011-12-06|Estimate||||2017-07-03|2017-08-07|Actual|March 2007||2007-03-31|November 2011|2011-11-30|May 14, 2012|Actual|2012-05-14|February 2010|Actual|2010-02-28||Interventional|||Three Different Programs of Paced Breathing in Treating Hot Flashes in Women|Paced Breathing for Hot Flashes: A Randomized Phase II Study|Completed||N/A|105|Actual|Mayo Clinic||3|||f||||||||||||||2018-06-01 02:41:37.030726|2018-06-01 02:41:37.030726
NCT00569153|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04||2016-03-04|2016-03-04|2007-12-04|2007-12-06|Estimate||||2016-03-04|2016-04-04|Estimate|2016-03-04|2016-04-04|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|TAK-700||Safety Study of TAK-700 in Subjects With Prostate Cancer.|A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects|Completed||Phase 1/Phase 2|123|Actual|Millennium Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 02:41:37.954559|2018-06-01 02:41:37.954559
NCT00569140|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2010-01-21|2007-12-05|2007-12-06|Estimate|||||||2010-01-21|2010-01-25|Estimate|December 2007||2007-12-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|||||Interventional|||A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration|A Phase 1, Single Ascending Dose Trial to Establish the Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Monotherapy and of E10030 Given in Combination With Lucentis®0.5 Mg/Eye in Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 1|18|Anticipated|Ophthotech Corporation||1|||f||||f||||||||||2018-06-01 02:41:38.072691|2018-06-01 02:41:38.072691
NCT00569127|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2016-02-18||2018-05-25|2007-12-05|2007-12-06|Estimate|2016-03-25|2016-04-28|Estimate||||2018-05-25|2018-05-30|Actual|December 1, 2007|Actual|2007-12-01|March 2018|2018-03-31||||January 1, 2015|Actual|2015-01-01||Interventional||Eligible patients|Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor|Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients|Active, not recruiting||Phase 3|427|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 02:41:38.326164|2018-06-01 02:41:38.326164
NCT00569114|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2010-03-16|2007-12-05|2007-12-06|Estimate|||||||2010-03-16|2010-03-17|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|||Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients|A Phase 1 Dose-Escalation Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients|Completed||Phase 1|45|Anticipated|Tragara Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:41:41.05014|2018-06-01 02:41:41.05014
NCT00569101|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2007-12-04|2007-12-04|2007-12-06|Estimate|||||||2007-12-04|2007-12-06|Estimate|September 2007||2007-09-30|December 2007|2007-12-31|March 2008|Anticipated|2008-03-31|||||Interventional|||A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis|A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis|Unknown status|Active, not recruiting|Phase 2|9|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-06-01 02:41:41.125868|2018-06-01 02:41:41.125868
NCT00569088|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2009-07-07|2007-12-05|2007-12-06|Estimate|||||||2009-07-07|2009-07-08|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|April 2010|Anticipated|2010-04-30||Interventional|||"Study of the Pathogenesis and Molecular Mechanism of YURE in Internal Intractable Diseases"|"973 Project for Pathology of Traditional Chinese Medicine"|Unknown status|Recruiting|Phase 2|300|Anticipated|Nanjing University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 02:41:41.20177|2018-06-01 02:41:41.20177
NCT00569062|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05||2009-07-22|2017-07-14|2007-12-05|2007-12-06|Estimate||||2009-07-22|2009-08-10|Estimate|2017-07-14|2017-07-18|Actual|September 12, 2007|Actual|2007-09-12|July 2017|2017-07-31|June 25, 2008|Actual|2008-06-25|June 25, 2008|Actual|2008-06-25||Interventional|||A Study of GW856553X For the Treatment of Depression|A Randomized, Double Blind, Placebo Controlled Study to Explore the Antidepressant Properties of P38a Kinase Inhibitor GW856553X 15mg Compared to PBO in Subjects With Major Depressive Disorder Exhibiting Symptoms of Loss of Energy and Interest and Psychomotor Retardation, for a Six Week Treatment Period|Terminated||Phase 2|30|Actual|GlaxoSmithKline||2||"Negative data from a GSK PoC study in RA combined with evidence of greater sensitivity of~   toll-like receptor pathways to p38 inhibition."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:41:41.345324|2018-06-01 02:41:41.345324
NCT00569049|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2012-04-04|2007-12-04|2007-12-06|Estimate|||||||2012-04-04|2012-04-06|Estimate|May 1996||1996-05-31|April 2012|2012-04-30||||May 2050|Anticipated|2050-05-31||Observational|||Molecular Analysis of Breast Cancer|Molecular Analysis of Breast Cancer|Active, not recruiting|||99999|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     tumor, normal tissue and blood~   "|||2018-06-01 02:41:41.579054|2018-06-01 02:41:41.579054
NCT00569036|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2013-08-13|2007-12-04|2007-12-06|Estimate|||||||2013-08-13|2013-08-14|Estimate|April 2008||2008-04-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors|A Phase I Multiple Ascending Dose Study of BMS-754807 in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|63|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:41:41.648456|2018-06-01 02:41:41.648456
NCT00569023|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-06-26|2007-12-05|2007-12-06|Estimate|||||||2012-06-26|2012-06-28|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|August 2009|Actual|2009-08-31||Interventional|||Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene|Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene|Completed||N/A|7|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:41:41.746124|2018-06-01 02:41:41.746124
NCT00569010|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2011-01-21||2012-07-26|2007-12-05|2007-12-06|Estimate|2011-01-21|2011-02-14|Estimate||||2012-07-26|2012-08-01|Estimate|December 2005||2005-12-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)|"Randomized Phase I/II Study of 5-Azacytidine in Combination With Cytosine Arabinoside in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High Risk Myelodysplastic Syndrome - SPORE"|Completed||Phase 1/Phase 2|36|Actual|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-06-01 02:41:41.835752|2018-06-01 02:41:41.835752
NCT00568997|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2017-12-08|2007-12-05|2007-12-06|Estimate|||||||2017-12-08|2017-12-12|Actual|June 27, 2005|Actual|2005-06-27|December 2017|2017-12-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|PEER||10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus|A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)|Recruiting|||8000|Anticipated|Valeant Pharmaceuticals International, Inc.|||1||f||||t||||||||||2018-06-01 02:41:42.217061|2018-06-01 02:41:42.217061
NCT00568984|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-02-17|2007-12-05|2007-12-06|Estimate|||||||2017-02-17|2017-02-20|Actual|November 21, 2002|Actual|2002-11-21|February 2017|2017-02-28|November 10, 2003|Actual|2003-11-10|November 10, 2003|Actual|2003-11-10||Interventional|||Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes|Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes Mellitus|Completed||Phase 4|324|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:41:42.309399|2018-06-01 02:41:42.309399
NCT00568971|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2010-01-26|2007-12-05|2007-12-06|Estimate|||||||2010-01-26|2010-01-27|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Weekly DCF to Treat Advanced Gastric Cancer|Phase II Study of Weekly Docetaxol Combined With Cisplatin and 5-Fu in Patients With Advanced Gastric Cancer|Terminated||Phase 2|40|Actual|Fudan University||1||The study has finished.|f||||f||||||||||2018-06-01 02:41:42.416078|2018-06-01 02:41:42.416078
NCT00568958|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2014-03-04||2014-07-22|2007-12-04|2007-12-06|Estimate|2014-07-22|2014-08-11|Estimate||||2014-07-22|2014-08-11|Estimate|February 2008||2008-02-29|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Naltrexone for Heavy Drinking in Young Adults|Naltrexone for Heavy Drinking in Young Adults|Completed||Phase 4|140|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:41:42.521136|2018-06-01 02:41:42.521136
NCT00568945|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2014-10-28|2007-12-04|2007-12-06|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.|Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation by Administration of Capadenoson in a Dose of 4 mg Once Daily for Five Days|Completed||Phase 2|28|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:41:42.959297|2018-06-01 02:41:42.959297
NCT00568906|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2010-07-02|2007-12-04|2007-12-06|Estimate|||||||2010-07-02|2010-07-07|Estimate|February 2002||2002-02-28|July 2010|2010-07-31|June 2011|Anticipated|2011-06-30|November 2010|Anticipated|2010-11-30||Observational|||Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma|Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma|Unknown status|Recruiting||150|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     Lung tissue or pleural fluid.~   "|||2018-06-01 02:41:43.047395|2018-06-01 02:41:43.047395
NCT00568893|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-05|2007-12-05|2007-12-06|Estimate|||||||2007-12-05|2007-12-06|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|October 2003|Actual|2003-10-31|||||Interventional|||An Open Label Study of Severe Sepsis in Adults|An Open Label Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis and Multiple Organ Dysfunctions A Phase IV Protocol|Completed||Phase 4|130|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:41:43.115287|2018-06-01 02:41:43.115287
NCT00568880|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-07-07|2007-12-05|2007-12-06|Estimate|||||||2009-07-07|2009-07-08|Estimate|November 2007||2007-11-30|July 2009|2009-07-31||||November 2009|Anticipated|2009-11-30||Interventional|||Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:41:43.242514|2018-06-01 02:41:43.242514
NCT00568867|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2011-04-07|2007-12-04|2007-12-06|Estimate|||||||2011-04-07|2011-04-11|Estimate|September 2006||2006-09-30|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample|Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample|Completed|||300|Actual|Stanford University|||||f||||t||||||Samples With DNA|"~     tumor tissue sample~   "|||2018-06-01 02:41:43.325008|2018-06-01 02:41:43.325008
NCT00568854|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2016-04-12||2016-06-30|2007-12-04|2007-12-06|Estimate|2016-06-30|2016-08-16|Estimate||||2016-06-30|2016-08-16|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Immunobiology of Diabetes and Tuberculosis|Converging Epidemics: Immunobiology of Diabetes Mellitus and Tuberculosis Infection|Terminated||N/A|10|Actual|Stanford University|This was a pilot/feasibility study to lay groundwork for a larger scale study of differences in immune responses in persons with diabetes versus persons without diabetes. The study aimed to optimize laboratory procedures for the full study.|2||Additional funding was not secured|f||||t||||||||No||2018-06-01 02:41:43.37572|2018-06-01 02:41:43.37572
NCT00568841|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-09-16|2007-12-05|2007-12-06|Estimate|||||||2009-09-16|2009-09-17|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|ERLOPET||Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)|A Phase-II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET for Early Prediction of Non-progression in Patients With Advanced NSCLC Treated With Erlotinib and to Associate PET Findings With Molecular Markers|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Lung Cancer Group Cologne||1|||f||||t||||||||||2018-06-01 02:41:43.73605|2018-06-01 02:41:43.73605
NCT00568828|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-05|2007-12-05|2007-12-06|Estimate|||||||2007-12-05|2007-12-06|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|February 2008|Anticipated|2008-02-29|||||Observational|MacTEL-Supp||MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin|Pilot Study to Evaluate the Changes of Macular Pigment Optical Density in Patients With Idiopathic Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin|Unknown status|Recruiting||12|Anticipated|The Lowy Medical Research Institute Limited|||||f||||f||||||||||2018-06-01 02:41:43.838221|2018-06-01 02:41:43.838221
NCT00568815|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-02-16|2007-12-05|2007-12-06|Estimate|||||||2012-02-16|2012-02-20|Estimate|April 2007||2007-04-30|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL|Completed||Phase 2|31|Actual|Fudan University||1|||f||||f||||||||||2018-06-01 02:41:43.916878|2018-06-01 02:41:43.916878
NCT00568802|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2008-12-02|2007-12-04|2007-12-06|Estimate|||||||2008-12-02|2008-12-03|Estimate|January 2004||2004-01-31|December 2008|2008-12-31||||||||Interventional|||A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients|A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients|Unknown status|Active, not recruiting|Phase 1/Phase 2|24||Stanford University|||||||||||||||||||2018-06-01 02:41:44.006174|2018-06-01 02:41:44.006174
NCT00568789|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2012-02-27|2007-12-04|2007-12-06|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2006||2006-06-30|February 2012|2012-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Safety of Ramelteon in Elderly Subjects|A Study of the Safety of Ramelteon in Elderly Subjects|Completed||Phase 4|33|Actual|Takeda||1|||f||||f||||||||||2018-06-01 02:41:44.090158|2018-06-01 02:41:44.090158
NCT00568776|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2011-09-27||2016-04-11|2007-12-04|2007-12-06|Estimate|2012-03-01|2012-03-29|Estimate||||2016-04-11|2016-05-16|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||ELND005 in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease|Completed||Phase 2|353|Actual|Transition Therapeutics Ireland Limited|The two high dose groups of ELND005 were discontinued before study end, so the efficacy analysis was based only on placebo and ELND005 250 mg bid groups.|4|||f||||t||||||||||2018-06-01 02:41:44.213452|2018-06-01 02:41:44.213452
NCT00568763|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2018-02-12|2007-12-05|2007-12-06|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2005|Actual|2005-11-30|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma|Endogenous Heat-shock Vaccines for Melanoma A Feasibility Study|Active, not recruiting||N/A|23|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:41:45.236438|2018-06-01 02:41:45.236438
NCT00568750|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2018-03-01|2007-12-05|2007-12-06|Estimate|||||||2018-03-01|2018-03-02|Actual|January 17, 2008|Actual|2008-01-17|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|January 18, 2012|Actual|2012-01-18||Interventional|||Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors|Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. A Multi Center Phase II Trial|Active, not recruiting||Phase 2|47|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-06-01 02:41:45.309871|2018-06-01 02:41:45.309871
NCT00568737|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-05|2007-12-05|2007-12-06|Estimate|||||||2007-12-05|2007-12-06|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|February 2005|Actual|2005-02-28|||||Interventional|||The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death|Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Early Stage Severe Sepsis|Completed||Phase 3|2640|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:41:45.411527|2018-06-01 02:41:45.411527
NCT00568724|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2012-09-13|2007-12-05|2007-12-06|Estimate|||||||2012-09-13|2012-09-14|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis|Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis|Completed|||45|Actual|University of Aarhus|||4||f||||f||||||Samples With DNA|"~     Urine and frozen pelvic tissue~   "|||2018-06-01 02:41:45.658308|2018-06-01 02:41:45.658308
NCT00568711|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-05|2007-12-05|2007-12-06|Estimate|||||||2007-12-05|2007-12-06|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Controlled Trial: 5-Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus|Controlled Trial: 5-Day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus|Unknown status|Recruiting|N/A|476|Anticipated|Chosun University Hospital||2|||f||||t||||||||||2018-06-01 02:41:45.727701|2018-06-01 02:41:45.727701
NCT00568698|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2009-07-07|2007-12-04|2007-12-06|Estimate|||||||2009-07-07|2009-07-08|Estimate|January 2004||2004-01-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients|A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients|Completed||Phase 1/Phase 2|18|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 02:41:45.865127|2018-06-01 02:41:45.865127
NCT00568685|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2009-11-11||2010-01-19|2007-12-04|2007-12-06|Estimate|2009-11-11|2009-12-14|Estimate||||2010-01-19|2010-01-26|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|153|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:41:45.976593|2018-06-01 02:41:45.976593
NCT00568672|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2008-04-23|2007-12-05|2007-12-06|Estimate|||||||2008-04-23|2008-04-25|Estimate|October 2007||2007-10-31|April 2008|2008-04-30|April 2008|Anticipated|2008-04-30|||||Interventional|OLA-D||Optimal Duration of Olanzapine Add-on Therapy in Major Depression|Optimal Duration of Olanzapine Add-on Therapy in Major Depression: a Placebo-Controlled, Randomized, Phase III, Pilot Study in Parallel Group Design|Withdrawn||Phase 3|30|Anticipated|Charite University, Berlin, Germany||2||Withdrawn because of personal ressources before inclusion of the first patient|f||||t||||||||||2018-06-01 02:41:46.707328|2018-06-01 02:41:46.707328
NCT00568659|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2015-04-27|2007-12-05|2007-12-06|Estimate|||||||2015-04-27|2015-04-28|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|November 2010|Actual|2010-11-30||Interventional|||The Specific Lung Elastance in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients in Supine and Prone Position|The Specific Lung Elastance in ALI/ARDS Patients in Supine and Prone Position|Completed||N/A|15|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 02:41:46.849177|2018-06-01 02:41:46.849177
NCT00568646|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2011-08-03|2007-12-04|2007-12-06|Estimate|||||||2011-08-03|2011-08-04|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer|A Phase 2 Study of Oral MKC 1, Administered Twice Daily for 14 Consecutive Days in a 28-Day Cycle, in Patients With Unresectable or Metastatic Pancreatic Cancer Who Have Failed at Least One Prior Chemotherapy Regimen in Either the Neoadjuvant, Adjuvant, or First-line Metastatic Setting|Completed||Phase 2|33|Anticipated|CASI Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 02:41:46.968563|2018-06-01 02:41:46.968563
NCT00568633|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2016-11-17|2007-12-04|2007-12-06|Estimate|||||||2016-11-17|2016-11-18|Estimate|August 2007||2007-08-31|November 2013|2013-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML|A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission|Terminated||Phase 3|150|Anticipated|Stanford University||1||Poor accrual|f||||t||||||||||2018-06-01 02:41:47.037632|2018-06-01 02:41:47.037632
NCT00568620|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2016-10-31|2007-12-04|2007-12-06|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2012|Actual|2012-06-30||Interventional|||The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus|The Role of the Duodenum in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Mellitus|Completed||N/A|19|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 02:41:47.128213|2018-06-01 02:41:47.128213
NCT00568607|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2010-09-07|2007-12-05|2007-12-06|Estimate|||||||2010-09-07|2010-09-08|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma|Phase II Study of a Combination Chemotherapy of DICE in the Patients With NK/T Cell Lymphoma|Unknown status|Recruiting|Phase 2|60|Anticipated|Fudan University||1|||f||||f||||||||||2018-06-01 02:41:47.185667|2018-06-01 02:41:47.185667
NCT00568594|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05||2012-10-22|2012-10-22|2007-12-05|2007-12-06|Estimate||||2012-10-22|2012-10-29|Estimate|2012-10-22|2012-10-29|Estimate|November 2007||2007-11-30|October 2012|2012-10-31||||September 2009|Actual|2009-09-30||Interventional|||Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)|A First-in-human, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose (Healthy Volunteers and CHD Patients) and Multiple Dose (CHD Patients) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180|Completed||Phase 1/Phase 2|176|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:41:47.264594|2018-06-01 02:41:47.264594
NCT00568568|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2013-01-18|2007-12-05|2007-12-06|Estimate|||||||2013-01-18|2013-01-21|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Metabolic Studies- Interactions Between GH and Insulin in GHDA|Metabolic Studies- Interactions Between GH and Insulin in GHDA. Insulin Resistance and GH Treatment: Dependence of Ambient GH Level Among Patients Treated With GH and Healthy Control Subjects|Completed||N/A|8|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 02:41:47.339695|2018-06-01 02:41:47.339695
NCT00568555|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2013-04-10||2015-09-21|2007-12-04|2007-12-06|Estimate|2015-09-21|2015-10-21|Estimate||||2015-09-21|2015-10-21|Estimate|June 2007||2007-06-30|September 2015|2015-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||"2 participants in the low dose naltrexone group did not have data to analyze (1 withdrew by patient choice, 1 had a malfunction with the data collection device)~1 participant in the placebo condition did not have data to analyze (withdrew by patient choice)"|Effects of Low Dose Naltrexone in Fibromyalgia|Effects of Low Dose Naltrexone in Fibromyalgia|Completed||N/A|53|Actual|Stanford University||2|||f||||||||||||||2018-06-01 02:41:47.434108|2018-06-01 02:41:47.434108
NCT00568542|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-08-03|2007-12-05|2007-12-06|Estimate|||||||2009-08-03|2009-08-04|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|EPOHeart||Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy|Pilot Study to Assess the Effect of Low Dose Epoetin Beta Administered for Six Month in Patients With Ischemic Heart Failure Subjected to Percutaneous Coronary Intervention (PCI)|Completed||Phase 4|28|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 02:41:47.71883|2018-06-01 02:41:47.71883
NCT00568529|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2010-05-25|2007-12-05|2007-12-06|Estimate|||||||2010-05-25|2010-05-26|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|February 2010|Anticipated|2010-02-28|June 2009|Actual|2009-06-30||Interventional|||Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer|Phase II Study on Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer|Suspended||Phase 2|30|Anticipated|Fudan University||1||There are not enough patients enrolled.|f||||f||||||||||2018-06-01 02:41:47.816729|2018-06-01 02:41:47.816729
NCT00568516|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2014-10-28|2007-12-05|2007-12-06|Estimate|||||||2014-10-28|2014-10-29|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase II Study of ASP3550 in Patients With Prostate Cancer|Phase II Study of ASP3550 - A Maintenance-dose Finding Study in Patients With Prostate Cancer|Completed||Phase 2|273|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:41:47.891197|2018-06-01 02:41:47.891197
NCT00568503|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2011-04-27|2007-12-05|2007-12-06|Estimate|||||||2011-04-27|2011-04-28|Estimate|October 2007||2007-10-31|April 2011|2011-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Partially Blinded, Single-dose, Cross-over Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide (Positive Control) and Placebo in Mild-to-moderate COPD Patients|Completed||Phase 1|29|Actual|Novartis||5|||f||||f||||||||||2018-06-01 02:41:47.97583|2018-06-01 02:41:47.97583
NCT00568490|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2016-07-11|2007-12-04|2007-12-06|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1998||1998-09-30|July 2016|2016-07-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers|Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers|Recruiting|||600|Anticipated|Stanford University|||||f||||||||||Samples Without DNA|"~     blood, tumor tissue~   "|||2018-06-01 02:41:48.058392|2018-06-01 02:41:48.058392
NCT00568477|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-09-30|2007-12-05|2007-12-06|Estimate|||||||2009-09-30|2009-10-01|Estimate|December 2007||2007-12-31|January 2008|2008-01-31|December 2010|Anticipated|2010-12-31|||||Interventional|Rituximab 2006||Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation|Prospective, Randomized, Open, 2-arm National Multi-center Study to Evaluate the Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation.|Terminated||Phase 2|200|Anticipated|Technische Universität München||2||lacking recruitment|f||||t||||||||||2018-06-01 02:41:48.136097|2018-06-01 02:41:48.136097
NCT00568464|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2009-07-06|2007-12-05|2007-12-06|Estimate|||||||2009-07-06|2009-07-07|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|September 2009|Anticipated|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)|Phase II Study of VCD/IE in the Treatment of the Patients With Ewing's Sarcoma Family of Tumors|Terminated||Phase 2|10|Actual|Fudan University||1||The enrollment is slower than expected|f||||f||||||||||2018-06-01 02:41:48.217086|2018-06-01 02:41:48.217086
NCT00568451|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2011-11-01||2015-11-25|2007-12-05|2007-12-06|Estimate|2012-03-05|2012-03-30|Estimate||||2015-11-25|2015-12-30|Estimate|June 2006||2006-06-30|March 2014|2014-03-31|April 2012|Actual|2012-04-30|May 2009|Actual|2009-05-31||Interventional|||Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma|Releasing the Cancer Patient's Immune System From Down-regulation With Timed Delivery of Standard Chemotherapy|Terminated||Phase 2|12|Actual|Mayo Clinic|This trial was stopped prior to achieving its accrual goals due to slow enrollment rate. Early termination leading to small numbers of subjects analyzed.|4||Slow accrual.|f||||t||||||||||2018-06-01 02:41:48.388921|2018-06-01 02:41:48.388921
NCT00568438|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-04-25|2007-12-04|2007-12-06|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2000||2000-10-31|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample|Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples|Recruiting|||300|Anticipated|Stanford University|||||f||||t||||||Samples Without DNA|"~     Cases will be identified from clinic patient medical records and linked to pathology reports.~     The surgical pathology record number will thus be obtained and used to retrieve the archival~     blocks and slides. Approximately three representative blocks will be selected and 4-6 four~     micron thick sections will be cut on a microtome. Cases with limited archived diagnostic~     material will not be selected nor blocks where there is little materials.~   "|||2018-06-01 02:41:48.799293|2018-06-01 02:41:48.799293
NCT00568425|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2012-11-29|2007-12-04|2007-12-06|Estimate|||||||2012-11-29|2012-12-03|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT|Quality of Life and Functional Outcomes After Combined Modality Therapy for Anal Cancer: A Comparison of Conventional Versus Intensity-Modulated Radiation Therapy (ANAL0002)|Terminated|||10|Actual|Stanford University||||Inadequate response to SRC letter|f||||t||||||||||2018-06-01 02:41:48.866694|2018-06-01 02:41:48.866694
NCT00568412|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2015-02-15|2007-12-05|2007-12-06|Estimate|||||||2015-02-15|2015-02-18|Estimate|December 2007||2007-12-31|February 2015|2015-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Clinical Study in Children and Adolescents With Mild to Moderate Atopic Dermatitis|A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents|Completed||Phase 4|80|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:41:48.928023|2018-06-01 02:41:48.928023
NCT00568399|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2011-09-26||2012-11-08|2007-12-05|2007-12-06|Estimate|2012-10-05|2012-11-06|Estimate||||2012-11-08|2012-11-20|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Sodium Thiosulfate Treatment of Vascular Calcification in ESRD|The Effect of Sodium Thiosulfate Treatment on Vascular Calcification in End Stage Renal Failure Patients|Completed||N/A|48|Actual|Washington University School of Medicine|This study did not enroll a prospective, randomized, placebo controlled, double-blind control group; therefore conclusive statements about the risks and benefits of thiosulfate cannot be made.|1|||f||||t||||||||||2018-06-01 02:41:49.033482|2018-06-01 02:41:49.033482
NCT00568386|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2008-12-18||2012-01-31|2007-12-05|2007-12-06|Estimate|2010-02-23|2010-03-10|Estimate||||2012-01-31|2012-02-02|Estimate|November 2007||2007-11-30|January 2012|2012-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Acute Comfort and Blur of Systane and Optive|Acute Comfort and Blurring Profile Evaluation Comparing Systane Lubricant Eye Drops to Optive Lubricant Eye Drops|Completed||N/A|40|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 02:41:49.234224|2018-06-01 02:41:49.234224
NCT00568373|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2018-03-28|2007-12-05|2007-12-06|Estimate|||||||2018-03-28|2018-03-30|Actual|June 2007|Actual|2007-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|HUD||Gastric Pacemaker Implantation for Gastroparesis|Gastric Electric Stimulation-Enterra Therapy for the Treatment of Chronic Intractable (Drug Refractory) Nausea and Vomiting Secondary to Gastroparesis of Diabetic or Idiopathic Etiology|Recruiting||N/A|200|Anticipated|Indiana University||1|||f||||f||||||||No||2018-06-01 02:41:49.436016|2018-06-01 02:41:49.436016
NCT00568360|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2012-05-16|2007-12-04|2007-12-06|Estimate|||||||2012-05-16|2012-05-18|Estimate|February 2004||2004-02-29|May 2012|2012-05-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Observational|||Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer|Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer|Terminated|||8|Actual|Stanford University||||Research cancelled; equipment broke|f||||||||||||||2018-06-01 02:41:49.528012|2018-06-01 02:41:49.528012
NCT00568347|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2015-03-13|2007-12-05|2007-12-06|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange|Evaluation of the Effects of Varying Doses of Inhaled Corticosteroids on Suppression of Total Exhaled, Bronchial, and Alveolar Nitric Oxide as Markers of Endogenous Inflammation in Patients With Moderate-to-severe COPD|Completed|||39|Actual|Gelb, Arthur F., M.D.|||3||f||||t||||||||||2018-06-01 02:41:49.591133|2018-06-01 02:41:49.591133
NCT00568334|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|2017-04-13||2017-04-13|2007-12-05|2007-12-06|Estimate|2017-04-13|2017-06-28|Actual||||2017-04-13|2017-06-28|Actual|November 1, 2007|Actual|2007-11-01|April 2017|2017-04-30|April 29, 2008|Actual|2008-04-29|March 18, 2008|Actual|2008-03-18||Interventional|||Study of Two Formulations of GSK Biologicals' Varicella Vaccine|Study of Two Formulations of GSK Biologicals' Varicella Vaccine Given as a 2-dose Course in the Second Year of Life|Completed||Phase 2|244|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:41:49.720248|2018-06-01 02:41:49.720248
NCT00568321|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03||2009-04-06|2009-10-21|2007-12-05|2007-12-06|Estimate||||2009-10-21|2009-10-23|Estimate|2009-10-21|2009-10-23|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||RN624 For Pain Of Post-Herpetic Neuralgia|A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of RN624 In Adult Patients With Post-Herpetic Neuralgia|Completed||Phase 2|99|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 02:41:50.265778|2018-06-01 02:41:50.265778
NCT00568308|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2011-06-13|2007-12-04|2007-12-06|Estimate|||||||2011-06-13|2011-06-15|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|PATHWAY||Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma|A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma|Terminated||Phase 3|600|Anticipated|Progen Pharmaceuticals||2||Commercial decision to discontinue the study|f||||t||||||||||2018-06-01 02:41:50.375494|2018-06-01 02:41:50.375494
NCT00568295|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2011-08-19|2007-12-04|2007-12-06|Estimate|||||||2011-08-19|2011-08-22|Estimate|October 1999||1999-10-31|August 2011|2011-08-31|October 2000|Actual|2000-10-31|October 2000|Actual|2000-10-31||Interventional|||A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee|A Four-Week Comparative Study Evaluating Acetaminophen Extended Release (3900 mg/Day) and Rofecoxib (12.5 mg/Day and 25 mg/Day)in the Treatment of Osteoarthritis of the Knee|Completed||Phase 3|403|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-06-01 02:41:50.470105|2018-06-01 02:41:50.470105
NCT00568282|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2013-10-23|2007-12-04|2007-12-06|Estimate|||||||2013-10-23|2013-10-25|Estimate|February 2007||2007-02-28|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients|Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)|Unknown status|Recruiting||100|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:41:50.542521|2018-06-01 02:41:50.542521
NCT00568269|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-05|||2007-12-05|2007-12-05|2007-12-06|Estimate|||||||2007-12-05|2007-12-06|Estimate|November 1996||1996-11-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Randomized Multicentre Study Comparing TEP With Lichtenstein Repair for Primary Inguinal Hernia|Randomized Multicentre Study Comparing TEP With Lichtenstein Repair for Primary Inguinal Hernia|Completed||N/A|1513|Actual|Uppsala University Hospital||2|||f||||||||||||||2018-06-01 02:41:50.609798|2018-06-01 02:41:50.609798
NCT00568256|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2012-02-24|2007-12-04|2007-12-06|Estimate|||||||2012-02-24|2012-02-27|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Mind/Body Medicine and IBD Flare-Up|Mind/Body Medicine and IBD Flare-Up|Completed||Phase 1|55|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-06-01 02:41:50.679172|2018-06-01 02:41:50.679172
NCT00568243|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2018-03-27|2007-12-04|2007-12-05|Estimate|||||||2018-03-27|2018-03-29|Actual|November 30, 2007||2007-11-30|June 5, 2017|2017-06-05||||||||Observational|||Visual Motor Coordination|Visual Motor Coordination|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:41:50.746592|2018-06-01 02:41:50.746592
NCT00568230|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2008-11-05|2007-12-04|2007-12-05|Estimate|||||||2008-11-05|2008-11-06|Estimate|April 2006||2006-04-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|PTOLEMY||Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device to Reduce Mitral Regurgitation|An Open-Label, Single-Arm Feasibility Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty (PTMA) Device Used to Reduce Mitral Regurgitation.|Completed||Phase 1|12|Actual|Viacor||1|||f||||t||||||||||2018-06-01 02:41:50.805052|2018-06-01 02:41:50.805052
NCT00568217|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2007-12-08|2007-12-04|2007-12-05|Estimate|||||||2007-12-08|2007-12-11|Estimate|September 1997||1997-09-30|December 2007|2007-12-31|August 2005|Actual|2005-08-31|||||Interventional|||Antipyretics for Preventing Recurrences of Febrile Seizures|Antipyretics for Preventing Recurrences of Febrile Seizures|Completed||Phase 4|231|Actual|University of Oulu||5|||f||||f||||||||||2018-06-01 02:41:50.859095|2018-06-01 02:41:50.859095
NCT00568204|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2013-10-16|2007-11-30|2007-12-05|Estimate|||||||2013-10-16|2013-10-17|Estimate|March 2002||2002-03-31|October 2013|2013-10-31|September 2005|Actual|2005-09-30|||||Interventional|Mexyn-A||Study of Effectiveness of Mexyn-A|Proof of Concept of MEXYN-A|Completed||N/A|279|Actual|Evangelical Synod Medical Centre||1|||f||||t||||||||||2018-06-01 02:41:50.916718|2018-06-01 02:41:50.916718
NCT00568191|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2007-12-04|2007-12-04|2007-12-05|Estimate|||||||2007-12-04|2007-12-05|Estimate|October 2007||2007-10-31|December 2007|2007-12-31|December 2007|Anticipated|2007-12-31|||||Observational|||Stratus Versus Cirrus OCT in AMD|Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT|Unknown status|Recruiting||100|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||2||f||||f||||||||||2018-06-01 02:41:50.982776|2018-06-01 02:41:50.982776
NCT00568178|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2009-08-11||2017-09-15|2007-12-03|2007-12-05|Estimate|2009-09-24|2009-10-30|Estimate||||2017-09-15|2017-10-17|Actual|June 1, 2007|Actual|2007-06-01|September 2017|2017-09-30|March 1, 2011|Actual|2011-03-01|September 1, 2008|Actual|2008-09-01||Interventional|||An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))|A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension|Completed||Phase 3|306|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:41:51.076245|2018-06-01 02:41:51.076245
NCT00568165|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2010-10-25|2007-12-04|2007-12-05|Estimate|||||||2010-10-25|2010-10-26|Estimate|February 2008||2008-02-29|August 2010|2010-08-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|EMEPIC||EMEPIC : Value of a Mobile Team of Cardiologist Using Echocardiography for Managing Patients With Acute Heart Failure|Value of a Mobile Team of Cardiologist Using Echocardiography for Managing Patients With Acute Heart Failure|Completed||N/A|504|Actual|University Paris 7 - Denis Diderot||2|||f||||f||||||||||2018-06-01 02:41:52.333908|2018-06-01 02:41:52.333908
NCT00568152|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2013-03-05|2007-12-04|2007-12-05|Estimate|||||||2013-03-05|2013-03-06|Estimate|May 2006||2006-05-31|March 2013|2013-03-31|May 2008|Actual|2008-05-31|||||Interventional|FLAVO||Effect of Apple Flavanols on Risk of Cardiovascular Disease|Effect of Apple Flavanols on Risk of Cardiovascular Disease|Completed||N/A|26|Actual|Quadram Institute||3|||f||||t||||||||||2018-06-01 02:41:52.415375|2018-06-01 02:41:52.415375
NCT00568139|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2016-10-28|2007-12-04|2007-12-05|Estimate|||||||2016-10-28|2016-11-01|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Side Effects of Mitotane|Evaluierung Von Nebenwirkungen Einer Therapie Mit Mitotane Beim Nebennierenkarzinom- Evaluation of Side Effects of Mitotane in Adrenocortical Carcinoma|Recruiting|||200|Anticipated|University of Wuerzburg|||2||f||||f||||||Samples Without DNA|"~     Serum, plasma, and urine samples will be collected.~   "|||2018-06-01 02:41:52.490788|2018-06-01 02:41:52.490788
NCT00568126|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03||2017-03-06|2017-03-06|2007-12-03|2007-12-05|Estimate||||2017-03-06|2017-03-08|Actual|2017-03-06|2017-03-08|Actual|November 2007||2007-11-30|March 2017|2017-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|MGH||Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females|A Double-Blind, Placebo Controlled Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females|Completed||Phase 3|80|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:41:52.55627|2018-06-01 02:41:52.55627
NCT00568113|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2007-12-04|2007-12-04|2007-12-05|Estimate|||||||2007-12-04|2007-12-05|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|NAC||N-Acetyl Cysteine for Prevention of Preterm Birth|Oral N-Acetyl Cysteine Can Prevent Preterm Labour in Multiparae With Previous Preterm Labour|Completed||Phase 4|120|Actual|Assiut University||2|||f||||f||||||||||2018-06-01 02:41:52.628159|2018-06-01 02:41:52.628159
NCT00568100|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2015-04-27|2007-12-04|2007-12-05|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of Pressure Support Ventilation and Neurally Adjusted Ventilatory Assist (NAVA) in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effect of Pressure Support Ventilation and Neurally Adjusted Ventilatory Assist (NAVA) in COPD Patients|Completed||N/A|15|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 02:41:52.698721|2018-06-01 02:41:52.698721
NCT00568087|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2013-06-14||2013-08-28|2007-12-04|2007-12-05|Estimate|2013-08-28|2013-11-01|Estimate||||2013-08-28|2013-11-01|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||N-acetylcysteine in Alcohol Dependence|N-acetylcysteine in Alcohol Dependence|Completed||Phase 1/Phase 2|46|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||t||||||||||2018-06-01 02:41:52.780641|2018-06-01 02:41:52.780641
NCT00568074|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-02-17|2007-12-04|2007-12-05|Estimate|||||||2017-02-17|2017-02-20|Actual|December 16, 2003||2003-12-16|February 2017|2017-02-28|September 2, 2004|Actual|2004-09-02|September 2, 2004|Actual|2004-09-02||Interventional|||Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes|Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|131|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:41:53.097519|2018-06-01 02:41:53.097519
NCT00568061|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2010-08-03||2016-05-12|2007-12-03|2007-12-05|Estimate|2010-08-03|2010-08-27|Estimate||||2016-05-12|2016-06-16|Estimate|June 2006||2006-06-30|May 2016|2016-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|NOMI||Nitric Oxide in Myocardial Infarction Size|The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size|Terminated||Phase 2|29|Actual|Mallinckrodt||1||Slow Enrollment|f||||t||||||||||2018-06-01 02:41:53.175948|2018-06-01 02:41:53.175948
NCT00568048|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2013-04-09|2007-12-04|2007-12-05|Estimate|||||||2013-04-09|2013-04-10|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|Temozolomide Combined With Bevacizumab in Metastatic Melanoma. A Multicenter Phase II Trial|Completed||Phase 2|62|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-06-01 02:41:53.433897|2018-06-01 02:41:53.433897
NCT00568035|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2009-01-07|2007-12-03|2007-12-05|Estimate|||||||2009-01-07|2009-01-08|Estimate|December 2006||2006-12-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy|Phase II Study of QR-333 for the Treatment of Symptomatic Diabetic Peripheral Neuropathy|Completed||Phase 2|140|Anticipated|Quigley Pharma, Inc.||2|||f||||f||||||||||2018-06-01 02:41:53.515731|2018-06-01 02:41:53.515731
NCT00568022|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2011-06-03||2016-02-09|2007-12-04|2007-12-05|Estimate|2011-07-21|2011-08-17|Estimate||||2016-02-09|2016-03-10|Estimate|February 2008||2008-02-29|February 2016|2016-02-29|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer|A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane|Completed||Phase 1|9|Actual|R-Pharm||1|||f||||t||||||||||2018-06-01 02:41:54.73484|2018-06-01 02:41:54.73484
NCT00568009|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2008-04-18|2007-12-04|2007-12-05|Estimate|||||||2008-04-18|2008-04-22|Estimate|October 2007||2007-10-31|April 2008|2008-04-30|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Observational|||Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function|Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function|Terminated|||300|Anticipated|Solvay Pharmaceuticals||||additional enrolment criteria made patients' recruitment not feasible anymore|f||||t||||||None Retained|"~     Not aplicable~   "|||2018-06-01 02:41:55.336454|2018-06-01 02:41:55.336454
NCT00567996|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2011-07-22||2011-07-22|2007-12-04|2007-12-05|Estimate|2011-07-22|2011-08-18|Estimate||||2011-07-22|2011-08-18|Estimate|November 2007||2007-11-30|July 2011|2011-07-31||||January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control|A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control|Completed||Phase 3|1002|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:41:55.671574|2018-06-01 02:41:55.671574
NCT00567970|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-11-14|2007-12-04|2007-12-05|Estimate|||||||2017-11-14|2017-11-17|Actual|April 2007|Actual|2007-04-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Stereotactic Radiation Therapy in Treating Patients With Liver Metastases|A Phase I Dose Finding Pilot Study of Stereotactic Body Radiotherapy for the Treatment of Liver Metastasis|Active, not recruiting||Phase 1|18|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 02:41:56.425792|2018-06-01 02:41:56.425792
NCT00567957|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2007-12-04|2007-12-04|2007-12-05|Estimate|||||||2007-12-04|2007-12-05|Estimate|February 2008||2008-02-29|December 2007|2007-12-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Remifentanil for General Anesthesia in Preeclamptics|Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Istanbul University||2|||f||||||||||||||2018-06-01 02:41:56.487386|2018-06-01 02:41:56.487386
NCT00567944|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2012-06-27|2007-12-03|2007-12-05|Estimate|||||||2012-06-27|2012-06-28|Estimate|June 2007||2007-06-30|June 2012|2012-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Use of the BrainPort® Balance Device to Improve Balance in Adults With Balance Deficits Due to Stroke|A Substitute Vestibular Information System Using the BrainPort® Balance Device for Adults With Chronic Vestibular Dysfunction Following Stroke|Completed||N/A|29|Actual|Wicab|||||f||||f||||||||||2018-06-01 02:41:56.658336|2018-06-01 02:41:56.658336
NCT00567931|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2014-07-23|2007-12-04|2007-12-05|Estimate|||||||2014-07-23|2014-07-24|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery|A Phase 1 Study of 1-Methyl-D-tryptophan in Patients With Advanced Malignancies|Completed||Phase 1|52|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:41:56.743047|2018-06-01 02:41:56.743047
NCT00567918|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2008-04-03|2007-12-03|2007-12-05|Estimate|||||||2008-04-03|2008-04-04|Estimate|May 2004||2004-05-31|April 2008|2008-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis|Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients|Completed||Phase 3|52|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 02:41:56.842274|2018-06-01 02:41:56.842274
NCT00567905|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2009-01-12|2007-12-04|2007-12-05|Estimate|||||||2009-01-12|2009-01-13|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|GTT-DM||Effect of Green Tea Extract on Type 2 Diabetes|Effect of Green Tea Extract on Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 2/Phase 3|32|Anticipated|Taipei Hospital, Taiwan||2|||f||||t||||||||||2018-06-01 02:41:56.960187|2018-06-01 02:41:56.960187
NCT00567892|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2012-04-11||2012-08-23|2007-12-03|2007-12-05|Estimate|2012-08-23|2012-08-27|Estimate||||2012-08-23|2012-08-27|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CTRWU||Collaborative Tinnitus Research at Washington University|Collaborative Tinnitus Research at Washington University|Completed||Phase 2|55|Actual|Washington University School of Medicine|Excluding subjects with Beck Depression Index of above 14 we treated an exclusive group of the Very bothered tinnitus patients, which may not be representative of the tinnitus population as a whole.|2|||f||||t||||||||||2018-06-01 02:41:57.093323|2018-06-01 02:41:57.093323
NCT00567879|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2016-04-04||2016-04-04|2007-12-04|2007-12-05|Estimate|2016-04-04|2016-05-09|Estimate||||2016-04-04|2016-05-09|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab|A Phase Ib/IIa Trial of Panobinostat in Combination With Trastuzumab in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed During or Following Therapy With Trastuzumab|Terminated||Phase 1/Phase 2|56|Actual|Novartis||1||The study was terminated early due to insufficient evidence of clinical benefit.|f||||||||||||||2018-06-01 02:41:57.466078|2018-06-01 02:41:57.466078
NCT00567866|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2010-07-12|2007-12-04|2007-12-05|Estimate|||||||2010-07-12|2010-07-13|Estimate|January 2008||2008-01-31|July 2010|2010-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Methamphetamine-Quetiapine Interactions in Humans|Methamphetamine-Quetiapine Interaction in Humans: A Pilot Study|Terminated||Early Phase 1|10|Actual|University of Arkansas||3||Study was terminated due to insufficient funds|f||||t||||||||||2018-06-01 02:41:59.059701|2018-06-01 02:41:59.059701
NCT00567853|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2015-01-22|2007-12-04|2007-12-05|Estimate|||||||2015-01-22|2015-01-26|Estimate|August 2007||2007-08-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MEMO3D||Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair|Clinical Investigation Of The Sorin 3D Annuloplasty Ring For Mitral Repair|Completed||Phase 3|278|Actual|Sorin Group USA, Inc.||1|||f||||f||||||||||2018-06-01 02:41:59.180331|2018-06-01 02:41:59.180331
NCT00567840|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2017-02-15||2017-04-10|2007-12-04|2007-12-05|Estimate|2017-02-15|2017-04-04|Actual||||2017-04-10|2017-05-15|Actual|August 2007||2007-08-31|January 2017|2017-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis|A Phase IIa Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of 14 Days' Treatment With Four Oral Doses of PA-824 in Adult Participants With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|Completed||Phase 2|69|Actual|Global Alliance for TB Drug Development||5|||f||||f||||||||||2018-06-01 02:41:59.256297|2018-06-01 02:41:59.256297
NCT00567827|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2010-06-23|2007-12-04|2007-12-05|Estimate|||||||2010-06-23|2010-06-24|Estimate|December 2007||2007-12-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|||Pathogen Identification of Bacterial Pneumonia Via DNA Detection|Identification of Bacterial Species and Their Antibiotic-Resistant Spectrum in Sputum Specimen From the Patients With Pneumonia Via Nuclear Acid Detection Assay|Completed|||2896|Actual|Peking University People's Hospital|||||f||||t||||||Samples With DNA|"~     DNA extracted from sputum specimen~   "|||2018-06-01 02:42:00.306369|2018-06-01 02:42:00.306369
NCT00567814|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2008-12-30|2007-12-03|2007-12-05|Estimate|||||||2008-12-30|2008-12-31|Estimate|December 2007||2007-12-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction|A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Two Dose Combinations of Metyrapone and Oxazepam in the Treatment of Cocaine Addiction|Completed||N/A|45|Anticipated|Embera NeuroTherapeutics, Inc.||3|||f||||f||||||||||2018-06-01 02:42:00.393743|2018-06-01 02:42:00.393743
NCT00559403|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2015-09-23|2007-11-15|2007-11-16|Estimate|||||||2015-09-23|2015-09-25|Estimate|October 2004||2004-10-31|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of HIV/STD Risk Reduction Program on South African Adolescents|South African Adolescent Health Promotion Project|Completed||Phase 2/Phase 3|1057|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 02:44:58.242231|2018-06-01 02:44:58.242231
NCT00567801|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2008-07-25|2007-12-04|2007-12-05|Estimate|||||||2008-07-25|2008-07-28|Estimate|September 2002||2002-09-30|July 2008|2008-07-31|September 2010|Anticipated|2010-09-30|September 2009|Anticipated|2009-09-30||Interventional|CRAIL||CRAIL - Controlled Reperfusion of the Acutely Ischemic Limb|Prospektive, Randomisierte Multicenter-Studie Zur Optimierung Der Therapie Der Akuten Ischämie Der Unteren Extremitäten Durch Die Kontrollierte Extremitätenreperfusion (Prospective, Randomized Multicenter - Study for Optimization of Therapy of the Acute Ischemic Limb by Controlled Reperfusion)|Terminated||Phase 3|250|Anticipated|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 02:42:00.512327|2018-06-01 02:42:00.512327
NCT00567788|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2007-12-04|2007-12-04|2007-12-05|Estimate|||||||2007-12-04|2007-12-05|Estimate|July 2006||2006-07-31|November 2007|2007-11-30|July 2008|Anticipated|2008-07-31|||||Interventional|||Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study|Comparison of Bimatoprost and Lataprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study|Unknown status|Active, not recruiting|N/A|60|Anticipated|Singapore National Eye Centre||2|||f||||t||||||||||2018-06-01 02:42:00.631524|2018-06-01 02:42:00.631524
NCT00567775|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2017-02-28|2007-12-04|2007-12-05|Estimate|||||||2017-02-28|2017-03-01|Actual|October 21, 2002|Actual|2002-10-21|February 2017|2017-02-28|November 20, 2002|Actual|2002-11-20|November 20, 2002|Actual|2002-11-20||Interventional|||Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes|Comparison of Pharmacokinetic Profiles of Human Soluble Insulin With Insulin Inhalation Solution in Paediatric Type 1 Diabetes Mellitus|Completed||Phase 2|27|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:42:00.716323|2018-06-01 02:42:00.716323
NCT00567762|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2014-08-29|2007-12-03|2007-12-05|Estimate|||||||2014-08-29|2014-09-01|Estimate|February 2004||2004-02-29|August 2014|2014-08-31|September 2004|Actual|2004-09-30|||||Interventional|||Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis|A Randomized, Placebo-controlled, Double-masked Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Vernal Keratoconjunctivitis|Completed||Phase 3|56|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 02:42:00.783753|2018-06-01 02:42:00.783753
NCT00567749|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2008-06-25|2007-12-04|2007-12-05|Estimate|||||||2008-06-25|2008-06-27|Estimate|December 2007||2007-12-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population|Clinical Sensitivity of the Clearview® COMPLETE HIV 1/2, PMA # BP050009 and the Clearview® HIV 1/2 STAT-PAK®, PMA #BP050010 in the 12 - 17 Year Old Pediatric Population|Completed|||10|Actual|Chembio Diagnostic Systems, Inc.|||1||f||||t||||||Samples Without DNA|"~     Whole blood, plasma and serum~   "|||2018-06-01 02:42:00.918874|2018-06-01 02:42:00.918874
NCT00567736|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2012-07-10|2007-12-04|2007-12-05|Estimate|||||||2012-07-10|2012-07-11|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|DISCI||Efficacy of Disci/Rhus Toxicodendron Comp.®, in Patients With Chronic Low Back Pain|Prospective Randomized Controlled Multicentre Trial for Patients With Chronic Low Back Pain Comparing Disci/Rhus Toxicodendron Comp.®, Placebo and Waiting List Group|Completed||Phase 3|150|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-06-01 02:42:00.983701|2018-06-01 02:42:00.983701
NCT00567723|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2016-06-15|2007-12-03|2007-12-05|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2006||2006-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)|A Phase-IV, Long-term, Observational Safety Study in End Stage Renal Disease Subjects Treated With Lanthanum Carbonate (Fosrenol)|Completed|||2105|Actual|Shire|||3||f||||f||||||||||2018-06-01 02:42:01.117093|2018-06-01 02:42:01.117093
NCT00567710|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2010-06-27|2007-12-04|2007-12-05|Estimate|||||||2010-06-27|2010-06-29|Estimate|July 2008||2008-07-31|June 2010|2010-06-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study|A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone|Completed||Phase 2|360|Anticipated|BioLineRx, Ltd.||4|||||||f||||||||||2018-06-01 02:42:01.570177|2018-06-01 02:42:01.570177
NCT00567697|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2012-01-18|2007-12-04|2007-12-05|Estimate|||||||2012-01-18|2012-01-19|Estimate|March 2007||2007-03-31|January 2012|2012-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO|A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO|Completed||Phase 3|32|Actual|Aleris Helse||2|||f||||t||||||||||2018-06-01 02:42:01.714121|2018-06-01 02:42:01.714121
NCT00567684|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2017-10-04|2007-12-03|2007-12-05|Estimate|||||||2017-10-04|2017-10-05|Actual|November 2007|Actual|2007-11-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors|Pilot Study Assessing the Technical Efficacy of Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) With Particular Focus on Patients at Risk of Urothelial Tumors|Active, not recruiting||N/A|135|Anticipated|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 02:42:01.812509|2018-06-01 02:42:01.812509
NCT00567671|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2010-09-01|2007-12-04|2007-12-05|Estimate|||||||2010-09-01|2010-09-02|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|CL||Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia or Progressive Keratoconus|Completed||Phase 2/Phase 3|160|Anticipated|Emory University||2|||f||||t||||||||||2018-06-01 02:42:01.934728|2018-06-01 02:42:01.934728
NCT00567658|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2013-09-04|2007-12-03|2007-12-05|Estimate|||||||2013-09-04|2013-09-06|Estimate|February 2008||2008-02-29|August 2013|2013-08-31|January 2010|Anticipated|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas|Effect of Aggressive Acid Suppression With Esomeprazole on Vocal Cord Granulomas: Randomized Placebo-Controlled Trial|Withdrawn||Phase 3|0|Actual|Vanderbilt University||2||"The decision of terminate the study was reached due to difficulties surrounding recruitment and~   enrollment of subjects since the inception of the study."|f||||f||||||||||2018-06-01 02:42:02.011574|2018-06-01 02:42:02.011574
NCT00567645|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2016-05-12|2007-12-04|2007-12-05|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2007||2007-07-31|May 2016|2016-05-31||||||||Observational|PET-CRT||Sympathetic Innervation of the Heart and Cardiac Resynchronization Therapy(CRT)|Identification of the Role of Sympathetic Innervation in Heart Failure Patients Treated With Cardiac Resynchronization Therapy. A Pilot Study|Withdrawn|||0|Actual|University Medical Center Groningen|||||f||||f||||||||||2018-06-01 02:42:02.115919|2018-06-01 02:42:02.115919
NCT00567632|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2011-01-14|2007-12-04|2007-12-05|Estimate|||||||2011-01-14|2011-01-17|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Observational|||Generation of Standard Laboratory Values for Pneumococci Antibodies|Generation of Standard Laboratory Values for Pneumococci Antibodies|Completed|||500|Actual|Johann Wolfgang Goethe University Hospital|||||f||||t||||||Samples Without DNA|"~     human serum~   "|||2018-06-01 02:42:02.19043|2018-06-01 02:42:02.19043
NCT00567619|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2008-02-14|2007-12-04|2007-12-05|Estimate|||||||2008-02-14|2008-02-18|Estimate|July 2007||2007-07-31|February 2008|2008-02-29||||||||Observational|||LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)|LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)|Completed|||900||AstraZeneca|||||f||||||||||||||2018-06-01 02:42:02.264221|2018-06-01 02:42:02.264221
NCT00567606|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2010-01-12|2007-12-03|2007-12-05|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2002||2002-04-30|January 2010|2010-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Prevention of Osteoporosis in Breast Cancer Survivors|Prevention of Osteoporosis in Breast Cancer Survivors|Completed||Phase 4|249|Actual|University of Nebraska||2|||f||||t||||||||||2018-06-01 02:42:02.338507|2018-06-01 02:42:02.338507
NCT00567593|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2013-12-20||2016-07-03|2007-12-03|2007-12-05|Estimate|2014-04-09|2014-05-08|Estimate||||2016-07-03|2016-08-01|Estimate|October 2007||2007-10-31|July 2016|2016-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|GReaT||Gene Regulation by Thiazolidinediones|Gene Regulation by Thiazolidinediones|Completed||Phase 4|12|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-06-01 02:42:02.437584|2018-06-01 02:42:02.437584
NCT00567580|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-12-21|2007-12-04|2007-12-05|Estimate|||||||2017-12-21|2017-12-26|Actual|February 2008||2008-02-29|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer|A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy|Active, not recruiting||Phase 3|1792|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-06-01 02:42:02.89001|2018-06-01 02:42:02.89001
NCT00567567|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2017-01-20||2017-06-26|2007-12-04|2007-12-05|Estimate|2017-05-22|2017-06-27|Actual||||2017-06-26|2017-07-26|Actual|November 2007||2007-11-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma|Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma|Completed||Phase 3|665|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 02:42:03.868409|2018-06-01 02:42:03.868409
NCT00567554|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2016-02-09|2007-12-04|2007-12-05|Estimate|||||||2016-02-09|2016-02-10|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|August 2011|Actual|2011-08-31||Interventional|GeparQuinto||Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer|A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer|Completed||Phase 3|2600|Actual|German Breast Group||6|||f||||t||||||||||2018-06-01 02:42:05.814282|2018-06-01 02:42:05.814282
NCT00567541|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2016-02-04||2016-03-02|2007-12-03|2007-12-05|Estimate|2016-03-02|2016-04-01|Estimate||||2016-03-02|2016-04-01|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|BBPM|fifteen of 16 subjects were randomized and their devices activated. One subject experienced and AE prior to device activation and was exited from the study|An Implantable Microneuromodulator for the Treatment of Chronic Shoulder Pain in Chronic Post-Stroke Subjects|Feasibility Study of the Bioness Battery-Powered Microneuromodulator (BBPM) to Treat Chronic Shoulder Pain in Chronic Post-Stroke Subjects|Completed||Phase 2|16|Actual|Bioness Inc|Further study plans terminated due to high migration/adverse event rates Small sample size Didn't include socio-environmental factors which could affect subject’s overall functionality Three different sites/subtle stimulator implantation variances|2|||f||||f||||||||No||2018-06-01 02:42:05.942099|2018-06-01 02:42:05.942099
NCT00567528|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2015-01-13|2007-12-03|2007-12-05|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes|Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes|Terminated||N/A|60|Actual|Akron Children's Hospital||2||Study was not producing meaningful data.|f||||f||||||||||2018-06-01 02:42:06.237583|2018-06-01 02:42:06.237583
NCT00567515|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2013-02-12|2007-12-03|2007-12-05|Estimate|||||||2013-02-12|2013-02-13|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|July 2010|Actual|2010-07-31||Interventional|||Safety and Effectiveness of Left Atrial Appendage Occlusion||Completed||Phase 2|41|Actual|AtriCure, Inc.||1|||f||||t||||||||||2018-06-01 02:42:06.311353|2018-06-01 02:42:06.311353
NCT00567502|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2015-03-25||2015-10-15|2007-12-04|2007-12-05|Estimate|2015-10-15|2015-11-17|Estimate||||2015-10-15|2015-11-17|Estimate|May 2005||2005-05-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational||First Treatment Safety Population included all participants who received at least 1 dose of cytoreductive treatment. Data of 2 participants were missing in the Other (Cytoreductives) treatment arm.|Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments|A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments|Completed|||3647|Actual|Shire|Results for other adverse events (excluding SAEs) was reported under OM 1 due to limitation in basic result’s format, as SAEs and non-SAEs were not planned to be reported separately.||3||f||||t||||||||||2018-06-01 02:42:06.45107|2018-06-01 02:42:06.45107
NCT00567489|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-04-19|2007-12-04|2007-12-05|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2008||2008-01-31|April 2017|2017-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Impendia||IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients|Multi-Center, Prospective, Randomized Trial To Demonstrate Improved Metabolic Control of PEN VS Dianeal Only in Diabetic CAPD and APD Patients - The Impendia Trial|Completed||Phase 4|137|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 02:42:07.476359|2018-06-01 02:42:07.476359
NCT00567294|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2012-05-14|2007-11-30|2007-12-04|Estimate|||||||2012-05-14|2012-05-15|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|January 2011|Actual|2011-01-31|December 2009|Actual|2009-12-31||Interventional|||Evaluating Ways to Improve Medication Use Among People With Osteoporosis|Improving Medication Adherence for Osteoporosis: A Community-Based Randomized Controlled Trial|Completed||Phase 3|2087|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-06-01 02:42:09.821239|2018-06-01 02:42:09.821239
NCT00567476|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|2011-04-26||2011-06-28|2007-12-04|2007-12-05|Estimate|2011-04-26|2011-05-23|Estimate||||2011-06-28|2011-06-30|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma|A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma|Completed||Phase 4|116|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:42:07.605234|2018-06-01 02:42:07.605234
NCT00567463|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2011-02-10|2007-12-04|2007-12-05|Estimate|||||||2011-02-10|2011-02-11|Estimate|December 1998||1998-12-31|December 2007|2007-12-31|December 2005|Actual|2005-12-31|||||Interventional|EATA||Early Antiinflammatory Treatment of Asthma|Early Anti-inflammatory Treatment of Asymptomatic or Mildly Symptomatic Airway Hyperresponsiveness|Terminated||N/A|83|Actual|Laval University||1||Completed|f||||f||||||||||2018-06-01 02:42:08.100577|2018-06-01 02:42:08.100577
NCT00567450|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2009-01-27|2007-12-04|2007-12-05|Estimate|||||||2009-01-27|2009-01-28|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Ropivacaine Versus Ropivacaine Plus Mepivacaine for Sciatic Block|Ropivacaine 0.75% vs Ropivacaine 0.75% Plus Mepivacaine 1.5% for Subgluteal Sciatic Bloc: a Prospective Double Blind Randomized Controlled Study|Completed||Phase 4|30|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-06-01 02:42:08.163235|2018-06-01 02:42:08.163235
NCT00567437|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2012-10-23|2007-12-04|2007-12-05|Estimate|||||||2012-10-23|2012-10-24|Estimate|December 2007||2007-12-31|November 2008|2008-11-30|December 2008|Actual|2008-12-31|||||Interventional|AS-BNP||Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis|Utility of Exercise-induced NT-pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis|Terminated||N/A|110|Anticipated|Duke University||2||Poor patient enrollment from clinic secondary to investigator illness.|f||||f||||||||||2018-06-01 02:42:08.232114|2018-06-01 02:42:08.232114
NCT00567424|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2013-04-01|2007-12-03|2007-12-05|Estimate|||||||2013-04-01|2013-04-04|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures|An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||||No longer viable|||||||||||||||2018-06-01 02:42:08.30185|2018-06-01 02:42:08.30185
NCT00567411|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2007-12-04|2007-12-04|2007-12-05|Estimate|||||||2007-12-04|2007-12-05|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|June 2009|Anticipated|2009-06-30|||||Interventional|||Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty|Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty|Unknown status|Recruiting|N/A|43|Anticipated|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 02:42:08.40191|2018-06-01 02:42:08.40191
NCT00567398|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-04|||2017-04-19|2007-12-04|2007-12-05|Estimate|||||||2017-04-19|2017-04-20|Actual|April 2008||2008-04-30|April 2017|2017-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Impendia||IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients|Multi-center,Prospective, Randomized Trial ToDemonstrate Improved Metabolic Control of PEN VS Dianeal In Diabetic CAPD and APD Patients - The Impendia Trial|Completed||Phase 3|43|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 02:42:08.489625|2018-06-01 02:42:08.489625
NCT00567385|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2017-02-27|2007-12-03|2007-12-04|Estimate|||||||2017-02-27|2017-02-28|Actual|March 10, 2003|Actual|2003-03-10|February 2017|2017-02-28|March 22, 2004|Actual|2004-03-22|March 22, 2004|Actual|2004-03-22||Interventional|||Liquid Somatropin Formulation in Children With Growth Hormone Deficiency|An Open, Multi-centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin® SimpleXx® in Children With GH Deficiency|Completed||Phase 4|176|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:42:08.609119|2018-06-01 02:42:08.609119
NCT00567372|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2008-12-05|2007-12-03|2007-12-04|Estimate|||||||2008-12-05|2008-12-08|Estimate|June 2008||2008-06-30|December 2008|2008-12-31|June 2009|Anticipated|2009-06-30|November 2008|Anticipated|2008-11-30||Interventional|||POSTERIOR SUB-TENON'S Avastin|POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA|Unknown status|Recruiting|Phase 4|7|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||f||||||||||2018-06-01 02:42:08.704094|2018-06-01 02:42:08.704094
NCT00567359|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2018-02-08|2007-11-30|2007-12-04|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2007||2007-12-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR|A Phase II Trial of Adjuvant Erlotinib in Patients With Resected, Early Stage Non-Small Cell Lung Cancer (NSCLC) With Confirmed Mutations in the Epidermal Growth Factor Receptor (EGFR)|Completed||Phase 2|100|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 02:42:09.026806|2018-06-01 02:42:09.026806
NCT00567346|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2010-05-04|2007-12-03|2007-12-04|Estimate|||||||2010-05-04|2010-05-05|Estimate|December 2006||2006-12-31|May 2010|2010-05-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of Grass Pollen Sublingual Immunotherapy|A Randomised, DB, Plcb Controlled, Multicentre, Multinational Phase II/III Study to Assess the Efficacy and Safety of Three Different Dose Regimens of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis|Completed||Phase 2/Phase 3|605|Actual|Artu Biologicals||4|||f||||t||||||||||2018-06-01 02:42:09.128552|2018-06-01 02:42:09.128552
NCT00567333|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2015-05-09|2007-12-03|2007-12-04|Estimate|||||||2015-05-09|2015-05-12|Estimate|June 2007||2007-06-30|May 2015|2015-05-31|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|||Individualized Chiropractic and Integrative Care for Low Back Pain|Individualized Chiropractic and Integrative Care for Low Back Pain|Completed||N/A|201|Actual|Northwestern Health Sciences University||2|||f||||t||||||||||2018-06-01 02:42:09.264918|2018-06-01 02:42:09.264918
NCT00567320|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2012-02-08||2013-01-31|2007-12-03|2007-12-04|Estimate|2012-03-13|2012-04-09|Estimate||||2013-01-31|2013-02-06|Estimate|March 2007||2007-03-31|January 2013|2013-01-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Varenicline in Methadone-Stabilized Cocaine Users|Efficacy of Varenicline in Methadone-Stabilized Cocaine Users|Completed||N/A|31|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:42:09.341644|2018-06-01 02:42:09.341644
NCT00567307|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2016-10-24||2017-05-09|2007-11-30|2007-12-04|Estimate|2016-10-24|2016-12-16|Estimate||||2017-05-09|2017-06-12|Actual|January 2009||2009-01-31|May 2017|2017-05-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Polypill For Prevention of Cardiovascular Disease|The Feasibility of a Polypill Clinical Trial for Primary Prevention of Cardiovascular Disease: A Pilot Study|Completed||Phase 2|216|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||Undecided||2018-06-01 02:42:09.543381|2018-06-01 02:42:09.543381
NCT00567281|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2016-08-23|2007-12-03|2007-12-04|Estimate|||||||2016-08-23|2016-08-24|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations|Bilateral rTMS Clinical Trial for Persistent Auditory Hallucinations|Recruiting||Phase 2|40|Anticipated|Yale University||3|||f||||t||||||||||2018-06-01 02:42:09.909098|2018-06-01 02:42:09.909098
NCT00567268|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2015-04-23||2015-09-30|2007-12-03|2007-12-04|Estimate|2015-04-23|2015-05-12|Estimate||||2015-09-30|2015-10-21|Estimate|August 2007||2007-08-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||"In total, 1194 participants were enrolled in the study. Of the 1194 participants, a total of 50 participants were excluded from the baseline analysis for the following reasons: protocol violation, lost to follow-up, no visit after first day of treatment, no drug administration, and safety evaluation Not Assessable."|Drug Use Investigation Of Gabapentin|Drug Use Investigation Of Gabapen|Completed|||1273|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:42:10.050467|2018-06-01 02:42:10.050467
NCT00567255|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2014-10-08|2012-10-30|2014-11-18|2007-11-30|2007-12-04|Estimate|2014-11-18|2014-11-21|Estimate|2012-10-30|2012-11-01|Estimate|2014-11-18|2014-11-21|Estimate|December 2007||2007-12-31|November 2014|2014-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||All randomized subjects|A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects|A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects|Completed||Phase 3|1496|Actual|Orexigen Therapeutics, Inc||2|||f||||t||||||||||2018-06-01 02:42:10.581484|2018-06-01 02:42:10.581484
NCT00567242|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2012-03-06||2012-04-30|2007-11-30|2007-12-04|Estimate|2012-04-27|2012-05-01|Estimate||||2012-04-30|2012-05-03|Estimate|March 2007||2007-03-31|April 2012|2012-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Treating Intention In Aphasia: Neuroplastic Substrates|Treating Intention In Aphasia: Neuroplastic Substrates|Completed||Phase 1/Phase 2|14|Actual|University of Florida|"Patients who had aphasia were enrolled. Groups were equated for anomia severity, but not type of aphasia. Aphasia types were not evenly distributed between groups which may affect results.~Intention subjects were older than Control Subjects."|2|||f||||t||||||||||2018-06-01 02:42:11.367311|2018-06-01 02:42:11.367311
NCT00567229|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|2015-10-19||2015-10-19|2007-12-01|2007-12-04|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma|Phase II Study of Lenalidomide and Rituximab for Patients With Relapsed and/or Refractory CD20+ Multiple Myeloma|Terminated||Phase 2|3|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of Accrual|f||||||||||||||2018-06-01 02:42:11.638667|2018-06-01 02:42:11.638667
NCT00567216|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-02|||2010-06-06|2007-12-02|2007-12-04|Estimate|||||||2010-06-06|2010-06-08|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|July 2010|Anticipated|2010-07-31|||||Interventional|GVO-nadolol||Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding|A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol|Unknown status|Recruiting|Phase 4|120|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-06-01 02:42:11.856182|2018-06-01 02:42:11.856182
NCT00567203|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2008-10-01|2007-12-03|2007-12-04|Estimate|||||||2008-10-01|2008-10-02|Estimate|November 2007||2007-11-30|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia|A Phase 1B Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-3463275 In Adjunctive Treatment Of Cognitive Deficits In Schizophrenia|Completed||Phase 1|36|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:42:11.936729|2018-06-01 02:42:11.936729
NCT00567190|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2012-08-14||2018-04-19|2007-12-03|2007-12-04|Estimate|2012-08-14|2012-09-13|Estimate||||2018-04-19|2018-04-24|Actual|February 12, 2008|Actual|2008-02-12|April 2018|2018-04-30|October 23, 2018|Anticipated|2018-10-23|May 13, 2011|Actual|2011-05-13||Interventional|CLEOPATRA|ITT population|A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer|A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer|Active, not recruiting||Phase 3|808|Actual|Genentech, Inc.||2|||f|||||t|f||||||||2018-06-01 02:42:12.104952|2018-06-01 02:42:12.104952
NCT00567177|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2010-07-29|2007-12-03|2007-12-04|Estimate|||||||2010-07-29|2010-07-30|Estimate|November 2007||2007-11-30|July 2010|2010-07-31|April 2008|Actual|2008-04-30|||||Interventional|||Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease|Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease|Completed||Phase 4|40|Anticipated|Innovative Medical||2|||f||||||||||||||2018-06-01 02:42:14.037328|2018-06-01 02:42:14.037328
NCT00567164|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2013-10-07|2010-11-15|2014-01-28|2007-12-03|2007-12-04|Estimate|2014-01-28|2014-03-12|Estimate|2010-11-15|2010-11-23|Estimate|2014-01-28|2014-03-12|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ|A Multicenter, Open-label, Three-arm, Active-controlled Study to Assess the Efficacy and Safety of the Oral Contraceptive SH T00186D (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in Two Flexible Extended Regimens and a Conventional Regimen of YAZ in 1756 Healthy Females for 1 Year|Completed||Phase 3|1887|Actual|Bayer|The Flexible (extended) Regimen no. 1 Group was enrolled under slightly different eligibility criteria for age, BMI, and fertility status than the other two treatment groups. This did not affect the results or interpretation of the results.|3|||f||||f||||||||||2018-06-01 02:42:14.24627|2018-06-01 02:42:14.24627
NCT00567151|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-02|||2009-06-20|2007-12-02|2007-12-04|Estimate|||||||2009-06-20|2009-06-23|Estimate|December 2007||2007-12-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Co-Infection of NTM in Patients With Smear Positive Pulmonary TB|Detection of Nontuberculous Mycobacterial co-Infection Using Duplex PCR for Mycobacterial Hsp 65 Gene and Its Clinical Significance in Patients With Smear Positive Pulmonary Tuberculosis|Completed|||200|Anticipated|Seoul National University Hospital|||||f||||f||||||Samples Without DNA|"~     Sputa with positive AFB smear~   "|||2018-06-01 02:42:15.175194|2018-06-01 02:42:15.175194
NCT00567125|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|||2007-12-03|2007-12-03|2007-12-04|Estimate|||||||2007-12-03|2007-12-04|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Observational|||Comparison of Systemic Response After Laparoscopies Performed With Standard and Low-Pressure Pneumoperitoneum|A Comparative Study of Angiogenic and Cytokine Responses After Laparoscopic Cholecystectomy Performed With Standard-Pressure and Low-Pressure Pneumoperitoneum|Completed|||40|Actual|Medical University of Lublin|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:42:15.238191|2018-06-01 02:42:15.238191
NCT00567112|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2012-07-17||2015-03-12|2007-11-30|2007-12-04|Estimate|2012-08-02|2012-09-05|Estimate||||2015-03-12|2015-03-23|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)|An Open-Label, Randomized, Partially Fixed-Sequence, 4-Period Crossover Study to Assess the Pharmacokinetics After Administration of the DFC and OCT Formulations and the Food Effect on the OCT Formulation of MK-0941 in Patients With Type 2 Diabetes|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:42:15.331646|2018-06-01 02:42:15.331646
NCT00567099|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2010-05-24|2007-12-03|2007-12-04|Estimate|||||||2010-05-24|2010-05-25|Estimate|August 2003||2003-08-31|December 2007|2007-12-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole|Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole|Unknown status|Recruiting|N/A|20|Anticipated|New Mexico VA Healthcare System|||||f||||t||||||||||2018-06-01 02:42:15.74131|2018-06-01 02:42:15.74131
NCT00567086|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2007-12-03|2007-12-03|2007-12-04|Estimate|||||||2007-12-03|2007-12-04|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine|A Double-Blind, Placebo-Controlled, Parallel Group Multicenter Study to Assess the Safety, Tolerance and Efficacy of a Single Subcutaneous Dose of TEZAMPANEL in Patients With Acute Migraine|Completed||Phase 2|306|Actual|TorreyPines Therapeutics||4|||f||||f||||||||||2018-06-01 02:42:15.822595|2018-06-01 02:42:15.822595
NCT00567073|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|||2017-08-17|2007-12-01|2007-12-04|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2011|Actual|2011-11-30|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Pompe Pregnancy Sub-Registry|A Sub-Registry to Observe the Effect of Myozyme (Alglucosidase Alfa) Treatment on Pregnancy and Infant Growth in Women With Pompe Disease|Recruiting|||20|Anticipated|Sanofi|||4||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 02:42:15.900538|2018-06-01 02:42:15.900538
NCT00567060|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2013-12-13|2007-11-30|2007-12-04|Estimate|||||||2013-12-13|2013-12-16|Estimate|May 2000||2000-05-31|September 2009|2009-09-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)|A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of 9600 and 4800 mg/Day Piracetam Taken for 12 Months by Subjects Suffering From Mild Cognitive Impairment (MCI)|Completed||N/A|676|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:42:15.978946|2018-06-01 02:42:15.978946
NCT00567047|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2009-03-24|2007-12-03|2007-12-04|Estimate|||||||2009-03-24|2009-03-25|Estimate|July 2007||2007-07-31|March 2009|2009-03-31||||January 2009|Actual|2009-01-31||Interventional|||Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment|An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate or Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Daily Doses of 50 mg Vildagliptin for 14 Days|Completed||Phase 1|96|Anticipated|Novartis||1|||f||||f||||||||||2018-06-01 02:42:16.047508|2018-06-01 02:42:16.047508
NCT00567034|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2013-10-24|2007-12-03|2007-12-04|Estimate|||||||2013-10-24|2013-10-25|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|Zyprexa||Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects|Augmenting Zyprexa With Naltrexone: Normalization of the Weight Gain Side Effect and the CNS Reward and Sensory Function|Completed||Phase 1|30|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 02:42:16.123072|2018-06-01 02:42:16.123072
NCT00567021|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2008-01-28|2007-12-03|2007-12-04|Estimate|||||||2008-01-28|2008-01-29|Estimate|September 2005||2005-09-30|January 2008|2008-01-31|December 2005|Actual|2005-12-31|||||Observational|||German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms|German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms|Completed|||67130|Actual|AstraZeneca|||1||f||||f||||||||||2018-06-01 02:42:16.357279|2018-06-01 02:42:16.357279
NCT00567008|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2013-07-17||2013-10-14|2007-12-03|2007-12-04|Estimate|2013-10-14|2013-11-07|Estimate||||2013-10-14|2013-11-07|Estimate|December 2007||2007-12-31|October 2013|2013-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Chantix for Treating Cocaine Dependence|A Double-Blind Placebo-Controlled Pilot Trial of Varenicline (Chantix) for the Treatment of Cocaine Dependence|Completed||Phase 2|37|Actual|University of Pennsylvania|This study was a small preliminary trial, and thus was underpowered for anything less than large effects.|2|||f||||t||||||||||2018-06-01 02:42:16.431794|2018-06-01 02:42:16.431794
NCT00566995|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|2015-02-12||2015-03-19|2007-12-01|2007-12-04|Estimate|2015-03-09|2015-03-11|Estimate||||2015-03-19|2015-04-07|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Interventional|||Phase II Study of Vandetanib in Individuals With Kidney Cancer|A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors|Completed||Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 02:42:16.765576|2018-06-01 02:42:16.765576
NCT00566982|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2013-03-19||2018-04-19|2007-11-30|2007-12-04|Estimate|2013-05-21|2013-06-28|Estimate||||2018-04-19|2018-05-18|Actual|October 2007||2007-10-31|April 2018|2018-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Clinical Study to Evaluate the Safety of Ospemifene|Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo|Completed||Phase 3|426|Actual|Shionogi Inc.||2|||f||||||||||||||2018-06-01 02:42:17.30629|2018-06-01 02:42:17.30629
NCT00566969|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2016-08-16||2018-01-16|2007-12-03|2007-12-04|Estimate|2016-08-16|2016-10-10|Estimate||||2018-01-16|2018-02-13|Actual|September 2007||2007-09-30|January 2018|2018-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|Carvedilol|106 subjects meeting inclusion criteria who were without exclusions and randomized to an intervention.|Cocaine Withdrawal and Pharmacotherapy Response|Cocaine Withdrawal and Pharmacotherapy Response|Completed||N/A|106|Actual|Yale University||3|||f||||t||||||||No||2018-06-01 02:42:18.578634|2018-06-01 02:42:18.578634
NCT00566956|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2015-07-20|2007-11-30|2007-12-04|Estimate|||||||2015-07-20|2015-07-21|Estimate|October 1999||1999-10-31|November 2007|2007-11-30|June 2004|Actual|2004-06-30|||||Interventional|||Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection|Ultrasound-guided Hydrosalpinx Aspiration During Egg Collection Improves Pregnancy Outcome in In-vitro Fertilization: a Randomised Controlled Trial|Terminated||Phase 2|66|Actual|Birmingham Women's NHS Foundation Trust||2||The study was terminated because it is very difficult to recruit more patients.|f||||t||||||||||2018-06-01 02:42:19.251072|2018-06-01 02:42:19.251072
NCT00565188|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2016-10-24|2007-11-28|2007-11-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2002||2002-03-31|November 2007|2007-11-30|October 2006|Actual|2006-10-31|||||Interventional|||Application of ATP Infusions in Palliative Home Care|Application of Adenosine 5'-Triphosphate (ATP) Infusions in Palliative Home Care|Completed||Phase 3|100|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 02:43:01.554585|2018-06-01 02:43:01.554585
NCT00566943|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2009-12-18||2017-04-19|2007-12-03|2007-12-04|Estimate|2012-05-23|2012-05-28|Estimate||||2017-04-19|2017-05-19|Actual|March 2006||2006-03-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|RESULTS||Reinforcement of Surgical Staple Lines Using Peri-Strips Dry (PSD) With Veritas Collagen Matrix|Synovis Life Technologies, Inc., Peri-Strips Dry With Veritas Collagen Matrix Staple Line Reinforcement. The RESULTS Trial|Completed||N/A|101|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 02:42:19.37305|2018-06-01 02:42:19.37305
NCT00566930|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2012-06-12||2012-09-13|2007-12-03|2007-12-04|Estimate|2012-08-17|2012-09-14|Estimate||||2012-09-13|2012-09-28|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Preventive Care of Chronic Cervical Pain and Disabilities|Preventive Care of Chronic Cervical Pain and Disabilities; Comparison of Spinal Manipulative Therapy and Individualized Home Exercise Programs|Completed||N/A|117|Actual|Université du Québec à Trois-Rivières||3|||f||||t||||||||||2018-06-01 02:42:19.698139|2018-06-01 02:42:19.698139
NCT00566917|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2010-01-28|2007-11-30|2007-12-04|Estimate|||||||2010-01-28|2010-01-29|Estimate|December 2007||2007-12-31|May 2008|2008-05-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Comparison Between Transvaginal Mesh and Traditional Surgery for Pelvic Organ Prolapse|A Randomised Controlled Trial of Transvaginal Mesh (PROLIFT) Versus Anterior Colporrhaphy in Anterior Vaginal Wall Prolapse|Completed||Phase 4|400|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 02:42:19.947028|2018-06-01 02:42:19.947028
NCT00566904|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2011-08-29|2007-11-30|2007-12-04|Estimate|||||||2011-08-29|2011-08-31|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||New Topical Treatment for Continued Pain After Shingles|Phase 1 Novel Topical Treatment for Post-herpetic Neuralgia|Completed||Phase 1|30|Actual|Biomedical Development Corporation||1|||f||||t||||||||||2018-06-01 02:42:20.081054|2018-06-01 02:42:20.081054
NCT00566891|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2011-02-01|2007-11-30|2007-12-04|Estimate|||||||2011-02-01|2011-02-02|Estimate|December 2007||2007-12-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|SANTISS||Safety of High-dose Tirofiban During Coronary Angioplasty|Safety of High-dose Tirofiban in Patient Undergoing Coronary Angioplasty.|Completed||Phase 4|2000|Actual|S. Anna Hospital||2|||f||||t||||||||||2018-06-01 02:42:20.195592|2018-06-01 02:42:20.195592
NCT00566878|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|||2017-12-21|2007-12-01|2007-12-04|Estimate|||||||2017-12-21|2017-12-26|Actual|March 2012||2012-03-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|November 2021|Anticipated|2021-11-30||Observational|||Pompe Lactation Sub-Registry|A Sub-Registry to Determine the Presence of Alglucosidase Alfa in Breast Milk From Women With Pompe Disease Treated With Alglucosidase Alfa.|Recruiting|||5|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 02:42:20.275476|2018-06-01 02:42:20.275476
NCT00566865|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2009-02-16|2007-12-03|2007-12-04|Estimate|||||||2009-02-16|2009-02-18|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil|A Double-Blind, Placebo-Controlled Study to Assess the Effect of Gemfibrozil Co-Administration on the Pharmacokinetics and Pharmacodynamics of Mitiglinide in Healthy Volunteers|Completed||Phase 1|14|Actual|Elixir Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:42:20.52771|2018-06-01 02:42:20.52771
NCT00566852|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|2016-04-19||2017-07-21|2007-12-01|2007-12-04|Estimate|2017-06-22|2017-07-21|Actual||||2017-07-21|2017-08-21|Actual|March 2008||2008-03-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|April 2011|Actual|2011-04-30||Interventional||All randomized eligible patients.|Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors|A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy|Completed||Phase 3|554|Actual|Radiation Therapy Oncology Group|Given the poor compliance of the HVLT-R at 24 weeks, there was only 35% statistical power to detect the hypothesized effect size. Please see linked manuscript.|2|||f||||t||||||||||2018-06-01 02:42:20.676125|2018-06-01 02:42:20.676125
NCT00566839|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2007-11-30|2007-11-30|2007-12-04|Estimate|||||||2007-11-30|2007-12-04|Estimate|December 2002||2002-12-31|October 2007|2007-10-31|October 2005|Actual|2005-10-31|||||Interventional|||Randomized Comparison of Awake Nonresectional Versus Nonawake Resectional Lung Volume Reduction Surgery|Randomized Comparison of Thoracoscopic Lung Volume Reduction Surgery Performed by Resectional Surgical Technique Under General Anesthesia or by a Non-Resectional Technique in Awake Patients Under Sole Epidural Anesthesia|Completed||Phase 2|60|Actual|University of Rome Tor Vergata||2|||f||||t||||||||||2018-06-01 02:42:21.843993|2018-06-01 02:42:21.843993
NCT00566826|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2013-02-24|2007-11-30|2007-12-04|Estimate|||||||2013-02-24|2013-02-26|Estimate|June 2008||2008-06-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Perioperative Intervention to Improve Post-TKR Support and Function|Perioperative Intervention to Improve Post-TKR Support and Function|Completed||Phase 2|196|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 02:42:21.932797|2018-06-01 02:42:21.932797
NCT00566813|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2011-08-05|2007-11-30|2007-12-04|Estimate|||||||2011-08-05|2011-08-08|Estimate|November 2004||2004-11-30|October 2007|2007-10-31|December 2013|Anticipated|2013-12-31|December 2008|Actual|2008-12-31||Interventional|||Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression|Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression|Unknown status|Active, not recruiting|Phase 1/Phase 2|10|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-06-01 02:42:22.0048|2018-06-01 02:42:22.0048
NCT00566800|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|||2013-09-16|2007-12-01|2007-12-04|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 2007||2007-07-31|January 2008|2008-01-31||||||||Interventional|||Erlotinib in Treating Patients With Barrett Esophagus|Chemoprevention Trial Using Erlotinib in Barrett's Esophagus With High-Grade Dysplasia|Unknown status|Recruiting|Phase 1|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:42:22.097365|2018-06-01 02:42:22.097365
NCT00566787|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|||2012-01-23|2007-12-03|2007-12-04|Estimate|||||||2012-01-23|2012-01-25|Estimate|January 2005||2005-01-31|January 2012|2012-01-31|November 2010|Actual|2010-11-30|December 2007|Actual|2007-12-31||Interventional|RESTORE SR||Concomitant Treatment of Permanent Atrial Fibrillation|A Prospective, Multi-center Study With Case Matched Controls to Evaluate the Safety and Efficacy of the AtriCure Bipolar System for the Treatment of Continuous Atrial Fibrillation as Adjunct Therapy to Elective Open Heart Surgery|Completed||Phase 3|39|Actual|AtriCure, Inc.|||||f||||||||||||||2018-06-01 02:42:22.170944|2018-06-01 02:42:22.170944
NCT00566774|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2016-01-07|2007-11-30|2007-12-04|Estimate|||||||2016-01-07|2016-01-11|Estimate|November 2007||2007-11-30|January 2016|2016-01-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|MI FREEE||A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies|Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial: a Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies|Completed||Phase 4|5860|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 02:42:22.250834|2018-06-01 02:42:22.250834
NCT00566761|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2007-11-30|2007-11-30|2007-12-04|Estimate|||||||2007-11-30|2007-12-04|Estimate|June 2007||2007-06-30|November 2007|2007-11-30|March 2008|Anticipated|2008-03-31|||||Interventional|MECROV||Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO|Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion|Unknown status|Recruiting|Phase 4|10|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||t||||||||||2018-06-01 02:42:22.322317|2018-06-01 02:42:22.322317
NCT00566735|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-03|2012-06-05||2012-11-02|2007-12-03|2007-12-04|Estimate|2012-11-02|2012-12-03|Estimate||||2012-11-02|2012-12-03|Estimate|July 2004||2004-07-31|November 2012|2012-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|Galantamine||The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning|The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning|Completed||Phase 3|39|Actual|Massachusetts General Hospital|The limitations of this study include a small sample size, absence of an optimal galantamine dose determination, and the inclusion of a heterogenous population including MDD, bipolar disorder, and schizoaffective order.|2|||f||||f||||||||||2018-06-01 02:42:22.397097|2018-06-01 02:42:22.397097
NCT00566722|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-01|2010-04-28||2011-04-08|2007-12-01|2007-12-04|Estimate|2010-04-28|2010-05-28|Estimate||||2011-04-08|2011-04-12|Estimate|January 2008||2008-01-31|April 2011|2011-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy|Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy|Completed||Phase 3|152|Actual|Abbott||1|||f||||f||||||||||2018-06-01 02:42:22.698144|2018-06-01 02:42:22.698144
NCT00566709|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2015-11-20||2016-03-21|2007-11-30|2007-12-03|Estimate|2016-02-12|2016-03-11|Estimate||||2016-03-21|2016-04-19|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional||"Patient included into to Intention to treat analysis"|Near Infrared Spectroscopy (NIRS) as Transfusion Indicator in Neurocritical Patients|Phase II Study of Usefulness of Near Infrared Spectroscopy to Optimize Red Blood Cells Transfusion in Neuro Critical Ill Patients With Severe Traumatic Brain Injury, Subarachnoid Hemorrhage or Intracerebral Hemorrhage.|Completed||Phase 2|102|Actual|Hospitales Universitarios Virgen del Rocío|Limited adherence to the protocol in the rSO2 arm|2|||f||||t||||||||||2018-06-01 02:42:23.405265|2018-06-01 02:42:23.405265
NCT00566696|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2016-01-27||2018-05-09|2007-11-29|2007-12-03|Estimate|2016-03-30|2016-05-03|Estimate||||2018-05-09|2018-05-11|Actual|December 2007|Actual|2007-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|January 2015|Actual|2015-01-31||Interventional|||Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies|A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation|Active, not recruiting||Phase 2|73|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 02:42:23.827857|2018-06-01 02:42:23.827857
NCT00566683|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2007-11-30|2007-11-30|2007-12-03|Estimate|||||||2007-11-30|2007-12-03|Estimate|July 2005||2005-07-31|November 2007|2007-11-30|June 2006|Actual|2006-06-30|||||Interventional|||Comparison Between Nurse-Administered Propofol Sedation and Diazemuls / Pethidine in Outpatient Colonoscopy|Nurse-Administered Propofol Sedation by PCA Pump Versus Diazemuls / Pethidine in Outpatient Colonoscopy: A Randomized Controlled Study|Completed||N/A|194|Actual|North District Hospital||2|||f||||f||||||||||2018-06-01 02:42:24.279476|2018-06-01 02:42:24.279476
NCT00566670|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2016-08-09|2007-11-30|2007-12-03|Estimate|||||||2016-08-09|2016-08-11|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease|Protein Intake, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease (CKD)|Completed|||145|Actual|University of Utah|||1||f||||t||||||Samples With DNA|"~     30 ml of blood drawn four times (months 1, 6, 12 and 18) for plasma/serum/DNA samples.~      Urine Collection: If patients are making more than ½ cup (200 ml) of urine a day.~   "|||2018-06-01 02:42:24.359632|2018-06-01 02:42:24.359632
NCT00566657|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30||2016-03-30|2016-03-30|2007-11-30|2007-12-03|Estimate||||2016-03-30|2016-05-02|Estimate|2016-03-30|2016-05-02|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Interventional|TAMARIS||Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions|A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions|Completed||Phase 3|525|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:42:24.450656|2018-06-01 02:42:24.450656
NCT00566644|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2013-07-09|2007-11-30|2007-12-03|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 2007||2007-07-31|October 2008|2008-10-31|August 2009|Actual|2009-08-31|October 2008|Actual|2008-10-31||Interventional|||Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome|Prevention of Endometrial Tumors (POET)|Terminated||Phase 3|600|Anticipated|National Cancer Institute (NCI)||||Withdrawn due to poor accrual|f||||||||||||||2018-06-01 02:42:24.584917|2018-06-01 02:42:24.584917
NCT00566631|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2013-04-03||2013-06-27|2007-11-29|2007-12-03|Estimate|2013-06-27|2013-08-02|Estimate||||2013-06-27|2013-08-02|Estimate|July 2007||2007-07-31|June 2013|2013-06-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|PERTAIN||An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia|Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects With Schizophrenia|Completed||Phase 3|294|Actual|Janssen-Cilag International NV||1|||f||||f||||||||||2018-06-01 02:42:24.732072|2018-06-01 02:42:24.732072
NCT00566618|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2018-01-08|2007-11-29|2007-12-03|Estimate|||||||2018-01-08|2018-01-10|Actual|November 2007|Actual|2007-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis|Phase I/II Study of Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis|Active, not recruiting||Phase 1/Phase 2|28|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:42:25.19852|2018-06-01 02:42:25.19852
NCT00566605|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-11-30|2007-11-30|2007-12-03|Estimate|||||||2007-11-30|2007-12-03|Estimate|August 2007||2007-08-31|November 2007|2007-11-30|August 2008|Anticipated|2008-08-31|||||Interventional|||Outcomes in a Comparison of Manual Penetrating Keratoplasty and the IntraLase® Enabled Keratoplasty|Visual Outcomes in a Comparison of Manual Penetrating Keratoplasty and the IntraLase® Enabled Keratoplasty|Unknown status|Active, not recruiting|Phase 1|60|Actual|Hospital Oftalmologico de Sorocaba||2|||f||||t||||||||||2018-06-01 02:42:25.279186|2018-06-01 02:42:25.279186
NCT00175786|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-24|2005-09-13|2005-09-15|Estimate|||||||2008-09-24|2008-09-25|Estimate|July 2005||2005-07-31|September 2008|2008-09-30||||||||Observational|||Magnetic Resonance Imaging of Patients With Normal Tension Glaucoma|Neuroradiologic Screening of Patients With Normal Tension Glaucoma|Completed|||50|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:37:44.103182|2018-06-01 04:37:44.103182
NCT00566592|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2014-09-23|2007-11-29|2007-12-03|Estimate|||||||2014-09-23|2014-09-25|Estimate|January 2005||2005-01-31|September 2014|2014-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Effect of Ethanol on Overnight Glucose Regulation in Type 2|The Effect of Ethanol on Overnight Glucose Regulation in Type 2 Diabetes Mellitus|Completed||N/A|24|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||f||||||||||2018-06-01 02:42:25.331522|2018-06-01 02:42:25.331522
NCT00566579|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|2010-06-01||2010-08-02|2007-11-30|2007-12-03|Estimate|2010-07-06|2010-08-02|Estimate||||2010-08-02|2010-08-10|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|Cryotherapy||Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions|Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions: a Randomized Controlled Trial|Terminated||N/A|100|Actual|Khon Kaen University||2||Lack of additional funding|f||||f||||||||||2018-06-01 02:42:25.397939|2018-06-01 02:42:25.397939
NCT00566566|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2007-11-30|2007-11-30|2007-12-03|Estimate|||||||2007-11-30|2007-12-03|Estimate|January 2008||2008-01-31|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Observational|||Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors|Adipocytokines as Predictors of the Metabolic Syndrome in Survivors of Childhood Acute Lymphoblastic Leukemia|Unknown status|Not yet recruiting||150|Anticipated|Sheba Medical Center|||1||f||||f||||||Samples Without DNA|"~     Serum leptin, resistin ,adiponectin ,CRP, PAI ,TNF-α, IL-6 will be taken as part of initial~     blood test screening in patients following an overnight fast. Adiponectin and leptin levels~     will be determined by RIA (Linco, St. Charles, MO), Insulin, will be determined by~     chemiluminescent immunometric method (Immulite 2000, Diagnostic Products Corporation, Los~     Angeles, CA).~   "|||2018-06-01 02:42:25.617374|2018-06-01 02:42:25.617374
NCT00566553|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2012-01-04|2007-11-30|2007-12-03|Estimate|||||||2012-01-04|2012-01-06|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women|The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women: A Pilot Study|Completed||N/A|39|Actual|Mayo Clinic||4|||f||||f||||||||||2018-06-01 02:42:25.682208|2018-06-01 02:42:25.682208
NCT00566540|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2016-10-20|2007-11-30|2007-12-03|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2007||2007-12-31|October 2016|2016-10-31||||February 2010|Actual|2010-02-28||Interventional|||Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer|Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Hypopharynx: Incorporation of Intensity Modulated Radiotherapy and Submandibular Gland Transfer to Minimize Treatment Morbidity; Correlative Imaging/Molecular Markers.|Active, not recruiting||Phase 2|50|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:42:25.90046|2018-06-01 02:42:25.90046
NCT00566527|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2017-10-04||2018-01-03|2007-11-29|2007-12-03|Estimate|2018-01-03|2018-01-30|Actual||||2018-01-03|2018-01-30|Actual|November 29, 2007|Actual|2007-11-29|January 2018|2018-01-31|December 29, 2008|Actual|2008-12-29|December 29, 2008|Actual|2008-12-29||Interventional|||Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)|An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA Administered to Healthy Children From 9 Months of Age|Completed||Phase 3|1620|Actual|Merck Sharp & Dohme Corp.||3|||f||||f|t|f|||t|||||2018-06-01 02:42:26.013666|2018-06-01 02:42:26.013666
NCT00566514|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2008-03-10|2007-11-29|2007-12-03|Estimate|||||||2008-03-10|2008-03-13|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||The Role of Ribose in Patients Diagnosed With Fibromyalgia|The Role of D-RIbose in Patients Diagnosed With Fibromyalgia|Suspended||N/A|200|Anticipated|Bioenergy Life Science, Inc.||2||Protocol Under Review|f||||f||||||||||2018-06-01 02:42:26.726075|2018-06-01 02:42:26.726075
NCT00566501|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2012-05-16||2014-06-26|2007-11-29|2007-12-03|Estimate|2012-05-16|2012-06-19|Estimate||||2014-06-26|2014-07-11|Estimate|December 2007||2007-12-31|May 2012|2012-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease|Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease|Completed||Phase 3|915|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 02:42:26.806721|2018-06-01 02:42:26.806721
NCT00566488|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2018-05-02|2007-11-30|2007-12-03|Estimate|||||||2018-05-02|2018-05-07|Actual|January 2005||2005-01-31|May 2018|2018-05-31|June 2027|Anticipated|2027-06-30|August 2007|Actual|2007-08-31||Interventional|||Parathyroid and Thymus Transplantation in DiGeorge #931|Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931|Active, not recruiting||Phase 1|25|Actual|Duke University||1|||f||||t|t|f||||||||2018-06-01 02:42:28.42045|2018-06-01 02:42:28.42045
NCT00566475|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2009-12-29|2007-11-30|2007-12-03|Estimate|||||||2009-12-29|2009-12-30|Estimate|January 2007||2007-01-31|December 2009|2009-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus|School Centered Telemedicine Program for Children With Type 1 Diabetes Mellitus|Completed||N/A|41|Actual|State University of New York - Upstate Medical University||2|||f||||f||||||||||2018-06-01 02:42:28.511853|2018-06-01 02:42:28.511853
NCT00566462|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2012-11-20||2017-07-27|2007-11-30|2007-12-03|Estimate|2012-11-20|2012-12-24|Estimate||||2017-07-27|2017-08-28|Actual|October 2007||2007-10-31|July 2017|2017-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT|Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT|Terminated||Phase 2|1|Actual|Eisai Inc.|This study was terminated at the sponsor request after only 1 subject was enrolled and completed the study and therefore the data is limited. Similiar research in this area have required a minimum of 5-6 completers to develop a valid analysis.|2||Study stopped due to lack of efficacy.|f||||||||||||||2018-06-01 02:42:28.597248|2018-06-01 02:42:28.597248
NCT00566449|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29||2011-06-02|2014-04-24|2007-11-29|2007-12-03|Estimate||||2011-06-02|2011-06-09|Estimate|2014-04-24|2014-05-13|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder.|A Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Investigate the Safety and Efficacy of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 2|32|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 02:42:28.826333|2018-06-01 02:42:28.826333
NCT00509613|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2009-09-17|2007-07-30|2007-07-31|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2007||2007-06-30|September 2009|2009-09-30||||May 2009|Actual|2009-05-31||Interventional|||Phase 1 Study With Sorafenib and Sirolimus|Phase 1 Dose Escalation Study With Sorafenib in Combination With Sirolimus in Patients With Solid Tumor|Completed||Phase 1|||Radboud University|||||f||||f||||||||||2018-06-01 03:01:58.360309|2018-06-01 03:01:58.360309
NCT00566436|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-11-29|2007-11-29|2007-12-03|Estimate|||||||2007-11-29|2007-12-03|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|March 2012|Anticipated|2012-03-31|||||Interventional|REVAS||Remote Endarterectomy Versus Suprageniculate Femoropopliteal Bypass|The Surgical Treatment of Long Occlusions of the Superficial Femoral Artery: Initial Success and Long Term Results of Remote Endarterectomy Versus Suprageniculate Bypass Surgery|Unknown status|Active, not recruiting|N/A|126|Actual|St. Antonius Hospital||2|||f||||f||||||||||2018-06-01 02:42:28.921329|2018-06-01 02:42:28.921329
NCT00566423|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2011-06-22|2007-11-30|2007-12-03|Estimate|||||||2011-06-22|2011-06-23|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|May 2008|Actual|2008-05-31||Interventional|Biomarkers||Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)|Biomarkers in the Diagnosis and Assessment of PAH|Completed||N/A|75|Actual|Northwell Health||1|||f||||f||||||||||2018-06-01 02:42:29.788646|2018-06-01 02:42:29.788646
NCT00566410|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2016-03-10|2007-11-30|2007-12-03|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|DCA||A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours|A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours|Completed||Phase 1|23|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 02:42:29.859953|2018-06-01 02:42:29.859953
NCT00566397|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29||2013-03-19|2013-03-19|2007-11-29|2007-12-03|Estimate||||2013-03-19|2013-03-25|Estimate|2013-03-19|2013-03-25|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease|A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease|Completed||Phase 2|402|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 02:42:29.947651|2018-06-01 02:42:29.947651
NCT00566384|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2014-11-30|2007-11-30|2007-12-03|Estimate|||||||2014-11-30|2014-12-02|Estimate|November 2007||2007-11-30|November 2014|2014-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido|Multi-center, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Daily Oral 100 mg Dehydroepiandrosterone (DHEA) Over 6 Treatment Cycles as a Concomitant Therapy to Oral Contraceptives (OC) to Alleviate Complaints of Reduced Libido in Women With Acquired Female Sexual Dysfunction (FSD) Associated With OC-use|Completed||Phase 2|100|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:42:30.200679|2018-06-01 02:42:30.200679
NCT00566371|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2010-08-13|2007-11-30|2007-12-03|Estimate|||||||2010-08-13|2010-08-16|Estimate|June 2005||2005-06-30|November 2007|2007-11-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents|The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia|Completed||Phase 4|36|Anticipated|Rhode Island Hospital||2|||f||||f||||||||||2018-06-01 02:42:30.567014|2018-06-01 02:42:30.567014
NCT00566358|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2010-07-20|2007-11-30|2007-12-03|Estimate|||||||2010-07-20|2010-07-21|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Surgical Treatment of Non-obese Type 2 Diabetic Patients With Duodenal Exclusion|Lightening the Hormonal Mechanisms of Surgical Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Surgery|Completed||Phase 1/Phase 2|18|Actual|University of Campinas, Brazil||1|||f||||f||||||||||2018-06-01 02:42:30.680994|2018-06-01 02:42:30.680994
NCT00566345|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30||2009-07-21|2009-07-21|2007-11-30|2007-12-03|Estimate||||2009-07-21|2009-08-10|Estimate|2009-07-21|2009-08-10|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)|Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII)|Completed||Phase 3|3670|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-06-01 02:42:30.845156|2018-06-01 02:42:30.845156
NCT00566332|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2015-08-18|2007-11-30|2007-12-03|Estimate|||||||2015-08-18|2015-08-19|Estimate|June 2001||2001-06-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|September 2009|Actual|2009-09-30||Interventional|||Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia|Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma|Completed||Phase 3|414|Actual|French Study Group on Chronic Lymphoid Leukemia||2|||f||||t||||||||||2018-06-01 02:42:31.020602|2018-06-01 02:42:31.020602
NCT00566319|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2008-11-25|2007-11-30|2007-12-03|Estimate|||||||2008-11-25|2008-11-26|Estimate|October 2006||2006-10-31|November 2007|2007-11-30|April 2008|Actual|2008-04-30|||||Interventional|PREPARE||Can Structured Education Promote Physical Activity in Those Identified With an Increased Risk of Developing Diabetes|A Randomised Controlled Trial to Investigate the Effect of a Structured Educational Programme on Physical Activity Levels and Glucose Tolerance in People With Impaired Glucose Tolerance|Completed||N/A|103|Actual|University Hospitals, Leicester||2|||f||||t||||||||||2018-06-01 02:42:31.222047|2018-06-01 02:42:31.222047
NCT00566306|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2008-08-25|2007-11-30|2007-12-03|Estimate|||||||2008-08-25|2008-08-26|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation|Influence of a New Polycationic Disinfectant on Clostridium Difficile Incidence and Environmental Colonisation|Completed||N/A|200|Anticipated|Helsinki University||2|||f||||f||||||||||2018-06-01 02:42:31.368561|2018-06-01 02:42:31.368561
NCT00566280|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2012-01-04|2007-11-30|2007-12-03|Estimate|||||||2012-01-04|2012-01-06|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Molecular Breast Imaging in Patients With a History of Bloody Nipple Discharge|Molecular Breast Imaging: Evaluation of a New Technique Using Scintimammography as an Additional Diagnostic Tool for Women Presenting With a History of Bloody Nipple Discharge and Negative Routine Imaging Studies - A Pilot Study|Completed||N/A|14|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:42:31.500686|2018-06-01 02:42:31.500686
NCT00566267|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-11-30|2007-11-30|2007-12-03|Estimate|||||||2007-11-30|2007-12-03|Estimate|April 2006||2006-04-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|LOCUST||A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet|A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet|Completed||Phase 2/Phase 3|58|Actual|Corporal Michael J. Crescenz VA Medical Center||1|||f||||f||||||||||2018-06-01 02:42:31.571595|2018-06-01 02:42:31.571595
NCT00566254|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2012-11-12||2013-05-09|2007-11-29|2007-12-03|Estimate|2012-11-12|2012-12-11|Estimate||||2013-05-09|2013-05-13|Estimate|December 2008||2008-12-31|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)|A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures|Completed||Phase 3|207|Actual|Eisai Inc.||2|||f||||f||||||||||2018-06-01 02:42:31.714373|2018-06-01 02:42:31.714373
NCT00566241|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2013-01-25|2007-11-30|2007-12-03|Estimate|||||||2013-01-25|2013-01-28|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||IGF-1 Therapy in Patients With Cystic Fibrosis|An Investigation Into the Use of IGF-1 Therapy in Patients With Cystic Fibrosis|Terminated||Phase 1|15|Actual|Stony Brook University||2||Insufficient recruitment|f||||t||||||||||2018-06-01 02:42:32.225572|2018-06-01 02:42:32.225572
NCT00566228|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2018-04-16|2007-11-30|2007-12-03|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2007|Actual|2007-12-31|April 2016|2016-04-30|January 15, 2015|Actual|2015-01-15|January 15, 2015|Actual|2015-01-15||Interventional|||Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma|Randomized, Double-Blind Phase III Clinical Trial Comparing Outcomes of Immunologic Autograft Engineering Versus Standard Autograft Collection in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma|Completed||Phase 3|122|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:42:32.333338|2018-06-01 02:42:32.333338
NCT00566215|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2010-07-22|2007-11-30|2007-12-03|Estimate|||||||2010-07-22|2010-07-23|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatment of Type 2 Diabetes Mellitus by Duodenal Exclusion Associated With Omentectomy: Clinical and Hormonal Study|Clinical and Hormonal Study of a New Surgical Treatment of Type 2 Diabetes Mellitus: Duodenal Exclusion Associated With Omentectomy|Terminated||Phase 1/Phase 2|6|Actual|University of Campinas, Brazil||2||"Benefit of duodenal exclusion alone less than expected for treatment of type 2 diabetes; an~   additional effect of combination with omentectomy not observed"|f||||f||||||||||2018-06-01 02:42:32.458072|2018-06-01 02:42:32.458072
NCT00566202|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29||2010-01-04|2014-08-01|2007-11-29|2007-12-03|Estimate||||2010-01-04|2010-01-06|Estimate|2014-08-01|2014-08-06|Estimate|December 2007||2007-12-31|August 2014|2014-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression|A Phase IIa Multicenter, Randomized, Double-blind, Double-dummy, and Placebo- and Active Controlled Study to Investigate the Safety and Efficacy of JNJ-18038683 Administered to Subjects With Major Depressive Disorder|Completed||Phase 2|67|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||||||||||||2018-06-01 02:42:32.58763|2018-06-01 02:42:32.58763
NCT00566189|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2013-03-07|2007-11-30|2007-12-03|Estimate|||||||2013-03-07|2013-03-08|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|August 2011|Actual|2011-08-31||Interventional|||New Frontiers on Bariatric Surgical Procedures: Classical Bypass for Type-2 Diabetic Patients With Obesity Grade I|New Frontiers on Bariatric Surgical Procedures. Classical Bypass for Type 2 Diabetic Patients With BMI Between 30 and 34.9 kg/m2|Completed||Phase 2/Phase 3|36|Actual|University of Campinas, Brazil||1|||f||||f||||||||||2018-06-01 02:42:32.724364|2018-06-01 02:42:32.724364
NCT00566176|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2013-02-04|2007-11-30|2007-12-03|Estimate|||||||2013-02-04|2013-02-05|Estimate|October 2005||2005-10-31|February 2013|2013-02-28|February 2017|Anticipated|2017-02-28|December 2007|Actual|2007-12-31||Interventional|RESTORE SR II||Sole-Therapy Treatment of Atrial Fibrillation|Thoracoscopically-Assisted Epicardial Bilateral Pulmonary Vein Isolations Using the AtriCure Bipolar System and Exclusion of the Left Atrial Appendage for the Treatment of Atrial Fibrillation|Unknown status|Active, not recruiting|Phase 2|25|Actual|AtriCure, Inc.|||||f||||||||||||||2018-06-01 02:42:32.815903|2018-06-01 02:42:32.815903
NCT00566150|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2009-10-02||2016-08-23|2007-11-30|2007-12-03|Estimate|2015-09-29|2015-11-02|Estimate||||2016-08-23|2016-09-30|Estimate|October 2005||2005-10-31|August 2016|2016-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Levetiracetam in the Management of Bipolar Depression|Levetiracetam in the Management of Bipolar Depression|Completed||N/A|35|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:42:32.910975|2018-06-01 02:42:32.910975
NCT00566137|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2010-03-08|2007-11-30|2007-12-03|Estimate|||||||2010-03-08|2010-03-09|Estimate|February 2006||2006-02-28|March 2010|2010-03-31|February 2007|Actual|2007-02-28|||||Observational|Scleroderma||Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient|Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient|Completed|||50|Actual|Northwell Health|||||f||||f||||||||||2018-06-01 02:42:33.284177|2018-06-01 02:42:33.284177
NCT00566124|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2007-11-30|2007-11-30|2007-12-03|Estimate|||||||2007-11-30|2007-12-03|Estimate|January 2005||2005-01-31|November 2007|2007-11-30|May 2005|Actual|2005-05-31|||||Interventional|||Basal Insulins - Pharmacodynamics|No Evidence for Essential Differences Between the Effects of Insulin Glargine, Insulin Detemir and NPH Insulin on Glucose Metabolism After a Single Injection as Assessed by 24-h Euglycemic Clamp Studies in Healthy Humans|Completed||Phase 4|10|Actual|University of Aarhus||3|||f||||f||||||||||2018-06-01 02:42:33.340519|2018-06-01 02:42:33.340519
NCT00566111|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2016-08-25||2016-08-25|2007-11-30|2007-12-03|Estimate|2016-08-25|2016-10-19|Estimate||||2016-08-25|2016-10-19|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Ceftriaxone in the Management of Bipolar Depression|Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression|Terminated||N/A|5|Actual|Yale University||2||Early indication of an unfavorable risk/benefit ratio.|f||||t||||||||||2018-06-01 02:42:33.446578|2018-06-01 02:42:33.446578
NCT00566098|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2015-10-30|2007-11-30|2007-12-03|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma|Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes in the Autologous Transplant Setting in Multiple Myeloma|Completed||Phase 1/Phase 2|25|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 02:42:33.716942|2018-06-01 02:42:33.716942
NCT00566085|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2012-01-04|2007-11-30|2007-12-03|Estimate|||||||2012-01-04|2012-01-06|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer|Molecular Breast Imaging: Evaluation of a New Technique Using Scintimammography as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer - A Pilot Study|Completed||N/A|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 02:42:33.788112|2018-06-01 02:42:33.788112
NCT00566072|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2007-12-04|2007-11-30|2007-12-03|Estimate|||||||2007-12-04|2007-12-06|Estimate|May 2001||2001-05-31|December 2007|2007-12-31|May 2003|Actual|2003-05-31|||||Interventional|||The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial|The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial|Completed||N/A|21|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:42:33.966409|2018-06-01 02:42:33.966409
NCT00566059|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-30|||2007-11-30|2007-11-30|2007-12-03|Estimate|||||||2007-11-30|2007-12-03|Estimate|May 2006||2006-05-31|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Observational|CARDUCCI||Computed Tomographic Angiography or Conventional Coronary Angiography in Clinical Decision Making|Comparison Between Invasive Coronary Angiography and Dual-Source Computed Tomography|Completed|||60|Actual|University Medical Center Groningen|||||f||||f||||||||||2018-06-01 02:42:34.046528|2018-06-01 02:42:34.046528
NCT00566046|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2012-06-20|2007-11-29|2007-11-30|Estimate|||||||2012-06-20|2012-06-21|Estimate|November 2007||2007-11-30|June 2012|2012-06-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|TRACK||Prevention of Post-traumatic Seizures With Levetiracetam|Prospective, Randomized, Double-blind Study Assessing the Effects of Levetiracetam Compared to Placebo in the Prevention of Early Epileptic Seizures and Late Epilepsy in Patients With Severe Traumatic Brain Injury|Terminated||Phase 3|23|Actual|Rennes University Hospital||2||Sponsor decision because of to small enrollment|f||||t||||||||||2018-06-01 02:42:34.104357|2018-06-01 02:42:34.104357
NCT00566033|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2012-01-27|2007-11-29|2007-11-30|Estimate|||||||2012-01-27|2012-01-31|Estimate|January 2006||2006-01-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MAURO||Multiple Intervention and AUdit in Renal Diseases to Optimize Care|Multiple Intervention and AUdit in Renal Diseases to Optimize Care: the MAURO Study.|Completed||Phase 4|788|Actual|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||t||||||||||2018-06-01 02:42:34.208943|2018-06-01 02:42:34.208943
NCT00566020|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2011-06-30||2017-03-07|2007-11-28|2007-11-30|Estimate|2011-06-30|2011-07-27|Estimate||||2017-03-07|2017-04-04|Actual|May 2008||2008-05-31|March 2017|2017-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -|Study SCA106052, a Clinical Evaluation of BW430C (Lamotrigine) in Bipolar I Disorder- Long-term Extension Study (Extension of Study SCA104779 (NCT00550407))|Completed||Phase 3|92|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:42:34.399213|2018-06-01 02:42:34.399213
NCT00566007|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2014-03-11|2007-11-29|2007-11-30|Estimate|||||||2014-03-11|2014-03-13|Estimate|December 2008||2008-12-31|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||The Effect of Ozone Therapy for Lumbar Herniated Disc|Trial on the Effect of Ozone Therapy for Lumbar Herniated Disc With Criteria for Surgery|Suspended||Phase 2|156|Anticipated|Kovacs Foundation||3|||f||||t||||||||||2018-06-01 02:42:36.00358|2018-06-01 02:42:36.00358
NCT00565994|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2010-09-27|2007-11-29|2007-11-30|Estimate|||||||2010-09-27|2010-09-28|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure|A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure According to Their Method of Vascular Access|Completed|||60|Actual|University of Oklahoma|||3||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:42:36.10127|2018-06-01 02:42:36.10127
NCT00565981|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2017-12-06|2007-11-29|2007-11-30|Estimate|||||||2017-12-06|2017-12-07|Actual|March 2004||2004-03-31|December 2017|2017-12-31|February 13, 2008|Actual|2008-02-13|February 13, 2008|Actual|2008-02-13||Interventional|||A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response|Subcutaneous MabCampath® (Alemtuzumab) and Oral Fludara® (Fludarabinephosphate) for the Treatment of Refractory or Relapsed Chronic Lymphocytic Leukemia in 2nd or 3rd Line of Treatment: A Pilot Trial (FLUSALEM) for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response|Completed||Phase 2|10|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||t||||||||||2018-06-01 02:42:36.202704|2018-06-01 02:42:36.202704
NCT00565968|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2015-03-05|2007-11-29|2007-11-30|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2007||2007-10-31|March 2015|2015-03-31||||August 2009|Actual|2009-08-31||Interventional|||Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg|A Phase I Dose Escalation Trial to Evaluate Safety and Efficacy of Oral Sorafenib (Nexavar) With Regional Melphalan Via Normothermic Isolated Limb Infusion (ILI) in Patients With Intransit Extremity Melanoma|Completed||Phase 1|20|Actual|Duke University||1|||f||||||||||||||2018-06-01 02:42:36.314515|2018-06-01 02:42:36.314515
NCT00565955|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2008-11-13|2007-11-29|2007-11-30|Estimate|||||||2008-11-13|2008-11-14|Estimate|March 2007||2007-03-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|Montelukast||Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children|Effect Of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children Between 5-15 Years of Age - A Randomized, Double Blind, Placebo Controlled Trial|Completed||Phase 3|116|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 02:42:36.399118|2018-06-01 02:42:36.399118
NCT00565942|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2007-11-28|2007-11-28|2007-11-30|Estimate|||||||2007-11-28|2007-11-30|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|January 2008|Anticipated|2008-01-31|||||Interventional|||Exploring Integrative Medicine in Swedish Primary Care|Integrative Medicine for Back and Neck Pain - A Pragmatic Randomized Clinical Pilot Trial|Unknown status|Active, not recruiting|N/A|80|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 02:42:36.506518|2018-06-01 02:42:36.506518
NCT00565929|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2013-08-01|2007-11-29|2007-11-30|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects|MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization|Completed||Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 02:42:36.606236|2018-06-01 02:42:36.606236
NCT00565916|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2012-04-27|2007-11-29|2007-11-30|Estimate|||||||2012-04-27|2012-05-01|Estimate|August 2004||2004-08-31|April 2012|2012-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|Estrogen||Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism|Role of Estrogen/SERMS on Cardiac Fatty Acid Metabolism (Aim #1- Human Studies)|Completed||N/A|38|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 02:42:36.690945|2018-06-01 02:42:36.690945
NCT00565903|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2017-07-16|2007-11-29|2007-11-30|Estimate|||||||2017-07-16|2017-07-19|Actual|March 2005||2005-03-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|PPB||Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome|Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome|Recruiting|||2000|Anticipated|Children's Research Institute|||||f||||f||||||Samples With DNA|"~     We are collecting blood samples or saliva samples. When available, we also collect tumor~     samples from prior surgical procedures.~   "|Yes|Sequence data deposited in ClinVar upon publication. Publication of all final results in NIHMS|2018-06-01 02:42:36.814387|2018-06-01 02:42:36.814387
NCT00565890|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2013-06-03|2007-11-29|2007-11-30|Estimate|||||||2013-06-03|2013-06-04|Estimate|December 2005||2005-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|March 2011|Actual|2011-03-31||Interventional|||Supplemental Thyroxine Treatment for Preterm Infants With Hypothyroxinemia|Randomized Controlled Clinical Trial of Thyroxine Supplementation for Very-low-birth-weight Infants With Hypothyroxinemia During the First Month of Age|Completed||N/A|100|Anticipated|Tokyo Women's Medical University||1|||f||||t||||||||||2018-06-01 02:42:36.899639|2018-06-01 02:42:36.899639
NCT00565877|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2014-03-17|2007-11-29|2007-11-30|Estimate|||||||2014-03-17|2014-03-18|Estimate|October 2004||2004-10-31|March 2014|2014-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||The Application of Neck Ultrasound in the Assessment of Peripherally Inserted Central Catheter (PICC) Tip Position|A Randomized, Controlled Trial Evaluating Post-Insertion Neck Ultrasound in Peripherally Inserted Central Catheter Procedures|Completed||N/A|300|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:42:36.9938|2018-06-01 02:42:36.9938
NCT00565864|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2013-11-07|2007-11-28|2007-11-30|Estimate|||||||2013-11-07|2013-11-08|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Neurocognitive and Metabolic Effects of Mild Hypothyroidism|Neurocognitive and Metabolic Effects of Mild Hypothyroidism|Completed||N/A|324|Actual|Oregon Health and Science University||6|||f||||f||||||||||2018-06-01 02:42:37.054596|2018-06-01 02:42:37.054596
NCT00565851|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2018-05-07|2007-11-29|2007-11-30|Estimate|||||||2018-05-07|2018-05-08|Actual|December 6, 2007|Actual|2007-12-06|February 2018|2018-02-28||||March 15, 2019|Anticipated|2019-03-15||Interventional|||Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)|Active, not recruiting||Phase 3|1038|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-06-01 02:42:37.248957|2018-06-01 02:42:37.248957
NCT00565838|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2007-11-28|2007-11-28|2007-11-30|Estimate|||||||2007-11-28|2007-11-30|Estimate|January 2001||2001-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||Quality-of-Life Outcomes After Autologous Fascial Sling and TVT: a Prospective Randomized Trial|Clinical and Quality-of-Life Outcomes After Autologous Fascial Sling and Tension-Free Vaginal Tape: a Prospective Randomized Trial|Completed|||40|Actual|UPECLIN HC FM Botucatu Unesp|||1||f||||f||||||||||2018-06-01 02:42:38.675567|2018-06-01 02:42:38.675567
NCT00565812|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2016-06-22|2013-02-20|2016-11-01|2007-11-29|2007-11-30|Estimate|2016-11-01|2016-12-30|Estimate|2013-02-20|2013-02-22|Estimate|2016-11-01|2016-12-30|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|ITIC|Full analysis set (FAS) included all participants randomized to the study.|A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee|A Long-Term, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Radiographic Study To Investigate The Safety And Efficacy Of Orally Administered SD-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee|Completed||Phase 2|1457|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 02:42:38.98339|2018-06-01 02:42:38.98339
NCT00565799|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2015-11-18|2007-11-28|2007-11-30|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2007||2007-11-30|November 2015|2015-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|OMT||A Pilot Study of Metabolic Effects of Omentectomy|A Pilot Study of Metabolic Effects of Omentectomy in Obese Patients With Type 2 Diabetes Mellitus Treated With Laparoscopic Adjustable Gastric Banding (LAGB)|Terminated||Phase 2|11|Actual|New York University School of Medicine||2||Conflicting interim data|f||||t||||||||||2018-06-01 02:42:45.791458|2018-06-01 02:42:45.791458
NCT00565786|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2016-08-01|2007-11-29|2007-11-30|Estimate|||||||2016-08-01|2016-08-02|Estimate|July 2004||2004-07-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Observational|||ArCom® and ArComXL® Polyethylene Data Collection|A Prospective Clinical Data Collection of ArCom® and ArComXL® Polyethylene|Active, not recruiting|||150|Actual|Zimmer Biomet|||2||f||||f||||||||||2018-06-01 02:42:46.040921|2018-06-01 02:42:46.040921
NCT00565773|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2018-03-19|2007-11-29|2007-11-30|Estimate|||||||2018-03-19|2018-03-21|Actual|December 2007||2007-12-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Belatacept Post Depletional Repopulation to Facilitate Tolerance|Use of Belatacept During Post Depletional Repopulation to Facilitate Tolerance in Renal Allograft Recipients|Active, not recruiting||Phase 2|40|Actual|Emory University||2|||f||||t||||||||||2018-06-01 02:42:46.180659|2018-06-01 02:42:46.180659
NCT00565760|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28||2010-08-25|2012-05-15|2007-11-29|2007-11-30|Estimate||||2010-08-25|2010-08-30|Estimate|2012-05-15|2012-05-17|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain|A Double-Blind, Multi-Center Extension Study to Evaluate the Safety and Efficacy of Q8003 in Patients With Acute Moderate to Severe Pain|Completed||Phase 3|16|Actual|QRxPharma Inc.||2|||f||||f||||||||||2018-06-01 02:42:46.333668|2018-06-01 02:42:46.333668
NCT00565747|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2013-05-07||2015-04-28|2007-11-28|2007-11-30|Estimate|2013-09-05|2013-11-08|Estimate||||2015-04-28|2015-05-15|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Interventional|GM-CSF||Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF|The Effect of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) During in Vitro Culture of Human Embryos on Subsequent Implantation Rates.|Completed||Phase 3|1332|Actual|Origio A/S||2|||f||||f||||||||||2018-06-01 02:42:46.470053|2018-06-01 02:42:46.470053
NCT00565734|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2015-03-05|2007-11-29|2007-11-30|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Observational|||Surgical Treatment of Cervical Spondylotic Myelopathy|An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy|Completed|||479|Actual|AO Clinical Investigation and Documentation|||2||f||||f||||||||||2018-06-01 02:42:46.910318|2018-06-01 02:42:46.910318
NCT00565721|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2014-06-03||2014-08-13|2007-11-28|2007-11-30|Estimate|2014-07-15|2014-08-08|Estimate||||2014-08-13|2014-08-18|Estimate|November 2007||2007-11-30|August 2014|2014-08-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional||33 subjects enrolled/ started the study. 25 subjects were used in this study analysis.|A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis|A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging|Completed||Phase 2|33|Actual|GE Healthcare||1|||f||||f||||||||||2018-06-01 02:42:47.0952|2018-06-01 02:42:47.0952
NCT00565708|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2017-12-29|2007-11-29|2007-11-30|Estimate|||||||2017-12-29|2018-01-02|Actual|December 2008||2008-12-31|December 2017|2017-12-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|ASCOLT||Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers|Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial|Recruiting||Phase 3|1200|Anticipated|National Cancer Centre, Singapore||2|||f||||t||||||||||2018-06-01 02:42:47.725435|2018-06-01 02:42:47.725435
NCT00565695|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2010-10-01|2007-11-29|2007-11-30|Estimate|||||||2010-10-01|2010-10-04|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|September 2008|Actual|2008-09-30|||||Observational|||Evaluation of the Aspheric ReSTOR Intraocular Lens (IOL) After Routine Cataract Extraction|Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction|Completed|||20|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-06-01 02:42:48.263385|2018-06-01 02:42:48.263385
NCT00565682|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-11-29|2007-11-29|2007-11-30|Estimate|||||||2007-11-29|2007-11-30|Estimate|April 2006||2006-04-30|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Pain Post Abdominal Laparoscopy Prevention With Arcoxia|Pain Post Abdominal Laparoscopy Prevention With Arcoxia|Completed||Phase 4|60|Actual|Hospital Vozandez||1|||f||||f||||||||||2018-06-01 02:42:48.47777|2018-06-01 02:42:48.47777
NCT00565669|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2016-05-03|2007-11-29|2007-11-30|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms|Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms|Completed||N/A|20|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-06-01 02:42:48.586742|2018-06-01 02:42:48.586742
NCT00565656|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2011-12-07|2007-11-29|2007-11-30|Estimate|||||||2011-12-07|2011-12-08|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts|A Phase II Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to IPSS) With Excess of Marrow Blasts|Terminated||Phase 2|40|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 02:42:48.71668|2018-06-01 02:42:48.71668
NCT00565643|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2015-12-30||2016-03-22|2007-11-29|2007-11-30|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Seprafilm® Adhesion Barrier and Cesarean Delivery|A Multicenter, Randomized, Controlled Trial of Seprafilm® Adhesion Barrier to Reduce Adhesion Formation Following Cesarean Delivery|Completed||Phase 4|753|Actual|Winthrop University Hospital||2|||f||||t||||||||No||2018-06-01 02:42:48.816395|2018-06-01 02:42:48.816395
NCT00565630|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2009-02-24|2007-11-29|2007-11-30|Estimate|||||||2009-02-24|2009-02-25|Estimate|January 2008||2008-01-31|November 2007|2007-11-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops|Pilot Study on Bioavailability of Vigamox Administered as Drops vs. as Spray|Withdrawn||N/A|16|Anticipated|Advanced Ophthalmic Pharma||2||Replaced with ongoing study|f||||f||||||||||2018-06-01 02:42:49.33312|2018-06-01 02:42:49.33312
NCT00565617|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2016-01-15||2018-05-15|2007-11-29|2007-11-30|Estimate|2017-08-18|2017-09-18|Actual||||2018-05-15|2018-05-17|Actual|October 2007||2007-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2009|Actual|2009-12-31||Interventional|EpCS-D||Epidural Cortical Stimulation for Depression|A Pilot Safety and Efficacy Study of Epidural Prefrontal Cortical Stimulation (EpCS) in Severe Treatment Resistant Depression|Active, not recruiting||N/A|5|Actual|Medical University of South Carolina||1|||f||||t|f|t|f|f||||Undecided|We are currently monitoring participants. Primary investigation is completed, but they have implanted devices for investigational treatment of depression. We will keep the study open while they are monitored.|2018-06-01 02:42:49.665284|2018-06-01 02:42:49.665284
NCT00565604|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2010-01-26||2015-12-08|2007-11-29|2007-11-30|Estimate|2011-02-21|2011-03-17|Estimate||||2015-12-08|2016-01-11|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|RELIEVE||Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins|Safety and Efficacy of Endovenous Laser Ablation for the Resolution of Incompetent Perforator Veins The RELIEVE Study|Completed||N/A|43|Actual|Vascular Solutions, Inc||1|||f||||f||||||||||2018-06-01 02:42:50.094639|2018-06-01 02:42:50.094639
NCT00565591|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2008-02-12|2007-11-29|2007-11-30|Estimate|||||||2008-02-12|2008-02-15|Estimate|November 2007||2007-11-30|February 2008|2008-02-29|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Study Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI|A Stepwise, Rising Dose Study of Male Subjects With Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI Compared With Placebo Acu-30™ DPI|Completed||Phase 1|12|Actual|Respirics Inc.||1|||f||||f||||||||||2018-06-01 02:42:50.468337|2018-06-01 02:42:50.468337
NCT00565565|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2016-08-09|2007-11-29|2007-11-30|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Single Dose Escalation Study in Patients With Chronic Heart Failure|Proof of Concept Study to Investigate Safety, Tolerability, Pharmacokinetics and the Impact on Pulmonary and Systemic Hemodynamics of a Single Oral Dose of BAY60-4552 in Patients With Biventricular Chronic Heart Failure and Pulmonary Hypertension in a Non-randomized, Non-blinded, Dose Escalation Design.|Completed||Phase 1|55|Actual|Bayer||5|||f||||f||||||||||2018-06-01 02:42:50.866878|2018-06-01 02:42:50.866878
NCT00565552|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-11-29|2007-11-29|2007-11-30|Estimate|||||||2007-11-29|2007-11-30|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|January 2009|Anticipated|2009-01-31|||||Interventional|||Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage|Influence of a Silicone Gel (Dermatix®) on Thoracic Scar Formation After Harvesting of Autologous Rib Cartilage for Standardised Total Ear Reconstruction|Unknown status|Recruiting|N/A|20|Anticipated|University of Schleswig-Holstein||1|||f||||f||||||||||2018-06-01 02:42:51.09157|2018-06-01 02:42:51.09157
NCT00565539|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2009-10-06|2007-11-29|2007-11-30|Estimate|||||||2009-10-06|2009-10-07|Estimate|December 2007||2007-12-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection|A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 1|56|Actual|ZymoGenetics|||||f||||t||||||||||2018-06-01 02:42:51.393722|2018-06-01 02:42:51.393722
NCT00565526|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2018-05-17|2007-11-29|2007-11-30|Estimate|||||||2018-05-17|2018-05-18|Actual|November 26, 2007||2007-11-26|April 10, 2014|2014-04-10|April 10, 2014||2014-04-10|||||Observational|||Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome|Clinical and Laboratory Evaluation of the Autonomic Nervous System in Primary Sjogren's Syndrome|Completed|||28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:42:52.044544|2018-06-01 02:42:52.044544
NCT00565513|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-11-29|2007-11-29|2007-11-30|Estimate|||||||2007-11-29|2007-11-30|Estimate|April 2002||2002-04-30|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Cryptorchidism: Impact of in Utero Exposure to Xenobiotics With Hormonal Action|Cryptorchidism: Impact of in Utero Exposure to Xenobiotics With Hormonal Action and Multidisciplinary|Completed||N/A|283|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-06-01 02:42:52.230273|2018-06-01 02:42:52.230273
NCT00565500|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2007-11-29|2007-11-29|2007-11-30|Estimate|||||||2007-11-29|2007-11-30|Estimate|April 2003||2003-04-30|November 2007|2007-11-30|April 2005|Actual|2005-04-30|||||Interventional|||Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin|A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.|Completed||Phase 4|24|Actual|G. d'Annunzio University||3|||f||||f||||||||||2018-06-01 02:42:52.546856|2018-06-01 02:42:52.546856
NCT00565487|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2018-05-17|2007-11-29|2007-11-30|Estimate|||||||2018-05-17|2018-05-21|Actual|December 2007||2007-12-31|May 2018|2018-05-31|August 5, 2014|Actual|2014-08-05|August 5, 2014|Actual|2014-08-05||Interventional|||Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer|Phase I Study of Combination of Capecitabine and Erlotinib Concurrent With Radiotherapy in Patients With Non-Operable Locally Advanced Pancreatic Cancer|Completed||Phase 1|15|Actual|Milton S. Hershey Medical Center||1|||f||||t||||||||||2018-06-01 02:42:52.635287|2018-06-01 02:42:52.635287
NCT00565474|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2017-02-21|2007-11-29|2007-11-30|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2001||2001-09-30|February 2017|2017-02-28||||October 2007|Actual|2007-10-31||Interventional|||Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant|A Multicenter, Prospective, Double-blind, Randomized, Placebo-controlled, 6-month Study to Establish the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vascular Graft Disease in de Novo Renal Transplant Patients|Completed||Phase 4|84|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:42:52.727046|2018-06-01 02:42:52.727046
NCT00565461|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2014-01-30||2014-03-17|2007-11-29|2007-11-30|Estimate|2014-03-17|2014-04-21|Estimate||||2014-03-17|2014-04-21|Estimate|November 2007||2007-11-30|March 2014|2014-03-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||LT Vaccine Patch Self-Administration Study|A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician|Completed||Phase 2|160|Actual|Intercell USA, Inc.||4|||f||||f||||||||||2018-06-01 02:42:52.880488|2018-06-01 02:42:52.880488
NCT00565448|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|2010-03-05||2015-07-02|2007-11-29|2007-11-30|Estimate|2010-03-05|2010-03-25|Estimate||||2015-07-02|2015-07-30|Estimate|November 2007||2007-11-30|July 2015|2015-07-31|January 2012|Actual|2012-01-31|March 2009|Actual|2009-03-31||Interventional||ITT population: all randomized participants.|Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents|International Randomized Study to Evaluate the Addition of Docetaxel to the Combination of Cisplatin-5-fluorouracil (TCF) vs. Cisplatin-5-fluorouracil (CF) in the Induction Treatment of Nasopharyngeal Carcinoma (NPC) in Children and Adolescents|Completed||Phase 2|75|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:42:53.425502|2018-06-01 02:42:53.425502
NCT00565435|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2008-11-13|2007-11-29|2007-11-30|Estimate|||||||2008-11-13|2008-11-14|Estimate|May 2002||2002-05-31|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|||||Observational|||Chiari Study Looking at Use of Duragen Versus Duraguard|Duragen vs. Duraguard in Chiari Surgery|Unknown status|Enrolling by invitation||100|Anticipated|University of Illinois at Chicago|||||f||||f||||||||||2018-06-01 02:42:54.020745|2018-06-01 02:42:54.020745
NCT00565422|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2008-05-23|2007-11-29|2007-11-30|Estimate|||||||2008-05-23|2008-05-28|Estimate|December 2002||2002-12-31|May 2008|2008-05-31|October 2004|Actual|2004-10-31|||||Interventional|||Efficacy of Escitalopram in the Treatment of Internet Addiction|Efficacy of Escitalopram in the Treatment of Internet Addiction|Completed||Phase 4|31|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-06-01 02:42:54.119267|2018-06-01 02:42:54.119267
NCT00565409|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2012-05-07||2015-08-04|2007-11-28|2007-11-30|Estimate|2015-08-04|2015-08-10|Estimate||||2015-08-04|2015-08-10|Estimate|March 2008||2008-03-31|August 2015|2015-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PRESERVE||Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis|Completed||Phase 4|834|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:42:54.61721|2018-06-01 02:42:54.61721
NCT00565396|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2007-11-29|2007-11-29|2007-11-30|Estimate|||||||2007-11-29|2007-11-30|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|July 2008|Anticipated|2008-07-31|||||Interventional|FLIP||Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3|Multi-Center,Double-Blind,Randomized,Controlled Clinical Trial of Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3|Unknown status|Active, not recruiting|N/A|400|Anticipated|Shanghai Municipal Health Bureau||4|||f||||t||||||||||2018-06-01 02:42:59.784643|2018-06-01 02:42:59.784643
NCT00565383|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-29|||2013-06-12|2007-11-29|2007-11-30|Estimate|||||||2013-06-12|2013-06-13|Estimate|August 2002||2002-08-31|June 2013|2013-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|Version||The Effect of Combined Spinal-Epidural Analgesia on the Success of External Cephalic Version (ECV) for Breech Position|The Effect of Combined Spinal-Epidural Analgesia on the Success of External Cephalic Version for Breech Position|Completed||N/A|101|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 02:42:59.890329|2018-06-01 02:42:59.890329
NCT00565175|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2012-03-19|2007-11-28|2007-11-29|Estimate|||||||2012-03-19|2012-03-20|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia|Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia|Completed||Phase 4|30|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:43:01.662657|2018-06-01 02:43:01.662657
NCT00565370|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2013-12-15||2017-07-13|2007-11-28|2007-11-29|Estimate|2015-08-01|2015-08-31|Estimate||||2017-07-13|2017-08-21|Actual|November 2007||2007-11-30|July 2017|2017-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|XP+Sorafenib|All enrolled patients were analyzed for analysis.|Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC)|A Phase I-II Study of Sorafenib (Nexavar®) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer|Completed||Phase 1/Phase 2|22|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 02:42:59.991324|2018-06-01 02:42:59.991324
NCT00565357|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2007-11-27|2007-11-27|2007-11-29|Estimate|||||||2007-11-27|2007-11-29|Estimate|June 2002||2002-06-30|November 2007|2007-11-30|August 2005|Actual|2005-08-31|||||Interventional|||Silicone Earplugs for VLBW Newborns in Intensive Care|Silicone Earplugs for VLBW Newborns in Intensive Care: Feasibility, Sound Attenuation, and Outcomes From a Randomized Clinical Trial|Completed||N/A|34|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||||||||||||2018-06-01 02:43:00.196619|2018-06-01 02:43:00.196619
NCT00565344|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2013-06-13|2007-11-27|2007-11-29|Estimate|||||||2013-06-13|2013-06-17|Estimate|July 2007||2007-07-31|November 2007|2007-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Medicaid Disenrollment: Intrastate Emergency Department Impact|Medicaid Disenrollment: Intrastate Emergency Department Impact|Completed|||5000000|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 02:43:00.250466|2018-06-01 02:43:00.250466
NCT00565331|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2015-11-09|2007-11-28|2007-11-29|Estimate|||||||2015-11-09|2015-11-10|Estimate|December 2007||2007-12-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Interventional|||Rituximab for Prevention of Rejection After Renal Transplantation|A Prospective Randomized Study on the Efficacy and Safety of the Prophylactic Use of Rituximab, Added to Standard Immunosuppressive Treatment in Comparison With Standard Immunosuppressive Treatment Alone in Renal Transplantation|Completed||Phase 2/Phase 3|280|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 02:43:00.362475|2018-06-01 02:43:00.362475
NCT00565318|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2009-11-13|2007-11-28|2007-11-29|Estimate|||||||2009-11-13|2009-11-16|Estimate|December 2007||2007-12-31|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Benfo||Benfotiamine in Diabetic Nephropathy|A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy|Completed||Phase 4|86|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 02:43:00.506044|2018-06-01 02:43:00.506044
NCT00565305|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2017-03-13|2007-11-28|2007-11-29|Estimate|||||||2017-03-13|2017-03-15|Actual|July 2003|Actual|2003-07-31|March 2017|2017-03-31|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Interventional|||Healing Touch, Quality of Life, and Immunity During Breast Cancer Treatment|Quality of Life and Immunity During Breast Cancer Treatment|Completed||N/A|150|Actual|University of Iowa||2|||f||||t|f|f||||||No||2018-06-01 02:43:00.604054|2018-06-01 02:43:00.604054
NCT00565292|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2015-02-24|2007-11-27|2007-11-29|Estimate|||||||2015-02-24|2015-02-25|Estimate|July 2006||2006-07-31|February 2015|2015-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)||Completed||Phase 1|50|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:43:00.711987|2018-06-01 02:43:00.711987
NCT00565279|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2008-06-02|2007-11-28|2007-11-29|Estimate|||||||2008-06-02|2008-06-03|Estimate|December 2007||2007-12-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis|Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial.|Completed||Phase 3|300|Anticipated|Astion Pharma A/S||3|||f||||f||||||||||2018-06-01 02:43:00.785935|2018-06-01 02:43:00.785935
NCT00565266|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2012-04-30||2018-04-20|2007-11-28|2007-11-29|Estimate|2013-04-05|2013-04-09|Estimate||||2018-04-20|2018-05-21|Actual|May 2008||2008-05-31|April 2018|2018-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TALC||Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)|Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)|Completed||Phase 3|210|Actual|Milton S. Hershey Medical Center|We evaluated only a small number of patients, with no treatment lasting longer than 14 weeks. We could not examine either the rate of asthma exacerbations or long-term safety issues, so our findings cannot be considered clinically directive.|6|||f||||t||||||||||2018-06-01 02:43:00.876882|2018-06-01 02:43:00.876882
NCT00565253|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2010-06-22|2007-11-28|2007-11-29|Estimate|||||||2010-06-22|2010-06-23|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Inhaled Nitric Oxide in Pulmonary Embolism|Inhaled Nitric Oxide in Pulmonary Embolism, a Randomized, Double-Blind Placebo-Controlled Study|Completed||Phase 2|30|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-06-01 02:43:01.194308|2018-06-01 02:43:01.194308
NCT00565240|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2010-04-20|2007-11-28|2007-11-29|Estimate|||||||2010-04-20|2010-04-22|Estimate|November 2007||2007-11-30|April 2010|2010-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women|Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women Protocol: WHIRL-07-2971|Completed||N/A|41|Actual|University of Saskatchewan||4|||f||||||||||||||2018-06-01 02:43:01.255188|2018-06-01 02:43:01.255188
NCT00565227|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2016-12-01|2007-11-28|2007-11-29|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2007||2007-04-30|December 2016|2016-12-31|September 2009|Actual|2009-09-30|November 2008|Actual|2008-11-30||Interventional|||Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.|A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies|Terminated||Phase 1|12|Actual|University of Michigan Cancer Center||1||closed due to toxicity|f||||t||||||||||2018-06-01 02:43:01.330269|2018-06-01 02:43:01.330269
NCT00565214|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2017-05-23|2007-11-27|2007-11-29|Estimate|||||||2017-05-23|2017-05-25|Actual|September 2007||2007-09-30|May 2017|2017-05-31|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers|Effect of Supplementary Vitamins on Oxidant Gene Expression in the Lungs of Healthy Smokers|Completed||N/A|46|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||Undecided||2018-06-01 02:43:01.403956|2018-06-01 02:43:01.403956
NCT00565201|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2013-08-09|2007-11-28|2007-11-29|Estimate|||||||2013-08-09|2013-08-13|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Interventional|Botox/Rehab||Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients|Evaluation of BOTOX® (Botulinum Toxin Type A) in Combination With Rehabilitation Therapy for the Treatment of Wrist and Hand Muscle Overactivity in Post-Stroke Patients|Completed||Early Phase 1|25|Actual|Emory University||2|||f||||f||||||||||2018-06-01 02:43:01.488248|2018-06-01 02:43:01.488248
NCT00565162|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2008-08-22|2007-11-28|2007-11-29|Estimate|||||||2008-08-22|2008-08-25|Estimate|November 2003||2003-11-30|August 2008|2008-08-31|June 2005|Actual|2005-06-30|||||Interventional|||Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus|A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating Lantus(Insulin Glargine) Therapy to Determine Metabolic and Economic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|124|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:43:01.822198|2018-06-01 02:43:01.822198
NCT00565149|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2016-01-22|2007-11-27|2007-11-29|Estimate|||||||2016-01-22|2016-01-25|Estimate|March 2005||2005-03-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|March 2008|Actual|2008-03-31||Interventional|PROOF||PROOF: PROtein OverFeeding Effect on Body Weight|Dietary Protein Content Determines Weight Gain During High Fat Overfeeding|Unknown status|Active, not recruiting|N/A|60|Anticipated|Pennington Biomedical Research Center||3|||f||||t||||||||||2018-06-01 02:43:01.895295|2018-06-01 02:43:01.895295
NCT00565136|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2013-05-01||2016-04-21|2007-11-27|2007-11-29|Estimate|2013-08-20|2013-08-22|Estimate||||2016-04-21|2016-05-23|Estimate|September 2007||2007-09-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|TOPAS|20-30 subjects were targeted for enrollment. There was no sample size and power analysis performed for this study.|Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms|Evaluation of the Outcomes of Restoring Pelvic Floor Support Using TOPAS, AMS Pelvic Floor Support System, in Women With Moderate Fecal Incontinence Symptoms|Completed||Phase 1/Phase 2|29|Actual|ASTORA Women's Health|This study was not powered to statistically evaluate device performance.|1|||f||||f||||||||No||2018-06-01 02:43:02.042609|2018-06-01 02:43:02.042609
NCT00565123|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2007-11-28|2007-11-28|2007-11-29|Estimate|||||||2007-11-28|2007-11-29|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis|A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis|Completed||Phase 2/Phase 3|119|Actual|Laser Microsurgery Centre, Poland||2|||f||||f||||||||||2018-06-01 02:43:02.720438|2018-06-01 02:43:02.720438
NCT00565110|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2017-03-10||2017-04-21|2007-11-27|2007-11-29|Estimate|2017-04-21|2017-07-24|Actual||||2017-04-21|2017-07-24|Actual|June 2004|Actual|2004-06-30|April 2017|2017-04-30|July 2010|Actual|2010-07-31|January 2009|Actual|2009-01-31||Interventional|ADAPt-C||Treating Depression Among Low-Income Patients With Cancer|Effectiveness Study of a Stepped Care Depression Algorithm for Patients With Cancer|Completed||N/A|472|Actual|University of Southern California||2|||f||||t||||||||Yes|"National Cancer Institute, Project ADAPT-C selected for Research-Tested Interventions NCI Program 2014, http://rtips.cancer.gov/rtips/programDetails.do?programId=3551008. https://researchtoreality.cancer.gov/featured-r2r-partners/kathleen-ell-dsw~1. ADAPt-C randomized clinical trial selected by the Predicting OptimaL cAncer RehabIlitation and Supportive care (POLARIS Consortia) led by the Netherlands"|2018-06-01 02:43:02.824373|2018-06-01 02:43:02.824373
NCT00565097|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2009-02-16|2007-11-28|2007-11-29|Estimate|||||||2009-02-16|2009-02-17|Estimate|October 2007||2007-10-31|February 2009|2009-02-28||||||||Interventional|LOCKCYST||Lanreotide as Treatment of Polycystic Livers|Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers|Completed||Phase 2/Phase 3|38|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 02:43:03.168076|2018-06-01 02:43:03.168076
NCT00565084|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2008-11-18||2015-03-23|2007-11-28|2007-11-29|Estimate|2009-05-21|2009-07-07|Estimate||||2015-03-23|2015-04-10|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)|A Randomized, Placebo-Controlled Single-Dose 3-Period Crossover Study to Assess the Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain|Completed||Phase 1|33|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 02:43:03.266115|2018-06-01 02:43:03.266115
NCT00565071|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2012-03-27|2007-11-28|2007-11-29|Estimate|||||||2012-03-27|2012-03-28|Estimate|October 2006||2006-10-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|March 2012|Anticipated|2012-03-31||Interventional|||Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness|Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness|Unknown status|Recruiting|N/A|102087|Anticipated|Makerere University||3|||f||||t||||||||||2018-06-01 02:43:03.499817|2018-06-01 02:43:03.499817
NCT00565058|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2015-06-29||2015-06-29|2007-11-27|2007-11-29|Estimate|2015-06-29|2015-07-27|Estimate||||2015-06-29|2015-07-27|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional||A total of 27 acute myeloid leukemia patients with either relapse (> 6 months) after First complete remission (CR1) or refractory/early relapse CR1 duration < 6 months were enrolled into the study from 6 sites.|Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML)|A Phase II Simon Two-stage Multicenter Study and Pilot Pharmacodynamic Investigation of GTI 2040 in Combination With High Dose Cytarabine (HiDAC) in Refractory and Relapsed Acute Myeloid Leukemia (AML)|Completed||Phase 2|27|Actual|Aptose Biosciences Inc.||2|||f||||f||||||||||2018-06-01 02:43:03.606103|2018-06-01 02:43:03.606103
NCT00565045|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2012-04-26||2016-10-06|2007-11-27|2007-11-29|Estimate|2013-05-07|2013-07-10|Estimate||||2016-10-06|2016-11-21|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Treatments for Recovery of Hand Function in Acute Stroke Survivors|Contralaterally Controlled Functional Electrical Stimulation for Hemiparetic Hand|Completed||Phase 1/Phase 2|21|Actual|MetroHealth Medical Center||2|||f||||f||||||||No||2018-06-01 02:43:04.173327|2018-06-01 02:43:04.173327
NCT00565032|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2010-01-26|2007-11-28|2007-11-29|Estimate|||||||2010-01-26|2010-01-28|Estimate|January 2000||2000-01-31|January 2010|2010-01-31|August 2001|Actual|2001-08-31|||||Observational|||Postpartum Thyroid Measures and Mood|Postpartum Thyroid Measures and Mood|Completed|||75|Actual|Oklahoma State University Center for Health Sciences|||||f||||f||||||||||2018-06-01 02:43:04.472145|2018-06-01 02:43:04.472145
NCT00565019|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2013-12-12|2007-11-28|2007-11-29|Estimate|||||||2013-12-12|2013-12-13|Estimate|November 2007||2007-11-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|August 2011|Actual|2011-08-31||Interventional|||Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture|The Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Patients With Dupuytren's Contracture: a Randomized Controlled Study|Completed||Phase 3|51|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 02:43:04.529752|2018-06-01 02:43:04.529752
NCT00565006|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2015-02-25|2007-11-27|2007-11-29|Estimate|||||||2015-02-25|2015-02-27|Estimate|July 2006||2006-07-31|February 2015|2015-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)||Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:43:04.600736|2018-06-01 02:43:04.600736
NCT00564993|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2012-06-05|2007-11-28|2007-11-29|Estimate|||||||2012-06-05|2012-06-06|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|||Cardiac Function Under Stress for Early Detection of the Right Ventricular Insufficiency After Repair of Tetralogy of Fallot|Cardiac Imaging Under Exercise Stress Test for Early Assessment of Right Ventricular Function in Patients With Tetralogy of Fallot and Pulmonary Regurgitation|Terminated||Phase 3|53|Actual|Competence Network for Congenital Heart Defects||2|||f||||f||||||||||2018-06-01 02:43:04.670964|2018-06-01 02:43:04.670964
NCT00564980|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2015-05-19|2007-11-27|2007-11-29|Estimate|||||||2015-05-19|2015-05-21|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|UAS||PRCT: Comparing Two Procedures for Ulno-Carpal Abutment Syndrome.|A Randomized Prospective Study Comparing TFCC Debridement and Wafer Procedure With TFCC Debridement and Ulnar Shortening Osteotomy for Ulno-Carpal Abutment Syndrome. (UAS Study)|Terminated||N/A|3|Actual|Simon Fraser Orthopaedic Fund||2||Inability to recruit required number of subjects.|f||||f||||||||||2018-06-01 02:43:04.786444|2018-06-01 02:43:04.786444
NCT00564967|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2010-10-25|2007-11-28|2007-11-29|Estimate|||||||2010-10-25|2010-10-26|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|IS1||A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy|A Comparison Between Internet-based Self-help Therapy and Group Therapy for Social Phobia - A Clinical Equivalence Trial Using Cognitive Behavioural Therapy (CBT)|Completed||Phase 3|128|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 02:43:04.87871|2018-06-01 02:43:04.87871
NCT00564954|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2008-11-25||2012-04-20|2007-11-27|2007-11-29|Estimate|2009-02-26|2009-03-30|Estimate||||2012-04-20|2012-04-27|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting|Completed||Phase 4|86|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:43:04.964146|2018-06-01 02:43:04.964146
NCT00564941|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2017-02-22|2007-11-28|2007-11-29|Estimate|||||||2017-02-22|2017-02-24|Actual|December 2007||2007-12-31|February 2017|2017-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload|Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload|Completed||Phase 4|309|Anticipated|Novartis||1|||f||||||||||||||2018-06-01 02:43:05.29298|2018-06-01 02:43:05.29298
NCT00564928|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27||2012-12-06|2012-12-07|2007-11-28|2007-11-29|Estimate||||2012-12-06|2012-12-10|Estimate|2012-12-07|2012-12-11|Estimate|November 2007||2007-11-30|December 2012|2012-12-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|IPI-504-04||A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer|A Phase 2 Open-Label Study to Investigate the Pharmacodynamics and Clinical Activity of IPI-504 in Patients With Castration-Resistant Prostate Cancer Stratified by Prior Chemotherapy|Completed||Phase 2|19|Actual|Infinity Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:43:05.389008|2018-06-01 02:43:05.389008
NCT00564915|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|||2007-11-28|2007-11-28|2007-11-29|Estimate|||||||2007-11-28|2007-11-29|Estimate|December 2001||2001-12-31|November 2007|2007-11-30|July 2006|Actual|2006-07-31|||||Interventional|||RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy|RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy|Completed||Phase 4|145|Actual|Institute of Child Health|||||f||||f||||||||||2018-06-01 02:43:05.473052|2018-06-01 02:43:05.473052
NCT00564902|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2011-11-11||2012-03-28|2007-11-27|2007-11-29|Estimate|2012-03-28|2012-03-29|Estimate||||2012-03-28|2012-03-29|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|ZVF||The Zeaxanthin and Visual Function Study|Randomized, Double Blind, Lutein Controlled Study of Zeaxanthin and Visual Function in Atrophic Age Related Macular Degeneration Patients|Completed||N/A|60|Actual|Chrysantis, Inc.||3|||f||||t||||||||||2018-06-01 02:43:05.562935|2018-06-01 02:43:05.562935
NCT00564889|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-28|2011-07-19||2013-04-10|2007-11-28|2007-11-29|Estimate|2011-07-19|2011-08-12|Estimate||||2013-04-10|2013-05-14|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|February 2009|Actual|2009-02-28||Interventional|||Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis|A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis|Completed||Phase 2|35|Actual|Mayo Clinic||1|||f||||||||||||||2018-06-01 02:43:06.055601|2018-06-01 02:43:06.055601
NCT00564876|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|2011-02-16||2015-01-27|2007-11-26|2007-11-28|Estimate|2013-03-05|2013-03-08|Estimate||||2015-01-27|2015-02-23|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|TOP0706||Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer|Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC).|Terminated||Phase 2|2|Actual|Duke University|Limitations for this trial were the trial was stopped due to poor enrollment.|1||Lack of accrual, study closed.|f||||t||||||||||2018-06-01 02:43:06.359325|2018-06-01 02:43:06.359325
NCT00564863|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2017-04-03|2007-11-27|2007-11-28|Estimate|||||||2017-04-03|2017-04-05|Actual|September 2007|Actual|2007-09-30|April 2017|2017-04-30|September 4, 2008|Actual|2008-09-04|May 2008|Actual|2008-05-31||Interventional|||Dose-Finding Study of CS19 Expressing ETEC Challenge Strains|Strain and Dose-Finding Study of DS26-1 and WS0115A Enterotoxigenic E. Coli (ETEC) Challenge Strains That Express CS19 Fimbriae|Completed||Phase 1|25|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||No||2018-06-01 02:43:06.616959|2018-06-01 02:43:06.616959
NCT00564850|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2011-11-01||2012-02-09|2007-11-27|2007-11-28|Estimate|2011-11-01|2011-12-01|Estimate||||2012-02-09|2012-02-13|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|DECAPUB||Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty|Phase III, Multicentre, Non-comparative, Open and Single Stage Study to Assess the Efficacy and Safety of Pamoate of Triptorelin 11.25 MG in Children With Precocious Puberty|Completed||Phase 3|37|Actual|Ipsen||1|||f||||f||||||||||2018-06-01 02:43:06.718318|2018-06-01 02:43:06.718318
NCT00564837|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2010-01-11|2007-11-26|2007-11-28|Estimate|||||||2010-01-11|2010-01-12|Estimate|September 1999||1999-09-30|January 2010|2010-01-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Home Vs. Physiotherapy Supervised Rehabilitation After ACL Reconstruction|Comparison of Home Vs. Physiotherapy-Supervised Rehabilitation Programs Following Reconstruction of the Anterior Cruciate Ligament (ACL)|Completed||N/A|145|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 02:43:07.139023|2018-06-01 02:43:07.139023
NCT00564824|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2010-02-24|2007-11-27|2007-11-28|Estimate|||||||2010-02-24|2010-02-25|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects and in Patients With Ischemic Heart Disease|The Impact of Caffeine on Brachial Endothelial Function in Healthy Subjects & in Patients With Ischemic Heart Disease|Completed||Phase 3|80|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 02:43:07.223922|2018-06-01 02:43:07.223922
NCT00564811|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2015-05-27|2007-11-27|2007-11-28|Estimate|||||||2015-05-27|2015-05-29|Estimate|March 2003||2003-03-31|May 2015|2015-05-31|September 2004|Actual|2004-09-30|||||Interventional|||Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)|Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom) on the Nutritional State and Liver Biochemistry in Hepatitis C Patients.|Completed||N/A|10|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||||2018-06-01 02:43:07.302591|2018-06-01 02:43:07.302591
NCT00564798|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2012-01-27|2007-11-27|2007-11-28|Estimate|||||||2012-01-27|2012-01-31|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Shapedown BC Program Evaluation|Shapedown BC Program Evaluation|Completed|||119|Actual|University of British Columbia|||2||f||||t||||||||||2018-06-01 02:43:07.388502|2018-06-01 02:43:07.388502
NCT00564785|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2007-11-27|2007-11-27|2007-11-28|Estimate|||||||2007-11-27|2007-11-28|Estimate|February 2007||2007-02-28|January 2007|2007-01-31|March 2007|Actual|2007-03-31|||||Interventional|||Synera™ for Epidural Needle Insertion|A Randomized, Double-Blind, Controlled Trial of the Synera™ vs. Lidocaine for Epidural Needle Insertion in Laboring Women|Completed||Phase 4|33|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 02:43:07.456687|2018-06-01 02:43:07.456687
NCT00564772|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2008-06-16|2007-11-27|2007-11-28|Estimate|||||||2008-06-16|2008-06-17|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|RAL-KAL||Raltegravir Kaletra Pharmacokinetics|An Open-Label, Sequential, 3-Period Study to Evaluate Pharmacokinetics of Coadministered Raltegravir (Isentress) and Lopinavir-Ritonavir (Kaletra) in Healthy Adults|Completed||Phase 4|15|Actual|Allina Hospitals and Clinics||1|||f||||f||||||||||2018-06-01 02:43:07.516595|2018-06-01 02:43:07.516595
NCT00564759|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-27|2007-11-27|2007-11-28|Estimate|||||||2007-11-27|2007-11-28|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Interventional|CGD||Gene Therapy for Chronic Granulomatous Disease|Phase I/II Gene Therapy Study for X-Linked Chronic Granulomatous Disease|Unknown status|Active, not recruiting|Phase 1/Phase 2|2|Actual|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-06-01 02:43:07.585652|2018-06-01 02:43:07.585652
NCT00564746|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2017-08-03|2007-11-26|2007-11-28|Estimate|||||||2017-08-03|2017-08-04|Actual|September 20, 2007|Actual|2007-09-20|August 2017|2017-08-31|October 26, 2007|Actual|2007-10-26|October 26, 2007|Actual|2007-10-26||Interventional|||To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males|A Study to Investigate the Excretion Balance of SB-681323 in Healthy Male Volunteers [Type 3C]|Completed||Phase 1|4|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 02:43:07.643354|2018-06-01 02:43:07.643354
NCT00564733|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|2016-08-29||2016-12-16|2007-11-27|2007-11-28|Estimate|2016-08-29|2016-10-21|Estimate||||2016-12-16|2017-02-10|Actual|October 2007||2007-10-31|December 2016|2016-12-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional||All patients that signed consent and received at least one dose of chemotherapy.|FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer|FDG-PET Based Chemotherapy Selection for Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|55|Actual|University of Washington||1|||f||||f||||||||No||2018-06-01 02:43:07.727003|2018-06-01 02:43:07.727003
NCT00564720|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2013-02-14|2007-11-27|2007-11-28|Estimate|||||||2013-02-14|2013-02-15|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer|Phase II Study of Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Terminated||Phase 2|140|Actual|Hellenic Oncology Research Group||2||Due to poor accrual of the study|f||||f||||||||||2018-06-01 02:43:07.940711|2018-06-01 02:43:07.940711
NCT00564707|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-26|2007-11-26|2007-11-28|Estimate|||||||2007-11-26|2007-11-28|Estimate|August 2007||2007-08-31|November 2007|2007-11-30|August 2009|Anticipated|2009-08-31|||||Interventional|||Comparison of Biofeedback vs. Botox Injection to Treat Levator Ani Syndrome|Comparison of Biofeedback Therapy and Botulinum Toxin Type A Injections for Treatment of Painful Levator Ani Syndrome in Women: A Randomized, Prospective Trial|Unknown status|Recruiting|N/A|84|Anticipated|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 02:43:08.050523|2018-06-01 02:43:08.050523
NCT00564694|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2013-10-28|2007-11-27|2007-11-28|Estimate|||||||2013-10-28|2013-10-29|Estimate|May 2007||2007-05-31|August 2009|2009-08-31||||June 2009|Actual|2009-06-30||Observational|||Studying a Quality of Life Questionnaire in Patients With Colorectal Cancer|Validation of an EORTC Quality of Life Questionnaire Module for Patients With Colorectal Cancer|Completed|||350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:43:08.135726|2018-06-01 02:43:08.135726
NCT00564681|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|2012-11-14|2010-09-24|2015-12-04|2007-11-26|2007-11-28|Estimate|2012-11-14|2012-12-11|Estimate|2010-09-24|2010-09-29|Estimate|2015-12-04|2016-01-05|Estimate|December 2007||2007-12-31|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia||Completed||Phase 2|242|Actual|Allergan||4|||f||||f||||||||||2018-06-01 02:43:08.234942|2018-06-01 02:43:08.234942
NCT00564668|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2017-02-28|2007-11-27|2007-11-28|Estimate|||||||2017-02-28|2017-03-01|Actual|June 19, 2004|Actual|2004-06-19|February 2017|2017-02-28|April 12, 2005|Actual|2005-04-12|April 12, 2005|Actual|2005-04-12||Interventional|||Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes|A 24-week, Randomised, Multi-centre, Double-blind, Parallel-group Trial to Investigate the Safety and the Efficacy of NN2000-Mix30 Compared to NN-X14Mix30 NovoRapid®30Mix) in Subjects With Type 2 Diabetes Mellitus on a Twice Daily Regimen|Completed||Phase 3|126|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:43:08.695615|2018-06-01 02:43:08.695615
NCT00564655|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2013-07-23|2007-11-27|2007-11-28|Estimate|||||||2013-07-23|2013-07-24|Estimate|October 2007||2007-10-31|July 2013|2013-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Regional Anesthesia Block of the Transversus Abdominis Plane in Children Undergoing Gastric Tube Insertion|Regional Anesthesia Block of the Transversus Abdominis Plane in Children Undergoing Gastric Tube Insertion|Terminated||Phase 3|3|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 02:43:08.754939|2018-06-01 02:43:08.754939
NCT00564473|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2010-10-28|2007-11-27|2007-11-28|Estimate|||||||2010-10-28|2010-10-29|Estimate|June 2008||2008-06-30|October 2010|2010-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Use of Herbal Medicine in Internal Medicine Wards|Use of Herbal Medicine Among Patients Hospitalized in a Department of Internal Medicine: A Cross-Sectional Survey|Completed|||200|Anticipated|Shaare Zedek Medical Center|||1||f||||f||||||||||2018-06-01 02:43:10.621025|2018-06-01 02:43:10.621025
NCT00564642|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2009-04-21|2007-11-27|2007-11-28|Estimate|||||||2009-04-21|2009-04-22|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity|Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity|Completed||N/A|60|Actual|National Research Institute of Tuberculosis and Lung Disease, Iran|||||f||||t||||||||||2018-06-01 02:43:08.820321|2018-06-01 02:43:08.820321
NCT00564629|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|2009-09-25|2009-04-03|2016-10-18|2007-11-26|2007-11-28|Estimate|2010-08-26|2010-09-21|Estimate|2010-08-26|2010-09-21|Estimate|2016-10-18|2016-10-19|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males|A Phase III, Randomized, Double-Blind, Double-Dummy, Single-Dose Study of the Efficacy and Safety of Intravenous Acetaminophen Versus Oral Acetaminophen for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males|Completed||Phase 3|105|Actual|Mallinckrodt|Protocol and statistical analysis plan were amended to clarify endpoints prior to database lock and analysis.|2|||f||||f||||||||||2018-06-01 02:43:08.884881|2018-06-01 02:43:08.884881
NCT00564616|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-26|2007-11-26|2007-11-28|Estimate|||||||2007-11-26|2007-11-28|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Simulation-Based Study of Adding Video Communication to Dispatch Instruction|A Randomized Controlled Study Focused on Impact of Adding Video Communication to Dispatch Instruction on the Quality of CPR, Including Chest Compressions and Rescue Breaths, in Simulated Cardiac Arrests|Completed||N/A|96|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 02:43:09.177905|2018-06-01 02:43:09.177905
NCT00564603|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2008-04-17|2007-11-26|2007-11-28|Estimate|||||||2008-04-17|2008-04-21|Estimate|August 2007||2007-08-31|April 2008|2008-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|DTMPCA||Continuous Infusion of Dexamethasone Plus Tramadol Adjunct to Morphine PCA After Abdominal Hysterectomy|Intravenous Continuous Infusion of Dexamethasone Plus Tramadol Combined With Standard Morphine Patient-Controlled Analgesia After Total Abdominal Hysterectomy|Completed||Phase 4|300|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-06-01 02:43:09.280205|2018-06-01 02:43:09.280205
NCT00564590|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-26|2007-11-26|2007-11-28|Estimate|||||||2007-11-26|2007-11-28|Estimate|October 2008||2008-10-31|November 2007|2007-11-30|January 2011|Anticipated|2011-01-31|||||Interventional|||SThe Effects of Melatonin on GERD Symptoms|The Effects of Melatonin on GERD Symptoms and Esophageal Acid Exposure|Unknown status|Not yet recruiting|Phase 1/Phase 2|150|Anticipated|Rabin Medical Center||3|||f||||f||||||||||2018-06-01 02:43:09.416547|2018-06-01 02:43:09.416547
NCT00564577|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2017-04-07|2007-11-27|2007-11-28|Estimate|||||||2017-04-07|2017-04-11|Actual|September 2006|Actual|2006-09-30|April 2017|2017-04-30|June 13, 2007|Actual|2007-06-13|June 13, 2007|Actual|2007-06-13||Interventional|||Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17|Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli (ETEC) Challenge Strains That Express CS17|Completed||Phase 1|13|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||No||2018-06-01 02:43:09.524485|2018-06-01 02:43:09.524485
NCT00564564|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2017-10-25|2007-11-26|2007-11-28|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2006||2006-01-31|October 2017|2017-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|QCAT||Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients|Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.|Completed||Phase 4|21|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 02:43:09.621721|2018-06-01 02:43:09.621721
NCT00564551|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2010-01-19|2007-11-26|2007-11-28|Estimate|||||||2010-01-19|2010-01-21|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Effect of Increased Intake of Low Fat Dairy Products on Weight Loss and Insulin Resistance|Impact of High Milk Product and Calcium Intake During Weight Loss on Markers of Insulin Resistance|Completed||N/A|49|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 02:43:09.730807|2018-06-01 02:43:09.730807
NCT00564538|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2007-11-27|2007-11-27|2007-11-28|Estimate|||||||2007-11-27|2007-11-28|Estimate|December 2007||2007-12-31|November 2007|2007-11-30|December 2009|Anticipated|2009-12-31|||||Interventional|thymo||A Study of Thymoglobulin and Tacrolimus in Liver Transplant|A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-06-01 02:43:09.843766|2018-06-01 02:43:09.843766
NCT00564525|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2007-11-27|2007-11-27|2007-11-28|Estimate|||||||2007-11-27|2007-11-28|Estimate|October 2002||2002-10-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Study of Medication for Functional Abdominal Pain in Children|Evaluation of the Efficacy of Amitriptyline in Children With Abdominal Pain of Non-Organic Origin|Completed||Phase 4|95|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-06-01 02:43:09.941813|2018-06-01 02:43:09.941813
NCT00564512|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2013-07-24|2007-11-27|2007-11-28|Estimate|||||||2013-07-24|2013-07-25|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|July 2013|Actual|2013-07-31|January 2009|Actual|2009-01-31||Interventional|||Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP|Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 3|178|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||||2018-06-01 02:43:10.036386|2018-06-01 02:43:10.036386
NCT00564499|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2011-01-27|2007-11-26|2007-11-28|Estimate|||||||2011-01-27|2011-01-28|Estimate|March 2006||2006-03-31|January 2011|2011-01-31|May 2007|Actual|2007-05-31|||||Observational|SRP COPD||SYMBICORT® in the Treatment of COPD|A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners|Completed|||||AstraZeneca|||||f||||f||||||||||2018-06-01 02:43:10.144117|2018-06-01 02:43:10.144117
NCT00564486|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|2009-09-25|2009-04-03|2016-09-08|2007-11-27|2007-11-28|Estimate|2010-10-29|2010-11-30|Estimate|2010-10-29|2010-11-30|Estimate|2016-09-08|2016-10-21|Estimate|November 2007||2007-11-30|September 2016|2016-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain|Phase 3 Randomized, Double-Blind Placebo-Controlled, Multicenter, Parallel-Group, Repeated-Dose Study of the Analgesic Efficacy & Safety of IV Acetaminophen Versus Placebo for the Treatment of Postop Pain|Completed||Phase 3|244|Actual|Mallinckrodt|One subject was randomized to receive IV APAP 1 g, but was administered IV APAP 650 mg. The subject was included in 1g IV APAP group for efficacy purposes and included in IV APAP 650 mg safety group for AE purposes.|4|||f||||f||||||||||2018-06-01 02:43:10.218575|2018-06-01 02:43:10.218575
NCT00564460|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2017-10-26|2007-11-26|2007-11-28|Estimate|||||||2017-10-26|2017-10-30|Actual|February 2008||2008-02-29|November 2009|2009-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)|On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)|Withdrawn||Phase 3|0|Actual|University of Alberta||2||Change of practice pattern. Green light laser|f||||f||||||||||2018-06-01 02:43:10.700404|2018-06-01 02:43:10.700404
NCT00564447|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2011-06-27||2011-09-20|2007-11-27|2007-11-28|Estimate|2011-06-27|2011-07-26|Estimate||||2011-09-20|2011-09-22|Estimate|December 2007||2007-12-31|September 2011|2011-09-30||||December 2007|Actual|2007-12-31||Interventional|||Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers|A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration|Completed||Phase 4|48|Actual|Merck Sharp & Dohme Corp.||8|||f||||||||||||||2018-06-01 02:43:10.800639|2018-06-01 02:43:10.800639
NCT00564434|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2007-11-27|2007-11-27|2007-11-28|Estimate|||||||2007-11-27|2007-11-28|Estimate|May 2005||2005-05-31|November 2007|2007-11-30|January 2007|Actual|2007-01-31|||||Observational|||Postoperative Delirium in Hip Fracture Patients|Postoperative Delirium in Hip Fracture Patients|Completed|||364||Ullevaal University Hospital|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-06-01 02:43:11.159984|2018-06-01 02:43:11.159984
NCT00564421|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27||2011-05-20|2017-03-23|2007-11-27|2007-11-28|Estimate||||2011-05-20|2011-05-23|Estimate|2017-03-23|2017-03-24|Actual|December 18, 2007|Actual|2007-12-18|March 2017|2017-03-31|February 14, 2008|Actual|2008-02-14|February 14, 2008|Actual|2008-02-14||Interventional|||Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)|A Phase 3 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple Dose Safety and Efficacy Study of Epinastine Nasal Spray vs. Placebo in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|798|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:43:11.224307|2018-06-01 02:43:11.224307
NCT00564408|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2009-07-31|2007-11-27|2007-11-28|Estimate|||||||2009-07-31|2009-08-03|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine Patients|Experimental Study That Investigates the Effect of an Acetylcholine Analogue in Terms of Headache and Changes in Intra- and Extra-cerebral Vessels During and After Infusion of Carbachol|Completed||N/A|12|Anticipated|Danish Headache Center||1|||f||||f||||||||||2018-06-01 02:43:11.292926|2018-06-01 02:43:11.292926
NCT00564395|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-27|||2015-09-10|2007-11-27|2007-11-28|Estimate|||||||2015-09-10|2015-09-14|Estimate|August 2007||2007-08-31|September 2015|2015-09-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Detemir: Role in Type 1 Diabetes|Detemir: Role in Type 1 Diabetes|Completed||Phase 4|13|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 02:43:11.353275|2018-06-01 02:43:11.353275
NCT00564382|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2011-10-02|2007-11-26|2007-11-28|Estimate|||||||2011-10-02|2011-10-04|Estimate|November 2007||2007-11-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||CMR in the Assessment of Patient With ACS in the Emergency Room|Cardiac MRI for the Diagnosis of Unstable Angina/ NSTEMI in the Emergency Room|Completed||N/A|100|Anticipated|University of Calgary||1|||f||||t||||||||||2018-06-01 02:43:11.424063|2018-06-01 02:43:11.424063
NCT00564369|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2013-11-25|2007-11-27|2007-11-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||CDC HIV Testing Guidelines: Unresolved Ethical Concerns|CDC HIV Testing Guidelines: Unresolved Ethical Concerns|Completed||N/A|1000|Anticipated|Rhode Island Hospital||2|||f||||f||||||||||2018-06-01 02:43:11.519493|2018-06-01 02:43:11.519493
NCT00564356|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2009-07-19|2007-11-26|2007-11-27|Estimate|||||||2009-07-19|2009-07-21|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|December 2010|Anticipated|2010-12-31|August 2008|Actual|2008-08-31||Interventional|||The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment|The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment|Unknown status|Recruiting|N/A|75|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:43:11.582696|2018-06-01 02:43:11.582696
NCT00564343|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2008-12-15|2007-11-26|2007-11-27|Estimate|||||||2008-12-15|2008-12-16|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Observational|||a Water Training Program to Improve Balance in Chronic Stroke Patients|a Water Training Program to Improve Balance in Chronic Stroke Patients: Cross- Sectional Pre-Post Study Design|Completed|||20|Anticipated|Soroka University Medical Center|||1||f||||t||||||||||2018-06-01 02:43:11.697958|2018-06-01 02:43:11.697958
NCT00564330|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2014-08-25|2007-11-26|2007-11-27|Estimate|||||||2014-08-25|2014-08-26|Estimate|November 2007||2007-11-30|August 2014|2014-08-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||In Vivo Quantification of Dental Demineralisation Using OCT With and Without Esomeprazole|In Vivo Quantification of Dental Demineralisation Using Optical Coherence Tomography Before and After Double-blind, Randomised Treatment With Esomeprazole or Placebo of Patients With Dental Erosions|Completed||Phase 1/Phase 2|30|Actual|Brain-Gut Research Group||2|||f||||f||||||||||2018-06-01 02:43:11.762046|2018-06-01 02:43:11.762046
NCT00564317|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-26|2007-11-26|2007-11-27|Estimate|||||||2007-11-26|2007-11-27|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Trial for the Treatment of Traumatized Children After War in Sri Lanka|KIDNET vs Meditation/Relaxation - a Dissemination Randomized Controlled Trial for the Treatment of Traumatized Children After War in Sri Lanka|Completed||Phase 3|48|Actual|University of Konstanz||4|||f||||f||||||||||2018-06-01 02:43:11.830519|2018-06-01 02:43:11.830519
NCT00564304|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2007-11-26|2007-11-26|2007-11-27|Estimate|||||||2007-11-26|2007-11-27|Estimate|March 2008||2008-03-31|November 2007|2007-11-30|March 2010|Anticipated|2010-03-31|||||Observational|||NPD Measurement in Infants|Nasal Potential Difference Measurement in Infants|Unknown status|Not yet recruiting||50|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:43:11.894522|2018-06-01 02:43:11.894522
NCT00564291|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2018-05-02|2007-11-26|2007-11-27|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2007|Actual|2007-01-31|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||Evaluation of Retinal Structure With High Resolution Optical Coherence Tomography (OCT)|Evaluation of Retinal Structure With High Resolution OCT|Recruiting|||700|Anticipated|University Hospital Inselspital, Berne|||7||f||||f||||||||||2018-06-01 02:43:11.936294|2018-06-01 02:43:11.936294
NCT00564278|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|2015-08-06||2016-02-11|2007-11-26|2007-11-27|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Patients who signed written informed consent and participated in baseline medication visit.|Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression|Motivational Antidepressant Therapy for Hispanics|Completed||N/A|217|Actual|New York State Psychiatric Institute|Focused only on Hispanics, so applicability to other populations unknown.|2|||f||||f||||||||No||2018-06-01 02:43:12.038783|2018-06-01 02:43:12.038783
NCT00564265|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|2008-11-03||2011-08-09|2007-11-26|2007-11-27|Estimate|2009-09-17|2009-10-21|Estimate||||2011-08-09|2011-08-11|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Observational|||Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo|Outcomes of Surgical Treatment of Gastrointestinal Stromal Tumors in the IV Region of Chile|Completed|||24|Actual|Cirujanos la Serena|||1||f||||f||||||||||2018-06-01 02:43:13.381742|2018-06-01 02:43:13.381742
NCT00564252|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-26|2007-11-26|2007-11-27|Estimate|||||||2007-11-26|2007-11-27|Estimate|February 2006||2006-02-28|November 2007|2007-11-30|October 2006|Actual|2006-10-31|||||Interventional|||Topical Finasteride in the Treatment of Idiopathic Hirsutism|The Efficacy of Topical Finasteride in the Treatment of Idiopathic Hirsutism|Completed||N/A|56|Actual|Iran University of Medical Sciences|||||f||||t||||||||||2018-06-01 02:43:13.529783|2018-06-01 02:43:13.529783
NCT00564239|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2018-04-26|2007-11-26|2007-11-27|Estimate|||||||2018-04-26|2018-04-30|Actual|November 2007||2007-11-30|April 2018|2018-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Psychological Prevention of Internalizing Disorders|Efficacy of Child-centered Cognitive-Behavioral Prevention of Internalizing Disorders and the Impact of Simultaneous Parent Training|Completed||N/A|77|Actual|Philipps University Marburg Medical Center||3|||f||||f||||||||||2018-06-01 02:43:13.583313|2018-06-01 02:43:13.583313
NCT00564226|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26||2016-04-27|2016-04-27|2007-11-26|2007-11-27|Estimate||||2016-04-27|2016-05-26|Estimate|2016-04-27|2016-05-26|Estimate|November 2007||2007-11-30|April 2016|2016-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|BILADY||SSR240600C Treatment in Women With Overactive Bladder|A Placebo Controlled Randomized, 12-week, Dose-ranging, Double-blind Study Versus Placebo Using Tolterodine as a Study Calibrator, to Evaluate Efficacy and Safety of SSR240600C in Women With Overactive Bladder Including Urge Urinary Incontinence|Completed||Phase 2|345|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 02:43:13.667438|2018-06-01 02:43:13.667438
NCT00564213|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2008-11-25|2007-11-26|2007-11-27|Estimate|||||||2008-11-25|2008-11-26|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|BQ-01-07-ARVO||Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds|Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds|Completed||Phase 4|36|Anticipated|Instituto de Olhos de Goiania||2|||f||||t||||||||||2018-06-01 02:43:13.75141|2018-06-01 02:43:13.75141
NCT00564200|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2014-10-27|2007-11-26|2007-11-27|Estimate|||||||2014-10-27|2014-10-28|Estimate|November 2007||2007-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|MINIALO-VELCAD||MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning|MINIALO-VELCADE2005: A Phase II National, Open-label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning|Completed||Phase 2|30|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 02:43:13.818218|2018-06-01 02:43:13.818218
NCT00564187|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-27|2007-11-26|2007-11-27|Estimate|||||||2007-11-27|2007-11-28|Estimate|February 2003||2003-02-28|November 2007|2007-11-30|December 2004|Actual|2004-12-31|||||Interventional|||Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice|Prospective, Multicentric, Randomized, Open, Comparative Phase IV Study Evaluating the Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice|Completed||Phase 4|115|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:43:13.990654|2018-06-01 02:43:13.990654
NCT00564174|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-26|2007-11-26|2007-11-27|Estimate|||||||2007-11-26|2007-11-27|Estimate|March 2000||2000-03-31|November 2007|2007-11-30|September 2005|Actual|2005-09-30|||||Interventional|HepASA||Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT|A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss|Terminated||N/A|88|Actual|Mount Sinai Hospital, Canada||2||interim analysis found no difference in LB rate and lower than expected event rate|f||||t||||||||||2018-06-01 02:43:14.070506|2018-06-01 02:43:14.070506
NCT00564161|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2016-09-01|2007-11-26|2007-11-27|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2008||2008-01-31|November 2007|2007-11-30|January 2009|Anticipated|2009-01-31|||||Observational|||VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants|VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants|Withdrawn|||0|Actual|Hadassah Medical Organization|||2||f||||f||||||Samples Without DNA|"~     CSF.~   "|||2018-06-01 02:43:14.165308|2018-06-01 02:43:14.165308
NCT00564148|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2011-07-20|2007-11-26|2007-11-27|Estimate|||||||2011-07-20|2011-07-22|Estimate|July 2007||2007-07-31|June 2008|2008-06-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|SITE-App||Intravitreal Avastin in Proliferative Retinopathies|Intravitreal Injections With Avastin in Proliferative Retinopathies Related to the Production of VEGF Having Different Causes|Completed||Phase 2|100|Anticipated|Ophthalmological Association Edelweiss||1|||f||||f||||||||||2018-06-01 02:43:14.225333|2018-06-01 02:43:14.225333
NCT00564135|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2015-06-02|2007-11-26|2007-11-27|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2007||2007-03-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||Postoperative Urinary Retention and Urinary Track Infection (UTI) After Laparoscopic Assisted Vaginal Hysterectomy (LAVH) for Benign Disease|Postoperative Urinary Retention and UTI After LAVH for Benign Disease|Completed||N/A|150|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-06-01 02:43:14.311752|2018-06-01 02:43:14.311752
NCT00564122|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2011-10-31|2007-11-26|2007-11-27|Estimate|||||||2011-10-31|2011-11-01|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|June 2008|Actual|2008-06-30|||||Observational|||The Accuracy of an Artificially-intelligent Stethoscope|A Comparison of the Accuracy of an Artificially-Intelligent Stethoscope Versus Pediatric Cardiologists in the Assessment of Pediatric Patients Referred to a Cardiologist for the Assessment of a Heart Murmur|Completed|||300|Anticipated|Akron Children's Hospital|||1||f||||t||||||||||2018-06-01 02:43:14.384493|2018-06-01 02:43:14.384493
NCT00173511|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|July 2005||2005-07-31|July 2005|2005-07-31|February 2006||2006-02-28|||||Observational|||Cardiovascular Events in Patients With CAD During Emergent Endoscopy for Upper Gastrointestinal Bleeding||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.720384|2018-06-01 04:38:10.720384
NCT00564109|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2008-03-17|2007-11-26|2007-11-27|Estimate|||||||2008-03-17|2008-03-18|Estimate|August 2005||2005-08-31|November 2007|2007-11-30|January 2008||2008-01-31|||||Observational|||Are the Pancreatic Serum Proteins Pancreatic Stone Protein (PSP) and Pancreatitis-Associated Protein (PAP) Predictive for the Development of Sepsis? Retrospective Study in Trauma Patients With Soft Tissue Defects.||Unknown status|Recruiting||15|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 02:43:14.499294|2018-06-01 02:43:14.499294
NCT00564096|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2010-03-02|2007-11-26|2007-11-27|Estimate|||||||2010-03-02|2010-03-03|Estimate|October 2008||2008-10-31|October 2009|2009-10-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Transcranial Magnetic Stimulation (TMS) in Schizophrenia|A Prospective Multicenter Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Schizophrenia Experiencing Auditory Hallucinations|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|BeerYaakov Mental Health Center||2|||f||||f||||||||||2018-06-01 02:43:14.580102|2018-06-01 02:43:14.580102
NCT00564083|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2011-03-21|2007-11-26|2007-11-27|Estimate|||||||2011-03-21|2011-03-22|Estimate|December 2005||2005-12-31|November 2007|2007-11-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Randomized Controlled Trial Comparing Acellular Collagen Biomesh (Pelvisoft) to Polypropylene Mesh(Pelvitex) for Sacral Colpopexy||Completed||N/A|120|Actual|Atlantic Health System|||||f||||f||||||||||2018-06-01 02:43:14.757286|2018-06-01 02:43:14.757286
NCT00564070|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|2014-08-04||2017-12-07|2007-11-23|2007-11-27|Estimate|2017-12-07|2018-01-08|Actual||||2017-12-07|2018-01-08|Actual|June 2007||2007-06-30|December 2017|2017-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||CBT for Adherence and Depression in Diabetes|CBT for Adherence and Depression in Diabetes|Completed||N/A|87|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:43:14.864337|2018-06-01 02:43:14.864337
NCT00564057|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-12-05|2007-11-26|2007-11-27|Estimate|||||||2007-12-05|2007-12-06|Estimate|September 2007||2007-09-30|November 2007|2007-11-30|September 2009|Anticipated|2009-09-30|||||Interventional|||Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine|Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine|Unknown status|Recruiting|Phase 4|30|Anticipated|Università degli Studi dell'Insubria||2|||f||||f||||||||||2018-06-01 02:43:15.276933|2018-06-01 02:43:15.276933
NCT00564044|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2007-11-26|2007-11-26|2007-11-27|Estimate|||||||2007-11-26|2007-11-27|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|July 2009|Anticipated|2009-07-31|||||Interventional|||The Immune Reactivity of Biofilms in Vaginal Mesh Erosion.|Does the Immune Reactivity of Bacteria Cause Vaginal Mesh (Polypropylene) Erosion? - A Ultrastructural, Microbiological and Immunohistochemical Analysis.|Unknown status|Active, not recruiting|N/A|82|Anticipated|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-06-01 02:43:15.36749|2018-06-01 02:43:15.36749
NCT00564031|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2007-11-26|2007-11-26|2007-11-27|Estimate|||||||2007-11-26|2007-11-27|Estimate|January 2003||2003-01-31|November 2007|2007-11-30|August 2004|Actual|2004-08-31|||||Interventional|HRT||Hormonal Replacement Therapy and Small Artery Function|Hormonal Replacement Therapy and Small Artery Function|Completed||Phase 3|66|Actual|Karolinska University Hospital||4|||f||||f||||||||||2018-06-01 02:43:15.542635|2018-06-01 02:43:15.542635
NCT00564018|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2012-06-12|2007-11-26|2007-11-27|Estimate|||||||2012-06-12|2012-06-14|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|April 2011|Actual|2011-04-30|February 2009|Actual|2009-02-28||Interventional|||Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH|Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH|Terminated||N/A|33|Actual|University of Texas Southwestern Medical Center||3||Presumed loss of clinical equipoise between the agents being investigated|f||||f||||||||||2018-06-01 02:43:15.619142|2018-06-01 02:43:15.619142
NCT00564005|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2015-02-10|2007-11-26|2007-11-27|Estimate|||||||2015-02-10|2015-02-11|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Mechanism and Efficacy of Rehabilitation Approaches|Mechanisms and Long-term Effects of Separate vs. Coupled Rehabilitation Approaches After Stroke|Completed||N/A|90|Actual|Chang Gung Memorial Hospital||4|||f||||f||||||||||2018-06-01 02:43:15.700593|2018-06-01 02:43:15.700593
NCT00563992|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2012-04-30|2007-11-23|2007-11-27|Estimate|||||||2012-04-30|2012-05-01|Estimate|January 2001||2001-01-31|April 2012|2012-04-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder|Pharmacotherapy of High-Risk Bipolar Disorder|Completed||Phase 1|98|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 02:43:15.784689|2018-06-01 02:43:15.784689
NCT00563979|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2015-06-10|2007-11-26|2007-11-27|Estimate|||||||2015-06-10|2015-06-12|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|EMPOLS||Enhancement of Macular Pigment Density by Oral Lutein Supplementation|Enhancement of Macular Pigment Density by Oral Lutein Supplementation|Completed||N/A|80|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 02:43:15.868168|2018-06-01 02:43:15.868168
NCT00563966|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-25|||2008-05-09|2007-11-26|2007-11-27|Estimate|||||||2008-05-09|2008-05-12|Estimate|April 2008||2008-04-30|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Observational|||The Stress Responses of Fetuses and Infants Whose Mothers Smoked During Pregnancy|The Stress Responses of Fetuses and Infants Whose Mothers Smoked During Pregnancy: Genes, Hormones and Psychological Modulators|Unknown status|Recruiting||200|Anticipated|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     DNA samples + salivery cortisol~   "|||2018-06-01 02:43:15.945978|2018-06-01 02:43:15.945978
NCT00563953|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2017-10-11|2007-11-26|2007-11-27|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2007||2007-09-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|February 2011|Actual|2011-02-28||Interventional|CAPRICE||Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years|A Phase II, Open-Label, Multicenter Clinical Trial of Pegylated Liposomal Doxorubicin (Caelyx®) as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease or Age Over 65 Years.|Completed||Phase 2|50|Actual|SOLTI Breast Cancer Research Group||1|||f||||f||||||||||2018-06-01 02:43:16.025688|2018-06-01 02:43:16.025688
NCT00563940|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-26|||2011-09-05|2007-11-26|2007-11-27|Estimate|||||||2011-09-05|2011-09-07|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|||||Observational|||Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema|Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema|Completed|||30|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 02:43:16.124037|2018-06-01 02:43:16.124037
NCT00563394|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-21|2007-11-21|2007-11-26|Estimate|||||||2007-11-21|2007-11-26|Estimate|August 1994||1994-08-31|November 2007|2007-11-30|July 1996|Actual|1996-07-31|||||Interventional|||MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers|MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers|Completed||Phase 3|584|Actual|MacroChem Corporation||2|||f||||f||||||||||2018-06-01 02:43:21.729378|2018-06-01 02:43:21.729378
NCT00563927|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|March 1999||1999-03-31|July 2010|2010-07-31|October 2009|Anticipated|2009-10-31|||||Interventional|||Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)|Prospective Randomized Study on Therapeutic Gain Achieved By Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting|N/A|340|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:16.190713|2018-06-01 02:43:16.190713
NCT00563914|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2009-12-18|2007-11-22|2007-11-26|Estimate|||||||2009-12-18|2009-12-21|Estimate|October 2007||2007-10-31|December 2009|2009-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria|An Open Label, 4 Escalating Dose, Randomized Multicentre Study Evaluating the Safety and Activity of Ferroquine Associated With Artesunate Versus a Positive Calibrator (Amodiaquine Associated With Artesunate) in African Adult Patients With Uncomplicated Malaria|Completed||Phase 1/Phase 2|72|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:43:16.273337|2018-06-01 02:43:16.273337
NCT00563901|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2014-03-02|2007-11-21|2007-11-26|Estimate|||||||2014-03-02|2014-03-04|Estimate|September 2000||2000-09-30|January 2008|2008-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Observational|||Analyzing How Genetics May Affect Response to High Blood Pressure Medications|GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT|Completed|||37939|Actual|University of Alabama at Birmingham|||1||f||||||||||Samples With DNA|"~     Blood samples with DNA~   "|||2018-06-01 02:43:16.360865|2018-06-01 02:43:16.360865
NCT00563888|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2007-11-23|2007-11-23|2007-11-26|Estimate|||||||2007-11-23|2007-11-26|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Change of Neural Network Indicators Through Narrative Treatment of PTSD in Torture Victims|Change of Neural Network Indicators Through Narrative Treatment of PTSD in Torture Victims|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Konstanz||2|||f||||f||||||||||2018-06-01 02:43:16.446241|2018-06-01 02:43:16.446241
NCT00563875|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2008-06-09|2007-11-23|2007-11-26|Estimate|||||||2008-06-09|2008-06-10|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Laboratory Aspirin Resistance in Diabetics and Non-Diabetics|Laboratory Aspirin Resistance in Coronary Artery Disease Patients With or Without Diabetes Mellitus|Completed||N/A|210|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 02:43:16.535356|2018-06-01 02:43:16.535356
NCT00563862|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-14|2007-11-23|2007-11-26|Estimate|||||||2011-06-14|2011-06-16|Estimate|July 1999||1999-07-31|June 2011|2011-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)|Prospective Randomized Study on Therapeutic Gain Achieved By Chemoradiation And/Or Accelerated Radiation For T3-4N0-1M0 Nasopharyngeal Carcinoma|Terminated||N/A|465|Actual|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:16.605313|2018-06-01 02:43:16.605313
NCT00563849|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-12-03|2007-11-23|2007-11-26|Estimate|||||||2007-12-03|2007-12-05|Estimate|May 2003||2003-05-31|December 2007|2007-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Leflunomide + Methotrexate in Rheumatoid Arthritis|An Open-Label, Multi-Center Study to Evaluation of Leflunomide Plus Methotexate for the Treatment of Rheumatoid Arthritis in DMARDs:(Disease-Modifying Antirheumatic Drug) na¿ve or Restart (Skip DMARDs More Than 4 Weeks) Subjects.|Completed||Phase 4|74|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:43:16.688658|2018-06-01 02:43:16.688658
NCT00563836|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2012-10-02|2007-11-23|2007-11-26|Estimate|||||||2012-10-02|2012-10-03|Estimate|November 2007||2007-11-30|August 2012|2012-08-31|August 2010|Actual|2010-08-31|September 2008|Actual|2008-09-30||Interventional|||Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer|Multicenter, Single-arm, Phase II Study of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intra- and Postoperatively in Patients With Epithelial Ovarian Cancer|Completed||Phase 2|41|Anticipated|Neovii Biotech||1|||f||||t||||||||||2018-06-01 02:43:16.753218|2018-06-01 02:43:16.753218
NCT00563823|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2013-08-01|2007-11-22|2007-11-26|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2006||2006-02-28|April 2008|2008-04-30|October 2010|Actual|2010-10-31|September 2008|Actual|2008-09-30||Interventional|||Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery|A Phase II Study to Evaluate the Efficacy and Safety of PTK787 in Patients With Metastatic Cutaneous Melanoma|Completed||Phase 2|34|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:43:16.835107|2018-06-01 02:43:16.835107
NCT00563810|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-23|2007-11-23|2007-11-26|Estimate|||||||2007-11-23|2007-11-26|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects|Completed||Phase 1|72||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 02:43:16.902586|2018-06-01 02:43:16.902586
NCT00563797|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2015-11-16||2016-03-21|2007-11-23|2007-11-26|Estimate|2016-03-21|2016-04-18|Estimate||||2016-03-21|2016-04-18|Estimate|August 2007||2007-08-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Participants were included in the study if they met criteria for major depression and alcohol dependence, had been on a stable antidepressant dose for 2 weeks, and were either smokers or nonsmokers.|Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence|Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence|Completed||Phase 3|21|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:43:16.959657|2018-06-01 02:43:16.959657
NCT00563784|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2018-03-22|2007-11-23|2007-11-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|November 2007|Actual|2007-11-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|48|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:43:17.451473|2018-06-01 02:43:17.451473
NCT00563771|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2008-01-24|2007-11-21|2007-11-26|Estimate|||||||2008-01-24|2008-01-28|Estimate|March 2003||2003-03-31|January 2008|2008-01-31|January 2004|Actual|2004-01-31|||||Interventional|||Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome|Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome|Completed||Phase 4|38|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:43:17.575687|2018-06-01 02:43:17.575687
NCT00557609|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12||2013-02-06|2013-02-06|2007-11-12|2007-11-14|Estimate||||2013-02-06|2013-02-08|Estimate|2013-02-06|2013-02-08|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Phase 2 Study in Patients With MiT Tumors|A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors|Completed||Phase 2|47|Actual|ArQule|||||f||||f||||||||||2018-06-01 02:45:54.284991|2018-06-01 02:45:54.284991
NCT00563758|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2011-06-14|2007-11-23|2007-11-26|Estimate|||||||2011-06-14|2011-06-16|Estimate|December 2004||2004-12-31|June 2011|2011-06-30|February 2006|Actual|2006-02-28|||||Interventional|||A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation|A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation|Terminated||N/A|250|Actual|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:17.635845|2018-06-01 02:43:17.635845
NCT00563745|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2015-03-05|2007-11-23|2007-11-26|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2004||2004-04-30|March 2015|2015-03-31|April 2007|Actual|2007-04-30|April 2005|Actual|2005-04-30||Interventional|||Telemedicine for Patients With Chronic Respiratory Insufficiency|Randomised Trial on Telemedicine to Save Health Care Requests for Patients With Severe Chronic Respiratory Failure.|Completed||N/A|240|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||||2018-06-01 02:43:17.711049|2018-06-01 02:43:17.711049
NCT00563732|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2008-09-08|2007-11-23|2007-11-26|Estimate|||||||2008-09-08|2008-09-09|Estimate|December 2007||2007-12-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin|An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Lecozotan SR and a Single Oral Dose of Digoxin When Administered Orally to Healthy Adult Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 02:43:17.81127|2018-06-01 02:43:17.81127
NCT00563706|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2014-02-03|2009-04-23|2014-02-03|2007-11-21|2007-11-26|Estimate|2014-02-03|2014-03-20|Estimate|2010-05-13|2010-05-14|Estimate|2014-02-03|2014-03-20|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional||Safety population included all randomized participants who received at least 1 dose of double-blind test article.|Study Evaluating Vabicaserin in Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects With Acute Exacerbations of Schizophrenia|Completed||Phase 2|199|Actual|Pfizer|Because of the failure of all vabicaserin doses to meet the primary efficacy objective, the study was terminated prematurely and planned analyses of secondary efficacy endpoints were not performed.|3|||f||||t||||||||||2018-06-01 02:43:17.975304|2018-06-01 02:43:17.975304
NCT00563693|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2015-12-02|2007-11-23|2007-11-26|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|3C||Chronic Heart Failure - Cheyne Stokes Respiration - CS2 (3C-study)|Open Randomized Study of Patients With Chronic Heart Failure and Cheyne Stokes Respiration Pattern, Treated With ASV. (Adaptive Servo Ventilator).|Completed||N/A|40|Actual|University of Oslo||2|||f||||f||||||||||2018-06-01 02:43:19.610948|2018-06-01 02:43:19.610948
NCT00563680|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21||2015-01-16|2016-10-26|2007-11-21|2007-11-26|Estimate||||2015-01-16|2015-01-28|Estimate|2016-10-26|2016-10-27|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|August 2012|Actual|2012-08-31|August 2009|Actual|2009-08-31||Interventional|||QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors|A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors|Completed||Phase 2|38|Actual|NantCell, Inc.||2|||f||||||||||||||2018-06-01 02:43:19.684986|2018-06-01 02:43:19.684986
NCT00563667|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|December 2003||2003-12-31|July 2010|2010-07-31|December 2004|Anticipated|2004-12-31|||||Interventional|||Effect of Pterygium Excision on Intraocular Lens Power Calculation for Subsequent Cataract Operation|Effect of Pterygium Excision on IOL Power Calculation: Concurrent Cataract and Pterygium|Unknown status|Active, not recruiting|N/A|40|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:19.754999|2018-06-01 02:43:19.754999
NCT00563654|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-15|2007-11-21|2007-11-26|Estimate|||||||2011-06-15|2011-06-16|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|November 2006|Actual|2006-11-30|||||Interventional|||Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up|Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo on the Successful Rate of Trial Without Catheter in Patients With Acute Urinary Retention With Long Term Follow up|Terminated||N/A|48|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:19.808457|2018-06-01 02:43:19.808457
NCT00563641|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2007-11-23|2007-11-23|2007-11-26|Estimate|||||||2007-11-23|2007-11-26|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|CNRNCPAP||Very Early Surfactant and NCPAP for Premature Infants With RDS|Very Early Surfactant Without Mandatory Ventilation In Premature Infants Treated With Early Continuous Positive Airway Pressure-A Randomized Controlled Trial|Completed||Phase 3|278|Actual|Colombian Neonatal Research Network||2|||f||||t||||||||||2018-06-01 02:43:19.947376|2018-06-01 02:43:19.947376
NCT00563628|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2007-11-23|2007-11-23|2007-11-26|Estimate|||||||2007-11-23|2007-11-26|Estimate|October 2007||2007-10-31|November 2007|2007-11-30|February 2008|Anticipated|2008-02-29|||||Interventional|||Changes in Macular Thickness After Patterns Scan Laser|Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment.|Unknown status|Recruiting|Phase 4|8|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||f||||||||||2018-06-01 02:43:20.022968|2018-06-01 02:43:20.022968
NCT00563615|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|November 2004||2004-11-30|July 2010|2010-07-31|October 2006|Anticipated|2006-10-31|||||Interventional|||Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method|Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method|Unknown status|Recruiting|N/A|60|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:20.100718|2018-06-01 02:43:20.100718
NCT00563602|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-22|2007-11-22|2007-11-26|Estimate|||||||2007-11-22|2007-11-26|Estimate|August 2007||2007-08-31|November 2007|2007-11-30|November 2007|Anticipated|2007-11-30|||||Interventional|||Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response|Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response|Unknown status|Recruiting|Phase 4|140|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-06-01 02:43:20.187682|2018-06-01 02:43:20.187682
NCT00563589|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|August 2003||2003-08-31|July 2010|2010-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation|A Randomized Single-center Trial of Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|N/A|30|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:20.295624|2018-06-01 02:43:20.295624
NCT00563576|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2010-10-11||2012-12-11|2007-11-21|2007-11-26|Estimate|2011-06-22|2011-07-21|Estimate||||2012-12-11|2012-12-13|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation|Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation|Completed||N/A|71|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 02:43:20.389151|2018-06-01 02:43:20.389151
NCT00563563|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21||2012-10-25|2012-10-31|2007-11-23|2007-11-26|Estimate||||2012-10-25|2012-10-31|Estimate|2012-10-31|2012-11-02|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent|An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR) in Combination With Bupropion Sustained Release (SR) in Overweight and Obese, Nicotine-Dependent Subjects|Completed||Phase 2|30|Actual|Orexigen Therapeutics, Inc||1|||f||||f||||||||||2018-06-01 02:43:20.684764|2018-06-01 02:43:20.684764
NCT00563537|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2010-03-18|2007-11-22|2007-11-26|Estimate|||||||2010-03-18|2010-03-19|Estimate|January 2007||2007-01-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|||||Interventional|||Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis|Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis|Unknown status|Recruiting|Phase 1|30|Anticipated|University Hospital, Tours||1|||f||||t||||||||||2018-06-01 02:43:20.776627|2018-06-01 02:43:20.776627
NCT00563524|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-03-09|2007-11-23|2007-11-26|Estimate|||||||2011-03-09|2011-03-10|Estimate|December 2007||2007-12-31|March 2011|2011-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis|An Ascending Multiple Dose Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Efficacy Of ILV-094 Administered Subcutaneously Or Intravenously To Subjects With Psoriasis|Completed||Phase 1|76|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:43:20.866516|2018-06-01 02:43:20.866516
NCT00563511|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-15|2007-11-23|2007-11-26|Estimate|||||||2011-06-15|2011-06-16|Estimate|January 2004||2004-01-31|June 2011|2011-06-30|August 2006|Actual|2006-08-31|||||Interventional|||A Randomized Controlled Trial on Smoking Cessation and Adherence Intervention on Patients With Erectile Dysfunction|A Randomized Controlled Trial on Smoking Cessation and Adherence Intervention on Patients With Erectile Dysfunction|Completed||N/A|1210|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:21.005101|2018-06-01 02:43:21.005101
NCT00563498|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|July 2004||2004-07-31|July 2010|2010-07-31|June 2006|Anticipated|2006-06-30|||||Interventional|||Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients|A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.|Unknown status|Recruiting|N/A|40|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:21.073716|2018-06-01 02:43:21.073716
NCT00563485|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-15|2007-11-21|2007-11-26|Estimate|||||||2011-06-15|2011-06-16|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|November 2006|Actual|2006-11-30|||||Interventional|||Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up|Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily in the Successful Rate of Trial Without Catheter in Acute Urinary Retention With Long Term Follow up|Terminated||N/A|120|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:21.152029|2018-06-01 02:43:21.152029
NCT00563472|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2012-05-04|2007-11-23|2007-11-26|Estimate|||||||2012-05-04|2012-05-07|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Feasibility Study Into the Contraceptive Effect of Estetrol|A Feasibility Study Into the Contraceptive Effect of Estetrol Alone or Combined With Either Progesterone or Desogestrel by Daily Oral Administration to Healthy Female Volunteers for 28 Days.|Completed||Phase 2|52|Actual|Pantarhei Bioscience||4|||f||||f||||||||||2018-06-01 02:43:21.211817|2018-06-01 02:43:21.211817
NCT00563459|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21||2013-01-15|2013-01-25|2007-11-21|2007-11-26|Estimate||||2013-01-25|2013-01-29|Estimate|2013-01-25|2013-01-29|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.|A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects With Partial Onset Seizures|Terminated||Phase 3|89|Actual|SK Life Science||3||"Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this~   indication were terminated."|f||||t||||||||||2018-06-01 02:43:21.28401|2018-06-01 02:43:21.28401
NCT00563446|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-14|2007-11-23|2007-11-26|Estimate|||||||2011-06-14|2011-06-16|Estimate|July 2005||2005-07-31|June 2011|2011-06-30|May 2006|Actual|2006-05-31|||||Interventional|||Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia|Conversion From Once Weekly Recombinant Human Erythropoietin to Once Monthly Darbepoetin Alfa for the Treatment of Renal Anemia in Continuous Ambulatory Peritoneal Dialysis Patients|Completed||N/A|16|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:21.359627|2018-06-01 02:43:21.359627
NCT00563433|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-21|2007-11-21|2007-11-26|Estimate|||||||2007-11-21|2007-11-26|Estimate|August 1994||1994-08-31|November 2007|2007-11-30|July 1996|Actual|1996-07-31|||||Interventional|||MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers|MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers|Completed||Phase 3|342|Actual|MacroChem Corporation||2|||f||||f||||||||||2018-06-01 02:43:21.41812|2018-06-01 02:43:21.41812
NCT00563420|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-10-22|2007-11-21|2007-11-26|Estimate|||||||2013-10-22|2013-10-23|Estimate|November 2002||2002-11-30|October 2013|2013-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer|Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer|Completed||N/A|400|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:21.501357|2018-06-01 02:43:21.501357
NCT00563407|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2016-02-23|2007-11-21|2007-11-26|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2006||2006-07-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy|Novel Surrogate Markers as Predictors of Radiation Toxicity in Breast Cancer Patients Undergoing Helical Tomotherapy Compared to Standard Radiation Therapy|Terminated|||16|Actual|AHS Cancer Control Alberta||||accrual goal met|f||||t||||||||||2018-06-01 02:43:21.667262|2018-06-01 02:43:21.667262
NCT00563381|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|2011-03-29||2013-11-27|2007-11-23|2007-11-26|Estimate|2011-05-13|2011-05-17|Estimate||||2013-11-27|2013-12-24|Estimate|January 2008||2008-01-31|July 2012|2012-07-31||||April 2010|Actual|2010-04-30||Interventional|||Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.|Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).|Completed||Phase 4|7376|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:43:21.99003|2018-06-01 02:43:21.99003
NCT00563368|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2012-07-31|2009-11-18|2015-03-10|2007-11-21|2007-11-26|Estimate|2012-07-31|2012-09-03|Estimate|2009-11-18|2009-11-20|Estimate|2015-03-10|2015-03-30|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults|A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults|Completed||Phase 3|756|Actual|VIVUS, Inc.||7|||f||||t||||||||||2018-06-01 02:43:25.313137|2018-06-01 02:43:25.313137
NCT00563355|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-14|2007-11-23|2007-11-26|Estimate|||||||2011-06-14|2011-06-16|Estimate|February 2001||2001-02-28|June 2011|2011-06-30|November 2003|Actual|2003-11-30|||||Interventional|||A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients|A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients|Completed||N/A|66|Actual|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:25.9567|2018-06-01 02:43:25.9567
NCT00563342|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2008-10-07|2007-11-22|2007-11-26|Estimate|||||||2008-10-07|2008-10-08|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Ethanol||Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients|Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients|Terminated||Phase 2|40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 02:43:26.017489|2018-06-01 02:43:26.017489
NCT00563329|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-10-22|2007-11-23|2007-11-26|Estimate|||||||2013-10-22|2013-10-23|Estimate|October 2004||2004-10-31|October 2013|2013-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Smoking Reduction Intervention for Smokers Not Willing to Quit Smoking: a Randomised Control Trial|Smoking Reduction Intervention for Smokers Not Willing to Quit Smoking: a Randomised Control Trial|Completed||N/A|3826|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:26.076188|2018-06-01 02:43:26.076188
NCT00563316|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2016-03-14||2016-03-14|2007-11-21|2007-11-26|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|June 2010|Actual|2010-06-30|March 2009|Actual|2009-03-31||Interventional||Safety analysis set (all participants who received at least 1 dose of panitumumab or irinotecan)|Effect of Panitumumab on the Pharmacokinetics of Irinotecan|A Phase I, Open-label Study to Determine the Effect of Panitumumab on the Pharmacokinetics of Irinotecan in Subjects With Unresectable Metastatic Colorectal Cancer|Completed||Phase 1|28|Actual|Amgen||1|||f||||||||||||||2018-06-01 02:43:26.15539|2018-06-01 02:43:26.15539
NCT00563303|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2010-04-20|2007-11-23|2007-11-26|Estimate|||||||2010-04-20|2010-04-23|Estimate|November 2006||2006-11-30|April 2010|2010-04-30|July 2009|Actual|2009-07-31|November 2006|Actual|2006-11-30||Interventional|Hypolyte||Treatment of Polytraumatisms With Corticoids|Interest of Treatment of Polytraumatisms With Corticoids (Hydrocortisone) for Patient With Relative Adrenocortical Insufficiency|Completed||Phase 2/Phase 3|150|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 02:43:26.596484|2018-06-01 02:43:26.596484
NCT00563290|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|2013-09-10||2015-05-21|2007-11-22|2007-11-26|Estimate|2015-03-18|2015-03-20|Estimate||||2015-05-21|2015-06-18|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|April 2012|Actual|2012-04-30||Interventional|||Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia|A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia|Completed||Phase 2|7|Actual|National Cancer Institute (NCI)|3 patients were treated with Dasatinib 100 mg PO twice daily and 4 patients were treated with Daatinib 70 mg PO twice daily.|2|||f||||f||||||||||2018-06-01 02:43:26.702604|2018-06-01 02:43:26.702604
NCT00563277|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|December 2006|Anticipated|2006-12-31|||||Interventional|||Surgical Treatment of Concurrent Cataract and Primary Pterygium|Surgical Treatment of Concurrent Cataract and Primary Pterygium: A Randomized Control Trial|Unknown status|Recruiting|N/A|75|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:27.01096|2018-06-01 02:43:27.01096
NCT00563264|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2014-07-10|2007-11-23|2007-11-26|Estimate|||||||2014-07-10|2014-07-11|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|KAN-DO||KAN-DO: A Family-based Intervention to Prevent Childhood Obesity|KAN-DO: A Family-based Intervention to Prevent Childhood Obesity|Completed||N/A|832|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:43:27.083106|2018-06-01 02:43:27.083106
NCT00563251|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-14|2007-11-21|2007-11-26|Estimate|||||||2011-06-14|2011-06-16|Estimate|April 2005||2005-04-30|June 2011|2011-06-30|March 2007|Actual|2007-03-31|||||Interventional|||Effectiveness of Azithromycin Therapy in Improvement of Symptoms and Lung Function in Patients With Bronchiolitis Obliterans After Bone Marrow Transplantation|Azithromycin Therapy for Bronchiolitis Obliterans Syndrome After Allogenic Bone Marrow Transplantation|Completed||N/A|30|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:27.22547|2018-06-01 02:43:27.22547
NCT00563238|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2017-02-24|2007-11-21|2007-11-26|Estimate|||||||2017-02-24|2017-02-28|Actual|November 2007||2007-11-30|February 2017|2017-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Beta-blocker Before Extubation|Use of Prophylactic Beta Blockade to Prevent Peri-extubation Cardiac Ischemia and Congestive Heart Failure|Withdrawn||N/A|0|Actual|University of Iowa||2|||f||||f||||||||||2018-06-01 02:43:27.289237|2018-06-01 02:43:27.289237
NCT00563225|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-23|2007-11-23|2007-11-26|Estimate|||||||2007-11-23|2007-11-26|Estimate|October 2002||2002-10-31|November 2007|2007-11-30|April 2004|Actual|2004-04-30|||||Interventional|||20 Week Bridging Study in Type II DM|A Multicenter, Non-Comparative, Open, Phase III Study to Evaluate the Efficacy and Safety of Insulin Glargine on Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|90|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:43:27.356841|2018-06-01 02:43:27.356841
NCT00563212|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2018-03-28|2007-11-21|2007-11-26|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2007||2007-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2010|Actual|2010-06-30||Interventional|||A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis|A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis|Active, not recruiting||Phase 1|12|Anticipated|New York University School of Medicine||1|||f||||t|t|f||||||||2018-06-01 02:43:27.420763|2018-06-01 02:43:27.420763
NCT00563199|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-14|2007-11-21|2007-11-26|Estimate|||||||2011-06-14|2011-06-16|Estimate|March 2002||2002-03-31|June 2011|2011-06-30|December 2005|Actual|2005-12-31|||||Interventional|||A Randomized Controlled Trial of a Nurse Delivered Stage-matched Smoking Cessation Intervention to Promote Heart Health of Cardiac Patients|A Randomized Controlled Trial of a Nurse Delivered Stage-matched Smoking Cessation Intervention to Promote Heart Health of Cardiac Patients|Completed||N/A|1824|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:27.501127|2018-06-01 02:43:27.501127
NCT00563186|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2009-03-06|2007-11-23|2007-11-26|Estimate|||||||2009-03-06|2009-03-10|Estimate|June 2007||2007-06-30|March 2009|2009-03-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Hospital Design and Risk of Nosocomial Infections: A Prospective Controlled Trial|Physical Plant Design and Engineering Controls and the Prevention of Nosocomial Infections and Antibiotic Resistant Organism Colonization Events - A Proposal for a Prospective Controlled Trial|Unknown status|Recruiting|Phase 3|3600|Anticipated|University of Calgary||2|||f||||f||||||||||2018-06-01 02:43:27.603692|2018-06-01 02:43:27.603692
NCT00563173|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2010-02-09|2007-11-23|2007-11-26|Estimate|||||||2010-02-09|2010-02-10|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients|A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C® in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naïve Patients With Low Viral Load|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Anticipated|Tripep AB||3|||f||||t||||||||||2018-06-01 02:43:27.696992|2018-06-01 02:43:27.696992
NCT00563160|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|May 2005||2005-05-31|July 2010|2010-07-31|February 2007|Anticipated|2007-02-28|||||Interventional|||Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery|Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery|Unknown status|Recruiting|Phase 2|50|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:27.757665|2018-06-01 02:43:27.757665
NCT00563147|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-09-30|2007-11-21|2007-11-26|Estimate|||||||2011-09-30|2011-10-04|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma|A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma|Completed||Phase 1|28|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:43:27.827988|2018-06-01 02:43:27.827988
NCT00563134|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|October 2005||2005-10-31|July 2010|2010-07-31|December 2006|Anticipated|2006-12-31|||||Interventional|||A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult|A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults|Suspended||N/A|1800|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:27.893818|2018-06-01 02:43:27.893818
NCT00563121|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-23|2007-11-23|2007-11-26|Estimate|||||||2007-11-23|2007-11-26|Estimate|March 2007||2007-03-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V|Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V|Completed||Phase 4|16|Actual|Asociación para Evitar la Ceguera en México|||||f||||t||||||||||2018-06-01 02:43:28.220714|2018-06-01 02:43:28.220714
NCT00563108|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-21|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2004||2004-06-30|July 2010|2010-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation|A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.|Unknown status|Recruiting|N/A|60|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:28.300904|2018-06-01 02:43:28.300904
NCT00563095|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|March 2004||2004-03-31|July 2010|2010-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer|A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma|Unknown status|Recruiting|N/A|100|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:28.36977|2018-06-01 02:43:28.36977
NCT00563082|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2014-03-20|2007-11-21|2007-11-26|Estimate|||||||2014-03-20|2014-03-21|Estimate|May 2000||2000-05-31|March 2014|2014-03-31|August 2007|Actual|2007-08-31|||||Observational|||Analyzing the Association of Gene Variants With Increased Risk of Coronary Heart Disease in Women With Systemic Lupus Erythematosus|Prothrombin Gene Varitaion and Risk of SLE and CHD|Completed|||1254|Actual|University of Pittsburgh|||2||f||||t||||||Samples With DNA|"~     DNA and serum~   "|||2018-06-01 02:43:28.471768|2018-06-01 02:43:28.471768
NCT00563069|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|September 2005||2005-09-30|July 2010|2010-07-31|December 2006|Anticipated|2006-12-31|||||Interventional|||Premedication With Oral Midazolam in Patients Undergoing Rigid Cystoscopy: A Randomized, Double-blind, Placebo-controlled Trial|Premedication With Oral Midazolam in Patients Undergoing Rigid Cystoscopy: A Randomized, Double-blind, Placebo-controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:28.53892|2018-06-01 02:43:28.53892
NCT00562913|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-11-24|2007-11-22|2007-11-26|Estimate|||||||2013-11-24|2013-11-26|Estimate|December 2007||2007-12-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin|Phase I Open-label, Non-randomized, Non-placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Tumor Response Profile of Sorafenib as Continuous Dosing in Combination With Cyclophosphamide and Doxorubicin in Patients With Advanced, Refractory Solid Tumors|Completed||Phase 1|21|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:43:30.299016|2018-06-01 02:43:30.299016
NCT00563056|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2012-08-09|2007-11-22|2007-11-26|Estimate|||||||2012-08-09|2012-08-10|Estimate|September 2007||2007-09-30|August 2012|2012-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma|Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy & Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent & Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma|Completed||Phase 3|227|Actual|Mundipharma Research Limited||2|||f||||||||||||||2018-06-01 02:43:28.618867|2018-06-01 02:43:28.618867
NCT00563043|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2007-12-05|2007-11-23|2007-11-26|Estimate|||||||2007-12-05|2007-12-07|Estimate|October 2007||2007-10-31|December 2007|2007-12-31|February 2008|Anticipated|2008-02-29|||||Interventional|||Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment|Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment.|Unknown status|Recruiting|Phase 4|8|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||f||||||||||2018-06-01 02:43:28.696836|2018-06-01 02:43:28.696836
NCT00563030|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2009-11-02|2007-11-23|2007-11-26|Estimate|||||||2009-11-02|2009-11-03|Estimate|December 2007||2007-12-31|November 2009|2009-11-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Observational|||Bands in Peripheral Blood After Coronary Artery Bypass Grafting With and Without Cardiopulmonary Bypass|Comparison of Granulocyte Subsets in Peripheral Blood After Coronary Bypass Grafting Operations With and Without Use of Cardiopulmonary Bypass|Completed|||44|Actual|Medical University of Gdansk|||2||f||||f||||||Samples Without DNA|"~     blood on EDTA vials for automatical morphology analysis and manual blood-smear preparation.~   "|||2018-06-01 02:43:28.826794|2018-06-01 02:43:28.826794
NCT00563017|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2010-07-06|2007-11-23|2007-11-26|Estimate|||||||2010-07-06|2010-07-07|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|November 2005|Anticipated|2005-11-30|||||Interventional|||Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone|Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone|Unknown status|Recruiting|N/A|30|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:28.897967|2018-06-01 02:43:28.897967
NCT00563004|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2013-02-27|2007-11-23|2007-11-26|Estimate|||||||2013-02-27|2013-02-28|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|December 2009|Actual|2009-12-31||Interventional|||The Effect of DBcare, a Food Supplement on Diabetes Control|A Double-blind Placebo Controlled Study Studying the Efficacy of DBCARE in Improving Diabetes Control|Completed||N/A|35|Actual|Meir Medical Center||2|||f||||f||||||||||2018-06-01 02:43:28.98188|2018-06-01 02:43:28.98188
NCT00562991|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-06-15|2007-11-23|2007-11-26|Estimate|||||||2011-06-15|2011-06-17|Estimate|October 2007||2007-10-31|November 2007|2007-11-30|December 2009|Actual|2009-12-31|||||Observational|NOASTHMA||Monitoring Asthma Treatment Using Exhaled Nitric Oxide|Monitoring Asthma Treatment Using Exhaled Nitric Oxide|Completed|||99|Actual|University Hospital, Antwerp|||2||f||||f||||||||||2018-06-01 02:43:29.068117|2018-06-01 02:43:29.068117
NCT00562978|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-22|||2018-01-09|2007-11-22|2007-11-26|Estimate|||||||2018-01-09|2018-01-11|Actual|September 1999||1999-09-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|A Phase I/II Trial of Escalating Dose of Yttrium-90-labeled Anti-CD20 Monoclonal Antibody in Combination With High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplantation for Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|54|Actual|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 02:43:29.153397|2018-06-01 02:43:29.153397
NCT00562965|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2017-07-24|2012-12-19|2017-12-08|2007-11-23|2007-11-26|Estimate|2017-12-08|2018-01-09|Actual|2012-12-19|2012-12-24|Estimate|2017-12-08|2018-01-09|Actual|November 2007|Actual|2007-11-30|December 2017|2017-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Intent-to-treat population included all participants who were randomized in to the study.|Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)|An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgkin's Lymphoma|Terminated||Phase 3|29|Actual|Pfizer|Study did not met estimated enrollment of approximately 978 participants,thus analysis and conclusions were limited by small number of enrolled participants.Termination was not prompted by identification of safety concerns with inotuzumab ozogamicin.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 02:43:29.286879|2018-06-01 02:43:29.286879
NCT00562952|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2012-05-02|2007-11-23|2007-11-26|Estimate|||||||2012-05-02|2012-05-03|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PONTIAC||Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients|Nt-proBNP Guided Prevention of Cardiovascular Events in a Population of Diabetic Patients Without a History of Cardiac Disease|Completed||Phase 2/Phase 3|300|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:43:29.956195|2018-06-01 02:43:29.956195
NCT00562939|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-23|||2009-01-20|2007-11-23|2007-11-26|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|ITAP||Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults|Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults|Completed||Phase 1/Phase 2|97|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:43:30.031507|2018-06-01 02:43:30.031507
NCT00562926|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-08-20|2007-11-23|2007-11-26|Estimate|||||||2013-08-20|2013-08-22|Estimate|July 2004||2004-07-31|August 2013|2013-08-31|June 2006|Actual|2006-06-30|||||Observational|||Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong Chinese|Single Nucleotide Polymorphism (SNP) in Schizophrenia and Schizophrenia Spectrum Disorders: a Population Association Analysis With Hong Kong Chinese|Completed|||32|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:30.104083|2018-06-01 02:43:30.104083
NCT00562900|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2007-11-23|2007-11-23|2007-11-26|Estimate|||||||2007-11-23|2007-11-26|Estimate|December 2004||2004-12-31|November 2007|2007-11-30|February 2007|Actual|2007-02-28|||||Interventional|||Robotic Assisted Versus Laparoscopic Cholecystectomy - Outcome and Cost Analyses of a Case-Matched Control Study|Robotic Assisted Versus Laparoscopic Cholecystectomy -|Completed||Phase 4|50|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 02:43:30.386361|2018-06-01 02:43:30.386361
NCT00562887|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21||2011-08-18|2011-08-18|2007-11-21|2007-11-26|Estimate||||2011-08-18|2011-08-23|Estimate|2011-08-18|2011-08-23|Estimate|November 2007||2007-11-30|August 2011|2011-08-31||||April 2010|Actual|2010-04-30||Interventional|||Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease|A Phase 2B, Multi-Center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs. Placebo in Subjects With Moderately to Severely Active Crohn's Disease.|Terminated||Phase 2|246|Actual|Abbott||3|||f||||t||||||||||2018-06-01 02:43:30.467711|2018-06-01 02:43:30.467711
NCT00562874|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-04-03|2007-11-21|2007-11-22|Estimate|||||||2013-04-03|2013-04-05|Estimate|June 2006||2006-06-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|HNP||Nutrition Intervention in Drug Naive HIV-infected Kenyan Women and Their Children|Increasing Animal Source Foods in Diets of HIV-Infected Kenyan Women and Their Children|Completed||N/A|808|Actual|Indiana University||3|||f||||f||||||||||2018-06-01 02:43:30.619341|2018-06-01 02:43:30.619341
NCT00562861|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2016-07-07||2017-02-21|2007-11-21|2007-11-22|Estimate|2016-12-20|2017-02-13|Actual||||2017-02-21|2017-03-24|Actual|November 2007||2007-11-30|February 2017|2017-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||These subjects met inclusion/exclusion criteria and were randomized to citalopram versus placebo.|Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram|Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram|Completed||Phase 2/Phase 3|119|Actual|Tufts Medical Center||2|||f||||t||||||||No||2018-06-01 02:43:30.767969|2018-06-01 02:43:30.767969
NCT00562848|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2017-08-05|2007-11-21|2007-11-22|Estimate|||||||2017-08-05|2017-08-08|Actual|September 10, 2007|Actual|2007-09-10|August 2017|2017-08-31|June 27, 2008|Actual|2008-06-27|June 27, 2008|Actual|2008-06-27||Interventional|||A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040|A First-Time-in-Human Randomized Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of the Oral Motilin Receptor Agonist GSK962040, in Male and Female Healthy Subjects|Completed||Phase 1|48|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:43:31.078624|2018-06-01 02:43:31.078624
NCT00562835|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|February 2008||2008-02-29|November 2007|2007-11-30|February 2009|Anticipated|2009-02-28|||||Interventional|||Steroids in Patients With Early ARDS|Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS)|Unknown status|Not yet recruiting|Phase 2/Phase 3|400|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 02:43:31.180037|2018-06-01 02:43:31.180037
NCT00562822|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2014-05-21|2007-11-21|2007-11-22|Estimate|||||||2014-05-21|2014-05-22|Estimate|January 1999||1999-01-31|May 2014|2014-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|MRC Knee||Surgery Versus No Surgery for Osteoarthritis (OA) of the Knee|Arthroscopic vs. Non-surgical Treatment of Osteoarthritis of the Knee|Completed||Phase 3|188|Actual|University of Western Ontario, Canada||2|||f||||t||||||||||2018-06-01 02:43:31.271674|2018-06-01 02:43:31.271674
NCT00562809|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-26|2007-11-21|2007-11-22|Estimate|||||||2007-11-26|2007-11-27|Estimate|July 2003||2003-07-31|November 2007|2007-11-30|August 2004|Actual|2004-08-31|||||Interventional|||The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension|A Multicenter, Open-Label Study Assessing the Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Hypertension Not Controlled by Monotherapy|Completed||Phase 4|1005|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:43:31.340416|2018-06-01 02:43:31.340416
NCT00562796|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-08-22|2007-11-21|2007-11-22|Estimate|||||||2011-08-22|2011-08-23|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|May 2011|Actual|2011-05-31|December 2009|Actual|2009-12-31||Observational|||Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity|Prevalence and Metabolic Consequences of Relative Growth Hormone Deficiency in Abdominal Obesity|Completed|||149|Actual|Massachusetts General Hospital|||3||f||||f||||||Samples With DNA|"~     Samples will include serum, plasma, whole blood, and white blood cells~   "|||2018-06-01 02:43:31.407668|2018-06-01 02:43:31.407668
NCT00562783|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2013-10-22|2007-11-21|2007-11-22|Estimate|||||||2013-10-22|2013-10-23|Estimate|January 2005||2005-01-31|October 2013|2013-10-31|May 2006|Actual|2006-05-31|||||Interventional|||A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis|A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis|Completed||Phase 2|90|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:43:31.476407|2018-06-01 02:43:31.476407
NCT00562770|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2012-07-27|2007-11-21|2007-11-22|Estimate|||||||2012-07-27|2012-07-31|Estimate|September 2003||2003-09-30|July 2012|2012-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Oral Valganciclovir Versus Valacyclovir|Open Label, Phase II Randomized Study of Oral Valganciclovir Versus Valacyclovir for Prophylaxis of Cytomegalovirus Reactivation in Patients Receiving Alemtuzumab (Campath).|Completed||Phase 2|46|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 02:43:31.540716|2018-06-01 02:43:31.540716
NCT00562757|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-20|2007-11-20|2007-11-22|Estimate|||||||2007-11-20|2007-11-22|Estimate|September 2003||2003-09-30|November 2007|2007-11-30|October 2009|Anticipated|2009-10-31|||||Observational|HIP||Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias|The Harbinger ICD Patient (HIP) Study|Unknown status|Active, not recruiting||320|Actual|Harbinger Medical, Inc.|||1||f||||f||||||||||2018-06-01 02:43:31.621788|2018-06-01 02:43:31.621788
NCT00562744|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Effect of Simulation on PALS Training|The Effect of High-Fidelity Simulation on Pediatric Advanced Life Support Training in Pediatric Housestaff: a Randomized Trial|Completed||N/A|51|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 02:43:31.682481|2018-06-01 02:43:31.682481
NCT00562731|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2008-03-28|2007-11-21|2007-11-22|Estimate|||||||2008-03-28|2008-04-01|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|June 2008|Anticipated|2008-06-30|||||Interventional|ARD-0403-010||Open-Label Study of ARD-0403 in Testosterone Deficient Men|A Phase III, Open-Label Follow-on Study for Long-Term Safety and Efficacy of Testosterone Cream, in Testosterone Deficinet Men Completing Study ARD-0403-004|Terminated||Phase 3|150|Anticipated|Ardana Bioscience Ltd||||Company strategic decision|f||||||||||||||2018-06-01 02:43:31.736524|2018-06-01 02:43:31.736524
NCT00562042|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-20|2007-11-20|2007-11-21|Estimate|||||||2007-11-20|2007-11-21|Estimate|June 2004||2004-06-30|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Observational|||Risk Stratification for Patients Presenting With Acute Pulmonary Embolism (PE)|Risk Stratification for Patients Presenting With Acute Pulmonary Embolism (PE)|Terminated|||28|Actual|Walter Reed Army Medical Center|||1|Study was stopped due to slow accrual of patients.|f||||f||||||||||2018-06-01 02:43:44.128973|2018-06-01 02:43:44.128973
NCT00562718|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2009-09-24|2007-11-21|2007-11-22|Estimate|||||||2009-09-24|2009-09-25|Estimate|September 2004||2004-09-30|September 2009|2009-09-30||||September 2009|Anticipated|2009-09-30||Interventional|||Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery|A Pilot Safety And Feasibility Study Of Concurrent Capecitabine (Xeloda) And External Beam Irradiation In The Adjuvant Treatment Of High Risk Early Stage Breast Cancer.|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:43:31.801694|2018-06-01 02:43:31.801694
NCT00562705|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-07-15|2007-11-21|2007-11-22|Estimate|||||||2013-07-15|2013-07-16|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Growth Hormone (GH) Treatment on Eating Regulation|Effects of Growth Hormone Treatment on Eating Regulation and Comparison Between the Growth Responses With or Without Nutritional Intervention in Short Stature Children|Completed||N/A|32|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 02:43:31.86406|2018-06-01 02:43:31.86406
NCT00562692|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2015-06-23|2007-11-21|2007-11-22|Estimate|||||||2015-06-23|2015-06-25|Estimate|September 2007||2007-09-30|June 2015|2015-06-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|BNP in OAD||Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease|Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease|Terminated||Phase 3|6|Actual|The Alfred||2||Recruitment very difficult. Study drug expired so we have stopped the study.|f||||f||||||||||2018-06-01 02:43:31.93629|2018-06-01 02:43:31.93629
NCT00562679|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2008-07-01|2007-11-21|2007-11-22|Estimate|||||||2008-07-01|2008-07-02|Estimate|March 1992||1992-03-31|June 2008|2008-06-30|October 2007|Actual|2007-10-31|||||Observational|||Coronary Artery Disease and Sleep Apnea|Long Term Effects of Sleep Apnea in Patients With Coronary Artery Disease|Completed|||408|Actual|Umeå University|||1||f||||||||||||||2018-06-01 02:43:32.002788|2018-06-01 02:43:32.002788
NCT00562666|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2012-06-21|2007-11-21|2007-11-22|Estimate|||||||2012-06-21|2012-06-22|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|ICAR||Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells|Immunotherapy of Hepatocellular Carcinoma by Hepatic Intra Arterial Injection of Autologous Gamma-delta T Lymphocytes: A Phase I Study|Terminated||Phase 1|2|Actual|Rennes University Hospital||4|||f||||t||||||||||2018-06-01 02:43:32.065542|2018-06-01 02:43:32.065542
NCT00562653|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|November 2008|Anticipated|2008-11-30|||||Observational|||Autoantibodies and Clinical Symptoms in Infective Endocarditis Patients|Study of Autoantibodies in Infective Endocarditis|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||t||||||None Retained|"~     serum~   "|||2018-06-01 02:43:32.131334|2018-06-01 02:43:32.131334
NCT00562640|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2017-11-06|2007-11-21|2007-11-22|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2007||2007-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)|A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Carcinomas|Active, not recruiting||Phase 1|21|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:43:32.198198|2018-06-01 02:43:32.198198
NCT00562627|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2011-05-24||2011-08-05|2007-11-21|2007-11-22|Estimate|2011-08-05|2011-08-08|Estimate||||2011-08-05|2011-08-08|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty|Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty|Completed||Phase 4|102|Actual|Asker & Baerum Hospital||3|||f||||f||||||||||2018-06-01 02:43:32.292004|2018-06-01 02:43:32.292004
NCT00562614|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2015-01-08|2007-11-20|2007-11-22|Estimate|||||||2015-01-08|2015-01-12|Estimate|June 2007||2007-06-30|January 2015|2015-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension|A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5 mg or 10 mg Once Daily for up to 14 Days in Patients With Hypertension|Completed||Phase 2|38|Actual|Kadmon Corporation, LLC||2|||f||||f||||||||||2018-06-01 02:43:32.781765|2018-06-01 02:43:32.781765
NCT00562601|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2018-05-11|2007-11-21|2007-11-22|Estimate|||||||2018-05-11|2018-05-14|Actual|October 8, 1987||1987-10-08|January 26, 2018|2018-01-26||||||||Observational|||LCI Apheresis to Obtain Plasma or White Blood Cells|Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies|Enrolling by invitation|||862|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:43:32.849883|2018-06-01 02:43:32.849883
NCT00562588|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|2010-01-29||2014-01-31|2007-11-21|2007-11-22|Estimate|2010-02-22|2010-03-11|Estimate||||2014-01-31|2014-03-19|Estimate|July 2007||2007-07-31|January 2014|2014-01-31||||February 2009|Actual|2009-02-28||Interventional|||EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA|EARLY: Prospective, Randomised, National, Multi-centre, Open-label, Blinded Endpoint Study to Compare Aggrenox b.i.d. (200 mg Dipyridamole MR + 25 mg Acetylsalicylic Acid) When Started Within 24 Hours of Stroke Onset on an Acute Stroke Unit, and Aggrenox b.i.d. When Started After a 7-day Therapy With ASA 100 mg Once Daily Outside Off an Acute Stroke Unit, in Symptomatic Ischaemic Stroke Patients Over a Three Months Treatment Period an Exploratory Study|Completed||Phase 4|551|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:43:32.964976|2018-06-01 02:43:32.964976
NCT00562575|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20||2014-12-09|2015-01-26|2007-11-21|2007-11-22|Estimate||||2014-12-09|2014-12-31|Estimate|2015-01-26|2015-02-02|Estimate|May 2007||2007-05-31|January 2015|2015-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides|A Randomised, Double-blind, Placebo Controlled Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics Profile of SLx-4090 Over 14 Days Dosing in Subjects With High Triglyceride Values|Completed||Phase 2|24|Actual|Kadmon Corporation, LLC||2|||f||||f||||||||||2018-06-01 02:43:33.624908|2018-06-01 02:43:33.624908
NCT00562562|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2017-04-19|2007-11-21|2007-11-22|Estimate|||||||2017-04-19|2017-04-21|Actual|September 2007||2007-09-30|April 2017|2017-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MRI-OMT||A Pilot MRI Study of Osteopathic Manipulative Treatment of Acute Low Back Pain|A Pilot MRI Study of Osteopathic Manipulative Treatment of Acute Low Back Pain|Completed||N/A|9|Actual|Ohio University||1|||f||||f||||||||||2018-06-01 02:43:33.7126|2018-06-01 02:43:33.7126
NCT00562549|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2015-01-08|2007-11-21|2007-11-22|Estimate|||||||2015-01-08|2015-01-12|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension|A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension|Completed||Phase 2|26|Actual|Kadmon Corporation, LLC||2|||f||||f||||||||||2018-06-01 02:43:33.790101|2018-06-01 02:43:33.790101
NCT00562536|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|November 2010|Anticipated|2010-11-30|||||Interventional|DUC||Delayed Umbilical Cord Clamping in Infants Less Than 32 Weeks|Delayed Umbilical Cord Clamping in Infants Less Than 32 Weeks: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|296|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-06-01 02:43:33.862968|2018-06-01 02:43:33.862968
NCT00562523|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-05-22|2007-11-21|2007-11-22|Estimate|||||||2013-05-22|2013-05-23|Estimate|November 2007||2007-11-30|May 2013|2013-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Sorafenib/Docetaxel Dose Escalation Trial|A Phase I Dose Escalation Study With Sorafenib Administered Continuously in Combination With Docetaxel Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.|Completed||Phase 1|17|Actual|Bayer||1|||f||||f||||||||||2018-06-01 02:43:33.948582|2018-06-01 02:43:33.948582
NCT00562510|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2015-06-05|2007-11-21|2007-11-22|Estimate|||||||2015-06-05|2015-06-09|Estimate|August 2008||2008-08-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery|A Phase 3, Randomized, Double Blinded, Placebo Controlled Study of Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery|Terminated||Phase 3|20|Actual|The Huesped Foundation||2||recruitment lower than estimated|f||||t||||||||||2018-06-01 02:43:34.024036|2018-06-01 02:43:34.024036
NCT00562497|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2014-12-02|2007-11-20|2007-11-22|Estimate|||||||2014-12-02|2014-12-04|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD|Completed||Phase 3|184|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-06-01 02:43:34.137414|2018-06-01 02:43:34.137414
NCT00562484|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2011-07-08||2017-10-18|2007-11-21|2007-11-22|Estimate|2011-08-07|2011-09-12|Estimate||||2017-10-18|2017-11-21|Actual|March 2008||2008-03-31|October 2017|2017-10-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|CSL's IVV||A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults|A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to < 65 Years.|Completed||Phase 4|7500|Actual|Seqirus||2|||f||||||||||||||2018-06-01 02:43:34.338691|2018-06-01 02:43:34.338691
NCT00562471|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|July 2003||2003-07-31|November 2007|2007-11-30|January 2005|Actual|2005-01-31|||||Interventional|||Safety and Efficacy Study of a Hydrogel, Applied Following Removal of Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of Postoperative Adhesion Formation|A Controlled Randomized Multicenter Study to Assess the Safety and Performance of Adhibit™ Adhesion Prevention Gel in Myomectomy Surgery|Completed||Phase 1/Phase 2|76|Actual|Angiotech Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:43:35.22508|2018-06-01 02:43:35.22508
NCT00562458|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-02-04|2007-11-21|2007-11-22|Estimate|||||||2013-02-04|2013-02-05|Estimate|December 2006||2006-12-31|February 2013|2013-02-28||||||||Observational|||Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer|ARIMIDEX Study ( Non-interventional Study to Evaluate Arimidex in Adjuvant Therapy in Partial or Complete Response or Stabilized Disease After First Line Chemotherapy in Postmenopausal Women With Advanced Breast Cancer)|Completed|||200|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:43:35.300378|2018-06-01 02:43:35.300378
NCT00562445|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|May 2007||2007-05-31|November 2007|2007-11-30|May 2008|Anticipated|2008-05-31|||||Observational|||Adrenal Insufficiency in Critical Emergencies in Digestive Diseases|Evaluation of the Incidence and Relevance of the Adrenal Insufficiency in Critical Emergencies in Digestive Diseases (GI Bleeding and Acute Pancreatitis)|Unknown status|Recruiting||75|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||3||f||||t||||||||||2018-06-01 02:43:35.35015|2018-06-01 02:43:35.35015
NCT00562432|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2011-03-08|2007-11-20|2007-11-22|Estimate|||||||2011-03-08|2011-03-10|Estimate|February 2008||2008-02-29|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Randomized Study to Demonstrate the Safety and Feasibility of Plexisyl-AF in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|A Randomized Study to Demonstrate the Safety and Feasibility of Plexisyl-AF Administered to the Epicardial Fat Pads in Patients Undergoing Open-chest Coronary Artery Bypass Grafting (CABG)|Completed||N/A|32|Actual|LoneStar Heart, Inc.||2|||f||||f||||||||||2018-06-01 02:43:35.43636|2018-06-01 02:43:35.43636
NCT00562419|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2010-10-26|2007-11-20|2007-11-22|Estimate|||||||2010-10-26|2010-10-27|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|June 2011|Anticipated|2011-06-30||Interventional|||CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan|Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme|Unknown status|Active, not recruiting|Phase 2|72|Anticipated|Adnexus, A Bristol-Myers Squibb R&D Company||2|||f||||f||||||||||2018-06-01 02:43:35.523405|2018-06-01 02:43:35.523405
NCT00562406|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2011-07-20|2007-11-21|2007-11-22|Estimate|||||||2011-07-20|2011-07-22|Estimate|November 2007||2007-11-30|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|RABAMES||Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)|Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)|Completed||N/A|30|Actual|Klinikum Ludwigshafen||3|||f||||f||||||||||2018-06-01 02:43:35.600167|2018-06-01 02:43:35.600167
NCT00562393|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2015-07-13|2007-11-21|2007-11-22|Estimate|||||||2015-07-13|2015-07-14|Estimate|April 2007||2007-04-30|July 2015|2015-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|EXCESS||Effects of Excess Energy Intake on Metabolic Risk|Effects of Excess Energy Intake on Metabolic Risk|Completed||N/A|41|Actual|Garvan Institute of Medical Research||1|||f||||f||||||||||2018-06-01 02:43:35.667968|2018-06-01 02:43:35.667968
NCT00562380|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2013-07-17|2007-11-21|2007-11-22|Estimate|||||||2013-07-17|2013-07-18|Estimate|October 2005||2005-10-31|April 2010|2010-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma|A Phase 1, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 479 in Subjects With Advanced Solid Tumors|Completed||Phase 1|64|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 02:43:35.733185|2018-06-01 02:43:35.733185
NCT00562367|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|October 2001||2001-10-31|November 2007|2007-11-30|September 2004|Actual|2004-09-30|||||Interventional|||Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones|Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones|Completed||N/A|30|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 02:43:35.802637|2018-06-01 02:43:35.802637
NCT00562354|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2011-08-11|2009-01-21|2011-10-05|2007-11-21|2007-11-22|Estimate|2011-10-05|2011-11-11|Estimate|2009-09-24|2009-09-28|Estimate|2011-10-05|2011-11-11|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Years|A Phase 3, Open-Label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13vPnC When Administered to Healthy Japanese Adults Aged >= 65 Years and 50 to 64 Years in Japan Who Have Not Received a Previous Dose of 23-Valent Pneumococcal Polysaccharide Vaccine|Completed||Phase 3|271|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:43:35.904347|2018-06-01 02:43:35.904347
NCT00562341|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-21|2007-11-21|2007-11-22|Estimate|||||||2007-11-21|2007-11-22|Estimate|November 2007||2007-11-30|September 2007|2007-09-30|December 2009|Anticipated|2009-12-31|||||Observational|||Effect of Lap-Band Induced Weight Loss on Serum PSA Levels|Effect of Lap-Band Induced Weight Loss on Serum PSA Levels, Testosterone, Estrogen and Other Serum Markers|Unknown status|Recruiting||20|Anticipated|Maimonides Medical Center|||1||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-06-01 02:43:38.254|2018-06-01 02:43:38.254
NCT00562328|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|2012-04-11||2017-05-23|2007-11-21|2007-11-22|Estimate|2012-04-11|2012-05-08|Estimate||||2017-05-23|2017-06-16|Actual|January 2008|Actual|2008-01-31|May 2017|2017-05-31|December 18, 2014|Actual|2014-12-18|August 2010|Actual|2010-08-31||Interventional|||Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia|Antibody Therapy With Alemtuzumab, Rituximab and GM-CSF for Initial Treatment of High Risk Chronic Lymphocytic Leukemia|Completed||Phase 2|33|Actual|Mayo Clinic||1|||f||||||||||||||2018-06-01 02:43:38.341246|2018-06-01 02:43:38.341246
NCT00562315|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2015-07-23||2016-06-17|2007-11-20|2007-11-22|Estimate|2015-07-23|2015-08-18|Estimate||||2016-06-17|2016-06-21|Estimate|October 2007||2007-10-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Participants completed both the FACBC PET-CT and the ProstaScint CT.|FACBC PET/CT for Recurrent Prostate Cancer|18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).|Completed||Phase 2|128|Actual|Emory University||1|||f||||t||||||||||2018-06-01 02:43:38.675981|2018-06-01 02:43:38.675981
NCT00562302|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2013-02-04|2010-11-19|2013-03-26|2007-11-20|2007-11-22|Estimate|2013-03-26|2013-03-27|Estimate|2010-11-19|2010-11-29|Estimate|2013-03-26|2013-03-27|Estimate|April 2005||2005-04-30|March 2013|2013-03-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure|A Prospective, Randomized, Multi-centered Safety and Efficacy Evaluation of the Bio-Seal Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy|Completed||Phase 3|339|Actual|Angiotech Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:43:38.978865|2018-06-01 02:43:38.978865
NCT00562289|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2017-10-18|2007-11-21|2007-11-22|Estimate|||||||2017-10-18|2017-10-19|Actual|December 2007||2007-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CLOSE||Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence|Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence|Completed||Phase 3|664|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-06-01 02:43:39.408969|2018-06-01 02:43:39.408969
NCT00562276|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2012-09-12|2007-11-21|2007-11-22|Estimate|||||||2012-09-12|2012-09-14|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PAIR||Immediate Versus Delayed Intrauterine Device (IUD) Insertion Following First Trimester Suction Aspiration Procedures|Immediate Versus Delayed IUD Insertion Following Suction Aspiration Between 5 and 12 Weeks Gestation: a Randomized Trial|Completed||Phase 4|578|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:43:39.492468|2018-06-01 02:43:39.492468
NCT00562263|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2014-03-28|2007-11-21|2007-11-22|Estimate|||||||2014-03-28|2014-03-31|Estimate|October 2007||2007-10-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|TEENS||Barriers to Effective Weight Loss in Overweight Adolescents|Barriers to Effective Weight Loss in Overweight Adolescents Enrolled in an Intensive, Team-based, Family-centered Lifestyle Modification Program|Completed||N/A|257|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 02:43:39.560447|2018-06-01 02:43:39.560447
NCT00562250|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-21|||2016-10-14|2007-11-21|2007-11-22|Estimate|||||||2016-10-14|2016-10-17|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects|Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects|Completed||Phase 1|11|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:43:39.63633|2018-06-01 02:43:39.63633
NCT00562237|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2008-10-24|2007-11-20|2007-11-21|Estimate|||||||2008-10-24|2008-10-27|Estimate|July 2007||2007-07-31|October 2008|2008-10-31|September 2008|Anticipated|2008-09-30|November 2007|Actual|2007-11-30||Interventional|||Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine|Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Surface Antigen Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.|Terminated||Phase 1|400|Anticipated|Solvay Pharmaceuticals||7||"This trial discontinued on 20 JUN 2008 because the interim immunogenicity results do not~   justify these formulations as pandemic vaccine candidates"|f||||f||||||||||2018-06-01 02:43:39.722212|2018-06-01 02:43:39.722212
NCT00562224|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2011-09-26|2007-11-19|2007-11-21|Estimate|||||||2011-09-26|2011-09-28|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients|Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer|Completed||Phase 1|36|Anticipated|Pharmacyclics LLC.||1|||f||||f||||||||||2018-06-01 02:43:39.818564|2018-06-01 02:43:39.818564
NCT00562211|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2014-05-05|2007-11-20|2007-11-21|Estimate|||||||2014-05-05|2014-05-06|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy of a New Topical Anesthetic|A Single-blind, Randomized, Controlled Trial to Assess the Efficacy of a New Topical Anesthetic in Reducing Pain Associated With Venipuncture in Children.|Completed||Phase 1/Phase 2|40|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-06-01 02:43:39.903893|2018-06-01 02:43:39.903893
NCT00562198|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2008-06-12|2007-11-20|2007-11-21|Estimate|||||||2008-06-12|2008-06-16|Estimate|January 2008||2008-01-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding|Effects of Single Doses of Stalevo 200 and Levodopa/Carbidopa 200/50mg on Striatal 11C-Raclopride Binding Potential in Parkinson's Disease Patients With Wearing-Off Symptoms;an Open, Randomised, Active-Controlled,Two-Period Crossover Study.|Terminated||Phase 2|16|Anticipated|Orion Corporation, Orion Pharma||1||Illogistical results found in interim evaluation.|f||||f||||||||||2018-06-01 02:43:39.966839|2018-06-01 02:43:39.966839
NCT00562185|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2017-11-16|2007-11-20|2007-11-21|Estimate|||||||2017-11-16|2017-11-20|Actual|May 2008||2008-05-31|October 2017|2017-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer|A Phase I/II Study of Intravenous Doxil and Intraperitoneal Carboplatin as Salvage Therapy in Patients With Recurrent Ovarian Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of Texas Southwestern Medical Center||||Funding source withdrew funding|f||||||||||||||2018-06-01 02:43:40.033341|2018-06-01 02:43:40.033341
NCT00562172|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2012-07-16|2007-11-20|2007-11-21|Estimate|||||||2012-07-16|2012-07-17|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)|Lantus vs Sulfonylurea as add-on Therapy in Type 2 Diabetic Patients Failing Metformin Monotherapy: Comparison of Effects on Beta Cell Function and Metabolic Profile.|Completed||Phase 4|75|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:43:40.209602|2018-06-01 02:43:40.209602
NCT00562159|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2012-08-07|2009-10-22|2017-01-18|2007-11-20|2007-11-21|Estimate|2012-08-07|2012-09-07|Estimate|2009-10-22|2009-10-26|Estimate|2017-01-18|2017-03-03|Actual|November 2007||2007-11-30|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma|Completed||Phase 3|439|Actual|ALK-Abelló A/S||2|||f||||t||||||||||2018-06-01 02:43:40.312979|2018-06-01 02:43:40.312979
NCT00562146|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2008-10-27|2007-11-20|2007-11-21|Estimate|||||||2008-10-27|2008-10-28|Estimate|December 2007||2007-12-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Rate of Postpyloric Migration of Spiral Nasojejunal Tubes in Brain Injured Patients|Rate of Postpyloric Migration of Spiral Nasojejunal Tubes in Brain Injured Patients|Completed|||120|Actual|Capital Medical University|||2||f||||t||||||||||2018-06-01 02:43:40.676903|2018-06-01 02:43:40.676903
NCT00562133|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-20|2007-11-20|2007-11-21|Estimate|||||||2007-11-20|2007-11-21|Estimate|December 2006||2006-12-31|November 2007|2007-11-30|March 2007|Actual|2007-03-31|||||Interventional|||Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes|Effect of Prandial Treatment With Insulin Glulisine Compared to Regular Human Insulin on Postprandial Endothelial Function and Microvascular Stress in Type 2 Diabetic Patients|Completed||Phase 3|15|Actual|IKFE Institute for Clinical Research and Development||2|||f||||f||||||||||2018-06-01 02:43:40.756956|2018-06-01 02:43:40.756956
NCT00562120|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2014-03-10|2009-03-24|2014-03-10|2007-11-19|2007-11-21|Estimate|2014-03-10|2014-04-16|Estimate|2010-11-12|2010-11-23|Estimate|2014-03-10|2014-04-16|Estimate|December 2007||2007-12-31|March 2014|2014-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||Safety analysis set included all participants randomized at baseline and who received at least 1 dose of double-blind treatment.|A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge|A Randomized, Double Blind, Double Dummy, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of An H3 Receptor Antagonist (PF-03654746) On Congestion Following A Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis.|Completed||Phase 2|21|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:43:40.86518|2018-06-01 02:43:40.86518
NCT00562107|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2014-09-26|2007-11-20|2007-11-21|Estimate|||||||2014-09-26|2014-09-29|Estimate|December 2007||2007-12-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|March 2011|Actual|2011-03-31||Interventional|ANSWER||Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication|Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication|Completed||Phase 4|650|Actual|LivaNova||2|||f||||t||||||||||2018-06-01 02:43:41.474652|2018-06-01 02:43:41.474652
NCT00562094|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2010-09-01||2012-05-04|2007-11-20|2007-11-21|Estimate|2010-09-01|2010-09-24|Estimate||||2012-05-04|2012-05-08|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|PULS||Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS)|Pantoprazole for the Treatment of GERD Associated Symptoms Focusing on Sleep Disorders.|Completed|||8616|Actual|Nycomed|||1||f||||f||||||||||2018-06-01 02:43:41.754668|2018-06-01 02:43:41.754668
NCT00562081|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2016-04-28|2007-11-20|2007-11-21|Estimate|||||||2016-04-28|2016-05-02|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|VAC||The Virtual Asthma Clinic|Evaluation of an Internet-based Approach to Long-term Treatment of Asthma.|Terminated||Phase 4|27|Actual|University of Alberta||2||Poor recruitment.|f||||f||||||||||2018-06-01 02:43:43.931343|2018-06-01 02:43:43.931343
NCT00562068|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2013-08-23|2007-11-20|2007-11-21|Estimate|||||||2013-08-23|2013-08-26|Estimate|May 2007||2007-05-31|November 2008|2008-11-30||||May 2009|Anticipated|2009-05-31||Interventional|||Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma|CHOP-Campath, A Pilot Study of CHOP Plus Campath for the Primary Treatment of ALK-ve Peripheral T Cell Lymphoma [CHOP-CAMPATH]|Unknown status|Recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:43:44.000704|2018-06-01 02:43:44.000704
NCT00562055|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2008-06-19|2007-11-19|2007-11-21|Estimate|||||||2008-06-19|2008-06-20|Estimate|November 2007||2007-11-30|June 2008|2008-06-30||||||||Interventional|||Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.|Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.|Withdrawn||Phase 2|96|Anticipated|Pfizer||||This study was withdrawn due to business reasons.|f||||||||||||||2018-06-01 02:43:44.076907|2018-06-01 02:43:44.076907
NCT00562029|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2015-05-19|2007-11-19|2007-11-21|Estimate|||||||2015-05-19|2015-05-21|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|DJB||Study of Duodenal-Jejunal Bypass(DJB) as a Potential Cure for Type 2 Diabetes Mellitus|"Modified Duodenal Switch Procedure Duodenal-Jejunal Bypass (Diabetes Surgery) As A Potential Cure for Type 2 Diabetes Mellitus in Non-Obese Patients- a Pilot Project to Validate a Prospective Randomized Control Trial"|Completed||N/A|10|Anticipated|Sound Shore Medical Center of Westchester||1|||f||||t||||||||||2018-06-01 02:43:44.181657|2018-06-01 02:43:44.181657
NCT00562016|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2011-03-18|2007-11-20|2007-11-21|Estimate|||||||2011-03-18|2011-03-21|Estimate|October 2007||2007-10-31|March 2011|2011-03-31|September 2011|Anticipated|2011-09-30|April 2011|Anticipated|2011-04-30||Interventional|PROTECT II||Protect II, A Prospective, Multicenter Randomized Controlled Trial|PROTECT II: A Prospective, Multi-center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump (IABP)in Patients Undergoing Non Emergent High Risk PCI|Terminated||Phase 3|452|Actual|Abiomed Inc.||2||"Futility on primary endpoint.Study confounded by statistically significant differences between~   the two arms re: atherectomy, duration of support."|f||||t||||||||||2018-06-01 02:43:44.373727|2018-06-01 02:43:44.373727
NCT00562003|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2011-01-25|2007-11-20|2007-11-21|Estimate|||||||2011-01-25|2011-01-26|Estimate|June 2007||2007-06-30|January 2011|2011-01-31|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|Ad5Delta24RGD||Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients|A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (Ad5-Delta 24 RGD)for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients (Infectivity Enhanced Virotherapy for Ovarian Cancer)|Completed||Phase 1|26|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 02:43:44.493425|2018-06-01 02:43:44.493425
NCT00561990|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2015-10-13|2007-11-20|2007-11-21|Estimate|||||||2015-10-13|2015-10-15|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Nimotuzumab in Adults With Pancreatic Cancer|A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER|Completed||Phase 2/Phase 3|188|Anticipated|Oncoscience AG||2|||f||||t||||||||||2018-06-01 02:43:44.56491|2018-06-01 02:43:44.56491
NCT00561977|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2010-01-18||2011-08-02|2007-11-20|2007-11-21|Estimate|2011-08-02|2011-09-02|Estimate||||2011-08-02|2011-09-02|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|February 2009|Actual|2009-02-28|May 2008|Actual|2008-05-31||Interventional|CanDo||Cancer Dietary Objectives Study|Finding a Simple Message to Improve Dietary Quality for Cancer and Heart Disease|Completed||N/A|36|Actual|University of Massachusetts, Worcester||3|||f||||f||||||||||2018-06-01 02:43:44.638357|2018-06-01 02:43:44.638357
NCT00561964|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-22|2007-11-20|2007-11-21|Estimate|||||||2007-11-22|2007-11-26|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|July 2005|Actual|2005-07-31|||||Interventional|PRIME||Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria|Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria|Completed||Phase 3|241|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:43:45.080912|2018-06-01 02:43:45.080912
NCT00561951|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2010-01-11||2011-07-11|2007-11-19|2007-11-21|Estimate|2010-08-18|2010-09-09|Estimate||||2011-07-11|2011-07-14|Estimate|November 2007||2007-11-30|July 2011|2011-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo In Patients With Overactive Bladder.|Completed||Phase 2|951|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:43:45.182135|2018-06-01 02:43:45.182135
NCT00561938|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2009-02-24|2007-11-20|2007-11-21|Estimate|||||||2009-02-24|2009-02-25|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Confocal Laser Endomicroscopy|Confocal Laser Endomicroscopy in the Digestive Tract: A Multicentre French Pilot Study.|Completed||N/A|61|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 02:43:46.104306|2018-06-01 02:43:46.104306
NCT00561925|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2011-12-13||2014-03-07|2007-11-20|2007-11-21|Estimate|2011-12-13|2012-01-19|Estimate||||2014-03-07|2014-04-07|Estimate|November 2007||2007-11-30|March 2014|2014-03-31||||November 2011|Actual|2011-11-30||Interventional|||VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients|A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)|Completed||Phase 3|1068|Actual|Boehringer Ingelheim|For the lead-in-period with NVP IR 200mg QD, MedDRA Version 12.1 was used for AE/SAE reporting.|2|||f||||||||||||||2018-06-01 02:43:46.27195|2018-06-01 02:43:46.27195
NCT00561912|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2011-11-22||2011-11-22|2007-11-20|2007-11-21|Estimate|2011-11-22|2011-12-26|Estimate||||2011-11-22|2011-12-26|Estimate|October 2007||2007-10-31|November 2011|2011-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma|Phase II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Interferon Alfa-2b in Advanced Renal Cell Carcinoma|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Low accrual.|f||||f||||||||||2018-06-01 02:43:49.152064|2018-06-01 02:43:49.152064
NCT00561899|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2017-01-25|2007-11-20|2007-11-21|Estimate|||||||2017-01-25|2017-01-26|Estimate|August 2007||2007-08-31|January 2017|2017-01-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children|Comparison of Safety, Tolerability and Efficacy of Three Drug Combinations for Intermittent Preventive Treatment in Children Aged 1-5 Years in an Area of Seasonal Malaria Transmission in Upper River Division, The Gambia|Completed||Phase 2/Phase 3|1295|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-06-01 02:43:49.315239|2018-06-01 02:43:49.315239
NCT00561886|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-20|2007-11-20|2007-11-21|Estimate|||||||2007-11-20|2007-11-21|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Change of Inspiratory Peak Flow in COPD|Change of Inspiratory Peak Flow After Bronchial Dilatation on Patients With Moderate to Severe COPD|Completed||Phase 4|40|Actual|Johannes Gutenberg University Mainz||1|||f||||t||||||||||2018-06-01 02:43:49.420613|2018-06-01 02:43:49.420613
NCT00561873|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-20|2007-11-20|2007-11-21|Estimate|||||||2007-11-20|2007-11-21|Estimate|June 2004||2004-06-30|November 2007|2007-11-30|February 2007|Actual|2007-02-28|||||Observational|||Nimotuzumab in Children With HGG|Phase-II-Study of Efficacy of OSAG 101 (Theraloc®) for Adolscent Patients With Recurrent High Grade Glioma|Completed|||45|Actual|Oncoscience AG|||||f||||t||||||||||2018-06-01 02:43:49.510484|2018-06-01 02:43:49.510484
NCT00561860|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2014-03-14|2007-11-20|2007-11-21|Estimate|||||||2014-03-14|2014-03-17|Estimate|November 2007||2007-11-30|March 2014|2014-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Use of a Remote-Monitoring System to Diagnose and Treat Obstructive Sleep Apnea|Use of a Remote-Monitoring System to Diagnose and Treat Obstructive Sleep Apnea|Completed||N/A|75|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 02:43:49.590909|2018-06-01 02:43:49.590909
NCT00561847|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2013-04-02|2007-11-20|2007-11-21|Estimate|||||||2013-04-02|2013-04-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:43:49.679498|2018-06-01 02:43:49.679498
NCT00561834|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2014-03-03||2016-08-23|2007-11-19|2007-11-21|Estimate|2016-06-13|2016-07-25|Estimate||||2016-08-23|2016-09-30|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|NAION||Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy|Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION)|Completed||Phase 1|2|Actual|University of Colorado, Denver||1|||f||||f||||||||No||2018-06-01 02:43:49.740383|2018-06-01 02:43:49.740383
NCT00561821|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2014-06-30|2010-02-03|2015-06-11|2007-11-19|2007-11-21|Estimate|2014-08-04|2014-08-05|Estimate|2010-02-03|2010-02-05|Estimate|2015-06-11|2015-07-09|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||All Subjects Treated (AST) population consisted of participants who received at least one dose of study medication.|Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)|A Double-Blind, Randomized, Parallel Group, Placebo- Controlled Sleep Laboratory Efficacy and Safety Study With Org 50081 in Elderly Subjects With Chronic Primary Insomnia|Completed||Phase 3|538|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:43:50.019026|2018-06-01 02:43:50.019026
NCT00561808|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2010-03-08|2007-11-19|2007-11-21|Estimate|||||||2010-03-08|2010-03-09|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|January 2009|Actual|2009-01-31|||||Interventional|IVM||In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF|In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF|Completed||N/A|30|Actual|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-06-01 02:43:51.827794|2018-06-01 02:43:51.827794
NCT00561795|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2009-11-19|2009-07-22|2012-03-15|2007-11-19|2007-11-21|Estimate|2010-12-03|2010-12-07|Estimate|2009-07-22|2009-08-10|Estimate|2012-03-15|2012-03-22|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors|A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors|Completed||Phase 2|12|Actual|GlaxoSmithKline|As defined in the protocol, a review of the safety data in Arm A showed that >=2 participants in each regimen of Arm A experienced dose-limiting toxicities. Thus the study was closed to further enrollment and no participants were enrolled into Arm B.|2|||f||||f||||||||||2018-06-01 02:43:52.181005|2018-06-01 02:43:52.181005
NCT00561782|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2014-09-16|2007-11-19|2007-11-21|Estimate|||||||2014-09-16|2014-09-17|Estimate|October 2007||2007-10-31|September 2014|2014-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|MRS||MR Spectroscopy as a Diagnostic and Outcome Measure in Pain and SCI|MR Spectroscopy (MRS) as a Diagnostic and Outcome Measure in Pain and SCI|Completed|||94|Actual|VA Office of Research and Development|||4||f||||f||||||||||2018-06-01 02:43:52.742047|2018-06-01 02:43:52.742047
NCT00561769|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2007-11-20|2007-11-20|2007-11-21|Estimate|||||||2007-11-20|2007-11-21|Estimate|January 2005||2005-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||Luteal Phase Commencing of Growth Hormone|Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response|Completed|||61|Actual|Gulhane School of Medicine|||1||f||||t||||||||||2018-06-01 02:43:52.823741|2018-06-01 02:43:52.823741
NCT00561756|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2015-11-16|2007-11-20|2007-11-21|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma|Phase I Trial to Assess Safety and Immunogenicity of Xenogeneic CD20 DNA Vaccination With Patients With B-Cell Lymphoma|Completed||Phase 1|8|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:43:52.884618|2018-06-01 02:43:52.884618
NCT00561743|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19||2011-06-07|2011-06-07|2007-11-19|2007-11-21|Estimate||||2011-06-07|2011-06-21|Estimate|2011-06-07|2011-06-21|Estimate|November 2005||2005-11-30|April 2010|2010-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients|A Phase II Study to Assess the Safety and Efficacy of DBd Combination Therapy (DOXIL/CAELYX) [Doxorubicin HCL Liposome Injection], VELCADE [Bortezomib] and Dexamethasone) for Previously Untreated Multiple Myeloma Patients|Completed||Phase 2|50|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 02:43:52.978895|2018-06-01 02:43:52.978895
NCT00561730|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2010-08-23||2012-05-04|2007-11-20|2007-11-21|Estimate|2010-08-23|2010-09-16|Estimate||||2012-05-04|2012-05-08|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|December 2008|Actual|2008-12-31|||||Observational|PANTHER||Efficacy of Pantoprazole in Patients Older Than 12 Years Who Have Symptoms of Non-Erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (eGERD)|Pantoprazole 20 mg/40 mg for the Treatment of Gastroesophageal Reflux Disease (GERD)|Completed|||1995|Actual|Nycomed|||1||f||||f||||||||||2018-06-01 02:43:53.106192|2018-06-01 02:43:53.106192
NCT00561717|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2013-05-05|2007-11-20|2007-11-21|Estimate|||||||2013-05-05|2013-05-07|Estimate|October 2007||2007-10-31|May 2013|2013-05-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|GEYSER||A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis|A Four-Way Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray and Antihistaminic Agents in Adult Subjects With Allergen Induced Seasonal Allergic Rhinitis|Completed||Phase 4|70|Actual|Bayer||4|||f||||f||||||||||2018-06-01 02:43:53.96218|2018-06-01 02:43:53.96218
NCT00561704|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2007-11-20|2007-11-20|2007-11-21|Estimate|||||||2007-11-20|2007-11-21|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Adiponectin in Obese Women With T2DN and Effects by RAS Blocker|Adiponectin in Obese Women With T2DN and Effects by RAS Blocker|Completed||N/A|80|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||t||||||||||2018-06-01 02:43:54.122487|2018-06-01 02:43:54.122487
NCT00561691|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2013-03-27|2007-11-20|2007-11-21|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2006||2006-04-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|||||Observational|||Nimotuzumab in Children With Intrinsic Pontine Glioma|Phase III Study on the Effectiveness of OSAG 101 (Theraloc®)in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents|Completed|||41|Actual|Oncoscience AG|||||f||||t||||||||||2018-06-01 02:43:54.310325|2018-06-01 02:43:54.310325
NCT00561678|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2017-02-10||2018-03-22|2007-11-20|2007-11-21|Estimate|2017-02-10|2017-03-29|Actual||||2018-03-22|2018-04-23|Actual|February 2008||2008-02-29|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve|Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve|Completed||Phase 4|404|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 02:43:54.439822|2018-06-01 02:43:54.439822
NCT00561652|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2014-11-06||2015-01-23|2007-11-19|2007-11-21|Estimate|2015-01-23|2015-02-10|Estimate||||2015-01-23|2015-02-10|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Education/Exercise and Chiropractic for Chronic Back Pain|Education/Exercise and Chiropractic for Chronic Back Pain|Completed||N/A|30|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 02:43:55.077539|2018-06-01 02:43:55.077539
NCT00561639|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2010-07-08|2007-11-20|2007-11-21|Estimate|||||||2010-07-08|2010-07-09|Estimate|December 2007||2007-12-31|July 2010|2010-07-31|November 2008|Actual|2008-11-30|||||Observational|SEPTIFAST||Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis|Benefit of Septifast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis|Completed|||76|Actual|University Hospital, Grenoble|||||f||||t||||||Samples Without DNA|"~     serum tube will routinely be kept in the serum bank for subsequent analysis~   "|||2018-06-01 02:43:55.503651|2018-06-01 02:43:55.503651
NCT00561626|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2017-02-22|2007-11-20|2007-11-21|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2008||2008-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Effects of High-fat and Low-fat Diet on the Gut|Effects of a High-fat and a Low-fat Diet on Early Biomarkers of Metabolic Stress in Blood and Gene Expression in the Small Intestine of Healthy Subjects|Completed||N/A|10|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 02:43:55.55802|2018-06-01 02:43:55.55802
NCT00561613|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2007-12-19|2007-11-19|2007-11-21|Estimate|||||||2007-12-19|2007-12-24|Estimate|August 2003||2003-08-31|December 2007|2007-12-31|October 2004|Actual|2004-10-31|||||Interventional|||Postcoital Testing of the SILCS Diaphragm|A Phase I Postcoital Testing and Safety Study of the SILCS Diaphragm, Prototype VI|Completed||Phase 1|40|Actual|CONRAD||2|||f||||f||||||||||2018-06-01 02:43:55.625504|2018-06-01 02:43:55.625504
NCT00561600|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2014-02-05||2017-07-10|2007-11-20|2007-11-21|Estimate|2014-04-07|2014-05-07|Estimate||||2017-07-10|2017-08-09|Actual|November 1, 2006|Actual|2006-11-01|June 2017|2017-06-30|January 1, 2012|Actual|2012-01-01|January 1, 2012|Actual|2012-01-01||Interventional|ASR||Multi-Center Comparative Trial of the ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System|A Randomized, Prospective, Comparative, Multi-Center Clinical Evaluation of the DePuy ASR™-XL Acetabular Cup System vs. the Pinnacle™ Metal- on- Metal Total Hip System Study|Completed||N/A|265|Actual|DePuy Orthopaedics|At study inception, information on whether or not an adverse event was deemed to be serious was not collected. Because of this caveat, the Sponsor has reported all adverse events that occurred.|2|||f||||f||||||||||2018-06-01 02:43:55.735754|2018-06-01 02:43:55.735754
NCT00561587|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2011-04-15|2007-11-20|2007-11-21|Estimate|||||||2011-04-15|2011-04-18|Estimate|November 2007||2007-11-30|January 2008|2008-01-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study|Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study|Completed||Phase 2|40|Anticipated|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||f||||||||||2018-06-01 02:43:56.787415|2018-06-01 02:43:56.787415
NCT00561574|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2014-06-05|2010-04-13|2015-05-18|2007-11-19|2007-11-21|Estimate|2014-06-05|2014-07-07|Estimate|2010-04-13|2010-04-15|Estimate|2015-05-18|2015-06-12|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|Jade||A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)|A Randomized Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of Org 50081|Completed||Phase 3|259|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:43:56.926912|2018-06-01 02:43:56.926912
NCT00561561|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2017-10-31|2007-11-20|2007-11-21|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2001||2001-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2013|Actual|2013-07-31||Observational|||Sensorimotor Gating in Schizophrenia|Sensorimotor Gating in Schizophrenia|Active, not recruiting|||500|Anticipated|Emory University|||4||f||||f||||||Samples With DNA|"~     Blood and extracted DNA~   "|||2018-06-01 02:43:57.368664|2018-06-01 02:43:57.368664
NCT00561548|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2011-05-27|2007-11-20|2007-11-21|Estimate|||||||2011-05-27|2011-05-30|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|April 2009|Actual|2009-04-30|May 2008|Actual|2008-05-31||Interventional|||Impact of Anti-Tumor Necrosis Factor (TNF) Antibodies on the T-lymphocyte and Macrophage Cooperation in Crohn Disease|Impact of Anti-TNF Antibodies on the T-lymphocyte and Macrophage Cooperation in the Crohn Disease|Terminated||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 02:43:57.436132|2018-06-01 02:43:57.436132
NCT00561535|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2011-01-26|2007-11-20|2007-11-21|Estimate|||||||2011-01-26|2011-01-27|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS Patients|Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS|Completed||Phase 2|60|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:43:57.507646|2018-06-01 02:43:57.507646
NCT00561522|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2010-07-20|2007-11-20|2007-11-21|Estimate|||||||2010-07-20|2010-07-21|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection|Capecitabine as Adjuvant Chemotherapy to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection: a Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|290|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 02:43:57.578706|2018-06-01 02:43:57.578706
NCT00561509|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2009-07-13|2007-11-19|2007-11-21|Estimate|||||||2009-07-13|2009-07-15|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|||||Observational|||Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months|A Prospective, Observational Study Comparing the Frequency of Treatment-Emergent Sexual Dysfunction Over 8 Weeks in Patients With Major Depressive Disorder Treated With Either Duloxetine Hydrochloride or a Selective Serotonin Reuptake Inhibitor Antidepressant and Evaluated Over 6 Months|Completed|||1626|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-06-01 02:43:57.652917|2018-06-01 02:43:57.652917
NCT00556309|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2017-02-08|2007-11-07|2007-11-09|Estimate|||||||2017-02-08|2017-02-10|Actual|January 2007||2007-01-31|February 2017|2017-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|OCT||Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.|Completed|||3|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:46:25.356376|2018-06-01 02:46:25.356376
NCT00561496|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2008-05-27|2007-11-20|2007-11-21|Estimate|||||||2008-05-27|2008-05-28|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel|Single Dose and 14-Day Once or Twice-Daily Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel|Completed||Phase 1|49|Actual|CONRAD||2|||f||||f||||||||||2018-06-01 02:43:57.821865|2018-06-01 02:43:57.821865
NCT00561483|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2017-01-05|2007-11-20|2007-11-21|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2007||2007-11-30|January 2017|2017-01-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Observational|||Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure|Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure|Completed|||64|Actual|The Cleveland Clinic|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-06-01 02:43:57.893493|2018-06-01 02:43:57.893493
NCT00561470|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2012-08-17|2012-03-14|2012-09-27|2007-11-20|2007-11-21|Estimate|2012-09-27|2012-09-28|Estimate|2012-03-14|2012-03-16|Estimate|2012-09-27|2012-09-28|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|June 2012|Actual|2012-06-30|February 2011|Actual|2011-02-28||Interventional|VELOUR||Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen|A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen|Completed||Phase 3|1226|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:43:58.033825|2018-06-01 02:43:58.033825
NCT00561457|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2009-05-26||2017-01-17|2007-11-20|2007-11-21|Estimate|2011-04-06|2011-05-04|Estimate||||2017-01-17|2017-03-01|Actual|June 2003||2003-06-30|January 2017|2017-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|Luminexx||A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System|A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System|Completed||N/A|134|Actual|C. R. Bard||1|||f||||f||||||||||2018-06-01 02:43:59.877538|2018-06-01 02:43:59.877538
NCT00561444|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2018-05-29|2007-11-20|2007-11-21|Estimate|||||||2018-05-29|2018-05-30|Actual|November 14, 2007|Actual|2007-11-14|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Quality of Life Study for Prostate Cancer Patients|A Comprehensive, Multimodality Quality of Life Study for Prostate Cancer Patients|Active, not recruiting|||1051|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 02:44:00.059242|2018-06-01 02:44:00.059242
NCT00561431|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2009-11-11||2015-03-24|2007-11-20|2007-11-21|Estimate|2010-02-24|2010-03-12|Estimate||||2015-03-24|2015-04-14|Estimate|July 2003||2003-07-31|March 2015|2015-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|CVVHDF||High Dose CVVHDF Compared to Standard Dose CVVHDF|A Randomized Prospective Study Comparing High Dose Continuous Venovenous Hemodiafiltration (CVVHDF) to Standard Dose CVVHDF in Critically Ill Patients With Acute Renal Failure at the University of Alabama at Birmingham|Completed||Phase 3|200|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 02:44:00.137275|2018-06-01 02:44:00.137275
NCT00561418|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|2015-04-20||2015-07-10|2007-11-20|2007-11-21|Estimate|2015-07-10|2015-07-16|Estimate||||2015-07-10|2015-07-16|Estimate|November 2007||2007-11-30|July 2015|2015-07-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma|Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma|Completed||Phase 1|23|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:44:00.477492|2018-06-01 02:44:00.477492
NCT00561405|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2011-09-23|2007-11-20|2007-11-21|Estimate|||||||2011-09-23|2011-09-26|Estimate|December 2006||2006-12-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||A Comparison of Two Intensive Walking Training Interventions in Community Dwelling Individuals With History of Stroke|A Motor Learning Based Walking Program Versus Body Weight Supported Treadmill Training in Community Dwelling Adults Within One Year of Stroke Onset: A Randomized Controlled Trial|Completed||Phase 2|71|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 02:44:00.705922|2018-06-01 02:44:00.705922
NCT00561392|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2010-12-15||2012-04-10|2007-11-19|2007-11-21|Estimate|2011-02-15|2011-03-11|Estimate||||2012-04-10|2012-04-16|Estimate|November 2007||2007-11-30|April 2012|2012-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|ADEPT||Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease|A 24-week, Multi-center, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE10-26)|Completed||Phase 4|208|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:44:00.81075|2018-06-01 02:44:00.81075
NCT00561379|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-20|||2013-06-12|2007-11-20|2007-11-21|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2005||2005-04-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab|Frontline Therapy of Diffuse Large B Cell Lymphoma of the Adult ( 18 to 60 Years Old): Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14 -Rituximab. Multicentric Randomized Prospective Trial.|Completed||N/A|350|Anticipated|Nantes University Hospital||2|||f||||||||||||||2018-06-01 02:44:01.066066|2018-06-01 02:44:01.066066
NCT00561366|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2012-02-08|2007-11-16|2007-11-20|Estimate|||||||2012-02-08|2012-02-09|Estimate||||February 2012|2012-02-29||||||||Interventional|||A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS|A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|Withdrawn||Phase 2|0|Actual|CytRx||2||Not moving forward with program.|f||||t||||||||||2018-06-01 02:44:01.128521|2018-06-01 02:44:01.128521
NCT00561353|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2013-12-18||2014-05-14|2007-11-19|2007-11-20|Estimate|2013-12-18|2014-02-06|Estimate||||2014-05-14|2014-05-20|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|May 2010|Actual|2010-05-31|December 2008|Actual|2008-12-31||Interventional|||A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection|A Blinded, Randomized, Placebo-controlled Trial in Genotype 1 Hepatitis C-Infected Subjects to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeated Doses of TMC435350, With or Without Peginterferon Alpha-2a and Ribavirin|Completed||Phase 2|121|Actual|Tibotec Pharmaceuticals, Ireland||10|||f||||t||||||||||2018-06-01 02:44:01.303729|2018-06-01 02:44:01.303729
NCT00561171|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2008-11-20|2007-11-19|2007-11-20|Estimate|||||||2008-11-20|2008-11-21|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Phase IIa Study to Investigate the Efficacy and Safety of SPP635 in Diabetic and Hypertensive Patients With Albuminuria|A Phase IIa, Double-Blind, Randomized, Parallel-Design, Four-Week Study to Investigate the Efficacy and Safety of Two Different Doses of the Renin-Inhibitor SPP635 Once Daily in Type II Diabetic Patients With Mild to Moderate Hypertension and Albuminuria|Completed||Phase 2|50|Anticipated|Speedel Pharma Ltd.||2|||f||||f||||||||||2018-06-01 02:44:08.601583|2018-06-01 02:44:08.601583
NCT00561340|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2014-12-29||2015-01-25|2007-11-19|2007-11-20|Estimate|2015-01-25|2015-02-09|Estimate||||2015-01-25|2015-02-09|Estimate|January 2006||2006-01-31|January 2015|2015-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||A total of 25 subjects were eligible for randomization. 4 subjects were not appropriate for randomization to caloric supplementation with pediasure so were included in the counseling only arm.|Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication|Caloric Supplementation During Long-Term Pharmacological Treatment of ADHD in Young Children|Completed||Phase 4|29|Actual|University of Nebraska|This is a follow-up study of 5 and 6 year olds who completed a DBPC study of atomoxetine for ADHD. Data is confounded by subjects having entered the study on different pre-study and concurrent pharmacotherapy. The population is small.|2|||f||||f||||||||||2018-06-01 02:44:06.405689|2018-06-01 02:44:06.405689
NCT00561327|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2007-11-16|2007-11-16|2007-11-20|Estimate|||||||2007-11-16|2007-11-20|Estimate|September 2007||2007-09-30|July 2007|2007-07-31||||||||Observational|||PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites||Unknown status|Recruiting||||German Heart Institute|||2||f||||f||||||||||2018-06-01 02:44:07.218106|2018-06-01 02:44:07.218106
NCT00561314|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-17|||2013-08-23|2007-11-17|2007-11-20|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|January 2012|Actual|2012-01-31|February 2009|Actual|2009-02-28||Interventional|||High-Intensity Focused Ultrasound Ablation in Treating Patients With Localized Prostate Cancer|An Evaluation of Focal Ablation Therapy Using High-Intensity Focused Ultrasound in the Treatment of Localized Adenocarcinoma of the Prostate|Completed||Phase 2|33|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:44:07.318792|2018-06-01 02:44:07.318792
NCT00561301|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-18|||2007-11-18|2007-11-18|2007-11-20|Estimate|||||||2007-11-18|2007-11-20|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|October 2009|Anticipated|2009-10-31|||||Interventional|||Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma|Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma|Unknown status|Recruiting|Phase 2|43|Anticipated|Cooperative Study Group A for Hematology||1|||f||||f||||||||||2018-06-01 02:44:07.441684|2018-06-01 02:44:07.441684
NCT00561288|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2008-06-23|2007-11-16|2007-11-20|Estimate|||||||2008-06-23|2008-06-25|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Acetaminophen on Hurt Feelings|Effects of Acetaminophen on Hurt Feelings|Completed||N/A|60|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 02:44:07.624158|2018-06-01 02:44:07.624158
NCT00561275|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2008-07-10|2007-11-19|2007-11-20|Estimate|||||||2008-07-10|2008-07-15|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Safety Study of Multiple Peptide Vaccine to Esophageal Cancer|Phase 1 Study of Multiple Peptide Vaccine Therapy and GM-CSF in Treating Patients With Esophageal Cancer|Completed||Phase 1|6|Actual|Japanese Foundation for Cancer Research|||||f||||f||||||||||2018-06-01 02:44:07.736737|2018-06-01 02:44:07.736737
NCT00561262|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-17|||2013-08-23|2007-11-17|2007-11-20|Estimate|||||||2013-08-23|2013-08-26|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|April 2011|Actual|2011-04-30|October 2009|Actual|2009-10-31||Interventional|||High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer|An Evaluation of Hemi-ablation Therapy Using High-Intensity Focused Ultrasound in the Treatment of Localized Adenocarcinoma of the Prostate|Completed||Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:44:07.852763|2018-06-01 02:44:07.852763
NCT00561249|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2014-01-24|2007-11-19|2007-11-20|Estimate|||||||2014-01-24|2014-01-27|Estimate|December 2007||2007-12-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Randomized Prospective Trial on the Use of Laser Assisted Hatching (LAH) for Transfer of Frozen/Thawed Embryos in Human IVF/ICSI|Randomized Prospective Trial on the Use of Laser Assisted Hatching (LAH) for Transfer of Frozen/Thawed Embryos in Human IVF/ICSI|Completed||N/A|293|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:44:07.951914|2018-06-01 02:44:07.951914
NCT00561236|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-18|||2016-09-07|2007-11-18|2007-11-20|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Observational|||Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function|Low Dose (1mcg ) ACTH Stimulation Test for Assessment of the Hypothalamo- Pituitary- Adrenal Axis in Patients Treated With Intravitreal Injection of Triamcinolone Acetonide|Completed|||28|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||No||2018-06-01 02:44:08.17494|2018-06-01 02:44:08.17494
NCT00561223|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2014-01-06|2007-11-19|2007-11-20|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|Iloprost||Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD)|The Effect of Iloprost on Gas Exchange and Pulmonary Mechanics in Patients With COPD|Completed||N/A|10|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 02:44:08.265031|2018-06-01 02:44:08.265031
NCT00561210|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2013-11-18|2007-11-19|2007-11-20|Estimate|||||||2013-11-18|2013-11-19|Estimate|November 2003||2003-11-30|November 2013|2013-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients|Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients|Completed||Phase 4|57|Actual|Nestlé||2|||f||||||||||||||2018-06-01 02:44:08.347512|2018-06-01 02:44:08.347512
NCT00561197|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2013-01-03|2007-11-19|2007-11-20|Estimate|||||||2013-01-03|2013-01-04|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer|An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer|Terminated||Phase 1/Phase 2|13|Actual|Ascenta Therapeutics||||Drug not being developed for this indication|f||||f||||||||||2018-06-01 02:44:08.443063|2018-06-01 02:44:08.443063
NCT00561184|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2016-11-30|2007-11-16|2007-11-20|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine|A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects|Completed||Phase 2|47|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:44:08.51158|2018-06-01 02:44:08.51158
NCT00561158|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2010-01-14|2007-11-19|2007-11-20|Estimate|||||||2010-01-14|2010-01-15|Estimate|June 1994||1994-06-30|January 2010|2010-01-31|May 1998|Actual|1998-05-31|||||Interventional|EWLW||Eat Well Live Well Nutrition Program|Dietary Changes in African American Women By Activation|Completed||Phase 2|398|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 02:44:08.684467|2018-06-01 02:44:08.684467
NCT00561145|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2012-03-20||2016-02-12|2007-11-19|2007-11-20|Estimate|2016-02-12|2016-03-11|Estimate||||2016-02-12|2016-03-11|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|March 2012|Actual|2012-03-31|March 2010|Actual|2010-03-31||Interventional|Balance||Impaired Regulation of Energy Balance in Elderly People (Balance Study)|Impaired Regulation of Energy Balance in Elderly People and the Underlying Physiological Mechanisms.|Completed||N/A|32|Actual|Wageningen University||2|||f||||f||||||||||2018-06-01 02:44:08.789839|2018-06-01 02:44:08.789839
NCT00561132|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2007-11-19|2007-11-19|2007-11-20|Estimate|||||||2007-11-19|2007-11-20|Estimate|November 2003||2003-11-30|November 2007|2007-11-30|November 2004|Actual|2004-11-30|||||Interventional|||Study of Vanadium Supplement in Patients With Impaired Glucose Tolerance|Effect of Vanadium on Insulin Sensitivity in Patients With Impaired Glucose Tolerance|Completed||Phase 3|14|Actual|Unidad de Investigacion Medica en Epidemiologia Clinica||2|||f||||t||||||||||2018-06-01 02:44:09.303431|2018-06-01 02:44:09.303431
NCT00561119|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-18|||2017-04-27|2007-11-18|2007-11-20|Estimate|||||||2017-04-27|2017-05-01|Actual|May 2007||2007-05-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer|Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Pts With Metastatic or Recurrent Breast Cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel(GP) as 1st-line Chemotherapy|Completed||Phase 3|326|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-06-01 02:44:09.427797|2018-06-01 02:44:09.427797
NCT00561106|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2007-11-19|2007-11-19|2007-11-20|Estimate|||||||2007-11-19|2007-11-20|Estimate|December 2002||2002-12-31|November 2007|2007-11-30|December 2003|Actual|2003-12-31|||||Interventional|PVBP||Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s Palsy|Treatment Bell´s Palsy: Prednisone vs Prednisone Valacyclovir|Completed||N/A|42|Actual|Universidad de la Republica||2|||f||||f||||||||||2018-06-01 02:44:09.561332|2018-06-01 02:44:09.561332
NCT00561093|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2015-05-20|2007-11-19|2007-11-20|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2008||2008-02-29|May 2015|2015-05-31|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|AIONID||Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients|Pilot/Feasibility Randomized Control Trial to Examine the Effect of Oral Nutritional Supplements With Anti-inflammatory/Anti-oxidative Properties and Pentoxiphylline on Malnutrition-inflammation-cachexia Syndrome in Maintenance Hemodialysis Patients|Completed||Phase 3|93|Actual|Los Angeles Biomedical Research Institute||4|||f||||t||||||||||2018-06-01 02:44:09.665473|2018-06-01 02:44:09.665473
NCT00561080|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2017-10-02||2018-01-21|2007-11-19|2007-11-20|Estimate|2017-12-21|2017-12-22|Actual||||2018-01-21|2018-02-16|Estimate|October 26, 2007|Actual|2007-10-26|January 2018|2018-01-31|June 3, 2009|Actual|2009-06-03|June 3, 2009|Actual|2009-06-03||Interventional||Baseline age missing for 1 participant in Group 2 and 1 participant in Group 3.|Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)|An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 1-dose Regimen and Different 2-dose Regimens of a Zoster Vaccine (Live), ZOSTAVAX ®, in Subjects ≥ 70 Years of Age|Completed||Phase 3|759|Actual|Merck Sharp & Dohme Corp.||3|||f|||||t|f|||t|||||2018-06-01 02:44:09.868648|2018-06-01 02:44:09.868648
NCT00561067|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2012-02-20|2007-11-19|2007-11-20|Estimate|||||||2012-02-20|2012-02-22|Estimate|April 2008||2008-04-30|February 2012|2012-02-29||||July 2008|Actual|2008-07-31||Interventional|||Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP)|Evaluation of the Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study VS Methylprednisolone (MP)|Suspended||Phase 3|100|Anticipated|Niguarda Hospital||2||Italian Medicines Agency decision|f||||t||||||||||2018-06-01 02:44:11.249217|2018-06-01 02:44:11.249217
NCT00561054|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2007-11-19|2007-11-19|2007-11-20|Estimate|||||||2007-11-19|2007-11-20|Estimate|March 2007||2007-03-31|November 2007|2007-11-30||||||||Interventional|Coimbra||Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC|Open-Label, Uncontrolled, Multicenter, Phase II Study Evaluating the Efficacy and Safety of Cetuximab in Combination With Cisplatin & Gemcitabine as First-Line Therapy in Patients With Advanced Non Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|47|Anticipated|Grupo Portugues de Estudo do Cancro do Pulmao||1|||f||||f||||||||||2018-06-01 02:44:11.674737|2018-06-01 02:44:11.674737
NCT00561041|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2007-11-19|2007-11-19|2007-11-20|Estimate|||||||2007-11-19|2007-11-20|Estimate|November 2005||2005-11-30|November 2007|2007-11-30|November 2006|Actual|2006-11-30|||||Interventional|||Aftercare for Adolescents Treated for Alcohol Abuse and Dependence|Maintenance of Treatment Gains in Adolescents With Alcohol Related Disorders|Completed||Phase 2|177|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||3|||f||||f||||||||||2018-06-01 02:44:11.880296|2018-06-01 02:44:11.880296
NCT00561028|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2007-11-19|2007-11-19|2007-11-20|Estimate|||||||2007-11-19|2007-11-20|Estimate|March 2002||2002-03-31|November 2007|2007-11-30|November 2004|Actual|2004-11-30|||||Observational|||Chlamydia and Mycoplasma in Coronary Artery Disease|Prevalence of Chlamydia Pneumoniae and Mycoplasma Pneumoniae in Different Forms of Obstructive Coronary Artery Disease|Completed|||138|Actual|Hospital de Base|||4||f||||f||||||Samples Without DNA|"~     Blood sample - serum~   "|||2018-06-01 02:44:12.052581|2018-06-01 02:44:12.052581
NCT00561015|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2013-03-08||2013-06-07|2007-11-19|2007-11-20|Estimate|2013-06-03|2013-06-04|Estimate||||2013-06-07|2013-06-17|Estimate|December 2007||2007-12-31|June 2013|2013-06-30|May 2009|Actual|2009-05-31|June 2008|Actual|2008-06-30||Interventional|||A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection|A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection|Completed||Phase 2|52|Actual|Tibotec BVBA||6|||f||||f||||||||||2018-06-01 02:44:12.601319|2018-06-01 02:44:12.601319
NCT00561002|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2009-07-20||2016-04-12|2007-11-19|2007-11-20|Estimate|2009-07-20|2009-08-27|Estimate||||2016-04-12|2016-04-14|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2007-2008 Formulation)|Completed||Phase 4|34|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:44:15.25254|2018-06-01 02:44:15.25254
NCT00560989|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2014-09-24|2007-11-16|2007-11-20|Estimate|||||||2014-09-24|2014-09-26|Estimate|March 2007||2007-03-31|September 2014|2014-09-30|March 2007|Actual|2007-03-31|||||Observational|||Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis|Shared Genetic Susceptibility in CBD and Sarcoidosis|Completed|||400|Actual|National Jewish Health|||4||f||||f||||||Samples With DNA|"~     DNA specimens~   "|||2018-06-01 02:44:16.197957|2018-06-01 02:44:16.197957
NCT00173498|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|July 2005||2005-07-31|July 2005|2005-07-31|October 2005||2005-10-31|||||Observational|||Common Allergens in Skin Tests for Adult Atopic Dermatitis|Common Allergens in Skin Tests for Adult Atopic Dermatitis|Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.816263|2018-06-01 04:38:10.816263
NCT00560976|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-18|||2013-04-17|2007-11-19|2007-11-20|Estimate|||||||2013-04-17|2013-04-18|Estimate|December 2005||2005-12-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Serum NGAL Levels in Hemodialysis (HD) Patients; Relation to Iron Status, HD and Intravenous (IV) Iron Administration|Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels in Hemodialysis (HD) Patients; Relation to Iron Status, Hemodialysis, and Intravenous (IV) Iron Administration|Unknown status|Recruiting|N/A|100|Anticipated|Soroka University Medical Center||1|||f||||f||||||||||2018-06-01 02:44:16.306439|2018-06-01 02:44:16.306439
NCT00560963|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2012-11-14|2007-11-19|2007-11-20|Estimate|||||||2012-11-14|2012-11-15|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine|Combination of Antiangiogenic Therapy Using the mTOR-inhibitor RAD001 and Low Dose Chemotherapy for Locally Advanced and/or Metastatic Pancreatic Cancer - a Dose Finding Study|Completed||Phase 1/Phase 2|21|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:44:16.505572|2018-06-01 02:44:16.505572
NCT00560950|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2009-03-30||2017-03-13|2007-11-19|2007-11-20|Estimate|2009-03-30|2009-05-25|Estimate||||2017-03-13|2017-04-11|Actual|July 2007||2007-07-31|March 2017|2017-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)|A Multicenter, Open-Label Study of the Safety, Tolerability, and Immunogenicity of Revaccination With PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.) in Older Adults|Completed||Phase 3|143|Actual|Merck Sharp & Dohme Corp.|Open-label non-randomized group of subjects enrolled in this extension. Subjects recruited from original study which completed five years previously.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:44:16.658386|2018-06-01 02:44:16.658386
NCT00560937|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2009-03-31||2015-08-11|2007-11-19|2007-11-20|Estimate|2010-11-30|2010-12-28|Estimate||||2015-08-11|2015-08-25|Estimate|June 2005||2005-06-30|August 2015|2015-08-31|April 2008|Actual|2008-04-30|April 2006|Actual|2006-04-30||Interventional|||Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia|Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia|Completed||N/A|28|Actual|Durham VA Medical Center||2|||f||||||||||||||2018-06-01 02:44:17.351125|2018-06-01 02:44:17.351125
NCT00560924|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2017-02-24|2007-11-19|2007-11-20|Estimate|||||||2017-02-24|2017-02-28|Actual|March 21, 2003|Actual|2003-03-21|February 2017|2017-02-28|March 17, 2004|Actual|2004-03-17|March 17, 2004|Actual|2004-03-17||Interventional|||Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women|Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women (RUTI) in Post-menopausal Women With Signs of Urogenital Ageing (UGA)|Terminated||Phase 3|6|Actual|Novo Nordisk A/S||||Trial prematurely discontinued due to slow recruitment|f||||f||||||||||2018-06-01 02:44:17.822016|2018-06-01 02:44:17.822016
NCT00560911|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-17|||2007-11-17|2007-11-17|2007-11-20|Estimate|||||||2007-11-17|2007-11-20|Estimate|March 2002||2002-03-31|November 2007|2007-11-30|February 2007|Actual|2007-02-28|||||Interventional|SPOG60+||Major Outcomes in Elderly Patients With Self-Management of Oral Anticoagulation (SPOG60+)|Impact of Self-Management of Oral Anticoagulation in the Elderly in Terms of Mortality and Morbidity: a Randomized Controlled Trial - SPOG 60+|Completed||Phase 4|216|Actual|Medical University of Graz||2|||f||||f||||||||||2018-06-01 02:44:17.922839|2018-06-01 02:44:17.922839
NCT00560898|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2008-05-19|2007-11-19|2007-11-20|Estimate|||||||2008-05-19|2008-05-20|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Two Multi-Purpose Solution and Lens Material Combinations on Corneal Barrier Function|Comparison of Two Multi-Purpose Solution and Contact Lens Material Combinations on Human Corneal Barrier Function|Completed||Phase 4|25|Anticipated|Southern California College of Optometry||4|||f||||f||||||||||2018-06-01 02:44:18.031509|2018-06-01 02:44:18.031509
NCT00560885|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2013-02-11||2013-03-20|2007-11-19|2007-11-20|Estimate|2013-02-11|2013-03-14|Estimate||||2013-03-20|2013-03-29|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2009|Actual|2009-12-31||Interventional|ABLATE||AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation|AtriCure Synergy Bipolar RF Energy Lesions for Permanent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery|Completed||Phase 3|55|Actual|AtriCure, Inc.||1|||f||||t||||||||||2018-06-01 02:44:18.123707|2018-06-01 02:44:18.123707
NCT00560872|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2009-12-22|2007-11-19|2007-11-20|Estimate|||||||2009-12-22|2009-12-23|Estimate|August 2007||2007-08-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Remote Magnetic Navigation For Cavotricuspid Isthmus Ablation|Randomized Controlled Study of Remote Magnetic Catheter Navigation for Cavotricuspid Isthmus Mapping and Ablation in Patients With Typical Atrial Flutter|Completed||N/A|100|Anticipated|University Hospital Goettingen||2|||f||||f||||||||||2018-06-01 02:44:18.671785|2018-06-01 02:44:18.671785
NCT00560859|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2015-07-13||2015-11-10|2007-11-19|2007-11-20|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|CHAT|These numbers represent all children randomized .|Childhood Adenotonsillectomy Study for Children With OSAS|A Randomized Controlled Study of Adenotonsillectomy for Children With Obstructive Sleep Apnea Syndrome|Completed||N/A|453|Actual|University of Pennsylvania|Children under 5 years of age, in whom OSAS is common, were not included. Children on medications for ADHD or with prolonged oxygen-hemoglobin desaturation were also excluded, so results cannot be extrapolated to such children.|2|||f||||t||||||||||2018-06-01 02:44:18.816337|2018-06-01 02:44:18.816337
NCT00560846|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2013-09-04|2007-11-19|2007-11-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|November 2007||2007-11-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Perioperative Nutrition in Upper Gastrointestinal (GI) Cancer Surgery|Perioperative Nutrition in Upper GI Cancer Surgery (Oesophagectomy or Gastrectomy)|Terminated||N/A|43|Actual|University Hospital, Geneva||2||Insufficient recruitment over time.|f||||f||||||||||2018-06-01 02:44:19.813339|2018-06-01 02:44:19.813339
NCT00560833|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2014-05-28||2017-05-29|2007-11-16|2007-11-20|Estimate|2014-05-28|2014-06-30|Estimate||||2017-05-29|2017-06-21|Actual|October 15, 2004|Actual|2004-10-15|May 2017|2017-05-31|January 15, 2006|Actual|2006-01-15|January 15, 2006|Actual|2006-01-15||Interventional||All participants who received any study drug (placebo or esmertazapine), whether or not randomized.|Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause|Completed||Phase 3|943|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 02:44:19.976724|2018-06-01 02:44:19.976724
NCT00560820|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2016-06-17|2007-11-19|2007-11-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|September 2007||2007-09-30|June 2016|2016-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload|Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload|Completed||Phase 1|11|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:44:20.784909|2018-06-01 02:44:20.784909
NCT00560807|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2015-09-22|2007-11-19|2007-11-20|Estimate|||||||2015-09-22|2015-09-23|Estimate||||September 2015|2015-09-30||||||||Interventional|||Manual Therapy Dosage Factorial Study|Manual Therapy Dosage Factorial Study|Withdrawn||Phase 2/Phase 3|0|Actual|McMaster University||12||The study was stopped because the study never received funding|f||||||||||||||2018-06-01 02:44:20.925182|2018-06-01 02:44:20.925182
NCT00560794|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2014-12-23||2015-01-12|2007-11-19|2007-11-20|Estimate|2014-12-23|2015-01-07|Estimate||||2015-01-12|2015-01-26|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2009|Actual|2009-09-30||Interventional||Full Analysis Set included all participants who received ≥ 1 infusion of blinatumomab who completed at least the first treatment cycle and for whom at least one minimal residual disease (MRD) response assessment was available.|Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)|Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE®) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia|Completed||Phase 2|21|Actual|Amgen Research (Munich) GmbH||1|||f||||t||||||||||2018-06-01 02:44:21.125422|2018-06-01 02:44:21.125422
NCT00560781|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2014-02-25|2007-11-19|2007-11-20|Estimate|||||||2014-02-25|2014-02-26|Estimate|April 2006||2006-04-30|February 2014|2014-02-28|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs|Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs|Completed||N/A|27|Actual|Durham VA Medical Center||2|||f||||||||||||||2018-06-01 02:44:21.680803|2018-06-01 02:44:21.680803
NCT00560768|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2015-01-09|2007-11-19|2007-11-20|Estimate|||||||2015-01-09|2015-01-12|Estimate|December 2007||2007-12-31|January 2015|2015-01-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|Prediction||Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications|Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications|Completed||Phase 4|198|Anticipated|LivaNova||1|||f||||f||||||||||2018-06-01 02:44:21.761481|2018-06-01 02:44:21.761481
NCT00560755|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2017-09-18||2017-09-18|2007-11-19|2007-11-20|Estimate|2017-09-18|2017-10-17|Actual||||2017-09-18|2017-10-17|Actual|October 24, 2007|Actual|2007-10-24|September 2017|2017-09-30|November 24, 2008|Actual|2008-11-24|November 24, 2008|Actual|2008-11-24||Interventional|||Safety Study of ProQuad® rHA in Infants (V221-037)|An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life|Completed||Phase 3|3388|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-06-01 02:44:21.895028|2018-06-01 02:44:21.895028
NCT00560742|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2007-11-16|2007-11-16|2007-11-20|Estimate|||||||2007-11-16|2007-11-20|Estimate|November 2002||2002-11-30|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Efficacy Study of Intramuscular or Intracoronary Injection of Autologous Bone Marrow Cells to Treat Scarred Myocardium|Efficacy of the Mode of Delivery of Autologous Bone Marrow Cells Into Heart Scar Muscle for the Recovery of Contractile Function|Completed||Phase 2|63|Actual|University Hospitals, Leicester||3|||f||||||||||||||2018-06-01 02:44:22.507965|2018-06-01 02:44:22.507965
NCT00560729|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2013-11-18|2007-11-19|2007-11-20|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2003||2003-10-31|November 2013|2013-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients|Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients|Terminated||Phase 3|63|Actual|Nestlé||4|||f||||f||||||||||2018-06-01 02:44:22.620698|2018-06-01 02:44:22.620698
NCT00560716|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2009-10-21|2007-11-16|2007-11-20|Estimate|||||||2009-10-21|2009-10-22|Estimate|June 2007||2007-06-30|November 2007|2007-11-30|November 2009|Anticipated|2009-11-30|January 2009|Actual|2009-01-31||Interventional|||A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors|A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors|Terminated||Phase 1|40|Anticipated|Cyclacel Pharmaceuticals, Inc.||||Sponsor decision|f||||f||||||||||2018-06-01 02:44:22.734165|2018-06-01 02:44:22.734165
NCT00560703|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2011-04-28||2011-12-09|2007-11-16|2007-11-20|Estimate|2011-12-09|2012-01-11|Estimate||||2011-12-09|2012-01-11|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Treatment of Patients With Blepharitis and Facial Rosacea|Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients With Facial Rosacea|Completed||Phase 2|70|Actual|Galderma||2|||f||||f||||||||||2018-06-01 02:44:22.856177|2018-06-01 02:44:22.856177
NCT00560690|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2015-04-02|2007-11-19|2007-11-20|Estimate|||||||2015-04-02|2015-04-06|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||The Effect of Adding Metformin to the Treatment of Hepatitis C|Effect and Safety of Adding Metformin to the Standard Treatment of Hepatitis C on Sustained Viral Response|Completed||Phase 4|140|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:44:23.378744|2018-06-01 02:44:23.378744
NCT00560677|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2018-01-30|2007-11-19|2007-11-20|Estimate|||||||2018-01-30|2018-02-01|Actual|March 2007||2007-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SAPPHIRE||Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)|Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation|Active, not recruiting|||400|Anticipated|Durham VA Medical Center|||||f||||f||||||Samples With DNA|"~     Serum and cells collected.~   "|||2018-06-01 02:44:23.520971|2018-06-01 02:44:23.520971
NCT00560664|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2014-07-30|2007-11-19|2007-11-20|Estimate|||||||2014-07-30|2014-07-31|Estimate|April 2007||2007-04-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|Cartipatch||Comparison of Autologous Chondrocyte Implantation Versus Mosaicoplasty: a Randomized Trial|Phase 3 Study Comparison of Autologous Chondrocyte Implantation Versus Mosaicoplasty|Completed||Phase 3|58|Actual|University Hospital, Brest||2|||f||||f||||||||||2018-06-01 02:44:23.650595|2018-06-01 02:44:23.650595
NCT00560651|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2018-04-23|2007-11-19|2007-11-20|Estimate|||||||2018-04-23|2018-04-24|Actual|November 2007||2007-11-30|April 2018|2018-04-30|November 2027|Anticipated|2027-11-30|November 2027|Anticipated|2027-11-30||Observational|||German Corneal Cross Linking Register|German Corneal Cross Linking Register|Recruiting|||7500|Anticipated|St. Franziskus Hospital|||1||f||||f||||||||||2018-06-01 02:44:23.799356|2018-06-01 02:44:23.799356
NCT00560638|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|||2011-07-14|2007-11-19|2007-11-20|Estimate|||||||2011-07-14|2011-07-18|Estimate|November 2005||2005-11-30|July 2011|2011-07-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye|A Double-Masked, Randomized, Placebo-Controlled Study of Loteprednol Etabonate Ophthalmic Suspension, 0.5% for the Treatment of Dry Eye Used Either TID or QID for a 2 Week Period|Completed||Phase 2|119|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 02:44:23.987014|2018-06-01 02:44:23.987014
NCT00560625|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-18|||2016-09-07|2007-11-18|2007-11-20|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Observational|||Does Inhaled Busedonide or Fluticasone Impair Adrenal Function?|Low Dose(1mcg) ACTH Stimulation Test for Assessment of the Hypothalamus-pituitary-adrenal Axis in Patients Treated With Inhaled Busedonide or Fluticasone.|Terminated|||50|Anticipated|HaEmek Medical Center, Israel||||recruiting subjects did not start.|f||||f||||||||||2018-06-01 02:44:24.156692|2018-06-01 02:44:24.156692
NCT00560612|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-19|2010-11-30||2018-01-30|2007-11-19|2007-11-20|Estimate|2010-12-29|2011-01-25|Estimate||||2018-01-30|2018-02-01|Actual|January 2006||2006-01-31|January 2018|2018-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)|Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)|Completed||Phase 4|12|Actual|Durham VA Medical Center||2|||f||||||||||||||2018-06-01 02:44:24.32958|2018-06-01 02:44:24.32958
NCT00560599|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2013-09-25|2007-11-16|2007-11-20|Estimate|||||||2013-09-25|2013-09-26|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|February 2012|Actual|2012-02-29||Interventional|PRIMO||A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection|A 2X2 Phase III Open-label Clinical Trial of Therapy for Patients With Recurrent Methicillin Resistant Staphylococcus Aureus Infections: Topical Nasal & Body Decolonization and/or Environmental Decontamination vs. Standard of Care|Completed||Phase 3|350|Anticipated|Los Angeles Biomedical Research Institute||4|||f||||t||||||||||2018-06-01 02:44:24.759157|2018-06-01 02:44:24.759157
NCT00560586|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2017-07-05|2007-11-16|2007-11-19|Estimate|||||||2017-07-05|2017-07-11|Actual|April 2004|Actual|2004-04-30|July 2017|2017-07-31|August 2007|Actual|2007-08-31|May 2006|Actual|2006-05-31||Interventional|||Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome|Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome|Completed||Phase 4|62|Actual|University of Louisville||2|||f||||f||||||||||2018-06-01 02:44:24.913866|2018-06-01 02:44:24.913866
NCT00560573|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2013-01-18||2013-03-15|2007-11-15|2007-11-19|Estimate|2013-01-18|2013-02-25|Estimate||||2013-03-15|2013-03-21|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|March 2010|Actual|2010-03-31|June 2008|Actual|2008-06-30||Interventional|||Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer|Phase 1, Dose Escalation Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|46|Actual|Pfizer|A total of 46 patients were enrolled in this study but only 45 of them were evaluable because 1 patient was enrolled but did not participate due to early symptomatic deterioration prior to starting treatment.|1|||f||||f||||||||||2018-06-01 02:44:25.131603|2018-06-01 02:44:25.131603
NCT00560560|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2013-01-18|2011-10-03|2013-05-16|2007-11-15|2007-11-19|Estimate|2013-05-08|2013-05-09|Estimate|2011-10-03|2011-10-05|Estimate|2013-05-16|2013-05-20|Estimate|December 2007||2007-12-31|May 2013|2013-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments|A Phase II, Single Arm Study Of CP-751,871 In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum|Completed||Phase 2|168|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:44:27.253269|2018-06-01 02:44:27.253269
NCT00560547|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2016-08-23|2007-11-16|2007-11-19|Estimate|||||||2016-08-23|2016-08-24|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|October 2009|Anticipated|2009-10-31|||||Interventional|||A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.|An Open Label Study to Assess the Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Monthly Administration of Mircera in Hemodialysis Patients With Chronic Renal Anemia.|Withdrawn||Phase 3|0|Actual|Hoffmann-La Roche||1||The study was cancelled before any patients were enrolled, due to operational reasons.|f||||||||||||||2018-06-01 02:44:29.832009|2018-06-01 02:44:29.832009
NCT00560534|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2009-08-18|2007-11-16|2007-11-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|June 2008||2008-06-30|August 2009|2009-08-31|March 2009|Actual|2009-03-31|||||Observational|||Whole Body Magnetic Resonance Angiography With Subsystolic Venous Compression|Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia. Experience With Venous Compression.|Completed|||36|Anticipated|Copenhagen University Hospital at Herlev|||||f||||t||||||||||2018-06-01 02:44:29.909457|2018-06-01 02:44:29.909457
NCT00560521|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2007-11-16|2007-11-16|2007-11-19|Estimate|||||||2007-11-16|2007-11-19|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|March 2007|Actual|2007-03-31|||||Interventional|||Continuous Positive Airway Pressure on Tuberculosis Pleural Effusion|Effect of Continuous Positive Airway Pressure on Fluid Absorption Among Patients With Pleural Effusion Due to Tuberculosis|Completed||N/A|20|Actual|Universidade Federal do Rio de Janeiro||1|||f||||t||||||||||2018-06-01 02:44:30.026232|2018-06-01 02:44:30.026232
NCT00560508|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2010-11-25||2014-07-29|2007-11-16|2007-11-19|Estimate|2011-01-14|2011-02-10|Estimate||||2014-07-29|2014-07-31|Estimate|November 2007||2007-11-30|July 2014|2014-07-31||||November 2009|Actual|2009-11-30||Interventional|||A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period|A Double-blind, Double-dummy, Randomised, Parallel-group Study to Investigate the Safety, Tolerability, Trough Plasma Concentration, and Efficacy of Pramipexole ER Versus Pramipexole Immediate Release (IR) Administered Orally for 12 Weeks in Patients With Parkinson's Disease (PD) on L-dopa Therapy, Followed by a 52-week Open-label Long-term Treatment Period to Evaluate the Long-term Safety and Efficacy of Pramipexole ER|Completed||Phase 2/Phase 3|112|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:44:30.175841|2018-06-01 02:44:30.175841
NCT00560495|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2012-02-08|2007-11-16|2007-11-19|Estimate|||||||2012-02-08|2012-02-10|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|The Combination of Radiotherapy With the Anti-Angiogenic Agent Tetrathiomolybdate (TM) in the Treatment of Stage I-IIIB Non-Small Cell Lung Cancer (NSCLC): A Phase I Study|Withdrawn||Phase 1|0|Actual|Roswell Park Cancer Institute|||||||||||||||||||2018-06-01 02:44:31.416228|2018-06-01 02:44:31.416228
NCT00560131|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2008-10-10|2007-11-16|2007-11-19|Estimate|||||||2008-10-10|2008-10-13|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|||||Observational|||Evaluation of Autonomic Cardiac Function in Patients With CRPS|Evaluation of Autonomic Cardiac Function in Patients With Complex Regional Pain Syndrome|Completed|||40|Actual|Danish Pain Research Center|||||f||||f||||||||||2018-06-01 02:44:44.195122|2018-06-01 02:44:44.195122
NCT00560482|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15||2014-06-02|2015-10-02|2007-11-15|2007-11-19|Estimate||||2014-06-17|2014-06-20|Estimate|2015-10-02|2015-10-26|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy Study of ABR-215050 to Treat Prostate Cancer|Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer|Completed||Phase 2|206|Actual|Active Biotech AB||2|||f||||f||||||||||2018-06-01 02:44:31.590403|2018-06-01 02:44:31.590403
NCT00560469|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2011-02-01|2007-11-16|2007-11-19|Estimate|||||||2011-02-01|2011-02-02|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies|Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies|Completed|||20|Actual|University of Vermont|||2||f||||f||||||Samples With DNA|"~     Adipose tissue, plasma~   "|||2018-06-01 02:44:31.793363|2018-06-01 02:44:31.793363
NCT00560456|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2010-04-19|2007-11-16|2007-11-19|Estimate|||||||2010-04-19|2010-04-20|Estimate|November 2007||2007-11-30|April 2010|2010-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|PRIVASOM||Chronic Sleep Restriction and Driving|Chronic Sleep Restriction and Driving in Healthy Subjects or Snorers : Interindividual Vulnerability and Recovery Factors|Completed||N/A|40|Anticipated|University Hospital, Bordeaux||4|||f||||f||||||||||2018-06-01 02:44:31.869126|2018-06-01 02:44:31.869126
NCT00560443|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2017-08-23|2007-11-16|2007-11-19|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2008|Actual|2008-02-29|August 2017|2017-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||RCT on Ketorolac and Tramadol in Bone Fractures Pain of Child|Randomized Controlled Trial on Effectiveness of Ketorolac and Tramadol in Not Compound Fractures of Child|Completed||Phase 4|133|Actual|IRCCS Burlo Garofolo||2|||f||||t||||||||||2018-06-01 02:44:32.065287|2018-06-01 02:44:32.065287
NCT00560430|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2010-07-14|2007-11-16|2007-11-19|Estimate|||||||2010-07-14|2010-07-15|Estimate|November 2007||2007-11-30|May 2008|2008-05-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|METATEL||Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients|Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients|Completed||Phase 3|56|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-06-01 02:44:32.160334|2018-06-01 02:44:32.160334
NCT00560417|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2010-11-12||2011-01-12|2007-11-15|2007-11-19|Estimate|2010-11-12|2010-12-14|Estimate||||2011-01-12|2011-01-13|Estimate|November 2007||2007-11-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide|A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide|Completed||Phase 3|339|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:44:32.333528|2018-06-01 02:44:32.333528
NCT00560404|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2016-01-19||2016-03-14|2007-11-16|2007-11-19|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Intent-to-treat (ITT) population included participants who have received at least one dose of C.E.R.A. (Week 0) and for whom data for at least one follow-up is available.|A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.|A Randomized, Open Label Study to Compare the Effect of Once Monthly Administration of Subcutaneous Mircera Versus Epoetin Alfa on Maintenance of Hemoglobin Levels, Safety and Tolerability in Dialysis Patients With Chronic Renal Anemia.|Completed||Phase 3|233|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:44:33.481991|2018-06-01 02:44:33.481991
NCT00560391|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2012-06-15||2016-07-06|2007-11-16|2007-11-19|Estimate|2012-06-15|2012-07-20|Estimate||||2016-07-06|2016-08-04|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional|||Dasatinib in Combination With Revlimid (and Dexamethasone)|A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel®) With Lenalidomide (Revlimid®) and Dexamethasone in Subjects With Relapsed and/ or Refractory Multiple Myeloma|Completed||Phase 1|35|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 02:44:34.63658|2018-06-01 02:44:34.63658
NCT00560378|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2014-09-17|2007-11-16|2007-11-19|Estimate|||||||2014-09-17|2014-09-18|Estimate|June 1998||1998-06-30|September 2014|2014-09-30|June 2005|Actual|2005-06-30|||||Interventional|||Long-term Safety of Protopic in Atopic Eczema|A Long-term, Open Label, Noncomparative Study to Evaluate the Safety of 0.1% Tacrolimus (FK506) Ointment for Treatment of Atopic Dermatitis|Completed||Phase 3|789|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 02:44:37.34122|2018-06-01 02:44:37.34122
NCT00560365|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2011-08-05|2007-11-16|2007-11-19|Estimate|||||||2011-08-05|2011-08-08|Estimate|March 2004||2004-03-31|August 2009|2009-08-31||||December 2013|Anticipated|2013-12-31||Observational|||Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer|A Randomised Controlled Trial to Assess the Cost-effectiveness of Intensive Versus no Scheduled Follow-up in Patients Who Have Undergone Resection for Colorectal Cancer With Curative Intent. (FACS - Follow-up After Colorectal Surgery)|Unknown status|Recruiting||4760|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:44:37.517024|2018-06-01 02:44:37.517024
NCT00560352|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2012-04-02||2017-02-01|2007-11-16|2007-11-19|Estimate|2012-06-05|2012-07-09|Estimate||||2017-02-01|2017-03-13|Actual|February 2008||2008-02-29|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma|A Phase I Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1|16|Actual|Bristol-Myers Squibb|The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase.|1|||f||||f|t|f||||||||2018-06-01 02:44:37.694774|2018-06-01 02:44:37.694774
NCT00560339|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-19|Estimate|||||||2007-11-15|2007-11-19|Estimate|September 2005||2005-09-30|November 2007|2007-11-30|January 2009|Anticipated|2009-01-31|||||Observational|IMPEDE-HF||Does Lung Impedance Correlate With Changes in BNP in Stable and Acutely Decompensated Heart Failure Patients?|Does Lung Impedance Correlate With Changes in BNP in Stable and Acutely Decompensated Heart Failure Patients?|Unknown status|Recruiting||100|Anticipated|Southern New Jersey Cardiac Specialists|||||f||||f||||||||||2018-06-01 02:44:38.636718|2018-06-01 02:44:38.636718
NCT00560326|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2014-08-28|2007-11-16|2007-11-19|Estimate|||||||2014-08-28|2014-09-01|Estimate|June 2003||2003-06-30|August 2014|2014-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis|A Long-term, Non-comparative Study to Evaluate the Safety and Efficacy of Tacrolimus Oint¬Ment in Paediatric Patients|Completed||Phase 2|50|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:44:38.76077|2018-06-01 02:44:38.76077
NCT00173485|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|June 2009||2009-06-30|||||Observational|||The Study of Infection and Cell Inflammation in Peritoneal Dialysate||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.887521|2018-06-01 04:38:10.887521
NCT00560313|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2011-06-06||2016-03-03|2007-11-16|2007-11-19|Estimate|2011-06-06|2011-07-08|Estimate||||2016-03-03|2016-04-01|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults|A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy At-risk Adults 18-50 Years of Age|Completed||Phase 2|54|Actual|Novartis||2|||f||||t||||||||||2018-06-01 02:44:38.938562|2018-06-01 02:44:38.938562
NCT00560300|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2010-01-12|2007-11-16|2007-11-19|Estimate|||||||2010-01-12|2010-01-14|Estimate|November 2000||2000-11-30|January 2010|2010-01-31|November 2006|Actual|2006-11-30|||||Interventional|||Regulation of Bone Formation in Renal Osteodystrophy|Regulation of Bone Formation in Renal Osteodystrophy|Completed||Phase 2|61|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||f||||||||||2018-06-01 02:44:39.525053|2018-06-01 02:44:39.525053
NCT00560287|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2010-03-26|2007-11-16|2007-11-19|Estimate|||||||2010-03-26|2010-03-29|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|August 2010|Anticipated|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis|Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode|Unknown status|Recruiting|Phase 4|50|Anticipated|Fondazione Salvatore Maugeri||2|||f||||t||||||||||2018-06-01 02:44:39.725627|2018-06-01 02:44:39.725627
NCT00560274|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2016-02-01|2007-11-16|2007-11-19|Estimate|||||||2016-02-01|2016-02-02|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.|An Open Label Study to Evaluate the Safety of NeoRecormon in the Treatment of Anemia in Patients With Chronic Hepatitis C Who Are Treated With Pegylated Interferon + Ribavirin Combination Therapy|Completed||Phase 4|190|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:44:39.938843|2018-06-01 02:44:39.938843
NCT00560261|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2012-08-02|2007-11-16|2007-11-19|Estimate|||||||2012-08-02|2012-08-03|Estimate|February 2008||2008-02-29|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|VOLCADREP||Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease|Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease|Completed||Phase 3|120|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:44:40.092143|2018-06-01 02:44:40.092143
NCT00560248|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2010-02-18|2007-11-16|2007-11-19|Estimate|||||||2010-02-18|2010-02-22|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|BEACON||The BEACON Registry: Best Expert Agreement for Care of Occult Myocardial Infarction (MI) Nationally|The BEACON Registry: Best Expert Agreement for Care of Occult MI Nationally|Terminated|||1897|Actual|The Cleveland Clinic|||1|Loss of funding|f||||t||||||||||2018-06-01 02:44:40.163481|2018-06-01 02:44:40.163481
NCT00560235|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2013-10-24|2011-05-18|2015-10-06|2007-11-15|2007-11-19|Estimate|2014-01-14|2014-02-28|Estimate|2011-05-18|2011-05-20|Estimate|2015-10-06|2015-10-28|Estimate|March 2008||2008-03-31|October 2015|2015-10-31|October 2012|Actual|2012-10-31|March 2010|Actual|2010-03-31||Interventional|||Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors|A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors|Completed||Phase 1/Phase 2|138|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:44:40.399047|2018-06-01 02:44:40.399047
NCT00560222|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-10-31|2007-11-15|2007-11-19|Estimate|||||||2011-10-31|2011-11-01|Estimate|February 2008||2008-02-29|October 2011|2011-10-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children|Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children|Completed||Phase 3|555|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 02:44:43.57552|2018-06-01 02:44:43.57552
NCT00560209|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2012-06-12|2007-11-16|2007-11-19|Estimate|||||||2012-06-12|2012-06-13|Estimate|November 2007||2007-11-30|June 2012|2012-06-30||||November 2008|Actual|2008-11-30||Interventional|||Study of ONO-1101 in Patients Scheduled for Coronary Angiography|Study of ONO-1101 in Patients Scheduled for Coronary Angiography, a Double-Blind, Randomized,Placebo-Controlled, Parallel Group, Multi-Center Study|Completed||Phase 2|183|Actual|Ono Pharmaceutical Co. Ltd||3|||f||||||||||||||2018-06-01 02:44:43.690656|2018-06-01 02:44:43.690656
NCT00560196|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2016-01-20|2007-11-16|2007-11-19|Estimate|||||||2016-01-20|2016-01-21|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Observational|||Pain Processing in Anxiety and Depression|Pain, Anxiety and Depression in Patients With Panic Anxiety Disorders Without Pain or Depression Without Pain Compared With Healthy Volunteers|Completed|||71|Actual|Danish Pain Research Center|||3||f||||t||||||||||2018-06-01 02:44:43.79528|2018-06-01 02:44:43.79528
NCT00560183|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14||2010-08-25|2012-05-15|2007-11-15|2007-11-19|Estimate||||2010-08-25|2010-08-30|Estimate|2012-05-15|2012-05-17|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain|A Placebo-controlled, Randomized, Double-blind Study of the Safety and Efficacy of Q8003 in the Management of Post-bunionectomy Pain|Completed||Phase 3|256|Actual|QRxPharma Inc.||2|||f||||f||||||||||2018-06-01 02:44:43.894774|2018-06-01 02:44:43.894774
NCT00560170|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2010-02-23|2007-11-16|2007-11-19|Estimate|||||||2010-02-23|2010-02-24|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Vascular Effects of Ezetimibe/Simvastatin and Simvastatin on Atherosclerosis|Rho-kinase in Patients With Atherosclerosis: Effects of Statins A Randomized Clinical Trial Comparing Ezetimibe/Simvastatin and Simvastatin|Completed||Phase 4|40|Actual|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-06-01 02:44:43.992051|2018-06-01 02:44:43.992051
NCT00560157|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2013-11-18|2007-11-16|2007-11-19|Estimate|||||||2013-11-18|2013-11-19|Estimate|December 2002||2002-12-31|November 2013|2013-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients|Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients|Completed||Phase 4|22|Actual|Nestlé||2|||f||||f||||||||||2018-06-01 02:44:44.069302|2018-06-01 02:44:44.069302
NCT00560144|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2016-10-29|2007-11-16|2007-11-19|Estimate|||||||2016-10-29|2016-11-01|Estimate|December 2007||2007-12-31|October 2016|2016-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.|Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors.|Completed||Phase 1|34|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 02:44:44.127371|2018-06-01 02:44:44.127371
NCT00560118|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2011-05-13|2007-11-16|2007-11-19|Estimate|||||||2011-05-13|2011-05-16|Estimate|August 2003||2003-08-31|December 2008|2008-12-31||||May 2011|Actual|2011-05-31||Interventional|||Fotemustine in Treating Patients With Metastatic Melanoma|Phase II Study of the Predictive Value of the Expression of Tumoral MGMT With Respect to the Therapeutic Response of Fotemustine in Patients With Metastatic Malignant Melanoma|Completed||Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:44:44.247074|2018-06-01 02:44:44.247074
NCT00560105|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2012-11-16||2015-03-04|2007-11-16|2007-11-19|Estimate|2015-03-04|2015-03-05|Estimate||||2015-03-04|2015-03-05|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute|A Proof of Principal Randomized Controlled Eight-Week Study of the Safety and Efficacy of the Lung Flute in Adults With Chronic Obstructive Pulmonary Disease. A FDA 510(k) Equivalency Study|Completed||N/A|40|Actual|Medical Acoustics LLC||2|||f||||f||||||||||2018-06-01 02:44:44.320773|2018-06-01 02:44:44.320773
NCT00560092|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2013-04-02|2007-11-16|2007-11-19|Estimate|||||||2013-04-02|2013-04-04|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Intrathecal Magnesium and Postoperative Analgesia|Effects of a Single Dose of Intrathecal Magnesium Sulfate on Postoperative Morphine Consumption After Total Hip Replacement|Completed||Phase 3|40|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-06-01 02:44:44.60851|2018-06-01 02:44:44.60851
NCT00560079|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2016-08-15|2007-11-15|2007-11-19|Estimate|||||||2016-08-15|2016-08-16|Estimate|November 2003||2003-11-30|August 2016|2016-08-31|April 2006|Actual|2006-04-30|April 2005|Actual|2005-04-30||Interventional|||Efficacy of Allopurinol and Dypiridamole in Acute Mania|A Double-blind, Randomized, Placebo-controlled 4-week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole in Acute Bipolar Mania.|Completed||Phase 4|180|Actual|Hospital Espirita de Porto Alegre||3|||f||||f||||||||||2018-06-01 02:44:44.831208|2018-06-01 02:44:44.831208
NCT00560066|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2012-11-21|2011-12-13|2016-01-19|2007-11-16|2007-11-19|Estimate|2013-04-17|2013-04-18|Estimate|2011-12-13|2011-12-22|Estimate|2016-01-19|2016-02-17|Estimate|November 2007||2007-11-30|January 2016|2016-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions|A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture (Optaflu®) or in Embryonated Hen Eggs (Agrippal®) in Adults and Elderly With and Without Underlying Medical Conditions, and to Evaluate the Immunogenicity in a Subset of Subjects With Underlying Medical Conditions|Completed||Phase 4|1398|Actual|Novartis|Because cTIV was not available, the second part of the study was not performed. In addition, as deviations from protocol procedures and GCP were identified at some sites, data collected for this study were not used to support licensure of cTIV.|2|||f||||||||||||||2018-06-01 02:44:44.941079|2018-06-01 02:44:44.941079
NCT00560053|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2008-11-26|2007-11-16|2007-11-19|Estimate|||||||2008-11-26|2008-11-27|Estimate|January 2000||2000-01-31|November 2008|2008-11-30|February 2005|Actual|2005-02-28|||||Interventional|||Pethema Multiple Myeloma 2000|Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response|Completed||Phase 3|500|Actual|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 02:44:45.615848|2018-06-01 02:44:45.615848
NCT00560040|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-16|2007-11-16|2007-11-19|Estimate|||||||2007-11-16|2007-11-19|Estimate|January 2006||2006-01-31|May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Observational|||Myocardial Injury is Not Related to Training Levels Among Recreational Participants in the Silicon Valley Marathon|Myocardial Injury is Not Related to Training Levels Among Recreational Participants in the Silicon Valley Marathon|Completed|||53|Actual|Stanford University|||||f||||t||||||||||2018-06-01 02:44:45.676217|2018-06-01 02:44:45.676217
NCT00560027|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2015-05-26|2007-11-16|2007-11-19|Estimate|||||||2015-05-26|2015-05-28|Estimate|July 2010||2010-07-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Case Management Study for Postpartum Depression and Intimate Partner Violence|Screening, Referral and Case Management for Postpartum Depression and Intimate Partner Violence in an Urban Pediatric Practice|Completed||N/A|173|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 02:44:45.740421|2018-06-01 02:44:45.740421
NCT00560014|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2007-11-16|2007-11-16|2007-11-19|Estimate|||||||2007-11-16|2007-11-19|Estimate|September 1997||1997-09-30|October 2007|2007-10-31|May 2005|Actual|2005-05-31|||||Interventional|||Nutrient Levels Alter Transplant Outcome|Role of Immunonutrient Levels in Preventing Complications After Renal Transplantation|Completed||N/A|54|Actual|University of Cincinnati||3|||f||||f||||||||||2018-06-01 02:44:45.813455|2018-06-01 02:44:45.813455
NCT00560001|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2009-10-07|2007-11-15|2007-11-19|Estimate|||||||2009-10-07|2009-10-08|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|May 2008|Anticipated|2008-05-31|||||Interventional|||MD.2 Medication Dispenser Medication Adherence Study|Medication Dispenser: MD2: Improving Health Outcomes|Unknown status|Recruiting|Phase 3|600|Anticipated|Interactive Medical Developments||2|||f||||t||||||||||2018-06-01 02:44:45.891942|2018-06-01 02:44:45.891942
NCT00559988|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2014-05-20||2017-11-01|2007-11-15|2007-11-19|Estimate|2014-05-20|2014-06-23|Estimate||||2017-11-01|2017-12-05|Actual|February 2008||2008-02-29|November 2017|2017-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|IMPACT|All enrolled subjects|Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk|The IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients With ICD and CRT-D Devices|Terminated||Phase 4|2718|Actual|Biotronik, Inc.|Study stopped early when primary endpoint met futility criteria. Continuation may have changed the outcome; however, unlikely to demonstrate a meaningful clinical benefit. Interpretation of secondary endpoints should be approached with caution.|2|||f||||t||||||||||2018-06-01 02:44:46.024708|2018-06-01 02:44:46.024708
NCT00559975|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|||2009-11-04|2007-11-16|2007-11-19|Estimate|||||||2009-11-04|2009-11-05|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|May 2008|Actual|2008-05-31|||||Interventional|||Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine|A Phase 1, Randomized, Controlled, Observer-Blinded, Dose Escalation Study of the Safety, Tolerability and Immunogenicity of a Single Dose of Adjuvanted Influenza Vaccine Combined With CpG7909 in Healthy Adults|Completed||Phase 1|60|Anticipated|Novartis||5|||f||||||||||||||2018-06-01 02:44:46.513577|2018-06-01 02:44:46.513577
NCT00559962|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2013-01-18||2018-02-21|2007-11-16|2007-11-19|Estimate|2013-01-18|2013-02-22|Estimate||||2018-02-21|2018-02-23|Actual|October 2007||2007-10-31|February 2018|2018-02-28|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy|Completed||Phase 2|260|Actual|Aegerion Pharmaceuticals, Inc.||8|||f||||t||||||||||2018-06-01 02:44:46.638673|2018-06-01 02:44:46.638673
NCT00559949|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-16|2016-12-02||2016-12-02|2007-11-16|2007-11-19|Estimate|2016-12-02|2017-01-30|Estimate||||2016-12-02|2017-01-30|Estimate|December 2007||2007-12-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||All participants, unless specified differently in an Outcome Measure.|Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine|Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements|Completed||Phase 2|39|Actual|National Cancer Institute (NCI)|Actuarial OS cannot be estimated due to long survival times in this disease.|1|||f||||t||||||||||2018-06-01 02:44:47.480378|2018-06-01 02:44:47.480378
NCT00559936|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2012-08-21||2012-10-02|2007-11-14|2007-11-16|Estimate|2012-08-21|2012-09-24|Estimate||||2012-10-02|2012-10-05|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Topical Avastin for Treatment of Corneal Neovascularization|Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization|Completed||Phase 1|24|Actual|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||||2018-06-01 02:44:47.912332|2018-06-01 02:44:47.912332
NCT00559910|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-04-22|2007-11-15|2007-11-16|Estimate|||||||2011-04-22|2011-04-26|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 (0.5, 3, 6 And 10 MG) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 2|230|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:44:48.113717|2018-06-01 02:44:48.113717
NCT00559897|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2015-01-26||2015-01-26|2007-11-15|2007-11-16|Estimate|2015-01-26|2015-02-04|Estimate||||2015-01-26|2015-02-04|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|||Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study Evaluating the Effect of Zolendronic Acid on Standardized Uptake Value (SUV) on FLT PET Scans in Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|6|Actual|Barbara Ann Karmanos Cancer Institute|None of the participants were evaluable.|1||Slow accrual|f||||t||||||||||2018-06-01 02:44:48.250582|2018-06-01 02:44:48.250582
NCT00559884|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2012-05-31|2007-11-14|2007-11-16|Estimate|||||||2012-05-31|2012-06-04|Estimate|November 2007||2007-11-30|February 2011|2011-02-28||||||||Interventional|||A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects|An Open-label, Randomized, Single Dose, Crossover Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Modified Release Formulations of GSK189075 in Healthy Volunteers|Completed||Phase 1|36|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:44:48.46118|2018-06-01 02:44:48.46118
NCT00559871|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2009-06-02|2007-11-15|2007-11-16|Estimate|||||||2009-06-02|2009-06-03|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|Fjord||Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Efficacy, Safety and Tolerability of Fipamezole as an Oromucosal Fast Dissolving Tablet in the Treatment of Parkinson's Disease Patients.|Completed||Phase 2|180|Actual|Juvantia Pharma Ltd||4|||f||||t||||||||||2018-06-01 02:44:48.547668|2018-06-01 02:44:48.547668
NCT00559858|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2013-08-01|2007-11-15|2007-11-16|Estimate|||||||2013-08-01|2013-08-02|Estimate|December 2004||2004-12-31|December 2008|2008-12-31||||December 2009|Anticipated|2009-12-31||Interventional|||Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer|A Randomised Placebo-controlled Study Evaluating the Role of Pyridoxine in Controlling Capecitabine-induced Hand-foot Syndrome|Unknown status|Active, not recruiting|Phase 3|270|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:44:48.7117|2018-06-01 02:44:48.7117
NCT00559845|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2016-10-31||2017-09-12|2007-11-15|2007-11-16|Estimate|2017-09-12|2018-04-09|Actual||||2017-09-12|2018-04-09|Actual|February 2008||2008-02-29|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Intention to Treat (ITT) population, defined as all participants that were included in the trial and underwent surgery.|A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer|Phase II, Open Label, Neoadjuvant Study of Bevacizumab in Patients With Inflammatory or Locally Advanced Breast Cancer|Completed||Phase 2|56|Actual|Hoffmann-La Roche||1|||f||||f||||||||||2018-06-01 02:44:48.836693|2018-06-01 02:44:48.836693
NCT00559832|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|March 2006||2006-03-31|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Prevention of Acute Mountain Sickness by Intermittent Hypoxia|Prevention of Acute Mountain Sickness by Sleeping at Simulated Altitude (Normobaric Hypoxia)|Completed||N/A|75|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 02:44:49.131801|2018-06-01 02:44:49.131801
NCT00559819|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2017-09-26|2007-11-14|2007-11-16|Estimate|||||||2017-09-26|2017-09-27|Actual|February 2008||2008-02-29|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|ALCDrive||Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving|Validation of Driving Simulator Measures and Calibration to Blood Alcohol Concentration Standards for Impaired Driving|Active, not recruiting||Phase 3|40|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 02:44:49.220351|2018-06-01 02:44:49.220351
NCT00559806|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||The Effect of Aging and Immobilisation on Muscle|The Effect of Aging and Immobilisation on Muscle|Completed||N/A|20|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-06-01 02:44:49.31858|2018-06-01 02:44:49.31858
NCT00559780|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|May 2000||2000-05-31|November 2007|2007-11-30|December 2003|Actual|2003-12-31|||||Interventional|||Muscle Function in Elderly Postoperative Patients|Muscle Function in the Elderly After Hip-Replacement Surgery - Effects of Long Term Disuse and Physical Training|Completed||N/A|36|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-06-01 02:44:49.391919|2018-06-01 02:44:49.391919
NCT00559767|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2017-06-30|2007-11-15|2007-11-16|Estimate|||||||2017-06-30|2017-07-02|Actual|June 30, 2006||2006-06-30|April 10, 2012|2012-04-10|April 10, 2012||2012-04-10|||||Observational|||Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium|Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium|Completed|||2860|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:44:49.457493|2018-06-01 02:44:49.457493
NCT00173238|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|June 2008||2008-06-30|||||Observational|||The Study of Human Atherosclerosis by Polarization-Sensitive Optical Coherence Tomography||Unknown status|Recruiting||5||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.099688|2018-06-01 04:38:12.099688
NCT00559754|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2014-05-16||2014-11-05|2007-11-15|2007-11-16|Estimate|2014-11-05|2014-11-10|Estimate||||2014-11-05|2014-11-10|Estimate|December 2007||2007-12-31|November 2014|2014-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||Intent to Treat (ITT) Population: all participants included in the study.|A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.|An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer|Completed||Phase 2|72|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:44:49.546721|2018-06-01 02:44:49.546721
NCT00559741|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-05-12|2007-11-15|2007-11-16|Estimate|||||||2011-05-12|2011-05-13|Estimate|October 2005||2005-10-31|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Interventional|||Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer|Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:44:49.957316|2018-06-01 02:44:49.957316
NCT00559728|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2015-09-03|2007-11-15|2007-11-16|Estimate|||||||2015-09-03|2015-09-07|Estimate|July 2008||2008-07-31|September 2015|2015-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Magnetic Resonance Imaging (MRI) Analysis of Coronary Artery Plaque Components||Completed|||100|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 02:44:50.019804|2018-06-01 02:44:50.019804
NCT00559715|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2009-03-25|2007-11-15|2007-11-16|Estimate|||||||2009-03-25|2009-03-26|Estimate|August 2008||2008-08-31|March 2009|2009-03-31|August 2010|Anticipated|2010-08-31|August 2009|Anticipated|2009-08-31||Interventional|VIBERA||Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab|Prevention of Vision Loss in Patients With Age-Related Neovascular Macular Degeneration by Intravitreal Injection of Bevacizumab and Ranibizumab in a Typical Outpatient Setting|Unknown status|Recruiting|Phase 3|366|Anticipated|Klinikum Bremen-Mitte, gGmbH||2|||f||||t||||||||||2018-06-01 02:44:50.064342|2018-06-01 02:44:50.064342
NCT00559702|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2014-09-05|2007-11-14|2007-11-16|Estimate|||||||2014-09-05|2014-09-09|Estimate|October 2007||2007-10-31|September 2014|2014-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)|A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis|Completed||Phase 1|76|Actual|Biogen||6|||f||||f||||||||||2018-06-01 02:44:50.309167|2018-06-01 02:44:50.309167
NCT00559689|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2009-03-13|2007-11-15|2007-11-16|Estimate|||||||2009-03-13|2009-03-16|Estimate|November 2005||2005-11-30|March 2009|2009-03-31|March 2007|Actual|2007-03-31|||||Observational|||Study of Inhaled Glucocorticosteroid Administration in Asthma Patients|Phase 4 Study of Once-Daily Inhaled Glucocorticosteroid Administration in Asthma Patients|Completed|||24|Actual|Hamamatsu University|||2||f||||f||||||||||2018-06-01 02:44:50.4233|2018-06-01 02:44:50.4233
NCT00559676|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-05-13|2007-11-15|2007-11-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|March 2005||2005-03-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer|Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer|Completed||Phase 4|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:44:50.541381|2018-06-01 02:44:50.541381
NCT00559663|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-16|2007-11-15|2007-11-16|Estimate|||||||2007-11-16|2007-11-20|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|April 2007|Actual|2007-04-30|||||Interventional|FEAST-CAL||Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile|Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile|Completed||N/A|35|Actual|LifeBridge Health||2|||f||||t||||||||||2018-06-01 02:44:50.632453|2018-06-01 02:44:50.632453
NCT00559650|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15||2015-09-22|2017-04-14|2007-11-15|2007-11-16|Estimate||||2015-09-22|2015-10-07|Estimate|2017-04-14|2017-04-18|Actual|December 2007||2007-12-31|April 2017|2017-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667|Placebo Controlled, Randomized, Double-blind, Multi-center, Multinational Phase IIb Study to Investigate the Efficacy and Tolerability of BAY58-2667 Given Intravenously in Patients With Decompensated Chronic Congestive Heart Failure|Terminated||Phase 2|150|Actual|Bayer||2|||f||||t||||||||||2018-06-01 02:44:50.712715|2018-06-01 02:44:50.712715
NCT00559637|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2016-03-08||2016-03-08|2007-11-15|2007-11-16|Estimate|2016-03-08|2016-04-06|Estimate||||2016-03-08|2016-04-06|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MERCUR|Safety population included all participants who received at least one dose of study medication.|A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis|Single-arm, Open Study to Investigate the Efficacy, Safety and Tolerability of Monthly Subcutaneously Administered C.E.R.A. in Patients With Renal Anemia Not Yet Subject to Dialysis and Not Yet Permanently Treated With ESAs|Completed||Phase 3|184|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:44:50.871163|2018-06-01 02:44:50.871163
NCT00559624|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-05-09|2007-11-15|2007-11-16|Estimate|||||||2011-05-09|2011-05-10|Estimate|December 2007||2007-12-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients|A Phase I/II Open Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients With B-cell Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|40|Anticipated|Advancell - Advanced In Vitro Cell Technologies, S.A.|||||f||||t||||||||||2018-06-01 02:44:52.157865|2018-06-01 02:44:52.157865
NCT00559611|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2018-03-27|2007-11-14|2007-11-16|Estimate|||||||2018-03-27|2018-03-29|Actual|October 19, 2007|Actual|2007-10-19|March 2018|2018-03-31|March 22, 2018|Actual|2018-03-22|March 22, 2018|Actual|2018-03-22||Interventional|||Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)|Prospective Comparison of Endobronchial Ultrasound Needle Biopsy Versus Mediastinoscopy for Staging of Mediastinal Nodes in Patients With Clinical Stage IIIA Non-Small Cell Lung Cancer (NSCLC)|Completed||N/A|53|Actual|M.D. Anderson Cancer Center||1|||f||||f|f|||||||||2018-06-01 02:44:52.232421|2018-06-01 02:44:52.232421
NCT00559598|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2012-03-07|2007-11-15|2007-11-16|Estimate|||||||2012-03-07|2012-03-08|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|April 2009|Actual|2009-04-30|||||Observational|||Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer|Use of Serum Proteome on the Early Diagnosis of Malignant Biliary-Pancreatic Disease|Completed|||502|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:44:52.311404|2018-06-01 02:44:52.311404
NCT00172991|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||January 2003|2003-01-31||||||||Observational|||Adiponectin Gene and Coronary Artery Disease||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.23836|2018-06-01 04:38:14.23836
NCT00559585|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2011-04-29||2015-11-05|2007-11-15|2007-11-16|Estimate|2011-06-08|2011-07-06|Estimate||||2015-11-05|2015-11-09|Estimate|January 2008||2008-01-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|November 2009|Actual|2009-11-30||Interventional||Per-protocol Population in ST Period.|Methotrexate-Inadequate Response Study|A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate|Completed||Phase 3|2492|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:44:52.54427|2018-06-01 02:44:52.54427
NCT00559572|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2013-01-14|2007-11-14|2007-11-16|Estimate|||||||2013-01-14|2013-01-16|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Motivating People With Schizophrenia to Exercise|Motivating Persons With Schizophrenia to Exercise|Completed||N/A|80|Actual|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-06-01 02:44:56.552546|2018-06-01 02:44:56.552546
NCT00559559|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2015-08-06|2007-11-15|2007-11-16|Estimate|||||||2015-08-06|2015-08-10|Estimate|December 2007||2007-12-31|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Panoramic||PAtient NOtifier Feature for Reduction of Anxiety|PAtient NOtifier Feature for Reduction of Anxiety: A Multicenter ICD Study|Completed||N/A|362|Actual|St. Jude Medical||2|||f||||f||||||||||2018-06-01 02:44:56.733734|2018-06-01 02:44:56.733734
NCT00559546|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|March 2007||2007-03-31|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Interventional|MONTAS||Montelukast as a Controller of Atopic Syndrome|Montelukast as a Controller of Atopic Syndrome|Completed||Phase 4|61|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 02:44:56.82874|2018-06-01 02:44:56.82874
NCT00559533|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2016-11-01|2007-11-15|2007-11-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors|A Multi-center, Open-label, Phase I Study of Single Agent R7112 Administered Orally in Patients With Advanced Malignancies, Except All Forms of Leukaemia|Completed||Phase 1|106|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:44:57.043673|2018-06-01 02:44:57.043673
NCT00559520|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2011-12-08|2007-11-15|2007-11-16|Estimate|||||||2011-12-08|2011-12-09|Estimate|February 2002||2002-02-28|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery|The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery|Completed||Phase 4|250|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 02:44:57.15464|2018-06-01 02:44:57.15464
NCT00559507|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2013-08-14||2014-04-02|2007-11-15|2007-11-16|Estimate|2013-12-17|2014-01-20|Estimate||||2014-04-02|2014-04-30|Estimate|October 2007||2007-10-31|December 2013|2013-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery|A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:44:57.265491|2018-06-01 02:44:57.265491
NCT00559494|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2013-03-15|2007-11-14|2007-11-16|Estimate|||||||2013-03-15|2013-03-18|Estimate|June 2004||2004-06-30|March 2013|2013-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury|A Pilot Study to Assess Clinical Safety and Tolerance of Minocycline and Spinal Perfusion Pressure Augmentation in Acute Spinal Cord Injury|Completed||Phase 1/Phase 2|52|Actual|University of Calgary||4|||f||||t||||||||||2018-06-01 02:44:57.602983|2018-06-01 02:44:57.602983
NCT00559481|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2013-01-31|2007-11-15|2007-11-16|Estimate|||||||2013-01-31|2013-02-01|Estimate|October 2007||2007-10-31|January 2013|2013-01-31||||September 2008|Actual|2008-09-30||Interventional|||Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy|Effect of Oral Ketoconazole on the Pharmacokinetics of Oral Dexamethasone and Oral Hydrocortisone in Patients With Androgen Independent Prostate Cancer|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||||Withdrawn due to low accrual|f||||||||||||||2018-06-01 02:44:57.703193|2018-06-01 02:44:57.703193
NCT00559468|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2017-06-15|2007-11-15|2007-11-16|Estimate|||||||2017-06-15|2017-06-16|Actual|December 7, 2006|Actual|2006-12-07|June 2017|2017-06-30|March 2, 2007|Actual|2007-03-02|March 2, 2007|Actual|2007-03-02||Interventional|||Org 25969 After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (19.4.312)(P05949)|A Multi -Center, Randomized, Parallel Group, Safety Assessor Blinded Trial Comparing Efficacy and Safety of 4.0 mg.Kg-1 Org 25969, Administered at T1 3-10% After Continuous Infusion of Rocuronium, and Pharmacokinetics of Rocuronium, Between Subjects Receiving Maintenance Anesthesia Using Propofol and Subjects Receiving Maintenance Anesthesia Using Sevoflurane|Completed||Phase 3|52|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:44:57.778232|2018-06-01 02:44:57.778232
NCT00559455|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-06-27|2007-11-15|2007-11-16|Estimate|||||||2011-06-27|2011-06-28|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma|Phase II Study of Oxaliplatin + 5-FluoroUracil/Leucovorin (Eloxatin+5-FU/LV) in Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 2|38|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:44:57.855044|2018-06-01 02:44:57.855044
NCT00559442|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2013-09-05|2007-11-15|2007-11-16|Estimate|||||||2013-09-05|2013-09-06|Estimate|June 2007||2007-06-30|November 2007|2007-11-30|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Susceptibility to High Altitude Pulmonary Edema in Subjects With Increased Hypoxic Pulmonary Vasoconstriction|Susceptibility to High Altitude Pulmonary Edema in Subjects With Increased Pulmonary Artery Pressure During Exercise in Normoxia and at Rest in Hypoxia|Completed||N/A|30|Actual|Heidelberg University||1|||f||||f||||||||||2018-06-01 02:44:57.934855|2018-06-01 02:44:57.934855
NCT00559429|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2008-12-16|2007-11-15|2007-11-16|Estimate|||||||2008-12-16|2008-12-17|Estimate|December 2004||2004-12-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|Tax-Sam||Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer|Phase I Trial With a Combination of Docetaxel +153 Sm-EDTMP (Samarium 153) in Patients With Hormone-Refractory Prostate Cancer|Completed||Phase 1|13|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4|||f||||t||||||||||2018-06-01 02:44:58.035086|2018-06-01 02:44:58.035086
NCT00559416|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2018-02-13|2007-11-15|2007-11-16|Estimate|||||||2018-02-13|2018-02-14|Actual|November 8, 2007||2007-11-08|September 30, 2016|2016-09-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy|"Immunologic and Virologic Response in HIV Infected Progressors After Infusion of Lymphocytes From HIV Infected Elite Long-Term Non-Progressors"|Terminated||Phase 1|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:44:58.137599|2018-06-01 02:44:58.137599
NCT00559390|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2013-04-03|2007-11-15|2007-11-16|Estimate|||||||2013-04-03|2013-04-05|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|PCOS||Research Study for Children With a Mother or Sister With Polycystic Ovary Syndrome|Metabolic Syndrome in PCOS: Precursors and Interventions|Completed|||136|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||2||f||||t||||||Samples With DNA|"~     Whole Blood, Serum and Plasma~   "|||2018-06-01 02:44:58.323584|2018-06-01 02:44:58.323584
NCT00559377|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2014-10-29||2016-12-28|2007-11-15|2007-11-16|Estimate|2015-06-03|2015-06-26|Estimate||||2016-12-28|2016-12-30|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|May 2014|Actual|2014-05-31|July 2012|Actual|2012-07-31||Interventional|||FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer|A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)|Small number of subjects enrolled and events limit meaningful statistical analysis.|1|||f||||f||||||||||2018-06-01 02:44:58.429038|2018-06-01 02:44:58.429038
NCT00559364|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2014-01-27||2017-02-07|2007-11-15|2007-11-16|Estimate|2014-01-27|2014-03-12|Estimate||||2017-02-07|2017-03-16|Actual|November 2007||2007-11-30|February 2017|2017-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Intent-to-treat (ITT) population included all randomized patients.|Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea|A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled, Phase III Study to Assess the Safety and Efficacy of Viokase® 16 for the Correction of Steatorrhea in Patients With Exocrine Pancreatic Insufficiency|Completed||Phase 3|50|Actual|Forest Laboratories|Results for percentage of stool characteristics per bowel movement and number of days with at least 1 stool of specific characteristic were not reported due to change in planned analysis.|2|||f||||f||||||||||2018-06-01 02:44:58.72306|2018-06-01 02:44:58.72306
NCT00559351|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|December 2001||2001-12-31|September 2007|2007-09-30|April 2004|Actual|2004-04-30|||||Interventional|||RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus|Possibilities for Improvement of an Outcome of the Treatment in Squamous Cell Carcinoma of the Thoracic Esophagus - a Multicenter Randomized Clinical Phase III Trial.|Terminated||Phase 3|84|Actual|Ministry of Scientific Research and Information Technology, Poland||3||difficulty in recruitment|f||||f||||||||||2018-06-01 02:44:59.142789|2018-06-01 02:44:59.142789
NCT00559338|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|December 2003||2003-12-31|November 2007|2007-11-30|April 2005|Actual|2005-04-30|||||Interventional|||Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department|Acutely Decompensated Heart Failure in a County Emergency Department: A Double Blind Randomized Controlled Comparison of Nesiritide vs. Placebo Treatment|Completed||Phase 4|104|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:44:59.213726|2018-06-01 02:44:59.213726
NCT00559312|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2012-12-14|2007-11-14|2007-11-16|Estimate|||||||2012-12-14|2012-12-17|Estimate|December 2007||2007-12-31|December 2012|2012-12-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD|A 6-week Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Fluticasone 250μg/Salmeterol 50μg Combination (FSC 250/50) on Exertional Dyspnea in Patients With Symptomatic Mild COPD|Completed||N/A|18|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 02:44:59.283019|2018-06-01 02:44:59.283019
NCT00559299|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2012-03-15|2007-11-14|2007-11-16|Estimate|||||||2012-03-15|2012-03-19|Estimate|November 2007||2007-11-30|February 2011|2011-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Patient Tolerability Study of GSK163090|A Randomized, Single-blind, Placebo-controlled, 2 Part Study to Evaluate the Safety and Tolerability of GSK163090 at Single and Repeat Doses in Subjects With MDD|Completed||Phase 1|20|Anticipated|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:44:59.350375|2018-06-01 02:44:59.350375
NCT00559286|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2009-01-28|2007-11-15|2007-11-16|Estimate|||||||2009-01-28|2009-01-29|Estimate|December 2007||2007-12-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|ITEM||Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels|Influence of the Angiotensin Receptor Blocker Telmisartan on the Red Blood Cell Function and the Microcirculatory Perfusion|Terminated||Phase 4|40|Anticipated|RWTH Aachen University||2||logistic reasons, patients could not be recruited|f||||t||||||||||2018-06-01 02:44:59.443132|2018-06-01 02:44:59.443132
NCT00559273|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2016-09-13||2016-09-13|2007-11-15|2007-11-16|Estimate|2016-09-13|2016-11-01|Estimate||||2016-09-13|2016-11-01|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Safety population included all randomized participants who received at least 1 dose of study medication and attended safety follow-up, whether they withdrew prematurely or not. Participants were assigned to the treatment group as treated. One participant randomized to Mircera, received darbepoetin alfa and included in darbepoetin alfa arm.|A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis|An Open-label, Randomized, Multicenter, Parallel-group Study to Demonstrate Correction of Anemia Using Once Every 4 Weeks Subcutaneous Injections of RO0503821 in Patients With Chronic Kidney Disease Who Are Not on Dialysis|Completed||Phase 3|307|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:44:59.565292|2018-06-01 02:44:59.565292
NCT00559260|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2008-09-12|2007-11-15|2007-11-16|Estimate|||||||2008-09-12|2008-09-15|Estimate|January 2003||2003-01-31|September 2008|2008-09-30||||||||Observational|||Evaluation of Cardiorespiratory Events in Subjects Undergoing an Upper and/or Lower Endoscopy Under Current Sedation Practices|Evaluation of Cardiorespiratory Events in Subjects Undergoing an Upper and/or Lower Endoscopy Under Current Sedation Practices While Being Passively Monitored|Completed|||300||Ethicon Endo-Surgery|||||f||||||||||||||2018-06-01 02:45:00.631658|2018-06-01 02:45:00.631658
NCT00559247|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15||2010-09-10|2010-09-10|2007-11-15|2007-11-16|Estimate||||2010-09-10|2010-09-13|Estimate|2010-09-10|2010-09-13|Estimate|January 2008||2008-01-31|September 2010|2010-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects|Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-650032 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1|Completed||Phase 1/Phase 2|24|Anticipated|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 02:45:00.715747|2018-06-01 02:45:00.715747
NCT00559234|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2017-06-30|2007-11-15|2007-11-16|Estimate|||||||2017-06-30|2017-07-02|Actual|November 9, 2007||2007-11-09|October 3, 2008|2008-10-03|October 3, 2008||2008-10-03|||||Observational|||Potential Research Participants for Future Studies of Inherited Eye Diseases|Evaluation and Treatment Protocol for Potential Research Participants With Inherited Ophthalmic Diseases|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:45:00.838674|2018-06-01 02:45:00.838674
NCT00559221|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2008-10-13|2007-11-15|2007-11-16|Estimate|||||||2008-10-13|2008-10-15|Estimate|December 2004||2004-12-31|November 2007|2007-11-30|June 2008|Anticipated|2008-06-30|||||Interventional|||FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML|Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia|Unknown status|Recruiting|Phase 2|37|Anticipated|Cooperative Study Group A for Hematology||1|||f||||f||||||||||2018-06-01 02:45:00.909423|2018-06-01 02:45:00.909423
NCT00559208|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-06-22|2007-11-15|2007-11-16|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2006||2006-10-31|November 2009|2009-11-30|December 2010|Actual|2010-12-31|||||Observational|||Children's Aid Societies: Differential Response and Wraparound Prevention Trial|The Comparative Effects and Expense of Augmenting Usual Children's Aid Society (CAS) Care With a Regional Differential Response and Wraparound Prevention Service for Children|Completed|||135|Actual|Hamilton Children's Aid Society|||1||f||||t||||||||||2018-06-01 02:45:01.036783|2018-06-01 02:45:01.036783
NCT00559195|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-05-13|2007-11-15|2007-11-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|November 2005||2005-11-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Interventional|||Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors|Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:45:01.102545|2018-06-01 02:45:01.102545
NCT00559182|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2015-07-17|2007-11-14|2007-11-16|Estimate|||||||2015-07-17|2015-07-20|Estimate|December 2007||2007-12-31|July 2015|2015-07-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)|A Phase I Dose Escalation Study of MK-8033 in Patients With Advanced Solid Tumors|Completed||Phase 1|47|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:45:01.198869|2018-06-01 02:45:01.198869
NCT00559169|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2010-04-07|2007-11-14|2007-11-16|Estimate|||||||2010-04-07|2010-04-08|Estimate|February 2009||2009-02-28|November 2007|2007-11-30|December 2010|Anticipated|2010-12-31|||||Interventional|||Verapamil and Catamenial Epilepsy|Study of Verapamil in Refractory Catamenial Epilepsy|Withdrawn||N/A|12|Anticipated|University Health Network, Toronto||||protocol changed and a new study using verapamil in epilepsy will be started in the near future|f||||f||||||||||2018-06-01 02:45:01.318514|2018-06-01 02:45:01.318514
NCT00559156|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-05-13|2007-11-15|2007-11-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|June 2005||2005-06-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Interventional|||Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|Phase 2 Study Assessing the Impact of Parenteral Administration of the Immunomodulater Oral IMPACT® for Postoperative Radiochemotherapy in Patients With Carcinoma of the Head and Neck|Completed||Phase 2|46|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:45:01.459206|2018-06-01 02:45:01.459206
NCT00559143|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-06-07|2007-11-15|2007-11-16|Estimate|||||||2011-06-07|2011-06-08|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|July 2011|Anticipated|2011-07-31|November 2009|Anticipated|2009-11-30||Interventional|BETTER||Biventricular Alternative Pacing|Better Pacing - Biventricular Pacing as Alternative Method in Patients With Disturbances of AV Conduction and Preserved LV Function|Withdrawn||Phase 4|38|Anticipated|Medtronic Hellas Medical Devices ΑEE||2||No patients enrolled for long period of time. No scientific interest any more|f||||f||||||||||2018-06-01 02:45:01.584353|2018-06-01 02:45:01.584353
NCT00559130|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2011-06-06|2007-11-14|2007-11-16|Estimate|||||||2011-06-06|2011-06-07|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis|Multi-Center, Efficacy Study of the MedaSorb CytoSorb™ Hemoperfusion Device as an Adjunctive Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) or Acute Lung Injury (ALI) in the Setting of Sepsis|Completed||N/A|100|Anticipated|MedaSorb Technologies, Inc|||||f||||t||||||||||2018-06-01 02:45:01.783327|2018-06-01 02:45:01.783327
NCT00559117|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2015-03-26|2007-11-15|2007-11-16|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer|A Phase I, Open-Label, Dose Ranging Study to Assess the Safety and Distribution of Single or Multiple Doses of VB-111 in Patients With Advanced Metastatic Cancer|Unknown status|Active, not recruiting|Phase 1|48|Anticipated|Vascular Biogenics Ltd. operating as VBL Therapeutics||1|||f||||t||||||||||2018-06-01 02:45:02.078161|2018-06-01 02:45:02.078161
NCT00559104|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|2015-07-17||2015-07-17|2007-11-15|2007-11-16|Estimate|2015-07-17|2015-08-11|Estimate||||2015-07-17|2015-08-11|Estimate|October 1998||1998-10-31|July 2015|2015-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|High-Dose Therapy and Autologous Stem Cell Transplantation During Remission in Poor-Risk Age-Adjusted International Prognostic Index High and High-Intermediate Risk Group Patients With Intermediate Grade and High-Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma|Completed||Phase 2|60|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 02:45:02.557562|2018-06-01 02:45:02.557562
NCT00559091|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2011-05-06|2007-11-15|2007-11-16|Estimate|||||||2011-05-06|2011-05-09|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|Borden-001||A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia|A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes|Completed||Phase 2|25|Anticipated|Jewish General Hospital||1|||f||||f||||||||||2018-06-01 02:45:03.383171|2018-06-01 02:45:03.383171
NCT00559078|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2009-11-06|2007-11-15|2007-11-16|Estimate|||||||2009-11-06|2009-11-09|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|May 2009|Actual|2009-05-31|||||Observational|CAH||Qualitative Research on Women With Congenital Adrenal Hyperplasia|Health-related Quality of Life, Mental Health and Psychotherapeutic Considerations for Women Diagnosed With a Disorder of Sexual Development: Congenital Adrenal Hyperplasia|Completed|||16|Anticipated|Lehigh University|||1||f||||f||||||||||2018-06-01 02:45:03.507796|2018-06-01 02:45:03.507796
NCT00559065|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2018-04-04|2007-11-15|2007-11-16|Estimate|||||||2018-04-04|2018-04-05|Actual|July 11, 2006||2006-07-11|October 18, 2017|2017-10-18||||||||Observational|||A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China|A Case - Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China|Completed|||3260|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:45:03.59869|2018-06-01 02:45:03.59869
NCT00172978|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-10-26|2005-09-12|2005-09-15|Estimate|||||||2005-10-26|2005-10-27|Estimate||||April 2005|2005-04-30||||||||Observational|||Indications and Related Factors for Caesarean Delivery, 1996 to 2002.||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.307053|2018-06-01 04:38:14.307053
NCT00559052|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2010-02-09|2007-11-14|2007-11-16|Estimate|||||||2010-02-09|2010-02-11|Estimate|March 2008||2008-03-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)|An Open-Label Cross-over Study to Evaluate the Intraduodenal Delivery of Lipase, Protease and Amylase From Administration of VIOKASE16 in Chronic Pancreatitis Subjects With Exocrine Pancreatic Insufficiency (EPI).|Completed||Phase 2|22|Anticipated|Axcan Pharma||2|||f||||f||||||||||2018-06-01 02:45:03.753187|2018-06-01 02:45:03.753187
NCT00559039|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2012-03-07|2007-11-15|2007-11-16|Estimate|||||||2012-03-07|2012-03-08|Estimate|October 2000||2000-10-31|March 2012|2012-03-31|October 2006|Actual|2006-10-31|||||Observational|||Effects of Fetal, Infant, and Early Childhood Exposures on Adult Cancer Risk in Women|Fetal, Infant and Early Childhood Antecedents of Cancer in Women: Maternal Cohort Study of the Nurses' Health Studies|Completed|||128700|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:45:03.869362|2018-06-01 02:45:03.869362
NCT00559026|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|DTIC-melvacc||Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients|Phase I/II Clinical Trial for the Evaluation of the Interaction Between Chemotherapy and Immunotherapy in Melanoma Patients|Completed||Phase 1|10|Actual|Istituto Superiore di Sanità||2|||f||||t||||||||||2018-06-01 02:45:03.943502|2018-06-01 02:45:03.943502
NCT00559013|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2009-12-15||2017-04-04|2007-11-15|2007-11-16|Estimate|2012-05-23|2012-05-24|Estimate||||2017-04-04|2017-05-10|Actual|March 2007||2007-03-31|April 2017|2017-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Peri-Strips Dry (PSD) Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery|Peri-Strips Dry With Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery|Completed||N/A|38|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-06-01 02:45:04.037341|2018-06-01 02:45:04.037341
NCT00559000|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2007-11-15|2007-11-15|2007-11-16|Estimate|||||||2007-11-15|2007-11-16|Estimate|December 2003||2003-12-31|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||The Efficacy of KIDNET in the Treatment of Traumatized Refugee Children in Germany|The Efficacy of KIDNET in the Treatment of Traumatized Refugee Children in Germany|Completed||Phase 3|25|Actual|University of Konstanz||2|||f||||f||||||||||2018-06-01 02:45:04.331036|2018-06-01 02:45:04.331036
NCT00558987|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2009-01-28|2007-11-15|2007-11-16|Estimate|||||||2009-01-28|2009-01-29|Estimate|February 2008||2008-02-29|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Parenting Videos In Primary Care|Enhancing Anticipatory Guidance About Discipline for Low-Income Families: A Video Intervention Project|Completed||N/A|122|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:45:04.467421|2018-06-01 02:45:04.467421
NCT00558961|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-15|||2010-04-14|2007-11-15|2007-11-16|Estimate|||||||2010-04-14|2010-04-15|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|GL-CLB-001||Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients|A Phase I-II Trial of Gleevec (Imatinib Mesylate) in Combination With Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia (CLL) Patients|Terminated||Phase 1/Phase 2|13|Actual|Jewish General Hospital||1||Unsatisfactory enrollment|f||||f||||||||||2018-06-01 02:45:04.646448|2018-06-01 02:45:04.646448
NCT00558948|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2009-08-18|2007-11-15|2007-11-16|Estimate|||||||2009-08-18|2009-08-19|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Musculoskeletal Outcomes After Bone Marrow Transplant|Musculoskeletal Outcomes After Bone Marrow Transplant|Completed|||48|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||t||||||||||2018-06-01 02:45:04.798301|2018-06-01 02:45:04.798301
NCT00558935|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2011-05-09|2007-11-15|2007-11-16|Estimate|||||||2011-05-09|2011-05-10|Estimate|October 2007||2007-10-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||The Effect of Alcohol on ABCA1 Expression and Lipid Metabolism||Terminated||N/A|20|Anticipated|Bayside Health||||It was found that 20g of alcohol daily had no effect on ABCA1 expression or HDL levels.|f||||||||||||||2018-06-01 02:45:04.874738|2018-06-01 02:45:04.874738
NCT00558922|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2009-07-29|2007-11-13|2007-11-15|Estimate|||||||2009-07-29|2009-07-30|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|October 2009|Anticipated|2009-10-31|August 2009|Anticipated|2009-08-31||Interventional|||A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer|A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|54|Actual|Aegera Therapeutics||||Unacceptable Neurotoxicity (2 cases)|f||||f||||||||||2018-06-01 02:45:04.989005|2018-06-01 02:45:04.989005
NCT00558909|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2014-04-30|2007-11-14|2007-11-15|Estimate|||||||2014-04-30|2014-05-01|Estimate|June 2007||2007-06-30|April 2014|2014-04-30||||November 2007|Actual|2007-11-30||Interventional|||4 Weeks Treatment of Type II Diabetic Patients With BI 44847|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Selected Oral Doses of BI 44847 as Tablet in Female and Male Patients With Type 2 Diabetes.|Completed||Phase 1|80|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:45:05.094441|2018-06-01 02:45:05.094441
NCT00558896|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2014-01-22||2018-03-20|2007-11-14|2007-11-15|Estimate|2014-05-28|2014-06-05|Estimate||||2018-03-20|2018-04-18|Actual|November 2007|Actual|2007-11-30|March 2018|2018-03-31|October 25, 2017|Actual|2017-10-25|September 2012|Actual|2012-09-30||Interventional|||CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis|A Phase II Trial of CC-4047 Plus Dexamethasone in Patients With Relapsed of Refractory Multiple Myeloma or Amyloidosis|Completed||Phase 2|378|Actual|Mayo Clinic||7|||f||||t||||||||||2018-06-01 02:45:05.310107|2018-06-01 02:45:05.310107
NCT00558883|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2008-04-10|2007-11-14|2007-11-15|Estimate|||||||2008-04-10|2008-04-11|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|May 2007|Actual|2007-05-31|||||Interventional|||AI(I)DA Acarbose and the Subclinical Inflammation|Placebo Controlled Investigation on Action of Acarbose on the Sub-Clinical Inflammation and Immune Response in Early Type 2 Diabetes and Atherosclerosis Risk|Completed||Phase 3|104|Actual|GWT-TUD GmbH||2|||f||||t||||||||||2018-06-01 02:45:07.572839|2018-06-01 02:45:07.572839
NCT00558870|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2016-02-01||2016-03-07|2007-11-14|2007-11-15|Estimate|2016-03-07|2016-04-05|Estimate||||2016-03-07|2016-04-05|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Role of Methadone As Co-Opioid Analgesic|Role of Methadone As Co-Opioid Analgesic in Cancer Patients|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center|The study sample size is too low for any of the differences or non-differences between the groups to be statistically significant.|2||Low Accrual.|f||||t||||||||||2018-06-01 02:45:07.671692|2018-06-01 02:45:07.671692
NCT00558857|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2011-02-16|2007-11-14|2007-11-15|Estimate|||||||2011-02-16|2011-02-17|Estimate|July 2007||2007-07-31|February 2011|2011-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|DSM||Dynamic Substrate Mapping (DSM) for Ischemic VT|Clinical Feasibility of Using Dynamic Substrate Mapping to Guide Ablation of Ischemic Ventricular Tachycardia|Terminated||Phase 1|5|Actual|St. Jude Medical||1||Low enrollment|f||||f||||||||||2018-06-01 02:45:08.045501|2018-06-01 02:45:08.045501
NCT00558844|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13||2016-09-29|2016-10-06|2007-11-13|2007-11-15|Estimate||||2016-09-29|2016-10-03|Estimate|2016-10-06|2016-10-07|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikace™) In Cystic Fibrosis Patients|Phase 1b/2a Multidose Safety and Tolerability Study of Liposomal Amikacin for Inhalation (Arikace™) in Cystic Fibrosis Patient With Chronic Infections Due to Pseudomonas Aeruginosa.|Completed||Phase 1/Phase 2|46|Actual|Insmed Incorporated||2|||f||||t||||||||||2018-06-01 02:45:08.132877|2018-06-01 02:45:08.132877
NCT00558831|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2010-10-12||2017-08-28|2007-11-13|2007-11-15|Estimate|2010-10-12|2010-11-22|Estimate||||2017-08-28|2017-09-26|Actual|October 2007||2007-10-31|August 2017|2017-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris|A Split-face, Paired-comparison Pilot Study to Evaluate the Safety and Efficacy of Topical Benzoyl Peroxide 2.5% Cream Alone Versus Benzoyl Peroxide 2.5% Cream Plus Moisturizing Lotion for Mild to Moderate Acne Vulgaris|Completed||N/A|11|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 02:45:08.253986|2018-06-01 02:45:08.253986
NCT00558818|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2012-07-24|2007-11-14|2007-11-15|Estimate|||||||2012-07-24|2012-07-26|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Long-term Study With Clevudine|A Phase lV Study to Evaluate the Long-term Safety and Efficacy of Clevudine in the Patients Chronically Infected With Hepatitis B Virus|Completed||Phase 4|150|Anticipated|Bukwang Pharmaceutical|||||f||||f||||||||||2018-06-01 02:45:08.556312|2018-06-01 02:45:08.556312
NCT00558805|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2007-11-14|2007-11-14|2007-11-15|Estimate|||||||2007-11-14|2007-11-15|Estimate|October 2003||2003-10-31|October 2007|2007-10-31||||||||Interventional|FISP||Family Intervention for Suicidal Youth: Emergency Care|Family Intervention for Suicidal Youth: Emergency Care|Completed||Phase 2|||Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 02:45:08.650642|2018-06-01 02:45:08.650642
NCT00558792|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2012-08-13||2012-10-18|2007-11-14|2007-11-15|Estimate|2012-09-18|2012-10-19|Estimate||||2012-10-18|2012-10-24|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Coronary MDCTA With Iopamidol Injection 370|A Phase II Multicenter Randomized Double Blind Dose Finding Study of Iopamidol Injection 370 in Multidetector Computed Tomographic Angiography (MDCTA) in Patients With Suspected Coronary Artery Stenosis|Completed||Phase 2|210|Actual|Bracco Diagnostics, Inc||3|||f||||f||||||||||2018-06-01 02:45:09.318089|2018-06-01 02:45:09.318089
NCT00558779|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2007-11-21|2007-11-14|2007-11-15|Estimate|||||||2007-11-21|2007-11-22|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|May 2010|Anticipated|2010-05-31|||||Interventional|||Surgical Manipulation of the Aorta and Cerebral Infarction|Surgical Manipulation of the Ascending Aorta and Cerebral Infarction Following CABG|Unknown status|Recruiting|Phase 2|200|Anticipated|University of Wuerzburg||2|||f||||t||||||||||2018-06-01 02:45:10.134052|2018-06-01 02:45:10.134052
NCT00558766|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2017-06-30|2007-11-14|2007-11-15|Estimate|||||||2017-06-30|2017-07-02|Actual|November 8, 2007||2007-11-08|June 13, 2011|2011-06-13|June 13, 2011||2011-06-13|||||Observational|||Motor Cortex Reward Signaling in Parkinson Disease|Motor Cortex Reward Signaling in Parkinson Disease|Completed|||35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:45:10.240249|2018-06-01 02:45:10.240249
NCT00558753|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2012-01-11||2016-04-26|2007-11-14|2007-11-15|Estimate|2012-07-25|2012-08-27|Estimate||||2016-04-26|2016-05-26|Estimate|April 2006||2006-04-30|April 2016|2016-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PregTKA||Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA|A Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset Complex Regional Pain Syndrome After Total Knee Arthroplasty|Completed||Phase 2|240|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 02:45:10.318601|2018-06-01 02:45:10.318601
NCT00558740|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2012-02-09|2007-11-14|2007-11-15|Estimate|||||||2012-02-09|2012-02-10|Estimate|January 2009||2009-01-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Effects of Dietary Proteins on Hepatic Lipid Metabolism|Effects of Dietary Proteins on Hepatic Lipid Metabolism|Completed|||22|Actual|University of Lausanne|||1||f||||f||||||||||2018-06-01 02:45:10.556383|2018-06-01 02:45:10.556383
NCT00558727|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2013-05-08|2007-11-13|2007-11-15|Estimate|||||||2013-05-08|2013-05-10|Estimate|November 2007||2007-11-30|May 2013|2013-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Protocol RH-1-002: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Dose-escalation Study of RH-1 Administered as a 3-hour Intravenous Infusion in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Terminated||Phase 1|12|Actual|Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 02:45:10.656347|2018-06-01 02:45:10.656347
NCT00558701|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2015-08-21||2016-04-26|2007-11-13|2007-11-15|Estimate|2016-04-26|2016-06-06|Estimate||||2016-04-26|2016-06-06|Estimate|December 2007||2007-12-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Microcurrent for Healing Autogenous Skin Donor Sites|Prospective, Randomized, Controlled Study of the Efficacy of a Silver-coated Nylon Dressing Plus Active or Sham Microcurrent for Healing Autogenous Skin Donor Sites|Completed||N/A|30|Actual|United States Army Institute of Surgical Research||2|||f||||f||||||||No||2018-06-01 02:45:10.746558|2018-06-01 02:45:10.746558
NCT00558688|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-02-19|2007-11-13|2007-11-15|Estimate|||||||2015-02-19|2015-02-20|Estimate|August 2007||2007-08-31|February 2015|2015-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Photodynamic Therapy for Treatment of Actinic Keratoses|A Photodynamic Therapy for Treatment of Actinic Keratoses|Completed||N/A|20|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 02:45:11.906775|2018-06-01 02:45:11.906775
NCT00558675|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-02-19|2007-11-13|2007-11-15|Estimate|||||||2015-02-19|2015-02-20|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy|A Phase I/II Study of Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) Conjugated With CD3/CD28-coated Microbeads in Patients With Relapsed or Refractory Hematological Malignancy|Completed||Phase 1/Phase 2|25|Anticipated|Immunovative Therapies, Ltd.||4|||f||||f||||||||||2018-06-01 02:45:11.980346|2018-06-01 02:45:11.980346
NCT00555958|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2012-02-01|2007-11-08|2007-11-09|Estimate|||||||2012-02-01|2012-02-02|Estimate|November 2005||2005-11-30|February 2012|2012-02-29|September 2014|Anticipated|2014-09-30|September 2011|Actual|2011-09-30||Interventional|||Vagal Blocking for Obesity Control|VBLOC™ Clinical Trial: Vagal Block for Obesity Control|Unknown status|Active, not recruiting|N/A|120|Anticipated|EnteroMedics||1|||f||||t||||||||||2018-06-01 02:46:30.025308|2018-06-01 02:46:30.025308
NCT00558662|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2011-11-17|2007-11-14|2007-11-15|Estimate|||||||2011-11-17|2011-11-18|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|September 2011|Actual|2011-09-30|April 2009|Actual|2009-04-30||Interventional|||Randomized Clinical Trial (RCT) to Compare the Efficacy of Coban 2 Versus SSB in the Treatment of Venous Leg Ulcers|Randomized Controlled Clinical Study to Assess the Clinical Efficacy of the 3M™ Coban™ 2 Layer Compression System Compared to a Short-stretch Compression Bandage in the Treatment of Venous Leg Ulcers|Completed||N/A|234|Actual|3M||2|||f||||t||||||||||2018-06-01 02:45:12.098724|2018-06-01 02:45:12.098724
NCT00558649|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-27|||2013-05-08|2007-11-14|2007-11-15|Estimate|||||||2013-05-08|2013-05-10|Estimate|May 2007||2007-05-31|November 2007|2007-11-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|NANOVAX||A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines|A Pilot, Controlled, Comparative and Single Blinded Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines Administered Intradermally Using Microneedle Injectors as Compared With Standard Dose Intramuscular Flu Vaccines as Reference.|Completed||N/A|180|Actual|NanoPass Technologies Ltd||3|||f||||f||||||||||2018-06-01 02:45:12.272623|2018-06-01 02:45:12.272623
NCT00558636|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2009-11-13||2013-12-02|2007-11-14|2007-11-15|Estimate|2010-10-04|2010-10-20|Estimate||||2013-12-02|2013-12-27|Estimate|September 2007||2007-09-30|December 2013|2013-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|91|Actual|Bayer|Due to early termination of the study, no comparison of treatments was possible. This study also provided limited opportunity to distinguish between Adverse Events associated with sorafenib and events associated with the underlying lung disease.|2||"Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in~   NSCLC and increased mortality in subjects with squamous subtype."|f||||t||||||||||2018-06-01 02:45:12.403288|2018-06-01 02:45:12.403288
NCT00558623|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2007-11-14|2007-11-14|2007-11-15|Estimate|||||||2007-11-14|2007-11-15|Estimate|January 2001||2001-01-31|November 2007|2007-11-30|April 2005|Actual|2005-04-30|||||Interventional|||Dietary Calcium Supplementation to Reduce Blood Lead in Pregnancy|Controlled Trial in Pregnancy of Dietary Supplements for Suppression of Bone Resorption and Mobilization of Lead Into Plasma|Completed||N/A|670|Actual|National Institute of Environmental Health Sciences (NIEHS)||1|||f||||f||||||||||2018-06-01 02:45:13.328584|2018-06-01 02:45:13.328584
NCT00558597|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2011-07-19|2007-11-14|2007-11-15|Estimate|||||||2011-07-19|2011-07-21|Estimate|March 2008||2008-03-31|September 2008|2008-09-30|December 2011|Anticipated|2011-12-31|||||Observational|||Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation|Proteomics Analysis for Recognition of Acute Cellular Rejection After Lung Transplantation|Unknown status|Recruiting||60|Anticipated|Hannover Medical School|||2||f||||f||||||Samples Without DNA|"~     BAL (broncho alveolar lavage) urine~   "|||2018-06-01 02:45:13.435617|2018-06-01 02:45:13.435617
NCT00558584|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2017-05-11|2007-11-14|2007-11-15|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2007||2007-12-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy|Multicentre, Randomized, Double-blind, Prospective Investigation on the Effects of Immunoadsorption on Cardiac Function in Patients With Dilated Cardiomyopathy|Recruiting||N/A|200|Anticipated|University Medicine Greifswald||2|||f||||t||||||||||2018-06-01 02:45:13.530619|2018-06-01 02:45:13.530619
NCT00558571|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2014-05-16||2014-07-16|2007-11-14|2007-11-15|Estimate|2014-07-16|2014-08-07|Estimate||||2014-07-16|2014-08-07|Estimate|January 2008||2008-01-31|July 2014|2014-07-31||||April 2008|Actual|2008-04-30||Interventional|||4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Weeks Treatment With Three Oral Doses of BI 10773 as Tablets in Female and Male Patients With Type 2 Diabetes|Completed||Phase 1|78|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 02:45:13.833709|2018-06-01 02:45:13.833709
NCT00558558|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2011-09-02||2016-04-06|2007-11-13|2007-11-15|Estimate|2011-09-02|2011-10-12|Estimate||||2016-04-06|2016-05-13|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Haelan and Nutrition in Cancer Patients|A Phase II Study Examining the Role of Fermented Soy Beverage for Improving Cancer-Associated Anorexia and Cachexia|Terminated||Phase 2|6|Actual|M.D. Anderson Cancer Center||1||Study terminated due to low recruitment.|f||||f||||||||||2018-06-01 02:45:15.221997|2018-06-01 02:45:15.221997
NCT00558545|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2009-11-30|2007-11-13|2007-11-15|Estimate|||||||2009-11-30|2009-12-02|Estimate|November 2007||2007-11-30|November 2009|2009-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer|A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer|Terminated||Phase 1/Phase 2|61|Anticipated|Aegera Therapeutics||||Avastin approved for first-in-line treatment.|f||||f||||||||||2018-06-01 02:45:15.641495|2018-06-01 02:45:15.641495
NCT00558532|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2016-06-10|2007-11-14|2007-11-15|Estimate|||||||2016-06-10|2016-06-13|Estimate|October 2007||2007-10-31|June 2016|2016-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment|Omega-3 Fatty Acid Status in Morbid Obesity Before and After Surgical Treatment|Withdrawn|||0|Actual|University of Cincinnati|||2|Investigator Retired.|f||||f||||||Samples With DNA|"~     Whole blood, plasma, fat tissue~   "|||2018-06-01 02:45:15.953241|2018-06-01 02:45:15.953241
NCT00558519|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2017-07-11|2007-11-14|2007-11-15|Estimate|||||||2017-07-11|2017-07-12|Actual|November 2007|Actual|2007-11-30|July 2017|2017-07-31||||September 2016|Actual|2016-09-30||Interventional|||Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting||Phase 2|300|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:45:16.093183|2018-06-01 02:45:16.093183
NCT00558506|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2008-02-25|2007-11-14|2007-11-15|Estimate|||||||2008-02-25|2008-02-26|Estimate|January 2008||2008-01-31|September 2007|2007-09-30|December 2009|Anticipated|2009-12-31|October 2009||2009-10-31||Interventional|Aba-AS-01||Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis|Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis|Unknown status|Recruiting|Phase 2|30|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 02:45:16.28242|2018-06-01 02:45:16.28242
NCT00553111|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2007-11-02|2007-11-02|2007-11-05|Estimate|||||||2007-11-02|2007-11-05|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|April 2007|Actual|2007-04-30|||||Interventional|||Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission|Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission|Completed||N/A|168|Actual|Jacobi Medical Center||4|||f||||||||||||||2018-06-01 02:47:37.66162|2018-06-01 02:47:37.66162
NCT00558493|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2012-07-24|2007-11-14|2007-11-15|Estimate|||||||2012-07-24|2012-07-26|Estimate|November 2007||2007-11-30|July 2012|2012-07-31||||||||Interventional|||Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients|Phase lV Study to Evaluate the Safety and Effectiveness of Switching Treatment From Lamivudine to Clevudine in the Chronic Hepatitis B Patients With Suboptimal Virologic Response During Lamivudine Treatment|Completed||Phase 4|100|Anticipated|Bukwang Pharmaceutical||1|||f||||f||||||||||2018-06-01 02:45:16.453838|2018-06-01 02:45:16.453838
NCT00558480|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2015-04-08|2007-11-14|2007-11-15|Estimate|||||||2015-04-08|2015-04-09|Estimate|July 2009||2009-07-31|April 2015|2015-04-30|December 2012|Anticipated|2012-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis|A Double Blind, Placebo Controlled Randomized Trial of Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Children Aged 5-14 Years With Latent Tuberculosis.|Withdrawn||N/A|0|Actual|Medical Research Council Unit, The Gambia||2|||f||||f||||||||||2018-06-01 02:45:16.517343|2018-06-01 02:45:16.517343
NCT00558467|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|2010-06-18||2014-05-07|2007-11-14|2007-11-15|Estimate|2010-10-04|2010-10-20|Estimate||||2014-05-07|2014-05-16|Estimate|January 2008||2008-01-31|March 2014|2014-03-31||||June 2009|Actual|2009-06-30||Interventional|||Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria|A Randomized, Double-blind, Placebo-controlled, Flexible Dose Study to Evaluate Efficacy and Safety of Pramipexole Immediate Release (0.125-0.5mg/Day) Versus Placebo for 6 Weeks in Children and Adolescents (Age 6-17 Inclusive) Diagnosed With Tourette Disorder According to DSM IV Criteria.|Completed||Phase 2|63|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:45:16.728075|2018-06-01 02:45:16.728075
NCT00558454|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2012-06-04|2007-11-14|2007-11-15|Estimate|||||||2012-06-04|2012-06-05|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|November 2014|Anticipated|2014-11-30|June 2008|Actual|2008-06-30||Interventional|JOHN||Iron Supplementation of Marginally Low Birth Weight Infants|Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g|Unknown status|Active, not recruiting|Phase 4|380|Actual|Umeå University||3|||f||||t||||||||||2018-06-01 02:45:18.058705|2018-06-01 02:45:18.058705
NCT00558441|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2007-11-14|2007-11-14|2007-11-15|Estimate|||||||2007-11-14|2007-11-15|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|November 2013|Anticipated|2013-11-30|||||Interventional|MIRACLE||Prospective Data Collection of IVMRI Cases|Prospective Data Collection in Clinical Cases Where Coronary Plaque Lipid Characterization by IVMRI Was Performed During Diagnostic or Interventional Catheterization Procedures|Unknown status|Not yet recruiting|N/A|1000|Anticipated|TopSpin Medical||1|||f||||f||||||||||2018-06-01 02:45:18.198082|2018-06-01 02:45:18.198082
NCT00558428|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2009-11-13||2014-06-17|2007-11-14|2007-11-15|Estimate|2009-11-13|2009-12-15|Estimate||||2014-06-17|2014-06-27|Estimate|October 2007||2007-10-31|May 2014|2014-05-31||||September 2008|Actual|2008-09-30||Interventional|||Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension|An Eight-week Randomized, 4-arm, Double-blind Study to Compare the Efficacy and Safety of Combinations of Telmisartan 40mg + Amlodipine 5mg Versus Telmisartan 80mg + Amlodipine 5mg Versus Amlodipine 5mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy|Completed||Phase 3|1098|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:45:18.392937|2018-06-01 02:45:18.392937
NCT00558402|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-14|||2014-10-27|2007-11-14|2007-11-15|Estimate|||||||2014-10-27|2014-10-29|Estimate|November 2007||2007-11-30|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Meditation or Education for Alzheimer Caregivers|Meditation for Alzheimer Caregivers: Stress & Physiology|Completed||Phase 2|72|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 02:45:19.419764|2018-06-01 02:45:19.419764
NCT00558376|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2009-05-04|2007-11-13|2007-11-14|Estimate|||||||2009-05-04|2009-05-05|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy|Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy - An Investigator Blinded Prospective Controlled Trial|Terminated||N/A|23|Actual|Sheba Medical Center||2||Study terminated due to FDA alert regarding Fleet phosphosoda|f||||f||||||||||2018-06-01 02:45:19.594816|2018-06-01 02:45:19.594816
NCT00558363|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2011-11-10||2012-03-15|2007-11-13|2007-11-14|Estimate|2011-11-10|2011-12-13|Estimate||||2012-03-15|2012-03-21|Estimate|November 2007||2007-11-30|December 2011|2011-12-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|ARTS||ARTS - AVODART After Radical Therapy For Prostate Cancer Study|A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men With Prostate Cancer and Biochemical Failure (PSA Increase) After Radical Therapy With Curative Intent|Completed||Phase 2|294|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:45:19.823814|2018-06-01 02:45:19.823814
NCT00558350|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2012-03-14|2007-11-13|2007-11-14|Estimate|||||||2012-03-14|2012-03-15|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery|Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery|Completed|||15|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-06-01 02:45:21.277233|2018-06-01 02:45:21.277233
NCT00558337|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2009-01-13|2007-11-13|2007-11-14|Estimate|||||||2009-01-13|2009-01-14|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease|An Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Relationship Study of L-Dopa/Carbidopa in a Novel Release Formulation in Parkinson's Disease Patients|Completed||Phase 2|78|Actual|Osmotica Pharmaceutical US LLC||2|||f||||t||||||||||2018-06-01 02:45:21.38072|2018-06-01 02:45:21.38072
NCT00558324|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2007-11-12|2007-11-12|2007-11-14|Estimate|||||||2007-11-12|2007-11-14|Estimate|February 2007||2007-02-28|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Corneal Flap Thickness Planed vs Measured After LASIK by Using Tree Different Systems Cut|Corneal Flap Thickness Planed vs Measured After LASIK by Using Tree Different Systems Cut|Completed||N/A|43|Actual|Asociación para Evitar la Ceguera en México||3|||f||||t||||||||||2018-06-01 02:45:22.34873|2018-06-01 02:45:22.34873
NCT00558155|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-13|2007-11-13|2007-11-14|Estimate|||||||2007-11-13|2007-11-14|Estimate|June 2001||2001-06-30|November 2007|2007-11-30|December 2005|Actual|2005-12-31|||||Interventional|||The Impact of Immunostimulating Nutrition on the Outcome of Surgery|Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.|Completed||Phase 4|214|Actual|Jagiellonian University||4|||f||||f||||||||||2018-06-01 02:45:37.325585|2018-06-01 02:45:37.325585
NCT00558311|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13||2011-03-25|2012-03-09|2007-11-13|2007-11-14|Estimate||||2011-03-25|2011-04-04|Estimate|2012-03-09|2012-03-13|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|CONSCIOUS-2||Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping|A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping.|Completed||Phase 3|1157|Actual|Actelion||2|||f||||t||||||||||2018-06-01 02:45:22.761691|2018-06-01 02:45:22.761691
NCT00558298|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2011-05-16|2007-11-12|2007-11-14|Estimate|||||||2011-05-16|2011-05-17|Estimate|February 2000||2000-02-29|April 2010|2010-04-30|February 2005|Actual|2005-02-28|||||Interventional|||A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.|Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open Label Follow up Trial of RIS-INT-57 and RIS-INT-61.|Completed||Phase 3|811|Actual|Janssen, LP|||||f||||||||||||||2018-06-01 02:45:23.518814|2018-06-01 02:45:23.518814
NCT00558285|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2012-10-23||2012-11-28|2007-11-13|2007-11-14|Estimate|2012-10-23|2012-11-22|Estimate||||2012-11-28|2012-11-30|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Determine the Effect of QVA149 on Mean 24-hours Heart Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|257|Actual|Novartis||5|||f||||||||||||||2018-06-01 02:45:23.757747|2018-06-01 02:45:23.757747
NCT00558272|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2011-05-27||2013-05-23|2007-11-13|2007-11-14|Estimate|2011-05-27|2011-06-27|Estimate||||2013-05-23|2013-05-27|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|August 2012|Actual|2012-08-31|January 2010|Actual|2010-01-31||Interventional|||Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease|A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.|Completed||Phase 2|139|Actual|AstraZeneca|Non-compliant patients were excluded from the biomarker analysis, in order to accurately assess effects due to treatment. The compliance criteria did not apply to the zoledronic acid arm, which led to an imbalance in the number of subjects analysed.|2|||f||||t||||||||||2018-06-01 02:45:26.564623|2018-06-01 02:45:26.564623
NCT00558259|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2012-01-31||2014-06-17|2007-11-13|2007-11-14|Estimate|2012-01-31|2012-03-02|Estimate||||2014-06-17|2014-06-27|Estimate|November 2007||2007-11-30|February 2014|2014-02-28||||February 2011|Actual|2011-02-28||Interventional|RE-SONATE||Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE|Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.|Completed||Phase 3|1353|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:45:31.441962|2018-06-01 02:45:31.441962
NCT00558246|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2012-06-13||2012-06-13|2007-11-09|2007-11-14|Estimate|2012-06-13|2012-07-19|Estimate||||2012-06-13|2012-07-19|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|October 2009|Actual|2009-10-31|September 2008|Actual|2008-09-30||Interventional|||Study of Prineo (Dermabond Protape) Versus Sutures in Breast Procedures|Multi-centre Study to Show Equivalence of Prineo (DERMABOND PROTAPE) to Intradermal Sutures for Skin Closure of Full-thickness Surgical Incisions Associated With Breast Procedures|Completed||Phase 4|79|Actual|Ethicon, Inc.|Limitations of this study include the fact that the patient served as her own control. Additionally, as in many device studies, because of the obvious difference in the investigated and the control devices, blinding was limited.|2|||f||||f||||||||||2018-06-01 02:45:34.366092|2018-06-01 02:45:34.366092
NCT00558233|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2017-11-06|2007-11-13|2007-11-14|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2007||2007-11-30|February 2017|2017-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|InfoPC||Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid|Overcoming Literacy Barriers in Colorectal Cancer Screening|Completed||N/A|264|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 02:45:35.755224|2018-06-01 02:45:35.755224
NCT00558220|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2007-11-10|2007-11-10|2007-11-14|Estimate|||||||2007-11-10|2007-11-14|Estimate|May 2002||2002-05-31|November 2007|2007-11-30|October 2006|Actual|2006-10-31|||||Interventional|R-MCEB||R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas|Phase II Study of Intensive Induction (R-MegaCHOP/ESHAP)Followed By Intensive Consolidation (BEAM) In Treatment Of High-Risk Aggressive B-Cell Lymphomas|Completed||Phase 2|106|Actual|Czech Lymphoma Study Group||1|||f||||f||||||||||2018-06-01 02:45:36.169676|2018-06-01 02:45:36.169676
NCT00558207|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12||2013-02-21|2013-02-21|2007-11-13|2007-11-14|Estimate||||2013-02-21|2013-02-25|Estimate|2013-02-21|2013-02-25|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma|A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|43|Actual|ArQule||2|||f||||f||||||||||2018-06-01 02:45:36.482778|2018-06-01 02:45:36.482778
NCT00558194|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2018-03-12|2007-11-13|2007-11-14|Estimate|||||||2018-03-12|2018-03-14|Actual|August 2009||2009-08-31|March 2018|2018-03-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment (Part 2)|Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment|Withdrawn||N/A|0|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||Lack of funds|f||||t||||||||||2018-06-01 02:45:36.923873|2018-06-01 02:45:36.923873
NCT00558181|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2010-02-22|2007-11-13|2007-11-14|Estimate|||||||2010-02-22|2010-02-23|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|LT-CLL-001||High-dose Methylprednisolone and Rituximab in High Risk B-CLL|Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients With High Risk Chronic B Lymphocytic Leukemia|Completed||Phase 2|29|Actual|Vilnius University||1|||f||||f||||||||||2018-06-01 02:45:37.057545|2018-06-01 02:45:37.057545
NCT00558168|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2008-07-25|2007-11-13|2007-11-14|Estimate|||||||2008-07-25|2008-07-28|Estimate|January 2004||2004-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|||||Observational|E-SAFE||Electronic Study for Anastrozole Pharmacovigilance Evaluation|Electronic Study for Anastrozole Pharmacovigilance Evaluation|Completed|||1850|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:45:37.26027|2018-06-01 02:45:37.26027
NCT00558142|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-06-04|2007-11-13|2007-11-14|Estimate|||||||2015-06-04|2015-06-08|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material|Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material|Completed||Phase 4|90|Actual|University of Edinburgh||4|||f||||f||||||||||2018-06-01 02:45:37.859338|2018-06-01 02:45:37.859338
NCT00558129|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2017-12-06|2007-11-13|2007-11-14|Estimate|||||||2017-12-06|2017-12-08|Actual|November 2007||2007-11-30|January 2012|2012-01-31|November 2011|Anticipated|2011-11-30|||||Interventional|EXELS||Effects of X-STOP® Versus Laminectomy Study|Prospective Randomized Trial Comparing X-STOP® Interspinous Process Decompression® System Versus Laminectomy for Treatment of Neurogenic Intermittent Claudication|Withdrawn||Phase 4|0|Actual|Medtronic Spinal and Biologics||2|||f||||f||||||||||2018-06-01 02:45:38.122263|2018-06-01 02:45:38.122263
NCT00558116|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2008-05-10|2007-11-12|2007-11-14|Estimate|||||||2008-05-10|2008-05-13|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|November 2008|Anticipated|2008-11-30||Interventional|||Treatment of Carpal Tunnel Syndrome With Dynamic Splinting|Treating Carpal Tunnel Syndrome With Dynamic Splinting: A Randomized, Controlled, Trial|Unknown status|Recruiting|N/A|80|Anticipated|Advanced Centers for Orthopaedic Surgery and Sports Medicine||2|||f||||f||||||||||2018-06-01 02:45:38.493181|2018-06-01 02:45:38.493181
NCT00558103|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2012-05-17||2013-01-31|2007-11-09|2007-11-14|Estimate|2012-06-14|2012-07-18|Estimate||||2013-01-31|2013-02-04|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer|A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer|Completed||Phase 2|163|Actual|GlaxoSmithKline||3|||f||||t||||||||||2018-06-01 02:45:38.66034|2018-06-01 02:45:38.66034
NCT00558090|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2010-03-29|2007-11-13|2007-11-14|Estimate|||||||2010-03-29|2010-03-30|Estimate|February 2008||2008-02-29|October 2008|2008-10-31|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional|OPCIC||The Optimization of Procedural Pain Control in Intensive Care Unit (ICU) Patients|Randomised Clinical Trial of the Optimization of Procedural Pain Control in ICU Patients|Completed||N/A|150|Anticipated|St. Antonius Hospital||1|||f||||f||||||||||2018-06-01 02:45:40.520021|2018-06-01 02:45:40.520021
NCT00558077|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2007-11-13|2007-11-13|2007-11-14|Estimate|||||||2007-11-13|2007-11-14|Estimate|February 2003||2003-02-28|November 2007|2007-11-30|October 2005||2005-10-31|||||Interventional|||Second-Line Treatments for Anovulatory Infertility in PCOS Patients|Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial|Completed||Phase 4|50|Actual|University Magna Graecia||2|||f||||t||||||||||2018-06-01 02:45:40.600273|2018-06-01 02:45:40.600273
NCT00558064|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2009-11-10||2014-06-24|2007-11-12|2007-11-14|Estimate|2010-01-07|2010-02-01|Estimate||||2014-06-24|2014-07-08|Estimate|October 2007||2007-10-31|December 2013|2013-12-31||||September 2008|Actual|2008-09-30||Interventional|||Filtered Trial for Amlodipine Non-responder|Filtered Trial for Amlodipine Non-responder|Completed||Phase 3|531|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:45:40.708818|2018-06-01 02:45:40.708818
NCT00558051|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2016-03-31|2007-11-13|2007-11-14|Estimate|||||||2016-03-31|2016-04-01|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|December 2011|Actual|2011-12-31||Interventional|||Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer|Phase I Evaluation of Semi-continuous Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer|Completed||Phase 1|15|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 02:45:41.891734|2018-06-01 02:45:41.891734
NCT00558038|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09||2013-07-26|2014-05-27|2007-11-09|2007-11-14|Estimate||||2014-05-27|2014-05-30|Estimate|2014-05-27|2014-05-30|Estimate|September 2007||2007-09-30|May 2014|2014-05-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|AST015||Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy|Comparison of Different Treatment Regimens in Patients With Stage 1-2 Type C Hepatic Encephalopathy: AST-120 vs Lactulose|Completed||Phase 2|40|Actual|Ocera Therapeutics||2|||f||||f||||||||||2018-06-01 02:45:42.224684|2018-06-01 02:45:42.224684
NCT00558025|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2009-05-26||2014-05-07|2007-11-13|2007-11-14|Estimate|2009-11-03|2009-11-20|Estimate||||2014-05-07|2014-05-16|Estimate|October 2007||2007-10-31|May 2012|2012-05-31||||May 2008|Actual|2008-05-31||Interventional|||Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease|A Double-blind, Double-dummy, Randomized, Parallel Groups Study to Assess the Efficacy, Safety and Tolerability of Switching Patients With Early Parkinson's Disease (PD) From Pramipexole IR to Pramipexole ER or Pramipexole IR|Completed||Phase 3|156|Actual|Boehringer Ingelheim|There were no serious adverse events in the trial and no non-serious adverse events with an incidence >5%.|2|||f||||||||||||||2018-06-01 02:45:42.589173|2018-06-01 02:45:42.589173
NCT00558012|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2015-06-15||2015-07-09|2007-11-13|2007-11-14|Estimate|2015-06-15|2015-07-08|Estimate||||2015-07-09|2015-07-31|Estimate|December 2007||2007-12-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ZEST||Zoledronic Acid for Osteoporosis in the Elderly|Maintenance of Skeletal Integrity in Frail Elders|Completed||N/A|181|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:45:44.558093|2018-06-01 02:45:44.558093
NCT00557999|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2007-11-13|2007-11-13|2007-11-14|Estimate|||||||2007-11-13|2007-11-14|Estimate|March 2006||2006-03-31|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Mechanical Ventilation Weaning Protocol in the Coronary Care Unit|Evaluation of the Effects of the Use of Mechanical Ventilation Weaning Protocol in the Coronary Care Unit: A Randomized Study|Completed||N/A|36|Actual|Hospital de Base||2|||f||||f||||||||||2018-06-01 02:45:45.197242|2018-06-01 02:45:45.197242
NCT00557986|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2016-08-10|2007-11-13|2007-11-14|Estimate|||||||2016-08-10|2016-08-12|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Local Surgery for Metastatic Breast Cancer|The Effect of Primary Surgical Treatment on Survival in Patients With Metastatic Breast Cancer at Diagnosis|Completed||N/A|281|Actual|Federation of Breast Diseases Societies||2|||f||||t||||||||||2018-06-01 02:45:45.340338|2018-06-01 02:45:45.340338
NCT00557973|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12||2010-09-08|2016-09-12|2007-11-12|2007-11-14|Estimate||||2010-09-08|2010-09-10|Estimate|2016-09-12|2016-09-23|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury|Multiple-Dose Efficacy and Safety Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury|Completed||Phase 2|37|Actual|Indivior Inc.||3|||f||||f||||||||||2018-06-01 02:45:45.465534|2018-06-01 02:45:45.465534
NCT00484588|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2007-06-08|2007-06-08|2007-06-11|Estimate|||||||2007-06-08|2007-06-11|Estimate|May 2005||2005-05-31|June 2007|2007-06-30|December 2006||2006-12-31|||||Observational|||A Multi-Center Observational Surveillance Study of VAP Causing Bacteria|A Multi-Center Observational Surveillance of VAP Causing Bacteria Study|Completed|||500||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:10:21.295434|2018-06-01 03:10:21.295434
NCT00557960|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2010-12-10|2007-11-12|2007-11-14|Estimate|||||||2010-12-10|2010-12-13|Estimate|February 2004||2004-02-29|March 2009|2009-03-31|October 2004|Actual|2004-10-31|||||Interventional|||ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD|A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With ADDERALL XR and STRATTERA Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|36|Actual|Shire|||||f||||f||||||||||2018-06-01 02:45:45.603487|2018-06-01 02:45:45.603487
NCT00557947|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2012-06-13||2012-06-13|2007-11-09|2007-11-14|Estimate|2012-06-13|2012-07-19|Estimate||||2012-06-13|2012-07-19|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Prineo (Dermabond Protape) Versus Sutures for Full-thickness Surgical Incisions|Multi-centre Study to Show Equivalence of Prineo (Dermabond Protape) to Intradermal Sutures for Skin Closure of Full-thickness Surgical Incisions|Completed||Phase 4|83|Actual|Ethicon, Inc.|Limitations of this study include the fact that the patient served as her own control. Additionally, as in many device studies, because of the obvious difference in the investigated and the control devices, blinding was limited.|2|||f||||f||||||||||2018-06-01 02:45:45.708774|2018-06-01 02:45:45.708774
NCT00557934|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2008-09-17|2007-11-13|2007-11-14|Estimate|||||||2008-09-17|2008-09-19|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|TOF-Cond||Right Ventricular Contractility Reserve Following Repair of Tetralogy of Fallot|Evaluation of Right Ventricular Contractility Reserve Function During Dobutamine Stress in Patients Following Surgical Repair of Tetralogy of Fallot|Completed||N/A|16|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-06-01 02:45:46.047959|2018-06-01 02:45:46.047959
NCT00557921|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2009-01-27|2007-11-12|2007-11-14|Estimate|||||||2009-01-27|2009-01-28|Estimate|December 2007||2007-12-31|January 2009|2009-01-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|COGENT-1||Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease|Terminated||Phase 3|5000|Anticipated|Cogentus Pharmaceuticals||2||Terminated by Sponsor|f||||t||||||||||2018-06-01 02:45:46.316644|2018-06-01 02:45:46.316644
NCT00557908|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2017-10-05|2007-11-13|2007-11-14|Estimate|||||||2017-10-05|2017-10-06|Actual|June 2007||2007-06-30|October 2017|2017-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|VIP||The Von Willebrand Disease (VWD) International Prophylaxis Study|The VWD International Prophylaxis (VIP) Study|Completed|||105|Actual|Skane University Hospital|||1||f||||t||||||||No||2018-06-01 02:45:47.257154|2018-06-01 02:45:47.257154
NCT00557895|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-10|||2018-05-17|2007-11-10|2007-11-14|Estimate|||||||2018-05-17|2018-05-18|Actual|August 26, 1996||1996-08-26|October 18, 2017|2017-10-18||||||||Observational|||Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders|Evaluation and Long Term Follow-up of Patients With Allergic and Inflammatory Disorders|Enrolling by invitation|||288|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:45:47.344483|2018-06-01 02:45:47.344483
NCT00557882|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-09-21|2007-11-13|2007-11-14|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2007||2007-06-30|September 2015|2015-09-30|November 2011|Actual|2011-11-30|October 2009|Actual|2009-10-31||Interventional|VAMP-A||Efficacy Study of Vaginal Mesh for Anterior Prolapse|A Randomized Clinical Trial of Vaginal Mesh for Anterior Prolapse|Completed||Phase 4|8|Actual|Medstar Health Research Institute||2|||f||||t||||||||||2018-06-01 02:45:47.434521|2018-06-01 02:45:47.434521
NCT00557869|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2011-12-18|2007-11-13|2007-11-14|Estimate|||||||2011-12-18|2011-12-20|Estimate|October 2002||2002-10-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Optimization of Cardiac-MR Protocols|Optimization of Native Cardiac-MR Protocols|Completed|||122|Actual|Medical University of Graz|||||f||||t||||||||||2018-06-01 02:45:47.506238|2018-06-01 02:45:47.506238
NCT00557856|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2015-07-16||2015-09-27|2007-11-12|2007-11-14|Estimate|2015-07-16|2015-08-13|Estimate||||2015-09-27|2015-10-19|Estimate|November 2007||2007-11-30|September 2015|2015-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Safety population included all enrolled participants who received at least one dose of study drug.|A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors|A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of Pf-03446962 In Patients With Advanced Solid Tumors|Completed||Phase 1|70|Actual|Pfizer|Results for tumor vascular function adopting dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) was not reported as per change in planned analysis.|1|||f||||f||||||||||2018-06-01 02:45:47.68365|2018-06-01 02:45:47.68365
NCT00557843|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2018-05-17|2007-11-13|2007-11-14|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2007|Actual|2007-11-30|April 2017|2017-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Continuous Bupivacaine Infusion Following Colonic Surgery|Influence of Continuous Bupivacaine Infusion on Tissue Oxygenation Following Colonic Surgery|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||No patients enrolled|f||||f||||||||No||2018-06-01 02:45:50.672982|2018-06-01 02:45:50.672982
NCT00557830|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2012-12-03||2013-07-17|2007-11-09|2007-11-14|Estimate|2013-07-17|2013-07-18|Estimate||||2013-07-17|2013-07-18|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma|Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC)|Terminated||Phase 2|12|Actual|Accelerated Community Oncology Research Network|The decision to close the study was made by the funder , Bayer HealthCare Pharmaceuticals, in collaboration with ACORN due to the low rate of accrual in light of study timelines and the lack of funds beyond the current level of support from Bayer.|2||"The study was closed to enrollment when it became clear that enrollment was too slow to~   complete the full enrollment target within the time frame allowed."|f||||f||||||||||2018-06-01 02:45:50.89217|2018-06-01 02:45:50.89217
NCT00557817|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2010-01-08|2007-11-13|2007-11-14|Estimate|||||||2010-01-08|2010-01-11|Estimate|March 2004||2004-03-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)|Darbepoetin-alpha and i.v. Iron Administration After Autologous Hematopoietic Stem Cell Transplantation : a Prospective Randomized Trial|Completed||Phase 2/Phase 3|125|Actual|University Hospital of Liege||3|||f||||f||||||||||2018-06-01 02:45:52.183128|2018-06-01 02:45:52.183128
NCT00557804|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2010-02-02|2007-11-09|2007-11-14|Estimate|||||||2010-02-02|2010-02-04|Estimate|December 2007||2007-12-31|February 2010|2010-02-28||||December 2009|Actual|2009-12-31||Observational|MUSIC||Monitoring in Congestive Heart Failure Study|Multi-Sensor Monitoring in Congestive Heart Failure Study|Completed|||362|Actual|Corventis, Inc.|||||f||||f||||||||||2018-06-01 02:45:52.294915|2018-06-01 02:45:52.294915
NCT00557791|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-03-05|2007-11-13|2007-11-14|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2009||2009-11-30|February 2011|2011-02-28|July 2012|Anticipated|2012-07-31|July 2011|Anticipated|2011-07-31||Interventional|CARBON||Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)|A Phase 3, Randomized, Double-masked, Parallel-assignment and Dose-finding Study of Intravitreal Bevasiranib Sodium, Administered Every 8 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).|Withdrawn||Phase 3|0|Actual|OPKO Health, Inc.||4||Study never initiated|f||||t||||||||||2018-06-01 02:45:52.354663|2018-06-01 02:45:52.354663
NCT00557778|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2011-04-27|2007-11-13|2007-11-14|Estimate|||||||2011-04-27|2011-04-28|Estimate|November 2007||2007-11-30|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|PRECAVER||Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia|Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia|Completed|||600|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 02:45:52.474435|2018-06-01 02:45:52.474435
NCT00557765|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2007-11-13|2007-11-13|2007-11-14|Estimate|||||||2007-11-13|2007-11-14|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Observational|||Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area|Production of Gamma-Interferon by Circulating Lymphocytes Exposed to Antigens Specific of Mycobacterium Tuberculosis: Contribution to the Identification of Latent Tuberculosis Infection in Contact Tracing|Completed|||295|Actual|University Hospital, Geneva|||||f||||t||||||||||2018-06-01 02:45:52.532348|2018-06-01 02:45:52.532348
NCT00557752|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2009-02-06|2007-11-13|2007-11-14|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of Non-Invasive Mechanical Ventilation in Early Hypoxia Secondary to Thoracic Trauma|Non-Invasive Ventilation in Early Severe Posttraumatic Hypoxia: a Randomized Controlled Trial|Terminated||Phase 4|50|Actual|Hospital Virgen de la Salud||2||Review Board stopped the study after interim analysis reaching stopping rule for efficacy.|f||||t||||||||||2018-06-01 02:45:52.599748|2018-06-01 02:45:52.599748
NCT00557739|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2008-09-24|2007-11-13|2007-11-14|Estimate|||||||2008-09-24|2008-09-25|Estimate|November 2007||2007-11-30|December 2007|2007-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of CRx-191 to Assess Activity in Plaque Psoriasis|A Single-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Activity of CRx-191 in Reducing the Psoriatic Infiltrate Band Thickness in Plaque Psoriasis|Completed||Phase 2|20|Anticipated|Zalicus||6|||f||||f||||||||||2018-06-01 02:45:52.698085|2018-06-01 02:45:52.698085
NCT00557726|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-10|||2018-03-27|2007-11-10|2007-11-14|Estimate|||||||2018-03-27|2018-03-29|Actual|February 17, 1978||1978-02-17|August 18, 2017|2017-08-18||||||||Observational|||Diagnosis and Management of Inflammatory and Infectious Diseases|Diagnosis and Management of Inflammatory and Infectious Diseases|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:45:52.78605|2018-06-01 02:45:52.78605
NCT00557713|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2007-11-13|2007-11-13|2007-11-14|Estimate|||||||2007-11-13|2007-11-14|Estimate|February 2007||2007-02-28|November 2007|2007-11-30|October 2013|Anticipated|2013-10-31|||||Interventional|||XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma|Treatment of Induction With XELOX-Bevacizumab in Locally Advanced Rectal Adenocarcinoma: Phase II Study|Unknown status|Recruiting|Phase 2|44|Anticipated|Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials||1|||f||||f||||||||||2018-06-01 02:45:53.108779|2018-06-01 02:45:53.108779
NCT00557700|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2010-06-15|2007-11-13|2007-11-14|Estimate|||||||2010-06-15|2010-06-16|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma|Study to Investigate the Effect of Inhaled Tiotropium Bromide on Neurokinin-A Induced Bronchoconstriction in Patients With Mild-to-moderate Asthma|Completed||Phase 2|15|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 02:45:53.224917|2018-06-01 02:45:53.224917
NCT00557687|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-02-25|2007-11-13|2007-11-14|Estimate|||||||2015-02-25|2015-02-26|Estimate|May 2005||2005-05-31|February 2015|2015-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Prediction of Ovarian Response|Prediction of Ovarian Response After Ovarian Stimulation for in Vitro Fertilization|Completed|||100|Actual|Aristotle University Of Thessaloniki|||||f||||||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:45:53.319783|2018-06-01 02:45:53.319783
NCT00557661|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2009-03-23|2007-11-12|2007-11-14|Estimate|||||||2009-03-23|2009-03-25|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|December 2008|Actual|2008-12-31|||||Interventional|||Safety Study of CD-NP in Heart Failure|A Multi-Center, Ascending Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CD-NP Infusions in Patients With Congestive Heart Failure|Completed||Phase 1|20|Actual|Nile Therapeutics|||||f||||f||||||||||2018-06-01 02:45:53.373758|2018-06-01 02:45:53.373758
NCT00557648|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2014-05-23|2007-11-13|2007-11-14|Estimate|||||||2014-05-23|2014-05-26|Estimate|October 2002||2002-10-31|May 2014|2014-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Evaluating the Effectiveness of Early Cognitive Behavioral Therapy With or Without Parental Involvement in Treating Anxious Children|Early Interventions for Anxious Children|Completed||N/A|61|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-06-01 02:45:53.493502|2018-06-01 02:45:53.493502
NCT00557635|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2009-09-22|2007-11-12|2007-11-14|Estimate|||||||2009-09-22|2009-09-23|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow|Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow|Suspended||Phase 2|50|Anticipated|University Hospital, Clermont-Ferrand||||no recruited patients|f||||||||||||||2018-06-01 02:45:53.599671|2018-06-01 02:45:53.599671
NCT00557622|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2009-09-02||2016-11-04|2007-11-12|2007-11-14|Estimate|2009-10-13|2009-11-19|Estimate||||2016-11-04|2016-12-28|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)|Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study -|Terminated||Phase 2|5|Actual|GlaxoSmithKline||2||difficulty in achieving target enrollment numbers|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:45:53.68605|2018-06-01 02:45:53.68605
NCT00557596|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2009-11-30|2007-11-13|2007-11-14|Estimate|||||||2009-11-30|2009-12-01|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer|A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer|Terminated||Phase 1/Phase 2|48|Anticipated|Aegera Therapeutics|||||f||||f||||||||||2018-06-01 02:45:54.358862|2018-06-01 02:45:54.358862
NCT00557583|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2013-12-27|2007-11-13|2007-11-14|Estimate|||||||2013-12-27|2013-12-31|Estimate|November 2007||2007-11-30|December 2013|2013-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults|A Randomized, Double-blinded, Placebo-controlled, Sequential, Single Ascending Dose Evaluation of the Safety and Pharmacokinetics of VBY-376 in Healthy Adults|Completed||Phase 1|48|Actual|Virobay Inc.|||||f||||f||||||||||2018-06-01 02:45:54.541918|2018-06-01 02:45:54.541918
NCT00557570|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-10|||2017-06-30|2007-11-10|2007-11-14|Estimate|||||||2017-06-30|2017-07-02|Actual|February 11, 1995||1995-02-11|October 29, 2009|2009-10-29||||October 29, 2009|Actual|2009-10-29||Observational|||Evaluation and Monitoring of Patients With HIV Infectionn|Clinical, Virologic, and Immunologic Evaluation and Monitoring of Patients With Known or Suspected HIV Infection|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:45:54.636297|2018-06-01 02:45:54.636297
NCT00557557|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2015-12-23|2007-11-13|2007-11-14|Estimate|||||||2015-12-23|2015-12-28|Estimate|July 2007||2007-07-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases|A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin and 5-fluorouracil (5-FU) Followed by Hepatic Arterial Infusion of FUDR for Patients With Unresectable Colorectal Liver Metastases|Completed||Phase 1|14|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:45:54.696307|2018-06-01 02:45:54.696307
NCT00557544|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2017-08-23|2007-11-13|2007-11-14|Estimate|||||||2017-08-23|2017-08-24|Actual|June 2009||2009-06-30|August 2017|2017-08-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Trial on Metoclopramide and Ketoprofen in Acute Migraine of Childhood|Randomized Controlled Trial on the Effectiveness of Metoclopramide Alone or in Combination With Ketoprofen in Acute Migraine of Child|Withdrawn||Phase 3|0|Actual|IRCCS Burlo Garofolo||3|||f||||t||||||||||2018-06-01 02:45:54.797184|2018-06-01 02:45:54.797184
NCT00557531|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2012-02-02|2007-11-13|2007-11-14|Estimate|||||||2012-02-02|2012-02-03|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|January 2014|Anticipated|2014-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Feasibility of the Injectable BL-1040 Implant|Safety and Feasibility of the Injectable BL-1040 Implant|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|BioLineRx, Ltd.||1|||f||||t||||||||||2018-06-01 02:45:54.872395|2018-06-01 02:45:54.872395
NCT00557518|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2009-01-29|2007-11-13|2007-11-14|Estimate|||||||2009-01-29|2009-01-30|Estimate|November 2007||2007-11-30|January 2009|2009-01-31|November 2009|Anticipated|2009-11-30|September 2009|Anticipated|2009-09-30||Interventional|||Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria|A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria|Terminated||Phase 2|80|Anticipated|Synvista Therapeutics, Inc||2||Study has been terminated early due to financial constraints.|f||||f||||||||||2018-06-01 02:45:54.97275|2018-06-01 02:45:54.97275
NCT00557505|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2012-01-10||2012-02-21|2007-11-12|2007-11-14|Estimate|2012-02-21|2012-03-26|Estimate||||2012-02-21|2012-03-26|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study Of PF-03732010 In Patients With Advanced Solid Tumors|A Phase 1 Pharmacokinetic And Pharmacodynamic Study Of PF-03732010 In Patients With Advanced Solid Tumors|Completed||Phase 1|43|Actual|Pfizer|Results are not provided because development of the study drug was terminated, as neither anti-tumor activity nor pharmacodynamic modulation was observed.|1|||f||||f||||||||||2018-06-01 02:45:55.332232|2018-06-01 02:45:55.332232
NCT00557492|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2016-08-10||2017-06-06|2007-11-13|2007-11-14|Estimate|2016-10-19|2016-12-12|Estimate||||2017-06-06|2017-07-07|Actual|December 2006||2006-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|March 2012|Actual|2012-03-31||Interventional|||Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer|Phase II Study of the Anti-Vascular Endothelial Growth Factor (α-VEGF) Monoclonal Antibody Bevacizumab in Combination With Fixed Dose Rate (FDR) Gemcitabine and Rapid-Fractionation Radiotherapy in the Pre-operative Treatment of Potentially- Resectable Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|59|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:45:57.273994|2018-06-01 02:45:57.273994
NCT00557466|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|2012-11-12||2012-12-12|2007-11-13|2007-11-14|Estimate|2012-12-12|2013-01-18|Estimate||||2012-12-12|2013-01-18|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Multi-center, Parallel Group, Double Blind, Placebo and Formoterol Controlled 14 Day Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Patients With COPD|Completed||Phase 2|568|Actual|Novartis||6|||f||||||||||||||2018-06-01 02:45:57.596936|2018-06-01 02:45:57.596936
NCT00557453|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-11|||2010-07-12|2007-11-11|2007-11-14|Estimate|||||||2010-07-12|2010-07-13|Estimate|April 2008||2008-04-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial|The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial|Completed|||120|Anticipated|Hadassah Medical Organization|||2||f||||t||||||||||2018-06-01 02:45:58.43715|2018-06-01 02:45:58.43715
NCT00557440|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2013-02-15||2013-02-15|2007-11-13|2007-11-14|Estimate|2013-02-15|2013-03-21|Estimate||||2013-02-15|2013-03-21|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma|A Multi-center, Randomized, Double-blind, Double Dummy, Placebo and Active Controlled Crossover Study, to Investigate the 24 Hour FEV1 Profile of a Single Dose of QMF TWISTHALER Device in Adult Patients With Persistent Asthma|Completed||Phase 2|37|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:45:58.524832|2018-06-01 02:45:58.524832
NCT00557427|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2011-06-23|2007-11-13|2007-11-14|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression|Open-labeled Randomized Comparative Study of the Efficacy and Tolerability of Two Times Daily 250mg Hypericum Versus Once Daily 20 - 40 mg Fluoxetine in Adolescent Patients With Mild to Moderate Depression|Terminated||Phase 4|30|Anticipated|Rafa Laboratories||2||Lack of enrollment|f||||f||||||||||2018-06-01 02:45:59.045843|2018-06-01 02:45:59.045843
NCT00557414|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2008-05-08|2007-11-12|2007-11-14|Estimate|||||||2008-05-08|2008-05-13|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|||||Observational|||Serial Changes of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Levels in Patients With Acute Respiratory Distress Syndrome|Serial Changes of sTREM-1 Levels in Patients With Acute Respiratory Distress Syndrome|Completed|||63|Actual|National Taiwan University Hospital|||||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:45:59.13288|2018-06-01 02:45:59.13288
NCT00557401|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12||2010-09-08|2016-09-09|2007-11-12|2007-11-14|Estimate||||2010-09-08|2010-09-10|Estimate|2016-09-09|2016-09-23|Estimate|November 2007||2007-11-30|September 2016|2016-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD|A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of XP19986 in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD)|Completed||Phase 2|156|Actual|Indivior Inc.||5|||f||||f||||||||||2018-06-01 02:45:59.193743|2018-06-01 02:45:59.193743
NCT00557388|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2011-09-13|2007-11-13|2007-11-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|December 2007||2007-12-31|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Dietary Strategies to Promote Muscle Protein Anabolism in the Elderly|Dietary Strategies to Promote Muscle Protein Anabolism in the Elderly|Completed||N/A|120|Actual|Maastricht University Medical Center||10|||f||||t||||||||||2018-06-01 02:45:59.284002|2018-06-01 02:45:59.284002
NCT00557375|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-13|||2009-09-17|2007-11-13|2007-11-14|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|November 2009|Anticipated|2009-11-30|||||Observational|||Brain Tumor Treatment Satisfaction Survey|Treatment Satisfaction Survey for Brain Tumor Patients and Their Caregivers|Unknown status|Recruiting||700|Anticipated|Methodist Healthcare|||2||f||||f||||||||||2018-06-01 02:45:59.365398|2018-06-01 02:45:59.365398
NCT00557362|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2013-06-14||2013-11-18|2007-11-09|2007-11-14|Estimate|2013-11-18|2013-12-19|Estimate||||2013-11-18|2013-12-19|Estimate|November 2007||2007-11-30|November 2013|2013-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|MUTT_TE||Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer|Mycotic Ulcer Treatment Trial Therapeutic Exploratory Study|Completed||Phase 1/Phase 2|120|Actual|University of California, San Francisco||4|||f||||f||||||||||2018-06-01 02:45:59.445617|2018-06-01 02:45:59.445617
NCT00557349|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2009-02-27||2016-11-22|2007-11-12|2007-11-14|Estimate|2016-11-22|2017-01-19|Estimate||||2016-11-22|2017-01-19|Estimate|November 2006||2006-11-30|September 2016|2016-09-30|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Ulcer Prevention Study in Post Gastric Bypass Patients|A Randomized, Double-blind Clinical Trial Comparing Zegerid Capsule to Famotidine in Preventing Anastomotic (Marginal) Ulcers in Post Gastric Bypass Patients|Completed||Phase 4|40|Actual|University of Missouri-Columbia||2|||f||||f||||||||Undecided||2018-06-01 02:45:59.820452|2018-06-01 02:45:59.820452
NCT00557336|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|||2017-02-27|2007-11-12|2007-11-14|Estimate|||||||2017-02-27|2017-02-28|Actual|July 28, 2003|Actual|2003-07-28|February 2017|2017-02-28|June 29, 2005|Actual|2005-06-29|June 29, 2005|Actual|2005-06-29||Interventional|||Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age|Evaluation of Efficacy and Safety of Somatropin in SGA Children Due to IUGR|Completed||Phase 3|160|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:46:00.095559|2018-06-01 02:46:00.095559
NCT00557323|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-12|2011-05-19||2015-03-04|2007-11-13|2007-11-14|Estimate|2011-05-19|2011-06-15|Estimate||||2015-03-04|2015-03-24|Estimate|August 2005||2005-08-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Long-term Effect of Lanthanum Carbonate on Bone|A Long-term, Observational Study to Monitor Mortality, Bone-related Adverse Events and the Safety of Subjects Who Were Recruited Into Study SPD405-309|Completed|||34|Actual|Shire|||1||f||||f||||||||||2018-06-01 02:46:00.226478|2018-06-01 02:46:00.226478
NCT00557310|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2011-10-07||2011-10-07|2007-11-09|2007-11-14|Estimate|2011-10-07|2011-11-11|Estimate||||2011-10-07|2011-11-11|Estimate|November 2007||2007-11-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Interventional|||A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide|The Effects of Teriparatide on Bone Microarchitecture as Determined by High Resolution Magnetic Resonance Imaging and Digital Topological Analysis|Completed||Phase 4|35|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:46:00.744765|2018-06-01 02:46:00.744765
NCT00557297|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2008-09-24|2007-11-13|2007-11-14|Estimate|||||||2008-09-24|2008-09-25|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|||||Observational|SYMCO||NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler|NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler|Completed|||250|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:46:01.327345|2018-06-01 02:46:01.327345
NCT00557284|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2013-07-30||2015-03-31|2007-11-09|2007-11-12|Estimate|2014-12-05|2014-12-09|Estimate||||2015-03-31|2015-04-21|Estimate|March 2008||2008-03-31|March 2015|2015-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens|Completed||Phase 4|20|Actual|IMMUNOe Research Centers||2|||f||||f||||||||||2018-06-01 02:46:01.413533|2018-06-01 02:46:01.413533
NCT00557258|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2009-02-12|2007-11-09|2007-11-12|Estimate|||||||2009-02-12|2009-02-13|Estimate|November 2007||2007-11-30|February 2009|2009-02-28||||November 2007|Actual|2007-11-30||Observational|||Cross-Sectional Study: Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs|Prevalence of Restless Legs Syndrome in Patients With Unpleasant Sensations of the Legs|Completed|||14956|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 02:46:01.908666|2018-06-01 02:46:01.908666
NCT00557245|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2014-10-30||2014-11-20|2007-11-09|2007-11-12|Estimate|2014-11-20|2014-11-27|Estimate||||2014-11-20|2014-11-27|Estimate|May 2008||2008-05-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|Partners PrEP|All randomized participants, less those who were found to be ineligible (n=11)|Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples|Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples|Completed||Phase 3|4758|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 02:46:02.460452|2018-06-01 02:46:02.460452
NCT00557232|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2011-11-25|2007-11-09|2007-11-12|Estimate|||||||2011-11-25|2011-11-29|Estimate|November 2006||2006-11-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Intraocular Bevacizumab (Avastin) for Rubeosis Iridis|The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion|Completed||Phase 4|25|Actual|Instituto de Olhos de Goiania|||||f||||t||||||||||2018-06-01 02:46:03.853246|2018-06-01 02:46:03.853246
NCT00557219|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2016-11-14|2007-11-09|2007-11-12|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2008||2008-04-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery|Influence of Fenoldopam and Ketanserin on Function and Kidney Injury Parameters in Patients With Increased Risk of Acute Kidney Failure After Cardiac Surgery|Terminated||Phase 3|60|Actual|Medical University of Gdansk||3||Main cooperator finished cooperation|f||||f||||||||Undecided|Upon reasonable request IPD can be made available to other researcher.|2018-06-01 02:46:03.917812|2018-06-01 02:46:03.917812
NCT00557206|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2013-11-04|2007-11-09|2007-11-12|Estimate|||||||2013-11-04|2013-11-05|Estimate|April 2005||2005-04-30|November 2013|2013-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer|Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck|Terminated||Phase 2|35|Actual|Minneapolis Veterans Affairs Medical Center||1||Funding was terminated|f||||f||||||||||2018-06-01 02:46:04.002046|2018-06-01 02:46:04.002046
NCT00557193|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2017-09-27|2007-11-09|2007-11-12|Estimate|||||||2017-09-27|2017-09-28|Actual|January 2008||2008-01-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)|Active, not recruiting||Phase 3|242|Anticipated|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 02:46:04.133562|2018-06-01 02:46:04.133562
NCT00557180|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2017-03-27|2007-11-09|2007-11-12|Estimate|||||||2017-03-27|2017-03-29|Actual|October 2007|Actual|2007-10-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications|Obesity, Inflammation and Response to Therapy in Asthma - Ancillary to Asthma Clinical Research Network (ACRN) Trials|Completed|||33|Actual|National Jewish Health|||2||f||||t||||||Samples Without DNA|"~     Plasma Serum~   "|||2018-06-01 02:46:04.597916|2018-06-01 02:46:04.597916
NCT00557154|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2017-02-13|2007-11-08|2007-11-12|Estimate|||||||2017-02-13|2017-02-15|Actual|August 2003||2003-08-31|November 2007|2007-11-30|July 2004|Actual|2004-07-31|||||Interventional|||Ultrasound Assisted Peripheral Venous Access in Young Children|Ultrasound Assisted Peripheral Venous Access in Young Children: A Pilot and Feasibility Randomized Controlled Trial|Completed||N/A|44|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 02:46:04.696673|2018-06-01 02:46:04.696673
NCT00557141|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2009-01-08|2007-11-09|2007-11-12|Estimate|||||||2009-01-08|2009-01-09|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|August 2009|Anticipated|2009-08-31|May 2009|Anticipated|2009-05-31||Observational|||Observational Study Regarding Adherence, Drug Use, Will to Take Part in Shared Decisioning in Asthma Outpatients|AsthmaCare Study Covering Adherence, Drug Use, Will to Take Part in Shared Decisioning in Asthma Outpatients|Unknown status|Active, not recruiting||1100|Anticipated|Heidelberg Metasystems GmbH|||1||f||||f||||||||||2018-06-01 02:46:04.777729|2018-06-01 02:46:04.777729
NCT00557128|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24||2010-10-13|2010-10-13|2007-11-09|2007-11-12|Estimate||||2010-10-13|2010-10-15|Estimate|2010-10-13|2010-10-15|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.|A Randomized, Open-label, Single-dose, 3-period Crossover Study to Assess the Effect of Food on the Pharmacokinetics of the Final Fixed Dose Combination Formulation of COREG CR and Lisinopril in the Fed and Fasted State.|Completed||Phase 1|24|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:46:04.844501|2018-06-01 02:46:04.844501
NCT00557115|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|January 2009|Anticipated|2009-01-31|||||Interventional|||Early Pulmonary Rehabilitation Following Acute COPD Exacerbation|Early Pulmonary Rehabilitation (PR) Following Hospitalisation For Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Recruiting|Phase 3|60|Anticipated|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-06-01 02:46:04.901702|2018-06-01 02:46:04.901702
NCT00557102|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2012-12-10|2007-11-09|2007-11-12|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ERBIFORT||Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung|"Frontline Chemotherapy Reinforced for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX"|Completed||Phase 2|24|Actual|National Cancer Institute, France||1|||f||||||||||||||2018-06-01 02:46:04.993412|2018-06-01 02:46:04.993412
NCT00557089|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2013-08-30|2007-11-09|2007-11-12|Estimate|||||||2013-08-30|2013-09-02|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis|Randomized, Placebo-controlled Trial on the Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis|Completed||Phase 4|17|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 02:46:05.064786|2018-06-01 02:46:05.064786
NCT00557076|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2014-10-21||2014-11-03|2007-11-08|2007-11-12|Estimate|2014-11-03|2014-11-10|Estimate||||2014-11-03|2014-11-10|Estimate|July 2008||2008-07-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|FAST||The Efficacy of Familiar Voice Stimulation During Coma Recovery|Can Neural Adaptation After Severe Brain Injury be Facilitated?|Completed||Phase 1/Phase 2|21|Actual|VA Office of Research and Development|A limitation is achieved sample size. Given restrictive eligibility criteria, enrollment was lower than planned.|2|||f||||t||||||||||2018-06-01 02:46:05.140865|2018-06-01 02:46:05.140865
NCT00557050|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|January 2008||2008-01-31|September 2007|2007-09-30|March 2009|Anticipated|2009-03-31|||||Interventional|||Acute Hamstring Strains in Danish Elite Soccer - Prevention and Rehabilitation|Acute Hamstring Strains in Danish Elite Soccer - Prevention and Rehabilitation|Unknown status|Enrolling by invitation|N/A|1000|Anticipated|Amager Hospital|||||f||||f||||||||||2018-06-01 02:46:06.531846|2018-06-01 02:46:06.531846
NCT00557037|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2010-04-06|2007-11-09|2007-11-12|Estimate|||||||2010-04-06|2010-04-08|Estimate|November 2007||2007-11-30|April 2010|2010-04-30|November 2009|Actual|2009-11-30|||||Interventional|||A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer|A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer|Completed||Phase 2|60|Anticipated|MEI Pharma, Inc.||2|||f||||||||||||||2018-06-01 02:46:06.595863|2018-06-01 02:46:06.595863
NCT00483665|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2008-11-17|2007-06-06|2007-06-07|Estimate|||||||2008-11-17|2008-11-19|Estimate|June 2006||2006-06-30|November 2008|2008-11-30||||||||Observational|||Vasovist Endoleak Study|Detection of Endoleak by Vasovist-Enhanced Magnetic Resonance Imaging|Completed|||20|Anticipated|UMC Utrecht|||||f||||f||||||||||2018-06-01 03:10:39.368647|2018-06-01 03:10:39.368647
NCT00557024|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2008-11-17|2007-11-09|2007-11-12|Estimate|||||||2008-11-17|2008-11-18|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|July 2010|Anticipated|2010-07-31|November 2009|Anticipated|2009-11-30||Interventional|RT-RFA||Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|80|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:46:06.664477|2018-06-01 02:46:06.664477
NCT00557011|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2011-05-23|2007-11-09|2007-11-12|Estimate|||||||2011-05-23|2011-05-25|Estimate|September 2004||2004-09-30|May 2011|2011-05-31|December 2004|Actual|2004-12-31|||||Interventional|||NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD|A Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled, 3-Treatment, 3-Period, Crossover Study With One Week Per Treatment and Once-a-Day Dosing of Either NRP104, Adderall XR, or Placebo in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|52|Actual|New River Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:46:06.783258|2018-06-01 02:46:06.783258
NCT00556998|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2010-08-02||2016-03-31|2007-11-09|2007-11-12|Estimate|2012-02-27|2012-03-16|Estimate||||2016-03-31|2016-05-05|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents|An Open-Label, Intravenous To Oral Switch, Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Immunocompromised Adolescents Aged 12 To <17 Years Who Are At High Risk For Systemic Fungal Infection|Completed||Phase 2|26|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:46:06.943396|2018-06-01 02:46:06.943396
NCT00556972|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2011-08-02||2012-11-29|2007-11-09|2007-11-12|Estimate|2012-11-29|2013-01-01|Estimate||||2012-11-29|2013-01-01|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Feasibility Study of a Fecal Incontinence Management System for Medical Use|A Feasibility Study of a Fecal Incontinence Management System for Medical Use|Terminated||Phase 1/Phase 2|4|Actual|Coloplast A/S|No overall conclusions could be drawn, due to the limited amount of data (N=4 due to delays and low recruitment rate). A new study, with a higher sample size needs to be executed, if the objectives set in this study are to be investigated thoroughly.|1||Due to numerous delays in study start-up process...|f||||f||||||||||2018-06-01 02:46:07.868509|2018-06-01 02:46:07.868509
NCT00556959|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2010-03-23|2007-11-09|2007-11-12|Estimate|||||||2010-03-23|2010-03-24|Estimate|October 2007||2007-10-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|236|Actual|Addrenex Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 02:46:08.194131|2018-06-01 02:46:08.194131
NCT00556946|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2016-02-05||2017-02-08|2007-11-09|2007-11-12|Estimate|2016-03-17|2016-04-19|Estimate||||2017-02-08|2017-03-17|Actual|August 2005||2005-08-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PDT/PDL||Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains|Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains|Completed||N/A|17|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 02:46:08.360618|2018-06-01 02:46:08.360618
NCT00556933|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2015-01-29||2015-02-16|2007-11-09|2007-11-12|Estimate|2015-02-16|2015-03-02|Estimate||||2015-02-16|2015-03-02|Estimate|April 2004||2004-04-30|February 2015|2015-02-28|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional||Two patients were enrolled into the study erroneously in a violation of protocol and were identified and excluded before any study-related interventions. (Additional patients excluded from outcome analyses are accounted for in the Participant Flow and Outcome modules.)|Improved Induction and Maintenance Immunosuppression in Kidney Transplantation|Prospective, Randomized 2 x 2 Factorial Trial of Rabbit Anti-thymocyte Globulin Induction (Single vs. Alternate Day Administration) at Renal Transplantation, With Delayed Calcineurin-inhibitor Withdrawal vs. Minimization|Completed||Phase 4|180|Actual|University of Nebraska|The trial is designed for analysis as 1st, rATG dosing, and 2nd, CNI withdrawal status. Results published as analysis of 2 induction protocols followed by analysis of 2 CNI maintenance regimens. Potential limitations = single-center & non-blinded.|4|||f||||f||||||||||2018-06-01 02:46:08.672838|2018-06-01 02:46:08.672838
NCT00556920|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09||2010-10-13|2010-10-13|2007-11-09|2007-11-12|Estimate||||2010-10-13|2010-10-15|Estimate|2010-10-13|2010-10-15|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components|A Randomized, Open-label, Single-dose, Three-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of COREG CR™ and Lisinopril to COREG CR and ZESTRIL|Completed||Phase 1|50|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:46:09.829024|2018-06-01 02:46:09.829024
NCT00556907|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2017-07-05|2007-11-09|2007-11-12|Estimate|||||||2017-07-05|2017-07-11|Actual|October 2007||2007-10-31|July 2017|2017-07-31|November 2016|Actual|2016-11-30|March 2015|Actual|2015-03-31||Interventional|||Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast|Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT.|Terminated||N/A|22|Actual|University of Southern California||1||Lack of Funding|f||||f|f|t|f||t|||||2018-06-01 02:46:09.903692|2018-06-01 02:46:09.903692
NCT00556894|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2015-02-24|2011-06-14|2018-02-27|2007-11-09|2007-11-12|Estimate|2015-02-24|2015-03-09|Estimate|2011-06-30|2011-07-01|Estimate|2018-02-27|2018-03-29|Actual|February 2008||2008-02-29|August 2011|2011-08-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis|Completed||Phase 2|253|Actual|Can-Fite BioPharma||3|||f||||f||||||||||2018-06-01 02:46:09.998261|2018-06-01 02:46:09.998261
NCT00556868|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|December 2005|Actual|2005-12-31|||||Interventional|||The Influence of Having Breakfast on Cognitive Performance and Mood|The Influence of Having Breakfast on Cognitive Performance and Mood in High School Students|Completed||N/A|104|Actual|University of Ulm||2|||f||||f||||||||||2018-06-01 02:46:10.306819|2018-06-01 02:46:10.306819
NCT00556855|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2009-01-09|2007-11-08|2007-11-12|Estimate|||||||2009-01-09|2009-01-12|Estimate|December 2007||2007-12-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Comparison Study With E-DO in Chronic Hand Dermatitis|A 4-Week Randomized, Double-Blind, Placebo-Controlled, Right-Left Comparison Study With E-DO in Chronic Hand Dermatitis|Completed||N/A|67|Actual|HenKan Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:46:10.39482|2018-06-01 02:46:10.39482
NCT00556842|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2017-06-20|2007-11-09|2007-11-12|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2009||2009-03-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|HEALTH||Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures|Hip Fracture Evaluation With Alternatives of Total Hip Arthroplasty Versus Hemi-Arthroplasty: A Multi-Centre Randomized Trial Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Patients With Displaced Femoral Neck Fractures|Active, not recruiting||N/A|1501|Actual|McMaster University||2|||f||||t||||||||Undecided||2018-06-01 02:46:10.502528|2018-06-01 02:46:10.502528
NCT00556816|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2015-09-17|2007-11-09|2007-11-12|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|COPD-C||Chronic Obstructive Pulmonary Disease (COPD) Outpatient on Demand Clinic|COPD-C: COPD Outpatient on Demand Clinic. Study to Determine the Efficacy and Safety of on Demand Outpatient Clinics in COPD Patients|Completed||N/A|100|Actual|Isala||2|||f||||t||||||||||2018-06-01 02:46:10.679139|2018-06-01 02:46:10.679139
NCT00556803|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2008-11-17|2007-11-09|2007-11-12|Estimate|||||||2008-11-17|2008-11-18|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|June 2010|Anticipated|2010-06-30|November 2009|Anticipated|2009-11-30||Interventional|TACE-RFA||TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|120|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:46:10.765695|2018-06-01 02:46:10.765695
NCT00556790|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|November 2004||2004-11-30|November 2007|2007-11-30|January 2007|Actual|2007-01-31|||||Interventional|||Fast Track in Open Colonic Surgery - A Multicentric Randomized Controlled Trial|Fast Track in Open Colonic Surgery - A Multicentric Randomized Controlled Trial|Terminated||N/A|150|Actual|University of Lausanne Hospitals||2||interim analysis|f||||f||||||||||2018-06-01 02:46:10.925524|2018-06-01 02:46:10.925524
NCT00556777|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2011-05-12|2007-11-09|2007-11-12|Estimate|||||||2011-05-12|2011-05-13|Estimate|January 2004||2004-01-31|December 2007|2007-12-31||||May 2011|Actual|2011-05-31||Interventional|||Radiation Therapy During Surgery in Treating Older Women With Stage I Breast Cancer|Phase 2 Study Evaluating the Feasibility and the Reproducibility of Concentrated Radiotherapy and Focalized Electrontherapy During Surgery for the Treatment of Older Patients With Breast Cancer|Completed||Phase 2|42|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:46:11.014046|2018-06-01 02:46:11.014046
NCT00556764|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2012-02-08|2007-11-09|2007-11-12|Estimate|||||||2012-02-08|2012-02-09|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|ANAM||Development of Cognitive Assessment Tools in Parkinson Disease|Development of Cognitive Assessment Tools in Parkinson Disease|Completed||Early Phase 1|75|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 02:46:11.095698|2018-06-01 02:46:11.095698
NCT00556751|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2016-02-17|2007-11-08|2007-11-12|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 1985||1985-01-31|December 2007|2007-12-31|September 2006|Actual|2006-09-30|||||Observational|CARDIA ECG||Evaluating Electrocardiogram (ECG) Abnormalities From Young Adulthood Through Middle Age|Epidemiology and Mechanisms of ECG Abnormalities: Young Adulthood to Middle Age|Completed|||5115|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||f||||||||||2018-06-01 02:46:11.216408|2018-06-01 02:46:11.216408
NCT00556738|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2010-05-12|2007-11-09|2007-11-12|Estimate|||||||2010-05-12|2010-05-13|Estimate|November 2007||2007-11-30|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|HFPV||Intrapulmonary Percussive Ventilation (IPV) Versus Nasal Continuous Positive Airway Pressure Ventilation (nCPAP) in Transient Respiratory Distress of the Newborn|Intrapulmonary Percussive Ventilation and Nasal Continuous Positive Airway Pressure Ventilation in Transient Respiratory Distress of the Newborn: A Randomized Controlled Trial|Completed||N/A|100|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 02:46:11.336371|2018-06-01 02:46:11.336371
NCT00556712|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2014-12-04||2015-01-27|2007-11-09|2007-11-12|Estimate|2015-01-27|2015-02-11|Estimate||||2015-01-27|2015-02-11|Estimate|January 2006||2006-01-31|January 2015|2015-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Full analysis set (FAS): all randomized participants presented according to the therapy that they were randomized to receive|A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic NSCLS Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy|Completed||Phase 3|889|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:46:11.529276|2018-06-01 02:46:11.529276
NCT00556699|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2014-03-18|2007-11-09|2007-11-12|Estimate|||||||2014-03-18|2014-03-20|Estimate|December 2007||2007-12-31|November 2011|2011-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma|An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics, and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed Following Previous Rituximab Therapy|Completed||Phase 1|22|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 02:46:13.593278|2018-06-01 02:46:13.593278
NCT00556686|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2015-04-20|2007-11-08|2007-11-12|Estimate|||||||2015-04-20|2015-04-22|Estimate|August 2006||2006-08-31|April 2015|2015-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Salivary Catecholamines in Aphthous Stomatitis (Canker Sores)|Salivary Catecholamines in Aphthous Stomatitis|Withdrawn|||0|Actual|University of California, Davis|||2|We are currently modifying the study|f||||f||||||Samples Without DNA|"~     saliva~   "|||2018-06-01 02:46:13.814716|2018-06-01 02:46:13.814716
NCT00556673|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2013-03-11||2013-03-11|2007-11-09|2007-11-12|Estimate|2013-03-11|2013-04-22|Estimate||||2013-03-11|2013-04-22|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma|An Exploratory, Multi-centre, Double-blind, Placebocontrolled Crossover Study, to Investigate the Bronchodilatory Efficacy of a Single Dose of Indacaterol in Fixed Combination With Mometasone Furoate Delivered Via a MDDPI (Twisthaler®) in Adult Patients With Persistent Asthma Using Open Label Seretide® Accuhaler® (50/250 Mcg b.i.d.) as an Active Control|Completed||Phase 2|31|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:46:14.018198|2018-06-01 02:46:14.018198
NCT00556660|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2008-07-23|2007-11-09|2007-11-12|Estimate|||||||2008-07-23|2008-07-24|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of [123I] AV51 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects||Completed||Phase 1|20|Anticipated|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 02:46:14.592167|2018-06-01 02:46:14.592167
NCT00556647|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2013-04-05|2007-11-09|2007-11-12|Estimate|||||||2013-04-05|2013-04-08|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Fast-track Diagnosis for Lung Cancer Suspects With PET-CT and EUS|A Prospective, Open, Single Center, Study of One-day Diagnostic Track for Lung Cancer Suspects From Chest X-ray Using PET-CT and Subsequent Multiple Endoscopic Investigations. (Including Bronchoscopy, EUS-FNA)|Completed|||297|Actual|Isala|||1||f||||t||||||||||2018-06-01 02:46:14.678019|2018-06-01 02:46:14.678019
NCT00556634|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2009-01-14|2007-11-09|2007-11-12|Estimate|||||||2009-01-14|2009-01-15|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Incidence and Severity of Neuropsychiatric Adverse Events of Efavirenz Given as a Stepped Dosage vs. the Usual Dosage|Randomized, Double-Blinded Clinical Trial to Evaluate the Incidence and Severity of Neuropsychiatric Side Effects and Antiviral Efficacy of Efavirenz Given as a Stepped Dosage Over 2 Weeks Versus the Usual Dosage in HIV-Infected Patients.|Completed||Phase 4|114|Actual|Sociedad Andaluza de Enfermedades Infecciosas||2|||f||||t||||||||||2018-06-01 02:46:14.744211|2018-06-01 02:46:14.744211
NCT00556621|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2015-07-29|2007-11-09|2007-11-12|Estimate|||||||2015-07-29|2015-07-30|Estimate|June 2005||2005-06-30|July 2015|2015-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|GEMCIRAV||Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer|Phase 1-2 Study of the Association of Gemzar ® - Cisplatin-concurrent Radiotherapy in Patients With Non-metastatic Tumors of the Bladder|Completed||Phase 1/Phase 2|14|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||||2018-06-01 02:46:14.888599|2018-06-01 02:46:14.888599
NCT00556608|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2012-12-03|2007-11-09|2007-11-12|Estimate|||||||2012-12-03|2012-12-04|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|May 2010|Actual|2010-05-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy Study of Intra-articular Hyaluronic Acid in the Knee Osteoarthritis|Efficacy Evaluation of Intra-articular Hyaluronic Acid (Sinovial®) vs Synvisc® in the Treatment of Symptomatic Knee Osteoarthritis. A Double-blind, Controlled, Randomised, Parallel-group Non-inferiority Study|Completed||Phase 4|381|Actual|IBSA Institut Biochimique SA||2|||f||||f||||||||||2018-06-01 02:46:14.970687|2018-06-01 02:46:14.970687
NCT00556595|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Interventional|CPVA-PAF||Primary Anatomical Versus Primary Electrophysiological Approach in Circumferential Pulmonary Vein Ablation|Circumferential Pulmonary Vein Ablation in Paroxysmal Atrial Fibrillation: Randomized Comparison Between a Primary Anatomical Versus a Primary Electrophysiological Approach|Unknown status|Not yet recruiting|N/A|200|Anticipated|University Hospital, Bonn||2|||f||||f||||||||||2018-06-01 02:46:15.086116|2018-06-01 02:46:15.086116
NCT00556569|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2018-02-20|2007-11-09|2007-11-12|Estimate|||||||2018-02-20|2018-02-22|Actual|December 2007||2007-12-31|February 2018|2018-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of CHAM JAM Increasing Physical Activity Levels in Students|Evaluation of CHAM JAM (Previously Known as the Moving Smart) Intervention in Increasing Physical Activity in Bronx Elementary School Students|Completed||N/A|10098|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-06-01 02:46:15.15413|2018-06-01 02:46:15.15413
NCT00556543|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2011-03-17||2011-06-07|2007-11-09|2007-11-12|Estimate|2011-04-13|2011-05-10|Estimate||||2011-06-07|2011-07-01|Estimate|November 2006||2006-11-30|June 2011|2011-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Clinical Study of the U-Plate Fracture Repair System to Treat Rib Fractures|Clinical Evaluation of the U-plate Fracture Repair System for the Fixation of Rib Fractures|Completed||N/A|10|Actual|Oregon Health and Science University||1|||f||||t||||||||||2018-06-01 02:46:15.274123|2018-06-01 02:46:15.274123
NCT00556530|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2017-01-23|2007-11-08|2007-11-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome|Genetic Modifiers of 22q11.2 Deletion Syndrome|Active, not recruiting|||1000|Anticipated|Albert Einstein College of Medicine, Inc.|||||f||||f||||||Samples With DNA|"~     Blood and saliva samples~   "|||2018-06-01 02:46:15.616153|2018-06-01 02:46:15.616153
NCT00556517|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|January 2008||2008-01-31|September 2007|2007-09-30|March 2009|Anticipated|2009-03-31|||||Observational|||Acute Hamstring Strains in Danish Elite Soccer - Diagnosis and Biomechanical Tests|Acute Hamstring Strains in Danish Elite Soccer - Diagnosis and Biomechanical Tests|Unknown status|Enrolling by invitation||100|Anticipated|Amager Hospital|||||f||||f||||||||||2018-06-01 02:46:15.685577|2018-06-01 02:46:15.685577
NCT00556504|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2013-06-05||2014-08-04|2007-11-09|2007-11-12|Estimate|2014-06-05|2014-07-08|Estimate||||2014-08-04|2014-08-07|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|TCM-700C||The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection|TCM-700C Phase II Trial The Effects of Adding a Chinese Formulation (TCM-700C) on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection|Completed||Phase 2|84|Actual|TCM Biotech International Corp.||2|||f||||f||||||||||2018-06-01 02:46:15.779461|2018-06-01 02:46:15.779461
NCT00556491|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2015-01-11||2017-11-27|2007-11-09|2007-11-12|Estimate|2015-03-05|2015-03-09|Estimate||||2017-11-27|2017-12-22|Actual|December 2007||2007-12-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|July 2011|Actual|2011-07-31||Interventional|||Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery|Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery|Completed||N/A|40|Actual|St. Louis University||2|||f||||t||||||||||2018-06-01 02:46:16.341262|2018-06-01 02:46:16.341262
NCT00556478|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2016-09-07||2016-09-07|2007-11-09|2007-11-12|Estimate|2016-09-07|2016-09-26|Estimate||||2016-09-07|2016-09-26|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation|A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled Study, With Open-label Follow on, to Evaluate the Efficacy, Safety and Tolerability of PSD502 in Subjects With Premature Ejaculation (PE)|Completed||Phase 2/Phase 3|256|Actual|Plethora Solutions Ltd||3|||f||||f||||||||No||2018-06-01 02:46:17.056692|2018-06-01 02:46:17.056692
NCT00556465|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy|Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy|Completed||Phase 2/Phase 3|60|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:46:17.637347|2018-06-01 02:46:17.637347
NCT00556452|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2014-11-26||2017-10-30|2007-11-09|2007-11-12|Estimate|2015-01-02|2015-01-13|Estimate||||2017-10-30|2017-12-05|Actual|October 2007||2007-10-31|October 2017|2017-10-31|September 2012|Actual|2012-09-30|June 2011|Actual|2011-06-30||Interventional||Experimental: Clo/BU4|Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen|Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen|Completed||Phase 1/Phase 2|46|Actual|University of Michigan Cancer Center||1|||f||||f||||||||||2018-06-01 02:46:17.726233|2018-06-01 02:46:17.726233
NCT00556439|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2017-04-25||2018-01-25|2007-11-09|2007-11-12|Estimate|2018-01-25|2018-02-26|Actual||||2018-01-25|2018-02-26|Actual|December 2008||2008-12-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Reflects the population that reached Week 12 blinded randomization. In the giant cell arteritis cohort, 8 of 49 were withdrawn at or before Week 12 with a total of 41 remaining in the active comparator group. In the Takayasu arteritis cohort, 8 of 34 were withdrawn at or before Week 12 with a total of 26 remaining in the active comparator group.|Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis|Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu's Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis|Completed||Phase 2|97|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Small sample size, challenges in assessing disease activity in giant cell arteritis and Takayasu arteritis, 84.6% of patients with Takayasu arteritis were enrolled for the treatment of a disease relapse.|2|||f||||t||||||||||2018-06-01 02:46:18.150397|2018-06-01 02:46:18.150397
NCT00556426|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2009-05-26||2012-05-25|2007-11-08|2007-11-12|Estimate|2011-05-09|2011-05-11|Estimate||||2012-05-25|2012-06-01|Estimate|December 2005||2005-12-31|May 2012|2012-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|EVEREST||Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.|The Bard® Recovery® Filter Registry (EVEREST) for Patients Who Are Candidates for an Optional (Retrievable) Inferior Vena Cava Filter That Undergo Placement of the Bard® Recovery® Filter.|Completed||N/A|100|Actual|C. R. Bard||1|||f||||t||||||||||2018-06-01 02:46:19.865588|2018-06-01 02:46:19.865588
NCT00556413|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2011-05-13|2007-11-09|2007-11-12|Estimate|||||||2011-05-13|2011-05-16|Estimate|September 2005||2005-09-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Interventional|||Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Study Evaluating the Efficacy and Safety of cétuximab Associated With the Protocol FOLFIRINOX (LV5FU Simplified Combined With Irinotecan and Oxaliplatin) in the First Line Treatment in Patients With Metastatic Colorectal Cancer Expressing EGFR or Not|Completed||Phase 2|39|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:46:20.19168|2018-06-01 02:46:20.19168
NCT00556400|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2013-05-21||2013-07-11|2007-11-09|2007-11-12|Estimate|2013-05-21|2013-07-11|Estimate||||2013-07-11|2013-07-19|Estimate|November 2007||2007-11-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones|Treatment of Menorrhagia in Women With Thrombocytopenia: Comparison of Platelet Transfusion Alone to Platelet Transfusion With Continuous Oral Contraceptive Pills|Terminated||Phase 1/Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|Early termination because of insufficient accrual. With only one study participant, data could not be analyzed.|2||Early termination because of insufficient accrual.|f||||f||||||||||2018-06-01 02:46:20.26763|2018-06-01 02:46:20.26763
NCT00556387|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2013-10-31|2007-11-09|2007-11-12|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection|Possible Neuroprotective Effects of Ketamine in Children With Severe Traumatic Brain Injury|Withdrawn||Phase 2|0|Actual|University of Arkansas||2||"This study has been withdraw from the IRB. The PI has transferred to another university. The~   IND was transferred."|f||||f||||||||||2018-06-01 02:46:20.616472|2018-06-01 02:46:20.616472
NCT00556374|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2015-10-06|2015-09-29|2017-11-24|2007-11-08|2007-11-12|Estimate|2015-10-06|2015-11-06|Estimate|2015-09-29|2015-10-07|Estimate|2017-11-24|2017-11-30|Actual|December 18, 2006|Actual|2006-12-18|November 2017|2017-11-30|July 8, 2020|Anticipated|2020-07-08|March 26, 2014|Actual|2014-03-26||Interventional|||Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy|A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy.|Active, not recruiting||Phase 3|3420|Actual|Amgen||2|||f||||t||||||||||2018-06-01 02:46:20.820741|2018-06-01 02:46:20.820741
NCT00556361|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2007-11-09|2007-11-09|2007-11-12|Estimate|||||||2007-11-09|2007-11-12|Estimate|July 2004||2004-07-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Use of Ketamine Prior to Cardiopulmonary Bypass in Children|Use of Ketamine Prior to Cardiopulmonary Bypass in Children|Completed||Phase 2|24|Actual|Arkansas Children's Hospital Research Institute||2|||f||||||||||||||2018-06-01 02:46:23.975313|2018-06-01 02:46:23.975313
NCT00556348|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2011-11-19|2007-11-09|2007-11-12|Estimate|||||||2011-11-19|2011-11-22|Estimate|November 2005||2005-11-30|November 2011|2011-11-30|November 2008|Actual|2008-11-30|October 2007|Actual|2007-10-31||Interventional|||Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration|Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration|Completed||Phase 4|500|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-06-01 02:46:24.061684|2018-06-01 02:46:24.061684
NCT00556335|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|||2013-04-05|2007-11-09|2007-11-12|Estimate|||||||2013-04-05|2013-04-08|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|pneumothorax||Pneumothorax Therapy: Manual Aspiration Versus Conventional Chest Tube Drainage|A Prospective, Randomised Trial in Pneumothorax Therapy: Manual Aspiration Versus Conventional Chest Tube Drainage|Completed||N/A|56|Actual|Isala||2|||f||||t||||||||||2018-06-01 02:46:24.13596|2018-06-01 02:46:24.13596
NCT00556322|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-09|2014-12-03||2015-02-04|2007-11-09|2007-11-12|Estimate|2015-02-04|2015-02-23|Estimate||||2015-02-04|2015-02-23|Estimate|March 2006||2006-03-31|February 2015|2015-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Full Analysis Set (FAS): All participants randomized were included according to the therapy that they were randomized to receive in the FAS population.|A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Randomized Study to Evaluate the Effect of Tarceva, Compared With Alimta (Pemetrexed) or Taxotere (Docetaxel),on Survival in Patients With Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer Who Have Experienced Disease Progression During Platinum-based Chemotherapy|Completed||Phase 3|424|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:46:24.284446|2018-06-01 02:46:24.284446
NCT00556296|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2011-06-20|2007-11-07|2007-11-09|Estimate|||||||2011-06-20|2011-06-21|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|September 2005|Actual|2005-09-30|||||Interventional|||Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD|A Phase 3, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder|Completed||Phase 3|297|Actual|New River Pharmaceuticals||4|||f||||||||||||||2018-06-01 02:46:25.448172|2018-06-01 02:46:25.448172
NCT00556283|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2013-12-17|2007-11-08|2007-11-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2004||2004-02-29|December 2013|2013-12-31|May 2007|Actual|2007-05-31|||||Interventional|ODS II||RCT: STARR vs Biofeedback|Outcomes of Stapled Trans-Anal Rectal Resection (STARR) vs. Biofeedback in the Treatment of Outlet Obstruction Associated With Rectal Intussusception and Rectocele: A Multi-center Randomized Controlled Trial|Completed||Phase 4|121|Actual|Ethicon Endo-Surgery (Europe) GmbH||2|||f||||t||||||||||2018-06-01 02:46:25.551507|2018-06-01 02:46:25.551507
NCT00556270|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2012-05-04|2007-11-08|2007-11-09|Estimate|||||||2012-05-04|2012-05-07|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|May 2008|Actual|2008-05-31|||||Observational|MATRIX II||Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain|Matrifen for Therapy of Severe, Chronic Pain.|Completed|||3000|Anticipated|Nycomed|||1||f||||f||||||||||2018-06-01 02:46:25.820278|2018-06-01 02:46:25.820278
NCT00556257|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2008-05-27|2007-11-08|2007-11-09|Estimate|||||||2008-05-27|2008-05-30|Estimate|August 2007||2007-08-31|May 2008|2008-05-31||||||||Interventional|||Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients|A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients|Withdrawn||Phase 2|0|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:46:27.160106|2018-06-01 02:46:27.160106
NCT00556244|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2007-11-08|2007-11-08|2007-11-09|Estimate|||||||2007-11-08|2007-11-09|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|November 2007|Anticipated|2007-11-30|||||Interventional|||Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling|Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 02:46:27.228216|2018-06-01 02:46:27.228216
NCT00556231|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2013-01-02|2007-11-07|2007-11-09|Estimate|||||||2013-01-02|2013-01-04|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Multi-site Near Infrared Spectroscopy (NIRS) Monitoring of Children During Exercise|Use of Multi-site Near Infrared Spectroscopy (NIRS) Monitoring for Global Hemodynamic Assessment During Exercise Testing in Children With and Without Heart Disease|Completed|||51|Actual|Medical College of Wisconsin|||6||f||||f||||||||||2018-06-01 02:46:27.293653|2018-06-01 02:46:27.293653
NCT00556218|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2017-08-04|2007-11-07|2007-11-09|Estimate|||||||2017-08-04|2017-08-08|Actual|October 2007|Actual|2007-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Meditation and Cognitive Function in Women With Breast Cancer|Feasibility Study of Meditation, Cognitive Function, and Quality of Life in Women With Breast Cancer|Active, not recruiting||N/A|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 02:46:27.367726|2018-06-01 02:46:27.367726
NCT00556205|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2016-03-23|2007-11-07|2007-11-09|Estimate|||||||2016-03-23|2016-03-24|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma|Phase II, Randomized Trial of Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||2||Toxicity of combination from other trials|f||||f||||||||No|No data to share|2018-06-01 02:46:27.539417|2018-06-01 02:46:27.539417
NCT00556192|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2012-02-10|2007-11-08|2007-11-09|Estimate|||||||2012-02-10|2012-02-13|Estimate|June 2006||2006-06-30|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus|Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy Restore Peripheral B Cell Abnormalities in Systemic Lupus Erythematosus(SLE)?|Completed||Phase 2|20|Anticipated|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 02:46:27.614208|2018-06-01 02:46:27.614208
NCT00556179|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2009-01-21|2007-11-08|2007-11-09|Estimate|||||||2009-01-21|2009-01-22|Estimate|September 2007||2007-09-30|January 2009|2009-01-31||||December 2008|Actual|2008-12-31||Interventional|||Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis|Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole.|Completed||Phase 4|122|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:46:27.699262|2018-06-01 02:46:27.699262
NCT00556166|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2016-04-18||2016-06-22|2007-11-08|2007-11-09|Estimate|2016-06-22|2016-08-02|Estimate||||2016-06-22|2016-08-02|Estimate|October 2004||2004-10-31|June 2016|2016-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Enterra||Enterra Therapy Gastric Stimulation System|Enterra Therapy Gastric Stimulation System|Terminated||Phase 4|4|Actual|Columbia University||1||Principal investigator left institution.|f||||f||||||||No|No data available to share as the PI left the institution before the study could finish.|2018-06-01 02:46:27.768511|2018-06-01 02:46:27.768511
NCT00556153|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2013-01-07|2007-11-08|2007-11-09|Estimate|||||||2013-01-07|2013-01-08|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|February 2013|Anticipated|2013-02-28|||||Observational|||[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children|[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children|Withdrawn|||0|Actual|Children's Hospital Medical Center, Cincinnati|||1|No participants ever enrolled.|f||||f||||||||||2018-06-01 02:46:27.908873|2018-06-01 02:46:27.908873
NCT00556140|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2012-06-01||2012-07-11|2007-11-08|2007-11-09|Estimate|2012-07-11|2012-08-20|Estimate||||2012-07-11|2012-08-20|Estimate|June 2003||2003-06-30|July 2012|2012-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|Abilify||The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression|The Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in the Acute Treatment of Psychotic Major Depression: Efficacy and Tolerability|Completed||Phase 3|16|Actual|Massachusetts General Hospital|We had several limitations to the study. The sample size was small, and we used an open and uncontrolled study design. We also excluded subjects who currently or recently abused alcohol, recreational drugs, and/or prescription drugs.|1|||f||||f||||||||||2018-06-01 02:46:27.972372|2018-06-01 02:46:27.972372
NCT00554723|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2014-04-30|2007-11-05|2007-11-07|Estimate|||||||2014-04-30|2014-05-01|Estimate|May 2007||2007-05-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|CHIMES||CHInese Medicine NeuroAid Efficacy on Stroke Recovery|A Double Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine NeuroAid Efficacy on Stroke Recovery|Completed||Phase 3|1100|Actual|CHIMES Society||2|||f||||t||||||||||2018-06-01 02:46:59.462309|2018-06-01 02:46:59.462309
NCT00556127|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2007-11-08|2007-11-08|2007-11-09|Estimate|||||||2007-11-08|2007-11-09|Estimate|June 2002||2002-06-30|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|DLBCL||Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma|Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive|Completed||Phase 2|94|Actual|Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie||1|||f||||f||||||||||2018-06-01 02:46:28.189844|2018-06-01 02:46:28.189844
NCT00556114|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2017-02-08|2007-11-07|2007-11-09|Estimate|||||||2017-02-08|2017-02-10|Actual|January 2007||2007-01-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging|A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging|Completed|||23|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:46:28.324489|2018-06-01 02:46:28.324489
NCT00556101|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2009-08-18|2007-11-08|2007-11-09|Estimate|||||||2009-08-18|2009-08-19|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|||||Observational|||Patient Acceptance of Whole Body Magnetic Resonance Angiography|Whole Body Magnetic Resonance Angiography: Questionnaire Examination of Patient Acceptance.|Completed|||81|Anticipated|Copenhagen University Hospital at Herlev|||||f||||t||||||||||2018-06-01 02:46:28.412611|2018-06-01 02:46:28.412611
NCT00556088|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2010-12-29|2007-11-08|2007-11-09|Estimate|||||||2010-12-29|2010-12-30|Estimate|December 2007||2007-12-31|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors|A Phase I Study of LBH589 in Combination With Paclitaxel and Carboplatin +/- Bevacizumab the Treatment of Solid Tumors|Completed||Phase 1|40|Anticipated|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:46:28.472545|2018-06-01 02:46:28.472545
NCT00556075|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2014-06-24||2014-08-08|2007-11-08|2007-11-09|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-08|2014-08-25|Estimate|November 2007||2007-11-30|August 2014|2014-08-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional||Safety population|Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis|A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis|Terminated||Phase 2|67|Actual|Repros Therapeutics Inc.|The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with complete study data.|3||Clinical hold for safety|f||||t||||||||||2018-06-01 02:46:28.57475|2018-06-01 02:46:28.57475
NCT00556062|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2007-11-08|2007-11-08|2007-11-09|Estimate|||||||2007-11-08|2007-11-09|Estimate|September 2007||2007-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Phase IV Clinical Trial of an Influenza Split Vaccine Anflu|The Clinical Trial for Three Consecutive Lots of Influenza Split Vaccine Anflu by Randomized, Double-Blind and Controlled Design|Completed||Phase 4|566|Actual|Sinovac Biotech Co., Ltd||4|||f||||||||||||||2018-06-01 02:46:29.003329|2018-06-01 02:46:29.003329
NCT00556049|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2015-03-24||2016-03-23|2007-11-07|2007-11-09|Estimate|2015-03-24|2015-04-03|Estimate||||2016-03-23|2016-04-21|Estimate|December 2007||2007-12-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma|Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|72|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-06-01 02:46:29.067688|2018-06-01 02:46:29.067688
NCT00556036|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2011-12-15|2007-11-07|2007-11-09|Estimate|||||||2011-12-15|2011-12-19|Estimate|March 2006||2006-03-31|December 2011|2011-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Hormone Dynamics and Bone Mineral Density in Anorexia Nervosa v. Hypothalamic Amenorrhea|Hormone Dynamics and Bone Mineral Density in Anorexia Nervosa v. Hypothalamic Amenorrhea|Completed|||61|Actual|Massachusetts General Hospital|||4||f||||t||||||Samples Without DNA|"~     whole blood, serum, urine, saliva, optional DNA substudy.~   "|||2018-06-01 02:46:29.21487|2018-06-01 02:46:29.21487
NCT00556023|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2012-06-05|2007-11-08|2007-11-09|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2008||2008-06-30|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer|A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer|Completed||Phase 1|37|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:46:29.283794|2018-06-01 02:46:29.283794
NCT00556010|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2012-07-19|2007-11-08|2007-11-09|Estimate|||||||2012-07-19|2012-07-20|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Intraoperative Three Dimensional Fluoroscopy Compared to Standard Fluoroscopy for the Assessment of Reduction of Ankle Fractures With Syndesmosis Disruption|Intraoperative Three Dimensional Fluoroscopy Compared to Standard Fluoroscopy for the Assessment of Reduction of Ankle Fractures With Syndesmosis Disruption|Completed|||40|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:46:29.353236|2018-06-01 02:46:29.353236
NCT00555997|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2013-07-09||2014-06-23|2007-11-07|2007-11-09|Estimate|2014-06-23|2014-07-03|Estimate||||2014-06-23|2014-07-03|Estimate|March 2008||2008-03-31|June 2014|2014-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|Geodon||A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder|Completed||Phase 2|120|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-06-01 02:46:29.416001|2018-06-01 02:46:29.416001
NCT00555984|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2017-04-19|2007-11-07|2007-11-09|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2007|Actual|2007-09-30|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|TIVA||Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors|Effect of Total Intravenous Anesthesia Versus Anesthesia With Volatile Agents on Inflammatory Markers Following Elective Craniotomy for Primary Brain Tumor|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||PI decision to terminate. No usable data collected|f||||t||||||||No|Study terminated early|2018-06-01 02:46:29.729597|2018-06-01 02:46:29.729597
NCT00555971|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2016-02-29|2007-11-08|2007-11-09|Estimate|||||||2016-02-29|2016-03-02|Estimate|May 2006||2006-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization|A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization|Completed||Phase 4|16|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-06-01 02:46:29.800303|2018-06-01 02:46:29.800303
NCT00555945|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2011-06-24|2007-11-07|2007-11-09|Estimate|||||||2011-06-24|2011-06-27|Estimate|May 2007||2007-05-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|REGAIN||Re-Evaluation of GAmma3 Intramedullary Nails in Hip Fracture (REGAIN)|Re-Evaluation of GAmma3 Intramedullary Nails in Hip Fracture: A Multi-Centre Randomized Controlled Trial of Gamma3 Intramedullary Nails Versus Sliding Hip Screws in the Management of Intertrochanteric Fractures of the Hip|Completed||N/A|90|Actual|Stryker Trauma GmbH||2|||f||||f||||||||||2018-06-01 02:46:30.09311|2018-06-01 02:46:30.09311
NCT00555932|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2015-05-19|2007-11-08|2007-11-09|Estimate|||||||2015-05-19|2015-05-20|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Modern Ultrasound Techniques in the Evaluation of Cerebral Venous Sinuses in Neonates|Utility of Modern Ultrasound Techniques in the Evaluation of Cerebral Venous Sinuses in Neonates|Completed||N/A|58|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 02:46:30.185188|2018-06-01 02:46:30.185188
NCT00555919|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2014-10-09|2007-11-08|2007-11-09|Estimate|||||||2014-10-09|2014-10-10|Estimate|March 2008||2008-03-31|October 2014|2014-10-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer|Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer|Completed||Phase 2|68|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:46:30.271841|2018-06-01 02:46:30.271841
NCT00555906|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2015-03-04|2013-09-12|2015-03-04|2007-11-08|2007-11-09|Estimate|2015-03-04|2015-03-19|Estimate|2013-09-12|2013-09-18|Estimate|2015-03-04|2015-03-19|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional||Full analysis set (FAS) included all enrolled participants.|An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.|Phase 1/2 Open-label Study Of The Safety And Efficacy Of Pd 0332991 In Combination With Bortezomib And Dexamethasone In Patients With Refractory Multiple Myeloma|Completed||Phase 2|53|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:46:30.520442|2018-06-01 02:46:30.520442
NCT00555893|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2015-01-07|2012-11-27|2015-01-13|2007-11-07|2007-11-09|Estimate|2015-01-07|2015-01-14|Estimate|2012-11-27|2012-12-06|Estimate|2015-01-13|2015-01-26|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza|Monitoring Influenza Severity on Tamiflu (MIST)|Completed||N/A|194|Actual|Marshfield Clinic Research Foundation||2|||f||||f||||||||||2018-06-01 02:46:32.664339|2018-06-01 02:46:32.664339
NCT00555880|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2015-04-13||2015-05-05|2007-11-08|2007-11-09|Estimate|2015-05-05|2015-05-21|Estimate||||2015-05-05|2015-05-21|Estimate|September 2004||2004-09-30|June 2010|2010-06-30|March 2005|Actual|2005-03-31|||||Interventional||The Safety and Full Analysis Set (FAS) populations, defined as all participants who received at least one dose of investigational product (Safety) and all participants who were randomized, received at least one dose of investigational product, and had at least one measurement of the time to near syncope during a tilt table test (FAS).|Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension|A Multi-Center, Double-Blind, Randomized, Placebo-controlled, Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Subjects With Moderate to Severe Neurogenic Orthostatic Hypotension|Completed||Phase 4|24|Actual|Shire||2|||f||||||||||||||2018-06-01 02:46:32.911636|2018-06-01 02:46:32.911636
NCT00555867|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2011-12-22|2007-11-07|2007-11-09|Estimate|||||||2011-12-22|2011-12-23|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|PACT||Patient's Anastrozole Compliance to Therapy Programme|A Randomised in Practice Evaluation of the Influence of Patient's Understanding of Her Disease and Therapy on Persistence and Compliance to Adjuvant Therapy for Post-menopausal Hormone Sensitive Early Breast Cancer|Terminated|||4923|Actual|AstraZeneca|||2|"High drop-out rate leads to the conclusion: not enough data will be available to perform proper~   analyses of data collected after follow-up month 24 visit"|f||||f||||||||||2018-06-01 02:46:33.686031|2018-06-01 02:46:33.686031
NCT00555854|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2011-02-23|2007-11-08|2007-11-09|Estimate|||||||2011-02-23|2011-02-24|Estimate|December 2005||2005-12-31|May 2008|2008-05-31|November 2010|Actual|2010-11-30|||||Interventional|||Self-care Behaviour Treatment in Patients With Diabetes - a Randomised Controlled Trial|Can a Behavioural Modifying Intervention Increase the Self-care and the Effect of the Diabetes Treatment in Chronically Ill Patients With Diabetes|Completed||N/A|349|Actual|Odense University Hospital|||||f||||f||||||||||2018-06-01 02:46:33.760171|2018-06-01 02:46:33.760171
NCT00555841|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2012-08-27|2007-11-08|2007-11-09|Estimate|||||||2012-08-27|2012-08-28|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue|Safety and Efficacy of Oral Acetyl-l-carnitine (ALC) in Non-anemic Potentially Curable Breast Cancer Subjects Undergoing Adjuvant Radiation Therapy Who Have Moderate to Severe Fatigue|Terminated||Phase 2|27|Actual|Sigma-Tau Research, Inc.||2||Sponsor decision|f||||t||||||||||2018-06-01 02:46:33.821782|2018-06-01 02:46:33.821782
NCT00555828|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2010-02-16|2007-11-08|2007-11-09|Estimate|||||||2010-02-16|2010-02-17|Estimate|March 2008||2008-03-31|June 2009|2009-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction|A Phase 1b/2a Dose Escalation Study to Assess the Safety and Feasibility of Transendocardial Delivery of 3 Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|Angioblast Systems||6|||f||||t||||||||||2018-06-01 02:46:33.907136|2018-06-01 02:46:33.907136
NCT00555815|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2007-11-08|2007-11-08|2007-11-09|Estimate|||||||2007-11-08|2007-11-09|Estimate|July 2005||2005-07-31|November 2007|2007-11-30|January 2007|Actual|2007-01-31|||||Observational|||Intraoperative Hygiene Measures and Surgical Site Infections|Intraoperative Hygiene Measures and Rates of Surgical Wound Infection in General Surgery|Completed|||1032|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 02:46:33.982068|2018-06-01 02:46:33.982068
NCT00555802|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2008-01-25|2007-11-08|2007-11-09|Estimate|||||||2008-01-25|2008-01-29|Estimate|April 2006||2006-04-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||The Effect of Motor Control Exercise Versus General Exercise on Lumbar Local Stabilizing Muscles Thickness|The Effect of Motor Control Exercise Versus General Exercise on Lumbar Local Stabilizing Muscles Thickness|Completed||N/A|49|Actual|Zahedan University of Medical Sciences|||||f||||f||||||||||2018-06-01 02:46:34.034392|2018-06-01 02:46:34.034392
NCT00554710|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2007-11-06|2007-11-06|2007-11-07|Estimate|||||||2007-11-06|2007-11-07|Estimate|May 2001||2001-05-31|November 2007|2007-11-30|January 2004|Actual|2004-01-31|||||Interventional|||Top Down Versus Step Up Strategies in Crohn's Disease|The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux|Completed||Phase 4|129|Actual|Belgian IBD Research Group||2|||f||||f||||||||||2018-06-01 02:46:59.633523|2018-06-01 02:46:59.633523
NCT00555789|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08||2012-07-09|2012-07-31|2007-11-08|2007-11-09|Estimate||||2012-07-31|2012-08-07|Estimate|2012-07-31|2012-08-07|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients|A 24 Month Extension to a 12-month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients|Terminated||Phase 2|137|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:46:34.110223|2018-06-01 02:46:34.110223
NCT00555776|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2009-01-05|2007-11-08|2007-11-09|Estimate|||||||2009-01-05|2009-01-06|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|October 2008|Anticipated|2008-10-31|April 2008|Anticipated|2008-04-30||Interventional|||Effect of Gabapentin on Idiopathic Subjective Tinnitus|Phase 2 Effect of Gabapentin on Idiopathic Subjective Tinnitus|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|Islamic Azad University of Mashhad||2|||f||||t||||||||||2018-06-01 02:46:34.232027|2018-06-01 02:46:34.232027
NCT00555763|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2011-07-13|2007-11-08|2007-11-09|Estimate|||||||2011-07-13|2011-07-14|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Assessment of a New Goldmann Applanation Tonometer|Assessment of a New Goldmann Applanation Tonometer|Completed||Phase 3|157|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 02:46:34.308842|2018-06-01 02:46:34.308842
NCT00555750|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2013-05-21||2013-11-15|2007-11-08|2007-11-09|Estimate|2013-07-21|2013-09-25|Estimate||||2013-11-15|2013-12-10|Estimate|March 2006||2006-03-31|November 2013|2013-11-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Sleep Loss and Mechanisms of Impaired Glucose Metabolism|The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia|Completed||N/A|20|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:46:34.395375|2018-06-01 02:46:34.395375
NCT00555737|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2009-03-25|2007-11-08|2007-11-09|Estimate|||||||2009-03-25|2009-03-26|Estimate|November 2003||2003-11-30|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Observational|||Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)|Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy|Completed|||102|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-06-01 02:46:34.784394|2018-06-01 02:46:34.784394
NCT00555724|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2017-01-05|2007-11-08|2007-11-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|July 2010|Actual|2010-07-31|April 2010|Actual|2010-04-30||Interventional|||Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors|A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors|Completed||Phase 1|40|Actual|Biogen||1|||f||||||||||||||2018-06-01 02:46:34.848641|2018-06-01 02:46:34.848641
NCT00555711|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2017-02-08|2007-11-07|2007-11-09|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2008||2008-11-30|February 2017|2017-02-28|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|MI||Monitoring Neural Tissues Properties by Modulated Imaging (MI)|Monitoring Neural Tissues Properties by Modulated Imaging (MI)|Withdrawn|||0|Actual|University of California, Irvine|||1|no subject|f||||f||||||||||2018-06-01 02:46:34.919106|2018-06-01 02:46:34.919106
NCT00555698|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2017-03-24|2007-11-08|2007-11-09|Estimate|||||||2017-03-24|2017-03-28|Actual|January 2004||2004-01-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression|Feasibility, Safety and Efficacy of Deep Brain Stimulation of the Internal Capsule for Severe and Medically Refractory Major Depression|Completed||Early Phase 1|8|Actual|Ohio State University||1|||f||||t||||||||No||2018-06-01 02:46:35.093507|2018-06-01 02:46:35.093507
NCT00555685|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|||2014-06-06|2007-11-08|2007-11-09|Estimate|||||||2014-06-06|2014-06-10|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Hypertonic Saline Solution in Heart Failure|Hypertonic Saline Solution in Decompensated Heart Failure|Completed||Phase 2|34|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 02:46:35.167397|2018-06-01 02:46:35.167397
NCT00555672|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-08|2010-12-15||2011-12-12|2007-11-08|2007-11-09|Estimate|2010-12-15|2011-01-05|Estimate||||2011-12-12|2011-12-19|Estimate|August 2008||2008-08-31|December 2011|2011-12-31|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional|||Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer|A Phase I Study Of Sunitinib Malate In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer|Completed||Phase 1|34|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:46:35.26773|2018-06-01 02:46:35.26773
NCT00555659|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2013-08-08|2007-11-07|2007-11-09|Estimate|||||||2013-08-08|2013-08-12|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|Aegis||Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody Fusions|Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody|Completed|||104|Actual|Columbia Orthopaedic Group, LLP|||||f||||t||||||||||2018-06-01 02:46:35.769131|2018-06-01 02:46:35.769131
NCT00555646|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2009-07-07|2007-11-07|2007-11-09|Estimate|||||||2009-07-07|2009-07-09|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|July 2009|Anticipated|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis|A Phase 2 Study of Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for the Treatment of Plaque Psoriasis|Terminated||Phase 2|25|Anticipated|Provectus Pharmaceuticals||1||Change of dose regimen (new protocol)|f||||f||||||||||2018-06-01 02:46:35.825012|2018-06-01 02:46:35.825012
NCT00555633|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2009-09-29|2007-11-07|2007-11-08|Estimate|||||||2009-09-29|2009-09-30|Estimate|October 2004||2004-10-31|September 2009|2009-09-30|February 2006|Actual|2006-02-28|||||Observational|||Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients|Regular Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients, Particularly in Xeroderma Pigmentosum and Basal Cell Nevus Syndrome|Completed|||13|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 02:46:35.882656|2018-06-01 02:46:35.882656
NCT00555620|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2011-08-04||2013-01-07|2007-11-06|2007-11-08|Estimate|2011-08-04|2011-09-05|Estimate||||2013-01-07|2013-01-14|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|August 2010|Actual|2010-08-31||Interventional|||Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer|A Phase 1 Study Of Sunitinib Malate In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer|Completed||Phase 1|76|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:46:35.984614|2018-06-01 02:46:35.984614
NCT00548106|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2012-06-13|2007-10-22|2007-10-23|Estimate|||||||2012-06-13|2012-06-14|Estimate||||July 2010|2010-07-31||||||||Interventional|||Safety Study of Infant Formula With Partially Hydrolized Whey|Evaluation of a New Cow's Milk Infant Formula Containing Partially Hydrolized Whey|Withdrawn||N/A|0|Actual|Soroka University Medical Center||2||Study withdrawn due to the company decision|f||||t||||||||||2018-06-01 02:49:30.016119|2018-06-01 02:49:30.016119
NCT00555607|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2018-03-19|2007-11-07|2007-11-08|Estimate|||||||2018-03-19|2018-03-20|Actual|March 2002||2002-03-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|April 2005|Actual|2005-04-30||Interventional|BIOAIR||Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease|Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease|Active, not recruiting||N/A|233|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 02:46:39.297334|2018-06-01 02:46:39.297334
NCT00555594|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2007-11-07|2007-11-07|2007-11-08|Estimate|||||||2007-11-07|2007-11-08|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization|Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization|Completed||Phase 2/Phase 3|18|Actual|Asociación para Evitar la Ceguera en México||2|||f||||t||||||||||2018-06-01 02:46:39.402618|2018-06-01 02:46:39.402618
NCT00555581|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2017-06-12||2018-01-09|2007-11-07|2007-11-08|Estimate|2018-01-09|2018-02-06|Actual||||2018-01-09|2018-02-06|Actual|August 2007||2007-08-31|January 2018|2018-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis|Phase IIA Study of the Safety and Tolerability of the Use of Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis|Completed||Phase 2|30|Actual|Hospital for Special Surgery, New York||1|||f||||t||||||||||2018-06-01 02:46:39.49778|2018-06-01 02:46:39.49778
NCT00555568|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2015-02-20||2015-06-22|2007-11-07|2007-11-08|Estimate|2015-06-22|2015-06-23|Estimate||||2015-06-22|2015-06-23|Estimate|January 2007||2007-01-31|June 2015|2015-06-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|Peer Support|veterans treated for a mental health condition at one of 2 VA medical centers|Mechanisms of Action and Outcome|Mechanisms of Action and Outcome in Peer Support Groups|Completed||N/A|298|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 02:46:39.878974|2018-06-01 02:46:39.878974
NCT00555555|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2018-03-08|2007-11-07|2007-11-08|Estimate|||||||2018-03-08|2018-03-12|Actual|September 2007|Actual|2007-09-30|March 2018|2018-03-31|March 2029|Anticipated|2029-03-31|December 2028|Anticipated|2028-12-31||Interventional|||Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients|A Post-marketing Observation Study to Assess the Efficacy and Safety of the FVIII/VWF Complex (Human,) Alphanate(R), in Preventing Excessive Bleeding During Surgery in Subjects With Congenital Type 3 Von Willebrand Disease|Active, not recruiting||Phase 4|15|Anticipated|Grifols Biologicals Inc.||1|||f||||t||||||||No||2018-06-01 02:46:40.315555|2018-06-01 02:46:40.315555
NCT00555542|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2008-05-07|2007-11-07|2007-11-08|Estimate|||||||2008-05-07|2008-05-09|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis|B Cell Depletion Therapy in Rheumatoid Arthritis: An Analysis of Peripheral Blood T Cell Subsets|Completed||Phase 2|10|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-06-01 02:46:40.383996|2018-06-01 02:46:40.383996
NCT00555529|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2007-11-07|2007-11-07|2007-11-08|Estimate|||||||2007-11-07|2007-11-08|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|November 2008|Anticipated|2008-11-30|||||Observational|||Systemic Endothelial Abnormalities in COPD|Systemic Endothelial Abnormalities in COPD Measured by Radial Artery Applanation Tonometry (RAAP)|Unknown status|Active, not recruiting||36|Anticipated|Imperial College London|||2||f||||||||||||||2018-06-01 02:46:40.466465|2018-06-01 02:46:40.466465
NCT00555516|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2007-11-07|2007-11-07|2007-11-08|Estimate|||||||2007-11-07|2007-11-08|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|June 2009|Anticipated|2009-06-30|||||Interventional|||A Pilot Study to Evaluate the Safety and Activities of EW02 in Reducing Neutropenia Caused by Chemotherapy|A Phase I/II Double-Blind, Randomized, Placebo-Control Pilot Study to Evaluate the Safety and Pharmacodynamic Activities of EW02 in Reducing Neutropenia Caused by Breast Cancer Chemotherapy|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Tri-Service General Hospital||2|||f||||t||||||||||2018-06-01 02:46:40.529412|2018-06-01 02:46:40.529412
NCT00555503|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2016-12-01|2007-11-07|2007-11-08|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||Registry of Mastectomy for Breast Cancer Risk Reduction|Registry of Mastectomy for Breast Cancer Risk Reduction|Completed|||261|Actual|Georgetown University|||1||f||||f||||||Samples With DNA|"~     Patient operative specimens, blood samples, and saliva samples.~   "|||2018-06-01 02:46:40.614484|2018-06-01 02:46:40.614484
NCT00555490|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2007-11-07|2007-11-07|2007-11-08|Estimate|||||||2007-11-07|2007-11-08|Estimate|April 2001||2001-04-30|November 2007|2007-11-30|September 2005|Actual|2005-09-30|||||Interventional|||Long-Term Effect of Soy Consumption on Cardio-Renal Indices and CRP in Type 2diabetes With Nephropathy|Soy-Protein Intake, Cardio-Renal Indices and C-Reactive Protein in Type 2 Diabetes With Nephropathy: a 4-y Randomized Clincal Trial|Completed||Phase 1|41|Actual|Isfahan University of Medical Sciences||1|||f||||||||||||||2018-06-01 02:46:40.676028|2018-06-01 02:46:40.676028
NCT00555477|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2014-04-16||2014-05-19|2007-11-07|2007-11-08|Estimate|2014-05-19|2014-06-19|Estimate||||2014-05-19|2014-06-19|Estimate|August 2007||2007-08-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|December 2011|Actual|2011-12-31||Interventional||Initiated treatment with Anastrozole, 1 mg orally daily.|Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure|Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure|Terminated||Phase 2|69|Actual|University of Michigan Cancer Center|Because of poor accrual, the trial was closed after 69 of a planned 150 patients were enrolled.|1||The study was stopped after 69 subjects were enrolled because of poor accrual.|f||||t||||||||||2018-06-01 02:46:40.763327|2018-06-01 02:46:40.763327
NCT00555464|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2013-02-19||2013-06-04|2007-11-07|2007-11-08|Estimate|2013-06-04|2013-06-11|Estimate||||2013-06-04|2013-06-11|Estimate|November 2007||2007-11-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas|A Phase II, Randomized, Clinical Trial Assessing Efficacy And Safety Of Oral Prednisolone vs Intravenous Vincristine In The Treatment Of Infantile|Terminated||Phase 2|8|Actual|Medical College of Wisconsin|The limitations of this trial include early termination of enrollment leading to small numbers of subjects analyzed.|2||The introduction of oral propranolol as a highly efficacious agent for infantile hemangiomas|f||||t||||||||||2018-06-01 02:46:41.007935|2018-06-01 02:46:41.007935
NCT00555451|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2010-05-11|2007-11-06|2007-11-08|Estimate|||||||2010-05-11|2010-05-13|Estimate|October 2007||2007-10-31|May 2010|2010-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects|A Phase I, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3286 When Administered Orally to Obese Adult Subjects for 28 Days|Completed||Phase 1|66|Anticipated|Harbor Therapeutics|||||f||||f||||||||||2018-06-01 02:46:41.29222|2018-06-01 02:46:41.29222
NCT00555438|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2010-09-15||2011-07-22|2007-11-07|2007-11-08|Estimate|2010-10-21|2010-11-17|Estimate||||2011-07-22|2011-08-17|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|PROPICE||Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.|Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux,in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. PROPICE Study|Completed||Phase 4|451|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 02:46:41.441694|2018-06-01 02:46:41.441694
NCT00555425|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2016-01-25||2017-01-23|2007-11-06|2007-11-08|Estimate|2016-11-29|2017-01-24|Estimate||||2017-01-23|2017-03-07|Actual|July 2008||2008-07-31|January 2017|2017-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence|Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence|Completed||Phase 4|113|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:46:41.767728|2018-06-01 02:46:41.767728
NCT00555412|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2017-03-13|2007-11-06|2007-11-08|Estimate|||||||2017-03-13|2017-03-15|Actual|October 2007||2007-10-31|June 2013|2013-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Staccato Loxapine Multidose PK|Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Staccato® Loxapine for Inhalation in Subjects on Chronic, Stable Antipsychotic Regimens|Completed||Phase 1|40|Actual|Alexza Pharmaceuticals, Inc.||4|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 02:46:42.105848|2018-06-01 02:46:42.105848
NCT00555399|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2017-09-28|2007-11-06|2007-11-08|Estimate|||||||2017-09-28|2017-10-02|Actual|November 2007|Actual|2007-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)|Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme|Active, not recruiting||Phase 1/Phase 2|135|Anticipated|M.D. Anderson Cancer Center||5|||f||||t|t|f||||||||2018-06-01 02:46:42.193154|2018-06-01 02:46:42.193154
NCT00555386|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2008-09-24|2007-11-07|2007-11-08|Estimate|||||||2008-09-24|2008-09-25|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Soy, Selenium and Breast Cancer Risk|A Pilot Study to Determine the Effect of Dietary Intervention on Novel Biomarkers of Breast Cancer Risk.|Completed||N/A|27|Actual|University of East Anglia||2|||f||||||||||||||2018-06-01 02:46:42.312461|2018-06-01 02:46:42.312461
NCT00555373|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2013-02-22|2007-11-06|2007-11-08|Estimate|||||||2013-02-22|2013-02-26|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CNI-W||Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression|Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression|Completed||N/A|52|Actual|Pediatric Nephrology of Alabama||1|||f||||t||||||||||2018-06-01 02:46:42.410263|2018-06-01 02:46:42.410263
NCT00555360|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2015-01-15||2015-08-12|2007-11-07|2007-11-08|Estimate|2015-08-12|2015-09-15|Estimate||||2015-08-12|2015-09-15|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|January 2013|Actual|2013-01-31||Interventional|||Enhancing Caregiver Support for Heart Failure Patients: the CarePartner Study|Enhancing Caregiver Support for Patients With Heart Failure|Completed||N/A|372|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:46:42.507194|2018-06-01 02:46:42.507194
NCT00555347|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2015-05-26|2007-11-07|2007-11-08|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Use of Armodafinil for Fatigue in Sarcoidosis|Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis|Completed||Phase 2/Phase 3|20|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 02:46:42.815737|2018-06-01 02:46:42.815737
NCT00555334|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2009-03-31|2007-11-07|2007-11-08|Estimate|||||||2009-03-31|2009-04-01|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|LAM-RFA||Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:46:42.895846|2018-06-01 02:46:42.895846
NCT00555321|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2012-09-17|2010-04-29|2012-09-17|2007-11-07|2007-11-08|Estimate|2012-09-17|2012-10-18|Estimate|2010-04-29|2010-05-03|Estimate|2012-09-17|2012-10-18|Estimate|January 2008||2008-01-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|||Belatacept in Liver Transplant Recipients|Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients|Terminated||Phase 2|260|Actual|Bristol-Myers Squibb||5|||f||||t||||||||||2018-06-01 02:46:43.226791|2018-06-01 02:46:43.226791
NCT00555308|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2009-07-21|2007-11-07|2007-11-08|Estimate|||||||2009-07-21|2009-07-22|Estimate|November 2007||2007-11-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Emergency Department Targeted Ultrasound for the Detection of Hydronephrosis|Emergency Department Targeted Ultrasound for the Detection of Hydronephrosis|Completed||N/A|200|Actual|Queen's University||1|||f||||f||||||||||2018-06-01 02:46:50.174305|2018-06-01 02:46:50.174305
NCT00555295|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-27|||2007-11-07|2007-11-07|2007-11-08|Estimate|||||||2007-11-07|2007-11-08|Estimate|December 2007||2007-12-31|June 2007|2007-06-30|February 2008|Anticipated|2008-02-29|||||Observational|||Laparoscopic Colorectal Surgery For Cancer- Long Term Survival|Survival After Laparoscopic Colorectal Surgery|Unknown status|Not yet recruiting||200|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||Samples Without DNA|"~     Colonic Resection~   "|||2018-06-01 02:46:50.257148|2018-06-01 02:46:50.257148
NCT00555282|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2010-02-04|2007-11-07|2007-11-08|Estimate|||||||2010-02-04|2010-02-05|Estimate|November 2005||2005-11-30|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of Two Different Central Venous Catheters (CVC)|Rate of Catheter Colonization and Risk of Bloodstream Infection During Use of a Standard Central Venous Catheter (CVC) in Comparison to a Coated CVC|Completed||Phase 4|680|Actual|B. Braun Melsungen AG||2|||f||||||||||||||2018-06-01 02:46:50.302563|2018-06-01 02:46:50.302563
NCT00555269|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2009-04-20|2007-11-07|2007-11-08|Estimate|||||||2009-04-20|2009-04-22|Estimate|October 2004||2004-10-31|April 2009|2009-04-30|December 2005|Actual|2005-12-31|||||Observational|||Membrane Blue Versus Infracyanine Green|Comparison of Macular Function and Visual Fields After Membrane Blue or Infracyanine Green Staining in Vitreoretinal Surgery|Completed|||30|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||2||f||||f||||||||||2018-06-01 02:46:50.381612|2018-06-01 02:46:50.381612
NCT00555256|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2016-05-05|2007-11-07|2007-11-08|Estimate|||||||2016-05-05|2016-05-06|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|February 2010|Actual|2010-02-28||Interventional|SU/Rapamycin||A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|19|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 02:46:50.437151|2018-06-01 02:46:50.437151
NCT00555243|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2013-01-18|2007-11-06|2007-11-08|Estimate|||||||2013-01-18|2013-01-21|Estimate|August 2005||2005-08-31|November 2007|2007-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Laparoscopic Simulator Training and Its Impact on Surgical Education|An Evaluation of Validated Laparoscopic Skills Simulators and the Impact on Operating Room Performance|Completed||N/A|108|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:46:50.521652|2018-06-01 02:46:50.521652
NCT00555230|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2011-01-26|2007-11-07|2007-11-08|Estimate|||||||2011-01-26|2011-01-27|Estimate|July 2007||2007-07-31|December 2008|2008-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis|Effects of HMG-coA Reductase Inhibitor on Progression of Carotid Intima-Media Thickness and Arterial Stiffness in Rheumatoid Arthritis|Completed||Phase 2|150|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 02:46:50.597355|2018-06-01 02:46:50.597355
NCT00555217|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|2015-04-17||2015-05-08|2007-11-07|2007-11-08|Estimate|2015-05-08|2015-05-29|Estimate||||2015-05-08|2015-05-29|Estimate|July 2008||2008-07-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|VA NEPHRON-D||VA NEPHRON-D: Diabetes iN Nephropathy Study|CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)|Terminated||Phase 3|1448|Actual|VA Office of Research and Development|In October, 2012 the DMC recommended that study treatment be stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.|2||"It was stopped primarily because of safety concerns along with low conditional power to detect~   a treatment effect on the primary outcome."|f||||t||||||||||2018-06-01 02:46:50.829526|2018-06-01 02:46:50.829526
NCT00555204|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07||2011-08-19|2011-08-19|2007-11-07|2007-11-08|Estimate||||2011-08-19|2011-08-23|Estimate|2011-08-19|2011-08-23|Estimate|November 2007||2007-11-30|August 2011|2011-08-31||||June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|Terminated||Phase 2|337|Actual|Abbott||7|||f||||t||||||||||2018-06-01 02:46:52.696911|2018-06-01 02:46:52.696911
NCT00555191|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2016-05-23|2007-11-07|2007-11-08|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|FINN||Fructose Malabsorption in Northern Norway|Fructose Malabsorption in Northern Norway. Fructose Malabsorption and Irritable Bowel Syndrome.|Completed||Phase 2/Phase 3|182|Actual|University Hospital of North Norway||2|||f||||f||||||||Yes|Data already published in two articles published in Scandinavian Journal of Gastroenterology 2013 48: 936-943 DOI: 10.2109/00365521.2013.812139 andWorld Journal of Gastroenterology 2015 May 14;21(18) 5445-5754 DOI: 10.3748/ wjg.v21.i18.5677|2018-06-01 02:46:53.107324|2018-06-01 02:46:53.107324
NCT00555178|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-07|||2015-05-06|2007-11-07|2007-11-08|Estimate|||||||2015-05-06|2015-05-07|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Regulatory T Cells (Tregs) in Polymorphic Light Eruption|Regulatory T Cells (Tregs) in Polymorphic Light Eruption|Completed|||92|Anticipated|Medical University of Graz|||4||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:46:53.198249|2018-06-01 02:46:53.198249
NCT00555165|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2012-11-13|2007-11-05|2007-11-07|Estimate|||||||2012-11-13|2012-11-14|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study of an Implantable Miniature Telescope in Patients With With End-Stage AMD|A Prospective Multicenter Clinical Study of the Implantable Miniature Telescope* in Patients With Central Vision Impairment Associated With AMD: IMT-UK Protocol (*IMT by Dr. Isaac Lipshitz)|Completed||N/A|18|Actual|VisionCare, Inc.||1|||f||||f||||||||||2018-06-01 02:46:53.275147|2018-06-01 02:46:53.275147
NCT00555152|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2015-07-24||2018-03-21|2007-11-06|2007-11-07|Estimate|2015-10-22|2015-11-25|Estimate||||2018-03-21|2018-04-20|Actual|August 19, 2009|Actual|2009-08-19|March 2018|2018-03-31|August 28, 2014|Actual|2014-08-28|August 28, 2014|Actual|2014-08-28||Interventional|||Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ|Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer|Completed||N/A|22|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 02:46:53.365415|2018-06-01 02:46:53.365415
NCT00555139|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2017-08-02|2007-11-05|2007-11-07|Estimate|||||||2017-08-02|2017-08-04|Actual|March 27, 2007|Actual|2007-03-27|August 2017|2017-08-31|January 10, 2008|Actual|2008-01-10|January 10, 2008|Actual|2008-01-10||Interventional|||A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder|Double-blind, Randomized, Placebo and Alprazolam-controlled Three-period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-like fRMI Activity of GW876008 and GSK561679 After Single-dose Administration in Subjects With Social Anxiety Disorder (SAD)|Completed||Phase 1|35|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:46:54.000834|2018-06-01 02:46:54.000834
NCT00555126|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2010-07-27|2007-11-06|2007-11-07|Estimate|||||||2010-07-27|2010-07-28|Estimate|May 2008||2008-05-31|July 2010|2010-07-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|FAEWPP||Forced Air Versus Endovascular Warming in Polytrauma Patients|A Comparison of Forced-air With Endovascular Warming for Treatment of Accidental Hypothermia in Polytrauma Victims|Suspended||Phase 4|100|Anticipated|Medical University of Vienna||2||Not enough patients|f||||t||||||||||2018-06-01 02:46:54.225606|2018-06-01 02:46:54.225606
NCT00555113|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2007-11-06|2007-11-06|2007-11-07|Estimate|||||||2007-11-06|2007-11-07|Estimate|January 2000||2000-01-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Observational|||Evolution of Visual Impairment During Pseudoxanthoma Elasticum|Evolution of Visual Impairment During Pseudoxanthoma Elasticum|Completed|||38|Actual|European Georges Pompidou Hospital|||1||f||||f||||||||||2018-06-01 02:46:54.298708|2018-06-01 02:46:54.298708
NCT00555100|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2016-11-30|2007-11-06|2007-11-07|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma|A Multicenter, Phase I Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma|Completed||Phase 1|15|Actual|Celgene Corporation|||||f||||t||||||||||2018-06-01 02:46:54.357569|2018-06-01 02:46:54.357569
NCT00555087|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2007-11-05|2007-11-05|2007-11-07|Estimate|||||||2007-11-05|2007-11-07|Estimate|May 2007||2007-05-31|November 2007|2007-11-30|January 2008|Anticipated|2008-01-31|||||Interventional|Nebidolocal||Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate|Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV.|Unknown status|Recruiting|Phase 4|50|Anticipated|Hospital Santa Fe||1|||f||||t||||||||||2018-06-01 02:46:54.456577|2018-06-01 02:46:54.456577
NCT00555074|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2010-03-30|2007-11-06|2007-11-07|Estimate|||||||2010-03-30|2010-03-31|Estimate|November 2007||2007-11-30|May 2008|2008-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|TROTA-1||Sodium Tungstate in Obesity|Efficacy of Oral Sodium Tungstate (200 mg/Day)on Weight Loss in Subjects With Grade I-II Obesity|Completed||Phase 2|44|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:46:54.541486|2018-06-01 02:46:54.541486
NCT00555061|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2009-08-10||2016-11-04|2007-11-06|2007-11-07|Estimate|2010-04-08|2010-04-30|Estimate||||2016-11-04|2016-12-28|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.|An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months|Completed||Phase 4|60|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:46:54.627828|2018-06-01 02:46:54.627828
NCT00555048|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2017-04-17||2017-04-17|2007-11-06|2007-11-07|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|September 2007||2007-09-30|April 2017|2017-04-30||||October 2010|Actual|2010-10-31||Interventional|||Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|A Prospective Trial to Evaluate the Role of In Vivo T Cell Depletion by Campath® (Alemtuzumab) in Reduction of Transplant Related Mortality in Transplantation From HLA-Class I or Class II Mismatched, Unrelated Donors|Terminated||Phase 1/Phase 2|1|Actual|Fred Hutchinson Cancer Research Center||1||Low accrual|f||||f||||||||||2018-06-01 02:46:54.910449|2018-06-01 02:46:54.910449
NCT00555035|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05||2010-10-13|2010-10-13|2007-11-05|2007-11-07|Estimate||||2010-10-13|2010-10-15|Estimate|2010-10-13|2010-10-15|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||GSK1349572 First Time in Human Study|A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1349572 in Healthy Subjects|Completed||Phase 1|20|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:46:55.121207|2018-06-01 02:46:55.121207
NCT00555022|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2017-09-05|2007-11-06|2007-11-07|Estimate|||||||2017-09-05|2017-09-08|Actual|December 12, 2007|Actual|2007-12-12|September 2017|2017-09-30|April 7, 2008|Actual|2008-04-07|April 7, 2008|Actual|2008-04-07||Interventional|||Effect of GSK1160724 In Healthy Volunteers|A Randomized Double-blind, Placebo-controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK1160724 and Tiotropium Bromide|Completed||Phase 1|21|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:46:55.44407|2018-06-01 02:46:55.44407
NCT00555009|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2009-12-22||2010-06-01|2007-11-06|2007-11-07|Estimate|2010-06-01|2010-06-02|Estimate||||2010-06-01|2010-06-02|Estimate|March 2008||2008-03-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury|Placebo Controlled Trial on the Efficacy of Growth Hormone Replacement Therapy in Patients With Growth Hormone Deficiency After Traumatic Brain Injury.|Terminated||Phase 4|10|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:46:55.573031|2018-06-01 02:46:55.573031
NCT00554996|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|2015-07-16||2015-09-25|2007-11-06|2007-11-07|Estimate|2015-08-14|2015-09-16|Estimate||||2015-09-25|2015-10-16|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||See Eligibility section.|Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study|Bacterial Interference for Prevention of Catheter-Associated UTI|Completed||Phase 1|10|Actual|VA Office of Research and Development|Our trial was a small study with no control group.|1|||f||||t||||||||||2018-06-01 02:46:55.874504|2018-06-01 02:46:55.874504
NCT00554983|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2013-11-07|2007-11-06|2007-11-07|Estimate|||||||2013-11-07|2013-11-08|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|May 2012|Actual|2012-05-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety From a Recombinant Folding Variant of Bet v 1|A Multicentre Randomised Placebo-controlled Double-blind Pivotal Clinical Trial for the Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, rBet v 1-FV|Completed||Phase 3|255|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 02:46:56.015559|2018-06-01 02:46:56.015559
NCT00554970|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2013-08-19||2013-12-09|2007-11-05|2007-11-07|Estimate|2013-08-19|2013-10-23|Estimate||||2013-12-09|2014-01-09|Estimate|November 2007||2007-11-30|December 2013|2013-12-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|P202||A Study of 2 Doses of MAP0010 in Adult Asthmatics|A Randomized, Open Label, Active-Controlled, 4-Treatment, 2-Period, 2 Parallel Block Crossover Pharmacokinetic and Safety Study of 2 Doses of MAP0010 in Adult Asthmatics|Completed||Phase 2|32|Actual|Allergan||4|||f||||f||||||||||2018-06-01 02:46:56.205173|2018-06-01 02:46:56.205173
NCT00554957|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2009-02-12|2007-11-05|2007-11-07|Estimate|||||||2009-02-12|2009-02-13|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|||||Observational|||Perception of Musculoskeletal Injury in Professional Dancers|Perception of Musculoskeletal Injury in Professional Dancers, an International Comparison|Completed|||266|Actual|University Health Network, Toronto|||6||f||||f||||||||||2018-06-01 02:46:56.598073|2018-06-01 02:46:56.598073
NCT00554944|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2017-01-20|2007-11-06|2007-11-07|Estimate|||||||2017-01-20|2017-01-23|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Intraoperative Goal-directed Fluid Management|Intraoperative Goal-directed Fluid Management in Lean and Obese Patients|Withdrawn||N/A|0|Actual|The Cleveland Clinic||||not progressing as anticipated|f||||t||||||||||2018-06-01 02:46:56.667327|2018-06-01 02:46:56.667327
NCT00554918|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2013-08-06|2007-11-06|2007-11-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|February 2005||2005-02-28|April 2008|2008-04-30|June 2013|Actual|2013-06-30|December 2008|Actual|2008-12-31||Interventional|||Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy|A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) Plus Strontium-89 in Hormone Refractory Prostate Cancer Metastatic to Bone.|Completed||Phase 2|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:46:56.749716|2018-06-01 02:46:56.749716
NCT00554905|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2009-02-06|2007-11-06|2007-11-07|Estimate|||||||2009-02-06|2009-02-10|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|February 2009|Anticipated|2009-02-28||Interventional|RFA and TACE||Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma|Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|180|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 02:46:56.853489|2018-06-01 02:46:56.853489
NCT00554892|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2010-06-29|2007-11-06|2007-11-07|Estimate|||||||2010-06-29|2010-06-30|Estimate|September 2007||2007-09-30|June 2010|2010-06-30|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|PREPACOL||Rectal Cancer Surgery Without Mechanical Bowel Preparation|ClinicalTrial in Rectal Cancer Surgery Without Mechanical Bowel Preparation|Completed||N/A|186|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:46:56.939356|2018-06-01 02:46:56.939356
NCT00554879|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2011-08-26|2007-11-06|2007-11-07|Estimate|||||||2011-08-26|2011-08-30|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Acupuncture Treatment of Dry Eye|Acupuncture Treatment of Dry Eye|Completed||N/A|20|Actual|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 02:46:57.021721|2018-06-01 02:46:57.021721
NCT00554866|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2015-10-27|2007-11-06|2007-11-07|Estimate|||||||2015-10-27|2015-10-28|Estimate|July 2007||2007-07-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2009|Actual|2009-12-31||Interventional|||L-arginine Concentrations and CPS Polymorphisms in VLBW Infants|Carbamoyl-phosphate Synthase Gene Polymorphisms Influencing Plasma L-arginine Concentrations in Preterm Infants|Completed||N/A|477|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 02:46:57.083256|2018-06-01 02:46:57.083256
NCT00554853|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2013-12-18||2016-12-07|2007-11-06|2007-11-07|Estimate|2016-12-07|2017-02-02|Estimate||||2016-12-07|2017-02-02|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|RAPPAR||PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease|Peroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease|Completed||Phase 3|143|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 02:46:57.163281|2018-06-01 02:46:57.163281
NCT00554840|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2016-05-11||2017-05-15|2007-11-06|2007-11-07|Estimate|2017-04-05|2017-05-15|Actual||||2017-05-15|2017-05-17|Actual|November 2007||2007-11-30|May 2017|2017-05-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional||One participant was withdrawn by the P.I. after assignment to the placebo group, but prior to receiving treatment.|Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia|Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia|Completed||Phase 2|16|Actual|University of Maryland|Larger studies are needed to confirm these encouraging results.|2|||f||||t||||||||||2018-06-01 02:46:57.641837|2018-06-01 02:46:57.641837
NCT00554827|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2013-05-08|2007-11-05|2007-11-07|Estimate|||||||2013-05-08|2013-05-10|Estimate|August 2007||2007-08-31|May 2013|2013-05-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma|A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma|Completed||Phase 1|55|Actual|Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 02:46:58.221601|2018-06-01 02:46:58.221601
NCT00554814|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2008-11-14|2007-11-06|2007-11-07|Estimate|||||||2008-11-14|2008-11-17|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|November 2008|Anticipated|2008-11-30||Interventional|||Interest of Biofer ® Compound Used in Blédilait Follow on Milk in Infant With Latent Iron Deficiency|Interest of Biofer ® Compound Used in Blédilait Follow on Milk and Growing Milk on Iron Status Evolution in Infant With Latent Iron Deficiency|Suspended||N/A|249|Anticipated|Bledina||3||insufficient recruitment|f||||t||||||||||2018-06-01 02:46:58.349462|2018-06-01 02:46:58.349462
NCT00554801|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|2014-11-04||2014-11-12|2007-11-05|2007-11-07|Estimate|2014-11-04|2014-11-13|Estimate||||2014-11-12|2014-11-24|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional||All participants who completed the study|Central Auditory Processing Disorders Associated With Blast Exposure|Central Auditory Processing Disorders Associated With Blast Exposure|Completed||N/A|84|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:46:58.442418|2018-06-01 02:46:58.442418
NCT00554788|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2017-05-05|2007-11-06|2007-11-07|Estimate|||||||2017-05-05|2017-05-08|Actual|February 2008||2008-02-29|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma|A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma|Active, not recruiting||Phase 3|60|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 02:46:58.654248|2018-06-01 02:46:58.654248
NCT00554775|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2011-12-09|2007-11-06|2007-11-07|Estimate|||||||2011-12-09|2011-12-12|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TACTIC||WBRT & Erlotinib in Advanced NSCLC and Brain Metastases|A Randomised Phase II Double Blind Placebo Controlled Trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Multiple Brain Metastases [TACTIC]|Terminated||Phase 2|80|Actual|University College, London||2||"IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was~   not met."|f||||t||||||||||2018-06-01 02:46:58.953541|2018-06-01 02:46:58.953541
NCT00554762|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2015-02-12|2007-11-05|2007-11-07|Estimate|||||||2015-02-12|2015-02-16|Estimate|November 2007||2007-11-30|February 2015|2015-02-28|March 2008|Anticipated|2008-03-31|March 2008|Anticipated|2008-03-31||Interventional|||Dose Response and Efficacy of GW842166 in Pain|A Phase I, Placebo Controlled, Randomised, Double Blind Two-way Crossover Study to Investigate the Dose Response and Efficacy of Single and Repeat Doses of GW842166 in Healthy Volunteers Using Pharmacodynamic Pain Assessments.|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||||Compound terminated|f||||f||||||||||2018-06-01 02:46:59.054411|2018-06-01 02:46:59.054411
NCT00554749|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2009-07-02||2010-11-18|2007-11-06|2007-11-07|Estimate|2010-10-12|2010-11-18|Estimate||||2010-11-18|2010-11-25|Estimate|November 2007||2007-11-30|November 2010|2010-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||What Treatment Works for Children With Selective Mutism?|What Treatment Works for Children With Selective Mutism? A Treatment Pilot Study|Completed||N/A|7|Actual|Regionsenter for barn og unges psykiske helse||1|||f||||f||||||||||2018-06-01 02:46:59.127992|2018-06-01 02:46:59.127992
NCT00554736|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2015-04-20|2007-11-05|2007-11-07|Estimate|||||||2015-04-20|2015-04-22|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|August 2008|Anticipated|2008-08-31|December 2007|Anticipated|2007-12-31||Interventional|||Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen|A Randomized, Double-blind, Placebo-controlled Trial of Lactobacillus Acidophilus L92 on Markers of Allergic Inflammation by Nasal Provocation With Grass Pollen|Withdrawn||Phase 3|0|Actual|University of California, Davis||1||Sponsor suspended study do to funding|f||||t||||||||||2018-06-01 02:46:59.363898|2018-06-01 02:46:59.363898
NCT00554697|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2017-03-14|2007-11-06|2007-11-07|Estimate|||||||2017-03-14|2017-03-16|Actual|November 2007||2007-11-30|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Diabetes Mellitus Type II and Tissue Oxygenation|Influence of Diabetes Mellitus Type II on Tissue Oxygenation in the Perioperative Period|Terminated|||60|Actual|The Cleveland Clinic|||2|Unable to recruit subjects|f||||t||||||||||2018-06-01 02:46:59.720382|2018-06-01 02:46:59.720382
NCT00554684|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2012-08-22|2007-11-05|2007-11-07|Estimate|||||||2012-08-22|2012-08-23|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|||||Observational|||Treatment Intensity/Factors Predicting Short and Long Term Outcomes in Elderly Critically Ill Patients|Treatment Intensity and Factors Predicting Short and Long Term Outcomes in Elderly and Very Elderly Patients Admitted to Intensive Care Units|Completed|||399|Actual|St. Luke's-Roosevelt Hospital Center|||||f||||f||||||||||2018-06-01 02:46:59.787645|2018-06-01 02:46:59.787645
NCT00554671|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|2014-12-04||2015-04-06|2007-11-06|2007-11-07|Estimate|2014-12-17|2014-12-31|Estimate||||2015-04-06|2015-04-24|Estimate|May 2008||2008-05-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|MEDIC-1 year||Pharmacist-led Group Medical Visits to Help With Diabetes Management|Group Intervention for DM Guideline Implementation|Completed||Phase 4|250|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 02:46:59.855305|2018-06-01 02:46:59.855305
NCT00554658|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2011-10-21|2007-11-06|2007-11-07|Estimate|||||||2011-10-21|2011-10-24|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients|Quetiapine Induced Neuroplasticity in Schizophrenic Patients: A Combined Transcranial Magnetic Stimulation (TMS) and Voxel-based Morphometry (VBM) Study|Completed||Phase 4|30|Actual|University of Regensburg||1|||f||||f||||||||||2018-06-01 02:47:00.134254|2018-06-01 02:47:00.134254
NCT00554645|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2007-11-05|2007-11-05|2007-11-07|Estimate|||||||2007-11-05|2007-11-07|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|GRIB-2004||GRIB Forsoeget-2004|Multi-Disciplinary Group Intervention Versus Traditional Information Towards Severely Overweight Children and Their Families -|Completed||Phase 2|45|Actual|Forskningspuljen||2|||f||||f||||||||||2018-06-01 02:47:00.311575|2018-06-01 02:47:00.311575
NCT00554632|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2007-11-06|2007-11-06|2007-11-07|Estimate|||||||2007-11-06|2007-11-07|Estimate|April 2003||2003-04-30|October 2007|2007-10-31|August 2005|Actual|2005-08-31|||||Interventional|PvP||Birth Control Pill vs Birth Control Patch Study|The Effects of Oral Contraceptive Pills vs Hormonal Patch on Coagulation Parameters|Completed||N/A|24|Actual|University of Vermont||2|||f||||t||||||||||2018-06-01 02:47:00.475123|2018-06-01 02:47:00.475123
NCT00554619|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|2011-10-20||2012-11-01|2007-11-05|2007-11-07|Estimate|2012-01-12|2012-02-13|Estimate||||2012-11-01|2012-11-05|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Evaluate GSK1325760A - a Long-Term Extension Study|Study AMB107818, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open Label Study of GSK1325760A to Evaluate the Safety and Efficacy of GSK1325760A - a Long-term Extension Study -|Completed||Phase 3|21|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 02:47:00.674732|2018-06-01 02:47:00.674732
NCT00554606|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2017-03-24|2007-11-06|2007-11-07|Estimate|||||||2017-03-24|2017-03-28|Actual|October 2007||2007-10-31|March 2017|2017-03-31||||August 2009|Actual|2009-08-31||Interventional|||Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis|A 54-week, Phase II, Multi-center, Open-label Extension Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1B Monoclonal Antibody) in Patients With Rheumatoid Arthritis|Completed||Phase 2|115|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:47:01.35182|2018-06-01 02:47:01.35182
NCT00554580|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2010-03-29|2007-11-06|2007-11-07|Estimate|||||||2010-03-29|2010-03-30|Estimate|October 2004||2004-10-31|March 2010|2010-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|CPAP||Continuous Positive Airway Pressure for Acute Pulmonary Edema|Effect of Continuous Positive Airway Pressure on Short Term Inhospital Prognosis for Acute Pulmonary Edema|Completed||Phase 3|208|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 02:47:01.490426|2018-06-01 02:47:01.490426
NCT00554567|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2016-03-07|2007-11-05|2007-11-07|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Utilization of HIV Clinical Services in Rural India|Utilization of Decentralized HIV Testing and Care Services in Rural Maharashtra, India|Completed||Phase 3|1300|Actual|Institute of Health Management, Pachod, India||1|||f||||t||||||||||2018-06-01 02:47:01.573662|2018-06-01 02:47:01.573662
NCT00554541|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2017-01-29|2007-11-06|2007-11-07|Estimate|||||||2017-01-29|2017-01-31|Estimate|November 2007|Actual|2007-11-30|January 2017|2017-01-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Observational|||Lower Extremity Venous Hemodynamics in Obese Patients Without Clinically Significant Venous Disease|Lower Extremity Venous Hemodynamics in Obese Patients Without Clinically Significant Venous Disease|Terminated|||16|Actual|The Cleveland Clinic|||3|Lack of study subjects|f||||f|f|f||||||No||2018-06-01 02:47:01.673328|2018-06-01 02:47:01.673328
NCT00554528|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2015-09-29|2007-11-05|2007-11-07|Estimate|||||||2015-09-29|2015-09-30|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PROCERV||Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level|Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level|Completed||Phase 4|200|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-06-01 02:47:01.788316|2018-06-01 02:47:01.788316
NCT00554515|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2017-04-13||2017-09-26|2007-11-06|2007-11-07|Estimate|2017-04-13|2017-05-19|Actual||||2017-09-26|2017-10-27|Actual|November 2006||2006-11-30|September 2017|2017-09-30|October 31, 2013|Actual|2013-10-31|October 31, 2013|Actual|2013-10-31||Interventional|SELECT|The analysis dataset is comprised of all treated participants.|"The High-Dose Aldesleukin (IL-2) Select Trial for Patients With Metastatic Renal Cell Carcinoma"|"The High-Dose Aldesleukin (IL-2) Select Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients With Metastatic Renal Cell Carcinoma"|Completed||Phase 2|123|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-06-01 02:47:01.878964|2018-06-01 02:47:01.878964
NCT00554502|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-09-21|2007-11-05|2007-11-07|Estimate|||||||2015-09-21|2015-09-22|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|STOP-IgAN||Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy|Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy|Completed||Phase 3|148|Anticipated|RWTH Aachen University||2|||f||||t||||||||||2018-06-01 02:47:02.498381|2018-06-01 02:47:02.498381
NCT00546624|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2015-10-30|2007-10-17|2007-10-19|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2002||2002-11-30|October 2015|2015-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)||Completed||Phase 2|38|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:50:06.426923|2018-06-01 02:50:06.426923
NCT00554489|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|||2017-08-14|2007-11-06|2007-11-07|Estimate|||||||2017-08-14|2017-08-17|Actual|July 2007||2007-07-31|August 2017|2017-08-31|April 2011|Actual|2011-04-30|November 2008|Actual|2008-11-30||Interventional|||Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy|A Feasibility Study of a Physical Activity Intervention in Older Adult Inpatients With Acute Leukemia|Completed||N/A|26|Actual|Wake Forest University Health Sciences|||||f||||f|f|f||||||||2018-06-01 02:47:04.247471|2018-06-01 02:47:04.247471
NCT00554476|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2007-11-05|2007-11-05|2007-11-07|Estimate|||||||2007-11-05|2007-11-07|Estimate|January 2003||2003-01-31|November 2007|2007-11-30|April 2006||2006-04-30|||||Interventional|||Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis|Comparison of Two Combined Therapeutic Methods for Treatment of Lateral Epicondylitis: A Randomized Clinical Trial|Terminated||Phase 4|50||Azad University of Medical Sciences||||Because the sample volume was completed during three years.|f||||t||||||||||2018-06-01 02:47:04.669556|2018-06-01 02:47:04.669556
NCT00554463|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-06|2014-09-23||2017-10-04|2007-11-06|2007-11-07|Estimate|2014-09-23|2014-09-29|Estimate||||2017-10-04|2017-11-06|Actual|January 2008||2008-01-31|October 2017|2017-10-31||||August 2011|Actual|2011-08-31||Interventional||All eligible patients.|G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer|A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer|Completed||Phase 2|5|Actual|Radiation Therapy Oncology Group|This study stopped accrual early due to unmet targeted accrual goals, therefore no analyses were performed. The small number of patients would not have provided meaningful results.|1|||f||||t||||||||||2018-06-01 02:47:04.92461|2018-06-01 02:47:04.92461
NCT00554450|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2016-10-14|2007-11-05|2007-11-07|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Renal Impairment in Type 2 Diabetic Subjects|The Pharmacodynamics, Pharmacokinetics, and Safety of Dapagliflozin in Type 2 Diabetic Subjects With Mild, Moderate, and Severe Renal Impairment|Completed||Phase 1|40|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:47:05.979759|2018-06-01 02:47:05.979759
NCT00554437|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2015-10-01|2007-11-02|2007-11-06|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2002||2002-05-31|November 2008|2008-11-30|June 2004|Actual|2004-06-30|||||Interventional|||Kenosha County Falls Prevention Study|Kenosha County Falls Prevention Study: An Intermediate-intensity, Community-based, Multifactorial Intervention|Completed||N/A|349|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 02:47:06.083119|2018-06-01 02:47:06.083119
NCT00554424|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-03|||2007-11-05|2007-11-05|2007-11-06|Estimate|||||||2007-11-05|2007-11-06|Estimate|March 2002||2002-03-31|November 2007|2007-11-30|July 2002|Actual|2002-07-31|||||Interventional|||Local Anaesthetic for Transvaginal Egg Collection in IVF|A Randomised Controlled Trial of Intravaginal Lignocaine Injection Versus Placebo for Analgesia During Oocyte Recovery in an IVF Cycle|Completed||N/A|75|Actual|The Fertility Centre, New Zealand||2|||f||||t||||||||||2018-06-01 02:47:06.160492|2018-06-01 02:47:06.160492
NCT00554411|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2017-01-26|2007-11-05|2007-11-06|Estimate|||||||2017-01-26|2017-01-27|Estimate|November 2007||2007-11-30|January 2017|2017-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Assessing Ocular Surface Changes After Changing Glaucoma Medications|Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.|Completed|||22|Actual|University of Colorado, Denver|||||f||||f||||||||No||2018-06-01 02:47:06.256398|2018-06-01 02:47:06.256398
NCT00554398|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2009-11-12|2007-11-05|2007-11-06|Estimate|||||||2009-11-12|2009-11-13|Estimate|November 2007||2007-11-30|November 2009|2009-11-30|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression|Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression|Completed||Phase 3|69|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 02:47:06.330314|2018-06-01 02:47:06.330314
NCT00554385|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05||2011-08-18|2011-08-18|2007-11-05|2007-11-06|Estimate||||2011-08-18|2011-08-23|Estimate|2011-08-18|2011-08-23|Estimate|November 2007||2007-11-30|August 2011|2011-08-31||||August 2008|Actual|2008-08-31||Interventional|||A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|The Long-term Safety and Tolerability of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD): An Open-Label Extension Study|Terminated||Phase 2|283|Actual|Abbott||1|||f||||t||||||||||2018-06-01 02:47:06.41946|2018-06-01 02:47:06.41946
NCT00554372|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2015-05-12||2016-01-06|2007-11-02|2007-11-06|Estimate|2015-07-22|2015-08-17|Estimate||||2016-01-06|2016-02-04|Estimate|August 2008||2008-08-31|October 2011|2011-10-31|February 2013|Actual|2013-02-28|December 2011|Actual|2011-12-31||Interventional|||A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma|A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma|Completed||Phase 2|30|Actual|SillaJen, Inc.||2|||f||||t||||||||||2018-06-01 02:47:06.648526|2018-06-01 02:47:06.648526
NCT00554359|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-04|||2011-02-22|2007-11-05|2007-11-06|Estimate|||||||2011-02-22|2011-02-23|Estimate|August 2007||2007-08-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||A Dose Escalation and Safety Study of I5NP in Patients Undergoing Major Cardiovascular Surgery|A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients Undergoing Major Cardiovascular Surgery|Completed||Phase 1|16|Actual|Quark Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:47:07.232384|2018-06-01 02:47:07.232384
NCT00554346|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-04|||2010-06-20|2007-11-05|2007-11-06|Estimate|||||||2010-06-20|2010-06-22|Estimate|May 2008||2008-05-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction|A Randomized, Double Blind, Placebo-controlled Study to Assess the the Preemptive Benefit of Etoricoxib in Patients Receiving Anterior Cruciate Ligament Reconstruction|Completed||Phase 4|64|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 02:47:07.34928|2018-06-01 02:47:07.34928
NCT00554333|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2018-03-15|2007-11-05|2007-11-06|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2007||2007-10-31|March 2018|2018-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine|An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine Administered by Intradermal Route (Flu-ID 15μg) Versus an Inactivated Adjuvanted Influenza Vaccine Administered by Intramuscular Route in Subjects 65 Years of Age or Older|Completed||Phase 3|795|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:47:07.44136|2018-06-01 02:47:07.44136
NCT00554320|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2009-09-17|2007-11-02|2007-11-06|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2009||2009-01-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain|Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain|Completed||N/A|24|Anticipated|Summa Health System||2|||f||||f||||||||||2018-06-01 02:47:07.524135|2018-06-01 02:47:07.524135
NCT00554307|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2015-01-22|2007-11-05|2007-11-06|Estimate|||||||2015-01-22|2015-01-26|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Brain, Gut and Kidney Blood Flow During Medical Closure of PDA|Comparison of Cerebral, Renal and Mesenteric Perfusion Using Near Infrared Spectroscopy in Neonates During Patent Ductus Arteriosus Closure With Ibuprofen or Indomethacin.|Withdrawn|||0|Actual|University of Louisville|||3|Not able to enroll patients|f||||f||||||||||2018-06-01 02:47:07.628349|2018-06-01 02:47:07.628349
NCT00554294|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|2009-03-31||2009-05-27|2007-11-05|2007-11-06|Estimate|2009-05-27|2009-07-16|Estimate||||2009-05-27|2009-07-16|Estimate|April 2006||2006-04-30|May 2009|2009-05-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Interventional|trinkfit||Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial|Promoting Water Consumption for Prevention of Overweight in School Children in a Controlled Intervention Trial|Completed||N/A|2950|Actual|Research Institute of Child Nutrition, Dortmund||2|||f||||||||||||||2018-06-01 02:47:07.711158|2018-06-01 02:47:07.711158
NCT00554281|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2011-09-12|2007-11-05|2007-11-06|Estimate|||||||2011-09-12|2011-09-13|Estimate|October 2006||2006-10-31|September 2011|2011-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Using Glucose Sensors to Prevent Hypoglycemia|Paradigm Real Time Continuous Glucose Monitoring Device for the Prevention of Hypoglycemia|Completed||Phase 3|16|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 02:47:08.032214|2018-06-01 02:47:08.032214
NCT00554268|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2016-02-17|2007-11-05|2007-11-06|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Trial of PBI-05204 in Advanced Cancer Patients|An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients|Completed||Phase 1|58|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:47:08.113562|2018-06-01 02:47:08.113562
NCT00554255|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2013-04-11|2007-11-02|2007-11-06|Estimate|||||||2013-04-11|2013-04-15|Estimate|October 2006||2006-10-31|April 2012|2012-04-30||||||||Interventional|||A Study of SB751689 in Japanese Postmenopausal Women|Phase I Study of SB751689 - Single and Multiple Oral Dose Study in Japanese Postmenopausal Women -|Completed||Phase 1|18|Anticipated|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:47:08.182063|2018-06-01 02:47:08.182063
NCT00554242|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2009-06-16|2007-11-05|2007-11-06|Estimate|||||||2009-06-16|2009-06-18|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function|Chronic Study of the Effect of Grape Seed Extract Plus Ascorbic Acid on Endothelial Function in Patients With Coronary Artery Disease|Completed||N/A|40|Anticipated|Boston University|||||f||||f||||||||||2018-06-01 02:47:08.245119|2018-06-01 02:47:08.245119
NCT00554229|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2012-04-26||2016-01-15|2007-11-02|2007-11-06|Estimate|2012-04-26|2012-05-31|Estimate||||2016-01-15|2016-02-08|Estimate|November 2007||2007-11-30|April 2012|2012-04-30|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|ENTHUSE M1||A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases|A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.|Completed||Phase 3|896|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 02:47:08.427468|2018-06-01 02:47:08.427468
NCT00554216|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-03|2012-07-31|2009-11-30|2012-09-05|2007-11-03|2007-11-06|Estimate|2012-07-31|2012-09-06|Estimate|2009-11-30|2009-12-02|Estimate|2012-09-05|2012-09-10|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults|A Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in an Adult Population With BMI ≥ 35|Completed||Phase 3|1267|Actual|VIVUS, Inc.||3|||f||||t||||||||||2018-06-01 02:47:09.649712|2018-06-01 02:47:09.649712
NCT00554203|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2008-05-13|2007-11-05|2007-11-06|Estimate|||||||2008-05-13|2008-05-15|Estimate|July 2003||2003-07-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Sulfasalazine and Endothelial Function|Effect of Sulfasalazine on Endothelial Function|Completed||N/A|60|Anticipated|Boston University|||||f||||f||||||||||2018-06-01 02:47:10.09596|2018-06-01 02:47:10.09596
NCT00554190|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2008-11-14||2009-04-22|2007-11-02|2007-11-06|Estimate|2009-04-22|2009-04-23|Estimate||||2009-04-22|2009-04-23|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel|A Prospective, Multi-Center, Randomized, Controlled, Subject-Blinded Study to Evaluate the Safety and Effectiveness of AdvaCoat Sinus Gel Following Endoscopic Ethmoid Sinus Surgery|Completed||Phase 4|29|Actual|Carbylan Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 02:47:10.158277|2018-06-01 02:47:10.158277
NCT00554177|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2016-03-15|2007-11-05|2007-11-06|Estimate|||||||2016-03-15|2016-03-17|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|MATTER||A Clinical Trial for Post Traumatic Stress Disorder|Mifepristone After Trauma to Enhance Resilience|Completed||Phase 1|5|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-06-01 02:47:10.333219|2018-06-01 02:47:10.333219
NCT00554164|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2017-05-04|2007-11-05|2007-11-06|Estimate|||||||2017-05-04|2017-05-05|Actual|November 2007||2007-11-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|PETAL||Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas|Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas|Completed||Phase 3|1073|Actual|University Hospital, Essen||4|||f||||t||||||||||2018-06-01 02:47:10.403284|2018-06-01 02:47:10.403284
NCT00554151|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2011-06-20|2007-11-02|2007-11-06|Estimate|||||||2011-06-20|2011-06-21|Estimate|July 2007||2007-07-31|February 2010|2010-02-28|April 2010|Actual|2010-04-30|March 2009|Actual|2009-03-31||Interventional|MAARS||Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study|Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study (MAARS) for Treatment of Patients With Mitral Valve Regurgitation in Open Surgical Repair|Completed||N/A|55|Anticipated|St. Jude Medical|||||f||||t||||||||||2018-06-01 02:47:10.484815|2018-06-01 02:47:10.484815
NCT00554138|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2008-09-22|2007-11-05|2007-11-06|Estimate|||||||2008-09-22|2008-09-23|Estimate|November 2007||2007-11-30|September 2008|2008-09-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||The Effect of Rosuvastatin on Adenosine Metabolism|Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.|Completed||N/A|24|Actual|Radboud University||2|||f||||||||||||||2018-06-01 02:47:10.547306|2018-06-01 02:47:10.547306
NCT00554125|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2007-11-05|2007-11-05|2007-11-06|Estimate|||||||2007-11-05|2007-11-06|Estimate|August 2007||2007-08-31|October 2007|2007-10-31|August 2013|Anticipated|2013-08-31|||||Interventional|||Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria|A Prospective Randomised, Open-Labeled Study Comparing Sirolimus Versus FK506 In OLT for Patients With HCC Exceeding Milan Criteria|Unknown status|Recruiting|Phase 3|220|Anticipated|Fudan University||1|||f||||t||||||||||2018-06-01 02:47:10.60963|2018-06-01 02:47:10.60963
NCT00554112|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2011-08-10|2007-11-05|2007-11-06|Estimate|||||||2011-08-10|2011-08-11|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Regulation of B-Cell Function & Glucose Tolerance in Older People|Regulation of B-Cell Function & Glucose Tolerance in Older People|Terminated||N/A|90|Anticipated|VA Office of Research and Development||3||PI left the VA, per Central Office|f||||t||||||||||2018-06-01 02:47:10.680212|2018-06-01 02:47:10.680212
NCT00554099|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2011-03-14||2013-04-15|2007-11-05|2007-11-06|Estimate|2011-05-20|2011-06-21|Estimate||||2013-04-15|2013-04-22|Estimate|November 2007||2007-11-30|April 2013|2013-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Asacol Acute Diverticulitis(DIVA)Study|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period|Completed||Phase 2|117|Actual|Warner Chilcott||3|||f||||f||||||||||2018-06-01 02:47:10.884168|2018-06-01 02:47:10.884168
NCT00554086|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2011-05-13|2007-11-05|2007-11-06|Estimate|||||||2011-05-13|2011-05-16|Estimate|November 2005||2005-11-30|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|CHICS||Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.|Phase 2 Trial of Maximum Androgen Blockade (MAB) Dose Escalation From 50 mg to 150 mg Bicalutamide (Casodex) for Biochemical Failure in Prostate Cancer Patients|Completed||Phase 2|65|Actual|Canadian Urology Research Consortium|||||f||||f||||||||||2018-06-01 02:47:12.279954|2018-06-01 02:47:12.279954
NCT00554073|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2009-08-18|2007-11-05|2007-11-06|Estimate|||||||2009-08-18|2009-08-19|Estimate|May 2008||2008-05-31|August 2009|2009-08-31|August 2009|Anticipated|2009-08-31|||||Observational|||Whole Body Magnetic Resonance Angiography in Ischemic Patients at 1.5 and 3T|Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia: A Comparison Between 1.5 and 3T MRI-systems|Suspended|||12|Anticipated|Copenhagen University Hospital at Herlev||||"It was not possible to perform 2 MRI studies in each patient due to practical problems. The~   study was not suspended due to safety issues."|f||||t||||||||||2018-06-01 02:47:12.57878|2018-06-01 02:47:12.57878
NCT00554047|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2011-01-07|2007-11-05|2007-11-06|Estimate|||||||2011-01-07|2011-01-10|Estimate|December 2007||2007-12-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|||||Interventional|AD-Euro||Comparison of Effectiveness and Costs of Post-diagnosis Treatment in Dementia|Effectiveness and Costs of Post-diagnosis Treatment in Dementia Coordinated by Multidisciplinary Memory Clinics in Comparison to Treatment Coordinated by General Practitioners|Completed||N/A|220|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 02:47:12.817047|2018-06-01 02:47:12.817047
NCT00554034|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2010-12-19|2007-11-05|2007-11-06|Estimate|||||||2010-12-19|2010-12-21|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect of Herbal Extracts on Gingival Inflammation|The Effect of Herbal Extracts on Inflammatory Enzymes in the Gingiva: a Dose Finding Study.|Completed||Phase 2|60|Anticipated|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 02:47:13.143119|2018-06-01 02:47:13.143119
NCT00554021|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2009-06-10|2007-11-05|2007-11-06|Estimate|||||||2009-06-10|2009-06-12|Estimate|November 2007||2007-11-30|June 2009|2009-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|CVL||Infections Related Central Venous Catheters|Infections Associated With the Use of Central Venous Catheters Related in Critical Care Center.|Completed|||60|Anticipated|National Defense Medical College, Japan|||1||f||||t||||||Samples With DNA|"~     We will use the DNA from the only clinical isolated bacteria.~   "|||2018-06-01 02:47:13.402968|2018-06-01 02:47:13.402968
NCT00554008|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2012-05-25|2007-11-05|2007-11-06|Estimate|||||||2012-05-25|2012-05-30|Estimate|December 2007||2007-12-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Comparative Study of Laparoscopic Versus Open Appendectomy in Children|Randomized, Prospective, Single Blinded Trial of Laparoscopic Versus Open Appendectomy in Children|Completed||N/A|400|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:47:13.723007|2018-06-01 02:47:13.723007
NCT00553995|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2017-03-08|2007-11-05|2007-11-06|Estimate|||||||2017-03-08|2017-03-10|Actual|May 2008|Actual|2008-05-31|March 2017|2017-03-31|December 1, 2014|Actual|2014-12-01|December 1, 2013|Actual|2013-12-01||Interventional|||Effect of Salsalate on Bed Rest-Induced Vascular Dysfunction|Effect of Physical Inactivity on Endothelial Function|Completed||Phase 1|60|Actual|Boston University||2|||f||||f||||||||||2018-06-01 02:47:14.143673|2018-06-01 02:47:14.143673
NCT00553982|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2016-04-14|2007-11-05|2007-11-06|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Patellar Resurfacing in Total Knee Arthroplasty|Patellar Resurfacing in Total Knee Arthroplasty. A Prospective, Randomised and Double Blind Study.|Completed||N/A|130|Actual|Sykehuset Innlandet HF||2|||f||||||||||||||2018-06-01 02:47:14.523762|2018-06-01 02:47:14.523762
NCT00553969|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|2013-12-16||2018-03-23|2007-11-05|2007-11-06|Estimate|2014-12-09|2014-12-17|Estimate||||2018-03-23|2018-04-24|Actual|November 2007||2007-11-30|March 2018|2018-03-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|DETECT||Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease|Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease. DETECT (DEtection and Treatment of Early Cardiovascular Disease Trial)|Completed||Phase 1/Phase 2|101|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-06-01 02:47:14.835997|2018-06-01 02:47:14.835997
NCT00553956|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2007-11-05|2007-11-05|2007-11-06|Estimate|||||||2007-11-05|2007-11-06|Estimate|August 2007||2007-08-31|November 2007|2007-11-30|February 2009|Anticipated|2009-02-28|||||Interventional|||A Randomized Controlled Clinical Trial With Orphans and Widows Who Experienced the Rwandan Genocide|Phase 1:Epidemiological Study of PTSD and Comorbid Disorders in Widows and Orphans Who Experienced the Rwandan Genocide Phase 2: A Randomized Controlled Clinical Trial With Orphans and Widows Who Experienced the Genocide Carried Out by Trained Local Psychologists -NET/IPT Versus Waiting List-|Unknown status|Recruiting|Phase 1|150|Anticipated|University of Konstanz||2|||f||||||||||||||2018-06-01 02:47:16.158604|2018-06-01 02:47:16.158604
NCT00553774|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2016-10-25|2007-11-05|2007-11-06|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|Cocoa||Effect of Cocoa Flavanols on Vascular Function|Effect of Cocoa Flavanols on Vascular Function in Optimally Treated Coronary Artery Disease Patients: Interaction Between Endothelial Progenitor Cells, Reactivity of Micro- and Macrocirculation|Completed||Phase 1|16|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:47:18.690319|2018-06-01 02:47:18.690319
NCT00553943|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2010-10-22|2007-11-05|2007-11-06|Estimate|||||||2010-10-22|2010-10-26|Estimate|July 2007||2007-07-31|October 2010|2010-10-31|June 2013|Anticipated|2013-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis|Prospective Multicentre Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® by Intrathecal Injection in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis|Unknown status|Recruiting|Phase 2|106|Anticipated|Lymphoma Study Association|||||f||||t||||||||||2018-06-01 02:47:16.435708|2018-06-01 02:47:16.435708
NCT00553930|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-03|||2010-05-16|2007-11-03|2007-11-06|Estimate|||||||2010-05-16|2010-05-18|Estimate|November 2007||2007-11-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|SAEI_IFN_1||Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients|Efficacy of Low Dose Pegylated Interferon-α 2a Plus Ribavirin for the Treatment of Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients.|Completed||Phase 4|71|Anticipated|Sociedad Andaluza de Enfermedades Infecciosas||1|||f||||t||||||||||2018-06-01 02:47:16.983272|2018-06-01 02:47:16.983272
NCT00553917|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2011-06-21|2007-11-05|2007-11-06|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|||||Observational|||Study to Evaluate the Effectiveness of Certain Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants During Pregnancy and Evaluate Newborn Outcomes|Study of the Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy|Terminated|||18|Actual|Indiana University|||4|Poor recruitment to experimental arms and study remained unfunded|f||||t||||||Samples With DNA|"~     whole Blood Plasma human milk~   "|||2018-06-01 02:47:17.087813|2018-06-01 02:47:17.087813
NCT00553904|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2009-06-16|2007-11-05|2007-11-06|Estimate|||||||2009-06-16|2009-06-18|Estimate|February 2008||2008-02-29|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Cranberry Juice on Endothelial Function|Long-Term Effects of Cranberry Juice on Endothelial Function in Patients With Coronary Artery Disease|Completed||N/A|40|Anticipated|Boston University|||||f||||f||||||||||2018-06-01 02:47:17.162925|2018-06-01 02:47:17.162925
NCT00553891|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2015-08-12|2007-11-05|2007-11-06|Estimate|||||||2015-08-12|2015-08-13|Estimate|May 2006||2006-05-31|August 2015|2015-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)|Double Blind, Placebo Controlled Trial, Evaluating the Role of Nasonex® in the Management of Nasal Obstruction Secondary to Adenoids Hypertrophy in Children|Terminated||Phase 4|285|Anticipated|Merck Sharp & Dohme Corp.||2||No enrollment because of war in the study country.|f||||f||||||||||2018-06-01 02:47:17.229874|2018-06-01 02:47:17.229874
NCT00553878|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2016-10-13|2007-11-05|2007-11-06|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2007||2007-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|September 2009|Actual|2009-09-30||Interventional|AVIAS||Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer|Multi Center Double Blind Study Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer|Completed||Phase 2/Phase 3|100|Anticipated|Canadian Urology Research Consortium||1|||f||||t||||||||Yes|plan to share in publication|2018-06-01 02:47:17.30354|2018-06-01 02:47:17.30354
NCT00553865|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-03|||2016-06-27|2007-11-05|2007-11-06|Estimate|||||||2016-06-27|2016-06-29|Estimate|November 2007||2007-11-30|September 2014|2014-09-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Clinical Trial to Evaluate the Efficacy and the Safety of Antihypertensive Tablets|A 8-Week, Randomized, Double-blind, Parallel Designed, Phase II Multi-center Clinical Trial to Evaluate the Antihypertensive Efficacy and the Safety of OJP-2028 Tablets in Patients With the Uncomplicated Essential Hypertension|Completed||Phase 2|120|Actual|Jeil Pharmaceutical Co., Ltd.||5|||f||||f||||||||No||2018-06-01 02:47:17.375627|2018-06-01 02:47:17.375627
NCT00553852|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2008-03-27|2007-11-05|2007-11-06|Estimate|||||||2008-03-27|2008-03-28|Estimate|July 2007||2007-07-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|GH&LASGB||Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity|Evaluation of GH/IGF-I Axis and of Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity: Relationships With Body Composition|Completed||Phase 3|24|Actual|Federico II University||2|||f||||t||||||||||2018-06-01 02:47:17.481224|2018-06-01 02:47:17.481224
NCT00553839|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|2016-02-04||2016-02-04|2007-11-05|2007-11-06|Estimate|2016-02-04|2016-02-08|Estimate||||2016-02-04|2016-02-08|Estimate|July 2007||2007-07-31|August 2014|2014-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||Children between 6 months to 18 years of age with cardiac diseases in order to rationalize an effective 2-h anesthetic medication personalized based on cardiac function and age|Pharmacokinetics of Ketamine in Infants and Children|Pharmacokinetics of Ketamine in Infants and Children|Completed||N/A|21|Actual|Stanford University||1|||f||||f||||||||||2018-06-01 02:47:17.573638|2018-06-01 02:47:17.573638
NCT00553813|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02||2012-07-16|2014-01-09|2007-11-02|2007-11-06|Estimate||||2012-07-16|2012-07-25|Estimate|2014-01-09|2014-01-22|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Interventional|||A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer|A Phase 2, Open Label, Single Arm Trial of TPI 287 in Patients With Advanced, Unresectable Pancreatic Cancer After Prior Treatment With a Gemcitabine-based Therapy|Terminated||Phase 2|23|Actual|Cortice Biosciences, Inc.||||Insufficient funding|f||||||||||||||2018-06-01 02:47:17.746381|2018-06-01 02:47:17.746381
NCT00553800|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2016-02-04|2007-11-05|2007-11-06|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|October 2013|Actual|2013-10-31||Interventional|NSCLC||Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer|Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer|Unknown status|Active, not recruiting|Phase 2|33|Anticipated|Fox Chase Cancer Center||1|||f||||f||||||||||2018-06-01 02:47:17.846097|2018-06-01 02:47:17.846097
NCT00553787|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-03|2012-07-31|2009-11-30|2012-09-05|2007-11-03|2007-11-06|Estimate|2012-07-31|2012-09-06|Estimate|2009-11-30|2009-12-02|Estimate|2012-09-05|2012-09-10|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions|A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions|Completed||Phase 3|2487|Actual|VIVUS, Inc.||3|||f||||t||||||||||2018-06-01 02:47:17.953854|2018-06-01 02:47:17.953854
NCT00553761|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2011-08-04|2007-11-05|2007-11-06|Estimate|||||||2011-08-04|2011-08-08|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Observational|||PERG and mfPERG in Band Atrophy|Pattern Electroretinogram and Multifocal Pattern Electroretinogram For the Detection of Neural Loss in Patients With Permanent Temporal Visual Field Defect From Chiasmal Compression|Completed|||30|Anticipated|University of Sao Paulo|||||f||||f||||||||||2018-06-01 02:47:18.764175|2018-06-01 02:47:18.764175
NCT00553748|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2008-07-01|2007-11-02|2007-11-06|Estimate|||||||2008-07-01|2008-07-03|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Phase I, Open Label, Single Center Safety Study of [F-18]FLT|A Phase I, Open Label, Single Center Safety Study of [F-18]FLT|Completed||Phase 1|11|Actual|Siemens Molecular Imaging||1|||f||||f||||||||||2018-06-01 02:47:18.845235|2018-06-01 02:47:18.845235
NCT00553735|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2012-10-02||2017-02-07|2007-11-05|2007-11-06|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|August 2007||2007-08-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye|The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye|Terminated||Phase 4|8|Actual|Massachusetts Eye and Ear Infirmary|The study was terminated early due to a high number of patients who withdrew themselves, failed to show for their appointments, or were lost to follow-up.|2||High number of withdrawals, appt. no-shows, or those lost to follow-up.|f||||f||||||||No||2018-06-01 02:47:19.003608|2018-06-01 02:47:19.003608
NCT00553722|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-05|||2007-11-05|2007-11-05|2007-11-06|Estimate|||||||2007-11-05|2007-11-06|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|November 2009|Anticipated|2009-11-30|||||Interventional|||Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?|Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?|Unknown status|Not yet recruiting|Phase 4|27|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 02:47:19.247921|2018-06-01 02:47:19.247921
NCT00553709|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2009-09-28|2007-11-02|2007-11-05|Estimate|||||||2009-09-28|2009-09-29|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|NicoPONV||Study of Nicotine for the Prevention of PONV|The Role of Transcutaneous Nicotine in the Prevention of Postoperative Nausea and Vomiting in Non-smokers|Terminated||Phase 2|200|Anticipated|University Hospital, Geneva||2||Unexpected difficult recruitment. Study drug expired|f||||t||||||||||2018-06-01 02:47:19.315596|2018-06-01 02:47:19.315596
NCT00553696|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2015-03-03||2015-03-03|2007-11-02|2007-11-05|Estimate|2015-03-03|2015-03-13|Estimate||||2015-03-03|2015-03-13|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|July 2009|Actual|2009-07-31||Interventional|||Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer|A Phase 1 Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer|Completed||Phase 1|27|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 02:47:19.41326|2018-06-01 02:47:19.41326
NCT00553683|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2014-01-11|2007-11-02|2007-11-05|Estimate|||||||2014-01-11|2014-01-14|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|February 2014|Anticipated|2014-02-28||Interventional|||Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer|Phase I/II Study of Autologous Tumor Cell Vaccination Using Metronomic Cyclophosphamide, 3-Dimensional Conformal Radiotherapy, Intra/Peri-Tumor Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Poly ICLC Boosting in Patients With Unresectable, Recurrent, or Metastatic Cancers in the Liver (Hepatoma, Cholangiocarcinoma, Neuroendocrine, Breast, Colon, Gastric, and Esophageal Cancer)|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Rutgers, The State University of New Jersey||1|||f||||||||||||||2018-06-01 02:47:20.973867|2018-06-01 02:47:20.973867
NCT00553670|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2011-03-28|2007-11-01|2007-11-05|Estimate|||||||2011-03-28|2011-03-30|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|May 2009|Actual|2009-05-31|||||Observational|PRESSURE||Mechanism and Predictor of Side Branch Jailing|Predictor and Mechanism of a Side Branch Jail After Main Branch Stent Implantation in Bifurcation Lesions|Completed|||100|Anticipated|Seoul National University Hospital|||1||f||||t||||||||||2018-06-01 02:47:21.149657|2018-06-01 02:47:21.149657
NCT00553657|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02||2010-10-13|2010-10-13|2007-11-02|2007-11-05|Estimate||||2010-10-13|2010-10-26|Estimate|2010-10-13|2010-10-26|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Standardization of Fluid Intake on the Variability of Measured Voiding Parameters in Female Patients With Idiopathic Overactive Bladder|Completed||Phase 1|55|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 02:47:21.238604|2018-06-01 02:47:21.238604
NCT00553644|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2014-01-06||2017-07-11|2007-11-02|2007-11-05|Estimate|2014-01-06|2014-02-20|Estimate||||2017-07-11|2017-08-10|Actual|November 2007||2007-11-30|July 2017|2017-07-31||||December 2012|Actual|2012-12-31||Interventional|||Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid™, CC-5013) (NSC #703813) for Relapsed/Refractory Mantle Cell Lymphoma|Active, not recruiting||Phase 2|53|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:47:21.44945|2018-06-01 02:47:21.44945
NCT00553631|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|2010-07-12||2015-07-16|2007-11-01|2007-11-05|Estimate|2010-12-03|2011-01-04|Estimate||||2015-07-16|2015-08-07|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease|A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease|Completed||Phase 3|34|Actual|Shire|Participants aged 2-4 years: 4 participants (23.5%) in imiglucerase group and 0 participants in GA-GCB group.|2|||f||||f||||||||||2018-06-01 02:47:22.021124|2018-06-01 02:47:22.021124
NCT00553618|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2017-11-03|2007-11-01|2007-11-05|Estimate|||||||2017-11-03|2017-11-07|Actual|August 2007||2007-08-31|November 2017|2017-11-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|DTIC||Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients|Adjuvant Interleukin2 (Proleukin)and 5-(3,3 Dimethyl-1-Triazeno) Imidazole-4-Carboxamide (DTIC) in Resected High-Risk Primary and Regionally Metastatic Melanoma|Active, not recruiting||Phase 2|160|Anticipated|James Graham Brown Cancer Center||1|||f||||t||||||||||2018-06-01 02:47:23.779671|2018-06-01 02:47:23.779671
NCT00553137|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2008-05-02|2007-11-02|2007-11-05|Estimate|||||||2008-05-02|2008-05-07|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|SDVS2WK||Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania|Oral Candidiasis in HIV Infected Individuals in Tanzania|Completed||Phase 4|220|Actual|Netherlands Organisation for Scientific Research||2|||f||||t||||||||||2018-06-01 02:47:37.477202|2018-06-01 02:47:37.477202
NCT00553605|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2012-12-20||2012-12-20|2007-11-02|2007-11-05|Estimate|2012-12-20|2013-01-28|Estimate||||2012-12-20|2013-01-28|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|NAP||Efficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic|A Double-Blind, Double-Dummy, Randomized, Multicenter Study Comparing The Analgesic Efficacy And Safety Of Parecoxib 40mg I.V. To Ketoprofen 100mg I.V. In Renal Colic|Completed||Phase 4|340|Actual|Pfizer|PR at all time points, proportion of participants with >= 1 grade improvement in PR 30 min were replaced by PR at 30 and 120 min; number of participants with response in PI included; time to RM reported as number, due to change in planned analysis.|2|||f||||f||||||||||2018-06-01 02:47:24.05322|2018-06-01 02:47:24.05322
NCT00553592|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2007-11-02|2007-11-02|2007-11-05|Estimate|||||||2007-11-02|2007-11-05|Estimate|September 2007||2007-09-30|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes|A Double-Blind, Randomized, Placebo-Controlled, Parallel, Multicenter Study of the Safety and Efficacy of Two Dosages of Bicifadine SR in Adult Outpatients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|Unknown status|Recruiting|Phase 2|336|Anticipated|XTL Biopharmaceuticals||3|||f||||f||||||||||2018-06-01 02:47:24.960782|2018-06-01 02:47:24.960782
NCT00553579|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2008-05-19|2007-11-02|2007-11-05|Estimate|||||||2008-05-19|2008-05-20|Estimate|June 2007||2007-06-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||The Relationship of Residence Time and Visual Effect of Optive and Systane in Dry Eye Subjects|The Relationship of Residence Time and Visual Effect of Optive and Systane in Dry Eye Subjects|Completed|||18|Anticipated|Southern California College of Optometry|||1||f||||f||||||||||2018-06-01 02:47:25.118082|2018-06-01 02:47:25.118082
NCT00553566|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2014-01-09|2007-11-02|2007-11-05|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2005||2005-12-31|February 2010|2010-02-28||||||||Observational|||Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [COHORT]|Unknown status|Recruiting||1600||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:47:25.245896|2018-06-01 02:47:25.245896
NCT00553553|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2008-12-30|2007-11-02|2007-11-05|Estimate|||||||2008-12-30|2008-12-31|Estimate|September 2007||2007-09-30|December 2008|2008-12-31|June 2008|Anticipated|2008-06-30|May 2008|Anticipated|2008-05-31||Interventional|RITM-IVM||Efficacy of Multimodal Opioid Therapy During Hepatic Resection Surgery|Efficacy Of IV Morphine vs Remifentanil-Intrathecal Morphine Analgesia During Hepatic Resection Surgery|Unknown status|Recruiting|N/A|45|Anticipated|St Vincent's University Hospital, Ireland||2|||f||||f||||||||||2018-06-01 02:47:25.352409|2018-06-01 02:47:25.352409
NCT00553540|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2017-04-11|2007-11-02|2007-11-05|Estimate|||||||2017-04-11|2017-04-13|Actual|October 2006||2006-10-31|June 2008|2008-06-30|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|||Study to Evaluate the Effectiveness of Orthopedic Spinal Supports in the Treatment of Low Back Pain|A Randomized Prospective Study to Evaluate the Effectiveness of Orthopedic Spinal Supports in the Treatment of Low Back Pain|Completed||N/A|50|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-06-01 02:47:25.502479|2018-06-01 02:47:25.502479
NCT00553527|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2009-08-05|2007-11-02|2007-11-05|Estimate|||||||2009-08-05|2009-08-06|Estimate|July 2007||2007-07-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Biomet Humeral Stem Data Collection|Biomet Humeral Stem Data Collection|Terminated||N/A|2|Actual|Vanderbilt University||1||Sponsor decided to terminate the project due to low multi-center enrollment.|f||||f||||||||||2018-06-01 02:47:25.685533|2018-06-01 02:47:25.685533
NCT00553514|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|2013-05-29||2014-01-20|2007-11-01|2007-11-05|Estimate|2013-05-29|2013-07-25|Estimate||||2014-01-20|2014-02-13|Estimate|December 2007||2007-12-31|January 2014|2014-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||AS900672-Enriched in Ovulation Induction|A Phase II, Multicentre, Randomised, Assessor-blinded, Active-comparator, Parallel-group Dose Finding Trial to Evaluate AS900672-enriched Versus Follitropin Alfa (GONAL-f®) in Oligo-anovulatory Infertile Women Undergoing Ovulation Induction (OI)|Terminated||Phase 2|71|Actual|Merck KGaA|The study was terminated after Merck Serono had taken the decision not to pursue the development of AS900672-enriched in ovulation induction|5||"The study was terminated after Merck Serono had taken the decision not to pursue the~   development of AS900672-enriched in ovulation induction"|f||||||||||||||2018-06-01 02:47:25.78976|2018-06-01 02:47:25.78976
NCT00553501|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2014-06-26||2016-07-01|2007-11-02|2007-11-05|Estimate|2014-06-26|2014-07-24|Estimate||||2016-07-01|2016-07-06|Estimate|March 2008||2008-03-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2010|Actual|2010-07-31||Interventional|||Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma|A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 2|60|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:47:26.770267|2018-06-01 02:47:26.770267
NCT00553488|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2008-08-21|2007-11-02|2007-11-05|Estimate|||||||2008-08-21|2008-08-22|Estimate|September 2007||2007-09-30|August 2008|2008-08-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating|A Mono Center Open Labeled, Randomized Study Examining the Effects of Intra-Dermal vs Subcutaneous Application of Regular Insulin or Rapid Acting Insulin Analogue on Postprandial Glycemic Excursions in Patients With Type 1 Diabetes|Completed||Phase 2|30|Actual|Becton, Dickinson and Company||5|||f||||f||||||||||2018-06-01 02:47:27.49911|2018-06-01 02:47:27.49911
NCT00553475|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2010-03-10||2010-07-16|2007-11-02|2007-11-05|Estimate|2010-05-24|2010-06-22|Estimate||||2010-07-16|2010-07-20|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy|Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy|Completed||Phase 3|314|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 02:47:27.692743|2018-06-01 02:47:27.692743
NCT00553462|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2016-11-23||2018-01-08|2007-11-02|2007-11-05|Estimate|2016-11-23|2017-01-20|Estimate||||2018-01-08|2018-01-31|Actual|March 2008||2008-03-31|January 2018|2018-01-31|June 15, 2017|Actual|2017-06-15|January 2014|Actual|2014-01-31||Interventional||Three participants did not receive any protocol treatment and were excluded from all analyses.|Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer|Completed||Phase 2|78|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:47:30.01501|2018-06-01 02:47:30.01501
NCT00553449|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2011-05-16|2007-11-01|2007-11-05|Estimate|||||||2011-05-16|2011-05-17|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|September 2005|Actual|2005-09-30|||||Interventional|||Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.|A Randomised, Controlled, Parallel-group, Open-label Study to Evaluate Different Dosing Regimens of Rabeprazole in Controlling Nocturnal Heartburn Symptoms in Patients With Gastroesophageal Reflux Disease.|Completed||Phase 3|48|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 02:47:30.773693|2018-06-01 02:47:30.773693
NCT00553436|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2009-10-20||2010-04-20|2007-11-02|2007-11-05|Estimate|2010-03-12|2010-03-26|Estimate||||2010-04-20|2010-04-27|Estimate|November 2007||2007-11-30|April 2010|2010-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Evaluation of an Endoscopic Suturing System for Tissue Apposition in Colonic Polypectomy|Evaluation of an Endoscopic Suturing System for Tissue Apposition in Colonic Polypectomy|Completed||N/A|7|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||||2018-06-01 02:47:30.906599|2018-06-01 02:47:30.906599
NCT00553423|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2007-11-02|2007-11-02|2007-11-05|Estimate|||||||2007-11-02|2007-11-05|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|November 2008|Anticipated|2008-11-30|||||Interventional|||Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage|Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage|Unknown status|Recruiting|Phase 3|128|Anticipated|Aga Khan University||2|||f||||t||||||||||2018-06-01 02:47:31.156125|2018-06-01 02:47:31.156125
NCT00553410|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2018-03-05|2007-11-02|2007-11-05|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2007||2007-08-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|SOLE||Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer|SOLE, Study of Letrozole Extension, A Phase III Trial Evaluating the Role of Continuous Letrozole Versus Intermittent Letrozole Following 4 to 6 Years of Prior Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone-Receptor Positive, Node Positive Early Stage Breast Cancer|Active, not recruiting||Phase 3|4884|Actual|International Breast Cancer Study Group||2|||f||||t||||||||||2018-06-01 02:47:31.366239|2018-06-01 02:47:31.366239
NCT00553397|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2017-03-23|2007-11-01|2007-11-05|Estimate|||||||2017-03-23|2017-03-27|Actual|October 2007||2007-10-31|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Live Lung Donor Retrospective Study|Live Lung Donor Retrospective Study (RELIVE-02)|Completed|||369|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 02:47:31.7281|2018-06-01 02:47:31.7281
NCT00553384|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2012-02-16|2007-11-02|2007-11-05|Estimate|||||||2012-02-16|2012-02-20|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Physiological Effects of Androstadienone Exposure|Physiological Effects of Androstadienone Exposure|Completed|||68|Actual|Rockefeller University|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 02:47:31.904391|2018-06-01 02:47:31.904391
NCT00553371|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2013-08-23|2007-11-02|2007-11-05|Estimate|||||||2013-08-23|2013-08-26|Estimate|April 2006||2006-04-30|October 2007|2007-10-31||||||||Observational|||Follow-up Evaluation Using CT Scans in Patients Who Have Been Treated For Metastatic Testicular Cancer|Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT)|Unknown status|Recruiting||300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:47:32.010905|2018-06-01 02:47:32.010905
NCT00553358|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|2011-05-26||2017-05-23|2007-11-01|2007-11-05|Estimate|2011-10-12|2011-10-13|Estimate||||2017-05-23|2017-06-16|Actual|January 5, 2008|Actual|2008-01-05|May 2017|2017-05-31|December 23, 2019|Anticipated|2019-12-23|May 27, 2010|Actual|2010-05-27||Interventional|Neo ALTTO||Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study|Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A Randomised, Multicenter Open-label Phase III Study of Neoadjuvant Lapatinib, Trastuzumab and Their Combination Plus Paclitaxel in Women With HER2/ErbB2 Positive Primary Breast Cancer|Active, not recruiting||Phase 3|455|Actual|Novartis||3|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 02:47:32.139028|2018-06-01 02:47:32.139028
NCT00553345|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2014-01-09|2007-11-02|2007-11-05|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2005||2005-12-31|February 2010|2010-02-28||||||||Interventional|||Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT]|Unknown status|Recruiting|Phase 3|515||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:47:33.420503|2018-06-01 02:47:33.420503
NCT00553332|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2015-09-11||2016-03-22|2007-11-02|2007-11-05|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||All patients had metastatic disease.|Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery|A Phase 2 Study of AZD6244 in Biliary Cancers|Completed||Phase 2|29|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:47:33.494293|2018-06-01 02:47:33.494293
NCT00553319|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2014-08-20||2016-05-16|2007-11-02|2007-11-05|Estimate|2014-08-20|2014-09-01|Estimate||||2016-05-16|2016-06-17|Estimate|December 2007||2007-12-31|May 2016|2016-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|CAMP|Description of 126 participants randomized to study arms.|Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence|A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence|Completed||Phase 2/Phase 3|139|Actual|New York State Psychiatric Institute|The dropout rate was relatively low, however, there were dropouts, and this does introduce uncertainly into the outcome assessment. Since all patients received CBT we cannot conclude whether CBT is necessary to derive benefit from the medication.|3|||f||||t||||||||||2018-06-01 02:47:33.72113|2018-06-01 02:47:33.72113
NCT00553124|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2014-01-09|2007-11-02|2007-11-05|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2005||2005-12-31|October 2007|2007-10-31||||||||Interventional|||Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial)|Unknown status|Recruiting|Phase 3|3400||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:47:37.564829|2018-06-01 02:47:37.564829
NCT00553306|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02||2017-02-13|2017-02-13|2007-11-02|2007-11-05|Estimate||||2017-02-13|2017-02-15|Actual|2017-02-13|2017-02-15|Actual|September 2007||2007-09-30|February 2017|2017-02-28|March 2012|Actual|2012-03-31|August 2010|Actual|2010-08-31||Interventional|||Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma|Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|10|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 02:47:34.105367|2018-06-01 02:47:34.105367
NCT00553293|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2007-11-02|2007-11-02|2007-11-05|Estimate|||||||2007-11-02|2007-11-05|Estimate|August 2003||2003-08-31|November 2007|2007-11-30|November 2004|Actual|2004-11-30|||||Interventional|||Nordic Luveris Study|Recombinant LH Supplementation to Recombinant FSH During the Final Days of Controlled Ovarian Stimulation for IVF: a Multicentre, Prospective, Randomized, Controlled Trial|Completed||Phase 4|526|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 02:47:34.198829|2018-06-01 02:47:34.198829
NCT00553280|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2010-12-07||2011-04-22|2007-11-02|2007-11-05|Estimate|2010-12-07|2011-01-05|Estimate||||2011-04-22|2011-04-26|Estimate|February 2008||2008-02-29|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy|An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For Pain Associated With Diabetic Peripheral Neuropathy|Completed||Phase 3|123|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:47:34.282308|2018-06-01 02:47:34.282308
NCT00553267|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|2009-11-18||2013-12-16|2007-11-02|2007-11-05|Estimate|2009-11-18|2009-12-22|Estimate||||2013-12-16|2014-02-13|Estimate|November 2007||2007-11-30|December 2013|2013-12-31||||October 2008|Actual|2008-10-31||Interventional|||Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension|An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy|Completed||Phase 3|947|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:47:34.597444|2018-06-01 02:47:34.597444
NCT00553254|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02||2011-11-15|2014-08-06|2007-11-02|2007-11-05|Estimate||||2011-11-15|2011-11-21|Estimate|2014-08-06|2014-08-08|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|July 2014|Actual|2014-07-31|August 2010|Actual|2010-08-31||Interventional|||Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer|A Phase 1/2, Open Label, Single Arm Trial To Determine The Recommended Phase 2 Dose And Evaluate The Efficacy Of Pf 00299804 In Patients In Korea With Kras Wild Type Advanced NSCLC, Which Is Refractory To Chemotherapy And Erlotinib Or Gefitinib|Completed||Phase 1/Phase 2|55|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:47:35.169707|2018-06-01 02:47:35.169707
NCT00553241|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2009-01-29|2007-11-02|2007-11-05|Estimate|||||||2009-01-29|2009-01-30|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|January 2009|Anticipated|2009-01-31|||||Observational|||Short-Term Prognosis Evaluation of Transient Ischemic Attack Patients Using ABCD2 Score|Phase 1 of Clinical Trial of Risk Factor, Prognosis, Imaging and Standard Management of Transient Ischemic Attack.|Unknown status|Recruiting||1|Anticipated|Capital Medical University|||1||f||||f||||||||||2018-06-01 02:47:35.279657|2018-06-01 02:47:35.279657
NCT00553228|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2016-06-22|2007-11-02|2007-11-05|Estimate|||||||2016-06-22|2016-06-23|Estimate|November 2007||2007-11-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pertussis Maternal Immunization Study|Immunization of Women With Diphtheria and Tetanus Toxoids Combined With Acellular Pertussis (Tdap) During the Mid Third Trimester of Pregnancy: An Evaluation of the Potential for Immunological Protection for the Neonate|Active, not recruiting||Phase 2/Phase 3|440|Anticipated|Dalhousie University||2|||f||||t||||||||||2018-06-01 02:47:35.358307|2018-06-01 02:47:35.358307
NCT00553215|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2014-01-09|2007-11-02|2007-11-05|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2005||2005-12-31|February 2010|2010-02-28||||||||Observational|||Quality of Life in Patients With Bladder Cancer|Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]|Unknown status|Recruiting||2700||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:47:35.455151|2018-06-01 02:47:35.455151
NCT00553202|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2016-10-31||2017-01-06|2007-11-02|2007-11-05|Estimate|2017-01-06|2017-02-24|Actual||||2017-01-06|2017-02-24|Actual|January 2008||2008-01-31|July 2016|2016-07-31||||June 2016|Actual|2016-06-30||Interventional|||Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia|Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study|Active, not recruiting||Phase 2|158|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 02:47:35.53895|2018-06-01 02:47:35.53895
NCT00553189|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2017-06-30|2007-11-02|2007-11-05|Estimate|||||||2017-06-30|2017-07-02|Actual|August 9, 2007||2007-08-09|September 28, 2011|2011-09-28|September 28, 2011|Actual|2011-09-28|February 1, 2008|Actual|2008-02-01||Interventional|||Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas|A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas|Completed||Phase 1|31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:47:36.008624|2018-06-01 02:47:36.008624
NCT00553176|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2013-03-01|2007-11-01|2007-11-05|Estimate|||||||2013-03-01|2013-03-04|Estimate|August 1999||1999-08-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|TREAT||The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry|Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry|Completed|||6273|Actual|Janssen Biotech, Inc.|||1||f||||f||||||||||2018-06-01 02:47:36.080348|2018-06-01 02:47:36.080348
NCT00553163|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2013-11-07|2007-11-02|2007-11-05|Estimate|||||||2013-11-07|2013-11-08|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial|Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial|Terminated||N/A|29|Actual|Queen Mary University of London||2||Unable to recruit sufficient numbers of patinets in the time available|f||||t||||||||||2018-06-01 02:47:36.171132|2018-06-01 02:47:36.171132
NCT00553150|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2016-11-14||2018-04-06|2007-11-02|2007-11-05|Estimate|2016-11-14|2017-01-11|Estimate||||2018-04-06|2018-05-08|Actual|March 2009||2009-03-31|April 2018|2018-04-30||||January 2012|Actual|2012-01-31||Interventional|||Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma|Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1/Phase 2|122|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:47:36.294659|2018-06-01 02:47:36.294659
NCT00553098|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|2017-04-13||2017-05-22|2007-11-02|2007-11-05|Estimate|2017-04-13|2017-05-19|Actual||||2017-05-22|2017-06-14|Actual|June 2006||2006-06-30|May 2017|2017-05-31||||March 2015|Actual|2015-03-31||Interventional|||Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders|Hematopoietic Cell Transplantation for Treatment of Patients With Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine With or Without Campath®|Active, not recruiting||Phase 2|29|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 02:47:37.887594|2018-06-01 02:47:37.887594
NCT00553085|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2014-06-19|2007-11-02|2007-11-05|Estimate|||||||2014-06-19|2014-06-20|Estimate|September 2007||2007-09-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|December 2009|Actual|2009-12-31||Observational|||Anxiety Disorders in Children - Association With Neurodevelopmental Delay/Disorder|Anxiety Disorders in Children - Association With Neurodevelopmental Delay/Disorder and Temperament/Personality. A Clinical Case-control Study|Completed|||141|Actual|Regionsenter for barn og unges psykiske helse|||3||f||||f||||||Samples Without DNA|"~     Saliva for measuring Cortisol~   "|||2018-06-01 02:47:38.409646|2018-06-01 02:47:38.409646
NCT00553072|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2016-10-12|2007-11-02|2007-11-05|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2004||2004-09-30|November 2013|2013-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|Magsulf||Magnesium Sulphate in Perinatal Asphyxia|Magnesium Sulphate in Perinatal Asphyxia: A Randomized Placebo Controlled Trial.|Completed||Phase 3|40|Actual|Sheri Kashmir Institute of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:47:38.47342|2018-06-01 02:47:38.47342
NCT00553059|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-02|||2014-09-04|2007-11-02|2007-11-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|May 2008||2008-05-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer|Randomized, Double-Blind, Placebo-Controlled Trial of Palonosetron/Dexamethasone With or Without Dronabinol for the Prevention of Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy|Completed||Phase 3|62|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:47:38.544507|2018-06-01 02:47:38.544507
NCT00553046|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2016-02-03|2007-11-01|2007-11-02|Estimate|||||||2016-02-03|2016-02-04|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Observational|||Last 3 Months of Life in Home Ventilated Patients|Italian Multicenter Survey on the Last 3 Months of Life in Patients Ventilated at Home|Completed|||180|Actual|Fondazione Salvatore Maugeri|||1||f||||f||||||||||2018-06-01 02:47:38.617841|2018-06-01 02:47:38.617841
NCT00553033|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2007-11-01|2007-11-01|2007-11-02|Estimate|||||||2007-11-01|2007-11-02|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|December 2008|Anticipated|2008-12-31|||||Observational|||Laparoscopic Liver Resection|Prospective Evaluation of Laparoscopic Liver Resection|Unknown status|Recruiting||40|Anticipated|IRCCS San Raffaele|||1||f||||||||||||||2018-06-01 02:47:38.680199|2018-06-01 02:47:38.680199
NCT00553020|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2007-10-31|2007-10-31|2007-11-02|Estimate|||||||2007-10-31|2007-11-02|Estimate|April 2004||2004-04-30|October 2007|2007-10-31|July 2005|Actual|2005-07-31|||||Interventional|||Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes|Assessment of Duration of Metabolic Effect of a Single Bolus of Subcutaneous Injected Lantus Compared to NPH-Insulin(Protaphan)in Patients With Type 2 Diabetes|Completed||Phase 4|16|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:47:38.772483|2018-06-01 02:47:38.772483
NCT00553007|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2007-11-01|2007-11-01|2007-11-02|Estimate|||||||2007-11-01|2007-11-02|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|October 2009|Anticipated|2009-10-31|||||Interventional|||The Relation Between Periodontal Disease and Metabolic Syndrome|The Relation Between Periodontal Disease and Metabolic Syndrome|Unknown status|Recruiting|N/A|80|Anticipated|Aichi Gakuin University|||||f||||f||||||||||2018-06-01 02:47:38.821723|2018-06-01 02:47:38.821723
NCT00552994|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2010-07-09|2007-10-31|2007-11-02|Estimate|||||||2010-07-09|2010-07-12|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|DIABEDES IV||Comparison of Coronary Xience V and the Cypher Select+ Stents in Diabetic Patients|A Danish Prospective Randomized Multicenter Comparison of the Xience V and the Cypher Select+ Stents in Unselective Patients With Diabetes Mellitus. An Intravascular Ultrasound Study.|Completed||N/A|150|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-06-01 02:47:38.877305|2018-06-01 02:47:38.877305
NCT00552981|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2012-07-09|2007-11-01|2007-11-02|Estimate|||||||2012-07-09|2012-07-10|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|HELI||Effectiveness of Local Application of Warm Air in Patients With Common Cold (HELI Study)|Effectiveness of Local Application of Warm Air in Patients With Common Cold (HELI Study)|Completed||N/A|157|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 02:47:38.932647|2018-06-01 02:47:38.932647
NCT00552968|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2016-10-12|2007-10-31|2007-11-02|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Pain Prevalence in the Trauma Population|Pain Prevalence in the Trauma Population at Sunnybrook Hospital|Completed|||44|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 02:47:38.997412|2018-06-01 02:47:38.997412
NCT00552955|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2018-02-13|2007-11-01|2007-11-02|Estimate|||||||2018-02-13|2018-02-14|Actual|October 26, 2007||2007-10-26|March 21, 2016|2016-03-21|March 21, 2016||2016-03-21|||||Observational|||Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women|Effect of Fasting on the Size of Lymphangioleiomyomas in Patients With Lymphangioleiomyomatosis|Completed|||35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:47:39.047|2018-06-01 02:47:39.047
NCT00552942|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2007-11-01|2007-11-01|2007-11-02|Estimate|||||||2007-11-01|2007-11-02|Estimate|July 2006||2006-07-31|November 2007|2007-11-30|July 2008|Anticipated|2008-07-31|||||Interventional|||Randomized Controlled Trial of Laparoscopic Gastric Bypass Plus Omentectomy Versus Laparoscopic Gastric Bypass Alone in Improving Diabetic Indices|Randomized Controlled Trial of Laparoscopic Gastric Bypass Plus Omentectomy Versus Laparoscopic Gastric Bypass Alone in Improving Diabetic Indices|Unknown status|Recruiting|Phase 3|40|Anticipated|Legacy Health System||2|||f||||f||||||||||2018-06-01 02:47:39.097656|2018-06-01 02:47:39.097656
NCT00552929|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2017-06-02|2007-10-31|2007-11-02|Estimate|||||||2017-06-02|2017-06-05|Actual|October 4, 2005|Actual|2005-10-04|June 2017|2017-06-30|September 15, 2006|Actual|2006-09-15|September 15, 2006|Actual|2006-09-15||Interventional|||A Bridging Trial Comparing Org 25969 at 1-2 PTC in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.209B)(P05974)|A Multi -Center, Randomized, Open -Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at 1-2 PTC After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part B: Caucasian Subjects.|Completed||Phase 2|100|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:47:39.185621|2018-06-01 02:47:39.185621
NCT00552916|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2008-08-19|2007-11-01|2007-11-02|Estimate|||||||2008-08-19|2008-08-20|Estimate|October 2007||2007-10-31|August 2008|2008-08-31|November 2010|Anticipated|2010-11-30|October 2010|Anticipated|2010-10-31||Interventional|||Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke|Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke|Unknown status|Recruiting|Phase 4|40|Anticipated|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-06-01 02:47:39.257432|2018-06-01 02:47:39.257432
NCT00552903|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2009-02-03|2007-11-01|2007-11-02|Estimate|||||||2009-02-03|2009-02-04|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|November 2009|Anticipated|2009-11-30||Interventional|TerVa||Randomised Trial of Health Coaching in Secondary Prevention of Diabetes and Heart Disease|Randomised Trial of Health Coaching in Secondary Prevention of Diabetes and Heart Disease|Unknown status|Active, not recruiting|Phase 3|1500|Anticipated|Paijat-Hame Hospital District||2|||f||||||||||||||2018-06-01 02:47:40.28285|2018-06-01 02:47:40.28285
NCT00552890|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2007-11-01|2007-11-01|2007-11-02|Estimate|||||||2007-11-01|2007-11-02|Estimate|December 2001||2001-12-31|December 2001|2001-12-31|February 2004|Actual|2004-02-29|||||Interventional|||Modified Atkins Diet and Type 2 Diabetic Patients|Influende of a Modified Atkins Diet on Glucose Metabolism and Weight Loss in Obese Type 2 Diabetic Patients - A Randomized Controlled Trial|Completed||N/A|52|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 02:47:40.390022|2018-06-01 02:47:40.390022
NCT00552877|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-08-12|2007-11-01|2007-11-02|Estimate|||||||2009-08-12|2009-08-13|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|SORT OUT IV||The SOURT OUT IV TRIAL|Randomized Clinical Comparison of the Xience V and the Cypher Coronary Stents in Non-selected Patients With Coronary Heart Disease|Completed||N/A|2678|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-06-01 02:47:40.534377|2018-06-01 02:47:40.534377
NCT00552864|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2007-10-31|2007-10-31|2007-11-02|Estimate|||||||2007-10-31|2007-11-02|Estimate|January 2003||2003-01-31|October 2007|2007-10-31|June 2005|Actual|2005-06-30|||||Interventional|||Comparison of Ropivacaine and Levobupivacaine in High Thoracic Epidural Anesthesia|High Thoracic Epidural Anesthesia and Postoperative Analgesia With Ropivacaine or Levobupivacaine for Coronary Surgery: A Prospective Randomized Double-Blind Comparison|Completed||Phase 4|61|Actual|Centro Cardiologico Monzino||2|||f||||f||||||||||2018-06-01 02:47:40.612583|2018-06-01 02:47:40.612583
NCT00552851|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2010-09-23|2007-11-01|2007-11-02|Estimate|||||||2010-09-23|2010-09-24|Estimate|June 2006||2006-06-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|||||Interventional|||Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant|Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study|Unknown status|Recruiting|Phase 4|4|Anticipated|University of Wuerzburg||1|||f||||t||||||||||2018-06-01 02:47:40.701661|2018-06-01 02:47:40.701661
NCT00552838|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-31|2007-10-31|2007-11-02|Estimate|||||||2007-10-31|2007-11-02|Estimate|October 2002||2002-10-31|September 2007|2007-09-30|August 2003|Actual|2003-08-31|||||Interventional|||The Impact of an Antimicrobial Utilization Program on Antimicrobial Use|The Impact of an Antimicrobial Utilization Program on Antimicrobial Use in a Large Public Hospital: A Randomized Controlled Trial|Completed||N/A|785|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 02:47:40.777658|2018-06-01 02:47:40.777658
NCT00552825|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2007-11-01|2007-11-01|2007-11-02|Estimate|||||||2007-11-01|2007-11-02|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|October 2006|Actual|2006-10-31|||||Observational|||Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children|Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years|Completed|||35|Actual|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 02:47:40.842626|2018-06-01 02:47:40.842626
NCT00552812|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2014-09-19||2016-02-14|2007-10-31|2007-11-02|Estimate|2014-09-19|2014-09-25|Estimate||||2016-02-14|2016-03-11|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|December 2012|Actual|2012-12-31||Interventional|COAST||Coarctation Of the Aorta Stent Trial|Coarctation Of the Aorta Stent Trial|Completed||N/A|105|Actual|Johns Hopkins University||1|||f||||t||||||||No|Individual patient data is confidential and is not shared.|2018-06-01 02:47:40.931151|2018-06-01 02:47:40.931151
NCT00552799|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2012-07-23|2007-11-01|2007-11-02|Estimate|||||||2012-07-23|2012-07-24|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|PATCH1||RCT to Investigate if Prophylactic Antibiotics Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg|Randomised Controlled Trial to Investigate Whether Prophylactic Antibiotics Can Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH I)|Completed||Phase 4|274|Actual|University of Nottingham||2|||f||||t||||||||||2018-06-01 02:47:41.224133|2018-06-01 02:47:41.224133
NCT00552786|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|2009-03-29||2010-07-01|2007-11-01|2007-11-02|Estimate|2010-07-01|2010-07-27|Estimate||||2010-07-01|2010-07-27|Estimate|November 2007||2007-11-30|November 2009|2009-11-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Antioxidation Medication for Noise-induced Hearing Loss|Antioxidation Medication for Noise-induced Hearing Loss|Completed||Phase 2|53|Actual|National Taiwan University Hospital|No text entered.|2|||f||||f||||||||||2018-06-01 02:47:41.372951|2018-06-01 02:47:41.372951
NCT00552773|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2013-05-31|2007-10-31|2007-11-02|Estimate|||||||2013-05-31|2013-06-04|Estimate|November 2007||2007-11-30|November 2011|2011-11-30|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis|A Randomized, Double-blind, Placebo Controlled, Parallel Group Trial of Cyclamen Europaeum Extract Nasal Spray 10% (v/v) in the Treatment of Subjects With Acute Sinusitis|Completed||N/A|48|Actual|Dey||2|||f||||t||||||||||2018-06-01 02:47:41.728502|2018-06-01 02:47:41.728502
NCT00552760|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2010-05-29||2014-03-17|2007-10-31|2007-11-02|Estimate|2010-06-01|2010-07-05|Estimate||||2014-03-17|2014-04-14|Estimate|November 2007||2007-11-30|March 2014|2014-03-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|Ram-TIME||Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder|A Double-Blind, Randomized, Placebo-Controlled Trial of Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder.|Completed||Phase 4|90|Actual|Lehigh Valley Hospital||2|||f||||t||||||||||2018-06-01 02:47:41.845816|2018-06-01 02:47:41.845816
NCT00552747|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2011-03-09|2007-11-01|2007-11-02|Estimate|||||||2011-03-09|2011-03-10|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease|The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal|Completed||Phase 4|76|Actual|National Heart Institute, Mexico||2|||f||||t||||||||||2018-06-01 02:47:42.183716|2018-06-01 02:47:42.183716
NCT00552734|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2015-08-10|2007-11-01|2007-11-02|Estimate|||||||2015-08-10|2015-08-13|Estimate|July 2005||2005-07-31|August 2015|2015-08-31|May 2007|Actual|2007-05-31|||||Observational|||Improved Glycemic Control in Adult Subjects With Type 1 Diabetes on MDI Using Insulin Guidance Software|Glycemic Control and Prevention of Hypoglycemia in Intensively Treated Subjects With Type 1 Diabetes Using Accu-Chek® Advisor Insulin Guidance Software|Completed|||123|Actual|University of Colorado, Denver|||2||f||||f||||||||||2018-06-01 02:47:42.34765|2018-06-01 02:47:42.34765
NCT00552721|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-09-04|2007-10-31|2007-11-02|Estimate|||||||2009-09-04|2009-09-07|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|||||Interventional|||Physical Therapy After Anti-spastic Treatment in Children With Cerebral Palsy|Physical Therapy With Versus Without Strength Training After Botulinum-toxin Treatment in Children With Cerebral Palsy|Completed||N/A|14|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-06-01 02:47:42.426648|2018-06-01 02:47:42.426648
NCT00552708|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31||2010-10-13|2010-10-13|2007-10-31|2007-11-02|Estimate||||2010-10-13|2010-10-15|Estimate|2010-10-13|2010-10-15|Estimate|September 2007||2007-09-30|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.|A Randomized, Open-label, Single-dose, Crossover Study to Demonstrate the Bioequivalence of the Final Fixed Dose Combination (FDC) Formulation (COREG CR & Lisinopril) to COREG CR & ZESTRIL Employed in the Phase III Factorial Study|Completed||Phase 1|55|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:47:42.520043|2018-06-01 02:47:42.520043
NCT00552695|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2009-10-16||2012-10-19|2007-10-31|2007-11-02|Estimate|2010-11-05|2010-12-06|Estimate||||2012-10-19|2012-10-22|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Lidocaine Patches Prior to Intravenous Insertion|Phase II Study of Lidoderm Patches Prior to Intravenous Catheter Insertion.|Completed||Phase 2|45|Actual|Stony Brook University||2|||f||||f||||||||||2018-06-01 02:47:42.599908|2018-06-01 02:47:42.599908
NCT00552682|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-07-20|2007-11-01|2007-11-02|Estimate|||||||2009-07-20|2009-07-21|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+|Pilot, Opened, Randomized Clinical Trial to Assess the Efficacy of Duloxetine in the Treatment of Fibromialgy in Patients With Infection by HIV 1+|Completed||Phase 3|10|Actual|Germans Trias i Pujol Hospital||2|||f||||t||||||||||2018-06-01 02:47:42.875993|2018-06-01 02:47:42.875993
NCT00552669|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|2009-03-31||2010-05-27|2007-11-01|2007-11-02|Estimate|2009-07-10|2009-08-20|Estimate||||2010-05-27|2010-06-02|Estimate|January 2006||2006-01-31|May 2009|2009-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|ORAR III||Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents|Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.|Completed||Phase 4|200|Actual|Centro de estudios en Cardiologia Intervencionista|It was an open label design. Multiple approved DES designs were used. Health Care system in Argentina differs from other world ones.|2|||f||||t||||||||||2018-06-01 02:47:42.973428|2018-06-01 02:47:42.973428
NCT00552656|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2008-08-11|2007-10-31|2007-11-02|Estimate|||||||2008-08-11|2008-08-12|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|August 2010|Anticipated|2010-08-31|||||Observational|FIREMAN||Long Term Efficacy and Safety of Firebird Sirolimus-Eluting Stent In Complex Coronary Lesions|Prospective, Multicenter Study of Firebird Sirolimus-Eluting Stent for Treatment of Complex Coronary Lesions. Clinical and Angiographic Outcomes of FIREMAN Study|Unknown status|Enrolling by invitation||1000|Anticipated|Xijing Hospital|||1||f||||t||||||||||2018-06-01 02:47:43.333485|2018-06-01 02:47:43.333485
NCT00552643|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2009-10-27|2007-11-01|2007-11-02|Estimate|||||||2009-10-27|2009-10-28|Estimate|May 2008||2008-05-31|October 2009|2009-10-31||||May 2009|Anticipated|2009-05-31||Interventional|||Study to Evaluate Polyheal-1 in Treatment of Recalcitrant Wounds|Study to Evaluate Polyheal-1 in Treatment of Recalcitrant Wounds|Unknown status|Recruiting|N/A|60|Anticipated|Polyheal Ltd.||2|||f||||f||||||||||2018-06-01 02:47:43.427424|2018-06-01 02:47:43.427424
NCT00552630|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2015-03-24|2007-11-01|2007-11-02|Estimate|||||||2015-03-24|2015-03-26|Estimate|September 2007||2007-09-30|December 2007|2007-12-31||||||||Interventional|||Penicillamine Chelation for Children With Lead Poisoning|A Phase 2/3 Trial of d-Penicillamine Chelation in Lead-Poisoned Children|Withdrawn||Phase 2/Phase 3|0|Actual|FDA Office of Orphan Products Development||2|||f||||t||||||||||2018-06-01 02:47:43.540822|2018-06-01 02:47:43.540822
NCT00552617|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2017-06-02|2007-10-31|2007-11-02|Estimate|||||||2017-06-02|2017-06-05|Actual|September 20, 2005|Actual|2005-09-20|June 2017|2017-06-30|August 31, 2006|Actual|2006-08-31|August 31, 2006|Actual|2006-08-31||Interventional|||A Bridging Trial Comparing Org 25969 at Reappearance of T2 in Japanese and Caucasian Subjects. Part B: Caucasian Subjects (19.4.208B)(P05971)|A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part B: Caucasian Subjects|Completed||Phase 2|100|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-06-01 02:47:43.630518|2018-06-01 02:47:43.630518
NCT00552604|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2015-03-24|2007-11-01|2007-11-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|MUSEC||MUltiple Sclerosis and Extract of Cannabis (MUSEC) Study|Randomised, Double-blind, Placebo-controlled Phase III Trial to Determine the Efficacy and Safety of a Standardised Oral Extract of Cannabis Sativa for the Symptomatic Relief of Muscle Stiffness and Pain in Multiple Sclerosis.|Terminated||Phase 3|279|Actual|Institut fur Klinische Forschung, Germany||2||due to recruitment problems / based on recommendation of Independent Review Board|f||||t||||||||||2018-06-01 02:47:43.715622|2018-06-01 02:47:43.715622
NCT00552591|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2011-12-07|2007-11-01|2007-11-02|Estimate|||||||2011-12-07|2011-12-08|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|FHHP-RCT||Family Heart Health Program: Randomized, Controlled Trial|Family Heart Health Program: Randomized, Controlled Trial|Completed||N/A|426|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-06-01 02:47:43.788515|2018-06-01 02:47:43.788515
NCT00552578|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|2009-01-21||2011-02-14|2007-11-01|2007-11-02|Estimate|2009-05-19|2009-07-07|Estimate||||2011-02-14|2011-02-17|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Buprenorphine as a Treatment in Opiate Dependent Pain Patients|A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients|Terminated||Phase 4|12|Actual|State University of New York at Buffalo||2||"Tapering doses protocol arm was not effective for treatment retention outcome."|f||||f||||||||||2018-06-01 02:47:43.867387|2018-06-01 02:47:43.867387
NCT00483470|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2014-01-17|2007-06-06|2007-06-07|Estimate|||||||2014-01-17|2014-01-22|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose||Completed||Phase 3|720|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:10:42.967989|2018-06-01 03:10:42.967989
NCT00552565|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-06-10|2007-10-31|2007-11-02|Estimate|||||||2009-06-10|2009-06-11|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ARDIS-1||Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)|A Randomized, Double-Blind, Placebo-Controlled Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)|Completed||Phase 3|711|Actual|AGI Therapeutics, Inc.||4|||f||||f||||||||||2018-06-01 02:47:44.151242|2018-06-01 02:47:44.151242
NCT00552552|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2007-11-01|2007-11-01|2007-11-02|Estimate|||||||2007-11-01|2007-11-02|Estimate|January 2008||2008-01-31|October 2007|2007-10-31|December 2009|Anticipated|2009-12-31|||||Interventional|FIBS||Development and Evaluation of a Cancer-Related Fatigue Patient Education Program|Development and Evaluation of a Cancer-Related Fatigue Patient Education Program|Unknown status|Not yet recruiting|N/A|300|Anticipated|University of Bremen||2|||f||||||||||||||2018-06-01 02:47:44.30266|2018-06-01 02:47:44.30266
NCT00552539|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2007-10-31|2007-10-31|2007-11-02|Estimate|||||||2007-10-31|2007-11-02|Estimate|June 2006||2006-06-30|October 2007|2007-10-31|August 2006|Actual|2006-08-31|||||Interventional|||Syphilis Video Tool to Promote Knowledge and Testing in the ED|Video Tool to Promote Syphilis Knowledge and Testing in the Emergency Department|Completed||N/A|220|Actual|Jacobi Medical Center||4|||f||||f||||||||||2018-06-01 02:47:44.385513|2018-06-01 02:47:44.385513
NCT00552526|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-03-18|2007-11-01|2007-11-02|Estimate|||||||2009-03-18|2009-03-19|Estimate|November 2007||2007-11-30|March 2009|2009-03-31|December 2013|Anticipated|2013-12-31|January 2011|Anticipated|2011-01-31||Interventional|||Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy|Comparing Ketogenic Diet With the Most Appropriate Antiepileptic Drug- a Randomized Study of Children With Mental Retardation and Drug Resistant Epilepsy|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 02:47:44.45661|2018-06-01 02:47:44.45661
NCT00552513|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2014-05-27||2014-05-27|2007-11-01|2007-11-02|Estimate|2014-05-27|2014-06-27|Estimate||||2014-05-27|2014-06-27|Estimate|May 2005||2005-05-31|May 2014|2014-05-31|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|TIMACS||Early Versus Delayed Timing of Intervention in Patients With Acute Coronary Syndromes|An International Randomised Trial of Early Versus Delayed Invasive Strategies in Patients With Non-ST Segment Elevation Acute Coronary Syndromes|Completed||N/A|3031|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-06-01 02:47:44.588295|2018-06-01 02:47:44.588295
NCT00552500|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|||2010-03-16|2007-11-01|2007-11-02|Estimate|||||||2010-03-16|2010-03-18|Estimate|February 2003||2003-02-28|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2004|Actual|2004-12-31||Interventional|DepIVGTT||Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia|Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia|Unknown status|Active, not recruiting|N/A|120|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:47:44.840728|2018-06-01 02:47:44.840728
NCT00552487|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2007-10-31|2007-10-31|2007-11-02|Estimate|||||||2007-10-31|2007-11-02|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis|Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis|Completed||N/A|62|Actual|University of Wuerzburg||4|||f||||t||||||||||2018-06-01 02:47:44.92409|2018-06-01 02:47:44.92409
NCT00552474|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31||2012-04-27|2017-02-22|2007-10-31|2007-11-02|Estimate||||2012-10-10|2012-10-12|Estimate|2017-02-22|2017-02-24|Actual|October 2005||2005-10-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2010|Actual|2010-10-31||Interventional|||Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease|A Clinical Evaluation of Bilateral Stimulation of the Subthalamic Nucleus (STN) Using the ANS Totally Implantable Deep Brain Stimulation System as an Adjunctive Treatment for Reducing Some of the Symptoms of Advanced, Levodopa-responsive Parkinson's Disease That Are Not Adequately Controlled With Medication.|Completed||N/A|136|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 02:47:45.007798|2018-06-01 02:47:45.007798
NCT00552461|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2008-05-06|2007-10-31|2007-11-02|Estimate|||||||2008-05-06|2008-05-09|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Interventional|PAP||Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis|Prospective Open-Label Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis|Unknown status|Recruiting|Phase 2|10|Anticipated|East Carolina University||1|||f||||t||||||||||2018-06-01 02:47:45.123338|2018-06-01 02:47:45.123338
NCT00552448|ClinicalTrials.gov processed this data on May 31, 2018|2007-11-01|2016-07-07||2016-09-12|2007-11-01|2007-11-02|Estimate|2016-09-12|2016-09-14|Estimate||||2016-09-12|2016-09-14|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Use of High Frequency Chest Compression in Pediatric Status Asthmaticus|Use of High Frequency Chest Compression (HFCC) in Pediatric Status Asthmaticus|Terminated||N/A|36|Actual|Texas Tech University Health Sciences Center||2||Continuing review not submitted to IRB within 365 days.|f||||t||||||||Undecided||2018-06-01 02:47:45.224422|2018-06-01 02:47:45.224422
NCT00552435|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2008-05-06|2007-10-31|2007-11-02|Estimate|||||||2008-05-06|2008-05-07|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Micropulse 810 Nanomolar (nm), Diode Laser for Diffuse Diabetic Macular Edema|Phase 2 Study of Micropulse 810nm Diode Laser Photocoagulation for Treatment of Diffuse Diabetic Macular Edema|Unknown status|Recruiting|Phase 2|50|Anticipated|Federal University of São Paulo||2|||f||||||||||||||2018-06-01 02:47:45.719236|2018-06-01 02:47:45.719236
NCT00552422|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2015-06-02||2015-06-17|2007-10-31|2007-11-01|Estimate|2015-06-17|2015-07-10|Estimate||||2015-06-17|2015-07-10|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Domperidone for Gastroparesis in Solid Organ Transplantation|Domperidone for Gastroparesis Associated With Solid Organ Transplantation|Terminated||N/A|6|Actual|Columbia University||1||Lack of perceived need for domperidone in this population|f||||f||||||||||2018-06-01 02:47:45.844659|2018-06-01 02:47:45.844659
NCT00552409|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2013-06-18||2014-04-09|2007-10-31|2007-11-01|Estimate|2013-09-26|2013-09-27|Estimate||||2014-04-09|2014-04-28|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease|Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease|Completed||Phase 2/Phase 3|22|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:47:46.193523|2018-06-01 02:47:46.193523
NCT00552396|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|2012-03-02||2016-03-03|2007-10-31|2007-11-01|Estimate|2012-05-24|2012-06-28|Estimate||||2016-03-03|2016-03-31|Estimate|May 2007||2007-05-31|March 2016|2016-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma|An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Multiple Dose Administrations of Anti-KIR (1-7F9) Human Monoclonal Antibody in Subjects With Multiple Myeloma|Completed||Phase 1|32|Actual|Innate Pharma|||||f||||t||||||||||2018-06-01 02:47:46.706725|2018-06-01 02:47:46.706725
NCT00552383|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2007-10-31|2007-10-31|2007-11-01|Estimate|||||||2007-10-31|2007-11-01|Estimate|September 1998||1998-09-30|October 2007|2007-10-31|December 2004|Actual|2004-12-31|||||Interventional|NIDCAP||The Edmonton Randomised Controlled Trial of NIDCAP - Based Developmental Care|The Impact of Developmental Care in the Neonatal Intensive Care Unit: The Edmonton Randomised Controlled Trial of NIDCAP (Newborn Individualised Developmental Care and Assessment Program)|Completed||N/A|120|Actual|University of Alberta|||||f||||f||||||||||2018-06-01 02:47:47.485137|2018-06-01 02:47:47.485137
NCT00552370|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-07-20|2007-10-31|2007-11-01|Estimate|||||||2009-07-20|2009-07-21|Estimate|March 2003||2003-03-31|July 2009|2009-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|GOT||Glycemic Optimization Treatment Study|A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus®(Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes.|Completed||Phase 4|5062|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:47:47.620254|2018-06-01 02:47:47.620254
NCT00552357|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2018-03-12|2007-10-31|2007-11-01|Estimate|||||||2018-03-12|2018-03-13|Actual|December 2007||2007-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation|Clinical Risk Factors for Primary Graft Dysfunction|Recruiting|||1150|Anticipated|University of Pennsylvania|||||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 02:47:47.682746|2018-06-01 02:47:47.682746
NCT00552344|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2015-12-14||2016-01-29|2007-10-31|2007-11-01|Estimate|2015-12-14|2016-01-21|Estimate||||2016-01-29|2016-02-29|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Baseline Characteristics refer to the Safety Population including all enrolled subjects who received at least 1 open-label injection of study medication. Demographics presented below were collected at Screening of the feeder study C87085.|A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease|A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085|Completed||Phase 3|403|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:47:47.771125|2018-06-01 02:47:47.771125
NCT00552331|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2011-06-27|2007-10-30|2007-11-01|Estimate|||||||2011-06-27|2011-06-28|Estimate|March 2003||2003-03-31|May 2009|2009-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Evaluation of the Effects of Less Invasive Stabilization System (LISS) Plating Techniques in Distal Femoral Fractures|Prospective Randomized Clinical Study to Evaluate the Effects of Less Invasive Stabilization System (LISS) Plating Techniques in Distal Femoral Fractures|Completed||Phase 4|150|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-06-01 02:47:48.394212|2018-06-01 02:47:48.394212
NCT00552305|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2011-02-23||2017-07-28|2007-10-31|2007-11-01|Estimate|2011-08-02|2011-09-02|Estimate||||2017-07-28|2017-08-25|Actual|August 2001||2001-08-31|July 2017|2017-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures|An Open-label Extension Trial to Determine Tolerability and Efficacy of Long-term Oral SPM 927 as Adjunctive Therapy in Patients With Partial Seizures|Completed||Phase 2|370|Actual|UCB Pharma||1|||f||||||||||||||2018-06-01 02:47:48.500249|2018-06-01 02:47:48.500249
NCT00552292|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2016-12-05|2007-10-31|2007-11-01|Estimate|||||||2016-12-05|2016-12-06|Estimate|December 2007||2007-12-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Complications in Hypertension and Obesity|National Investigation of Cardiovascular Complications in Arterial Hypertension and Obesity|Recruiting|||30000|Anticipated|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|||||f||||f||||||Samples With DNA|"~     Blood, urine, serum~   "|||2018-06-01 02:47:49.025947|2018-06-01 02:47:49.025947
NCT00552279|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2010-02-12|2009-08-19|2017-04-20|2007-10-31|2007-11-01|Estimate|2010-02-12|2010-03-05|Estimate|2009-08-19|2009-08-21|Estimate|2017-04-20|2017-05-17|Actual|November 12, 2007||2007-11-12|April 2017|2017-04-30|July 20, 2009|Actual|2009-07-20|February 26, 2009|Actual|2009-02-26||Interventional|||Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age|Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 Administered According to an Alternative Dosing Schedule as Compared to the Standard Dosing Schedule in Young Female Subjects Aged 15-25 Years|Completed||Phase 3|805|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:47:49.103348|2018-06-01 02:47:49.103348
NCT00552266|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2007-10-31|2007-10-31|2007-11-01|Estimate|||||||2007-10-31|2007-11-01|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|October 2009|Anticipated|2009-10-31|||||Interventional|||Methylphenidate in ADHD With Trichotillomania|Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania|Unknown status|Recruiting|Phase 4|30|Anticipated|Geha Mental Health Center|||||f||||f||||||||||2018-06-01 02:47:49.505116|2018-06-01 02:47:49.505116
NCT00552253|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2010-12-21|2007-10-31|2007-11-01|Estimate|||||||2010-12-21|2010-12-22|Estimate|October 2007||2007-10-31|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Levothyroxine Treatment in Thyroid Benign Nodular Goiter|Levothyroxine Treatment in Thyroid Benign Nodular Goiter|Completed||N/A|10|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 02:47:49.59637|2018-06-01 02:47:49.59637
NCT00552240|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2011-03-16||2013-12-09|2007-10-31|2007-11-01|Estimate|2011-04-21|2011-05-23|Estimate||||2013-12-09|2014-01-27|Estimate|September 2007||2007-09-30|December 2013|2013-12-31||||March 2010|Actual|2010-03-31||Interventional||Full Analysis Set (FAS)|Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)|Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone|Completed||Phase 4|154|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:47:49.747051|2018-06-01 02:47:49.747051
NCT00552227|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2016-07-25|2007-10-30|2007-11-01|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2002||2002-09-30|July 2016|2016-07-31|July 2005|Actual|2005-07-31|||||Interventional|||Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus|The Effect of Protein Kinase C (PKC) β Specific Inhibitor on Oxidant Stress in Patient With Type 2 Diabetes Mellitus|Completed||Phase 1|48|Actual|Chromaderm, Inc.||2|||f||||f||||||||||2018-06-01 02:47:50.928848|2018-06-01 02:47:50.928848
NCT00552214|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2007-11-05|2007-10-30|2007-11-01|Estimate|||||||2007-11-05|2007-11-06|Estimate|August 2007||2007-08-31|October 2007|2007-10-31||||||||Interventional|||Evaluation of HIV-1, HCV and HBV Blood Screening Tests With Human Blood Donor Specimens|Evaluation of a TMA Assay for the Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens|Unknown status|Enrolling by invitation|N/A|10500|Anticipated|Novartis|||||f||||||||||||||2018-06-01 02:47:50.995112|2018-06-01 02:47:50.995112
NCT00552201|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2010-05-26|2007-10-31|2007-11-01|Estimate|||||||2010-05-26|2010-05-27|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Interventional|||TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic|Randomized Therapeutic Study of a Treatment by Tacrolimus Adapted or Not According to the Genotype of the Cytochrome P450 3A5 After Renal Transplantation|Completed||Phase 4|280|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||t||||||||||2018-06-01 02:47:51.062334|2018-06-01 02:47:51.062334
NCT00552188|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2013-06-06||2013-06-06|2007-10-31|2007-11-01|Estimate|2013-06-06|2013-08-09|Estimate||||2013-06-06|2013-08-09|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event|Completed||Phase 2|52|Actual|Tallikut Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 02:47:51.15403|2018-06-01 02:47:51.15403
NCT00552175|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2010-03-26||2010-03-26|2007-10-31|2007-11-01|Estimate|2010-03-26|2010-04-13|Estimate||||2010-03-26|2010-04-13|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study for the Treatment of Diabetic Peripheral Neuropathic Pain|A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain|Completed||Phase 3|339|Actual|Eli Lilly and Company|The protocol-specified primary analyses for this study were comparisons between combined duloxetine arms (40 mg + 60 mg) and placebo. The study was powered on combined duloxetine arms and statistical comparisons were not performed among single arms.|3|||f||||t||||||||||2018-06-01 02:47:51.621254|2018-06-01 02:47:51.621254
NCT00552162|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2016-04-13|2007-10-31|2007-11-01|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|July 2020|Anticipated|2020-07-31|January 2018|Anticipated|2018-01-31||Interventional|||NOTES Transvaginal Cholecystectomy and Appendectomy|NOTES Transvaginal Cholecystectomy and Appendectomy|Recruiting||N/A|40|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 02:47:54.521245|2018-06-01 02:47:54.521245
NCT00552149|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2012-06-12|2007-10-31|2007-11-01|Estimate|||||||2012-06-12|2012-06-13|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin|A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine - Oxaliplatin Chemotherapy Alone or in Combination With Cetuximab in Patients With Advanced Biliary Cancer.|Completed||Phase 2|150|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-06-01 02:47:54.64704|2018-06-01 02:47:54.64704
NCT00552136|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2016-06-02|2007-10-30|2007-11-01|Estimate|||||||2016-06-02|2016-06-03|Estimate|February 2005||2005-02-28|June 2016|2016-06-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study|Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study|Recruiting||Phase 4|100|Anticipated|Nova Scotia Health Authority|||||f||||||||||||||2018-06-01 02:47:54.721327|2018-06-01 02:47:54.721327
NCT00552110|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2009-05-15||2017-03-13|2007-10-31|2007-11-01|Estimate|2009-05-15|2009-07-08|Estimate||||2017-03-13|2017-04-11|Actual|July 2007||2007-07-31|March 2017|2017-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)|Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis|Completed||Phase 2|707|Actual|Merck Sharp & Dohme Corp.|Subject symptom data were not collected during the post-treatment period. Thus, daily diary data for rebound congestion was not analyzed.|5|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:47:54.810739|2018-06-01 02:47:54.810739
NCT00552097|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2017-05-10|2007-10-31|2007-11-01|Estimate|||||||2017-05-10|2017-05-11|Actual|June 1, 2002|Actual|2002-06-01|May 2017|2017-05-31|April 25, 2006|Actual|2006-04-25|April 25, 2006|Actual|2006-04-25||Interventional|ENHANCE||Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)|Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial)|Completed||Phase 3|720|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:47:55.483716|2018-06-01 02:47:55.483716
NCT00552084|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2014-11-10||2014-11-18|2007-10-31|2007-11-01|Estimate|2014-11-10|2014-11-18|Estimate||||2014-11-18|2014-12-03|Estimate|November 2007||2007-11-30|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation|Fish Oil for Atrial Fibrillation - Effect and Mechanisms|Completed||Phase 4|190|Actual|Vanderbilt University|We determined recurrence of Atrial Fibrillation(AF) by both routine and symptomatic TTM transmissions. We did not examine the effect of therapy on total AF burden. Sample size was relatively small, and included a heterogeneous patient population.|2|||f||||t||||||||||2018-06-01 02:47:55.571222|2018-06-01 02:47:55.571222
NCT00552071|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2010-08-18|2007-10-31|2007-11-01|Estimate|||||||2010-08-18|2010-08-19|Estimate|July 2007||2007-07-31|August 2010|2010-08-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Ultrasound Guided Sandostatin LAR Injection in Acromegaly|Does Ultrasound-Guidance Improve the Delivery and Efficacy of Intramuscular (IM) Injection of Sandostatin LAR in the Treatment of Acromegaly|Unknown status|Recruiting|N/A|20|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-06-01 02:47:55.820905|2018-06-01 02:47:55.820905
NCT00552058|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2010-10-08||2011-10-14|2007-10-31|2007-11-01|Estimate|2010-12-01|2010-12-30|Estimate||||2011-10-14|2011-10-20|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease|Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.|Completed||Phase 3|439|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 02:47:55.992398|2018-06-01 02:47:55.992398
NCT00552045|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2014-01-15|2007-10-30|2007-11-01|Estimate|||||||2014-01-15|2014-01-16|Estimate|November 2007||2007-11-30|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|December 2013|Actual|2013-12-31||Observational|EPGP||Epilepsy Phenome/Genome Project|Epilepsy Phenome/Genome Project: A Phenotype/Genotype Analysis of Epilepsy|Unknown status|Active, not recruiting||4150|Actual|University of California, San Francisco|||1||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 02:47:56.917661|2018-06-01 02:47:56.917661
NCT00552032|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|2011-12-22|2011-01-13|2017-03-24|2007-10-31|2007-11-01|Estimate|2011-12-22|2012-01-31|Estimate|2011-01-13|2011-02-03|Estimate|2017-03-24|2017-04-24|Actual|August 1, 2007|Actual|2007-08-01|March 2017|2017-03-31|January 1, 2010|Actual|2010-01-01|January 1, 2010|Actual|2010-01-01||Interventional|SNORE||Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)|A Double-blind Placebo-controlled, Randomized, Parallel-group, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy SNORE Study|Completed||Phase 3|132|Actual|Merck Sharp & Dohme Corp.|The results of this study as presented are drawn from the clinical study report and should be reviewed with caution as there were inaccuracies in the database resulting from medication errors in some participants.|2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:47:57.067982|2018-06-01 02:47:57.067982
NCT00552019|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-11-17|2007-10-31|2007-11-01|Estimate|||||||2009-11-17|2009-11-18|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Intraocular Pressure (IOP) Assessed by Dynamic Contour Tonometer (DCT) and Goldman Applanation Tonometry (GAT)|Inflammatory Changes of Corneal Thickness and Influence on Assessment of Intraocular Pressure|Completed|||30|Actual|St. Franziskus Hospital|||||f||||f||||||||||2018-06-01 02:47:57.831352|2018-06-01 02:47:57.831352
NCT00552006|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2011-03-07|2007-10-31|2007-11-01|Estimate|||||||2011-03-07|2011-03-08|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Treatment of Formerly Abducted Children (FAC) in Uganda|A Randomized Controlled Clinical Trial (RCCT) to Test the Effectiveness of Narrative Exposure Therapy (NET) Versus an Attention Control Condition (AC) in Reducing Trauma Related Symptoms in Formerly Abducted Children and Former Child Soldiers Suffering From Posttraumatic Stress Disorder (PTSD)|Completed||N/A|85|Actual|University of Konstanz||3|||f||||f||||||||||2018-06-01 02:47:57.886049|2018-06-01 02:47:57.886049
NCT00551993|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2014-02-18|2007-10-31|2007-11-01|Estimate|||||||2014-02-18|2014-02-19|Estimate|September 2006||2006-09-30|February 2014|2014-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Laparoscopic Versus Robotic Assisted Laparoscopic Sacrocolpopexy for Vaginal Prolapse|Conventional Laparoscopic Versus Robotic Assisted Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial|Completed||N/A|78|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 02:47:57.956068|2018-06-01 02:47:57.956068
NCT00551980|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2009-11-12|2007-10-31|2007-11-01|Estimate|||||||2009-11-12|2009-11-13|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||The Efficacy of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Working Community|Effectiveness of a Workplace Cognitive and Physical Program in Reducing Headache,Neck and Shoulder Pain in an Extensive Working Community. A Randomized Controlled Trial|Completed||Phase 3|2895|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-06-01 02:47:58.047844|2018-06-01 02:47:58.047844
NCT00551967|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2017-05-02|2007-10-30|2007-11-01|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2007||2007-10-31|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA|Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary Total Hip Arthroplasty Using Radiostereometric Analysis (RSA)|Active, not recruiting||N/A|50|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 02:47:58.11199|2018-06-01 02:47:58.11199
NCT00551954|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-31|||2013-02-28|2007-10-31|2007-11-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|July 2006||2006-07-31|February 2013|2013-02-28||||July 2007|Actual|2007-07-31||Interventional|||Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes||Completed||Phase 3|||Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 02:47:58.169147|2018-06-01 02:47:58.169147
NCT00551941|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2015-06-03|2007-10-31|2007-11-01|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||A Prospective Randomized Controlled Trial on the Use of Bone Morphogenetic 7 (BMP-7) (OP-1®) and Demineralized Bone Matrix in Tibial Non-union|A Prospective Randomised Controlled Trial on the Use of BMP-7 (OP-1®) and Demineralised Bone Matrix in Tibial Non-union|Suspended||Phase 4|30|Anticipated|University Hospital, Ghent||2||Recruitment problems|f||||f||||||||||2018-06-01 02:47:58.222504|2018-06-01 02:47:58.222504
NCT00551928|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2017-09-05|2007-10-30|2007-10-31|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2007||2007-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|MPRvsMEL200||Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients|A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS|Active, not recruiting||Phase 3|402|Actual|Fondazione Neoplasie Sangue Onlus||2|||f||||t||||||||||2018-06-01 02:47:58.374631|2018-06-01 02:47:58.374631
NCT00551915|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-10-29|2007-10-29|2007-10-31|Estimate|||||||2015-10-29|2015-10-30|Estimate|May 2001||2001-05-31|October 2015|2015-10-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)|Safety, Tolerability, and Immunogenicity of 3 Different Formulations of a Liquid Hexavalent Combination Vaccine, HR5I When Administered to Healthy Hepatitis B Vaccine-Naive Infants at 2, 4, 6, and 12-14 Months of Age|Completed||Phase 2|756|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:47:58.450902|2018-06-01 02:47:58.450902
NCT00551902|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-09-21|2007-10-29|2007-10-31|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of an Anterior Chamber Infusion System on Trabeculectomy Outcomes|Effect of an Anterior Chamber Infusion System on Trabeculectomy Outcomes|Withdrawn||Phase 1|0|Actual|Queen's University||2||Efficacy study indicated that further study is not warranted|f||||f||||||||||2018-06-01 02:47:58.561776|2018-06-01 02:47:58.561776
NCT00551889|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2012-11-08|2007-10-30|2007-10-31|Estimate|||||||2012-11-08|2012-11-12|Estimate|September 2001||2001-09-30|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer|Phase I Trial of Oral Cyclophosphamide in Combination With Celecoxib in Patients With Advanced Malignancies|Completed||Phase 1|57|Actual|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:47:58.642203|2018-06-01 02:47:58.642203
NCT00551551|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2013-07-25|2007-10-30|2007-10-31|Estimate|||||||2013-07-25|2013-07-26|Estimate|November 2007||2007-11-30|July 2013|2013-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Prenatal Pelvic Floor Prevention (3PN)|Urinary Postpartum Handicap Prevention: Pelvic Floor Exercises vs Control. Multicentric Randomized Trial|Completed||Phase 3|280|Actual|Centre Hospitalier Universitaire de la Réunion||2|||f||||f||||||||||2018-06-01 02:48:02.936991|2018-06-01 02:48:02.936991
NCT00551876|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2017-02-24|2007-10-29|2007-10-31|Estimate|||||||2017-02-24|2017-02-28|Actual|December 2001||2001-12-31|February 2017|2017-02-28|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)|A Randomized, Double-Blind, Parallel, Multicenter Study to Evaluate the Efficacy and Safety of Simvastatin Monotherapy Compared With Simvastatin Plus Ezetimibe (SCH 58235) in Type 2 Diabetic Patients Treated With Thiazolidinediones|Completed||Phase 3|214|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:47:58.715913|2018-06-01 02:47:58.715913
NCT00551863|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2015-08-04|2007-10-30|2007-10-31|Estimate|||||||2015-08-04|2015-08-07|Estimate|June 2004||2004-06-30|August 2015|2015-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Developing Violence Prevention Therapy for Substance Abusers|Development of Violence Therapy for Substance Abusers|Completed||Phase 1/Phase 2|131|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 02:47:58.786315|2018-06-01 02:47:58.786315
NCT00551850|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2011-09-30|2007-10-30|2007-10-31|Estimate|||||||2011-09-30|2011-10-04|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|May 2010|Actual|2010-05-31|October 2009|Actual|2009-10-31||Interventional|||A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients|A Phase I, Multi-Center, Dose-Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of AV-412 Administered Orally Three Times Weekly to Subjects With Advanced Solid Tumors|Completed||Phase 1|37|Actual|AVEO Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:47:58.871244|2018-06-01 02:47:58.871244
NCT00551837|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2017-10-20|2007-10-30|2007-10-31|Estimate|||||||2017-10-20|2017-10-24|Actual|November 2006||2006-11-30|October 2017|2017-10-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Observational|||Immune Response to Influenza Vaccination|Immune Response to Influenza Vaccination|Completed|||82|Actual|The Cleveland Clinic|||||f||||||||||||||2018-06-01 02:47:58.946331|2018-06-01 02:47:58.946331
NCT00551824|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2008-04-07|2007-10-30|2007-10-31|Estimate|||||||2008-04-07|2008-04-09|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|March 2009|Anticipated|2009-03-31|December 2008|Anticipated|2008-12-31||Interventional|||Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children|Evaluation of Topical Mitomycin C as Adjuvant Drug to Endoscopic Esophageal Dilation in Children|Unknown status|Recruiting|N/A|10|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-06-01 02:47:59.03168|2018-06-01 02:47:59.03168
NCT00551811|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2017-08-04|2007-10-29|2007-10-31|Estimate|||||||2017-08-04|2017-08-07|Actual|October 8, 2007|Actual|2007-10-08|August 2017|2017-08-31|July 22, 2008|Actual|2008-07-22|July 22, 2008|Actual|2008-07-22||Interventional|||Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone|A Dose Ranging Study to Assess the Effect of Pre-treatment With a Single Dose of Oral SB656933 on Lung Inflammation Following Challenge With Inhaled Ozone and Intermittent Exercise in Healthy Volunteers, Relative to Placebo|Completed||Phase 1|23|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 02:47:59.116811|2018-06-01 02:47:59.116811
NCT00551798|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2011-05-16|2007-10-30|2007-10-31|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|MIBI||Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade|Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade|Completed||N/A|90|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 02:47:59.192933|2018-06-01 02:47:59.192933
NCT00551785|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2015-03-24|2007-10-30|2007-10-31|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|EMPOWER||Surveillance Study of Women Taking Intrinsa®|The Multinational Postmarketing Observational Study of Women Prescribed Intrinsa|Terminated|||328|Actual|Center for Epidemiology and Health Research, Germany|||2|The marketing authorization for Intrinsa was withdrawn.|f||||t||||||||||2018-06-01 02:47:59.293788|2018-06-01 02:47:59.293788
NCT00551772|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2008-12-23|2007-10-29|2007-10-31|Estimate|||||||2008-12-23|2008-12-25|Estimate|August 2007||2007-08-31|December 2008|2008-12-31||||||||Interventional|||A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.|An Open-Label, Randomised, Two-Part Crossover Study to Assess the Pharmacokinetics of a Single Dose of SB-742457 Formulated as a Capsule and a Tablet in Healthy Elderly Volunteers.|Completed||Phase 1|12|Anticipated|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:47:59.476455|2018-06-01 02:47:59.476455
NCT00551759|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2014-01-17||2017-10-19|2007-10-30|2007-10-31|Estimate|2014-01-17|2014-02-28|Estimate||||2017-10-19|2017-11-21|Actual|June 2008||2008-06-30|October 2017|2017-10-31|February 2014|Actual|2014-02-28|October 2011|Actual|2011-10-31||Interventional||Eligible and treated patients|Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer|A Phase II Study to Measure Response Rate and Toxicity of Neo-adjuvant Chemoradiotherapy With Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative Docetaxel and Cetuximab in Patients With Operable Adenocarcinoma of the Esophagus|Terminated||Phase 2|22|Actual|Eastern Cooperative Oncology Group||1||"The study used a two-stage design. After stage one, the study was terminated due to excess~   toxicity."|f||||f||||||||||2018-06-01 02:47:59.735821|2018-06-01 02:47:59.735821
NCT00551746|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2011-07-11||2011-09-13|2007-10-30|2007-10-31|Estimate|2011-08-05|2011-09-07|Estimate||||2011-09-13|2011-09-16|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||The Purple Grape Juice Study|Anti-thrombotic Effects of Long Term Consumption of Purple Grape Juice in Healthy People|Completed||N/A|70|Actual|Intermountain Health Care, Inc.||2|||f||||f||||||||||2018-06-01 02:48:00.590473|2018-06-01 02:48:00.590473
NCT00551733|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2010-12-15|2007-10-30|2007-10-31|Estimate|||||||2010-12-15|2010-12-16|Estimate|August 2007||2007-08-31|April 2008|2008-04-30||||||||Interventional|||Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Paclitaxel Poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) in Women With Estradiol >30 pg/mL|Unknown status|Recruiting|Phase 3|450|Anticipated|National Cancer Institute (NCI)||2|||||||||||||||||2018-06-01 02:48:00.814188|2018-06-01 02:48:00.814188
NCT00551720|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2017-01-11|2007-10-30|2007-10-31|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 1999||1999-01-31|October 2007|2007-10-31|December 2004|Actual|2004-12-31|||||Interventional|Positive PATHS||Motivation and Patch Treatment for HIV-positive Smokers|Motivation and Patch Treatment for HIV-positive Smokers|Completed||Phase 3|444|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 02:48:01.070836|2018-06-01 02:48:01.070836
NCT00551707|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2014-02-10||2014-03-27|2007-10-29|2007-10-31|Estimate|2014-03-27|2014-04-29|Estimate||||2014-03-27|2014-04-29|Estimate|October 2007||2007-10-31|March 2014|2014-03-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|MARS-1||Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Superiority of CRx-102 Over Each of Its Components When Given to Subjects With Active Rheumatoid Arthritis (RA)|Completed||Phase 2|51|Actual|Zalicus||5|||f||||t||||||||||2018-06-01 02:48:01.155987|2018-06-01 02:48:01.155987
NCT00551694|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2012-05-31|2007-10-29|2007-10-31|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Second Study to Determine the Effect of GSK256073A on HVTs|A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects|Completed||Phase 1|4|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:48:01.585552|2018-06-01 02:48:01.585552
NCT00551681|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2016-04-20|2007-10-30|2007-10-31|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2007||2007-11-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|CONTRACT||Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure|Effects of Left Ventricular Pacing Optimilization on Cardiac Perfusion, Contractile Force, and Clinical Performance in Patients With Ventricular Dysfunction and Heart Failure|Completed||N/A|52|Actual|R&D Cardiologie||2|||f||||f||||||||||2018-06-01 02:48:01.674318|2018-06-01 02:48:01.674318
NCT00551668|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2007-10-30|2007-10-30|2007-10-31|Estimate|||||||2007-10-30|2007-10-31|Estimate|January 1998||1998-01-31|October 2007|2007-10-31|December 2000|Actual|2000-12-31|||||Interventional|||A Prospective, Randomized Study of Operative and Nonoperative Treatment for Primary Traumatic Patellar Dislocation|A Prospective, Randomized Study of Operative and Nonoperative Treatment for Primary Traumatic Patellar Dislocation in Young Adults With a Median 7-Year Follow-Up|Completed||N/A|40|Actual|Finnish Defense Forces||2|||f||||f||||||||||2018-06-01 02:48:01.747507|2018-06-01 02:48:01.747507
NCT00551655|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2007-11-05|2007-10-30|2007-10-31|Estimate|||||||2007-11-05|2007-11-06|Estimate|May 2007||2007-05-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Observational|||Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients|Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients|Completed|||684|Actual|AIDS Arms Inc.|||||f||||f||||||||||2018-06-01 02:48:01.807082|2018-06-01 02:48:01.807082
NCT00551642|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2010-09-03||2016-11-03|2007-10-30|2007-10-31|Estimate|2010-09-30|2010-10-18|Estimate||||2016-11-03|2016-12-21|Estimate|May 2005||2005-05-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies|The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants|Completed||Phase 3|800|Actual|Mallinckrodt||2|||f||||t||||||||||2018-06-01 02:48:01.896228|2018-06-01 02:48:01.896228
NCT00551629|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-10-29|2007-10-30|2007-10-31|Estimate|||||||2015-10-29|2015-10-30|Estimate|May 2001||2001-05-31|October 2015|2015-10-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)|Safety, Tolerability, and Immunogenicity of Four Different Formulations of a Liquid Hexavalent Combination Vaccine, HR5I (Haemophilus Influenzae Type b Conjugate, Recombinant Hepatitis B Surface Antigen, Diphtheria Toxoid, Tetanus Toxoid, 5-Component Acellular Pertussis Vaccine, and Inactivated Poliovirus Type 1, 2, and 3), When Administered to Healthy Hepatitis B Vaccine-Naïve Infants at 2, 3, 4, and 12 to 14 Months of Age|Completed||Phase 2|708|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-06-01 02:48:02.316551|2018-06-01 02:48:02.316551
NCT00551616|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2010-06-16|2007-10-30|2007-10-31|Estimate|||||||2010-06-16|2010-06-17|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception||Completed||Phase 3|2321|Actual|HRA Pharma||2|||f||||t||||||||||2018-06-01 02:48:02.379192|2018-06-01 02:48:02.379192
NCT00551603|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2017-12-21|2007-10-30|2007-10-31|Estimate|||||||2017-12-21|2017-12-22|Actual|July 2006|Actual|2006-07-31|December 2017|2017-12-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|VAES||Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules|Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules|Withdrawn||Phase 4|0|Actual|Anemia Working Group Romania||2||Logistic reasons, financial contrastraints|f||||f||||||||||2018-06-01 02:48:02.465373|2018-06-01 02:48:02.465373
NCT00551590|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2011-10-03|2007-10-30|2007-10-31|Estimate|||||||2011-10-03|2011-10-04|Estimate|December 2007||2007-12-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|December 2008|Actual|2008-12-31||Interventional|||Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus|A Randomized, Placebo-Controlled, 4-period, Crossover Study to Assess the Impact of MK-0431 (Sitagliptin) on Incretin Effect and the Role of Specific Incretin Hormones in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|24|Actual|Ludwig-Maximilians - University of Munich||4|||f||||t||||||||||2018-06-01 02:48:02.539498|2018-06-01 02:48:02.539498
NCT00551577|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2007-10-30|2007-10-30|2007-10-31|Estimate|||||||2007-10-30|2007-10-31|Estimate|March 2003||2003-03-31|October 2007|2007-10-31|January 2008|Anticipated|2008-01-31|||||Interventional|PRIMOVAR-1||Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, Randomized Phase II Clinical Trial|Prospective, Randomized Phase II Clinical Trial to Select Primary Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer Stage FIGO IIIC and IV|Unknown status|Recruiting|Phase 2|100|Anticipated|University Hospital, Bonn||2|||f||||f||||||||||2018-06-01 02:48:02.729151|2018-06-01 02:48:02.729151
NCT00551564|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2017-08-02|2007-10-29|2007-10-31|Estimate|||||||2017-08-02|2017-08-04|Actual|July 31, 2007|Actual|2007-07-31|August 2017|2017-08-31|September 8, 2008|Actual|2008-09-08|September 8, 2008|Actual|2008-09-08||Interventional|||Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate|A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:48:02.818367|2018-06-01 02:48:02.818367
NCT00551538|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2010-10-12|2007-10-29|2007-10-31|Estimate|||||||2010-10-12|2010-10-13|Estimate|May 2003||2003-05-31|October 2010|2010-10-31|December 2004|Actual|2004-12-31|||||Interventional|||24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine|Twenty-Four-Hour Plasma Glucose Profiles Observed in Patients With Type 2 Diabetes During Therapy Consisting of Oral Agent(s) Plus Twice-Daily Insulin Lispro Low Mixture or Once-Daily Insulin Glargine|Completed||Phase 4|15|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:48:03.036081|2018-06-01 02:48:03.036081
NCT00551525|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2016-09-06||2017-06-26|2007-10-30|2007-10-31|Estimate|2017-06-26|2017-07-25|Actual||||2017-06-26|2017-07-25|Actual|April 2008||2008-04-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|July 2014|Actual|2014-07-31||Interventional||All eligible patients|Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer|A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy|Completed||Phase 2|67|Actual|Radiation Therapy Oncology Group|Comparison of freedom from progression rate at two years with Kattan Nomograms was not possible because the pretreatment data needed for the Kattan Nomograms was not collected.|1|||f||||t||||||||||2018-06-01 02:48:03.13252|2018-06-01 02:48:03.13252
NCT00551512|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2017-03-13|2007-10-29|2007-10-31|Estimate|||||||2017-03-13|2017-03-14|Actual|November 2006||2006-11-30|March 2017|2017-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors|Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors|Completed||Phase 1|48|Actual|CanBas Co. Ltd.||1|||f||||f|t|f||||||No||2018-06-01 02:48:03.474241|2018-06-01 02:48:03.474241
NCT00551499|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2017-12-22|2007-10-30|2007-10-31|Estimate|||||||2017-12-22|2017-12-27|Actual|June 2005|Actual|2005-06-30|December 2017|2017-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|Morpheus||Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF|Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF|Completed||Phase 4|44|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||||2018-06-01 02:48:03.556225|2018-06-01 02:48:03.556225
NCT00551486|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2007-10-30|2007-10-30|2007-10-31|Estimate|||||||2007-10-30|2007-10-31|Estimate|June 2006||2006-06-30|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Observational|||Pyrosequencing of the BRAFV600E Mutation|Diagnostic Value of Pyrosequencing for the BRAFV600E Mutation in Ultrasound-Guided Fine-Needle Aspiration Biopsy Samples of Thyroid Incidentalomas|Completed|||101|Actual|Chungnam National University|||1||f||||t||||||Samples With DNA|"~     Fine needle aspiration samples of thyroid nodule~   "|||2018-06-01 02:48:03.625284|2018-06-01 02:48:03.625284
NCT00551473|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2012-05-31|2007-10-29|2007-10-31|Estimate|||||||2012-05-31|2012-06-04|Estimate|May 2007||2007-05-31|February 2011|2011-02-28||||||||Interventional|||Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.|An Open-Label Study of the Development of Pharmacodynamic Tolerance to 7-days Administration of Lavoltidine 40mg|Completed||Phase 1|18|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:48:03.694445|2018-06-01 02:48:03.694445
NCT00551460|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2017-11-21||2017-12-21|2007-10-30|2007-10-31|Estimate|2017-12-21|2017-12-22|Actual||||2017-12-21|2017-12-22|Actual|November 2007||2007-11-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional||Baseline Participants includes eligible and analyzable patients. Ineligible patients and not analyzable patients from Participant Flow are excluded.|S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia|S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia|Completed||Phase 2|78|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 02:48:03.81196|2018-06-01 02:48:03.81196
NCT00551447|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2017-02-24|2007-10-29|2007-10-31|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2002||2002-01-31|February 2017|2017-02-28|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)|A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata Low-Density Lipoprotein Cholesterol (LDL-c)|Completed||Phase 3|616|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:48:04.61326|2018-06-01 02:48:04.61326
NCT00551434|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2007-10-30|2007-10-30|2007-10-31|Estimate|||||||2007-10-30|2007-10-31|Estimate|August 2002||2002-08-31|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Effect of Creatine and L-Arginine on Endothelial Function|Effect of Creatine and L-Arginine on Endothelial Function in Patients With Coronary Artery Disease|Completed||N/A|119|Actual|Boston University||4|||f||||f||||||||||2018-06-01 02:48:04.687853|2018-06-01 02:48:04.687853
NCT00551421|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2014-12-17||2015-03-11|2007-10-30|2007-10-31|Estimate|2015-02-20|2015-02-23|Estimate||||2015-03-11|2015-03-31|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|November 2010|Actual|2010-11-30||Interventional|||Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer|A Phase I/II Trial of Pertuzumab in Combination With Cetuximab and Irinotecan in Previously Treated Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|17|Actual|National Cancer Institute (NCI)|Combination intolerable due to overlapping toxicities of diarrhea, rash and mucositis; a unique rash with desquamation seen in most patients across all dose levels. Correlative study inconclusive with too few patients and timepoints with results.|1|||f||||t||||||||||2018-06-01 02:48:04.850598|2018-06-01 02:48:04.850598
NCT00551408|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-30|2007-10-30|2007-10-31|Estimate|||||||2007-10-30|2007-10-31|Estimate|August 2007||2007-08-31|October 2007|2007-10-31|February 2008|Anticipated|2008-02-29|||||Observational|||Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension|The Determination of Endothelial Progenitor Cells in Pulmonary Idiopathic Arterial Hypertension.|Unknown status|Active, not recruiting||25|Anticipated|Unidad de Investigacion Clinica en Medicina S.C.|||2||f||||f||||||Samples With DNA|"~     whole blood.~   "|||2018-06-01 02:48:05.110788|2018-06-01 02:48:05.110788
NCT00551395|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-09-21|2007-10-30|2007-10-31|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Timing of Treatment Completion in Staged Selective Laser Trabeculoplasty (SLT): Early vs. Late Completion|Timing of Treatment Completion in Staged Selective Laser Trabeculoplasty (SLT): Early vs. Late Completion|Terminated||Phase 3|20|Actual|Queen's University||2||Poor recruitment|f||||f||||||||||2018-06-01 02:48:05.17284|2018-06-01 02:48:05.17284
NCT00551382|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|||2010-03-16|2007-10-30|2007-10-31|Estimate|||||||2010-03-16|2010-03-17|Estimate|November 2007||2007-11-30|March 2010|2010-03-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study|Phase 3 Study of Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children|Unknown status|Recruiting|Phase 3|500|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 02:48:05.249792|2018-06-01 02:48:05.249792
NCT00551369|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-30|2016-09-06||2018-02-14|2007-10-30|2007-10-31|Estimate|2016-09-06|2016-10-27|Estimate||||2018-02-14|2018-03-14|Actual|December 2007||2007-12-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2012|Actual|2012-05-31||Interventional||All eligible patients who started study treatment|Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery|A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Operable Stage I/II Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|33|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 02:48:05.352052|2018-06-01 02:48:05.352052
NCT00551356|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-31|Estimate|||||||2007-10-29|2007-10-31|Estimate|November 2002||2002-11-30|October 2007|2007-10-31|July 2003|Actual|2003-07-31|||||Interventional|IOOL||Lispro Mix 25 vs. Glargine in Type 2 Diabetics|Comparison of the Insulin Therapies: Insulin Lispro Low Mix (25%) and Insulin Glargine in Patients With Diabetes Mellitus Type 2|Completed||Phase 3|53|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:48:05.649047|2018-06-01 02:48:05.649047
NCT00551343|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome|Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.|Unknown status|Recruiting|N/A|20|Anticipated|Garvan Institute of Medical Research||2|||f||||f||||||||||2018-06-01 02:48:05.762225|2018-06-01 02:48:05.762225
NCT00551330|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-12-18|2007-10-29|2007-10-30|Estimate|||||||2015-12-18|2015-12-21|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)|Vicriviroc in Combination Treatment With an Optimized ART Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057)|Completed||Phase 2|111|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:48:05.853829|2018-06-01 02:48:05.853829
NCT00551317|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2016-12-02|2007-10-29|2007-10-30|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2007||2007-07-31|December 2016|2016-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of Darapladib (SB480848) in Healthy Japanese Male Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:48:05.948857|2018-06-01 02:48:05.948857
NCT00551304|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2012-11-02|2007-10-26|2007-10-30|Estimate|||||||2012-11-02|2012-11-06|Estimate|October 2007||2007-10-31|November 2012|2012-11-30||||||||Interventional|||Native Kidney Denervation in Patients With End Stage Renal Disease|Native Kidney Denervation in Patients With End Stage Renal Disease|Completed||Phase 1|||Medtronic Vascular|||||f||||t||||||||||2018-06-01 02:48:06.055289|2018-06-01 02:48:06.055289
NCT00551291|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2016-05-16||2016-06-24|2007-10-29|2007-10-30|Estimate|2016-05-16|2016-06-23|Estimate||||2016-06-24|2016-07-25|Estimate|August 2007||2007-08-31|June 2016|2016-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.|An Open Label Study of the Effects of a Combination of NeoRecormon, CellCept and Prednisone on Hematological Parameters and Cytogenesis in Patients With Low or Intermediate Risk Myelodysplastic Syndromes.¿|Completed||Phase 2|10|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:48:06.15312|2018-06-01 02:48:06.15312
NCT00551278|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2016-01-11|2007-10-29|2007-10-30|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2007||2007-10-31|January 2016|2016-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer|GeneSearch™ Breast Lymph Node (BLN) Assay for Molecular Testing Protocol|Completed|||80|Actual|Janssen Diagnostics, LLC|||1||f||||f||||||Samples With DNA|"~     Samples of the tissue homogenate and extracted RNA will be retained and may be used for for~     further testing.~   "|||2018-06-01 02:48:06.481534|2018-06-01 02:48:06.481534
NCT00551265|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2017-07-12|2007-10-25|2007-10-30|Estimate|||||||2017-07-12|2017-07-14|Actual|October 2007||2007-10-31|July 2017|2017-07-31||||January 2009|Actual|2009-01-31||Interventional|||Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy|A Randomized Pilot Trial of Consolidation With an Adjuvant Ovarian Cancer Vaccine Oregovomab (Ovarex ®) With/Without Single-Dose Cyclophosphamide After a Complete Clinical Response to Second-Line Taxane/Platinum-Based Therapy to Determine Immune Response and Time to Progression in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Withdrawn||N/A|0|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 02:48:06.550105|2018-06-01 02:48:06.550105
NCT00551252|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|January 2008||2008-01-31|October 2007|2007-10-31|December 2009|Anticipated|2009-12-31|||||Interventional|||A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma|A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit|Unknown status|Not yet recruiting|Phase 2|56|Anticipated|Gruppo Italiano MEsotelioma||1|||f||||t||||||||||2018-06-01 02:48:06.673421|2018-06-01 02:48:06.673421
NCT00551239|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2011-05-20|2007-10-25|2007-10-30|Estimate|||||||2011-05-20|2011-05-23|Estimate|August 2007||2007-08-31|April 2008|2008-04-30||||||||Interventional|||Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma|A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Cancer Institute (NCI)||2|||||||||||||||||2018-06-01 02:48:06.778594|2018-06-01 02:48:06.778594
NCT00551226|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-27|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|November 2008|Anticipated|2008-11-30|||||Observational|||Follow up of Autoantibodies in Active Tuberculosis|Follow up of Autoantibodies in Active Tuberculosis|Unknown status|Not yet recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||Samples Without DNA|"~     Serum of patients~   "|||2018-06-01 02:48:06.849703|2018-06-01 02:48:06.849703
NCT00551213|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2015-11-10|2009-09-10|2015-12-22|2007-10-29|2007-10-30|Estimate|2015-11-10|2015-12-15|Estimate|2009-09-10|2009-09-11|Estimate|2015-12-22|2016-01-28|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)|A Fixed-Sequence, Open-Label Study to Determine the Activity of SCH 717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed or Recurrent Colorectal Cancer|Completed||Phase 2|67|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:48:06.939364|2018-06-01 02:48:06.939364
NCT00551200|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2013-08-28||2017-01-13|2007-10-26|2007-10-30|Estimate|2015-04-22|2015-05-12|Estimate||||2017-01-13|2017-01-16|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders|A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders|Completed||Phase 2|14|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||t||||||||||2018-06-01 02:48:07.528214|2018-06-01 02:48:07.528214
NCT00551187|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-06-05|2007-10-29|2007-10-30|Estimate|||||||2015-06-05|2015-06-08|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)|A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women|Completed||Phase 2|620|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:48:07.768062|2018-06-01 02:48:07.768062
NCT00551174|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2009-06-30||2011-07-20|2007-10-29|2007-10-30|Estimate|2011-04-28|2011-05-30|Estimate||||2011-07-20|2011-07-22|Estimate|October 2004||2004-10-31|July 2011|2011-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment|Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550|Completed||Phase 4|781|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:48:07.875821|2018-06-01 02:48:07.875821
NCT00551161|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2013-04-30||2013-12-20|2007-10-29|2007-10-30|Estimate|2013-10-28|2013-12-18|Estimate||||2013-12-20|2014-01-28|Estimate|August 2007||2007-08-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease|An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 4|12|Actual|Northwell Health||1|||f||||f||||||||||2018-06-01 02:48:08.683957|2018-06-01 02:48:08.683957
NCT00551148|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-27||2009-03-20|2012-07-17|2007-10-27|2007-10-30|Estimate||||2009-09-25|2009-09-30|Estimate|2012-07-17|2012-07-25|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia|PD 0200390 Dose-ranging Trial: A Randomized, Double-blind, Placebo-controlled, 5-way Crossover, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia|Completed||Phase 2|92|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 02:48:09.912946|2018-06-01 02:48:09.912946
NCT00551135|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2010-06-08||2010-06-08|2007-10-26|2007-10-30|Estimate|2010-06-08|2010-07-15|Estimate||||2010-06-08|2010-07-15|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Surgical Pain After Inguinal Hernia Repair (SPAIHR)|A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair|Completed||Phase 3|425|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:48:10.227359|2018-06-01 02:48:10.227359
NCT00551122|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2013-01-22|2007-10-25|2007-10-30|Estimate|||||||2013-01-22|2013-01-23|Estimate|November 2006||2006-11-30|October 2007|2007-10-31||||April 2013|Anticipated|2013-04-30||Interventional|GemTIP||Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors|Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer|Unknown status|Recruiting|Phase 1/Phase 2|23|Anticipated|University of Southampton||1|||f||||t||||||||||2018-06-01 02:48:14.150838|2018-06-01 02:48:14.150838
NCT00551109|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2008-12-17|2007-10-29|2007-10-30|Estimate|||||||2008-12-17|2008-12-18|Estimate|November 2007||2007-11-30|December 2008|2008-12-31|September 2008|Actual|2008-09-30|||||Interventional|||SA4503 8-Week Study in Major Depressive Disorder (MDD)|A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment With SA4503, Once Daily for 8 Weeks, in Subjects With Major Depressive Disorder|Completed||Phase 2|150|Anticipated|M's Science Corporation||3|||f||||t||||||||||2018-06-01 02:48:14.372083|2018-06-01 02:48:14.372083
NCT00551096|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2013-12-23|2007-10-29|2007-10-30|Estimate|||||||2013-12-23|2013-12-25|Estimate|October 2007||2007-10-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors|A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.|Completed||Phase 1|23|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-06-01 02:48:14.511274|2018-06-01 02:48:14.511274
NCT00551083|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|March 2005||2005-03-31|October 2007|2007-10-31|June 2006|Actual|2006-06-30|||||Interventional|CDSS-D||Efficacy Study of a Computer Decision Support System to Treat Depression|A Pilot Efficacy Trial of a Computer Decision Support System Compared to Usual Care for Depression Treatment in Primary Care|Completed||N/A|60|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 02:48:14.646659|2018-06-01 02:48:14.646659
NCT00550888|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2010-06-08|2007-10-29|2007-10-30|Estimate|||||||2010-06-08|2010-06-09|Estimate|August 2005||2005-08-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|EXT||Comparison of Uterine Exteriorization Versus in Situ Repair at Cesarean Section: a Randomized Clinical Trial||Completed||Phase 3|||Instituto Materno Infantil Prof. Fernando Figueira|||||f||||||||||||||2018-06-01 02:48:18.278428|2018-06-01 02:48:18.278428
NCT00551070|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2015-06-10||2018-03-30|2007-10-25|2007-10-30|Estimate|2015-06-10|2015-06-29|Estimate||||2018-03-30|2018-04-30|Actual|December 17, 2007|Actual|2007-12-17|March 2018|2018-03-31||||July 23, 2013|Actual|2013-07-23||Interventional||Eligible and treated patients.|Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer|A Phase II Trial of AZD6244 (NSC# 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum|Active, not recruiting||Phase 2|52|Actual|National Cancer Institute (NCI)|Study began with 100mg BID mix & drink (MD) formulation. AstraZeneca (AZ) switched to hydrogen-sulfate capsule (HC). AZ deemed 100mg BID MD equivalent to 50mg BID HC. As of 12/31/2010, patients got 50mg BID HC; four patients were on treatment then.|1|||f||||f||||||||||2018-06-01 02:48:14.764737|2018-06-01 02:48:14.764737
NCT00551057|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2010-09-16|2007-10-29|2007-10-30|Estimate|||||||2010-09-16|2010-09-17|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|October 2012|Anticipated|2012-10-31|||||Observational|||Expression of Inflammatory Proteins in Pancreatic Cancer|Expression of Inflammatory Proteins in Pancreatic Cancer|Unknown status|Recruiting||150|Anticipated|University of Zurich|||||f||||f||||||None Retained|"~     To investigate the expression of different inflammatory proteins in cancer and normal~     pancreatic tissue~   "|||2018-06-01 02:48:15.335232|2018-06-01 02:48:15.335232
NCT00551044|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|August 2003||2003-08-31|August 2007|2007-08-31|August 2005|Actual|2005-08-31|||||Interventional|||Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer|Bicalutamide Monotherapy Preserves Bone Mineral Density, Muscle Strength and Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer|Completed||N/A|42|Actual|Wirral University Teaching Hospital NHS Trust||1|||f||||t||||||||||2018-06-01 02:48:15.424842|2018-06-01 02:48:15.424842
NCT00551031|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2011-10-13|2010-03-31|2016-04-12|2007-10-29|2007-10-30|Estimate|2011-10-13|2011-11-24|Estimate|2010-03-31|2010-04-02|Estimate|2016-04-12|2016-05-16|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects|Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.|Completed||Phase 2|2098|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 02:48:15.571533|2018-06-01 02:48:15.571533
NCT00551018|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2015-02-05|2007-10-29|2007-10-30|Estimate|||||||2015-02-05|2015-02-06|Estimate|December 2007||2007-12-31|February 2015|2015-02-28|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)|Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects|Completed||Phase 2|218|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:48:17.088547|2018-06-01 02:48:17.088547
NCT00551005|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2012-11-21|2007-10-26|2007-10-30|Estimate|||||||2012-11-21|2012-11-22|Estimate|December 2001||2001-12-31|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Etoposide and Celecoxib in Patients With Advanced Cancer|Phase I Trial of Oral Etoposide in Combination With Celecoxib in Patients With Advanced Malignancies|Completed||Phase 1|58|Actual|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:48:17.158072|2018-06-01 02:48:17.158072
NCT00550992|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2014-02-14|2007-10-25|2007-10-30|Estimate|||||||2014-02-14|2014-02-17|Estimate|June 2007||2007-06-30|February 2014|2014-02-28||||June 2014|Anticipated|2014-06-30||Interventional|Interfant06||Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia|International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia|Unknown status|Recruiting|N/A|445|Anticipated|Dutch Childhood Oncology Group|||||f||||t||||||||||2018-06-01 02:48:17.265128|2018-06-01 02:48:17.265128
NCT00550979|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2013-08-28|2007-10-26|2007-10-30|Estimate|||||||2013-08-28|2013-08-29|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Observational|||Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk|Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk|Unknown status|Recruiting||96|Anticipated|Brigham and Women's Hospital|||4||f||||f||||||Samples With DNA|"~     blood and urine~   "|||2018-06-01 02:48:17.429525|2018-06-01 02:48:17.429525
NCT00550966|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|February 2010|Anticipated|2010-02-28|||||Interventional|FIBRO-Qol||Efficacy of a Psychoeducative Program for Improving Quality of Life in Fibromyalgic Patients [Study Protocol]|Efficacy of a Psychoeducative Program for Improving Quality of Life in Fibromyalgic Patients [Study Protocol]|Unknown status|Enrolling by invitation|N/A|109|Anticipated|Institut Catala de Salut||1|||f||||f||||||||||2018-06-01 02:48:17.520146|2018-06-01 02:48:17.520146
NCT00550953|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2009-11-12||2013-12-12|2007-10-29|2007-10-30|Estimate|2010-01-07|2010-02-02|Estimate||||2013-12-12|2014-01-30|Estimate|October 2007||2007-10-31|December 2013|2013-12-31||||July 2008|Actual|2008-07-31||Interventional|||Filtered Trial for Telmisartan 40mg Non-responder|Filtered Trial for Telmisartan 40mg Non-responder|Completed||Phase 3|314|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:48:17.618049|2018-06-01 02:48:17.618049
NCT00550940|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2012-05-16|2007-10-29|2007-10-30|Estimate|||||||2012-05-16|2012-05-17|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|December 2007|Actual|2007-12-31|||||Observational|||Emotion/Behavior Problems, Neuropsychological Functioning, and Parental Adjustment in Children With Epilepsy|Emotion/Behavior Problems, Neuropsychological Functioning, and Parental Adjustment in Children and Adolescents With Epilepsy|Completed|||65|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 02:48:17.959272|2018-06-01 02:48:17.959272
NCT00550927|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2013-05-14|2007-10-25|2007-10-30|Estimate|||||||2013-05-14|2013-05-15|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|September 2012|Actual|2012-09-30|March 2010|Actual|2010-03-31||Interventional|||Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer|A Phase 1 Safety Evaluation of Oral Enzastaurin in Combination With Bevacizumab in Patients With Advanced/Metastatic Cancer|Completed||Phase 1|42|Anticipated|Eli Lilly and Company|||||||||||||||||||2018-06-01 02:48:18.055523|2018-06-01 02:48:18.055523
NCT00550914|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2010-07-06|2007-10-26|2007-10-30|Estimate|||||||2010-07-06|2010-07-08|Estimate|January 2007||2007-01-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|||||Observational|||Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP|A Multi-Center, Randomized, Controlled Trial of the Pulsed Dye Laser for Juvenile Onset Recurrent Respiratory Papillomatosis|Completed|||34|Anticipated|Massachusetts Eye and Ear Infirmary|||2||f||||f||||||||||2018-06-01 02:48:18.12323|2018-06-01 02:48:18.12323
NCT00550901|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2015-06-03|2007-10-26|2007-10-30|Estimate|||||||2015-06-03|2015-06-08|Estimate|February 2001||2001-02-28|June 2015|2015-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of Cis-Diamminedicholoroplatinum in Combination With ICRF-187 in the Treatment of Advanced Malignancies|Completed||Phase 1|25|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:48:18.193356|2018-06-01 02:48:18.193356
NCT00550875|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2011-07-12|2007-10-29|2007-10-30|Estimate|||||||2011-07-12|2011-07-13|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|GPIT||Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis|A Randomised Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Sublingual Immunotherapy With a Depigmented and Polymerized Grass Pollen Extracts in Patients Suffering From Allergic Rhinoconjunctivitis.|Completed||Phase 2|90|Anticipated|Laboratorios Leti, S.L.||3|||f||||t||||||||||2018-06-01 02:48:18.330094|2018-06-01 02:48:18.330094
NCT00550862|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-27|2011-06-10||2012-02-10|2007-10-27|2007-10-30|Estimate|2011-12-16|2012-01-23|Estimate||||2012-02-10|2012-02-14|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|August 2009|Actual|2009-08-31||Interventional|||Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)|A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis|Completed||Phase 2|165|Actual|Intercept Pharmaceuticals||4|||f||||t||||||||||2018-06-01 02:48:18.410772|2018-06-01 02:48:18.410772
NCT00550849|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2007-11-06|2007-10-26|2007-10-30|Estimate|||||||2007-11-06|2007-11-07|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction|Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 (CDDO-Me) Administered Orally for 14 Days in Patients With Hepatic Dysfunction|Terminated||Phase 1/Phase 2|16|Actual|Reata Pharmaceuticals, Inc.||3||Enrollment discontinued after second cohort completed.|f||||f||||||||||2018-06-01 02:48:18.961165|2018-06-01 02:48:18.961165
NCT00550836|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2017-02-21||2017-02-21|2007-10-26|2007-10-30|Estimate|2017-02-21|2017-04-05|Actual||||2017-02-21|2017-04-05|Actual|March 2009||2009-03-31|February 2017|2017-02-28|May 2013|Actual|2013-05-31|November 2010|Actual|2010-11-30||Interventional|||Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer|Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine vs. Erlotinib and Gemcitabine in Patients With Untreated, Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|104|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 02:48:19.158386|2018-06-01 02:48:19.158386
NCT00550823|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-27|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|November 2008|Anticipated|2008-11-30|||||Interventional|cardiac CT||Cardiac Computarized Tomography in Infective Endocarditis|The Use of Cardiac Computarized Tomography in Infective Endocarditis|Unknown status|Not yet recruiting|N/A|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-06-01 02:48:20.213465|2018-06-01 02:48:20.213465
NCT00550810|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2011-12-06|2007-10-29|2007-10-30|Estimate|||||||2011-12-06|2011-12-07|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|November 2012|Anticipated|2012-11-30|||||Interventional|SMART||Sutent Maintenance After Response to Taxotere|A Phase II Study of SU011248 for Maintenance Therapy in Hormone Refractory Prostate Cancer After First Line Chemotherapy|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 02:48:20.279739|2018-06-01 02:48:20.279739
NCT00550797|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2013-11-18|2007-10-29|2007-10-30|Estimate|||||||2013-11-18|2013-11-20|Estimate|January 2008||2008-01-31|November 2013|2013-11-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Study to Evaluate the Safety and Efficacy TPI ASM8 in Subjects With Asthma|A Multi-center, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of 14-day Inhaled TPI ASM8 in Subjects With Asthma|Completed||Phase 2|18|Actual|Pharmaxis||2|||f||||f||||||||||2018-06-01 02:48:20.362281|2018-06-01 02:48:20.362281
NCT00550784|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2014-10-03|2007-10-25|2007-10-30|Estimate|||||||2014-10-03|2014-10-07|Estimate|January 2001||2001-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Phase I Trial of Tandem Chemotherapy Cycles as Consolidation Therapy for High-Risk Epithelial Ovarian and Primary Peritoneal Cancer Utilizing Intraperitoneal Paclitaxel/IV Cyclophosphamide Followed by IV Topotecan/Intraperitoneal Cisplatin/IV Melphalan Using Hematopoietic Stem Cell Support|Completed||Phase 1|8|Actual|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:48:20.450612|2018-06-01 02:48:20.450612
NCT00550771|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2011-08-26||2017-05-15|2007-10-29|2007-10-30|Estimate|2011-08-26|2011-10-03|Estimate||||2017-05-15|2017-06-07|Actual|July 16, 2007|Actual|2007-07-16|May 2017|2017-05-31|August 23, 2010|Actual|2010-08-23|August 23, 2010|Actual|2010-08-23||Interventional|||Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)|Randomized Phase II Multinational Trial to Evaluate the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy in Patients With HER2-positive Breast Cancer: Caelyx + Cyclophosphamide + Trastuzumab (C+C+H) or Doxorubicin + Cyclophosphamide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H) BACH|Completed||Phase 2|181|Actual|Merck Sharp & Dohme Corp.|Any follow-up data from this study should be considered with caution as the planned 2-year follow-up was curtailed because of administrative reasons.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:48:20.526705|2018-06-01 02:48:20.526705
NCT00550758|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-20|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|May 2004||2004-05-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|MCH-preschool||Spirometry and Methacholine Challenge Test in Asthmatic Children Age 3-6years|The Effect of Singular (Montelukast) 4mg on Hypersensitivity of the Airways in Children 3-5 Years Old. + Extended Study Hyprsensitivity of the Airways in Asthmatic Children Age 3-6years|Terminated||N/A|84|Actual|Rambam Health Care Campus||||the study has recently ended, all information gathred as planed|f||||t||||||||||2018-06-01 02:48:21.06246|2018-06-01 02:48:21.06246
NCT00550745|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2010-01-07||2017-03-14|2007-10-29|2007-10-30|Estimate|2010-01-07|2010-02-02|Estimate||||2017-03-14|2017-04-12|Actual|September 2007||2007-09-30|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)|A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age|Completed||Phase 4|11999|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:48:21.177736|2018-06-01 02:48:21.177736
NCT00549874|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-11-08|2007-10-24|2007-10-26|Estimate|||||||2007-11-08|2007-11-09|Estimate|February 2002||2002-02-28|October 2007|2007-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes|Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes|Completed||N/A|27|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 02:48:47.313748|2018-06-01 02:48:47.313748
NCT00550732|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2013-09-11||2017-03-09|2007-10-29|2007-10-30|Estimate|2013-12-03|2013-12-27|Estimate||||2017-03-09|2017-04-07|Actual|December 2007||2007-12-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TIP||A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)|"A Phase II Study on Treatment of Refractory Fungal Infections With Posaconazole. The TIP Study."|Completed||Phase 2|40|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:48:23.498642|2018-06-01 02:48:23.498642
NCT00550706|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2013-06-10|2007-10-29|2007-10-30|Estimate|||||||2013-06-10|2013-06-11|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Drug Utilization Prevalence in a Pediatric Care Medical Center|Drug Utilization Prevalence in a Pediatric Care Medical Center|Completed|||567|Actual|Rambam Health Care Campus|||2||f||||f||||||||||2018-06-01 02:48:23.748081|2018-06-01 02:48:23.748081
NCT00550693|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|April 2004||2004-04-30|October 2007|2007-10-31|March 2005|Actual|2005-03-31|||||Interventional|||Trial Evaluating the Efficacy of a Chlorhexidine-Impregnated Sponge (BIOPATCH®) to Reduce Catheter-Related Bloodstream Infections in Hemodialysis Patients|A Crossover Intervention Trial Evaluating the Efficacy of a Chlorhexidine-Impregnated Sponge (BIOPATCH®) to Reduce Catheter-Related Bloodstream Infections in Hemodialysis Patients|Completed||Phase 4|121|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 02:48:23.805595|2018-06-01 02:48:23.805595
NCT00550680|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2016-02-29||2016-02-29|2007-10-29|2007-10-30|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||Safety Population: All participants who received at least one dose of Mircera/CERA and had at least one safety follow-up assessment.|A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia|A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia|Completed||Phase 3|208|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:48:24.025039|2018-06-01 02:48:24.025039
NCT00550667|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2012-05-16|2007-10-29|2007-10-30|Estimate|||||||2012-05-16|2012-05-17|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|||||Observational|||Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood|Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood|Unknown status|Recruiting||1120|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 02:48:24.28664|2018-06-01 02:48:24.28664
NCT00550654|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2012-08-20||2016-11-16|2007-10-25|2007-10-30|Estimate|2012-08-20|2012-09-18|Estimate||||2016-11-16|2017-01-13|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain|A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligo|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)||1||Study was terminated due to poor accrual.|f||||f||||||||No||2018-06-01 02:48:24.374383|2018-06-01 02:48:24.374383
NCT00550641|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2010-04-05|2007-10-26|2007-10-30|Estimate|||||||2010-04-05|2010-04-06|Estimate|March 2006||2006-03-31|September 2007|2007-09-30|December 2006|Actual|2006-12-31|||||Interventional|||Pool-based Exercise in Fibromyalgia Management|Pool-based Exercise in Fibromyalgia Management: a Prospective Randomized Comparison Between Stretching and Ai Chi|Completed||Phase 4|90|Actual|Universidad de Granada||2|||f||||f||||||||||2018-06-01 02:48:24.623326|2018-06-01 02:48:24.623326
NCT00550628|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2015-12-22|2007-10-25|2007-10-30|Estimate|||||||2015-12-22|2015-12-23|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer|Pilot Study of Ex-Vivo Molecular Polyp Imaging Using 18-F Fluorodeoxyglucose (FGD) Positron Emission Tomography (PET) in the Determination of Protein and Gene Expression Signatures of Premalignant Polyps|Completed|||8|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     tissue~   "|||2018-06-01 02:48:24.710759|2018-06-01 02:48:24.710759
NCT00550615|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2017-08-15|2007-10-29|2007-10-30|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2007||2007-09-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129)|Active, not recruiting||Phase 1/Phase 2|47|Anticipated|University of Nebraska||3|||f||||t||||||||||2018-06-01 02:48:24.816052|2018-06-01 02:48:24.816052
NCT00550602|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2017-02-02|2007-10-26|2007-10-30|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2002||2002-01-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Tracheobronchomalacia: Treatment Outcomes|Tracheobronchomalacia: Treatment Outcomes|Completed|||150|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||||||2018-06-01 02:48:24.911328|2018-06-01 02:48:24.911328
NCT00550589|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2011-05-24|2011-05-10|2015-11-17|2007-10-26|2007-10-30|Estimate|2011-05-24|2011-06-22|Estimate|2011-05-20|2011-05-23|Estimate|2015-11-17|2015-12-21|Estimate|September 2007||2007-09-30|November 2015|2015-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus|Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women|Completed||Phase 2|33|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 02:48:24.988898|2018-06-01 02:48:24.988898
NCT00550576|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2013-06-10|2007-10-29|2007-10-30|Estimate|||||||2013-06-10|2013-06-11|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Antibodies to Digoxin for Bipolar Disorder|Antibodies to Digoxin for Bipolar Disorder|Completed||Phase 2|18|Actual|Rambam Health Care Campus||1|||f||||f||||||||||2018-06-01 02:48:25.380839|2018-06-01 02:48:25.380839
NCT00550563|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2017-03-31|2007-10-25|2007-10-30|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2007||2007-08-31|March 2017|2017-03-31|July 2010|Actual|2010-07-31|April 2009|Actual|2009-04-30||Interventional|||DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements|Identification of 24-Hydroxylase Polymorphisms and Splicing Variants That Modulate Vitamin D Oxidative Metabolism and Serum Pharmacokinetics in Patients With Colorectal Cancer on Cholecalciferol Therapy|Completed||N/A|50|Actual|Roswell Park Cancer Institute||1|||f||||t|f|f||||||||2018-06-01 02:48:25.5175|2018-06-01 02:48:25.5175
NCT00550550|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|2012-08-07|2009-10-22|2017-01-18|2007-10-29|2007-10-30|Estimate|2012-08-07|2012-09-07|Estimate|2009-10-22|2009-10-26|Estimate|2017-01-18|2017-03-03|Actual|November 2007||2007-11-30|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma|Completed||Phase 3|345|Actual|ALK-Abelló A/S||2|||f||||t||||||||||2018-06-01 02:48:25.707572|2018-06-01 02:48:25.707572
NCT00550537|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2017-03-14||2017-05-12|2007-10-26|2007-10-30|Estimate|2017-03-14|2017-04-25|Actual||||2017-05-12|2017-06-08|Actual|October 2007||2007-10-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|September 2011|Actual|2011-09-30||Interventional|||Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients With Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Treated With the EGFR-TKI, Erlotinib|Completed||Phase 2|116|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 02:48:26.436144|2018-06-01 02:48:26.436144
NCT00550524|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-27|||2010-11-19|2007-10-27|2007-10-30|Estimate|||||||2010-11-19|2010-11-22|Estimate|December 2007||2007-12-31|November 2010|2010-11-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Stem Cell Transplantation for the Treatment of Knee Osteoarthritis|Phase 1 Study of Bone Marrow - Derived Stem Cell for the Treatment of Knee Osteoarthritis|Unknown status|Enrolling by invitation|Phase 1|5|Anticipated|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 02:48:26.8541|2018-06-01 02:48:26.8541
NCT00550511|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2007-10-29|2007-10-29|2007-10-30|Estimate|||||||2007-10-29|2007-10-30|Estimate|February 2004||2004-02-29|October 2007|2007-10-31|June 2005|Actual|2005-06-30|||||Interventional|||Randomized Study Evaluating the Role of Surgeon-Performed Ultrasound in the Management of the Acute Abdomen|Randomized Study Evaluating the Role of Surgeon-Performed Ultrasound in the Management of the Acute Abdomen|Completed||N/A|800|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 02:48:26.935645|2018-06-01 02:48:26.935645
NCT00550498|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-27|||2015-11-09|2007-10-27|2007-10-30|Estimate|||||||2015-11-09|2015-11-10|Estimate|December 2007||2007-12-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Stem Cell Transplantation in Ocular Lesions of Behcet's Disease|Phase 1 Study of Bone Marrow - Derived Stem Cell in the Treatment of Ocular Lesions of Behcet's Disease|Terminated||Phase 1|5|Actual|Tehran University of Medical Sciences||1||No improvement obtained in 3 cases. Retinal detachment observed in 2 cases|f||||t||||||||||2018-06-01 02:48:27.000905|2018-06-01 02:48:27.000905
NCT00550485|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-29|||2018-04-03|2007-10-29|2007-10-30|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2007||2007-10-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene|Blood-brain-barrier Permeability of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene: Effect on Sleep and Procedural Learning|Recruiting||N/A|300|Anticipated|Max-Planck-Institute of Psychiatry||2|||f||||f||||||||||2018-06-01 02:48:27.070743|2018-06-01 02:48:27.070743
NCT00550472|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2008-04-10|2007-10-25|2007-10-29|Estimate|||||||2008-04-10|2008-04-15|Estimate|December 2004||2004-12-31|April 2008|2008-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||The Effect of a Probiotic Intervention in Healthy Subjects and Patients With Atopic Dermatitis|Intervention Study on the Effects of a Probiotic Yoghurt Drink on the Immune System and Further Physiological Parameters in Patients With Atopic Dermatitis and Healthy Persons|Completed||N/A|30|Actual|University of Jena||1|||f||||t||||||||||2018-06-01 02:48:27.138341|2018-06-01 02:48:27.138341
NCT00550459|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2010-08-05|2010-02-24|2011-04-26|2007-10-26|2007-10-29|Estimate|2011-04-26|2011-04-28|Estimate|2010-02-24|2010-03-04|Estimate|2011-04-26|2011-04-28|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|INSIGHT||Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients|A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients|Completed||Phase 3|57|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|Pilot study powered only for serum Na+ improvements. Trial lacked sufficient power to detect changes in neurocognitive test scores and SF-12 and HDS outcomes.|2|||f||||t||||||||||2018-06-01 02:48:27.251258|2018-06-01 02:48:27.251258
NCT00550446|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2012-11-29|2009-04-24|2012-11-29|2007-10-25|2007-10-29|Estimate|2012-11-29|2013-01-03|Estimate|2009-10-07|2009-10-12|Estimate|2012-11-29|2013-01-03|Estimate|September 2007||2007-09-30|November 2012|2012-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis|A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|386|Actual|Pfizer||7|||f||||f||||||||||2018-06-01 02:48:28.262827|2018-06-01 02:48:28.262827
NCT00550433|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2008-01-11|2007-10-25|2007-10-29|Estimate|||||||2008-01-11|2008-01-16|Estimate|September 2007||2007-09-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|||||Interventional|||Study Evaluating Bazedoxifene/CE in Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Clinical and Commercial Formulations of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 02:48:36.415266|2018-06-01 02:48:36.415266
NCT00550420|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2017-08-31|2010-03-29|2017-10-09|2007-10-25|2007-10-29|Estimate|2017-10-09|2017-11-08|Actual|2010-03-29|2010-05-03|Estimate|2017-10-09|2017-11-08|Actual|October 1, 2007|Actual|2007-10-01|August 2017|2017-08-31|February 12, 2009|Actual|2009-02-12|February 12, 2009|Actual|2009-02-12||Interventional|||Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers|An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.|Terminated||Phase 3|331|Actual|GlaxoSmithKline|The study was early terminated on 12 February 2009 because RSG XR as monotherapy in Alzheimer’s disease failed to demonstrate efficacy.|1||Based on preliminary parent study results|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:48:36.51475|2018-06-01 02:48:36.51475
NCT00548977|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-24|2007-10-24|2007-10-25|Estimate|||||||2007-10-24|2007-10-25|Estimate|January 2001||2001-01-31|October 2007|2007-10-31|February 2005|Actual|2005-02-28|||||Observational|||Genetic Studies Spermatogenic Failure||Completed|||283|Actual|National Cheng-Kung University Hospital|||||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 02:49:13.865381|2018-06-01 02:49:13.865381
NCT00550407|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2010-05-24||2016-10-11|2007-10-26|2007-10-29|Estimate|2010-07-01|2010-07-27|Estimate||||2016-10-11|2016-11-23|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients|Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients|Completed||Phase 3|215|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:48:37.54946|2018-06-01 02:48:37.54946
NCT00550394|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2016-05-19||2017-04-21|2007-10-25|2007-10-29|Estimate|2017-04-21|2017-05-23|Actual||||2017-04-21|2017-05-23|Actual|April 2008||2008-04-30|October 2014|2014-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults|Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Alcohol Use in Adolescents & Young Adults|Completed||Phase 4|56|Actual|University of Cincinnati|Additional studies are needed as topiramate has not been systematically assessed. This study was to collect pilot data and more data will need to be collected.|2|||f||||f||||||||No||2018-06-01 02:48:38.323717|2018-06-01 02:48:38.323717
NCT00550381|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2009-07-08|2007-10-26|2007-10-29|Estimate|||||||2009-07-08|2009-07-10|Estimate|January 2008||2008-01-31|July 2009|2009-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects|Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of HKI-357 Administered Orally to Healthy Subjects|Completed||Phase 1|72|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||10|||f||||f||||||||||2018-06-01 02:48:38.590468|2018-06-01 02:48:38.590468
NCT00550368|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2016-02-23||2016-10-13|2007-10-25|2007-10-29|Estimate|2016-10-13|2016-12-06|Estimate||||2016-10-13|2016-12-06|Estimate|August 2005||2005-08-31|October 2016|2016-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Clinical Experiment of Helicobacter Pylori Transmission|Effect of Gastric Acid and H. Pylori Infection on Infection With Enteropathogenic E. Coli|Completed||N/A|45|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 02:48:38.665033|2018-06-01 02:48:38.665033
NCT00550355|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2009-07-13|2007-10-25|2007-10-29|Estimate|||||||2009-07-13|2009-07-14|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Subject and Investigator-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Intravenously Administered Doses of PD-0360324 in Patients With Rheumatoid Arthritis Receiving Methotrexate|Completed||Phase 1|78|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:48:38.975656|2018-06-01 02:48:38.975656
NCT00550342|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2017-09-12|2007-10-26|2007-10-29|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2008||2008-01-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Rituximab Treatment of Focal Segmental Glomerulosclerosis|Anti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS)|Completed||Phase 2|10|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t|t|f||||||||2018-06-01 02:48:39.075286|2018-06-01 02:48:39.075286
NCT00550329|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2008-10-17|2007-10-26|2007-10-29|Estimate|||||||2008-10-17|2008-10-21|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|November 2007|Actual|2007-11-30|||||Observational|||Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets|An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets Manufactured At Brooklyn, New York Versus At Barceloneta, Puerto Rico In Healthy Subjects|Completed|||32||Pfizer|||||f||||||||||||||2018-06-01 02:48:39.300549|2018-06-01 02:48:39.300549
NCT00550303|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2007-12-18|2007-10-25|2007-10-29|Estimate|||||||2007-12-18|2007-12-27|Estimate|October 2007||2007-10-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens|An Open-Label, Single-Dose, Non-Randomized, 4-Period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women|Completed||Phase 1|28|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:48:39.361776|2018-06-01 02:48:39.361776
NCT00550290|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2009-06-24|2007-10-26|2007-10-29|Estimate|||||||2009-06-24|2009-06-25|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy|Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy|Completed||N/A|160|Anticipated|Aultman Health Foundation||2|||f||||f||||||||||2018-06-01 02:48:39.412067|2018-06-01 02:48:39.412067
NCT00550277|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|2012-08-22||2012-10-31|2007-10-26|2007-10-29|Estimate|2012-10-31|2012-11-30|Estimate||||2012-10-31|2012-11-30|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||LBH589 Treatment for Refractory Clear Cell Renal Carcinoma|A Phase II Study of LBH589 in the Treatment of Patients With Refractory Clear Cell Renal Carcinoma|Completed||Phase 2|20|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:48:39.506493|2018-06-01 02:48:39.506493
NCT00550264|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2011-06-27|2007-10-25|2007-10-29|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2007||2007-02-28|June 2011|2011-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of Physician Awareness of and Communication About Patient Readmissions to the Hospital|Physician Awareness of and Communication About Hospital Readmissions|Completed||N/A|500|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 02:48:39.690788|2018-06-01 02:48:39.690788
NCT00550251|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2018-05-03|2007-10-25|2007-10-29|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2010||2010-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients? Formal Study|Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients? Formal Study|Recruiting||N/A|58|Anticipated|Sue Ryder Care||2|||f||||f||||||||||2018-06-01 02:48:39.756551|2018-06-01 02:48:39.756551
NCT00550238|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2017-04-18|2007-10-26|2007-10-29|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2007||2007-07-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis|A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease|Active, not recruiting||Phase 3|500|Anticipated|ACADIA Pharmaceuticals Inc.||1|||f||||f|t|f||||||No||2018-06-01 02:48:39.868295|2018-06-01 02:48:39.868295
NCT00472602|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2010-08-26|2007-05-10|2007-05-11|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2007||2007-08-31|May 2007|2007-05-31||||||||Observational|||Pathogenesis of Liver Fluke Induced Cancer in Thailand|Pathogenesis of Liver Fluke Induced Cancer in Thailand|Unknown status|Recruiting||6000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:14:03.815308|2018-06-01 03:14:03.815308
NCT00550225|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2017-08-02|2007-10-26|2007-10-29|Estimate|||||||2017-08-02|2017-08-04|Actual|November 29, 2007|Actual|2007-11-29|August 2017|2017-08-31|January 8, 2008|Actual|2008-01-08|January 8, 2008|Actual|2008-01-08||Interventional|||Succinate Salt Version of GSK961081 for Healthy Volunteers|A Randomised, Double-blind, Dose Escalating Study in Healthy Volunteers to Assess the Safety, Tolerability, Extra Pulmonary Pharmacodynamics and Pharmacokinetics of Single Doses of GSK961081 (Succinate Salt)|Completed||Phase 1|18|Actual|GlaxoSmithKline||8|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:48:40.231389|2018-06-01 02:48:40.231389
NCT00550212|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2012-05-10|2007-10-26|2007-10-29|Estimate|||||||2012-05-10|2012-05-14|Estimate|March 2008||2008-03-31|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects|An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Puma Biotechnology, Inc.||1|||f||||f||||||||||2018-06-01 02:48:40.40617|2018-06-01 02:48:40.40617
NCT00550199|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2013-08-15|2007-10-26|2007-10-29|Estimate|||||||2013-08-15|2013-08-19|Estimate|November 2007||2007-11-30|August 2013|2013-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||LBH589 and Gemcitabine in the Treatment of Solid Tumors|A Phase I Study of LBH589 in Combination With Gemcitabine in the Treatment of Solid Tumors|Terminated||Phase 1|17|Actual|SCRI Development Innovations, LLC||1||Study terminated due to LBH589 toxicity.|f||||f||||||||||2018-06-01 02:48:40.513056|2018-06-01 02:48:40.513056
NCT00550186|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-26|||2016-06-27|2007-10-26|2007-10-29|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2007||2007-10-31|June 2016|2016-06-30||||December 2007|Actual|2007-12-31||Interventional|||Effect of Preload on Bladder Retention Volume During Spinal Anesthesia|The Effect of Intravascular Preload on Bladder Retention Volume During Spinal Anesthesia Induced Detrusor Blockade|Completed||N/A|144|Actual|Rijnstate Hospital||3|||f||||f||||||||||2018-06-01 02:48:40.600602|2018-06-01 02:48:40.600602
NCT00550173|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2013-01-10||2013-01-10|2007-10-25|2007-10-29|Estimate|2013-01-10|2013-02-13|Estimate||||2013-01-10|2013-02-13|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer|A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer|Completed||Phase 2|247|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:48:40.715685|2018-06-01 02:48:40.715685
NCT00550160|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2015-09-17|2007-10-25|2007-10-29|Estimate|||||||2015-09-17|2015-09-18|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|KNUST-COMDIS||The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children|The Clinical Impact of Seasonal Intermittent Preventive Treatment (IPT) and Home Management of Malaria (HMM) Using AQ+AS in Ghanaian Children Under 5 Years of Age - a Cluster Randomised Placebo Controlled Trial.|Completed||Phase 4|1490|Actual|Kwame Nkrumah University of Science and Technology||2|||f||||f||||||||||2018-06-01 02:48:42.441152|2018-06-01 02:48:42.441152
NCT00550147|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2009-04-03||2015-05-08|2007-10-26|2007-10-29|Estimate|2015-05-08|2015-05-13|Estimate||||2015-05-08|2015-05-13|Estimate|February 2004||2004-02-29|May 2015|2015-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior.|An Open-Label Study of Quetiapine Added to Oros Methylphenidate in the Treatment of ADHD and Aggressive Behavior|Completed||Phase 2|30|Actual|Indiana University|There were no unanticipated limitations/caveats. All of the typical caveats of open-label studies apply: As a result, bias, placebo effects, demand characteristics, and other non-treatment related effects may have contributed to results.|1|||f||||t||||||||||2018-06-01 02:48:42.531394|2018-06-01 02:48:42.531394
NCT00550134|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2017-11-06|2007-10-25|2007-10-29|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2007||2007-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cognitive Changes Associated With Breast Cancer Treatment|Cognitive Changes Associated With Breast Cancer Treatment|Active, not recruiting|||80|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples With DNA|"~     blood~   "|||2018-06-01 02:48:42.854157|2018-06-01 02:48:42.854157
NCT00550121|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2008-10-13|2007-10-25|2007-10-26|Estimate|||||||2008-10-13|2008-10-15|Estimate|August 2007||2007-08-31|October 2008|2008-10-31|April 2008|Actual|2008-04-30|||||Interventional|||Does Ascorbic Acid Reduce Sympathoexcitation in CHF?||Completed||N/A|||Radboud University||2|||f||||||||||||||2018-06-01 02:48:42.942528|2018-06-01 02:48:42.942528
NCT00550108|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2008-06-23|2007-10-24|2007-10-26|Estimate|||||||2008-06-23|2008-06-26|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Management of Incidentally Discovered Pancreatic Cysts|A Prospective Study of the Management of Incidentally Discovered Pancreatic Cysts|Terminated||Phase 3|0|Actual|Massachusetts General Hospital||2||Inability to enroll subjects.|f||||t||||||||||2018-06-01 02:48:43.107927|2018-06-01 02:48:43.107927
NCT00550095|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2017-02-21|2007-10-25|2007-10-26|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2007||2007-06-30|February 2017|2017-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus|A 24 Week, Multi-centre, Open Label, Non Controlled Study to Assess the Efficacy of Valsartan in Reducing Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|509|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:48:43.222513|2018-06-01 02:48:43.222513
NCT00550082|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2012-02-09|2007-10-25|2007-10-26|Estimate|||||||2012-02-09|2012-02-10|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||3 Screen Electronic Alert|Multi-Screen Electronic Alert for Venous Thromboembolism Prevention|Completed|||880|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 02:48:43.325999|2018-06-01 02:48:43.325999
NCT00550069|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2007-12-24|2007-10-25|2007-10-26|Estimate|||||||2007-12-24|2007-12-27|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|January 2009|Anticipated|2009-01-31|||||Observational|||Observational Study of Infants Born at 34 to 37 Weeks of Gestation Until the Age of 1 Year|Late Preterm Infants:Clinical Course and Outcome From Birth Through Out the First Year of Life.|Unknown status|Not yet recruiting||300|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 02:48:43.427194|2018-06-01 02:48:43.427194
NCT00550056|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2007-10-25|2007-10-25|2007-10-26|Estimate|||||||2007-10-25|2007-10-26|Estimate|January 2003||2003-01-31|October 2007|2007-10-31|April 2004|Actual|2004-04-30|||||Interventional|||Treatment of Posttraumatic Stress Disorder by Trained Lay Counsellors in an African Refugee Settlement|Talking About Traumatic Events - A Randomized Controlled Dissemination Study of the Treatment of PTSD in an African Refugee Settlement|Completed||Phase 3|277|Actual|University of Konstanz||3|||f||||f||||||||||2018-06-01 02:48:43.534083|2018-06-01 02:48:43.534083
NCT00550043|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2015-02-09||2015-03-09|2007-10-24|2007-10-26|Estimate|2015-03-09|2015-03-23|Estimate||||2015-03-09|2015-03-23|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis|A Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|50|Actual|Incyte Corporation||5|||f||||f||||||||||2018-06-01 02:48:43.644772|2018-06-01 02:48:43.644772
NCT00550030|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2012-03-15|2007-10-24|2007-10-26|Estimate|||||||2012-03-15|2012-03-16|Estimate|August 2006||2006-08-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Etanercept Plus UVB-311nm Phototherapy in Psoriasis|Prospective, Randomized Half-side Study on the Efficacy of UVB-311nm Phototherapy in Patients With Psoriasis Undergoing Etanercept Treatment|Completed||N/A|6|Actual|Medical University of Graz||1|||f||||f||||||||||2018-06-01 02:48:44.34752|2018-06-01 02:48:44.34752
NCT00550017|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24||2011-06-21|2015-09-23|2007-10-24|2007-10-26|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|December 2007||2007-12-31|September 2015|2015-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)|A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)|Terminated||Phase 1/Phase 2|39|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:48:44.410309|2018-06-01 02:48:44.410309
NCT00550004|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2011-06-06|2007-10-25|2007-10-26|Estimate|||||||2011-06-06|2011-06-08|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|RP101||Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine|Randomized, Double Blind, Placebo Controlled, Phase 2 Study Evaluating the Efficacy & Safety of RP101 or Placebo in Combination With Gemcitabine Administered as First-Line Treatment to Subjects With Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinoma|Terminated||Phase 2|153|Anticipated|SciClone Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:48:44.472512|2018-06-01 02:48:44.472512
NCT00549991|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2013-11-26|2007-10-24|2007-10-26|Estimate|||||||2013-11-26|2013-11-27|Estimate|August 2007||2007-08-31|April 2009|2009-04-30|June 2012|Actual|2012-06-30|||||Observational|||Analyzing Genes That May Increase the Risk of Developing High Blood Pressure|Fine Mapping of Hypertension Genes Detected by Admixture Mapping in the FBPP|Completed|||8687|Actual|Case Western Reserve University|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:48:44.707866|2018-06-01 02:48:44.707866
NCT00549978|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2010-07-21|2007-10-25|2007-10-26|Estimate|||||||2010-07-21|2010-07-23|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Safety and Pharmacokinetics of Probucol and Cilostazol|Phase IV, Safety and Pharmacokinetics of Probucol and Cilostazol When Coadministered in Healthy Subjects|Completed||Phase 4|32|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:48:44.768245|2018-06-01 02:48:44.768245
NCT00549965|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-26|2007-10-24|2007-10-26|Estimate|||||||2007-10-26|2007-10-30|Estimate|October 2003||2003-10-31|October 2007|2007-10-31||||||||Interventional|||Satisfaction and Compliance of Risedronate in PMO|A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg|Completed||Phase 4|202|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:48:44.828608|2018-06-01 02:48:44.828608
NCT00549952|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2007-10-25|2007-10-25|2007-10-26|Estimate|||||||2007-10-25|2007-10-26|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|March 2008|Anticipated|2008-03-31|||||Observational|||Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients|Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients|Unknown status|Recruiting||||Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||f||||||||||2018-06-01 02:48:44.881184|2018-06-01 02:48:44.881184
NCT00549939|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2011-01-13|2010-03-08|2014-10-21|2007-10-25|2007-10-26|Estimate|2011-01-13|2011-02-08|Estimate|2010-03-08|2010-03-09|Estimate|2014-10-21|2014-10-29|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|ALFACHIN||Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction|12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension|Completed||Phase 3|172|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 02:48:44.97517|2018-06-01 02:48:44.97517
NCT00549926|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2010-02-16|2007-10-25|2007-10-26|Estimate|||||||2010-02-16|2010-02-17|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|||||Interventional|Yokohama-ACS||Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and Atorvastatin in Acute Coronary Syndrome (Yokohama-ACS)|Yokohama Assessment of Fluvastatin, Pravastatin, Pitavastatin and Atorvastatin in Acute Coronary Syndrome (Yokohama-ACS)|Completed||Phase 4|200|Anticipated|Yokohama City University Medical Center||4|||f||||f||||||||||2018-06-01 02:48:45.662126|2018-06-01 02:48:45.662126
NCT00549913|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2014-11-06|2007-10-25|2007-10-26|Estimate|||||||2014-11-06|2014-11-07|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)|A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation.|Completed||Phase 1/Phase 2|6|Actual|Mesoblast, Ltd.||6|||f||||t||||||||||2018-06-01 02:48:45.782186|2018-06-01 02:48:45.782186
NCT00549900|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2009-11-12||2016-10-27|2007-10-25|2007-10-26|Estimate|2009-11-12|2009-12-17|Estimate||||2016-10-27|2016-12-09|Estimate|December 2007||2007-12-31|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females|Safety and Immunogenicity Study of the HPV Vaccine (GSK-580299) in Healthy, Chinese, Female Subjects|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:48:45.882331|2018-06-01 02:48:45.882331
NCT00549887|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2010-03-15|2007-10-23|2007-10-26|Estimate|||||||2010-03-15|2010-03-16|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|SWING||An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin|Resource Utilisation and Patient Satisfaction With SWitching INsulin (SWING)|Completed|||2459|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-06-01 02:48:47.201296|2018-06-01 02:48:47.201296
NCT00549861|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2011-10-02|2007-10-25|2007-10-26|Estimate|||||||2011-10-02|2011-10-04|Estimate|September 2007||2007-09-30|October 2011|2011-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR|Characterization of Irreversible Myocardial Injury in Dilated Forms of Cardiomyopathies by Gadobutrol (Gadovist®)-Enhanced Cardiovascular Magnetic Resonance Imaging|Completed||N/A|40|Actual|University of Calgary||1|||f||||t||||||||||2018-06-01 02:48:47.378682|2018-06-01 02:48:47.378682
NCT00549848|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2018-05-02|2007-10-25|2007-10-26|Estimate|||||||2018-05-02|2018-05-04|Actual|October 29, 2007|Actual|2007-10-29|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 3|600|Actual|St. Jude Children's Research Hospital||2|||f||||t|t|f||||||||2018-06-01 02:48:47.455509|2018-06-01 02:48:47.455509
NCT00549835|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2015-04-07|2007-10-24|2007-10-26|Estimate|||||||2015-04-07|2015-04-08|Estimate|August 2007||2007-08-31|March 2015|2015-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Acupuncture for Mucositis Pain in Cancer Care|Acupuncture for Mucositis Pain in Cancer Care|Withdrawn||N/A|0|Actual|Johns Hopkins University||2||Inadequate funding|f||||f||||||||||2018-06-01 02:48:47.545264|2018-06-01 02:48:47.545264
NCT00549822|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2016-10-26||2017-02-01|2007-10-24|2007-10-26|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|October 2007|Actual|2007-10-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|May 2010|Actual|2010-05-31||Interventional|||Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer|A Phase II Clinical Trial of Intermittent Letrozole Therapy in Postmenopausal Women With CA 15-3 Positive (Carcinoma Antigen 15-3), Hormone Receptor Positive, Metastatic Breast Cancer|Terminated||Phase 2|3|Actual|Massachusetts General Hospital|The study closed prematurely before the planned enrollment of 20 patients due to poor patient accrual. The patient population was highly selected, were likely to have had disease with an indolent natural history.|1||Slow Accrual|f||||t||||||||No||2018-06-01 02:48:47.759338|2018-06-01 02:48:47.759338
NCT00549809|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2008-06-27|2007-10-25|2007-10-26|Estimate|||||||2008-06-27|2008-07-02|Estimate|October 2005||2005-10-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Interventional|||Comparison Between IMV and SIMV/PS for Ventilatory Support of Children: a Randomized Clinical Trial|Comparison Between IMV and SIMV/PS for Ventilatory Support of Children: a Randomized Clinical Trial|Completed||Phase 3|70|Actual|UPECLIN HC FM Botucatu Unesp||1|||f||||f||||||||||2018-06-01 02:48:47.998413|2018-06-01 02:48:47.998413
NCT00549796|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2014-09-10|2007-10-25|2007-10-26|Estimate|||||||2014-09-10|2014-09-11|Estimate|April 2006||2006-04-30|September 2014|2014-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery|Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery|Completed||N/A|18876|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 02:48:48.153478|2018-06-01 02:48:48.153478
NCT00549783|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2011-11-14||2012-07-18|2007-10-25|2007-10-26|Estimate|2012-07-18|2012-08-22|Estimate||||2012-07-18|2012-08-22|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|||BOTOX® Economic Spasticity Trial (BEST)||Completed||Phase 4|274|Actual|Allergan||2|||f||||f||||||||||2018-06-01 02:48:48.366195|2018-06-01 02:48:48.366195
NCT00549770|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2012-08-10||2015-08-11|2007-10-25|2007-10-26|Estimate|2015-07-11|2015-08-10|Estimate||||2015-08-11|2015-08-25|Estimate|September 2007||2007-09-30|August 2015|2015-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety of LCZ696A in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension|Completed||Phase 2|1334|Actual|Novartis||8|||f||||f||||||||||2018-06-01 02:48:48.984965|2018-06-01 02:48:48.984965
NCT00549757|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2014-02-03||2014-04-01|2007-10-25|2007-10-26|Estimate|2014-02-03|2014-03-18|Estimate||||2014-04-01|2014-04-21|Estimate|October 2007||2007-10-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ALTITUDE|Full Analysis Set (FAS) : All patients randomized except mis-randomized patients who did not receive study drug.|Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality|Terminated||Phase 3|8606|Actual|Novartis||2||Lack of benefit and safety concern|f||||||||||||||2018-06-01 02:48:51.509615|2018-06-01 02:48:51.509615
NCT00549744|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25||2009-07-22|2017-06-22|2007-10-25|2007-10-26|Estimate||||2009-07-22|2009-08-10|Estimate|2017-06-22|2017-06-26|Actual|November 16, 2007|Actual|2007-11-16|June 2017|2017-06-30|August 27, 2008|Actual|2008-08-27|August 27, 2008|Actual|2008-08-27||Interventional|||Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing|A Randomized, Double-blind, Double-dummy, Placebocontrolled,Three-period, Incomplete Block, Crossover Study, to a Investigate the Effect of 14 Days Repeat Inhaled Dosing With GSK256066 in Mild/Moderate Asthmatic Patients.|Completed||Phase 2|78|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:49:00.33133|2018-06-01 02:49:00.33133
NCT00549731|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2013-05-31|2007-10-25|2007-10-26|Estimate|||||||2013-05-31|2013-06-04|Estimate|June 2005||2005-06-30|April 2012|2012-04-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Participant Database for Autism Research Studies|Participant Database for Persons Interested in Autism Research Studies: Recruiting, Pre-Screening and Diagnostic Assessment|Unknown status|Recruiting||5000|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 02:49:00.419524|2018-06-01 02:49:00.419524
NCT00549718|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2010-11-08||2014-06-05|2007-10-25|2007-10-26|Estimate|2010-11-08|2010-12-14|Estimate||||2014-06-05|2014-06-11|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia|A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia|Completed||Phase 3|489|Actual|Sunovion||4|||f||||t||||||||||2018-06-01 02:49:00.479746|2018-06-01 02:49:00.479746
NCT00549705|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-09-15|2007-10-25|2007-10-26|Estimate|||||||2009-09-15|2009-09-17|Estimate|July 2007||2007-07-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Registry of Hospitalized Patients Treated With Fondaparinux|Registry of Hospitalized Patients Treated With Fondaparinux|Completed|||220|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 02:49:01.055071|2018-06-01 02:49:01.055071
NCT00549692|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2012-09-25|2007-10-25|2007-10-26|Estimate|||||||2012-09-25|2012-09-27|Estimate|November 2007||2007-11-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|IgAN||Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy|Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy|Completed||Phase 3|152|Actual|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:49:01.120032|2018-06-01 02:49:01.120032
NCT00549679|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24||2009-11-30|2017-07-25|2007-10-25|2007-10-26|Estimate||||2009-11-30|2009-12-02|Estimate|2017-07-25|2017-07-28|Actual|October 4, 2007||2007-10-04|July 2017|2017-07-31|December 15, 2008|Actual|2008-12-15|December 15, 2008|Actual|2008-12-15||Interventional|||Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients|Completed||Phase 2|104|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 02:49:01.324351|2018-06-01 02:49:01.324351
NCT00549666|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2011-09-12|2007-10-25|2007-10-26|Estimate|||||||2011-09-12|2011-09-14|Estimate|August 2007||2007-08-31|September 2011|2011-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|OC-DDI||A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects|A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects|Completed||Phase 1|23|Actual|Sunovion||3|||f||||t||||||||||2018-06-01 02:49:01.452396|2018-06-01 02:49:01.452396
NCT00549653|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2012-05-31|2007-10-25|2007-10-26|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men|A Randomized, Single Blind, Repeat Dose, Placebo-controlled, Single-period, Parallel Group Study to Investigate the Safety, Tolerability and Potential Pharmacokinetic Interactions Between GW856553 and Rosuvastatin (10mg), When Co-administered in Healthy Adult Male Subjects|Completed||Phase 1|44|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:49:01.527636|2018-06-01 02:49:01.527636
NCT00549640|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2010-09-08||2011-04-15|2007-10-25|2007-10-26|Estimate|2010-10-08|2010-11-01|Estimate||||2011-04-15|2011-04-19|Estimate|January 2008||2008-01-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|||Testing Methylphenidate for Smoking Abstinence|Efficacy of Methylphenidate for Treating Tobacco Dependence|Completed||Phase 2|80|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 02:49:01.609271|2018-06-01 02:49:01.609271
NCT00549627|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-02-03|2007-10-24|2007-10-26|Estimate|||||||2009-02-03|2009-02-04|Estimate|August 2005||2005-08-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|November 2008|Actual|2008-11-30||Interventional|||Evaluation of the PediGuard™ for Pedicle Screw Insertion|Evaluation of the PediGuard™ for Pedicle Screw Insertion|Suspended||N/A|108|Actual|Shriners Hospitals for Children||||New funding sources being sought|f||||f||||||||||2018-06-01 02:49:01.947403|2018-06-01 02:49:01.947403
NCT00549614|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2009-10-06|2007-10-25|2007-10-26|Estimate|||||||2009-10-06|2009-10-07|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|ACME||Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure|Effect of 4 Weeks Treatment With Acipimox on Left Ventricular Function, Work Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure|Completed||N/A|28|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-06-01 02:49:02.017646|2018-06-01 02:49:02.017646
NCT00549601|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2011-01-05||2011-02-24|2007-10-25|2007-10-26|Estimate|2011-02-24|2011-03-24|Estimate||||2011-02-24|2011-03-24|Estimate|September 2007||2007-09-30|February 2011|2011-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|KAPA||Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease|A Multi-center, Randomised, Open-label Study to Evaluate Convenience and Safety of Change in the Mode of Administration of Rivastigmine (From Capsules to a Transdermal Patch) in Patients With Alzheimer's Disease|Completed||Phase 4|142|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:49:02.117662|2018-06-01 02:49:02.117662
NCT00549588|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-09-29|2007-10-24|2007-10-26|Estimate|||||||2009-09-29|2009-09-30|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|August 2006|Actual|2006-08-31|June 2004|Actual|2004-06-30||Interventional|||Sunscreen and After-sun-lotion Protection in Polymorphic Light Eruption|The Efficacy of a Sunscreen With SPF30 and a After-sun-lotion in the Prevention of Polymorphic Light Eruption|Completed||N/A|14|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 02:49:02.525041|2018-06-01 02:49:02.525041
NCT00549575|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-25|2007-10-25|2007-10-26|Estimate|||||||2007-10-25|2007-10-26|Estimate|July 2000||2000-07-31|October 2007|2007-10-31|June 2006|Actual|2006-06-30|||||Interventional|||L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)|L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial|Terminated||Phase 3|44|Actual|Nantes University Hospital||2||terminated|f||||||||||||||2018-06-01 02:49:02.61236|2018-06-01 02:49:02.61236
NCT00549562|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|2017-04-11||2017-04-11|2007-10-25|2007-10-26|Estimate|2017-04-11|2017-05-16|Actual||||2017-04-11|2017-05-16|Actual|November 2007||2007-11-30|April 2017|2017-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of Paliperidone ER in Adolescents and Young Adults With Autism|A Prospective, Open-Label Study of Paliperidone ER in Adolescents and Young Adults With Autism|Completed||Phase 3|25|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 02:49:02.710053|2018-06-01 02:49:02.710053
NCT00549549|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2010-12-17||2011-01-27|2007-10-24|2007-10-26|Estimate|2011-01-27|2011-02-24|Estimate||||2011-01-27|2011-02-24|Estimate|February 2008||2008-02-29|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Celebrex In Acute Gouty Arthritis Study|A Phase 3, Randomized, Double-Blind, Multicenter, Active-Controlled Trial To Evaluate The Efficacy And Safety Of Celecoxib (Celebrex®) And Indomethacin In The Treatment Of Moderate To Severe Acute Gouty Arthritis|Completed||Phase 3|402|Actual|Pfizer|Patients Global Evaluation of study medication data was collected at Day 9 only.|4|||f||||t||||||||||2018-06-01 02:49:03.081326|2018-06-01 02:49:03.081326
NCT00549536|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-25|||2008-07-02|2007-10-25|2007-10-26|Estimate|||||||2008-07-02|2008-07-04|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effect of Calcium Supplementation on Insulin Resistance and 24h Blood Pressure|The Effect of Oral Calcium Supplementation on Insulin Sensitivity, Intracellular Cationic Concentrations and the Transmembrane Sodium/Hydrogen Exchanger Activity in Subjects With Type 2 Diabetes and Hypertension|Completed||Phase 4|31|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 02:49:06.276739|2018-06-01 02:49:06.276739
NCT00549523|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2016-10-07|2007-10-25|2007-10-26|Estimate|||||||2016-10-07|2016-10-10|Estimate|April 2008||2008-04-30|October 2016|2016-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults|A Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of Lessertia Frutescens (L.)Goldblatt and J.C. Manning (Syn. Sutherlandia Frutescens (L.)R. Br.)in HIV-infected South African Adults|Completed||Phase 1/Phase 2|133|Actual|University of Missouri-Columbia||4|||f||||t||||||||No||2018-06-01 02:49:06.349402|2018-06-01 02:49:06.349402
NCT00549510|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23||2010-10-13|2010-10-13|2007-10-23|2007-10-25|Estimate||||2010-10-13|2010-10-15|Estimate|2010-10-13|2010-10-15|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.|A Non-randomized, Open-label, Single-dose, Crossover Study to Evaluate the Dose Proportionality of the Final Fixed Dose Combination Formulation of COREG CR™ and Lisinopril.|Completed||Phase 1|29|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:49:06.43018|2018-06-01 02:49:06.43018
NCT00549497|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2017-02-02|2007-10-24|2007-10-25|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2007|Actual|2007-09-30|February 2011|2011-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Dose Ascending, 3-cohort Parallel Group Study to Measure the Systemic Cortisol Profile and Evaluate the Safety, Tolerability and Pharmacokinetics of GW870086X, Administered as Single Doses (12mg and 15mg), and Repeat Doses Over 3 Days (6mg, 12mg and 15mg) in Healthy Male Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:49:06.500722|2018-06-01 02:49:06.500722
NCT00549484|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2008-01-16|2007-10-24|2007-10-25|Estimate|||||||2008-01-16|2008-01-18|Estimate|May 2003||2003-05-31|January 2008|2008-01-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Observational|||Thrombopoietin Levels and Platelet Transfusion in Neonates|Thrombopoietin Levels Following Platelet Transfusion in Neonates With Thrombocytopenia|Completed|||20|Actual|Christiana Care Health Services|||2||f||||f||||||Samples With DNA|"~     Blood samples were collected pre and post platelet transfusion. Samples included platelet~     count, thrombopoietin, and platelet factor 4.~   "|||2018-06-01 02:49:06.5687|2018-06-01 02:49:06.5687
NCT00549471|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2011-04-20|2007-10-24|2007-10-25|Estimate|||||||2011-04-20|2011-04-21|Estimate|September 2007||2007-09-30|April 2011|2011-04-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy|Improvement After Botulinum Toxin A Injections to the Upper Extremities in Children With Cerebral Palsy|Terminated||Phase 4|3|Actual|Shaare Zedek Medical Center||2||no funding|f||||f||||||||||2018-06-01 02:49:06.721437|2018-06-01 02:49:06.721437
NCT00549458|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-09-17|2007-10-24|2007-10-25|Estimate|||||||2009-09-17|2009-09-18|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Randomized Controlled Trial Comparing Traditional Pelvic Floor Rehabilitation to Pilates in Increasing Pelvic Muscles Strength.||Completed||N/A|60|Anticipated|Atlantic Health System|||||f||||f||||||||||2018-06-01 02:49:06.79924|2018-06-01 02:49:06.79924
NCT00549445|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2017-04-13||2017-08-31|2007-10-24|2007-10-25|Estimate|2017-07-07|2017-08-14|Actual||||2017-08-31|2017-09-29|Actual|August 2007||2007-08-31|August 2017|2017-08-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Observational||The number of participants included in this study is small as sputum samples were available only from a minority of participants in the parent trial. Therefore, this greatly reduced the overall number of participants analyzed.|Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Macrolide Treatment on a Novel Pathway of Neutrophilic Inflammation in COPD|Completed|||53|Actual|University of Alabama at Birmingham|We were limited by the number of participants included in this study is small, as sputum samples were available only from a minority of participants in the parent trial.||2||f||||f|t|f|||f|Samples Without DNA|"~     Serum and Plasma~   "|||2018-06-01 02:49:06.878374|2018-06-01 02:49:06.878374
NCT00549432|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-05-14|2007-10-24|2007-10-25|Estimate|||||||2009-05-14|2009-05-15|Estimate|October 2002||2002-10-31|May 2009|2009-05-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|l||Clinical Study of Abdominal Aortic Aneurysm Exclusion (TALENT Abdominal)|Clinical Study of Abdominal Aortic Aneurysm Exclusion Using the TALENT Enhanced LPS Endoluminal Stent-Graft System|Unknown status|Active, not recruiting|N/A|75|Anticipated|Arizona Heart Institute||1|||f||||f||||||||||2018-06-01 02:49:07.138773|2018-06-01 02:49:07.138773
NCT00549419|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2009-12-21|2007-10-24|2007-10-25|Estimate|||||||2009-12-21|2009-12-23|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|REPEAT||Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Abdominal Surgery|Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Therapy in Patients Undergoing Major Abdominal Surgery|Completed||Phase 4|60|Actual|Klinikum Ludwigshafen||2|||f||||t||||||||||2018-06-01 02:49:07.219487|2018-06-01 02:49:07.219487
NCT00549406|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2014-12-19|2007-10-24|2007-10-25|Estimate|||||||2014-12-19|2014-12-23|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|||Visual Training Program to Improve Balance and Prevent Falls in Older Adults|"Visual Processing and Postural Reactions: Development and Pilot Testing of a Visual Training Program to Improve Balance Control and Prevent Falls in Older Adults"|Completed||Phase 1|33|Actual|Sunnybrook Health Sciences Centre||3|||f||||f||||||||||2018-06-01 02:49:07.283689|2018-06-01 02:49:07.283689
NCT00549393|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2015-03-31||2017-05-19|2007-10-24|2007-10-25|Estimate|2015-09-01|2015-10-02|Estimate||||2017-05-19|2017-06-14|Actual|February 2008||2008-02-29|May 2017|2017-05-31|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|||Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit|Impact of Daily Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit|Completed||Phase 2/Phase 3|5659|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:49:07.381743|2018-06-01 02:49:07.381743
NCT00549380|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2010-05-25|2007-10-24|2007-10-25|Estimate|||||||2010-05-25|2010-05-27|Estimate|October 1999||1999-10-31|May 2009|2009-05-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|Endologix||Clinical Study of Aneurysm Exclusion|A Clinical Study of Aneurysm Exclusion Using Endologix, Inc. Endoluminal Technology|Unknown status|Active, not recruiting|Phase 1|88|Anticipated|Arizona Heart Institute||1|||f||||f||||||||||2018-06-01 02:49:07.756976|2018-06-01 02:49:07.756976
NCT00548964|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2014-05-22|2007-10-24|2007-10-25|Estimate|||||||2014-05-22|2014-05-23|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Continuation Ketamine in Major Depression|Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention|Completed||Phase 1|36|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 02:49:13.937289|2018-06-01 02:49:13.937289
NCT00549367|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2017-05-08|2007-10-24|2007-10-25|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2007||2007-11-30|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|TACH001||The Role of Diet Education and Nutritional Counselling in the Ongoing Care of People Living With HIV in Thailand|The Role of Diet Education and Nutritional Counselling in the Ongoing Care of People Living With HIV in Thailand (TACH001)|Active, not recruiting||Phase 1|153|Anticipated|Thai Red Cross AIDS Research Centre||1|||f||||f||||||||||2018-06-01 02:49:07.825415|2018-06-01 02:49:07.825415
NCT00549354|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2015-06-02|2007-10-24|2007-10-25|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2000||2000-08-31|October 2007|2007-10-31|December 2012|Anticipated|2012-12-31|||||Interventional|||Abdominal Aortic/Aorto-Iliac Aneurysm Endoluminal Graft Study|Endologix Bifurcated PowerLink System Clinical Study|Unknown status|Active, not recruiting|Phase 2|34|Actual|Arizona Heart Institute|||||f||||f||||||||||2018-06-01 02:49:07.899558|2018-06-01 02:49:07.899558
NCT00549341|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2016-03-25|2007-10-23|2007-10-25|Estimate|||||||2016-03-25|2016-03-29|Estimate|May 2006||2006-05-31|March 2016|2016-03-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia|A Phase I, Single-dose, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety of PurTox for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia and to Explore Dose-associated Efficacy|Completed||Phase 1|70|Actual|Mentor Worldwide, LLC||2|||f||||f||||||||||2018-06-01 02:49:07.980349|2018-06-01 02:49:07.980349
NCT00549328|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|2009-12-22||2014-11-06|2007-10-23|2007-10-25|Estimate|2009-12-22|2010-01-27|Estimate||||2014-11-06|2014-11-19|Estimate|February 2008||2008-02-29|November 2014|2014-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer|A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|14|Actual|GlaxoSmithKline||1||"Study enrolment was delayed in starting and too slow to support further development in this~   setting"|f||||||||||||||2018-06-01 02:49:08.079357|2018-06-01 02:49:08.079357
NCT00549315|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-05-14|2007-10-24|2007-10-25|Estimate|||||||2009-05-14|2009-05-15|Estimate|October 2002||2002-10-31|May 2009|2009-05-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|Valiant||Clinical Study of Thoracic Aortic Aneurysm Exclusion|Clinical Study of Thoracic Aortic Aneurysm Exclusion Using the VALIANT System|Unknown status|Recruiting|N/A|60|Anticipated|Arizona Heart Institute||1|||f||||f||||||||||2018-06-01 02:49:08.348094|2018-06-01 02:49:08.348094
NCT00549302|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|2013-01-16||2013-04-01|2007-10-23|2007-10-25|Estimate|2013-01-16|2013-02-18|Estimate||||2013-04-01|2013-04-09|Estimate|December 2005||2005-12-31|April 2013|2013-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs|An Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients With Pulmonary Arterial Hypertension|Completed||Phase 3|357|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:49:08.482186|2018-06-01 02:49:08.482186
NCT00549289|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-24|2007-10-24|2007-10-25|Estimate|||||||2007-10-24|2007-10-25|Estimate||||October 2007|2007-10-31||||||||Interventional|||Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)||Completed||Phase 3|||Sirion Therapeutics, Inc.|||||||||||||||||||2018-06-01 02:49:09.446335|2018-06-01 02:49:09.446335
NCT00549276|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2007-10-23|2007-10-23|2007-10-25|Estimate|||||||2007-10-23|2007-10-25|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|November 2006|Actual|2006-11-30|||||Observational|||Randomized Comparison of Curved Cutter Stapler and Linear Stapler||Completed|||||Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:49:09.517337|2018-06-01 02:49:09.517337
NCT00549263|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2015-02-19|2007-10-23|2007-10-25|Estimate|||||||2015-02-19|2015-02-23|Estimate|February 2008||2008-02-29|February 2015|2015-02-28||||||||Interventional|||Bioequivalence Study of SB797620 in Healthy Japanese Volunteers|A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone (RSG) and Glimepiride (GLIM)(4mg/2mg) Compared to Concomitant Dosing of RSG 4mg Tablet and GLIM 1mg Commercial Tablet x 2 (4mg+2mg) in Japanese Healthy Male Subjects|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||||No subjects enrolled, bio equivalence study, canceled before active.|f||||f||||||||||2018-06-01 02:49:09.672276|2018-06-01 02:49:09.672276
NCT00549250|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2010-07-01|2007-10-24|2007-10-25|Estimate|||||||2010-07-01|2010-07-05|Estimate|November 2007||2007-11-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|June 2008|Actual|2008-06-30||Observational|||Human Papillomavirus 6/11 in the Lower Airway of Neonates|Human Papillomavirus 6/11 in the Lower Airway of Neonates|Completed|||114|Actual|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Bronchial lavage fluid~   "|||2018-06-01 02:49:09.72861|2018-06-01 02:49:09.72861
NCT00549237|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2013-09-05|2007-10-24|2007-10-25|Estimate|||||||2013-09-05|2013-09-06|Estimate|November 2007||2007-11-30|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Perioperative Nutrition in Gastric Bypass Surgery|Perioperative Nutrition in Gastric Bypass Surgery for Morbid Obesity|Completed||N/A|200|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 02:49:09.795755|2018-06-01 02:49:09.795755
NCT00549211|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2012-03-15|2007-10-23|2007-10-25|Estimate|||||||2012-03-15|2012-03-19|Estimate|October 2007||2007-10-31|February 2011|2011-02-28||||||||Interventional|||A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.|A Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of GSK557296 in a Randomized, Single-Blind, Placebo-Controlled, Dose-Rising Design, and to Evaluate the Effect of Food on Single Oral Doses of GSK557296 in Healthy Adult Subjects|Completed||Phase 1|42|Anticipated|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:49:09.872168|2018-06-01 02:49:09.872168
NCT00549198|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2010-09-23||2011-04-07|2007-10-24|2007-10-25|Estimate|2010-09-23|2010-10-15|Estimate||||2011-04-07|2011-04-12|Estimate|June 2007||2007-06-30|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ASSERT||KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects|Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects|Completed||Phase 4|392|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:49:10.070079|2018-06-01 02:49:10.070079
NCT00549185|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2012-02-13|2007-10-24|2007-10-25|Estimate|||||||2012-02-13|2012-02-14|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma|An Open-label Multi-dose-escalation, Safety and Pharmacokinetic Study of SAR3419 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 1|39|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:49:12.240585|2018-06-01 02:49:12.240585
NCT00549172|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|2015-03-16||2015-03-16|2007-10-24|2007-10-25|Estimate|2015-03-16|2015-03-23|Estimate||||2015-03-16|2015-03-23|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Age, Sex, Weight, Height, BMI, Duration of medial knee pain, Type of onset of symptoms, Radiographic assessment (Kellfren-Lawrence), Clinical meniscal tests|Arthroscopy in the Treatment of Degenerative Medial Meniscus Tear|Efficacy of Arthroscopic Partial Resection for the Degenerative Tear of the Medial Meniscus of a Knee|Completed||Phase 2/Phase 3|146|Actual|University of Tampere||2|||f||||t||||||||||2018-06-01 02:49:12.300403|2018-06-01 02:49:12.300403
NCT00549159|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2008-05-19|2007-10-24|2007-10-25|Estimate|||||||2008-05-19|2008-05-22|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||CavatermTM vs TCRE in Women With DUB|Multicenter Randomized Clinical Trial to Evaluate the Safety and Effectiveness of Cavaterm TM Thermal Balloon Endometrial Ablation in Women With Dysfunctional Uterine Bleeding Compared to Transcervical Resection of the Endometrium (TCRE)|Unknown status|Recruiting|Phase 4|158|Anticipated|Pnn Medical A/S||2|||f||||f||||||||||2018-06-01 02:49:12.657649|2018-06-01 02:49:12.657649
NCT00549146|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2017-01-19|2007-10-24|2007-10-25|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2003|Actual|2003-11-30|January 2017|2017-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease|Multi-centre, DB, R and Stratified Parallel Group Study to Compare the Efficacy and Safety of FP 500mcg Bid vs. SRT 50/250mcg Via Diskus in COPD Pts With Partial Reversible Obstruction|Completed||Phase 3|290|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:49:12.751638|2018-06-01 02:49:12.751638
NCT00549133|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-24|2007-10-24|2007-10-25|Estimate|||||||2007-10-24|2007-10-25|Estimate|October 2003||2003-10-31|October 2007|2007-10-31|April 2005|Actual|2005-04-30|||||Interventional|IREDIS||Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol|Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol|Completed||Phase 4|44|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:49:12.863802|2018-06-01 02:49:12.863802
NCT00549120|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2017-08-02|2007-10-23|2007-10-25|Estimate|||||||2017-08-02|2017-08-04|Actual|August 15, 2007|Actual|2007-08-15|August 2017|2017-08-31|October 26, 2007|Actual|2007-10-26|October 26, 2007|Actual|2007-10-26||Interventional|||Optimising the Propranolol Block Model|A Study to Optimise the Propranolol Block Model for Assessment of the Pharmacological Activity of Bronchodilators in Healthy Volunteers.|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:49:12.931973|2018-06-01 02:49:12.931973
NCT00549107|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-24|2007-10-24|2007-10-25|Estimate|||||||2007-10-24|2007-10-25|Estimate|September 2007||2007-09-30|October 2007|2007-10-31||||||||Interventional|Levomil||Prophylactic Use of Levosimendan Versus Milrinone in Open Heart Surgery in Infants|Phase 2 Prospective, Randomized, Double-Blind Pilot Study on Cardiac Output Following Corrective Open Heart Surgery in Children Less Than One Year: Use of Levosimendan Versus Milrinone.|Unknown status|Recruiting|Phase 2|40|Anticipated|Ludwig Boltzmann Gesellschaft||2|||f||||t||||||||||2018-06-01 02:49:13.051175|2018-06-01 02:49:13.051175
NCT00549081|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-24|2007-10-24|2007-10-25|Estimate|||||||2007-10-24|2007-10-25|Estimate|January 2008||2008-01-31|October 2007|2007-10-31|December 2008||2008-12-31|||||Interventional|||DHEA Supplementation for Low Ovarian Response IVF Patients||Unknown status|Not yet recruiting|N/A|||Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 02:49:13.15318|2018-06-01 02:49:13.15318
NCT00549068|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-12-04|2007-10-24|2007-10-25|Estimate|||||||2009-12-04|2009-12-07|Estimate|February 2003||2003-02-28|December 2009|2009-12-31|November 2004|Actual|2004-11-30|||||Interventional|||POWER Point of Care Effect on Satisfaction of Treatment|Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study|Completed||Phase 4|2433|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:49:13.240356|2018-06-01 02:49:13.240356
NCT00549055|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|2010-10-01||2011-02-15|2007-10-23|2007-10-25|Estimate|2010-10-01|2010-10-27|Estimate||||2011-02-15|2011-02-18|Estimate|November 2007||2007-11-30|February 2011|2011-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|MACURELI||A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.|A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration (AMD) In Real Life (Macureli Study).|Completed|||38|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:49:13.31577|2018-06-01 02:49:13.31577
NCT00549042|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2012-03-20|2007-10-23|2007-10-25|Estimate|||||||2012-03-20|2012-03-21|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain|A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS® Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients With Chronic Low Back Pain|Completed||Phase 3|266|Actual|Mallinckrodt||2|||f||||||||||||||2018-06-01 02:49:13.514455|2018-06-01 02:49:13.514455
NCT00549029|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-24|2007-10-24|2007-10-25|Estimate|||||||2007-10-24|2007-10-25|Estimate|August 2007||2007-08-31|October 2007|2007-10-31|January 2008|Anticipated|2008-01-31|||||Observational|||The Association of Genetic Polymorphisms With Statin-Induced Myopathy.|Association Analysis Between Single Nucleotide Polymorphisms in Statin-Related Genes and The Incidence of Myopathy Among Statin-Treated Patients|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 02:49:13.600639|2018-06-01 02:49:13.600639
NCT00549016|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-05-14|2007-10-24|2007-10-25|Estimate|||||||2009-05-14|2009-05-15|Estimate|November 2002||2002-11-30|May 2009|2009-05-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|EndoMed||Clinical Study of Aneurysm Exclusion|Clinical Study of Aneurysm Exclusion Using PTFE Encapsulation of Nitinol Stents|Unknown status|Recruiting|N/A|150|Anticipated|Arizona Heart Institute||1|||f||||f||||||||||2018-06-01 02:49:13.686167|2018-06-01 02:49:13.686167
NCT00549003|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2007-10-24|2007-10-24|2007-10-25|Estimate|||||||2007-10-24|2007-10-25|Estimate|February 2005||2005-02-28|October 2007|2007-10-31|August 2005|Actual|2005-08-31|||||Interventional|ZRDT||Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar|Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar|Completed||Phase 4|9346|Actual|Karolinska University Hospital|||||f||||f||||||||||2018-06-01 02:49:13.760099|2018-06-01 02:49:13.760099
NCT00548990|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-24|||2009-01-23|2007-10-24|2007-10-25|Estimate|||||||2009-01-23|2009-01-27|Estimate|August 2002||2002-08-31|January 2009|2009-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|ImFIT||The Immune Function Intervention Trial|Physical Activity, Aging and Immune Function|Completed||N/A|150|Actual|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 02:49:13.80691|2018-06-01 02:49:13.80691
NCT00548951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-14|2007-10-22|2007-10-24|Estimate|||||||2015-12-14|2015-12-16|Estimate|September 2005||2005-09-30|December 2015|2015-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Alzheimer Patients and the Snoezelen Program|The Connection Between Sensory Deprivation and Social Withdrawal in Clients of a Long Term Care Facility Living With Alzheimer's Disease and the Effects of a Snoezelen Program.|Completed||Phase 1|18|Actual|Queen's University||3|||f||||f||||||||||2018-06-01 02:49:14.020222|2018-06-01 02:49:14.020222
NCT00548938|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2009-09-17|2007-10-23|2007-10-24|Estimate|||||||2009-09-17|2009-09-18|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|October 2010|Anticipated|2010-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM|A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed by Metronomic Therapy With Temozolomide for Newly Diagnosed Malignant High Grade Glioma|Terminated||Phase 2|40|Anticipated|Methodist Healthcare||||Principal Investigator has left the institution|f||||t||||||||||2018-06-01 02:49:14.087831|2018-06-01 02:49:14.087831
NCT00548925|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22||2011-09-21|2013-01-11|2007-10-22|2007-10-24|Estimate||||2011-09-21|2011-10-05|Estimate|2013-01-11|2013-01-21|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain|A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 Versus Placebo in Subjects With Diabetic Neuropathic Pain|Completed||Phase 2|124|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 02:49:14.174095|2018-06-01 02:49:14.174095
NCT00548912|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2007-10-23|2007-10-23|2007-10-24|Estimate|||||||2007-10-23|2007-10-24|Estimate||||October 2007|2007-10-31||||||||Interventional|||Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease||Completed||Phase 4|||West Penn Allegheny Health System|||||f||||||||||||||2018-06-01 02:49:14.269467|2018-06-01 02:49:14.269467
NCT00548899|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2015-03-06|2007-10-23|2007-10-24|Estimate|||||||2015-03-06|2015-03-09|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|SOFIA||Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer|Phase II Study of Neoadjuvant Epirubicin, Cyclophosphamide (EC) + Sorafenib Followed by Paclitaxel (P) + Sorafenib in Women With Previously Untreated|Completed||Phase 2|36|Actual|German Breast Group||1|||f||||t||||||||||2018-06-01 02:49:14.34792|2018-06-01 02:49:14.34792
NCT00548886|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2015-02-20||2017-11-01|2007-10-23|2007-10-24|Estimate|2015-02-20|2015-03-06|Estimate||||2017-11-01|2017-12-06|Actual|February 2008||2008-02-29|November 2017|2017-11-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|LEAP||Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients|Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients|Terminated||N/A|7|Actual|Emory University|Slow enrollment lead to an early termination of the study|1||Lack of enrollment|f||||f||||||||||2018-06-01 02:49:14.544993|2018-06-01 02:49:14.544993
NCT00548860|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2013-10-08||2018-01-22|2007-10-22|2007-10-24|Estimate|2015-05-11|2015-05-29|Estimate||||2018-01-22|2018-02-20|Actual|October 2007||2007-10-31|January 2018|2018-01-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients|A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients|Completed||Phase 3|2018|Actual|Luitpold Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:49:14.696843|2018-06-01 02:49:14.696843
NCT00548847|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2016-07-08||2016-09-18|2007-10-23|2007-10-24|Estimate|2016-07-08|2016-08-18|Estimate||||2016-09-18|2016-10-26|Estimate|January 2007||2007-01-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation|A Pilot Phase II Study of Immunotherapy for the Treatment of AML, ALL, BP CML, and MDS Relapsed After Allogeneic Transplantation|Completed||Phase 2|15|Actual|Emory University||1|||f||||t||||||||||2018-06-01 02:49:14.935779|2018-06-01 02:49:14.935779
NCT00548834|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2013-09-03|2007-10-23|2007-10-24|Estimate|||||||2013-09-03|2013-09-04|Estimate|June 2003||2003-06-30|February 2010|2010-02-28|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis|Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD|Completed||Phase 3|220|Anticipated|UCB Pharma|||||f||||f||||||||||2018-06-01 02:49:15.1411|2018-06-01 02:49:15.1411
NCT00548821|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2008-05-13|2007-10-23|2007-10-24|Estimate|||||||2008-05-13|2008-05-15|Estimate||||May 2008|2008-05-31||||||||Interventional|||Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer|A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer|Unknown status|Not yet recruiting|Phase 3|||National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 02:49:15.265625|2018-06-01 02:49:15.265625
NCT00548808|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2010-08-20||2010-08-20|2007-10-22|2007-10-24|Estimate|2010-08-20|2010-09-15|Estimate||||2010-08-20|2010-09-15|Estimate|November 2007||2007-11-30|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study for Type 2 Diabetic Patients|Comparison of Insulin Lispro Low Mixture With Insulin Glargine When Initiating and Intensifying Insulin Therapy As Required in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Oral Antihyperglycemic Medication|Completed||Phase 4|426|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:49:15.39115|2018-06-01 02:49:15.39115
NCT00548795|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2017-03-27|2007-10-22|2007-10-24|Estimate|||||||2017-03-27|2017-03-29|Actual|August 2007||2007-08-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Observational|||Viral-Related Neutrophil Response and Condition Severity in People With ARDS|A Prospective Assessment of Viral-induced Adaptation of Neutrophil Response in ARDS - Ancillary to ARDS Network Trials|Completed|||132|Actual|National Jewish Health|||||f||||t||||||||||2018-06-01 02:49:16.349569|2018-06-01 02:49:16.349569
NCT00548782|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2013-06-20|2007-10-22|2007-10-24|Estimate|||||||2013-06-20|2013-06-21|Estimate|September 2007||2007-09-30|June 2013|2013-06-30||||June 2013|Actual|2013-06-30||Interventional|||Paleolithic Diets vs T2D and Improvements in the Metabolic Syndrome|Paleolithic Diets and Metabolic Control in Type 2 Diabetes Mellitus|Completed||N/A|22|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:49:16.417156|2018-06-01 02:49:16.417156
NCT00548613|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2011-04-27|2007-10-22|2007-10-24|Estimate|||||||2011-04-27|2011-04-28|Estimate|October 2007||2007-10-31|April 2011|2011-04-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium|Phase I Study to Determine the Safety and Feasibility of the Use of a Combination Stem Cell Therapy in Patients With Acute Myocardial Infarction|Completed||Phase 1|20|Anticipated|TCA Cellular Therapy||2|||f||||f||||||||||2018-06-01 02:49:19.237181|2018-06-01 02:49:19.237181
NCT00548769|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2017-07-31|2007-10-23|2007-10-24|Estimate|||||||2017-07-31|2017-08-01|Actual|April 21, 2007|Actual|2007-04-21|July 2017|2017-07-31|November 26, 2007|Actual|2007-11-26|November 26, 2007|Actual|2007-11-26||Interventional|||Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients|An Open-label, Randomised, Four Period Crossover Study to Investigate the Relative Pharmacokinetic Profiles of Tablets From Three Batches of Firategrast With Different Surface Areas and Two Different Tablet Formulations Containing the Same Batch of Firategrast, Given as Single 900mg Doses to Male and Female Subjects With a Diagnosis of Multiple Sclerosis|Completed||Phase 1|37|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 02:49:16.523532|2018-06-01 02:49:16.523532
NCT00548756|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2018-01-12|2007-10-22|2007-10-24|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2001|Actual|2001-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy|A Phase III Prospective Randomized Trial Comparing Radiosurgery With Versus Without Whole Brain Radiotherapy for 1-3 Newly Diagnosed Brain Metastases|Active, not recruiting||Phase 3|152|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 02:49:16.611817|2018-06-01 02:49:16.611817
NCT00548743|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-12-03|2007-10-22|2007-10-24|Estimate|||||||2007-12-03|2007-12-04|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|August 2010|Anticipated|2010-08-31|||||Interventional|TRIPPD||Translating Research Into Practice for Postpartum Depression|Practice Based Clinical Trial of Screening, Diagnosis and Follow up Management for Postpartum Depression in Family Medicine Practices.|Unknown status|Recruiting|N/A|3000|Anticipated|Olmsted Medical Center||2|||f||||t||||||||||2018-06-01 02:49:16.709077|2018-06-01 02:49:16.709077
NCT00548730|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2009-02-06|2007-10-22|2007-10-24|Estimate|||||||2009-02-06|2009-02-10|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|December 2010|Anticipated|2010-12-31|||||Observational|NWA||Comparison Trial of White Light, Autofluorescence and Narrow Band Imaging Bronchoscopy|A Clinical Comparison Trial of White Light Bronchoscopy, Autofluorescence Bronchoscopy and Narrow Band Imaged Bronchoscopy|Unknown status|Recruiting||100|Anticipated|Maimonides Medical Center|||1||f||||f||||||Samples Without DNA|"~     Endobronchial biopsies of normal and abnormal mucosa for histopathology~   "|||2018-06-01 02:49:16.798548|2018-06-01 02:49:16.798548
NCT00548717|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|2014-09-29||2014-10-20|2007-10-23|2007-10-24|Estimate|2014-10-20|2014-10-21|Estimate||||2014-10-20|2014-10-21|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation|Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease Prophylaxis After Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation|Terminated||Phase 2|15|Actual|Dana-Farber Cancer Institute|Early termination leading to small numbers of subjects analyzed. Results are reported for transparency only, and should not be used to extrapolate significant conclusions.|2||"First two patients enrolled after trial reopened, developed grade III-IV acute GVHD and~   subsequently passed away."|f||||t||||||||||2018-06-01 02:49:17.052124|2018-06-01 02:49:17.052124
NCT00548704|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2015-10-20|2007-10-23|2007-10-24|Estimate|||||||2015-10-20|2015-10-21|Estimate|April 2002||2002-04-30|November 2013|2013-11-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines|A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents|Completed||Phase 2/Phase 3|57|Actual|Onxeo|||||f||||f||||||||||2018-06-01 02:49:17.477568|2018-06-01 02:49:17.477568
NCT00548691|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2013-09-16||2018-01-22|2007-10-22|2007-10-24|Estimate|2015-05-11|2015-05-13|Estimate||||2018-01-22|2018-02-20|Estimate|October 2007||2007-10-31|January 2018|2018-01-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional||Safety population - of the 517 total subjects randomized, 4 subjects randomized to FCM were discontinued from the study prior to dosing due to selection critirea/study compliance (3 subjects) and subject request (1 subject)|Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients|A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients|Completed||Phase 3|513|Actual|Luitpold Pharmaceuticals||2|||f||||t||||||||||2018-06-01 02:49:17.597598|2018-06-01 02:49:17.597598
NCT00548678|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2008-07-15|2007-10-23|2007-10-24|Estimate|||||||2008-07-15|2008-07-16|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers|Open-Label, Randomized, Single-Dose, Four-Treatment Crossover Study to Evaluate Platelet Function in Healthy Adult Males After Administration of IV Diclofenac Sodium, Oral Diclofenac Potasssium, IV Ketorolac Tromethamine, and Acetylsalicylic Acid|Completed||Phase 1|30|Actual|Javelin Pharmaceuticals||4|||f||||f||||||||||2018-06-01 02:49:17.866204|2018-06-01 02:49:17.866204
NCT00548665|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2014-12-02|2007-10-23|2007-10-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2007||2007-11-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|CAROSS||Carotid Plaque Screening Trial in Smokers|Impact of Carotid Plaque Screening on Smoking Cessation and Control of Other Cardiovascular Risk Factors: A Randomized Controlled Trial.|Completed||Phase 4|536|Actual|University of Lausanne||2|||f||||f||||||||||2018-06-01 02:49:17.957413|2018-06-01 02:49:17.957413
NCT00548652|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2014-03-19|2007-10-23|2007-10-24|Estimate|||||||2014-03-19|2014-03-20|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Role of Apathy in the Effectiveness of Weight Loss Interventions|Role of Apathy in the Effectiveness of Weight Loss Interventions in Obese Patients|Completed||N/A|125|Actual|VA Nebraska Western Iowa Health Care System||5|||f||||f||||||||||2018-06-01 02:49:18.031992|2018-06-01 02:49:18.031992
NCT00548639|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2009-05-04|2007-10-23|2007-10-24|Estimate|||||||2009-05-04|2009-05-05|Estimate|August 2007||2007-08-31|May 2009|2009-05-31||||April 2010|Anticipated|2010-04-30||Interventional|||The STATIN CHOICE Decision Aid for Type 2 Diabetes Patients|The STATIN CHOICE Decision Aid for Type 2 Diabetes Patients|Unknown status|Active, not recruiting|N/A|152|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 02:49:18.10848|2018-06-01 02:49:18.10848
NCT00548626|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2015-12-18|2007-10-23|2007-10-24|Estimate|||||||2015-12-18|2015-12-21|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|EMUNE-07||Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer|EMUNE-07 Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer|Completed||N/A|47|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:49:18.169526|2018-06-01 02:49:18.169526
NCT00548600|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-10-22|2007-10-22|2007-10-24|Estimate|||||||2007-10-22|2007-10-24|Estimate|May 1992||1992-05-31|October 2007|2007-10-31|September 2006|Actual|2006-09-30|||||Interventional|||Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy With Temporary Iridium Implant Plus External Beam Radiation in Carcinoma of the Prostate|A Randomized Clinical Trial Comparing Radical Radiotherapy by External Beam Radiation Versus Radical Radiotherapy Using a Combination of a Temporaory Iridium Implant Plus External Beam Radiation in Surgically Staged B2 and C Carcinoma of the Prostate|Completed||Phase 3|112|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||f||||||||||2018-06-01 02:49:19.297316|2018-06-01 02:49:19.297316
NCT00548587|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22||2013-05-21|2016-01-05|2007-10-22|2007-10-24|Estimate||||2013-05-21|2013-05-29|Estimate|2016-01-05|2016-02-04|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome|A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Clinical Events and Biomarkers in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome|Completed||Phase 2|600|Actual|Eisai Inc.||4|||f||||t||||||||||2018-06-01 02:49:19.362298|2018-06-01 02:49:19.362298
NCT00548574|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2015-03-03|2007-10-23|2007-10-24|Estimate|||||||2015-03-03|2015-03-05|Estimate|December 2003||2003-12-31|November 2007|2007-11-30|July 2005|Actual|2005-07-31|||||Interventional|||Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis|A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, in Subjects With Mild to Moderate Ulcerative Colitis|Completed||Phase 3|343|Actual|Shire|||||f||||f||||||||||2018-06-01 02:49:19.428565|2018-06-01 02:49:19.428565
NCT00548561|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2015-10-20|2007-10-23|2007-10-24|Estimate|||||||2015-10-20|2015-10-21|Estimate|June 2001||2001-06-30|November 2013|2013-11-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines|A Clinical Trial on TopotectTM (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents|Completed||Phase 2/Phase 3|23|Actual|Onxeo|||||f||||f||||||||||2018-06-01 02:49:19.492848|2018-06-01 02:49:19.492848
NCT00548548|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|2011-12-15||2017-05-16|2007-10-23|2007-10-24|Estimate|2011-12-15|2012-01-19|Estimate||||2017-05-16|2017-06-14|Actual|September 2007|Actual|2007-09-30|May 2017|2017-05-31|November 2013|Actual|2013-11-30|November 2009|Actual|2009-11-30||Interventional|AVAGAST||A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer|A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer|Completed||Phase 3|774|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 02:49:19.62087|2018-06-01 02:49:19.62087
NCT00548535|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2007-10-23|2007-10-23|2007-10-24|Estimate|||||||2007-10-23|2007-10-24|Estimate|January 2007||2007-01-31|October 2007|2007-10-31|January 2008||2008-01-31|||||Observational|||Is Self-Reported Quality Assessment in Surgery Reliable?||Unknown status|Recruiting||||University of Zurich|||||f||||f||||||||||2018-06-01 02:49:20.603509|2018-06-01 02:49:20.603509
NCT00548522|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2014-05-20|2007-10-23|2007-10-24|Estimate|||||||2014-05-20|2014-05-22|Estimate|August 2007||2007-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Pancreatic Islet Mass in Pregnancy in Type 1 Diabetes|Pancreatic Islet Mass in Pregnancy - Pilot Study|Terminated|||12|Actual|University of Alberta|||4|Difficulty in finding staff to help with study|f||||f||||||Samples Without DNA|"~     Plasma Samples kept for batching of antibody assays~   "|||2018-06-01 02:49:20.663967|2018-06-01 02:49:20.663967
NCT00548509|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2007-10-23|2007-10-23|2007-10-24|Estimate|||||||2007-10-23|2007-10-24|Estimate|February 2002||2002-02-28|October 2007|2007-10-31||||||||Interventional|||The Effect of Vitamin K2 on Bone Turnover|Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study|Completed||Phase 4|100||Eisai Inc.|||||f||||||||||||||2018-06-01 02:49:20.729145|2018-06-01 02:49:20.729145
NCT00548496|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2017-04-11|2007-10-23|2007-10-24|Estimate|||||||2017-04-11|2017-04-12|Actual|September 20, 2007|Actual|2007-09-20|April 2017|2017-04-30|November 26, 2008|Actual|2008-11-26|November 26, 2008|Actual|2008-11-26||Interventional|||A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius|A Proof-of-Concept Study Of SB-751689 In Men And Post-menopausal Women With A Fractured Distal Radius|Terminated||Phase 2|86|Actual|GlaxoSmithKline||1||Lack of efficacy|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:49:20.831384|2018-06-01 02:49:20.831384
NCT00548483|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2008-05-27|2007-10-23|2007-10-24|Estimate|||||||2008-05-27|2008-05-28|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|May 2008|Anticipated|2008-05-31|March 2008|Anticipated|2008-03-31||Interventional|||Comparison of High Dose and Low Dose Dexamethasone in Preventing Post-Extubation Airway Obstruction in Adults|Phase 2 Study of Comparison of High Dose and Low Dose Dexamethasone in Preventing Post-Extubation Airway Obstruction in Adults|Unknown status|Recruiting|Phase 2|80|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:49:21.096426|2018-06-01 02:49:21.096426
NCT00548470|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2016-12-17||2017-10-12|2007-10-23|2007-10-24|Estimate|2017-08-02|2017-09-05|Actual||||2017-10-12|2017-11-14|Actual|June 2007||2007-06-30|October 2017|2017-10-31|December 2010|Actual|2010-12-31|September 2009|Actual|2009-09-30||Interventional|||Varenicline Effects In Schizophrenic Smokers|Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking|Completed||Phase 4|14|Actual|Nathan Kline Institute for Psychiatric Research||1|||f||||f||||||||||2018-06-01 02:49:21.191073|2018-06-01 02:49:21.191073
NCT00548457|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2008-01-28|2007-10-23|2007-10-24|Estimate|||||||2008-01-28|2008-01-29|Estimate|May 2006||2006-05-31|January 2008|2008-01-31||||||||Observational|||Endothelial Function in Patients With Ectatic Compared to Normal Coronary Arteries|Endothelial Function in Patients With Ectatic Compared to Normal Coronary Arteries|Unknown status|Recruiting||76|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 02:49:21.405518|2018-06-01 02:49:21.405518
NCT00548444|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2010-01-15|2007-10-23|2007-10-24|Estimate|||||||2010-01-15|2010-01-18|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||T−Cell Turnover Following Vaccination With MVA85A|Measurement of Human T−Cell Turnover Following Vaccination With the Tuberculosis Vaccine MVA85A|Completed||Phase 1|12|Actual|University of Oxford||3|||f||||f||||||||||2018-06-01 02:49:21.492585|2018-06-01 02:49:21.492585
NCT00548431|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|2009-06-24||2016-11-19|2007-10-23|2007-10-24|Estimate|2010-10-12|2010-11-03|Estimate||||2016-11-19|2017-01-09|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|||NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia|Phase II Study of Individual 6-mercaptopurine(6MP) Dose Increments in Children With Acute Lymphoblastic Leukemia (ALL) Receiving High-dose Methotrexate (HDM) and PEG-asparaginase|Completed||Phase 2|38|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||Yes|Data published (Frandsen et al, Br J Haematol Oct 2011) Anonymised data on individual patients can be provided by study chair (kschmiegelow@rh.dk) including studyno, gender, age, thiopurine methyltransferase status, immunophenotype, white blood cell count at diagnosis, dose increments at time point 1 and 2 for dose adjustment, and dose-limiting toxicities|2018-06-01 02:49:21.610469|2018-06-01 02:49:21.610469
NCT00548418|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|2014-06-27||2014-07-28|2007-10-23|2007-10-24|Estimate|2014-06-27|2014-07-28|Estimate||||2014-07-28|2014-08-01|Estimate|February 2007||2007-02-28|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer|Phase II Trial of Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer|Completed||Phase 2|27|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 02:49:21.962155|2018-06-01 02:49:21.962155
NCT00548405|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2014-11-17|2012-11-30|2017-03-17|2007-10-22|2007-10-24|Estimate|2015-01-06|2015-01-08|Estimate|2012-11-30|2012-12-04|Estimate|2017-03-17|2017-04-17|Actual|October 2007||2007-10-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|CARE-MS II|Full analysis set (FAS) population included all randomized participants who received at least 1 dose of study drug as per initial randomization.|Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two|A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy|Completed||Phase 3|840|Actual|Sanofi|Efficacy analysis was not performed for Alemtuzumab 24 mg as recruitment to this arm was closed early to reduce overall sample size, duration of enrollment period, overall duration of study.|3|||f||||t||||||||||2018-06-01 02:49:22.773458|2018-06-01 02:49:22.773458
NCT00548392|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2008-12-29|2007-10-22|2007-10-24|Estimate|||||||2008-12-29|2008-12-31|Estimate|May 2007||2007-05-31|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement|Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement|Completed|||25|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||f||||||None Retained|"~     none/not applicable~   "|||2018-06-01 02:49:24.469317|2018-06-01 02:49:24.469317
NCT00548379|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-23|||2008-05-15|2007-10-23|2007-10-24|Estimate|||||||2008-05-15|2008-05-16|Estimate|November 2007||2007-11-30|May 2008|2008-05-31|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|||Kabul Vitamin D Supplementation Trial|The Effect of Vitamin D Supplementation on the Incidence of Pneumonia in Children in Afghanistan: a Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 3|3048|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 02:49:24.53237|2018-06-01 02:49:24.53237
NCT00548366|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2010-09-10|2007-10-22|2007-10-23|Estimate|||||||2010-09-10|2010-09-14|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|||Sodium Restriction in the Management of Cirrhotic Ascites|Comparison of Efficacy of 2 Gram Versus 4 Gram Sodium Restriction in the Management of Cirrhotic Ascites|Terminated||Phase 4|68|Anticipated|University of Texas Southwestern Medical Center||2||Failure to recruit.|f||||f||||||||||2018-06-01 02:49:24.617054|2018-06-01 02:49:24.617054
NCT00548353|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2014-12-18|2007-10-19|2007-10-23|Estimate|||||||2014-12-18|2014-12-19|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|February 2010|Actual|2010-02-28|April 2008|Actual|2008-04-30||Interventional|||A Study of Gastric Delay in Migraine Patients (3207-003)|A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks|Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:49:24.762071|2018-06-01 02:49:24.762071
NCT00548340|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2014-02-28|2011-06-09|2014-10-08|2007-10-19|2007-10-23|Estimate|2014-10-08|2014-10-15|Estimate|2011-06-09|2011-06-27|Estimate|2014-10-08|2014-10-15|Estimate|November 2007||2007-11-30|October 2014|2014-10-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||VEC-162 Study in Adult Patients With Primary Insomnia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20 mg/Day and 50 mg/Day) in the Treatment of Primary Insomnia|Completed||Phase 3|322|Actual|Vanda Pharmaceuticals||3|||f||||||||||||||2018-06-01 02:49:24.877294|2018-06-01 02:49:24.877294
NCT00548327|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2013-02-13||2013-04-30|2007-10-19|2007-10-23|Estimate|2013-04-30|2013-06-14|Estimate||||2013-04-30|2013-06-14|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|Atomoxetine||The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype|Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Atomoxetine on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||2||The scientific director decided to terminate: low priority study with slow accrual|f||||f||||||||||2018-06-01 02:49:25.392427|2018-06-01 02:49:25.392427
NCT00548314|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2011-03-23|2007-10-22|2007-10-23|Estimate|||||||2011-03-23|2011-03-24|Estimate|October 2007||2007-10-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|May 2010|Actual|2010-05-31||Interventional|VAC-M||Dermal Substitute and Topical Negative Pressure in Burns|Application of a Dermal Substitute and Topical Negative Pressure to Improve the Healing of Burn Wounds|Completed||Phase 3|86|Actual|Association of Dutch Burn Centres||4|||f||||t||||||||||2018-06-01 02:49:25.786675|2018-06-01 02:49:25.786675
NCT00548301|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2011-06-29|2007-10-22|2007-10-23|Estimate|||||||2011-06-29|2011-07-01|Estimate||||June 2011|2011-06-30||||||||Interventional|||Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)||Completed||Phase 3|||Sirion Therapeutics, Inc.|||||||||||||||||||2018-06-01 02:49:25.871192|2018-06-01 02:49:25.871192
NCT00548288|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-10-22|2007-10-22|2007-10-23|Estimate|||||||2007-10-22|2007-10-23|Estimate|November 2007||2007-11-30|October 2007|2007-10-31||||||||Interventional|||Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty|Phase 1 Study of the Effect of Local Pamidronate Application in Preventing Periprosthetic Bone Loss After Total Cemented Hip Arthroplasty|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|General and Teaching Hospital Celje|||||f||||f||||||||||2018-06-01 02:49:25.924752|2018-06-01 02:49:25.924752
NCT00548275|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2014-07-08|2007-10-19|2007-10-23|Estimate|||||||2014-07-08|2014-07-09|Estimate|July 2006||2006-07-31|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Project RED||Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence|Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence|Completed||Phase 2|22|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:49:25.982589|2018-06-01 02:49:25.982589
NCT00548262|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2010-10-06||2010-12-15|2007-10-19|2007-10-23|Estimate|2010-12-15|2011-01-17|Estimate||||2010-12-15|2011-01-17|Estimate|February 2008||2008-02-29|December 2010|2010-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis|Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients|Completed||Phase 4|54|Actual|Pfizer|Protocol registration indicated timeframes for EIVT and/or Week 2 F/U for time to event, mortality, vital signs, and labs; however, analyses were continuous and reported from baseline to EIVT (up to Day 42), Week 2 F/U, or Week 6 telephone F/U visit.|1|||f||||f||||||||||2018-06-01 02:49:26.138475|2018-06-01 02:49:26.138475
NCT00548249|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2010-11-10||2011-02-07|2007-10-22|2007-10-23|Estimate|2011-02-07|2011-02-08|Estimate||||2011-02-07|2011-02-08|Estimate|August 2007||2007-08-31|February 2011|2011-02-28|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis|A Dose Ranging Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) Versus Control in Subjects With ESRD Receiving Chronic Hemodialysis.|Completed||Phase 2|131|Actual|Rockwell Medical Technologies, Inc.|"AE tabulation best summarizes the primary safety outcome.~Lack of accuracy in analytical method for measuring iron concentration in inflow and outflow from dialysis machine impaired ability to assess secondary outcome of amount SFP transferred."|5|||f||||t||||||||||2018-06-01 02:49:27.462504|2018-06-01 02:49:27.462504
NCT00548236|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2016-06-01|2007-10-22|2007-10-23|Estimate|||||||2016-06-01|2016-06-02|Estimate|October 2007||2007-10-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|March 2010|Actual|2010-03-31||Interventional|AACT||The Active After Cancer Trial (AACT)|Pilot Study of a Multicenter, Telephone-Based Exercise Intervention for Patients With Early-Stage Breast and Colorectal Cancer: The Active After Cancer Trial (AACT)|Active, not recruiting||N/A|120|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 02:49:28.461076|2018-06-01 02:49:28.461076
NCT00548223|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2013-08-05|2007-10-22|2007-10-23|Estimate|||||||2013-08-05|2013-08-07|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SPIRITDZSM1||The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule|Model Study on the Comprehensive Treating Protocol and Effect Evaluation of Ischemic Stroke With Traditional Chinese Medicine|Completed||Phase 4|3143|Actual|Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 02:49:28.649045|2018-06-01 02:49:28.649045
NCT00548210|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-10-22|2007-10-22|2007-10-23|Estimate|||||||2007-10-22|2007-10-23|Estimate||||October 2007|2007-10-31||||||||Observational|||Effectivity of Dermatix in Promoting Scar Maturation|Dermatix; A Randomized Controlled Trial Measuring Effectivity of Dermatix in Promoting Scar Maturation of Hypertrophic Scars.|Unknown status|Recruiting||25|Anticipated|Association of Dutch Burn Centres|||||f||||||||||||||2018-06-01 02:49:28.859998|2018-06-01 02:49:28.859998
NCT00548197|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-10-22|2007-10-22|2007-10-23|Estimate|||||||2007-10-22|2007-10-23|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment|Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment|Unknown status|Recruiting|Phase 1|50|Anticipated|Iran University of Medical Sciences||1|||f||||f||||||||||2018-06-01 02:49:28.973551|2018-06-01 02:49:28.973551
NCT00548184|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2012-05-01||2018-04-01|2007-10-22|2007-10-23|Estimate|2012-05-01|2012-06-01|Estimate||||2018-04-01|2018-05-01|Actual|May 2008|Actual|2008-05-31|January 2018|2018-01-31|January 2014|Actual|2014-01-31|January 2011|Actual|2011-01-31||Interventional|||Lapatinib and Trastuzumab With or Without Endocrine Therapy|A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients|Completed||Phase 2|65|Actual|Baylor Breast Care Center||1|||f||||t||||||||||2018-06-01 02:49:29.071377|2018-06-01 02:49:29.071377
NCT00548171|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22||2009-09-09|2016-11-02|2007-10-22|2007-10-23|Estimate||||2009-09-09|2009-09-11|Estimate|2016-11-02|2016-11-03|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination|Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting.|Completed||Phase 4|205|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:49:29.250664|2018-06-01 02:49:29.250664
NCT00548158|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2007-10-19|2007-10-19|2007-10-23|Estimate|||||||2007-10-19|2007-10-23|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|April 2006|Actual|2006-04-30|||||Observational|||Effect of Pioglitazone Therapy for Type 2 Diabetes on Vision|Preliminary Safety Study of Pioglitazone Therapy for Diabetes on Macular Thickness and Vision in Type 2 Diabetes|Completed|||19|Actual|University of California, San Diego|||||f||||f||||||||||2018-06-01 02:49:29.354709|2018-06-01 02:49:29.354709
NCT00548145|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2011-12-28||2012-05-14|2007-10-22|2007-10-23|Estimate|2012-05-14|2012-06-14|Estimate||||2012-05-14|2012-06-14|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|PIT-ROAD||The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease||Terminated||N/A|38|Actual|Osaka University||2|||f||||||||||||||2018-06-01 02:49:29.432428|2018-06-01 02:49:29.432428
NCT00548132|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|2013-06-12||2013-08-28|2007-10-22|2007-10-23|Estimate|2013-06-12|2013-08-22|Estimate||||2013-08-28|2013-09-12|Estimate|February 2006||2006-02-28|August 2013|2013-08-31|May 2009|Actual|2009-05-31|February 2008|Actual|2008-02-29||Interventional|||Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)|Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)|Completed||Phase 4|1088|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:49:29.661483|2018-06-01 02:49:29.661483
NCT00548119|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19||2012-08-16|2014-03-25|2007-10-19|2007-10-23|Estimate||||2012-08-16|2012-08-23|Estimate|2014-03-25|2014-04-21|Estimate|December 2006||2006-12-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|November 2009|Actual|2009-11-30||Interventional|||NeoCart Phase 2 Clinical Trial|A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee|Completed||Phase 2|30|Actual|Histogenics Corporation||2|||f||||f||||||||||2018-06-01 02:49:29.933608|2018-06-01 02:49:29.933608
NCT00548093|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19||2011-06-03|2012-06-04|2007-10-19|2007-10-23|Estimate||||2011-06-03|2011-06-16|Estimate|2012-06-04|2012-06-07|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|March 2010|Actual|2010-03-31||Interventional|||PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib|A Phase 2, Open Label, Two Arm Trial To Evaluate The Efficacy Of PF-00299804 In Patients With Advanced NSCLC After Failure Of At Least One Prior Chemotherapy And Erlotinib|Completed||Phase 2|66|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:49:30.097382|2018-06-01 02:49:30.097382
NCT00548080|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2015-12-16|2007-10-22|2007-10-23|Estimate|||||||2015-12-16|2015-12-17|Estimate|March 2006||2006-03-31|December 2015|2015-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)|A Non-Comparative, Multicenter, Open-Label, Study to Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia|Completed||Phase 3|131|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:49:30.181191|2018-06-01 02:49:30.181191
NCT00548067|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2010-09-24|2007-10-22|2007-10-23|Estimate|||||||2010-09-24|2010-09-27|Estimate|September 2007||2007-09-30|September 2010|2010-09-30|March 2008|Actual|2008-03-31|||||Interventional|||Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension|A Multi-center, Multiple Dose, Open-label, Four-cohort, Parallel Study to Assess the Pharmacokinetic Drug Interaction Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension.|Completed||Phase 3|111|Actual|Novartis||4|||f||||f||||||||||2018-06-01 02:49:30.232675|2018-06-01 02:49:30.232675
NCT00548054|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-21|||2015-05-01|2007-10-21|2007-10-23|Estimate|||||||2015-05-01|2015-05-04|Estimate|December 2015||2015-12-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants|Safety and Immunogenicity of a Killed Oral Cholera Vaccine Among Infants 10 Weeks to Less Than 12 Months of Age When Given Concomitantly With EPI Vaccines|Unknown status|Not yet recruiting|Phase 2|300|Anticipated|International Vaccine Institute||6|||f||||t||||||||||2018-06-01 02:49:30.3176|2018-06-01 02:49:30.3176
NCT00548041|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2015-04-20||2015-10-05|2007-10-22|2007-10-23|Estimate|2015-10-05|2015-11-02|Estimate||||2015-10-05|2015-11-02|Estimate|April 2007||2007-04-30|October 2015|2015-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Rapid HIV Testing Program in the Emergency Department|Pilot Study to Evaluate a Rapid HIV Testing Program in the Emergency Department|Completed||N/A|100|Actual|Temple University||1|||f||||f||||||||||2018-06-01 02:49:30.577496|2018-06-01 02:49:30.577496
NCT00548015|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2009-09-30|2007-10-22|2007-10-23|Estimate|||||||2009-09-30|2009-10-01|Estimate|March 2008||2008-03-31|October 2007|2007-10-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Helping Hands: Promoting Hand Hygiene in Hospital Nurses|HELPING HANDS: a Comparison of Short- and Long Term Effects of Alternative Strategies for Promoting Hand Hygiene in Hospital Nurses.|Unknown status|Active, not recruiting|N/A|900|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 02:49:30.746007|2018-06-01 02:49:30.746007
NCT00548002|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-10-22|2007-10-22|2007-10-23|Estimate|||||||2007-10-22|2007-10-23|Estimate|January 1999||1999-01-31|October 2007|2007-10-31|August 2002|Actual|2002-08-31|||||Observational|FINLEVO||Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia||Completed|||430|Actual|Helsinki University|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 02:49:30.818816|2018-06-01 02:49:30.818816
NCT00547989|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2014-06-10|2007-10-22|2007-10-23|Estimate|||||||2014-06-10|2014-06-11|Estimate|October 2006||2006-10-31|June 2014|2014-06-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?|Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?|Completed||Phase 3|46|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-06-01 02:49:30.885182|2018-06-01 02:49:30.885182
NCT00547976|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-20|||2012-04-26|2007-10-20|2007-10-23|Estimate|||||||2012-04-26|2012-04-27|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:49:30.947854|2018-06-01 02:49:30.947854
NCT00547963|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2008-10-07|2007-10-19|2007-10-23|Estimate|||||||2008-10-07|2008-10-08|Estimate|December 2003||2003-12-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use|Reducing Injury, ETOH and THC Use Among ED Patients|Unknown status|Active, not recruiting|Phase 2/Phase 3|554|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||1|||f||||t||||||||||2018-06-01 02:49:31.004231|2018-06-01 02:49:31.004231
NCT00547950|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-10-28|2007-10-22|2007-10-23|Estimate|||||||2007-10-28|2007-10-30|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|October 2009|Anticipated|2009-10-31|||||Interventional|||A Multiple-Centered, Prospective Cohort Study: the Second Prevention Trial for Ischemic Stroke With Deng Zhan Sheng Mai Capsule（SPIRIT—DZSM-2）|A Model Study on the Comprehensive Treating Protocol of Secondary Prevention and Effect Evaluation of Ischemic Stroke With Traditional Chinese Medicine|Unknown status|Not yet recruiting|N/A|12000|Anticipated|Guangzhou University of Traditional Chinese Medicine||1|||f||||t||||||||||2018-06-01 02:49:31.070439|2018-06-01 02:49:31.070439
NCT00547937|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2007-11-07|2007-10-22|2007-10-23|Estimate|||||||2007-11-07|2007-11-09|Estimate|May 2001||2001-05-31|October 2007|2007-10-31|December 2003|Actual|2003-12-31|||||Interventional|||Sleep Apnea and Oxidative Stress and Nitric Oxide|Nitrate and Oxidative Stress in Sleep Apnea Syndrome. Effect of Continuous Positive Airway Pressure|Completed||Phase 4|31|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||t||||||||||2018-06-01 02:49:31.202049|2018-06-01 02:49:31.202049
NCT00547924|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2014-04-09|2007-10-22|2007-10-23|Estimate|||||||2014-04-09|2014-04-10|Estimate|April 2006||2006-04-30|April 2014|2014-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Transoesophageal Echocardiography in Liver Transplantation|Transoesophageal Echocardiography in Liver Transplantation: Left Ventricular Function During Reperfusion|Completed|||17|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 02:49:31.277014|2018-06-01 02:49:31.277014
NCT00547911|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2014-06-17||2014-06-17|2007-10-20|2007-10-23|Estimate|2014-06-17|2014-07-17|Estimate||||2014-06-17|2014-07-17|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Augmenting Effects of L-DOPS With Carbidopa and Entacapone|L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone|Terminated||Phase 1/Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)|Study was prematurely terminated due to a small amount of DOPAL contamination in the droxidopa. Because of the early termination only a small number of subjects were enrolled in each condition. Recently, the FDA has approved droxidopa.|6||Study terminated due to contamination droxidopa|f||||f||||||||||2018-06-01 02:49:31.36304|2018-06-01 02:49:31.36304
NCT00547898|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-21|||2011-12-22|2007-10-22|2007-10-23|Estimate|||||||2011-12-22|2011-12-23|Estimate|October 2007||2007-10-31|December 2011|2011-12-31||||||||Interventional|ADVENT||Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea|Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of 3 Doses of Crofelemer Orally Twice Daily for the Treatment of HIV-Associated Diarrhea|Completed||Phase 3|350|Anticipated|Valeant Pharmaceuticals International, Inc.||4|||f||||t||||||||||2018-06-01 02:49:31.925128|2018-06-01 02:49:31.925128
NCT00547885|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2014-12-30|2007-10-22|2007-10-23|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain|Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-Malignant Pain|Completed||Phase 4|60|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-06-01 02:49:32.119177|2018-06-01 02:49:32.119177
NCT00547872|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2012-11-19|2007-10-22|2007-10-23|Estimate|||||||2012-11-19|2012-11-21|Estimate|September 2007||2007-09-30|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|DADDY-D||Exercise Testing to Screen for Unknown Coronary Artery Disease in Diabetic Patients: Does it Contribute to a Risk Reduction in Very High Risk Patients?|Screening Asymptomatic Patients With Diabetes for Unknown Coronary Artery Disease: an Open-label Randomized Study Comparing Exercise Testing Strategy With Management Based on Pharmacological/Behavioral Treatment of Traditional Risk Factors|Completed||Phase 3|400|Actual|Azienda Unita' Sanitaria Locale Di Modena||2|||f||||t||||||||||2018-06-01 02:49:32.188153|2018-06-01 02:49:32.188153
NCT00547859|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2008-11-25|2007-10-22|2007-10-23|Estimate|||||||2008-11-25|2008-11-26|Estimate|November 2007||2007-11-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Observational|||Relationship Between Microcirculatory Flow Alterations and Tissue Metabolism|Correlation Between Microcirculatory Flow and Rectal Anaerobe Cellular CO2 Production in Patients After Cardiac Surgery|Completed|||30|Anticipated|Medical Centre Leeuwarden|||||f||||f||||||||||2018-06-01 02:49:32.267102|2018-06-01 02:49:32.267102
NCT00547846|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2009-01-08|2007-10-22|2007-10-23|Estimate|||||||2009-01-08|2009-01-12|Estimate|October 2007||2007-10-31|January 2009|2009-01-31||||||||Interventional|||A Phase II Clinical Study of PDC-748 in Patients With Acute Cough|A Phase II Clinical Study of PDC-748 in Patients With Acute Cough|Completed||Phase 2|||PhytoHealth Corporation|||||f||||t||||||||||2018-06-01 02:49:32.325954|2018-06-01 02:49:32.325954
NCT00547833|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2016-09-30|2007-10-22|2007-10-23|Estimate|||||||2016-09-30|2016-10-04|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Partial Word Knowledge Growth in Children With LLD|Partial Word Knowledge Growth in Children With LLD|Completed|||81|Actual|University of Missouri-Columbia|||3||f||||f||||||||No||2018-06-01 02:49:32.375299|2018-06-01 02:49:32.375299
NCT00547820|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-20|||2009-10-27|2007-10-22|2007-10-23|Estimate|||||||2009-10-27|2009-10-28|Estimate|July 2007||2007-07-31|October 2007|2007-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Urinary Sensor for Cystourethrography|Urinary Sensor for Cystourethrography|Completed||N/A|20|Anticipated|Rambam Health Care Campus||2|||f||||||||||||||2018-06-01 02:49:32.431109|2018-06-01 02:49:32.431109
NCT00547807|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2009-02-25|2007-10-22|2007-10-23|Estimate|||||||2009-02-25|2009-02-26|Estimate|January 2007||2007-01-31|February 2009|2009-02-28||||February 2009|Actual|2009-02-28||Interventional|||Non-Nutritive Sucking and Swaddling for Pain Relief in Term Neonates: Randomised Controlled Trial|Non-Nutritive Sucking and Swaddling for Pain Relief in Term Neonates: a Randomised Controlled Trial|Unknown status|Recruiting|N/A|34|Anticipated|Sociedade Hospital Samaritano|||||f||||f||||||||||2018-06-01 02:49:32.493676|2018-06-01 02:49:32.493676
NCT00547794|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2015-05-06|2007-10-22|2007-10-23|Estimate|||||||2015-05-06|2015-05-08|Estimate|June 2007||2007-06-30|May 2015|2015-05-31|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Observational|AVERT-AF||AVJ Ablation Followed by Resynchronization Therapy in Patients With CHF and AF|AVERT-AF: Atrio-VEntricular Junction Ablation Followed by Resynchronization Therapy in Patients With Congestive Heart Failure and Atrial Fibrillation|Terminated|||14|Actual|St. Jude Medical|||2|Difficulty in patient enrollment|f||||t||||||||||2018-06-01 02:49:32.575067|2018-06-01 02:49:32.575067
NCT00547781|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2012-03-30|2007-10-22|2007-10-23|Estimate|||||||2012-03-30|2012-04-02|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Implantation Failure and PGD||Completed||Phase 4|250|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||||||||||||2018-06-01 02:49:32.636469|2018-06-01 02:49:32.636469
NCT00547768|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-22|||2011-01-10|2007-10-22|2007-10-23|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2002||2002-11-30|January 2011|2011-01-31|December 2002|Actual|2002-12-31|||||Interventional|||Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.||Completed||Phase 4|36|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:49:32.679958|2018-06-01 02:49:32.679958
NCT00547742|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2010-07-16|2007-10-22|2007-10-23|Estimate|||||||2010-07-16|2010-07-20|Estimate|July 2005||2005-07-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Observational|||Correlation of PET-CT Studies With Serum Protein Analysis|Correlation of PET-CT Studies With Serum Protein Analysis|Completed|||1500|Anticipated|Stanford University|||||f||||||||||Samples Without DNA|"~     blood~   "|||2018-06-01 02:49:32.730139|2018-06-01 02:49:32.730139
NCT00547729|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19||2016-05-18|2016-06-09|2007-10-19|2007-10-23|Estimate||||2016-06-02|2016-06-07|Estimate|2016-06-09|2016-06-13|Estimate|March 2005||2005-03-31|June 2016|2016-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|HOMEOSTASIS||Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS)|Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients: A Prospective, Multi-center, Non-randomized, Open Label Study.|Completed||Phase 1/Phase 2|40|Actual|St. Jude Medical||1|||f||||t||||||||No||2018-06-01 02:49:32.877694|2018-06-01 02:49:32.877694
NCT00547716|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2017-01-05|2007-10-22|2007-10-23|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2009||2009-06-30|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection|The Effect of Omega-3 Fatty Acids (Omacor@) on the Response Rate to Antiviral Therapy in Patients With Chronic Hepatitis C Infection|Withdrawn||N/A|0|Actual|University of Missouri, Kansas City||2||Lack of study enrollment.|f||||f||||||||||2018-06-01 02:49:32.955645|2018-06-01 02:49:32.955645
NCT00547703|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2012-02-20||2017-04-12|2007-10-19|2007-10-23|Estimate|2012-06-07|2012-07-10|Estimate||||2017-04-12|2017-05-17|Actual|February 2008||2008-02-29|April 2017|2017-04-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia|Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia|Terminated||N/A|5|Actual|The Cleveland Clinic|We were unable to recruit an adequate number of patients to make any meaningful conclusion.|2||Not enough participants - only 5 since the study started|f||||f||||||||No||2018-06-01 02:49:33.053789|2018-06-01 02:49:33.053789
NCT00547690|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2012-06-04|2007-10-18|2007-10-22|Estimate|||||||2012-06-04|2012-06-06|Estimate|April 2003||2003-04-30|June 2012|2012-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Acupuncture in Stroke Rehabilitation|Electro-acupuncture and Strengthening Exercise for Hemiplegic Elbow and Wrist Joints|Terminated||Phase 2|20|Anticipated|University of Kansas Medical Center||2||Expired IRB approval|f||||f||||||||||2018-06-01 02:49:33.287125|2018-06-01 02:49:33.287125
NCT00547677|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2009-02-06|2007-10-19|2007-10-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2004||2004-07-31|January 2008|2008-01-31||||December 2007|Anticipated|2007-12-31||Interventional|||Stereotactic Radiosurgery in Treating Patients With Liver Metastases|A Phase I Trial of Stereotactic Radiosurgery for Patients With Hepatic Metastases (SBRT Liver)|Unknown status|Active, not recruiting|Phase 1|27|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:49:33.356653|2018-06-01 02:49:33.356653
NCT00547664|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2014-02-27|2007-10-19|2007-10-22|Estimate|||||||2014-02-27|2014-02-28|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients||Completed||N/A|88|Actual|HPC Healthcare, Inc.||2|||f||||t||||||||||2018-06-01 02:49:33.452069|2018-06-01 02:49:33.452069
NCT00547651|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18||2011-07-19|2016-10-31|2007-10-18|2007-10-22|Estimate||||2011-07-19|2011-07-22|Estimate|2016-10-31|2016-11-01|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy|AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy|Completed||Phase 3|637|Actual|Celgene Corporation||2|||f||||t||||||||||2018-06-01 02:49:33.631592|2018-06-01 02:49:33.631592
NCT00547638|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2013-03-01||2013-08-02|2007-10-19|2007-10-22|Estimate|2013-08-02|2013-08-06|Estimate||||2013-08-02|2013-08-06|Estimate|August 2007||2007-08-31|August 2013|2013-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure|Multicenter, Prospective, Randomized Controlled Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Closure of Simple, Thoroughly Cleansed, Trauma-induced Wounds in the Emergency Department|Completed||Phase 2|216|Actual|Ethicon, Inc.|The percentages of participants who withdrew prematurely from the study from each group could represent a possible study limitation.|2|||f||||f||||||||||2018-06-01 02:49:34.000504|2018-06-01 02:49:34.000504
NCT00547625|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|July 2005|Actual|2005-07-31|||||Interventional|PILUTS||Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems|A Multicenter, Parallel-Arm, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Tadalafil Administered Once Daily to Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia|Completed||Phase 2|275|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:49:34.387586|2018-06-01 02:49:34.387586
NCT00547612|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2012-03-14|2007-10-19|2007-10-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer|Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma|Completed||Phase 1|33|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 02:49:34.469374|2018-06-01 02:49:34.469374
NCT00547599|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|April 2003||2003-04-30|October 2007|2007-10-31|January 2004|Actual|2004-01-31|||||Interventional|||Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects|Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction?|Completed||Phase 4|659|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:49:34.531143|2018-06-01 02:49:34.531143
NCT00547586|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19||2009-03-02|2011-07-22|2007-10-19|2007-10-22|Estimate||||2009-09-28|2009-09-30|Estimate|2011-07-22|2011-07-28|Estimate|October 2007||2007-10-31|July 2011|2011-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid- Induced Bowel Dysfunction in Subjects With Chronic Nonmalignant Pain|Completed||Phase 2|120|Actual|Valeant Pharmaceuticals International, Inc.||5|||f||||t||||||||||2018-06-01 02:49:34.592268|2018-06-01 02:49:34.592268
NCT00547573|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|April 2003||2003-04-30|October 2007|2007-10-31|December 2003|Actual|2003-12-31|||||Interventional|||Determine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection|"A Multinational, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil Administered On Demand to Asian Men With Erectile Dysfunction"|Completed||Phase 3|367|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:49:34.699978|2018-06-01 02:49:34.699978
NCT00547560|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2011-04-01|2007-10-18|2007-10-22|Estimate|||||||2011-04-01|2011-04-04|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population|An Ascending Multiple Dose Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GSI-953 Administered Orally To Healthy Elderly Subjects|Completed||Phase 1|49|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:49:34.778245|2018-06-01 02:49:34.778245
NCT00547547|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2015-11-04|2007-10-19|2007-10-22|Estimate|||||||2015-11-04|2015-11-06|Estimate|April 2006||2006-04-30|November 2015|2015-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer|A Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine|Completed||Phase 1|22|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:49:34.936773|2018-06-01 02:49:34.936773
NCT00547534|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2011-04-06||2015-07-15|2007-10-18|2007-10-22|Estimate|2011-05-04|2011-06-06|Estimate||||2015-07-15|2015-08-06|Estimate|October 2007||2007-10-31|July 2015|2015-07-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|BVR||Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma|Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|31|Actual|University of Rochester|19 patients received a full 6 cycles of therapy. All patients received at least one cycle of therapy, 25 patients received at least 4 cycles. Reasons for early termination included progressive disease and toxicity|1|||f||||t||||||||||2018-06-01 02:49:35.027689|2018-06-01 02:49:35.027689
NCT00547521|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2010-10-15||2015-03-13|2007-10-19|2007-10-22|Estimate|2010-12-23|2011-01-24|Estimate||||2015-03-13|2015-03-23|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|December 2008|Actual|2008-12-31||Interventional|||Phase IIIB Subcutaneous Abatacept Monotherapy Study|A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate|Completed||Phase 3|119|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:49:35.329881|2018-06-01 02:49:35.329881
NCT00547508|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|October 2002||2002-10-31|October 2007|2007-10-31|September 2003|Actual|2003-09-30|||||Interventional|||To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking|A Randomized, Double-Blind, Parallel, Placebo-Controlled Study in Men With Erectile Dysfunction to Evaluate the Efficacy and Safety of Tadalafil When Sexual Attempts Occur at Specific Time Points After Dosing|Completed||Phase 3|485|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-06-01 02:49:37.930915|2018-06-01 02:49:37.930915
NCT00547495|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|March 2004||2004-03-31|October 2007|2007-10-31|November 2004|Actual|2004-11-30|||||Interventional|||Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection|"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Tadalafil Administered On Demand to Patients With Erectile Dysfunction"|Completed||Phase 3|343|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 02:49:38.028809|2018-06-01 02:49:38.028809
NCT00547482|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2010-12-15|2007-10-19|2007-10-22|Estimate|||||||2010-12-15|2010-12-16|Estimate|September 2007||2007-09-30|April 2008|2008-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study|The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study|Terminated||N/A|300|Actual|MetaCure (USA), Inc.||2||Protocol design under review.|f||||t||||||||||2018-06-01 02:49:38.270607|2018-06-01 02:49:38.270607
NCT00547469|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2008-04-07|2007-10-19|2007-10-22|Estimate|||||||2008-04-07|2008-04-08|Estimate|October 2007||2007-10-31|April 2008|2008-04-30||||||||Interventional|||A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of DDP733 in Female Patients With Irritable Bowel Syndrome With Constipation|Unknown status|Recruiting|Phase 2/Phase 3|360|Anticipated|Dynogen Pharmaceuticals|||||f||||t||||||||||2018-06-01 02:49:38.387821|2018-06-01 02:49:38.387821
NCT00547456|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2015-05-27||2015-11-13|2007-10-19|2007-10-22|Estimate|2015-11-13|2015-12-16|Estimate||||2015-11-13|2015-12-16|Estimate|October 2005||2005-10-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Consequences of Nocturnal and Daytime Hypoxemia in COPD||Terminated||N/A|20|Actual|Northwell Health||1|||f||||f||||||||||2018-06-01 02:49:38.680135|2018-06-01 02:49:38.680135
NCT00547443|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2010-10-19|2007-10-19|2007-10-22|Estimate|||||||2010-10-19|2010-10-20|Estimate|July 2007||2007-07-31|October 2008|2008-10-31||||July 2009|Anticipated|2009-07-31||Interventional|||Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Randomized Phase I/II Study Of Sorafenib In Combination With High Does Chemoradiation In Patients With Stage IIIA/B Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 1/Phase 2|84|Anticipated|National Cancer Institute (NCI)||2||Withdrawn as the sponsor has stopped the drug for NSCLC population|||||||||||||||2018-06-01 02:49:38.825852|2018-06-01 02:49:38.825852
NCT00547417|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|July 2003||2003-07-31|October 2007|2007-10-31|March 2004|Actual|2004-03-31|||||Interventional|||To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections|"An Open-Label Study to Evaluate the Efficacy and Safety of Tadalafil Administered On Demand to Men of Various Populations With Erectile Dysfunction"|Completed||Phase 3|1933|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:49:38.901218|2018-06-01 02:49:38.901218
NCT00547404|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2009-04-21|2007-10-19|2007-10-22|Estimate|||||||2009-04-21|2009-04-23|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|July 2010|Anticipated|2010-07-31|December 2009|Anticipated|2009-12-31||Interventional|||Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma|An Open Label, Multicenter Phase I Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma|Withdrawn||Phase 1|35|Anticipated|Piramal Enterprises Limited||||Not to expose the patients to subtherapeutic dose|f||||f||||||||||2018-06-01 02:49:38.981217|2018-06-01 02:49:38.981217
NCT00547391|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2012-04-17|2007-10-19|2007-10-22|Estimate|||||||2012-04-17|2012-04-19|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Recurrent Throat Infections and Tonsillectomy|Recurrent Throat Infections and Tonsillectomy|Completed||Phase 4|87|Actual|Oulu University Hospital||2|||f||||f||||||||||2018-06-01 02:49:39.121086|2018-06-01 02:49:39.121086
NCT00547378|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2017-07-19||2017-11-06|2007-10-19|2007-10-22|Estimate|2017-11-06|2017-12-12|Actual||||2017-11-06|2017-12-12|Actual|October 2007||2007-10-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|InSite - OAB||InSite for Over Active Bladder|Prospective, Multicenter Trial Evaluating the Safety and Efficacy of InterStim® Therapy in Subjects With Symptoms of Overactive Bladder (InSite OAB)|Completed||Phase 4|571|Actual|MedtronicNeuro|Predominantly female and Caucasian subjects could detract from generalizability. Centers followed individual protocols for peri-op antibiotics, lead choice, and procedure techniques. Lack of standardization may have impacted overall study results.|2|||f||||f||||||||||2018-06-01 02:49:39.286698|2018-06-01 02:49:39.286698
NCT00547365|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2013-02-04||2013-09-16|2007-10-19|2007-10-22|Estimate|2013-09-16|2013-09-19|Estimate||||2013-09-16|2013-09-19|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Patients with cardiac-dominant AL amyloidosis, as determined from standard clinical tests (IVS, BNP),were entered on study.|Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction|Therapeutic Potential of Human Immune Globulin Intravenous (IGIV) in Patients With Cardiac-Associated Light Chain (AL) Amyloidosis|Completed||Phase 1/Phase 2|10|Actual|University of Tennessee||1|||f||||f||||||||||2018-06-01 02:49:40.530478|2018-06-01 02:49:40.530478
NCT00547352|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|June 2004||2004-06-30|October 2007|2007-10-31|June 2005|Actual|2005-06-30|||||Interventional|||Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection|Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference|Completed||Phase 4|160|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:49:40.766034|2018-06-01 02:49:40.766034
NCT00547339|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2011-02-18|2007-10-19|2007-10-22|Estimate|||||||2011-02-18|2011-02-21|Estimate|July 2006||2006-07-31|June 2010|2010-06-30||||October 2010|Anticipated|2010-10-31||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer|A Phase I and II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer (SBRT Prostate)|Unknown status|Recruiting|Phase 1/Phase 2|97|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:49:40.834817|2018-06-01 02:49:40.834817
NCT00547326|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2008-04-07|2007-10-19|2007-10-22|Estimate|||||||2008-04-07|2008-04-08|Estimate||||April 2008|2008-04-30||||||||Interventional|||The Effect of Osteopatic Cranial Techniques on the Audiometric and Tympanometric Values in Children Suffering From Otitis Media With Effusion.|The Effect of Osteopatic Cranial Techniques on the Audiometric and Tympanometric Values in Children Suffering From Otitis Media With Effusion.|Withdrawn||N/A|60|Anticipated|University Hospital, Ghent||2||Ethics Committee approval denied|f||||f||||||||||2018-06-01 02:49:40.910852|2018-06-01 02:49:40.910852
NCT00547300|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2009-01-12|2007-10-19|2007-10-22|Estimate|||||||2009-01-12|2009-01-13|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|October 2008||2008-10-31|||||Interventional|||Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-Release (ER) for Hypertension|Tolerability of Nebivolol Compared With Metoprolol ER in Patients With Mild to Moderate Hypertension Taking Hydrochlorothiazide|Completed||Phase 3|400|Anticipated|Forest Laboratories|||||||||||||||||||2018-06-01 02:49:41.096417|2018-06-01 02:49:41.096417
NCT00547287|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|November 2002||2002-11-30|October 2007|2007-10-31|May 2004|Actual|2004-05-31|||||Interventional|||Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations|Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Multinational Assessment of Treatment Preference|Completed||Phase 3|2760|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:49:41.280122|2018-06-01 02:49:41.280122
NCT00547274|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2015-06-11|2007-10-19|2007-10-22|Estimate|||||||2015-06-11|2015-06-12|Estimate|July 2003||2003-07-31|June 2015|2015-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Dyslipidemia in Type 2 Diabetes (0767-034)||Terminated||Phase 3|111|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:49:41.358312|2018-06-01 02:49:41.358312
NCT00547261|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2009-04-16|2007-10-18|2007-10-22|Estimate|||||||2009-04-16|2009-04-17|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer|Phase I Dose Escalation and Pharmacokinetic Study of SSR97225 Administered as a 1 Hour IV Infusion D1 Every 3 Weeks (Arm A) or Administered as a 1hour IV Infusion D1, D8, D15 Every 3 Weeks (Arm B) in Patients With Refractory Solid Tumors|Terminated||Phase 1|6|Actual|Sanofi||2||Due to lack of supply of the investigational product.|f||||||||||||||2018-06-01 02:49:41.499963|2018-06-01 02:49:41.499963
NCT00547248|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19||2009-05-20|2016-10-26|2007-10-19|2007-10-22|Estimate||||2009-09-25|2009-09-28|Estimate|2016-10-26|2016-10-27|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines|Booster Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in Children Who Completed the Primary Vaccination Course in Study 107007|Completed||Phase 3|756|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:49:41.607402|2018-06-01 02:49:41.607402
NCT00547235|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2010-08-23|2007-10-19|2007-10-22|Estimate|||||||2010-08-23|2010-08-24|Estimate|September 2007||2007-09-30|August 2010|2010-08-31||||December 2012|Anticipated|2012-12-31||Expanded Access|||Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection|Protocol For The Emergency Use Of Adoptive Immunotherapy With CMV-Specific T Cells Following HLA-Matched Unrelated Donor Bone Marrow Transplant Of An Infant With ADA-SCIDs And Pre Transplant CMV Infection|No longer available|||||Fred Hutchinson Cancer Research Center||||No accrual|||||||||||||||2018-06-01 02:49:41.795673|2018-06-01 02:49:41.795673
NCT00547209|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2016-09-23|2007-10-19|2007-10-22|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|Drone-N2O||Effect of Nitrous Oxide on Intravenous Closed-loop Anesthesia|"Anesthésie Totale Intraveineuse en  Boucle d'Asservissement  guidée Par l'Index Bispectral : Effet de l'Adjonction de Protoxyde d'Azote (Effect of Nitrous Oxide on Intravenous Closed-loop Anesthesia)"|Completed||Phase 4|672|Actual|Hopital Foch||2|||f||||f||||||||||2018-06-01 02:49:41.927021|2018-06-01 02:49:41.927021
NCT00547196|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2018-02-09|2007-10-19|2007-10-22|Estimate|||||||2018-02-09|2018-02-12|Actual|August 9, 2005||2005-08-09|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of Four Different Chemotherapy Regimens With or Without Total-Body Irradiation Followed by Umbilical Cord Blood Transplant in Treating Patients With Relapsed or Refractory Hematologic Cancer|Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units|Active, not recruiting||N/A|10|Anticipated|City of Hope Medical Center||4|||f||||t||||||||||2018-06-01 02:49:42.170147|2018-06-01 02:49:42.170147
NCT00547183|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|May 2005|Actual|2005-05-31|||||Interventional|||Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection|A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5 mg and 5 mg) Administered Once Daily to Men With Diabetes Mellitus and Erectile Dysfunction|Completed||Phase 3|298|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:49:42.335033|2018-06-01 02:49:42.335033
NCT00547170|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2008-05-14|2007-10-19|2007-10-22|Estimate|||||||2008-05-14|2008-05-16|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Tu Du Doxy||Doxycycline Prophylaxis at Vacuum Aspiration Trial|Efficacy and Side-Effects of Two Dosing Regimens of Doxycycline at Surgical Abortion: A Randomized Double-Blind Trial|Completed||Phase 4|1000|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 02:49:42.417462|2018-06-01 02:49:42.417462
NCT00547157|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2013-12-16||2017-02-07|2007-10-18|2007-10-22|Estimate|2014-04-23|2014-05-23|Estimate||||2017-02-07|2017-03-15|Actual|November 2007||2007-11-30|February 2017|2017-02-28|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|152|Actual|Amgen||2|||f||||t||||||||||2018-06-01 02:49:42.525162|2018-06-01 02:49:42.525162
NCT00547144|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2012-11-06|2007-10-18|2007-10-22|Estimate|||||||2012-11-06|2012-11-08|Estimate|October 2005||2005-10-31|August 2012|2012-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer|A Phase I/II Trial of Intratumoral Dendritic Cell Immunotherapy in Combination With Gemcitabine and Stereotactic Radiosurgery in Unresectable Pancreatic Cancer|Completed||Phase 1|2|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 02:49:43.333939|2018-06-01 02:49:43.333939
NCT00547131|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|||2018-04-12|2007-10-19|2007-10-22|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2006||2006-01-31|April 2018|2018-04-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Temozolomide in Treating Patients With Primary Brain Tumors or Metastatic Brain Tumors|A Pilot Feasibility Study of Intracerebral Microdialysis to Determine the Neuropharmacokinetics of Temozolomide|Completed||Phase 1|12|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:49:43.415477|2018-06-01 02:49:43.415477
NCT00547118|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2014-05-05||2018-01-16|2007-10-19|2007-10-22|Estimate|2015-02-24|2015-02-27|Estimate||||2018-01-16|2018-01-17|Actual|November 2007||2007-11-30|January 2018|2018-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||18 participants signed consent, 1 withdrawn prior to randomization, 17 subjects were randomized to study medication (rimonabant n=8, placebo n=9). Of these 17, 1 participant from each group was withdrawn prior to the receipt of study medication, thus n=15 analyzed for aims 1, 2,8,9,10; n=14 analyzed for aims 3-7.|The Effects of Rimonabant, on Weight and Metabolic Risk Factors|The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant, on Weight and Metabolic Risk Factors in People With Schizophrenia|Terminated||Phase 2|17|Actual|University of Maryland||2||Withdrawn due to medication withdrawal from the EMEA|f||||t||||||||||2018-06-01 02:49:43.521214|2018-06-01 02:49:43.521214
NCT00547105|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-19|2017-12-05||2018-04-23|2007-10-19|2007-10-22|Estimate|2018-03-22|2018-04-23|Actual||||2018-04-23|2018-05-22|Actual|June 25, 2007|Actual|2007-06-25|April 2018|2018-04-30|July 6, 2017|Actual|2017-07-06|July 6, 2016|Actual|2016-07-06||Interventional|||Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Trial of Erlotinib (Tarceva®) in Combination With Stereotactic Body Radiation Therapy (SBRT) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|24|Actual|University of Texas Southwestern Medical Center||1|||f||||||||||||||2018-06-01 02:49:44.155489|2018-06-01 02:49:44.155489
NCT00547092|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-22|Estimate|||||||2007-10-18|2007-10-22|Estimate|October 2003||2003-10-31|October 2007|2007-10-31|November 2004|Actual|2004-11-30|||||Interventional|||Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection|A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction|Completed||Phase 4|386|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:49:44.356342|2018-06-01 02:49:44.356342
NCT00547066|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2016-03-18|2007-10-17|2007-10-19|Estimate|||||||2016-03-18|2016-03-21|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Veltuzumab (hA20) at Different Doses in Patients With ITP|A Phase I/II Study of Immunotherapy With Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients With Chronic Immune Thrombocytopenic Purpura|Unknown status|Active, not recruiting|Phase 1/Phase 2|66|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-06-01 02:49:44.442309|2018-06-01 02:49:44.442309
NCT00547053|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2011-05-12|2007-10-17|2007-10-19|Estimate|||||||2011-05-12|2011-05-13|Estimate|December 2006||2006-12-31|May 2011|2011-05-31|January 2011|Actual|2011-01-31|January 2008|Actual|2008-01-31||Interventional|||Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis|A Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis|Completed||Phase 1|25|Anticipated|Boston Children’s Hospital|||||f||||t||||||||||2018-06-01 02:49:44.52883|2018-06-01 02:49:44.52883
NCT00547040|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2011-10-05|2007-10-18|2007-10-19|Estimate|||||||2011-10-05|2011-10-06|Estimate|October 2006||2006-10-31|October 2011|2011-10-31|October 2013|Anticipated|2013-10-31|||||Observational|ASCIT||Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients|Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients|Unknown status|Recruiting||100|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples Without DNA|"~     serum, plasma, urine~   "|||2018-06-01 02:49:44.588969|2018-06-01 02:49:44.588969
NCT00547027|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2015-03-04|2007-10-17|2007-10-19|Estimate|||||||2015-03-04|2015-03-06|Estimate|April 2006||2006-04-30|March 2015|2015-03-31|July 2007|Actual|2007-07-31|||||Interventional|||Promoting Physical Activity Among Patients With Type 2 Diabetes|Promoting Physical Activity Among Patients With Type 2 Diabetes in a Community-Based Clinic|Completed||Phase 2/Phase 3|85|Actual|Florida State University|||||f||||f||||||||||2018-06-01 02:49:44.6593|2018-06-01 02:49:44.6593
NCT00547014|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2009-03-18|2007-10-18|2007-10-19|Estimate|||||||2009-03-18|2009-03-19|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|April 2008|Actual|2008-04-30|||||Interventional|||First Safety Study in Humans of a Single Dose of CPG 52364|Oral Administration Of CPG 52364 In Healthy Subjects: A Phase 1, Within-Cohort Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose, Single-Center Study|Completed||Phase 1|61|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 02:49:44.724219|2018-06-01 02:49:44.724219
NCT00547001|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2008-07-17|2007-10-18|2007-10-19|Estimate|||||||2008-07-17|2008-07-18|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|November 2009|Anticipated|2009-11-30|||||Interventional|||Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes|A Comparison of Hormonal Therapy: Tapering Regimens for Mediating Hot Flashes|Unknown status|Recruiting|N/A|235|Anticipated|Hartford Hospital||3|||f||||f||||||||||2018-06-01 02:49:44.824112|2018-06-01 02:49:44.824112
NCT00546988|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2007-10-17|2007-10-17|2007-10-19|Estimate|||||||2007-10-17|2007-10-19|Estimate|October 2001||2001-10-31|October 2007|2007-10-31|January 2008|Anticipated|2008-01-31|||||Interventional|||Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years|Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III|Unknown status|Recruiting|Phase 3|600|Anticipated|University of Wuerzburg||4|||f||||f||||||||||2018-06-01 02:49:44.903404|2018-06-01 02:49:44.903404
NCT00546975|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2011-06-24|2007-10-18|2007-10-19|Estimate|||||||2011-06-24|2011-06-27|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effect of Oral Nutritional Supplements With Specialized Nutrients on Functional Recovery and Morbidity After Gastrointestinal Surgery||Terminated||N/A|||Charite University, Berlin, Germany||3||Compliance unacceptably low.|f||||t||||||||||2018-06-01 02:49:45.034602|2018-06-01 02:49:45.034602
NCT00546962|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2011-05-12|2007-10-18|2007-10-19|Estimate|||||||2011-05-12|2011-05-13|Estimate|April 1999||1999-04-30|May 2011|2011-05-31||||||||Observational|||Tissue Bank for Pulmonary Diseases|Tissue Bank for Pulmonary Diseases|Unknown status|Recruiting||400|Anticipated|Boston Children’s Hospital|||||f||||t||||||||||2018-06-01 02:49:45.139483|2018-06-01 02:49:45.139483
NCT00546949|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2016-02-24|2007-10-18|2007-10-19|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|September 2011|Actual|2011-09-30||Interventional|LSSS||Treatment of Lumbar Spinal Stenosis; Comparison of Two Different Surgical Methods; Mini-invasive Decompression to X-stop|Treatment of Lumbar Spinal Stenosis; Comparison of Two Different Surgical Methods; Mini-Invasive Decompression to X-Stop (LSSS)|Terminated||N/A|96|Actual|Norwegian University of Science and Technology||2||analysis at 50% inclusion showed 4 times larger reoperation rate in X-stop group|f||||t||||||||||2018-06-01 02:49:45.228011|2018-06-01 02:49:45.228011
NCT00546936|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2009-04-15|2007-10-18|2007-10-19|Estimate|||||||2009-04-15|2009-04-16|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|April 2010|Anticipated|2010-04-30|October 2009|Anticipated|2009-10-31||Interventional|||Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis|Ranibizumab vs PDT for Presumed Ocular Histoplasmosis|Unknown status|Recruiting|Phase 2|30|Anticipated|Barnes Retina Institute||2|||f||||t||||||||||2018-06-01 02:49:45.321863|2018-06-01 02:49:45.321863
NCT00546923|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-19|Estimate|||||||2007-10-18|2007-10-19|Estimate|August 2004||2004-08-31|October 2007|2007-10-31|June 2006|Actual|2006-06-30|||||Interventional|||Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients|A Randomized, Double-Blind, Placebo-Controlled, Pilot Study To Evaluate The Efficacy And Safety Of Venlafaxine Extended-Release In Depressed And Anxious Patients With Multiple, Unexplained Somatic Symptoms|Completed||Phase 4|210||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:49:45.425375|2018-06-01 02:49:45.425375
NCT00546910|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2010-05-21||2010-08-04|2007-10-17|2007-10-19|Estimate|2010-05-21|2010-06-23|Estimate||||2010-08-04|2010-08-10|Estimate|October 2007||2007-10-31|August 2010|2010-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double Blind Comparison of the Effects of Atomoxetine Versus Placebo on Neuropsychological Outcomes Across the Day in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) by Use of a Computer Based Continuous Performance Test (cb CPT)|Completed||Phase 4|125|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:49:45.508102|2018-06-01 02:49:45.508102
NCT00546897|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2014-09-19||2014-09-26|2007-10-18|2007-10-19|Estimate|2014-09-26|2014-09-29|Estimate||||2014-09-26|2014-09-29|Estimate|February 2007||2007-02-28|September 2014|2014-09-30|March 2012|Actual|2012-03-31|June 2010|Actual|2010-06-30||Interventional|||Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities|Phase II Trial of Lenalidomide in Older Patients (>/= 60 Years) With Untreated Acute Myeloid Leukemia Without Chromosome 5q Abnormalities|Completed||Phase 2|48|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:49:46.508276|2018-06-01 02:49:46.508276
NCT00546884|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2016-06-27||2017-06-16|2007-10-18|2007-10-19|Estimate|2017-01-24|2017-03-14|Actual||||2017-06-16|2017-07-13|Actual|November 2007||2007-11-30|June 2017|2017-06-30|July 2010|Actual|2010-07-31|August 2008|Actual|2008-08-31||Interventional|SELPH||Intervention to Improve Expression of End of Life Preferences for Homeless Persons|Intervention to Improve Expression of End of Life Preferences for Homeless Persons|Completed||N/A|262|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 02:49:47.53217|2018-06-01 02:49:47.53217
NCT00546871|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2011-11-15|2010-07-27|2018-01-23|2007-10-18|2007-10-19|Estimate|2012-07-19|2012-08-23|Estimate|2010-07-27|2010-07-29|Estimate|2018-01-23|2018-02-21|Estimate|October 3, 2007|Actual|2007-10-03|January 2018|2018-01-31|September 1, 2009|Actual|2009-09-01|July 1, 2009|Actual|2009-07-01||Interventional|||Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects|Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases|Completed||Phase 2/Phase 3|49|Actual|Shire|||||f||||f||||||||||2018-06-01 02:49:48.419189|2018-06-01 02:49:48.419189
NCT00546858|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2009-05-04|2007-10-18|2007-10-19|Estimate|||||||2009-05-04|2009-05-05|Estimate|October 2007||2007-10-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Relationship of Interstitial Cystitis to Vulvodynia|Part A: STUDY OF THE RELATIONSHIP OF INTERSTITIAL CYSTITIS TO VULVODYNIA|Completed|||350|Anticipated|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 02:50:00.795943|2018-06-01 02:50:00.795943
NCT00546845|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2011-08-04|2007-10-17|2007-10-19|Estimate|||||||2011-08-04|2011-08-08|Estimate|September 2007||2007-09-30|October 2007|2007-10-31|June 2014|Anticipated|2014-06-30|March 2012|Anticipated|2012-03-31||Interventional|XXS||Balloon Angioplasty Versus Xpert Stent in CLI Patients XXS Study|Xpert Stent Versus Balloon Angioplasty in Complex Lesions of Small Arteries Below the Knee|Unknown status|Recruiting|Phase 4|180|Anticipated|University Hospital Tuebingen|||||f||||f||||||||||2018-06-01 02:50:00.861813|2018-06-01 02:50:00.861813
NCT00546832|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2010-10-11|2007-10-17|2007-10-19|Estimate|||||||2010-10-11|2010-10-13|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II|The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study II|Completed||Phase 3|650|Actual|Mika Pharma GmbH||3|||f||||f||||||||||2018-06-01 02:50:00.952138|2018-06-01 02:50:00.952138
NCT00546819|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2011-07-20||2017-03-14|2007-10-17|2007-10-19|Estimate|2011-07-20|2011-08-15|Estimate||||2017-03-14|2017-04-12|Actual|October 2007||2007-10-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)|A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids|Completed||Phase 2|309|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:50:01.114471|2018-06-01 02:50:01.114471
NCT00546806|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2012-05-23|2007-10-18|2007-10-19|Estimate|||||||2012-05-23|2012-05-24|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|WIT||University Health Network Whiplash Intervention Trial|The University Health Network Whiplash Intervention Trial: A Randomized Controlled Trial of the Effectiveness and Cost-effectiveness of Three Programs of Care for the Treatment of Whiplash-associated Disorders|Completed||Phase 3|340|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-06-01 02:50:01.725329|2018-06-01 02:50:01.725329
NCT00546793|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2013-03-25|2007-10-17|2007-10-19|Estimate|||||||2013-03-25|2013-03-27|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL|Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|32|Actual|Immunomedics, Inc.||1|||f||||f||||||||||2018-06-01 02:50:01.872675|2018-06-01 02:50:01.872675
NCT00546780|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17||2011-06-21|2011-06-21|2007-10-18|2007-10-19|Estimate||||2011-06-21|2011-06-28|Estimate|2011-06-21|2011-06-28|Estimate|February 2008||2008-02-29|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|BMS TIME-1||A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse|Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse|Completed||Phase 3|31|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 02:50:02.00378|2018-06-01 02:50:02.00378
NCT00546767|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2014-09-15|2007-10-18|2007-10-19|Estimate|||||||2014-09-15|2014-09-16|Estimate|September 2007||2007-09-30|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HBA||Home-Based Assessment for Alzheimer Disease Prevention|Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer Disease Prevention Research in People Over 75 Years Old|Completed||N/A|640|Actual|Alzheimer's Disease Cooperative Study (ADCS)||4|||f||||t||||||||||2018-06-01 02:50:02.140284|2018-06-01 02:50:02.140284
NCT00546754|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2010-03-26||2017-03-31|2007-10-17|2007-10-19|Estimate|2010-03-26|2010-04-13|Estimate||||2017-03-31|2017-05-05|Actual|May 1, 2007|Actual|2007-05-01|March 2017|2017-03-31|May 1, 2009|Actual|2009-05-01|April 1, 2009|Actual|2009-04-01||Interventional|EASE||BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)|BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure With|Completed||Phase 3|808|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:50:02.499658|2018-06-01 02:50:02.499658
NCT00546741|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2016-12-19|2007-10-18|2007-10-19|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Drug Interaction With Metformin|Pharmacokinetic Drug Interaction Study With Dapagliflozin and Metformin in Healthy Subjects|Completed||Phase 1|18|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:50:03.22391|2018-06-01 02:50:03.22391
NCT00546728|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2012-04-23||2013-09-05|2007-10-17|2007-10-19|Estimate|2013-09-05|2013-11-08|Estimate||||2013-09-05|2013-11-08|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes|The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance|Completed||Phase 4|50|Actual|St. Paul Heart Clinic|unblinded study design|2|||f||||f||||||||||2018-06-01 02:50:03.379569|2018-06-01 02:50:03.379569
NCT00546715|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2015-08-10||2015-10-20|2007-10-17|2007-10-19|Estimate|2015-08-10|2015-09-10|Estimate||||2015-10-20|2015-11-18|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||The analysis was performed in the safety population defined as all participants who received any study drug treatment.|A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects|Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1|Completed||Phase 1/Phase 2|95|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 02:50:03.651066|2018-06-01 02:50:03.651066
NCT00546702|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2009-06-12|2007-10-18|2007-10-19|Estimate|||||||2009-06-12|2009-06-15|Estimate|September 2004||2004-09-30|June 2009|2009-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Glulisine + Lantus in Type I Patients|Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine During 26 Weeks of Therapy|Completed||Phase 3|142|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:50:04.387254|2018-06-01 02:50:04.387254
NCT00546689|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2008-04-17|2007-10-18|2007-10-19|Estimate|||||||2008-04-17|2008-04-18|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Observational|||Correlation Between Intestinal Parasites and Serum Level of Eosinophils and IgE in Individuals With HIV or AIDS|Phase 1 Correlation Between Intestinal Parasites and Serum Level of Eosinophils and IgE in Individuals With HIV or AIDS|Completed|||30|Actual|UPECLIN HC FM Botucatu Unesp|||1||f||||t||||||Samples Without DNA|"~     Sample of Blood Sample of Feces~   "|||2018-06-01 02:50:04.44518|2018-06-01 02:50:04.44518
NCT00546676|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-11-13|2007-10-18|2007-10-19|Estimate|||||||2007-11-13|2007-11-14|Estimate|May 2004||2004-05-31|November 2007|2007-11-30|December 2004|Actual|2004-12-31|||||Interventional|||Ketek in CAP / AECB in Ambulatory Adult Patients|A Canadian Multicenter, Prospective, Open Label, Non-Comparative Study of the Effectiveness and Safety of Oral Telithromycin, 800mg Once Daily in the Treatment of Either Community Acquired Pneumonia or Acute Exacerbation of Chronic Bronchitis in Ambulator|Completed||Phase 4|174|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:50:04.499528|2018-06-01 02:50:04.499528
NCT00546663|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2011-08-22|2007-10-17|2007-10-19|Estimate|||||||2011-08-22|2011-08-24|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|ISIS Pilot||Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis|A Pilot Study to Evaluate the Tolerability of Inhaled 7% Hypertonic Saline in Infants With Cystic Fibrosis|Completed||N/A|19|Actual|CF Therapeutics Development Network Coordinating Center||1|||f||||t||||||||||2018-06-01 02:50:04.555569|2018-06-01 02:50:04.555569
NCT00546650|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2016-02-02|2007-10-18|2007-10-19|Estimate|||||||2016-02-02|2016-02-03|Estimate|November 2007||2007-11-30|February 2016|2016-02-29|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®|A Phase I, Single Center, Open Label, Randomized, Single-Dose, Five-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® in Healthy Volunteers|Completed||Phase 1|25|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-06-01 02:50:04.636728|2018-06-01 02:50:04.636728
NCT00546637|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2010-01-11||2011-02-15|2007-10-18|2007-10-19|Estimate|2010-10-22|2010-11-22|Estimate||||2011-02-15|2011-02-18|Estimate|November 2007||2007-11-30|February 2011|2011-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||"Fesoterodine add-on Male Overactive Bladder Study"|"A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An Add-On Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms."|Completed||Phase 3|947|Actual|Pfizer||2|||f||||||||||||||2018-06-01 02:50:04.929509|2018-06-01 02:50:04.929509
NCT00546611|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2016-01-26|2007-10-18|2007-10-19|Estimate|||||||2016-01-26|2016-01-28|Estimate|October 2007||2007-10-31|January 2016|2016-01-31||||||||Interventional|||The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)|A Phase I, Single-Centre, Open-Label, Fixed-Dose Study of the Safety and Efficacy of up- to Three-Days Application of 0.05% PEP005 Topical Gel in the Treatment of Patients With Common Wart(s) (Verruca[e] Vulgaris) on the Dorsal Hand|Withdrawn||Phase 1|0|Actual|Peplin||1||No enrolement|f||||f||||||||||2018-06-01 02:50:06.479301|2018-06-01 02:50:06.479301
NCT00546598|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2014-06-25|2007-10-18|2007-10-19|Estimate|||||||2014-06-25|2014-06-26|Estimate|January 2006||2006-01-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System|DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System PMA Post-approval Study|Terminated||Phase 4|106|Actual|DePuy Orthopaedics||1||Sponsor withdrew PMA|f||||f||||||||||2018-06-01 02:50:06.548128|2018-06-01 02:50:06.548128
NCT00546585|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18||2011-07-20|2013-08-15|2007-10-18|2007-10-19|Estimate||||2011-07-20|2011-07-22|Estimate|2013-08-15|2013-08-23|Estimate|March 2008||2008-03-31|January 2010|2010-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults|A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H7N7 Vaccine in Healthy Adults|Completed||Phase 1/Phase 2|126|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 02:50:06.634853|2018-06-01 02:50:06.634853
NCT00546572|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2011-04-29||2011-07-12|2007-10-18|2007-10-19|Estimate|2011-04-29|2011-05-30|Estimate||||2011-07-12|2011-07-14|Estimate|November 2007||2007-11-30|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment|Completed||Phase 3|938|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:50:06.83264|2018-06-01 02:50:06.83264
NCT00546559|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2008-08-28|2007-10-18|2007-10-19|Estimate|||||||2008-08-28|2008-08-29|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|March 2008||2008-03-31|||||Observational|||Differential Metabolic Effects of Statins||Completed|||||Gachon University Gil Medical Center|||||f||||t||||||||||2018-06-01 02:50:11.293695|2018-06-01 02:50:11.293695
NCT00546546|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2015-04-26|2007-10-18|2007-10-19|Estimate|||||||2015-04-26|2015-04-28|Estimate|July 2005||2005-07-31|August 2011|2011-08-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|RAPID||Early Immunosuppressants in Crohn's Disease|Effect of Early Prescription of Immunosuppressants on First Three-year Course of Crohn's Disease|Completed||Phase 4|120|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||2|||f||||f||||||||||2018-06-01 02:50:11.375277|2018-06-01 02:50:11.375277
NCT00546533|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-19|Estimate|||||||2007-10-18|2007-10-19|Estimate|January 2003||2003-01-31|October 2007|2007-10-31|February 2005|Actual|2005-02-28|||||Interventional|||Study Evaluating the Efficacy and Safety of Etanercept|Open-Label Evaluation Of The Efficacy And Safety Of Etanercept In Patients With Active Rheumatoid Arthritis (RA)|Completed||Phase 4|40||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:50:11.53011|2018-06-01 02:50:11.53011
NCT00546520|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2016-12-05|2007-10-18|2007-10-19|Estimate|||||||2016-12-05|2016-12-07|Estimate|April 2002||2002-04-30|December 2016|2016-12-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)|A 3-period Double-blind, Cross-over Study on the Onset of Action of Inhaled Ciclesonide (7 Days of 400 mcg Sid Versus 800 mcg Bid Versus Placebo) on Airway Responsiveness to Adenosine Monophosphate (AMP), Sputum Eosinophiles and Exhaled Breath Nitric Oxide (NO) in Patients With Asthma|Completed||Phase 3|21|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:50:11.590284|2018-06-01 02:50:11.590284
NCT00546507|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2010-10-11|2007-10-17|2007-10-19|Estimate|||||||2010-10-11|2010-10-13|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I|The Efficacy and Safety of TDS-943 in the Treatment of Osteoarthritis of the Knee: Pivotal Study I|Completed||Phase 3|650|Actual|Mika Pharma GmbH||3|||f||||f||||||||||2018-06-01 02:50:11.673734|2018-06-01 02:50:11.673734
NCT00546494|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2007-10-18|2007-10-18|2007-10-19|Estimate|||||||2007-10-18|2007-10-19|Estimate|February 2004||2004-02-29|October 2007|2007-10-31|March 2005|Actual|2005-03-31|||||Interventional|||Study Evaluating Effexor® (Venlafaxine) in Achieving Response and Maintaining Remission|A Study Of The Utility Of Effexor® (Venlafaxine) In Achieving Response And Maintaining Remission Among Taiwanese Patients With Depression|Completed||Phase 4|350||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:50:11.825074|2018-06-01 02:50:11.825074
NCT00546481|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|2016-04-12||2016-08-09|2007-10-18|2007-10-19|Estimate|2016-06-06|2016-07-18|Estimate||||2016-08-09|2016-09-19|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||The Intent-to-Treat (ITT) population included all randomized participants.|A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.|An Open-label, Randomized, Multi-center, Parallel Group Study to Demonstrate Correction of Anemia Using Intravenous Injections of RO0503821 in Patients With Chronic Kidney Disease Who Are on Dialysis|Completed||Phase 3|80|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:50:11.925823|2018-06-01 02:50:11.925823
NCT00546468|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-18|||2012-05-22|2007-10-18|2007-10-19|Estimate|||||||2012-05-22|2012-05-24|Estimate|June 2003||2003-06-30|May 2012|2012-05-31|December 2010|Actual|2010-12-31|November 2005|Actual|2005-11-30||Interventional|NCC052||Clinical Study on Laparoscopic Gastrectomy for Early Gastric Cancer (COACT_0301)|Prospective Randomized Trial of Laparoscopy-assisted Distal Gastrectomy (LADG) Versus Open Distal Gastrectomy (ODG) in Patients With Early Gastric Cancer (EGC)|Completed||Phase 3|164|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-06-01 02:50:12.783177|2018-06-01 02:50:12.783177
NCT00546455|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2013-02-11|2007-10-18|2007-10-19|Estimate|||||||2013-02-11|2013-02-12|Estimate|December 2007||2007-12-31|July 2010|2010-07-31|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Interventional|||A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity|Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver|Unknown status|Recruiting|Phase 2|120|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 02:50:12.866173|2018-06-01 02:50:12.866173
NCT00546442|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2007-10-17|2007-10-17|2007-10-19|Estimate|||||||2007-10-17|2007-10-19|Estimate|May 2006||2006-05-31|October 2007|2007-10-31|January 2007|Actual|2007-01-31|||||Interventional|TRIC-1||Treatment Insulin Resistence in HCV G-1 Patient|Effect of Treatment of Insulin Resistance in Patients With Chronic Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a in Combination With Ribavirin in Current Clinical Practice|Completed||Phase 4|126|Actual|Valme University Hospital||2|||f||||t||||||||||2018-06-01 02:50:12.951|2018-06-01 02:50:12.951
NCT00546429|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2010-09-29||2012-02-28|2007-10-18|2007-10-19|Estimate|2010-11-12|2010-12-10|Estimate||||2012-02-28|2012-02-29|Estimate|September 2006||2006-09-30|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|ATN||DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial|Clinical Trial to Monitor the Clinical Effectiveness of the DePuy ATN Trochanteric Nailing System in the Treatment of Trochanteric Fractures of the Proximal Femur|Completed||Phase 4|62|Actual|DePuy Orthopaedics||1|||f||||f||||||||||2018-06-01 02:50:13.068397|2018-06-01 02:50:13.068397
NCT00546403|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2009-02-20|2007-10-17|2007-10-19|Estimate|||||||2009-02-20|2009-02-24|Estimate|February 2003||2003-02-28|October 2007|2007-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia|An Eight Week, Double-Blind, Placebo Controlled, Adjunctive Study of the Primary Effects of the Use of Flexible Doses of Modafinil 50mg to 200mg, on the Negative Symptoms, Cognition, and Excessive Daytime Sleepiness in Schizophrenic Patients|Completed||N/A|26|Actual|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-06-01 02:50:13.313382|2018-06-01 02:50:13.313382
NCT00546390|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2012-02-14|2007-10-16|2007-10-18|Estimate|||||||2012-02-14|2012-02-16|Estimate|November 2007||2007-11-30|February 2012|2012-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study|Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study|Completed||N/A|100|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 02:50:13.393954|2018-06-01 02:50:13.393954
NCT00546377|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2015-12-17||2016-04-07|2007-10-17|2007-10-18|Estimate|2016-04-07|2016-05-12|Estimate||||2016-04-07|2016-05-12|Estimate|July 2005||2005-07-31|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer|A Phase I-II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Previously Treated Patients With Chronic Lymphocytic Leukemia and Other Low Grade B-Cell Neoplasms|Completed||Phase 1/Phase 2|50|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||f||||||||||2018-06-01 02:50:13.499607|2018-06-01 02:50:13.499607
NCT00546364|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2011-05-06||2016-02-09|2007-10-17|2007-10-18|Estimate|2011-05-06|2011-06-01|Estimate||||2016-02-09|2016-03-10|Estimate|February 2008||2008-02-29|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|IXTEND||Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer|IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or Capecitabine Plus Docetaxel in the Treatment of Metastatic Breast Cancer|Terminated||Phase 2|62|Actual|R-Pharm||3||Slow Accrual|f||||f||||||||||2018-06-01 02:50:13.870802|2018-06-01 02:50:13.870802
NCT00546351|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2011-12-21||2017-07-28|2007-10-17|2007-10-18|Estimate|2012-03-26|2012-04-19|Estimate||||2017-07-28|2017-08-28|Actual|May 2004||2004-05-31|July 2017|2017-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.|A Multi-center, Open-label, follow-on Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Including a Double-blind, Randomized Time Point Withdrawal Subtrial.|Completed||Phase 3|621|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:50:15.044229|2018-06-01 02:50:15.044229
NCT00546325|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2010-12-09|2007-10-17|2007-10-18|Estimate|||||||2010-12-09|2010-12-10|Estimate|October 2007||2007-10-31|December 2010|2010-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|REASSURE||REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents|REASURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents|Completed||Phase 3|358|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:50:16.415534|2018-06-01 02:50:16.415534
NCT00546312|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2010-05-25|2007-10-16|2007-10-18|Estimate|||||||2010-05-25|2010-05-27|Estimate|February 2000||2000-02-29|May 2009|2009-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|Gore Thoracic||Clinical Study of Thoracic Excluder Endoprosthesis to Treat Descending Thoracic Aortic Diseases|A Clinical Study Evaluating Use of the Thoracic EXCLUDER Endoprosthesis in the Treatment of Descending Thoracic Aortic Diseases|Unknown status|Active, not recruiting|N/A|332|Anticipated|Arizona Heart Institute|||||f||||f||||||||||2018-06-01 02:50:16.497863|2018-06-01 02:50:16.497863
NCT00546299|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2007-10-17|2007-10-17|2007-10-18|Estimate|||||||2007-10-17|2007-10-18|Estimate|February 2003||2003-02-28|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Gas Usage for Those With COPD Who Experience Low Oxygen Levels During Activities Only|Ambulatory Gas Usage in Patients With COPD and Exertional Hypoxemia|Completed||N/A|27|Actual|West Park Healthcare Centre|||||f||||f||||||||||2018-06-01 02:50:16.573574|2018-06-01 02:50:16.573574
NCT00546286|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2017-03-31|2007-10-16|2007-10-18|Estimate|||||||2017-03-31|2017-04-04|Actual|May 31, 2006|Actual|2006-05-31|March 2017|2017-03-31|August 23, 2007|Actual|2007-08-23|August 23, 2007|Actual|2007-08-23||Interventional|||A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)|A 12 Week, Open-Label, Study to Evaluate the Effectiveness of Dorzolamide-Timolol as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH)|Completed||Phase 3|170|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:50:16.647677|2018-06-01 02:50:16.647677
NCT00546273|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2008-10-31||2009-05-14|2007-10-17|2007-10-18|Estimate|2009-03-24|2009-03-25|Estimate||||2009-05-14|2009-05-27|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Clinical Trial to Study 4 Different Doses of the Vaccine RUTI in Healthy Volunteers|Double-Blind, Randomized, Placebo-Controlled Phase I Study, to Study the Tolerability and Immunogenicity of 4 RUTI Antituberculous Vaccine Different Doses (5, 25, 100 y 200µg of FCMtb) in Healthy Volunteers|Completed||Phase 1|24|Actual|Germans Trias i Pujol Hospital||5|||f||||t||||||||||2018-06-01 02:50:16.751334|2018-06-01 02:50:16.751334
NCT00545792|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2013-06-14||2017-02-06|2007-10-15|2007-10-17|Estimate|2014-05-30|2014-07-02|Estimate||||2017-02-06|2017-03-15|Actual|May 2007||2007-05-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|November 2010|Actual|2010-11-30||Interventional||Modified intention to treat (ITT), i.e., include all subjects that received and completed treatment.|Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers|A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers|Completed||Phase 2|21|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 02:50:24.248375|2018-06-01 02:50:24.248375
NCT00546260|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2010-11-23||2010-12-28|2007-10-17|2007-10-18|Estimate|2010-12-28|2011-01-25|Estimate||||2010-12-28|2011-01-25|Estimate|November 2007||2007-11-30|December 2010|2010-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|ERASE-MI||Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI|Randomized Trial to Evaluate Effect of Adjunctive Antiplatelet Therapy With Intravenous PRT060128, a Selective P2Y12-Receptor Inhibitor, Before Primary Percutaneous Intervention (PCI) in ST-Elevation Myocardial Infarction (STEMI) Patients|Terminated||Phase 2|70|Actual|Portola Pharmaceuticals|Because Part II of the study was not completed and Part I had a small sample size, no conclusions could be drawn regarding efficacy.|2||Administrative reasons.|f||||t||||||||||2018-06-01 02:50:17.150021|2018-06-01 02:50:17.150021
NCT00546247|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17||2011-06-21|2015-09-23|2007-10-17|2007-10-18|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)|A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1)|Terminated||Phase 1/Phase 2|26|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 02:50:17.542957|2018-06-01 02:50:17.542957
NCT00546234|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2016-05-24|2007-10-16|2007-10-18|Estimate|||||||2016-05-24|2016-05-26|Estimate|November 2007||2007-11-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Tiotropium for Smoking Asthmatics Study|Assessing Treatment Options for Smokers With Asthma.|Withdrawn||Phase 4|0|Actual|University of Alberta||2||No subjects enrolled and no ongoing funding.|f||||f||||||||||2018-06-01 02:50:17.620045|2018-06-01 02:50:17.620045
NCT00546221|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2011-03-02|2007-10-17|2007-10-18|Estimate|||||||2011-03-02|2011-03-03|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Promoting Wellbeing for Women With Depression: A Pragmatic Randomised Controlled Trial (RCT) of an Exercise Programme|Pragmatic Randomised Controlled Trial of a Preferred Intensity Exercise Programme to Improve Physiological and Associated Psychological, Social, and Wellbeing Outcomes of Women Living With Depression|Completed||Phase 2|43|Actual|University of Nottingham||2|||f||||f||||||||||2018-06-01 02:50:17.710536|2018-06-01 02:50:17.710536
NCT00546208|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2008-03-13|2007-10-17|2007-10-18|Estimate|||||||2008-03-13|2008-03-17|Estimate|February 2008||2008-02-29|March 2008|2008-03-31||||||||Observational|ureterostomy||Unilateral Cutaneous Ureterostomy - Long Term Follow up|Bladder Function Following Temporary Unilateral Cutaneous Ureterostomy - Long Term Follow up|Unknown status|Recruiting||30|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 02:50:17.795329|2018-06-01 02:50:17.795329
NCT00546195|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2017-06-30|2007-10-17|2007-10-18|Estimate|||||||2017-06-30|2017-07-02|Actual|October 15, 2007||2007-10-15|March 29, 2011|2011-03-29|March 29, 2011||2011-03-29|||||Observational|||Infant Immune Response to Bacterial Infection|Expression Profiling of Bacterial Lipopolysaccharide Activated Neutrophil in Pre-Term, Term Infants and Adults|Completed|||45|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:50:17.861072|2018-06-01 02:50:17.861072
NCT00546182|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2007-10-17|2007-10-17|2007-10-18|Estimate|||||||2007-10-17|2007-10-18|Estimate|January 2004||2004-01-31|October 2007|2007-10-31||||||||Observational|||Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity|Phase 4 Study of Simvastatin That Affects Insulin Sensitivity|Completed|||||Gachon University Gil Medical Center|||||f||||t||||||||||2018-06-01 02:50:17.913395|2018-06-01 02:50:17.913395
NCT00546169|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2012-05-04|2007-10-17|2007-10-18|Estimate|||||||2012-05-04|2012-05-07|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)|Non-interventional Trial About Treatment of Haemorrhages in Cholecystectomy With TachoSil (TC-027-DE)|Completed|||500|Anticipated|Nycomed|||1||f||||t||||||||||2018-06-01 02:50:17.972123|2018-06-01 02:50:17.972123
NCT00546156|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2013-03-22||2013-03-22|2007-10-17|2007-10-18|Estimate|2013-03-22|2013-05-10|Estimate||||2013-03-22|2013-05-10|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer|A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer|Completed||Phase 2|104|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 02:50:18.056869|2018-06-01 02:50:18.056869
NCT00546143|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2010-09-01|2007-10-17|2007-10-18|Estimate|||||||2010-09-01|2010-09-02|Estimate|July 2007||2007-07-31|September 2010|2010-09-30||||August 2008|Actual|2008-08-31||Interventional|||Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma|Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab|Completed||Phase 4|32|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:50:18.48173|2018-06-01 02:50:18.48173
NCT00546130|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2008-09-02|2007-10-17|2007-10-18|Estimate|||||||2008-09-02|2008-09-03|Estimate|November 2007||2007-11-30|August 2008|2008-08-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|RNCLC||Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer|Feasibility Study for Multicenter Randomized Controlled Phase III Clinical Trial of Cisplatin + Irinotecan Therapy and Cisplatin + Irinotecan + Krestin Therapy for Extensive-Stage Disease (ED) Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|45|Anticipated|University of Toyama||1|||f||||t||||||||||2018-06-01 02:50:18.573003|2018-06-01 02:50:18.573003
NCT00546117|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2010-12-10||2018-02-10|2007-10-17|2007-10-18|Estimate|2010-12-10|2011-01-11|Estimate||||2018-02-10|2018-03-09|Actual|October 2007||2007-10-31|February 2018|2018-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion|A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion|Completed||N/A|16|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 02:50:18.722772|2018-06-01 02:50:18.722772
NCT00546104|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2013-01-22||2013-07-15|2007-10-16|2007-10-18|Estimate|2013-07-15|2013-07-17|Estimate||||2013-07-15|2013-07-17|Estimate|October 2007||2007-10-31|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Phase II Dasatinib Study in Advanced Breast Cancer|A Phase II Trial of Dasatinib to Treat Women With Stage IV or Inoperable Stage III Advanced Breast Cancer|Completed||Phase 2|31|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:50:18.964735|2018-06-01 02:50:18.964735
NCT00546091|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2017-10-05|2007-10-17|2007-10-18|Estimate|||||||2017-10-05|2017-10-06|Actual|October 15, 2007||2007-10-15|October 19, 2012|2012-10-19|October 19, 2012||2012-10-19|||||Observational|||Calibrating Imaging Techniques to Study Blood Flow|Calibration of Non-Invasive Non-Ionizing Imaging Techniques to Study Vasculature of Healthy Volunteers|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:50:19.323634|2018-06-01 02:50:19.323634
NCT00546078|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2009-11-12||2016-10-06|2007-10-17|2007-10-18|Estimate|2009-11-12|2009-12-15|Estimate||||2016-10-06|2016-11-09|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America|Safety and Immunogenicity Study of an Additional Dose of HPV Vaccine (580299) in Young, Adult Women in North America.|Completed||Phase 2|116|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:50:19.428101|2018-06-01 02:50:19.428101
NCT00546065|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2011-11-25|2007-10-17|2007-10-18|Estimate|||||||2011-11-25|2011-11-29|Estimate|August 2006||2006-08-31|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|APE||APE-Study: Ablation of Barrett's Mucosa vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs. Placebo for Symptomatic Reflux Control After Successful Barrett's Ablation|APE-Study: Tumor-free Survival After Ablation of Barrett's Mucosa Plus Esomeprazole vs. Surveillance Without Ablation in Patients Cured From Barrett's Cancer Combined With Randomization of Esomeprazole vs Placebo for Symptomatic Reflux Control After Successful Ablation of Barrett's Mucosa|Terminated||N/A|68|Actual|HSK Wiesbaden||2||"Intermediate results have shown a significant difference in the outcome of ablation and~   non-ablation patients. Therefore, the study was stopped."|f||||t||||||||||2018-06-01 02:50:20.190207|2018-06-01 02:50:20.190207
NCT00546052|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|2009-01-08||2017-03-31|2007-10-17|2007-10-18|Estimate|2009-05-04|2009-06-23|Estimate||||2017-03-31|2017-05-05|Actual|September 1, 2005|Actual|2005-09-01|March 2017|2017-03-31|January 1, 2008|Actual|2008-01-01|January 1, 2008|Actual|2008-01-01||Interventional|||A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)|52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome|Completed||Phase 3|1738|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:50:20.286933|2018-06-01 02:50:20.286933
NCT00546039|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2008-09-29|2007-10-17|2007-10-18|Estimate|||||||2008-09-29|2008-09-30|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|January 2009|Anticipated|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer|Effects of Synthetic Genistein Supplementation on Blood and Tissue Biomarkers in Patients With Localized Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|47|Actual|University Hospital, Aker||2|||f||||t||||||||||2018-06-01 02:50:20.748757|2018-06-01 02:50:20.748757
NCT00546026|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2007-10-17|2007-10-17|2007-10-18|Estimate|||||||2007-10-17|2007-10-18|Estimate||||October 2007|2007-10-31||||||||Interventional|||Does Mid-Gestation Placental Function Assessment Reduce Psychological Distress in Women With High-Risk Pregnancies?|Does Mid-Gestation Placental Function Assessment Reduce Psychological Distress in Women With High-Risk Pregnancies?|Unknown status|Not yet recruiting|Phase 1|160|Anticipated|Mount Sinai Hospital, Canada||1|||f||||f||||||||||2018-06-01 02:50:20.838944|2018-06-01 02:50:20.838944
NCT00546013|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2007-10-17|2007-10-17|2007-10-18|Estimate|||||||2007-10-17|2007-10-18|Estimate|December 2001||2001-12-31|October 2007|2007-10-31|July 2002|Actual|2002-07-31|||||Observational|||Abdominal Aortic Aneurysms and Pseudoexfoliation Syndrome|Abdominal Aortic Aneurysms Are Associated With Pseudoexfoliation Syndrome|Terminated|||208|Actual|European Georges Pompidou Hospital|||1|all patients required included|f||||f||||||||||2018-06-01 02:50:20.906026|2018-06-01 02:50:20.906026
NCT00546000|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2014-06-25||2014-06-25|2007-10-16|2007-10-18|Estimate|2014-06-25|2014-07-24|Estimate||||2014-06-25|2014-07-24|Estimate|July 2007||2007-07-31|June 2014|2014-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cutivate Lotion HPA Axis Pediatric Study|A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population|Completed||Phase 4|56|Actual|Fougera Pharmaceuticals Inc.||1|||f||||f||||||||||2018-06-01 02:50:20.970904|2018-06-01 02:50:20.970904
NCT00545987|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2011-05-04|2007-10-17|2007-10-18|Estimate|||||||2011-05-04|2011-05-05|Estimate|September 2007||2007-09-30|May 2011|2011-05-31|April 2011|Actual|2011-04-30|October 2009|Actual|2009-10-31||Interventional|ADVAX-EP||Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers|Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/N-t, by Ichor TriGrid™ in Vivo Electroporation to HIV-Uninfected, Healthy Volunteers|Completed||Phase 1|40|Anticipated|Rockefeller University||2|||f||||t||||||||||2018-06-01 02:50:21.167437|2018-06-01 02:50:21.167437
NCT00545974|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2013-04-22||2013-12-13|2007-10-17|2007-10-18|Estimate|2013-12-13|2014-02-05|Estimate||||2013-12-13|2014-02-05|Estimate|October 2007||2007-10-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia|A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia|Completed||Phase 4|81|Actual|University of California, San Francisco|Lower enrollment than planned may have limited ability detect a treatment effect; Small size of semantic dementia group limits generalizability of results to FTD syndrome;Newer tools have been developed to better capture FTD-specific behaviors.|2|||f||||t||||||||||2018-06-01 02:50:21.247264|2018-06-01 02:50:21.247264
NCT00545961|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-17|||2007-10-18|2007-10-17|2007-10-18|Estimate|||||||2007-10-18|2007-10-19|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Middle Meatal Bacteriology During Acute Respiratory Infection in Children|Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Oulu University Hospital||2|||f||||f||||||||||2018-06-01 02:50:21.730726|2018-06-01 02:50:21.730726
NCT00545779|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2016-07-19||2016-09-09|2007-10-16|2007-10-17|Estimate|2016-09-09|2016-10-28|Estimate||||2016-09-09|2016-10-28|Estimate|December 2006||2006-12-31|September 2016|2016-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Analysis population included all enrolled participants in Part A who provided the baseline information.|BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.|'Open, Prospective, Multi-center, Two-part Study of Patient Preference With Monthly Ibandronate Therapy in Women With Postmenopausal Osteoporosis Switched From Once-daily or Once Weekly Alendronate or Risendronate - BONCURE (BONviva for Current Bisphosphonate Users - Regional European Trial)'|Completed||Phase 3|677|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:50:24.566722|2018-06-01 02:50:24.566722
NCT00545948|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2014-05-07||2014-06-25|2007-10-17|2007-10-18|Estimate|2014-05-07|2014-06-09|Estimate||||2014-06-25|2014-07-21|Estimate|December 2007||2007-12-31|June 2014|2014-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|TOP0703|One patient in each of the vinorelbine and pemetrexed arms did not undergo protocol-based treatment, resulting in 22 total patients who were treated with either vinorelbine or pemetrexed. These two enrolled patients who were not administered treatment were added to the 7 original screen failures.|Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer|Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy|Terminated||Phase 2|31|Actual|Duke University||2||Study terminated due to reproducibility issues with genomics prediction model.|f||||t||||||||||2018-06-01 02:50:21.86581|2018-06-01 02:50:21.86581
NCT00545935|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2009-02-02|2007-10-16|2007-10-17|Estimate|||||||2009-02-02|2009-02-03|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|October 2007||2007-10-31|||||Interventional|||Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso|Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso: RCT in the Frame of the A8 Project of SFB 544|Completed||Phase 2|186||Heidelberg University||3|||f||||||||||||||2018-06-01 02:50:22.545001|2018-06-01 02:50:22.545001
NCT00545922|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2007-11-14|2007-10-16|2007-10-17|Estimate|||||||2007-11-14|2007-11-16|Estimate|April 2005||2005-04-30|October 2007|2007-10-31|November 2007|Actual|2007-11-30|||||Interventional|||Cognitive Behavioral Therapy for Anxiety and Depression in COPD|Cognitive Behavior Therapy for Anxiety and Depression for Patients With Chronic Obstructive Pulmonary Disease (COPD): A Randomized, Controlled Clinical Trial in an Outpatient Pulmonary Clinic.|Completed||Phase 2|51|Actual|University of Bergen||2|||f||||f||||||||||2018-06-01 02:50:22.629828|2018-06-01 02:50:22.629828
NCT00545909|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2016-11-01|2007-10-16|2007-10-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2006||2006-03-31|November 2016|2016-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis|A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis.|Completed||Phase 4|585|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:50:22.722095|2018-06-01 02:50:22.722095
NCT00545896|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2011-07-15|2007-10-16|2007-10-17|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Extracorporeal Shockwave Treatment for Chronic Soft Tissue Wounds|Safety and Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Chronic Soft Tissue Wounds|Completed||Phase 2|282|Actual|AUVA|||||f||||f||||||||||2018-06-01 02:50:22.891269|2018-06-01 02:50:22.891269
NCT00545883|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2012-01-25|2007-10-16|2007-10-17|Estimate|||||||2012-01-25|2012-01-26|Estimate|June 2006||2006-06-30|January 2012|2012-01-31|March 2008|Actual|2008-03-31|||||Observational|Alegria||Impact of GERD on Daily Life (NIS)|An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life of GERD in Patients With Erosive Gastroesophageal Reflux Disease.|Completed|||2001|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:50:23.003589|2018-06-01 02:50:23.003589
NCT00545870|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2015-04-14|2007-10-16|2007-10-17|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2008||2008-06-30|April 2015|2015-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Bevacizumab Versus Ranibizumab for Diabetic Retinopathy|A Randomized, Double-masked Study With Intraocular Bevacizumab Compared With Intravitreal Ranibizumab in Patients With Persistent Diabetic Macular Edema or Persistent Active Neovascularisation Following Lasercoagulation|Completed||Phase 3|30|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:50:23.235081|2018-06-01 02:50:23.235081
NCT00545857|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2012-05-30|2007-10-16|2007-10-17|Estimate|||||||2012-05-30|2012-05-31|Estimate|June 2002||2002-06-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus|Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus|Completed||Phase 1|15|Actual|Stony Brook University||2|||f||||t||||||||||2018-06-01 02:50:23.304746|2018-06-01 02:50:23.304746
NCT00545844|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2008-12-19||2017-09-14|2007-10-16|2007-10-17|Estimate|2009-07-07|2009-08-19|Estimate||||2017-09-14|2017-10-16|Actual|April 1, 2007|Actual|2007-04-01|September 2017|2017-09-30|January 1, 2008|Actual|2008-01-01|January 1, 2008|Actual|2008-01-01||Interventional|||Singulair(R) In Asthma And Allergic Rhinitis (0476-383)|An 8 Week Study to Evaluate the Effectiveness of Adding Montelukast to Inhaled Corticosteroid (ICS) to the ICS/Long-Acting Beta 2-Agonist Therapy in Adult Subjects With Asthma and Allergic Rhinitis|Completed||Phase 4|313|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:50:23.634651|2018-06-01 02:50:23.634651
NCT00545831|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2013-03-04|2007-10-16|2007-10-17|Estimate|||||||2013-03-04|2013-03-05|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|Nutrilock||Effect of Taurolidin on Prevention of Bloodstream Infection|Prevention of Central Veinous Device Related Sepsis Relapse With Taurolidine in Patients on Parenteral Nutrition in Long-term Home|Terminated||N/A|39|Actual|University Hospital, Rouen||2||lack of recruitment|f||||f||||||||||2018-06-01 02:50:23.967742|2018-06-01 02:50:23.967742
NCT00545818|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2017-08-21|2007-10-16|2007-10-17|Estimate|||||||2017-08-21|2017-08-22|Actual|November 2007||2007-11-30|August 2017|2017-08-31||||June 2016|Actual|2016-06-30||Interventional|||Study Comparing OsseoSpeed™ Implants of Two Different Lengths in the Upper and Lower Posterior Jaw|An Open, Prospective, Randomized, Multi-center Study Comparing OsseoSpeed™ Implant 6 mm With OsseoSpeed™ Implant 11 mm in the Posterior Maxilla and Mandible. A 5-year Follow-up Study.|Completed||N/A|97|Actual|Dentsply Sirona Implants||2|||f||||f||||||||||2018-06-01 02:50:24.042114|2018-06-01 02:50:24.042114
NCT00545805|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2013-02-17|2007-10-16|2007-10-17|Estimate|||||||2013-02-17|2013-02-20|Estimate|October 2005||2005-10-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Surgical Removal of Visceral Fat Tissue (Omentectomy) Associated to Bariatric Surgery: Effects on Insulin Sensitivity|Effects of the Surgical Removal of Visceral Fat Tissue (Omentectomy) on Insulin Sensitivity in Grade III Obese Volunteers Subjected to Bariatric Surgery|Completed||Phase 2/Phase 3|20|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-06-01 02:50:24.120611|2018-06-01 02:50:24.120611
NCT00545766|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2013-02-25||2016-03-10|2007-10-15|2007-10-17|Estimate|2013-02-25|2013-04-04|Estimate||||2016-03-10|2016-04-08|Estimate|May 2007||2007-05-31|March 2016|2016-03-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Vinflunine in Hormone Refractory Prostate Cancer (HRPC)|A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)|Completed||Phase 2|41|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:50:24.918509|2018-06-01 02:50:24.918509
NCT00545753|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2012-08-02||2012-09-10|2007-10-15|2007-10-17|Estimate|2012-09-10|2012-10-11|Estimate||||2012-09-10|2012-10-11|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice|A Phase 3 Comparative Safety and Efficacy Study Between NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects >6 Months of Age or Older With Pediculosis Capitis|Completed||Phase 3|558|Actual|ParaPRO LLC||3|||f||||f||||||||||2018-06-01 02:50:25.168224|2018-06-01 02:50:25.168224
NCT00545740|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2012-12-19||2014-06-06|2007-10-16|2007-10-17|Estimate|2012-12-19|2013-01-25|Estimate||||2014-06-06|2014-06-12|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|PREVENT1||Prevention of Recurrence of Diverticulitis|A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.|Completed||Phase 3|590|Actual|Shire||4|||f||||f||||||||||2018-06-01 02:50:25.645872|2018-06-01 02:50:25.645872
NCT00545727|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2007-10-16|2007-10-16|2007-10-17|Estimate|||||||2007-10-16|2007-10-17|Estimate|July 2006||2006-07-31|September 2007|2007-09-30|August 2006|Actual|2006-08-31|||||Interventional|||Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes|Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes|Completed||N/A|36|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-06-01 02:50:27.179437|2018-06-01 02:50:27.179437
NCT00545714|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2016-11-01|2007-10-16|2007-10-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)|Multicentre, Non-randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Induction Treatment With Rituximab, Fludarabine, Cyclophosphamide, Followed by Rituximab Maintenance Therapy (R-Fc-Rm) in the First Line Treatment of Chronic Lymphocytic Leukaemia|Completed||Phase 2|90|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:50:27.310827|2018-06-01 02:50:27.310827
NCT00545701|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2014-01-10|2007-10-15|2007-10-17|Estimate|||||||2014-01-10|2014-01-14|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults||Completed||Phase 2|100|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:50:27.441366|2018-06-01 02:50:27.441366
NCT00545688|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2015-12-16||2017-07-05|2007-10-16|2007-10-17|Estimate|2015-12-16|2016-01-26|Estimate||||2017-07-05|2017-08-15|Actual|June 26, 2006|Actual|2006-06-26|July 2017|2017-07-31|September 22, 2014|Actual|2014-09-22|September 22, 2014|Actual|2014-09-22||Interventional||Intent-To-Treat (ITT) Population included all randomized participants who received any amount of study medication. Analysis was performed according to initial randomization.|A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.|A Randomized, Open Label Study to Compare the Complete Pathological Response Rate Achieved With 4 Combinations of Herceptin, Docetaxel and Pertuzumab in Patients With Locally Advanced, Inflammatory or Early Stage HER2 Positive Breast Cancer|Completed||Phase 2|417|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 02:50:27.572715|2018-06-01 02:50:27.572715
NCT00545675|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2010-08-10|2007-10-16|2007-10-17|Estimate|||||||2010-08-10|2010-08-12|Estimate|December 2007||2007-12-31|December 2009|2009-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SMART-M||Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness|Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote|Completed||Phase 4|146|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:50:29.138058|2018-06-01 02:50:29.138058
NCT00545662|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2011-11-29||2012-11-16|2007-10-16|2007-10-17|Estimate|2012-11-16|2012-12-19|Estimate||||2012-11-16|2012-12-19|Estimate|July 2007||2007-07-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|COBRIT||Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)|Citicoline Brain Injury Treatment Trial|Terminated||Phase 3|1213|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2||Trial stopped due to futility.|f||||t||||||||||2018-06-01 02:50:29.318849|2018-06-01 02:50:29.318849
NCT00545649|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2007-10-16|2007-10-16|2007-10-17|Estimate|||||||2007-10-16|2007-10-17|Estimate|May 2004||2004-05-31|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Development of Treatments Aiming at Improvement of Function in Patients With Chronic Widespread Pain|Development of Treatments Aiming at Improvement of Function in Patients With Chronic Widespread Pain|Completed||N/A|164|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 02:50:29.7027|2018-06-01 02:50:29.7027
NCT00545636|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2012-06-07|2007-10-16|2007-10-17|Estimate|||||||2012-06-07|2012-06-08|Estimate|March 2008||2008-03-31|June 2012|2012-06-30||||March 2009|Anticipated|2009-03-31||Interventional|||The Influence of Education of Medical Team on Duration of Fasting Before Elective Medical Interventions Performed Under General Anesthesia in Children|The Influence of Education of Medical Team on Duration of Fasting Before Elective Medical Interventions Performed Under General Anesthesia in Children|Withdrawn||N/A|0|Actual|Sheba Medical Center||||unfortunately lacked manpower to carry out the study|f||||f||||||||||2018-06-01 02:50:29.78386|2018-06-01 02:50:29.78386
NCT00545623|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2014-07-25||2014-08-31|2007-10-16|2007-10-17|Estimate|2014-08-31|2014-09-03|Estimate||||2014-08-31|2014-09-03|Estimate|April 2007||2007-04-30|August 2014|2014-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||A total of 15 patients did not start the intervention after enrollment, 1, 4, 6, and 4 patients in ACUP+RR, SHAM+RR, ACUP+EDU, and SHAM+EDU arms respectively. As such there are a total of 115 patients with baseline data.|Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence|Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence|Completed||Phase 2|130|Actual|Boston University||4|||f||||f||||||||||2018-06-01 02:50:30.060523|2018-06-01 02:50:30.060523
NCT00545610|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2017-10-19|2007-10-16|2007-10-17|Estimate|||||||2017-10-19|2017-10-23|Actual|October 2007||2007-10-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Observational|||ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)|A 12-Month Follow-Up Study to Protocol 24779 (A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia [ACT34-CMI])|Completed|||150|Anticipated|Shire|||3||f||||f||||||||||2018-06-01 02:50:30.595579|2018-06-01 02:50:30.595579
NCT00172952|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|January 2006||2006-01-31|||||Observational|||The Role of SNP of ECM and MMP on the Development of Pathological High Myopia|National Taiwan University Hospital|Unknown status|Recruiting||600||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.419744|2018-06-01 04:38:14.419744
NCT00545597|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2012-03-01|2007-10-16|2007-10-17|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2005||2005-03-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy|A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy|Terminated||Phase 3|240|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||||Upon recommendation of DSMB|f||||t||||||||||2018-06-01 02:50:30.846076|2018-06-01 02:50:30.846076
NCT00545584|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2011-04-19|2010-11-18|2017-04-07|2007-10-16|2007-10-17|Estimate|2011-04-19|2011-05-11|Estimate|2011-02-17|2011-03-08|Estimate|2017-04-07|2017-05-12|Actual|April 1, 2007|Actual|2007-04-01|April 2017|2017-04-30|November 19, 2009|Actual|2009-11-19|November 19, 2009|Actual|2009-11-19||Interventional|||Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)|Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy|Completed||Phase 3|1512|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:50:30.930366|2018-06-01 02:50:30.930366
NCT00545571|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2016-04-12||2016-05-19|2007-10-16|2007-10-17|Estimate|2016-04-12|2016-05-18|Estimate||||2016-05-19|2016-06-24|Estimate|October 2007||2007-10-31|May 2016|2016-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Intent-to-Treat (ITT) Population: All participants who received at least one dose of study drug and for whom data were available from at least one follow-up variable.|MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia|A Single Arm, Open Label, Interventional Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Hemoglobin Levels in Hemodialysis Patients With Chronic Renal Anemia|Completed||Phase 3|120|Actual|Hoffmann-La Roche|The Study was prematurely terminated in Austria as a consequence of Mircera reimbursement denial. However, the Study completed regularly in Switzerland and the overall status of the Study is considered completed.|1|||f||||||||||||||2018-06-01 02:50:31.722004|2018-06-01 02:50:31.722004
NCT00545558|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2014-08-08|2007-10-15|2007-10-17|Estimate|||||||2014-08-08|2014-08-12|Estimate|April 2006||2006-04-30|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|ART and HCV||Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV|Antiretroviral Therapy and the Hepatitis C Virus|Completed||Phase 1|18|Actual|University of Cincinnati||1|||f||||f||||||||||2018-06-01 02:50:32.520012|2018-06-01 02:50:32.520012
NCT00545545|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2010-03-30|2007-10-16|2007-10-17|Estimate|||||||2010-03-30|2010-03-31|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma|A Phase 1b, Safety, PK, and Efficacy, Multicenter, Dose-Escalating Study of Imprime PGG in Combination With Cetuximab With and Without Irinotecan Therapy in Patients With Recurrent/Progressive Colorectal Carcinoma Following Treatment With a 5-FU Regimen.|Completed||Phase 1/Phase 2|48|Anticipated|Biothera||6|||f||||t||||||||||2018-06-01 02:50:32.689508|2018-06-01 02:50:32.689508
NCT00545532|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2017-06-20|2007-10-16|2007-10-17|Estimate|||||||2017-06-20|2017-06-21|Actual|February 4, 2008|Actual|2008-02-04|June 2017|2017-06-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.|A Double-blind, Randomized, Stratified Multi-center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza|Completed||Phase 3|225|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-06-01 02:50:32.882506|2018-06-01 02:50:32.882506
NCT00545519|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2013-04-22|2007-10-16|2007-10-17|Estimate|||||||2013-04-22|2013-04-23|Estimate|October 2006||2006-10-31|April 2013|2013-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma|A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma|Completed||Phase 1|6|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 02:50:33.595557|2018-06-01 02:50:33.595557
NCT00545506|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2010-07-22||2010-08-30|2007-10-16|2007-10-17|Estimate|2010-08-30|2010-09-21|Estimate||||2010-08-30|2010-09-21|Estimate|November 2007||2007-11-30|August 2010|2010-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||The Influence of a Warmed Surgical Bandage System on Subcutaneous Tissue Oxygen Tension After Cardiac Surgery|The Influence of a Warmed Surgical Bandage System on Subcutaneous Tiisue Oxygen Tension After Cardiac Surgery|Terminated||Phase 3|3|Actual|Medical University of Vienna|Tissue oxygen tension maybe difficult to measure in the sternal wound|2||lack of eligible patients|f||||t||||||||||2018-06-01 02:50:33.796319|2018-06-01 02:50:33.796319
NCT00545493|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2009-04-09|2007-10-16|2007-10-17|Estimate|||||||2009-04-09|2009-04-10|Estimate|November 2002||2002-11-30|April 2009|2009-04-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis|Efficacy of Tacrolimus and i.v.-Immunoglobulins in Rasmussen Encephalitis With Start of Treatment in the Acute Disease Stage. Prospective, Randomised, Open Parallel Group Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|16|Anticipated|University Hospital, Bonn||2|||f||||f||||||||||2018-06-01 02:50:34.288288|2018-06-01 02:50:34.288288
NCT00545480|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2015-08-17|2007-10-16|2007-10-17|Estimate|||||||2015-08-17|2015-08-18|Estimate|July 2006||2006-07-31|August 2015|2015-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.|A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.|Completed||Phase 4|596|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:50:34.790317|2018-06-01 02:50:34.790317
NCT00545467|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2012-05-16|2007-10-15|2007-10-17|Estimate|||||||2012-05-16|2012-05-17|Estimate|August 2007||2007-08-31|January 2012|2012-01-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents|Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents: Combination of Pharmacogenomics and Therapeutic Drug Monitoring|Completed||Phase 4|79|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 02:50:35.09775|2018-06-01 02:50:35.09775
NCT00544583|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2010-01-26|2007-10-15|2007-10-16|Estimate|||||||2010-01-26|2010-01-27|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|April 2012|Anticipated|2012-04-30|April 2011|Anticipated|2011-04-30||Interventional|CONTINT||Continuous Versus Interrupted Abdominal Wall Closure After Emergency Midline Laparotomy|Continuous Versus Interrupted Abdominal Wall Closure After Emergency Midline Laparotomy: CONTINT - A Randomized Controlled Study|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-06-01 02:50:58.679016|2018-06-01 02:50:58.679016
NCT00545454|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16||2017-08-04|2017-08-04|2007-10-16|2007-10-17|Estimate||||2017-08-04|2017-08-08|Actual|2017-08-04|2017-08-08|Actual|October 2007||2007-10-31|August 2017|2017-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|ACCORD-RA||Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis|Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis (RA): A 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of 90 µg Administered Once Daily and 90 µg Once Every Other Day|Completed||Phase 2|79|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 02:50:35.321587|2018-06-01 02:50:35.321587
NCT00545441|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2014-10-24||2014-12-02|2007-10-16|2007-10-17|Estimate|2014-10-24|2014-10-29|Estimate||||2014-12-02|2014-12-17|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Surgisis® AFP|Patients that were not treated were not included in the analysis. There was 1 patient in the Surgisis arm and 3 patients in the Flap arm that were not treated.|A Randomized Clinical Trial Comparing Surgisis AFP to Advancement Flap for the Repair of Anal Fistulas|A Randomized Clinical Trial Comparing Surgisis AFP to Advancement Flap for the Repair of Anal Fistulas|Completed||N/A|86|Actual|Cook Group Incorporated||2|||f||||f||||||||||2018-06-01 02:50:35.523935|2018-06-01 02:50:35.523935
NCT00545428|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2009-02-03|2007-10-16|2007-10-17|Estimate|||||||2009-02-03|2009-02-04|Estimate|April 2006||2006-04-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Mastoid Bone Autograft for Dorsal Nasal Augmentation|Mastoid Bone Autograft for Dorsal Nasal Augmentation|Completed||N/A|15|Actual|Federal University of Uberlandia||1|||f||||f||||||||||2018-06-01 02:50:35.951307|2018-06-01 02:50:35.951307
NCT00545415|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2017-02-22|2007-10-16|2007-10-17|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2008||2008-01-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||The Effect of Fruit and Fruit Juice on Plasma Total Antioxidant Capacity|The Effect of Fruit and Fruit Juice on Plasma Total Antioxidant Capacity|Completed||N/A|24|Actual|Maastricht University Medical Center||6|||f||||f||||||||||2018-06-01 02:50:36.101787|2018-06-01 02:50:36.101787
NCT00545402|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2014-06-09||2014-06-09|2007-10-16|2007-10-17|Estimate|2014-06-09|2014-07-14|Estimate||||2014-06-09|2014-07-14|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Intent to treat (ITT) population includes all randomized participants who received at least 1 dose of MMF.|A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.|A Randomized, Open Label Study Comparing the Effect of CellCept With Therapeutic Drug Monitoring, Tacrolimus and a Corticosteroid-sparing Regimen Versus Fixed Dose CellCept, Tacrolimus and Corticosteroids Maintained up to 6 Months, on Acute Rejection and Safety in Liver Transplant Patients.|Completed||Phase 4|180|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|2|||f||||||||||||||2018-06-01 02:50:36.360725|2018-06-01 02:50:36.360725
NCT00545389|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2009-06-18|2007-10-16|2007-10-17|Estimate|||||||2009-06-18|2009-06-19|Estimate|February 2003||2003-02-28|November 2007|2007-11-30|October 2004|Actual|2004-10-31|||||Interventional|||Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476|A Phase II, Randomized, Multi-Centre, Double-Blind, Parallel-Group, Dose-Ranging, Exploratory Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (Mesalazine) Once Daily|Completed||Phase 2|38|Actual|Shire|||||f||||||||||||||2018-06-01 02:50:38.027601|2018-06-01 02:50:38.027601
NCT00545376|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2008-02-11|2007-10-16|2007-10-17|Estimate|||||||2008-02-11|2008-02-13|Estimate|October 2007||2007-10-31|September 2007|2007-09-30|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Effect of OMT on Asthma Symptoms in Southwest Virginia|The Use of Osteopathic Manipulation in a Clinic and Home Setting to Address Pulmonary Distress as Related to Asthma in Southwest Virginia|Completed||N/A|32|Actual|Edward Via Virginia College of Osteopathic Medicine||3|||f||||t||||||||||2018-06-01 02:50:38.281042|2018-06-01 02:50:38.281042
NCT00545363|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2016-07-02||2016-08-31|2007-10-16|2007-10-17|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|April 2006||2006-04-30|August 2016|2016-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||Safety population included participants who received at least 1 dose of study drug.|A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)|A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program|Completed||Phase 4|716|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:50:38.606854|2018-06-01 02:50:38.606854
NCT00545350|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2014-04-02|2007-10-16|2007-10-17|Estimate|||||||2014-04-02|2014-04-03|Estimate|November 2007||2007-11-30|May 2012|2012-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Ossébo||Exercise Intervention to Prevent Fall-related Fractures and Other Injuries : The Ossébo Study|Randomized Controlled Trial of Prevention of Fall-related Fractures and Other Injuries by Physical Exercise Among Community Dwelling Elderly Women|Completed||N/A|706|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:50:40.109434|2018-06-01 02:50:40.109434
NCT00545337|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2009-10-15|2007-10-15|2007-10-17|Estimate|||||||2009-10-15|2009-10-16|Estimate|September 2004||2004-09-30|October 2009|2009-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Glulisine + Lantus in Type I Patients|26-week, International Multicenter, Open, Non-randomized Phase III Clinical Trial for Evaluation of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Subjects With Type 1 Diabetes Mellitus Also Using Insulin Glargine|Completed||Phase 3|60|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:50:40.594338|2018-06-01 02:50:40.594338
NCT00545324|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2017-03-17|2007-10-16|2007-10-17|Estimate|||||||2017-03-17|2017-03-21|Actual|September 2002||2002-09-30|March 2017|2017-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|FIRST||First Step With Singulair® Therapy (0476-323)|"A 12 Week Multicenter, Open-Label, Randomized, Observational Study Comparing Singulair® 10 Mg As Controller Monotherapy In Adults With Mild Asthma To Low Dose Inhaled Corticosteroid Treatment"|Completed||Phase 4|399|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:50:40.699692|2018-06-01 02:50:40.699692
NCT00545311|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2007-12-27|2007-10-15|2007-10-17|Estimate|||||||2007-12-27|2008-01-08|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Inhaled NVA237 Doses at Four Dose Levels in COPD Patients|Completed||Phase 1|40|Actual|Novartis||5|||f||||f||||||||||2018-06-01 02:50:40.771772|2018-06-01 02:50:40.771772
NCT00545298|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2012-08-08||2012-10-18|2007-10-16|2007-10-17|Estimate|2012-10-18|2012-11-19|Estimate||||2012-10-18|2012-11-19|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers|An Investigation of the Topical Application of Gaseous Nitric Oxide on Safety and Efficacy in Venous Stasis Leg Ulcers of the Lower Extremities|Terminated||Phase 2|4|Actual|Nitric BioTherapeutics, Inc|Early termination due to small number of subjects enrolled|3||Strategic direction of the sponsor changed|f||||t||||||||||2018-06-01 02:50:41.082|2018-06-01 02:50:41.082
NCT00545285|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2017-05-02|2007-10-16|2007-10-17|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2007||2007-11-30|May 2017|2017-05-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|||Long-Term Multi-center Evaluation of E-Poly and Regenerex|Long-Term Multi-center Evaluation of E-Poly and Regenerex Cementless Acetabular Components: Clinical and Radiographic Outcomes|Active, not recruiting||N/A|1000|Anticipated|Massachusetts General Hospital||4|||f||||f||||||||||2018-06-01 02:50:42.142579|2018-06-01 02:50:42.142579
NCT00545272|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2012-11-12||2012-12-12|2007-10-16|2007-10-17|Estimate|2012-12-12|2013-01-18|Estimate||||2012-12-12|2013-01-18|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma|A Randomized, Multi-center, Parallel Group, Double Blind, Placebo and Formoterol Controlled 14 Day Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma|Completed||Phase 2|392|Actual|Novartis||6|||f||||||||||||||2018-06-01 02:50:42.569771|2018-06-01 02:50:42.569771
NCT00545259|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2011-04-08|2007-10-16|2007-10-17|Estimate|||||||2011-04-08|2011-04-11|Estimate|October 2007||2007-10-31|February 2008|2008-02-29||||February 2009|Actual|2009-02-28||Interventional|||Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation|An Open-label, Two-period, Multi-center, Single Dose Study to Assess the Pharmacokinetics of AEB071 in de Novo Liver Transplant Patients|Completed||Phase 1|13|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:50:44.138513|2018-06-01 02:50:44.138513
NCT00545246|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2013-10-12|2007-10-16|2007-10-17|Estimate|||||||2013-10-12|2013-10-16|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients|A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Docetaxel Administered Every 3 Weeks in Patients With Advanced Solid Malignancies|Completed||Phase 1|12|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:50:44.3488|2018-06-01 02:50:44.3488
NCT00545233|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2012-02-08||2012-04-10|2007-10-16|2007-10-17|Estimate|2012-04-10|2012-05-07|Estimate||||2012-04-10|2012-05-07|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.|A Randomized, Open-label Study of the Effect of PEGASYS ® Plus COPEGUS® With or Without Concomitant Pioglitazone (Actos®) on Early Viral Kinetics in Treatment-naive Patients With Chronic Hepatitis C, Genotype-1, and Insulin Resistance|Completed||Phase 4|155|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:50:44.798873|2018-06-01 02:50:44.798873
NCT00545220|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2016-02-17|2007-10-16|2007-10-17|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Problem Solving Training and Low Vision Rehabilitation|Problem Solving Training and Low Vision Rehabilitation|Completed||N/A|430|Actual|University of Alabama at Birmingham||2|||f||||||||||||||2018-06-01 02:50:47.090684|2018-06-01 02:50:47.090684
NCT00545207|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2017-01-25|2007-10-16|2007-10-17|Estimate|||||||2017-01-25|2017-01-26|Estimate||||January 2017|2017-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.|A Randomized, Double-blind Study of the Effect of Oral Monthly Bonviva on in Vivo Bone Micro-architecture Parameters in Post-menopausal Women With Osteopenia|Completed||Phase 3|150|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:50:47.310787|2018-06-01 02:50:47.310787
NCT00545194|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2007-10-16|2007-10-16|2007-10-17|Estimate|||||||2007-10-16|2007-10-17|Estimate|January 2002||2002-01-31|October 2007|2007-10-31|October 2004|Actual|2004-10-31|||||Interventional|||Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess|Randomized Study on Removable PGE2 Vaginal Insert Versus PGE2 Intravaginal Gel for Cervical Priming and Labour Induction in Term Pregnancy|Completed||Phase 3|446|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-06-01 02:50:47.474609|2018-06-01 02:50:47.474609
NCT00545181|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2009-12-02||2010-01-06|2007-10-16|2007-10-17|Estimate|2009-12-02|2010-01-07|Estimate||||2010-01-06|2010-01-12|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial|Recurrent Bacterial Vaginosis (RBV): Efficiency of Metronidazole in Comparison to Metronidazole and Intravaginal Acidifying Gel: A Randomized Investigator-blinded Controlled Trial|Completed||N/A|55|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 02:50:47.629322|2018-06-01 02:50:47.629322
NCT00545168|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2012-08-02||2012-09-10|2007-10-15|2007-10-17|Estimate|2012-09-10|2012-10-11|Estimate||||2012-09-10|2012-10-11|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice|A Phase 3 Comparative Safety and Efficacy Study Between NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects > 6 Months of Age With Pediculosis Capitis|Completed||Phase 3|480|Actual|ParaPRO LLC||3|||f||||f||||||||||2018-06-01 02:50:48.238952|2018-06-01 02:50:48.238952
NCT00545155|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2011-08-02||2015-05-22|2007-10-16|2007-10-17|Estimate|2012-08-23|2012-09-28|Estimate||||2015-05-22|2015-06-19|Estimate|June 2007||2007-06-30|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Screening and Interventions in an Acute Care Setting|Screening and Interventions in an Acute Care Setting|Completed|||187|Actual|University of Rochester|"administration of one measure was done by individuals not blinded to another, potentially improving the concurrent criterion validity results.~a number of subjects did not consent or could not consent to participate in the study."||1||f||||f||||||||||2018-06-01 02:50:48.648294|2018-06-01 02:50:48.648294
NCT00545142|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2010-06-24|2007-10-16|2007-10-17|Estimate|||||||2010-06-24|2010-06-25|Estimate|October 2007||2007-10-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|SMART-A||Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness|Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder|Completed||Phase 4|280|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||f||||||||||2018-06-01 02:50:48.898996|2018-06-01 02:50:48.898996
NCT00545129|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15||2013-01-10|2013-01-10|2007-10-16|2007-10-17|Estimate||||2013-01-10|2013-01-18|Estimate|2013-01-10|2013-01-18|Estimate|April 2009||2009-04-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone|Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy And Safety Study Of Tanezumab As Add-On Therapy To Opioid Medication In Patients With Pain Due To Bone Metastases|Completed||Phase 2|59|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:50:48.971241|2018-06-01 02:50:48.971241
NCT00545116|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2015-10-05|2007-10-16|2007-10-17|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women|Short-term Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women: a Randomized Placebo-controlled Trial|Completed||Phase 2|144|Actual|Nestlé||4|||f||||f||||||||||2018-06-01 02:50:49.091492|2018-06-01 02:50:49.091492
NCT00545103|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2012-10-11||2014-06-06|2007-10-16|2007-10-17|Estimate|2012-11-19|2012-12-19|Estimate||||2014-06-06|2014-06-12|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|PREVENT2||Prevention of Recurrence of Diverticulitis|A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 Versus Placebo Over 104 Weeks in the Prevention of Recurrence of Diverticulitis.|Completed||Phase 3|592|Actual|Shire||4|||f||||f||||||||||2018-06-01 02:50:49.219383|2018-06-01 02:50:49.219383
NCT00545090|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2016-11-08|2007-10-16|2007-10-17|Estimate|||||||2016-11-08|2016-11-10|Estimate|August 2006||2006-08-31|November 2016|2016-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.|An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva|Completed||Phase 4|561|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:50:50.380195|2018-06-01 02:50:50.380195
NCT00545077|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|||2015-05-18|2007-10-16|2007-10-17|Estimate|||||||2015-05-18|2015-05-19|Estimate|November 2007||2007-11-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer|Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment Compared to Endocrine Treatment Alone, in Postmenopausal Women With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line Treatment|Completed||Phase 3|378|Actual|Spanish Breast Cancer Research Group||2|||f||||t||||||||||2018-06-01 02:50:50.608939|2018-06-01 02:50:50.608939
NCT00545064|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2009-08-20||2017-05-25|2007-10-16|2007-10-17|Estimate|2010-01-05|2010-02-01|Estimate||||2017-05-25|2017-06-20|Actual|May 23, 2007|Actual|2007-05-23|May 2017|2017-05-31|September 15, 2008|Actual|2008-09-15|September 15, 2008|Actual|2008-09-15||Interventional|DISCOVER||Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)|A Multicenter, Open-Label Study To Evaluate The Tolerability Of Preservative Free Dorzolamide-Timolol Therapy In Patients Untreated With Open-Angle Glaucoma Or Ocular Hypertension And Dry Eye(s)|Completed||Phase 4|176|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:50:50.799881|2018-06-01 02:50:50.799881
NCT00545051|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-16|2016-04-05||2016-04-05|2007-10-16|2007-10-17|Estimate|2016-04-05|2016-05-12|Estimate||||2016-04-05|2016-05-12|Estimate|May 2006||2006-05-31|April 2016|2016-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||The intent-to-treat (ITT) population included all participants randomized and who had at least one follow up efficacy data time point available.|A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.|A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women|Completed||Phase 4|140|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:50:51.116397|2018-06-01 02:50:51.116397
NCT00545025|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2013-03-21|2009-05-20|2016-11-03|2007-10-15|2007-10-16|Estimate|2013-03-21|2013-05-07|Estimate|2009-09-28|2009-09-30|Estimate|2016-11-03|2016-12-16|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Revaccination With Influenza Vaccine GSK1247446A|Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656|Completed||Phase 2|243|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:50:51.631904|2018-06-01 02:50:51.631904
NCT00545012|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2013-09-16|2007-10-15|2007-10-16|Estimate|||||||2013-09-16|2013-09-17|Estimate|May 2000||2000-05-31|September 2009|2009-09-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures|A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)|Completed||Phase 2|4|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:50:52.110445|2018-06-01 02:50:52.110445
NCT00544999|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2013-09-16|2007-10-13|2007-10-16|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2007||2007-09-30|July 2009|2009-07-31||||April 2010|Anticipated|2010-04-30||Interventional|||Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia|Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse|Unknown status|Recruiting|Phase 1|21|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:50:52.167013|2018-06-01 02:50:52.167013
NCT00544986|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2013-01-29|2007-10-15|2007-10-16|Estimate|||||||2013-01-29|2013-01-30|Estimate|June 2005||2005-06-30|January 2013|2013-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer|A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer|Completed||Phase 4|||AstraZeneca|||||f||||f||||||||||2018-06-01 02:50:52.233074|2018-06-01 02:50:52.233074
NCT00544960|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12||2010-08-12|2010-08-24|2007-10-12|2007-10-16|Estimate||||2010-08-12|2010-08-17|Estimate|2010-08-24|2010-08-27|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer|A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|106|Actual|Ascenta Therapeutics||2|||f||||f||||||||||2018-06-01 02:50:52.296548|2018-06-01 02:50:52.296548
NCT00544947|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2009-02-03|2007-10-12|2007-10-16|Estimate|||||||2009-02-03|2009-02-04|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids for Caesarean Section|Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids: a Comparison Between Diamorphine and Fentanyl Combined With Postoperative Morphine PCA Using a Carbon Dioxide Tension and Pulse Oximetry Sensor (TOSCA)|Completed|||90|Actual|NHS Greater Clyde and Glasgow|||1||f||||f||||||||||2018-06-01 02:50:52.379156|2018-06-01 02:50:52.379156
NCT00544934|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2016-02-09|2007-10-15|2007-10-16|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2007||2007-02-28|February 2016|2016-02-29|October 2007|Actual|2007-10-31|||||Interventional|||Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects|A Dose-ranging Study to Evaluate the Safety, Metabolism and Therapeutic Dosing of Three Multiple Dose Levels of GLY-230 in Healthy and Diabetic Subjects|Completed||Phase 1/Phase 2|42|Actual|Glycadia||4|||f||||f||||||||||2018-06-01 02:50:52.434229|2018-06-01 02:50:52.434229
NCT00544921|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2016-02-09|2007-10-15|2007-10-16|Estimate|||||||2016-02-09|2016-02-10|Estimate|October 2005||2005-10-31|February 2016|2016-02-29|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects|Phase 1 Study of Anti-glycation Agent GLY-230|Completed||Phase 1|54|Actual|Glycadia||7|||f||||f||||||||||2018-06-01 02:50:52.48445|2018-06-01 02:50:52.48445
NCT00544908|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|2015-08-19||2015-09-18|2007-10-13|2007-10-16|Estimate|2015-08-19|2015-09-17|Estimate||||2015-09-18|2015-10-05|Estimate|September 2007||2007-09-30|September 2015|2015-09-30||||October 2012|Actual|2012-10-31||Interventional|||Dasatinib in Treating Patients With Stage IV Pancreatic Cancer|A Phase II Clinical Trial of Dasatinib in Patients With Metastatic Pancreatic Cancer|Terminated||Phase 2|7|Actual|City of Hope Medical Center|Study was terminated early due to toxicity.|1||Toxicity|f||||||||||||||2018-06-01 02:50:52.552044|2018-06-01 02:50:52.552044
NCT00544895|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2011-06-22|2007-10-15|2007-10-16|Estimate|||||||2011-06-22|2011-06-23|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|||||Observational|NEOBRAIN||Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants|Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants|Completed|||600|Anticipated|Hannover Medical School|||||f||||f||||||Samples With DNA|"~     whole blood, urine~   "|||2018-06-01 02:50:52.878168|2018-06-01 02:50:52.878168
NCT00544882|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|2014-05-08|2011-06-08|2016-08-04|2007-10-12|2007-10-16|Estimate|2014-05-08|2014-06-10|Estimate|2011-06-08|2011-06-22|Estimate|2016-08-04|2016-09-29|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||The Intent-to-treat (ITT) cohort consisted of all randomized participants who took at least one dose of randomized study medication and had at least one post-baseline efficacy measurement for at least one of the primary efficacy endpoints (FSH, inhibin-B, or estradiol).|A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021|A Prospective, Multicenter, Randomized, Double-Blind Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With the Oral Contraceptive Regimen DR-1021|Completed||Phase 3|61|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 02:50:53.004829|2018-06-01 02:50:53.004829
NCT00544869|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2013-11-05||2013-12-24|2007-10-15|2007-10-16|Estimate|2013-12-24|2014-01-30|Estimate||||2013-12-24|2014-01-30|Estimate|October 2007||2007-10-31|December 2013|2013-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||"1 Subject of Arm Continued at 15 mg/day was excluded from analysis because of GCP incompliance"|A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)|Phase 3 Open-label, Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure) — an Investigation of the Safety of Treatment Beyond 7 Days and the Effect of Dose Escalation to 30 mg|Completed||Phase 3|52|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 02:50:53.654777|2018-06-01 02:50:53.654777
NCT00544856|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2009-01-28|2007-10-12|2007-10-16|Estimate|||||||2009-01-28|2009-01-29|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease||Completed||N/A|39||Ludwig-Maximilians - University of Munich||2|||f||||||||||||||2018-06-01 02:50:54.007711|2018-06-01 02:50:54.007711
NCT00544830|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2017-11-29|2007-10-13|2007-10-16|Estimate|||||||2017-11-29|2017-12-02|Actual|July 18, 2006|Actual|2006-07-18|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Androgen Deprivation Therapy for Metastatic Prostate Cancer|Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer|Active, not recruiting||Phase 2|29|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:50:55.548839|2018-06-01 02:50:55.548839
NCT00544817|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2012-11-15||2016-07-21|2007-10-15|2007-10-16|Estimate|2012-11-15|2012-12-13|Estimate||||2016-07-21|2016-09-01|Estimate|April 2007||2007-04-30|July 2016|2016-07-31|August 2010|Actual|2010-08-31|June 2008|Actual|2008-06-30||Interventional|||Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme|A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme|Completed||Phase 2|47|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:50:55.682179|2018-06-01 02:50:55.682179
NCT00544804|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2014-07-01|2007-10-13|2007-10-16|Estimate|||||||2014-07-01|2014-07-02|Estimate|August 2007||2007-08-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2|A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer|Completed||Phase 1|41|Actual|University of California, San Francisco||1|||f||||||||||||||2018-06-01 02:50:55.936064|2018-06-01 02:50:55.936064
NCT00544791|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14|||2007-10-15|2007-10-15|2007-10-16|Estimate|||||||2007-10-15|2007-10-16|Estimate|October 2007||2007-10-31|June 2007|2007-06-30|October 2010|Anticipated|2010-10-31|||||Interventional|MCI||The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment|The Effect of Melatonin on Memory and Other Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI): A Placebo- Controlled Study.|Unknown status|Recruiting|Phase 2|50|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 02:50:56.01821|2018-06-01 02:50:56.01821
NCT00544596|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2014-04-01|2007-10-13|2007-10-16|Estimate|||||||2014-04-01|2014-04-02|Estimate|September 2007||2007-09-30|June 2012|2012-06-30||||July 2013|Actual|2013-07-31||Interventional|||R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer|A Phase 1 Study of R-(-)-Gossypol (AT-101) in Combination With Cisplatin and Etoposide in Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer|Completed||Phase 1|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:50:58.602663|2018-06-01 02:50:58.602663
NCT00544778|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|2014-06-12||2014-08-19|2007-10-13|2007-10-16|Estimate|2014-08-19|2014-08-28|Estimate||||2014-08-19|2014-08-28|Estimate|August 2001||2001-08-31|August 2014|2014-08-31||||November 2011|Actual|2011-11-30||Interventional|||Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma|Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas|Terminated||Phase 2|7|Actual|City of Hope Medical Center|The study was terminated…protocol objectives not met. It was closed prematurely due to withdrawal of support by the sponsor. Subjects have been followed, but there is not enough data generated to continue following the subjects.”|1||The study was terminated prematurely due to withdrawal of support by the sponsor.|f||||||||||||||2018-06-01 02:50:56.267079|2018-06-01 02:50:56.267079
NCT00544765|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2016-02-09|2007-10-15|2007-10-16|Estimate|||||||2016-02-09|2016-02-10|Estimate|September 2002||2002-09-30|February 2016|2016-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|GeparTrio||Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer|A Multi-center Randomized Phase III Study Evaluating 4 Cycles of Docetaxel, Doxorubicin and Cyclophosphamide Versus 4 Cycles of Vinorelbine and Capecitabine in Patients Not Sufficiently Responding to 2 Cycles of TAC and 4 Cycles of TAC Versus 6 Cycles of TAC in Patients Sufficiently Responding to 2 Cycles of TAC as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer|Completed||Phase 3|2014|Actual|German Breast Group||4|||f||||t||||||||||2018-06-01 02:50:56.498575|2018-06-01 02:50:56.498575
NCT00544752|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2011-04-13|2007-10-12|2007-10-16|Estimate|||||||2011-04-13|2011-04-14|Estimate|January 2005||2005-01-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Indoor Temperature and Sleep Apnea|Indoor Temperature and Sleep Apnea|Completed||N/A|40|Actual|Umeå University||3|||f||||||||||||||2018-06-01 02:50:56.586576|2018-06-01 02:50:56.586576
NCT00544739|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2012-01-16|2007-10-15|2007-10-16|Estimate|||||||2012-01-16|2012-01-18|Estimate|April 2005||2005-04-30|January 2012|2012-01-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Observational|PRECADIW||Premature Coronary Artery Disease in Women - Risk Factors and Prognosis|Premature Coronary Artery Disease in Women - Risk Factors and Prognosis|Completed|||670|Actual|Institute of Cardiology, Warsaw, Poland|||2||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-06-01 02:50:56.66194|2018-06-01 02:50:56.66194
NCT00544726|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2008-04-06|2007-10-15|2007-10-16|Estimate|||||||2008-04-06|2008-04-08|Estimate|February 2008||2008-02-29|October 2007|2007-10-31||||||||Interventional|||Rehabilitation for Patients With Pulmonary Arterial Hypertension||Unknown status|Enrolling by invitation|N/A|45|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 02:50:56.74183|2018-06-01 02:50:56.74183
NCT00544713|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|2009-06-29||2011-11-09|2007-10-15|2007-10-16|Estimate|2011-11-09|2011-12-14|Estimate||||2011-11-09|2011-12-14|Estimate|September 2007||2007-09-30|November 2011|2011-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery||Completed||N/A|228|Actual|Allergan||2|||f||||f||||||||||2018-06-01 02:50:56.868948|2018-06-01 02:50:56.868948
NCT00544700|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2018-02-09|2007-10-13|2007-10-16|Estimate|||||||2018-02-09|2018-02-12|Actual|October 5, 2007|Actual|2007-10-05|February 2018|2018-02-28|January 30, 2019|Anticipated|2019-01-30|January 21, 2013|Actual|2013-01-21||Interventional|||Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer|Bevacizumab Maintenance Versus no Maintenance After Stop of First-line Chemotherapy in Patients With Metastatic Colorectal Cancer. A Randomized Multicenter Phase III Non-inferiority Trial|Active, not recruiting||Phase 3|265|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||No||2018-06-01 02:50:57.311642|2018-06-01 02:50:57.311642
NCT00544687|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2007-11-14|2007-10-15|2007-10-16|Estimate|||||||2007-11-14|2007-11-15|Estimate|September 2007||2007-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Phase I Study of Topical CRx-191 in Normal Healthy Volunteers|A Phase I, Single-Center, Randomized, Vehicle and Active-Controlled Study to Assess and Compare the Atrophy-Causing Potential of Topical CRx-191 Formulations in Healthy Volunteers|Completed||Phase 1|20|Actual|Zalicus||6|||f||||f||||||||||2018-06-01 02:50:57.518881|2018-06-01 02:50:57.518881
NCT00544674|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|2011-06-13||2012-12-06|2007-10-13|2007-10-16|Estimate|2011-06-13|2011-07-07|Estimate||||2012-12-06|2012-12-10|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|||PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer|A Phase II, Multi-Center, Open-Label, Trial of PR104 in Treatment Naive and Sensitive-relapse Small Cell Lung Cancer|Terminated||Phase 2|5|Actual|Proacta, Incorporated|Decision to close study early based on new data showing that PR104A could also be activated under oxic conditions in tumors that express high levels of AKR1C3. SCLC does not express meaningful levels of the enzyme aldo keto reductase 1C3 (AKR1C3).|1||Terminated early due to discovery of new mechanism of activation.|f||||||||||||||2018-06-01 02:50:57.612128|2018-06-01 02:50:57.612128
NCT00544648|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|2014-03-19||2014-05-21|2007-10-13|2007-10-16|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|November 2007||2007-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Consented patients|Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC|A Phase I/II Study of Nab-Paclitaxel and Carboplatin With Concurrent Radiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer (NSCLC)|Terminated||Phase 1/Phase 2|13|Actual|Vanderbilt-Ingram Cancer Center|This Phase I/II study progressed into Phase II, but terminated shortly thereafter due to lack of funding.|1||"Ph I completed. Funding became unavailable causing Ph II to cease after two patients were~   enrolled."|f||||t||||||||||2018-06-01 02:50:57.869503|2018-06-01 02:50:57.869503
NCT00544635|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2014-07-25|2007-10-12|2007-10-16|Estimate|||||||2014-07-25|2014-07-29|Estimate|November 2005||2005-11-30|July 2014|2014-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||The Effect Of Light On Scar Appearance|The Effect Of Light On Scar Appearance|Terminated||N/A|50|Anticipated|Northwestern University||2||Study personnel left institution before study completion.|f||||f||||||||||2018-06-01 02:50:58.37621|2018-06-01 02:50:58.37621
NCT00544622|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2008-10-16|2007-10-12|2007-10-16|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2002||2002-01-31|October 2008|2008-10-31|March 2003||2003-03-31|||||Interventional|||Structured Stroke Management Improves Outcome at 6 Months|Structured Stroke Management Improves Outcome at 6 Months|Completed||N/A|||Kantonsspital Baden|||||f||||t||||||||||2018-06-01 02:50:58.454883|2018-06-01 02:50:58.454883
NCT00544609|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2014-10-01|2007-10-15|2007-10-16|Estimate|||||||2014-10-01|2014-10-02|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|May 2012|Actual|2012-05-31|August 2010|Actual|2010-08-31||Interventional|SOGUG-07-01||Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent|Phase I Trial of Sorafenib in Combination With Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent|Completed||Phase 1|10|Actual|Spanish Oncology Genito-Urinary Group||1|||f||||t||||||||||2018-06-01 02:50:58.525731|2018-06-01 02:50:58.525731
NCT00544570|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2010-02-05|2007-10-13|2007-10-16|Estimate|||||||2010-02-05|2010-02-09|Estimate|April 1998||1998-04-30|February 2010|2010-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma|High Dose Sequential Therapy for Poor Risk Recurrent or Refractory Hodgkin's Disease|Completed||N/A|30|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:50:58.748674|2018-06-01 02:50:58.748674
NCT00544557|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2015-04-23||2015-04-23|2007-10-15|2007-10-16|Estimate|2015-04-23|2015-05-12|Estimate||||2015-04-23|2015-05-12|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||Safety population included all treated participants with available post-baseline safety data.|Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis|Observational Study Of The Use Of Enbrel (Registered) (Etanercept) In Routine Clinical Practice To Treat Ankylosing Spondylitis (as) Patients: An Effectiveness, Safety, And Health Economic Evaluation|Completed|||1715|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 02:50:58.948593|2018-06-01 02:50:58.948593
NCT00544544|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|2010-06-24||2012-03-09|2007-10-12|2007-10-16|Estimate|2010-07-22|2010-08-18|Estimate||||2012-03-09|2012-03-13|Estimate|June 2007||2007-06-30|March 2012|2012-03-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Riluzole in the Treatment of Bipolar Depression|Riluzole in the Treatment of Bipolar Depression: A Study of the Association Between Clinical Response and Change in Brain Glutamate Levels as Measured by Proton Magnetic Resonance Spectroscopy|Completed||N/A|14|Actual|Mclean Hospital||1|||f||||f||||||||||2018-06-01 02:51:00.182488|2018-06-01 02:51:00.182488
NCT00544531|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14|||2007-10-15|2007-10-15|2007-10-16|Estimate|||||||2007-10-15|2007-10-16|Estimate|October 2005||2005-10-31|September 2005|2005-09-30|March 2007|Actual|2007-03-31|||||Observational|||The Cytogenetic Constitution of Embryos Resulting From Immature Oocytes (M1)||Completed|||23907|Actual|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 02:51:00.35002|2018-06-01 02:51:00.35002
NCT00544518|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2008-05-21|2007-10-15|2007-10-16|Estimate|||||||2008-05-21|2008-05-22|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|October 2008|Anticipated|2008-10-31|September 2008|Anticipated|2008-09-30||Interventional|||Impact of Benfluorex Versus Metformin on Glucose Control and Insulin Secretion in Chinese Type 2 Diabetic Patients||Unknown status|Active, not recruiting|Phase 2|240|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-06-01 02:51:00.400112|2018-06-01 02:51:00.400112
NCT00544505|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2011-12-11|2007-10-15|2007-10-16|Estimate|||||||2011-12-11|2011-12-13|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)||Unknown status|Active, not recruiting|N/A|10|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:51:00.468591|2018-06-01 02:51:00.468591
NCT00544492|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2011-12-17|2007-10-15|2007-10-16|Estimate|||||||2011-12-17|2011-12-20|Estimate|October 2007||2007-10-31|December 2011|2011-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients|Study of Pain, Anxiety, Complications Related to AV Fistula Cannulation in Chronic Hemodialysis Patients. A. Buttonhole vs. Rope Ladder Technique B. Catheters With Cylindrical Point vs. Catheters With Bevel Point in Rope Ladder Technique|Completed||Phase 4|40|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||t||||||||||2018-06-01 02:51:00.518773|2018-06-01 02:51:00.518773
NCT00544479|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2015-05-19|2007-10-15|2007-10-16|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||No Routine CXR After Bronchoscopy|Is Routine Chest-X-Ray Necessary After Bronchoscpy With Thransbronchial Biopsie? A Prospective Study|Completed|||250|Actual|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 02:51:00.593603|2018-06-01 02:51:00.593603
NCT00544466|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2018-01-17|2007-10-13|2007-10-16|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2006||2006-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Allogeneic Stem Cell Transplant With a Novel Conditioning Therapy Using Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:51:00.653804|2018-06-01 02:51:00.653804
NCT00544453|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2009-08-20|2007-10-12|2007-10-16|Estimate|||||||2009-08-20|2009-08-21|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|July 2008|Actual|2008-07-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC|Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Terminated||Phase 1|2|Actual|Molecular NeuroImaging||||Preliminary data showed [123I] MNI-308 not a useful tool in detection of AD.|f||||f||||||||||2018-06-01 02:51:00.734618|2018-06-01 02:51:00.734618
NCT00544440|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2013-08-28||2014-07-03|2007-10-15|2007-10-16|Estimate|2013-08-28|2013-11-01|Estimate||||2014-07-03|2014-07-17|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma|An Observational Study of Continuous Oral Dosing of an Irreversible CYP17 Inhibitor, Abiraterone Acetate (CB7630), in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma|Completed||Phase 2|57|Actual|Janssen Research & Development, LLC||1|||f||||t||||||||||2018-06-01 02:51:00.893335|2018-06-01 02:51:00.893335
NCT00544427|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2018-02-12|2007-10-12|2007-10-16|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2003||2003-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Near Infrared Optical Coherence Tomography of the Upper Aero-Digestive Tract|Near Infrared Optical Coherence Tomography of the Upper Aero-Digestive Tract|Recruiting|||800|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-06-01 02:51:01.202777|2018-06-01 02:51:01.202777
NCT00544414|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2018-01-17|2007-10-13|2007-10-16|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2000||2000-04-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer|Multimodality Management of Head and Neck Cancer: A Phase II Trial of Induction Chemotherapy, Organ Preservation Surgery, and Concurrent Chemoradiotherapy|Active, not recruiting||Phase 2|30|Anticipated|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 02:51:01.297263|2018-06-01 02:51:01.297263
NCT00544401|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2010-06-08|2007-10-15|2007-10-16|Estimate|||||||2010-06-08|2010-06-09|Estimate|November 2008||2008-11-30|June 2010|2010-06-30||||August 2010|Anticipated|2010-08-31||Interventional|||Hypnopuncture for In Vitro Fertilization (IVF)|Effect of Hypnosis and Acupuncture (Hypnopuncture) on Pregnancy Rates Following Assisted Reproductive Treatment (IVF/ICSI): A Pilot Study|Terminated||Phase 2/Phase 3|6|Actual|Shaare Zedek Medical Center||2||Lack of participants|f||||f||||||||||2018-06-01 02:51:01.395868|2018-06-01 02:51:01.395868
NCT00544388|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2013-12-13|2007-10-15|2007-10-16|Estimate|||||||2013-12-13|2013-12-16|Estimate|April 2004||2004-04-30|September 2009|2009-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects|Trial to Compare the Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects Exposed to Pollen Challenge in an Environmental Exposure Unit (EEU).|Completed||Phase 3|570|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:51:01.474128|2018-06-01 02:51:01.474128
NCT00544375|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2017-02-08|2007-10-12|2007-10-16|Estimate|||||||2017-02-08|2017-02-10|Actual|June 2002||2002-06-30|February 2017|2017-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Measurements of Anemia and Physiologic Tissue Response to Blood Transfusions in VLBW Infants Using Quantitative NIRS|Non-Invasive Measurements of Anemia and Physiologic Tissue Response to Blood Transfusions in Very Low Birth Weight Infants Using Quantitative Near-Infrared Spectroscopy|Completed|||120|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:51:01.526298|2018-06-01 02:51:01.526298
NCT00544362|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2016-05-27|2007-10-13|2007-10-16|Estimate|||||||2016-05-27|2016-05-30|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|January 2011|Actual|2011-01-31||Interventional|||Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery|Neoadjuvant Treatment for Operable Esophageal Cancer With 5-fluorouracil, Cisplatin, and Cetuximab and Concurrent Radiotherapy: Phase I/II Study|Completed||Phase 1/Phase 2|33|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||f||||||||||2018-06-01 02:51:01.591035|2018-06-01 02:51:01.591035
NCT00544349|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2011-05-14|2007-10-13|2007-10-16|Estimate|||||||2011-05-14|2011-05-17|Estimate|October 2006||2006-10-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery|Phase II Study Evaluating the Effectiveness of the Association of Chemotherapy LV5FU2 Simplified and Cetuximab With Intra-arterial Hepatic Chemotherapy Using Oxaliplatin in Patients With Colorectal Cancer and Nonresectable Hepatic Metastases|Completed||Phase 2|45|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:01.697241|2018-06-01 02:51:01.697241
NCT00544336|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2012-09-07|2007-10-13|2007-10-16|Estimate|||||||2012-09-07|2012-09-10|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Observational|||Family Quality of Life Among Families With a Member Who is a Cancer Patient|Assessment of Family Quality of Life Among Families With a Member Who is a Cancer Patient|Completed|||366|Actual|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||||||2018-06-01 02:51:01.803208|2018-06-01 02:51:01.803208
NCT00544323|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14|||2009-02-01|2007-10-15|2007-10-16|Estimate|||||||2009-02-01|2009-02-03|Estimate|November 2007||2007-11-30|October 2007|2007-10-31||||||||Interventional|||Alveolar Bone Loss Around 3 Different Designs of Dental Implant: Prospective Comparative Clinical Trail|Alveolar Bone Loss Around 3 Different Designs of Dental Implant: Prospective Comparative Clinical Trail|Unknown status|Not yet recruiting|N/A|25||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:51:01.910028|2018-06-01 02:51:01.910028
NCT00544310|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2008-08-19|2007-10-15|2007-10-16|Estimate|||||||2008-08-19|2008-08-20|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|October 2008|Anticipated|2008-10-31|||||Interventional|||Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil|A Prospective, Controlled, Randomized, Multi-Center, Exploratory Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil|Unknown status|Active, not recruiting|Phase 1/Phase 2|25||OMRIX Biopharmaceuticals||1|||f||||||||||||||2018-06-01 02:51:01.980374|2018-06-01 02:51:01.980374
NCT00544297|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14||2010-07-13|2015-03-13|2007-10-15|2007-10-16|Estimate||||2010-07-13|2010-07-15|Estimate|2015-03-13|2015-04-02|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand|A Multi-center, Open-label Study to Examine the Safety and Toleration of 0.05% PEP005 Topical Gel in Patients With Actinic Keratoses on the Dorsum of the Hand|Completed||Phase 2|12|Actual|Peplin||1|||f||||f||||||||||2018-06-01 02:51:02.040746|2018-06-01 02:51:02.040746
NCT00544284|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2013-02-14|2007-10-13|2007-10-16|Estimate|||||||2013-02-14|2013-02-15|Estimate|January 2005||2005-01-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment|A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors|Completed||Phase 1|25|Actual|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 02:51:02.125942|2018-06-01 02:51:02.125942
NCT00544271|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2016-09-06|2007-10-15|2007-10-16|Estimate|||||||2016-09-06|2016-09-07|Estimate|May 2003||2003-05-31|September 2016|2016-09-30|January 2004|Actual|2004-01-31|||||Interventional|||Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.|Phase IIIb Study to Evaluate Immunogenicity, Antibody Persistency and Reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX Vaccines Administered to Healthy Children Previously Primed With 3 Doses of DTPa Vaccine Compared to Placebo (HAVRIX®JUNIOR)|Terminated||Phase 4|720|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:51:02.194817|2018-06-01 02:51:02.194817
NCT00544258|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14|||2015-02-11|2007-10-15|2007-10-16|Estimate|||||||2015-02-11|2015-02-12|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005|A Phase I, Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005, When Applied as 0.05% PEP005 Topical Gel to a 100 cm2 (5 cm x 20 cm) Contiguous Actinic Keratosis(AK) Treatment Area on the Extensor (Dorsal Aspect) Forearm.|Completed||Phase 1|8|Actual|Peplin||1|||f||||f||||||||||2018-06-01 02:51:02.272742|2018-06-01 02:51:02.272742
NCT00544245|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2011-08-14|2007-10-12|2007-10-16|Estimate|||||||2011-08-14|2011-08-16|Estimate|October 2007||2007-10-31|August 2011|2011-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|UHPAWS||Is Monitoring Activity Important for Short- and Long-term Weight Loss?||Completed||N/A|83|Actual|University of Hawaii|||||f||||f||||||||||2018-06-01 02:51:02.361306|2018-06-01 02:51:02.361306
NCT00544232|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2016-02-12|2007-10-15|2007-10-16|Estimate|||||||2016-02-12|2016-02-15|Estimate|August 2002||2002-08-31|February 2016|2016-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)|Randomized Comparison of a Preoperative, Dose-Intensified, Interval-Shortened, Sequential Chemotherapy With Epirubicin, Paclitaxel and CMF ± Darbepoetin Alfa Versus a Preoperative, Sequential Chemotherapy With Epirubicin and Cyclophosphamide Followed by Paclitaxel in Standard Dosage ± Darbepoetin Alfa in Patients With Primary Breast Cancer|Completed||Phase 3|720|Actual|German Breast Group||2|||f||||t||||||||||2018-06-01 02:51:02.501383|2018-06-01 02:51:02.501383
NCT00544219|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2016-06-14|2007-10-13|2007-10-16|Estimate|||||||2016-06-14|2016-06-15|Estimate|September 2007||2007-09-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|September 2012|Actual|2012-09-30||Interventional|||PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone|Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study|Completed||N/A|156|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-06-01 02:51:02.584796|2018-06-01 02:51:02.584796
NCT00544206|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2008-09-22|2007-10-12|2007-10-16|Estimate|||||||2008-09-22|2008-09-23|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes|Comparison of Enteral Products for Tube Fed Patients With Type 2 Diabetes|Completed||Phase 2|11|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-06-01 02:51:02.693058|2018-06-01 02:51:02.693058
NCT00544193|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2015-06-03|2007-10-13|2007-10-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 1997||1997-12-31|June 2015|2015-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer|Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies|Completed||Phase 1|16|Actual|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:51:02.775535|2018-06-01 02:51:02.775535
NCT00544180|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2009-09-24|2007-10-15|2007-10-16|Estimate|||||||2009-09-24|2009-09-25|Estimate|May 2005||2005-05-31|September 2009|2009-09-30||||September 2006|Actual|2006-09-30||Interventional|||ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week|Record on Satisfaction of Patients With Actonel 35 mg Once a Week|Terminated||Phase 4|7|Actual|Sanofi||||The trial was terminated due to lack of compliance with GCP regulations.|f||||f||||||||||2018-06-01 02:51:02.843905|2018-06-01 02:51:02.843905
NCT00544167|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|2012-12-19||2013-03-25|2007-10-15|2007-10-16|Estimate|2012-12-19|2013-01-25|Estimate||||2013-03-25|2013-04-01|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|April 2011|Actual|2011-04-30|January 2008|Actual|2008-01-31||Interventional|||Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer|A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer|Completed||N/A|45|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:51:02.904418|2018-06-01 02:51:02.904418
NCT00544154|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2013-09-03|2007-10-15|2007-10-16|Estimate|||||||2013-09-03|2013-09-04|Estimate|October 2002||2002-10-31|September 2009|2009-09-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis|Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate|Completed||Phase 3|247|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:51:03.182125|2018-06-01 02:51:03.182125
NCT00544141|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14|||2008-04-23|2007-10-15|2007-10-16|Estimate|||||||2008-04-23|2008-04-24|Estimate||||April 2008|2008-04-30||||||||Observational|||Clinical Evaluation of the Care On Line Thermometer||Unknown status|Recruiting||||Medisim Ltd|||||f||||f||||||||||2018-06-01 02:51:03.276679|2018-06-01 02:51:03.276679
NCT00544128|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2015-03-27|2007-10-15|2007-10-16|Estimate|||||||2015-03-27|2015-03-30|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment|A Randomized, Open Label, Multicenter Study Comparing the Safety and Efficacy of Once Daily Regimen Containing Epzicom or Truvada Combined With Ritonavir Boosted Atazanavir as Initial Therapy for HIV-1 Infection (ET Study)|Completed||Phase 4|109|Actual|International Medical Center of Japan||2|||f||||t||||||||||2018-06-01 02:51:03.338333|2018-06-01 02:51:03.338333
NCT00544115|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2017-09-26|2007-10-13|2007-10-16|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2001||2001-09-30|September 2017|2017-09-30|September 2018||2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders|A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders|Active, not recruiting||Phase 2|260|Anticipated|City of Hope Medical Center||6|||f||||||||||||||2018-06-01 02:51:03.440799|2018-06-01 02:51:03.440799
NCT00544102|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14|||2018-05-24|2007-10-14|2007-10-16|Estimate|||||||2018-05-24|2018-05-25|Actual|October 11, 2007||2007-10-11|September 7, 2017|2017-09-07|September 7, 2017||2017-09-07|||||Observational|||Insulin Resistance and Atherosclerosis in Women With Lupus|Insulin Resistance and Atherosclerosis in a Sample of Women With Systemic Lupus Erythematosus|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:51:03.597707|2018-06-01 02:51:03.597707
NCT00544089|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-14|||2007-10-15|2007-10-15|2007-10-16|Estimate|||||||2007-10-15|2007-10-16|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|September 2007|Actual|2007-09-30|||||Observational|||Chromosomal and Morphological Structure of Mature and Immature Male Germ Cells and Recognition of IL-18 in Testicular Tissue of Azoospermic Men||Completed|||25907|Actual|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 02:51:03.689365|2018-06-01 02:51:03.689365
NCT00544076|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2015-06-03|2007-10-13|2007-10-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Sildenafil Citrate and Alprostadil in Treating Patients Undergoing Bilateral Nerve-Sparing Robotic-Assisted Prostatectomy for Nonmetastatic Prostate Cancer|Erectile Dysfunction Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy (BNS-RAP) for Prostate Cancer|Completed||N/A|110|Actual|City of Hope Medical Center||3|||f||||t||||||||||2018-06-01 02:51:03.766192|2018-06-01 02:51:03.766192
NCT00544063|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2009-12-13|2007-10-13|2007-10-16|Estimate|||||||2009-12-13|2009-12-15|Estimate|October 2006||2006-10-31|July 2009|2009-07-31||||December 2011|Anticipated|2011-12-31||Interventional|||Capecitabine, Irinotecan, and Oxaliplatin in Treating Patients With Metastatic Cancer|Phase I Study Evaluating the Feasibility of Chemotherapy With Capecitabine, Irinotecan, and Oxaliplatin in Patients With Metastatic Carcinoma|Unknown status|Recruiting|Phase 1|33|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:03.872461|2018-06-01 02:51:03.872461
NCT00544050|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2013-11-14|2007-10-15|2007-10-16|Estimate|||||||2013-11-14|2013-11-15|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old|An Open-Label, Single Dose, Pharmacokinetic Study of 20 mg/kg of Levetiracetam Oral Solution in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old|Completed||Phase 2|13|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:51:03.965706|2018-06-01 02:51:03.965706
NCT00544037|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-15|||2012-03-02|2007-10-15|2007-10-16|Estimate|||||||2012-03-02|2012-03-05|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||BENEFIT Extension Study|Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis|Completed|||283|Actual|Bayer|||1||f||||f||||||None Retained|"~     Population of Benefit Studies~   "|||2018-06-01 02:51:04.034203|2018-06-01 02:51:04.034203
NCT00544024|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2007-10-12|2007-10-12|2007-10-16|Estimate|||||||2007-10-12|2007-10-16|Estimate|March 2004||2004-03-31|October 2007|2007-10-31|March 2007|Actual|2007-03-31|||||Observational|||Mefloquine Bioequivalence Among 3 Commercially Available Tablets.|Mefloquine Bioequivalence Among Three Commercial Tablet Formulations in Peruvian Subjects With Uncomplicated Plasmodium Falciparum Malaria|Completed|||39|Actual|Centers for Disease Control and Prevention|||3||f||||f||||||None Retained|"~     Whole blood was obtained for analysis, but has been subsequently disposed after completion of~     drug analysis.~   "|||2018-06-01 02:51:04.13242|2018-06-01 02:51:04.13242
NCT00544011|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-13|||2011-06-23|2007-10-13|2007-10-16|Estimate|||||||2011-06-23|2011-06-27|Estimate|April 2007||2007-04-30|July 2009|2009-07-31||||||||Interventional|||Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Study Evaluating the Association of Bevacizumab and Chemotherapy of the Type Modified FOLFIRI 3 in Patients With Metastatic Colorectal Adenocarcinoma|Unknown status|Recruiting|Phase 2|47|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:04.22352|2018-06-01 02:51:04.22352
NCT00543998|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2017-02-08|2007-10-12|2007-10-16|Estimate|||||||2017-02-08|2017-02-10|Actual|May 2003||2003-05-31|February 2017|2017-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Observational|||Near Infrared Transillumination of the Paranasal Sinuses|Near Infrared Transillumination of the Paranasal Sinuses|Completed|||33|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:51:04.305737|2018-06-01 02:51:04.305737
NCT00543985|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2010-01-11||2017-01-17|2007-10-12|2007-10-15|Estimate|2016-09-29|2016-11-22|Estimate||||2017-01-17|2017-03-01|Actual|October 2007||2007-10-31|November 2016|2016-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)|Exercise in Patients With Metabolic Syndrome and Weight Regain - Echocardiography Substudy|Completed||N/A|36|Actual|University of Missouri-Columbia||1|||f||||f||||||||||2018-06-01 02:51:04.384108|2018-06-01 02:51:04.384108
NCT00543972|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2009-05-13|2007-10-12|2007-10-15|Estimate|||||||2009-05-13|2009-05-14|Estimate|September 2007||2007-09-30|May 2009|2009-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia|An Open Label, Dose-Escalation Safety and Pharmacokinetic Study of AVE9633 Administered as a Single Agent by Intravenous Infusion on Day 1, Day 4 and Day 7 of a 4-Week Cycle in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML)|Terminated||Phase 1|12|Actual|Sanofi||||due to absence of evidence of clinical activity up to toxic doses|f||||f||||||||||2018-06-01 02:51:04.554582|2018-06-01 02:51:04.554582
NCT00543959|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-22|2007-10-11|2007-10-15|Estimate|||||||2015-06-22|2015-06-23|Estimate|June 2006||2006-06-30|June 2015|2015-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)|An Efficacy and Tolerability Study of MK0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Terminated||Phase 2|346|Actual|Merck Sharp & Dohme Corp.||7||"This study is being discontinued based on data suggesting that none of the doses tested~   demonstrated both glycemic & body fluid benefits vs. the comparitor"|f||||||||||||||2018-06-01 02:51:04.612926|2018-06-01 02:51:04.612926
NCT00543946|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2009-01-28|2007-10-11|2007-10-15|Estimate|||||||2009-01-28|2009-01-29|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Single Ascending Dose of GAP-134 as a 24-Hour IV Infusion in Healthy Japanese Males|Ascending Single Dose Study of The Safety, Tolerability, Pharmacokinetics, of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Japanese Male Subjects|Completed||Phase 1|56|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:51:04.680405|2018-06-01 02:51:04.680405
NCT00543933|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2017-01-26|2007-10-11|2007-10-15|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2007|Actual|2007-10-31|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease|Acute Effect of Inhaled Nitric Oxide on Pulmonary Insufficiency in Congenital Heart Disease|Terminated||Early Phase 1|18|Actual|The Cleveland Clinic||1||Investigator left institution|f||||f|t|f|||t|||No||2018-06-01 02:51:04.741718|2018-06-01 02:51:04.741718
NCT00543920|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-11-25|2007-10-12|2007-10-15|Estimate|||||||2015-11-25|2015-11-26|Estimate|August 2002||2002-08-31|November 2015|2015-11-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)||Completed||Phase 2|60|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:04.81347|2018-06-01 02:51:04.81347
NCT00543907|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2018-03-25|2007-10-12|2007-10-15|Estimate|||||||2018-03-25|2018-03-27|Actual|September 2007||2007-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Outcomes of a Deep Inferior Epigastric Perforator Flap Program|Outcomes of a Deep Inferior Epigastric Perforator Flap Program|Recruiting|||2400|Anticipated|Beth Israel Deaconess Medical Center|||2||f||||f||||||||No||2018-06-01 02:51:04.857771|2018-06-01 02:51:04.857771
NCT00543894|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2008-08-11|2007-10-12|2007-10-15|Estimate|||||||2008-08-11|2008-08-12|Estimate|February 2006||2006-02-28|June 2007|2007-06-30||||||||Observational|ANTHICUS||Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients|Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A Prospective, Observational, Multicenter Study (ANTHICUS)|Completed|||500|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:51:04.911456|2018-06-01 02:51:04.911456
NCT00543881|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2016-12-20|2007-10-12|2007-10-15|Estimate|||||||2016-12-20|2016-12-21|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|TIM-HF||Telemedical Interventional Monitoring in Heart Failure|Telemedical Interventional Monitoring in Heart Failure (TIM-HF)|Completed||Phase 3|710|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:51:04.95993|2018-06-01 02:51:04.95993
NCT00543855|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2013-01-16||2013-03-05|2007-10-12|2007-10-15|Estimate|2013-01-16|2013-02-18|Estimate||||2013-03-05|2013-03-08|Estimate|November 2007||2007-11-30|March 2013|2013-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)|Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II|Completed||Phase 2|167|Actual|Eisai Inc.||4|||f||||||||||||||2018-06-01 02:51:05.104115|2018-06-01 02:51:05.104115
NCT00543842|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2015-02-24|2007-10-11|2007-10-15|Estimate|||||||2015-02-24|2015-02-26|Estimate|December 2007||2007-12-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer|Phase I/II Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Rectal Cancer|Completed||Phase 1|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:51:05.690547|2018-06-01 02:51:05.690547
NCT00543829|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2007-10-16|2007-10-12|2007-10-15|Estimate|||||||2007-10-16|2007-10-17|Estimate|April 1998||1998-04-30|October 2007|2007-10-31|June 1999|Actual|1999-06-30|||||Interventional|||German Preoperative Adriamycin Docetaxel Study|A Randomised, Controlled, Open Phase II b Study Comparing a Combination of Dose-Intensified Doxorubicin and Docetaxel With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast (T>=3cm N0-2 M0)|Completed||Phase 2|250|Actual|German Breast Group||2|||f||||t||||||||||2018-06-01 02:51:05.769911|2018-06-01 02:51:05.769911
NCT00543816|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-22|2007-10-12|2007-10-15|Estimate|||||||2015-06-22|2015-06-23|Estimate|August 2003||2003-08-31|June 2015|2015-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)||Terminated||Phase 3|100|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:05.831617|2018-06-01 02:51:05.831617
NCT00543803|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|2010-12-17||2014-05-13|2007-10-12|2007-10-15|Estimate|2010-12-17|2011-01-13|Estimate||||2014-05-13|2014-05-20|Estimate|February 2006||2006-02-28|May 2014|2014-05-31||||December 2009|Actual|2009-12-31||Observational||FAS - All patients were considered for the full analysis set.|Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients|Observational Non-interventional Study Evaluating the Safety and Efficacy of Truvada + Nevirapine|Completed|||334|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:51:05.893163|2018-06-01 02:51:05.893163
NCT00543790|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2010-10-27|2007-10-11|2007-10-15|Estimate|||||||2010-10-27|2010-10-28|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women|A Randomized, Placebo-Controlled, Double-Blind, Sponsor-Unblinded, Multiple-Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PRA-027 Administered Orally To Cycling Or Postmenopausal Women|Completed||Phase 1|48|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:51:06.40617|2018-06-01 02:51:06.40617
NCT00543777|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2018-02-13|2007-10-12|2007-10-15|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2007|Actual|2007-09-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease|Validation Study of Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:51:06.496984|2018-06-01 02:51:06.496984
NCT00543764|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|2010-10-19||2012-05-25|2007-10-12|2007-10-15|Estimate|2012-05-25|2012-07-06|Estimate||||2012-05-25|2012-07-06|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|December 2008|Actual|2008-12-31||Observational|||Intraoperative Pathway in DIEP Flap Breast Reconstruction|Intraoperative Pathway in DIEP Flap Breast Reconstruction|Completed|||150|Actual|Beth Israel Deaconess Medical Center|More patient enrollment is necessary to ascertain long term outcomes||2||f||||f||||||||||2018-06-01 02:51:06.591916|2018-06-01 02:51:06.591916
NCT00543751|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-16|2007-10-12|2007-10-15|Estimate|||||||2015-06-16|2015-06-17|Estimate|January 2003||2003-01-31|June 2015|2015-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)||Terminated||Phase 3|610|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:06.777761|2018-06-01 02:51:06.777761
NCT00543738|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-16|2007-10-12|2007-10-15|Estimate|||||||2015-06-16|2015-06-17|Estimate|June 2003||2003-06-30|June 2015|2015-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||MK0767 and Metformin Combination Study (0767-028)||Terminated||Phase 3|114|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:06.829556|2018-06-01 02:51:06.829556
NCT00543725|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2011-06-14||2016-03-03|2007-10-11|2007-10-15|Estimate|2011-06-14|2011-07-12|Estimate||||2016-03-03|2016-04-01|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|February 2012|Actual|2012-02-29|January 2010|Actual|2010-01-31||Interventional|||TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors|A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.|Completed||Phase 3|680|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||t||||||||||2018-06-01 02:51:06.936439|2018-06-01 02:51:06.936439
NCT00543712|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12||2013-06-19|2013-06-19|2007-10-12|2007-10-15|Estimate||||2013-06-19|2013-06-27|Estimate|2013-06-19|2013-06-27|Estimate|June 2007||2007-06-30|June 2013|2013-06-30||||May 2008|Actual|2008-05-31||Interventional|||A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)|A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma|Terminated||Phase 2|90|Anticipated|Genentech, Inc.||||Efficacy not evident in this population.|f||||||||||||||2018-06-01 02:51:07.759802|2018-06-01 02:51:07.759802
NCT00543686|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2009-02-03|2007-10-12|2007-10-15|Estimate|||||||2009-02-03|2009-02-04|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|LOS||Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma|A Randomised Controlled Open-Label Phase IV Mono Centre Study to Compare the Response Profiles of Montelukast Versus Fluticasone in Children With Pre-School Asthma|Completed||Phase 2|100|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-06-01 02:51:07.8187|2018-06-01 02:51:07.8187
NCT00543673|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2008-07-03|2007-10-12|2007-10-15|Estimate|||||||2008-07-03|2008-07-04|Estimate|September 2007||2007-09-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Tolerance of Healthy, Term Infants to Infant Formulas|Tolerance of Healthy, Term Infants to Infant Formulas|Completed||Phase 2/Phase 3|180|Actual|Abbott Nutrition||4|||f||||f||||||||||2018-06-01 02:51:07.884446|2018-06-01 02:51:07.884446
NCT00543660|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2018-03-27|2007-10-11|2007-10-15|Estimate|||||||2018-03-27|2018-03-29|Actual|March 1998||1998-03-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|DSAEK||Descemet Stripping (Automated) Endothelial Keratoplasty (DSEK or DSAEK)|Descemet Stripping (Automated) Endothelial Keratoplasty (DSEK or DSAEK)|Recruiting||N/A|1000|Anticipated|Netherlands Institute for Innovative Ocular Surgery||1|||f||||t||||||||||2018-06-01 02:51:07.980834|2018-06-01 02:51:07.980834
NCT00543647|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2015-01-16|2007-10-12|2007-10-15|Estimate|||||||2015-01-16|2015-01-19|Estimate|August 2002||2002-08-31|October 2007|2007-10-31|March 2003|Actual|2003-03-31|||||Interventional|||Effect of Fenofibrate on Kidney Function: a Six-week Randomized Cross-over Trial in Healthy People|A Double-blind, Cross-over, Placebo-controlled Study Evaluating the Effect of Fenofibrate 160 mg Tablets on Glomerular Filtration Rate and Other Renal Function Test in Healthy Subjects|Completed||Phase 1|24|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:51:08.071483|2018-06-01 02:51:08.071483
NCT00543634|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2010-06-17|2007-10-11|2007-10-15|Estimate|||||||2010-06-17|2010-06-22|Estimate|October 2007||2007-10-31|June 2010|2010-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women|Open-Label, Single-Dose, Partially Randomized, 6-Period, 6-Treatment, Crossover Bioavailability Study of 3 Pilot Formulations of Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations of Premarin®/MPA (PREMPRO®) and MPA Suspension (Provera®) in Healthy Postmenopausal Women|Completed||Phase 1|30|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 02:51:08.12694|2018-06-01 02:51:08.12694
NCT00543621|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2007-10-12|2007-10-12|2007-10-15|Estimate|||||||2007-10-12|2007-10-15|Estimate|May 2005||2005-05-31|October 2007|2007-10-31||||||||Interventional|||An Intervention Program to Control Diabetes|An Intervention Program to Control Diabetes|Completed||Phase 4|150|Actual|Abbott Nutrition|||||f||||f||||||||||2018-06-01 02:51:08.18621|2018-06-01 02:51:08.18621
NCT00543608|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2009-02-12|2007-10-12|2007-10-15|Estimate|||||||2009-02-12|2009-02-13|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|May 2009|Anticipated|2009-05-31|April 2009|Anticipated|2009-04-30||Interventional|||Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia|Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia Suspected or Confirmed to be Due to Gram-Positive Pathogens|Terminated||Phase 2|135|Anticipated|Arpida AG||3||Trial terminated due to financial resource limitations|f||||t||||||||||2018-06-01 02:51:08.230461|2018-06-01 02:51:08.230461
NCT00543595|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-05-21|2007-10-12|2007-10-15|Estimate|||||||2015-05-21|2015-05-22|Estimate|August 2004||2004-08-31|May 2015|2015-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)||Completed||Phase 2|154|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:08.311341|2018-06-01 02:51:08.311341
NCT00543582|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11||2015-06-04|2015-06-04|2007-10-11|2007-10-15|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma|A Phase 2, Open-label Trial to Evaluate the Efficacy and Safety of MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma, and to Evaluate the Pharmacokinetics of Different Formulations of MGCD0103|Terminated||Phase 2|23|Actual|Mirati Therapeutics Inc.||1||"Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.~   All Celgene-sponsored trials with MGCD0103 will be closed."|f||||f||||||||||2018-06-01 02:51:08.355629|2018-06-01 02:51:08.355629
NCT00543569|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2015-11-06||2015-11-06|2007-10-12|2007-10-15|Estimate|2015-11-06|2015-12-11|Estimate||||2015-11-06|2015-12-11|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional||Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug.|A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients|A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients|Completed||Phase 2|323|Actual|Astellas Pharma Inc||4|||f||||t||||||||||2018-06-01 02:51:08.490559|2018-06-01 02:51:08.490559
NCT00543556|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-12|2007-10-12|2007-10-15|Estimate|||||||2015-06-12|2015-06-15|Estimate|October 2001||2001-10-31|June 2015|2015-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||MK0767 in Type 2 Diabetes (0767-012)||Terminated||Phase 2|514|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:12.225803|2018-06-01 02:51:12.225803
NCT00543543|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|2014-12-12||2017-10-11|2007-10-12|2007-10-15|Estimate|2014-12-12|2014-12-19|Estimate||||2017-10-11|2017-11-13|Actual|September 24, 2007|Actual|2007-09-24|October 2017|2017-10-31|July 7, 2016|Actual|2016-07-07|April 10, 2013|Actual|2013-04-10||Interventional|||Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)|A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women|Completed||Phase 3|14840|Actual|Merck Sharp & Dohme Corp.||4|||f||||t|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:51:12.355376|2018-06-01 02:51:12.355376
NCT00543530|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-11-26|2007-10-12|2007-10-15|Estimate|||||||2015-11-26|2015-11-30|Estimate|March 2001||2001-03-31|November 2015|2015-11-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Pediatric Expanded Access Program-Oral Solution (0831-908)|A Noncomparative,Open, Multisite Study to Monitor the Safety and Tolerability of Efavirenz Oral Solution Given in Combination Antiretroviral Therapy (ART) in ART-naive or Experienced HIV-1 Infected Patients Age 3 to 16 Years Who Have Failed Therapy or Are Intorerant to Their Current ART Regimen|Completed||Phase 3|||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:14.245741|2018-06-01 02:51:14.245741
NCT00543517|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-02-09|2007-10-12|2007-10-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2003||2003-02-28|February 2015|2015-02-28|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Study A - MK0767 Monotherapy Study||Terminated||Phase 3|99|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:14.304552|2018-06-01 02:51:14.304552
NCT00543504|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2017-12-13|2007-10-11|2007-10-15|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2007|Actual|2007-10-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Bevacizumab in Multiple Phase I Combinations|A Phase 1 Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib|Active, not recruiting||Phase 1|354|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-06-01 02:51:14.374063|2018-06-01 02:51:14.374063
NCT00543478|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2007-10-12|2007-10-12|2007-10-15|Estimate|||||||2007-10-12|2007-10-15|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|July 2008|Anticipated|2008-07-31|||||Interventional|SBIBS||Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome|Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome|Unknown status|Recruiting|Phase 4|42|Anticipated|Aga Khan University||2|||f||||t||||||||||2018-06-01 02:51:14.525327|2018-06-01 02:51:14.525327
NCT00543465|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-01|2007-10-12|2007-10-15|Estimate|||||||2015-06-01|2015-06-02|Estimate|August 2004||2004-08-31|June 2015|2015-06-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003)||Terminated||Phase 2|49|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:14.60743|2018-06-01 02:51:14.60743
NCT00543452|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2011-04-06|2007-10-12|2007-10-15|Estimate|||||||2011-04-06|2011-04-07|Estimate|February 2005||2005-02-28|March 2011|2011-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effect of Oxygen on Core Temperature|Effect of Oxygen on Core Temperature|Completed||N/A|40|Actual|Umeå University||2|||f||||||||||||||2018-06-01 02:51:14.652046|2018-06-01 02:51:14.652046
NCT00543439|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2018-05-24|2007-10-11|2007-10-15|Estimate|||||||2018-05-24|2018-05-25|Actual|December 11, 2007|Actual|2007-12-11|May 2018|2018-05-31|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII|An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A|Completed||Phase 3|66|Actual|Pfizer||2|||f||||t|t|f||||||||2018-06-01 02:51:14.720436|2018-06-01 02:51:14.720436
NCT00543426|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2013-03-06|2007-10-12|2007-10-15|Estimate|||||||2013-03-06|2013-03-07|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis|Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis|Completed||Phase 4|200|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-06-01 02:51:14.836917|2018-06-01 02:51:14.836917
NCT00543413|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-10-15|2007-10-12|2007-10-15|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study to Determine the Effectiveness and Tolerability of MK8141 in Patients With High Blood Pressure (MK-8141-006)|A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Assess the Efficacy and Tolerability of MK8141 in Hypertensive Patients|Completed||Phase 2|160|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 02:51:14.90859|2018-06-01 02:51:14.90859
NCT00543400|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2013-10-25||2018-01-02|2007-10-12|2007-10-15|Estimate|2017-11-13|2017-12-12|Actual||||2018-01-02|2018-01-25|Actual|September 2007||2007-09-30|January 2018|2018-01-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|EMINENCE||Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)|A Randomized, Open-label, Parallel Group Feasibility Study to Determine the Safety and Efficacy of M118 vs. Unfractionated Heparin (UFH) in Subjects With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (PCI)|Completed||Phase 2|503|Actual|Momenta Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-06-01 02:51:14.992638|2018-06-01 02:51:14.992638
NCT00543387|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-12|||2016-01-21|2007-10-12|2007-10-15|Estimate|||||||2016-01-21|2016-01-22|Estimate|March 2008||2008-03-31|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4)|A Phase I Investigation of MK-5108 and MK-5108 With Docetaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|37|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:51:15.42322|2018-06-01 02:51:15.42322
NCT00543374|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11||2010-08-24|2016-10-12|2007-10-12|2007-10-15|Estimate||||2011-10-06|2011-10-10|Estimate|2016-10-12|2016-10-13|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease|A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease|Completed||Phase 3|98|Actual|Mesoblast, Ltd.||3|||f||||t||||||||||2018-06-01 02:51:15.55923|2018-06-01 02:51:15.55923
NCT00543361|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-11|2007-10-11|2007-10-15|Estimate|||||||2015-06-11|2015-06-12|Estimate|May 2003||2003-05-31|June 2015|2015-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)|A Double-Blind, Randomized, Active-Controlled MK0767 and Metformin Comparator Study in Type 2 Diabetic Patients Inadequately Controlled on Diet and Exercise|Terminated||Phase 3|382|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:15.728715|2018-06-01 02:51:15.728715
NCT00543348|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2007-10-11|2007-10-11|2007-10-12|Estimate|||||||2007-10-11|2007-10-12|Estimate|September 2007||2007-09-30|October 2007|2007-10-31||||||||Interventional|||RCT of the Cutting Balloon Versus a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses|A Randomised-Controlled Study Comparing the Peripheral Cutting BalloonTM (Boston Scientific Co.) With a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses|Unknown status|Recruiting|N/A|100|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-06-01 02:51:15.792754|2018-06-01 02:51:15.792754
NCT00543335|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2012-07-05|2007-10-11|2007-10-12|Estimate|||||||2012-07-05|2012-07-09|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer|Phase I Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|10|Actual|M.D. Anderson Cancer Center||1||Lack of Accrual.|f||||f||||||||||2018-06-01 02:51:15.859329|2018-06-01 02:51:15.859329
NCT00543322|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2007-10-11|2007-10-11|2007-10-12|Estimate|||||||2007-10-11|2007-10-12|Estimate|July 2001||2001-07-31|October 2007|2007-10-31|July 2006|Actual|2006-07-31|||||Observational|||PET Study of the Nicotinic Receptors in Human|PET Study of the Nicotinic Receptors in Human : Brain Distribution and Quantification|Terminated|||||Commissariat A L'energie Atomique|||||f||||||||||||||2018-06-01 02:51:15.931547|2018-06-01 02:51:15.931547
NCT00543309|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2013-11-01|2007-10-10|2007-10-12|Estimate|||||||2013-11-01|2013-11-04|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery|Impact of Empiric Nesiritide or Milrinone Infusion on Early Postoperative Recovery Following Fontan Surgery: a Randomized, Double-blind, Placebo-controlled Clinical Trial|Terminated||Phase 2|106|Actual|Boston Children’s Hospital||3||DSMB recommended termination based on interim outcomes analysis|f||||t||||||||||2018-06-01 02:51:15.991436|2018-06-01 02:51:15.991436
NCT00543296|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2013-08-08||2015-03-12|2007-10-11|2007-10-12|Estimate|2014-06-09|2014-07-09|Estimate||||2015-03-12|2015-03-31|Estimate|March 2004||2004-03-31|June 2014|2014-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional||Of 21 consented subjects only 14 completed the 9 months follow-up in whom fluocinolone acetonide implants were replaced or who needed a second implant.|Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment|Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment|Completed||Phase 4|21|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:51:16.095763|2018-06-01 02:51:16.095763
NCT00543270|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2010-02-22|2007-10-11|2007-10-12|Estimate|||||||2010-02-22|2010-02-24|Estimate|October 2005||2005-10-31|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Powerlink Bifurcated Stent Graft Long-Term Follow-up Study|Endologix Powerlink Long-Term Follow-up Study|Completed||Phase 2/Phase 3|231|Anticipated|Endologix||2|||f||||t||||||||||2018-06-01 02:51:16.514607|2018-06-01 02:51:16.514607
NCT00543257|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2017-10-04|2007-10-10|2007-10-12|Estimate|||||||2017-10-04|2017-10-06|Actual|December 2007|Actual|2007-12-31|October 2017|2017-10-31|June 2014|Actual|2014-06-30|March 2009|Actual|2009-03-31||Observational|||Parents at the Center: Information Management in ADHD - Clinical Trial|Parents at the Center: Information Management in ADHD - Clinical Trial|Completed|||194|Actual|Boston Children’s Hospital|||1||f||||f||||||||||2018-06-01 02:51:16.60894|2018-06-01 02:51:16.60894
NCT00543244|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2008-11-20|2007-10-10|2007-10-12|Estimate|||||||2008-11-20|2008-11-21|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|December 2008|Anticipated|2008-12-31|October 2008|Anticipated|2008-10-31||Observational|||Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan|Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 02:51:16.684782|2018-06-01 02:51:16.684782
NCT00543231|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-11|2007-10-11|2007-10-12|Estimate|||||||2007-10-11|2007-10-12|Estimate|December 2005||2005-12-31|December 2005|2005-12-31|December 2006||2006-12-31|||||Interventional|||A Phase I Study of G3139 Subcutaneous in Solid Tumors|A Pharmacokinetic and Safety Assessment of G3139 Administered by Subcutaneous Injection to Patients With Solid Tumors|Completed||Phase 1|8|Anticipated|Genta Incorporated|||||f||||||||||||||2018-06-01 02:51:16.797539|2018-06-01 02:51:16.797539
NCT00543218|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-12|Estimate|||||||2007-10-10|2007-10-12|Estimate|December 2002||2002-12-31|October 2007|2007-10-31|June 2004|Actual|2004-06-30|||||Interventional|||PTH Comparison in Post Menopausal Women|Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|63|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:51:16.845769|2018-06-01 02:51:16.845769
NCT00543205|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2011-11-04|2007-10-10|2007-10-12|Estimate|||||||2011-11-04|2011-11-07|Estimate|August 2005||2005-08-31|March 2009|2009-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment|A Pharmacokinetic Study of Genasense® (Bcl-2 Antisense Oligonucleotide) in Combination With Dacarbazine (DTIC) in Subjects With Advanced Melanoma and Normal or Impaired Hepatic Function|Terminated||Phase 2/Phase 3|6|Actual|Genta Incorporated||||Terminated due to very slow enrollment|f||||f||||||||||2018-06-01 02:51:16.912095|2018-06-01 02:51:16.912095
NCT00543192|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2015-09-30|2007-10-10|2007-10-12|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Sexual Functioning in Endometrial Cancer|Sexual Functioning in Endometrial Cancer Survivors|Completed|||73|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 02:51:17.024128|2018-06-01 02:51:17.024128
NCT00543179|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2007-10-11|2007-10-11|2007-10-12|Estimate|||||||2007-10-11|2007-10-12|Estimate|October 2007||2007-10-31|October 2007|2007-10-31||||||||Interventional|||Treatment of the Dumping Syndrome With Lanreotide Autogel®|Treatment of the Dumping Syndrome With Lanreotide Autogel®|Unknown status|Recruiting|Phase 4|||Radboud University|||||f||||t||||||||||2018-06-01 02:51:17.089166|2018-06-01 02:51:17.089166
NCT00543166|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2007-11-02|2007-10-11|2007-10-12|Estimate|||||||2007-11-02|2007-11-05|Estimate|February 2003||2003-02-28|October 2007|2007-10-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue|Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue|Unknown status|Active, not recruiting|Phase 4|107|Actual|Helsinki University||1|||f||||t||||||||||2018-06-01 02:51:17.161301|2018-06-01 02:51:17.161301
NCT00543153|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2012-07-27|2007-10-11|2007-10-12|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||The Exceptional Patient in Cancer Care|The Exceptional Patient in Cancer Care|Completed|||13|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:51:17.269086|2018-06-01 02:51:17.269086
NCT00543140|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2016-01-11||2016-02-09|2007-10-11|2007-10-12|Estimate|2016-02-09|2016-03-09|Estimate||||2016-02-09|2016-03-09|Estimate|August 2006||2006-08-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SAGB-PM|All subjects implanted with the SAGB.|Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band|A Post Implantation/Post Market Evaluation of Safety and Quality of Life in Subjects Implanted With the Swedish Adjustable Gastric Band (SAGB) During Protocol CI-02-0006|Completed||Phase 4|303|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||No|There is no plan to share IPD. Cumulative data from the study will be published.|2018-06-01 02:51:17.390862|2018-06-01 02:51:17.390862
NCT00543127|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2011-10-25|2007-10-11|2007-10-12|Estimate|||||||2011-10-25|2011-10-26|Estimate|November 2007||2007-11-30|October 2011|2011-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Fulvestrant (Faslodex) + Anastrozol (Arimidex) vs Anastrozol|A Randomized, Multicentral, Phase III Study of Parallel Groups to Compare the Efficiency and Tolerance of Fulvestrant Administered for Three Years in Combination With Anastrozol for 5 Years Versus Anastrozol for 5 Years as Adjuvant Hormonotherapy in Postmenopausal Women With Early Breast Cancer and + HRs.|Terminated||Phase 3|872|Actual|Spanish Breast Cancer Research Group||2||Unjustified decision of company that funded the trial.|f||||f||||||||||2018-06-01 02:51:17.821045|2018-06-01 02:51:17.821045
NCT00543114|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2016-05-26|2007-10-10|2007-10-12|Estimate|||||||2016-05-26|2016-05-27|Estimate|October 2007||2007-10-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|June 2009|Actual|2009-06-30||Interventional|||Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL|A Phase I Dose Escalation Study of Lenalidomide (Revlimid) in Combination With Fludarabine-Rituximab (Rituxan) for Previously Untreated CLL/SLL|Terminated||Phase 1|9|Actual|Dana-Farber Cancer Institute||1||lack of efficacy and tolerability|f||||t||||||||||2018-06-01 02:51:17.913895|2018-06-01 02:51:17.913895
NCT00472212|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2014-10-14|2007-05-10|2007-05-11|Estimate|||||||2014-10-14|2014-10-16|Estimate|November 2003||2003-11-30|October 2014|2014-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|CHICS||Correction of Farsightedness in Children Study|Correction of Hyperopia in Children Study|Completed||N/A|48|Actual|Ohio State University||2|||f||||f||||||||||2018-06-01 03:14:10.758304|2018-06-01 03:14:10.758304
NCT00543101|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2010-04-12||2017-07-18|2007-10-11|2007-10-12|Estimate|2010-07-22|2010-08-17|Estimate||||2017-07-18|2017-07-21|Actual|October 2007||2007-10-31|July 2017|2017-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|DVD||Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors|A Randomized, Controlled Trial to Evaluate the Efficacy of Substituting Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors in Individuals With Virologic Suppression for at Least 12 Weeks|Completed||Phase 4|24|Actual|Community Research Initiative of New England|The foremost problem was the small number of participants enrolled. By the time we were open for enrollment, most clinicians in the community had already switched their patients from dual boosted regimens to darunavir/ritonavir.|2|||f||||t||||||||||2018-06-01 02:51:18.021836|2018-06-01 02:51:18.021836
NCT00543088|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2009-04-22|2007-10-11|2007-10-12|Estimate|||||||2009-04-22|2009-04-23|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|June 2008|Actual|2008-06-30|||||Observational|Serenity||Effectiveness of Anti-Psychotic in GPs Setting|SERENITY: Evaluating the Effectiveness of Atypical Antipsychotics in the Community - a Prospective, Multicentre, Observational Study to Evaluate the Impact on Quality of Life of GP-Bases Management of Antipsychotic Treatment in Belgium.|Completed|||250||AstraZeneca|||||f||||f||||||||||2018-06-01 02:51:18.500847|2018-06-01 02:51:18.500847
NCT00543075|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2012-03-11|2007-10-11|2007-10-12|Estimate|||||||2012-03-11|2012-03-13|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|September 2009|Actual|2009-09-30|November 2007|Actual|2007-11-30||Interventional|||Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function|A Phase I Pharmacokinetic Study of Genasense® in Subjects With Normal Renal Function and Mildly and Moderately Impaired Renal Function|Completed||Phase 1|23|Actual|Genta Incorporated|||||f||||f||||||||||2018-06-01 02:51:18.634077|2018-06-01 02:51:18.634077
NCT00543062|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2017-01-31|2007-10-10|2007-10-12|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2007||2007-10-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Staccato Prochlorperazine Thorough QT/QTc|Thorough QT/QTc Study of Staccato® Prochlorperazine for Inhalation in Healthy Volunteers|Completed||Phase 1|48|Actual|Alexza Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:51:18.697571|2018-06-01 02:51:18.697571
NCT00543049|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2014-03-06|2007-10-10|2007-10-12|Estimate|||||||2014-03-06|2014-03-07|Estimate|September 2007||2007-09-30|March 2014|2014-03-31||||June 2012|Actual|2012-06-30||Interventional|||Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor|Phase II Trial in Platinum-refractory Ovarian Cancer: A Randomized Multicenter Trial With SU11248 to Evaluate Dosage, Tolerability, Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Monotherapy|Completed||Phase 2|73|Actual|AGO Study Group||2|||f||||f||||||||||2018-06-01 02:51:18.793148|2018-06-01 02:51:18.793148
NCT00543036|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2007-10-11|2007-10-11|2007-10-12|Estimate|||||||2007-10-11|2007-10-12|Estimate||||August 2007|2007-08-31||||||||Interventional|||Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction||Unknown status|Recruiting|Phase 1/Phase 2|||Shalvata Mental Health Center|||||f||||||||||||||2018-06-01 02:51:18.883136|2018-06-01 02:51:18.883136
NCT00543023|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-12|Estimate|||||||2007-10-10|2007-10-12|Estimate|June 2003||2003-06-30|October 2007|2007-10-31|August 2004|Actual|2004-08-31|||||Interventional|||A Study of the Treatment of Postmenopausal Women With Osteoporosis|Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|104|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:51:19.012472|2018-06-01 02:51:19.012472
NCT00543010|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-06-11|2007-10-11|2007-10-12|Estimate|||||||2015-06-11|2015-06-12|Estimate|November 2002||2002-11-30|June 2015|2015-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)||Terminated||Phase 3|247|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:19.091343|2018-06-01 02:51:19.091343
NCT00542997|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2011-02-08||2011-08-02|2007-10-11|2007-10-12|Estimate|2011-02-17|2011-03-15|Estimate||||2011-08-02|2011-09-01|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy|A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency|Completed||Phase 3|51|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 02:51:19.183374|2018-06-01 02:51:19.183374
NCT00542984|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-12|Estimate|||||||2007-10-10|2007-10-12|Estimate|August 2003||2003-08-31|October 2007|2007-10-31|November 2004|Actual|2004-11-30|||||Interventional|||Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis|Comparison of Teriparatide and Calcitonin in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|70|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:51:19.511424|2018-06-01 02:51:19.511424
NCT00542971|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2012-06-12||2012-06-12|2007-10-11|2007-10-12|Estimate|2012-06-12|2012-07-13|Estimate||||2012-06-12|2012-07-13|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)|Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral VEGF, RAF and FLT3 Inhibitor, in Patients With High-risk MDS and AML|Completed||Phase 1/Phase 2|78|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:51:19.600898|2018-06-01 02:51:19.600898
NCT00542958|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2013-03-18|2007-10-11|2007-10-12|Estimate|||||||2013-03-18|2013-03-20|Estimate|March 2007||2007-03-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|April 2008|Actual|2008-04-30||Interventional|||Study of NK012 in Patients With Refractory Solid Tumors|A Phase I Dose-escalation Study of NK012 Administered Intravenously as a Single Dose Every Three Weeks in Patients With Refractory Solid Tumors|Completed||Phase 1|39|Actual|Nippon Kayaku Co.,Ltd.||1|||f||||f||||||||||2018-06-01 02:51:19.805061|2018-06-01 02:51:19.805061
NCT00542945|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2015-03-05|2007-10-11|2007-10-12|Estimate|||||||2015-03-05|2015-03-06|Estimate|December 2007||2007-12-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|DANISH||Danish ICD Study in Patients With Dilated Cardiomyopathy|A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study|Unknown status|Active, not recruiting|Phase 4|1000|Anticipated|Danish Study Group||2|||f||||t||||||||||2018-06-01 02:51:19.868994|2018-06-01 02:51:19.868994
NCT00542932|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2007-10-11|2007-10-11|2007-10-12|Estimate|||||||2007-10-11|2007-10-12|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|October 2006|Actual|2006-10-31|||||Interventional|||The Effects of a Home Exercise Video Programme for Patients With COPD|The Effects of a Home Exercise Video Programme for Patients With Chronic Obstructive Pulmonary Disease:Pilot Study|Completed||Phase 2|27|Actual|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-06-01 02:51:19.933195|2018-06-01 02:51:19.933195
NCT00542919|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10||2011-02-25|2018-04-09|2007-10-10|2007-10-12|Estimate||||2011-08-09|2011-08-15|Estimate|2018-04-09|2018-04-11|Actual|November 2007||2007-11-30|April 2018|2018-04-30|February 27, 2018|Actual|2018-02-27|March 2010|Actual|2010-03-31||Interventional|||A Study for Patients With Non-Hodgkin's Lymphomas|A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas|Completed||Phase 2|57|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:51:19.998208|2018-06-01 02:51:19.998208
NCT00542906|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2009-06-16|2007-10-11|2007-10-12|Estimate|||||||2009-06-16|2009-06-17|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Functional Organization of Somatosensory Responses in the Secondary Somatosensitive Area and Insula|Functional Organization of Somatosensory Responses in the Secondary Somatosensitive Area (SII) and Insula : an fMRI Study|Completed||N/A|25|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 02:51:20.086857|2018-06-01 02:51:20.086857
NCT00542893|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2012-03-11|2007-10-10|2007-10-12|Estimate|||||||2012-03-11|2012-03-13|Estimate|April 2006||2006-04-30|March 2012|2012-03-31|September 2007|Actual|2007-09-30|||||Interventional|||A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine|A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma|Completed||Phase 1|||Genta Incorporated||2|||f||||f||||||||||2018-06-01 02:51:20.14574|2018-06-01 02:51:20.14574
NCT00542880|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2009-08-04||2012-07-27|2007-10-10|2007-10-12|Estimate|2012-07-27|2012-08-30|Estimate||||2012-07-27|2012-08-30|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|SPEED||Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®|A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 μg, Compared With Seretide® Diskus® 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each.|Completed||Phase 4|442|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:51:20.23572|2018-06-01 02:51:20.23572
NCT00542867|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2007-11-19|2007-10-11|2007-10-12|Estimate|||||||2007-11-19|2007-11-20|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|CEPHEUS||Pan-European Survey on the Under Treatment of Hypercholesterolemia|Pan-European Survey on the Under Treatment of Hypercholesterolemia|Completed|||6500|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:51:20.79332|2018-06-01 02:51:20.79332
NCT00542854|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2009-01-27|2007-10-10|2007-10-12|Estimate|||||||2009-01-27|2009-01-28|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||iPod and Other MP3 Players on ICDs and Pacemakers in Children|A Pilot Study on the Effects of Digital Music Players on Implantable Cardioverter Defibrillators and Pacemakers in Pediatrics and Congenital Heart Disease|Completed|||100|Anticipated|Boston Children’s Hospital|||1||f||||f||||||||||2018-06-01 02:51:20.84525|2018-06-01 02:51:20.84525
NCT00542841|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2015-12-10|2007-10-10|2007-10-12|Estimate|||||||2015-12-10|2015-12-14|Estimate|August 2007||2007-08-31|December 2015|2015-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Examining Genetic Differences Among People With 21-Hydroxylase Deficiency|Modifier Genes in 21-Hydroxylase Deficiency|Completed||N/A|99|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-06-01 02:51:20.914615|2018-06-01 02:51:20.914615
NCT00542828|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2010-04-07||2015-03-17|2007-10-11|2007-10-12|Estimate|2010-04-07|2010-04-27|Estimate||||2015-03-17|2015-04-03|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|RISE||Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome|A Phase II Study of the Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in Patients With Low and Intermediate-1 Risk Myelodysplastic Syndrome|Terminated||Phase 2|16|Actual|Sanofi|The study was terminated early due to a slow enrollment rate; therefore, only safety data were collected from participants for 45 days following the last day of infusion (Day 5).|1||Study terminated due to slow enrollment.|f||||f||||||||||2018-06-01 02:51:21.028287|2018-06-01 02:51:21.028287
NCT00542815|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2014-09-16||2014-09-24|2007-10-10|2007-10-12|Estimate|2014-09-16|2014-09-23|Estimate||||2014-09-24|2014-10-02|Estimate|November 2007||2007-11-30|September 2014|2014-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia|A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia|Completed||Phase 3|632|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 02:51:21.536227|2018-06-01 02:51:21.536227
NCT00542802|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|||2008-05-26|2007-10-11|2007-10-12|Estimate|||||||2008-05-26|2008-05-30|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|EpIc||Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis|Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis|Unknown status|Recruiting|Phase 3|630|Anticipated|Scienze Neurologiche Ospedaliere||2|||f||||f||||||||||2018-06-01 02:51:22.790343|2018-06-01 02:51:22.790343
NCT00542789|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-11|2010-02-16||2010-05-10|2007-10-11|2007-10-12|Estimate|2010-05-10|2010-05-28|Estimate||||2010-05-10|2010-05-28|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|February 2009|Actual|2009-02-28|||||Interventional|||Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID|A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use|Completed||Phase 3|343|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:51:23.083942|2018-06-01 02:51:23.083942
NCT00542776|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2008-04-30|2007-10-09|2007-10-11|Estimate|||||||2008-04-30|2008-05-01|Estimate|October 2007||2007-10-31|December 2007|2007-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine|Impact of Immunosuppression in Patients With Inflammatory Bowel Disease on Responsiveness to Influenza Vaccine|Completed|||146|Actual|Boston Children’s Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood for seroprotection rate and antibody titers~   "|||2018-06-01 02:51:23.473633|2018-06-01 02:51:23.473633
NCT00542763|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-11|Estimate|||||||2007-10-10|2007-10-11|Estimate|April 2005||2005-04-30|August 2004|2004-08-31|September 2007|Actual|2007-09-30|||||Interventional|||Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome|Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome - An Open Label Pilot Trial|Completed||Phase 1|12|Actual|University Hospital Muenster|||||f||||f||||||||||2018-06-01 02:51:23.556456|2018-06-01 02:51:23.556456
NCT00542750|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2010-09-23||2018-04-23|2007-10-10|2007-10-11|Estimate|2018-04-23|2018-05-23|Actual||||2018-04-23|2018-05-23|Actual|January 2008||2008-01-31|April 2018|2018-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|NAC MJ Pilot||An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents|An Open-Label Trial of N-Acetylcysteine in Cannabis Dependent Adolescents|Completed||Phase 1/Phase 2|24|Actual|Medical University of South Carolina|This was a small, open-label, non-controlled trial, with the associated limitations. A controlled trial is needed to test the effects of N-acetylcysteine relative to placebo.|1|||f||||t||||||||||2018-06-01 02:51:23.627573|2018-06-01 02:51:23.627573
NCT00542737|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2013-07-09|2007-10-10|2007-10-11|Estimate|||||||2013-07-09|2013-07-11|Estimate|February 2009||2009-02-28|August 2010|2010-08-31|July 2014|Anticipated|2014-07-31|September 2013|Anticipated|2013-09-30||Interventional|LINK||Evaluating a Web-Based Ventilator Management Educational Program for Clinicians (The Lung Injury Knowledge Network [LINK] Study)|Improving Ventilator Management and Preventing Injury to Patients With Acute Respiratory Failure|Unknown status|Active, not recruiting|N/A|120|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 02:51:23.802204|2018-06-01 02:51:23.802204
NCT00542724|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05||2010-01-21|2015-07-30|2007-10-09|2007-10-11|Estimate||||2010-01-21|2010-02-15|Estimate|2015-07-30|2015-08-03|Estimate|September 2006||2006-09-30|July 2015|2015-07-31||||July 2008|Actual|2008-07-31||Interventional|||An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus|An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|462|Actual|Biodel||2|||f||||f||||||||||2018-06-01 02:51:23.868924|2018-06-01 02:51:23.868924
NCT00542711|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2015-08-19|2007-10-10|2007-10-11|Estimate|||||||2015-08-19|2015-08-20|Estimate||||August 2015|2015-08-31||||||||Interventional|||Bio-availability of a New Liquid Tumeric Extract|Liquid Tumeric Extract for Increasing Bio-availability of Curcumin in the Human Body: Pharmacokinetic Study.|Withdrawn||Phase 1|0|Actual|Hadassah Medical Organization||||Technical difficulties|f||||||||||||||2018-06-01 02:51:23.933643|2018-06-01 02:51:23.933643
NCT00542698|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-11|Estimate|||||||2007-10-10|2007-10-11|Estimate|July 2004||2004-07-31|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Changing Physical Activity Behavior in Individuals With Type 2 Diabetes Using Counceling and Information From Continuous Glucose Monitoring|Changing Activity Behavior With Glucose Sensor Feedback|Completed||Phase 1|52|Actual|National Institute of Nursing Research (NINR)||2|||f||||||||||||||2018-06-01 02:51:24.013259|2018-06-01 02:51:24.013259
NCT00542685|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10||2009-12-10|2012-11-09|2007-10-10|2007-10-11|Estimate||||2009-12-10|2009-12-14|Estimate|2012-11-09|2012-11-16|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder|A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group, 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder|Completed||Phase 3|551|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 02:51:24.077168|2018-06-01 02:51:24.077168
NCT00542672|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2013-05-20|2007-10-10|2007-10-11|Estimate|||||||2013-05-20|2013-05-22|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Evaluating Parental Influences on Obesity Among Mexican American Children|Parental Influences on Obesity Among Mexican American Children|Completed|||831|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 02:51:25.171665|2018-06-01 02:51:25.171665
NCT00542659|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2011-07-22|2007-10-10|2007-10-11|Estimate|||||||2011-07-22|2011-07-25|Estimate|February 2005||2005-02-28|July 2011|2011-07-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Observational|||Biochemical Marker to Predict the Recurrence of Atrial Fibrillation After Surgical Maze Procedure|Plasma ANP and NT-pro-BNP, Atrial Anatomical Change May Determine the Outcome of Maze Operation|Completed|||86|Anticipated|Samsung Medical Center|||||f||||f||||||Samples Without DNA|"~     plasma mRNA~   "|||2018-06-01 02:51:25.231074|2018-06-01 02:51:25.231074
NCT00542646|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-11-27|2007-10-10|2007-10-11|Estimate|||||||2007-11-27|2007-11-28|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|November 2010|Anticipated|2010-11-30|||||Interventional|||Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System|Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System|Unknown status|Recruiting|Early Phase 1|45|Anticipated|PeriTec Biosciences Ltd.|||||f||||f||||||||||2018-06-01 02:51:25.28907|2018-06-01 02:51:25.28907
NCT00542633|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09||2010-01-21|2015-07-28|2007-10-09|2007-10-11|Estimate||||2010-01-21|2010-02-15|Estimate|2015-07-28|2015-08-18|Estimate|December 2006||2006-12-31|July 2015|2015-07-31||||August 2008|Actual|2008-08-31||Interventional|||An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus|An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|472|Actual|Biodel||2|||f||||f||||||||||2018-06-01 02:51:25.357772|2018-06-01 02:51:25.357772
NCT00542620|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2011-12-05||2014-10-24|2007-10-10|2007-10-11|Estimate|2012-12-11|2013-01-18|Estimate||||2014-10-24|2014-11-03|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|MIXING||Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial|A Randomised, Multicentric, Open Labelled, Parallel Group Trial With Insulin Aspart and Insulin Detemir, Investigating the Glycaemic Effect and Profile in Children With Type 1 Diabetes, of Two Separate Levemir® + NovoRapid® Injections and Extemporaneous Mixing - The Paediatric MIXING Trial|Completed||Phase 4|25|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 02:51:25.478346|2018-06-01 02:51:25.478346
NCT00542607|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2013-12-11|2007-10-10|2007-10-11|Estimate|||||||2013-12-11|2013-12-12|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis|Trial to Compare the Efficacy and Safety of Levocetirizine 5 mg od and Fexofenadine 120 mg od in Reducing Symptoms of Seasonal Allergic Rhinitis in Grass Pollen Sensitized Adults|Completed||Phase 4|94|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:51:26.480364|2018-06-01 02:51:26.480364
NCT00542594|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2013-02-06|2007-10-10|2007-10-11|Estimate|||||||2013-02-06|2013-02-07|Estimate|November 2005||2005-11-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|ARIES||Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy|A Report Upon a Cohort of Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy for Hormone-dependant Breast Cancer. Long-term Tolerance Evaluation|Terminated|||1840|Actual|AstraZeneca||||No results are avaialble as the study did not complete according to the protocol|f||||f||||||||||2018-06-01 02:51:26.539143|2018-06-01 02:51:26.539143
NCT00542581|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2016-05-03|2007-10-10|2007-10-11|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|TORILIOL||Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.|Evaluation of the Acrysof Toric SN60T3 Intraocular Lens in Patients With Predicted Residual Corneal Astigmatism Between 0.75 and 1.00 D.|Completed||N/A|4|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-06-01 02:51:26.586238|2018-06-01 02:51:26.586238
NCT00542568|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2014-04-16|2007-10-10|2007-10-11|Estimate|||||||2014-04-16|2014-04-17|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Efficacy of Sustained Erythropoietin Therapy|Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients Using EPODURE Biopump|Completed||Phase 1/Phase 2|19|Actual|Medgenics Medical Israel Ltd.||3|||f||||t||||||||||2018-06-01 02:51:26.664169|2018-06-01 02:51:26.664169
NCT00542555|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2011-06-16|2007-10-10|2007-10-11|Estimate|||||||2011-06-16|2011-06-17|Estimate|December 2005||2005-12-31|June 2011|2011-06-30|September 2007|Actual|2007-09-30|||||Interventional|||Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee|301: A Phase 3 Study of the Analgesic Efficacy and Safety of HCT 3012: A Parallel, Randomized, Double Blind, 13 Week Placebo and Naproxen Controlled, Multicenter Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Patients With Osteoarthritis of the Knee, Followed by Its Extension (301E): A Parallel, Randomized, Open-Label, Multicenter, 52-Week Follow-up Safety Study of HCT 3012 (375 mg Bid and 750 mg Bid) in Subjects With Osteoarthritis of the Knee|Completed||Phase 3|918|Actual|NicOx||4|||f||||t||||||||||2018-06-01 02:51:26.747663|2018-06-01 02:51:26.747663
NCT00542542|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2015-03-31||2015-03-31|2007-10-10|2007-10-11|Estimate|2015-03-31|2015-04-13|Estimate||||2015-03-31|2015-04-13|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||One participant was removed prior to study randomization.|Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery|Prospective Randomized Clinical Trial to Evaluate the Use of Paravertebral Blocks in Reconstructive Breast Surgery|Completed||Phase 3|89|Actual|M.D. Anderson Cancer Center|The study completed with measurement reporting issues (inconsistencies) leading to uninterpretable data.|2|||f||||t||||||||||2018-06-01 02:51:26.816479|2018-06-01 02:51:26.816479
NCT00542529|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-11|Estimate|||||||2007-10-10|2007-10-11|Estimate|November 2006||2006-11-30|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Phase I/II, Randomized, Double-Blind, Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone|Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Single-Center Study of the Progenitor Cell Mobilizing Effects of Imprime PGG™ Injection Administered at Varied Dosing Regimens With G-CSF Versus G-CSF Alone in Healthy Subjects|Completed||Phase 1/Phase 2|66|Actual|Biothera||2|||f||||t||||||||||2018-06-01 02:51:27.069042|2018-06-01 02:51:27.069042
NCT00542516|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2009-02-18|2007-10-09|2007-10-11|Estimate|||||||2009-02-18|2009-02-19|Estimate|September 2006||2006-09-30|February 2009|2009-02-28|November 2008|Actual|2008-11-30|||||Interventional|||Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty|Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty: Hydroxyethyl Starch Versus Ringer's Lactate|Completed||Phase 4|48|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 02:51:27.136929|2018-06-01 02:51:27.136929
NCT00542503|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-10-20|2007-10-10|2007-10-11|Estimate|||||||2017-10-20|2017-10-24|Actual|June 2007||2007-06-30|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PREDICT||Using Magnetic Resonance Imaging to Predict People Who Are Likely to Develop Flash Pulmonary Edema (The PREDICT Study)|Vascular Stiffness and Pulmonary Congestion|Completed|||579|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 02:51:27.239041|2018-06-01 02:51:27.239041
NCT00542490|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2017-04-14||2017-09-25|2007-10-10|2007-10-11|Estimate|2017-09-25|2017-09-27|Actual||||2017-09-25|2017-09-27|Actual|September 2007||2007-09-30|September 2017|2017-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer|Phase II Trial of Vaginal Cuff Brachytherapy Followed by Carboplatin and Paclitaxel Chemotherapy in Patients With Stage I-IIb Papillary Serous, Clear Cell and Endometrioid Endometrial Cancer With High-Intermediate Risk Factors|Completed||Phase 2|23|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 02:51:27.309744|2018-06-01 02:51:27.309744
NCT00542477|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2008-04-29|2007-10-09|2007-10-11|Estimate|||||||2008-04-29|2008-05-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:51:27.495608|2018-06-01 02:51:27.495608
NCT00542464|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-11|Estimate|||||||2007-10-10|2007-10-11|Estimate|May 2006||2006-05-31|October 2007|2007-10-31|September 2006|Actual|2006-09-30|||||Interventional|||Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Imprime PGG™ Injection|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG™ Injection in Healthy Adult Subjects|Completed||Phase 1|12|Actual|Biothera||3|||f||||t||||||||||2018-06-01 02:51:27.529436|2018-06-01 02:51:27.529436
NCT00542451|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2018-01-30|2007-10-09|2007-10-11|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2007||2007-10-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer|A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer|Active, not recruiting||Phase 2|420|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 02:51:27.5898|2018-06-01 02:51:27.5898
NCT00542438|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2017-10-13|2007-10-10|2007-10-11|Estimate|||||||2017-10-13|2017-10-16|Actual|October 2007|Actual|2007-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Home-Based Measures of Physical Activity and Body Composition|Feasibility and Validity of Home-Based Measures of Physical Activity and Body Composition|Active, not recruiting||N/A|75|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 02:51:27.685049|2018-06-01 02:51:27.685049
NCT00542425|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2010-06-30||2017-09-27|2007-10-10|2007-10-11|Estimate|2010-06-30|2010-07-29|Estimate||||2017-09-27|2017-10-30|Actual|April 2007||2007-04-30|September 2017|2017-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis|A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 2|222|Actual|Radius Health, Inc.||5|||f||||f||||||||||2018-06-01 02:51:27.785016|2018-06-01 02:51:27.785016
NCT00542412|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-11|Estimate|||||||2007-10-10|2007-10-11|Estimate|January 2001||2001-01-31|October 2007|2007-10-31|December 2004|Actual|2004-12-31|||||Interventional|||CARE Canadian ALS Riluzole Evaluation|Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls|Completed||Phase 4|414|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:51:28.386278|2018-06-01 02:51:28.386278
NCT00542399|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2011-11-01|2007-10-10|2007-10-11|Estimate|||||||2011-11-01|2011-11-02|Estimate|November 2007||2007-11-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections|Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections in Children and Adolescence With Type 1 Diabetes Mellitus.|Completed||Phase 4|50|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 02:51:28.434718|2018-06-01 02:51:28.434718
NCT00542386|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2014-04-10|2010-06-24|2014-09-30|2007-10-10|2007-10-11|Estimate|2014-09-30|2014-10-06|Estimate|2010-06-24|2010-06-25|Estimate|2014-09-30|2014-10-06|Estimate|December 2007||2007-12-31|September 2014|2014-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||Each one subject in the MCI-196 9 g group, MCI-196 12 g group, and MCI-196 15 g group were randomised but did not receive any study medication. Therefore these 3 subjects were excluded in the baseline characteristics analysis population.|A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia|A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups)|Completed||Phase 3|642|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||t||||||||||2018-06-01 02:51:28.574788|2018-06-01 02:51:28.574788
NCT00542373|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2017-08-17|2007-10-10|2007-10-11|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2007|Actual|2007-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Fluorescence & Reflectance Imaging to Detect Oral Neoplasia|Fluorescence & Reflectance Imaging to Detect Oral Neoplasia|Recruiting||N/A|300|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:51:30.306848|2018-06-01 02:51:30.306848
NCT00542360|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2015-03-05|2007-10-09|2007-10-11|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Marketing Fall Prevention Classes to Older Adults in Faith-Based Congregations|Marketing Fall Prevention Classes to Older Adults in Faith-Based Congregations: Cluster Randomized Controlled Trial|Completed||N/A|51|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 02:51:30.393453|2018-06-01 02:51:30.393453
NCT00542347|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2018-04-04|2007-10-09|2007-10-11|Estimate|||||||2018-04-04|2018-04-06|Actual|September 2007||2007-09-30|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole|Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole|Completed||Phase 3|20|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:51:30.47026|2018-06-01 02:51:30.47026
NCT00542334|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2010-01-25|2007-10-10|2007-10-11|Estimate|||||||2010-01-25|2010-01-26|Estimate|September 2008||2008-09-30|November 2008|2008-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Prevalence of Nocturnal Hypoglycemia in Children on a Type 1 Diabetes (TID) Insulin Regimen Using a Continuous Glucose Monitoring System (CGMS)|Prevalence of Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes on a Standard (TID) Insulin Regimen Using a Continuous Glucose Monitoring System (CGMS) - A Pilot Study|Completed|||30|Actual|Children's Hospital of Eastern Ontario|||||f||||f||||||||||2018-06-01 02:51:30.528737|2018-06-01 02:51:30.528737
NCT00542321|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|2012-10-02||2016-03-08|2007-10-09|2007-10-11|Estimate|2013-06-18|2013-07-24|Estimate||||2016-03-08|2016-04-06|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pilot Study of Lateral Rotation Interventions for Efficacy and Safety in ICU Care|Multi-site Randomized Clinical Trial of Horizontal Positioning to Prevent and Treat Pulmonary Complications in Mechanically Ventilated Critically Ill Patients|Completed||N/A|16|Actual|The University of Texas Health Science Center, Houston|Reliance on chest X-ray interpretation only for detection of preventable pulmonary complications; small pilot study; kinetic therapy bed turn angle was less than 45 degrees|2|||f||||t||||||||||2018-06-01 02:51:30.597395|2018-06-01 02:51:30.597395
NCT00542308|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|2014-08-12||2014-08-12|2007-10-10|2007-10-11|Estimate|2014-08-12|2014-08-27|Estimate||||2014-08-12|2014-08-27|Estimate|January 2008||2008-01-31|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All patients attending Visit 2 were included in the full analysis set irrespective of their compliance with the planned course of zalutumumab.|Zalutumumab in Non-curable Patients With SCCHN|An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.|Completed||Phase 2|90|Actual|Genmab|This was an uncontrolled single-arm open-label trial with no formal statistical tests planned.|1|||f||||t||||||||||2018-06-01 02:51:31.145373|2018-06-01 02:51:31.145373
NCT00542295|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2008-09-30|2007-10-10|2007-10-11|Estimate|||||||2008-09-30|2008-10-01|Estimate|July 2007||2007-07-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome|Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial|Completed||Phase 4|400|Anticipated|Laboratoires Mayoly Spindler||2|||f||||t||||||||||2018-06-01 02:51:31.413631|2018-06-01 02:51:31.413631
NCT00542282|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2009-06-15|2007-10-10|2007-10-11|Estimate|||||||2009-06-15|2009-06-16|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|August 2007|Actual|2007-08-31|||||Observational|||Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma|Evaluation of Vibration Response Imaging (VRI) in Chronic Obstructive Pulmonary Disease and Asthma Patients Before and After Bronchodilators|Completed|||75|Anticipated|Deep Breeze|||1||f||||f||||||||||2018-06-01 02:51:31.510712|2018-06-01 02:51:31.510712
NCT00542269|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|2011-01-06||2011-04-26|2007-10-10|2007-10-11|Estimate|2011-04-26|2011-05-24|Estimate||||2011-04-26|2011-05-24|Estimate|March 2008||2008-03-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ALTO||Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome|A Twelve Week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Ramipril/Amlodipine (300/10/5-10 mg) Compared to the Combinations of Ramipril/Amlodipine (10/5-10 mg) and Aliskiren/Amlodipine (300/5-10 mg) in Patients With Essential Hypertension and Metabolic Syndrome Not Adequately Responsive to Amlodipine 5-10 mg|Terminated||Phase 4|178|Actual|Novartis||3||Early termination of the study due to slow recruitment.|f||||f||||||||||2018-06-01 02:51:31.579993|2018-06-01 02:51:31.579993
NCT00542256|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2017-03-17|2007-10-10|2007-10-11|Estimate|||||||2017-03-17|2017-03-21|Actual|September 2007||2007-09-30|March 2017|2017-03-31|November 10, 2014|Actual|2014-11-10|November 10, 2014|Actual|2014-11-10||Interventional|||tDCS and Physical Therapy in Stroke|Effects of Transcranial DC Stimulation Coupled With Constraint Induced Movement Therapy on Motor Function in Stroke Patients|Completed||N/A|85|Actual|Beth Israel Deaconess Medical Center||2|||f||||t|f|f||||||||2018-06-01 02:51:32.225124|2018-06-01 02:51:32.225124
NCT00542243|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2015-12-07|2007-10-09|2007-10-11|Estimate|||||||2015-12-07|2015-12-09|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Prostress||A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy|A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of PROSCAR in Men With Initial Negative Prostate Biopsies|Completed||Phase 3|19|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:51:32.307105|2018-06-01 02:51:32.307105
NCT00542230|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2018-05-18|2007-10-10|2007-10-11|Estimate|||||||2018-05-18|2018-05-21|Actual|October 9, 2007||2007-10-09|November 28, 2017|2017-11-28||||||||Observational|||Blood Sampling for Research Related to Sickle Cell Disease|High Sensitivity Screening of Compound Libraries to Discover a Drug for the Treatment of Sickle Cell Disease|Enrolling by invitation|||36|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:51:32.380701|2018-06-01 02:51:32.380701
NCT00542217|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-10|||2007-10-10|2007-10-10|2007-10-11|Estimate|||||||2007-10-10|2007-10-11|Estimate|December 2005||2005-12-31|October 2007|2007-10-31|April 2006|Actual|2006-04-30|||||Interventional|||Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection|Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG™ Injection in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Biothera||5|||f||||t||||||||||2018-06-01 02:51:32.440194|2018-06-01 02:51:32.440194
NCT00542204|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2015-04-27|2007-10-09|2007-10-10|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2008||2008-03-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|EMPOWER-D||Use of Online Personalized Health Record System to Promote Self-Management of Diabetes|Patient-Centered Online Disease Management Using a Personal Health Record System|Completed||N/A|415|Actual|Palo Alto Medical Foundation||2|||f||||t||||||||||2018-06-01 02:51:32.512086|2018-06-01 02:51:32.512086
NCT00542191|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2017-08-22|2007-10-09|2007-10-10|Estimate|||||||2017-08-22|2017-08-24|Actual|July 2007||2007-07-31|August 2017|2017-08-31|August 2, 2016|Actual|2016-08-02|August 2, 2016|Actual|2016-08-02||Interventional|||Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer|Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer|Terminated||Phase 2|30|Actual|Leo W. Jenkins Cancer Center||1||Enrollment Completed|f||||f||||||||||2018-06-01 02:51:32.589811|2018-06-01 02:51:32.589811
NCT00542178|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|2012-04-27||2013-11-22|2007-10-09|2007-10-10|Estimate|2013-11-22|2013-11-26|Estimate||||2013-11-22|2013-11-26|Estimate|October 2003||2003-10-31|November 2013|2013-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||All participants were enrolled in either the intensive or standard glycemia control arms. In addition, participants were included as either part of the blood pressure trial (randomized to intensive or standard) OR the lipid trial (fibrate or fibrate placebo). We completed analysis on participants for whom we had baseline and follow-up data.|Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)|Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study|Completed||Phase 3|3472|Actual|National Heart, Lung, and Blood Institute (NHLBI)|The glycemia trial was stopped early, potentially underestimating the reported effect of glycemia treatment on diabetic retinopathy.|6|||f||||t||||||||||2018-06-01 02:51:32.765259|2018-06-01 02:51:32.765259
NCT00542165|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2007-10-10|2007-10-09|2007-10-10|Estimate|||||||2007-10-10|2007-10-11|Estimate|March 2004||2004-03-31|October 2007|2007-10-31|December 2004|Actual|2004-12-31|||||Interventional|||Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy|Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL) in Patients With Benign Prostatic Hypertrophy|Completed||Phase 4|166|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:51:33.694054|2018-06-01 02:51:33.694054
NCT00542152|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2011-08-30|2007-10-09|2007-10-10|Estimate|||||||2011-08-30|2011-08-31|Estimate|June 2007||2007-06-30|August 2011|2011-08-31|October 2010|Actual|2010-10-31|June 2007|Actual|2007-06-30||Interventional|CYSIF||Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis|A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis|Completed||Phase 4|115|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||2|||f||||f||||||||||2018-06-01 02:51:33.776312|2018-06-01 02:51:33.776312
NCT00542139|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-07|||2008-11-09|2007-10-09|2007-10-10|Estimate|||||||2008-11-09|2008-11-11|Estimate|December 2007||2007-12-31|October 2007|2007-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of Diprospan Injection to the Knee on Rehabilitation of Patients After TKR of the Contralateral Knee|Evaluation of the Efficacy of Diprospan Injection to the Knee on Rehabilitation of Patients With Bilateral Knee Osteoarthritis After TKR of the Contralateral Knee.|Completed||Phase 4|50|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 02:51:33.918182|2018-06-01 02:51:33.918182
NCT00542126|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-10-09|2007-10-09|2007-10-10|Estimate|||||||2007-10-09|2007-10-10|Estimate|December 2007||2007-12-31|September 2007|2007-09-30|September 2009|Anticipated|2009-09-30|||||Interventional|||Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles||Unknown status|Not yet recruiting|N/A|||Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 02:51:33.981497|2018-06-01 02:51:33.981497
NCT00542113|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2014-11-05|2007-10-09|2007-10-10|Estimate|||||||2014-11-05|2014-11-07|Estimate|September 2001||2001-09-30|November 2014|2014-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|DvtENERGY||Diabetes Virtual Trek: Obesity and Diabetes Prevention Through Science Enrichment|Diabetes Virtual Trek Prevention: Obesity and Diabetes Prevention Through Science Enrichment|Completed||N/A|1703|Actual|Colorado State University||3|||f||||f||||||||||2018-06-01 02:51:34.044261|2018-06-01 02:51:34.044261
NCT00542100|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-07|||2007-10-09|2007-10-09|2007-10-10|Estimate|||||||2007-10-09|2007-10-10|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|November 2008|Anticipated|2008-11-30|||||Interventional|PCMRI||PCMRI - an MRI/TRUS System for the Evaluation of the Prostate||Unknown status|Not yet recruiting|N/A|50|Anticipated|TopSpin Medical||2|||f||||f||||||||||2018-06-01 02:51:34.111308|2018-06-01 02:51:34.111308
NCT00542087|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-04-06|2007-10-05|2007-10-10|Estimate|||||||2017-04-06|2017-04-10|Actual|March 22, 2002|Actual|2002-03-22|April 2017|2017-04-30|December 20, 2002|Actual|2002-12-20|December 20, 2002|Actual|2002-12-20||Interventional|||Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)|A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Etoricoxib 60 mg and Diclofenac Sodium 150 mg in Patient With Osteoarthritis of the Knee or Hip|Completed||Phase 3|516|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:34.275567|2018-06-01 02:51:34.275567
NCT00542061|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2010-03-08|2007-10-08|2007-10-10|Estimate|||||||2010-03-08|2010-03-09|Estimate|March 2005||2005-03-31|October 2007|2007-10-31|April 2008|Actual|2008-04-30|February 2007|Actual|2007-02-28||Interventional|Monaco||Monitoring Asthma and COPD in Primary Care|Clinical Effectiveness and Cost-effectiveness of a Monitoring System for Patients With COPD and Asthma With Persistent Obstruction in Primary Care; a Multicentre Randomised Nested Clinical Trial|Completed||N/A|200||Radboud University||2|||f||||f||||||||||2018-06-01 02:51:34.431448|2018-06-01 02:51:34.431448
NCT00542048|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2010-02-08|2007-10-09|2007-10-10|Estimate|||||||2010-02-08|2010-02-09|Estimate|November 2007||2007-11-30|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases|An Open-label, Uncontrolled, Phase II Trial Evaluating the Single-dose and Steady-state Pharmacokinetics of EndoTAG®-1 and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma|Completed||Phase 2|20|Actual|MediGene||1|||f||||f||||||||||2018-06-01 02:51:34.509821|2018-06-01 02:51:34.509821
NCT00542035|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05||2009-12-09|2012-01-06|2007-10-05|2007-10-10|Estimate||||2009-12-09|2009-12-11|Estimate|2012-01-06|2012-01-11|Estimate|October 2007||2007-10-31|January 2012|2012-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction||Completed||Phase 2|103|Actual|Array BioPharma||3|||f||||f||||||||||2018-06-01 02:51:34.576056|2018-06-01 02:51:34.576056
NCT00542022|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2015-10-19|2007-10-05|2007-10-10|Estimate|||||||2015-10-19|2015-10-20|Estimate|June 2004||2004-06-30|October 2015|2015-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)|A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0812 in Rheumatoid Arthritis Patients|Completed||Phase 2|149|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:34.646848|2018-06-01 02:51:34.646848
NCT00542009|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05||2009-08-12|2012-11-05|2007-10-05|2007-10-10|Estimate||||2009-08-12|2009-08-13|Estimate|2012-11-05|2012-11-07|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight|A 12-Week, Phase 2A, Randomized, Subject And Investigator Blinded, Placebo-Controlled Trial To Evaluate The Safety, Tolerability And Efficacy Of CE-326,597 On Glucose Control And Body Weight In Overweight Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|252|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 02:51:34.716254|2018-06-01 02:51:34.716254
NCT00541996|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2007-12-03|2007-10-09|2007-10-10|Estimate|||||||2007-12-03|2007-12-05|Estimate|August 2007||2007-08-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Study Comparing Bioavailability of Oral Formulations of Vabicaserin|A Randomized, Open-Label, Single-Dose, 4-Period Crossover, Comparative Bioavailability Study of 3 Sustained- Release Formulations and an Immediate- Release Formulation of Vabicaserin (SCA-136) in Healthy Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 02:51:34.9243|2018-06-01 02:51:34.9243
NCT00541983|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2010-05-02|2007-10-08|2007-10-10|Estimate|||||||2010-05-02|2010-05-04|Estimate|September 2007||2007-09-30|May 2010|2010-05-31|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Single-dose, Dose-escalation Study of Safety, PK, and Preliminary Efficacy of XOMA 052 in Type 2 Diabetes Mellitus|A Phase I, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|36|Anticipated|XOMA (US) LLC||2|||f||||t||||||||||2018-06-01 02:51:34.97985|2018-06-01 02:51:34.97985
NCT00541970|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|2012-10-18||2016-09-22|2007-10-09|2007-10-10|Estimate|2014-03-13|2014-04-17|Estimate||||2016-09-22|2016-09-23|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs|Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing|Completed||Phase 1|961|Actual|GlaxoSmithKline|If appropriate, describe significant limitations of the trial. Examples: Early termination leading to small number of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.|4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:51:35.130443|2018-06-01 02:51:35.130443
NCT00541957|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2011-07-06|2007-10-08|2007-10-10|Estimate|||||||2011-07-06|2011-07-08|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients|Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients|Completed||Phase 1|40|Anticipated|Butler Hospital||2|||f||||f||||||||||2018-06-01 02:51:37.381274|2018-06-01 02:51:37.381274
NCT00541944|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2008-04-25|2007-10-09|2007-10-10|Estimate|||||||2008-04-25|2008-04-28|Estimate|April 2007||2007-04-30|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|||||Observational|CONA||Establishment of an Algorithm for a Clinical Classfication of Hypoosmolar Hyponatremia||Unknown status|Recruiting||120|Anticipated|University of Wuerzburg|||||f||||f||||||Samples Without DNA|"~     Serum, plasma and urine~   "|||2018-06-01 02:51:37.449616|2018-06-01 02:51:37.449616
NCT00541931|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2015-02-05||2017-11-15|2007-10-09|2007-10-10|Estimate|2017-11-15|2017-11-20|Actual||||2017-11-15|2017-11-20|Actual|October 2007||2007-10-31|November 2017|2017-11-30|January 2012|Actual|2012-01-31|March 2008|Actual|2008-03-31||Interventional||Participants completing the protocol were included in the analysis.|Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women|Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women|Completed||N/A|37|Actual|Stanford University|Sample size limitation, short term nature of study|2|||f||||t||||||||||2018-06-01 02:51:37.504241|2018-06-01 02:51:37.504241
NCT00541918|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2015-10-27|2007-10-09|2007-10-10|Estimate|||||||2015-10-27|2015-10-28|Estimate|June 2007||2007-06-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||COGNITIVE - Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations|COGNITIVE - Comparison of Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations|Withdrawn||Phase 4|0|Actual|Medical University of Gdansk||2||study suspended due to staff indisposition|f||||f||||||||||2018-06-01 02:51:37.816802|2018-06-01 02:51:37.816802
NCT00541736|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2008-05-28|2007-10-09|2007-10-10|Estimate|||||||2008-05-28|2008-05-29|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine|Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine|Completed||N/A|30|Actual|Danish Headache Center||2|||f||||f||||||||||2018-06-01 02:51:42.012877|2018-06-01 02:51:42.012877
NCT00541905|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2013-06-03|2007-10-08|2007-10-10|Estimate|||||||2013-06-03|2013-06-04|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|May 2010|Actual|2010-05-31|October 2008|Actual|2008-10-31||Interventional|||Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia|Prospective, Single-arm, Multicenter Trial to Investigate the Efficacy and Safety of NT 201 and the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Patients With Cervical Dystonia|Completed||Phase 4|82|Actual|Merz Pharmaceuticals GmbH||1|||f||||||||||||||2018-06-01 02:51:37.909044|2018-06-01 02:51:37.909044
NCT00541892|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2015-05-19|2007-10-09|2007-10-10|Estimate|||||||2015-05-19|2015-05-20|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine|Sibling Oocyte Study of Medium for IVF/ICSI With no Human Serum Albumine|Withdrawn||Phase 2|0|Actual|Sykehuset Telemark||2||senior coworker retired|f||||||||||||||2018-06-01 02:51:37.986961|2018-06-01 02:51:37.986961
NCT00541879|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2014-11-05|2007-10-09|2007-10-10|Estimate|||||||2014-11-05|2014-11-07|Estimate|August 2001||2001-08-31|November 2014|2014-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|DKENERGY||Obesity and Diabetes Prevention Through Science Enrichment|Type 2 Diabetes Knowledge: Obesity and Diabetes Prevention Through Science Enrichment|Completed||N/A|2909|Actual|Colorado State University||2|||f||||f||||||||||2018-06-01 02:51:38.081861|2018-06-01 02:51:38.081861
NCT00541866|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|2017-03-31||2017-12-11|2007-10-09|2007-10-10|Estimate|2017-12-11|2018-01-09|Actual||||2017-12-11|2018-01-09|Actual|October 6, 2007|Actual|2007-10-06|December 2017|2017-12-31|February 15, 2012|Actual|2012-02-15|February 15, 2012|Actual|2012-02-15||Interventional|||Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans|Phase 1b/2, Open-Label, Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and PK and PD Profiles of Voreloxin Injection in Combination With Cytarabine in Patients With Relapsed or Refractory AML|Completed||Phase 1/Phase 2|110|Actual|Sunesis Pharmaceuticals|Further study is needed to confirm the results due to limited sampling size. Statistical fields are not included here because no statistical testings were performed to compare any of the treatment groups. No p-values or odds ratios were reported.|1|||f||||f||||||||No|Aggregate data of Adverse Events|2018-06-01 02:51:38.269935|2018-06-01 02:51:38.269935
NCT00541853|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2007-10-17|2007-10-09|2007-10-10|Estimate|||||||2007-10-17|2007-10-18|Estimate|December 2007||2007-12-31|October 2007|2007-10-31|November 2012|Anticipated|2012-11-30|||||Interventional|||CCB Safety Study in Treatment of Hypertension of ADPKD|Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Kyorin University||3|||f||||t||||||||||2018-06-01 02:51:40.737284|2018-06-01 02:51:40.737284
NCT00541840|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2008-05-08|2007-10-09|2007-10-10|Estimate|||||||2008-05-08|2008-05-12|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|April 2010|Anticipated|2010-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma|Phase I-II, Not-Randomized, Multicenter Clinical Trial to Evaluate Safety and Efficacy of Sorafenib (BAY-43-9006) in Combination With Ifosfamide in Soft Tissue Sarcoma.|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|Grupo Espanol de Investigacion en Sarcomas|||||f||||t||||||||||2018-06-01 02:51:40.956094|2018-06-01 02:51:40.956094
NCT00541827|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2013-09-26|2007-10-09|2007-10-10|Estimate|||||||2013-09-26|2013-09-27|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Observational|||Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis|Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis|Completed|||50|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||t||||||Samples With DNA|"~     muscle tissue, platelets, plasma~   "|||2018-06-01 02:51:41.036761|2018-06-01 02:51:41.036761
NCT00541814|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2008-09-05|2007-10-09|2007-10-10|Estimate|||||||2008-09-05|2008-09-08|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|February 2010|Anticipated|2010-02-28|||||Interventional|CNIM-SRT||Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function|Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial|Unknown status|Recruiting|Phase 4|90|Anticipated|University Hospital Birmingham||2|||f||||t||||||||||2018-06-01 02:51:41.097266|2018-06-01 02:51:41.097266
NCT00541801|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2011-06-22|2007-10-09|2007-10-10|Estimate|||||||2011-06-22|2011-06-27|Estimate|March 2007||2007-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography|Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography in Patients With Cytostatic Therapies|Completed||N/A|||Luzerner Kantonsspital|||||f||||t||||||||||2018-06-01 02:51:41.174767|2018-06-01 02:51:41.174767
NCT00541788|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2010-09-16|2007-10-09|2007-10-10|Estimate|||||||2010-09-16|2010-09-17|Estimate|October 2007||2007-10-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Evaluation of the Efficacy and Safety of Common Sage in Controlling Hot Flashes in Prostate Cancer Patients Treated by Androgen Deprivation|Evaluation of the Efficacy and Safety of Common Sage in Controlling Hot Flashes in Prostate Cancer Patients Treated by Androgen Deprivation|Completed||Phase 1|10|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 02:51:41.260616|2018-06-01 02:51:41.260616
NCT00541775|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2010-05-17||2015-08-21|2007-10-05|2007-10-10|Estimate|2010-05-17|2010-06-17|Estimate||||2015-08-21|2015-08-24|Estimate|June 2006||2006-06-30|August 2015|2015-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)|A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|273|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 02:51:41.360258|2018-06-01 02:51:41.360258
NCT00541762|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2015-03-09|2007-10-09|2007-10-10|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects|Mechanistic Study (Physiology)|Completed||N/A|34|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 02:51:41.834032|2018-06-01 02:51:41.834032
NCT00541749|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-07|||2011-09-21|2007-10-07|2007-10-10|Estimate|||||||2011-09-21|2011-09-22|Estimate|February 2007||2007-02-28|September 2011|2011-09-30||||||||Interventional|||A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus|Completed||Phase 1|60|Anticipated|Genentech, Inc.|||||f||||||||||||||2018-06-01 02:51:41.94574|2018-06-01 02:51:41.94574
NCT00541723|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2012-03-07|2007-10-08|2007-10-10|Estimate|||||||2012-03-07|2012-03-08|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles|A Prospective, Randomized, Double-Blind, Multicenter Trial to Investigate the Efficacy and Safety of NT 201 in Comparison to Placebo and to Compare Two Different Application Schemes of NT 201 in the Treatment of Lateral Periorbital Wrinkles|Completed||Phase 3|111|Actual|Merz Pharmaceuticals GmbH||4|||f||||f||||||||||2018-06-01 02:51:42.097356|2018-06-01 02:51:42.097356
NCT00541710|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2012-09-13|2007-10-09|2007-10-10|Estimate|||||||2012-09-13|2012-09-14|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||Effect of Genistein in Women With Metabolic Syndrome|Genistein Use in Postmenopausal Women With Metabolic Syndrome|Completed||Phase 2/Phase 3|120|Actual|University of Messina||2|||f||||f||||||||||2018-06-01 02:51:42.197353|2018-06-01 02:51:42.197353
NCT00541697|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-04-05|2007-10-05|2007-10-10|Estimate|||||||2017-04-05|2017-04-07|Actual|January 19, 2005|Actual|2005-01-19|April 2017|2017-04-30|October 14, 2005|Actual|2005-10-14|September 28, 2005|Actual|2005-09-28||Interventional|||Eze/Simva Switch Study in Diabetics (0653A-807)|A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes.|Completed||Phase 3|648|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:42.291177|2018-06-01 02:51:42.291177
NCT00541684|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-04-10|2007-10-05|2007-10-10|Estimate|||||||2017-04-10|2017-04-12|Actual|July 11, 2001|Actual|2001-07-11|April 2017|2017-04-30|January 23, 2003|Actual|2003-01-23|January 23, 2003|Actual|2003-01-23||Interventional|||Health Assessment Study (0954-946)|A Randomized, Double-Blind, Two Arm, Parallel Group Health Assessment Study of Losartan or Atenolol in Patients With Mild to Moderate Hypertension|Completed||Phase 3|143|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:42.357197|2018-06-01 02:51:42.357197
NCT00541671|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2012-05-29||2014-03-12|2007-10-05|2007-10-10|Estimate|2014-03-12|2014-03-13|Estimate||||2014-03-12|2014-03-13|Estimate|February 2007||2007-02-28|March 2014|2014-03-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional||Not enough subjects were enrolled into this study. No analysis of data was performed.|Prevention of Narcotic-Induced Nausea|Prevention of Narcotic-induced Nausea With Promethazine, a Randomized, Double-blind Placebo-controlled Trial|Terminated||N/A|25|Actual|Christiana Care Health Services|Early termination due to small numbers of subjects and incomplete data for analysis|2||"Terminated: recruiting or enrolling participants has halted prematurely and will not resume;~   participants are no longer being examined or treated"|f||||f||||||||||2018-06-01 02:51:42.432844|2018-06-01 02:51:42.432844
NCT00541658|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2011-04-13||2013-04-15|2007-10-05|2007-10-10|Estimate|2011-05-23|2011-06-21|Estimate||||2013-04-15|2013-04-22|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis|A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, & 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis.|Completed||Phase 3|923|Actual|Warner Chilcott||3|||f||||f||||||||||2018-06-01 02:51:42.747421|2018-06-01 02:51:42.747421
NCT00541645|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-07|||2008-03-17|2007-10-09|2007-10-10|Estimate|||||||2008-03-17|2008-03-18|Estimate||||March 2008|2008-03-31||||||||Observational|||Transient Osteoporosis of Pregnancy: A Possible Peptide Mediator||Suspended|||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:51:45.071183|2018-06-01 02:51:45.071183
NCT00541632|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-06|||2008-05-14|2007-10-06|2007-10-10|Estimate|||||||2008-05-14|2008-05-15|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|||||Observational|||BacLite Rapid MRSA Clinical Performance|BacLite Rapid MRSA Clinical Performance|Terminated|||||3M||||performance variability|f||||f||||||||||2018-06-01 02:51:45.111677|2018-06-01 02:51:45.111677
NCT00541619|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2013-04-16|2007-10-09|2007-10-10|Estimate|||||||2013-04-16|2013-04-17|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Sympathetic Overactivity in Essential Hypertension|Sympathetic Overactivity in Essential Hypertension|Withdrawn|||0|Actual|University of Erlangen-Nürnberg Medical School|||1|No patients could be recruited.|f||||||||||||||2018-06-01 02:51:45.168182|2018-06-01 02:51:45.168182
NCT00541606|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2009-05-15|2007-10-09|2007-10-10|Estimate|||||||2009-05-15|2009-05-19|Estimate|September 2000||2000-09-30|May 2009|2009-05-31|July 2004|Actual|2004-07-31|||||Interventional|PAMPERED||Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes|Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED)|Completed||N/A|285|Actual|Lahey Clinic||2|||f||||t||||||||||2018-06-01 02:51:46.253407|2018-06-01 02:51:46.253407
NCT00541593|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-07|2011-06-23||2013-09-03|2007-10-09|2007-10-10|Estimate|2013-09-03|2013-11-07|Estimate||||2013-09-03|2013-11-07|Estimate|September 2007||2007-09-30|September 2013|2013-09-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Natural Orifice Translumenal Endoscopic Surgery (NOTES) Cystgastrostomy for the Treatment of Pancreatic Pseudocysts|Natural Orifice Translumenal Endoscopic Surgery (NOTES) Cystgastrostomy for the Treatment of Pancreatic Pseudocysts|Terminated||N/A|5|Actual|Baystate Medical Center|Early termination due to the company that made the device going out of business; the company that acquired it chose not to market the device. Given the lack of clinical support, we chose to terminate the study.|1||SurgAssist device is no longer clinically available.|f||||f||||||||||2018-06-01 02:51:46.337226|2018-06-01 02:51:46.337226
NCT00541580|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-07|||2011-09-15|2007-10-09|2007-10-10|Estimate|||||||2011-09-15|2011-09-16|Estimate||||September 2011|2011-09-30||||||||Observational|||Comparative Results of Conservatively and Surgically Treated Adolescents With Triplane and Juvenile Tillaux Ankle Fractures After Skeletal Maturity||Terminated|||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:51:46.481701|2018-06-01 02:51:46.481701
NCT00541567|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2008-01-08|2007-10-09|2007-10-10|Estimate|||||||2008-01-08|2008-01-09|Estimate|March 2008||2008-03-31|January 2008|2008-01-31|June 2010|Anticipated|2010-06-30|||||Interventional|||BMS-646256 in Obese and Overweight Type 2 Diabetics|A Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Multicenter, Dose-Ranging Phase IIb Trial to Assess Glycemic and Weight Loss Efficacy and Safety of BMS-646256 in Overweight and Obese Patients With Type 2 Diabetes Inadequately Controlled by Diet and Exercise Only or With Metformin or Sulfonylurea Monotherapy|Withdrawn||Phase 2/Phase 3|600|Anticipated|Solvay Pharmaceuticals||4|||f||||t||||||||||2018-06-01 02:51:46.522334|2018-06-01 02:51:46.522334
NCT00541554|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2007-10-09|2007-10-09|2007-10-10|Estimate|||||||2007-10-09|2007-10-10|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|February 2009|Anticipated|2009-02-28|||||Interventional|||Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia|Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial|Unknown status|Not yet recruiting|Phase 4|||Genovate Biotechnology Co., Ltd.,|||||f||||f||||||||||2018-06-01 02:51:46.585516|2018-06-01 02:51:46.585516
NCT00541541|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2013-04-16|2007-10-08|2007-10-10|Estimate|||||||2013-04-16|2013-04-17|Estimate|February 2007||2007-02-28|April 2013|2013-04-30||||May 2012|Actual|2012-05-31||Interventional|||Acoustic Cardiographic Assessment of Heart Function and the Role of Phrenic Nerve Stimulation|Acoustic Cardiographic Assessment of Heart Function and the Role of Phrenic Nerve Stimulation Following Open Heart Surgery|Completed||N/A|||Luzerner Kantonsspital|||||f||||t||||||||||2018-06-01 02:51:46.648433|2018-06-01 02:51:46.648433
NCT00541515|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2016-04-07|2007-10-09|2007-10-10|Estimate|||||||2016-04-07|2016-04-08|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Closing the Loop Between Glucose Sensor and Insulin Pump-developing an Algorithm|Closing the Loop Between Glucose Sensor and Insulin Pump-developing an Algorithm|Completed||N/A|38|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-06-01 02:51:46.710001|2018-06-01 02:51:46.710001
NCT00541502|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2007-10-09|2007-10-09|2007-10-10|Estimate|||||||2007-10-09|2007-10-10|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|October 2008|Anticipated|2008-10-31|||||Observational|||Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder|A Obervational, Prospective Study to Evaluate the Effectiveness of Improving Cognitive Function of Aripiprazole in Treating Adolescents and Young Adults With Psychotic Disorder in Taiwan|Unknown status|Not yet recruiting||||Genovate Biotechnology Co., Ltd.,|||||f||||f||||||||||2018-06-01 02:51:47.604045|2018-06-01 02:51:47.604045
NCT00541489|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2009-02-19|2007-10-09|2007-10-10|Estimate|||||||2009-02-19|2009-02-20|Estimate|June 2007||2007-06-30|February 2009|2009-02-28||||September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip|A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Bid and Naproxen 500 mg Bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT3012) 750 mg Bid, in Patients With Osteoarthritis of the Hip|Completed||Phase 3|800|Anticipated|NicOx||3|||f||||t||||||||||2018-06-01 02:51:47.660296|2018-06-01 02:51:47.660296
NCT00541476|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2008-11-20|2007-10-08|2007-10-10|Estimate|||||||2008-11-20|2008-11-24|Estimate|June 2007||2007-06-30|November 2008|2008-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica|Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Undergoing Symptomatic Treatment With Lyrica|Completed|||746|Actual|Pfizer|||||f||||||||||||||2018-06-01 02:51:47.850562|2018-06-01 02:51:47.850562
NCT00541463|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2017-02-16|2007-10-09|2007-10-10|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2001||2001-01-31|February 2017|2017-02-28|May 2003|Actual|2003-05-31|||||Interventional|||A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)|A Multicenter, Open-Label, Randomized, Study to Compare the Efficacy and Safety of Indinavir 800 mg b.i.d. Plus Ritonavir 100 mg b.i.d. Plus Two NRTIs vs. Nelfinavir 1250 mg b.i.d. Plus Two NRTIs in HIV-1 Seropositive Patients Who Have Failed or Are Intolerant to an NNRTI Containing Regimen|Completed||Phase 2|330|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:51:47.898866|2018-06-01 02:51:47.898866
NCT00541450|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2011-01-13||2017-04-07|2007-10-05|2007-10-10|Estimate|2011-03-11|2011-04-14|Estimate||||2017-04-07|2017-05-12|Actual|January 15, 2008|Actual|2008-01-15|April 2017|2017-04-30|January 16, 2010|Actual|2010-01-16|January 8, 2010|Actual|2010-01-08||Interventional|||A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)|A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|492|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:51:48.002686|2018-06-01 02:51:48.002686
NCT00541437|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2007-10-09|2007-10-09|2007-10-10|Estimate|||||||2007-10-09|2007-10-10|Estimate|May 2006||2006-05-31|October 2007|2007-10-31|February 2007|Actual|2007-02-28|||||Observational|||Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet|An Open-Label Study to Investigate the Efficacy and Safety of Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet|Completed|||12|Actual|Genovate Biotechnology Co., Ltd.,|||||f||||f||||||||||2018-06-01 02:51:48.658164|2018-06-01 02:51:48.658164
NCT00541424|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|||2012-12-05|2007-10-08|2007-10-10|Estimate|||||||2012-12-05|2012-12-06|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma|Feasibility of Combined CT Colonography and PET Imaging for Detection of Colonic Involvement by Mantle Cell Lymphoma|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1|No study recruitment due to time constraints and lack of support.|f||||f||||||||||2018-06-01 02:51:48.766153|2018-06-01 02:51:48.766153
NCT00541411|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2012-04-16|2007-10-09|2007-10-10|Estimate|||||||2012-04-16|2012-04-17|Estimate|June 2003||2003-06-30|April 2012|2012-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma||Unknown status|Active, not recruiting|N/A|10|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:51:48.841436|2018-06-01 02:51:48.841436
NCT00541398|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2009-10-30|2007-10-09|2007-10-10|Estimate|||||||2009-10-30|2009-11-02|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|January 2009|Actual|2009-01-31||Interventional|||Antipsychotic Polypharmacy: Prevalence, Background and Consequences|Antipsychotic Polypharmacy: Prevalence, Background and Consequences|Completed||N/A|222|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-06-01 02:51:48.942|2018-06-01 02:51:48.942
NCT00541385|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2009-01-21|2007-10-09|2007-10-10|Estimate|||||||2009-01-21|2009-01-22|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients|Phase III Comparative, Open-Labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 3|534|Anticipated|Medicines for Malaria Venture||2|||f||||t||||||||||2018-06-01 02:51:49.037608|2018-06-01 02:51:49.037608
NCT00541372|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2009-03-13|2007-10-09|2007-10-10|Estimate|||||||2009-03-13|2009-03-17|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|INOBESE||Needle Length In Obese Insulin-Using Diabetic Subjects|The Influence of the Needle Length on Long Term Glycaemic Control in Insulin Using Obese Diabetic Subjects|Completed||Phase 4|130|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 02:51:49.138173|2018-06-01 02:51:49.138173
NCT00541359|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-08-07|2007-10-05|2007-10-10|Estimate|||||||2017-08-07|2017-08-09|Actual|January 2004||2004-01-31|August 2017|2017-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors|A Phase I Trial of PS-341 in Combination With Topotecan in Advanced Solid Tumor Malignancies|Completed||Phase 1|54|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:51:49.23188|2018-06-01 02:51:49.23188
NCT00541346|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-08|2010-11-15||2013-12-19|2007-10-08|2007-10-10|Estimate|2013-12-19|2014-02-06|Estimate||||2013-12-19|2014-02-06|Estimate|September 2007||2007-09-30|December 2013|2013-12-31|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|||A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms|Phase III Study of Autism Co-Morbid for Attention Deficit Hyperactivity Disorder|Completed||Phase 3|16|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 02:51:49.365804|2018-06-01 02:51:49.365804
NCT00541333|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2013-05-02|2007-10-09|2007-10-10|Estimate|||||||2013-05-02|2013-05-03|Estimate|December 2007||2007-12-31|May 2013|2013-05-31||||December 2012|Actual|2012-12-31||Interventional|||Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration|Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration|Suspended||Phase 1|15|Actual|The New York Eye & Ear Infirmary||2||Reviewing data|f||||t||||||||||2018-06-01 02:51:49.867829|2018-06-01 02:51:49.867829
NCT00541320|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2013-04-01|2007-10-09|2007-10-10|Estimate|||||||2013-04-01|2013-04-04|Estimate|February 2007||2007-02-28|April 2013|2013-04-30||||||||Interventional|||Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)|Dose Ranging Trial for the Evaluation of the Safety and Efficacy of GW813893 in the Prophylaxis of Venous Thromboembolism Post Total Knee Replacement Surgery.|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||||No longer viable|f||||||||||||||2018-06-01 02:51:49.944558|2018-06-01 02:51:49.944558
NCT00541307|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|2012-06-22||2012-11-26|2007-10-09|2007-10-10|Estimate|2012-11-26|2012-12-27|Estimate||||2012-11-26|2012-12-27|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|VIPER||GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)|Post Marketing Study of the GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease (VIPER)|Completed||N/A|119|Actual|W.L.Gore & Associates||1|||f||||f||||||||||2018-06-01 02:51:50.071327|2018-06-01 02:51:50.071327
NCT00541294|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2010-08-02|2007-10-09|2007-10-10|Estimate|||||||2010-08-02|2010-08-03|Estimate|October 2007||2007-10-31|August 2010|2010-08-31|September 2010|Anticipated|2010-09-30|||||Observational|ThrasherIGRA||Diagnosis of Tuberculosis Infection in HIV Co-infected Children|Diagnosis of Tuberculosis Infection in HIV Co-infected Children|Unknown status|Recruiting||250|Anticipated|Case Western Reserve University|||2||f||||f||||||||||2018-06-01 02:51:50.361772|2018-06-01 02:51:50.361772
NCT00541281|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2009-10-26|2007-10-09|2007-10-10|Estimate|||||||2009-10-26|2009-10-27|Estimate|December 2003||2003-12-31|October 2009|2009-10-31|February 2006|Actual|2006-02-28|||||Interventional|||Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer|Randomized Phase Ii Trial Of Weekly Docetaxel, Estramustine And Prednisone Versus Docetaxel And Prednisone In Patient With Hormone-Resistant Prostate Cancer|Completed||Phase 2|150|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-06-01 02:51:50.461227|2018-06-01 02:51:50.461227
NCT00541268|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2016-06-17|2007-10-09|2007-10-10|Estimate|||||||2016-06-17|2016-06-20|Estimate|February 2008||2008-02-29|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|DANISH||Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality|A DANish Randomized, Controlled, Multicenter Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality. The DANISH Study|Active, not recruiting||Phase 4|1000|Anticipated|Danish Study Group||2|||f||||t||||||||||2018-06-01 02:51:50.592423|2018-06-01 02:51:50.592423
NCT00541255|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2015-10-06|2007-10-09|2007-10-10|Estimate|||||||2015-10-06|2015-10-07|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|May 2012|Actual|2012-05-31||Observational|||A Long-Term Examination of Asthma From Childhood Through Adolescence|Epidemiology of Asthma and Allergic Disease: Risk and Prognosis in a Cohort From Birth to Adolescence|Unknown status|Active, not recruiting||1200|Anticipated|Isle of Wight NHS Trust|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, saliva, urine~   "|||2018-06-01 02:51:50.73116|2018-06-01 02:51:50.73116
NCT00541242|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2011-09-19||2011-09-19|2007-10-05|2007-10-10|Estimate|2011-09-19|2011-10-27|Estimate||||2011-09-19|2011-10-27|Estimate|December 2007||2007-12-31|September 2011|2011-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 4|586|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:51:50.810877|2018-06-01 02:51:50.810877
NCT00541229|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2009-06-05||2017-04-07|2007-10-05|2007-10-10|Estimate|2009-06-05|2009-07-28|Estimate||||2017-04-07|2017-05-12|Actual|August 24, 2007|Actual|2007-08-24|April 2017|2017-04-30|July 1, 2008|Actual|2008-07-01|June 17, 2008|Actual|2008-06-17||Interventional|||Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)|A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Clinical Trial of Sitagliptin 100 mg and Sitagliptin 200 mg in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet and Exercise|Completed||Phase 1|103|Actual|Merck Sharp & Dohme Corp.|The pre-specified rule for non-superiority of sitagliptin 200 mg compared with 100 mg was met at the planned interim analysis. As such, the trial was terminated as pre-specified.|3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:51:51.150734|2018-06-01 02:51:51.150734
NCT00541216|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-07|||2007-10-09|2007-10-09|2007-10-10|Estimate|||||||2007-10-09|2007-10-10|Estimate|October 2007||2007-10-31|October 2007|2007-10-31||||||||Interventional|||Ephedrine for the Treatment of Congenital Myasthenia||Unknown status|Enrolling by invitation|Phase 1/Phase 2|15|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 02:51:51.825221|2018-06-01 02:51:51.825221
NCT00541203|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2012-03-20|2007-10-09|2007-10-10|Estimate|||||||2012-03-20|2012-03-21|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|CT-MPACT||Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests|Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests|Completed|||45|Actual|William Beaumont Hospitals|||||f||||t||||||||||2018-06-01 02:51:51.897516|2018-06-01 02:51:51.897516
NCT00541190|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2011-08-09||2017-07-24|2007-10-09|2007-10-10|Estimate|2012-01-03|2012-02-03|Estimate||||2017-07-24|2017-08-24|Actual|October 2007||2007-10-31|July 2017|2017-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Absorptive Clearance in the Cystic Fibrosis Airway|Absorptive Clearance in the Cystic Fibrosis Airway|Completed||N/A|21|Actual|University of Pittsburgh||2|||f||||t||||||||Yes||2018-06-01 02:51:52.007967|2018-06-01 02:51:52.007967
NCT00541177|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-06|||2007-10-09|2007-10-09|2007-10-10|Estimate|||||||2007-10-09|2007-10-10|Estimate|April 2007||2007-04-30|October 2007|2007-10-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Study of Myopia Prevention in Children With Low Concentration of Atropine|Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine|Unknown status|Recruiting|Phase 4|60|Anticipated|Min-Sheng General Hospital||2|||f||||t||||||||||2018-06-01 02:51:52.282232|2018-06-01 02:51:52.282232
NCT00541164|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-09|||2013-07-11|2007-10-09|2007-10-10|Estimate|||||||2013-07-11|2013-07-15|Estimate|September 2007||2007-09-30|June 2010|2010-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease|Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study|Completed||Phase 1/Phase 2|23|Actual|Memorial Medical Center||2|||f||||f||||||||||2018-06-01 02:51:52.383174|2018-06-01 02:51:52.383174
NCT00541151|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2010-08-26|2007-10-05|2007-10-10|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|November 2010|Anticipated|2010-11-30|August 2010|Anticipated|2010-08-31||Observational|MiniArc||MiniArc Study: Long-Term Effectiveness Trial for AMS Sling Systems|Long-Term Effectiveness Trial for AMS Sling Systems|Unknown status|Active, not recruiting||188|Actual|American Medical Systems|||||f||||f||||||||||2018-06-01 02:51:52.537236|2018-06-01 02:51:52.537236
NCT00541138|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2011-09-20|2007-10-05|2007-10-08|Estimate|||||||2011-09-20|2011-09-21|Estimate|May 2003||2003-05-31|September 2011|2011-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors|A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases|Completed||Phase 2|50|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 02:51:52.666304|2018-06-01 02:51:52.666304
NCT00541125|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2016-05-27|2007-10-05|2007-10-08|Estimate|||||||2016-05-27|2016-05-30|Estimate|November 2007||2007-11-30|May 2016|2016-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer|Phase II, Multicenter Study Evaluating G-CSF as Primary Prophylaxis for Neutropenia Associated With First-line Chemotherapy Regimen FOLFIRI and Bevacizumab in Patients With Metastatic Colorectal Cancer Who Are Homozygous for UGT1A1*28 Polymorphism, the Promoter of the Gene Encoding for the Enzyme UGT1A1|Completed||Phase 2|20|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-06-01 02:51:52.763|2018-06-01 02:51:52.763
NCT00541112|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2009-02-19|2007-10-05|2007-10-08|Estimate|||||||2009-02-19|2009-02-20|Estimate|July 2007||2007-07-31|October 2007|2007-10-31||||||||Interventional|||Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery|Phase II Multicenter Study of the Impact of the Therapeutic Sequence of Radiochemotherapy (50 Gy + Capecitabine + Oxaliplatin + Cetuximab) Followed by Total Mesorectal Excision Surgery Then Post-Surgery Chemotherapy (FOLFOX 4 + Cetuximab) in Synchronous Locally Advanced or Metastatic Cancers of the Rectum With Metastases Resectable From the Start (T3-4 Nx or T2 N+ M1).|Unknown status|Recruiting|Phase 2|103|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:52.910153|2018-06-01 02:51:52.910153
NCT00541099|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2014-08-05||2017-11-15|2007-10-05|2007-10-08|Estimate|2014-08-05|2014-08-21|Estimate||||2017-11-15|2017-12-14|Actual|January 2008||2008-01-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Evaluation of Bevacizumab and Weekly Docetaxel in Elderly (≥ 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|11|Actual|Barbara Ann Karmanos Cancer Institute|The increased use of pemetrexed in the front line setting affected accrual.|1|||f||||t||||||||||2018-06-01 02:51:53.057147|2018-06-01 02:51:53.057147
NCT00541086|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-07-31|2007-10-05|2007-10-08|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2007|Actual|2007-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery|A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer|Active, not recruiting||Phase 3|3697|Actual|Gruppo Italiano Mammella (GIM)||6|||f||||t||||||||||2018-06-01 02:51:53.346341|2018-06-01 02:51:53.346341
NCT00541073|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2011-05-14|2007-10-05|2007-10-08|Estimate|||||||2011-05-14|2011-05-17|Estimate|June 2007||2007-06-30|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery|Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma|Completed||Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:53.445564|2018-06-01 02:51:53.445564
NCT00541060|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2010-12-17|2007-10-04|2007-10-08|Estimate|||||||2010-12-17|2010-12-20|Estimate|October 2007||2007-10-31|November 2010|2010-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|Cariogene||Study of Factors of Genetic Susceptibility Associated to Severe Caries Phenotype|Study of Factors of Genetic Susceptibility Associated to Severe Caries Phenotype in Young Patients. First Approach by Systematic Screening of Candidate Genes|Completed||N/A|390|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:51:53.518089|2018-06-01 02:51:53.518089
NCT00541047|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-10-12|2007-10-05|2007-10-08|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2007||2007-11-30|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)|RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery|Active, not recruiting||Phase 3|4236|Actual|Medical Research Council||5|||f||||t||||||||||2018-06-01 02:51:53.670825|2018-06-01 02:51:53.670825
NCT00541034|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2017-01-09||2017-07-13|2007-10-05|2007-10-08|Estimate|2017-01-09|2017-02-27|Actual||||2017-07-13|2017-08-11|Actual|May 2005||2005-05-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia|Phase II Study of Pentostatin With Cyclophosphamide and Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia|Completed||Phase 2|49|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:51:53.83474|2018-06-01 02:51:53.83474
NCT00541021|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2009-12-13|2007-10-05|2007-10-08|Estimate|||||||2009-12-13|2009-12-15|Estimate|December 2006||2006-12-31|July 2009|2009-07-31||||December 2010|Anticipated|2010-12-31||Interventional|||Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase III Randomized, Double-blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients With Locally Advanced or Metastatic Cancer of the Pancreas.|Unknown status|Recruiting|Phase 3|104|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:54.039143|2018-06-01 02:51:54.039143
NCT00541008|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2011-08-13|2007-10-05|2007-10-08|Estimate|||||||2011-08-13|2011-08-16|Estimate|September 2007||2007-09-30|August 2011|2011-08-31||||||||Interventional|||Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer|Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP|Unknown status|Recruiting|Phase 2|92|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:54.252381|2018-06-01 02:51:54.252381
NCT00540995|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2018-04-04|2007-10-05|2007-10-08|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2, 2006||2006-10-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer|Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Advanced Myeloid Malignancies|Active, not recruiting||Phase 1/Phase 2|25|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:51:54.511862|2018-06-01 02:51:54.511862
NCT00540982|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-11-06|2007-10-05|2007-10-08|Estimate|||||||2017-11-06|2017-11-08|Actual|December 1996||1996-12-31|November 2017|2017-11-30|May 20, 2010|Actual|2010-05-20|May 20, 2010|Actual|2010-05-20||Interventional|||Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction|Pilot Pharmacokinetic Study of Dose Adjustment of Vinorelbine in Patients With Varying Degree of Liver Dysfunction|Completed||Phase 1/Phase 2|47|Actual|City of Hope Medical Center||4|||f||||t||||||||||2018-06-01 02:51:54.643591|2018-06-01 02:51:54.643591
NCT00540969|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2016-12-07||2016-12-07|2007-10-05|2007-10-08|Estimate|2016-12-07|2017-02-01|Estimate||||2016-12-07|2017-02-01|Estimate|February 2008||2008-02-29|December 2016|2016-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Not enough patients were accrued. In order to avoid identification of patients, no results will be entered.|Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases|A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases|Completed||Phase 3|3|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 02:51:54.762842|2018-06-01 02:51:54.762842
NCT00540956|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2011-05-13|2007-10-05|2007-10-08|Estimate|||||||2011-05-13|2011-05-16|Estimate|November 2006||2006-11-30|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Natural Killer Cells in Older Patients With Acute Myeloid Leukemia|Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission.|Completed||N/A|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:51:54.949352|2018-06-01 02:51:54.949352
NCT00540943|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-11-27|2007-10-05|2007-10-08|Estimate|||||||2017-11-27|2017-11-29|Actual|July 13, 2007|Actual|2007-07-13|November 2017|2017-11-30|May 3, 2010|Actual|2010-05-03|May 3, 2010|Actual|2010-05-03||Interventional|||Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer|Phase I Study of Safety and Pharmacokinetics of Pazopanib in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer|Completed||Phase 1|25|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:51:55.048455|2018-06-01 02:51:55.048455
NCT00540930|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2007-10-05|2007-10-05|2007-10-08|Estimate|||||||2007-10-05|2007-10-08|Estimate|April 2007||2007-04-30|October 2007|2007-10-31|April 2009|Anticipated|2009-04-30|||||Interventional|||Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy|A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma|Unknown status|Active, not recruiting|Phase 4|400|Anticipated|Shields, Shields and Associates|||||f||||t||||||||||2018-06-01 02:51:55.140569|2018-06-01 02:51:55.140569
NCT00540917|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2017-02-08|2007-10-04|2007-10-08|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2002||2002-07-31|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Measurement Skin Temperature During Pulsed Laser Exposure|Phase II Clinical Trial is to Compare Epidermal Temperature Measurements During 1.Laser Treatment at Standard Treatment Energies 2.Cryogen Spray Cooling (CSC) Plus Laser Treatment. 3.Contact Cooling Plus Laser Treatment.|Completed||Phase 2|118|Actual|University of California, Irvine||1|||f||||f||||||||||2018-06-01 02:51:55.208303|2018-06-01 02:51:55.208303
NCT00540904|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2014-02-27|2007-10-05|2007-10-08|Estimate|||||||2014-02-27|2014-03-03|Estimate|September 2007||2007-09-30|February 2014|2014-02-28|September 2009|Actual|2009-09-30|August 2008|Actual|2008-08-31||Interventional|||Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate|Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate|Completed||Phase 2|27|Actual|Barretos Cancer Hospital||2|||f||||t||||||||||2018-06-01 02:51:55.274174|2018-06-01 02:51:55.274174
NCT00540891|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2007-10-04|2007-10-04|2007-10-08|Estimate|||||||2007-10-04|2007-10-08|Estimate|February 2003||2003-02-28|October 2007|2007-10-31|October 2004|Actual|2004-10-31|||||Interventional|ALF-ACUTE||The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score|The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score|Completed||Phase 3|372|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:51:55.340242|2018-06-01 02:51:55.340242
NCT00540878|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2009-05-15|2007-10-04|2007-10-08|Estimate|||||||2009-05-15|2009-05-18|Estimate|April 2007||2007-04-30|May 2009|2009-05-31||||||||Interventional|||A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women|An Open-Label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400mg SB-751689 (a Calcium-Sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females|Completed||Phase 1|25|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:51:55.396301|2018-06-01 02:51:55.396301
NCT00540865|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2014-12-09|2007-10-04|2007-10-08|Estimate|||||||2014-12-09|2014-12-10|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness of Case Management Versus Case Management Plus Problem-solving Therapy to Treat Depression in Low-income Elders|Case Management and Problem Solving Therapy for Depressed, Homebound, Low-Income Elders|Completed||N/A|187|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 02:51:55.452105|2018-06-01 02:51:55.452105
NCT00540852|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2017-02-22|2007-10-04|2007-10-08|Estimate|||||||2017-02-22|2017-02-24|Actual|June 2002||2002-06-30|February 2017|2017-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy|Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy|Completed||N/A|77|Actual|University of California, Irvine||1|||f||||f||||||||||2018-06-01 02:51:55.552344|2018-06-01 02:51:55.552344
NCT00540839|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2015-06-09|2007-10-04|2007-10-08|Estimate|||||||2015-06-09|2015-06-10|Estimate|November 2007||2007-11-30|June 2015|2015-06-30||||March 2008|Actual|2008-03-31||Interventional|||A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303)|A Phase III Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Prospectively Evaluate Efficacy of Montelukast in Patients Aged 6 Months to 5 Years With Chronic Asthma|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2||"Based on input from regulatory agencies, it is not necessary to conduct this study. An ongoing~   study was sufficient for regulatory purposes."|f||||f||||||||||2018-06-01 02:51:55.61238|2018-06-01 02:51:55.61238
NCT00540826|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2009-08-26|2007-10-05|2007-10-08|Estimate|||||||2009-08-26|2009-08-27|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|June 2009|Actual|2009-06-30|||||Observational|COMPLY||Treatment Compliance in Children and Adolescents on ADHD Medication|Treatment Adherence and Compliance in Children and Adolescents on ADHD Medication and Emotional Expression in Clinical Practice|Completed|||518|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-06-01 02:51:55.697816|2018-06-01 02:51:55.697816
NCT00540813|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2017-02-22|2007-10-05|2007-10-08|Estimate|||||||2017-02-22|2017-02-23|Actual|October 2007||2007-10-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|May 2011|Actual|2011-05-31||Interventional|PEPCAD V||Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions|Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions|Completed||N/A|28|Actual|Heart Centre Rotenburg||1|||f||||f||||||||||2018-06-01 02:51:55.764306|2018-06-01 02:51:55.764306
NCT00540800|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2016-01-13|2007-10-05|2007-10-08|Estimate|||||||2016-01-13|2016-01-14|Estimate|February 2004||2004-02-29|January 2016|2016-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|BREAST-10||BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer|Phase III Multicenter Study of the Effects on Quality of Life of Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer|Completed||Phase 3|139|Actual|National Cancer Institute, Naples||2|||f||||f||||||||||2018-06-01 02:51:55.830177|2018-06-01 02:51:55.830177
NCT00540787|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2012-02-21|2007-10-05|2007-10-08|Estimate|||||||2012-02-21|2012-02-22|Estimate|August 2003||2003-08-31|February 2012|2012-02-29|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation|A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation|Completed||Phase 4|112|Actual|Biosense Webster, Inc.||2|||f||||||||||||||2018-06-01 02:51:55.914142|2018-06-01 02:51:55.914142
NCT00540774|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2018-01-23|2007-10-04|2007-10-08|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2003||2003-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Optical Sensor for Photodynamic Detection of Oral Pathology|Optical Sensor for Photodynamic Detection of Oral Pathology|Withdrawn|||0|Actual|University of California, Irvine|||1|Not a clinical trial study.|f||||f||||||||||2018-06-01 02:51:56.012171|2018-06-01 02:51:56.012171
NCT00540761|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2018-01-23|2007-10-05|2007-10-08|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2007||2007-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique|Natural History of Vulnerable Coronary Plaques|Recruiting||Phase 1|320|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:51:56.094168|2018-06-01 02:51:56.094168
NCT00540748|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2010-04-15|2007-10-04|2007-10-08|Estimate|||||||2010-04-15|2010-04-16|Estimate|October 2007||2007-10-31|May 2009|2009-05-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|oxystudien||Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful?|Is Oxytocin Given During Surgical Procedure for Abortion Before 12 Weeks of Pregnancy Useful ?|Completed||N/A|400|Anticipated|Asker & Baerum Hospital||2|||f||||f||||||||||2018-06-01 02:51:56.176419|2018-06-01 02:51:56.176419
NCT00540735|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2010-02-03|2007-10-05|2007-10-08|Estimate|||||||2010-02-03|2010-02-04|Estimate|April 2008||2008-04-30|October 2007|2007-10-31|November 2009||2009-11-30|||||Interventional|CK/PDT||Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas|Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas - A Prospective, Multicentric and Randomized Study.|Terminated||Phase 3|80||University Hospital, Angers||2||Big difficulties to enroll patients|f||||t||||||||||2018-06-01 02:51:56.241638|2018-06-01 02:51:56.241638
NCT00540722|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2017-06-15||2017-07-12|2007-10-05|2007-10-08|Estimate|2017-06-15|2017-07-12|Actual||||2017-07-12|2017-08-11|Actual|January 2008||2008-01-31|July 2017|2017-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||No||2018-06-01 02:51:56.365922|2018-06-01 02:51:56.365922
NCT00540709|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2012-02-15|2007-10-05|2007-10-08|Estimate|||||||2012-02-15|2012-02-17|Estimate|November 2002||2002-11-30|February 2012|2012-02-29|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro||Completed||Phase 4|58|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:51:56.566118|2018-06-01 02:51:56.566118
NCT00540696|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2013-04-24|2007-10-04|2007-10-08|Estimate|||||||2013-04-24|2013-04-26|Estimate|September 2001||2001-09-30|April 2013|2013-04-30|September 2003|Actual|2003-09-30|June 2003|Actual|2003-06-30||Interventional|||Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa|An Open-label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa (NESP)|Completed||Phase 2|300|Anticipated|Amgen||1|||f||||||||||||||2018-06-01 02:51:56.614166|2018-06-01 02:51:56.614166
NCT00540683|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2018-04-16|2007-10-04|2007-10-08|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2004||2004-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Measurement of the Distribution of Optical Properties in Adult Human Muscle|Measurement of the Distribution of Optical Properties in Adult Human Muscle|Withdrawn|||0|Actual|University of California, Irvine||||Not NIH defined clinical trials.|f||||f||||||||||2018-06-01 02:51:56.681026|2018-06-01 02:51:56.681026
NCT00540670|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2013-05-09|2007-10-04|2007-10-08|Estimate|||||||2013-05-09|2013-05-13|Estimate|October 2007||2007-10-31|February 2010|2010-02-28||||March 2009|Actual|2009-03-31||Interventional|||A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease|A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease|Completed||Phase 2|240|Actual|Eisai Inc.||4|||f||||||||||||||2018-06-01 02:51:56.831785|2018-06-01 02:51:56.831785
NCT00540657|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2008-07-21|2007-10-05|2007-10-08|Estimate|||||||2008-07-21|2008-07-22|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||A Phase II Study of CCX282-B in Patients With Celiac Disease|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease|Completed||Phase 2|90|Anticipated|ChemoCentryx||2|||f||||f||||||||||2018-06-01 02:51:56.972329|2018-06-01 02:51:56.972329
NCT00540644|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2016-04-05||2016-05-12|2007-10-05|2007-10-08|Estimate|2016-05-12|2016-06-21|Estimate||||2016-05-12|2016-06-21|Estimate|October 2007||2007-10-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|December 2012|Actual|2012-12-31||Interventional|||Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma|Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma|Completed||Phase 2|70|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 02:51:57.081294|2018-06-01 02:51:57.081294
NCT00540631|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2013-02-08|2007-10-05|2007-10-08|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|August 2010|Actual|2010-08-31||Interventional|ACRI||Multicenter Trial of Immunotherapy With House Dust Mite Allergoid|A Multicentre Randomized Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale|Completed||Phase 3|108|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 02:51:57.764449|2018-06-01 02:51:57.764449
NCT00540618|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2007-11-27|2007-10-04|2007-10-08|Estimate|||||||2007-11-27|2007-11-28|Estimate|September 2001||2001-09-30|November 2007|2007-11-30|July 2003|Actual|2003-07-31|||||Interventional|||A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis|A Phase II Randomized, Placebo-Controlled, Double-Blind Study of MEDI-507, A Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis.|Completed||Phase 2|420|Actual|MedImmune LLC||4|||f||||f||||||||||2018-06-01 02:51:57.879908|2018-06-01 02:51:57.879908
NCT00540605|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2012-05-17|2007-10-05|2007-10-08|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|January 2010|Actual|2010-01-31|||||Interventional|||Blood Levels of Tenofovir Gel in HIV Uninfected Pregnant Women Planning Cesarean Delivery|Phase I Study of the Maternal Single-Dose Pharmacokinetics and Placental Transfer of Tenofovir 1% Vaginal Gel Among Healthy Term Gravidas|Completed||Phase 1|21|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 02:51:58.028341|2018-06-01 02:51:58.028341
NCT00540592|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2012-04-26|2009-05-20|2016-10-27|2007-10-05|2007-10-08|Estimate|2012-04-26|2012-05-30|Estimate|2009-09-28|2009-09-30|Estimate|2016-10-27|2016-12-09|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A|Observer Blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A With Various Formulations in Adults Aged 65 Years and Above|Completed||Phase 2|2007|Actual|GlaxoSmithKline||10|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:51:58.284036|2018-06-01 02:51:58.284036
NCT00540579|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2013-02-08||2013-02-08|2007-10-05|2007-10-08|Estimate|2013-02-08|2013-03-13|Estimate||||2013-02-08|2013-03-13|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|January 2011|Actual|2011-01-31|December 2008|Actual|2008-12-31||Interventional|||CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas|A Phase I/II Study of CC-4047 in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas|Completed||Phase 1/Phase 2|23|Actual|SCRI Development Innovations, LLC||1|||f||||t||||||||||2018-06-01 02:52:03.966603|2018-06-01 02:52:03.966603
NCT00540566|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2017-02-08|2007-10-04|2007-10-08|Estimate|||||||2017-02-08|2017-02-10|Actual|June 1999||1999-06-30|February 2017|2017-02-28|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Observational|||Optical Biopsy of Human Skin in Conjunction With Laser Treatment|Optical Biopsy of Human Skin in Conjunction With Laser Treatment|Completed|||113|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:52:04.275513|2018-06-01 02:52:04.275513
NCT00540553|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2012-03-15|2007-10-04|2007-10-08|Estimate|||||||2012-03-15|2012-03-19|Estimate|August 2007||2007-08-31|February 2011|2011-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males|A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers|Completed||Phase 1|126|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:52:04.467255|2018-06-01 02:52:04.467255
NCT00540540|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2018-01-26|2007-10-04|2007-10-08|Estimate|||||||2018-01-26|2018-01-30|Actual|December 1995||1995-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Measurements of Breast Tissue Optical Properties|Measurements of Breast Tissue Optical Properties|Withdrawn|||0|Actual|University of California, Irvine||||"According to NIH definition of clinical trial studies, this study does not meet requirement for~   clinical trial study."|f||||f||||||||||2018-06-01 02:52:04.532693|2018-06-01 02:52:04.532693
NCT00540527|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2012-10-24|2007-10-05|2007-10-08|Estimate|||||||2012-10-24|2012-10-26|Estimate|January 2004||2004-01-31|October 2012|2012-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS)|SYNTHESIS: a Randomized Controlled Trial on Intra-arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke. Start up Phase.|Completed||Phase 3|54|Actual|Niguarda Hospital||2|||f||||t||||||||||2018-06-01 02:52:04.604522|2018-06-01 02:52:04.604522
NCT00540514|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2013-06-07||2017-04-24|2007-10-05|2007-10-08|Estimate|2013-08-16|2013-08-19|Estimate||||2017-04-24|2017-04-26|Actual|November 2007||2007-11-30|April 2017|2017-04-30|February 2013|Actual|2013-02-28|October 2009|Actual|2009-10-31||Interventional|||Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|1052|Actual|Celgene||2|||f||||t||||||||||2018-06-01 02:52:04.739282|2018-06-01 02:52:04.739282
NCT00469313|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-05-21|2007-05-02|2007-05-04|Estimate|||||||2008-05-21|2008-05-22|Estimate|May 2007||2007-05-31|May 2008|2008-05-31||||||||Observational|||Efficacy of Inspiratory Muscle Training on Inspiratory Capacity in Patients With COPD|Efficacy of Inspiratory Muscle Training on Inspiratory Capacity in Patients|Unknown status|Enrolling by invitation||||Hospital Hietzing|||||f||||f||||||||||2018-06-01 03:15:03.151751|2018-06-01 03:15:03.151751
NCT00540501|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2010-05-27|2007-10-04|2007-10-08|Estimate|||||||2010-05-27|2010-05-31|Estimate|October 2007||2007-10-31|May 2010|2010-05-31|October 2007|Anticipated|2007-10-31|October 2007|Anticipated|2007-10-31||Interventional|||A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects|Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||4||Contract agreement not reached|f||||||||||||||2018-06-01 02:52:06.058244|2018-06-01 02:52:06.058244
NCT00540488|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2007-10-12|2007-10-05|2007-10-08|Estimate|||||||2007-10-12|2007-10-15|Estimate|August 2002||2002-08-31|October 2007|2007-10-31||||||||Interventional|||Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas|Randomized, Double Blind, Three Way Crossover Comparison of Glucose and Insulin Responses During a Meal Glucose Tolerance Test in Subjects With Type 2 Diabetes Consuming Disease-Specific Versus Standard Nutritional Formula|Completed||Phase 3|54|Actual|Abbott Nutrition|||||f||||||||||||||2018-06-01 02:52:06.128223|2018-06-01 02:52:06.128223
NCT00540475|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2017-07-24|2007-10-04|2007-10-08|Estimate|||||||2017-07-24|2017-07-25|Actual|September 2007||2007-09-30|July 2017|2017-07-31|November 2050|Anticipated|2050-11-30|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|PA-IPF||Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry|The Pennsylvania Idiopathic Pulmonary Fibrosis State-wide Research Registry|Recruiting|||9999|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:52:06.195354|2018-06-01 02:52:06.195354
NCT00540462|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2008-11-13|2007-10-05|2007-10-08|Estimate|||||||2008-11-13|2008-11-14|Estimate|August 2007||2007-08-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|August 2008|Anticipated|2008-08-31||Interventional|T2DM||Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus|Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus|Unknown status|Recruiting|Phase 4|120|Anticipated|Min-Sheng General Hospital||3|||f||||t||||||||||2018-06-01 02:52:06.295572|2018-06-01 02:52:06.295572
NCT00540449|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2011-06-14||2016-03-01|2007-10-04|2007-10-08|Estimate|2011-06-14|2011-07-11|Estimate||||2016-03-01|2016-03-29|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|February 2010|Actual|2010-02-28||Interventional||The analysis population included intent to treat (ITT) population defined as all randomized participants who received at least one dose of the study medication.|TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.|A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.|Completed||Phase 3|694|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||t||||||||||2018-06-01 02:52:06.521004|2018-06-01 02:52:06.521004
NCT00540436|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2009-08-10||2012-10-11|2007-10-05|2007-10-08|Estimate|2009-10-05|2009-11-10|Estimate||||2012-10-11|2012-10-15|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension|Study AMB107816, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open-Label Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A -<Classification: Exploratory and Confirmatory Clinical Trial>|Completed||Phase 2|25|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 02:52:07.484556|2018-06-01 02:52:07.484556
NCT00540423|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|2009-08-11||2011-03-29|2007-10-05|2007-10-08|Estimate|2009-11-24|2009-12-31|Estimate||||2011-03-29|2011-03-30|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) -A Multicenter Study in Subjects With Chronic ITP Receiving a Double-Blind, Placebo-Controlled, Short-Term Treatment Followed by an Open-Label, Uncontrolled, Long-Term Treatment- <Phase II/III Study>|Completed||Phase 3|23|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:52:07.980164|2018-06-01 02:52:07.980164
NCT00540410|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2010-06-22|2007-10-05|2007-10-08|Estimate|||||||2010-06-22|2010-06-23|Estimate|September 2007||2007-09-30|June 2010|2010-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks|A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal|Completed||Phase 4|366|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:52:08.931133|2018-06-01 02:52:08.931133
NCT00540397|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2007-10-05|2007-10-05|2007-10-08|Estimate|||||||2007-10-05|2007-10-08|Estimate||||October 2007|2007-10-31||||||||Interventional|||TCM Etiological Study on the Theory of XuSunShengJi in Liver Cirrhosis|Traditional Chinese Medicine Etiological Study on the Theory of XuSunShengJi in Liver Cirrhosis|Unknown status|Recruiting|N/A|||Shanghai University of Traditional Chinese Medicine|||||f||||t||||||||||2018-06-01 02:52:09.023377|2018-06-01 02:52:09.023377
NCT00540384|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2013-05-06|2007-10-04|2007-10-08|Estimate|||||||2013-05-06|2013-05-08|Estimate|July 1999||1999-07-31|May 2013|2013-05-31|June 2002|Actual|2002-06-30|March 2002|Actual|2002-03-31||Interventional|||Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy|A Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) Administered by Subcutaneous (SC) Injection for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy|Completed||Phase 1/Phase 2|405|Anticipated|Amgen||6|||f||||||||||||||2018-06-01 02:52:09.08181|2018-06-01 02:52:09.08181
NCT00540371|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2017-02-08|2007-10-04|2007-10-08|Estimate|||||||2017-02-08|2017-02-10|Actual|December 1999||1999-12-31|February 2017|2017-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain Birthmark at High Fluences|Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain|Completed|||136|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:52:09.170662|2018-06-01 02:52:09.170662
NCT00540358|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04||2011-07-21|2012-12-21|2007-10-05|2007-10-08|Estimate||||2011-07-21|2011-07-25|Estimate|2012-12-21|2012-12-28|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer|A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without BSI-201, in Patients With ER, PR and HER2-negative Metastatic Breast Cancer|Completed||Phase 2|123|Actual|Sanofi||2|||t||||f||||||||||2018-06-01 02:52:09.348826|2018-06-01 02:52:09.348826
NCT00540345|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-05|||2014-12-24|2007-10-05|2007-10-08|Estimate|||||||2014-12-24|2014-12-30|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C|Four Arms, Multicenter, Open Label Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C|Completed||Phase 4|300|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||4|||f||||t||||||||||2018-06-01 02:52:09.46823|2018-06-01 02:52:09.46823
NCT00540332|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2009-02-27|2007-10-04|2007-10-08|Estimate|||||||2009-02-27|2009-03-02|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|September 2008|Anticipated|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy|A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy|Withdrawn||Phase 1/Phase 2|0|Actual|Swedish Orphan Biovitrum||2||The 20070201 study was terminated based on evaluation of Palifermin solid tumor data.|f||||||||||||||2018-06-01 02:52:09.581978|2018-06-01 02:52:09.581978
NCT00540319|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2013-08-05|2007-10-05|2007-10-08|Estimate|||||||2013-08-05|2013-08-07|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|HIP||The Health in Pregnancy (HIP) Study|Prevention for Prenatal Health: the Health in Pregnancy (HIP) Study|Completed||N/A|410|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 02:52:09.67451|2018-06-01 02:52:09.67451
NCT00540306|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2017-02-08|2007-10-04|2007-10-08|Estimate|||||||2017-02-08|2017-02-10|Actual|February 2006||2006-02-28|February 2017|2017-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Monitoring Functional Variation in the Breast During Menstrual Cycle by Using Diffuse Optical Spectroscopy|Monitoring Functional Variation in the Breast During Menstrual Cycle by Using Diffuse Optical Spectroscopy|Completed|||13|Actual|University of California, Irvine|||1||f||||f||||||||||2018-06-01 02:52:09.756316|2018-06-01 02:52:09.756316
NCT00540293|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2009-05-08||2009-08-14|2007-10-04|2007-10-08|Estimate|2009-05-08|2009-06-26|Estimate||||2009-08-14|2009-08-25|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|AT GOAL||Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study|A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label Study Assessing The Percentage Of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 MG, 20 MG, And 40 MG.|Completed||Phase 4|425|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:52:09.85167|2018-06-01 02:52:09.85167
NCT00540280|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2011-03-06|2007-10-04|2007-10-05|Estimate|||||||2011-03-06|2011-03-08|Estimate|October 2003||2003-10-31|March 2011|2011-03-31|October 2013|Anticipated|2013-10-31|October 2003|Anticipated|2003-10-31||Interventional|||Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer||Suspended||Phase 3|10|Anticipated|King Faisal Specialist Hospital & Research Center||1||Follow up only|f||||||||||||||2018-06-01 02:52:10.387659|2018-06-01 02:52:10.387659
NCT00540267|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2008-11-03|2007-10-04|2007-10-05|Estimate|||||||2008-11-03|2008-11-04|Estimate|November 2007||2007-11-30|October 2008|2008-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Bone Density in Patients With Schizophrenia|Bone Mineral Density in the Korean Patients With Chronic Schizophrenia With Alcohol Abuse|Completed|||300|Anticipated|Inje University|||1||f||||f||||||||||2018-06-01 02:52:10.559271|2018-06-01 02:52:10.559271
NCT00540254|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2013-02-28|2007-10-04|2007-10-05|Estimate|||||||2013-02-28|2013-03-01|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Behavioral Insomnia Therapy With Chronic Fatigue Syndrome|Behavioral Insomnia Therapy With Chronic Fatigue Syndrome|Completed||Phase 1/Phase 2|24|Actual|Duke University||2|||f||||t||||||||||2018-06-01 02:52:10.634519|2018-06-01 02:52:10.634519
NCT00540241|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2011-03-28|2007-10-04|2007-10-05|Estimate|||||||2011-03-28|2011-03-29|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Observational|PERFORMANCE||Performance Status During Treatment With Pemetrexed in Patients With NSCLC|Performance Status and Influencing Factors During Second-Line Treatment With Pemetrexed in Patients With Stage III/IVNon Small Cell Lung Cancer|Completed|||542|Actual|Eli Lilly and Company|||1||f||||f||||||||||2018-06-01 02:52:10.728064|2018-06-01 02:52:10.728064
NCT00540228|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2013-03-14|2009-05-08|2017-06-02|2007-10-04|2007-10-05|Estimate|2013-03-14|2013-04-30|Estimate|2009-09-25|2009-09-28|Estimate|2017-06-02|2017-07-02|Actual|October 5, 2007||2007-10-05|November 2016|2016-11-30|May 8, 2008|Actual|2008-05-08|May 8, 2008|Actual|2008-05-08||Interventional|||Study to Evaluate an Influenza Vaccine Candidate|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza Vaccine GSK1247446A With Various Formulations in Subjects Aged 18-64 Years|Completed||Phase 2|1006|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:52:10.851046|2018-06-01 02:52:10.851046
NCT00540215|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2011-02-10|2007-10-04|2007-10-05|Estimate|||||||2011-02-10|2011-02-11|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||GLP-2 (Glucagonlike Peptide-2) and Blood Flow|The Role of GLP-2 in Univercal Changes in Blood Flow in Humans|Completed||N/A|15|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-06-01 02:52:12.263394|2018-06-01 02:52:12.263394
NCT00540202|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2007-10-04|2007-10-04|2007-10-05|Estimate|||||||2007-10-04|2007-10-05|Estimate|September 2007||2007-09-30|October 2007|2007-10-31|April 2008|Anticipated|2008-04-30|||||Interventional|QALE||Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children|Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children|Unknown status|Recruiting|Phase 4|302|Anticipated|Makerere University||2|||f||||t||||||||||2018-06-01 02:52:12.328232|2018-06-01 02:52:12.328232
NCT00540189|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2016-12-16|2007-10-04|2007-10-05|Estimate|||||||2016-12-16|2016-12-19|Estimate|May 2008||2008-05-31|December 2016|2016-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children|Initial Versus Delayed Operation for Treatment of Complicated Appendicitis In Children|Terminated||N/A|23|Actual|University of Michigan||2||Unable to adequatly recruit|f||||f||||||||||2018-06-01 02:52:12.427709|2018-06-01 02:52:12.427709
NCT00540176|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2014-10-10|2007-10-04|2007-10-05|Estimate|||||||2014-10-10|2014-10-13|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Safety and Efficacy of DCA for the Treatment of Brain Cancer|A Phase II Open-labeled, Double-arm Clinical Study of Dichloroacetate (DCA) in Malignant Gliomas and Glioblastome Multiforme (GBM) Patients|Completed||Phase 2|40|Actual|University of Alberta||2|||f||||t||||||||||2018-06-01 02:52:12.493806|2018-06-01 02:52:12.493806
NCT00540163|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2013-11-27|2007-10-04|2007-10-05|Estimate|||||||2013-11-27|2013-11-28|Estimate|April 2007||2007-04-30|October 2013|2013-10-31||||November 2007|Actual|2007-11-30||Observational|||Observational Non-interventional Study With Spiriva in Chronic Obstructive Pulmonary Disease Patients With Exercise-induced Dyspnoea|Improvement in Physical Functioning (SF-36 Activity Score) in COPD Patients With Exercise-induced Dyspnoea on Treatment With Spiriva® 18 Microgram (Capsules Containing 18 μg Tiotropium).|Completed|||1296|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:52:12.620491|2018-06-01 02:52:12.620491
NCT00540150|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2007-10-04|2007-10-04|2007-10-05|Estimate|||||||2007-10-04|2007-10-05|Estimate|May 2004||2004-05-31|September 2007|2007-09-30|March 2005|Actual|2005-03-31|||||Interventional|||Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy|Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy in a Randomized Study Depending on Mite-Depot Supplement in Children and Adolescents With Allergic Bronchial Asthma.|Completed||Phase 3|34|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-06-01 02:52:12.997688|2018-06-01 02:52:12.997688
NCT00540137|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2014-05-20|2007-10-04|2007-10-05|Estimate|||||||2014-05-20|2014-05-21|Estimate|July 2007||2007-07-31|May 2010|2010-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects|A Randomised Prospective Study Assessing Changes in Neurocognitive Function, Using a Computerised Test Battery, in Treatment Naïve HIV-1 Positive Subjects Commencing Two Different Antiretroviral Regimens|Completed||Phase 4|21|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 02:52:13.0728|2018-06-01 02:52:13.0728
NCT00540124|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|2009-06-01||2010-11-18|2007-10-03|2007-10-05|Estimate|2009-06-01|2009-07-20|Estimate||||2010-11-18|2010-11-25|Estimate|October 2007||2007-10-31|November 2010|2010-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Pilot Study to Evaluate the Efficacy and Safety of Tadalafil and Tamsulosin Once-a-Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 2|151|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:52:13.171766|2018-06-01 02:52:13.171766
NCT00540111|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2010-02-09|2007-10-04|2007-10-05|Estimate|||||||2010-02-09|2010-02-10|Estimate|March 2005||2005-03-31|February 2010|2010-02-28|October 2007|Actual|2007-10-31|July 2007|Actual|2007-07-31||Interventional|||Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals.|Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals on Highly Active Antiretroviral Therapy|Completed||N/A|19|Actual|UPECLIN HC FM Botucatu Unesp||1|||f||||t||||||||||2018-06-01 02:52:14.387941|2018-06-01 02:52:14.387941
NCT00540098|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-04|2007-10-04|2007-10-05|Estimate|||||||2007-10-04|2007-10-05|Estimate|September 2001||2001-09-30|October 2007|2007-10-31|June 2005|Actual|2005-06-30|||||Interventional|Exparox||Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder|A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder|Completed||Phase 4|75|Actual|University of Göttingen||4|||f||||f||||||||||2018-06-01 02:52:14.503349|2018-06-01 02:52:14.503349
NCT00540085|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2009-10-15|2007-10-04|2007-10-05|Estimate|||||||2009-10-15|2009-10-16|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Pharmacodynamic Trial on Rocuronium in Obese Patients|Pharmacodynamic Trial on Rocuronium in Obese Patients|Completed||Phase 4|51|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-06-01 02:52:14.596771|2018-06-01 02:52:14.596771
NCT00540072|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2015-07-16|2007-10-04|2007-10-05|Estimate|||||||2015-07-16|2015-07-17|Estimate|July 2001||2001-07-31|October 2007|2007-10-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae||Completed||Phase 3|||Cubist Pharmaceuticals LLC|||||f||||||||||||||2018-06-01 02:52:14.855027|2018-06-01 02:52:14.855027
NCT00540059|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-04|2007-10-04|2007-10-05|Estimate|||||||2007-10-04|2007-10-05|Estimate|June 2005||2005-06-30|August 2007|2007-08-31||||||||Observational|||Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial|Quality Assurance Project in Patients With Advanced Prostate Carcinoma - Evaluation of Tolerability, Quality of Life and Usage of Zoladex 10,8 SafeSystem|Completed|||1950|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:52:14.90391|2018-06-01 02:52:14.90391
NCT00540046|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2015-01-01||2015-01-23|2007-10-04|2007-10-05|Estimate|2015-01-01|2015-01-13|Estimate||||2015-01-23|2015-02-09|Estimate|April 2007||2007-04-30|January 2015|2015-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||215 subjects were enrolled and randomized to the A/Immediate or B/Delayed group.|Immediate vs. Delayed Insertion of Copper T 380A IUD After Termination of Pregnancy Over 12-weeks Gestation|Immediate vs. Delayed Post-abortal Copper T 380A IUD Insertion in Cases Over 12 Weeks of Gestation|Completed||N/A|215|Actual|New York University School of Medicine|"IUD presence not always confirmed by a provider at 6-month visit but self-reported.~Study not powered to detect a difference in expulsion rates due to prohibitively high sample size.~Very high-risk population."|2|||f||||f||||||||||2018-06-01 02:52:15.182173|2018-06-01 02:52:15.182173
NCT00540033|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-04|2007-10-04|2007-10-05|Estimate|||||||2007-10-04|2007-10-05|Estimate|February 2005||2005-02-28|October 2007|2007-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Probiotics Reduce Incidence of Necrotizing Enterocolitis for Very Low Birth Weight Infants|Phase 2 Study of Oral Probiotics Reduce the Incidence and Severity of Necrotizing Enterocolitis for Very Low Birth Weight Infants -Multi-Center Randomized Control Trial|Terminated||Phase 2|217|Actual|China Medical University Hospital||1||terminated because of enough case number|f||||t||||||||||2018-06-01 02:52:15.581388|2018-06-01 02:52:15.581388
NCT00540020|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2007-10-04|2007-10-04|2007-10-05|Estimate|||||||2007-10-04|2007-10-05|Estimate|July 1996||1996-07-31|October 2007|2007-10-31|May 2003|Actual|2003-05-31|||||Interventional|||Rehabilitation of Traumatic Brain Injury in Active Duty Military Personnel and Veterans|Rehabilitation of Traumatic Brain Injury in Active Duty Military Personnel and Veterans: DVBIC Randomized Clinical Trial of Two Rehabilitation Approaches|Completed||N/A|360|Actual|Walter Reed Army Medical Center||2|||f||||||||||||||2018-06-01 02:52:15.652602|2018-06-01 02:52:15.652602
NCT00540007|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2017-08-31||2017-10-05|2007-10-04|2007-10-05|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|September 6, 2007|Actual|2007-09-06|October 2017|2017-10-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma|A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma|Completed||Phase 2|80|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-06-01 02:52:15.793733|2018-06-01 02:52:15.793733
NCT00539994|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2009-01-09||2016-11-02|2007-10-04|2007-10-05|Estimate|2010-07-22|2010-08-20|Estimate||||2016-11-02|2016-12-15|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus|Completed||Phase 2|57|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:52:17.021407|2018-06-01 02:52:17.021407
NCT00539981|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03||2011-04-28|2011-05-16|2007-10-04|2007-10-05|Estimate||||2011-05-16|2011-05-19|Estimate|2011-05-16|2011-05-19|Estimate|September 2007||2007-09-30|May 2011|2011-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok|Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49|Completed||Phase 3|4648|Actual|Protein Sciences Corporation||2|||f||||f||||||||||2018-06-01 02:52:18.495078|2018-06-01 02:52:18.495078
NCT00539968|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2015-02-04|2007-10-04|2007-10-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|June 2007||2007-06-30|February 2015|2015-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)|An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel|Terminated||Phase 1/Phase 2|5|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:52:18.671684|2018-06-01 02:52:18.671684
NCT00539955|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2012-12-17|2007-10-04|2007-10-05|Estimate|||||||2012-12-17|2012-12-18|Estimate|July 2003||2003-07-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Brief Intervention to Reduce Drinking Among Batterers|Brief Intervention to Reduce Drinking Among Batterers|Unknown status|Active, not recruiting|Phase 2|253|Anticipated|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-06-01 02:52:18.747275|2018-06-01 02:52:18.747275
NCT00539942|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|2012-02-07||2017-02-22|2007-10-04|2007-10-05|Estimate|2012-02-07|2012-03-09|Estimate||||2017-02-22|2017-03-27|Actual|April 2007||2007-04-30|February 2017|2017-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy|Extended Deep Venous Thrombosis Prophylaxis in Gynecologic Oncology Surgery With Intermittent Compression Devices (ICD) With or Without Postoperative Arixtra (Fondaparinux Sodium): A Randomized Controlled Trial|Terminated||Phase 3|7|Actual|University of Alabama at Birmingham|This trial was terminated early due to poor enrollment and recruitment and the very small number of subjects analyzed. As such, the data is uninterpretable.|2||Problems with accrual|f||||t||||||||||2018-06-01 02:52:19.020196|2018-06-01 02:52:19.020196
NCT00539929|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03||2013-05-21|2017-02-03|2007-10-03|2007-10-05|Estimate||||2013-05-21|2013-05-29|Estimate|2017-02-03|2017-02-06|Estimate|September 2007||2007-09-30|January 2017|2017-01-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis|Proof of Principle, Randomized, Parallel-Group, Double-Blind, Vehicle-Controlled, Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis|Completed||Phase 2|100|Actual|Eisai Inc.||4|||f||||f||||||||||2018-06-01 02:52:19.351547|2018-06-01 02:52:19.351547
NCT00539916|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2008-08-15|2007-10-04|2007-10-05|Estimate|||||||2008-08-15|2008-08-18|Estimate|October 2007||2007-10-31|August 2008|2008-08-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|AGRUVASC||Effects of Regular and Consequent Citrus Fruits Consumption on Vascular Protection|Effects of Regular and Consequent Citrus Fruit Consumption on Vascular Protection Specific Role of the Component Phytomicronutrients|Completed||N/A|30|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 02:52:19.595228|2018-06-01 02:52:19.595228
NCT00539903|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2009-02-05|2007-10-04|2007-10-05|Estimate|||||||2009-02-05|2009-02-06|Estimate|August 2008||2008-08-31|February 2009|2009-02-28||||||||Interventional|FAM||Physical Activity and Immigrant Health||Completed||N/A|||Norwegian School of Sport Sciences|||||f||||||||||||||2018-06-01 02:52:19.66783|2018-06-01 02:52:19.66783
NCT00539890|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2009-10-12|2007-10-03|2007-10-05|Estimate|||||||2009-10-12|2009-10-14|Estimate|November 2005||2005-11-30|October 2009|2009-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus|A Phase 3 Randomized, Open Label, Multi-Center Comparative Study of Technosphere /Insulin Versus Rapid Acting Insulin in Subjects With Type-2 Diabetes Mellitus Receiving Lantus as Basal Insulin|Completed||Phase 3|0||Mannkind Corporation|||||f||||||||||||||2018-06-01 02:52:19.737475|2018-06-01 02:52:19.737475
NCT00539877|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2010-06-22|2007-10-03|2007-10-05|Estimate|||||||2010-06-22|2010-06-23|Estimate|October 2004||2004-10-31|June 2010|2010-06-30|August 2007|Actual|2007-08-31|December 2006|Actual|2006-12-31||Interventional|||Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding|Phase I Study of Interperitoneal Chenotherapy in Patients With Gastric Adenocarainoma With Peritoneal Seeding|Completed||Phase 1|17|Actual|Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:52:19.858935|2018-06-01 02:52:19.858935
NCT00539864|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|2011-05-16||2011-07-25|2007-10-04|2007-10-05|Estimate|2011-07-25|2011-07-27|Estimate||||2011-07-25|2011-07-27|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV|Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64|Completed||Phase 3|602|Actual|Protein Sciences Corporation||2|||f||||f||||||||||2018-06-01 02:52:19.966252|2018-06-01 02:52:19.966252
NCT00539851|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2010-03-18|2007-10-04|2007-10-05|Estimate|||||||2010-03-18|2010-03-19|Estimate|November 2005||2005-11-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Observational|||Risk Factors for Diabetes After Stem Cell Transplantation|Risk Factors for Developing Diabetes Mellitus After Allogenic Stem Cell Transplantation|Completed|||87|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 02:52:20.370151|2018-06-01 02:52:20.370151
NCT00539656|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2013-10-24|2007-10-03|2007-10-04|Estimate|||||||2013-10-24|2013-10-28|Estimate|October 2007||2007-10-31|October 2013|2013-10-31||||December 2010|Actual|2010-12-31||Interventional|Cord Blood||Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers|Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies|Terminated||Phase 1/Phase 2|3|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||The manufacturer discontinued necessary reagents.|f||||f||||||||||2018-06-01 02:52:21.990677|2018-06-01 02:52:21.990677
NCT00539838|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03||2013-01-17|2017-05-11|2007-10-03|2007-10-05|Estimate||||2013-01-17|2013-01-25|Estimate|2017-05-11|2017-05-15|Actual|December 2007||2007-12-31|May 2017|2017-05-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|BEGIN||A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)|A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus|Terminated||Phase 3|33|Actual|Genentech, Inc.||2||"The study was terminated prematurely when the decision was made that ocrelizumab was not likely~   to benefit this patient population."|f||||||||||||||2018-06-01 02:52:20.424094|2018-06-01 02:52:20.424094
NCT00539825|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2016-10-28|2007-10-04|2007-10-05|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effect of GSK704838 In Healthy Volunteers|A Randomized Double-blind, Placebo-controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK704838 and Tiotropium Bromide|Completed||Phase 1|20|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:52:20.502136|2018-06-01 02:52:20.502136
NCT00539812|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2012-12-17|2007-10-04|2007-10-05|Estimate|||||||2012-12-17|2012-12-18|Estimate|May 2007||2007-05-31|December 2012|2012-12-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women|Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women|Unknown status|Recruiting|Phase 2|225|Anticipated|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-06-01 02:52:20.615795|2018-06-01 02:52:20.615795
NCT00539799|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2008-05-28|2007-10-04|2007-10-05|Estimate|||||||2008-05-28|2008-05-29|Estimate||||May 2008|2008-05-31||||||||Interventional|SIMPL||Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis|Corticosteroids in the Maintenance Therapy of Proliferative Lupus Nephritis: a Randomized Pilot Study|Withdrawn||Phase 3|15|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2||Local pharmacy unwilling to comply with study protocol|f||||t||||||||||2018-06-01 02:52:20.714059|2018-06-01 02:52:20.714059
NCT00539786|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2014-05-14|2007-10-04|2007-10-05|Estimate|||||||2014-05-14|2014-05-16|Estimate|March 2006||2006-03-31|May 2014|2014-05-31||||April 2011|Actual|2011-04-30||Interventional|||The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD|Clinical Usefulness of Proton Pump Inhibitor Test for Identifying Gastroesophageal Reflux Disease in Patients With Extraesophageal Symptoms|Unknown status|Recruiting|N/A|100|Anticipated|Samsung Medical Center|||||f||||||||||||||2018-06-01 02:52:20.781444|2018-06-01 02:52:20.781444
NCT00539773|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2015-12-16|2007-10-04|2007-10-05|Estimate|||||||2015-12-16|2015-12-17|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder|Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder|Completed||N/A|10|Actual|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:52:20.874273|2018-06-01 02:52:20.874273
NCT00539760|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2017-08-11|2007-10-04|2007-10-05|Estimate|||||||2017-08-11|2017-08-15|Actual|September 5, 2007|Actual|2007-09-05|August 2017|2017-08-31|April 5, 2008|Actual|2008-04-05|April 5, 2008|Actual|2008-04-05||Interventional|||A Phase I Rheumatoid Arthritis Study in Healthy Volunteers|A Phase I, Randomized, Observer- and Subject-Blind, Placebo-Controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1827771 in Healthy Volunteers|Completed||Phase 1|45|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 02:52:20.936714|2018-06-01 02:52:20.936714
NCT00539747|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-04|||2017-06-30|2007-10-04|2007-10-05|Estimate|||||||2017-06-30|2017-07-02|Actual|October 1, 2007||2007-10-01|August 5, 2008|2008-08-05|August 5, 2008||2008-08-05|||||Observational|||Making Sense of a Positive Genetic Test Result for Huntington Disease|Meaning Making Among Asymptomatic Individuals With a Positive Presymptomatic Genetic Test Result for Huntington Disease|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:52:21.020223|2018-06-01 02:52:21.020223
NCT00539734|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2011-02-08||2011-04-11|2007-10-02|2007-10-04|Estimate|2011-03-07|2011-04-08|Estimate||||2011-04-11|2011-04-15|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration|Electrophysiologic Changes After Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration|Completed||N/A|25|Actual|Prince of Songkla University|Small number of participants||||f||||t||||||||||2018-06-01 02:52:21.091726|2018-06-01 02:52:21.091726
NCT00539721|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02||2009-04-14|2013-10-08|2007-10-03|2007-10-04|Estimate||||2009-10-16|2009-10-20|Estimate|2013-10-08|2013-11-01|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)|A Randomized, Double-Blind, Double-Dummy, Dose-Ranging, Active- and Placebo-Controlled Study of Single-Dose Oral Rolapitant Monotherapy for the Prevention of Postoperative Nausea and Vomiting (PONV)|Completed||Phase 2|619|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 02:52:21.242756|2018-06-01 02:52:21.242756
NCT00539708|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2008-05-06|2007-10-03|2007-10-04|Estimate|||||||2008-05-06|2008-05-12|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Non-Invasive Ventilation After Extubation in Hypercapnic Patients|Non-Invasive Ventilation After Extubation in Hypercapnic Patients|Completed||N/A|106|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 02:52:21.317054|2018-06-01 02:52:21.317054
NCT00539695|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2014-04-22||2018-04-03|2007-10-02|2007-10-04|Estimate|2014-06-03|2014-07-04|Estimate||||2018-04-03|2018-05-04|Actual|June 2007||2007-06-30|April 2018|2018-04-30|March 2014|Actual|2014-03-31|April 2013|Actual|2013-04-30||Interventional|IL2 for GVHD||Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD|Phase II Trial Using Low Dose IL-2 to Induce Regulatory T Cells in Patients After Allogeneic Hematopoietic Stem Cell Transplantation as Graft Versus Host Disease Prophylaxis|Completed||Phase 2|25|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 02:52:21.399635|2018-06-01 02:52:21.399635
NCT00539669|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-03|2007-10-03|2007-10-04|Estimate|||||||2007-10-03|2007-10-04|Estimate|March 2003||2003-03-31|October 2007|2007-10-31||||||||Interventional|||TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian||Completed||Phase 2|47|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:52:21.925733|2018-06-01 02:52:21.925733
NCT00538746|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2007-10-02|2007-10-02|2007-10-03|Estimate|||||||2007-10-02|2007-10-03|Estimate|February 2005||2005-02-28|October 2007|2007-10-31||||||||Interventional|||Effect of Increased Muscular Work During Different Weaning Strategies in Critically Ill Patients||Unknown status|Recruiting|N/A|||Università degli Studi dell'Insubria||3|||f||||||||||||||2018-06-01 02:52:43.381467|2018-06-01 02:52:43.381467
NCT00539643|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2018-02-23|2007-10-03|2007-10-04|Estimate|||||||2018-02-23|2018-02-26|Actual|November 2007|Actual|2007-11-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma|A Randomized Single Blind Controlled Trial of Beads vs. Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma (HCC)|Active, not recruiting||Phase 2|101|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 02:52:22.061439|2018-06-01 02:52:22.061439
NCT00539630|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-03|2007-10-03|2007-10-04|Estimate|||||||2007-10-03|2007-10-04|Estimate|November 2002||2002-11-30|October 2007|2007-10-31||||||||Interventional|||TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN||Completed||Phase 3|86|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:52:22.138835|2018-06-01 02:52:22.138835
NCT00539617|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2012-09-12||2012-09-12|2007-10-03|2007-10-04|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|October 2007||2007-10-31|September 2012|2012-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery|A Single-Arm, Phase II Study of Tarceva Plus FOLFOX6 in Patients With Unresectable or Metastatic Cancer of Esophagus or Gastroesophageal Junction|Terminated||Phase 2|7|Actual|University of California, San Francisco|Early termination leading to small numbers of subjects analyzed.|1||For slow accrual|f||||t||||||||||2018-06-01 02:52:22.213901|2018-06-01 02:52:22.213901
NCT00539604|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-03|2007-10-03|2007-10-04|Estimate|||||||2007-10-03|2007-10-04|Estimate|July 2004||2004-07-31|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||Non Invasive Multicenter Italian Study for Coronary Artery Disease|Phase IV Multicenter, Intra-Individually Controlled, Comparison Study to Evaluate the Negative Predictive Value of 16-64 Slice MDCT Imaging in Patients Scheduled for Coronary Angiography|Completed||Phase 4|350||Società Italiana di Radiologia Medica|||||f||||||||||||||2018-06-01 02:52:22.530297|2018-06-01 02:52:22.530297
NCT00539591|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2013-09-10||2017-02-20|2007-10-03|2007-10-04|Estimate|2014-01-08|2014-02-27|Estimate||||2017-02-20|2017-03-23|Actual|October 2007||2007-10-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma|Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma|Completed||Phase 2|29|Actual|St. Jude Children's Research Hospital|The study closed early due to poor accrual to stratum B1.|2|||f||||f||||||||||2018-06-01 02:52:22.68193|2018-06-01 02:52:22.68193
NCT00539578|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-10-30|2007-10-03|2007-10-04|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2002||2002-09-30|October 2015|2015-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Treatment of Patients With Anxiety Disorder (0777-022)|A Double-Blind, Mulitcenter, Placebo-Controlled, Flexible-Dose Replicate Study of MK0777 Gel Extrusion Module (GEM) 3 mg B.I.D. to 8 mg B.I.D. in the Treatment of Outpatients With Generalized Anxiety Disorder|Completed||Phase 2|270|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:52:23.750613|2018-06-01 02:52:23.750613
NCT00539565|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-03|2007-10-03|2007-10-04|Estimate|||||||2007-10-03|2007-10-04|Estimate|January 2000||2000-01-31|September 2007|2007-09-30|September 2008|Anticipated|2008-09-30|||||Interventional|||RCT of Steroids Following Kasai Portoenterostomy for Biliary Atresia.|Phase IIIb Study of Corticosteroids as Post-Operative Adjuvant Therapy in Biliary Atresia|Unknown status|Enrolling by invitation|Phase 3|100|Anticipated|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-06-01 02:52:23.801019|2018-06-01 02:52:23.801019
NCT00539539|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2010-12-30||2012-05-21|2007-10-03|2007-10-04|Estimate|2012-05-21|2012-06-25|Estimate||||2012-05-21|2012-06-25|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Automated Real-time Feedback on CPR Study|Controlled Study of the Clinical Effectiveness of Automated Real-Time Feedback on CPR Process Conducted at a Subset of ROC Sites|Completed||Phase 2|1586|Actual|University of Washington|Open label study - providers not blinded to intervention. High rates of missing CPR process measures.|2|||f||||t||||||||||2018-06-01 02:52:23.87993|2018-06-01 02:52:23.87993
NCT00539526|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2011-09-22||2011-09-22|2007-10-03|2007-10-04|Estimate|2011-09-22|2011-10-31|Estimate||||2011-09-22|2011-10-31|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues||Completed||Phase 4|106|Actual|Allergan||3|||f||||f||||||||||2018-06-01 02:52:24.364116|2018-06-01 02:52:24.364116
NCT00539513|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2012-12-21||2013-03-25|2007-10-02|2007-10-04|Estimate|2013-01-30|2013-03-08|Estimate||||2013-03-25|2013-04-01|Estimate|June 2006||2006-06-30|March 2013|2013-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder|A Double-Blind Study of N-Acetylcysteine Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder and Depression|Terminated||Phase 2|10|Actual|Yale University||2||Researchers terminated study due to limited enrollment.|f||||f||||||||||2018-06-01 02:52:24.63923|2018-06-01 02:52:24.63923
NCT00539500|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2012-09-07|2007-10-02|2007-10-04|Estimate|||||||2012-09-07|2012-09-11|Estimate|October 2007||2007-10-31|September 2012|2012-09-30||||September 2012|Actual|2012-09-30||Interventional|||Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma|Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma|Terminated||Phase 2/Phase 3|3|Actual|M.D. Anderson Cancer Center||1||Slow Accrual.|f||||f||||||||||2018-06-01 02:52:24.874905|2018-06-01 02:52:24.874905
NCT00539487|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2013-11-07|2007-10-03|2007-10-04|Estimate|||||||2013-11-07|2013-11-08|Estimate|January 2007||2007-01-31|November 2013|2013-11-30||||November 2007|Actual|2007-11-30||Observational|||Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives|TOP -Study Telmisartan - Therapy of Hypertension and Life-style Changes in Cardiovascular Risk Patients|Completed|||5827|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:52:25.207155|2018-06-01 02:52:25.207155
NCT00539474|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2011-12-22|2007-10-03|2007-10-04|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|June 2010|Actual|2010-06-30||Interventional|ROLL||"The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"|"The Efficacy of 'Radioguided Occult Lesion Localization' (ROLL) Versus 'Wire-guided Localization' (WGL) in Breast Conserving Surgery for Non-palpable Breast Cancer: a Randomized Clinical Trial"|Completed||Phase 3|316|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 02:52:30.028487|2018-06-01 02:52:30.028487
NCT00539461|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2013-10-31|2007-10-02|2007-10-04|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 2007||2007-02-28|October 2013|2013-10-31||||November 2007|Actual|2007-11-30||Observational|||Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of Life|Sifrol® (Pramipexole) Impact on RLS Related Quality of Life: A 12-weeks Observational Study in Patients With Primary RLS|Completed|||2023|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:52:30.124383|2018-06-01 02:52:30.124383
NCT00539448|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2009-09-24|2007-10-03|2007-10-04|Estimate|||||||2009-09-24|2009-09-25|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|GLANS||Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study|Phase IV, Open Label, Non-comparative, Multi-center, Study of the Effects of Both Insulin Glargine & Insulin Glulisine in Type I Diabetes Mellitus Patients.|Completed||Phase 4|98|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:52:30.692064|2018-06-01 02:52:30.692064
NCT00539435|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2016-08-08|2007-10-03|2007-10-04|Estimate|||||||2016-08-08|2016-08-10|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes|Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes|Withdrawn||Phase 3|0|Actual|Florida Atlantic University||1||Administrative|f||||t||||||||||2018-06-01 02:52:30.765594|2018-06-01 02:52:30.765594
NCT00539422|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2007-10-03|2007-10-03|2007-10-04|Estimate|||||||2007-10-03|2007-10-04|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Observational|||Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism,in Malignant Breast Diseases|Role of Cytochrome P450 2D6 (CYP2D6) *4 Polymorphism, Oxidative Stress and Ferretin in Benign and Malignant Breast Diseases|Completed|||||Mansoura University|||3||f||||f||||||||||2018-06-01 02:52:30.831932|2018-06-01 02:52:30.831932
NCT00539409|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2016-08-08|2007-10-03|2007-10-04|Estimate|||||||2016-08-08|2016-08-10|Estimate|November 2006||2006-11-30|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus|Effects on Diabetic Metabolic Integrity With Treatment of Pulsatile Intravenous Insulin Therapy as Evidenced by Monitoring of Diabetic Complications.|Terminated||Phase 2/Phase 3|152|Actual|Florida Atlantic University||2||Administrative|f||||t||||||||||2018-06-01 02:52:30.987559|2018-06-01 02:52:30.987559
NCT00539396|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2009-10-12|2007-10-03|2007-10-04|Estimate|||||||2009-10-12|2009-10-14|Estimate|March 2005||2005-03-31|October 2009|2009-10-31|December 2005|Actual|2005-12-31|||||Interventional|||A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine|A Phase 2 Randomized, Open Label, Multi-Center Study of the Use of Prandial Inhaled Technosphere Insulin in Combination With Basal Subcutaneous Lantus as Basal Insulin Versus Prandial Subcutaneous NovoRapid in Combination With Basal Subcutaneous Lantus Insulin in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 2|110|Anticipated|Mannkind Corporation|||||f||||f||||||||||2018-06-01 02:52:31.067774|2018-06-01 02:52:31.067774
NCT00539383|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2014-07-30|2007-10-03|2007-10-04|Estimate|||||||2014-07-30|2014-07-31|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer|A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer|Completed||Phase 1|56|Actual|Angiochem Inc||1|||f||||f||||||||||2018-06-01 02:52:31.117603|2018-06-01 02:52:31.117603
NCT00539370|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2012-06-13|2007-10-03|2007-10-04|Estimate|||||||2012-06-13|2012-06-14|Estimate|August 2007||2007-08-31|June 2012|2012-06-30||||||||Observational|||Human Samples and Data Repository|Laboratory of Immunology/National Eye Institute Repository|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:52:31.212264|2018-06-01 02:52:31.212264
NCT00539357|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2016-08-04|2007-10-02|2007-10-04|Estimate|||||||2016-08-04|2016-08-08|Estimate|August 2005||2005-08-31|August 2016|2016-08-31|March 2006|Actual|2006-03-31|||||Interventional|||A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder||Completed||Phase 4|12|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-06-01 02:52:31.297029|2018-06-01 02:52:31.297029
NCT00539344|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2014-07-30|2007-10-03|2007-10-04|Estimate|||||||2014-07-30|2014-07-31|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma|A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma|Completed||Phase 1|63|Actual|Angiochem Inc||1|||f||||f||||||||||2018-06-01 02:52:31.364532|2018-06-01 02:52:31.364532
NCT00539331|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2011-05-30|2007-10-03|2007-10-04|Estimate|||||||2011-05-30|2011-06-01|Estimate|September 2007||2007-09-30|May 2011|2011-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients|A Two-Part Study in Japanese Patients With Advanced or Metastatic NSCLC. Open-Label Phase I to Assess the Safety & Tolerability of AZD2171 in Combination With Pac/Carb, Then a Phase II, Randomised, Double-Blind Study to Assess the Efficacy of Pac/Carb Alone and in Combination With AZD2171 and Pac/Carb|Terminated||Phase 1|6|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:52:31.513944|2018-06-01 02:52:31.513944
NCT00539318|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2009-08-13|2007-10-03|2007-10-04|Estimate|||||||2009-08-13|2009-08-14|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|||||Observational|||Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers|Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers|Terminated|||60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1|Low Recruitment|f||||t||||||||||2018-06-01 02:52:31.617695|2018-06-01 02:52:31.617695
NCT00539305|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|2013-03-15||2014-07-10|2007-10-03|2007-10-04|Estimate|2014-07-10|2014-07-14|Estimate||||2014-07-10|2014-07-14|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|July 2011|Actual|2011-07-31||Interventional|HIP||Hormone and Information Processing Study|Testosterone Supplementation in Men With MCI|Completed||Phase 3|22|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:52:31.707086|2018-06-01 02:52:31.707086
NCT00539292|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2007-10-02|2007-10-02|2007-10-04|Estimate|||||||2007-10-02|2007-10-04|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Evaluating the Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis|A Multi-Centre, Prospective Randomized Trial to Evaluate Routine Use of a Silastic Spring-Loaded Silo for Infants With Gastroschisis|Completed||Phase 2|88|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 02:52:32.042434|2018-06-01 02:52:32.042434
NCT00539279|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2015-04-29||2015-08-11|2007-10-03|2007-10-04|Estimate|2015-08-11|2015-08-19|Estimate||||2015-08-11|2015-08-19|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Treatment of Older Veterans With Chronic Posttraumatic Stress Disorder|Treatment of Older Veterans With Chronic Posttraumatic Stress Disorder|Completed||N/A|87|Actual|VA Office of Research and Development|Early termination leading to smaller numbers of subjects analyzed at post-treatment and follow-up; Results generalize only to older male combat veterans who were treatment-seeking for PTSD|2|||f||||f||||||||||2018-06-01 02:52:32.140974|2018-06-01 02:52:32.140974
NCT00539266|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2011-07-05|2007-10-03|2007-10-04|Estimate|||||||2011-07-05|2011-07-06|Estimate|October 2007||2007-10-31|October 2007|2007-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|ABC||Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia|Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients|Unknown status|Recruiting|Phase 2/Phase 3|108|Anticipated|Leiden University Medical Center||4|||f||||f||||||||||2018-06-01 02:52:32.629253|2018-06-01 02:52:32.629253
NCT00539253|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2016-10-12||2017-08-28|2007-10-03|2007-10-04|Estimate|2017-08-28|2017-09-26|Actual||||2017-08-28|2017-09-26|Actual|September 2007||2007-09-30|August 2017|2017-08-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|TACE||Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.|Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)|Completed||N/A|45|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||No||2018-06-01 02:52:32.711765|2018-06-01 02:52:32.711765
NCT00539240|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|2014-02-07||2014-07-29|2007-10-03|2007-10-04|Estimate|2014-07-29|2014-08-18|Estimate||||2014-07-29|2014-08-18|Estimate|April 2006||2006-04-30|July 2014|2014-07-31|November 2011|Actual|2011-11-30|April 2010|Actual|2010-04-30||Interventional||Number of randomized subjects|Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI|Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI|Completed||Phase 2/Phase 3|236|Actual|VA Office of Research and Development|"Recruitment challenges, including difficulty finding patients who fail PPI but had not already been prescribed doubled dose. Necessitated a no-cost extension to complete recruitment"|3|||f||||t||||||||||2018-06-01 02:52:32.838229|2018-06-01 02:52:32.838229
NCT00539227|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2013-08-23|2007-10-02|2007-10-04|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy|A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy|Completed|||37|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:52:33.247846|2018-06-01 02:52:33.247846
NCT00539214|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2013-10-31|2007-10-02|2007-10-04|Estimate|||||||2013-10-31|2013-11-01|Estimate|March 2007||2007-03-31|October 2013|2013-10-31||||December 2007|Actual|2007-12-31||Observational|||Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease|Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment|Completed|||1192|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:52:33.366559|2018-06-01 02:52:33.366559
NCT00539201|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02||2010-10-13|2010-10-13|2007-10-02|2007-10-04|Estimate||||2010-10-13|2010-10-19|Estimate|2010-10-13|2010-10-19|Estimate|September 2007||2007-09-30|October 2010|2010-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||GSK706769 A First Time in Human Study For Males and Females|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects|Terminated||Phase 1|34|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:52:33.882668|2018-06-01 02:52:33.882668
NCT00539188|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2012-12-21||2013-03-25|2007-10-03|2007-10-04|Estimate|2013-01-29|2013-03-06|Estimate||||2013-03-25|2013-04-01|Estimate|September 2007||2007-09-30|March 2013|2013-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD|A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder|Terminated||Phase 2|6|Actual|Yale University||2||Study terminated due to poor subject compliance.|f||||f||||||||||2018-06-01 02:52:33.961031|2018-06-01 02:52:33.961031
NCT00539175|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2007-10-03|2007-10-03|2007-10-04|Estimate|||||||2007-10-03|2007-10-04|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Treatment of Painful Diabetic Neuropathy With Photon Stimulation|Treatment of Painful Diabetic Neuropathy With Photon Stimulation|Completed||N/A|120|Actual|East Bay Institute for Research and Education||2|||f||||f||||||||||2018-06-01 02:52:34.213486|2018-06-01 02:52:34.213486
NCT00539162|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03|||2018-02-22|2007-10-03|2007-10-04|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2, 2001|Actual|2001-07-02|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 1, 2019|Anticipated|2019-07-01||Observational|||Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women|Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women|Recruiting|||8000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Yearly blood draw of 2 to 3 tablespoons, with CA-125 analysis performed each time. Urine~     specimen obtained at each UT MDACC visit.~   "|||2018-06-01 02:52:34.296318|2018-06-01 02:52:34.296318
NCT00539149|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2010-05-21|2007-10-02|2007-10-04|Estimate|||||||2010-05-21|2010-05-24|Estimate|April 1996||1996-04-30|October 2007|2007-10-31|March 2001|Actual|2001-03-31|||||Interventional|COMIT1||Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children|Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.|Completed||Phase 4|126|Actual|Menzies School of Health Research||2|||f||||t||||||||||2018-06-01 02:52:34.418897|2018-06-01 02:52:34.418897
NCT00539136|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-03||2010-10-14|2010-10-14|2007-10-03|2007-10-04|Estimate||||2010-10-14|2010-10-19|Estimate|2010-10-14|2010-10-19|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers|An Open-label, Single-dose, Non-randomized, Balanced Design Three-way Cross-over Study to Examine the Variability in Absorption of GSK561679 Using Gamma Scintigraphy, PillCam™ SB Capsule and the Acoustic Vest in Healthy Males Volunteers|Completed||Phase 1|12|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:52:34.490479|2018-06-01 02:52:34.490479
NCT00539123|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2009-06-03|2007-10-02|2007-10-04|Estimate|||||||2009-06-03|2009-06-04|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia|Drug Counseling and Abstinent-Contingent Take-Home Buprenorphine in Malaysia|Unknown status|Recruiting|Phase 2|240|Anticipated|Yale University||4|||f||||t||||||||||2018-06-01 02:52:34.554556|2018-06-01 02:52:34.554556
NCT00539110|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2014-05-25||2016-06-26|2007-10-03|2007-10-04|Estimate|2014-09-13|2014-09-18|Estimate||||2016-06-26|2016-07-27|Estimate|December 2009||2009-12-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|Sleep3|"There were ten patients total, crossover design, so each of the 10 patients received both zolpidem and ramelteon.~Mean age 7.8 years"|Differential Effects of Zolpidem Versus Ramelteon in Burned Children|Differential Effects of Zolpidem Versus Ramelteon on Nocturnal Sleep in Pediatric Burn Patients: A Prospective, Randomized Crossover Trial With Polysomnographic Recordings|Completed||Phase 2|10|Actual|Shriners Hospitals for Children||2|||f||||t||||||||No||2018-06-01 02:52:34.637495|2018-06-01 02:52:34.637495
NCT00539097|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2012-06-18|2007-10-01|2007-10-03|Estimate|||||||2012-06-18|2012-06-19|Estimate|June 2005||2005-06-30|June 2012|2012-06-30||||October 2007|Actual|2007-10-31||Interventional|||Evaluation Perioperative Nutrition on Donor Site Healing in Patients Undergoing Reconstructive Burn Surg||Terminated||Phase 2/Phase 3|38|Actual|Shriners Hospitals for Children||2||change in donor site care protocol; donor site healing is a study endpoint|f||||||||||||||2018-06-01 02:52:34.802279|2018-06-01 02:52:34.802279
NCT00539084|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2013-05-08|2007-10-02|2007-10-03|Estimate|||||||2013-05-08|2013-05-10|Estimate|October 2007||2007-10-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||A Study to Assess the Safety and Efficacy of a Microneedle Device for Local Anesthesia|A Controlled Comparative Pilot Study to Assess the Safety and Efficacy of the MicronJet Microneedle Device Following Intradermal Injection of Lidocaine for Local Anesthesia|Completed||N/A|40|Actual|NanoPass Technologies Ltd||2|||f||||f||||||||||2018-06-01 02:52:34.863421|2018-06-01 02:52:34.863421
NCT00539071|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2010-11-01|2007-10-02|2007-10-03|Estimate|||||||2010-11-01|2010-11-03|Estimate|April 2008||2008-04-30|November 2010|2010-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone|High Dose Risperidone Consta for Patients With Schizophrenia With Unsatisfactory Response to Standard Dose Risperidone or Long-Acting Injectable|Unknown status|Recruiting|Phase 4|160|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 02:52:35.01255|2018-06-01 02:52:35.01255
NCT00539045|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2018-02-13|2007-10-02|2007-10-03|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2007||2007-03-31|February 2018|2018-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction|Diagnostic Utility of Contrast Echocardiography for Detection of Left Ventricular Thrombi Post ST Elevation Myocardial Infarction|Completed|||250|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 02:52:35.100728|2018-06-01 02:52:35.100728
NCT00539032|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2009-09-09||2016-04-12|2007-10-02|2007-10-03|Estimate|2010-12-22|2011-01-24|Estimate||||2016-04-12|2016-04-14|Estimate|September 2007||2007-09-30|April 2016|2016-04-30|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||Immunology and Safety of Menactra® in Children in Saudi Arabia|Evaluation of the Response to a Single Dose of Menactra® in Children Aged 5 to 8 Years Who Had Previously Received Two Doses of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide Vaccine Before Age 2 Years in Saudi Arabia|Completed||Phase 3|238|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:52:35.184783|2018-06-01 02:52:35.184783
NCT00539019|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2012-06-18|2007-10-01|2007-10-03|Estimate|||||||2012-06-18|2012-06-19|Estimate|October 2006||2006-10-31|June 2012|2012-06-30||||||||Observational|||Quantification and Derivation of Metabolic Needs in Children During Burn Rehabilitation||Withdrawn|||0|Actual|Shriners Hospitals for Children|||1|"indirect calorimetry no longer employed at the institution; calorimeter is not~   accurate/reliable"|f||||||||||||||2018-06-01 02:52:35.583265|2018-06-01 02:52:35.583265
NCT00539006|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2008-11-14||2016-10-27|2007-10-02|2007-10-03|Estimate|2009-09-29|2009-09-30|Estimate||||2016-10-27|2016-12-09|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS|A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis|Completed||Phase 4|377|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:52:35.693046|2018-06-01 02:52:35.693046
NCT00538993|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2007-10-01|2007-10-01|2007-10-03|Estimate|||||||2007-10-01|2007-10-03|Estimate|September 2003||2003-09-30|September 2007|2007-09-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Improving Provider Counseling Interventions in HIV Practice||Unknown status|Active, not recruiting|N/A|425|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 02:52:36.416687|2018-06-01 02:52:36.416687
NCT00538980|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2017-05-23||2017-05-23|2007-10-02|2007-10-03|Estimate|2017-05-23|2017-06-20|Actual||||2017-05-23|2017-06-20|Actual|April 30, 2007|Actual|2007-04-30|May 2017|2017-05-31|August 27, 2010|Actual|2010-08-27|August 25, 2010|Actual|2010-08-25||Interventional|||Dasatinib in Polycythemia Vera|A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104|Terminated||Phase 2|10|Actual|Weill Medical College of Cornell University||1||This study was terminated due to lack of efficacy.|f||||||||||||||2018-06-01 02:52:36.492004|2018-06-01 02:52:36.492004
NCT00538967|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2007-10-02|2007-10-02|2007-10-03|Estimate|||||||2007-10-02|2007-10-03|Estimate|May 2002||2002-05-31|October 2007|2007-10-31|August 2005|Actual|2005-08-31|||||Interventional|||The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm|The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm|Completed||Phase 2|60|Actual|Leiden University Medical Center||4|||f||||f||||||||||2018-06-01 02:52:36.694268|2018-06-01 02:52:36.694268
NCT00538954|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2010-11-04|2007-10-02|2007-10-03|Estimate|||||||2010-11-04|2010-11-05|Estimate|August 2006||2006-08-31|October 2007|2007-10-31|August 2008|Actual|2008-08-31|||||Interventional|ORANGE||Optimised Recovery With Accelerated Nutrition and GI Enhancement|A Randomised Controlled Trial of Optimised Surgical Recovery: the Potential Synergy Between Enhanced Gastrointestinal Motility and Oral Nutritional/ Metabolic Support|Completed||N/A|64|Anticipated|University of Edinburgh||4|||f||||f||||||||||2018-06-01 02:52:36.759327|2018-06-01 02:52:36.759327
NCT00538941|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2009-10-27|2007-10-02|2007-10-03|Estimate|||||||2009-10-27|2009-10-28|Estimate|November 2005||2005-11-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effects of Chocolate in Patients With Chronic Heart Failure|Effects of Swiss Dark Chocolate on Endothelial and Baroreceptor Function and Markers of Inflammation in Patients With Chronic Heart Failure|Completed||N/A|22|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 02:52:36.82975|2018-06-01 02:52:36.82975
NCT00538928|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2011-03-01|2007-10-02|2007-10-03|Estimate|||||||2011-03-01|2011-03-02|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|Xtravent||Extrapulmonary Interventional Ventilatory Support in Severe Acute Respiratory Distress Syndrome (ARDS)|Extrapulmonary Interventional Ventilatory Support for Lung Protection in Severe Acute Respiratory Distress - a Prospective Randomized Multi Centre Study|Completed||N/A|120|Anticipated|University of Regensburg||2|||f||||t||||||||||2018-06-01 02:52:36.902529|2018-06-01 02:52:36.902529
NCT00538577|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-30|||2009-10-04|2007-10-01|2007-10-02|Estimate|||||||2009-10-04|2009-10-06|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Observational|||Outcome and Related Factors of Necrotizing Fasciitis of the Limb||Completed|||25|Anticipated|Tehran University of Medical Sciences|||||f||||t||||||||||2018-06-01 02:52:46.943237|2018-06-01 02:52:46.943237
NCT00538915|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2012-01-04||2017-01-30|2007-10-01|2007-10-03|Estimate|2012-02-23|2012-03-26|Estimate||||2017-01-30|2017-03-10|Actual|September 2007||2007-09-30|February 2012|2012-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)|Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)|Completed||Phase 3|63|Actual|Biotest Pharmaceuticals Corporation||1|||f||||f||||||||||2018-06-01 02:52:37.068464|2018-06-01 02:52:37.068464
NCT00538902|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2009-11-23||2011-04-07|2007-10-01|2007-10-03|Estimate|2009-11-23|2009-12-30|Estimate||||2011-04-07|2011-04-11|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|December 2009|Actual|2009-12-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate|A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate|Completed||Phase 2/Phase 3|302|Actual|Abbott||3|||f||||f||||||||||2018-06-01 02:52:37.295754|2018-06-01 02:52:37.295754
NCT00538889|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2007-12-09|2007-10-02|2007-10-03|Estimate|||||||2007-12-09|2007-12-11|Estimate|August 2007||2007-08-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Study Evaluating a Combined Administration of Lecozotan SR and Citalopram in Young Healthy Subjects|Combined Administration of Lecozotan SR and Citalopram: a Double Blind, Multiple Dose Study in Young Healthy Subjects|Completed||Phase 1|40|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:52:38.008747|2018-06-01 02:52:38.008747
NCT00538876|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2011-06-29|2007-10-02|2007-10-03|Estimate|||||||2011-06-29|2011-06-30|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML|Phase I Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)|Completed||Phase 1|30|Anticipated|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 02:52:39.095295|2018-06-01 02:52:39.095295
NCT00538863|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2012-09-11||2013-08-06|2007-10-02|2007-10-03|Estimate|2013-08-06|2013-10-11|Estimate||||2013-08-06|2013-10-11|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||The total number of patients enrolled in the study is 319.|Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain|Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain|Completed||Phase 3|319|Actual|INSYS Therapeutics Inc||2|||f||||f||||||||||2018-06-01 02:52:39.188226|2018-06-01 02:52:39.188226
NCT00538850|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2013-05-08||2014-01-14|2007-10-02|2007-10-03|Estimate|2014-01-14|2014-03-05|Estimate||||2014-01-14|2014-03-05|Estimate|October 2007||2007-10-31|January 2014|2014-01-31|October 2010|Actual|2010-10-31|February 2010|Actual|2010-02-28||Interventional|||Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain|A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain|Completed||Phase 3|130|Actual|INSYS Therapeutics Inc||1|||f||||||||||||||2018-06-01 02:52:39.867589|2018-06-01 02:52:39.867589
NCT00538824|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2017-02-22||2017-05-03|2007-10-02|2007-10-03|Estimate|2017-05-03|2017-06-08|Actual||||2017-05-03|2017-06-08|Actual|December 2007|Actual|2007-12-31|May 2017|2017-05-31|September 22, 2010|Actual|2010-09-22|September 22, 2010|Actual|2010-09-22||Interventional|DexTR||Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 2|5|Actual|Weill Medical College of Cornell University|The study was terminated early due to lack of sufficient accrual|1||low enrollment|f||||f||||||||||2018-06-01 02:52:40.775463|2018-06-01 02:52:40.775463
NCT00538811|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2010-10-26|2007-10-02|2007-10-03|Estimate|||||||2010-10-26|2010-10-27|Estimate||||October 2010|2010-10-31||||||||Interventional|||Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders|Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin|Completed||Phase 2/Phase 3|40|Anticipated|Aga Khan University||2|||f||||t||||||||||2018-06-01 02:52:41.048759|2018-06-01 02:52:41.048759
NCT00538798|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2017-10-05|2007-10-02|2007-10-03|Estimate|||||||2017-10-05|2017-10-06|Actual|September 28, 2007||2007-09-28|March 17, 2015|2015-03-17|March 17, 2015|Actual|2015-03-17|||||Interventional|||PET Imaging of Brain mGluR5 Receptors Using [18F]SP203|PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 and [11C]SP203|Completed||Phase 1|50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:52:41.202639|2018-06-01 02:52:41.202639
NCT00538785|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2012-01-11||2012-02-14|2007-10-01|2007-10-03|Estimate|2012-01-11|2012-02-14|Estimate||||2012-02-14|2012-02-16|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children With Hemodynamically Significant Congenital Heart Disease|Completed||Phase 2|1236|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 02:52:41.354225|2018-06-01 02:52:41.354225
NCT00538772|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2010-11-03|2007-10-02|2007-10-03|Estimate|||||||2010-11-03|2010-11-05|Estimate|July 2008||2008-07-31|November 2010|2010-11-30||||||||Observational|||An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy|An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy|Withdrawn|||50|Anticipated|British Columbia Cancer Agency|||1||f||||f||||||Samples With DNA|"~     Approx. 40ml of blood for correlative studies will be drawn at predetermined time points:~     baseline, after cycle 1, at time of treatment failure/discontinuation of protocol therapy.~      10 unstained slides from original patient specimen (nephrectomy specimens only) will be~     collected within 6 months after enrollment.~   "|||2018-06-01 02:52:43.181196|2018-06-01 02:52:43.181196
NCT00538759|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2013-05-09|2007-10-01|2007-10-03|Estimate|||||||2013-05-09|2013-05-13|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|RADAR||Radiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis|RADiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis|Terminated||Phase 2/Phase 3|21|Actual|Minneapolis Heart Institute Foundation||1||Funding shortfall|f||||t||||||||||2018-06-01 02:52:43.277521|2018-06-01 02:52:43.277521
NCT00538733|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2017-02-21||2017-06-20|2007-10-02|2007-10-03|Estimate|2017-06-20|2017-06-23|Actual||||2017-06-20|2017-06-23|Actual|October 2007|Actual|2007-10-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|July 2010|Actual|2010-07-31||Interventional|T-BiRD||Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma|A Phase II Study of Thalidomide (THALOMID®), Clarithromycin (BIAXIN®), Lenalidomide(REVLIMID®), and Dexamethasone (DECADRON®) for Subjects With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|26|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 02:52:43.49683|2018-06-01 02:52:43.49683
NCT00538720|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2018-04-10|2007-10-02|2007-10-03|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2007|Actual|2007-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)|Pilot Study to Detect and Assess the Effect of Vitamin D Replacement on Gland Size by 4DCT in Patients With Primary Hyperparathyroidism (PHPT)|Active, not recruiting||Phase 1|22|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 02:52:43.887827|2018-06-01 02:52:43.887827
NCT00538707|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2010-02-09|2007-10-02|2007-10-03|Estimate|||||||2010-02-09|2010-02-10|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Mental Stress on Platelet Function|Effect of Mental Stress on Platelet Function in Healthy Subjects|Completed||N/A|32|Anticipated|University of Zurich||2|||f||||f||||||||||2018-06-01 02:52:43.989367|2018-06-01 02:52:43.989367
NCT00538694|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-07-16|2007-10-02|2007-10-03|Estimate|||||||2015-07-16|2015-07-17|Estimate|October 2000||2000-10-31|October 2007|2007-10-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia|A Randomized, Double-Blind, Phase III, Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae|Completed||Phase 3|||Cubist Pharmaceuticals LLC|||||||||||||||||||2018-06-01 02:52:44.073799|2018-06-01 02:52:44.073799
NCT00538681|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01||2009-10-16|2009-10-16|2007-10-01|2007-10-03|Estimate||||2009-10-16|2009-10-19|Estimate|2009-10-16|2009-10-19|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study for Patients With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo|Randomized, Double-Blind, Placebo Controlled, Phase 2 Study of Pemetrexed and Cisplatin Plus Enzastaurin Versus Pemetrexed and Cisplatin Plus Placebo in Chemonaive Patients With Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer|Completed||Phase 2|27|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:52:44.137197|2018-06-01 02:52:44.137197
NCT00538668|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2018-02-27|2007-10-02|2007-10-03|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2007|Actual|2007-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2015|Actual|2015-10-31||Interventional|||Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody|Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer Using 177Lu-J591 Antibody: Dose Fractionation Regimen|Active, not recruiting||Phase 1|54|Actual|Weill Medical College of Cornell University||9|||f||||t||||||||No||2018-06-01 02:52:44.234675|2018-06-01 02:52:44.234675
NCT00538655|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|||2013-05-30|2007-10-02|2007-10-03|Estimate|||||||2013-05-30|2013-06-03|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|January 2009|Actual|2009-01-31||Interventional|||A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence|A Pilot Trial of Modafinil for Treatment of Methamphetamine Dependence|Completed||Phase 2|20|Actual|California Pacific Medical Center Research Institute||1|||f||||t||||||||||2018-06-01 02:52:44.310156|2018-06-01 02:52:44.310156
NCT00538642|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-02|2012-09-13||2012-11-27|2007-10-02|2007-10-03|Estimate|2012-10-18|2012-11-19|Estimate||||2012-11-27|2012-11-29|Estimate|August 2007||2007-08-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|||Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone|Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone|Completed||N/A|24|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-06-01 02:52:44.402361|2018-06-01 02:52:44.402361
NCT00538629|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2009-04-30||2009-08-21|2007-10-01|2007-10-02|Estimate|2009-07-08|2009-08-19|Estimate||||2009-08-21|2009-08-25|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Noninterventional Study in Bipolar Disorder and Schizophrenia With Zeldox|Noninterventional Study (NIS) in Patients With Bipolar Disorder (Manic or Mixed Episodes) and Schizophrenia Undergoing Treatment With Zeldox|Completed|||471|Actual|Pfizer|In this noninterventional study, patients received Zeldox in compliance with the Summary of Product Characteristics (SPC) and based solely on therapeutic need. Data were included from 2 patients <18 years; the SPC does not address this age group.||2||f||||f||||||||||2018-06-01 02:52:45.079538|2018-06-01 02:52:45.079538
NCT00538616|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2012-12-12||2013-03-01|2007-10-01|2007-10-02|Estimate|2013-03-01|2013-04-11|Estimate||||2013-03-01|2013-04-11|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|April 2010|Actual|2010-04-30|February 2008|Actual|2008-02-29||Interventional|PrePARE||Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion|A Phase IV Single Center Cross Over Clinical Study Comparing Two Different Sedations Strategies for Mechanically Ventilated Patients With Neurological Critical Illness|Completed||Phase 1/Phase 2|8|Actual|Duke University||2|||f||||f||||||||||2018-06-01 02:52:46.304738|2018-06-01 02:52:46.304738
NCT00538603|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-12-16|2007-10-01|2007-10-02|Estimate|||||||2015-12-16|2015-12-17|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)|Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)|Completed||N/A|8|Actual|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:52:46.573468|2018-06-01 02:52:46.573468
NCT00538590|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-29|2012-01-19||2012-04-01|2007-10-01|2007-10-02|Estimate|2012-04-01|2012-04-25|Estimate||||2012-04-01|2012-04-25|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery|Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery|Completed||Phase 4|20|Actual|Pro Top & Mediking Company Limited|Stat Methods and limited sample size.|2|||f||||t||||||||||2018-06-01 02:52:46.64365|2018-06-01 02:52:46.64365
NCT00538564|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2016-09-20|2007-10-01|2007-10-02|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2006||2006-11-30|September 2016|2016-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia|Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||2||Trial closed just prior to study receiving Investigational Review Board approval|f||||f||||||||||2018-06-01 02:52:47.007076|2018-06-01 02:52:47.007076
NCT00538551|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2011-12-11|2007-10-01|2007-10-02|Estimate|||||||2011-12-11|2011-12-13|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|July 2015|Anticipated|2015-07-31|July 2012|Anticipated|2012-07-31||Observational|||Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases|Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases|Unknown status|Recruiting||350|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:52:47.0901|2018-06-01 02:52:47.0901
NCT00538538|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2016-08-04|2007-10-01|2007-10-02|Estimate|||||||2016-08-04|2016-08-08|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)|Use of Subretinal Ranibizumab (Lucentis) in the Management of Submacular Hemorrhage in Neovascular Age-Related Macular Degeneration (AMD)|Withdrawn||Phase 1|0|Actual|William Beaumont Hospitals||2||This condition can now be managed in the office with an injection of Lucentis.|f||||f||||||||||2018-06-01 02:52:47.156801|2018-06-01 02:52:47.156801
NCT00538525|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2012-05-26|2007-10-01|2007-10-02|Estimate|||||||2012-05-26|2012-05-30|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase II Study of Neoadjuvant Chemotherapy With Doxorubicin Followed by Docetaxel-Cisplatin in Locally Advanced Breast Cancer||Completed||N/A|10|Actual|King Faisal Specialist Hospital & Research Center||1|||f||||||||||||||2018-06-01 02:52:47.226809|2018-06-01 02:52:47.226809
NCT00538512|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2011-08-08||2017-11-01|2007-10-01|2007-10-02|Estimate|2011-08-08|2011-09-12|Estimate||||2017-11-01|2017-12-06|Actual|September 2007||2007-09-30|November 2017|2017-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|FLUVACS||Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4|Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4|Completed||Phase 4|1952|Actual|University of Michigan||3|||f||||f||||||||||2018-06-01 02:52:47.3098|2018-06-01 02:52:47.3098
NCT00538499|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2017-02-08|2007-10-01|2007-10-02|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 28, 2004|Actual|2004-10-28|February 2017|2017-02-28|September 2009|Actual|2009-09-30|July 27, 2007|Actual|2007-07-27||Interventional|||Fentanyl With or Without Bupivacaine in Reducing Pain in Patients Undergoing Video-Assisted Chest Surgery|Optimal Pain Management After Video-Assisted Thoracic Surgery|Completed||N/A|30|Actual|Roswell Park Cancer Institute||3|||f||||t||||||||||2018-06-01 02:52:47.825522|2018-06-01 02:52:47.825522
NCT00538486|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2013-05-12|2007-10-01|2007-10-02|Estimate|||||||2013-05-12|2013-05-14|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|HOT-ACME||A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients|Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1)|Completed||Phase 4|360|Actual|Third Military Medical University||6|||f||||t||||||||||2018-06-01 02:52:47.905998|2018-06-01 02:52:47.905998
NCT00538473|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2012-04-19|2009-05-20|2016-11-03|2007-10-01|2007-10-02|Estimate|2012-06-21|2012-07-27|Estimate|2009-09-28|2009-09-30|Estimate|2016-11-03|2016-12-16|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults|Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (≥67 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Will be Used as Reference.|Completed||Phase 2|68|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:52:48.015898|2018-06-01 02:52:48.015898
NCT00538460|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2010-02-26|2007-10-01|2007-10-02|Estimate|||||||2010-02-26|2010-03-01|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|DSTAT||Evaluate the Effectiveness and Cost of Stress Cardiac Magnetic Resonance Imaging (MRI) for Non-invasive Evaluation of Lesions Discovered on Computed Tomography Angiography (CCTA)|Dual-Source CT and STress Cardiac Magnetic Resonance Assessment in the Triage of Patients With Suspected Acute Coronary Syndromes (D-STAT)|Terminated|||1|Actual|William Beaumont Hospitals||||Lack of staff and funding.|f||||t||||||||||2018-06-01 02:52:48.808223|2018-06-01 02:52:48.808223
NCT00538447|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2011-12-11|2007-10-01|2007-10-02|Estimate|||||||2011-12-11|2011-12-13|Estimate|June 2007||2007-06-30|December 2011|2011-12-31|June 2020|Anticipated|2020-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Prospective Database for Chronic Myelogenous Leukemia||Active, not recruiting||N/A|2000|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:52:48.863832|2018-06-01 02:52:48.863832
NCT00538434|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2016-03-23|2013-08-16|2016-07-21|2007-10-01|2007-10-02|Estimate|2016-07-21|2016-09-02|Estimate|2013-08-16|2013-08-26|Estimate|2016-07-21|2016-09-02|Estimate|March 2008||2008-03-31|July 2016|2016-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||ITT population: all randomized participants who received any amount of study drug.|Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years|An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years|Completed||Phase 2/Phase 3|227|Actual|Teva Pharmaceutical Industries||4|||f||||t||||||||||2018-06-01 02:52:48.954072|2018-06-01 02:52:48.954072
NCT00538421|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2013-03-08|2007-10-01|2007-10-02|Estimate|||||||2013-03-08|2013-03-11|Estimate|March 2008||2008-03-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|ABSENT||Opioid-potentiated Volative Anaesthetic Vs. Remifentanil And Propofol During Abdominal Aortic Aneurysm Surgery|Opioid-potentiated Volative Anaesthetic(Sevoflurane)Compared to Remifentanil and Propofol During Abdominal Aortic Aneurysm Surgery|Completed||Phase 4|193|Actual|Sykehuset i Vestfold HF||2|||f||||f||||||||||2018-06-01 02:52:49.650879|2018-06-01 02:52:49.650879
NCT00538408|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2009-02-01|2007-10-01|2007-10-02|Estimate|||||||2009-02-01|2009-02-03|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|January 2010|Anticipated|2010-01-31|||||Observational|||Whole Body Magnetic Resonance Angiography in Ischemic Patients|Whole Body Magnetic Resonance Angiography in Patients With Symptomatic Peripheral Ischemia|Unknown status|Recruiting||80|Anticipated|Copenhagen University Hospital at Herlev|||||f||||t||||||||||2018-06-01 02:52:49.731616|2018-06-01 02:52:49.731616
NCT00161109|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-12|2005-09-08|2005-09-12|Estimate|||||||2006-10-12|2006-10-13|Estimate|October 2002||2002-10-31|October 2004|2004-10-31|October 2012||2012-10-31|||||Observational|||Genetics and Psychopathology in the 22q11 Deletion Syndrome|Genetics and Psychopathology in the 22q11 Deletion Syndrome|Unknown status|Recruiting||175||UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.471263|2018-06-01 04:40:52.471263
NCT00538395|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2011-12-11|2007-10-01|2007-10-02|Estimate|||||||2011-12-11|2011-12-13|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer||Unknown status|Active, not recruiting|N/A|100|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:52:49.815024|2018-06-01 02:52:49.815024
NCT00538382|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2014-07-29|2007-09-28|2007-10-02|Estimate|||||||2014-07-29|2014-07-31|Estimate|May 2007||2007-05-31|July 2014|2014-07-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo|Phase I Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo|Completed||Phase 1|51|Actual|NICHD Global Network for Women's and Children's Health||3|||f||||t||||||||||2018-06-01 02:52:49.866036|2018-06-01 02:52:49.866036
NCT00538369|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-10-11|2007-10-01|2007-10-02|Estimate|||||||2015-10-11|2015-10-14|Estimate|November 2006||2006-11-30|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|COST||Combining Observational and Physiologic Sedation Assessment Tools|Combining Observational and Physiologic Sedation Assessment Tools|Terminated||Phase 4|67|Actual|Duke University||2||Lack of equipoise|f||||t||||||||||2018-06-01 02:52:49.936378|2018-06-01 02:52:49.936378
NCT00538356|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2014-12-19|2007-10-01|2007-10-02|Estimate|||||||2014-12-19|2014-12-23|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|March 2012|Actual|2012-03-31||Interventional|IN-TIME||Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function|IN-TIME: Influence of Home Monitoring on the Clinical Status of Heart Failure Patients|Completed||Phase 4|720|Actual|Biotronik SE & Co. KG||2|||f||||f||||||||||2018-06-01 02:52:50.041838|2018-06-01 02:52:50.041838
NCT00538343|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28||2012-08-15|2014-11-13|2007-09-28|2007-10-02|Estimate||||2014-11-13|2014-11-26|Estimate|2014-11-13|2014-11-26|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases|A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases|Terminated||Phase 2|14|Actual|Reata Pharmaceuticals, Inc.||1||Business Decision|f||||f||||||||||2018-06-01 02:52:50.185737|2018-06-01 02:52:50.185737
NCT00538330|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2011-12-11|2007-10-01|2007-10-02|Estimate|||||||2011-12-11|2011-12-13|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer||Active, not recruiting||N/A|2000|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:52:50.295823|2018-06-01 02:52:50.295823
NCT00538317|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2008-11-21|2007-10-01|2007-10-02|Estimate|||||||2008-11-21|2008-11-24|Estimate|July 2007||2007-07-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|AGIR2||GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction|Comparison of Administration of Tirofiban in the Ambulance or in the Cathlab in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty|Completed||Phase 4|320|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 02:52:50.354192|2018-06-01 02:52:50.354192
NCT00538304|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2011-09-19||2011-09-19|2007-10-01|2007-10-02|Estimate|2011-09-19|2011-10-27|Estimate||||2011-09-19|2011-10-27|Estimate|November 2007||2007-11-30|September 2011|2011-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 2|222|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:52:50.625254|2018-06-01 02:52:50.625254
NCT00538291|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2014-06-12||2014-08-19|2007-10-01|2007-10-02|Estimate|2014-08-19|2014-08-28|Estimate||||2014-08-19|2014-08-28|Estimate|August 2005||2005-08-31|August 2014|2014-08-31||||February 2009|Actual|2009-02-28||Interventional|||Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment|CA225103: A Phase II Study of a Combination of Cetuximab and Capecitabine in Patients With Metastatic Colorectal Cancer After Progression on Previous Fluoropyrimidine Containing Therapy|Terminated||Phase 2|13|Actual|City of Hope Medical Center|Study was terminated due to a lack of efficacy (less than 2 of 13 patients responded to treatment in the first stage of a Simon's two stage design).|1||Study was terminated early due to lack of efficacy.|f||||||||||||||2018-06-01 02:52:51.072999|2018-06-01 02:52:51.072999
NCT00538278|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2011-12-11|2007-10-01|2007-10-02|Estimate|||||||2011-12-11|2011-12-13|Estimate|October 2007||2007-10-31|December 2011|2011-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Prospective Database for Acute Myeloblastic Leukemia||Active, not recruiting||N/A|2000|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:52:51.413367|2018-06-01 02:52:51.413367
NCT00538265|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2011-02-02|2007-10-01|2007-10-02|Estimate|||||||2011-02-02|2011-02-03|Estimate|May 2005||2005-05-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|BEFIRTH||Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation|Evaluation of the Benefit of Antithymocyte Induction Therapy on Hepatic Fibrosis in de Novo Hepatitis C Virus Liver Transplant Patients.|Completed||Phase 4|100|Anticipated|University Hospital, Toulouse||3|||f||||f||||||||||2018-06-01 02:52:51.484457|2018-06-01 02:52:51.484457
NCT00538252|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2013-12-10|2007-10-01|2007-10-02|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Parental Involvement and Children's Extra-Familial Contexts|Parental Involvement, Extra-Familial Contexts and Prevention of Drug Use Risk|Completed|||731|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:52:51.570007|2018-06-01 02:52:51.570007
NCT00538239|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2015-02-12|2007-10-01|2007-10-02|Estimate|||||||2015-02-12|2015-02-13|Estimate|October 2007||2007-10-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|October 2010|Actual|2010-10-31||Interventional|SUCCEED||Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)|A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas|Completed||Phase 3|711|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:52:51.732088|2018-06-01 02:52:51.732088
NCT00538226|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-29|||2008-03-03|2007-09-29|2007-10-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|November 2007|Actual|2007-11-30|||||Interventional|||Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg|To Evaluate the Increase of Local Circulation in the Leg Using the Flowaid Device|Completed||Phase 1|||Rosenblum, Jonathan I., DPM|||||f||||t||||||||||2018-06-01 02:52:51.833302|2018-06-01 02:52:51.833302
NCT00155636|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|January 2002||2002-01-31|January 2002|2002-01-31|December 2005||2005-12-31|||||Observational|||A Study on Etiological Factors of Schizophrenia|A Study on Etiological Factors of Schizophrenia|Terminated|||1056||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.843104|2018-06-01 04:42:10.843104
NCT00538213|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|2012-04-05|2009-05-20|2016-11-03|2007-10-01|2007-10-02|Estimate|2012-08-02|2012-09-05|Estimate|2009-09-28|2009-09-30|Estimate|2016-11-03|2016-12-16|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults|Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (≥66 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Will be Used as Reference|Completed||Phase 2|133|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:52:51.992815|2018-06-01 02:52:51.992815
NCT00538200|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2014-12-05|2007-10-01|2007-10-02|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Chronic Obstructive Pulmonary Disease (COPD) Nutrition Support Trial|A Randomised Trial of Oral Nutritional Supplements Versus Dietary Advice on Clinical Outcomes in Patients With COPD|Completed||N/A|85|Actual|University of Southampton||2|||f||||f||||||||||2018-06-01 02:52:53.266054|2018-06-01 02:52:53.266054
NCT00538187|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-12-03|2007-10-01|2007-10-02|Estimate|||||||2015-12-03|2015-12-04|Estimate|December 2007||2007-12-31|May 2013|2013-05-31||||April 2011|Actual|2011-04-30||Interventional|||Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma|Phase I Study of GX15-070 (NSC # 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma|Terminated||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:52:53.339109|2018-06-01 02:52:53.339109
NCT00538174|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-03-20|2007-10-01|2007-10-02|Estimate|||||||2015-03-20|2015-03-23|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|MAD||Phase I Multiple-Ascending Dose (Japan)|A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Diabetic Japanese Subjects|Completed||Phase 1|36|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:52:53.447029|2018-06-01 02:52:53.447029
NCT00538161|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-30|||2017-03-15|2007-10-01|2007-10-02|Estimate|||||||2017-03-15|2017-03-17|Actual|October 2007||2007-10-31|March 2017|2017-03-31|January 2011|Actual|2011-01-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Low Tidal Volume Ventilation in Improving Oxygenation and Thus Reducing Acute Lung Injury in the Cardiac Surgical Patient|Effect of Low Tidal Volume Ventilation in Improving Oxygenation and Thus Reducing Acute Lung Injury in the Cardiac Surgical Patient|Completed||N/A|150|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-06-01 02:52:53.553748|2018-06-01 02:52:53.553748
NCT00538148|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2012-02-15|2007-10-01|2007-10-02|Estimate|||||||2012-02-15|2012-02-17|Estimate|November 2002||2002-11-30|February 2012|2012-02-29|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD|A Multicenter, Multinational, Randomized, DB Controlled Study of the Efficacy & Safety of Oral Telithromycin 800 mg Once QD for 5 Days vs Azithromycin in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD.|Completed||Phase 4|668|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:52:53.669773|2018-06-01 02:52:53.669773
NCT00538135|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-29|||2007-09-29|2007-09-29|2007-10-02|Estimate|||||||2007-09-29|2007-10-02|Estimate|February 2002||2002-02-28|September 2007|2007-09-30|March 2005|Actual|2005-03-31|||||Interventional|BOSCOT||BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder|BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder|Completed||Phase 3|106|Actual|University of Aberdeen||2|||f||||f||||||||||2018-06-01 02:52:53.737263|2018-06-01 02:52:53.737263
NCT00538122|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2009-01-23|2007-10-01|2007-10-02|Estimate|||||||2009-01-23|2009-01-27|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Observational|||Changes in Heart Rhythms Associated With Antipsychotic Drug Treatment|Evaluating the Risks of Arrhythmia and Sudden Death Associated With Antipsychotic Drugs by Assessing the T Wave Abnormalities in the Holter Electrocardiogram|Completed|||12|Anticipated|Vanderbilt University|||1||f||||f||||||||||2018-06-01 02:52:53.862426|2018-06-01 02:52:53.862426
NCT00538109|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-12-15|2007-10-01|2007-10-02|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase|Completed||N/A|8|Actual|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:52:53.978573|2018-06-01 02:52:53.978573
NCT00538096|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2008-09-04|2007-10-01|2007-10-02|Estimate|||||||2008-09-04|2008-09-05|Estimate|September 2007||2007-09-30|September 2008|2008-09-30|May 2010|Anticipated|2010-05-31|March 2010|Anticipated|2010-03-31||Interventional|||A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma|A Phase I, Multicenter, Open-Label, Single-Arm, Dose-Escalation, Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 in Adults With B-Cell Non-Hodgkin's Lymphoma Not Eligible for Curative Therapy|Withdrawn||Phase 1|18|Anticipated|MedImmune LLC||3||Replacing this trial with a new trial.|f||||f||||||||||2018-06-01 02:52:54.032929|2018-06-01 02:52:54.032929
NCT00538083|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2007-09-28|2007-09-28|2007-10-02|Estimate|||||||2007-09-28|2007-10-02|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|May 2006|Actual|2006-05-31|||||Interventional|Chocolate||Cocoa and Endothelial Function in Adults With Elevated BMI|Dark Chocolate and Cocoa Ingestion and Endothelial Function: A Randomized, Placebo Controlled, Cross-Over Trial|Completed||Phase 1|45|Actual|Griffin Hospital||3|||f||||f||||||||||2018-06-01 02:52:54.167828|2018-06-01 02:52:54.167828
NCT00538070|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2012-09-17|2007-10-01|2007-10-02|Estimate|||||||2012-09-17|2012-09-18|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|Sarc||A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia|The Effects of Glycine Transport Inhibition on Brain Glycine Concentration|Completed||N/A|68|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 02:52:54.412465|2018-06-01 02:52:54.412465
NCT00537875|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-10-07|2007-10-01|2007-10-02|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens|Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens|Completed||N/A|36|Actual|National Research Institute of Tuberculosis and Lung Disease, Iran||2|||f||||t||||||||||2018-06-01 02:52:58.223187|2018-06-01 02:52:58.223187
NCT00538057|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2017-08-02|2007-10-01|2007-10-02|Estimate|||||||2017-08-02|2017-08-04|Actual|October 2, 2007|Actual|2007-10-02|August 2017|2017-08-31|December 1, 2007|Actual|2007-12-01|December 1, 2007|Actual|2007-12-01||Interventional|||Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects|A Randomised, Double-blind, Placebo-controlled, Four-way Crossover Study to Compare the Pharmacodynamics and Pharmacokinetics of GW685698X and GW642444M When Administered Separately and in Combination as a Single Dose From a Novel Dry Powder Device in Healthy Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:52:54.585396|2018-06-01 02:52:54.585396
NCT00538044|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2007-10-01|2007-10-01|2007-10-02|Estimate|||||||2007-10-01|2007-10-02|Estimate|January 2009||2009-01-31|September 2007|2007-09-30|January 2012|Anticipated|2012-01-31|||||Interventional|||Simvatstatin Used to Treat Pulmonary Hypertension|the Clinical Research Using Simvastatin as a Medication to Treat Advanced Secondary Pulmonary Hypertension|Unknown status|Not yet recruiting|Phase 1|||Capital Medical University||2|||f||||t||||||||||2018-06-01 02:52:54.714345|2018-06-01 02:52:54.714345
NCT00538031|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2018-02-09|2007-10-01|2007-10-02|Estimate|||||||2018-02-09|2018-02-12|Actual|December 22, 2003||2003-12-22|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Randomized Pilot Trial of Oral Cyclophosphamide Versus Oral Cyclophosphamide With Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|27|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 02:52:54.798631|2018-06-01 02:52:54.798631
NCT00538018|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2012-02-15|2007-10-01|2007-10-02|Estimate|||||||2012-02-15|2012-02-17|Estimate|January 2003||2003-01-31|February 2012|2012-02-29|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas||Completed||Phase 4|978|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:52:54.907443|2018-06-01 02:52:54.907443
NCT00538005|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2014-01-09|2007-10-01|2007-10-02|Estimate|||||||2014-01-09|2014-01-10|Estimate|May 2007||2007-05-31|July 2009|2009-07-31||||July 2009|Anticipated|2009-07-31||Interventional|||Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma|A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma|Unknown status|Recruiting|Phase 1/Phase 2|54|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:52:54.988615|2018-06-01 02:52:54.988615
NCT00537992|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2007-10-01|2007-10-01|2007-10-02|Estimate|||||||2007-10-01|2007-10-02|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|March 2006|Actual|2006-03-31|||||Interventional|||Blue-Blocking IOLs in Combined Surgery|Blue Light-Filter IOLs in Vitrectomy Combined With Cataract Surgery: Results of a Randomized Controlled Clinical Trial.|Completed||N/A|60|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||||f||||f||||||||||2018-06-01 02:52:55.075085|2018-06-01 02:52:55.075085
NCT00537979|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2011-07-20||2011-09-16|2007-09-28|2007-10-02|Estimate|2011-09-16|2011-10-25|Estimate||||2011-09-16|2011-10-25|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis|Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis|Completed||Phase 4|147|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:52:55.293852|2018-06-01 02:52:55.293852
NCT00537966|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2017-11-07|2007-10-01|2007-10-02|Estimate|||||||2017-11-07|2017-11-08|Actual|January 2002||2002-01-31|November 2017|2017-11-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study|Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study|Recruiting||N/A|2017|Anticipated|University of Zurich||2|||f||||f||||||||||2018-06-01 02:52:55.773325|2018-06-01 02:52:55.773325
NCT00537953|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2007-09-28|2007-09-28|2007-10-02|Estimate|||||||2007-09-28|2007-10-02|Estimate||||September 2007|2007-09-30||||||||Interventional|||Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia|EFFICACY AND SAFETY OF A SHORT COURSE OF THE COMBINATION OF MILTEFOSINE AND ANTIMONY TO TREAT CUTANEOUS LEISHMANIASIS IN BOLIVIA|Unknown status|Recruiting|Phase 2|||Centro de Investigaciones Bioclínicas de la Fundación Fader|||||f||||f||||||||||2018-06-01 02:52:56.949556|2018-06-01 02:52:56.949556
NCT00537940|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2014-07-15||2014-11-12|2007-09-28|2007-10-02|Estimate|2014-07-15|2014-08-08|Estimate||||2014-11-12|2014-11-24|Estimate|February 2008||2008-02-29|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures|A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures.|Completed||Phase 4|484|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:52:57.062414|2018-06-01 02:52:57.062414
NCT00537927|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2009-02-17|2007-10-01|2007-10-02|Estimate|||||||2009-02-17|2009-02-18|Estimate|August 2005||2005-08-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|LACH||LACH-Trial: LAparoscopic Correction of Hernia|The Effect of Mesh Fixation Technique on Postoperative Pain in Laparoscopic Correction of Incisional and Ventral Abdominal Wall Hernias.|Completed||N/A|215|Actual|Ziekenhuisgroep Twente||3|||f||||t||||||||||2018-06-01 02:52:57.814437|2018-06-01 02:52:57.814437
NCT00537914|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2017-06-08|2007-10-01|2007-10-02|Estimate|||||||2017-06-08|2017-06-09|Actual|February 2008||2008-02-29|June 2017|2017-06-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)|Long-term Phase IV Multicentre Study on the Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)|Active, not recruiting||Phase 4|278|Actual|Sandoz||1|||f||||f||||||||||2018-06-01 02:52:57.927446|2018-06-01 02:52:57.927446
NCT00537901|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2015-12-16|2007-10-01|2007-10-02|Estimate|||||||2015-12-16|2015-12-17|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study|First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study|Completed||N/A|100|Actual|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:52:58.052689|2018-06-01 02:52:58.052689
NCT00537888|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2010-12-13|2007-10-01|2007-10-02|Estimate|||||||2010-12-13|2010-12-14|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week|Diagnosis of Pulmonary Candidiasis|Unknown status|Recruiting|Phase 4|200|Anticipated|Capital Medical University|||||f||||t||||||||||2018-06-01 02:52:58.128965|2018-06-01 02:52:58.128965
NCT00537862|ClinicalTrials.gov processed this data on May 31, 2018|2007-10-01|||2017-02-22|2007-10-01|2007-10-02|Estimate|||||||2017-02-22|2017-02-24|Actual|May 2006||2006-05-31|February 2017|2017-02-28||||February 2007|Actual|2007-02-28||Interventional|||Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients|Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients ; A Prospective, Open Label, Multi-center Study|Completed||Phase 4|200|Actual|Novartis|||||f||||||||||||||2018-06-01 02:52:58.294251|2018-06-01 02:52:58.294251
NCT00537849|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2009-09-28|2007-09-30|2007-10-01|Estimate|||||||2009-09-28|2009-09-29|Estimate|December 2007||2007-12-31|April 2008|2008-04-30|March 2008|Anticipated|2008-03-31|March 2008|Anticipated|2008-03-31||Interventional|||Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate 500 (SB-500) System in Canada|Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate 500 (SB-500) System in Canada|Withdrawn||N/A|||SonaCare Medical||||Sponsor withdrew request to conduct study|f||||f||||||||||2018-06-01 02:52:58.371517|2018-06-01 02:52:58.371517
NCT00537836|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2015-04-08|2007-09-28|2007-10-01|Estimate|||||||2015-04-08|2015-04-09|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||ZK283197 for Treatment of Vasomotor Symptoms|A Double-blind, Randomized, Placebo and Active Controlled, Multicenter Study to Investigate Efficacy and Safety After Oral Administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and Placebo Once Daily for 8 Weeks in Postmenopausal Women With Hot Flushes|Completed||Phase 2|116|Actual|Bayer||4|||f||||f||||||||||2018-06-01 02:52:58.43735|2018-06-01 02:52:58.43735
NCT00537823|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2016-08-31||2016-10-27|2007-09-30|2007-10-01|Estimate|2016-10-27|2016-12-20|Estimate||||2016-10-27|2016-12-20|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|||Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement|Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases|Terminated||Phase 2|9|Actual|Washington University School of Medicine||2||Poor accrual.|f||||f||||||||||2018-06-01 02:52:58.642452|2018-06-01 02:52:58.642452
NCT00537810|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2014-06-19||2014-12-11|2007-09-30|2007-10-01|Estimate|2014-12-11|2014-12-12|Estimate||||2014-12-11|2014-12-12|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Treatment of Binge Eating in Obese Patients in Primary Care|Treatment of Binge Eating in Obese Patients in Primary Care|Completed||Phase 4|104|Actual|Yale University||4|||f||||t||||||||||2018-06-01 02:52:59.220693|2018-06-01 02:52:59.220693
NCT00537797|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2014-09-18|2007-09-30|2007-10-01|Estimate|||||||2014-09-18|2014-09-22|Estimate|August 2004||2004-08-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|September 2011|Actual|2011-09-30||Interventional|||Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules|Limited Neck FDG-PET Imaging for Indeterminate Thyroid Nodules|Completed||N/A|84|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 02:52:59.642671|2018-06-01 02:52:59.642671
NCT00537784|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2013-06-17|2007-09-28|2007-10-01|Estimate|||||||2013-06-17|2013-06-19|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Platelet Concentrate in Achilles Tendon Repair||Completed||N/A|30|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-06-01 02:52:59.723414|2018-06-01 02:52:59.723414
NCT00537771|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2012-12-20||2012-12-20|2007-09-27|2007-10-01|Estimate|2012-12-20|2013-01-25|Estimate||||2012-12-20|2013-01-25|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|HEART||Liver Safety Under Upfront Arimidex vs Tamoxifen|A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer|Completed||Phase 4|384|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:52:59.81466|2018-06-01 02:52:59.81466
NCT00537758|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2007-09-27|2007-09-27|2007-10-01|Estimate|||||||2007-09-27|2007-10-01|Estimate|July 2002||2002-07-31|September 2007|2007-09-30||||||||Interventional|||Treatment for Obesity and Binge Eating Disorder|Treatment for Obesity and Binge Eating Disorder|Completed||N/A|125|Actual|Yale University||3|||f||||||||||||||2018-06-01 02:53:00.085051|2018-06-01 02:53:00.085051
NCT00537745|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2011-07-20||2012-08-23|2007-09-30|2007-10-01|Estimate|2012-08-23|2012-08-27|Estimate||||2012-08-23|2012-08-27|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders|Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders-a Pilot Study|Completed||Phase 4|14|Actual|Pacific Institute for Research and Evaluation|Fourteen subjects were consented, and began the screening process. Two subjects did not meet entry criteria and 1 withdrew consent prior to injection. Of the remaining 11 subjects, 7 received 3, 2 received 2, and 2 received 1 injection(s).|1|||f||||f||||||||||2018-06-01 02:53:00.23819|2018-06-01 02:53:00.23819
NCT00537732|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2014-02-24|2007-09-28|2007-10-01|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2007||2007-04-30|February 2014|2014-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|GERD||Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing|Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing|Terminated||Phase 4|68|Actual|Robert Bosch Gesellschaft für Medizinische Forschung mbH||2||recruitment problems|f||||t||||||||||2018-06-01 02:53:00.386683|2018-06-01 02:53:00.386683
NCT00537719|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2017-08-15|2007-09-28|2007-10-01|Estimate|||||||2017-08-15|2017-08-17|Actual|December 7, 2007|Actual|2007-12-07|August 2017|2017-08-31|April 4, 2008|Actual|2008-04-04|April 4, 2008|Actual|2008-04-04||Interventional|||Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.|A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal|Completed||Phase 1|34|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:53:00.470311|2018-06-01 02:53:00.470311
NCT00537706|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2017-06-30|2007-09-28|2007-10-01|Estimate|||||||2017-06-30|2017-07-02|Actual|September 21, 2007||2007-09-21|October 31, 2011|2011-10-31|October 31, 2011||2011-10-31|||||Observational|||Choosing Healthful Interventions|Engaging Low-Income Urban Residents in Prioritizing Interventions to Address Socio-Economic Determinants of Health|Completed|||442|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:53:00.58343|2018-06-01 02:53:00.58343
NCT00537693|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2010-09-01|2007-09-27|2007-10-01|Estimate|||||||2010-09-01|2010-09-02|Estimate|September 2007||2007-09-30|September 2010|2010-09-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Cytokine Removal by CRRT in Pediatric Sepsis|Cytokine Removal by CRRT in Pediatric Sepsis: A Comparison of Convection Versus Diffusion|Completed||N/A|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||||||||||||2018-06-01 02:53:00.646472|2018-06-01 02:53:00.646472
NCT00537680|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2011-06-07||2012-02-02|2007-09-28|2007-10-01|Estimate|2011-11-22|2011-12-29|Estimate||||2012-02-02|2012-02-03|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|IONIA||Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia|A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients|Completed||Phase 3|70|Actual|Santhera Pharmaceuticals||3|||f||||t||||||||||2018-06-01 02:53:00.736631|2018-06-01 02:53:00.736631
NCT00537667|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2009-11-25|2007-09-27|2007-10-01|Estimate|||||||2009-11-25|2009-11-26|Estimate|August 2001||2001-08-31|December 2008|2008-12-31|June 2003|Actual|2003-06-30|March 2003|Actual|2003-03-31||Interventional|||The SPECTRA Study|A Single Centre, Open-Label, Randomised, Study to Evaluate the Effect of Anakinra (r-metHuIL-1ra) Alone and in Combination With PEGylated Recombinant Methionyl Human Soluble Tumour Necrosis Factor Receptor Type I (PEG sTNF-RI) on Synovial Inflammation in Subjects With Rheumatoid Arthritis.|Terminated||Phase 2|22|Actual|Swedish Orphan Biovitrum||2||The safety profile of combination therapy became unacceptable.|f||||||||||||||2018-06-01 02:53:01.014819|2018-06-01 02:53:01.014819
NCT00537654|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2017-08-15|2007-09-28|2007-10-01|Estimate|||||||2017-08-15|2017-08-17|Actual|October 18, 2007|Actual|2007-10-18|August 2017|2017-08-31|February 22, 2008|Actual|2008-02-22|February 22, 2008|Actual|2008-02-22||Interventional|||A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State|An Open-Label, Randomized, Single Dose Three-Period Partial Crossover Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.4mg) Compared to Concomitant Dosing of AVODART™ 0.5mg and Flomax 0.4mg Commercial Capsules in Healthy Male Subjects|Completed||Phase 1|81|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:53:01.090236|2018-06-01 02:53:01.090236
NCT00537641|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2015-07-02|2007-09-27|2007-10-01|Estimate|||||||2015-07-02|2015-07-07|Estimate|May 2007||2007-05-31|July 2015|2015-07-31|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Observational|||Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)|Prevalence and Severity of Nocturnal Oxygenation and Ventilation Failure in Patients With Amyotrophic Lateral Sclerosis Using Noninvasive Ventilation|Completed|||25|Actual|Columbia University|||||f||||f||||||||||2018-06-01 02:53:01.206546|2018-06-01 02:53:01.206546
NCT00537628|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2008-07-30|2007-09-28|2007-10-01|Estimate|||||||2008-07-30|2008-08-01|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Observational|BACH||Biomarkers in Acute Heart Failure|Biomarkers in Acute Heart Failure: An International, Multi-Center Trial Evaluating the Prognostic and Diagnostic Utility of Biomarkers in Patients With Heart Failure Presenting With Shortness of Breath|Completed|||1641|Actual|Brahms AG|||||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 02:53:01.270552|2018-06-01 02:53:01.270552
NCT00537615|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2010-02-16|2007-09-28|2007-10-01|Estimate|||||||2010-02-16|2010-02-17|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|October 2007|Actual|2007-10-31|||||Interventional|||An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers|A Phase 1 Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0332334 In Six Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer|||||f||||||||||||||2018-06-01 02:53:01.348259|2018-06-01 02:53:01.348259
NCT00537602|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2010-02-11|2007-09-28|2007-10-01|Estimate|||||||2010-02-11|2010-02-12|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Miglustat / OGT 918 in the Treatment of Cystic Fibrosis|Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation|Terminated||Phase 2|6|Actual|Actelion||2||Methodology applied did not meet all criteria required per guidelines|f||||f||||||||||2018-06-01 02:53:01.416448|2018-06-01 02:53:01.416448
NCT00537589|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2007-10-03|2007-09-28|2007-10-01|Estimate|||||||2007-10-03|2007-10-04|Estimate|December 2004||2004-12-31|September 2007|2007-09-30|August 2006|Actual|2006-08-31|||||Interventional|UGA||Ultrasound Guided Arthrocentesis|Randomized Control Trial of Ultrasound-Guided Peripheral Arthrocentesis|Completed||N/A|132|Actual|Carolinas Healthcare System|||||f||||f||||||||||2018-06-01 02:53:01.494107|2018-06-01 02:53:01.494107
NCT00537576|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2009-05-06|2007-09-27|2007-10-01|Estimate|||||||2009-05-06|2009-05-07|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Safety Study of Lactobacillus Administered Vaginally to Healthy Women|A Phase I Study of the Safety of LACTIN-V Administered Vaginally to Healthy Women|Completed||Phase 1|12|Actual|Osel, Inc.||4|||f||||f||||||||||2018-06-01 02:53:01.550495|2018-06-01 02:53:01.550495
NCT00537563|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2012-02-15|2007-09-28|2007-10-01|Estimate|||||||2012-02-15|2012-02-17|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||AMS VS MOXI Ketek vs Avelox in AMS||Completed||Phase 3|351|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:53:01.659296|2018-06-01 02:53:01.659296
NCT00537550|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2007-09-28|2007-09-28|2007-10-01|Estimate|||||||2007-09-28|2007-10-01|Estimate|July 2000||2000-07-31|September 2007|2007-09-30|June 2006|Actual|2006-06-30|||||Interventional|LAL2000||Adult ALL Treatment at Diagnosis|GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis|Completed||N/A|||Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 02:53:01.716572|2018-06-01 02:53:01.716572
NCT00537537|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2017-06-21|2007-09-27|2007-10-01|Estimate|||||||2017-06-21|2017-06-23|Actual|August 2007||2007-08-31|April 2016|2016-04-30||||June 2011|Actual|2011-06-30||Interventional|||To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)|An Open Label, Response Adaptive Study of Telbivudine in Adults With HBeAg Positive Compensated CHB|Completed||Phase 4|100|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:53:01.793949|2018-06-01 02:53:01.793949
NCT00537524|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2012-02-14|2007-09-28|2007-10-01|Estimate|||||||2012-02-14|2012-02-16|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years|A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years|Completed||Phase 2|471|Actual|Novartis||2|||f||||t||||||||||2018-06-01 02:53:01.91955|2018-06-01 02:53:01.91955
NCT00537212|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2012-02-01|2007-09-28|2007-10-01|Estimate|||||||2012-02-01|2012-02-02|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy|A Single-Center, Prospective, Single-Blinded, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy|Completed||Phase 4|||Bagel, Jerry, M.D.||3|||f||||t||||||||||2018-06-01 02:53:12.57849|2018-06-01 02:53:12.57849
NCT00537511|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2013-03-06||2013-05-07|2007-09-27|2007-10-01|Estimate|2013-03-06|2013-04-17|Estimate||||2013-05-07|2013-05-10|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional||Safety Population|A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide|A Multicenter, Phase I/IIA, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose and To Evaluate the Safety Profile of CC-4047 Administered in Combination With Cisplatin and Etoposide in Patients With Extensive Disease Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|22|Actual|Celgene||1||This study was terminated for administrative reasons.|f||||f||||||||||2018-06-01 02:53:02.171164|2018-06-01 02:53:02.171164
NCT00537498|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2010-03-24|2007-09-28|2007-10-01|Estimate|||||||2010-03-24|2010-03-25|Estimate|February 2002||2002-02-28|September 2007|2007-09-30|December 2006|Actual|2006-12-31|||||Interventional|||Urokinase Therapy in Diabetic Foot Syndrome|Phase II Study of Urokinase Therapy for Treatment of Angiopathic or Angioneuropathic Diabetic Foot Syndrome|Completed||Phase 2|77|Actual|medac GmbH||1|||f||||f||||||||||2018-06-01 02:53:03.358316|2018-06-01 02:53:03.358316
NCT00537485|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2014-02-03||2014-02-03|2007-09-28|2007-10-01|Estimate|2014-02-03|2014-03-19|Estimate||||2014-02-03|2014-03-19|Estimate|September 2007||2007-09-30|February 2014|2014-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||Excluded 3 subjects (SPM962:2, placebo:1) because lack of assessment of efficacy, and 1 (plasebo) for not matching with the inclusion criteria.|A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients|A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa|Completed||Phase 2/Phase 3|180|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:53:03.463582|2018-06-01 02:53:03.463582
NCT00537472|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2009-04-16|2007-09-28|2007-10-01|Estimate|||||||2009-04-16|2009-04-17|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Low Dose Spinal Bupivacaine for Total Knee Replacement and Recovery Room Wait Time|Low Dose Spinal Bupivacaine for Total Knee Arthroplasty and Recovery Room Wait Time|Completed||N/A|140|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:53:04.210624|2018-06-01 02:53:04.210624
NCT00537459|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-03-15|2007-09-27|2007-10-01|Estimate|||||||2012-03-15|2012-03-19|Estimate|December 2006||2006-12-31|February 2011|2011-02-28||||||||Interventional|||A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation|A Randomized, Double-blind, Placebo-controlled, Two-session Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an 16448 in Healthy Males With Premature Ejaculation.|Completed||Phase 2|18|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:53:04.286911|2018-06-01 02:53:04.286911
NCT00537446|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2011-10-12|2007-09-27|2007-10-01|Estimate|||||||2011-10-12|2011-10-13|Estimate|September 2007||2007-09-30|October 2011|2011-10-31||||August 2012|Anticipated|2012-08-31||Interventional|||Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis|Effect of Noninvasive Positive Pressure Ventilation on Pulmonary Function Testing in Amyotrophic Lateral Sclerosis|Unknown status|Recruiting|N/A|20|Anticipated|Columbia University||2|||f||||f||||||||||2018-06-01 02:53:04.347115|2018-06-01 02:53:04.347115
NCT00537433|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2007-09-28|2007-09-28|2007-10-01|Estimate|||||||2007-09-28|2007-10-01|Estimate|July 2006||2006-07-31|September 2007|2007-09-30|January 2007|Actual|2007-01-31|||||Interventional|||Improving Parental Understanding of Medication Instructions Through a Pictogram-Based Intervention|An RCT to Reduce Liquid Medication Dosing Errors and Improve Adherence in Caregivers of Young Children Through a Pictogram-Based Intervention|Completed||Phase 1|251|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 02:53:04.442974|2018-06-01 02:53:04.442974
NCT00537420|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2008-09-12|2007-09-28|2007-10-01|Estimate|||||||2008-09-12|2008-09-15|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||A Study of Nasal PYY3-36 and Placebo for Weight Loss in Obese Subjects|A 24-Week, Blinded, Randomized, Placebo-Controlled Dose-Ranging Trial of Nasal PYY3-36 for Weight Loss in Healthy Obese Patients|Completed||Phase 2|551|Actual|Nastech Pharmaceutical Company, Inc.||6|||f||||f||||||||||2018-06-01 02:53:04.508048|2018-06-01 02:53:04.508048
NCT00537407|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2015-04-01|2014-08-04|2016-02-12|2007-09-28|2007-10-01|Estimate|2015-05-01|2015-05-07|Estimate|2014-08-04|2014-08-06|Estimate|2016-02-12|2016-02-17|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Intent-to-treat population: All randomized participants with at least a Baseline and 1 on- or post-treatment hepatitis C virus RNA assessment.|A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment|An Open-label, Randomized, 5-arm, Parallel-group Study of the Effects on Viral Kinetics, Safety and Pharmacokinetics of Different Dosing Regimens of Debio 025 in Combination With Peginterferon Alpha-2a and Ribavirin in Chronic HCV Genotype 1 Patients Who Are Non Responders to Standard Peginterferon Alpha and Ribavirin Treatment|Completed||Phase 2|50|Actual|Debiopharm International SA||5|||f||||t||||||||||2018-06-01 02:53:04.711129|2018-06-01 02:53:04.711129
NCT00537394|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2013-06-14||2016-05-24|2007-09-27|2007-10-01|Estimate|2014-07-14|2014-08-07|Estimate||||2016-05-24|2016-05-26|Estimate|January 2008||2008-01-31|May 2016|2016-05-31|April 2013|Actual|2013-04-30|May 2012|Actual|2012-05-31||Interventional||Everyone randomized (ITT study sample), plus non-randomized group.|Optimizing Treatment for Treatment-Experienced, HIV-Infected People|The Optimized Treatment That Includes or Omits NRTIs Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen|Completed||Phase 3|517|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||t||||||||||||||2018-06-01 02:53:05.862237|2018-06-01 02:53:05.862237
NCT00537381|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2013-03-28||2013-06-12|2007-09-27|2007-10-01|Estimate|2013-03-28|2013-05-20|Estimate||||2013-06-12|2013-06-20|Estimate|May 2007||2007-05-31|June 2013|2013-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer|A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|131|Actual|Centocor, Inc.|Treatment with intetumumab/placebo was permanently discontinued after a planned, preliminary review of interim analysis data. Therefore, study treatment with intetumumab was not completed for some participants.|2|||f||||t||||||||||2018-06-01 02:53:07.127315|2018-06-01 02:53:07.127315
NCT00537368|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2010-10-21|2007-09-28|2007-10-01|Estimate|||||||2010-10-21|2010-10-22|Estimate|September 2007||2007-09-30|October 2010|2010-10-31|March 2010|Actual|2010-03-31|||||Interventional|||First Study of the Safety of CNTO 888 in Patients With Solid Tumors|A Phase 1 Study of CNTO 888, a Human Monoclonal Antibody Against CC-Chemokine Ligand 2 in Subjects With Solid Tumors|Completed||Phase 1|44|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 02:53:08.195267|2018-06-01 02:53:08.195267
NCT00537355|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2018-02-27|2007-09-27|2007-10-01|Estimate|||||||2018-02-27|2018-03-01|Actual|September 2007||2007-09-30|February 2018|2018-02-28|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of TOLAMBA™ in the Control of Symptoms of Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model|Completed||Phase 2|271|Actual|Dynavax Technologies Corporation||2|||f||||f||||||||No|"The IND for Tolamba was withdrawn. There is no intention to conduct clinical studies with this compound. All studies were conducted in Canada, no U.S. sites participated in study. CT PRS states DR status will be removed from study. 3/1/2017 - no update"|2018-06-01 02:53:08.312113|2018-06-01 02:53:08.312113
NCT00537342|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2010-12-16|2007-09-28|2007-10-01|Estimate|||||||2010-12-16|2010-12-17|Estimate|October 2007||2007-10-31|December 2010|2010-12-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)|Prospective, Randomised, Double Blind, Placebo Controlled Study of Treatment With Sublingual Immunotherapy of Depigmented and Polymerised Allergen Extract of O. Europaea in Two Groups of Patients With Allergic Rhinitis /Rhinoconjunctivitis|Completed||Phase 3|83|Actual|Laboratorios Leti, S.L.||2|||f||||f||||||||||2018-06-01 02:53:08.413214|2018-06-01 02:53:08.413214
NCT00537329|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2010-01-19||2010-03-04|2007-09-27|2007-10-01|Estimate|2010-01-19|2010-02-17|Estimate||||2010-03-04|2010-03-09|Estimate|January 2008||2008-01-31|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Anidulafungin In Treatment Of Candidemia In Asian Subjects|A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients|Completed||Phase 3|43|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:53:08.545648|2018-06-01 02:53:08.545648
NCT00537316|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2011-11-11|2011-02-10|2017-03-15|2007-09-28|2007-10-01|Estimate|2011-11-11|2011-12-16|Estimate|2011-02-10|2011-02-14|Estimate|2017-03-15|2017-04-12|Actual|July 2007||2007-07-31|March 2017|2017-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)|Comparison of the Efficacy and Safety of Infliximab, as Monotherapy or in Combination With Azathioprine, Versus Azathioprine Monotherapy in Moderate to Severe Active Ulcerative Colitis (Part 1) Comparison of Maintenance Versus Intermittent Infliximab Treatment in Maintaining Remission: A Follow-Up of Efficacy and Safety (Part 2)|Terminated||Phase 3|242|Actual|Merck Sharp & Dohme Corp.||7||"Infusion reactions during re-induction cycles after a period of no treatment in another study~   [P04563, NCT0358670]"|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:53:09.203305|2018-06-01 02:53:09.203305
NCT00537303|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2010-07-16||2017-01-30|2007-09-28|2007-10-01|Estimate|2010-07-16|2010-08-13|Estimate||||2017-01-30|2017-03-10|Actual|October 2007||2007-10-31|January 2017|2017-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes|Comparison of the Efficacy and Safety of Step-wise Addition of Short Acting Insulin Analogue Insulin Aspart to Once Daily Insulin Detemir and Oral Anti-diabetic Treatment in Patients With Type 2 Diabetes|Completed||Phase 4|296|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 02:53:10.429459|2018-06-01 02:53:10.429459
NCT00537290|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2017-04-20||2017-10-02|2007-09-28|2007-10-01|Estimate|2017-10-02|2017-10-31|Actual||||2017-10-02|2017-10-31|Actual|September 2007||2007-09-30|October 2017|2017-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|RITAPS|Patients included in the study|A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome|A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome (RITAPS)|Completed||Phase 2|19|Actual|Hospital for Special Surgery, New York||1|||f||||t||||||||No||2018-06-01 02:53:11.105127|2018-06-01 02:53:11.105127
NCT00537277|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|2010-07-19||2014-11-20|2007-09-28|2007-10-01|Estimate|2010-07-19|2010-08-17|Estimate||||2014-11-20|2014-12-08|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|IMPROVE||Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs|A Titrate-To-Target Study of the Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs With / Without Once Daily Basal Insulin Therapy|Completed||Phase 4|161|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 02:53:11.34284|2018-06-01 02:53:11.34284
NCT00537264|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2018-04-16|2007-09-28|2007-10-01|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2007||2007-11-30|April 2018|2018-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Comparison of Computerised Versus Interviewer-administered Approach for Assessing Health-related Quality of Life|A Randomized Controlled Trial Comparing Computer- Versus Interviewer-administered Approach for Assessing Health-related Quality of Life in Multi-Ethnic Singapore|Completed||N/A|4800|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-06-01 02:53:11.520166|2018-06-01 02:53:11.520166
NCT00537251|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-28|||2007-09-28|2007-09-28|2007-10-01|Estimate|||||||2007-09-28|2007-10-01|Estimate|November 2001||2001-11-30|September 2007|2007-09-30|February 2004|Actual|2004-02-29|||||Interventional|||32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus|32-Week, Open, Randomized, Cross-Over, Local, Multicenter Clinical Trial Comparing Insulin Glargine in Combination With Insulin Analogue (Insulin Lispro) to NPH Insulin in Combination With Regular Insulin in Type 1 Diabetes Mellitus Patients in an Intensified Insulin Regimen.|Completed||Phase 3|80|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:53:11.622573|2018-06-01 02:53:11.622573
NCT00537238|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2013-05-21||2013-05-21|2007-09-27|2007-10-01|Estimate|2013-05-21|2013-07-11|Estimate||||2013-05-21|2013-07-11|Estimate|October 2007||2007-10-31|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pregabalin Versus Levetiracetam In Partial Seizures|A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures|Completed||Phase 3|509|Actual|Pfizer|Results for BPRS were provided as change in scores at Week 16 compared to baseline instead of absolute scores as per planned analysis.|2|||f||||t||||||||||2018-06-01 02:53:11.777433|2018-06-01 02:53:11.777433
NCT00537225|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2017-04-18|2007-09-28|2007-10-01|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2006||2006-09-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VIGOR2||Multifactor Risk Reduction for Optimal Management of PAD|Multifactor Risk Reduction for Optimal Management of PAD|Active, not recruiting||N/A|300|Actual|Palo Alto Veterans Institute for Research||2|||f||||t||||||||No||2018-06-01 02:53:12.512384|2018-06-01 02:53:12.512384
NCT00537199|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2009-12-11||2016-04-05|2007-09-27|2007-09-28|Estimate|2009-12-11|2010-01-18|Estimate||||2016-04-05|2016-05-13|Estimate|November 2006||2006-11-30|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||OraTest in Combination With Visual Examination and Visual Examination Alone|Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401)|Terminated||Phase 3|1|Actual|M.D. Anderson Cancer Center|Early termination by sponsor resulted in only 1 patient enrolled and no analysis.|1||Study terminated early as per request by sponsor, Zila Biotechnology, Inc.|f||||f||||||||||2018-06-01 02:53:12.67205|2018-06-01 02:53:12.67205
NCT00537186|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2008-10-07|2007-09-27|2007-09-28|Estimate|||||||2008-10-07|2008-10-08|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of Iron Oligosaccharide in CHF Patients|A Non-Comparative Open-Label Study of Iron Oligosaccharide in CHF Patients With Iron Deficiency (Either Absolute or Functional) Anaemia and a Need for Parenteral Iron|Completed||Phase 3|20|Actual|Pharmacosmos A/S||1|||f||||f||||||||||2018-06-01 02:53:13.008131|2018-06-01 02:53:13.008131
NCT00537173|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2017-01-24|2007-09-26|2007-09-28|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2007||2007-09-30|January 2017|2017-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study|Terminated|||11|Actual|Hoosier Cancer Research Network|||1|Lack of Accrual|f||||t||||||Samples With DNA|"~     Blood and tumor samples~   "|||2018-06-01 02:53:13.084859|2018-06-01 02:53:13.084859
NCT00537160|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2012-10-25|2007-09-27|2007-09-28|Estimate|||||||2012-10-25|2012-10-29|Estimate|April 2006||2006-04-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Diet and Exercise in Overweight Children Postburn|The Impact of a Diet and Exercise Program in Overweight Pediatric Patients During Burn Rehabilitation|Withdrawn||Early Phase 1|0|Actual|Shriners Hospitals for Children|||||f||||t||||||||||2018-06-01 02:53:13.161343|2018-06-01 02:53:13.161343
NCT00537147|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2012-12-31|2007-09-27|2007-09-28|Estimate|||||||2012-12-31|2013-01-03|Estimate|March 2008||2008-03-31|December 2012|2012-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3'delta30 Chimeric Virus Vaccine (WN/DEN4delta30), a Live Attenuated Vaccine for West Nile Encephalitis|Completed||Phase 1|26|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 02:53:13.217042|2018-06-01 02:53:13.217042
NCT00537134|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2018-01-24|2007-09-27|2007-09-28|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2006||2006-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|TEAM||Trial on Endovascular Aneurysm Management|Safety and Efficacy of Endovascular Treatment of Unruptured Intracranial Aneurysms in the Prevention of Aneurysmal Haemorrhages: A Randomized Comparison With Indefinite Deferral of Treatment in 2002 Patients Followed for 10 Years|Suspended||N/A|2002|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2||The CIHR Financial support was withdrawn because of insufficient recruitment|f||||t||||||||||2018-06-01 02:53:13.303594|2018-06-01 02:53:13.303594
NCT00537121|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2013-06-26|2007-09-27|2007-09-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|||Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer|Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers|Completed||Phase 1|23|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 02:53:13.395121|2018-06-01 02:53:13.395121
NCT00537108|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2015-05-26|2007-09-27|2007-09-28|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|BRIDGES||Community-Based Care Management For Teen/Young Adult Mothers and Fathers|BRIDGES: A Randomized Trial of Community-Based Care Management For Teen/Young Adult Mothers and Fathers|Completed||N/A|200|Actual|University of Maryland||2|||f||||f||||||||||2018-06-01 02:53:13.462695|2018-06-01 02:53:13.462695
NCT00537095|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2011-04-27||2017-11-02|2007-09-27|2007-09-28|Estimate|2011-06-10|2011-07-08|Estimate||||2017-11-02|2017-12-07|Actual|September 29, 2007|Actual|2007-09-29|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer|A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy|Active, not recruiting||Phase 2|165|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:53:13.626972|2018-06-01 02:53:13.626972
NCT00537082|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2011-02-21||2011-04-19|2007-09-27|2007-09-28|Estimate|2011-02-22|2011-03-23|Estimate||||2011-04-19|2011-04-21|Estimate|September 2007||2007-09-30|April 2011|2011-04-30||||February 2010|Actual|2010-02-28||Interventional|||Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)|A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis|Completed||Phase 2|171|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:53:14.090363|2018-06-01 02:53:14.090363
NCT00537056|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2017-02-01||2017-05-12|2007-09-27|2007-09-28|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|October 2007||2007-10-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI|Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI|Completed||N/A|17|Actual|Stanford University|The utility of the MRI- and CT-scans was significantly limited by low image quality.|1|||f||||t||||||||Yes|De-identified (anonymized) patient data is routinely provided upon request. Protecting patient privacy and confidentiality is the utmost consideration when sharing individual patient data. In all cases of data sharing, patient data is always anonymized to protect privacy. All potential identifiers (name, hospital ID, address,etc) are removed.|2018-06-01 02:53:14.498868|2018-06-01 02:53:14.498868
NCT00536549|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2008-05-19|2007-09-27|2007-09-28|Estimate|||||||2008-05-19|2008-05-20|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Real Time Continuous Glucose Monitoring System on the Management of Type 2 Diabetes||Completed||N/A|127|Actual|Korea University||2|||f||||t||||||||||2018-06-01 02:53:22.018009|2018-06-01 02:53:22.018009
NCT00537043|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27||2010-10-13|2010-10-13|2007-09-27|2007-09-28|Estimate||||2010-10-13|2010-10-19|Estimate|2010-10-13|2010-10-19|Estimate|October 2007||2007-10-31|October 2010|2010-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure|An Open-label, Randomized, Crossover, Repeat-dose Study to Evaluate the Steady-State Pharmacokinetic Profile of the Final Fixed Dose Combination (FDC) Formulation of COREG CR and Lisinopril as Compared to COREG CR in Subjects With Essential Hypertension|Completed||Phase 1|24|Anticipated|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:53:14.930571|2018-06-01 02:53:14.930571
NCT00537030|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2013-10-07||2016-12-22|2007-09-27|2007-09-28|Estimate|2014-08-06|2014-08-22|Estimate||||2016-12-22|2017-02-10|Actual|February 2008||2008-02-29|March 2016|2016-03-31||||February 2011|Actual|2011-02-28||Interventional|||Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia|Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase®; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children With Acute Lymphoblastic Leukemia (ALL)|Unknown status|Active, not recruiting|N/A|59|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 02:53:15.011846|2018-06-01 02:53:15.011846
NCT00537017|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2016-10-11||2016-12-19|2007-09-27|2007-09-28|Estimate|2016-10-11|2016-12-06|Estimate||||2016-12-19|2017-02-10|Actual|November 2007||2007-11-30|December 2016|2016-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)|A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)|Completed||Phase 2|140|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-06-01 02:53:15.31307|2018-06-01 02:53:15.31307
NCT00537004|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2017-09-12|2007-09-26|2007-09-28|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2007||2007-05-31|September 2017|2017-09-30|April 2023|Anticipated|2023-04-30|April 2022|Anticipated|2022-04-30||Observational|||Language in Primary Progressive Aphasia|Language in Primary Progressive Aphasia|Recruiting|||300|Anticipated|Northwestern University|||2||f||||f||||||||||2018-06-01 02:53:15.858374|2018-06-01 02:53:15.858374
NCT00536991|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2017-04-05||2017-05-15|2007-09-27|2007-09-28|Estimate|2017-04-05|2017-05-15|Actual||||2017-05-15|2017-06-14|Actual|October 2006||2006-10-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||All treated and eligible patients|Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer|A Phase I/II Study of Oral Calcitriol in Combination With Ketoconazole in Androgen Independent Prostate Cancer|Terminated||Phase 1/Phase 2|51|Actual|Roswell Park Cancer Institute||1||difficult to recruit|f||||t||||||||||2018-06-01 02:53:16.036586|2018-06-01 02:53:16.036586
NCT00536978|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2012-04-23||2012-04-23|2007-09-27|2007-09-28|Estimate|2012-04-23|2012-05-22|Estimate||||2012-04-23|2012-05-22|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies|T-Cell or Natural Killer (NK) Cell Adback in Patients With Lymphoid Malignancies Receiving Allogeneic Stem Cell Transplantation With Campath-IH Containing Conditioning Regimens|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:53:16.716963|2018-06-01 02:53:16.716963
NCT00536965|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2014-10-29|2007-09-27|2007-09-28|Estimate|||||||2014-10-29|2014-10-30|Estimate|July 2007||2007-07-31|October 2014|2014-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets|Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets|Completed|||951|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:53:17.043004|2018-06-01 02:53:17.043004
NCT00536952|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2013-06-25|2007-09-27|2007-09-28|Estimate|||||||2013-06-25|2013-06-27|Estimate|February 2008||2008-02-29|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy|A Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation and Chemotherapy|Unknown status|Active, not recruiting|Early Phase 1|36|Anticipated|Northwestern University||2|||f||||t||||||||||2018-06-01 02:53:17.27668|2018-06-01 02:53:17.27668
NCT00536939|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26||2009-03-26|2009-10-05|2007-09-26|2007-09-28|Estimate||||2009-10-05|2009-10-07|Estimate|2009-10-05|2009-10-07|Estimate|November 2007||2007-11-30|October 2009|2009-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer|A Randomized, Double-Blind, Phase 2 Trial of Paclitaxel Plus Bevacizumab and Enzastaurin Versus Paclitaxel Plus Bevacizumab and Placebo for Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 2|2|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:53:17.479807|2018-06-01 02:53:17.479807
NCT00536926|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2011-07-19|2007-09-27|2007-09-28|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2007||2007-07-31|October 2008|2008-10-31|July 2009|Actual|2009-07-31|November 2008|Actual|2008-11-30||Interventional|TeleTx||Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation|Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation - an Open, Randomised Trial|Completed||Phase 3|56|Actual|Hannover Medical School||2|||f||||f||||||||||2018-06-01 02:53:17.560667|2018-06-01 02:53:17.560667
NCT00536913|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2009-02-16||2012-04-05|2007-09-27|2007-09-28|Estimate|2012-01-23|2012-02-27|Estimate||||2012-04-05|2012-04-06|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|Spacer||Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma|A 4-week, Open-label, Randomized, Multi-centre, Parallel-group Study Evaluating the Safety and Efficacy of 4 Actuations Symbicort® (Budesonide/Formoterol) HFA pMDI 40/2.25 μg Twice Daily, With and Without Spacer, in Children (6-11 Years) With Asthma|Completed||Phase 3|107|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:53:17.692298|2018-06-01 02:53:17.692298
NCT00536900|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2014-07-16|2007-09-27|2007-09-28|Estimate|||||||2014-07-16|2014-07-17|Estimate|June 2004||2004-06-30|July 2014|2014-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Clinical Trial of Abstinence-Linked Money Management|Abstinence-Linked Money Management|Completed||Phase 2|90|Actual|Yale University||2|||f||||t||||||||||2018-06-01 02:53:18.015076|2018-06-01 02:53:18.015076
NCT00536887|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2012-04-06|2007-09-27|2007-09-28|Estimate|||||||2012-04-06|2012-04-09|Estimate|July 2005||2005-07-31|April 2012|2012-04-30|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|||Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction|Phase 4 Study of Atorvastatin 10mg vs. 40mg in Follow-up CFR in AMI Patients|Completed||Phase 4|100|Anticipated|Korea University Anam Hospital|||||f||||t||||||||||2018-06-01 02:53:18.087839|2018-06-01 02:53:18.087839
NCT00536874|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2013-11-27||2017-02-07|2007-09-27|2007-09-28|Estimate|2015-11-16|2015-12-17|Estimate||||2017-02-07|2017-03-16|Actual|October 2007||2007-10-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|September 2012|Actual|2012-09-30||Interventional|||Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|A Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma|Completed||Phase 2|39|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:53:18.16063|2018-06-01 02:53:18.16063
NCT00536861|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2008-05-27|2007-09-27|2007-09-28|Estimate|||||||2008-05-27|2008-05-29|Estimate|May 2006||2006-05-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer|A Phase I Study of Radiotherapy Concurrent With Erlotinib (Tarceva®) in the Treatment of Brain Metastases From Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|11|Actual|VU University Medical Center||1|||f||||f||||||||||2018-06-01 02:53:18.458252|2018-06-01 02:53:18.458252
NCT00536848|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2009-01-29|2007-09-27|2007-09-28|Estimate|||||||2009-01-29|2009-01-30|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Interventional|||The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients|The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|65|Actual|National Institute for Medical Research, Tanzania||2|||f||||f||||||||||2018-06-01 02:53:18.580769|2018-06-01 02:53:18.580769
NCT00536835|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2017-06-23|2007-09-27|2007-09-28|Estimate|||||||2017-06-23|2017-06-26|Actual|August 16, 2007|Actual|2007-08-16|June 2017|2017-06-30|September 29, 2009|Actual|2009-09-29|September 29, 2009|Actual|2009-09-29||Interventional|||Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma|A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects With Advanced Solid Tumor or Non-Hodgkins Lymphoma|Completed||Phase 1|41|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:53:18.725984|2018-06-01 02:53:18.725984
NCT00536822|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2013-06-15|2007-09-27|2007-09-28|Estimate|||||||2013-06-15|2013-06-18|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Antioxidant Status During Burn Rehabilitation|Prospective Assessment of Antioxidant Status of Pediatric Patients During Burn Rehabilitation|Withdrawn|||0|Actual|Shriners Hospitals for Children||||Study withdrawn due to hospital emphasis on funded studies.|f||||t||||||None Retained|"~     No specimens.~   "|||2018-06-01 02:53:18.811972|2018-06-01 02:53:18.811972
NCT00536809|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2010-01-19||2017-11-13|2007-09-27|2007-09-28|Estimate|2010-05-13|2010-06-09|Estimate||||2017-11-13|2017-12-18|Actual|September 26, 2007|Actual|2007-09-26|November 2017|2017-11-30|October 31, 2008|Actual|2008-10-31|October 31, 2008|Actual|2008-10-31||Interventional|||Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer|A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer|Completed||Phase 1|12|Actual|GlaxoSmithKline|Phase II of the study was terminated due to lake of interest. Two participants were enrolled prior to termination. Due to the small sample size in Phase II, the data were not analyzed. The two participants' data were analyzed with Phase I data.|2|||f||||f||||||||||2018-06-01 02:53:18.879506|2018-06-01 02:53:18.879506
NCT00536796|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2014-10-29|2007-09-27|2007-09-28|Estimate|||||||2014-10-29|2014-10-30|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets|Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets|Completed|||1096|Actual|AstraZeneca|||4||f||||||||||||||2018-06-01 02:53:19.388243|2018-06-01 02:53:19.388243
NCT00536783|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2007-12-20|2007-09-27|2007-09-28|Estimate|||||||2007-12-20|2007-12-31|Estimate|April 2004||2004-04-30|September 2007|2007-09-30|March 2006|Actual|2006-03-31|||||Observational|||Schizophrenia Sensory Gating Deficit With Quetiapine|Schizophrenia Sensory Gating Deficit With Quetiapine|Completed|||20|Anticipated|New Mexico VA Healthcare System|||||f||||t||||||||||2018-06-01 02:53:19.48318|2018-06-01 02:53:19.48318
NCT00536770|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-11-02|2007-09-27|2007-09-28|Estimate|||||||2007-11-02|2007-11-06|Estimate|September 2007||2007-09-30|November 2007|2007-11-30||||||||Interventional|||A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer|A Randomized Phase 2 Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Subjects With Advanced Pancreatic Adenocarcinoma|Suspended||Phase 2|132|Anticipated|Novacea||4||DSMB|f||||f||||||||||2018-06-01 02:53:19.547985|2018-06-01 02:53:19.547985
NCT00536744|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2014-03-07||2014-03-07|2007-09-26|2007-09-28|Estimate|2014-03-07|2014-04-14|Estimate||||2014-03-07|2014-04-14|Estimate|October 2007||2007-10-31|March 2014|2014-03-31|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers|Use of the dermaPACE™ (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care in the Treatment of Diabetic Foot Ulcers|Completed||Phase 3|206|Actual|SANUWAVE, Inc.||2|||f||||f||||||||||2018-06-01 02:53:19.656933|2018-06-01 02:53:19.656933
NCT00536731|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|2009-04-01||2012-08-14|2007-09-27|2007-09-28|Estimate|2012-08-14|2012-08-15|Estimate||||2012-08-14|2012-08-15|Estimate|September 2007||2007-09-30|August 2012|2012-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|ESTHER||Symbicort Rapihaler Therapeutic Equivalence Study|A 6-week, Phase III, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy and Safety of 2 Actuations Symbicort®pMDI® 40/2.25 μg Twice Daily Compared With 1 Inhalation Symbicort Turbuhaler® 80/4.5 μg Twice Daily and 1 Inhalation Pulmicort®Turbuhaler® 100 μg Twice Daily|Completed||Phase 3|742|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:53:20.046668|2018-06-01 02:53:20.046668
NCT00536718|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2013-08-09|2007-09-27|2007-09-28|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2007||2007-06-30|September 2007|2007-09-30||||||||Observational|||Genetics of Women With Lobular Carcinoma in Situ of the Breast|GLACIER: A Study to Investigate the Genetics of LobulAr Carcinoma In Situ in EuRope|Unknown status|Recruiting||3000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:53:20.582929|2018-06-01 02:53:20.582929
NCT00536536|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2011-08-23|2007-09-27|2007-09-28|Estimate|||||||2011-08-23|2011-08-24|Estimate|April 2008||2008-04-30|February 2009|2009-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Evaluating the Transferability of a Successful, Hospital-based, Childhood Obesity Clinic to Primary Care: a Pilot Study|Evaluating the Transferability of a Successful, Hospital-based, Childhood Obesity Clinic to Primary Care: a Pilot Study|Completed||Phase 1|100|Anticipated|University of Bristol||2|||f||||f||||||||||2018-06-01 02:53:22.104002|2018-06-01 02:53:22.104002
NCT00536705|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2011-07-26|2007-09-27|2007-09-28|Estimate|||||||2011-07-26|2011-07-27|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|March 2011|Actual|2011-03-31|June 2010|Actual|2010-06-30||Observational|||Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma||Completed|||112|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||||||||Samples Without DNA|"~     Subjects inhaled hypertonic saline (3%) via an ultrasonic nebulizer with the output set at~     maximum for 20 minutes. To collect sputum, subjects were asked to expectorate the sputum onto~     a plastic Petri dish after the 20-min period of inhalation. During the inducing procedure,~     macroscopic characteristics of the sputum were recorded and adequate plugs of sputum were~     separated from saliva and processed immediately after expectoration.The complete blood count,~     platelet count, and serum biochemical analyses were done meanwhile.~   "|||2018-06-01 02:53:20.688988|2018-06-01 02:53:20.688988
NCT00536692|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2008-04-03|2007-09-26|2007-09-28|Estimate|||||||2008-04-03|2008-04-08|Estimate|September 2007||2007-09-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|||||Interventional|||Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)|Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)|Completed||Phase 2|||CoMentis|||||||||f||||||||||2018-06-01 02:53:20.756206|2018-06-01 02:53:20.756206
NCT00536679|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2017-08-01|2007-09-27|2007-09-28|Estimate|||||||2017-08-01|2017-08-03|Actual|September 20, 2007|Actual|2007-09-20|August 2017|2017-08-31|November 5, 2007|Actual|2007-11-05|November 5, 2007|Actual|2007-11-05||Interventional|||Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers|An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of Two Different Formulations of GSK163090 and the Effect of Food on the Pharmacokinetics of a Tablet Formulation in Healthy Male and Female Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 02:53:20.846679|2018-06-01 02:53:20.846679
NCT00536666|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2008-10-07|2007-09-27|2007-09-28|Estimate|||||||2008-10-07|2008-10-08|Estimate|May 2007||2007-05-31|October 2008|2008-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients|A Non-Comparative Open-Label Study of Iron Oligosaccharide in Chronic Kidney Disease Patients With a Need for Parenteral Iron|Completed||Phase 3|182|Actual|Pharmacosmos A/S||1|||f||||f||||||||||2018-06-01 02:53:20.947025|2018-06-01 02:53:20.947025
NCT00536653|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2007-09-27|2007-09-27|2007-09-28|Estimate|||||||2007-09-27|2007-09-28|Estimate|October 1999||1999-10-31|August 2007|2007-08-31|January 2007|Actual|2007-01-31|||||Interventional|||Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer|Long Term Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer, With Stratification of Treatment Based on Presenting Values|Completed||N/A|618|Actual|Wirral University Teaching Hospital NHS Trust||3|||f||||t||||||||||2018-06-01 02:53:21.051685|2018-06-01 02:53:21.051685
NCT00536640|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2013-06-11|2007-09-27|2007-09-28|Estimate|||||||2013-06-11|2013-06-12|Estimate|November 2007||2007-11-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|INNOVATIONS||Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab|Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabin/Cisplatin Plus Bevacizumab|Completed||Phase 2|224|Actual|Aktion Bronchialkarzinom e.V.||2|||f||||t||||||||||2018-06-01 02:53:21.149566|2018-06-01 02:53:21.149566
NCT00536627|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2011-12-16|2007-09-27|2007-09-28|Estimate|||||||2011-12-16|2011-12-19|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|VAC-ADN||Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis|Randomised, Opened, Multicentre Phase I/II Trial in Patients With Chronic Hepatitis B With HBV VL < 12 IU/ml and Under Treatment With NRTI, Which Evaluated Efficacy and Tolerance of Vaccination With Naked DNA on Viral Replication After Analogs' Treatment Interruption. ANRS HB02 VAC-ADN|Completed||Phase 1/Phase 2|70|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||t||||||||||2018-06-01 02:53:21.2643|2018-06-01 02:53:21.2643
NCT00536614|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2007-09-27|2007-09-27|2007-09-28|Estimate|||||||2007-09-27|2007-09-28|Estimate|May 2005||2005-05-31|September 2007|2007-09-30|September 2006|Actual|2006-09-30|||||Interventional|SPaCe-01||Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer|A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Cetuximab to Evaluate the Efficacy in Patients With Locally Advanced or Metastatic EGFR-EGFR-Positive Pancreatic Cancer. SpaCe Trial|Completed||Phase 2|86|Actual|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||1|||f||||f||||||||||2018-06-01 02:53:21.332231|2018-06-01 02:53:21.332231
NCT00536601|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2018-04-05|2007-09-27|2007-09-28|Estimate|||||||2018-04-05|2018-04-06|Actual|June 29, 2006|Actual|2006-06-29|April 2018|2018-04-30|April 18, 2022|Anticipated|2022-04-18|April 18, 2022|Anticipated|2022-04-18||Interventional|||High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors|Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Selected Solid Tumors|Active, not recruiting||N/A|174|Actual|Roswell Park Cancer Institute||7|||f||||t||||||||||2018-06-01 02:53:21.406491|2018-06-01 02:53:21.406491
NCT00536588|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2015-03-26|2007-09-26|2007-09-28|Estimate|||||||2015-03-26|2015-03-27|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)|A Phase 1 Study of the Safety and Tolerability of Intravesical Administration of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder|Completed||Phase 1|17|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 02:53:21.52483|2018-06-01 02:53:21.52483
NCT00536575|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2013-01-23||2013-01-23|2007-09-27|2007-09-28|Estimate|2013-01-23|2013-02-27|Estimate||||2013-01-23|2013-02-27|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional|||Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients|Phase I/II Trial of Sorafenib and Weekly Bortezomib in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|13|Actual|SCRI Development Innovations, LLC|The 15% response rate was substantially lower than the designed rate of 60% for this trial. Coupled with the influx of new compounds for the treatment of multiple myeloma it was decided that this study should be closed early.|1|||f||||f||||||||||2018-06-01 02:53:21.717633|2018-06-01 02:53:21.717633
NCT00536562|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2017-08-25|2007-09-27|2007-09-28|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2007||2007-09-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 15, 2014|Actual|2014-06-15||Interventional|CR-TIA||Cardiac Rehabilitation for TIA Patients|Comprehensive Cardiac Rehabilitation Programming For Patients Following Transient Ischemic Attack|Active, not recruiting||Phase 3|200|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 02:53:21.947738|2018-06-01 02:53:21.947738
NCT00536523|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-27|||2014-08-21|2007-09-27|2007-09-28|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2007||2007-04-30|August 2014|2014-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Women's Cancer Center Protocol #52: Alterations in Serum Serotonin Levels as a Mechanism for Chemotherapy Induced Constipation|Terminated|||13|Actual|University of Minnesota - Clinical and Translational Science Institute|||1|Funding unavailable|f||||t||||||Samples With DNA|"~     A blood sample (5 ml red top tube) will be drawn before the patient's first chemotherapy~     treatment, after the 3rd cycle of chemotherapy, at the post chemotherapy follow-up visit~     (approximately 30 days after chemotherapy is completed) and approximately 4 months after~     completion of chemotherapy at the time of a routine follow-up visit. Whenever possible, the~     blood will be drawn at the same time blood is being collected for clinical purposes therefore~     flexibility is allowed in the timing of the research related bloods.~   "|||2018-06-01 02:53:22.182836|2018-06-01 02:53:22.182836
NCT00536510|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2009-02-13||2015-09-01|2007-09-26|2007-09-27|Estimate|2009-03-27|2009-05-13|Estimate||||2015-09-01|2015-09-02|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of MK0524A on Cholesterol Levels (0524A-048)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Lipid-Altering Efficacy and Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|Completed||Phase 3|646|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:53:22.261789|2018-06-01 02:53:22.261789
NCT00536497|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2015-02-12|2007-09-25|2007-09-27|Estimate|||||||2015-02-12|2015-02-16|Estimate|September 2007||2007-09-30|February 2015|2015-02-28||||||||Interventional|||Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.|A 2 Part Open-label, Randomised, Crossover Study to Compare the Effects of Formulation, Food and Particle Size on the Pharmacokinetic Profiles of a Single 175mg Dose of GW842166X in Healthy Male and Female Volunteers|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||||Compound terminated|||||f||||||||||2018-06-01 02:53:22.577321|2018-06-01 02:53:22.577321
NCT00536484|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2009-03-12||2009-09-10|2007-09-25|2007-09-27|Estimate|2009-08-03|2009-09-11|Estimate||||2009-09-10|2009-09-15|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Fesoterodine Flexible Dose Study|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.|Completed||Phase 3|896|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:53:22.665463|2018-06-01 02:53:22.665463
NCT00536471|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2009-05-28||2009-11-17|2007-09-25|2007-09-27|Estimate|2009-05-28|2009-07-17|Estimate||||2009-11-17|2009-11-20|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients|Duloxetine Versus Placebo in Patients With Major Depressive Disorder (MDD): Assessment of Energy and Vitality in MDD|Completed||Phase 4|776|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:53:24.821466|2018-06-01 02:53:24.821466
NCT00536458|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-10-31|2007-09-26|2007-09-27|Estimate|||||||2007-10-31|2007-11-01|Estimate|March 1999||1999-03-31|September 2007|2007-09-30|December 2006|Actual|2006-12-31|||||Interventional|||Treatment of Localized Low Grade Lymphomas|Phase III Study of Treatment of Localized Lymphomas: Radiotherapy Versus Radio-Chemotherapie|Completed||Phase 3|132|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||||2018-06-01 02:53:29.518165|2018-06-01 02:53:29.518165
NCT00536445|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2016-05-30|2007-09-26|2007-09-27|Estimate|||||||2016-05-30|2016-06-01|Estimate|October 2007||2007-10-31|May 2016|2016-05-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Use of NAVA in Intubated Preterm|Use of Neurally Adjusted Ventilatory Assist (NAVA) in an Intubated Premature Infant: A Case Control Study on the Servoi Ventilator|Withdrawn||Phase 1/Phase 2|0|Actual|Sunnybrook Health Sciences Centre||||Another institution performed the study|f||||f||||||||||2018-06-01 02:53:29.602319|2018-06-01 02:53:29.602319
NCT00536432|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2012-06-05|2007-09-26|2007-09-27|Estimate|||||||2012-06-05|2012-06-06|Estimate|September 2007||2007-09-30|October 2010|2010-10-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Observational|||Early Re-intervention in Infants and Small Children After Correction of Tetralogy of Fallot|Early Re-intervention in Infants and Small Children After Correction of Tetralogy of Fallot: Prospective Analysis of Myocardial Benefit Using Cardiac MRI and Echocardiography|Completed|||93|Actual|Competence Network for Congenital Heart Defects|||||f||||f||||||||||2018-06-01 02:53:29.733609|2018-06-01 02:53:29.733609
NCT00536419|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-09-26|2007-09-26|2007-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|September 2008|Anticipated|2008-09-30|||||Interventional|||Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents|Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents|Unknown status|Recruiting|Phase 4|53|Anticipated|Federal University of Rio Grande do Sul||2|||f||||||||||||||2018-06-01 02:53:29.806983|2018-06-01 02:53:29.806983
NCT00536406|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2017-04-11|2007-09-25|2007-09-27|Estimate|||||||2017-04-11|2017-04-13|Actual|August 2007||2007-08-31|April 2017|2017-04-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|BE-ACTIV||Evaluating a Behavioral Activities Treatment Program for Depressed Nursing Home Residents|BE-ACTIV: Treating Depression in Nursing Homes|Completed||N/A|20|Actual|University of Louisville||2|||f||||t||||||||||2018-06-01 02:53:29.898382|2018-06-01 02:53:29.898382
NCT00536393|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-10-31|2007-09-26|2007-09-27|Estimate|||||||2007-10-31|2007-11-01|Estimate|October 2000||2000-10-31|September 2007|2007-09-30|October 2004|Actual|2004-10-31|||||Interventional|||Treatment of Disseminated High Grade Lymphoma|Phase III Study of Treatment of Disseminated and Agressive Lymphoma R CHOP Versus R CLOP( With Liposomal Doxorubicin)|Completed||Phase 2/Phase 3|100|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||||2018-06-01 02:53:29.973215|2018-06-01 02:53:29.973215
NCT00536380|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2010-02-24||2017-03-15|2007-09-26|2007-09-27|Estimate|2010-04-08|2010-05-03|Estimate||||2017-03-15|2017-04-12|Actual|September 2007||2007-09-30|March 2017|2017-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)|A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily)|Completed||Phase 4|314|Actual|Merck Sharp & Dohme Corp.|Due to poor enrollment (even after extending the enrollment period), only 314 participants (not 600 participants) were randomized to the study and hence the study was inconclusive due to the lacking of statistical power and robustness.|3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:53:30.04499|2018-06-01 02:53:30.04499
NCT00536367|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2014-06-11|2007-09-25|2007-09-27|Estimate|||||||2014-06-11|2014-06-12|Estimate|January 2006||2006-01-31|June 2014|2014-06-30|March 2008|Actual|2008-03-31|July 2007|Actual|2007-07-31||Observational|||Validation of a Mortality Prediction Model for Acutely Decompensated Heart Failure Patients|Validation of a Mortality Prediction Model for Acutely Decompensated Heart Failure Patients|Completed|||226|Actual|Ohio State University|||1||f||||f||||||||||2018-06-01 02:53:30.290788|2018-06-01 02:53:30.290788
NCT00536354|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2007-09-26|2007-09-26|2007-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|December 2005|Actual|2005-12-31|||||Interventional|||Postural Orientation In The Use Of School Backpacks|Effects Of Postural Orientation In The Use Of School Backpacks In Elementary School Students|Completed||Early Phase 1|||University of Sao Paulo|||||f||||t||||||||||2018-06-01 02:53:30.361714|2018-06-01 02:53:30.361714
NCT00536341|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2016-03-31||2016-11-29|2007-09-26|2007-09-27|Estimate|2016-03-31|2016-05-04|Estimate||||2016-11-29|2017-01-16|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|April 2013|Actual|2013-04-30||Interventional||All enrolled and treated patients|Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated and Untreated Patients With Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|64|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 02:53:30.435738|2018-06-01 02:53:30.435738
NCT00536328|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2008-07-07|2007-09-26|2007-09-27|Estimate|||||||2008-07-07|2008-07-09|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|||||Observational|PREDICT||What is the Predictive Value of the Reflux Impact Scale|What is the Value of the Use of Validated Questionnaire (Reflux Impact Scale) for Predicting Treatment Success With PPI|Terminated|||938|Anticipated|AstraZeneca||||"due to very low recruitment. For this reason, there will be no further analysis and reporting~   of this study."|f||||||||||||||2018-06-01 02:53:30.857839|2018-06-01 02:53:30.857839
NCT00536315|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2017-03-08|2007-09-26|2007-09-27|Estimate|||||||2017-03-08|2017-03-10|Actual|March 1, 1999|Actual|1999-03-01|February 2010|2010-02-28|June 2009|Actual|2009-06-30|July 2008|Actual|2008-07-31||Observational|||Tracheal Mechanics During Bronchoscopy|Tracheal Mechanics During Bronchoscopy|Completed|||145|Actual|Beth Israel Deaconess Medical Center|||3||f||||f||||||||||2018-06-01 02:53:30.903464|2018-06-01 02:53:30.903464
NCT00536302|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2009-02-05|2007-09-26|2007-09-27|Estimate|||||||2009-02-05|2009-02-06|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|NMR||A Placebo-Controlled Study of Collagen Hydrolysate in Subjects With Knee Osteoarthritis (OA)|A Single Center, Prospective, Randomized, Placebo-Controlled, Double-Blind Pilot Clinical Trial to Evaluate the Sensitivity of Magnetic Resonance Imaging to Detect Change in Cartilage Structure and Composition in 30 Participants Diagnosed With Osteoarthritis of the Knee and Treated With Collagen Hydrolysate|Completed||Phase 2/Phase 3|30|Actual|GELITA||2|||f||||t||||||||||2018-06-01 02:53:30.976697|2018-06-01 02:53:30.976697
NCT00536289|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-09-26|2007-09-26|2007-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|January 2005||2005-01-31|January 2006|2006-01-31|September 2006|Actual|2006-09-30|||||Interventional|||Blunt Needles do Not Reduce Needlestick Injuries to Doctors During Suturing After Child-Birth|The Use of Blunt Needles Does Not Reduce Needlestick Injury During Obstetrical Laceration Repair|Completed||N/A|438|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 02:53:31.060996|2018-06-01 02:53:31.060996
NCT00536276|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2012-05-08|2007-09-26|2007-09-27|Estimate|||||||2012-05-08|2012-05-09|Estimate|March 2003||2003-03-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|December 2009|Actual|2009-12-31||Interventional|VitaminD||Evaluation of Vitamin D Status in Children With Acute Burns|Vitamin D Deficiency in Acutely Injured Pediatric Burn Patients: Incidence, Etiology, Metabolic Sequelae and Prevention|Completed||Phase 1|50|Actual|Shriners Hospitals for Children|||||f||||t||||||||||2018-06-01 02:53:31.117502|2018-06-01 02:53:31.117502
NCT00536263|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2010-11-23||2017-03-09|2007-09-26|2007-09-27|Estimate|2010-11-23|2010-12-21|Estimate||||2017-03-09|2017-04-07|Actual|September 2007||2007-09-30|March 2017|2017-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)|An Open-label, Randomized Study of PegIntron in the Treatment of HBeAg Positive Chronic Hepatitis B Patients|Completed||Phase 3|671|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:53:31.218459|2018-06-01 02:53:31.218459
NCT00536250|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2018-01-16|2007-09-25|2007-09-27|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2001|Actual|2001-09-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth|Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth|Completed|||255|Actual|Yale University|||||f||||t||||||||No||2018-06-01 02:53:32.007551|2018-06-01 02:53:32.007551
NCT00536237|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2015-08-24|2007-09-26|2007-09-27|Estimate|||||||2015-08-24|2015-08-25|Estimate|August 2004||2004-08-31|August 2015|2015-08-31|December 2006|Actual|2006-12-31|February 2005|Actual|2005-02-28||Interventional|||MK0524A Phase IIb Study (0524A-011)(COMPLETED)|Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients|Completed||Phase 2|154|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:53:32.065468|2018-06-01 02:53:32.065468
NCT00536224|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2018-04-24|2007-09-26|2007-09-27|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2007||2007-09-30|April 2018|2018-04-30|January 2017|Actual|2017-01-31|July 2009|Actual|2009-07-31||Interventional|||Chest Pain Observation Unit Risk Reduction Trial|Brief Intervention to Promote Cardiovascular Risk Reduction in Patients Admitted to Chest Pain Observation Units|Completed||N/A|140|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 02:53:32.182366|2018-06-01 02:53:32.182366
NCT00536211|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2015-08-10|2007-09-25|2007-09-27|Estimate|||||||2015-08-10|2015-08-11|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|December 2011|Anticipated|2011-12-31|October 2011|Anticipated|2011-10-31||Interventional|||Physical Inactivity and Insulin Resistance in Skeletal Muscle.|Physical Inactivity and Insulin Resistance in Skeletal Muscle.|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||2||protocol not approved by VA R&D|f||||f||||||||||2018-06-01 02:53:32.263622|2018-06-01 02:53:32.263622
NCT00536198|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2016-01-05||2017-03-16|2007-09-25|2007-09-27|Estimate|2016-08-25|2016-10-19|Estimate||||2017-03-16|2017-04-14|Actual|November 6, 2007|Actual|2007-11-06|March 2017|2017-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Analysis included all women enrolled.|Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder|Symptom Onset Antidepressant Treatment for PMDD|Completed||Phase 4|252|Actual|Yale University|Limitations of this study include attrition over time and the restricted dose range of 25-100mg sertraline.|2|||f||||t||||||||No|we will share data with a data request that is reviewed by investigators|2018-06-01 02:53:32.503767|2018-06-01 02:53:32.503767
NCT00536172|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2013-12-20||2018-01-08|2007-09-26|2007-09-27|Estimate|2013-12-20|2014-02-14|Estimate||||2018-01-08|2018-02-02|Estimate|December 2007||2007-12-31|January 2018|2018-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PROTECT||Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment|Prevention of Depression in Patients Being Treated for Head and Neck Cancer|Completed||Phase 4|160|Actual|University of Nebraska||2|||f||||t||||||||||2018-06-01 02:53:33.534581|2018-06-01 02:53:33.534581
NCT00536159|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-26|2007-09-26|2007-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|January 1997||1997-01-31|September 2007|2007-09-30|August 2000|Actual|2000-08-31|||||Interventional|||Medicaid Enhanced Prenatal/Postnatal Services Using a Nurse-Community Health Worker Team|Improving the Health and Development of Low-Income Pregnant Women|Completed||N/A|613|Actual|Michigan State University||2|||f||||f||||||||||2018-06-01 02:53:33.982189|2018-06-01 02:53:33.982189
NCT00536146|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2017-06-30|2007-09-26|2007-09-27|Estimate|||||||2017-06-30|2017-07-02|Actual|September 24, 2007||2007-09-24|January 29, 2009|2009-01-29|January 29, 2009||2009-01-29|||||Observational|||The Stress-Hormone System in Alcohol-Dependent Subjects|Trauma, Stress and Persistence of HPA Dysregulation in Alcoholism|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:53:34.129822|2018-06-01 02:53:34.129822
NCT00536133|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2009-08-03|2007-09-26|2007-09-27|Estimate|||||||2009-08-03|2009-08-06|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Role of Zinc in Recurrent Acute Lower Respiratory Infections|Role of Zinc in Recurrent Acute Lower Respiratory Infections|Completed||Phase 3|208|Actual|Jawaharlal Nehru Medical College||2|||f||||t||||||||||2018-06-01 02:53:34.182297|2018-06-01 02:53:34.182297
NCT00536120|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2011-03-17||2016-12-29|2007-09-26|2007-09-27|Estimate|2011-06-30|2011-07-29|Estimate||||2016-12-29|2017-02-15|Actual|January 2008||2008-01-31|December 2016|2016-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis|A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis|Completed||Phase 4|60|Actual|Biogen||2|||f||||f||||||||||2018-06-01 02:53:34.277757|2018-06-01 02:53:34.277757
NCT00536107|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|2013-08-01||2013-08-01|2007-09-26|2007-09-27|Estimate|2013-08-01|2013-10-01|Estimate||||2013-08-01|2013-10-01|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy|Terminated||Phase 4|14|Actual|AstraZeneca|This study was terminated early because the purpose of this study had been fulfilled by other supporting data, and due to small number of patients enrolled (14 patients).|2|||f||||f||||||||||2018-06-01 02:53:34.711742|2018-06-01 02:53:34.711742
NCT00536094|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2013-09-23|2007-09-25|2007-09-27|Estimate|||||||2013-09-23|2013-09-24|Estimate|October 2006||2006-10-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||School-based Treatment for Anxious Children|School-Based CBT for Anxious African-American Children|Completed||Phase 3|40|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 02:53:35.034975|2018-06-01 02:53:35.034975
NCT00536081|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2009-12-22|2007-09-25|2007-09-27|Estimate|||||||2009-12-22|2009-12-23|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|December 2010|Anticipated|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Various G-CSF Regimens to Prevent Infection During Chemotherapy|Primary G-CSF Prophylaxis During the First Two Cycles Only or Throughout All Chemotherapy Cycles in Breast Cancer Patients at Risk of Febrile Neutropenia|Terminated||Phase 3|172|Actual|Academisch Ziekenhuis Maastricht||2||"More cases of Febrile Neutropenia were observed in experimental group compared to standard~   treatment."|f||||f||||||||||2018-06-01 02:53:35.107164|2018-06-01 02:53:35.107164
NCT00536068|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-09-27|2007-09-26|2007-09-27|Estimate|||||||2007-09-27|2007-09-28|Estimate|August 2006||2006-08-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Platelet Inhibition by Aspirin, Acetaminophen and NSAID||Completed||N/A|11|Actual|Kantonsspital Graubünden||1|||f||||f||||||||||2018-06-01 02:53:35.196673|2018-06-01 02:53:35.196673
NCT00536055|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-09-26|2007-09-26|2007-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|October 2007||2007-10-31|September 2007|2007-09-30|August 2008|Anticipated|2008-08-31|||||Observational|||Dyadic Coping in Breast and Prostate Cancer Patients and Their Spouses|Dyadic Coping in Breast and Prostate Cancer Patients and Their Spouses - A Pilot Stdy|Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 02:53:35.255636|2018-06-01 02:53:35.255636
NCT00536042|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2018-04-23|2007-09-26|2007-09-27|Estimate|||||||2018-04-23|2018-04-25|Actual|October 1997||1997-10-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Open-Label Trial of the Use of Minocycline in the Treatment of Asthma|Open-Label Trial of the Use of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma|Enrolling by invitation||Phase 2|20|Anticipated|State University of New York - Downstate Medical Center||1|||f||||f||||||||Undecided||2018-06-01 02:53:36.318972|2018-06-01 02:53:36.318972
NCT00536029|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-09-26|2007-09-26|2007-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|February 2007||2007-02-28|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Observational|||MicroRNA Expression and Function in Cutaneous Malignant Melanoma|MicroRNA Expression and Function in Cutaneous Malignant Melanoma|Completed|||68|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-06-01 02:53:36.390909|2018-06-01 02:53:36.390909
NCT00536016|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2010-09-20|2007-09-26|2007-09-27|Estimate|||||||2010-09-20|2010-09-21|Estimate|September 2007||2007-09-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD|A Phase 1 Open Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeated Doses of JSM6427 Following Administration by Intravitreal Injection in Patients With Neovascular AMD|Completed||Phase 1|36|Anticipated|Jerini Ophthalmic|||||f||||t||||||||||2018-06-01 02:53:36.451276|2018-06-01 02:53:36.451276
NCT00536003|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2012-06-05|2007-09-26|2007-09-27|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 2006||2006-07-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|4P||Vaginal Progesterone to Prevent Preterm Delivery in Women With Preterm Labor|Prevention of Preterm Delivery With Vaginal Progesterone in Women With Preterm Labor|Terminated||Phase 3|384|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 02:53:36.543438|2018-06-01 02:53:36.543438
NCT00150033|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-05-21|2005-09-06|2005-09-08|Estimate|||||||2008-05-21|2008-05-22|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|||||Observational|||Health-Related Quality of Life for Thyroid Patients|Development and Validation of a Thyroid-Specific Quality of Life Measure|Completed|||1200|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:43:46.260763|2018-06-01 04:43:46.260763
NCT00535990|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2016-10-24|2007-09-25|2007-09-27|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Minimally Invasive Surgery (MIS) Database for the Purpose of Research|Minimally Invasive Surgery (MIS) Database Looking at Patterns of Care, Outcomes, and Prognostic Analysis for the Purpose of Research|Completed|||250|Actual|University of California, San Diego|||||f||||f||||||||||2018-06-01 02:53:36.695759|2018-06-01 02:53:36.695759
NCT00535977|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-09-26|2007-09-26|2007-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|April 2005||2005-04-30|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||Broccoli, Peas and PIN|A Human Intervention Trial Studying Gene Expression in High-Grade Prostatic Intraepithelial Neoplasia Following Consumption of Broccoli or Peas|Completed||N/A|22|Actual|Quadram Institute||2|||f||||f||||||||||2018-06-01 02:53:36.759516|2018-06-01 02:53:36.759516
NCT00535964|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2013-04-09|2007-09-25|2007-09-27|Estimate|||||||2013-04-09|2013-04-11|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Evaluating the Relationship Between Tobacco Use, Anxiety Sensitivity, and Panic in Adolescents|Anxiety Sensitivity, Tobacco Use, and Panic Among Adolescents|Completed|||180|Actual|University of Arkansas, Fayetteville|||1||f||||f||||||||||2018-06-01 02:53:36.927604|2018-06-01 02:53:36.927604
NCT00535951|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2012-11-26|2007-09-26|2007-09-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|November 2007||2007-11-30|November 2012|2012-11-30||||January 2009|Actual|2009-01-31||Interventional|||Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma|A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 on Dextromethorphan, a CYP2D6 Substrate, and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors|Completed||Phase 1|18|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:53:37.000904|2018-06-01 02:53:37.000904
NCT00535938|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2014-09-04||2014-09-04|2007-09-25|2007-09-27|Estimate|2014-09-04|2014-09-10|Estimate||||2014-09-04|2014-09-10|Estimate|September 2007||2007-09-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||MDs on Botox Utility (MOBILITY)||Completed|||1372|Actual|Allergan|||2||f||||f||||||||||2018-06-01 02:53:37.125192|2018-06-01 02:53:37.125192
NCT00535925|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2011-12-20|2007-09-26|2007-09-27|Estimate|||||||2011-12-20|2011-12-21|Estimate|March 2003||2003-03-31|December 2011|2011-12-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|NID-2||Nephropathy In Type 2 Diabetes and Cardio-renal Events|Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events.|Unknown status|Active, not recruiting|Phase 4|850|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||||2018-06-01 02:53:37.761621|2018-06-01 02:53:37.761621
NCT00535912|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-26|||2007-10-31|2007-09-26|2007-09-27|Estimate|||||||2007-10-31|2007-11-01|Estimate|January 1999||1999-01-31|September 2007|2007-09-30|March 2006|Actual|2006-03-31|||||Interventional|||Phase III Study Treatment of CLL B and C|A Multicentric Phase III Study in Patients With CLL B and C < 60 Years Not Treated: 6 Montly CHOP + 6 CHOP Every 3 Months Versus 3 Montly CHOP + Intensification and Autograft|Completed||Phase 3|140|Actual|French Innovative Leukemia Organisation||2|||f||||t||||||||||2018-06-01 02:53:37.852689|2018-06-01 02:53:37.852689
NCT00535899|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2008-05-22|2007-09-25|2007-09-26|Estimate|||||||2008-05-22|2008-05-26|Estimate|September 2007||2007-09-30|May 2008|2008-05-31||||||||Observational|SPArKLE-AS||Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)|Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)|Terminated|||50|Anticipated|The Cleveland Clinic||||unable to find subjects meeting inclusion criteria|f||||f||||||||||2018-06-01 02:53:37.913079|2018-06-01 02:53:37.913079
NCT00535886|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2008-05-05|2007-09-21|2007-09-26|Estimate|||||||2008-05-05|2008-05-07|Estimate|November 2005||2005-11-30|September 2007|2007-09-30|April 2006|Actual|2006-04-30|||||Interventional|||The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study|The Effects of Natural Versus Man-Made Trans Fatty Acids on Lipoprotein Profiles: A Pilot Study|Completed||N/A|15|Actual|Children's Hospital & Research Center Oakland||3|||f||||f||||||||||2018-06-01 02:53:37.966922|2018-06-01 02:53:37.966922
NCT00535873|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2013-06-19||2013-06-19|2007-09-25|2007-09-26|Estimate|2013-06-19|2013-09-02|Estimate||||2013-06-19|2013-09-02|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||One of the sixty-one participants who signed consent did not receive study medication and was not included in the analysis for this study.|Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older|A Phase II Study of Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia Age 65 or Older.|Completed||Phase 2|61|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 02:53:38.152561|2018-06-01 02:53:38.152561
NCT00535860|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2009-07-09|2007-09-25|2007-09-26|Estimate|||||||2009-07-09|2009-07-10|Estimate|April 2008||2008-04-30|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis|A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) in Comparison to Subcutaneous Injection of Forteo in Postmenopausal Women With Osteoporosis|Completed||Phase 2|104|Actual|TransPharma Medical||3|||f||||f||||||||||2018-06-01 02:53:38.37871|2018-06-01 02:53:38.37871
NCT00535847|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2011-06-22||2014-07-09|2007-09-25|2007-09-26|Estimate|2011-06-22|2011-07-25|Estimate||||2014-07-09|2014-08-05|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||The full analysis (FA) set included all enrolled subjects who received at least 1 dose of study drug in this study (VX06-950-107 [NCT00535847]).|A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy|A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who Did Not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response|Completed||Phase 2|117|Actual|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-06-01 02:53:38.521927|2018-06-01 02:53:38.521927
NCT00535834|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2012-03-14|2007-09-25|2007-09-26|Estimate|||||||2012-03-14|2012-03-16|Estimate||||March 2012|2012-03-31|March 2011|Actual|2011-03-31|||||Observational|||Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154|Data Analysis for 00-C-0154, A Randomized Phase II Study of a PSA-based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy|Completed|||48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:53:39.179165|2018-06-01 02:53:39.179165
NCT00133614|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2005-10-28|2005-08-19|2005-08-23|Estimate|||||||2005-10-28|2005-10-31|Estimate|August 2001||2001-08-31|August 2005|2005-08-31|April 2004||2004-04-30|||||Interventional|||Prone Positioning in Pediatric Acute Lung Injury|Prone Positioning in Pediatric Acute Lung Injury|Completed||Phase 3|102||National Institute of Nursing Research (NINR)|||||f||||||||||||||2018-06-01 04:48:50.88613|2018-06-01 04:48:50.88613
NCT00535821|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2014-05-22||2014-05-22|2007-09-24|2007-09-26|Estimate|2014-05-22|2014-06-25|Estimate||||2014-05-22|2014-06-25|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|MiCHO||Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock|A Multi-center Randomized Comparison of a Minimally-invasive Cardiovascular Hemodynamic Optimization (MiCHO) Protocol Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock Patients Presenting to the Emergency Department|Terminated||Phase 4|5|Actual|Loma Linda University||2||slow enrollement unavailable technology|f||||f||||||||||2018-06-01 02:53:39.257945|2018-06-01 02:53:39.257945
NCT00535808|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2012-07-12|2007-09-25|2007-09-26|Estimate|||||||2012-07-12|2012-07-13|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study|Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: a Randomized Study|Completed||Phase 2|30|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 02:53:39.480642|2018-06-01 02:53:39.480642
NCT00535795|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2016-02-24|2007-09-24|2007-09-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA|A Phase III Study to Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA|Completed||Phase 3|200|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||t||||||||Undecided||2018-06-01 02:53:39.542655|2018-06-01 02:53:39.542655
NCT00535782|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2012-08-08||2017-06-28|2007-09-24|2007-09-26|Estimate|2012-11-08|2012-11-14|Estimate||||2017-06-28|2017-07-26|Actual|October 31, 2007|Actual|2007-10-31|June 2017|2017-06-30|January 31, 2011|Actual|2011-01-31|September 30, 2008|Actual|2008-09-30||Interventional|||A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis|A Mechanism of Action Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) on Lipids, Arterial Stiffness, and Markers of Atherogenic Risk in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA).|Completed||Phase 3|132|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:53:39.678415|2018-06-01 02:53:39.678415
NCT00535769|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2012-05-15||2012-07-18|2007-09-24|2007-09-26|Estimate|2012-06-16|2012-07-18|Estimate||||2012-07-18|2012-07-20|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use|Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use|Completed||Early Phase 1|70|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 02:53:41.213179|2018-06-01 02:53:41.213179
NCT00535756|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2011-08-16|2007-09-25|2007-09-26|Estimate|||||||2011-08-16|2011-08-18|Estimate|April 2008||2008-04-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Creon After Pancreatic Surgery|One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheres™ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year|Completed||Phase 4|58|Actual|Abbott||2|||f||||f||||||||||2018-06-01 02:53:41.460756|2018-06-01 02:53:41.460756
NCT00535743|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2017-08-18|2007-09-25|2007-09-26|Estimate|||||||2017-08-18|2017-08-22|Actual|March 4, 2004|Actual|2004-03-04|August 2017|2017-08-31|July 20, 2004|Actual|2004-07-20|July 20, 2004|Actual|2004-07-20||Interventional|||Dose-Finding Trial With Sugammadex at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Subjects of ASA Class 1-3 (19.4.206)(P05944)|A Multi-Center, Randomized, Safety Assessor-Blinded, Placebo- Controlled, Phase II, Parallel Dose-Finding Trial in Subjects of ASA 1-3 to Assess the Efficacy and Safety of 5 Doses of Sugammadex Administered at 3 and 15 Minutes After Administration of 1.0 and 1.2 mg/kg Rocuronium Bromide|Completed||Phase 2|174|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 02:53:41.609554|2018-06-01 02:53:41.609554
NCT00535730|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2009-01-21||2017-03-14|2007-09-21|2007-09-26|Estimate|2009-05-12|2009-05-13|Estimate||||2017-03-14|2017-04-12|Actual|June 2007||2007-06-30|March 2017|2017-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)|A Phase III Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With PNEUMOVAX™ 23 in Subjects 60 Years of Age and Older|Completed||Phase 3|473|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:53:41.718844|2018-06-01 02:53:41.718844
NCT00535717|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2007-09-25|2007-09-25|2007-09-26|Estimate|||||||2007-09-25|2007-09-26|Estimate||||September 2007|2007-09-30||||||||Interventional|||Role of Uttarbasti in the Management of Mutra Marga Sankoch (Urethral Stricture)|Role of Uttarbasti in the Management of Mutra Marga Sankoch (Urethral Stricture)|Completed||Phase 2|||Maharashtra University of Health Sciences|||||f||||t||||||||||2018-06-01 02:53:42.190184|2018-06-01 02:53:42.190184
NCT00535704|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2017-01-10|2007-09-24|2007-09-26|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2007||2007-11-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Preventing Substance Use and Risky Behavior Among Rural African American Youth|Preventing Substance Use and Risky Behavior Among Rural African American Youth|Completed||N/A|502|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 02:53:42.317489|2018-06-01 02:53:42.317489
NCT00535691|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2014-08-28|2007-09-24|2007-09-26|Estimate|||||||2014-08-28|2014-09-01|Estimate|April 2003||2003-04-30|August 2014|2014-08-31|December 2004|Actual|2004-12-31|||||Interventional|||Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis|A Randomised, Multi-centre, Double-blind, Pharmacokinetic Study of Tacrolimus Ointment (0.03%) in Paediatric Patients (Aged 3 Months to 24 Months) With Atopic Dermatitis Following First and Repeated Once Daily or Twice Daily Application of the Tacrolimus Ointment|Completed||Phase 2|53|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 02:53:42.378835|2018-06-01 02:53:42.378835
NCT00535678|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2010-05-13|2007-09-25|2007-09-26|Estimate|||||||2010-05-13|2010-05-14|Estimate|June 2007||2007-06-30|April 2010|2010-04-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||Testing Digital Breast Tomosynthesis vs. Regular Mammogram in Detecting Breast Cancer in Women Having Screening Mammogram|A Multicenter Study to Test Digital Breast Tomosynthesis (DBT) Compared to Full-Field Digital Mammography (FFDM) in Detecting Breast Cancer. Part 1. Women Undergoing Screening Mammography|Completed|||400|Anticipated|GE Healthcare|||||f||||f||||||||||2018-06-01 02:53:42.46304|2018-06-01 02:53:42.46304
NCT00535665|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2007-11-08|2007-09-24|2007-09-26|Estimate|||||||2007-11-08|2007-11-09|Estimate|September 2007||2007-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine|The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion， Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study|Completed||Phase 2|402|Actual|Sinovac Biotech Co., Ltd||4|||f||||t||||||||||2018-06-01 02:53:42.532898|2018-06-01 02:53:42.532898
NCT00535652|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2015-06-23||2016-12-16|2007-09-24|2007-09-26|Estimate|2016-10-24|2016-12-16|Estimate||||2016-12-16|2017-02-10|Actual|September 2007||2007-09-30|December 2016|2016-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Concentration of Ertapenem in Colorectal Tissue|Konzentrationen Von Ertapenem in Kolorektalem Gewebe|Completed||Phase 4|23|Actual|University of Ulm||1|||f||||t||||||||||2018-06-01 02:53:42.659383|2018-06-01 02:53:42.659383
NCT00535639|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2008-02-28|2007-09-25|2007-09-26|Estimate|||||||2008-02-28|2008-02-29|Estimate|October 2007||2007-10-31|February 2008|2008-02-29||||December 2007|Actual|2007-12-31||Interventional|||Tolerability of ALK Tree Tablet|A Randomised, Multiple Dose, Dose Escalation, Double-Blind, Placebo-Controlled Phase I Study Investigating the Safety of ALK Tree Tablet in Adult Subjects With Birch Pollen Induced Rhinoconjunctivitis (With/Without Asthma).|Completed||Phase 1|||ALK-Abelló A/S|||||f||||||||||||||2018-06-01 02:53:42.876134|2018-06-01 02:53:42.876134
NCT00535626|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2017-08-17||2017-11-17|2007-09-24|2007-09-26|Estimate|2017-11-17|2017-11-20|Actual||||2017-11-17|2017-11-20|Actual|November 2006||2006-11-30|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Participants who were not censored from analysis|Trident® Tritanium™ Acetabular Shell Revision Study|A Post-market, Non-randomized, Open Label, Multi-center Clinical Study of the Trident Tritanium Acetabular Shell|Completed||N/A|241|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 02:53:43.04169|2018-06-01 02:53:43.04169
NCT00535613|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-23|||2015-10-09|2007-09-23|2007-09-26|Estimate|||||||2015-10-09|2015-10-14|Estimate|August 2007||2007-08-31|October 2015|2015-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Propofol in Emergence Agitation|Does a Single Dose of Propofol Decrease the Incidence of Emergence Agitation in Children?|Completed||Phase 4|100|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 02:53:43.593247|2018-06-01 02:53:43.593247
NCT00535600|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2018-05-19|2007-09-25|2007-09-26|Estimate|||||||2018-05-19|2018-05-22|Actual|September 21, 2007||2007-09-21|March 19, 2014|2014-03-19|March 19, 2014||2014-03-19|||||Observational|||Effects of Bariatric Surgery on Insulin|Effects of Bariatric Surgery on Changes in Insulin Secretion and Insulin Action|Completed|||28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:53:43.661414|2018-06-01 02:53:43.661414
NCT00535587|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2011-03-21||2011-03-23|2007-09-21|2007-09-26|Estimate|2011-03-23|2011-04-18|Estimate||||2011-03-23|2011-04-18|Estimate|September 2002||2002-09-30|March 2011|2011-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Testing Mestinon and Exercise in Fibromyalgia|Maximizing Exercise Effectiveness in Fibromyalgia|Completed||Phase 2|178|Actual|Oregon Health and Science University|"6 discontinued due to medical reasons unrelated to the study 4 were unwilling to complete~1 relocated"|4|||f||||||||||||||2018-06-01 02:53:43.773462|2018-06-01 02:53:43.773462
NCT00535574|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2012-07-25|2007-09-24|2007-09-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|November 2008||2008-11-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia|Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia: a 6-week, Randomized, Double-blind Placebo-controlled Trial|Completed||Phase 3|90|Actual|Beersheva Mental Health Center||2|||f||||t||||||||||2018-06-01 02:53:44.214143|2018-06-01 02:53:44.214143
NCT00535561|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2012-02-16|2007-09-25|2007-09-26|Estimate|||||||2012-02-16|2012-02-17|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|September 2007|Actual|2007-09-30|||||Interventional|||Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism|Iron Deficiency Anemia Can be an Indication for Treatment of Subclinical Hypothyroidism: A Randomized, Double Blinded Study|Completed||Phase 1|||Duzce University||2|||f||||f||||||||||2018-06-01 02:53:44.352585|2018-06-01 02:53:44.352585
NCT00535548|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2007-09-24|2007-09-24|2007-09-26|Estimate|||||||2007-09-24|2007-09-26|Estimate|January 2007||2007-01-31|September 2007|2007-09-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Hematopoietic Stem Cell Therapy in Chronic Wounds Using a Pressure Sore Model|Effect of Hematopoietic Stem Cells in Chronic Wounds Using a Pressure Sore Model: A Pilot Study on Feasibility, Safety and Potential Effects|Unknown status|Recruiting|Phase 1|||University Hospital, Basel, Switzerland|||||f||||t||||||||||2018-06-01 02:53:44.419016|2018-06-01 02:53:44.419016
NCT00535535|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2013-09-19|2007-09-25|2007-09-26|Estimate|||||||2013-09-19|2013-09-23|Estimate|August 2007||2007-08-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Fructose-Induced Palmitate Synthesis in Overweight Subjects|Fructose-Induced Palmitate Synthesis in Overweight Subjects|Completed||Phase 1|15|Anticipated|Rockefeller University|||||f||||||||||||||2018-06-01 02:53:44.512326|2018-06-01 02:53:44.512326
NCT00535522|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2011-12-07|2007-09-21|2007-09-26|Estimate|||||||2011-12-07|2011-12-09|Estimate|August 2007||2007-08-31|December 2011|2011-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer|A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer|Completed||Phase 1|56|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 02:53:44.663491|2018-06-01 02:53:44.663491
NCT00535509|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2015-12-16|2007-09-24|2007-09-26|Estimate|||||||2015-12-16|2015-12-17|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer|Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer|Completed||N/A|285|Actual|King Faisal Specialist Hospital & Research Center|||||f||||f||||||||||2018-06-01 02:53:44.729963|2018-06-01 02:53:44.729963
NCT00535496|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2013-05-01||2015-02-26|2007-09-25|2007-09-26|Estimate|2013-07-29|2013-09-02|Estimate||||2015-02-26|2015-03-17|Estimate|September 2007||2007-09-30|February 2015|2015-02-28|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)|Comparison of the T4/T1 Ratio Measured by Means of the TOF Watch® SX With the Reappearance of T4 Measured by Means of a Peripheral Nerve Stimulator in Adult Subjects Receiving 4.0 mg.Kg-1 Sugammadex at 15 Minutes After Rocuronium|Completed||Phase 3|91|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 02:53:44.813469|2018-06-01 02:53:44.813469
NCT00533520|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2013-11-21|2007-09-19|2007-09-21|Estimate|||||||2013-11-21|2013-11-25|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|BGB/IST||Evaluation of Dosing Interval of Higher Doses of Ranibizumab|Evaluation of Dosing Interval of Higher Doses of Ranibizumab|Completed||Phase 4|37|Actual|Tennessee Retina||3|||f||||t||||||||||2018-06-01 02:54:20.551205|2018-06-01 02:54:20.551205
NCT00535483|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2014-04-03|2007-09-24|2007-09-26|Estimate|||||||2014-04-03|2014-04-04|Estimate|August 2007||2007-08-31|April 2014|2014-04-30|September 2007|Actual|2007-09-30|||||Observational|||Closed Loop Insulin Therapy in Type 1 Diabetics Based on Blood Microdialysis, Online Sensors and an eMPC Algorithm|An Open, Mono-centre Pilot Study to Investigate a Novel Technique to Establish Glycaemic Control for Critically Ill Patients, Tested in Type 1 Diabetic Subjects for a Period of 30 Hours.|Completed|||4|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 02:53:45.239742|2018-06-01 02:53:45.239742
NCT00535470|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2012-08-07|2007-09-25|2007-09-26|Estimate|||||||2012-08-07|2012-08-09|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides|An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response|Completed||Phase 2|100|Actual|Yaupon Therapeutics||1|||f||||f||||||||||2018-06-01 02:53:45.393677|2018-06-01 02:53:45.393677
NCT00535457|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-23|||2012-06-07|2007-09-25|2007-09-26|Estimate|||||||2012-06-07|2012-06-08|Estimate||||June 2012|2012-06-30||||||||Interventional|||The Effects of Pre-operative Magic Tricks Performance on Pre-operative Anxiety in Children|The Effects of Pre-operative Magic Tricks Performance on Pre-operative Anxiety in Children|Withdrawn||Phase 1|0|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 02:53:45.538056|2018-06-01 02:53:45.538056
NCT00535444|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2016-11-07|2007-09-25|2007-09-26|Estimate|||||||2016-11-07|2016-11-09|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Health and Faith Working to Control Blood Pressure|Health and Faith Working Together to Control Blood Pressure|Completed||N/A|100|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-06-01 02:53:45.667977|2018-06-01 02:53:45.667977
NCT00535431|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-22|||2007-09-22|2007-09-22|2007-09-26|Estimate|||||||2007-09-22|2007-09-26|Estimate|December 2005||2005-12-31|September 2007|2007-09-30|October 2006|Actual|2006-10-31|||||Interventional|||Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics|A Study To Investigate The Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatic Subjects|Completed||Phase 2|32|Actual|Aerovance, Inc.||2|||f||||f||||||||||2018-06-01 02:53:45.762812|2018-06-01 02:53:45.762812
NCT00535418|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2017-08-31|2007-09-25|2007-09-26|Estimate|||||||2017-08-31|2017-09-05|Actual|June 2000||2000-06-30|August 2017|2017-08-31||||July 2002|Actual|2002-07-31||Interventional|||Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers|Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers|Completed||Phase 2/Phase 3|35|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:53:45.894954|2018-06-01 02:53:45.894954
NCT00535405|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2010-04-26||2017-03-17|2007-09-25|2007-09-26|Estimate|2010-04-26|2010-05-25|Estimate||||2017-03-17|2017-04-14|Actual|November 2007||2007-11-30|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)|A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart Disease|Completed||Phase 3|1289|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:53:45.991396|2018-06-01 02:53:45.991396
NCT00535392|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|2011-01-28||2011-08-30|2007-09-25|2007-09-26|Estimate|2011-01-28|2011-02-25|Estimate||||2011-08-30|2011-08-31|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy|Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (4 - 16 Years Old) With Epilepsy.|Completed||Phase 2|33|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:53:47.013876|2018-06-01 02:53:47.013876
NCT00535379|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2010-08-27|2007-09-25|2007-09-26|Estimate|||||||2010-08-27|2010-08-30|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|January 2011|Anticipated|2011-01-31|December 2010|Anticipated|2010-12-31||Interventional|SURGE01-07||SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme|SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|Medical University Innsbruck||1|||f||||t||||||||||2018-06-01 02:53:47.207933|2018-06-01 02:53:47.207933
NCT00535366|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25||2014-04-30|2014-05-22|2007-09-25|2007-09-26|Estimate||||2014-05-22|2014-05-30|Estimate|2014-05-22|2014-05-30|Estimate|October 2007||2007-10-31|May 2014|2014-05-31||||September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD|A Randomised, Phase II, Double-Blind, Double-Dummy, Four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 mcg Bid, MDI), Ciclesonide (400 mcg qd, MDI), Ciclesonide (800 mcg qd, MDI) or Placebo in Free Combination With Open-Label Tiotropium (18 mcg qd, HandiHaler) and Salmeterol (50 mcg Bid, Diskus) in Patients With COPD.|Completed||Phase 2|103|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 02:53:47.395163|2018-06-01 02:53:47.395163
NCT00535353|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2016-05-02|2007-09-25|2007-09-26|Estimate|||||||2016-05-02|2016-05-03|Estimate|August 2007||2007-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|September 2012|Actual|2012-09-30||Interventional|||AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase I Study of AZD2281 in Combination With Irinotecan in Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer|Completed||Phase 1|26|Actual|Canadian Cancer Trials Group|||||f||||f||||||||||2018-06-01 02:53:47.500253|2018-06-01 02:53:47.500253
NCT00535340|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2009-03-10|2007-09-25|2007-09-26|Estimate|||||||2009-03-10|2009-03-12|Estimate|March 2007||2007-03-31|March 2009|2009-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|GEMINI||An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder|An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients With Generalized Anxiety Disorder With an Optional Twenty-Four Week Extension|Terminated||Phase 3|55|Actual|Sanofi||||reprioritization of indications|f||||||||||||||2018-06-01 02:53:47.583981|2018-06-01 02:53:47.583981
NCT00535327|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2010-05-13|2007-09-25|2007-09-26|Estimate|||||||2010-05-13|2010-05-14|Estimate|August 2007||2007-08-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Test of Digital Breast Tomosynthesis vs. Regular Mammography in Detecting Breast Cancer in Women Undergoing Diagnostic Mammography|A Multicenter Study to Test Digital Breast Tomosynthesis (DBT) Compared to Full-Field Digital Mammography (FFDM) in Detecting Breast Cancer. Part 2. Women Undergoing Diagnostic Mammography|Completed|||220|Anticipated|GE Healthcare|||||f||||f||||||||||2018-06-01 02:53:47.653157|2018-06-01 02:53:47.653157
NCT00535314|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2014-10-27|2007-09-24|2007-09-26|Estimate|||||||2014-10-27|2014-10-29|Estimate||||October 2014|2014-10-31||||||||Interventional|||Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma|A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma|Withdrawn||Phase 2|0|Actual|Reata Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:53:47.722431|2018-06-01 02:53:47.722431
NCT00535301|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2011-05-04||2015-04-02|2007-09-24|2007-09-26|Estimate|2011-06-28|2011-07-28|Estimate||||2015-04-02|2015-04-22|Estimate|January 2005||2005-01-31|April 2015|2015-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Outcomes of Anterior Colporrhaphy Versus Graft Reinforced Anterior Prolapse Repair|Outcome After Anterior Vaginal Prolapse Repair: A Randomized Controlled Trial|Completed||Phase 4|75|Actual|Kaiser Permanente|-Small number of subjects, Single surgeon, Medium follow-up, Limited ability to detect uncommon adverse events and small differences in quality of life and sexual symptom scores, Concurrent pelvic reconstructive and anti-incontinence procedures|2|||f||||f||||||||||2018-06-01 02:53:47.805458|2018-06-01 02:53:47.805458
NCT00535288|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2014-06-16||2017-05-29|2007-09-25|2007-09-26|Estimate|2014-07-29|2014-07-30|Estimate||||2017-05-29|2017-06-21|Actual|September 15, 2004|Actual|2004-09-15|May 2017|2017-05-31|January 15, 2006|Actual|2006-01-15|January 15, 2006|Actual|2006-01-15||Interventional|||Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause|Completed||Phase 3|946|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 02:53:48.228534|2018-06-01 02:53:48.228534
NCT00535275|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2015-02-12|2007-09-25|2007-09-26|Estimate|||||||2015-02-12|2015-02-16|Estimate|September 2007||2007-09-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy|Comparison of 2 Chemotherapy Regimens in Non-small-cell Lung Cancer (NSCLC) Patients Relapsing After Surgery and Peri-operative Chemotherapy. A Randomized Phase III Study.|Terminated||Phase 3|88|Actual|Intergroupe Francophone de Cancerologie Thoracique||2||Final analysis done, follow-up of patients no more necessary|f||||t||||||||||2018-06-01 02:53:49.548953|2018-06-01 02:53:49.548953
NCT00535262|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2014-10-01||2014-10-24|2007-09-24|2007-09-26|Estimate|2014-10-24|2014-10-28|Estimate||||2014-10-24|2014-10-28|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Seeking pilot data|A Pilot Study Assessing EmSam in Bipolar Depression|A Pilot Study Assessing Efficacy, Safety, and Tolerability of EmSam in Bipolar Depression|Terminated||Phase 4|3|Actual|New York State Psychiatric Institute|Early termination due to lack of financial support; only 3 participants were entered into the study; no data was analyzed.|1||Current lack of medication support.|f||||t||||||||||2018-06-01 02:53:49.781054|2018-06-01 02:53:49.781054
NCT00535236|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2015-10-05|2007-09-25|2007-09-26|Estimate|||||||2015-10-05|2015-10-06|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of an Investigational V212/Heat-Treated VZV Vaccine in Immunocompromised Adults (V212-002)(COMPLETED)|A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults|Completed||Phase 1|341|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:53:49.914256|2018-06-01 02:53:49.914256
NCT00535223|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2014-12-22||2015-03-23|2007-09-24|2007-09-26|Estimate|2015-03-23|2015-03-26|Estimate||||2015-03-23|2015-03-26|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|August 2012|Actual|2012-08-31|July 2010|Actual|2010-07-31||Interventional|||Group Based Exposure Therapy for Combat-Related PTSD|Group Based Exposure Therapy for Combat PTSD: RCT and Feasibility Study|Completed||N/A|81|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:53:49.983932|2018-06-01 02:53:49.983932
NCT00535210|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2017-05-08|2007-09-25|2007-09-26|Estimate|||||||2017-05-08|2017-05-10|Actual|September 2007||2007-09-30|May 2017|2017-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||The Effect of an Exercise Program on Physical Function After a Spinal Cord Injury|The Effects of a Group Exercise Program on Function in Spinal Cord Injury Rehabilitation: A Pilot Randomized Controlled Trial|Terminated||N/A|9|Actual|University of British Columbia||2||Unsuccessful recruiting patients, never got beyond pilot testing of patients|f||||f||||||||||2018-06-01 02:53:50.185033|2018-06-01 02:53:50.185033
NCT00535197|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2016-02-15|2007-09-25|2007-09-26|Estimate|||||||2016-02-15|2016-02-17|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Autologous Bone Marrow Stem Cells in Ischemic Stroke.|A Phase I/II Safety and Tolerability Study Following the Autologous Infusion of Immuno-selected CD34+ Subset Bone Marrow Stem Cells Into Patients With Acute Total Anterior Circulation Ischaemic Stroke|Completed||Phase 1/Phase 2|5|Actual|Imperial College London|||||f||||t||||||||||2018-06-01 02:53:50.246092|2018-06-01 02:53:50.246092
NCT00535184|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2012-03-21|2007-09-25|2007-09-26|Estimate|||||||2012-03-21|2012-03-22|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Test of Digital Breast Tomosynthesis vs. Common Mammography to Detect Breast Cancer for Women Undergoing Breast Biopsy|A Multicenter Study to Test Digital Breast Tomosynthesis (DBT) Compared to Full-Field Digital Mammography (FFDM) in Detecting Breast Cancer. Part 3. Women Undergoing Breast Biopsy|Completed|||220|Actual|GE Healthcare|||||f||||f||||||||||2018-06-01 02:53:50.293634|2018-06-01 02:53:50.293634
NCT00535171|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2010-01-21|2007-09-25|2007-09-26|Estimate|||||||2010-01-21|2010-01-22|Estimate|June 2007||2007-06-30|January 2010|2010-01-31||||August 2008|Actual|2008-08-31||Observational|||Venous Thromboembolism Taskforce Audit Program|Venous Thromboembolism Taskforce Audit Program|Completed|||8764|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:53:50.33583|2018-06-01 02:53:50.33583
NCT00535158|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2017-03-14|2007-09-25|2007-09-26|Estimate|||||||2017-03-14|2017-03-16|Actual|June 1, 2008|Actual|2008-06-01|March 2017|2017-03-31|June 1, 2009|Actual|2009-06-01|June 1, 2009|Actual|2009-06-01||Observational|D2D||Vitamin D 2 to Dialysis Patients|Vitamin D and Muscle Strength in the Dialysis Population|Terminated|||18|Actual|Brigham and Women's Hospital||||Because of departure of study personnel and lack of funding|f||||f||||||||||2018-06-01 02:53:50.377088|2018-06-01 02:53:50.377088
NCT00535145|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2013-07-17||2014-07-14|2007-09-24|2007-09-26|Estimate|2013-07-17|2013-09-20|Estimate||||2014-07-14|2014-07-25|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease|A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease|Completed||Phase 4|121|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|Please see the Clinical Study Report Synopsis for results on the primary outcome measure.|1|||f||||f||||||||||2018-06-01 02:53:50.436027|2018-06-01 02:53:50.436027
NCT00535132|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2009-07-17||2014-04-24|2007-09-24|2007-09-26|Estimate|2009-09-16|2009-10-20|Estimate||||2014-04-24|2014-05-09|Estimate|October 2007||2007-10-31|April 2014|2014-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone|A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone|Completed||Phase 4|201|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 02:53:51.76577|2018-06-01 02:53:51.76577
NCT00535119|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2015-05-21|2007-09-25|2007-09-26|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2007||2007-09-30|April 2015|2015-04-30||||October 2012|Actual|2012-10-31||Interventional|||Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer|A Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies|Completed||Phase 1|107|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:53:52.66124|2018-06-01 02:53:52.66124
NCT00535106|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2009-10-18|2007-09-25|2007-09-26|Estimate|||||||2009-10-18|2009-10-19|Estimate|May 2006||2006-05-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SmartCPR||SmartCPR Trial: An Analysis of a Waveform-Based Automated External Defibrillation (AED) Algorithm on Survival From Out-of-Hospital Ventricular Fibrillation|An International, Randomized, Controlled Prehospital Trial of a Waveform-Based Automated External Defibrillation Algorithm for the Management of Ventricular Fibrillation|Completed||N/A|900|Actual|New York City Fire Department||3|||f||||t||||||||||2018-06-01 02:53:52.781167|2018-06-01 02:53:52.781167
NCT00535093|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2010-05-02|2007-09-25|2007-09-26|Estimate|||||||2010-05-02|2010-05-04|Estimate|October 2007||2007-10-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||An Assessment of Rapid Streptococcal Tests in Community Clinics in Israel|A Comparison of Available Rapid Streptococcus A Tests in Community Clinics in Israel: Accuracy, Ease of Use and Acceptability.|Completed||N/A|7000|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-06-01 02:53:52.885336|2018-06-01 02:53:52.885336
NCT00535080|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2009-10-27|2007-09-24|2007-09-26|Estimate|||||||2009-10-27|2009-10-28|Estimate||||October 2009|2009-10-31||||||||Expanded Access|||Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease|Compassionate Use of Metvix® (Methyl Aminolevulinate) PDT in Subjects With Field Actinic Keratoses, Large/Multiple Superficial BCCs, or Bowen's Disease|No longer available|||||Galderma|||||f||||||||||||||2018-06-01 02:53:52.955763|2018-06-01 02:53:52.955763
NCT00535067|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2015-01-07|2007-09-24|2007-09-26|Estimate|||||||2015-01-07|2015-01-09|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Neuropathic Pain in Survivors of Breast Cancer|Neuropathic Pain in Survivors of Breast Cancer|Completed|||239|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:53:53.008427|2018-06-01 02:53:53.008427
NCT00535054|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-23|||2010-02-07|2007-09-24|2007-09-26|Estimate|||||||2010-02-07|2010-02-09|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study to Assess the Safety and Patients' Satisfaction of Tears Again* in the Treatment of Dry Eye Symptoms|An Open Study to Assess the Safety and Patients' Satisfaction Tears Again* in the Treatment of Dry Eye Symptoms|Completed||N/A|125|Anticipated|Trima, Israel Pharmaceutical Products||1|||f||||t||||||||||2018-06-01 02:53:53.085002|2018-06-01 02:53:53.085002
NCT00535041|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2016-01-04|2007-09-24|2007-09-26|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2007||2007-09-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA|Pilot Trial of Pre-operative Chemo/RT Using Xeloda and External Beam RT Followed by Definite Surgery in Patients With Localized Rectal CA|Completed||N/A|200|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:53:53.147718|2018-06-01 02:53:53.147718
NCT00535028|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-21|2007-09-21|2007-09-26|Estimate|||||||2007-09-21|2007-09-26|Estimate|January 2005||2005-01-31|September 2007|2007-09-30|May 2005|Actual|2005-05-31|||||Interventional|||A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)|A Phase IIa Study To Investigate The Effects of AER 001 on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration.|Completed||Phase 2|24|Actual|Aerovance, Inc.||2|||f||||f||||||||||2018-06-01 02:53:53.2147|2018-06-01 02:53:53.2147
NCT00535015|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-23|||2008-07-19|2007-09-23|2007-09-26|Estimate|||||||2008-07-19|2008-07-22|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|August 2008|Anticipated|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer|A Randomized, Double-Blind, Pilot Study Comparing the Safety and Efficacy of Betamarc Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of CACS in Patients With Advanced NSCLC|Terminated||Phase 2|70|Anticipated|Anaborex||||Objectives of study could not be met within a reasonable timeframe.|f||||t||||||||||2018-06-01 02:53:53.394503|2018-06-01 02:53:53.394503
NCT00535002|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2013-07-31||2017-05-04|2007-09-25|2007-09-26|Estimate|2017-05-04|2017-06-07|Actual||||2017-05-04|2017-06-07|Actual|September 2007||2007-09-30|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Effect of Yohimbine on Cocaine Cue Reactivity|SCOR on Sex and Gender Factors Affecting Women's Health|Completed||Phase 2|112|Actual|Medical University of South Carolina||8|||f||||f||||||||||2018-06-01 02:53:53.494522|2018-06-01 02:53:53.494522
NCT00534989|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2015-12-16|2007-09-24|2007-09-26|Estimate|||||||2015-12-16|2015-12-17|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT|Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT|Completed||N/A|10|Actual|King Faisal Specialist Hospital & Research Center|||||f||||||||||||||2018-06-01 02:53:54.446007|2018-06-01 02:53:54.446007
NCT00457665|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2015-05-29|2007-04-05|2007-04-06|Estimate|||||||2015-05-29|2015-06-01|Estimate|February 2002||2002-02-28|August 2014|2014-08-31|October 2014|Actual|2014-10-31|October 2007|Actual|2007-10-31||Interventional|||Mechanisms of Lipodystrophy in HIV-Infected Pateints|Mecahnisms of Lipodystrophy in HIV-Infected Patients|Completed||Phase 4|200||University of Texas Southwestern Medical Center|||||f||||t||||||||||2018-06-01 03:18:54.465292|2018-06-01 03:18:54.465292
NCT00534976|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2011-03-11||2017-03-09|2007-09-25|2007-09-26|Estimate|2011-03-11|2011-04-07|Estimate||||2017-03-09|2017-04-06|Actual|February 2008||2008-02-29|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared With Placebo, on Exercise-Induced Bronchoconstriction (EIB) in Pediatric Patients Aged 4 to 14 Years|Completed||Phase 4|364|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:53:54.528742|2018-06-01 02:53:54.528742
NCT00534963|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-23|||2017-10-24|2007-09-23|2007-09-26|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2004||2004-12-31|October 2017|2017-10-31|August 2005|Actual|2005-08-31|||||Interventional|||Optimal Catheter Placement During Sonohysterography: Comparison of Cervical to Uterine Placement|Optimal Catheter Placement During Sonohysterography: A Randomized Clinical Trial Comparing Cervical to Uterine Placement|Completed||N/A|69|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 02:53:54.886721|2018-06-01 02:53:54.886721
NCT00534950|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2016-02-24|2007-09-24|2007-09-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck||Completed||N/A|200|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:53:54.956806|2018-06-01 02:53:54.956806
NCT00534937|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2012-11-29||2013-01-28|2007-09-24|2007-09-26|Estimate|2013-01-28|2013-03-01|Estimate||||2013-01-28|2013-03-01|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Flexitouch Compression System for Venous Stasis Ulcer|A Randomized Trial of the Flexitouch Compression System as an Adjunctive Treatment for Venous Stasis Ulcer|Terminated||Phase 4|89|Actual|West Penn Allegheny Health System|The study was terminated early due to lack of enrollment which ultimately lead to a limited number of subjects to include in an analysis.|2||Ineffective Recruitment (Business Decision)|f||||t||||||||||2018-06-01 02:53:55.068476|2018-06-01 02:53:55.068476
NCT00534924|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2007-09-24|2007-09-24|2007-09-26|Estimate|||||||2007-09-24|2007-09-26|Estimate|August 2007||2007-08-31|September 2007|2007-09-30||||||||Interventional|IRI in MRI||The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels|The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels|Unknown status|Recruiting|N/A|||Medical University of Vienna||3|||f||||t||||||||||2018-06-01 02:53:55.304035|2018-06-01 02:53:55.304035
NCT00534911|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2018-01-04|2007-09-21|2007-09-26|Estimate|||||||2018-01-04|2018-01-08|Actual|September 2007||2007-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Interventional|||Reducing Depressive Symptoms in Physically Ill Youth|Reducing Depressive Symptoms in Physically Ill Youth|Active, not recruiting||N/A|76|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 02:53:55.367372|2018-06-01 02:53:55.367372
NCT00534898|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2010-06-28|2007-09-24|2007-09-26|Estimate|||||||2010-06-28|2010-06-29|Estimate||||September 2007|2007-09-30||||||||Interventional|||Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients|Comparison Efficacy of Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients: Double-blind Placebo Controlled Study|Withdrawn||Phase 3|||Beersheva Mental Health Center||||The study withdrawn due to lack financial support|f||||t||||||||||2018-06-01 02:53:55.435547|2018-06-01 02:53:55.435547
NCT00534885|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2016-04-25|2007-09-24|2007-09-26|Estimate|||||||2016-04-25|2016-04-27|Estimate|March 2006||2006-03-31|November 2015|2015-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine|The Phase Ⅳ Clinical Trial to Evaluate the Safety, Immunogenicity, and Immune Persistence of Three Consecutive Lots of an Inactivated Hepatitis A Vaccine in Healthy Children|Completed||Phase 4|400|Actual|Sinovac Biotech Co., Ltd||4|||f||||t||||||||||2018-06-01 02:53:55.488308|2018-06-01 02:53:55.488308
NCT00534872|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2015-04-15|2007-09-24|2007-09-26|Estimate|||||||2015-04-15|2015-04-17|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|October 2007|Anticipated|2007-10-31|October 2007|Anticipated|2007-10-31||Interventional|||A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population|"A Single-centre, Open Label, Single-dose, Four Parallel Cohorts Study to Investigate the Pharmacokinetics, Safety and Tolerability of SB-649868 10mg in Healthy Female Non-childbearing Potential, Healthy Male and in Healthy Elderly Subjects"|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1||The study was stoppend before recruitment start for preclinical safety finding in rats.|f||||||||||||||2018-06-01 02:53:55.562039|2018-06-01 02:53:55.562039
NCT00534859|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2011-03-18|2007-09-24|2007-09-26|Estimate|||||||2011-03-18|2011-03-21|Estimate|August 2006||2006-08-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|June 2010|Actual|2010-06-30||Interventional|PROTECT I||PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI|PROTECT I, A Prospective Feasibility Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI|Completed||Phase 2|28|Actual|Abiomed Inc.|||||f||||f||||||||||2018-06-01 02:53:55.628859|2018-06-01 02:53:55.628859
NCT00534846|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2009-05-12|2007-09-24|2007-09-26|Estimate|||||||2009-05-12|2009-05-13|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|February 2009|Actual|2009-02-28|May 2008|Actual|2008-05-31||Interventional|||The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia|The Effect of Toremifene Treatment to the Magnetic Resonance Imaging Findings in Women Suffering From Premenstrual Mastalgia|Completed||Phase 3|10|Actual|Satakunta Central Hospital||2|||f||||f||||||||||2018-06-01 02:53:55.692352|2018-06-01 02:53:55.692352
NCT00534833|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2013-09-19||2013-09-19|2007-09-24|2007-09-26|Estimate|2013-09-19|2013-11-21|Estimate||||2013-09-19|2013-11-21|Estimate|September 2007||2007-09-30|September 2013|2013-09-30|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™|Immunogenicity Study of the Antibody Persistence and Booster Effect of DTaP-Hep B-PRP-T Combined Vaccine or Tritanrix HepB/Hib™ at 15 to 18 Months of Age Following a Primary Series at 6, 10 and 14 Weeks of Age in Healthy Filipino Infants|Completed||Phase 3|362|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:53:55.876059|2018-06-01 02:53:55.876059
NCT00534820|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2015-12-16|2007-09-24|2007-09-26|Estimate|||||||2015-12-16|2015-12-17|Estimate|June 2004||2004-06-30|December 2015|2015-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease||Completed||N/A|450|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:53:56.285304|2018-06-01 02:53:56.285304
NCT00534807|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-25|||2015-08-31|2007-09-25|2007-09-26|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2007||2007-09-30|October 2007|2007-10-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer|Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-06-01 02:53:56.356049|2018-06-01 02:53:56.356049
NCT00534794|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2009-01-30||2015-04-27|2007-09-21|2007-09-26|Estimate|2009-04-03|2009-05-27|Estimate||||2015-04-27|2015-05-13|Estimate|October 2007||2007-10-31|April 2015|2015-04-30||||January 2008|Actual|2008-01-31||Interventional|||Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis|A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model|Completed||Phase 4|79|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:53:56.421187|2018-06-01 02:53:56.421187
NCT00534781|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2013-07-10|2007-09-25|2007-09-26|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2007||2007-09-30|July 2013|2013-07-31|September 2010|Actual|2010-09-30|July 2008|Actual|2008-07-31||Interventional|||Achilles Tendinosis Study; Comparison of Radiofrequency to Surgical MicroDebridement|"Radiofrequency-based Plasma Microdebridement Compared to Surgical Microdebridement for Treating Achilles Tendinosis: A Prospective, Randomized, Controlled Multi-Center Study"|Completed||Phase 4|60|Actual|ArthroCare Corporation||2|||f||||f||||||||||2018-06-01 02:53:56.658248|2018-06-01 02:53:56.658248
NCT00534768|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2008-01-11|2007-09-24|2007-09-26|Estimate|||||||2008-01-11|2008-01-14|Estimate|January 2003||2003-01-31|January 2008|2008-01-31||||||||Interventional|||Postoperative Treatment After Endoscopic Sinus Surgery|Postoperative Treatment After Endoscopic Sinus Surgery|Completed||N/A|||Kuopio University Hospital||2|||f||||||||||||||2018-06-01 02:53:56.746989|2018-06-01 02:53:56.746989
NCT00534755|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2016-02-24|2007-09-24|2007-09-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 2005||2005-06-30|December 2011|2011-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Prospective & Retrospective Data Collection of Breast Cancer Cases From 2000 to Present||Completed||Early Phase 1|10000|Actual|King Faisal Specialist Hospital & Research Center||1|||f||||t||||||||||2018-06-01 02:53:56.812364|2018-06-01 02:53:56.812364
NCT00534742|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2011-12-13|2007-09-21|2007-09-26|Estimate|||||||2011-12-13|2011-12-14|Estimate|June 2005||2005-06-30|December 2011|2011-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|FISSIC||Fangshan / Family-based Ischemic Stroke Study In China|A Family-based Ischemic Stroke Study on Association and Interactions of Multi-pathway Genetic Polymorphisms|Unknown status|Recruiting||1500|Anticipated|Peking University|||||f||||f||||||Samples With DNA|"~     serum, white cells~   "|||2018-06-01 02:53:56.877952|2018-06-01 02:53:56.877952
NCT00534729|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2016-01-04|2007-09-24|2007-09-26|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2007||2007-09-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA||Completed||N/A|200|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:53:56.963003|2018-06-01 02:53:56.963003
NCT00534716|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2008-05-06|2007-09-24|2007-09-26|Estimate|||||||2008-05-06|2008-05-12|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Observational|||Cannabis Cigarettes Used for Doping: Delta-9-Tetrahydrocannabinol (THC) Urine Detection|Cannabis and Doping - Pharmacokinetics of Smoked Cannabis Under Controlled Clinical Conditions|Completed|||12|Actual|Federal Office of Sports, Switzerland|||||f||||t||||||Samples Without DNA|"~     Plasma, urine~   "|||2018-06-01 02:53:57.024871|2018-06-01 02:53:57.024871
NCT00534703|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2016-02-23|2007-09-24|2007-09-26|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SERCA-LVAD||Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure|Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device|Terminated||Phase 2|5|Actual|Imperial College London||2||Early termination following Trial Steering Committee recommendation|f||||t||||||||||2018-06-01 02:53:57.086849|2018-06-01 02:53:57.086849
NCT00534690|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2010-01-20|2007-09-24|2007-09-26|Estimate|||||||2010-01-20|2010-01-21|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|REVOLU||Does PEP Compensate the Reduction of Tidal Volume During One Lung Ventilation?|Lowering VT and Increasing PEP During One-Lung Ventilation (OLV), Impact on Oxygenation|Completed||N/A|88|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 02:53:57.160141|2018-06-01 02:53:57.160141
NCT00534677|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2007-12-04|2007-09-24|2007-09-26|Estimate|||||||2007-12-04|2007-12-05|Estimate|May 2004||2004-05-31|September 2007|2007-09-30|July 2005|Actual|2005-07-31|||||Interventional|||The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed|Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices|Completed||Phase 4|320|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 02:53:57.250231|2018-06-01 02:53:57.250231
NCT00534664|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2007-09-24|2007-09-24|2007-09-26|Estimate|||||||2007-09-24|2007-09-26|Estimate|October 2005||2005-10-31|September 2007|2007-09-30|February 2007|Actual|2007-02-28|||||Interventional|TheraBionic||Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma|Phase II Study to Determine the Effectiveness of Intrabuccally Administered Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|40|Actual|University of Sao Paulo|||||f||||f||||||||||2018-06-01 02:53:57.322277|2018-06-01 02:53:57.322277
NCT00534651|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2010-03-15|2007-09-24|2007-09-26|Estimate|||||||2010-03-15|2010-03-16|Estimate|November 2006||2006-11-30|March 2010|2010-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease|Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease|Completed||Phase 4|37|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 02:53:57.3698|2018-06-01 02:53:57.3698
NCT00534638|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2015-12-17||2017-04-24|2007-09-24|2007-09-26|Estimate|2015-12-17|2016-01-26|Estimate||||2017-04-24|2017-06-05|Actual|October 4, 2007||2007-10-04|April 2017|2017-04-30|December 17, 2014|Actual|2014-12-17|December 17, 2014|Actual|2014-12-17||Interventional|||Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents|Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix™) Administered in Healthy Adolescents|Completed||Phase 4|34206|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:53:57.455068|2018-06-01 02:53:57.455068
NCT00105846|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-17|||2015-04-06|2005-03-17|2005-03-18|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|June 2004|Actual|2004-06-30|||||Interventional|||An Evaluation of Home-Based Telemedicine Services|An Evaluation of Home-Based Telemedicine Services|Completed||Phase 2|200|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:45.496481|2018-06-01 04:57:45.496481
NCT00534625|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2008-03-19|2007-09-24|2007-09-26|Estimate|||||||2008-03-19|2008-03-21|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients|Phase 2 Study of the Assessment of Pulmonary Function, Safety, Tolerability, and PK of Zileuton Injection in Patients With Chronic Stable Asthma|Completed||Phase 2|36|Actual|Critical Therapeutics||3|||f||||f||||||||||2018-06-01 02:53:58.234096|2018-06-01 02:53:58.234096
NCT00534612|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-24|2007-09-24|2007-09-26|Estimate|||||||2007-09-24|2007-09-26|Estimate|January 2003||2003-01-31|January 2003|2003-01-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Diagnostic Accuracy of Fine Needle Aspiration in Parotid Tumors|Accuracy of Fine Needle Aspiration Biopsy in the Pre-Operative Diagnosis of Malignancy in Patients With Parotid Gland Masses|Unknown status|Recruiting|Early Phase 1|150|Anticipated|National Institute of Cancerología||1|||f||||f||||||||||2018-06-01 02:53:58.300627|2018-06-01 02:53:58.300627
NCT00534599|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2009-08-13||2011-04-12|2007-09-24|2007-09-26|Estimate|2011-03-06|2011-04-05|Estimate||||2011-04-12|2011-04-14|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Generalized Anxiety Disorder Adjunct Study|A Multicenter, Rand., Double-blind, Parallel-group, Pbo-controlled Study of the Efficacy and Safety of SEROQUEL® XR Compared With Pbo as an Adjunct to Treatment in Patients With Generalized Anxiety Disorder Who Demonstrate Partial or No Response to a SSRI or SNRI Alone or in Combination With a Benzo|Completed||Phase 3|409|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 02:53:58.410168|2018-06-01 02:53:58.410168
NCT00534586|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2007-09-24|2007-09-24|2007-09-26|Estimate|||||||2007-09-24|2007-09-26|Estimate|December 2005||2005-12-31|December 2005|2005-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Anesthetics and Auditory, Visceral, and Heat Evoked Potentials|Influence of Anesthetics on Sedation and Antinociception: an Analysis of Auditory Evoked, Visceral Evoked and Heat Evoked Potentials|Completed||Phase 4|60|Actual|Technische Universität München||4|||f||||f||||||||||2018-06-01 02:53:59.112473|2018-06-01 02:53:59.112473
NCT00534573|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2012-07-25|2007-09-24|2007-09-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|November 2008||2008-11-30|November 2009|2009-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|CIH||Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation|Comparison of Benzamide Derivates (Amisulpride, Moclobemide and Tiapride) as Treatment of Clozapine-induced Hypersalivation: Pilot Double Phase Study: Open and Double-blind|Completed||Phase 3|54|Actual|Beersheva Mental Health Center||2|||f||||f||||||||||2018-06-01 02:53:59.204602|2018-06-01 02:53:59.204602
NCT00534560|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2009-03-30|2007-09-24|2007-09-26|Estimate|||||||2009-03-30|2009-03-31|Estimate|October 2007||2007-10-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|TEMPUS||Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache|Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension|Completed||Phase 2|542|Actual|Minster Research Ltd||3|||f||||f||||||||||2018-06-01 02:53:59.279143|2018-06-01 02:53:59.279143
NCT00534547|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2015-07-23|2007-09-24|2007-09-26|Estimate|||||||2015-07-23|2015-07-27|Estimate||||July 2015|2015-07-31||||||||Interventional|||Duodenal Exclusion for the Treatment of Type 2 Diabetes|Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM)|Withdrawn||N/A|0|Actual|Medtronic - MITG||||business reasons|f||||f||||||||||2018-06-01 02:53:59.354671|2018-06-01 02:53:59.354671
NCT00534534|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-24|2007-09-24|2007-09-26|Estimate|||||||2007-09-24|2007-09-26|Estimate|January 2001||2001-01-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||Decrease of Recurrent Pancreatitis|Randomized Clinical Trial of the Effect of Standard Versus Intensive Intervention Protocol in Attempting to Reduce Recurrent Episodes of Acute Alcoholic Pancreatitis|Completed||N/A|120|Anticipated|University of Tampere||2|||f||||f||||||||||2018-06-01 02:53:59.403904|2018-06-01 02:53:59.403904
NCT00534521|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2007-09-24|2007-09-24|2007-09-26|Estimate|||||||2007-09-24|2007-09-26|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Posterior Tibial Nerve Stimulation vs. Sham|Posterior Tibial Nerve Stimulation vs. Sham|Completed||Phase 3|30|Actual|William Beaumont Hospitals||2|||f||||f||||||||||2018-06-01 02:53:59.480934|2018-06-01 02:53:59.480934
NCT00534508|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2014-09-17|2007-09-21|2007-09-26|Estimate|||||||2014-09-17|2014-09-18|Estimate|December 2000||2000-12-31|September 2014|2014-09-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Distribution of Tacrolimus in Skin, Atopic Dermatitis|A Study to Determine the Distribution of Tacrolimus in the Skin and the Systemic Pharmacokinetics of Tacrolimus in Adult Patients With Moderate to Severe Atopic Dermatitis Following First and Repeated Application of the Tacrolimus Ointment.|Completed||Phase 2|14|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-06-01 02:53:59.548857|2018-06-01 02:53:59.548857
NCT00534495|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|2015-11-05||2015-11-05|2007-09-24|2007-09-26|Estimate|2015-11-05|2015-12-11|Estimate||||2015-11-05|2015-12-11|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults|Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)|Completed||Phase 2|71|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 02:53:59.652393|2018-06-01 02:53:59.652393
NCT00534482|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-24|||2011-05-09|2007-09-24|2007-09-26|Estimate|||||||2011-05-09|2011-05-10|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|AIM-HI||"Evaluation of the Americans in Motion - Healthy Interventions Project"|The Impact of Brief Primary Care Counseling and Novel Physiological Measures on Patient Physical and Emotional Health|Completed||N/A|950|Anticipated|American Academy of Family Physicians||4|||f||||f||||||||||2018-06-01 02:54:00.282385|2018-06-01 02:54:00.282385
NCT00534469|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-02-07|2007-09-20|2007-09-24|Estimate|||||||2018-02-07|2018-02-09|Actual|October 2000||2000-10-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission|Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients </=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as the Preparative Regimen|Active, not recruiting||Phase 2|50|Anticipated|City of Hope Medical Center||2|||f||||||||||||||2018-06-01 02:54:00.353201|2018-06-01 02:54:00.353201
NCT00534456|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2011-04-07|2007-09-20|2007-09-24|Estimate|||||||2011-04-07|2011-04-08|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial|Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Darbepoetin Alfa Treatment on Cardiac Function and Disease Specific Biomarkers in Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia: An Exploratory Sub-study for the RED-HF™ Trial|Terminated||Phase 3|12|Actual|Amgen||2||Study terminated|f||||||||||||||2018-06-01 02:54:00.425133|2018-06-01 02:54:00.425133
NCT00534443|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2011-08-08|2007-09-21|2007-09-24|Estimate|||||||2011-08-08|2011-08-09|Estimate|February 2007||2007-02-28|June 2008|2008-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment|A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease|Completed||Phase 4|150|Actual|University of Athens||1|||f||||t||||||||||2018-06-01 02:54:00.495515|2018-06-01 02:54:00.495515
NCT00534430|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-02-07|2007-09-20|2007-09-24|Estimate|||||||2018-02-07|2018-02-09|Actual|January 2000||2000-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer|Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies|Active, not recruiting||Phase 2|50|Anticipated|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 02:54:00.564122|2018-06-01 02:54:00.564122
NCT00534417|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2012-12-28||2012-12-28|2007-09-21|2007-09-24|Estimate|2012-12-28|2013-02-01|Estimate||||2012-12-28|2013-02-01|Estimate|October 2007||2007-10-31|December 2012|2012-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer|Phase II Trial of Capecitabine in Combination With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer|Completed||Phase 2|41|Actual|Accelerated Community Oncology Research Network||1|||f||||f||||||||||2018-06-01 02:54:00.737908|2018-06-01 02:54:00.737908
NCT00534404|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2015-01-21||2015-01-21|2007-09-21|2007-09-24|Estimate|2015-01-21|2015-02-03|Estimate||||2015-01-21|2015-02-03|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|iQS||A Randomized Trial of Internet Access to Nicotine Patches|iQuit Smoking: A Randomized Trial of Internet Access to Nicotine Patches|Completed||N/A|2485|Actual|University of Michigan||3|||f||||t||||||||||2018-06-01 02:54:01.392526|2018-06-01 02:54:01.392526
NCT00534391|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2010-11-22|2007-09-21|2007-09-24|Estimate|||||||2010-11-22|2010-11-23|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage|Dose Antibiotic Need in Hordeolum After Incision and Curettage? : A Randomized, Placebo-controlled Trial|Unknown status|Recruiting|Phase 3|120|Anticipated|Chulalongkorn University||2|||f||||t||||||||||2018-06-01 02:54:01.950235|2018-06-01 02:54:01.950235
NCT00534378|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|July 2006||2006-07-31|September 2007|2007-09-30|December 2006|Actual|2006-12-31|||||Interventional|AAS||Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector|Phase I, Open-Label, Single-Center Study to Evaluate the Safety and Dose Linearity of Intramuscular Administration of Midazolam Using|Completed||Phase 1|39|Actual|U.S. Army Office of the Surgeon General||1|||f||||t||||||||||2018-06-01 02:54:02.03895|2018-06-01 02:54:02.03895
NCT00534365|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2017-01-09||2017-05-08|2007-09-20|2007-09-24|Estimate|2017-05-08|2017-06-09|Actual||||2017-05-08|2017-06-09|Actual|August 2007||2007-08-31|May 2017|2017-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|SECURiTy||Study Comparing TVT With TVT-SECUR for the Treatment of Stress Urinary Incontinence|A Randomized Trial Comparing Tension-free Vaginal Tape (TVT) to the TVT-SECUR for the Surgical Treatment of Stress Urinary Incontinence|Completed||Phase 3|281|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 02:54:02.139158|2018-06-01 02:54:02.139158
NCT00534352|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2009-05-06||2015-03-26|2007-09-21|2007-09-24|Estimate|2010-03-25|2010-04-12|Estimate||||2015-03-26|2015-04-16|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|March 2009|Actual|2009-03-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).|A Multicenter Study to Evaluate the Pharmacokinetic Profile and Safety of TMC125 Plus Tenofovir DF/Emtricitabine All Dosed Once Daily With and Without Darunavir (PREZISTA™)/ Ritonavir Once Daily in Antiretroviral naïve HIV-1 Infected Subjects|Completed||Phase 2|23|Actual|Tibotec, Inc||1|||f||||||||||||||2018-06-01 02:54:02.54068|2018-06-01 02:54:02.54068
NCT00534339|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2014-10-03|2007-09-21|2007-09-24|Estimate|||||||2014-10-03|2014-10-07|Estimate|December 2010||2010-12-31|November 2010|2010-11-30|February 2016|Anticipated|2016-02-29|April 2012|Anticipated|2012-04-30||Interventional|||EasyBand GOAL Trial||Withdrawn||N/A|0|Actual|Allergan||||"This study was withdrawn to further optimize the device. No patients were enrolled in the~   trial."|f||||||||||||||2018-06-01 02:54:03.177225|2018-06-01 02:54:03.177225
NCT00534326|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-01-10|2007-09-20|2007-09-24|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2006||2006-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|STAFF||Standard Reaming Versus Reaming/Irrigating/Aspirating for Intramedullary Nailing of Femoral Shaft Fractures|Standard Reaming Versus Reaming/Irrigating/Aspirating for Intramedullary Nailing of Femoral Shaft Fractures|Active, not recruiting||N/A|550|Anticipated|Greenville Health System||2|||f||||f||||||||||2018-06-01 02:54:03.24058|2018-06-01 02:54:03.24058
NCT00534313|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2010-10-29||2012-07-25|2007-09-21|2007-09-24|Estimate|2010-10-29|2010-11-22|Estimate||||2012-07-25|2012-08-01|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|May 2011|Actual|2011-05-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis|A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis|Terminated||Phase 2|191|Actual|Bristol-Myers Squibb||4||Lack of efficacy with respect to skin-related lesions in the short-term phase|f||||f||||||||||2018-06-01 02:54:03.348898|2018-06-01 02:54:03.348898
NCT00534300|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2015-04-15|2007-09-21|2007-09-24|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker|Intravenous Infusion of n-3 Polyunsaturated Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)|Completed||Phase 1/Phase 2|8|Actual|Aalborg Universitetshospital||2|||f||||t||||||||||2018-06-01 02:54:05.854909|2018-06-01 02:54:05.854909
NCT00534118|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-03-19|2007-09-20|2007-09-24|Estimate|||||||2018-03-19|2018-03-20|Actual|October 1, 2003|Actual|2003-10-01|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|August 28, 2018|Anticipated|2018-08-28||Interventional|||Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant|Cellular Infusions in Patients With Recurrent or Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplant|Active, not recruiting||N/A|39|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 02:54:08.51072|2018-06-01 02:54:08.51072
NCT00534287|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2012-06-28|2007-09-21|2007-09-24|Estimate|||||||2012-06-28|2012-06-29|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|MaxSep||Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock|Prospective, Randomized, Open, Multicentre Study About the Effect of an Empirical Antibiotic Monotherapy With Meropenem (Meronem®) Versus a Combination Therapy With Moxifloxacin (Avalox®) on Organ Dysfunction in Patients With Severe Sepsis and Septic Shock|Completed||Phase 3|600|Actual|Kompetenznetz Sepsis||2|||f||||t||||||||||2018-06-01 02:54:05.985278|2018-06-01 02:54:05.985278
NCT00534274|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2014-12-14|2007-09-20|2007-09-24|Estimate|||||||2014-12-14|2014-12-16|Estimate|November 2006||2006-11-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|April 2012|Actual|2012-04-30||Interventional|||Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy|Study of Positron Emission Tomography With 3'-Deoxy-3'-[18F] Fluoro-thymidine ([18F]-FLT) for the Evaluation of Response to Neoadjuvant Chemotherapy for Cancers of the Breast|Completed||N/A|97|Actual|UNICANCER||1|||f||||f||||||||||2018-06-01 02:54:06.193116|2018-06-01 02:54:06.193116
NCT00534261|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-12-11|2007-09-21|2007-09-24|Estimate|||||||2007-12-11|2007-12-13|Estimate|November 1999||1999-11-30|December 2007|2007-12-31|February 2004|Actual|2004-02-29|||||Interventional|FLAIR||Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?|Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®)|Completed||Phase 4|284|Actual|Biogen||1|||f||||t||||||||||2018-06-01 02:54:06.283577|2018-06-01 02:54:06.283577
NCT00534248|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|2011-01-04||2017-03-14|2007-09-21|2007-09-24|Estimate|2011-03-31|2011-05-02|Estimate||||2017-03-14|2017-04-12|Actual|October 2007||2007-10-31|March 2017|2017-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)|A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax™ in Subjects 50-59 Years of Age|Completed||Phase 3|22439|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:54:06.524056|2018-06-01 02:54:06.524056
NCT00534235|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2017-02-02|2007-09-21|2007-09-24|Estimate|||||||2017-02-02|2017-02-06|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Post-Approval Clinical Trial Comparing the Long Term Safety and Effectiveness Coflex vs. Fusion to Treat Lumbar Spinal Stenosis|Post-Approval Study to Investigate The Long Term (5-Year) Survivorship of Coflex Compared to Control Fusion Study Patients|Completed||N/A|396|Actual|Paradigm Spine||2|||f||||t||||||||Undecided||2018-06-01 02:54:07.521419|2018-06-01 02:54:07.521419
NCT00534222|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2011-12-13|2007-09-21|2007-09-24|Estimate|||||||2011-12-13|2011-12-14|Estimate|September 2005||2005-09-30|April 2009|2009-04-30|December 2007|Actual|2007-12-31|||||Observational|UPTAQE||Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect|Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect|Completed|||387|Actual|AstraZeneca|||3||f||||f||||||||||2018-06-01 02:54:07.590245|2018-06-01 02:54:07.590245
NCT00534209|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2013-01-17||2017-09-14|2007-09-20|2007-09-24|Estimate|2013-01-17|2013-02-20|Estimate||||2017-09-14|2017-10-16|Actual|January 2009|Actual|2009-01-31|September 2017|2017-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy|Phase I/II Clinical Trial of Immunotherapy With an Allogeneic B7.1/HLA-A1 Transfected Tumor Cell Vaccine in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer That Have Completed First Line Chemotherapy|Terminated||Phase 1/Phase 2|1|Actual|University of Miami|Study closed early due to low enrollment. A minimum of 2 patients were required for Phase 1, however, this requirement was not met.|2||Per request of Principal Investigator this study was closed.|f||||t||||||||||2018-06-01 02:54:07.668176|2018-06-01 02:54:07.668176
NCT00534196|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-04-16|2007-09-20|2007-09-24|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2005||2005-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 30, 2016|Actual|2016-11-30||Observational|J-POPS||Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer|Japanese Prostate Cancer Outcome Study by Permanent I-125 Seed Implantation [J-POPS]|Active, not recruiting|||6927|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||t||||||||||2018-06-01 02:54:07.881357|2018-06-01 02:54:07.881357
NCT00534183|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|June 2006||2006-06-30|September 2007|2007-09-30|December 2006|Actual|2006-12-31|||||Interventional|MetS||Metabolic Profile and Anthropometric Changes in Schizophrenia|Metabolic Profile and Anthropometric Changes in Schizophrenia|Completed||N/A|2006|Actual|Central Institute of Psychiatry, Ranchi, India||3|||f||||t||||||||||2018-06-01 02:54:08.097809|2018-06-01 02:54:08.097809
NCT00534170|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|January 2008|Anticipated|2008-01-31|||||Interventional|Yakult||Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea|Randomized Controlled Field Trial of a Probiotics to Assess Its Role in The Prevention of Acute Diarrhoeal Diseases in Children|Unknown status|Active, not recruiting|Phase 3|4000|Actual|Indian Council of Medical Research||1|||f||||t||||||||||2018-06-01 02:54:08.172371|2018-06-01 02:54:08.172371
NCT00534157|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|June 2004||2004-06-30|March 2007|2007-03-31|April 2007|Actual|2007-04-30|||||Observational|||Study of Eye Pressure as a Predictor of Intracranial Pressure in the Acutely Head-Injured Population|Intraocular Pressure as a Predictor of Intracranial Pressure in the Acutely Head-Injured Population|Completed|||37|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 02:54:08.253043|2018-06-01 02:54:08.253043
NCT00534144|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2011-09-22|2007-09-20|2007-09-24|Estimate|||||||2011-09-22|2011-09-23|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Comparison Between Effects of Two Iron Preparations on Protein in the Urine|A Randomized Controlled Trial of the Effect of IV Iron on Proteinuria in Non-Dialysis Chronic Kidney Disease Patients|Completed||Phase 1|74|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:54:08.308217|2018-06-01 02:54:08.308217
NCT00534131|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2010-07-27|2007-09-21|2007-09-24|Estimate|||||||2010-07-27|2010-07-28|Estimate|April 2004||2004-04-30|June 2008|2008-06-30|March 2012|Anticipated|2012-03-31|January 2012|Anticipated|2012-01-31||Interventional|APPEAR||Anterior Perineal Plane for Ultra Low Anterior Resection of the Rectum|A Multicentre Trial of the Anterior Perineal PlanE for Ultra Low Anterior Resection of the Rectum (The APPEAR Technique) in the Prevention of Permanent Stoma in Benign and Malignant Disease|Unknown status|Recruiting|N/A|30|Anticipated|Queen Mary University of London||3|||f||||t||||||||||2018-06-01 02:54:08.425047|2018-06-01 02:54:08.425047
NCT00534092|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2011-06-02||2017-12-06|2007-09-21|2007-09-24|Estimate|2011-07-27|2011-07-29|Estimate||||2017-12-06|2018-01-02|Actual|December 2006||2006-12-31|March 2015|2015-03-31|June 2010|Actual|2010-06-30|||||Observational|||Long-Term Outcomes for Lumbar Spinal Stenosis Patients Treated With X STOP®|Long-term Outcomes Among Patients With Lumbar Spinal Stenosis Treated With the X STOP® Interspinous Process Decompression System: Five-Year Follow-up of IDE Patient Cohorts|Completed|||69|Actual|Medtronic Spinal and Biologics|||||f||||f||||||||||2018-06-01 02:54:08.978039|2018-06-01 02:54:08.978039
NCT00534079|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2014-12-03|2007-09-21|2007-09-24|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical Study|Completed||Phase 3|23|Actual|University of Jena||2|||f||||t||||||||||2018-06-01 02:54:09.875791|2018-06-01 02:54:09.875791
NCT00534066|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|September 2002||2002-09-30|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Observational|||Utility of Serial BNP Levels in Emergency Department CHF|The Utility of Serial BNP Levels as a Predictor of Adverse Outcomes in Emergency Department CHF|Completed|||52|Actual|Ohio State University|||2||f||||f||||||||||2018-06-01 02:54:09.948567|2018-06-01 02:54:09.948567
NCT00534053|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-24|Estimate|||||||2007-09-20|2007-09-24|Estimate|June 2007||2007-06-30|September 2007|2007-09-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial|Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial|Unknown status|Recruiting|N/A|800|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-06-01 02:54:09.998293|2018-06-01 02:54:09.998293
NCT00534027|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20||2015-12-14|2015-12-14|2007-09-20|2007-09-24|Estimate||||2015-12-14|2016-01-14|Estimate|2015-12-14|2016-01-14|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer|A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|172|Actual|Amgen||3|||f||||||||||||||2018-06-01 02:54:10.073097|2018-06-01 02:54:10.073097
NCT00534014|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2008-03-31|2007-09-21|2007-09-24|Estimate|||||||2008-03-31|2008-04-03|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|May 2007|Actual|2007-05-31|March 2007|Actual|2007-03-31||Interventional|||Vitamin C and Cardiovascular Risk|Vitamin C Therapy in Type 2 Diabetes and Cardiovascular Risk|Completed||N/A|8|Actual|University of New Mexico||4|||f||||t||||||||||2018-06-01 02:54:10.154191|2018-06-01 02:54:10.154191
NCT00534001|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2017-02-20||2017-04-24|2007-09-20|2007-09-24|Estimate|2017-04-24|2017-05-30|Actual||||2017-04-24|2017-05-30|Actual|January 2006||2006-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|May 2008|Actual|2008-05-31||Interventional|||Bupropion in Helping Adults Stop Smoking|A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation|Completed||Phase 2|95|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 02:54:10.227256|2018-06-01 02:54:10.227256
NCT00533988|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-28|2007-09-21|2007-09-24|Estimate|||||||2007-09-28|2007-10-01|Estimate|January 1996||1996-01-31|September 2007|2007-09-30|December 1999|Actual|1999-12-31|||||Interventional|||Central Venous Catheter-Related Infection|Central Venous Catheter-Related Infection: A Prospective Randomized Double-Blind Study|Completed||Phase 4|118|Actual|University of Witwatersrand, South Africa||2|||f||||f||||||||||2018-06-01 02:54:10.539779|2018-06-01 02:54:10.539779
NCT00533975|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-24|Estimate|||||||2007-09-20|2007-09-24|Estimate|September 2007||2007-09-30|June 2007|2007-06-30|December 2008|Anticipated|2008-12-31|||||Observational|||A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy|A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy|Unknown status|Not yet recruiting||500|Anticipated|University of California, San Diego|||||f||||f||||||||||2018-06-01 02:54:10.606313|2018-06-01 02:54:10.606313
NCT00533962|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|August 2007||2007-08-31|September 2007|2007-09-30||||||||Interventional|||IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients|Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Glaucoma Patients|Unknown status|Active, not recruiting|N/A|30|Actual|Federal University of São Paulo|||||f||||f||||||||||2018-06-01 02:54:10.67294|2018-06-01 02:54:10.67294
NCT00533949|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2017-01-17||2018-04-10|2007-09-20|2007-09-24|Estimate|2017-03-23|2017-05-05|Actual||||2018-04-10|2018-05-09|Actual|November 2007||2007-11-30|April 2018|2018-04-30||||June 2013|Actual|2013-06-30||Interventional||All eligible patients who did not withdraw consent.|High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|544|Actual|Radiation Therapy Oncology Group|Cetuximab arms were added after the study opened, therefore the first 34 patients were excluded from cetuximab analysis. High dose RT arms closed early (at n=474), therefore later patients enrolled to low dose RT arm were excluded from RT analysis.|4|||f||||t||||||||||2018-06-01 02:54:10.801164|2018-06-01 02:54:10.801164
NCT00533936|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2013-08-23|2007-09-20|2007-09-24|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2006||2006-09-30|March 2008|2008-03-31||||December 2009|Anticipated|2009-12-31||Interventional|||Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer|Adjuvant Trastuzumab vs Observation in Locally Advanced Breast Cancer Treated With Neoadjuvant Trastuzumab|Unknown status|Recruiting|Phase 2|160|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:54:12.56247|2018-06-01 02:54:12.56247
NCT00533923|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2016-07-14|2007-09-21|2007-09-24|Estimate|||||||2016-07-14|2016-07-18|Estimate|December 2002||2002-12-31|July 2016|2016-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders|Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders|Completed||Phase 2|25|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||||||2018-06-01 02:54:12.636716|2018-06-01 02:54:12.636716
NCT00533533|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2009-01-12|2007-09-20|2007-09-21|Estimate|||||||2009-01-12|2009-01-14|Estimate|January 2006||2006-01-31|November 2006|2006-11-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|DO for AGC||A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer|A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer|Completed||Phase 1/Phase 2|68|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:54:20.485292|2018-06-01 02:54:20.485292
NCT00533910|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2013-03-19|2007-09-21|2007-09-24|Estimate|||||||2013-03-19|2013-03-20|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Rifaximin in Minimal Hepatic Encephalopathy|Effect of Rifaximin on Driving Performance, Psychometric Test Performance and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy: Randomized, Double-blind, Placebo-controlled Trial.|Completed||N/A|42|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||2|||f||||f||||||||||2018-06-01 02:54:12.707197|2018-06-01 02:54:12.707197
NCT00533897|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2011-01-10||2015-04-22|2007-09-21|2007-09-24|Estimate|2011-05-31|2011-06-03|Estimate||||2015-04-22|2015-04-23|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|December 2008|Actual|2008-12-31||Interventional||All Period 1 Non-responders and Period 2 participants who received at least one dose of abatacept during the study were summarized.|Phase IIIB Subcutaneous Missed Dose Study|A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis|Completed||Phase 3|270|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 02:54:12.953237|2018-06-01 02:54:12.953237
NCT00533884|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2017-04-05|2007-09-20|2007-09-24|Estimate|||||||2017-04-05|2017-04-07|Actual|October 2007||2007-10-31|April 2017|2017-04-30|June 2013|Actual|2013-06-30|May 2010|Actual|2010-05-31||Observational|||Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic|Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers|Completed|||86|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||||2018-06-01 02:54:16.8718|2018-06-01 02:54:16.8718
NCT00533871|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|February 2003||2003-02-28|September 2007|2007-09-30|June 2005|Actual|2005-06-30|||||Observational|||Study to Determine if Serum BNP Levels Are Elevated in Pregnant Women With Pre-Eclampsia|Utilization of Serum BNP to Distinguish Pre-Eclampsia From Hypertension in Pregnancy|Completed|||61|Actual|Ohio State University|||3||f||||f||||||||||2018-06-01 02:54:16.973643|2018-06-01 02:54:16.973643
NCT00533858|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-21|||2008-10-18|2007-09-21|2007-09-24|Estimate|||||||2008-10-18|2008-10-21|Estimate|September 2007||2007-09-30|October 2008|2008-10-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients||Unknown status|Recruiting|Phase 4|160|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 02:54:17.03897|2018-06-01 02:54:17.03897
NCT00533845|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2013-05-25|2007-09-21|2007-09-24|Estimate|||||||2013-05-25|2013-05-29|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery|Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery|Completed||Phase 4|30|Actual|Maimonides Medical Center||2|||f||||f||||||||||2018-06-01 02:54:17.109875|2018-06-01 02:54:17.109875
NCT00533832|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-21|2007-09-21|2007-09-24|Estimate|||||||2007-09-21|2007-09-24|Estimate|July 2000||2000-07-31|September 2007|2007-09-30|July 2005|Actual|2005-07-31|||||Interventional|||Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)|A Multicernter, Pivotal, Safety and Efficacy Study of the NeuroCtybernetic Prosthesis (NCP(R)) System in Patients With Depression|Completed||N/A|266|Actual|Cyberonics, Inc.||2|||f||||t||||||||||2018-06-01 02:54:17.185609|2018-06-01 02:54:17.185609
NCT00533819|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2008-10-14|2007-09-20|2007-09-21|Estimate|||||||2008-10-14|2008-10-15|Estimate|September 2007||2007-09-30|October 2008|2008-10-31|May 2008|Anticipated|2008-05-31|||||Interventional|||Exercise Intervention in Female School Children: Effect on Blood Pressure, Body Mass Index (BMI), and Maths Scores|A Phase II Non Randomized Community Intervention Trial in 4 Public Sectors Schools in Karachi. Exercise Intervention in Female School Children: Effect on Blood Pressure, BMI, and Maths Scores|Unknown status|Recruiting|Phase 2|280|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-06-01 02:54:17.252529|2018-06-01 02:54:17.252529
NCT00533806|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2013-03-07|2007-09-19|2007-09-21|Estimate|||||||2013-03-07|2013-03-11|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder|Family Based Treatment for Early Childhood OCD|Completed||Phase 3|127|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-06-01 02:54:17.334022|2018-06-01 02:54:17.334022
NCT00533793|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2012-03-15|2007-09-20|2007-09-21|Estimate|||||||2012-03-15|2012-03-16|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|TSF||Adjunctive Therapy to Treat Tibial Shaft Fractures|A Phase II Randomized, Controlled, Open-labeled (Dose-blinded) Dose Finding Study of the Safety and Efficacy of I-040202 in the Treatment of Patients With Acute Open Tibial Shaft Fractures|Completed||Phase 2|201|Actual|Kuros Biosurgery AG||4|||f||||f||||||||||2018-06-01 02:54:17.491605|2018-06-01 02:54:17.491605
NCT00533780|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2010-06-01|2007-09-20|2007-09-21|Estimate|||||||2010-06-01|2010-06-02|Estimate|January 2005||2005-01-31|June 2010|2010-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer|Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer|Completed||N/A|200|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 02:54:17.714803|2018-06-01 02:54:17.714803
NCT00533767|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2014-12-05|2007-09-20|2007-09-21|Estimate|||||||2014-12-05|2014-12-08|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Hantavirus Transmission in Households in Chile|Prospective Follow Up of Household Contacts and Hantavirus Transmission Study Among Index and Additional Cases in Chile|Completed|||197|Actual|University of New Mexico|||||f||||f||||||||||2018-06-01 02:54:17.794186|2018-06-01 02:54:17.794186
NCT00533754|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate|July 2006||2006-07-31|September 2007|2007-09-30|November 2007|Anticipated|2007-11-30|||||Interventional|||Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population|Y402H Comlement Factor H Polymorphism and Age-Related Macular Degeneration in the Austrian Population|Unknown status|Active, not recruiting|N/A|||Rudolf Foundation Clinic|||||f||||f||||||||||2018-06-01 02:54:17.874303|2018-06-01 02:54:17.874303
NCT00533741|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2012-11-29|2007-09-20|2007-09-21|Estimate|||||||2012-11-29|2012-12-03|Estimate||||March 2010|2010-03-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||SARS Coronavirus Vaccine (SARS-CoV)|Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV) Vaccine Administered by the Intramuscular Route|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 02:54:17.947527|2018-06-01 02:54:17.947527
NCT00456729|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-05|Estimate|||||||2007-04-04|2007-04-05|Estimate|May 2006||2006-05-31|January 2007|2007-01-31|July 2006|Actual|2006-07-31|||||Interventional|||Malabsorption as a Cause of Iron Treatment Failure in Infants|Malabsorption as a Cause of Iron Treatment Failure in Infants - A Clinical Observational Study|Completed||N/A|100||HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:19:09.194212|2018-06-01 03:19:09.194212
NCT00533728|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2009-03-02|2007-09-20|2007-09-21|Estimate|||||||2009-03-02|2009-03-04|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma|A Phase I Study to Determine the Safety and Effect of Soluble Beta-Glucan (SBG) in Combination With Rituximab and COP/CHOP in Patients With Non'Hodgkin's Lymphoma|Completed||Phase 1|12|Anticipated|Biotec Pharmacon ASA|||||f||||f||||||||||2018-06-01 02:54:18.039697|2018-06-01 02:54:18.039697
NCT00533715|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate|January 2003||2003-01-31|September 2007|2007-09-30|October 2005|Actual|2005-10-31|||||Observational|||Forced Inspiratory Flow Volume Curve in Healthy Young Children|Forced Inspiratory Flow Volume Curve in Healthy Young Children|Completed|||157|Actual|Sheba Medical Center|||1||f||||f||||||||||2018-06-01 02:54:18.100201|2018-06-01 02:54:18.100201
NCT00533702|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|2014-05-16|2010-09-14|2014-07-29|2007-09-19|2007-09-21|Estimate|2014-05-16|2014-06-18|Estimate|2010-09-14|2010-09-16|Estimate|2014-07-29|2014-08-01|Estimate|November 2007||2007-11-30|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||All enrolled participants who were treated with any quantity of study drug.|A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma|Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma|Completed||Phase 2|106|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:54:18.209194|2018-06-01 02:54:18.209194
NCT00533689|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate|January 2008||2008-01-31|September 2007|2007-09-30|January 2010|Anticipated|2010-01-31|||||Interventional|||Study of the Long-Term Effect of Frequent Anti-VEGF Dosing on Retinal Function in Patients With Neovascular AMD||Unknown status|Not yet recruiting|Phase 3|2008|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 02:54:18.978903|2018-06-01 02:54:18.978903
NCT00533676|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2017-02-16|2007-09-19|2007-09-21|Estimate|||||||2017-02-16|2017-02-17|Actual|August 2004||2004-08-31|February 2017|2017-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Endpoint Validation Study (0524A-015)|A Randomized, Double-Blind, Placebo-Controlled Endpoint Selection and Questionnaire Validation Study to Assess the Niacin Induced Flushing Caused by NIASPAN (TM)|Completed||Phase 2|165||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:19.199824|2018-06-01 02:54:19.199824
NCT00533663|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2013-06-03|2007-09-20|2007-09-21|Estimate|||||||2013-06-03|2013-06-05|Estimate|April 2007||2007-04-30|June 2013|2013-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Healing Touch During Chemotherapy Infusions for Women With Breast Cancer|Healing Touch During Chemotherapy Infusions for Women With Breast Cancer|Completed||N/A|32|Actual|Stanford University||3|||f||||||||||||||2018-06-01 02:54:19.491031|2018-06-01 02:54:19.491031
NCT00533650|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2016-07-28|2007-09-19|2007-09-21|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2000||2000-12-31|May 2016|2016-05-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)||Completed||Phase 2|227|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:19.56597|2018-06-01 02:54:19.56597
NCT00533637|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2008-02-29|2007-09-20|2007-09-21|Estimate|||||||2008-02-29|2008-03-05|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|December 2007|Actual|2007-12-31|||||Interventional|||Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis|A Double-Blind, Randomized, Placebo-Controlled, Cross-Over, Allergen Challenge Study to Evaluate Taste and Local Tolerance of NLA Nasal Spray in Patients With Allergic Rhinitis|Completed||Phase 2|28|Actual|Biolipox AB||3|||f||||f||||||||||2018-06-01 02:54:19.644464|2018-06-01 02:54:19.644464
NCT00533624|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-19|2007-09-19|2007-09-21|Estimate|||||||2007-09-19|2007-09-21|Estimate|December 2004||2004-12-31|September 2007|2007-09-30|February 2006|Actual|2006-02-28|||||Interventional|||Myfortic vs. Cellcept in Kidney Transplant Recipients|Head to Head Comparison of Myfortic vs. Cellcept in the Treatment of Kidney Transplant Recipients Using Our Current Center Standardized Concomitant Immunosuppressive Protocol|Completed||Phase 2/Phase 3|150|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 02:54:19.727778|2018-06-01 02:54:19.727778
NCT00533611|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2017-02-16|2007-09-19|2007-09-21|Estimate|||||||2017-02-16|2017-02-17|Actual|April 2007||2007-04-30|February 2017|2017-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effect of MK0524A on Flushing Caused by Niacin (0524A-056)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients|Completed||Phase 3|330||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:19.815014|2018-06-01 02:54:19.815014
NCT00533598|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2016-09-06|2007-09-20|2007-09-21|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2002||2002-09-30|September 2016|2016-09-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)||Completed||Phase 2|||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:19.883129|2018-06-01 02:54:19.883129
NCT00533585|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2016-02-09|2007-09-20|2007-09-21|Estimate|||||||2016-02-09|2016-02-10|Estimate|May 2006||2006-05-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:54:19.930284|2018-06-01 02:54:19.930284
NCT00533572|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2015-05-22|2007-09-20|2007-09-21|Estimate|||||||2015-05-22|2015-05-27|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer|Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer|Terminated|||1|Actual|Stanford University||||"Study was suspended until FDA approved the IND. Study has since been terminated and a new~   screening process has been implemented."|f||||||||||||||2018-06-01 02:54:20.033054|2018-06-01 02:54:20.033054
NCT00533559|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2010-06-24|2007-09-19|2007-09-21|Estimate|||||||2010-06-24|2010-06-25|Estimate|September 2007||2007-09-30|August 2007|2007-08-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl|Mechanism of Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion - Effect of Buphenyl|Completed||Phase 4|10|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:54:20.110279|2018-06-01 02:54:20.110279
NCT00533546|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2015-10-16||2016-09-01|2007-09-19|2007-09-21|Estimate|2016-09-01|2016-10-24|Estimate||||2016-09-01|2016-10-24|Estimate|September 2007||2007-09-30|September 2016|2016-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|APCAST||Activated Protein C in Acute Stroke Trial|Activated Protein C in Acute Stroke Trial|Terminated||Phase 2|12|Actual|University of Rochester|Study was terminated after completion of Tier One dosing level (n=12 subjects) due to lack of recruitment.|1||Lack of recruitment|f||||t||||||||||2018-06-01 02:54:20.215212|2018-06-01 02:54:20.215212
NCT00533507|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2009-06-05||2016-10-27|2007-09-20|2007-09-21|Estimate|2009-06-05|2009-07-24|Estimate||||2016-10-27|2016-12-09|Estimate|September 2007||2007-09-30|October 2016|2016-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix|Completed||Phase 3|230|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:54:20.656633|2018-06-01 02:54:20.656633
NCT00533494|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-11-11|2007-09-20|2007-09-21|Estimate|||||||2007-11-11|2007-11-14|Estimate|January 2000||2000-01-31|April 2003|2003-04-30|September 2003|Actual|2003-09-30|||||Interventional|||The Effect of Patients' Participation in Improving Diabetes Care||Completed||Phase 3|||Soroka University Medical Center||2|||f||||f||||||||||2018-06-01 02:54:21.013599|2018-06-01 02:54:21.013599
NCT00533481|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2016-09-15|2007-09-19|2007-09-21|Estimate|||||||2016-09-15|2016-09-16|Estimate|February 2004||2004-02-29|September 2016|2016-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)||Completed||Phase 2|497|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:21.112283|2018-06-01 02:54:21.112283
NCT00533468|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2011-03-23|2007-09-19|2007-09-21|Estimate|||||||2011-03-23|2011-03-24|Estimate|March 2007||2007-03-31|March 2011|2011-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||"Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."|"Lidocaine 4% Cream (LMX4) vs Placebo for Pain Due to Lumbar Puncture in Infants 0-60 Days of Age."|Completed||Phase 4|70|Actual|State University of New York at Buffalo|||||f||||t||||||||||2018-06-01 02:54:21.157217|2018-06-01 02:54:21.157217
NCT00533455|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-21|2007-09-19|2007-09-21|Estimate|||||||2007-09-21|2007-09-24|Estimate|March 2004||2004-03-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Gabapentin for the Treatment of Neuroleptic-Induced Tremor|A 4 Week, Parallel-Design, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Treatment of Neuroleptic-Induced Tremor: Clinical and Instrumental Ratings of Outcome.|Terminated||Phase 3|40|Anticipated|Minneapolis Veterans Affairs Medical Center||||Failure to recruit due to polypharmacy|f||||f||||||||||2018-06-01 02:54:21.470764|2018-06-01 02:54:21.470764
NCT00533442|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2017-03-06||2017-06-12|2007-09-19|2007-09-21|Estimate|2017-06-12|2017-07-12|Actual||||2017-06-12|2017-07-12|Actual|September 2000||2000-09-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients|Tacrolimus and Mycophenolate Mofetil vs Tacrolimus and Sirolimus in SPK, Pancreas After Kidney or Pancreas Transplant Alone|Completed||Phase 2|170|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 02:54:21.734912|2018-06-01 02:54:21.734912
NCT00533429|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19||2010-02-16|2010-02-16|2007-09-19|2007-09-21|Estimate||||2010-02-16|2010-02-18|Estimate|2010-02-16|2010-02-18|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy|Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer|Completed||Phase 2|40|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:54:22.157637|2018-06-01 02:54:22.157637
NCT00533416|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-05-18|2007-09-20|2007-09-21|Estimate|||||||2018-05-18|2018-05-21|Actual|September 14, 2007||2007-09-14|April 27, 2016|2016-04-27|June 4, 2012|Actual|2012-06-04|June 4, 2012|Actual|2012-06-04||Interventional|||Safety of ON 01910.Na in Patients With Myelodysplasia|A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8|Completed||Phase 1|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:54:22.320075|2018-06-01 02:54:22.320075
NCT00533403|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2015-06-25|2007-09-19|2007-09-21|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2004||2004-07-31|June 2015|2015-06-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||MK0686 in Postsurgery Dental Pain (0686-002)||Completed||Phase 2|114|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:22.410262|2018-06-01 02:54:22.410262
NCT00533390|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2015-11-07|2007-09-20|2007-09-21|Estimate|||||||2015-11-07|2015-11-10|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|IPEC-EFV||Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg|Anti-retroviral Efficacy, Tolerance and Other Pharmacologic Interactions of the Non Nucleoside Analog Efavirenz in Association With Rifampicin to Treat Tuberculosis and AIDS|Terminated||Phase 4|130|Actual|Oswaldo Cruz Foundation||2||Lack of financial support and low inclusion rate|f||||f||||||||||2018-06-01 02:54:22.516132|2018-06-01 02:54:22.516132
NCT00533377|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20||2012-02-15|2012-02-15|2007-09-20|2007-09-21|Estimate||||2012-02-15|2012-02-17|Estimate|2012-02-15|2012-02-17|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||ACTiF- Assessment of Closed Tibial Fractures|A Randomized, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of CP-533,536 In Subjects With Closed Fracture Of The Tibial Shaft|Completed||Phase 2|276|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 02:54:22.676347|2018-06-01 02:54:22.676347
NCT00533364|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2010-02-17|2007-09-20|2007-09-21|Estimate|||||||2010-02-17|2010-02-18|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Effect of SBG in Patients With Breast Cancer|A Phase I/II Study to Assess the Effect of Soluble Beta-1,3/1,6-glucan in Combination With Standard Therapy in Patients With Breast Cancer|Completed||Phase 1/Phase 2|11|Actual|Biotec Pharmacon ASA|||||f||||||||||||||2018-06-01 02:54:22.860456|2018-06-01 02:54:22.860456
NCT00533351|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2011-12-15||2016-01-27|2007-09-19|2007-09-21|Estimate|2011-12-15|2012-01-19|Estimate||||2016-01-27|2016-02-24|Estimate|March 2008||2008-03-31|January 2016|2016-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy of AGN201781 in Neuropathic Pain||Terminated||Phase 2|9|Actual|Allergan|This study was terminated early due to low enrollment (only 9 of the required 40 subjects had been enrolled). Due to the low number of patients who completed the treatment period of the study, no analyses were performed.|2||This study was terminated early due to low enrollment.|f||||f||||||||||2018-06-01 02:54:22.937555|2018-06-01 02:54:22.937555
NCT00533338|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2017-10-04|2007-09-19|2007-09-21|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2007|Actual|2007-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Weight Gain Prevention for Breast Cancer Survivors|Weight Gain Prevention for Breast Cancer Survivors|Active, not recruiting||N/A|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:54:23.136691|2018-06-01 02:54:23.136691
NCT00533312|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2017-04-05|2007-09-19|2007-09-21|Estimate|||||||2017-04-05|2017-04-07|Actual|April 2005||2005-04-30|March 2017|2017-03-31|January 2007|Actual|2007-01-31|July 2005|Actual|2005-07-31||Interventional|||MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)|A Multicenter, Randomized, Double-Blinded, Parallel-Design Study to Evaluate the Lipid-Altering Efficacy of 2 Formulations of MK0524A Compared to NIASPAN (TM)|Completed||Phase 2|407|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:23.215393|2018-06-01 02:54:23.215393
NCT00533299|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Hydralazine Valproate for Ovarian Cancer|Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer.|Unknown status|Recruiting|Phase 3|211|Anticipated|National Institute of Cancerología||2|||f||||t||||||||||2018-06-01 02:54:23.281671|2018-06-01 02:54:23.281671
NCT00533286|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate|August 2002||2002-08-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||Do Benzodiazepines Improve the Outcome of Mechanical Physiotherapy for Lumbar Disk Prolapse|Do Benzodiazepines Improve the Outcome of Mechanical Physiotherapy for Lumbar Disk Prolapse: a Prospective Randomized Clinical Trial|Completed||Phase 2|||University Hospital Tuebingen||2|||f||||t||||||||||2018-06-01 02:54:23.351715|2018-06-01 02:54:23.351715
NCT00533273|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2010-09-24||2017-10-26|2007-09-20|2007-09-21|Estimate|2010-09-24|2010-10-22|Estimate||||2017-10-26|2017-12-02|Actual|August 2007|Actual|2007-08-31|October 2017|2017-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|CORD-II||Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease Followed by an Open-Label Extension Phase|Completed||Phase 3|66|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:54:23.443297|2018-06-01 02:54:23.443297
NCT00533260|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2010-12-07|2007-09-20|2007-09-21|Estimate|||||||2010-12-07|2010-12-09|Estimate|July 2007||2007-07-31|December 2010|2010-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|SEQUEL||A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)|A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel®|Completed|||128|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:54:24.108102|2018-06-01 02:54:24.108102
NCT00533247|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate||||September 2007|2007-09-30||||||||Interventional|||Arthroplasty Inflammation Prophylaxis With Celecoxib|Preemptive Anti-Inflammatory Use of Celecoxib in Knee Arthroplasty Surgery: a Double Blinded, Placebo-Controlled Study.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Zanbilowicz, Adam, DPM MS|||||f||||t||||||||||2018-06-01 02:54:24.278511|2018-06-01 02:54:24.278511
NCT00533234|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2017-06-19|2007-09-20|2007-09-21|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2009||2009-12-31|June 2017|2017-06-30|June 2010|Actual|2010-06-30|||||Observational|||ExploR® Modular Radial Head Data Collection|ExploR® Modular Radial Head Data Collection|Terminated|||4|Actual|Zimmer Biomet||||There was a lack of business need to continue this data collection.|f||||f||||||||||2018-06-01 02:54:24.347882|2018-06-01 02:54:24.347882
NCT00533221|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2013-12-17|2007-09-20|2007-09-21|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2007||2007-10-31|December 2013|2013-12-31|August 2011|Actual|2011-08-31|February 2010|Actual|2010-02-28||Interventional|||Pilot Study of Growth Hormon to Treat SMA Typ II and III|Can Treatment With Human Growth Hormone Increase Strength in Spinal Muscular Atrophy Type II and III?|Completed||Phase 2|20|Actual|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 02:54:24.417601|2018-06-01 02:54:24.417601
NCT00533208|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2015-12-21|2007-09-19|2007-09-21|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2003||2003-07-31|December 2015|2015-12-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)||Completed||Phase 2|766|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:54:24.507307|2018-06-01 02:54:24.507307
NCT00533195|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2009-01-13|2007-09-19|2007-09-21|Estimate|||||||2009-01-13|2009-01-14|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis|UVA1 Phototherapy Versus 5-MOP UVA Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis|Completed||Phase 3|20|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:54:24.555563|2018-06-01 02:54:24.555563
NCT00533182|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-05-23|2007-09-20|2007-09-21|Estimate|||||||2018-05-23|2018-05-24|Actual|September 19, 2007||2007-09-19|January 3, 2018|2018-01-03||||||||Observational|||Influenza in People With Normal and Weakened Immune Systems|Influenza in the Non-immunocompromised and Immunocompromised Host|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:54:24.634611|2018-06-01 02:54:24.634611
NCT00533169|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2011-12-13|2007-09-19|2007-09-21|Estimate|||||||2011-12-13|2011-12-15|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma|A Phase I Study of ZD6474 (Zactima) Alone and in Combination With Retinoic Acid in Relapsed and Refractory Pediatric Neuroblastoma|Terminated||Phase 1|10|Actual|M.D. Anderson Cancer Center||1||Lack of enrollment.|f||||f||||||||||2018-06-01 02:54:24.71432|2018-06-01 02:54:24.71432
NCT00533156|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2012-02-27|2007-09-20|2007-09-21|Estimate|||||||2012-02-27|2012-02-28|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|August 2007|Actual|2007-08-31|||||Interventional|PACS 7F||Plug Arterial Closure System (PACS, 7F)|Feasibility Study of the 7F Ensure Medical Plug Arterial Closure System (PACS, 7F)|Completed||Phase 2|30|Actual|Cordis Corporation|||||f||||f||||||||||2018-06-01 02:54:24.800902|2018-06-01 02:54:24.800902
NCT00533143|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2012-07-16|2007-09-20|2007-09-21|Estimate|||||||2012-07-16|2012-07-17|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Non-invasive Ventilation in Terminally Ill Cancer Patients|Multicenter, Randomised Study of the Use of Non-Invasive Ventilation (NIV) Versus Oxygen Therapy (O2) in Reducing Dyspnea in End-stage Solid Cancer Patients With Respiratory Failure and Distress|Completed||Phase 4|200|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t||||||||||2018-06-01 02:54:24.880643|2018-06-01 02:54:24.880643
NCT00533130|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate|August 2007||2007-08-31|September 2007|2007-09-30|July 2008|Anticipated|2008-07-31|||||Observational|AO-PC||Evaluation of the AO Pediatric Classification for Long Bones Fractures Like a Guide for Treatment and Prognosis|Phase 2/3 Eficacy Study of the AO Pediatric Classification in Treatment and Prognosis of Long Bones Fractures|Unknown status|Recruiting||100|Anticipated|Hospital Cruz Roja Mexicana|||1||f||||t||||||||||2018-06-01 02:54:24.96109|2018-06-01 02:54:24.96109
NCT00533117|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2016-10-06||2017-07-24|2007-09-19|2007-09-21|Estimate|2017-07-24|2017-08-28|Actual||||2017-07-24|2017-08-28|Actual|March 2001||2001-03-31|July 2017|2017-07-31|December 2012|Actual|2012-12-31|January 2008|Actual|2008-01-31||Interventional||Suicidal and/or self injuring individuals with borderline personality disorder.|Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder|Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder|Completed||Phase 4|91|Actual|New York State Psychiatric Institute||4|||f||||t||||||||No||2018-06-01 02:54:25.058067|2018-06-01 02:54:25.058067
NCT00533104|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2009-02-05|2007-09-19|2007-09-21|Estimate|||||||2009-02-05|2009-02-06|Estimate|October 2004||2004-10-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Cell Therapy in Chronic Limb Ischemia|Critical Limb Ischemia Treatment by Local Intra-Muscular Injection of Autologous Mononuclear Cells|Completed||Phase 1/Phase 2|40|Actual|CHU de Reims||2|||f||||t||||||||||2018-06-01 02:54:25.304802|2018-06-01 02:54:25.304802
NCT00533091|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2012-05-25|2007-09-20|2007-09-21|Estimate|||||||2012-05-25|2012-05-28|Estimate|April 2008||2008-04-30|May 2012|2012-05-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis|A Phase 1B, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Safety of Multiple-Dose, Intravenously Administered MEDI-545, A Fully Human Anti Interferon-Alpha Monoclonal Antibody, In Adult Patients With Dermatomyositis or Polymyositis|Completed||Phase 1|51|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 02:54:25.395678|2018-06-01 02:54:25.395678
NCT00533078|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2015-07-22|2007-09-19|2007-09-21|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2007||2007-11-30|July 2015|2015-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|LUNCH1||Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies|Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies (LUNCH1)|Completed||Phase 2|14|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 02:54:25.492766|2018-06-01 02:54:25.492766
NCT00533065|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2009-08-06|2007-09-19|2007-09-21|Estimate|||||||2009-08-06|2009-08-07|Estimate|September 2007||2007-09-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|GH-003||Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone|Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone|Completed||N/A|80|Actual|Ludwig Boltzmann Gesellschaft|||||f||||f||||||||||2018-06-01 02:54:25.559137|2018-06-01 02:54:25.559137
NCT00533052|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2018-03-12|2007-09-20|2007-09-21|Estimate|||||||2018-03-12|2018-03-14|Actual|October 2007|Actual|2007-10-31|March 2018|2018-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment|Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment|Completed||N/A|21|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t|f|f||||||||2018-06-01 02:54:25.648827|2018-06-01 02:54:25.648827
NCT00533039|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2009-10-08|2007-09-20|2007-09-21|Estimate|||||||2009-10-08|2009-10-09|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SPIDER-PCI||sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial|sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial|Completed||Phase 2|164|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 02:54:25.741031|2018-06-01 02:54:25.741031
NCT00533026|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2008-09-26|2007-09-19|2007-09-21|Estimate|||||||2008-09-26|2008-10-02|Estimate|July 2007||2007-07-31|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Duloxetine - Warfarin Pharmacodynamic Study|Evaluation of the Effect of Duloxetine on the Pharmacodynamics of Warfarin at Steady-State in Healthy Subjects|Completed||Phase 1|60|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:54:25.815372|2018-06-01 02:54:25.815372
NCT00533013|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2013-04-25|2007-09-20|2007-09-21|Estimate|||||||2013-04-25|2013-04-26|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Comprehensive Heart Failure Disease Management Community Program|Comprehensive Program for Disease Management in Heart Failure Patients in the Community|Completed||N/A|1360|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 02:54:25.887957|2018-06-01 02:54:25.887957
NCT00533000|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2008-06-10|2007-09-19|2007-09-21|Estimate|||||||2008-06-10|2008-06-11|Estimate|January 2004||2004-01-31|September 2007|2007-09-30|January 2008|Anticipated|2008-01-31|||||Interventional|||Smoking Cessation and Postoperative Complications|Short Term Perioperative Smoking Cessation and the Effect on Postoperative Complications. A Randomized Clinical Trial.|Unknown status|Active, not recruiting|N/A|584|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 02:54:25.950509|2018-06-01 02:54:25.950509
NCT00532987|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2012-02-24|2007-09-20|2007-09-21|Estimate|||||||2012-02-24|2012-02-28|Estimate|December 2003||2003-12-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer|Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer|Terminated|||22|Actual|Stanford University|||||f||||t||||||||||2018-06-01 02:54:26.006948|2018-06-01 02:54:26.006948
NCT00532974|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-12-19|2007-09-20|2007-09-21|Estimate|||||||2007-12-19|2007-12-24|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|April 2008|Anticipated|2008-04-30|||||Interventional|EP1090||A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)|A Phase 1 Safety and Immunogenicity Study of the Pharmexa-Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) Administered Using a Biojector 2000 Needle Free Immunization Device in HIV-1 Infected Individuals Receiving Potent Combination Antiretroviral Therapy (ART)|Unknown status|Active, not recruiting|Phase 1|32|Anticipated|Epimmune|||||f||||t||||||||||2018-06-01 02:54:26.063853|2018-06-01 02:54:26.063853
NCT00532961|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2011-12-07|2007-09-20|2007-09-21|Estimate|||||||2011-12-07|2011-12-08|Estimate|February 2005||2005-02-28|December 2011|2011-12-31|June 2005|Actual|2005-06-30|April 2005|Actual|2005-04-30||Interventional|||Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex|A Randomized, Double-masked, Parallel Comparison of Ocular Tolerance and IOP Effects of Zylet vs TobraDex Administered Four Times Daily for Four Weeks in Healthy Volunteers|Completed||Phase 4|310|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 02:54:26.1282|2018-06-01 02:54:26.1282
NCT00532948|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2015-12-28||2016-10-25|2007-09-20|2007-09-21|Estimate|2016-02-17|2016-03-15|Estimate||||2016-10-25|2016-12-07|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||Intent to treat population defined as all participants enrolled.|A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas|A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas and High Grade Gliomas|Completed||Phase 1|24|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:54:26.289649|2018-06-01 02:54:26.289649
NCT00532935|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2010-09-23||2017-05-11|2007-09-20|2007-09-21|Estimate|2010-09-23|2010-10-18|Estimate||||2017-05-11|2017-06-09|Actual|January 26, 2008|Actual|2008-01-26|May 2017|2017-05-31|October 23, 2009|Actual|2009-10-23|October 23, 2009|Actual|2009-10-23||Interventional|||MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)|A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of the MK0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|517|Actual|Merck Sharp & Dohme Corp.|Unknown to the Sponsor and the investigators, two patients in the study were randomized twice (each at two different sites). Data for these patients were deemed unreliable and excluded from all analyses (efficacy and safety).|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:54:27.096167|2018-06-01 02:54:27.096167
NCT00532922|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2009-06-08|2007-09-20|2007-09-21|Estimate|||||||2009-06-08|2009-06-09|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|November 2007|Actual|2007-11-30|||||Observational|Symb NIS||A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®|A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®|Completed|||310|Actual|AstraZeneca|||1||f||||t||||||||||2018-06-01 02:54:27.78322|2018-06-01 02:54:27.78322
NCT00532909|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2012-07-12|2007-09-20|2007-09-21|Estimate|||||||2012-07-12|2012-07-16|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer|A Phase I Trial of Vandetanib Combined With Capecitabine, Oxaliplatin and Bevacizumab for the First-Line Treatment of Metastatic Colorectal Cancer|Completed||Phase 1|13|Actual|Stanford University|||||f||||||||||||||2018-06-01 02:54:27.883581|2018-06-01 02:54:27.883581
NCT00532896|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2012-02-20|2007-09-19|2007-09-21|Estimate|||||||2012-02-20|2012-02-22|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Observational|||Impact of Weight Loss Following Bariatric Surgery on Pulmonary Function in Patients With Morbid Obesity|Impact of Weight Loss Following Bariatric Surgery on Pulmonary Function in Patients With Morbid Obesity|Completed|||60|Actual|Laval University|||2||f||||f||||||Samples Without DNA|"~     serum plasma~   "|||2018-06-01 02:54:27.981004|2018-06-01 02:54:27.981004
NCT00532883|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|2010-04-01||2013-01-14|2007-09-20|2007-09-21|Estimate|2010-04-21|2010-05-11|Estimate||||2013-01-14|2013-01-18|Estimate|January 2007||2007-01-31|January 2010|2010-01-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease|Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial|Terminated||Phase 2|44|Actual|St. Jude Children's Research Hospital|This study was stopped early due to slow enrollment. It should therefore be viewed as a pilot study.|4||Enrollment has been terminated due to a slow rate of enrollment.|f||||t||||||||||2018-06-01 02:54:28.131744|2018-06-01 02:54:28.131744
NCT00532870|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-20|||2007-09-20|2007-09-20|2007-09-21|Estimate|||||||2007-09-20|2007-09-21|Estimate|March 2003||2003-03-31|September 2007|2007-09-30|December 2004|Actual|2004-12-31|||||Interventional|||Laparoscopic Intraperitoneal Mesh Repair of Ventral Hernia: Comparison to Conventional Mesh Repair||Completed||N/A|||Mansoura University||1|||f||||t||||||||||2018-06-01 02:54:28.847262|2018-06-01 02:54:28.847262
NCT00532857|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2012-01-01|2007-09-19|2007-09-20|Estimate|||||||2012-01-01|2012-01-04|Estimate|March 2007||2007-03-31|January 2012|2012-01-31|September 2011|Actual|2011-09-30|February 2008|Actual|2008-02-29||Interventional|PGH||Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab|Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab in Patients With HER2 Positive Operable Breast Cancer|Completed||Phase 2|53|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 02:54:28.912076|2018-06-01 02:54:28.912076
NCT00532844|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2014-12-15|2007-09-18|2007-09-20|Estimate|||||||2014-12-15|2014-12-17|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||A Phase 2, Pharmacokinetic Study of the Effects of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction|A Phase 2, Randomized, Open-label, 2-Treatment, 2-Sequence, 2-Period Crossover, Pharmacokinetic (PK) Study to Compare the Plasma Concentrations of BH4 in Subjects With Endothelial Dysfunction Following 14 Days of Treatment by Each of 2 Regimens: 6R-BH4 With Vitamin C and 6R-BH4 Alone|Completed||Phase 2|52|Actual|BioMarin Pharmaceutical||2|||f||||f||||||||||2018-06-01 02:54:29.008128|2018-06-01 02:54:29.008128
NCT00532831|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2012-02-20|2007-09-18|2007-09-20|Estimate|||||||2012-02-20|2012-02-22|Estimate|August 2005||2005-08-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|||||Observational|||Characterisation of Asthma in Obese Subjects|Characterisation of Asthma in Obese Subjects. Relationships Between Asthma and Obesity, Potential Mechanisms by Which Obesity Can Contribute to Asthma and Modify Treatment Responses|Completed|||44|Actual|Laval University|||2||f||||f||||||Samples Without DNA|"~     serum plasma~   "|||2018-06-01 02:54:29.079217|2018-06-01 02:54:29.079217
NCT00532818|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2009-03-27|2007-09-18|2007-09-20|Estimate|||||||2009-03-27|2009-03-30|Estimate|July 2007||2007-07-31|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||Hydralazine Valproate for Cervical Cancer|Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.|Unknown status|Recruiting|Phase 3|143|Anticipated|National Institute of Cancerología||2|||f||||t||||||||||2018-06-01 02:54:29.161865|2018-06-01 02:54:29.161865
NCT00532805|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2018-01-21|2007-09-18|2007-09-20|Estimate|||||||2018-01-21|2018-01-23|Actual|August 2007||2007-08-31|January 2018|2018-01-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Observational|QUANTUM-1||The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency|QUANTitative Chest Computed Tomography UnMasking Emphysema Progression in Alpha-1 Antitrypsin Deficiency|Completed|||49|Actual|Medical University of South Carolina|||||f||||t||||||Samples With DNA|"~     50 cc of serum at visits baseline, 6 months, 12 months, 18 months, 24 months and 36 months~     will be retained. These are kept at the University of Florida in the laboratory of Dr. Mark~     Brantly.~      There is an associated but independent DNA collection that is done if the patient is willing~     through an independent study and consent process with the University of Florida Alpha-1 DNA~     and Tissue Bank. This is a public resource with a scientific advisory committee with samples~     available for researcher access.~   "|||2018-06-01 02:54:29.262819|2018-06-01 02:54:29.262819
NCT00532792|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2012-03-13|2007-09-19|2007-09-20|Estimate|||||||2012-03-13|2012-03-14|Estimate|August 2007||2007-08-31|January 2012|2012-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A/H5N1 Dose Ranging Study With Adjuvant Patch|A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Administered With and Without an Adjuvant Patch in Healthy Adults|Completed||Phase 1|501|Actual|Intercell USA, Inc.||10|||f||||t||||||||||2018-06-01 02:54:29.363804|2018-06-01 02:54:29.363804
NCT00532779|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2014-10-20|2012-10-31|2014-11-18|2007-09-19|2007-09-20|Estimate|2014-11-18|2014-11-21|Estimate|2012-10-31|2012-11-02|Estimate|2014-11-18|2014-11-21|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||All randomized subjects|A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects|A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects|Completed||Phase 3|1742|Actual|Orexigen Therapeutics, Inc||3|||f||||t||||||||||2018-06-01 02:54:29.561778|2018-06-01 02:54:29.561778
NCT00532766|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-24|2007-09-19|2007-09-20|Estimate|||||||2007-09-24|2007-09-26|Estimate|November 2006||2006-11-30|September 2007|2007-09-30|February 2007|Actual|2007-02-28|||||Interventional|||Evaluating Pharmacokinetics and Pharmacodynamics of Jusline|Bioequivalence of Jusline Following Subcutaneous Administration in Healthy Subjects|Completed||N/A|20|Actual|King Saud University||1|||f||||t||||||||||2018-06-01 02:54:31.708973|2018-06-01 02:54:31.708973
NCT00532753|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2008-07-31|2007-09-18|2007-09-20|Estimate|||||||2008-07-31|2008-08-04|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|May 2016|Anticipated|2016-05-31|August 2010||2010-08-31||Interventional|||Evaluating the Hunger Project in Ghana|Evaluating the Hunger Project's Scaling-up of Epicenter Strategy in Ghana|Unknown status|Recruiting|Early Phase 1|20000|Anticipated|University of California, Berkeley|||||f||||||||||||||2018-06-01 02:54:31.783271|2018-06-01 02:54:31.783271
NCT00532740|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2018-01-04|2007-09-18|2007-09-20|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2004||2004-12-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery|A Humanitarian Device Exemption Compassionate Use Protocol of TheraSphere for Treatment of Unresectable Metastatic Cancer to the Liver|Recruiting|||2000|Anticipated|Northwestern University|||1||f||||t||||||||||2018-06-01 02:54:31.875298|2018-06-01 02:54:31.875298
NCT00532727|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2017-03-30|2007-09-19|2007-09-20|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2008|Actual|2008-01-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|March 2016|Actual|2016-03-31||Interventional|TNT||Triple Negative Breast Cancer Trial|Triple Negative Trial: A Randomised Phase III Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic or Recurrent Locally Advanced ER-, PR- and HER2- Breast Cancer.|Active, not recruiting||Phase 3|400|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-06-01 02:54:31.975086|2018-06-01 02:54:31.975086
NCT00532714|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2011-12-27|2007-09-19|2007-09-20|Estimate|||||||2011-12-27|2011-12-30|Estimate|August 2006||2006-08-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|April 2008|Actual|2008-04-30||Interventional|||Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC|Phase II Study of Irinotecan Plus Capecitabine in Patients With Antracycline and Taxane Pretreated Metastatic Breast Cancer|Completed||Phase 2|36|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 02:54:32.05775|2018-06-01 02:54:32.05775
NCT00532701|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2014-06-03|2007-09-18|2007-09-20|Estimate|||||||2014-06-03|2014-06-04|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR|Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response|Completed||Phase 4|880|Actual|National Taiwan University Hospital||5|||f||||t||||||||||2018-06-01 02:54:32.256094|2018-06-01 02:54:32.256094
NCT00532688|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-19|2007-09-19|2007-09-20|Estimate|||||||2007-09-19|2007-09-20|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|February 2008|Anticipated|2008-02-29|||||Interventional|||N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure|Randomised Control Pilot Trial of n-Acetylcysteine in the Treatment of Chronic Heart Failure With Coexistent Chronic Renal Failure.|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Bayside Health||2|||f||||f||||||||||2018-06-01 02:54:32.394556|2018-06-01 02:54:32.394556
NCT00532675|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2017-10-13|2007-09-18|2007-09-20|Estimate|||||||2017-10-13|2017-10-16|Actual|April 22, 2008|Actual|2008-04-22|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.|A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Oral Lenalidomide & Dexamethasone in Adult Patients With Multiple Myeloma|Active, not recruiting||Phase 1|46|Actual|Novartis||1|||f||||f|t|f||||||Undecided||2018-06-01 02:54:32.497996|2018-06-01 02:54:32.497996
NCT00532662|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2010-11-17|2007-09-19|2007-09-20|Estimate|||||||2010-11-17|2010-11-18|Estimate|November 2007||2007-11-30|November 2010|2010-11-30|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|||Postoperative Analgesia by Epidural vs IV Ketamine Concurrent With Caudal Anesthesia in Pediatric Orthopedic Surgery|Intravenous Versus Caudal Supplementation of Ketamine for Postoperative Pain Control in Children,A Double-blind Controlled Clinical Trial.|Unknown status|Recruiting|Phase 4|40|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:54:32.579081|2018-06-01 02:54:32.579081
NCT00532636|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2009-03-25|2007-09-19|2007-09-20|Estimate|||||||2009-03-25|2009-03-26|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|December 2006|Actual|2006-12-31|||||Interventional|||Head Position Angles in Children|Head Position Angles in Children to Open the Upper Airway|Terminated||N/A|78|Actual|Medical University Innsbruck||2||Recruitment completed|f||||t||||||||||2018-06-01 02:54:32.666036|2018-06-01 02:54:32.666036
NCT00532623|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2011-06-24|2007-09-19|2007-09-20|Estimate|||||||2011-06-24|2011-06-27|Estimate|May 2004||2004-05-31|September 2007|2007-09-30|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer|A Phase II Study of Gemcitabine in Combination With Vinorelbine vs. Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer|Completed||Phase 2|82|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 02:54:32.74004|2018-06-01 02:54:32.74004
NCT00532610|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2012-03-15|2007-09-18|2007-09-20|Estimate|||||||2012-03-15|2012-03-19|Estimate|September 2007||2007-09-30|February 2011|2011-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults|A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial to Investigate the Effect of GSK189075 on Cardiac Repolarization as Compared to Placebo and a Single Dose of Moxifloxacin in Healthy Adult Subjects|Completed||Phase 1|78|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 02:54:32.814994|2018-06-01 02:54:32.814994
NCT00532246|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-20|Estimate|||||||2007-09-18|2007-09-20|Estimate|March 2003||2003-03-31|September 2007|2007-09-30|August 2003|Actual|2003-08-31|||||Interventional|||Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo|A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo|Completed||Phase 4|147|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:54:38.814198|2018-06-01 02:54:38.814198
NCT00532597|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-19|2007-09-19|2007-09-20|Estimate|||||||2007-09-19|2007-09-20|Estimate|April 2007||2007-04-30|September 2007|2007-09-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients|Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients|Unknown status|Recruiting|Phase 4|20|Anticipated|Eulji General Hospital||2|||f||||t||||||||||2018-06-01 02:54:32.907698|2018-06-01 02:54:32.907698
NCT00532584|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2016-05-03|2007-09-19|2007-09-20|Estimate|||||||2016-05-03|2016-05-04|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Steroids on Gene Expression in the Healthy Smokers Lungs|Effect of Inhaled Steroids in Combination With a Long Acting Bronchodilator on Gene Expression in the Lungs of Healthy Smokers|Withdrawn||Phase 4|0|Actual|Weill Medical College of Cornell University||3||Study not initiated due to funding.|f||||f||||||||Undecided||2018-06-01 02:54:32.996996|2018-06-01 02:54:32.996996
NCT00532571|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-19|2007-09-19|2007-09-20|Estimate|||||||2007-09-19|2007-09-20|Estimate|January 2004||2004-01-31|September 2007|2007-09-30|September 2005||2005-09-30|||||Interventional|||Effects of Coenzyme Q10 in PSP and CBD|Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study|Completed||Phase 2/Phase 3|||Lahey Clinic|||||f||||f||||||||||2018-06-01 02:54:33.10255|2018-06-01 02:54:33.10255
NCT00532558|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2012-05-23|2007-09-18|2007-09-20|Estimate|||||||2012-05-23|2012-05-24|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg vs Placebo in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension|Terminated||Phase 3|657|Actual|Takeda||2||"Overall profile of the compound does not offer significant clinical advantage to patients over~   currently available lipid lowering agents"|f||||f||||||||||2018-06-01 02:54:33.186903|2018-06-01 02:54:33.186903
NCT00532545|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-20|Estimate|||||||2007-09-18|2007-09-20|Estimate|April 2003||2003-04-30|September 2007|2007-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis|Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis|Completed||Phase 4|45|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:54:33.409128|2018-06-01 02:54:33.409128
NCT00532532|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2008-11-03|2007-09-18|2007-09-20|Estimate|||||||2008-11-03|2008-11-04|Estimate|September 2007||2007-09-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis|AV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis|Terminated||Phase 2|150|Anticipated|Avigen||3|||f||||f||||||||||2018-06-01 02:54:33.489422|2018-06-01 02:54:33.489422
NCT00532519|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2007-09-19|2007-09-19|2007-09-20|Estimate|||||||2007-09-19|2007-09-20|Estimate||||September 2007|2007-09-30||||||||Interventional|||Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis||Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 02:54:33.602742|2018-06-01 02:54:33.602742
NCT00532506|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2008-10-08|2007-09-19|2007-09-20|Estimate|||||||2008-10-08|2008-10-10|Estimate||||October 2008|2008-10-31||||||||Interventional|||Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus||Completed||Phase 2|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 02:54:33.681001|2018-06-01 02:54:33.681001
NCT00532493|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2014-04-02||2018-03-30|2007-09-19|2007-09-20|Estimate|2014-05-19|2014-06-18|Estimate||||2018-03-30|2018-05-01|Actual|January 6, 2010|Actual|2010-01-06|March 2018|2018-03-31|May 31, 2013|Actual|2013-05-31|February 28, 2013|Actual|2013-02-28||Interventional|PACT|PTSD clinicians ascertain interest and eligibility among their patients with nightmare. Informed consent obtained; screening assessments to determine eligibility|Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD|CSP #563 - Prazosin and Combat Trauma PTSD (PACT)|Completed||Phase 3|304|Actual|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-06-01 02:54:33.82425|2018-06-01 02:54:33.82425
NCT00532480|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2013-04-10||2016-08-08|2007-09-19|2007-09-20|Estimate|2016-08-08|2016-10-03|Estimate||||2016-08-08|2016-10-03|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine|Duloxetine Effects on Brain fMRI Response to Emotionally Valenced Pictures in the Treatment of Patients With Major Depression|Completed||Phase 4|10|Actual|Indiana University|Small numbers of subjects analyzed.|1|||f||||f||||||||No||2018-06-01 02:54:35.076306|2018-06-01 02:54:35.076306
NCT00532467|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2008-03-11|2007-09-19|2007-09-20|Estimate|||||||2008-03-11|2008-03-13|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Multiple Dose Safety Study of SRX251 Capsules in Healthy Volunteers|Phase I, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic Study of SRX251 Capsules in Healthy Volunteers|Completed||Phase 1|50|Actual|Azevan Pharmaceuticals|||||f||||f||||||||||2018-06-01 02:54:35.314218|2018-06-01 02:54:35.314218
NCT00532454|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2010-02-09|2007-09-19|2007-09-20|Estimate|||||||2010-02-09|2010-02-10|Estimate|June 2006||2006-06-30|September 2007|2007-09-30|December 2007|Actual|2007-12-31|June 2006|Actual|2006-06-30||Interventional|||Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen|A Clinical Study for the Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen in Patients With Metastatic Breast Cancer|Terminated||Phase 2|21|Actual|National Cancer Center, Korea||1||planned to design a prospective study|f||||f||||||||||2018-06-01 02:54:35.372165|2018-06-01 02:54:35.372165
NCT00532441|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2015-12-10||2016-01-14|2007-09-18|2007-09-20|Estimate|2016-01-14|2016-02-12|Estimate||||2016-01-14|2016-02-12|Estimate|September 2007||2007-09-30|January 2016|2016-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas|Phase II Trial of Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas: Hoosier Oncology Group GI06-101|Terminated||Phase 2|25|Actual|Hoosier Cancer Research Network|No statistical correlations with PFS and OS could be performed due to the small number of KRAS mutations.|2||Terminated due to funding issues.|f||||t||||||||||2018-06-01 02:54:35.473506|2018-06-01 02:54:35.473506
NCT00532428|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-20|Estimate|||||||2007-09-18|2007-09-20|Estimate|April 2003||2003-04-30|September 2007|2007-09-30|September 2003|Actual|2003-09-30|||||Interventional|||Long Term Effects of Raloxifene Treatment on Bone Quality|Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study|Completed||Phase 4|31|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 02:54:35.907836|2018-06-01 02:54:35.907836
NCT00532415|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2012-04-03|2007-09-19|2007-09-20|Estimate|||||||2012-04-03|2012-04-05|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy|Clinical Evaluation of the Safety and Efficacy of Triamcinolone Acetonide Suspension for Visualization During Vitrectomy Surgery|Completed||Phase 3|60|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 02:54:35.995927|2018-06-01 02:54:35.995927
NCT00532402|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2012-10-29|2007-09-19|2007-09-20|Estimate|||||||2012-10-29|2012-10-30|Estimate|September 2007||2007-09-30|October 2012|2012-10-31|December 2010|Actual|2010-12-31|||||Observational|||Continuous and Discontinuous Determination of Propofol Concentration in Breathing Gas|Continuous and Discontinuous Determination of Propofol Concentration in Breathing Gas - Compared With Propofol Concentration in Plasma (Before and) After Lung Passage and Neurophysiological Parameters|Completed|||16|Anticipated|University of Luebeck|||||f||||f||||||||||2018-06-01 02:54:36.052394|2018-06-01 02:54:36.052394
NCT00532389|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2014-10-31|2007-09-18|2007-09-20|Estimate|||||||2014-10-31|2014-11-03|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma|A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Bortezomib in Adult Patients With Multiple Myeloma|Completed||Phase 1|62|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:54:36.114154|2018-06-01 02:54:36.114154
NCT00532376|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2009-02-06|2007-09-19|2007-09-20|Estimate|||||||2009-02-06|2009-02-10|Estimate|September 2005||2005-09-30|February 2009|2009-02-28||||||||Observational|||fMRI Investigation of Depression in Patients With Epilepsy|fMRI Investigation of Depression in Patients With Epilepsy|Withdrawn|||250|Anticipated|Weill Medical College of Cornell University||||Enrollment by invitation only|f||||f||||||||||2018-06-01 02:54:36.200604|2018-06-01 02:54:36.200604
NCT00532363|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2012-02-20|2007-09-18|2007-09-20|Estimate|||||||2012-02-20|2012-02-22|Estimate|September 2005||2005-09-30|February 2012|2012-02-29|September 2010|Actual|2010-09-30|||||Observational|ORPA||Obesity and Asthma:a Specific Phenotype|Obesity-related Pseudo-asthma (ORPA): Description of a Novel Clinical Entity|Completed|||44|Actual|Laval University|||2||f||||f||||||Samples Without DNA|"~     Serum plasma~   "|||2018-06-01 02:54:36.249881|2018-06-01 02:54:36.249881
NCT00532350|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2010-09-01|2007-09-19|2007-09-20|Estimate|||||||2010-09-01|2010-09-02|Estimate|July 2007||2007-07-31|September 2010|2010-09-30|January 2008|Actual|2008-01-31|||||Interventional|||Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Efficacious Dose of QAT370 Compared to Open-label Tiotropium Bromide Following Once Daily Dosing for 7 Days in COPD Patients|Completed||Phase 1|22|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:54:36.303969|2018-06-01 02:54:36.303969
NCT00532337|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2012-06-12|2007-09-19|2007-09-20|Estimate|||||||2012-06-12|2012-06-13|Estimate|October 2007||2007-10-31|June 2012|2012-06-30||||July 2010|Actual|2010-07-31||Interventional|||Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis|A Multi-centre, Randomized, Double Blind, Parallel Group Study to Investigate Efficacy and Safety of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis|Completed||Phase 2|285|Actual|Ono Pharmaceutical Co. Ltd||5|||f||||||||||||||2018-06-01 02:54:36.379286|2018-06-01 02:54:36.379286
NCT00532324|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2011-03-10|2007-09-19|2007-09-20|Estimate|||||||2011-03-10|2011-03-11|Estimate|January 2008||2008-01-31|April 2009|2009-04-30|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|||Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns|Community-Acquired Methicillin Resistant Staphylococcus Aureus (CA-MRSA) Vaginal and Nasal Colonization in Pregnant Women and Frequency of CA-MRSA Infections in Previously Healthy Term and Near-Term Neonates|Unknown status|Recruiting|N/A|1500|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-06-01 02:54:36.458454|2018-06-01 02:54:36.458454
NCT00532311|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18||2016-06-20|2016-06-20|2007-09-19|2007-09-20|Estimate||||2016-06-20|2016-06-22|Estimate|2016-06-20|2016-06-22|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg or Placebo When Co-administered With Statins in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension|Terminated||Phase 3|411|Actual|Takeda||2||"Overall profile of the compound does not offer significant clinical advantage to patients over~   currently available lipid lowering agents"|f||||f||||||||||2018-06-01 02:54:36.564109|2018-06-01 02:54:36.564109
NCT00532298|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2012-04-23|2009-05-20|2016-11-03|2007-09-19|2007-09-20|Estimate|2012-04-23|2012-05-22|Estimate|2009-09-28|2009-09-30|Estimate|2016-11-03|2016-12-16|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over|Non-Inferiority of GlaxoSmithKline Biologicals' Influenza Vaccine (GSK576389A) 1 Container Over 2 Container Presentation in Adults Aged 65 Years and Over|Completed||Phase 2|1596|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:54:36.834335|2018-06-01 02:54:36.834335
NCT00532285|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2011-06-22|2007-09-19|2007-09-20|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2005||2005-09-30|September 2007|2007-09-30|August 2009|Actual|2009-08-31|April 2006|Actual|2006-04-30||Interventional|||Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer|Phase II Study of Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer|Terminated||Phase 2|44|Actual|National Cancer Center, Korea||1||terminated|f||||f||||||||||2018-06-01 02:54:38.148573|2018-06-01 02:54:38.148573
NCT00532272|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2011-06-24|2007-09-19|2007-09-20|Estimate|||||||2011-06-24|2011-06-27|Estimate|October 2005||2005-10-31|September 2007|2007-09-30|August 2010|Actual|2010-08-31|April 2008|Actual|2008-04-30||Interventional|||Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC|A Phase II Non-randomized, Parallel Group Study of Goserelin or Leuprorelin Plus Letrozole in Premenopausal Patients Versus Letrozole Alone in Postmenopausal Patients With Metastatic Breast Cancer|Completed||Phase 2|78|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 02:54:38.211412|2018-06-01 02:54:38.211412
NCT00532259|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2013-09-22||2014-09-08|2007-09-19|2007-09-20|Estimate|2014-09-08|2014-09-12|Estimate||||2014-09-08|2014-09-12|Estimate|October 2007||2007-10-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||CT-011 MAb in DLBCL Patients Following ASCT|Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation|Completed||Phase 2|72|Actual|CureTech Ltd||1|||f||||t||||||||||2018-06-01 02:54:38.338405|2018-06-01 02:54:38.338405
NCT00532233|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2017-06-20|2007-09-19|2007-09-20|Estimate|||||||2017-06-20|2017-06-22|Actual|September 2007||2007-09-30|June 2017|2017-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||SD, IL-13 Production Rate in IPF|A Open-label, Multicenter Study, With a Single Intravenous Dose of QAX576 to Determine IL-13 Production in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|52|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:54:38.880218|2018-06-01 02:54:38.880218
NCT00532220|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2015-08-25|2007-09-19|2007-09-20|Estimate|||||||2015-08-25|2015-08-26|Estimate|December 2007||2007-12-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial|Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial|Completed||Phase 3|30|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 02:54:39.006818|2018-06-01 02:54:39.006818
NCT00532207|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-20|Estimate|||||||2007-09-18|2007-09-20|Estimate|November 2003||2003-11-30|September 2007|2007-09-30|December 2004|Actual|2004-12-31|||||Interventional|||Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis|Efficacy and Safety of Teriparatide 20 Micrograms in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|50|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:54:39.078238|2018-06-01 02:54:39.078238
NCT00532194|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|||2015-09-21|2007-09-19|2007-09-20|Estimate|||||||2015-09-21|2015-09-23|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|April 2013|Actual|2013-04-30||Interventional|ICON6||An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer|A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer|Unknown status|Active, not recruiting|Phase 3|486|Actual|Medical Research Council||3|||f||||t||||||||||2018-06-01 02:54:39.146148|2018-06-01 02:54:39.146148
NCT00532181|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-19|2007-09-19|2007-09-20|Estimate|||||||2007-09-19|2007-09-20|Estimate|April 2008||2008-04-30|September 2007|2007-09-30|December 2011|Anticipated|2011-12-31|||||Interventional|||Micro-Health Insurance in Cambodia|A Randomized Control Trial of Micro-Health Insurance in Cambodia|Unknown status|Not yet recruiting|Early Phase 1|||University of California, Berkeley|||||f||||||||||||||2018-06-01 02:54:39.237238|2018-06-01 02:54:39.237238
NCT00532168|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2013-02-21|2007-09-19|2007-09-20|Estimate|||||||2013-02-21|2013-02-22|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ADVANZ-3||Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl|Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, Randomized, Multicentre, Open Clinical Study.|Completed||Phase 4|108|Actual|Hospital Clinic of Barcelona||3|||f||||f||||||||||2018-06-01 02:54:39.314612|2018-06-01 02:54:39.314612
NCT00532155|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-19|2012-08-17|2012-02-17|2016-05-04|2007-09-19|2007-09-20|Estimate|2012-11-30|2013-01-01|Estimate|2012-02-17|2012-02-22|Estimate|2016-05-04|2016-06-07|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|October 2011|Actual|2011-10-31|January 2011|Actual|2011-01-31||Interventional|VITAL||A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer|A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer|Completed||Phase 3|913|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:54:39.422123|2018-06-01 02:54:39.422123
NCT00532142|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2009-10-29|2007-09-18|2007-09-20|Estimate|||||||2009-10-29|2009-10-30|Estimate|April 2005||2005-04-30|October 2009|2009-10-31|August 2009|Actual|2009-08-31|||||Interventional|||The ROVO Study: Radial Optic Neurotomy for CVO|A Multicenter Trial for Surgical Treatment of Central Retinal Vein Occlusion - Radial Optic Neurotomy for CVO The ROVO Study|Completed||Phase 2/Phase 3|||Rudolf Foundation Clinic|||||f||||f||||||||||2018-06-01 02:54:40.573483|2018-06-01 02:54:40.573483
NCT00532129|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2016-03-06||2016-03-06|2007-09-18|2007-09-19|Estimate|2016-03-06|2016-04-06|Estimate||||2016-03-06|2016-04-06|Estimate|November 2007||2007-11-30|March 2016|2016-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Full analysis set (FAS) comprised all participants recruited into the study and known to have received at least one dose of study treatment.|A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.|An Open-Label Study to Characterize the Safety and Response Rate of MabThera (Rituximab) Plus Chlorambucil in Previously Untreated Patients With CD20-Positive B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|100|Actual|Hoffmann-La Roche||1|||f||||t||||||||No||2018-06-01 02:54:40.685865|2018-06-01 02:54:40.685865
NCT00532116|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-19|Estimate|||||||2007-09-18|2007-09-19|Estimate|April 2007||2007-04-30|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly|Pharmacokinetic Comparison of the 6mg/24hr and 12mg/24hr EMSAM (Selegiline Transdermal System) in Healthy Elderly and Non-Elderly Volunteers|Completed||Phase 4|32|Actual|Somerset Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:54:41.464513|2018-06-01 02:54:41.464513
NCT00532103|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2008-09-19|2007-09-18|2007-09-19|Estimate|||||||2008-09-19|2008-09-22|Estimate|July 2007||2007-07-31|September 2008|2008-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|SAMS||Assessing Treatment Emergent Suicidal Ideation in Patients With Major Depression|Suicide Assessment Methodology Study (SAMS)|Completed|||300|Anticipated|National Institute of Mental Health (NIMH)|||||f||||t||||||||||2018-06-01 02:54:41.750942|2018-06-01 02:54:41.750942
NCT00532090|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2016-11-01|2007-09-18|2007-09-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.|Multiple Ascending Dose (MAD) Study of R4733 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors|Completed||Phase 1|110|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 02:54:41.837193|2018-06-01 02:54:41.837193
NCT00532077|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17||2010-10-13|2010-10-13|2007-09-17|2007-09-19|Estimate||||2010-10-13|2010-10-19|Estimate|2010-10-13|2010-10-19|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women|An Exploratory, Open Label, Multicenter Parallel Group Study to Evaluate the Effects of Single and Repeat Dosing of SB-751689 (400 mg or 100 mg) or rhPTH(1-34) on the Fractional Renal Excretion of Calcium and Phosphate in Healthy Postmenopausal Females.|Completed||Phase 1|40|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:54:41.919823|2018-06-01 02:54:41.919823
NCT00532064|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2018-05-07|2007-09-18|2007-09-19|Estimate|||||||2018-05-07|2018-05-08|Actual|September 12, 2007|Actual|2007-09-12|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02||Observational|||Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers|Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers|Completed|||55|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     During the standard-of-care blood draws, additional blood will be drawn to test troponin I~     and/or T and BNP levels.~   "|||2018-06-01 02:54:41.996751|2018-06-01 02:54:41.996751
NCT00532051|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2018-04-09|2007-09-18|2007-09-19|Estimate|||||||2018-04-09|2018-04-11|Actual|April 2011||2011-04-30|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|OCT IOL||Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography|Guiding the Treatment of Anterior Eye Diseases With Optical Coherence Tomography|Recruiting|||360|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-06-01 02:54:42.076467|2018-06-01 02:54:42.076467
NCT00532038|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18||2012-03-14|2012-03-14|2007-09-18|2007-09-19|Estimate||||2012-03-14|2012-03-16|Estimate|2012-03-14|2012-03-16|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.|An Open-Label, Long-Term Safety Study to Evaluate the Safety of ThermoProfen™ for the Treatment of Mild to Moderate Pain Associated With Osteoarthritis of the Knee|Terminated||Phase 3|179|Actual|ZARS Pharma Inc.||||Corporate decision|f||||f||||||||||2018-06-01 02:54:42.159563|2018-06-01 02:54:42.159563
NCT00532025|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2009-07-24|2007-09-18|2007-09-19|Estimate|||||||2009-07-24|2009-07-28|Estimate|September 2007||2007-09-30|July 2009|2009-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|SIRN||Sorafenib in Resected Non-small Cell Lung Carcinoma|A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment Following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients Not Eligible for Cisplatin-based Adjuvant Chemotherapy|Terminated||Phase 2|134|Anticipated|Johannes Gutenberg University Mainz||1|||f||||t||||||||||2018-06-01 02:54:42.322382|2018-06-01 02:54:42.322382
NCT00532012|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2008-07-15|2007-09-18|2007-09-19|Estimate|||||||2008-07-15|2008-07-16|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®|An Open-Label, Partially Randomized, Cross-Over, Monocentric Phase I Study Evaluating the Pharmacokinetic Profile of RhuDex® in Order to Determine Optimum Doses of Meglumine and RhuDex®|Completed||Phase 1|10|Actual|MediGene|||||f||||f||||||||||2018-06-01 02:54:42.399936|2018-06-01 02:54:42.399936
NCT00531999|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2010-08-13|2007-09-18|2007-09-19|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2007||2007-10-31|August 2010|2010-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Raltegravir Insulin Sensitivity Study|An Open Label Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment With Lopinavir / Ritonavir (400 / 100 mg Twice Daily) or Raltegravir 400 mg Twice Daily in HIV Negative Male Volunteers.|Completed||Phase 1|18|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-06-01 02:54:42.47427|2018-06-01 02:54:42.47427
NCT00531986|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2009-05-29|2007-09-18|2007-09-19|Estimate|||||||2009-05-29|2009-06-03|Estimate|January 2007||2007-01-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|MOST||HIV - Monotherapy in Switzerland (MOST-ch)|HIV- Monotherapy in Switzerland (MOST- ch)|Terminated||Phase 4|60|Actual|Cantonal Hospital of St. Gallen||2||Unexpectedely high rates of treatment-failure|f||||t||||||||||2018-06-01 02:54:42.560581|2018-06-01 02:54:42.560581
NCT00531973|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2009-02-17|2007-09-18|2007-09-19|Estimate|||||||2009-02-17|2009-02-18|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|August 2008|Anticipated|2008-08-31||Interventional|LITE||A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging|Liposomal Doxorubicin-Investigational Chemotherapy-Tissue Doppler Imaging Evaluation (LITE) Randomized Pilot Study|Unknown status|Recruiting|Phase 4|80|Anticipated|Catholic University, Italy||2|||f||||f||||||||||2018-06-01 02:54:42.66002|2018-06-01 02:54:42.66002
NCT00531960|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2014-11-04||2014-11-04|2007-09-18|2007-09-19|Estimate|2014-11-04|2014-11-11|Estimate||||2014-11-04|2014-11-11|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Full analysis set (FAS): all randomized participants.|A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.|A Randomized, Open-label Study Comparing the Anti-tumor Effect of Treatment With Tarceva Plus Avastin Versus Chemotherapy Plus Avastin in Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|124|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:54:42.810097|2018-06-01 02:54:42.810097
NCT00531947|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2012-12-27||2013-12-12|2007-09-18|2007-09-19|Estimate|2013-05-16|2013-06-26|Estimate||||2013-12-12|2014-01-15|Estimate|July 2007||2007-07-31|December 2013|2013-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression|A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression|Completed||Phase 4|308|Actual|Somerset Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:54:43.796656|2018-06-01 02:54:43.796656
NCT00531934|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2014-06-23||2015-02-05|2007-09-18|2007-09-19|Estimate|2014-08-25|2014-08-26|Estimate||||2015-02-05|2015-02-25|Estimate|October 2007||2007-10-31|February 2015|2015-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||"Intent-to-Treat population (ITT): all randomized participants who received at least~1 dose of erlotinib."|A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.|A Randomized, Open Label Study to Evaluate the Effect of Doxycycline on Tarceva-induced Skin Rash in Patients With Non-small Cell Lung Cancer After Failure of First Line Chemotherapy|Completed||Phase 2|147|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:54:44.683363|2018-06-01 02:54:44.683363
NCT00531921|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2013-06-03|2007-09-18|2007-09-19|Estimate|||||||2013-06-03|2013-06-04|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival|Correlation of Donor Proinflammatory mRNA Profiles With Early Outcomes of Thoracic and Abdominal Transplantation|Completed|||313|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||t||||||Samples With DNA|"~     Blood and tissue samples to evaluate the heart, kidney, liver, and lung~   "|||2018-06-01 02:54:45.857084|2018-06-01 02:54:45.857084
NCT00531908|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2011-12-06|2007-09-18|2007-09-19|Estimate|||||||2011-12-06|2011-12-07|Estimate|September 2007||2007-09-30|August 2008|2008-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|AcromEnaC||Physiopathology of Sodium Retention in Acromegaly|Physiopathology of Sodium Retention in Acromegaly|Completed||N/A|12|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 02:54:45.933057|2018-06-01 02:54:45.933057
NCT00531895|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-19|Estimate|||||||2007-09-18|2007-09-19|Estimate|April 2006||2006-04-30|August 2007|2007-08-31|March 2007|Actual|2007-03-31|||||Interventional|||An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache|An Open Trial of Duloxetine on Comorbid Major Depression and Chronic Headache|Completed||Phase 4|30|Actual|Kraepelin Psiquiatria Clinica|||||f||||f||||||||||2018-06-01 02:54:46.006001|2018-06-01 02:54:46.006001
NCT00531882|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2015-01-13||2017-09-06|2007-09-18|2007-09-19|Estimate|2017-06-29|2017-07-28|Actual||||2017-09-06|2017-10-05|Actual|September 2007||2007-09-30|September 2017|2017-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||This study was conducted to provide data as proof of concept and to provide pilot data to support an FDA grant to be submitted at a later date.|Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers|A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects|Completed||N/A|25|Actual|University Hospitals Cleveland Medical Center||3|||f||||f||||||||No||2018-06-01 02:54:46.152538|2018-06-01 02:54:46.152538
NCT00531869|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2008-07-31|2007-09-18|2007-09-19|Estimate|||||||2008-07-31|2008-08-04|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|October 2010|Anticipated|2010-10-31|May 2010|Anticipated|2010-05-31||Interventional|||Safe Water Techniques in Kenya|A Study of End-User Preferences for and Use of POU Safe Water Technologies in Kenya|Unknown status|Recruiting|Early Phase 1|||University of California, Berkeley|||||f||||||||||||||2018-06-01 02:54:46.420834|2018-06-01 02:54:46.420834
NCT00531856|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2016-10-18|2007-09-18|2007-09-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Tolerability Study of Inhaled Carbon Monoxide in Kidney Transplant Patients|A Prospective, Multicenter, Single-blind, Placebo-controlled, Safety and Tolerability Study of the Effects of Carbon Monoxide for Inhalation in Patients Receiving Kidney Transplants.|Withdrawn||Phase 2|0|Actual|Mallinckrodt||2||Clinical Hold pending additional data review and protocol amendment|f||||t||||||||||2018-06-01 02:54:46.517795|2018-06-01 02:54:46.517795
NCT00531843|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|2013-06-10||2013-10-31|2007-09-17|2007-09-19|Estimate|2013-10-31|2013-12-24|Estimate||||2013-10-31|2013-12-24|Estimate|December 2007||2007-12-31|October 2013|2013-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients|The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients|Completed||Phase 2/Phase 3|105|Actual|University of California, San Francisco||4|||f||||f||||||||||2018-06-01 02:54:46.620578|2018-06-01 02:54:46.620578
NCT00531830|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-25|2007-09-18|2007-09-19|Estimate|||||||2007-09-25|2007-09-26|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|September 2011|Anticipated|2011-09-30|||||Observational|||Assessment of Factors Which Predict Improvement in Children With PDD After a Year of Integrative Therapy|Assessment of Factors Which Predict Improvement in Children With PDD After a Year of Integrative Therapy|Unknown status|Not yet recruiting||60|Anticipated|BeerYaakov Mental Health Center|||2||f||||f||||||||||2018-06-01 02:54:46.874205|2018-06-01 02:54:46.874205
NCT00531817|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2010-07-06||2012-08-13|2007-09-18|2007-09-19|Estimate|2010-07-06|2010-08-04|Estimate||||2012-08-13|2012-08-20|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|June 2009|Actual|2009-06-30||Interventional|ROSE||A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Tocilizumab (TCZ) Versus Placebo in Combination With Disease Modifying Antirheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)|Completed||Phase 3|619|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:54:47.023916|2018-06-01 02:54:47.023916
NCT00531804|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2016-11-01|2007-09-18|2007-09-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2006||2006-12-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.|A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4909832 Following Intravenous Infusion in AD Patients|Completed||Phase 1|60|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:54:48.263134|2018-06-01 02:54:48.263134
NCT00531791|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2011-06-16|2007-09-17|2007-09-19|Estimate|||||||2011-06-16|2011-06-17|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation|Effects of Fluticasone/Salmeterol (Advair®) in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation|Completed||Phase 3|14|Actual|Laval University||2|||f||||f||||||||||2018-06-01 02:54:48.327226|2018-06-01 02:54:48.327226
NCT00531778|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2011-01-10|2007-09-18|2007-09-19|Estimate|||||||2011-01-10|2011-01-11|Estimate|June 2004||2004-06-30|January 2011|2011-01-31|November 2010|Actual|2010-11-30|||||Observational|||NYU Ovarian Cancer Early Detection Program Blood and Genetics|NYU Ovarian Cancer Early Detection Program Blood and Genetics|Terminated|||890|Actual|New York University School of Medicine|||1|insufficient funding and resource|f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, urine, ovarian tissue~   "|||2018-06-01 02:54:48.404031|2018-06-01 02:54:48.404031
NCT00531765|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2010-07-24|2007-09-17|2007-09-19|Estimate|||||||2010-07-24|2010-07-27|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|SIPCIN||Sodium Bicarbonate in Preventing Contrast Induced Nephropathy|Sodium Bicarbonate in Preventing Contrast Induced Nephropathy (SIPCIN): A Randomized Controlled Study|Completed||N/A|220|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||f||||||||||2018-06-01 02:54:48.456563|2018-06-01 02:54:48.456563
NCT00531752|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2014-04-02|2009-09-09|2016-01-22|2007-09-18|2007-09-19|Estimate|2016-01-22|2016-02-19|Estimate|2009-09-09|2009-09-11|Estimate|2016-01-22|2016-02-19|Estimate|December 2007||2007-12-31|January 2016|2016-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Safety analysis population included all participants who received at least 1 dose of study medication.|A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).|A Phase Iia, Randomized, Double Blind, Placebo Controlled, Three-treatment, Two-period Crossover Study Of The Efficacy And Safety Of Two Doses Of Pf-03654746 In Adults With Attention Deficit Hyperactivity Disorder|Completed||Phase 2|66|Actual|Pfizer|Instead of time to sustained response, data for percentage of sustained responders in time-sensitive ADHD symptom scale (TASS) total score was reported as per planned analysis.|3|||f||||f||||||||||2018-06-01 02:54:49.642165|2018-06-01 02:54:49.642165
NCT00531739|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2010-10-05|2007-09-18|2007-09-19|Estimate|||||||2010-10-05|2010-10-07|Estimate|March 2006||2006-03-31|October 2010|2010-10-31|July 2009|Actual|2009-07-31|||||Interventional|||SurgiWrapTM to Reduce Soft Tissue Attachment & Incidence Early Post-Operative Bowel Obstruction in Colorectal Surgery|Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery|Completed||Phase 4|60|Anticipated|Cytori Therapeutics||2|||f||||f||||||||||2018-06-01 02:54:51.767422|2018-06-01 02:54:51.767422
NCT00531726|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2018-01-23|2007-09-18|2007-09-19|Estimate|||||||2018-01-23|2018-01-24|Actual|September 2007||2007-09-30|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|BDDS||Berlin Deep Brain Stimulation Depression Study|Investigation of Efficacy and Safety of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression in a Multicenter, Double-blind, Prospectivly-designed Delayed-onset Study (Tiefe Hirnstimulation Zur Behandlung Therapieresistenter Depressionen-eine Multizentrische, Doppelblinde, Prospektive Studie Mit Einem Delayed-onset Design)|Completed||N/A|11|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:54:51.833729|2018-06-01 02:54:51.833729
NCT00531713|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-19|Estimate|||||||2007-09-18|2007-09-19|Estimate|April 2003||2003-04-30|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|T4-T3||Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism|Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism,a Double Blind Randomized Cross-Over Study.|Completed||Phase 4|59|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-06-01 02:54:51.893994|2018-06-01 02:54:51.893994
NCT00531700|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2009-04-30|2007-09-18|2007-09-19|Estimate|||||||2009-04-30|2009-05-01|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|Indivo at MIT||Testing a Personally Controlled Health Record to Ameliorate Influenza at MIT|Test of the PING/INDIVO Personal Health Record System at MIT|Completed||N/A|800|Anticipated|Boston Children’s Hospital||4|||f||||||||||||||2018-06-01 02:54:51.958122|2018-06-01 02:54:51.958122
NCT00531687|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2017-09-29|2007-09-18|2007-09-19|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2007||2007-09-30|September 2017|2017-09-30|October 2016|Actual|2016-10-31|February 2012|Actual|2012-02-29||Interventional|||Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer|Phase II Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer|Terminated||Phase 2|8|Actual|Rigshospitalet, Denmark||1||slow accrual|f||||f||||||||No||2018-06-01 02:54:52.040046|2018-06-01 02:54:52.040046
NCT00531674|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2014-11-06|2007-09-18|2007-09-19|Estimate|||||||2014-11-06|2014-11-07|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy of 3 Nutritional Supplements to Improve Diverse Outcomes in Children Under 2 Years of Age and Pregnant Women||Completed||N/A|||Mexican National Institute of Public Health||2|||f||||f||||||||||2018-06-01 02:54:52.155461|2018-06-01 02:54:52.155461
NCT00531661|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2012-11-16||2015-01-16|2007-09-18|2007-09-19|Estimate|2013-02-28|2013-04-09|Estimate||||2015-01-16|2015-01-28|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|May 2010|Actual|2010-05-31||Interventional|CHAMPION||CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients|CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients|Completed||N/A|550|Actual|CardioMEMS||2|||f||||t||||||||||2018-06-01 02:54:52.312782|2018-06-01 02:54:52.312782
NCT00531648|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-19|Estimate|||||||2007-09-18|2007-09-19|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|November 2008|Anticipated|2008-11-30|||||Observational|||Relationships Between Toddlers With Feeding Disorder and SPD and Their Parents|The System of Relationships Between Parents and Their Toddlers, With Eating Disorders and Sensory Processing Disorders Within Meal and Play Situations|Unknown status|Not yet recruiting||6|Anticipated|BeerYaakov Mental Health Center|||1||f||||f||||||||||2018-06-01 02:54:52.719523|2018-06-01 02:54:52.719523
NCT00531635|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2011-12-11|2007-09-17|2007-09-19|Estimate|||||||2011-12-11|2011-12-13|Estimate|July 2002||2002-07-31|December 2011|2011-12-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil|Unknown status|Recruiting|Phase 1|350|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:54:52.790549|2018-06-01 02:54:52.790549
NCT00531622|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18||2016-04-25|2016-04-25|2007-09-18|2007-09-19|Estimate||||2016-04-25|2016-05-24|Estimate|2016-04-25|2016-05-24|Estimate|September 2007||2007-09-30|April 2016|2016-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder|An Eight-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Saredutant 100 mg Once Daily in Combination With Escitalopram 10 mg Once Daily in Patients With Major Depressive Disorder|Completed||Phase 3|643|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 02:54:52.876417|2018-06-01 02:54:52.876417
NCT00531596|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2007-09-18|2007-09-18|2007-09-19|Estimate|||||||2007-09-18|2007-09-19|Estimate|April 2007||2007-04-30|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Evaluation of Adhesion and Dermal Tolerability of EMSAM|A PHASE IV, OPEN-LABEL STUDY OF THE ADHESION AND DERMAL TOLERABILITY OF EMSAM (SELEGILINE TRANSDERMAL SYSTEM) IN HEALTHY ADULT SUBJECTS OF TWO AGE GROUPS (18 - 64 YEARS, AND 65 YEARS AND OLDER)|Completed||Phase 4|300|Actual|Somerset Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:54:52.951259|2018-06-01 02:54:52.951259
NCT00531583|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2016-01-04|2007-09-18|2007-09-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|March 2001||2001-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor|Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor|Completed||N/A|350|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:54:53.02487|2018-06-01 02:54:53.02487
NCT00531570|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2010-09-22|2007-09-18|2007-09-19|Estimate|||||||2010-09-22|2010-09-23|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|April 2009|Actual|2009-04-30|||||Observational|||Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma|Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma|Completed|||100|Anticipated|New York University School of Medicine|||||f||||f||||||||||2018-06-01 02:54:53.231245|2018-06-01 02:54:53.231245
NCT00531557|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2010-08-13|2007-09-18|2007-09-19|Estimate|||||||2010-08-13|2010-08-16|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Double Protease Inhibitor to Darunavir Switch Study|Phase IV Cohort Study Assessing Feasibility of Substituting Double Ritonavir-boosted Protease Inhibitors With Ritonavir-boosted Darunavir in HIV-infected Individuals With Viral Suppression on Highly Active Antiretroviral Therapy.|Completed||Phase 4|12|Actual|St Stephens Aids Trust||1|||f||||f||||||||||2018-06-01 02:54:53.290437|2018-06-01 02:54:53.290437
NCT00531544|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2016-01-04|2007-09-18|2007-09-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|February 2007||2007-02-28|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248|A SU011248 Expanded Access Protocol for Metastatic RCC Patients Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248|Completed||N/A|350|Actual|King Faisal Specialist Hospital & Research Center|||||f||||t||||||||||2018-06-01 02:54:53.365728|2018-06-01 02:54:53.365728
NCT00531531|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2011-08-22|2007-09-18|2007-09-19|Estimate|||||||2011-08-22|2011-08-23|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of People With Cystic Fibrosis|Control and Prevention of Respiratory Infections in Cystic Fibrosis Patients: an Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of Infected Persons Through Coughing and Conversation.|Completed|||42|Actual|University of Florence|||||f||||||||||||||2018-06-01 02:54:53.449022|2018-06-01 02:54:53.449022
NCT00531518|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|2016-01-20||2016-07-06|2007-09-18|2007-09-19|Estimate|2016-07-06|2016-08-15|Estimate||||2016-07-06|2016-08-15|Estimate|October 2007||2007-10-31|July 2016|2016-07-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|EDIPP|All eligible participants (n=292) were entered into the outcome analysis. This was an intent-to-treat study and statistical analysis.|Early Detection and Intervention for the Prevention of Psychosis|Early Detection and Intervention for the Prevention of Psychosis Project|Completed||N/A|292|Actual|Maine Medical Center||2|||f||||t||||||||Yes|Currently, on request, data will be shared with legitimate organizations for specific analyses approved by the PI and the Maine Medical Center Institutional Review Board.|2018-06-01 02:54:53.553427|2018-06-01 02:54:53.553427
NCT00531505|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-18|||2015-10-14|2007-09-18|2007-09-19|Estimate|||||||2015-10-14|2015-10-16|Estimate|March 2007||2007-03-31|October 2015|2015-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|2a||Obesity and Memory, mRNA, Body Composition, Comorbidity Scale|Morbid Obesity and Memory, Visceral and Subcutaneous mRNA Analysis, Body Composition, and Comorbidity Scale.|Terminated|||13|Actual|Oregon Health and Science University|||1|Surgeon mistakenly removed liver and fat tissue from a non-LABS2a participant|f||||t||||||Samples With DNA|"~     Liver and fatty samples were voluntarily given by participant consent.~   "|||2018-06-01 02:54:54.193942|2018-06-01 02:54:54.193942
NCT00531492|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2011-12-08|2007-09-17|2007-09-18|Estimate|||||||2011-12-08|2011-12-12|Estimate|August 2007||2007-08-31|December 2011|2011-12-31|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|EtudeTK||Efficacy of Continuous Skin to Skin Care (Technique Kangaroo: TK) After Birth for Low Birth Weight (LBW) Infants and Their Mothers in Developing Countries|Randomized Controlled Trial of Continuous Skin to Skin Care (Technique Kangourou: TK) for Low Birth Weight (LBW) Infants and Their Mothers at University Hospital Center of Mahajanga (Centre Hospitalier Universitaire de Mahajanga: CHUM), Madagascar|Completed||N/A|73|Actual|Foundation for Advanced Studies on International Development||2|||f||||f||||||||||2018-06-01 02:54:54.361629|2018-06-01 02:54:54.361629
NCT00531479|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2012-04-03||2012-04-03|2007-09-14|2007-09-18|Estimate|2012-04-03|2012-04-30|Estimate||||2012-04-03|2012-04-30|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis|A Prospective, Randomized Trial Comparing The Efficacy Of Anidulafungin And Voriconazole In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Proven Or Probable Invasive Aspergillosis|Completed||Phase 3|459|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 02:54:54.592968|2018-06-01 02:54:54.592968
NCT00531466|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2008-11-03|2007-09-17|2007-09-18|Estimate|||||||2008-11-03|2008-11-04|Estimate|September 2007||2007-09-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury|AV650-014: A Four Week, Prospective, Randomized, Double Blind, Placebo-Controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV650 in Patients With Spasticity Due to Spinal Cord Injury|Terminated||Phase 2|120|Anticipated|Avigen||2|||f||||f||||||||||2018-06-01 02:54:55.633241|2018-06-01 02:54:55.633241
NCT00531453|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2010-04-09||2012-01-25|2007-09-14|2007-09-18|Estimate|2010-05-04|2010-06-04|Estimate||||2012-01-25|2012-01-26|Estimate|October 2007||2007-10-31|January 2012|2012-01-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma|A Phase 2, Randomized Study of VELCADE® (Bortezomib), Dexamethasone, and Thalidomide Versus VELCADE® (Bortezomib), Dexamethasone, Thalidomide, and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma Who Are Candidates for Autologous Transplantation|Completed||Phase 2|98|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||||||||||||2018-06-01 02:54:55.755872|2018-06-01 02:54:55.755872
NCT00531440|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2011-11-01|2007-09-17|2007-09-18|Estimate|||||||2011-11-01|2011-11-02|Estimate|November 2001||2001-11-30|November 2011|2011-11-30||||August 2005|Actual|2005-08-31||Interventional|||This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.|A 2 Year Extension to a 1 Year Multicenter, Randomized, Open Label, Parallel Group Study of the Safety, Tolerability and Efficacy of Two Doses (1.5 and 3 mg/Day) of Everolimus (RAD001) With Basiliximab, Corticosteroids and Optimized Administration of Cyclosporine in de Novo Renal Transplant Recipients.|Completed||Phase 3|256|Actual|Novartis|||||f||||||||||||||2018-06-01 02:54:56.545862|2018-06-01 02:54:56.545862
NCT00531427|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|2010-07-28||2012-09-05|2007-09-17|2007-09-18|Estimate|2010-08-24|2010-09-21|Estimate||||2012-09-05|2012-09-10|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|||Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee|Randomized, Double-blind, Placebo-controlled With Open-label Run-in Assessing Efficacy, Tolerability,Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects w/Moderate to Severe, Chronic Pain Due to OA of Knee|Completed||Phase 3|567|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-06-01 02:54:56.663837|2018-06-01 02:54:56.663837
NCT00531414|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-16|||2008-04-07|2007-09-17|2007-09-18|Estimate|||||||2008-04-07|2008-04-10|Estimate|November 2007||2007-11-30|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Inspiratory Flow Using the Osmohaler|Inspiratory Flow and VOlumes in Asthmatic and Healthy Individuals Using the Osmohaler|Completed|||30|Anticipated|Pharmaxis|||||f||||f||||||||||2018-06-01 02:54:57.410672|2018-06-01 02:54:57.410672
NCT00531401|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2011-06-08|2007-09-17|2007-09-18|Estimate|||||||2011-06-08|2011-06-09|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study of Salirasib to Treat Non-Small Cell Lung Cancer|Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study|Completed||Phase 2|71|Anticipated|Concordia Pharmaceuticals, Inc|||||f||||f||||||||||2018-06-01 02:54:57.476659|2018-06-01 02:54:57.476659
NCT00531362|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2009-09-28|2007-09-17|2007-09-18|Estimate|||||||2009-09-28|2009-09-29|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Enteric Coating as a Factor in Aspirin Resistance|Enteric Coating as a Factor in Aspirin Resistance|Completed|||250|Actual|Royal College of Surgeons, Ireland|||1||f||||f||||||Samples Without DNA|"~     Serum samples will be collected and stored for later analysis~   "|||2018-06-01 02:54:57.660662|2018-06-01 02:54:57.660662
NCT00531349|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2016-05-05|2007-09-17|2007-09-18|Estimate|||||||2016-05-05|2016-05-09|Estimate|November 2007||2007-11-30|May 2016|2016-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|ECA/R||Regional Anesthesia and Endometrial Cancer Recurrence|Regional Anesthesia and Endometrial Cancer Recurrence|Withdrawn||Phase 3|0|Actual|The Cleveland Clinic||2||Lack of study population|f||||t||||||||No||2018-06-01 02:54:57.820957|2018-06-01 02:54:57.820957
NCT00531336|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-15|||2009-06-30|2007-09-17|2007-09-18|Estimate|||||||2009-06-30|2009-07-02|Estimate|July 2006||2006-07-31|October 2008|2008-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen|Comparison of Combined Therapy of Intravitreal Injection of Avastin and Macugen Versus Mono-Therapy The MAAM Study - a Pilot Study|Completed||Phase 2|60|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||3|||f||||f||||||||||2018-06-01 02:54:57.945821|2018-06-01 02:54:57.945821
NCT00531323|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2008-09-04|2007-09-17|2007-09-18|Estimate|||||||2008-09-04|2008-09-05|Estimate|September 2007||2007-09-30|September 2008|2008-09-30|December 2007|Actual|2007-12-31|||||Interventional|||TMC 125 Blood Levels Study|Evaluation of the Pharmacokinetics and Safety of TMC125 Administered Once and Twice-Daily and Following a 2-Week-Treatment Period With Efavirenz in Male and Female Healthy Volunteers.|Completed||Phase 1|24|Anticipated|St Stephens Aids Trust||2|||f||||f||||||||||2018-06-01 02:54:58.035396|2018-06-01 02:54:58.035396
NCT00531310|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-15|||2011-04-12|2007-09-17|2007-09-18|Estimate|||||||2011-04-12|2011-04-14|Estimate|January 2003||2003-01-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|December 2007|Actual|2007-12-31||Interventional|CML||Reduced Intensity AlloSCT in(CML) With Persistent Disease|A Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Chronic Myeloid Leukemia (CML) and Adoptive Cellular Immunotherapy Only in Patients With Persistent Disease and Matched Family Donors|Terminated||Phase 2|5|Actual|Columbia University||2||Poor accrual|f||||t||||||||||2018-06-01 02:54:58.189034|2018-06-01 02:54:58.189034
NCT00531297|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2013-01-23|2007-09-17|2007-09-18|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 2005||2005-12-31|January 2013|2013-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Endoscopic Posterior Mesorectal Resection in T1 Rectal Cancer|Endoscopic Posterior Mesorectal Resection in T1 Rectal Cancer|Recruiting||Phase 3|96|Anticipated|Cantonal Hospital of St. Gallen|||||f||||f||||||||||2018-06-01 02:54:58.285771|2018-06-01 02:54:58.285771
NCT00531284|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2015-10-05||2017-07-14|2007-09-14|2007-09-18|Estimate|2015-12-05|2015-12-09|Estimate||||2017-07-14|2017-08-15|Actual|September 2007||2007-09-30|July 2017|2017-07-31|May 22, 2017|Actual|2017-05-22|October 2014|Actual|2014-10-31||Interventional|||Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma|Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma|Completed||Phase 1/Phase 2|184|Actual|Amgen||17|||f||||f||||||||||2018-06-01 02:54:58.655719|2018-06-01 02:54:58.655719
NCT00531271|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2009-06-11|2007-09-14|2007-09-18|Estimate|||||||2009-06-11|2009-06-15|Estimate|November 2007||2007-11-30|June 2009|2009-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||ABI-008 Trial in Patients With Metastatic Breast Cancer|A Phase I/II Trial of ABI-008 (Nab-Docetaxel) in Patients With Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|85|Anticipated|Celgene Corporation|||||f||||f||||||||||2018-06-01 02:55:06.004687|2018-06-01 02:55:06.004687
NCT00531258|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2008-05-05|2007-09-17|2007-09-18|Estimate|||||||2008-05-05|2008-05-09|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||TMS in the Treatment of the Sequelae of Closed Brain Injury|The Use of Non Invasive Brain Stimulation in the Treatment of the Sequelae of Closed Brain Injury|Unknown status|Recruiting|Phase 2|50|Anticipated|Bayside Health||2|||f||||f||||||||||2018-06-01 02:55:06.069848|2018-06-01 02:55:06.069848
NCT00531245|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2009-06-29|2007-09-17|2007-09-18|Estimate|||||||2009-06-29|2009-07-02|Estimate|August 2006||2006-08-31|August 2007|2007-08-31|March 2009|Actual|2009-03-31|June 2008|Actual|2008-06-30||Interventional|||A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer|A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer|Completed||Phase 1/Phase 2|77|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:55:06.291227|2018-06-01 02:55:06.291227
NCT00531232|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14||2011-12-16|2014-03-17|2007-09-17|2007-09-18|Estimate||||2011-12-16|2011-12-22|Estimate|2014-03-17|2014-04-14|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)|A Phase IIa Open-label, Dose Confirmation Study of Oral Clofarabine in Adult Patients Previously Treated for Myelodysplastic Syndromes(MDS)|Completed||Phase 2|36|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:55:06.391921|2018-06-01 02:55:06.391921
NCT00531219|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2018-04-30|2007-09-17|2007-09-18|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2008||2008-02-29|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|December 2018|Anticipated|2018-12-31||Observational|NOTES||Minimally Invasive Surgery: Using Natural Orifice Translumenal Endoscopic Surgery (NOTES)|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Transgastric Appendectomy and Cholecystectomy|Recruiting|||20|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-06-01 02:55:06.511455|2018-06-01 02:55:06.511455
NCT00531206|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|2010-01-28||2014-02-24|2007-09-17|2007-09-18|Estimate|2010-04-21|2010-05-12|Estimate||||2014-02-24|2014-04-07|Estimate|August 2006||2006-08-31|February 2014|2014-02-28||||January 2009|Actual|2009-01-31||Observational|||Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.|Observational Non-interventional Study About Antiretroviral Combination Treatment With Aptivus in Combination With Low-dose Ritonavir in HIV Type 1 Infected Patients|Completed|||65|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 02:55:06.643488|2018-06-01 02:55:06.643488
NCT00531193|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2008-07-29|2007-09-17|2007-09-18|Estimate|||||||2008-07-29|2008-07-30|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers|An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of BIIB014 at Multiple Dose Levels in Healthy Male Volunteers|Completed||Phase 1|32|Actual|Biogen||1|||f||||f||||||||||2018-06-01 02:55:07.274516|2018-06-01 02:55:07.274516
NCT00088335|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2008-03-03|2004-07-23|2004-07-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2004||2004-07-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Biological Markers in Parkinson's Disease|Investigation of Biomarkers in Parkinson's Disease|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:47.95196|2018-06-01 05:05:47.95196
NCT00531180|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2017-10-04|2007-09-14|2007-09-18|Estimate|||||||2017-10-04|2017-10-05|Actual|August 2007|Actual|2007-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||4-Dimensional CT Derived Ventilation Versus SPECT Aerosol Ventilation in Patients With Thoracic Malignancies|Phase II Trial Comparing 4-Dimensional Computed Tomography Derived Ventilation Versus SPECT/CT Tc-99m Aerosol Ventilation in Patients With Thoracic Malignancies|Active, not recruiting|||36|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:55:07.415958|2018-06-01 02:55:07.415958
NCT00531167|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2012-10-18|2007-09-17|2007-09-18|Estimate|||||||2012-10-18|2012-10-22|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional|||Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B|Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B|Completed||Phase 4|219|Actual|Korea University||2|||f||||t||||||||||2018-06-01 02:55:07.530051|2018-06-01 02:55:07.530051
NCT00531154|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2007-09-17|2007-09-17|2007-09-18|Estimate|||||||2007-09-17|2007-09-18|Estimate||||September 2007|2007-09-30||||||||Observational|||Evaluation of the Dental Health Condition in Obesity Patients Before and After Bariatric Surgery||Unknown status|Not yet recruiting||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 02:55:07.719106|2018-06-01 02:55:07.719106
NCT00531141|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-15|||2009-06-23|2007-09-17|2007-09-18|Estimate|||||||2009-06-23|2009-06-24|Estimate|May 2007||2007-05-31|June 2009|2009-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||The Optical Coherence Tomography in Age-Related Macular Degeneration Study: The OCT in AMD Study|Reproducibility of Retinal Thickness Measurements by Optical Coherence Tomography in Age-Related Macular Degeneration The OCT in AMD Study|Completed|||200|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||4||f||||f||||||||||2018-06-01 02:55:08.144761|2018-06-01 02:55:08.144761
NCT00531128|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2018-05-18|2007-09-14|2007-09-18|Estimate|||||||2018-05-18|2018-05-21|Actual|September 10, 2007||2007-09-10|May 17, 2018|2018-05-17|May 17, 2018|Actual|2018-05-17|July 27, 2012|Actual|2012-07-27||Interventional|||The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol|A Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy Metabolism|Completed||N/A|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:55:08.220819|2018-06-01 02:55:08.220819
NCT00531115|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2013-02-19|2007-09-17|2007-09-18|Estimate|||||||2013-02-19|2013-02-20|Estimate|November 2007||2007-11-30|February 2013|2013-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.|Multicentre, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With Oxaliplatin and Capecitabine (XELOX) for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.|Terminated||Phase 2|28|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1||"According to the study design, in the first step the number of responses was lower than the~   number required (< 7)."|f||||f||||||||||2018-06-01 02:55:08.294173|2018-06-01 02:55:08.294173
NCT00531102|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2016-10-11|2007-09-17|2007-09-18|Estimate|||||||2016-10-11|2016-10-12|Estimate|February 2008||2008-02-29|October 2016|2016-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect of Establishing Functional Residual Capacity During Newborn Resuscitation on Oxygenation|Effects of Oxygen and Functional Residual Capacity on the Oxygen Saturations of Infants ≥ 35 Weeks Gestation During Delivery Room Resuscitation.|Terminated||N/A|40|Actual|University of Calgary||2||Slow enrolment|f||||f||||||||No||2018-06-01 02:55:08.387929|2018-06-01 02:55:08.387929
NCT00531089|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2010-05-18|2007-09-17|2007-09-18|Estimate|||||||2010-05-18|2010-05-19|Estimate|December 2007||2007-12-31|September 2007|2007-09-30|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Rituximab in Patients With Relapsed or Refractory TTP-HUS|A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed/Refractory Thrombotic Thrombocytopenic Purpura (TTP) - Hemolytic Uremic Syndrome (HUS)|Unknown status|Recruiting|Phase 2|60|Anticipated|McMaster University||1|||f||||t||||||||||2018-06-01 02:55:08.480941|2018-06-01 02:55:08.480941
NCT00531076|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2011-04-04|2007-09-17|2007-09-18|Estimate|||||||2011-04-04|2011-04-05|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer|Phase I Study of Concurrent Bevacizumab (Avastin) With Involved-field Thoracic Radiotherapy for Inoperable Non-squamous Non-small Cell Lung Cancer, Followed by Both Concurrent and Maintenance Bevacizumab|Terminated||Phase 1|6|Actual|VU University Medical Center||||Study terminated due to toxicity|f||||f||||||||||2018-06-01 02:55:08.639253|2018-06-01 02:55:08.639253
NCT00531063|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2011-11-01|2007-09-17|2007-09-18|Estimate|||||||2011-11-01|2011-11-02|Estimate|November 2001||2001-11-30|November 2011|2011-11-30||||August 2005|Actual|2005-08-31||Interventional|||This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus|A 2-year Extension to a 1-year Multicenter, Randomized, Open Label, Parallel Group Study of the Safety, Tolerability and Efficacy of Two Doses (1.5 and 3 mg/Day) of Everolimus With Steroids and Optimized Administration of Cyclosporine in de Novo Renal Transplant Recipients.|Completed||Phase 3|237|Anticipated|Novartis|||||f||||||||||||||2018-06-01 02:55:08.705477|2018-06-01 02:55:08.705477
NCT00531050|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|2011-07-29||2012-04-23|2007-09-17|2007-09-18|Estimate|2012-04-23|2012-05-23|Estimate||||2012-04-23|2012-05-23|Estimate|August 2007||2007-08-31|April 2012|2012-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol|A Double-blind, Randomized, Cross-over, Placebo-controlled, 2-part Study to Compare the Effect of Exercise and High-dose Salbutamol on Maximal Heart-rate in Patients With COPD Following Therapeutic Doses of Inhaled QAB149 and Salmeterol|Completed||Phase 2|27|Actual|Novartis||6|||f||||f||||||||||2018-06-01 02:55:08.922902|2018-06-01 02:55:08.922902
NCT00531037|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2017-11-10|2007-09-17|2007-09-18|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2007||2007-06-30|November 2017|2017-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|NATURE||Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers|Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers|Completed|||1440|Actual|LivaNova|||||f||||f||||||||||2018-06-01 02:55:09.727113|2018-06-01 02:55:09.727113
NCT00528385|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2007-09-11|2007-09-11|2007-09-12|Estimate|||||||2007-09-11|2007-09-12|Estimate|March 2005||2005-03-31|September 2007|2007-09-30||||||||Interventional|||Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System|Influence of Adding Aldosterone Receptor Blocker to Dual Renin-Angiotensin-Aldosterone System Blockade on Proteinuria|Completed||N/A|||Medical University of Gdansk|||||f||||||||||||||2018-06-01 02:56:14.293028|2018-06-01 02:56:14.293028
NCT00531024|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-15|||2009-04-20|2007-09-17|2007-09-18|Estimate|||||||2009-04-20|2009-04-22|Estimate|August 2005||2005-08-31|April 2009|2009-04-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|BEAT-AMD||Systemic Avastin Therapy in Age-Related Macular Degeneration|Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration|Completed||Phase 2/Phase 3|30|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||2|||f||||f||||||||||2018-06-01 02:55:10.098508|2018-06-01 02:55:10.098508
NCT00531011|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2011-05-16||2015-05-12|2007-09-14|2007-09-18|Estimate|2011-07-14|2011-08-15|Estimate||||2015-05-12|2015-06-08|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|EXecutive||EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease|EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease.|Completed||Phase 4|200|Actual|Abbott Vascular||2|||f||||f||||||||||2018-06-01 02:55:10.217404|2018-06-01 02:55:10.217404
NCT00530998|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2018-04-30|2007-09-17|2007-09-18|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2007||2007-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|NOTES||Minimally Invasive Surgery: Using Natural Orfices|Natural Orifice Translumenal Endoscopic Surgery (NOTES): Laparoscopic Assisted Trans-Vaginal Appendectomy and Cholecystectomy|Recruiting|||120|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-06-01 02:55:10.910754|2018-06-01 02:55:10.910754
NCT00530985|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-16|||2009-06-30|2007-09-17|2007-09-18|Estimate|||||||2009-06-30|2009-07-02|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Preserving Function Among Disability Applicants|Preserving Function Among Disability Applicants: A Motivational Enhancement Approach to Benefits Counseling|Completed||Phase 1|120|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 02:55:11.021452|2018-06-01 02:55:11.021452
NCT00530972|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2009-09-04|2007-09-17|2007-09-18|Estimate|||||||2009-09-04|2009-09-07|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PILOT-NR||Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies|Treatment of Patients With Chronic Hepatitis C Co-infected With HIV Relapsers or Non Responders, Previous Exposed to Sub-optimal Therapies: Open, Pilot Trial|Completed||Phase 4|50|Actual|Hospital Carlos III, Madrid||1|||f||||t||||||||||2018-06-01 02:55:11.111478|2018-06-01 02:55:11.111478
NCT00530946|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2009-03-10||2009-04-28|2007-09-14|2007-09-18|Estimate|2009-03-10|2009-04-13|Estimate||||2009-04-28|2009-05-12|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin|A Multi-Center, Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin In The Treatment Of Concurrent Hypertension And Hyper-LDL-Cholesterolemia|Completed||Phase 3|165|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 02:55:11.219997|2018-06-01 02:55:11.219997
NCT00530933|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-15|||2007-09-15|2007-09-15|2007-09-18|Estimate|||||||2007-09-15|2007-09-18|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|April 2009|Anticipated|2009-04-30|||||Interventional|||Tibial Nerve Stimulation for Faecal Incontinence|Prospective Randomised Placebo Controlled Study Into Percutaneous and Transcutaneous Tibial Nerve Stimulation for Faecal Incontinence|Unknown status|Recruiting|N/A|66|Anticipated|London North West Healthcare NHS Trust||3|||f||||f||||||||||2018-06-01 02:55:12.010422|2018-06-01 02:55:12.010422
NCT00530920|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|2009-05-15||2014-05-27|2007-09-17|2007-09-18|Estimate|2009-05-15|2009-07-08|Estimate||||2014-05-27|2014-06-06|Estimate|October 2007||2007-10-31|May 2014|2014-05-31||||May 2008|Actual|2008-05-31||Interventional||Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment|Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients|A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-state Pharmacokinetics and Short-term Efficacy and Safety in HIV-1 Positive Treatment naïve Patients|Completed||Phase 2|85|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:55:12.134736|2018-06-01 02:55:12.134736
NCT00530907|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2015-01-07|2007-09-14|2007-09-18|Estimate|||||||2015-01-07|2015-01-08|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Valproic Acid and Bevacizumab in Patients With Advanced Cancer|Phase I Study of Valproic Acid Given in Combination With Bevacizumab in Patients With Advanced Cancer to Determine Safety and Tolerability|Completed||Phase 1|71|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:55:12.744312|2018-06-01 02:55:12.744312
NCT00530894|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2016-03-07||2017-08-14|2007-09-14|2007-09-18|Estimate|2017-04-03|2017-05-11|Actual||||2017-08-14|2017-09-13|Actual|April 2007|Actual|2007-04-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|September 2010|Actual|2010-09-30||Interventional|PARTNER|The inoperable and high risk groups were not randomized against each other and were essentially two separate trials, therefore the pooled mean and standard deviations do not provide meaningful data and were not reported.|THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial|THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve|Completed||N/A|1057|Actual|Edwards Lifesciences||4|||f||||t||||||||||2018-06-01 02:55:12.843802|2018-06-01 02:55:12.843802
NCT00530881|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2007-09-17|2007-09-17|2007-09-18|Estimate|||||||2007-09-17|2007-09-18|Estimate|April 2006||2006-04-30|September 2007|2007-09-30|October 2006|Actual|2006-10-31|||||Interventional|||Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Establish Proof of Concept With PHX1149 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|180|Actual|Phenomix||2|||f||||f||||||||||2018-06-01 02:55:13.902925|2018-06-01 02:55:13.902925
NCT00530868|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2018-02-28|2007-09-17|2007-09-18|Estimate|||||||2018-02-28|2018-03-02|Actual|October 2007||2007-10-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer|A Phase II, Randomized, Open Label Trial of Pre-operative (Neoadjuvant)Letrozole (Femara) vs. Letrozole in Combination With Avastin in Post Menopausal Women With Newly Diagnosed Operable Breast Cancer|Active, not recruiting||Phase 2|75|Actual|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-06-01 02:55:13.964121|2018-06-01 02:55:13.964121
NCT00530699|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2009-09-10|2007-09-14|2007-09-17|Estimate|||||||2009-09-10|2009-09-11|Estimate|November 2007||2007-11-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)|A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1152 in Japanese Patients With Acute Myeloid Leukaemia.|Completed||Phase 1|30|Anticipated|AstraZeneca|||||f||||t||||||||||2018-06-01 02:55:21.03503|2018-06-01 02:55:21.03503
NCT00530855|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2015-05-18||2017-07-28|2007-09-14|2007-09-18|Estimate|2015-05-18|2015-06-03|Estimate||||2017-07-28|2017-08-28|Actual|February 2008||2008-02-29|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Baseline Characteristics refer to the Safety Set, which is defined as all subjects who met the inclusion/exclusion criteria, signed an informed consent form, and took at least 1 dose of Trial medication.|Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures|A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects With Partial-onset Seizures|Completed||Phase 3|322|Actual|UCB Pharma||1|||f||||||||||||||2018-06-01 02:55:14.069007|2018-06-01 02:55:14.069007
NCT00530842|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|2009-12-30||2013-11-27|2007-09-17|2007-09-18|Estimate|2010-02-15|2010-03-10|Estimate||||2013-11-27|2013-12-24|Estimate|September 2007||2007-09-30|September 2013|2013-09-30||||January 2009|Actual|2009-01-31||Interventional|||Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD|Effect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients (a Randomised, Double-blind, Double Dummy, 16 (2 x 8) Weeks, Crossover Study).|Completed||Phase 4|344|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:55:14.680459|2018-06-01 02:55:14.680459
NCT00530829|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-17|||2010-03-08|2007-09-17|2007-09-18|Estimate|||||||2010-03-08|2010-03-09|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Impact of Home Zinc Treatment for Acute Diarrhea in Children|Clinical Effectiveness and Preventive Impact of Home Zinc Treatment for Acute Diarrhea in Children: A Cluster-randomized Field Trial in Rural Western Kenya|Completed||Phase 3|3000|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:55:15.839133|2018-06-01 02:55:15.839133
NCT00530816|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2013-10-15||2017-04-28|2007-09-14|2007-09-18|Estimate|2015-10-28|2015-12-03|Estimate||||2017-04-28|2017-05-02|Actual|September 2007||2007-09-30|April 2017|2017-04-30|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional||Safety Population: All patients enrolled on study and who received at least 1 dose of carfilzomib.|Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma|An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|164|Actual|Amgen||1|||f||||||||||||||2018-06-01 02:55:15.95539|2018-06-01 02:55:15.95539
NCT00530803|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2009-10-26|2007-09-13|2007-09-17|Estimate|||||||2009-10-26|2009-10-27|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children|The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children|Completed||N/A|100|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-06-01 02:55:17.127167|2018-06-01 02:55:17.127167
NCT00530790|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2009-02-02||2017-01-16|2007-09-14|2007-09-17|Estimate|2009-06-04|2009-07-24|Estimate||||2017-01-16|2017-02-28|Actual|August 2007||2007-08-31|January 2017|2017-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome|Clinical Evaluation of Ropinirole CR-RLS Tablets in Restless Legs Syndrome-Open-Label, Uncontrolled Study. Classification: Clinical Pharmacology, Exploratory|Completed||Phase 2|35|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:55:17.341517|2018-06-01 02:55:17.341517
NCT00530777|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2012-03-22||2012-03-22|2007-09-14|2007-09-17|Estimate|2012-03-22|2012-04-18|Estimate||||2012-03-22|2012-04-18|Estimate|April 2008||2008-04-30|March 2012|2012-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|VIP||HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding|HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding|Completed||Phase 2|148|Actual|University of Washington|Unable to evaluate the effect of valacyclovir on MTCT or on change in HIV-1 RNA among women who were eligible for HAART. Underpowered to detect association between treatment and mother to child HIV transmission.|2|||f||||t||||||||||2018-06-01 02:55:18.387411|2018-06-01 02:55:18.387411
NCT00530764|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2011-03-02||2013-06-13|2007-09-13|2007-09-17|Estimate|2011-06-16|2011-06-17|Estimate||||2013-06-13|2013-06-20|Estimate|November 2007||2007-11-30|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|SPRAY||A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.|A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.|Completed||Phase 2|360|Actual|GW Pharmaceuticals Ltd.||4|||f||||t||||||||||2018-06-01 02:55:18.666958|2018-06-01 02:55:18.666958
NCT00530751|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2015-10-01|2007-09-13|2007-09-17|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2007||2007-03-31|October 2015|2015-10-31||||October 2008|Actual|2008-10-31||Observational|||Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation|Patient Perspectives on Sharing Family Medical Histories|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||PI left|f||||f||||||||||2018-06-01 02:55:19.533629|2018-06-01 02:55:19.533629
NCT00530738|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2014-07-17|2007-09-14|2007-09-17|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2007||2007-09-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety and Efficacy of Longterm HPN With Two Lipid Emulsions|Efficacy, Safety and Quality of Life of a Long-term Home Parenteral Nutrition Regimen With Either LIPIDEM® or LIPOFUNDIN® MCT a Mono-center, Randomized, Double Blind Study|Completed||Phase 4|42|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-06-01 02:55:19.594484|2018-06-01 02:55:19.594484
NCT00530725|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2017-10-24|2007-09-14|2007-09-17|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2006||2006-08-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|OPTICC||Management of Occult Pneumothoraces in Mechanically Ventilated Patients|Prospective Randomized Trial of the Management of Occult Pneumothoraces in Mechanically Ventilated Patients|Recruiting||N/A|300|Anticipated|University of Calgary||2|||f||||f||||||||No|No plan.|2018-06-01 02:55:19.656876|2018-06-01 02:55:19.656876
NCT00530712|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2014-07-28||2015-08-14|2007-09-14|2007-09-17|Estimate|2014-07-28|2014-08-15|Estimate||||2015-08-14|2015-08-26|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|July 2013|Actual|2013-07-31|March 2012|Actual|2012-03-31||Interventional|DURABILITY II||Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis|The US StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol STent SYstem II|Completed||Phase 2/Phase 3|287|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 02:55:19.756371|2018-06-01 02:55:19.756371
NCT00530686|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2017-04-21|2007-09-13|2007-09-17|Estimate|||||||2017-04-21|2017-04-24|Actual|July 2008|Actual|2008-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment|Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment|Completed||Phase 1|1|Actual|Baylor Research Institute|||||f||||t|t|f||||||Undecided||2018-06-01 02:55:21.149235|2018-06-01 02:55:21.149235
NCT00530660|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2015-10-07|2007-09-14|2007-09-17|Estimate|||||||2015-10-07|2015-10-09|Estimate|September 2007||2007-09-30|December 2008|2008-12-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)|An Open-label Phase II Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Heterologous Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Young Adult Population (Follow Up to Study 810501)|Completed||Phase 2|141|Anticipated|Ology Bioservices|||||f||||t||||||||||2018-06-01 02:55:21.221748|2018-06-01 02:55:21.221748
NCT00530647|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-17|Estimate|||||||2007-09-13|2007-09-17|Estimate||||October 2006|2006-10-31||||||||Observational|||fMRI Study of Brain Neural Network and Plasticity After Stroke||Unknown status|Recruiting||||Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:55:21.313809|2018-06-01 02:55:21.313809
NCT00530634|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2015-08-19||2015-10-07|2007-09-13|2007-09-17|Estimate|2015-08-19|2015-09-17|Estimate||||2015-10-07|2015-10-29|Estimate|August 1999||1999-08-31|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer|Multimodality Therapy for Stages II and III Non-Small Cell Lung Cancer: Surgical Resection Followed by Sequential Administration of Gemcitabine Plus Cisplatin Chemotherapy and Radiation Therapy|Terminated||Phase 2|3|Actual|City of Hope Medical Center|Study was closed early due to poor accrual. Reported data are not statistically powered to provide meaningful conclusions|1||Poor accrual|f||||||||||||||2018-06-01 02:55:21.398247|2018-06-01 02:55:21.398247
NCT00530621|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13||2009-10-16|2009-10-16|2007-09-13|2007-09-17|Estimate||||2009-10-16|2009-10-19|Estimate|2009-10-16|2009-10-19|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of Enzastaurin Versus Placebo With Pemetrexed for Patients With Advanced or Metastatic Lung Cancer|A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl Versus Placebo Concurrently With Pemetrexed (Alimta®) as Second-Line Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|149|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 02:55:22.368827|2018-06-01 02:55:22.368827
NCT00530608|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2010-02-09|2007-09-13|2007-09-17|Estimate|||||||2010-02-09|2010-02-10|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|November 2007|Actual|2007-11-30|||||Observational|||Electrophysiological Properties of the Pulmonary Veins|Electrophysiological Properties of the Pulmonary Veins|Completed|||35|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-06-01 02:55:22.485281|2018-06-01 02:55:22.485281
NCT00530595|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-14|2007-09-14|2007-09-17|Estimate|||||||2007-09-14|2007-09-17|Estimate||||September 2007|2007-09-30||||||||Interventional|||Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients||Completed||N/A|||Saitama Medical University|||||f||||f||||||||||2018-06-01 02:55:22.531724|2018-06-01 02:55:22.531724
NCT00530582|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2007-09-14|2007-09-14|2007-09-17|Estimate|||||||2007-09-14|2007-09-17|Estimate|November 2003||2003-11-30|September 2007|2007-09-30|July 2004|Actual|2004-07-31|||||Interventional|||Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women|Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women|Completed||Phase 4|10|Actual|Max-Planck-Institute of Psychiatry|||||f||||f||||||||||2018-06-01 02:55:22.583697|2018-06-01 02:55:22.583697
NCT00530569|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2013-01-24|2007-09-14|2007-09-17|Estimate|||||||2013-01-24|2013-01-28|Estimate|August 2007||2007-08-31|January 2012|2012-01-31||||||||Observational|HER 2||Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy|Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy|Unknown status|Active, not recruiting||60|Anticipated|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 02:55:22.655471|2018-06-01 02:55:22.655471
NCT00530556|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2012-02-15|2007-09-14|2007-09-17|Estimate|||||||2012-02-15|2012-02-17|Estimate|March 2003||2003-03-31|February 2012|2012-02-29|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Insomnia and Daytime Function in Osteoarthritis|Effect of Zolpidem vs Placebo on Insomnia and Daytime Function in Patients With Insomnia Associated With Osteoarthritis|Completed||Phase 4|170|Actual|Sanofi|||||f||||||||||||||2018-06-01 02:55:22.717244|2018-06-01 02:55:22.717244
NCT00530543|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-17|Estimate|||||||2007-09-13|2007-09-17|Estimate||||May 2007|2007-05-31||||||||Interventional|||Effects of Gait Training With Assistance of a Robot-Driven Gait Orthosis in Hemiparetic Patients After Stroke||Unknown status|Recruiting|N/A|||Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:55:22.865453|2018-06-01 02:55:22.865453
NCT00530530|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2014-10-28|2007-09-13|2007-09-17|Estimate|||||||2014-10-28|2014-10-29|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||ASP8825 - Study in Patients With Restless Legs Syndrome|ASP8825 Phase ⅡStudy—A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP8825 in Patients With Restless Legs Syndrome|Completed||Phase 2|474|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 02:55:22.933665|2018-06-01 02:55:22.933665
NCT00530517|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2008-02-07|2007-09-13|2007-09-17|Estimate|||||||2008-02-07|2008-02-18|Estimate|September 2007||2007-09-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study on the Usability of the Needle-Free Intraject® System in Adult Patients During Acute Migraine Attack|A Multi-Center, Open-Label, Single-Dose, Single-Arm Study to Evaluate the Usability of Subcutaneously Administered Sumatriptan Delivered Via the Intraject® System in Adult Patients During Acute Migraine Attack|Completed||Phase 2|54|Actual|Zogenix, Inc.||1|||f||||t||||||||||2018-06-01 02:55:23.04617|2018-06-01 02:55:23.04617
NCT00530504|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2015-07-28||2015-09-24|2007-09-14|2007-09-17|Estimate|2015-08-14|2015-09-16|Estimate||||2015-09-24|2015-10-16|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CREATE PAS||Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study|Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study|Completed||Phase 4|1500|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 02:55:23.150447|2018-06-01 02:55:23.150447
NCT00530491|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2008-02-01|2007-09-14|2007-09-17|Estimate|||||||2008-02-01|2008-02-14|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|October 2008|Anticipated|2008-10-31|September 2008|Anticipated|2008-09-30||Interventional|||Prospective Trial to Reduce Morbidity and Mortality After Lung Surgery in Patients With Reduced Pulmonary Capacity|Prospective Randomized Controlled Trial to Reduce Morbidity and Mortality After Lung Surgery in Patients With FEV1 < 70% of Expected Value or < 1.5L|Unknown status|Recruiting|N/A|90|Anticipated|University of Ulm||2|||f||||f||||||||||2018-06-01 02:55:23.406274|2018-06-01 02:55:23.406274
NCT00530452|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2008-06-12|2007-09-13|2007-09-17|Estimate|||||||2008-06-12|2008-06-13|Estimate|October 2007||2007-10-31|June 2008|2008-06-30|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects|Double-Blind, Placebo Controlled Phase II Repeat Dose Study of the Safety and Efficacy of Three Parallel Loading and Maintenance Dose Regimens of CG100649 Versus Placebo for the Treatment of Primary Osteoarthritis in Male Subjects|Unknown status|Recruiting|Phase 2|240|Anticipated|CrystalGenomics, Inc.||4|||f||||f||||||||||2018-06-01 02:55:23.56726|2018-06-01 02:55:23.56726
NCT00530439|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2011-06-13||2011-07-15|2007-09-13|2007-09-17|Estimate|2011-06-13|2011-07-14|Estimate||||2011-07-15|2011-07-22|Estimate|October 2007||2007-10-31|April 2008|2008-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|LiP||Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women|Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women|Completed||N/A|360|Actual|Odense University Hospital||2|||f||||f||||||||||2018-06-01 02:55:23.680223|2018-06-01 02:55:23.680223
NCT00530426|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2014-01-30|2007-09-13|2007-09-17|Estimate|||||||2014-01-30|2014-01-31|Estimate|September 2001||2001-09-30|October 2007|2007-10-31|February 2005|Actual|2005-02-28|||||Observational|||Heart Failure Registry|ADHERE Core II - Acute Decompensated HEart Failure REgistry|Completed|||150000||Scios, Inc.|||||f||||||||||||||2018-06-01 02:55:23.901753|2018-06-01 02:55:23.901753
NCT00530413|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2014-12-09|2007-09-13|2007-09-17|Estimate|||||||2014-12-09|2014-12-10|Estimate|March 2007||2007-03-31|December 2014|2014-12-31||||March 2009|Anticipated|2009-03-31||Interventional|||Study of Phenobarbital Inhibition of Catamenial Epilepsy|Study of Phenobarbital Inhibition of Catamenial Epilepsy|Withdrawn||N/A|0|Actual|University of Toledo Health Science Campus||2||IRB needs updated|f||||f||||||||||2018-06-01 02:55:23.986001|2018-06-01 02:55:23.986001
NCT00530400|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-14|2007-09-14|2007-09-17|Estimate|||||||2007-09-14|2007-09-17|Estimate|April 1994||1994-04-30|September 2007|2007-09-30|March 2000|Actual|2000-03-31|||||Interventional|||Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgical Site Infection in Herniated Disk Surgery|Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of Single-Dose Cefuroxime Prophylaxis in Herniated Disk Surgery|Completed||Phase 4|1369|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-06-01 02:55:24.053296|2018-06-01 02:55:24.053296
NCT00530387|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2011-08-03|2007-09-14|2007-09-17|Estimate|||||||2011-08-03|2011-08-04|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Multi-Centre European Photopatch Test Study|A Prospective, Open, Multi-Centre Photopatch Test Study of Patients Suspected of Photoallergy to Organic Sunscreens and Topical Nonsteroidal Anti-inflammatory Drugs Used Within Europe.|Completed||N/A|1000|Actual|NHS Tayside|||||f||||f||||||||||2018-06-01 02:55:24.248935|2018-06-01 02:55:24.248935
NCT00530374|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2009-05-25|2007-09-13|2007-09-17|Estimate|||||||2009-05-25|2009-05-27|Estimate|November 2007||2007-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Impact of Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent|Impact of Oral Iron Supplementation With Sprinkles on Infectious Morbidity When Moderate to Severe Pediatric Malnutrition Is Highly Prevalent - A Non-Inferiority Safety Trial|Completed||Phase 3|268|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 02:55:24.341389|2018-06-01 02:55:24.341389
NCT00530361|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2016-09-19|2007-09-13|2007-09-17|Estimate|||||||2016-09-19|2016-09-20|Estimate||||July 2011|2011-07-31|September 2009|Anticipated|2009-09-30|||||Interventional|||An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)|A Double-Blind, Randomized, Placebo-Controlled Study of Nesiritide Administered After Induction of Anesthesia in Heart Failure Patients With Renal Insufficiency Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (NAPA-CS)|Withdrawn||Phase 3|0|Actual|Scios, Inc.||||Study was withdrawn prior to patient dosing based on a business decision.|||||f||||||||||2018-06-01 02:55:24.434843|2018-06-01 02:55:24.434843
NCT00530348|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2014-11-17|2012-05-31|2014-11-17|2007-09-13|2007-09-17|Estimate|2014-11-17|2014-11-24|Estimate|2012-05-31|2012-06-05|Estimate|2014-11-17|2014-11-24|Estimate|August 2007||2007-08-31|November 2014|2014-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|CARE-MS I|Full analysis set (FAS) population included all randomized participants who received at least 1 dose of study drug.|Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One|A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|581|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 02:55:24.588933|2018-06-01 02:55:24.588933
NCT00530335|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2009-04-22||2011-07-25|2007-09-14|2007-09-17|Estimate|2009-04-22|2009-06-10|Estimate||||2011-07-25|2011-07-27|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)|An Open-Label Pilot Study for Atomoxetine in Adult Subjects With Attention Deficit/Hyperactivity Disorder|Completed||Phase 2|45|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:55:25.449312|2018-06-01 02:55:25.449312
NCT00530322|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-17|Estimate|||||||2007-09-13|2007-09-17|Estimate|June 2006||2006-06-30|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Observational|||Adhesion Formation Following Laparoscopic and Open Colorectal Surgery|Adhesion Formation Following Laparoscopic and Open Colorectal Surgery|Completed|||46|Actual|University of Surrey|||2||f||||f||||||||||2018-06-01 02:55:25.923376|2018-06-01 02:55:25.923376
NCT00530309|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2017-08-15|2007-09-14|2007-09-17|Estimate|||||||2017-08-15|2017-08-17|Actual|August 1, 2007|Actual|2007-08-01|August 2017|2017-08-31|April 17, 2008|Actual|2008-04-17|April 17, 2008|Actual|2008-04-17||Interventional|||Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus|Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|40|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:55:25.997836|2018-06-01 02:55:25.997836
NCT00530296|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2007-09-14|2007-09-14|2007-09-17|Estimate|||||||2007-09-14|2007-09-17|Estimate|June 2005||2005-06-30|September 2007|2007-09-30|June 2008|Anticipated|2008-06-30|||||Interventional|CBTRPat||CBT to Treat Depression in Renal Patients|Effectiveness of Cognitive Behavioral Therapy in Patients With End-Stage Renal Disease in Hemodialysis and With Depression|Unknown status|Recruiting|N/A|80|Anticipated|Federal University of São Paulo|||||f||||f||||||||||2018-06-01 02:55:26.134962|2018-06-01 02:55:26.134962
NCT00069680|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2018-05-18|2003-09-29|2003-09-30|Estimate|||||||2018-05-18|2018-05-21|Actual|September 29, 2003||2003-09-29|May 17, 2018|2018-05-17|May 17, 2018||2018-05-17|||||Observational|||Genetic Analysis of Gray Platelet Syndrome|Genetic Analysis of Gray Platelet Syndrome|Completed|||123|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:59.885507|2018-06-01 05:16:59.885507
NCT00530283|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2012-01-18|2007-09-14|2007-09-17|Estimate|||||||2012-01-18|2012-01-19|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|||||Observational|||PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy|The Clinical Utility of PET-CT in the Management of Squamous Cell Carcinoma of the Neck Nodes With Unknown Primary Malignancy|Completed|||58|Anticipated|AHS Cancer Control Alberta|||1||f||||f||||||||||2018-06-01 02:55:26.210519|2018-06-01 02:55:26.210519
NCT00530270|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2009-07-16||2013-03-29|2007-09-14|2007-09-17|Estimate|2009-11-24|2009-12-31|Estimate||||2013-03-29|2013-04-09|Estimate|December 2006||2006-12-31|March 2013|2013-03-31|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease|Randomized Trial of Oral Dexamethasone for Acute Chest Syndrome|Terminated||Phase 3|12|Actual|Children's Hospital Medical Center, Cincinnati|Primary limitation of this study is that is was terminated prior to enrolling all of the subjects necessary to address the primary question.|2||Study was closed June 23, 2008 due to low enrollment.|f||||t||||||||||2018-06-01 02:55:26.294991|2018-06-01 02:55:26.294991
NCT00530257|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2011-03-29||2011-11-15|2007-09-13|2007-09-17|Estimate|2011-11-15|2011-12-19|Estimate||||2011-11-15|2011-12-19|Estimate|June 2004||2004-06-30|November 2011|2011-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|CHOP||Study of the Effects of Osmotic-Release Oral System (OROS) Methylphenidate (Concerta) on Attention and Memory|Effect of OROS-Methylphenidate (Concerta) on Different Domains of Attention and Working Memory in Children With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 4|30|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 02:55:26.686688|2018-06-01 02:55:26.686688
NCT00530244|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2018-03-05|2007-09-13|2007-09-17|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2003||2003-03-31|March 2018|2018-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|DHA||Use of Formula Fortified With DHA in Infants With Cystic Fibrosis|The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)|Completed||N/A|76|Actual|University of Massachusetts, Worcester||2|||f||||t|f|f|||t|||||2018-06-01 02:55:27.086307|2018-06-01 02:55:27.086307
NCT00530231|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-17|Estimate|||||||2007-09-13|2007-09-17|Estimate||||May 2007|2007-05-31||||||||Observational|||Capsule Endoscopic Miss Rates Determined by Back-to-Back Capsule Endoscopy|Capsule Endoscopic Miss Rates Determined by Back-to-Back Capsule Endoscopy|Unknown status|Recruiting||||Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:55:27.18978|2018-06-01 02:55:27.18978
NCT00530218|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2015-07-08||2017-10-25|2007-09-13|2007-09-17|Estimate|2017-10-25|2017-12-02|Actual||||2017-10-25|2017-12-02|Actual|March 1999||1999-03-31|October 2017|2017-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||"All patients start out in the No CMV Reactivation period, at least until day 21 when the first blood culture or PCR tests are performed. After one positive blood culture or two consecutive positive PCR tests, patients move to the CMV Reactivation Detected period. Tests are performed twice weekly from day 21 post-transplant to day 100."|Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant|Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant|Completed||Phase 2|61|Actual|City of Hope Medical Center||1|||f||||t||||||||No||2018-06-01 02:55:27.282806|2018-06-01 02:55:27.282806
NCT00530205|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2011-07-13|2007-09-13|2007-09-17|Estimate|||||||2011-07-13|2011-07-14|Estimate|February 2007||2007-02-28|July 2011|2011-07-31||||||||Observational|||Effects of Radiation Therapy on the Body in Patients With Stage III Non-Small Cell Lung Cancer|An Observation of the Change in Percent Lean Body Mass of Stage III Non-Small Cell Lung Cancer Undergoing Radiation Treatment|Withdrawn|||0|Actual|Case Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 02:55:27.741082|2018-06-01 02:55:27.741082
NCT00530192|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2009-07-09|2007-09-14|2007-09-17|Estimate|||||||2009-07-09|2009-07-10|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|March 2009||2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Molecular Profiling Protocol (SCRI-CA-001)|A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers|Completed||Early Phase 1|86|Actual|Scottsdale Healthcare|||||f||||t||||||||||2018-06-01 02:55:27.802852|2018-06-01 02:55:27.802852
NCT00530179|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2011-12-06|2007-09-14|2007-09-17|Estimate|||||||2011-12-06|2011-12-07|Estimate|July 2007||2007-07-31|August 2011|2011-08-31||||August 2011|Actual|2011-08-31||Interventional|PET Chop||FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma|FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma|Unknown status|Active, not recruiting|N/A|80|Anticipated|AHS Cancer Control Alberta||2|||f||||t||||||||||2018-06-01 02:55:27.951034|2018-06-01 02:55:27.951034
NCT00530166|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13||2011-06-01|2014-06-03|2007-09-13|2007-09-17|Estimate||||2011-06-01|2011-06-07|Estimate|2014-06-03|2014-06-18|Estimate|July 2007||2007-07-31|June 2014|2014-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of JNJ-18054478 in Subjects With Asthma|Terminated||Phase 2|26|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||Lack of efficacy following an interim analysis|f||||t||||||||||2018-06-01 02:55:28.047411|2018-06-01 02:55:28.047411
NCT00530153|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2009-09-29|2007-09-14|2007-09-17|Estimate|||||||2009-09-29|2009-09-30|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|May 2008|Anticipated|2008-05-31|||||Interventional|||School Intervention Study of Nutrition, Wellbeing and Dental Health|School Intervention Study of Nutrition, Wellbeing and Dental Health|Unknown status|Active, not recruiting|N/A|769|Actual|National Institute for Health and Welfare, Finland|||||f||||||||||||||2018-06-01 02:55:28.166317|2018-06-01 02:55:28.166317
NCT00530140|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2011-10-05|2007-09-13|2007-09-17|Estimate|||||||2011-10-05|2011-10-06|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|September 2022|Anticipated|2022-09-30|September 2013|Anticipated|2013-09-30||Interventional|FLIDVAX2006||Idiotypic Vaccination for Follicular Lymphoma Patients|Idiotypic Vaccination for Poor-prognosis Follicular Lymphoma Patients in First Relapse|Recruiting||Phase 2|100|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-06-01 02:55:28.233972|2018-06-01 02:55:28.233972
NCT00530127|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2010-05-31|2007-09-14|2007-09-17|Estimate|||||||2010-05-31|2010-06-02|Estimate|April 2008||2008-04-30|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia|A Six-month Double-blind, Randomized, Placebo-controlled Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia|Completed||Phase 1/Phase 2|80|Anticipated|ApoPharma||5|||f||||t||||||||||2018-06-01 02:55:28.327035|2018-06-01 02:55:28.327035
NCT00529945|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2007-12-18|2007-09-13|2007-09-14|Estimate|||||||2007-12-18|2007-12-21|Estimate|August 2007||2007-08-31|December 2007|2007-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|Paradigm IV||PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness|The Paradigm IV Trial - PFx Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness|Suspended||N/A|200|Anticipated|Cierra|||||f||||f||||||||||2018-06-01 02:55:31.113456|2018-06-01 02:55:31.113456
NCT00530114|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13||2016-02-16|2016-02-16|2007-09-13|2007-09-17|Estimate||||2016-02-16|2016-03-14|Estimate|2016-02-16|2016-03-14|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Fixed Dose Study of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia|Completed||Phase 2|167|Actual|Amgen||2|||f||||||||||||||2018-06-01 02:55:28.449652|2018-06-01 02:55:28.449652
NCT00530101|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2008-06-03|2007-09-14|2007-09-17|Estimate|||||||2008-06-03|2008-06-04|Estimate|July 2004||2004-07-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity|The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity|Completed||Phase 1|3|Actual|University of Miami|||||f||||f||||||||||2018-06-01 02:55:28.548211|2018-06-01 02:55:28.548211
NCT00530088|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2014-01-29||2014-06-03|2007-09-13|2007-09-17|Estimate|2014-06-03|2014-07-04|Estimate||||2014-06-03|2014-07-04|Estimate|October 2001||2001-10-31|June 2014|2014-06-30|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional||All treated and eligible patients|Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat|Photodynamic Therapy With Photofrin® for Treatment of Dysplasia, Carcinoma In Situ and Stage I Carcinoma of the Oral Cavity and the Larynx: A Pilot Study|Terminated||N/A|30|Actual|Roswell Park Cancer Institute|Due to the study's early termination, as a result of new competing studies, target accrual was not reached.|1||new competing studies|f||||t||||||||||2018-06-01 02:55:28.692428|2018-06-01 02:55:28.692428
NCT00530075|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|2016-04-18||2017-01-16|2007-09-14|2007-09-17|Estimate|2017-01-16|2017-03-06|Actual||||2017-01-16|2017-03-06|Actual|December 2003||2003-12-31|September 2007|2007-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis|Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis|Completed||Phase 2|45|Actual|Nippon Kayaku Co.,Ltd.||1|||f||||f||||||||||2018-06-01 02:55:29.017189|2018-06-01 02:55:29.017189
NCT00530062|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14||2017-10-12|2018-01-08|2007-09-14|2007-09-17|Estimate||||2011-12-12|2011-12-22|Estimate|2018-01-08|2018-01-12|Actual|January 2007||2007-01-31|January 2018|2018-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Comparison of Single-Dose of Albuterol Breath Activated Inhaler Versus Albuterol Metered Dose Inhaler in Asthmatics|Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability|Completed||Phase 4|49|Actual|Teva Pharmaceutical Industries||2|||f||||t|t|f||||||||2018-06-01 02:55:29.516766|2018-06-01 02:55:29.516766
NCT00530049|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2017-09-05|2007-09-13|2007-09-17|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2007||2007-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure|Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure|Active, not recruiting|||1745|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-06-01 02:55:29.651315|2018-06-01 02:55:29.651315
NCT00530036|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-14|||2007-09-14|2007-09-14|2007-09-17|Estimate|||||||2007-09-14|2007-09-17|Estimate|January 2004||2004-01-31|August 2007|2007-08-31|December 2007|Anticipated|2007-12-31|||||Observational|||Burden of Urinary Incontinence in Home Care Patients in the State of Geneva||Unknown status|Active, not recruiting||699|Actual|University Hospital, Geneva|||2||f||||f||||||||||2018-06-01 02:55:29.909881|2018-06-01 02:55:29.909881
NCT00530023|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2010-12-17||2011-05-09|2007-09-13|2007-09-17|Estimate|2011-05-09|2011-06-10|Estimate||||2011-05-09|2011-06-10|Estimate|February 2006||2006-02-28|May 2011|2011-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|STAR2||Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness|Pilot Study To Identify Effective Methods Of Training Pump Naïve Subjects To Use The Paradigm® 722 System And To Describe Clinical Effectiveness Compared To Subjects Continuing With Multiple Dose Injections (MDI) of Insulin|Completed||Phase 4|29|Actual|Medtronic Diabetes||2|||f||||f||||||||||2018-06-01 02:55:30.066012|2018-06-01 02:55:30.066012
NCT00530010|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2017-03-29|2007-09-13|2007-09-17|Estimate|||||||2017-03-29|2017-03-30|Actual|December 2004||2004-12-31|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma|Recruiting|||500|Anticipated|Northwestern University|||||f||||t||||||||||2018-06-01 02:55:30.563253|2018-06-01 02:55:30.563253
NCT00529997|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2010-08-10|2007-09-14|2007-09-17|Estimate|||||||2010-08-10|2010-08-11|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Dynamic Stabilization for Lumbar Spinal Stenosis With Stabilimax NZ® Dynamic Spine Stabilization System|Clinical Study Comparing Dynamic Stabilization of the Lumbar Spine With the Stabilimax NZ® Dynamic Spine Stabilization System to Posterolateral Instrumented Fusion - In Patients With Lumbar Spinal Stenosis|Terminated||N/A|480|Anticipated|Applied Spine Technologies||2||Company has ceased operation|f||||t||||||||||2018-06-01 02:55:30.691998|2018-06-01 02:55:30.691998
NCT00529984|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2012-07-11|2007-09-13|2007-09-14|Estimate|||||||2012-07-11|2012-07-12|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|CEA(6D)VRP||A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies|A Phase I/II Study of Active Immunotherapy With CEA(6D)VRP Vaccine(AVX701)in Patients With Advanced or Metastatic Malignancies Expressing CEA or Stage III Colon Cancer|Completed||Phase 1/Phase 2|28|Actual|AlphaVax, Inc.||5|||f||||t||||||||||2018-06-01 02:55:30.799724|2018-06-01 02:55:30.799724
NCT00529971|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2007-10-02|2007-09-12|2007-09-14|Estimate|||||||2007-10-02|2007-10-03|Estimate|December 2003||2003-12-31|September 2007|2007-09-30|December 2006|Actual|2006-12-31|||||Interventional|||A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV|A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV|Completed||Phase 3|117|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-06-01 02:55:30.926627|2018-06-01 02:55:30.926627
NCT00529958|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2016-08-17|2007-09-12|2007-09-14|Estimate|||||||2016-08-17|2016-08-19|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Three Methods for Anterior Cruciate Ligament Reconstruction|A Randomized Clinical Trial Comparing Three Methods for Anterior Cruciate Ligament Reconstruction: Patellar Tendon, Quadruple Semitendinosus/Gracilis and Double-Bundle Semitendinosus/Gracilis Grafts.|Active, not recruiting||N/A|330|Actual|University of Calgary||3|||f||||f||||||||No||2018-06-01 02:55:31.018977|2018-06-01 02:55:31.018977
NCT00529932|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2015-04-21|2007-09-13|2007-09-14|Estimate|||||||2015-04-21|2015-04-22|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|SELECT-AMI||A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction|Terminated||N/A|19|Actual|Onze Lieve Vrouw Hospital||2||Insufficient recruitment|f||||t||||||||||2018-06-01 02:55:31.229087|2018-06-01 02:55:31.229087
NCT00529919|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2007-09-12|2007-09-12|2007-09-14|Estimate|||||||2007-09-12|2007-09-14|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|Muffin||Effects of Medium Chain Triglyceride Oil, Versus Olive Oil, for Weight Loss|The Effects of a Weight Loss Diet Containing Medium Chain Triglyceride Oil, Versus Olive Oil, on Body Composition in Free-Living Adults|Completed||N/A|53|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 02:55:31.330057|2018-06-01 02:55:31.330057
NCT00529906|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2009-12-14|2007-09-13|2007-09-14|Estimate|||||||2009-12-14|2009-12-15|Estimate|August 2007||2007-08-31|December 2009|2009-12-31|August 2010|Anticipated|2010-08-31|||||Observational|||Endophenotype, Molecular Genetic Study on Attention-Deficit/Hyperactivity Disorder|Endophenotype, Molecular Genetic Study on Attention-deficit/ Hyperactivity Disorder|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments~   "|||2018-06-01 02:55:31.459213|2018-06-01 02:55:31.459213
NCT00529893|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2013-10-18|2007-09-13|2007-09-14|Estimate|||||||2013-10-18|2013-10-21|Estimate|July 2007||2007-07-31|October 2013|2013-10-31||||April 2013|Actual|2013-04-30||Observational|||Efficacy of Atomoxetine in the Neuropsychological Tests Among Children With ADHD|Efficacy of Atomoxetine in the Neuropsychological Tests Among Children With ADHD|Unknown status|Active, not recruiting||30|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 02:55:31.525587|2018-06-01 02:55:31.525587
NCT00529880|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2007-09-26|2007-09-12|2007-09-14|Estimate|||||||2007-09-26|2007-09-27|Estimate|December 2004||2004-12-31|September 2007|2007-09-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML||Unknown status|Recruiting|Phase 2|19|Anticipated|Cooperative Study Group A for Hematology|||||f||||f||||||||||2018-06-01 02:55:31.588414|2018-06-01 02:55:31.588414
NCT00529867|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2008-01-17|2007-09-12|2007-09-14|Estimate|||||||2008-01-17|2008-01-18|Estimate|May 2007||2007-05-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria|A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya|Completed||Phase 4|267|Actual|Dafra Pharma||2|||f||||f||||||||||2018-06-01 02:55:31.761566|2018-06-01 02:55:31.761566
NCT00529854|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2008-02-26|2007-09-13|2007-09-14|Estimate|||||||2008-02-26|2008-02-27|Estimate|October 2007||2007-10-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|SIC-IR||SIC-IR Billing and Documentation|Surgical and Trauma Intensive Care Unit Documentation and Billing Improvements With Medical Informatics|Completed|||814|Actual|MetroHealth Medical Center|||2||f||||f||||||||||2018-06-01 02:55:31.897847|2018-06-01 02:55:31.897847
NCT00529841|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2015-09-10|2007-09-13|2007-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia|A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia|Completed||N/A|7|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-06-01 02:55:32.025842|2018-06-01 02:55:32.025842
NCT00529828|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2008-01-10|2007-09-12|2007-09-14|Estimate|||||||2008-01-10|2008-01-16|Estimate|September 2007||2007-09-30|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|CLARINeT||Health Effects of CLA Versus Industrial Trans Fatty Acids|Health Effects of CLA Versus Industrial Trans Fatty Acids in Healthy Volunteers (CLARINeT-Study)|Completed||N/A|60|Anticipated|Wageningen University|||||f||||f||||||||||2018-06-01 02:55:32.144856|2018-06-01 02:55:32.144856
NCT00529815|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2010-02-24|2007-09-13|2007-09-14|Estimate|||||||2010-02-24|2010-02-25|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|September 2010|Anticipated|2010-09-30|March 2010|Anticipated|2010-03-31||Interventional|CGM||Continuous Glucose Monitoring in Patients With Type 2 Diabetes|A Pilot Study to Determine the Impact of Real-Time Continuous Glucose Monitoring (CGM) on Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 02:55:32.246508|2018-06-01 02:55:32.246508
NCT00529802|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2016-10-27||2018-03-27|2007-09-12|2007-09-14|Estimate|2017-10-11|2017-11-09|Actual||||2018-03-27|2018-04-25|Actual|September 2007||2007-09-30|March 2018|2018-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer|An Exploratory Study Evaluating FDG-PET as a Predictive Marker for mTOR Directed Therapy With RAD001 in Metastatic Renal Cell Cancer|Completed||Phase 2|60|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 02:55:32.414265|2018-06-01 02:55:32.414265
NCT00529789|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2009-09-22||2011-10-18|2007-09-12|2007-09-14|Estimate|2009-11-04|2009-12-09|Estimate||||2011-10-18|2011-10-24|Estimate|August 2007||2007-08-31|October 2011|2011-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder|F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder|Completed||Phase 2|72|Actual|Eli Lilly and Company|The Results Record was revised as a result of correcting identified errors in the number of participants with potentially significant changes in blood pressure.|1|||f||||f||||||||||2018-06-01 02:55:32.868554|2018-06-01 02:55:32.868554
NCT00529776|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2008-06-10|2007-09-12|2007-09-14|Estimate|||||||2008-06-10|2008-06-11|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|||||Interventional|||Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy|Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy|Completed||N/A|150|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:55:33.663425|2018-06-01 02:55:33.663425
NCT00529581|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2008-05-23|2007-09-13|2007-09-14|Estimate|||||||2008-05-23|2008-05-28|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment|Completed||Phase 2|150|Anticipated|Cognition Pharmaceuticals, LLC|||||f||||f||||||||||2018-06-01 02:55:38.976822|2018-06-01 02:55:38.976822
NCT00529763|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2011-01-31||2017-11-29|2007-09-13|2007-09-14|Estimate|2011-03-08|2011-04-05|Estimate||||2017-11-29|2017-12-26|Actual|November 30, 2007|Actual|2007-11-30|November 2017|2017-11-30|October 22, 2022|Anticipated|2022-10-22|June 17, 2009|Actual|2009-06-17||Interventional|||Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects|A Phase II Study to Determine the Activity of Dasatinib Administered Orally (PO) at a Dose of 100 mg Once Daily (QD) in Chronic Phase Chronic Myelogenous Leukemia (CML), at a Dose of 70 mg Twice Daily (BID) in Advanced Phase Chronic Myelogenous Leukemia (CML) Chinese Subjects Who Are Resistant to or Intolerant of Imatinib Mesylate (Gleevec®)|Active, not recruiting||Phase 2|140|Actual|Bristol-Myers Squibb||1|||f||||f|t|f|||t|||||2018-06-01 02:55:33.835345|2018-06-01 02:55:33.835345
NCT00529750|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2011-01-11|2007-09-12|2007-09-14|Estimate|||||||2011-01-11|2011-01-12|Estimate|July 2002||2002-07-31|January 2011|2011-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension|Comparative Trial of the Effects of Irbesartan vs Atenolol on the Endothelial Function of Hypertensive Patients With Metabolic Syndrome|Completed||Phase 4|108|Actual|Sanofi||2|||f||||||||||||||2018-06-01 02:55:35.033459|2018-06-01 02:55:35.033459
NCT00529737|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2012-07-26|2007-09-13|2007-09-14|Estimate|||||||2012-07-26|2012-07-30|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effect on Clip Markers After Vacuum-Assisted Biopsy by Postprocedure Mammogram|The Effect on Clip Markers Migration After Vacuum-Assisted Biopsy by Postprocedure Mammogram|Completed||N/A|61|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:55:35.105137|2018-06-01 02:55:35.105137
NCT00529724|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2011-01-18|2007-09-13|2007-09-14|Estimate|||||||2011-01-18|2011-01-19|Estimate|September 2007||2007-09-30|January 2011|2011-01-31|June 2009|Anticipated|2009-06-30|May 2009|Anticipated|2009-05-31||Interventional|||Body Weight Gain, Parkinson, Subthalamic Stimulation|Mechanisms of Body Weight Gain in Patients With Parkinson's Disease After Subthalamic Stimulation|Unknown status|Recruiting|Phase 2|32|Anticipated|University Hospital, Clermont-Ferrand|||||f||||f||||||||||2018-06-01 02:55:35.21113|2018-06-01 02:55:35.21113
NCT00529711|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2007-09-12|2007-09-12|2007-09-14|Estimate|||||||2007-09-12|2007-09-14|Estimate|July 2005||2005-07-31|September 2007|2007-09-30|July 2006|Actual|2006-07-31|||||Interventional|||The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients|The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients|Completed||Phase 3|66|Actual|Innogene Kalbiotech Pte. Ltd||2|||f||||f||||||||||2018-06-01 02:55:35.349481|2018-06-01 02:55:35.349481
NCT00529698|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2011-02-28|2007-09-13|2007-09-14|Estimate|||||||2011-02-28|2011-03-01|Estimate|January 2004||2004-01-31|July 2007|2007-07-31|November 2007|Actual|2007-11-30|||||Interventional|ISSP-001||Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein|A Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat Protein in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|20|Actual|Istituto Superiore di Sanità||2|||f||||t||||||||||2018-06-01 02:55:35.454923|2018-06-01 02:55:35.454923
NCT00529685|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2010-08-26|2007-09-13|2007-09-14|Estimate|||||||2010-08-26|2010-08-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 02:55:36.443752|2018-06-01 02:55:36.443752
NCT00529672|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2010-11-15|2007-09-13|2007-09-14|Estimate|||||||2010-11-15|2010-11-16|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|Magna||Surgery or Noninvasive Therapy for Varicose Veins|Randomized Single Center Comparative Study of the Treatment of Insufficient Greater Saphenous Vein: Surgery vs Ultrasound Guided Sclerotherapy With Foam and Endovenous Laser Therapy|Unknown status|Recruiting|Phase 3|240|Anticipated|Erasmus Medical Center||3|||f||||f||||||||||2018-06-01 02:55:36.544709|2018-06-01 02:55:36.544709
NCT00529659|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2012-04-06||2015-01-29|2007-09-12|2007-09-14|Estimate|2012-05-29|2012-07-02|Estimate||||2015-01-29|2015-02-16|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)|A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients With Sarcopenia|Completed||Phase 2|170|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 02:55:36.727621|2018-06-01 02:55:36.727621
NCT00529646|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2008-12-29|2007-09-13|2007-09-14|Estimate|||||||2008-12-29|2008-12-30|Estimate|July 2007||2007-07-31|December 2008|2008-12-31||||||||Interventional|||Single-Dose Safety Study of APD791 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Assess the Tolerability, Pharmacokinetics, and Pharmacodynamics of APD791 Administered to Healthy Adult Subjects|Completed||Phase 1|90|Anticipated|Arena Pharmaceuticals|||||f||||f||||||||||2018-06-01 02:55:37.455095|2018-06-01 02:55:37.455095
NCT00529633|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2016-03-25||2018-03-06|2007-09-12|2007-09-14|Estimate|2016-10-27|2016-10-28|Estimate||||2018-03-06|2018-04-02|Actual|September 2007||2007-09-30|March 2018|2018-03-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|ICM||The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients|Phase 3 Study: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients|Terminated||Phase 3|16|Actual|University of California, Davis|Early termination -- Study is terminated due to low enrollment of subjects willing to enter this study|2||Low enrollment -- We could not recruit patients willing to be enrolled|f||||t||||||||No||2018-06-01 02:55:37.737085|2018-06-01 02:55:37.737085
NCT00529620|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2010-05-26|2007-09-13|2007-09-14|Estimate|||||||2010-05-26|2010-05-27|Estimate|September 2007||2007-09-30|May 2010|2010-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal|Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal|Completed||Phase 3|1833|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-06-01 02:55:38.415075|2018-06-01 02:55:38.415075
NCT00529607|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2009-03-19|2007-09-12|2007-09-14|Estimate|||||||2009-03-19|2009-03-20|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Diagnostics for the Reperfusion Injury Following MI|New Imaging and Diagnostic Techniques for the Assessment of Reperfusion Injury in Myocardial Infarction.|Completed|||200|Anticipated|RWTH Aachen University|||3||f||||t||||||Samples Without DNA|"~     Biomarkers for Infarction and Inflammation~   "|||2018-06-01 02:55:38.737763|2018-06-01 02:55:38.737763
NCT00529594|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-14|Estimate|||||||2007-09-13|2007-09-14|Estimate|August 2006||2006-08-31|March 2007|2007-03-31|November 2006|Actual|2006-11-30|||||Interventional|||Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation|Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation|Completed||N/A|44|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 02:55:38.836197|2018-06-01 02:55:38.836197
NCT00529568|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2012-04-19||2013-10-10|2007-09-12|2007-09-14|Estimate|2012-04-19|2012-05-17|Estimate||||2013-10-10|2013-11-05|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease|Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)|Completed||Phase 3|759|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:55:39.268644|2018-06-01 02:55:39.268644
NCT00529555|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2013-07-10||2014-04-10|2007-09-11|2007-09-14|Estimate|2014-04-10|2014-05-09|Estimate||||2014-04-10|2014-05-09|Estimate|January 2006||2006-01-31|April 2014|2014-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis|A 9 Month,3-arm Multicenter Clinical Trial of Treatment With Periocline Gel (2.1% Minocycline HCl) for Adjunctive Use to Scaling and Root Planing (SRP) in Adults With Periodontal Disease.|Completed||Phase 3|602|Actual|Sunstar Americas||3|||f||||f||||||||||2018-06-01 02:55:42.333261|2018-06-01 02:55:42.333261
NCT00529542|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2013-02-15||2014-09-15|2007-09-12|2007-09-14|Estimate|2013-03-27|2013-05-08|Estimate||||2014-09-15|2014-09-25|Estimate|December 2004||2004-12-31|September 2014|2014-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol|A Six-week Double Blinded, Randomized Trial of Atorvastatin for the Treatment of PCOS Women With Elevated LDL Cholesterol|Completed||Phase 2|20|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 02:55:42.747711|2018-06-01 02:55:42.747711
NCT00529529|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2011-07-22||2011-08-25|2007-09-12|2007-09-14|Estimate|2011-07-22|2011-08-19|Estimate||||2011-08-25|2011-08-29|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma|A 26-week Treatment, Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study to Assess the Safety of Indacaterol (300 and 600 µg o.d.) in Patients With Moderate to Severe Persistent Asthma, Using Salmeterol (50 µg b.i.d.) as an Active Control|Completed||Phase 3|805|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:55:43.439088|2018-06-01 02:55:43.439088
NCT00529516|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2012-04-26|2009-05-12|2017-04-20|2007-09-13|2007-09-14|Estimate|2012-04-26|2012-05-30|Estimate|2009-09-25|2009-09-28|Estimate|2017-04-20|2017-05-17|Actual|October 15, 2007||2007-10-15|April 2017|2017-04-30|June 4, 2008|Actual|2008-06-04|December 21, 2007|Actual|2007-12-21||Interventional|||Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults|Observer Blind Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals Influenza Vaccine GSK576389A Administered to Adults Over 65 Years Previously Vaccinated With the Same Vaccine, Compared to Fluarix™|Completed||Phase 3|1252|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:55:44.501773|2018-06-01 02:55:44.501773
NCT00529503|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11||2011-06-16|2015-02-06|2007-09-12|2007-09-14|Estimate||||2011-06-16|2011-06-27|Estimate|2015-02-06|2015-02-25|Estimate|September 2007||2007-09-30|February 2015|2015-02-28|May 2011|Actual|2011-05-31|December 2009|Actual|2009-12-31||Interventional|||A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL|A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)|Terminated||Phase 2|151|Actual|Seattle Genetics, Inc.||2|||f||||t||||||||||2018-06-01 02:55:46.026928|2018-06-01 02:55:46.026928
NCT00529490|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2007-09-12|2007-09-12|2007-09-14|Estimate|||||||2007-09-12|2007-09-14|Estimate|March 2002||2002-03-31|September 2007|2007-09-30|June 2003|Actual|2003-06-30|||||Interventional|||Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG Pats|The Efficacy and Safety of Hypertonic Lactate Solution as Fluid Resuscitation Compared With Ringer's Lactate in Post-CABG (Coronary Artery Bypass Grafting) Patients|Completed||Phase 3|230|Actual|Innogene Kalbiotech Pte. Ltd||2|||f||||f||||||||||2018-06-01 02:55:46.221944|2018-06-01 02:55:46.221944
NCT00529477|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2009-10-20|2007-09-11|2007-09-14|Estimate|||||||2009-10-20|2009-10-21|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||The Effects Of Methacholine Challenge Administered Using Three Different Nebulizers On Small Airways Function|The Effects of Methacholine Challenge Administered Using Three Different Nebulizers on Small Airways Function|Completed||N/A|8|Actual|McMaster University||3|||f||||f||||||||||2018-06-01 02:55:46.300176|2018-06-01 02:55:46.300176
NCT00529464|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2009-09-01||2016-04-05|2007-09-12|2007-09-14|Estimate|2010-11-09|2010-12-08|Estimate||||2016-04-05|2016-05-09|Estimate|November 2006||2006-11-30|December 2012|2012-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Spectroscopy Versus Standard Care in Cervical Cancer Patients|A Randomized Trial of Spectroscopy Versus Standard Care in Cervical Intraepithelial Neoplasia|Terminated||Phase 3|2|Actual|M.D. Anderson Cancer Center|This study was terminated due to difficulty enrolling subjects.|3||Two participants enrolled, both inevaluable.|f||||t||||||||||2018-06-01 02:55:46.394794|2018-06-01 02:55:46.394794
NCT00529451|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2010-12-16||2011-02-28|2007-09-13|2007-09-14|Estimate|2011-02-28|2011-03-25|Estimate||||2011-02-28|2011-03-25|Estimate|September 2007||2007-09-30|February 2011|2011-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg|An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension|Completed||Phase 3|1613|Actual|Novartis||4|||f||||f||||||||||2018-06-01 02:55:46.718503|2018-06-01 02:55:46.718503
NCT00529438|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2014-11-04|2007-09-12|2007-09-14|Estimate|||||||2014-11-04|2014-11-05|Estimate|April 2006||2006-04-30|November 2014|2014-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies|A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies|Completed||Phase 1|47|Actual|Reata Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 02:55:47.087166|2018-06-01 02:55:47.087166
NCT00529425|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2010-05-05|2007-09-12|2007-09-14|Estimate|||||||2010-05-05|2010-05-06|Estimate|January 2008||2008-01-31|April 2010|2010-04-30|December 2008|Actual|2008-12-31|||||Interventional|||Postoperative Analgesia With Local Infiltration After Femoral Neck Fracture|Postoperative Analgesia With Local Infiltration After Femoral Neck Fracture vs. Traditional Treatment of Pain With Opioids|Completed||Phase 4|50|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 02:55:47.16677|2018-06-01 02:55:47.16677
NCT00529412|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-14|Estimate|||||||2007-09-13|2007-09-14|Estimate|August 2003||2003-08-31|June 2007|2007-06-30|March 2007|Actual|2007-03-31|||||Interventional|||Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction|Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial|Completed||Phase 3|150|Actual|Nihon University||2|||f||||t||||||||||2018-06-01 02:55:47.307429|2018-06-01 02:55:47.307429
NCT00529399|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2016-05-12||2016-10-15|2007-09-12|2007-09-14|Estimate|2016-10-15|2016-12-07|Estimate||||2016-10-15|2016-12-07|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects|Effects of Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated in Alum (GAD-alum) on the Progression of Type 1 Diabetes in New Onset Subjects|Completed||Phase 2|145|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 02:55:47.564697|2018-06-01 02:55:47.564697
NCT00529386|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2011-09-13|2007-09-12|2007-09-14|Estimate|||||||2011-09-13|2011-09-14|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|A Prospective Pilot Randomized Sham Controlled Study to Evaluate the Safety and Efficacy of Botox™ for the Treatment of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome|Completed||Phase 2|15|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:55:48.060113|2018-06-01 02:55:48.060113
NCT00529373|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2017-02-09|2007-09-12|2007-09-14|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2007||2007-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|November 2012|Actual|2012-11-30||Interventional|||A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium|Completed||Phase 3|16713|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:55:48.145132|2018-06-01 02:55:48.145132
NCT00529360|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2016-03-23|2007-09-12|2007-09-14|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL|Clofarabine in Combination With Cytarabine and Total Body Irradiation Followed by Allogeneic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia and Acute Non-Lymphoblastic Leukemia|Completed||Phase 1/Phase 2|32|Actual|New York Medical College||2|||f||||t||||||||||2018-06-01 02:55:48.249047|2018-06-01 02:55:48.249047
NCT00529347|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2009-09-07|2007-09-12|2007-09-14|Estimate|||||||2009-09-07|2009-09-09|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|||Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern|The Effect of Positive End Expiratory Pressure (PEEP) on the Breathing Pattern During Neurally Adjusted Ventilatory Assist (NAVA)|Completed||Phase 1|20|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 02:55:48.389254|2018-06-01 02:55:48.389254
NCT00529334|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2013-11-19|2007-09-12|2007-09-14|Estimate|||||||2013-11-19|2013-11-20|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|CK-PBI||A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast|A Pilot Study of CyberKnife Radiosurgery Delivered to the Partial Breast for Women With Stage 0, 1, or IIA (<=3cm) Breast Cancer|Withdrawn||N/A|0|Actual|Georgetown University||1||PI left institution|f||||t||||||||||2018-06-01 02:55:48.44772|2018-06-01 02:55:48.44772
NCT00529321|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2010-09-02|2007-09-12|2007-09-14|Estimate|||||||2010-09-02|2010-09-03|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus|Open-label, Dose-escalating, Phase I Study of TG4040 (MVA-HCV) in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus (HCV Genotype 1)|Completed||Phase 1|42|Anticipated|Transgene|||||f||||||||||||||2018-06-01 02:55:48.538004|2018-06-01 02:55:48.538004
NCT00529308|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2012-11-13||2015-08-13|2007-09-13|2007-09-14|Estimate|2013-01-11|2013-02-15|Estimate||||2015-08-13|2015-08-26|Estimate|July 2007||2007-07-31|August 2015|2015-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|TMS||Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome|Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome|Completed||Phase 2|20|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:55:48.605021|2018-06-01 02:55:48.605021
NCT00529295|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-13|2007-09-13|2007-09-14|Estimate|||||||2007-09-13|2007-09-14|Estimate|June 2005||2005-06-30|September 2006|2006-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term||Completed||Phase 3|220|Actual|China Medical University Hospital||2|||f||||f||||||||||2018-06-01 02:55:48.968409|2018-06-01 02:55:48.968409
NCT00529282|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2010-01-26||2012-07-26|2007-09-12|2007-09-14|Estimate|2010-03-11|2010-03-29|Estimate||||2012-07-26|2012-08-01|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of Ceftobiprole in Patients With Fever and Neutropenia.|Multicenter, Randomized, Double-Blind Study of Ceftobiprole Versus Comparators in the Treatment of Patients With Fever and Neutropenia|Terminated||Phase 3|2|Actual|Basilea Pharmaceutica|No analysis was performed due to early termination of the study.|2||Study discontinued due to administrative reasons unrelated to safety|f||||f||||||||||2018-06-01 02:55:49.0955|2018-06-01 02:55:49.0955
NCT00529269|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2017-07-05|2007-09-12|2007-09-14|Estimate|||||||2017-07-05|2017-07-07|Actual|December 2006||2006-12-31|July 2017|2017-07-31||||June 2007|Actual|2007-06-30||Interventional|||Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms|Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal Symptoms|Completed||Phase 4|200|Anticipated|Novartis|||||f||||||||||||||2018-06-01 02:55:49.469015|2018-06-01 02:55:49.469015
NCT00529256|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2007-09-12|2007-09-12|2007-09-14|Estimate|||||||2007-09-12|2007-09-14|Estimate|December 2001||2001-12-31|April 2005|2005-04-30|April 2005|Actual|2005-04-30|||||Interventional|ESCMMP||Evaluation of Organisational Changes to Promote Smoking Cessation|Evaluation of Organisational Changes to Promote Smoking Cessation|Completed||N/A|87|Actual|Great Lakes Research Into Practice Network||1|||f||||t||||||||||2018-06-01 02:55:49.54361|2018-06-01 02:55:49.54361
NCT00528931|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2010-09-24||2017-09-07|2007-09-11|2007-09-12|Estimate|2012-07-11|2012-08-20|Estimate||||2017-09-07|2017-10-05|Actual|September 2007||2007-09-30|September 2017|2017-09-30|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture|A Phase 1, Open-Label Study to Assess the Pharmacokinetics and Safety of a Single Injection of AA4500 0.58 mg in Subjects With Dupuytren's Contracture|Completed||Phase 1|16|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:55:59.496305|2018-06-01 02:55:59.496305
NCT00529243|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2011-05-09||2015-03-10|2007-09-13|2007-09-14|Estimate|2011-05-09|2011-06-08|Estimate||||2015-03-10|2015-03-30|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|September 2009|Actual|2009-09-30|July 2008|Actual|2008-07-31||Interventional|CHEER||Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects|Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen|Completed||Phase 3|52|Actual|Kaiser Permanente|A limitation of our study was the lack of a separate control arm. However, patients did serve as their own control by virtue of at least 6 months of HIV-1 ribonucleic acid(RNA)levels below the level of quantification before enrollment in the study.|1|||f||||f||||||||||2018-06-01 02:55:49.626117|2018-06-01 02:55:49.626117
NCT00529230|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2012-07-31|2007-09-13|2007-09-14|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2001||2001-12-31|July 2012|2012-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes|Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes|Terminated|||46|Actual|M.D. Anderson Cancer Center|||1|Low accrual rate.|f||||f||||||Samples Without DNA|"~     Blood draws to assess gonadal function.~   "|||2018-06-01 02:55:49.938882|2018-06-01 02:55:49.938882
NCT00529217|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2012-12-13||2014-09-16|2007-09-13|2007-09-14|Estimate|2014-09-16|2014-09-22|Estimate||||2014-09-16|2014-09-22|Estimate|May 2006||2006-05-31|November 2013|2013-11-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|TMS||Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)|Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)|Completed||Phase 2|10|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-06-01 02:55:50.038306|2018-06-01 02:55:50.038306
NCT00529204|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2014-12-08||2017-05-25|2007-09-12|2007-09-14|Estimate|2014-12-15|2014-12-22|Estimate||||2017-05-25|2017-06-20|Actual|October 2007||2007-10-31|May 2017|2017-05-31|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease|Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease|Terminated||Phase 2|1|Actual|University of California, Davis||1||Lack of recruitment|f||||t||||||||||2018-06-01 02:55:50.231131|2018-06-01 02:55:50.231131
NCT00529191|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|2012-12-20||2017-01-23|2007-09-13|2007-09-14|Estimate|2013-02-05|2013-03-08|Estimate||||2017-01-23|2017-03-13|Actual|July 2007||2007-07-31|January 2017|2017-01-31|July 2013|Actual|2013-07-31|July 2011|Actual|2011-07-31||Interventional|TIDM||Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)|Phase II, Double Blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin in Subjects With Newly Diagnosed Type 1 Diabetes Mellitus.|Completed||Phase 2|40|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||No|There is no plan to share these data, except in aggregate.|2018-06-01 02:55:50.497724|2018-06-01 02:55:50.497724
NCT00529178|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13||2011-04-12|2011-04-12|2007-09-13|2007-09-14|Estimate||||2011-04-12|2011-04-25|Estimate|2011-04-12|2011-04-25|Estimate|December 2002||2002-12-31|April 2011|2011-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease|A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine the Efficacy and Safety of Pravastatin 80 mg Administered Once Daily to Hypercholesterolemic Subjects With Chronic, Well Compensated Liver Disease|Completed||Phase 4|232|Anticipated|Bristol-Myers Squibb|||||f||||t||||||||||2018-06-01 02:55:51.09556|2018-06-01 02:55:51.09556
NCT00529165|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2009-01-12|2007-09-13|2007-09-14|Estimate|||||||2009-01-12|2009-01-14|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|||The Necessity of an Injection-Meal-Interval in Patients With Type 2 Diabetes Mellitus and Therapy With Human Insulin||Completed||N/A|100|Anticipated|University of Jena||2|||f||||f||||||||||2018-06-01 02:55:51.276979|2018-06-01 02:55:51.276979
NCT00529152|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2009-06-26||2009-08-25|2007-09-12|2007-09-14|Estimate|2009-08-11|2009-08-12|Estimate||||2009-08-25|2009-09-02|Estimate|August 2007||2007-08-31|August 2009|2009-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients|A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia|Completed||Phase 3|100|Actual|ApoPharma||1|||f||||t||||||||||2018-06-01 02:55:51.368201|2018-06-01 02:55:51.368201
NCT00529139|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-13|||2007-09-14|2007-09-13|2007-09-14|Estimate|||||||2007-09-14|2007-09-17|Estimate|July 2003||2003-07-31|September 2007|2007-09-30|May 2006|Actual|2006-05-31|||||Interventional|HAND-OUT||Hannover Dialysis Outcome Study|The Hannover-Dialysis-Outcome (HAN-D-OUT)-Study: Comparison of Standard Versus Intensified Extended Dialysis in Treatment of Patients With Acute Kidney Injury in the Intensive-Care Unit|Completed||Phase 4|157|Actual|Hannover Medical School||2|||f||||f||||||||||2018-06-01 02:55:51.544811|2018-06-01 02:55:51.544811
NCT00529126|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2011-11-23|2010-08-25|2013-07-03|2007-09-12|2007-09-14|Estimate|2013-07-03|2013-08-06|Estimate|2010-09-01|2010-09-06|Estimate|2013-07-03|2013-08-06|Estimate|September 2007||2007-09-30|July 2013|2013-07-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy|A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy|Completed||Phase 2|100|Actual|Pacira Pharmaceuticals, Inc||4|||f||||f||||||||||2018-06-01 02:55:51.620792|2018-06-01 02:55:51.620792
NCT00529113|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12||2011-06-06|2014-11-13|2007-09-12|2007-09-14|Estimate||||2011-06-21|2011-06-29|Estimate|2014-11-13|2014-11-26|Estimate|September 2007||2007-09-30|November 2014|2014-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer|A Randomized Phase I/II Study With Gemcitabine and RTA 402 or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer|Terminated||Phase 1/Phase 2|33|Actual|Reata Pharmaceuticals, Inc.||9||To pursue other indications|f||||||||||||||2018-06-01 02:55:52.012155|2018-06-01 02:55:52.012155
NCT00529100|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|2011-08-23||2013-07-03|2007-09-12|2007-09-14|Estimate|2011-08-23|2011-09-28|Estimate||||2013-07-03|2013-07-09|Estimate|December 2005||2005-12-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|August 2010|Actual|2010-08-31||Interventional||All participants who received study drug in Phase 1, Phase 1 and 2, or Phase 2.|Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer|A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|49|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:55:52.217553|2018-06-01 02:55:52.217553
NCT00527384|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2015-04-13|2007-09-07|2007-09-10|Estimate|||||||2015-04-13|2015-04-14|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Biomarker Analysis of Stress|Biomarker Signatures of Biological, Chemical, or Psychological Stress|Completed|||50|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||f||||||||||2018-06-01 02:56:35.956422|2018-06-01 02:56:35.956422
NCT00529087|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2009-12-24||2011-09-07|2007-09-11|2007-09-14|Estimate|2010-04-20|2010-05-11|Estimate||||2011-09-07|2011-09-12|Estimate|August 2007||2007-08-31|September 2011|2011-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain|A Mulitcenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain|Completed||Phase 3|460|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||||||||||||2018-06-01 02:55:53.209418|2018-06-01 02:55:53.209418
NCT00529074|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2016-08-15|2007-09-11|2007-09-14|Estimate|||||||2016-08-15|2016-08-16|Estimate|February 2006||2006-02-28|May 2016|2016-05-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Epidural Anesthesia /Analgesia Versus PCA for Laparoscopic Complex Ventral Hernia Repair: A Randomized Controlled Trial|Epidural Anesthesia /Analgesia Versus PCA for Laparoscopic Complex Ventral Hernia Repair: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||||never activated|f||||f||||||||||2018-06-01 02:55:54.618466|2018-06-01 02:55:54.618466
NCT00529061|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2016-07-11|2007-09-12|2007-09-14|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2005||2005-03-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|C-Data||Establishing a Database of People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Data Project [C-Data])|Comprehensive Sickle Cell Centers Collaborative Data Project (C-Data)|Terminated|||3640|Actual|National Heart, Lung, and Blood Institute (NHLBI)||||Funds for study ended September 30, 2008.|f||||t||||||||||2018-06-01 02:55:54.741819|2018-06-01 02:55:54.741819
NCT00529048|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2009-10-19|2007-09-12|2007-09-14|Estimate|||||||2009-10-19|2009-10-20|Estimate|October 2007||2007-10-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|||||Observational|||Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes|Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes Using Increasing Amounts of Oral Glucose Challenges|Completed|||16|Actual|Herlev Hospital|||2||f||||f||||||Samples With DNA|"~     p-Glucose p-Glucagon p-insulin p-c-pep. p-GLP-1 p-GIP Buffy coat s-paracetamol~   "|||2018-06-01 02:55:54.808348|2018-06-01 02:55:54.808348
NCT00529035|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2012-08-09||2017-10-03|2007-09-11|2007-09-14|Estimate|2013-12-11|2014-01-29|Estimate||||2017-10-03|2017-11-06|Actual|August 2007||2007-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2011|Actual|2011-06-30||Interventional|||Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease|A Phase I Study of Ultra-Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease|Active, not recruiting||Phase 1|29|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 02:55:54.946661|2018-06-01 02:55:54.946661
NCT00529022|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2013-02-19|2007-09-11|2007-09-14|Estimate|||||||2013-02-19|2013-02-20|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer|Phase I Trial of Sequential Azacitidine and Valproic Acid Plus Carboplatin in the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer|Completed||Phase 1|36|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:55:55.26819|2018-06-01 02:55:55.26819
NCT00529009|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12|||2010-05-05|2007-09-12|2007-09-14|Estimate|||||||2010-05-05|2010-05-06|Estimate|May 2007||2007-05-31|May 2010|2010-05-31||||||||Interventional|||Pharmacokinetic Investigation of UDCA in Bile and Serum||Completed||Phase 1|||Dr. Falk Pharma GmbH|||||f||||f||||||||||2018-06-01 02:55:55.336397|2018-06-01 02:55:55.336397
NCT00528996|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-12||2014-04-30|2014-04-30|2007-09-12|2007-09-14|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|September 2007||2007-09-30|April 2014|2014-04-30||||May 2009|Actual|2009-05-31||Interventional|||An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.|A Multinational, Randomised, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison Over 24 Weeks of Three Doses (50µg, 100µg, 200µg) of BEA 2180 BR to Tiotropium 5µg, Delivered by the Respimat Inhaler and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|2080|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:55:56.434454|2018-06-01 02:55:56.434454
NCT00528983|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2016-12-05|2007-09-12|2007-09-14|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2007||2007-09-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|July 2013|Actual|2013-07-31||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia|A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).|Completed||Phase 1|133|Actual|Celgene Corporation||2|||f||||f||||||||||2018-06-01 02:55:56.934611|2018-06-01 02:55:56.934611
NCT00528970|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11||2009-12-14|2011-07-22|2007-09-11|2007-09-14|Estimate||||2009-12-14|2009-12-15|Estimate|2011-07-22|2011-07-28|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study Evaluating IV MOA-728 for the Treatment of POI In Subjects After Ventral Hernia Repair|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus After Ventral Hernia Repair|Completed||Phase 3|500|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||||||||||||2018-06-01 02:55:57.217027|2018-06-01 02:55:57.217027
NCT00528957|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2012-02-15|2011-06-08|2018-02-14|2007-09-10|2007-09-14|Estimate|2012-02-15|2012-03-22|Estimate|2011-06-08|2011-06-23|Estimate|2018-02-14|2018-03-14|Actual|December 28, 2006|Actual|2006-12-28|February 2018|2018-02-28|August 16, 2017|Actual|2017-08-16|April 6, 2009|Actual|2009-04-06||Interventional||Randomized and Treated Set: participants who were randomized and received at least 1 dose of study drug|Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children|A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Active Antiretroviral Therapy|Completed||Phase 3|97|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-06-01 02:55:57.696949|2018-06-01 02:55:57.696949
NCT00528944|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2015-07-02|2007-09-12|2007-09-14|Estimate|||||||2015-07-02|2015-07-07|Estimate|January 2006||2006-01-31|July 2015|2015-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity|Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity|Completed|||73|Actual|Columbia University|||3||f||||f||||||||||2018-06-01 02:55:59.308798|2018-06-01 02:55:59.308798
NCT00528918|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2014-07-23|2007-09-11|2007-09-12|Estimate|||||||2014-07-23|2014-07-24|Estimate|June 2007||2007-06-30|August 2007|2007-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|Apidra||Comparison of Apidra to Regular Insulin in Hospitalized Patients|Comparison of Apidra to Regular Insulin in Hospitalized Patients|Completed||N/A|300|Actual|Carl T. Hayden VA Medical Center||2|||f||||t||||||||||2018-06-01 02:55:59.735563|2018-06-01 02:55:59.735563
NCT00528905|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2008-11-21|2007-09-11|2007-09-12|Estimate|||||||2008-11-21|2008-11-25|Estimate|August 2007||2007-08-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|HALO||Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia|A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study With 3 Oral Groups of AZD3480 During 12 Weeks Treatment of Cognitive Deficits in Patients With Schizophrenia|Completed||Phase 2|400|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:55:59.840219|2018-06-01 02:55:59.840219
NCT00528892|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2010-03-30|2007-09-11|2007-09-12|Estimate|||||||2010-03-30|2010-03-31|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|SPIRAL||Switching From PI to RALtegravir in HIV Stable Patients|An Open-label, Randomized, 48-Week Study to Assess the Safety, Tolerability and Activity of Raltegravir When Replacing the Ritonavir-boosted PI Component of HAART in HIV-Infected Individuals With Viral Load Suppression on a Ritonavir-Boosted PI Containing Regimen.|Completed||Phase 3|282|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-06-01 02:56:00.045478|2018-06-01 02:56:00.045478
NCT00528879|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2014-02-06||2015-09-30|2007-09-11|2007-09-12|Estimate|2014-04-01|2014-05-02|Estimate||||2015-09-30|2015-10-20|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|May 2010|Actual|2010-05-31|November 2008|Actual|2008-11-30||Interventional||All randomized participants who received at least 1 dose of study medication|A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone|Completed||Phase 3|915|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 02:56:00.216041|2018-06-01 02:56:00.216041
NCT00528866|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2016-11-23||2017-06-02|2007-09-10|2007-09-12|Estimate|2017-06-02|2017-06-06|Actual||||2017-06-02|2017-06-06|Actual|April 2008||2008-04-30|June 2017|2017-06-30||||December 2013|Actual|2013-12-31||Interventional||Eligible and started protocol treatment|Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy|Adjuvant 3DCRT/IMRT in Combination With Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial|Active, not recruiting||Phase 2|80|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 02:56:02.224459|2018-06-01 02:56:02.224459
NCT00528853|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2016-08-18|2007-09-11|2007-09-12|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2007||2007-08-31|August 2016|2016-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation|Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation. Can We Help Diagnose Acute Rejection and Better Predict Bronchiolitis Obliterans?|Completed|||10|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 02:56:02.72694|2018-06-01 02:56:02.72694
NCT00528840|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2010-09-24||2017-10-26|2007-09-11|2007-09-12|Estimate|2010-09-24|2010-10-22|Estimate||||2017-10-26|2017-12-02|Actual|October 2007|Actual|2007-10-31|October 2017|2017-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|JOINT-I||Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease|A Phase 3, Open-Label Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease|Completed||Phase 3|201|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:56:02.826262|2018-06-01 02:56:02.826262
NCT00528827|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2012-03-15|2007-09-11|2007-09-12|Estimate|||||||2012-03-15|2012-03-16|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension|A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension|Withdrawn||Phase 2|0|Actual|Facet Biotech||4||"Due to the sale of Cardene IV, the sponsor has stopped enrollment and withdrawn the study. No~   safety issues were identified."|f||||t||||||||||2018-06-01 02:56:03.218483|2018-06-01 02:56:03.218483
NCT00528814|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2017-11-22|2007-09-10|2007-09-12|Estimate|||||||2017-11-22|2017-11-27|Actual|January 2009||2009-01-31|November 2017|2017-11-30|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|||Effectiveness of a School-Based Hand Sanitizer Program on Reducing Asthma Exacerbations|Effect of a School Based Hand Sanitizer Program on Asthma|Completed||N/A|527|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 02:56:03.301529|2018-06-01 02:56:03.301529
NCT00528801|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2009-08-28||2017-02-14|2007-09-10|2007-09-12|Estimate|2009-10-15|2009-11-26|Estimate||||2017-02-14|2017-03-21|Actual|December 2004||2004-12-31|February 2017|2017-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease|Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults With Sickle Cell Disease|Completed|||212|Actual|Children's Hospital & Research Center Oakland|As a cross-sectional study, follow-up of patients not included. Age range of cases and controls not weighted enough to include elder population. Functional or perfusion brain measures not included. Biologic and genetic risk factors not included.||2||f||||t||||||||||2018-06-01 02:56:03.39482|2018-06-01 02:56:03.39482
NCT00528788|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2013-09-20||2016-01-20|2007-09-10|2007-09-12|Estimate|2014-03-07|2014-04-14|Estimate||||2016-01-20|2016-01-22|Estimate|September 2007||2007-09-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis|Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease|Completed||Phase 4|24|Actual|Duke University||1|||f||||t||||||||||2018-06-01 02:56:03.69779|2018-06-01 02:56:03.69779
NCT00528775|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2014-05-09||2014-05-09|2007-09-10|2007-09-12|Estimate|2014-05-09|2014-06-10|Estimate||||2014-05-09|2014-06-10|Estimate|August 2007||2007-08-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|November 2009|Actual|2009-11-30||Interventional||All treated and eligible patients|Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages|A Phase II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Advanced Obstructing Endobronchial Lung Cancer|Terminated||Phase 2|6|Actual|Roswell Park Cancer Institute|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.|1||drug cannot be prepared commercially|f||||t||||||||||2018-06-01 02:56:03.873169|2018-06-01 02:56:03.873169
NCT00528762|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2012-07-26|2007-09-11|2007-09-12|Estimate|||||||2012-07-26|2012-07-30|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Mexican and African American Family Focus Groups on Puberty|Mexican and African American Family Focus Groups on Puberty|Completed|||37|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:56:04.047389|2018-06-01 02:56:04.047389
NCT00528723|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2017-03-28|2007-09-11|2007-09-12|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2007||2007-11-30|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma|Multicentre, Multinational, Randomised, Double Blind, Double Dummy, Active Drug Controlled, Parallel Group Study Design Clinical Trial of the Efficacy and Tolerability of Beclomethasone Dipropionate 250 mcg Plus Salbutamol 100 mcg in HFA pMDI Fixed Combination vs. Beclomethasone Dipropionate 250 mcg Plus Salbutamol 100 mcg in CFC pMDI (Clenil® Compositum 250) Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma|Completed||Phase 3|180|Anticipated|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 02:56:04.471901|2018-06-01 02:56:04.471901
NCT00528710|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2007-09-11|2007-09-11|2007-09-12|Estimate|||||||2007-09-11|2007-09-12|Estimate|November 2006||2006-11-30|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Efficacy of S-Adenosylmethionine in Fibromyalgia|Double-Blind, Placebo-Controlled Trial of the Impact of S-Adenosyl-L-Methionine (SAM-e) on the Mood and Other Symptoms in Fibromyalgia|Completed||Phase 2|70|Actual|Deakin University||1|||f||||f||||||||||2018-06-01 02:56:04.595421|2018-06-01 02:56:04.595421
NCT00528697|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11||2011-08-18|2013-01-21|2007-09-11|2007-09-12|Estimate||||2011-08-18|2011-08-23|Estimate|2013-01-21|2013-01-29|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Children With Attention Deficit-Hyperactivity Disorder (ADHD)|Completed||Phase 2|278|Actual|AbbVie||6|||f||||t||||||||||2018-06-01 02:56:04.67014|2018-06-01 02:56:04.67014
NCT00528684|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2014-09-30|2007-09-10|2007-09-12|Estimate|||||||2014-09-30|2014-10-02|Estimate|July 2006||2006-07-31|September 2011|2011-09-30|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas|A Phase I/II Clinical Trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN® for the Treatment of Patients With Histologically Confirmed Recurrent Malignant Gliomas|Completed||Phase 1|18|Actual|Oncolytics Biotech|||||f||||t||||||||||2018-06-01 02:56:04.782449|2018-06-01 02:56:04.782449
NCT00528671|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2013-12-10|2007-09-11|2007-09-12|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ESCAT III||Very Low Dose Oral Anticoagulation and Thromboembolic and Bleeding Complications|Effects of Very Low Dose Oral Anticoagulation on Thromboembolism and Bleeding Events in Patients With Mechanical Heart Valve Replacement|Terminated||Phase 4|1571|Actual|Heart and Diabetes Center North-Rhine Westfalia||3|||f||||t||||||||||2018-06-01 02:56:04.912236|2018-06-01 02:56:04.912236
NCT00528658|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2009-01-28|2007-09-11|2007-09-12|Estimate|||||||2009-01-28|2009-01-29|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cost-Effectiveness of Two Painkillers for Treating Pain After Limb Injuries|Cost-Effectiveness Analysis of Oral Paracetamol and Ibuprofen for Treating Pain After Soft Tissue Limb Injuries: Double-Blind, Randomised Controlled Trial|Completed||Phase 2|783|Anticipated|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 02:56:05.008558|2018-06-01 02:56:05.008558
NCT00528645|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2013-12-05||2017-11-02|2007-09-10|2007-09-12|Estimate|2013-12-18|2014-02-11|Estimate||||2017-11-02|2017-12-07|Actual|November 2007||2007-11-30|November 2017|2017-11-30|May 2013|Actual|2013-05-31|November 2008|Actual|2008-11-30||Interventional|||AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer|Phase II Study of the c-SRC Inhibitor AZD0530 After Four Cycles of Cytoreductive Chemotherapy for Patients With Extensive Stage Small Cell Lung Carcinoma|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 02:56:05.114716|2018-06-01 02:56:05.114716
NCT00528632|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2011-08-09|2007-09-10|2007-09-12|Estimate|||||||2011-08-09|2011-08-10|Estimate|March 2008||2008-03-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||Gallbladder Cholesterolosis, Body Mass Index and Serum Cholesterol and Triglycerides|Association of Gallbladder Cholesterolosis to Body Mass Index and Levels of Serum Cholesterol and Triglycerides.|Completed|||406|Actual|Cirujanos la Serena|||2||f||||f||||||||||2018-06-01 02:56:05.35235|2018-06-01 02:56:05.35235
NCT00528619|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2011-04-07|2007-09-10|2007-09-12|Estimate|||||||2011-04-07|2011-04-08|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors|Phase I Study Of SU011248 In Combination With Pemetrexed, Pemetrexed/Cisplatin And Pemetrexed/Carboplatin In Patients With Advanced Solid Malignancies|Completed||Phase 1|96|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 02:56:05.416082|2018-06-01 02:56:05.416082
NCT00528606|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2010-09-24||2017-10-26|2007-09-11|2007-09-12|Estimate|2010-09-24|2010-10-22|Estimate||||2017-10-26|2017-12-02|Actual|August 2007|Actual|2007-08-31|October 2017|2017-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|CORD-I||AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Dupuytren's Contracture|Completed||Phase 3|308|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:56:05.50922|2018-06-01 02:56:05.50922
NCT00528593|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2011-08-08|2007-09-11|2007-09-12|Estimate|||||||2011-08-08|2011-08-09|Estimate|November 2007||2007-11-30|August 2011|2011-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Epoetin Alfa for HIV-Associated Neuropathy Trial|A Randomized, Multi-center Pilot Study to Evaluate the Efficacy and Safety of Epoetin Alfa (Procrit) in the Treatment of HIV-associated Sensory Neuropathy|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1||lack of pharmaceutical support|f||||||||||||||2018-06-01 02:56:06.044841|2018-06-01 02:56:06.044841
NCT00528580|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2012-02-23|2007-09-11|2007-09-12|Estimate|||||||2012-02-23|2012-02-24|Estimate|February 2008||2008-02-29|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|March 2012|Anticipated|2012-03-31||Interventional|SETS||Statins for the Early Treatment of Sepsis|Statins for the Early Treatment of Sepsis|Unknown status|Active, not recruiting|Phase 2|250|Anticipated|University of Chicago||2|||f||||t||||||||||2018-06-01 02:56:06.118081|2018-06-01 02:56:06.118081
NCT00528567|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2013-02-28||2015-08-05|2007-09-11|2007-09-12|Estimate|2013-06-28|2013-09-10|Estimate||||2015-08-05|2015-09-04|Estimate|December 2007||2007-12-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|February 2012|Actual|2012-02-29||Interventional|||BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer|"An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in Triple Negative Breast Cancer."|Completed||Phase 3|2591|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:56:06.29023|2018-06-01 02:56:06.29023
NCT00528554|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2007-09-17|2007-09-11|2007-09-12|Estimate|||||||2007-09-17|2007-09-18|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|September 2009|Anticipated|2009-09-30|||||Interventional|||Laser Acupuncture Against Nausea in Children|Laser Acupuncture to Alleviate Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy. A Prospective, Double-Blinded, Placebo-Controlled Clinical Trial|Unknown status|Recruiting|N/A|25|Anticipated|University Children Hospital Homburg||2|||f||||f||||||||||2018-06-01 02:56:09.102064|2018-06-01 02:56:09.102064
NCT00528541|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2011-11-14||2011-11-14|2007-09-10|2007-09-12|Estimate|2011-11-14|2011-12-16|Estimate||||2011-11-14|2011-12-16|Estimate|September 2007||2007-09-30|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia||Completed||Phase 4|145|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:56:09.238632|2018-06-01 02:56:09.238632
NCT00528528|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2013-03-18||2014-06-13|2007-09-10|2007-09-12|Estimate|2013-03-18|2013-05-01|Estimate||||2014-06-13|2014-06-25|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants|A Phase IIa Randomized, Open-Label Study of Telaprevir (VX-950) Administered Every 12 or Every 8 Hours in Combination With Either Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol) in Treatment-Naive Subjects With Chronic Genotype 1 Hepatitis C Infection|Completed||Phase 2|166|Actual|Tibotec BVBA||4|||f||||f||||||||||2018-06-01 02:56:09.701317|2018-06-01 02:56:09.701317
NCT00528515|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2008-05-15|2007-09-11|2007-09-12|Estimate|||||||2008-05-15|2008-05-16|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Desflurane Versus Propofol Anesthesia for Off-Pump CABG|Comparison of Desflurane and Propofol Anesthesia for Off-Pump Coronary Artery Bypass Grafting Surgery|Completed||Phase 4|80|Actual|Medical University of Gdansk||2|||f||||f||||||||||2018-06-01 02:56:10.703053|2018-06-01 02:56:10.703053
NCT00528502|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2012-12-05|2007-09-11|2007-09-12|Estimate|||||||2012-12-05|2012-12-07|Estimate|June 2006||2006-06-30|December 2012|2012-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Lidocaine Supplement for Minimal Invasive Parathyroid Surgery|Prevention of Laryngeal Reflexes in Minimal Invasive Parathyroid Surgery by the Use of Topical Lidocaine|Withdrawn||Phase 3|0|Actual|M.D. Anderson Cancer Center||2||Terminated due to no patient enrollment.|f||||t||||||||||2018-06-01 02:56:10.865138|2018-06-01 02:56:10.865138
NCT00528489|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2013-08-06|2007-09-10|2007-09-12|Estimate|||||||2013-08-06|2013-08-09|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-B (Gag, Pol, Env) Given Alone, With IL-12 DNA, or With a Dose Escalation of IL-15 DNA, in Healthy, HIV-1-uninfected Adults Participants|Completed||Phase 1|120|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 02:56:10.955689|2018-06-01 02:56:10.955689
NCT00528476|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2007-09-11|2007-09-11|2007-09-12|Estimate|||||||2007-09-11|2007-09-12|Estimate|November 2004||2004-11-30|September 2007|2007-09-30|January 2007|Actual|2007-01-31|||||Observational|||Risk Factors for Recurrent Urinary Tract Infection in Children|Role of Clinical and Urodynamic Risk Factors for Recurrent Urinary Tract Infection in 5-18 Years Old Children|Completed|||161|Actual|Kaunas University of Medicine|||2||f||||f||||||||||2018-06-01 02:56:11.053903|2018-06-01 02:56:11.053903
NCT00528463|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2010-02-01|2007-09-11|2007-09-12|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2005||2005-01-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Pre-emptive Sciatic Bloc to Prevent Lower Limb Phantom Pain|a Prospective Case Series of Pre-emptive Pre-amputation Sciatic Nerve Block to Prevent Lower Limb Phantom Pain|Completed||Phase 4|17|Actual|Université de Sherbrooke||1|||f||||f||||||||||2018-06-01 02:56:11.15587|2018-06-01 02:56:11.15587
NCT00528450|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2015-12-23||2015-12-23|2007-09-10|2007-09-12|Estimate|2015-12-23|2016-01-29|Estimate||||2015-12-23|2016-01-29|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia|Phase II Study of Combined All-Trans Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy|Terminated||Phase 2|1|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-06-01 02:56:11.219449|2018-06-01 02:56:11.219449
NCT00528437|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2017-10-17|2007-09-11|2007-09-12|Estimate|||||||2017-10-17|2017-10-19|Actual|October 2005|Actual|2005-10-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors|NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors|Active, not recruiting||Phase 2|46|Actual|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-06-01 02:56:11.419535|2018-06-01 02:56:11.419535
NCT00528424|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2010-09-24||2017-10-26|2007-09-11|2007-09-12|Estimate|2010-09-24|2010-10-22|Estimate||||2017-10-26|2017-12-02|Actual|December 2007|Actual|2007-12-31|October 2017|2017-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease|A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease|Completed||Phase 3|286|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:56:11.541041|2018-06-01 02:56:11.541041
NCT00528411|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2011-01-27||2012-01-12|2007-09-11|2007-09-12|Estimate|2011-12-06|2012-01-11|Estimate||||2012-01-12|2012-01-13|Estimate|October 2007||2007-10-31|January 2012|2012-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin|A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD)|Completed||Phase 2|123|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:56:12.114657|2018-06-01 02:56:12.114657
NCT00528398|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2016-12-12||2016-12-12|2007-09-10|2007-09-12|Estimate|2016-12-12|2017-02-06|Estimate||||2016-12-12|2017-02-06|Estimate|September 1994||1994-09-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia|Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML)|Completed||Phase 2|111|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 02:56:13.038487|2018-06-01 02:56:13.038487
NCT00528372|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2014-02-06||2015-09-30|2007-09-11|2007-09-12|Estimate|2014-04-15|2014-05-14|Estimate||||2015-09-30|2015-10-20|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|July 2010|Actual|2010-07-31|February 2009|Actual|2009-02-28||Interventional||Participants with hemoglobin AIc (HbA1c) concentration ≥7% and ≤10% at enrollment (Group 1) and those with a concentration of HbA1c ≥10.1% and ≤12% at enrollment (Group 2) who received at least 1 dose of study medication.|A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 3|1067|Actual|AstraZeneca|Group 2 (patients with enrollment baseline HbA1c >10% and ≤2%) was an exploratory group, included to obtain initial efficacy and safety data. No comparator arm was included. Thus, only key safety and efficacy analyses were performed for Group 2.|9|||f||||f||||||||||2018-06-01 02:56:14.472207|2018-06-01 02:56:14.472207
NCT00528359|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2008-03-10|2007-09-11|2007-09-12|Estimate|||||||2008-03-10|2008-03-11|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|February 2007|Actual|2007-02-28|||||Observational|SANAT||β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS|Phase 1 Study of Insulin Sensitivity, Adjusted β-Cell Function and Adiponectin Among Lean Drug-naïve Schizophrenic Subjects Treated With Atypical Antipsychotic Drugs|Completed|||36|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||||2018-06-01 02:56:17.137963|2018-06-01 02:56:17.137963
NCT00528346|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2011-04-25|2007-09-11|2007-09-12|Estimate|||||||2011-04-25|2011-04-26|Estimate|September 2007||2007-09-30|April 2011|2011-04-30|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Treatment Of Chronic Pain Using Real Time fMRI|Treatment Of Chronic Pain Using Real-time Functional MRI Trial|Unknown status|Active, not recruiting|Phase 2|144|Anticipated|Omneuron||2|||f||||f||||||||||2018-06-01 02:56:17.239112|2018-06-01 02:56:17.239112
NCT00528333|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10||2011-10-07|2014-12-17|2007-09-11|2007-09-12|Estimate||||2011-10-07|2011-10-12|Estimate|2014-12-17|2015-01-07|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML|A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML|Completed||Phase 2|211|Actual|Seattle Genetics, Inc.||2|||f||||t||||||||||2018-06-01 02:56:17.361531|2018-06-01 02:56:17.361531
NCT00528320|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2013-11-26|2007-09-10|2007-09-12|Estimate|||||||2013-11-26|2013-11-27|Estimate||||November 2013|2013-11-30||||||||Expanded Access|||Clinical Evaluation of Cardiac Resynchronization Therapy (CRT) Using the Ovatio CRT Implantable Cardioverter-defibrillator (ICD) System|Clinical Evaluation of Cardiac Resynchronization Therapy With Implantable Cardioverter-defibrillator Therapy|Approved for marketing|||||ELA Medical, Inc.|||||||||||||||||||2018-06-01 02:56:17.474284|2018-06-01 02:56:17.474284
NCT00528307|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2014-11-04|2007-09-11|2007-09-12|Estimate|||||||2014-11-04|2014-11-05|Estimate|October 2007||2007-10-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|SOS||Changes in Myocardial Perfusion During Chronic Multi Site Biventricular Versus Right Ventricular Apex Pacing in Patients With Normal Left Ventricular Function Undergoing His Bundle Ablation for Drug-refractory Atrial Fibrillation|Changes in Myocardial Perfusion During Chronic Multi Site Biventricular Versus Right Ventricular Apex Pacing in Patients With Normal Left Ventricular Function Undergoing His Bundle Ablation for Drug-refractory Atrial Fibrillation|Terminated||N/A|5|Actual|R&D Cardiologie||2|||f||||f||||||||||2018-06-01 02:56:17.525118|2018-06-01 02:56:17.525118
NCT00528294|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2014-12-04|2007-09-11|2007-09-12|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2007||2007-02-28|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area|Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 02:56:17.609825|2018-06-01 02:56:17.609825
NCT00528281|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2017-11-13|2007-09-11|2007-09-12|Estimate|||||||2017-11-13|2017-11-17|Actual|September 20, 2007|Actual|2007-09-20|November 2017|2017-11-30|May 27, 2009|Actual|2009-05-27|May 27, 2009|Actual|2009-05-27||Interventional|||A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase|A Single-arm, Two-stage Phase II Study of Lapatinib and Pemetrexed in the Second Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 1|18|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:56:17.767708|2018-06-01 02:56:17.767708
NCT00528268|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2015-06-14||2015-06-14|2007-09-10|2007-09-12|Estimate|2015-06-14|2015-07-03|Estimate||||2015-06-14|2015-07-03|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|STOPSMA||Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy|Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy|Completed||Phase 1/Phase 2|14|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 02:56:17.857476|2018-06-01 02:56:17.857476
NCT00528255|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2012-06-15|2007-09-10|2007-09-12|Estimate|||||||2012-06-15|2012-06-18|Estimate||||June 2012|2012-06-30||||||||Interventional|Miso-Obs-203||Pharmacokinetics and Safety of the 100 Mcg Misoprostol Vaginal Insert (MVI 100)|A Multicenter, Open-Label, Phase II Study of the Pharmacokinetics and Safety of the100 Mcg Misoprostol Vaginal Insert (MVI 100) in Women Requiring Cervical Ripening and Induction of Labor|Withdrawn||Phase 2|0|Actual|Ferring Pharmaceuticals||1||PK portion will be included in a future protocol|f||||f||||||||||2018-06-01 02:56:18.274417|2018-06-01 02:56:18.274417
NCT00528242|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11||2014-12-09|2015-01-26|2007-09-11|2007-09-12|Estimate||||2014-12-09|2014-12-31|Estimate|2015-01-26|2015-02-02|Estimate|June 2007||2007-06-30|January 2015|2015-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease|A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease.|Completed||Phase 2|17|Actual|Kadmon Corporation, LLC||2|||f||||f||||||||||2018-06-01 02:56:18.346029|2018-06-01 02:56:18.346029
NCT00528229|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2007-09-11|2007-09-11|2007-09-12|Estimate|||||||2007-09-11|2007-09-12|Estimate|September 2007||2007-09-30|June 2007|2007-06-30||||||||Observational|||Multi-Slice CT of the Chest( MSCT Findings After Lung Transplantation)||Unknown status|Recruiting||||Rigshospitalet, Denmark|||||f||||t||||||||||2018-06-01 02:56:18.406924|2018-06-01 02:56:18.406924
NCT00528216|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2008-03-04|2007-09-10|2007-09-12|Estimate|||||||2008-03-04|2008-03-06|Estimate||||March 2008|2008-03-31||||||||Interventional|||Study of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function|A Randomized, Controlled, Single-Blind Study to Investigate the Effect of Three Capsaicin Dermal Liquid Formulations on Epidermal Nerve Fiber Immunostaining and Sensory Function In Healthy Volunteers|Completed||Phase 1|20|Anticipated|NeurogesX|||||||||||||||||||2018-06-01 02:56:18.457128|2018-06-01 02:56:18.457128
NCT00528203|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2016-07-11|2007-09-10|2007-09-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2007||2007-08-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|Gen/Phen||Establishing a Repository of Blood and DNA Samples From People With Sickle Cell Disease (Comprehensive Sickle Cell Centers Collaborative Genotype-Phenotype Database and Sample Repository)|Comprehensive Sickle Cell Centers (CSCC) Collaborative Genotype-Phenotype Database and Sample Repository|Terminated|||3640|Actual|National Heart, Lung, and Blood Institute (NHLBI)||||Funds for study ended September 30, 2008.|f||||t||||||Samples With DNA|"~     Plasma, Lymphocytes, Whole blood, RBC hemolysate, DNA~   "|||2018-06-01 02:56:18.503881|2018-06-01 02:56:18.503881
NCT00528190|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2017-02-01||2017-04-03|2007-09-11|2007-09-12|Estimate|2017-02-01|2017-03-23|Actual||||2017-04-03|2017-05-10|Actual|October 2007||2007-10-31|February 2017|2017-02-28|May 2011|Actual|2011-05-31|August 2010|Actual|2010-08-31||Interventional|||Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis|Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial|Completed||Phase 4|35|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||No||2018-06-01 02:56:18.57091|2018-06-01 02:56:18.57091
NCT00528177|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2011-07-03|2007-09-11|2007-09-12|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2007||2007-09-30|June 2007|2007-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Morphine vs. Oxycodone for Postoperative Pain Management|Phase 4: A Comparison of Intravenous Administration of Morphine vs. Oxycodone for Postoperative Pain Management Following Laparoscopic Hysterectomy or Myomectomy|Completed||Phase 4|90|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 02:56:18.776811|2018-06-01 02:56:18.776811
NCT00528164|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2013-02-15|2007-09-11|2007-09-12|Estimate|||||||2013-02-15|2013-02-18|Estimate|September 2006||2006-09-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Team PLAY||Team PLAY (Positive Lifestyles for Active Youngsters)|Treating Childhood Obesity With Family Lifestyle Change|Completed||Phase 2/Phase 3|270|Actual|University of Tennessee||2|||f||||t||||||||||2018-06-01 02:56:18.842199|2018-06-01 02:56:18.842199
NCT00528151|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2012-12-20|2007-09-11|2007-09-12|Estimate|||||||2012-12-20|2012-12-24|Estimate|May 2005||2005-05-31|August 2004|2004-08-31|December 2007|Actual|2007-12-31|||||Interventional|||A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)|A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)|Completed||Phase 3|70|Anticipated|Mahidol University||1|||f||||t||||||||||2018-06-01 02:56:18.907809|2018-06-01 02:56:18.907809
NCT00528138|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2009-11-09|2007-09-11|2007-09-12|Estimate|||||||2009-11-09|2009-11-10|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Hyperbilirubinemia in Acute Appendicitis as a Predictor of Perforation|Prospective Study Comparing Hyperbilirubinemia, CRP, White Blood Cell Count, and Other Clinical Parameters for the Preoperative Diagnosis of Perforated Acute Appendicitis|Completed|||132|Actual|Cirujanos la Serena|||2||f||||f||||||||||2018-06-01 02:56:19.107688|2018-06-01 02:56:19.107688
NCT00528125|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|||2018-03-27|2007-09-11|2007-09-12|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2007||2007-09-30|March 2008|2008-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Laser Acupuncture for Pain Prevention in Neonates|Laser Acupuncture for Pain Prevention in Neonates Undergoing Heel Prick. A Prospective, Randomized, Double-blinded Clinical Trial|Completed||N/A|50|Anticipated|University Children Hospital Homburg||2|||f||||f||||||||||2018-06-01 02:56:19.175311|2018-06-01 02:56:19.175311
NCT00528112|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-11|2012-07-11||2016-12-01|2007-09-11|2007-09-12|Estimate|2012-08-22|2012-09-24|Estimate||||2016-12-01|2017-01-25|Estimate|August 2007||2007-08-31|December 2016|2016-12-31|June 2013|Actual|2013-06-30|July 2011|Actual|2011-07-31||Interventional|||Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study|Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years|Completed||Phase 3|2885|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:56:19.340838|2018-06-01 02:56:19.340838
NCT00528099|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2009-07-22|2007-09-10|2007-09-12|Estimate|||||||2009-07-22|2009-07-23|Estimate|October 2007||2007-10-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study Evaluating IMA-026 in Healthy Japanese Males|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-026 Administered Subcutaneously or Intravenously to Healthy Japanese Male Subjects|Completed||Phase 1|50|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:56:20.705006|2018-06-01 02:56:20.705006
NCT00528086|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2010-05-24|2007-09-07|2007-09-11|Estimate|||||||2010-05-24|2010-05-25|Estimate|September 2007||2007-09-30|May 2010|2010-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|GROUP-PD||A Pilot, Randomized Controlled Trial of Group Visits for Persons With Parkinson's Disease|A Single Center, Randomized Controlled, Pilot Study Comparing Group Visits Versus Routine Clinical Care for Participants With Parkinson's Disease (PD).|Completed|||40|Anticipated|University of Rochester|||2||f||||t||||||||||2018-06-01 02:56:20.756229|2018-06-01 02:56:20.756229
NCT00528073|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2010-02-19|2007-09-10|2007-09-11|Estimate|||||||2010-02-19|2010-02-22|Estimate|September 2007||2007-09-30|February 2010|2010-02-28|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Interventional|||Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease|A Phase II, Multicentre, Double-blind, Randomised, Dose Range Finding Placebo Controlled Study of Rifaximin-EIR Tablet: Clinical Effectiveness and Tolerability in the Treatment of Moderate, Active Crohn's Disease|Completed||Phase 2|410|Actual|Alfasigma S.p.A.||4|||f||||t||||||||||2018-06-01 02:56:20.938732|2018-06-01 02:56:20.938732
NCT00528060|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2011-12-21|2007-09-10|2007-09-11|Estimate|||||||2011-12-21|2011-12-22|Estimate|January 2008||2008-01-31|December 2011|2011-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|ANRS134COPHAR3||Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada|Pilot Study to Measure Exposure to Atazanavir, as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to Tenofovir/Emtricitabine. ANRS 134 Cophar 3|Completed||Phase 2|35|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 02:56:21.093023|2018-06-01 02:56:21.093023
NCT00528047|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2012-01-03|2007-09-07|2007-09-11|Estimate|||||||2012-01-03|2012-01-05|Estimate|August 2007||2007-08-31|January 2012|2012-01-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors|A Phase I, Multi-center, Open-Label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of PRLX 93936 Administered Intravenously Daily for Five Days Followed by a 23-Day Rest Period in Patients With Advanced Solid Tumors|Completed||Phase 1|37|Actual|Prolexys Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:56:21.167485|2018-06-01 02:56:21.167485
NCT00528034|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2012-07-31|2007-09-10|2007-09-11|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2002||2002-09-30|July 2012|2012-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Lymphoscintigraphy in Patients With Vaginal Cancer|Lymphoscintigraphy and Selective Lymphatic Mapping in Patients With Invasive Vaginal Cancer|Completed||N/A|14|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:56:21.242718|2018-06-01 02:56:21.242718
NCT00528021|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2009-02-20||2010-11-30|2007-09-10|2007-09-11|Estimate|2010-11-30|2010-12-28|Estimate||||2010-11-30|2010-12-28|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation|A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation|Completed||Phase 2|230|Actual|BTG International Inc.||4|||f||||f||||||||||2018-06-01 02:56:21.398202|2018-06-01 02:56:21.398202
NCT00528008|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2012-11-08|2007-09-10|2007-09-11|Estimate|||||||2012-11-08|2012-11-09|Estimate|December 2007||2007-12-31|November 2012|2012-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections|Povidone-iodine vs. Chlorhexidine Gluconate - A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections|Terminated||Phase 3|268|Actual|Memorial University of Newfoundland||2||Study was stopped following interim analysis.|f||||f||||||||||2018-06-01 02:56:21.692186|2018-06-01 02:56:21.692186
NCT00527995|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2007-09-10|2007-09-10|2007-09-11|Estimate|||||||2007-09-10|2007-09-11|Estimate|August 2001||2001-08-31|September 2007|2007-09-30|June 2003|Actual|2003-06-30|||||Interventional|||Acute Effects of Sildenafil on Endothelial Function in People With Diabetes|Acute Effects of Sildenafil on Flow Mediated Dilatation and Cardiovascular Autonomic Nerve Function in Type 2 Diabetic Patients|Completed||Phase 3|40|Actual|Ruhr University of Bochum|||||f||||f||||||||||2018-06-01 02:56:21.7706|2018-06-01 02:56:21.7706
NCT00527982|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2011-01-06||2012-12-04|2007-09-10|2007-09-11|Estimate|2011-03-21|2011-04-20|Estimate||||2012-12-04|2012-12-06|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer|Celecoxib as Adjuvant Biologic Therapy in Patients With Early Stage Head and Neck and Lung Cancer|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||2||Termination due to poor accrual.|f||||f||||||||||2018-06-01 02:56:21.837535|2018-06-01 02:56:21.837535
NCT00527969|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2008-03-10|2007-09-10|2007-09-11|Estimate|||||||2008-03-10|2008-03-12|Estimate|July 2007||2007-07-31|March 2008|2008-03-31||||||||Interventional|REMEMBER-fX||Cognitive, Emotional, Physical and Psychosocial Effects of Panax Quinquefolius L|Cognitive, Emotional, Physical, and Psychosocial Effects of Three Weeks' Prospective Double-Blind Placebo Controlled Cross-Over Exposure to Panax Quinquefolius L (REMEMBER-fX), With Optional Six Months' Open Label Follow-up|Completed||Phase 2|72|Anticipated|Afexa Life Sciences Inc|||||f||||f||||||||||2018-06-01 02:56:22.023248|2018-06-01 02:56:22.023248
NCT00527956|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2008-06-06|2007-09-10|2007-09-11|Estimate|||||||2008-06-06|2008-06-09|Estimate|September 2007||2007-09-30|June 2008|2008-06-30|April 2008|Actual|2008-04-30|||||Observational|||Facilitation and Barriers to Breastfeeding in the NICU||Completed|||8|Anticipated|McGill University Health Center|||||f||||f||||||||||2018-06-01 02:56:22.077214|2018-06-01 02:56:22.077214
NCT00527943|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2014-05-09||2017-03-31|2007-09-07|2007-09-11|Estimate|2014-05-09|2014-06-09|Estimate||||2017-03-31|2017-05-05|Actual|December 1, 2007|Actual|2007-12-01|March 2017|2017-03-31|July 1, 2011|Actual|2011-07-01|July 1, 2011|Actual|2011-07-01||Interventional|||Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)|Terminated||Phase 3|12944|Actual|Merck Sharp & Dohme Corp.|Prior to the planned study completion, the Data Safety Monitoring Board recommended that all participants stop treatment and that the study be closed-out. The protocol-defined target number of primary efficacy endpoints had been reached by this time.|2||The trial was terminated at the request of the Data and Safety Monitoring Board.|f||||t||||||||||2018-06-01 02:56:22.21775|2018-06-01 02:56:22.21775
NCT00527930|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-08|||2013-10-09|2007-09-08|2007-09-11|Estimate|||||||2013-10-09|2013-10-10|Estimate|September 2007||2007-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|TORCH||Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer|Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer (MBC) Previously Treated With or Resistant to an Anthracycline and Taxane|Completed||Phase 2|87|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-06-01 02:56:25.389426|2018-06-01 02:56:25.389426
NCT00527917|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2009-12-07|2007-09-10|2007-09-11|Estimate|||||||2009-12-07|2009-12-09|Estimate|September 2007||2007-09-30|December 2009|2009-12-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.|A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Efficacy and Safety of Uracyst® (Intravesical Sodium Chondroitin Sulfate) Versus Vehicle Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.|Completed||Phase 2|65|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 02:56:25.456065|2018-06-01 02:56:25.456065
NCT00527904|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2010-05-28|2010-03-15|2010-08-27|2007-09-10|2007-09-11|Estimate|2010-07-23|2010-08-20|Estimate|2010-03-15|2010-03-17|Estimate|2010-08-27|2010-08-31|Estimate|March 2007||2007-03-31|August 2010|2010-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)|A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 in Subjects Who Are at Risk for Developing NSAID-associated Ulcers|Completed||Phase 3|239|Actual|POZEN||1|||f||||t||||||||||2018-06-01 02:56:25.545269|2018-06-01 02:56:25.545269
NCT00527891|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2012-07-30|2007-09-10|2007-09-11|Estimate|||||||2012-07-30|2012-07-31|Estimate|June 2004||2004-06-30|July 2012|2012-07-31||||September 2007|Actual|2007-09-30||Observational|||Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions|Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions|Completed|||16|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:56:25.725703|2018-06-01 02:56:25.725703
NCT00527878|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-08|2013-02-01||2013-02-01|2007-09-08|2007-09-11|Estimate|2013-02-01|2013-02-04|Estimate||||2013-02-01|2013-02-04|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||All participants whether or not they were randomized.|Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome|A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations|Terminated||Phase 2|16|Actual|National Institutes of Health Clinical Center (CC)||2||Failure to enroll adequate patient numbers due to small number of eligible patients|f||||||||||||||2018-06-01 02:56:25.898591|2018-06-01 02:56:25.898591
NCT00527865|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2009-01-06|2007-09-10|2007-09-11|Estimate|||||||2009-01-06|2009-01-08|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Single Dose Escalating Study of DAS181 in Adults|Study 181-1-06-01 - Phase 1A Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalating Study in Healthy Adults|Completed||Phase 1|36|Anticipated|Ansun Biopharma, Inc.||4|||f||||||||||||||2018-06-01 02:56:26.154532|2018-06-01 02:56:26.154532
NCT00527852|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2018-04-17|2007-09-10|2007-09-11|Estimate|||||||2018-04-17|2018-04-18|Actual|September 2007||2007-09-30|July 2007|2007-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Assessment of Flocked Swabs for the Identification of Group A Streptococcal Pharyngitis||Completed||N/A|350|Actual|Children's Hospital of Eastern Ontario|||||f||||t||||||||||2018-06-01 02:56:26.250089|2018-06-01 02:56:26.250089
NCT00527839|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2018-05-24|2007-09-10|2007-09-11|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2007||2007-04-30|May 2018|2018-05-31|April 2027|Anticipated|2027-04-30|April 2027|Anticipated|2027-04-30||Observational|||Hospital for Special Surgery Shoulder Arthroplasty Cohort|Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: HSS Shoulder Arthroplasty Cohort|Recruiting|||250|Anticipated|Hospital for Special Surgery, New York|||||f||||t||||||||||2018-06-01 02:56:26.311541|2018-06-01 02:56:26.311541
NCT00527826|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2010-03-10||2012-10-25|2007-09-10|2007-09-11|Estimate|2010-05-27|2010-06-24|Estimate||||2012-10-25|2012-10-30|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV|A 12 Month Open-label Randomized Parallel Group Study to Investigate the Influence of Salmeterol Xinafoate/Fluticasone Propionate Either in Fixed Combination or Separately Via Diskus Inhalers on the Course of the Disease and Frequency of Exacerbations in Subjects With Severe and Very Severe COPD.|Completed||Phase 4|214|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 02:56:26.540185|2018-06-01 02:56:26.540185
NCT00527813|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2015-05-06|2007-09-10|2007-09-11|Estimate|||||||2015-05-06|2015-05-07|Estimate|January 2008||2008-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|Proseva||Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome|Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome|Completed||N/A|474|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 02:56:27.212589|2018-06-01 02:56:27.212589
NCT00527800|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2013-10-09|2007-09-10|2007-09-11|Estimate|||||||2013-10-09|2013-10-11|Estimate|August 2007||2007-08-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|TCC||Interactions Between HIV and Malaria in African Children|Interactions Between HIV and Malaria in African Children|Completed||Phase 3|351|Actual|University of California, San Francisco||4|||f||||f||||||||||2018-06-01 02:56:27.281172|2018-06-01 02:56:27.281172
NCT00527787|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2010-05-27|2009-10-13|2010-11-29|2007-09-10|2007-09-11|Estimate|2010-11-29|2010-12-28|Estimate|2009-10-14|2009-10-16|Estimate|2010-11-29|2010-12-28|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen|6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers|Completed||Phase 3|434|Actual|POZEN||2|||f||||t||||||||||2018-06-01 02:56:27.380038|2018-06-01 02:56:27.380038
NCT00527774|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2016-05-04|2007-09-10|2007-09-11|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2007||2007-09-30|May 2016|2016-05-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Observational|||Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients|Impact of Hepatitis C Virus Infection on Insulin Resistance and Inflammatory Biomarkers in Patients With Maintenance Hemodialysis|Completed|||200|Actual|St. Martin De Porress Hospital|||2||f||||t||||||Samples With DNA|"~     Check HCV viral load and genotype in first month and sixth month~   "|||2018-06-01 02:56:27.716848|2018-06-01 02:56:27.716848
NCT00527761|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2012-07-26|2007-09-10|2007-09-11|Estimate|||||||2012-07-26|2012-07-30|Estimate|August 2004||2004-08-31|July 2012|2012-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Taxotere/Temodar/Cisplatin Study in Melanoma Patients|Phase I Study of TTC (Taxotere/Temodar/Cisplatin) in Metastatic Melanoma Patients|Completed||Phase 1|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:56:27.786042|2018-06-01 02:56:27.786042
NCT00527748|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2016-09-21||2017-04-19|2007-09-07|2007-09-11|Estimate|2017-04-19|2017-04-21|Actual||||2017-04-19|2017-04-21|Actual|September 2007||2007-09-30|March 2017|2017-03-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional||Although 23 participants completed the study, we do not know their baseline characteristics or to which arm/group they were assigned as the investigator left the institution without making this information available.|Foot and Ankle Range of Motion (Stretching) Apparatus|The Use of a New Foot and Ankle Range of Motion (Stretching) Apparatus in Subjects With Stiff Ankles|Terminated||N/A|26|Actual|University of Missouri-Columbia|No participant data were analyzed because the investigator left the institution before doing so. The results are unavailable.|2||Investigator left institution. No data analysis completed.|f||||f||||||||No||2018-06-01 02:56:27.856848|2018-06-01 02:56:27.856848
NCT00527735|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2012-02-23|2011-01-29|2012-06-11|2007-09-10|2007-09-11|Estimate|2012-06-11|2012-07-16|Estimate|2011-01-29|2011-05-18|Estimate|2012-06-11|2012-07-16|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|December 2011|Actual|2011-12-31|October 2009|Actual|2009-10-31||Interventional|||Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)|A Randomized, Double Blind, Parallel, Three Arm Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination With Paclitaxel/Carboplatin Compared to Paclitaxel/Carboplatin Alone in Previously Untreated Subjects With Lung Cancer|Completed||Phase 2|334|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 02:56:28.345632|2018-06-01 02:56:28.345632
NCT00527722|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2011-05-10||2012-08-01|2007-09-10|2007-09-11|Estimate|2011-06-13|2011-07-11|Estimate||||2012-08-01|2012-08-07|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of the Bio-Seal Biopsy Track Plug|A Prospective Randomized Multi-Centered Study and Efficacy Evaluation of the Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedures|Completed||Phase 2/Phase 3|77|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:56:30.997705|2018-06-01 02:56:30.997705
NCT00527709|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2014-02-01|2007-09-10|2007-09-11|Estimate|||||||2014-02-01|2014-02-04|Estimate|August 2006||2006-08-31|February 2014|2014-02-28||||August 2006||2006-08-31||Observational|||Hold Parameters on Likely Cardiovascular Depressant Medications|Hold Parameters on Likely Cardiovascular Depressant Medications (HOLD)|Unknown status|Active, not recruiting||||Hackensack University Medical Center|||||f||||||||||||||2018-06-01 02:56:31.311225|2018-06-01 02:56:31.311225
NCT00527696|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2016-01-08|2007-09-10|2007-09-11|Estimate|||||||2016-01-08|2016-01-12|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Trial Comparing TVT SECUR System and Trans Vaginal Obturator Tape for Surgical Management of Stress Urinary Incontinence|Randomized Clinical Trial Comparing TVT SECUR System (TVT S) and Trans Vaginal Obturator Tape (TVT-O) for Surgical Management of Stress Urinary Incontinence|Terminated||Phase 3|106|Actual|University of Manitoba||2||statistical Significance was reached for primary outcome|f||||t||||||||||2018-06-01 02:56:31.366004|2018-06-01 02:56:31.366004
NCT00527683|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2008-04-07|2007-09-10|2007-09-11|Estimate|||||||2008-04-07|2008-04-11|Estimate|April 2007||2007-04-30|April 2008|2008-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence|Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees|Completed||Phase 2|100|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 02:56:31.427969|2018-06-01 02:56:31.427969
NCT00527670|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2016-08-05|2007-09-07|2007-09-11|Estimate|||||||2016-08-05|2016-08-08|Estimate|August 2007||2007-08-31|August 2016|2016-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias|Pilot Study to Identify the Influence of Genetic Profile Aberrations on Patients With Recurrent Hernias|Terminated|||41|Actual|University of Missouri-Columbia|||2|PI left institution|f||||f||||||Samples With DNA|"~     Tissue samples.~   "|No||2018-06-01 02:56:31.515218|2018-06-01 02:56:31.515218
NCT00527657|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2013-05-29|2007-09-10|2007-09-11|Estimate|||||||2013-05-29|2013-05-31|Estimate|February 2006||2006-02-28|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients|A Phase I Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain|Completed||Phase 1|17|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:56:31.57809|2018-06-01 02:56:31.57809
NCT00527644|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2017-10-24||2017-11-28|2007-09-10|2007-09-11|Estimate|2017-11-28|2017-12-06|Actual||||2017-11-28|2017-12-06|Actual|July 2007||2007-07-31|November 2017|2017-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Clinical Evaluation of Spring-Type Laparoscopic Clip Technology|Clinical Evaluation of Spring-Type Laparoscopic Clip Technology|Terminated||N/A|14|Actual|University of Missouri-Columbia|Study was terminated before expected enrollment was reached due to insufficient funds.|1||Insufficient funding to complete study|f||||f||||||||||2018-06-01 02:56:31.658733|2018-06-01 02:56:31.658733
NCT00527631|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2007-09-07|2007-09-07|2007-09-11|Estimate|||||||2007-09-07|2007-09-11|Estimate|July 2006||2006-07-31|August 2007|2007-08-31|November 2012|Anticipated|2012-11-30|||||Interventional|OVAR-IMRT-01||Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer|Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer: Pilot Trial of a Phase I/II Study|Unknown status|Recruiting|Phase 1|8|Anticipated|Heidelberg University|||||f||||f||||||||||2018-06-01 02:56:31.856456|2018-06-01 02:56:31.856456
NCT00527618|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2012-06-26||2013-01-18|2007-09-10|2007-09-11|Estimate|2012-06-26|2012-07-31|Estimate||||2013-01-18|2013-01-25|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV|A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons|Completed||Phase 4|28|Actual|University of Washington|Our findings are limited by the high loss to follow up, which is especially problematic in cross-over studies.|2|||f||||f||||||||||2018-06-01 02:56:31.930076|2018-06-01 02:56:31.930076
NCT00527605|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2010-02-22||2012-03-15|2007-09-10|2007-09-11|Estimate|2010-02-22|2010-03-11|Estimate||||2012-03-15|2012-03-21|Estimate|October 2007||2007-10-31|May 2011|2011-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)|A Randomized, Double-blind, Placebo-controlled, Six-month Parallel-group Study to Assess Efficacy and Safety of Dutasteride 0.5mg Once Daily in Chinese Patients With Benign Prostatic Hyperplasia (BPH), Followed by a 12-month Open-label Treatment Phase|Completed||Phase 3|253|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:56:32.197014|2018-06-01 02:56:32.197014
NCT00527592|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2009-11-13||2012-05-11|2007-09-10|2007-09-11|Estimate|2010-01-25|2010-02-10|Estimate||||2012-05-11|2012-05-18|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 4|54|Actual|Alcon Research|None specified.|2|||f||||f||||||||||2018-06-01 02:56:32.6672|2018-06-01 02:56:32.6672
NCT00527579|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-08|||2017-10-05|2007-09-08|2007-09-11|Estimate|||||||2017-10-05|2017-10-06|Actual|September 4, 2007||2007-09-04|November 26, 2013|2013-11-26|November 26, 2013|Actual|2013-11-26|November 26, 2013|Actual|2013-11-26||Interventional|||PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FBR|Completed||Phase 1|24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:56:32.807055|2018-06-01 02:56:32.807055
NCT00527566|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2011-06-22||2017-02-01|2007-09-07|2007-09-11|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|September 2007||2007-09-30|February 2017|2017-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|MATOCSS||Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome|Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome|Completed||Phase 1/Phase 2|10|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-06-01 02:56:32.877912|2018-06-01 02:56:32.877912
NCT00527553|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|||2018-04-25|2007-09-10|2007-09-11|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2007||2007-10-31|November 2008|2008-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Effect of Eggs and Egg Products on Macular Pigment|The Effect of Modified Eggs and Egg Products on the Measurable Macular Pigment in Healthy Subjects|Completed||N/A|100|Actual|Maastricht University Medical Center||5|||f||||f||||||||||2018-06-01 02:56:33.08601|2018-06-01 02:56:33.08601
NCT00527540|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-08|||2009-01-18|2007-09-08|2007-09-11|Estimate|||||||2009-01-18|2009-01-21|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C|Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C|Completed||Phase 3|60|Anticipated|Tehran Hepatitis Center|||||f||||t||||||||||2018-06-01 02:56:33.148848|2018-06-01 02:56:33.148848
NCT00527527|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-08|||2011-10-07|2007-09-08|2007-09-11|Estimate|||||||2011-10-07|2011-10-12|Estimate|September 2007||2007-09-30|October 2011|2011-10-31||||January 2010|Actual|2010-01-31||Interventional|||Chiropractic Dosage for Lumbar Stenosis|Chiropractic Dosage for Lumbar Stenosis|Completed||Phase 2|60|Anticipated|National University of Health Sciences||4|||f||||t||||||||||2018-06-01 02:56:33.393581|2018-06-01 02:56:33.393581
NCT00527514|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2009-05-05||2009-11-04|2007-09-10|2007-09-11|Estimate|2009-08-14|2009-09-23|Estimate||||2009-11-04|2009-11-11|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension|A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension|Completed||Phase 3|185|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 02:56:33.48377|2018-06-01 02:56:33.48377
NCT00527501|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2012-04-12|2007-09-10|2007-09-11|Estimate|||||||2012-04-12|2012-04-16|Estimate|August 2007||2007-08-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension|IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|136|Actual|Alcon Research|||||f||||f||||||||||2018-06-01 02:56:33.768679|2018-06-01 02:56:33.768679
NCT00527488|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|2010-08-16|2010-04-09|2015-04-14|2007-09-10|2007-09-11|Estimate|2010-10-27|2010-11-25|Estimate|2010-04-09|2010-04-12|Estimate|2015-04-14|2015-05-04|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.|A Single-centre, Open-label, Randomised Explorative Pharmacokinetic/Pharmacodynamic Study of the Gonadotropin-releasing Hormone Receptor Antagonist Degarelix (FE 200486) in Patients With Benign Prostatic Hyperplasia.|Completed||Phase 2|52|Actual|Ferring Pharmaceuticals||4|||f||||f||||||||||2018-06-01 02:56:33.848752|2018-06-01 02:56:33.848752
NCT00527475|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-09|2013-04-19||2013-06-05|2007-09-09|2007-09-11|Estimate|2013-06-05|2013-06-07|Estimate||||2013-06-05|2013-06-07|Estimate|May 2007||2007-05-31|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|RAP||Ranibizumab and Reduced Fluence PDT for AMD|Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration|Completed||Phase 2|60|Actual|Texas Retina Associates||2|||f||||f||||||||||2018-06-01 02:56:34.602554|2018-06-01 02:56:34.602554
NCT00527462|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-10|||2008-04-28|2007-09-10|2007-09-11|Estimate|||||||2008-04-28|2008-04-30|Estimate|September 2007||2007-09-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study to Explore the Effects of Two Hour Inhalation of Ultrafine Carbon Black Particles on Airway Inflammation in Asthmatics|Mono-Center, Double-Blind, Cross-Over Study to Explore the Effects of Two Hour Inhalation of Ultrafine Carbon Black Particles Versus Filtered Air on Airway Inflammation Induced by Segmental Allergen Challenge in Asthmatics|Completed||N/A|15|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||||||||||||2018-06-01 02:56:34.782849|2018-06-01 02:56:34.782849
NCT00527449|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2010-01-14|2007-09-07|2007-09-10|Estimate|||||||2010-01-14|2010-01-15|Estimate|May 2006||2006-05-31|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|ETCat01||Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel|Neoadjuvant Chemotherapy With 3x Epirubicin/Docetaxel Followed by 3x Carboplatin/Docetaxel in Patients With Primary Breast Cancer|Completed||Phase 2|50|Actual|Klinikum Weissenfels|||||f||||f||||||||||2018-06-01 02:56:34.856715|2018-06-01 02:56:34.856715
NCT00527436|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2007-09-06|2007-09-06|2007-09-10|Estimate|||||||2007-09-06|2007-09-10|Estimate||||September 2007|2007-09-30||||||||Interventional|||Fish Oil and Biomarkers of Cardiovascular Risk|Fish Oil and Biomarkers of Cardiovascular Risk|Unknown status|Not yet recruiting|N/A|||Penn State University|||||f||||t||||||||||2018-06-01 02:56:34.920221|2018-06-01 02:56:34.920221
NCT00527423|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2012-11-02|2011-04-25|2013-06-10|2007-09-07|2007-09-10|Estimate|2013-06-10|2013-06-12|Estimate|2011-04-25|2011-04-29|Estimate|2013-06-10|2013-06-12|Estimate|August 2007||2007-08-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD|A Randomized, Single-Masked , Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects With Neovascular Age-related Macular Degeneration|Completed||Phase 2|157|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:56:34.995775|2018-06-01 02:56:34.995775
NCT00527410|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2014-11-12|2007-09-07|2007-09-10|Estimate|||||||2014-11-12|2014-11-13|Estimate|October 2006||2006-10-31|November 2014|2014-11-30||||December 2008|Actual|2008-12-31||Interventional|LMD||A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis|A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis|Terminated||Phase 1|9|Actual|Reata Pharmaceuticals, Inc.||1||Business Decision|f||||f||||||||||2018-06-01 02:56:35.406862|2018-06-01 02:56:35.406862
NCT00527397|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2009-07-15||2009-10-05|2007-09-07|2007-09-10|Estimate|2009-09-01|2009-10-05|Estimate||||2009-10-05|2009-10-15|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes|An Open-Label, Uncontrolled Long-Term Safety Study Of CP-464,005 (Inhaled Insulin) In Japanese Patients With Type 1 Or Type 2 Diabetes|Terminated||Phase 3|24|Actual|Pfizer|As a result of Pfizer's decision (18 Oct 2007) to return the worldwide rights for CP-464,005 (insulin human [rDNA origin]) Inhalation Powder) to Nektar, from which Pfizer licensed inhaled insulin technology, it was decided to terminate this study.|3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 02:56:35.475271|2018-06-01 02:56:35.475271
NCT00527371|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2018-02-08|2007-09-07|2007-09-10|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2008||2008-01-31|February 2018|2018-02-28|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Interventional|PVP||PVP Compared to TURP for the Treatment of Benign Hyperplasia of the Prostate|Prospective Controlled Trial Comparing Photoselective Vaporization of the Prostate (PVP-120W) to Transurethral Resection of the Prostate (TURP) for the Treatment of Benign Hyperplasia of the Prostate (BPH)|Completed||N/A|164|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-06-01 02:56:36.010314|2018-06-01 02:56:36.010314
NCT00527358|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2012-02-08|2007-09-06|2007-09-10|Estimate|||||||2012-02-08|2012-02-10|Estimate|September 2006||2006-09-30|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of SAFER Latinos' Program to Prevent Youth Violence|Evaluation of SAFER Latinos' Program to Prevent Youth Violence|Completed||Phase 2/Phase 3|1400|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:56:36.100362|2018-06-01 02:56:36.100362
NCT00527345|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2015-04-13|2007-09-06|2007-09-10|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2005||2005-03-31|April 2015|2015-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Children's Exposures/Health Effects/Diesel Exhaust|Children's Exposure and Health Effects From Diesel Exhaust Before and After Switch of Schoool Bus Fleets|Completed|||450|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||3||f||||f||||||||||2018-06-01 02:56:36.171894|2018-06-01 02:56:36.171894
NCT00527332|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2011-11-14||2012-01-24|2007-09-07|2007-09-10|Estimate|2011-11-14|2011-12-21|Estimate||||2012-01-24|2012-01-26|Estimate|March 2007||2007-03-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Effects of General Anesthesia and Spinal-Morphine Anesthesia on Recovery and Comfort After Benign Abdominal Hysterectomy|General Anesthesia Versus Spinal Anesthesia Combined With Intrathecal Morphine in Abdominal Hysterectomy for Benign Gynecological Diseases. A Randomized Open Controlled Study.|Completed||Phase 4|180|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-06-01 02:56:36.235211|2018-06-01 02:56:36.235211
NCT00527319|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2012-11-08||2012-12-19|2007-09-06|2007-09-10|Estimate|2012-12-19|2013-01-30|Estimate||||2012-12-19|2013-01-30|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|VT-122||Regimen for the Treatment of Cachexia in Subjects With NSCLC|A Pilot Open Label Randomized Controlled Study to Evaluate the Dose Tolerance Safety and Efficacy of VT-122 Regimen for the Treatment of Cachexia in Subjects With Stage IV Non-Small Cell Lung Cancer|Completed||Phase 2|37|Actual|Vicus Therapeutics||3|||f||||t||||||||||2018-06-01 02:56:36.570195|2018-06-01 02:56:36.570195
NCT00527306|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2010-03-30|2007-09-06|2007-09-10|Estimate|||||||2010-03-30|2010-03-31|Estimate|December 2005||2005-12-31|March 2010|2010-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Prevention of Recurrent Aphthous Stomatitis Using Vitamins|Prevention of Recurrent Aphthous Stomatitis Using Vitamins|Completed||Phase 3|160|Actual|UConn Health||2|||f||||f||||||||||2018-06-01 02:56:37.067615|2018-06-01 02:56:37.067615
NCT00527293|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2015-08-21|2007-09-07|2007-09-10|Estimate|||||||2015-08-21|2015-08-25|Estimate|June 2007||2007-06-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|October 2010|Actual|2010-10-31||Interventional|||Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer|Partial Breast Irradiation for Patients Undergoing Breast Conservation Therapy for Early Stage Breast Cancer: A Pilot Study|Completed||Early Phase 1|29|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:56:37.146899|2018-06-01 02:56:37.146899
NCT00527280|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2017-03-21|2007-09-06|2007-09-10|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2007||2007-01-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Face Reconstruction by Allotransplantation of Composite Tissues|Face Reconstruction by Allotransplantation of Composite Tissues|Completed||Phase 2|7|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 02:56:37.229639|2018-06-01 02:56:37.229639
NCT00527267|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2009-01-22|2007-09-06|2007-09-10|Estimate|||||||2009-01-22|2009-01-26|Estimate|February 2002||2002-02-28|January 2009|2009-01-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects|A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis|Completed||Phase 3|320|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 02:56:37.327979|2018-06-01 02:56:37.327979
NCT00527254|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2007-09-07|2007-09-07|2007-09-10|Estimate|||||||2007-09-07|2007-09-10|Estimate|October 2003||2003-10-31|September 2007|2007-09-30|June 2005|Actual|2005-06-30|||||Interventional|||Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient||Completed||N/A|328|Actual|Province of Malaga Health Department||2|||f||||f||||||||||2018-06-01 02:56:37.397829|2018-06-01 02:56:37.397829
NCT00527241|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2012-02-08|2007-09-06|2007-09-10|Estimate|||||||2012-02-08|2012-02-10|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy Trial of Raices Nuevas|Efficacy Trial of Raices Nuevas|Completed||Phase 2/Phase 3|160|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:56:37.456065|2018-06-01 02:56:37.456065
NCT00527228|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2015-08-31|2007-09-06|2007-09-10|Estimate|||||||2015-08-31|2015-09-02|Estimate|September 2003||2003-09-30|August 2015|2015-08-31|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|||Deflazacort in Dysferlinopathies|Deflazacort in Dysferlinopathies (LGMD2B/MM) - a Double Blind, Placebo-controlled Clinical Study|Completed||Phase 2/Phase 3|25|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 02:56:37.520768|2018-06-01 02:56:37.520768
NCT00527215|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2009-05-21|2007-09-06|2007-09-10|Estimate|||||||2009-05-21|2009-05-22|Estimate|March 2002||2002-03-31|May 2009|2009-05-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Phase 2 Study of Darbepoetin Alfa Extended Dosing|A Study of Darbepoetin Alfa Administered Once Every Four Weeks in Chronic Renal Insufficiency (CRI) Subjects With Anemia|Completed||Phase 2|98|Actual|Amgen||1|||f||||||||||||||2018-06-01 02:56:37.595114|2018-06-01 02:56:37.595114
NCT00527202|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2007-09-07|2007-09-07|2007-09-10|Estimate|||||||2007-09-07|2007-09-10|Estimate|June 2004||2004-06-30|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Efficacy Study of Botox to Treat Neuropathic Pain|Randomized Placebo-Controlled Study of the Efficacy of Botulinum Toxin Type A (Botox) in Spontaneous Pain and Allodynia Related to Traumatic Nerve Injury or Postherpetic Neuralgia|Completed||Phase 4|29|Actual|Hospital Ambroise Paré Paris||2|||f||||f||||||||||2018-06-01 02:56:37.679205|2018-06-01 02:56:37.679205
NCT00527189|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2007-09-07|2007-09-07|2007-09-10|Estimate|||||||2007-09-07|2007-09-10|Estimate|January 2006||2006-01-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||Balance Impairment and Falls Risk in People With Lower Limb Arthritis, and Can These be Improved With Exercise?|Which Measures of Balance Best Discriminate Balance Impairment and Falls Risk in People With Lower Limb Arthritis, and Can These be Improved With Exercise?|Completed||N/A|||National Ageing Research Institute, Australia|||||f||||f||||||||||2018-06-01 02:56:37.736344|2018-06-01 02:56:37.736344
NCT00527163|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2018-05-19|2007-09-07|2007-09-10|Estimate|||||||2018-05-19|2018-05-22|Actual|September 4, 2007||2007-09-04|March 30, 2015|2015-03-30|March 30, 2015||2015-03-30|||||Observational|||Role of Nitric Oxide in Malaria|Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria|Completed|||103|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:56:37.837432|2018-06-01 02:56:37.837432
NCT00527150|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2010-01-07|2007-09-07|2007-09-10|Estimate|||||||2010-01-07|2010-01-11|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Multiple Dose, Dose Escalation Study of Varenicline Controlled Release Formulation in Adult Smokers|A Phase 1, Investigator And Subject Blind (Sponsor Open), Randomized, Placebo Controlled, Parallel Group, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Varenicline Amt-8 Controlled Release Formulation In Adult Smokers|Completed||Phase 1|48|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 02:56:37.892319|2018-06-01 02:56:37.892319
NCT00527137|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2013-05-06|2007-09-06|2007-09-10|Estimate|||||||2013-05-06|2013-05-08|Estimate|August 2000||2000-08-31|May 2013|2013-05-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||NESP Pediatric Study|An Open-label, Randomized, Non-inferiority Study of Novel Erythropoiesis Stimulating Protein (NESP) and Recombinant Human Erythropoietin (rHuEPO) for the Treatment of Anemia in Pediatric Subjects With Chronic Renal Insufficiency (CRI) or End-stage Renal Disease (ESRD) Receiving Dialysis|Completed||Phase 3|120|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 02:56:38.167606|2018-06-01 02:56:38.167606
NCT00527124|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2013-07-09||2018-02-07|2007-09-07|2007-09-10|Estimate|2014-02-07|2014-03-11|Estimate||||2018-02-07|2018-03-12|Actual|November 2007||2007-11-30|February 2018|2018-02-28|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Interventional|||Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Randomized, Phase II Trial of AZD2171, Docetaxel, and Prednisone Compared to Docetaxel and Prednisone in Patients With Metastatic, Hormone Refractory Prostate Cancer|Terminated||Phase 2|57|Actual|National Cancer Institute (NCI)|Closure was recommended by CTEP due to slow accrual.|2||Closure was recommended by CTEP due to slow accrual.|f||||t||||||||||2018-06-01 02:56:38.264796|2018-06-01 02:56:38.264796
NCT00527111|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2016-01-12||2016-09-15|2007-09-07|2007-09-10|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|February 2007||2007-02-28|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||ITT population|Pre-op Rectal ChemoRad +/- Cetuximab|A Randomized Phase II Trial of Pre-operative Chemoradiotherapy With or Without Cetuximab (ERBITUX(R)) in Locally-advanced Adenocarcinoma of the Rectum|Completed||Phase 2|139|Actual|US Oncology Research||2|||f||||f||||||||||2018-06-01 02:56:38.736025|2018-06-01 02:56:38.736025
NCT00527098|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2011-04-01||2013-02-20|2007-09-06|2007-09-10|Estimate|2011-04-01|2011-05-04|Estimate||||2013-02-20|2013-02-22|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Optimal Fluid Resuscitation for Trauma Patients|Optimal Fluid Resuscitation for Trauma Patients|Completed|||119|Actual|University of Miami|||||f||||f||||||||||2018-06-01 02:56:39.080365|2018-06-01 02:56:39.080365
NCT00527085|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2013-05-06|2007-09-06|2007-09-10|Estimate|||||||2013-05-06|2013-05-08|Estimate|October 2001||2001-10-31|May 2013|2013-05-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||12-month Study of AMG 073 in Renal Osteodystrophy|A Multicenter, Randomized, Placebo-controlled, Double-blind, 12-month Study to Assess the Effects of an Oral Calcimimetic Agent (AMG 073) on Renal Osteodystrophy in Hemodialysis Patients With Secondary Hyperparathyroidism|Completed||Phase 2|45|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 02:56:39.252535|2018-06-01 02:56:39.252535
NCT00527072|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2010-05-28||2012-08-28|2007-09-06|2007-09-10|Estimate|2010-05-28|2010-06-24|Estimate||||2012-08-28|2012-09-03|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept|A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab (REMICADE�) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL�)|Completed||Phase 3|217|Actual|Centocor Ortho Biotech Services, L.L.C.||1|||f||||f||||||||||2018-06-01 02:56:40.306753|2018-06-01 02:56:40.306753
NCT00527059|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2007-09-07|2007-09-07|2007-09-10|Estimate|||||||2007-09-07|2007-09-10|Estimate|October 2007||2007-10-31|September 2007|2007-09-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure|Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure|Unknown status|Not yet recruiting|Phase 4|21|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-06-01 02:56:40.496442|2018-06-01 02:56:40.496442
NCT00527046|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06||2012-01-30|2012-01-30|2007-09-06|2007-09-10|Estimate||||2012-01-30|2012-02-02|Estimate|2012-01-30|2012-02-02|Estimate|December 1999||1999-12-31|January 2012|2012-01-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults|A Randomized, Double Blind, Placebo Controlled, Five Parallel Group Study Of The Effect Of CP-424,391 On Physical Performance And Body Composition In Older Subjects|Terminated||Phase 2|396|Actual|Pfizer|||||||||||||||||||2018-06-01 02:56:40.57302|2018-06-01 02:56:40.57302
NCT00527033|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2017-02-14|2007-09-06|2007-09-10|Estimate|||||||2017-02-14|2017-02-16|Actual|September 2007||2007-09-30|February 2017|2017-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of YM178 in Patients With Symptomatic Overactive Bladder|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder|Completed||Phase 2|842|Actual|Astellas Pharma Inc||4|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 02:56:40.655955|2018-06-01 02:56:40.655955
NCT00527020|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2017-08-03|2007-09-06|2007-09-10|Estimate|||||||2017-08-03|2017-08-04|Actual|August 10, 2007|Actual|2007-08-10|August 2017|2017-08-31|July 12, 2008|Actual|2008-07-12|July 12, 2008|Actual|2008-07-12||Interventional|||First Time in Human Study With GSK1018921|Single-Blind, Randomised, Placebo-controlled First Time in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Escalating Doses of GSK1018921 in Healty Volunteers and a Randomized, Double-blind, Double Dummy, Placebo Controlled, Three-way Crossover Study in a Separate Cohort of Healthy Volunteers to Test the Effect of Single Doses of GSK1018921 and Nicotine on qEEG and MMN in Healthy Volunteers|Completed||Phase 1|27|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-06-01 02:56:40.740947|2018-06-01 02:56:40.740947
NCT00527007|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2010-07-21|2007-09-07|2007-09-10|Estimate|||||||2010-07-21|2010-07-22|Estimate|October 2007||2007-10-31|August 2008|2008-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|sepsis-cool||External Cooling in Septic Shock Patients|Impact of External Cooling in Septic Shock Patients|Completed||N/A|200|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:56:40.917986|2018-06-01 02:56:40.917986
NCT00526994|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2013-02-12||2013-07-29|2007-09-06|2007-09-10|Estimate|2013-07-29|2013-07-31|Estimate||||2013-07-29|2013-07-31|Estimate|May 2008||2008-05-31|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Randomized Controlled Trial of Routine Screening for IPV|Randomized Controlled Trial of Routine Screening for Intimate Partner Violence|Completed||Phase 2/Phase 3|2700|Actual|Centers for Disease Control and Prevention|12% lost to follow-up differed in age, education, and insurance status from those retained. Generalizability of the findings is limited by the urban setting; exclusion of some participants.|3|||f||||f||||||||||2018-06-01 02:56:41.051159|2018-06-01 02:56:41.051159
NCT00526981|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2011-09-19|2007-09-06|2007-09-10|Estimate|||||||2011-09-19|2011-09-20|Estimate|September 2007||2007-09-30|September 2011|2011-09-30||||December 2011|Anticipated|2011-12-31||Interventional|||Prone Position for Non-intubated Patients With Acute Respiratory Failure|Prone Position for Non-intubated Patients With Acute Respiratory Failure|Unknown status|Recruiting|N/A|24|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-06-01 02:56:41.627447|2018-06-01 02:56:41.627447
NCT00526968|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2008-02-14|2007-09-07|2007-09-10|Estimate|||||||2008-02-14|2008-02-18|Estimate|September 2007||2007-09-30|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function|A Double Blind, Placebo Controlled Study to Investigate the Role of NMDA Receptor NR2B Subunit Selective Antagonism on Cognitive Functions and Neurophysiology in Healthy Subjects as Measured With MRI|Completed||Phase 1|19|Actual|Evotec Neurosciences GmbH||3|||f||||f||||||||||2018-06-01 02:56:41.698958|2018-06-01 02:56:41.698958
NCT00526955|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2008-08-06|2007-09-07|2007-09-10|Estimate|||||||2008-08-06|2008-08-07|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||Duration and Force Variations in Applied Kinesiology Manual Muscle Testing|Duration and Force Variations in Applied Kinesiology Manual Muscle Testing|Completed|||||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 02:56:41.773243|2018-06-01 02:56:41.773243
NCT00526942|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2007-09-10|2007-09-07|2007-09-10|Estimate|||||||2007-09-10|2007-09-11|Estimate|August 2007||2007-08-31|September 2007|2007-09-30|August 2008|Anticipated|2008-08-31|||||Interventional|||Behavioral and Physiological Effects of Visual Training|Computer-Based Cognitive Training in Normal Healthy Aging: Pilot Study of Behavioral and Physiological Effects of Visual Sweeps Training Exercise, 2-Arm Model|Unknown status|Recruiting|Phase 1/Phase 2|54|Anticipated|Posit Science Corporation||2|||f||||f||||||||||2018-06-01 02:56:41.828641|2018-06-01 02:56:41.828641
NCT00526929|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2009-05-21|2007-09-06|2007-09-10|Estimate|||||||2009-05-21|2009-05-22|Estimate|May 2000||2000-05-31|May 2009|2009-05-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Fixed Dose NESP Study in Subjects With CRI|A Pilot Study Evaluating Once Every Other Week Administration of Fixed Doses of Novel Erythropoiesis Stimulating Protein (NESP) to Subjects With Chronic Renal Insufficiency (CRI)|Completed||Phase 2|75|Anticipated|Amgen||1|||f||||||||||||||2018-06-01 02:56:41.927524|2018-06-01 02:56:41.927524
NCT00526916|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2018-04-18|2007-09-07|2007-09-10|Estimate|||||||2018-04-18|2018-04-19|Actual|September 4, 2007||2007-09-04|September 5, 2014|2014-09-05|September 5, 2014|Actual|2014-09-05|||||Interventional|||PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28|PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28|Completed||Phase 1|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:56:41.99487|2018-06-01 02:56:41.99487
NCT00526903|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2016-03-04|2007-09-07|2007-09-10|Estimate|||||||2016-03-04|2016-03-08|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Recurrent Abdominal Pain in Children|Recurrent Abdominal Pain in Children|Completed||Phase 2|168|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 02:56:42.062979|2018-06-01 02:56:42.062979
NCT00526890|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|2015-01-08||2017-10-23|2007-09-07|2007-09-10|Estimate|2015-01-08|2015-01-15|Estimate||||2017-10-23|2017-11-28|Actual|October 2006||2006-10-31|October 2017|2017-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II, Multi-Center Trial|Terminated||Phase 2|16|Actual|Roswell Park Cancer Institute||1||lack of efficacy|f||||t||||||||||2018-06-01 02:56:42.160447|2018-06-01 02:56:42.160447
NCT00526877|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2014-02-27|2007-09-06|2007-09-10|Estimate|||||||2014-02-27|2014-02-28|Estimate|July 2007||2007-07-31|February 2014|2014-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment|Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Schizoaffective Disorders, Who is Receiving Psychiatric Home-care Treatment, When Switching From Typical Depot or Oral Antipsychotics to Long-acting Risperidone Microspheres|Completed||Phase 4|31|Actual|Johnson & Johnson Taiwan Ltd||1|||f||||f||||||||||2018-06-01 02:56:42.546488|2018-06-01 02:56:42.546488
NCT00526864|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2015-09-21|2007-09-07|2007-09-10|Estimate|||||||2015-09-21|2015-09-23|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Measuring Herpes Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand|Measuring Herpes Zoster and Post-Herpetic Neuralgia Associated Burden of Illness and Health Care Utilization and Costs in Thailand|Completed|||180|Actual|Mahidol University|||3||f||||f||||||||||2018-06-01 02:56:42.650486|2018-06-01 02:56:42.650486
NCT00526851|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2014-02-04|2007-09-07|2007-09-10|Estimate|||||||2014-02-04|2014-02-05|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Observational|||Oral Cancer Screening Among Nursing Home Dentists in Ohio|Oral Cancer Screening: Practices, Knowledge and Opinions of Ohio Nursing Home Dentists|Completed|||37|Actual|Case Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 02:56:42.78705|2018-06-01 02:56:42.78705
NCT00526838|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2015-08-19|2007-09-06|2007-09-10|Estimate|||||||2015-08-19|2015-08-21|Estimate|September 2007||2007-09-30|August 2015|2015-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies|Terminated||Phase 1|84|Actual|Exelixis||2||Sponsor decision|f||||||||||||||2018-06-01 02:56:42.852239|2018-06-01 02:56:42.852239
NCT00526084|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-05|2007-09-05|2007-09-06|Estimate|||||||2007-09-05|2007-09-06|Estimate|March 2007||2007-03-31|December 2005|2005-12-31|December 2009|Anticipated|2009-12-31|||||Observational|||Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan|Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan|Unknown status|Recruiting||500|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 02:57:01.249125|2018-06-01 02:57:01.249125
NCT00526812|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-07|||2014-11-05|2007-09-07|2007-09-10|Estimate|||||||2014-11-05|2014-11-07|Estimate|November 2005||2005-11-30|November 2014|2014-11-30||||December 2008|Actual|2008-12-31||Interventional|||A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas|A Phase I Dose-finding and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent or Refractory Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Anaplastic Mixed Oligo-astrocytoma (AOA), Glioblastoma Multiforme (GBM) or Gliosarcoma (GS), With or Without Concurrent Treatment With Enzyme-inducing Anticonvulsant Therapy|Completed||Phase 1|54|Actual|Reata Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 02:56:42.924943|2018-06-01 02:56:42.924943
NCT00526799|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2015-12-15||2016-02-04|2007-09-05|2007-09-10|Estimate|2016-02-04|2016-03-03|Estimate||||2016-02-04|2016-03-03|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|||Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer|A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111|Terminated||Phase 1/Phase 2|30|Actual|Hoosier Cancer Research Network||2||Study closed to accrual due unfavorable interim analysis|f||||t||||||||No||2018-06-01 02:56:43.047744|2018-06-01 02:56:43.047744
NCT00526786|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2014-03-12|2007-09-05|2007-09-10|Estimate|||||||2014-03-12|2014-03-14|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|ICE||Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus|A Prospective, Multi-center, Longitudinal Cohort Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus (LCS Dysplasia)|Terminated||Phase 4|78|Actual|CSA Medical, Inc.||||Business Reasons|f||||t||||||||||2018-06-01 02:56:43.571421|2018-06-01 02:56:43.571421
NCT00526773|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2010-10-11|2007-09-05|2007-09-10|Estimate|||||||2010-10-11|2010-10-13|Estimate|January 2007||2007-01-31|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Enhancing Heart Failure Self-Care|Enhancing Heart Failure Self-Care|Completed||N/A|50|Anticipated|Christiana Care Health Services||2|||f||||f||||||||||2018-06-01 02:56:43.674395|2018-06-01 02:56:43.674395
NCT00526760|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2015-06-29|2007-09-05|2007-09-10|Estimate|||||||2015-06-29|2015-06-30|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Long-term Clinical Study Evaluating the Safety and Efficacy of Dexmedetomidine in ICU Subjects|A Phase 3, Open-Label Study Evaluating the Safety and Efficacy of Dexmedetomidine in ICU Subjects Requiring Greater Than 24 Hours of Continuous Sedation|Completed||Phase 3|80|Actual|Hospira, now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:56:43.742232|2018-06-01 02:56:43.742232
NCT00526747|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2013-04-09|2007-09-06|2007-09-10|Estimate|||||||2013-04-09|2013-04-11|Estimate|August 2007||2007-08-31|November 2008|2008-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Erythropoietin Resistance in Anemia of Chronic Kidney Disease|Novel Biomarkers of Erythropoietin Resistant Anemia Among Patients With Chronic Kidney Disease|Completed|||32|Actual|Duke University|||2||f||||t||||||||||2018-06-01 02:56:43.823693|2018-06-01 02:56:43.823693
NCT00526734|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2013-08-09|2007-09-05|2007-09-10|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2006||2006-02-28|September 2007|2007-09-30||||||||Interventional|||High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma|A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM)|Unknown status|Recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:56:43.887426|2018-06-01 02:56:43.887426
NCT00526721|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2012-03-19|2007-09-06|2007-09-10|Estimate|||||||2012-03-19|2012-03-20|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|REVORUTION||Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION|An Observational, Non-interventional, Multi-center Study to Evaluate Efficacy and Tolerability of High Dose Rosuvastatin in High Risk Patients After Titration|Completed|||1482|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:56:44.047773|2018-06-01 02:56:44.047773
NCT00526708|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2010-11-30|2007-09-06|2007-09-10|Estimate|||||||2010-11-30|2010-12-01|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|RUSH||Crestor RUSH (The Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension )|RUSH (Evaluating the Efficacy of RosUvaStatin for Korean Dyslipidemia Patients With Hypertension in Real World Practice)|Completed|||5000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:56:44.108003|2018-06-01 02:56:44.108003
NCT00526695|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2008-07-17|2007-09-06|2007-09-10|Estimate|||||||2008-07-17|2008-07-18|Estimate|January 2005||2005-01-31|July 2008|2008-07-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion|Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion, Leukocyte/Thrombocyte Activation, and Endothelial Function After Tourniquet-Induced Ischemia/Reperfusion Injury in the Forearm of Volunteers|Unknown status|Recruiting|Phase 4|10|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 02:56:44.181993|2018-06-01 02:56:44.181993
NCT00526682|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2007-09-06|2007-09-06|2007-09-10|Estimate|||||||2007-09-06|2007-09-10|Estimate|January 2007||2007-01-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||The Use of Irvingia Gabonensis (Bush Mango)and Cissus Quadrangularis to Reduce Weight and Blood Lipids|The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases|Completed||N/A|72|Actual|Gateway Health Alliance||1|||f||||t||||||||||2018-06-01 02:56:44.260531|2018-06-01 02:56:44.260531
NCT00526669|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2012-02-16||2015-12-24|2007-09-06|2007-09-10|Estimate|2012-08-30|2012-10-01|Estimate||||2015-12-24|2016-01-29|Estimate|March 2008||2008-03-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|April 2011|Actual|2011-04-30||Interventional|||Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib|An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer|Completed||Phase 2|68|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:56:44.467234|2018-06-01 02:56:44.467234
NCT00526656|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2012-06-14|2007-09-05|2007-09-10|Estimate|||||||2012-06-14|2012-06-15|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Sunitinib in Treating Patients With Locally Advanced Bladder Cancer|Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder|Completed||Phase 2|9|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 02:56:46.531799|2018-06-01 02:56:46.531799
NCT00526643|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2017-03-27|2007-09-06|2007-09-10|Estimate|||||||2017-03-27|2017-03-28|Actual|November 2007||2007-11-30|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CAPPA-2||CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients|Gemcitabine Versus Cisplatin and Gemcitabine in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer in Poor Physical Condition (Performance Status 2)|Terminated||Phase 3|57|Actual|National Cancer Institute, Naples||2||scarce enrolment and presentation of positive results of similar study in June 2012.|f||||f||||||||||2018-06-01 02:56:46.614963|2018-06-01 02:56:46.614963
NCT00526630|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2013-12-09||2015-04-13|2007-09-05|2007-09-10|Estimate|2015-04-13|2015-04-22|Estimate||||2015-04-13|2015-04-22|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease|Methylphenidate for the Treatment of Gain Impairment in Parkinson's Disease: a Randomized Double-Blind, Placebo-Controlled, Cross-over Study|Completed||Phase 4|23|Actual|University of Cincinnati||2|||f||||t||||||||||2018-06-01 02:56:46.722452|2018-06-01 02:56:46.722452
NCT00526617|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2017-11-17|2007-09-05|2007-09-10|Estimate|||||||2017-11-17|2017-11-21|Actual|August 2007||2007-08-31|January 2012|2012-01-31||||June 2010|Actual|2010-06-30||Interventional|||A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients|A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)|Completed||Phase 1|41|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 02:56:47.125504|2018-06-01 02:56:47.125504
NCT00526604|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2011-07-03|2007-09-06|2007-09-10|Estimate|||||||2011-07-03|2011-07-06|Estimate|January 2008||2008-01-31|December 2008|2008-12-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Work Related Rehabilitation in Patients With Low Back Pain|A Study on the Effect of Employment Follow-up on Return to Work in Sick Listed Patients With Low Back Pain|Terminated||Phase 3|260|Anticipated|Oslo University Hospital||1||The study was stopped, as the another multicentre-RCT on the same patients started.|f||||t||||||||||2018-06-01 02:56:47.218987|2018-06-01 02:56:47.218987
NCT00526591|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2012-06-14|2007-09-05|2007-09-10|Estimate|||||||2012-06-14|2012-06-15|Estimate|September 2007||2007-09-30|June 2012|2012-06-30||||July 2011|Actual|2011-07-31||Interventional|||Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer|Randomized Phase II Study of Two Different Doses of RAD-001 (Everolimus) as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|17|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:56:47.296924|2018-06-01 02:56:47.296924
NCT00526578|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2017-06-16|2007-09-05|2007-09-10|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2002|Actual|2002-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Pancreatic Cancer Genetic Epidemiology (PACGENE) Study|Pancreatic Cancer Genetic Epidemiology (PACGENE) Study|Active, not recruiting|||4770|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood sample will be collected.~   "|||2018-06-01 02:56:47.373158|2018-06-01 02:56:47.373158
NCT00526565|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2011-10-04|2007-09-06|2007-09-10|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|LIFE||Randomized Trial of Tapas Acupressure for Weight Loss Maintenance|Randomized Trial of Tapas Acupressure for Weight Loss Maintenance|Completed||Phase 2/Phase 3|472|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 02:56:47.43899|2018-06-01 02:56:47.43899
NCT00526552|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2010-03-29|2007-09-06|2007-09-10|Estimate|||||||2010-03-29|2010-03-30|Estimate|June 2007||2007-06-30|March 2010|2010-03-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Observational|RAPID||Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)|RAPID (Evaluating the Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes in Real World Practice)|Completed|||5000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:56:47.496491|2018-06-01 02:56:47.496491
NCT00526539|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2011-07-03|2007-09-06|2007-09-10|Estimate|||||||2011-07-03|2011-07-06|Estimate||||September 2007|2007-09-30||||||||Interventional|||Is There Increased Polyethylene Wear and Increased Periprosthetic Bone Loss in Femur in Reverse Hybrid Technique Compared With Conventional Cemented Technique in Total Hip Replacement?||Completed||N/A|||Oslo University Hospital|||||f||||||||||||||2018-06-01 02:56:47.549312|2018-06-01 02:56:47.549312
NCT00526513|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2010-09-10|2007-09-06|2007-09-10|Estimate|||||||2010-09-10|2010-09-13|Estimate|July 2007||2007-07-31|September 2010|2010-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|SCALE||Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus|Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus|Completed||Phase 4|188|Actual|Sanofi|||||f||||f||||||||||2018-06-01 02:56:47.596137|2018-06-01 02:56:47.596137
NCT00526500|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2008-11-10|2007-09-06|2007-09-10|Estimate|||||||2008-11-10|2008-11-11|Estimate|August 2006||2006-08-31|November 2008|2008-11-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Brain Injury.|Effect of Proprioceptive Stimulation With Passive Gait Training on the Cortical Activity in Patients With Impaired Consciousness Due to Severe Brain Injury.|Unknown status|Recruiting|Early Phase 1|60|Anticipated|University of Aarhus||4|||f||||f||||||||||2018-06-01 02:56:47.655468|2018-06-01 02:56:47.655468
NCT00526487|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2017-02-27|2007-09-06|2007-09-10|Estimate|||||||2017-02-27|2017-03-01|Actual|December 2007||2007-12-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|July 2011|Actual|2011-07-31||Interventional|||Clinical Study to Assess Safety and Effectiveness of the Zenith® Dissection Endovascular System in Patients With Aortic Dissection|Evaluation of the Safety and Effectiveness Performance of the Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissection Involving the Descending Thoracic Aorta|Completed||N/A|60|Actual|Cook Group Incorporated||1|||f||||f||||||||||2018-06-01 02:56:47.735726|2018-06-01 02:56:47.735726
NCT00526474|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2014-05-16||2017-03-31|2007-09-06|2007-09-10|Estimate|2014-05-16|2014-06-18|Estimate||||2017-03-31|2017-05-05|Actual|September 1, 2007|Actual|2007-09-01|March 2017|2017-03-31|December 1, 2011|Actual|2011-12-01|December 1, 2011|Actual|2011-12-01||Interventional||The Intent to Treat (ITT) Population, defined as all enrolled participants who were randomly assigned to a treatment group.|Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)|Completed||Phase 3|26449|Actual|Merck Sharp & Dohme Corp.|Prior to the completion of the study, based on a communication from the Data and Safety Monitoring Board, all participants who had experienced a stroke either before or during the study had study drug discontinued.|2|||f||||t||||||||||2018-06-01 02:56:48.089169|2018-06-01 02:56:48.089169
NCT00526461|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2014-05-06|2007-09-05|2007-09-10|Estimate|||||||2014-05-06|2014-05-07|Estimate|February 2004||2004-02-29|May 2014|2014-05-31|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|||Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer|A Phase I Study Light Dose for Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-Small Cell Carcinoma in Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study|Completed||Phase 1|17|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 02:56:52.479821|2018-06-01 02:56:52.479821
NCT00526448|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2009-01-28|2007-09-07|2007-09-10|Estimate|||||||2009-01-28|2009-01-29|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|February 2010|Anticipated|2010-02-28|||||Interventional|PERICO||Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients|Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4|Unknown status|Recruiting|Phase 4|384|Anticipated|Hospital Carlos III, Madrid||2|||f||||t||||||||||2018-06-01 02:56:52.546011|2018-06-01 02:56:52.546011
NCT00526435|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2011-03-23|2007-09-06|2007-09-10|Estimate|||||||2011-03-23|2011-03-24|Estimate|October 2007||2007-10-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|WWE||Evaluation of Walk With Ease in Arthritis|Evaluation of the Walk With Ease Program Among People With Arthritis|Completed||Phase 3|468|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:56:52.920556|2018-06-01 02:56:52.920556
NCT00526422|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2011-06-14|2007-09-06|2007-09-10|Estimate|||||||2011-06-14|2011-06-16|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|January 2007|Actual|2007-01-31|||||Observational|||DPBRN Assessment of Caries Diagnosis & Caries Treatment|Assessment of Caries Diagnosis & Caries Treatment|Completed|||532|Actual|Dental Practice-Based Research Network|||||f||||f||||||||||2018-06-01 02:56:52.984981|2018-06-01 02:56:52.984981
NCT00526409|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2014-10-27|2007-09-06|2007-09-10|Estimate|||||||2014-10-27|2014-10-28|Estimate|June 2005||2005-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|LAL-AR-N-2005||LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia|LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia|Completed||Phase 4|40|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 02:56:53.046881|2018-06-01 02:56:53.046881
NCT00526396|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2015-04-08|2007-09-06|2007-09-10|Estimate|||||||2015-04-08|2015-04-09|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|STAD-1||STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study|Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer.|Unknown status|Active, not recruiting|Phase 3|160|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||||2018-06-01 02:56:53.176936|2018-06-01 02:56:53.176936
NCT00526383|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2014-04-16|2007-09-07|2007-09-10|Estimate|||||||2014-04-16|2014-04-17|Estimate|November 2007||2007-11-30|September 2007|2007-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|METADAP||Do Antidepressants Induce Metabolic Syndromes METADAP Study|Do Antidepressants Induce Metabolic Syndromes|Completed||N/A|624|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 02:56:53.279492|2018-06-01 02:56:53.279492
NCT00526370|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2008-08-12|2007-09-06|2007-09-10|Estimate|||||||2008-08-12|2008-08-13|Estimate|August 2007||2007-08-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Observational|||Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests|Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests|Completed|||72|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Tampon self-test from cervix~   "|||2018-06-01 02:56:53.361446|2018-06-01 02:56:53.361446
NCT00526357|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2012-03-15|2007-09-06|2007-09-10|Estimate|||||||2012-03-15|2012-03-16|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|February 2009|Actual|2009-02-28||Interventional|||Effect of Dietary Supplements With Fish Oil on Mannitol-induced Airway Sensitivity & Inflammation in Persons With Asthma|The Effect of Dietary Supplementation With Encapsulated Fish Oil on Mannitol-induced Airway Sensitivity and Inflammation in Persons With Asthma|Completed||Phase 2|24|Actual|Firestone Institute for Respiratory Health||2|||f||||f||||||||||2018-06-01 02:56:53.429432|2018-06-01 02:56:53.429432
NCT00526344|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2011-02-10|2007-09-05|2007-09-10|Estimate|||||||2011-02-10|2011-02-14|Estimate|September 2007||2007-09-30|February 2011|2011-02-28|March 2011|Anticipated|2011-03-31|||||Observational|||Bronchoscopy With Bronchial Biopsies Sub-study of: Persistence of Airway Inflammation and Remodeling in Asthma Remission|Bronchoscopy and Bronchial Biopsies. Sub-study of: Characteristics of Asthma Remissions|Withdrawn|||36|Anticipated|Laval University|||4|No funding, study not done|f||||f||||||Samples With DNA|"~     Tissue (bronchial biopsies)~   "|||2018-06-01 02:56:53.524595|2018-06-01 02:56:53.524595
NCT00526331|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2011-12-08||2011-12-08|2007-09-05|2007-09-10|Estimate|2011-12-08|2012-01-16|Estimate||||2011-12-08|2012-01-16|Estimate|August 2007||2007-08-31|December 2011|2011-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy|Randomized Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy|Completed||Phase 4|49|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:56:53.615103|2018-06-01 02:56:53.615103
NCT00526318|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2015-07-15|2007-09-07|2007-09-10|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2007||2007-01-31|July 2015|2015-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma|Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR)|Unknown status|Recruiting|N/A|360|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:56:53.806504|2018-06-01 02:56:53.806504
NCT00526305|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2010-01-03|2007-09-06|2007-09-10|Estimate|||||||2010-01-03|2010-01-05|Estimate|January 2000||2000-01-31|January 2010|2010-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive|LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive|Completed||Phase 4|100|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 02:56:54.17894|2018-06-01 02:56:54.17894
NCT00526292|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2016-01-14||2016-01-14|2007-09-05|2007-09-10|Estimate|2016-01-14|2016-02-12|Estimate||||2016-01-14|2016-02-12|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant|Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant|Completed||Phase 2|12|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:56:54.396375|2018-06-01 02:56:54.396375
NCT00526279|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2010-11-30|2007-09-06|2007-09-10|Estimate|||||||2010-11-30|2010-12-01|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|COMBAT||COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus|A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension|Completed|||9000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:56:54.565243|2018-06-01 02:56:54.565243
NCT00526266|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2018-04-23|2007-09-06|2007-09-10|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2007||2007-09-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Evaluating Physiological Markers of Emotional Trauma: A Randomized Controlled Comparison of Mind-Body Therapies|Evaluating Physiological Markers of Emotional Trauma: A Randomized Controlled Comparison of Mind-Body Therapies|Completed||N/A|37|Actual|Soul Medicine Institute||3|||f||||t||||||||||2018-06-01 02:56:54.615957|2018-06-01 02:56:54.615957
NCT00526253|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2017-07-20|2007-09-06|2007-09-10|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2007||2007-09-30|July 2017|2017-07-31||||February 2019|Anticipated|2019-02-28||Interventional|MARVEL||To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction|A Multicenter Study to Assess the Safety and Cardiovascular Effects of Myocell™ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)|Active, not recruiting||Phase 2/Phase 3|170|Anticipated|Bioheart, Inc.||3|||f||||t||||||||||2018-06-01 02:56:54.703494|2018-06-01 02:56:54.703494
NCT00526227|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2009-01-13||2009-04-21|2007-09-06|2007-09-10|Estimate|2009-04-21|2009-06-10|Estimate||||2009-04-21|2009-06-10|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|December 2007|Actual|2007-12-31||Interventional|||SecuraTM ICD Clinical Evaluation Study|Clinical Study to Evaluate System Safety and Clinical Performance of the SecuraTM ICD|Completed||N/A|81|Actual|Medtronic Bakken Research Center||1|||f||||f||||||||||2018-06-01 02:56:54.832668|2018-06-01 02:56:54.832668
NCT00526214|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2016-04-14|2007-09-06|2007-09-10|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|ACE-ICH||Administration of Celecoxib for Treatment of Intracerebral Hemorrhage : A Pilot Study|Multi-center, Prospective Randomized, Comparative Open With Blinded Endpoints (PROBE) Trial to Assess the Safety and Effectiveness of Administration of Celecoxib in Patients With Intracerebral Hemorrhage|Completed||N/A|44|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 02:56:55.193619|2018-06-01 02:56:55.193619
NCT00526201|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2015-12-22|2007-09-06|2007-09-10|Estimate|||||||2015-12-22|2015-12-24|Estimate|May 2009||2009-05-31|December 2015|2015-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|HARE||Help Arthritis With Exercise in West Virginia|Arthritis Benefits of a Physical Activity Program in West Virginia: Evaluation of EnhanceFitness|Completed||Phase 3|323|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 02:56:55.288403|2018-06-01 02:56:55.288403
NCT00526188|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2009-10-05||2015-04-13|2007-09-06|2007-09-10|Estimate|2009-11-29|2009-12-30|Estimate||||2015-04-13|2015-05-01|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of Primovist in Chinese Patients|A Multicenter, Open-label Phase III Study of the Efficacy and Safety of Primovist as a Contrast Agent for Enhanced MR Imaging of Focal Liver Lesions in Chinese Patients|Completed||Phase 3|234|Actual|Bayer||1|||f||||t||||||||||2018-06-01 02:56:55.390765|2018-06-01 02:56:55.390765
NCT00526175|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|||2016-01-16|2007-09-06|2007-09-10|Estimate|||||||2016-01-16|2016-01-20|Estimate|June 2001||2001-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||LAL-BR/2001: Study Treatment to Low Risk ALL|LAL-BR/2001: Study Treatment to Low Risk ALL|Completed||Phase 4|150|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 02:56:55.661783|2018-06-01 02:56:55.661783
NCT00526162|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-06|2009-02-06||2009-04-21|2007-09-06|2007-09-10|Estimate|2009-04-21|2009-06-10|Estimate||||2009-04-21|2009-06-10|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|January 2008|Actual|2008-01-31||Interventional|||ConsultaTM CRT-D Clinical Evaluation Study|Clinical Study to Evaluate System Safety and Clinical Performance of the ConsultaTM CRT-D Device|Completed||N/A|83|Actual|Medtronic Bakken Research Center||1|||f||||f||||||||||2018-06-01 02:56:55.752495|2018-06-01 02:56:55.752495
NCT00526149|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2013-10-04|2007-09-05|2007-09-10|Estimate|||||||2013-10-04|2013-10-07|Estimate|July 2007||2007-07-31|October 2013|2013-10-31||||September 2008|Actual|2008-09-30||Interventional|||BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors|Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)|Completed||Phase 2|76|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 02:56:55.918237|2018-06-01 02:56:55.918237
NCT00526136|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2008-12-17|2007-09-06|2007-09-10|Estimate|||||||2008-12-17|2008-12-18|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|July 2008|Actual|2008-07-31|||||Interventional|||Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study|Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study|Completed||Phase 2|735|Actual|Cardiome Pharma||4|||f||||f||||||||||2018-06-01 02:56:56.001794|2018-06-01 02:56:56.001794
NCT00526123|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2012-08-30||2013-01-03|2007-09-05|2007-09-06|Estimate|2013-01-03|2013-01-07|Estimate||||2013-01-03|2013-01-07|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Dialysis Catheter Comparative Clinical Trial|A Randomized, Open-label Comparison of the Performance and Longevity of a Split-tip Versus a Symmetric Tip Hemodialysis|Completed||N/A|599|Actual|Tyco Healthcare Group||2|||f||||f||||||||||2018-06-01 02:56:57.237811|2018-06-01 02:56:57.237811
NCT00526110|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2016-06-28||2016-09-14|2007-09-04|2007-09-06|Estimate|2016-09-14|2016-10-31|Estimate||||2016-09-14|2016-10-31|Estimate|August 2004||2004-08-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients|A Phase I/II Study of Docetaxel, 5-Fluorouracil and Oxaliplatin (D-FOX) in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction|Completed||Phase 1/Phase 2|98|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:56:58.318008|2018-06-01 02:56:58.318008
NCT00526097|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2010-05-27||2013-12-13|2007-09-05|2007-09-06|Estimate|2010-07-12|2010-08-06|Estimate||||2013-12-13|2014-01-15|Estimate|September 2007||2007-09-30|December 2013|2013-12-31||||June 2009|Actual|2009-06-30||Interventional|||Dulcolax vs Placebo in Functional Constipation|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks Treatment With Bisacodyl (Dulcolax) Tablets 10mg Administered Orally, Once Daily, in Patients With Functional Constipation.|Completed||Phase 3|368|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:56:58.90593|2018-06-01 02:56:58.90593
NCT00526071|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05||2013-07-18|2013-12-19|2007-09-05|2007-09-06|Estimate||||2013-07-18|2013-07-22|Estimate|2013-12-19|2014-01-27|Estimate|September 2007||2007-09-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study|Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease|Completed||Phase 2|23|Actual|Amicus Therapeutics||1|||f||||f||||||||||2018-06-01 02:57:01.308259|2018-06-01 02:57:01.308259
NCT00526058|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2010-05-25||2013-07-15|2007-09-05|2007-09-06|Estimate|2010-07-01|2010-07-30|Estimate||||2013-07-15|2013-07-19|Estimate|August 2007||2007-08-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|FUTURA||(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol|Randomized Multicenter Crossover Study to Compare the Plasmat® Futura Heparin Induced Extracorporeal Lower Density Lipo-Protein (LDL) Precipitation (H.E.L.P.) Apheresis System to the Approved Secura System in the Reduction of LDL-c in Patients With Hypercholesterolemia|Completed||N/A|18|Actual|B. Braun Medical Inc.||2|||f||||f||||||||||2018-06-01 02:57:01.390027|2018-06-01 02:57:01.390027
NCT00526045|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2013-05-10|2007-09-05|2007-09-06|Estimate|||||||2013-05-10|2013-05-14|Estimate|July 2007||2007-07-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients|A Phase I Dose Escalation, Multi-center, Open-label Study of AUY922 Administered IV on a Once Weekly Schedule in Adult Patients With Advanced Solid Malignancies Including Phase II Expansion Arms in Patients With Either HER2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer.|Completed||Phase 1/Phase 2|117|Actual|Novartis||3|||f||||||||||||||2018-06-01 02:57:01.784748|2018-06-01 02:57:01.784748
NCT00526032|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2012-01-26|2007-09-05|2007-09-06|Estimate|||||||2012-01-26|2012-01-31|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Melanoma Detection by Oblique-Incidence Optical Spectroscopy|Melanoma Detection by Oblique-Incidence Optical Spectroscopy|Completed|||490|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:57:01.870803|2018-06-01 02:57:01.870803
NCT00526019|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2012-02-20|2007-09-05|2007-09-06|Estimate|||||||2012-02-20|2012-02-22|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Observational|||Persistence of Airway Inflammation and Remodeling in Subjects With Symptomatic or Complete Asthma Remission|Characteristics of Symptomatic Asthma Remissions|Completed|||85|Actual|Laval University|||4||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 02:57:01.949112|2018-06-01 02:57:01.949112
NCT00526006|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2007-09-05|2007-09-05|2007-09-06|Estimate|||||||2007-09-05|2007-09-06|Estimate|September 2007||2007-09-30|August 2007|2007-08-31|March 2008|Anticipated|2008-03-31|||||Interventional|||PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena||Unknown status|Recruiting|Phase 4|||Zealand University Hospital|||||f||||t||||||||||2018-06-01 02:57:02.001848|2018-06-01 02:57:02.001848
NCT00525993|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2008-10-20|2007-09-04|2007-09-06|Estimate|||||||2008-10-20|2008-10-21|Estimate|December 2008||2008-12-31|October 2008|2008-10-31|September 2009|Anticipated|2009-09-30|August 2009|Anticipated|2009-08-31||Interventional|||Efficacy and Safety of Etoricoxib in Acute Ankle Sprain: A Double-Blind Comparative Study Among 2 Treatments Protocols|Efficacy and Safety of the Non-Steroidal Anti-Inflammatory Drug Etoricoxib in the Treatment of Acute Ankle Sprain in Sports: A Randomized Double-Blind Comparative Study Among 2 Treatments in the Acute Phase|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Núcleo de Estudos em Esportes e Ortopedia, Brazil||2|||f||||t||||||||||2018-06-01 02:57:02.067223|2018-06-01 02:57:02.067223
NCT00525980|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-04-08|2007-09-05|2007-09-06|Estimate|||||||2013-04-08|2013-04-10|Estimate|February 2007||2007-02-28|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Cancer Genetics CD-ROM for Hispanics|Interactive CD-ROM on Cancer Genetics for Hispanics|Completed||N/A|37|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-06-01 02:57:02.1759|2018-06-01 02:57:02.1759
NCT00525967|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2007-09-05|2007-09-05|2007-09-06|Estimate|||||||2007-09-05|2007-09-06|Estimate|February 2006||2006-02-28|September 2007|2007-09-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain|Switching From Morphine to Oral Methadone Plus Acetaminophen in the Treatment of Cancer Pain: A Randomized, Double-Blind Study|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Faculdade de Medicina do ABC||2|||f||||f||||||||||2018-06-01 02:57:02.262483|2018-06-01 02:57:02.262483
NCT00525954|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2008-01-03|2007-09-05|2007-09-06|Estimate|||||||2008-01-03|2008-01-07|Estimate|September 2007||2007-09-30|January 2008|2008-01-31|December 2007||2007-12-31|||||Interventional|PLASMA 2||PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease|Phospholipase Levels And Serological Markers of Atherosclerosis 2: An Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease|Completed||Phase 2|120|Anticipated|Anthera Pharmaceuticals|||||f||||||||||||||2018-06-01 02:57:02.367619|2018-06-01 02:57:02.367619
NCT00525941|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05||2011-06-27|2015-04-23|2007-09-05|2007-09-06|Estimate||||2011-06-27|2011-06-29|Estimate|2015-04-23|2015-05-12|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||An Exploratory Study of NBI-34060 Capsules and Next Day Functioning|An Exploratory Phase IIIb, Single-Blind, Outpatient Study to Assess Next-Day Functioning in Adult Primary Insomnia Patients Following the Administration of NBI-34060 Capsules During the Night|Withdrawn||Phase 3|0|Actual|Neurocrine Biosciences||||Study discontinued due to Approvable decision|f||||f||||||||||2018-06-01 02:57:02.441413|2018-06-01 02:57:02.441413
NCT00525928|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2015-07-20|2007-09-04|2007-09-06|Estimate|||||||2015-07-20|2015-07-21|Estimate|October 2007||2007-10-31|July 2015|2015-07-31|October 2008|Anticipated|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Mood and Anti-craving Effects of Varenicline in Psychiatric Inpatients|Assessment of Response to Open-label Treatment With Varenicline in Psychiatric Inpatients|Withdrawn||N/A|0|Actual|Butler Hospital||||insufficient recuirment|f||||||||||||||2018-06-01 02:57:02.512281|2018-06-01 02:57:02.512281
NCT00525915|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2015-01-27||2015-01-27|2007-09-04|2007-09-06|Estimate|2015-01-27|2015-02-09|Estimate||||2015-01-27|2015-02-09|Estimate|April 2005||2005-04-30|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Of the 126 randomized, 2 participants in Arm A declined therapy after randomization; and 13 (6 in Arm A and 7 in Arm B) experienced treatment failure before surgery leaving 55 in Arm A participants and 54 in Arm B who underwent surgery.|Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma|An Oxaliplatin-Based Phase II Randomized Study of Induction Chemotherapy Followed by Preoperative Chemoradiotherapy or Preoperative Chemoradiotherapy in Patients With Resectable Esophageal or Gastroesophageal Carcinoma|Completed||Phase 2|126|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:57:02.603337|2018-06-01 02:57:02.603337
NCT00525902|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2012-02-03||2012-04-06|2007-09-04|2007-09-06|Estimate|2012-03-13|2012-04-09|Estimate||||2012-04-06|2012-04-11|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis|An Open-label, Multicenter, Phase II Trial of Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis|Completed||Phase 2|31|Actual|Oregon Health and Science University|2 had to discontinue for methodologic reasons (pregnancy, loss to follow up wk 42), leading to their classification as failures. As a three-center study, differences between the study population are possible.|1|||f||||||||||||||2018-06-01 02:57:03.020227|2018-06-01 02:57:03.020227
NCT00525889|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-02-06|2007-09-05|2007-09-06|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 2007||2007-08-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2011|Actual|2011-09-30||Interventional|||Proleukin and Rapamune in Type 1 Diabetes|A Phase I Trial of Proleukin and Rapamune in Recent-onset Type 1 Diabetes Mellitus (ITN018AI)|Completed||Phase 1|9|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 02:57:03.175678|2018-06-01 02:57:03.175678
NCT00525876|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2011-11-02||2011-11-02|2007-09-04|2007-09-06|Estimate|2011-11-02|2011-12-07|Estimate||||2011-11-02|2011-12-07|Estimate|January 2005||2005-01-31|November 2011|2011-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Non-Myeloablative Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen for Advanced/Recurrent Mantle Cell Lymphoma|Completed||N/A|49|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 02:57:03.278039|2018-06-01 02:57:03.278039
NCT00525863|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2008-05-26|2007-09-05|2007-09-06|Estimate|||||||2008-05-26|2008-05-28|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Oxygen Therapy in Schizophrenia|Oxygen Therapy in Schizophrenia|Unknown status|Recruiting|Phase 3|20|Anticipated|Beersheva Mental Health Center|||||f||||t||||||||||2018-06-01 02:57:03.543509|2018-06-01 02:57:03.543509
NCT00525850|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2011-08-01|2007-09-05|2007-09-06|Estimate|||||||2011-08-01|2011-08-02|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|HFD||High Fat Diet II on Weight Loss|Effect of High Saturated Fat No Starch Diet vs. Low Saturated Fat, Low Trans Fat, High Fiber Diet on Weight Loss and Markers of Atherosclerotic Cardiovascular Disease|Completed||N/A|20|Anticipated|Christiana Care Health Services||2|||f||||f||||||||||2018-06-01 02:57:03.604494|2018-06-01 02:57:03.604494
NCT00525837|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2010-10-04||2017-09-14|2007-09-04|2007-09-06|Estimate|2011-04-21|2011-05-23|Estimate||||2017-09-14|2017-09-18|Actual|September 2007||2007-09-30|September 2017|2017-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of Mood Effects of Varenicline (Chantix) in Depressed Outpatient Smokers|Systematic Assessment of Response to Open-label Treatment With Varenicline in Depressed Outpatient Smokers|Completed||N/A|18|Actual|Butler Hospital||1|||f||||f||||||||||2018-06-01 02:57:03.69303|2018-06-01 02:57:03.69303
NCT00525824|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2009-09-03||2011-05-11|2007-09-05|2007-09-06|Estimate|2009-09-03|2009-10-07|Estimate||||2011-05-11|2011-05-13|Estimate|August 2007||2007-08-31|May 2011|2011-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|GRAVITY||12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe|A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD|Completed||Phase 3|1743|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 02:57:03.963107|2018-06-01 02:57:03.963107
NCT00525811|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2008-06-23|2007-09-05|2007-09-06|Estimate|||||||2008-06-23|2008-06-24|Estimate|June 2007||2007-06-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Development of a Web-Based Interactive Patient Decision Aid for the Treatment of Acute Low Back Pain and Depression||Completed||N/A|741|Actual|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 02:57:04.780291|2018-06-01 02:57:04.780291
NCT00525798|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2012-09-14||2012-10-22|2007-09-05|2007-09-06|Estimate|2012-09-14|2012-10-18|Estimate||||2012-10-22|2012-10-29|Estimate|March 2007||2007-03-31|October 2012|2012-10-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D|Completed||Phase 3|4665|Actual|Nordic Bioscience A/S||2|||f||||t||||||||||2018-06-01 02:57:04.914486|2018-06-01 02:57:04.914486
NCT00525785|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2016-01-20|2007-09-04|2007-09-06|Estimate|||||||2016-01-20|2016-01-22|Estimate|January 2004||2004-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)|A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach and Gastroesophageal Junction|Completed||Phase 2|58|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:57:06.22398|2018-06-01 02:57:06.22398
NCT00525772|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2009-10-20|2007-09-05|2007-09-06|Estimate|||||||2009-10-20|2009-10-21|Estimate|November 2001||2001-11-30|October 2009|2009-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Effect of Ciclesonide on Exercise Induced Bronchoconstriction|Effect of Ciclesonide on Exercise Induced Bronchoconstriction|Completed||Phase 3|26|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 02:57:06.397964|2018-06-01 02:57:06.397964
NCT00525759|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2010-11-03|2007-09-05|2007-09-06|Estimate|||||||2010-11-03|2010-11-04|Estimate|July 2007||2007-07-31|November 2010|2010-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|ANZAC||Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer|A Randomised Phase II Feasibility Study Investigating the Biological Effects of the Addition of Zoledronic Acid to Neoadjuvant Combination Chemotherapy on Invasive Breast Cancer|Completed||Phase 2|40|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 02:57:06.469984|2018-06-01 02:57:06.469984
NCT00525746|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-12-01|2007-09-05|2007-09-06|Estimate|||||||2017-12-01|2017-12-05|Actual|March 2006|Actual|2006-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)|Molecular Epidemiology of Treatment-Related Acute Myeloid Leukemia/Myelodysplastic Syndrome|Active, not recruiting|||600|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||Samples With DNA|"~     Saliva or blood sample collected for special tests that will look for biologic factors~     associated with treatment-related AML/MDS.~   "|||2018-06-01 02:57:06.54835|2018-06-01 02:57:06.54835
NCT00525733|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2015-01-21||2015-02-24|2007-09-05|2007-09-06|Estimate|2015-02-24|2015-03-09|Estimate||||2015-02-24|2015-03-09|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||This is an as treated analysis. Baseline characteristics describe subjects available for primary endpoint analysis at week 48. There were 34 subjects available for primary endpoint analysis however 2 subjects were not able to be analyzed due to primer mismatch therefore results are available for 32 subjects in the primary endpoint analysis.|Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)|A Phase II, Randomized Trial of Open-Label Truvada With Darunavir/Ritonavir Versus Multiclass Therapy With Truvada, Darunavir/Ritonavir, Maraviroc and Raltegravir in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects|Completed||N/A|40|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 02:57:06.618249|2018-06-01 02:57:06.618249
NCT00525720|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-11-03|2007-09-04|2007-09-06|Estimate|||||||2017-11-03|2017-11-07|Actual|August 2006|Actual|2006-08-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Brachytherapy for Prostatic Carcinoma Patients|Transperineal Interstitial Permanent Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma|Active, not recruiting||Phase 2|300|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 02:57:06.867816|2018-06-01 02:57:06.867816
NCT00525707|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31||2010-02-11|2010-02-11|2007-09-05|2007-09-06|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|April 2003||2003-04-30|February 2010|2010-02-28|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|VERITAS 1||Tezosentan in Acute Heart Failure|Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.|Completed||Phase 3|735|Actual|Actelion||2|||f||||t||||||||||2018-06-01 02:57:06.953125|2018-06-01 02:57:06.953125
NCT00525694|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2016-07-07|2007-09-05|2007-09-06|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2007||2007-02-28|July 2016|2016-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|GGT||Zero Calorie Drink Products|Determination of Clinically Significant Carbohydrates Added to Zero Calorie Drink Products|Completed||N/A|12|Actual|Christiana Care Health Services||3|||f||||f||||||||||2018-06-01 02:57:07.060045|2018-06-01 02:57:07.060045
NCT00525681|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|||2014-12-02|2007-09-05|2007-09-06|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|RIMONA-PILOT||Interaction Between Rimonabant and Cyclosporine and Tacrolimus|The Effect of Rimonabant Treatment on Cardiovascular Risk Factors in Renal Transplant Recipients -- Pilot Safety Study|Completed||Phase 4|18|Actual|University of Oslo School of Pharmacy||2|||f||||f||||||||||2018-06-01 02:57:07.126099|2018-06-01 02:57:07.126099
NCT00525668|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-12-21|2007-09-05|2007-09-06|Estimate|||||||2017-12-21|2017-12-22|Actual|September 2007||2007-09-30|December 2017|2017-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SuniMS||Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)|Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)|Completed||Phase 1/Phase 2|120|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 02:57:07.20718|2018-06-01 02:57:07.20718
NCT00525655|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2018-05-25|2007-09-05|2007-09-06|Estimate|||||||2018-05-25|2018-05-30|Actual|August 2007|Actual|2007-08-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)|Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)|Active, not recruiting||N/A|55|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-06-01 02:57:07.279295|2018-06-01 02:57:07.279295
NCT00525642|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-04|2007-09-04|2007-09-06|Estimate|||||||2007-09-04|2007-09-06|Estimate|June 2003||2003-06-30|August 2007|2007-08-31|June 2015|Anticipated|2015-06-30|||||Interventional|||Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer|A Chinese Multi-Center,Randomized Study of Combination or Sequential Use of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy for Node Positive Breast Cancer|Unknown status|Active, not recruiting|Phase 2/Phase 3|603|Actual|Fudan University||2|||f||||t||||||||||2018-06-01 02:57:07.354953|2018-06-01 02:57:07.354953
NCT00525629|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-05|2017-01-05||2017-06-21|2007-09-05|2007-09-06|Estimate|2017-01-05|2017-02-23|Actual||||2017-06-21|2017-12-15|Actual|February 2007||2007-02-28|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome|The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome|Completed||N/A|40|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 02:57:07.650051|2018-06-01 02:57:07.650051
NCT00525616|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2014-09-05|2007-09-05|2007-09-06|Estimate|||||||2014-09-05|2014-09-08|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Rituximab2||Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid|Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.|Completed||Phase 3|18|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-06-01 02:57:07.798842|2018-06-01 02:57:07.798842
NCT00525603|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2012-10-04||2013-01-25|2007-09-05|2007-09-06|Estimate|2013-01-25|2013-03-04|Estimate||||2013-01-25|2013-03-04|Estimate|June 2005||2005-06-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||CFAR Study in Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) in High-Risk Previously Untreated Patients With CLL|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:57:07.876071|2018-06-01 02:57:07.876071
NCT00525590|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2015-11-16|2007-09-04|2007-09-06|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2007||2007-09-30|November 2015|2015-11-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer|A Phase 2, Multicenter, Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer|Completed||Phase 2|69|Actual|Eisai Inc.||1|||f||||t||||||||||2018-06-01 02:57:08.07167|2018-06-01 02:57:08.07167
NCT00525577|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2008-02-04|2007-09-04|2007-09-06|Estimate|||||||2008-02-04|2008-02-06|Estimate|August 2007||2007-08-31|February 2008|2008-02-29|September 2008|Anticipated|2008-09-30|June 2008|Anticipated|2008-06-30||Interventional|ANDES||ANDES-AGI-1067 as a Novel Antidiabetic Agent Evaluation Study|AGI-1067 as a Novel Antidiabetic Agent Evaluation Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|1012|Anticipated|AtheroGenics||3|||f||||t||||||||||2018-06-01 02:57:08.228563|2018-06-01 02:57:08.228563
NCT00525564|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-05|2007-09-05|2007-09-06|Estimate|||||||2007-09-05|2007-09-06|Estimate|May 2006||2006-05-31|September 2007|2007-09-30|October 2006|Actual|2006-10-31|||||Interventional|||Effects of Salmeterol on Walking Capacity in Patients With COPD|Effects of Salmeterol on Walking Capacity in Patients With COPD|Completed||Phase 4|28|Actual|Laval University||2|||f||||f||||||||||2018-06-01 02:57:08.399263|2018-06-01 02:57:08.399263
NCT00525525|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2014-10-28||2014-11-05|2007-09-04|2007-09-05|Estimate|2014-11-05|2014-11-14|Estimate||||2014-11-05|2014-11-14|Estimate|September 2007||2007-09-30|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|AVF4120s||Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma|A Phase II Study of Bevacizumab Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation|Completed||Phase 2|74|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 02:57:08.64315|2018-06-01 02:57:08.64315
NCT00525512|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|2011-06-27||2013-11-27|2007-09-03|2007-09-05|Estimate|2011-08-18|2011-09-23|Estimate||||2013-11-27|2013-12-24|Estimate|August 2007||2007-08-31|September 2013|2013-09-30||||June 2010|Actual|2010-06-30||Interventional|||Tiotropium In Exercise|A Randomized, Double-blind, Placebo-controlled Two-year Trial to Examine the Changes in Exercise Endurance and COPD Treated With Tiotropium Once Daily (EXACTT)|Completed||Phase 4|519|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 02:57:09.1053|2018-06-01 02:57:09.1053
NCT00525499|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2011-01-31||2011-11-16|2007-08-31|2007-09-05|Estimate|2011-03-15|2011-04-18|Estimate||||2011-11-16|2011-11-23|Estimate|August 2007||2007-08-31|November 2011|2011-11-30|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Dose-Ranging Clinical Study to Evaluate the Safety and Efficacy of ASC-J9 Cream Applied Twice Daily for 12 Weeks for the Treatment of Facial Acne Vulgaris|Completed||Phase 2|186|Actual|AndroScience Corp||4|||f||||f||||||||||2018-06-01 02:57:11.351596|2018-06-01 02:57:11.351596
NCT00525486|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-02|||2010-12-22|2007-09-04|2007-09-05|Estimate|||||||2010-12-22|2010-12-23|Estimate|December 2007||2007-12-31|December 2010|2010-12-31||||||||Interventional|||Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery|Extended Release Nifedipine Treatment as Maintenance Tocolysis to Prevent Preterm Delivery:A Prospective Interventional Study|Terminated||N/A|||The Baruch Padeh Medical Center, Poriya||2|||f||||f||||||||||2018-06-01 02:57:11.648733|2018-06-01 02:57:11.648733
NCT00525473|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|||2012-05-16|2007-09-03|2007-09-05|Estimate|||||||2012-05-16|2012-05-17|Estimate|February 2007||2007-02-28|January 2012|2012-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Observational|||Correlation of Genetic Polymorphism of Azathioprine Metabolizing Enzymes and Correlation to Clinical Adverse Effects|Correlation of Genetic Polymorphism of Two Azathioprine Metabolizing Enzymes and Their Correlation to Clinical Adverse Effects|Completed|||166|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 02:57:11.715852|2018-06-01 02:57:11.715852
NCT00525460|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2016-11-17|2007-09-04|2007-09-05|Estimate|||||||2016-11-17|2016-11-18|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function|A Pilot Study of Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function|Completed|||16|Actual|Dana-Farber Cancer Institute|||||f||||f||||||||||2018-06-01 02:57:11.769628|2018-06-01 02:57:11.769628
NCT00525447|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2014-10-07|2007-09-04|2007-09-05|Estimate|||||||2014-10-07|2014-10-09|Estimate|August 2007||2007-08-31|October 2014|2014-10-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma|A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)|Completed||Phase 1|36|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 02:57:11.856517|2018-06-01 02:57:11.856517
NCT00525434|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2011-06-08|2007-09-04|2007-09-05|Estimate|||||||2011-06-08|2011-06-09|Estimate|November 2008||2008-11-30|May 2008|2008-05-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Evaluation of Safety and Efficacy of Using Seraffix LTB - System for Excisional Biopsy Wounds Closure|Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System for Excisional Biopsy Wounds Closure|Terminated||N/A|10|Anticipated|Seraffix||1||sponsor has decide to pospone this study|f||||f||||||||||2018-06-01 02:57:12.044945|2018-06-01 02:57:12.044945
NCT00525421|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2013-05-22||2013-08-05|2007-09-04|2007-09-05|Estimate|2013-08-05|2013-08-07|Estimate||||2013-08-05|2013-08-07|Estimate|October 2007||2007-10-31|August 2013|2013-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus|A Randomized, Placebo-Controlled, Double-Blind Trial of a Two Week Course of Curcuminoids in Oral Lichen Planus|Completed||Phase 2|20|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:57:12.143947|2018-06-01 02:57:12.143947
NCT00525408|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-01|||2012-03-09|2007-09-04|2007-09-05|Estimate|||||||2012-03-09|2012-03-12|Estimate|November 2007||2007-11-30|March 2012|2012-03-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|HRPC||A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer|Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.|Terminated||Phase 2|134|Actual|Cadila Pharnmaceuticals||2||Interim Analysis report indicates trial futility|f||||t||||||||||2018-06-01 02:57:12.481495|2018-06-01 02:57:12.481495
NCT00525395|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2010-06-01|2007-09-04|2007-09-05|Estimate|||||||2010-06-01|2010-06-02|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|VETF||Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol|Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients|Unknown status|Recruiting|Phase 3|200|Anticipated|Istituti Fisioterapici Ospitalieri||2|||f||||t||||||||||2018-06-01 02:57:12.57313|2018-06-01 02:57:12.57313
NCT00525382|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-12-11|2007-09-04|2007-09-05|Estimate|||||||2013-12-11|2013-12-12|Estimate|August 2003||2003-08-31|September 2009|2009-09-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic Urticaria|A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU)|Completed||Phase 3|134|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:57:12.643255|2018-06-01 02:57:12.643255
NCT00525369|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate||||September 2007|2007-09-30||||||||Observational|||IL 6 Measurement Using a New Densitometric Bedside (POC) Test||Completed|||||Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 02:57:12.764431|2018-06-01 02:57:12.764431
NCT00525356|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2015-10-28|2007-09-04|2007-09-05|Estimate|||||||2015-10-28|2015-10-29|Estimate|February 2002||2002-02-28|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|INSTEAD||INSTEAD Trial: INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection|INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection|Completed||Phase 3|136|Actual|Medtronic Cardiovascular||1|||f||||t||||||||||2018-06-01 02:57:12.826709|2018-06-01 02:57:12.826709
NCT00525343|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2010-03-05|2007-09-04|2007-09-05|Estimate|||||||2010-03-05|2010-03-08|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Observational|15yASSURANCE||Avonex 15 Year Long Term Follow-up Study|Avonex® Fifteen Year Long Term Follow Up of Patients With Relapsing Multiple Sclerosis: ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs|Completed|||122|Actual|Biogen|||||f||||f||||||||||2018-06-01 02:57:12.893594|2018-06-01 02:57:12.893594
NCT00525330|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03||2011-06-07|2013-08-14|2007-09-04|2007-09-05|Estimate||||2011-06-07|2011-06-21|Estimate|2013-08-14|2013-08-22|Estimate|September 2007||2007-09-30|August 2013|2013-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of KRP-104 in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone|Completed||Phase 2|213|Actual|ActivX Biosciences, Inc.||3|||f||||||||||||||2018-06-01 02:57:12.959607|2018-06-01 02:57:12.959607
NCT00525317|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-12-16|2007-09-04|2007-09-05|Estimate|||||||2013-12-16|2013-12-17|Estimate|January 2002||2002-01-31|December 2013|2013-12-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Does Oral Magnesium Substitution Relieve Pregnancy Induced Leg Cramps ?|Does Oral Magnesium Substitution Relieve Magnesium Induced Leg Cramps ?|Completed||Phase 4|45|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 02:57:13.033503|2018-06-01 02:57:13.033503
NCT00525304|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-04-14|2007-09-04|2007-09-05|Estimate|||||||2017-04-14|2017-04-18|Actual|September 2007||2007-09-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition|Optimizing Chronic Illness Self-Management for Individuals With Schizophrenia|Completed||N/A|100|Actual|University of Maryland||2|||f||||f||||||||||2018-06-01 02:57:13.098538|2018-06-01 02:57:13.098538
NCT00525291|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2009-02-17|2007-09-04|2007-09-05|Estimate|||||||2009-02-17|2009-02-18|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|3T-AI||Triple Target Treatment (3T) Which Combines Stimulation With Amplitude Modulated Middle Frequency (AM-MF), Electromyography (EMG)-Triggered Stimulation and EMG-Biofeedback Compared With EMG-Biofeedback in Anal Incontinence|Prospective, Randomized Multicenter Study to Assess the Outcome of Conservative 3T Treatment With EMG-Biofeedback|Completed||Phase 3|158|Actual|University of Giessen||2|||f||||t||||||||||2018-06-01 02:57:13.169673|2018-06-01 02:57:13.169673
NCT00525278|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-12-13|2007-09-04|2007-09-05|Estimate|||||||2013-12-13|2013-12-16|Estimate|August 2003||2003-08-31|September 2009|2009-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis|Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Seasonal Allergic Rhinitis (SAR)|Completed||Phase 3|67|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:57:13.23043|2018-06-01 02:57:13.23043
NCT00525265|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|2013-11-01||2013-11-06|2007-09-03|2007-09-05|Estimate|2013-11-06|2013-12-25|Estimate||||2013-11-06|2013-12-25|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)|A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)|Completed||Phase 3|20|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 02:57:13.284273|2018-06-01 02:57:13.284273
NCT00525252|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate|February 2003||2003-02-28|September 2007|2007-09-30|November 2006|Actual|2006-11-30|||||Interventional|||Efficacy of Baclofen in the Treatment of Alcohol Addiction|Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study|Completed||Phase 1/Phase 2|86||Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-06-01 02:57:13.540005|2018-06-01 02:57:13.540005
NCT00525239|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2011-03-15|2007-09-04|2007-09-05|Estimate|||||||2011-03-15|2011-03-16|Estimate|March 2004||2004-03-31|March 2011|2011-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||HIV Antiretroviral Drugs and Metabolism||Unknown status|Recruiting|N/A|60|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t||||||||||2018-06-01 02:57:13.599381|2018-06-01 02:57:13.599381
NCT00525226|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-11-19|2007-09-04|2007-09-05|Estimate|||||||2013-11-19|2013-11-20|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Evaluating the Effects of Stress in Pregnancy|Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability|Completed|||1431|Actual|Emory University|||1||f||||t||||||Samples With DNA|"~     Plasm, serum, and urine samples are processed and stored at each research visit.~   "|||2018-06-01 02:57:13.676783|2018-06-01 02:57:13.676783
NCT00525213|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2009-08-20|2007-09-04|2007-09-05|Estimate|||||||2009-08-20|2009-08-21|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|ROBUST||Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Methotrexate|A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 When Added to Stable Methotrexate|Completed||Phase 2|224|Actual|OxyPharma||4|||f||||f||||||||||2018-06-01 02:57:13.924739|2018-06-01 02:57:13.924739
NCT00525200|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2012-12-20|2007-09-04|2007-09-05|Estimate|||||||2012-12-20|2012-12-21|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|PANCHO||p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer|p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer: A Multicenter, Randomized Controlled, Predictive Marker Clinical Trial|Completed||Phase 3|170|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 02:57:14.058186|2018-06-01 02:57:14.058186
NCT00525187|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate|December 2000||2000-12-31|August 2007|2007-08-31|January 2005|Actual|2005-01-31|||||Observational|||Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients|Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients|Completed|||100|Actual|Vésale Hospital|||||f||||f||||||||||2018-06-01 02:57:14.150903|2018-06-01 02:57:14.150903
NCT00524966|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2011-07-07|2007-09-04|2007-09-05|Estimate|||||||2011-07-07|2011-07-11|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Randomized Controlled Trial of Bipolar Versus Ultrasonic Hemostasis Techniques in Thyroidectomy|Randomized Controlled Trial of Bipolar Versus Ultrasonic Hemostasis Techniques in Thyroidectomy|Completed||N/A|100|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-06-01 02:57:18.707327|2018-06-01 02:57:18.707327
NCT00525174|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2011-04-22||2016-07-07|2007-08-31|2007-09-05|Estimate|2011-05-18|2011-06-17|Estimate||||2016-07-07|2016-07-13|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|ATS10||Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children|A Randomized Trial of Full-time Bangerter Filters Versus Part-time Daily Patching for the Treatment of Moderate Amblyopia in Children|Completed||Phase 3|186|Actual|Jaeb Center for Health Research|Compliance assessment was based on parents' diaries and judgment by the researchers. Because we did not use an objective method to measure occlusion or spectacle wear, we cannot guarantee that the patients adhered to their prescribed regimens.|2|||f||||t||||||||||2018-06-01 02:57:14.25154|2018-06-01 02:57:14.25154
NCT00525161|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|2014-12-18||2015-01-12|2007-09-03|2007-09-05|Estimate|2015-01-08|2015-01-13|Estimate||||2015-01-12|2015-01-26|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2013|Actual|2013-01-31||Interventional|||Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer|A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer|Terminated||Phase 2|11|Actual|University of Kentucky|Early termination of study due to slow accrual.|1||Slow accrual and loss of funding|f||||t||||||||||2018-06-01 02:57:15.342914|2018-06-01 02:57:15.342914
NCT00525148|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|2013-08-08||2016-07-28|2007-09-03|2007-09-05|Estimate|2013-08-08|2013-10-14|Estimate||||2016-07-28|2016-09-16|Estimate|August 2007||2007-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|February 2010|Actual|2010-02-28||Interventional||Treated set: The patients who had taken at least one dose of afatinib were included in the treated set.|"LUX Lung 2 Phase II Single Arm BIBW 2992 Afatinib in NSCLC With EGFR Activating Mutations"|LUX Lung 2 A Phase II Single-arm Trial of BIBW 2992 in Non-small Cell Lung Cancer Patients With EGFR Activating Mutations|Completed||Phase 2|129|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 02:57:15.619538|2018-06-01 02:57:15.619538
NCT00525135|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2015-01-21||2015-01-21|2007-09-04|2007-09-05|Estimate|2015-01-21|2015-02-03|Estimate||||2015-01-21|2015-02-03|Estimate|August 2007||2007-08-31|January 2015|2015-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer|A Phase II Trial of Valproic Acid (Depakote ER ®) in Patients With Advanced Thyroid Cancers of Follicular Origin, Who Are Thyroglobulin Positive/RAI Unresponsive|Terminated||Phase 2|5|Actual|University of California, San Francisco||2||PI left university and study was halted prematurely. No data was analyzed.|f||||t||||||||||2018-06-01 02:57:16.402617|2018-06-01 02:57:16.402617
NCT00525122|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2008-05-21|2007-09-04|2007-09-05|Estimate|||||||2008-05-21|2008-05-22|Estimate|September 2007||2007-09-30|May 2008|2008-05-31||||||||Observational|||Treatment of M.Graves With Radioactive Iodine: Follow-up Study||Unknown status|Recruiting||100|Anticipated|Medisch Centrum Rijnmond-Zuid, Netherlands|||1||f||||f||||||||||2018-06-01 02:57:16.596487|2018-06-01 02:57:16.596487
NCT00525109|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-03-16|2007-09-04|2007-09-05|Estimate|||||||2017-03-16|2017-03-20|Actual|June 2004||2004-06-30|March 2017|2017-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Elevated Serum HDL in Four Generations of a Nashville Family|Elevated Serum HDL in Four Generations of a Nashville Family|Terminated|||3|Actual|Vanderbilt University Medical Center|||1|Unable to complete enrollment due lack of family interest.|f||||f||||||Samples With DNA|"~     Plasma, Serum, DNA~   "|||2018-06-01 02:57:16.648186|2018-06-01 02:57:16.648186
NCT00525096|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|||2011-06-29|2007-09-03|2007-09-05|Estimate|||||||2011-06-29|2011-06-30|Estimate|July 2003||2003-07-31|June 2011|2011-06-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer|A Multicenter Randomized Phase III, Double-blind Study Comparing Efficacy of the Association of Exemestane and Celecoxib Versus Exemestane and Placebo in Menopausal Patients With Metastatic Breast Cancer.|Completed||Phase 3|157|Actual|ARCAGY/ GINECO GROUP||2|||f||||f||||||||||2018-06-01 02:57:16.718795|2018-06-01 02:57:16.718795
NCT00525083|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-03-30|2007-09-04|2007-09-05|Estimate|||||||2017-03-30|2017-04-04|Actual|June 2005|Actual|2005-06-30|March 2017|2017-03-31|November 3, 2014|Actual|2014-11-03|November 3, 2014|Actual|2014-11-03||Observational|||Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C|Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C|Terminated|||19|Actual|Vanderbilt University Medical Center||||PI left for another institution|f||||f||||||Samples With DNA|"~     Plasma, HDL preps, genomic DNA~   "|||2018-06-01 02:57:16.961132|2018-06-01 02:57:16.961132
NCT00525057|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-09-12|2007-09-04|2007-09-05|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2006|Actual|2006-07-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study|DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study|Active, not recruiting||N/A|70|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-06-01 02:57:17.18436|2018-06-01 02:57:17.18436
NCT00525044|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03||2014-04-30|2014-04-30|2007-09-03|2007-09-05|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|August 2007||2007-08-31|April 2014|2014-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat|Double-blind, Randomized, Placebo-controlled Trial to Investigate the Efficacy and Tolerance of Ambroxol Lozenges 20 mg in the Treatment of Sore Throat in Patients With Acute Viral Pharyngitis|Completed||Phase 3|249|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:57:17.50451|2018-06-01 02:57:17.50451
NCT00525031|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2017-06-29||2017-06-29|2007-08-31|2007-09-05|Estimate|2017-06-29|2017-07-02|Actual||||2017-06-29|2017-07-02|Actual|August 2006||2006-08-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients|Randomized Phase II Neoadjuvant Study of Temozolomide Alone or With Pegylated Interferon-alpha 2b in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB/IIIC or Stage IV (M1a) Metastatic Melanoma|Completed||Phase 2|55|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:57:17.76057|2018-06-01 02:57:17.76057
NCT00525018|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|||2007-09-03|2007-09-03|2007-09-05|Estimate|||||||2007-09-03|2007-09-05|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|July 2008|Anticipated|2008-07-31|||||Observational|||Brain Activation During Thermal Stimulation in Neuropathic Pain|Brain Activation During Thermal Stimulation in Neuropathic Pain|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 02:57:18.464589|2018-06-01 02:57:18.464589
NCT00525005|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2012-09-20|2007-09-04|2007-09-05|Estimate|||||||2012-09-20|2012-09-21|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer|A Phase II Study of Docetaxel, Oxaliplatin and S-1 (DOS) in Patients With Advanced Gastric Cancer|Completed||Phase 2|44|Actual|Hallym University Medical Center||1|||f||||f||||||||||2018-06-01 02:57:18.52055|2018-06-01 02:57:18.52055
NCT00524953|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2015-06-10|2007-09-04|2007-09-05|Estimate|||||||2015-06-10|2015-06-11|Estimate|September 2007||2007-09-30|August 2007|2007-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT|Phase I - Clinical Trial to Assess Safety of Ultraviolet (UV) Phototherapy for the Prevention of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation|Withdrawn||Phase 1|0|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 02:57:18.769496|2018-06-01 02:57:18.769496
NCT00524940|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2009-02-24||2016-04-12|2007-09-04|2007-09-05|Estimate|2009-02-24|2009-03-30|Estimate||||2016-04-12|2016-04-14|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Trial to Describe the Safety and Immunogenicity of Fluzone®|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)|Completed||Phase 2|124|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 02:57:18.841775|2018-06-01 02:57:18.841775
NCT00524927|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-02|||2010-01-27|2007-09-02|2007-09-05|Estimate|||||||2010-01-27|2010-01-28|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|November 2009|Actual|2009-11-30|||||Interventional|||Safety and Efficacy of Methoxyflurane for Treatment of Incident Pain|A Phase IV, Randomized, Double Blind, Single Centre, Placebo Controlled Study to Assess the Safety and Efficacy of Methoxyflurane [Penthrox] for the Treatment of Incident Pain in Participants Undergoing a Bone Marrow Biopsy Procedure|Completed||Phase 4|110|Anticipated|Medical Developments International Limited||2|||f||||t||||||||||2018-06-01 02:57:19.013027|2018-06-01 02:57:19.013027
NCT00524914|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2008-04-10|2007-09-04|2007-09-05|Estimate|||||||2008-04-10|2008-04-11|Estimate|September 2007||2007-09-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|APODOUL||Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study|Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study.|Completed||N/A|16|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 02:57:19.078954|2018-06-01 02:57:19.078954
NCT00524901|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-02-13|2007-09-04|2007-09-05|Estimate|||||||2013-02-13|2013-02-15|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|DREAM||Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia|An Open Label Study to Evaluate the Effect of Intravenous Erythropoietin on Erythropoietin Receptor Signaling and Markers for Apoptosis, Myocardial Damage and Renal Dysfunction in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|Completed||Phase 2|10|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 02:57:19.148934|2018-06-01 02:57:19.148934
NCT00524888|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate|September 2007||2007-09-30|August 2007|2007-08-31||||||||Interventional|sutvsglu||Suturing vs Biological Adhesive in Simple Lacerations of Hand|Suturing Vs Adhesion for Hand Lacerations in the ER A Randomized Prospective Study|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 02:57:19.227472|2018-06-01 02:57:19.227472
NCT00524875|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients||Unknown status|Recruiting|N/A|80|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:57:19.307651|2018-06-01 02:57:19.307651
NCT00524862|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2015-07-30|2007-08-31|2007-09-05|Estimate|||||||2015-07-30|2015-07-31|Estimate|October 2007||2007-10-31|July 2015|2015-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|SMART-ICD||Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death|Selective Strategy to Manage Arrhythmia Risk and Therapy With ICD|Terminated||N/A|5000|Anticipated|St. Michael's Hospital, Toronto||2||Poor recruitment|f||||t||||||||||2018-06-01 02:57:19.488094|2018-06-01 02:57:19.488094
NCT00524849|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2010-09-13|2007-09-04|2007-09-05|Estimate|||||||2010-09-13|2010-09-14|Estimate|November 2006||2006-11-30|September 2010|2010-09-30|January 2010|Actual|2010-01-31|August 2008|Actual|2008-08-31||Interventional|||Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis|Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases|Completed||Phase 2/Phase 3|60|Actual|Fudan University||2|||f||||f||||||||||2018-06-01 02:57:19.572329|2018-06-01 02:57:19.572329
NCT00524836|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2013-12-13|2007-09-04|2007-09-05|Estimate|||||||2013-12-13|2013-12-16|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis|A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Perennial Allergic Rhinitis.|Completed||Phase 3|71|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:57:19.654685|2018-06-01 02:57:19.654685
NCT00524823|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate|August 2007||2007-08-31|August 2007|2007-08-31||||||||Observational|FACS||Early Detection of Prostate Cancer by FACS||Unknown status|Recruiting||40|Anticipated|Ziv Hospital|||4||f||||t||||||||||2018-06-01 02:57:19.708382|2018-06-01 02:57:19.708382
NCT00524810|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-03|||2011-06-29|2007-09-04|2007-09-05|Estimate|||||||2011-06-29|2011-06-30|Estimate|February 2004||2004-02-29|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer|A Multi-center Phase II Study Evaluating the Efficacy and Tolerance of the Association of Liposomal Doxorubicin and Docetaxel in First Line Chemotherapy in Patients With Metastatic Breast Cancer|Completed||Phase 2|67|Actual|ARCAGY/ GINECO GROUP||1|||f||||f||||||||||2018-06-01 02:57:19.780685|2018-06-01 02:57:19.780685
NCT00524797|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-02|||2007-09-02|2007-09-02|2007-09-05|Estimate|||||||2007-09-02|2007-09-05|Estimate|September 2007||2007-09-30|September 2007|2007-09-30||||||||Interventional|||Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy|Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy|Unknown status|Recruiting|N/A|50|Anticipated|Ziv Hospital||1|||f||||f||||||||||2018-06-01 02:57:19.868222|2018-06-01 02:57:19.868222
NCT00524784|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2015-06-10|2007-09-04|2007-09-05|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2009||2009-06-30|June 2009|2009-06-30|April 2016|Anticipated|2016-04-30|December 2012|Actual|2012-12-31||Interventional|||Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD|Phase 1/2a, Multicenter, Open-Label Study Designed to Evaluate the Safety, Tolerability and Preliminary Efficacy of ApoCell Administration, a Donor Apoptotic Cell-Based Product, for the Prevention of Acute Graft Versus Host Disease (GvHD) in Subjects With Hematologic Malignancies Undergoing Allogeneic Sibling HLA-Matched Hematopoietic Stem Cell Transplantation (HSCT)|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-06-01 02:57:19.942577|2018-06-01 02:57:19.942577
NCT00524771|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|2014-03-03||2014-03-03|2007-09-04|2007-09-05|Estimate|2014-03-03|2014-04-09|Estimate||||2014-03-03|2014-04-09|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Observational|TASC|All study participants that were not excluded due to protocol violations.|Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)|Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)|Completed|||34100|Actual|Center for Epidemiology and Health Research, Germany|In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.||2||f||||t||||||||||2018-06-01 02:57:20.085476|2018-06-01 02:57:20.085476
NCT00524758|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2017-06-26|2007-09-04|2007-09-05|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2007||2007-07-31|June 2017|2017-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Oculusgen (Ologen) Glaucoma MMC Control in Estonia|Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery|Completed||Phase 3|20|Anticipated|Pro Top & Mediking Company Limited||2|||f||||t||||||||||2018-06-01 02:57:20.412365|2018-06-01 02:57:20.412365
NCT00524745|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2011-08-03||2017-04-12|2007-09-04|2007-09-05|Estimate|2011-08-03|2011-09-08|Estimate||||2017-04-12|2017-04-14|Actual|October 2007||2007-10-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil|Comparison of the Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Vaccine to Prevent HPV Infection|Completed||N/A|903|Actual|PATH||4|||f||||f||||||||||2018-06-01 02:57:20.530408|2018-06-01 02:57:20.530408
NCT00524732|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2014-01-10|2007-09-04|2007-09-05|Estimate|||||||2014-01-10|2014-01-14|Estimate|September 2004||2004-09-30|January 2014|2014-01-31|September 2005|Actual|2005-09-30|December 2004|Actual|2004-12-31||Observational|||Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age||Completed|||7156|Actual|Sanofi|||9||f||||f||||||||||2018-06-01 02:57:20.902763|2018-06-01 02:57:20.902763
NCT00524719|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2018-02-12|2007-09-04|2007-09-05|Estimate|||||||2018-02-12|2018-02-14|Actual|January 2007||2007-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|December 2016|Actual|2016-12-31||Interventional|DRF||Comparison of Three Fixation Techniques for Displaced Distal Radius Fractures|A Prospective Randomised Trial Comparing Open Reduction and Internal Fixation, Non-Spanning External Fixation, and Closed Reduction With Percutaneous Fixation in Displaced Distal Radius Fractures With Joint Congruity|Active, not recruiting||N/A|324|Anticipated|McGill University Health Center||3|||f||||f||||||||No||2018-06-01 02:57:20.981103|2018-06-01 02:57:20.981103
NCT00524706|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2008-11-12|2007-09-04|2007-09-05|Estimate|||||||2008-11-12|2008-11-13|Estimate|August 2007||2007-08-31|November 2008|2008-11-30|April 2011|Anticipated|2011-04-30|||||Interventional|||Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer|Phase I/II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) in Patients With Untreated Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|42|Anticipated|Shizuoka Cancer Center|||||f||||t||||||||||2018-06-01 02:57:21.056718|2018-06-01 02:57:21.056718
NCT00524693|ClinicalTrials.gov processed this data on May 31, 2018|2007-09-04|||2007-09-04|2007-09-04|2007-09-05|Estimate|||||||2007-09-04|2007-09-05|Estimate|January 2006||2006-01-31|September 2007|2007-09-30||||||||Interventional|||Montelukast in Acute RSV Bronchiolitis|A Double-Blind Placebo Controlled Randomized Trial of Montelukast in Acute Respiratory Syncytial Virus Bronchiolitis|Completed||N/A|51|Actual|Ziv Hospital||2|||f||||f||||||||||2018-06-01 02:57:21.124933|2018-06-01 02:57:21.124933
NCT00524680|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2015-03-17||2015-09-30|2007-08-31|2007-09-03|Estimate|2015-09-30|2015-11-02|Estimate||||2015-09-30|2015-11-02|Estimate|June 2007||2007-06-30|September 2015|2015-09-30|March 2013|Actual|2013-03-31|May 2011|Actual|2011-05-31||Interventional||All treated and eligible patients|Vitamin D in Treating Patients With Prostate Cancer|Study of Serum 25(OH) D3 Level Variability in Response to Different Doses of Oral Vitamin D Supplementation in Prostate Cancer Patients|Completed||Phase 2|148|Actual|Roswell Park Cancer Institute||4|||f||||t||||||||||2018-06-01 02:57:21.236107|2018-06-01 02:57:21.236107
NCT00524667|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2011-07-18|2007-08-31|2007-09-03|Estimate|||||||2011-07-18|2011-07-20|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia|HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia|Terminated||Phase 2|6|Actual|CancerCare Manitoba||1||Terminated due to poor accrual.|f||||f||||||||||2018-06-01 02:57:21.943347|2018-06-01 02:57:21.943347
NCT00524654|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2008-10-16|2007-08-31|2007-09-03|Estimate|||||||2008-10-16|2008-10-17|Estimate|August 2007||2007-08-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effects of Cervical Spine Manipulation On Postural Control||Completed||Phase 2|30|Actual|Logan College of Chiropractic|||||f||||||||||||||2018-06-01 02:57:22.042641|2018-06-01 02:57:22.042641
NCT00524641|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2009-07-08|2007-08-31|2007-09-03|Estimate|||||||2009-07-08|2009-07-09|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Observational|||"Asthma Control-A Patient Follow up Programme Maintenance and Reliever Therapy in a Single Inhaler"|A Patient Follow-up Program to Assess Asthma Control in Patients Using Symbicort® as Maintenance and Relief Therapy in a Single Inhaler (Symbicort® SMART: Budesonide/Formoterol 160/4.5 Mcg, 1 or 2 Inhalations x 2 Times Plus Additional Inhalations as Needed)|Completed|||1254|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:22.132573|2018-06-01 02:57:22.132573
NCT00524615|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2012-06-19|2007-08-31|2007-09-03|Estimate|||||||2012-06-19|2012-06-20|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|ASPIRANT||Addition of Spironolactone in Patients With Resistant Arterial Hypertension|Addition of Spironolactone in Patients With Resistant Arterial Hypertension|Unknown status|Recruiting|Phase 4|160|Anticipated|University Hospital Olomouc||2|||f||||f||||||||||2018-06-01 02:57:22.2644|2018-06-01 02:57:22.2644
NCT00524602|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2011-08-10|2007-08-31|2007-09-03|Estimate|||||||2011-08-10|2011-08-11|Estimate|June 2007||2007-06-30|August 2007|2007-08-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|||The Use of Remote Magnetic Navigation in Catheter Ablation of Heart Arrythmia|A Nonrandomized Observertionel Study That Will Show the Utility and the Safety by Using the Remote Magnetic Navigation of Ablationcatheters and the Stereotaxis Equipment|Unknown status|Recruiting|N/A|2000|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 02:57:22.494024|2018-06-01 02:57:22.494024
NCT00524589|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2014-01-27||2017-10-17|2007-08-31|2007-09-03|Estimate|2014-01-27|2014-03-10|Estimate||||2017-10-17|2017-11-20|Actual|April 2006||2006-04-30|October 2017|2017-10-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional||All treated and eligible patients|Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|Phase II Study of Weekly Intravenous 1,25 Dihydroxycholecelciferol (Calcitriol) + Dexamethasone in Androgen Independent Prostate Cancer|Terminated||Phase 2|18|Actual|Roswell Park Cancer Institute||1||closed due to futility|f||||t||||||||||2018-06-01 02:57:22.655033|2018-06-01 02:57:22.655033
NCT00524576|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2009-05-14||2016-11-02|2007-08-31|2007-09-03|Estimate|2009-05-15|2009-07-08|Estimate||||2016-11-02|2016-12-16|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine|Administration of a Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine.|Completed||Phase 4|144|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:57:22.974873|2018-06-01 02:57:22.974873
NCT00524563|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2017-06-23|2007-08-31|2007-09-03|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2007|Actual|2007-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Clinical Outcomes and Global Epidemiology -Data Coordinating Center|Clinical Outcomes and Global Epidemiology -Data Coordinating Center|Completed|||400|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:57:23.324304|2018-06-01 02:57:23.324304
NCT00524550|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2010-08-11|2007-08-31|2007-09-03|Estimate|||||||2010-08-11|2010-08-12|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Postprandial Insulin Secretion and Appetite Regulation After Moderate Alcohol Consumption|Effect of Moderate Alcohol Consumption on Postprandial Insulin Secretion, Appetite Regulation, Glucose Homeostasis and Insulin Resistance.|Completed||N/A|24|Anticipated|TNO|||||f||||||||||||||2018-06-01 02:57:23.372494|2018-06-01 02:57:23.372494
NCT00524537|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2016-11-18||2017-01-20|2007-08-31|2007-09-03|Estimate|2017-01-20|2017-01-24|Estimate||||2017-01-20|2017-01-24|Estimate|September 2007||2007-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational||All Treated Population: All participants who received at least 1 injection of Humira in the registry|A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)|A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)|Completed|||5025|Actual|AbbVie|||1||f||||f||||||||||2018-06-01 02:57:24.574074|2018-06-01 02:57:24.574074
NCT00524524|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2011-10-17|2007-08-30|2007-09-03|Estimate|||||||2011-10-17|2011-10-19|Estimate|August 2007||2007-08-31|October 2011|2011-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors|An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors|Completed||Phase 1|9|Actual|ArQule|||||f||||f||||||||||2018-06-01 02:57:26.637278|2018-06-01 02:57:26.637278
NCT00524511|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2012-10-24||2013-01-24|2007-08-31|2007-09-03|Estimate|2013-01-24|2013-03-05|Estimate||||2013-01-24|2013-03-05|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Comparison Study of Wound Closure at Time of Cesarean Delivery: Dermabond Glue Versus Surgical Staples|A Comparative Study of Closure Techniques After Cesarean Section: Staples vs. Dermabond|Terminated||N/A|136|Actual|University of Massachusetts, Worcester||2||Poor enrollment, much data was missing as patients were lost to follow up|f||||f||||||||||2018-06-01 02:57:26.703858|2018-06-01 02:57:26.703858
NCT00524498|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2015-10-13|2007-08-31|2007-09-03|Estimate|||||||2015-10-13|2015-10-15|Estimate|September 2007||2007-09-30|October 2015|2015-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma|A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma|Completed||Phase 2|60|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-06-01 02:57:26.881332|2018-06-01 02:57:26.881332
NCT00524485|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2017-04-12||2017-05-17|2007-08-31|2007-09-03|Estimate|2017-04-12|2017-05-17|Actual||||2017-05-17|2017-06-14|Actual|May 2005||2005-05-31|May 2017|2017-05-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional||All treated and eligible patients|Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis|A Pilot Study to Investigate the Use of Topical Levulan® With Vbeam® Laser for the Treatment of Actinic Keratoses|Terminated||N/A|12|Actual|Roswell Park Cancer Institute|Study was activated prior to RPCI putting a centralize data entry and data management. Data entry of the treatment arm assignments and outcomes was done by PI's staff and has since been lost. PI died, all attempts to retrieve the data have failed.|5||Withdrawn due to low accrual|f||||t||||||||||2018-06-01 02:57:26.960825|2018-06-01 02:57:26.960825
NCT00524472|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2017-01-31|2007-08-31|2007-09-03|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2007||2007-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery|The Effect of Hyperinsulinemic Glucose Control on Outcomes Following Cardiac Surgery|Recruiting||N/A|418|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-06-01 02:57:27.195284|2018-06-01 02:57:27.195284
NCT00524459|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2014-08-06||2014-08-21|2007-08-31|2007-09-03|Estimate|2014-08-06|2014-08-22|Estimate||||2014-08-21|2014-08-29|Estimate|May 2007||2007-05-31|August 2014|2014-08-31||||August 2008|Actual|2008-08-31||Interventional||All treated and eligible patients|Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery|Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Locally Advanced Operable Breast Cancer|Terminated||Phase 2|6|Actual|Roswell Park Cancer Institute|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.|||Terminated by sponsor due to lack of funding|f||||t||||||||||2018-06-01 02:57:27.313967|2018-06-01 02:57:27.313967
NCT00524446|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2014-05-20|2007-08-31|2007-09-03|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|June 2011|Actual|2011-06-30||Interventional|LCNI-5||Controlled Trial to Test the Efficacy of Lipid-based Nutrient Supplements to Prevent Severe Stunting Among Infants|A Single-centre, Randomised, Single-blind, Parallel Group Clinical Trial in Rural Malawi, Testing the Growth Promoting Effect of Long-term Complementary Feeding of Infants With a High-energy, Micronutrient Fortified Spread|Completed||Phase 3|840|Anticipated|University of Tampere||4|||f||||t||||||||||2018-06-01 02:57:27.526849|2018-06-01 02:57:27.526849
NCT00524433|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31||2010-02-11|2010-02-11|2007-08-31|2007-09-03|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|April 2003||2003-04-30|February 2010|2010-02-28|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|VERITAS 2||Tezosentan in the Treatment of Acute Heart Failure|Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.|Completed||Phase 3|713|Actual|Actelion||2|||f||||||||||||||2018-06-01 02:57:27.628419|2018-06-01 02:57:27.628419
NCT00524251|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2008-09-16|2007-08-31|2007-09-03|Estimate|||||||2008-09-16|2008-09-17|Estimate|June 2004||2004-06-30|September 2008|2008-09-30|March 2008|Actual|2008-03-31|||||Observational|||The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients||Completed|||990|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:31.272277|2018-06-01 02:57:31.272277
NCT00524420|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2013-02-13||2013-04-13|2007-08-30|2007-09-03|Estimate|2013-04-13|2013-05-23|Estimate||||2013-04-13|2013-05-23|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain|Transcranial Magnetic Stimulation (TMS) in the Treatment of Chronic Widespread Pain (CWP)|Completed||Phase 2|19|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:57:27.771513|2018-06-01 02:57:27.771513
NCT00524407|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2010-04-01|2007-08-30|2007-09-03|Estimate|||||||2010-04-01|2010-04-02|Estimate|July 1996||1996-07-31|April 2010|2010-04-30|November 2002|Actual|2002-11-30|||||Interventional|||Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy|The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia|Completed||Phase 4|273|Actual|Ortho Biotech Clinical Affairs, L.L.C.|||||f||||||||||||||2018-06-01 02:57:28.139685|2018-06-01 02:57:28.139685
NCT00524394|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2013-07-17||2015-11-05|2007-08-31|2007-09-03|Estimate|2015-11-05|2015-12-14|Estimate||||2015-11-05|2015-12-14|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|AOS||Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation|Characteristics of Cord Blood Immunologic Parameters of Infants < 32 Weeks Gestation|Terminated|||2|Actual|The University of Texas Health Science Center, Houston|Early termination leading to small numbers of subjects analyzed|||recruitment not possible|f||||t||||||Samples Without DNA|"~     Serum only~   "|||2018-06-01 02:57:28.197175|2018-06-01 02:57:28.197175
NCT00524381|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2010-02-22|2007-08-30|2007-09-03|Estimate|||||||2010-02-22|2010-02-23|Estimate|August 2007||2007-08-31|February 2010|2010-02-28|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Etanercept Treatment in the Early Course of Polymyalgia Rheumatica|The Effect of Etanercept on the Early Clinical Course of Polymyalgia Rheumatica (Pilot Study)|Completed||Phase 3|40|Anticipated|Bispebjerg Hospital|||||f||||t||||||||||2018-06-01 02:57:28.320192|2018-06-01 02:57:28.320192
NCT00524368|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2010-08-27||2013-02-12|2007-08-30|2007-09-03|Estimate|2010-08-27|2010-09-22|Estimate||||2013-02-12|2013-02-15|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|August 2009|Actual|2009-08-31||Interventional|ODIN||A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)|A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects|Completed||Phase 3|590|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||t||||||||||2018-06-01 02:57:28.404392|2018-06-01 02:57:28.404392
NCT00524355|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2009-07-16|2007-08-30|2007-09-03|Estimate|||||||2009-07-16|2009-07-17|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|November 2007|Actual|2007-11-30|||||Observational|||Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD|Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of the Gastroesophageal Reflux Disease|Completed|||2717|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:29.284445|2018-06-01 02:57:29.284445
NCT00524342|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2014-06-04||2018-01-05|2007-08-31|2007-09-03|Estimate|2014-11-05|2014-11-07|Estimate||||2018-01-05|2018-01-31|Actual|January 2008||2008-01-31|January 2018|2018-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia|Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory Menorrhagia|Completed||Phase 2|7|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 02:57:29.355587|2018-06-01 02:57:29.355587
NCT00524329|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2008-09-25|2007-08-31|2007-09-03|Estimate|||||||2008-09-25|2008-09-26|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|October 2007|Actual|2007-10-31|March 2007|Actual|2007-03-31||Observational|Synchronise||Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage|SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response|Completed|||1220|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 02:57:29.537729|2018-06-01 02:57:29.537729
NCT00524316|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2013-12-26||2017-03-31|2007-08-31|2007-09-03|Estimate|2014-05-19|2014-06-04|Estimate||||2017-03-31|2017-05-09|Actual|April 2007||2007-04-30|March 2017|2017-03-31|May 2014|Actual|2014-05-31|December 2010|Actual|2010-12-31||Interventional|||Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Phase II Study of SUNITINIB MALATE (Sutent) and Chemoembolization in Patients With Unresectable Hepatocellular Cancer|Terminated||Phase 2|16|Actual|Roswell Park Cancer Institute|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.|1||low accrual|f||||t||||||||||2018-06-01 02:57:29.616198|2018-06-01 02:57:29.616198
NCT00524303|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2011-07-14||2016-09-23|2007-08-31|2007-09-03|Estimate|2011-07-14|2011-08-11|Estimate||||2016-09-23|2016-11-11|Estimate|August 2007||2007-08-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|October 2010|Actual|2010-10-31||Interventional|||Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.|Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib Plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women With ErbB2- (HER2/Neu-) Overexpressing Invasive Breast Cancer|Completed||Phase 2|100|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 02:57:29.968287|2018-06-01 02:57:29.968287
NCT00524290|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2017-06-08|2007-08-31|2007-09-03|Estimate|||||||2017-06-08|2017-06-09|Actual|April 2009||2009-04-30|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol|Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol|Recruiting|||100|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:57:30.735198|2018-06-01 02:57:30.735198
NCT00524277|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2015-11-16|2007-08-31|2007-09-03|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Vaccine Therapy in Treating Patients With Breast Cancer|Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 2|600|Anticipated|San Antonio Military Medical Center||4|||f||||t||||||||||2018-06-01 02:57:30.886789|2018-06-01 02:57:30.886789
NCT00524264|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2009-08-19|2009-09-29|2009-09-29|2007-08-30|2007-09-03|Estimate|2009-09-29|2009-10-01|Estimate|2009-09-29|2009-10-01|Estimate|2009-09-29|2009-10-01|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery||Completed||Phase 3|248|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:57:31.001515|2018-06-01 02:57:31.001515
NCT00524225|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2014-07-22||2018-02-14|2007-08-31|2007-09-03|Estimate|2014-11-05|2014-11-07|Estimate||||2018-02-14|2018-03-13|Actual|February 2008||2008-02-29|February 2018|2018-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||IL-11 in Adults With Von Willebrand Disease Undergoing Surgery|Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing Surgery|Terminated||Phase 2|3|Actual|University of Pittsburgh|There were too few subjects for reporting in a manuscript.|1||Recruitment slow as single center conducting in rare disease|f||||t||||||||||2018-06-01 02:57:31.516592|2018-06-01 02:57:31.516592
NCT00524212|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2010-01-19|2007-08-31|2007-09-03|Estimate|||||||2010-01-19|2010-01-20|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|May 2009|Actual|2009-05-31|||||Observational|||How to Improve Diagnosis in Infective Endocarditis|Ph. D Student, Jane Byriel Knudsen, Aarhus University|Completed|||761|Actual|University of Aarhus|||2||f||||f||||||Samples Without DNA|"~     A venous blood sample was obtained from each patients and all samples were centrifuged and~     immediately frozen.~   "|||2018-06-01 02:57:31.675907|2018-06-01 02:57:31.675907
NCT00524199|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-08-31|2007-08-31|2007-09-03|Estimate|||||||2007-08-31|2007-09-03|Estimate|March 2007||2007-03-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Effects of Mesna on Homocysteine in Kidney Failure|The Effects of 12 mg/kg Intravenous Mesna on Plasma Total Homocysteine Concentration in Patients With End-Stage Renal Disease Requiring Hemodialysis|Completed||Phase 2|10|Actual|Lawson Health Research Institute||2|||f||||||||||||||2018-06-01 02:57:31.727068|2018-06-01 02:57:31.727068
NCT00524186|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2016-06-20|2007-08-31|2007-09-03|Estimate|||||||2016-06-20|2016-06-21|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|August 2013|Actual|2013-08-31||Interventional|||Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer|Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers|Terminated||Phase 1|23|Actual|Roswell Park Cancer Institute||1||PI left institute|f||||t||||||||||2018-06-01 02:57:31.79585|2018-06-01 02:57:31.79585
NCT00524173|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2018-03-20||2018-03-20|2007-08-31|2007-09-03|Estimate|2018-03-20|2018-04-18|Actual||||2018-03-20|2018-04-18|Actual|August 29, 2007||2007-08-29|March 16, 2018|2018-03-16|February 16, 2017|Actual|2017-02-16|February 16, 2017|Actual|2017-02-16||Interventional|||Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B|Tenofovir Disoproxil Fumarate Alone Versus Its Combination With Emtricitabine for Treatment of Chronic Hepatitis B|Terminated||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||||2018-06-01 02:57:31.888487|2018-06-01 02:57:31.888487
NCT00524160|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2010-11-24|2007-08-31|2007-09-03|Estimate|||||||2010-11-24|2010-11-25|Estimate|July 2001||2001-07-31|November 2010|2010-11-30|December 2002|Actual|2002-12-31|||||Interventional|||A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis|Open-Label Study To Assess The Effect On Pain Control Of Durogesic (Fentanyl Transdermic Therapeutic System) Treatment In Subjects With Rheumatoid Arthritis Or Osteoarthritis Of The Knee Or Hip.|Completed||Phase 4|264|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 02:57:32.144034|2018-06-01 02:57:32.144034
NCT00524147|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2010-12-28|2007-08-31|2007-09-03|Estimate|||||||2010-12-28|2010-12-30|Estimate|October 2003||2003-10-31|December 2010|2010-12-31|December 2006|Actual|2006-12-31|October 2005|Actual|2005-10-31||Interventional|||Drainage of Tuberculous Pleural Effusions|Drainage of Tuberculous Pleural Effusions|Completed||N/A|64|Actual|Taipei Medical University Hospital|||||f||||f||||||||||2018-06-01 02:57:32.204861|2018-06-01 02:57:32.204861
NCT00524134|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2016-03-23||2016-04-21|2007-08-31|2007-09-03|Estimate|2016-03-23|2016-04-22|Estimate||||2016-04-21|2016-05-23|Estimate|December 2008||2008-12-31|April 2016|2016-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.|An Open-label Pilot Study Using Carvedilol-CR as a P-glycoprotein Inhibitor as Adjunct Therapy in the Treatment of Medically-refractory Epilepsy|Terminated||Phase 2/Phase 3|6|Actual|Columbia University||1||PI left the institution.|f||||t||||||||||2018-06-01 02:57:32.272901|2018-06-01 02:57:32.272901
NCT00524121|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2013-08-23||2016-03-14|2007-08-31|2007-09-03|Estimate|2015-02-19|2015-03-05|Estimate||||2016-03-14|2016-04-14|Estimate|March 2006||2006-03-31|March 2016|2016-03-31|October 2011|Actual|2011-10-31|May 2010|Actual|2010-05-31||Interventional||All Treated Patients|Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer|Phase II Study of Erlotinib (Tarceva®) and Radiotherapy for Elderly Patients With Esophageal Carcinoma|Completed||Phase 2|22|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 02:57:32.439929|2018-06-01 02:57:32.439929
NCT00524108|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2012-08-14|2007-08-31|2007-09-03|Estimate|||||||2012-08-14|2012-08-16|Estimate|August 2007||2007-08-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Retrospective Analysis of Clinical Features in Ventriculoperitoneal Shunt Infectionsin Adults|Retrospective Analysis of Clinical Features in Ventriculoperitoneal Shunt Infections and Time to Re-Implantation in Adults|Completed|||350|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:57:32.818854|2018-06-01 02:57:32.818854
NCT00524095|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2009-03-12|2007-08-31|2007-09-03|Estimate|||||||2009-03-12|2009-03-13|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis|Bronchiectasis in COPD Patients : Role of Prophylaxis With Inhaled Steroids and Antibiotic on the Natural History of the Disease|Terminated||Phase 2|210|Actual|University of Milan||3||we decided not to go on treatment phase|f||||t||||||||||2018-06-01 02:57:32.868413|2018-06-01 02:57:32.868413
NCT00524069|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2013-01-31|2007-08-31|2007-09-03|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2007||2007-01-31|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|A Pilot Study of Bevacizumab Based Peri-Operative Therapy for Operable Pancreatic Adenocarcinoma|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||||Withdrawn due to no accrual|f||||||||||||||2018-06-01 02:57:32.967602|2018-06-01 02:57:32.967602
NCT00524056|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31||2013-01-15|2013-01-15|2007-08-31|2007-09-03|Estimate||||2013-01-15|2013-01-24|Estimate|2013-01-15|2013-01-24|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor|A Randomized, Double Blind, Placebo-Controlled, Crossover, Proof of Concept Study to Evaluate the Effectiveness and Safety of Carisbamate in the Treatment of Essential Tremor|Completed||Phase 2|62|Actual|SK Life Science||2|||f||||||||||||||2018-06-01 02:57:33.033769|2018-06-01 02:57:33.033769
NCT00523900|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2018-03-30|2007-08-31|2007-09-03|Estimate|||||||2018-03-30|2018-04-03|Actual|August 2007||2007-08-31|March 2018|2018-03-31|December 2008|Actual|2008-12-31|||||Interventional|||Effectiveness of Quaker Complete Nutrition Supplements for Malnourished Adults|Effectiveness of Quaker Complete Nutrition Supplements for Malnourished Adults|Completed||N/A|40|Anticipated|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||||2018-06-01 02:57:39.464999|2018-06-01 02:57:39.464999
NCT00524043|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2009-11-19||2014-05-21|2007-08-30|2007-09-03|Estimate|2010-02-08|2010-02-26|Estimate||||2014-05-21|2014-06-04|Estimate|September 2007||2007-09-30|May 2014|2014-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia|A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia|Completed||Phase 4|201|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No information from this study about efficacy and safety with treatment beyond 6 weeks. Study not designed to establish efficacy of 6 mg dose relative to 1.5 mg dose. No information on efficacy of paliperidone ER doses between 1.5 and 3 mg.|3|||f||||||||||||||2018-06-01 02:57:33.102604|2018-06-01 02:57:33.102604
NCT00524030|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2012-04-11||2012-05-15|2007-08-30|2007-09-03|Estimate|2012-04-11|2012-05-10|Estimate||||2012-05-15|2012-05-22|Estimate|September 2007||2007-09-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures|A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures|Terminated||Phase 3|161|Actual|Pfizer|External Data Monitoring Committee (DMC) determined study met criteria to stop early for positive efficacy. Exit rate was the basis for primary analysis and is what is reported here.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 02:57:33.561288|2018-06-01 02:57:33.561288
NCT00524017|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2012-01-27|2007-08-31|2007-09-03|Estimate|||||||2012-01-27|2012-01-31|Estimate|May 2007||2007-05-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract|Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions|Completed||Phase 2|35|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-06-01 02:57:34.013032|2018-06-01 02:57:34.013032
NCT00524004|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2017-04-04|2007-08-31|2007-09-03|Estimate|||||||2017-04-04|2017-04-05|Actual|January 30, 2007|Actual|2007-01-30|April 2017|2017-04-30|October 26, 2007|Actual|2007-10-26|October 26, 2007|Actual|2007-10-26||Interventional|BIgGII||Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD|Protective Efficacy of Orally Delivered Bovine Immunoglobulin, Specific for CS17 Fimbriae and CS17 Minor Fimbrial Adhesin CsbD Against Challenge With a CS17 Strain of Enterotoxigenic Escherichia Coli (ETEC)|Completed||Phase 2|36|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||No||2018-06-01 02:57:34.117387|2018-06-01 02:57:34.117387
NCT00523991|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2011-07-01||2014-05-12|2007-08-31|2007-09-03|Estimate|2011-11-25|2011-12-29|Estimate||||2014-05-12|2014-05-20|Estimate|April 2007||2007-04-30|May 2014|2014-05-31||||July 2010|Actual|2010-07-31||Interventional|||Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).|A 24 Week, Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by HandiHaler Once-daily Plus PRN Albuterol (Salbutamol) vs. Placebo Plus PRN Albuterol (Salbutamol) in Chronic Obstructive Pulmonary Disease Subjects Naive to Maintenance Therapy|Completed||Phase 4|457|Actual|Boehringer Ingelheim|For individual outcome measures, only timepoints that had data collected are presented here.|2|||f||||||||||||||2018-06-01 02:57:34.298104|2018-06-01 02:57:34.298104
NCT00523978|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2012-04-10||2012-07-25|2007-08-31|2007-09-03|Estimate|2012-07-25|2012-08-28|Estimate||||2012-07-25|2012-08-28|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|Stop-AF||A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation|A Randomized, Controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation.|Completed||Phase 3|245|Actual|Medtronic Atrial Fibrillation Solutions||2|||f||||f||||||||||2018-06-01 02:57:36.706137|2018-06-01 02:57:36.706137
NCT00523965|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2010-05-25|2007-08-31|2007-09-03|Estimate|||||||2010-05-25|2010-05-26|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Combination Therapy in Indian Visceral Leishmaniasis|A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL)|Completed||Phase 3|624|Anticipated|Banaras Hindu University||4|||f||||t||||||||||2018-06-01 02:57:38.087795|2018-06-01 02:57:38.087795
NCT00523952|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2014-08-28|2007-08-31|2007-09-03|Estimate|||||||2014-08-28|2014-09-01|Estimate|January 2004||2004-01-31|August 2014|2014-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients|A 12-week, Exploratory, Non-comparative, Multi-centre Study to Evaluate the Efficacy and Safety of 0.1% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis|Completed||Phase 3|303|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 02:57:38.167153|2018-06-01 02:57:38.167153
NCT00523939|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2011-02-16||2013-06-07|2007-08-31|2007-09-03|Estimate|2011-02-16|2011-03-14|Estimate||||2013-06-07|2013-06-17|Estimate|June 2006||2006-06-30|November 2012|2012-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||DepoCyt for Active Lymphomatous or Leukemic Meningitis|Phase II Study of Intrathecal Therapy With DepoCyt for Active Lymphomatous or Leukemic Meningitis|Terminated||Phase 2|4|Actual|Duke University|Adverse events for both arms, lymphomatous and leukemic, were combined due to low accrual and early study termination.|2||Low accrual.|f||||f||||||||||2018-06-01 02:57:38.304497|2018-06-01 02:57:38.304497
NCT00523926|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2012-08-14|2007-08-30|2007-09-03|Estimate|||||||2012-08-14|2012-08-15|Estimate|May 2005||2005-05-31|August 2012|2012-08-31|October 2005|Actual|2005-10-31|||||Interventional|||TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis|An Open-label Study to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of TMC207 in Treatment-na�ve Subjects With Sputum Smear Positive Pulmonary Tuberculosis.|Completed||Phase 2|75|Actual|Tibotec BVBA|||||f||||||||||||||2018-06-01 02:57:38.535848|2018-06-01 02:57:38.535848
NCT00523913|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2016-10-26|2007-08-31|2007-09-03|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2005||2005-11-30|October 2016|2016-10-31|April 2007|Actual|2007-04-30|||||Interventional|||A Study Of BRL49653C For The Treatment Of Type 2 Diabetes|Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus -Long-term Study of Rosiglitazone Maleate-|Completed||Phase 3|70|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:57:39.355939|2018-06-01 02:57:39.355939
NCT00523861|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-09-10|2007-08-30|2007-09-03|Estimate|||||||2007-09-10|2007-09-14|Estimate|May 2005||2005-05-31|August 2007|2007-08-31|June 2005|Actual|2005-06-30|||||Interventional|||Moderate Alcohol Consumption, Glucose Metabolism and Gastric Emptying|The Effect of Moderate Alcohol Consumption on Glucose Metabolism and Gastric Emptying in Healthy, Lean and Overweight Young Men|Completed||N/A|17|Actual|TNO|||||f||||||||||||||2018-06-01 02:57:39.649573|2018-06-01 02:57:39.649573
NCT00523848|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2013-07-12||2017-01-09|2007-08-31|2007-09-03|Estimate|2013-07-12|2013-09-17|Estimate||||2017-01-09|2017-02-23|Actual|June 2006||2006-06-30|January 2017|2017-01-31|October 2012|Actual|2012-10-31|September 2011|Actual|2011-09-30||Interventional||Evaluable Patients|Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma|Phase II Study of VDT (VELCADE, Doxil® and Thalidomide) as Frontline Therapy for Patients With Previously Untreated Multiple Myeloma (MM)|Completed||Phase 2|46|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 02:57:39.735927|2018-06-01 02:57:39.735927
NCT00523835|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2007-08-31|2007-08-31|2007-09-03|Estimate|||||||2007-08-31|2007-09-03|Estimate|April 2002||2002-04-30|August 2007|2007-08-31|November 2004|Actual|2004-11-30|||||Observational|||Body Composition, Bone Mineral Density, Insulin Sensitivity and Echocardiographic Measurements in Klinefelter Syndrome||Completed|||140||University of Aarhus|||2||f||||f||||||||||2018-06-01 02:57:40.267882|2018-06-01 02:57:40.267882
NCT00523822|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|||2008-08-01|2007-08-31|2007-09-03|Estimate|||||||2008-08-01|2008-08-05|Estimate||||August 2008|2008-08-31||||||||Interventional|||Sacroiliac Orthopedic Blocking and Cervical Spine Function||Completed||N/A|||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 02:57:40.322159|2018-06-01 02:57:40.322159
NCT00523809|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-31|2012-12-21||2012-12-21|2007-08-31|2007-09-03|Estimate|2012-12-21|2013-01-28|Estimate||||2012-12-21|2013-01-28|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 02:57:40.393191|2018-06-01 02:57:40.393191
NCT00523796|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2011-02-15|2007-08-31|2007-09-03|Estimate|||||||2011-02-15|2011-02-16|Estimate|February 2007||2007-02-28|February 2011|2011-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||InPractice Survey on the Treatment of Hypercholesterolemia|InPractice Survey on the Treatment of Hypercholesterolemia|Completed|||2500|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:40.534692|2018-06-01 02:57:40.534692
NCT00523783|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2008-10-03|2007-08-30|2007-08-31|Estimate|||||||2008-10-03|2008-10-06|Estimate|May 2007||2007-05-31|August 2007|2007-08-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Observational|SELECT||Seroquel Long-Term NIS for Schizophrenia Patients|24-Week Naturalistic Observational Study of Efficacy of Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder|Completed|||1000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:40.58813|2018-06-01 02:57:40.58813
NCT00523770|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2017-02-07|2007-08-30|2007-08-31|Estimate|||||||2017-02-07|2017-02-09|Estimate|September 2007||2007-09-30|February 2017|2017-02-28||||September 2007|Actual|2007-09-30||Observational|||Exploratory Study in Healthy Elderly Subjects to Collect Urine for Development of Assays to Detect S. Pneumoniae|An Exploratory Study in Healthy Elderly Subjects to Collect Urine for the Development of Assays to Detect Streptococcus Pneumoniae.|Completed|||50|Actual|GlaxoSmithKline|||1||f||||f||||||Samples With DNA|"~     Urine sample~   "|||2018-06-01 02:57:40.641975|2018-06-01 02:57:40.641975
NCT00523757|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2010-04-05|2007-08-29|2007-08-31|Estimate|||||||2010-04-05|2010-04-06|Estimate|August 2007||2007-08-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|||||Interventional|ARCTIC-D||Aldosterone Blockade in Heart Failure|Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic|Completed||Phase 3|10|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 02:57:40.700498|2018-06-01 02:57:40.700498
NCT00523744|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2011-01-10||2011-06-08|2007-08-30|2007-08-31|Estimate|2011-04-25|2011-05-25|Estimate||||2011-06-08|2011-06-10|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension|An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Amlodipine 10 mg Plus Valsartan 160 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combination of an Angiotensin Receptor Blocker (Olmesartan 20 mg) Plus Amlodipine 10 mg|Completed||Phase 3|257|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:57:40.87765|2018-06-01 02:57:40.87765
NCT00523731|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-08-30|2007-08-30|2007-08-31|Estimate|||||||2007-08-30|2007-08-31|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|March 2007|Actual|2007-03-31|||||Interventional|||ACPs in Severe PAD/CLI by Direct Intramuscular Injection|A Study of Blood-Borne Autologous Angiogenic Cells Precursors Therapy in Patients With Critical Limb Ischemia|Completed||Phase 1|6|Actual|TheraVitae Ltd.|||||f||||t||||||||||2018-06-01 02:57:41.144664|2018-06-01 02:57:41.144664
NCT00523718|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|2016-02-22||2016-05-25|2007-08-29|2007-08-31|Estimate|2016-02-22|2016-03-23|Estimate||||2016-05-25|2016-07-04|Estimate|September 2006||2006-09-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||One individual was excluded from analysis (they were in the riluzole group) before unblinding due to a protocol violation.|Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder|A Double-blind Study of Riluzole Augmentation in Serotonin Reuptake Inhibitor-refractory Obsessive-compulsive Disorder and Depression|Completed||Phase 2|40|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:57:41.216151|2018-06-01 02:57:41.216151
NCT00523705|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2012-06-13||2014-05-29|2007-08-30|2007-08-31|Estimate|2014-05-29|2014-06-06|Estimate||||2014-05-29|2014-06-06|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study|Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study|Terminated||Phase 4|11|Actual|University of Pennsylvania||2||Enrollment too slow.|f||||f||||||||||2018-06-01 02:57:41.523513|2018-06-01 02:57:41.523513
NCT00523692|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-08-30|2007-08-30|2007-08-31|Estimate|||||||2007-08-30|2007-08-31|Estimate|September 2007||2007-09-30|August 2007|2007-08-31||||||||Interventional|RIVERA||Remission Induction in Very Early Rheumatoid Arthritis|Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|University Hospital Birmingham||2|||f||||f||||||||||2018-06-01 02:57:41.78621|2018-06-01 02:57:41.78621
NCT00523679|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-07-10|2007-08-29|2007-08-31|Estimate|||||||2009-07-10|2009-07-13|Estimate|July 2007||2007-07-31|July 2009|2009-07-31|July 2008|Actual|2008-07-31|||||Observational|SMART||Symbicort SMART (Symbicort Maintenance And Reliever Therapy)|SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice|Completed|||2000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:41.866076|2018-06-01 02:57:41.866076
NCT00523666|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2007-08-29|2007-08-29|2007-08-31|Estimate|||||||2007-08-29|2007-08-31|Estimate|September 2006||2006-09-30|August 2007|2007-08-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)|Diffusion Tensor Weighted MRI in Alzheimer's Disease: Prediction and Mapping of Symptomatic and Disease Modifying Treatment Effects of Galantamine (Reminyl®)|Unknown status|Recruiting|Phase 4|20|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 02:57:41.921555|2018-06-01 02:57:41.921555
NCT00523653|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2008-03-17|2007-08-29|2007-08-31|Estimate|||||||2008-03-17|2008-03-19|Estimate|January 2008||2008-01-31|March 2008|2008-03-31|December 2008|Anticipated|2008-12-31|||||Observational|||The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study||Unknown status|Recruiting||200|Anticipated|McGill University Health Center|||||f||||f||||||||||2018-06-01 02:57:41.994766|2018-06-01 02:57:41.994766
NCT00523640|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2011-08-15||2014-01-16|2007-08-30|2007-08-31|Estimate|2011-11-18|2011-12-22|Estimate||||2014-01-16|2014-02-11|Estimate|March 2005||2005-03-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma|A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma|Terminated||Phase 2|30|Actual|University of Chicago|Trial was designed with a maximum target accrual of 55 patients. The trial was halted early because emerging data with VEGF inhibitors challenged clinical relevance of the study and availability of multiple therapies challenged accrual.|1||Too slow accrual|f||||t||||||||||2018-06-01 02:57:42.061173|2018-06-01 02:57:42.061173
NCT00523627|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2017-10-05|2007-08-30|2007-08-31|Estimate|||||||2017-10-05|2017-10-06|Actual|August 29, 2007||2007-08-29|September 26, 2017|2017-09-26||||||||Observational|||Effects of Diet Changes on Metabolism|Study of Short-Term Metabolic Adaptation: Prediction of Weight Change and Effects of Macronutrient Manipulations|Recruiting|||350|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:57:42.375642|2018-06-01 02:57:42.375642
NCT00523614|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2009-06-22||2010-03-19|2007-08-30|2007-08-31|Estimate|2009-10-23|2009-12-02|Estimate||||2010-03-19|2010-03-23|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|June 2008|Actual|2008-06-30|||||Observational|||Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism|Use of OCs Containing Dienogest and Risk of Venous Thromboembolism|Completed|||3400|Actual|Center for Epidemiology and Health Research, Germany|This is an observational study. The possibility of bias and residual confounding cannot be entirely eliminated.||2||f||||f||||||||||2018-06-01 02:57:42.450062|2018-06-01 02:57:42.450062
NCT00523601|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2008-10-03|2007-08-30|2007-08-31|Estimate|||||||2008-10-03|2008-10-06|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Observational|QUEEN||Quetiapine Efficacy in Bipolar Depression Study|A 8-Week, Multicenter, Open-Label, Observational Study of the Efficacy of Quetiapine Fumarate (SEROQUEL) Immediate-Release Tablets in Adult Patients With Bipolar Depression|Completed|||2000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:42.658028|2018-06-01 02:57:42.658028
NCT00523588|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2010-06-24|2007-08-30|2007-08-31|Estimate|||||||2010-06-24|2010-06-25|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|February 2009|Actual|2009-02-28||Interventional|||Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser|Single Blind, Controlled, Single-Center Study of Laser Treatment in Cutaneous Lupus Erythematosus|Completed||Phase 2|10|Anticipated|University of Pennsylvania|||||f||||t||||||||||2018-06-01 02:57:42.719277|2018-06-01 02:57:42.719277
NCT00523575|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2011-07-19|2007-08-30|2007-08-31|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Nutritional Intervention in Hip Fracture Patients|Effectiveness and Cost-effectiveness of Nutritional Screening and Intervention in Elderly Subjects After Hip Fracture|Completed||N/A|210|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 02:57:42.797206|2018-06-01 02:57:42.797206
NCT00523562|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2010-10-27|2007-08-30|2007-08-31|Estimate|||||||2010-10-27|2010-10-28|Estimate|July 2006||2006-07-31|June 2010|2010-06-30|January 2009|Actual|2009-01-31|April 2008|Actual|2008-04-30||Interventional|MACRONUTR||Effects of Macronutrients on Hepatic Lipids, Plasma Triglycerides, and Insulin Sensitivity|Study of the Role of Insulin Resistance in the Pathogenesis of the Metabolic Syndrome and of Non-alcoholic Steatohepatitis|Completed||N/A|41|Actual|University of Lausanne||4|||f||||f||||||||||2018-06-01 02:57:42.879909|2018-06-01 02:57:42.879909
NCT00523549|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2010-12-06||2012-04-19|2007-08-30|2007-08-31|Estimate|2011-02-09|2011-03-10|Estimate||||2012-04-19|2012-04-23|Estimate|November 2006||2006-11-30|April 2012|2012-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction|A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction|Completed||Phase 4|229|Actual|Novartis||2|||f||||f||||||||||2018-06-01 02:57:42.988268|2018-06-01 02:57:42.988268
NCT00523536|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2013-08-29|2007-08-30|2007-08-31|Estimate|||||||2013-08-29|2013-09-02|Estimate|May 2007||2007-05-31|April 2009|2009-04-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk|Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Evaluation of a Navigator-Nurse Care Team on Hypertension and Cardiovascular Disease Risk|Completed||N/A|800|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||||2018-06-01 02:57:43.339798|2018-06-01 02:57:43.339798
NCT00523523|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2012-02-03|2007-08-29|2007-08-31|Estimate|||||||2012-02-03|2012-02-06|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Training the Arm and Hand After Stroke Using Auditory Rhythm Cues|Auditory Rhythm Cues + Task Practice: Effects on UE Motor Function Post-stroke|Completed||Phase 1/Phase 2|11|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 02:57:43.426138|2018-06-01 02:57:43.426138
NCT00523510|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2012-02-13|2007-08-30|2007-08-31|Estimate|||||||2012-02-13|2012-02-14|Estimate|March 2008||2008-03-31|February 2012|2012-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|Flash-heat||Feasibility and Pilot Efficacy of Flash-heated Breast Milk to Reduce Maternal-to-Child-Transmission of HIV in Tanzania|Feasibility and Pilot Efficacy of Flash-heated Breast Milk for Reduction of Maternal-to-Child Transmission of HIV in Tanzania|Completed||N/A|144|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 02:57:43.524197|2018-06-01 02:57:43.524197
NCT00523146|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2010-02-02|2007-08-29|2007-08-31|Estimate|||||||2010-02-02|2010-02-03|Estimate|April 2007||2007-04-30|February 2010|2010-02-28|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Treatment of Primary Menstrual Pain With Kanion Capsule|Treatment of Primary Dysmenorrhea With Kanion Capsule (GF) A Randomized, Double-blind, Placebo-controlled, Repeated-Dose and Multi-Center Clinical Phase II Trial|Completed||Phase 2|||Lianyungang Kanion Group, Ltd.|||||f||||t||||||||||2018-06-01 02:57:50.449515|2018-06-01 02:57:50.449515
NCT00523497|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-08-30|2007-08-30|2007-08-31|Estimate|||||||2007-08-30|2007-08-31|Estimate||||August 2007|2007-08-31||||||||Interventional|NIMV AND SCAP||Efects of Noninvasive Mechanical Ventilation and Conventional Mechanical Ventilation in Patients With Severe Comunity Pneumonia|Noninvasive Mechanical Ventilation in Severe Community-Acquired Pneumonia and Acute Hypoxemic Respiratory Failure. A Prospective, Randomized and Controlled Study|Terminated||N/A|||Hospital Privado del Sur||||"Interim analysis of the present study showed a significant decrease in mortality rate (p= 0.04)~   as well as in the number of days at the ICU p=0.0002."|f||||t||||||||||2018-06-01 02:57:43.614178|2018-06-01 02:57:43.614178
NCT00523484|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2010-01-25|2007-08-30|2007-08-31|Estimate|||||||2010-01-25|2010-01-26|Estimate|May 2007||2007-05-31|January 2010|2010-01-31||||November 2008|Actual|2008-11-30||Observational|CHAMPION||Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts|An Observational Study to Assess Correlation Between Prostate Specific Antigen & Beck Anxiety Index in Prostate Cancer Patients Under Hormonal Therapy|Completed|||1200|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:43.679798|2018-06-01 02:57:43.679798
NCT00523471|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2016-02-24|2007-08-30|2007-08-31|Estimate|||||||2016-02-24|2016-02-26|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Blood Test to Measure DNA Damage in Blood|Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity|Terminated|||40|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 02:57:43.738673|2018-06-01 02:57:43.738673
NCT00523458|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2011-07-20|2007-08-29|2007-08-31|Estimate|||||||2011-07-20|2011-07-22|Estimate|July 2007||2007-07-31|July 2011|2011-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|OPTI-NNRTI||A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV||Terminated||Phase 4|5|Actual|Stanford University||4||"A delay in protocol approval and approval of laboratory sites in Salvador, Brazil left too~   little time for completion of enrollment into the study."|f||||t||||||||||2018-06-01 02:57:43.807458|2018-06-01 02:57:43.807458
NCT00523445|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2009-08-03|2007-08-30|2007-08-31|Estimate|||||||2009-08-03|2009-08-06|Estimate|September 2007||2007-09-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia|Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial|Completed||Phase 3|120|Anticipated|Inje University||2|||f||||t||||||||||2018-06-01 02:57:43.951137|2018-06-01 02:57:43.951137
NCT00523432|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2013-09-04|2007-08-29|2007-08-31|Estimate|||||||2013-09-04|2013-09-05|Estimate|August 2007||2007-08-31|September 2013|2013-09-30|December 2010|Actual|2010-12-31|September 2009|Actual|2009-09-30||Interventional|||A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies|A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies|Completed||Phase 1|15|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:57:44.047223|2018-06-01 02:57:44.047223
NCT00523419|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|2010-06-23||2011-06-24|2007-08-29|2007-08-31|Estimate|2010-08-31|2010-09-21|Estimate||||2011-06-24|2011-06-28|Estimate|September 2007||2007-09-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Chemotherapy for Patients With Osteosarcoma|Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas|Completed||Phase 2|32|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:57:44.133259|2018-06-01 02:57:44.133259
NCT00523406|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2013-05-02|2007-08-30|2007-08-31|Estimate|||||||2013-05-02|2013-05-03|Estimate|August 2005||2005-08-31|May 2013|2013-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Comparison of Reduced Fluence Versus Standard Photodynamic Therapy (in Combination With Intravitreal Triamcinolone Acetate)||Completed||Phase 3|40|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 02:57:44.544236|2018-06-01 02:57:44.544236
NCT00523393|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-02-12|2007-08-29|2007-08-31|Estimate|||||||2009-02-12|2009-02-13|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|December 2009|Anticipated|2009-12-31||Interventional|||Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells|Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells in Patients With Type 2 Diabetes: a Partially Double-Blind, Randomized, Three-Arm Unicenter Study|Unknown status|Recruiting|Phase 4|75|Anticipated|Heidelberg University||3|||f||||f||||||||||2018-06-01 02:57:44.615901|2018-06-01 02:57:44.615901
NCT00523380|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2017-02-28|2007-08-30|2007-08-31|Estimate|||||||2017-02-28|2017-03-01|Actual|October 4, 2007|Actual|2007-10-04|February 2017|2017-02-28|January 7, 2009|Actual|2009-01-07|January 7, 2009|Actual|2009-01-07||Interventional|||Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer|An Open-Label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients With Persistent or Progressive Disease After, or Relapse Within One Year of, Completion of Standard First Line Therapy|Completed||Phase 2|10|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 02:57:44.69266|2018-06-01 02:57:44.69266
NCT00523367|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2012-03-08||2013-01-15|2007-08-30|2007-08-31|Estimate|2012-06-18|2012-07-24|Estimate||||2013-01-15|2013-01-18|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|GERD/COPD||COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI|COPD Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole)|Terminated||N/A|25|Actual|University of Florida||1||terminated due to enrollment|f||||t||||||||||2018-06-01 02:57:44.799592|2018-06-01 02:57:44.799592
NCT00523354|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2009-04-06|2007-08-30|2007-08-31|Estimate|||||||2009-04-06|2009-04-07|Estimate|August 2007||2007-08-31|April 2009|2009-04-30|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|IEE||Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis|Phase 2 Proof-of-Concept Study to Analyze the Efficacy of in TNF-Alpha Blockade in Adult Patients With Severe, Corticosteroid-Dependent Eosinophilic Esophagitis|Completed||Phase 2|||Swiss EE Study Group||1|||f||||t||||||||||2018-06-01 02:57:44.970033|2018-06-01 02:57:44.970033
NCT00523341|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|2016-06-01||2017-02-09|2007-08-30|2007-08-31|Estimate|2016-06-01|2016-07-12|Estimate||||2017-02-09|2017-03-17|Actual|August 2007||2007-08-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis|Completed||Phase 3|4550|Actual|Amgen||1|||f||||f||||||||||2018-06-01 02:57:45.178118|2018-06-01 02:57:45.178118
NCT00523133|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-08-30|2007-08-30|2007-08-31|Estimate|||||||2007-08-30|2007-08-31|Estimate|September 2000||2000-09-30|August 2007|2007-08-31|July 2005|Actual|2005-07-31|||||Interventional|RITA||Research on Individualized Treatment for Alcoholism|Posttreatment Effects of Naltrexone|Completed||Phase 2|185|Actual|Indiana University|||||f||||t||||||||||2018-06-01 02:57:50.509687|2018-06-01 02:57:50.509687
NCT00523328|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17||2015-12-17|2015-12-17|2007-08-29|2007-08-31|Estimate||||2015-12-17|2016-01-21|Estimate|2015-12-17|2016-01-21|Estimate|August 2007||2007-08-31|December 2015|2015-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)|An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects With Rheumatoid Arthritis Who Previously Participated in Study 104RA203|Terminated||Phase 2|72|Actual|Biogen||1||Analysis of data from 104RA203 failed to meet primary endpoint.|f||||t||||||||||2018-06-01 02:57:49.065288|2018-06-01 02:57:49.065288
NCT00523315|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2011-05-19|2007-08-30|2007-08-31|Estimate|||||||2011-05-19|2011-05-20|Estimate|May 2007||2007-05-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|APOLLO||APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)|A Prospective Observational Study of Compliance in the Patients Receiving Aromatase Inhibitor as an Adjuvant Therapy in Postmenopausal Early Breast Cancer|Completed|||862|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 02:57:49.146712|2018-06-01 02:57:49.146712
NCT00523302|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2012-01-24|2007-08-30|2007-08-31|Estimate|||||||2012-01-24|2012-01-25|Estimate|July 2007||2007-07-31|January 2012|2012-01-31||||||||Interventional|||A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia|A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia|Completed||N/A|20|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 02:57:49.213397|2018-06-01 02:57:49.213397
NCT00523289|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-02-18|2007-08-29|2007-08-31|Estimate|||||||2009-02-18|2009-02-19|Estimate|October 2007||2007-10-31|February 2009|2009-02-28|July 2009|Anticipated|2009-07-31|March 2009|Anticipated|2009-03-31||Interventional|||Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block||Unknown status|Active, not recruiting|Phase 4|48|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 02:57:49.29071|2018-06-01 02:57:49.29071
NCT00523276|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2013-04-25|2007-08-30|2007-08-31|Estimate|||||||2013-04-25|2013-04-29|Estimate||||April 2011|2011-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Observational|||SARS Survivor Evaluations|Immune Responses, Transmission and Nucleotide Polymorphisms in Families With SARS Virus Infections|Withdrawn|||0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||||||||Samples With DNA|"~     Sera, PBMCs~   "|||2018-06-01 02:57:49.350547|2018-06-01 02:57:49.350547
NCT00523263|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-08-30|2007-08-30|2007-08-31|Estimate|||||||2007-08-30|2007-08-31|Estimate|January 1996||1996-01-31|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|DaDa||Dacron vs Dardik for Fem-Pop Bypass|Heparin Bonded and Collagen Coated Polyester or Human Umbilical Vein for Femoropopliteal Bypass: a Prospective Randomised Multicentre Trial.|Completed||Phase 3|||Radboud University||2|||f||||f||||||||||2018-06-01 02:57:49.405494|2018-06-01 02:57:49.405494
NCT00523250|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30||2014-02-17|2014-04-18|2007-08-30|2007-08-31|Estimate||||2014-03-25|2014-04-21|Estimate|2014-04-18|2014-05-08|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Ocular Hypotensive Efficacy of AR-102|A Phase II, First-in-human Dose-escalation, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-102 in Subjects With Elevated Intraocular Pressure|Completed||Phase 2|82|Actual|Aerie Pharmaceuticals||5|||f||||f||||||||||2018-06-01 02:57:49.572839|2018-06-01 02:57:49.572839
NCT00523237|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|2011-07-20||2011-10-31|2007-08-30|2007-08-31|Estimate|2011-09-20|2011-10-28|Estimate||||2011-10-31|2011-11-02|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||RAL-eve Study: Raltegravir Substitution Study|Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study|Completed||N/A|14|Actual|Stanford University|||||f||||f||||||||||2018-06-01 02:57:49.67585|2018-06-01 02:57:49.67585
NCT00523224|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2007-08-30|2007-08-30|2007-08-31|Estimate|||||||2007-08-30|2007-08-31|Estimate|January 2006||2006-01-31|May 2007|2007-05-31|September 2007|Anticipated|2007-09-30|||||Interventional|||ACPs Combined With CABG in Patients With CHF|A Study of Combined Coronary Artery Bypass Grafting (CABG) and Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Congestive Heart Failure Due to Ischemic Heart Disease|Unknown status|Recruiting|Phase 1|5|Anticipated|TheraVitae Ltd.||1|||f||||t||||||||||2018-06-01 02:57:49.900809|2018-06-01 02:57:49.900809
NCT00523211|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2015-09-24|2007-08-30|2007-08-31|Estimate|||||||2015-09-24|2015-09-25|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|June 2009|Actual|2009-06-30||Interventional|||Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)|Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E3)|Completed||Phase 3|506|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:57:49.990003|2018-06-01 02:57:49.990003
NCT00523198|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2014-12-02|2007-08-30|2007-08-31|Estimate|||||||2014-12-02|2014-12-04|Estimate|February 2007||2007-02-28|December 2014|2014-12-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Observational|||Correlation Salivary Cortisol and Free Serum Cortisol to Total Serum Cortisol in MICU Septic Shock|Correlation Between Salivary Cortisol and Free Serum Cortisol Compared to Total Serum Cortisol in MICU Patients With Septic Shock|Completed|||60|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-06-01 02:57:50.06321|2018-06-01 02:57:50.06321
NCT00523185|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2007-08-29|2007-08-29|2007-08-31|Estimate|||||||2007-08-29|2007-08-31|Estimate|May 2003||2003-05-31|August 2007|2007-08-31|November 2004|Actual|2004-11-30|||||Interventional|||A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal|A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal|Completed||N/A|55|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 02:57:50.131966|2018-06-01 02:57:50.131966
NCT00523172|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2010-07-16|2007-08-30|2007-08-31|Estimate|||||||2010-07-16|2010-07-19|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|January 2010|Actual|2010-01-31||Interventional|||Clinical Assessment of Two Manipulative Protocols in Treatment of Hip Osteoarthritis|A Randomized Clinical Trial Comparing Two Manipulative Protocols to Assess Changes in Pain, ROM, Quality of Life, Cost and Risk for Falls in Subjects With Hip Osteoarthritis|Unknown status|Active, not recruiting|Early Phase 1|120|Anticipated|Cleveland Chiropractic College||3|||f||||f||||||||||2018-06-01 02:57:50.237621|2018-06-01 02:57:50.237621
NCT00523159|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-30|||2012-07-09|2007-08-30|2007-08-31|Estimate|||||||2012-07-09|2012-07-10|Estimate|May 2007||2007-05-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|IMA901-202||IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease|Phase 2, Randomized, Open Label, Multicenter Study of Intradermal IMA901 Plus GM-CSF With or Without Low Dose Cyclophosphamide Pre-treatment in Advanced Renal Cell Carcinoma Patients With Measurable Disease|Completed||Phase 2|68|Actual|immatics Biotechnologies GmbH||2|||f||||t||||||||||2018-06-01 02:57:50.327169|2018-06-01 02:57:50.327169
NCT00069199|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-17|||2008-03-03|2003-09-17|2003-09-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2003||2003-09-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Optical Coherence Tomography Comparative Study|Optical Coherence Tomography Comparative Study|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:10.080483|2018-06-01 05:17:10.080483
NCT00523107|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2015-11-03|2007-08-28|2007-08-30|Estimate|||||||2015-11-03|2015-11-04|Estimate|August 2007||2007-08-31|June 2009|2009-06-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care|PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care|Completed||Phase 2/Phase 3|91|Actual|PhytoHealth Corporation||2|||f||||f||||||||||2018-06-01 02:57:50.86858|2018-06-01 02:57:50.86858
NCT00523094|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-06-15|2007-08-29|2007-08-30|Estimate|||||||2009-06-15|2009-06-16|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|July 2008|Anticipated|2008-07-31|||||Observational|||Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure|Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure|Suspended|||75|Anticipated|Deep Breeze||||Enrollment was too slow and principal investigator moved to another country|f||||f||||||||||2018-06-01 02:57:50.939469|2018-06-01 02:57:50.939469
NCT00523081|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2014-01-30|2007-08-29|2007-08-30|Estimate|||||||2014-01-30|2014-02-03|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|January 2014|Actual|2014-01-31|March 2012|Actual|2012-03-31||Interventional|STAND||Study of Adolescence and Depression|Brief, Primary Care Cognitive Behavioral Therapy (CBT) for Unmedicated Youth|Completed||Phase 3|212|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 02:57:51.004121|2018-06-01 02:57:51.004121
NCT00523068|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2007-11-06|2007-08-29|2007-08-30|Estimate|||||||2007-11-06|2007-11-07|Estimate|September 2007||2007-09-30|August 2007|2007-08-31|January 2010|Anticipated|2010-01-31|||||Interventional|||Pharmacological vs Surgical Treatment for Mixed Incontinence|Randomized Pilot Study on the Treatment of Mixed Urinary Incontinence: Pharmacological Treatment (Tolterodine SR) vs Surgery With Tension Free Vaginal Tape|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Imperial College London||2|||f||||f||||||||||2018-06-01 02:57:51.087388|2018-06-01 02:57:51.087388
NCT00523055|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2017-05-09|2007-08-28|2007-08-30|Estimate|||||||2017-05-09|2017-05-10|Actual|May 2008||2008-05-31|April 2011|2011-04-30||||April 2012|Actual|2012-04-30||Interventional|||Ultrasound-guided Supraclavicular Brachial Plexus Blockade|Ultrasound-guided Supraclavicular Brachial Plexus Blockade: A Pharmacokinetic Study of Lidocaine and Adrenaline|Terminated||N/A|10|Actual|University of Manitoba||||Clinical volume of patients for recruitment stopped.|f||||t||||||||||2018-06-01 02:57:51.15901|2018-06-01 02:57:51.15901
NCT00523042|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2017-02-28|2007-08-29|2007-08-30|Estimate|||||||2017-02-28|2017-03-01|Actual|August 30, 2007|Actual|2007-08-30|February 2017|2017-02-28|February 28, 2008|Actual|2008-02-28|February 28, 2008|Actual|2008-02-28||Interventional|iINHALE 9||Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma|Inhaled Preprandial Human Insulin With the AERx® iMS Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Asthma: A 52-week, Open-label, Multinational, Randomised, Parallel Trial to Investigate Long-term Safety|Terminated||Phase 3|10|Actual|Novo Nordisk A/S||2||See termination reason in detailed description|f||||f||||||||||2018-06-01 02:57:51.244469|2018-06-01 02:57:51.244469
NCT00523029|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2013-12-09|2007-08-28|2007-08-30|Estimate|||||||2013-12-09|2013-12-10|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Developing a Self-Management Program for People With Depression and Chronic Medical Illness|Self-Management of Depression and Medical Illness|Completed||N/A|104|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 02:57:51.42391|2018-06-01 02:57:51.42391
NCT00523016|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2013-05-20|2007-08-29|2007-08-30|Estimate|||||||2013-05-20|2013-05-22|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|APSCI||Acupuncture Treatment to Reduce Burning Pain in Spinal Cord Injury|A Pilot Study Investigating the Feasibility of Using Acupuncture Treatment to Reduce Below-Level Neuropathic Pain in Spinal Cord Injury.|Completed||N/A|33|Actual|Toronto Rehabilitation Institute||2|||f||||t||||||||||2018-06-01 02:57:51.493782|2018-06-01 02:57:51.493782
NCT00523003|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2008-10-16|2007-08-28|2007-08-30|Estimate|||||||2008-10-16|2008-10-17|Estimate|May 2004||2004-05-31|October 2008|2008-10-31|March 2006|Actual|2006-03-31|||||Interventional|||A Controlled Trial of Protein Enrichment of Meal Replacements for Weight Reduction With Retention of Lean Body Mass|A Controlled Trial of Protein Enrichment of Meal Replacements for Weight Reduction With Retention of Lean Body Mass|Completed||N/A|100|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 02:57:51.5884|2018-06-01 02:57:51.5884
NCT00522990|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29||2016-01-08|2016-01-08|2007-08-29|2007-08-30|Estimate||||2016-01-08|2016-02-05|Estimate|2016-01-08|2016-02-05|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias|A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies|Terminated||Phase 1/Phase 2|48|Actual|Astex Pharmaceuticals||1||Recommended Phase II dose determined|f||||f||||||||||2018-06-01 02:57:51.663492|2018-06-01 02:57:51.663492
NCT00522977|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2008-02-25|2007-08-29|2007-08-30|Estimate|||||||2008-02-25|2008-02-29|Estimate|August 2007||2007-08-31|February 2008|2008-02-29|September 2009|Anticipated|2009-09-30|||||Observational|||Echo-Cardiographic Assessment of Cardiovascular Characteristics During Pregnancy and Postpartum Periods||Unknown status|Recruiting||400|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-06-01 02:57:51.740012|2018-06-01 02:57:51.740012
NCT00522964|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2009-08-16|2007-08-29|2007-08-30|Estimate|||||||2009-08-16|2009-08-18|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ABC||Educational Intervention on Weight Management in Chinese-American Children|Educational Intervention on Weight Management in Chinese American Children|Completed||Phase 3|80|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 02:57:51.80557|2018-06-01 02:57:51.80557
NCT00522951|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|2011-07-05||2017-07-28|2007-08-29|2007-08-30|Estimate|2011-07-05|2011-08-03|Estimate||||2017-07-28|2017-08-28|Actual|August 2007||2007-08-31|July 2017|2017-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study|Multi-center, Randomized, Controlled, Single-blind, Intra-individual Comparisons of 2 Dose of Gadobutrol 1.0 Molar and Gadoteridol (ProHance) Crossover Studies With Corresponding Blinded Image Evaluation Following Multiple Injections of 0.1 mmol/kg bw of Gadobutrol and Gadoteridol in Patients With Known or Suspected Brain Metastasis|Completed||Phase 3|165|Actual|Bayer||3|||f||||f||||||||||2018-06-01 02:57:51.904786|2018-06-01 02:57:51.904786
NCT00522938|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2012-06-27|2007-08-29|2007-08-30|Estimate|||||||2012-06-27|2012-06-28|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase I-II, Multicenter, Open-label Trial of Co-administered CHR-2797 and Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|Terminated||Phase 1/Phase 2|2|Actual|Chroma Therapeutics||||Very poor recruitment of patients to the study|f||||t||||||||||2018-06-01 02:57:52.470548|2018-06-01 02:57:52.470548
NCT00522925|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|2010-01-18||2011-09-13|2007-08-29|2007-08-30|Estimate|2011-08-10|2011-09-14|Estimate||||2011-09-13|2011-09-16|Estimate|August 2007||2007-08-31|September 2011|2011-09-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension|Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin and Endothelin Receptor Antagonist (PS433540) in Subjects With Stage I and II Hypertension|Completed||Phase 2|280|Actual|Ligand Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:57:52.543456|2018-06-01 02:57:52.543456
NCT00522912|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2012-01-11|2007-08-28|2007-08-30|Estimate|||||||2012-01-11|2012-01-12|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Trial of Epilation Verses Surgery for Minor Trichiasis|A Randomised Controlled Trial of Epilation Verses Immediate Surgery for the Management of Minor Trachomatous Trichiasis|Completed||N/A|1300|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 02:57:52.832737|2018-06-01 02:57:52.832737
NCT00522899|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2012-04-06|2007-08-29|2007-08-30|Estimate|||||||2012-04-06|2012-04-09|Estimate|August 2007||2007-08-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|MAX||The Mental Activity and eXercise Trial for Seniors|The Effects of Mental Activity and Exercise on Cognitive Function in Older Adults Who Self-Report a Recent Decline in Memory or Thinking|Completed||N/A|126|Actual|University of California, San Francisco||4|||f||||t||||||||||2018-06-01 02:57:52.960267|2018-06-01 02:57:52.960267
NCT00522886|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2011-07-18|2007-08-29|2007-08-30|Estimate|||||||2011-07-18|2011-07-19|Estimate|April 2007||2007-04-30|July 2011|2011-07-31||||July 2011|Actual|2011-07-31||Interventional|||Phase I Cetuximab and Concurrent Radio-chemotherapy|Determination of the Toxicity of Standard Dose Cetuximab Together With Concurrent Individualised, Isotoxic Accelerated Radiotherapy and Cisplatin-vinorelbine for Patients With Stage III Non-small Cell Lung Cancer: A Phase I Study|Completed||Phase 1|24|Anticipated|Maastricht Radiation Oncology|||||f||||t||||||||||2018-06-01 02:57:53.13238|2018-06-01 02:57:53.13238
NCT00522873|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|2012-03-23|2010-09-21|2014-12-10|2007-08-29|2007-08-30|Estimate|2012-05-24|2012-06-28|Estimate|2010-09-21|2010-09-24|Estimate|2014-12-10|2014-12-31|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Endometrial Safety Study|A Double-blind, Randomized, Multi-center Study to Investigate the Endometrial Safety of a Continuous, Combined, Oral Estrogen/Progestin Preparation (17b-estradiol [E2] / Drospirenone [DRSP]) and to Compare the Bleeding Pattern of Subjects Treated With E2 / DRSP With the Bleeding Pattern of Subjects Treated With E2 / Norethisterone Acetate (NETA) When Used for Hormone Therapy (HT) for 1 Year in Post-menopausal Women|Completed||Phase 3|662|Actual|Bayer||2|||f||||f||||||||||2018-06-01 02:57:53.234241|2018-06-01 02:57:53.234241
NCT00522860|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2012-01-11|2007-08-28|2007-08-30|Estimate|||||||2012-01-11|2012-01-12|Estimate|March 2008||2008-03-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery|A Randomised Controlled Trial of Non-absorbable (Silk) Sutures Verses Absorbable (Vicryl) Sutures During the Surgical Treatment of Trachomatous Trichiasis|Completed||Phase 4|1300|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 02:57:53.72723|2018-06-01 02:57:53.72723
NCT00522847|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-02-12|2007-08-29|2007-08-30|Estimate|||||||2009-02-12|2009-02-16|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|GARNET||Biochemical Factors for a Dry Eyed Population|Biochemical Factors for a Dry Eyed Population|Completed|||40|Actual|University of Waterloo|||||f||||f||||||Samples Without DNA|"~     Tears~   "|||2018-06-01 02:57:53.804463|2018-06-01 02:57:53.804463
NCT00522834|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28||2014-01-31|2014-01-31|2007-08-29|2007-08-30|Estimate||||2014-01-31|2014-03-04|Estimate|2014-01-31|2014-03-04|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma|A Randomized, Double-blind, Phase 3 Trial of Elesclomol (STA-4783) in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects With Stage IV Metastatic Melanoma (SYMMETRY)|Terminated||Phase 3|630|Actual|Synta Pharmaceuticals Corp.||2|||f||||t||||||||||2018-06-01 02:57:53.941368|2018-06-01 02:57:53.941368
NCT00522821|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2015-04-03|2007-08-29|2007-08-30|Estimate|||||||2015-04-03|2015-04-06|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Subklasse||Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response|Treatment in Patients With Recurrent Infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response|Completed||Phase 4|55|Actual|Sanquin||2|||f||||f||||||||||2018-06-01 02:57:54.154208|2018-06-01 02:57:54.154208
NCT00522808|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2008-09-26|2007-08-29|2007-08-30|Estimate|||||||2008-09-26|2008-09-29|Estimate|August 2007||2007-08-31|September 2008|2008-09-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|CP104||A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers|A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease|Terminated||Phase 1/Phase 2|36|Anticipated|Arrow Therapeutics||||Need for re-formulation|f||||t||||||||||2018-06-01 02:57:54.27383|2018-06-01 02:57:54.27383
NCT00522795|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2013-05-21||2014-06-26|2007-08-29|2007-08-30|Estimate|2013-07-09|2013-08-22|Estimate||||2014-06-26|2014-07-11|Estimate|August 2007||2007-08-31|June 2014|2014-06-30|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)|BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001|Completed||Phase 2|40|Actual|Brown University||1|||f||||t||||||||||2018-06-01 02:57:54.353353|2018-06-01 02:57:54.353353
NCT00522782|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2009-01-22|2007-08-28|2007-08-30|Estimate|||||||2009-01-22|2009-01-23|Estimate|August 2007||2007-08-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children|Phase IV Study of the Effect of Nebulized Budesonide on Exhaled Nitric Oxide in Children, Four to Six Years of Age, With Asthma|Completed||Phase 4|16|Actual|AAADRS Clinical Research Center||1|||f||||t||||||||||2018-06-01 02:57:54.568641|2018-06-01 02:57:54.568641
NCT00522769|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2010-02-12|2007-08-29|2007-08-30|Estimate|||||||2010-02-12|2010-02-15|Estimate|September 2005||2005-09-30|February 2010|2010-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|claire||Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents|Development of CBT Model for Adolescent Bulimia Nervosa|Completed||Phase 1/Phase 2|26|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 02:57:54.647879|2018-06-01 02:57:54.647879
NCT00522223|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2017-10-23|2007-08-28|2007-08-29|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2002|Actual|2002-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Sexual Functioning in Cervical Cancer Survivors|Sexual Functioning and Quality of Life in Women With Cervical Cancer|Active, not recruiting|||165|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:58:03.223036|2018-06-01 02:58:03.223036
NCT00522756|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2012-10-22|2007-08-29|2007-08-30|Estimate|||||||2012-10-22|2012-10-24|Estimate|May 2006||2006-05-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|PARACHUTE||Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy|Preventing Acute Renal Failure After Cardiac Surgery in High Risk Patients Using Sodium Bicarbonate Therapy (PARACHUTE) - Pilot Study|Unknown status|Recruiting|Phase 3|200|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-06-01 02:57:54.734297|2018-06-01 02:57:54.734297
NCT00522743|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2010-07-13|2007-08-29|2007-08-30|Estimate|||||||2010-07-13|2010-07-14|Estimate|May 2005||2005-05-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Growth and Metabolic Response to GH and GnRHa Treatment Versus GH Alone in Boys Born SGA.|Two Arms, Open, Controlled, Prospective, Intervention Study to Evaluate the Growth and Metabolic Response to Growth Hormone and Gonadotropin-releasing Hormone Agonist Treatment Versus Growth Hormone Alone in Boys Born SGA|Completed||N/A|17|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 02:57:54.818048|2018-06-01 02:57:54.818048
NCT00522730|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-09-02|2007-08-29|2007-08-30|Estimate|||||||2009-09-02|2009-09-03|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|SELLIFA||Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure|Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition.|Completed||Phase 4|45|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-06-01 02:57:54.878799|2018-06-01 02:57:54.878799
NCT00522717|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2015-11-30|2007-08-29|2007-08-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2005||2005-07-31|November 2015|2015-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Enhancing Recovery After Cardiac Surgery|Enhancing Recovery After Cardiac Surgery|Completed||N/A|808|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 02:57:54.964778|2018-06-01 02:57:54.964778
NCT00522704|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2014-11-04|2007-08-29|2007-08-30|Estimate|||||||2014-11-04|2014-11-06|Estimate|March 2008||2008-03-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Observational|||Correlation Between Access Blood Flow and Extracorporeal Blood Flow|Correlation Between Access Blood Flow and Extracorporeal Blood Flow|Unknown status|Recruiting||30|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez|||||f||||t||||||||||2018-06-01 02:57:55.027366|2018-06-01 02:57:55.027366
NCT00522691|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2015-06-23|2007-08-28|2007-08-30|Estimate|||||||2015-06-23|2015-06-24|Estimate|September 2007||2007-09-30|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SNStest||Efficacy of Sacral Nerve Stimulation Before Definitive Implantation|Efficacy of Sacral Nerve Stimulation Before Definitive Implantation: a Multicenter Randomized, Double Blind, Crossover Trial|Withdrawn||N/A|0|Actual|University of Lausanne Hospitals||2||slow recruitment|f||||t||||||||||2018-06-01 02:57:55.092452|2018-06-01 02:57:55.092452
NCT00522678|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2017-08-02|2007-08-28|2007-08-30|Estimate|||||||2017-08-02|2017-08-04|Actual|February 15, 2007|Actual|2007-02-15|August 2017|2017-08-31|April 25, 2007|Actual|2007-04-25|April 25, 2007|Actual|2007-04-25||Interventional|||Repeat Dose GW685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Volunteers|A Randomised, Double Blind, Placebo Controlled, Parallel Group, 14 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled GW685698X Containing Magnesium Stearate in Healthy Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:57:55.17496|2018-06-01 02:57:55.17496
NCT00522665|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2015-05-14|2007-08-28|2007-08-30|Estimate|||||||2015-05-14|2015-05-15|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|May 2011|Actual|2011-05-31||Interventional|||Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer|Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102|Completed||Phase 1/Phase 2|41|Actual|Hoosier Cancer Research Network||2|||f||||t||||||||||2018-06-01 02:57:55.263416|2018-06-01 02:57:55.263416
NCT00522652|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2018-05-14|2007-08-29|2007-08-30|Estimate|||||||2018-05-14|2018-05-17|Actual|August 2007||2007-08-31|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase I Trial of PX-478|A Phase 1 Trial of Oral PX-478 (a HIF-1α Inhibitor) in Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|45|Anticipated|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 02:57:55.37727|2018-06-01 02:57:55.37727
NCT00522639|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-06-29|2007-08-29|2007-08-30|Estimate|||||||2009-06-29|2009-06-30|Estimate|October 2008||2008-10-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|||||Interventional|FDG-PET lung||Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation|Determination of the Predictive Value of FDG-PET-CT Scans, Blood Proteins and Blood Cells for the Prognosis for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation|Terminated||Phase 3|120|Anticipated|Maastricht Radiation Oncology||||Poor accrual|f||||f||||||||||2018-06-01 02:57:55.428599|2018-06-01 02:57:55.428599
NCT00522626|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|2012-04-25||2016-02-29|2007-08-29|2007-08-30|Estimate|2014-04-17|2014-05-16|Estimate||||2016-02-29|2016-03-01|Estimate|August 2006||2006-08-31|February 2013|2013-02-28|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Observational|||Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment|Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment|Completed|||19|Actual|Johns Hopkins University|Difficulty in recruiting leading to small number of subjects analyzed||1||f||||f||||||||||2018-06-01 02:57:55.584761|2018-06-01 02:57:55.584761
NCT00522613|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-02-03|2007-08-29|2007-08-30|Estimate|||||||2009-02-03|2009-02-04|Estimate|July 2005||2005-07-31|September 2006|2006-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Recovery Group Pilot|Recovery Group Pilot|Completed||N/A|50|Actual|Kaiser Permanente|||||f||||f||||||||||2018-06-01 02:57:55.736104|2018-06-01 02:57:55.736104
NCT00522600|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-29|||2009-07-21|2007-08-29|2007-08-30|Estimate|||||||2009-07-21|2009-07-22|Estimate|February 2007||2007-02-28|July 2009|2009-07-31|July 2007|Actual|2007-07-31|||||Observational|||Eye Drop Use in Glaucoma Patients Through Patient Surveys and Video Observations|Evaluation of Eye Drop Administration in Glaucoma Patients|Completed|||200|Actual|Robin, Alan L., M.D.|||||f||||f||||||||||2018-06-01 02:57:55.814585|2018-06-01 02:57:55.814585
NCT00522210|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2014-08-29|2007-08-28|2007-08-29|Estimate|||||||2014-08-29|2014-09-03|Estimate|March 2008||2008-03-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes|A Comparison of Insulin Detemir in a BID Insulin Regimen Versus a TID Insulin Regimen in Children With Type 1 Diabetes: A Randomized Controlled Trial|Completed||N/A|18|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 02:58:03.396705|2018-06-01 02:58:03.396705
NCT00522587|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2013-01-29|2007-08-27|2007-08-29|Estimate|||||||2013-01-29|2013-01-30|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|July 2009|Actual|2009-07-31||Interventional|||Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance|Sevoflurane-Remifentanil Interaction: Multiple Response Surfaces, Validation of Calibration Stimuli, Validation of the Intraoperative Isobole Concept and Investigating Remifentanil Induced Opioid Tolerance|Completed||Phase 2|40|Actual|University Hospital, Ghent||12|||f||||f||||||||||2018-06-01 02:57:55.982837|2018-06-01 02:57:55.982837
NCT00522574|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2011-04-04|2007-08-27|2007-08-29|Estimate|||||||2011-04-04|2011-04-05|Estimate|August 2007||2007-08-31|April 2011|2011-04-30||||||||Interventional|||A Safety Study of XL019 in Adults With Myelofibrosis|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Myelofibrosis|Terminated||Phase 1|100|Anticipated|Exelixis||||Due to emerging safety data|f||||t||||||||||2018-06-01 02:57:56.099744|2018-06-01 02:57:56.099744
NCT00522561|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2009-06-09|2007-08-28|2007-08-29|Estimate|||||||2009-06-09|2009-06-12|Estimate|January 2008||2008-01-31|June 2009|2009-06-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Lower Limb Mechanical Characteristics: Effect on Running Mechanics and Energetics|Lower Limb Mechanical Characteristics: Effect on Running Mechanics and Energetics|Completed||N/A|20|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 02:57:56.161337|2018-06-01 02:57:56.161337
NCT00522548|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2013-07-23||2017-12-20|2007-08-28|2007-08-29|Estimate|2017-12-20|2018-01-23|Actual||||2017-12-20|2018-01-23|Actual|March 2007||2007-03-31|December 2017|2017-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients|Gastrointestinal Adverse Effect Outcomes of De Novo African American Kidney Transplant Recipients Treated With Tacrolimus, Corticosteroids and Mycophenolate Mofetil or Enteric Coated Mycophenolate Sodium|Terminated||Phase 4|37|Actual|University of Pennsylvania|Limitations of our study include small sample size and patient drop out-though not significantly different between the MMF and EC-MPS groups and limited follow-up|2||enrollment halted in order to have all patients complete follow-up by Jan 2011|f||||f|t|f|||f|||No||2018-06-01 02:57:56.315392|2018-06-01 02:57:56.315392
NCT00522535|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2015-06-17|2007-08-28|2007-08-29|Estimate|||||||2015-06-17|2015-06-18|Estimate|April 2006||2006-04-30|June 2015|2015-06-30|January 2018|Anticipated|2018-01-31|September 2011|Actual|2011-09-30||Interventional|PYTHAGORAS||Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft|Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft|Unknown status|Active, not recruiting|N/A|210|Anticipated|Lombard Medical||3|||f||||t||||||||||2018-06-01 02:57:57.034327|2018-06-01 02:57:57.034327
NCT00522522|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2012-05-29|2007-08-27|2007-08-29|Estimate|||||||2012-05-29|2012-05-30|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy|Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy Until Being Confirmed (EPILIVE Study)|Completed|||400|Actual|UCB Pharma|||||f||||t||||||||||2018-06-01 02:57:57.168256|2018-06-01 02:57:57.168256
NCT00522509|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2007-08-28|2007-08-28|2007-08-29|Estimate|||||||2007-08-28|2007-08-29|Estimate|December 1995||1995-12-31|May 2007|2007-05-31||||||||Observational|||Preoperative Hepatic Arterial Infusion Chemotherapy|Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases|Unknown status|Active, not recruiting||||IRCCS San Raffaele|||||f||||||||||||||2018-06-01 02:57:57.214373|2018-06-01 02:57:57.214373
NCT00522496|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2009-02-20|2007-08-27|2007-08-29|Estimate|||||||2009-02-20|2009-02-24|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|August 2009|Anticipated|2009-08-31|||||Observational|||Proteomics of Severe Traumatic Brain Injury: A Feasibility Study|Proteomics of Severe Traumatic Brain Injury: A Feasibility Study|Unknown status|Recruiting||8|Anticipated|University of Calgary|||||f||||f||||||||||2018-06-01 02:57:57.264321|2018-06-01 02:57:57.264321
NCT00522470|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2008-05-07|2007-08-27|2007-08-29|Estimate|||||||2008-05-07|2008-05-09|Estimate||||May 2008|2008-05-31||||||||Interventional|||Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels|Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels in Diabetic Women|Completed||Phase 4|||Baskent University|||||f||||t||||||||||2018-06-01 02:57:57.324191|2018-06-01 02:57:57.324191
NCT00522457|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2011-03-01||2011-04-28|2007-08-28|2007-08-29|Estimate|2011-04-28|2011-04-29|Estimate||||2011-04-28|2011-04-29|Estimate|January 2008||2008-01-31|April 2011|2011-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy|Phase II Study Of The Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Overexpressing (3+ Or 2+/FISH+) Metastatic Breast Cancer Progressing After Trastuzumab Treatment|Terminated||Phase 2|19|Actual|Neovii Biotech|The study was prematurely terminated. This decision was based on strategic changes in the company's research and development program and resulted in limited patient data.|||change in development plan, not due to safety concerns.|f||||t||||||||||2018-06-01 02:57:57.390313|2018-06-01 02:57:57.390313
NCT00522444|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2014-02-05|2007-08-28|2007-08-29|Estimate|||||||2014-02-05|2014-02-06|Estimate|September 2007||2007-09-30|August 2007|2007-08-31||||||||Interventional|||Nebulized Magnesium Sulfate in Pediatric Asthma|Nebulized Magnesium Sulfate Compared to Saline in Addition to Albuterol and Ipratropium Treatments in Moderate to Severe Pediatric Asthmatic Patients: A Randomized Controlled Clinical Trial|Terminated||Phase 3|34|Actual|Children's Hospital Medical Center, Cincinnati||||institution in Canada is conducting a similar clinical trial with potential of validating use.|t||||t||||||||||2018-06-01 02:57:57.728498|2018-06-01 02:57:57.728498
NCT00522431|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2014-01-24||2017-09-07|2007-08-28|2007-08-29|Estimate|2014-01-24|2014-03-07|Estimate||||2017-09-07|2017-10-05|Actual|August 2007||2007-08-31|September 2017|2017-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||All enrolled participants|A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone|An Open Label Phase 3 Study of Fortigel Testosterone Gel 2% in Hypogonadal Males|Completed||Phase 3|149|Actual|Endo Pharmaceuticals||1|||f||||||||||||||2018-06-01 02:57:57.797281|2018-06-01 02:57:57.797281
NCT00522236|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2012-01-24|2007-08-28|2007-08-29|Estimate|||||||2012-01-24|2012-01-25|Estimate|June 2007||2007-06-30|January 2012|2012-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Elderly Subjects|Completed||Phase 2|56|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:58:03.154996|2018-06-01 02:58:03.154996
NCT00522418|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2010-04-02||2015-01-09|2007-08-27|2007-08-29|Estimate|2010-04-28|2010-05-17|Estimate||||2015-01-09|2015-01-26|Estimate|February 2006||2006-02-28|October 2012|2012-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||All participants who completed the baseline assessment and at least one postbaseline follow-up QOLIE-89 assessment, and met local IRB consent requirements|Study Comparing Best Medical Practice With or Without VNS Therapy in Pharmacoresistant Partial Epilepsy Patients|An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy|Terminated||Phase 4|122|Actual|Cyberonics, Inc.|This study was terminated as a result of a decision by Cyberonics, Inc. The decision to terminate the study was primarily due to insufficient enrollment. The decision was not the result of a safety or efficacy signal.|2||Insufficient enrollment|f||||t||||||||||2018-06-01 02:57:58.082644|2018-06-01 02:57:58.082644
NCT00522405|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2012-07-13|2007-08-27|2007-08-29|Estimate|||||||2012-07-13|2012-07-16|Estimate|October 2007||2007-10-31|August 2007|2007-08-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma||Unknown status|Recruiting|Phase 2/Phase 3|||All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 02:57:58.686642|2018-06-01 02:57:58.686642
NCT00522392|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2015-03-05||2015-06-23|2007-08-28|2007-08-29|Estimate|2015-06-23|2015-06-26|Estimate||||2015-06-23|2015-06-26|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|July 2014|Actual|2014-07-31|August 2012|Actual|2012-08-31||Interventional||All randomized patients.|Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone|Randomized Phase III Trial of Consolidation Therapy With Bortezomib (Velcade®)-Lenalidomide (Revlimid®) -Dexamethasone (VRD) Versus Bortezomib (Velcade®)-Dexamethasone (VD) for Patients With Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen|Terminated||Phase 3|48|Actual|National Cancer Institute (NCI)||2||Slow accrual|f||||t||||||||||2018-06-01 02:57:58.787279|2018-06-01 02:57:58.787279
NCT00522379|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2012-07-03||2014-10-17|2007-08-28|2007-08-29|Estimate|2012-12-07|2012-12-10|Estimate||||2014-10-17|2014-10-27|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch|A Multicenter, Randomized, Double-blind, Placebo-controlled, 5-arm, Parallel-group Trial to Assess Rotigotine Transdermal System Dose Response in Subjects With Advanced-stage Parkinson's Disease|Completed||Phase 3|514|Actual|UCB Pharma||5|||f||||f||||||||||2018-06-01 02:58:00.567703|2018-06-01 02:58:00.567703
NCT00522353|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2008-05-21|2007-08-27|2007-08-29|Estimate|||||||2008-05-21|2008-05-23|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults|Effect of Oligofructose Versus Placebo on Body Weight and Satiety Hormone Secretion in Overweight and Obese Adults.|Completed||N/A|48|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 02:58:01.967902|2018-06-01 02:58:01.967902
NCT00522340|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2014-11-07|2007-08-27|2007-08-29|Estimate|||||||2014-11-07|2014-11-10|Estimate|November 2007||2007-11-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Exercise After an ICD|Anti-Arrhythmic Effects of Exercise After an Implantable Cardioverter Defibrillator (ICD)|Completed||Phase 2|160|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 02:58:02.056076|2018-06-01 02:58:02.056076
NCT00522327|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2015-07-02|2007-08-27|2007-08-29|Estimate|||||||2015-07-02|2015-07-07|Estimate|November 2004||2004-11-30|July 2015|2015-07-31|October 2006|Actual|2006-10-31|||||Interventional|RSMI||Remote Simultaneous Medical Interpreting and Medical Outcomes|Remote Simultaneous Medical Interpretation: Medical Outcomes|Completed||N/A|1200|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-06-01 02:58:02.118309|2018-06-01 02:58:02.118309
NCT00522314|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2007-08-28|2007-08-28|2007-08-29|Estimate|||||||2007-08-28|2007-08-29|Estimate|October 2003||2003-10-31|August 2007|2007-08-31|April 2006|Actual|2006-04-30|||||Interventional|||Airway Clearance in Bronchiectasis: is Non-Invasive Ventilation a Useful Adjunct in Moderate to Severe Disease?|Airway Clearance in Bronchiectasis: is Non-Invasive Ventilation a Useful Adjunct in Moderate to Severe Disease?A Pilot Study.|Completed||N/A|20|Actual|University of Ulster||2|||f||||t||||||||||2018-06-01 02:58:02.167078|2018-06-01 02:58:02.167078
NCT00522301|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2015-10-21||2016-02-01|2007-08-28|2007-08-29|Estimate|2016-02-01|2016-02-29|Estimate||||2016-02-01|2016-02-29|Estimate|July 2007||2007-07-31|February 2016|2016-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission|A Phase II Trial of Oral Sorafenib (Bay43-9006) In Women With Epithelial Ovarian, Fallopian Tube Or Peritoneal Carcinoma In Second Or Greater Remission|Terminated||Phase 2|6|Actual|Memorial Sloan Kettering Cancer Center|Early termination as it would not meet it's primary endpoint of improved survival. None of the patients completed the study.|1|||f||||||||||||||2018-06-01 02:58:02.226867|2018-06-01 02:58:02.226867
NCT00522288|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2011-03-17|2007-08-28|2007-08-29|Estimate|||||||2011-03-17|2011-03-21|Estimate|September 2003||2003-09-30|March 2011|2011-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|ACHIEVE||Effects of Contact Lens Wear on Children's Self-Perceptions|Adolescent and Child Health Initiative to Encourage Vision Empowerment (ACHIEVE) Study|Completed||N/A|484|Actual|Ohio State University||2|||f||||t||||||||||2018-06-01 02:58:02.436484|2018-06-01 02:58:02.436484
NCT00522275|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2010-10-28||2017-07-28|2007-08-27|2007-08-29|Estimate|2010-10-28|2010-11-22|Estimate||||2017-07-28|2017-08-28|Actual|October 2004||2004-10-31|July 2017|2017-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures|An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients With Partial Seizures|Completed||Phase 3|308|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 02:58:02.549945|2018-06-01 02:58:02.549945
NCT00522262|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2015-01-14|2007-08-27|2007-08-29|Estimate|||||||2015-01-14|2015-01-15|Estimate|June 2002||2002-06-30|January 2015|2015-01-31|July 2007|Actual|2007-07-31|June 2006|Actual|2006-06-30||Interventional|||Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial|Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial|Completed||N/A|320|Actual|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-06-01 02:58:02.966575|2018-06-01 02:58:02.966575
NCT00522249|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2016-03-15|2007-08-27|2007-08-29|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2007||2007-05-31|March 2016|2016-03-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC|A Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|10|Actual|The Methodist Hospital System||1||PI decision|f||||f||||||||No||2018-06-01 02:58:03.053913|2018-06-01 02:58:03.053913
NCT00522197|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2012-03-07|2007-08-28|2007-08-29|Estimate|||||||2012-03-07|2012-03-09|Estimate|September 2002||2002-09-30|March 2012|2012-03-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia|A Phase II Trial of ACAPHA in Former Smokers With Intraepithelial Neoplasia|Completed||Phase 2|90|Actual|British Columbia Cancer Agency||2|||f||||t||||||||||2018-06-01 02:58:03.472317|2018-06-01 02:58:03.472317
NCT00522184|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-08-27|2007-08-27|2007-08-29|Estimate|||||||2007-08-27|2007-08-29|Estimate|February 2005||2005-02-28|August 2007|2007-08-31|November 2006|Actual|2006-11-30|||||Interventional|||Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study|Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis|Completed||Phase 3|34|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||t||||||||||2018-06-01 02:58:03.549369|2018-06-01 02:58:03.549369
NCT00522171|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2009-10-19||2009-11-30|2007-08-28|2007-08-29|Estimate|2009-10-19|2009-11-20|Estimate||||2009-11-30|2009-12-09|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Observational|LBL||Harmonic Versus Electro Surgery in Lower Body Lift Procedures|A Randomized, Prospective, Parallel Group Study Comparing the Harmonic™ to Electro Surgery in Lower Body Lift Procedures|Terminated|||30|Actual|Ethicon Endo-Surgery|||1|This study was terminated early due to lack of adequate enrollment.|f||||f||||||||||2018-06-01 02:58:03.658913|2018-06-01 02:58:03.658913
NCT00522158|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-08-28|2007-08-28|2007-08-29|Estimate|||||||2007-08-28|2007-08-29|Estimate||||August 2007|2007-08-31||||||||Interventional|||Effects of Achieving Very Low LDL-Cholesterol After Treatment With Statins on Steroidogenesis and Cognition||Completed||Phase 4|||Baskent University|||||f||||t||||||||||2018-06-01 02:58:03.980198|2018-06-01 02:58:03.980198
NCT00522145|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27||2012-01-24|2012-01-24|2007-08-27|2007-08-29|Estimate||||2012-01-24|2012-01-30|Estimate|2012-01-24|2012-01-30|Estimate|May 2007||2007-05-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|||Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib|A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib|Completed||Phase 2|41|Actual|Kadmon Corporation, LLC||1|||f||||t||||||||||2018-06-01 02:58:04.022905|2018-06-01 02:58:04.022905
NCT00522132|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2011-09-15|2007-08-28|2007-08-29|Estimate|||||||2011-09-15|2011-09-16|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Phase II Artesunate Study in Severe Malaria|Phase II Randomized, Double-Blind Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous Artesunate in Children With Severe Malaria|Completed||Phase 2|200|Anticipated|Medicines for Malaria Venture||2|||f||||t||||||||||2018-06-01 02:58:04.16365|2018-06-01 02:58:04.16365
NCT00522119|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2017-03-29|2007-08-27|2007-08-29|Estimate|||||||2017-03-29|2017-03-31|Actual|August 2003|Actual|2003-08-31|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2006|Actual|2006-07-31||Observational|||Analysis of Genes That Predispose People to Develop High Blood Pressure|Genetic and Functional Analyses of Chromosome 1 Hypertension Susceptibility|Completed|||||University of Maryland|||||f||||f||||||||||2018-06-01 02:58:04.251397|2018-06-01 02:58:04.251397
NCT00522106|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2007-08-28|2007-08-28|2007-08-29|Estimate|||||||2007-08-28|2007-08-29|Estimate|May 2001||2001-05-31|August 2007|2007-08-31|May 2008|Anticipated|2008-05-31|||||Interventional|GRADIT||The Effectiveness of Behavioral Graded Activity in Patients With Osteoarthritis of the Hip and/or Knee|The Effectiveness of Behavioral Graded Activity in Patients With Osteoarthritis of the Hip and/or Knee: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|200|Actual|Netherlands Instititute for Health Services Research||2|||f||||f||||||||||2018-06-01 02:58:04.312087|2018-06-01 02:58:04.312087
NCT00522093|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2011-08-21|2007-08-27|2007-08-29|Estimate|||||||2011-08-21|2011-08-23|Estimate|August 2007||2007-08-31|October 2009|2009-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of TJ-100 in the Treatment of Chronic Constipation||Completed||N/A|60|Anticipated|Showa Inan General Hospital|||||f||||t||||||||||2018-06-01 02:58:04.416902|2018-06-01 02:58:04.416902
NCT00522080|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-08-27|2007-08-27|2007-08-29|Estimate|||||||2007-08-27|2007-08-29|Estimate|March 2005||2005-03-31|August 2007|2007-08-31|December 2005|Actual|2005-12-31|||||Observational|||Screening for Hip and Knee Osteoarthritis in the General Population: Predictive Value of a Questionnaire and Prevalence Estimates|Screening for Hip and Knee Osteoarthritis in the General Population: Predictive Value of a Questionnaire and Prevalence Estimates|Terminated|||||Centre Hospitalier Universitaire de Nice||||terminated study|f||||t||||||||||2018-06-01 02:58:04.473206|2018-06-01 02:58:04.473206
NCT00522067|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2016-11-30|2007-08-28|2007-08-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2007||2007-06-30|January 2012|2012-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.|A Phase II, Open Label, Uncontrolled, Multi-Center Study to Support Annual Strain Update and to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects Aged 18-64 Years Affected by Chronic Diseases|Completed||Phase 2|52|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:58:04.525066|2018-06-01 02:58:04.525066
NCT00522054|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-08-27|2007-08-27|2007-08-29|Estimate|||||||2007-08-27|2007-08-29|Estimate|September 2004||2004-09-30|August 2007|2007-08-31|March 2005|Actual|2005-03-31|||||Interventional|||Tai Chi for Patients With Rheumatoid Arthritis|Tai Chi for Patients With Rheumatoid Arthritis: A Quantitative and Qualitative Study|Completed||N/A|15|Actual|Diakonhjemmet Hospital||1|||f||||f||||||||||2018-06-01 02:58:04.59493|2018-06-01 02:58:04.59493
NCT00522041|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|2014-01-27||2016-09-15|2007-08-28|2007-08-29|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|August 2007||2007-08-31|September 2016|2016-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Safety population: All participants who received at least 1 application of study medication.|A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures|A Randomized. Double-blind, Placebo-controlled, Multi-national Study to Determine the Effect of Cellegesic Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With a Chronic Anal Fissure|Completed||Phase 3|248|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 02:58:04.668433|2018-06-01 02:58:04.668433
NCT00522028|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2016-05-20|2007-08-28|2007-08-29|Estimate|||||||2016-05-20|2016-05-23|Estimate|October 1998||1998-10-31|June 1996|1996-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|SIPH||Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial|Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial|Completed|||191|Actual|Oslo University Hospital|||||f||||f||||||||||2018-06-01 02:58:05.040272|2018-06-01 02:58:05.040272
NCT00522015|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2008-02-14|2007-08-27|2007-08-29|Estimate|||||||2008-02-14|2008-02-18|Estimate|February 2008||2008-02-29|August 2007|2007-08-31|February 2010||2010-02-28|December 2009||2009-12-31||Interventional|psp||Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy|Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study|Unknown status|Recruiting|Phase 2|20|Anticipated|University Hospital Tuebingen||1|||f||||t||||||||||2018-06-01 02:58:05.106131|2018-06-01 02:58:05.106131
NCT00522002|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-28|||2017-08-28|2007-08-28|2007-08-29|Estimate|||||||2017-08-28|2017-08-30|Actual|August 2007||2007-08-31|August 2017|2017-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|CLUE||CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study|Connective Tissue Disease Leg Ulcer Etiology Study|Completed|||40|Actual|George Washington University|||||f||||f||||||||||2018-06-01 02:58:05.187957|2018-06-01 02:58:05.187957
NCT00521989|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2014-02-10||2014-03-26|2007-08-27|2007-08-29|Estimate|2014-03-26|2014-04-29|Estimate||||2014-03-26|2014-04-29|Estimate|August 2007||2007-08-31|March 2014|2014-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|COMET-1||CRx-102 Osteoarthritis Multicenter Evaluation Trial|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension|Terminated||Phase 2|279|Actual|Zalicus||5||CRx-102-006 study results, negative|f||||t||||||||||2018-06-01 02:58:05.260301|2018-06-01 02:58:05.260301
NCT00521976|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2009-01-09||2015-05-19|2007-08-27|2007-08-28|Estimate|2009-06-22|2009-08-11|Estimate||||2015-05-19|2015-06-15|Estimate|November 2002||2002-11-30|May 2015|2015-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|RACS||Risk Markers in the Acute Coronary Syndromes|An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.|Completed|||871|Actual|Helse Stavanger HF|||1||f||||f||||||Samples Without DNA|"~     Serum, Citrated plasma, EDTA-plasma and packed red blood cells are kept in suitable aliquots~     at -80 degrees Celcius.~   "|||2018-06-01 02:58:05.613235|2018-06-01 02:58:05.613235
NCT00521963|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2015-06-25|2007-08-27|2007-08-28|Estimate|||||||2015-06-25|2015-06-26|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Intraarticular Injection of Infliximab|Interventional Study: Administration of Intraarticular Injection of Infliximab in Patients With Inflammatory Arthritis Who Failed Intraarticular Injection of Corticosteroids|Withdrawn||Phase 2/Phase 3|0|Actual|HaEmek Medical Center, Israel||1||poor accrual|f||||f||||||||||2018-06-01 02:58:05.88679|2018-06-01 02:58:05.88679
NCT00521950|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2014-03-27|2007-08-27|2007-08-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TOPIC||Cost-effectiveness of TPMT Pharmacogenetics|Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.|Completed||N/A|853|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 02:58:05.955852|2018-06-01 02:58:05.955852
NCT00521937|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2010-12-14|2007-08-27|2007-08-28|Estimate|||||||2010-12-14|2010-12-15|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|DERMAGEN®||Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer|A Prospective, Randomised, Multi-centre, Blind-observer, Controlled, Parallel-group Study Comparing the Efficacy and Safety of DERMAGEN® Versus Conventional Treatment in the Treatment of Diabetic Neuropathic Foot Ulcer|Unknown status|Active, not recruiting|Phase 3|388|Anticipated|Laboratoires Genévrier||2|||f||||f||||||||||2018-06-01 02:58:06.041604|2018-06-01 02:58:06.041604
NCT00521924|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2009-04-03||2017-03-14|2007-08-27|2007-08-28|Estimate|2009-04-03|2009-06-01|Estimate||||2017-03-14|2017-04-12|Actual|June 2007||2007-06-30|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)|Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-therapy|Terminated||Phase 3|8|Actual|Merck Sharp & Dohme Corp.||2||Slow Enrollment|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:58:06.113939|2018-06-01 02:58:06.113939
NCT00521911|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2008-12-24|2007-08-27|2007-08-28|Estimate|||||||2008-12-24|2008-12-25|Estimate|August 2007||2007-08-31|December 2008|2008-12-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Detection and Treatment of Depression in Patients Admitted to the General Hospital||Unknown status|Recruiting|Phase 2|60|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 02:58:06.265048|2018-06-01 02:58:06.265048
NCT00521898|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2018-03-27|2007-08-24|2007-08-28|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2005||2005-02-28|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|DMEK||Descemet Membrane Endothelial Keratoplasty (DMEK)|Prospective Clinical Study on Descemet Membrane Endothelial Keratoplasty (DMEK)|Recruiting||N/A|100|Anticipated|Netherlands Institute for Innovative Ocular Surgery||1|||f||||t||||||||||2018-06-01 02:58:06.39745|2018-06-01 02:58:06.39745
NCT00521885|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2017-10-04||2017-11-10|2007-08-27|2007-08-28|Estimate|2017-10-04|2017-11-01|Actual||||2017-11-10|2017-12-06|Actual|September 2007||2007-09-30|November 2017|2017-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|BRiEF||Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients|Arixtra(Fondaparinux) vs. Lovenox (Enoxaparin) in Prevention of DVT in Acute Medically Ill, Non-surgical Patients|Terminated||N/A|1|Actual|Lehigh Valley Hospital|"Began 2007 and ended 2009-1 subject enrolled-no SAE noted. No records which arm enrolled subject was assigned, so cannot accurately fill the patient flow section as 1 to match enroll number. Unknown what arm subject in. Only blinded pharm.was aware"|2||Study stopped due to lack of accrual|f||||t||||||||||2018-06-01 02:58:06.482934|2018-06-01 02:58:06.482934
NCT00521872|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2008-06-25|2007-08-27|2007-08-28|Estimate|||||||2008-06-25|2008-06-26|Estimate|April 2004||2004-04-30|August 2007|2007-08-31|October 2007|Actual|2007-10-31|||||Interventional|||Stapled Trans Anal Rectal Resection (STARR) for Outlet Obstruction: Functional and Morphological Outcome|Stapled Trans Anal Rectal Resection (STARR) for Outlet Obstruction: Functional and Morphological Outcome|Completed||Phase 4|||University of Zurich|||||f||||f||||||||||2018-06-01 02:58:06.636625|2018-06-01 02:58:06.636625
NCT00521859|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2012-07-27|2007-08-27|2007-08-28|Estimate|||||||2012-07-27|2012-07-31|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies|Dose Escalation Trial of Cloretazine (VNP40101M) and Hematopoietic Cell Transplantation for Patients With Selected, Poor-Prognosis Hematologic Malignancies|Completed||Phase 1|5|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:58:06.695795|2018-06-01 02:58:06.695795
NCT00521846|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2018-03-01|2007-08-27|2007-08-28|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2007||2007-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||ExploR™ Modular Radial Head Data Collection|ExploR™ Modular Radial Head Data Collection|Recruiting|||50|Anticipated|Vanderbilt University Medical Center|||1||f||||f|f|t|f|f||||No|Will not be shared.|2018-06-01 02:58:06.77185|2018-06-01 02:58:06.77185
NCT00521833|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-09-04|2007-08-27|2007-08-28|Estimate|||||||2007-09-04|2007-09-05|Estimate|June 2005||2005-06-30|August 2007|2007-08-31|August 2006|Actual|2006-08-31|||||Interventional|||Surgically Induced Astigmatism of Temporal Versus Nasal Clear Corneal Phacoemulsification||Completed||N/A|20|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 02:58:06.854881|2018-06-01 02:58:06.854881
NCT00521820|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-25|||2012-02-27|2007-08-27|2007-08-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2000||2000-06-30|February 2012|2012-02-29|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure|A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Subjects With Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild to Moderate Congestive Heart Failure|Terminated||Phase 3|518|Actual|Takeda||2||"Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated~   subjects compared to glyburide treated subjects."|f||||t||||||||||2018-06-01 02:58:06.936313|2018-06-01 02:58:06.936313
NCT00521807|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2008-10-17|2007-08-27|2007-08-28|Estimate|||||||2008-10-17|2008-10-20|Estimate|March 2001||2001-03-31|August 2007|2007-08-31|May 2005|Actual|2005-05-31|||||Interventional|||Hypnosis as a Treatment of Chronic Widespread Pain in General Practice. A Pilot Study.||Completed||N/A|18|Actual|University of Oslo||2|||f||||f||||||||||2018-06-01 02:58:07.017132|2018-06-01 02:58:07.017132
NCT00521794|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2013-01-15|2007-08-24|2007-08-28|Estimate|||||||2013-01-15|2013-01-16|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Characteristics of Andersen-Tawil Syndrome|Andersen-Tawil Syndrome: Genotype-Phenotype Correlation and Longitudinal Study|Completed|||28|Actual|University of Rochester|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 02:58:07.073259|2018-06-01 02:58:07.073259
NCT00521781|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2016-03-15|2007-08-24|2007-08-28|Estimate|||||||2016-03-15|2016-03-17|Estimate|August 2007||2007-08-31|March 2016|2016-03-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer|Phase II Trial of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Adenocarcinoma of the Prostate|Terminated||Phase 2|14|Actual|The Methodist Hospital System||1||Sponsor decision|f||||f||||||||No||2018-06-01 02:58:07.14094|2018-06-01 02:58:07.14094
NCT00521768|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2015-07-06|2007-08-27|2007-08-28|Estimate|||||||2015-07-06|2015-07-07|Estimate||||July 2015|2015-07-31||||||||Interventional|||Effectiveness of Prolonged Exposure of PTSD in a Community Setting of PTSD Sufferers||Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel|||||f||||||||||||||2018-06-01 02:58:07.232355|2018-06-01 02:58:07.232355
NCT00521755|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-26|||2011-06-08|2007-08-26|2007-08-28|Estimate|||||||2011-06-08|2011-06-09|Estimate|December 2008||2008-12-31|June 2009|2009-06-30|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System|Evaluation of Safety and Efficacy of Using Seraffix LTB - (Laser Tissue Bonding) System|Completed||N/A|15|Anticipated|Seraffix||1|||f||||f||||||||||2018-06-01 02:58:07.293824|2018-06-01 02:58:07.293824
NCT00521742|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-25|||2012-02-27|2007-08-25|2007-08-28|Estimate|||||||2012-02-27|2012-02-28|Estimate|March 2001||2001-03-31|February 2012|2012-02-29|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease|A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Patients With Type 2 (Non-Insulin-Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I)|Completed||Phase 3|300|Actual|Takeda||4|||f||||t||||||||||2018-06-01 02:58:07.370829|2018-06-01 02:58:07.370829
NCT00521729|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-25|||2018-04-19|2007-08-25|2007-08-28|Estimate|||||||2018-04-19|2018-04-20|Actual|August 24, 2007||2007-08-24|February 2, 2018|2018-02-02|January 12, 2015|Actual|2015-01-12|January 12, 2015|Actual|2015-01-12||Interventional|||Metabolism and Thyroid Hormone Changes During Exposure to Cold Temperatures|Thyroid Hormones Homeostasis and Energy Metabolism Changes During Exposure to Cold Temperature in Humans|Completed||N/A|160|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:58:07.459106|2018-06-01 02:58:07.459106
NCT00521716|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-26|||2009-01-09|2007-08-27|2007-08-28|Estimate|||||||2009-01-09|2009-01-12|Estimate|September 2007||2007-09-30|February 2008|2008-02-29|December 2009|Anticipated|2009-12-31|March 2008|Anticipated|2008-03-31||Interventional|||Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation|A Single Arm, Uni-Center, Prospective Clinical Investigation to Evaluate Safety and Efficacy of the WaisFix100i for Intracapsular Femoral Fracture Fixation|Suspended||N/A|20|Anticipated|OrthoMediTec||1|||f||||t||||||||||2018-06-01 02:58:07.516853|2018-06-01 02:58:07.516853
NCT00521703|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2008-05-22|2007-08-27|2007-08-28|Estimate|||||||2008-05-22|2008-05-23|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|||||Interventional|||Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children|Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children and Teenagers|Completed||Phase 3|78|Actual|Hospital Infantil Cândido Fontoura||2|||f||||f||||||||||2018-06-01 02:58:07.582913|2018-06-01 02:58:07.582913
NCT00521690|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2014-11-25|2007-08-27|2007-08-28|Estimate|||||||2014-11-25|2014-11-26|Estimate|December 2006||2006-12-31|November 2014|2014-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD|Safety and Therapeutic Effect of Insulin Detemir in Taiwanese Patients With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets With OAD With/Without Once-daily NPH Insulin Treatment|Completed||Phase 4|25|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:58:07.649793|2018-06-01 02:58:07.649793
NCT00521677|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2015-06-21|2007-08-27|2007-08-28|Estimate|||||||2015-06-21|2015-06-23|Estimate|September 2007||2007-09-30|June 2015|2015-06-30|October 2009|Actual|2009-10-31|February 2009|Actual|2009-02-28||Interventional|||Comparison Between Two Methods of Oral Care on the Incidence of VAP||Completed||N/A|108|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-06-01 02:58:07.726547|2018-06-01 02:58:07.726547
NCT00521664|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2011-05-18|2007-08-27|2007-08-28|Estimate|||||||2011-05-18|2011-05-19|Estimate|September 2004||2004-09-30|May 2011|2011-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups|Prospective Randomized Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups: 1)in Patients With Acute Myeloid Leukemia After Intensive Chemotherapy and 2) After Autologous Blood Stem Cell Transplantation|Completed||Phase 3|400|Actual|Technische Universität Dresden||2|||f||||t||||||||||2018-06-01 02:58:07.813103|2018-06-01 02:58:07.813103
NCT00521651|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-25|||2018-05-16|2007-08-25|2007-08-28|Estimate|||||||2018-05-16|2018-05-17|Actual|August 1, 2005||2005-08-01|October 18, 2017|2017-10-18||||||||Observational|||PRelationship Between Physical Activity and Cancer Ris|Physical Activity and Its Components in Relation to Plasma Inflammatory Markers of Cancer Risk Among Chinese Adults|Completed|||620|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 02:58:07.885951|2018-06-01 02:58:07.885951
NCT00521638|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24||2013-01-07|2013-01-07|2007-08-24|2007-08-28|Estimate||||2013-01-07|2013-01-14|Estimate|2013-01-07|2013-01-14|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma|A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|120|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:58:07.944415|2018-06-01 02:58:07.944415
NCT00521625|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2008-05-21|2007-08-24|2007-08-28|Estimate|||||||2008-05-21|2008-05-22|Estimate|June 2007||2007-06-30|May 2008|2008-05-31|November 2007|Actual|2007-11-30|||||Observational|PALIVE1||Epidemiologic Multicenter Study on Mechanical Ventilation Management in Children With Acute Lung Injury|Epidemiologic Multicenter Study on Mechanical Ventilation Management in Children With Acute Lung Injury - Phase 1 PALIVE 1 (for Pediatric Acute Lung Injury Mechanical VEntilation Strategies)|Completed|||||St. Justine's Hospital|||||f||||f||||||||||2018-06-01 02:58:08.015101|2018-06-01 02:58:08.015101
NCT00521612|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-12-26|2007-08-27|2007-08-28|Estimate|||||||2007-12-26|2008-01-07|Estimate|September 2007||2007-09-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Sevoflurane vs. Isoflurane for Low-Flow General Anaesthesia for Abdominal Surgery|Prospective Randomised Controled Trial: Comparison of Volatile Anaesthetics Sevoflurane vs. Isoflurane for Low-Flow General Anaesthesia for Abdominal Surgery|Completed||N/A|82|Actual|General Hospital Dubrovnik||2|||f||||t||||||||||2018-06-01 02:58:08.167511|2018-06-01 02:58:08.167511
NCT00521599|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|2010-02-26||2017-03-15|2007-08-27|2007-08-28|Estimate|2010-02-26|2010-03-23|Estimate||||2017-03-15|2017-04-12|Actual|May 2007||2007-05-31|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)|A Study of the Therapeutic Equivalency of MF DPI 100 mcg and 200 mcg Inhalers in Corticosteroid-Dependent Subjects With Moderate Asthma|Completed||Phase 4|672|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:58:08.381397|2018-06-01 02:58:08.381397
NCT00521586|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2014-12-10||2015-04-07|2007-08-27|2007-08-28|Estimate|2015-04-07|2015-04-09|Estimate||||2015-04-07|2015-04-09|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Safety analysis set included all randomized participants who had received at least 1 dose of study treatment.|Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine|A Phase 3, Randomized, Double-blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vpnc Administered 5 Years After Initial 13vpnc Vaccination|Completed||Phase 3|1116|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 02:58:08.922175|2018-06-01 02:58:08.922175
NCT00521573|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-08-27|2007-08-27|2007-08-28|Estimate|||||||2007-08-27|2007-08-28|Estimate||||August 2007|2007-08-31||||||||Interventional|||Effects of Chocolate on Coronary Vasomotion in Patients After Heart Transplantation||Completed||Phase 1|||University of Zurich|||||f||||f||||||||||2018-06-01 02:58:14.667059|2018-06-01 02:58:14.667059
NCT00521560|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2013-02-13|2007-08-27|2007-08-28|Estimate|||||||2013-02-13|2013-02-15|Estimate|March 2006||2006-03-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2009|Actual|2009-08-31||Interventional|escZ-BEAM||A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas|Phase I/II Study Concomitant High-Dose Radio-Immuno- and Chemotherapy With Simultaneous Application of Zevalin and BEAM Followed by Autologous Peripheral Stem Cell Transplantation in Relapsed and Refractory CD 20+ Non-Hodgkin's Lymphoma|Completed||Phase 2|28|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||1|||f||||t||||||||||2018-06-01 02:58:14.72504|2018-06-01 02:58:14.72504
NCT00521547|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2007-08-27|2007-08-27|2007-08-28|Estimate|||||||2007-08-27|2007-08-28|Estimate|September 2003||2003-09-30|August 2007|2007-08-31|January 2007|Actual|2007-01-31|||||Interventional|||To Study the Mechanisms of Acupuncture Through Functional Magnetic Resonance Imaging and Peripheral Neurosensory Testing|Healthy Subject Studies to Assess the Effect of Different Electroacupuncture Parameters on Analgesia, Peripheral Sensory Thresholds and Central Pain Processing.|Completed||N/A|40|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 02:58:14.862253|2018-06-01 02:58:14.862253
NCT00521534|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2012-09-17|2007-08-24|2007-08-28|Estimate|||||||2012-09-17|2012-09-18|Estimate|March 2006||2006-03-31|September 2012|2012-09-30|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Observational|IMPACT||Impact of Resynchronization Therapy on Sleep Disordered Breathing in Advanced Congestive Heart Failure|Impact of Resynchronization Therapy on Sleep Disordered Breathing in Advanced Congestive Heart Failure|Completed|||19|Actual|VA Pittsburgh Healthcare System|||2||f||||f||||||||||2018-06-01 02:58:14.946792|2018-06-01 02:58:14.946792
NCT00521521|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2009-12-04|2007-08-27|2007-08-28|Estimate|||||||2009-12-04|2009-12-07|Estimate|July 2001||2001-07-31|December 2009|2009-12-31||||May 2006|Actual|2006-05-31||Interventional|TAX200006||Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer|A Multicenter, Randomized, Phase II Study of the Combination of Docetaxel (TAXOTERE) and Concomitant Radiotherapy With or Without Cisplatin in Patients With Locally Advanced Head and Neck Cancer|Completed||Phase 2|86|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 02:58:15.040176|2018-06-01 02:58:15.040176
NCT00521508|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2010-09-28|2007-08-27|2007-08-28|Estimate|||||||2010-09-28|2010-09-29|Estimate|April 2008||2008-04-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy|Role of CD4+CD25+FoxP3+ Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy|Completed||N/A|45|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f||||||||||2018-06-01 02:58:15.167021|2018-06-01 02:58:15.167021
NCT00521495|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2009-11-23|2007-08-24|2007-08-28|Estimate|||||||2009-11-23|2009-11-25|Estimate|September 2006||2006-09-30|November 2009|2009-11-30|August 2009|Anticipated|2009-08-31|June 2009|Anticipated|2009-06-30||Interventional|CTS/SMF||Carpal Tunnel Syndrome and Static Magnetic Field Therapy|Carpal Tunnel Syndrome and Static Magnetic Field Therapy|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|National University of Natural Medicine||3|||f||||f||||||||||2018-06-01 02:58:15.286267|2018-06-01 02:58:15.286267
NCT00521482|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-27|||2007-08-27|2007-08-27|2007-08-28|Estimate|||||||2007-08-27|2007-08-28|Estimate|September 2007||2007-09-30|August 2007|2007-08-31|January 2009|Anticipated|2009-01-31|||||Interventional|||Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma|Intensive Dose Temozolomide Treatment or Temozolomide With Thalidomide Treatment in Recurrent Glioblastoma After Standard Therapy:a Randomized Phase II Trial|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|University of Zurich||2|||f||||f||||||||||2018-06-01 02:58:15.535641|2018-06-01 02:58:15.535641
NCT00521469|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2008-10-16|2007-08-24|2007-08-28|Estimate|||||||2008-10-16|2008-10-17|Estimate|March 2007||2007-03-31|August 2007|2007-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control|A Randomized Controlled Single-Blind Study of the Effects of Instrument-Applied Spinal Manipulative Therapy on Postural Control|Completed||Phase 2|||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 02:58:15.618088|2018-06-01 02:58:15.618088
NCT00521456|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2009-08-19|2009-09-29|2009-09-29|2007-08-23|2007-08-27|Estimate|2009-09-29|2009-10-01|Estimate|2009-09-29|2009-10-01|Estimate|2009-09-29|2009-10-01|Estimate|October 2007||2007-10-31|August 2009|2009-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery||Completed||Phase 3|263|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:58:15.682861|2018-06-01 02:58:15.682861
NCT00521443|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2007-08-24|2007-08-24|2007-08-27|Estimate|||||||2007-08-24|2007-08-27|Estimate||||August 2007|2007-08-31||||||||Observational|||Cryosurvival of Embryos From Dysmorphic Oocytes||Completed|||||V.K.V. American Hospital, Istanbul|||12||f||||||||||||||2018-06-01 02:58:15.934926|2018-06-01 02:58:15.934926
NCT00521430|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2013-03-25|2007-08-24|2007-08-27|Estimate|||||||2013-03-25|2013-03-26|Estimate|April 2004||2004-04-30|October 2007|2007-10-31|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease|NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING|Completed||N/A|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:58:16.007594|2018-06-01 02:58:16.007594
NCT00521417|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2016-04-29|2007-08-24|2007-08-27|Estimate|||||||2016-04-29|2016-05-02|Estimate|August 2005||2005-08-31|April 2016|2016-04-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|KOLG-P||Short- and Long-term Group Psychotherapy|A Randomized Controlled Study of the Efficacy of Analytic Oriented Group Psychotherapy for Psychiatric Outpatients|Active, not recruiting||Phase 2|140|Anticipated|University of Oslo||2|||f||||t||||||||||2018-06-01 02:58:16.272003|2018-06-01 02:58:16.272003
NCT00521404|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24||2010-10-27|2010-10-27|2007-08-24|2007-08-27|Estimate||||2010-10-27|2010-11-01|Estimate|2010-10-27|2010-11-01|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Open-label Study of CS1008 for Subjects With Untreated and Unresectable Pancreatic Cancer|Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer|Completed||Phase 2|65|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 02:58:16.398001|2018-06-01 02:58:16.398001
NCT00521391|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2007-08-24|2007-08-24|2007-08-27|Estimate|||||||2007-08-24|2007-08-27|Estimate|April 2003||2003-04-30|August 2007|2007-08-31|December 2005|Actual|2005-12-31|||||Interventional|PHASMO||Physical Activity as an Aid for Smoking Cessation|Physical Activity as an Aid for Smoking Cessation: a Randomized Controlled Trial|Terminated||Phase 3|600|Actual|University of Lausanne Hospitals||2||End of the recruitment|f||||f||||||||||2018-06-01 02:58:16.726477|2018-06-01 02:58:16.726477
NCT00521378|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2009-01-10|2007-08-24|2007-08-27|Estimate|||||||2009-01-10|2009-01-13|Estimate||||January 2009|2009-01-31||||||||Observational|||A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus|A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral HDV-Insulin in Patients With Type 2 Diabetes Mellitus|Completed|||20|Anticipated|Diasome Pharmaceuticals|||||f||||f||||||||||2018-06-01 02:58:16.820468|2018-06-01 02:58:16.820468
NCT00521365|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2010-08-11||2012-06-12|2007-08-24|2007-08-27|Estimate|2012-06-12|2012-07-17|Estimate||||2012-06-12|2012-07-17|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|EMMY||Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.|A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder.|Completed||Phase 4|88|Actual|AstraZeneca|Open label, non comparative study|1|||f||||||||||||||2018-06-01 02:58:16.900575|2018-06-01 02:58:16.900575
NCT00521352|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2012-12-13||2014-09-16|2007-08-23|2007-08-27|Estimate|2014-09-16|2014-09-22|Estimate||||2014-09-16|2014-09-22|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|rTMS||Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression|Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder (PD) With Comorbid Major Depression|Completed||Phase 2|25|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 02:58:17.198749|2018-06-01 02:58:17.198749
NCT00521339|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2014-10-14|2010-08-24|2017-10-03|2007-08-24|2007-08-27|Estimate|2010-04-30|2010-05-27|Estimate|2010-08-24|2010-08-27|Estimate|2017-10-03|2017-11-06|Actual|August 1, 2007|Actual|2007-08-01|October 2017|2017-10-31|May 1, 2009|Actual|2009-05-01|April 1, 2009|Actual|2009-04-01||Interventional||Safety population consisted of all participants who were enrolled and received at least one dose of study medication.|Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis|A Phase 2, Open-label Multi-center Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Apremilast in Subjects With Recalcitrant Plaque-type Psoriasis|Completed||Phase 2|31|Actual|Celgene||1|||f||||t||||||||||2018-06-01 02:58:17.650477|2018-06-01 02:58:17.650477
NCT00521326|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2007-08-24|2007-08-24|2007-08-27|Estimate|||||||2007-08-24|2007-08-27|Estimate|August 2007||2007-08-31|March 2007|2007-03-31||||||||Observational|||Diagnosis and Characterization of Coronary Artery Stenosis by Doppler Ultrasound|Diagnosis and Characterization of Coronary Artery Stenosis by Transthoracic Doppler Ultrasound|Unknown status|Not yet recruiting||||Hillel Yaffe Medical Center|||1||f||||f||||||||||2018-06-01 02:58:18.410106|2018-06-01 02:58:18.410106
NCT00521300|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2014-05-30|2007-08-24|2007-08-27|Estimate|||||||2014-05-30|2014-06-02|Estimate|September 1999||1999-09-30|May 2014|2014-05-31|May 2010|Actual|2010-05-31|June 2005|Actual|2005-06-30||Interventional|POTA||Preoperative Octreotide Treatment of Acromegaly|Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas|Completed||Phase 4|62|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-06-01 02:58:18.471066|2018-06-01 02:58:18.471066
NCT00520585|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2007-08-22|2007-08-22|2007-08-24|Estimate|||||||2007-08-22|2007-08-24|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|November 2007|Anticipated|2007-11-30|||||Interventional|ATORVA||Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes|Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes|Unknown status|Not yet recruiting|N/A|||Masaryk University|||||f||||f||||||||||2018-06-01 02:58:31.634539|2018-06-01 02:58:31.634539
NCT00521287|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2008-02-29|2007-08-24|2007-08-27|Estimate|||||||2008-02-29|2008-03-03|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|December 2009|Anticipated|2009-12-31|September 2007|Actual|2007-09-30||Interventional|||Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection|Adjustment of Optimal Immune System by Using Cytokine Cocktails Before Applying DC Vaccine|Unknown status|Recruiting|Phase 2|150|Anticipated|Mackay Memorial Hospital||3|||f||||f||||||||||2018-06-01 02:58:18.549622|2018-06-01 02:58:18.549622
NCT00521274|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2016-03-15|2007-08-23|2007-08-27|Estimate|||||||2016-03-15|2016-03-17|Estimate|August 2007||2007-08-31|March 2016|2016-03-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer|A Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (HRPC)|Terminated||Phase 2|11|Actual|The Methodist Hospital System||2||Oxford BioMedica halted TroVax injections|f||||f||||||||No||2018-06-01 02:58:18.760777|2018-06-01 02:58:18.760777
NCT00521261|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2014-03-04|2007-08-24|2007-08-27|Estimate|||||||2014-03-04|2014-03-05|Estimate|October 2007||2007-10-31|March 2014|2014-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Immune Consolidation With Allogeneic Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Allogeneic Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphoma (Phase I)|Withdrawn||Phase 1|0|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 02:58:18.838333|2018-06-01 02:58:18.838333
NCT00521248|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2017-01-11|2007-08-23|2007-08-27|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2004||2004-04-30|December 2009|2009-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Buprenorphine for the Treatment of Neonatal Abstinence Syndrome|Buprenorphine for the Treatment of Neonatal Abstinence Syndrome|Completed||Phase 1|60|Anticipated|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 02:58:18.902265|2018-06-01 02:58:18.902265
NCT00521235|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2011-08-10|2007-08-24|2007-08-27|Estimate|||||||2011-08-10|2011-08-11|Estimate|June 2012||2012-06-30|August 2011|2011-08-31|December 2012|Anticipated|2012-12-31|||||Observational|||Effect of Different Working Conditions on Risk Factors in Dentists Versus Trainers|Effects of Different Working Condition on Risk Factors in Dentists Versus Trainers. A Combined Crosssectional and Longitudinal Trial With Student and Senior Employees.|Unknown status|Not yet recruiting||300|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 02:58:18.981446|2018-06-01 02:58:18.981446
NCT00521222|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2013-06-07|2007-08-24|2007-08-27|Estimate|||||||2013-06-07|2013-06-11|Estimate|June 2007||2007-06-30|June 2013|2013-06-30|November 2013|Anticipated|2013-11-30|November 2010|Actual|2010-11-30||Interventional|ARGARG||Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes|Arg/Arg Genotype and Long Acting Beta Agonists in Asthma. Improved Quality of Care for Patients With Asthma.|Unknown status|Active, not recruiting|N/A|89|Actual|Columbia University||4|||f||||t||||||||||2018-06-01 02:58:19.047397|2018-06-01 02:58:19.047397
NCT00521209|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2018-02-20|2007-08-24|2007-08-27|Estimate|||||||2018-02-20|2018-02-22|Actual|March 2008|Actual|2008-03-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Patient-Directed Lifestyle Change and Health Promotion Program or Usual Care in Low-Income, Uninsured Participants in Los Angeles County, California|Improving Health Habits: Self-Care Priorities|Active, not recruiting||N/A|97|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||No||2018-06-01 02:58:19.129591|2018-06-01 02:58:19.129591
NCT00521196|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2017-03-17|2007-08-24|2007-08-27|Estimate|||||||2017-03-17|2017-03-21|Actual|July 2007|Actual|2007-07-31|March 2017|2017-03-31|January 13, 2012|Actual|2012-01-13|January 13, 2012|Actual|2012-01-13||Interventional|||Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine)|Phase 2 Study of the Effect of Transcranial Direct Current Stimulation (tDCS) on Pain and Headache Frequency in Migraine.|Completed||N/A|13|Actual|Beth Israel Deaconess Medical Center||4|||f||||t|f|f||||||||2018-06-01 02:58:19.194755|2018-06-01 02:58:19.194755
NCT00521183|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2014-11-24|2007-08-24|2007-08-27|Estimate|||||||2014-11-24|2014-11-25|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain|Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With External Brain Radiation for Metastatic Carcinoma to the Brain|Completed||Phase 1|2|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 02:58:19.33386|2018-06-01 02:58:19.33386
NCT00521170|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2013-12-13|2007-08-24|2007-08-27|Estimate|||||||2013-12-13|2013-12-16|Estimate|November 2004||2004-11-30|September 2009|2009-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.|Randomized, Monocenter, Double Blind, Placebo-controlled, Single Oral Dose, Three-way Cross Over Study, to Compare Levocetirizine and Desloratadine on Allergen-induced Wheal and Flare Reaction During 24 Hours in 18 Adult Allergic Volunteers.|Completed||Phase 1|||UCB Pharma|||||f||||||||||||||2018-06-01 02:58:19.60545|2018-06-01 02:58:19.60545
NCT00521157|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2009-05-04|2007-08-24|2007-08-27|Estimate|||||||2009-05-04|2009-05-05|Estimate|January 2006||2006-01-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction|Naltrexone Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction - a Randomised Study|Completed||Phase 2/Phase 3|56|Actual|University of Oslo||2|||f||||f||||||||||2018-06-01 02:58:19.666434|2018-06-01 02:58:19.666434
NCT00521144|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2013-10-11||2015-04-14|2007-08-24|2007-08-27|Estimate|2014-07-21|2014-07-22|Estimate||||2015-04-14|2015-05-05|Estimate|August 2007||2007-08-31|December 2013|2013-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors|Phase I/II Study of Obatoclax Mesylate (GX15-070MS), a Bcl-2 Antagonist, Plus Topotecan in Relapsed Small Cell Lung Carcinoma|Completed||Phase 1/Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 02:58:19.764471|2018-06-01 02:58:19.764471
NCT00521131|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2013-12-13|2007-08-24|2007-08-27|Estimate|||||||2013-12-13|2013-12-16|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites|Evaluation of Efficacy, Using the Number of Comfortable Days and the Safety of Levocetirizine Dihydrochloride, Administered Once Daily in the Evening for 30 Days, to Subjects Suffering From Perennial Allergic Rhinitis to House Dust Mites|Completed||Phase 4|453|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:58:20.650914|2018-06-01 02:58:20.650914
NCT00521118|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2017-08-23|2007-08-24|2007-08-27|Estimate|||||||2017-08-23|2017-08-24|Actual|October 9, 2007|Actual|2007-10-09|August 2017|2017-08-31|June 25, 2015|Actual|2015-06-25|June 25, 2015|Actual|2015-06-25||Interventional|||Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors|A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia|Completed||Phase 2|64|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 02:58:20.71359|2018-06-01 02:58:20.71359
NCT00521105|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2011-10-05|2007-08-24|2007-08-27|Estimate|||||||2011-10-05|2011-10-06|Estimate|August 2005||2005-08-31|October 2011|2011-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Assessment of an Alternative Model of Follow-up of Children and Adolescents With Type 1 Diabetes|Assessment of an Alternative Model Using Telemedicine Follow-up of Children and Adolescents With Type 1 Diabetes|Completed||N/A|82|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 02:58:20.822112|2018-06-01 02:58:20.822112
NCT00521092|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2014-05-02|2007-08-24|2007-08-27|Estimate|||||||2014-05-02|2014-05-05|Estimate|January 2009||2009-01-31|December 2012|2012-12-31||||October 2010|Actual|2010-10-31||Interventional|||Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma|Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1||No participants enrolled.|f||||||||||||||2018-06-01 02:58:20.938208|2018-06-01 02:58:20.938208
NCT00521079|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2016-08-23||2018-01-25|2007-08-23|2007-08-27|Estimate|2016-12-28|2017-02-20|Actual||||2018-01-25|2018-02-22|Actual|August 2007||2007-08-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|October 2009|Actual|2009-10-31||Interventional|EMPOWER||EMPOWER Clinical Trial: Vagal Blocking for Obesity Control|EMPOWER Clinical Trial: Vagal Blocking for Obesity Control|Active, not recruiting||N/A|294|Actual|EnteroMedics|Two confounding efficacy factors: Variable hours of therapy in both arms due to inconsistent external power source use and altered vagal excitability in the control arm due to small electrical inputs delivered to vagal nerves for safety checks.|2|||f||||t||||||||No||2018-06-01 02:58:21.098724|2018-06-01 02:58:21.098724
NCT00521066|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2014-05-05|2007-08-24|2007-08-27|Estimate|||||||2014-05-05|2014-05-06|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|June 2010|Actual|2010-06-30|October 2008|Actual|2008-10-31||Observational|||GYNECARE PROSIMA* Pelvic Floor Repair System for Pelvic Organ Prolapse|A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROSIMA* Pelvic Floor Repair System as a Procedure for Pelvic Organ Prolapse|Completed|||150|Actual|Ethicon, Inc.|||1||f||||f||||||||||2018-06-01 02:58:21.537182|2018-06-01 02:58:21.537182
NCT00521053|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2014-06-12||2014-08-07|2007-08-24|2007-08-27|Estimate|2014-08-07|2014-08-25|Estimate||||2014-08-07|2014-08-25|Estimate|September 2007||2007-09-30|August 2014|2014-08-31|June 2012|Actual|2012-06-30|May 2010|Actual|2010-05-31||Interventional|||Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma|A Phase 2 Study of Intralesional PV-10 in the Treatment of Metastatic Melanoma|Completed||Phase 2|80|Actual|Provectus Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:58:21.826862|2018-06-01 02:58:21.826862
NCT00521040|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2013-12-11|2007-08-24|2007-08-27|Estimate|||||||2013-12-11|2013-12-12|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR|Evaluation of the Efficacy and Safety of Levocetirizine During 8 Weeks Preceding and Following the Anticipated Onset of the Grass Pollen Season in Subjects Suffering From Seasonal Allergic Rhinitis Associated With Pollen-induced Asthma|Completed||N/A|459|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:58:22.135567|2018-06-01 02:58:22.135567
NCT00521027|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2018-02-14|2007-08-23|2007-08-27|Estimate|||||||2018-02-14|2018-02-16|Estimate|April 2006||2006-04-30|February 2018|2018-02-28|September 2006|Actual|2006-09-30|||||Interventional|||Study Comparing VERSAJET With Conventional Surgical Procedures in the Removal of Unhealthy Tissue From Lower Limb Ulcers|A Prospective, Comparative, Single-centre Clinical Evaluation to Investigate the Skin-to-skin Time of the First Surgical Debridement of Lower Extremity Ulcers With VERSAJET™ Hydrosurgery System and Conventional Debridement Techniques.|Completed||Phase 4|46|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-06-01 02:58:22.189716|2018-06-01 02:58:22.189716
NCT00521014|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2015-10-19||2015-11-18|2007-08-24|2007-08-27|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma|A Phase II Study of GM-CSF (Sargramostim) and Rituximab Following Autologous Transplantation For Relapsed Follicular Lymphoma|Completed||Phase 2|14|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 02:58:22.343554|2018-06-01 02:58:22.343554
NCT00521001|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2017-01-17||2017-07-07|2007-08-24|2007-08-27|Estimate|2017-01-17|2017-03-07|Actual||||2017-07-07|2017-08-14|Actual|January 2008||2008-01-31|July 2017|2017-07-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery|A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma|Completed||Phase 2|49|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:58:22.549033|2018-06-01 02:58:22.549033
NCT00520988|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2012-04-26|2007-08-24|2007-08-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|March 2006||2006-03-31|April 2012|2012-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Improving Blood Pressure in Colorado|Improving Blood Pressure in Colorado|Completed||N/A|290|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 02:58:23.182763|2018-06-01 02:58:23.182763
NCT00520975|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2016-10-05||2016-12-12|2007-08-24|2007-08-27|Estimate|2016-10-05|2016-11-29|Estimate||||2016-12-12|2017-02-06|Estimate|November 2007||2007-11-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||All randomized patients|Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU|A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients With HER-2/NEU Over-Expressing Metastatic Breast Cancer|Terminated||Phase 3|96|Actual|National Cancer Institute (NCI)||2||Closed early due to slow accrual|f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 02:58:23.372627|2018-06-01 02:58:23.372627
NCT00520962|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2007-08-24|2007-08-24|2007-08-27|Estimate|||||||2007-08-24|2007-08-27|Estimate|June 1997||1997-06-30|August 2007|2007-08-31|May 2006|Actual|2006-05-31|||||Observational|||Screening for Undiagnosed Type 2 Diabetes in New Classes of Subjects at High Risk|New Physiopathogenics Mechanisms Susceptible of Pharmacological Developments (Insulin Resistance and Atherosclerosis)|Completed|||1997|Actual|IRCCS San Raffaele|||2||f||||t||||||||||2018-06-01 02:58:24.402549|2018-06-01 02:58:24.402549
NCT00447044|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2009-06-17|2007-03-12|2007-03-13|Estimate|||||||2009-06-17|2009-06-19|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Combined Effects of Nutritional and Exercise Countermeasures|Combined Effects of Nutritional and Exercise Countermeasures|Completed||N/A|31|Actual|University of Arkansas||3|||f||||||||||||||2018-06-01 03:22:15.179371|2018-06-01 03:22:15.179371
NCT00520949|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2009-04-07|2007-08-24|2007-08-27|Estimate|||||||2009-04-07|2009-04-08|Estimate|October 2006||2006-10-31|April 2009|2009-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|QT-Hp||Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection|Quadruple Therapy Using Esomeprazole, Colloidal Bismuth Subcitrate, Amoxicillin-Clavulanate, and Furazolidone in Patients Who Failed to Eradicate H. Pylori With Triple Therapy|Completed||N/A|176|Actual|Aga Khan University||1|||f||||t||||||||||2018-06-01 02:58:24.46713|2018-06-01 02:58:24.46713
NCT00520936|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2011-02-01||2011-02-23|2007-08-24|2007-08-27|Estimate|2011-02-01|2011-02-23|Estimate||||2011-02-23|2011-02-25|Estimate|September 2007||2007-09-30|February 2011|2011-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of Pemetrexed in Children With Recurrent Cancer|A Phase II Study of Pemetrexed in Children With Recurrent Malignancies|Completed||Phase 2|72|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 02:58:24.563404|2018-06-01 02:58:24.563404
NCT00520923|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24||2009-10-16|2009-10-16|2007-08-24|2007-08-27|Estimate||||2009-10-16|2009-10-19|Estimate|2009-10-16|2009-10-19|Estimate|September 2007||2007-09-30|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study for Patients With Schizophrenia|A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia|Completed||Phase 2|654|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-06-01 02:58:25.715941|2018-06-01 02:58:25.715941
NCT00520910|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2010-10-18|2007-08-24|2007-08-27|Estimate|||||||2010-10-18|2010-10-19|Estimate|August 2007||2007-08-31|June 2008|2008-06-30|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|Heliocare||Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing Ultraviolet A (UVA) Premutagenic and Photoaging Markers|Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|University of Miami||2|||f||||f||||||||||2018-06-01 02:58:25.825043|2018-06-01 02:58:25.825043
NCT00520897|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2012-06-04|2007-08-24|2007-08-27|Estimate|||||||2012-06-04|2012-06-05|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|November 2011|Actual|2011-11-30|February 2009|Actual|2009-02-28||Interventional|||Integrase Inhibitor (MK-0518) Viral Decay|Effect of Integrase Inhibitor (MK-0518) on Decay of Low Level Viral Replication in HIV Reservoirs in Infected Individuals Who Initiated Conventional Antiretroviral Therapy During the Chronic Phase of Infection|Completed||Phase 2|24|Actual|Canadian Immunodeficiency Research Collaborative||2|||f||||||||||||||2018-06-01 02:58:25.996751|2018-06-01 02:58:25.996751
NCT00520884|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2011-05-23|2007-08-23|2007-08-27|Estimate|||||||2011-05-23|2011-05-24|Estimate|March 2007||2007-03-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Ghrelin in Older Women|A Pilot Study of Ghrelin in Healthy and Frail Older Women|Completed||Phase 1/Phase 2|10|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 02:58:26.094272|2018-06-01 02:58:26.094272
NCT00520871|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2007-08-24|2007-08-24|2007-08-27|Estimate|||||||2007-08-24|2007-08-27|Estimate|March 2003||2003-03-31|August 2007|2007-08-31|April 2004|Actual|2004-04-30|||||Interventional|||The Water-Blueberry Study|The Effect of Blueberry Juice on Cardiovascular Risk Factors, and Markers of Antioxidant Status, Oxidative Stress Status and Inflammation.|Completed||Phase 1/Phase 2|62|Actual|University of Oslo|||||f||||f||||||||||2018-06-01 02:58:26.182329|2018-06-01 02:58:26.182329
NCT00520858|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2008-04-21|2007-08-24|2007-08-27|Estimate|||||||2008-04-21|2008-04-22|Estimate|September 2003||2003-09-30|April 2008|2008-04-30||||||||Interventional|||Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women|Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women|Completed||N/A|145|Actual|Queen's University||4|||f||||f||||||||||2018-06-01 02:58:26.255005|2018-06-01 02:58:26.255005
NCT00520845|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2014-10-05||2017-02-10|2007-08-24|2007-08-27|Estimate|2014-10-05|2014-10-09|Estimate||||2017-02-10|2017-03-20|Actual|October 2007||2007-10-31|February 2017|2017-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer|"A Phase II Trial of Celecoxib Plus Chemotherapy [Docetaxel or Pemetrexed] in Patients With Previously Treated, COX Dependent Recurrent Non-Small Cell Lung Cancer"|Terminated||Phase 2|23|Actual|Vanderbilt-Ingram Cancer Center||1||slow accrual|f||||t||||||||||2018-06-01 02:58:26.37218|2018-06-01 02:58:26.37218
NCT00520832|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2008-10-16|2007-08-23|2007-08-27|Estimate|||||||2008-10-16|2008-10-17|Estimate|September 2007||2007-09-30|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys|A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys|Completed||Phase 2|20|Anticipated|Logan College of Chiropractic||2|||f||||||||||||||2018-06-01 02:58:26.657725|2018-06-01 02:58:26.657725
NCT00520819|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2007-08-24|2007-08-24|2007-08-27|Estimate|||||||2007-08-24|2007-08-27|Estimate|February 2003||2003-02-28|August 2007|2007-08-31|March 2005|Actual|2005-03-31|||||Interventional|||Oslo Antioxidant Study|Dietary Antioxidant Intervention in Smoking Middle-Aged and Elderly Men|Completed||Phase 1/Phase 2|102|Actual|University of Oslo|||||f||||f||||||||||2018-06-01 02:58:26.725967|2018-06-01 02:58:26.725967
NCT00520806|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2012-10-26|2007-08-24|2007-08-27|Estimate|||||||2012-10-26|2012-10-30|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|RELAX-AHF||Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure|A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure|Completed||Phase 2/Phase 3|1161|Actual|Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies||2|||f||||t||||||||||2018-06-01 02:58:26.78544|2018-06-01 02:58:26.78544
NCT00520780|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2009-10-15|2007-08-24|2007-08-27|Estimate|||||||2009-10-15|2009-10-16|Estimate|April 2007||2007-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|FAIR-HF||Ferinject® Assessment in Patients With IRon Deficiency and Chronic Heart Failure (FAIR-HF)|A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency|Completed||Phase 3|456|Actual|Vifor Inc.||2|||f||||t||||||||||2018-06-01 02:58:26.865742|2018-06-01 02:58:26.865742
NCT00520767|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2015-03-18||2017-04-05|2007-08-24|2007-08-27|Estimate|2015-03-18|2015-03-30|Estimate||||2017-04-05|2017-05-11|Actual|September 2007||2007-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2010|Actual|2010-10-31||Interventional|||Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease|A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease|Active, not recruiting||Phase 2|35|Actual|Barbara Ann Karmanos Cancer Institute|Mix of previously treated & newly diagnosed pts (populations which may have different prognoses), plus the relatively small trial size limit conclusions one can draw re: relative efficacy of MDV (vs CyBorD or Mel-Dex, for example)|1|||f||||t||||||||||2018-06-01 02:58:26.984061|2018-06-01 02:58:26.984061
NCT00520754|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|||2013-12-11|2007-08-24|2007-08-27|Estimate|||||||2013-12-11|2013-12-12|Estimate|December 2001||2001-12-31|September 2009|2009-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children|The Efficacy and Safety of Levocetirizine Dihydrochloride Oral Drops Given 0.125 mg/kg b.i.d. During 90 Days in the Treatment of Recurrent Cough Associated With Other Allergic Symptoms, e.g. Wheezing, in Children Aged 1-2 Years.|Completed||Phase 2|15|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 02:58:27.295951|2018-06-01 02:58:27.295951
NCT00520741|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-24|2013-11-26||2017-07-28|2007-08-24|2007-08-27|Estimate|2014-03-20|2014-04-23|Estimate||||2017-07-28|2017-08-28|Actual|August 2007||2007-08-31|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ALEX-MT|The Baseline Analysis Population refers to the Safety Set (SS) which includes the unique randomized subjects who took at least one dose of study medication.|Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures|A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400 mg/Day Monotherapy in Subjects With Partial-onset Seizures|Completed||Phase 3|426|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 02:58:27.415431|2018-06-01 02:58:27.415431
NCT00520728|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2015-09-01|2007-08-22|2007-08-24|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2007||2007-08-31|September 2015|2015-09-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Efficacy of an Occupational Time Use Intervention for People With Serious Mental Illness|Efficacy of an Occupational Time Use Intervention|Completed||Phase 1|18|Actual|Queen's University||1|||f||||t||||||||||2018-06-01 02:58:28.222221|2018-06-01 02:58:28.222221
NCT00520715|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2015-06-22|2007-08-23|2007-08-24|Estimate|||||||2015-06-22|2015-06-23|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Observational|||Epidemiology of Fluoroquinolone Resistance in Human Commensal Flora in Patients Hospitalised in Medical Wards|Epidemiology and Risk Factors Study of the Carriage of Fluoroquinolone Resistant Bacteria in the Commensal Flora of Patients Hospitalised in Medical Wards|Completed|||640|Actual|Association Pour le Recherche en Infectiologie et en Médecine Interne|||1||f||||f||||||||||2018-06-01 02:58:28.286825|2018-06-01 02:58:28.286825
NCT00520702|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2017-10-04|2007-08-22|2007-08-24|Estimate|||||||2017-10-04|2017-10-05|Actual|August 2007|Actual|2007-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy|A Randomized Trial to Compare Time to Common Toxicity Criteria for Adverse Effect (CTC AEC) 3.0 Grade. 3 Treatment Related Pneumonitis (TRP) in Patients With Locally Advanced Non-Small Cell Lung Carcinoma (NSCLC) Receiving Concurrent Chemoradiation Radiation Treated With 3-Dimensional Conformal Radiation Therapy (3D CRT, ARM 1) Versus Intensity Modulated Radiation Therapy (IMRT, ARM 2) Using 4-Dimensional CT Planning and Image Guided Adaptive Radiation Therapy (IGART)|Active, not recruiting||Phase 2|168|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 02:58:29.394155|2018-06-01 02:58:29.394155
NCT00520689|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2009-02-12|2007-08-22|2007-08-24|Estimate|||||||2009-02-12|2009-02-16|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|Amethyst||Multipurpose Disinfecting Solution Compatibility With a Silicone Hydrogel Contact Lens|Multipurpose Solution Compatibility With a Silicone Hydrogel Lens|Completed||Phase 3|25|Actual|University of Waterloo||4|||f||||f||||||||||2018-06-01 02:58:29.67404|2018-06-01 02:58:29.67404
NCT00520676|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|2011-06-17||2011-08-08|2007-08-22|2007-08-24|Estimate|2011-06-17|2011-07-18|Estimate||||2011-08-08|2011-08-10|Estimate|October 2007||2007-10-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer|A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|260|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 02:58:29.811827|2018-06-01 02:58:29.811827
NCT00520663|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2017-08-01|2007-08-23|2007-08-24|Estimate|||||||2017-08-01|2017-08-02|Actual|June 8, 2007|Actual|2007-06-08|August 2017|2017-08-31|August 10, 2007|Actual|2007-08-10|August 10, 2007|Actual|2007-08-10||Interventional|||Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug|An Open-label Study to Determine the Excretion, Balance and Pharmacokinetics of SB649868 After a Single Oral Administration of 14C-SB649868 in Healthy Volunteers|Completed||Phase 1|8|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:58:30.897667|2018-06-01 02:58:30.897667
NCT00520650|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2009-12-15|2007-08-23|2007-08-24|Estimate|||||||2009-12-15|2009-12-16|Estimate|August 2006||2006-08-31|December 2009|2009-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|HEALTH||Health Evaluation of Abilify Long-term Therapy|Health Evaluation of Abilify Long-term Therapy|Completed||Phase 4|245|Actual|Taiwan Otsuka Pharm. Co., Ltd|||||f||||f||||||||||2018-06-01 02:58:31.015455|2018-06-01 02:58:31.015455
NCT00520637|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2009-10-08|2007-08-23|2007-08-24|Estimate|||||||2009-10-08|2009-10-09|Estimate|May 2007||2007-05-31|October 2009|2009-10-31||||||||Interventional|||A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)|A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 (PEG-SN38) Administered Every 3 Weeks in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)|Completed||Phase 1|34||Enzon Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 02:58:31.190911|2018-06-01 02:58:31.190911
NCT00520624|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2013-11-05|2007-08-23|2007-08-24|Estimate|||||||2013-11-05|2013-11-06|Estimate||||November 2013|2013-11-30||||||||Interventional|EIL||Treatment of Exercise-induced Laryngomalacia in Elite Athletes||Unknown status|Not yet recruiting|N/A|95|Anticipated|Bispebjerg Hospital||5|||f||||f||||||||||2018-06-01 02:58:31.258828|2018-06-01 02:58:31.258828
NCT00520611|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2015-06-10|2007-08-22|2007-08-24|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2007||2007-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Evaluating the Effectiveness of Financial Incentives in Promoting Weight Loss Among Obese Individuals.|Evaluating the Effectiveness of Financial Incentives in Promoting Weight Loss Among Obese Individuals.|Completed||N/A|57|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 02:58:31.469773|2018-06-01 02:58:31.469773
NCT00520598|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2015-11-25|2007-08-22|2007-08-24|Estimate|||||||2015-11-25|2015-11-26|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)|A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women|Completed||Phase 2|511|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 02:58:31.553337|2018-06-01 02:58:31.553337
NCT00520572|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|2010-07-22||2013-01-31|2007-08-23|2007-08-24|Estimate|2010-09-15|2010-10-04|Estimate||||2013-01-31|2013-02-04|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|March 2009|Actual|2009-03-31|||||Interventional|||A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)|A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine|Completed||Phase 2|385|Actual|AstraZeneca|Hybrid ACR, ACRn, individual ACR components, Erythrocyte sedimentation rate, Short-form-36, Rheumatoid Arthritis Quality of Life, Patient Assessment of Fatigue and DEXA X-ray scanning did not provide extra information so are not presented|6|||f||||||||||||||2018-06-01 02:58:31.731132|2018-06-01 02:58:31.731132
NCT00520559|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2007-08-23|2007-08-23|2007-08-24|Estimate|||||||2007-08-23|2007-08-24|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Observational|||T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients|Incidence of Cardiac Complications in Patients With Cardiac Siderosis During 1 Year Follow−up and the Normal T2* Ranges in LVF, MI and Normal Population.|Completed|||665|Actual|Imperial College London|||||f||||f||||||||||2018-06-01 02:58:32.6425|2018-06-01 02:58:32.6425
NCT00520546|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2011-07-20||2012-06-03|2007-08-23|2007-08-24|Estimate|2012-06-03|2012-06-20|Estimate||||2012-06-03|2012-06-20|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|FEC-PET/MRI||Clinical Value of FEC-PET Combined With Endorectal MRI for Pre-therapeutic Staging of Prostate Cancer|Clinical Value of [18]Fluoroethylcholine Positron-Emission-Tomography Combined With Endorectal Magnetic Resonance Imaging by Software Fusion for Pre-therapeutic Staging of Prostate Cancer|Completed||Phase 3|44|Actual|German Federal Armed Forces||1|||f||||t||||||||||2018-06-01 02:58:32.725842|2018-06-01 02:58:32.725842
NCT00520533|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2013-02-27|2007-08-22|2007-08-24|Estimate|||||||2013-02-27|2013-02-28|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|||Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma|A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma|Terminated||N/A|6|Actual|Ludwig Institute for Cancer Research||1||Closed prematurely due to toxicity|f||||f||||||||||2018-06-01 02:58:33.297187|2018-06-01 02:58:33.297187
NCT00520520|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2015-08-03|2007-08-23|2007-08-24|Estimate|||||||2015-08-03|2015-08-04|Estimate|December 2009||2009-12-31|July 2009|2009-07-31||||||||Observational|INCA||Influence of Mild Therapeutic Hypothermia on Leukocyte Count||Terminated|||||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 02:58:33.383137|2018-06-01 02:58:33.383137
NCT00520507|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2015-12-14|2007-08-22|2007-08-24|Estimate|||||||2015-12-14|2015-12-16|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients|An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients|Completed||Phase 4|27|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 02:58:33.430975|2018-06-01 02:58:33.430975
NCT00520494|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2013-03-18||2013-06-12|2007-08-23|2007-08-24|Estimate|2013-03-18|2013-05-03|Estimate||||2013-06-12|2013-06-20|Estimate|March 2007||2007-03-31|June 2013|2013-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency|A Multicenter Study on the Efficacy and Safety of Vivaglobin® in Previously Untreated Patients (PUPs) With Primary Immunodeficiency (PID)|Completed||Phase 4|18|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 02:58:33.549338|2018-06-01 02:58:33.549338
NCT00520481|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22||2010-11-09|2014-01-22|2007-08-22|2007-08-24|Estimate||||2010-11-09|2010-11-16|Estimate|2014-01-22|2014-02-17|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|January 2012|Actual|2012-01-31||Interventional|||Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer|Phase 2 Single Arm, Open-Label Study of IMC-A12 in Asymptomatic, Chemotherapy-Naïve Patients With Metastatic Androgen-Independent Prostate Cancer|Completed||Phase 2|41|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 02:58:34.139841|2018-06-01 02:58:34.139841
NCT00520468|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2009-09-24||2012-08-01|2007-08-23|2007-08-24|Estimate|2011-03-11|2011-04-14|Estimate||||2012-08-01|2012-08-07|Estimate|June 2004||2004-06-30|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS|Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS|Completed||Phase 2|15|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 02:58:34.233294|2018-06-01 02:58:34.233294
NCT00520455|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2007-11-13|2007-08-22|2007-08-24|Estimate|||||||2007-11-13|2007-11-15|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|June 2005|Actual|2005-06-30|||||Interventional|||Randomized Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia|Randomized Controlled Trial of Advanced Provision Emergency Contraception Among Women With Gonorrhea or Chlamydia|Completed||N/A|177|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 02:58:34.466109|2018-06-01 02:58:34.466109
NCT00520442|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2008-03-06|2007-08-22|2007-08-24|Estimate|||||||2008-03-06|2008-03-07|Estimate|September 2003||2003-09-30|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Acute Pediatric Fracture Analgesia Study|Ibuprofen Versus Acetaminophen With Codeine In Acute Pediatric Forearm Fractures|Completed||N/A|335|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-06-01 02:58:34.543725|2018-06-01 02:58:34.543725
NCT00520429|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2009-01-05|2007-08-23|2007-08-24|Estimate|||||||2009-01-05|2009-01-07|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Transforming Psychotherapy for Chronically Ill Patients|Transforming Psychotherapy for Chronically Ill Patients|Completed||Phase 1/Phase 2|23|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 02:58:34.628555|2018-06-01 02:58:34.628555
NCT00520416|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2017-03-15|2007-08-22|2007-08-24|Estimate|||||||2017-03-15|2017-03-17|Actual|October 2006||2006-10-31|March 2017|2017-03-31|July 20, 2008|Actual|2008-07-20|||||Observational|||Prospective, Non-Randomized Evaluation of Carbon Dioxide Gas as a Contrast Agent in Comparison With Iodinated Contrast in Endovascular Aneurysm Repair||Completed|||||University of Southern California|||1||f||||f|f|f||||||||2018-06-01 02:58:34.708914|2018-06-01 02:58:34.708914
NCT00520234|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2011-03-15||2011-04-08|2007-08-22|2007-08-23|Estimate|2011-04-08|2011-05-09|Estimate||||2011-04-08|2011-05-09|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|MSG-01||Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)|A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting|Completed||Phase 4|222|Actual|Mycoses Study Group||2|||f||||t||||||||||2018-06-01 02:58:37.440396|2018-06-01 02:58:37.440396
NCT00520403|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2014-08-14||2014-10-09|2007-08-23|2007-08-24|Estimate|2014-10-09|2014-10-13|Estimate||||2014-10-09|2014-10-13|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Safety Population: included all participants, even those who withdrew from the study prematurely and who received at least 1 dose of bevacizumab and had a safety follow-up visit.|A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.|An Open-label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Standard Therapy on Progression-free Survival in Patients With Metastatic Renal Cell Cancer.|Completed||Phase 2|25|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:58:34.791223|2018-06-01 02:58:34.791223
NCT00520390|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2010-04-01|2007-08-23|2007-08-24|Estimate|||||||2010-04-01|2010-04-02|Estimate|May 2007||2007-05-31|April 2010|2010-04-30||||||||Interventional|||A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)|A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38) Administered Weekly for 3 Weeks in 4-Week Cycles in Patients With Advanced Solid Tumors or Ymphoma (EZN-2208-02)|Completed||Phase 1|34||Enzon Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 02:58:35.139025|2018-06-01 02:58:35.139025
NCT00520377|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2008-04-22|2007-08-23|2007-08-24|Estimate|||||||2008-04-22|2008-04-23|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|May 2008|Anticipated|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation|Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation|Unknown status|Active, not recruiting|Phase 2|31|Actual|Scil Technology GmbH||2|||f||||f||||||||||2018-06-01 02:58:35.229769|2018-06-01 02:58:35.229769
NCT00520364|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2016-09-24|2007-08-23|2007-08-24|Estimate|||||||2016-09-24|2016-09-27|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||In Vitro Fertilization and Pregnancy After Use of Chemotherapy||Enrolling by invitation|||100|Anticipated|New York Medical College|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-06-01 02:58:35.314138|2018-06-01 02:58:35.314138
NCT00520351|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2010-03-26||2010-08-20|2007-08-23|2007-08-24|Estimate|2010-08-20|2010-09-16|Estimate||||2010-08-20|2010-09-16|Estimate|August 2007||2007-08-31|August 2010|2010-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)|Comparison of Lens Care Regimens With a Silicone Hydrogel Lens (Emerald)|Completed||Phase 3|30|Actual|University of Waterloo||2|||f||||f||||||||||2018-06-01 02:58:35.38487|2018-06-01 02:58:35.38487
NCT00520338|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2010-11-06|2007-08-23|2007-08-24|Estimate|||||||2010-11-06|2010-11-09|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial|Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial|Completed||Phase 4|80|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 02:58:35.610331|2018-06-01 02:58:35.610331
NCT00520325|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2012-09-04|2007-08-23|2007-08-24|Estimate|||||||2012-09-04|2012-09-05|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia|A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia|Withdrawn||Phase 1|0|Actual|Enzon Pharmaceuticals, Inc.||2||Sponsor decision to terminate the study|f||||||||||||||2018-06-01 02:58:35.67667|2018-06-01 02:58:35.67667
NCT00520312|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|||2014-04-07|2007-08-23|2007-08-24|Estimate|||||||2014-04-07|2014-04-09|Estimate|October 2007||2007-10-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease|Magnetic Resonance in Peripheral Arterial Disease|Completed|||519|Actual|Northwestern University|||||f||||t||||||Samples With DNA|"~     Plasma, serum, and whole blood samples are stored for future analysis~   "|||2018-06-01 02:58:35.739663|2018-06-01 02:58:35.739663
NCT00520299|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|2016-11-30|2011-05-09|2017-10-19|2007-08-22|2007-08-24|Estimate|2017-03-16|2017-04-26|Actual|2011-05-09|2011-05-13|Estimate|2017-10-19|2017-11-21|Actual|July 2007||2007-07-31|October 2017|2017-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Safety Analysis Set (all subjects who received at least 1 dose of ADI-PEG 20)|Study of ADI-PEG 20 in Patients With Advanced Melanoma|Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma|Completed||Phase 1/Phase 2|31|Actual|Ludwig Institute for Cancer Research||3|||f||||f||||||||Yes||2018-06-01 02:58:35.836059|2018-06-01 02:58:35.836059
NCT00520286|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-23|2016-12-30||2017-02-23|2007-08-23|2007-08-24|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|December 2007||2007-12-31|February 2017|2017-02-28|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence|Phase2, Double-blind, Placebo-controlled Trial of Modafinil for the Treatment of Methamphetamine Dependence|Completed||Phase 2|210|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||No||2018-06-01 02:58:36.969334|2018-06-01 02:58:36.969334
NCT00520273|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2016-03-01|2007-08-22|2007-08-23|Estimate|||||||2016-03-01|2016-03-02|Estimate|August 2007||2007-08-31|June 2010|2010-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA|A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA, HCV RNA, and HIV-1 RNA|Completed||N/A|100000|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:58:37.224021|2018-06-01 02:58:37.224021
NCT00520260|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2009-02-17|2007-08-22|2007-08-23|Estimate|||||||2009-02-17|2009-02-19|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase|Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients|Completed||Phase 4|42|Actual|Florida Eye Microsurgical Institute||2|||f||||t||||||||||2018-06-01 02:58:37.282678|2018-06-01 02:58:37.282678
NCT00520247|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2007-08-22|2007-08-22|2007-08-23|Estimate|||||||2007-08-22|2007-08-23|Estimate|September 2005||2005-09-30|August 2007|2007-08-31|February 2006|Actual|2006-02-28|||||Interventional|||Effect of Enalapril Plus Folic Acid on Blood Pressure and Glycometabolism|Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial|Completed||Phase 2|443|Actual|Anhui Medical University|||||f||||t||||||||||2018-06-01 02:58:37.358841|2018-06-01 02:58:37.358841
NCT00520221|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2007-08-22|2007-08-22|2007-08-23|Estimate|||||||2007-08-22|2007-08-23|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|July 2007|Actual|2007-07-31|||||Observational|||Intrapleural Minocycline Following Simple Aspiration for Primary Spontaneous Pneumothorax|Intrapleural Minocycline Following Simple Aspiration for Initial Treatment of Primary Spontaneous Pneumothorax: a Retrospective Study|Completed|||64|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 02:58:37.885682|2018-06-01 02:58:37.885682
NCT00520208|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2013-02-11|2007-08-21|2007-08-23|Estimate|||||||2013-02-11|2013-02-13|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|STAR-1||Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL|A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy With ATRA and Arsenic Trioxide (STAR-1)|Completed||Phase 2|15|Actual|CytRx|||||f||||f||||||||||2018-06-01 02:58:37.93461|2018-06-01 02:58:37.93461
NCT00520195|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2007-08-21|2007-08-21|2007-08-23|Estimate|||||||2007-08-21|2007-08-23|Estimate|March 2007||2007-03-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Stair Instead of Elevator Use at Work: Cardiovascular Primary Preventive Effects on Hospital Employees.||Completed||N/A|77|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-06-01 02:58:37.992485|2018-06-01 02:58:37.992485
NCT00520182|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2007-09-19|2007-08-22|2007-08-23|Estimate|||||||2007-09-19|2007-09-20|Estimate|March 2004||2004-03-31|September 2007|2007-09-30|February 2008|Anticipated|2008-02-29|||||Interventional|DIPAC||Dietary Interventions in Type 2 Obese Diabetic Patients in the Community|Community Trial to Assess the Effect of Nutritional Intervention Models on Medical Outcomes Among Obese Type 2 Diabetic Patients|Unknown status|Active, not recruiting|Phase 3|259|Actual|Ben-Gurion University of the Negev||3|||f||||f||||||||||2018-06-01 02:58:38.048491|2018-06-01 02:58:38.048491
NCT00520169|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-01-09|2007-08-22|2007-08-23|Estimate|||||||2008-01-09|2008-01-10|Estimate|July 2007||2007-07-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine|A Randomized, Open Label, Single Center, Single-Dose, Cross-Over Study to Determine the Absolute Bioavailability and the Nasopharyngeal Absorption of PMI-150 (Intranasal Ketamine) in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Javelin Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:58:38.197929|2018-06-01 02:58:38.197929
NCT00520156|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2007-08-21|2007-08-21|2007-08-23|Estimate|||||||2007-08-21|2007-08-23|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2008|Anticipated|2008-08-31|||||Observational|||Analysis of the Prevalence and Characteristics of Concomitant Sleep and Headache Disorders, and the Efficacy of CPAP Treatment for Headache Among Those Patients Diagnosed With Obstructive Sleep Apnea|Analysis of the Prevalence and Characteristics of Co-Morbid Sleep and Headache Disorders in Patients Being Evaluated at the WRAMC Sleep Disorders Laboratory, and the Efficacy of CPAP Treatment on Headache Burden in Obstructive Sleep Apnea Patients With a Co-Morbid Headache Disorder|Unknown status|Not yet recruiting||600|Anticipated|Walter Reed Army Medical Center|||||f||||t||||||||||2018-06-01 02:58:38.275528|2018-06-01 02:58:38.275528
NCT00520143|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2014-02-04|2007-08-22|2007-08-23|Estimate|||||||2014-02-04|2014-02-06|Estimate||||February 2014|2014-02-28||||||||Expanded Access|ATAP||Alglucosidase Alfa Temporary Access Program|Alglucosidase Alfa Temporary Access Program|Approved for marketing|||||Sanofi|||||||||||||||||||2018-06-01 02:58:38.337214|2018-06-01 02:58:38.337214
NCT00520130|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2016-11-17||2017-08-23|2007-08-21|2007-08-23|Estimate|2017-08-23|2017-08-24|Actual||||2017-08-23|2017-08-24|Actual|October 30, 2007|Actual|2007-10-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|October 14, 2015|Actual|2015-10-14||Interventional||There were 89 participants in the study. 3 patients enrolled and their cancers progressed prior to randomization so they were taken off study. 3 of these participants went back into remission with additional chemo and were re-enrolled on the protocol and randomized. They are counted twice in the enrolment (e.g. 92) but only once in the Started row.|Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System|Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders|Active, not recruiting||Phase 1/Phase 2|92|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f||||||No||2018-06-01 02:58:38.528594|2018-06-01 02:58:38.528594
NCT00520117|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2013-12-27|2007-08-22|2007-08-23|Estimate|||||||2013-12-27|2013-12-30|Estimate|June 2007||2007-06-30|August 2007|2007-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Assessing the Psychosocial Burden in Women With an Abnormal Pap Results After Screening Interventions|Assessing the Psychosocial Burden in Women With an Abnormal Pap Results After Screening Interventions|Completed|||151|Actual|Mahidol University|||2||f||||f||||||||||2018-06-01 02:58:39.906726|2018-06-01 02:58:39.906726
NCT00520104|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-02-27|2007-08-21|2007-08-23|Estimate|||||||2008-02-27|2008-02-29|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|March 2008|Anticipated|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine|A Randomized, Open Label, Single Center, Single-Dose Study to Assess the Effects of Certain Nasal Medications on the Pharmacokinetics, Safety and Tolerability of PMI-150 (Intranasal Ketamine Hydrochloride) 30 mg|Unknown status|Active, not recruiting|Phase 1|48|Anticipated|Javelin Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:58:39.966541|2018-06-01 02:58:39.966541
NCT00520091|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2012-05-16|2007-08-21|2007-08-23|Estimate|||||||2012-05-16|2012-05-18|Estimate|March 2005||2005-03-31|May 2012|2012-05-31|September 2010|Actual|2010-09-30|November 2006|Actual|2006-11-30||Interventional|||Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer|A Pilot Study of the Biologic Efficacy and Safety of the Addition of Celecoxib to a Program of Induction Chemotherapy and Neo-Adjuvant Chemo-Radiotherapy for the Treatment of Esophageal Cancer|Completed||Phase 2|14|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 02:58:40.0451|2018-06-01 02:58:40.0451
NCT00520078|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2007-08-21|2007-08-21|2007-08-23|Estimate|||||||2007-08-21|2007-08-23|Estimate|August 2007||2007-08-31|February 2007|2007-02-28|August 2008|Anticipated|2008-08-31|||||Observational|||Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection|Clinicopathological and Molecular Correlation of Acrochordon in Relation to Human Papillomavirus Infection|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 02:58:40.126672|2018-06-01 02:58:40.126672
NCT00520065|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-07-02|2007-08-21|2007-08-23|Estimate|||||||2008-07-02|2008-07-04|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Comparison of Nutritional Products for People With Type 2 Diabetes|Comparison of Nutritional Products for People With Type 2 Diabetes|Completed||Phase 2|33|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-06-01 02:58:40.214259|2018-06-01 02:58:40.214259
NCT00520052|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2007-08-22|2007-08-22|2007-08-23|Estimate|||||||2007-08-22|2007-08-23|Estimate|August 2003||2003-08-31|August 2007|2007-08-31|August 2005|Actual|2005-08-31|||||Interventional|||Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer|Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer|Completed||N/A|58|Actual|Wirral University Teaching Hospital NHS Trust||2|||f||||t||||||||||2018-06-01 02:58:40.293489|2018-06-01 02:58:40.293489
NCT00520039|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|2016-11-10||2017-08-28|2007-08-22|2007-08-23|Estimate|2017-08-28|2018-03-26|Estimate||||2017-08-28|2018-03-26|Estimate|September 2007||2007-09-30|August 2017|2017-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|OOMRS|52 participants were enrolled and 12 excluded due to normal tympanograms at first study visit, leaving 19 subjects in the SCO and 21 subjects in the SC+OMM group.|Osteopathic Otitis Media Research Study|Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry|Completed||N/A|52|Actual|West Virginia School of Osteopathic Medicine|One site closed after year 1 due to lower than expected subject recruitment. Lower than expected recruitment overall.|2|||f||||t||||||||No||2018-06-01 02:58:40.376715|2018-06-01 02:58:40.376715
NCT00520026|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2007-08-22|2007-08-22|2007-08-23|Estimate|||||||2007-08-22|2007-08-23|Estimate|January 2001||2001-01-31|August 2007|2007-08-31|June 2006|Actual|2006-06-30|||||Interventional|SUPLI||Suicide Prevention by Lithium - the Lithium Intervention Study||Terminated||N/A|167|Actual|University of Schleswig-Holstein||2||number of enrolled individuals after 5 years still off the estimated sample size|f||||f||||||||||2018-06-01 02:58:40.641387|2018-06-01 02:58:40.641387
NCT00520013|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|2015-04-08||2017-05-04|2007-08-22|2007-08-23|Estimate|2015-06-11|2015-07-03|Estimate||||2017-05-04|2017-06-05|Actual|August 2007||2007-08-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|October 2010|Actual|2010-10-31||Interventional||The analysis dataset is comprised of treated patients.|Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors|A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors|Completed||Phase 2|60|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-06-01 02:58:40.818937|2018-06-01 02:58:40.818937
NCT00520000|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2012-03-05|2007-08-21|2007-08-23|Estimate|||||||2012-03-05|2012-03-06|Estimate|December 2004||2004-12-31|March 2012|2012-03-31|September 2007|Actual|2007-09-30|May 2006|Actual|2006-05-31||Interventional|||Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Trial of Carboplatin and Abraxane in Patients With Solid Tumors|Completed||Phase 1|47|Actual|UNC Lineberger Comprehensive Cancer Center||3|||f||||t||||||||||2018-06-01 02:58:41.492647|2018-06-01 02:58:41.492647
NCT00519987|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-01-09|2007-08-21|2007-08-23|Estimate|||||||2008-01-09|2008-01-10|Estimate|June 2007||2007-06-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Multiple Dose Pharmacokinetics of Intranasal Ketamine|An Open Label, Single Center Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Administrations of 30 mg PMI-150 (Intranasal Ketamine) in Healthy Adult Volunteers|Completed||Phase 1|18|Actual|Javelin Pharmaceuticals||1|||f||||f||||||||||2018-06-01 02:58:41.575314|2018-06-01 02:58:41.575314
NCT00519974|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2015-09-29|2007-08-21|2007-08-23|Estimate|||||||2015-09-29|2015-10-01|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women|Decision-Making About Breast Reconstruction After Mastectomy Among Ethnic Minority Women: An Exploratory Study of Qualitative Themes|Completed|||55|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 02:58:41.647621|2018-06-01 02:58:41.647621
NCT00519961|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2011-03-15|2007-08-22|2007-08-23|Estimate|||||||2011-03-15|2011-03-16|Estimate|February 2007||2007-02-28|March 2011|2011-03-31|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery|A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery|Unknown status|Recruiting|N/A|1800|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:58:41.737335|2018-06-01 02:58:41.737335
NCT00519948|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-06-16|2007-08-22|2007-08-23|Estimate|||||||2008-06-16|2008-06-19|Estimate||||June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Comfort and Cleaning Evaluation of Multipurpose Solutions in Contact Lens Patients||Completed||Phase 4|20|Actual|Innovative Medical|||||f||||||||||||||2018-06-01 02:58:41.814462|2018-06-01 02:58:41.814462
NCT00519935|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2017-05-31|2007-08-22|2007-08-23|Estimate|||||||2017-05-31|2017-06-02|Actual|July 2001||2001-07-31|May 2017|2017-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Testing MST to Improve Adherence Among Youth With Chronic Poor Metabolic Control|Adherence to IDDM Regimen in Urban Youth|Completed||N/A|127|Actual|Wayne State University||2|||f||||f||||||||No||2018-06-01 02:58:41.866921|2018-06-01 02:58:41.866921
NCT00519922|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-07-21|2007-08-22|2007-08-23|Estimate|||||||2008-07-21|2008-07-22|Estimate|January 2008||2008-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|KBA Exercise||A Study of the Effectiveness of Different Types of Exercise for People With Knee Osteoarthritis|Efficacy of Kinesthesia, Balance and Agility Exercise Training as Treatment of Knee Osteoarthritis: A Pilot Study|Completed||N/A|30|Anticipated|The Arthritis Research Institute of America||2|||f||||f||||||||||2018-06-01 02:58:41.943159|2018-06-01 02:58:41.943159
NCT00519909|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2007-08-22|2007-08-22|2007-08-23|Estimate|||||||2007-08-22|2007-08-23|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|February 2008|Anticipated|2008-02-29|||||Interventional|||The Effect of Calcium on Fecal Fat and Energy Excretion||Unknown status|Recruiting|N/A|15|Anticipated|University of Copenhagen||5|||f||||f||||||||||2018-06-01 02:58:42.02896|2018-06-01 02:58:42.02896
NCT00519896|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2017-01-17||2017-03-13|2007-08-21|2007-08-23|Estimate|2017-03-13|2017-04-25|Actual||||2017-03-13|2017-04-25|Actual|July 2007||2007-07-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional||All 35 patients that signed consent and received at least one dose of study therapy are included.|Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer|Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation|Completed||Phase 2|35|Actual|University of Washington||1|||f||||f||||||||No||2018-06-01 02:58:42.128322|2018-06-01 02:58:42.128322
NCT00519857|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2017-02-16|2007-08-21|2007-08-23|Estimate|||||||2017-02-16|2017-02-17|Actual|July 2001||2001-07-31|February 2017|2017-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|LIFT||Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)|A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group,Placebo Controlled Clinical Trial of the Effects of Tibolone (Org OD-14 1.25mg) on the Incidence of New Vertebral Fractures in Osteoporotic Postmenopausal Women.|Completed||Phase 3|4534|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:58:42.494617|2018-06-01 02:58:42.494617
NCT00519844|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2015-11-11|2007-08-22|2007-08-23|Estimate|||||||2015-11-11|2015-11-13|Estimate|July 2005||2005-07-31|November 2015|2015-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction|Assessment of Satisfaction With Growth Hormone Treatment in Children Born Small for Gestational Age: Benefits of Galenic Form of the Product|Completed||Phase 4|5|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:58:42.559659|2018-06-01 02:58:42.559659
NCT00519831|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2017-03-24||2017-05-10|2007-08-21|2007-08-23|Estimate|2017-05-10|2017-06-09|Actual||||2017-05-10|2017-06-09|Actual|August 2007||2007-08-31|May 2017|2017-05-31|November 2009|Actual|2009-11-30|February 2008|Actual|2008-02-29||Interventional|||Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC|Phase II Study of Vinflunine and Cetuximab in the Second Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer|Terminated||Phase 2|18|Actual|UNC Lineberger Comprehensive Cancer Center|Study was terminated early due to unavailable drug/funding. Preliminary analysis reported.|1||Drug unavailable|f||||t||||||||||2018-06-01 02:58:42.623811|2018-06-01 02:58:42.623811
NCT00519818|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|2011-06-28||2016-02-26|2007-08-22|2007-08-23|Estimate|2014-08-12|2014-08-27|Estimate||||2016-02-26|2016-03-24|Estimate|August 2007||2007-08-31|February 2016|2016-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia|A Phase 2, Open Label, Crossover Pharmacokinetic and Pharmacodynamic Study to Compare Chronocort Versus Cortef in Patients With CAH|Completed||Phase 1/Phase 2|20|Actual|Diurnal Limited||1|||f||||f||||||||||2018-06-01 02:58:42.883793|2018-06-01 02:58:42.883793
NCT00519805|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2011-08-05|2007-08-21|2007-08-23|Estimate|||||||2011-08-05|2011-08-08|Estimate|August 2007||2007-08-31|March 2008|2008-03-31||||August 2012|Anticipated|2012-08-31||Interventional|||Dalteparin in Preventing Blood Clots in Patients With Lung Cancer|FRAGMATIC - A Randomised Phase III Clinical Trial Investigating the Effect of FRAGMin Added to Standard Therapy In Patients With Lung Cancer|Unknown status|Recruiting|Phase 3|2200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:58:43.104321|2018-06-01 02:58:43.104321
NCT00519792|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2011-06-06|2007-08-21|2007-08-23|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2007||2007-08-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment|Phase Ib Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Omega DUROS® and Ribavirin in Subjects With Chronic Hepatitis C Previously Treated With Pegylated Interferon and Ribavirin|Completed||Phase 1|60|Actual|Intarcia Therapeutics||2|||f||||f||||||||||2018-06-01 02:58:43.27568|2018-06-01 02:58:43.27568
NCT00519779|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2011-11-07||2012-03-22|2007-08-21|2007-08-23|Estimate|2012-02-16|2012-03-22|Estimate||||2012-03-22|2012-03-27|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention|Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention|Completed||Phase 2|68|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||f||||||||||2018-06-01 02:58:43.355141|2018-06-01 02:58:43.355141
NCT00519766|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2014-05-22|2007-08-21|2007-08-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|September 1997||1997-09-30|May 2014|2014-05-31|November 2002|Actual|2002-11-30|March 1999|Actual|1999-03-31||Observational|SCRIPT||Examining a New Biomarker of Nicotine Use Among Pregnant Women Who Participated in the New England SCRIPT|Assessment of Nicotine Metabolism Among Underserved Pregnant Women From NE SCRIPT|Completed|||252|Actual|Memorial Hospital of Rhode Island|||||f||||f||||||||||2018-06-01 02:58:44.690253|2018-06-01 02:58:44.690253
NCT00519753|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2016-11-17|2007-08-21|2007-08-23|Estimate|||||||2016-11-17|2016-11-18|Estimate|August 2007||2007-08-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav|Safety and Efficacy of Switching to the Travoprost/Timolol Maleate Fixed Combination (DUOTRAV®) From Prior Mono or Two-Drug Therapy in Germany|Completed||Phase 4|522|Actual|Alcon Research||1|||f||||f||||||||||2018-06-01 02:58:44.752111|2018-06-01 02:58:44.752111
NCT00519740|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2009-02-03|2007-08-22|2007-08-23|Estimate|||||||2009-02-03|2009-02-04|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Influence of Nutrition on Nasal and Bronchial Affliction in Patients With Allergy on Grass-Pollen|Influence of Nutrition on Nasal and Bronchial Affliction in Patients With Allergy on Grass-Pollen After Low-Dosed Specific Bronchial Provocation|Completed||N/A|120|Actual|Johann Wolfgang Goethe University Hospital|||||f||||t||||||||||2018-06-01 02:58:44.823692|2018-06-01 02:58:44.823692
NCT00519727|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-08-15|2007-08-21|2007-08-23|Estimate|||||||2008-08-15|2008-08-19|Estimate|August 2007||2007-08-31|August 2008|2008-08-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Safety Study of ISIS 325568 in Healthy Volunteers|A Phase I, Double-Blind, Placebo-Controlled, Dose- Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 325568 Administered to Healthy Volunteers|Completed||Phase 1|60|Anticipated|Ionis Pharmaceuticals, Inc.||8|||f||||f||||||||||2018-06-01 02:58:44.888007|2018-06-01 02:58:44.888007
NCT00519714|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2010-06-18|2007-08-21|2007-08-23|Estimate|||||||2010-06-18|2010-06-22|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)|Completed||Phase 2/Phase 3|195|Anticipated|Montreal Heart Institute||3|||f||||f||||||||||2018-06-01 02:58:44.972076|2018-06-01 02:58:44.972076
NCT00519701|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2007-08-22|2007-08-22|2007-08-23|Estimate|||||||2007-08-22|2007-08-23|Estimate|April 2002||2002-04-30|August 2007|2007-08-31|February 2007|Actual|2007-02-28|||||Interventional|||Hydroxyurea in Young Children With Sickle Cell Anemia|Effects of Hydroxyurea on the Prevention of Chronic Organ Damage in Young Children With Sickle Cell Anemia|Completed||N/A|14|Actual|Duke University||1|||f||||f||||||||||2018-06-01 02:58:45.139488|2018-06-01 02:58:45.139488
NCT00519688|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2011-10-13|2007-08-22|2007-08-23|Estimate|||||||2011-10-13|2011-10-17|Estimate|July 2006||2006-07-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma|A Phase II Study of Tegafur/Uracil(UFUR) Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)|Completed||Phase 2|44|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 02:58:45.22786|2018-06-01 02:58:45.22786
NCT00519675|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-22|||2010-07-16|2007-08-22|2007-08-23|Estimate|||||||2010-07-16|2010-07-19|Estimate|May 2007||2007-05-31|July 2010|2010-07-31||||||||Interventional|||Alitretinoin in the Treatment of Chronic Hand Eczema|Open Label Treatment of Patients With Chronic Hand Dermatitis Who Have Participated in a Previous Clinical Trial Involving Oral Alitretinoin|Completed||Phase 3|150|Anticipated|Basilea Pharmaceutica|||||f||||f||||||||||2018-06-01 02:58:45.32885|2018-06-01 02:58:45.32885
NCT00519662|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2017-03-30|2007-08-21|2007-08-22|Estimate|||||||2017-03-30|2017-04-04|Actual|August 2007||2007-08-31|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors|Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors|Completed||Phase 1|32|Actual|Sunesis Pharmaceuticals||1|||f||||f||||||||No||2018-06-01 02:58:45.403099|2018-06-01 02:58:45.403099
NCT00519649|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2008-12-17||2016-11-03|2007-08-21|2007-08-22|Estimate|2009-04-01|2009-05-27|Estimate||||2016-11-03|2016-12-16|Estimate|August 2007||2007-08-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.|An Open, Phase IV, Single-group, Multicentre Study to Assess the Long-term Persistence of Antibodies Against Hepatitis B and the Immune Response to a Hepatitis B (HBV) Vaccine Challenge in Children Aged 7-8 Years of Age and Previously Vaccinated in Infancy With GSK Biologicals' HBV Vaccine (Engerix™-B).|Completed||Phase 4|301|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:58:45.506154|2018-06-01 02:58:45.506154
NCT00519636|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2008-11-07||2016-10-27|2007-08-21|2007-08-22|Estimate|2009-12-08|2010-01-15|Estimate||||2016-10-27|2016-12-09|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS|A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects With Seasonal Allergic Rhinitis|Completed||Phase 4|360|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:58:45.854282|2018-06-01 02:58:45.854282
NCT00519623|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2010-12-03||2010-12-03|2007-08-20|2007-08-22|Estimate|2010-12-03|2010-12-30|Estimate||||2010-12-03|2010-12-30|Estimate|August 2007||2007-08-31|December 2010|2010-12-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Transdermal Basal Insulin Patch Study in Type 1 Diabetes|Pharmacokinetic/Pharmacodynamic Study of the PassPort(R) Transdermal Insulin Delivery System in Type 1 Diabetes Patients|Completed||Phase 1/Phase 2|9|Actual|Altea Therapeutics|This was a small exploratory study to evaluate the PK, PD and tolerability of a selected Basal Insulin PassPort(r) System configuration in C-peptide negative type 1 diabetes subjects.|1|||f||||f||||||||||2018-06-01 02:58:46.596495|2018-06-01 02:58:46.596495
NCT00519610|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2012-08-14|2007-08-21|2007-08-22|Estimate|||||||2012-08-14|2012-08-15|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|July 2010|Actual|2010-07-31|||||Observational|PHTN||Assessing Outcome After H-graft Shunt Placement|A Study Assessing Patient Outcomes After Placement of H-graft Portacaval Shunts for the Treatment of Portal Hypertension|Completed|||66|Actual|University of South Florida|||1||f||||f||||||||||2018-06-01 02:58:46.820438|2018-06-01 02:58:46.820438
NCT00519597|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2013-07-08|2007-08-20|2007-08-22|Estimate|||||||2013-07-08|2013-07-09|Estimate|December 2005||2005-12-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|RICCADSA||Continuous Positive Airway Pressure (CPAP) Treatment in Coronary Artery Disease and Sleep Apnea|Randomized Intervention With CPAP in Coronary Artery Disease and Sleep Apnea - RICCADSA Trial|Completed||Phase 4|511|Actual|Skaraborg Hospital||4|||f||||t||||||||||2018-06-01 02:58:46.895303|2018-06-01 02:58:46.895303
NCT00519584|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2017-04-18||2017-06-21|2007-08-21|2007-08-22|Estimate|2017-06-21|2017-07-21|Actual||||2017-06-21|2017-07-21|Actual|July 2007||2007-07-31|June 2017|2017-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|Ropivacaine||Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone|Duration of Interscalene Nerve Blocks With Ropivacaine Alone, Ropivacaine Mixed With Dexamethasone, and Ropivacaine Alone Combined With Systemic Dexamethasone|Terminated||N/A|218|Actual|The Cleveland Clinic||4||Collected study data was not usable due to process miscommunications|f||||f||||||||No||2018-06-01 02:58:46.999287|2018-06-01 02:58:46.999287
NCT00519571|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2008-05-08|2007-08-20|2007-08-22|Estimate|||||||2008-05-08|2008-05-09|Estimate|July 2008||2008-07-31|May 2008|2008-05-31|July 2009|Anticipated|2009-07-31|June 2009|Anticipated|2009-06-30||Interventional|||Evaluation of the Safety and Efficacy of Using ImplantLock Device - Dental Implant Accessory|Evaluation of the Safety and Efficacy of Using ImplantLock Device - Dental Implant Accessory|Unknown status|Not yet recruiting|N/A|15|Anticipated|Innovative Implant Solutions||1|||f||||f||||||||||2018-06-01 02:58:47.39728|2018-06-01 02:58:47.39728
NCT00519558|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2017-02-27|2007-08-21|2007-08-22|Estimate|||||||2017-02-27|2017-02-28|Actual|May 31, 2003|Actual|2003-05-31|February 2017|2017-02-28|January 24, 2005|Actual|2005-01-24|January 24, 2005|Actual|2005-01-24||Interventional|||Growth Hormone Deficiency in Adults (GHDA)|Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency|Completed||Phase 3|121|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 02:58:47.479251|2018-06-01 02:58:47.479251
NCT00519545|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2012-01-23|2007-08-20|2007-08-22|Estimate|||||||2012-01-23|2012-01-24|Estimate|March 2006||2006-03-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Prayer as a Possible Adjuvant Treatment for Breast Cancer|Prayer as a Possible Adjuvant Treatment for Breast Cancer - A Randomized Partially Blinded Controlled Clinical Trial Evaluating the Effect of Prayer on Humoral and Biochemical Parameters in Stage I-IV Breast Cancer|Completed||N/A|15|Actual|Southwestern Regional Medical Center||2|||f||||f||||||||||2018-06-01 02:58:47.543075|2018-06-01 02:58:47.543075
NCT00519532|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2010-03-17||2014-10-17|2007-08-21|2007-08-22|Estimate|2010-03-17|2010-04-02|Estimate||||2014-10-17|2014-10-27|Estimate|July 2007||2007-07-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease|A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease|Terminated||Phase 3|84|Actual|UCB Pharma|Because the manufacturing process for rotigotine patches was changed, enrollment into SP915 was stopped in April 2008 to ensure sufficient trial medication for all subjects enrolled at that time to complete the trial according to the protocol.|1||Due to clinical trial supplies shortage|f||||f||||||||||2018-06-01 02:58:47.649932|2018-06-01 02:58:47.649932
NCT00519519|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2017-02-08|2007-08-21|2007-08-22|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2004||2004-07-31|February 2017|2017-02-28|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Optimal Dose of Omeprazole After Endoscopic Treatment of Bleeding Peptic Ulcers|Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers|Completed||Phase 3|126|Actual|Singapore General Hospital||1|||f||||f||||||||||2018-06-01 02:58:47.961456|2018-06-01 02:58:47.961456
NCT00519506|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2009-04-12|2007-08-20|2007-08-22|Estimate|||||||2009-04-12|2009-04-14|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli|A Phase II Study to Evaluate the Efficacy of Anti-Fibrin Humanized Monoclonal Antibody(DI-DD3B6/22-80B3) Fab' Fragment (ThromboView®) Conjugated With Technetium-99m in the Detection of Pulmonary Emboli|Completed||Phase 2|61|Actual|Agen Biomedical|||||f||||f||||||||||2018-06-01 02:58:48.058316|2018-06-01 02:58:48.058316
NCT00519493|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2010-10-18|2007-08-21|2007-08-22|Estimate|||||||2010-10-18|2010-10-19|Estimate|August 2007||2007-08-31|June 2008|2008-06-30|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|||A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids|A Two Part Study: An Investigator-initiated, Single-center, Single-blinded, Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids|Unknown status|Active, not recruiting|Phase 4|15|Anticipated|University of Miami||2|||f||||f||||||||||2018-06-01 02:58:48.118865|2018-06-01 02:58:48.118865
NCT00519480|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2017-09-01|2007-08-20|2007-08-22|Estimate|||||||2017-09-01|2017-09-06|Actual|September 11, 2007|Actual|2007-09-11|September 2017|2017-09-30|April 1, 2008|Actual|2008-04-01|April 1, 2008|Actual|2008-04-01||Interventional|||A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin|A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered With Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|50|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 02:58:48.186516|2018-06-01 02:58:48.186516
NCT00519467|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2016-12-02|2007-08-21|2007-08-22|Estimate|||||||2016-12-02|2016-12-06|Estimate|June 2003||2003-06-30|December 2016|2016-12-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria|An Open, Randomised, Multi-centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate|Completed||Phase 2|120|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:58:48.270561|2018-06-01 02:58:48.270561
NCT00519454|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2010-09-03|2007-08-21|2007-08-22|Estimate|||||||2010-09-03|2010-09-08|Estimate|April 2005||2005-04-30|September 2010|2010-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Estrogen and Gender Biased Autoimmunity|Estrogen and Gender Biased Autoimmunity in Systemic Lupus Erythematosus|Unknown status|Recruiting||75|Anticipated|The Center for Rheumatic Disease, Allergy, & Immunology|||1||f||||f||||||||||2018-06-01 02:58:48.487255|2018-06-01 02:58:48.487255
NCT00519441|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2012-08-14|2007-08-21|2007-08-22|Estimate|||||||2012-08-14|2012-08-15|Estimate|June 2007||2007-06-30|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Do Patients Who Have Had Surgery for Achalasia Suffer From Reflux|Gastroesophageal Reflux in Patients With Achalasia|Completed||N/A|100|Actual|University of South Florida||1|||f||||f||||||||||2018-06-01 02:58:48.594305|2018-06-01 02:58:48.594305
NCT00519428|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|2016-10-06||2017-09-05|2007-08-20|2007-08-22|Estimate|2017-09-05|2017-10-04|Actual||||2017-09-05|2017-10-04|Actual|August 2007||2007-08-31|September 2017|2017-09-30|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Interventional|||Does Dual Therapy Hasten Antidepressant Response?|Combining Antidepressants to Hasten Remission From Depression|Completed||Phase 4|245|Actual|New York State Psychiatric Institute|Sample size may have limited demonstration of differences.|3|||f||||t||||||||No||2018-06-01 02:58:48.681235|2018-06-01 02:58:48.681235
NCT00519415|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2008-12-18|2007-08-20|2007-08-22|Estimate|||||||2008-12-18|2008-12-19|Estimate|September 2007||2007-09-30|December 2008|2008-12-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Comparative Results of Maxillary Deficiency Treatment by Tongue Plate and Facemask in Growing Patients|This Study is to Apply the Tongue Force to Correct the Dentofacial Deformities|Completed||Phase 3|20|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-06-01 02:58:49.089731|2018-06-01 02:58:49.089731
NCT00519402|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2017-11-08|2007-08-21|2007-08-22|Estimate|||||||2017-11-08|2017-11-13|Actual||||November 2017|2017-11-30||||||||Observational|||Outcomes of Partial Versus Complete Tonsillectomy for Obstructive Sleep Disordered Breathing|Outcomes of Partial Versus Complete Tonsillectomy for Obstructive Sleep Disordered Breathing in Children|Withdrawn|||0|Actual|The Cleveland Clinic|||2||f||||||||||||||2018-06-01 02:58:49.182724|2018-06-01 02:58:49.182724
NCT00519389|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20||2013-06-12|2013-06-12|2007-08-20|2007-08-22|Estimate||||2013-06-12|2013-06-21|Estimate|2013-06-12|2013-06-21|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety, Reactogenicity and Immunogenicity of an H5N1 VLP|A Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant)|Completed||Phase 1/Phase 2|230|Actual|Novavax||4|||f||||t||||||||||2018-06-01 02:58:49.265081|2018-06-01 02:58:49.265081
NCT00519376|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2013-06-12|2009-07-22|2017-02-03|2007-08-21|2007-08-22|Estimate|2013-12-05|2013-12-30|Estimate|2009-07-22|2009-08-10|Estimate|2017-02-03|2017-03-23|Actual|August 2007||2007-08-31|December 2016|2016-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.|A Randomised, Single-dose, Dose Ascending, Double-blind, Placebo Controlled, Four-way, Incomplete Block Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With Magnesium Stearate in COPD Patients.|Completed||Phase 2|20|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:58:49.423419|2018-06-01 02:58:49.423419
NCT00519363|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2010-03-23|2007-08-21|2007-08-22|Estimate|||||||2010-03-23|2010-03-24|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors|Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors.|Completed||Phase 1/Phase 2|15|Anticipated|The Center for Rheumatic Disease, Allergy, & Immunology|||||f||||f||||||||||2018-06-01 02:58:51.122497|2018-06-01 02:58:51.122497
NCT00519350|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2017-02-22|2007-08-21|2007-08-22|Estimate|||||||2017-02-22|2017-02-24|Actual|August 2007||2007-08-31|March 2010|2010-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Towards a High-fat Feeding Intervention Study: Identification of Markers for Inflammation and Organ Damage|Towards a High-fat Feeding Intervention Study: Identification of Markers for Inflammation and Organ Damage|Completed|||24|Actual|Maastricht University Medical Center|||3||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 02:58:51.201966|2018-06-01 02:58:51.201966
NCT00519337|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2012-01-03|2007-08-21|2007-08-22|Estimate|||||||2012-01-03|2012-01-05|Estimate|October 2008||2008-10-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|October 2009|Actual|2009-10-31||Interventional|AFIST||Impact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation|The Impact of Ascorbic Acid Therapy on Inflammatory Mediators in Cardiothoracic Surgery Patients: The Atrial Fibrillation Suppression Trial IV (AFIST IV) Pilot Study|Completed||Phase 4|25|Actual|Hartford Hospital||2|||f||||t||||||||||2018-06-01 02:58:51.282235|2018-06-01 02:58:51.282235
NCT00519324|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2016-11-16|2007-08-21|2007-08-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|August 2007||2007-08-31|November 2016|2016-11-30||||January 2009|Actual|2009-01-31||Interventional|||Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer|A Single Arm, Multi-center Phase II Study of RAD001 in Patients With Advanced Gastric Carcinoma Whose Cancer Has Progressed Despite Prior Treatment|Completed||Phase 2|54|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:58:51.36793|2018-06-01 02:58:51.36793
NCT00519311|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2017-01-11|2007-08-21|2007-08-22|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|Ask||Health Intervention for Adolescents With Intellectual Disability|RCT of an Intervention to Improve the Health of Adolescents With Intellectual Disability|Completed||N/A|732|Actual|The University of Queensland||2|||f||||f||||||||||2018-06-01 02:58:51.463747|2018-06-01 02:58:51.463747
NCT00519298|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2008-04-21|2007-08-21|2007-08-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|October 2007||2007-10-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects|A Double-Blind, Placebo-Controlled, Balanced, 4-Way, Incomplete Block Design to Evaluate the Effects of a Single Administration of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG (qEEG) in Healthy Subjects|Completed||Phase 1|25|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||||||||||||2018-06-01 02:58:51.547284|2018-06-01 02:58:51.547284
NCT00519285|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|2013-04-25||2016-06-21|2007-08-21|2007-08-22|Estimate|2013-08-02|2013-10-10|Estimate||||2016-06-21|2016-07-22|Estimate|August 2007||2007-08-31|June 2016|2016-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|VENICE||Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer|A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer|Completed||Phase 3|1224|Actual|Sanofi|Pain response initially defined as a key secondary endpoint together with PSA response, time to occurence of SRE and PFS was finally considered as an exploratory endpoint in final statistical analysis plan.|2|||f||||t||||||||||2018-06-01 02:58:51.688417|2018-06-01 02:58:51.688417
NCT00519272|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2017-06-19|2007-08-21|2007-08-22|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2006|Actual|2006-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients|A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients|Active, not recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 02:58:53.028517|2018-06-01 02:58:53.028517
NCT00519259|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2017-01-10|2007-08-21|2007-08-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2006||2006-02-28|June 2006|2006-06-30||||||||Interventional|||Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1|Tolerability, Safety, and Pharmacokinetics of Repeated Sublingual Doses of Lobeline|Unknown status|Active, not recruiting|Phase 1|12||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 02:58:53.102418|2018-06-01 02:58:53.102418
NCT00519246|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2009-03-30|2007-08-21|2007-08-22|Estimate|||||||2009-03-30|2009-03-31|Estimate|February 2007||2007-02-28|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|COPTEAM||Comparison of Pain Therapeutic Effects After Benign Mastectomy|Clinical Comparison of Postoperative Pain Therapeutic Effects After Benign Mastectomy|Completed||Phase 4|2000|Actual|Nanjing Medical University||7|||f||||t||||||||||2018-06-01 02:58:53.247143|2018-06-01 02:58:53.247143
NCT00519233|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2014-04-30|2007-08-20|2007-08-22|Estimate|||||||2014-04-30|2014-05-02|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer|A Phase I Investigation of the Intravenous Administration of AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer|Completed||Phase 1|13|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 02:58:53.337723|2018-06-01 02:58:53.337723
NCT00519220|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2012-08-14|2007-08-21|2007-08-22|Estimate|||||||2012-08-14|2012-08-15|Estimate|December 2006||2006-12-31|August 2012|2012-08-31|December 2017|Anticipated|2017-12-31|||||Observational|Achalasia||Outcome of Symptoms in Patients Undergoing a Heller Myotomy|Short and Long Term Outcomes of Heller Myotomy|Unknown status|Recruiting||800|Anticipated|University of South Florida|||1||f||||f||||||||||2018-06-01 02:58:53.413072|2018-06-01 02:58:53.413072
NCT00519207|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2011-07-18|2007-08-20|2007-08-22|Estimate|||||||2011-07-18|2011-07-19|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Evaluation of Topical Liposomal Lidocaine and Oral Sucrose for Treatment of Pain in Newborns Undergoing Venipuncture|Evaluation of Topical Liposomal Lidocaine and Oral Sucrose for Treatment of Pain in Newborn Infants Undergoing Venipuncture: A Randomized Controlled Trial|Completed||Phase 3|330|Actual|The Hospital for Sick Children||3|||f||||t||||||||||2018-06-01 02:58:53.479576|2018-06-01 02:58:53.479576
NCT00519194|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|2014-03-31||2014-05-14|2007-08-20|2007-08-22|Estimate|2014-04-01|2014-05-05|Estimate||||2014-05-14|2014-05-20|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CONVERT-AF|Subjects treated|CONcomitant eValuation of Epicor Left atRial Therapy for AF|CONcomitant eValuation of Epicor Left atRial Therapy for AF|Terminated||N/A|112|Actual|St. Jude Medical||1|||f||||t||||||||||2018-06-01 02:58:53.567519|2018-06-01 02:58:53.567519
NCT00519181|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2007-08-20|2007-08-20|2007-08-22|Estimate|||||||2007-08-20|2007-08-22|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|VALPROHAM||Safety and Efficiency Study of Valproic Acid In HAM/TSP|Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP|Terminated||N/A|19|Actual|University Hospital Pierre Zobda-Quitman|||||f||||t||||||||||2018-06-01 02:58:53.762686|2018-06-01 02:58:53.762686
NCT00519168|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2017-10-04|2007-08-20|2007-08-22|Estimate|||||||2017-10-04|2017-10-06|Actual|September 2006||2006-09-30|October 2017|2017-10-31|August 31, 2011|Actual|2011-08-31|August 31, 2011|Actual|2011-08-31||Observational|||Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival|Sleep, Circadian, Hormonal Dysregulation, and Breast Cancer Survival|Completed|||141|Actual|Stanford University|||||f||||t||||||Samples Without DNA|"~     Saliva and blood~   "|||2018-06-01 02:58:53.82444|2018-06-01 02:58:53.82444
NCT00519155|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2008-04-21|2007-08-21|2007-08-22|Estimate|||||||2008-04-21|2008-04-23|Estimate|July 2007||2007-07-31|April 2008|2008-04-30|November 2008|Anticipated|2008-11-30|October 2008|Anticipated|2008-10-31||Interventional|||Pilot Study on MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery|Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Scil Technology GmbH||2|||f||||f||||||||||2018-06-01 02:58:53.907067|2018-06-01 02:58:53.907067
NCT00519142|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20||2009-09-16|2009-09-16|2007-08-20|2007-08-22|Estimate||||2009-09-16|2009-09-17|Estimate|2009-09-16|2009-09-17|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus|A Rapid Onset and Short Duration Insulin Secretogogue, Mitiglinide, in Combination With Metformin Versus Metformin Alone in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial for 6 Months|Completed||Phase 3|367|Actual|Elixir Pharmaceuticals||3|||f||||f||||||||||2018-06-01 02:58:54.016605|2018-06-01 02:58:54.016605
NCT00519129|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-21|||2011-08-17|2007-08-21|2007-08-22|Estimate|||||||2011-08-17|2011-08-18|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Improving Quality of Colonoscopy Using a 3D-imager|Magnetic Endoscopic Imaging Versus Standard Colonoscopy in a Routine Colonoscopy Setting: A Randomised Controlled Trial|Completed||Phase 3|800|Actual|Sorlandet Hospital HF|||||f||||t||||||||||2018-06-01 02:58:54.215202|2018-06-01 02:58:54.215202
NCT00519116|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate|October 2000||2000-10-31|August 2007|2007-08-31|August 2001||2001-08-31|||||Interventional|||Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients|An Open-Label, Concentration-Controlled, Randomized, 6-Month Study of 'Standard Dose' Tacrolimus + Sirolimus + Corticosteroids Compared to 'Reduced-Dose' Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients|Completed||Phase 4|150||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:58:54.376267|2018-06-01 02:58:54.376267
NCT00519103|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2007-08-29|2007-08-20|2007-08-21|Estimate|||||||2007-08-29|2007-08-30|Estimate|December 2002||2002-12-31|August 2007|2007-08-31|March 2003|Actual|2003-03-31|||||Interventional|||Resistance Exercise Reduces the Expression of Inflammation and Fibrosis Associated Genes in Autoimmune Myositis Patients||Completed||N/A|8|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-06-01 02:58:54.456821|2018-06-01 02:58:54.456821
NCT00519090|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2010-11-11||2011-11-04|2007-08-20|2007-08-21|Estimate|2011-04-07|2011-05-10|Estimate||||2011-11-04|2011-11-07|Estimate|October 2007||2007-10-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ENEST||Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|A Phase III Randomized, Open- Label Multi-center Study of Nilotinib Versus Imatinib in Adult Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have a Suboptimal Cytogenetic Response (CyR) on Imatinib|Terminated||Phase 3|6|Actual|Novartis||2||This study was terminated due to limited enrollment.|f||||t||||||||||2018-06-01 02:58:54.547418|2018-06-01 02:58:54.547418
NCT00519077|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2013-08-14||2016-06-02|2007-08-17|2007-08-21|Estimate|2013-10-28|2013-11-21|Estimate||||2016-06-02|2016-07-01|Estimate|March 2005||2005-03-31|June 2016|2016-06-30|May 2013|Actual|2013-05-31|May 2008|Actual|2008-05-31||Interventional|||Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck|Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) as Monotherapy in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|44|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 02:58:55.069696|2018-06-01 02:58:55.069696
NCT00519064|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2016-11-30|2007-08-20|2007-08-21|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|May 2007|Actual|2007-05-31|December 2006|Actual|2006-12-31||Interventional|||Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases|A Phase III, Randomized, Controlled, Observer-blind, Single-center Study to Compare Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases|Completed||Phase 3|361|Actual|Novartis||2|||f||||||||||||||2018-06-01 02:58:55.276501|2018-06-01 02:58:55.276501
NCT00519051|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate|March 2004||2004-03-31|August 2007|2007-08-31|December 2006|Actual|2006-12-31|||||Interventional|DMH||A Randomized Clinical Trial for Depressed Mothers at Primary Care Level|Efectividad de la Farmacoterapia Monitorizada en Pacientes Deprimidas de la atención Primaria de Salud y su repercusión Sobre la Salud Mental de Sus Hijos|Completed||N/A|345|Actual|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile||1|||f||||f||||||||||2018-06-01 02:58:55.34479|2018-06-01 02:58:55.34479
NCT00519038|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate|March 2003||2003-03-31|August 2007|2007-08-31|December 2006|Actual|2006-12-31|||||Interventional|EPSEEIC2004||Experimental Prospective Study on the Effectiveness and Efficiency of the Implementation of Clinical Pathways|Experimental Prospective Study on the Effectiveness and Efficiency of the Implementation of Clinical Pathways|Completed||N/A|424|Actual|Agenzia Regionale Sanitaria delle Marche||2|||f||||t||||||||||2018-06-01 02:58:55.403783|2018-06-01 02:58:55.403783
NCT00519025|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2017-06-09|2007-08-17|2007-08-21|Estimate|||||||2017-06-09|2017-06-12|Actual|August 2007||2007-08-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Risk Factors for Linezolid Resistance in Staphylococcus Aureus|Risk Factors for Linezolid Resistance in Staphylococcus Aureus|Active, not recruiting|||360|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:58:55.467995|2018-06-01 02:58:55.467995
NCT00519012|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2009-09-26|2007-08-20|2007-08-21|Estimate|||||||2009-09-26|2009-09-28|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Benefits of Switching Antidepressants Following Early Nonresponse|Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2|Unknown status|Recruiting|Phase 4|200|Anticipated|Oizumi Hospital||2|||f||||t||||||||||2018-06-01 02:58:55.594593|2018-06-01 02:58:55.594593
NCT00518999|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2008|Anticipated|2008-08-31|||||Observational|||Emotional and Cognitive Abilites of Schizophrenia Patients at Various Time Points|Emotional and Cognitive Abilites of Schizophrenia Patients at Various Time Points|Unknown status|Not yet recruiting||120|Anticipated|Shalvata Mental Health Center|||1||f||||t||||||||||2018-06-01 02:58:55.676823|2018-06-01 02:58:55.676823
NCT00518986|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2010-03-30||2013-07-12|2007-08-20|2007-08-21|Estimate|2011-03-28|2011-03-29|Estimate||||2013-07-12|2013-07-19|Estimate|October 2007||2007-10-31|July 2013|2013-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression|Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder|Completed||Phase 4|249|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 02:58:55.797163|2018-06-01 02:58:55.797163
NCT00518973|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2010-02-16|2007-08-20|2007-08-21|Estimate|||||||2010-02-16|2010-02-17|Estimate|July 2006||2006-07-31|December 2009|2009-12-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Trial of Quetiapine in Anorexia Nervosa|Double-blind Placebo-controlled Trial of Quetiapine in Anorexia Nervosa|Unknown status|Recruiting|N/A|10|Anticipated|University of California, San Diego|||||f||||f||||||||||2018-06-01 02:58:57.534183|2018-06-01 02:58:57.534183
NCT00518960|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2007-08-17|2007-08-17|2007-08-21|Estimate|||||||2007-08-17|2007-08-21|Estimate|April 2007||2007-04-30|August 2007|2007-08-31|September 2007|Anticipated|2007-09-30|||||Interventional|||The Effects of ProAlgaZyme on HDL Cholesterol in Individuals With Metabolic Syndrome|The Effects of ProAlgaZyme Novel Algae Infusion on HDL Cholesterol and C-Reactive Protein in Individuals With Metabolic Syndrome|Unknown status|Active, not recruiting|N/A|28|Actual|Health Enhancement Products, Inc.|||||f||||f||||||||||2018-06-01 02:58:57.611119|2018-06-01 02:58:57.611119
NCT00518947|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2011-02-24|2007-08-20|2007-08-21|Estimate|||||||2011-02-24|2011-02-25|Estimate|November 1994||1994-11-30|February 2011|2011-02-28|June 1999|Actual|1999-06-30|||||Interventional|TRM||Pharmacotherapy of Treatment-Resistant Mania|Pharmacotherapy of Treatment-Resistant Mania|Completed||Phase 3|45|Actual|University of Pittsburgh||3|||f||||f||||||||||2018-06-01 02:58:57.689464|2018-06-01 02:58:57.689464
NCT00518934|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-19|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate||||May 2007|2007-05-31||||||||Interventional|||Study for Safety and Efficiency of Therapeutic Angiogenesis for Patients With Limb Ischemia by Transplantation of Human Cord Blood Mononuclear Cell||Unknown status|Recruiting|Phase 1/Phase 2|||Samsung Medical Center|||||f||||||||||||||2018-06-01 02:58:57.83614|2018-06-01 02:58:57.83614
NCT00518921|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2011-01-12|2007-08-20|2007-08-21|Estimate|||||||2011-01-12|2011-01-13|Estimate|March 2008||2008-03-31|January 2011|2011-01-31|November 2008|Anticipated|2008-11-30|||||Interventional|||Capadenoson in Angina Pectoris|Phase IIa Efficacy and Safety Trial of Capadenoson in Patients With Chronic Stable Angina|Withdrawn||Phase 2|0|Actual|Bayer||4|||f||||f||||||||||2018-06-01 02:58:59.067806|2018-06-01 02:58:59.067806
NCT00518908|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2011-07-18|2007-08-20|2007-08-21|Estimate|||||||2011-07-18|2011-07-19|Estimate|January 2008||2008-01-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Organ Protection With Sevoflurane Postconditioning|Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion: Postconditioning|Completed||N/A|125|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 02:58:59.200518|2018-06-01 02:58:59.200518
NCT00518895|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2011-11-04|2007-08-17|2007-08-21|Estimate|||||||2011-11-04|2011-11-07|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|AGENDA||Trial of Dacarbazine With or Without Genasense in Advanced Melanoma|A Multicenter, Randomized, Double-blind Study of Dacarbazine With or Without Genasense in Chemotherapy-naive Subjects With Advanced Melanoma and Low LDH (The AGENDA Trial)|Completed||Phase 3|300|Anticipated|Genta Incorporated||2|||f||||t||||||||||2018-06-01 02:58:59.334581|2018-06-01 02:58:59.334581
NCT00518882|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|2010-02-23|2009-11-09|2017-01-25|2007-08-20|2007-08-21|Estimate|2010-02-23|2010-03-23|Estimate|2009-11-09|2009-11-11|Estimate|2017-01-25|2017-03-08|Actual|August 2007||2007-08-31|January 2017|2017-01-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|LEAD-6||Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes|Completed||Phase 3|467|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 02:58:59.794273|2018-06-01 02:58:59.794273
NCT00518869|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-18|||2015-11-03|2007-08-20|2007-08-21|Estimate|||||||2015-11-03|2015-11-04|Estimate|September 2007||2007-09-30|November 2015|2015-11-30|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue||Terminated||Phase 2/Phase 3|210|Anticipated|PhytoHealth Corporation||2||Sponsor's decision|f||||f||||||||||2018-06-01 02:59:01.68921|2018-06-01 02:59:01.68921
NCT00518856|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2011-03-29|2007-08-20|2007-08-21|Estimate|||||||2011-03-29|2011-03-31|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|July 2009|Actual|2009-07-31|September 2008|Actual|2008-09-30||Interventional|LUNESP||Lufwanyama Neonatal Survival Project|Lufwanyama Neonatal Survival Project|Completed||N/A|3559|Actual|Boston University||2|||f||||f||||||||||2018-06-01 02:59:01.767284|2018-06-01 02:59:01.767284
NCT00518843|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2013-09-04|2007-08-17|2007-08-21|Estimate|||||||2013-09-04|2013-09-05|Estimate|April 2001||2001-04-30|September 2013|2013-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Family Therapy for Adolescent Bulimia Nervosa|Family Therapy for Adolescent Bulimia Nervosa: A Controlled Comparison|Completed||Phase 2|80|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 02:59:01.922708|2018-06-01 02:59:01.922708
NCT00518830|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate|March 2004||2004-03-31|July 2007|2007-07-31|July 2006|Actual|2006-07-31|||||Interventional|DPP||Treatment of Postnatal Depression for Low-Income Mothers in Primary Care in Santiago, Chile|Randomized Clinical Trial for the Treatment of Postnatal Depression|Completed||N/A|230|Actual|Fondo Nacional de Desarrollo Científico y Tecnológico, Chile||2|||f||||f||||||||||2018-06-01 02:59:02.000375|2018-06-01 02:59:02.000375
NCT00518817|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2009|Anticipated|2009-08-31|||||Observational|||The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy||Unknown status|Not yet recruiting||60|Anticipated|Baylor College of Medicine|||||f||||f||||||||||2018-06-01 02:59:02.070229|2018-06-01 02:59:02.070229
NCT00518804|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2008-12-04|2007-08-17|2007-08-21|Estimate|||||||2008-12-04|2008-12-05|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|August 2009|Anticipated|2009-08-31|||||Interventional|||Functional Behavioural Skill Training for Young Children With Severe Autism||Unknown status|Recruiting|N/A|32|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 02:59:02.13287|2018-06-01 02:59:02.13287
NCT00518791|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2010-11-04|2007-08-20|2007-08-21|Estimate|||||||2010-11-04|2010-11-05|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial|Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled Trial|Completed||Phase 3|301|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 02:59:02.210883|2018-06-01 02:59:02.210883
NCT00518778|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2009-12-02|2007-08-20|2007-08-21|Estimate|||||||2009-12-02|2009-12-03|Estimate|August 2007||2007-08-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Observational|||Fusariosis in Solid-Organ Transplant Recipients|Fusariosis in Solid-Organ Transplant Recipients|Completed|||50|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:59:02.3043|2018-06-01 02:59:02.3043
NCT00518765|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2010-10-05|2007-08-20|2007-08-21|Estimate|||||||2010-10-05|2010-10-06|Estimate|October 2005||2005-10-31|October 2010|2010-10-31||||August 2007|Actual|2007-08-31||Interventional|||Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet|"A Single-center, Placebo-controlled Study of the Effects of Ascending Single Oral Doses of Aliskiren Compared With Captopril on Renal Hemodynamics in Healthy Volunteers on a Low and High Sodium Diet Renin Inhibition and the Kidney"|Completed||Phase 3|32|Actual|Novartis||4|||t||||f||||||||||2018-06-01 02:59:02.371772|2018-06-01 02:59:02.371772
NCT00518752|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2013-01-14|2007-08-20|2007-08-21|Estimate|||||||2013-01-14|2013-01-16|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||Effects of Oral Care in the Neuroscience ICU|Comprehensive Oral Care for the Intubated Neuroscience ICU Patient: A Comparison of the Safety and Efficacy Between 2 Protocols|Completed||N/A|113|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||||2018-06-01 02:59:02.462992|2018-06-01 02:59:02.462992
NCT00518739|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2015-03-26|2007-08-17|2007-08-21|Estimate|||||||2015-03-26|2015-03-27|Estimate|February 2007||2007-02-28|March 2015|2015-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)|A Phase I Dose Escalation Study of MK2461 in Patients With Advanced Cancer|Completed||Phase 1|25|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:59:02.552235|2018-06-01 02:59:02.552235
NCT00518726|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2016-11-30|2007-08-20|2007-08-21|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Surface Antigen, Inactivated, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects|Completed||Phase 2|125|Actual|Novartis||1|||f||||||||||||||2018-06-01 02:59:02.624457|2018-06-01 02:59:02.624457
NCT00518713|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|2011-11-07||2012-01-06|2007-08-20|2007-08-21|Estimate|2012-01-06|2012-02-09|Estimate||||2012-01-06|2012-02-09|Estimate|August 2007||2007-08-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Clobazam in Patients With Lennox-Gastaut Syndrome|Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome|Completed||Phase 3|238|Actual|Lundbeck LLC||4|||f||||t||||||||||2018-06-01 02:59:02.74687|2018-06-01 02:59:02.74687
NCT00518700|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2008-04-21|2007-08-20|2007-08-21|Estimate|||||||2008-04-21|2008-04-24|Estimate||||April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comfort Evaluation of a New MPS vs. Replenish in Contact Lens Patients||Completed||Phase 4|24|Actual|Innovative Medical|||||f||||||||||||||2018-06-01 02:59:03.72682|2018-06-01 02:59:03.72682
NCT00518687|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2012-10-02||2015-10-01|2007-08-17|2007-08-21|Estimate|2012-10-02|2012-11-05|Estimate||||2015-10-01|2015-10-02|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)|A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery|Terminated||Phase 2/Phase 3|8031|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 02:59:03.799654|2018-06-01 02:59:03.799654
NCT00518674|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2007-08-20|2007-08-20|2007-08-21|Estimate|||||||2007-08-20|2007-08-21|Estimate|January 2007||2007-01-31|July 2007|2007-07-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Local Anesthetics After Total Knee Arthroplasty|Local Anesthetics After Total Knee Arthroplasty: Intra- vs. Extraarticular Administration? A Randomized, Double-Blind, Placebo-Controlled Study|Unknown status|Active, not recruiting|N/A|32|Actual|Hvidovre University Hospital|||||f||||f||||||||||2018-06-01 02:59:04.698867|2018-06-01 02:59:04.698867
NCT00518661|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2017-06-08|2007-08-17|2007-08-21|Estimate|||||||2017-06-08|2017-06-09|Actual|August 2007||2007-08-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species|Risk Factors for Quinolone Resistance Among Extended-Spectrum Beta-Lactamase-Producing Klebsiella Species|Active, not recruiting|||500|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 02:59:04.754818|2018-06-01 02:59:04.754818
NCT00518648|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2010-11-22|2007-08-20|2007-08-21|Estimate|||||||2010-11-22|2010-11-23|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|REFINE-PD||Reduction of Falls in the Elderly - Parkinson's Disease|Reduction of Falls in the Elderly - Parkinson's Disease|Completed||Phase 3|187|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 02:59:04.819851|2018-06-01 02:59:04.819851
NCT00518635|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2013-02-18|2007-08-17|2007-08-21|Estimate|||||||2013-02-18|2013-02-20|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Low Dose Growth Hormone in Obese PCOS Women|Effects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Metabolic Profile, Adipocyte IGF-I and Insulin Signaling, Intramyocellular Lipids, and Cortisol Metabolism in Obese Women With Polycystic Ovary Syndrome (PCOS)|Withdrawn||N/A|0|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-06-01 02:59:04.908173|2018-06-01 02:59:04.908173
NCT00518622|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2009-08-10||2015-08-11|2007-08-17|2007-08-21|Estimate|2009-08-10|2009-09-16|Estimate||||2015-08-11|2015-08-25|Estimate|July 2007||2007-07-31|August 2015|2015-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)|A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-06-01 02:59:05.019303|2018-06-01 02:59:05.019303
NCT00518609|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2014-07-29|2007-08-20|2007-08-21|Estimate|||||||2014-07-29|2014-07-31|Estimate|July 2003||2003-07-31|July 2014|2014-07-31|July 2006|Actual|2006-07-31|||||Observational|||Prevention of Infection in Indian Neonates - Phase I Observational Study|Prevention of Infection in Indian Neonates - Phase I Observational Study|Completed|||1326|Actual|NICHD Global Network for Women's and Children's Health|||1||f||||t||||||||||2018-06-01 02:59:05.839245|2018-06-01 02:59:05.839245
NCT00518596|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-20|||2017-06-13|2007-08-20|2007-08-21|Estimate|||||||2017-06-13|2017-06-15|Actual|July 2005||2005-07-31|June 2017|2017-06-30|August 2006|Actual|2006-08-31|||||Interventional|||Prevention of Infection in Indian Neonates - Phase II Probiotics Study|Prevention of Infection in Indian Neonates - Phase II Probiotics Study|Completed||Phase 2|284|Actual|NICHD Global Network for Women's and Children's Health||2|||f||||||||||||||2018-06-01 02:59:05.907663|2018-06-01 02:59:05.907663
NCT00518583|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2010-01-14|2007-08-17|2007-08-20|Estimate|||||||2010-01-14|2010-01-15|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|September 2009|Anticipated|2009-09-30|January 2009|Anticipated|2009-01-31||Interventional|||Phase II Study in Patients With Operable Breast Cancer|A Phase II Study of Pre-Operative Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, and Trastuzumab in Patients With Operable Breast Cancer Over-expressing Her2-neu|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Aptium Oncology Research Network|||||f||||f||||||||||2018-06-01 02:59:05.982305|2018-06-01 02:59:05.982305
NCT00518570|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2007-08-17|2007-08-17|2007-08-20|Estimate|||||||2007-08-17|2007-08-20|Estimate|November 2003||2003-11-30|August 2007|2007-08-31|October 2006|Actual|2006-10-31|||||Interventional|pmdd||Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)|A Pilot Study: Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder|Completed||N/A|7|Actual|Berkshire Health Systems||1|||f||||f||||||||||2018-06-01 02:59:06.047592|2018-06-01 02:59:06.047592
NCT00518557|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2009-01-21|2007-08-17|2007-08-20|Estimate|||||||2009-01-21|2009-01-22|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|||||Interventional|TACE HCC||Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using TACE With Antiangiogenesis|Combination Treatment of TACE With Recombinant Human Endostatin Administrated Via Hepatic Artery in Hepatocellular Carcinoma|Unknown status|Recruiting|N/A|60|Anticipated|Southeast University, China||2|||f||||t||||||||||2018-06-01 02:59:06.110532|2018-06-01 02:59:06.110532
NCT00518544|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2007-08-16|2007-08-16|2007-08-20|Estimate|||||||2007-08-16|2007-08-20|Estimate|July 2007||2007-07-31|August 2007|2007-08-31||||||||Interventional|||Hemostatic Effect of Various Colloid Solutions|Hemostatic Effect of Various Colloid Solutions According to Blood Types|Unknown status|Recruiting|N/A|||Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:59:06.187002|2018-06-01 02:59:06.187002
NCT00518531|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2010-07-01||2017-02-07|2007-08-16|2007-08-20|Estimate|2013-11-19|2014-01-07|Estimate||||2017-02-07|2017-03-15|Actual|September 2007||2007-09-30|February 2017|2017-02-28|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Denosumab Adherence Preference Satisfaction Study|A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate in Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 3|250|Actual|Amgen||2|||f||||||||||||||2018-06-01 02:59:06.273477|2018-06-01 02:59:06.273477
NCT00518518|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2009-05-14|2007-08-17|2007-08-20|Estimate|||||||2009-05-14|2009-05-15|Estimate|March 2006||2006-03-31|May 2009|2009-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of Ultra-Rush Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen|Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study.|Completed||Phase 4|50|Actual|Medical Universtity of Lodz||2|||f||||t||||||||||2018-06-01 02:59:06.972736|2018-06-01 02:59:06.972736
NCT00518505|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2012-08-14|2007-08-17|2007-08-20|Estimate|||||||2012-08-14|2012-08-15|Estimate|December 2006||2006-12-31|August 2012|2012-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|GERD||Assessing Outcomes After Surgery for Gastroesophageal Reflux Disorder|Long and Short Term Outcomes After Laparoscopic Surgery for Gastroesophageal Reflux Disease|Unknown status|Recruiting|N/A|1500|Anticipated|University of South Florida||1|||f||||f||||||||||2018-06-01 02:59:07.050329|2018-06-01 02:59:07.050329
NCT00518492|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2009-09-15|2007-08-17|2007-08-20|Estimate|||||||2009-09-15|2009-09-16|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study Evaluating the Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500|Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500|Completed||Phase 1|73|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 02:59:07.142574|2018-06-01 02:59:07.142574
NCT00518479|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2012-08-15|2007-08-17|2007-08-20|Estimate|||||||2012-08-15|2012-08-16|Estimate|September 2003||2003-09-30|August 2012|2012-08-31|April 2004|Actual|2004-04-30|||||Interventional|||Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression|Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression|Completed||N/A|42|Actual|University of Leeds||2|||f||||f||||||||||2018-06-01 02:59:07.221772|2018-06-01 02:59:07.221772
NCT00518466|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2011-06-06|2007-08-16|2007-08-20|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults|A Phase Ib, Open Label, Parallel-Design Single- and Multiple-Dose Study Comparing Modified Release Topiramate Formulations to Immediate Release Formulations of Topiramate Dosed in Combination With Immediate Release Phentermine in Obese Adults|Completed||Phase 1|64|Actual|VIVUS, Inc.||4|||f||||f||||||||||2018-06-01 02:59:07.305694|2018-06-01 02:59:07.305694
NCT00518453|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2016-11-30|2007-08-17|2007-08-20|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2007||2007-07-31|November 2011|2011-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008|A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Ph.Eur, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects|Completed||Phase 2|129|Actual|Novartis||1|||f||||f||||||||||2018-06-01 02:59:07.392691|2018-06-01 02:59:07.392691
NCT00518440|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2018-01-10|2007-08-17|2007-08-20|Estimate|||||||2018-01-10|2018-01-12|Actual|January 1998||1998-01-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|ALFSG||A Multi-Center Trial to Study Acute Liver Failure in Adults|A Multi-Center Trial to Study Acute Liver Failure in Adults|Recruiting|||3000|Anticipated|University of Texas Southwestern Medical Center|||||f||||t||||||Samples With DNA|"~     Serum, Plasma, Urine, DNA and Tissue if available are collected and stored at the NIDDK~     Central Repository~   "|||2018-06-01 02:59:07.500573|2018-06-01 02:59:07.500573
NCT00518427|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2009-12-04|2007-08-17|2007-08-20|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|QoL||Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine|A Multicenter Clinical Trial to Evaluate Quality of Life in Patients With Type 2 Diabetes Before and After Changing Therapy to a Combination of Insulin Glargine and Oral Antidiabetic Drugs in a Real Life Situation|Completed||Phase 4|26|Actual|Sanofi||1|||f||||||||||||||2018-06-01 02:59:07.661802|2018-06-01 02:59:07.661802
NCT00518401|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2011-04-27|2007-08-17|2007-08-20|Estimate|||||||2011-04-27|2011-04-28|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|October 2009|Actual|2009-10-31|August 2008|Actual|2008-08-31||Interventional|mesendo||Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia|Phase I Study of A Combination Stem Cell Therapy is Safe and Feasible in the Development of Mature Stable Vessels in Ischemic Limbs|Completed||Phase 1|10|Actual|TCA Cellular Therapy|||||f||||f||||||||||2018-06-01 02:59:07.837142|2018-06-01 02:59:07.837142
NCT00518388|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2016-01-14|2007-08-17|2007-08-20|Estimate|||||||2016-01-14|2016-01-15|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Perceptions of Cervical Cancer Among Asian Americans|Perceptions of Cervical Cancer and Human Papillomavirus Among Asian Americans|Completed|||52|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 02:59:07.912499|2018-06-01 02:59:07.912499
NCT00518375|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2007-08-16|2007-08-16|2007-08-20|Estimate|||||||2007-08-16|2007-08-20|Estimate|April 2000||2000-04-30|August 2007|2007-08-31|May 2001||2001-05-31|||||Interventional|||Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus|A Comparative, Open-Label Study to Evaluate Graft Function in de Novo Renal Allograft Recipients Treated With Either a 'Reduced Dose' or a 'Standard Dose' of Cyclosporine in Combination With Sirolimus and Corticosteroids|Completed||Phase 4|250||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:59:08.006476|2018-06-01 02:59:08.006476
NCT00518362|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2010-05-25|2007-08-16|2007-08-20|Estimate|||||||2010-05-25|2010-05-27|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)|To Compare the Efficacy and Safety of TW vs Valsartan in the DN|Completed||N/A|67|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 02:59:08.169835|2018-06-01 02:59:08.169835
NCT00518349|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2013-01-07||2017-09-15|2007-08-17|2007-08-20|Estimate|2017-09-15|2018-05-28|Estimate||||2017-09-15|2018-05-28|Estimate|August 2003||2003-08-31|September 2017|2017-09-30|December 2009|Actual|2009-12-31|December 2007|Actual|2007-12-31||Interventional||Patients referred to routine outpatients' colonoscopy|Colonoscope Passive Bending Function|Evaluation of a Novel Colonoscope Designed for Easier Passage Through Flexures: A Randomised Study|Completed||N/A|120|Actual|Norwegian Department of Health and Social Affairs||2|||f||||f||||||||||2018-06-01 02:59:08.274802|2018-06-01 02:59:08.274802
NCT00518336|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2010-07-12||2016-10-27|2007-08-17|2007-08-20|Estimate|2011-09-15|2011-10-25|Estimate||||2016-10-27|2016-12-09|Estimate|November 2007||2007-11-30|October 2016|2016-10-31|September 2010|Actual|2010-09-30|July 2008|Actual|2008-07-31||Interventional|||Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil|Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil|Completed||Phase 2|433|Actual|GlaxoSmithKline|Interim analysis at Year 7 and Year 8 are superseded by the final analysis at Year 9.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:59:08.625447|2018-06-01 02:59:08.625447
NCT00518323|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2010-03-23||2014-03-25|2007-08-16|2007-08-20|Estimate|2010-05-17|2010-06-09|Estimate||||2014-03-25|2014-04-16|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients|A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age|Completed||Phase 3|201|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No information about longer-term (ie, >6 weeks) efficacy and safety in adolescents or in young (<12 years) children with schizophrenia. Results with doses less than 1.5 mg or more than 12 mg cannot be extrapolated from the data.|4|||f||||||||||||||2018-06-01 02:59:10.949228|2018-06-01 02:59:10.949228
NCT00518310|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2007-08-16|2007-08-16|2007-08-20|Estimate|||||||2007-08-16|2007-08-20|Estimate|May 2005||2005-05-31|August 2007|2007-08-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis|Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study|Unknown status|Recruiting|N/A|100|Anticipated|Thorax National Institute||2|||f||||t||||||||||2018-06-01 02:59:11.642473|2018-06-01 02:59:11.642473
NCT00518297|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2010-02-03|2007-08-17|2007-08-20|Estimate|||||||2010-02-03|2010-02-04|Estimate|August 2007||2007-08-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||DDI HV (ATV - Merck)|Open Label, Multiple Dose, Sequential, Drug-Drug Interaction Study to Assess the Pharmacokinetics and Safety of Atazanavir and Raltegravir Co-Administered Twice Daily in Healthy Subjects|Completed||Phase 1|22|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 02:59:11.736448|2018-06-01 02:59:11.736448
NCT00518284|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2012-02-21||2012-02-21|2007-08-17|2007-08-20|Estimate|2012-02-21|2012-03-13|Estimate||||2012-02-21|2012-03-13|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Prevention of Restenosis Following Revascularization|A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA)|Terminated||Phase 2|6|Actual|Celgene||4||"Study was terminated due to changing sponsor priorities, and was not based on safety or~   outcomes data."|f||||f||||||||||2018-06-01 02:59:11.898257|2018-06-01 02:59:11.898257
NCT00518271|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2007-08-16|2007-08-16|2007-08-20|Estimate|||||||2007-08-16|2007-08-20|Estimate|April 2000||2000-04-30|August 2007|2007-08-31|June 2002|Actual|2002-06-30|||||Interventional|||Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients|A Phase II, Open-Label, Concentration-Controlled, Randomized, 6-Month Study of 'Standard Dose' Tacrolimus + Sirolimus + Corticosteroids Compared to 'Reduced Dose' Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients|Completed||Phase 2|120|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 02:59:12.45202|2018-06-01 02:59:12.45202
NCT00518258|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2013-05-16|2007-08-16|2007-08-20|Estimate|||||||2013-05-16|2013-05-17|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Neuroimaging Studies of Depression in Parkinson's Disease|Neuroimaging Studies of Depression in Parkinson's Disease|Completed|||120|Anticipated|University of Kentucky|||2||f||||f||||||||||2018-06-01 02:59:12.521076|2018-06-01 02:59:12.521076
NCT00518050|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2015-07-15|2007-08-15|2007-08-17|Estimate|||||||2015-07-15|2015-07-16|Estimate|October 2006||2006-10-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns|Melanoma Survivors: Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns|Completed|||160|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-06-01 02:59:20.902364|2018-06-01 02:59:20.902364
NCT00518245|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2016-01-26|2007-08-17|2007-08-20|Estimate|||||||2016-01-26|2016-01-27|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|IDEAL||Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)|A Prospective, Open Label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus no Enoxaparin in Subjects With Chest Pain Syndrome and no ECG or Biomarker Abnormalities|Terminated||Phase 4|11|Actual|Canadian Heart Research Centre||2||Low rate of patient recruitment. Cannot achieve sample size.|f||||t||||||||No|insufficient data|2018-06-01 02:59:12.595963|2018-06-01 02:59:12.595963
NCT00518232|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2010-04-26|2007-08-16|2007-08-20|Estimate|||||||2010-04-26|2010-04-28|Estimate|September 2006||2006-09-30|April 2010|2010-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study to Determine Effective and Tolerable Titration Scheme for OROS-Methylphenidate in Children With Attention-deficit Hyperactivity Disorder|The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate|Completed||Phase 4|520|Actual|Johnson & Johnson Taiwan Ltd|||||f||||||||||||||2018-06-01 02:59:12.692203|2018-06-01 02:59:12.692203
NCT00518219|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2010-05-25|2007-08-16|2007-08-20|Estimate|||||||2010-05-25|2010-05-27|Estimate|July 2007||2007-07-31|March 2009|2009-03-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)|To Compare the Efficacy and Safety of TW vs Valsartan in the MN|Completed||Phase 4|68|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 02:59:12.75543|2018-06-01 02:59:12.75543
NCT00518206|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2017-04-06||2017-06-29|2007-08-16|2007-08-20|Estimate|2017-04-06|2017-06-23|Actual||||2017-06-29|2017-08-14|Actual|November 28, 2003|Actual|2003-11-28|June 2017|2017-06-30|January 22, 2010|Actual|2010-01-22|January 22, 2010|Actual|2010-01-22||Interventional||All enrolled subjects|Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma|A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM® Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma|Completed||Phase 2|46|Actual|Ludwig Institute for Cancer Research||2|||f||||f|f|f||||||Yes|Data have been published|2018-06-01 02:59:12.884971|2018-06-01 02:59:12.884971
NCT00518193|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2011-06-29|2007-08-17|2007-08-20|Estimate|||||||2011-06-29|2011-06-30|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|September 2008|Actual|2008-09-30|July 2007|Actual|2007-07-31||Interventional|ERBUS||Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix||Terminated||Phase 2|44|Actual|ARCAGY/ GINECO GROUP||||high rate of medullar aplasia with infectious troubles.|f||||t||||||||||2018-06-01 02:59:13.557209|2018-06-01 02:59:13.557209
NCT00518180|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2010-03-19|2009-08-12|2016-04-18|2007-08-17|2007-08-20|Estimate|2010-09-15|2010-10-04|Estimate|2009-08-03|2009-08-10|Estimate|2016-04-18|2016-05-18|Estimate|July 2007||2007-07-31|April 2016|2016-04-30|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents|A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents|Completed||Phase 3|1620|Actual|Novartis||3|||f||||f||||||||||2018-06-01 02:59:13.647605|2018-06-01 02:59:13.647605
NCT00518167|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2011-08-31|2007-08-16|2007-08-20|Estimate|||||||2011-08-31|2011-09-02|Estimate|November 1993||1993-11-30|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|DPS||The Finnish Diabetes Prevention Study|The Finnish Diabetes Prevention Study: A Follow-up Study on the Effect of a Dietary and Exercise Intervention in the Prevention of Diabetes and Its Vascular Complications|Unknown status|Active, not recruiting|N/A|522|Actual|National Institute for Health and Welfare, Finland||2|||f||||t||||||||||2018-06-01 02:59:14.521543|2018-06-01 02:59:14.521543
NCT00518154|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2009-04-16|2007-08-17|2007-08-20|Estimate|||||||2009-04-16|2009-04-17|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response|Pilot Study of an ACh-E Inhibitor Upon Immune Activation Markers in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy (HAART) Showing an Incomplete Immune Response.|Completed||Phase 2|7|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1|||f||||f||||||||||2018-06-01 02:59:14.595916|2018-06-01 02:59:14.595916
NCT00518141|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|||2011-07-20|2007-08-17|2007-08-20|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)|Use of Acetylsalicylic Acid and Terbutalin in ART|Completed||N/A|300|Actual|Sykehuset Telemark||6|||f||||f||||||||||2018-06-01 02:59:14.696617|2018-06-01 02:59:14.696617
NCT00518128|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2012-05-18|2007-08-16|2007-08-20|Estimate|||||||2012-05-18|2012-05-22|Estimate|July 2007||2007-07-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Measuring Effectiveness in Sleep Apnea Surgery|Measuring Effectiveness in Sleep Apnea Surgery|Completed||N/A|60|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 02:59:14.784914|2018-06-01 02:59:14.784914
NCT00518115|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-17|2014-05-01|2009-07-22|2016-11-03|2007-08-17|2007-08-20|Estimate|2014-06-19|2014-06-23|Estimate|2009-07-22|2009-08-10|Estimate|2016-11-03|2016-12-16|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only|A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, With Byetta as an Open Label Active Reference, in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|361|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:59:14.929419|2018-06-01 02:59:14.929419
NCT00518102|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2016-07-15|2007-08-16|2007-08-20|Estimate|||||||2016-07-15|2016-07-19|Estimate|January 2003||2003-01-31|July 2016|2016-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Observational|||The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])|A Matched Cohort Study of Regranex (Becaplermin) and the Risk of Cancer|Completed|||4431|Actual|Ethicon, Inc.|||2||f||||||||||||||2018-06-01 02:59:20.463937|2018-06-01 02:59:20.463937
NCT00518089|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2010-06-15|2009-11-30|2011-10-24|2007-08-16|2007-08-20|Estimate|2011-10-24|2011-11-30|Estimate|2009-11-30|2009-12-02|Estimate|2011-10-24|2011-11-30|Estimate|February 2008||2008-02-29|October 2011|2011-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis||Completed||Phase 3|859|Actual|Allergan||2|||f||||||||||||||2018-06-01 02:59:20.527748|2018-06-01 02:59:20.527748
NCT00518024|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2010-06-28|2007-08-15|2007-08-17|Estimate|||||||2010-06-28|2010-06-29|Estimate||||June 2010|2010-06-30||||||||Interventional|||Safety and Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus|Safety and Effectiveness of Bilateral Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation) in the Treatment of Chronic Tinnitus|Completed||Phase 2|48|Anticipated|University Hospital Tuebingen||3|||f||||t||||||||||2018-06-01 02:59:21.060171|2018-06-01 02:59:21.060171
NCT00518011|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2015-12-31||2016-04-11|2007-08-16|2007-08-17|Estimate|2016-03-03|2016-04-01|Estimate||||2016-04-11|2016-05-16|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||Intention-to-treat (ITT) population included all randomized participants.|A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.|A Randomized, Open Label Study Comparing the Effect of First-line Therapy With Tarceva + Gemcitabine Versus Gemcitabine Monotherapy on Treatment Response in Treatment-naïve Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|17|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 02:59:21.156924|2018-06-01 02:59:21.156924
NCT00517998|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2010-01-14|2007-08-16|2007-08-17|Estimate|||||||2010-01-14|2010-01-18|Estimate|May 2007||2007-05-31|January 2010|2010-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study|Phase 1 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema|Completed||Phase 1|16|Actual|Aeris Therapeutics||2|||f||||t||||||||||2018-06-01 02:59:21.721145|2018-06-01 02:59:21.721145
NCT00517985|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2012-07-05|2007-08-16|2007-08-17|Estimate|||||||2012-07-05|2012-07-09|Estimate|February 2007||2007-02-28|July 2012|2012-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Duloxetine for Perimenopausal Depression|Duloxetine for Perimenopausal Depression|Completed||Phase 4|7|Actual|University of Arizona|||||f||||f||||||||||2018-06-01 02:59:21.796953|2018-06-01 02:59:21.796953
NCT00517972|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2012-03-27|2007-08-15|2007-08-17|Estimate|||||||2012-03-27|2012-03-29|Estimate||||March 2012|2012-03-31||||||||Interventional|||Omacor for Perimenopausal Depression|Omacor for Perimenopausal Depression|Withdrawn||Phase 2|0|Actual|University of Arizona|||||f||||f||||||||||2018-06-01 02:59:21.860622|2018-06-01 02:59:21.860622
NCT00517959|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2012-12-08|2007-08-16|2007-08-17|Estimate|||||||2012-12-08|2012-12-11|Estimate|May 2001||2001-05-31|June 2012|2012-06-30|June 2017|Anticipated|2017-06-30|March 2013|Anticipated|2013-03-31||Interventional|SCRT||SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors|Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial|Unknown status|Active, not recruiting|Phase 3|200|Actual|Tata Memorial Hospital||2|||f||||t||||||||||2018-06-01 02:59:21.92051|2018-06-01 02:59:21.92051
NCT00517946|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2013-08-30|2007-08-15|2007-08-17|Estimate|||||||2013-08-30|2013-09-02|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.|An Investigation to Evaluate the Technique of MRI as an Assessment of the Effect of Anti-allergy Drug Treatment on Internal Nasal and Sinus Mucosal Anatomy Following Intranasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis.|Completed|||21|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:59:21.995348|2018-06-01 02:59:21.995348
NCT00517933|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|2010-11-05||2015-06-22|2007-08-15|2007-08-17|Estimate|2013-07-23|2013-08-23|Estimate||||2015-06-22|2015-06-24|Estimate|August 2007||2007-08-31|June 2015|2015-06-30|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|STEP-IPF||Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis|Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis|Completed||Phase 3|180|Actual|Duke University|Findings are limited to patients with advanced IPF. It is unknown if treatment effect was driven by particular subgroup of patients. Study was too short and enrolled too few to assess duration of effect.|2|||f||||t||||||||||2018-06-01 02:59:22.124094|2018-06-01 02:59:22.124094
NCT00517920|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16||2012-06-29|2013-01-02|2007-08-16|2007-08-17|Estimate||||2012-06-29|2012-07-03|Estimate|2013-01-02|2013-01-04|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)|An Open-Label, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 2|44|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 02:59:23.048498|2018-06-01 02:59:23.048498
NCT00517907|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2015-06-10|2007-08-16|2007-08-17|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2016||2016-01-31|August 2008|2008-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PIF1GVHD||Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD)|Phase I Clinical Trial to Assess Safety of Synthetic Preimplantation Factor (PIF-1) in Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Stem-Cell Transplantation|Unknown status|Not yet recruiting|Phase 1|6|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-06-01 02:59:23.117361|2018-06-01 02:59:23.117361
NCT00517894|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2007-08-15|2007-08-15|2007-08-17|Estimate|||||||2007-08-15|2007-08-17|Estimate||||August 2007|2007-08-31||||||||Expanded Access|||Dose-Dense Therapy in Aggressive Lymphoma|Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma|No longer available|||||Arbeitsgemeinschaft medikamentoese Tumortherapie|||||f||||||||||||||2018-06-01 02:59:23.190233|2018-06-01 02:59:23.190233
NCT00517881|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2016-04-21||2016-04-21|2007-08-16|2007-08-17|Estimate|2016-04-21|2016-05-27|Estimate||||2016-04-21|2016-05-27|Estimate|June 2007||2007-06-30|April 2016|2016-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional||The safety population included all participants who were treated with at least 1 dose of the study drug and a safety follow-up, whether withdrawn prematurely or not.|Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia|A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of Subcutaneous C.E.R.A. for the Maintenance of Haemoglobin Levels in Pre-dialysis Patients With Chronic Renal Anaemia|Terminated||Phase 3|29|Actual|Hoffmann-La Roche|The study was terminated early due to the slow recruitment rate.|1||The study was terminated due to the slow recruitment rate.|f||||f||||||||||2018-06-01 02:59:23.250734|2018-06-01 02:59:23.250734
NCT00517868|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2008-04-07|2007-08-15|2007-08-17|Estimate|||||||2008-04-07|2008-04-10|Estimate|August 2007||2007-08-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis|URG101 Pharmacodynamic and Safety Study: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Cross-Over Study to Investigate the Pharmacodynamic Profile of URG101 in Subjects With Pelvic Pain of Bladder Origin.|Completed||Phase 2|28|Actual|Urigen||2|||f||||f||||||||||2018-06-01 02:59:23.424929|2018-06-01 02:59:23.424929
NCT00517855|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2008-05-01|2007-08-15|2007-08-17|Estimate|||||||2008-05-01|2008-05-06|Estimate|June 2007||2007-06-30|May 2008|2008-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of PRTX-100 in Healthy Adult Volunteers|A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single-Dose Escalation Study of the Safety and Pharmacokinetics of Intravenous Doses of PRTX-100 in Healthy Adult Subjects|Completed||Phase 1|20|Anticipated|Protalex, Inc.|||||f||||f||||||||||2018-06-01 02:59:23.495223|2018-06-01 02:59:23.495223
NCT00517842|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2013-09-03|2007-08-16|2007-08-17|Estimate|||||||2013-09-03|2013-09-05|Estimate|October 2005||2005-10-31|July 2013|2013-07-31|September 2008|Actual|2008-09-30|||||Interventional|||A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease|A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease|Completed||N/A|160|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:23.687983|2018-06-01 02:59:23.687983
NCT00517829|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|2016-01-12||2016-10-14|2007-08-16|2007-08-17|Estimate|2016-01-12|2016-02-11|Estimate||||2016-10-14|2016-11-28|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||ITT population|Docetaxel+Oxali+/-Cetux Met Gastric/GEJ|Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With or Without Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma|Completed||Phase 2|150|Actual|US Oncology Research||2|||f||||f||||||||No||2018-06-01 02:59:23.796475|2018-06-01 02:59:23.796475
NCT00517816|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2016-11-01|2007-08-16|2007-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.|A Randomized, Double-blind, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Pharmacodynamic Biomarkers of an Intravenous Infusion of R1671 in Patients With Mild, Intermittent Asymptomatic Asthma|Completed||Phase 1|43|Actual|Hoffmann-La Roche||8|||f||||||||||||||2018-06-01 02:59:24.457367|2018-06-01 02:59:24.457367
NCT00517803|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2017-08-25|2007-08-16|2007-08-17|Estimate|||||||2017-08-25|2017-08-28|Actual|September 7, 2007|Actual|2007-09-07|August 2017|2017-08-31|March 2, 2009|Actual|2009-03-02|March 2, 2009|Actual|2009-03-02||Interventional|||Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies|Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies: A Randomized, Placebo-controlled Trial|Completed||N/A|24|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 02:59:24.54366|2018-06-01 02:59:24.54366
NCT00517790|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16||2012-07-13|2013-03-29|2007-08-16|2007-08-17|Estimate||||2012-07-13|2012-07-23|Estimate|2013-03-29|2013-04-05|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)|An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|140|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 02:59:24.633967|2018-06-01 02:59:24.633967
NCT00517777|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2007-08-15|2007-08-15|2007-08-17|Estimate|||||||2007-08-15|2007-08-17|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2010|Anticipated|2010-08-31|||||Interventional|||Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage|Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome|Unknown status|Recruiting|Phase 4|100|Anticipated|Università degli Studi dell'Insubria||2|||f||||t||||||||||2018-06-01 02:59:24.729769|2018-06-01 02:59:24.729769
NCT00517764|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2013-08-06|2007-08-16|2007-08-17|Estimate|||||||2013-08-06|2013-08-09|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression|The Role of Childhood Adversity and Genetic Polymorphisms in the Serotonin and Brain-Derived Neurotrophic Factor Systems in the Sensitization to Stress in First-Onset Major Depression (Blue Sky Project)|Completed||N/A|299|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 02:59:24.815731|2018-06-01 02:59:24.815731
NCT00517751|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|2015-12-01||2017-12-06|2007-08-16|2007-08-17|Estimate|2016-01-14|2016-02-12|Estimate||||2017-12-06|2018-01-02|Actual|August 2007||2007-08-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|COAST||Condition of Approval Study|Treatment of Lumbar Spinal Stenosis With X-STOP® PEEK Spacer in Moderately Symptomatic Patients|Terminated||Phase 4|176|Actual|Medtronic Spinal and Biologics|Study strengths include collection of 5-year data and radiographic examinations. Study weaknesses include single-arm design and early termination of the study without reaching the desired sample size.|1||"Due to Medtronic's voluntary withdrawal of PMA P040001 for X-STOP systems; post-approval study~   costs outweighed business benefits for marketing X-STOP in US."|f||||f||||||||||2018-06-01 02:59:24.931275|2018-06-01 02:59:24.931275
NCT00517738|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2015-10-07|2007-08-16|2007-08-17|Estimate|||||||2015-10-07|2015-10-08|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Physical Training Program on Health-related Quality of Life in Cirrhosis|Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension|Completed||Phase 2|29|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||4|||f||||f||||||||||2018-06-01 02:59:25.968666|2018-06-01 02:59:25.968666
NCT00517725|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2010-09-15|2007-08-16|2007-08-17|Estimate|||||||2010-09-15|2010-09-16|Estimate|July 2007||2007-07-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|||||Interventional|CARNEBI||Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure|Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function|Completed||Phase 4|60|Actual|Centro Cardiologico Monzino||3|||f||||f||||||||||2018-06-01 02:59:26.113375|2018-06-01 02:59:26.113375
NCT00517712|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2007-08-16|2007-08-16|2007-08-17|Estimate|||||||2007-08-16|2007-08-17|Estimate|June 2004||2004-06-30|August 2007|2007-08-31|July 2009|Anticipated|2009-07-31|||||Interventional|IAPLSG04||Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia|Molecular Remission With Arsenic Trioxide in Acute Promyelocytic Leukemia: Indian APL Study Group - IAPLSG|Unknown status|Recruiting|Phase 2/Phase 3|400|Anticipated|Christian Medical College, Vellore, India||2|||f||||f||||||||||2018-06-01 02:59:26.217985|2018-06-01 02:59:26.217985
NCT00517374|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2015-09-24|2007-08-15|2007-08-16|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2005||2005-09-30|September 2015|2015-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||A Multi-Centre Clinical Study in Spinal Cord Injury Patients in Mainland China and Hong Kong|A Multi-Centre Clinical Study in Spinal Cord Injury Patients in Mainland China and Hong Kong|Completed|||600|Actual|China Spinal Cord Injury Network|||||f||||f||||||||||2018-06-01 02:59:32.258228|2018-06-01 02:59:32.258228
NCT00517699|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2014-06-09||2014-07-15|2007-08-16|2007-08-17|Estimate|2014-07-15|2014-08-08|Estimate||||2014-07-15|2014-08-08|Estimate|September 2007||2007-09-30|July 2014|2014-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||Safety population: all participants who received any amount of study drug.|A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.|An Open Label Study of the Effect of Rituxan, High Dose Methotrexate and High Dose Cytarabine on Response Rate in Patients With Primary Central Nervous System Lymphoma.|Terminated||Phase 2|5|Actual|Hoffmann-La Roche|The study was terminated early due to lack of enrollment.|1||Study was terminated early due to lack of enrollment.|f||||||||||||||2018-06-01 02:59:26.412298|2018-06-01 02:59:26.412298
NCT00517686|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2012-08-01|2007-08-16|2007-08-17|Estimate|||||||2012-08-01|2012-08-03|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|FIT||Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT)|Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT)|Completed||N/A|16584|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 02:59:26.768257|2018-06-01 02:59:26.768257
NCT00517673|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2012-03-15|2007-08-15|2007-08-17|Estimate|||||||2012-03-15|2012-03-19|Estimate|July 2007||2007-07-31|October 2011|2011-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single Doses Of GSK945237 In Healthy Subjects|A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK945237 and the Effect of Food on Single Oral Doses of GSK945237 in Healthy Adult Subjects|Completed||Phase 1|68|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 02:59:26.881175|2018-06-01 02:59:26.881175
NCT00517660|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2013-08-21|2007-08-16|2007-08-17|Estimate|||||||2013-08-21|2013-08-22|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|June 2006|Actual|2006-06-30|||||Observational|||Source Profiling of Biohazardous Aerosols in Hospitals|Source Profiling of Biohazardous Aerosols in Hospitals|Completed|||60|Actual|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:26.986708|2018-06-01 02:59:26.986708
NCT00517647|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2012-07-05|2007-08-15|2007-08-17|Estimate|||||||2012-07-05|2012-07-09|Estimate|April 2004||2004-04-30|July 2012|2012-07-31||||March 2008|Actual|2008-03-31||Interventional|||Atomoxetine Pilot Study in Preschool Children With ADHD|Atomoxetine Pilot Study in Preschool Children With ADHD|Completed||Phase 4|31|Actual|University of Arizona|||||f||||f||||||||||2018-06-01 02:59:27.104364|2018-06-01 02:59:27.104364
NCT00517634|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2009-07-23||2016-11-03|2007-08-16|2007-08-17|Estimate|2009-07-23|2009-09-02|Estimate||||2016-11-03|2016-12-16|Estimate|August 2007||2007-08-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects|A 12-week, Randomised, Double-blind, Placebo-controlled, Three-period, Cross-over Pilot Study Comparing the Effect of Salmeterol/Fluticasone Propionate, Fluticasone Propionate and Placebo on Perpheral Blood Eosinophils and Serum IL-5 in Response to Allergen Challenge in Asthma Subjects When Allergen Challenge is Administered at 1 Hour or 11-12 Hours Post-dose of the Dosing Interval|Completed||Phase 4|23|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:59:27.238623|2018-06-01 02:59:27.238623
NCT00517621|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2011-02-24|2007-08-16|2007-08-17|Estimate|||||||2011-02-24|2011-02-25|Estimate|February 2006||2006-02-28|February 2011|2011-02-28|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire|A Multicenter Prospective Phase II Study Evaluating Peripheral Neurotoxicity by Using FACT-GOG/NTX Questionnaire in Patients With Ovarian Cancer in Relapse Treated by Paclitaxel +/- EPO. Validation of a French Version of This Questionnaire|Completed||Phase 2|100|Anticipated|ARCAGY/ GINECO GROUP|||||f||||||||||||||2018-06-01 02:59:27.635465|2018-06-01 02:59:27.635465
NCT00517608|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2007-08-20|2007-08-16|2007-08-17|Estimate|||||||2007-08-20|2007-08-21|Estimate|August 2005||2005-08-31|August 2007|2007-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Monopolar Scissors vs Bipolar Vessel Sealer vs Ultrasonic Shears: A Prospective Randomized Study in Laparoscopic Colorectal Surgery||Completed||N/A|||University of Zurich|||||f||||f||||||||||2018-06-01 02:59:27.716221|2018-06-01 02:59:27.716221
NCT00517595|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2011-10-11||2012-03-08|2007-08-16|2007-08-17|Estimate|2012-02-07|2012-03-08|Estimate||||2012-03-08|2012-03-12|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC|A Phase II Study of Pemetrexed and Gemcitabine Plus Bevacizumab as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 2|48|Actual|Accelerated Community Oncology Research Network|||||f||||f||||||||||2018-06-01 02:59:27.805359|2018-06-01 02:59:27.805359
NCT00517582|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2015-12-16|2007-08-15|2007-08-17|Estimate|||||||2015-12-16|2015-12-18|Estimate|September 2007||2007-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2011|Actual|2011-09-30||Interventional|||Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema|Study of a Bradykinin Receptor Blocker in Angiotensin Converting Enzyme Inhibitor-Associated Angioedema|Terminated||Phase 1|13|Actual|Vanderbilt University||2||This study was stopped to allow initiation of a mult-center study|f||||f||||||||||2018-06-01 02:59:28.239963|2018-06-01 02:59:28.239963
NCT00517569|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2008-05-08|2007-08-16|2007-08-17|Estimate|||||||2008-05-08|2008-05-12|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients|Phase I Study for Assessment of Safety of Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients|Unknown status|Recruiting|Phase 1|12|Anticipated|Genexine, Inc.||1|||f||||f||||||||||2018-06-01 02:59:28.308575|2018-06-01 02:59:28.308575
NCT00517556|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2017-01-26||2017-03-20|2007-08-15|2007-08-17|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|August 2007||2007-08-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|Dysmenorrhea||Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea|Continuous Administration of a Monophasic Oral Contraceptive in the Treatment of Primary Dysmenorrhea|Completed||Phase 1/Phase 2|38|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 02:59:28.368332|2018-06-01 02:59:28.368332
NCT00517543|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16||2010-10-13|2010-10-13|2007-08-16|2007-08-17|Estimate||||2010-10-13|2010-10-14|Estimate|2010-10-13|2010-10-14|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability|A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553|Completed||Phase 1|36|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 02:59:28.712317|2018-06-01 02:59:28.712317
NCT00517530|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2015-07-14||2016-08-18|2007-08-16|2007-08-17|Estimate|2015-08-19|2015-09-22|Estimate||||2016-08-18|2016-10-11|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Safety population: All enrolled participants who had received at least 1 dose of obinutuzumab.|A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)|An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease.|Completed||Phase 1/Phase 2|134|Actual|Hoffmann-La Roche|Pharmacodynamic results were limited because number of participants was inversely proportional to length of follow-up. In other words, there were fewer participants still in the trial as the follow-up period became longer.|8|||f||||f||||||||||2018-06-01 02:59:28.818815|2018-06-01 02:59:28.818815
NCT00517517|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2015-10-07|2007-08-16|2007-08-17|Estimate|||||||2015-10-07|2015-10-09|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|February 2008|Actual|2008-02-29|September 2007|Actual|2007-09-30||Interventional|||Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)|An Open-Label Phase I/II Study to Assess the Safety and Immunogenicity of Two Doses of a Vero Cell Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Volunteers Aged 21 to 45 Years|Completed||Phase 1/Phase 2|110|Actual|Ology Bioservices||2|||f||||t||||||||||2018-06-01 02:59:29.701107|2018-06-01 02:59:29.701107
NCT00517504|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2012-07-03|2007-08-15|2007-08-17|Estimate|||||||2012-07-03|2012-07-04|Estimate|May 2001||2001-05-31|July 2012|2012-07-31||||March 2008|Actual|2008-03-31||Interventional|||Methylphenidate Study in Young Children With Developmental Disorders|Methylphenidate Study in Young Children With Developmental Disorders|Completed||Phase 4|48|Actual|University of Arizona|||||f||||f||||||||||2018-06-01 02:59:29.764422|2018-06-01 02:59:29.764422
NCT00517491|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2015-09-29|2007-08-16|2007-08-17|Estimate|||||||2015-09-29|2015-10-01|Estimate|May 2008||2008-05-31|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)|A Pilot Study to Evaluate the Correlation Between Plasma Lanreotide Levels and GH/IGF-1 Dynamics and Clinical Improvement in Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)|Withdrawn||Phase 2|0|Actual|Ipsen||1||Administrative reasons|f||||||||||||||2018-06-01 02:59:29.813284|2018-06-01 02:59:29.813284
NCT00517478|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2007-08-16|2007-08-16|2007-08-17|Estimate|||||||2007-08-16|2007-08-17|Estimate|August 2007||2007-08-31|July 2007|2007-07-31|February 2008|Anticipated|2008-02-29|||||Observational|||Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI||Unknown status|Not yet recruiting||50|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 02:59:29.864779|2018-06-01 02:59:29.864779
NCT00517465|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2016-11-01|2007-08-16|2007-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple-ascending-dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of R1511 in Type 2 Diabetic (T2D) Patients|Completed||Phase 1|41|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 02:59:29.922932|2018-06-01 02:59:29.922932
NCT00517452|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2011-01-04|2007-08-16|2007-08-17|Estimate|||||||2011-01-04|2011-01-05|Estimate|May 2007||2007-05-31|January 2011|2011-01-31|December 2007|Actual|2007-12-31|||||Observational|PRP||Platelet Rich Plasma Study in Lower Extremity Bypass Surgery|Phase 2-3 Observational Wound Care Study Comparing Application of Platelet Rich Plasma With Standard of Care Wound Closure in Vascular Patients Requiring a Groin Incision.|Completed|||81|Actual|Lawson Health Research Institute|||2||f||||f||||||||||2018-06-01 02:59:30.945316|2018-06-01 02:59:30.945316
NCT00517439|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16||2016-07-07|2016-11-01|2007-08-16|2007-08-17|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.|A Randomized, Double-blinded Study to Evaluate the Safety and Effect on Sustained Virological Response of HCV Polymerase Inhibitor Pro-drug in Combination With PEGASYS Plus Copegus, Compared With the Currently Approved Combination of PEGASYS Plus Copegus, in Treatment-naïve Patients With Chronic he|Completed||Phase 2|516|Actual|Hoffmann-La Roche||7|||f||||||||||||||2018-06-01 02:59:31.028962|2018-06-01 02:59:31.028962
NCT00517426|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2016-01-27|2007-08-16|2007-08-17|Estimate|||||||2016-01-27|2016-01-28|Estimate|July 2007||2007-07-31|January 2016|2016-01-31|August 2012|Actual|2012-08-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure||Completed||Phase 4|20|Actual|Centro Cardiologico Monzino||1|||f||||f||||||||||2018-06-01 02:59:31.1879|2018-06-01 02:59:31.1879
NCT00517413|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|2016-02-24||2016-03-29|2007-08-16|2007-08-17|Estimate|2016-03-29|2016-04-29|Estimate||||2016-03-29|2016-04-29|Estimate|October 2007||2007-10-31|March 2016|2016-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||The Intention To Treat (ITT) population included participants who received at least 1 dose of C.E.R.A. (Week 0) and for whom data for at least one follow-up variable were available.|LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.|A Single-Arm Open-Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous and/or Subcutaneous C.E.R.A for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia|Completed||Phase 3|163|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 02:59:31.336958|2018-06-01 02:59:31.336958
NCT00517400|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-16|||2015-04-19|2007-08-16|2007-08-17|Estimate|||||||2015-04-19|2015-04-21|Estimate|February 2008||2008-02-29|July 2010|2010-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Deep Transcranial Magnetic Stimulation (TMS)- Treatment for Post Traumatic Stress Disorder|Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device- Treatment for Post Traumatic Stress Disorder|Completed||Phase 1/Phase 2|30|Actual|Hadassah Medical Organization||3|||f||||||||||||||2018-06-01 02:59:32.098685|2018-06-01 02:59:32.098685
NCT00517387|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2010-11-12|2007-08-14|2007-08-16|Estimate|||||||2010-11-12|2010-11-16|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression|The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression|Completed||Phase 3|64|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-06-01 02:59:32.182127|2018-06-01 02:59:32.182127
NCT00514852|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2009-05-19||2009-11-10|2007-08-08|2007-08-10|Estimate|2009-11-10|2009-12-15|Estimate||||2009-11-10|2009-12-15|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye||Completed||N/A|316|Actual|Allergan||2|||f||||f||||||||||2018-06-01 03:00:27.897627|2018-06-01 03:00:27.897627
NCT00517361|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2014-01-22||2014-03-10|2007-08-14|2007-08-16|Estimate|2014-03-10|2014-04-15|Estimate||||2014-03-10|2014-04-15|Estimate|August 2007||2007-08-31|March 2014|2014-03-31|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer|A Phase II Study of Carboplatin and Bevacizumab (Avastin) Combination Therapy for ER Negative, PR Negative, and HER2/Neu Negative Metastatic Breast Cancer|Terminated||Phase 2|11|Actual|University of Chicago||1||This study has been terminated due to poor accrual|f||||t||||||||||2018-06-01 02:59:32.34379|2018-06-01 02:59:32.34379
NCT00517348|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2009-06-24|2007-08-15|2007-08-16|Estimate|||||||2009-06-24|2009-06-25|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating IMA-026 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-026 Administered Subcutaneously or Intravenously to Healthy Subjects|Completed||Phase 1|50|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 02:59:32.612028|2018-06-01 02:59:32.612028
NCT00517335|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2016-03-07|2007-08-14|2007-08-16|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Evaluating the Brain's Response to Natural Versus Artificial Sweetener in Women Who Have Had an Eating Disorder|The Evaluation of Brain Neuronal Activity in Response to Natural (Sucrose) and Artificial (Sucralose) Taste Stimuli- Does Caloric Content Matter to the Brain?|Completed|||60|Actual|University of California, San Diego|||3||f||||||||||Samples With DNA|"~     If desired subjects have a chance to be a part of a DNA blood draw aspect of the study~   "|||2018-06-01 02:59:32.670759|2018-06-01 02:59:32.670759
NCT00517322|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2007-08-15|2007-08-15|2007-08-16|Estimate|||||||2007-08-15|2007-08-16|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2010|Anticipated|2010-08-31|||||Interventional|||Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan|Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan|Unknown status|Recruiting|Phase 4|80|Anticipated|Università degli Studi dell'Insubria||2|||f||||t||||||||||2018-06-01 02:59:32.752152|2018-06-01 02:59:32.752152
NCT00517309|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2017-03-20|2007-08-15|2007-08-16|Estimate|||||||2017-03-20|2017-03-22|Actual|December 28, 2001|Actual|2001-12-28|March 2017|2017-03-31|June 11, 2004|Actual|2004-06-11|June 8, 2004|Actual|2004-06-08||Interventional|FUTURE||Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)|Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease|Completed||Phase 3|1877|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 02:59:32.851934|2018-06-01 02:59:32.851934
NCT00517296|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|2016-08-25||2017-03-10|2007-08-15|2007-08-16|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|January 2008||2008-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas|EUS Guided Treatment With Humira for Crohn's Perianal Fistulas|Completed||Phase 4|21|Actual|Vanderbilt University Medical Center|Small sample size which increases the chance of type II error.|2|||f||||f||||||||No||2018-06-01 02:59:32.93517|2018-06-01 02:59:32.93517
NCT00517283|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2015-02-20|2007-08-14|2007-08-16|Estimate|||||||2015-02-20|2015-02-23|Estimate|January 2005||2005-01-31|January 2015|2015-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes|A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes|Completed||Phase 1|17|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:59:33.264258|2018-06-01 02:59:33.264258
NCT00517270|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2010-07-06|2007-08-15|2007-08-16|Estimate|||||||2010-07-06|2010-07-07|Estimate|March 2003||2003-03-31|July 2010|2010-07-31|April 2008|Anticipated|2008-04-30|||||Interventional|||A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study|High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study.|Unknown status|Recruiting|N/A|200|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:33.341376|2018-06-01 02:59:33.341376
NCT00517257|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2008-06-23|2007-08-14|2007-08-16|Estimate|||||||2008-06-23|2008-06-25|Estimate|August 2007||2007-08-31|June 2008|2008-06-30|September 2009|Anticipated|2009-09-30|||||Interventional|ATORVO||Atorvastatin for the Treatment of Retinal Vein Occlusion|Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO)|Unknown status|Recruiting|Phase 3|180|Anticipated|University of Toronto||2|||f||||t||||||||||2018-06-01 02:59:33.414306|2018-06-01 02:59:33.414306
NCT00517244|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2016-03-10|2007-08-14|2007-08-16|Estimate|||||||2016-03-10|2016-03-11|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders|Child Anxiety Disorders: Parenting and Temperament Effects|Completed|||180|Actual|Rhode Island Hospital|||3||f||||f||||||||||2018-06-01 02:59:33.512408|2018-06-01 02:59:33.512408
NCT00517231|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2015-07-06|2007-08-14|2007-08-16|Estimate|||||||2015-07-06|2015-07-07|Estimate|June 2005||2005-06-30|July 2015|2015-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment||Withdrawn|||0|Actual|UPECLIN HC FM Botucatu Unesp||||The investigator left the research center and the study was not carried out|f||||f||||||||||2018-06-01 02:59:33.585402|2018-06-01 02:59:33.585402
NCT00517218|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2008-02-07|2007-08-15|2007-08-16|Estimate|||||||2008-02-07|2008-02-11|Estimate|June 2006||2006-06-30|August 2007|2007-08-31|June 2009||2009-06-30|||||Interventional|||This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)|A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense® (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia|Withdrawn||Phase 3|||Genta Incorporated|||||f||||||||||||||2018-06-01 02:59:33.654256|2018-06-01 02:59:33.654256
NCT00517205|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2011-06-14|2007-08-15|2007-08-16|Estimate|||||||2011-06-14|2011-06-16|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|||||Observational|||Study on 'The Use of Non-contrast Helical Computerized Tomogram in Predicting Treatment Outcomes of Upper Ureteric Stone by Extracorporeal Shock Wave Lithotripsy Using the Sonolith 4000+ Lithotripter'|The Use of Non-contrast Helical Computerized Tomogram in Predicting Treatment Outcome of Upper Ureteric Stone by Extracorporeal Shock Wave Lithotripsy Using the Sonolith 4000+ Lithotripter|Completed|||100|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:33.701528|2018-06-01 02:59:33.701528
NCT00517192|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|2009-09-18||2014-04-25|2007-08-15|2007-08-16|Estimate|2009-09-18|2009-10-23|Estimate||||2014-04-25|2014-05-14|Estimate|September 2007||2007-09-30|April 2014|2014-04-30||||September 2008|Actual|2008-09-30||Interventional|||Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI|A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to That of Prezista® (Darunavir, DRV/r) in Three-class (NRTI, NNRTI, and PI) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients|Terminated||Phase 3|40|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 02:59:33.792093|2018-06-01 02:59:33.792093
NCT00517179|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2011-06-14|2007-08-15|2007-08-16|Estimate|||||||2011-06-14|2011-06-16|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS|Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS for the Treatment of Benign Prostatic Hyperplasia|Completed||N/A|40|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:34.365453|2018-06-01 02:59:34.365453
NCT00517166|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2011-12-19|2007-08-14|2007-08-16|Estimate|||||||2011-12-19|2011-12-20|Estimate|August 2006||2006-08-31|December 2011|2011-12-31|March 2008|Actual|2008-03-31|||||Observational|||Survey of Tourniquet Use in a Combat Support Hospital|Survey of Tourniquet Use in a Combat Support Hospital|Completed|||584|Actual|United States Army Institute of Surgical Research|||1||f||||f||||||||||2018-06-01 02:59:34.440231|2018-06-01 02:59:34.440231
NCT00517153|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15||2010-02-11|2010-03-24|2007-08-15|2007-08-16|Estimate||||2010-02-11|2010-02-15|Estimate|2010-03-24|2010-03-26|Estimate|January 2002||2002-01-31|March 2010|2010-03-31|January 2008|Actual|2008-01-31|September 2006|Actual|2006-09-30||Interventional|||Miglustat in Niemann-Pick Type C Disease|A Phase II Randomized Controlled Study of Miglustat in Adult and Juvenile Patients With Niemann-Pick Type C Disease|Completed||Phase 2|29|Actual|Actelion||2|||f||||f||||||||||2018-06-01 02:59:34.546857|2018-06-01 02:59:34.546857
NCT00517140|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2011-06-14|2007-08-15|2007-08-16|Estimate|||||||2011-06-14|2011-06-16|Estimate|September 2003||2003-09-30|June 2011|2011-06-30|April 2007|Actual|2007-04-30|||||Interventional|||Vaginal Birth After Caesarean Section - Effect on Maternal Psychosocial Function|Vaginal Birth After Caesarean Section - Effect on Maternal Psychosocial Function|Completed||N/A|262|Actual|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:34.682991|2018-06-01 02:59:34.682991
NCT00517127|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2018-01-08|2007-08-15|2007-08-16|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2006||2006-09-30|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|CC||Crystalloids Versus Colloids During Surgery|A Comparison of Crystalloids vs. Colloids for Intraoperative Goal-directed Fluid Management|Completed||Phase 4|1109|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 02:59:34.762069|2018-06-01 02:59:34.762069
NCT00517114|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2013-10-22|2007-08-15|2007-08-16|Estimate|||||||2013-10-22|2013-10-23|Estimate|January 2005||2005-01-31|October 2013|2013-10-31|December 2008|Actual|2008-12-31|||||Interventional|||Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients|Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients|Completed||N/A|200|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:34.851687|2018-06-01 02:59:34.851687
NCT00517101|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2007-08-15|2007-08-15|2007-08-16|Estimate|||||||2007-08-15|2007-08-16|Estimate|September 2007||2007-09-30|August 2007|2007-08-31||||||||Observational|||Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy||Unknown status|Not yet recruiting||||Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 02:59:34.919066|2018-06-01 02:59:34.919066
NCT00517088|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2014-05-29|2007-08-15|2007-08-16|Estimate|||||||2014-05-29|2014-05-30|Estimate|May 2006||2006-05-31|August 2007|2007-08-31|March 2007|Actual|2007-03-31|||||Interventional|PABC||Level of Physical Activities in Patients Before and After Breast Cancer Treatment|Level of Physical Activities in Patients Before and After Breast Cancer Treatment|Completed||N/A|2007|Actual|UPECLIN HC FM Botucatu Unesp||1|||t||||t||||||||||2018-06-01 02:59:34.969149|2018-06-01 02:59:34.969149
NCT00517075|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2017-01-12||2017-01-12|2007-08-14|2007-08-16|Estimate|2017-01-12|2017-01-13|Estimate||||2017-01-12|2017-01-13|Estimate|September 2004||2004-09-30|January 2017|2017-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.|Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)|Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms and Social Dysfunction in Schizophrenia Patients|Terminated||Phase 2|14|Actual|New York State Psychiatric Institute||4||Unable to adequately recruit subjects.|f||||f||||||||||2018-06-01 02:59:35.03956|2018-06-01 02:59:35.03956
NCT00517062|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2012-05-02|2007-08-15|2007-08-16|Estimate|||||||2012-05-02|2012-05-03|Estimate|January 2006||2006-01-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates|Effects of Low Dose Growth Hormone (GH) Therapy on Insulin Sensitivity, Adipocyte Insulin-like Growth Factor-I (IGF-I) and IGF-I/Insulin Receptor Density and Regulation of Cortisol Metabolism in GH Deficient Adults|Completed||Early Phase 1|16|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 02:59:35.361916|2018-06-01 02:59:35.361916
NCT00517049|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14||2010-06-18|2017-05-31|2007-08-14|2007-08-16|Estimate||||2010-06-18|2010-06-22|Estimate|2017-05-31|2017-06-06|Actual|March 2008|Actual|2008-03-31|May 2017|2017-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)|A Phase II, Single-Arm, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of Multiple Doses of PRO95780 Administered Intravenously in Combination With Rituximab in Patients With Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy|Completed||Phase 2|49|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 02:59:35.458211|2018-06-01 02:59:35.458211
NCT00517036|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2013-04-02|2007-08-14|2007-08-16|Estimate|||||||2013-04-02|2013-04-04|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Omega-3 Fatty Acids for Treating Adults With Major Depression|Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters|Completed||Phase 3|196|Actual|Cedars-Sinai Medical Center||3|||f||||t||||||||||2018-06-01 02:59:35.524604|2018-06-01 02:59:35.524604
NCT00517023|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2008-05-06|2007-08-15|2007-08-16|Estimate|||||||2008-05-06|2008-05-09|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|August 2009|Anticipated|2009-08-31|July 2008|Anticipated|2008-07-31||Interventional|EaSyAS II||Eastbourne Syncope Assessment Study II|Eastbourne Syncope Assessment Study II|Unknown status|Recruiting|N/A|240|Anticipated|Eastbourne General Hospital||4|||f||||f||||||||||2018-06-01 02:59:35.600141|2018-06-01 02:59:35.600141
NCT00517010|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|2015-12-02||2016-06-28|2007-08-15|2007-08-16|Estimate|2016-06-28|2016-07-11|Estimate||||2016-06-28|2016-07-11|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration|Phase 1 Pilot Open Label Prospective Observational Study of Safety and Tolerability of Lucentis Combined With Proton Beam Irradiation in Treating Exudative Age-related Macular Degeneration|Completed||Early Phase 1|6|Actual|University of California, Davis||1|||f||||f||||||||Yes|Findings have been presented at national and international venues and published in scientific peer-reviewed journal|2018-06-01 02:59:35.685132|2018-06-01 02:59:35.685132
NCT00516984|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2008-08-21|2007-08-15|2007-08-16|Estimate|||||||2008-08-21|2008-08-22|Estimate|January 2005||2005-01-31|August 2008|2008-08-31|October 2007|Actual|2007-10-31|||||Interventional|||Osteopathic Manipulative Treatment and Its Relationship to Autonomic Nervous System Activity|Osteopathic Manipulative Treatment and Its Relationship to Autonomic Nervous System Activity as Demonstrated by Heart Rate Variability|Completed||N/A|30|Actual|University of Oklahoma||3|||f||||f||||||||||2018-06-01 02:59:35.871247|2018-06-01 02:59:35.871247
NCT00516971|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2010-07-06|2007-08-15|2007-08-16|Estimate|||||||2010-07-06|2010-07-07|Estimate|January 2003||2003-01-31|July 2010|2010-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population|The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population|Unknown status|Recruiting|N/A|200|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:35.947249|2018-06-01 02:59:35.947249
NCT00516958|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2008-01-07|2007-08-14|2007-08-16|Estimate|||||||2008-01-07|2008-01-14|Estimate|May 2007||2007-05-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections|An Open Label, Three Arm, Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care vs. Oral Levofloxacin vs. Combined Therapy for Mild Diabetic Foot Infections|Completed||Phase 2|65|Anticipated|Oculus Innovative Sciences, Inc.||3|||f||||f||||||||||2018-06-01 02:59:36.016158|2018-06-01 02:59:36.016158
NCT00516945|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2013-09-03|2007-08-15|2007-08-16|Estimate|||||||2013-09-03|2013-09-05|Estimate|September 2004||2004-09-30|July 2013|2013-07-31|June 2008|Actual|2008-06-30|||||Interventional|||A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers|A Randomized Controlled Study Comparing the Impact of Prophylactic Versus Deferred Lamivudine on the Delivery of Cytotoxic Chemotherapy in Hepatitis B Surface-antigen Positive Patients With Malignant Solid Tumor|Completed||N/A|110|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:36.100695|2018-06-01 02:59:36.100695
NCT00516932|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2015-04-16|2007-08-14|2007-08-16|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|PARCA||Pharmacogenomics of Antidepressant Response in Children and Adolescents|Pharmacogenomics of Antidepressant Response in Children and Adolescents|Completed|||211|Actual|Duke University|||||f||||t||||||Samples With DNA|"~     Salivary DNA retained at the Duke Center for Human Genetics~   "|||2018-06-01 02:59:36.150702|2018-06-01 02:59:36.150702
NCT00516919|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|2012-07-31||2013-01-07|2007-08-15|2007-08-16|Estimate|2013-01-07|2013-02-07|Estimate||||2013-01-07|2013-02-07|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons|Controlled Trial of Orlistat With Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons|Completed||Phase 4|79|Actual|Yale University||2|||f||||f||||||||||2018-06-01 02:59:36.214711|2018-06-01 02:59:36.214711
NCT00516906|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2010-03-03||2012-07-25|2007-08-14|2007-08-16|Estimate|2012-01-20|2012-02-23|Estimate||||2012-07-25|2012-08-01|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Clinical Performance of a Chlorhexidine Antimicrobial Dressing|Clinical Performance of a Chlorhexidine Antimicrobial Dressing|Completed||Phase 2/Phase 3|68|Actual|3M|This trial evaluated the dressing for it's securement and ease of use adaption into healthcare practices compared to a standard transparent dressing. The sample size was too small to evaluate any effect on Catheter Related-Bloodstream Infection.|2|||f||||f||||||||||2018-06-01 02:59:36.444738|2018-06-01 02:59:36.444738
NCT00516893|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2009-06-30||2014-05-01|2007-08-15|2007-08-16|Estimate|2009-06-30|2009-08-13|Estimate||||2014-05-01|2014-05-15|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Natalizumab High Titer Immunogenicity and Safety|A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis|Completed||Phase 2|113|Actual|Biogen||1|||f||||f||||||||||2018-06-01 02:59:36.738282|2018-06-01 02:59:36.738282
NCT00516880|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2010-07-06|2007-08-15|2007-08-16|Estimate|||||||2010-07-06|2010-07-07|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|November 2008|Anticipated|2008-11-30|||||Interventional|||Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?|Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?|Unknown status|Recruiting|N/A|160|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:37.049103|2018-06-01 02:59:37.049103
NCT00516867|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2007-08-15|2007-08-15|2007-08-16|Estimate|||||||2007-08-15|2007-08-16|Estimate|February 2006||2006-02-28|August 2007|2007-08-31|April 2006|Actual|2006-04-30|||||Interventional|||Does Sunbed Radiation With Mainly UVA Provoke Cutaneous Vitamin D Synthesis in Humans?|Sunbed Radiation Provoke Cutaneous Vitamin D Synthesis in Humans, a Randomized Controlled Trial|Completed||N/A|41|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-06-01 02:59:37.120929|2018-06-01 02:59:37.120929
NCT00516854|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-15|||2010-07-06|2007-08-15|2007-08-16|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2002||2002-06-30|July 2010|2010-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study|A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study|Unknown status|Recruiting|N/A|100|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 02:59:37.216029|2018-06-01 02:59:37.216029
NCT00516841|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2012-08-21|2007-08-15|2007-08-16|Estimate|||||||2012-08-21|2012-08-23|Estimate|August 2007||2007-08-31|August 2012|2012-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer||Terminated||Phase 2|16|Actual|Facet Biotech||1||Decision to terminate recruitment based on lack of efficacy|f||||f||||||||||2018-06-01 02:59:37.304088|2018-06-01 02:59:37.304088
NCT00516828|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2015-10-05|2007-08-14|2007-08-15|Estimate|||||||2015-10-05|2015-10-06|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|January 2013|Actual|2013-01-31|March 2010|Actual|2010-03-31||Interventional|||Sorafenib and Low Dose Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS|Completed||Phase 1/Phase 2|21|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-06-01 02:59:37.431608|2018-06-01 02:59:37.431608
NCT00516802|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2009-05-14|2007-08-13|2007-08-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|January 2007||2007-01-31|May 2009|2009-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine|A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours|Completed||Phase 1|40|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 02:59:37.542042|2018-06-01 02:59:37.542042
NCT00516776|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2018-02-12|2007-08-14|2007-08-15|Estimate|||||||2018-02-12|2018-02-14|Actual|June 2007|Actual|2007-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||The Innate Immune System and Inflammatory Bowel Disease|The Innate Immune System and Inflammatory Bowel Disease|Completed|||400|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Intestinal biopsies Plasma/serum Peripheral blood monocytes~   "|No||2018-06-01 02:59:37.628859|2018-06-01 02:59:37.628859
NCT00516750|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2013-07-09|2007-08-14|2007-08-15|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 2007||2007-07-31|March 2008|2008-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin|Phase II Clinical Trial Concerning Gene Expression Profiling to Predict the Chemosensitivity of Invasive Bladder Cancer|Terminated||Phase 2|100|Anticipated|National Cancer Institute (NCI)||||Withdrawn due to lack of enrollment.|f||||||||||||||2018-06-01 02:59:37.689025|2018-06-01 02:59:37.689025
NCT00516737|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|2009-03-12||2017-05-11|2007-08-13|2007-08-15|Estimate|2009-03-12|2009-04-14|Estimate||||2017-05-11|2017-06-09|Actual|October 3, 2007|Actual|2007-10-03|May 2017|2017-05-31|April 8, 2008|Actual|2008-04-08|April 8, 2008|Actual|2008-04-08||Interventional|||Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine|Completed||Phase 3|207|Actual|Merck Sharp & Dohme Corp.|In the Adverse Events section, all non-serious adverse experiences reported are post-treatment, up to the time of taking rescue medication or 14 days post-dose, whichever comes first.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 02:59:37.777666|2018-06-01 02:59:37.777666
NCT00516724|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2018-02-27|2007-08-13|2007-08-15|Estimate|||||||2018-02-27|2018-02-28|Actual|June 29, 2007|Actual|2007-06-29|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|January 4, 2013|Actual|2013-01-04||Interventional|||Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel|A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin, KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|188|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 02:59:38.083707|2018-06-01 02:59:38.083707
NCT00516711|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2010-09-14|2007-08-14|2007-08-15|Estimate|||||||2010-09-14|2010-09-15|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Role of Volatile Anesthetics for Hepatic Protection|Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion|Completed||N/A|||University of Zurich|||||f||||f||||||||||2018-06-01 02:59:38.172114|2018-06-01 02:59:38.172114
NCT00516698|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2016-07-12|2007-08-14|2007-08-15|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2007||2007-09-30|July 2016|2016-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer|Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy|Completed|||140|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 02:59:38.259459|2018-06-01 02:59:38.259459
NCT00516685|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2011-09-29|2007-08-14|2007-08-15|Estimate|||||||2011-09-29|2011-09-30|Estimate|July 2007||2007-07-31|September 2011|2011-09-30||||||||Interventional|NSCLC||Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV|A Phase II/III Trial to Assess the Safety, Immunogenicity and Preliminary Efficacy of Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Administered to Patients With Non-Small-Cell Lung Cancer (NSCLC) After Receiving Conventional First Line Chemotherapy|Terminated||Phase 2/Phase 3|230|Anticipated|Bioven Sdn. Bhd.||2||"Due to inability of patient enrollment, decision taken to terminate in the interests of~   patients and later Malaysia is incorporated into global Phase 3 trial."|f||||||||||||||2018-06-01 02:59:38.492693|2018-06-01 02:59:38.492693
NCT00516672|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2017-11-08|2007-08-13|2007-08-15|Estimate|||||||2017-11-08|2017-11-13|Actual|September 10, 2007|Actual|2007-09-10|November 2017|2017-11-30|October 14, 2015|Actual|2015-10-14|August 30, 2010|Actual|2010-08-30||Interventional|||Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors|A Phase I, Open-Label, Multiple Dose of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 02:59:38.654857|2018-06-01 02:59:38.654857
NCT00516659|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2012-03-13|2007-08-14|2007-08-15|Estimate|||||||2012-03-13|2012-03-14|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|December 2007|Actual|2007-12-31|January 2007|Actual|2007-01-31||Interventional|Trek||ETEC Logistics Trial (TREK)|A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting|Completed||Phase 2|201|Actual|Intercell USA, Inc.||2|||f||||t||||||||||2018-06-01 02:59:38.784223|2018-06-01 02:59:38.784223
NCT00516646|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2010-01-12|2007-08-13|2007-08-15|Estimate|||||||2010-01-12|2010-01-13|Estimate|August 2007||2007-08-31|April 2009|2009-04-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|BENEFICIAL||The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure|A Double-blind, Placebo-controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure|Completed||Phase 2|100|Anticipated|Synvista Therapeutics, Inc||2|||f||||f||||||||||2018-06-01 02:59:38.918834|2018-06-01 02:59:38.918834
NCT00516633|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-14|2007-08-14|2007-08-15|Estimate|||||||2007-08-14|2007-08-15|Estimate|April 1998||1998-04-30|August 2007|2007-08-31|December 2005|Actual|2005-12-31|||||Interventional|||Intervention Study to Improve Adherence in Asthma|Does Improved Information in the Form of Group Discussions With Parents of Newly Diagnosed Asth-Matic Children Lead to a Better Quality of Life for the Families, an Improved Adherence and Better Devel-Opment of the Lung Function of the Children?|Completed||N/A|60|Actual|Värmland County Council, Sweden||2|||f||||t||||||||||2018-06-01 02:59:39.010915|2018-06-01 02:59:39.010915
NCT00516620|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2015-12-08|2007-08-13|2007-08-15|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2005||2005-01-31|December 2015|2015-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Fruits, Vegetables, and Whole Grains: A Community-based Intervention|Fruits, Vegetables, and Whole Grains: A Community-based Intervention|Completed||Phase 1|960|Actual|University of Toronto||4|||f||||f||||||||||2018-06-01 02:59:39.090302|2018-06-01 02:59:39.090302
NCT00516607|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2015-02-09|2007-08-14|2007-08-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|July 2007||2007-07-31|February 2015|2015-02-28||||November 2008|Actual|2008-11-30||Interventional|||Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas|Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas|Unknown status|Active, not recruiting|Phase 1|28|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 02:59:39.202061|2018-06-01 02:59:39.202061
NCT00516594|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2009-01-16|2007-08-13|2007-08-15|Estimate|||||||2009-01-16|2009-01-21|Estimate||||January 2009|2009-01-31||||||||Interventional|||The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption|"The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption on Blood Lipids Risk Factors for Heart Disease in Healthy Normal and Hyperlipidemic Subjects"|Completed||Phase 2|||University of Toronto|||||f||||||||||||||2018-06-01 02:59:39.358155|2018-06-01 02:59:39.358155
NCT00516581|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2008-09-04|2007-08-14|2007-08-15|Estimate|||||||2008-09-04|2008-09-05|Estimate|February 2003||2003-02-28|September 2008|2008-09-30|February 2005|Actual|2005-02-28|||||Observational|||Occurrence of Pneumocystis Pneumonia in HIV-Infected Patients and the Interference of the HAART|Occurrence of Pneumocystis Pneumonia in HIV-Infected Patients and the Interference of the Highly Active Antiretroviral Therapy|Completed|||376|Actual|UPECLIN HC FM Botucatu Unesp|||2||f||||t||||||||||2018-06-01 02:59:39.437155|2018-06-01 02:59:39.437155
NCT00516555|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2013-03-18|2007-08-13|2007-08-15|Estimate|||||||2013-03-18|2013-03-19|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||EBIS: The Eindhoven Breech Intervention Study|Ebis: The Eindhoven Breech Intervention Study|Completed|||250|Actual|Catharina Ziekenhuis Eindhoven|||1||f||||t||||||Samples Without DNA|"~     Blood samples for thyroid hormone status (Tsh, Ft4, anti-TPO)~   "|||2018-06-01 02:59:39.536632|2018-06-01 02:59:39.536632
NCT00516542|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2012-07-23|2007-08-14|2007-08-15|Estimate|||||||2012-07-23|2012-07-24|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Interventional|||Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer|A Phase I Study of DHEA in Combination With Letrozole in ER- Breast Cancer|Terminated||Phase 1|6|Actual|OHSU Knight Cancer Institute||||Study was terminated due to lack of accrual|f||||t||||||||||2018-06-01 02:59:39.624519|2018-06-01 02:59:39.624519
NCT00516516|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2017-04-18|2007-08-14|2007-08-15|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2008||2008-07-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Oral Carnitine for Cramps in Pregnancy|Oral L-Carnitine for the Treatment of Muscle Cramps in Pregnancy: A Randomized, Controlled Trial|Terminated||N/A|30|Actual|University of Southern California||2||Low interest in study, slow recruitment|f||||t|f|f||||||||2018-06-01 02:59:39.728908|2018-06-01 02:59:39.728908
NCT00516503|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2016-11-02||2017-07-25|2007-08-14|2007-08-15|Estimate|2017-07-25|2017-08-24|Actual||||2017-07-25|2017-08-24|Actual|February 2008||2008-02-29|July 2017|2017-07-31|January 2010|Actual|2010-01-31|April 2009|Actual|2009-04-30||Interventional|||Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer|The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study|Completed||Phase 3|208|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 02:59:39.915953|2018-06-01 02:59:39.915953
NCT00516490|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2007-08-14|2007-08-14|2007-08-15|Estimate|||||||2007-08-14|2007-08-15|Estimate|September 2006||2006-09-30|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles||Completed||N/A|570|Actual|V.K.V. American Hospital, Istanbul||2|||f||||f||||||||||2018-06-01 02:59:40.829276|2018-06-01 02:59:40.829276
NCT00516477|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2018-03-28|2007-08-13|2007-08-15|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2007|Actual|2007-09-30|March 2018|2018-03-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Interventional|||Safety Study in Subjects With Leber Congenital Amaurosis|A Phase 1 Safety Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 Into the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-101]|Active, not recruiting||Phase 1|12|Anticipated|Spark Therapeutics||3|||f||||t|t|f||||||||2018-06-01 02:59:40.922593|2018-06-01 02:59:40.922593
NCT00516464|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2007-08-14|2007-08-14|2007-08-15|Estimate|||||||2007-08-14|2007-08-15|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2008|Anticipated|2008-08-31|||||Interventional|||Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy|Evaluation of Ranibizumab on the Ease of Procedure and Complication Rate in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy|Unknown status|Recruiting|Phase 3|40|Anticipated|Retina Associates, Kansas City|||||f||||f||||||||||2018-06-01 02:59:41.015737|2018-06-01 02:59:41.015737
NCT00516451|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2008-10-10|2007-08-14|2007-08-15|Estimate|||||||2008-10-10|2008-10-13|Estimate|November 2007||2007-11-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors|Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors|Completed||Phase 1|9|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 02:59:41.077435|2018-06-01 02:59:41.077435
NCT00516438|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2010-12-07|2007-08-13|2007-08-15|Estimate|||||||2010-12-07|2010-12-08|Estimate|July 2007||2007-07-31|December 2010|2010-12-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan|A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Topotecan in the Treatment of Patients With Advanced Solid Tumours|Completed||Phase 1|48|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 02:59:41.132557|2018-06-01 02:59:41.132557
NCT00516425|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2013-08-06|2007-08-14|2007-08-15|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2007||2007-01-31|September 2007|2007-09-30||||||||Interventional|||Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer|Adjuvant Cytotoxic Chemotherapy In Older Women|Unknown status|Recruiting|Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:59:41.214663|2018-06-01 02:59:41.214663
NCT00516412|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2015-09-28|2007-08-14|2007-08-15|Estimate|||||||2015-09-28|2015-09-29|Estimate|August 2007||2007-08-31|September 2015|2015-09-30|August 2012|Actual|2012-08-31|January 2010|Actual|2010-01-31||Interventional|||Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Everolimus (RAD001) for the Treatment of Patients With Relapsed or Therapy Resistant Mantle Cell Lymphoma|Completed||Phase 2|35|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||||2018-06-01 02:59:42.217289|2018-06-01 02:59:42.217289
NCT00516399|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2014-12-03|2007-08-14|2007-08-15|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine|A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine|Terminated||Phase 3|78|Actual|University of California, Los Angeles||2||"The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of~   povidone-iodine to Natamycin."|f||||t||||||||||2018-06-01 02:59:42.708737|2018-06-01 02:59:42.708737
NCT00516386|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|2010-11-23||2013-12-10|2007-08-14|2007-08-15|Estimate|2011-07-11|2011-08-04|Estimate||||2013-12-10|2014-01-10|Estimate|March 2007||2007-03-31|December 2013|2013-12-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents|Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents|Completed||Phase 1/Phase 2|16|Actual|Massachusetts General Hospital|A limitation of our study is that this was not a randomized controlled trial of rhIGF-1 versus placebo.|1|||f||||t||||||||||2018-06-01 02:59:43.071236|2018-06-01 02:59:43.071236
NCT00516373|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2018-02-27|2007-08-13|2007-08-15|Estimate|||||||2018-02-27|2018-02-28|Actual|July 4, 2005|Actual|2005-07-04|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|December 17, 2008|Actual|2008-12-17||Interventional|||A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)|A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients With Advanced Tumours.|Active, not recruiting||Phase 1|90|Actual|AstraZeneca||1|||f||||t||||||||||2018-06-01 02:59:43.332961|2018-06-01 02:59:43.332961
NCT00516360|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2008-05-28|2007-08-13|2007-08-15|Estimate|||||||2008-05-28|2008-05-30|Estimate|July 2007||2007-07-31|August 2007|2007-08-31|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Interventional|||Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants|Chlorhexidine and the Prevention of Central Catheter Related Infections in Neonates|Unknown status|Recruiting|Phase 4|150|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 02:59:43.431019|2018-06-01 02:59:43.431019
NCT00516347|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2013-08-09|2007-08-14|2007-08-15|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2002||2002-06-30|October 2007|2007-10-31||||||||Observational|||Studying Genes for Barrett's Esophagus in Brothers and Sisters|A Sibling Pair Study To Identify Barrett's Oesophagus Susceptibility Genes|Unknown status|Recruiting||400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 02:59:43.892983|2018-06-01 02:59:43.892983
NCT00516334|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2012-07-26|2007-08-13|2007-08-15|Estimate|||||||2012-07-26|2012-07-27|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|May 2013|Anticipated|2013-05-31|May 2009|Actual|2009-05-31||Observational|BrainZ||Study of Bedside EEG to Evaluate Brain Injury in Premature Newborns|Advanced Electrophysiological Studies of the Premature Newborn Infant Brain: Understanding Brain Injury|Unknown status|Active, not recruiting||100|Anticipated|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 02:59:44.38385|2018-06-01 02:59:44.38385
NCT00516321|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|2012-03-22||2013-10-10|2007-08-13|2007-08-15|Estimate|2012-06-21|2012-07-30|Estimate||||2013-10-10|2013-11-05|Estimate|October 2007||2007-10-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease|Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin|Completed||Phase 3|687|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 02:59:44.871107|2018-06-01 02:59:44.871107
NCT00516308|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2008-01-16|2007-08-14|2007-08-15|Estimate|||||||2008-01-16|2008-01-18|Estimate|August 2007||2007-08-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|NightHawk||A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease|A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease|Terminated||Phase 2|100|Anticipated|FoxHollow Technologies||||Other|f||||f||||||||||2018-06-01 02:59:49.839931|2018-06-01 02:59:49.839931
NCT00516295|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2013-12-18||2014-08-20|2007-08-14|2007-08-15|Estimate|2014-08-20|2014-09-02|Estimate||||2014-08-20|2014-09-02|Estimate|February 2008||2008-02-29|July 2014|2014-07-31|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma|A Randomized Phase II Study of Bevacizumab (NSC 704865) Combined With Vincristine, Topotecan and Cyclophosphamide in Patients With First Recurrent Ewing Sarcoma|Completed||Phase 2|7|Actual|National Cancer Institute (NCI)|In preparing to re-open for randomized enrollment in November, 2008 the study committee was asked to amend the study and the decision was made to close AEWS0521 for administrative purpose.|3|||f||||t||||||||||2018-06-01 02:59:49.985992|2018-06-01 02:59:49.985992
NCT00516282|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2011-08-24|2007-08-14|2007-08-15|Estimate|||||||2011-08-24|2011-08-26|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma|A Phase I/II Trial of Cloretazine® (VNP40101M) and Temodar® (Temozolomide) for Patients With Malignant Glioma in First Relapse or Progression|Terminated||Phase 1|14|Actual|Northwestern University||||"The pharmaceutical collaborator filed for bankruptcy and as a result, the study was unable to~   move into the phase II portion."|f||||t||||||||||2018-06-01 02:59:51.056867|2018-06-01 02:59:51.056867
NCT00516269|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2012-09-18||2017-12-08|2007-08-14|2007-08-15|Estimate|2013-04-24|2013-04-26|Estimate||||2017-12-08|2018-01-03|Actual|August 2004||2004-08-31|December 2017|2017-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients|A Randomized, Double Blind, Two Period, Placebo-Controlled Crossover Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients|Terminated||Phase 3|42|Actual|M.D. Anderson Cancer Center|Early termination due to slow accrual.|2||Slow Accrual|f||||t|t|f||||||||2018-06-01 02:59:51.267598|2018-06-01 02:59:51.267598
NCT00068120|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-08|||2010-01-12|2003-09-08|2003-09-09|Estimate|||||||2010-01-12|2010-01-14|Estimate||||January 2010|2010-01-31||||||||Observational|||ORWH:SCOR - Sex/Gender Factors Affecting Women's Health|ORWH:SCOR - Sex/Gender Factors Affecting Women's Health|Completed|||200|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:17:38.086238|2018-06-01 05:17:38.086238
NCT00516256|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2017-10-04|2007-08-14|2007-08-15|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2007|Actual|2007-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||CHESS: Human and Computer Mentors for Prostate Cancer Patients|CHESS: Human and Computer Mentors for Prostate Cancer Patients|Active, not recruiting||N/A|654|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 02:59:52.160773|2018-06-01 02:59:52.160773
NCT00516243|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2014-09-11|2007-08-14|2007-08-15|Estimate|||||||2014-09-11|2014-09-12|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast Cancer|Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 02:59:52.313533|2018-06-01 02:59:52.313533
NCT00516230|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-13|2007-08-13|2007-08-15|Estimate|||||||2007-08-13|2007-08-15|Estimate|January 2006||2006-01-31|August 2007|2007-08-31|December 2011|Anticipated|2011-12-31|||||Observational|||Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer|Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer|Unknown status|Recruiting||200|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-06-01 02:59:52.478085|2018-06-01 02:59:52.478085
NCT00516217|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|2015-01-26||2016-07-01|2007-08-14|2007-08-15|Estimate|2015-01-26|2015-02-04|Estimate||||2016-07-01|2016-07-06|Estimate|June 2008||2008-06-30|July 2016|2016-07-31|February 2015|Actual|2015-02-28|September 2011|Actual|2011-09-30||Interventional|||Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma|Completed||Phase 2|30|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 02:59:52.568205|2018-06-01 02:59:52.568205
NCT00516204|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2014-10-29|2007-08-14|2007-08-15|Estimate|||||||2014-10-29|2014-10-30|Estimate|July 2007||2007-07-31|October 2014|2014-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Diabetic Under 70 (Diabetics Below 70)|Diabetic Under 70 (Diabetics Below 70)|Completed|||685|Actual|AstraZeneca|||4||f||||||||||||||2018-06-01 02:59:53.512515|2018-06-01 02:59:53.512515
NCT00516191|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2015-03-03|2007-08-13|2007-08-15|Estimate|||||||2015-03-03|2015-03-04|Estimate|October 2004||2004-10-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|DMV||A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma|A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, San Francisco||||low accrual|f||||t||||||||||2018-06-01 02:59:53.819405|2018-06-01 02:59:53.819405
NCT00516178|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-14|||2016-02-14|2007-08-14|2007-08-15|Estimate|||||||2016-02-14|2016-02-17|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|FO-cardiac||Intravenous Fish Oil in Critically Ill Cardiac Patients|Effects of Intravenous n-3 Polyunsaturated Fatty Acid Administration in Critically Ill Cardiac Surgery and Myocardial Infarction Patients|Completed||Phase 3|31|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-06-01 02:59:54.078647|2018-06-01 02:59:54.078647
NCT00516165|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|2014-12-03||2016-12-14|2007-08-13|2007-08-15|Estimate|2016-12-14|2017-02-07|Estimate||||2016-12-14|2017-02-07|Estimate|August 2007||2007-08-31|December 2016|2016-12-31|November 2011|Actual|2011-11-30|January 2010|Actual|2010-01-31||Interventional|||RAD001 in Advanced Hepatocellular Carcinoma|A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|28|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 02:59:54.363976|2018-06-01 02:59:54.363976
NCT00516152|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2009-01-22|2007-08-13|2007-08-15|Estimate|||||||2009-01-22|2009-01-26|Estimate|November 2002||2002-11-30|January 2009|2009-01-31|November 2007|Actual|2007-11-30|||||Interventional|||Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT|Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation|Completed||Phase 2|36|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-06-01 02:59:55.055681|2018-06-01 02:59:55.055681
NCT00516139|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|2011-07-15||2016-11-30|2007-08-13|2007-08-15|Estimate|2011-12-08|2012-01-13|Estimate||||2016-11-30|2017-01-18|Estimate|August 2007||2007-08-31|November 2016|2016-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Lamotrigine Extended-Release In Elderly Patients With Epilepsy|Lamotrigine Extended-Release in Elderly Patients With Epilepsy|Completed||Phase 3|122|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 02:59:55.292937|2018-06-01 02:59:55.292937
NCT00516126|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2013-01-10|2007-08-13|2007-08-14|Estimate|||||||2013-01-10|2013-01-11|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery|Goal-orientated Therapy of Perioperative Disturbance in Hemostasis With MULTIPLATE and ROTEM in Cardiac Surgery Patients Under Platelets Inhibitors|Completed|||200|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||||||2018-06-01 02:59:56.975674|2018-06-01 02:59:56.975674
NCT00516113|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-12-06|2007-08-13|2007-08-14|Estimate|||||||2007-12-06|2007-12-07|Estimate|October 2000||2000-10-31|August 2007|2007-08-31|November 2002|Actual|2002-11-30|||||Interventional|||A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria|A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine When Used for the Treatment of Premenstrual Dysphoria|Completed||Phase 4|24|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 02:59:57.318027|2018-06-01 02:59:57.318027
NCT00516100|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2010-01-14|2007-08-13|2007-08-14|Estimate|||||||2010-01-14|2010-01-15|Estimate|January 2006||2006-01-31|January 2010|2010-01-31|August 2012|Anticipated|2012-08-31|January 2010|Anticipated|2010-01-31||Interventional|||Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC|Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|62|Anticipated|Aptium Oncology Research Network|||||f||||f||||||||||2018-06-01 02:59:57.665112|2018-06-01 02:59:57.665112
NCT00516087|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2017-02-03|2007-08-13|2007-08-14|Estimate|||||||2017-02-03|2017-02-07|Estimate|August 2007||2007-08-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|NATELLA||LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)|Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes to Patients With EBV-Positive Nasopharyngeal Carcinoma|Completed||Phase 1|23|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-06-01 02:59:58.575403|2018-06-01 02:59:58.575403
NCT00516074|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2009-04-24||2015-03-19|2007-08-10|2007-08-14|Estimate|2009-04-24|2009-06-12|Estimate||||2015-03-19|2015-04-07|Estimate|September 2007||2007-09-30|March 2015|2015-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes|A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes|Completed||Phase 3|54|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 02:59:58.988393|2018-06-01 02:59:58.988393
NCT00516061|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-13|2007-08-13|2007-08-14|Estimate|||||||2007-08-13|2007-08-14|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|December 2007|Anticipated|2007-12-31|||||Observational|||Relationship of Peritoneal Solute Transport Rate With VEGF in Children Undergoing Peritoneal Dialysis||Unknown status|Recruiting||40|Anticipated|Samsung Medical Center|||||f||||t||||||||||2018-06-01 03:00:00.234955|2018-06-01 03:00:00.234955
NCT00516048|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2009-04-29||2015-03-19|2007-08-10|2007-08-14|Estimate|2009-04-29|2009-06-17|Estimate||||2015-03-19|2015-04-07|Estimate|August 2007||2007-08-31|March 2015|2015-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes|An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes|Completed||Phase 3|58|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:00:01.282545|2018-06-01 03:00:01.282545
NCT00516035|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2015-05-15|2007-08-13|2007-08-14|Estimate|||||||2015-05-15|2015-05-18|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults|Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H7N3 Infection in the Event of a Pandemic|Completed||Phase 1|22|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-06-01 03:00:02.513442|2018-06-01 03:00:02.513442
NCT00516022|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2011-09-26|2007-08-13|2007-08-14|Estimate|||||||2011-09-26|2011-09-27|Estimate|April 2007||2007-04-30|September 2011|2011-09-30|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|Iscador||Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination.|Mistletoe as Complementary Treatment in Patients With Advanced Non-small-cell Lung Cancer (NSCLC), Treated With Carboplatin/Gemcitabine Chemotherapy Combination: Randomized Phase II Study|Completed||Phase 2|79|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-06-01 03:00:02.727139|2018-06-01 03:00:02.727139
NCT00516009|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-13|2007-08-13|2007-08-14|Estimate|||||||2007-08-13|2007-08-14|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica|Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica|Unknown status|Recruiting|N/A|40|Anticipated|Ziv Hospital||2|||f||||f||||||||||2018-06-01 03:00:02.943637|2018-06-01 03:00:02.943637
NCT00515996|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-13|2007-08-13|2007-08-14|Estimate|||||||2007-08-13|2007-08-14|Estimate|January 2006||2006-01-31|August 2007|2007-08-31|December 2008|Anticipated|2008-12-31|||||Observational|||Genetic Abnormalities and Biological Changes of Panic Disorder Patients After Pharmacotherapy|Genetic Abnormalities and Changes of Autonomic Nervous System, Serotonin System, and Neuroendocrine System According to Pharmacotherapy in Panic Disorder|Unknown status|Recruiting||80|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-06-01 03:00:03.145822|2018-06-01 03:00:03.145822
NCT00515983|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2007-08-10|2007-08-10|2007-08-14|Estimate|||||||2007-08-10|2007-08-14|Estimate|October 2004||2004-10-31|August 2007|2007-08-31|December 2005|Actual|2005-12-31|||||Interventional|||Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells|Phase I Clinical Trial of a Therapeutic Vaccine Composed of Autologous Dendritic Cells Loaded With Allogeneic Apoptotic Tumor Cells in Patients With Melanoma Stages IIB, IIC, III and IV|Completed||Phase 1|16|Actual|José Mordoh, M.D., Ph.D.|||||f||||||||||||||2018-06-01 03:00:03.373316|2018-06-01 03:00:03.373316
NCT00515970|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2010-06-14|2007-08-13|2007-08-14|Estimate|||||||2010-06-14|2010-06-15|Estimate|December 2007||2007-12-31|June 2010|2010-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas|Prospective Randomized Trial: Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas|Suspended||N/A|400|Anticipated|University Hospital Tuebingen||4||Problems with the electronic data collection program|f||||t||||||||||2018-06-01 03:00:03.482792|2018-06-01 03:00:03.482792
NCT00515957|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2012-04-13|2007-08-13|2007-08-14|Estimate|||||||2012-04-13|2012-04-16|Estimate|August 2007||2007-08-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|DELLA||Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)|Administration of LMP1- and LMP2-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody Administration to Patients With EBV-Positive Nasopharyngeal Carcinoma|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 03:00:03.60674|2018-06-01 03:00:03.60674
NCT00515944|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2009-03-31|2007-08-13|2007-08-14|Estimate|||||||2009-03-31|2009-04-01|Estimate|August 2007||2007-08-31|March 2009|2009-03-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products||Completed||Phase 1|30|Anticipated|Merz Pharmaceuticals GmbH|||||f||||||||||||||2018-06-01 03:00:03.7284|2018-06-01 03:00:03.7284
NCT00515931|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2014-10-06|2007-08-13|2007-08-14|Estimate|||||||2014-10-06|2014-10-07|Estimate|August 2007||2007-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|GIST-RT||Radiation Therapy as Palliative Treatment of GIST|Radiation Therapy as Palliative Treatment of GIST Progressing During or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study|Completed||Phase 1/Phase 2|25|Actual|Helsinki University||1|||f||||f||||||||||2018-06-01 03:00:03.87449|2018-06-01 03:00:03.87449
NCT00515918|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-13|2007-08-13|2007-08-14|Estimate|||||||2007-08-13|2007-08-14|Estimate|September 2007||2007-09-30|August 2007|2007-08-31|September 2010|Anticipated|2010-09-30|||||Observational|IDBB||The Effect of Early Iron Deficiency on Developmental Brain and Behavior in Infants||Unknown status|Not yet recruiting||||Zhejiang University|||2||f||||t||||||||||2018-06-01 03:00:04.056287|2018-06-01 03:00:04.056287
NCT00515905|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2010-09-14|2007-08-13|2007-08-14|Estimate|||||||2010-09-14|2010-09-15|Estimate|October 2004||2004-10-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators|Lung: One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators After Deflation and Re-expansion of the Lung During Thoracic Surgery|Completed||N/A|76|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 03:00:04.1966|2018-06-01 03:00:04.1966
NCT00515892|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2007-08-10|2007-08-10|2007-08-14|Estimate|||||||2007-08-10|2007-08-14|Estimate|August 2007||2007-08-31|August 2007|2007-08-31||||||||Interventional|NHL||Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Non-Hodgkin'd Lymphoma (NHL)|Unknown status|Recruiting|Phase 1|50|Anticipated|Cambridge Antibody Technology|||||f||||f||||||||||2018-06-01 03:00:04.340121|2018-06-01 03:00:04.340121
NCT00515879|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2013-08-02||2018-01-16|2007-08-10|2007-08-14|Estimate|2015-07-20|2015-07-23|Estimate||||2018-01-16|2018-02-14|Actual|December 2007||2007-12-31|January 2018|2018-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia|D-cycloserine Enhancement of Exposure in Social Phobia|Completed||Phase 3|169|Actual|Boston University Charles River Campus||2|||f||||t||||||||||2018-06-01 03:00:04.450293|2018-06-01 03:00:04.450293
NCT00515866|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2013-12-19|2007-08-13|2007-08-14|Estimate|||||||2013-12-19|2013-12-20|Estimate|August 2007||2007-08-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|October 2011|Actual|2011-10-31||Interventional|||Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer|A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 in Combination With Gemcitabine in the Treatment of Patients With Advanced Solid Tumours|Completed||Phase 1|68|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 03:00:04.931261|2018-06-01 03:00:04.931261
NCT00515853|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2008-06-03|2007-08-10|2007-08-14|Estimate|||||||2008-06-03|2008-06-04|Estimate|November 2006||2006-11-30|June 2008|2008-06-30||||||||Interventional|||The Role of Biofeedback in Improving Continence After Anterior Resection||Unknown status|Recruiting|N/A|110||University of Southampton|||||f||||t||||||||||2018-06-01 03:00:05.085593|2018-06-01 03:00:05.085593
NCT00515840|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2015-11-04|2007-08-13|2007-08-14|Estimate|||||||2015-11-04|2015-11-05|Estimate|October 2003||2003-10-31|November 2015|2015-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|GLAD||GPIAG and Leicester Asthma and Dysfunctional Breathing (GLAD) Study: a Randomised Controlled Study|GPIAG and Leicester Asthma and Dysfunctional Breathing (GLAD) Study: a Randomised Controlled Study|Completed||Phase 3|182|Actual|University of Aberdeen||1|||f||||t||||||||||2018-06-01 03:00:05.195202|2018-06-01 03:00:05.195202
NCT00515827|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2011-01-25||2014-11-19|2007-08-10|2007-08-14|Estimate|2011-05-24|2011-06-23|Estimate||||2014-11-19|2014-12-05|Estimate|November 2007||2007-11-30|November 2013|2013-11-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load|A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens|Completed||Phase 2|53|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:00:05.29829|2018-06-01 03:00:05.29829
NCT00515814|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2011-06-08|2007-08-13|2007-08-14|Estimate|||||||2011-06-08|2011-06-09|Estimate|September 2005||2005-09-30|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors|A Prospective Open Pilot Study With Functional Placebo-control to Evaluate the Efficacy and Tolerability/Safety of a Subretinal Implant in Blind Patients in Accordance With ICH/GCP Guidelines|Completed||N/A|15|Anticipated|Retina Implant AG||1|||f||||t||||||||||2018-06-01 03:00:06.03648|2018-06-01 03:00:06.03648
NCT00515801|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2012-03-08|2007-08-13|2007-08-14|Estimate|||||||2012-03-08|2012-03-09|Estimate|June 2007||2007-06-30|March 2012|2012-03-31||||||||Interventional|||Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM|Effect of a Sulfonylurea Compound on the Glucagon Response to Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus|Completed||Phase 2/Phase 3|18|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 03:00:06.176537|2018-06-01 03:00:06.176537
NCT00515788|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2012-03-08|2007-08-13|2007-08-14|Estimate|||||||2012-03-08|2012-03-12|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis|Phase I Study of Temozolomide and Intrathecal DepoCyt in Patients With Neoplastic Meningitis|Terminated||Phase 1|11|Actual|M.D. Anderson Cancer Center||1||Study terminated due to slow accrual with no expansion to additional phase.|f||||f||||||||||2018-06-01 03:00:06.295149|2018-06-01 03:00:06.295149
NCT00515775|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2009-02-12|2007-08-13|2007-08-14|Estimate|||||||2009-02-12|2009-02-13|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Observational|||Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children||Completed|||27|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 03:00:06.410396|2018-06-01 03:00:06.410396
NCT00515762|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2011-08-08|2007-08-13|2007-08-14|Estimate|||||||2011-08-08|2011-08-09|Estimate|May 2007||2007-05-31|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling|Pilot Trial of Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling (ELASTO-GEL CAPS)in Breast Cancer Patients|Completed||Phase 2|150|Actual|Hospital San Carlos, Madrid||1|||f||||t||||||||||2018-06-01 03:00:06.480136|2018-06-01 03:00:06.480136
NCT00515736|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2010-07-29|2007-08-13|2007-08-14|Estimate|||||||2010-07-29|2010-07-30|Estimate|January 2003||2003-01-31|April 2008|2008-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|Etude-AOX||Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome|Influence Of Early Antioxidant Supplements On Clinical Evolution And Organ Function In Critically Ill Cardiac Surgery, Major Trauma And Subarachnoid Hemorrhage Patients|Terminated||Phase 3|200|Actual|Centre Hospitalier Universitaire Vaudois||2||enrollment was completed|f||||t||||||||||2018-06-01 03:00:06.669035|2018-06-01 03:00:06.669035
NCT00515723|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2011-02-25|2007-08-13|2007-08-14|Estimate|||||||2011-02-25|2011-02-28|Estimate|September 2001||2001-09-30|February 2011|2011-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|Glulipid||Glucose and Lipid Metabolism on Antipsychotic Medication|Glucose and Lipid Metabolism on Antipsychotic Medication|Completed||Phase 4|216|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 03:00:06.825196|2018-06-01 03:00:06.825196
NCT00515710|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2018-03-28|2007-08-13|2007-08-14|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2007||2007-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||LTFU for Gene Transfer Subjects With Hemophilia B|A Long-Term Follow-Up Study in Subjects With Sever Hemophilia B Who Received Adeno-Associated Viral Vectors Expressing Human Factor IX|Active, not recruiting|||9|Anticipated|Spark Therapeutics|||1||f||||t||||||||||2018-06-01 03:00:06.925608|2018-06-01 03:00:06.925608
NCT00515697|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|2014-05-16|2010-07-29|2014-05-16|2007-08-13|2007-08-14|Estimate|2014-05-16|2014-06-18|Estimate|2010-07-29|2010-08-02|Estimate|2014-05-16|2014-06-18|Estimate|November 2007||2007-11-30|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Intent-to-treat population: participants who received any quantity of ramucirumab.|A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma|Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy|Completed||Phase 2|39|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:00:07.028738|2018-06-01 03:00:07.028738
NCT00515684|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2015-04-29|2007-08-13|2007-08-14|Estimate|||||||2015-04-29|2015-05-01|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Corneal Thinning During Topical Bevacizumab Therapy||Withdrawn||N/A|0|Actual|Yonsei University||||Side effect can increase the risk of the research|f||||t||||||||||2018-06-01 03:00:07.417255|2018-06-01 03:00:07.417255
NCT00515671|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2014-10-03||2015-04-06|2007-08-10|2007-08-14|Estimate|2014-10-08|2014-10-10|Estimate||||2015-04-06|2015-04-24|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|April 2012|Actual|2012-04-30||Interventional|||Illness Management and Recovery for Veterans With Severe Mental Illness|Illness Management and Recovery for Veterans With Severe Mental Illness|Completed||N/A|118|Actual|VA Office of Research and Development|"Low attendance in both groups, may not have had enough exposure Study embedded in a treatment-rich environment, cannot sort out other impacts on outcomes."|2|||f||||f||||||||||2018-06-01 03:00:07.505294|2018-06-01 03:00:07.505294
NCT00515658|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-13|2007-08-13|2007-08-14|Estimate|||||||2007-08-13|2007-08-14|Estimate|March 2007||2007-03-31|August 2007|2007-08-31||||||||Interventional|||Antidepressant Effect of Theta-Burst rTMS|Antidepressant Effect of Theta-Burst rTMS|Unknown status|Recruiting|Phase 2|||Rambam Health Care Campus|||||f||||t||||||||||2018-06-01 03:00:07.776637|2018-06-01 03:00:07.776637
NCT00515645|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2011-07-18|2007-08-13|2007-08-14|Estimate|||||||2011-07-18|2011-07-19|Estimate|April 2008||2008-04-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|IMMERSION||Cardiac Autonomic Functions During Head-out Immersion and During Head Down Tilt|Cardiac Autonomic Functions During Head-out Immersion and During Head Down Tilt|Completed||N/A|15|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 03:00:07.993798|2018-06-01 03:00:07.993798
NCT00515632|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2010-07-22|2007-08-13|2007-08-14|Estimate|||||||2010-07-22|2010-07-23|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|BALLET||Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy|A Randomized, Double-blind, Parallel-group, Placebo and Active Comparator (Pioglitazone)-Controlled Clinical Study to Determine the Efficacy and Safety of Balaglitazone in Patients With Type 2 Diabetes on Stable Insulin Therapy|Completed||Phase 3|409|Actual|Rheoscience A/S||4|||f||||f||||||||||2018-06-01 03:00:08.110584|2018-06-01 03:00:08.110584
NCT00515619|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|2011-08-05||2017-07-28|2007-08-13|2007-08-14|Estimate|2011-08-05|2011-09-09|Estimate||||2017-07-28|2017-08-28|Actual|December 2004||2004-12-31|July 2017|2017-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures|An International Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral Lacosamide (SPM 927) in Patients With Partial Seizures|Completed||Phase 3|376|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:00:08.22514|2018-06-01 03:00:08.22514
NCT00515606|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2007-08-13|2007-08-13|2007-08-14|Estimate|||||||2007-08-13|2007-08-14|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|June 2007||2007-06-30|||||Interventional|||Noninvasive Positive Pressure Ventilation Using Helium:Oxygen Versus Air:Oxygen in Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease Patients Exposed to Sulfur Mustard||Completed||Phase 3|||Baqiyatallah Medical Sciences University|||||f||||||||||||||2018-06-01 03:00:08.793904|2018-06-01 03:00:08.793904
NCT00515593|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-13|||2012-05-04|2007-08-13|2007-08-14|Estimate|||||||2012-05-04|2012-05-07|Estimate|September 2006||2006-09-30|May 2012|2012-05-31|July 2008|Actual|2008-07-31|||||Observational|||PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)|Non-interventional Open Single Arm, Multicentre Study to Observe the Use of Preotact in Patients With Severe Postmenopausal Osteoporosis|Completed|||110|Actual|Nycomed|||||f||||t||||||||||2018-06-01 03:00:08.865835|2018-06-01 03:00:08.865835
NCT00515580|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-12|||2012-12-18|2007-08-12|2007-08-14|Estimate|||||||2012-12-18|2012-12-20|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|||Minimally Invasive Tongue Suture For Obstructive Sleep Apnea|Minimally Invasive Genioglossus And Hyoid Advancement For Obstructive Sleep Apnea Using Silhouette Sutures: A Pilot Study|Terminated||N/A|5|Actual|West Side ENT||1||"Results from first few subjects was not significantly improved over standard, traditional~   procedures."|f||||f||||||||||2018-06-01 03:00:08.952015|2018-06-01 03:00:08.952015
NCT00515567|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2018-04-19|2007-08-09|2007-08-13|Estimate|||||||2018-04-19|2018-04-20|Actual|February 2006||2006-02-28|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Explanted Lung Tissues With Pulmonary Fibrosis|Utilization of Explanted Lungs for Isolation of Tissue Samples and Primary Cell Lines to Study Pulmonary Fibrosis|Recruiting|||90|Anticipated|University of Chicago|||||f||||f||||||Samples With DNA|"~     explanted lung tissue~   "|||2018-06-01 03:00:09.091001|2018-06-01 03:00:09.091001
NCT00515554|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2018-03-21|2007-08-10|2007-08-13|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2008||2008-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||HD18 for Advanced Stages in Hodgkins Lymphoma||Active, not recruiting||Phase 3|1500|Anticipated|University of Cologne||4|||f||||t||||||||||2018-06-01 03:00:09.196481|2018-06-01 03:00:09.196481
NCT00515541|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2013-06-27||2013-06-27|2007-08-10|2007-08-13|Estimate|2013-06-27|2013-07-09|Estimate||||2013-06-27|2013-07-09|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|LEAP|The number of subjects for baseline does not represent the number of subjects that completed the 24 week study.|Lovaza's Effect on the Activation of Platelets|Effect of the Omega n3 Fatty on Human Platelet Function|Completed||Phase 2|43|Actual|Invitrox|Major limitation for this pilot study was the small number of patients analyzed per group. Despite the small numbers we were able to show the statistical significance for a change in the platelet surface charge with Lovaza.|4|||f||||t||||||||||2018-06-01 03:00:09.318489|2018-06-01 03:00:09.318489
NCT00515528|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2017-09-08|2007-08-09|2007-08-13|Estimate|||||||2017-09-08|2017-09-12|Actual|April 23, 2007|Actual|2007-04-23|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Vaccination Plus Ontak in Patients With Metastatic Melanoma|Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma|Active, not recruiting||Phase 2|24|Anticipated|University of Chicago||2|||f||||t||||||||||2018-06-01 03:00:09.817805|2018-06-01 03:00:09.817805
NCT00515502|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2013-12-19||2017-08-21|2007-08-10|2007-08-13|Estimate|2014-03-27|2014-04-24|Estimate||||2017-08-21|2017-08-22|Actual|June 21, 2007|Actual|2007-06-21|August 2017|2017-08-31|November 6, 2007|Actual|2007-11-06|November 6, 2007|Actual|2007-11-06||Interventional|||Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double Blind, Placebo-controlled, Double Dummy, 4-way Cross-over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 (250, 500 and 1000 μg) and Tiotropium Bromide (18 μg) Via DPI in COPD Patients.|Completed||Phase 2|24|Actual|GlaxoSmithKline||12|||f||||f|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:00:10.080211|2018-06-01 03:00:10.080211
NCT00515489|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2011-05-18|2007-08-10|2007-08-13|Estimate|||||||2011-05-18|2011-05-19|Estimate|November 2001||2001-11-30|March 2011|2011-03-31|August 2002|Actual|2002-08-31|||||Observational|||Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients|Aggressiveness and Agitation of Acute Psychotic Patients: Influence in Safety and Effectiveness of Risperidone Treatment|Terminated|||1882|Actual|Janssen-Cilag, S.A.|||1|Due to the achievement of minimum required sample size and new changes in local regulations.|f||||f||||||||||2018-06-01 03:00:12.134415|2018-06-01 03:00:12.134415
NCT00515476|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2010-06-22|2007-08-09|2007-08-13|Estimate|||||||2010-06-22|2010-06-23|Estimate|June 2007||2007-06-30|November 2009|2009-11-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|HERMET||Effect of Exercise Training on the Function of the High Density Lipoprotein (HDL)-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Metabolic Syndrome(HERMET-Study)|Randomized, Clinical Trial to Study the Effect of Exercise Training on the Function of HDL-Cholesterol, Endothelial Function, Oxidative Stress and Regenerative Capacity of Endothelial Progenitor Cells in Patients With Metabolic Syndrome|Completed||N/A|24|Anticipated|Hannover Medical School|||||f||||||||||||||2018-06-01 03:00:13.342791|2018-06-01 03:00:13.342791
NCT00515463|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2010-06-18|2009-11-23|2013-08-27|2007-08-09|2007-08-13|Estimate|2013-08-27|2013-10-31|Estimate|2009-11-23|2009-11-25|Estimate|2013-08-27|2013-10-31|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density|A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density|Completed||Phase 3|311|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:00:13.563393|2018-06-01 03:00:13.563393
NCT00515450|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2010-07-29|2007-08-10|2007-08-13|Estimate|||||||2010-07-29|2010-07-30|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis|A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis|Completed||Phase 3|46|Anticipated|Benesis Corporation||2|||f||||f||||||||||2018-06-01 03:00:15.107241|2018-06-01 03:00:15.107241
NCT00515437|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2009-05-12||2009-06-30|2007-08-10|2007-08-13|Estimate|2009-06-30|2009-08-13|Estimate||||2009-06-30|2009-08-13|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients|Completed||Phase 2|54|Actual|Solstice Neurosciences||4|||f||||t||||||||||2018-06-01 03:00:15.201203|2018-06-01 03:00:15.201203
NCT00515424|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2007-12-19|2007-08-10|2007-08-13|Estimate|||||||2007-12-19|2007-12-28|Estimate|July 2007||2007-07-31|December 2007|2007-12-31||||||||Interventional|||Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension|A Multicenter, Randomized, Placebo-Controlled, Latanoprost-Controlled, Parallel Group Study to Assess the Tolerability, Safety and Efficacy of RKI983 Ophthalmic Solution Given Twice a Day Over One Week in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 1|90||Novartis|||||||||||||||||||2018-06-01 03:00:15.747042|2018-06-01 03:00:15.747042
NCT00515411|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2017-10-03|2007-08-10|2007-08-13|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2006||2006-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma|A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 2|111|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-06-01 03:00:15.82746|2018-06-01 03:00:15.82746
NCT00515398|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2008-06-04|2007-08-10|2007-08-13|Estimate|||||||2008-06-04|2008-06-05|Estimate|August 2007||2007-08-31|June 2008|2008-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease|A Multicenter Study to Evaluate and Characterize the Effects of Pharmacological Chaperones in Cell Lines Derived From Blood and Skin Samples From Patients With Pompe Disease|Completed|||30|Actual|Amicus Therapeutics|||1||f||||f||||||Samples With DNA|"~     White blood cells~   "|||2018-06-01 03:00:15.93841|2018-06-01 03:00:15.93841
NCT00515385|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2009-07-14|2007-08-10|2007-08-13|Estimate|||||||2009-07-14|2009-07-15|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults|A Phase 1, Randomized, Double-Blind, Dose-Escalation Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of MGAWN1, a Neutralizing, Humanized, Monoclonal Antibody (IgG1k) to West Nile Virus, in Healthy Adults|Completed||Phase 1|40|Anticipated|MacroGenics||10|||f||||t||||||||||2018-06-01 03:00:16.015436|2018-06-01 03:00:16.015436
NCT00515372|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2018-01-22|2007-08-10|2007-08-13|Estimate|||||||2018-01-22|2018-01-24|Actual|December 2002|Actual|2002-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Depression Treatment and Screening in Ovarian Cancer Patients|Depression Treatment and Screening in Ovarian Cancer Patients|Active, not recruiting||Phase 1|588|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-06-01 03:00:16.108598|2018-06-01 03:00:16.108598
NCT00515359|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2010-01-26|2007-08-10|2007-08-13|Estimate|||||||2010-01-26|2010-01-27|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||RCT for Intermittent Versus Continuous Propofol Sedation for Pediatric Brain and Spine MRI Studies|RCT for Intermittent Versus Continuous Propofol Sedation for Pediatric Brain and Spine MRI Studies|Completed||N/A|500|Anticipated|Spectrum Health Hospitals||1|||f||||f||||||||||2018-06-01 03:00:16.197379|2018-06-01 03:00:16.197379
NCT00515346|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2013-12-16|2007-08-09|2007-08-13|Estimate|||||||2013-12-16|2013-12-18|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|September 2011|Actual|2011-09-30|December 2009|Actual|2009-12-31||Interventional|XCELL||Study to Evaluate the Safety & Performance of the Xpert(TM) Stent in Treating Below-the-knee Lesions in Patients Undergoing Percutaneous Intervention for Chronic CLI.|Phase 1 Study of Xpert(TM) Nitinol Stenting for Critically Ischemic Lower Limbs|Completed||Phase 1|120|Actual|VIVA Physicians|||||f||||t||||||||||2018-06-01 03:00:16.285051|2018-06-01 03:00:16.285051
NCT00515333|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2008-02-19|2007-08-10|2007-08-13|Estimate|||||||2008-02-19|2008-02-20|Estimate|August 2004||2004-08-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||TRx0014 in Patients With Mild or Moderate Alzheimer's Disease|An Exploratory Placebo-Controlled, Dose-Ranging Study of the Effects of TRx0014 30 MG TID, 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type|Completed||Phase 2|323|Actual|TauRx Therapeutics Ltd||4|||f||||f||||||||||2018-06-01 03:00:16.355474|2018-06-01 03:00:16.355474
NCT00515320|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2012-04-26|2007-08-10|2007-08-13|Estimate|||||||2012-04-26|2012-04-27|Estimate|August 2007||2007-08-31|April 2012|2012-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|SOFIA||Study of Fluoxetine in Autism|Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder.|Completed||Phase 3|158|Actual|Neuropharm||2|||f||||t||||||||||2018-06-01 03:00:16.444474|2018-06-01 03:00:16.444474
NCT00515307|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2008-08-28|2007-08-09|2007-08-13|Estimate|||||||2008-08-28|2008-08-29|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia|In-Vitro Transdifferentiation of Mesenchymal Stem Cells to Hepatocytes and Allogenic Transplantation of Hepatocytes to the Patients With Homozygous Familial Hypercholesterolemia|Completed||Phase 1|1|Actual|University of Tehran||1|||f||||t||||||||||2018-06-01 03:00:16.549709|2018-06-01 03:00:16.549709
NCT00515294|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2017-03-06||2017-05-26|2007-08-10|2007-08-13|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|October 2006||2006-10-31|May 2017|2017-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||We compared participants across groups by age and sex.|Acute and Residual Effects of Caffeinated Beer|Acute and Residual Effects of Beer VS. Caffeinated Beer On Simulated Driving|Completed||Phase 1/Phase 2|154|Actual|Boston University|Difficulties with the driver simulator resulted in invalid data for 6 participants so their results were not included in the lane position deviation results. Inaccurate caffeine doses resulted in exclusion of 12 participants from the trial.|4|||f||||t|t|f|||f|||No||2018-06-01 03:00:16.641765|2018-06-01 03:00:16.641765
NCT00515281|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2018-05-11|2007-08-10|2007-08-13|Estimate|||||||2018-05-11|2018-05-14|Actual|May 2008||2008-05-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|NOVA2||Inhaled Nitric Oxide and Neuroprotection in Premature Infants|Inhaled Nitric Oxide and Neuroprotection in Premature Infants|Active, not recruiting||Phase 2/Phase 3|484|Anticipated|University of Chicago||2|||f||||t||||||||Undecided||2018-06-01 03:00:17.068445|2018-06-01 03:00:17.068445
NCT00515268|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2017-08-04|2007-08-10|2007-08-13|Estimate|||||||2017-08-04|2017-08-07|Actual|September 27, 2007|Actual|2007-09-27|August 2017|2017-08-31|April 23, 2008|Actual|2008-04-23|April 23, 2008|Actual|2008-04-23||Interventional|||Endotoxin Challenge Study For Healthy Men and Women|A Double Blind, Placebo Controlled, Repeat Dose Study to Compare the Effectiveness of Two Doses of GSK256066 With Placebo in Reducing Lung Inflammation Following Segmental LPS Challenge in Healthy Volunteers|Completed||Phase 1|37|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:00:17.157139|2018-06-01 03:00:17.157139
NCT00515255|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2012-04-26|2007-08-10|2007-08-13|Estimate|||||||2012-04-26|2012-04-27|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)|Open-Label Exploratory Investigation Of NPL-2003 In Adolescents With Obsessive Compulsive Disorder|Terminated||Phase 2|6|Actual|Neuropharm||||Recruitment Goal of 20 Not Met|f||||||||||||||2018-06-01 03:00:17.228954|2018-06-01 03:00:17.228954
NCT00515242|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2017-10-11|2007-08-10|2007-08-13|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2007||2007-09-30|October 2017|2017-10-31|August 2009|Actual|2009-08-31|October 2008|Actual|2008-10-31||Interventional|CALM||Therapeutic Massage for Generalized Anxiety Disorder|Therapeutic Massage for Generalized Anxiety Disorder|Completed||Phase 1/Phase 2|68|Actual|Kaiser Permanente||3|||f||||t||||||||||2018-06-01 03:00:17.290168|2018-06-01 03:00:17.290168
NCT00515229|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2007-08-10|2007-08-10|2007-08-13|Estimate|||||||2007-08-10|2007-08-13|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo|Protocol for a Phase II-Study Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo - Randomised, Double-Blinded, Placebo-Controlled, Cross Over - Study -|Completed||Phase 2|18|Actual|University Hospital Tuebingen||4|||f||||t||||||||||2018-06-01 03:00:17.372601|2018-06-01 03:00:17.372601
NCT00515216|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2015-02-11||2015-12-08|2007-08-10|2007-08-13|Estimate|2015-02-11|2015-02-27|Estimate||||2015-12-08|2016-01-07|Estimate|August 2007||2007-08-31|December 2015|2015-12-31|November 2013|Actual|2013-11-30|August 2011|Actual|2011-08-31||Interventional|||Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors|Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study|Completed||Phase 2|26|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 03:00:17.55599|2018-06-01 03:00:17.55599
NCT00515203|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2010-10-28||2014-07-18|2007-08-09|2007-08-13|Estimate|2011-02-04|2011-03-01|Estimate||||2014-07-18|2014-07-25|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects|A Randomized, Double-Blind, Placebo-controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Pediatric Subjects With Chronic Immune (Idiopathic) Thrombocytopenic Purpura|Completed||Phase 1/Phase 2|22|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:00:18.120682|2018-06-01 03:00:18.120682
NCT00515190|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2007-12-21|2007-08-10|2007-08-13|Estimate|||||||2007-12-21|2008-01-07|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma|A Randomized Phase II Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma|Unknown status|Recruiting|Phase 2|198|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 03:00:18.78944|2018-06-01 03:00:18.78944
NCT00514839|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2014-04-01|2007-08-09|2007-08-10|Estimate|||||||2014-04-01|2014-04-02|Estimate|November 2005||2005-11-30|April 2014|2014-04-30|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|MIMIK||Brief Intervention for Prescription Drug Misuse in General Hospital|Brief Intervention for Regular Prescription Drug Use and Prescription Drug Use Disorders in General Hospital|Completed||Phase 2|126|Actual|University of Luebeck||2|||f||||t||||||||||2018-06-01 03:00:28.415574|2018-06-01 03:00:28.415574
NCT00515177|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2012-12-18||2013-02-20|2007-08-10|2007-08-13|Estimate|2013-02-20|2013-03-29|Estimate||||2013-02-20|2013-03-29|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|MVP#1||Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study|Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study|Completed||Phase 2/Phase 3|30|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 03:00:18.964217|2018-06-01 03:00:18.964217
NCT00515164|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2011-10-21|2007-08-10|2007-08-13|Estimate|||||||2011-10-21|2011-10-24|Estimate|August 2007||2007-08-31|October 2011|2011-10-31|December 2009|Actual|2009-12-31|April 2008|Actual|2008-04-30||Interventional|||US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study|Phase 2 Study of the 20 mL Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema|Completed||Phase 2|22|Actual|Aeris Therapeutics||2|||f||||t||||||||||2018-06-01 03:00:19.33221|2018-06-01 03:00:19.33221
NCT00515151|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2007-08-10|2007-08-10|2007-08-13|Estimate|||||||2007-08-10|2007-08-13|Estimate|May 2002||2002-05-31|August 2007|2007-08-31|April 2005|Actual|2005-04-30|||||Interventional|||Prevention of Catheter-Associated Infection With the Skin Disinfectant Octenidine Dihydrochloride|Skin Disinfection With Octenidine Dihydrochloride for the Prevention of Catheter-Associated Infections - A Double-Blind, Randomized, Controlled Trial|Completed||Phase 4|400|Actual|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 03:00:19.422154|2018-06-01 03:00:19.422154
NCT00515138|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2012-04-11|2007-08-10|2007-08-13|Estimate|||||||2012-04-11|2012-04-12|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant|A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant|Terminated||Early Phase 1|7|Actual|University of California, San Francisco||||Investigator left institution. 7 patients accrued and there is insufficient data to analyze.|f||||t||||||||||2018-06-01 03:00:19.50774|2018-06-01 03:00:19.50774
NCT00515125|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2015-09-10|2007-08-10|2007-08-13|Estimate|||||||2015-09-10|2015-09-11|Estimate|August 2007||2007-08-31|June 2015|2015-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Community Oral Nutrition Support Trial|A Randomised Trial of Oral Nutritional Supplements Versus Dietary Advice on Clinical Nutrition in the Community.|Completed||N/A|104|Actual|University of Southampton||2|||f||||f||||||||||2018-06-01 03:00:19.567468|2018-06-01 03:00:19.567468
NCT00515112|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2014-05-12||2014-05-12|2007-08-10|2007-08-13|Estimate|2014-05-12|2014-06-11|Estimate||||2014-05-12|2014-06-11|Estimate|July 2007||2007-07-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|November 2010|Actual|2010-11-30||Interventional|||Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer|A Randomized, Double Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer|Terminated||Phase 2|6|Actual|University of Chicago||2||This study has been terminated due to poor accrual|f||||t||||||||||2018-06-01 03:00:19.662576|2018-06-01 03:00:19.662576
NCT00515099|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2014-02-10||2017-04-05|2007-08-10|2007-08-13|Estimate|2014-03-25|2014-04-21|Estimate||||2017-04-05|2017-05-11|Actual|August 2007||2007-08-31|April 2017|2017-04-30|July 2013|Actual|2013-07-31|June 2012|Actual|2012-06-30||Interventional|START|Intent-to-treat|Study of Antithymocyte Globulin for Treatment of New-onset T1DM|Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus|Terminated||Phase 2|58|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Enrollment for this trial was closed at 58 participants and did not meet the planned sample size of 66 participants due to slow accrual.|2||Slow accrual|f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal. ITN TrialShare makes data from the consortium's clinical trials publicly available.|2018-06-01 03:00:19.917262|2018-06-01 03:00:19.917262
NCT00515086|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2010-12-15||2011-09-20|2007-08-10|2007-08-13|Estimate|2011-06-28|2011-07-27|Estimate||||2011-09-20|2011-09-22|Estimate|August 2007||2007-08-31|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)|A Phase II Trial of RAD001 in Patients With Recurrent Glioblastoma Multiforme|Terminated||Phase 2|41|Actual|Novartis|Due to the early termination of this study, the analysis of some of the planned objectives is not included in this clinical study report.|4||Early termination due to slow enrollment and protocol-defined stopping rule.|f||||||||||||||2018-06-01 03:00:20.860995|2018-06-01 03:00:20.860995
NCT00515073|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2014-05-30||2014-05-30|2007-08-09|2007-08-13|Estimate|2014-05-30|2014-07-03|Estimate||||2014-05-30|2014-07-03|Estimate|April 2001||2001-04-30|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Papillary Serous Carcinoma of the Endometrium|A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:00:21.849081|2018-06-01 03:00:21.849081
NCT00515060|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2017-11-03|2007-08-10|2007-08-13|Estimate|||||||2017-11-03|2017-11-07|Actual|January 2001|Actual|2001-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Psychophysical Studies of Cancer Therapy Pain|Psychophysical Studies of Cancer Therapy-Induced Pain: A Feasibility Study|Recruiting|||450|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:00:22.059274|2018-06-01 03:00:22.059274
NCT00515047|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|||2014-04-01|2007-08-10|2007-08-13|Estimate|||||||2014-04-01|2014-04-02|Estimate|May 2006||2006-05-31|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|Genetics||Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis|Genetics of Atopic Dermatitis - Eczema Herpeticum|Completed|||900|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||t||||||Samples With DNA|"~     Skin scrapings and blood collection may occur~   "|||2018-06-01 03:00:22.132936|2018-06-01 03:00:22.132936
NCT00515034|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-10|2009-11-13||2011-05-09|2007-08-10|2007-08-13|Estimate|2010-05-20|2010-06-22|Estimate||||2011-05-09|2011-05-10|Estimate|October 2007||2007-10-31|May 2011|2011-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia|A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventilator Associated Pneumonia|Completed||Phase 2|146|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|open-label study design and limited number of subjects in the comparator group|4|||f||||||||||||||2018-06-01 03:00:22.230345|2018-06-01 03:00:22.230345
NCT00515021|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2009-01-27|2007-08-10|2007-08-13|Estimate|||||||2009-01-27|2009-01-29|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Diurnal Variation of Plasminogen Activator Inhibitor-1|The Effects of Night-Time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Vanderbilt University||1|||f||||f||||||||||2018-06-01 03:00:23.060147|2018-06-01 03:00:23.060147
NCT00515008|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2015-11-04||2016-02-09|2007-08-09|2007-08-13|Estimate|2016-02-09|2016-03-08|Estimate||||2016-02-09|2016-03-08|Estimate|June 2007||2007-06-30|February 2016|2016-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Tai Chi Mind-Body Therapy for Fibromyalgia|Tai Chi Mind-Body Therapy for Fibromyalgia: a Pilot Single-Blind Randomized Controlled Trial.|Completed||N/A|66|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-06-01 03:00:23.184506|2018-06-01 03:00:23.184506
NCT00514995|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2011-06-21|2007-08-08|2007-08-10|Estimate|||||||2011-06-21|2011-06-22|Estimate|August 2007||2007-08-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Sodium Oxybate in the Treatment of Binge Eating Disorder||Completed||Phase 2/Phase 3|15|Anticipated|Lindner Center of HOPE||1|||f||||||||||||||2018-06-01 03:00:23.687571|2018-06-01 03:00:23.687571
NCT00514982|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2017-06-30|2007-08-09|2007-08-10|Estimate|||||||2017-06-30|2017-07-02|Actual|August 7, 2007||2007-08-07|March 8, 2011|2011-03-08|March 8, 2011|Actual|2011-03-08|March 8, 2011|Actual|2011-03-08||Interventional|||Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome|An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-06-01 03:00:23.784171|2018-06-01 03:00:23.784171
NCT00514969|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2007-08-09|2007-08-09|2007-08-10|Estimate|||||||2007-08-09|2007-08-10|Estimate|August 2000||2000-08-31|July 2007|2007-07-31||||||||Interventional|CML003||Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase|Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase. A Phase II Study|Completed||Phase 2|||University of Bologna|||||f||||||||||||||2018-06-01 03:00:23.911921|2018-06-01 03:00:23.911921
NCT00514956|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2009-09-21|2007-08-09|2007-08-10|Estimate|||||||2009-09-21|2009-09-22|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effect of Emotional Freedom Technique and Diaphragmatic Breathing on Post Traumatic Stress Disorder (PTSD)|Effect of Emotional Freedom Technique and Diaphragmatic Breathing on PTSD|Completed||Phase 1|12|Anticipated|Soul Medicine Institute|||||f||||t||||||||||2018-06-01 03:00:24.025644|2018-06-01 03:00:24.025644
NCT00514943|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2013-08-08||2016-06-24|2007-08-09|2007-08-10|Estimate|2013-11-27|2013-12-25|Estimate||||2016-06-24|2016-07-26|Estimate|August 2007||2007-08-31|June 2016|2016-06-30|July 2013|Actual|2013-07-31|March 2010|Actual|2010-03-31||Interventional|||BIBW 2992 (Afatinib) in Head & Neck Cancer|A Randomized, Open-label Phase II Study of BIBW 2992 Versus Cetuximab (Erbitux) in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy With a Cross-over Period for Progressing Patients|Completed||Phase 2|124|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 03:00:24.207538|2018-06-01 03:00:24.207538
NCT00514930|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2007-08-09|2007-08-09|2007-08-10|Estimate|||||||2007-08-09|2007-08-10|Estimate|February 2007||2007-02-28|August 2007|2007-08-31|August 2007|Anticipated|2007-08-31|||||Interventional|||Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver|A Multicentre Prospective Clinical Trial of a New Bipolar Radiofrequency Ablation/Aspirator Device (Hexablate) in the Management of Primary and Secondary Liver Cancers|Unknown status|Recruiting|Phase 1/Phase 2|||University of Thessaly|||||f||||||||||||||2018-06-01 03:00:25.881414|2018-06-01 03:00:25.881414
NCT00514917|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2013-08-30||2013-08-30|2007-08-09|2007-08-10|Estimate|2013-08-30|2013-11-04|Estimate||||2013-08-30|2013-11-04|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|Rising PSA|Safety population included all randomized participants who received at least part of one dose of any of the study drugs.|A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)|A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy|Terminated||Phase 3|413|Actual|Sanofi||2||Company decision to discontinue the study, not due to any safety or efficacy concerns|f||||t||||||||||2018-06-01 03:00:25.968187|2018-06-01 03:00:25.968187
NCT00514904|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2017-05-11|2009-09-03|2017-05-11|2007-08-09|2007-08-10|Estimate|2017-05-11|2017-10-06|Actual|2009-09-03|2009-09-04|Estimate|2017-05-11|2017-10-06|Actual|September 18, 2007||2007-09-18|October 2016|2016-10-31|January 6, 2009|Actual|2009-01-06|September 3, 2008|Actual|2008-09-03||Interventional|||Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects|Non-inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Versus Mencevax™ in Healthy Subjects Aged 2 Through 10 Years of Age|Completed||Phase 3|1505|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:00:26.780438|2018-06-01 03:00:26.780438
NCT00514891|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2011-02-26|2007-08-09|2007-08-10|Estimate|||||||2011-02-26|2011-03-01|Estimate|August 2007||2007-08-31|January 2011|2011-01-31|December 2012|Anticipated|2012-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts|Evaluation of the Impact on Mortality and Morbidity of the WHO Recommended Vitamin A Supplementation at First Immunisation Contact After 6 Months of Age|Terminated||Phase 4|9500|Anticipated|Bandim Health Project||2||Reccomended by DSMB after review of planned interim analyses.|f||||t||||||||||2018-06-01 03:00:27.633611|2018-06-01 03:00:27.633611
NCT00514878|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2009-10-30|2007-08-08|2007-08-10|Estimate|||||||2009-10-30|2009-11-02|Estimate|August 2007||2007-08-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Observational|Apfel-PDNV||Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)|Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)|Completed|||2000|Anticipated|University of California, San Francisco|||1||f||||f||||||||||2018-06-01 03:00:27.713875|2018-06-01 03:00:27.713875
NCT00514865|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07||2013-11-30|2013-11-30|2007-08-08|2007-08-10|Estimate||||2013-11-30|2013-12-25|Estimate|2013-11-30|2013-12-25|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder|Completed||Phase 2|278|Actual|Ono Pharmaceutical Co. Ltd||3|||f||||||||||||||2018-06-01 03:00:27.78646|2018-06-01 03:00:27.78646
NCT00514813|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2009-08-18||2014-06-06|2007-08-09|2007-08-10|Estimate|2009-09-29|2009-11-09|Estimate||||2014-06-06|2014-06-12|Estimate|June 2007||2007-06-30|November 2009|2009-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Dynepo Long-Term Safety Study|An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease|Terminated||Phase 4|152|Actual|Shire|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.|1||"The termination of the study is not linked to a product recall or result of any safety signal.~   Rather it was sponsor's commercial decision to withdraw the MA"|f||||f||||||||||2018-06-01 03:00:28.603782|2018-06-01 03:00:28.603782
NCT00514800|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2015-06-05|2007-08-09|2007-08-10|Estimate|||||||2015-06-05|2015-06-09|Estimate|March 2007||2007-03-31|August 2007|2007-08-31|April 2009|Actual|2009-04-30|||||Interventional|||Home Blood Pressure Monitoring Trial|Community Based Trial of Home Blood Pressure Monitoring With Nurse Led Support in Patients With Stroke or TIA Recently Discharged From Hospital|Completed||Phase 3|360|Anticipated|St George's, University of London||2|||f||||f||||||||||2018-06-01 03:00:29.293623|2018-06-01 03:00:29.293623
NCT00514787|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2009-03-26|2007-08-09|2007-08-10|Estimate|||||||2009-03-26|2009-03-27|Estimate||||March 2009|2009-03-31||||||||Observational|||Be SMART NIS, Moderate to Servere Asthma Patient Observation|Be SMART NIS, Moderate to Servere Asthma Patient Observation|Completed|||900|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 03:00:29.460513|2018-06-01 03:00:29.460513
NCT00514774|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2009-02-04|2007-08-08|2007-08-10|Estimate|||||||2009-02-04|2009-02-05|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|UDCA-HD||Ursodiol in Huntington's Disease|Ursodiol in Huntington's Disease|Unknown status|Active, not recruiting|Phase 1|21|Anticipated|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 03:00:29.5211|2018-06-01 03:00:29.5211
NCT00514761|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2014-08-12|2007-08-09|2007-08-10|Estimate|||||||2014-08-12|2014-08-13|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|July 2008|Actual|2008-07-31|June 2007|Actual|2007-06-30||Interventional|||Phase II Efficacy Study of AZD6244 in Colorectal Cancer|A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.|Completed||Phase 2|64|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:00:29.632135|2018-06-01 03:00:29.632135
NCT00514748|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2009-06-23|2007-08-09|2007-08-10|Estimate|||||||2009-06-23|2009-06-24|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|August 2008|Actual|2008-08-31||Interventional|||A Bilateral Interconnected DIEP Flap Based on One Vessel Pedicle for Breast Reconstruction||Completed||N/A|||Chinese Academy of Sciences||2|||f||||f||||||||||2018-06-01 03:00:29.732805|2018-06-01 03:00:29.732805
NCT00514735|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2012-01-25|2011-09-15|2012-04-11|2007-08-08|2007-08-10|Estimate|2012-04-11|2012-05-09|Estimate|2011-09-15|2011-09-26|Estimate|2012-04-11|2012-05-09|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TTOP-AF||Tailored Treatment of Permanent Atrial Fibrillation|Tailored Treatment of Permanent Atrial Fibrillation - TTOP-AF|Completed||Phase 3|210|Actual|Medtronic Atrial Fibrillation Solutions|- The study population was mostly Caucasian men.|2|||f||||t||||||||||2018-06-01 03:00:29.845491|2018-06-01 03:00:29.845491
NCT00514722|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-08-13|2007-08-09|2007-08-10|Estimate|||||||2013-08-13|2013-08-14|Estimate|October 2002||2002-10-31|August 2013|2013-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies|Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies|Terminated||N/A|4|Actual|University of California, San Francisco||||low accrual|f||||t||||||||||2018-06-01 03:00:30.554337|2018-06-01 03:00:30.554337
NCT00514709|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2013-09-09||2016-07-05|2007-08-09|2007-08-10|Estimate|2013-09-09|2013-11-14|Estimate||||2016-07-05|2016-08-02|Estimate|September 2007||2007-09-30|July 2016|2016-07-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants|Immunogenicity Study of the Antibody Persistence and Booster Effect of DTaP-Hep B-PRP-T Combined Vaccine at 12 to 18 Months of Age Following a Primary Series at 6, 10 and 14 Weeks of Age in Healthy Filipino Infants Having Received Hepatitis B Vaccine at Birth|Completed||Phase 3|1843|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:00:30.670076|2018-06-01 03:00:30.670076
NCT00514696|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-06-14|2007-08-09|2007-08-10|Estimate|||||||2013-06-14|2013-06-17|Estimate|February 2007||2007-02-28|June 2013|2013-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|PR-CS008||Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia|Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia|Completed||Phase 2|12|Actual|La Jolla Pharmaceutical Company||1|||f||||t||||||||||2018-06-01 03:00:31.041096|2018-06-01 03:00:31.041096
NCT00514683|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2014-11-14|2014-06-02|2015-01-05|2007-08-09|2007-08-10|Estimate|2015-01-05|2015-01-06|Estimate|2014-06-02|2014-06-17|Estimate|2015-01-05|2015-01-06|Estimate|August 2007||2007-08-31|January 2015|2015-01-31||||June 2010|Actual|2010-06-30||Interventional||Treated Set: This patient set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis|A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.|Completed||Phase 2|432|Actual|Boehringer Ingelheim|There were numerous additional pre-specified endpoints. Full results are available under the BI Transparency web page ( http://trials.boehringer-ingelheim.com/trial_results.html )|5|||f||||||||||||||2018-06-01 03:00:31.204057|2018-06-01 03:00:31.204057
NCT00514670|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2007-08-09|2007-08-09|2007-08-10|Estimate|||||||2007-08-09|2007-08-10|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|May 2006|Actual|2006-05-31|||||Interventional|||A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program|A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program|Completed||N/A|285|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-06-01 03:00:37.437975|2018-06-01 03:00:37.437975
NCT00514657|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2007-08-09|2007-08-09|2007-08-10|Estimate|||||||2007-08-09|2007-08-10|Estimate|December 2001||2001-12-31|August 2007|2007-08-31|February 2004|Actual|2004-02-29|||||Interventional|||Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2|Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2 (Randomised Controlled Phase II Clinical Trial)|Completed||Phase 2|91|Actual|Kaken Pharmaceutical||4|||f||||f||||||||||2018-06-01 03:00:37.720637|2018-06-01 03:00:37.720637
NCT00514644|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2012-01-09|2007-08-09|2007-08-10|Estimate|||||||2012-01-09|2012-01-10|Estimate|August 2007||2007-08-31|January 2012|2012-01-31|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|SPACE||Stroke and Panorama - Analyzing Carotid Endocalcifications (SPACE)|Stroke and Panorama - Analyzing Carotid Endocalcifications|Completed||N/A|266|Actual|Umeå University||2|||f||||f||||||||||2018-06-01 03:00:38.160741|2018-06-01 03:00:38.160741
NCT00514618|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2011-04-04|2007-08-09|2007-08-10|Estimate|||||||2011-04-04|2011-04-05|Estimate|March 2006||2006-03-31|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Outpatient Cervical Ripening With Orally Administered Misoprostol in Diabetics|Outpatient Cervical Ripening and Labor Induction With Orally Administered Misoprostol for Term Pregnancies Complicated by Diabetes Mellitus|Terminated||N/A|5|Actual|University of California, Irvine||2||Poor enrollment|f||||f||||||||||2018-06-01 03:00:38.514975|2018-06-01 03:00:38.514975
NCT00514605|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2007-12-10|2007-08-09|2007-08-10|Estimate|||||||2007-12-10|2007-12-12|Estimate|July 2007||2007-07-31|December 2007|2007-12-31||||||||Interventional|||Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection|A Study to Evaluate the Point-of-Care Use and Laboratory Investigational Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection|Completed||Phase 2/Phase 3|2500|Anticipated|bioLytical Laboratories|||||f||||f||||||||||2018-06-01 03:00:38.848851|2018-06-01 03:00:38.848851
NCT00514592|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2013-07-08||2013-09-16|2007-08-09|2007-08-10|Estimate|2013-07-08|2013-09-13|Estimate||||2013-09-16|2013-10-23|Estimate|August 2007||2007-08-31|September 2013|2013-09-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Observational|ANSYSCAP||Additional Neurological Symptoms Before Surgery of the Carotid Arteries - A Prospective Study (ANSYSCAP)|Additional Neurological Symptoms Before Surgery of the Carotid Arteries - A Prospective Study|Completed|||230|Actual|Umeå University|||1||f||||f||||||||||2018-06-01 03:00:39.171069|2018-06-01 03:00:39.171069
NCT00514579|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2014-03-07|2007-08-09|2007-08-10|Estimate|||||||2014-03-07|2014-03-10|Estimate|August 2007||2007-08-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Adult Double Cord Blood Transplant Study|A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults With Hematologic Malignancy|Completed||Phase 2|56|Actual|Center for International Blood and Marrow Transplant Research||1|||f||||t||||||||||2018-06-01 03:00:39.452598|2018-06-01 03:00:39.452598
NCT00514566|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2007-08-08|2007-08-08|2007-08-10|Estimate|||||||2007-08-08|2007-08-10|Estimate|October 2004||2004-10-31|August 2007|2007-08-31|April 2006|Actual|2006-04-30|||||Interventional|PPMAC||PDS vs Polyamide for Midline Abdominal Closure|Is Polydioxanone 'THE' Suture of Choice for Midline Abdominal Closure? Results of a Prospective Randomized Clinical Trial|Terminated||N/A|64|Actual|Christian Medical College and Hospital, Ludhiana, India||1||Unacceptable incidence of wound dehiscence in the PDS group|f||||t||||||||||2018-06-01 03:00:39.548681|2018-06-01 03:00:39.548681
NCT00514553|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2017-06-30|2007-08-09|2007-08-10|Estimate|||||||2017-06-30|2017-07-02|Actual|August 7, 2007||2007-08-07|May 31, 2011|2011-05-31|May 31, 2011||2011-05-31|||||Observational|||Informed Choice Regarding Invasive Prenatal Testing|Deliberation With and Without Attention: Can We Enhance Informed Choices About Invasive Prenatal Testing? A Proof of Principle Study|Completed|||37|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:00:39.612588|2018-06-01 03:00:39.612588
NCT00514540|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2014-01-16|2007-08-09|2007-08-10|Estimate|||||||2014-01-16|2014-01-20|Estimate|May 2006||2006-05-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer|Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma|Completed||Phase 2|121|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:00:39.666453|2018-06-01 03:00:39.666453
NCT00514527|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2008-08-13|2007-08-08|2007-08-10|Estimate|||||||2008-08-13|2008-08-14|Estimate|August 2007||2007-08-31|August 2008|2008-08-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|SIMPLIFI||A Study for Patients With Complicated Skin and Skin Structure Infections|Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)|Completed||Phase 2|294|Anticipated|Targanta Therapeutics Corporation||3|||f||||f||||||||||2018-06-01 03:00:39.800419|2018-06-01 03:00:39.800419
NCT00514514|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|2016-06-03||2016-11-21|2007-08-09|2007-08-10|Estimate|2016-11-21|2017-01-18|Estimate||||2016-11-21|2017-01-18|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen|Multi-center, Open-label, Prospective, Randomized, Parallel Group, Long-term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI-free Regimen and a CNI-low Dose Regimen|Completed||Phase 3|802|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:00:40.234393|2018-06-01 03:00:40.234393
NCT00514501|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2015-12-15||2016-02-29|2007-08-09|2007-08-10|Estimate|2015-12-15|2016-01-25|Estimate||||2016-02-29|2016-03-31|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|Zeus-ACS||Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome|Open-label, Phase 2 Study of the Safety and Efficacy of B-methyl-P-(123I)- Iodophenyl-pentadecanoic Acid (Iodofiltic Acid I 123) For Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (Spect) in Adults With Symptoms Consistent With Acute Coronary Syndrome (ACS).|Completed||Phase 2|510|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 03:00:41.608405|2018-06-01 03:00:41.608405
NCT00514488|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2007-08-09|2007-08-09|2007-08-10|Estimate|||||||2007-08-09|2007-08-10|Estimate|June 2004||2004-06-30|July 2007|2007-07-31||||||||Interventional|CML022||Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day)|A Phase III Study Comparing Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) in the Treatment of Newly Diagnosed High Risk Chronic Myeloid Leukemia in Chronic Phase|Completed||Phase 3|||University of Bologna|||||f||||f||||||||||2018-06-01 03:00:41.954063|2018-06-01 03:00:41.954063
NCT00514475|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2012-05-03|2007-08-09|2007-08-10|Estimate|||||||2012-05-03|2012-05-04|Estimate|November 2005||2005-11-30|May 2008|2008-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma|High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment|Completed||Phase 2|160|Actual|Oslo University Hospital|||||f||||t||||||||||2018-06-01 03:00:42.032564|2018-06-01 03:00:42.032564
NCT00514462|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2007-08-09|2007-08-09|2007-08-10|Estimate|||||||2007-08-09|2007-08-10|Estimate|July 2007||2007-07-31|August 2007|2007-08-31|August 2007|Anticipated|2007-08-31|||||Interventional|CTS||Carpal Tunnel Syndrome Treated With 830nm Diode Laser|Instiutional Review Board of Chung Shan Medical University Hospital|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Chung Shan Medical University||1|||f||||t||||||||||2018-06-01 03:00:42.108602|2018-06-01 03:00:42.108602
NCT00514449|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2011-12-02||2018-05-04|2007-08-09|2007-08-10|Estimate|2018-05-04|2018-05-09|Actual||||2018-05-04|2018-05-09|Actual|June 2007||2007-06-30|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SEAMS||Systematic Evaluation of Antiviral Medication in Schizophrenia|A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients|Completed||Phase 2|31|Actual|University of Pittsburgh|This was a small sample study designed as a proof of concept. A larger study will follow.|2|||f||||f||||||||||2018-06-01 03:00:42.195526|2018-06-01 03:00:42.195526
NCT00514436|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2015-12-08|2007-08-08|2007-08-10|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 1997||1997-01-31|December 2015|2015-12-31|January 2001|Actual|2001-01-31|||||Interventional|||Case Management and Environmental Control in Asthma||Completed||Phase 3|189|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 03:00:42.484067|2018-06-01 03:00:42.484067
NCT00514423|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2014-08-28|2007-08-09|2007-08-10|Estimate|||||||2014-08-28|2014-08-29|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs|How Can Rehospitalisations of Patients With Schizophrenia be Avoided? A Comparison Between Different Compliance Programs|Completed||N/A|896|Anticipated|Technische Universität München||4|||f||||||||||||||2018-06-01 03:00:42.563636|2018-06-01 03:00:42.563636
NCT00514410|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-09|||2011-10-11|2007-08-09|2007-08-10|Estimate|||||||2011-10-11|2011-10-12|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|FolATED||Folate Augmentation of Treatment - Evaluation for Depression: a Randomised Controlled Trial|Folate Augmentation of Treatment - Evaluation for Depression: a Randomised Controlled Trial|Completed||Phase 4|730|Anticipated|Bangor University||2|||f||||t||||||||||2018-06-01 03:00:42.657353|2018-06-01 03:00:42.657353
NCT00514397|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-08-09|2007-08-08|2007-08-09|Estimate|||||||2013-08-09|2013-08-12|Estimate|January 2008||2008-01-31|June 2009|2009-06-30||||||||Interventional|||Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma|A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas|Unknown status|Recruiting|Phase 2|43|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:00:42.754433|2018-06-01 03:00:42.754433
NCT00514384|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2014-12-02|2007-08-08|2007-08-09|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2007||2007-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|||Serial Measurements of Biomarker in Patients With Acute Decompensated Heart Failure|Prognostic Value of Serial Biomarker Measurements in Patients With ADHF|Completed|||350|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:00:42.870679|2018-06-01 03:00:42.870679
NCT00514371|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08||2010-09-10|2015-11-06|2007-08-08|2007-08-09|Estimate||||2010-09-10|2010-09-14|Estimate|2015-11-06|2015-12-07|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|TIME-2||A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma|Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma|Completed||Phase 2/Phase 3|22|Actual|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 03:00:42.936005|2018-06-01 03:00:42.936005
NCT00514358|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2011-07-06|2007-08-08|2007-08-09|Estimate|||||||2011-07-06|2011-07-07|Estimate|November 2005||2005-11-30|July 2011|2011-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Fluconazole Pharmacokinetics in Infants|A Multicenter, Open Label Pharmacokinetic Study of Fluconazole in Infants|Completed|||55|Actual|Children's Hospital of Philadelphia|||1||f||||t||||||||||2018-06-01 03:00:43.062873|2018-06-01 03:00:43.062873
NCT00514345|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-08-09|2007-08-08|2007-08-09|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2007||2007-07-31|June 2009|2009-06-30||||||||Observational|||CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide|CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children|Unknown status|Recruiting||300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:00:43.279829|2018-06-01 03:00:43.279829
NCT00514332|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2007-08-08|2007-08-08|2007-08-09|Estimate|||||||2007-08-08|2007-08-09|Estimate|December 2002||2002-12-31|August 2007|2007-08-31|October 2006|Actual|2006-10-31|||||Interventional|||Comparison Between Colorectal Stents and Primary Surgery in Obstructive Colonic Cancer. A Randomized, Controlled Study|Etude Prospective Multicentrique randomisée Comparant Deux stratégies thérapeutiques Pour Les Cancers Coliques en Occlusion : stratégie Chirurgicale Exclusive Versus stratégie thérapeutique Avec Stent Colique Initial|Terminated||N/A|70|Actual|University Hospital, Montpellier||1||enrolling participants stopped|f||||f||||||||||2018-06-01 03:00:43.433684|2018-06-01 03:00:43.433684
NCT00514306|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2011-09-12|2007-08-08|2007-08-09|Estimate|||||||2011-09-12|2011-09-13|Estimate|June 2007||2007-06-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of Intermittent OSI-906 Dosing|A Phase I Dose Escalation Study of Intermittent Oral OSI-906 Dosing in Patients With Advanced Solid Tumors|Completed||Phase 1|79|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 03:00:43.506855|2018-06-01 03:00:43.506855
NCT00514293|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2014-01-09|2007-08-08|2007-08-09|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2007||2007-01-31|August 2008|2008-08-31||||December 2011|Anticipated|2011-12-31||Interventional|||Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Bexarotene (Targretin) Capsules With Tretinoin and Chemotherapy in Patients With Advanced Non-small-cell Lung Cancer|Unknown status|Recruiting|Phase 2|39|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:00:43.575389|2018-06-01 03:00:43.575389
NCT00514280|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2017-06-30|2007-08-08|2007-08-09|Estimate|||||||2017-06-30|2017-07-02|Actual|August 2, 2007||2007-08-02|May 11, 2011|2011-05-11|May 11, 2011||2011-05-11|||||Observational|||Tobacco Smoke and Lead Exposure During Pregnancy|Tobacco Smoke and Lead Exposure During Pregnancy: Intervention to Reduce Effects on Birth-Weight and Gestational Age|Completed|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:00:43.680167|2018-06-01 03:00:43.680167
NCT00514267|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07||2015-07-23|2015-07-23|2007-08-08|2007-08-09|Estimate||||2015-07-23|2015-08-13|Estimate|2015-07-23|2015-08-13|Estimate|May 2007||2007-05-31|July 2015|2015-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors|A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors|Completed||Phase 1/Phase 2|32|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:00:43.72961|2018-06-01 03:00:43.72961
NCT00514254|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2018-02-23|2007-08-08|2007-08-09|Estimate|||||||2018-02-23|2018-02-27|Actual|July 2007||2007-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Risk Factors for Endometrial Cancer in Black Women|Endometrial Cancer in Black Women|Active, not recruiting|||59|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     saliva/buccal specimens~   "|||2018-06-01 03:00:43.863313|2018-06-01 03:00:43.863313
NCT00514241|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2017-05-17|2007-08-08|2007-08-09|Estimate|||||||2017-05-17|2017-05-19|Actual|January 2006||2006-01-31|May 2017|2017-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Evaluate Use of Gravitational Platelet Separation System on Leg Wound Healing in Coronary Bypass Surgery|A Clinical Study to Evaluate the Use of Gravitational Platelet Separation System on Leg Wound Healing in Coronary Bypass Surgery|Completed||Phase 1|140|Actual|Zimmer Biomet||2|||f||||||||||||No||2018-06-01 03:00:43.957852|2018-06-01 03:00:43.957852
NCT00514228|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2012-06-25|2007-08-08|2007-08-09|Estimate|||||||2012-06-25|2012-06-26|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|Continuous Sunitinib Treatment in Patients With Unresectable Hepatocellular Carcinoma A Multicenter Phase II Trial|Completed||Phase 2|45|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-06-01 03:00:44.037971|2018-06-01 03:00:44.037971
NCT00514215|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2015-02-09||2015-02-09|2007-08-08|2007-08-09|Estimate|2015-02-09|2015-02-23|Estimate||||2015-02-09|2015-02-23|Estimate|January 2006||2006-01-31|February 2015|2015-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer|Percutaneous Cryotherapy and Aerosolized GM-CSF for Pulmonary Metastases and Primary Lung Cancer|Completed||Phase 2|8|Actual|Barbara Ann Karmanos Cancer Institute|Small sample size.|1|||f||||t||||||||||2018-06-01 03:00:44.13262|2018-06-01 03:00:44.13262
NCT00514202|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2012-02-21|2007-08-08|2007-08-09|Estimate|||||||2012-02-21|2012-02-22|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)|Dextroamphetamine Treatment for Comorbid Cocaine Dependence and ADHD|Terminated||Phase 2|5|Actual|The University of Texas Health Science Center, Houston||2||Investigator left UTHSC-Houston|f||||t||||||||||2018-06-01 03:00:44.310118|2018-06-01 03:00:44.310118
NCT00514189|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2012-07-27|2007-08-08|2007-08-09|Estimate|||||||2012-07-27|2012-07-30|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines|Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines|Terminated||Phase 1|2|Actual|M.D. Anderson Cancer Center||1||Terminated early due to slow accrual.|f||||f||||||||||2018-06-01 03:00:44.390949|2018-06-01 03:00:44.390949
NCT00514163|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2011-06-27|2007-08-08|2007-08-09|Estimate|||||||2011-06-27|2011-06-28|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||GEM vs GEM+TS-1 for Advanced Pancreatic Cancer|Randomized Phase II Study of Gemcitabine (GEM) Versus GEM+TS-1 for Advanced Pancreatic Cancer|Completed||Phase 2|110|Anticipated|Japan Clinical Cancer Research Organization||2|||f||||t||||||||||2018-06-01 03:00:44.478368|2018-06-01 03:00:44.478368
NCT00514150|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2008-09-04|2007-08-08|2007-08-09|Estimate|||||||2008-09-04|2008-09-05|Estimate|August 2007||2007-08-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN)|Comparing Sodium Bicarbonate Plus Isotonic Normal Saline Versus Isotonic Normal Saline Alone to Prevent Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Randomized Controlled Trial|Completed||Phase 3|265|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-06-01 03:00:44.563239|2018-06-01 03:00:44.563239
NCT00514137|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2013-01-30||2014-05-12|2007-08-08|2007-08-09|Estimate|2013-01-30|2013-03-06|Estimate||||2014-05-12|2014-05-28|Estimate|September 2007||2007-09-30|March 2013|2013-03-31|August 2010|Actual|2010-08-31|March 2009|Actual|2009-03-31||Interventional|||Sunitinib in Treating Patients With Relapsed Multiple Myeloma|A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma|Completed||Phase 2|13|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:00:44.659028|2018-06-01 03:00:44.659028
NCT00514111|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2009-03-19|2007-08-08|2007-08-09|Estimate|||||||2009-03-19|2009-03-20|Estimate|August 2007||2007-08-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Observational|||Factors Associated to Success of Hepatitis C Therapy|Factors Associated to Success of Hepatitis C Therapy|Completed|||100|Actual|UPECLIN HC FM Botucatu Unesp|||1||f||||t||||||||||2018-06-01 03:00:44.897607|2018-06-01 03:00:44.897607
NCT00514098|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2017-08-28|2007-08-08|2007-08-09|Estimate|||||||2017-08-28|2017-08-30|Actual|August 2008||2008-08-31|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials|An Observational Cohort Study of Women Following HIV-1 Seroconversion in Microbicide Trials|Recruiting|||500|Anticipated|Microbicide Trials Network|||||f||||f||||||Samples With DNA|"~     Blood and urine collection, pelvic, vaginal, and cervicovaginal sampling~   "|||2018-06-01 03:00:44.967874|2018-06-01 03:00:44.967874
NCT00514085|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2016-11-25|2007-08-08|2007-08-09|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|September 2010|Actual|2010-09-30||Interventional|||Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma|A Phase II Study of Interleukin-21 (IL-21) in Patients With Metastatic or Recurrent Malignant Melanoma|Completed||Phase 2|40|Actual|Canadian Cancer Trials Group|||||f||||t||||||||||2018-06-01 03:00:45.081093|2018-06-01 03:00:45.081093
NCT00514072|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2012-08-08|2007-08-08|2007-08-09|Estimate|||||||2012-08-08|2012-08-09|Estimate|March 2007||2007-03-31|August 2012|2012-08-31||||September 2012|Anticipated|2012-09-30||Interventional|||Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer|A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation|Unknown status|Active, not recruiting|Phase 2|54|Anticipated|Kael-GemVax Co., Ltd.||2|||f||||||||||||||2018-06-01 03:00:45.153855|2018-06-01 03:00:45.153855
NCT00514059|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2007-08-08|2007-08-08|2007-08-09|Estimate|||||||2007-08-08|2007-08-09|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|June 2007|Actual|2007-06-30|||||Interventional|||Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine|Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age.|Completed||Phase 4|83|Actual|Norwegian Institute of Public Health||1|||f||||f||||||||||2018-06-01 03:00:45.219477|2018-06-01 03:00:45.219477
NCT00514046|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2018-05-22|2007-08-08|2007-08-09|Estimate|||||||2018-05-22|2018-05-23|Actual|July 10, 2007||2007-07-10|May 4, 2018|2018-05-04|July 27, 2022|Anticipated|2022-07-27|April 1, 2022|Anticipated|2022-04-01||Interventional|||Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer|Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Carcinoma|Active, not recruiting||Phase 1/Phase 2|17|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 03:00:45.282934|2018-06-01 03:00:45.282934
NCT00514033|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2012-03-15|2007-08-08|2007-08-09|Estimate|||||||2012-03-15|2012-03-19|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children|Open, Multicentric, PMS Study to Monitor Safety and Reactogenicity of GlaxoSmithKline Biologicals' Poliomyelitis Vaccine (Inactivated)-Poliorix, Administered in Korean Children as a Primary Vaccination in Healthy Subjects Aged 2 to 6 Months or as a Booster Vaccination in Subjects Aged 4 to 6 Years|Completed|||349|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 03:00:45.352763|2018-06-01 03:00:45.352763
NCT00514020|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2012-09-18||2012-10-30|2007-08-08|2007-08-09|Estimate|2012-09-18|2012-10-18|Estimate||||2012-10-30|2012-11-01|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer|Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study|Completed||Phase 2|33|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:00:45.42137|2018-06-01 03:00:45.42137
NCT00514007|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2012-04-16|2007-08-08|2007-08-09|Estimate|||||||2012-04-16|2012-04-18|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Continuous OSI-906 Dosing|A Phase I Dose Escalation Study of Continuous Oral OSI-906 Dosing in Patients With Advanced Solid Tumors|Completed||Phase 1|95|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:00:45.775846|2018-06-01 03:00:45.775846
NCT00513994|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2008-04-08|2007-08-08|2007-08-09|Estimate|||||||2008-04-08|2008-04-11|Estimate|August 2007||2007-08-31|April 2008|2008-04-30|October 2007|Actual|2007-10-31|||||Interventional|||MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects|MQX-503 Applied to the Fingers vs. Nitroglycerin Ointment 2%, USP, Applied to the Chest: A Pharmacokinetic Comparison in Normal Subjects|Completed||Phase 1|6|Anticipated|MediQuest Therapeutics||1|||f||||f||||||||||2018-06-01 03:00:45.847818|2018-06-01 03:00:45.847818
NCT00513981|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-06-25|2007-08-08|2007-08-09|Estimate|||||||2013-06-25|2013-06-26|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|August 2009|Actual|2009-08-31|March 2008|Actual|2008-03-31||Interventional|||High-Dose Methotrexate in Treating Young Patients With Solid Tumors|Study to Determine the Maximum Tolerated Time of Infusion for High-Dose Methotrexate, Administered as a Continuous Intravenous Infusion at a Dose of 6g/m² Per 24 Hours of Infusion Time|Completed||Phase 1|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:00:45.911606|2018-06-01 03:00:45.911606
NCT00513968|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2012-08-03|2007-08-08|2007-08-09|Estimate|||||||2012-08-03|2012-08-06|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine|A Single Center, Randomized, Open-label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-week Period|Completed||Phase 1|27|Actual|Genexine, Inc.||2|||f||||f||||||||||2018-06-01 03:00:46.021712|2018-06-01 03:00:46.021712
NCT00513955|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2014-11-04|2007-08-08|2007-08-09|Estimate|||||||2014-11-04|2014-11-05|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma|Completed||Phase 2|50|Actual|University Hospital Plymouth NHS Trust||1|||f||||t||||||||||2018-06-01 03:00:46.088382|2018-06-01 03:00:46.088382
NCT00513942|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2014-10-17|2007-08-08|2007-08-09|Estimate|||||||2014-10-17|2014-10-20|Estimate|August 2007||2007-08-31|October 2014|2014-10-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Effects of Fetal Movement Counting in Third Trimester of Pregnancy|Effects of Fetal Movement Counting - a Randomized Controlled Trial of an Unselected Population|Completed||N/A|1200|Actual|Norwegian Institute of Public Health||2|||f||||f||||||||||2018-06-01 03:00:46.28006|2018-06-01 03:00:46.28006
NCT00513929|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2009-01-27|2007-08-08|2007-08-09|Estimate|||||||2009-01-27|2009-01-29|Estimate|August 2007||2007-08-31|January 2009|2009-01-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|EcuaPAZ||Zinc as Adjunct to Treatment of Pneumonia|Effects of Zinc as an Adjunct to Treatment of Pneumonia in Young Children|Unknown status|Recruiting|N/A|450|Anticipated|Corporacion Ecuatoriana de Biotecnologia||1|||f||||t||||||||||2018-06-01 03:00:46.361004|2018-06-01 03:00:46.361004
NCT00513916|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-12-18|2007-08-08|2007-08-09|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women|Effects of Soy on Estrogens in Breast Fluid and Urine|Completed||Phase 3|100|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:00:46.452028|2018-06-01 03:00:46.452028
NCT00513903|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2014-08-18|2007-08-07|2007-08-09|Estimate|||||||2014-08-18|2014-08-19|Estimate|March 2008||2008-03-31|August 2014|2014-08-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|IowaCOC||Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases|Enhanced Continuity of Pharmacy Care for Cardiovascular or Pulmonary Diseases|Completed||Phase 3|954|Actual|University of Iowa||3|||f||||f||||||||||2018-06-01 03:00:46.523034|2018-06-01 03:00:46.523034
NCT00513890|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-10-23|2007-08-08|2007-08-09|Estimate|||||||2013-10-23|2013-10-24|Estimate|October 2006||2006-10-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Interest of Non Invasive Ventilation Versus Oxygen During the Intial Managment of Infant With Bronchiolitis|Interest of Non Invasive Ventilation Versus Oxygen During the Intial Managment of Infant With Bronchiolitis Who Didn't Require Mechanical Ventilation|Completed||N/A|19|Actual|University Hospital, Montpellier|||||f||||t||||||||||2018-06-01 03:00:46.605879|2018-06-01 03:00:46.605879
NCT00513877|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2014-12-30|2007-08-08|2007-08-09|Estimate|||||||2014-12-30|2014-12-31|Estimate|May 2006||2006-05-31|January 2013|2013-01-31||||December 2009|Actual|2009-12-31||Interventional|||Bortezomib in Treating Patients With Malignant Pleural Mesothelioma|An Open Label Phase II Multicentre Clinical Trial of Single Agent Bortezomib in Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|33|Actual|Cancer Trials Ireland||1|||f||||||||||||||2018-06-01 03:00:46.673744|2018-06-01 03:00:46.673744
NCT00513864|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2014-12-19|2007-08-08|2007-08-09|Estimate|||||||2014-12-19|2014-12-23|Estimate|November 2006||2006-11-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Assessment of Opioid Analgesia in Sickle Cell|Non-Invasive Assessment of Opioid Analgesia in Children With Sickle Cell Disease|Withdrawn||Phase 4|0|Actual|Children's Research Institute||2||lack of funding|f||||t||||||||||2018-06-01 03:00:46.772374|2018-06-01 03:00:46.772374
NCT00439023|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2015-09-14|2007-02-21|2007-02-22|Estimate|||||||2015-09-14|2015-09-15|Estimate|May 2006||2006-05-31|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Glucose in Dialysis Water in Non-diabetics|Effect of Glucose in Dialysis Water on Blood Pressure and Vasoactive Hormones in Dialysis Patients|Completed||Phase 4|18|Actual|Regional Hospital Holstebro|||||f||||f||||||||||2018-06-01 03:25:17.094554|2018-06-01 03:25:17.094554
NCT00513851|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2011-09-26|2007-08-08|2007-08-09|Estimate|||||||2011-09-26|2011-09-27|Estimate|April 2006||2006-04-30|September 2011|2011-09-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Phase 1 Study of OSI-930 in Cancer Patients|A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients With Advanced Solid Tumors|Completed||Phase 1|60|Anticipated|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:00:46.870773|2018-06-01 03:00:46.870773
NCT00513825|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2008-11-23|2007-08-08|2007-08-09|Estimate|||||||2008-11-23|2008-11-26|Estimate|August 2007||2007-08-31|November 2008|2008-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN|The Evaluation of the Effect of Sodium Bicarbonate Solution in Decreasing the Incidence of Contrast Induced Nephropathy (CIN) in Patients With Pulmonary Edema,Severe Heart Failure or Uncontrolled Hypertension|Completed||Phase 2|72|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-06-01 03:00:46.96181|2018-06-01 03:00:46.96181
NCT00513799|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2011-03-02||2015-07-07|2007-08-08|2007-08-09|Estimate|2011-03-02|2011-03-29|Estimate||||2015-07-07|2015-07-30|Estimate|March 2007||2007-03-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|June 2009|Actual|2009-06-30||Interventional|StLStaRS||The Natural History of Community-Associated MRSA Infections and Decolonization Strategies|The Natural History of Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections and an Evaluation of Decolonization Strategies|Completed||N/A|300|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 03:00:47.07314|2018-06-01 03:00:47.07314
NCT00513786|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2017-07-28|2007-08-08|2007-08-09|Estimate|||||||2017-07-28|2017-08-01|Actual|August 1, 2007|Actual|2007-08-01|July 2017|2017-07-31|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Interventional|||Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma|A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma|Completed||Phase 2|38|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:00:47.421164|2018-06-01 03:00:47.421164
NCT00513773|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2017-04-05|2007-08-08|2007-08-09|Estimate|||||||2017-04-05|2017-04-07|Actual|July 2008||2008-07-31|April 2017|2017-04-30|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Observational|||Inflammation and Risk Prediction in Patients With Abdominal Aortic Aneurysm|Inflammation and Risk Prediction in Patients With Abdominal Aortic Aneurysm|Completed|||14|Actual|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     Serum/plasma for biomarker analysis~   "|||2018-06-01 03:00:47.499136|2018-06-01 03:00:47.499136
NCT00513760|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2014-01-23|2007-08-08|2007-08-09|Estimate|||||||2014-01-23|2014-01-24|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|TPORT||Transporter Mediated Uptake of Montelukast|Characterization of Transporter Mediated Uptake of Montelukast in Humans|Unknown status|Recruiting|N/A|27|Anticipated|Nemours Children's Clinic||3|||f||||f||||||||||2018-06-01 03:00:47.557565|2018-06-01 03:00:47.557565
NCT00513747|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2017-09-20|2007-08-08|2007-08-09|Estimate|||||||2017-09-20|2017-09-21|Actual|January 2008||2008-01-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia|A Phase III Intergroup CLL Study of Asymptomatic Patients With Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation With Later Treatment in the High Risk Genetic Subset With IGVH Unmutated Disease|Terminated||Phase 3|84|Actual|Alliance for Clinical Trials in Oncology||2||Insufficient accrual|f||||t||||||||||2018-06-01 03:00:47.702297|2018-06-01 03:00:47.702297
NCT00513734|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2007-08-08|2007-08-08|2007-08-09|Estimate|||||||2007-08-08|2007-08-09|Estimate|September 2004||2004-09-30|August 2007|2007-08-31|February 2005|Actual|2005-02-28|||||Interventional|||A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically Ill|Randomised Trial Comparing the Efficacy of Ocular Lubricant (Lacrilube) and Polyacrylamide Hydrogel Dressing (Geliperm) for the Prevention of Exposure Keratopathy in the Critically Ill|Completed||N/A|40|Actual|Barts & The London NHS Trust||2|||f||||t||||||||||2018-06-01 03:00:48.438701|2018-06-01 03:00:48.438701
NCT00513721|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2009-05-04|2007-08-08|2007-08-09|Estimate|||||||2009-05-04|2009-05-05|Estimate|July 2007||2007-07-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Retrospective Study of Positive Biopsy Specimens on Patients Undergoing a Prostatectomy|Do Positive Lateral Biopsy Cores on TRUS Directed Biopsies Predict Capsular Penetration and Positive Surgical Margins?|Completed|||400|Anticipated|William Beaumont Hospitals|||1||f||||f||||||||||2018-06-01 03:00:48.530348|2018-06-01 03:00:48.530348
NCT00513708|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|2011-02-14||2011-04-15|2007-08-07|2007-08-09|Estimate|2011-02-14|2011-03-08|Estimate||||2011-04-15|2011-04-19|Estimate|July 2007||2007-07-31|April 2011|2011-04-30|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Facilitating Aftercare for Alcohol Detox Patients|Helping Alcoholics Link to Substance Abuse Treatment Programs After Being in the Hospital for Detoxification|Completed||N/A|150|Actual|State University of New York at Buffalo||3|||f||||f||||||||||2018-06-01 03:00:48.604216|2018-06-01 03:00:48.604216
NCT00513695|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|2017-03-24||2017-05-15|2007-08-08|2007-08-09|Estimate|2017-03-24|2017-05-10|Actual||||2017-05-15|2017-06-14|Actual|June 2007||2007-06-30|May 2017|2017-05-31||||August 2012|Actual|2012-08-31||Interventional|||Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer|A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer|Active, not recruiting||Phase 2|68|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:00:48.923565|2018-06-01 03:00:48.923565
NCT00513682|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|2010-11-03||2017-02-07|2007-08-07|2007-08-09|Estimate|2014-03-05|2014-04-10|Estimate||||2017-02-07|2017-03-16|Actual|July 2007||2007-07-31|February 2017|2017-02-28|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional||Analysis population included all the participants who were enrolled in the study.|Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)|Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA%) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)|Completed||Phase 3|9|Actual|Forest Laboratories|No limitations|1|||f||||t||||||||||2018-06-01 03:00:49.221815|2018-06-01 03:00:49.221815
NCT00513669|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2013-03-14|2007-08-08|2007-08-09|Estimate|||||||2013-03-14|2013-03-15|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|PMAL03||Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania|A Phase Ib Double-blind Randomized Placebo Controlled Age-deescalating Trial of Two Virosome Formulated Anti-malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-immune Tanzanian Volunteers|Completed||Phase 1|50|Actual|Swiss Tropical & Public Health Institute||2|||f||||t||||||||||2018-06-01 03:00:49.399805|2018-06-01 03:00:49.399805
NCT00513656|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2012-08-09|2007-08-08|2007-08-09|Estimate|||||||2012-08-09|2012-08-10|Estimate|September 2007||2007-09-30|August 2012|2012-08-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain|A Randomised, Double-blind, Active-controlled, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Cancer Pain|Completed||Phase 2|230|Anticipated|Mundipharma Research GmbH & Co KG||2|||f||||f||||||||||2018-06-01 03:00:49.468112|2018-06-01 03:00:49.468112
NCT00513643|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-08|||2007-08-08|2007-08-08|2007-08-09|Estimate|||||||2007-08-08|2007-08-09|Estimate|April 2002||2002-04-30|August 2007|2007-08-31|June 2002|Actual|2002-06-30|||||Interventional|||Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses|Pharmacodynamic and Pharmacokinetic Properties of Insulin Aspart: Dose - Ranging vs. Human Soluble Insulin|Completed||Phase 1|16|Actual|Profil Institut für Stoffwechselforschung GmbH||6|||f||||f||||||||||2018-06-01 03:00:49.539778|2018-06-01 03:00:49.539778
NCT00513630|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2011-04-25|2007-08-07|2007-08-08|Estimate|||||||2011-04-25|2011-04-26|Estimate|June 2004||2004-06-30|December 2010|2010-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SPREADDIMCAD||Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease|Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease|Completed||Phase 4|304|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-06-01 03:00:49.70038|2018-06-01 03:00:49.70038
NCT00513617|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2009-02-23||2017-02-28|2007-08-06|2007-08-08|Estimate|2009-06-19|2009-08-04|Estimate||||2017-02-28|2017-03-29|Actual|June 2004||2004-06-30|June 2009|2009-06-30|January 2008|Actual|2008-01-31|September 2007|Actual|2007-09-30||Interventional|Arginine||Effectiveness of Arginine as a Treatment for Sickle Cell Anemia|Arginine Supplementation in Sickle Cell Anemia: Physiological and Prophylactic Effects|Completed||Phase 2|128|Actual|Children's Hospital & Research Center Oakland|Adult enrollment was slower than expected. Adult subjects were more likely than peds to drop-out due to SCD pain crisis. Higher doses of arginine (such as used in animal studies) were limited by number of daily pills required.|3|||f||||t||||||||||2018-06-01 03:00:49.798621|2018-06-01 03:00:49.798621
NCT00513604|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2013-02-19||2013-05-29|2007-08-06|2007-08-08|Estimate|2013-04-03|2013-05-27|Estimate||||2013-05-29|2013-06-03|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma|A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma|Completed||Phase 2|158|Actual|National Institutes of Health Clinical Center (CC)||5|||f||||t||||||||||2018-06-01 03:00:50.183825|2018-06-01 03:00:50.183825
NCT00513591|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-06-15|2007-08-07|2007-08-08|Estimate|||||||2017-06-15|2017-06-16|Actual|August 2007||2007-08-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|DAP Registry||Duke Autoimmunity in Pregnancy Registry|Duke Autoimmunity in Pregnancy Registry|Recruiting|||1000|Anticipated|Duke University|||3||f||||f||||||Samples With DNA|"~     Blood samples will be collected and stored for future analysis.~   "|||2018-06-01 03:00:51.227729|2018-06-01 03:00:51.227729
NCT00513578|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2014-01-03|2007-08-06|2007-08-08|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2007||2007-01-31|February 2009|2009-02-28||||January 2009|Anticipated|2009-01-31||Interventional|||Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome|Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:00:51.2839|2018-06-01 03:00:51.2839
NCT00513565|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-07-18|2007-08-06|2007-08-08|Estimate|||||||2017-07-18|2017-07-21|Actual|September 13, 2007|Actual|2007-09-13|July 2017|2017-07-31|May 14, 2009|Actual|2009-05-14|May 14, 2009|Actual|2009-05-14||Interventional|||A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers|A Randomised, Placebo-controlled, Double-dummy, Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GSK561679 and Lorazepam (Comparator) in Healthy Subjects|Completed||Phase 1|22|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:00:51.339279|2018-06-01 03:00:51.339279
NCT00513552|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2007-08-07|2007-08-07|2007-08-08|Estimate|||||||2007-08-07|2007-08-08|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis|Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis|Unknown status|Recruiting|Phase 4|20|Anticipated|Medstar Health Research Institute|||||f||||f||||||||||2018-06-01 03:00:52.356809|2018-06-01 03:00:52.356809
NCT00513539|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2013-02-18|2007-08-06|2007-08-08|Estimate|||||||2013-02-18|2013-02-20|Estimate|July 2007||2007-07-31|February 2013|2013-02-28||||December 2009|Actual|2009-12-31||Interventional|Photostent-02||Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery|Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study|Completed||Phase 3|92|Actual|University College, London||2|||f||||t||||||||||2018-06-01 03:00:52.422915|2018-06-01 03:00:52.422915
NCT00513526|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2011-06-28||2015-08-27|2007-08-06|2007-08-08|Estimate|2011-06-28|2011-07-26|Estimate||||2015-08-27|2015-09-17|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|October 2011|Actual|2011-10-31|May 2010|Actual|2010-05-31||Interventional|||Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection|A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men|Completed||Phase 2|112|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 03:00:52.523508|2018-06-01 03:00:52.523508
NCT00513513|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2010-04-22|2007-08-06|2007-08-08|Estimate|||||||2010-04-22|2010-04-26|Estimate|September 2006||2006-09-30|April 2010|2010-04-30|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously|A Phase II, Open Label Trial in Treatment na�ve, HIV 1 Infected Subjects Who Will Receive TMC114/Rtv as a Monotherapy|Terminated||Phase 2|7|Actual|Tibotec Pharmaceuticals, Ireland||||Poor recruitment.|f||||f||||||||||2018-06-01 03:00:52.812169|2018-06-01 03:00:52.812169
NCT00510172|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2007-07-30|2007-07-30|2007-08-01|Estimate|||||||2007-07-30|2007-08-01|Estimate|December 2006||2006-12-31|July 2007|2007-07-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2|Migraine Inducing Effects and Changes in Brain Haemodynamics of PGI2|Unknown status|Recruiting|N/A|12|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-06-01 03:01:43.014976|2018-06-01 03:01:43.014976
NCT00513500|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|2010-04-27||2010-07-13|2007-08-07|2007-08-08|Estimate|2010-06-15|2010-07-13|Estimate||||2010-07-13|2010-07-20|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|ZIMMAPS||Zambia Integrated Management of Malaria and Pneumonia Study|Zambia Integrated Management of Malaria and Pneumonia Study|Completed||N/A|3125|Actual|Boston University|Imbalance in enrollment. More patients enrolled in the control arm possibly due to many control community health workers working full time and available to see patients all day.|2|||f||||t||||||||||2018-06-01 03:00:52.986364|2018-06-01 03:00:52.986364
NCT00513487|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2008-07-14|2007-08-07|2007-08-08|Estimate|||||||2008-07-14|2008-07-15|Estimate|July 2007||2007-07-31|July 2008|2008-07-31|November 2007|Actual|2007-11-30|||||Interventional|||Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity|Assessment of the Effects of Multiple Nasal Antigen Challenges With Dust Mite Allergen on Local and Systemic Allergic Inflammation and Bronchoreactivity in Subjects With Allergic Rhinitis Sensitive to House Dust Mite - a Feasibility and Site Evaluation Study|Completed||N/A|18|Anticipated|Novartis|||||f||||f||||||||||2018-06-01 03:00:53.309373|2018-06-01 03:00:53.309373
NCT00513474|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2017-02-27||2017-04-20|2007-08-06|2007-08-08|Estimate|2017-02-27|2017-04-11|Actual||||2017-04-20|2017-05-25|Actual|January 2008||2008-01-31|April 2017|2017-04-30|February 12, 2013|Actual|2013-02-12|February 12, 2013|Actual|2013-02-12||Interventional||Intent-to-treat participants included in the analyses.|Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant|Rasburicase to Prevent Graft -Versus-Host Disease|Completed||Phase 1|46|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:00:53.422628|2018-06-01 03:00:53.422628
NCT00513461|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2013-02-15|2007-08-06|2007-08-08|Estimate|||||||2013-02-15|2013-02-18|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|August 2012|Actual|2012-08-31||Interventional|||S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate in Preventing Liver Cancer in Patients With Chronic Hepatitis C Infection|A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP|Unknown status|Active, not recruiting|Phase 2|110|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 03:00:53.849403|2018-06-01 03:00:53.849403
NCT00513448|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2007-08-07|2007-08-07|2007-08-08|Estimate|||||||2007-08-07|2007-08-08|Estimate|April 2005||2005-04-30|August 2007|2007-08-31|November 2005|Actual|2005-11-30|||||Interventional|||Promoting Physical Activity for Persons With Multiple Sclerosis|Comparing Individualized Rehabilitation to a Group Wellness Intervention for Persons With Multiple Sclerosis|Completed||N/A|50|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 03:00:53.938831|2018-06-01 03:00:53.938831
NCT00513435|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2013-08-13||2014-04-02|2007-08-06|2007-08-08|Estimate|2013-08-13|2013-10-18|Estimate||||2014-04-02|2014-04-30|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|Completed||Phase 2|9|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:00:54.039512|2018-06-01 03:00:54.039512
NCT00513422|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2010-06-29|2007-08-07|2007-08-08|Estimate|||||||2010-06-29|2010-06-30|Estimate|October 2007||2007-10-31|June 2010|2010-06-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|LEGS||The Long-term Evaluation of Glucosamine Sulphate Study|The Effect of Glucosamine Sulphate on Structural Disease Progression in Knee Osteoarthritis and the Cost-effectiveness of Glucosamine Sulphate for Knee Arthritis.|Unknown status|Active, not recruiting|Phase 4|600|Anticipated|University of Sydney||4|||f||||f||||||||||2018-06-01 03:00:54.230461|2018-06-01 03:00:54.230461
NCT00513409|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|2009-03-11||2016-10-26|2007-08-07|2007-08-08|Estimate|2009-06-25|2009-08-11|Estimate||||2016-10-26|2016-12-08|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|February 2008|Actual|2008-02-29||Interventional|||Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule|Phase II, Observer-blind Follow-up Study to Assess reacto-and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine (GSK1024850A), When Given as Booster in Primed Children or as 2-dose Catch-up in Unprimed Children.|Completed||Phase 2|163|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:00:54.476234|2018-06-01 03:00:54.476234
NCT00513396|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2007-08-06|2007-08-06|2007-08-08|Estimate|||||||2007-08-06|2007-08-08|Estimate|January 2004||2004-01-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis|A Randomized Control Trial Of High-Dose Isoniazid Adjuvant Therapy For Multidrug Resistant Tuberculosis|Completed||Phase 2/Phase 3|134|Actual|GSVM Medical College||3|||f||||f||||||||||2018-06-01 03:00:55.172035|2018-06-01 03:00:55.172035
NCT00513383|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2017-02-27|2007-08-07|2007-08-08|Estimate|||||||2017-02-27|2017-03-01|Actual|April 2006||2006-04-30|February 2017|2017-02-28|October 2012|Actual|2012-10-31|October 2010|Actual|2010-10-31||Interventional|||Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck|Phase I Study Panitumumab Plus Chemoradiotherapy and Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck|Completed||Phase 1|34|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:00:55.256856|2018-06-01 03:00:55.256856
NCT00513370|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2009-08-21||2011-04-07|2007-08-06|2007-08-08|Estimate|2009-10-13|2009-11-20|Estimate||||2011-04-07|2011-04-11|Estimate|September 2007||2007-09-30|April 2011|2011-04-30||||September 2008|Actual|2008-09-30||Interventional|PRIDE||A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis|A Canadian Open-Label Access Program to Evaluate the Safety and the Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis|Completed||Phase 3|203|Actual|Abbott||1|||f||||f||||||||||2018-06-01 03:00:55.389182|2018-06-01 03:00:55.389182
NCT00513357|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2012-06-06||2012-12-07|2007-08-06|2007-08-08|Estimate|2012-08-17|2012-09-14|Estimate||||2012-12-07|2012-12-11|Estimate|June 2006||2006-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients|A Randomized Clinical Trial of Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients|Completed||Phase 3|82|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:00:55.783087|2018-06-01 03:00:55.783087
NCT00513344|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2013-03-28||2013-07-12|2007-08-06|2007-08-08|Estimate|2013-07-12|2013-08-14|Estimate||||2013-07-12|2013-08-14|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|April 2012|Actual|2012-04-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Polyphenols From Milk and Dark Chocolate|Efficacy of Polyphenols From Milk and Dark Chocolate|Completed||N/A|6|Actual|Nestlé||3|||f||||f||||||||||2018-06-01 03:00:55.995325|2018-06-01 03:00:55.995325
NCT00513331|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2013-12-31|2007-08-07|2007-08-08|Estimate|||||||2013-12-31|2014-01-01|Estimate|July 2007||2007-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Barrett's Esophagus & Gastroesophageal Reflux Disease|The Valley Hospital Center for Barrett's Esophagus and Gastroesophageal Reflux Disease (GERD)|Completed|||125|Actual|Valley Health System|||3||f||||f||||||Samples With DNA|"~     Tissue and blood for future analysis~   "|||2018-06-01 03:00:56.15945|2018-06-01 03:00:56.15945
NCT00513318|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2013-08-01|2007-08-07|2007-08-08|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 2004||2004-08-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies|Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies|Terminated|||15|Anticipated|University of California, San Francisco||||Insufficient enrollment to justify keeping open.|f||||t||||||||||2018-06-01 03:00:56.310717|2018-06-01 03:00:56.310717
NCT00513305|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2010-07-29||2012-07-24|2007-08-07|2007-08-08|Estimate|2011-03-28|2011-03-29|Estimate||||2012-07-24|2012-08-01|Estimate|October 2007||2007-10-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia|An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination With Arsenic Trioxide Compared With Low-Dose Cytarabine Alone for the Treatment of Elderly Patients With Acute Myeloid Leukemia|Terminated||Phase 3|67|Actual|Teva Pharmaceutical Industries|In September 2009, the sponsor decided to stop the study due to difficulty in enrollment. The study was stopped prior to the first planned interim analysis. Most of the analysis planned in the protocol was not performed.|2||Study has been stopped by sponsor decision|f||||||||||||||2018-06-01 03:00:56.422317|2018-06-01 03:00:56.422317
NCT00513292|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2015-07-14||2016-11-14|2007-08-06|2007-08-08|Estimate|2015-08-26|2015-09-29|Estimate||||2016-11-14|2016-11-16|Estimate|July 2007||2007-07-31|November 2016|2016-11-30||||June 2012|Actual|2012-06-30||Interventional||Total enrolled: 282, 2 withdrew consent before start of treatment|Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery|A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer|Active, not recruiting||Phase 3|280|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:00:57.24808|2018-06-01 03:00:57.24808
NCT00513279|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-09-14|2007-08-06|2007-08-08|Estimate|||||||2017-09-14|2017-09-15|Actual|June 28, 2007|Actual|2007-06-28|September 2017|2017-09-30|October 4, 2007|Actual|2007-10-04|October 4, 2007|Actual|2007-10-04||Interventional|||To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334|A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:00:58.455057|2018-06-01 03:00:58.455057
NCT00513266|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2009-08-06|2007-08-06|2007-08-08|Estimate|||||||2009-08-06|2009-08-07|Estimate|June 2007||2007-06-30|June 2009|2009-06-30||||||||Interventional|||Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery|Oxaliplatin-CPT-11-5-FU-Leucovarin + Bevacizumab and Cetuximab (OCFL-BC) as a Combination Regimen for Systemic Treatment of Advanced Colorectal Carcinoma With Potentially Resectable Liver and/or Lung Metastases. A Phase II Study|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:00:58.536363|2018-06-01 03:00:58.536363
NCT00513253|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2015-02-12|2007-08-06|2007-08-08|Estimate|||||||2015-02-12|2015-02-16|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|||A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib|Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||||It was determined not to be needed based on the clinical development plan of Tykerb.|||||f||||||||||2018-06-01 03:00:58.618535|2018-06-01 03:00:58.618535
NCT00513240|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|2014-01-24||2016-11-09|2007-08-07|2007-08-08|Estimate|2014-04-17|2014-05-19|Estimate||||2016-11-09|2017-01-06|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|September 2012|Actual|2012-09-30||Interventional||These were the number of subjects followed for the intention-to-treat analysis because they received at least one dose of study drug/placebo.|Erythropoetin Neuroprotection for Neonatal Cardiac Surgery|Erythropoetin Neuroprotection for Neonatal Cardiac Surgery|Active, not recruiting||Phase 1/Phase 2|62|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 03:00:58.711204|2018-06-01 03:00:58.711204
NCT00513214|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2011-09-30|2007-08-07|2007-08-08|Estimate|||||||2011-09-30|2011-10-04|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|June 2009|Actual|2009-06-30||Interventional|||Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus|A Phase 1/2a, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of XOMA 052 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|68|Actual|XOMA (US) LLC||2|||f||||t||||||||||2018-06-01 03:00:58.983195|2018-06-01 03:00:58.983195
NCT00513201|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2007-08-07|2007-08-07|2007-08-08|Estimate|||||||2007-08-07|2007-08-08|Estimate||||August 2007|2007-08-31||||||||Interventional|||Lyspro Insulin vs Regular Insulin in Cirrhotic Patients||Completed||Phase 4|||"University of Campania Luigi Vanvitelli"|||||f||||f||||||||||2018-06-01 03:00:59.062215|2018-06-01 03:00:59.062215
NCT00513188|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2016-12-14|2007-08-06|2007-08-08|Estimate|||||||2016-12-14|2016-12-15|Estimate|February 2007||2007-02-28|December 2016|2016-12-31||||June 2008|Actual|2008-06-30||Interventional|||Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma|A Pilot Study of the Efficacy of the Chop-Montak Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma|Withdrawn||N/A|0|Actual|University of Miami|||||f||||t||||||||||2018-06-01 03:00:59.123702|2018-06-01 03:00:59.123702
NCT00513175|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2012-11-07|2007-08-07|2007-08-08|Estimate|||||||2012-11-07|2012-11-09|Estimate|October 2001||2001-10-31|November 2012|2012-11-30|November 2007|Actual|2007-11-30|||||Observational|||Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia|Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia|Completed|||44||University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:00:59.202347|2018-06-01 03:00:59.202347
NCT00051805|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2007-09-17|2003-01-16|2003-01-17|Estimate|||||||2007-09-17|2007-09-18|Estimate|August 2002||2002-08-31|August 2007|2007-08-31|July 2006|Actual|2006-07-31|||||Interventional|||Promoting Adherence to Anti-HIV Drug Regimens|Promoting Adherence to Antiretroviral Regimens|Completed||N/A|119||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:29:20.970553|2018-06-01 05:29:20.970553
NCT00513162|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2012-09-18|2007-08-07|2007-08-08|Estimate|||||||2012-09-18|2012-09-19|Estimate|July 2007||2007-07-31|September 2012|2012-09-30||||September 2012|Actual|2012-09-30||Interventional|||Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases|Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases|Completed||Phase 1|8|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:00:59.260078|2018-06-01 03:00:59.260078
NCT00513149|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2011-01-20|2007-08-07|2007-08-08|Estimate|||||||2011-01-20|2011-01-24|Estimate|July 2006||2006-07-31|January 2011|2011-01-31|July 2011|Anticipated|2011-07-31|June 2011|Anticipated|2011-06-30||Interventional|||Platelet Function Assessment for Atherothrombotic Patients|Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study|Unknown status|Recruiting|Phase 4|150|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 03:00:59.339371|2018-06-01 03:00:59.339371
NCT00513136|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2012-04-18|2007-08-07|2007-08-08|Estimate|||||||2012-04-18|2012-04-19|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Fatigue Intervention Trial for Breast Cancer Survivors|A Randomized Trial to Evaluate a Family-focused Mind Body Medicine Intervention to Reduce Fatigue Among Breast Cancer Survivors|Completed||Phase 3|40|Anticipated|Mercy Medical Center||2|||f||||f||||||||||2018-06-01 03:00:59.413396|2018-06-01 03:00:59.413396
NCT00513123|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2012-07-31|2007-08-07|2007-08-08|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2002||2002-09-30|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia|A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of Cervical Intraepithelial Neoplasia|Completed|||100|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:00:59.477625|2018-06-01 03:00:59.477625
NCT00513110|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2009-09-30|2007-08-07|2007-08-08|Estimate|||||||2009-09-30|2009-10-01|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Possible Therapeutic Role for Adenosine During Inflammation|A Possible Therapeutic Role for Adenosine During Inflammation|Completed||Phase 1|33|Anticipated|Radboud University||3|||f||||f||||||||||2018-06-01 03:00:59.566195|2018-06-01 03:00:59.566195
NCT00513097|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-10-31|2007-08-07|2007-08-08|Estimate|||||||2017-10-31|2017-11-06|Actual|July 25, 2006|Actual|2006-07-25|October 2017|2017-10-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|||Curbing Tobacco Use in Suburban and Rural Schools|Curbing Tobacco Use in Suburban and Rural Schools|Completed||Phase 1|1289|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:00:59.656248|2018-06-01 03:00:59.656248
NCT00513084|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2007-08-07|2007-08-07|2007-08-08|Estimate|||||||2007-08-07|2007-08-08|Estimate|July 2004||2004-07-31|July 2007|2007-07-31|July 2009|Anticipated|2009-07-31|||||Interventional|PESO||Promotion of Exercise and Health in Obesity|Moderators and Mediators of Physical Activity, Body Weight, and Body Composition Change During Obesity Treatment in Women|Unknown status|Active, not recruiting|N/A|259|Actual|Technical University of Lisbon||2|||f||||f||||||||||2018-06-01 03:00:59.763452|2018-06-01 03:00:59.763452
NCT00513071|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2014-07-30||2018-03-21|2007-08-06|2007-08-08|Estimate|2014-10-01|2014-10-03|Estimate||||2018-03-21|2018-04-19|Actual|August 2007||2007-08-31|March 2018|2018-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC)|Completed||Phase 2|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:00:59.842897|2018-06-01 03:00:59.842897
NCT00513058|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2014-01-13|2007-08-06|2007-08-08|Estimate|||||||2014-01-13|2014-01-14|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|April 2012|Actual|2012-04-30|May 2010|Actual|2010-05-31||Interventional|||Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer|Phase I Study Evaluating the Combination of Lapatinib + Vinorelbine in Patients With Locally Advanced or Metastatic Breast Cancer Overexpressing HER2|Completed||Phase 1|33|Actual|UNICANCER||1|||f||||t||||||||||2018-06-01 03:01:00.097126|2018-06-01 03:01:00.097126
NCT00513045|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2008-11-18|2007-08-07|2007-08-08|Estimate|||||||2008-11-18|2008-11-19|Estimate|April 2007||2007-04-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|Nightmares||A Self-Help Method for Nightmares|A Self-Help Method for Nightmares|Completed||N/A|399|Actual|Utrecht University||4|||f||||t||||||||||2018-06-01 03:01:00.172712|2018-06-01 03:01:00.172712
NCT00513032|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2007-08-07|2007-08-07|2007-08-08|Estimate|||||||2007-08-07|2007-08-08|Estimate|January 2005||2005-01-31|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Observational|||Interaction Between Anaesthetics and Methylene Blue|Effects of Methylene Blue on Propofol Requirement During Anaesthesia Induction and Surgery|Completed|||22|Actual|University Hospital, Geneva|||2||f||||f||||||||||2018-06-01 03:01:00.237667|2018-06-01 03:01:00.237667
NCT00513019|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|2012-03-01||2013-08-06|2007-08-07|2007-08-08|Estimate|2013-08-06|2013-09-27|Estimate||||2013-08-06|2013-09-27|Estimate|August 2007||2007-08-31|August 2013|2013-08-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Double-Blind Lamictal (Lamotrigine) in Neurotic Excoriation|A Double-Blind Study of Lamictal in Neurotic Excoriation|Completed||Phase 2|35|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 03:01:00.385611|2018-06-01 03:01:00.385611
NCT00512993|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2015-03-04|2007-08-07|2007-08-08|Estimate|||||||2015-03-04|2015-03-05|Estimate|December 2004||2004-12-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|NATAN||Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy|A Randomized, Multicenter, Open Phase III Study Comparing the Postoperative Use of Zoledronic Acid Versus no Treatment in Patients With Histological Tumor Residuals After Preoperative Anthracycline and Taxane Containing Chemotherapy for Primary Breast Cancer|Completed||Phase 3|654|Anticipated|German Breast Group||2|||f||||t||||||||||2018-06-01 03:01:00.598524|2018-06-01 03:01:00.598524
NCT00512980|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2015-12-01|2007-08-07|2007-08-08|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2008||2008-08-31|December 2015|2015-12-31||||November 2013|Actual|2013-11-30||Interventional|||PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma|A Randomized Phase II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Patients With Intermediate Stage Hodgkin's Lymphoma|Terminated||Phase 2|||University of Cologne||2||lower recruitment rates as expected|f||||f||||||||||2018-06-01 03:01:00.750397|2018-06-01 03:01:00.750397
NCT00512967|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2017-02-22|2007-08-07|2007-08-08|Estimate|||||||2017-02-22|2017-02-24|Actual|September 2005||2005-09-30|February 2008|2008-02-29|June 2006|Actual|2006-06-30|||||Observational|||The Occurence of Inflammation and Oxidative Stress in Lung Diseases|The Inflammatory and Antioxidant Status in Pulmonary Sarcoidosis, Idiopathic Pulmonary Fibrosis and COPD: a Potential Role for Antioxidants|Completed|||76|Actual|Maastricht University Medical Center|||4||f||||f||||||Samples With DNA|"~     blood samples were collected~   "|||2018-06-01 03:01:00.822874|2018-06-01 03:01:00.822874
NCT00512954|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2011-01-18|2007-08-07|2007-08-08|Estimate|||||||2011-01-18|2011-01-19|Estimate|April 2007||2007-04-30|July 2009|2009-07-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Observational|||Causes, Characteristics and Mechanisms of Infective Exacerbations in Subjects With Asthma and Chronic Obstructive Pulmonary Disease (COPD)|A Prospective One Year Study of the Causes, Characteristics, Mechanisms and Kinetics of Exacerbations in Subjects With Asthma|Completed|||100|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 03:01:00.887164|2018-06-01 03:01:00.887164
NCT00512941|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2008-09-04|2007-08-07|2007-08-08|Estimate|||||||2008-09-04|2008-09-05|Estimate|June 2007||2007-06-30|September 2008|2008-09-30|August 2007|Actual|2007-08-31|||||Observational|||Laboratory Profile of Hepatitis B and C in Users of a Reference Service|Laboratory Profile of Hepatitis B and C in Users of a Reference Service|Completed|||531|Actual|UPECLIN HC FM Botucatu Unesp|||7||f||||t||||||||||2018-06-01 03:01:00.949025|2018-06-01 03:01:00.949025
NCT00512928|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2008-03-25|2007-08-07|2007-08-08|Estimate|||||||2008-03-25|2008-03-26|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers|Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers|Completed||N/A|20|Actual|Maastricht University Medical Center|||||f||||f||||||||||2018-06-01 03:01:01.018524|2018-06-01 03:01:01.018524
NCT00512915|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2009-03-04|2007-08-07|2007-08-08|Estimate|||||||2009-03-04|2009-03-05|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|Avoid FFS||Avoid FFS - Use of the Atrial Pacemaker Lead 1699 With Very Short Tip Ring Spacing to Avoid Far Field Sensing|Atriale Vorhofsonde 1699 Mit Sehr Kurzem Bipolabstand Zur Vermeidung Von Far Field Sensing|Completed||Phase 4|204|Actual|St. Jude Medical||2|||f||||f||||||||||2018-06-01 03:01:01.128506|2018-06-01 03:01:01.128506
NCT00512902|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2012-04-20||2014-10-24|2007-08-06|2007-08-08|Estimate|2014-10-24|2014-10-27|Estimate||||2014-10-24|2014-10-27|Estimate|August 2007||2007-08-31|October 2014|2014-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis|Pilot Study to Examine The Use of Imatinib (Gleevec) For The Treatment of Active Alveolitis in Systemic Sclerosis|Completed||Phase 1/Phase 2|20|Actual|University of California, Los Angeles|Open label, small.|1|||f||||f||||||||||2018-06-01 03:01:01.44305|2018-06-01 03:01:01.44305
NCT00512889|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2013-02-28|2007-08-07|2007-08-08|Estimate|||||||2013-02-28|2013-03-01|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|February 2011|Actual|2011-02-28||Interventional|||Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma|A Pilot Study of the Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma|Completed||Phase 1|9|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-06-01 03:01:01.636667|2018-06-01 03:01:01.636667
NCT00512876|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2013-05-15||2013-07-03|2007-08-06|2007-08-08|Estimate|2013-05-15|2013-07-03|Estimate||||2013-07-03|2013-07-22|Estimate|August 2007||2007-08-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization|Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization|Completed||N/A|24|Actual|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:01:01.720419|2018-06-01 03:01:01.720419
NCT00512863|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2007-11-05|2007-08-06|2007-08-08|Estimate|||||||2007-11-05|2007-11-06|Estimate|August 2007||2007-08-31|November 2007|2007-11-30||||||||Interventional|||A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma|A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma|Withdrawn||Phase 2|272|Anticipated|Abbott|||||f||||f||||||||||2018-06-01 03:01:01.906871|2018-06-01 03:01:01.906871
NCT00512850|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-03-02|2007-08-06|2007-08-08|Estimate|||||||2017-03-02|2017-03-03|Actual|May 1996||1996-05-31|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|March 2004|Actual|2004-03-31||Interventional|||Folic Acid in Preventing Colorectal Polyps in Patients With Previous Colorectal Polyps|The Nurses' Health Study (NHS) and Health Professionals Follow-Up Study (HPFS) Folic Acid Prevention Trial|Completed||N/A|672|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 03:01:02.045507|2018-06-01 03:01:02.045507
NCT00512837|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2016-01-20|2007-08-07|2007-08-08|Estimate|||||||2016-01-20|2016-01-21|Estimate|November 2007||2007-11-30|June 2008|2008-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Mobile Phone Based Structured Intervention|A Mobile Phone Based Structured Intervention to Achieve Asthma Control in Patients With Uncontrolled Persistent Asthma: Pragmatic Randomised Controlled Trial|Completed||N/A|312|Anticipated|University of Aberdeen||1|||f||||t||||||||||2018-06-01 03:01:02.123839|2018-06-01 03:01:02.123839
NCT00512824|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2011-01-07|2007-08-07|2007-08-08|Estimate|||||||2011-01-07|2011-01-10|Estimate|August 2007||2007-08-31|January 2011|2011-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Calcium, Probiotics and Acute Diarrheal Disease Among Indonesian Children|Calcium, Probiotics and Acute Diarrheal Disease Among Indonesian Children Aged 1-6 Years in Low Socio-economic Urban Area of East Jakarta|Completed||N/A|494|Actual|Wageningen University||4|||f||||t||||||||||2018-06-01 03:01:02.191736|2018-06-01 03:01:02.191736
NCT00512811|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2007-08-07|2007-08-07|2007-08-08|Estimate|||||||2007-08-07|2007-08-08|Estimate||||August 2007|2007-08-31||||||||Interventional|||Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients|Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients: a Double-Blind Randomized Study|Completed||Phase 3|||Baqiyatallah Medical Sciences University|||||f||||t||||||||||2018-06-01 03:01:02.262493|2018-06-01 03:01:02.262493
NCT00512798|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2012-06-27||2012-09-19|2007-08-06|2007-08-08|Estimate|2012-06-27|2012-08-03|Estimate||||2012-09-19|2012-10-02|Estimate|June 2003||2003-06-30|September 2012|2012-09-30|March 2008|Actual|2008-03-31|July 2006|Actual|2006-07-31||Interventional|||Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma|(Inhibition of NF-kB Signaling in Melanoma Therapy) A Phase I/II Clinical Trial of PS-341, a Proteasome Inhibitor, in Combination With an Extended Continuous Oral Schedule of Temozolomide in Patients With Advanced Refractory Solid Tumors With the Phase II Component Only in Patients With Melanoma|Terminated||Phase 1/Phase 2|47|Actual|Vanderbilt-Ingram Cancer Center||2||This study was terminated due to lack of efficacy|f||||t||||||||||2018-06-01 03:01:02.350709|2018-06-01 03:01:02.350709
NCT00512785|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2012-06-12|2007-08-07|2007-08-08|Estimate|||||||2012-06-12|2012-06-13|Estimate|August 2007||2007-08-31|June 2012|2012-06-30||||May 2009|Actual|2009-05-31||Interventional|||Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder|An Open-label Study to Evaluate the Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder|Completed||Phase 3|435|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 03:01:02.836904|2018-06-01 03:01:02.836904
NCT00424359|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2011-05-12|2007-01-18|2007-01-19|Estimate|||||||2011-05-12|2011-05-16|Estimate|April 2005||2005-04-30|May 2011|2011-05-31|January 2009|Actual|2009-01-31|||||Observational|||Ambulation Study in Multiple Sclerosis|A Prospective Study of Clinical Indices as Predictors of Ambulatory Effectiveness in Multiple Sclerosis|Completed|||40|Anticipated|Brown, Theodore R., M.D., MPH|||||f||||f||||||||||2018-06-01 03:29:50.380282|2018-06-01 03:29:50.380282
NCT00512772|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2010-12-17|2007-08-07|2007-08-08|Estimate|||||||2010-12-17|2010-12-20|Estimate|October 2007||2007-10-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Improved Use of Antibiotic Guidelines in Hospital Environment|Improved Use of Antibiotic Guidelines in in Hospital Environment: Research on an Implementation Model and the Role of the Hospital Pharmacist.|Completed|||823|Actual|Katholieke Universiteit Leuven|||||f||||f||||||||||2018-06-01 03:01:02.898748|2018-06-01 03:01:02.898748
NCT00512759|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2018-02-24|2007-08-07|2007-08-08|Estimate|||||||2018-02-24|2018-02-27|Actual|September 2007|Actual|2007-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|GALACTIC||Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study|Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC)|Active, not recruiting||Phase 4|770|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 03:01:02.963559|2018-06-01 03:01:02.963559
NCT00512746|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2011-12-20|2007-08-06|2007-08-08|Estimate|||||||2011-12-20|2011-12-21|Estimate|August 2007||2007-08-31|December 2011|2011-12-31||||March 2011|Actual|2011-03-31||Interventional|||Screening for Lung Cancer in Current or Past Smokers With Chronic Obstructive Pulmonary Disease|A Randomised Controlled Trial of Surveillance for the Early Detection of Lung Cancer in an at Risk Group [Lung-SEARCH Trial]|Completed||N/A|1569|Actual|University College, London||2|||f||||t||||||||||2018-06-01 03:01:03.050183|2018-06-01 03:01:03.050183
NCT00512733|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2014-08-08|2007-08-07|2007-08-08|Estimate|||||||2014-08-08|2014-08-11|Estimate|March 2006||2006-03-31|August 2014|2014-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Validation of Dietary Calcium Questionnaires Using Diet Records|Validation of Dietary Calcium Questionnaires Using Diet Records|Completed|||160|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 03:01:03.1181|2018-06-01 03:01:03.1181
NCT00512720|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2013-02-20|2007-08-07|2007-08-08|Estimate|||||||2013-02-20|2013-02-21|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|FIX-IT Retro||Clinical Outcomes of Three Different Percutaneous Revascularization Strategies for the Treatment of Lifestyle Limiting Claudication: A Retrospective Analysis|Clinical Outcomes of Three Different Percutaneous Revascularization Strategies for the Treatment of Lifestyle Limiting Claudication: A Retrospective Analysis|Completed|||355|Actual|Spectrum Health Hospitals|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:01:03.163493|2018-06-01 03:01:03.163493
NCT00512707|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|2017-03-25||2017-05-28|2007-08-07|2007-08-08|Estimate|2017-05-28|2017-06-29|Actual||||2017-05-28|2017-06-29|Actual|November 2006||2006-11-30|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TED|Baseline characteristic are provided prior to sildenafil administration (week -7)|Effect of Testosterone in Men With Erectile Dysfunction|Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction|Completed||Phase 4|140|Actual|Boston University||2|||f||||t|t|f|||t|||No||2018-06-01 03:01:03.379384|2018-06-01 03:01:03.379384
NCT00512694|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-07-27|2007-08-06|2007-08-08|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2007||2007-07-31|July 2017|2017-07-31||||June 2019|Anticipated|2019-06-30||Observational|||Duke Lupus Registry|Duke Lupus Registry|Recruiting|||1000|Anticipated|Duke University|||||f||||f||||||Samples Without DNA|"~     Blood samples will be collected for future research.~   "|||2018-06-01 03:01:04.481234|2018-06-01 03:01:04.481234
NCT00512681|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2009-09-17|2007-08-07|2007-08-08|Estimate|||||||2009-09-17|2009-09-18|Estimate|July 2007||2007-07-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|TIROX2||A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer|A Phase II Study of S-1 Combined With Irinotecan and Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma|Completed||Phase 2|44|Anticipated|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 03:01:04.544922|2018-06-01 03:01:04.544922
NCT00512668|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2013-01-04|2007-08-06|2007-08-08|Estimate|||||||2013-01-04|2013-01-07|Estimate|September 2007||2007-09-30|January 2013|2013-01-31||||January 2008|Actual|2008-01-31||Interventional|||Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer|Phase Ib Study of Limited Androgen Ablation and Two Dose Levels of Temsirolimus (NSC#683864) in Patients With Prostate Cancer Who Have a Biochemical Relapse After Prostatectomy and/or Radiotherapy|Terminated||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:01:04.608435|2018-06-01 03:01:04.608435
NCT00512655|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2010-07-06|2007-08-07|2007-08-08|Estimate|||||||2010-07-06|2010-07-07|Estimate|January 2008||2008-01-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|CP||Trial to Reduce Falls Incidence Rate in Frail Elderly|Randomized Controlled Trial to Reduce Falls Incidence Rate in Frail Elderly|Terminated||N/A|320|Anticipated|Radboud University||2||Extremely difficult recruitment. Preliminary analysis showed no effect of the intervention.|f||||f||||||||||2018-06-01 03:01:04.704656|2018-06-01 03:01:04.704656
NCT00512642|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-07|||2018-05-10|2007-08-07|2007-08-08|Estimate|||||||2018-05-10|2018-05-11|Actual|July 29, 1999||1999-07-29|February 2, 2018|2018-02-02||||||||Observational|||Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Bronchial Lesions: Novel Approaches for Early Detection of Lung Cancer in High Risk Patients|Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Bronchial Lesions: Novel Approaches for Early Detection of Lung Cancer in High Risk Patients|Completed|||120|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:01:04.775175|2018-06-01 03:01:04.775175
NCT00512629|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2011-12-14|2007-08-07|2007-08-08|Estimate|||||||2011-12-14|2011-12-15|Estimate|July 2007||2007-07-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Cholestasis Prevention: Efficacy of IV Fish Oil|Cholestasis Prevention: Efficacy of IV Fish Oil|Completed||Phase 1|19|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 03:01:04.836098|2018-06-01 03:01:04.836098
NCT00512616|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-04|||2017-06-30|2007-08-04|2007-08-07|Estimate|||||||2017-06-30|2017-07-02|Actual|August 1, 2007||2007-08-01|September 15, 2009|2009-09-15|September 15, 2009|Anticipated|2009-09-15|September 15, 2009|Actual|2009-09-15||Interventional|||A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder|An Investigation of the Efficacy of the Glutamate Transporter GLT 1 in the Treatment of Bipolar Depression|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:01:04.90427|2018-06-01 03:01:04.90427
NCT00512603|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-05|||2013-01-15|2007-08-06|2007-08-07|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2007||2007-01-31|May 2007|2007-05-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Observational|||Association Between Levels of D-Dimer, Fibrinogen and PAI-1 in Elderly Patients With Infection and Occurrence of Cardio- and Cerebro-vascular Disease After Discharge||Completed|||52|Actual|Wolfson Medical Center|||||f||||f||||||||||2018-06-01 03:01:04.961703|2018-06-01 03:01:04.961703
NCT00512590|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2007-08-03|2007-08-03|2007-08-07|Estimate|||||||2007-08-03|2007-08-07|Estimate|April 2005||2005-04-30|August 2007|2007-08-31|June 2006|Actual|2006-06-30|||||Interventional|||Pilot Study: Relaxation and Guided Imagery in Hispanic Persons Diagnosed With Fibromyalgia|Effects of Guided Imagery on Pain, Distress, Functional Status and Self-Efficacy in Hispanics Diagnosed With Fibromyalgia|Completed||N/A|14|Actual|Florida International University||1|||f||||f||||||||||2018-06-01 03:01:05.008282|2018-06-01 03:01:05.008282
NCT00512564|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-05|||2011-08-25|2007-08-06|2007-08-07|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2008||2008-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia|Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia - An Observational and Laboratory Study|Completed|||50|Anticipated|HaEmek Medical Center, Israel|||1||f||||||||||||||2018-06-01 03:01:05.201201|2018-06-01 03:01:05.201201
NCT00512551|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2017-11-28|2007-08-03|2007-08-07|Estimate|||||||2017-11-28|2017-11-30|Actual|June 20, 2000|Actual|2000-06-20|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Observational|||DNA Array Analysis of Patients With Cervical Cancer|A Pilot Study of Early Changes in DNA Array Expression Following Chemo-Radiation Treatment of Cervical Cancer|Completed|||18|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Two biopsies of the cervix will be performed to obtain tumor cells.~   "|||2018-06-01 03:01:05.288707|2018-06-01 03:01:05.288707
NCT00512538|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2007-08-03|2007-08-03|2007-08-07|Estimate|||||||2007-08-03|2007-08-07|Estimate|October 2000||2000-10-31|August 2007|2007-08-31|September 2002|Actual|2002-09-30|||||Interventional|||Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers|A Randomized, Open-Label, Multi-Center Study to Compare the Safety and Efficacy of Apligraf Versus Standard Therapy (i.e., Saline Moistened Dressing Regimen) in the Treatment of Diabetic (Primarily Neuropathic) Foot Ulcers|Terminated||Phase 3|82|Actual|Organogenesis||||Interruption of business relations between Study Sponsor and Device Manufacturer|f||||f||||||||||2018-06-01 03:01:05.391687|2018-06-01 03:01:05.391687
NCT00512525|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2009-09-08|2007-08-06|2007-08-07|Estimate|||||||2009-09-08|2009-09-09|Estimate|January 2003||2003-01-31|September 2009|2009-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Ghrelin Decreases Insulin Sensitivity|Intravenous Ghrelin Infusion Decreases Insulin Sensitivity in Healthy Young Men|Completed||Phase 1|8|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 03:01:05.457134|2018-06-01 03:01:05.457134
NCT00512512|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2010-06-30|2007-08-06|2007-08-07|Estimate|||||||2010-06-30|2010-07-01|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|January 2008|Actual|2008-01-31||Observational|||Transoral Endoscopic Liver Biopsy During Laparoscopic Gastric Bypass|Transoral Endoscopic Liver Biopsy During Laparoscopic Gastric Bypass|Completed|||4|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 03:01:05.519084|2018-06-01 03:01:05.519084
NCT00512499|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2018-01-06|2007-08-03|2007-08-07|Estimate|||||||2018-01-06|2018-01-09|Actual|February 2007||2007-02-28|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2013|Actual|2013-07-31||Interventional|OPTIMUS||Strategies to Treat Osteoporosis Following a Fragility Fracture|Osteoporosis and Peripheral Fractures: Treatment and Investigation Multidisciplinary at the chUS|Completed||N/A|1410|Actual|Université de Sherbrooke||3|||f||||t||||||||Undecided||2018-06-01 03:01:05.581227|2018-06-01 03:01:05.581227
NCT00512486|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2008-11-26|2007-08-06|2007-08-07|Estimate|||||||2008-11-26|2008-11-27|Estimate|November 2006||2006-11-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||A Sequential Dose-Escalation Study in Subjects With Mild Asthma|A Multi-Center, Open-Label, Single Administration, Sequential Dose Escalation of BIW-8405/MEDI-563 in Subjects With Mild Asthma|Completed||Phase 1|42|Anticipated|MedImmune LLC||1|||f||||t||||||||||2018-06-01 03:01:05.651653|2018-06-01 03:01:05.651653
NCT00512473|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2007-08-06|2007-08-06|2007-08-07|Estimate|||||||2007-08-06|2007-08-07|Estimate|September 2005||2005-09-30|August 2007|2007-08-31|April 2006|Actual|2006-04-30|||||Interventional|||Growth Hormone Signaling in Vivo in Humans|Growth Hormone (GH) Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background and gh Receptor Blockade|Completed||N/A|8|Actual|University of Aarhus||3|||f||||f||||||||||2018-06-01 03:01:05.721138|2018-06-01 03:01:05.721138
NCT00512460|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2016-05-12|2007-08-03|2007-08-07|Estimate|||||||2016-05-12|2016-05-16|Estimate|September 2006||2006-09-30|May 2016|2016-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||RTA 744 Injection in Patients With Leptomeningeal Disease|A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis|Terminated||Phase 1|7|Actual|M.D. Anderson Cancer Center||1||Study was closed due to loss of industry sponsorship|f||||f||||||||||2018-06-01 03:01:05.896133|2018-06-01 03:01:05.896133
NCT00512447|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2010-09-13|2007-08-06|2007-08-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|July 2007||2007-07-31|September 2010|2010-09-30||||||||Observational|||Normal Values of Brain Oxygenation|Normal Values of Cerebral Oxygenation|Completed|||171|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:01:05.97199|2018-06-01 03:01:05.97199
NCT00512434|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-05-03|2007-08-06|2007-08-07|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2007||2007-09-30|May 2017|2017-05-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|IMOCA||Percutaneous Autologous Bone-marrow Grafting for Open Tibial Shaft Fracture|Injection of Concentrated Autologous Bone-marrow (IMOCA) and Bone Union of Open Tibial Shaft Fracture: Randomized Study to Assess Efficiency of IMOCA in Addition to Standard of Care.|Completed||N/A|85|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-06-01 03:01:06.057096|2018-06-01 03:01:06.057096
NCT00512421|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-05|||2011-09-15|2007-08-05|2007-08-07|Estimate|||||||2011-09-15|2011-09-16|Estimate||||August 2011|2011-08-31||||||||Observational|||Navigated EM Total Knee Replacement: Accuracy Study|Phase 2 Study of Computer Assisted Surgery vs Conservative Surgery- Accuracy Study.|Terminated|||200|Anticipated|Hadassah Medical Organization|||3||f||||||||||||||2018-06-01 03:01:06.138441|2018-06-01 03:01:06.138441
NCT00512408|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2008-10-16|2007-08-06|2007-08-07|Estimate|||||||2008-10-16|2008-10-17|Estimate|July 2006||2006-07-31|August 2007|2007-08-31|March 2007|Actual|2007-03-31|||||Observational|||Testosterone Improves Exercise Oxygen Uptake, Insulin Resistance and Muscle Strength in Elderly Patients With Chronic Heart Failure|Long-Acting Testosterone Improves Exercise Oxygen Uptake, Insulin Resistance and Muscle Strength in Elderly Patients With Chronic Heart Failure|Terminated|||||IRCCS San Raffaele|||2||f||||||||||||||2018-06-01 03:01:06.198061|2018-06-01 03:01:06.198061
NCT00512395|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2015-03-09|2007-08-06|2007-08-07|Estimate|||||||2015-03-09|2015-03-10|Estimate|November 2004||2004-11-30|March 2015|2015-03-31|January 2007|Actual|2007-01-31|||||Interventional|||Influence of Epidural Analgesia in Elective Laparoscopic Colorectal Resections|Influence of Epidural Analgesia in Elective Laparoscopic Colorectal Resections|Completed||Phase 4|75|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 03:01:06.257109|2018-06-01 03:01:06.257109
NCT00512382|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2011-09-04|2007-08-06|2007-08-07|Estimate|||||||2011-09-04|2011-09-07|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Observational|||The Nature of Reflux-respiratory Symptoms Association in Difficult to Treat Wheezing\Coughing Babies|The Nature of Reflux-respiratory Symptoms Association in Difficult to Treat Asthmatic/Wheezing Babies Using Impedance and Wheezy Monitoring|Completed|||15|Actual|Wolfson Medical Center|||2||f||||t||||||||||2018-06-01 03:01:06.330475|2018-06-01 03:01:06.330475
NCT00512369|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2011-07-14|2007-08-06|2007-08-07|Estimate|||||||2011-07-14|2011-07-18|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|||||Observational|||Effects of PA-1 Transcriptional Regulation on Monocyte Function|Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function|Terminated|||125|Anticipated|Vanderbilt University||||Investigator left institution|f||||f||||||||||2018-06-01 03:01:06.468404|2018-06-01 03:01:06.468404
NCT00512356|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2017-08-03|2007-08-06|2007-08-07|Estimate|||||||2017-08-03|2017-08-04|Actual|December 2000||2000-12-31|August 2017|2017-08-31|April 2003|Actual|2003-04-30|February 25, 2003|Actual|2003-02-25||Interventional|||Efficacy and Safety Study of Anti-Adhesion Product in the Prevention of Intraperitoneal Adhesions|Study to Evaluate the Efficacy and Safety of Anti-Adhesion Product in the Prevention of Intraperitoneal Adhesions|Completed||Phase 2|46|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-06-01 03:01:06.522863|2018-06-01 03:01:06.522863
NCT00512343|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2018-01-06|2007-08-03|2007-08-07|Estimate|||||||2018-01-06|2018-01-09|Actual|June 2002|Actual|2002-06-30|January 2018|2018-01-31|September 2030|Anticipated|2030-09-30|December 2020|Anticipated|2020-12-31||Observational|||Synovial Fluid Bank From Arthritic Patients|Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.|Recruiting|||500|Anticipated|Université de Sherbrooke|||||f||||t||||||Samples Without DNA|"~     Synovial fluids from joints with effusion Sereum samples drawn on the same day~   "|No||2018-06-01 03:01:06.583498|2018-06-01 03:01:06.583498
NCT00512330|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2008-08-05|2007-08-06|2007-08-07|Estimate|||||||2008-08-05|2008-08-06|Estimate|August 2007||2007-08-31|August 2008|2008-08-31|August 2008|Anticipated|2008-08-31|||||Observational|||Lipoarabinomannan (LAM) Enzyme-Linked Immunosorbent Assay (ELISA) in Diagnostics of Childhood Tuberculosis (TB)|Evaluation of Urine Lipoarabinomannan ELISA In Diagnostics of Childhood Tuberculosis|Unknown status|Recruiting||250|Anticipated|University Hospital, Bonn|||||f||||f||||||||||2018-06-01 03:01:06.651194|2018-06-01 03:01:06.651194
NCT00512317|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03||2012-04-18|2013-10-14|2007-08-06|2007-08-07|Estimate||||2012-04-18|2012-04-20|Estimate|2013-10-14|2013-11-07|Estimate|June 2007||2007-06-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2009|Actual|2009-12-31||Interventional|||Open-label Extension to Protocol 1042-0600|An Open-label Extension Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as add-on Therapy in Adult Patients With Epilepsy Consisting of Uncontrolled Partial-onset Seizures.|Completed||Phase 2|125|Actual|Marinus Pharmaceuticals||1|||f||||f||||||||||2018-06-01 03:01:06.721102|2018-06-01 03:01:06.721102
NCT00512304|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2013-03-04|2007-08-06|2007-08-07|Estimate|||||||2013-03-04|2013-03-05|Estimate|August 2007||2007-08-31|March 2013|2013-03-31||||December 2012|Actual|2012-12-31||Interventional|TRACE||Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)|Feasibility Study of 2 Parallel Phases II Pre or Postgastrectomy in Patients With Gastric Cancer (FOLFIRI-radiotherapy Plus 5 Fluorouracil-surgery or Surgery-FOLFIRI-radiotherapy Plus 5 Fluorouracil)|Completed||Phase 2|63|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-06-01 03:01:06.812604|2018-06-01 03:01:06.812604
NCT00512291|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2011-09-26|2007-08-06|2007-08-07|Estimate|||||||2011-09-26|2011-09-27|Estimate|June 2005||2005-06-30|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2007|Actual|2007-08-31||Interventional|||Subcutaneous Olanzapine for Hyperactive or Mixed Delirium|Study of Subcutaneous Olanzapine for Hyperactive or Mixed Delirium|Completed||N/A|25|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:01:06.87651|2018-06-01 03:01:06.87651
NCT00512278|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|2017-03-31||2017-08-15|2007-08-03|2007-08-07|Estimate|2017-08-15|2017-09-13|Actual||||2017-08-15|2017-09-13|Actual|July 2007||2007-07-31|August 2017|2017-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PARTNER||Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C|Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection|Completed||Phase 2|146|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-06-01 03:01:06.970911|2018-06-01 03:01:06.970911
NCT00512265|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2013-08-27|2007-08-06|2007-08-07|Estimate|||||||2013-08-27|2013-08-28|Estimate|January 2006||2006-01-31|August 2013|2013-08-31|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|||Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer|Influence of N-Acetylcysteine on Morbidity, Oxygenation and Cytokine Levels in Partial or Total Esophagectomy for Cancer. A Multicenter, Prospective, Randomised Double Blind, Placebo-controlled Study|Completed||Phase 4|29|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 03:01:07.34839|2018-06-01 03:01:07.34839
NCT00512252|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2014-07-28||2016-10-27|2007-08-06|2007-08-07|Estimate|2014-09-12|2014-09-22|Estimate||||2016-10-27|2016-12-12|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|AMD3100+MEC|The 6 participants that were enrolled in Dose Level 3 in the Phase I portion of the study were carried over to the Phase II analysis. 40 additional patients were enrolled in the Phase II portion of the study using the Dose Level 3 dose.|AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia|A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML|Completed||Phase 1/Phase 2|52|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 03:01:07.501135|2018-06-01 03:01:07.501135
NCT00512239|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2018-01-06|2007-08-06|2007-08-07|Estimate|||||||2018-01-06|2018-01-09|Actual|November 1999|Actual|1999-11-30|January 2018|2018-01-31|September 2027|Anticipated|2027-09-30|June 2022|Anticipated|2022-06-30|10 Years|Observational [Patient Registry]|EUPA||Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset|Early Prediction of Patient-related and Radiological Outcomes in Patients With Recent-onset Inflammatory Polyarthritis (EPA) Using Established and Novel Independent Predictors|Recruiting|||1000|Anticipated|Université de Sherbrooke|||1||f||||t||||||Samples With DNA|"~     Serum, genomic DNA and RNA from peripheral blood, PBMC used for in vitro osteoclastogenesis~   "|No|Anonymized data to be shared following individual agreements|2018-06-01 03:01:08.461627|2018-06-01 03:01:08.461627
NCT00512226|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-05|||2011-08-25|2007-08-06|2007-08-07|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia|Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia Using T2* Cardiac MRI.|Completed||N/A|50|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:01:08.534236|2018-06-01 03:01:08.534236
NCT00512213|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2012-04-21|2007-08-06|2007-08-07|Estimate|||||||2012-04-21|2012-04-24|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery|Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery: A Single-center Double-blinded Controlled Randomized Superiority Trial|Completed||N/A|154|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-06-01 03:01:08.590427|2018-06-01 03:01:08.590427
NCT00512200|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2015-10-14|2007-08-06|2007-08-07|Estimate|||||||2015-10-14|2015-10-16|Estimate|July 2007||2007-07-31|October 2015|2015-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Postoperative Cognitive Dysfunction in Geriatric Patients|Postoperative Cognitive Dysfunction in Geriatric Patients: the Role of Intraoperative Cerebral Perfusion and Perioperative Anticholinergic Medication|Completed|||280|Actual|University Hospital, Basel, Switzerland|||3||f||||f||||||||||2018-06-01 03:01:08.76185|2018-06-01 03:01:08.76185
NCT00512187|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2007-08-06|2007-08-06|2007-08-07|Estimate|||||||2007-08-06|2007-08-07|Estimate|November 2005||2005-11-30|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial|Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial|Completed||Phase 4|||Universita di Verona||1|||f||||f||||||||||2018-06-01 03:01:08.838365|2018-06-01 03:01:08.838365
NCT00512174|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2007-08-06|2007-08-06|2007-08-07|Estimate|||||||2007-08-06|2007-08-07|Estimate|August 2007||2007-08-31|August 2007|2007-08-31||||||||Interventional|||Prospective Trial to Evaluate Efficacy and Accuracy of a Portable Ultrasound Scanner for Non-Invasive Bladder Volume Measurement (BladderScan BVI3000) in Patients After Radical Cystectomy and Bladder Reconstruction|Prospective Trial to Evaluate Efficacy and Accuracy of a Portable Ultrasound Scanner for Non-Invasive Bladder Volume Measurement (BladderScan BVI3000) in Patients After Radical Cystectomy and Bladder Reconstruction|Unknown status|Recruiting|N/A|||Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:01:08.902604|2018-06-01 03:01:08.902604
NCT00512161|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2017-01-17|2007-08-06|2007-08-07|Estimate|||||||2017-01-17|2017-01-19|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Placement of Permanent Pacemaker Study|A Retrospective Study to Determine the Frequency of Indications That Lead to the Placement of Permanent Pacemakers After Cardiac Surgery|Completed|||500|Actual|Weill Medical College of Cornell University|||||f||||f||||||||No||2018-06-01 03:01:08.969765|2018-06-01 03:01:08.969765
NCT00512148|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|2010-12-20||2017-10-11|2007-08-03|2007-08-07|Estimate|2011-02-01|2011-02-03|Estimate||||2017-10-11|2017-11-13|Actual|July 2007||2007-07-31|October 2017|2017-10-31|April 2011|Actual|2011-04-30|January 2010|Actual|2010-01-31||Interventional|||Study of Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury|An Open Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Neurogenic Bladder Following Spinal Cord Injury|Terminated||Phase 2|7|Actual|Tengion||1||24 months follow up completed without substantial change to the profile.|f||||t||||||||||2018-06-01 03:01:09.03972|2018-06-01 03:01:09.03972
NCT00512135|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2013-02-21|2007-08-06|2007-08-07|Estimate|||||||2013-02-21|2013-02-22|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of IncobotulinumtoxinA (Xeomin) in the Treatment of Glabellar Frown Lines|A Prospective, Open-label, Multicenter, Repeat-dose Trial to Investigate the Safety and Efficacy of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines|Completed||Phase 3|796|Actual|Merz Pharmaceuticals GmbH||1|||f||||f||||||||||2018-06-01 03:01:09.249704|2018-06-01 03:01:09.249704
NCT00512122|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2015-07-29|2007-08-03|2007-08-07|Estimate|||||||2015-07-29|2015-07-31|Estimate|August 2007||2007-08-31|July 2015|2015-07-31|December 2021|Anticipated|2021-12-31|February 2011|Actual|2011-02-28||Interventional|EPaNIC||Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients|Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients|Active, not recruiting||Phase 4|4640|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-06-01 03:01:09.420807|2018-06-01 03:01:09.420807
NCT00512109|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2018-04-20|2007-08-03|2007-08-07|Estimate|||||||2018-04-20|2018-04-24|Actual|August 2007||2007-08-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|VISION||Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study (VISION)|Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study|Completed|||40060|Actual|McMaster University|||||f||||f||||||||||2018-06-01 03:01:09.53897|2018-06-01 03:01:09.53897
NCT00512096|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|2010-11-03||2012-07-27|2007-08-06|2007-08-07|Estimate|2010-11-03|2010-12-08|Estimate||||2012-07-27|2012-08-01|Estimate|August 1999||1999-08-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis|A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:01:09.631941|2018-06-01 03:01:09.631941
NCT00512083|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2009-09-24|2007-08-06|2007-08-07|Estimate|||||||2009-09-24|2009-09-25|Estimate|July 2007||2007-07-31|September 2009|2009-09-30||||April 2009|Actual|2009-04-30||Interventional|||Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia|An Open Label Randomized Controlled Dose Escalating Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia|Completed||Phase 2|70|Anticipated|Antisoma Research|||||||||||||||||||2018-06-01 03:01:09.840281|2018-06-01 03:01:09.840281
NCT00512070|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2017-11-08|2007-08-06|2007-08-07|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2007||2007-07-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine|Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality|Active, not recruiting||N/A|20|Anticipated|Seattle Institute for Biomedical and Clinical Research||2|||f||||t||||||||||2018-06-01 03:01:09.933115|2018-06-01 03:01:09.933115
NCT00512057|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2010-06-25|2007-08-06|2007-08-07|Estimate|||||||2010-06-25|2010-06-28|Estimate|June 2008||2008-06-30|February 2009|2009-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|APEX||APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X|APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X|Completed||Phase 4|40|Anticipated|University of Dundee||2|||f||||t||||||||||2018-06-01 03:01:10.029122|2018-06-01 03:01:10.029122
NCT00512044|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2015-06-23|2007-08-06|2007-08-07|Estimate|||||||2015-06-23|2015-06-24|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|May 2008|Anticipated|2008-05-31|November 2007|Actual|2007-11-30||Interventional|||Local Versus General Anaesthesia in Stapled Hemorrhoidectomy|Local vs General Anaesthesia in Stapled Hemorrhoidectomy: A Multicentric Controlled Randomized Trial|Withdrawn||Phase 4|0|Actual|University of Lausanne Hospitals||2||slow recruitment, internal problems with the study protocol|f||||f||||||||||2018-06-01 03:01:10.102338|2018-06-01 03:01:10.102338
NCT00512031|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2011-07-15|2007-08-06|2007-08-07|Estimate|||||||2011-07-15|2011-07-18|Estimate|January 2007||2007-01-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Characterizing PAI-1 Modulation on Monocyte Adhesion|Characterizing the Effects of PAI-1 Modulation on Human Monocyte Function - The Effect of PAI-1 Post-transcriptional Regulation on Human Monocyte Adhesion|Terminated|||50|Anticipated|Vanderbilt University||||Investigator left institution|f||||f||||||||||2018-06-01 03:01:10.183959|2018-06-01 03:01:10.183959
NCT00512018|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2013-04-17|2007-08-06|2007-08-07|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2005||2005-01-31|April 2013|2013-04-30|July 2007|Actual|2007-07-31|December 2006|Actual|2006-12-31||Interventional|||Neuromuscular Electrical Stimulation and Isokinetic Training|Neuromuscular Electrical Stimulation and Isokinetic Training: Effects on Strength and Neuromuscular Properties|Completed||N/A|20|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-06-01 03:01:10.246515|2018-06-01 03:01:10.246515
NCT00512005|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-06|||2009-06-23|2007-08-06|2007-08-07|Estimate|||||||2009-06-23|2009-06-24|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|December 2013|Anticipated|2013-12-31|December 2009|Anticipated|2009-12-31||Interventional|VIVID||VIVID - Valvular and Ventricular Improvement Via iCoapsys Delivery - Feasibility Study|Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) Feasibility Study|Unknown status|Recruiting|Phase 1|30|Anticipated|Myocor|||||f||||t||||||||||2018-06-01 03:01:10.314408|2018-06-01 03:01:10.314408
NCT00511992|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|2017-04-14||2017-06-02|2007-08-03|2007-08-06|Estimate|2017-06-02|2017-07-02|Actual||||2017-06-02|2017-07-02|Actual|July 2007||2007-07-31|June 2017|2017-06-30|August 3, 2015|Actual|2015-08-03|August 3, 2015|Actual|2015-08-03||Interventional|||Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer|Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer|Completed||Phase 2|20|Actual|University of Oklahoma||1|||f||||t||||||||||2018-06-01 03:01:10.407013|2018-06-01 03:01:10.407013
NCT00511979|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2012-06-25|2007-08-03|2007-08-06|Estimate|||||||2012-06-25|2012-06-26|Estimate|August 1999||1999-08-31|June 2012|2012-06-30|June 2000|Actual|2000-06-30|February 2000|Actual|2000-02-29||Interventional|||Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin|Effect of Different Doses of Inhaled Technosphere Insulin on Glucose Infusion Rates During Euglycemic Clamps in Comparison to a Subcutaneous Injection of Regular Human Insulin|Completed||Phase 1|12|Actual|Mannkind Corporation||4|||f||||||||||||||2018-06-01 03:01:10.587549|2018-06-01 03:01:10.587549
NCT00511966|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2011-05-18|2007-08-02|2007-08-06|Estimate|||||||2011-05-18|2011-05-19|Estimate||||April 2010|2010-04-30|November 2002|Actual|2002-11-30|||||Observational|||Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol|Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol|Terminated|||1049|Actual|Janssen-Cilag, S.A.|||2|Due to the achievement of minimum required sample size and new changes in local regulations.|f||||f||||||||||2018-06-01 03:01:10.643051|2018-06-01 03:01:10.643051
NCT00511953|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2011-06-06|2007-08-02|2007-08-06|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women|A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 2|108|Anticipated|Depomed||2|||f||||f||||||||||2018-06-01 03:01:10.732119|2018-06-01 03:01:10.732119
NCT00511940|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2011-06-21|2007-08-03|2007-08-06|Estimate|||||||2011-06-21|2011-06-22|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Acamprosate in the Treatment of Binge-Eating Disorder||Completed||Phase 2/Phase 3|40|Anticipated|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 03:01:10.834028|2018-06-01 03:01:10.834028
NCT00511927|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2014-02-18|2007-08-03|2007-08-06|Estimate|||||||2014-02-18|2014-02-20|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Growth Hormone Deficiency in Chronic Heart Failure: an Observational Study|Observational Study on Prevalence and Prognostic Value of Growth Hormone Deficiency in Patients With Chronic Heart Failure|Completed|||250|Actual|Federico II University|||2||f||||f||||||Samples Without DNA|"~     Sera of the patients at time-points upon recruitment and after 12 months~   "|||2018-06-01 03:01:10.901896|2018-06-01 03:01:10.901896
NCT00511914|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|2012-12-10||2013-01-18|2007-08-03|2007-08-06|Estimate|2012-12-10|2013-01-17|Estimate||||2013-01-18|2013-01-24|Estimate|July 2007||2007-07-31|January 2013|2013-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008|A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture, Using the Strain Composition 2007/2008, When Administered to Adult and Elderly Subjects|Completed||Phase 3|135|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:01:10.977003|2018-06-01 03:01:10.977003
NCT00511901|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|2013-08-27||2013-12-27|2007-08-03|2007-08-06|Estimate|2013-08-27|2013-11-11|Estimate||||2013-12-27|2014-01-31|Estimate|November 2005||2005-11-30|November 2011|2011-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Intention to treat|Prevalence and Treatment of Anemia in Rehabilitation Patients|Prevalence and Treatment of Anemia in Patients Admitted to Subacute Rehabilitation Hospital|Terminated||Phase 4|22|Actual|Rutgers, The State University of New Jersey|Limited number of eligible subjects, burdensome protocol requirements impeded recruitment, controversy concerning safety of epoetin alpha which led to early termination of study|2||"Study enrollment was suspended in response to an FDA alert regarding the study drug. The study~   was subsequently terminated"|f||||t||||||||||2018-06-01 03:01:11.261682|2018-06-01 03:01:11.261682
NCT00511888|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2008-10-16|2007-08-03|2007-08-06|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2004||2004-01-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Observational|||Nebivolol Versus Carvedilol in Patients With Heart Failure|Effects of Nebivolol Versus Carvedilol in Hypertensive Patients With Chronic Heart Failure|Terminated|||160|Actual|IRCCS San Raffaele||||is finish|f||||t||||||||||2018-06-01 03:01:11.801148|2018-06-01 03:01:11.801148
NCT00511875|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2012-10-04|2007-08-03|2007-08-06|Estimate|||||||2012-10-04|2012-10-08|Estimate|July 2008||2008-07-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|POC1||Evaluation of Doxycyline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy|Evaluation of Effect of Doxycyline Verses Placebo on Diabetic Retinopathy Progression and Retinal Function in Patients With Severe Non-proliferative or Mild or Moderate (Non-high-risk) Proliferative Diabetic Retinopathy|Completed||Phase 2|28|Actual|Penn State University||2|||f||||t||||||||||2018-06-01 03:01:11.863445|2018-06-01 03:01:11.863445
NCT00511862|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2013-10-17||2014-06-05|2007-08-03|2007-08-06|Estimate|2014-04-28|2014-05-23|Estimate||||2014-06-05|2014-06-10|Estimate|January 2007||2007-01-31|February 2014|2014-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||Subjects treated with TheraSphere were enrolled and assigned to groups based on their primary cancer type. The total population and each subgroup population was analyzed for safety, progression and survival endpoints. In the neuroendocrine group, a median overall survival was not achieved so a post-hoc analysis of 2 year survival was performed.|TheraSphere for the Treatment of Liver Metastases|TheraSphere for the Treatment of Liver Metastases: An Open Label Trial of TheraSphere in Patients With Liver Metastases From Primary Colorectal Cancer, Neuroendocrine Cancer or Non-colorectal/Non-neuroendocrine Cancer|Completed||Phase 2|151|Actual|BTG International Inc.||1|||f||||f||||||||||2018-06-01 03:01:11.961194|2018-06-01 03:01:11.961194
NCT00511849|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2010-02-16|2007-08-03|2007-08-06|Estimate|||||||2010-02-16|2010-02-17|Estimate|November 2005||2005-11-30|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors|Phase I Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Malignancies|Completed||Phase 1|43|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:01:12.253334|2018-06-01 03:01:12.253334
NCT00511836|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2010-06-10||2017-06-08|2007-08-03|2007-08-06|Estimate|2010-11-08|2010-12-07|Estimate||||2017-06-08|2017-07-11|Actual|July 2007||2007-07-31|June 2017|2017-06-30|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults|The Effects of VIVITROL® on Alcohol-Related Cue-Induced Craving and BOLD [Blood Oxygen-level-dependent] Functional Magnetic Resolution Imaging (fMRI) Signal Activation Patterns|Completed||Phase 4|31|Actual|Alkermes, Inc.|The study was powered to detect whether VIVITROL blocks the fMRI BOLD signal increase in response to alcohol-related cues as compared to placebo. Results of the secondary endpoints should be interpreted with caution.|2|||f||||f||||||||||2018-06-01 03:01:12.324503|2018-06-01 03:01:12.324503
NCT00511823|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2017-08-02|2007-08-02|2007-08-06|Estimate|||||||2017-08-02|2017-08-03|Actual|July 23, 2007|Actual|2007-07-23|August 2017|2017-08-31|September 21, 2007|Actual|2007-09-21|September 21, 2007|Actual|2007-09-21||Interventional|||The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects|An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:01:12.633234|2018-06-01 03:01:12.633234
NCT00511810|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|2013-03-21||2016-04-29|2007-08-03|2007-08-06|Estimate|2014-12-03|2014-12-04|Estimate||||2016-04-29|2016-05-27|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder|Evaluation of Omega-3 Fatty Acids as a Treatment-adjunct in Adolescent Patients With Major Depressive Disorder Exhibiting Partial Response to SSRI Medications: An Open-label Neuroimaging Trial|Completed||Phase 2/Phase 3|20|Actual|University of Cincinnati||2|||f||||t||||||||No||2018-06-01 03:01:12.727794|2018-06-01 03:01:12.727794
NCT00511797|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|2010-04-15||2016-11-30|2007-08-03|2007-08-06|Estimate|2010-09-10|2010-10-04|Estimate||||2016-11-30|2017-01-26|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study|A Multicenter, Double-blind, Randomized, Placebo-controlled Comparative Study to Investigate the Optimal Dose of Drospirenone for Dysmenorrhea With SH T04740A [Drospirenone 1 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)], SH T 04740E [Drospirenone 2 mg/Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] and SH T00186D [Drospirenone 3 mg/ Ethinylestradiol 20 µg (as ß-cyclodextrin Clathrate)] Administered Orally for 16 Weeks (4 Cycles), and to Confirm the Efficacy of SH T00186D for Dysmenorrhea.|Completed||Phase 2/Phase 3|249|Actual|Bayer||4|||f||||f||||||||||2018-06-01 03:01:13.898697|2018-06-01 03:01:13.898697
NCT00511784|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2016-07-15|2007-08-02|2007-08-06|Estimate|||||||2016-07-15|2016-07-19|Estimate|November 2006||2006-11-30|July 2016|2016-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.|Postmarketing Study of ORTHO EVRA and Levonorgestrel Oral Contraceptives in Relation to Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction.|Completed|||440|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||2||f||||||||||||||2018-06-01 03:01:15.76949|2018-06-01 03:01:15.76949
NCT00511771|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2010-11-16|2007-08-03|2007-08-06|Estimate|||||||2010-11-16|2010-11-18|Estimate||||November 2010|2010-11-30||||||||Expanded Access|||A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation|A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation|No longer available|||||Novartis|||||||||||||||||||2018-06-01 03:01:15.828151|2018-06-01 03:01:15.828151
NCT00511758|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2012-07-31|2007-08-03|2007-08-06|Estimate|||||||2012-07-31|2012-08-01|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Digital Imaging Aid for Assessment of Cervical Dysplasia|Pilot Study of a Digital Imaging Aid for Assessment of Cervical Dysplasia|Terminated|||3|Actual|M.D. Anderson Cancer Center|||1|Low accrual rate.|f||||f||||||||||2018-06-01 03:01:15.879583|2018-06-01 03:01:15.879583
NCT00511745|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2011-05-18|2007-08-02|2007-08-06|Estimate|||||||2011-05-18|2011-05-19|Estimate||||April 2010|2010-04-30|November 2002|Actual|2002-11-30|||||Observational|||Safety of Rabeprazole in Patients Under Multiple Treatments|Safety of Rabeprazole in Patients Under Multiple Treatments|Terminated|||2157|Actual|Janssen-Cilag, S.A.|||1|Due to the achievement of minimum required sample size and new changes in local regulations.|f||||f||||||||||2018-06-01 03:01:15.96666|2018-06-01 03:01:15.96666
NCT00511732|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2012-04-27|2007-08-03|2007-08-06|Estimate|||||||2012-04-27|2012-04-30|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|August 2007|Actual|2007-08-31|August 2005|Actual|2005-08-31||Interventional|||18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes|A Randomized, Double-blind, Controlled, Stepwise Titration Study to Evaluate Dose Response to Prandial Administration of Inhaled Technosphere/Insulin or Technosphere in Patients With Type 2 Diabetes Mellitus Who Are Sub-optimally Treated|Completed||Phase 2|227|Actual|Mannkind Corporation||2|||f||||||||||||||2018-06-01 03:01:16.127248|2018-06-01 03:01:16.127248
NCT00511719|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2011-06-28|2007-08-03|2007-08-06|Estimate|||||||2011-06-28|2011-06-29|Estimate|February 2004||2004-02-29|June 2011|2011-06-30|March 2005|Actual|2005-03-31|April 2004|Actual|2004-04-30||Interventional|||Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes|A Prospective, Controlled, Single-Center, Open-Label,Randomized, Replicated, Crossover Isoglycemic Glucose Clamp Study Evaluating Intrapatient Variability in Bioavailability of Technosphere® Insulin Compared With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes|Completed||Phase 2|13|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-06-01 03:01:16.2112|2018-06-01 03:01:16.2112
NCT00511706|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2012-08-01|2010-04-15|2012-08-01|2007-08-03|2007-08-06|Estimate|2012-08-01|2012-09-03|Estimate|2010-04-15|2010-04-20|Estimate|2012-08-01|2012-09-03|Estimate|November 2007||2007-11-30|August 2012|2012-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)||Completed||Phase 2|243|Actual|Allergan||2|||f||||f||||||||||2018-06-01 03:01:16.296776|2018-06-01 03:01:16.296776
NCT00511693|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2007-08-06|2007-08-03|2007-08-06|Estimate|||||||2007-08-06|2007-08-07|Estimate|June 2007||2007-06-30|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|ROCKET||Osteoporosis Coordinator for Low Volume Community Hospitals|Regional Osteoporosis Coordinator Knowledge Exchange Trial|Unknown status|Recruiting|N/A|300|Anticipated|Ontario Ministry of Health and Long Term Care||2|||f||||f||||||||||2018-06-01 03:01:16.6222|2018-06-01 03:01:16.6222
NCT00511680|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2012-08-07|2007-08-03|2007-08-06|Estimate|||||||2012-08-07|2012-08-08|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Beat the Blues: Treating Depression in African American Elders|Treating Depression in African American Elders: A Community-Academic Partnership|Completed||Phase 3|192|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:01:16.721567|2018-06-01 03:01:16.721567
NCT00511667|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2012-04-04||2016-08-23|2007-08-03|2007-08-06|Estimate|2012-05-22|2012-06-26|Estimate||||2016-08-23|2016-08-24|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes|Completed||Phase 1|70|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:01:16.817246|2018-06-01 03:01:16.817246
NCT00511654|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2017-08-02|2007-08-02|2007-08-06|Estimate|||||||2017-08-02|2017-08-04|Actual|June 12, 2007|Actual|2007-06-12|August 2017|2017-08-31|January 11, 2008|Actual|2008-01-11|January 11, 2008|Actual|2008-01-11||Interventional|||28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)|A Parallel Group, Single-Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GW823296 and Its Effect on the Pharmacokinetics of Midazolam After Once-Daily Repeated Oral Doses in Healthy Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:01:17.164705|2018-06-01 03:01:17.164705
NCT00511641|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2017-06-01|2007-08-03|2007-08-06|Estimate|||||||2017-06-01|2017-06-05|Actual|February 12, 2002|Actual|2002-02-12|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer|Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer|Active, not recruiting|||1342|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:01:17.256292|2018-06-01 03:01:17.256292
NCT00511628|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2011-05-18|2007-08-02|2007-08-06|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 2001||2001-07-31|March 2011|2011-03-31|January 2003|Actual|2003-01-31|||||Observational|||Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia|BMI-2002 Study: Evaluation of Functionality and Evolution of Body Weight of Psychotic Patients With a High Body Mass Index|Terminated|||1717|Actual|Janssen-Cilag, S.A.|||1|Due to the achievement of minimum required sample size and new changes in local regulations.|f||||f||||||||||2018-06-01 03:01:17.328029|2018-06-01 03:01:17.328029
NCT00511615|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2012-07-31|2007-08-03|2007-08-06|Estimate|||||||2012-07-31|2012-08-01|Estimate|March 2005||2005-03-31|July 2012|2012-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia|A Feasibility Study of Molecular Imaging for Detection of Cervical Intraepithelial Neoplasia|Completed|||30|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Tissue sample removal from the cervix using LEEP during the scheduled colposcopy.~   "|||2018-06-01 03:01:17.42326|2018-06-01 03:01:17.42326
NCT00511602|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2012-04-27|2007-08-03|2007-08-06|Estimate|||||||2012-04-27|2012-04-30|Estimate|December 2003||2003-12-31|April 2012|2012-04-30|December 2005|Actual|2005-12-31|November 2004|Actual|2004-11-30||Interventional|||Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes|Efficacy and Safety of Inhaled Technosphere Insulin Compared to Technosphere Placebo in Patients With Type 2 Diabetes Mellitus Following Diabetes Education|Completed||Phase 2|123|Actual|Mannkind Corporation||2|||f||||||||||||||2018-06-01 03:01:17.561576|2018-06-01 03:01:17.561576
NCT00511589|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2011-03-23|2007-08-03|2007-08-06|Estimate|||||||2011-03-23|2011-03-24|Estimate||||August 2007|2007-08-31||||||||Interventional|||Chagas Disease Diagnostic - Inconclusive Serology|PCR in Blood Cultures of Individuals With Positive and Inconclusive Serology for Chagas' Disease|Completed||N/A|||UPECLIN HC FM Botucatu Unesp|||||f||||||||||||||2018-06-01 03:01:17.621238|2018-06-01 03:01:17.621238
NCT00511576|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2015-01-06|2007-08-03|2007-08-06|Estimate|||||||2015-01-06|2015-01-08|Estimate|August 2007||2007-08-31|January 2015|2015-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors|A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination With Docetaxel (Taxotere®) in Subjects With Advanced Solid Malignancies|Terminated||Phase 1|54|Anticipated|Mirati Therapeutics Inc.||2||"Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103.~   All Celgene-sponsored trials with MGCD0103 will be closed."|f||||f||||||||||2018-06-01 03:01:17.682624|2018-06-01 03:01:17.682624
NCT00511563|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2015-02-26|2007-08-02|2007-08-06|Estimate|||||||2015-02-26|2015-03-02|Estimate|August 2007||2007-08-31|February 2015|2015-02-28||||November 2012|Actual|2012-11-30||Interventional|||A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679|A Double-blind, Randomised, Placebo-controlled, Three-period Crossover Study to Investigate the Pharmacodynamic Effect of Two CRF-1 Antagonists GSK561679 and GW876008 on Meal Induced Cortisol Responses in Patients With IBS.|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||1||Cancelled before active due to the results of emerging scientific data|f||||f||||||||||2018-06-01 03:01:17.77453|2018-06-01 03:01:17.77453
NCT00511550|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2008-03-03|2007-08-03|2007-08-06|Estimate|||||||2008-03-03|2008-03-05|Estimate|August 2005||2005-08-31|July 2007|2007-07-31|November 2007||2007-11-30|||||Observational|||Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors|Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors|Completed|||15||University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:01:17.834372|2018-06-01 03:01:17.834372
NCT00511537|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2013-08-01|2007-08-02|2007-08-06|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 1999||1999-01-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders|Standard of Care Trial: Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders|Completed|||30|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:01:17.885926|2018-06-01 03:01:17.885926
NCT00511524|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2017-08-03|2007-08-02|2007-08-06|Estimate|||||||2017-08-03|2017-08-07|Actual|June 26, 2007|Actual|2007-06-26|August 2017|2017-08-31|July 4, 2007|Actual|2007-07-04|July 4, 2007|Actual|2007-07-04||Interventional|||An Imaging Study to Investigate the Distribution of GW842166X in the Brain.|An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [11C]GW842166 in Healthy Subjects|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:01:17.9476|2018-06-01 03:01:17.9476
NCT00511511|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2010-01-04|2007-08-03|2007-08-06|Estimate|||||||2010-01-04|2010-01-05|Estimate|August 2007||2007-08-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|||||Observational|||Angiogenesis Inhibitors and Hypertension: Clinical Aspects|Angiogenesis Inhibitors and Hypertension: Clinical Aspects|Completed|||80|Anticipated|Erasmus Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood and urine samples~   "|||2018-06-01 03:01:18.010932|2018-06-01 03:01:18.010932
NCT00511498|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-03|||2008-11-28|2007-08-03|2007-08-06|Estimate|||||||2008-11-28|2008-12-01|Estimate|March 2006||2006-03-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Laparoscopic Radical Prostatectomy|Effect of Nightly Versus Prn Sildenafil on Early Return of Erectile Function Following Nerve-Sparing Laparoscopic Radical Prostatectomy|Completed||N/A|100|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:01:18.079386|2018-06-01 03:01:18.079386
NCT00511485|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02||2012-03-05|2015-02-09|2007-08-02|2007-08-06|Estimate||||2012-03-05|2012-03-08|Estimate|2015-02-09|2015-02-27|Estimate|August 2007||2007-08-31|February 2015|2015-02-28|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)|Protocol EC-FV-03: A Phase II Study of EC145 in Patients With Progressive Adenocarcinoma of the Lung|Completed||Phase 2|43|Actual|Endocyte||1|||f||||f||||||||||2018-06-01 03:01:18.15366|2018-06-01 03:01:18.15366
NCT00511472|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2012-04-10||2015-06-19|2007-08-03|2007-08-06|Estimate|2012-06-06|2012-07-11|Estimate||||2015-06-19|2015-07-15|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)|A Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK-0941 Before Each Meal (q.a.c) in Subjects With Type 2 Diabetes Being Treated With Basal Insulin|Completed||Phase 1|70|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:01:18.26188|2018-06-01 03:01:18.26188
NCT00511459|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02||2014-03-27|2015-10-07|2007-08-02|2007-08-03|Estimate||||2014-03-27|2014-04-23|Estimate|2015-10-07|2015-10-29|Estimate|July 2007||2007-07-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|August 2010|Actual|2010-08-31||Interventional|||Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients|A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination With Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer|Completed||Phase 2|228|Actual|Amgen||4|||f||||f||||||||||2018-06-01 03:01:18.702494|2018-06-01 03:01:18.702494
NCT00511446|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2013-06-25|2007-08-02|2007-08-03|Estimate|||||||2013-06-25|2013-06-26|Estimate|August 2007||2007-08-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|May 2010|Actual|2010-05-31||Interventional|||Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer|Phase II Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer|Completed||Phase 2|56|Actual|Martin-Luther-Universität Halle-Wittenberg||1|||f||||t||||||||||2018-06-01 03:01:18.864971|2018-06-01 03:01:18.864971
NCT00511433|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2011-07-28|2009-04-23|2014-11-14|2007-08-02|2007-08-03|Estimate|2011-07-28|2011-08-29|Estimate|2009-10-02|2009-10-06|Estimate|2014-11-14|2014-11-26|Estimate|October 2006||2006-10-31|November 2014|2014-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)|A Randomized, Open-Label, Comparative Trial to Evaluate the Effects on Ovarian Function of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 ug Ethinyl Estradiol (EE)|Completed||Phase 3|48|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:01:18.971208|2018-06-01 03:01:18.971208
NCT00511420|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2007-08-02|2007-08-02|2007-08-03|Estimate|||||||2007-08-02|2007-08-03|Estimate|April 2005||2005-04-30|August 2007|2007-08-31|December 2005|Actual|2005-12-31|||||Interventional|CoCD||Effects of Cocoa Products on Cardiovascular Disease Risk Factors|Effects of Cocoa Products on Cardiovascular Disease Risk Factors|Completed||Phase 3|113|Actual|University Rovira i Virgili||4|||f||||f||||||||||2018-06-01 03:01:20.350709|2018-06-01 03:01:20.350709
NCT00511407|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2012-11-29|2007-08-02|2007-08-03|Estimate|||||||2012-11-29|2012-12-03|Estimate|March 2004||2004-03-31|November 2012|2012-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure|A Multi-Center, Randomized, Phase II Study To Assess Safety and Efficacy With the Renal Assist Device (RAD) In Patients With Acute Renal Failure|Completed||Phase 2|58|Actual|RenaMed Biologics||2|||||||t||||||||||2018-06-01 03:01:20.869747|2018-06-01 03:01:20.869747
NCT00511394|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2008-10-14|2007-08-02|2007-08-03|Estimate|||||||2008-10-14|2008-10-15|Estimate|May 2007||2007-05-31|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis|Acute Hemodynamic Effects of Albumin Versus Normal Saline in Patients With Cirrhosis With Ascites: A Randomized Controlled Trial|Suspended||N/A|16|Anticipated|Govind Ballabh Pant Hospital||2|||f||||f||||||||||2018-06-01 03:01:21.256598|2018-06-01 03:01:21.256598
NCT00511381|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2012-02-28|2007-08-02|2007-08-03|Estimate|||||||2012-02-28|2012-03-01|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Observational|SoundGene||Genetic Testing in Detection of Late-Onset Hearing Loss|Utility of Genetic Testing in Detection of Late-Onset Hearing Loss|Completed|||3681|Actual|Mednax Center for Research, Education, Quality and Safety|||||f||||t||||||||||2018-06-01 03:01:21.558333|2018-06-01 03:01:21.558333
NCT00511368|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2010-01-15|2007-08-02|2007-08-03|Estimate|||||||2010-01-15|2010-01-20|Estimate|April 2006||2006-04-30|January 2010|2010-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*|Phase 2 Dose-escalating, P-C, D-B, Parallel Group Study in HIV Treatment-experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days *(PART B)|Completed||Phase 2|92|Actual|Myrexis Inc.||2|||f||||t||||||||||2018-06-01 03:01:21.761976|2018-06-01 03:01:21.761976
NCT00511355|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2011-07-28|2009-04-23|2017-03-10|2007-08-02|2007-08-03|Estimate|2011-07-28|2011-08-30|Estimate|2009-10-02|2009-10-06|Estimate|2017-03-10|2017-04-10|Actual|October 2006||2006-10-31|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)|A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate the Effects on Hemostasis, Lipids and Carbohydrate Metabolism, and on Adrenal and Thyroid Function of a Monophasic COC Containing 2.5 mg NOMAC and 1.5 mg E2 Compared to a Monophasic COC Containing 150 ug LNG and 30 ug EE|Completed||Phase 3|121|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:01:21.997017|2018-06-01 03:01:21.997017
NCT00511342|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2011-07-28|2009-09-10|2015-02-12|2007-08-02|2007-08-03|Estimate|2011-07-28|2011-08-29|Estimate|2009-09-10|2009-09-11|Estimate|2015-02-12|2015-03-03|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effects on Bone Mineral Density (BMD) of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG/EE (292005)(P05765)(COMPLETED)|An Open-Label, Randomized, Single Center Trial in Healthy Young Women, to Evaluate the Effects of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg NOMAC and 1.5 mg E2 on Bone Mineral Density (BMD) Compared to a Monophasic COC Containing 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol|Completed||Phase 3|110|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:01:23.424159|2018-06-01 03:01:23.424159
NCT00511329|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2015-05-15||2018-03-14|2007-08-02|2007-08-03|Estimate|2018-03-14|2018-04-12|Actual||||2018-03-14|2018-04-12|Actual|August 2007||2007-08-31|March 2018|2018-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||PI left institution suddenly in 2010 and studies were closed. Study records for participants cannot be located and possibly have been destroyed.|Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease|Growth and the Effect of Genotropin in Chronically Ill Children With Juvenile Rheumatoid Arthritis and With Crohn's Disease|Terminated||Phase 2/Phase 3|10|Actual|Nationwide Children's Hospital||1||PI left the institution|f||||f||||||||||2018-06-01 03:01:24.309481|2018-06-01 03:01:24.309481
NCT00511316|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2015-11-02|2007-08-02|2007-08-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Trial of Montelukast in Eosinophilic Esophagitis|A Randomized Placebo-Controlled Trial of Montelukast in Maintenance Therapy of Asymptomatic Eosinophilic Esophagitis|Completed||Phase 1|41|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:01:24.433716|2018-06-01 03:01:24.433716
NCT00511303|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2007-08-02|2007-08-02|2007-08-03|Estimate|||||||2007-08-02|2007-08-03|Estimate|August 2000||2000-08-31|August 2007|2007-08-31||||||||Interventional|||Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia|Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia Who Are Resistant to or Intolerant of *-Interferon. A Phase II Study|Completed||Phase 2|200||University of Bologna|||||f||||t||||||||||2018-06-01 03:01:24.504159|2018-06-01 03:01:24.504159
NCT00511290|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2007-08-02|2007-08-02|2007-08-03|Estimate|||||||2007-08-02|2007-08-03|Estimate||||August 2007|2007-08-31||||||||Observational|||Measurement of Soluble Factors and Particulate Matter in Induced Sputum and EBC in Inflammatory Diseases of the Lung||Completed|||||Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 03:01:24.557129|2018-06-01 03:01:24.557129
NCT00511277|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2011-06-20|2007-08-02|2007-08-03|Estimate|||||||2011-06-20|2011-06-21|Estimate|August 2007||2007-08-31|June 2011|2011-06-30|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode psychosis-a Pilot Study|Single-arm, Open-label and Multicenter Phase IV Study: Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode Psychosis - a Pilot Study|Completed||Phase 4|60|Anticipated|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|||||f||||f||||||||||2018-06-01 03:01:24.623644|2018-06-01 03:01:24.623644
NCT00511264|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2008-05-27|2007-08-02|2007-08-03|Estimate|||||||2008-05-27|2008-05-29|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Laparoscopic Ultrasound Guided Tissue Sampling in Patients With Cancer of the Upper Gastrointestinal Tract|Prospective Evaluation of the Impact of Laparoscopic Ultrasound (LUS) Guided Fine-Needle Aspiration or Tru-Cut Biopsy in Patients With Upper GI Tract Cancer|Completed|||250|Anticipated|Odense University Hospital|||||f||||f||||||||||2018-06-01 03:01:24.696276|2018-06-01 03:01:24.696276
NCT00511251|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2007-08-02|2007-08-02|2007-08-03|Estimate|||||||2007-08-02|2007-08-03|Estimate|January 2005||2005-01-31|August 2007|2007-08-31|April 2006|Actual|2006-04-30|||||Observational|||Analysis of Induced Sputum and Lung Biopsies by SEM: a Tool to Identify Source of Exposure of Workers to Hazardous Dust||Completed|||||Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 03:01:24.745836|2018-06-01 03:01:24.745836
NCT00511238|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2013-09-27||2017-08-02|2007-08-01|2007-08-03|Estimate|2013-10-11|2013-12-09|Estimate||||2017-08-02|2017-08-31|Actual|August 2007||2007-08-31|August 2017|2017-08-31|October 2012|Actual|2012-10-31|November 2010|Actual|2010-11-30||Interventional||Safety population: The safety population consists of all enrolled patients who received at least 1 dose of carfilzomib.|Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma|An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma|Completed||Phase 2|312|Actual|Amgen||2|||f||||f||||||||||2018-06-01 03:01:24.810113|2018-06-01 03:01:24.810113
NCT00511225|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2012-06-29|2007-08-02|2007-08-03|Estimate|||||||2012-06-29|2012-07-03|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|September 2011|Actual|2011-09-30|June 2010|Actual|2010-06-30||Interventional|Neph||Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease|Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease|Completed||N/A|47|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 03:01:25.645026|2018-06-01 03:01:25.645026
NCT00511212|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2011-07-20|2007-08-02|2007-08-03|Estimate|||||||2011-07-20|2011-07-21|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|June 2009|Anticipated|2009-06-30|||||Interventional|||Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive Tract|Clinical Study of Intravenous Immunoglobulin (IVIG) in Combination Therapy With Antibacterial Agents for Surgical Site Infection of the Lower Digestive Tract|Withdrawn||N/A|60|Anticipated|Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group||||No eligible patient.|f||||t||||||||||2018-06-01 03:01:25.736322|2018-06-01 03:01:25.736322
NCT00511199|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2011-07-28|2009-05-01|2014-11-14|2007-08-02|2007-08-03|Estimate|2011-07-28|2011-08-29|Estimate|2009-10-02|2009-10-06|Estimate|2014-11-14|2014-11-26|Estimate|May 2006||2006-05-31|November 2014|2014-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)|A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE)|Completed||Phase 3|2152|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:01:25.840485|2018-06-01 03:01:25.840485
NCT00511186|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2012-03-30|2007-08-02|2007-08-03|Estimate|||||||2012-03-30|2012-04-02|Estimate|May 2008||2008-05-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study in Sepsis Patients With Renal Failure|A Phase-IIa, Double-blind, Randomized, Placebo-controlled Study on the Safety and Early Efficacy of Alkaline Phosphatase in Sepsis Patients With Renal Failure|Terminated||Phase 2|36|Actual|AM-Pharma||2||sufficient POC to switch development from bovine AP to recombinant AP|f||||t||||||||||2018-06-01 03:01:26.548831|2018-06-01 03:01:26.548831
NCT00511173|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2012-04-17||2012-12-07|2007-08-02|2007-08-03|Estimate|2012-12-07|2012-12-11|Estimate||||2012-12-07|2012-12-11|Estimate|August 2006||2006-08-31|December 2012|2012-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm|Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing|Completed||Phase 4|102|Actual|Creighton University||1|||f||||f||||||||||2018-06-01 03:01:26.644597|2018-06-01 03:01:26.644597
NCT00511160|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2016-10-04|2007-08-02|2007-08-03|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae|Prevalence of Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae|Terminated||N/A|120|Actual|Robert Bosch Gesellschaft für Medizinische Forschung mbH||2||Study suspended due to logistical/personnel difficulties|f||||t||||||||No||2018-06-01 03:01:26.815133|2018-06-01 03:01:26.815133
NCT00511147|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2017-03-03||2017-05-08|2007-08-02|2007-08-03|Estimate|2017-03-24|2017-05-05|Actual||||2017-05-08|2017-06-12|Actual|May 2008||2008-05-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||IGIV Study for Chronic ITP Patients Ages 3-70|A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura|Completed||Phase 3|64|Actual|Grifols Biologicals Inc.||1|||f||||f|t|f||||||||2018-06-01 03:01:26.895075|2018-06-01 03:01:26.895075
NCT00511134|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2009-09-28||2012-03-09|2007-08-02|2007-08-03|Estimate|2009-11-03|2009-12-04|Estimate||||2012-03-09|2012-03-13|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban|A Placebo-Controlled, Randomized Trial of Eszopiclone for the Treatment of Bupropion- and Abstinence-Related Insomnia During Smoking Cessation|Terminated||Phase 4|4|Actual|Yale University||2||Study has been terminated due low recruitment of participant population.|f||||f||||||||||2018-06-01 03:01:27.155176|2018-06-01 03:01:27.155176
NCT00511121|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2007-08-02|2007-08-02|2007-08-03|Estimate|||||||2007-08-02|2007-08-03|Estimate|April 2001||2001-04-30|August 2007|2007-08-31||||||||Interventional|||Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)|An Exploratory Phase II Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON) in the Treatment of Chronic Myeloid Leukemia in Chronic Phase|Terminated||Phase 2|5||University of Bologna|||||f||||t||||||||||2018-06-01 03:01:27.351039|2018-06-01 03:01:27.351039
NCT00511108|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2010-01-08||2017-04-07|2007-08-02|2007-08-03|Estimate|2010-02-10|2010-03-05|Estimate||||2017-04-07|2017-05-12|Actual|July 11, 2007|Actual|2007-07-11|April 2017|2017-04-30|February 24, 2009|Actual|2009-02-24|February 24, 2009|Actual|2009-02-24||Interventional|||Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)|A Phase I Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Study the Safety, Efficacy, and Mechanism of Action of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet and Exercise|Completed||Phase 1|211|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:01:27.412707|2018-06-01 03:01:27.412707
NCT00511095|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2017-03-01|2010-06-17|2017-03-01|2007-08-01|2007-08-03|Estimate|2017-03-01|2017-04-12|Actual|2010-06-17|2010-06-22|Estimate|2017-03-01|2017-04-12|Actual|June 2007||2007-06-30|March 2017|2017-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine|An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV™|Completed||Phase 2|207|Actual|Dynavax Technologies Corporation||1|||f||||t||||||||Yes|There is a BLA in progress at this time. Data to be shared post approval. CRL accepted by FDA 3/2017|2018-06-01 03:01:27.988151|2018-06-01 03:01:27.988151
NCT00511082|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2008-07-01|2007-08-02|2007-08-03|Estimate|||||||2008-07-01|2008-07-02|Estimate|December 2007||2007-12-31|July 2008|2008-07-31|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma|Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma|Unknown status|Recruiting|Phase 1|42|Anticipated|Otsuka Beijing Research Institute||1|||f||||t||||||||||2018-06-01 03:01:28.291086|2018-06-01 03:01:28.291086
NCT00511069|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2008-11-21|2007-08-02|2007-08-03|Estimate|||||||2008-11-21|2008-11-24|Estimate|July 2006||2006-07-31|November 2008|2008-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia|A Phase II Study of Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia|Completed||Phase 2|3|Actual|University of Bologna|||||f||||||||||||||2018-06-01 03:01:28.384344|2018-06-01 03:01:28.384344
NCT00511056|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2011-07-07|2007-08-02|2007-08-03|Estimate|||||||2011-07-07|2011-07-11|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Observational|ARB||Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy|Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy|Completed|||700|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||f||||||Samples With DNA|"~     Blood samples required to provide Viral Load data and CD4 cell count~   "|||2018-06-01 03:01:28.452687|2018-06-01 03:01:28.452687
NCT00511043|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01||2012-09-07|2014-11-19|2007-08-01|2007-08-03|Estimate||||2012-09-11|2012-09-13|Estimate|2014-11-19|2014-12-09|Estimate|November 2005||2005-11-30|November 2014|2014-11-30|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma|Phase II Open Label Study of PTK787/ZK222584 in Adults Patients With Refractory or Relapsed Diffuse Large Cell Lymphoma|Terminated||Phase 2|20|Actual|Duke University||1||Manufacturer stopped drug development|f||||t||||||||||2018-06-01 03:01:28.520853|2018-06-01 03:01:28.520853
NCT00511030|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2008-01-21|2007-08-01|2007-08-03|Estimate|||||||2008-01-21|2008-01-23|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Assessment of Stability of Mail-in Capillary Hemoglobin A1c Test Kit|Assessment of Stability and Ease of Use of a Mail-in Capillary Blood Hemoglobin A!c Sample Kit|Completed|||23|Actual|Children's Mercy Hospital Kansas City|||||f||||f||||||None Retained|"~     Capillary blood~   "|||2018-06-01 03:01:28.601782|2018-06-01 03:01:28.601782
NCT00511017|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2012-07-27|2007-08-02|2007-08-03|Estimate|||||||2012-07-27|2012-07-31|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Doxercalciferol in Recurrent Pediatric Solid Tumors|A Phase I Study of Doxercalciferol in Recurrent Pediatric Solid Tumors|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 03:01:28.665014|2018-06-01 03:01:28.665014
NCT00511004|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|2015-07-02||2015-07-30|2007-08-02|2007-08-03|Estimate|2015-07-30|2015-08-31|Estimate||||2015-07-30|2015-08-31|Estimate|July 2007||2007-07-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effect of Albendazole Dose on Treatment of Lymphatic Filariasis|Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study|Completed||Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)|Study never fully enrolled so sample size was smaller than hoped for.|3|||f||||f||||||||||2018-06-01 03:01:28.772369|2018-06-01 03:01:28.772369
NCT00510991|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2008-02-26|2007-08-02|2007-08-03|Estimate|||||||2008-02-26|2008-03-03|Estimate|July 2006||2006-07-31|February 2008|2008-02-29|February 2008|Anticipated|2008-02-29|||||Interventional|||Non Invasive Ventilation in Acute Asthma|Non Invasive Ventilation in Acute Asthma|Unknown status|Recruiting|Phase 3|100|Anticipated|Postgraduate Institute of Medical Education and Research||1|||f||||t||||||||||2018-06-01 03:01:29.17038|2018-06-01 03:01:29.17038
NCT00510978|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2011-06-13|2007-08-02|2007-08-03|Estimate|||||||2011-06-13|2011-06-14|Estimate|January 2002||2002-01-31|August 2007|2007-08-31|November 2007||2007-11-30|||||Interventional|PROGID||Probiotics in GastroIntestinal Disorders|One Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative Colitis|Unknown status|Active, not recruiting|Phase 2/Phase 3|360|Actual|University College Cork||3|||f||||t||||||||||2018-06-01 03:01:29.269252|2018-06-01 03:01:29.269252
NCT00510965|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2012-06-14|2007-08-02|2007-08-03|Estimate|||||||2012-06-14|2012-06-15|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)|Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome)|Completed||Phase 2|10|Actual|University Hospital, Bonn||1|||f||||f||||||||||2018-06-01 03:01:29.356485|2018-06-01 03:01:29.356485
NCT00510952|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2009-09-25||2010-10-12|2007-08-01|2007-08-03|Estimate|2009-09-25|2009-11-03|Estimate||||2010-10-12|2010-10-21|Estimate|August 2007||2007-08-31|October 2010|2010-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|IOPE||Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)|The PERSISTENT Trial: A Prospective Randomized Trial Comparing Insulin Lispro Protamine Suspension to Insulin Glargine in Patients With Type 2 Diabetes on Anti-hyperglycemic Medications|Completed||Phase 3|471|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:01:29.466927|2018-06-01 03:01:29.466927
NCT00510939|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2009-08-13|2007-08-02|2007-08-03|Estimate|||||||2009-08-13|2009-08-14|Estimate|March 2007||2007-03-31|August 2009|2009-08-31||||||||Interventional|HEMOS AML 0106||Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia|Phase II, Open-Label, Multi-centre, 2-part Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Conventional Chemotherapy ( >18 Years) or in Patients With Acute Myeloid Leukemia in First Relapse ( >60 Years)|Unknown status|Recruiting|Phase 2|72|Anticipated|University of Bologna|||||f||||t||||||||||2018-06-01 03:01:30.22901|2018-06-01 03:01:30.22901
NCT00510926|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-02|||2007-08-02|2007-08-02|2007-08-03|Estimate|||||||2007-08-02|2007-08-03|Estimate|January 2004||2004-01-31|August 2007|2007-08-31|November 2006||2006-11-30|||||Interventional|||Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase|"CML/021 A Phase II Exploratory Study of IMATINIB High Dose (800mg/gg) in the Treatment of Newly Diagnosed Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase"|Completed||Phase 2|80||University of Bologna|||||f||||||||||||||2018-06-01 03:01:30.286613|2018-06-01 03:01:30.286613
NCT00510913|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2007-07-31|2007-07-31|2007-08-02|Estimate|||||||2007-07-31|2007-08-02|Estimate|February 1999||1999-02-28|July 2007|2007-07-31|September 2000|Actual|2000-09-30|||||Interventional|CRAF||A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure|Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure|Completed||Phase 4|450|Anticipated|Astellas Pharma Inc|||||f||||t||||||||||2018-06-01 03:01:30.349098|2018-06-01 03:01:30.349098
NCT00510900|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2016-01-04|2007-08-01|2007-08-02|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2005||2005-08-31|January 2016|2016-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Effects of Left Atrial Appendage Occlusion|Effects of Left Atrial Appendage Occlusion|Withdrawn|||0|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:01:30.41976|2018-06-01 03:01:30.41976
NCT00510887|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2013-12-18||2014-04-29|2007-08-01|2007-08-02|Estimate|2014-03-19|2014-04-21|Estimate||||2014-04-29|2014-05-12|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|November 2012|Actual|2012-11-30||Interventional||All patients who were consented are included in the baseline analysis population.|Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma|A Phase II Study of Bortezomib in Combination With Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (VR-FND) for Relapsed or Refractory Follicular Lymphoma|Terminated||Phase 2|14|Actual|Duke University||1||Low accrual.|f||||f||||||||||2018-06-01 03:01:31.485626|2018-06-01 03:01:31.485626
NCT00509808|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2010-04-05|2007-07-31|2007-08-01|Estimate|||||||2010-04-05|2010-04-06|Estimate|January 2007||2007-01-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2008|Actual|2008-04-30||Interventional|GenNarino||Evaluation of an Electro-stimulator for the Treatment of Xerostomia|Safety and Performance Evaluation of an Electro-stimulator Mounted on an Intra-oral Removable Appliance (Saliwell GenNarino) for the Treatment of Xerostomia|Completed||Phase 4|200|Anticipated|Saliwell Ltd.||1|||f||||f||||||||||2018-06-01 03:01:53.483161|2018-06-01 03:01:53.483161
NCT00510874|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2013-12-19||2016-10-18|2007-08-01|2007-08-02|Estimate|2013-12-19|2014-02-07|Estimate||||2016-10-18|2016-11-29|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults|A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant|Completed||Phase 1|780|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:01:31.806441|2018-06-01 03:01:31.806441
NCT00510861|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2017-04-27|2007-08-01|2007-08-02|Estimate|||||||2017-04-27|2017-04-28|Actual|February 2007||2007-02-28|April 2017|2017-04-30|May 2007|Actual|2007-05-31|||||Observational|MALE AGING||Influence of Paternal Age on Assisted Reproduction Outcome|Influence of Paternal Age on Assisted Reproduction Outcome|Completed|||||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-06-01 03:01:33.163929|2018-06-01 03:01:33.163929
NCT00510848|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2014-12-04|2007-08-01|2007-08-02|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Hamstrings Autograft Versus Tibialis Allograft for Reconstruction of Anterior Cruciate Ligament|Hamstrings Autograft Versus Tibialis Allograft for Reconstruction of Anterior Cruciate Ligament: Randomized Clinical Trial With 2 Year Follow-up|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 03:01:33.218604|2018-06-01 03:01:33.218604
NCT00510835|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|2016-12-01||2016-12-01|2007-08-01|2007-08-02|Estimate|2016-12-01|2017-01-26|Estimate||||2016-12-01|2017-01-26|Estimate|March 2008||2008-03-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|ProCESS||Protocolized Care for Early Septic Shock|Protocolized Care for Early Septic Shock|Completed||N/A|1351|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 03:01:33.31964|2018-06-01 03:01:33.31964
NCT00510822|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2013-11-12|2007-08-01|2007-08-02|Estimate|||||||2013-11-12|2013-11-13|Estimate|October 2007||2007-10-31|November 2013|2013-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Cimicoxib for the Treatment of Major Depression (SECIM)|Safety and Efficacy of Cimicoxib, a Selective COX-2 Inhibitor, in Combination With Sertraline Compared to Sertraline Combined With Placebo in Treatment of Major Depression|Completed||Phase 2|169|Actual|Affectis Pharmaceuticals AG||2|||f||||f||||||||||2018-06-01 03:01:33.756491|2018-06-01 03:01:33.756491
NCT00510809|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2012-05-11||2015-09-22|2007-08-01|2007-08-02|Estimate|2012-06-18|2012-07-20|Estimate||||2015-09-22|2015-10-08|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy|Safety and Efficacy of Policosanol Monotherapy and When Added to Chronic Statin Therapy: A Pilot Study|Completed||N/A|54|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-06-01 03:01:33.87732|2018-06-01 03:01:33.87732
NCT00510796|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2016-02-15|2007-08-01|2007-08-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|March 2002||2002-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Combined Colon and Endometrial Cancer Screening in Women With HNPCC|A Pilot Study for Combined Colon and Endometrial Cancer Screening in Women at High-Risk for Colon and Endometrial Cancer|Completed|||50|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:01:34.238743|2018-06-01 03:01:34.238743
NCT00510783|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|2011-01-08||2013-11-18|2007-07-31|2007-08-02|Estimate|2013-07-01|2013-08-05|Estimate||||2013-11-18|2013-12-12|Estimate|July 2007||2007-07-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures|IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures|Completed||Phase 4|158|Actual|Emory University|Several patients were lost to follow-up.|2|||f||||t||||||||||2018-06-01 03:01:34.312607|2018-06-01 03:01:34.312607
NCT00510770|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2009-02-17|2007-08-01|2007-08-02|Estimate|||||||2009-02-17|2009-02-18|Estimate|December 2004||2004-12-31|February 2009|2009-02-28||||||||Interventional|||CPAP in Liver Transplant|Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia in Liver Transplant|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Turin, Italy|||||f||||t||||||||||2018-06-01 03:01:34.536734|2018-06-01 03:01:34.536734
NCT00510757|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2008-10-16|2007-07-31|2007-08-02|Estimate|||||||2008-10-16|2008-10-17|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|||Multi Cervical Unit Measures of Cervical Isometric Strength and Range of Motion: A Pilot Study||Unknown status|Recruiting||200|Anticipated|Logan College of Chiropractic|||2||f||||||||||||||2018-06-01 03:01:34.625917|2018-06-01 03:01:34.625917
NCT00510744|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2016-04-26||2016-04-26|2007-08-01|2007-08-02|Estimate|2016-04-26|2016-06-02|Estimate||||2016-04-26|2016-06-02|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients|Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients|Completed||N/A|5|Actual|University of Pittsburgh||1|||f||||t||||||||Yes|with publication|2018-06-01 03:01:34.681908|2018-06-01 03:01:34.681908
NCT00510731|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2015-12-07|2007-08-01|2007-08-02|Estimate|||||||2015-12-07|2015-12-09|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|VITAL||The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events|Prospective, Multi-Center Study Of The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of VentrIcular TachyArrhythmic Events Such As, Sudden Cardiac Death, VentricuLar Fibrillation or Ventricular Tachycardia in High Risk Patients|Withdrawn|||0|Actual|Vicor Technologies, Inc.||||Lack of funding|f||||t||||||||||2018-06-01 03:01:35.09111|2018-06-01 03:01:35.09111
NCT00510718|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2018-04-10|2007-07-31|2007-08-02|Estimate|||||||2018-04-10|2018-04-11|Actual|July 2007|Actual|2007-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|December 2008|Actual|2008-12-31||Interventional|||A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer|A Phase 1, Open-label, Dose-escalation Safety And Pharmacokinetic Study Of Mdv3100 In Patients With Castration-resistant Prostate Cancer|Completed||Phase 1|140|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:01:35.187703|2018-06-01 03:01:35.187703
NCT00510705|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2014-12-02|2007-08-01|2007-08-02|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2007||2007-07-31|December 2014|2014-12-31||||July 2012|Actual|2012-07-31||Interventional|KFO||Chronic Inflammatory Activation in Fat Tissue: An Atherogenic Factor in Severe Coronary Artery Disease||Terminated||N/A|29|Actual|University of Leipzig||4|||f||||||||||||||2018-06-01 03:01:35.273625|2018-06-01 03:01:35.273625
NCT00508612|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2016-07-11|2007-07-27|2007-07-30|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|March 2010|Actual|2010-03-31|May 2009|Actual|2009-05-31||Interventional|||Effectiveness of an Anger and Stress Management Program on Reducing Blood Pressure Levels in Youth|Impact of LifeSkills Training on Blood Pressure in Youth|Completed||Phase 2|259|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||f||||||||||2018-06-01 03:02:20.654916|2018-06-01 03:02:20.654916
NCT00510692|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2014-07-07||2014-08-06|2007-08-01|2007-08-02|Estimate|2014-08-06|2014-08-22|Estimate||||2014-08-06|2014-08-22|Estimate|November 2006||2006-11-30|August 2014|2014-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||The baseline characteristics are presented for the full analysis set which constitutes 55 of the 58 randomised subjects. The full analysis set includes all subjects who were randomised into the study, took at least one dose of study medication provided both at baseline and at least one treatment measurement for efficacy.|Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA|A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid|Completed||Phase 2/Phase 3|58|Actual|S.L.A. Pharma AG||2|||f||||f||||||||||2018-06-01 03:01:35.360973|2018-06-01 03:01:35.360973
NCT00510679|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2007-08-01|2007-08-01|2007-08-02|Estimate|||||||2007-08-01|2007-08-02|Estimate|July 1999||1999-07-31|August 2007|2007-08-31|October 2004|Actual|2004-10-31|||||Interventional|||Study of Post-Training Supports for Health Workers in Benin|A Randomized Controlled Trial of Post-Training Supports for Health Workers Trained in the Use of Integrated Management of Childhood Illness Guidelines in Ouémé Department, Benin|Completed||N/A|1577|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 03:01:35.779826|2018-06-01 03:01:35.779826
NCT00510666|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2009-03-30|2007-08-01|2007-08-02|Estimate|||||||2009-03-30|2009-03-31|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|BATPCAH||Comparison of Butorphanol and Tramadol Associated Patient-Controlled Analgesia (PCA) After Hysterectomy|Butorphanol and Tramadol for Morphine PCA Pain Management After Total Hysterectomy|Completed||Phase 4|841|Actual|Nanjing Medical University||4|||f||||t||||||||||2018-06-01 03:01:35.874788|2018-06-01 03:01:35.874788
NCT00510653|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|2013-06-14||2013-06-14|2007-07-31|2007-08-02|Estimate|2013-06-14|2013-08-23|Estimate||||2013-06-14|2013-08-23|Estimate|March 2002||2002-03-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Gleevec Study for Patients With Ovarian Cancer|A Phase II Study of Gleevec in Patients With Recurrent Platinum-Resistant, Taxane-Resistant Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Completed||Phase 2|73|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:01:35.970254|2018-06-01 03:01:35.970254
NCT00510640|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2013-02-27|2007-08-01|2007-08-02|Estimate|||||||2013-02-27|2013-02-28|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|THYSU||Thyroid Cancer and Sunitinib|Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer|Completed||Phase 2|71|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-06-01 03:01:36.124777|2018-06-01 03:01:36.124777
NCT00510627|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2017-03-02|2007-08-01|2007-08-02|Estimate|||||||2017-03-02|2017-03-03|Actual|August 2007||2007-08-31|March 2017|2017-03-31|December 2010|Anticipated|2010-12-31|||||Interventional|Prometheus||Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases|A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Least First-Line Chemotherapy|Withdrawn||Phase 4|0|Actual|Boston Scientific Corporation||2||Boston Scientific has decided to close the Study.|f||||f||||||||||2018-06-01 03:01:36.212243|2018-06-01 03:01:36.212243
NCT00510614|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2011-02-16|2007-08-01|2007-08-02|Estimate|||||||2011-02-16|2011-02-18|Estimate|October 2007||2007-10-31|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study|Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study|Completed||Early Phase 1|37|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:01:36.306466|2018-06-01 03:01:36.306466
NCT00510601|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2016-01-12|2007-08-01|2007-08-02|Estimate|||||||2016-01-12|2016-01-13|Estimate|July 2007||2007-07-31|January 2016|2016-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Treating Congestive Heart Failure Using a Device to Remove Cholesterol|LDL Apheresis for the Treatment of Congestive Heart Failure|Completed||Early Phase 1|5|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 03:01:36.384821|2018-06-01 03:01:36.384821
NCT00510588|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2014-12-02|2007-08-01|2007-08-02|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|KFO||Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease||Completed||N/A|120|Actual|University of Leipzig||4|||f||||||||||||||2018-06-01 03:01:36.451281|2018-06-01 03:01:36.451281
NCT00510575|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2013-01-15|2007-08-01|2007-08-02|Estimate|||||||2013-01-15|2013-01-16|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis|Surgical Outcomes Using Variable Rod Diameters in the Treatment of Idiopathic Scoliosis|Completed||Phase 4|300|Actual|Shriners Hospitals for Children||2|||f||||f||||||||||2018-06-01 03:01:36.636961|2018-06-01 03:01:36.636961
NCT00510562|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2013-04-02|2007-08-01|2007-08-02|Estimate|||||||2013-04-02|2013-04-04|Estimate|October 2001||2001-10-31|April 2013|2013-04-30|February 2002|Actual|2002-02-28|||||Interventional|||Effect of Cranial Osteopathy on Visual Function|Effect of Cranial Osteopathy on Visual Function|Completed||N/A|29|Actual|Nova Southeastern University||2|||f||||f||||||||||2018-06-01 03:01:36.737796|2018-06-01 03:01:36.737796
NCT00510549|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2008-09-25|2007-08-01|2007-08-02|Estimate|||||||2008-09-25|2008-09-29|Estimate|July 2007||2007-07-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of the Impact of Dialysis Treatment Type on Patient Survival|A Prospective, Randomized, Multicenter, Open Label, Interventional Pilot Study To Compare Mortality, Morbidity and QOL in Hemodialysis Versus Peritoneal Dialysis Subjects|Completed||Phase 4|50|Anticipated|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-06-01 03:01:36.797774|2018-06-01 03:01:36.797774
NCT00510536|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2009-04-08|2007-08-01|2007-08-02|Estimate|||||||2009-04-08|2009-04-10|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Treatment of Mild to Moderate Joint Pain in Patients With Chronic Plaque Psoriasis Receiving Efalizumab|A Phase 4 Study to Assess the Practical Management of Mild to Moderate Arthritic or Arthralgic Events in Patients With Chronic Plaque Psoriasis Receiving Efalizumab|Completed||Phase 4|50|Anticipated|Probity Medical Research|||||f||||f||||||||||2018-06-01 03:01:36.866465|2018-06-01 03:01:36.866465
NCT00510523|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2013-05-02|2007-08-01|2007-08-02|Estimate|||||||2013-05-02|2013-05-03|Estimate|October 2006||2006-10-31|May 2013|2013-05-31|November 2007||2007-11-30|||||Interventional|||Whole Body Vibration Therapy in Participants With MS Related Balance Deficits|Whole Body Vibration Therapy in Participants With MS Related Balance Deficits|Completed||N/A|80|Anticipated|Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:01:36.926847|2018-06-01 03:01:36.926847
NCT00510510|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2010-12-23||2012-05-14|2007-08-01|2007-08-02|Estimate|2010-12-23|2011-01-21|Estimate||||2012-05-14|2012-05-21|Estimate|August 2007||2007-08-31|May 2012|2012-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|281|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:01:37.020655|2018-06-01 03:01:37.020655
NCT00510497|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2016-01-12||2016-05-12|2007-08-01|2007-08-02|Estimate|2016-03-03|2016-04-04|Estimate||||2016-05-12|2016-06-16|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||11 particpants were enrolled but one received no study vaccines and was withdrawn and not included in any analyses.|Autologous Dendritic Cell Vaccine in HIV1 Infection|Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells|Completed||Phase 1/Phase 2|11|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:01:37.714282|2018-06-01 03:01:37.714282
NCT00510484|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2009-05-29||2010-05-26|2007-08-01|2007-08-02|Estimate|2009-05-29|2009-07-20|Estimate||||2010-05-26|2010-06-03|Estimate|November 2007||2007-11-30|August 2009|2009-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis|A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Completed||Phase 3|35|Actual|Solvay Pharmaceuticals|Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and include events started prior to the 1st administration but which worsened after the 1st intake.|2|||f||||f||||||||||2018-06-01 03:01:37.86379|2018-06-01 03:01:37.86379
NCT00510471|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2008-03-14|2007-07-31|2007-08-02|Estimate|||||||2008-03-14|2008-03-18|Estimate|May 2007||2007-05-31|March 2008|2008-03-31||||||||Interventional|||Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma|A Phase 2 Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With Follicular Non-Hodgkin's Lymphoma (fNHL) Following Primary Treatment With Rituximab and Chemotherapy (R-Chemo)|Terminated||Phase 2|||Genitope Corporation|||||f||||||||||||||2018-06-01 03:01:38.575082|2018-06-01 03:01:38.575082
NCT00510458|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|2017-12-01||2018-02-22|2007-08-01|2007-08-02|Estimate|2018-02-22|2018-03-12|Actual||||2018-02-22|2018-03-12|Actual|April 2007||2007-04-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|LFIT||LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study - An Open Label, Prospective, Post-market, Multi-center Clinical Evaluation of the LFIT™ Anatomic CoCr Femoral Heads With X3® Inserts|Completed||N/A|89|Actual|Stryker Orthopaedics||1|||f||||f||||||||||2018-06-01 03:01:38.695693|2018-06-01 03:01:38.695693
NCT00510445|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2015-12-22|2007-07-31|2007-08-02|Estimate|||||||2015-12-22|2015-12-24|Estimate|July 2007||2007-07-31|December 2015|2015-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer|A Phase I Study of GRN163L in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 1|27|Actual|Geron Corporation||1|||f||||f||||||||||2018-06-01 03:01:39.290064|2018-06-01 03:01:39.290064
NCT00510432|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2009-08-18|2007-08-01|2007-08-02|Estimate|||||||2009-08-18|2009-08-19|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|January 2009|Anticipated|2009-01-31|||||Observational|||Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients|Inzidenz Und Art Heparin-induzierter Hautveränderungen|Unknown status|Recruiting||500|Anticipated|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||||||2018-06-01 03:01:39.374198|2018-06-01 03:01:39.374198
NCT00510419|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2012-06-06|2007-08-01|2007-08-02|Estimate|||||||2012-06-06|2012-06-08|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack|A Phase 3 Open-Label Study to Assess Subcutaneous Self-Injection With Sumatriptan Succinate Using an Auto-injector During a Single Migraine Attack|Completed||Phase 3|73|Actual|Pfizer|||||f||||t||||||||||2018-06-01 03:01:39.45179|2018-06-01 03:01:39.45179
NCT00510406|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2014-08-19|2007-07-31|2007-08-02|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|SATURN||A Study With Combination Treatment (Tamsulosin Hydrochloride and Solifenacin Succinate) in Male Patients With LUTS/BPH|A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi Center Dose Ranging Study of Solifenacin Succinate in Combination With Tamsulosin Hydrochloride Compared With Solifenacin Succinate Monotherapy and Tamsulosin Hydrochloride Monotherapy in Males With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)|Completed||Phase 2|919|Actual|Astellas Pharma Inc||8|||f||||f||||||||||2018-06-01 03:01:39.527303|2018-06-01 03:01:39.527303
NCT00510393|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2010-12-01|2007-08-01|2007-08-02|Estimate|||||||2010-12-01|2010-12-02|Estimate|March 2008||2008-03-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|DESTINY||Drug Eluting Stents In The Critically Ischemic Lower Leg|The DESTINY Trial: a Prospective Randomized Multicenter Trial Comparing the Implant of a Drug Eluting Stent (XIENCE V, Abbott Vascular) vs. a Bare Metal Stent (MULTILINK VISION, Abbott Vascular) in the Critically Ischemic Lower Leg|Completed||Phase 2|140|Actual|Flanders Medical Research Program||2|||f||||t||||||||||2018-06-01 03:01:39.725855|2018-06-01 03:01:39.725855
NCT00510380|ClinicalTrials.gov processed this data on May 31, 2018|2007-08-01|||2009-09-18|2007-08-01|2007-08-02|Estimate|||||||2009-09-18|2009-09-21|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|April 2009|Actual|2009-04-30|||||Observational|||Epigenetic Markers in Growth Restricted Human Pregnancies: a Case-controlled Study|Epigenetic Markets in Growth Restricted Human Pregnancies: A Case- Control Study|Completed|||40|Anticipated|National University Hospital, Singapore|||2||f||||t||||||||||2018-06-01 03:01:39.834693|2018-06-01 03:01:39.834693
NCT00510367|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2018-03-14|2007-08-01|2007-08-02|Estimate|||||||2018-03-14|2018-03-16|Actual|August 2001|Actual|2001-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Primary Breast Cancer Occurring Concomitant With Pregnancy|Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy|Active, not recruiting||Early Phase 1|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:01:39.890347|2018-06-01 03:01:39.890347
NCT00510354|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2016-11-16|2007-07-31|2007-08-02|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2006||2006-10-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Radix||Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate|Multicenter, Single-arm, Two Stage Phase II Trial of RAD001 (Everolimus) With Imatinib in Imatinib-resistant Patients With Progressive GIST|Completed||Phase 4|28|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:01:39.969213|2018-06-01 03:01:39.969213
NCT00510341|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2012-12-18|2007-07-31|2007-08-02|Estimate|||||||2012-12-18|2012-12-20|Estimate|April 2006||2006-04-30|December 2012|2012-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|CMP||Evaluating the Collaborative Management in Pediatrics (CMP) Training Program Among Pediatric Resident Doctors and Their Patients With Asthma or Obesity|Asthma Management Support Training in Pediatrics|Completed||N/A|18|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:01:40.057471|2018-06-01 03:01:40.057471
NCT00510328|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2007-08-01|2007-08-01|2007-08-02|Estimate|||||||2007-08-01|2007-08-02|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Vibration Therapy Effects on Muscle Firing Patterns|Vibration Therapy Effects on Muscle Firing Patterns|Completed||Phase 1/Phase 2|60|Anticipated|Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:01:40.189329|2018-06-01 03:01:40.189329
NCT00510315|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2018-01-12|2007-08-01|2007-08-02|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2007||2007-07-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant|Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related IllnessFollowing Total Body Irradiation and Stem Cell Transplant|Active, not recruiting|||11|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 03:01:40.252806|2018-06-01 03:01:40.252806
NCT00510302|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2017-07-13|2007-08-01|2007-08-02|Estimate|||||||2017-07-13|2017-07-14|Actual|November 2002||2002-11-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Melanoma Risk-Reduction Among Patients and Family Members|Melanoma Risk-Reduction Practices Among Melanoma Patients and Their Family Members|Active, not recruiting|||170|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:01:40.325701|2018-06-01 03:01:40.325701
NCT00510289|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2013-10-30||2016-03-21|2007-07-30|2007-08-01|Estimate|2013-12-20|2014-02-11|Estimate||||2016-03-21|2016-04-19|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||All patients who signed consent|Sorafenib in Myelodysplastic Syndrome|Phase II Trial of Sorafenib in Patients With Myelodysplastic Syndrome|Terminated||Phase 2|19|Actual|Duke University|The limitations of our study include the small sample size, the poor toxicity profile and the lack of response.|1||Early closure of study due to poor response|f||||t||||||||||2018-06-01 03:01:40.419143|2018-06-01 03:01:40.419143
NCT00510276|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2010-01-27||2010-04-07|2007-07-30|2007-08-01|Estimate|2010-01-27|2010-03-03|Estimate||||2010-04-07|2010-04-14|Estimate|August 2007||2007-08-31|April 2010|2010-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes|A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes|Completed||Phase 4|445|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:01:40.683124|2018-06-01 03:01:40.683124
NCT00510263|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2008-06-03|2007-07-30|2007-08-01|Estimate|||||||2008-06-03|2008-06-04|Estimate|May 2001||2001-05-31|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|SBPS||Scandinavian Bell's Palsy Study|A Multicentre Placebo-Controlled Evaluation of Prednisolone and/or Valaciclovir for the Treatment of Bell's Palsy|Completed||Phase 4|839|Actual|Uppsala University Hospital||4|||f||||t||||||||||2018-06-01 03:01:42.21406|2018-06-01 03:01:42.21406
NCT00510250|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2015-07-24|2007-07-31|2007-08-01|Estimate|||||||2015-07-24|2015-07-27|Estimate|June 2007||2007-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|September 2010|Actual|2010-09-30||Interventional|||A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer|A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer|Completed||Phase 1/Phase 2|13|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 03:01:42.285749|2018-06-01 03:01:42.285749
NCT00510237|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2017-03-02|2007-07-31|2007-08-01|Estimate|||||||2017-03-02|2017-03-06|Actual|February 2007||2007-02-28|August 2016|2016-08-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||Intervention for Newly Diagnosed Youth With HIV|Intervention Development for Newly Diagnosed Youth With HIV|Completed||N/A|50|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 03:01:42.357172|2018-06-01 03:01:42.357172
NCT00510224|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2013-10-17||2013-10-17|2007-07-31|2007-08-01|Estimate|2013-10-17|2013-12-11|Estimate||||2013-10-17|2013-12-11|Estimate|July 2007||2007-07-31|October 2013|2013-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Sandostatin for Patients With Androgen Independent Prostate Cancer|A Phase II Study of the Somatostatin Analog Sandostatin LAR in Patients With Androgen Independent Prostate Cancer|Terminated||Phase 2|13|Actual|University of California, San Francisco||1||Stopped at interim analyses phase due to lack of efficacy|f||||t||||||||||2018-06-01 03:01:42.44874|2018-06-01 03:01:42.44874
NCT00510211|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2009-07-31|2007-07-30|2007-08-01|Estimate|||||||2009-07-31|2009-08-03|Estimate|April 2007||2007-04-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|||||Observational|||An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.|An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.|Completed|||1131|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-06-01 03:01:42.698507|2018-06-01 03:01:42.698507
NCT00510198|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2009-06-08|2007-07-31|2007-08-01|Estimate|||||||2009-06-08|2009-06-11|Estimate|October 2007||2007-10-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|PRECEDE-HF||Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure|PRECEDE-HF -Prospective, Randomized Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure|Terminated||N/A|120|Actual|Medtronic Cardiac Rhythm and Heart Failure||2||Study enrollment significantly below protocol expectation|f||||t||||||||||2018-06-01 03:01:42.788608|2018-06-01 03:01:42.788608
NCT00510185|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2012-02-22|2007-07-31|2007-08-01|Estimate|||||||2012-02-22|2012-02-23|Estimate|October 2007||2007-10-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Early Aggressive Versus Initially Conservative Therapy in Elderly Patients With Non-ST-Elevation Acute Coronary Syndrome|Italian Elderly ACS Study|Completed||N/A|313|Actual|Niguarda Hospital||2|||f||||t||||||||||2018-06-01 03:01:42.895546|2018-06-01 03:01:42.895546
NCT00510159|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2008-01-17|2007-07-31|2007-08-01|Estimate|||||||2008-01-17|2008-01-18|Estimate|August 2007||2007-08-31|July 2007|2007-07-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis|Randomized Double Blind Clinical Trial in Mali, Comparing the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel in the Treatment of S. Haematobium in Children|Completed||Phase 2/Phase 3|800|Actual|Dafra Pharma|||||f||||f||||||||||2018-06-01 03:01:43.131007|2018-06-01 03:01:43.131007
NCT00510146|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2011-02-15||2011-04-26|2007-07-30|2007-08-01|Estimate|2011-04-26|2011-05-26|Estimate||||2011-04-26|2011-05-26|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Olanzapine Treatment of Patients With Bipolar I Disorder|Efficacy and Safety of Olanzapine in the Treatment of Patients With Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison With Placebo|Completed||Phase 3|514|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-06-01 03:01:43.260309|2018-06-01 03:01:43.260309
NCT00510133|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2014-08-11|2007-07-30|2007-08-01|Estimate|||||||2014-08-11|2014-08-13|Estimate|July 2007||2007-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|December 2011|Actual|2011-12-31||Interventional|||A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)|A Phase II Study of Active Immunotherapy With GRNVAC1, Autologous Mature Dendritic Cells Transfected With mRNA Encoding Human Telomerase Reverse Transcriptase, in Patients With Acute Myelogenous Leukemia in Complete Clinical Remission|Completed||Phase 2|21|Actual|Asterias Biotherapeutics, Inc.||1|||f||||f||||||||||2018-06-01 03:01:45.9133|2018-06-01 03:01:45.9133
NCT00510120|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2013-06-06|2007-07-30|2007-08-01|Estimate|||||||2013-06-06|2013-06-07|Estimate|June 2007||2007-06-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder|Mediators, Moderators, and Treatment Outcomes With ODD Youth|Completed||N/A|150|Actual|Virginia Polytechnic Institute and State University||3|||f||||f||||||||||2018-06-01 03:01:45.985519|2018-06-01 03:01:45.985519
NCT00510107|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2007-07-31|2007-07-31|2007-08-01|Estimate|||||||2007-07-31|2007-08-01|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|July 2009|Anticipated|2009-07-31|||||Interventional|||Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC|A Randomized Phase II Trial of Weekly Docetaxel/Cisplatin Versus Weekly Docetaxel/Oxaliplatin in Previously Untreated Patients With Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|90|Anticipated|Gachon University Gil Medical Center||2|||f||||f||||||||||2018-06-01 03:01:46.060935|2018-06-01 03:01:46.060935
NCT00510094|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2015-06-03|2007-07-30|2007-08-01|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Effectiveness of Treatment for Relational Aggression in Urban African American Girls|Determining the Efficacy of a Relational Aggression Intervention for Urban African American Girls|Completed||Phase 3|144|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 03:01:46.218565|2018-06-01 03:01:46.218565
NCT00510081|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2014-12-05|2007-07-31|2007-08-01|Estimate|||||||2014-12-05|2014-12-09|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|February 2009||2009-02-28|February 2009||2009-02-28||Interventional|||An Evaluation of an Injectable Material for Correction of Wrinkles|An Open Label Evaluation of the Safety and Efficacy of Calcium Hydroxylapatite (Radiesse®) Injection in the Correction of Jowl-Associated Chin Notches|Withdrawn||Phase 3|0|Actual|Northwestern University||1||The study was not executed. No subjects were enrolled.|f||||f||||||||||2018-06-01 03:01:46.316906|2018-06-01 03:01:46.316906
NCT00510068|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|2011-11-11||2015-06-04|2007-07-31|2007-08-01|Estimate|2011-11-11|2011-12-15|Estimate||||2015-06-04|2015-07-01|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|February 2010|Actual|2010-02-28||Interventional|RADIANT-3||Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors|A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)|Completed||Phase 3|410|Actual|Novartis||2|||f||||t||||||||||2018-06-01 03:01:46.466001|2018-06-01 03:01:46.466001
NCT00510055|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2012-09-14|2007-07-31|2007-08-01|Estimate|||||||2012-09-14|2012-09-17|Estimate|June 2007||2007-06-30|September 2012|2012-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Treatment of Acne Scarring With a Novel Procedure Combination|The Effect of Subcision and Calcium Hydroxylapatite (Radiesse) Injection on Rolling Acne Scarring Appearance|Completed||N/A|30|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 03:01:48.469273|2018-06-01 03:01:48.469273
NCT00510042|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2010-04-23|2007-07-31|2007-08-01|Estimate|||||||2010-04-23|2010-04-26|Estimate|July 2007||2007-07-31|April 2010|2010-04-30|September 2009|Actual|2009-09-30|||||Observational|WiN||National Study of Moderate and Severe Von Willebrand Disease in the Netherlands|National Study of Moderate and Severe Von Willebrand Disease in the Netherlands|Completed|||1100|Anticipated|Erasmus Medical Center|||||f||||f||||||Samples With DNA|"~     plasma, DNA~   "|||2018-06-01 03:01:48.698398|2018-06-01 03:01:48.698398
NCT00510029|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2008-03-12|2007-07-31|2007-08-01|Estimate|||||||2008-03-12|2008-03-13|Estimate|September 2007||2007-09-30|March 2008|2008-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Subjects.|Completed||Phase 1|72|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 03:01:48.80131|2018-06-01 03:01:48.80131
NCT00510016|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2017-01-10|2007-07-31|2007-08-01|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2002||2002-07-31|July 2007|2007-07-31|December 2005|Actual|2005-12-31|||||Interventional|NAS||Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome|Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial|Completed||Phase 2|80|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||t||||||||||2018-06-01 03:01:48.915827|2018-06-01 03:01:48.915827
NCT00510003|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2016-11-16|2007-07-31|2007-08-01|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2004||2004-12-31|November 2016|2016-11-30||||January 2006|Actual|2006-01-31||Interventional|||Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old|A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis|Completed||Phase 4|117|Actual|Novartis|||||f||||||||||||||2018-06-01 03:01:48.996199|2018-06-01 03:01:48.996199
NCT00509626|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2010-02-11|2007-07-30|2007-07-31|Estimate|||||||2010-02-11|2010-02-12|Estimate|June 2007||2007-06-30|February 2010|2010-02-28||||July 2008|Actual|2008-07-31||Interventional|||Physical Activity or Usual Care in Preventing Weight Gain in Women With Stage I or Stage II Breast Cancer Undergoing Chemotherapy|A Physical Activity Intervention to Prevent Weight Gain in Breast Cancer Patients|Completed||Phase 1/Phase 2|380|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 03:01:58.266743|2018-06-01 03:01:58.266743
NCT00509990|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2018-04-16|2007-07-31|2007-08-01|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2005||2005-04-30|April 2018|2018-04-30||||September 2007|Actual|2007-09-30||Interventional|||Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting|Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting|Completed||Phase 4|200|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:01:49.270983|2018-06-01 03:01:49.270983
NCT00509977|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2012-09-14|2007-07-31|2007-08-01|Estimate|||||||2012-09-14|2012-09-17|Estimate|April 2007||2007-04-30|September 2012|2012-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Light Treatment and Laser Treatment for Melasma|A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of Intense Pulse Light vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.|Completed||N/A|17|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 03:01:49.409599|2018-06-01 03:01:49.409599
NCT00509964|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2007-07-31|2007-07-31|2007-08-01|Estimate|||||||2007-07-31|2007-08-01|Estimate|May 2007||2007-05-31|July 2007|2007-07-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Second-Line Irinotecan vs. ILF for AGC|A Randomized Phase II Trial of Irinotecan Monotherapy Versus Irinotecan, Leucovorin and 5-FU (ILF) Combination Chemotherapy in Patients With Advanced Gastric Cancer Failing Prior Chemotherapy|Unknown status|Recruiting|Phase 2|50|Anticipated|Gachon University Gil Medical Center||2|||f||||f||||||||||2018-06-01 03:01:49.60888|2018-06-01 03:01:49.60888
NCT00509951|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2013-06-06|2007-07-30|2007-08-01|Estimate|||||||2013-06-06|2013-06-07|Estimate|July 2007||2007-07-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Parent-Augmented Cognitive Behavioral Therapy to Treat Children With Specific Phobias|Augmented Treatment of Specific Phobias in Children|Completed||N/A|154|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-06-01 03:01:49.735741|2018-06-01 03:01:49.735741
NCT00509938|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2008-10-16|2007-07-31|2007-08-01|Estimate|||||||2008-10-16|2008-10-17|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients|Safety and Efficacy of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients Part A: Clinical Study Protocol SC12: Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients|Completed||Phase 1/Phase 2|8|Actual|AM-Pharma||1|||f||||t||||||||||2018-06-01 03:01:49.926907|2018-06-01 03:01:49.926907
NCT00509925|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|2010-04-19||2017-01-30|2007-07-31|2007-08-01|Estimate|2010-07-06|2010-08-04|Estimate||||2017-01-30|2017-03-10|Actual|July 2007||2007-07-31|January 2017|2017-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes|A 32-week National, Single-centre, Open-labelled, Randomised, Crossover Trial Comparing Energy Expenditure With Insulin Detemir Versus NPH Insulin Using a Basal-Bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes|Terminated||Phase 4|23|Actual|Novo Nordisk A/S|This open-label study was terminated prematurely due to 2 unplanned interim analyses having been performed. At this point, only 23 out of the planned 30 patients had been randomised into the study.|2||See detailed description|f||||f||||||||||2018-06-01 03:01:50.17449|2018-06-01 03:01:50.17449
NCT00509899|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2011-12-15|2010-06-18|2018-02-13|2007-07-30|2007-08-01|Estimate|2012-06-29|2012-08-02|Estimate|2010-07-01|2010-07-07|Estimate|2018-02-13|2018-03-12|Actual|June 2007||2007-06-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|December 2007|Actual|2007-12-31||Interventional|||Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis|A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)|Completed||Phase 1/Phase 2|154|Actual|Incyte Corporation||1|||f||||f||||||||||2018-06-01 03:01:50.902964|2018-06-01 03:01:50.902964
NCT00509886|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2014-11-07|2007-07-31|2007-08-01|Estimate|||||||2014-11-07|2014-11-10|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating|Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating|Completed||N/A|24|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 03:01:52.730313|2018-06-01 03:01:52.730313
NCT00509873|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2010-06-15|2009-07-23|2011-10-24|2007-07-30|2007-08-01|Estimate|2011-10-24|2011-11-30|Estimate|2009-07-23|2009-08-10|Estimate|2011-10-24|2011-11-30|Estimate|August 2007||2007-08-31|October 2011|2011-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis||Completed||Phase 3|578|Actual|Allergan||2|||f||||||||||||||2018-06-01 03:01:52.906412|2018-06-01 03:01:52.906412
NCT00509860|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2012-12-28|2007-07-30|2007-08-01|Estimate|||||||2012-12-28|2013-01-03|Estimate|March 2003||2003-03-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|August 2007|Actual|2007-08-31||Interventional|||Irinotecan (Camptosar) in Patients With Advanced Sarcomas|A Phase II Study of Irinotecan (Camptosar) in Patients With Advanced Sarcomas|Completed||Phase 2|38|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:01:53.155746|2018-06-01 03:01:53.155746
NCT00509847|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2014-05-26|2007-07-31|2007-08-01|Estimate|||||||2014-05-26|2014-05-28|Estimate|February 2009||2009-02-28|January 2010|2010-01-31|October 2009|Anticipated|2009-10-31|July 2009|Anticipated|2009-07-31||Interventional|LIST||A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis|A Phase-IIa, Double-blind, Randomized, Controlled Study on the Tolerability and Early Efficacy of hLF1-11 in Hospitalized Patients With Bacteremia Due to Staphylococcus Epidermidis|Withdrawn||Phase 1/Phase 2|0|Actual|AM-Pharma||||conduct (recruitment) not feasible within timeframe|f||||t||||||||||2018-06-01 03:01:53.230203|2018-06-01 03:01:53.230203
NCT00509834|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2015-06-29|2007-07-31|2007-08-01|Estimate|||||||2015-06-29|2015-06-30|Estimate|July 2008||2008-07-31|April 2008|2008-04-30|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|SLIC||A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia|A Phase-IIa, Double-blind, Randomized Study on the Tolerability and Early Efficacy of hLF1-11 in Hospitalized Patients With Proven Candidaemia. (SLIC: Study of Lactoferrin Peptide in Infections With Candida)|Withdrawn||Phase 1/Phase 2|0|Actual|AM-Pharma||2||Patient population not available|f||||t||||||||||2018-06-01 03:01:53.306116|2018-06-01 03:01:53.306116
NCT00509821|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30||2010-12-09|2016-04-22|2007-07-30|2007-08-01|Estimate||||2010-12-09|2010-12-15|Estimate|2016-04-22|2016-05-23|Estimate|October 2007||2007-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2010|Actual|2010-02-28||Interventional|||Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Patients With Newly Diagnosed Glioblastoma|Enzastaurin Before and Concomitant With Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma Without Methylation of the Promoter Gene of MGMT Enzyme - a Phase II Study|Completed||Phase 2|60|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:01:53.388827|2018-06-01 03:01:53.388827
NCT00509795|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|2011-12-16|2011-01-05|2012-12-20|2007-07-31|2007-08-01|Estimate|2012-04-13|2012-04-16|Estimate|2011-01-05|2011-01-10|Estimate|2012-12-20|2012-12-28|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|September 2010|Actual|2010-09-30||Interventional|VIEW1||Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)|A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 3|1217|Actual|Regeneron Pharmaceuticals||4|||f||||t||||||||||2018-06-01 03:01:53.623859|2018-06-01 03:01:53.623859
NCT00509782|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2012-07-31|2007-07-30|2007-07-31|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase I Trial of ZIO-101 in Patients With Solid Tumors|Phase I Trial of ZIO-101 in Patients With Solid Tumors|Completed||Phase 1|47|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:01:56.613654|2018-06-01 03:01:56.613654
NCT00509769|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2013-02-22||2013-02-22|2007-07-27|2007-07-31|Estimate|2013-02-22|2013-04-02|Estimate||||2013-02-22|2013-04-02|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer|A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy|Completed||Phase 2|112|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:01:56.743305|2018-06-01 03:01:56.743305
NCT00509756|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2010-10-21|2007-07-30|2007-07-31|Estimate|||||||2010-10-21|2010-10-22|Estimate|November 2007||2007-11-30|October 2010|2010-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study Evaluating FXR-450 in Healthy Japanese Men|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of FXR-450 Administered Orally to Healthy Japanese Male Subjects|Terminated||Phase 1|56|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2||Please see termination statement in the detailed description.|f||||||||||||||2018-06-01 03:01:57.237184|2018-06-01 03:01:57.237184
NCT00509743|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2009-02-11|2007-07-30|2007-07-31|Estimate|||||||2009-02-11|2009-02-12|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|DFC-PK-008||Study to Assess Effects of Age, Weight, and Body Composition on the Pharmacokinetics of IV Diclofenac Sodium|An Open-Label, Single-Dose Study to Assess the Effects of Age, Weight, and Body Composition on the Pharmacokinetic Profile, Safety, and Tolerability of Intravenous Diclofenac Sodium (DIC075V) in Adult Volunteers|Completed||Phase 1|89|Anticipated|Javelin Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:01:57.329712|2018-06-01 03:01:57.329712
NCT00509730|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2009-10-06|2007-07-30|2007-07-31|Estimate|||||||2009-10-06|2009-10-07|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|March 2010|Anticipated|2010-03-31|||||Interventional|VUSIS||Value of Urodynamics Prior to Stress Incontinence Surgery|Multicentered Randomized Controlled Trail to Test the Cost Effectiveness of Urodynamics in Women With Symptoms of Stress Urinary Incontinence in Whom Surgical Treatment is Considered|Terminated||N/A|290|Anticipated|Radboud University|||||f||||t||||||||||2018-06-01 03:01:57.406578|2018-06-01 03:01:57.406578
NCT00509717|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2008-07-09|2007-07-30|2007-07-31|Estimate|||||||2008-07-09|2008-07-10|Estimate|October 2006||2006-10-31|July 2008|2008-07-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs|Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs. A Randomized Trial.|Completed||N/A|70|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 03:01:57.488356|2018-06-01 03:01:57.488356
NCT00509704|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2010-11-08|2007-07-30|2007-07-31|Estimate|||||||2010-11-08|2010-11-09|Estimate|October 2008||2008-10-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|||||Observational|||Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma|Pilot Study on the Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma|Completed|||10|Anticipated|Radboud University|||||f||||f||||||||||2018-06-01 03:01:57.571068|2018-06-01 03:01:57.571068
NCT00509691|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2017-05-08|2007-07-30|2007-07-31|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2007||2007-06-30|May 2017|2017-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy|A Phase I Trial to Examine the Safety, Clinical, Immunologic and Virologic Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistent or Therapy Refractory Infections|Completed||Phase 1|20|Actual|University of Louisville||1|||f||||t||||||||||2018-06-01 03:01:57.638377|2018-06-01 03:01:57.638377
NCT00509678|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2012-01-16|2007-07-30|2007-07-31|Estimate|||||||2012-01-16|2012-01-18|Estimate|December 2006||2006-12-31|January 2012|2012-01-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Rituxan With or Without Methotrexate in Psoriatic Arthritis|Phase IB, Investigator-Initiated, Open-Label, Multi-Center Trial of Rituximab With or Without Methotrexate In Subjects With Psoriatic Arthritis and Psoriasis|Completed||Phase 1|6|Actual|Swedish Medical Center|||||f||||t||||||||||2018-06-01 03:01:57.744473|2018-06-01 03:01:57.744473
NCT00509665|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2012-04-26|2007-07-30|2007-07-31|Estimate|||||||2012-04-26|2012-04-30|Estimate|June 2005||2005-06-30|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer|A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer|Completed||Phase 2|17|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 03:01:57.831228|2018-06-01 03:01:57.831228
NCT00509652|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2007-07-27|2007-07-27|2007-07-31|Estimate|||||||2007-07-27|2007-07-31|Estimate|January 2006||2006-01-31|July 2007|2007-07-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Erythrocyte Apheresis Versus Phlebotomy in Hemochromatosis|Therapeutic Effect of Erythrocyte Apheresis as Compared to Full Blood Phlebotomy in Patients With Hereditary Hemochromatosis|Unknown status|Recruiting|N/A|67|Anticipated|University of Bergen||2|||f||||f||||||||||2018-06-01 03:01:58.017338|2018-06-01 03:01:58.017338
NCT00509639|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2012-12-12|2007-07-30|2007-07-31|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease|Phase III Study to Evaluate the Effect of 10% Metronidazole Ointment, Applied Topically Three Times a Day in and Around the Anus and the Change in Perianal Crohn's Disease Activity|Completed||Phase 3|74|Actual|S.L.A. Pharma AG||2|||f||||f||||||||||2018-06-01 03:01:58.166047|2018-06-01 03:01:58.166047
NCT00509600|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2009-08-31||2012-08-01|2007-07-30|2007-07-31|Estimate|2010-11-03|2010-12-02|Estimate||||2012-08-01|2012-08-07|Estimate|September 2004||2004-09-30|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia|Phase IIA Window Study of Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center|Early termination due to low accrual. Rare disease with less than 100 cases diagnosed per year.|1||Slow enrollment; study terminated.|f||||t||||||||||2018-06-01 03:01:58.44457|2018-06-01 03:01:58.44457
NCT00509587|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2015-08-10||2016-10-20|2007-07-30|2007-07-31|Estimate|2016-10-20|2016-12-14|Estimate||||2016-10-20|2016-12-14|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|August 2013|Actual|2013-08-31|July 2009|Actual|2009-07-31||Interventional|||Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer|A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:01:58.668638|2018-06-01 03:01:58.668638
NCT00509574|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-29|||2010-12-10|2007-07-30|2007-07-31|Estimate|||||||2010-12-10|2010-12-13|Estimate|March 2007||2007-03-31|November 2010|2010-11-30|February 2010|Anticipated|2010-02-28|||||Observational|||Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy|Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     blood samples are obtained for genomic DNA extraction.~   "|||2018-06-01 03:01:59.937611|2018-06-01 03:01:59.937611
NCT00509561|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2012-12-17|2007-07-30|2007-07-31|Estimate|||||||2012-12-17|2012-12-18|Estimate|February 2008||2008-02-29|December 2012|2012-12-31||||September 2012|Actual|2012-09-30||Interventional|||Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer|A Randomised Phase II/III Multi-Centre Clinical Trial of Definitive Chemotherapy, With or Without Cetuximab, in Carcinoma of the Oesophagus|Unknown status|Active, not recruiting|Phase 2/Phase 3|259|Actual|Wales Cancer Trials Unit||2|||f||||t||||||||||2018-06-01 03:02:00.020995|2018-06-01 03:02:00.020995
NCT00509548|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2010-03-25|2007-07-27|2007-07-31|Estimate|||||||2010-03-25|2010-03-29|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD|An Open-Label Randomized Pilot Study of Safety and Preliminary Efficacy of TG100801 in Patients With Choroidal Neovascularization Due to Age-Related Macular Degeneration|Terminated||Phase 2|7|Actual|TargeGen||2|||f||||f||||||||||2018-06-01 03:02:00.183997|2018-06-01 03:02:00.183997
NCT00509535|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2007-07-30|2007-07-30|2007-07-31|Estimate|||||||2007-07-30|2007-07-31|Estimate|January 2005||2005-01-31|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic Probands|Prospective, Randomized, Double Blind Comparative Study on the Use of Two Creams in Xerosis Atopic Probands Biomedical Findings With Vitreoscilla Filiformis|Completed||N/A|75|Actual|L'Oreal|||||f||||t||||||||||2018-06-01 03:02:00.26407|2018-06-01 03:02:00.26407
NCT00509509|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-29|||2012-05-22|2007-07-30|2007-07-31|Estimate|||||||2012-05-22|2012-05-24|Estimate||||May 2012|2012-05-31||||||||Observational|||High Risk Breast Cancer Screening Program|High Risk Breast Cancer Screening Program|Unknown status|Recruiting||||Organisation for Oncology and Translational Research|||||f||||||||||||||2018-06-01 03:02:00.411191|2018-06-01 03:02:00.411191
NCT00509496|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2012-10-31||2013-01-04|2007-07-30|2007-07-31|Estimate|2012-10-31|2012-12-04|Estimate||||2013-01-04|2013-01-15|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-gp100:154-162 TCR-Gene Engineered Lymphocytes|Terminated||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)||2||Low accrual|f||||t||||||||||2018-06-01 03:02:00.495927|2018-06-01 03:02:00.495927
NCT00509483|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2008-10-16|2007-07-27|2007-07-31|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2002||2002-01-31|October 2008|2008-10-31|December 2006||2006-12-31|||||Interventional|||Three-Year Follow-up of Radioiodine Therapy for Goitre|Long-Term Follow-up and Outcome of Administering Recombinant Human Thyrotropin as an Adjuvant of Therapy With Radioiodine in the Outpatient Treatment of Multinodular Goitres|Completed||N/A|40||University of Sao Paulo|||||f||||f||||||||||2018-06-01 03:02:01.064341|2018-06-01 03:02:01.064341
NCT00509470|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-28|||2016-10-17|2007-07-28|2007-07-31|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|ONEAST||Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine|ONgoing Evaluation of Depressor Effect And Safety of Combination Therapy With Telmisartan and Low-dose Hydrochlorothiazide in Patients With Hypertension Uncontrolled on Amlodipine Treatment|Completed||Phase 4|75|Actual|Tokyo University||2|||f||||f||||||||||2018-06-01 03:02:01.139069|2018-06-01 03:02:01.139069
NCT00509457|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2011-06-30|2007-07-30|2007-07-31|Estimate|||||||2011-06-30|2011-07-01|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|||||Interventional|||GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)|Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC). A Phase II Study of GV 1001 Telomerase Peptide Vaccination in Patients With Locally Advanced NSCLC|Completed||N/A|20|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:02:01.231091|2018-06-01 03:02:01.231091
NCT00509444|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2017-04-19|2007-07-30|2007-07-31|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2006||2006-10-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|CPTD||Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial|Cancer Prevention and Treatment Among African American Older Adults|Completed||Phase 3|200|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 03:02:01.290253|2018-06-01 03:02:01.290253
NCT00509431|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2016-02-05|2007-07-30|2007-07-31|Estimate|||||||2016-02-05|2016-02-08|Estimate|August 2006||2006-08-31|February 2016|2016-02-29|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma|A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus in Patients With Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics|Completed||Phase 1|19|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:02:01.374705|2018-06-01 03:02:01.374705
NCT00509418|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2009-01-09|2007-07-30|2007-07-31|Estimate|||||||2009-01-09|2009-01-12|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis|Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized, Controlled and Open Label Study|Completed||Phase 3|60|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 03:02:01.450613|2018-06-01 03:02:01.450613
NCT00509405|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2012-04-23|2007-07-30|2007-07-31|Estimate|||||||2012-04-23|2012-04-24|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Neutralization of Endogenous Acid Production on BMD and Bone Microarchitectural|Effect of Neutralization of Endogenous Acid Production on Bone Mineral Density and Microarchitectural Composition of Bone in Humans|Completed||Phase 3|202|Actual|Kantonsspital Baselland Bruderholz||1|||f||||f||||||||||2018-06-01 03:02:01.526089|2018-06-01 03:02:01.526089
NCT00509392|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2012-03-22||2017-06-13|2007-07-27|2007-07-31|Estimate|2017-06-13|2017-07-12|Actual||||2017-06-13|2017-07-12|Actual|March 2007||2007-03-31|June 2017|2017-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|RECOVERY|69 subjects were enrolled and 87 limbs were treated. There were 4 enrolled subjects that had bilateral treatment where one limb was treated with RF and the other limb was treated with EVL. To account for this, 2 subjects were added to the total number of baseline RF participant group and 2 were added to the baseline EVL participant group.|ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.|Radiofrequency Endovenous ClosureFAST vs. Laser Ablation for the Treatment of Great Saphenous Reflux: A Multicenter, Single-Blinded, Randomized Study (RECOVERY)|Completed||Phase 4|69|Actual|Medtronic Endovascular||2|||f||||f||||||||Yes||2018-06-01 03:02:01.732834|2018-06-01 03:02:01.732834
NCT00509379|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2011-01-27|2007-07-30|2007-07-31|Estimate|||||||2011-01-27|2011-01-28|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|January 2011|Actual|2011-01-31|November 2007|Actual|2007-11-30||Interventional|LYM-2023||Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma|A Phase II Multicenter Non-randomized Study to Assess Safety, Toxicity and Clinical Activity of the Association of Bortezomib(VELCADE)With Rituximab in Relapsed/Refractory Indolent Non Follicular and Mantle-cell Non-Hodgkin Lymphoma|Completed||Phase 2|48|Actual|Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie||1|||f||||t||||||||||2018-06-01 03:02:02.540828|2018-06-01 03:02:02.540828
NCT00509366|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2014-05-07||2014-08-15|2007-07-30|2007-07-31|Estimate|2014-08-15|2014-08-28|Estimate||||2014-08-15|2014-08-28|Estimate|May 2007||2007-05-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TOP0602|The number of participants in each group reflects the number of participants at the end of the study period (COMPLETED) in the Participant Flow Analysis, with the exception of 3 patients who were assigned treatment, but not treated, and were added to the number of screen failures.|Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer|Phase II Prospective Study Evaluating the Role of Personalized Chemotherapy Regimens for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy|Terminated||Phase 2|101|Actual|Duke University|The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.|4||Study terminated due to reproducibility issues with genomics prediction model.|f||||t||||||||||2018-06-01 03:02:02.730469|2018-06-01 03:02:02.730469
NCT00509353|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2014-08-28|2007-07-30|2007-07-31|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|October 2010|Actual|2010-10-31||Interventional|||N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma|Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma, A Phase I Study|Completed||Phase 1|26|Actual|Children's Hospital Los Angeles|||||f||||t||||||||||2018-06-01 03:02:04.145399|2018-06-01 03:02:04.145399
NCT00509340|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2013-06-20|2007-07-30|2007-07-31|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 2007||2007-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cognitive Behavioral Therapy to Help HIV Infected Adults With Depression to Adhere to Antiretroviral Therapy|Cognitive Behavioral Adherence Intervention for Depressed HIV Patients|Terminated||Phase 1|7|Actual|RAND||2||Inability to recruit enough eligible participants at study site.|f||||t||||||||||2018-06-01 03:02:04.238731|2018-06-01 03:02:04.238731
NCT00509327|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2007-07-30|2007-07-30|2007-07-31|Estimate|||||||2007-07-30|2007-07-31|Estimate|November 2004||2004-11-30|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery|Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery|Completed||Phase 4|200|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 03:02:04.311568|2018-06-01 03:02:04.311568
NCT00509314|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-29|||2007-07-29|2007-07-29|2007-07-31|Estimate|||||||2007-07-29|2007-07-31|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|December 2016|Anticipated|2016-12-31|||||Observational|||The Mechanism of Melanocyte Self-Assembly on Biomaterials and the Functional Analysis|The Mechanism of Melanocyte Self-Assembly on Biomaterials and the Functional Analysis|Unknown status|Recruiting||400|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:02:04.391253|2018-06-01 03:02:04.391253
NCT00509301|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2011-08-03|2007-07-27|2007-07-31|Estimate|||||||2011-08-03|2011-08-05|Estimate|November 2006||2006-11-30|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme|Open-label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme|Completed||Phase 1|12|Anticipated|Peregrine Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:02:04.468289|2018-06-01 03:02:04.468289
NCT00509288|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2012-11-14||2012-12-27|2007-07-30|2007-07-31|Estimate|2012-11-14|2012-12-18|Estimate||||2012-12-27|2012-12-28|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes|Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes|Completed||Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 03:02:04.569046|2018-06-01 03:02:04.569046
NCT00509275|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2017-05-24|2007-07-30|2007-07-31|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2007||2007-07-31|May 2017|2017-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP)|A Phase Ib, Randomized, Double Blind, Placebo Controlled Study to Investigate the Pharmacokinetics, Safety and Efficacy of 3 Different Doses of W0027 and Placebo Capsules in Subjects With Clinically and Mycologically Proven MTTP|Completed||Phase 1|120|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:02:05.130239|2018-06-01 03:02:05.130239
NCT00501566|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2007-07-13|2007-07-13|2007-07-16|Estimate|||||||2007-07-13|2007-07-16|Estimate|April 2004||2004-04-30|July 2007|2007-07-31|January 2005|Actual|2005-01-31|||||Interventional|Normo~CAT||Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites|SR121463B in Cirrhotic Ascites Treatment With Normonatraemia: A Placebo-Controlled, Dose-Comparison Study|Completed||Phase 2|148|Actual|Sanofi|||||f||||t||||||||||2018-06-01 03:04:36.850848|2018-06-01 03:04:36.850848
NCT00509262|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2012-02-28||2017-04-07|2007-07-27|2007-07-31|Estimate|2012-02-28|2012-03-28|Estimate||||2017-04-07|2017-05-12|Actual|October 9, 2007|Actual|2007-10-09|April 2017|2017-04-30|March 16, 2011|Actual|2011-03-16|March 16, 2011|Actual|2011-03-16||Interventional|||Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control|Completed||Phase 3|426|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:02:05.290255|2018-06-01 03:02:05.290255
NCT00509249|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2014-12-12||2015-01-07|2007-07-30|2007-07-31|Estimate|2015-01-07|2015-01-08|Estimate||||2015-01-07|2015-01-08|Estimate|September 2007||2007-09-30|November 2012|2012-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Aflibercept in Treating Patients With Myelodysplastic Syndromes|A Phase II Study of VEGF Trap (NSC 724770) in Patients With MDS|Terminated||Phase 2|18|Actual|National Cancer Institute (NCI)|Study was terminiated after completion of the first stage due to a lack of activity (no hematological responses were observed).|1||Early termination for discouraging results|f||||t||||||||||2018-06-01 03:02:05.803258|2018-06-01 03:02:05.803258
NCT00509236|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2012-02-13||2017-04-07|2007-07-27|2007-07-31|Estimate|2012-04-06|2012-05-03|Estimate||||2017-04-07|2017-05-12|Actual|October 19, 2007|Actual|2007-10-19|April 2017|2017-04-30|March 14, 2011|Actual|2011-03-14|March 14, 2011|Actual|2011-03-14||Interventional|||Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)|A Multicenter, Randomized Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control|Completed||Phase 3|129|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:02:06.070449|2018-06-01 03:02:06.070449
NCT00509223|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-29|2013-08-08||2013-12-04|2007-07-29|2007-07-31|Estimate|2013-08-08|2013-10-17|Estimate||||2013-12-04|2013-12-30|Estimate|July 2007||2007-07-31|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||118 subjects (of the 416 that started in the participant flow module) were not included in endpoint analysis due to reanalysis of OSA inclusion criteria. Thus, 298 of the 416 were included for final analysis.|GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes|Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes and Obstructive Sleep Apnea|Completed||N/A|416|Actual|ResMed||2|||f||||f||||||||||2018-06-01 03:02:06.664239|2018-06-01 03:02:06.664239
NCT00509210|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2008-10-28|2007-07-30|2007-07-31|Estimate|||||||2008-10-28|2008-10-29|Estimate|September 2007||2007-09-30|October 2008|2008-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Telaprevir in Subjects With Hepatic Impairment||Completed||Phase 1|||Vertex Pharmaceuticals Incorporated|||||f||||t||||||||||2018-06-01 03:02:07.005567|2018-06-01 03:02:07.005567
NCT00509197|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2015-05-26||2016-07-05|2007-07-27|2007-07-31|Estimate|2016-07-05|2016-08-15|Estimate||||2016-07-05|2016-08-15|Estimate|October 2007||2007-10-31|July 2016|2016-07-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?|Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?|Terminated||N/A|12|Actual|Université de Montréal|Very small sample size. Impossible to recruit the anticipated number of subjects.|2||Inability to complete the recruitment.|f||||f||||||||No||2018-06-01 03:02:07.092154|2018-06-01 03:02:07.092154
NCT00509184|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2013-07-21|2007-07-30|2007-07-31|Estimate|||||||2013-07-21|2013-07-23|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MIR||Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma|Therapy of Nodal Follicular Lymphoma (Grade I/II) Clinical Stage I or II Using Involved Field Radiotherapy in Combination With Rituximab|Completed||Phase 2|85|Actual|Heidelberg University|||||f||||t||||||||||2018-06-01 03:02:07.42014|2018-06-01 03:02:07.42014
NCT00509171|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2016-12-06|2007-07-30|2007-07-31|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2005||2005-01-31|December 2016|2016-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|RIA||Effect of a Novel Reamer-Irrigator-Aspirator on the Incidence of Fat Embolism|A Prospective Randomized Trial Investigating the Effect of a Novel Reamer-Irrigator-Aspirator on the Incidence of Fat Embolism and Respiratory Function During Intramedullary Nailing of Femoral Shaft Fractures|Completed||N/A|22|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-06-01 03:02:07.506497|2018-06-01 03:02:07.506497
NCT00509158|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2010-02-22|2007-07-30|2007-07-31|Estimate|||||||2010-02-22|2010-02-23|Estimate|October 2007||2007-10-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|LSA-3-rec||Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine|Phase I and IIa Trial for Assessment of Safety, Immunogenicity and Efficacy Against Sporozoite Challenge of the Candidate Malaria Vaccine PfLSA-3-rec|Completed||Phase 1/Phase 2|36|Anticipated|Radboud University|||||f||||t||||||||||2018-06-01 03:02:07.599782|2018-06-01 03:02:07.599782
NCT00509145|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27||2012-02-16|2012-02-16|2007-07-30|2007-07-31|Estimate||||2012-02-16|2012-02-20|Estimate|2012-02-16|2012-02-20|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|ALLEGRO||Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|Completed||Phase 3|1106|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 03:02:07.699237|2018-06-01 03:02:07.699237
NCT00509132|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2008-01-08|2007-07-27|2007-07-31|Estimate|||||||2008-01-08|2008-01-09|Estimate|May 2007||2007-05-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers|A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine in Healthy Volunteers|Completed||Phase 1|42|Anticipated|Genaera Corporation|||||f||||||||||||||2018-06-01 03:02:07.770053|2018-06-01 03:02:07.770053
NCT00509119|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2015-04-24|2007-07-30|2007-07-31|Estimate|||||||2015-04-24|2015-04-27|Estimate|December 2006||2006-12-31|October 2010|2010-10-31|December 2008|Anticipated|2008-12-31|||||Observational|||ICP Waveform Analysis in Stroke Patients|Retrospective ICP Waveform Analysis in Stroke Patients Followed Prospectively|Withdrawn|||0|Actual|Oslo University Hospital||||Change of workplace for leading investigator, not replaced|f||||f||||||||||2018-06-01 03:02:07.824603|2018-06-01 03:02:07.824603
NCT00509106|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2010-10-12||2017-02-02|2007-07-27|2007-07-31|Estimate|2010-10-12|2010-11-08|Estimate||||2017-02-02|2017-03-14|Actual|July 2007||2007-07-31|February 2017|2017-02-28|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|CAP||Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia|Completed||Phase 3|622|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 03:02:07.919648|2018-06-01 03:02:07.919648
NCT00509093|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2016-10-31|2007-07-30|2007-07-31|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2008||2008-12-31|October 2016|2016-10-31||||April 2013|Actual|2013-04-30||Interventional|||Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy|A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia|Active, not recruiting||Phase 2|32|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:02:08.572247|2018-06-01 03:02:08.572247
NCT00509080|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2018-02-23|2007-07-30|2007-07-31|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2006|Actual|2006-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Prognosis in Asymptomatic Mitral Regurgitation (PAMIR) Study|Prognosis in Asymptomatic Mitral Regurgitation (PAMIR) Study|Active, not recruiting|||200|Anticipated|University Hospital, Basel, Switzerland|||||f||||t||||||Samples Without DNA|"~     Blood samples~   "|No||2018-06-01 03:02:08.740539|2018-06-01 03:02:08.740539
NCT00509067|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2013-07-01||2018-03-13|2007-07-30|2007-07-31|Estimate|2014-01-09|2014-02-07|Estimate||||2018-03-13|2018-04-11|Actual|November 2007||2007-11-30|February 2018|2018-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|STAR-1||Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia|Interventions to Test the Alpha7 Nicotinic Receptor Model in Schizophrenia|Completed||Phase 2|43|Actual|Georgetown University||2|||f||||f||||||||||2018-06-01 03:02:08.819462|2018-06-01 03:02:08.819462
NCT00509054|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2008-04-15|2007-07-30|2007-07-31|Estimate|||||||2008-04-15|2008-04-16|Estimate|January 2001||2001-01-31|January 2001|2001-01-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Prevention of Parastomal Hernia With a Mesh|Randomised Clinical Trial of the Use of a Prosthetic Mesh to Prevent Parastomal Hernia|Completed||Phase 4|54|Anticipated|Sundsvall Hospital|||||f||||t||||||||||2018-06-01 03:02:09.215166|2018-06-01 03:02:09.215166
NCT00509041|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|2012-12-11||2016-07-11|2007-07-30|2007-07-31|Estimate|2012-12-11|2013-01-17|Estimate||||2016-07-11|2016-08-11|Estimate|August 2007||2007-08-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|February 2010|Actual|2010-02-28||Interventional|||Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma|A Phase II Study of Dasatinib (NSC #732517) in Patients With Previously Treated Malignant Mesothelioma|Completed||Phase 2|46|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 03:02:09.323154|2018-06-01 03:02:09.323154
NCT00509028|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2009-10-06||2012-07-24|2007-07-30|2007-07-31|Estimate|2012-07-24|2012-08-27|Estimate||||2012-07-24|2012-08-27|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma|An Open-label, Multi-center, Long Term Study to Investigate the Safety and Efficacy of Budesonide Turbuhaler® Treatment for 48 Weeks (Following 6 Weeks Phase III Study) in Japanese Children With Bronchial Asthma Aged 5 Years to 15 Years Old|Completed||Phase 3|241|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:02:09.870633|2018-06-01 03:02:09.870633
NCT00509015|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-30|||2008-08-12|2007-07-30|2007-07-31|Estimate|||||||2008-08-12|2008-08-13|Estimate|February 2008||2008-02-29|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|MDATRANS||Mass-Drug Administration to Reduce Malaria Transmission|Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine|Completed||N/A|6000|Anticipated|Radboud University||2|||f||||t||||||||||2018-06-01 03:02:10.344739|2018-06-01 03:02:10.344739
NCT00509002|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2017-10-25||2017-10-25|2007-07-27|2007-07-30|Estimate|2017-10-25|2017-11-24|Actual||||2017-10-25|2017-11-24|Actual|May 2004||2004-05-31|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Iressa Study in Patients With Salivary Gland Cancer|Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198)|Completed||Phase 2|37|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:02:10.436353|2018-06-01 03:02:10.436353
NCT00508989|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2018-02-13|2007-07-27|2007-07-30|Estimate|||||||2018-02-13|2018-02-14|Actual|July 24, 2007||2007-07-24|December 24, 2015|2015-12-24|December 24, 2015|Actual|2015-12-24|December 31, 2010|Actual|2010-12-31||Interventional|||Niacin to Improve Blood Flow in People With Sickle Cell Disease|Niacin Therapy to Improve Endothelial Function in Sickle Cell Disease|Completed||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:02:10.602841|2018-06-01 03:02:10.602841
NCT00508976|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2012-05-09|2007-07-26|2007-07-30|Estimate|||||||2012-05-09|2012-05-10|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic|Evaluation of Aerosolized Bupivacaine Versus Pre-incision Lidocaine Versus Instilled Liquid Bupivacaine Versus Post-operative Bupivacaine Injection for Optimization of Post-operative Pain Control in Laparoscopic Bariatric Surgical Patients|Completed||Phase 2|100|Actual|Pinnacle Health System||4|||f||||t||||||||||2018-06-01 03:02:10.760353|2018-06-01 03:02:10.760353
NCT00508963|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2014-12-12|2007-07-27|2007-07-30|Estimate|||||||2014-12-12|2014-12-15|Estimate||||December 2014|2014-12-31||||||||Expanded Access|||Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis|Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis|Available|||||University of California, San Francisco|||||||||||||||||||2018-06-01 03:02:10.937609|2018-06-01 03:02:10.937609
NCT00508950|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2016-08-16|2007-07-27|2007-07-30|Estimate|||||||2016-08-16|2016-08-17|Estimate|August 2007||2007-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay|Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Pneumococcal Opsonophagocytic Assay Development.|Completed||N/A|152|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:02:11.014994|2018-06-01 03:02:11.014994
NCT00508937|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2011-10-04|2007-07-27|2007-07-30|Estimate|||||||2011-10-04|2011-10-05|Estimate|February 2007||2007-02-28|October 2011|2011-10-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Dietary Protein and Insulin Sensitivity Study|The Effects of Increased Dietary Protein Intake on Insulin Sensitivity in Stable Weight Individuals, Independent of Dietary Content of Carbohydrate and Saturated Fat|Completed||N/A|250|Anticipated|Children's Hospital & Research Center Oakland||5|||f||||f||||||||||2018-06-01 03:02:11.170284|2018-06-01 03:02:11.170284
NCT00508924|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2012-11-06||2012-11-06|2007-07-26|2007-07-30|Estimate|2012-11-06|2012-12-05|Estimate||||2012-11-06|2012-12-05|Estimate|August 2005||2005-08-31|November 2012|2012-11-30|October 2006|Actual|2006-10-31|||||Interventional|||Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)|A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in Comparison With Unfractionated Heparin, Clopidogrel and Aspirin|Completed||Phase 2|140|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||||||||||||2018-06-01 03:02:11.368591|2018-06-01 03:02:11.368591
NCT00508911|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2017-08-03|2007-07-26|2007-07-30|Estimate|||||||2017-08-03|2017-08-04|Actual|June 8, 2007|Actual|2007-06-08|August 2017|2017-08-31|October 22, 2007|Actual|2007-10-22|October 22, 2007|Actual|2007-10-22||Interventional|||A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills|An Open-label, Repeat-dose, Single-sequence Study to Investigate the Effects of Once-daily Repeat Oral Administration of GW876008 125mg on the Pharmacokinetics of the Combined Oral Contraceptive in Female Volunteers|Terminated||Phase 1|4|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:02:12.125793|2018-06-01 03:02:12.125793
NCT00508898|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2015-07-31|2007-07-27|2007-07-30|Estimate|||||||2015-07-31|2015-08-04|Estimate|May 2008||2008-05-31|January 2009|2009-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria|The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria|Withdrawn||Phase 4|0|Actual|Chinese University of Hong Kong||2||Funding problem; trial abandoned.|f||||f||||||||||2018-06-01 03:02:12.205658|2018-06-01 03:02:12.205658
NCT00508885|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2007-07-26|2007-07-26|2007-07-30|Estimate|||||||2007-07-26|2007-07-30|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients|The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients|Completed||Phase 1/Phase 2|17|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 03:02:12.482377|2018-06-01 03:02:12.482377
NCT00508872|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2010-10-08||2012-07-27|2007-07-27|2007-07-30|Estimate|2010-10-08|2010-11-04|Estimate||||2012-07-27|2012-08-01|Estimate|November 2005||2005-11-30|July 2012|2012-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Folfox-B Study for Patients With Colorectal Liver Metastases|Single-Institution Phase II Trial of Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab (Folfox-B) for Initially Unresectable Colorectal Liver Metastases: Downstaging Followed By Hepatic Resection|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Slow accrual, study terminated.|f||||f||||||||||2018-06-01 03:02:12.660233|2018-06-01 03:02:12.660233
NCT00508859|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2007-07-27|2007-07-27|2007-07-30|Estimate|||||||2007-07-27|2007-07-30|Estimate|July 1997||1997-07-31|July 2007|2007-07-31||||||||Interventional|MTAD||Maintenance Study for Adolescent Depression||Completed||Phase 4|93|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 03:02:12.913776|2018-06-01 03:02:12.913776
NCT00508846|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2016-03-10|2007-07-26|2007-07-30|Estimate|||||||2016-03-10|2016-03-11|Estimate|May 2003||2003-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients|Screening for Gynecologic Cancers Among Women With Hereditary Non-Polyposis Colon Cancer (HNPCC)|Completed|||93|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:13.040524|2018-06-01 03:02:13.040524
NCT00508833|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2007-07-27|2007-07-27|2007-07-30|Estimate|||||||2007-07-27|2007-07-30|Estimate|March 2000||2000-03-31|July 2007|2007-07-31||||||||Interventional|||Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)|Safety and the Efficacy of GSK Biologicals' Candidate Adjuvanted Vaccines (287615) Containing HBsAg With Various Adjuvants to Induce Cytotoxic T Lymphocytes (CTL) in Healthy Adult Volunteers|Completed||Phase 1/Phase 2|200|Anticipated|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:02:13.153606|2018-06-01 03:02:13.153606
NCT00508820|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2012-01-11||2017-02-07|2007-07-26|2007-07-30|Estimate|2012-01-11|2012-02-13|Estimate||||2017-02-07|2017-02-09|Estimate|February 2005||2005-02-28|February 2017|2017-02-28|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP|An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Completed||Phase 3|407|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:02:13.279541|2018-06-01 03:02:13.279541
NCT00508807|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2012-07-27|2007-07-26|2007-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies|Clinical Study Protocol RTA 402-C-0501: A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDO-Me) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies|Completed||Phase 1|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:14.310849|2018-06-01 03:02:14.310849
NCT00508794|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2018-05-02|2007-07-27|2007-07-30|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2006|Actual|2006-03-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Effects of Yoga in Breast Cancer Patients|Biobehavioral Effects of Yoga During Breast Cancer Treatment|Active, not recruiting||N/A|180|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|f|f||||||||2018-06-01 03:02:14.394078|2018-06-01 03:02:14.394078
NCT00508781|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2007-07-26|2007-07-26|2007-07-30|Estimate|||||||2007-07-26|2007-07-30|Estimate|November 2002||2002-11-30|November 2002|2002-11-30|December 2012|Anticipated|2012-12-31|||||Observational|||Multiphoton Laser Scanning Microscopy in Cutaneous Optical Pathology|Multiphoton Laser Scanning Microscopy in Cutaneous Optical Pathology|Unknown status|Recruiting||400|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:02:14.500678|2018-06-01 03:02:14.500678
NCT00508768|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2011-05-18|2007-07-27|2007-07-30|Estimate|||||||2011-05-18|2011-05-19|Estimate||||April 2010|2010-04-30|December 2002|Actual|2002-12-31|||||Interventional|||A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid Arthritis|A Randomized, Double-Blind, Parallel-Group, Pharmacokinetic Study of Oral SCIO-469 (90 mg qd and 30 mg Tid) in Female Subjects With Active Rheumatoid Arthritis|Completed||Phase 1|16|Actual|Scios, Inc.|||||||||||||||||||2018-06-01 03:02:14.558203|2018-06-01 03:02:14.558203
NCT00508599|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2008-04-22|2007-07-27|2007-07-30|Estimate|||||||2008-04-22|2008-04-23|Estimate|May 2003||2003-05-31|April 2008|2008-04-30|February 2006|Actual|2006-02-28|October 2004|Actual|2004-10-31||Interventional|||The Effects of Two Days of Bedrest on Insulin Resistance in Type 2 Diabetics|Effect of a 2-Day Bed Rest on Metabolic and Cardiovascular Risk Factors in Type 2 Diabetic Patients|Completed||N/A|16|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 03:02:20.749663|2018-06-01 03:02:20.749663
NCT00508755|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2013-10-18||2014-04-08|2007-07-27|2007-07-30|Estimate|2014-02-18|2014-04-02|Estimate||||2014-04-08|2014-04-25|Estimate|August 2005||2005-08-31|April 2014|2014-04-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional||This was a feasibility study of six subjects. Sample size was constrained by funding limit.|Feasibility and Practice Characteristics of FNS and Gait Robot|Feasibility and Practice Characteristics of FNS and Gait Robot|Completed||N/A|6|Actual|VA Office of Research and Development|This was a feasibility study to determine the possibility of combining two technologies. Further study of the combined treatment is needed to determine whether the feasible combined treatment is more effective than other methods.|1|||f||||f||||||||||2018-06-01 03:02:14.612699|2018-06-01 03:02:14.612699
NCT00508742|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2012-06-12||2013-05-06|2007-07-27|2007-07-30|Estimate|2012-06-12|2012-07-13|Estimate||||2013-05-06|2013-05-10|Estimate|December 2007||2007-12-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Infants in Israel.|Completed||Phase 3|1866|Actual|Pfizer|Study designated analysis of effect of 13vPnC on serotypes 6A+19A, changed prior to unblinding, to effect on 6A’+19A. Serotype 6A found to include serotype 6A isolates and isolates of newly identified serotype 6C. Serotype 6A assessed as 6A+6C (6A’).|2|||f||||f||||||||||2018-06-01 03:02:14.92706|2018-06-01 03:02:14.92706
NCT00508729|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2007-07-29|2007-07-27|2007-07-30|Estimate|||||||2007-07-29|2007-07-31|Estimate|October 2007||2007-10-31|July 2007|2007-07-31|October 2010|Anticipated|2010-10-31|||||Interventional|||Effect of Traditional Chinese Medicine on GI Function Recovery and Nutrition Support in SAP|Effect of Traditional Chinese Medicine on Gastrointestinal Function Recovery and Nutrition Support in Severe Acute Pancreatitis|Unknown status|Not yet recruiting|Phase 2/Phase 3|300|Anticipated|Tianjin Nankai Hospital|||||f||||f||||||||||2018-06-01 03:02:18.441847|2018-06-01 03:02:18.441847
NCT00508716|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2015-03-15||2015-03-25|2007-07-27|2007-07-30|Estimate|2015-03-15|2015-03-25|Estimate||||2015-03-25|2015-04-15|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|||Health Literacy in Patients With Congestive Heart Failure|A Randomized-Controlled Trial of a Health Literacy Tailored Educational Intervention for Hospitalized Congestive Heart Failure Patients|Completed||N/A|124|Actual|Griffin Hospital||2|||f||||f||||||||||2018-06-01 03:02:18.570839|2018-06-01 03:02:18.570839
NCT00508703|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2017-09-11|2007-07-26|2007-07-30|Estimate|||||||2017-09-11|2017-09-12|Actual|March 5, 2003|Actual|2003-03-05|September 2017|2017-09-30|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Observational|||Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy|Pilot Study of Intensity Modulated Radiotherapy (IMRT) to Pelvis Post-Hysterectomy With Analysis of Clinical Target Volume Motion and Relation to Position and Volume of Bladder and Rectum During Course of Radiotherapy for Use in Optimization of Margin Size|Completed|||24|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:18.84368|2018-06-01 03:02:18.84368
NCT00508690|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2012-09-18|2007-07-27|2007-07-30|Estimate|||||||2012-09-18|2012-09-19|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics|Randomized Controlled Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics|Completed||Phase 3|584|Actual|Japan Multinational Trial Organization||2|||f||||t||||||||||2018-06-01 03:02:18.918145|2018-06-01 03:02:18.918145
NCT00508677|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2009-09-30|2007-07-26|2007-07-30|Estimate|||||||2009-09-30|2009-10-01|Estimate|March 2008||2008-03-31|July 2007|2007-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|MAZDAH||Mazindol in Children With ADHD : Open-label, Efficacy, Safety and Pharmacokinetic Pilot Trial|Mazindol in Children With Attention Deficit Hyperactivity Disorder Design Study to Explore the Effectiveness, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Orally Administered Doses of Mazindol.|Completed|||24|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 03:02:18.990239|2018-06-01 03:02:18.990239
NCT00508664|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2015-06-01|2007-07-27|2007-07-30|Estimate|||||||2015-06-01|2015-06-02|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|DeLOS II||Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)|Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx|Completed||Phase 2|180|Actual|University of Leipzig||2|||f||||f||||||||||2018-06-01 03:02:19.164814|2018-06-01 03:02:19.164814
NCT00508651|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2011-09-08||2011-11-28|2007-07-27|2007-07-30|Estimate|2011-11-28|2011-12-30|Estimate||||2011-11-28|2011-12-30|Estimate|October 2007||2007-10-31|November 2011|2011-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age|An Expanded Phase1/2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-560, A Live, Attenuated Recombinant Parainfluenza Virus Type 3 (PIV3) Vaccine, Administered Intranasally to Healthy Infants 1 to <12 Mos. of Age|Terminated||Phase 1/Phase 2|30|Actual|MedImmune LLC|Cohort 2 was not enrolled due to a sponsor decision.|2||"The study was closed prior to enrollment of Cohort 2 due to a non-safety related sponsor~   decision."|f||||f||||||||||2018-06-01 03:02:19.379188|2018-06-01 03:02:19.379188
NCT00508638|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2017-04-18|2007-07-26|2007-07-30|Estimate|||||||2017-04-18|2017-04-19|Actual|May 2007||2007-05-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|Stratify||Identifying High- and Low-Risk Heart Failure Patients in the Emergency Department (The Stratify Study)|Improving Heart Failure Risk Stratification in the ED|Completed|||1033|Actual|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 03:02:20.368378|2018-06-01 03:02:20.368378
NCT00508625|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26||2016-03-02|2016-06-10|2007-07-26|2007-07-30|Estimate||||2016-03-02|2016-03-30|Estimate|2016-06-10|2016-06-14|Estimate|June 2006||2006-06-30|June 2016|2016-06-30|November 2011|Actual|2011-11-30|March 2009|Actual|2009-03-31||Interventional|||A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab|A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects With Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy With or Without Bevacizumab|Completed||Phase 2|213|Actual|Amgen||5|||f||||||||||||||2018-06-01 03:02:20.444304|2018-06-01 03:02:20.444304
NCT00508417|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2017-06-30|2007-07-27|2007-07-30|Estimate|||||||2017-06-30|2017-07-02|Actual|July 24, 2007||2007-07-24|February 11, 2011|2011-02-11|February 11, 2011||2011-02-11|||||Observational|||Malaria Incidence in Infants in Bancoumana, Mali|Malaria Incidence in Infants in Bancoumana, Mali|Completed|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:02:24.110554|2018-06-01 03:02:24.110554
NCT00508586|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2016-03-01|2007-07-26|2007-07-30|Estimate|||||||2016-03-01|2016-03-03|Estimate|November 2007||2007-11-30|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer|A Phase 1b Study to Assess the Safety, Feasibility, Pharmacokinetics, and Activity of PTC299 Monotherapy or Combination Therapy With Hormonal Agents in Patients With Metastatic Breast Cancer|Completed||Phase 1|33|Actual|PTC Therapeutics||1|||f||||f||||||||||2018-06-01 03:02:20.824026|2018-06-01 03:02:20.824026
NCT00508573|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2018-01-08|2007-07-27|2007-07-30|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2007|Actual|2007-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Registry for Women Who Are At Risk Or May Have Lynch Syndrome|Registry for Women Who Are At Risk Or May Have Lynch Syndrome|Recruiting|||1000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Leftover tissue samples will be collected from surgery performed. These samples will be~     stored and used to perform molecular studies to characterize Lynch syndrome tumors.~   "|||2018-06-01 03:02:20.979405|2018-06-01 03:02:20.979405
NCT00508560|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2015-06-25|2007-07-27|2007-07-30|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders|Contingency Management for Smoking Cessation Among Veterans With Schizophrenia or Other Psychoses|Terminated||N/A|23|Actual|VA Office of Research and Development||2||Stopped due to low recruitment.|f||||f||||||||||2018-06-01 03:02:21.095745|2018-06-01 03:02:21.095745
NCT00508547|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2018-02-02|2007-07-27|2007-07-30|Estimate|||||||2018-02-02|2018-02-05|Actual|June 21, 2007|Actual|2007-06-21|February 2018|2018-02-28|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Observational|||Psoriasis Longitudinal Assessment and Registry (PSOLAR)|A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics|Active, not recruiting|||12052|Actual|Janssen Scientific Affairs, LLC|||4||f||||f||f||||||||2018-06-01 03:02:21.259965|2018-06-01 03:02:21.259965
NCT00508534|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2009-05-15|2007-07-26|2007-07-30|Estimate|||||||2009-05-15|2009-05-18|Estimate|July 2007||2007-07-31|May 2009|2009-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy People|An Open-Label Study to Evaluate the Effects of Repeat Dosing of Esomeprazole on the Pharmacokinetics of SB-751689 in Healthy Adult Subjects|Completed||Phase 1|13|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:02:21.777337|2018-06-01 03:02:21.777337
NCT00508521|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|2013-10-30||2013-12-19|2007-07-27|2007-07-30|Estimate|2013-12-19|2014-02-07|Estimate||||2013-12-19|2014-02-07|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Treatment of Hand Dysfunction After Stroke|Treatment of Hand Dysfunction After Stroke|Completed||N/A|4|Actual|VA Office of Research and Development|This was a small pilot feasibility study providing data for future work.|2|||f||||f||||||||||2018-06-01 03:02:21.889471|2018-06-01 03:02:21.889471
NCT00508508|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2013-06-17|2007-07-27|2007-07-30|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effectiveness of Peer Support in Improving Heart Failure Self-Management and Care|Mobilizing Peer Support for Effective Heart Failure Self-Management|Completed||N/A|266|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 03:02:22.19823|2018-06-01 03:02:22.19823
NCT00508495|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2011-08-10|2007-07-26|2007-07-30|Estimate|||||||2011-08-10|2011-08-11|Estimate|August 2007||2007-08-31|August 2011|2011-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-Containing Solutions in Post-Surgical Hip Replacement Pain|Single-Dose Comparison of the Analgesic Efficacy, Safety and Tolerability of Two Paracetamol 1%-Containing Solutions and Placebo in a Post-Surgical Total Hip Replacement Model|Completed||Phase 3|148|Actual|Baxter Healthcare Corporation||3|||f||||f||||||||||2018-06-01 03:02:22.396105|2018-06-01 03:02:22.396105
NCT00508482|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2012-11-28||2014-05-22|2007-07-26|2007-07-30|Estimate|2013-02-13|2013-03-15|Estimate||||2014-05-22|2014-06-04|Estimate|April 2008||2008-04-30|May 2014|2014-05-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||A Clinical Standardization Study of the Preferred Acupuncture Treatment Protocol to Treat Functional Constipation|A Clinical Standardization Study of the Preferred Acupuncture Treatment Protocol to Treat Functional Constipation|Completed||Phase 2|475|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|Spontaneous bowel movements were used as the primary outcome in our trial rather than complete, spontaneous bowel movements. Outcomes of follow-up were not the mean value of weekly data.|3|||f||||t||||||||||2018-06-01 03:02:22.519297|2018-06-01 03:02:22.519297
NCT00508469|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2012-06-08||2012-06-08|2007-07-27|2007-07-30|Estimate|2012-06-08|2012-07-12|Estimate||||2012-06-08|2012-07-12|Estimate|October 2007||2007-10-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Adherence Assessment With Travalert Dosing Aid|Adherence of Patients Using Travalert® for Instillation of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Compared to a Concomitant Regimen of Travoprost 0.004% and Timolol 0.5%|Completed||Phase 4|102|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 03:02:23.412606|2018-06-01 03:02:23.412606
NCT00508456|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2012-01-12|2007-07-27|2007-07-30|Estimate|||||||2012-01-12|2012-01-16|Estimate|August 2004||2004-08-31|January 2012|2012-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM|A Phase I Study of Dietary Methionine Restriction and Temodar® (Temozolomide) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme|Terminated||Phase 1|18|Actual|M.D. Anderson Cancer Center||1||Low Accrual|f||||f||||||||||2018-06-01 03:02:23.636039|2018-06-01 03:02:23.636039
NCT00508443|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2018-02-06|2007-07-27|2007-07-30|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2002|Actual|2002-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)|Phase I/II Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS) for the Treatment of Metastatic Spine Disease|Active, not recruiting||Phase 1/Phase 2|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:23.808928|2018-06-01 03:02:23.808928
NCT00508430|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2008-12-04|2007-07-26|2007-07-30|Estimate|||||||2008-12-04|2008-12-05|Estimate|July 2007||2007-07-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy|ASP 8825 Phase II Study—A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy|Terminated||Phase 2|199|Actual|Astellas Pharma Inc||4||"An independent DMC determined continuation was unlikely to demonstrate a statistically~   significant advantage of ASP8825 over placebo on the primary endpoint"|f||||t||||||||||2018-06-01 03:02:23.955598|2018-06-01 03:02:23.955598
NCT00508404|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2015-12-18|2010-07-20|2016-12-15|2007-07-26|2007-07-30|Estimate|2015-12-18|2016-01-26|Estimate|2010-07-20|2010-07-22|Estimate|2016-12-15|2017-02-08|Estimate|May 2007||2007-05-31|December 2016|2016-12-31|June 2012|Actual|2012-06-30|June 2009|Actual|2009-06-30||Interventional|||Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer|A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|154|Actual|Amgen||1|||f||||f||||||||||2018-06-01 03:02:24.213538|2018-06-01 03:02:24.213538
NCT00508391|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2009-10-27||2010-01-21|2007-07-26|2007-07-30|Estimate|2009-12-09|2010-01-18|Estimate||||2010-01-21|2010-01-26|Estimate|July 2007||2007-07-31|January 2010|2010-01-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||Interventricular Delay of Lumax HF-T for Heart Failure|Clinical Investigation to Study Safety and Efficacy of the Interventricular Delay Feature of the Lumax HF-T Device for Heart Failure.|Completed||Phase 2|122|Actual|Biotronik, Inc.||2|||f||||f||||||||||2018-06-01 03:02:24.850226|2018-06-01 03:02:24.850226
NCT00508378|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-27|||2017-10-23|2007-07-27|2007-07-30|Estimate|||||||2017-10-23|2017-10-25|Actual|January 2001|Actual|2001-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Chemotherapy-Related Toxicities In Ovarian Cancer Patients|Chemotherapy-Related Toxicities In Ovarian Cancer Patients: Preference Assessments of Patients, Family Members, Ancillary Staff and Gynecologic Oncologists, and Patients' Quality of Life|Active, not recruiting|||288|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:25.145297|2018-06-01 03:02:25.145297
NCT00508365|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2017-08-08|2007-07-26|2007-07-30|Estimate|||||||2017-08-08|2017-08-09|Actual|September 25, 2007|Actual|2007-09-25|August 2017|2017-08-31|June 3, 2008|Actual|2008-06-03|June 3, 2008|Actual|2008-06-03||Interventional|||Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives|A Study to Evaluate the Potential Incidence of Orthostatic Hypotension in Elderly Hypertensive Patients Following Administration of a Combination of COREG CR and Lisinopril|Completed||Phase 1|62|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:02:25.221749|2018-06-01 03:02:25.221749
NCT00508352|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2013-05-31|2007-07-26|2007-07-27|Estimate|||||||2013-05-31|2013-06-03|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer|Post-operative Locoregional Irradiation Using Helical Tomotherapy IMRT in the Management of Stage IIb-III Breast Cancer: a Feasibility Study|Completed||Phase 1/Phase 2|30|Actual|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-06-01 03:02:25.391777|2018-06-01 03:02:25.391777
NCT00508339|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2012-07-31|2007-07-26|2007-07-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2006||2006-09-30|July 2012|2012-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Functional Outcomes Following Limb Sparing Surgery for Sarcoma Patients|Functional Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma and Pre-Operative Radiotherapy|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:25.468638|2018-06-01 03:02:25.468638
NCT00508326|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-07-27|2007-07-25|2007-07-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|October 2005||2005-10-31|July 2012|2012-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement|Phase I Study of Paclitaxel Administered by Hepatic Artery Infusion to Patients With Advanced Cancer and Dominant Liver Involvement|Completed||Phase 1|27|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:25.540623|2018-06-01 03:02:25.540623
NCT00508313|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2016-04-06|2007-07-26|2007-07-27|Estimate|||||||2016-04-06|2016-04-08|Estimate|July 2007||2007-07-31|September 2009|2009-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Thermal Signature of Patients Undergoing Radiation Therapy|Phase I Assessment of Thermal Signature of Patients Undergoing Radiation Therapy|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||2|Study closed early without enrollment.|f||||f||||||||||2018-06-01 03:02:25.618667|2018-06-01 03:02:25.618667
NCT00508300|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2014-02-21|2007-07-26|2007-07-27|Estimate|||||||2014-02-21|2014-02-24|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EVA||Epidural Analgesia (EDA) Versus Patient Controlled Analgesia (PCA) in Laparoscopic Colon Surgery|Epidural Analgesia (EDA) Versus Patient Controlled Analgesia (PCA) in Laparoscopic Colon Surgery: A Monocentric Controlled Non-blinded Randomized Superiority Trial|Completed||N/A|128|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-06-01 03:02:25.726757|2018-06-01 03:02:25.726757
NCT00508287|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2009-03-13|2007-07-26|2007-07-27|Estimate|||||||2009-03-13|2009-03-16|Estimate|August 2007||2007-08-31|March 2009|2009-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes|Randomized, Placebo-Controlled, Single-Dose, Crossover Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes|Completed||Phase 1|36|Anticipated|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 03:02:25.845618|2018-06-01 03:02:25.845618
NCT00508274|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2009-07-24||2018-03-01|2007-07-26|2007-07-27|Estimate|2009-07-24|2009-09-03|Estimate||||2018-03-01|2018-03-29|Actual|July 18, 2007|Actual|2007-07-18|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 2, 2015|Actual|2015-12-02||Interventional|||Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China|An Open-Label Multicenter Study Administering Lapatinib and Capecitabine in Women With Advanced or MEtastatic Breast Cancer|Active, not recruiting||Phase 3|52|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 03:02:25.969777|2018-06-01 03:02:25.969777
NCT00508261|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26||2009-09-03|2016-10-18|2007-07-26|2007-07-27|Estimate||||2009-09-03|2009-09-04|Estimate|2016-10-18|2016-10-19|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine|Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix Hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children|Completed||Phase 3|793|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:02:26.25073|2018-06-01 03:02:26.25073
NCT00508248|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2016-10-24|2007-07-26|2007-07-27|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|November 2008|Anticipated|2008-11-30|January 2005||2005-01-31||Interventional|||Omega 3 Fatty Acids and Atrial Fibrillation|Use of Omega 3 Polyunsaturated Fatty Acids Supplements to Maintain Sinus Rhythm in Persistent Atrial Fibrillation|Withdrawn||N/A|0|Actual|University of Dundee||2||Funding|f||||t||||||||||2018-06-01 03:02:26.511065|2018-06-01 03:02:26.511065
NCT00508235|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2012-07-31|2007-07-26|2007-07-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2004||2004-12-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Quality of Friendships in Children With Neurofibromatosis|Quality of Friendships in Children With Neurofibromatosis: Relationship to Disease Severity|Completed|||61|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:26.605841|2018-06-01 03:02:26.605841
NCT00508222|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-05-28|2007-07-26|2007-07-27|Estimate|||||||2012-05-28|2012-05-30|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Kaletra Monotherapy in HIV/HCV Co-infected Subjects|A Pilot, Prospective, Open-label Study to Evaluate the Safety and Efficacy of Kaletra® Monotherapy in HIV/HCV Co-infected Subjects.|Completed||Phase 3|22|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 03:02:26.680826|2018-06-01 03:02:26.680826
NCT00508209|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2010-06-17|2007-07-26|2007-07-27|Estimate|||||||2010-06-17|2010-06-22|Estimate|July 2007||2007-07-31|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|June 2009|Actual|2009-06-30||Interventional|||Bortezomib and High-dose Melphalan at Myeloma Relapse|Phase II Study of Bortezomib Dexamethasone and High-dose Melphalan in Patients With Relapse After High-dose Melphalan With Autologous Stem Cell Support|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Nordic Myeloma Study Group|||||f||||t||||||||||2018-06-01 03:02:26.756503|2018-06-01 03:02:26.756503
NCT00508196|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2007-07-26|2007-07-26|2007-07-27|Estimate|||||||2007-07-26|2007-07-27|Estimate|November 2006||2006-11-30|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Endothelial Function and Cardiac Output in RV Pacing|Endothelial Function and Cardiac Output in Right Ventricular Pacing|Completed||N/A|22|Actual|University of Dundee||3|||f||||t||||||||||2018-06-01 03:02:26.832048|2018-06-01 03:02:26.832048
NCT00508183|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2017-04-04||2018-02-15|2007-07-26|2007-07-27|Estimate|2017-07-05|2018-01-29|Actual||||2018-02-15|2018-03-15|Actual|June 2007|Actual|2007-06-30|February 2018|2018-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Types of Fixation in Arthroscopic Rotator Cuff Repair|Single Row Versus Double Row Fixation in Arthroscopic Cuff Repair; a Randomized Controlled Sutdy.|Completed||N/A|90|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 03:02:26.917877|2018-06-01 03:02:26.917877
NCT00508170|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-07-27|2007-07-26|2007-07-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|March 2006||2006-03-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection|Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection|Completed|||252|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 03:02:27.179718|2018-06-01 03:02:27.179718
NCT00508157|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2010-06-22||2013-11-20|2007-07-26|2007-07-27|Estimate|2010-06-22|2010-07-20|Estimate||||2013-11-20|2013-12-13|Estimate|November 2007||2007-11-30|November 2013|2013-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome|A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome|Terminated||Phase 4|125|Actual|Bristol-Myers Squibb|Following a review of all studies in development, a strategic decision was made to terminate this study due to slow accrual. Patients randomized and treated at the time of study termination could continue the study as per protocol until completion.|2||Slow Accrual|f||||f||||||||||2018-06-01 03:02:27.291115|2018-06-01 03:02:27.291115
NCT00508144|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2016-12-20||2016-12-20|2007-07-26|2007-07-27|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|September 2005||2005-09-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer|Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|64|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:27.875872|2018-06-01 03:02:27.875872
NCT00508131|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2007-07-26|2007-07-26|2007-07-27|Estimate|||||||2007-07-26|2007-07-27|Estimate|May 2003||2003-05-31|July 2007|2007-07-31|July 2004|Actual|2004-07-31|||||Interventional|||Effectiveness of Iron-Fortified Milk on Iron Status and Anemia in Young Children in Mexico||Completed||Phase 3|798|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||f||||||||||2018-06-01 03:02:28.19406|2018-06-01 03:02:28.19406
NCT00508118|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2011-09-21||2014-07-29|2007-07-26|2007-07-27|Estimate|2013-01-31|2013-03-08|Estimate||||2014-07-29|2014-08-01|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|NICNACS||NICardipine Neuroprotection in AortiC Surgery (NICNACS)|NICardipine Neuroprotection in AortiC Surgery (NICNACS)|Terminated||Phase 2|7|Actual|Duke University|This study was terminated early because of safety concerns in the active treatment group. In 3 patients randomized, the blind was broken in 3 because of refractory hypotension and acidosis requiring vasopressor therapy. All 3 were on active drug.|2||3/7 subjects experienced hypotension. Study was terminated.|f||||f||||||||||2018-06-01 03:02:28.28568|2018-06-01 03:02:28.28568
NCT00508105|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-04-11|2007-07-26|2007-07-27|Estimate|||||||2012-04-11|2012-04-12|Estimate|November 2006||2006-11-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparing Two Surgical Methods of Fixation of Subscapularis During Shoulder Arthroplasty|Comparison of Two Methods of Fixation of Subscapularis During Shoulder Arthroplasty|Completed||N/A|87|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 03:02:28.57775|2018-06-01 03:02:28.57775
NCT00508092|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2008-04-22|2007-07-26|2007-07-27|Estimate|||||||2008-04-22|2008-04-24|Estimate|January 2007||2007-01-31|April 2008|2008-04-30||||||||Interventional|||Combined Nerve Blockade and Local Infiltration Anesthesia in Appendectomy - A Blinded Randomized Study|Combined Nerve Blockade and Local Infiltration Anesthesia in Appendectomy - A Blinded Randomized Study|Completed||N/A|75|Anticipated|Royal Berkshire NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 03:02:28.713167|2018-06-01 03:02:28.713167
NCT00508079|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2013-07-10|2007-07-25|2007-07-27|Estimate|||||||2013-07-10|2013-07-12|Estimate|July 2007||2007-07-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Evaluating the Occurence of New and Progression of Existing Peripheral Venous Disease in Leg Veins|Incidence and Progression of Peripheral Venous Disease|Completed|||1103|Actual|University of California, San Diego|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-06-01 03:02:28.811135|2018-06-01 03:02:28.811135
NCT00508066|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25||2013-01-15|2013-01-15|2007-07-25|2007-07-27|Estimate||||2013-01-15|2013-01-25|Estimate|2013-01-15|2013-01-25|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery|Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery|Completed||Phase 4|60|Actual|Shriners Hospitals for Children||2|||f||||f||||||||||2018-06-01 03:02:28.913678|2018-06-01 03:02:28.913678
NCT00508053|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2007-07-27|2007-07-26|2007-07-27|Estimate|||||||2007-07-27|2007-07-30|Estimate|January 2001||2001-01-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||When Closing Midline Incisions, do Small Stitches Reduce the Risk for Incisional Hernia, Wound Infection or Dehiscence?||Completed||N/A|737|Actual|Sundsvall Hospital||2|||f||||f||||||||||2018-06-01 03:02:29.06047|2018-06-01 03:02:29.06047
NCT00508040|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2013-01-22|2007-07-26|2007-07-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|September 2007||2007-09-30|October 2008|2008-10-31|January 2013|Actual|2013-01-31|October 2011|Actual|2011-10-31||Interventional|BIRDFERON||Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a|Evaluation of Birdshot RETINE CHOROIDOPATHY Treatment by Either Steroid or Interferon alpha2a|Completed||Phase 2|58|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:02:29.168836|2018-06-01 03:02:29.168836
NCT00508027|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2013-02-11||2013-08-20|2007-07-26|2007-07-27|Estimate|2013-05-21|2013-08-16|Estimate||||2013-08-20|2013-09-17|Estimate|June 2007||2007-06-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||42 subjects started the study; of these,12 were withdrawn from the study and 30 completed the study: dose level 1 (n=16); dose level 2 (n=12), dose level 3 (n=2). Only those participants who completed the study were included in the final analyses (n=30).|Simvastatin (Zocor) Therapy in Sickle Cell Disease|Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease|Completed||Phase 1/Phase 2|42|Actual|Children's Hospital & Research Center Oakland||1|||f||||t||||||||||2018-06-01 03:02:29.280536|2018-06-01 03:02:29.280536
NCT00508014|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2013-10-10|2007-07-26|2007-07-27|Estimate|||||||2013-10-10|2013-10-14|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Assessing the Effectiveness of Concurrent Peer Review for Patients With Cardiovascular Disease and Diabetes|Concurrent Peer Review Visits to Reduce Cardiovascular Risk Factors|Completed||N/A|727|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 03:02:29.717052|2018-06-01 03:02:29.717052
NCT00508001|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2011-05-09||2016-08-29|2007-07-26|2007-07-27|Estimate|2012-06-12|2012-07-17|Estimate||||2016-08-29|2016-10-10|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)|A Randomised, Double-blind, Parallel Group, Multi-centre, Phase II Study to Assess the Efficacy and Safety of Best Support Care (BSC) Plus ZD6474(Vandetanib) 300 mg, BSC Plus ZD6474(Vandetanib) 100 mg, and BSC Plus Placebo in Patients With Inoperable Hepatocellular Carcinoma (HCC)|Completed||Phase 2|67|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:02:29.879161|2018-06-01 03:02:29.879161
NCT00507988|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2009-05-14|2007-07-25|2007-07-27|Estimate|||||||2009-05-14|2009-05-15|Estimate|August 2007||2007-08-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Complex Problem Solving Training in Schizophrenic Patients|Complex Problem Solving Training in Schizophrenic Patients|Completed||N/A|91|Actual|Heidelberg University||2|||f||||t||||||||||2018-06-01 03:02:30.51209|2018-06-01 03:02:30.51209
NCT00507975|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-12-12|2007-07-26|2007-07-27|Estimate|||||||2012-12-12|2012-12-13|Estimate|November 2007||2007-11-30|July 2007|2007-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SNIPP||Study of Nicotine Patch in Pregnancy (SNIPP)|Assessment of the Effectiveness of Nicotine Replacement Therapies (Nicotine Patches Delivering Nicotine 16 h/24 h) in 400 Pregnant Smokers. Randomized, Placebo-controlled, Multicenter, National Study. The SNIPP.|Completed||Phase 3|404|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:02:30.660242|2018-06-01 03:02:30.660242
NCT00507962|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-08-01|2007-07-25|2007-07-27|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 2005||2005-03-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement|A Phase I Study Dose Escalation Clinical Study Of Hepatic Intraarterial Cisplatin, In Combination With Systemic Intravenous Liposomal Doxorubicin Administered Every Four Weeks to Patients With Advanced Cancer And Dominant Liver Involvement|Completed||Phase 1|51|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:30.731248|2018-06-01 03:02:30.731248
NCT00507949|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2011-06-07|2007-07-26|2007-07-27|Estimate|||||||2011-06-07|2011-06-08|Estimate|October 2006||2006-10-31|June 2011|2011-06-30|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight|Randomized Trial,Comparative With Placebo, Double Blind, to Evaluate the Effect of the Treatment With 320 mg/d of Megestrol Acetate in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) and Loss of Body Weight. Pilot Study|Completed||Phase 2|40|Anticipated|Rottapharm Spain||2|||f||||f||||||||||2018-06-01 03:02:30.813482|2018-06-01 03:02:30.813482
NCT00507936|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25||2011-09-21|2013-01-15|2007-07-25|2007-07-27|Estimate||||2011-09-21|2011-10-05|Estimate|2013-01-15|2013-01-23|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain|A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain|Completed||Phase 2|280|Actual|AbbVie||5|||f||||f||||||||||2018-06-01 03:02:30.943617|2018-06-01 03:02:30.943617
NCT00507923|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2018-03-14|2007-07-26|2007-07-27|Estimate|||||||2018-03-14|2018-03-16|Actual|November 2006|Actual|2006-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Effects of Tibetan Yoga on Fatigue and Sleep in Cancer|Effects of Tibetan Yoga on Fatigue and Sleep in Cancer|Active, not recruiting||N/A|480|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|f|f||||||||2018-06-01 03:02:31.186018|2018-06-01 03:02:31.186018
NCT00507910|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2011-07-19|2007-07-26|2007-07-27|Estimate|||||||2011-07-19|2011-07-21|Estimate|December 2006||2006-12-31|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||The Development of Flat Foot After Ankle Fractures|Pes Planus After Weber B and C Ankle Fractures|Completed|||25|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 03:02:31.307103|2018-06-01 03:02:31.307103
NCT00507897|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2008-02-06|2007-07-26|2007-07-27|Estimate|||||||2008-02-06|2008-02-07|Estimate||||February 2008|2008-02-29|December 2007|Actual|2007-12-31|||||Observational|||Hemodynamic Parameters in Euthyroid Patients With Thyroid Nodules||Terminated|||100|Anticipated|Yaroslavl State Medical Academy|||4|The received reliability with increase in quantity of participants of research did not vary|f||||f||||||||||2018-06-01 03:02:31.368828|2018-06-01 03:02:31.368828
NCT00507884|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2018-01-18|2007-07-26|2007-07-27|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2005|Actual|2005-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors|Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors|Active, not recruiting|||45|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:31.422266|2018-06-01 03:02:31.422266
NCT00507871|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2009-12-02|2007-07-26|2007-07-27|Estimate|||||||2009-12-02|2009-12-03|Estimate|October 2007||2007-10-31|September 2007|2007-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Transmission and the Respiratory Tract in Cryptosporidiosis|Prevalence and Clinical Presentation of Respiratory Cryptosporidiosis Among Children With Diarrhea in Mulago Hospital, Uganda|Completed|||480||Tufts University|||||f||||||||||||||2018-06-01 03:02:31.492083|2018-06-01 03:02:31.492083
NCT00507858|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2011-09-22|2007-07-26|2007-07-27|Estimate|||||||2011-09-22|2011-09-23|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer|A Phase I Dose Escalation Study of Pemetrexed in Patients With Advanced Head and Neck Squamous Cell Cancer|Completed||Phase 1|36|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 03:02:31.605798|2018-06-01 03:02:31.605798
NCT00507845|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2009-04-16|2007-07-26|2007-07-27|Estimate|||||||2009-04-16|2009-04-17|Estimate|June 2007||2007-06-30|April 2009|2009-04-30||||April 2008|Actual|2008-04-30||Interventional|RAFEHELP||Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina|Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina|Completed||Phase 4|271|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:02:31.696231|2018-06-01 03:02:31.696231
NCT00507832|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2010-07-06|2007-07-26|2007-07-27|Estimate|||||||2010-07-06|2010-07-07|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|CASM981CDE21||Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease|Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease|Completed||Phase 2|30|Actual|University Hospital Muenster||2|||f||||t||||||||||2018-06-01 03:02:31.768246|2018-06-01 03:02:31.768246
NCT00507819|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2011-02-09||2015-05-04|2007-07-25|2007-07-27|Estimate|2015-05-04|2015-05-05|Estimate||||2015-05-04|2015-05-05|Estimate|December 2007||2007-12-31|May 2015|2015-05-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|SAFO|All subjects who consented to participate and were randomized, completed at least the first six-week study period.|Sildenafil After the Fontan Operation|The Sildenafil After Fontan Operation Study|Completed||Phase 2|28|Actual|Children's Hospital of Philadelphia|Characteristics of screened but not enrolled subjects was not evaluated, so enrolled subjects may not be a representative sample from the group at large. Safety of Sildenafil over a prolonged (>6week) period of continuous use was not evaluated.|2|||f||||f||||||||||2018-06-01 03:02:31.917765|2018-06-01 03:02:31.917765
NCT00507806|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2007-07-25|2007-07-25|2007-07-27|Estimate|||||||2007-07-25|2007-07-27|Estimate|March 2005||2005-03-31|July 2007|2007-07-31|May 2006|Actual|2006-05-31|||||Interventional|||Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke|Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke|Terminated||Phase 1/Phase 2|||ImaRx Therapeutics||||for administrative reasons|f||||t||||||||||2018-06-01 03:02:32.273639|2018-06-01 03:02:32.273639
NCT00507793|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2007-07-26|2007-07-26|2007-07-27|Estimate|||||||2007-07-26|2007-07-27|Estimate|April 2000||2000-04-30|July 2007|2007-07-31|June 2002|Actual|2002-06-30|||||Interventional|||Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus|An Open-Label Study to Evaluate the Efficacy and Safety of Cyclosporine Reduction in de Novo Renal Allograft Recipients Receiving Sirolimus: a Dose Comparative Study|Completed||Phase 4|385|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:02:32.350157|2018-06-01 03:02:32.350157
NCT00507780|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|||2017-06-30|2007-07-26|2007-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|July 18, 2007||2007-07-18|July 22, 2010|2010-07-22|July 22, 2010|Actual|2010-07-22|July 22, 2010|Actual|2010-07-22||Interventional|||Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy|Use of the GnRH Agonist Leuprolide Acetate (Lupron(Registered Trademark)) to Preserve Ovarian Function in Women Undergoing Chemotherapy|Withdrawn||Phase 4|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:02:32.425227|2018-06-01 03:02:32.425227
NCT00507767|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-26|2012-04-18||2014-09-17|2007-07-26|2007-07-27|Estimate|2012-07-26|2012-07-27|Estimate||||2014-09-17|2014-10-01|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma|Completed||Phase 2|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:02:32.525383|2018-06-01 03:02:32.525383
NCT00507754|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2011-09-22|2007-07-25|2007-07-27|Estimate|||||||2011-09-22|2011-09-26|Estimate|June 2007||2007-06-30|September 2011|2011-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Latent Tuberculosis Infection in Cancer Patients|Latent Mycobacterium Tuberculosis Infection Among Cancer Patients|Completed|||24|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     A blood sample will be collected and used to perform the T-SPOT. TB test.~   "|||2018-06-01 03:02:32.768315|2018-06-01 03:02:32.768315
NCT00507741|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24||2011-03-21|2014-12-18|2007-07-24|2007-07-26|Estimate||||2011-03-21|2011-03-28|Estimate|2014-12-18|2015-01-07|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)|Protocol EC-FV-02: A Phase II Study of EC145 in Patients With Advanced Ovarian and Endometrial Cancers|Completed||Phase 2|49|Actual|Endocyte||1|||f||||f||||||||||2018-06-01 03:02:32.84249|2018-06-01 03:02:32.84249
NCT00507728|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2018-01-31|2007-07-25|2007-07-26|Estimate|||||||2018-01-31|2018-02-01|Actual|December 5, 2005|Actual|2005-12-05|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Pharmacogenetics, Emotional Reactivity and Smoking|Pharmacogenetics, Emotional Reactivity and Smoking|Active, not recruiting||Phase 2/Phase 3|646|Actual|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-06-01 03:02:32.917554|2018-06-01 03:02:32.917554
NCT00507715|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2007-07-25|2007-07-25|2007-07-26|Estimate|||||||2007-07-25|2007-07-26|Estimate|September 2006||2006-09-30|July 2007|2007-07-31|November 2006|Actual|2006-11-30|||||Interventional|||Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk|Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk|Completed||Phase 1|18|Actual|Rottapharm Spain||2|||f||||f||||||||||2018-06-01 03:02:33.026142|2018-06-01 03:02:33.026142
NCT00507702|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-07-05|2007-07-25|2007-07-26|Estimate|||||||2012-07-05|2012-07-09|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Identification of Key Blood Molecular Markers for Immunotherapy|Identification of Key Blood Molecular Markers for Immunotherapy|Suspended|||300|Anticipated|Stanford University||||Improving assay methods|f||||t||||||||||2018-06-01 03:02:33.092937|2018-06-01 03:02:33.092937
NCT00507689|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2013-07-15|2012-05-02|2014-02-12|2007-07-25|2007-07-26|Estimate|2013-07-15|2013-09-19|Estimate|2012-05-02|2012-05-04|Estimate|2014-02-12|2014-03-14|Estimate|September 2007||2007-09-30|February 2014|2014-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Three groups are reported for baseline characteristics: the 2 treatment groups in the randomized period, and non-randomized participants who discontinued prior to the randomized period.|Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant|A Phase 2, Open-Label Randomized Study to Evaluate the Efficacy and Safety of the Combination Product, Emtricitabine/Tenofovir Disoproxil Fumarate in the Presence or Absence of Hepatitis B Immunoglobulin (HBIg) in Preventing Recurrence of Chronic Hepatitis B (CHB) Post-Orthotopic Liver Transplant (OLT)|Completed||Phase 2|40|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 03:02:33.173961|2018-06-01 03:02:33.173961
NCT00507676|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-03-29|2007-07-25|2007-07-26|Estimate|||||||2012-03-29|2012-03-30|Estimate|October 2000||2000-10-31|January 2011|2011-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing|Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing|Completed|||220|Actual|Indiana University|||3||f||||t||||||Samples Without DNA|"~     We collect hair samples to analyzed for nicotine and cotinine.~   "|||2018-06-01 03:02:33.708537|2018-06-01 03:02:33.708537
NCT00507663|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2016-03-14|2007-07-25|2007-07-26|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2002||2002-09-30|March 2016|2016-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Elder Surgery - Functional Recovery Following Beta Blockade|Elder Surgery - Functional Recovery Following Beta Blockade|Completed||Phase 4|359|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 03:02:33.762757|2018-06-01 03:02:33.762757
NCT00507650|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2015-03-05|2007-07-25|2007-07-26|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2003||2003-09-30|March 2015|2015-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Increasing Fluids in Older Adults to Prevent & Treat Pressure Ulcers|Supplement Fluid & Collagen Deposition|Completed||N/A|63|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 03:02:33.839508|2018-06-01 03:02:33.839508
NCT00507637|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-02-03|2007-07-25|2007-07-26|Estimate|||||||2012-02-03|2012-02-06|Estimate|August 2007||2007-08-31|February 2012|2012-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Blepharospasm Short Interval|Prospective, Open-label, Single-arm, Single-center Trial to Investigate the Tolerability of NT 201 and Quality of Life of Patients in the Treatment of Blepharospasm With Shortened Injection Intervals|Terminated||Phase 2|8|Actual|Merz Pharmaceuticals GmbH||1||primary efficacy endpoint not attainable.|f||||f||||||||||2018-06-01 03:02:33.903328|2018-06-01 03:02:33.903328
NCT00507611|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-09-23|2007-07-25|2007-07-26|Estimate|||||||2012-09-23|2012-09-25|Estimate|October 2006||2006-10-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients|Sentinel Lymph Node Mapping and Biopsy For Predicting the Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients Who Had Biopsy-Proven Axillary Lymph Node Involvement at Initial Presentation|Completed||N/A|11|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:02:33.969394|2018-06-01 03:02:33.969394
NCT00507598|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2014-09-10|2007-07-25|2007-07-26|Estimate|||||||2014-09-10|2014-09-11|Estimate|July 2007||2007-07-31|September 2014|2014-09-30|November 2012|Actual|2012-11-30|March 2009|Actual|2009-03-31||Observational|metabolomics||Metabolomics-Based Detection of Colorectal Cancer|Metabolomics-Based Detection of Colorectal Cancer|Completed|||69|Actual|Indiana University|||||f||||t||||||Samples With DNA|"~     serum, urine~   "|||2018-06-01 03:02:34.040262|2018-06-01 03:02:34.040262
NCT00507585|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-07-26|2007-07-24|2007-07-26|Estimate|||||||2012-07-26|2012-07-30|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin|A Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Avastin for Patients With Advanced Solid Tumors Metastatic to the Liver|Completed||Phase 1|63|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:34.100583|2018-06-01 03:02:34.100583
NCT00507572|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2017-09-13|2007-07-25|2007-07-26|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2005|Actual|2005-12-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Collection of Outcomes Data for Pregnant Patients With Cancer|Collection of Outcomes Data for Pregnant Patients With Cancer|Recruiting|||500|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:02:34.179523|2018-06-01 03:02:34.179523
NCT00507559|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|2016-04-21||2016-10-07|2007-07-25|2007-07-26|Estimate|2016-04-21|2016-05-27|Estimate||||2016-10-07|2016-11-22|Estimate|September 2007||2007-09-30|April 2016|2016-04-30|May 2014|Actual|2014-05-31|March 2010|Actual|2010-03-31||Interventional|STAPLE-2||The Pivotal Study of the Aptus Endovascular AAA Repair System|The Pivotal Study of the Aptus Endovascular AAA Repair System|Completed||N/A|155|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-06-01 03:02:34.253786|2018-06-01 03:02:34.253786
NCT00507546|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2013-09-13||2014-04-25|2007-07-25|2007-07-26|Estimate|2014-04-25|2014-05-22|Estimate||||2014-04-25|2014-05-22|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia|Melatonin Replacement for Treatment of Sleep Disruption|Completed||Phase 4|12|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:02:34.732654|2018-06-01 03:02:34.732654
NCT00507533|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2009-02-17|2007-07-25|2007-07-26|Estimate|||||||2009-02-17|2009-02-18|Estimate|October 2005||2005-10-31|February 2009|2009-02-28||||November 2007|Actual|2007-11-30||Interventional|HEMOCPAP||Early Application of CPAP in Hematologic|Early Application of CPAP in Hematologic Neutropenic Patients Avoid Acute Respiratory Failure|Completed||Phase 4|40|Anticipated|University of Turin, Italy|||||f||||t||||||||||2018-06-01 03:02:34.973679|2018-06-01 03:02:34.973679
NCT00507520|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2007-07-25|2007-07-25|2007-07-26|Estimate|||||||2007-07-25|2007-07-26|Estimate|December 1999||1999-12-31|July 2007|2007-07-31|September 2001|Actual|2001-09-30|||||Interventional|||Almond Dose Response Study.|The Effect of Almonds on Coronary Heart Disease Risk Factors: Dose Response Study.|Completed||Phase 2|27|Actual|University of Toronto|||||f||||||||||||||2018-06-01 03:02:35.089061|2018-06-01 03:02:35.089061
NCT00507507|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2013-05-23|2012-12-12|2015-07-07|2007-07-25|2007-07-26|Estimate|2013-05-23|2013-08-08|Estimate|2012-12-17|2012-12-19|Estimate|2015-07-07|2015-07-17|Estimate|September 2007||2007-09-30|July 2015|2015-07-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional||Participants who were randomized and treated were analyzed for baseline characteristics.|A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)|A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B|Completed||Phase 2|126|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 03:02:35.207437|2018-06-01 03:02:35.207437
NCT00507494|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2011-10-27|2007-07-25|2007-07-26|Estimate|||||||2011-10-27|2011-10-28|Estimate|July 2007||2007-07-31|October 2011|2011-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Influence of Pioglitazone for Renal Transplant Function in Diabetics|Influence of Pioglitazone for Renal Transplant Function in Diabetics - a Double Blind Randomised Placebo Controlled Cross Over Study|Completed||Phase 3|||Technische Universität Dresden|||||f||||t||||||||||2018-06-01 03:02:36.346972|2018-06-01 03:02:36.346972
NCT00507481|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2008-06-03|2007-07-25|2007-07-26|Estimate|||||||2008-06-03|2008-06-04|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|September 2007|Actual|2007-09-30|||||Observational|||Evaluation of Risk Factors of Sleep Quality in Intensive Care Unit|Evaluation of Risk Factors of Sleep Quality in Critically Ill Patients|Completed|||||University of Turin, Italy|||||f||||f||||||||||2018-06-01 03:02:36.446751|2018-06-01 03:02:36.446751
NCT00507468|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-22|||2009-11-02|2007-07-25|2007-07-26|Estimate|||||||2009-11-02|2009-11-03|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|TABMMI||Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone|Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone|Completed||Phase 1|20|Actual|BioCardia, Inc.|||||f||||t||||||||||2018-06-01 03:02:36.545862|2018-06-01 03:02:36.545862
NCT00507455|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2014-07-14|2009-09-25|2014-07-14|2007-07-25|2007-07-26|Estimate|2014-07-14|2014-08-06|Estimate|2009-09-25|2009-09-28|Estimate|2014-07-14|2014-08-06|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction|A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)|Completed||Phase 2|222|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||f||||||||||2018-06-01 03:02:36.668211|2018-06-01 03:02:36.668211
NCT00507442|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2011-11-28||2013-07-18|2007-07-25|2007-07-26|Estimate|2011-11-28|2011-12-29|Estimate||||2013-07-18|2013-07-26|Estimate|August 2007||2007-08-31|April 2012|2012-04-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|EVOLUTION||Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients|Phase 1/2 Study of VELCADE® (Bortezomib), Dexamethasone, and Revlimid® (Lenalidomide) Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid Versus VELCADE, Dexamethasone and Cyclophosphamide in Subjects With Previously Untreated Multiple Myeloma|Completed||Phase 1/Phase 2|158|Actual|Millennium Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-06-01 03:02:37.823738|2018-06-01 03:02:37.823738
NCT00507429|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2013-08-16||2014-05-12|2007-07-25|2007-07-26|Estimate|2014-05-12|2014-06-09|Estimate||||2014-05-12|2014-06-09|Estimate|August 2007||2007-08-31|February 2014|2014-02-28|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|FACT||Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer|A Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin in Comparison With Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma [FACT]|Terminated||Phase 2/Phase 3|80|Actual|Mateon Therapeutics|The study was to enroll 180 subjects. Enrollment was terminated early due to low accrual rate. Eighty subjects were enrolled.|2||Low rate of subject accrual|f||||t||||||||||2018-06-01 03:02:39.44478|2018-06-01 03:02:39.44478
NCT00507416|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2014-03-28||2014-03-28|2007-07-25|2007-07-26|Estimate|2014-03-28|2014-05-01|Estimate||||2014-03-28|2014-05-01|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|UPFRONT|Intention to treat population, defined as all participants randomized|Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone|Randomized Phase 3b Study of Three Treatment Regimens in Subjects With Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE, Thalidomide, and Dexamethasone Versus VELCADE and Dexamethasone Versus VELCADE, Melphalan, and Prednisone|Completed||Phase 3|502|Actual|Millennium Pharmaceuticals, Inc.||3|||f||||||||||||||2018-06-01 03:02:41.112953|2018-06-01 03:02:41.112953
NCT00507403|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2017-01-13|2007-07-24|2007-07-26|Estimate|||||||2017-01-13|2017-01-16|Estimate|October 2007||2007-10-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|SPAXIM||Infliximab and Methotrexate in Ankylosing Spondylitis|Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis|Completed||Phase 4|30|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-06-01 03:02:43.509849|2018-06-01 03:02:43.509849
NCT00507390|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2016-10-24|2007-07-25|2007-07-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia|The Effect of Omega-3 Polyunsaturated Fatty Acid Supplements on Microvolt T Wave Alternans in Patients With Ventricular Arrhythmia|Withdrawn||Phase 4|0|Actual|University of Dundee||2||funding not secured|f||||t||||||||No||2018-06-01 03:02:43.583551|2018-06-01 03:02:43.583551
NCT00507377|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2018-05-02|2007-07-25|2007-07-26|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2005||2005-09-30|May 2018|2018-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|GERDSurgery||Foreshortened Esophagus and Its Surgical Therapy|Frequency, Predictors, Intraoperative Assessment and Outcome of Foreshortened Esophagus and Its Surgical Therapy in Patients Treated for Gastro-Esophageal Reflux Disease (GERD)|Completed|||180|Actual|University of Bologna|||||f||||t||||||||||2018-06-01 03:02:43.679771|2018-06-01 03:02:43.679771
NCT00507364|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2007-07-25|2007-07-25|2007-07-26|Estimate|||||||2007-07-25|2007-07-26|Estimate||||July 2007|2007-07-31||||||||Interventional|||Treatment of Anal Fissure by Activated Human Macrophages|Treatment of Anal Fissure by Activated Human Macrophages|Unknown status|Not yet recruiting|Phase 3|||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:02:43.739475|2018-06-01 03:02:43.739475
NCT00507351|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-07-31|2007-07-24|2007-07-26|Estimate|||||||2012-07-31|2012-08-01|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Ambulatory Cancer Pain Management: A Feasibility Study|Ambulatory Cancer Pain Management: A Feasibility Study|Completed|||30|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:43.801054|2018-06-01 03:02:43.801054
NCT00507338|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2009-01-08|2007-07-24|2007-07-26|Estimate|||||||2009-01-08|2009-01-09|Estimate|October 2007||2007-10-31|January 2009|2009-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|vITAL-1||Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI|A Phase 2 Study of an Aptameric Von Willebrand Factor Antagonist, ARC1779, in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention|Terminated||Phase 2|300|Anticipated|Archemix Corp.||4|||f||||t||||||||||2018-06-01 03:02:43.866556|2018-06-01 03:02:43.866556
NCT00507325|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2017-09-12|2007-07-25|2007-07-26|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2006|Actual|2006-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Sample Collection From Melanoma Patients|Blood and Tumor Sample Collection From Patients With Malignant Melanoma for Long Term Storage|Active, not recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Patients will provide blood and tumor samples to help researchers learn about melanoma and~     other cancers.~   "|||2018-06-01 03:02:43.973113|2018-06-01 03:02:43.973113
NCT00507312|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2015-06-02|2007-07-25|2007-07-26|Estimate|||||||2015-06-02|2015-06-04|Estimate|October 2007||2007-10-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|January 2009|Actual|2009-01-31||Interventional|||Assessment of Myocardial Disease in Man Using Novel Non-invasive Diagnostic Tools|Assessment of Myocardial Disease in Man Using Novel Non-invasive Diagnostic Tools|Terminated||Phase 1|41|Actual|Monash University||3||Suspended while we determine if usable data can be collected from this device.|f||||f||||||||||2018-06-01 03:02:44.100356|2018-06-01 03:02:44.100356
NCT00507299|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2017-09-26|2007-07-25|2007-07-26|Estimate|||||||2017-09-26|2017-09-28|Actual|June 2002|Actual|2002-06-30|September 2017|2017-09-30|December 31, 2006|Actual|2006-12-31|December 31, 2005|Actual|2005-12-31||Interventional|SEEK||A Safe Environment for Every Kid (SEEK) I|A Safe Environment for Every Kid (SEEK) I: Preventing Child Maltreatment - A Role for Pediatrics|Completed||N/A|660|Actual|University of Maryland||2|||f||||f||||||||||2018-06-01 03:02:44.166111|2018-06-01 03:02:44.166111
NCT00507286|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2009-01-27|2007-07-25|2007-07-26|Estimate|||||||2009-01-27|2009-01-28|Estimate|May 2007||2007-05-31|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|September 2008|Anticipated|2008-09-30||Interventional|||Efficacy and Safety Study of Combined Oral and Injection Therapy for Erectile Dysfunction|Efficacy and Safety Study of Using Oral Sildenafil and Intracavernosal Alprostadil Injection as a Combined Pharmacotherapy for Men With Difficult to Treat Erectile Dysfunction.|Unknown status|Active, not recruiting|N/A|20|Anticipated|Keogh Institute for Medical Research|||||f||||t||||||||||2018-06-01 03:02:44.232108|2018-06-01 03:02:44.232108
NCT00507273|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2012-08-01|2007-07-25|2007-07-26|Estimate|||||||2012-08-01|2012-08-02|Estimate|August 2005||2005-08-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Gastrointestinal Stromal Tumors (GIST) Registry|Gastrointestinal Stromal Tumors (GIST) Registry Protocol: reGISTry|Completed|||1800|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:44.286857|2018-06-01 03:02:44.286857
NCT00507260|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2014-12-23|2007-07-24|2007-07-26|Estimate|||||||2014-12-23|2014-12-24|Estimate|September 2006||2006-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Nutritional Assessment Intervention to Improve Cancer-Related Fatigue|A Pilot Study to Evaluate a Nutritional Assessment Intervention to Improve Cancer-Related Fatigue Among Post-Allogeneic Blood and Marrow Transplantation Recipients|Completed||N/A|10|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:02:44.359253|2018-06-01 03:02:44.359253
NCT00507247|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2016-07-18|2007-07-25|2007-07-26|Estimate|||||||2016-07-18|2016-07-20|Estimate|May 2006||2006-05-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|October 2007|Actual|2007-10-31||Interventional|||Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus|Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Bloodstream Infections|Completed||Phase 2|11|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:02:44.435031|2018-06-01 03:02:44.435031
NCT00507234|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2010-11-10|2007-07-24|2007-07-26|Estimate|||||||2010-11-10|2010-11-11|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Interventional|||Study in Subjects Greater Than 40 Years of Age With COPD|A 6-Week Trial to Compare the Efficacy and Safety of Concomitant Treatment With Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|128|Actual|Dey|||||f||||t||||||||||2018-06-01 03:02:44.509806|2018-06-01 03:02:44.509806
NCT00507221|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2014-11-18|2007-07-24|2007-07-26|Estimate|||||||2014-11-18|2014-11-20|Estimate|February 2008||2008-02-29|November 2014|2014-11-30|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|THE or PHE||Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression|Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression|Completed||N/A|948|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:02:44.592252|2018-06-01 03:02:44.592252
NCT00507208|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|2016-06-14||2016-08-01|2007-07-25|2007-07-26|Estimate|2016-06-14|2016-07-25|Estimate||||2016-08-01|2016-09-13|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Dynasplint Therapy for Trismus in Head and Neck Cancer|Dynasplint Therapy for Trismus in Head and Neck Cancer|Completed||N/A|53|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-06-01 03:02:44.676742|2018-06-01 03:02:44.676742
NCT00507195|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-24|2007-07-24|2007-07-26|Estimate|||||||2007-07-24|2007-07-26|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Observational|||Postanesthesia Cognitive Recovery and Neuropsychologic Complications|Post Operative Cognitive Recovery and Neuropsychological Complications After General Anesthesia. A Comparison Between Different Techniques of Anesthesia: A Multi-Center Observational Study|Unknown status|Recruiting||1200|Anticipated|University of Roma La Sapienza|||||f||||t||||||||||2018-06-01 03:02:45.009432|2018-06-01 03:02:45.009432
NCT00507182|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2018-01-17|2007-07-25|2007-07-26|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2, 1999|Actual|1999-07-02|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|||Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions|Fluorescence and Reflectance Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions|Completed||N/A|381|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:45.259594|2018-06-01 03:02:45.259594
NCT00507169|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-25|||2011-06-07|2007-07-25|2007-07-26|Estimate|||||||2011-06-07|2011-06-08|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||SVT-40776 in Patients Suffering From Overactive Bladder Syndrome||Completed||Phase 2|||Salvat|||||f||||||||||||||2018-06-01 03:02:45.341308|2018-06-01 03:02:45.341308
NCT00507156|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2016-10-05|2007-07-23|2007-07-25|Estimate|||||||2016-10-05|2016-10-06|Estimate|July 2007||2007-07-31|October 2016|2016-10-31||||November 2008|Actual|2008-11-30||Interventional|POSTCON||Postconditioning in the Treatment of Acute ST-segment Elevation Myocardial Infarction|Postconditioning Used to Limit Final Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction|Completed||Phase 4|200|Anticipated|Rigshospitalet, Denmark||2|||f||||||||||||||2018-06-01 03:02:45.393158|2018-06-01 03:02:45.393158
NCT00506610|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-06-06|2007-07-24|2007-07-25|Estimate|||||||2012-06-06|2012-06-07|Estimate||||June 2012|2012-06-30||||||||Interventional|||A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Flexible Escalating -Dose, Pilot Analgesic Efficacy Study of T-62 in Subjects With Postherpetic Neuralgia|Withdrawn||Phase 2|0|Actual|Pfizer|||||f||||f||||||||||2018-06-01 03:02:51.869608|2018-06-01 03:02:51.869608
NCT00507143|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|August 2006||2006-08-31|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan|A Clinical Study for the Evaluation of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on the Pharmacokinetics and Treatment Effects of Irinotecan in Patients With Colorectal and Gastric Cancer|Unknown status|Recruiting|N/A|100|Anticipated|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 03:02:45.47328|2018-06-01 03:02:45.47328
NCT00507130|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2013-10-17|2012-09-13|2013-10-17|2007-07-23|2007-07-25|Estimate|2013-10-17|2013-12-11|Estimate|2012-09-13|2012-09-17|Estimate|2013-10-17|2013-12-11|Estimate|July 2007||2007-07-31|October 2013|2013-10-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled,Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple-Dose Subcutaneous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody,When Administered to Adults With Mild Persistent Asthma|Completed||Phase 2|36|Actual|MedImmune LLC||4|||f||||f||||||||||2018-06-01 03:02:45.584941|2018-06-01 03:02:45.584941
NCT00507117|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-11-29|2007-07-24|2007-07-25|Estimate|||||||2007-11-29|2007-11-30|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Ezopiclone Improves the Quality of Overnight Polysomnography|Prospective, Randomized, Placebo Controlled Trial Assessing the Effects of Ezopiclone on the Quality of Overnight Polysomnography and CPAP Titration|Completed||Phase 4|300|Anticipated|Walter Reed Army Medical Center||1|||f||||t||||||||||2018-06-01 03:02:46.381451|2018-06-01 03:02:46.381451
NCT00507104|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2007-09-27|2007-07-24|2007-07-25|Estimate|||||||2007-09-27|2007-09-28|Estimate|September 2006||2006-09-30|July 2007|2007-07-31||||||||Observational|||Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)|Prospective Longitudinal Study on Pituitary Functions After TBI and/or SAH|Unknown status|Recruiting||100|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 03:02:46.454368|2018-06-01 03:02:46.454368
NCT00507091|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2016-08-24|2007-07-24|2007-07-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|August 2005||2005-08-31|August 2016|2016-08-31|June 2008|Actual|2008-06-30|May 2006|Actual|2006-05-31||Interventional|||Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination|A Phase I Open Label Study to Asses the Safety and Tolerability of ZD6474 (Vandetanib)in Combination With Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as First or Second Line Therapy in Patients With Metastatic Colorectal Adenocarcinoma.|Completed||Phase 1|24|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:02:46.538366|2018-06-01 03:02:46.538366
NCT00507078|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2012-05-18|2007-07-24|2007-07-25|Estimate|||||||2012-05-18|2012-05-21|Estimate|June 2005||2005-06-30|May 2012|2012-05-31|June 2007|Actual|2007-06-30|||||Interventional|||Biomarkers in Obstructive Sleep Apnea Surgery|Biomarkers in Obstructive Sleep Apnea Surgery|Completed||N/A|60|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 03:02:46.634542|2018-06-01 03:02:46.634542
NCT00507065|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2015-03-04|2007-07-23|2007-07-25|Estimate|||||||2015-03-04|2015-03-05|Estimate|May 2003||2003-05-31|November 2007|2007-11-30|April 2004|Actual|2004-04-30|||||Interventional|||Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)|A Phase III, Randomized, Multicenter, Double-blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of ADDERALL XR With an Open Label Extension, in the Treatment of Adolescents Aged 13-17 With ADHD|Completed||Phase 3|329|Actual|Shire||5|||f||||f||||||||||2018-06-01 03:02:46.714715|2018-06-01 03:02:46.714715
NCT00507052|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2007-07-24|2007-07-24|2007-07-25|Estimate|||||||2007-07-24|2007-07-25|Estimate||||July 2007|2007-07-31||||||||Interventional|||Effect of N-Acetylcysteine on Residual Renal Function in Chronic Hemodialysis Patients||Unknown status|Not yet recruiting|N/A|||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:02:46.789689|2018-06-01 03:02:46.789689
NCT00507039|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2011-10-07|2007-07-23|2007-07-25|Estimate|||||||2011-10-07|2011-10-12|Estimate|February 2007||2007-02-28|October 2011|2011-10-31|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Observational|||Safety and Repeatability of Bronchial Challenge With Grass-pollen|Repeatability of a Single Concentration and Single-step Bronchial Allergen Challenge With Grass Pollen|Completed|||47|Actual|Johann Wolfgang Goethe University Hospital|||1||f||||t||||||||||2018-06-01 03:02:46.874006|2018-06-01 03:02:46.874006
NCT00507026|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2009-02-11|2007-07-23|2007-07-25|Estimate|||||||2009-02-11|2009-02-12|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery|Randomized, Double-Blind, Active-and Placebo-Controlled Study of the Analgesic Efficacy and Safety of Repeated Dosing of DIC075V Versus Parenteral Ketorolac and Placebo in Acute Post-Operative Pain After Elective Orthopedic Surgery|Completed||Phase 3|277|Actual|Javelin Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:02:46.954304|2018-06-01 03:02:46.954304
NCT00507013|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2008-04-22|2007-07-23|2007-07-25|Estimate|||||||2008-04-22|2008-04-24|Estimate|July 2007||2007-07-31|April 2008|2008-04-30|September 2007|Actual|2007-09-30|||||Interventional|||Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose|The QuickClose Study: Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose: a Prospective, Non-Randomized Clinical Study|Completed||Phase 1/Phase 2|8|Actual|CardioDex||1|||f||||f||||||||||2018-06-01 03:02:47.04371|2018-06-01 03:02:47.04371
NCT00507000|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2011-01-26|2007-07-23|2007-07-25|Estimate|||||||2011-01-26|2011-01-27|Estimate|May 2008||2008-05-31|July 2009|2009-07-31|September 2012|Anticipated|2012-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Pulmonary Tuberculosis and Vitamin D|Role of Oral Vitamin D as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters. (Double-blind, Randomized, Placebo-Controlled, Clinical Trial)|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|Indian Council of Medical Research||2|||f||||t||||||||||2018-06-01 03:02:47.108322|2018-06-01 03:02:47.108322
NCT00506987|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2015-08-13|2007-07-23|2007-07-25|Estimate|||||||2015-08-13|2015-08-14|Estimate|January 2007||2007-01-31|August 2015|2015-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)|Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Idiopathic Cough|Completed||Phase 2|31|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:02:47.18329|2018-06-01 03:02:47.18329
NCT00506974|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2008-09-25|2007-07-24|2007-07-25|Estimate|||||||2008-09-25|2008-09-26|Estimate|May 2007||2007-05-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Enhancing Slow Wave Sleep With Sodium Oxybate|Enhancing Slow Wave Sleep With Sodium Oxybate to Reduce the Behavioral and Physiological Impact of Sleep Loss|Completed||Phase 4|60|Actual|St. Luke's Hospital, Chesterfield, Missouri|||||f||||f||||||||||2018-06-01 03:02:47.238734|2018-06-01 03:02:47.238734
NCT00506961|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2011-12-05|2007-07-24|2007-07-25|Estimate|||||||2011-12-05|2011-12-06|Estimate|June 2006||2006-06-30|December 2011|2011-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia|A Phase IV, Randomized, Open-label, Parallel-arm, Comparative and Forced- Titration Study to Compare the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Patients With Type 2 DM and Dyslipidemia|Completed||Phase 4|90|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-06-01 03:02:47.332728|2018-06-01 03:02:47.332728
NCT00506948|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2014-01-07||2014-01-07|2007-07-20|2007-07-25|Estimate|2014-01-07|2014-02-20|Estimate||||2014-01-07|2014-02-20|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)|Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation|Terminated||Phase 2|13|Actual|M.D. Anderson Cancer Center|A decision to terminate this trial was made due to the high incidence of veno-occlusive disease of the liver in participants receiving this graft-versus-host disease (GVHD) prophylaxis regimen.|1||Halted due to high incidence of veno-oclusive disease of the liver.|f||||f||||||||||2018-06-01 03:02:47.540131|2018-06-01 03:02:47.540131
NCT00506935|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2017-07-11|2007-07-24|2007-07-25|Estimate|||||||2017-07-11|2017-07-13|Actual|July 2006||2006-07-31|July 2017|2017-07-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Assessment of GVG for the Treatment of Methamphetamine Dependence|Phase 1 Study of Vigabatrin (GVG) for Methamphetamine Dependence|Completed||Phase 1|17|Actual|Baylor College of Medicine||2|||f||||||||||||||2018-06-01 03:02:47.734166|2018-06-01 03:02:47.734166
NCT00506922|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2011-03-01||2015-04-06|2007-07-20|2007-07-25|Estimate|2011-03-01|2011-03-28|Estimate||||2015-04-06|2015-04-28|Estimate|September 2000||2000-09-30|August 2012|2012-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT|Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After Matched-Unrelated Donor Blood and Marrow Transplantation|Completed||Phase 1/Phase 2|150|Actual|M.D. Anderson Cancer Center||5|||f||||f||||||||||2018-06-01 03:02:47.814653|2018-06-01 03:02:47.814653
NCT00506909|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2017-01-11|2007-07-24|2007-07-25|Estimate|||||||2017-01-11|2017-01-13|Estimate|March 2008||2008-03-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Oxytocin||Oxytocin Add on Study for Stable Schizophrenic Patients|Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study of Intranasal Oxytocin Augmentation of Antipsychotic Medication in Schizophrenia Patients|Suspended||N/A|40|Anticipated|University of California, San Diego||2||Break in funding|f||||f||||||||||2018-06-01 03:02:48.14884|2018-06-01 03:02:48.14884
NCT00506896|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2007-07-20|2007-07-20|2007-07-25|Estimate|||||||2007-07-20|2007-07-25|Estimate|July 2004||2004-07-31|July 2007|2007-07-31|January 2006|Actual|2006-01-31|||||Interventional|||Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients|Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study|Completed||Phase 2|60|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 03:02:48.226608|2018-06-01 03:02:48.226608
NCT00506883|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2009-08-12||2012-10-30|2007-07-24|2007-07-25|Estimate|2009-09-21|2009-09-22|Estimate||||2012-10-30|2012-11-01|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|AGREE||MPC-004 for the Treatment of an Acute Gout Flare|A Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, 1 Week, Dose Comparison Study to Evaluate the Efficacy, Safety, and Tolerability of MPC-004 in Patients With an Acute Gout Flare|Completed||Phase 3|185|Actual|Takeda||3|||f||||f||||||||||2018-06-01 03:02:48.435913|2018-06-01 03:02:48.435913
NCT00506870|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2010-12-13|2007-07-23|2007-07-25|Estimate|||||||2010-12-13|2010-12-14|Estimate|June 2007||2007-06-30|December 2010|2010-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|4A||Benefit of Self-monitoring of Anticoagulation Instrument|Economic and Medical Evaluation of Self-monitoring of Anticoagulation in a Population of Patients Recently Fitted With a Mechanical Heart Valve Compared to Conventional Anticoagulation Follow-up|Completed||N/A|919|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 03:02:48.901713|2018-06-01 03:02:48.901713
NCT00506857|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2012-01-24||2012-01-24|2007-07-23|2007-07-25|Estimate|2012-01-24|2012-02-28|Estimate||||2012-01-24|2012-02-28|Estimate|November 2003||2003-11-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support|Phase I/II Trial of Fludarabine in Combination With Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients With Hematologic Malignancies|Completed||Phase 1/Phase 2|82|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:48.987399|2018-06-01 03:02:48.987399
NCT00506844|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|May 2006||2006-05-31|July 2007|2007-07-31|May 2010|Anticipated|2010-05-31|||||Interventional|ERBIRIX||Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer|A Phase II Study of Pre-Operative Concurrent Chemoradiotherapy With Cetuximab, Irinotecan, and Capecitabine in Resectable Rectal Cancer|Unknown status|Active, not recruiting|Phase 2|40|Actual|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 03:02:49.188834|2018-06-01 03:02:49.188834
NCT00506831|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|2012-06-06||2018-04-19|2007-07-24|2007-07-25|Estimate|2012-07-10|2012-08-17|Estimate||||2018-04-19|2018-05-21|Actual|July 2007||2007-07-31|April 2018|2018-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Imatinib in Systemic Sclerosis|A Pilot Study of Imatinib in the Treatment of Refractory Systemic Sclerosis|Completed||Phase 1/Phase 2|9|Actual|Stanford University|Open label, uncontrolled study. Small study population at a single center.|1|||f|||||t|f||||||||2018-06-01 03:02:49.268718|2018-06-01 03:02:49.268718
NCT00506818|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2009-09-18|2007-07-23|2007-07-25|Estimate|||||||2009-09-18|2009-09-21|Estimate|February 2007||2007-02-28|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Cognitive and Emotional Impairment After Stroke|Cognitive and Emotional Impairment After Stroke|Completed||N/A|250|Anticipated|Sykehuset Asker og Baerum||1|||f||||f||||||||||2018-06-01 03:02:49.424252|2018-06-01 03:02:49.424252
NCT00506805|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-05-25|2007-07-24|2007-07-25|Estimate|||||||2012-05-25|2012-05-28|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies|A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma|Completed||Phase 1|44|Actual|Esanex Inc.||1|||f||||f||||||||||2018-06-01 03:02:49.488327|2018-06-01 03:02:49.488327
NCT00506792|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-22||2012-05-02|2012-05-02|2007-07-23|2007-07-25|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|July 2007||2007-07-31|May 2012|2012-05-31|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis|A Two-part, Randomized, Double-blind, Placebo-controlled, Ascending Single-dose, Adaptive Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAU145 Administered Via a Nasal Spray Pump to Patients With Cystic Fibrosis|Completed||Phase 2|9|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:02:49.550179|2018-06-01 03:02:49.550179
NCT00506779|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2015-04-13|2007-07-23|2007-07-25|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2003||2003-12-31|April 2015|2015-04-30||||April 2015|Actual|2015-04-30||Interventional|||Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma|A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC)|Completed||Phase 1/Phase 2|17|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:02:49.614655|2018-06-01 03:02:49.614655
NCT00506766|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|September 2000||2000-09-30|July 2007|2007-07-31|August 2006|Actual|2006-08-31|||||Interventional|||Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up|Promoting Self Care to Prevent Urinary Incontinence (UI): A Four-Year Follow-up|Completed||Phase 3|360|Actual|University of Michigan|||||f||||f||||||||||2018-06-01 03:02:49.694839|2018-06-01 03:02:49.694839
NCT00506753|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2017-06-02|2007-07-23|2007-07-25|Estimate|||||||2017-06-02|2017-06-05|Actual|September 2004||2004-09-30|June 2017|2017-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SMART||Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail|Prison Study: Motivation and Skills for THC/ETOH+ Teens in Jail|Completed||N/A|205|Actual|University of Rhode Island||2|||f||||t||||||||Yes|With appropriate request and procedure.|2018-06-01 03:02:49.758394|2018-06-01 03:02:49.758394
NCT00506740|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2015-08-03|2007-07-24|2007-07-25|Estimate|||||||2015-08-03|2015-08-04|Estimate|October 2006||2006-10-31|August 2015|2015-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Harmonic™ vs. Electrocautery in Abdominoplasties|A Randomized, Prospective, Parallel Group Study Comparing the Harmonic™ to Electrocautery in Abdominoplasties|Completed||N/A|70|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||||2018-06-01 03:02:49.834074|2018-06-01 03:02:49.834074
NCT00506727|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2015-03-04|2007-07-23|2007-07-25|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2003||2003-08-31|November 2007|2007-11-30|August 2004|Actual|2004-08-31|||||Interventional|||Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD|A Randomized, Double-Blind, Parallel-Group, Analog Classroom Study, Evaluating ADDERALL XR Versus STRATTERA, Dosed Once Daily, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 4|215|Actual|Shire||2|||f||||||||||||||2018-06-01 03:02:49.898708|2018-06-01 03:02:49.898708
NCT00506714|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2012-02-06||2012-09-28|2007-07-20|2007-07-25|Estimate|2012-08-29|2012-09-28|Estimate||||2012-09-28|2012-10-04|Estimate|July 2007||2007-07-31|September 2012|2012-09-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Walking Aids in the Management of Hip Osteoarthritis|Walking Aids in the Management of Hip Osteoarthritis|Completed||N/A|26|Actual|Arthritis Foundation||2|||f||||f||||||||||2018-06-01 03:02:49.962761|2018-06-01 03:02:49.962761
NCT00506701|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2015-03-17|2007-07-23|2007-07-25|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2008||2008-02-29|July 2007|2007-07-31|February 2010|Anticipated|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension|Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease|Withdrawn||N/A|0|Actual|Herlev Hospital||1||due to lack of finance|f||||t||||||||||2018-06-01 03:02:50.266785|2018-06-01 03:02:50.266785
NCT00506688|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-07-06|2007-07-24|2007-07-25|Estimate|||||||2012-07-06|2012-07-10|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients|Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24-week Inhalation Treatment With Glutathione in Cystic Fibrosis Patients|Completed||Phase 2|153|Actual|Mukoviszidose Institut gGmbH|||||f||||t||||||||||2018-06-01 03:02:50.371779|2018-06-01 03:02:50.371779
NCT00506675|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2010-09-14||2016-07-06|2007-07-20|2007-07-25|Estimate|2011-02-25|2011-03-23|Estimate||||2016-07-06|2016-07-13|Estimate|October 2007||2007-10-31|July 2016|2016-07-31|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|ATS11||Combined Patching-Atropine for Residual Amblyopia|A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia|Terminated||Phase 3|55|Actual|Jaeb Center for Health Research|This trial was stopped after 18 months due to inadequate recruitment.|2||Poor enrollment and infeasibility of ever reaching the necessary sample size|f||||t||||||||||2018-06-01 03:02:50.471697|2018-06-01 03:02:50.471697
NCT00506662|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|2010-10-19||2016-05-11|2007-07-24|2007-07-25|Estimate|2010-10-19|2010-11-17|Estimate||||2016-05-11|2016-06-16|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|3L||Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes|The Effect of Insulin Detemir on Glucose Control in Ageing Subjects With Type 2 Diabetes.|Terminated||Phase 4|86|Actual|Novo Nordisk A/S|Trial terminated prematurely due to low recruitment, and thus it was not possible to assess efficacy in this trial due to the small number of patients in each treatment group.|2||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:02:51.181726|2018-06-01 03:02:51.181726
NCT00506649|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|August 2003||2003-08-31|July 2007|2007-07-31|November 2005|Actual|2005-11-30|||||Observational|||Improved ICU Outcomes With Protocolized Management of Analgesia, Sedation and Delirium|Comparison of no Protocol vs Protocolized Approach to Pain, Sedation and Delirium Management in the ICU|Completed|||1214|Actual|Maisonneuve-Rosemont Hospital|||||f||||f||||||||||2018-06-01 03:02:51.67965|2018-06-01 03:02:51.67965
NCT00506636|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|December 2016|Anticipated|2016-12-31|||||Observational|||Tissue Engineering for Hair Follicle Regeneration|Study of Tissue Engineering for Hair Follicle Regeneration|Unknown status|Recruiting||400|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:02:51.741634|2018-06-01 03:02:51.741634
NCT00506623|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|July 2004||2004-07-31|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer|A Phase Ⅱ Study of Pre-Operative Concurrent Chemoradiotherapy With Capecitabine Plus Irinotecan in Resectable Rectal Cancer.|Unknown status|Active, not recruiting|Phase 2|48|Actual|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 03:02:51.804799|2018-06-01 03:02:51.804799
NCT00506597|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2013-10-17||2014-09-04|2007-07-20|2007-07-25|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-04|2014-09-11|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Erwinase Study in Patients With Acute Lymphoblastic Leukemia|Erwinia L-Asparaginase (Erwinase) Study in Patients With Acute Lymphoblastic Leukemia|Completed||N/A|33|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:02:51.944961|2018-06-01 03:02:51.944961
NCT00506584|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2010-02-16|2007-07-23|2007-07-25|Estimate|||||||2010-02-16|2010-02-18|Estimate|July 2007||2007-07-31|February 2010|2010-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Randomized Study of Human-Milk Based Nutrition Versus Formula in Premature Infants|A Randomized Study of Human Milk-Based Versus Bovine-based Nutrition for Very Low Birth Weight Pre-Term Infants|Completed||N/A|260|Actual|Prolacta Bioscience||5|||f||||t||||||||||2018-06-01 03:02:52.09826|2018-06-01 03:02:52.09826
NCT00506571|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|July 2007||2007-07-31|April 2007|2007-04-30|June 2010|Anticipated|2010-06-30|||||Interventional|TIROX2||Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer|Phase II Study of S-1 Combined With Irinotecan and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 2|42|Anticipated|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 03:02:52.181039|2018-06-01 03:02:52.181039
NCT00506558|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-08-28|2007-07-24|2007-07-25|Estimate|||||||2012-08-28|2012-08-29|Estimate|November 2006||2006-11-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|CSM||The CSM Trial: A Multicenter Study Comparing Ventral to Dorsal Surgery for Cervical Spondylotic Myelopathy|The CSM Trial: A Multicenter Study Comparing Ventral to Dorsal Surgery for Cervical Spondylotic Myelopathy|Completed||Phase 3|103|Actual|Greenwich Hospital||2|||f||||t||||||||||2018-06-01 03:02:52.241781|2018-06-01 03:02:52.241781
NCT00506545|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2013-11-26|2007-07-23|2007-07-25|Estimate|||||||2013-11-26|2013-11-27|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)|Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Idiopathic Cough|Completed||Phase 2|35|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:02:52.306655|2018-06-01 03:02:52.306655
NCT00506532|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-15|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|January 2005||2005-01-31|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study|The Use of Surfactant in Lung Transplantation: A Randomized Control Pilot Study|Unknown status|Recruiting|Phase 2/Phase 3|42|Anticipated|Rabin Medical Center|||||f||||||||||||||2018-06-01 03:02:52.486844|2018-06-01 03:02:52.486844
NCT00506519|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2010-08-23|2007-07-23|2007-07-25|Estimate|||||||2010-08-23|2010-08-24|Estimate|July 2007||2007-07-31|August 2010|2010-08-31|March 2009|Actual|2009-03-31|||||Interventional|||Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis|Exploratory Efficacy and Safety, Pharmacokinetics and Dose Finding Study of ATryn® (Antithrombin Alfa) in Patients With Disseminated Intravascular Coagulation Associated With Severe Sepsis|Terminated||Phase 2|200|Anticipated|LEO Pharma|||||f||||t||||||||||2018-06-01 03:02:52.571831|2018-06-01 03:02:52.571831
NCT00506506|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2009-04-14|2007-07-23|2007-07-25|Estimate|||||||2009-04-14|2009-04-15|Estimate|October 2007||2007-10-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease|Randomized Controlled Trial Examining the Effect of N-Acetylcysteine on Serum Creatinine in Patients With Stage 3 Chronic Kidney Disease|Completed||Phase 3|60|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 03:02:52.640272|2018-06-01 03:02:52.640272
NCT00506493|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-22|2013-08-09|2012-05-17|2013-12-11|2007-07-22|2007-07-25|Estimate|2013-08-09|2013-10-16|Estimate|2012-10-01|2012-10-05|Estimate|2013-12-11|2014-01-13|Estimate|September 2007||2007-09-30|December 2013|2013-12-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|CURE-AF/Perst||Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent|Medtronic Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF)/Persistent Study|Completed||Phase 3|75|Actual|Medtronic Cardiovascular|"Slow/delayed enrollment~Medical management of subjects by non-investigators leading to medication washout protocol deviations~Missing endpoint data (attrition) due to cohort demographics (old age, dementia, relocation, etc.)"||||f||||t||||||||||2018-06-01 03:02:52.736463|2018-06-01 03:02:52.736463
NCT00506480|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-22|||2010-02-04|2007-07-22|2007-07-25|Estimate|||||||2010-02-04|2010-02-05|Estimate|August 2007||2007-08-31|July 2007|2007-07-31||||||||Interventional|ERPOD||Assessment of Endometrial Receptivity in Recipients of Donated Oocytes|Phase 1 Study of Endometrial Markers of Endometrial Receptivity in Oocyte Donation|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 03:02:52.988547|2018-06-01 03:02:52.988547
NCT00506467|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2012-07-31|2007-07-24|2007-07-25|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Vibration Response Imaging (VRI) in Lung Cancer Patients|Vibration Response Imaging (VRI) in Patients Who Are Candidates for Undergoing Surgical Resection Due to Lung Cancer or Other Intrathoracic Malignancy|Completed|||100|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:53.138006|2018-06-01 03:02:53.138006
NCT00506454|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2011-06-10||2011-09-16|2007-07-24|2007-07-25|Estimate|2011-07-12|2011-08-15|Estimate||||2011-09-16|2011-09-20|Estimate|August 2007||2007-08-31|September 2011|2011-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|LIPIDOSE||Lipid Infusion in Dialysis Patients With Endotoxemia|A Phase II, Double-Blind, Placebo-Controlled, Randomized Study of the Effects of a Lipid Emulsion (Lipidose) on Endotoxin Levels in Patients on Chronic Hemodialysis|Completed||Phase 2|22|Actual|Sepsicure|There was no significant difference between endotoxin activity assay values in the active versus placebo recipients in this study.|2|||f||||t||||||||||2018-06-01 03:02:53.223264|2018-06-01 03:02:53.223264
NCT00506441|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|2014-04-10|2010-05-26|2014-09-05|2007-07-24|2007-07-25|Estimate|2014-06-26|2014-07-25|Estimate|2010-06-07|2010-06-08|Estimate|2014-09-05|2014-09-15|Estimate|September 2007||2007-09-30|September 2014|2014-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia|Completed||Phase 3|245|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 03:02:53.497896|2018-06-01 03:02:53.497896
NCT00506428|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2009-04-28|2007-07-20|2007-07-25|Estimate|||||||2009-04-28|2009-04-29|Estimate|December 2006||2006-12-31|April 2009|2009-04-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Effects of Chronic Sleep Restriction in Young and Older People|Sleep, Aging, and Circadian Rhythm Disorders|Unknown status|Recruiting|N/A|25|Anticipated|National Institute on Aging (NIA)|||||f||||f||||||||||2018-06-01 03:02:55.884174|2018-06-01 03:02:55.884174
NCT00506415|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2012-05-01||2012-09-17|2007-07-20|2007-07-25|Estimate|2012-09-17|2012-09-19|Estimate||||2012-09-17|2012-09-19|Estimate|June 2007||2007-06-30|September 2012|2012-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline|A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline|Completed||Phase 3|1584|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:02:56.205782|2018-06-01 03:02:56.205782
NCT00506402|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2009-05-04|2007-07-24|2007-07-25|Estimate|||||||2009-05-04|2009-05-05|Estimate|November 2006||2006-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies|A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies|Completed||Phase 1|30|Anticipated|CASI Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 03:02:58.511205|2018-06-01 03:02:58.511205
NCT00506389|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2014-07-14|2009-04-23|2015-08-04|2007-07-23|2007-07-25|Estimate|2014-07-14|2014-08-06|Estimate|2009-09-30|2009-10-02|Estimate|2015-08-04|2015-08-21|Estimate|June 2007||2007-06-30|August 2015|2015-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)|A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia|Completed||Phase 3|419|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 03:02:58.701264|2018-06-01 03:02:58.701264
NCT00506376|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2016-02-25|2007-07-20|2007-07-25|Estimate|||||||2016-02-25|2016-02-26|Estimate|January 2003||2003-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Simple Versus Radical Hysterectomy for Stage I Cervical Cancer|Simple Versus Radical Hysterectomy for Stage I Cervical Cancer: Preferences of Women at High-Risk for Developing Cervix Cancer vs. Women Diagnosed With Cervix Cancer|Completed|||85|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:02:59.076001|2018-06-01 03:02:59.076001
NCT00506363|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2009-10-04|2007-07-23|2007-07-25|Estimate|||||||2009-10-04|2009-10-06|Estimate|January 2008||2008-01-31|October 2009|2009-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Different Onset Times of Treatment With Pulsed Dye Laser on Improvement of Surgical Scars|The Effect of Different Onset Times of Treatment With 595-nm Pulsed Dye Laser on Improvement of Surgical Scars: A Double Blind Randomised Clinical Trial|Terminated||N/A|15|Anticipated|Tehran University of Medical Sciences||3||"The trial was terminated on May 2008 after inclusion of 10 patients due to low recruitment and~   patient compliance."|f||||f||||||||||2018-06-01 03:02:59.29631|2018-06-01 03:02:59.29631
NCT00506350|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|2017-09-11|2011-02-04|2017-09-11|2007-07-24|2007-07-25|Estimate|2017-09-11|2017-10-04|Actual|2011-02-04|2011-02-09|Estimate|2017-09-11|2017-10-04|Actual|August 1, 2007|Actual|2007-08-01|September 2017|2017-09-30|October 12, 2009|Actual|2009-10-12|October 12, 2009|Actual|2009-10-12||Interventional|||Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults|Evaluate the Reactogenicity & Immunogenicity of 1 or 2 Booster Administrations of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults Aged Between 19 & 61 Years|Completed||Phase 2|350|Actual|GlaxoSmithKline||9|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:02:59.619672|2018-06-01 03:02:59.619672
NCT00506337|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-29|2007-07-23|2007-07-25|Estimate|||||||2007-07-29|2007-07-31|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|October 2009|Anticipated|2009-10-31|||||Interventional|||Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis|Evaluation of Effect of Integrated Treatment by Traditional Chinese and Western Medicine for Severe Acute Pancreatitis|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Tianjin Nankai Hospital|||||f||||t||||||||||2018-06-01 03:03:05.323995|2018-06-01 03:03:05.323995
NCT00506324|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2015-07-10|2007-07-23|2007-07-25|Estimate|||||||2015-07-10|2015-07-14|Estimate|June 2006||2006-06-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Oropharyngeal Function After Radiotherapy With IMRT|Oropharyngeal Function After Radiotherapy With IMRT|Terminated|||125|Anticipated|Northwestern University||||Physician deceased|f||||t||||||||||2018-06-01 03:03:05.485264|2018-06-01 03:03:05.485264
NCT00506311|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2012-08-01|2007-07-23|2007-07-25|Estimate|||||||2012-08-01|2012-08-02|Estimate|February 2003||2003-02-28|August 2012|2012-08-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients|A Randomized Trial Evaluating the Use of Fibrin Tissue Adhesive Following Superficial Groin Dissection in Patients With Melanoma|Completed||N/A|53|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:03:05.584339|2018-06-01 03:03:05.584339
NCT00506298|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2009-05-12|2007-07-20|2007-07-25|Estimate|||||||2009-05-12|2009-05-13|Estimate|July 2007||2007-07-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes|A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin.|Completed||Phase 2|150|Anticipated|Zalicus||2|||f||||f||||||||||2018-06-01 03:03:05.939468|2018-06-01 03:03:05.939468
NCT00506285|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2012-10-19||2015-01-15|2007-07-24|2007-07-25|Estimate|2015-01-15|2015-01-16|Estimate||||2015-01-15|2015-01-16|Estimate|June 2007||2007-06-30|January 2015|2015-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD|Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD|Completed||Phase 3|92|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 03:03:06.320518|2018-06-01 03:03:06.320518
NCT00506272|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2015-12-11|2007-07-23|2007-07-25|Estimate|||||||2015-12-11|2015-12-14|Estimate|December 2007||2007-12-31|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Interventional|ISMAS||Inpatient Self Monitoring and Administration Study (ISMAS)|Inpatient Self Monitoring and Administration Study (ISMAS)|Unknown status|Active, not recruiting|N/A|1|Actual|Atlanta VA Medical Center||2|||f||||t||||||||||2018-06-01 03:03:07.744134|2018-06-01 03:03:07.744134
NCT00506259|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-21|||2018-05-23|2007-07-21|2007-07-25|Estimate|||||||2018-05-23|2018-05-24|Actual|July 17, 2007||2007-07-17|May 22, 2018|2018-05-22|May 22, 2018|Actual|2018-05-22|May 22, 2018|Actual|2018-05-22||Interventional|||Treatment Strategies for Children With Smith-Magenis Syndrome|A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)|Completed||Phase 1|23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:03:07.932423|2018-06-01 03:03:07.932423
NCT00503737|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2018-05-24|2007-07-17|2007-07-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 2007||2007-09-30|May 2018|2018-05-31|September 1, 2010|Actual|2010-09-01|September 1, 2010|Actual|2010-09-01||Interventional|||Pilot Study of the National Colorectal Cancer Roundtable Toolbox (NCCRT) to Increase Colorectal Cancer Screening Rates||Completed||N/A|287|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-06-01 03:03:51.350721|2018-06-01 03:03:51.350721
NCT00506246|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2008-02-22|2007-07-24|2007-07-25|Estimate|||||||2008-02-22|2008-02-25|Estimate|June 2007||2007-06-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety Study of Two Propofol Formulations|A Multi-Center, Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy and Safety of Propofol(Propofol®-Lipuro) in Total Intravenous Anaesthesia|Completed||Phase 3|220|Anticipated|B. Braun Melsungen AG||2|||f||||f||||||||||2018-06-01 03:03:08.239922|2018-06-01 03:03:08.239922
NCT00506233|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2012-07-30|2007-07-23|2007-07-25|Estimate|||||||2012-07-30|2012-07-31|Estimate|August 2006||2006-08-31|July 2012|2012-07-31||||September 2007|Actual|2007-09-30||Observational|||Feasibility Study of Collecting Multicenter Chronic GVHD Data|Feasibility Study of Collecting Multicenter Chronic GVHD Data|Completed|||13|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:03:08.393507|2018-06-01 03:03:08.393507
NCT00506220|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2009-07-14|2007-07-20|2007-07-25|Estimate|||||||2009-07-14|2009-07-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 03:03:08.57509|2018-06-01 03:03:08.57509
NCT00506207|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|September 2006||2006-09-30|July 2007|2007-07-31|December 2009|Anticipated|2009-12-31|||||Interventional|TIROX||A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy|A Phase I and Pharmacokinetic Study of S-1 Combined With Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy|Unknown status|Active, not recruiting|Phase 1|23|Actual|National Cancer Center, Korea|||||f||||f||||||||||2018-06-01 03:03:08.655328|2018-06-01 03:03:08.655328
NCT00506194|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2013-09-30|2007-07-24|2007-07-25|Estimate|||||||2013-09-30|2013-10-01|Estimate|October 2005||2005-10-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|August 2007|Actual|2007-08-31||Interventional|||Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control|Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control Is Associated With Improvement of ß-Cell Function in Newly Diagnosed Type 2 Diabetic Patients|Completed||N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-06-01 03:03:08.794517|2018-06-01 03:03:08.794517
NCT00506181|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-22|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Probiotics: is it Really That Good? Cost-Effectiveness of Treating the in-Patient|Phase 3 Study of Probiotics, to Provide a Legitimate Reason for the Administration of Probiotic Therapy in the Hospitalized Patient, Particularly in Patients on Antibiotic Therapy|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-06-01 03:03:08.993785|2018-06-01 03:03:08.993785
NCT00506168|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|November 2001||2001-11-30|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer|Phase II Study of Irinotecan in Combination With Capecitabine in Previously Untreated Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|37|Actual|National Cancer Center, Korea||||The study drugs are not covered anymore by insurance.|f||||f||||||||||2018-06-01 03:03:09.148549|2018-06-01 03:03:09.148549
NCT00506155|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2016-03-01||2016-03-01|2007-07-23|2007-07-25|Estimate|2016-03-01|2016-03-31|Estimate||||2016-03-01|2016-03-31|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer|A Phase II Clinical Trial of Neoadjuvant Chemotherapy With M-VAC Plus Avastin in Patients With Locally Advanced Urothelial Cancer|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:03:09.433733|2018-06-01 03:03:09.433733
NCT00506142|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2015-06-02|2007-07-23|2007-07-25|Estimate|||||||2015-06-02|2015-06-04|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma|A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma|Completed||Phase 2|54|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 03:03:10.681314|2018-06-01 03:03:10.681314
NCT00506129|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2015-06-19|2007-07-23|2007-07-25|Estimate|||||||2015-06-19|2015-06-22|Estimate|September 2003||2003-09-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma|Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)|Completed||Phase 2|33|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:03:11.017866|2018-06-01 03:03:11.017866
NCT00506116|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-30|2007-07-23|2007-07-25|Estimate|||||||2007-07-30|2007-07-31|Estimate|July 1996||1996-07-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|PERL||Promoting Effective Recovery From Labor Urinary Incontinence (PERL)|Promoting Effective Recovery From Labor Urinary Incontinence: Prevention Reducing Birthing Risk|Completed||Phase 3|140|Actual|University of Michigan|||||f||||f||||||||||2018-06-01 03:03:11.733603|2018-06-01 03:03:11.733603
NCT00506103|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-21|||2007-07-25|2007-07-24|2007-07-25|Estimate|||||||2007-07-25|2007-07-26|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Observational|||The No-Tie Technique Using the Harmonic Scalpel in Total Thyroidectomy With Central Neck Dissection: A Prospective Randomized Study||Completed|||||Soonchunhyang University Hospital|||||f||||t||||||||||2018-06-01 03:03:11.917613|2018-06-01 03:03:11.917613
NCT00506090|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2009-10-04|2007-07-23|2007-07-25|Estimate|||||||2009-10-04|2009-10-06|Estimate|July 2007||2007-07-31|October 2009|2009-10-31||||||||Interventional|||Safety and Efficacy of Different Intervals of Pulsed Dye Laser Sessions on Improvement of Surgical Scars|The Effect of Different Intervals of 595-nm Pulsed Dye Laser Sessions on Improvement of Surgical Scars: A Double Blind Randomised Clinical Trial|Withdrawn||N/A|0|Actual|Tehran University of Medical Sciences||3||"Because of unsatisfactory results of previous trial which assessed the effect of different~   onset times of PDL on surgical scars."|f||||f||||||||||2018-06-01 03:03:12.055146|2018-06-01 03:03:12.055146
NCT00506077|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|2010-10-13||2015-07-31|2007-07-24|2007-07-25|Estimate|2011-02-10|2011-03-07|Estimate||||2015-07-31|2015-08-03|Estimate|December 2007||2007-12-31|July 2015|2015-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia|Completed||Phase 2|55|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:03:12.163697|2018-06-01 03:03:12.163697
NCT00506064|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|2010-03-29||2012-12-03|2007-07-23|2007-07-25|Estimate|2010-12-28|2011-01-25|Estimate||||2012-12-03|2012-12-05|Estimate|February 2004||2004-02-29|December 2012|2012-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Melatonin Postoperative Sleep Study in Breast Cancer Patients|Melatonin Postoperative Sleep Study in Breast Cancer Patients|Terminated||Phase 1|4|Actual|M.D. Anderson Cancer Center|Study terminated early due to low recruitment, no analysis done.|2||Terminated due to low accrual.|f||||f||||||||||2018-06-01 03:03:12.988617|2018-06-01 03:03:12.988617
NCT00506051|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-08-24|2007-07-24|2007-07-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|July 2005||2005-07-31|August 2016|2016-08-31|October 2011|Actual|2011-10-31|May 2006|Actual|2006-05-31||Interventional|||ZD6474(Vandetanib) + Alimta Combo Study|A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.|Completed||Phase 1|21|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:03:13.36834|2018-06-01 03:03:13.36834
NCT00506038|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2009-06-21|2007-07-24|2007-07-25|Estimate|||||||2009-06-21|2009-06-23|Estimate||||November 2008|2008-11-30||||||||Interventional|||Efficacy Study of Fine Needle Technique on Calcific Tendinitis|Phase 2 Study of the Fine Needle Technique on Calcific Tendinitis|Terminated||Phase 2|40|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:03:13.509817|2018-06-01 03:03:13.509817
NCT00506025|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|2009-12-03||2017-11-17|2007-07-24|2007-07-25|Estimate|2010-05-13|2010-06-08|Estimate||||2017-11-17|2017-12-18|Actual|August 2006||2006-08-31|November 2017|2017-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effectiveness of Cranberry Ingestion on Bacterial Adhesion: An Adjunct Study|Effectiveness of Cranberry Ingestion on Bacterial Adhesion: Adjunct to Pilot Study of Daily Cranberry Ingestion of Cranberry Juice for the Prevention of Asymptomatic Bacteriuria in Pregnancy|Completed||N/A|51|Actual|University of California, Irvine|Our study methodology could have been improved with a series of timed urine collections such as collections at pre-treatment, 2, 4 and 6 hours after ingestion of the cranberry juice cocktail and placebo to determine time of maximal effect.|3|||f||||f||||||||No||2018-06-01 03:03:13.560016|2018-06-01 03:03:13.560016
NCT00506012|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2013-12-19|2007-07-23|2007-07-25|Estimate|||||||2013-12-19|2013-12-23|Estimate|August 2007||2007-08-31|November 2013|2013-11-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||Pilot Efficacy Study of T2000 in Myoclonus Dystonia|Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Myoclonus Dystonia: An Open Label Sequential Dose Escalation Study|Terminated||Phase 2|5|Anticipated|Taro Pharmaceuticals USA||1||Slow Recruitment of eligible patients|f||||||||||||||2018-06-01 03:03:13.956967|2018-06-01 03:03:13.956967
NCT00505999|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2017-11-10|2007-07-24|2007-07-25|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2006|Actual|2006-07-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Etiology of Multiple Myeloma: A Case-Control Study|Etiology of Multiple Myeloma: A Case-Control Study|Active, not recruiting|||500|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood and saliva samples that will be used for special tests to look for any biological~     factors associated with Multiple Myemloma (MM).~   "|||2018-06-01 03:03:14.060062|2018-06-01 03:03:14.060062
NCT00505986|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2012-03-30|2007-07-23|2007-07-25|Estimate|||||||2012-03-30|2012-04-02|Estimate|June 2007||2007-06-30|March 2012|2012-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Genomic Endometrial Expression in Obesity||Completed||N/A|||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||||||||||||2018-06-01 03:03:14.178025|2018-06-01 03:03:14.178025
NCT00505973|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2007-12-03|2007-07-24|2007-07-25|Estimate|||||||2007-12-03|2007-12-05|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SCA-136 Administered Orally to Healthy Japanese Male Subjects|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:03:14.255493|2018-06-01 03:03:14.255493
NCT00505960|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2010-12-20|2007-07-20|2007-07-25|Estimate|||||||2010-12-20|2010-12-21|Estimate|September 2007||2007-09-30|December 2010|2010-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Culturally Tailored Behavioral Diabetes Care Intervention for Korean Americans|Diabetes Care for Korean Americans|Completed||Phase 1|80|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 03:03:14.312438|2018-06-01 03:03:14.312438
NCT00505947|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2009-02-19|2007-07-23|2007-07-25|Estimate|||||||2009-02-19|2009-02-20|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Treatment of Refractory Diabetic Macular Edema With Infliximab|Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study|Terminated||Phase 3|12|Actual|University of Athens||2||The number of the anticipated participants was not achieved|f||||t||||||||||2018-06-01 03:03:14.40554|2018-06-01 03:03:14.40554
NCT00505934|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2011-01-28||2015-06-22|2007-07-20|2007-07-25|Estimate|2011-01-28|2011-02-25|Estimate||||2015-06-22|2015-07-15|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy|Open-label, Single-arm, Multi-center, Pharmacokinetic, Safety and Tolerability Study of Levetiracetam Intravenous Infusion in Children (1 Month- 4 Years Old) With Epilepsy|Completed||Phase 2|19|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:03:14.499797|2018-06-01 03:03:14.499797
NCT00505921|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2011-09-30||2011-11-08|2007-07-23|2007-07-25|Estimate|2011-09-30|2011-11-07|Estimate||||2011-11-08|2011-11-16|Estimate|March 2003||2003-03-31|November 2011|2011-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma|Autologous and Allogeneic Transplantation for T-Cell Lymphoma: Impact of Campath -1H and Soluble CD52|Terminated||Phase 2|27|Actual|M.D. Anderson Cancer Center|Early termination due to slow accrual.|1||Slow Accrual.|f||||f||||||||||2018-06-01 03:03:14.79713|2018-06-01 03:03:14.79713
NCT00505908|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2011-02-17|2007-07-24|2007-07-25|Estimate|||||||2011-02-17|2011-02-18|Estimate|July 2007||2007-07-31|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|||||Observational|NIFTI||Non-Interventional F-Two Isoprostane Trial (NIFTI)|Non-Interventional F-Two Isoprostane Trial|Unknown status|Recruiting||50|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:03:15.026212|2018-06-01 03:03:15.026212
NCT00505895|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2014-10-03||2014-10-03|2007-07-23|2007-07-25|Estimate|2014-10-03|2014-10-17|Estimate||||2014-10-03|2014-10-17|Estimate|January 2002||2002-01-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||FM 140 vs FM100 Study in Patients With Multiple Myeloma|A Randomized Phase II Trial of Fludarabine/Melphalan 140 VS. Fludarabine/Melphalan 100 Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation for Patients With Multiple Myeloma|Completed||Phase 2|52|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:03:15.099291|2018-06-01 03:03:15.099291
NCT00505882|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2009-05-08|2007-07-24|2007-07-25|Estimate|||||||2009-05-08|2009-05-11|Estimate|July 2007||2007-07-31|May 2009|2009-05-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes|The Pilot Study:Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes|Withdrawn||Phase 4|24|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 03:03:15.381766|2018-06-01 03:03:15.381766
NCT00505869|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2012-08-01|2007-07-23|2007-07-25|Estimate|||||||2012-08-01|2012-08-02|Estimate|August 2004||2004-08-31|August 2012|2012-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||A Mood Management Intervention for Pregnant Smokers|A Mood Management Intervention for Pregnant Smokers|Completed|||338|Actual|M.D. Anderson Cancer Center|||2||f||||t||||||Samples Without DNA|"~     Saliva sample for cotinine.~   "|||2018-06-01 03:03:15.447498|2018-06-01 03:03:15.447498
NCT00505856|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2008-12-11|2007-07-23|2007-07-25|Estimate|||||||2008-12-11|2008-12-12|Estimate|July 2007||2007-07-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|||||Observational|||Dermabond Skin Adhesives vs Skin Staples for Closure of Repeat Cesarean Section Skin Incisions|Dermabond Skin Adhesives vs Skin Staples for Closure of Repeat Cesarean Section Skin Incisions|Terminated|||50|Anticipated|Texas Tech University Health Sciences Center||||Resident project--resident left institution and was not picked up by anyone else|f||||f||||||||||2018-06-01 03:03:15.506689|2018-06-01 03:03:15.506689
NCT00505843|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-24|||2015-01-28|2007-07-24|2007-07-25|Estimate|||||||2015-01-28|2015-01-29|Estimate|May 2007||2007-05-31|January 2015|2015-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study of MK0657 in Parkinson's Disease Patients (0657-006)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate Effectiveness of Single-Dose MK0657 in Combination With Levodopa on Motor Symptoms and Dyskinesias in Patients With Parkinson's Disease|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:03:15.71178|2018-06-01 03:03:15.71178
NCT00505830|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2007-07-23|2007-07-23|2007-07-25|Estimate|||||||2007-07-23|2007-07-25|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|July 2009|Anticipated|2009-07-31|||||Observational|||Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ|Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)|Unknown status|Recruiting||450|Anticipated|Groupe Francais d'Epidemiologie Psychiatrique|||4||f||||f||||||||||2018-06-01 03:03:15.779532|2018-06-01 03:03:15.779532
NCT00505817|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2009-01-09|2007-07-23|2007-07-25|Estimate|||||||2009-01-09|2009-01-12|Estimate||||January 2009|2009-01-31||||||||Interventional|||GnRH Agonist and Antagonists in an Oocyte Donation Program||Completed||Phase 4|||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||||||||||||2018-06-01 03:03:15.860276|2018-06-01 03:03:15.860276
NCT00505804|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-23|||2013-01-22|2007-07-24|2007-07-25|Estimate|||||||2013-01-22|2013-01-24|Estimate|January 2005||2005-01-31|January 2013|2013-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|Dex||A Comparison of Dexmedetomidine and Haloperidol in Patients With Intensive Care Unit (ICU)-Associated Agitation and Delirium|A Randomised Open Label Pilot Study of the Efficacy of Dexmedetomidine and Haloperidol in Ventilated Patients With ICU-associated Agitation and Delirium|Completed||Phase 2|20|Actual|Austin Health||2|||f||||f||||||||||2018-06-01 03:03:15.929427|2018-06-01 03:03:15.929427
NCT00505791|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2015-11-09|2007-07-20|2007-07-23|Estimate|||||||2015-11-09|2015-11-11|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF|Double Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction|Withdrawn||Phase 4|0|Actual|Rutgers, The State University of New Jersey||2||Unable to enroll patients|f||||f||||||||||2018-06-01 03:03:16.031341|2018-06-01 03:03:16.031341
NCT00505778|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2011-04-18||2013-04-15|2007-07-20|2007-07-23|Estimate|2011-04-18|2011-05-12|Estimate||||2013-04-15|2013-04-22|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Comparison of Once a Day Dose Compared to 2 Doses/Day|A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis|Completed||Phase 3|1027|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:03:16.210033|2018-06-01 03:03:16.210033
NCT00505765|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2014-12-03||2017-01-30|2007-07-20|2007-07-23|Estimate|2016-12-02|2017-01-27|Estimate||||2017-01-30|2017-03-10|Actual|July 2007||2007-07-31|January 2017|2017-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|AL-108|Of 69 randomized participants, 6 were excluded prior to starting double-blind medication; 63 participants exposed to drug or placebo were included in analyses.|A Multicenter Study of NAP (AL-108) in Schizophrenia|A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia|Completed||Phase 2|63|Actual|University of California, Los Angeles||4|||f||||t||||||||||2018-06-01 03:03:17.250411|2018-06-01 03:03:17.250411
NCT00505752|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2013-05-29||2014-01-20|2007-07-20|2007-07-23|Estimate|2013-05-29|2013-07-24|Estimate||||2014-01-20|2014-02-13|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)|A Phase II, Multicenter, Randomized, Assessor-blinded, Active-comparator, Dose-finding Study to Evaluate AS900672 Enriched Versus Follitropin Alfa (Gonal-f®) in Stimulating Multiple Follicular Development in Infertile Women Undergoing Assisted Reproductive Technology (ART)|Completed||Phase 2|520|Actual|Merck KGaA||4|||f||||||||||||||2018-06-01 03:03:17.760285|2018-06-01 03:03:17.760285
NCT00505739|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2012-07-26|2007-07-19|2007-07-23|Estimate|||||||2012-07-26|2012-07-30|Estimate|September 2001||2001-09-30|July 2012|2012-07-31|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Mifepristone for Patients With Endometrial Cancer and LGESS|Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS)|Completed||Phase 2|13|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:03:18.387533|2018-06-01 03:03:18.387533
NCT00505726|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2012-07-31|2007-07-20|2007-07-23|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2001||2001-11-30|July 2012|2012-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Reflectance Confocal Imaging in Cervical Cancer Patients|Reflectance Confocal Imaging of Cervical Intraepithelial Neoplasia (CIN)|Completed|||39|Actual|M.D. Anderson Cancer Center|||1||f||||t||||||||||2018-06-01 03:03:18.508134|2018-06-01 03:03:18.508134
NCT00505713|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2011-06-09|2007-07-20|2007-07-23|Estimate|||||||2011-06-09|2011-06-10|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy Study Using Rexin-G for Sarcoma|Evaluation of Safety and Efficacy of Rexin-G as Intervention for Recurrent or Metastatic Sarcoma|Completed||Phase 1/Phase 2|36|Actual|Epeius Biotechnologies||5|||f||||t||||||||||2018-06-01 03:03:18.57759|2018-06-01 03:03:18.57759
NCT00505700|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2010-09-23|2007-07-20|2007-07-23|Estimate|||||||2010-09-23|2010-09-24|Estimate|July 2003||2003-07-31|September 2010|2010-09-30||||September 2005|Actual|2005-09-30||Interventional|||VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia|Phase I Dose Escalating Trial of VELCADE (PS-341) in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia|Completed||Phase 1|36|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 03:03:18.647629|2018-06-01 03:03:18.647629
NCT00505687|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2009-12-08||2014-09-24|2007-07-20|2007-07-23|Estimate|2009-12-08|2010-01-12|Estimate||||2014-09-24|2014-10-02|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease|A Multicenter, Multinational, Phase 3b, Open-Label Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine Patch in Subjects With Idiopathic Parkinson's Disease|Completed||Phase 3|186|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:03:18.719676|2018-06-01 03:03:18.719676
NCT00505661|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2010-09-28||2012-04-16|2007-07-19|2007-07-23|Estimate|2010-09-28|2010-10-19|Estimate||||2012-04-16|2012-04-18|Estimate|September 2003||2003-09-30|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Letrozole in Patients With Ovarian Tumors|Phase II Study of Letrozole in Patients With Recurrent Advanced Borderline Tumors or Low Grade Epithelial Cancers of the Ovary, Fallopian Tube and Primary Peritoneum|Terminated||Phase 2|16|Actual|M.D. Anderson Cancer Center||1||Terminated due to slow patient accrual.|f||||f||||||||||2018-06-01 03:03:19.197069|2018-06-01 03:03:19.197069
NCT00505648|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2015-03-23|2007-07-20|2007-07-23|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|DRESS2||Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)|Treatment of DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) With Tegeline®|Terminated||Phase 3|6|Actual|University Hospital, Rouen||||Side effects valuation|f||||f||||||||||2018-06-01 03:03:19.664682|2018-06-01 03:03:19.664682
NCT00505635|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2012-03-26||2016-05-16|2007-07-20|2007-07-23|Estimate|2012-03-26|2012-04-18|Estimate||||2016-05-16|2016-06-17|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Biochemotherapy With Temozolomide for Metastatic Melanoma|Biochemotherapy With Temozolomide, Velban, Cisplatin, Interleukin-2, Interferon-alpha and Thalidomide for Metastatic Melanoma With Optional Intrathecal Interleukin-2 Treatment|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center||1||Slow accrual|f||||f||||||||||2018-06-01 03:03:19.772357|2018-06-01 03:03:19.772357
NCT00505622|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2012-10-23||2015-12-17|2007-07-20|2007-07-23|Estimate|2012-10-23|2012-11-22|Estimate||||2015-12-17|2016-01-21|Estimate|July 2007||2007-07-31|November 2015|2015-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations|A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations|Terminated||Phase 3|328|Actual|Eisai Inc.|Due to early termination, no subjects completed this open-label extension study.|1||Study stopped due to lack of efficacy.|f||||||||||||||2018-06-01 03:03:20.078464|2018-06-01 03:03:20.078464
NCT00505609|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2007-07-20|2007-07-20|2007-07-23|Estimate|||||||2007-07-20|2007-07-23|Estimate|November 1999||1999-11-30|July 2007|2007-07-31|October 2001|Actual|2001-10-31|||||Interventional|||Efficacy of the Standard Days Method of Family Planning|Efficacy of the Standard Days Method of Family Planning|Completed||N/A|478|Actual|Georgetown University||1|||f||||f||||||||||2018-06-01 03:03:20.829588|2018-06-01 03:03:20.829588
NCT00505596|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2014-10-17|2007-07-20|2007-07-23|Estimate|||||||2014-10-17|2014-10-21|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|EPIC||Expanded Prenatal Testing Options and Informed Choice|Expanded Prenatal Testing Options and Informed Choice|Completed||N/A|744|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 03:03:20.92435|2018-06-01 03:03:20.92435
NCT00505583|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-07-22|2007-07-20|2007-07-23|Estimate|||||||2011-07-22|2011-07-25|Estimate|July 2007||2007-07-31|July 2011|2011-07-31|December 2007|Anticipated|2007-12-31|December 2007|Anticipated|2007-12-31||Interventional|||Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy|A Randomized, Double-Blind, Triple-Dummy, 3-Period Crossover Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Formulation of MOA-728 in Subjects on Stable Methadone Maintenance|Withdrawn||Phase 1|||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:03:21.021391|2018-06-01 03:03:21.021391
NCT00505570|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2015-04-06|2007-07-20|2007-07-23|Estimate|||||||2015-04-06|2015-04-08|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PRIMA||PRIMA PFO Migraine Trial|Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial)|Terminated||Phase 2|107|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 03:03:21.136214|2018-06-01 03:03:21.136214
NCT00505557|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2009-06-23|2007-07-20|2007-07-23|Estimate|||||||2009-06-23|2009-06-24|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|April 2008|Actual|2008-04-30|April 2007|Actual|2007-04-30||Interventional|||Dual-Plane Breast Augmentation: Axillary Approach With Assistant of Endoscope||Completed||Phase 1|||Chinese Academy of Sciences|||||f||||t||||||||||2018-06-01 03:03:21.311806|2018-06-01 03:03:21.311806
NCT00505544|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2017-12-01|2007-07-19|2007-07-23|Estimate|||||||2017-12-01|2017-12-05|Actual|August 2005|Actual|2005-08-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Measuring Sleep Disturbance Among Cancer Patients|The Brief Sleep Disturbance Scale: Measuring Sleep Disturbance Among Cancer Patients|Active, not recruiting|||570|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 03:03:21.383014|2018-06-01 03:03:21.383014
NCT00505531|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2018-03-21|2007-07-20|2007-07-23|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2007||2007-06-30|March 2018|2018-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics|Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics|Terminated|||7|Actual|Massachusetts General Hospital|||3|Not enough data to analyze the results.|f||||f||||||||||2018-06-01 03:03:21.493936|2018-06-01 03:03:21.493936
NCT00505518|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2012-02-24||2013-07-09|2007-07-19|2007-07-23|Estimate|2013-07-09|2013-09-17|Estimate||||2013-07-09|2013-09-17|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home|Feasibility and Effectiveness of Telepsychiatry for Collaborative Management of Chinese Americans With Psychiatric Disorders in a Nursing Home|Completed||N/A|9|Actual|Massachusetts General Hospital|Many subjects in the study suffered from dementia and psychotic symptoms, thus their responses may not be reliable.||||f||||t||||||||||2018-06-01 03:03:21.615308|2018-06-01 03:03:21.615308
NCT00505505|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2008-08-06|2007-07-20|2007-07-23|Estimate|||||||2008-08-06|2008-08-07|Estimate|January 2002||2002-01-31|July 2007|2007-07-31||||||||Interventional|||Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy|Effects of Intensive Insulin Therapy on Mortality, Morbidity and Long Term Neurologic Outcome in Neurosurgical Intensive Care Patients|Unknown status|Recruiting|Phase 4|800|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-06-01 03:03:22.086759|2018-06-01 03:03:22.086759
NCT00505492|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2011-09-13|2007-07-19|2007-07-23|Estimate|||||||2011-09-13|2011-09-15|Estimate|February 2002||2002-02-28|September 2011|2011-09-30|December 2010|Actual|2010-12-31|February 2006|Actual|2006-02-28||Interventional|||Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy|A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus.|Terminated||Phase 2|4|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 03:03:22.408291|2018-06-01 03:03:22.408291
NCT00505479|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2007-07-20|2007-07-20|2007-07-23|Estimate|||||||2007-07-20|2007-07-23|Estimate|May 2007||2007-05-31|July 2007|2007-07-31|May 2010|Anticipated|2010-05-31|||||Observational|||Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy?||Unknown status|Recruiting||||Zhejiang University|||||f||||t||||||||||2018-06-01 03:03:22.649286|2018-06-01 03:03:22.649286
NCT00505466|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2017-08-11|2007-07-20|2007-07-23|Estimate|||||||2017-08-11|2017-08-15|Actual|May 6, 1999|Actual|1999-05-06|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Transition From Research to Disclosure in Human Genetics|Transition From Research to Disclosure in Human Genetics|Recruiting|||800|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Optional small sample of blood (about 6 tablespoons) for genetic testing for p53 following~     pre-test genetic counseling.~   "|||2018-06-01 03:03:22.960763|2018-06-01 03:03:22.960763
NCT00505453|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2016-11-03|2007-07-20|2007-07-23|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|August 2007|Actual|2007-08-31|||||Interventional|||A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine|A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007 - 2008 Season) in Adults Ranging in Age From 18 to 60 Years and 61 Years and Over|Completed||Phase 3|110|Anticipated|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:03:23.079932|2018-06-01 03:03:23.079932
NCT00505440|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2013-04-22|2007-07-19|2007-07-23|Estimate|||||||2013-04-22|2013-04-23|Estimate|June 2005||2005-06-30|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|TARAA||Trial of Automated Risk Appraisal for Adolescents|Trial of Automated Risk Appraisal for Adolescents|Completed||N/A|1185|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-06-01 03:03:23.620593|2018-06-01 03:03:23.620593
NCT00505427|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2013-06-28|2007-07-20|2007-07-23|Estimate|||||||2013-06-28|2013-07-01|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Alpha Lipoic Acid and Polycystic Ovary Syndrome|Alpha Lipoic Acid and Polycystic Ovary Syndrome|Completed||Phase 1|22|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:03:23.715231|2018-06-01 03:03:23.715231
NCT00505414|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2010-05-27||2016-06-14|2007-07-20|2007-07-23|Estimate|2010-05-27|2010-07-02|Estimate||||2016-06-14|2016-07-13|Estimate|June 2007||2007-06-30|June 2016|2016-06-30|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional||"Safety Analysis Set. The information is correct for each treatment arm. The demographic details for the total population is for the 93 participants that started treatment in the titration phase of the trial.~The tapentadol titration population was subject to a randomized withdrawal-trial design."|A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine|"A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). PR is Synonymous With ER and is Interchangeable."|Terminated||Phase 3|136|Actual|Grünenthal GmbH|Early termination, due to a recall of the morphine rescue medication and issues regarding supply of an alternative, lead to only 93 participants out of the 573 planned (16%) being available for analysis. The data should be interpreted with caution.|3||Recall of rescue medication, alternative rescue medication availability issues.|f||||f||||||||||2018-06-01 03:03:23.874552|2018-06-01 03:03:23.874552
NCT00505401|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2011-02-28|2007-07-20|2007-07-23|Estimate|||||||2011-02-28|2011-03-01|Estimate|December 2003||2003-12-31|July 2007|2007-07-31|November 2007|Actual|2007-11-30|||||Interventional|ISST-001||Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS|A Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat in HIV-1 Infected Adult Volunteers|Completed||Phase 1|27|Actual|Istituto Superiore di Sanità||2|||f||||t||||||||||2018-06-01 03:03:24.683187|2018-06-01 03:03:24.683187
NCT00505388|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2010-04-23|2007-07-20|2007-07-23|Estimate|||||||2010-04-23|2010-04-26|Estimate|July 2007||2007-07-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice|A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice|Completed|||5137|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:03:25.811706|2018-06-01 03:03:25.811706
NCT00505375|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2016-05-12||2016-07-07|2007-07-20|2007-07-23|Estimate|2016-07-07|2016-08-16|Estimate||||2016-07-07|2016-08-16|Estimate|February 2008||2008-02-29|July 2016|2016-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus|Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects|Completed||Phase 2|112|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 03:03:27.72517|2018-06-01 03:03:27.72517
NCT00505362|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2016-11-28||2017-10-02|2007-07-20|2007-07-23|Estimate|2017-02-06|2017-03-27|Actual||||2017-10-02|2017-11-06|Actual|June 2006||2006-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|August 2014|Actual|2014-08-31||Interventional|||Pain Study of Rectus Muscle Closure at Cesarean Delivery|Rectus Muscle Closure vs. Non-Closure at Primary Cesarean Delivery and Post-Operative Pain|Completed||N/A|63|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 03:03:28.110011|2018-06-01 03:03:28.110011
NCT00505349|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2016-02-04|2007-07-20|2007-07-23|Estimate|||||||2016-02-04|2016-02-05|Estimate|June 2007||2007-06-30|February 2016|2016-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Blood Neurotrophic Factors in Adults|Blood Neurotrophic Factors in Adults|Withdrawn||N/A|0|Actual|Posit Science Corporation||2|||f||||f||||||||||2018-06-01 03:03:28.420379|2018-06-01 03:03:28.420379
NCT00505336|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2009-02-10|2007-07-20|2007-07-23|Estimate|||||||2009-02-10|2009-02-11|Estimate|April 2006||2006-04-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure|The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure|Completed||N/A|43|Actual|St Vincent's University Hospital, Ireland||3|||f||||f||||||||||2018-06-01 03:03:28.479732|2018-06-01 03:03:28.479732
NCT00505323|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2014-07-04|2007-07-20|2007-07-23|Estimate|||||||2014-07-04|2014-07-08|Estimate|September 2007||2007-09-30|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CORDYS||Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Palliadal Lesion : Evaluation of Safety and Effectiveness|Motor and Premotor Cortex Stimulation for Treatment of Secondary Focal Dystonia With Striato Pallidal Lesion : Evaluation of Safety and Effectiveness|Completed||Phase 1|5|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:03:28.662936|2018-06-01 03:03:28.662936
NCT00505310|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2018-05-03|2007-07-20|2007-07-23|Estimate|||||||2018-05-03|2018-05-07|Actual|August 2002|Actual|2002-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Biobehavioral Effects of Emotional Expression in Cancer|Biobehavioral Effects of Emotional Expression in Cancer|Active, not recruiting||N/A|710|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-06-01 03:03:28.731342|2018-06-01 03:03:28.731342
NCT00505297|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2007-07-20|2007-07-20|2007-07-23|Estimate|||||||2007-07-20|2007-07-23|Estimate|August 2004||2004-08-31|October 2006|2006-10-31|July 2007|Actual|2007-07-31|||||Observational|||A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography|A Longitudinal Study of Osteoarthritis (OA) Disease Progression Measured by MRI, dGEMRIC, and Radiography|Completed|||18|Actual|University of California, San Francisco|||2||f||||t||||||||||2018-06-01 03:03:28.823577|2018-06-01 03:03:28.823577
NCT00505284|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|2012-10-23|2012-08-23|2014-06-26|2007-07-20|2007-07-23|Estimate|2013-02-06|2013-02-08|Estimate|2012-08-23|2012-08-30|Estimate|2014-06-26|2014-07-11|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy|Completed||Phase 2/Phase 3|352|Actual|Eisai Inc.||5|||f||||f||||||||||2018-06-01 03:03:28.926757|2018-06-01 03:03:28.926757
NCT00505271|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2011-06-09|2007-07-19|2007-07-23|Estimate|||||||2011-06-09|2011-06-10|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy Study Using Rexin-G for Breast Cancer|Phase I/II Evaluation of Safety and Efficacy of Pathotropic Nanoparticles Bearing a Dominant Negative Cyclin G1 Construct (Rexin-G) as Intervention for Recurrent or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|20|Actual|Epeius Biotechnologies||1|||f||||t||||||||||2018-06-01 03:03:30.114748|2018-06-01 03:03:30.114748
NCT00505258|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2013-02-19|2007-07-19|2007-07-23|Estimate|||||||2013-02-19|2013-02-20|Estimate||||February 2013|2013-02-28|April 2009|Anticipated|2009-04-30|||||Interventional|||Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia|Randomized, Open-Label Study Evaluating the Safety and Rate of Bacterial Clearance of Ceftobiprole 500 Milligram Every 8 Hours Compared to Conventional Therapy in the Treatment of Hospitalized Subjects With Staphylococcus Aureus Bacteremia|Withdrawn||Phase 2|0|Actual|Basilea Pharmaceutica||||The study was withdrawn due to lack of an appropriate patient population.|||||f||||||||||2018-06-01 03:03:30.172683|2018-06-01 03:03:30.172683
NCT00505245|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2018-04-17|2007-07-20|2007-07-23|Estimate|||||||2018-04-17|2018-04-19|Actual|April 1999|Actual|1999-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|||M.D. Anderson Symptom Inventory (MDASI) Validation Study in Cancer Patients|Measuring the Symptom Distress of Cancer Patients: Development of a New Assessment System|Recruiting|||5000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:03:30.231775|2018-06-01 03:03:30.231775
NCT00505232|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2011-12-30|2007-07-20|2007-07-23|Estimate|||||||2011-12-30|2012-01-02|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|March 2010|Actual|2010-03-31||Interventional|LCM-04-02||Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)|Induction Treatment With Anti-CD20 Plus Hyper-CVAD and Methotrexate/Cytarabine Followed by Consolidation Treatment With Y90 Ibritumomab-Tiuxetan in Patients With Mantle Cell Lymphoma|Completed||Phase 2|30|Actual|CABYC||1|||f||||f||||||||||2018-06-01 03:03:30.302287|2018-06-01 03:03:30.302287
NCT00505219|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20||2016-06-27|2017-06-01|2007-07-20|2007-07-23|Estimate||||2016-06-29|2016-07-01|Estimate|2017-06-01|2017-06-06|Actual|September 2007||2007-09-30|June 2017|2017-06-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|ON-CORE||Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head|Multi-center Clinical Trial of the Application of Ixmyelocel-T in the Treatment of Osteonecrosis of the Femoral Head|Completed||Phase 2|11|Actual|Vericel Corporation||2|||f||||f||||||||||2018-06-01 03:03:30.381663|2018-06-01 03:03:30.381663
NCT00505180|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2007-07-19|2007-07-19|2007-07-23|Estimate|||||||2007-07-19|2007-07-23|Estimate|June 2004||2004-06-30|July 2007|2007-07-31|June 2006|Actual|2006-06-30|||||Observational|ArMORR||Accelerated Mortality on Renal Replacement|Accelerated Mortality on Renal Replacement|Completed|||10018|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 03:03:30.5463|2018-06-01 03:03:30.5463
NCT00505167|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2008-12-26|2007-07-20|2007-07-23|Estimate|||||||2008-12-26|2008-12-29|Estimate|July 2007||2007-07-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Memantine Versus Donepezil in Early Stages of Alzheimer's Disease|Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.|Completed||Phase 4|64|Actual|Hospital Miguel Servet||2|||f||||f||||||||||2018-06-01 03:03:30.599161|2018-06-01 03:03:30.599161
NCT00505154|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2014-01-24|2007-07-20|2007-07-23|Estimate|||||||2014-01-24|2014-01-27|Estimate|July 2007||2007-07-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Rosuvastatin on Left Ventricular Remodeling|A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure|Completed||Phase 3|75|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 03:03:30.682417|2018-06-01 03:03:30.682417
NCT00505141|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2007-07-20|2007-07-20|2007-07-23|Estimate|||||||2007-07-20|2007-07-23|Estimate|September 2004||2004-09-30|July 2007|2007-07-31|February 2006|Actual|2006-02-28|||||Observational|||Urban Environmental Exposures and Childhood Cancer|Case-Control Study of Urban Environmental Effects on Childhood Leukemia and Brain Cancer|Completed|||||Georgetown University|||||f||||||||||||||2018-06-01 03:03:30.809174|2018-06-01 03:03:30.809174
NCT00505128|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2011-05-06|2007-07-20|2007-07-23|Estimate|||||||2011-05-06|2011-05-09|Estimate|July 2007||2007-07-31|May 2007|2007-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|EEPAB||Impact on Outcome of Early Endoscopic Extraction of Bile Duct Stones in Biliary Pancreatitis|Impact on Outcome of Early Endoscopic Extraction of Bile Duct Stones in Biliary Pancreatitis: a Prospective Multicenter Randomized Controlled Study|Completed||N/A|900|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 03:03:30.885584|2018-06-01 03:03:30.885584
NCT00505115|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-20|||2007-07-20|2007-07-20|2007-07-23|Estimate|||||||2007-07-20|2007-07-23|Estimate||||July 2007|2007-07-31||||||||Observational|||The Human Blastocyst Secretome and Implantome||Completed|||||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-06-01 03:03:31.062449|2018-06-01 03:03:31.062449
NCT00505102|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2008-02-12|2007-07-19|2007-07-20|Estimate|||||||2008-02-12|2008-02-13|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|SAREFU||Safe Renal Function In Long Term Heart Transplanted Patients|Efficacy and Safety of Everolimus to SAve REnal Function (SAREFU) in Long Term Heart Transplanted Patients|Unknown status|Active, not recruiting|Phase 4|200|Anticipated|A.O. Ospedale Papa Giovanni XXIII||1|||f||||t||||||||||2018-06-01 03:03:31.119328|2018-06-01 03:03:31.119328
NCT00505089|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2009-08-24|2007-07-19|2007-07-20|Estimate|||||||2009-08-24|2009-08-25|Estimate|August 2007||2007-08-31|August 2009|2009-08-31||||May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis|An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis|Terminated||Phase 1/Phase 2|11|Actual|Novartis||4|||f||||f||||||||||2018-06-01 03:03:31.220491|2018-06-01 03:03:31.220491
NCT00505076|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2011-04-27||2014-10-30|2007-07-19|2007-07-20|Estimate|2014-10-30|2014-10-31|Estimate||||2014-10-30|2014-10-31|Estimate|July 2007||2007-07-31|October 2014|2014-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|TURNS||Treatment Study for Cognitive Deficits in Schizophrenia|MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia|Completed||Phase 2|63|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-06-01 03:03:31.335395|2018-06-01 03:03:31.335395
NCT00505063|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2017-08-03|2007-07-19|2007-07-20|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2007||2007-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Prospective Trial of Vaccine Responses in Childhood Cancer Survivors|Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors|Active, not recruiting||Phase 2|75|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 03:03:31.709162|2018-06-01 03:03:31.709162
NCT00505050|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2007-07-18|2007-07-18|2007-07-20|Estimate|||||||2007-07-18|2007-07-20|Estimate|October 1999||1999-10-31|July 2007|2007-07-31|September 2006|Actual|2006-09-30|||||Interventional|REMADHE||A Long-Term Prospective Randomized Controlled Study Using Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure Outpatients – The REMADHE Study||Completed||Phase 3|||University of Sao Paulo||1|||f||||f||||||||||2018-06-01 03:03:31.802421|2018-06-01 03:03:31.802421
NCT00505037|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2011-03-21|2007-07-18|2007-07-20|Estimate|||||||2011-03-21|2011-03-22|Estimate|October 2007||2007-10-31|March 2011|2011-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis|A Phase 2, Randomized, Double-blind-placebo-controlled and Open-label-Sevelamer Hydrochloride-controlled, Dose-ranging Study for ASP1585 in Patients With Chronic Kidney Disease(CKD) and Hyperphosphatemia on Hemodialysis|Completed||Phase 2|156|Actual|Astellas Pharma Inc||5|||f||||t||||||||||2018-06-01 03:03:31.875227|2018-06-01 03:03:31.875227
NCT00505024|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2012-07-27|2007-07-18|2007-07-20|Estimate|||||||2012-07-27|2012-07-30|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery|A Randomized Clinical Trial of the Efficacy of an Interactive Voice Response System (IVRS) for Managing Symptoms of Patients Following Thoracic Surgery|Completed||N/A|100|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:03:31.953581|2018-06-01 03:03:31.953581
NCT00505011|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2007-07-19|2007-07-19|2007-07-20|Estimate|||||||2007-07-19|2007-07-20|Estimate|February 1998||1998-02-28|July 2007|2007-07-31|February 2007|Actual|2007-02-28|||||Observational|||Genetic Polymorphisms Associated With Cigarette Smoking and Risk of Graves’ Disease|Study of the Influence of the GST, CYP and TP53 Gene Polymorphisms in the Risk of Graves' Disease and Its Outcome.|Completed|||1998|Actual|University of Campinas, Brazil|||||f||||f||||||||||2018-06-01 03:03:32.130005|2018-06-01 03:03:32.130005
NCT00504998|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2011-06-09|2007-07-18|2007-07-20|Estimate|||||||2011-06-09|2011-06-10|Estimate|July 2007||2007-07-31|February 2010|2010-02-28|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer|Phase I/II Evaluation of Safety and Efficacy of Rexin-G for Recurrent or Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|20|Actual|Epeius Biotechnologies||5|||f||||t||||||||||2018-06-01 03:03:32.181794|2018-06-01 03:03:32.181794
NCT00504985|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|2010-03-26||2012-07-26|2007-07-18|2007-07-20|Estimate|2010-04-13|2010-05-04|Estimate||||2012-07-26|2012-08-01|Estimate|August 2005||2005-08-31|July 2012|2012-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Fatigue in Emergency Center Patients|Fatigue and Its Symptom Cluster Related to Inflammatory Cytokine Profiles in Cancer Patients Seeking Emergency Care|Terminated|||14|Actual|M.D. Anderson Cancer Center|Early termination led to small numbers of subjects, too little data to analyze.||1|Low Accrual|f||||f||||||Samples Without DNA|"~     About 1 tablespoon of blood drawn for cytokine testing.~   "|||2018-06-01 03:03:32.265773|2018-06-01 03:03:32.265773
NCT00504972|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2018-05-25|2007-07-19|2007-07-20|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2007||2007-06-30|May 2018|2018-05-31|October 7, 2015|Actual|2015-10-07|April 1, 2011|Actual|2011-04-01||Interventional|||Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies|Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies|Completed||Phase 1|23|Actual|Weill Medical College of Cornell University||1|||f||||t|t|f||||||Undecided||2018-06-01 03:03:32.405289|2018-06-01 03:03:32.405289
NCT00504959|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2016-03-02|2007-07-19|2007-07-20|Estimate|||||||2016-03-02|2016-03-04|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|Completed||Phase 4|234|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:03:32.481994|2018-06-01 03:03:32.481994
NCT00504946|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2008-04-08|2007-07-19|2007-07-20|Estimate|||||||2008-04-08|2008-04-11|Estimate|September 2005||2005-09-30|April 2008|2008-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Pharmacological Modulations of Allergen-Specific Immunotherapy|The Effect of Glucocorticosteroid and Vitamin D3 Administration and Montelukast Treatment on Early Clinical and Immunological Effect of Allergen-Specific Immunotherapy in Asthmatic Children, Double-Blind, Placebo-Controlled Study|Completed||Phase 3|85|Actual|Medical Universtity of Lodz||5|||f||||t||||||||||2018-06-01 03:03:32.590976|2018-06-01 03:03:32.590976
NCT00504933|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2012-04-04|2007-07-19|2007-07-20|Estimate|||||||2012-04-04|2012-04-05|Estimate|May 2005||2005-05-31|April 2012|2012-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis|Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.|Completed||Phase 3|683|Actual|Faes Farma, S.A.||3|||f||||f||||||||||2018-06-01 03:03:32.732588|2018-06-01 03:03:32.732588
NCT00504920|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2012-07-31|2007-07-18|2007-07-20|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2004||2004-05-31|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients|Feasibility Study of the Assessment of Symptom-Related Cytokines in AML/MDS Patients Undergoing Allogeneic Blood or Marrow Transplantation|Completed|||30|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     At admission, blood sample drawn (around 2½ tablespoons) to measure levels of cytokines~     before transplant procedure, then another three days postadmission, on day of transplant, 1~     day after transplant, 3 days, 8 days, 15 days, 22 days, 29 days postransplant, then between~     50 - 60 days postransplant and again 80 - 100 days after transplant.~   "|||2018-06-01 03:03:32.811408|2018-06-01 03:03:32.811408
NCT00504907|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2018-05-29|2007-07-18|2007-07-20|Estimate|||||||2018-05-29|2018-05-30|Actual|July 2007||2007-07-31|May 2018|2018-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety Study of Oral BTA9881 to Treat RSV Infection|A Phase I, Single-Centre, Double-Blind, Placebo-Controlled, Escalating Single Oral Dose, Safety and Tolerability Clinical Trial With BTA9881 in Healthy Subjects|Completed||Phase 1|63|Actual|Vaxart||7|||f||||t||||||||||2018-06-01 03:03:32.888298|2018-06-01 03:03:32.888298
NCT00504894|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2017-02-28||2017-04-13|2007-07-19|2007-07-20|Estimate|2017-04-13|2017-05-18|Actual||||2017-04-13|2017-05-18|Actual|March 2007|Actual|2007-03-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|December 2015|Actual|2015-12-31||Interventional|Amygdala||Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes|Neuroimaging the Effects of Intravenous Anesthetic on Amygdala Dependent Memory Processes|Active, not recruiting||Phase 4|35|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-06-01 03:03:32.980437|2018-06-01 03:03:32.980437
NCT00504881|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2016-03-14|2010-02-01|2018-03-08|2007-07-19|2007-07-20|Estimate|2017-01-27|2017-03-17|Actual|2009-08-26|2009-08-27|Estimate|2018-03-08|2018-04-03|Actual|October 2007||2007-10-31|March 2018|2018-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional||Baseline characteristics refer to the Randomized Set (RS).|Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy|An International, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Study: Evaluation of the Safety and Efficacy of Brivaracetam in Subjects (≥ 16 to 70 Years Old) Suffering From Localization-related or Generalized Epilepsy.|Completed||Phase 3|480|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 03:03:33.228432|2018-06-01 03:03:33.228432
NCT00504855|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2013-04-05|2007-07-19|2007-07-20|Estimate|||||||2013-04-05|2013-04-08|Estimate|July 2007||2007-07-31|April 2013|2013-04-30|March 2014|Anticipated|2014-03-31|February 2012|Actual|2012-02-29||Interventional|||Cast Sores With Waterproof Vs. Standard Cast Padding|Cast Sores With Waterproof Vs. Standard Cast Padding in a Pediatric Population|Terminated||N/A|84|Actual|Shriners Hospitals for Children||2||"Staffing changes resulted in the expiration of IRB approval (2/15/12), and recruitment halted~   (n=84). IRB approval is now current for retrospective analysis."|f||||f||||||||||2018-06-01 03:03:33.990728|2018-06-01 03:03:33.990728
NCT00504842|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2008-04-11|2007-07-19|2007-07-20|Estimate|||||||2008-04-11|2008-04-15|Estimate|December 2006||2006-12-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|||||Interventional|TUCSON||Transcranial Ultrasound in Clinical SONothrombolysis|A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 With Continuous Ultrasound Administration in Subjects With Acute Ischemic Stroke Receiving Treatment With Intravenous Tissue Plasminogen Activator|Terminated||Phase 1/Phase 2|72|Anticipated|ImaRx Therapeutics||||Sponsor decision|f||||t||||||||||2018-06-01 03:03:34.068388|2018-06-01 03:03:34.068388
NCT00504829|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2008-04-11|2007-07-18|2007-07-20|Estimate|||||||2008-04-11|2008-04-15|Estimate|July 2007||2007-07-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia|A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-AtorFen in Subjects With Dyslipidemia|Completed||Phase 2|220|Actual|Veloxis Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:03:34.144162|2018-06-01 03:03:34.144162
NCT00504816|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-05-31|2007-07-18|2007-07-20|Estimate|||||||2012-05-31|2012-06-04|Estimate|April 2007||2007-04-30|February 2011|2011-02-28|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers|An Open Label, Single-sequence, Repeat-dose Study to Investigate the Effects of GSK189075 on the Pharmacokinetics of an Oral Contraceptive Pill When Coadministered to Healthy Female Volunteers|Completed||Phase 1|22|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:03:34.256683|2018-06-01 03:03:34.256683
NCT00504803|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2011-09-01|2007-07-19|2007-07-20|Estimate|||||||2011-09-01|2011-09-02|Estimate|December 2006||2006-12-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease|Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study|Completed||Phase 2|30|Anticipated|University Hospital of Liege||1|||f||||f||||||||||2018-06-01 03:03:34.367257|2018-06-01 03:03:34.367257
NCT00504790|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2017-06-19|2007-07-18|2007-07-20|Estimate|||||||2017-06-19|2017-06-20|Actual|June 25, 2007|Actual|2007-06-25|June 2017|2017-06-30|May 8, 2012|Actual|2012-05-08|May 8, 2012|Actual|2012-05-08||Interventional|||Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer|A Phase I, Open-Label, Dose-Escalation, First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics, and Pharmacodynamics of GSK923295 in Subjects With Refractory Cancers|Completed||Phase 1|39|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:03:34.463834|2018-06-01 03:03:34.463834
NCT00504777|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2014-07-09||2014-07-09|2007-07-19|2007-07-20|Estimate|2014-07-09|2014-08-04|Estimate||||2014-07-09|2014-08-04|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Intent-to-Treat (ITT) Population: all participants who recieved any part of an infusion.|A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Agents.|An Open Label Study to Evaluate the Safety, and Effect on Treatment Response, of MabThera in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One or More Anti-TNF Agents.|Completed||Phase 4|36|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:03:34.621111|2018-06-01 03:03:34.621111
NCT00504764|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2014-10-27|2007-07-19|2007-07-20|Estimate|||||||2014-10-27|2014-10-28|Estimate|July 2007||2007-07-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)|APL-R2007: Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)|Completed||Phase 4|60|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:03:34.861319|2018-06-01 03:03:34.861319
NCT00504751|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2017-02-23||2017-02-23|2007-07-19|2007-07-20|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|May 2007|Actual|2007-05-31|February 2017|2017-02-28|February 17, 2012|Actual|2012-02-17|December 2010|Actual|2010-12-31||Interventional|||"Phase II Study of VIPER Chemotherapy in Rel/Ref DLBCL"|"Phase II Trial of VIPER Chemotherapy in Relapsed and Refractory Diffuse Large B-cell Lymphoma (NHL)"|Completed||Phase 2|15|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 03:03:35.145171|2018-06-01 03:03:35.145171
NCT00504738|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2015-04-20|2007-07-19|2007-07-20|Estimate|||||||2015-04-20|2015-04-21|Estimate|April 2006||2006-04-30|April 2015|2015-04-30|April 2007|Actual|2007-04-30|||||Observational|Q-LD||Lung Disease Collection (Qatar): Evaluation of the Lungs of Individuals With Lung Disease|Evaluation of the Lungs of Individuals With Lung Disease With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy (Qatar)|Completed|||75|Actual|Weill Medical College of Cornell University|||||f||||t||||||Samples With DNA|"~     The purpose of this protocol is to obtain biologic samples from the blood and lungs from~     patients with lung diseases in order to study the causes and indications of these disorders,~     learn how these lung disease manifest and progress, and how the lung disease can be treated.~   "|||2018-06-01 03:03:35.313457|2018-06-01 03:03:35.313457
NCT00504725|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|2011-09-29||2014-07-18|2007-07-19|2007-07-20|Estimate|2012-11-14|2012-11-16|Estimate||||2014-07-18|2014-07-25|Estimate|July 2007||2007-07-31|November 2012|2012-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|KITS||Ketamine In Thoracic Surgery (KITS) Trial|Ketamine In Thoracic Surgery (KITS) Trial|Completed||Phase 2|40|Actual|Duke University||2|||f||||f||||||||||2018-06-01 03:03:35.411472|2018-06-01 03:03:35.411472
NCT00504712|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2007-07-19|2007-07-19|2007-07-20|Estimate|||||||2007-07-19|2007-07-20|Estimate|February 2006||2006-02-28|July 2007|2007-07-31|February 2008|Anticipated|2008-02-29|||||Interventional|||Testosterone for Peripheral Vascular Disease|A Randomised, Double Blind, Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 4|30|Anticipated|Barnsley Hospital||2|||f||||f||||||||||2018-06-01 03:03:35.775523|2018-06-01 03:03:35.775523
NCT00504699|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2018-03-27|2007-07-19|2007-07-20|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2002||2002-01-31|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients|Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study|Terminated||N/A|120|Actual|New York Medical College||2||The PI left the Institution.|f||||f||||||||No||2018-06-01 03:03:35.867701|2018-06-01 03:03:35.867701
NCT00504686|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2009-02-02|2007-07-18|2007-07-20|Estimate|||||||2009-02-02|2009-02-03|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Patients With Neck Pain Likely to Benefit From Thoracic Spine Thrust Mobilization|Validation of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Thoracic Spine Thrust Mobilization: A Randomized Clinical Trial|Completed||Phase 1|140|Anticipated|Franklin Pierce University||2|||f||||f||||||||||2018-06-01 03:03:35.965497|2018-06-01 03:03:35.965497
NCT00504673|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2014-11-20|2007-07-19|2007-07-20|Estimate|||||||2014-11-20|2014-11-21|Estimate|April 2005||2005-04-30|November 2014|2014-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|PREDICTIVE™||Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes|Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes|Completed||Phase 3|277|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:03:36.053814|2018-06-01 03:03:36.053814
NCT00504660|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|2011-12-06||2011-12-06|2007-07-18|2007-07-20|Estimate|2011-12-06|2012-01-11|Estimate||||2011-12-06|2012-01-11|Estimate|September 2003||2003-09-30|December 2011|2011-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients|Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma and Glioblastoma Multiforme|Completed||Phase 2|75|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 03:03:36.159357|2018-06-01 03:03:36.159357
NCT00504647|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2007-07-18|2007-07-18|2007-07-20|Estimate|||||||2007-07-18|2007-07-20|Estimate|June 2006||2006-06-30|July 2007|2007-07-31|August 2008|Anticipated|2008-08-31|||||Interventional|||Biventricular Pacing in Hypertrophic Cardiomyopathy|Diastolic Ventricular Interaction and the Effects Of Biventricular Pacing in Hypertrophic Cardiomyopathy|Unknown status|Recruiting|Phase 1|30|Anticipated|University Hospital Birmingham|||||f||||f||||||||||2018-06-01 03:03:36.489008|2018-06-01 03:03:36.489008
NCT00504634|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2011-09-14|2007-07-18|2007-07-20|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2004||2004-01-31|September 2011|2011-09-30|May 2010|Actual|2010-05-31|August 2007|Actual|2007-08-31||Interventional|||Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma|A Phase II Trial of Bortezomib (Velcade) After Allogenic Peripheral Blood Stem Cell or Bone Marrow Transplantation for Patients With Multiple Myeloma|Completed||Phase 2|8|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:03:36.560931|2018-06-01 03:03:36.560931
NCT00504621|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2014-03-25|2007-07-19|2007-07-20|Estimate|||||||2014-03-25|2014-03-26|Estimate|August 2007||2007-08-31|March 2014|2014-03-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Observational|||The Influence of Personality on Pulmonary Fibrosis and Sarcoidosis|The Influence of Personality on Quality of Life, Fatigue, Prognosis, and Health Care Consumption in Pulmonary Fibrosis and Sarcoidosis|Completed|||450|Actual|Maastricht University Medical Center|||2||f||||f||||||||||2018-06-01 03:03:36.661059|2018-06-01 03:03:36.661059
NCT00504608|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2017-01-03|2007-07-18|2007-07-20|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 2003||2003-04-30|January 2017|2017-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure|A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure|Completed||Phase 1/Phase 2|150|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 03:03:36.721991|2018-06-01 03:03:36.721991
NCT00504595|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2011-01-20||2012-08-02|2007-07-19|2007-07-20|Estimate|2011-05-24|2011-06-23|Estimate||||2012-08-02|2012-08-07|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis|A 12-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR20) and to Determine a Biomarker Profile in Adult Patients With Established Rheumatoid Arthritis Responding to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) as Compared to Healthy Subjects Exposed to ACZ885|Completed||Phase 2|80|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:03:36.782958|2018-06-01 03:03:36.782958
NCT00504582|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2017-09-28|2007-07-19|2007-07-20|Estimate|||||||2017-09-28|2017-09-29|Actual|May 2002|Actual|2002-05-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Fibrin Melanoma Axillary Node Study in Patients With Melanoma|A Randomized Trial Evaluating the Use of Fibrin Tissue Adhesive Following Axillary Node Dissection in Patients With Melanoma|Active, not recruiting||N/A|115|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:03:37.221065|2018-06-01 03:03:37.221065
NCT00504556|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|2015-02-05|2010-08-25|2015-03-12|2007-07-18|2007-07-20|Estimate|2015-03-12|2015-03-13|Estimate|2010-08-25|2010-08-27|Estimate|2015-03-12|2015-03-13|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation|A Phase 2, Randomized, Parallel Group, Multi Center, Multi National Study for the Evaluation of Safety of Four Fixed Dose Regimens of DU-176b in Subjects With Non- Valvular Atrial Fibrillation|Completed||Phase 2|1146|Actual|Daiichi Sankyo, Inc.||5|||f||||t||||||||||2018-06-01 03:03:37.354918|2018-06-01 03:03:37.354918
NCT00504543|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2016-11-16|2007-07-19|2007-07-20|Estimate|||||||2016-11-16|2016-11-18|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|AEB071||Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients|A 12 Month Open-label, Randomized, Multicenter, Sequential Cohort-group, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients.|Completed||Phase 2|311|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:03:39.933738|2018-06-01 03:03:39.933738
NCT00504530|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2017-01-03|2007-07-18|2007-07-20|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2001||2001-09-30|December 2016|2016-12-31|April 2002|Actual|2002-04-30|||||Interventional|||r-hLIF for Improving Embryo Implantation in IVF|A Randomised, Double-blind, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Acceptability of r-hLIF for Improving Embryo Implantation Following in Vitro Fertilisation (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure.|Completed||Phase 1/Phase 2|50|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 03:03:40.055789|2018-06-01 03:03:40.055789
NCT00504517|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2012-08-15|2007-07-19|2007-07-20|Estimate|||||||2012-08-15|2012-08-16|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|P4||Preparing the Personal Physician for Practice (P4)|Preparing the Personal Physician for Practice (P4)|Completed|||35|Actual|Christiana Care Health Services|||||f||||f||||||||||2018-06-01 03:03:40.158717|2018-06-01 03:03:40.158717
NCT00504504|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2013-05-20||2013-05-20|2007-07-19|2007-07-20|Estimate|2013-05-20|2013-07-09|Estimate||||2013-05-20|2013-07-09|Estimate|March 2001||2001-03-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Rituximab and ABVD for Hodgkin's Patients|A Phase II Study of Rituximab + ABVD for Patients With Hodgkin's Disease|Completed||Phase 2|85|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:03:40.250323|2018-06-01 03:03:40.250323
NCT00504491|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2011-12-28|2007-07-19|2007-07-20|Estimate|||||||2011-12-28|2011-12-30|Estimate|July 2007||2007-07-31|December 2011|2011-12-31|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|R-CHOP||R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia|Rescue Treatment With Rituximab-CHOP Therapy and Alemtuzumab (R-CHOP-A) in Refractory or Recidivant Patients With Chronic Lymphocytic Leukemia After Purine-analogous Treatment|Withdrawn||Phase 2|0|Actual|CABYC||1||IMP new owner decision|f||||t||||||||||2018-06-01 03:03:40.611651|2018-06-01 03:03:40.611651
NCT00504478|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2007-07-19|2007-07-19|2007-07-20|Estimate|||||||2007-07-19|2007-07-20|Estimate|January 2008||2008-01-31|April 2007|2007-04-30|December 2009|Anticipated|2009-12-31|||||Interventional|HCCD||Effect of HCCD Supplemented With Omega-3 Fatty-Acids on Inflammation in Healthy, Overweight Subjects||Unknown status|Not yet recruiting|N/A|150|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-06-01 03:03:40.764353|2018-06-01 03:03:40.764353
NCT00504465|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2007-07-19|2007-07-19|2007-07-20|Estimate|||||||2007-07-19|2007-07-20|Estimate|May 2002||2002-05-31|July 2007|2007-07-31|April 2007|Actual|2007-04-30|||||Interventional|||Combined Agent Randomized Trial of Induction of Labor|Cervical Ripening and Induction of Labor: a Randomized Controlled Trial of Combined Versus Sequential Use of Dinoprostone and Oxytocin.|Completed||N/A|210||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 03:03:40.88523|2018-06-01 03:03:40.88523
NCT00504452|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2011-11-03|2007-07-19|2007-07-20|Estimate|||||||2011-11-03|2011-11-07|Estimate|July 2007||2007-07-31|November 2008|2008-11-30|June 2009|Actual|2009-06-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients|An Open-Label, Multicenter, Mechanism Validation Study to Evaluate the Safety, Efficacy and Tolerability of KP-1461 as Monotherapy for 124 Days in Antiretroviral-experienced, HIV-1-infected Subjects|Terminated||Phase 2|27|Actual|Koronis Pharmaceuticals.||||"Corroboration of supporting in vitro data~    - Data successfully corroborated 2009"|f||||t||||||||||2018-06-01 03:03:41.008395|2018-06-01 03:03:41.008395
NCT00504439|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2017-08-02|2007-07-18|2007-07-20|Estimate|||||||2017-08-02|2017-08-03|Actual|June 4, 2007|Actual|2007-06-04|August 2017|2017-08-31|September 6, 2007|Actual|2007-09-06|September 6, 2007|Actual|2007-09-06||Interventional|||A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects|A Randomised, Double-blind, Placebo Controlled, Dose Ascending, Parallel Group Study to Evaluate the Safety, Tolerability, Steady State Pharmacokinetics and Pharmacodynamics of SB-656933-AAA Following Repeated Doses in Healthy Adult Subjects. The Pharmacokinetic Interaction Between Repeated Doses of SB-656933-AAA and Single Dose of Simvastatin Will Also be Assessed|Completed||Phase 1|36|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:03:41.129482|2018-06-01 03:03:41.129482
NCT00504426|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2013-07-01||2013-12-24|2007-07-19|2007-07-20|Estimate|2013-12-24|2014-01-30|Estimate||||2013-12-24|2014-01-30|Estimate|July 2007||2007-07-31|December 2013|2013-12-31|May 2009|Actual|2009-05-31|July 2008|Actual|2008-07-31||Interventional|||Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis|Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis|Completed||Phase 2|101|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 03:03:41.241543|2018-06-01 03:03:41.241543
NCT00504413|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2010-10-11|2007-07-18|2007-07-20|Estimate|||||||2010-10-11|2010-10-13|Estimate|July 2007||2007-07-31|October 2010|2010-10-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone|Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects|Unknown status|Recruiting|Phase 1|20|Anticipated|University of Washington|||||f||||t||||||||||2018-06-01 03:03:41.745316|2018-06-01 03:03:41.745316
NCT00501553|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2011-06-23|2007-07-13|2007-07-16|Estimate|||||||2011-06-23|2011-06-27|Estimate|June 2005||2005-06-30|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Observational|KarViD||Vitamin D in Patients With Heart Failure||Completed|||148|Actual|Hvidovre University Hospital|||||f||||t||||||||||2018-06-01 03:04:36.93243|2018-06-01 03:04:36.93243
NCT00504400|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2009-09-21|2007-07-18|2007-07-20|Estimate|||||||2009-09-21|2009-09-22|Estimate|August 2007||2007-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)|Ranibizumab in Idiopathic Macular Telangiectasia, Type 2. A Prospective Interventional Non-randomized Study Comparing the Efficacy and Safety of Intravitreal Ranibizumab in Type 2 Idiopathic Macular Telangiectasia.|Completed||Phase 2|10|Actual|University Hospital, Bonn||1|||f||||f||||||||||2018-06-01 03:03:41.885358|2018-06-01 03:03:41.885358
NCT00504387|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2012-12-20|2007-07-19|2007-07-20|Estimate|||||||2012-12-20|2012-12-21|Estimate|April 2007||2007-04-30|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Burning Mouth Disorder (BMD) - A Neuropathic Pain Disorder|Burning Mouth Disorder (BMD) - a Neuropathic Pain Disorder? An Investigation Using Qualitative and Quantitative Sensory Testing (QST)|Unknown status|Recruiting||12|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-06-01 03:03:41.96153|2018-06-01 03:03:41.96153
NCT00504374|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2017-05-04|2007-07-19|2007-07-20|Estimate|||||||2017-05-04|2017-05-08|Actual|June 13, 2006|Actual|2006-06-13|May 2017|2017-05-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Observational|||Gene Polymorphisms and Symptoms in Lung Cancer Patients|Gene Polymorphisms and Symptoms in Lung Cancer Patients|Completed|||235|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Leftover blood sample to look at certain genes in your blood that may affect your symptoms.~     If you did not have blood collected in the previous lung cancer study, you will have a blood~     sample (one tablespoon) drawn when you first agree to participate in this study.~   "|||2018-06-01 03:03:42.142754|2018-06-01 03:03:42.142754
NCT00504361|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2016-04-29|2007-07-19|2007-07-20|Estimate|||||||2016-04-29|2016-05-02|Estimate|May 2006||2006-05-31|April 2016|2016-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|Q-BC||Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)|Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)|Completed|||600|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples With DNA|"~     This protocol is designed to collect a small amount of blood for extraction of DNA (genetic~     material) for the study of the genetic basis of lung disease. Genomic DNA will be extracted,~     and genome wide SNP analysis and promoter sequences for genes will be obtained. The goal is~     to find single nucleotide polymorphims (SNP), small changes in single genes that affect~     disease risk, to see if they correlate with lung disease.~   "|Undecided||2018-06-01 03:03:42.285427|2018-06-01 03:03:42.285427
NCT00504348|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2017-11-16|2007-07-19|2007-07-20|Estimate|||||||2017-11-16|2017-11-17|Actual|July 2007||2007-07-31|November 2017|2017-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|IMPPACT||Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus|An Open-label Clinical Trial of the Combination Treatment of Tacrolimus and Corticosteroid in Polymyositis/Dermatomyositis Patients With Interstitial Pneumonitis, With Comparison Against Corticosteroid-treated Historical Controls|Completed||Phase 2/Phase 3|26|Actual|Tokyo Medical and Dental University||1|||f||||f||||||||||2018-06-01 03:03:42.438233|2018-06-01 03:03:42.438233
NCT00504335|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2015-03-16|2007-07-19|2007-07-20|Estimate|||||||2015-03-16|2015-03-17|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Safety and Pharmacokinetic Study of BIO 300 Capsules|A Dose Escalation Trial Evaluating the Safety and Pharmacokinetic Profiles of BIO 300 Capsules in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Humanetics Corporation||4|||f||||f||||||||||2018-06-01 03:03:42.589621|2018-06-01 03:03:42.589621
NCT00504322|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|||2016-05-03|2007-07-19|2007-07-20|Estimate|||||||2016-05-03|2016-05-04|Estimate|July 2011||2011-07-31|May 2016|2016-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|cd40||Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma|Phase II, Randomized, Double-blinded, Placebo-Control, Toxicity/Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Stage I, II or III Esophageal Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Weill Medical College of Cornell University||2||No funding available.|f||||t||||||||Undecided||2018-06-01 03:03:42.764637|2018-06-01 03:03:42.764637
NCT00504309|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-19|2011-06-24||2018-02-13|2007-07-19|2007-07-20|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|July 2007||2007-07-31|February 2018|2018-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|OMEGA|"1 subject in the Placebo, 4 g P-OM3, 1 g P-OM3 sequence and 1 subject in the 1 g P-OM3, Placebo, 4 g P-OM3 sequence did not complete the study and were not included in the baseline analysis."|Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides|Omacor: Measures of Endothelial Function and triGlyceride Alteration|Completed||N/A|28|Actual|Penn State University||6|||f||||f||||||||||2018-06-01 03:03:42.873998|2018-06-01 03:03:42.873998
NCT00504296|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2012-05-31|2007-07-17|2007-07-19|Estimate|||||||2012-05-31|2012-06-01|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|||SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Clinical and Pharmacokinetic Study of SB939 in Patients With Advanced Cancer|Completed||Phase 1|39|Actual|Canadian Cancer Trials Group|||||f||||t||||||||||2018-06-01 03:03:43.53621|2018-06-01 03:03:43.53621
NCT00504283|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-10-17|2007-07-18|2007-07-19|Estimate|||||||2007-10-17|2007-10-18|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||An Analgesia Protocol for Acute Renal Colic in the Emergency Department|An Analgesia Protocol for Acute Renal Colic in the DHMC Emergency Department|Completed||N/A|45|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 03:03:43.668967|2018-06-01 03:03:43.668967
NCT00504270|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18||2016-07-06|2016-11-01|2007-07-18|2007-07-19|Estimate||||2016-07-06|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.|A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|66|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:03:43.738035|2018-06-01 03:03:43.738035
NCT00504257|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2013-05-28||2014-01-07|2007-07-17|2007-07-19|Estimate|2013-09-30|2013-10-11|Estimate||||2014-01-07|2014-02-06|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Participants who were evaluable for the outcome measures.|Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma|A Phase II Trial of Avastin in Combination With Docetaxel in Patients With Recurrence of Epithelial Carcinoma of the Ovary/Fallopian Tube/Peritoneum Within 12 Months of Platinum Therapy|Completed||Phase 2|45|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 03:03:43.842973|2018-06-01 03:03:43.842973
NCT00504244|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2010-11-15|2007-07-18|2007-07-19|Estimate|||||||2010-11-15|2010-11-16|Estimate|July 2007||2007-07-31|November 2010|2010-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Myfortic Versus Azathioprine in Systemic Lupus Erythematosus|A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy.|Terminated||Phase 3|12|Actual|Erasmus Medical Center||||Insufficient recruitment|f||||f||||||||||2018-06-01 03:03:44.126263|2018-06-01 03:03:44.126263
NCT00504231|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2012-01-11||2012-06-08|2007-07-18|2007-07-19|Estimate|2012-06-08|2012-07-13|Estimate||||2012-06-08|2012-07-13|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Intradermal Influenza Vaccine Study in Elders|Intradermal vs. Intramuscular Delivery of Influenza Vaccine in Immunocompetent Elders|Completed||Phase 2|257|Actual|PATH||4|||f||||t||||||||||2018-06-01 03:03:44.208537|2018-06-01 03:03:44.208537
NCT00504218|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2018-03-27|2007-07-18|2007-07-19|Estimate|||||||2018-03-27|2018-03-29|Actual|July 17, 2007||2007-07-17|October 27, 2017|2017-10-27||||||||Observational|||Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients|Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoitic Stem Cell Transplant Recipients|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:03:44.966685|2018-06-01 03:03:44.966685
NCT00504205|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2013-08-01|2007-07-17|2007-07-19|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|March 2010|Actual|2010-03-31|December 2008|Actual|2008-12-31||Interventional|||MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma|Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies|Terminated||N/A|30|Anticipated|National Cancer Institute (NCI)||||Withdrawn as trial was never activated by SuperGen|||||||||||||||2018-06-01 03:03:45.070289|2018-06-01 03:03:45.070289
NCT00504192|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2014-05-19|2007-07-18|2007-07-19|Estimate|||||||2014-05-19|2014-05-20|Estimate|September 2006||2006-09-30|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer|A Phase II Study of Gemcitabine in Combination With Oxaliplatin as First Line Chemotherapy in Patients With Inoperable Biliary Tract Adenocarcinoma|Completed||Phase 2|40|Actual|Soonchunhyang University Hospital|||||f||||t||||||||||2018-06-01 03:03:45.143228|2018-06-01 03:03:45.143228
NCT00504179|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-07-17|2007-07-17|2007-07-19|Estimate|||||||2007-07-17|2007-07-19|Estimate|April 2001||2001-04-30|July 2007|2007-07-31|October 2005|Actual|2005-10-31|||||Interventional|CABGOMT||The Effect of Osteopathic Manipulative Treatment on Recovery of Coronary Bypass Patients|The Effect of Osteopathic Manipulative Treatment on Post-Operative Medical and Functional Recovery of Coronary Artery Bypass Graft Patients|Completed||N/A|53|Actual|Michigan State University|||||f||||t||||||||||2018-06-01 03:03:45.204359|2018-06-01 03:03:45.204359
NCT00504166|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2011-07-13||2013-07-31|2007-07-17|2007-07-19|Estimate|2011-07-13|2011-08-10|Estimate||||2013-07-31|2013-08-14|Estimate|February 2006||2006-02-28|July 2013|2013-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women|Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal|Completed||Phase 4|53|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 03:03:45.294855|2018-06-01 03:03:45.294855
NCT00504153|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2013-07-01||2014-04-30|2007-07-17|2007-07-19|Estimate|2013-07-01|2013-09-10|Estimate||||2014-04-30|2014-05-19|Estimate|July 2007||2007-07-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer|A Phase II Study of Dasatinib (NSC 732517) in Previously-Treated Patients With Metastatic Colorectal Cancer|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:03:45.649796|2018-06-01 03:03:45.649796
NCT00504140|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2012-08-01|2007-07-18|2007-07-19|Estimate|||||||2012-08-01|2012-08-02|Estimate|November 1996||1996-11-30|August 2012|2012-08-31|March 2009|Actual|2009-03-31|November 2007|Actual|2007-11-30||Interventional|||Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma|Phase II Study of Recombinant Interferon Alpha and Etoposide in Patients With Relapsed Osteosarcoma|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:03:45.870478|2018-06-01 03:03:45.870478
NCT00504127|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2011-06-16|2007-07-17|2007-07-19|Estimate|||||||2011-06-16|2011-06-17|Estimate|April 2007||2007-04-30|June 2011|2011-06-30||||December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee|A Phase 3, 53 Weeks Study on Analgesic Efficacy and Safety of Naproxcinod (HCT 3012): 26-Week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks)- and Naproxen (26 Weeks)-Controlled, Multicenter Study of Naproxcinod (375 mg Bid and 750 mg Bid) With a 26-Week Naproxen-Controlled Safety Follow-up in Subjects With Osteoarthritis of the Knee, and a 1-week Post-treatment Safety Follow-up|Completed||Phase 3|1020|Actual|NicOx||4|||f||||t||||||||||2018-06-01 03:03:46.023173|2018-06-01 03:03:46.023173
NCT00504114|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2013-12-11|2007-07-17|2007-07-19|Estimate|||||||2013-12-11|2013-12-12|Estimate|August 2006||2006-08-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||MR Imaging of Knee Osteoarthritis and Acute Knee Injuries|MR Imaging of Knee Osteoarthritis and Acute Knee Injuries|Completed|||139|Actual|University of California, San Francisco|||5||f||||f||||||Samples Without DNA|"~     Bone/cartilage tissue will be collected after the total knee replacement surgery. The tissue~     will further studied using advanced MR imaging techniques.~   "|||2018-06-01 03:03:46.206651|2018-06-01 03:03:46.206651
NCT00504101|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2016-12-14|2007-07-17|2007-07-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma|Phase I Clinical Trial of Dose Escalated Bortezomib + ATO (Arsenic Trioxide) + Melphalan as a Conditioning Regimen for Multiple Myeloma|Withdrawn||Phase 1|0|Actual|University of Miami||||Temporarily closed to accrual pending availablity of drug.|f||||t||||||||||2018-06-01 03:03:46.269541|2018-06-01 03:03:46.269541
NCT00504088|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2008-08-19|2007-07-17|2007-07-19|Estimate|||||||2008-08-19|2008-08-20|Estimate|October 2006||2006-10-31|August 2007|2007-08-31||||||||Interventional|PROOF||Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia|Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia|Terminated||Phase 4|||FoxHollow Technologies||||Company decision to halt study|f||||||||||||||2018-06-01 03:03:46.335684|2018-06-01 03:03:46.335684
NCT00500994|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2018-05-16|2007-07-12|2007-07-13|Estimate|||||||2018-05-16|2018-05-17|Actual|July 11, 2007||2007-07-11|March 1, 2018|2018-03-01||||||||Observational|||Neurobiology of Psychogenic Movement Disorder and Non-Epileptic Seizures|Neurobiological Studies of Psychogenic Movement Disorders and Non-Epileptic Seizures|Recruiting|||354|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:04:48.713005|2018-06-01 03:04:48.713005
NCT00504075|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|2012-05-04||2013-02-26|2007-07-18|2007-07-19|Estimate|2012-05-04|2012-06-06|Estimate||||2013-02-26|2013-03-01|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura|Completed||Phase 3|35|Actual|Bio Products Laboratory||1|||f||||f||||||||||2018-06-01 03:03:46.517518|2018-06-01 03:03:46.517518
NCT00504062|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2011-08-23|2007-07-17|2007-07-19|Estimate|||||||2011-08-23|2011-08-24|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|October 2007|Actual|2007-10-31|||||Interventional|||Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma|A Randomized, Open-label, Parallel-group, 6 Week Treatment, Multi-center, Phase III Study to Investigate the Efficacy and Safety of 100ug and 200ug Twice Daily of Budesonide Turbuhaler® and 50ug and 100umg Twice Daily of Fluticasone Diskus® in Japanese Children With Bronchial Asthma Aged 5-15|Completed||Phase 3|240|Actual|AstraZeneca|||||f||||f||||||||||2018-06-01 03:03:46.780956|2018-06-01 03:03:46.780956
NCT00504049|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2010-07-21|2007-07-17|2007-07-19|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|March 2009|Actual|2009-03-31|||||Observational|||Wavelet Analysis of Electromyography (EMG) in Cerebral Palsy|Wavelet Analysis of Surface EMG in Cerebral Palsy|Completed|||32|Actual|Shriners Hospitals for Children|||||f||||f||||||||||2018-06-01 03:03:46.843646|2018-06-01 03:03:46.843646
NCT00504036|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2011-10-31|2007-07-18|2007-07-19|Estimate|||||||2011-10-31|2011-11-01|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|BIGPOM||Efficacy of Preoperative Intra Gastric Balloon in Morbidly Obese Patients Selected for Gastric By-pass|Medico Economic Evaluation of a Temporary (6 Months) Intra-gastric Balloon in Morbidly Obese Patients Before a Gastric By-pass. A Randomised Multicenter Study Comparing the Usual Strategy to Two Types of Gastric Balloon|Completed||N/A|314|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:03:46.907899|2018-06-01 03:03:46.907899
NCT00504023|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2018-04-05||2018-04-05|2007-07-17|2007-07-19|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|April 2007|Actual|2007-04-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva|A Pilot Study of Topical Imiquimod Therapy for the Treatment of Recurrent Extramammary Paget's Disease|Completed||N/A|8|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:03:46.984964|2018-06-01 03:03:46.984964
NCT00504010|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2009-01-06|2007-07-17|2007-07-19|Estimate|||||||2009-01-06|2009-01-07|Estimate|August 2007||2007-08-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Arnica||The Role of Arnica on Muscle Pain Following Eccentric Exercise|The Role of Arnica on Muscle Pain Following Eccentric Exercise|Completed||Phase 1|55|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 03:03:47.178015|2018-06-01 03:03:47.178015
NCT00503997|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2012-02-07||2012-05-07|2007-07-17|2007-07-19|Estimate|2012-02-07|2012-03-12|Estimate||||2012-05-07|2012-05-10|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer|Phase II Trial: Efficacy and Toxicity of Induction Pemetrexed (ALIMTA) and Oxaliplatin (ELOXATIN) in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma|Completed||Phase 2|42|Actual|Vanderbilt-Ingram Cancer Center|The two cohorts of pemetrexed and oxaliplatin patients represented similar populations, thus the response data were combined.|1|||f||||t||||||||||2018-06-01 03:03:47.27491|2018-06-01 03:03:47.27491
NCT00503984|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2015-12-09||2016-05-03|2007-07-17|2007-07-19|Estimate|2015-12-09|2016-01-20|Estimate||||2016-05-03|2016-06-09|Estimate|May 2007||2007-05-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients|A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen.|Terminated||Phase 1/Phase 2|22|Actual|University of Miami||2||Withdrawal of Funding|f||||t||||||||||2018-06-01 03:03:47.583412|2018-06-01 03:03:47.583412
NCT00503971|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2012-10-19|2007-07-18|2007-07-19|Estimate|||||||2012-10-19|2012-10-22|Estimate|December 2007||2007-12-31|April 2008|2008-04-30|December 2011|Actual|2011-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.|Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment|Terminated||Phase 1/Phase 2|50|Actual|Spanish Lung Cancer Group||1|||f||||f||||||||||2018-06-01 03:03:48.40806|2018-06-01 03:03:48.40806
NCT00503958|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2013-05-14|2007-07-17|2007-07-19|Estimate|||||||2013-05-14|2013-05-15|Estimate|August 1998||1998-08-31|November 2007|2007-11-30||||||||Observational|||Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung Cancer|Liverpool Lung Project|Unknown status|Recruiting||8300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:03:48.492416|2018-06-01 03:03:48.492416
NCT00503945|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2007-07-18|2007-07-18|2007-07-19|Estimate|||||||2007-07-18|2007-07-19|Estimate|November 2004||2004-11-30|July 2007|2007-07-31|November 2006|Actual|2006-11-30|||||Interventional|||Cardiac Dysfunction in Obstructive Sleep Apnea Patients: Prevalence of and Effect of nCPAP|The Clinical Significance of an Index of Cardiac Function, Tei-Index, in Obstructive Sleep Apnea Syndrome Patients.|Completed||N/A|27|Actual|Nagasaki University|||||f||||f||||||||||2018-06-01 03:03:48.559602|2018-06-01 03:03:48.559602
NCT00503932|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2012-03-21|2007-07-17|2007-07-19|Estimate|||||||2012-03-21|2012-03-22|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Proton Therapy With Capecitabine for Rectal Cancer|A Phase I/II Trial of Proton Therapy With Concurrent Capecitabine for Locally Advanced and Recurrent Rectal Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1||No participant enrollment.|f||||f||||||||||2018-06-01 03:03:48.615254|2018-06-01 03:03:48.615254
NCT00503919|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2016-04-06|2007-07-17|2007-07-19|Estimate|||||||2016-04-06|2016-04-08|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Measurement of Digital Colposcopy for Fluorescence Spectroscopy of TNC Using a Second Device|A Pilot Study: Measurement of Digital Colposcopy for Fluorescence Spectroscopy of the Normal Cervix for Screening, Using a Second Generation Device|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Study closed early with no enrollment.|f||||f||||||||||2018-06-01 03:03:48.677972|2018-06-01 03:03:48.677972
NCT00500799|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-06-30|2007-07-12|2007-07-13|Estimate|||||||2017-06-30|2017-07-02|Actual|July 9, 2007||2007-07-09|April 14, 2009|2009-04-14|April 14, 2009||2009-04-14|||||Observational|||Brain Changes in Blepharospasm|Role of the Cortical Medial Frontal Areas in Blepharospasm|Completed|||72||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:04:50.432862|2018-06-01 03:04:50.432862
NCT00503906|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2013-01-22||2017-05-10|2007-07-17|2007-07-19|Estimate|2013-02-25|2013-04-02|Estimate||||2017-05-10|2017-05-12|Actual|June 2007||2007-06-30|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer|A Phase II Study of Abraxane, Avastin and Gemcitabine for First Line Metastatic Breast Cancer|Completed||Phase 2|30|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 03:03:48.790115|2018-06-01 03:03:48.790115
NCT00503893|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2017-07-12|2007-07-18|2007-07-19|Estimate|||||||2017-07-12|2017-07-14|Actual|December 1980|Actual|1980-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies|Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies|Recruiting|||1500|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood sample(s) for genetic testing. Also, tissue samples, and/or bodily fluids (whether~     healthy or cancerous) left over from surgeries or procedures performed as part of standard~     care. The purpose of this clinical research study is to find out why some people develop~     cancers and tumors, why some families have more cancers than others, and whether certain~     genes or regions of DNA affect a person's risk of getting cancer.~   "|||2018-06-01 03:03:49.192468|2018-06-01 03:03:49.192468
NCT00503880|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2018-01-19||2018-04-11|2007-07-17|2007-07-19|Estimate|2018-04-11|2018-04-13|Actual||||2018-04-11|2018-04-13|Actual|May 2007||2007-05-31|April 2018|2018-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes|A Dose Escalation Phase I/II Study of Clofarabine Plus Cytarabine With Growth Factor Priming in Patients Who Are Not Felt to be Candidates for More Aggressive Treatment, With Int-2 and High-Risk MDS|Terminated||Phase 1/Phase 2|2|Actual|University of Nebraska||1||Genzyme discontinued Funding|f||||||||||||||2018-06-01 03:03:49.384144|2018-06-01 03:03:49.384144
NCT00503867|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2012-05-04|2007-07-18|2007-07-19|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma|A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma|Terminated||Phase 2|10|Actual|Sirtex Medical||||low patient recruitment|f||||t||||||||||2018-06-01 03:03:49.61649|2018-06-01 03:03:49.61649
NCT00503854|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2018-04-16|2007-07-18|2007-07-19|Estimate|||||||2018-04-16|2018-04-17|Actual|May 31, 2007|Actual|2007-05-31|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|April 5, 2018|Actual|2018-04-05||Observational|||Fatigue and Symptom Burden in Febrile Neutropenia|Fatigue and Symptom Burden in Febrile Neutropenia|Completed|||70|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:03:49.696974|2018-06-01 03:03:49.696974
NCT00503841|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2013-01-09||2013-03-27|2007-07-17|2007-07-19|Estimate|2013-01-09|2013-02-12|Estimate||||2013-03-27|2013-04-04|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer|A Pilot Study of the Effect of Erlotinib (Tarceva®) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1α|Terminated||N/A|44|Actual|Barbara Ann Karmanos Cancer Institute||1||All enrolled participants were screen failures, no data were collected for outcome measures.|f||||t||||||||||2018-06-01 03:03:49.80428|2018-06-01 03:03:49.80428
NCT00503828|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2010-01-11|2007-07-18|2007-07-19|Estimate|||||||2010-01-11|2010-01-13|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Derris Scandens Benth Extract VS Naproxen in Knee OA|The Efficacy and Safety of Derris Scandens Benth Extract and Naproxen for Therapy of Patients With Knee Osteoarthritis|Completed||Phase 3|120|Actual|Mahidol University||2|||f||||t||||||||||2018-06-01 03:03:49.956694|2018-06-01 03:03:49.956694
NCT00503815|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-12-20|2007-07-18|2007-07-19|Estimate|||||||2007-12-20|2007-12-27|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||BLI-800-302: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|A Safety and Efficacy Evaluation of BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|Completed||Phase 3|360|Anticipated|Braintree Laboratories|||||f||||f||||||||||2018-06-01 03:03:50.038646|2018-06-01 03:03:50.038646
NCT00503802|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2013-06-17|2007-07-17|2007-07-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|July 2007||2007-07-31|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|TURBO||Randomized Clinical Trial of Nasal Turbinate Reduction to Improve Continuous Positive Airway Pressure (CPAP) Outcomes for Sleep Apnea|Turbinate Reduction & CPAP Use: A Randomized Blinded OSA (TURBO) Trial|Completed||Phase 2|242|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:03:50.127361|2018-06-01 03:03:50.127361
NCT00503789|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2008-09-04|2007-07-18|2007-07-19|Estimate|||||||2008-09-04|2008-09-05|Estimate|August 2007||2007-08-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Effect of Infant Feeding on Stool Characteristics|The Effect of Infant Feeding on Stool Characteristics|Completed||N/A|280|Anticipated|Mead Johnson Nutrition||3|||f||||f||||||||||2018-06-01 03:03:50.229483|2018-06-01 03:03:50.229483
NCT00503776|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2011-11-03||2017-05-28|2007-07-17|2007-07-19|Estimate|2011-11-03|2011-12-08|Estimate||||2017-05-28|2017-06-20|Actual|January 2006||2006-01-31|May 2017|2017-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia|Randomized Pilot Trial of Chemoradiation Plus or Minus Amifostine to Assess Potential Nutritional, Inflammatory and Physical Outcomes Related to Xerostomia, Mucositis and Dysphagia|Terminated||Phase 2|41|Actual|Vanderbilt-Ingram Cancer Center||4||funding became unavailable|f||||t||||||||||2018-06-01 03:03:50.401388|2018-06-01 03:03:50.401388
NCT00503763|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2015-04-15|2007-07-18|2007-07-19|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2007||2007-09-30|July 2007|2007-07-31|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|PSMMSS||Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma|Open -Label Phase IIa Trial of the Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma|Withdrawn||Phase 2|0|Actual|Meir Medical Center||||We found out that there is another study on the same issue|f||||f||||||||||2018-06-01 03:03:51.117369|2018-06-01 03:03:51.117369
NCT00503750|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2012-03-26||2012-06-16|2007-07-18|2007-07-19|Estimate|2012-05-13|2012-06-14|Estimate||||2012-06-16|2012-06-25|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)|Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer|Completed||Phase 2|27|Actual|Emory University||1|||f||||t||||||||||2018-06-01 03:03:51.182509|2018-06-01 03:03:51.182509
NCT00503724|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2012-03-02|2007-07-17|2007-07-19|Estimate|||||||2012-03-02|2012-03-06|Estimate|June 2007||2007-06-30|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors|Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors|Completed||Phase 1|32|Actual|Pediatric Brain Tumor Consortium|||||f||||t||||||||||2018-06-01 03:03:51.423183|2018-06-01 03:03:51.423183
NCT00503711|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2016-08-29|2007-07-18|2007-07-19|Estimate|||||||2016-08-29|2016-08-31|Estimate|September 2006||2006-09-30|August 2016|2016-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Phase I Chinese PK|An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor|Completed||Phase 1|36|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:03:51.512856|2018-06-01 03:03:51.512856
NCT00503698|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|2009-12-15||2017-01-23|2007-07-18|2007-07-19|Estimate|2010-06-14|2010-07-13|Estimate||||2017-01-23|2017-03-07|Actual|July 2007||2007-07-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|OPPORTUNITY||The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis|Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis|Terminated||Phase 3|712|Actual|Novo Nordisk A/S|Trial terminated early due to slow recruitment, which largely reduced the power of showing differences. The end of trial visit was used to describe week 104.|2||See termination reason in detailed description|f||||t||||||||||2018-06-01 03:03:51.654337|2018-06-01 03:03:51.654337
NCT00503685|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17||2010-10-12|2011-10-12|2007-07-18|2007-07-19|Estimate||||2010-10-12|2010-10-19|Estimate|2011-10-12|2011-10-21|Estimate|June 2007||2007-06-30|October 2011|2011-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy|A Randomized Phase 2 Clinical Trial of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Metastatic Colorectal Cancer With Disease Progression on Prior Anti-EGFR Therapy|Completed||Phase 2|65|Actual|ImClone LLC||3|||f||||f||||||||||2018-06-01 03:03:53.510673|2018-06-01 03:03:53.510673
NCT00503672|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2017-11-06|2007-07-18|2007-07-19|Estimate|||||||2017-11-06|2017-11-08|Actual|July 2007|Actual|2007-07-31|November 2017|2017-11-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||Assessment of Activity in Pregnancy Using an Actigraph|Assessment of Activity in Pregnancy Using an Actigraph|Withdrawn|||0|Actual|University of California, Irvine||||Data from the Actigraph devices could no longer be read/analyzed|f||||f||||||||No||2018-06-01 03:03:53.603398|2018-06-01 03:03:53.603398
NCT00503659|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2011-10-07|2007-07-18|2007-07-19|Estimate|||||||2011-10-07|2011-10-12|Estimate|February 2007||2007-02-28|October 2011|2011-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Two Methods of Bronchial Methacholine Provocation|Comparison of Two Methods of Bronchial Methacholine Provocation: PC 20 FEV1 Versus PD 20 FEV1|Completed||N/A|48|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-06-01 03:03:53.655236|2018-06-01 03:03:53.655236
NCT00503646|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2013-09-16|2007-07-17|2007-07-19|Estimate|||||||2013-09-16|2013-09-17|Estimate|May 2007||2007-05-31|July 2009|2009-07-31||||May 2010|Anticipated|2010-05-31||Interventional|||Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their Partners|Communication and Intimacy-Enhancing Intervention for Men Diagnosed With Early Stage Prostate Cancer and Their Partners: A Pilot and Feasibility Trial|Unknown status|Recruiting|N/A|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:03:53.755179|2018-06-01 03:03:53.755179
NCT00503633|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2010-06-22|2007-07-17|2007-07-19|Estimate|||||||2010-06-22|2010-06-23|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|SAG||Biomarkers of Insomnia and Fatigue in HIV/AIDS (Symptoms and Genetics Study)|Biomarkers of Insomnia and Fatigue in HIV/AIDS|Completed|||350|Actual|University of California, San Francisco|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:03:53.841032|2018-06-01 03:03:53.841032
NCT00503620|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2010-07-21|2007-07-18|2007-07-19|Estimate|||||||2010-07-21|2010-07-22|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|June 2009|Actual|2009-06-30|||||Observational|||The Effect of Botox on Children With Cerebral Palsy|The Effect of Botulinum Toxin on Neuromuscular Function in the Child With Cerebral Palsy|Completed|||11|Actual|Shriners Hospitals for Children|||||f||||f||||||||||2018-06-01 03:03:53.903882|2018-06-01 03:03:53.903882
NCT00503607|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-12-20|2007-07-18|2007-07-19|Estimate|||||||2007-12-20|2007-12-27|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||BLI-800-301: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|A Safety and Efficacy Evaluation of BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy|Completed||Phase 3|400|Anticipated|Braintree Laboratories|||||f||||f||||||||||2018-06-01 03:03:53.96051|2018-06-01 03:03:53.96051
NCT00503594|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-18|||2012-07-27|2007-07-18|2007-07-19|Estimate|||||||2012-07-27|2012-07-30|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|July 2012|Anticipated|2012-07-31|July 2010|Actual|2010-07-31||Interventional|CNSLymphoma||Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine|Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly|Unknown status|Recruiting|Phase 2|92|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:03:54.136204|2018-06-01 03:03:54.136204
NCT00503581|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2015-05-27|2007-07-17|2007-07-19|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 2007||2007-07-31|May 2015|2015-05-31||||July 2012|Actual|2012-07-31||Interventional|||Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia|A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire Uterine Preservation|Terminated||Phase 2|9|Actual|Gynecologic Oncology Group||3|||f||||||||||||||2018-06-01 03:03:54.258909|2018-06-01 03:03:54.258909
NCT00503568|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2016-12-14|2007-07-17|2007-07-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|May 2007||2007-05-31|December 2016|2016-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy|Novel Tumor Vaccine gp96-Ig Fusion Protein in Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed First Line Chemotherapy|Completed||Phase 1|19|Actual|University of Miami||3|||f||||t||||||||||2018-06-01 03:03:55.390734|2018-06-01 03:03:55.390734
NCT00503555|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-08-29|2007-07-17|2007-07-18|Estimate|||||||2007-08-29|2007-08-30|Estimate|June 2006||2006-06-30|October 2006|2006-10-31|October 2006|Anticipated|2006-10-31|||||Observational|||Creation of a PBRN to Study Healthcare Delivery to a Transitioning Community|Creation of a PBRN to Study Healthcare Delivery to a Transitioning Community|Unknown status|Recruiting||||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 03:03:55.467589|2018-06-01 03:03:55.467589
NCT00503542|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2014-01-07|2007-07-17|2007-07-18|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2007||2007-02-28|September 2007|2007-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|VCAT||Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network|Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network|Completed||Early Phase 1|46|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||f||||||||||2018-06-01 03:03:55.541727|2018-06-01 03:03:55.541727
NCT00503529|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2015-05-20|2007-07-17|2007-07-18|Estimate|||||||2015-05-20|2015-05-21|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)|Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223)|Completed||Phase 4|314|Actual|Pfizer|||||f||||t||||||||||2018-06-01 03:03:55.643937|2018-06-01 03:03:55.643937
NCT00503516|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2011-06-07|2007-07-17|2007-07-18|Estimate|||||||2011-06-07|2011-06-08|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients|Multicenter, Double Blind, Randomized, Clinical Trial, Controlled With Placebo, to Evaluate the Effect of the Treatment With 320 mg/Day of Megestrol Acetate During 24 Weeks in the Weight Loss in Mixed Dementia Patients.|Terminated||Phase 2/Phase 3|39|Actual|Rottapharm Spain||2||Difficulties to recruit the patients following the inclusion criteria|f||||f||||||||||2018-06-01 03:03:55.733424|2018-06-01 03:03:55.733424
NCT00503503|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-12-20|2007-07-16|2007-07-18|Estimate|||||||2007-12-20|2007-12-28|Estimate|March 2005||2005-03-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Study Evaluating the Efficacy of Enbrel (Etanercept) in Subjects in Japan|Safety and Efficacy From Large Scale All Cases Surveillance for Etanercept in Japan|Completed|||||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:03:55.820523|2018-06-01 03:03:55.820523
NCT00503490|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2018-01-17|2007-07-16|2007-07-18|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2007||2007-06-30|January 2018|2018-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis|Phase I, Single and Multi-dose, Placebo Controlled, Randomized, Dose-Escalation Study to Evaluate the Safety, Tolerability and PK Profile of MP-376 Using the PARI eFlow Nebulizer for 14 Days to CF Patients|Completed||Phase 1|40|Actual|Horizon Pharma USA, Inc.||2|||f||||t||||||||||2018-06-01 03:03:55.960368|2018-06-01 03:03:55.960368
NCT00503477|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2009-06-11|2007-07-16|2007-07-18|Estimate|||||||2009-06-11|2009-06-12|Estimate|October 2005||2005-10-31|June 2009|2009-06-30|January 2009|Actual|2009-01-31|July 2007|Actual|2007-07-31||Interventional|||A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan|A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies|Completed||Phase 1|40|Actual|AstraZeneca|||||f||||t||||||||||2018-06-01 03:03:56.054533|2018-06-01 03:03:56.054533
NCT00503464|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2012-07-18|2007-07-17|2007-07-18|Estimate|||||||2012-07-18|2012-07-19|Estimate|September 2006||2006-09-30|July 2012|2012-07-31||||||||Observational|||"Assessing Barriers to ADA Guideline Adherence"|"Assessing Barriers to American Diabetes Association Guideline Adherence"|Unknown status|Recruiting||||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 03:03:56.117722|2018-06-01 03:03:56.117722
NCT00503451|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2012-11-26|2007-07-17|2007-07-18|Estimate|||||||2012-11-26|2012-11-27|Estimate|September 2007||2007-09-30|November 2012|2012-11-30||||April 2010|Actual|2010-04-30||Interventional|||A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors|A Phase IB, Study to Investigate the Effect of Ketoconazole, a CYP3A4 Inhibitor, on Oral LBH589 and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors.|Completed||Phase 1|14|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:03:56.188136|2018-06-01 03:03:56.188136
NCT00503438|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2017-07-28|2007-07-17|2007-07-18|Estimate|||||||2017-07-28|2017-08-01|Actual|July 2007||2007-07-31|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ankle Joint Replacement Outcomes Study|Salto Talaris Anatomic Ankle Arthroplasty Outcomes Study|Active, not recruiting||N/A|75|Anticipated|Integra LifeSciences Corporation||1|||f||||f||||||||||2018-06-01 03:03:56.270369|2018-06-01 03:03:56.270369
NCT00503425|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2016-03-16||2017-07-06|2007-07-17|2007-07-18|Estimate|2016-05-16|2016-06-23|Estimate||||2017-07-06|2017-08-15|Actual|June 30, 2005|Actual|2005-06-30|June 2017|2017-06-30|May 26, 2013|Actual|2013-05-26|May 26, 2013|Actual|2013-05-26||Interventional||Intent to treat (ITT) population: All participants who had received any part of infusion of study medication. Participants who prematurely withdrew from study for any reason and for whom assessment is not performed for whatever reason were also included in ITT analysis. Due to incomplete database only 209 participants were considered for analysis.|A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.|An Open Label Study to Assess the Safety and Effect on Disease Activity of MabThera in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With DMARDs and/or One Anti-TNF Alpha Agent|Completed||Phase 3|215|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:03:56.484879|2018-06-01 03:03:56.484879
NCT00503412|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2009-01-15|2007-07-16|2007-07-18|Estimate|||||||2009-01-15|2009-01-19|Estimate|November 2005||2005-11-30|January 2009|2009-01-31|May 2006|Actual|2006-05-31|||||Interventional|||Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors|A Phase 1, Open Label, Non-Randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients With Solid Metastatic Tumours|Completed||Phase 1|6|Actual|AstraZeneca|||||f||||t||||||||||2018-06-01 03:03:56.839316|2018-06-01 03:03:56.839316
NCT00503399|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2011-10-04||2012-03-12|2007-07-16|2007-07-18|Estimate|2011-10-04|2011-11-08|Estimate||||2012-03-12|2012-03-13|Estimate|July 2007||2007-07-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|EuroGIOPS||Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis|Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men|Completed||Phase 3|92|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:03:56.93369|2018-06-01 03:03:56.93369
NCT00503386|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2010-09-16|2007-07-17|2007-07-18|Estimate|||||||2010-09-16|2010-09-17|Estimate|April 2006||2006-04-30|September 2010|2010-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting|A Phase II,Multicenter,Randomized,Double-blind,Cross-over Study of Palonosetron Compared With Granisetron in Prevention of Chemotherapy-induced Nausea and Vomiting in Asian Population|Completed||Phase 2|144|Actual|Hangzhou Jiuyuan Gene Engineering Co. Ltd.,|||||f||||t||||||||||2018-06-01 03:03:57.740542|2018-06-01 03:03:57.740542
NCT00503360|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2008-04-23|2007-07-17|2007-07-18|Estimate|||||||2008-04-23|2008-04-24|Estimate|April 2007||2007-04-30|April 2008|2008-04-30||||||||Interventional|||Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension|A Multicenter, Randomized, Placebo-Controlled, Double-Masked, 4-Arm Parallel Group Study to Assess the Tolerability, Safety and Efficacy of Two Doses of SAD448 in Subjects With Ocular Hypertension|Completed||Phase 1|80|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:03:57.817943|2018-06-01 03:03:57.817943
NCT00503347|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-06-07|2007-07-17|2007-07-18|Estimate|||||||2011-06-07|2011-06-09|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus|A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus|Completed||Phase 1|24|Anticipated|Peregrine Pharmaceuticals||4|||f||||||||||||||2018-06-01 03:03:57.878993|2018-06-01 03:03:57.878993
NCT00503334|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2008-12-05|2007-07-17|2007-07-18|Estimate|||||||2008-12-05|2008-12-08|Estimate|July 2007||2007-07-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Preoperative Oral Nutritional Supplement (preOP Booster) in Visceral Surgery|Efficacy and Tolerability of a Preoperative Oral Nutritional Supplement (preOP Booster) Versus Placebo in Visceral Surgery|Completed||N/A|36|Actual|Fresenius Kabi||2|||f||||f||||||||||2018-06-01 03:03:57.957167|2018-06-01 03:03:57.957167
NCT00503321|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2009-01-22|2007-07-16|2007-07-18|Estimate|||||||2009-01-22|2009-01-23|Estimate|October 2006||2006-10-31|January 2009|2009-01-31|August 2011|Anticipated|2011-08-31|August 2009|Anticipated|2009-08-31||Interventional|eNCIT-Japan||Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma|Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma|Terminated||Phase 2/Phase 3|13|Actual|Eastern Network of Cancer Immunological Therapy, Japan||2||Patients' enrollment was not sufficient.|f||||t||||||||||2018-06-01 03:03:58.038316|2018-06-01 03:03:58.038316
NCT00503308|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2009-09-24||2015-05-06|2007-07-17|2007-07-18|Estimate|2011-06-07|2011-07-01|Estimate||||2015-05-06|2015-05-22|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|February 2008|Actual|2008-02-29|September 2007|Actual|2007-09-30||Interventional|||HIV Testing Strategies in the Perinatal Setting|Patient Perspectives and Testing Uptake With Abbreviated Versus Standard HIV Consenting in the Prenatal Setting: A Randomized-Controlled, Non-Inferiority Trial|Completed||N/A|281|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 03:03:58.143662|2018-06-01 03:03:58.143662
NCT00503295|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2014-09-30|2007-07-16|2007-07-18|Estimate|||||||2014-09-30|2014-10-02|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung|A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung|Completed||Phase 2|53|Actual|Oncolytics Biotech|||||f||||f||||||||||2018-06-01 03:03:58.462247|2018-06-01 03:03:58.462247
NCT00503282|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-07-17|2007-07-17|2007-07-18|Estimate|||||||2007-07-17|2007-07-18|Estimate|October 2007||2007-10-31|July 2007|2007-07-31|October 2007|Anticipated|2007-10-31|||||Observational|||Urinary Catheter Exchange on Admission of Septic Elderly With Permanent Catheter Before Initiation of Antibiotics||Unknown status|Not yet recruiting||||Shaare Zedek Medical Center|||||f||||f||||||||||2018-06-01 03:03:58.521076|2018-06-01 03:03:58.521076
NCT00503269|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2008-10-16|2007-07-16|2007-07-18|Estimate|||||||2008-10-16|2008-10-17|Estimate|July 2005||2005-07-31|October 2008|2008-10-31|July 2007|Actual|2007-07-31|||||Interventional|||Local Anaesthetic Day-Care Haemorrhoidectomy Challenges Traditional Concepts - a Randomised Controlled Trial|Cost Effectiveness of Local Anaesthetic Day Surgical Haemorrhoidectomy|Completed||N/A|42|Actual|East Kent Hospitals University NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 03:03:58.5583|2018-06-01 03:03:58.5583
NCT00503256|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2017-11-30|2007-07-17|2007-07-18|Estimate|||||||2017-11-30|2017-12-04|Actual|September 2003|Actual|2003-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Genetic Study of Chronic Lymphocytic Leukemia Families|Genetic Study of Chronic Lymphocytic Leukemia Families|Active, not recruiting|||4000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood and cheek cell sample collection that will be used for special tests to look for genes~     that may play a role in the development of CLL.~   "|||2018-06-01 03:03:58.627809|2018-06-01 03:03:58.627809
NCT00503243|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2014-06-06|2007-07-16|2007-07-18|Estimate|||||||2014-06-06|2014-06-09|Estimate|September 2003||2003-09-30|November 2007|2007-11-30|August 2005|Actual|2005-08-31|||||Interventional|||Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis|A Phase III, Randomized, Multi-Centre, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) Versus SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis|Completed||Phase 3|280|Actual|Shire|||||f||||||||||||||2018-06-01 03:03:58.711313|2018-06-01 03:03:58.711313
NCT00503230|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2013-05-02|2007-07-17|2007-07-18|Estimate|||||||2013-05-02|2013-05-03|Estimate|October 2005||2005-10-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|AURORA||Reducing Ethnic Health Disparities: Motivating HIV+ Latinos to Quit Smoking|Reducing Ethnic Health Disparities: Motivating HIV+ Latinos to Quit Smoking|Completed||Phase 3|400|Actual|Butler Hospital||2|||f||||t||||||||||2018-06-01 03:03:58.777653|2018-06-01 03:03:58.777653
NCT00503217|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2016-09-05|2007-07-17|2007-07-18|Estimate|||||||2016-09-05|2016-09-07|Estimate|February 2005||2005-02-28|September 2016|2016-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||GnRH Agonist and Intrauterine Insemination|Effect of GnRH Agonist Administration at the Time of Implantation in Intrauterine Insemination Cycles: A Randomized Controlled Trial|Completed||Phase 4|||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-06-01 03:03:58.954258|2018-06-01 03:03:58.954258
NCT00503204|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2009-11-24|2007-07-16|2007-07-18|Estimate|||||||2009-11-24|2009-11-25|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour|A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard Therapy|Completed||Phase 1|20|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 03:03:59.042304|2018-06-01 03:03:59.042304
NCT00503191|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2014-01-19|2007-07-16|2007-07-18|Estimate|||||||2014-01-19|2014-01-22|Estimate|July 2007||2007-07-31|January 2014|2014-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|NMT||NeuroModulation Technique Treatment of Autism|Intention-based Therapy for Autism Spectrum Disorder: Promising Results of a Wait-List Control Study in Children|Completed||Phase 1|18|Actual|NeuroModulation Technique Research Institute||1|||f||||||||||||||2018-06-01 03:03:59.131139|2018-06-01 03:03:59.131139
NCT00503178|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2014-12-04|2007-07-17|2007-07-18|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2006||2006-04-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)|Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)|Unknown status|Recruiting|Phase 2|20|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 03:03:59.203106|2018-06-01 03:03:59.203106
NCT00503165|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2008-04-30|2007-07-17|2007-07-18|Estimate|||||||2008-04-30|2008-05-01|Estimate|July 2007||2007-07-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|||||Interventional|||A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix|A Phase IV, Single Group Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of a Licensed Hib and Meningococcal C Conjugate Combined Vaccine (Menitorix)|Completed||Phase 4|30|Anticipated|Public Health England|||||f||||f||||||||||2018-06-01 03:03:59.286096|2018-06-01 03:03:59.286096
NCT00503152|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2016-09-15|2007-07-17|2007-07-18|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|VARIETY||Preventing Microalbuminuria in Type 2 Diabetes|A Prospective, Randomized, Probe Trial to Evaluate Whether, at Comparable Blood Pressure Control, Combined Therapy With the ACEI Benazepril and the ARB Valsartan, Reduces the Incidence of Microalbuminuria More Effectively Than BEN or VAL Alone in Hypertensive Patients With Type 2 Diabetes and High-normal Albuminuria|Completed||Phase 3|613|Actual|Mario Negri Institute for Pharmacological Research||3|||f||||f||||||||||2018-06-01 03:03:59.344422|2018-06-01 03:03:59.344422
NCT00503139|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2014-03-27||2017-01-09|2007-07-16|2007-07-18|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|July 2007||2007-07-31|January 2017|2017-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan|Enbrel Special Use Result Surveillance|Completed|||684|Actual|Pfizer|||||f||||f||||||||||2018-06-01 03:03:59.449292|2018-06-01 03:03:59.449292
NCT00503126|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-11-08|2007-07-17|2007-07-18|Estimate|||||||2011-11-08|2011-11-10|Estimate|August 2007||2007-08-31|November 2011|2011-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Bivalirudin as a Procedural Anticoagulant in Pediatrics|Bivalirudin (Angiomax®) As A Procedural Anticoagulant In The Pediatric Population Undergoing Intravascular Procedures For Congenital Heart Disease|Completed||Phase 2|110|Actual|The Medicines Company|||||f||||t||||||||||2018-06-01 03:03:59.954904|2018-06-01 03:03:59.954904
NCT00503113|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2011-03-31||2011-05-17|2007-07-17|2007-07-18|Estimate|2011-05-17|2011-06-17|Estimate||||2011-05-17|2011-06-17|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.|A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.|Completed||Phase 4|801|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:04:00.059822|2018-06-01 03:04:00.059822
NCT00503100|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2015-05-20|2007-07-17|2007-07-18|Estimate|||||||2015-05-20|2015-05-21|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Somatosensory Evoked Potentials and Pain Thresholds in Term and Preterm-Born Adolescents After Early Exposure to Pain; a Quantitative Study||Terminated|||10|Actual|Soroka University Medical Center|||4|Difficulties in recruiting|f||||t||||||||||2018-06-01 03:04:00.706428|2018-06-01 03:04:00.706428
NCT00503087|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-08-07|2007-07-17|2007-07-18|Estimate|||||||2007-08-07|2007-08-08|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Evaluation of Pain Reduction in the Administration of Saline Injections by the Usage of Pneumatic Skin Flattening|Evaluation of Pain Reduction in the Administration of Saline Injections by the Usage of Pneumatic Skin Flattening (PSF)|Unknown status|Recruiting|Phase 1|20|Anticipated|PalJect Ltd.|||||f||||t||||||||||2018-06-01 03:04:00.871938|2018-06-01 03:04:00.871938
NCT00503074|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2009-11-18|2007-07-16|2007-07-18|Estimate|||||||2009-11-18|2009-11-20|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|||Starting Healthy Staying Healthy Pilot Trial|Starting Healthy Staying Healthy Pilot Trial|Completed||N/A|70|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 03:04:00.944292|2018-06-01 03:04:00.944292
NCT00503061|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2010-11-30|2007-07-17|2007-07-18|Estimate|||||||2010-11-30|2010-12-01|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART|A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database|Completed|||1000|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:04:01.007367|2018-06-01 03:04:01.007367
NCT00503048|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2008-12-23|2007-07-17|2007-07-18|Estimate|||||||2008-12-23|2008-12-25|Estimate|December 2003||2003-12-31|December 2008|2008-12-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Observational|||Markers of Atopy in Children With Presumed Early Exposure to Allergens, Unhygienic Conditions, and Infections|Markers of Atopy in Children With Presumed Early Exposure to Allergens, Unhygienic Conditions, and Infections|Completed|||915|Actual|Medical Universtity of Lodz|||2||f||||t||||||Samples With DNA|"~     whole blood samples~   "|||2018-06-01 03:04:01.069851|2018-06-01 03:04:01.069851
NCT00503035|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2018-01-12|2007-07-16|2007-07-18|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2003|Actual|2003-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers|Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:04:01.132159|2018-06-01 03:04:01.132159
NCT00503022|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2007-12-19|2007-07-17|2007-07-18|Estimate|||||||2007-12-19|2007-12-28|Estimate|July 2006||2006-07-31|December 2007|2007-12-31||||||||Interventional|||Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration|A Randomized, Double-Masked, Multi-Center Phase I Study of 6 Months Duration to Assess the Safety and Tolerability of Intravenous ACZ885 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|Completed||Phase 1|20||Novartis|||||f||||||||||||||2018-06-01 03:04:01.219455|2018-06-01 03:04:01.219455
NCT00502671|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2015-08-06||2015-08-06|2007-07-17|2007-07-18|Estimate|2015-08-06|2015-09-03|Estimate||||2015-08-06|2015-09-03|Estimate|July 2007||2007-07-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Safety Population: All enrolled participants who received a dose of study medication.|A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.|An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C.|Completed||Phase 4|228|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:04:10.308319|2018-06-01 03:04:10.308319
NCT00503009|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2009-07-06||2016-11-04|2007-07-17|2007-07-18|Estimate|2009-07-06|2009-08-17|Estimate||||2016-11-04|2016-12-28|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Of RV-39 In Patients Who Also Have Asthma|An Exploratory Study to Evaluate the Response of Salmeterol Plus Fluticasone vs Fluticasone Alone to Experimental Nasal Inoculation With Rhinovirus|Terminated||Phase 4|16|Actual|GlaxoSmithKline|Due to the small sample size, efficacy measures were not analyzed.|3||lack of data|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:04:01.297643|2018-06-01 03:04:01.297643
NCT00502996|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2016-06-29||2016-08-22|2007-07-17|2007-07-18|Estimate|2016-08-22|2016-10-14|Estimate||||2016-08-22|2016-10-14|Estimate|February 2006||2006-02-28|August 2016|2016-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||The safety population included all eligible participants who received one treatment dose of rituximab and have completed the follow up period (Week 48) regardless of whether withdrawn or not from the study.|A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.|Multicenter Non-Comparative Expanded Access Program of to Assess Safety of Rituximab (Mab Anti Cd-20) in Patients With Rheumatoid Arthritis (Ser)|Completed||Phase 3|246|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:04:01.791688|2018-06-01 03:04:01.791688
NCT00502983|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2018-04-12|2007-07-17|2007-07-18|Estimate|||||||2018-04-12|2018-04-13|Actual|September 2003|Actual|2003-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Molecular Epidemiology of Acute Myelogenous Leukemia|Molecular Epidemiology of Acute Myelogenous Leukemia|Active, not recruiting|||1200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood sample collection to look for any biologic factors associated with AML.~   "|||2018-06-01 03:04:02.436218|2018-06-01 03:04:02.436218
NCT00502970|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2008-01-09|2007-07-16|2007-07-18|Estimate|||||||2008-01-09|2008-01-11|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|STAR||Short Course of Interferon Treatment in Patients With HCV Infection|A Randomized Trial Comparing a Short Course Versus Standard Treatment in Patients With Chronic Hepatitis C Virus Infection|Completed||Phase 4|150|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 03:04:02.515968|2018-06-01 03:04:02.515968
NCT00502957|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2010-06-24|2007-07-16|2007-07-18|Estimate|||||||2010-06-24|2010-06-25|Estimate|March 2005||2005-03-31|August 2009|2009-08-31|November 2007|Actual|2007-11-30|||||Interventional|||Biofeedback Treatment for Functional Constipation|Biofeedback for Functional Constipation: Efficacy and Predictive Factors of Success|Completed||N/A|15|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:04:02.599585|2018-06-01 03:04:02.599585
NCT00502944|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2012-05-03||2012-07-16|2007-07-16|2007-07-18|Estimate|2012-06-10|2012-07-13|Estimate||||2012-07-16|2012-07-19|Estimate|February 2007||2007-02-28|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Two Approaches to Routine HIV Testing in a Hospital Emergency Department|Optimizing Strategies for Universal HIV Testing (The USHER Trial)|Completed||N/A|4855|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:04:02.692742|2018-06-01 03:04:02.692742
NCT00502931|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-07-16|2007-07-16|2007-07-18|Estimate|||||||2007-07-16|2007-07-18|Estimate|November 2006||2006-11-30|July 2007|2007-07-31||||||||Observational|||A Systematic Review on the Accuracy and Reliability the BodyGem/MedGem Metabolic Devices|A Systematic Review on the Accuracy and Reliability of a Hand-Held Indirect Calorimeter for Assessing Energy Needs in Adults & Children|Completed|||||Microlife|||||f||||f||||||||||2018-06-01 03:04:03.275238|2018-06-01 03:04:03.275238
NCT00502918|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2009-12-27|2007-07-17|2007-07-18|Estimate|||||||2009-12-27|2009-12-29|Estimate|February 2008||2008-02-29|July 2007|2007-07-31|August 2008|Actual|2008-08-31|July 2008|Anticipated|2008-07-31||Observational|||Clinical Feasibility of Computerized Labor Monitor (CLM) -Heart Application (HA)|Feasibility Study -Clinical Feasibility of Computerized Labor Monitor (CLM) -Heart Application|Terminated|||3|Actual|Barnev Ltd|||1|The study was terimnated - low rate of cases|f||||f||||||||||2018-06-01 03:04:03.31507|2018-06-01 03:04:03.31507
NCT00502905|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2012-04-17||2012-05-23|2007-07-16|2007-07-18|Estimate|2012-04-17|2012-05-15|Estimate||||2012-05-23|2012-05-28|Estimate|October 2003||2003-10-31|May 2012|2012-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Busulfan and Fludarabine in Patients With AML and MDS|A Phase II Study of High-Dose Intravenous Busulfan and Fludarabine With Allogeneic Marrow and Peripheral Blood Progenitor Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes|Completed||Phase 2|200|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:03.387985|2018-06-01 03:04:03.387985
NCT00502892|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2012-07-31|2007-07-16|2007-07-18|Estimate|||||||2012-07-31|2012-08-01|Estimate|August 2004||2004-08-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors|A Phase I Study of a Novel Chemotherapeutic Regimen: Topotecan, Ifosfamide and Carboplatin (TIC) in Children and Young Adults With Solid Tumors-- A Limited Multi-Institution Study|Completed||Phase 1|2|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:03.588382|2018-06-01 03:04:03.588382
NCT00502879|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-12-04|2007-07-17|2007-07-18|Estimate|||||||2007-12-04|2007-12-06|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating Etanercept 25mg or 50mg Administered Subcutaneously to Healthy Chinese Male Subjects|A Randomized, Open-Label, Single-Dose Administration, Parallel-Group Study of the Pharmacokinetics of Etanercept, 25mg or 50 mg, Administered Subcutaneously to Healthy Chinese Male Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:04:03.814207|2018-06-01 03:04:03.814207
NCT00502866|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2014-01-07|2007-07-17|2007-07-18|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2006||2006-06-30|October 2006|2006-10-31|June 2008|Actual|2008-06-30|||||Observational|||Study to Assess the Use of a Simple Lab Test to Screen for Rickets in Children|The Feasibility of Assessing the Prevalence of Rickets in Children|Completed|||246|Actual|Agency for Healthcare Research and Quality (AHRQ)|||1||f||||f||||||||||2018-06-01 03:04:03.885575|2018-06-01 03:04:03.885575
NCT00502853|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2014-07-16||2017-07-07|2007-07-17|2007-07-18|Estimate|2015-03-10|2015-03-12|Estimate||||2017-07-07|2017-08-16|Actual|October 25, 2007|Actual|2007-10-25|June 2017|2017-06-30|July 23, 2010|Actual|2010-07-23|July 23, 2010|Actual|2010-07-23||Interventional||Safety population: all participants who received any part of an infusion of study drug.|A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.|Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.|Completed||Phase 4|10|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:04:03.998828|2018-06-01 03:04:03.998828
NCT00502840|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2014-06-04||2017-07-11|2007-07-17|2007-07-18|Estimate|2014-09-03|2014-09-10|Estimate||||2017-07-11|2017-08-18|Actual|July 23, 2007|Actual|2007-07-23|July 2017|2017-07-31|September 20, 2011|Actual|2011-09-20|September 20, 2011|Actual|2011-09-20||Interventional||Safety Population: all participants who received at least 1 dose of the trial medication and had at least 1 safety follow-up, whether withdrawn prematurely or not. A safety follow-up was assumed if the participant had at least 1 documented study visit after baseline or if at least 1 adverse event had been documented with start date after baseline.|A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.|An Open Label Study to Evaluate the Safety of Re-treatment With MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent (Extension Study to ML19070).|Completed||Phase 3|193|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:04:04.891241|2018-06-01 03:04:04.891241
NCT00502827|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2016-02-25|2007-07-17|2007-07-18|Estimate|||||||2016-02-25|2016-02-26|Estimate|January 2004||2004-01-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Smoking Cessation for HIV/AIDS Patients|An Innovative Telephone Intervention for HIV-Positive Smokers|Completed||N/A|706|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:04:05.772733|2018-06-01 03:04:05.772733
NCT00502814|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2012-02-20|2007-07-17|2007-07-18|Estimate|||||||2012-02-20|2012-02-22|Estimate|January 2003||2003-01-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||3-Dimensional Form and Soft Tissue Biomechanics of the Breast|3-Dimensional Form and Soft Tissue Biomechanics of the Breast|Terminated|||45|Actual|M.D. Anderson Cancer Center|||1|Sample size too small for data analysis.|f||||f||||||||||2018-06-01 03:04:06.733339|2018-06-01 03:04:06.733339
NCT00502801|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2013-02-13||2013-09-19|2007-07-16|2007-07-18|Estimate|2013-09-19|2013-09-25|Estimate||||2013-09-19|2013-09-25|Estimate|August 2007||2007-08-31|September 2013|2013-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia|A Phase 2 Study of Doripenem In The Treatment of Nosocomial and Ventilator-Associated Pneumonia In Hospitals|Completed||Phase 2|185|Actual|PriCara, Unit of Ortho-McNeil, Inc.||1|||f||||f||||||||||2018-06-01 03:04:06.895069|2018-06-01 03:04:06.895069
NCT00502788|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2014-03-03|2007-07-16|2007-07-18|Estimate|||||||2014-03-03|2014-03-04|Estimate|May 2003||2003-05-31|March 2014|2014-03-31|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|HepC||Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)|Thalassemia Clinical Research Network - Hepatitis C Clinical Trial|Completed||Phase 2|21|Actual|New England Research Institutes|||||t||||t||||||||||2018-06-01 03:04:07.506343|2018-06-01 03:04:07.506343
NCT00502775|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|2008-11-17||2016-10-27|2007-07-17|2007-07-18|Estimate|2009-03-19|2009-03-20|Estimate||||2016-10-27|2016-12-09|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine|A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 4|680|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:04:07.821814|2018-06-01 03:04:07.821814
NCT00502762|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2008-03-10|2007-07-16|2007-07-18|Estimate|||||||2008-03-10|2008-03-12|Estimate|September 2004||2004-09-30|March 2008|2008-03-31|August 2007|Anticipated|2007-08-31|||||Interventional|||Topotecan for Irinotecan-Refractory SCLC|Salvage Treatment With Topotecan in Patients With Irinotecan-Refractory Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|||Gachon University Gil Medical Center|||||f||||f||||||||||2018-06-01 03:04:08.963498|2018-06-01 03:04:08.963498
NCT00502749|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-10-14|2007-07-17|2007-07-18|Estimate|||||||2011-10-14|2011-10-17|Estimate|February 2003||2003-02-28|October 2011|2011-10-31|October 2010|Actual|2010-10-31|November 2007|Actual|2007-11-30||Interventional|||Exercise Program for Adolescents and Young Adults With Cancer|Feasibility, Safety, and Effect of an Exercise Program for Adolescents and Young Adults With Cancer|Completed||N/A|37|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:09.033447|2018-06-01 03:04:09.033447
NCT00502736|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2014-01-20|2007-07-17|2007-07-18|Estimate|||||||2014-01-20|2014-01-22|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.|An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Bone Pain in Patients With Breast Cancer and Skeletal Metastases|Completed||Phase 2|13|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:04:09.101448|2018-06-01 03:04:09.101448
NCT00502723|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2012-07-27|2007-07-17|2007-07-18|Estimate|||||||2012-07-27|2012-07-30|Estimate|December 2007||2007-12-31|January 2008|2008-01-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|PROPENLAP||Multicentric Study Comparing Carcinological and Functional Results of Surgery|Prostate Cancer: Multicentric Study Comparing Carcinological and Functional Results of Surgery|Unknown status|Recruiting|Phase 3|1440|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:04:09.165269|2018-06-01 03:04:09.165269
NCT00502710|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17||2016-07-28|2016-08-03|2007-07-17|2007-07-18|Estimate||||2016-08-03|2016-08-05|Estimate|2016-08-03|2016-08-05|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.|A Randomized, Double-blind Dose-ranging Study of the Effect of DPP-IV on HbA1c, Other Efficacy Parameters, Pharmacokinetics and Safety in Patients With Type 2 Diabetes (BC20779)|Completed||Phase 2|289|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-06-01 03:04:09.396195|2018-06-01 03:04:09.396195
NCT00502697|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2015-04-13||2017-04-05|2007-07-16|2007-07-18|Estimate|2016-03-07|2016-03-16|Estimate||||2017-04-05|2017-04-07|Actual|November 2006||2006-11-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BBO|We analyzed data for participants who remained in the study for at least four weeks following enrollment. The final sample totaled 211 women: 109 intervention and 102 controls.|Tennessee Connections for Better Birth Outcomes|Tennessee Connections for Better Birth Outcomes|Completed||N/A|236|Actual|Vanderbilt University||2|||f||||f||||||||Undecided||2018-06-01 03:04:09.673549|2018-06-01 03:04:09.673549
NCT00502684|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-17|||2014-06-29|2007-07-17|2007-07-18|Estimate|||||||2014-06-29|2014-07-01|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery|Perioperative Administration of COX 2 Inhibitors and Beta Blockers in Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence|Unknown status|Recruiting|N/A|32|Anticipated|Kaplan Medical Center||2|||f||||f||||||||||2018-06-01 03:04:10.182185|2018-06-01 03:04:10.182185
NCT00502658|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2008-03-26|2007-07-13|2007-07-17|Estimate|||||||2008-03-26|2008-03-28|Estimate|July 2007||2007-07-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dietary Supplements and Personal Energy Tracking Device to Promote and Maintain Healthy Weight|Evaluation of Dietary Supplements (Shakes and Supplements) and Personal Energy Tracking Device to Promote and Maintain Healthy Weight|Completed||N/A|120|Anticipated|Pharmanex|||||f||||f||||||||||2018-06-01 03:04:10.65002|2018-06-01 03:04:10.65002
NCT00502645|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-15|||2007-07-15|2007-07-15|2007-07-17|Estimate|||||||2007-07-15|2007-07-17|Estimate|April 2007||2007-04-30|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Clinical Risk Assesment of CS-1 Decision Support System|SINGLE-CENTER,OPEN,NON-CONTROLLED FEASIBILITY STUDY ON THE PERFORMANCE OF THE CS-1 DECISION SUPPORT SYSTEM WITH INCORPORATED SOFTWARE-ALGORITHM eMPC USED FOR BLOOD GLUCOSE CONTROL OVER 72 HOURS IN CRITICALLY ILL PATIENTS AT THE INTENSIVE CARE UNIT|Completed||N/A|10|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 03:04:10.754325|2018-06-01 03:04:10.754325
NCT00502632|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2008-05-09|2007-07-16|2007-07-17|Estimate|||||||2008-05-09|2008-05-12|Estimate|October 2007||2007-10-31|May 2008|2008-05-31|October 2009|Anticipated|2009-10-31|||||Interventional|DUKE||Dornase Alfa and Urokinase for Kids With Pleural Empyema|Multicentre Randomized Double-Blinded Trial of Intrapleural Dornase Alfa and Urokinase vs Urokinase Alone for Complicated Parapneumonic Effusions in Children|Unknown status|Recruiting|Phase 2/Phase 3|94|Anticipated|Azienda Ospedaliera di Padova||2|||f||||f||||||||||2018-06-01 03:04:10.880802|2018-06-01 03:04:10.880802
NCT00502619|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-08-02|2007-07-16|2007-07-17|Estimate|||||||2011-08-02|2011-08-04|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Assessment of Acupuncture to Improve Function, Exercise Capacity, and Pain|Pilot Study to Determine the Efficacy and Feasibility of a Structured Acupuncture and Treadmill Program to Treat Chronic Low Back Pain Patients to Improve Function, Exercise Capacity, and Pain Control.|Terminated||Phase 1|10|Actual|VA Maryland Health Care System||1||Inadequate recruitment of study subjects and inadequate retention.|f||||t||||||||||2018-06-01 03:04:11.00216|2018-06-01 03:04:11.00216
NCT00502606|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2010-01-05|2007-07-16|2007-07-17|Estimate|||||||2010-01-05|2010-01-06|Estimate|February 2007||2007-02-28|October 2009|2009-10-31|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Observational|IABN||a Clinical Study.the Effect of Addition of Insoluble Antibacterial Nanoparticles(IABN) in Resin Base Provisional Cement|Clinical Study :The Effect of Antibacterial Nanoparticles, Incorporated in Provisional Resin Based Cement, on S.Mutans in the Margins of Provisional Restorations|Unknown status|Active, not recruiting||10|Actual|Hadassah Medical Organization|||1||f||||f||||||||||2018-06-01 03:04:11.106183|2018-06-01 03:04:11.106183
NCT00502593|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2012-12-20|2012-03-09|2017-06-30|2007-07-16|2007-07-17|Estimate|2014-05-01|2014-06-03|Estimate|2012-03-09|2012-03-14|Estimate|2017-06-30|2017-08-15|Actual|July 23, 2007||2007-07-23|October 2016|2016-10-31|December 4, 2009|Actual|2009-12-04|December 4, 2009|Actual|2009-12-04||Interventional|||Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children|A Phase II, Randomized, Open, Controlled Study to Evaluate the Safety and Immunogenicity of Different Formulations of a Pandemic Influenza Vaccine Candidate (Split Virus Formulation Adjuvanted With AS03) Given Following a Two-administration Schedule (21 Days Apart) in Children Between 3 and 9 Years of Age.|Completed||Phase 2|138|Actual|GlaxoSmithKline||12|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:04:12.113854|2018-06-01 03:04:12.113854
NCT00502580|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-07-26|2007-07-16|2007-07-17|Estimate|||||||2012-07-26|2012-07-30|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions|Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions|Completed|||45|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Pictures of suspicious and normal oral cavity lesions along with small sample of oral lesion~     (2-4 mm each, the size of a small eraser) will be removed or biopsied from the areas imaged.~   "|||2018-06-01 03:04:23.658216|2018-06-01 03:04:23.658216
NCT00502567|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-07-26|2007-07-16|2007-07-17|Estimate|||||||2011-07-26|2011-07-27|Estimate|January 2005||2005-01-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors|A Phase 1, Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2171 and Selected Chemotherapy Regimens When Given in Combination to Patients With Advanced Solid Tumors|Completed||Phase 1|104|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:04:23.755683|2018-06-01 03:04:23.755683
NCT00502554|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-07-25|2007-07-16|2007-07-17|Estimate|||||||2011-07-25|2011-07-26|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation|Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation|Terminated||N/A|12|Actual|Hannover Medical School||2||insufficient patient recruitment and ECP capacity|f||||t||||||||||2018-06-01 03:04:23.850937|2018-06-01 03:04:23.850937
NCT00502541|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2013-11-27|2007-07-13|2007-07-17|Estimate|||||||2013-11-27|2013-11-28|Estimate|September 2001||2001-09-30|November 2013|2013-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema|A Multicenter, Randomized, Masked, Controlled Study to Evaluate Retisert, and Intravitreal Fluocinolone Acetonide Implant, in the Treatment of Patients With Diabetic Macular Edema|Completed||Phase 2/Phase 3|196|Actual|Bausch & Lomb Incorporated||2|||f||||t||||||||||2018-06-01 03:04:23.950428|2018-06-01 03:04:23.950428
NCT00502528|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2013-04-27|2007-07-16|2007-07-17|Estimate|||||||2013-04-27|2013-04-30|Estimate|May 2007||2007-05-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2009|Actual|2009-08-31||Interventional|||Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction|Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction|Completed||Phase 2|57|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 03:04:24.050132|2018-06-01 03:04:24.050132
NCT00502515|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16||2017-08-04|2017-08-04|2007-07-16|2007-07-17|Estimate||||2017-08-04|2017-08-08|Actual|2017-08-04|2017-08-08|Actual|July 2007||2007-07-31|August 2017|2017-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Dose-effect of SSR180575 in Diabetic Neuropathy|A Multi-center, Randomized, Double-blind, Placebo Controlled Study of the Effect of SSR180575 at Two Doses for 24 Weeks Treatment on the Rate of Regeneration of Epidermal Nerve Fibers in Patients With Mild Diabetic Peripheral Neuropathy|Completed||Phase 2|309|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:04:24.16454|2018-06-01 03:04:24.16454
NCT00420459|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2015-07-29||2017-03-29|2007-01-09|2007-01-11|Estimate|2017-03-29|2017-04-18|Actual||||2017-03-29|2017-04-18|Actual|April 2007||2007-04-30|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome|Aripiprazole in Fragile X Syndrome|Completed||Phase 2|12|Actual|Indiana University||1|||f||||t||||||||No||2018-06-01 03:31:27.570622|2018-06-01 03:31:27.570622
NCT00502502|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2012-07-18|2007-07-16|2007-07-17|Estimate|||||||2012-07-18|2012-07-20|Estimate|November 2002||2002-11-30|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients|Feasibility Study of the Assessment of Symptom-Related Cytokines in Lung and GI Cancer Patients Undergoing Chemoradiation Therapy|Completed|||205|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected to study the levels of cytokines in your blood.~   "|||2018-06-01 03:04:24.234638|2018-06-01 03:04:24.234638
NCT00502489|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-15|||2007-07-16|2007-07-16|2007-07-17|Estimate|||||||2007-07-16|2007-07-17|Estimate|October 2007||2007-10-31|May 2007|2007-05-31|November 2008|Anticipated|2008-11-30|||||Interventional|||Computer Driven Management of Weaning Following Prolonged Mechanical Ventilation|Computer Driven Management of Weaning Following Prolonged Mechanical Ventilation: a Pilot Study|Unknown status|Not yet recruiting|N/A|50|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:04:24.314997|2018-06-01 03:04:24.314997
NCT00502476|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-08-06|2007-07-16|2007-07-17|Estimate|||||||2007-08-06|2007-08-07|Estimate|August 2007||2007-08-31|August 2007|2007-08-31|September 2009|Anticipated|2009-09-30|||||Observational|CBET||Multicenter Trial of Daily Chlorhexidine Bathing to Reduce Nosocomial Infections|Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin Preparation in Reducing Nosocomial Infections Including MRSA and VRE|Unknown status|Recruiting||14000|Anticipated|Hunter Holmes Mcguire Veteran Affairs Medical Center|||||f||||f||||||||||2018-06-01 03:04:24.374664|2018-06-01 03:04:24.374664
NCT00502463|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-15|||2009-07-30|2007-07-16|2007-07-17|Estimate|||||||2009-07-30|2009-07-31|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|December 2013|Anticipated|2013-12-31|February 2009|Actual|2009-02-28||Interventional|ASOG-HNO1||Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial|Induction by Docetaxel/Cisplatin/5-Fluorouracil (TCF) Prior to Radiotherapy With Concomintant Cetuximab in Locally Advanced Inoperable Head and Neck Tumours - a Methodical Trial|Unknown status|Active, not recruiting|N/A|50|Actual|Austrian South Oncology Group|||||f||||f||||||||||2018-06-01 03:04:24.505629|2018-06-01 03:04:24.505629
NCT00502450|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-15|||2013-07-18|2007-07-15|2007-07-17|Estimate|||||||2013-07-18|2013-07-19|Estimate|September 2007||2007-09-30|July 2007|2007-07-31||||||||Observational|||Is There Hearing Loss After Acute Mastoiditis||Withdrawn|||0|Actual|Rabin Medical Center|||||f||||||||||||||2018-06-01 03:04:24.574281|2018-06-01 03:04:24.574281
NCT00502437|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2010-11-28|2007-07-16|2007-07-17|Estimate|||||||2010-11-28|2010-11-30|Estimate||||June 2007|2007-06-30||||||||Interventional|||The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations||Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:04:24.638194|2018-06-01 03:04:24.638194
NCT00502424|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-07-16|2007-07-16|2007-07-17|Estimate|||||||2007-07-16|2007-07-17|Estimate|July 2004||2004-07-31|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Interventional|||The Effectiveness of a Nighttime Positioning Hand Splint in Patients With Rheumatoid Arthritis|Study of the Effectiveness of a Positioning Hand Splint for Wrist, Fingers and Thumb in Patients With Arthritis Rheumatoid|Completed||Phase 2|50|Actual|Federal University of São Paulo|||||f||||t||||||||||2018-06-01 03:04:24.708361|2018-06-01 03:04:24.708361
NCT00502411|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2015-11-17|2007-07-16|2007-07-17|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2003||2003-01-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma|A Phase I Study of Post-Operative Concurrent Chemoradiation for Extremity and Trunk Soft Tissue Sarcoma|Completed||Phase 1|4|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:24.793039|2018-06-01 03:04:24.793039
NCT00502398|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-15|||2007-10-14|2007-07-15|2007-07-17|Estimate|||||||2007-10-14|2007-10-16|Estimate|September 2007||2007-09-30|October 2007|2007-10-31||||||||Observational|||Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension?||Unknown status|Recruiting||||Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:04:24.92047|2018-06-01 03:04:24.92047
NCT00502385|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2011-01-20|2007-07-13|2007-07-17|Estimate|||||||2011-01-20|2011-01-21|Estimate|April 2004||2004-04-30|January 2011|2011-01-31||||||||Interventional|||Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML||Completed||Phase 1|54|Anticipated|AstraZeneca|||||f||||t||||||||||2018-06-01 03:04:24.991193|2018-06-01 03:04:24.991193
NCT00502372|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2015-12-14|2007-07-13|2007-07-17|Estimate|||||||2015-12-14|2015-12-15|Estimate|December 2008||2008-12-31|December 2015|2015-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)|Nutritional Effect of an Oral Supplement Enriched in Arginine, Glutamine and Leucine Metabolite B-Hydroxy B-Methylbutyrate|Terminated||Phase 1|9|Actual|Central Arkansas Veterans Healthcare System||2||VA never granted approval following suspension of enrollment.|f||||t||||||||||2018-06-01 03:04:25.047254|2018-06-01 03:04:25.047254
NCT00502359|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-07-19|2007-07-16|2007-07-17|Estimate|||||||2007-07-19|2007-07-20|Estimate|April 2005||2005-04-30|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Observational|||Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose|Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose Values in Pregnancy|Completed|||2005|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 03:04:25.109105|2018-06-01 03:04:25.109105
NCT00502346|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-09-07|2007-07-16|2007-07-17|Estimate|||||||2017-09-07|2017-09-08|Actual|July 3, 2007|Actual|2007-07-03|September 2017|2017-09-30|November 2, 2007|Actual|2007-11-02|November 2, 2007|Actual|2007-11-02||Interventional|||A Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers|A Randomized, Double-blind, Double-dummy, Placebo-controlled Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers|Completed||Phase 1|342|Anticipated|Baxter Healthcare Corporation|||||f||||f||||||||||2018-06-01 03:04:26.269381|2018-06-01 03:04:26.269381
NCT00502333|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2014-03-11|2007-07-16|2007-07-17|Estimate|||||||2014-03-11|2014-03-13|Estimate|November 2006||2006-11-30|March 2014|2014-03-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Observational|||The Influence of Coping Strategies and Catastrophizing on Patients With Back and Neck Pain|The Influence of Coping Strategies and Catastrophizing on Patients With Back and Neck Pain Treated Within the Spanish National Health Service|Completed|||1400|Actual|Kovacs Foundation|||||f||||t||||||||||2018-06-01 03:04:26.358317|2018-06-01 03:04:26.358317
NCT00502320|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2009-07-21||2009-10-02|2007-07-13|2007-07-17|Estimate|2009-08-28|2009-10-05|Estimate||||2009-10-02|2009-10-06|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|SAM-SAD||Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder|Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder|Completed||Phase 4|50|Actual|Lehigh Valley Hospital||2|||f||||f||||||||||2018-06-01 03:04:26.47255|2018-06-01 03:04:26.47255
NCT00420446|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-07-25|2007-01-10|2007-01-11|Estimate|||||||2007-07-25|2007-07-27|Estimate|January 2007||2007-01-31|February 2007|2007-02-28|July 2007|Actual|2007-07-31|||||Interventional|||The Effect of Daily Intakes of Dairy Products on Blood Pressure in Human Beings||Completed||N/A|||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 03:31:27.807063|2018-06-01 03:31:27.807063
NCT00502307|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16||2012-06-01|2012-10-02|2007-07-16|2007-07-17|Estimate||||2012-06-06|2012-06-08|Estimate|2012-10-02|2012-10-05|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma|A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma|Completed||Phase 2|272|Actual|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 03:04:26.786593|2018-06-01 03:04:26.786593
NCT00502294|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2009-06-23|2007-07-13|2007-07-17|Estimate|||||||2009-06-23|2009-06-25|Estimate||||July 2008|2008-07-31||||||||Interventional|||A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis|Withdrawn||Phase 3|150|Anticipated|Facet Biotech|||||f||||t||||||||||2018-06-01 03:04:26.88846|2018-06-01 03:04:26.88846
NCT00502281|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2013-04-05|2007-07-16|2007-07-17|Estimate|||||||2013-04-05|2013-04-09|Estimate|January 2007||2007-01-31|April 2013|2013-04-30||||March 2013|Actual|2013-03-31||Interventional|||Controlled Ovarian Stimulation Followed by Timed Intercourse or Intrauterine Insemination in Infertile PCOS Patients|Timed Intercourse Versus Intrauterine Insemination in Infertile Patients Undergoing Gonadotropin Ovarian Stimulation|Suspended||Phase 4|100|Anticipated|University Magna Graecia||2|||f||||||||||||||2018-06-01 03:04:27.749059|2018-06-01 03:04:27.749059
NCT00502268|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2016-03-25|2007-07-16|2007-07-17|Estimate|||||||2016-03-25|2016-03-28|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Vitamin D and Carboxy PTH Fragments in Coronary Calcification|A Prospective, Randomized, Open-Label Trial Investigating the Effect of 1 Alpha Hydroxy Vitamin D2 on the Development of Coronary Calcification in New ESRD Patients Using the 1-84/7-84 PTH Ratio to Determine Dosing|Withdrawn||Phase 4|0|Actual|Southeast Renal Research Institute||2||study never initiated|f||||f||||||||||2018-06-01 03:04:27.848682|2018-06-01 03:04:27.848682
NCT00502255|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2015-04-07|2007-07-16|2007-07-17|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2007||2007-10-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|TEHAF2||Telemonitoring in Patients With Heart Failure|Telemonitoring in Patients With Heart Failure|Completed||N/A|382|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-06-01 03:04:27.921756|2018-06-01 03:04:27.921756
NCT00502242|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2014-08-13||2014-08-13|2007-07-16|2007-07-17|Estimate|2014-08-13|2014-08-27|Estimate||||2014-08-13|2014-08-27|Estimate|December 2007||2007-12-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus|A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus|Completed||Phase 4|229|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:04:28.148284|2018-06-01 03:04:28.148284
NCT00502229|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2013-04-05|2007-07-16|2007-07-17|Estimate|||||||2013-04-05|2013-04-09|Estimate|January 2010||2010-01-31|April 2013|2013-04-30||||January 2011|Actual|2011-01-31||Interventional|||Therapy for Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin|What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study.|Withdrawn||Phase 4|0|Actual|University Magna Graecia||2|||f||||||||||||||2018-06-01 03:04:29.919653|2018-06-01 03:04:29.919653
NCT00502216|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2010-06-03||2018-01-12|2007-07-16|2007-07-17|Estimate|2010-08-30|2010-09-21|Estimate||||2018-01-12|2018-01-17|Actual|July 2007||2007-07-31|January 2018|2018-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers|Naltrexone and Varenicline: Weight Gain and Tolerability in Smokers|Completed||Phase 1/Phase 2|40|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:04:30.040796|2018-06-01 03:04:30.040796
NCT00502203|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2011-12-05||2016-04-05|2007-07-16|2007-07-17|Estimate|2011-12-05|2012-01-09|Estimate||||2016-04-05|2016-05-09|Estimate|August 2001||2001-08-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus|A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus|Completed||Phase 2|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:30.281414|2018-06-01 03:04:30.281414
NCT00502190|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2011-11-09|2007-07-16|2007-07-17|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 2007||2007-06-30|April 2007|2007-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|EPEGE||Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG (EPEGE)|Evaluation Of Pessaries In Twin Pregnancies With A Short Cervix (25 mm) Between 20-28 WG|Completed||Phase 3|220|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:04:30.52578|2018-06-01 03:04:30.52578
NCT00502177|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2018-01-22|2007-07-16|2007-07-17|Estimate|||||||2018-01-22|2018-01-25|Actual|June 2007|Actual|2007-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin|Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin|Active, not recruiting|||48|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:04:30.59873|2018-06-01 03:04:30.59873
NCT00502164|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2011-01-20|2007-07-13|2007-07-17|Estimate|||||||2011-01-20|2011-01-21|Estimate|March 2004||2004-03-31|January 2009|2009-01-31||||||||Interventional|AZD2171IL/0003||Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer|A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.|Completed||Phase 1|40|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:04:30.683634|2018-06-01 03:04:30.683634
NCT00502138|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2013-01-15|2007-07-16|2007-07-17|Estimate|||||||2013-01-15|2013-01-16|Estimate|July 2007||2007-07-31|January 2013|2013-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes|A Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Pramlintide Acetate When Administered by Subcutaneous Infusion in a Basal-Bolus Manner as an Adjunct to Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes|Completed||Phase 4|12|Actual|University Diabetes & Endocrine Consultants||1|||f||||t||||||||||2018-06-01 03:04:30.773017|2018-06-01 03:04:30.773017
NCT00501943|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2013-11-19||2014-03-11|2007-07-13|2007-07-16|Estimate|2014-03-11|2014-04-09|Estimate||||2014-03-11|2014-04-09|Estimate|July 2006||2006-07-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Neuroprotection With Riluzole Patients With Early Multiple Sclerosis|Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis|Completed||Phase 2|43|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 03:04:32.843824|2018-06-01 03:04:32.843824
NCT00502125|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-07-31|2007-07-13|2007-07-17|Estimate|||||||2012-07-31|2012-08-01|Estimate|January 2003||2003-01-31|July 2012|2012-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||In Vivo Confocal Imaging of Oral Mucosa|A Pilot Study: In Vivo Reflectance Confocal Imaging for Detection of Neoplasia of Oral Mucosa|Completed|||12|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Tissue samples will be removed.~   "|||2018-06-01 03:04:30.848615|2018-06-01 03:04:30.848615
NCT00502112|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2011-10-07|2007-07-16|2007-07-17|Estimate|||||||2011-10-07|2011-10-12|Estimate|March 2008||2008-03-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)|A Phase I Combination Trial of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) and Lenalidomide (Revlimid®) in Patients With Myelodysplastic Syndromes (MDS)|Completed||Phase 1|13|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 03:04:30.922275|2018-06-01 03:04:30.922275
NCT00502099|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-15|||2012-10-21|2007-07-16|2007-07-17|Estimate|||||||2012-10-21|2012-10-23|Estimate|January 2006||2006-01-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4|Phase 4 Comparative Study of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4|Completed||Phase 4|217|Actual|Ain Shams University||2|||f||||t||||||||||2018-06-01 03:04:31.012746|2018-06-01 03:04:31.012746
NCT00502086|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2011-02-10|2007-07-13|2007-07-17|Estimate|||||||2011-02-10|2011-02-11|Estimate|May 2005||2005-05-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.|Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study.|Completed||Phase 3|100|Actual|Catalysis SL||2|||f||||t||||||||||2018-06-01 03:04:31.093445|2018-06-01 03:04:31.093445
NCT00502073|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2011-06-29|2007-07-13|2007-07-17|Estimate|||||||2011-06-29|2011-07-01|Estimate||||June 2011|2011-06-30||||||||Interventional|||Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)||Completed||Phase 3|||Sirion Therapeutics, Inc.|||||||||||||||||||2018-06-01 03:04:31.29794|2018-06-01 03:04:31.29794
NCT00502060|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2009-05-13|2007-07-13|2007-07-17|Estimate|||||||2009-05-13|2009-05-14|Estimate|August 2004||2004-08-31|May 2009|2009-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer|A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer|Completed||Phase 1|65|Anticipated|AstraZeneca|||||f||||t||||||||||2018-06-01 03:04:31.38298|2018-06-01 03:04:31.38298
NCT00502047|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-07-16|2007-07-16|2007-07-17|Estimate|||||||2007-07-16|2007-07-17|Estimate|September 2005||2005-09-30|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Effect of the Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia|Multicentre, Comparative, Double-Blind, Two-Arm Parallel Clinical Trial of the Effects of Treatment With Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia|Completed||Phase 2/Phase 3|255|Actual|Rottapharm Spain|||||f||||f||||||||||2018-06-01 03:04:31.444383|2018-06-01 03:04:31.444383
NCT00502034|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2013-07-09|2007-07-16|2007-07-17|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 1994||1994-07-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|April 2007|Actual|2007-04-30||Interventional|||Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.|Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC).|Completed||Phase 3|310|Actual|Gruppo Oncologico Italiano di Ricerca Clinica||2|||f||||t||||||||||2018-06-01 03:04:31.512512|2018-06-01 03:04:31.512512
NCT00502021|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2012-09-27|2007-07-16|2007-07-17|Estimate|||||||2012-09-27|2012-09-28|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|||Use of Flaxseed(Alpha Linolenic Acid) Powder in Morbidly Obese Patients With Systemic Inflammation|Inflammatory Indicators and Arterial Stiffness in Patients With Severe Obesity. Response to Supplementation of Alpha Linolenic Acid|Unknown status|Recruiting|Phase 2|90|Anticipated|University of Sao Paulo||4|||f||||f||||||||||2018-06-01 03:04:31.602653|2018-06-01 03:04:31.602653
NCT00502008|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2007-07-16|2007-07-16|2007-07-17|Estimate|||||||2007-07-16|2007-07-17|Estimate|November 2005||2005-11-30|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Interventional|||Effect of Coccinia Cordifolia Extract on Blood Sugar of Newly Diagnosed Diabetics|Efficacy of Coccinia Cordifolia Extract in Improving Blood Glucose Levels of Newly Diagnosed Diabetic Patients|Completed||N/A|60|Actual|St. John's Research Institute|||||f||||f||||||||||2018-06-01 03:04:31.688688|2018-06-01 03:04:31.688688
NCT00501995|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2014-03-25||2017-05-15|2007-07-13|2007-07-17|Estimate|2014-06-02|2014-07-02|Estimate||||2017-05-15|2017-06-14|Actual|February 2001||2001-02-28|May 2017|2017-05-31|May 2010|Actual|2010-05-31|July 2008|Actual|2008-07-31||Interventional||Patients with scleroderma were considered eligible for this open-label trial if they had a diagnosis of diffuse cutaneous scleroderma and evidence of clinically active disease.|High Dose Cyclophosphamide for Treatment of Scleroderma|High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma)|Completed||Phase 3|6|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 03:04:31.757333|2018-06-01 03:04:31.757333
NCT00501982|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2018-04-12|2007-07-16|2007-07-17|Estimate|||||||2018-04-12|2018-04-13|Actual|March 2007||2007-03-31|April 2018|2018-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|Curpap||Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study|An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome|Completed||Phase 4|208|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||||||||||||2018-06-01 03:04:32.019932|2018-06-01 03:04:32.019932
NCT00501969|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|2009-12-08||2014-09-24|2007-07-16|2007-07-17|Estimate|2009-12-08|2010-01-12|Estimate||||2014-09-24|2014-10-02|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease|An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa|Completed||Phase 3|395|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:04:32.16735|2018-06-01 03:04:32.16735
NCT00501956|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-16|||2016-03-01|2007-07-16|2007-07-17|Estimate|||||||2016-03-01|2016-03-03|Estimate|July 2004||2004-07-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|IDPNHD||Intradialytic Parenteral Nutrition in Hemodialysis Patients|Randomized Study on the Effect of Intradialytic Parenteral Nutrition in Malnourished Hemodialysis Patients|Completed||Phase 4|140|Actual|Fresenius Kabi||2|||f||||f||||||||No||2018-06-01 03:04:32.755864|2018-06-01 03:04:32.755864
NCT00501930|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-05-31|2007-07-13|2007-07-16|Estimate|||||||2012-05-31|2012-06-04|Estimate|April 2007||2007-04-30|February 2011|2011-02-28||||||||Interventional|||A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers|A Randomized, Placebo-Controlled, Double-Blind, Repeat Dose, Dose Escalation Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Supratherapeutic Doses of GSK189075 Administered for 3 Days in Healthy Volunteers|Completed||Phase 1|12|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:04:33.139517|2018-06-01 03:04:33.139517
NCT00501917|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2007-07-13|2007-07-13|2007-07-16|Estimate|||||||2007-07-13|2007-07-16|Estimate|March 2007||2007-03-31|July 2007|2007-07-31|February 2010|Anticipated|2010-02-28|||||Interventional|MAGIC Cell-5||MAGIC Cell-5-Combicytokine Trial|Single Center, Prospective, Randomized, Partly-Double Blinded, Controlled Trial to Assess the Safety and Feasibility of Intracoronary Cell Infusion Mobilized With G-CSF and Darbepoetin and Their Effects on Improvement of Cardiac Function in Patients With Myocardial Infarction: Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Erythropoietin Mobilization and Intra-Coronary Cell Infusion –5-Combination Cytokine Therapy Trial|Unknown status|Recruiting|Phase 2/Phase 3|116|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 03:04:33.33518|2018-06-01 03:04:33.33518
NCT00501904|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2015-12-01|2007-07-13|2007-07-16|Estimate|||||||2015-12-01|2015-12-03|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Metformin in Infertile PCOS Patients|Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients|Unknown status|Recruiting|Phase 4|20|Anticipated|University Magna Graecia||2|||f||||t||||||||||2018-06-01 03:04:33.404645|2018-06-01 03:04:33.404645
NCT00501891|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2013-02-06||2013-05-17|2007-07-13|2007-07-16|Estimate|2013-03-11|2013-04-22|Estimate||||2013-05-17|2013-05-27|Estimate|July 2007||2007-07-31|March 2013|2013-03-31|November 2009|Actual|2009-11-30|December 2007|Actual|2007-12-31||Interventional|||Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma|A Phase II Study of Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma|Completed||Phase 2|32|Actual|Duke University||1|||f||||t||||||||||2018-06-01 03:04:33.510371|2018-06-01 03:04:33.510371
NCT00501878|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-03-07|2007-07-13|2007-07-16|Estimate|||||||2012-03-07|2012-03-09|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|July 2007|Actual|2007-07-31|||||Interventional|||2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides|2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides|Completed||Phase 4|100|Actual|Khon Kaen University|||||f||||t||||||||||2018-06-01 03:04:33.709451|2018-06-01 03:04:33.709451
NCT00501865|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2017-08-03|2007-07-13|2007-07-16|Estimate|||||||2017-08-03|2017-08-04|Actual|August 6, 2007|Actual|2007-08-06|August 2017|2017-08-31|October 11, 2007|Actual|2007-10-11|October 11, 2007|Actual|2007-10-11||Interventional|||Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers|An Open, Randomised, Two-period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of GW273225 Administered Immediately After Food and Administered in Fasted State to Healthy Male and Female Subjects|Completed||Phase 1|14|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:04:33.775756|2018-06-01 03:04:33.775756
NCT00501852|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2010-12-22||2012-05-03|2007-07-13|2007-07-16|Estimate|2010-12-22|2011-01-21|Estimate||||2012-05-03|2012-05-08|Estimate|July 2007||2007-07-31|December 2010|2010-12-31||||December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium|A Randomized, Double-blind, Placebo-controlled, 4 Period Incomplete Block Cross-over, Multi-center, Multiple Dose (7 Days) Dose-ranging Study to Assess the Efficacy and Safety of 4 Doses of NVA237 in Patients With Stable COPD, Compared to Seven Days Treatment With Tiotropium (18μg Once Daily, Open Label) as an Active Control|Completed||Phase 2|83|Actual|Novartis||6|||f||||||||||||||2018-06-01 03:04:33.861384|2018-06-01 03:04:33.861384
NCT00501839|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2013-04-05|2007-07-12|2007-07-16|Estimate|||||||2013-04-05|2013-04-09|Estimate|August 2008||2008-08-31|April 2013|2013-04-30||||September 2010|Actual|2010-09-30||Interventional|||Clomiphene Citrate in Infertile PCOS Patients|How Long Should First-line Treatment be Continued in Infertile PCOS Patients Who Ovulate Under Clomiphene Citrate? A Randomized Controlled Clinical Study.|Withdrawn||Phase 4|0|Actual|University Magna Graecia||3|||f||||||||||||||2018-06-01 03:04:34.287836|2018-06-01 03:04:34.287836
NCT00501826|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-11-10|2007-07-13|2007-07-16|Estimate|||||||2017-11-10|2017-11-14|Actual|July 11, 2007|Actual|2007-07-11|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma|Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:04:34.367064|2018-06-01 03:04:34.367064
NCT00501813|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2010-07-29|2007-07-13|2007-07-16|Estimate|||||||2010-07-29|2010-07-30|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|July 2010|Anticipated|2010-07-31|December 2009|Anticipated|2009-12-31||Interventional|MDTforHCC||Multimodality Therapy for Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion|A Randomized Controlled Trial of Multimodality Therapy in the Treatment of Palliative Resectable Hepatocellular Carcinoma With Intrahepatic Vessels Invasion|Unknown status|Recruiting|Phase 3|160|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-06-01 03:04:34.482091|2018-06-01 03:04:34.482091
NCT00501800|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-10-25|2007-07-13|2007-07-16|Estimate|||||||2017-10-25|2017-10-26|Actual|November 2006||2006-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Observational|||Genetic Epidemiology of Ovarian Aging|Genetic Epidemiology of Ovarian Aging|Active, not recruiting|||1250|Anticipated|University of California, San Francisco|||5||f||||f||||||Samples With DNA|"~     Blood, urine~   "|||2018-06-01 03:04:34.574412|2018-06-01 03:04:34.574412
NCT00501787|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2013-04-05|2007-07-13|2007-07-16|Estimate|||||||2013-04-05|2013-04-09|Estimate|January 2008||2008-01-31|April 2013|2013-04-30||||October 2012|Actual|2012-10-31||Interventional|||Metformin Administration in Infertile Anovulatory PCOS Patients|Tailored Versus Non-tailored Metformin Protocol for Ovulation Induction in Infertile Anovulatory PCOS Patients. A Randomized Controlled Clinical Study|Withdrawn||Phase 4|0|Actual|University Magna Graecia||2|||f||||||||||||||2018-06-01 03:04:34.640006|2018-06-01 03:04:34.640006
NCT00501774|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2007-07-13|2007-07-13|2007-07-16|Estimate|||||||2007-07-13|2007-07-16|Estimate|May 2004||2004-05-31|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Observational|||A Search for Helicobacter Pylori in Localized Vulvodynia|A Laboratory and Clinical Search for the Presence of H. Pylori and Treatment Against it in Localized Vulvodynia (Vestibulitis, Vestibulodynia).|Completed|||27|Actual|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-06-01 03:04:34.714023|2018-06-01 03:04:34.714023
NCT00501579|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2008-08-27|2007-07-13|2007-07-16|Estimate|||||||2008-08-27|2008-08-29|Estimate||||August 2008|2008-08-31||||||||Interventional|||Study of Difluprednate in the Treatment of Uveitis||Completed||Phase 3|||Sirion Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:04:36.777675|2018-06-01 03:04:36.777675
NCT00501761|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-12-01|2007-07-13|2007-07-16|Estimate|||||||2017-12-01|2017-12-05|Actual|May 2005|Actual|2005-05-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Physical Activity After Endometrial Cancer|Social Cognitive Theory and Physical Activity After Endometrial Cancer|Active, not recruiting|||326|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||Samples With DNA|"~     Saliva samples 5 times per day for 2 consecutive days.~   "|||2018-06-01 03:04:34.762462|2018-06-01 03:04:34.762462
NCT00501748|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2011-09-23|2007-07-13|2007-07-16|Estimate|||||||2011-09-23|2011-09-27|Estimate|January 2004||2004-01-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Tolerability of Rituximab in Neuromyelitis Optica|Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis|Completed||Phase 1|20|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 03:04:34.845602|2018-06-01 03:04:34.845602
NCT00501735|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12||2012-01-18|2012-01-18|2007-07-13|2007-07-16|Estimate||||2012-01-18|2012-01-23|Estimate|2012-01-18|2012-01-23|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31||Interventional|||Forodesine in the Treatment of Cutaneous T-Cell Lymphoma|Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma|Completed||Phase 2|144|Actual|BioCryst Pharmaceuticals|||||f||||t||||||||||2018-06-01 03:04:34.923126|2018-06-01 03:04:34.923126
NCT00501722|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2009-01-09|2007-07-13|2007-07-16|Estimate|||||||2009-01-09|2009-01-12|Estimate|April 2004||2004-04-30|January 2009|2009-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|Hypo~CAT||Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites|SR121463B in Cirrhotic Ascites Treatment With Hyponatraemia: A Placebo-Controlled, Dose-Comparison Study|Completed||Phase 2|110|Actual|Sanofi|||||f||||t||||||||||2018-06-01 03:04:35.031972|2018-06-01 03:04:35.031972
NCT00501709|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2016-12-22|2007-07-13|2007-07-16|Estimate|||||||2016-12-22|2016-12-23|Estimate|February 2004||2004-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus||Completed||Phase 1/Phase 2|30|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:04:35.112514|2018-06-01 03:04:35.112514
NCT00501696|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2008-05-15|2007-07-13|2007-07-16|Estimate|||||||2008-05-15|2008-05-19|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone|A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54)|Completed||Phase 3|80|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 03:04:35.163766|2018-06-01 03:04:35.163766
NCT00501683|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-05-31|2007-07-13|2007-07-16|Estimate|||||||2012-05-31|2012-06-04|Estimate|November 2006||2006-11-30|February 2011|2011-02-28||||||||Interventional|||A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers|A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects|Completed||Phase 1|8|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:04:35.238516|2018-06-01 03:04:35.238516
NCT00501670|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2014-01-09|2007-07-13|2007-07-16|Estimate|||||||2014-01-09|2014-01-13|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||VZV PCR Sampling Validation Study|A Non-therapeutic Study to Validate the Sampling Method to Confirm Presence of Varicella-zoster Virus (VZV) DNA by PCR in Clinical Samples From Lesions Collected From Adults (≥50 Years) With Clinically Diagnosed Herpes Zoster|Completed|||41|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     lesion samples~   "|||2018-06-01 03:04:35.289179|2018-06-01 03:04:35.289179
NCT00501657|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2015-10-27|2007-07-13|2007-07-16|Estimate|||||||2015-10-27|2015-10-29|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|June 2008|Actual|2008-06-30||Interventional|||Effects of Sitagliptin on Gastric Emptying in Healthy Subjects|Effects of Sitagliptin on Gastric Emptying in Healthy Subjects|Completed||Phase 1|15|Actual|Royal Adelaide Hospital||2|||f||||f||||||||||2018-06-01 03:04:35.504994|2018-06-01 03:04:35.504994
NCT00501644|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2010-12-23||2012-08-01|2007-07-13|2007-07-16|Estimate|2010-12-23|2011-01-10|Estimate||||2012-08-01|2012-08-07|Estimate|January 2003||2003-01-31|August 2012|2012-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer|A Phase II Study of Chemoimmunotherapy for Patients With Potentially Platinum Sensitive Müllerian (Epithelial Ovarian, Peritoneal, or Fallopian Tube) Carcinomas|Completed||Phase 2|59|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:35.637557|2018-06-01 03:04:35.637557
NCT00501631|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2011-03-23||2011-09-20|2007-07-12|2007-07-16|Estimate|2011-03-23|2011-04-13|Estimate||||2011-09-20|2011-09-22|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence|Efficacy and Safety of VIVITROL® in Adults Completing Inpatient Treatment for Alcohol Dependence|Completed||Phase 3|300|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-06-01 03:04:35.853529|2018-06-01 03:04:35.853529
NCT00501618|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2015-04-14|2007-07-13|2007-07-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2006||2006-11-30|April 2015|2015-04-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder|An Open-Label Study Changing Generic Clozapine Formulation to FazaClo® (Clozapine, USP) Orally Disintegrating Tablets in Stable Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|20|Actual|Manhattan Psychiatric Center||1|||f||||t||||||||||2018-06-01 03:04:36.226132|2018-06-01 03:04:36.226132
NCT00501605|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2011-01-20|2007-07-13|2007-07-16|Estimate|||||||2011-01-20|2011-01-21|Estimate|February 2003||2003-02-28|January 2009|2009-01-31|February 2006|Actual|2006-02-28|April 2005|Actual|2005-04-30||Interventional|||Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases|A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases|Completed||Phase 1|80|Anticipated|AstraZeneca|||||f||||t||||||||||2018-06-01 03:04:36.360487|2018-06-01 03:04:36.360487
NCT00501592|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2011-06-07||2012-04-17|2007-07-13|2007-07-16|Estimate|2011-12-21|2012-01-27|Estimate||||2012-04-17|2012-04-20|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Study of INT-747 in Patients With Diabetes and Presumed NAFLD|An Exploratory Study of INT-747 in Patients With Type 2 Diabetes Mellitus and Presumed Nonalcoholic Fatty Liver Disease|Completed||Phase 2|64|Actual|Intercept Pharmaceuticals||3|||f||||t||||||||||2018-06-01 03:04:36.432479|2018-06-01 03:04:36.432479
NCT00501540|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2016-12-05||2017-03-22|2007-07-13|2007-07-16|Estimate|2017-03-22|2017-05-03|Actual||||2017-03-22|2017-05-03|Actual|July 2007||2007-07-31|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Participants with histologically confirmed metastatic low-grade neuroendocrine neoplasms were enrolled.|Lithium for Low-Grade Neuroendocrine Tumors|A Phase II Clinical and Biological Study of Lithium Carbonate in Patients With Low-Grade Neuroendocrine Tumors|Completed||Phase 2|15|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 03:04:37.018011|2018-06-01 03:04:37.018011
NCT00501527|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2010-12-16|2007-07-13|2007-07-16|Estimate|||||||2010-12-16|2010-12-17|Estimate|September 2007||2007-09-30|December 2010|2010-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense|Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense in Patients Suffering From Allergic Rhinoconjunctivitis and/or Asthma|Completed||Phase 2|80|Actual|Laboratorios Leti, S.L.||3|||f||||f||||||||||2018-06-01 03:04:37.300254|2018-06-01 03:04:37.300254
NCT00501514|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2009-01-28|2007-07-12|2007-07-16|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 1997||1997-11-30|January 2009|2009-01-31|November 2005|Actual|2005-11-30|||||Interventional|||Effects of Growth Hormone on Exercise Capacity|Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients With Chronic Heart Failure|Completed||Phase 3|22|Actual|Federico II University|||||f||||t||||||||||2018-06-01 03:04:37.424501|2018-06-01 03:04:37.424501
NCT00501501|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2007-07-13|2007-07-13|2007-07-16|Estimate|||||||2007-07-13|2007-07-16|Estimate|January 1999||1999-01-31|July 2007|2007-07-31|December 2000|Actual|2000-12-31|||||Observational|||The Association Between Delivery Method and Maternal Rehospitalization|The Association Between Delivery Method and Maternal Rehospitalization|Completed|||92|Actual|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-06-01 03:04:37.515315|2018-06-01 03:04:37.515315
NCT00501488|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2007-07-19|2007-07-13|2007-07-16|Estimate|||||||2007-07-19|2007-07-20|Estimate|March 2006||2006-03-31|July 2007|2007-07-31|February 2007|Actual|2007-02-28|||||Observational|||Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response||Completed|||42|Actual|Central South University|||||f||||t||||||||||2018-06-01 03:04:37.58507|2018-06-01 03:04:37.58507
NCT00501475|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2010-07-23|2007-07-13|2007-07-16|Estimate|||||||2010-07-23|2010-07-27|Estimate|March 2007||2007-03-31|July 2010|2010-07-31|October 2010|Anticipated|2010-10-31|||||Interventional|||NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED||Unknown status|Recruiting|Phase 4|||Seoul National University Hospital|||||f||||f||||||||||2018-06-01 03:04:37.656338|2018-06-01 03:04:37.656338
NCT00501462|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-03-15|2007-07-13|2007-07-16|Estimate|||||||2012-03-15|2012-03-19|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function|An Evaluation of the Pharmacokinetics of a Single Oral Dose of GSK189075 in Patients With Varying Degrees of Renal Insufficiency Compared to Volunteers With Normal Renal Function|Completed||Phase 1|29|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:04:37.726027|2018-06-01 03:04:37.726027
NCT00501449|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2018-01-08|2007-07-13|2007-07-16|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2007|Actual|2007-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes|Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes|Active, not recruiting|||581|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:04:37.802712|2018-06-01 03:04:37.802712
NCT00501423|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2014-01-30|2007-07-13|2007-07-16|Estimate|||||||2014-01-30|2014-01-31|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|ADRIE||Antiplatelet Drug Resistances and Ischemic Events|Antiplatelet Drug Resistances and Ischemic Events|Completed|||771|Actual|University Hospital, Geneva|||||f||||t||||||||||2018-06-01 03:04:37.915017|2018-06-01 03:04:37.915017
NCT00501410|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-03-10|2007-07-13|2007-07-16|Estimate|||||||2017-03-10|2017-03-14|Actual|April 23, 2007|Actual|2007-04-23|March 2017|2017-03-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer|Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined With FOLFOX Chemotherapy in Metastatic Colorectal Cancer (CA180048)|Completed||Phase 1|86|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:04:38.012956|2018-06-01 03:04:38.012956
NCT00501397|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2012-05-31|2007-07-13|2007-07-16|Estimate|||||||2012-05-31|2012-06-04|Estimate|February 2007||2007-02-28|February 2011|2011-02-28||||||||Interventional|||A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers|An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK189075|Completed||Phase 1|22|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:04:38.115785|2018-06-01 03:04:38.115785
NCT00501384|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2009-01-09|2007-07-13|2007-07-16|Estimate|||||||2009-01-09|2009-01-12|Estimate|April 2004||2004-04-30|January 2009|2009-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|SPA||Satavaptan Dose-Ranging Study in the Prevention of Ascites|Study for the Prevention of Ascites (SPA): Comparison of Fixed Doses of SR121463B Versus Placebo in the Reduction of Recurrence of Cirrhotic Ascites|Completed||Phase 2|151|Actual|Sanofi|||||f||||t||||||||||2018-06-01 03:04:38.217502|2018-06-01 03:04:38.217502
NCT00501371|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2011-12-13|2007-07-12|2007-07-16|Estimate|||||||2011-12-13|2011-12-14|Estimate|July 2007||2007-07-31|December 2011|2011-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia|Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia|Terminated||Phase 3|85|Actual|Health Ever Bio-Tech Co., Ltd.||2||"Study terminated for re-design. A new IND study (US FDA, July 2009) will be conducted in US and~   Taiwan. Termination not related to safety concerns."|f||||f||||||||||2018-06-01 03:04:38.31525|2018-06-01 03:04:38.31525
NCT00501358|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2007-07-13|2007-07-13|2007-07-16|Estimate|||||||2007-07-13|2007-07-16|Estimate||||July 2007|2007-07-31||||||||Observational|||Sleep Apnea and Tromboembolic Disease|Assessment of Sleep Apnea Syndrome as a Risk Factor for Venous Thromboembolism|Unknown status|Recruiting||||Sociedad Española de Neumología y Cirugía Torácica|||||f||||t||||||||||2018-06-01 03:04:38.401727|2018-06-01 03:04:38.401727
NCT00501345|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|2009-09-24||2012-07-27|2007-07-13|2007-07-16|Estimate|2010-09-16|2010-10-13|Estimate||||2012-07-27|2012-08-01|Estimate|February 2002||2002-02-28|July 2012|2012-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Aspirin in Patients With Myocardial Infarction and Thrombocytopenia|Effects of Aspirin on Platelet Function and Clinical Outcome in Patients With Thrombocytopenia, Neoplasm, and Myocardial Infarction|Terminated||Phase 3|5|Actual|M.D. Anderson Cancer Center|A change in hospital practice where patients with thrombocytopenia now routinely receive aspirin for acute coronary syndromes makes it difficult to obtain a baseline thromboelastogram.|1||Low accrual, study terminated.|f||||f||||||||||2018-06-01 03:04:38.463006|2018-06-01 03:04:38.463006
NCT00501332|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2007-12-19|2007-07-12|2007-07-16|Estimate|||||||2007-12-19|2007-12-24|Estimate|July 2007||2007-07-31|December 2007|2007-12-31||||||||Interventional|||Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy|A Phase IIa, Open Label, Controlled, Dose Ranging Study of Maxy-G34 as an Adjunct to TAC Chemotherapy in High-Risk Patients With Stage I, II, or IIIa Breast Cancer.|Unknown status|Recruiting|Phase 2|30|Anticipated|Maxygen Holdings Ltd.||1|||f||||t||||||||||2018-06-01 03:04:38.576402|2018-06-01 03:04:38.576402
NCT00501319|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2011-11-07|2007-07-13|2007-07-16|Estimate|||||||2011-11-07|2011-11-08|Estimate|April 2003||2003-04-30|November 2011|2011-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery|Longitudinal Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery|Completed|||127|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:04:38.821274|2018-06-01 03:04:38.821274
NCT00501306|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2011-06-21|2007-07-13|2007-07-16|Estimate|||||||2011-06-21|2011-06-23|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men|Assessing Drivers and Barriers to Follow-Up Screening for Anal Cancer in Men Who Have Sex With Men|Completed|||195|Actual|Laser Surgery Care|||||f||||f||||||||||2018-06-01 03:04:38.912872|2018-06-01 03:04:38.912872
NCT00501293|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2009-10-05||2017-03-27|2007-07-13|2007-07-16|Estimate|2009-12-10|2010-01-15|Estimate||||2017-03-27|2017-04-26|Actual|August 2007||2007-08-31|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD|A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|163|Actual|Noven Therapeutics||1|||f||||f||||||||No||2018-06-01 03:04:39.00923|2018-06-01 03:04:39.00923
NCT00501280|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2013-04-01|2007-07-13|2007-07-16|Estimate|||||||2013-04-01|2013-04-04|Estimate|June 2004||2004-06-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Genetic Susceptibility in Migrant Farmworker Children|Biomarkers of Genetic Susceptibility in Environmentally-Exposed Migrant/Seasonal Farmworker Women and Their Children|Completed|||768|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||Samples With DNA|"~     10 teaspoons of blood drawn and a urine sample from each mother/child.~   "|||2018-06-01 03:04:39.697034|2018-06-01 03:04:39.697034
NCT00501267|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2015-04-14|2007-07-13|2007-07-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2007||2007-06-30|April 2015|2015-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder|A Randomized, Repeat Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Solabegron (GW427353) in Combination With Oxybutynin in Healthy Adult Subjects.|Completed||Phase 1|24|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:04:39.812547|2018-06-01 03:04:39.812547
NCT00501254|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-13|||2007-07-17|2007-07-13|2007-07-16|Estimate|||||||2007-07-17|2007-07-18|Estimate|February 2005||2005-02-28|July 2007|2007-07-31|February 2007|Actual|2007-02-28|||||Interventional|||Pharmacodynamic Trial, of Slow Release ASA, in Platelet Functionalism, a Long Term Treatment Period|Randomised Clinical Trial, Parallel, Double Blind, to Evaluate the Influence of the ASA-SR (Slow-Release) in the Platelet Parameters and the Oxidative Status, in Patients With Coronary Disease of Chronic Evolution During 12 Months|Completed||Phase 2/Phase 3|100|Actual|Rottapharm Spain|||||f||||||||||||||2018-06-01 03:04:39.881839|2018-06-01 03:04:39.881839
NCT00501241|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2009-06-16|2007-07-12|2007-07-16|Estimate|||||||2009-06-16|2009-06-17|Estimate|July 2007||2007-07-31|February 2008|2008-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation|A Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation|Terminated||Phase 2|214|Anticipated|Procter and Gamble||5|||f||||f||||||||||2018-06-01 03:04:39.953205|2018-06-01 03:04:39.953205
NCT00501228|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2009-03-03||2012-07-31|2007-07-13|2007-07-16|Estimate|2009-10-19|2009-11-20|Estimate||||2012-07-31|2012-08-07|Estimate|February 2003||2003-02-28|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Tissue Repair in Stem Cell Transplant Recipients|RhG-CSF (Filgrastim) Treatment of Severe Epithelial/Endothelial or Solid Organ-Specific Tissue Damage In Stem Cell Transplant Recipients|Terminated||N/A|2|Actual|M.D. Anderson Cancer Center|Study was closed because of the very limited number of patients enrolled. Patients eligible for enrollment were not willing to undergo 4 weekly cycles of G-CSF treatment because of the well known side effect of bone pain.|1|||f||||f||||||||||2018-06-01 03:04:40.069486|2018-06-01 03:04:40.069486
NCT00501215|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-07-14|2007-07-13|2007-07-16|Estimate|||||||2017-07-14|2017-07-18|Actual|May 25, 2007|Actual|2007-05-25|July 2017|2017-07-31|July 9, 2017|Actual|2017-07-09|July 9, 2017|Actual|2017-07-09||Interventional|||Effect of Parathyroidectomy on Sleep|Pilot Study on the Effect of Parathyroidectomy on Sleep|Completed||N/A|15|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-06-01 03:04:40.230775|2018-06-01 03:04:40.230775
NCT00501202|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12||2013-01-15|2018-04-27|2007-07-12|2007-07-16|Estimate||||2013-01-15|2013-01-24|Estimate|2018-04-27|2018-05-01|Actual|March 2007||2007-03-31|April 2018|2018-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of RWJ 333369 for the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy.|Completed||Phase 2|132|Actual|SK Life Science||2|||f||||||||||||||2018-06-01 03:04:40.32697|2018-06-01 03:04:40.32697
NCT00501189|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2008-08-01|2007-07-13|2007-07-16|Estimate|||||||2008-08-01|2008-08-04|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|July 2009|Anticipated|2009-07-31|||||Observational|||Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities|Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities|Unknown status|Enrolling by invitation||300|Anticipated|Eisenhower Army Medical Center|||2||f||||f||||||||||2018-06-01 03:04:40.413045|2018-06-01 03:04:40.413045
NCT00501176|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2014-06-11|2007-07-12|2007-07-13|Estimate|||||||2014-06-11|2014-06-13|Estimate|December 2006||2006-12-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Preoperative Stent Study|Randomized Study Comparing the Effect of Plastic Stents to That of Expandable Metal Stents Prior to Pancreaticoduodenectomy|Unknown status|Recruiting|N/A|50|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 03:04:40.477686|2018-06-01 03:04:40.477686
NCT00501163|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2010-03-16|2007-07-11|2007-07-13|Estimate|||||||2010-03-16|2010-03-18|Estimate|August 2007||2007-08-31|March 2010|2010-03-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients|Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients|Unknown status|Recruiting||90|Anticipated|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 03:04:40.561733|2018-06-01 03:04:40.561733
NCT00501150|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2015-05-27|2007-07-12|2007-07-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2005||2005-09-30|November 2005|2005-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections|A Prospective Implementation of an IV-oral Switch Policy to Treat Proven or Suspected Infections Due to Resistant Gram Positive Bacteria in a London Hospital Trust|Completed||N/A|100|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 03:04:40.617292|2018-06-01 03:04:40.617292
NCT00501137|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2015-04-08|2007-07-12|2007-07-13|Estimate|||||||2015-04-08|2015-04-10|Estimate|July 2007||2007-07-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|February 2008|Actual|2008-02-29||Interventional|BCGov-01||A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine|A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine|Completed||Phase 3|830|Actual|University of British Columbia||3|||f||||t||||||||||2018-06-01 03:04:40.684729|2018-06-01 03:04:40.684729
NCT00501124|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2010-12-21|2007-07-12|2007-07-13|Estimate|||||||2010-12-21|2010-12-22|Estimate|May 2007||2007-05-31|August 2009|2009-08-31||||July 2010|Actual|2010-07-31||Interventional|||Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV|Phase IV Study to Evaluate the Safety and Efficacy of Clevudine Compared With Clevudine and Vaccine in Patients Chronically Infected With HBV, HBeAg(+)|Completed||Phase 4|70|Anticipated|Bukwang Pharmaceutical|||||f||||f||||||||||2018-06-01 03:04:40.761724|2018-06-01 03:04:40.761724
NCT00501111|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2014-07-22|2007-07-12|2007-07-13|Estimate|||||||2014-07-22|2014-07-23|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Sirocco||Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease|A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease|Completed||Phase 2|659|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 03:04:40.830454|2018-06-01 03:04:40.830454
NCT00501098|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2009-09-21|2007-07-12|2007-07-13|Estimate|||||||2009-09-21|2009-09-22|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PROFIL-C||Prophylaxis of Fungal Invasive Infections in Leukemia|A Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy of Caspofungin as Prophylactic Treatment of Invasive Fungal Infections in Patients With Acute Leukemia Undergoing Induction Chemotherapy|Completed||Phase 2|100|Anticipated|Northern Italy Leukemia Group||1|||f||||t||||||||||2018-06-01 03:04:41.110136|2018-06-01 03:04:41.110136
NCT00501085|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|2015-01-08||2015-01-15|2007-07-12|2007-07-13|Estimate|2015-01-15|2015-01-19|Estimate||||2015-01-15|2015-01-19|Estimate|June 2007||2007-06-30|January 2015|2015-01-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Observational||The analysis population is defined as the number of subjects who underwent treatment with the LAP-BAND System.|LAP-BAND AP Early Experience Trial (APEX)||Completed|||521|Actual|Apollo Endosurgery, Inc.|||1||f||||||||||||||2018-06-01 03:04:41.210444|2018-06-01 03:04:41.210444
NCT00501072|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2008-04-08|2007-07-12|2007-07-13|Estimate|||||||2008-04-08|2008-04-11|Estimate|November 2007||2007-11-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|IP_RT-CGMS||Safety and Efficacy of RT-CGMS in Patients With Type 1 Diabetes Mellitus Treated With an Implantable Pump|Use of a Real Time Continuous Glucose Monitoring System (RT-CGMS) in Type 1 Diabetes Patients on Continuous Intraperitoneal Insulin Infusion (CIPII. A Feasibility Study|Completed||N/A|12|Actual|Medical Research Foundation, The Netherlands||2|||f||||f||||||||||2018-06-01 03:04:41.484111|2018-06-01 03:04:41.484111
NCT00501059|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2017-11-15|2017-09-19|2018-01-04|2007-07-12|2007-07-13|Estimate|2018-01-04|2018-01-08|Actual|2017-09-19|2017-09-27|Actual|2018-01-04|2018-01-08|Actual|July 5, 2007|Actual|2007-07-05|January 2018|2018-01-31|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|ARRIVE||A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease|Completed||Phase 3|12546|Actual|Bayer|The reported analyses are limited to endpoint events that met strict criteria. Further blinded review of events is ongoing to identify endpoints based on pragmatic criteria. Interpretations for clinical decision making should await future reporting.|2|||f||||t||||||||||2018-06-01 03:04:41.704525|2018-06-01 03:04:41.704525
NCT00501046|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|2015-02-15|2012-10-01|2015-03-02|2007-07-11|2007-07-13|Estimate|2015-02-15|2015-03-02|Estimate|2012-10-01|2012-10-05|Estimate|2015-03-02|2015-03-20|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment of Quality of Life|Completed||Phase 3|1015|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||t||||||||||2018-06-01 03:04:47.097868|2018-06-01 03:04:47.097868
NCT00501033|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2008-05-02|2007-07-12|2007-07-13|Estimate|||||||2008-05-02|2008-05-08|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||A Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter|A Prospective Comparative Study of Induction of Labor With a Cervical Ripening Double Balloon vs Foley Catheter|Completed||N/A|200|Anticipated|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-06-01 03:04:48.396382|2018-06-01 03:04:48.396382
NCT00501020|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-10-05|2007-07-12|2007-07-13|Estimate|||||||2017-10-05|2017-10-09|Actual|June 5, 2001|Actual|2001-06-05|October 2017|2017-10-31|February 13, 2003|Actual|2003-02-13|February 13, 2003|Actual|2003-02-13||Interventional|||Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin|A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA When Added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy When Administered to Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|750||GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:04:48.454877|2018-06-01 03:04:48.454877
NCT00501007|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|2013-01-07||2017-07-13|2007-07-12|2007-07-13|Estimate|2013-12-06|2013-12-13|Estimate||||2017-07-13|2017-07-17|Actual|February 2005||2005-02-28|July 2017|2017-07-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Predictors of Treatment Outcome for Smokers With and Without Schizophrenia|Predictors of Treatment Outcome for Smokers With and Without Schizophrenia|Completed|||203|Actual|Rutgers, The State University of New Jersey|||2||f||||f||||||||||2018-06-01 03:04:48.552565|2018-06-01 03:04:48.552565
NCT00500981|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2012-07-25|2007-07-11|2007-07-13|Estimate|||||||2012-07-25|2012-07-26|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|October 2007|Actual|2007-10-31||Interventional|||Internal Jugular Vein Ultrasound Measures and Fluid Responsiveness in Post-Operative Cardiac Surgical Patients|Do Internal Jugular Vein Measurements Made By Ultrasound Correlate With Fluid Responsiveness in Ventilated Post-Operative Cardiac Surgical Patients?|Completed||Phase 1|40|Actual|University of Calgary||1|||f||||f||||||||||2018-06-01 03:04:48.782728|2018-06-01 03:04:48.782728
NCT00500968|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2011-04-06|2007-07-12|2007-07-13|Estimate|||||||2011-04-06|2011-04-07|Estimate|November 2006||2006-11-30|September 2007|2007-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail|Randomized Study Assessing the Effect of Transpapillary Pancreas Duct Stent in Resection of the Pancreatic Tail|Completed||N/A|50|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 03:04:48.839928|2018-06-01 03:04:48.839928
NCT00500955|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2016-09-13|2007-07-12|2007-07-13|Estimate|||||||2016-09-13|2016-09-15|Estimate|April 2000||2000-04-30|September 2016|2016-09-30|June 2004|Actual|2004-06-30|||||Interventional|||Rosiglitazone on Microalbuminuria in Type 2 Diabetics|A Study to Evaluate the Efficacy of Rosiglitazone (BRL-049653) on Reduction of Microalbuminuria in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|336||GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:04:49.170075|2018-06-01 03:04:49.170075
NCT00500942|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2012-08-01|2007-07-12|2007-07-13|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2003||2003-01-31|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Pain Quantification and Pain Management in Interventional Radiology (IR)|Pain Quantification and Management for Standard Interventional Radiology (IR) Procedures With Subsequent Patient Satisfaction Analysis|Completed|||374|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:04:49.446294|2018-06-01 03:04:49.446294
NCT00500929|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2009-03-23|2007-07-12|2007-07-13|Estimate|||||||2009-03-23|2009-03-25|Estimate|July 2007||2007-07-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|MiniMetrxics||A Clinical Trial in Higher Risk Geriatric Patients Undergoing OHSP|Mini-Metrxics: A Single-Centre, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Clinical Trial of CMI X-11S in Higher Risk Geriatric Patients Undergoing Open-Heart Surgical Procedures (OHSP)|Completed||Phase 2|80|Anticipated|Cardiometabolics|||||f||||t||||||||||2018-06-01 03:04:49.582409|2018-06-01 03:04:49.582409
NCT00500916|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2007-12-03|2007-07-11|2007-07-13|Estimate|||||||2007-12-03|2007-12-04|Estimate|March 2007||2007-03-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Different Techniques for Insertion of the ProSeal Laryngeal Mask Airway in Patients With Difficult Airway|Different Techniques for Insertion of the ProSeal Laryngeal Mask Airway in Patients With Difficult Airway|Completed||N/A|0|Anticipated|Medical University Innsbruck|||||f||||f||||||||||2018-06-01 03:04:49.645382|2018-06-01 03:04:49.645382
NCT00500903|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2013-11-15|2007-07-12|2007-07-13|Estimate|||||||2013-11-15|2013-11-18|Estimate|May 2007||2007-05-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|August 2010|Actual|2010-08-31||Interventional|||A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors|An Open-Label, Dose Escalation Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors|Completed||Phase 1|87|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 03:04:49.702556|2018-06-01 03:04:49.702556
NCT00500890|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2017-12-28|2007-07-11|2007-07-13|Estimate|||||||2017-12-28|2018-01-02|Actual|September 2, 2005|Actual|2005-09-02|December 2017|2017-12-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||Treatment of Tumors of the Choroid Plexus Epithelium|A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors|Completed||Phase 3|2|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 03:04:49.782536|2018-06-01 03:04:49.782536
NCT00500877|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2016-07-19|2007-07-11|2007-07-13|Estimate|||||||2016-07-19|2016-07-20|Estimate|February 2007||2007-02-28|July 2016|2016-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Mood Management Phone Counseling in Smoking Cessation|Mood Management Phone Counseling in Smoking Cessation|Completed||Phase 2|53|Actual|Butler Hospital||2|||f||||f||||||||||2018-06-01 03:04:49.878962|2018-06-01 03:04:49.878962
NCT00500864|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2008-06-27|2007-07-12|2007-07-13|Estimate|||||||2008-06-27|2008-07-02|Estimate|August 2004||2004-08-31|June 2008|2008-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Magnesium Loading in Chronic Obstructive Pulmonary Disease|Effects of Acute Intravenous Magnesium Loading on Pulmonary Function Parameters and Maximal Exercise Capacity of Patients With Chronic Obstructive Pulmonary Disease in Stable Clinical Conditions.|Completed||Phase 1/Phase 2|24|Actual|University of Sao Paulo|||||f||||f||||||||||2018-06-01 03:04:49.943501|2018-06-01 03:04:49.943501
NCT00500851|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2010-11-29|2007-07-12|2007-07-13|Estimate|||||||2010-11-29|2010-11-30|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Evaluation of Jejunal Placement of Enteral Feeding Tubes|Evaluation of Two Methods of Jejunal Placement of Enteral Feeding Tubes in Critically Ill Patients: Endoscopic Versus Electromagnetic Method (CORTRAK™)|Completed||N/A|66|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 03:04:50.021737|2018-06-01 03:04:50.021737
NCT00500838|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2016-05-18|2007-07-11|2007-07-13|Estimate|||||||2016-05-18|2016-05-20|Estimate|July 2007||2007-07-31|May 2016|2016-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Cardiac Resynchronization Therapy Defibrillator Based Impedance Monitoring Study|CRT-D Based Impedance Monitoring Feasibility Study|Completed||Phase 2|75|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 03:04:50.140525|2018-06-01 03:04:50.140525
NCT00500825|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2008-05-15|2007-07-11|2007-07-13|Estimate|||||||2008-05-15|2008-05-16|Estimate|July 2005||2005-07-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Observational|||Influence of Therapeutic Hypothermia on Resting Energy Expenditure|Influence of Therapeutic Hypothermia on Resting Energy Expenditure in Patients After Cardiopulmonary Resuscitation|Completed|||25|Actual|Medical University of Vienna|||1||f||||t||||||||||2018-06-01 03:04:50.278584|2018-06-01 03:04:50.278584
NCT00500812|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11||2015-03-09|2016-03-15|2007-07-11|2007-07-13|Estimate||||2015-03-09|2015-03-30|Estimate|2016-03-15|2016-04-14|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries|A Phase I/IIa Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA-210 and the Neurological Status of Patients Following Administration of a Single Extradural Application of Cethrin During Surgery for Acute Thoracic and Cervical Spinal Cord Injury|Completed||Phase 1/Phase 2|48|Actual|Vertex Pharmaceuticals Incorporated||5|||f||||t||||||||||2018-06-01 03:04:50.342411|2018-06-01 03:04:50.342411
NCT00500786|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2012-08-20|2007-07-12|2007-07-13|Estimate|||||||2012-08-20|2012-08-21|Estimate|November 2004||2004-11-30|August 2012|2012-08-31|April 2007|Actual|2007-04-30|September 2006|Actual|2006-09-30||Interventional|||Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb||Completed||Phase 1/Phase 2|88|Actual|Cytos Biotechnology AG||5|||f||||t||||||||||2018-06-01 03:04:50.707597|2018-06-01 03:04:50.707597
NCT00500773|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2014-04-30|2007-07-11|2007-07-13|Estimate|||||||2014-04-30|2014-05-01|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Observational|MMS||Investigation of Cardiac Function and Cardiovascular Risk Factors in Marathon Runners- The Munich Marathon Study|Investigation of Myocardial Injury, Ventricular Dysfunction and Cardiovascular Risk Factors in Different Groups of Marathon Runners|Completed|||60|Actual|Technische Universität München|||||f||||t||||||||||2018-06-01 03:04:50.767374|2018-06-01 03:04:50.767374
NCT00500760|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2014-02-13||2014-07-10|2007-07-12|2007-07-13|Estimate|2014-07-10|2014-08-05|Estimate||||2014-07-10|2014-08-05|Estimate|October 2007||2007-10-31|July 2014|2014-07-31|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|||Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer|A Phase 2, Randomized Trial of Chemoradiation With or Without Panitumumab in Subjects With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|153|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:04:50.867733|2018-06-01 03:04:50.867733
NCT00500747|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2011-06-09|2007-07-12|2007-07-13|Estimate|||||||2011-06-09|2011-06-10|Estimate|August 2003||2003-08-31|April 2010|2010-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Chiron Corp HCV E1/E2 Vaccine|A Phase I Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Chiron Corporation's HCV E1E2/MF59 Vaccine Administered to Healthy HCV-Negative Adults|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 03:04:51.642126|2018-06-01 03:04:51.642126
NCT00500734|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2018-05-09|2007-07-12|2007-07-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 10, 2002|Actual|2002-12-10|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Cardiomyopathy Tissue Bank in a Cancer Population|Cardiomyopathy Tissue Bank in a Cancer Population|Recruiting|||1000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood and tissue collection. This blood may be studied in the future to try to find possible~     genetic or biochemical markers that may be the cause of CHF.~   "|||2018-06-01 03:04:51.723793|2018-06-01 03:04:51.723793
NCT00500721|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2008-04-10|2007-07-11|2007-07-13|Estimate|||||||2008-04-10|2008-04-14|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine|An Open-Label, Single-Dose Desipramine, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Desipramine|Completed||Phase 1|22|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 03:04:51.802173|2018-06-01 03:04:51.802173
NCT00500708|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2017-10-17|2007-07-11|2007-07-13|Estimate|||||||2017-10-17|2017-10-19|Actual|July 2007||2007-07-31|October 2017|2017-10-31|August 1, 2011|Actual|2011-08-01|August 1, 2011|Actual|2011-08-01||Observational|DISCERN||Diagnostic Investigation of Sudden Cardiac Event Risk|Identifying Markers That Predict Ventricular Arrhythmia Risk|Completed|||1564|Actual|CardioDx|||||f||||f||||||Samples With DNA|"~     whole blood, buffy coat, spun plasma, saliva~   "|||2018-06-01 03:04:51.88371|2018-06-01 03:04:51.88371
NCT00500695|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-07-13|2007-07-12|2007-07-13|Estimate|||||||2017-07-13|2017-07-18|Actual|May 2006||2006-05-31|July 2017|2017-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness|Enhancing Motivation To Quit Smoking In Smokers With Serious Mental Illness|Completed||Phase 1|98|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 03:04:51.969063|2018-06-01 03:04:51.969063
NCT00500682|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|2015-02-15|2012-10-01|2015-03-02|2007-07-11|2007-07-13|Estimate|2015-02-15|2015-03-02|Estimate|2012-10-01|2012-10-05|Estimate|2015-03-02|2015-03-20|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease|Completed||Phase 3|1020|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||t||||||||||2018-06-01 03:04:52.097836|2018-06-01 03:04:52.097836
NCT00500669|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2017-04-10|2007-07-12|2007-07-13|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2004||2004-06-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Randomised Study to Assess Betadine in the Groin Wound of Patients Undergoing Primary Varicose Vein Surgery|A Randomised, Blinded Study to Assess the Effect of Betadine in the Groin Wound of Patients Undergoing Primary Varicose Vein Surgery|Terminated||Phase 3|60|Actual|Royal Hobart Hospital||2||Recruitement too slow|f||||f||||||||||2018-06-01 03:04:53.358967|2018-06-01 03:04:53.358967
NCT00500656|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|2013-10-30||2015-01-29|2007-07-12|2007-07-13|Estimate|2014-05-20|2014-06-09|Estimate||||2015-01-29|2015-02-16|Estimate|March 2005||2005-03-31|May 2014|2014-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|FAST2||Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)|Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE)|Completed||Phase 3|85|Actual|Shire||4|||f||||t||||||||||2018-06-01 03:04:53.536199|2018-06-01 03:04:53.536199
NCT00500630|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-12|||2007-07-12|2007-07-12|2007-07-13|Estimate|||||||2007-07-12|2007-07-13|Estimate||||July 2007|2007-07-31||||||||Interventional|||Objective Evaluation of Shoulder Pathology and Surgery||Completed||N/A|||University of Lausanne Hospitals|||||f||||||||||||||2018-06-01 03:04:54.383121|2018-06-01 03:04:54.383121
NCT00500617|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2018-02-21|2007-07-11|2007-07-13|Estimate|||||||2018-02-21|2018-02-23|Actual|July 2007||2007-07-31|February 2018|2018-02-28|September 2011|Actual|2011-09-30|January 2010|Actual|2010-01-31||Observational|PREDICT||Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree|Identification of Gene Expression Patterns in Circulating Cells That Predict the Presence of Coronary Artery Disease|Completed|||4350|Actual|CardioDx|||4||f||||f||||||Samples With DNA|"~     whole blood, buffy coat, spun plasma, RNA~   "|||2018-06-01 03:04:54.546691|2018-06-01 03:04:54.546691
NCT00500604|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2010-07-16|2007-07-11|2007-07-12|Estimate|||||||2010-07-16|2010-07-19|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|COSIMA2||Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension|A Comparative Study of the Efficacy of Irbesartan/Hydrochlorothiazide 300/25 mg Versus Valsartan/Hydrochlorothiazide 160/25 mg Using Home Blood Pressure Monitoring in the Treatment of Mild to Moderate Hypertension|Completed||Phase 4|1617|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:04:54.671181|2018-06-01 03:04:54.671181
NCT00500591|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-11-28|2007-07-11|2007-07-12|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2004|Actual|2004-06-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Prevalence of Endometrial Abnormalities In Obese Women|Prevalence of Endometrial Abnormalities In Obese Women|Active, not recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood samples used to look at different hormone levels related to risk of endometrial~     abnormalities. An endometrial biopsy will be performed to collect a tissue sample.~   "|||2018-06-01 03:04:54.764914|2018-06-01 03:04:54.764914
NCT00500578|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2010-06-01||2012-07-27|2007-07-11|2007-07-12|Estimate|2010-08-20|2010-09-16|Estimate||||2012-07-27|2012-08-01|Estimate|February 2003||2003-02-28|July 2012|2012-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Intermittent Use of Aerosolized Ribavirin for Treatment of RSV|A Randomized Study Evaluating Two Different Schedules of Aerosolized Ribavirin For Treatment of RSV Upper Respiratory Infections in Patients With Hematological Malignancies|Completed||Phase 4|51|Actual|M.D. Anderson Cancer Center|The interpretation of our data is limited by our study’s open-label design, which may bias assessments of tolerability or toxicity but would be less likely to bias assessments of therapeutic endpoints.|2|||f||||f||||||||||2018-06-01 03:04:54.844512|2018-06-01 03:04:54.844512
NCT00500565|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2013-10-10|2007-07-11|2007-07-12|Estimate|||||||2013-10-10|2013-10-11|Estimate|December 2003||2003-12-31|October 2013|2013-10-31|June 2008|Actual|2008-06-30|June 2006|Actual|2006-06-30||Interventional|||Pain Management Following TRAM Flap for Breast Reconstruction|Randomized, Double Blind, Controlled Trial of Two Methods of Postoperative Pain Management Following Free Transverse Rectus Abdominous Musculocutaneous (TRAM) Flap for Breast Reconstruction|Completed||N/A|61|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:04:55.166783|2018-06-01 03:04:55.166783
NCT00500552|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2010-11-03|2007-07-10|2007-07-12|Estimate|||||||2010-11-03|2010-11-04|Estimate|December 2006||2006-12-31|August 2010|2010-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|METAL-HCM||Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy|Metabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)|Completed||Phase 2|44|Anticipated|University Hospital Birmingham|||||f||||t||||||||||2018-06-01 03:04:55.262565|2018-06-01 03:04:55.262565
NCT00500539|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|2010-11-17||2011-05-31|2007-07-11|2007-07-12|Estimate|2011-03-30|2011-04-27|Estimate||||2011-05-31|2011-06-02|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.|An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma|Completed||Phase 3|155|Actual|Novartis|||||f||||||||||||||2018-06-01 03:04:55.354379|2018-06-01 03:04:55.354379
NCT00500526|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2008-06-27|2007-07-11|2007-07-12|Estimate|||||||2008-06-27|2008-07-02|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Singing in Chronic Obstructive Pulmonary Disease|Effects of Singing on Dyspnea, Quality of Life and Pulmonary Function Parameters of COPD Patients in Stable Conditions.|Completed||Phase 1/Phase 2|43|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 03:04:55.853433|2018-06-01 03:04:55.853433
NCT00500513|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2013-01-30|2007-07-10|2007-07-12|Estimate|||||||2013-01-30|2013-02-01|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|June 2007|Actual|2007-06-30||Interventional|||Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials|Assessment of the Reliability of Implanted Fiducials for Tracking of Respiratory-Induced Tumor Motion|Completed||N/A|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:55.936453|2018-06-01 03:04:55.936453
NCT00500500|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2013-10-10|2007-07-11|2007-07-12|Estimate|||||||2013-10-10|2013-10-11|Estimate|July 2005||2005-07-31|October 2013|2013-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease|Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.|Terminated||Phase 2|40|Actual|Ipsen||2||Inability to recruit sufficient number of patients|f||||||||||||||2018-06-01 03:04:56.021295|2018-06-01 03:04:56.021295
NCT00500487|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2015-01-09|2007-07-11|2007-07-12|Estimate|||||||2015-01-09|2015-01-12|Estimate|April 2003||2003-04-30|October 2009|2009-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Therapeutic Schools: Affect Management and HIV Prevention|Therapeutic Schools: Affect Management and HIV Prevention|Completed||Phase 1|420|Anticipated|Rhode Island Hospital||3|||f||||t||||||||||2018-06-01 03:04:56.102772|2018-06-01 03:04:56.102772
NCT00500474|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2007-07-23|2007-07-11|2007-07-12|Estimate|||||||2007-07-23|2007-07-25|Estimate|April 1996||1996-04-30|July 2007|2007-07-31|March 2005|Actual|2005-03-31|||||Interventional|EDSS||Effects of Endolymphatic Sac Drainage With Steroids for Meniere’s Disease|Clinical Study of Endolymphatic Sac Drainage With or Without Steroids for Intractable Meniere's Disease|Completed||N/A|197|Actual|Osaka University|||||f||||t||||||||||2018-06-01 03:04:56.232176|2018-06-01 03:04:56.232176
NCT00500461|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-08-03|2007-07-10|2007-07-12|Estimate|||||||2017-08-03|2017-08-07|Actual|June 4, 2007|Actual|2007-06-04|August 2017|2017-08-31|July 25, 2007|Actual|2007-07-25|July 1, 2007|Actual|2007-07-01||Interventional|||Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705|A Single-centre, Open-label, Sequential Ascending Cross Over Study to Examine Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Ascending Single Doses, Nominally 10, 30, 70 and 110µg Intravenous Doses and a Single 250µg Oral Dose of GSK233705 in Healthy Volunteers.|Completed||Phase 1|9|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:04:56.368374|2018-06-01 03:04:56.368374
NCT00500448|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2015-04-26||2016-07-18|2007-07-10|2007-07-12|Estimate|2016-07-18|2016-08-29|Estimate||||2016-07-18|2016-08-29|Estimate|July 2007||2007-07-31|July 2016|2016-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||An Intervention of Electrical Stimulation in Osteoarthritis|The Efficacy of Neuromuscular Electrical Stimulation for Improving Quadriceps Activation in Women With Medial Tibiofemoral Osteoarthritis|Completed||N/A|30|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 03:04:56.484691|2018-06-01 03:04:56.484691
NCT00500435|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2012-03-22|2007-07-10|2007-07-12|Estimate|||||||2012-03-22|2012-03-26|Estimate|October 2003||2003-10-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Extraperitoneal Lymph Node Dissection in Patients With Cervical Cancer|A Pilot Study of Laparoscopic Extraperitoneal Lymph Node Dissection in Patients With Locally Advanced Cervical Cancer|Completed|||65|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:04:56.872653|2018-06-01 03:04:56.872653
NCT00500422|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2013-02-11|2007-07-10|2007-07-12|Estimate|||||||2013-02-11|2013-02-13|Estimate|January 2005||2005-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients|Phase I Study of a Combination of Doxil, Velcade, and Gemcitabine in Advanced Cancer|Completed||Phase 1|134|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:04:56.945853|2018-06-01 03:04:56.945853
NCT00500409|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2014-12-15|2007-07-11|2007-07-12|Estimate|||||||2014-12-15|2014-12-16|Estimate|December 2005||2005-12-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis|Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis. A Randomized Controlled Open-label Multicentre Study in India|Completed||Phase 3|82|Actual|Virchow Group||2|||f||||f||||||||||2018-06-01 03:04:57.024024|2018-06-01 03:04:57.024024
NCT00500396|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2007-11-21|2007-07-10|2007-07-12|Estimate|||||||2007-11-21|2007-11-26|Estimate|March 2007||2007-03-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Vascular Endothelial Growth Factor in Stage V ROP|Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V.|Completed||Phase 4|15|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||f||||||||||2018-06-01 03:04:57.104952|2018-06-01 03:04:57.104952
NCT00500383|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2016-03-22|2007-07-11|2007-07-12|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Observational|||Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)|Breast Cancer Risk Assessment Using Optical Breast Spectroscopy (OBS)|Completed|||372|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 03:04:57.18952|2018-06-01 03:04:57.18952
NCT00500370|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2009-02-26||2015-03-19|2007-07-10|2007-07-12|Estimate|2009-07-30|2009-09-04|Estimate||||2015-03-19|2015-04-07|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients|A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients|Completed||Phase 2|163|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:04:57.267343|2018-06-01 03:04:57.267343
NCT00500357|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2011-01-21|2009-01-21|2011-04-15|2007-07-10|2007-07-12|Estimate|2011-01-21|2011-02-17|Estimate|2009-09-24|2009-09-28|Estimate|2011-04-15|2011-04-19|Estimate|November 2007||2007-11-30|April 2011|2011-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects|A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine Administered to One Group of Individuals Who Participated in Study 6115A1-500|Completed||Phase 3|105|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 03:04:57.860352|2018-06-01 03:04:57.860352
NCT00500344|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2018-04-30|2007-07-11|2007-07-12|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2007||2007-07-31|April 2018|2018-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|CAPTAIN||CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography|CAPTAIN: Choroidal Neovascularization Assessment by Pattern Electroretinography After Ranibizumab in Naive Age-related Macular Degeneration Patients|Completed||Phase 1|17|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 03:04:59.572676|2018-06-01 03:04:59.572676
NCT00500331|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|2017-09-26|2009-07-22|2017-11-02|2007-07-10|2007-07-12|Estimate|2017-11-02|2017-12-06|Actual|2009-07-23|2009-08-10|Estimate|2017-11-02|2017-12-06|Actual|January 23, 2007|Actual|2007-01-23|September 2017|2017-09-30|February 14, 2008|Actual|2008-02-14|February 14, 2008|Actual|2008-02-14||Interventional|||Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)|A Double-blind, Randomized 12-week Study to Evaluate the Safety and Efficacy of GSK189075 Tablets vs Pioglitazone in Treatment Naive Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|334|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:04:59.818338|2018-06-01 03:04:59.818338
NCT00500318|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2012-08-14|2011-09-09|2016-11-16|2007-07-10|2007-07-12|Estimate|2012-11-16|2012-12-17|Estimate|2011-09-09|2011-09-21|Estimate|2016-11-16|2017-01-06|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|December 2008|Actual|2008-12-31||Interventional|||A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide (LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe COPD|Completed||Phase 3|181|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:05:01.844727|2018-06-01 03:05:01.844727
NCT00500305|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2018-05-01|2007-07-10|2007-07-12|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2004||2004-04-30|May 2018|2018-05-31|March 2007|Actual|2007-03-31|||||Interventional|||The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants||Completed||N/A|60|Actual|University of Virginia|||||f||||f||||||||||2018-06-01 03:05:02.413984|2018-06-01 03:05:02.413984
NCT00500292|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2011-04-27||2018-01-24|2007-07-11|2007-07-12|Estimate|2011-04-27|2011-05-24|Estimate||||2018-01-24|2018-01-25|Actual|March 2007||2007-03-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|March 2008|Actual|2008-03-31||Interventional|||A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer|A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Irinotecan and Fluoropyrimidine Regimen|Completed||Phase 2|109|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:05:02.517445|2018-06-01 03:05:02.517445
NCT00500279|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2007-07-10|2007-07-10|2007-07-12|Estimate|||||||2007-07-10|2007-07-12|Estimate|November 2006||2006-11-30|July 2007|2007-07-31|October 2009|Anticipated|2009-10-31|||||Interventional|mini-COREA||Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial||Unknown status|Recruiting|Phase 4|900|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-06-01 03:05:02.99437|2018-06-01 03:05:02.99437
NCT00500253|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2013-02-06|2007-07-11|2007-07-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|February 2007||2007-02-28|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma|Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma|Unknown status|Recruiting|Phase 4|120|Anticipated|Medical Universtity of Lodz||2|||f||||t||||||||||2018-06-01 03:05:03.100858|2018-06-01 03:05:03.100858
NCT00499733|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2011-02-24|2007-07-10|2007-07-11|Estimate|||||||2011-02-24|2011-02-25|Estimate|June 2007||2007-06-30|July 2009|2009-07-31||||July 2010|Anticipated|2010-07-31||Interventional|||Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer|Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer|Unknown status|Recruiting|N/A|23|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:05:12.060493|2018-06-01 03:05:12.060493
NCT00500240|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-06-05||2015-06-02|2007-07-11|2007-07-12|Estimate|2014-07-14|2014-08-07|Estimate||||2015-06-02|2015-06-03|Estimate|April 2004||2004-04-30|June 2015|2015-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)|Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia|Terminated||Phase 3|52|Actual|M.D. Anderson Cancer Center|Study terminated early due to futility at the pre-determined interim analysis point.|2||Terminated early due to futility.|f||||f||||||||||2018-06-01 03:05:04.302522|2018-06-01 03:05:04.302522
NCT00500227|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2012-07-30|2007-07-11|2007-07-12|Estimate|||||||2012-07-30|2012-07-31|Estimate|September 2007||2007-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|ESPORA||Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery|Observational Study to Evaluate, in Acromegalic Patients With Disease Persistence After Surgery, Those Histopathologic, Clinical, Morphologic and Biochemical Factors Predictors of Hormonal Control Under Somatostatin Analogue Treatment|Completed|||55|Actual|Ipsen|||||f||||||||||||||2018-06-01 03:05:04.587419|2018-06-01 03:05:04.587419
NCT00500214|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2007-07-11|2007-07-11|2007-07-12|Estimate|||||||2007-07-11|2007-07-12|Estimate|April 2005||2005-04-30|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Ilioinguinal Nerve Excision in Open Mesh Repair of Inguinal Hernia,a Randomized Clinical Trial||Completed||Phase 2|||Shahid Beheshti University of Medical Sciences|||||f||||f||||||||||2018-06-01 03:05:04.693975|2018-06-01 03:05:04.693975
NCT00500201|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-08-05|2007-07-10|2007-07-12|Estimate|||||||2017-08-05|2017-08-08|Actual|May 24, 2007|Actual|2007-05-24|August 2017|2017-08-31|July 25, 2007|Actual|2007-07-25|July 25, 2007|Actual|2007-07-25||Interventional|||A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.|A Single Blind, Double Dummy, Placebo Controlled, Randomized, 2 Period Crossover Study to Assess the Relative Bioavailability of a 120mg Tablet Compared to Two 60 mg SB-773812 Tablets in Healthy Volunteers|Completed||Phase 1|18|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:05:04.75584|2018-06-01 03:05:04.75584
NCT00500188|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2011-08-04|2007-07-10|2007-07-12|Estimate|||||||2011-08-04|2011-08-08|Estimate|July 2003||2003-07-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST|A Prospective, Randomized, Phase II Study of Preoperative Plus Postoperative Imatinib Mesylate (Gleevec, Formerly STI-571) in Patients With Primary, Recurrent, or Metastatic Resectable, Kit-Expressing, Gastrointestinal Stromal Tumor (GIST)|Completed||Phase 2|28|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-06-01 03:05:04.833449|2018-06-01 03:05:04.833449
NCT00500175|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2007-07-11|2007-07-11|2007-07-12|Estimate|||||||2007-07-11|2007-07-12|Estimate|January 2007||2007-01-31|July 2007|2007-07-31|June 2008|Anticipated|2008-06-30|||||Interventional|TempTouchRM||Novel Home Care Device for High-Risk Diabetic Patients|Novel Home Care Device for High-Risk Diabetic Patients|Unknown status|Recruiting|N/A|110|Anticipated|Diabetica Solutions Inc.|||||f||||t||||||||||2018-06-01 03:05:05.021589|2018-06-01 03:05:05.021589
NCT00500162|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2009-03-05|2007-07-11|2007-07-12|Estimate|||||||2009-03-05|2009-03-06|Estimate|November 2006||2006-11-30|March 2009|2009-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|CLARA||Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma|Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma|Completed||Phase 4|340|Actual|Galderma||2|||f||||f||||||||||2018-06-01 03:05:05.105511|2018-06-01 03:05:05.105511
NCT00500149|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2008-12-02||2015-03-03|2007-07-10|2007-07-12|Estimate|2009-06-04|2009-06-05|Estimate||||2015-03-03|2015-03-23|Estimate|June 2007||2007-06-30|February 2011|2011-02-28|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)|A Phase IIIb, Randomized, Double-Blind, Multi-Center, Placebo- Controlled, Dose-Optimization, Cross-Over, Analog Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|129|Actual|Shire||2|||f||||||||||||||2018-06-01 03:05:05.219538|2018-06-01 03:05:05.219538
NCT00500136|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2016-10-03|2007-07-10|2007-07-12|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Psychosocial Effect of Thoughts of Personal Mortality on Cardiac Risk Assessment by Medical Students|The Effects of Religion and Motivation on Medical Decision Making: A Terror Management Approach|Completed||N/A|49|Actual|University of Missouri-Columbia|||||f||||t||||||||Undecided||2018-06-01 03:05:05.617433|2018-06-01 03:05:05.617433
NCT00500123|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2018-01-21|2007-07-11|2007-07-12|Estimate|||||||2018-01-21|2018-01-23|Actual|January 2001||2001-01-31|January 2018|2018-01-31|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31|50 Years|Observational [Patient Registry]|ACT||Alpha-1 Coded Testing(ACT) Study|Alpha-1 Coded Testing(ACT) Study|Recruiting|||50000|Anticipated|Medical University of South Carolina|||||f||||t||||||Samples With DNA|"~     A blood card is mailed to the participants home. The provide lancet is used for fingerstick~     collection of sufficient bloodspots to genotype for alpha-1 antitrypsin (AAT) deficiency~     alleles and to estimate an AAT level.~   "|Yes|Data sharing is encouraged by MUSC coordinator contact|2018-06-01 03:05:05.725157|2018-06-01 03:05:05.725157
NCT00500110|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2011-07-11||2015-04-06|2007-07-11|2007-07-12|Estimate|2011-07-11|2011-08-04|Estimate||||2015-04-06|2015-04-28|Estimate|June 2003||2003-06-30|August 2012|2012-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer|Neoadjuvant Hormonal Ablation, Imatinib Mesylate and Docetaxel Followed by Radical Prostatectomy for High-Risk Localized Prostate Cancer|Completed||Phase 2|39|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:05:05.840803|2018-06-01 03:05:05.840803
NCT00500097|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2007-07-27|2007-07-11|2007-07-12|Estimate|||||||2007-07-27|2007-07-31|Estimate|May 2005||2005-05-31|July 2007|2007-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Diabetic Retinopathy and Diabetic Macular Edema Screening by Non-Physicians With Limited Training||Completed||N/A|840|Actual|Ministry of Health, Thailand|||||f||||t||||||||||2018-06-01 03:05:06.101653|2018-06-01 03:05:06.101653
NCT00500084|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10||2010-12-13|2014-10-15|2007-07-10|2007-07-12|Estimate||||2010-12-13|2010-12-16|Estimate|2014-10-15|2014-10-24|Estimate|December 2007||2007-12-31|October 2014|2014-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|DIGEST CP||Phase III ALTU-135 CP Safety Trial|An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy|Terminated||Phase 3|39|Actual|Anthera Pharmaceuticals||1||Sponsor decision.|f||||t||||||||||2018-06-01 03:05:06.190772|2018-06-01 03:05:06.190772
NCT00498316|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2016-10-27|2007-07-09|2007-07-10|Estimate|||||||2016-10-27|2016-10-31|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Cord Blood Expansion on Mesenchymal Stem Cells|Cord Blood Expansion on Mesenchymal Stem Cells|Completed||Phase 1|98|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:05:56.555203|2018-06-01 03:05:56.555203
NCT00500071|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2009-05-26||2011-01-14|2007-07-10|2007-07-12|Estimate|2009-07-20|2009-09-01|Estimate||||2011-01-14|2011-01-19|Estimate|July 2007||2007-07-31|January 2011|2011-01-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD|A Prospective, Open-Label, Multi-Center, Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) 20-70mg in Children Aged 6-12 Diagnosed With ADHD|Completed||Phase 4|318|Actual|Shire||1|||f||||||||||||||2018-06-01 03:05:06.337498|2018-06-01 03:05:06.337498
NCT00500058|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-07-24|2007-07-10|2007-07-12|Estimate|||||||2017-07-24|2017-07-26|Actual|July 31, 2007|Actual|2007-07-31|July 2017|2017-07-31|March 4, 2010|Actual|2010-03-04|March 4, 2010|Actual|2010-03-04||Interventional|||A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18|"A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma"|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:05:06.853074|2018-06-01 03:05:06.853074
NCT00500045|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-04-06|2007-07-10|2007-07-12|Estimate|||||||2017-04-06|2017-04-10|Actual|February 2007||2007-02-28|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions|"Retrospective Study of Niacin (as a Vasodilator), Combined With a Topical Steroid (for Macular Edema), For CRVO, HRVO, BRVO."|Completed||Phase 2/Phase 3|36|Actual|Palo Alto Medical Foundation||1|||f||||f||||||||||2018-06-01 03:05:06.989167|2018-06-01 03:05:06.989167
NCT00500032|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2009-09-15|2007-07-11|2007-07-12|Estimate|||||||2009-09-15|2009-09-16|Estimate|March 2007||2007-03-31|September 2009|2009-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Blood Collection for Use in Serological Assay Development From Healthy Adult Volunteers|Blood Collection for Use in Serological Assay Development From Healthy Adult Volunteers Who Completed Study 6108A1-500|Completed||N/A|87|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 03:05:07.078409|2018-06-01 03:05:07.078409
NCT00500019|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2009-03-30|2007-07-11|2007-07-12|Estimate|||||||2009-03-30|2009-03-31|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|September 2008|Actual|2008-09-30|||||Observational|||Uterine Flora During Elective and Urgent Cesarean Sections|Uterine Flora During Elective and Urgent Cesarean Sections and Its Relationship to Postpartum Complications.|Completed|||600|Anticipated|Western Galilee Hospital-Nahariya|||2||f||||t||||||Samples Without DNA|"~     Uterine bacteriological cultures~   "|||2018-06-01 03:05:07.172743|2018-06-01 03:05:07.172743
NCT00500006|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2015-01-29|2007-07-11|2007-07-12|Estimate|||||||2015-01-29|2015-01-30|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)|A Phase I Dose Escalation of MK0457 in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|Terminated||Phase 1|3|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:05:07.258617|2018-06-01 03:05:07.258617
NCT00499993|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2009-12-21|2007-07-11|2007-07-12|Estimate|||||||2009-12-21|2009-12-22|Estimate|January 2001||2001-01-31|December 2009|2009-12-31|May 2003|Actual|2003-05-31|||||Interventional|||Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly|Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly|Completed||Phase 3|63|Actual|Ipsen|||||f||||||||||||||2018-06-01 03:05:07.355922|2018-06-01 03:05:07.355922
NCT00499980|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2007-07-11|2007-07-11|2007-07-12|Estimate|||||||2007-07-11|2007-07-12|Estimate|March 2005||2005-03-31|July 2007|2007-07-31|August 2005|Actual|2005-08-31|||||Observational|NIR||Near Infrared/ Ultrasound Dual Modal Imaging for Breast Cancer Diagnosis|A Prospective Pilot Clinical Trial Evaluating the Utility of a Dynamic Near Infrared Imaging Device for Characterizing Suspicious Breast Lesions|Completed|||50|Actual|Ohio State University|||||f||||t||||||||||2018-06-01 03:05:07.476367|2018-06-01 03:05:07.476367
NCT00499967|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2009-04-07|2007-07-10|2007-07-12|Estimate|||||||2009-04-07|2009-04-09|Estimate|August 2007||2007-08-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection|Completed||Phase 1|202|Actual|Gilead Sciences||6|||f||||f||||||||||2018-06-01 03:05:07.551997|2018-06-01 03:05:07.551997
NCT00499954|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2007-07-11|2007-07-11|2007-07-12|Estimate|||||||2007-07-11|2007-07-12|Estimate|February 2006||2006-02-28|April 2006|2006-04-30||||||||Observational|||Investigation of Correlation Between Concentrations of Glucose in Blood and Interstitial Fluid in Type 1 Diabetics|An Open, Mono-Centre Trial to Investigate the Correlation Between Concentrations of Glucose in Arterialized Venous Blood and Subcutaneous Interstitial Fluid Applying Different Extracorporeal Sensor Techniques in Type 1 Diabetics|Completed|||16|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 03:05:07.694662|2018-06-01 03:05:07.694662
NCT00499941|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2018-01-21|2007-07-11|2007-07-12|Estimate|||||||2018-01-21|2018-01-23|Actual|April 2000||2000-04-30|January 2018|2018-01-31|June 2050|Anticipated|2050-06-30|June 2050|Anticipated|2050-06-30|50 Years|Observational [Patient Registry]|||Alpha-1 Foundation Research Registry|Alpha-1 Foundation Research Registry|Recruiting|||10000|Anticipated|Medical University of South Carolina|||||f||||t||||||||Yes|Data sharing is encouraged by coordinator contact at MUSC|2018-06-01 03:05:07.77036|2018-06-01 03:05:07.77036
NCT00499928|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2009-05-15|2007-07-10|2007-07-12|Estimate|||||||2009-05-15|2009-05-18|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women|An Open-Label Study to Investigate the Excretion and Metabolic Disposition of a Single, Oral Dose of [14C]-SB-751689 (a Calcium-Sensing Receptor Antagonist) in Healthy Male Subjects and Healthy Postmenopausal Female Subjects|Completed||Phase 1|6|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:05:07.863232|2018-06-01 03:05:07.863232
NCT00499915|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2015-09-15||2015-10-20|2007-07-10|2007-07-12|Estimate|2015-10-20|2015-11-23|Estimate||||2015-10-20|2015-11-23|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||NICU Asthma Education and Secondhand Smoke Reduction Study|Preventing Respiratory Illness Among Premature Infants: An Asthma Education and Secondhand Smoke Reduction Study|Completed||N/A|165|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 03:05:07.93285|2018-06-01 03:05:07.93285
NCT00499902|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2008-04-22|2007-07-10|2007-07-12|Estimate|||||||2008-04-22|2008-04-24|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke|Phase 2, Multicenter, Open-Label, Two-Stage Study to Evaluate the Safety and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Function and Rapid Opening of Arteries in Stroke (CARNEROS-1)|Terminated||Phase 2|7|Actual|ARCA Biopharma, Inc.||1||"CO Phase 2 data did not show sufficient improvement in cath opening at higher~   dose/concentration evaluated. Nuvelo ended further clinical dev of alfimeprase."|f||||t||||||||||2018-06-01 03:05:08.168194|2018-06-01 03:05:08.168194
NCT00499889|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2011-09-30||2012-04-19|2007-07-11|2007-07-12|Estimate|2011-09-30|2011-11-07|Estimate||||2012-04-19|2012-04-23|Estimate|February 2003||2003-02-28|April 2012|2012-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients|Imatinib Mesylate, Busulfan, Fludarabine, Antithymocyte Globulin and Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia|Terminated||Phase 2|42|Actual|M.D. Anderson Cancer Center|Study completed early due to support issues.|1||Support issue.|f||||f||||||||||2018-06-01 03:05:08.445675|2018-06-01 03:05:08.445675
NCT00499876|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2017-01-25|2007-07-11|2007-07-12|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2007||2007-10-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||The Effect of Malaria on Disease Progression of HIV/AIDS|The Effect of Malaria on Disease Progression of HIV/AIDS in Kumasi, Ghana|Completed||N/A|197|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 03:05:08.756303|2018-06-01 03:05:08.756303
NCT00499863|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2009-04-24||2017-03-27|2007-07-11|2007-07-12|Estimate|2009-04-24|2009-06-11|Estimate||||2017-03-27|2017-04-26|Actual|July 2007||2007-07-31|March 2017|2017-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD|A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD|Completed||Phase 3|217|Actual|Noven Therapeutics||2|||f||||f||||||||No||2018-06-01 03:05:08.88306|2018-06-01 03:05:08.88306
NCT00499850|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2016-08-24|2007-07-11|2007-07-12|Estimate|||||||2016-08-24|2016-08-25|Estimate|August 2005||2005-08-31|August 2016|2016-08-31|April 2008|Actual|2008-04-30|June 2006|Actual|2006-06-30||Interventional|||Phase I FOLFOX Combination|A Phase I,Open Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as First and Second Line Therapy in Patients With Advanced Colorectal Adenocarcinoma.|Completed||Phase 1|18|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:05:09.490957|2018-06-01 03:05:09.490957
NCT00499837|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-11|||2016-06-08|2007-07-11|2007-07-12|Estimate|||||||2016-06-08|2016-06-09|Estimate|September 2007||2007-09-30|April 2016|2016-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients|Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients|Completed||Phase 2|21|Actual|Kamada, Ltd.||2|||f||||f||||||||No||2018-06-01 03:05:09.581487|2018-06-01 03:05:09.581487
NCT00500266|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2011-08-11|2010-03-02|2011-08-11|2007-07-10|2007-07-11|Estimate|2011-08-11|2011-09-16|Estimate|2010-03-02|2010-03-03|Estimate|2011-08-11|2011-09-16|Estimate|May 2008||2008-05-31|August 2011|2011-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects|A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, & Reactogenicity of a 13vPnC Vaccine in Ambulatory Elderly Adults Aged 68 Years & Older Who Received 1 or More Doses of 23vPS Vaccine at Least 3 Years Before Study Enrollment|Completed||Phase 3|1053|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:05:09.745991|2018-06-01 03:05:09.745991
NCT00499824|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2010-05-03|2007-07-10|2007-07-11|Estimate|||||||2010-05-03|2010-05-04|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|GIANT||GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets|GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets|Completed||N/A|386|Actual|International Diabetes Institute, Australia||2|||f||||f||||||||||2018-06-01 03:05:10.638424|2018-06-01 03:05:10.638424
NCT00499811|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2014-02-21|2007-07-10|2007-07-11|Estimate|||||||2014-02-21|2014-02-24|Estimate|June 2007||2007-06-30|October 2011|2011-10-31||||August 2011|Actual|2011-08-31||Interventional|||Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction|Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction|Completed||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:05:10.824959|2018-06-01 03:05:10.824959
NCT00499798|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-05-25|2007-07-10|2007-07-11|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2004||2004-08-31|July 2013|2013-07-31|September 2014|Actual|2014-09-30|June 2009|Actual|2009-06-30||Observational|||Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors|Temozolomide Induced Changes in Semen/Sperm Analysis in Men With Newly Diagnosed, Progressive or Recurrent Primary Malignant Brain Tumors|Completed|||16|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-06-01 03:05:10.975421|2018-06-01 03:05:10.975421
NCT00499785|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-05-25|2007-07-10|2007-07-11|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2007||2007-06-30|October 2015|2015-10-31|January 2012|Actual|2012-01-31|January 2009|Actual|2009-01-31||Observational|||Physical and Mental Assessment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Inpatient Functional and Cognitive Assessment in Older Adults With Acute Myelogenous Leukemia|Completed|||11|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-06-01 03:05:11.07248|2018-06-01 03:05:11.07248
NCT00499759|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2012-03-05|2007-07-10|2007-07-11|Estimate|||||||2012-03-05|2012-03-06|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|August 2009|Actual|2009-08-31|January 2007|Actual|2007-01-31||Interventional|||Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia|In-Hospital Individualized Prescriptive Exercise Intervention for Acute Leukemia Patients Undergoing Chemotherapy|Completed||N/A|10|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 03:05:11.145939|2018-06-01 03:05:11.145939
NCT00499746|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2012-08-18||2017-09-14|2007-07-10|2007-07-11|Estimate|2017-09-14|2017-10-17|Actual||||2017-09-14|2017-10-17|Actual|November 2007||2007-11-30|September 2017|2017-09-30|August 2011|Actual|2011-08-31|April 2010|Actual|2010-04-30||Interventional|||The Discriminative Effects of Tramadol in Humans|Medications Development for Drug Abuse Disorders|Completed||Phase 1/Phase 2|20|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||f||||||||||2018-06-01 03:05:11.262978|2018-06-01 03:05:11.262978
NCT00499720|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2011-07-29|2007-07-09|2007-07-11|Estimate|||||||2011-07-29|2011-08-02|Estimate||||July 2011|2011-07-31||||||||Expanded Access|||Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection|Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression|Approved for marketing|||||Gilead Sciences|||||||||||||||||||2018-06-01 03:05:12.200565|2018-06-01 03:05:12.200565
NCT00499707|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2018-03-19|2007-07-09|2007-07-11|Estimate|||||||2018-03-19|2018-03-21|Actual|October 8, 2003||2003-10-08|March 2018|2018-03-31|December 16, 2004|Actual|2004-12-16|December 1, 2004|Actual|2004-12-01||Interventional|||Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects|A Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Fixed Dose Rosiglitazone/Metformin Combination Therapy Compared to Both Rosiglitazone and Metformin Monotherapies in Drug Naive Type 2 Diabetes Mellitus Subjects|Completed||Phase 3|453|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:05:12.418098|2018-06-01 03:05:12.418098
NCT00499694|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2014-08-09||2018-02-11|2007-07-10|2007-07-11|Estimate|2014-08-09|2014-08-25|Estimate||||2018-02-11|2018-03-12|Actual|October 2007||2007-10-31|February 2018|2018-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel|Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer|Completed||N/A|31|Actual|Barbara Ann Karmanos Cancer Institute|Small sample size, correlative ERCC testing conducted in only a subset of patients (14 of 30 pts) and the findings of this study are hypothesis generating however validation in larger sample size would be needed.|1|||f||||t||||||||||2018-06-01 03:05:12.681457|2018-06-01 03:05:12.681457
NCT00499681|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2011-10-17||2012-08-07|2007-07-10|2007-07-11|Estimate|2012-06-07|2012-07-10|Estimate||||2012-08-07|2012-08-10|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE|A Phase II Neo-Adjuvant Study of Letrozole in Combination With Lapatinib in Post -Menopausal Patients With HER2-Positive and Hormone Receptor-Positive Operable Breast Cancer|Terminated||Phase 2|6|Actual|Vanderbilt-Ingram Cancer Center|Due to the restrictive nature of the eligibility criteria, only a total of 6 out of the planned 36 patients were accrued in 2 years, leading to early termination of the study. Hence, both clinical and correlative data were deemed uninterpretable.|2||slow accrual|f||||t||||||||||2018-06-01 03:05:12.963133|2018-06-01 03:05:12.963133
NCT00499668|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2013-03-29|2007-07-10|2007-07-11|Estimate|||||||2013-03-29|2013-04-02|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer|A Pilot Study of Aprepitant Versus Ondansetron for the Treatment of Opioid Induced Nausea and Vomiting|Withdrawn||N/A|0|Actual|Vanderbilt-Ingram Cancer Center||2||slow accrual|f||||t||||||||||2018-06-01 03:05:13.389019|2018-06-01 03:05:13.389019
NCT00499655|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2017-01-06||2017-02-28|2007-07-10|2007-07-11|Estimate|2017-01-06|2017-03-01|Actual||||2017-02-28|2017-03-29|Actual|November 2007||2007-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer|A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Erlotinib (Tarceva) and Celecoxib (Celebrex) Versus Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients|Completed||Phase 2|107|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 03:05:13.548391|2018-06-01 03:05:13.548391
NCT00499642|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2007-12-19|2007-07-10|2007-07-11|Estimate|||||||2007-12-19|2007-12-28|Estimate|June 2007||2007-06-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating the Effect of Lecozotan SR on the QTc Interval|A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:05:13.916011|2018-06-01 03:05:13.916011
NCT00499629|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2008-03-12|2007-07-10|2007-07-11|Estimate|||||||2008-03-12|2008-03-13|Estimate|October 2007||2007-10-31|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study Evaluating the Safety of FXR-450 in Healthy Subjects|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of FXR-450 Administered Orally to Healthy Subjects|Completed||Phase 1|64|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:05:14.001784|2018-06-01 03:05:14.001784
NCT00499616|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2015-12-01||2017-06-26|2007-07-10|2007-07-11|Estimate|2017-05-22|2017-06-27|Actual||||2017-06-26|2017-06-29|Actual|October 2007||2007-10-31|June 2015|2015-06-30||||June 2014|Actual|2014-06-30||Interventional|||Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma|Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma|Completed||Phase 3|464|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 03:05:14.165234|2018-06-01 03:05:14.165234
NCT00499603|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2013-04-01||2016-09-12|2007-07-09|2007-07-11|Estimate|2013-08-27|2013-10-31|Estimate||||2016-09-12|2016-11-01|Estimate|July 2007||2007-07-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2012|Actual|2012-04-30||Interventional|||Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer|Open Label Randomized Clinical Trial of Standard Neoadjuvant Chemotherapy (Paclitaxel Followed by FEC) Versus the Combination of Paclitaxel and RAD001 Followed by FEC in Women With Triple Receptor-Negative Breast Cancer (CRAD001C24101)|Active, not recruiting||Phase 2|62|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:05:15.982147|2018-06-01 03:05:15.982147
NCT00499590|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2014-09-25||2014-09-29|2007-07-10|2007-07-11|Estimate|2014-09-29|2014-10-06|Estimate||||2014-09-29|2014-10-06|Estimate|August 2007||2007-08-31|September 2014|2014-09-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|COBALT||Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD|A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD).|Terminated||Phase 3|338|Actual|OPKO Health, Inc.|Study was terminated early.|3|||f||||t||||||||||2018-06-01 03:05:16.559536|2018-06-01 03:05:16.559536
NCT00499577|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2014-01-09|2007-07-10|2007-07-11|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2006||2006-12-31|August 2009|2009-08-31||||February 2009|Actual|2009-02-28||Interventional|||Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma|Phase I/II Combination Immunotherapy After ASCT for Advanced Myeloma to Study HTERT Vaccination Followed by Adoptive Transfer of Vaccine-Primed Autologous T Cells|Completed||Phase 1/Phase 2|56|Anticipated|National Cancer Institute (NCI)||4|||||||||||||||||2018-06-01 03:05:17.445608|2018-06-01 03:05:17.445608
NCT00499551|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2008-07-08|2007-07-10|2007-07-11|Estimate|||||||2008-07-08|2008-07-10|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|September 2009|Anticipated|2009-09-30|||||Interventional|||A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis|A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device|Withdrawn||Phase 1/Phase 2|30|Anticipated|Asociación para Evitar la Ceguera en México||||The drug needed for the study is not available in Mexico anymore.|f||||t||||||||||2018-06-01 03:05:17.570274|2018-06-01 03:05:17.570274
NCT00499538|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2007-12-18|2007-07-10|2007-07-11|Estimate|||||||2007-12-18|2007-12-27|Estimate|July 2007||2007-07-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Study Evaluating 3 New Formulations of SKI-606 in Healthy Adult Subjects|A Single Dose Bioavailability Study of 3 New Formulations of SKI-606 (500 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects|Completed||Phase 1|40|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:05:17.696973|2018-06-01 03:05:17.696973
NCT00499525|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2018-04-11|2007-07-10|2007-07-11|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2007||2007-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer|A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer|Active, not recruiting||Phase 2|180|Anticipated|Northwestern University||2|||f||||t||||||||||2018-06-01 03:05:17.800509|2018-06-01 03:05:17.800509
NCT00499512|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2018-04-12|2007-07-10|2007-07-11|Estimate|||||||2018-04-12|2018-04-13|Actual|August 2005|Actual|2005-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer|Evaluation of the Role of Spirituality in Coping With and Surviving Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Active, not recruiting|||115|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:05:17.984212|2018-06-01 03:05:17.984212
NCT00499499|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2009-02-03|2007-07-09|2007-07-11|Estimate|||||||2009-02-03|2009-02-04|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|June 2009|Anticipated|2009-06-30||Interventional|||A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors|A Phase I Open-Label, Single-Arm, Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors|Suspended||Phase 1|40|Anticipated|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:05:18.09456|2018-06-01 03:05:18.09456
NCT00499486|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-03-18||2016-10-18|2007-07-10|2007-07-11|Estimate|2016-10-18|2016-10-19|Estimate||||2016-10-18|2016-10-19|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|September 2008|Actual|2008-09-30||Interventional||All patients had previously progressed to a gemcitabine-containing regimen, including 22 patients who had received previous chemotherapy for metastatic disease.|Sirolimus in Treating Patients With Advanced Pancreatic Cancer|Phase II Clinical, Biological and Pharmacological Study of Rapamycin (Rapamune®, Sirolimus) in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|47|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||Undecided||2018-06-01 03:05:18.209624|2018-06-01 03:05:18.209624
NCT00499473|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2015-08-25||2016-01-29|2007-07-10|2007-07-11|Estimate|2016-01-29|2016-02-29|Estimate||||2016-01-29|2016-02-29|Estimate|June 2007||2007-06-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|June 2009|Actual|2009-06-30||Interventional|||Sunitinib in Treating Patients With Recurrent Malignant Gliomas|A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas|Completed||Phase 2|31|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:05:18.51501|2018-06-01 03:05:18.51501
NCT00499460|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2017-02-07||2017-04-05|2007-07-10|2007-07-11|Estimate|2017-04-05|2017-04-07|Actual||||2017-04-05|2017-04-07|Actual|November 2006||2006-11-30|April 2017|2017-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||Of the 15 enrollees, 6 subjects completed the study protocol in each assigned arm; hence, baseline analysis is only available in those 12 subjects.|Effects of Garlic Supplements on Opioids in Healthy Volunteers|Modulation of Opioid Effects by Garlic Supplements|Completed||Phase 4|15|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f|t|f|||f|||No||2018-06-01 03:05:18.926419|2018-06-01 03:05:18.926419
NCT00499447|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-01-25||2017-12-18|2007-07-10|2007-07-11|Estimate|2013-01-25|2013-03-01|Estimate||||2017-12-18|2018-01-18|Actual|May 2007|Actual|2007-05-31|March 2016|2016-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase II Study of Radiofrequency Ablation Combined With External Beam Radiation Therapy for Patients With Medically Inoperable Non-Small Cell Lung Cancer (Stage Ia and Select Ib) and the Predictive Value of Positron Emission Tomography|Completed||N/A|13|Actual|Wake Forest University Health Sciences|adverse events were tracked in two cycles, one during treatment and one longer term|1|||f||||t||||||||||2018-06-01 03:05:19.328629|2018-06-01 03:05:19.328629
NCT00499434|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2009-12-03|2007-07-10|2007-07-11|Estimate|||||||2009-12-03|2009-12-04|Estimate|August 2007||2007-08-31|December 2009|2009-12-31|February 2010|Anticipated|2010-02-28|January 2009|Anticipated|2009-01-31||Observational|||Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus|Correlation Between Values of Serum Cytokines and of Those Dosed by mRNA Expression Through the Use of Real-time PCR and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus|Unknown status|Active, not recruiting||110|Anticipated|UPECLIN HC FM Botucatu Unesp|||||f||||t||||||||||2018-06-01 03:05:19.545104|2018-06-01 03:05:19.545104
NCT00499421|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2018-05-03|2007-07-10|2007-07-11|Estimate|||||||2018-05-03|2018-05-07|Actual|September 2005|Actual|2005-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Evaluation of Intraprostatic Fiducial Markers For External Beam Radiation Therapy|Evaluation of Intraprostatic Fiducial Markers For Targeting of External Beam Radiation Therapy|Active, not recruiting|||20|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:05:19.641675|2018-06-01 03:05:19.641675
NCT00499408|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-11-15||2017-10-31|2007-07-10|2007-07-11|Estimate|2014-01-03|2014-02-17|Estimate||||2017-10-31|2017-12-06|Actual|April 2007||2007-04-30|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer|Phase II Trial of Vitamin D and Soy Supplementation for Biochemically Recurrent Prostate Cancer Following Definitive Local Therapy|Completed||N/A|26|Actual|Wake Forest University Health Sciences|only the most severe of each type of adverse event during treatment was recorded.||||f||||t|f|f||||||||2018-06-01 03:05:19.725107|2018-06-01 03:05:19.725107
NCT00499395|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2012-04-02|2007-07-10|2007-07-11|Estimate|||||||2012-04-02|2012-04-03|Estimate|July 2005||2005-07-31|April 2012|2012-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer|Detection of Residual Colorectal Liver Metastases Within 24 Hours After RFA With 18-F FDG PET|Completed||N/A|4|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 03:05:19.943982|2018-06-01 03:05:19.943982
NCT00499382|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2012-07-31|2007-07-10|2007-07-11|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2004||2004-09-30|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging|Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging|Terminated|||5|Actual|M.D. Anderson Cancer Center|||1|Slow accrual; study terminated.|f||||f||||||||||2018-06-01 03:05:20.010645|2018-06-01 03:05:20.010645
NCT00499369|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-10-22||2014-07-25|2007-07-10|2007-07-11|Estimate|2013-12-12|2014-01-15|Estimate||||2014-07-25|2014-07-31|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||All eligible patients are included in this analysis.|Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy|Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients With Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab With Either FOLFOX, OPTIMOX or XELOX|Terminated||Phase 3|72|Actual|National Cancer Institute (NCI)|Due to inadequate accrual, study was terminated and limited outcome data was reported.|3||Due to inadequate accrual, study was terminated and limited outcome data was reported.|f||||||||||||||2018-06-01 03:05:20.175537|2018-06-01 03:05:20.175537
NCT00499356|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2007-07-10|2007-07-10|2007-07-11|Estimate|||||||2007-07-10|2007-07-11|Estimate|May 2002||2002-05-31|July 2007|2007-07-31|January 2005|Actual|2005-01-31|||||Interventional|GlideSoft||Shear and Pressure Reducing Insoles for the Diabetic Foot|Shear and Pressure Reducing Insoles for the Diabetic Foot|Completed||N/A|299|Actual|Diabetica Solutions Inc.|||||f||||t||||||||||2018-06-01 03:05:26.880905|2018-06-01 03:05:26.880905
NCT00499343|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2009-03-03||2013-06-03|2007-07-10|2007-07-11|Estimate|2009-05-21|2009-07-07|Estimate||||2013-06-03|2013-08-02|Estimate|January 2004||2004-01-31|June 2013|2013-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients|A Randomized Study Comparing Chemotherapy Followed by G-CSF Alone Versus G-CSF Plus GM-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas|Completed||Phase 2|84|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:05:27.054367|2018-06-01 03:05:27.054367
NCT00499330|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2018-05-25|2007-07-10|2007-07-11|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2007||2007-06-30|May 2018|2018-05-31||||March 2021|Anticipated|2021-03-31||Interventional|||Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer|A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|701|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 03:05:27.52355|2018-06-01 03:05:27.52355
NCT00499317|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2017-07-28|2007-07-09|2007-07-11|Estimate|||||||2017-07-28|2017-08-01|Actual|January 15, 2007|Actual|2007-01-15|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|CP/CPPS||Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|Recruiting|||500|Anticipated|Boston Children’s Hospital|||||f||||t|f|f||||Samples With DNA|"~     DNA sample via saliva and urine samples will be collected and stored.~   "|Yes|Data from individual participants will be shared with other researchers, but participants will be de-identified.|2018-06-01 03:05:28.471818|2018-06-01 03:05:28.471818
NCT00499304|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2008-06-05|2007-07-10|2007-07-11|Estimate|||||||2008-06-05|2008-06-06|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Forced Oscillation Technique (FOT) and Expiratory Flow Limitation (EFL)|Diagnosing Expiratory Flow Limitation in COPD Patients With the Forced Oscillation Technique Using Linear Regression in the Time Frequency Domain|Completed|||60|Anticipated|Medical Center Alkmaar|||||f||||f||||||||||2018-06-01 03:05:28.600291|2018-06-01 03:05:28.600291
NCT00499291|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2015-10-06|2007-07-10|2007-07-11|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 2006||2006-09-30|October 2015|2015-10-31||||October 2007|Anticipated|2007-10-31||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors|Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors|Withdrawn||N/A|0|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 03:05:28.687524|2018-06-01 03:05:28.687524
NCT00499278|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2007-07-09|2007-07-09|2007-07-11|Estimate|||||||2007-07-09|2007-07-11|Estimate|November 2005||2005-11-30|July 2007|2007-07-31|February 2007|Actual|2007-02-28|||||Observational|JOINTS||JOINTS Study - Joint Replacement Outcome in Inpatient Rehabilitation Facilities and Nursing Treatment Sites|Joint Replacement Outcome in Inpatient Rehabilitation Facilities and Nursing Treatment Sites|Completed|||2384|Actual|MedStar National Rehabilitation Network|||||f||||f||||||||||2018-06-01 03:05:28.928391|2018-06-01 03:05:28.928391
NCT00499265|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2012-03-28|2007-07-10|2007-07-11|Estimate|||||||2012-03-28|2012-03-29|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|A Randomized, Open Label, Phase II Proof of Concept Study of WX-671 in Combination With Gemcitabine vs.Gemcitabine Alone in Patients With Locally Advanced, Non Resectable Pancreatic Cancer in Order to Evaluate the Anti-Tumor Activity of the Combination Therapy|Completed||Phase 2|95|Actual|Wilex||3|||f||||f||||||||||2018-06-01 03:05:29.079175|2018-06-01 03:05:29.079175
NCT00499252|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-10-23||2017-12-14|2007-07-10|2007-07-11|Estimate|2013-10-23|2013-12-13|Estimate||||2017-12-14|2018-01-11|Actual|June 2007||2007-06-30|March 2015|2015-03-31||||July 2011|Actual|2011-07-31||Interventional||Eligible and treated patients|Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed||Phase 2|51|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 03:05:29.364797|2018-06-01 03:05:29.364797
NCT00497562|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate|May 2004||2004-05-31|July 2007|2007-07-31|November 2005|Actual|2005-11-30|||||Interventional|||Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters)|Exploratory Study to Investigate the Efficacy and Safety of Recombinant Growth Hormone as Add-on Treatment in Patients With Severe Fibromialgia|Completed||Phase 2|||Centro Medico Teknon|||||f||||t||||||||||2018-06-01 03:06:08.654166|2018-06-01 03:06:08.654166
NCT00499239|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09||2014-01-03|2014-01-03|2007-07-10|2007-07-11|Estimate||||2014-01-03|2014-02-04|Estimate|2014-01-03|2014-02-04|Estimate|July 2007||2007-07-31|January 2014|2014-01-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)|Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma|Terminated||Phase 1/Phase 2|32|Actual|Gilead Sciences||1||Unacceptable safety profile|f||||t||||||||||2018-06-01 03:05:30.01787|2018-06-01 03:05:30.01787
NCT00499213|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2009-02-06|2007-07-09|2007-07-11|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Observational|||Rates of Hospitalization in Home Care Assisted Peritoneal Dialysis|Home Care Assisted Peritoneal Dialysis: The Impact of Expanding Eligibility for Peritoneal Dialysis on Rates of Hospitalization|Unknown status|Active, not recruiting||||Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 03:05:30.644004|2018-06-01 03:05:30.644004
NCT00499200|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2008-07-07|2007-07-10|2007-07-11|Estimate|||||||2008-07-07|2008-07-09|Estimate|October 2007||2007-10-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy|A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease|Completed||Phase 1|42|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 03:05:31.376159|2018-06-01 03:05:31.376159
NCT00499187|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2014-03-14|2007-07-09|2007-07-11|Estimate|||||||2014-03-14|2014-03-17|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Fanconi Syndrome Due to ARVs in HIV-Infected Persons|A Preliminary Evaluation of Fanconi Syndrome Due to Antiretroviral Therapies in HIV-Infected Persons|Completed|||56|Actual|Gilead Sciences|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 03:05:32.634933|2018-06-01 03:05:32.634933
NCT00499174|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2015-10-05|2007-07-10|2007-07-11|Estimate|||||||2015-10-05|2015-10-06|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional|||Observation or Radical Treatment in Patients With Prostate Cancer|A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favourable Risk Prostate Cancer [START]|Terminated||Phase 3|180|Actual|Canadian Cancer Trials Group||2||Not meeting accrual target.|f||||t||||||||||2018-06-01 03:05:33.324491|2018-06-01 03:05:33.324491
NCT00499161|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2008-02-15|2007-07-10|2007-07-11|Estimate|||||||2008-02-15|2008-02-18|Estimate|April 2007||2007-04-30|February 2008|2008-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|PCC||Effect of Patient-Centered Care (PCC) on Patient Satisfaction at Hospital Discharge|Effect of Patient-Centered Care (PCC) on Patient Satisfaction at Hospital Discharge|Completed||N/A|80|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:05:34.198598|2018-06-01 03:05:34.198598
NCT00499148|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2010-07-29|2007-07-10|2007-07-11|Estimate|||||||2010-07-29|2010-07-30|Estimate|August 2006||2006-08-31|April 2009|2009-04-30|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy Study Testing Herbal Extract on Metabolic Parameters in Subjects With Type 2 Diabetes|Effect of Herbal Extract on Metabolic Parameters in Subjects With Type 2 Diabetes|Completed||Phase 2/Phase 3|59|Actual|Abbott Nutrition|||||f||||f||||||||||2018-06-01 03:05:34.678858|2018-06-01 03:05:34.678858
NCT00499135|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-10-09|2007-07-10|2007-07-11|Estimate|||||||2017-10-09|2017-10-10|Actual|May 22, 2007|Actual|2007-05-22|October 2017|2017-10-31|May 14, 2014|Actual|2014-05-14|May 14, 2014|Actual|2014-05-14||Interventional|||Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors|Pharmacodynamic Study of Sunitinib Malate in Patients With Renal Cell Cancer and Other Advanced Solid Malignancies|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:05:34.932587|2018-06-01 03:05:34.932587
NCT00499122|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-01-18||2017-12-06|2007-07-10|2007-07-11|Estimate|2013-02-20|2013-03-29|Estimate||||2017-12-06|2018-01-02|Actual|June 4, 2007|Actual|2007-06-04|December 2017|2017-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer|Phase II Study of Neoadjuvant Treatment With NOV-002 in Combination With Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patients With Stages IIB-IIIC Breast Cancer|Completed||Phase 2|41|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 03:05:35.797291|2018-06-01 03:05:35.797291
NCT00499109|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2013-09-12||2014-06-25|2007-07-10|2007-07-11|Estimate|2014-02-27|2014-03-26|Estimate||||2014-06-25|2014-07-09|Estimate|May 2007||2007-05-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional||All Participants|Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC|Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy Versus Standard of Care for 1st Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer|Completed||Phase 3|275|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 03:05:37.694782|2018-06-01 03:05:37.694782
NCT00499096|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2014-10-17||2014-11-12|2007-07-10|2007-07-11|Estimate|2014-11-12|2014-11-20|Estimate||||2014-11-12|2014-11-20|Estimate|May 2008||2008-05-31|November 2014|2014-11-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|SMAHRT||Self-Management Addressing Heart Disease Risk Trial|Cardiovascular Risk Factors in Veterans With Bipolar Disorder|Completed||Phase 3|118|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:05:40.430166|2018-06-01 03:05:40.430166
NCT00499083|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2017-10-24|2007-07-10|2007-07-11|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2006||2006-05-31|October 2017|2017-10-31|January 2010|Actual|2010-01-31|July 2009|Actual|2009-07-31||Interventional|||Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer|Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translation of Biotechnology Into the Clinic|Completed||Phase 2|17|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 03:05:41.01145|2018-06-01 03:05:41.01145
NCT00499070|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2015-01-15|2007-07-10|2007-07-11|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment|TCR Vbeta Repertoire and PNH Clones in Children With Refractory Cytopenia (RC). An Open Nonrandomised Multi-Center Prospective Study|Completed|||119|Actual|University Hospital Freiburg|||||f||||f||||||Samples With DNA|"~     Bone Marrow Peripheral blood cells~   "|||2018-06-01 03:05:41.122049|2018-06-01 03:05:41.122049
NCT00001385|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1994||1994-05-31|May 1999|1999-05-31|April 2000||2000-04-30|||||Observational|||Positron Emission Tomography in Patients With Breast Cancer|Positron Emission Tomography in Patients With Breast Cancer|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.852975|2018-06-01 05:29:54.852975
NCT00499057|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2014-12-19|2007-07-10|2007-07-11|Estimate|||||||2014-12-19|2014-12-23|Estimate|August 2003||2003-08-31|June 2010|2010-06-30|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Partial Breast Irradiation With Interstitial High Dose Rate Brachytherapy|Interstitial High Dose-Rate Brachytherapy for Partial Breast Irradiation in Early Breast Cancer: Results of Phase II Prospective Study|Unknown status|Recruiting|Phase 2|150|Anticipated|University Of Perugia||1|||f||||f||||||||||2018-06-01 03:05:41.491381|2018-06-01 03:05:41.491381
NCT00499044|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2009-11-25|2007-07-09|2007-07-11|Estimate|||||||2009-11-25|2009-11-26|Estimate|December 2007||2007-12-31|November 2009|2009-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Comparison of Two Cognitive Batteries in People With Schizophrenia|CDR Versus MATRICS Cognitive Batteries in Patients With Schizophrenia|Completed||N/A|32|Actual|North Suffolk Mental Health Association||2|||f||||f||||||||||2018-06-01 03:05:41.727178|2018-06-01 03:05:41.727178
NCT00499031|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2014-05-22||2014-12-29|2007-07-10|2007-07-11|Estimate|2014-05-22|2014-06-24|Estimate||||2014-12-29|2015-01-13|Estimate|June 2007||2007-06-30|December 2014|2014-12-31||||January 2012|Actual|2012-01-31||Interventional||Total number eligible and evaluable participants|Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix|Completed||Phase 2|38|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 03:05:41.973302|2018-06-01 03:05:41.973302
NCT00499018|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2011-02-14|2007-07-10|2007-07-11|Estimate|||||||2011-02-14|2011-02-15|Estimate|January 2006||2006-01-31|February 2011|2011-02-28|September 2013|Anticipated|2013-09-30|June 2011|Anticipated|2011-06-30||Interventional|DLCL04||Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma|A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells.|Unknown status|Active, not recruiting|Phase 3|399|Anticipated|Fondazione Italiana Linfomi ONLUS||4|||f||||f||||||||||2018-06-01 03:05:42.767116|2018-06-01 03:05:42.767116
NCT00499005|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2009-09-18|2007-07-10|2007-07-11|Estimate|||||||2009-09-18|2009-09-21|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Carbetocin Versus Syntometrine for the Third Stage of Labour|Carbetocin Versus Syntometrine for the Third Stage of Labour Following Vaginal Delivery - A Double-blind Randomised Trial|Completed||Phase 4|720|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 03:05:43.158149|2018-06-01 03:05:43.158149
NCT00498992|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2013-09-19|2007-07-10|2007-07-11|Estimate|||||||2013-09-19|2013-09-20|Estimate|July 2006||2006-07-31|July 2009|2009-07-31||||||||Interventional|||Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer|Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients|Unknown status|Recruiting|N/A|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:05:43.424691|2018-06-01 03:05:43.424691
NCT00498979|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2015-09-29|2007-07-10|2007-07-11|Estimate|||||||2015-09-29|2015-09-30|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|January 2012|Actual|2012-01-31|May 2010|Actual|2010-05-31||Interventional|||Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers|Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons|Completed||Phase 1|22|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:05:43.639969|2018-06-01 03:05:43.639969
NCT00498966|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09||2018-01-25|2018-02-02|2007-07-09|2007-07-11|Estimate||||2018-01-30|2018-01-31|Actual|2018-02-02|2018-02-05|Actual|July 2007||2007-07-31|February 2018|2018-02-28|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Ph II Study of Perifosine for Patients With Carcinoma of the Kidney|Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor|Completed||Phase 2|50|Actual|AEterna Zentaris||2|||f||||f||||||||||2018-06-01 03:05:43.771493|2018-06-01 03:05:43.771493
NCT00498953|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2013-01-07|2007-07-10|2007-07-11|Estimate|||||||2013-01-07|2013-01-08|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx|Phase I/II Study on Induction Chemotherapy Followed by Chemoradiation With or Without Lapatinib, a Dual EGFR/ErbB2 Kinase Inhibitor, in Patients With Locally Advanced Larynx and Hypopharynx Squamous Cell Carcinoma|Completed||Phase 1/Phase 2|7|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 03:05:43.944489|2018-06-01 03:05:43.944489
NCT00498940|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2014-02-03||2018-01-23|2007-07-10|2007-07-11|Estimate|2014-04-01|2014-05-02|Estimate||||2018-01-23|2018-02-21|Estimate|October 2006||2006-10-31|January 2018|2018-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|BIPACS||Biventricular Pacing After Cardiopulmonary Bypass|Biventricular Pacing After Cardiopulmonary Bypass|Terminated||N/A|111|Actual|Columbia University||2||Accrual too slow; grant renewal unlikely; AAI as effective as BiV in Phase III|f||||t|f|t|f|f||||||2018-06-01 03:05:44.14653|2018-06-01 03:05:44.14653
NCT00498927|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|2015-10-05||2016-02-01|2007-07-10|2007-07-11|Estimate|2016-02-01|2016-02-29|Estimate||||2016-02-01|2016-02-29|Estimate|June 2007||2007-06-30|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma|A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma|Completed||Phase 2|47|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:05:44.535649|2018-06-01 03:05:44.535649
NCT00498914|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10||2015-08-20|2015-08-20|2007-07-10|2007-07-11|Estimate||||2015-08-20|2015-09-04|Estimate|2015-08-20|2015-09-04|Estimate|June 2007||2007-06-30|August 2015|2015-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects|A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects|Terminated||Phase 2|41|Actual|Astellas Pharma Inc||1||Futility boundary at interim analysis not met|f||||t||||||||||2018-06-01 03:05:45.11397|2018-06-01 03:05:45.11397
NCT00498901|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2013-05-07|2007-07-10|2007-07-11|Estimate|||||||2013-05-07|2013-05-09|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|November 2008|Actual|2008-11-30|December 2007|Actual|2007-12-31||Interventional|||Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer|Phase II Pilot of Aromatase Inhibitor Therapy With Femara® (Letrozole) and Ovarian Suppression in Premenopausal Estrogen Receptor Positive Women With Stage IV Carcinoma of the Breast|Terminated||Phase 2|1|Actual|University of Washington|||||f||||||||||||||2018-06-01 03:05:45.284524|2018-06-01 03:05:45.284524
NCT00498888|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-10|||2012-11-28|2007-07-10|2007-07-11|Estimate|||||||2012-11-28|2012-11-29|Estimate|June 2007||2007-06-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|January 2012|Actual|2012-01-31||Interventional|UUI||The Long Term Outcomes of Rehabilitation and Drug Treatment for in Urgency Urinary Incontinence|Is the a Difference Between Rehabilitation Treatment, Pelvic Floor Muscle Training, Bladder Training and Anticholinergic Drug Treatment in UUI in the Long Term: A Study of Impairment, Quality of Life, and Cost Effectiveness|Completed||N/A|164|Actual|Assuta Hospital Systems||4|||f||||t||||||||||2018-06-01 03:05:45.386026|2018-06-01 03:05:45.386026
NCT00498875|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2017-09-28|2007-07-09|2007-07-10|Estimate|||||||2017-09-28|2017-09-29|Actual|March 2005|Actual|2005-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Depression and Adherence in Head and Neck Cancer|Depression and Adherence in Head and Neck Cancer|Active, not recruiting|||350|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:05:45.669555|2018-06-01 03:05:45.669555
NCT00498862|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2007-07-09|2007-07-09|2007-07-10|Estimate|||||||2007-07-09|2007-07-10|Estimate|September 2006||2006-09-30|September 2006|2006-09-30||||||||Observational|||Catecholamines Can Attenuate Intermittent Hypoxia-Induced Expression of TNF in Human Monocytes||Unknown status|Recruiting||15|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:05:45.903559|2018-06-01 03:05:45.903559
NCT00498849|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2007-07-08|2007-07-08|2007-07-10|Estimate|||||||2007-07-08|2007-07-10|Estimate|February 2005||2005-02-28|January 2005|2005-01-31|December 2007|Anticipated|2007-12-31|||||Interventional|||The Changes of Patterns of Microarray in Patients With Obstructive Sleep Apnea|The Changes of Patterns of Microarray in Patients With Obstructive Sleep Apnea|Unknown status|Recruiting|N/A|20|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:05:46.052286|2018-06-01 03:05:46.052286
NCT00498836|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09||2013-08-28|2013-08-28|2007-07-09|2007-07-10|Estimate||||2013-08-28|2013-09-12|Estimate|2013-08-28|2013-09-12|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma|A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma|Completed||Phase 2|18|Actual|Clavis Pharma|||||f||||f||||||||||2018-06-01 03:05:46.153487|2018-06-01 03:05:46.153487
NCT00498810|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2011-01-27|2007-07-09|2007-07-10|Estimate|||||||2011-01-27|2011-01-28|Estimate|September 2007||2007-09-30|January 2011|2011-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|COMPAC||COMplete Versus PArtial Open inCisional Hernia Repair (COMPAC-TRIAL)|COMplete Versus PArtial Open inCisional Hernia Repair (COMPAC-TRIAL)|Terminated||N/A|160|Anticipated|University Hospital, Ghent||||patients had to be converted to the other study arm|f||||f||||||||||2018-06-01 03:05:46.277914|2018-06-01 03:05:46.277914
NCT00498797|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2011-04-27||2016-08-25|2007-07-09|2007-07-10|Estimate|2011-04-27|2011-05-24|Estimate||||2016-08-25|2016-10-07|Estimate|December 2005||2005-12-31|August 2016|2016-08-31|September 2008|Actual|2008-09-30|July 2007|Actual|2007-07-31||Interventional|||E3-Hormone Refractory Prostrate Cancer Taxotere Combination|A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)|Completed||Phase 2|86|Actual|Sanofi|||||f||||f||||||||||2018-06-01 03:05:46.393665|2018-06-01 03:05:46.393665
NCT00498784|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2013-01-21|2007-07-09|2007-07-10|Estimate|||||||2013-01-21|2013-01-23|Estimate|November 2005||2005-11-30|January 2013|2013-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||HR-QoL and Sexuality in Mirena Inserted Contraception Users|A Multicenter, Open Labelled, Uncontrolled, Phase IV Clinical Study to Evaluate the Health-related Quality of Life and Sexual Well-being in Young (18-35) Healthy Mirena Users Switching From OC, Over the First Year Post-insertion.|Completed||Phase 4|141|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:05:46.849999|2018-06-01 03:05:46.849999
NCT00498771|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2017-06-09|2007-07-09|2007-07-10|Estimate|||||||2017-06-09|2017-06-12|Actual|July 2006||2006-07-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|December 2009|Actual|2009-12-31||Interventional|||Aquatic Exercise Study for Breast Cancer Patients With Lymphedema|Aquatic Exercise Study for Breast Cancer Patients With Lymphedema|Completed||N/A|35|Actual|Baylor Research Institute||2|||f||||f||||||||||2018-06-01 03:05:47.028826|2018-06-01 03:05:47.028826
NCT00498758|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2007-07-09|2007-07-09|2007-07-10|Estimate|||||||2007-07-09|2007-07-10|Estimate|August 2007||2007-08-31|July 2007|2007-07-31|August 2008|Anticipated|2008-08-31|||||Interventional|||The APOS System: Effects on Gait, Mobility and QOL in Patients With Parkinson's Disease||Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 03:05:47.196188|2018-06-01 03:05:47.196188
NCT00498745|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2012-05-10|2007-07-09|2007-07-10|Estimate|||||||2012-05-10|2012-05-14|Estimate|July 2007||2007-07-31|May 2012|2012-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects|A Single Dose Bioavailability Study of 2 New Formulations of HKI-272 (240 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects|Completed||Phase 1|36||Puma Biotechnology, Inc.|||||||||||||||||||2018-06-01 03:05:47.333572|2018-06-01 03:05:47.333572
NCT00498732|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2010-11-30|2007-07-09|2007-07-10|Estimate|||||||2010-11-30|2010-12-01|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|July 2008|Actual|2008-07-31|March 2008|Actual|2008-03-31||Observational|||Dissection of Differentially Expressed Genes and Pathways in Patients With OSAS Before and After CPAP Treatment|Dissection of Differentially Expressed Genes and Pathways in Patients With Obstructive Sleep Apnea Syndrome Before and After CPAP Treatment|Completed|||50|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:05:47.41143|2018-06-01 03:05:47.41143
NCT00498719|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2017-09-28|2007-07-09|2007-07-10|Estimate|||||||2017-09-28|2017-09-29|Actual|April 2004|Actual|2004-04-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Cognitive Training in Attenuating Attention Deficits/Child Treatment for Cancer|A Pilot Study of the Effectiveness of Cognitive Training in Preventing Attention Deficits Among Children in Treatment for Cancer|Active, not recruiting|||30|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 03:05:47.53735|2018-06-01 03:05:47.53735
NCT00498706|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|2012-08-20||2013-07-15|2007-07-09|2007-07-10|Estimate|2013-07-15|2013-07-17|Estimate||||2013-07-15|2013-07-17|Estimate|December 2007||2007-12-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effectiveness of Telephone Versus Face-to-Face CBT in Treating People With Depression|Telephone Versus Face-to-Face Administration of CBT for Depression|Completed||Phase 3|325|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 03:05:47.728079|2018-06-01 03:05:47.728079
NCT00498693|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2009-01-12|2007-07-08|2007-07-10|Estimate|||||||2009-01-12|2009-01-14|Estimate|March 2006||2006-03-31|January 2009|2009-01-31||||||||Observational|||Hypoxia Inducible factor1-Alpha Genetic Polymorphism of Obstructive Sleep Apnea||Unknown status|Recruiting||1000|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:05:48.096398|2018-06-01 03:05:48.096398
NCT00498680|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2010-10-21|2007-07-09|2007-07-10|Estimate|||||||2010-10-21|2010-10-22|Estimate|March 2007||2007-03-31|January 2007|2007-01-31|June 2011|Anticipated|2011-06-30|January 2011|Anticipated|2011-01-31||Interventional|||Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i|A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment|Unknown status|Recruiting|Phase 4|46|Anticipated|Rambam Health Care Campus||3|||f||||f||||||||||2018-06-01 03:05:48.286369|2018-06-01 03:05:48.286369
NCT00498667|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2015-05-05|2007-07-08|2007-07-10|Estimate|||||||2015-05-05|2015-05-06|Estimate|December 2006||2006-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2009|Actual|2009-12-31||Observational|||The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma|Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma|Withdrawn|||0|Actual|Rambam Health Care Campus|||1||f||||f||||||None Retained|"~     no biopsies are to be retained~   "|||2018-06-01 03:05:48.582835|2018-06-01 03:05:48.582835
NCT00498654|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2008-06-27|2007-07-09|2007-07-10|Estimate|||||||2008-06-27|2008-07-02|Estimate|July 2007||2007-07-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|October 2007|Actual|2007-10-31||Interventional|||Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects|Completed||Phase 2|180|Anticipated|Avant Immunotherapeutics|||||f||||t||||||||||2018-06-01 03:05:48.705373|2018-06-01 03:05:48.705373
NCT00498641|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2007-07-09|2007-07-09|2007-07-10|Estimate|||||||2007-07-09|2007-07-10|Estimate|January 2005||2005-01-31|July 2007|2007-07-31|January 2007|Actual|2007-01-31|||||Interventional|||Anisometropia Amblyopia Improved by Perceptual Learning and Patching||Completed||Phase 3|||Tri-Service General Hospital|||||f||||t||||||||||2018-06-01 03:05:48.816958|2018-06-01 03:05:48.816958
NCT00498628|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|2012-04-25|2011-02-10|2018-03-27|2007-07-09|2007-07-10|Estimate|2012-04-25|2012-05-30|Estimate|2011-03-02|2011-03-16|Estimate|2018-03-27|2018-04-25|Actual|December 2007||2007-12-31|March 2018|2018-03-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency|A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Quetiapine Fumarate Extended Release for the Treatment of Alcohol Dependence in Very Heavy Drinkers.|Completed||Phase 2|224|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||t||||||||||2018-06-01 03:05:48.903271|2018-06-01 03:05:48.903271
NCT00498615|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|2014-03-25||2014-11-03|2007-07-06|2007-07-10|Estimate|2014-11-03|2014-11-04|Estimate||||2014-11-03|2014-11-04|Estimate|April 2007||2007-04-30|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||Men and women between ages 18–80 years with a clinical diagnosis of Raynauds Phenomenon secondary to Scleroderma were eligible for the study.|A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon|Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon|Completed||Phase 3|17|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-06-01 03:05:49.336381|2018-06-01 03:05:49.336381
NCT00498602|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2014-04-23||2015-11-30|2007-07-09|2007-07-10|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|November 2007||2007-11-30|November 2015|2015-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||245 participants were randomized in both studies (86 participants in NCT00479557 and 159 participants in NCT00498602) are included in the analysis below. One participant of the randomized participants did not receive treatment.|Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease|Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease|Completed||Phase 2|160|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 03:05:49.909813|2018-06-01 03:05:49.909813
NCT00498589|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2015-02-04|2007-07-09|2007-07-10|Estimate|||||||2015-02-04|2015-02-05|Estimate|September 2007||2007-09-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|METEOR||Comparison of Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis|A Controlled, Randomized, Double-blind, Multicenter Study, Comparing Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis|Completed||Phase 2|110|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-06-01 03:05:52.155375|2018-06-01 03:05:52.155375
NCT00498576|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2009-06-29|2007-07-08|2007-07-10|Estimate|||||||2009-06-29|2009-06-30|Estimate|September 2007||2007-09-30|June 2009|2009-06-30||||||||Observational|||Melatonin and Adiponectin in Hypertensive Kidney Transplant||Completed|||60|Anticipated|Sheba Medical Center|||3||f||||f||||||||||2018-06-01 03:05:52.425629|2018-06-01 03:05:52.425629
NCT00498563|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2015-04-22|2007-07-09|2007-07-10|Estimate|||||||2015-04-22|2015-04-24|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effects of Mild Hypobaric Hypoxia on Sleep and Post-sleep Performance|Investigation to Determine the Effects of Mild Hypobaric Hypoxia on Sleep and Post-Sleep Neurobehavioral Performance|Completed||N/A|34|Actual|Oklahoma State University Center for Health Sciences|||||f||||f||||||||||2018-06-01 03:05:52.498727|2018-06-01 03:05:52.498727
NCT00498550|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|2011-09-28||2018-03-12|2007-07-06|2007-07-10|Estimate|2011-12-15|2012-01-19|Estimate||||2018-03-12|2018-03-14|Actual|October 2000||2000-10-31|March 2018|2018-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual|Cannabis and Schizophrenia: Effects of Clozapine|Completed||Phase 4|31|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 03:05:52.587683|2018-06-01 03:05:52.587683
NCT00498537|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2008-10-16|2007-07-06|2007-07-10|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2003||2003-01-31|May 2008|2008-05-31|June 2006|Actual|2006-06-30|December 2005|Actual|2005-12-31||Interventional|||Spironolactone for Reducing Proteinuria in Diabetic Nephropathy|Spironolactone for Reducing Proteinuria in Diabetic Nephropathy|Completed||N/A|30|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:05:53.008864|2018-06-01 03:05:53.008864
NCT00498524|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2012-12-06|2007-07-09|2007-07-10|Estimate|||||||2012-12-06|2012-12-07|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|SIBFIB||Risk of Life-threatening Heart Rhythm Disturbances in Siblings|The Sibling Concordance for Implantable Cardioverter-defibrillator Therapies in Ischemic Cardiomyopathy Study|Completed|||2047|Actual|Duke University|||2||f||||f||||||||||2018-06-01 03:05:53.101677|2018-06-01 03:05:53.101677
NCT00498511|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2007-07-12|2007-07-08|2007-07-10|Estimate|||||||2007-07-12|2007-07-13|Estimate|August 2007||2007-08-31|June 2007|2007-06-30||||||||Observational|||Gastrointestinal Evaluation in Young Men With Iron Deficiency Anemia|Prospective Evaluation of the Gastrointestinal Tract in Young Men With Iron Deficiency Anemia|Unknown status|Not yet recruiting||||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:05:53.252069|2018-06-01 03:05:53.252069
NCT00498498|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2011-11-15|2007-07-09|2007-07-10|Estimate|||||||2011-11-15|2011-11-16|Estimate|July 2007||2007-07-31|November 2011|2011-11-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|Endothelin||Observational Endothelin and Markers of Cellular Apoptosis In CSF Head Injury|A Multicenter Observational Study to Evaluate Dynamics of Endothelin and Markers of Cellular Apoptosis in Cerebrospinal Fluid and Plasma in Moderate and Severe Human Head Injury|Completed|||51|Actual|Virginia Commonwealth University|||||f||||f||||||Samples Without DNA|"~     CSF, plasma~   "|||2018-06-01 03:05:53.33356|2018-06-01 03:05:53.33356
NCT00498485|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2015-05-15||2016-05-18|2007-07-09|2007-07-10|Estimate|2016-03-21|2016-04-21|Estimate||||2016-05-18|2016-05-19|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||No info available|Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome|Phase IV - A Trial of Xyrem in the Treatment of Chronic Fatigue Syndrome.|Terminated||Phase 4|17|Actual|Rutgers, The State University of New Jersey|Too few subjects to get any definitive data. Based on the preliminary data analysis done with available subjects, we infer that had we completed the study, we might have found a significant effect for drug treated over placebo treated subjects.|2||Withdrawal of support.|f||||f||||||||No||2018-06-01 03:05:53.453496|2018-06-01 03:05:53.453496
NCT00498472|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2010-06-14|2007-07-09|2007-07-10|Estimate|||||||2010-06-14|2010-06-15|Estimate|July 2006||2006-07-31|July 2007|2007-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|BOT_AcuteHF||NT-proBNP in the Optimization of Treatment After Recent Acute Heart Failure Trial|NT-proBNP in the Optimization of Treatment After Recent Acute Heart Failure (BOT-AcuteHF) Trial|Completed||Phase 4|330|Anticipated|Università degli Studi di Brescia||2|||f||||f||||||||||2018-06-01 03:05:53.771061|2018-06-01 03:05:53.771061
NCT00498459|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2018-03-05|2007-07-09|2007-07-10|Estimate|||||||2018-03-05|2018-03-07|Actual|September 2002||2002-09-30|March 2018|2018-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|ICAPS||Intervention Centered on Adolescents' Physical Activity and Sedentary Behavior (ICAPS)|Intervention Centered on Adolescents' Physical Activity and Sedentary Behavior (ICAPS)|Completed||N/A|954|Actual|Louis Pasteur University, Strasbourg||2|||f||||t||||||||No||2018-06-01 03:05:53.861805|2018-06-01 03:05:53.861805
NCT00498446|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2013-06-18|2007-07-09|2007-07-10|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2002||2002-07-31|July 2007|2007-07-31|July 2004|Actual|2004-07-31|||||Observational|||Magnetic Resonance Imaging of Atrial Septal Defects|Imaging of Atrial Septal Defects by Velocity Encoded Cardiovascular Magnetic Resonance|Completed|||44|Actual|Duke University|||||f||||f||||||||||2018-06-01 03:05:53.961865|2018-06-01 03:05:53.961865
NCT00498433|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|2013-03-21||2014-09-09|2007-07-08|2007-07-10|Estimate|2013-10-23|2013-10-24|Estimate||||2014-09-09|2014-09-10|Estimate|June 2007||2007-06-30|September 2014|2014-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||"Part 1 : Baseline measures are on all patients.~Part 2: Randomized population of double-blind period used for Baseline/Demographic measurements."|Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension|Part 1: An Open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin- Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity. Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity|Terminated||Phase 2|46|Actual|Novartis||2||Early termination resulted from interim analysis of the ALTITUDE trial|f||||t||||||||||2018-06-01 03:05:54.060538|2018-06-01 03:05:54.060538
NCT00498420|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2016-09-01|2007-07-09|2007-07-10|Estimate|||||||2016-09-01|2016-09-02|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Observational|HUE-MAN||The Natural History of Alpha-Mannosidosis|A Multicenter, Multinational Study That Will Evaluate Clinical and Surrogate Parameters Known to be Affected in Alpha-Mannosidosis Patients|Completed|||45|Actual|Chiesi Farmaceutici S.p.A.|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 03:05:54.921076|2018-06-01 03:05:54.921076
NCT00498407|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2009-06-03|2007-07-09|2007-07-10|Estimate|||||||2009-06-03|2009-06-04|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer|A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer|Completed||Phase 2|16|Actual|Clavis Pharma|||||f||||f||||||||||2018-06-01 03:05:55.018788|2018-06-01 03:05:55.018788
NCT00498394|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2007-07-06|2007-07-06|2007-07-10|Estimate|||||||2007-07-06|2007-07-10|Estimate|June 2000||2000-06-30|July 2007|2007-07-31|October 2002|Actual|2002-10-31|||||Interventional|||Effects of a Ketogenic Diet on Body Weight and Cardiovascular Risk Factors|Effects of a Ketogenic Diet on Body Weight and Cardiovascular Risk Factors|Completed||Phase 1|103|Actual|University of Cincinnati|||||f||||f||||||||||2018-06-01 03:05:55.429753|2018-06-01 03:05:55.429753
NCT00498381|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-08|||2007-07-08|2007-07-08|2007-07-10|Estimate|||||||2007-07-08|2007-07-10|Estimate|August 2005||2005-08-31|February 2005|2005-02-28|August 2006|Actual|2006-08-31|||||Interventional|OSA||The Induction of IL-6 by NF-kB in PBMC in OSA||Completed||N/A|20|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:05:55.51587|2018-06-01 03:05:55.51587
NCT00498368|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2016-09-28||2016-12-06|2007-07-09|2007-07-10|Estimate|2016-09-28|2016-11-18|Estimate||||2016-12-06|2017-02-01|Estimate|February 2009||2009-02-28|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy|A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy|Completed||Phase 4|34|Actual|Mayo Clinic||2|||f||||t||||||||Undecided||2018-06-01 03:05:55.626906|2018-06-01 03:05:55.626906
NCT00498355|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|2012-06-20||2017-10-24|2007-07-09|2007-07-10|Estimate|2012-09-19|2012-09-21|Estimate||||2017-10-24|2017-11-30|Actual|July 2007||2007-07-31|October 2017|2017-10-31|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|LIME||Lucentis for Inflammatory Macular Edema Trial|Effect of Ranibizumab on Refractory Macular Edema in Uveitis|Completed||Phase 1/Phase 2|7|Actual|University of California, San Francisco|Limitations of the study include a small sample size and lack of a control group.|1|||f||||t||||||||||2018-06-01 03:05:56.024767|2018-06-01 03:05:56.024767
NCT00498342|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2008-02-11|2007-07-06|2007-07-10|Estimate|||||||2008-02-11|2008-02-18|Estimate|June 2007||2007-06-30|July 2007|2007-07-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease|The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease|Completed||N/A|||University of Vermont|||||f||||f||||||||||2018-06-01 03:05:56.335559|2018-06-01 03:05:56.335559
NCT00498329|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-07|||2017-06-30|2007-07-07|2007-07-10|Estimate|||||||2017-06-30|2017-07-02|Actual|July 3, 2007||2007-07-03|November 18, 2011|2011-11-18|November 18, 2011||2011-11-18|||||Observational|||Brain Function in Performance of Motor Tasks|Brain Connectivity and Sensorimotor Integration During Dual/Single Motor Tasks|Completed|||144|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:05:56.482423|2018-06-01 03:05:56.482423
NCT00498303|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2008-04-21|2007-07-09|2007-07-10|Estimate|||||||2008-04-21|2008-04-22|Estimate|June 2007||2007-06-30|April 2008|2008-04-30||||||||Interventional|||Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008|A Phase III, Multicenter, Uncontrolled, Open-Label Study to Evaluate Safety and Immunogenicity of Preservative Free, Inactivated Split Influenza Vaccine, Using the Strain Composition 2007/2008 When Administered to Adult and Elderly Subjects|Completed||Phase 3|120||Novartis|||||f||||f||||||||||2018-06-01 03:05:56.682718|2018-06-01 03:05:56.682718
NCT00498290|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2009-03-24|2007-07-09|2007-07-10|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|March 2010|Anticipated|2010-03-31|February 2009|Actual|2009-02-28||Interventional|ERAS||The Protocol of Enhanced Recovery After Surgery in Colorectal Surgery|The Protocol of Enhanced Recovery After Surgery in Colorectal Surgery|Unknown status|Recruiting|N/A|500|Anticipated|Fudan University||2|||f||||t||||||||||2018-06-01 03:05:56.754288|2018-06-01 03:05:56.754288
NCT00498277|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2012-07-31|2007-07-09|2007-07-10|Estimate|||||||2012-07-31|2012-08-01|Estimate|August 2004||2004-08-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Quantitative Diffusion and Fat Imaging of the Spine|Quantitative Diffusion and Fat Imaging of Vertebral Fractures|Completed|||21|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:05:56.830526|2018-06-01 03:05:56.830526
NCT00498264|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-09|||2007-07-09|2007-07-09|2007-07-10|Estimate|||||||2007-07-09|2007-07-10|Estimate|January 2005||2005-01-31|June 2007|2007-06-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Effectiveness of Physical Exercise in Women With Fibromyalgia|Effectiveness of Physical Exercise on Decrease of Pain in Patients With Fibromyalgia:Randomized Clinical Trial|Unknown status|Recruiting|Phase 2|90|Anticipated|Federal University of São Paulo|||||f||||t||||||||||2018-06-01 03:05:56.939431|2018-06-01 03:05:56.939431
NCT00498251|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2007-07-09|2007-07-09|2007-07-10|Estimate|||||||2007-07-09|2007-07-10|Estimate|September 2004||2004-09-30|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Prevention of Lung Edema After Thoracic Surgery|Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study|Completed||N/A|30|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-06-01 03:05:57.039768|2018-06-01 03:05:57.039768
NCT00498238|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2007-07-06|2007-07-06|2007-07-09|Estimate|||||||2007-07-06|2007-07-09|Estimate|July 2003||2003-07-31|July 2007|2007-07-31|September 2005|Actual|2005-09-30|||||Interventional|||The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism|The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients|Completed||N/A|34|Actual|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:05:57.128729|2018-06-01 03:05:57.128729
NCT00498225|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2012-11-01|2007-07-06|2007-07-09|Estimate|||||||2012-11-01|2012-11-02|Estimate|July 2007||2007-07-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|July 2011|Actual|2011-07-31||Interventional|GEST||Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer|Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)|Completed||Phase 3|834|Actual|Taiho Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-06-01 03:05:57.220617|2018-06-01 03:05:57.220617
NCT00498212|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05||2014-06-16|2018-02-20|2007-07-05|2007-07-09|Estimate||||2014-06-16|2014-06-19|Estimate|2018-02-20|2018-02-22|Actual|July 2007||2007-07-31|February 2018|2018-02-28|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease|A Phase 2, Single-Blind, Randomized Study of Safety and Immunogenicity Following Vaccination With Single or Double Doses of HEPLISAV™ in Adults With End-Stage Renal Disease|Terminated||Phase 2|41|Actual|Dynavax Technologies Corporation||2||Voluntary halt due to an FDA Clinical Hold issued in relation to DV2-HBV-10.|f||||t||||||||No||2018-06-01 03:05:57.346715|2018-06-01 03:05:57.346715
NCT00498199|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2010-09-29|2007-07-06|2007-07-09|Estimate|||||||2010-09-29|2010-09-30|Estimate|April 2007||2007-04-30|July 2007|2007-07-31||||||||Observational|||Visual Impairment, Oscillopsia and Multiple Sclerosis|Visual Impairment, Oscillopsia and Multiple Sclerosis|Terminated|||100|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:05:57.480749|2018-06-01 03:05:57.480749
NCT00498186|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|2010-03-23||2014-09-24|2007-07-06|2007-07-09|Estimate|2010-03-23|2010-04-13|Estimate||||2014-09-24|2014-10-02|Estimate|July 2003||2003-07-31|October 2011|2011-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)|An Open-label Extension Trial to Determine Safety and Tolerability of Long-term Transdermal Application of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|Completed||Phase 2|295|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:05:57.585984|2018-06-01 03:05:57.585984
NCT00498173|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|2017-03-17||2017-08-11|2007-07-06|2007-07-09|Estimate|2017-08-11|2017-08-14|Actual||||2017-08-11|2017-08-14|Actual|July 2007||2007-07-31|August 2017|2017-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism|Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism|Completed||Phase 3|60|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:05:58.110747|2018-06-01 03:05:58.110747
NCT00498160|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2018-04-19|2007-07-06|2007-07-09|Estimate|||||||2018-04-19|2018-04-20|Actual|January 2005||2005-01-31|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion|1) Induction of Donor Specific Tolerance in Recipients of Kidney Allografts by Donor Bone Marrow Cell Infusion (Deceased Donors) and 2) Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion|Active, not recruiting||Phase 1/Phase 2|38|Actual|University of Louisville||1|||t||||t|t|f||||||Undecided||2018-06-01 03:05:59.15218|2018-06-01 03:05:59.15218
NCT00498147|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2009-10-05|2007-07-06|2007-07-09|Estimate|||||||2009-10-05|2009-10-06|Estimate|July 2007||2007-07-31|October 2009|2009-10-31|July 2010|Anticipated|2010-07-31|March 2010|Anticipated|2010-03-31||Observational|DECIDE||Determining Rates of Cardiovascular Complications Among Patients of a Managed Diabetes Care Program|Does Managed Diabetes Care Decrease Cardiovascular Complications of Diabetes?|Unknown status|Active, not recruiting||1213|Actual|Group Health Centre|||2||f||||f||||||||||2018-06-01 03:05:59.256816|2018-06-01 03:05:59.256816
NCT00498134|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2010-07-06|2007-07-06|2007-07-09|Estimate|||||||2010-07-06|2010-07-07|Estimate|March 2004||2004-03-31|July 2010|2010-07-31|April 2013|Anticipated|2013-04-30|||||Interventional|||Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway|Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway|Unknown status|Active, not recruiting|N/A|1200|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:05:59.361723|2018-06-01 03:05:59.361723
NCT00411294|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-13|Estimate|||||||2006-12-11|2006-12-13|Estimate||||December 2006|2006-12-31||||||||Observational|||Ergocalciferol in Chronic Kidney Disease|The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4|Completed|||||Saint Louis VA Medical Center|||||f||||||||||||||2018-06-01 03:34:29.152638|2018-06-01 03:34:29.152638
NCT00498121|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2009-12-17|2007-07-06|2007-07-09|Estimate|||||||2009-12-17|2009-12-18|Estimate|July 2007||2007-07-31|December 2009|2009-12-31|May 2009|Actual|2009-05-31|||||Observational|||The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)|The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)|Terminated|||50|Anticipated|McGill University Health Center|||1|One of the principal investigators has moved to a different institution|f||||t||||||||||2018-06-01 03:05:59.440232|2018-06-01 03:05:59.440232
NCT00498108|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2014-09-24|2007-07-06|2007-07-09|Estimate|||||||2014-09-24|2014-09-25|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects|An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|Completed||Phase 3|341|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 03:05:59.575337|2018-06-01 03:05:59.575337
NCT00498095|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2011-06-14|2007-07-06|2007-07-09|Estimate|||||||2011-06-14|2011-06-16|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|December 2006|Actual|2006-12-31|||||Observational|||A Study on a New Staining Method (C4d Staining) of Transplanted Kidney Biopsies|Experience of C4d Staining in Renal Allograft Biopsies|Completed|||52|Actual|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:05:59.666721|2018-06-01 03:05:59.666721
NCT00498082|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2007-09-05|2007-07-06|2007-07-09|Estimate|||||||2007-09-05|2007-09-06|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|September 2008|Anticipated|2008-09-30|||||Observational|||Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease|Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease|Unknown status|Recruiting||||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-06-01 03:05:59.755966|2018-06-01 03:05:59.755966
NCT00498069|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2015-03-17|2007-07-06|2007-07-09|Estimate|||||||2015-03-17|2015-03-19|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)|Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease|Completed||N/A|48|Actual|Harvest Technologies||2|||f||||f||||||||||2018-06-01 03:05:59.869708|2018-06-01 03:05:59.869708
NCT00498056|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2012-03-23|2007-07-05|2007-07-09|Estimate|||||||2012-03-23|2012-03-27|Estimate||||March 2012|2012-03-31||||||||Interventional|||Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa|A Phase IIB Test-of-Concept, Randomized, Double-Blind, Placebo-Controlled, International Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Persons|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 03:06:00.105075|2018-06-01 03:06:00.105075
NCT00498043|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2014-08-12|2007-07-05|2007-07-09|Estimate|||||||2014-08-12|2014-08-13|Estimate|July 2007||2007-07-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|LNH2007-3B||A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma|Randomized Phase II Study of Two Associations of Rituximab and Chemotherapy, With a PET -Driven Strategy, in Patients From 18 to 59 With DLBCL CD20+ Lymphoma and 2 or 3 Adverse Prognostic Factors of the Age-adjusted IPI|Completed||Phase 2|222|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 03:06:00.295853|2018-06-01 03:06:00.295853
NCT00498030|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2018-03-29|2007-07-06|2007-07-09|Estimate|||||||2018-03-29|2018-03-30|Actual|December 2005|Actual|2005-12-31|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Observational|||Predicting Insulin Resistance in American Indian Youth|Predicting Insulin Resistance in American Indian Youth|Completed|||202|Actual|University of Nebraska|||||f||||t||||||Samples Without DNA|"~     Samples are only retained until specific tests are completed. Some tests are done in the~     clinical lab and some tests are done in the research lab.~   "|||2018-06-01 03:06:00.449159|2018-06-01 03:06:00.449159
NCT00498017|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2011-06-14|2007-07-06|2007-07-09|Estimate|||||||2011-06-14|2011-06-16|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|||||Observational|||Infections After Renal Transplantation: Diseases Pattern in Hong Kong|Infections After Renal Transplantation: Diseases Pattern in Hong Kong|Completed|||58|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:06:00.569189|2018-06-01 03:06:00.569189
NCT00498004|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2008-11-03|2007-07-06|2007-07-09|Estimate|||||||2008-11-03|2008-11-04|Estimate|August 2007||2007-08-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Quality of Life (QOL) in Female Patient With Schizophrenia|Randomized, Open Label, 8-Week Study of Quetiapine and Risperidone on Quality of Life in Female With Schizophrenia|Terminated||Phase 4|100|Anticipated|Inje University||||difficult to recruit subject|f||||t||||||||||2018-06-01 03:06:00.659356|2018-06-01 03:06:00.659356
NCT00497991|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2010-12-07|2007-07-05|2007-07-09|Estimate|||||||2010-12-07|2010-12-08|Estimate|May 2006||2006-05-31|December 2010|2010-12-31|April 2010|Actual|2010-04-30|October 2009|Actual|2009-10-31||Interventional|||Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia|A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia.|Completed||Phase 1|65|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:06:00.802941|2018-06-01 03:06:00.802941
NCT00497978|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2011-12-27|2007-07-06|2007-07-09|Estimate|||||||2011-12-27|2011-12-30|Estimate|March 2008||2008-03-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|TAUP||The Effect of Taurine on Morbidity and Mortality in the Elderly Hip Fracture Patient|The Effect of Taurine on Morbidity and Mortality in the Elderly Hip Fracture Patient|Completed||N/A|236|Actual|Medical Center Alkmaar||2|||f||||f||||||||||2018-06-01 03:06:00.942541|2018-06-01 03:06:00.942541
NCT00497965|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2010-04-16|2007-07-05|2007-07-09|Estimate|||||||2010-04-16|2010-04-20|Estimate|April 2007||2007-04-30|April 2010|2010-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pilot Study: Does Chiropractic Care Decrease Fall Risk in Older Adults|Pilot Study: Does Chiropractic Care Decrease Fall Risk in Older Adults?|Completed||N/A|30|Anticipated|Cleveland Chiropractic College|||||f||||f||||||||||2018-06-01 03:06:01.071944|2018-06-01 03:06:01.071944
NCT00497952|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2018-05-18|2007-07-06|2007-07-09|Estimate|||||||2018-05-18|2018-05-22|Actual|July 2007||2007-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis|Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis|Active, not recruiting||Phase 1/Phase 2|3|Actual|University of Louisville||1|||t||||t|t|f||||||Undecided||2018-06-01 03:06:01.183493|2018-06-01 03:06:01.183493
NCT00497939|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2010-07-06|2007-07-06|2007-07-09|Estimate|||||||2010-07-06|2010-07-07|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|March 2008|Anticipated|2008-03-31|||||Interventional|||The Effectiveness of Saw Palmetto and Sanmiaoshan on Benign Prostatic Hyperplasia in Chinese Patients|The Effectiveness of Saw Palmetto and Sanmiaoshan on International Prostate Symptom Score and Peak Urinary Flow Rate of Chinese Patients With Benign Prostatic Hyperplasia|Unknown status|Recruiting|N/A|40|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:06:01.295346|2018-06-01 03:06:01.295346
NCT00497926|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2018-04-19|2007-07-06|2007-07-09|Estimate|||||||2018-04-19|2018-04-20|Actual|March 2008||2008-03-31|April 2018|2018-04-30|March 2031|Anticipated|2031-03-31|March 2026|Anticipated|2026-03-31||Interventional|||Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion|Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion|Active, not recruiting||Phase 2|60|Anticipated|University of Louisville||1|||f||||t|t|f||||||Undecided||2018-06-01 03:06:01.391358|2018-06-01 03:06:01.391358
NCT00497913|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2008-04-22|2007-07-06|2007-07-09|Estimate|||||||2008-04-22|2008-04-23|Estimate|August 2007||2007-08-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|DCLE||Dysport® Injection in the Treatment of Chronic Lateral Epicondylitis||Completed||Phase 3|52|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 03:06:01.481971|2018-06-01 03:06:01.481971
NCT00497900|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2015-06-02|2007-07-06|2007-07-09|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2007||2007-08-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|KarViDII||The Effect of Calcium and Vitamin D in Patients With Heart Failure||Completed||Phase 4|45|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-06-01 03:06:01.590648|2018-06-01 03:06:01.590648
NCT00497887|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2010-10-18|2007-07-06|2007-07-09|Estimate|||||||2010-10-18|2010-10-19|Estimate|December 2006||2006-12-31|January 2010|2010-01-31||||||||Observational|LE-Heart||Genetic- and Biological-Markers of Predisposition to Atherosclerosis: Leipzig-Heart Study|Observational Study for Identification of Genetic- and Biological-Markers of Predisposition to Atherosclerosis: Leipzig-Heart Study (LE-Heart)|Unknown status|Recruiting||4000|Anticipated|University of Leipzig|||||f||||f||||||Samples With DNA|"~     serum, plasma, whole blood (DNA), blood cells~   "|||2018-06-01 03:06:01.690556|2018-06-01 03:06:01.690556
NCT00497874|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|2011-06-22||2015-07-10|2007-07-05|2007-07-09|Estimate|2015-06-11|2015-07-07|Estimate||||2015-07-10|2015-07-31|Estimate|July 2003||2003-07-31|July 2015|2015-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||An Expert System to Reduce Depression in Primary Care|An Expert System to Reduce Depression in Primary Care|Completed||Phase 2|902|Actual|Pro-Change Behavior Systems|"There was only a single follow up assessment administered at 9 months post-baseline.~The study attrition rate was > 30%."|2|||f||||f||||||||||2018-06-01 03:06:01.787845|2018-06-01 03:06:01.787845
NCT00497861|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-06|2007-07-06|2007-07-09|Estimate|||||||2007-07-06|2007-07-09|Estimate|December 2004||2004-12-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Comparison of Activator Manipulation Versus Manual Side Posture Manipulation in Patients With Low Back Pain|Comparison of Mechanical Force, Manually Assisted Activator Manipulation Versus Manual Side Posture Manipulation in Patients With Low Back Pain: a Randomized Pilot Study|Completed||N/A|40|Actual|Cleveland Chiropractic College|||||f||||f||||||||||2018-06-01 03:06:02.369775|2018-06-01 03:06:02.369775
NCT00497848|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2011-06-23|2007-07-06|2007-07-09|Estimate|||||||2011-06-23|2011-06-27|Estimate|May 2007||2007-05-31|July 2007|2007-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Compliance Project Concerning People With Schizophrenia|Individual Versus System Orientated Interventions in Handling Drug Related Problems in People With Schizophrenia|Completed||N/A|70|Actual|Ministry of the Interior and Health, Denmark||2|||f||||t||||||||||2018-06-01 03:06:02.456297|2018-06-01 03:06:02.456297
NCT00497835|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2011-06-14|2007-07-06|2007-07-09|Estimate|||||||2011-06-14|2011-06-15|Estimate|October 2007||2007-10-31|July 2007|2007-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Study of Algorithm for Epilepsy Alert Device|Epilepsy Alert Device - Epilert Performance|Completed|||15|Actual|Biolert|||||f||||t|||||||"~     no Biospecimen~   "|||2018-06-01 03:06:02.545627|2018-06-01 03:06:02.545627
NCT00497822|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2010-07-06|2007-07-06|2007-07-09|Estimate|||||||2010-07-06|2010-07-07|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|October 2007|Anticipated|2007-10-31|||||Interventional|||A Randomized Controlled Trial on the Effect of Exercise on Physical, Cognitive and Affective Function in Dementia Subjects|To Study the Effect of Exercise Training in Term of Aerobic Exercise for 3 Months, on the Physical, Cognitive and Affective Function in Dementia Subjects|Unknown status|Recruiting|N/A|64|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:06:02.603834|2018-06-01 03:06:02.603834
NCT00497809|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2011-05-02|2007-07-05|2007-07-09|Estimate|||||||2011-05-02|2011-05-03|Estimate|August 2007||2007-08-31|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia|An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (G-CSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia|Completed||Phase 2|189|Actual|AviGenics||4|||f||||t||||||||||2018-06-01 03:06:02.904071|2018-06-01 03:06:02.904071
NCT00497796|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|2015-05-04||2015-05-20|2007-07-05|2007-07-09|Estimate|2015-05-20|2015-06-04|Estimate||||2015-05-20|2015-06-04|Estimate|July 2007||2007-07-31|March 2014|2014-03-31|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional||The Intent-to-Treat Safety (ITT-S) population, defined as all randomized subjects who received at least one dose of study drug, regardless of whether they had any post-baseline evaluations.|Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients|A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants|Completed||Phase 3|307|Actual|Shire||2|||f||||t||||||||||2018-06-01 03:06:03.285407|2018-06-01 03:06:03.285407
NCT00497783|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2008-05-19|2007-07-06|2007-07-09|Estimate|||||||2008-05-19|2008-05-20|Estimate|May 2007||2007-05-31|May 2008|2008-05-31||||||||Interventional|||Acceptability Lactoserum (Dermacyd Delicata - New Fragrance)|Safety Dermatological Evaluation of the Acceptability With Gynecological Follow up for Dermacyd Femina Delicata|Completed||Phase 4|30|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 03:06:05.592441|2018-06-01 03:06:05.592441
NCT00497601|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2008-09-11|2007-07-05|2007-07-06|Estimate|||||||2008-09-11|2008-09-12|Estimate|February 2007||2007-02-28|September 2008|2008-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar|A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar).|Completed||Phase 2|60|Actual|Banaras Hindu University||4|||f||||f||||||||||2018-06-01 03:06:08.383126|2018-06-01 03:06:08.383126
NCT00497770|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|2012-03-15||2012-04-27|2007-07-05|2007-07-09|Estimate|2012-03-15|2012-04-11|Estimate||||2012-04-27|2012-05-02|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed|Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study|Completed|||434|Actual|Eli Lilly and Company|This is an observational study, as such, the investigators followed the label recommendations and any changes to the label which occurred during the study.||4||f||||f||||||||||2018-06-01 03:06:05.738042|2018-06-01 03:06:05.738042
NCT00497757|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06||2013-02-22|2018-05-18|2007-07-06|2007-07-09|Estimate||||2013-02-22|2013-02-28|Estimate|2018-05-18|2018-05-22|Actual|July 2003||2003-07-31|May 2018|2018-05-31|December 1, 2016|Actual|2016-12-01|November 7, 2011|Actual|2011-11-07||Interventional|||Induction of Donor Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion|1) Induction of Donor-Specific Tolerance in Recipients of Cardiac Allografts by Donor Stem Cell Infusion 2) Induction of Donor-Specific Tolerance by Donor Facilitating Cell (FC): Stem Cell Infusion in Recipients of Hepatic Allografts|Completed||Phase 1/Phase 2|62|Actual|University of Louisville||1|||f||||t|t|f||||||No||2018-06-01 03:06:07.30637|2018-06-01 03:06:07.30637
NCT00497744|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2011-06-14|2007-07-06|2007-07-09|Estimate|||||||2011-06-14|2011-06-16|Estimate|November 2005||2005-11-30|June 2011|2011-06-30|December 2007|Actual|2007-12-31|||||Observational|||A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis|Research Study on the Pharmacokinetic Profile of Intraperitoneal Cefepime in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis|Completed|||6|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:06:07.375729|2018-06-01 03:06:07.375729
NCT00497731|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2009-06-19|2007-07-05|2007-07-09|Estimate|||||||2009-06-19|2009-06-22|Estimate|May 2005||2005-05-31|June 2009|2009-06-30|April 2009|Anticipated|2009-04-30|June 2008|Actual|2008-06-30||Interventional|||AZD1152 in Patients With Advanced Solid Malignancies-Study 1|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2 Hour Intravenous Infusion on Two Dose Schedules in Patients With Advanced Solid Malignancies|Terminated||Phase 1|70|Anticipated|AstraZeneca||||"Efficacy seen in the solid tumour patient population was not sufficient to continue research~   with AZD1152 monotherapy in solid tumors at that time."|f||||f||||||||||2018-06-01 03:06:07.452738|2018-06-01 03:06:07.452738
NCT00497718|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2010-04-16|2007-07-06|2007-07-09|Estimate|||||||2010-04-16|2010-04-20|Estimate|February 2007||2007-02-28|April 2010|2010-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of Chiropractic Manipulation on Spine-related Pain and Balance in Older Adults|The Effect of Chiropractic Manipulation on Spine-related Pain and Balance in Older Adults|Completed||N/A|75|Anticipated|Cleveland Chiropractic College|||||f||||f||||||||||2018-06-01 03:06:07.51946|2018-06-01 03:06:07.51946
NCT00497705|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2017-06-30|2007-07-06|2007-07-09|Estimate|||||||2017-06-30|2017-07-02|Actual|July 3, 2007||2007-07-03|July 7, 2009|2009-07-07||||July 7, 2009|Actual|2009-07-07||Observational|||Genes Causing Ebstein's Anomaly|Genes Causing Congenital Ebstein's Anomaly|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:06:07.596192|2018-06-01 03:06:07.596192
NCT00497692|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2008-05-19|2007-07-06|2007-07-09|Estimate|||||||2008-05-19|2008-05-20|Estimate|May 2007||2007-05-31|May 2008|2008-05-31||||||||Interventional|||Topic Compatibility Lactoserum (Dermacyd Delicata - New Fragrance)|Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensitivity) for Dermacyd Femina Delicata|Completed||Phase 4|30|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 03:06:07.674896|2018-06-01 03:06:07.674896
NCT00497679|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2009-05-13|2007-07-05|2007-07-09|Estimate|||||||2009-05-13|2009-05-14|Estimate|August 2006||2006-08-31|May 2009|2009-05-31|July 2007|Actual|2007-07-31|||||Interventional|||AZD1152 in Patients With Advanced Solid Malignancies-Study 3|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies|Terminated||Phase 1|45|Anticipated|AstraZeneca||||"Study is now terminated due to technical difficulties with administration of study drug in this~   patient population with this schedule"|f||||f||||||||||2018-06-01 03:06:07.732537|2018-06-01 03:06:07.732537
NCT00497666|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-06|||2007-07-06|2007-07-06|2007-07-09|Estimate|||||||2007-07-06|2007-07-09|Estimate|August 2007||2007-08-31|July 2007|2007-07-31|December 2007|Anticipated|2007-12-31|||||Observational|||Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study|Retrospective Study Evaluating the Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study|Unknown status|Not yet recruiting||||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:06:07.894707|2018-06-01 03:06:07.894707
NCT00497653|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2011-11-15|2007-07-05|2007-07-09|Estimate|||||||2011-11-15|2011-11-16|Estimate|February 2001||2001-02-28|November 2011|2011-11-30|July 2009|Actual|2009-07-31|July 2007|Actual|2007-07-31||Interventional|PCOS||Oral Administration of DCI to Women With PCOS|Determination if Oral DCI Administration to Women With PCOS Increases Total DCI Content in Urine and Blood...|Terminated||Phase 2/Phase 3|13|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-06-01 03:06:07.977637|2018-06-01 03:06:07.977637
NCT00497640|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2016-01-14|2007-07-05|2007-07-06|Estimate|||||||2016-01-14|2016-01-15|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|July 2008|Actual|2008-07-31||Interventional|||CPAP Titration Using an Artificial Neural Network: A Randomized Controlled Study|CPAP Titration Using an Artificial Neural Network: A Randomized Controlled Study|Withdrawn||N/A|0|Actual|State University of New York at Buffalo|||||f||||t||||||||||2018-06-01 03:06:08.090211|2018-06-01 03:06:08.090211
NCT00497627|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2016-05-11|2007-07-05|2007-07-06|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2007||2007-01-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Observational|||Quality of Life and Cardiometabolic Risk Factors in Patients After Debanding|Quality of Life and Cardiometabolic Risk Factors in Patients After Debanding|Completed|||12|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 03:06:08.205679|2018-06-01 03:06:08.205679
NCT00497614|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2008-12-04|2007-07-05|2007-07-06|Estimate|||||||2008-12-04|2008-12-05|Estimate|May 2006||2006-05-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|PETRA||Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)|18F-FDG Positron Emission Tomography to Study the Response to Adalimumab in Rheumatoid Arthritis. A Monocentric Pilot Study|Completed||N/A|8|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-06-01 03:06:08.289193|2018-06-01 03:06:08.289193
NCT00497588|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2013-07-10|2007-07-05|2007-07-06|Estimate|||||||2013-07-10|2013-07-11|Estimate|March 2007||2007-03-31|July 2013|2013-07-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy||Unknown status|Recruiting|Phase 3|33|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-06-01 03:06:08.475802|2018-06-01 03:06:08.475802
NCT00497549|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2011-05-09|2007-07-05|2007-07-06|Estimate|||||||2011-05-09|2011-05-10|Estimate|July 2004||2004-07-31|April 2011|2011-04-30|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|||Trial Comparing Side-to-Side Stapled and Hand-sewn Esophagogastric Anastomosis in Neck|Prospective Randomized Controlled Trial Comparing Side to Side Stapled and Hand Sewn Esophagogastric Anastomosis in the Neck|Completed||N/A|174|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||||||||||||2018-06-01 03:06:08.720094|2018-06-01 03:06:08.720094
NCT00497536|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2009-02-04|2007-07-04|2007-07-06|Estimate|||||||2009-02-04|2009-02-05|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Pharmacokinetics of IAsp Following CSII in Patients With T1DM|Pharmacokinetics of Insulin Aspart (IAsp) Following Continuous Subcutaneous Insulin Infusion (CSII) in Patients With Type 1 Diabetes Mellitus (T1DM)- Basal Rate Resolution.|Completed||Phase 4|12|Anticipated|University of Aarhus||3|||f||||t||||||||||2018-06-01 03:06:08.814214|2018-06-01 03:06:08.814214
NCT00497523|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2015-03-18|2007-07-05|2007-07-06|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|January 2007|Actual|2007-01-31|||||Interventional|||Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms|Double Blind, Multinational, Multicentre, Parallel-group, Placebo-controlled Design Trial of the Efficacy and Safety of Nebulised Beclometahsone Dipropionate (400 μg b.i.d.) Plus as Needed Salbutamol Versus as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination, in the 12-week Treatment of Young Children With Asthma Symptoms|Completed||Phase 3|283|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-06-01 03:06:08.901046|2018-06-01 03:06:08.901046
NCT00497510|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Feasibility Study of Short-Term Effects of Chiropractic Manipulation on Older Adults With Impaired Balance|Feasibility Study of Short-Term Effects of Chiropractic Manipulation on Older Adults With Impaired Balance|Completed||N/A|11|Actual|Cleveland Chiropractic College|||||f||||f||||||||||2018-06-01 03:06:09.169987|2018-06-01 03:06:09.169987
NCT00497497|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2017-05-18|2007-07-03|2007-07-06|Estimate|||||||2017-05-18|2017-05-19|Actual|October 2007|Actual|2007-10-31|May 2017|2017-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)|A Phase Ib, Dose-Escalation Study of the Safety and Pharmacokinetics of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer|Completed||Phase 1|20|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:06:09.260417|2018-06-01 03:06:09.260417
NCT00497484|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate||||June 2007|2007-06-30||||||||Interventional|||Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)|Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)|Unknown status|Active, not recruiting|N/A|||University of Milan|||||f||||||||||||||2018-06-01 03:06:09.358093|2018-06-01 03:06:09.358093
NCT00497471|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate|February 1995||1995-02-28|July 2007|2007-07-31|July 1999|Actual|1999-07-31|||||Interventional|||RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants|The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission|Terminated||N/A|832|Actual|Hospital Clinic of Barcelona||||Follow-up end in 1999|f||||t||||||||||2018-06-01 03:06:09.446539|2018-06-01 03:06:09.446539
NCT00497458|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2009-04-07|2007-07-04|2007-07-06|Estimate|||||||2009-04-07|2009-04-09|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Interventional|ART2||Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects|Phase II Study of Testosterone Replacement in Women Experiencing Aromatase Inhibitor Side-Effects in Adjuvant Therapy for Breast Cancer|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|Havah Therapeutics Pty Ltd||3|||f||||f||||||||||2018-06-01 03:06:09.544511|2018-06-01 03:06:09.544511
NCT00497445|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2009-11-05|2007-07-05|2007-07-06|Estimate|||||||2009-11-05|2009-11-06|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|NETP-extra||The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease|Additional Exercise Therapy in Patients With Peripheral Arterial Disease: The Value of Supervised Exercise Therapy After Invasive Treatment of Peripheral Arterial Disease.|Completed||N/A|86|Actual|Atrium Medical Center||2|||f||||f||||||||||2018-06-01 03:06:09.665839|2018-06-01 03:06:09.665839
NCT00497432|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2013-05-30|2007-07-05|2007-07-06|Estimate|||||||2013-05-30|2013-05-31|Estimate|July 2007||2007-07-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Observational|||Hyperbaric Oxygen Treatment in Patients With White Matter Hyperintensities|Hyperbaric Oxygen Treatment In Patients With White Matter Hyperintensities On Magnetic Resonance Imaging and Neurologic Deficits|Completed|||20|Actual|St. Luke's Hospital, Chesterfield, Missouri|||||f||||f||||||||||2018-06-01 03:06:09.746203|2018-06-01 03:06:09.746203
NCT00497419|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2008-08-19|2007-07-05|2007-07-06|Estimate|||||||2008-08-19|2008-08-20|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Reperfusion Time in ST Segment Elevation Myocardial Infarction (STEMI)|Evaluation of a Fast Track for Patients With STEMI|Completed||N/A|150|Anticipated|University Hospital, Geneva|||||f||||t||||||||||2018-06-01 03:06:09.887075|2018-06-01 03:06:09.887075
NCT00497406|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-03-14|2007-07-03|2007-07-06|Estimate|||||||2016-03-14|2016-03-16|Estimate|December 2005||2005-12-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Tx & IMRT Tomo to Reduce Xerostomia|A Pilot Study to Evaluate the Feasibility of Combining Submandibular Salivary Gland Transfer Procedure and Intensity Modulated Radiation Therapy (Helical Tomotherapy) to Reduce Dryness of Mouth (Xerostomia) in Head and Neck Cancer Patients After Surgery|Unknown status|Active, not recruiting|N/A|46|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:06:09.967878|2018-06-01 03:06:09.967878
NCT00497393|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2008-09-11|2007-07-05|2007-07-06|Estimate|||||||2008-09-11|2008-09-12|Estimate|July 2007||2007-07-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Clinical Decision Unit (CDU) - Evaluation of a Novel Approach to Address Emergency Department Overcrowding|Clinical Decision Unit (CDU) - Evaluation of a Novel Approach to Address Emergency Department Overcrowding|Completed||Phase 4|6217|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 03:06:10.060716|2018-06-01 03:06:10.060716
NCT00497380|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2018-04-24|2007-07-05|2007-07-06|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2009||2009-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|July 2012|Actual|2012-07-31||Interventional|||Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery|Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery|Active, not recruiting||N/A|32|Anticipated|Texas A&M University||2|||f||||f||||||||||2018-06-01 03:06:10.147324|2018-06-01 03:06:10.147324
NCT00497367|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2015-03-25|2007-07-05|2007-07-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|July 2008|Actual|2008-07-31||Interventional|||Safety Study to Assess the Feasibility of Use in Humans of the TAXUS Petal Bifurcation Coronary Stent System|A Prospective, Single-arm, Multicenter 2-phase Feasibility Study to Assess the TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System (TAXUS Petal)for the Treatment of de Novo Atherosclerotic Bifurcation Lesions|Completed||Phase 1|28|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 03:06:10.23113|2018-06-01 03:06:10.23113
NCT00497354|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2010-06-14|2007-07-04|2007-07-06|Estimate|||||||2010-06-14|2010-06-15|Estimate|July 2007||2007-07-31|June 2010|2010-06-30|December 2007|Actual|2007-12-31|||||Interventional|||Does a Low Volume Ultrasound-Guided Technique Reduce Common Complications of Interscalene Brachial Plexus Block?|Does a Low Volume Ultrasound-Guided Technique Reduce Common Complications of Interscalene Brachial Plexus Block?|Completed||Phase 3|38|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 03:06:10.31699|2018-06-01 03:06:10.31699
NCT00497341|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2016-02-17|2007-07-05|2007-07-06|Estimate|||||||2016-02-17|2016-02-19|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Antibiotic Prophylaxis in Total Knee Prosthesis|Randomised And Double Blind Study To Evaluate The Best Moment To Infuse The Prophylactic Antibiotic In Knee Arthroplasty Performed Under Ischemia|Completed||Phase 4|1332|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 03:06:10.384318|2018-06-01 03:06:10.384318
NCT00497328|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2014-01-13|2007-07-05|2007-07-06|Estimate|||||||2014-01-13|2014-01-14|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|CONTRAST||COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Adverse Side Effect of contrasT|An Open Labelled Randomized Multi-center Study of COmbined N-acetylcysteine and Bicarbonate in PCI To Reduce Incidence of Contrast Induced Nephropathy|Completed||Phase 2/Phase 3|477|Actual|National University Hospital, Singapore||3|||f||||t||||||||||2018-06-01 03:06:10.46364|2018-06-01 03:06:10.46364
NCT00497315|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2009-04-09|2007-07-04|2007-07-06|Estimate|||||||2009-04-09|2009-04-10|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|PACCORA||Evaluation of Pemetrexed Combined With Cisplatin and Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|A Randomized Multicenter Phase II Study Of Induction Therapy With Pemetrexed And Cisplatin Followed By Chemoradiation With Pemetrexed Versus Chemoradiation With Pemetrexed Followed By Consolidation Therapy With Pemetrexed And Cisplatin In Patients With Stage III Non-Small Cell Lung Cancer: Paccora Trial|Completed||Phase 2|30|Actual|University Hospital, Antwerp||2|||f||||f||||||||||2018-06-01 03:06:10.55685|2018-06-01 03:06:10.55685
NCT00497302|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2013-03-01|2007-07-05|2007-07-06|Estimate|||||||2013-03-01|2013-03-05|Estimate|November 2004||2004-11-30|March 2013|2013-03-31|August 2009|Actual|2009-08-31|June 2008|Actual|2008-06-30||Interventional|HOME||Recovery Housing For Drug Dependent Pregnant Women|Recovery Housing For Drug Dependent Pregnant Women|Completed||Phase 2/Phase 3|128|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 03:06:10.636983|2018-06-01 03:06:10.636983
NCT00497289|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2011-06-08|2007-07-04|2007-07-06|Estimate|||||||2011-06-08|2011-06-09|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants|Double-blind, Prospective, Randomized Comparison of a MCT/LCT/FO Containing 20% Lipid Emulsion With a MCT/LCT Emulsion (20%) for Parenteral Nutrition in Preterm Infants|Completed||Phase 2|34|Anticipated|B. Braun Melsungen AG||2|||f||||f||||||||||2018-06-01 03:06:10.718003|2018-06-01 03:06:10.718003
NCT00497276|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2009-12-18|2007-07-04|2007-07-06|Estimate|||||||2009-12-18|2009-12-21|Estimate|August 2007||2007-08-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparison of Ultrasound and Nerve Stimulation Technique for Continuous Sciatic Nerve Block|A Prospective, Randomized Comparison of Ultrasound Versus Nerve Stimulation Guidance of Popliteal, Sciatic Catheter Placement After Major Foot and Ankle Surgery: Clinical Outcome and Cost Analysis|Completed||N/A|100|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 03:06:10.801672|2018-06-01 03:06:10.801672
NCT00497263|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2011-06-28|2007-07-04|2007-07-06|Estimate|||||||2011-06-28|2011-06-29|Estimate||||June 2011|2011-06-30||||||||Interventional|||End-to-End Compression Anastomosis for Left-sided Colectomy Endo-CAR Study||Completed||Phase 2|||Niti Medical Technologies Ltd.|||||f||||t||||||||||2018-06-01 03:06:10.876128|2018-06-01 03:06:10.876128
NCT00497250|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2008-10-20|2007-07-05|2007-07-06|Estimate|||||||2008-10-20|2008-10-21|Estimate|July 2007||2007-07-31|October 2008|2008-10-31|October 2009|Anticipated|2009-10-31|March 2009|Anticipated|2009-03-31||Interventional|||Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy|Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy|Unknown status|Recruiting|Phase 1|32|Anticipated|Fudan University||1|||f||||t||||||||||2018-06-01 03:06:10.940143|2018-06-01 03:06:10.940143
NCT00497237|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2017-03-28|2007-07-05|2007-07-06|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2007||2007-04-30|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|FORTE||Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma|Prospective, Randomised, Open-label, Multicentre, Active Drug Controlled, Parallel Group Design Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate 400 mcg + Formoterol 24 mcg pMDI Via HFA-134a (Foster™) vs. Fluticasone Propionate 500 mcg + Salmeterol Xinafoate 100 mcg DPI (Seretide Diskus®) in the 6 Months Stepdown Treatment of Adult Patients With Controlled Asthma|Completed||Phase 3|382|Anticipated|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 03:06:11.030244|2018-06-01 03:06:11.030244
NCT00497224|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2013-07-08|2007-07-05|2007-07-06|Estimate|||||||2013-07-08|2013-07-09|Estimate|November 2006||2006-11-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|December 2008|Actual|2008-12-31||Interventional|||Phase II Trial of Erlotinib in Advanced Pancreatic Cancer|Phase II Trial of Erlotinib in Advanced Pancreatic Cancer|Completed||Phase 2|51|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 03:06:11.127907|2018-06-01 03:06:11.127907
NCT00497211|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate||||July 2007|2007-07-31||||||||Interventional|||Intracoronary Infusion of BM-Derived Mononuclear Cells in Patients With Large Acute Myocardial Infarction||Unknown status|Recruiting|Phase 2/Phase 3|||University Hospital, Antwerp|||||f||||f||||||||||2018-06-01 03:06:11.208732|2018-06-01 03:06:11.208732
NCT00497198|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|2011-07-14||2012-06-03|2007-07-05|2007-07-06|Estimate|2011-07-15|2011-08-11|Estimate||||2012-06-03|2012-06-08|Estimate|October 2005||2005-10-31|June 2012|2012-06-30|September 2007|Actual|2007-09-30|||||Interventional|||Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes|An Exploratory Study of MCI-196 for Treatment of Type 2 Diabetes in Randomized, Double-Blind, Parallel-Assignment, Placebo-Controlled Manner|Completed||Phase 2|183|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 03:06:11.436488|2018-06-01 03:06:11.436488
NCT00497185|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2011-11-11|2007-07-05|2007-07-06|Estimate|||||||2011-11-11|2011-11-16|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Mindfulness-based Cognitive Therapy for Patients With Functional Disorders|Mindfulness-based Cognitive Therapy for Patients With Functional Disorders. A Randomized Controlled Trial|Completed||N/A|150|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 03:06:11.857027|2018-06-01 03:06:11.857027
NCT00497172|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2010-02-03|2007-07-04|2007-07-06|Estimate|||||||2010-02-03|2010-02-04|Estimate|January 2004||2004-01-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|March 2006|Actual|2006-03-31||Interventional|DESSERT||Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial|An Italian Multicenter, Randomized, Single Blind Study of the Sirolimus Eluting Stent in the Treatment Of Diabetic Patients With De Novo Coronary Artery Lesions|Completed||Phase 4|150|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 03:06:11.936907|2018-06-01 03:06:11.936907
NCT00497159|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03||2015-05-16|2015-05-16|2007-07-03|2007-07-06|Estimate||||2015-05-16|2015-06-08|Estimate|2015-05-16|2015-06-08|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|DIMOND||A Study of the Novel Drug Dimebon in Patients With Huntington's Disease|A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease|Completed||Phase 2|91|Actual|Medivation, Inc.||2|||f||||t||||||||||2018-06-01 03:06:12.018775|2018-06-01 03:06:12.018775
NCT00497146|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2011-09-22||2013-03-08|2007-07-03|2007-07-06|Estimate|2011-11-21|2011-12-23|Estimate||||2013-03-08|2013-03-12|Estimate|February 2008||2008-02-29|March 2013|2013-03-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|PRIMO||The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4|The PRIMO Study: Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4|Completed||Phase 3|227|Actual|AbbVie||2|||f||||t||||||||||2018-06-01 03:06:12.193235|2018-06-01 03:06:12.193235
NCT00497133|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2008-06-03|2007-07-05|2007-07-06|Estimate|||||||2008-06-03|2008-06-04|Estimate|July 2007||2007-07-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Alpha-Cell Sensitivity to GLP-1 in Patients With Type 2 Diabetes||Completed|||20|Anticipated|University of Copenhagen|||||f||||f||||||Samples With DNA|"~     Blood for further analyzes and buffy coat~   "|||2018-06-01 03:06:13.536367|2018-06-01 03:06:13.536367
NCT00497120|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate||||July 2007|2007-07-31||||||||Interventional|||A Combined Surgical and Medical Approach in Mild Sleep Apnea||Unknown status|Recruiting|N/A|||University Hospital, Antwerp|||||f||||||||||||||2018-06-01 03:06:13.638587|2018-06-01 03:06:13.638587
NCT00497107|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2008-07-30|2007-07-05|2007-07-06|Estimate|||||||2008-07-30|2008-07-31|Estimate|July 2007||2007-07-31|July 2008|2008-07-31|May 2013|Anticipated|2013-05-31|||||Interventional|ICOG||Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer|Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer|Unknown status|Recruiting|Phase 3|300|Anticipated|Iwate Medical University||2|||f||||t||||||||||2018-06-01 03:06:13.715106|2018-06-01 03:06:13.715106
NCT00497094|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2013-02-27|2007-07-05|2007-07-06|Estimate|||||||2013-02-27|2013-02-28|Estimate|March 2004||2004-03-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|June 2010|Actual|2010-06-30||Interventional|||Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis|Stenting vs. Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis - a Randomized Controlled Trial|Completed||N/A|148|Actual|Vienna General Hospital||2|||f||||f||||||||||2018-06-01 03:06:13.80834|2018-06-01 03:06:13.80834
NCT00497081|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|2014-10-07||2014-12-12|2007-07-05|2007-07-06|Estimate|2014-10-15|2014-10-20|Estimate||||2014-12-12|2015-01-05|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors|Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors|Completed||Phase 2|60|Actual|San Francisco Department of Public Health||2|||f||||t||||||||||2018-06-01 03:06:13.88233|2018-06-01 03:06:13.88233
NCT00497068|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2013-03-01|2007-07-05|2007-07-06|Estimate|||||||2013-03-01|2013-03-05|Estimate|January 2005||2005-01-31|March 2013|2013-03-31|June 2010|Actual|2010-06-30|September 2009|Actual|2009-09-30||Interventional|ROSE||Tobacco Use in Opioid Agonist Treated Pregnant Women|Tobacco Use in Opioid Agonist Treated Pregnant Women|Completed||Phase 2/Phase 3|210|Anticipated|Johns Hopkins University||3|||f||||f||||||||||2018-06-01 03:06:14.352002|2018-06-01 03:06:14.352002
NCT00497055|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|2012-12-12||2014-02-05|2007-07-05|2007-07-06|Estimate|2014-02-05|2014-03-24|Estimate||||2014-02-05|2014-03-24|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals|Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals|Completed||Phase 2|90|Actual|San Francisco Department of Public Health||2|||f||||t||||||||||2018-06-01 03:06:14.460469|2018-06-01 03:06:14.460469
NCT00497042|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2007-07-10|2007-07-05|2007-07-06|Estimate|||||||2007-07-10|2007-07-11|Estimate||||July 2007|2007-07-31||||||||Interventional|||Safety and Efficacy of Using the Endodontic Self Adjusting File - SAF for Root Canal Treatment|Safety and Efficacy of Using the Endodontic Self Adjusting File - SAF for Root Canal Treatment|Unknown status|Not yet recruiting|N/A|100|Anticipated|ReDent Nova|||||f||||t||||||||||2018-06-01 03:06:14.867523|2018-06-01 03:06:14.867523
NCT00497029|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate|June 2004||2004-06-30|July 2007|2007-07-31|August 2006|Actual|2006-08-31|||||Interventional|||Early Childhood Caries Prevention at a Pediatric Clinic||Completed||N/A|219|Actual|University of Maryland Baltimore Dental School|||||f||||f||||||||||2018-06-01 03:06:15.016135|2018-06-01 03:06:15.016135
NCT00497016|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2008-09-29|2007-07-04|2007-07-06|Estimate|||||||2008-09-29|2008-09-30|Estimate|May 2007||2007-05-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|||||Interventional|||Does Statin Therapy Reduce Sympathoexcitation in Hypertension?|Does Statin Therapy Reduce Sympathoexcitation in Hypertension?|Completed||N/A|13|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 03:06:15.100158|2018-06-01 03:06:15.100158
NCT00497003|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-10-12|2007-07-05|2007-07-06|Estimate|||||||2007-10-12|2007-10-15|Estimate|February 2004||2004-02-29|July 2007|2007-07-31|October 2007|Actual|2007-10-31|||||Interventional|||Effect of Beta Blocker Treatment on Endothelial Function in Patients With Type 2 Diabetes or Chronic Heart Failure||Completed||Phase 4|50|Actual|Bispebjerg Hospital|||||f||||f||||||||||2018-06-01 03:06:15.198832|2018-06-01 03:06:15.198832
NCT00496990|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2013-03-01|2007-07-05|2007-07-06|Estimate|||||||2013-03-01|2013-03-05|Estimate|October 2005||2005-10-31|March 2013|2013-03-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|HOPE||Treating the Partners of Drug Using Pregnant Women: Stage II|Treating the Partners of Drug Using Pregnant Women: Stage II|Completed||Phase 2/Phase 3|158|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 03:06:15.270545|2018-06-01 03:06:15.270545
NCT00496977|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2007-07-05|2007-07-05|2007-07-06|Estimate|||||||2007-07-05|2007-07-06|Estimate|October 2004||2004-10-31|June 2007|2007-06-30|January 2010|Anticipated|2010-01-31|||||Interventional|DLCST||Danish Lung Cancer Screening Trial (DLCST)|Screening for Lung Cancer. A Randomised Controlled Trial of Low-Dose CT-Scanning.|Unknown status|Active, not recruiting|N/A|4104|Actual|Danish Lung Cancer Group|||||f||||t||||||||||2018-06-01 03:06:15.405275|2018-06-01 03:06:15.405275
NCT00496964|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|2011-03-14||2017-09-20|2007-07-05|2007-07-06|Estimate|2011-04-22|2011-05-18|Estimate||||2017-09-20|2017-10-23|Actual|May 2005||2005-05-31|September 2017|2017-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Botox for Non-surgical Lateral Release in Patellofemoral Pain|Botox for Non-surgical Lateral Release in Patellofemoral Pain|Terminated||Phase 3|5|Actual|Virginia Commonwealth University|Early termination due to small number of subjects. No statistical analysis of data due to small number of subjects.|2||Insufficient recruitment in a reasonable time + expiration of study medication|f||||f||||||||||2018-06-01 03:06:15.494512|2018-06-01 03:06:15.494512
NCT00496951|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2017-08-15|2007-07-05|2007-07-06|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2006||2006-09-30|August 2017|2017-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|NAS||Vagal Tone and Neonatal Abstinence Syndrome|Vagal Tone and Neonatal Abstinence Syndrome|Completed|||65|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 03:06:15.898043|2018-06-01 03:06:15.898043
NCT00496938|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2015-05-12|2007-07-05|2007-07-06|Estimate|||||||2015-05-12|2015-05-13|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|||XIENCE V: SPIRIT WOMEN|A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions|Completed||Phase 4|1600|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 03:06:15.996121|2018-06-01 03:06:15.996121
NCT00496925|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2010-01-31|2007-07-05|2007-07-06|Estimate|||||||2010-01-31|2010-02-02|Estimate|November 2007||2007-11-30|January 2010|2010-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Examining the Usage of Dopamine Blockers in OCD Patients|Examining the Usage of Dopamine Blockers in OCD Patients|Completed|||63|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:06:16.228825|2018-06-01 03:06:16.228825
NCT00496899|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-04|||2008-05-08|2007-07-04|2007-07-06|Estimate|||||||2008-05-08|2008-05-09|Estimate|June 2007||2007-06-30|July 2007|2007-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|CLM||Clinical Evaluation of New Computerized Labor Monitoring System|Clinical Evaluation of New Computerized Labor Monitoring System.|Terminated|||3|Actual|Barnev Ltd|||1|The study was stopped prematurally due to low recruiting|f||||f||||||||||2018-06-01 03:06:16.294435|2018-06-01 03:06:16.294435
NCT00496886|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-05|||2015-10-01|2007-07-05|2007-07-06|Estimate|||||||2015-10-01|2015-10-02|Estimate|April 2006||2006-04-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Observational|||Determining How the Nervous System Processes Pain in Adults With Fibromyalgia|Imaging the Cognitive Modulation of Pain|Completed|||137|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 03:06:16.353857|2018-06-01 03:06:16.353857
NCT00496873|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2016-07-13||2016-07-13|2007-07-03|2007-07-04|Estimate|2016-07-13|2016-08-23|Estimate||||2016-07-13|2016-08-23|Estimate|June 2005||2005-06-30|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan|"A Single-Center, Open-Label Study to Evaluate the Safety and Efficacy of Nipent, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin's Lymphoma or Bulky Lymphoma"|Completed||Phase 2|100|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:06:16.623014|2018-06-01 03:06:16.623014
NCT00496860|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2013-04-02||2013-07-17|2007-07-03|2007-07-04|Estimate|2013-06-10|2013-07-15|Estimate||||2013-07-17|2013-07-22|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies|Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies|Completed||Phase 1|26|Actual|Altor BioScience|||||f||||t||||||||||2018-06-01 03:06:16.87846|2018-06-01 03:06:16.87846
NCT00496847|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2014-12-15|2007-07-03|2007-07-04|Estimate|||||||2014-12-15|2014-12-16|Estimate|August 2007||2007-08-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect|Study on the Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect - A Double-blind, Controlled, Randomised,Parallel,Multi-centre Study|Completed||Phase 3|60|Actual|Virchow Group||2|||f||||f||||||||||2018-06-01 03:06:17.531986|2018-06-01 03:06:17.531986
NCT00496834|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2010-08-26||2017-03-31|2007-07-03|2007-07-04|Estimate|2010-11-18|2010-12-15|Estimate||||2017-03-31|2017-05-05|Actual|February 1, 2008|Actual|2008-02-01|March 2017|2017-03-31|September 1, 2009|Actual|2009-09-01|September 1, 2009|Actual|2009-09-01||Interventional|||LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)|A Randomized, Open-label, Comparative, Non-inferiority, Multicenter Study to Compare Efficacy of Losartan Potassium Group and Carvedilol Group on Arterial Stiffness in Essential Hypertension Patients|Completed||Phase 4|201|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:06:17.738204|2018-06-01 03:06:17.738204
NCT00496821|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2007-11-29|2007-07-03|2007-07-04|Estimate|||||||2007-11-29|2007-11-30|Estimate|July 2007||2007-07-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus|A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus|Completed||Phase 2|88|Anticipated|Alnylam Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:06:18.283106|2018-06-01 03:06:18.283106
NCT00496808|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2011-06-27||2012-04-19|2007-07-03|2007-07-04|Estimate|2012-04-19|2012-05-18|Estimate||||2012-04-19|2012-05-18|Estimate|March 2005||2005-03-31|April 2012|2012-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast|Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast|Completed||N/A|69|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:06:18.389407|2018-06-01 03:06:18.389407
NCT00496795|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2017-10-27|2007-07-03|2007-07-04|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2007||2007-09-30|October 2017|2017-10-31|May 2026|Anticipated|2026-05-31|May 2016|Actual|2016-05-31||Interventional|MEDOBREC||Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer|Molecular Markers Predictive Response to Dose Dense Chemotherapy With Epirubicin and Docetaxel in Sequences for Locally Advanced Breast Cancer.|Active, not recruiting||Phase 2|100|Anticipated|University of Bergen||1|||f||||f||||||||||2018-06-01 03:06:18.595466|2018-06-01 03:06:18.595466
NCT00496782|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2009-06-23||2010-11-10|2007-07-03|2007-07-04|Estimate|2010-03-08|2010-03-19|Estimate||||2010-11-10|2010-11-19|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay|Surrogate Marker For Tropism-A Multi-Center, Open Label, Pilot Study|Terminated||Phase 1|16|Actual|ViiV Healthcare|Study terminated prematurely due to slow enrollment. Premature termination of study was not due to any safety concerns. Efficacy data not summarized due to low sample size; only safety was summarized.|1||See Detailed Description|f||||f||||||||||2018-06-01 03:06:18.70679|2018-06-01 03:06:18.70679
NCT00496769|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2013-08-01|2012-02-23|2018-02-07|2007-07-02|2007-07-04|Estimate|2013-10-22|2013-11-14|Estimate|2012-02-23|2012-02-27|Estimate|2018-02-07|2018-03-08|Actual|August 31, 2007|Actual|2007-08-31|February 2018|2018-02-28|May 25, 2017|Actual|2017-05-25|November 30, 2010|Actual|2010-11-30||Interventional|AVERROES||A Phase III Study of Apixaban in Patients With Atrial Fibrillation|Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial|Completed||Phase 3|6421|Actual|Bristol-Myers Squibb|On May 28, 2010, after a planned interim analysis for efficacy, the Data Monitoring Committee recommended early termination due to apixaban's superior efficacy over ASA, with an acceptable safety profile. The open-label phase is ongoing.|2|||f||||t||||||||||2018-06-01 03:06:19.249161|2018-06-01 03:06:19.249161
NCT00496756|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-05-10|2007-07-03|2007-07-04|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2007||2007-03-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|October 2009|Actual|2009-10-31||Interventional|||Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|14|Actual|University of Nebraska||1||Low accrual rate.|f||||t||||||||||2018-06-01 03:06:22.235198|2018-06-01 03:06:22.235198
NCT00496743|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2007-07-02|2007-07-02|2007-07-04|Estimate|||||||2007-07-02|2007-07-04|Estimate|January 2002||2002-01-31|July 2007|2007-07-31|January 2006|Actual|2006-01-31|||||Interventional|||Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides|A Prospective, Open-Label Study on Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides|Terminated||N/A|10|Actual|Bispebjerg Hospital||||The study was discontinued after the first 10 patients because of discouraging results.|f||||f||||||||||2018-06-01 03:06:22.325255|2018-06-01 03:06:22.325255
NCT00496730|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2009-09-03||2017-03-17|2007-07-02|2007-07-04|Estimate|2009-10-14|2009-11-17|Estimate||||2017-03-17|2017-04-14|Actual|July 2007||2007-07-31|March 2017|2017-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)|A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea|Completed||Phase 3|256|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:06:22.39806|2018-06-01 03:06:22.39806
NCT00496717|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2011-07-27|2007-07-03|2007-07-04|Estimate|||||||2011-07-27|2011-07-28|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Aorta Calcium Scoring|Measurement of an Abdominal Aorta Calcium Scoring and Its Correlation With Cardiovascular Risk Factors|Completed|||60|Anticipated|University Hospital, Strasbourg, France|||1||f||||||||||||||2018-06-01 03:06:22.891673|2018-06-01 03:06:22.891673
NCT00496704|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2009-08-20|2007-07-03|2007-07-04|Estimate|||||||2009-08-20|2009-08-21|Estimate|January 2007||2007-01-31|August 2009|2009-08-31||||August 2009|Anticipated|2009-08-31||Interventional|||Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan|A Phase I/II Study to Determine the Safety and Efficacy of Second-Line Treatment With XELOX Plus Gemcitabine in Irinotecan Pre-Treated Advanced Colorectal Cancer Patients|Unknown status|Recruiting|Phase 1/Phase 2|56|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:06:22.975589|2018-06-01 03:06:22.975589
NCT00496691|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-05-19|2007-07-03|2007-07-04|Estimate|||||||2016-05-19|2016-05-20|Estimate|April 2002||2002-04-30|January 2015|2015-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||HIV Prevention for Youth With Severe Mental Illness|HIV Prevention for Youth With Severe Mental Illness|Completed||Phase 1|718|Actual|Rhode Island Hospital||3|||f||||t||||||||||2018-06-01 03:06:23.082227|2018-06-01 03:06:23.082227
NCT00496678|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2013-08-06|2007-07-03|2007-07-04|Estimate|||||||2013-08-06|2013-08-09|Estimate|April 2007||2007-04-30|December 2007|2007-12-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Trial of Patient Navigation-Activation|RCT of Primary Care-based Patient Navigation-Activation|Completed||Phase 4|900|Anticipated|University of Rochester||2|||f||||f||||||||||2018-06-01 03:06:23.181435|2018-06-01 03:06:23.181435
NCT00496665|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2013-11-14|2007-07-03|2007-07-04|Estimate|||||||2013-11-14|2013-11-18|Estimate|July 2007||2007-07-31|November 2013|2013-11-30|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|||ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer|A Phase I Study of ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer|Completed||Phase 1|25|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:06:23.264222|2018-06-01 03:06:23.264222
NCT00496652|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-11-22|2007-07-03|2007-07-04|Estimate|||||||2016-11-22|2016-11-25|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|July 2012|Actual|2012-07-31||Interventional|||DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC|DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|619|Actual|Danish Head and Neck Cancer Group||2|||f||||t||||||||||2018-06-01 03:06:23.357411|2018-06-01 03:06:23.357411
NCT00496639|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2008-05-21|2007-07-03|2007-07-04|Estimate|||||||2008-05-21|2008-05-22|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes|Stent vs. Angioplasty for Treatment of Thrombosed AV Grfats: Long-Term Outcomes|Unknown status|Recruiting|N/A|130|Anticipated|National Kidney Foundation|||||f||||f||||||||||2018-06-01 03:06:23.439527|2018-06-01 03:06:23.439527
NCT00496444|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2012-07-31|2007-07-03|2007-07-04|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Azacytidine and Valproic Acid in Patients With Advanced Cancers|Phase I Study of Low-Dose Hypomethylating Agent Azacitidine Combined With the Histone Deacetylase Inhibitor Valproic Acid in Patients With Advanced Cancers|Completed||Phase 1|69|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:06:27.498637|2018-06-01 03:06:27.498637
NCT00496626|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2010-02-08||2017-03-20|2007-07-03|2007-07-04|Estimate|2010-06-08|2010-07-09|Estimate||||2017-03-20|2017-04-17|Actual|July 20, 2008|Actual|2008-07-20|March 2017|2017-03-31|February 28, 2009|Actual|2009-02-28|February 28, 2009|Actual|2009-02-28||Interventional|||An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)|An Immunogenicity and Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years|Completed||Phase 3|600|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:06:23.5385|2018-06-01 03:06:23.5385
NCT00496613|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2017-07-05|2007-07-03|2007-07-04|Estimate|||||||2017-07-05|2017-07-06|Actual|June 2007||2007-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Chemotherapy-Induced Changes to Cognition and DNA in Breast Cancer Survivors|Chemotherapy-Induced Cognitive Change and DNA Damage in Breast Cancer Survivors|Active, not recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 03:06:23.976255|2018-06-01 03:06:23.976255
NCT00496600|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2012-06-13|2007-07-03|2007-07-04|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Phase I Study of Patupilone and RAD001|Phase I Study of Patupilone and RAD001 in Patients With Refractory Solid Tumor Malignancy|Completed||Phase 1|42|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 03:06:24.097203|2018-06-01 03:06:24.097203
NCT00496587|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2017-05-26||2017-06-21|2007-07-03|2007-07-04|Estimate|2017-05-26|2017-06-22|Actual||||2017-06-21|2017-07-19|Actual|July 2007||2007-07-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma|Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma|Completed||Phase 2|34|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:06:24.195754|2018-06-01 03:06:24.195754
NCT00496574|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2013-02-06|2007-07-03|2007-07-04|Estimate|||||||2013-02-06|2013-02-07|Estimate|May 2006||2006-05-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma|Evaluation of Long-term Clinical Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma|Unknown status|Recruiting|Phase 4|60|Anticipated|Medical Universtity of Lodz||2|||f||||t||||||||||2018-06-01 03:06:24.540867|2018-06-01 03:06:24.540867
NCT00496561|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2013-02-06|2007-07-03|2007-07-04|Estimate|||||||2013-02-06|2013-02-07|Estimate|August 2006||2006-08-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Effect of Specific Immunotherapy to Dust Mites in Children With Asthma|Evaluation of Early Clinical and Immunological Efficacy of Specific Immunotherapy to Dust Mites in Children With Asthma|Unknown status|Recruiting|Phase 4|80|Anticipated|Medical Universtity of Lodz||2|||f||||t||||||||||2018-06-01 03:06:24.623222|2018-06-01 03:06:24.623222
NCT00496548|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2017-04-30|2007-07-03|2007-07-04|Estimate|||||||2017-04-30|2017-05-02|Actual|August 2007||2007-08-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity|Urinary PGE-M, A Metabolite of PGE2: A Novel Biomarker of Crohn's Disease Activity|Completed||N/A|159|Actual|Vanderbilt University Medical Center||1|||f||||t||||||||No||2018-06-01 03:06:24.714412|2018-06-01 03:06:24.714412
NCT00496535|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2012-02-22|2007-07-02|2007-07-04|Estimate|||||||2012-02-22|2012-02-23|Estimate||||May 2011|2011-05-31||||||||Interventional|||A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer|"A Phase I/II Safety, Tolerability, and Proof of Concept Study of TNFerade™ Biologic in Combination With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) for Patients With Unresectable Recurrent Head and Neck Cancer"|Completed||Phase 1/Phase 2|||GenVec|||||||||||||||||||2018-06-01 03:06:24.937053|2018-06-01 03:06:24.937053
NCT00496522|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2017-07-10|2007-07-02|2007-07-04|Estimate|||||||2017-07-10|2017-07-13|Actual|April 2006|Actual|2006-04-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Proton Beam Therapy for Chondrosarcoma|Phase II Evaluation of Proton Beam Therapy for Skull Base Chondrosarcoma|Active, not recruiting||Phase 2|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|||||||||2018-06-01 03:06:25.019084|2018-06-01 03:06:25.019084
NCT00496509|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-08-25|2007-07-03|2007-07-04|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2006||2006-08-31|August 2016|2016-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Phase I Efficacy On Vascular Permeability In Patients With Advanced Colorectal Cancer|A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients With Advanced Colorectal Cancer and Liver Metastases|Completed||Phase 1|24|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:06:25.104627|2018-06-01 03:06:25.104627
NCT00496483|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2014-05-29||2015-06-25|2007-07-02|2007-07-04|Estimate|2015-06-25|2015-07-23|Estimate||||2015-06-25|2015-07-23|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients|A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day|Completed||Phase 2|60|Actual|Veloxis Pharmaceuticals||1|||f||||f||||||||||2018-06-01 03:06:25.227146|2018-06-01 03:06:25.227146
NCT00496470|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2009-06-15||2012-10-10|2007-07-03|2007-07-04|Estimate|2012-10-10|2012-11-09|Estimate||||2012-10-10|2012-11-09|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.|A 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, Study to Evaluate Efficacy and Safety of Budesonide/Formoterol (Symbicort Turbuhaler®) 320/9 µg One Inhalation Twice Daily on Top of Tiotropium (Spiriva®) 18 µg One Inhalation Once Daily|Completed||Phase 4|660|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:06:25.567494|2018-06-01 03:06:25.567494
NCT00496457|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2016-11-21|2007-07-03|2007-07-04|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy|A Double-Blind, Randomized, Multicenter Study With 500 mg QD of TRO19622 Versus Placebo in Patients With Painful Peripheral Diabetic Neuropathy|Completed||Phase 2|159|Actual|Hoffmann-La Roche||2|||f||||f||||||||||2018-06-01 03:06:27.34625|2018-06-01 03:06:27.34625
NCT00496431|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2013-05-23|2007-07-03|2007-07-04|Estimate|||||||2013-05-23|2013-05-24|Estimate|May 2007||2007-05-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients|Phase II Study of the Histone-deacetylase Inhibitor ITF2357 in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients|Terminated||Phase 1/Phase 2|19|Actual|Italfarmaco||1||"ITF2357 (Givinostat) was well tollerated but had limited activity against refractory/relapsed~   HL"|f||||t||||||||||2018-06-01 03:06:28.496624|2018-06-01 03:06:28.496624
NCT00496418|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2015-01-12|2007-07-03|2007-07-04|Estimate|||||||2015-01-12|2015-01-14|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|September 2011|Actual|2011-09-30||Interventional|||Peristomal Mesh for Prophylaxis of Parastomal Hernia|Randomized Controlled Open Interventional Study for Evaluation of Use of Peristomal Mesh for Prophylaxis of Parastomal Hernia|Completed||Phase 3|60|Actual|Oslo University Hospital||2|||f||||||||||||||2018-06-01 03:06:28.600476|2018-06-01 03:06:28.600476
NCT00496405|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2007-10-11|2007-07-03|2007-07-04|Estimate|||||||2007-10-11|2007-10-12|Estimate|April 2007||2007-04-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Unilateral Bevacizumab for Bilateral Diabetic Macular Edema|The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study.|Completed||Phase 4|13|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||f||||||||||2018-06-01 03:06:28.72675|2018-06-01 03:06:28.72675
NCT00496392|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2012-05-04|2007-07-03|2007-07-04|Estimate|||||||2012-05-04|2012-05-07|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)|An Open Label, Comparative, Randomised, Balanced Crossover Trial Comparing Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq®) in Breakthrough Pain in Patients With Cancer|Completed||Phase 3|115|Anticipated|Nycomed|||||f||||t||||||||||2018-06-01 03:06:28.819309|2018-06-01 03:06:28.819309
NCT00496379|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2012-11-30||2013-03-12|2007-07-03|2007-07-04|Estimate|2013-02-07|2013-03-12|Estimate||||2013-03-12|2013-03-14|Estimate|July 2007||2007-07-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|October 2009|Actual|2009-10-31||Interventional|||ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases|A Phase 2 Study of ZK219477 (ZK-EPO) in Patients With Breast Cancer and Brain Metastases|Terminated||Phase 2|15|Actual|Dana-Farber Cancer Institute||1||This study has closed to accrual early due to slow accrual.|f||||f||||||||||2018-06-01 03:06:28.905747|2018-06-01 03:06:28.905747
NCT00496366|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2017-03-20||2017-03-20|2007-07-03|2007-07-04|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|July 23, 2007|Actual|2007-07-23|March 2017|2017-03-31|March 20, 2017|Actual|2017-03-20|December 31, 2009|Actual|2009-12-31||Interventional|||Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer|Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer|Terminated||Phase 2|11|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 03:06:29.302637|2018-06-01 03:06:29.302637
NCT00496353|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2015-03-30|2007-07-02|2007-07-04|Estimate|||||||2015-03-30|2015-03-31|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)|A Phase I/II Dose Escalation and Proof-of-Concept Study of MK2461 in Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|26|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:06:29.619172|2018-06-01 03:06:29.619172
NCT00496340|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2014-03-27||2014-05-30|2007-07-03|2007-07-04|Estimate|2014-05-30|2014-06-05|Estimate||||2014-05-30|2014-06-05|Estimate|July 2007||2007-07-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|Pento & tBU|All participants. Bone marrow chimerism data were available for only 38 patients at day +28 and for only 36 patients at day +100.|Phase II Trial of Pentostatin and Targeted Busulfan|Phase II Trial of Pentostatin and Targeted Busulfan as a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Using Laboratory-Guided (CD4-guided) Immunosuppression.|Completed||Phase 2|42|Actual|H. Lee Moffitt Cancer Center and Research Institute|Bone marrow chimerism data were available for only 38 patients at day +28 and for only 36 patients at day +100.|1|||f||||f||||||||||2018-06-01 03:06:29.749396|2018-06-01 03:06:29.749396
NCT00496327|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2017-03-14|2007-07-03|2007-07-04|Estimate|||||||2017-03-14|2017-03-15|Actual|June 2005||2005-06-30|March 2017|2017-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)|Evaluation of Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX (V210)in Healthy Indian Children|Completed||Phase 3|100|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 03:06:30.130955|2018-06-01 03:06:30.130955
NCT00496314|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2008-06-13|2007-07-02|2007-07-04|Estimate|||||||2008-06-13|2008-06-17|Estimate|May 2007||2007-05-31|June 2008|2008-06-30|January 2008|Actual|2008-01-31|||||Observational|||Physician's Comfort Level and Satisfaction Study With The e2TM Collector Compared to the Spatula/CytoBrush Technique|Clinical Study Assessing Physician's Comfort Level and Satisfaction When Using The e2TM Cervical Cell Collector Compared to the Standard Spatula/CytoBrush Technique|Terminated|||30|Anticipated|CytoCore, Inc.||||Terminated for lack of resources to complete.|f||||f||||||||||2018-06-01 03:06:30.194311|2018-06-01 03:06:30.194311
NCT00496301|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2009-01-13|2007-07-03|2007-07-04|Estimate|||||||2009-01-13|2009-01-14|Estimate|November 2006||2006-11-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|SOGUG-02-06||Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC|Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)|Completed||Phase 2|40|Anticipated|Spanish Oncology Genito-Urinary Group|||||f||||t||||||||||2018-06-01 03:06:30.25929|2018-06-01 03:06:30.25929
NCT00496288|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2011-04-04|2007-07-03|2007-07-04|Estimate|||||||2011-04-04|2011-04-05|Estimate|March 2008||2008-03-31|June 2008|2008-06-30||||March 2023|Anticipated|2023-03-31||Interventional|||Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer|Phase II Multicenter Clinical Trial of Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers Undergoing Treatment for Breast Cancer|Recruiting||Phase 2|240|Anticipated|Assaf-Harofeh Medical Center||2|||f||||t||||||||||2018-06-01 03:06:30.354136|2018-06-01 03:06:30.354136
NCT00496275|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-08-25|2007-07-03|2007-07-04|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2006||2006-08-31|August 2016|2016-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC|A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.|Completed||Phase 1|17|Actual|Sanofi|||||f||||f||||||||||2018-06-01 03:06:30.451712|2018-06-01 03:06:30.451712
NCT00496262|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2009-05-19||2016-07-27|2007-07-03|2007-07-04|Estimate|2009-05-19|2009-07-10|Estimate||||2016-07-27|2016-09-15|Estimate|July 2007||2007-07-31|February 2011|2011-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Human Fibrinogen - Pharmacokinetics|Pharmacokinetics of Haemocomplettan® P in Subjects With Congenital Fibrinogen Deficiency|Completed||Phase 2|15|Actual|CSL Behring||1|||f||||f||||||||||2018-06-01 03:06:30.676529|2018-06-01 03:06:30.676529
NCT00496249|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2015-12-21|2007-07-03|2007-07-04|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2007||2007-07-31|December 2015|2015-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||The Effect of Radiation on Semen Quality and Fertility in Men With Prostate Cancer|The Effect of Radiation on Semen Quality and Fertility in Men Treated With External Beam Radiation or Brachytherapy for Early Stage Prostate Cancer|Completed|||19|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 03:06:30.965989|2018-06-01 03:06:30.965989
NCT00496236|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2012-02-22|2007-07-02|2007-07-04|Estimate|||||||2012-02-22|2012-02-23|Estimate||||May 2011|2011-05-31||||||||Interventional|||Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer|"A Phase I/II Safety, Tolerability and Proof of Concept Study of Radiotherapy, Cetuximab, and Intratumoral Injections of TNFerade™ Biologic (AdGVEGR.TNF.11D) for Elderly or Frail Patients or Intermediate Stage Patients With Head and Neck Cancer"|Completed||Phase 1/Phase 2|||GenVec|||||||||||||||||||2018-06-01 03:06:31.047722|2018-06-01 03:06:31.047722
NCT00496223|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2011-02-21|2007-07-03|2007-07-04|Estimate|||||||2011-02-21|2011-02-23|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Phase I/II Study of Sunitinib and Dacarbazine|A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma|Terminated||Phase 1/Phase 2|11|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||toxicities required dose reduction compromising effectiveness and PI left Moffitt|f||||t||||||||||2018-06-01 03:06:31.121811|2018-06-01 03:06:31.121811
NCT00496210|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2018-04-12|2007-07-03|2007-07-04|Estimate|||||||2018-04-12|2018-04-13|Actual|June 27, 2007||2007-06-27|December 7, 2015|2015-12-07|December 7, 2015||2015-12-07|||||Observational|||Predictors of Caregiver Adaptation to Pervasive Developmental Disorders|Understanding Caregiver Adaptation to Pervasive Developmental Disorders|Completed|||324|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:06:31.236246|2018-06-01 03:06:31.236246
NCT00496197|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2011-05-12||2011-08-29|2007-07-03|2007-07-04|Estimate|2011-08-29|2011-10-03|Estimate||||2011-08-29|2011-10-03|Estimate|July 2007||2007-07-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis|Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis|Completed||Phase 4|282|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 03:06:31.410065|2018-06-01 03:06:31.410065
NCT00496184|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2008-05-02|2007-07-03|2007-07-04|Estimate|||||||2008-05-02|2008-05-08|Estimate|April 2006||2006-04-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy Study of Topical Application of Nifedipine Cream to Treat Vulvar Vestibulitis|Topical Application of Nifedipine Cream for the Treatment of Vulvar Vestibulitis Syndrome|Completed||Phase 3|30|Anticipated|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-06-01 03:06:32.421958|2018-06-01 03:06:32.421958
NCT00496171|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2009-01-15|2007-07-03|2007-07-04|Estimate|||||||2009-01-15|2009-01-16|Estimate||||January 2009|2009-01-31||||||||Observational|||Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers|A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers|Terminated|||||Photocure|||||f||||||||||||||2018-06-01 03:06:32.506761|2018-06-01 03:06:32.506761
NCT00496158|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2009-04-23|2007-07-03|2007-07-04|Estimate|||||||2009-04-23|2009-04-27|Estimate|August 2007||2007-08-31|April 2009|2009-04-30||||||||Interventional|QUASH2||Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus|A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus|Terminated||Phase 3|||Pharmasset||||The study was terminated in the interest of patient safety.|f||||||||||||||2018-06-01 03:06:32.590354|2018-06-01 03:06:32.590354
NCT00496145|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2016-04-18|2007-07-03|2007-07-04|Estimate|||||||2016-04-18|2016-04-19|Estimate|August 2002||2002-08-31|April 2016|2016-04-30|September 2006|Actual|2006-09-30|September 2005|Actual|2005-09-30||Interventional|SDSMP||Spanish Diabetes Self-Management Program|Spanish Diabetes Self-Management Program|Completed||N/A|567|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 03:06:32.837176|2018-06-01 03:06:32.837176
NCT00496132|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03||2013-01-18|2017-06-26|2007-07-03|2007-07-04|Estimate||||2013-01-18|2013-01-28|Estimate|2017-06-26|2017-07-02|Actual|August 27, 2007|Actual|2007-08-27|June 2017|2017-06-30|June 17, 2009|Actual|2009-06-17|June 17, 2009|Actual|2009-06-17||Interventional|||A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Have Been Treated With a Purine Nucleoside Analogue-Containing Regimen|Terminated||Phase 1/Phase 2|16|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:06:32.971588|2018-06-01 03:06:32.971588
NCT00496119|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2017-10-23|2007-07-02|2007-07-04|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2006|Actual|2006-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Proton Beam Therapy for Chordoma Patients|Phase II Evaluation of Proton Beam Therapy for Skull Base Chordoma|Active, not recruiting||Phase 2|15|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:06:33.069409|2018-06-01 03:06:33.069409
NCT00496106|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2010-12-15|2007-07-02|2007-07-04|Estimate|||||||2010-12-15|2010-12-16|Estimate|August 2007||2007-08-31|December 2010|2010-12-31|February 2011|Anticipated|2011-02-28|August 2010|Anticipated|2010-08-31||Interventional|CXR01||Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes|Stress, Immunity & Cervical Cancer: Biobehavioral Outcomes of a Randomized Trial|Unknown status|Recruiting|Phase 2|939|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-06-01 03:06:33.172822|2018-06-01 03:06:33.172822
NCT00496093|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2017-03-13|2007-07-03|2007-07-04|Estimate|||||||2017-03-13|2017-03-14|Actual|October 2005||2005-10-31|March 2017|2017-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)|Safety, Tolerability and Immunogenicity of Pneumovax 23 (V110) in Healthy Adults in India|Completed||Phase 3|133|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 03:06:33.266352|2018-06-01 03:06:33.266352
NCT00494598|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2013-07-31|2007-06-29|2007-07-02|Estimate|||||||2013-07-31|2013-08-01|Estimate|March 2007||2007-03-31|October 2008|2008-10-31|June 2007|Actual|2007-06-30|||||Observational|||The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion|The Pharmacokinetics of Opioids and Sedative/Hypnotics During Selective Cerebral Perfusion|Completed|||6|Actual|Columbia University|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 03:06:58.987947|2018-06-01 03:06:58.987947
NCT00496080|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2012-06-19||2012-09-06|2007-07-03|2007-07-04|Estimate|2012-06-19|2012-07-24|Estimate||||2012-09-06|2012-09-10|Estimate|June 2007||2007-06-30|September 2012|2012-09-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|DUAO||Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding|A Pivotal Study of Doppler Guided Uterine Artery Occlusion as Treatment for the Reduction of Fibroid Associated Bleeding|Terminated||N/A|87|Actual|Ethicon, Inc.|Study was terminated early because 6 mo interim analysis of parallel European study showed that device was not meeting the primary endpoint. Target enrollment was 200 subjects, but results are based on 87 subjects who were treated with the device.|1||Trial terminated early due to results from a similar study.|f||||t||||||||||2018-06-01 03:06:33.36459|2018-06-01 03:06:33.36459
NCT00496067|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2011-03-08|2007-07-03|2007-07-04|Estimate|||||||2011-03-08|2011-03-09|Estimate|April 2007||2007-04-30|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Uterine Artery Occlusion for Fibroid Related Bleeding|An Evaluation of a Doppler-Guided Uterine Artery Occlusion Device as Treatment for the Reduction of Fibroid-Associated Bleeding|Terminated||N/A|91|Actual|Ethicon, Inc.||1||Data required further pilot work to be undertaken.|f||||t||||||||||2018-06-01 03:06:33.708012|2018-06-01 03:06:33.708012
NCT00496054|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|2009-11-12||2017-03-16|2007-07-03|2007-07-04|Estimate|2010-02-17|2010-03-11|Estimate||||2017-03-16|2017-04-13|Actual|May 2008||2008-05-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)|Evaluation of Safety,Tolerability and Immunogenicity of Vaccination With Rotateq (V260) in Healthy Infants in India|Completed||Phase 3|110|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:06:33.857146|2018-06-01 03:06:33.857146
NCT00496041|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2014-12-04|2007-07-03|2007-07-04|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2007||2007-07-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Belgian Prospective Multicentre Registry on the Performance of the Smart Stent in the Superficial Femoral Artery According to the New Tasc II-classification|Belgian Prospective Multicentre Registry on the Performance of the Smart Stent in the Superficial Femoral Artery According to the New Tasc II-classification|Unknown status|Recruiting|N/A|200|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 03:06:34.263002|2018-06-01 03:06:34.263002
NCT00496028|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2010-09-21|2007-07-03|2007-07-04|Estimate|||||||2010-09-21|2010-09-22|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Phase I Study in Patients With Solid Tumours|A Phase I, Open-label Study to Assess the Safety and Tolerability of AZD0530 in Combination With Carboplatin and/or Paclitaxel Chemotherapy in Patients With Solid Tumours|Completed||Phase 1|148|Actual|AstraZeneca||3|||f||||t||||||||||2018-06-01 03:06:34.349549|2018-06-01 03:06:34.349549
NCT00496015|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03||2009-05-20|2017-05-08|2007-07-03|2007-07-04|Estimate||||2009-09-25|2009-09-28|Estimate|2017-05-08|2017-05-09|Actual|July 2, 2007|Actual|2007-07-02|May 2017|2017-05-31|February 17, 2009|Actual|2009-02-17|March 25, 2008|Actual|2008-03-25||Interventional|||Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A|Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Vaccine GSK1024850A and DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) and Assessment of Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage|Completed||Phase 3|750|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:06:34.445205|2018-06-01 03:06:34.445205
NCT00496002|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2009-04-23|2007-07-03|2007-07-04|Estimate|||||||2009-04-23|2009-04-27|Estimate|August 2007||2007-08-31|April 2009|2009-04-30||||||||Interventional|QUASH 1||Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus|A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus|Terminated||Phase 3|||Pharmasset||||The study was terminated in the interest of patient safety.|f||||||||||||||2018-06-01 03:06:34.700082|2018-06-01 03:06:34.700082
NCT00495989|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-03|||2009-04-09|2007-07-03|2007-07-04|Estimate|||||||2009-04-09|2009-04-10|Estimate|June 2007||2007-06-30|April 2009|2009-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Saliva and Dental Calculus in Handicapped People|The Relationship Between Saliva and Dental Calculus in a Population of Institutionalized Handicapped Persons|Completed||N/A|100|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:06:34.947334|2018-06-01 03:06:34.947334
NCT00495976|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2008-03-21|2007-07-02|2007-07-03|Estimate|||||||2008-03-21|2008-03-24|Estimate|September 2007||2007-09-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study to Investigate the Effects of Hot Drinks on Nasal Airway Resistance and Symptoms of Common Cold|A Pilot Study to Investigate the Effects of Hot Drinks on Nasal Airway Resistance and Symptoms of Common Cold|Completed||N/A|60|Actual|Cardiff University|||||f||||f||||||||||2018-06-01 03:06:35.020925|2018-06-01 03:06:35.020925
NCT00495963|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2008-10-16|2007-07-02|2007-07-03|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2003||2003-01-31|July 2007|2007-07-31|September 2003|Actual|2003-09-30|||||Interventional|||Diagnosis of Ventilator- Associated Pneumonia in Children: A Comparative Study of Bronchoscopic and Non-Bronchoscopic Methods||Completed||Phase 3|||Sir Ganga Ram Hospital|||||f||||f||||||||||2018-06-01 03:06:35.107087|2018-06-01 03:06:35.107087
NCT00495950|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2016-11-23|2007-07-02|2007-07-03|Estimate|||||||2016-11-23|2016-11-25|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Prospective Measurement of Post-Treatment Lymphedema|Prospective Measurement of Post-Treatment Lymphedema in Patients With Melanoma|Completed|||350|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:06:35.201015|2018-06-01 03:06:35.201015
NCT00495924|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2009-07-07|2007-07-02|2007-07-03|Estimate|||||||2009-07-07|2009-07-08|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|October 2008|Actual|2008-10-31|||||Observational|||Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma|Prognostic Relevance of Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma|Completed|||100|Anticipated|Katholieke Universiteit Leuven|||1||f||||t||||||Samples With DNA|"~     Tissue, serum, blood~   "|||2018-06-01 03:06:35.32119|2018-06-01 03:06:35.32119
NCT00495898|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2009-12-02|2007-07-02|2007-07-03|Estimate|||||||2009-12-02|2009-12-03|Estimate|November 2002||2002-11-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|May 2005|Actual|2005-05-31||Interventional|SCORPIUS||A Study of Diabetic Patients With De Novo Native Coronary Artery Lesions|A German Multicenter, Randomized, Controlled, Open-Label Study of the Cypher Sirolimus-Eluting Stent in the Treatment of Diabetic Patients With De Novo Native Coronary Artery Lesions|Completed||Phase 4|200|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 03:06:35.408808|2018-06-01 03:06:35.408808
NCT00495885|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02||2016-04-26|2016-04-26|2007-07-02|2007-07-03|Estimate||||2016-04-26|2016-05-26|Estimate|2016-04-26|2016-05-26|Estimate|June 2007||2007-06-30|April 2016|2016-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|SAMS12||Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus|Efficacy and Safety of 2 mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 3|848|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:06:35.518761|2018-06-01 03:06:35.518761
NCT00495872|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2012-10-16|2007-07-02|2007-07-03|Estimate|||||||2012-10-16|2012-10-18|Estimate|June 2007||2007-06-30|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|||Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor|A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor|Completed||Phase 1|204|Actual|M.D. Anderson Cancer Center||6|||f||||f||||||||||2018-06-01 03:06:35.633531|2018-06-01 03:06:35.633531
NCT00495859|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2008-04-02|2007-07-02|2007-07-03|Estimate|||||||2008-04-02|2008-04-04|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|PROUD||Effects of Preoperative Long-Term Immunonutrition in Patients Listed for Liver Transplantation|Randomized Controlled Double Blind Multi-Center Clinical Trial to Assess the Effects of Preoperative Long-Term Immunonutrition in Patients Listed for Liver Transplantation|Unknown status|Recruiting|N/A|156|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-06-01 03:06:35.784017|2018-06-01 03:06:35.784017
NCT00495846|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2009-08-14|2007-07-02|2007-07-03|Estimate|||||||2009-08-14|2009-08-17|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|SS-HCC||GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma|Treatment of Advanced Hepatocellular Carcinoma With Depot Somatostatin Analogues: a Pilot Prospective Study Based on Somatostatin Receptors Tumors Expression|Completed||Phase 2/Phase 3|25|Actual|Federico II University||2|||f||||t||||||||||2018-06-01 03:06:35.892384|2018-06-01 03:06:35.892384
NCT00495833|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2010-06-25|2007-06-29|2007-07-03|Estimate|||||||2010-06-25|2010-06-29|Estimate|June 2007||2007-06-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||SPHERE Hypertension Intervention Study|SPHERE Hypertension Intervention Study|Completed||N/A|8000|Anticipated|University of Washington||7|||f||||t||||||||||2018-06-01 03:06:36.035906|2018-06-01 03:06:36.035906
NCT00495820|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2014-01-21||2015-10-19|2007-07-02|2007-07-03|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|August 2007||2007-08-31|October 2015|2015-10-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study|Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study|Completed||Phase 4|60|Actual|VA Office of Research and Development|Small sample size and short duration of the study are two important limitations of the study. All male subjects in the study also make it difficult to generalize the results.|2|||f||||t||||||||||2018-06-01 03:06:36.159826|2018-06-01 03:06:36.159826
NCT00495807|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2008-07-11|2007-07-02|2007-07-03|Estimate|||||||2008-07-11|2008-07-15|Estimate|June 2006||2006-06-30|April 2008|2008-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|NWPOP||Nurses' Negative Words and Postoperative Pain Management|Influence on Pain Management of Nurses' Negative Words After Total Hysterectomy|Completed||N/A|1500|Actual|Nanjing Medical University||4|||f||||t||||||||||2018-06-01 03:06:36.551181|2018-06-01 03:06:36.551181
NCT00495794|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2014-09-03||2015-04-06|2007-07-02|2007-07-03|Estimate|2014-09-03|2014-09-11|Estimate||||2015-04-06|2015-04-28|Estimate|August 2008||2008-08-31|July 2014|2014-07-31|July 2012|Actual|2012-07-31|March 2010|Actual|2010-03-31||Interventional|||Adherence and Intensification of Medications (AIM) Implementation Study|Adherence and Intensification of Medications: A Population-Based Clinical Pharmacists Implementation Study Among Hypertensive Diabetes Patients|Completed||N/A|4622|Actual|VA Office of Research and Development|In the intervention arm, only 53% of subjects had a pharmacist encounter. Higher rates of participation might have led to a more substantial initial improvement and a detectable longer term effect.|2|||f||||t||||||||||2018-06-01 03:06:36.673051|2018-06-01 03:06:36.673051
NCT00495781|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2007-07-02|2007-07-02|2007-07-03|Estimate|||||||2007-07-02|2007-07-03|Estimate|October 2004||2004-10-31|July 2007|2007-07-31|May 2006|Actual|2006-05-31|||||Interventional|SFIDS||Out Come Study To Define Laboratory Parameters That Are Best Suited to Diagnose Functional Iron Deficiency|Swiss Functional Iron Deficiency Study|Completed||N/A|77|Actual|Spital Zollikerberg|||||f||||f||||||||||2018-06-01 03:06:36.940458|2018-06-01 03:06:36.940458
NCT00495768|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2007-12-13|2007-07-02|2007-07-03|Estimate|||||||2007-12-13|2007-12-14|Estimate|July 2004||2004-07-31|December 2007|2007-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Reducing Depressive Symptoms During HCV Therapy: A Randomized Study|Reducing Depressive Symptoms During HCV Therapy: A Randomized Study|Unknown status|Active, not recruiting|N/A|90|Anticipated|South Texas Veterans Health Care System|||||f||||t||||||||||2018-06-01 03:06:37.005937|2018-06-01 03:06:37.005937
NCT00495755|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2013-04-14||2013-08-07|2007-07-02|2007-07-03|Estimate|2013-08-07|2013-08-09|Estimate||||2013-08-07|2013-08-09|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||Campath in Chronic GVHD|An Open Label Phase I Trial of Alemtuzumab (Campath 1-H) Therapy for Refractory Chronic Graft-vs-Host Disease|Completed||Phase 1|13|Actual|Dana-Farber Cancer Institute||1|||f||||f||||||||||2018-06-01 03:06:37.076363|2018-06-01 03:06:37.076363
NCT00495729|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2017-08-05|2007-06-29|2007-07-03|Estimate|||||||2017-08-05|2017-08-08|Actual|April 18, 2007|Actual|2007-04-18|August 2017|2017-08-31|August 4, 2007|Actual|2007-08-04|August 4, 2007|Actual|2007-08-04||Interventional|||15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.|A Single-blind, Randomised, Placebo-controlled, 15 Day Repeated-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-649868 and Its Interaction With the CYP3A4 Isoenzyme in Healthy Male Subjects.|Completed||Phase 1|36|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:06:37.240606|2018-06-01 03:06:37.240606
NCT00495716|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2016-10-26|2007-07-02|2007-07-03|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of HSV-2 Suppressive Therapy on Sexual Behavior|Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission|Active, not recruiting||Phase 4|72|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:06:37.309286|2018-06-01 03:06:37.309286
NCT00495703|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2017-03-30|2007-07-02|2007-07-03|Estimate|||||||2017-03-30|2017-04-04|Actual|February 2006||2006-02-28|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|TACTIC||The Activity Intervention for Chemobrain|Exercise Intervention for Chemotherapy-Related Cognitive Dysfunction|Completed||Phase 2|64|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 03:06:37.382726|2018-06-01 03:06:37.382726
NCT00495690|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-30|||2011-09-14|2007-07-02|2007-07-03|Estimate|||||||2011-09-14|2011-09-15|Estimate|November 2004||2004-11-30|September 2011|2011-09-30|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional|||Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease|Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Mortality and Severe Disease Requiring Hospitalization|Completed||Phase 3|2012|Actual|Society for Applied Studies|||||f||||f||||||||||2018-06-01 03:06:37.448398|2018-06-01 03:06:37.448398
NCT00495677|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2013-08-26|2009-03-20|2013-08-26|2007-06-29|2007-07-03|Estimate|2013-08-26|2013-10-30|Estimate|2009-09-21|2009-09-28|Estimate|2013-08-26|2013-10-30|Estimate|June 2007||2007-06-30|August 2013|2013-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase 2 Study Of PF-00232798 In HIV Positive Patients|A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798|Completed||Phase 2|43|Actual|Pfizer||6|||f||||f||||||||||2018-06-01 03:06:37.636448|2018-06-01 03:06:37.636448
NCT00495664|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2012-09-05|2007-07-02|2007-07-03|Estimate|||||||2012-09-05|2012-09-06|Estimate|December 2005||2005-12-31|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|TITAX AMI||Titanium Nitride Oxide Coated Stents and Paclitaxel Eluting Stents for Acute Myocardial Infarction|Titanium Nitride Oxide Coated Stents Versus Paclitaxel Eluting Stents for Acute Myocardial Infarction|Completed||N/A|425|Actual|The Hospital District of Satakunta||2|||f||||t||||||||||2018-06-01 03:06:38.737136|2018-06-01 03:06:38.737136
NCT00495651|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2015-06-01|2007-07-02|2007-07-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TEMPRANO||Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)|Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)|Completed||Phase 3|2073|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||4|||f||||t||||||||||2018-06-01 03:06:38.824961|2018-06-01 03:06:38.824961
NCT00495638|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-30|||2018-05-05|2007-06-30|2007-07-03|Estimate|||||||2018-05-05|2018-05-08|Actual|June 28, 2007||2007-06-28|December 2, 2014|2014-12-02|December 2, 2014||2014-12-02|||||Observational|||Pulmonary Hypertension, Hypoxia and Sickle Cell Disease|Pulmonary Hypertension and the Hypoxic Response in SCD|Completed|||29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:06:38.944581|2018-06-01 03:06:38.944581
NCT00495625|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2012-01-12||2012-03-22|2007-07-02|2007-07-03|Estimate|2012-02-16|2012-03-23|Estimate||||2012-03-22|2012-03-27|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)|Phase II Open-Label Study of Sunitinib Malate (SUO11248) in Adult Subjects With Metastatic and/or Surgically Unresectable Hepatocellular Cancers (HCC)|Terminated||Phase 2|33|Actual|H. Lee Moffitt Cancer Center and Research Institute|The Principal Investigator who initiated the study left Moffitt before reaching the target enrollment required to perform the planned analysis.|1|||f||||t||||||||||2018-06-01 03:06:39.043668|2018-06-01 03:06:39.043668
NCT00495612|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2012-12-10||2017-05-15|2007-06-29|2007-07-03|Estimate|2013-03-25|2013-03-27|Estimate||||2017-05-15|2017-06-08|Actual|September 2007|Actual|2007-09-30|May 2017|2017-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|AERO||A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma|A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma|Completed||Phase 4|69|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:06:39.376312|2018-06-01 03:06:39.376312
NCT00495599|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2016-11-17|2007-07-02|2007-07-03|Estimate|||||||2016-11-17|2016-11-21|Estimate|March 2006||2006-03-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Adipose Secretory Function in Patients Before & After Laparoscopic Surgery|Adipose Secretory Function in Patients Before & After Laparoscopic Surgery|Completed||Phase 3|107|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 03:06:39.68941|2018-06-01 03:06:39.68941
NCT00495586|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2012-01-08||2012-03-11|2007-07-02|2007-07-03|Estimate|2012-03-11|2012-03-13|Estimate||||2012-03-11|2012-03-13|Estimate|October 2007||2007-10-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|TRANCE||Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease|Situations That do Not Require Antibiotics for Acute Exacerbations of Mild-to-moderate Chronic Obstructive Pulmonary Disease|Completed||Phase 4|318|Actual|Catalan Society of Family Medicine|The required sample size could not be achieved. This clinical trial was only partially funded by an independent academic institution without any other source of funding. However, due differences obtained the sample size allowed for a power of 80%.|2|||f||||f||||||||||2018-06-01 03:06:39.766162|2018-06-01 03:06:39.766162
NCT00495573|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2012-03-21|2007-07-02|2007-07-03|Estimate|||||||2012-03-21|2012-03-22|Estimate|June 2007||2007-06-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|November 2009|Actual|2009-11-30||Observational|||HSV-2 Shedding Resolution After Acyclovir Treatment|Half-life and Pattern of Resolution of Herpes Simplex Virus Type 2 (HSV-2) Shedding After Beginning Acyclovir Treatment|Completed|||36|Actual|University of Washington|||2||f||||f||||||Samples With DNA|"~     whole blood, genital swab specimens~   "|||2018-06-01 03:06:40.038601|2018-06-01 03:06:40.038601
NCT00495560|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2008-10-03|2007-07-02|2007-07-03|Estimate|||||||2008-10-03|2008-10-07|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Pilot Study of Priming Before Induction Termination of Pregnancy|A Pilot Study of Priming Before Induction Termination of Pregnancy|Completed||N/A|25|Actual|Boston University|||||f||||f||||||||||2018-06-01 03:06:40.119791|2018-06-01 03:06:40.119791
NCT00495547|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2014-04-04|2007-07-02|2007-07-03|Estimate|||||||2014-04-04|2014-04-07|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|SIMIDIS||SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome|A Multicenter, Non-Randomized, Open-Label Study to Evaluate Efficacy and Safety of Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Red Cell Transfusion Dependent With Low or Intermediate -1 Risk.|Terminated||Phase 2|16|Actual|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:06:40.18667|2018-06-01 03:06:40.18667
NCT00495183|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2010-05-26|2007-06-29|2007-07-02|Estimate|||||||2010-05-26|2010-05-27|Estimate|January 2009||2009-01-31|May 2010|2010-05-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence|Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence|Unknown status|Recruiting|Phase 4|108|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||t||||||||||2018-06-01 03:06:47.662047|2018-06-01 03:06:47.662047
NCT00495521|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2017-06-05||2017-08-23|2007-06-29|2007-07-03|Estimate|2017-08-23|2017-09-21|Actual||||2017-08-23|2017-09-21|Actual|June 2007||2007-06-30|August 2017|2017-08-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children|A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease|Terminated||Phase 2|2|Actual|Jacobus Pharmaceutical||2||Efforts at recruitment have halted as recruitment was poor|f||||f||||||||No||2018-06-01 03:06:41.419508|2018-06-01 03:06:41.419508
NCT00495508|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2010-05-12|2007-07-02|2007-07-03|Estimate|||||||2010-05-12|2010-05-13|Estimate|October 2006||2006-10-31|May 2010|2010-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy|A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007)|Completed||Phase 4|300|Anticipated|Epicentre|||||f||||t||||||||||2018-06-01 03:06:41.818341|2018-06-01 03:06:41.818341
NCT00495495|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-01|2010-10-12||2015-02-02|2007-07-01|2007-07-03|Estimate|2010-11-29|2010-12-23|Estimate||||2015-02-02|2015-02-20|Estimate|February 2007||2007-02-28|February 2015|2015-02-28|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Healozone Study to Evaluate the Safety and Efficacy of the Use of Ozone for Management of Dental Caries|A Multi-Center Study to Evaluate the Safety and Efficacy of the Use of Ozone for the Management of Fissure Caries|Completed||Phase 2/Phase 3|394|Actual|Indiana University|Study length may have been too brief to permit progression of early stage caries; Low caries increment in study population; Difficult to establish that lesions were truly active at baseline.|2|||f||||t||||||||||2018-06-01 03:06:41.915122|2018-06-01 03:06:41.915122
NCT00495482|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2012-11-12|2007-07-02|2007-07-03|Estimate|||||||2012-11-12|2012-11-14|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|January 2010|Actual|2010-01-31|||||Observational|ESPIL||Incurable Ill Patients Attitudes Towards Euthanasia and Assisted Suicide|Incurable Ill Patients Attitudes to Euthanasia and Assisted Suicide: A Prospective, Multi-Centre Trial in Palliative Care Units in Saxony|Completed|||200|Actual|Klinikum St. Georg gGmbH|||1||f||||f||||||||||2018-06-01 03:06:42.294212|2018-06-01 03:06:42.294212
NCT00495469|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2017-09-26|2009-07-22|2017-09-26|2007-06-29|2007-07-03|Estimate|2017-09-26|2017-10-30|Actual|2009-07-23|2009-08-10|Estimate|2017-09-26|2017-10-30|Actual|August 17, 2007|Actual|2007-08-17|September 2017|2017-09-30|June 5, 2008|Actual|2008-06-05|June 5, 2008|Actual|2008-06-05||Interventional|||Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive|A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects|Completed||Phase 2|250|Actual|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-06-01 03:06:42.545477|2018-06-01 03:06:42.545477
NCT00495456|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2017-09-20|2007-07-02|2007-07-03|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2007||2007-08-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|CLEAR||Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Study|Cardiovascular Longitudinal Evaluation & Assessment of Risk Study|Recruiting|||999999|Anticipated|Monash University|||||f||||t||||||||||2018-06-01 03:06:45.203533|2018-06-01 03:06:45.203533
NCT00495443|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-01|||2007-07-01|2007-07-01|2007-07-03|Estimate|||||||2007-07-01|2007-07-03|Estimate|September 2007||2007-09-30|July 2007|2007-07-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Enhanced Safety Aesthetic Laser System|Peterio™ – an Add-on Device for Enhanced Safety of Aesthetic Laser Treatments|Unknown status|Not yet recruiting|N/A|25|Anticipated|Scilex Ltd.|||||f||||f||||||||||2018-06-01 03:06:45.290496|2018-06-01 03:06:45.290496
NCT00495430|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-01|||2009-06-15|2007-07-01|2007-07-03|Estimate|||||||2009-06-15|2009-06-16|Estimate|December 2004||2004-12-31|June 2009|2009-06-30|July 2009|Anticipated|2009-07-31|||||Observational|||Vibration Response Imaging in Healthy Subjects|Passive Acoustic Imaging With the Vibration Response Imaging Device in Healthy Subjects|Unknown status|Active, not recruiting||310|Anticipated|Deep Breeze|||||f||||f||||||||||2018-06-01 03:06:45.378518|2018-06-01 03:06:45.378518
NCT00495417|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2010-10-18|2007-07-02|2007-07-03|Estimate|||||||2010-10-18|2010-10-19|Estimate|July 2007||2007-07-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease|Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Phase I Pilot Study to Assess Tolerability and Safety of Repeated s.c. Administration of a Single-dose of Affitope AD01 Applied With or Without Adjuvant to Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|24|Actual|Affiris AG||2|||f||||t||||||||||2018-06-01 03:06:45.448248|2018-06-01 03:06:45.448248
NCT00495404|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2015-04-06|2007-07-02|2007-07-03|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2001||2001-08-31|June 2007|2007-06-30|March 2005|Actual|2005-03-31|||||Interventional|||Health Outcomes From Opioid Therapy for Chronic Pain|Health Outcomes From Opioid Therapy for Chronic Pain|Completed||N/A|135|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:06:45.52375|2018-06-01 03:06:45.52375
NCT00495391|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|2013-11-18||2014-04-08|2007-07-02|2007-07-03|Estimate|2013-11-18|2014-01-06|Estimate||||2014-04-08|2014-05-08|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|STEALTHC-2||Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C|Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin|Completed||Phase 2|64|Actual|Romark Laboratories L.C.||2|||f||||t||||||||||2018-06-01 03:06:45.607998|2018-06-01 03:06:45.607998
NCT00495378|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2016-12-19|2007-07-02|2007-07-03|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2002||2002-11-30|June 2007|2007-06-30|March 2003|Actual|2003-03-31|||||Interventional|||RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia|Retrospective Review of Alternate PROCRIT Dosing In Patients With Chemotherapy Related Anemia|Terminated||Phase 4|25|Actual|Ortho Biotech Products, L.P.||||This study was stopped due to slow enrollment after enrolling 25 of 200 patients.|f||||f||||||||||2018-06-01 03:06:46.202097|2018-06-01 03:06:46.202097
NCT00495365|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2011-05-17|2007-07-02|2007-07-03|Estimate|||||||2011-05-17|2011-05-19|Estimate|June 2003||2003-06-30|April 2010|2010-04-30|September 2003|Actual|2003-09-30|||||Interventional|||A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.|Evaluation of Dose Conversion From Variable Dosing Intervals of Darbepoetin Alfa to Variable Dosing Intervals of Epoetin Alfa in Patients With the Anemia of Chronic Kidney Disease|Terminated||Phase 4|8|Actual|Ortho Biotech Products, L.P.||||This study was stopped due to slow enrollment|f||||f||||||||||2018-06-01 03:06:46.279823|2018-06-01 03:06:46.279823
NCT00493467|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2015-11-17|2007-06-27|2007-06-28|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2006||2006-06-30|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas|Phase II Study of Zevalin for the Treatment of Early-Stage Indolent Lymphomas|Completed||Phase 2|31|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:07:17.971266|2018-06-01 03:07:17.971266
NCT00495352|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-30|||2010-04-13|2007-07-02|2007-07-03|Estimate|||||||2010-04-13|2010-04-14|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|December 2008|Actual|2008-12-31|||||Interventional|PSIAARP||The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia|1. The Pharmacogenetic Study of Interaction Among Antipsychotics, Readiness to Change, and Pharmacological Intervention for Smoking Cessation Among Schizophrenic Patients 2. Stages of Change and Outcomes of Nicotine Replacement Therapy in Chronic Schizophrenic Patients|Completed||Phase 4|360|Actual|Yu-Li Hospital||1|||f||||t||||||||||2018-06-01 03:06:46.351618|2018-06-01 03:06:46.351618
NCT00495339|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2009-03-03|2007-07-02|2007-07-03|Estimate|||||||2009-03-03|2009-03-04|Estimate|June 2007||2007-06-30|June 2008|2008-06-30||||April 2008|Actual|2008-04-30||Interventional|||MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis|Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB)|Completed||Phase 4|100|Anticipated|Sanofi||1|||f||||||||||||||2018-06-01 03:06:46.428703|2018-06-01 03:06:46.428703
NCT00495326|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2012-02-14|2007-07-02|2007-07-03|Estimate|||||||2012-02-14|2012-02-15|Estimate|December 2007||2007-12-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|CARINEMO||Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)|Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)|Completed||Phase 2/Phase 3|570|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||t||||||||||2018-06-01 03:06:46.498222|2018-06-01 03:06:46.498222
NCT00495313|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2008-12-11|2007-06-29|2007-07-03|Estimate|||||||2008-12-11|2008-12-16|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens|Determine the Effects of COL-101 Administered Once Daily With Metronidazole Topical Gel, 1% Versus Doxycycline Hyclate 100 mg Administered Once Daily With Metronidazole Topical Gel, 1% in Patients With Moderate to Severe Rosacea|Completed||Phase 4|91|Actual|CollaGenex Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:06:46.607399|2018-06-01 03:06:46.607399
NCT00495300|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-30|||2018-03-27|2007-06-30|2007-07-03|Estimate|||||||2018-03-27|2018-03-29|Actual|June 29, 2007||2007-06-29|December 4, 2017|2017-12-04||||||||Observational|||Collection of Samples and Data for the National Marrow Donor Program Repository|The Collection of Research Samples and/or Data for Repository From Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:06:46.700089|2018-06-01 03:06:46.700089
NCT00495287|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2016-03-29|2007-07-02|2007-07-03|Estimate|||||||2016-03-29|2016-03-31|Estimate|November 2006||2006-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)|Phase III Trial in AML Comparing Standard-dose vs High-dose Remission Induction and, Within a Risk-oriented Postremission Strategy, Autologous Blood Stem Cell Transplantation vs Blood Stem Cell-supported Multicycle High-dose Program|Completed||Phase 3|573|Actual|Northern Italy Leukemia Group||2|||f||||t||||||||||2018-06-01 03:06:46.78105|2018-06-01 03:06:46.78105
NCT00495274|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2017-08-04|2007-06-29|2007-07-03|Estimate|||||||2017-08-04|2017-08-07|Actual|July 2, 2007|Actual|2007-07-02|August 2017|2017-08-31|September 26, 2007|Actual|2007-09-26|September 26, 2007|Actual|2007-09-26||Interventional|||Bioequivalence and Food Effect Study in Healthy Volunteers|A Single-centre, Open-label, Randomized, Single-dose, 6-way Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of 6 Different Formulations of SB-649868 30 mg (Part A) and the Effect of Food on the Selected Formulation of SB-649868 Pharmacokinetic (Part B) in Healthy Male Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:06:46.903362|2018-06-01 03:06:46.903362
NCT00495261|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2008-01-14|2007-06-29|2007-07-03|Estimate|||||||2008-01-14|2008-01-16|Estimate|February 2007||2007-02-28|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Development and Validation of a Mindfulness Intervention for Problem Gambling: An Exploratory Study|Development and Validation of a Mindfulness Intervention for Problem Gambling: An Exploratory Study|Completed||N/A|24|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 03:06:46.996793|2018-06-01 03:06:46.996793
NCT00495248|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2011-08-08|2007-07-02|2007-07-03|Estimate|||||||2011-08-08|2011-08-09|Estimate|January 2007||2007-01-31|August 2011|2011-08-31|September 2011|Anticipated|2011-09-30|September 2009|Actual|2009-09-30||Interventional|||Thriving, Activity and Social Participation After Stroke|Well-being, Activity and Social Participation After Stroke/TIA. RCT-psycho Social Intervention Study.|Unknown status|Active, not recruiting|Phase 1/Phase 2|140|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 03:06:47.194609|2018-06-01 03:06:47.194609
NCT00495235|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-02|||2014-05-20|2007-07-02|2007-07-03|Estimate|||||||2014-05-20|2014-05-21|Estimate|October 2005||2005-10-31|May 2014|2014-05-31||||May 2014|Actual|2014-05-31||Observational|||Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas|Case-Control Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas|Completed|||147|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||Samples With DNA|"~     Blood sample and, if diagnosed with endometrial cancer and had surgical removal of uterus, a~     piece of leftover tumor and surrounding normal tissue will be tested for markers of insulin~     resistance and PCOS.~   "|||2018-06-01 03:06:47.276382|2018-06-01 03:06:47.276382
NCT00495222|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2009-04-21||2009-09-08|2007-07-02|2007-07-03|Estimate|2009-08-10|2009-08-11|Estimate||||2009-09-08|2009-09-10|Estimate|February 2007||2007-02-28|September 2009|2009-09-30|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Endoscopic Suturing System for Tissue Apposition|Evaluation of an Endoscopic Suturing System for Tissue Apposition|Completed||N/A|9|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||||2018-06-01 03:06:47.377023|2018-06-01 03:06:47.377023
NCT00495209|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2018-02-20|2007-06-29|2007-07-02|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 2006|Actual|2006-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pre-Surgical Qigong Therapy for Women With Breast Cancer|Pre-Surgical Qigong Therapy for Women With Breast Cancer|Active, not recruiting|||7|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:06:47.521436|2018-06-01 03:06:47.521436
NCT00495196|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2010-07-25|2007-06-28|2007-07-02|Estimate|||||||2010-07-25|2010-07-27|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Cardiovascular Responses in Congestive Heart Failure With Cheyne- Stokes Respiration|Cardiovascular Response to Peripheral Chemoreceptor Stimulation in Congestive Heart Failure With Cheyne- Stokes Respiration|Completed||N/A|50|Actual|ResMed||2|||f||||f||||||||||2018-06-01 03:06:47.594423|2018-06-01 03:06:47.594423
NCT00495170|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-06-20|2007-06-28|2007-07-02|Estimate|||||||2017-06-20|2017-06-21|Actual|April 14, 2006|Actual|2006-04-14|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|Phase II Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|84|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:06:47.815408|2018-06-01 03:06:47.815408
NCT00495157|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2012-04-30||2013-04-05|2007-06-28|2007-07-02|Estimate|2012-04-30|2012-05-31|Estimate||||2013-04-05|2013-04-11|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|BASALT||Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)|Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)|Completed||Phase 3|342|Actual|Milton S. Hershey Medical Center||3|||f||||t||||||||||2018-06-01 03:06:47.923928|2018-06-01 03:06:47.923928
NCT00495144|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2012-07-25|2007-06-29|2007-07-02|Estimate|||||||2012-07-25|2012-07-27|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors|A Phase I, Multi-Center, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors|Completed||Phase 1|129|Actual|Threshold Pharmaceuticals|||||f||||t||||||||||2018-06-01 03:06:48.256361|2018-06-01 03:06:48.256361
NCT00495131|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2008-12-21||2009-09-07|2007-06-29|2007-07-02|Estimate|2009-07-31|2009-09-07|Estimate||||2009-09-07|2009-09-10|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients|Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan|Completed||Phase 4|308|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 03:06:48.347567|2018-06-01 03:06:48.347567
NCT00495118|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2011-05-16|2007-06-29|2007-07-02|Estimate|||||||2011-05-16|2011-05-17|Estimate|October 2001||2001-10-31|May 2010|2010-05-31|March 2005|Actual|2005-03-31|||||Interventional|||A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.|Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85.|Completed||Phase 3|314|Actual|Janssen, LP|||||f||||||||||||||2018-06-01 03:06:48.661418|2018-06-01 03:06:48.661418
NCT00495105|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2013-02-08|2007-06-29|2007-07-02|Estimate|||||||2013-02-08|2013-02-12|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Dairy Foods and Blood Pressure in Multi-Ethnic Children|Dairy Foods and Blood Pressure in Multi-Ethnic Children|Completed||N/A|2115|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 03:06:48.734374|2018-06-01 03:06:48.734374
NCT00495092|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2012-02-29|2007-06-29|2007-07-02|Estimate|||||||2012-02-29|2012-03-01|Estimate|January 2005||2005-01-31|February 2012|2012-02-29|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients|Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients|Completed||Phase 2/Phase 3|85|Actual|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||t||||||||||2018-06-01 03:06:48.829403|2018-06-01 03:06:48.829403
NCT00495079|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2012-03-15||2013-12-02|2007-06-28|2007-07-02|Estimate|2012-10-30|2012-11-29|Estimate||||2013-12-02|2013-12-27|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia|A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (Vincristine Sulfate Liposomes Injection) in Adult Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients With Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy|Completed||Phase 2|65|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||||||||||||2018-06-01 03:06:48.95341|2018-06-01 03:06:48.95341
NCT00495066|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2013-05-30|2007-06-29|2007-07-02|Estimate|||||||2013-05-30|2013-06-03|Estimate||||May 2013|2013-05-31||||||||Expanded Access|||Compassionate Use Trial for Unresectable Melanoma With Ipilimumab|A Multicenter Treatment Protocol for Expanded Access Use of Ipilimumab (BMS-734016) Monotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma|No longer available|||||Bristol-Myers Squibb|||||||||f||||||||||2018-06-01 03:06:49.39396|2018-06-01 03:06:49.39396
NCT00495053|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2012-03-21|2007-06-29|2007-07-02|Estimate|||||||2012-03-21|2012-03-22|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|November 2009|Actual|2009-11-30|July 2008|Actual|2008-07-31||Interventional|||Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder Syndrome and Detrusor Overactivity|A Phase 1 Multicenter Study of Three Escalating Doses of hMaxi-K Gene Transfer in Female Participants With Overactive Bladder Syndrome and Detrusor Overactivity|Completed||Phase 1|21|Actual|Ion Channel Innovations||2|||f||||t||||||||||2018-06-01 03:06:49.459436|2018-06-01 03:06:49.459436
NCT00495040|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-06-20|2007-06-28|2007-07-02|Estimate|||||||2017-06-20|2017-06-21|Actual|May 4, 2006|Actual|2006-05-04|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|38|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:06:49.536612|2018-06-01 03:06:49.536612
NCT00495027|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2007-06-28|2007-06-28|2007-07-02|Estimate|||||||2007-06-28|2007-07-02|Estimate|March 2002||2002-03-31|June 2007|2007-06-30|August 2005|Actual|2005-08-31|||||Interventional|||Brief Cognitive-Behavioral Treatment for Victims of Mass Violence|Brief Cognitive-Behavioral Treatment for Victims of Mass Violence|Completed||Phase 1|45|Actual|Boston University|||||f||||f||||||||||2018-06-01 03:06:49.624423|2018-06-01 03:06:49.624423
NCT00495014|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28||2010-10-13|2010-10-13|2007-06-28|2007-07-02|Estimate||||2010-10-13|2010-10-15|Estimate|2010-10-13|2010-10-15|Estimate|June 2007||2007-06-30|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects|A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study With Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects|Completed||Phase 1|70|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:06:49.685452|2018-06-01 03:06:49.685452
NCT00494793|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2017-12-28|2007-06-29|2007-07-02|Estimate|||||||2017-12-28|2017-12-29|Actual|April 1, 2006|Actual|2006-04-01|December 2017|2017-12-31|April 1, 2015|Actual|2015-04-01|August 31, 2009|Actual|2009-08-31||Interventional|||Vacuum Assisted Wound Closure (VAWC) and Mesh Mediated Fascial Traction|Vacuum Assisted Wound Closure (VAWC) and Mesh Mediated Fascial Traction - Prospective Study of a Novel Technique for Open Abdomen Closure|Completed||N/A|111|Actual|Skane University Hospital||1|||f||||f||||||||||2018-06-01 03:06:54.084698|2018-06-01 03:06:54.084698
NCT00494988|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2016-03-03|2007-06-29|2007-07-02|Estimate|||||||2016-03-03|2016-03-04|Estimate|December 2004||2004-12-31|March 2016|2016-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart|Self-control Trial to Evaluate the Remission Rate and Safety in Newly Diagnosed Type 2 Diabetes Patients After Short-term Intensive Insulin Aspart and Insulin NPH Treatment|Completed||Phase 4|33|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:06:49.866687|2018-06-01 03:06:49.866687
NCT00494975|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2010-10-05||2011-01-26|2007-06-29|2007-07-02|Estimate|2011-01-06|2011-01-25|Estimate||||2011-01-26|2011-01-27|Estimate|June 2007||2007-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease|The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease|Completed||N/A|21|Actual|National Taiwan University Hospital|small numbers of subjects analyzed|2|||f||||f||||||||||2018-06-01 03:06:49.958314|2018-06-01 03:06:49.958314
NCT00494962|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2007-12-03|2007-06-29|2007-07-02|Estimate|||||||2007-12-03|2007-12-05|Estimate|June 2007||2007-06-30|December 2007|2007-12-31|June 2007||2007-06-30|||||Interventional|||Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy Subjects|An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between Two 5-mg Tablets and a New 10-mg Tablet Formulation of Lecozotan SR in Healthy Subjects.|Completed||Phase 1|40||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:06:50.27477|2018-06-01 03:06:50.27477
NCT00494949|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2013-08-15|2007-06-28|2007-07-02|Estimate|||||||2013-08-15|2013-08-19|Estimate|April 2003||2003-04-30|August 2013|2013-08-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients|A Clinical Safety (Phase Ib/II) Increasing Dose Study of MP4 (Hemospan) in Orthopedic Surgery Patients|Completed||Phase 1/Phase 2|30|Actual|Sangart||2|||f||||t||||||||||2018-06-01 03:06:50.328834|2018-06-01 03:06:50.328834
NCT00494936|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2015-05-21|2007-06-28|2007-07-02|Estimate|||||||2015-05-21|2015-05-25|Estimate|May 2006||2006-05-31|May 2015|2015-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Effects of HIV and Hepatitis C Virus on the Brain|HIV/HCV: Neuropsychiatric and Neurophysiological Features|Completed|||78|Actual|Icahn School of Medicine at Mount Sinai|||4||f||||f||||||||||2018-06-01 03:06:50.415304|2018-06-01 03:06:50.415304
NCT00494923|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2013-12-11|2007-06-29|2007-07-02|Estimate|||||||2013-12-11|2013-12-12|Estimate|January 1999||1999-01-31|December 2013|2013-12-31|December 2020|Anticipated|2020-12-31|December 2015|Anticipated|2015-12-31||Observational|||Early Diagnosis, Pathogenesis and Progression of Open Angle Glaucoma|Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)|Recruiting|||2500|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 03:06:50.47892|2018-06-01 03:06:50.47892
NCT00494910|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2017-08-03|2007-06-29|2007-07-02|Estimate|||||||2017-08-03|2017-08-04|Actual|June 2007||2007-06-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients|A Randomized Controlled Trial of Group Psychotherapy Interventions for Cancer Patients|Active, not recruiting||Phase 3|253|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 03:06:50.644222|2018-06-01 03:06:50.644222
NCT00494897|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2009-05-15|2007-06-29|2007-07-02|Estimate|||||||2009-05-15|2009-05-19|Estimate|June 1996||1996-06-30|May 2009|2009-05-31|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Interventional|||PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia|PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia|Completed||Phase 4|374|Actual|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:06:50.769733|2018-06-01 03:06:50.769733
NCT00494884|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2017-02-23|2007-06-29|2007-07-02|Estimate|||||||2017-02-23|2017-02-27|Actual|June 2007||2007-06-30|February 2017|2017-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin|A Multicenter, Randomized, Double-blind, Parallel-group Study to Investigate the Glucose Lowering Effect, Safety and Tolerability of 24 Weeks Treatment With Vildagliptin 100 mg o.d. Versus Placebo Followed by a 12 Weeks Treatment Period With Open-label Vildagliptin 100 mg o.d. as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin|Completed||Phase 3|||Novartis|||||f||||||||||||||2018-06-01 03:06:51.077212|2018-06-01 03:06:51.077212
NCT00494871|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2012-03-28||2015-04-01|2007-06-29|2007-07-02|Estimate|2012-03-28|2012-04-19|Estimate||||2015-04-01|2015-04-20|Estimate|June 2007||2007-06-30|April 2015|2015-04-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation|Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation|Completed||Phase 3|1280|Actual|Bayer||2|||f||||t||||||||||2018-06-01 03:06:51.306856|2018-06-01 03:06:51.306856
NCT00494858|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2016-07-18|2007-06-28|2007-07-02|Estimate|||||||2016-07-18|2016-07-20|Estimate|July 2007||2007-07-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa|Treatment of Bulimia Nervosa: Dysregulated Subtype|Completed||Phase 2|50|Actual|Boston University||2|||f||||f||||||||||2018-06-01 03:06:53.384453|2018-06-01 03:06:53.384453
NCT00494845|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2016-01-13|2007-06-29|2007-07-02|Estimate|||||||2016-01-13|2016-01-15|Estimate|July 2007||2007-07-31|January 2016|2016-01-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Mindfulness Meditation for Chronic Low Back Pain in Older Adults|Mindfulness Meditation for Chronic Low Back Pain in Older Adults|Completed||Phase 4|40|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:06:53.456495|2018-06-01 03:06:53.456495
NCT00494832|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2012-09-12|2007-06-28|2007-07-02|Estimate|||||||2012-09-12|2012-09-14|Estimate|February 2008||2008-02-29|September 2012|2012-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery|Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery|Completed||N/A|40|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:06:53.529417|2018-06-01 03:06:53.529417
NCT00494819|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2012-11-12|2007-06-29|2007-07-02|Estimate|||||||2012-11-12|2012-11-14|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|August 2006|Actual|2006-08-31|||||Observational|||Validity of ADHD Subtypes Using Neuropsychological Measure|Discriminate Validity of ADHD Subtypes Using Neuropsychological Test|Completed|||122|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:06:53.627585|2018-06-01 03:06:53.627585
NCT00494806|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2009-08-31||2012-07-31|2007-06-29|2007-07-02|Estimate|2009-10-22|2009-11-26|Estimate||||2012-07-31|2012-08-07|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effects of Rocking on Postoperative Ileus Duration Study|The Effects of Rocking Chair Motion on Postoperative Ileus Duration, Subjective Pain and Time to Discharge Following Abdominal Surgery|Completed||Early Phase 1|66|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:06:53.735051|2018-06-01 03:06:53.735051
NCT00494780|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|2011-07-28||2014-06-26|2007-06-29|2007-07-02|Estimate|2011-07-28|2011-08-26|Estimate||||2014-06-26|2014-07-11|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|April 2009|Actual|2009-04-30||Interventional|MUNIN||Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients|An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With CHOP, in Patients With Previously Untreated Follicular Lymphoma (FL).|Completed||Phase 2|59|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 03:06:54.30267|2018-06-01 03:06:54.30267
NCT00494767|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2017-08-04|2007-06-28|2007-07-02|Estimate|||||||2017-08-04|2017-08-07|Actual|September 29, 2006|Actual|2006-09-29|August 2017|2017-08-31|June 7, 2007|Actual|2007-06-07|June 7, 2007|Actual|2007-06-07||Interventional|||Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs|An Exploratory Study to Evaluate Weight Loss, Body Composition Changes, Food Intake and Urine Glucose Excretion in Healthy Obese Subjects Over 8 Weeks of Dosing With GSK189075, GW869682 Versus Placebo|Completed||Phase 1|27|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:06:56.299474|2018-06-01 03:06:56.299474
NCT00494754|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2009-12-14|2007-06-29|2007-07-02|Estimate|||||||2009-12-14|2009-12-15|Estimate|May 2007||2007-05-31|December 2009|2009-12-31|January 2010|Anticipated|2010-01-31|||||Observational|||Clinical and Genetic Study of Autism Spectrum Disorder|Clinical and Genetic Study of Autism Spectrum Disorder|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-06-01 03:06:56.39077|2018-06-01 03:06:56.39077
NCT00494741|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2017-12-12|2007-06-29|2007-07-02|Estimate|||||||2017-12-12|2017-12-13|Actual|May 2007||2007-05-31|December 2017|2017-12-31|November 29, 2017|Actual|2017-11-29|July 2016|Actual|2016-07-31||Interventional|ATHENA||MMF vs. AZA for Kidney Transplantation|A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients|Completed||Phase 4|233|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-06-01 03:06:57.365307|2018-06-01 03:06:57.365307
NCT00494728|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2018-05-03|2007-06-29|2007-07-02|Estimate|||||||2018-05-03|2018-05-07|Actual|June 2007|Actual|2007-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Smoking Cessation for Depressed Smokers|Smoking Cessation Intervention for Depressed Smokers: Treatment Development|Active, not recruiting||Phase 1/Phase 2|202|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 03:06:57.47399|2018-06-01 03:06:57.47399
NCT00494715|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2016-05-31|2007-06-29|2007-07-02|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2007||2007-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|VALID||Preventing ESRD in Overt Nephropathy of Type 2 Diabetes|A Prospective, Randomized, Probe Trial to Evaluate Whether,at Comparable Blood Pressure Control,Combined Therapy With ACEI BEN and ARB VAL Reduces Progression to ESRD More Effectively Than BEN or VAL Alone in High Risk Patients With Type 2 Diabetes and Overt Nephropathy|Completed||Phase 3|102|Actual|Mario Negri Institute for Pharmacological Research||3|||f||||f||||||||||2018-06-01 03:06:57.568516|2018-06-01 03:06:57.568516
NCT00494702|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2008-10-14|2007-06-28|2007-07-02|Estimate|||||||2008-10-14|2008-10-15|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|OXTOX||Oxygen Toxicity in the Resuscitation in Extremely Premature Infants|Achievement of a Targeted Saturation in Extremely Low Gestational Age Neonates Resuscitated With Low or High Oxygen Concentration: A Prospective Randomized Trial|Completed||Phase 3|88|Actual|Fundacion Para La Investigacion Hospital La Fe||2|||f||||t||||||||||2018-06-01 03:06:57.705491|2018-06-01 03:06:57.705491
NCT00494689|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2007-06-28|2007-06-28|2007-07-02|Estimate|||||||2007-06-28|2007-07-02|Estimate|January 2002||2002-01-31|June 2007|2007-06-30|June 2007|Anticipated|2007-06-30|||||Observational|||Transcranial and Rapid Magnetic Stimulation for Gait Apraxia Due to Normal Pressure Hydrocephalus and Cerebral Ischemia||Unknown status|Recruiting||30|Anticipated|Devathasan Neurology Practice Pte Ltd|||||f||||t||||||||||2018-06-01 03:06:57.811445|2018-06-01 03:06:57.811445
NCT00494676|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2013-07-07||2017-04-01|2007-06-29|2007-07-02|Estimate|2013-07-07|2013-09-13|Estimate||||2017-04-01|2017-04-04|Actual|September 2007||2007-09-30|April 2017|2017-04-30|April 2010|Actual|2010-04-30|July 2009|Actual|2009-07-31||Interventional|||Clinical Trial of Peripheral Prism Glasses for Hemianopia|Community-based Multi-center Randomized Control Trial of Peripheral Prism Glasses for Hemianopia|Completed||N/A|73|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||||2018-06-01 03:06:57.916729|2018-06-01 03:06:57.916729
NCT00494663|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2008-11-11|2007-06-28|2007-07-02|Estimate|||||||2008-11-11|2008-11-13|Estimate|July 2007||2007-07-31|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|March 2008|Anticipated|2008-03-31||Interventional|||A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes|A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment With DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-502)|Terminated||Phase 2|200|Anticipated|DiObex||8||Program Terminated|f||||f||||||||||2018-06-01 03:06:58.35975|2018-06-01 03:06:58.35975
NCT00494650|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2012-08-07|2007-06-28|2007-07-02|Estimate|||||||2012-08-07|2012-08-08|Estimate|April 2008||2008-04-30|August 2012|2012-08-31||||July 2012|Actual|2012-07-31||Interventional|||Cognitive Behavioral Treatment for Post-Traumatic Stress Disorder in People With Additional Serious Mental Illnesses|Cognitive Behavioral Treatment of Post-Traumatic Stress Disorder in Clients With Severe Mental Illness (in New Jersey)|Completed||N/A|200|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 03:06:58.550956|2018-06-01 03:06:58.550956
NCT00494637|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2009-01-27|2007-06-29|2007-07-02|Estimate|||||||2009-01-27|2009-01-28|Estimate|July 2007||2007-07-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy||Terminated||N/A|468|Anticipated|Lenox Hill Hospital||||Not reaching recruitment and endpoint goals|f||||f||||||||||2018-06-01 03:06:58.656959|2018-06-01 03:06:58.656959
NCT00494624|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-29|||2007-06-29|2007-06-29|2007-07-02|Estimate|||||||2007-06-29|2007-07-02|Estimate|September 2000||2000-09-30|June 2007|2007-06-30|May 2008|Anticipated|2008-05-31|||||Interventional|VINKU||Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children||Unknown status|Recruiting|Phase 4|300|Anticipated|University of Turku|||||f||||f||||||||||2018-06-01 03:06:58.723383|2018-06-01 03:06:58.723383
NCT00494611|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2011-05-18|2007-06-29|2007-07-02|Estimate|||||||2011-05-18|2011-05-19|Estimate|September 2007||2007-09-30|June 2010|2010-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients|A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients|Terminated||Phase 1|25|Anticipated|St. Luke's-Roosevelt Hospital Center||||Unable to recruit subjects in timely fashion for the study|f||||f||||||||||2018-06-01 03:06:58.92002|2018-06-01 03:06:58.92002
NCT00494585|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2011-04-07||2012-06-19|2007-06-28|2007-06-29|Estimate|2011-04-07|2011-05-04|Estimate||||2012-06-19|2012-06-25|Estimate|June 2007||2007-06-30|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||CEP-701 for PH-negative Myelofibrosis|Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis|Completed||Phase 2|27|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:06:59.068869|2018-06-01 03:06:59.068869
NCT00494572|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2008-12-15|2007-06-28|2007-06-29|Estimate|||||||2008-12-15|2008-12-16|Estimate|December 2006||2006-12-31|November 2008|2008-11-30|October 2010|Anticipated|2010-10-31|January 2010|Anticipated|2010-01-31||Interventional|||Montelukast With Status Asthmaticus, Ages 6-18|Pharmacokinetics and Pharmacodynamics of Montelukast in Children, Ages 6 Through 18 Years Old, With Status Asthmaticus Unresponsive to Conventional Treatment|Unknown status|Recruiting|Phase 2/Phase 3|52|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 03:06:59.238291|2018-06-01 03:06:59.238291
NCT00494559|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2016-02-24|2007-06-28|2007-06-29|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2007||2007-07-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers|Phase 4 Study of Pioglitazone on Neointima Volume and Inflammatory Markers in Diabetic Patients|Completed||Phase 4|240|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-06-01 03:06:59.318679|2018-06-01 03:06:59.318679
NCT00494546|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2007-06-28|2007-06-28|2007-06-29|Estimate|||||||2007-06-28|2007-06-29|Estimate|January 1999||1999-01-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer|High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer|Completed||Phase 3|568|Actual|VA Puget Sound Health Care System|||||f||||f||||||||||2018-06-01 03:06:59.439835|2018-06-01 03:06:59.439835
NCT00494533|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2014-01-28|2007-06-28|2007-06-29|Estimate|||||||2014-01-28|2014-01-29|Estimate|March 2005||2005-03-31|January 2014|2014-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|TRUST-1||Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension|Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension|Terminated||Phase 4|45|Actual|United Therapeutics||||Safety issues related to outpatient intravenous infusion in India|f||||t||||||||||2018-06-01 03:06:59.614063|2018-06-01 03:06:59.614063
NCT00494520|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-09-15|2007-06-28|2007-06-29|Estimate|||||||2017-09-15|2017-09-19|Actual|July 2004||2004-07-31|April 2014|2014-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Cognitive Therapy to Improve Word Finding|Learning Paradigms in Aphasia Rehabilitation|Completed||N/A|78|Actual|Georgetown University||2|||f||||f||||||||No||2018-06-01 03:06:59.740335|2018-06-01 03:06:59.740335
NCT00494507|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2014-04-30||2017-05-15|2007-06-28|2007-06-29|Estimate|2014-04-30|2014-05-30|Estimate||||2017-05-15|2017-06-14|Actual|June 2007||2007-06-30|May 2017|2017-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|HYP-HOP||Hyper- and Hypokalemic Periodic Paralysis Study|Dichlorphenamide vs. Placebo for Periodic Paralysis|Completed||Phase 3|71|Actual|University of Rochester|Sample sizes in the trial were limited by slow recruitment and the trial was concluded before attainment of the target numbers of subjects. Statistical analyses were conducted using smaller group sizes than planned, particularly for HYP subjects.|4|||f||||t||||||||||2018-06-01 03:06:59.986366|2018-06-01 03:06:59.986366
NCT00494494|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2011-04-11||2011-06-13|2007-06-28|2007-06-29|Estimate|2011-06-13|2011-07-12|Estimate||||2011-06-13|2011-07-12|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery|Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery|Completed||Phase 4|82|Actual|University of North Carolina, Chapel Hill|Although the peak incidence of CME is said to be at 4–12 weeks after surgery, we may have missed the time course for detecting the maximum increased OCT measured macular thickness.|2|||f||||t||||||||||2018-06-01 03:07:01.118854|2018-06-01 03:07:01.118854
NCT00494481|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2011-04-27||2016-08-24|2007-06-28|2007-06-29|Estimate|2011-04-27|2011-05-24|Estimate||||2016-08-24|2016-09-30|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|January 2009|Actual|2009-01-31|June 2007|Actual|2007-06-30||Interventional|||E3 Breast Cancer Taxotere Combination|A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).|Completed||Phase 2|64|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:07:01.426544|2018-06-01 03:07:01.426544
NCT00494468|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2007-06-28|2007-06-28|2007-06-29|Estimate|||||||2007-06-28|2007-06-29|Estimate|October 2002||2002-10-31|November 2005|2005-11-30|March 2004||2004-03-31|||||Interventional|||Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children|Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Zolpidem Doses in Children Ages 2 to 18 Years of Age|Completed||Phase 1/Phase 2|63||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:07:02.006749|2018-06-01 03:07:02.006749
NCT00494455|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2008-02-19|2007-06-27|2007-06-29|Estimate|||||||2008-02-19|2008-02-29|Estimate|April 2005||2005-04-30|June 2007|2007-06-30|March 2007|Actual|2007-03-31|April 2006|Actual|2006-04-30||Interventional|||Continuous Glucose Monitoring in Critically Ill Patients|Accuracy and Reliability of Continuous Glucose Monitoring in Critically Ill Patients With Shock Requiring Norepinephrine Therapy|Completed||N/A|50|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 03:07:02.140838|2018-06-01 03:07:02.140838
NCT00494442|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2015-01-15|2013-09-17|2017-09-14|2007-06-28|2007-06-29|Estimate|2015-01-15|2015-01-26|Estimate|2013-09-17|2013-09-20|Estimate|2017-09-14|2017-10-16|Actual|June 11, 2007|Actual|2007-06-11|September 2017|2017-09-30|July 20, 2017|Actual|2017-07-20|March 17, 2009|Actual|2009-03-17||Interventional|ICEBERG 2||Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer|A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Ovarian Cancer|Completed||Phase 2|57|Actual|AstraZeneca||2|||t||||t||||||||||2018-06-01 03:07:02.267094|2018-06-01 03:07:02.267094
NCT00494429|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2016-07-25|2007-06-28|2007-06-29|Estimate|||||||2016-07-25|2016-07-27|Estimate|May 2005||2005-05-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|||Optimizing the Use of Morphine in Pre-Term Neonates|Optimizing Pain Treatment in Pre-Term Neonates|Completed||Phase 2|33|Actual|Children's Research Institute||2|||f||||f||||||||||2018-06-01 03:07:02.88712|2018-06-01 03:07:02.88712
NCT00493675|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2010-06-24|2007-06-27|2007-06-28|Estimate|||||||2010-06-24|2010-06-28|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|June 2010|Anticipated|2010-06-30|||||Interventional|||Biodegradable Biliary Stent for Post Operative Cystic Duct Leakage|Biodegradable Biliary Stent for Post Operative Cystic Duct Leakage. Pilot Study|Withdrawn||Phase 1|||University of Tampere||||Difficulties in getting suitable applicators for biodegradable stents.|f||||f||||||||||2018-06-01 03:07:13.98254|2018-06-01 03:07:13.98254
NCT00494416|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-01-25|2007-06-28|2007-06-29|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Different Approaches for Delivery of IPT in Pregnancy in Burkina Faso|A Comparison of Different Approaches for Delivery of Intermittent Preventive Treatment (IPT)to Pregnant Women in Burkina Faso With Regard to Coverage and Compliance|Completed||N/A|11523|Actual|London School of Hygiene and Tropical Medicine||3|||f||||f||||||||||2018-06-01 03:07:03.003595|2018-06-01 03:07:03.003595
NCT00494403|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2013-05-01|2007-06-27|2007-06-29|Estimate|||||||2013-05-01|2013-05-03|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Chronic Ankle Instability and Proprioception|Effects of Ankle Instability on Cervical Proprioception|Completed|||60|Actual|Logan College of Chiropractic|||||f||||f||||||||||2018-06-01 03:07:03.135397|2018-06-01 03:07:03.135397
NCT00494390|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2008-03-18|2007-06-27|2007-06-29|Estimate|||||||2008-03-18|2008-03-19|Estimate|July 2007||2007-07-31|July 2007|2007-07-31||||March 2008|Actual|2008-03-31||Observational|||Evaluation Study for a Non-Contact Biometer|Neuartige Kontaktlose Biometrische Messungen|Completed|||95|Anticipated|University Hospital Inselspital, Berne|||||f||||t||||||||||2018-06-01 03:07:03.232713|2018-06-01 03:07:03.232713
NCT00494377|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2007-06-28|2007-06-27|2007-06-29|Estimate|||||||2007-06-28|2007-07-02|Estimate|February 2004||2004-02-29|June 2007|2007-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression|Duloxetine Versus Duloxetine Plus Non-Pharmacological Intervention in the Treatment of Depression|Completed||Phase 4|940||Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:07:03.32815|2018-06-01 03:07:03.32815
NCT00494364|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-11-08|2007-06-28|2007-06-29|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2007||2007-06-30|November 2017|2017-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3a Part ii|Gas Supply, Demand and Middle Ear Gas Balance: Sp Aim 3a Pt ii|Completed|||28|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 03:07:03.440425|2018-06-01 03:07:03.440425
NCT00494351|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2010-05-20|2007-06-28|2007-06-29|Estimate|||||||2010-05-20|2010-05-21|Estimate|June 2007||2007-06-30|May 2010|2010-05-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa|Prospective Controlled Study of the Efficacy of NdYag for Hidradenitis Suppurativa|Completed||N/A|20|Actual|Henry Ford Health System|||||f||||f||||||||||2018-06-01 03:07:03.536779|2018-06-01 03:07:03.536779
NCT00494338|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2009-09-30|2007-06-28|2007-06-29|Estimate|||||||2009-09-30|2009-10-01|Estimate|November 2004||2004-11-30|September 2009|2009-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer|A Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer|Terminated||Phase 2|6|Actual|Sanofi||||due to celecoxib safety issues|f||||||||||||||2018-06-01 03:07:03.698357|2018-06-01 03:07:03.698357
NCT00494325|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2018-05-02|2007-06-27|2007-06-29|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2005||2005-10-31|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|December 2010|Actual|2010-12-31||Observational|||The Role of Macular Pigment in Patients With Age-related Macular Degeneration|The Role of Macular Pigment in Patients With Age-related Macular Degeneration|Completed|||480|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 03:07:03.931645|2018-06-01 03:07:03.931645
NCT00494312|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2012-02-27|2007-06-28|2007-06-29|Estimate|||||||2012-02-27|2012-02-28|Estimate|October 2000||2000-10-31|February 2012|2012-02-29|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Safety Study of Pioglitazone Compared To Glyburide on Liver Function|A Randomized, Comparator Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl vs Glyburide With Metformin and Insulin as Part of Step Therapy in Subjects With Type 2 (Non-Insulin Dependent) Diabetes|Completed||Phase 4|2120|Actual|Takeda||2|||f||||t||||||||||2018-06-01 03:07:04.074621|2018-06-01 03:07:04.074621
NCT00494299|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2010-12-21||2013-11-26|2007-06-28|2007-06-29|Estimate|2010-12-21|2011-01-20|Estimate||||2013-11-26|2013-12-20|Estimate|April 2006||2006-04-30|November 2013|2013-11-30|November 2010|Actual|2010-11-30|July 2009|Actual|2009-07-31||Interventional|||Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)|Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)|Completed||Phase 3|458|Actual|Bayer||2|||f||||t||||||||||2018-06-01 03:07:04.24909|2018-06-01 03:07:04.24909
NCT00494286|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2013-02-15|2007-06-27|2007-06-29|Estimate|||||||2013-02-15|2013-02-18|Estimate|September 2006||2006-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PFF||Abuse-Focused Cognitive Behavioral Therapy for Children Who Have Been Physically Abused|Treatment of Child Physical Abuse: An Effectiveness Trial (PFF)|Completed||Phase 1|280|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:07:05.112785|2018-06-01 03:07:05.112785
NCT00494273|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2014-10-28|2007-06-28|2007-06-29|Estimate|||||||2014-10-28|2014-10-29|Estimate|December 2002||2002-12-31|September 2014|2014-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||HIV Prevention in Haitian American Adolescents|HIV Prevention in Haitian Youths (HAP)|Completed||Phase 1/Phase 2|320||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:07:05.20378|2018-06-01 03:07:05.20378
NCT00494260|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2016-03-30|2007-06-28|2007-06-29|Estimate|||||||2016-03-30|2016-03-31|Estimate|November 2003||2003-11-30|March 2016|2016-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Managing Recurrent Abdominal Pain|Intergenerational Transmission of Illness Behavior|Completed||Phase 2|200|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||||||||||||2018-06-01 03:07:05.298834|2018-06-01 03:07:05.298834
NCT00494247|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2010-06-18|2007-06-28|2007-06-29|Estimate|||||||2010-06-18|2010-06-22|Estimate|October 2007||2007-10-31|November 2009|2009-11-30|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|JACK-EPC||Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes|Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes|Completed||Phase 4|60|Anticipated|Silesian School of Medicine|||||f||||t||||||||||2018-06-01 03:07:05.390375|2018-06-01 03:07:05.390375
NCT00494234|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2015-01-16|2013-09-16|2018-02-27|2007-06-28|2007-06-29|Estimate|2015-01-16|2015-01-26|Estimate|2013-09-16|2013-09-19|Estimate|2018-02-27|2018-03-01|Actual|June 15, 2007|Actual|2007-06-15|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|February 27, 2009|Actual|2009-02-27||Interventional|ICEBERG 1||Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer|A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer|Active, not recruiting||Phase 2|54|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 03:07:05.507521|2018-06-01 03:07:05.507521
NCT00494221|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2012-03-28||2014-02-26|2007-06-27|2007-06-29|Estimate|2012-05-02|2012-06-05|Estimate||||2014-02-26|2014-03-27|Estimate|June 2007||2007-06-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|October 2009|Actual|2009-10-31||Interventional|||A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX|A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib (AZD2171) in Combination With FOLFOX|Completed||Phase 1/Phase 2|172|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 03:07:06.194096|2018-06-01 03:07:06.194096
NCT00494208|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2013-04-30|2007-06-28|2007-06-29|Estimate|||||||2013-04-30|2013-05-01|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||TDSM- Testosterone Dose Response in Surgically Menopausal Women|Testosterone Dose Response in Surgically Menopausal Women|Completed||N/A|270|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||5|||f||||||||||||||2018-06-01 03:07:06.962357|2018-06-01 03:07:06.962357
NCT00494195|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2013-02-04|2007-06-27|2007-06-29|Estimate|||||||2013-02-04|2013-02-05|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Gene Transfer Therapy for Treating Children and Adults With Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)|Phase I Gene Transfer of rAAV1.tMCK.Human-alpha-sarcoglycan for Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)|Completed||Phase 1|6|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-06-01 03:07:07.047657|2018-06-01 03:07:07.047657
NCT00494182|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-08-14|2007-06-28|2007-06-29|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2007|Actual|2007-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Sorafenib Plus Carboplatin and Paclitaxel in Head and Neck Squamous Cell Cancer|A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer|Active, not recruiting||Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:07:07.195604|2018-06-01 03:07:07.195604
NCT00494169|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-08-31|2007-06-28|2007-06-29|Estimate|||||||2017-08-31|2017-09-01|Actual|January 1999||1999-01-31|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders|Molecular Basis of Inherited Reproductive Disorders|Recruiting|||5000|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||Samples With DNA|"~     WBC are transformed into immortalized cell lines.~   "|||2018-06-01 03:07:07.305793|2018-06-01 03:07:07.305793
NCT00494156|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2015-10-20|2007-06-28|2007-06-29|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2003||2003-07-31|October 2015|2015-10-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||Anticoagulation in Blunt Cerebrovascular Injuries|Anticoagulation in the Management of Grade I-III Blunt Cerebrovascular Injuries|Withdrawn||N/A|0|Actual|Denver Health and Hospital Authority||||Study halted prematurely prior to enrollment of first participant.|f||||||||||||||2018-06-01 03:07:07.399534|2018-06-01 03:07:07.399534
NCT00494143|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2013-08-30||2014-05-21|2007-06-28|2007-06-29|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|July 2007||2007-07-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|May 2009|Actual|2009-05-31||Interventional|||Metabolic Cost Savings for Transtibial Amputees Wearing the Controlled Energy Storage and Return (CESR) Foot|Metabolic Cost Savings for Transtibial Amputees Walking With the CESR Foot|Completed||Phase 3|7|Actual|VA Office of Research and Development|Acclimatization to a prosthetic foot type can alter the measured performance. In this study, subjects were most experienced using their prescribed foot. The CESR foot was also only available in one foot size which can affect gait characteristics.|3|||f||||f||||||||||2018-06-01 03:07:07.464834|2018-06-01 03:07:07.464834
NCT00494117|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2010-07-25|2007-06-28|2007-06-29|Estimate|||||||2010-07-25|2010-07-27|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Investigation of Heart Failure Status Over Time Using Respiratory Parameters|Investigation of Heart Failure Status Over Time Using Respiratory Parameters|Completed|||50|Actual|ResMed|||||f||||f||||||||||2018-06-01 03:07:07.802952|2018-06-01 03:07:07.802952
NCT00494104|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2012-12-14|2007-06-28|2007-06-29|Estimate|||||||2012-12-14|2012-12-18|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Prevention of Vitamin D Deficiency|Prevention of Vitamin D Deficiency in Breastfed Infants|Completed||N/A|398|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||4|||f||||t||||||||||2018-06-01 03:07:07.871023|2018-06-01 03:07:07.871023
NCT00494091|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2012-05-31||2013-03-15|2007-06-28|2007-06-29|Estimate|2012-05-31|2012-07-09|Estimate||||2013-03-15|2013-03-21|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma|Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC)|Completed||Phase 2|82|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:07:07.993656|2018-06-01 03:07:07.993656
NCT00494078|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2010-11-29|2007-06-27|2007-06-29|Estimate|||||||2010-11-29|2010-11-30|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficiency of Continuous Glucose Monitoring in Critically Ill Patients|Efficiency of Real Time Continuous Glucose Monitoring to Achieve Normoglycemia in Critically Ill Patients - a Prospective, Randomized Study|Completed||N/A|120|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 03:07:09.075483|2018-06-01 03:07:09.075483
NCT00494065|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2014-01-30|2007-06-28|2007-06-29|Estimate|||||||2014-01-30|2014-01-31|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Chiropractic and Self-care for Back-Related Leg Pain|Chiropractic and Self-care for Back-Related Leg Pain|Completed||N/A|192|Actual|Northwestern Health Sciences University||2|||f||||||||||||||2018-06-01 03:07:09.164653|2018-06-01 03:07:09.164653
NCT00494052|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2013-01-25|2007-06-28|2007-06-29|Estimate|||||||2013-01-25|2013-01-28|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluating a Web-Based Educational Program for Adults at Risk for Coronary Heart Disease (The Heart to Heart Feasibility Study)|An Intervention to Enhance CHD Risk Factor Modification: The Heart to Heart Feasibility Study|Completed||N/A|186|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 03:07:09.256958|2018-06-01 03:07:09.256958
NCT00494039|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2007-06-28|2007-06-28|2007-06-29|Estimate|||||||2007-06-28|2007-06-29|Estimate|January 1998||1998-01-31|June 2007|2007-06-30|January 2010|Anticipated|2010-01-31|||||Interventional|||I-125 Versus Pd-103 for Low Risk Prostate Cancer|I-125 Versus Pd-103 for Low Risk Prostate Cancer|Unknown status|Active, not recruiting|Phase 3|602|Actual|VA Puget Sound Health Care System|||||f||||t||||||||||2018-06-01 03:07:09.340619|2018-06-01 03:07:09.340619
NCT00494026|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2009-10-14||2009-11-17|2007-06-27|2007-06-29|Estimate|2009-10-14|2009-11-17|Estimate||||2009-11-17|2009-11-20|Estimate|September 2007||2007-09-30|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)|Phase II Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage of Small Cell Lung Cancer|Terminated||Phase 2|4|Actual|Eli Lilly and Company||1||"Study stopped early based on interim results of another trial, showing inferior activity of~   pemetrexed/carboplatin compared to etoposide/carboplatin in SCLC."|f||||t||||||||||2018-06-01 03:07:09.429104|2018-06-01 03:07:09.429104
NCT00494013|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2009-09-25||2009-11-04|2007-06-27|2007-06-29|Estimate|2009-09-25|2009-11-04|Estimate||||2009-11-04|2009-11-11|Estimate|August 2007||2007-08-31|November 2009|2009-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|IOOY||Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)|Treat-to-Target Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Comparator) in Basal Therapy for Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|442|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:07:09.700708|2018-06-01 03:07:09.700708
NCT00493987|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2010-05-12|2007-06-28|2007-06-29|Estimate|||||||2010-05-12|2010-05-13|Estimate|November 2002||2002-11-30|January 2009|2009-01-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|5aR||The Role of 5-alpha Reductase in Mediating Testosterone Actions|The Role of 5-alpha Reductase in Mediating Testosterone Actions|Completed||Phase 4|184|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||||||||||||2018-06-01 03:07:10.591716|2018-06-01 03:07:10.591716
NCT00493974|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|2009-12-18||2016-08-24|2007-06-28|2007-06-29|Estimate|2010-02-02|2010-03-03|Estimate||||2016-08-24|2016-10-03|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|LEUKO||Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)|Antileukotriene Therapy for COPD Exacerbations|Terminated||Phase 3|119|Actual|University of Minnesota - Clinical and Translational Science Institute|Early termination leading to small numbers of subjects recruited|2||Lack of feasibility due to low recruitment|f||||t||||||||No||2018-06-01 03:07:10.794384|2018-06-01 03:07:10.794384
NCT00493961|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2018-03-27|2007-06-28|2007-06-29|Estimate|||||||2018-03-27|2018-03-29|Actual|January 1999||1999-01-31|March 2018|2018-03-31|May 2025|Anticipated|2025-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism|The Effects of 7 Days of Exogenous Pulsatile GnRH Treatment on the Pituitary-Gonadal Axis in Hypogonadotropic Hypogonadal Subjects|Active, not recruiting||N/A|50|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||||||2018-06-01 03:07:11.49213|2018-06-01 03:07:11.49213
NCT00493948|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2009-11-09|2007-06-28|2007-06-29|Estimate|||||||2009-11-09|2009-11-11|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Evaluation of a Portable Device for Assessing Sleep Disordered Breathing in Congestive Heart Failure|Evaluation of a Portable Device for Assessing Sleep Disordered Breathing in Congestive Heart Failure|Completed|||35|Actual|ResMed|||||f||||f||||||||||2018-06-01 03:07:11.625418|2018-06-01 03:07:11.625418
NCT00493935|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2016-09-02|2007-06-28|2007-06-29|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2006||2006-03-31|September 2016|2016-09-30|August 2007|Actual|2007-08-31|||||Observational|||Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia|Nocturnal Hypoglycemia Prevention Study: Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia|Completed|||100|Anticipated|Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 03:07:11.711308|2018-06-01 03:07:11.711308
NCT00493922|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2017-01-11|2007-06-28|2007-06-29|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2007||2007-07-31|January 2017|2017-01-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|RDT||Trial of Rapid Diagnostic Tests in Rural Ghana|An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana|Completed||Phase 4|7263|Actual|London School of Hygiene and Tropical Medicine||3|||f||||f||||||||||2018-06-01 03:07:11.790777|2018-06-01 03:07:11.790777
NCT00493909|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-28|||2009-02-12|2007-06-28|2007-06-29|Estimate|||||||2009-02-12|2009-02-16|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Prospective, Randomised, Single-Blinded, Monocentric Clinical Study to Compare Postoperative Analgesia and Outcome After Combined Paravertebral and Intrathecal Versus Thoracic Epidural Analgesia for Thoracotomy|Prospective, Randomised, Single-Blinded, Monocentric Clinical Study to Compare Postoperative Analgesia and Outcome After Combined Paravertebral and Intrathecal Versus Thoracic Epidural Analgesia for Thoracotomy|Completed||Phase 4|200|Anticipated|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 03:07:11.896773|2018-06-01 03:07:11.896773
NCT00493896|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2014-01-13|2007-06-27|2007-06-28|Estimate|||||||2014-01-13|2014-01-14|Estimate|July 2007||2007-07-31|September 2012|2012-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients|Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients: An Investigator Initiated Protocol|Terminated||Phase 3|27|Actual|Eastern Virginia Medical School||2||low enrollment|f||||t||||||||||2018-06-01 03:07:11.983569|2018-06-01 03:07:11.983569
NCT00493883|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2015-05-12|2007-06-27|2007-06-28|Estimate|||||||2015-05-12|2015-05-13|Estimate|December 2006||2006-12-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors|Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors|Completed||Phase 1/Phase 2|81|Actual|Southwestern Regional Medical Center||1|||f||||f||||||||||2018-06-01 03:07:12.072951|2018-06-01 03:07:12.072951
NCT00493870|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2016-09-15|2007-06-27|2007-06-28|Estimate|||||||2016-09-15|2016-09-19|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2015|Actual|2015-05-31||Interventional|||TAC Versus TC for Adjuvant Breast Cancer|Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients|Active, not recruiting||Phase 3|1296|Actual|US Oncology Research||2|||f||||f||||||||||2018-06-01 03:07:12.195177|2018-06-01 03:07:12.195177
NCT00493857|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2008-11-14|2007-06-27|2007-06-28|Estimate|||||||2008-11-14|2008-11-17|Estimate|June 2007||2007-06-30|November 2008|2008-11-30|December 2008|Anticipated|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer|A Phase II Open-Label, 2-Cohort Study of Nimotuzumab 400 mg Weekly Plus Irinotecan (Cohort 1) and Nimotuzumab 400 mg Every 2 Weeks Plus Irinotecan (Cohort 2) in Patients With Irinotecan-Refractory Metastatic Colorectal Cancer|Terminated||Phase 2|100|Anticipated|YM BioSciences||1||Cohort 2 not going forward. Manadate changes in Company|f||||t||||||||||2018-06-01 03:07:12.422706|2018-06-01 03:07:12.422706
NCT00493662|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2008-01-11|2007-06-27|2007-06-28|Estimate|||||||2008-01-11|2008-01-15|Estimate||||January 2008|2008-01-31||||||||Interventional|||Cross-Over Evaluation of Two Lubricating Eye Drops||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:07:15.065656|2018-06-01 03:07:15.065656
NCT00493844|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2016-10-24|2007-06-26|2007-06-28|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||N-terminal Pro B-type Natriuretic Peptide (Nt-proBNP) Versus Exercise Test for Evaluation of Acute Chest Pain|Clinical History and NT-proBNP Versus Exercise Testing for Evaluation of Patients With Acute Chest Pain Without Ischemic Changes in the Electrocardiogram or Troponin Elevation|Completed||N/A|320|Actual|University of Valencia||2|||f||||f||||||||No||2018-06-01 03:07:12.505041|2018-06-01 03:07:12.505041
NCT00493831|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2007-06-27|2007-06-27|2007-06-28|Estimate|||||||2007-06-27|2007-06-28|Estimate|May 2006||2006-05-31|June 2007|2007-06-30|July 2007|Anticipated|2007-07-31|||||Interventional|||Analysis of Lipid Biomarkers of Exposure and Host Response||Unknown status|Active, not recruiting|N/A|20|Actual|University of Nebraska|||||f||||f||||||||||2018-06-01 03:07:12.593502|2018-06-01 03:07:12.593502
NCT00493818|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2017-01-16|2007-06-27|2007-06-28|Estimate|||||||2017-01-16|2017-01-18|Estimate|April 2007||2007-04-30|January 2017|2017-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693|An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 Given on Various Schedules in Subjects With Solid Tumors or Lymphoma|Terminated||Phase 1|70|Anticipated|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:07:12.644223|2018-06-01 03:07:12.644223
NCT00493805|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2010-10-27||2017-03-09|2007-06-26|2007-06-28|Estimate|2011-01-12|2011-02-09|Estimate||||2017-03-09|2017-04-07|Actual|April 2007||2007-04-30|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)|Study to Evaluate Response Rates in Chronic Hepatitis C (CHC) Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders|Terminated||Phase 4|59|Actual|Merck Sharp & Dohme Corp.||2||Slow Enrollment|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:07:12.759283|2018-06-01 03:07:12.759283
NCT00493792|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2017-09-17|2007-06-26|2007-06-28|Estimate|||||||2017-09-17|2017-09-19|Actual|February 2007||2007-02-28|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||X-3 Polyethylene Survival Outcomes Study|A Prospective, Randomized Study Comparing the Survival for X-3 Polyethylene to N2Vac Polyethylene When Used With the Triathlon Posterior Stabilized (PS) Total Knee System.|Active, not recruiting||Phase 4|516|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 03:07:13.087319|2018-06-01 03:07:13.087319
NCT00493779|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2009-06-05||2010-08-03|2007-06-27|2007-06-28|Estimate|2009-08-10|2009-08-11|Estimate||||2010-08-03|2010-08-10|Estimate|October 2007||2007-10-31|June 2010|2010-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|DECADES||A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients|An Exploratory, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA)|Completed||Phase 4|103|Actual|Bristol-Myers Squibb|The open-label and exploratory nature of this small study and the absence of control group inherently limit the interpretability of the results.|1|||f||||||||||||||2018-06-01 03:07:13.196672|2018-06-01 03:07:13.196672
NCT00493766|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2012-11-26|2007-06-26|2007-06-28|Estimate|||||||2012-11-26|2012-11-27|Estimate|May 2006||2006-05-31|November 2012|2012-11-30||||July 2008|Actual|2008-07-31||Interventional|||Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone|A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC)|Terminated||Phase 1|16|Actual|Novartis||2||Because of a strategic decision by Novartis|f||||||||||||||2018-06-01 03:07:13.429629|2018-06-01 03:07:13.429629
NCT00493753|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2007-06-26|2007-06-26|2007-06-28|Estimate|||||||2007-06-26|2007-06-28|Estimate|November 2004||2004-11-30|June 2007|2007-06-30|April 2006|Actual|2006-04-30|||||Interventional|||Feasibility and Safety of Acupuncture for Systemic Lupus|Feasibility and Safety of Acupuncture for Systemic Lupus Erythematosus|Completed||N/A|24|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:07:13.495104|2018-06-01 03:07:13.495104
NCT00493740|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2007-07-05|2007-06-27|2007-06-28|Estimate|||||||2007-07-05|2007-07-06|Estimate|July 2007||2007-07-31|June 2007|2007-06-30|December 2007|Anticipated|2007-12-31|||||Interventional|Cephalic chemo||Cephalic Phase of Oncology Patients Before and After Chemotherapy as Compared to Healthy Controls|Cephalic Phase of Oncology Patients Before and After Chemotherapy as Compared to Healthy Controls|Unknown status|Recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 03:07:13.546596|2018-06-01 03:07:13.546596
NCT00493727|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2008-05-16|2007-06-27|2007-06-28|Estimate|||||||2008-05-16|2008-05-19|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria|Use of Mucomyst (NAC) to Ameliorate Oxidant Stress in Diabetic Patients as Measurable by Surrogate Serum Markers|Completed||N/A|15|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 03:07:13.636065|2018-06-01 03:07:13.636065
NCT00493714|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2012-07-27|2007-06-27|2007-06-28|Estimate|||||||2012-07-27|2012-07-30|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Delirium Recall in Advanced Cancer Patients|The Impact of Acute Delirium On the Level of Distress In Patients With Advanced Cancer and Their Caregivers|Completed|||200|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-06-01 03:07:13.725532|2018-06-01 03:07:13.725532
NCT00493701|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2016-01-22|2007-06-26|2007-06-28|Estimate|||||||2016-01-22|2016-01-25|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||"ADAPT The Adaptation to High Fat Diets Extention"|ADAPT-The Adaptation to High Fat Diets|Active, not recruiting||N/A|65|Anticipated|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-06-01 03:07:13.836085|2018-06-01 03:07:13.836085
NCT00493688|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2018-01-05|2007-06-27|2007-06-28|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2005|Actual|2005-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes|A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes|Active, not recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:07:13.91342|2018-06-01 03:07:13.91342
NCT00493649|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2016-01-12||2016-09-15|2007-06-27|2007-06-28|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|June 2007||2007-06-30|September 2016|2016-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||ITT population|Adj TC + Herceptin Early Stage Breast Cancer|Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients|Completed||Phase 2|493|Actual|US Oncology Research||1|||f||||f||||||||||2018-06-01 03:07:15.153671|2018-06-01 03:07:15.153671
NCT00493636|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2014-04-17||2014-05-15|2007-06-27|2007-06-28|Estimate|2014-04-17|2014-05-16|Estimate||||2014-05-15|2014-05-20|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|November 2012|Actual|2012-11-30|September 2010|Actual|2010-09-30||Interventional||All randomized patients are included (i.e., the intent-to-treat population)|1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy|A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy|Completed||Phase 2|160|Actual|Accelerated Community Oncology Research Network||2|||f||||t||||||||||2018-06-01 03:07:16.361525|2018-06-01 03:07:16.361525
NCT00493623|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2016-03-01|2007-06-27|2007-06-28|Estimate|||||||2016-03-01|2016-03-02|Estimate|June 2007||2007-06-30|March 2016|2016-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.|A Randomized, Double-blind Study of the Efficacy of Intravenous Bonviva in the Relief of Pain After Recent Vertebral Osteoporotic Fracture in Osteoporotic Patients.|Completed||Phase 3|68|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:07:16.840119|2018-06-01 03:07:16.840119
NCT00493610|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2010-01-07|2007-06-27|2007-06-28|Estimate|||||||2010-01-07|2010-01-08|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Mucomyst for Hepatitis C|Use of Mucomyst (NAC) to Ameliorate Oxidant Stress as Measured by Surrogate Serum in Patients With Hepatitis C|Suspended||N/A|5|Anticipated|VA Office of Research and Development||1||Collaborator no longer interested, short of funds|f||||f||||||||||2018-06-01 03:07:17.06241|2018-06-01 03:07:17.06241
NCT00493597|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2009-01-30|2007-06-27|2007-06-28|Estimate|||||||2009-01-30|2009-02-02|Estimate|October 2007||2007-10-31|October 2007|2007-10-31||||||||Observational|||Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of in-Stent Restenosis|Blood Endothelium Progenitor Cells and Dendritic Cells as Novel Predictive Biomarkers of in-Stent Restenosis After Percutaneous Coronary Intervention.|Unknown status|Recruiting||250|Anticipated|University Hospital, Antwerp|||||f||||f||||||||||2018-06-01 03:07:17.147716|2018-06-01 03:07:17.147716
NCT00493584|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2009-05-19|2007-06-27|2007-06-28|Estimate|||||||2009-05-19|2009-05-20|Estimate|March 2008||2008-03-31|May 2009|2009-05-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|DaNSTEMI2||Acute Balloon Angioplasty vs. Traditional Early Invasive Treatment of Non-ST-Elevation Myocardial Infarction|Acute Angioplasty (Primary PCI) Versus Traditional Early Invasive Treatment of Patients Presenting With NSTEMI (The Second Danish Non-ST-Elevation MI Trial - DaNSTEMI-2)|Terminated||N/A|14|Actual|University of Aarhus||2||Due to insufficient patient inclusion the study has been stopped prematurely.|f||||t||||||||||2018-06-01 03:07:17.234067|2018-06-01 03:07:17.234067
NCT00493571|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2015-05-11|2007-06-27|2007-06-28|Estimate|||||||2015-05-11|2015-05-13|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes|Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes|Completed||Phase 1|16|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:07:17.335648|2018-06-01 03:07:17.335648
NCT00493558|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2013-02-18|2007-06-27|2007-06-28|Estimate|||||||2013-02-18|2013-02-20|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SpineRSA||Spine Research With Roentgen Stereophotogrammetric Analysis|A Consecutive Case Series of One-Level Lumbar Fusions With Pedicle Screw Instrumentation and the Trabecular Metal™ Intervertebral Cage Using Roentgen Stereophotogrammetric Analysis (RSA)|Completed||Phase 4|17|Actual|Nova Scotia Health Authority|||||f||||f||||||||||2018-06-01 03:07:17.417334|2018-06-01 03:07:17.417334
NCT00493545|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2008-05-05|2007-06-26|2007-06-28|Estimate|||||||2008-05-05|2008-05-07|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia|A Multicenter, Nonrandomized, Open-Label Phase 1 Safety Study of HspE7 and Poly-ICLC Administered Concomitantly in Cervical Intraepithelial Neoplasia (CIN) Subjects|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|Nventa Biopharmaceuticals Corporation|||||f||||f||||||||||2018-06-01 03:07:17.497178|2018-06-01 03:07:17.497178
NCT00493532|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2016-11-01|2007-06-27|2007-06-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Expanded Access|||A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.|An Open Label Study to Evaluate the Effect on Bone Mineral Density, and the Safety, of Quarterly Intravenous Bonviva in Patients With Post-menopausal Osteoporosis.|No longer available|||||Hoffmann-La Roche|||||f||||||||||||||2018-06-01 03:07:17.582654|2018-06-01 03:07:17.582654
NCT00493519|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2007-07-04|2007-06-27|2007-06-28|Estimate|||||||2007-07-04|2007-07-06|Estimate|July 2007||2007-07-31|April 2007|2007-04-30|December 2007|Anticipated|2007-12-31|||||Interventional|Cephalic 1||Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters|Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters|Unknown status|Recruiting|N/A|75|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 03:07:17.668192|2018-06-01 03:07:17.668192
NCT00493506|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2007-06-27|2007-06-27|2007-06-28|Estimate|||||||2007-06-27|2007-06-28|Estimate|May 2006||2006-05-31|June 2007|2007-06-30|September 2006|Actual|2006-09-30|||||Interventional|||ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency|The Effects of ProAlgaZyme Novel Algae Infusion Alone or in Combination With HAART on Markers of Immune Status, Dyslipidemia, Inflammation and Oxidative Stress in HIV or HIV/HBV Patients|Completed||N/A|59|Actual|Health Enhancement Products, Inc.|||||f||||f||||||||||2018-06-01 03:07:17.760798|2018-06-01 03:07:17.760798
NCT00493493|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2007-06-27|2007-06-27|2007-06-28|Estimate|||||||2007-06-27|2007-06-28|Estimate|January 2007||2007-01-31|June 2007|2007-06-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Pore Excision, Curettage, and Injection of Cymetra for Pilonidal Disease|Pore Excision, Curettage, and Injection of a Tissue Scaffold as Treatment for Pilonidal Disease|Unknown status|Recruiting|N/A|50|Anticipated|Matino, James, M.D.|||||f||||f||||||||||2018-06-01 03:07:17.844514|2018-06-01 03:07:17.844514
NCT00493480|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2009-08-07|2007-06-27|2007-06-28|Estimate|||||||2009-08-07|2009-08-10|Estimate|September 2003||2003-09-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|DACAPO||Danish Carvedilol Study in Portal Hypertension|Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices|Completed||Phase 3|40|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||||2018-06-01 03:07:17.908013|2018-06-01 03:07:17.908013
NCT00493454|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2012-09-28||2013-05-30|2007-06-27|2007-06-28|Estimate|2013-05-30|2013-05-31|Estimate||||2013-05-30|2013-05-31|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas|Multicenter Phase II Study for Zevalin® in Patients With Relapsed/Refractory Indolent Lymphomas: Extranodal Marginal Lymphoma of MALT Type, Nodal Marginal Zone B-Cell Lymphoma, and Splenic Marginal B-Cell Lymphoma|Terminated||Phase 2|6|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 03:07:18.179393|2018-06-01 03:07:18.179393
NCT00493441|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2014-08-05|2007-06-26|2007-06-28|Estimate|||||||2014-08-05|2014-08-07|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer|A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer|Terminated||Phase 2|28|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||t||||||||||2018-06-01 03:07:18.358633|2018-06-01 03:07:18.358633
NCT00493428|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2014-05-15|2007-06-27|2007-06-28|Estimate|||||||2014-05-15|2014-05-16|Estimate|July 2007||2007-07-31|May 2014|2014-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study|Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study|Withdrawn||Phase 2|0|Actual|University of Manitoba||||The study have been stoped because the protocol is going to be modify.|f||||f||||||||||2018-06-01 03:07:18.4505|2018-06-01 03:07:18.4505
NCT00493415|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2008-07-15|2007-06-27|2007-06-28|Estimate|||||||2008-07-15|2008-07-16|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|NISMIS||The Effect of Nitroglycerine on Microcirculatory Abnormalities During Sepsis|The Evaluation of the Effect of Nitroglycerine Versus Placebo on the Microcirculation by Means of SDF Imaging in Septic Patients on the ICU|Completed||Phase 3|70|Actual|Medical Centre Leeuwarden||2|||f||||f||||||||||2018-06-01 03:07:18.537494|2018-06-01 03:07:18.537494
NCT00493402|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2012-12-12|2007-06-27|2007-06-28|Estimate|||||||2012-12-12|2012-12-17|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|TACEforHCC||Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma|The Efficacy, Safety, and Patient Reported Outcomes of Different Regimens of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma|Completed||Phase 3|365|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-06-01 03:07:18.638109|2018-06-01 03:07:18.638109
NCT00493389|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2008-08-01|2007-06-26|2007-06-28|Estimate|||||||2008-08-01|2008-08-06|Estimate|July 2007||2007-07-31|July 2008|2008-07-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|CRAAS||Cortisol Response to Adrenocorticotrophin (ACTH) in Acute Stress|Improving The Assessment of Hypothalamic Pituitary Adrenal Function In Acute Stress|Unknown status|Recruiting|N/A|80|Anticipated|University of Ottawa|||||f||||t||||||||||2018-06-01 03:07:18.740528|2018-06-01 03:07:18.740528
NCT00493376|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2012-02-01|2007-06-26|2007-06-28|Estimate|||||||2012-02-01|2012-02-02|Estimate|August 2007||2007-08-31|February 2012|2012-02-29||||||||Observational|||Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer|Prospective Study of Tirapazamine Targeting in Cervical Cancer|Terminated|||1|Actual|British Columbia Cancer Agency||||"This study was a companion study to another one. The other study closed early so this one did~   as well."|f||||f||||||||||2018-06-01 03:07:18.835572|2018-06-01 03:07:18.835572
NCT00493363|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2018-05-01|2007-06-27|2007-06-28|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2007||2007-06-30|May 2018|2018-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia|Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia|Completed||N/A|40|Actual|University of Oxford||2|||f||||t||||||||Undecided||2018-06-01 03:07:18.904871|2018-06-01 03:07:18.904871
NCT00493350|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2012-07-27|2007-06-26|2007-06-28|Estimate|||||||2012-07-27|2012-07-31|Estimate|October 2005||2005-10-31|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer|International Stage IV Stratification Study (ISSS): Prospective Validation Trial of Circulating Tumor Cells (CTCs) as Prognostic and Predictive Markers in Women With Metastatic Breast Cancer About to Start First-Line Treatment|Completed|||660|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood collected prior to the initiation of chemotherapy as follows: 1 x 4 ml (serum tube),~     2x10 ml (CellSave Tube), and 1x10 ml EDTA (selected centers); To perform global gene~     profiling on selected specimens and correlate the profiles with clinical outcomes.~   "|||2018-06-01 03:07:19.001271|2018-06-01 03:07:19.001271
NCT00493337|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2010-06-24|2007-06-27|2007-06-28|Estimate|||||||2010-06-24|2010-06-28|Estimate|May 2008||2008-05-31|June 2007|2007-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment|A Community Pharmacist-led Intervention to Improve Adherence to Lipid-lowering Treatment|Completed||N/A|373|Actual|Utrecht Institute for Pharmaceutical Sciences||3|||f||||f||||||||||2018-06-01 03:07:19.087508|2018-06-01 03:07:19.087508
NCT00493324|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2012-02-01|2007-06-27|2007-06-28|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis|An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept|Completed||Phase 4|43|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 03:07:19.20628|2018-06-01 03:07:19.20628
NCT00493311|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2009-09-25|2009-04-03|2016-10-18|2007-06-27|2007-06-28|Estimate|2010-08-26|2010-09-21|Estimate|2010-08-26|2010-09-21|Estimate|2016-10-18|2016-10-19|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Efficacy and Safety of Intravenous Acetaminophen Versus Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males|Completed||Phase 3|60|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 03:07:19.342878|2018-06-01 03:07:19.342878
NCT00493298|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2018-05-28|2007-06-27|2007-06-28|Estimate|||||||2018-05-28|2018-05-30|Actual|June 29, 2007|Actual|2007-06-29|May 2018|2018-05-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|TOP||Tysabri Observational Program|TOP: Tysabri® Observational Program|Recruiting|||6000|Anticipated|Biogen|||1||f||||t||||||||||2018-06-01 03:07:19.789777|2018-06-01 03:07:19.789777
NCT00493285|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2012-03-12||2012-07-13|2007-06-27|2007-06-28|Estimate|2012-03-12|2012-04-09|Estimate||||2012-07-13|2012-07-19|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|CP149||Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age|Completed||Phase 1|49|Actual|MedImmune LLC||3|||f||||t||||||||||2018-06-01 03:07:20.586424|2018-06-01 03:07:20.586424
NCT00493272|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2015-11-30|2007-06-27|2007-06-28|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2007||2007-06-30|November 2015|2015-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Dilutional Coagulopathy in Patients Undergoing Elective Surgery|Fibrinogen vs Placebo for Improvement of Clot Strength|Completed||Phase 1/Phase 2|20|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 03:07:22.567854|2018-06-01 03:07:22.567854
NCT00493259|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2008-01-21|2007-06-27|2007-06-28|Estimate|||||||2008-01-21|2008-01-23|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Observational|||Health Related QOL, Depression and Lifestyle Changes in Insulin Resistant Adolescents|Health-Related Quality of Life, Depression and the Impact on Successful Incorporation of Lifestyle Changes in Insulin Resistant Adolescents as Evidenced by Changes in BMI, Waist Circumference and Metabolic Parameters|Unknown status|Recruiting||100|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 03:07:22.656222|2018-06-01 03:07:22.656222
NCT00493246|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|2009-09-25||2016-09-08|2007-06-27|2007-06-28|Estimate|2010-11-30|2010-12-29|Estimate||||2016-09-08|2016-10-21|Estimate|June 2007||2007-06-30|September 2016|2016-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients|A Prospective, Multi-Center, Randomized, Open-Label, Single and Repeated Dose, 48 Hour Study, of Intravenous Acetaminophen in Pediatric Inpatients to Determine Pharmacokinetics (PK) and Safety in Acute Pain and Fever|Completed||Phase 1|75|Actual|Mallinckrodt|"Median ranges were not calculated or not assessable for neonates at the following due to limited samples.:~12.5 mg/kg q6h- t1/2 (h)~15 mg/kg q8h -Cmax, Tmax, AUC0-t and t1/2."|2|||f||||f||||||||||2018-06-01 03:07:22.784638|2018-06-01 03:07:22.784638
NCT00493233|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2009-05-18|2007-06-27|2007-06-28|Estimate|||||||2009-05-18|2009-05-19|Estimate|November 2006||2006-11-30|May 2009|2009-05-31||||December 2008|Actual|2008-12-31||Interventional|||Antipsychotic Polypharmacy in Schizophrenia|Antipsychotic Polypharmacy in Schizophrenia|Completed||N/A|100|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 03:07:23.816125|2018-06-01 03:07:23.816125
NCT00493220|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2011-09-12||2011-10-24|2007-06-27|2007-06-28|Estimate|2011-10-24|2011-12-02|Estimate||||2011-10-24|2011-12-02|Estimate|June 2007||2007-06-30|October 2011|2011-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|INFUSE-Cftrx||Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration|INcreased Flow Utilizing Subcutaneously-Enabled Ceftriaxone (INFUSE-Ceftriaxone) Study: A Phase I Study Comparing the Safety and Pharmacokinetics of Ceftriaxone Administered Subcutaneously With and Without Human Recombinant Hyaluronidase (HYLENEX Recombinant) and Intravenously in Human Volunteers|Completed||Phase 1|30|Actual|Baxter Healthcare Corporation||6|||f||||f||||||||||2018-06-01 03:07:23.938588|2018-06-01 03:07:23.938588
NCT00493194|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2008-11-25|2007-06-27|2007-06-28|Estimate|||||||2008-11-25|2008-11-26|Estimate|May 2005||2005-05-31|October 2005|2005-10-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Fibrosis in Renal Allografts|Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic)|Unknown status|Recruiting|Phase 4|100|Anticipated|University Hospital, Antwerp|||||f||||||||||||||2018-06-01 03:07:24.635812|2018-06-01 03:07:24.635812
NCT00493181|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2011-04-01||2012-02-17|2007-06-27|2007-06-28|Estimate|2011-04-01|2011-05-04|Estimate||||2012-02-17|2012-02-20|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients|The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia|Completed||Phase 2|8|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:07:24.73607|2018-06-01 03:07:24.73607
NCT00493168|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2013-05-24|2007-06-26|2007-06-28|Estimate|||||||2013-05-24|2013-05-27|Estimate|January 1998||1998-01-31|June 2007|2007-06-30|November 2006|Actual|2006-11-30|||||Observational|||Determination of the Prevalence and Prognostic Importance of Unrecognized Non-Q-wave Myocardial Infarction by MRI|Unrecognized Non-Q-wave Myocardial Infarction: Prevalence, Angiographic Correlation, and Prognostic Significance in Patients With Suspected Coronary Disease|Completed|||185|Actual|Duke University|||||f||||||||||||||2018-06-01 03:07:24.85664|2018-06-01 03:07:24.85664
NCT00493155|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-27|||2016-11-01|2007-06-27|2007-06-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2005||2005-10-31|November 2016|2016-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.|"An Open-label, Multiple Ascending Dose Study to Determine the Maximum Tolerated Dose of R1530 in Patients With Advanced Solid Tumors."|Completed||Phase 1|48|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:07:24.927191|2018-06-01 03:07:24.927191
NCT00493142|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2016-09-14|2007-06-26|2007-06-28|Estimate|||||||2016-09-14|2016-09-16|Estimate|July 2008||2008-07-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|July 2013|Actual|2013-07-31||Interventional|PREP||Pre-operative Rehabilitation Exercise Program for Total Knee Arthroplasty|Impact of a Pre-operative Rehabilitation Exercise Program for Patients With Severe Dysfunction Awaiting Total Knee Arthroplasty|Active, not recruiting||N/A|240|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 03:07:24.986528|2018-06-01 03:07:24.986528
NCT00493129|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2012-02-07|2007-06-26|2007-06-28|Estimate|||||||2012-02-07|2012-02-08|Estimate|July 2004||2004-07-31|February 2012|2012-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)|ONTAK (Denileukin Diftitox) in Patients With Systemic Mastocytosis|Completed||Phase 2|8|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:07:25.044836|2018-06-01 03:07:25.044836
NCT00493116|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2013-09-12|2007-06-25|2007-06-27|Estimate|||||||2013-09-12|2013-09-16|Estimate|October 2003||2003-10-31|July 2011|2011-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|RENeu||Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta|A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability|Completed||Phase 4|20|Actual|Biogen||1|||f||||f||||||||||2018-06-01 03:07:25.123604|2018-06-01 03:07:25.123604
NCT00493103|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-06-25|2007-06-25|2007-06-27|Estimate|||||||2007-06-25|2007-06-27|Estimate|July 2003||2003-07-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Observational|||TG Gene Mutations and Congenital Hypothyroidism|Congenital Hypothyroidism Due to Thyroglobulin Mutations in an Inbred Brazilian Family: A Novel Compound Heterozygous Constellation and Intronic Mutation Related to Fetal Goiter.|Completed|||||University of Sao Paulo|||||f||||f||||||||||2018-06-01 03:07:25.210147|2018-06-01 03:07:25.210147
NCT00493090|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2016-01-20|2007-06-26|2007-06-27|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2005||2005-10-31|November 2015|2015-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluating the Impact of GP and Practice Nurse Training in Self Regulations Skills on Patient Outcomes|Effects of Patient-centred Asthma Education for GPs and Practice Nurses:Evaluating the Impact of Training in Self Regulation Skills on Patient Outcomes:a Randomised Controlled Trial|Completed||N/A|360|Actual|University of Aberdeen|||||f||||t||||||||||2018-06-01 03:07:25.289455|2018-06-01 03:07:25.289455
NCT00493077|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2008-01-28|2007-06-25|2007-06-27|Estimate|||||||2008-01-28|2008-01-30|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|SAFE||Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy|A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy|Completed||Phase 4|3|Actual|Biogen||1|||f||||t||||||||||2018-06-01 03:07:25.419585|2018-06-01 03:07:25.419585
NCT00493064|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2017-04-06|2007-06-25|2007-06-27|Estimate|||||||2017-04-06|2017-04-10|Actual|October 2006||2006-10-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions|Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO|Completed||Phase 2/Phase 3|63|Actual|Palo Alto Medical Foundation||1|||f||||f||||||||||2018-06-01 03:07:25.502579|2018-06-01 03:07:25.502579
NCT00493051|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2010-02-08|2007-06-25|2007-06-27|Estimate|||||||2010-02-08|2010-02-10|Estimate|November 2007||2007-11-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MATRIX||Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities|A Randomized, Double-Blind, Placebo-Controlled, Single- and Double-Dose, Comparator Arm (Standard of Care), Multicenter Phase 2b Study of Topical GAM501 (Ad5PDGF-B/Bovine Type I Collagen Gel) in the Treatment of Non-Healing Diabetic Ulcers of the Lower Extremities|Completed||Phase 2|124|Actual|Tissue Repair Company||5|||f||||t||||||||||2018-06-01 03:07:25.594666|2018-06-01 03:07:25.594666
NCT00493038|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2009-01-20||2014-11-03|2007-06-26|2007-06-27|Estimate|2009-03-09|2009-04-13|Estimate||||2014-11-03|2014-11-07|Estimate|February 2006||2006-02-28|November 2014|2014-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis|Prospective, Multicenter, Randomized, Double Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg OD for 7 Days Versus a Standard Antibiotic Therapy for 10 Days in the Treatment of Acute Bacterial Rhino Sinusitis|Terminated||Phase 4|293|Actual|Bayer|The study was prematurely terminated due to slow enrollment beyond the planned study timelines.|2||The study was prematurely terminated due to slow enrollment beyond the planned study timelines.|f||||f||||||||||2018-06-01 03:07:25.741664|2018-06-01 03:07:25.741664
NCT00493025|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2011-08-15|2007-06-25|2007-06-27|Estimate|||||||2011-08-15|2011-08-16|Estimate|April 2005||2005-04-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery|Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel (Taxol®, Bristol-Myers Squibb), Cisplatin (Platinol®, Abbott Laboratories), ZD1839 (IRESSA®) and Radiotherapy Followed by Postoperative ZD1839|Terminated||Phase 2|36|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||Completed as planned|f||||||||||||||2018-06-01 03:07:26.105688|2018-06-01 03:07:26.105688
NCT00493012|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2011-03-29||2017-03-16|2007-06-26|2007-06-27|Estimate|2012-02-07|2012-03-08|Estimate||||2017-03-16|2017-04-13|Actual|January 2006||2006-01-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|SMART||Vitamin D Effects in Overweight Patients|Effects of a Vitamin D (Cholecalciferol) Supplement on Body Composition, Blood Pressure, and Lipid and Diabetes Parameters in Overweight Patients Attending a Telemedically Guided Weight Loss Program|Completed||N/A|200|Actual|Heart and Diabetes Center North-Rhine Westfalia||2|||f||||f||||||||No||2018-06-01 03:07:26.293787|2018-06-01 03:07:26.293787
NCT00492999|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2018-02-02|2007-06-25|2007-06-27|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2007|Actual|2007-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver|A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic Chemotherapy|Active, not recruiting||Phase 2|64|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 03:07:26.646483|2018-06-01 03:07:26.646483
NCT00492986|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2014-12-26|2007-06-26|2007-06-27|Estimate|||||||2014-12-26|2014-12-30|Estimate|October 2005||2005-10-31|December 2014|2014-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma|An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 3|1150|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:07:26.914532|2018-06-01 03:07:26.914532
NCT00492973|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2012-10-18||2013-10-29|2007-06-25|2007-06-27|Estimate|2013-10-29|2013-12-19|Estimate||||2013-10-29|2013-12-19|Estimate|March 2006||2006-03-31|April 2013|2013-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?|Peri-articular Injections Containing a Corticosteroid During Total Knee Arthroplasty|Completed||N/A|101|Actual|New Lexington Clinic|One patient died 25 days after the surgery as a result of complications associated with deep knee joint sepsis.|2|||f||||f||||||||||2018-06-01 03:07:27.050858|2018-06-01 03:07:27.050858
NCT00492453|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2010-01-13|2007-06-26|2007-06-27|Estimate|||||||2010-01-13|2010-01-14|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|SALC||Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy|A Controlled Randomized Trial Comparing Spinal Versus General Anesthesia for Elective Laparoscopic Cholecystectomy in Fit Patients|Unknown status|Recruiting|N/A|300|Anticipated|University of Thessaly||2|||f||||t||||||||||2018-06-01 03:07:38.606804|2018-06-01 03:07:38.606804
NCT00492960|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25||2010-08-30|2017-09-15|2007-06-25|2007-06-27|Estimate||||2017-09-15|2017-09-20|Actual|2017-09-15|2017-09-20|Actual|August 2007|Actual|2007-08-31|September 2017|2017-09-30|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|||Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease|A Phase IIb, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During a Gluten Challenge|Completed||Phase 2|171|Actual|Innovate Biopharmaceuticals||4|||f||||f|t|f||||||No||2018-06-01 03:07:27.355357|2018-06-01 03:07:27.355357
NCT00492947|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2013-01-10|2007-06-26|2007-06-27|Estimate|||||||2013-01-10|2013-01-11|Estimate|June 2007||2007-06-30|May 2010|2010-05-31|June 2012|Anticipated|2012-06-30|June 2010|Anticipated|2010-06-30||Interventional|Dendritic||Dendritic Cell Vaccine for Head and Neck Cancer|0608 GCC:Phase I Study of Intra-tumoral Injection of Dendritic Cells for the Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Withdrawn||Phase 1|0|Actual|University of Maryland||||major amendments in progress|f||||t||||||||||2018-06-01 03:07:27.538235|2018-06-01 03:07:27.538235
NCT00492934|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2014-09-09|2007-06-26|2007-06-27|Estimate|||||||2014-09-09|2014-09-10|Estimate|January 2004||2004-01-31|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||What is the Best Preparation for Embryo Transfer in Cryo Cycles: a Natural Cycle or Light Hormonal Stimulation?|Natural Cycle Versus Stimulation With Human Menopausal Gonadotropin in Cycles With Cryopreserved Embryos|Unknown status|Active, not recruiting|N/A|300|Anticipated|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-06-01 03:07:27.635489|2018-06-01 03:07:27.635489
NCT00492921|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2013-06-03|2007-06-25|2007-06-27|Estimate|||||||2013-06-03|2013-06-05|Estimate|May 2007||2007-05-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||High-Dose Cyclophosphamide in Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond to Steroid Therapy||Completed||Phase 2|12|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:07:27.724265|2018-06-01 03:07:27.724265
NCT00492908|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2014-04-30|2007-06-25|2007-06-27|Estimate|||||||2014-04-30|2014-05-01|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|August 2013|Actual|2013-08-31|March 2009|Actual|2009-03-31||Interventional|||Randomized Trial Comparing Titan Stent With Zotarolimus-Eluting Stent|Randomized Clinical Trial Comparing A Titanium-Nitride-Oxide Coated Stent With A Zotarolimus-Eluting Stent in Patients With Coronary Artery Disease|Completed||Phase 4|303|Actual|University of Bern||2|||f||||f||||||||||2018-06-01 03:07:27.824672|2018-06-01 03:07:27.824672
NCT00492895|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2013-01-28|2007-06-26|2007-06-27|Estimate|||||||2013-01-28|2013-01-29|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients|Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients|Completed||Phase 4|25|Actual|University of Zurich||1|||f||||f||||||||||2018-06-01 03:07:27.910077|2018-06-01 03:07:27.910077
NCT00492882|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2007-06-26|2007-06-26|2007-06-27|Estimate|||||||2007-06-26|2007-06-27|Estimate|November 2003||2003-11-30|September 2003|2003-09-30|January 2007|Actual|2007-01-31|||||Observational|SOPK||Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome|Dynamic Changes in the Serum Anti-Müllerian Hormone Level During Low-Dose recFSH Administration Further Support Its Role in the Anovulation of Polycystic Ovary Syndrome|Completed|||30|Actual|University Hospital, Lille|||||f||||f||||||||||2018-06-01 03:07:27.973335|2018-06-01 03:07:27.973335
NCT00492869|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2016-09-22|2007-06-26|2007-06-27|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2007||2007-01-31|September 2016|2016-09-30||||May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation|A 12-month Open-label, Randomized, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients|Completed||Phase 1/Phase 2|124|Actual|Novartis|||||f||||||||||||||2018-06-01 03:07:28.05804|2018-06-01 03:07:28.05804
NCT00492856|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2014-04-22||2016-04-14|2007-06-25|2007-06-27|Estimate|2014-06-18|2014-07-18|Estimate||||2016-04-14|2016-05-17|Estimate|June 2007||2007-06-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|December 2013|Actual|2013-12-31||Interventional|||S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia|S0521, A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III|Completed||Phase 3|105|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 03:07:28.268137|2018-06-01 03:07:28.268137
NCT00492843|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2016-02-14|2007-06-26|2007-06-27|Estimate|||||||2016-02-14|2016-02-17|Estimate|July 2007||2007-07-31|February 2016|2016-02-29|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis|A Randomized Study to Evaluate the Safety and Efficacy of Loading Dose of Bondronat Versus Standard Dose of Bondronat in Patients With Lung Cancer and Skeletal Metastasis Experiencing Moderate to Severe Pain|Terminated||Phase 4|20|Actual|Chinese Society of Lung Cancer||2||It is too difficult to recruit suitable patients.|f||||t||||||||||2018-06-01 03:07:29.937779|2018-06-01 03:07:29.937779
NCT00492830|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2010-02-03|2007-06-26|2007-06-27|Estimate|||||||2010-02-03|2010-02-05|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase 1, Open-label, Dose Escalation Study of the Humanized Monoclonal Antibody, TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|19|Actual|Tracon Pharmaceuticals Inc.|||||f||||f||||||||||2018-06-01 03:07:30.048167|2018-06-01 03:07:30.048167
NCT00492817|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2018-02-13|2007-06-26|2007-06-27|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2005|Actual|2005-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of Single Session Stereotactic Body Radiotherapy|Phase I/II Evaluation of Single Session Stereotactic Body Radiotherapy for Spinal or Paraspinal Metastases|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:07:30.124895|2018-06-01 03:07:30.124895
NCT00492804|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2013-01-25|2007-06-26|2007-06-27|Estimate|||||||2013-01-25|2013-01-28|Estimate|July 2005||2005-07-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Elective Neurectomy During Inguinal Hernia Repair|Effect of Elective Intraoperative Neurectomy on Chronic Pain After Lichtenstein Hernia Repair. A Prospective, Single-blind, Randomized, Controlled Clinical Trial|Completed||Phase 2|200|Actual|Cantonal Hospital of St. Gallen||2|||f||||f||||||||||2018-06-01 03:07:30.204732|2018-06-01 03:07:30.204732
NCT00492791|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2012-04-16|2007-06-26|2007-06-27|Estimate|||||||2012-04-16|2012-04-17|Estimate|March 2007||2007-03-31|August 2011|2011-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|CAPSCDEIS||Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy|Development and Validation of an Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy|Completed|||158|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|||1||f||||f||||||||||2018-06-01 03:07:30.29491|2018-06-01 03:07:30.29491
NCT00492778|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2018-02-14|2007-06-25|2007-06-27|Estimate|||||||2018-02-14|2018-02-16|Estimate|February 25, 2008|Actual|2008-02-25|February 2018|2018-02-28||||July 1, 2022|Anticipated|2022-07-01||Interventional|||Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer|A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus|Recruiting||Phase 2|164|Anticipated|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 03:07:30.517616|2018-06-01 03:07:30.517616
NCT00492765|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2010-10-14|2007-06-25|2007-06-27|Estimate|||||||2010-10-14|2010-10-15|Estimate|February 2006||2006-02-28|October 2010|2010-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|SIMCOMBIN||Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis|A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis|Completed||Phase 4|380|Actual|Biogen||2|||f||||t||||||||||2018-06-01 03:07:32.036229|2018-06-01 03:07:32.036229
NCT00492752|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2010-12-08||2014-03-26|2007-06-26|2007-06-27|Estimate|2010-12-08|2011-01-13|Estimate||||2014-03-26|2014-04-16|Estimate|October 2005||2005-10-31|March 2014|2014-03-31|July 2009|Actual|2009-07-31|March 2007|Actual|2007-03-31||Interventional|||A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Randomized, Double-blinded, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 3|226|Actual|Bayer|On review of unblinded data, up to 19 Mar. 2007, the independent Data Monitoring Committee concluded the efficacy results can be considered positive, recommended subjects under placebo to cross over to Sorafenib; study continued to extension phase.|2|||f||||t||||||||||2018-06-01 03:07:32.186202|2018-06-01 03:07:32.186202
NCT00492739|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2016-12-29|2007-06-26|2007-06-27|Estimate|||||||2016-12-29|2016-12-30|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|VZVinOLTx||Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients|Induction and Maintenance of Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients: a Retrospective and Prospective Nationwide Study in Switzerland|Recruiting||Phase 2/Phase 3|80|Anticipated|University Hospital, Geneva||1|||f||||t||||||||Undecided||2018-06-01 03:07:33.159849|2018-06-01 03:07:33.159849
NCT00492726|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2010-02-11||2014-11-03|2007-06-26|2007-06-27|Estimate|2010-02-11|2010-03-03|Estimate||||2014-11-03|2014-11-07|Estimate|July 2006||2006-07-31|November 2014|2014-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem|A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Complicated Intra-abdominal Infections (PROMISE Study)|Completed||Phase 3|804|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:07:33.266582|2018-06-01 03:07:33.266582
NCT00492713|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2013-03-27|2007-06-26|2007-06-27|Estimate|||||||2013-03-27|2013-03-29|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|April 2012|Actual|2012-04-30|September 2008|Actual|2008-09-30||Interventional|||Polyphenol Bioavailability From Chocolate|Comparison of the Bioavailability of Polyphenols From Milk and Dark Chocolate|Completed||N/A|18|Actual|Nestlé||3|||f||||f||||||||||2018-06-01 03:07:34.296843|2018-06-01 03:07:34.296843
NCT00492700|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2007-06-26|2007-06-26|2007-06-27|Estimate|||||||2007-06-26|2007-06-27|Estimate|January 2003||2003-01-31|June 2007|2007-06-30||||||||Interventional|FLIRT||A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis|A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis|Completed||Phase 2|63|Actual|Association pour la Recherche sur les Maladies Hépatiques Virales|||||f||||f||||||||||2018-06-01 03:07:34.375654|2018-06-01 03:07:34.375654
NCT00492687|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2014-01-09|2007-06-25|2007-06-27|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2006||2006-12-31|July 2009|2009-07-31||||July 2009|Anticipated|2009-07-31||Interventional|||Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas|A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas|Unknown status|Recruiting|Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:07:34.447634|2018-06-01 03:07:34.447634
NCT00492674|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2007-06-26|2007-06-26|2007-06-27|Estimate|||||||2007-06-26|2007-06-27|Estimate||||April 2007|2007-04-30||||||||Interventional|||The Effect of Perioperative Neuromuscular Training on the Outcome of Total Knee Arthroplasty|The Effect of Perioperative Neuromuscular Training on the Outcome of Total Knee Arthroplasty: A Double Blind Randomized Prospective Study|Unknown status|Not yet recruiting|N/A|||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:07:34.517984|2018-06-01 03:07:34.517984
NCT00492661|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2013-05-24|2007-06-25|2007-06-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|July 2007||2007-07-31|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PRIDE||A Pilot Trial to Evaluate the Effect of Diet and Exercise in Renal Transplant Recipients on Tacrolimus|A Pilot Trial of the Effect of Dietary and Exercise Intervention on Insulin Resistance and Metabolic Parameters in De Novo Renal Transplant Recipients on Prograf (Tacrolimus)|Completed||Phase 4|55|Actual|Janssen-Cilag Pty Ltd||1|||f||||f||||||||||2018-06-01 03:07:34.581256|2018-06-01 03:07:34.581256
NCT00492648|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2016-04-04|2007-06-26|2007-06-27|Estimate|||||||2016-04-04|2016-04-05|Estimate|June 2007||2007-06-30|June 2012|2012-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Month 30 & 42 Extension Studies of CRD-004 Primary Study|An Extension Study to Evaluate the Persistence of the Immune Responses Induced by GSK Biologicals Zoster Vaccine, GSK324332A, Administered in Healthy Adult Subjects Aged 18-30 Years and 50-70 Years|Completed||Phase 2|34|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:07:34.683841|2018-06-01 03:07:34.683841
NCT00492466|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2008-01-28|2007-06-26|2007-06-27|Estimate|||||||2008-01-28|2008-01-30|Estimate|March 2003||2003-03-31|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|RECOVER||Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies|A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies|Completed||Phase 4|14|Actual|Biogen||1|||f||||t||||||||||2018-06-01 03:07:38.422317|2018-06-01 03:07:38.422317
NCT00492635|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2014-10-27|2007-06-26|2007-06-27|Estimate|||||||2014-10-27|2014-10-28|Estimate|December 2004||2004-12-31|October 2014|2014-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED|A Randomized, Double-blind, Double-dummy, Multicenter Parallel Group Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil Versus Vardenafil PRN Versus Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving Erectile Function|Completed||Phase 3|628|Actual|Bayer||3|||f||||||||||||||2018-06-01 03:07:34.79815|2018-06-01 03:07:34.79815
NCT00492622|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2017-04-06||2017-06-29|2007-06-26|2007-06-27|Estimate|2017-06-29|2017-07-28|Actual||||2017-06-29|2017-07-28|Actual|June 2007||2007-06-30|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis|Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis|Completed||Phase 4|12|Actual|University of Louisville||2|||f||||f||||||||||2018-06-01 03:07:34.980974|2018-06-01 03:07:34.980974
NCT00492609|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2009-11-10|2007-06-26|2007-06-27|Estimate|||||||2009-11-10|2009-11-11|Estimate|May 2006||2006-05-31|November 2009|2009-11-30|April 2008|Actual|2008-04-30|||||Observational|||Medical and Economical Evaluation of Computer-assisted Reconstruction of the Anterior Cruciate Ligament (ACL)|Medical and Economical Evaluation of Computer-assisted Reconstruction of the ACL|Completed|||285|Actual|University Hospital, Grenoble|||2||f||||t||||||||||2018-06-01 03:07:35.174682|2018-06-01 03:07:35.174682
NCT00492596|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25||2014-08-07|2014-08-07|2007-06-25|2007-06-27|Estimate||||2014-08-07|2014-08-11|Estimate|2014-08-07|2014-08-11|Estimate|June 2006||2006-06-30|August 2014|2014-08-31|June 2011|Actual|2011-06-30|April 2011|Actual|2011-04-30||Interventional|||The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence|An Evaluation of the AttenueX IntraVesical System in the Management of Female Subjects With Stress Urinary Incontinence|Completed||Phase 3|166|Actual|Solace Therapeutics, Inc.||2|||f||||f||||||||||2018-06-01 03:07:35.240736|2018-06-01 03:07:35.240736
NCT00492583|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2011-06-21||2011-07-21|2007-06-25|2007-06-27|Estimate|2011-07-21|2011-08-17|Estimate||||2011-07-21|2011-08-17|Estimate|July 2007||2007-07-31|June 2011|2011-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|SIPPY||Study to Investigate the Potential of Probiotics in Yogurt|Study to Investigate the Potential of Probiotics in Yogurt|Completed||Phase 3|182|Actual|Georgetown University||2|||f||||t||||||||||2018-06-01 03:07:35.525089|2018-06-01 03:07:35.525089
NCT00492570|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2009-06-15|2007-06-25|2007-06-27|Estimate|||||||2009-06-15|2009-06-16|Estimate|April 2006||2006-04-30|June 2009|2009-06-30|December 2008|Actual|2008-12-31|October 2007|Actual|2007-10-31||Observational|FIT||GER-009-06-AVX Early Therapy in Multiple Sclerosis|GER-009-06-AVX Early Therapy in Multiple Sclerosis|Completed|||230|Actual|Biogen|||||f||||f||||||||||2018-06-01 03:07:35.740439|2018-06-01 03:07:35.740439
NCT00492557|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2012-01-17|2009-01-21|2012-01-17|2007-06-26|2007-06-27|Estimate|2012-01-17|2012-02-17|Estimate|2009-09-24|2009-09-28|Estimate|2012-01-17|2012-02-17|Estimate|September 2007||2007-09-30|January 2012|2012-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults|A Phase 3, Randomized, Double-blind Trial to Evaluate Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine in Healthy Adults 65 Years of Age or Older, Who Are Naive to 23-Valent Pneumococcal Polysaccharide Vaccine|Completed||Phase 3|1185|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:07:35.846174|2018-06-01 03:07:35.846174
NCT00492544|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2009-11-12|2009-08-20|2017-01-16|2007-06-26|2007-06-27|Estimate|2009-11-12|2009-12-21|Estimate|2009-08-20|2009-08-21|Estimate|2017-01-16|2017-02-28|Actual|July 2007||2007-07-31|January 2017|2017-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age|Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 When Administered as a 3-dose Schedule in Healthy Japanese Pre-adolescent and Adolescent Female Subjects.|Completed||Phase 3|100|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:07:37.030182|2018-06-01 03:07:37.030182
NCT00492531|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2011-04-28||2015-12-07|2007-06-26|2007-06-27|Estimate|2011-06-03|2011-06-06|Estimate||||2015-12-07|2016-01-06|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease|Treatment of Pulmonary Hypertension and Sickle Cell Disease With Sildenafil Therapy|Terminated||Phase 2|74|Actual|National Heart, Lung, and Blood Institute (NHLBI)|As a result of early termination due to safety findings, the study was underpowered to assess the effects of sildenafil therapy on the predetermined efficacy endpoints.|2||Subjects on drug were more likely to have severe pain crises requiring hospitalization.|f||||t||||||||||2018-06-01 03:07:37.465582|2018-06-01 03:07:37.465582
NCT00492518|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2007-06-26|2007-06-26|2007-06-27|Estimate|||||||2007-06-26|2007-06-27|Estimate|February 2002||2002-02-28|June 2007|2007-06-30|October 2004|Actual|2004-10-31|||||Interventional|ATHENS||Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy|Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy: A Placebo Controlled Randomized Study|Completed||Phase 4|254|Actual|Technische Universität München|||||f||||t||||||||||2018-06-01 03:07:37.906247|2018-06-01 03:07:37.906247
NCT00492505|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2014-01-09|2007-06-25|2007-06-27|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2007||2007-04-30|July 2009|2009-07-31||||December 2011|Anticipated|2011-12-31||Interventional|||Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma|A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma|Unknown status|Recruiting|Phase 2|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:07:38.013912|2018-06-01 03:07:38.013912
NCT00492492|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2016-09-06|2007-06-26|2007-06-27|Estimate|||||||2016-09-06|2016-09-07|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|fradius||Treatement of Extension Fractures of the Distal Radius|Treatement of Extension Fractures of the Distal Radius : Prospective Randomized Postoperative Comparison Between Trans-styloid and Intrafical Pinning on the One Side and Volar Fixed-angle Plating on the Other Side.|Completed||N/A|110|Actual|University Hospital, Limoges||2|||f||||t||||||||||2018-06-01 03:07:38.134821|2018-06-01 03:07:38.134821
NCT00492479|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-12-18|2007-06-26|2007-06-27|Estimate|||||||2007-12-18|2007-12-24|Estimate|June 2007||2007-06-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||An Evaluation of Kinerase Pro+Therapy Regimen Vs. Kinerase Vs. Control for the Treatment of Skin Aging||Terminated||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:07:38.264627|2018-06-01 03:07:38.264627
NCT00492440|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2012-10-17|2007-06-25|2007-06-27|Estimate|||||||2012-10-17|2012-10-18|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer|"A Phase I Study of Subcutaneous CYT 107 (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma"|Terminated||Phase 1|9|Actual|Cytheris SA||1|||f||||f||||||||||2018-06-01 03:07:38.728788|2018-06-01 03:07:38.728788
NCT00492427|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2009-01-06|2007-06-26|2007-06-27|Estimate|||||||2009-01-06|2009-01-08|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|||Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)|Correction and Maintenance Study of Subcutaneous Injections of R744 to Predialysis Patients ( Phase III, Comparative Study in Comparison With Epoetin Beta)|Completed||Phase 3|187|Actual|Chugai Pharmaceutical||2|||f||||t||||||||||2018-06-01 03:07:38.873311|2018-06-01 03:07:38.873311
NCT00492414|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2007-08-07|2007-06-26|2007-06-27|Estimate|||||||2007-08-07|2007-08-08|Estimate||||March 2007|2007-03-31||||||||Interventional|||Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release||Unknown status|Recruiting|Phase 4|||Inje University|||||f||||||||||||||2018-06-01 03:07:38.951739|2018-06-01 03:07:38.951739
NCT00492401|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2015-10-22||2016-05-18|2007-06-25|2007-06-27|Estimate|2016-05-18|2016-06-27|Estimate||||2016-05-18|2016-06-27|Estimate|May 2007||2007-05-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|December 2010|Actual|2010-12-31||Interventional|||Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia|Phase II Study of Decitabine in Acute Myeloid Leukemia|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)|After completing the target accrual of 33 subjects, the study was expanded to include 22 additional patients. All patients who received decitabine are included in the analyses, except for two who had not completed therapy at the time of the analysis.|1|||f||||||||||||||2018-06-01 03:07:39.038422|2018-06-01 03:07:39.038422
NCT00492388|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2012-01-10|2007-06-26|2007-06-27|Estimate|||||||2012-01-10|2012-01-11|Estimate|June 2007||2007-06-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Comparing the Efficacy and Safety of PMI-150 (Intranasal Ketamine) to Placebo as an Analgesic for the Treatment of Breakthrough Pain in Cancer Patients|Terminated||Phase 3|2|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2||Business decision not to continue development|f||||f||||||||||2018-06-01 03:07:39.360748|2018-06-01 03:07:39.360748
NCT00492362|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2008-06-02|2007-06-26|2007-06-27|Estimate|||||||2008-06-02|2008-06-04|Estimate|July 2007||2007-07-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Trial of Aerobic Exercise in Patients Undergoing Outpatient Hemodialysis|A Randomized Controlled Trial of Aerobic Exercise in Patients With End Stage Renal Disease During Outpatient Hemodialysis|Completed||N/A|60|Actual|University of Manitoba||2|||f||||t||||||||||2018-06-01 03:07:39.430357|2018-06-01 03:07:39.430357
NCT00492349|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2017-04-13||2017-12-09|2007-06-26|2007-06-27|Estimate|2017-12-08|2017-12-11|Actual||||2017-12-09|2018-01-04|Actual|May 2007||2007-05-31|December 2017|2017-12-31|April 2011|Actual|2011-04-30|May 2010|Actual|2010-05-31||Interventional|||Varenicline Adjunctive Treatment in Schizophrenia|Varenicline Adjunctive Treatment in Schizophrenia|Completed||Phase 4|91|Actual|University of Maryland|The small number of nonsmokers in the placebo arm could have led to reduced power and false negatives.|2|||f||||t||||||||No||2018-06-01 03:07:39.951655|2018-06-01 03:07:39.951655
NCT00492336|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2013-02-01||2018-03-20|2007-06-26|2007-06-27|Estimate|2013-06-17|2013-06-19|Estimate||||2018-03-20|2018-04-20|Actual|January 2007||2007-01-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia|Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia|Completed||Phase 4|84|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 03:07:40.516294|2018-06-01 03:07:40.516294
NCT00492323|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25||2013-01-15|2018-04-27|2007-06-25|2007-06-27|Estimate||||2013-01-15|2013-01-24|Estimate|2018-04-27|2018-05-01|Actual|March 2007||2007-03-31|April 2018|2018-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group With a Crossover Confirmation Period Study of RWJ-333369 for the Treatment of Postherpetic Neuralgia.|Completed||Phase 2|91|Actual|SK Life Science||2|||f||||||||||||||2018-06-01 03:07:41.042347|2018-06-01 03:07:41.042347
NCT00492310|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2010-07-19|2007-06-25|2007-06-27|Estimate|||||||2010-07-19|2010-07-20|Estimate|August 2007||2007-08-31|July 2010|2010-07-31|March 2011|Anticipated|2011-03-31|February 2010|Actual|2010-02-28||Interventional|||Yoga for Women Attempting Smoking Cessation|Yoga for Women Attempting Smoking Cessation: an Initial Investigation|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|The Miriam Hospital||2|||f||||f||||||||||2018-06-01 03:07:41.144483|2018-06-01 03:07:41.144483
NCT00492297|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2009-10-28||2014-10-23|2007-06-26|2007-06-27|Estimate|2010-12-21|2011-01-25|Estimate||||2014-10-23|2014-10-31|Estimate|April 2005||2005-04-30|October 2014|2014-10-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma|A Phase II, Multi-center, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of BAY 43-9006 Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma.|Completed||Phase 2|83|Actual|Bayer|Due to the small number of patients, no conclusions can be drawn from these data in terms of BRAF mutations.|1|||f||||f||||||||||2018-06-01 03:07:41.279638|2018-06-01 03:07:41.279638
NCT00492284|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2010-04-13||2011-05-31|2007-06-26|2007-06-27|Estimate|2010-05-20|2010-06-22|Estimate||||2011-05-31|2011-06-02|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|RADICAL||Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)|A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne®-Lucentis® Combination Therapies and Lucentis® Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD.|Completed||Phase 2|162|Actual|QLT Inc.|Retreatment and vision analysis limitations, sample size, lack of standard monotherapy regimen used in practice, no treatment regimen approved by regulatory authorities, potential for bias in FA assessment, no central reading center, single-masked|4|||f||||t||||||||||2018-06-01 03:07:42.621862|2018-06-01 03:07:42.621862
NCT00492271|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2008-07-22|2007-06-25|2007-06-27|Estimate|||||||2008-07-22|2008-07-23|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||First Time in Man Trial for Friulimicin B|A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single (Part A) and Multiple (Part B) Intravenous Doses of Friulimicin B in Healthy Subjects|Terminated||Phase 1|31|Actual|MerLion Pharmaceuticals GmbH||1||Unfavourable Pharmakokinetics|f||||f||||||||||2018-06-01 03:07:43.913464|2018-06-01 03:07:43.913464
NCT00492258|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2013-08-09|2007-06-25|2007-06-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer|SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse|Completed||Phase 3|1656|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:07:43.993123|2018-06-01 03:07:43.993123
NCT00492245|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2008-08-01|2007-06-26|2007-06-27|Estimate|||||||2008-08-01|2008-08-04|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|December 2008|Anticipated|2008-12-31|May 2008||2008-05-31||Interventional|||Phototherapeutic Keratectomy (PTK) With Mitomycin in Adenoviral Opacities|Phototherapeutic Keratectomy With Mitomycin C in Adenoviral Infiltrates|Unknown status|Active, not recruiting|N/A|30|Anticipated|Federal University of São Paulo|||||f||||f||||||||||2018-06-01 03:07:44.115942|2018-06-01 03:07:44.115942
NCT00492232|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2009-05-28||2010-07-13|2007-06-25|2007-06-27|Estimate|2009-05-28|2009-07-17|Estimate||||2010-07-13|2010-07-20|Estimate|April 2007||2007-04-30|July 2010|2010-07-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Facilitation of Zolpidem (≥10 mg) Discontinuation Through Use of Ramelteon in Subjects With Chronic Insomnia|Randomized, Double Blind, Placebo-Controlled Study to Assess Whether the Administration of Ramelteon Could Facilitate the Discontinuation of Zolpidem (Ambien®) ≥10 mg Therapy in Subjects With Chronic Insomnia|Completed||Phase 4|135|Actual|Takeda||2|||f||||f||||||||||2018-06-01 03:07:44.23652|2018-06-01 03:07:44.23652
NCT00492219|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2012-10-18|2007-06-26|2007-06-27|Estimate|||||||2012-10-18|2012-10-19|Estimate|October 2006||2006-10-31|June 2007|2007-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Postoperative Function Following Partial and Total Knee Replacement|Postoperative Function Following Partial and Total Knee Replacement|Terminated||N/A|324|Anticipated|New Lexington Clinic||4||No longer have access to equipment used for functional data collection|f||||f||||||||||2018-06-01 03:07:44.980332|2018-06-01 03:07:44.980332
NCT00492206|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2016-01-14||2016-12-07|2007-06-26|2007-06-27|Estimate|2016-12-07|2017-02-01|Estimate||||2016-12-07|2017-02-01|Estimate|June 2006||2006-06-30|December 2016|2016-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Number of patients with surgically unresectable stage IIIA or IIIB NSCLC accrued|Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC|A Phase II Study of Cetuximab in Combination With External Beam Radiation Followed By Consolidation Chemotherapy for Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|40|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:07:45.0896|2018-06-01 03:07:45.0896
NCT00492193|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2014-12-12|2007-06-25|2007-06-27|Estimate|||||||2014-12-12|2014-12-15|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Early Post-Op Recovery After Partial Large Bowel Resection|A Prospective, Observational, Multi-center Study Assessing Early Post-Operative Recovery Following Laparoscopic Partial Large Bowel Resection|Completed|||139|Actual|University Hospitals Cleveland Medical Center|||||f||||f||||||||||2018-06-01 03:07:45.404209|2018-06-01 03:07:45.404209
NCT00492167|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2018-02-23|2007-06-25|2007-06-27|Estimate|||||||2018-02-23|2018-02-27|Actual|August 2005||2005-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma|Phase I Study of Oral Yeast β-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma|Active, not recruiting||Phase 1|45|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:07:45.478956|2018-06-01 03:07:45.478956
NCT00492154|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2009-07-20|2007-06-26|2007-06-27|Estimate|||||||2009-07-20|2009-07-21|Estimate|September 2008||2008-09-30|June 2009|2009-06-30||||||||Observational|||Fracture of Distal Radius and Ulna Healed With Shortening of One Bone. Clinical Significance at Skeletal Maturity|Fracture of Distal Radius and Ulna Healed With Shortening of One Bone. Clinical Significance at Skeletal Maturity|Terminated|||20|Anticipated|Hadassah Medical Organization||||the study stopped because we could not recruit enough patients.|f||||f||||||||||2018-06-01 03:07:45.57198|2018-06-01 03:07:45.57198
NCT00492141|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2012-08-01|2007-06-26|2007-06-27|Estimate|||||||2012-08-01|2012-08-02|Estimate|June 2006||2006-06-30|August 2012|2012-08-31|September 2009|Actual|2009-09-30|May 2007|Actual|2007-05-31||Interventional|||Aerosol L9-NC and Temozolomide in Ewing's Sarcoma|Aerosol Liposomal 9-Nitro-20(S)-Camptothecin (L9-NC) and Temozolomide in Ewing's Sarcoma and Other Solid Tumors With Lung Involvement|Completed||Phase 1/Phase 2|10|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:07:45.649126|2018-06-01 03:07:45.649126
NCT00492128|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2015-01-28|2007-06-26|2007-06-27|Estimate|||||||2015-01-28|2015-01-30|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|August 2010|Actual|2010-08-31|May 2009|Actual|2009-05-31||Interventional|||Kanagawa Combination Anti-hypertensive Therapy (K-CAT)|Comparative Trial of Combination Therapy of ARB/Diuretic Versus ARB/CCB in Uncontrolled Hypertensive Patients With Monotherapy of ARB|Completed||Phase 4|196|Actual|Yokohama City University Medical Center||2|||f||||f||||||||||2018-06-01 03:07:45.754606|2018-06-01 03:07:45.754606
NCT00492115|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2013-06-17|2007-06-26|2007-06-27|Estimate|||||||2013-06-17|2013-06-18|Estimate|July 2007||2007-07-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TAP||Cognitive Benefits of Treating Sleep Apnea in Parkinson's Disease|Cognitive Benefits of Treating Sleep Apnea in Dementia|Completed||N/A|96|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 03:07:45.834948|2018-06-01 03:07:45.834948
NCT00492102|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2012-08-01|2007-06-26|2007-06-27|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Montelukast in Very Low Birthweight Infants|Pharmacokinetics of Montelukast in Very Low Birthweight (VLBW) Preterm Infants|Completed||Phase 1|9|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 03:07:45.939674|2018-06-01 03:07:45.939674
NCT00492089|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2012-06-15||2014-04-21|2007-06-25|2007-06-27|Estimate|2013-04-09|2013-06-14|Estimate||||2014-04-21|2014-05-09|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer|A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage|Completed||Phase 2|11|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:07:46.076245|2018-06-01 03:07:46.076245
NCT00492076|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2008-10-15|2007-06-26|2007-06-27|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2006||2006-10-31|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma|A Randomised, Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract, Quantified in Mass Units, in Subjects With Perennial Mite Induced Asthma|Completed||Phase 4|45|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-06-01 03:07:46.373957|2018-06-01 03:07:46.373957
NCT00492063|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2012-12-11||2015-12-03|2007-06-26|2007-06-27|Estimate|2013-01-18|2013-02-21|Estimate||||2015-12-03|2016-01-01|Estimate|September 2004||2004-09-30|December 2015|2015-12-31|May 2005|Actual|2005-05-31|December 2004|Actual|2004-12-31||Interventional|||Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly|A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture and of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects|Completed||Phase 3|2654|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:07:46.472201|2018-06-01 03:07:46.472201
NCT00492050|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2018-05-17|2007-06-26|2007-06-27|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2006|Actual|2006-08-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia|Primary Treatment of Waldenstrom's Macroglobulinemia With Bortezomib (Velcade) and Rituximab (Rituxan) Followed by Autologous Stem Cell Collection|Active, not recruiting||Phase 2|38|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:07:47.227872|2018-06-01 03:07:47.227872
NCT00492037|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2014-04-30|2007-06-25|2007-06-27|Estimate|||||||2014-04-30|2014-05-02|Estimate|January 2000||2000-01-31|April 2014|2014-04-30|February 2002|Actual|2002-02-28|||||Interventional|||Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia|A 5-Day, Double-Blind, Placebo-Controlled Multicenter Study of Oral YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia|Completed||Phase 3|83|Actual|Cumberland Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:07:47.334629|2018-06-01 03:07:47.334629
NCT00492024|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|2009-03-19||2013-10-31|2007-06-26|2007-06-27|Estimate|2009-10-28|2009-12-02|Estimate||||2013-10-31|2013-11-26|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||BAY12-8039: 5 Days for Sinusitis vs Placebo|Prospective, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Moxifloxacin 400 mg QD for 5 Days Versus Placebo in the Treatment of Acute Bacterial Sinusitis|Completed||Phase 3|374|Actual|Bayer|Confounding factors include concomitant medication for symptomatic relief not standardised, TOC visit occured earlier than for other sinusitis studies, response on placebo underestimated and short-term relief provided by the sinus tap.|2|||f||||f||||||||||2018-06-01 03:07:47.480225|2018-06-01 03:07:47.480225
NCT00492011|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2012-02-27|2007-06-26|2007-06-27|Estimate|||||||2012-02-27|2012-02-28|Estimate|February 2007||2007-02-28|February 2012|2012-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia Symptoms Associated With Eastward Bound Jet Lag Across 5 Time Zones in Healthy Adult Volunteers|Completed||Phase 4|110|Actual|Takeda||4|||f||||f||||||||||2018-06-01 03:07:48.008956|2018-06-01 03:07:48.008956
NCT00491998|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2011-07-21|2007-06-26|2007-06-27|Estimate|||||||2011-07-21|2011-07-25|Estimate|November 2006||2006-11-30|July 2011|2011-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets|Randomised, Double-blind, Double-dummy, Two-period, Cross-over Study to Determine the PK, PD and Safety of Multiple Doses of V1512 Effervescent Tablets in Parkinson's Disease Patients Compared to Sinemet® Oral Tablets|Completed||Phase 1/Phase 2|27|Anticipated|Vernalis (R&D) Ltd||3|||f||||f||||||||||2018-06-01 03:07:48.122727|2018-06-01 03:07:48.122727
NCT00491985|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-26|||2014-01-10|2007-06-26|2007-06-27|Estimate|||||||2014-01-10|2014-01-14|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children||Completed||Phase 2|240|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:07:48.255618|2018-06-01 03:07:48.255618
NCT00491959|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2010-05-03|2007-06-23|2007-06-26|Estimate|||||||2010-05-03|2010-05-04|Estimate|September 2007||2007-09-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||The Application of Oral Mucosal Epithelial Cell Sheets Cultivated on Amino Membrane in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon.|Phase 1 Study of Oral Mucosal Epithelial Cell Sheets in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon|Terminated||Phase 1|0|Actual|National Taiwan University Hospital||||Due to unstalbe cell sheet quality. We didn't use this tech on patients.|f||||t||||||||||2018-06-01 03:07:48.345051|2018-06-01 03:07:48.345051
NCT00491946|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-25|2007-06-25|2007-06-26|Estimate|||||||2007-06-25|2007-06-26|Estimate|June 2004||2004-06-30|June 2007|2007-06-30||||||||Interventional|||A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer|A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer|Unknown status|Recruiting|Phase 4|24|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:07:48.410322|2018-06-01 03:07:48.410322
NCT00491933|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-06-25|2007-06-25|2007-06-26|Estimate|||||||2007-06-25|2007-06-26|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|October 2007|Anticipated|2007-10-31|||||Interventional|TNFTB||Quantiferon-TB Gold in the Assessment of Latent TB in Patients Candidate to Treatment or Treated With TNFα Antagonists|Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in the Assessment of Latent Mycobacterium Tuberculosis Infection in Patients Candidate to Treatment or Treated With TNFα Antagonists|Unknown status|Recruiting|N/A|100|Anticipated|ASST Fatebenefratelli Sacco|||||f||||f||||||||||2018-06-01 03:07:48.470113|2018-06-01 03:07:48.470113
NCT00491920|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2011-11-02|2007-06-25|2007-06-26|Estimate|||||||2011-11-02|2011-11-03|Estimate|February 2007||2007-02-28|November 2011|2011-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||High Dosage Vitamin D and Osteoporosis|High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women|Completed||Phase 4|297|Actual|University Hospital of North Norway|||||f||||f||||||||||2018-06-01 03:07:48.544463|2018-06-01 03:07:48.544463
NCT00491907|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-10-01|2007-06-25|2007-06-26|Estimate|||||||2007-10-01|2007-10-02|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure|Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure|Terminated||Phase 4|||University of Zurich||||recruitment is finished|f||||f||||||||||2018-06-01 03:07:48.624747|2018-06-01 03:07:48.624747
NCT00491569|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-24|||2007-06-24|2007-06-24|2007-06-26|Estimate|||||||2007-06-24|2007-06-26|Estimate|January 2005||2005-01-31|June 2007|2007-06-30|December 2006|Actual|2006-12-31|||||Interventional|||Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia|NMDA Enhancers in the Treatment of Schizophrenia: Sarcosine vs. D-Serine|Completed||Phase 2|60|Actual|China Medical University Hospital|||||f||||f||||||||||2018-06-01 03:07:52.725942|2018-06-01 03:07:52.725942
NCT00491894|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2010-08-02||2012-06-05|2007-06-25|2007-06-26|Estimate|2012-06-05|2012-07-09|Estimate||||2012-06-05|2012-07-09|Estimate|March 2007||2007-03-31|April 2012|2012-04-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions|A Six-Month, Multi-Center, Open-Label Study to Assess the Safety and Efficacy of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions|Completed||Phase 3|137|Actual|Shionogi Inc.|There were no limitations of the trial|1|||f||||f||||||||||2018-06-01 03:07:48.697793|2018-06-01 03:07:48.697793
NCT00491881|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-08-02|2007-06-25|2007-06-26|Estimate|||||||2007-08-02|2007-08-03|Estimate|May 2005||2005-05-31|June 2007|2007-06-30|May 2006|Actual|2006-05-31|||||Interventional|||Effect of no Added Salt Diet on Urinary Sodium and Blood Pressure|"Effect of no Added Salt Diet  on Blood Pressure Control & 24 Hour Urinary Sodium Excretion in Mild to Moderate Hypertension"|Completed||N/A|2005|Actual|Shiraz University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:07:48.966853|2018-06-01 03:07:48.966853
NCT00491868|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2009-01-29|2007-06-25|2007-06-26|Estimate|||||||2009-01-29|2009-02-02|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Clinical Study of R744 to Hemodialysis Patients|Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase III, Double Blind Study in Comparison With Epoetin Beta).|Completed||Phase 3|134|Actual|Chugai Pharmaceutical||4|||f||||t||||||||||2018-06-01 03:07:49.021577|2018-06-01 03:07:49.021577
NCT00491855|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2012-12-31|2007-06-25|2007-06-26|Estimate|||||||2012-12-31|2013-01-03|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis|Phase I Trial of Intraperitoneal Oxaliplatin and Paclitaxel Plus Intravenous Paclitaxel and Bevacizumab in the Treatment of Advanced Peritoneal Carcinomatosis|Completed||Phase 1|3|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:07:49.103253|2018-06-01 03:07:49.103253
NCT00491842|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2018-04-04|2007-06-23|2007-06-26|Estimate|||||||2018-04-04|2018-04-05|Actual|June 22, 2007||2007-06-22|March 27, 2018|2018-03-27||||||||Observational|||Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD|Individuals' Patterns of Disclosure About Huntington's Disease and Association With Adaptation to HD|Completed|||315|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:07:49.173657|2018-06-01 03:07:49.173657
NCT00491829|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2014-04-02||2014-05-06|2007-06-25|2007-06-26|Estimate|2014-05-06|2014-06-02|Estimate||||2014-05-06|2014-06-02|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Flibanserin Versus Placebo in Premenopausal Women With HSDD|A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder|Completed||Phase 3|945|Actual|Sprout Pharmaceuticals, Inc||3|||f||||t||||||||||2018-06-01 03:07:49.245086|2018-06-01 03:07:49.245086
NCT00491816|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2017-01-18|2007-06-25|2007-06-26|Estimate|||||||2017-01-18|2017-01-19|Estimate|July 2007||2007-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Interventional|||Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer|Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer|Active, not recruiting||Phase 2|32|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 03:07:50.009427|2018-06-01 03:07:50.009427
NCT00491803|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2009-11-09|2007-06-22|2007-06-26|Estimate|||||||2009-11-09|2009-11-10|Estimate|June 2007||2007-06-30|November 2009|2009-11-30|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|SIL-COPD-01||Sildenafil Effects on Pulmonary Haemodynamics and Gas Exchange in Chronic Obstructive Pulmonary Disease (COPD)|Acute Effects of a Single Dose of Sildenafil (20mg/40mg) on Pulmonary Haemodynamics and Gas Exchange at Rest and During Exercise in COPD Patients With Pulmonary Hypertension|Completed||Phase 4|20|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 03:07:50.131253|2018-06-01 03:07:50.131253
NCT00491790|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2008-12-15|2007-06-22|2007-06-26|Estimate|||||||2008-12-15|2008-12-16|Estimate|December 2006||2006-12-31|November 2008|2008-11-30|October 2010|Anticipated|2010-10-31|January 2010|Anticipated|2010-01-31||Interventional|||Montelukast With Status Asthmaticus, Ages 2-5||Unknown status|Recruiting|Phase 2/Phase 3|52|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 03:07:50.201396|2018-06-01 03:07:50.201396
NCT00491777|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-22|2007-06-22|2007-06-26|Estimate|||||||2007-06-22|2007-06-26|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|NMT-CT||Correlation Research Study: IQ2, NcIQ and IQ101|Correlation Study of NMT's IQ2, NcIQ and Its' Predicate Technology, IQ101.|Completed||Phase 1|25|Actual|Noninvasive Medical Technologies, Inc.|||||||||t||||||||||2018-06-01 03:07:50.284977|2018-06-01 03:07:50.284977
NCT00491764|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2009-12-23||2017-03-09|2007-06-25|2007-06-26|Estimate|2009-12-23|2010-01-28|Estimate||||2017-03-09|2017-04-07|Actual|June 2007||2007-06-30|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)|An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail|Completed||Phase 2|218|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:07:50.377528|2018-06-01 03:07:50.377528
NCT00491751|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2012-05-23|2007-06-22|2007-06-26|Estimate|||||||2012-05-23|2012-05-25|Estimate|May 2004||2004-05-31|May 2012|2012-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Clinical Utility of Endothelial Dysfunction in PAD|Clinical Utility of Endothelial Dysfunction in PAD|Unknown status|Active, not recruiting|N/A|400|Anticipated|Boston University|||||f||||t||||||||||2018-06-01 03:07:51.020443|2018-06-01 03:07:51.020443
NCT00491556|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2016-03-18||2017-02-27|2007-06-22|2007-06-26|Estimate|2016-05-16|2016-06-24|Estimate||||2017-02-27|2017-03-29|Actual|October 2007||2007-10-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||75 subjects were randomized to the experimental arm, however 2 subjects withdrew from the study at the pre-entry visit. Therefore, only 73 experimental arm subjects were available for the baseline analyses.|Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)|Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r) in Adolescents With CD4 + T Cells > 350 Cells/mm3 Initiating HAART|Completed||N/A|102|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 03:07:52.850052|2018-06-01 03:07:52.850052
NCT00491738|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2009-02-06||2009-04-09|2007-06-25|2007-06-26|Estimate|2009-04-09|2009-04-10|Estimate||||2009-04-09|2009-04-10|Estimate|August 2007||2007-08-31|April 2009|2009-04-30||||January 2008|Actual|2008-01-31||Interventional|||A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)|A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer|Terminated||Phase 2|16|Actual|Genentech, Inc.|Based on the early safety results from this study, Genentech terminated further recruitment and discontinued treatment. Insufficient efficacy information was available to perform additional outcome analyses.|2||"Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly~   tolerated."|f||||||||||||||2018-06-01 03:07:51.115926|2018-06-01 03:07:51.115926
NCT00491725|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2016-03-02|2007-06-25|2007-06-26|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2005||2005-09-30|March 2016|2016-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs|A Multi-centre, Single Armed, Open Labelled Trial to Study the Efficacy and Safety Profile of Repaglinide & Metformin Combination Therapy in Chinese Type 2 Diabetics|Completed||Phase 4|187|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:07:51.420249|2018-06-01 03:07:51.420249
NCT00491712|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-06-25|2007-06-25|2007-06-26|Estimate|||||||2007-06-25|2007-06-26|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|June 2007|Anticipated|2007-06-30|||||Interventional|||Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection|Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection|Unknown status|Active, not recruiting|N/A|49|Actual|Federal University of São Paulo|||||f||||f||||||||||2018-06-01 03:07:51.48033|2018-06-01 03:07:51.48033
NCT00491699|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2010-02-18|2007-06-22|2007-06-26|Estimate|||||||2010-02-18|2010-02-19|Estimate|August 2007||2007-08-31|February 2010|2010-02-28|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer|A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)|Terminated||Phase 1|2|Actual|Symphony Evolution, Inc.||||The study was stopped due to safety concerns|f||||t||||||||||2018-06-01 03:07:51.540566|2018-06-01 03:07:51.540566
NCT00491686|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2011-01-20|2007-06-25|2007-06-26|Estimate|||||||2011-01-20|2011-01-21|Estimate|July 2007||2007-07-31|January 2011|2011-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||AZD6765 for Treatment Resistant Depression|A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients|Completed||Phase 2|34|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:07:51.723933|2018-06-01 03:07:51.723933
NCT00491673|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2010-09-23|2007-06-25|2007-06-26|Estimate|||||||2010-09-23|2010-09-24|Estimate|September 2004||2004-09-30|September 2010|2010-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|HEMI04||A Prospective Randomized Trial of Uncemented Versus Cemented Hemiarthroplasty for Displaced Femoral Neck Fractures|A Prospective Randomized Trial of Uncemented Versus Cemented Hemiarthroplasty for Displaced Femoral Neck Fractures|Unknown status|Active, not recruiting|N/A|230|Actual|Ullevaal University Hospital||2|||f||||f||||||||||2018-06-01 03:07:51.788143|2018-06-01 03:07:51.788143
NCT00491660|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-06-25|2007-06-25|2007-06-26|Estimate|||||||2007-06-25|2007-06-26|Estimate|January 2005||2005-01-31|June 2007|2007-06-30|July 2006|Actual|2006-07-31|||||Interventional|||Effect of Gravity on Tracheal Colonization During Mechanical Ventilation in Infants||Completed||N/A|60|Actual|Cairo University|||||f||||||||||||||2018-06-01 03:07:51.879487|2018-06-01 03:07:51.879487
NCT00491647|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2012-11-12|2007-06-25|2007-06-26|Estimate|||||||2012-11-12|2012-11-14|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|June 2007|Actual|2007-06-30|||||Observational|||Time Perception Deficits and Attention-Deficit/Hyperactivity Disorder|Time Perception Deficits and Behaviors of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder|Completed|||258|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:07:51.941882|2018-06-01 03:07:51.941882
NCT00491634|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2015-11-30|2007-06-25|2007-06-26|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2007||2007-06-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Treosulfan-based Conditioning for Transplantation in AML/MDS|Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.|Completed||Phase 2|24|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 03:07:52.007828|2018-06-01 03:07:52.007828
NCT00491621|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2015-06-03|2007-06-25|2007-06-26|Estimate|||||||2015-06-03|2015-06-04|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CMM||Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer|Study Evaluating the Interest of Cytology-molecular Tumor Markers Association for the Diagnostic Strategy in Adult Kidney Tumors|Terminated||N/A|74|Actual|Centre Hospitalier Universitaire de Saint Etienne||1||No enough inclusion. The aim is no longer relevant. The sponsor decided to stop this study.|f||||f||||||||||2018-06-01 03:07:52.081298|2018-06-01 03:07:52.081298
NCT00491608|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2011-11-03||2012-01-11|2007-06-25|2007-06-26|Estimate|2011-12-08|2012-01-12|Estimate||||2012-01-11|2012-01-13|Estimate|June 2007||2007-06-30|January 2012|2012-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis|A Phase 3b, Open-Label, Single-Group Immunogenicity and Safety Study of Topical Recombinant Thrombin (rThrombin) in Surgical Hemostasis|Completed||Phase 3|234|Actual|ZymoGenetics||1|||f||||f||||||||||2018-06-01 03:07:52.187911|2018-06-01 03:07:52.187911
NCT00491595|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-25|2007-06-25|2007-06-26|Estimate|||||||2007-06-25|2007-06-26|Estimate|March 2004||2004-03-31|June 2007|2007-06-30|July 2005|Actual|2005-07-31|||||Interventional|||Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women|Phase I Multiple-Dose Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women|Completed||Phase 1|36|Actual|University of North Carolina, Chapel Hill|||||t||||t||||||||||2018-06-01 03:07:52.603048|2018-06-01 03:07:52.603048
NCT00491582|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2013-08-12|2007-06-25|2007-06-26|Estimate|||||||2013-08-12|2013-08-13|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|July 2009|Actual|2009-07-31||Interventional|||The Effects of Growth Hormone (GH) on Lipid Depots|The Effect of Growth Hormone (GH) on Intramyocellular Lipids (IMCL), Intrahepatocellular Lipids (IHCL) and Visceral Fat Mass in Relation to Insulin Resistance|Completed||N/A|34|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 03:07:52.657805|2018-06-01 03:07:52.657805
NCT00491543|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2008-07-01|2007-06-23|2007-06-26|Estimate|||||||2008-07-01|2008-07-02|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|May 2008|Actual|2008-05-31|||||Interventional|||Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ALT 2074 in Subjects With Type 2 Diabetes Who Have a Haptoglobin Type 2-2 Genotype and Coronary Artery Disease|Completed||Phase 2|66|Anticipated|Synvista Therapeutics, Inc|||||f||||f||||||||||2018-06-01 03:07:53.959653|2018-06-01 03:07:53.959653
NCT00491530|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2009-11-03||2012-01-18|2007-06-25|2007-06-26|Estimate|2009-11-03|2009-12-07|Estimate||||2012-01-18|2012-01-20|Estimate|June 2007||2007-06-30|January 2012|2012-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia|A Year 2, Long-Term, Open-Label, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia|Completed||Phase 3|310|Actual|Abbott|This was an open-label study designed to assess the long-term safety of the combination therapies. Evaluation of efficacy outcomes was a secondary objective.|3|||f||||f||||||||||2018-06-01 03:07:54.146727|2018-06-01 03:07:54.146727
NCT00491517|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2013-04-23|2007-06-25|2007-06-26|Estimate|||||||2013-04-23|2013-04-24|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|SIRENA||Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety|Sirolimus Treatment in Patients With ADPKD|Completed||Phase 2|22|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||t||||||||||2018-06-01 03:07:55.072347|2018-06-01 03:07:55.072347
NCT00491504|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2010-03-11||2015-02-24|2007-06-25|2007-06-26|Estimate|2010-03-11|2010-04-05|Estimate||||2015-02-24|2015-03-13|Estimate|February 2007||2007-02-28|February 2015|2015-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Using Subjective and Objective Measures to Evaluate the Clinical Efficacy of Mometasone Furoate Nasal Spray (MFNS) Following Initial and Maintenance Dosing in Subjects With Allergen-Induced Seasonal Allergic Rhinitis (SAR) in an Environmental Exposure Chamber (EEC)|Completed||Phase 4|310|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:07:55.19211|2018-06-01 03:07:55.19211
NCT00491491|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2015-12-01|2007-06-25|2007-06-26|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Zevalin-beam for Aggressive Lymphoma|SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma|Completed||Phase 3|60|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 03:07:55.588087|2018-06-01 03:07:55.588087
NCT00491478|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-22|2007-06-22|2007-06-26|Estimate|||||||2007-06-22|2007-06-26|Estimate|September 1992||1992-09-30|May 2003|2003-05-31||||||||Interventional|||Repetitive Behavior Disorders in People With Severe Mental Retardation|Stereotypies and Mental Retardation: Neurobiological Basis|Unknown status|Recruiting|Phase 3|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:07:55.689222|2018-06-01 03:07:55.689222
NCT00491465|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-06-25|2007-06-25|2007-06-26|Estimate|||||||2007-06-25|2007-06-26|Estimate|July 2007||2007-07-31|June 2007|2007-06-30|July 2009|Anticipated|2009-07-31|||||Interventional|4301||The Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.|Randomized,Controlled,Open,Cross-Over Intervention Study for Evaluating the Role of Physical Activity in the Treatment of Children With Type 1 Diabetes.|Unknown status|Not yet recruiting|N/A|2007|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:07:55.751466|2018-06-01 03:07:55.751466
NCT00491452|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2011-05-26|2007-06-25|2007-06-26|Estimate|||||||2011-05-26|2011-05-27|Estimate|April 2007||2007-04-30|May 2011|2011-05-31|July 2009|Actual|2009-07-31|||||Observational|IMR2||Repair of Ischemic Mitral Regurgitation: Comparison Between Flexible and Rigid Annuloplasty Rings||Completed|||||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:07:55.815727|2018-06-01 03:07:55.815727
NCT00491439|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2012-04-01|2007-06-23|2007-06-26|Estimate|||||||2012-04-01|2012-04-03|Estimate|April 2007||2007-04-30|November 2010|2010-11-30|September 2010|Actual|2010-09-30|||||Observational|||Using in Vivo Confocal Microscope to Evaluate the Corneal Wound Healing After Various Ocular Surgeries|Phase 1 Study of in Vivo Confocal Microscope to Evaluate the Corneal Wound Healing After Various Ocular Surgeries|Completed|||120|Actual|National Taiwan University Hospital|||3||f||||f||||||||||2018-06-01 03:07:55.872789|2018-06-01 03:07:55.872789
NCT00491426|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2012-11-16|2007-06-22|2007-06-26|Estimate|||||||2012-11-16|2012-11-19|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Observational|||Antimicrobial PK in Infants With Suspected or Confirmed Infection|Antimicrobial Pharmacokinetics in High Risk Infants (Urinary Proteomics in Antimicrobial/Antifungal-Treated Newborns - add-on Study)|Completed|||450|Actual|Duke University|||3||f||||t||||||||||2018-06-01 03:07:55.935012|2018-06-01 03:07:55.935012
NCT00491413|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-22|2007-06-22|2007-06-26|Estimate|||||||2007-06-22|2007-06-26|Estimate||||August 2003|2003-08-31||||||||Interventional|||Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth|High Dose Erythropoietin for Neonates With Asphyxia|Unknown status|Not yet recruiting|Phase 1|15|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:07:56.161274|2018-06-01 03:07:56.161274
NCT00491400|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2012-05-23||2012-09-24|2007-06-25|2007-06-26|Estimate|2012-09-24|2012-10-24|Estimate||||2012-09-24|2012-10-24|Estimate|September 2005||2005-09-30|September 2012|2012-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of a Fibrate and a Statin on Endothelial Dysfunction|Effect of a Fibrate (Fenofibrate) and a Statin (Atorvastatin) and on Endothelial Dysfunction in Diabetes Mellitus and the Metabolic Syndrome|Terminated||N/A|28|Actual|Boston University|Early termination due to inadequate enrollment|2||Insufficient enrollment|f||||f||||||||||2018-06-01 03:07:56.261489|2018-06-01 03:07:56.261489
NCT00491387|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2011-02-22||2018-02-02|2007-06-22|2007-06-26|Estimate|2011-03-17|2011-04-19|Estimate||||2018-02-02|2018-02-07|Actual|August 2007||2007-08-31|February 2018|2018-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Sympathetic Nervous System Modulation in Hypertension|Sympathetic Nervous System Modulation in Hypertension by Beta-adrenergic Blockade|Terminated||Phase 4|24|Actual|University of Cincinnati|Early termination due to a publication in the literature suggesting potential increased cardiac mortality in hypertensive patients treated primarily with beta blockers. Did not feel that continued treatment in volunteer subjects could be justified.|1||Adverse events reported with beta-blockers as primary therapy.|f||||f||||||||No||2018-06-01 03:07:56.551168|2018-06-01 03:07:56.551168
NCT00491374|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|2008-11-26||2009-01-05|2007-06-25|2007-06-26|Estimate|2009-01-05|2009-01-06|Estimate||||2009-01-05|2009-01-06|Estimate|September 2006||2006-09-30|January 2009|2009-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)|A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study Of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Mild-Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) Associated With Perennial Allergic Rhinitis (PAR) Using Polysomnographic Recordings of Sleep Parameters|Terminated||Phase 4|0|Actual|Schering-Plough|This study was difficult to enroll subjects, and after 5 months of screening, the screen failure rate was 100%. At that time the decision was made to terminate the study. No subject was treated and no data were collected.|2||Very poor enrollment|f||||f||||||||||2018-06-01 03:07:56.812598|2018-06-01 03:07:56.812598
NCT00491361|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2012-11-12|2007-06-25|2007-06-26|Estimate|||||||2012-11-12|2012-11-14|Estimate|January 2005||2005-01-31|August 2008|2008-08-31|July 2006|Actual|2006-07-31|||||Observational|||Chinese Versions of the Swanson, Nolan, and Pelham, Version IV (SNAP-IV) Scale and Strengths Difficulties Questionnaire.|Psychometric Study of the Chinese Versions of the Swanson, Nolan, and Pelham, Version IV (SNAP-IV) Scale and Strengths Difficulties Questionnaire.|Completed|||3600|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 03:07:57.246926|2018-06-01 03:07:57.246926
NCT00491348|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2008-12-21|2007-06-25|2007-06-26|Estimate|||||||2008-12-21|2008-12-23|Estimate|April 2007||2007-04-30|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study|Effects of Duloxetine on Pathological Worry in Patients With Generalized Anxiety Disorder: A fMRI Study|Terminated||N/A|23|Actual|National Taiwan University Hospital||||Change of MRI mode|f||||t||||||||||2018-06-01 03:07:57.389835|2018-06-01 03:07:57.389835
NCT00491335|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|||2017-06-30|2007-06-23|2007-06-26|Estimate|||||||2017-06-30|2017-07-02|Actual|June 18, 2007||2007-06-18|February 16, 2010|2010-02-16|February 16, 2010||2010-02-16|||||Observational|||HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers|HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, MD: A Pilot Study of Biomarkers|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:07:57.538653|2018-06-01 03:07:57.538653
NCT00491322|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2013-10-25||2018-04-02|2007-06-22|2007-06-26|Estimate|2018-04-02|2018-05-02|Actual||||2018-04-02|2018-05-02|Actual|May 2006||2006-05-31|April 2018|2018-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||While 92 subjects were enrolled, 2 subjects, 1 in each group, were withdrawn from the study and their data never analyzed due to pregnancy that prevented initiation of the study drug and 6 week non-compliance with the study medication due to a non-related illness.|Vitamin D Deficiency, Insulin Resistance and FGF-23|Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23|Completed||N/A|92|Actual|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-06-01 03:07:57.656927|2018-06-01 03:07:57.656927
NCT00491309|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2014-07-01|2007-06-25|2007-06-26|Estimate|||||||2014-07-01|2014-07-02|Estimate|July 2011||2011-07-31|July 2014|2014-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension|Exercise and Respiratory Therapy in Patients With Rheumatoid Arthritis / Collagenosis and Pulmonary Hypertension|Unknown status|Recruiting|Phase 2|45|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-06-01 03:07:58.003739|2018-06-01 03:07:58.003739
NCT00491296|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2008-11-05|2007-06-25|2007-06-26|Estimate|||||||2008-11-05|2008-11-07|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|June 2007|Anticipated|2007-06-30|||||Observational|||Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With Hyperthermia||Unknown status|Not yet recruiting||||HaEmek Medical Center, Israel|||||f||||t||||||||||2018-06-01 03:07:58.091005|2018-06-01 03:07:58.091005
NCT00491283|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2008-01-23|2007-06-25|2007-06-26|Estimate|||||||2008-01-23|2008-01-28|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||QuickVue Influenza A+B Clinical Field Trial|Comparison of Swab Types for Specimen Collection|Completed||N/A|||Quidel Corporation|||||f||||f||||||||||2018-06-01 03:07:58.155484|2018-06-01 03:07:58.155484
NCT00491270|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-24|||2011-05-24|2007-06-25|2007-06-26|Estimate|||||||2011-05-24|2011-05-25|Estimate|January 2011||2011-01-31|May 2011|2011-05-31|August 2013|Anticipated|2013-08-31|January 2012|Anticipated|2012-01-31||Interventional|||Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery|Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Western Galilee Hospital-Nahariya|||||f||||t||||||||||2018-06-01 03:07:58.214627|2018-06-01 03:07:58.214627
NCT00491257|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2014-01-16|2007-06-25|2007-06-26|Estimate|||||||2014-01-16|2014-01-17|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)|Completed||Phase 2|130|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:07:58.28558|2018-06-01 03:07:58.28558
NCT00491244|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|2013-09-29||2014-01-13|2007-06-23|2007-06-26|Estimate|2013-09-29|2013-12-13|Estimate||||2014-01-13|2014-02-10|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C|Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Versus Pegylated Interferon Alfa-2a Alone for Treatment-naïve Hemodialysis Patients With Chronic Hepatitis C|Completed||Phase 4|377|Actual|National Taiwan University Hospital|"Open-label trial~Results may not be generalizable to peritoneal dialysis patients~Higher percentages of favorable IL28B genotypes~Secondary endpoint may not be powered to detect the differences"|2|||f||||t||||||||||2018-06-01 03:07:58.379345|2018-06-01 03:07:58.379345
NCT00491231|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-11-15|2007-06-25|2007-06-26|Estimate|||||||2007-11-15|2007-11-19|Estimate|July 2007||2007-07-31|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Observational|||Is Orthostatic Hypotension Associated With Nondipping Hypertension||Unknown status|Recruiting||400|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:07:58.723226|2018-06-01 03:07:58.723226
NCT00491218|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-22|2007-06-22|2007-06-26|Estimate|||||||2007-06-22|2007-06-26|Estimate|June 2007||2007-06-30|June 2007|2007-06-30||||||||Observational|CT-EXTRA||The Addition of Cardiac CT to Exercise Treadmill Testing in the Evaluation of Angina|The Addition of Cardiac Computed Tomography to Exercise Treadmill Testing in the Evaluation of Angina|Unknown status|Recruiting||||Walter Reed Army Medical Center|||||f||||f||||||||||2018-06-01 03:07:58.788352|2018-06-01 03:07:58.788352
NCT00491192|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-25|||2007-09-19|2007-06-25|2007-06-26|Estimate|||||||2007-09-19|2007-09-20|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|June 2009||2009-06-30|||||Interventional|||Normothermia in Patients With Acute Cerebral Damage|Normothermia in Patients With Acute Cerebral Damage|Unknown status|Recruiting|Phase 4|||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||f||||||||||2018-06-01 03:07:58.860978|2018-06-01 03:07:58.860978
NCT00491179|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-23|2008-12-21||2009-10-07|2007-06-23|2007-06-26|Estimate|2009-10-07|2009-11-13|Estimate||||2009-10-07|2009-11-13|Estimate|June 2006||2006-06-30|October 2009|2009-10-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin|Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Who Fail Interferon Alfa or Pegylated Interferon Alfa Monotherapy - a Pilot Study|Completed||Phase 4|35|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 03:07:58.971166|2018-06-01 03:07:58.971166
NCT00491166|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-22|2007-06-22|2007-06-25|Estimate|||||||2007-06-22|2007-06-25|Estimate|June 2007||2007-06-30|June 2007|2007-06-30||||||||Interventional|||Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser|A Single-Center, Investigator-Sponsored Pilot Study to Assess Safety and Biologic Activity of Bromfenac Ophthalmic Solution, 0.09%, in Subjects With Diffuse DME Refractory to Laser|Unknown status|Recruiting|Phase 1|10|Anticipated|Ophthalmic Consultants of Boston|||||f||||f||||||||||2018-06-01 03:07:59.338987|2018-06-01 03:07:59.338987
NCT00491153|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2013-12-17|2007-06-22|2007-06-25|Estimate|||||||2013-12-17|2013-12-19|Estimate|September 2007||2007-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist|Sensitivity and Specificity of Aridol Challenge for a Diagnosis of Asthma by a Specialist Pulmonologist|Terminated|||35|Actual|St. Olavs Hospital||||due to low recruitment rate secondary to very stringent inclusion criteria|f||||f||||||||||2018-06-01 03:07:59.411101|2018-06-01 03:07:59.411101
NCT00491140|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2008-09-30|2007-06-22|2007-06-25|Estimate|||||||2008-09-30|2008-10-01|Estimate|December 2006||2006-12-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|May 2007|Actual|2007-05-31||Observational|||Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab|Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients|Completed|||85|Actual|Istituto Clinico Humanitas|||1||f||||f||||||Samples With DNA|"~     Paraffine embedded tumor sections~   "|||2018-06-01 03:07:59.471094|2018-06-01 03:07:59.471094
NCT00491127|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate|April 2003||2003-04-30|June 2007|2007-06-30|June 2004|Actual|2004-06-30|||||Interventional|||Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma|Phase II Study of Cisplatin With Gemcitabine in Fixed Dose Rate Infusion and Dexamethasone in Second-Line in Patients With Aggressive Non-Hodgkin’s Lymphoma|Completed||Phase 2|10|Actual|Eli Lilly and Company|||||f||||t||||||||||2018-06-01 03:07:59.559531|2018-06-01 03:07:59.559531
NCT00491114|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate|July 2003||2003-07-31|June 2007|2007-06-30|August 2004|Actual|2004-08-31|||||Interventional|||Intravesical Chemotherapy Treatment of Superficial Bladder Cancer|Intravesical Gemcitabine Therapy in Intermediate Risk Superficial Bladder Cancer: A Phase II Study With the Marker Lesion|Completed||Phase 2|8|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:07:59.632844|2018-06-01 03:07:59.632844
NCT00491101|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2010-09-10|2007-06-22|2007-06-25|Estimate|||||||2010-09-10|2010-09-13|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Valuation of Quality of Life in Children With Asthma|Valuation of Quality of Life in Children With Asthma|Completed|||110|Actual|Medical Universtity of Lodz|||1||f||||t||||||||||2018-06-01 03:07:59.849277|2018-06-01 03:07:59.849277
NCT00491088|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2010-02-25|2007-06-22|2007-06-25|Estimate|||||||2010-02-25|2010-03-01|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||The CPAP Effect in Severe Obstructive- Sleep- Apnea Patients Without Daytime Sleepiness: A Control Randomized Trial|The CPAP Effect in Severe Obstructive- Sleep- Apnea Patients Without Daytime Sleepiness: A Control Randomized Trial|Completed||N/A|96|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:07:59.925258|2018-06-01 03:07:59.925258
NCT00491075|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2012-04-06||2013-04-16|2007-06-22|2007-06-25|Estimate|2012-04-06|2012-05-03|Estimate||||2013-04-16|2013-04-24|Estimate|December 2005||2005-12-31|April 2013|2013-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Pemetrexed Plus Gemcitabine in Renal Cell Cancer|Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Advanced Non-Clear Cell Renal Cell Cancer|Terminated||Phase 2|16|Actual|M.D. Anderson Cancer Center||1||Closed early for poor accrual.|f||||f||||||||||2018-06-01 03:08:00.016302|2018-06-01 03:08:00.016302
NCT00491062|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2010-11-15|2007-06-22|2007-06-25|Estimate|||||||2010-11-15|2010-11-16|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|November 2009|Actual|2009-11-30|||||Interventional|ENTEROPARK||Enteric Nervous System in Parkinson's Disease|Analysis of Dopamine Neuronal Cell Loss Within the Enteric Nervous System in Parkinson's Disease|Completed||N/A|||Nantes University Hospital||4|||f||||f||||||||||2018-06-01 03:08:00.22797|2018-06-01 03:08:00.22797
NCT00491049|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate|September 2004||2004-09-30|June 2007|2007-06-30|April 2005|Actual|2005-04-30|||||Interventional|||Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery|Phase 4 Study on Effectiveness of Topical 0.5% Levofloxacin on Reduction of Preoperative Conjunctival Flora in Patients Scheduled for Intraocular Surgery|Completed||Phase 4|140|Actual|Ludwig-Maximilians - University of Munich|||||f||||f||||||||||2018-06-01 03:08:00.296457|2018-06-01 03:08:00.296457
NCT00491036|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2017-05-01|2007-06-22|2007-06-25|Estimate|||||||2017-05-01|2017-05-02|Actual|June 2009||2009-06-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|June 2012|Actual|2012-06-30||Interventional|IABP-SHOCK II||Intraaortic Balloon Pump in Cardiogenic Shock II|Randomized Clinical Study of Intraaortic Balloon Pump Use in Cardiogenic Shock Complicating Acute Myocardial Infarction|Completed||Phase 4|600|Actual|University of Leipzig||2|||f||||t||||||||||2018-06-01 03:08:00.36857|2018-06-01 03:08:00.36857
NCT00491023|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2013-02-08|2007-06-22|2007-06-25|Estimate|||||||2013-02-08|2013-02-12|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Observational|||Examining Macrophage Influx and Vascularization in Chronic Pancreatitis|Examining Macrophage Influx and Vascularization in Chronic Pancreatitis|Completed|||||University of Colorado, Denver|||||f||||t||||||||||2018-06-01 03:08:00.544306|2018-06-01 03:08:00.544306
NCT00491010|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate|July 2006||2006-07-31|June 2007|2007-06-30|February 2008|Anticipated|2008-02-29|||||Interventional|||Maximum Targeted Ablation of Atrial Flutter|Maximum Targeted Ablation of Atrial Flutter|Unknown status|Recruiting|Phase 4|||Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 03:08:00.610259|2018-06-01 03:08:00.610259
NCT00490997|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2017-08-24|2007-06-22|2007-06-25|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2007||2007-06-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Ketamine/Propofol vs Ketamine Alone for Pediatric Fracture Reduction|A Prospective Randomized Double Blind Evaluation of Ketamine/Propofol vs Ketamine Alone for Pediatric Extremity Fracture Reduction|Completed||Phase 4|140|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 03:08:00.736174|2018-06-01 03:08:00.736174
NCT00490984|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2009-12-22|2007-06-21|2007-06-25|Estimate|||||||2009-12-22|2009-12-23|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Tongue Advancement for Obstructive Sleep Apnea|Tongue Advancement for Obstructive Sleep Apnea. An Evaluation fo the Aspire Medical Advance System.|Completed||N/A|60|Anticipated|Aspire Medical|||||f||||t||||||||||2018-06-01 03:08:00.852292|2018-06-01 03:08:00.852292
NCT00490971|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2011-04-26||2015-03-25|2007-06-21|2007-06-25|Estimate|2012-01-31|2012-03-05|Estimate||||2015-03-25|2015-04-15|Estimate|May 2006||2006-05-31|March 2015|2015-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder|A Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder|Completed||Phase 3|768|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|The study employed a randomized withdrawal design, and as such, was enriched for responders to the study drug. Thus, the long-term efficacy demonstrated cannot be extrapolated to a population of patients without prior exposure to paliperidone ER.|3|||f||||t||||||||||2018-06-01 03:08:01.083247|2018-06-01 03:08:01.083247
NCT00490958|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2008-10-16|2007-06-22|2007-06-25|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 1999||1999-01-31|November 2007|2007-11-30|June 2005|Actual|2005-06-30|||||Interventional|||Telmisartan in Haemodialysis Patients With Chronic Heart Failure|Effects Of Telmisartan Added To Angiotensin Converting Enzyme Inhibitors On Mortality And Morbidity In Haemodialysed Patients With Chronic Heart Failure: A Double-Blind Placebo-Controlled Trial|Completed||Phase 4|351|Actual|"University of Campania Luigi Vanvitelli"|||||f||||f||||||||||2018-06-01 03:08:02.629253|2018-06-01 03:08:02.629253
NCT00490945|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2014-02-28||2014-08-08|2007-06-22|2007-06-25|Estimate|2014-08-08|2014-08-26|Estimate||||2014-08-08|2014-08-26|Estimate|July 2004||2004-07-31|August 2014|2014-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers|A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of VEC-162 on Circadian Rhythm in Healthy Subjects|Completed||Phase 2|45|Actual|Vanda Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:08:02.749227|2018-06-01 03:08:02.749227
NCT00490932|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-22|2007-06-22|2007-06-25|Estimate|||||||2007-06-22|2007-06-25|Estimate|March 2005||2005-03-31|February 2007|2007-02-28|April 2007|Actual|2007-04-30|||||Interventional|||New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects|Introduction of New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Management of Diarrhoeal Diseases – A Phase IV Surveillance Study|Completed||Phase 4|27966|Actual|Society for Applied Studies|||||f||||f||||||||||2018-06-01 03:08:03.830951|2018-06-01 03:08:03.830951
NCT00490919|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2010-07-15||2012-09-05|2007-06-22|2007-06-25|Estimate|2010-08-17|2010-09-09|Estimate||||2012-09-05|2012-09-10|Estimate|June 2007||2007-06-30|September 2012|2012-09-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain|Multi-center, Randomized, Double-blind, Placebo-controlled With Open Label run-in Study Assessing Efficacy, Tolerability, Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects With Moderate to Severe, Chronic Low Back Pain|Completed||Phase 3|539|Actual|Purdue Pharma LP||2|||f||||f||||||||||2018-06-01 03:08:03.931303|2018-06-01 03:08:03.931303
NCT00490906|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2014-01-17|2007-06-22|2007-06-25|Estimate|||||||2014-01-17|2014-01-22|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|February 2009|Actual|2009-02-28||Observational|||Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis|Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study|Completed|||60|Actual|University of Kansas Medical Center|||2||f||||t||||||||||2018-06-01 03:08:04.335321|2018-06-01 03:08:04.335321
NCT00490893|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2007-06-22|2007-06-22|2007-06-25|Estimate|||||||2007-06-22|2007-06-25|Estimate|March 2006||2006-03-31|June 2007|2007-06-30|December 2006|Actual|2006-12-31|||||Interventional|||Hypoglycemia Counterregulation and Symptom Perception With Insulin Detemir|Effects of Insulin Detemir Versus Regular Insulin (Actrapid) on Hormonal Counterregulation, Cognitive Function and Symptom Perception During Hypoglycemia|Terminated||Phase 4|12|Actual|University Hospital Tuebingen|||||f||||f||||||||||2018-06-01 03:08:04.405057|2018-06-01 03:08:04.405057
NCT00490880|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate|November 2003||2003-11-30|June 2007|2007-06-30|August 2004|Actual|2004-08-31|||||Interventional|||Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer|The Evaluation of Efficacy and Toxicity of Combined Treatment: Neoadjuvant Chemotherapy (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer Stage T2b-T3 NO/Nx M0|Completed||Phase 2|2|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:04.459196|2018-06-01 03:08:04.459196
NCT00490867|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2018-03-19|2007-06-22|2007-06-25|Estimate|||||||2018-03-19|2018-03-20|Actual|July 2004||2004-07-31|June 2007|2007-06-30|August 2007|Actual|2007-08-31|||||Interventional|||Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes|Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes|Completed||Phase 2|30|Actual|Medical University of Vienna|||||f||||f||||||||||2018-06-01 03:08:05.524055|2018-06-01 03:08:05.524055
NCT00490854|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2008-07-03|2007-06-21|2007-06-25|Estimate|||||||2008-07-03|2008-07-10|Estimate|July 2007||2007-07-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study for Patients With Type 2 Diabetes Mellitus|A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Once-Daily NPH in Insulin-Naïve Patients With Type 2 Diabetes Mellitus on Oral Agents|Completed||Phase 2/Phase 3|129|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:08:05.666711|2018-06-01 03:08:05.666711
NCT00490841|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2011-09-06|2011-03-21|2012-12-13|2007-06-21|2007-06-25|Estimate|2011-12-20|2012-01-30|Estimate|2011-03-21|2011-04-01|Estimate|2012-12-13|2012-12-18|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|June 2010|Actual|2010-06-30||Interventional|HERCULES||The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis|A Clinical Trial to Assess the Safety and Efficacy of the RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Suboptimal Post-procedural Percutaneous Transluminal Angioplasty (PTA) in de Novo or Restenotic Renal Artery Stenoses in Patients With Uncontrolled Hypertension.|Completed||N/A|202|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 03:08:05.81446|2018-06-01 03:08:05.81446
NCT00490828|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2008-09-02|2007-06-22|2007-06-25|Estimate|||||||2008-09-02|2008-09-03|Estimate|June 2007||2007-06-30|September 2008|2008-09-30|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional|||Influence of Hydrocortisone on Immunologic Markers and Health Care Related Quality of Life in Patients After Cardiac Surgery|Influence of Hydrocortisone on Humoral and Cellular Immunologic Markers in High Risk Patients After Cardiac Surgery|Completed||Phase 4|120|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-06-01 03:08:06.357488|2018-06-01 03:08:06.357488
NCT00490815|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2013-09-27||2014-01-17|2007-06-21|2007-06-25|Estimate|2014-01-17|2014-02-13|Estimate||||2014-01-17|2014-02-13|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|April 2011|Actual|2011-04-30|September 2009|Actual|2009-09-30||Interventional|||Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema|An Open Label Pharmacokinetic and Efficacy Study of 0.5 μg/Day and 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts in Subjects With Diabetic Macular Edema|Completed||Phase 3|37|Actual|Alimera Sciences||2|||f||||||||||||||2018-06-01 03:08:06.507767|2018-06-01 03:08:06.507767
NCT00490802|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|2013-04-26||2015-10-21|2007-06-22|2007-06-25|Estimate|2014-10-30|2014-11-05|Estimate||||2015-10-21|2015-10-23|Estimate|June 2006||2006-06-30|October 2015|2015-10-31|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||Intranasal Oxytocin in the Treatment of Autism|Intranasal Oxytocin in the Treatment of Autism|Completed||Phase 2|19|Actual|Anagnostou, Evdokia, M.D.|Small sample size resulted in baseline differences; short duration of study; didn't examine impact of other characteristics; short-half life in the blood; inactive ingredients not identical in placebo; no participant follow-up after study|2|||f||||t||||||||||2018-06-01 03:08:07.178655|2018-06-01 03:08:07.178655
NCT00490789|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2008-04-29|2007-06-21|2007-06-25|Estimate|||||||2008-04-29|2008-04-30|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|TESSTAL||Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM|A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis|Unknown status|Active, not recruiting|Phase 2|14|Anticipated|Cardiff University|||||f||||t||||||||||2018-06-01 03:08:07.465106|2018-06-01 03:08:07.465106
NCT00490776|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2017-02-22|2007-06-21|2007-06-25|Estimate|||||||2017-02-22|2017-02-24|Actual|June 2007||2007-06-30|February 2017|2017-02-28||||September 2009|Actual|2009-09-30||Interventional|||Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma|A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor|Completed||Phase 2/Phase 3|9|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:08:07.546294|2018-06-01 03:08:07.546294
NCT00490763|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2018-03-14|2007-06-21|2007-06-25|Estimate|||||||2018-03-14|2018-03-16|Actual|February 2006|Actual|2006-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||Active Surveillance in Prostate Cancer|Active Surveillance in Prostate Cancer: A Prospective Cohort Study|Active, not recruiting|||1139|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:08:07.720695|2018-06-01 03:08:07.720695
NCT00490750|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2015-12-07|2007-06-21|2007-06-25|Estimate|||||||2015-12-07|2015-12-09|Estimate|March 2003||2003-03-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Laparoscopic Dor Versus Toupet Fundoplication for the Treatment of Idiopathic Esophageal Achalasia|Randomized Prospective Trial of Laparoscopic Heller Myotomy and Partial Fundoplication for the Treatment of Idiopathic Esophageal Achalasia|Completed||N/A|60|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 03:08:07.812986|2018-06-01 03:08:07.812986
NCT00490737|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2018-01-07|2007-06-22|2007-06-25|Estimate|||||||2018-01-07|2018-01-09|Actual|August 12, 2007|Actual|2007-08-12|January 2018|2018-01-31|May 12, 2008|Actual|2008-05-12|May 12, 2008|Actual|2008-05-12||Interventional|||Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)|An Evaluation of the Pharmacokinetic Profile and Safety and Tolerability of Multiple Doses of 6mg/kg Intravenous Daptomycin in Non-Infected Adult Subjects With End Stage Renal Disease on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis|Completed||Phase 1|12|Actual|Cubist Pharmaceuticals LLC||2|||f||||f|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:08:07.9007|2018-06-01 03:08:07.9007
NCT00490724|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2013-06-07||2013-12-31|2007-06-21|2007-06-25|Estimate|2013-12-31|2014-02-03|Estimate||||2013-12-31|2014-02-03|Estimate|March 2007||2007-03-31|December 2013|2013-12-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional||The per protocol set (PPS) included all participants who met the principal criteria for eligibility, received at least 1 dose of study medication and had one efficacy assessment after randomization except those participants who had significant protocol deviations|An Exploratory Study of Nesiritide in Participants With Acute Heart Failure|An Exploratory Study of JNS004 (Nesiritide) in Patients With Acute Heart Failure (J2)|Completed||Phase 2|67|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-06-01 03:08:08.094528|2018-06-01 03:08:08.094528
NCT00490711|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate|July 2003||2003-07-31|June 2007|2007-06-30|April 2005|Actual|2005-04-30|||||Interventional|||Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer|Phase II Study of Sequential Therapy With Paclitaxel Plus Carboplatin Followed by Gemzar Plus Carboplatin in the Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages III-IV|Completed||Phase 2|7|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:09.843439|2018-06-01 03:08:09.843439
NCT00490698|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2013-02-13||2013-02-13|2007-06-22|2007-06-25|Estimate|2013-02-13|2013-03-18|Estimate||||2013-02-13|2013-03-18|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Zoledronate With Atorvastatin in Renal Cell Carcinoma|Bone-Targeted Therapy Combining Zoledronate With Atorvastatin in Renal Cell Carcinoma: A Phase II Study|Completed||Phase 2|11|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:08:09.91866|2018-06-01 03:08:09.91866
NCT00490685|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-22|||2010-09-01|2007-06-22|2007-06-25|Estimate|||||||2010-09-01|2010-09-02|Estimate|April 2007||2007-04-30|August 2009|2009-08-31||||June 2008|Actual|2008-06-30||Interventional|||Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|Randomized Continuation, Dose Escalation Trial of Sorafenib in Patients With Advanced HCC With Radiological Progression on Prior Sorafenib Treatment (Phase II Study)|Completed||Phase 2|142|Actual|Istituto Clinico Humanitas|||||f||||t||||||||||2018-06-01 03:08:10.071522|2018-06-01 03:08:10.071522
NCT00490672|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2015-04-06|2007-06-21|2007-06-25|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2007||2007-08-31|April 2010|2010-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|CORFIS||Community Based Multiple Risk Factors Intervention Strategy|Community Based Multiple Risk Factors Intervention Strategy to Prevent Cardiovascular and Chronic Kidney Diseases [CORFIS]|Completed||Phase 4|770|Actual|Ministry of Health, Malaysia||2|||f||||t||||||||||2018-06-01 03:08:10.144393|2018-06-01 03:08:10.144393
NCT00490490|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2016-12-19||2017-02-09|2007-06-20|2007-06-22|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|January 2007||2007-01-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|June 2011|Actual|2011-06-30||Interventional|||Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy|Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma|Terminated||Phase 2|8|Actual|Stanford University||1||Low Accrual|f||||t||||||||||2018-06-01 03:08:14.358101|2018-06-01 03:08:14.358101
NCT00490659|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate|September 2003||2003-09-30|June 2007|2007-06-30|December 2004|Actual|2004-12-31|||||Interventional|||Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes|A Phase II Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (-With Weekly Low-Dose Gemcitabine) in the Treatment of Nodes Positive NSCLC Patients|Completed||Phase 2|13|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:10.314339|2018-06-01 03:08:10.314339
NCT00490646|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2012-06-14||2016-02-09|2007-06-22|2007-06-25|Estimate|2012-06-14|2012-07-18|Estimate||||2016-02-09|2016-03-10|Estimate|February 2008||2008-02-29|February 2016|2016-02-29|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|||A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer|Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer|Completed||Phase 2|50|Actual|R-Pharm||2|||f||||f||||||||||2018-06-01 03:08:10.402299|2018-06-01 03:08:10.402299
NCT00490633|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2011-08-18|2007-06-22|2007-06-25|Estimate|||||||2011-08-18|2011-08-19|Estimate|October 2006||2006-10-31|June 2007|2007-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|M-FLU||Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza Transmission|Reducing the Transmission of Influenza by Face Masks|Completed||N/A|1420|Actual|University of Michigan||3|||f||||t||||||||||2018-06-01 03:08:11.089116|2018-06-01 03:08:11.089116
NCT00490620|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-10-31|2007-06-21|2007-06-25|Estimate|||||||2007-10-31|2007-11-01|Estimate|January 2004||2004-01-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Study of Combivir for Patients With Primary Biliary Cirrhosis|Randomized Controlled Pilot Study of Combivir for Patients With Primary Biliary Cirrhosis|Completed||Phase 2/Phase 3|59|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 03:08:11.169991|2018-06-01 03:08:11.169991
NCT00490607|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-25|Estimate|||||||2007-06-21|2007-06-25|Estimate||||June 2007|2007-06-30||||||||Observational|||A Prospective Study Comparing the Incidence of Infantile Hemangiomas Following Normal Pregnancies Versus Pregnancies Complicated by Placental Abnormalities||Unknown status|Recruiting||||Rady Children's Hospital, San Diego|||||f||||||||||||||2018-06-01 03:08:11.254528|2018-06-01 03:08:11.254528
NCT00490594|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2008-10-17|2007-06-21|2007-06-22|Estimate|||||||2008-10-17|2008-10-20|Estimate|June 2007||2007-06-30|October 2008|2008-10-31||||October 2008|Anticipated|2008-10-31||Interventional|||SeriACL™ Device Trial for Anterior Cruciate Ligament (ACL) Reconstruction|A Multi-Center Open Study to Evaluate the SeriACL™ Device for Primary Anterior Cruciate Ligament Repair|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Serica Technologies, Inc.|||||f||||f||||||||||2018-06-01 03:08:11.352559|2018-06-01 03:08:11.352559
NCT00490581|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2008-09-09|2007-06-20|2007-06-22|Estimate|||||||2008-09-09|2008-09-10|Estimate|September 2003||2003-09-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|CHHP||Evaluation of Housing First Initiative for Chicago Homeless With Chronic Medical Illness|Evaluation of the Housing First Initiative of Chicago Housing for Health Partnership|Completed||N/A|407|Actual|John H. Stroger Hospital||2|||f||||f||||||||||2018-06-01 03:08:11.432835|2018-06-01 03:08:11.432835
NCT00490568|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2017-09-05|2010-03-29|2017-10-11|2007-06-21|2007-06-22|Estimate|2017-10-11|2017-11-13|Actual|2010-03-29|2010-05-03|Estimate|2017-10-11|2017-11-13|Actual|August 8, 2007|Actual|2007-08-08|September 2017|2017-09-30|June 1, 2009|Actual|2009-06-01|June 1, 2009|Actual|2009-06-01||Interventional|||Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers|An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.|Terminated||Phase 3|1461|Actual|GlaxoSmithKline||1||Based on preliminary parent study results|f||||||||||||||2018-06-01 03:08:11.653913|2018-06-01 03:08:11.653913
NCT00490555|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2013-06-19||2013-09-12|2007-06-21|2007-06-22|Estimate|2013-09-12|2013-11-15|Estimate||||2013-09-12|2013-11-15|Estimate|January 2009||2009-01-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|PROS-1||PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue|The Effect of Male Hormonal Contraceptive Regimens on Prostate Tissue In Normal Men|Completed||Phase 2/Phase 3|32|Actual|University of Washington||4|||f||||f||||||||||2018-06-01 03:08:13.146601|2018-06-01 03:08:13.146601
NCT00490542|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2011-08-03||2016-07-12|2007-06-21|2007-06-22|Estimate|2013-11-19|2014-01-08|Estimate||||2016-07-12|2016-07-29|Estimate|December 2006||2006-12-31|July 2016|2016-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State|Double-blind, Placebo-controlled Trial of Ziprasidone (Geodon) for the Depressive Mixed State|Completed||Phase 2|73|Actual|Tufts Medical Center|One potential limitation in relation to secondary analyses would be sample size. The randomized study design should account for most potential confounding effects, but residual confounding cannot be completely eliminated without larger studies.|2|||f||||f||||||||||2018-06-01 03:08:13.663217|2018-06-01 03:08:13.663217
NCT00490529|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2018-01-19|2007-06-20|2007-06-22|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2009||2009-08-31|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL|"Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for Mantle Cell Lymphoma"|Completed||Phase 2|61|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 03:08:14.049386|2018-06-01 03:08:14.049386
NCT00490516|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2017-04-18|2007-06-21|2007-06-22|Estimate|||||||2017-04-18|2017-04-20|Actual|June 2007||2007-06-30|April 2017|2017-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||ACP-104 in Acutely Psychotic Subjects With Schizophrenia|A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia|Completed||Phase 2|247|Actual|ACADIA Pharmaceuticals Inc.||3|||f||||f||f||||||No||2018-06-01 03:08:14.149347|2018-06-01 03:08:14.149347
NCT00490503|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-10-18|2007-06-21|2007-06-22|Estimate|||||||2017-10-18|2017-10-20|Actual|October 2006|Actual|2006-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Non-Invasive Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy Techniques (MRS) for Assessing Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer|Non-Invasive MRI and MRS Techniques for Assessing Therapeutic Response to Pre-surgical Chemotherapy in Breast Cancer Patients|Active, not recruiting|||28|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples Without DNA|"~     The tissues removed during surgery (mastectomy) will be collected as part of this study.~   "|||2018-06-01 03:08:14.260666|2018-06-01 03:08:14.260666
NCT00489775|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-19|2007-06-19|2007-06-21|Estimate|||||||2007-06-19|2007-06-21|Estimate|January 2004||2004-01-31|June 2007|2007-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Duloxetine Versus Paroxetine for Major Depression|Duloxetine Versus Paroxetine in the Acute Treatment of Major Depression|Completed||Phase 3|480||Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:32.295229|2018-06-01 03:08:32.295229
NCT00490477|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2010-03-09||2010-06-04|2007-06-21|2007-06-22|Estimate|2010-05-06|2010-06-04|Estimate||||2010-06-04|2010-06-08|Estimate|May 2006||2006-05-31|June 2007|2007-06-30|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial|Polymyxin-B Hemoperfusion Inactivates Circulating Proapoptotic Factors|Completed||Phase 3|16|Actual|University of Turin, Italy||2|||f||||t||||||||||2018-06-01 03:08:14.695068|2018-06-01 03:08:14.695068
NCT00490464|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-21|2007-06-21|2007-06-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|June 2004||2004-06-30|June 2007|2007-06-30|February 2007|Actual|2007-02-28|||||Observational|||Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH||Completed|||163|Actual|University of Illinois at Chicago|||||f||||f||||||||||2018-06-01 03:08:14.941632|2018-06-01 03:08:14.941632
NCT00490451|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2018-03-17|2010-12-09|2018-05-01|2007-06-20|2007-06-22|Estimate|2018-05-01|2018-05-02|Actual|2010-12-09|2010-12-15|Estimate|2018-05-01|2018-05-02|Actual|August 2007||2007-08-31|May 2018|2018-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma|A Phase 2 Study of LY573636-Sodium Administered as Second-line or Third-line Treatment in Patients With Unresectable or Metastatic Soft Tissue Sarcoma|Completed||Phase 2|101|Actual|Eli Lilly and Company||1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 03:08:15.031084|2018-06-01 03:08:15.031084
NCT00490438|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-22|Estimate|||||||2007-06-20|2007-06-22|Estimate|January 2007||2007-01-31|September 2006|2006-09-30|July 2007|Anticipated|2007-07-31|||||Observational|||Measurement of Vaginal Squeeze Pressure in Incontinent Patients||Unknown status|Recruiting||||Hospital de Clinicas de Porto Alegre|||||f||||t||||||||||2018-06-01 03:08:15.71666|2018-06-01 03:08:15.71666
NCT00490425|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|October 2002||2002-10-31|June 2007|2007-06-30|October 2006|Actual|2006-10-31|||||Interventional|FRALAC||Prevention of Asthma and Allergy by Probiotic Lactobacillus GG|Efficacy of Lactbacillus GG on Wheeze and Allergic Sensitization in Infants at Risk|Completed||Phase 4|131|Actual|Johann Wolfgang Goethe University Hospital|||||f||||t||||||||||2018-06-01 03:08:15.773838|2018-06-01 03:08:15.773838
NCT00490412|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2017-02-27|2007-06-21|2007-06-22|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2007||2007-12-31|February 2016|2016-02-29|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection|Randomized, Placebo-controlled Trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease Bone Turnover in Adolescents and Young Adults With HIV Infection Being Treated With Antiretroviral Therapy Containing Tenofovir Compared to Those Being Treated With Antiretroviral Therapy Not Containing Tenofovir|Completed||N/A|207|Actual|University of North Carolina, Chapel Hill||4|||f||||t||||||||||2018-06-01 03:08:15.836608|2018-06-01 03:08:15.836608
NCT00490399|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-22|Estimate|||||||2007-06-20|2007-06-22|Estimate|March 2003||2003-03-31|June 2007|2007-06-30|September 2004|Actual|2004-09-30|||||Interventional|||Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas|A Phase II Trial of GEMZAR Combined With Cisplatin in Patients With Inoperable Biliary Tract Carcinomas|Completed||Phase 2|39|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:15.928642|2018-06-01 03:08:15.928642
NCT00490386|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-21|2007-06-21|2007-06-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|June 2006||2006-06-30|June 2007|2007-06-30||||||||Observational|||Helicobacter Pylori and Acute Alcohol Induced Pancreatitis|Alkoholihaimatulehduksen Uusiminen|Completed|||100|Actual|University of Tampere|||||f||||f||||||||||2018-06-01 03:08:15.987118|2018-06-01 03:08:15.987118
NCT00490373|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-22|Estimate|||||||2007-06-20|2007-06-22|Estimate|October 2003||2003-10-31|June 2007|2007-06-30|April 2005|Actual|2005-04-30|||||Interventional|||Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic|A Phase 2 Trial of ALIMTA in Pretreated Patients With Unresectable or Metastatic Cancer of the Pancreas|Completed||Phase 2|52|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:16.040522|2018-06-01 03:08:16.040522
NCT00490360|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|October 2001||2001-10-31|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head|Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head|Completed||Phase 2|2007|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 03:08:16.096087|2018-06-01 03:08:16.096087
NCT00490347|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2008-01-15|2007-06-21|2007-06-22|Estimate|||||||2008-01-15|2008-01-17|Estimate|July 2005||2005-07-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|||||Interventional|||VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial|Evaluation of the VentrAssistTM Left Ventricular Assist Device as a Bridge to Cardiac Transplantation - Feasibility Trial|Completed||Phase 2|30|Anticipated|Ventracor|||||f||||t||||||||||2018-06-01 03:08:16.295849|2018-06-01 03:08:16.295849
NCT00490334|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2015-05-19|2007-06-20|2007-06-22|Estimate|||||||2015-05-19|2015-05-21|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer|Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer|Completed|||72|Actual|Stanford University|||2||f||||t||||||||||2018-06-01 03:08:16.364443|2018-06-01 03:08:16.364443
NCT00490321|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2009-09-04|2007-06-20|2007-06-22|Estimate|||||||2009-09-04|2009-09-09|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|June 2012|Anticipated|2012-06-30|||||Interventional|||VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy|Evaluation of the VentrAssistTM Left Ventricular Assist Device for the Treatment of Advanced Heart Failure - Destination Therapy|Unknown status|Active, not recruiting|Phase 3|225|Anticipated|Ventracor|||||f||||t||||||||||2018-06-01 03:08:16.440456|2018-06-01 03:08:16.440456
NCT00490308|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-24|2007-06-21|2007-06-22|Estimate|||||||2007-06-24|2007-06-26|Estimate|August 2007||2007-08-31|June 2007|2007-06-30|August 2008|Anticipated|2008-08-31|||||Interventional|||The Influence of Estradiol Supplementation During the Luteal in Patients Undergoing IVF Treatment|Blinded Randomised Trial About the Influence of Estradiol Supplementation During the Luteal in Patients Undergoing in Vitro Fertilization (IVF) Treatment|Unknown status|Not yet recruiting|Phase 1|120|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:08:16.538219|2018-06-01 03:08:16.538219
NCT00490295|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2013-11-25|2007-06-21|2007-06-22|Estimate|||||||2013-11-25|2013-11-27|Estimate|March 2008||2008-03-31|November 2013|2013-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Biomarkers for Detection of Brain Ischemia|Biomarkers for the Detection of Brain Ischemia in Neonates With Congenial Heart Disease Requiring Cardiac Surgery|Completed|||10|Actual|Emory University|||1||f||||f||||||||||2018-06-01 03:08:16.606788|2018-06-01 03:08:16.606788
NCT00490282|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2016-02-25|2007-06-21|2007-06-22|Estimate|||||||2016-02-25|2016-02-26|Estimate|June 2007||2007-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer|A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer|Completed||N/A|25|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:08:16.686983|2018-06-01 03:08:16.686983
NCT00490269|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2012-12-19||2017-01-11|2007-06-21|2007-06-22|Estimate|2013-03-05|2013-04-08|Estimate||||2017-01-11|2017-01-12|Estimate|October 2006||2006-10-31|August 2016|2016-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Ph1 Marinol Interaction Study - Part 2 - 1|Phase 1, Pilot Study to Examine the Cardiovascular Effects of Smoked Marijuana, Interactions With Oral Dronabinol, and Effects of Dronabinol on Withdrawal in Marijuana Dependent Volunteers|Completed||Phase 1|12|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||||||||||||2018-06-01 03:08:16.78014|2018-06-01 03:08:16.78014
NCT00490256|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2011-07-08||2014-05-21|2007-06-20|2007-06-22|Estimate|2011-07-08|2011-08-05|Estimate||||2014-05-21|2014-06-03|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||Modified Perfusion for Neonatal Aortic Arch Reconstruction|Evaluation of a Modified Perfusion Strategy for Neonatal Aortic Arch Reconstruction: Does Perfusing the Lower Body During Arch Repair Help?|Completed||N/A|14|Actual|Emory University|Early termination leading to small numbers for analysis|2|||f||||f||||||||||2018-06-01 03:08:17.110653|2018-06-01 03:08:17.110653
NCT00490243|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-27|2007-06-21|2007-06-22|Estimate|||||||2007-06-27|2007-06-28|Estimate|July 2003||2003-07-31|June 2007|2007-06-30|October 2006|Actual|2006-10-31|||||Interventional|||Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma|A Randomized, Double-Blind Trial of the Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma|Completed||Phase 4|150|Actual|Medical Universtity of Lodz|||||f||||t||||||||||2018-06-01 03:08:17.355751|2018-06-01 03:08:17.355751
NCT00490230|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2015-12-31|2007-06-21|2007-06-22|Estimate|||||||2015-12-31|2016-01-01|Estimate|April 2007||2007-04-30|December 2015|2015-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|SCAR||Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application|Assessment of Cutaneous Leishmaniasis Scar (Caused by Leishmania Major) for Cosmetic Outcome After Treatment With WR279396 (Paromomycin/Gentamicin Cream in Vehicle) Versus a No Treatment Control Group (Natural Healing)|Completed||N/A|108|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-06-01 03:08:17.421145|2018-06-01 03:08:17.421145
NCT00490217|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|December 1993||1993-12-31|June 2007|2007-06-30|March 2007|Actual|2007-03-31|||||Observational|||Spontaneous Bacterial Peritonitis: Incidence, Risk Factors and Outcome|Spontaani Bakterielli Peritoniitti: Esiintyvyys, riskitekijät ja Vaikutus Ennusteeseen|Completed|||240|Actual|University of Tampere|||||f||||f||||||||||2018-06-01 03:08:17.504254|2018-06-01 03:08:17.504254
NCT00490204|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2017-08-28|2007-06-21|2007-06-22|Estimate|||||||2017-08-28|2017-08-29|Actual|July 27, 2007|Actual|2007-07-27|August 2017|2017-08-31|October 3, 2007|Actual|2007-10-03|October 3, 2007|Actual|2007-10-03||Interventional|||Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis|A Randomized, Double Blind, Placebo Controlled Study for Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup (CTZ DS) (2.5 mg or 5 mg Twice a Day) in Children (2 Years of Age or Older But Under 15 Years Old) Suffering From Perennial Allergic Rhinitis.|Completed||Phase 3|239|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:08:17.558673|2018-06-01 03:08:17.558673
NCT00490191|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-22|Estimate|||||||2007-06-20|2007-06-22|Estimate|January 1999||1999-01-31|June 2007|2007-06-30|July 2001|Actual|2001-07-31|||||Interventional|||Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency|Comparison of an Incremental Weight-Based Dose Regimen With an Individualized Dosage Adjusted According to the IGF-I Response in Adults With Growth Hormone Deficiency|Completed||Phase 4|387|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:17.658759|2018-06-01 03:08:17.658759
NCT00490178|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-08-31|2007-06-21|2007-06-22|Estimate|||||||2007-08-31|2007-09-03|Estimate|March 2007||2007-03-31|August 2007|2007-08-31||||||||Interventional|||Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia|An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia|Completed||Phase 3|29|Actual|Solvay Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:08:17.754572|2018-06-01 03:08:17.754572
NCT00490165|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2012-04-05|2007-06-20|2007-06-22|Estimate|||||||2012-04-05|2012-04-06|Estimate|March 2007||2007-03-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Periodontal and Periapical Inflammation and Pregnancy|Associations Between Periodontal and Periapical Inflammation and Pregnancy Outcomes|Completed|||30|Actual|University of Mississippi Medical Center|||||f||||f||||||||||2018-06-01 03:08:17.813898|2018-06-01 03:08:17.813898
NCT00490152|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2017-02-27|2007-06-21|2007-06-22|Estimate|||||||2017-02-27|2017-02-28|Actual|August 2007||2007-08-31|May 2016|2016-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Microbicides Acceptability Among Sexually Active Young Women|"Microbicide-Use Adherence, Acceptability, and Attitudes Among Sexually Active Young Women Participating in a Phase I Microbicide Trial (MTN 004) Tell Juliana"|Completed|||59|Actual|University of North Carolina, Chapel Hill|||3||f||||t||||||||||2018-06-01 03:08:17.865971|2018-06-01 03:08:17.865971
NCT00490139|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2014-07-30||2017-10-09|2007-06-20|2007-06-22|Estimate|2014-07-30|2014-08-18|Estimate||||2017-10-09|2017-11-08|Actual|May 16, 2007|Actual|2007-05-16|October 2017|2017-10-31|November 21, 2022|Anticipated|2022-11-21|December 6, 2013|Actual|2013-12-06||Interventional|ALTTO||ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D|A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients With HER2/ErbB2 Positive Primary Breast Cancer|Active, not recruiting||Phase 3|8386|Actual|Novartis||4|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 03:08:18.346609|2018-06-01 03:08:18.346609
NCT00490126|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2018-01-08|2007-06-21|2007-06-22|Estimate|||||||2018-01-08|2018-01-10|Actual|June 2006|Actual|2006-06-30|January 2018|2018-01-31|June 2027|Anticipated|2027-06-30|June 2027|Anticipated|2027-06-30||Observational|||Data Collection of Demographics and Perioperative Care of Patients Undergoing Laparoscopic Surgery|Data Collection of Demographics and Perioperative Care of Patients Undergoing Laparoscopic Surgery in the Department of Gynecologic Oncology|Recruiting|||5000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:08:24.177064|2018-06-01 03:08:24.177064
NCT00490113|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-01-03|2007-06-21|2007-06-22|Estimate|||||||2017-01-03|2017-01-05|Estimate|January 2007||2007-01-31|January 2017|2017-01-31||||||||Interventional|||A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria|Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria|Withdrawn||Phase 2|0|Actual|University of Kansas Medical Center||1||Drug unavailable|f||||t||||||||||2018-06-01 03:08:24.291605|2018-06-01 03:08:24.291605
NCT00490100|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2014-03-18||2015-07-02|2007-06-21|2007-06-22|Estimate|2015-07-02|2015-07-03|Estimate||||2015-07-02|2015-07-03|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1|Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment With Insulin-like Growth Factor-1 (IGF-1)|Terminated||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)|Due to limited subject participation, there is insufficient complete data to generate meaningful statistics for the outcome measures. Instead, this data will be reported as a case series.|1||Insufficient patient participation|f||||t||||||||||2018-06-01 03:08:24.36681|2018-06-01 03:08:24.36681
NCT00490087|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2011-09-01|2007-06-20|2007-06-22|Estimate|||||||2011-09-01|2011-09-02|Estimate|January 1999||1999-01-31|June 2007|2007-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women|Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits|Completed||Phase 3|21|Actual|IRCCS Burlo Garofolo||2|||f||||f||||||||||2018-06-01 03:08:24.677967|2018-06-01 03:08:24.677967
NCT00490074|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2009-11-25|2007-06-21|2007-06-22|Estimate|||||||2009-11-25|2009-11-26|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|EV03/ANRSVAC20||Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers|A Phase I/II Trial to Compare the Immunogenicity and Safety of 3 DNA C Prime Followed by 1 NYVAC C Boost to 2 DNA C Prime Followed by 2 NYVAC C Boost|Completed||Phase 1/Phase 2|147|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||t||||||||||2018-06-01 03:08:24.769363|2018-06-01 03:08:24.769363
NCT00490061|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2016-11-11||2017-01-13|2007-06-20|2007-06-22|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|July 2007||2007-07-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|January 2013|Actual|2013-01-31||Interventional|||Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy|A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.|Terminated||Phase 2|17|Actual|Stanford University|Due to low accrual, this study was terminated prior to reaching 60 subjects.|1||Poor accrual.|f||||t||||||||No||2018-06-01 03:08:24.856044|2018-06-01 03:08:24.856044
NCT00490048|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|||2007-06-21|2007-06-21|2007-06-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Assessment of Pulmonary Involvement inUlcerative Colitis by Induced Sputum||Completed||N/A|20|Anticipated|Hillel Yaffe Medical Center|||||f||||||||||||||2018-06-01 03:08:25.032363|2018-06-01 03:08:25.032363
NCT00490035|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2016-03-14|2010-02-24|2017-12-11|2007-06-21|2007-06-22|Estimate|2016-03-14|2016-04-13|Estimate|2009-08-26|2009-08-27|Estimate|2017-12-11|2018-01-08|Actual|September 2007||2007-09-30|December 2017|2017-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||Baseline Characteristics refer to the Randomized Set.|Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures|A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.|Completed||Phase 3|399|Actual|UCB Pharma||4|||f||||f||||||||||2018-06-01 03:08:25.168309|2018-06-01 03:08:25.168309
NCT00490022|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2011-01-10||2011-06-20|2007-06-21|2007-06-22|Estimate|2011-05-10|2011-06-09|Estimate||||2011-06-20|2011-06-27|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|DHT-3||Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]|The Effect of Dihydrotestosterone (DHT) on Prostate Tissue Androgen Concentrations and Inflammation in Normal Men|Completed||Phase 1/Phase 2|31|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:08:27.681362|2018-06-01 03:08:27.681362
NCT00490009|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2017-01-09||2017-02-28|2007-06-20|2007-06-22|Estimate|2017-01-09|2017-02-28|Actual||||2017-02-28|2017-03-30|Actual|September 2004||2004-09-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|April 2010|Actual|2010-04-30||Interventional|||Phase 2 Study of Bexxar in Relapsed/Refractory DLCL|Phase 2 Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL)|Completed||Phase 2|9|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 03:08:28.071911|2018-06-01 03:08:28.071911
NCT00489996|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-22|Estimate|||||||2007-06-20|2007-06-22|Estimate|January 2003||2003-01-31|June 2007|2007-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Trial Comparing 3 and 4 Week Regimen of Gemcitabine and Cisplatin in Patients With Lung Cancer|A Multicenter, Randomized Trial Comparing a Combined Gemcitabine and Cisplatin 3-Week Regimen With a 4-Week Regimen in Non-Small Cell Lung Cancer Patients|Completed||Phase 2|100|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:28.491638|2018-06-01 03:08:28.491638
NCT00489983|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-22|Estimate|||||||2007-06-20|2007-06-22|Estimate|July 2003||2003-07-31|June 2007|2007-06-30|March 2005|Actual|2005-03-31|||||Interventional|||Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy|A Multicenter Phase 2 Randomized Trial of Single-Agent ALIMTA or ALIMTA With Sequentially Administered GEMZAR as First-Line Chemotherapy in Elderly Patients or Patients Who Are Not Eligible for Platinum-Based Chemotherapy With Advanced NSCLC|Completed||Phase 2|91|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:08:28.575769|2018-06-01 03:08:28.575769
NCT00489970|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-21|2010-07-15||2016-05-26|2007-06-21|2007-06-22|Estimate|2010-07-15|2010-08-11|Estimate||||2016-05-26|2016-06-28|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|September 2011|Actual|2011-09-30||Interventional|||Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9|Persistence Study of GSK Biologicals' Tdap Vaccine (776423), 1, 3, 5 and 9 Years Following Administration as a Single Dose in NCT00346073 Study and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9|Completed||Phase 3|1592|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:08:28.715007|2018-06-01 03:08:28.715007
NCT00489957|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2013-11-25|2007-06-21|2007-06-22|Estimate|||||||2013-11-25|2013-11-27|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|December 2009|Actual|2009-12-31|May 2008|Actual|2008-05-31||Observational|||Speckle Tracking in Pediatric Patients|Speckle Tracking and Function Assessment in Pediatric Patients|Completed|||70|Actual|Emory University|||2||f||||f||||||||||2018-06-01 03:08:29.279137|2018-06-01 03:08:29.279137
NCT00489944|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2014-01-09|2007-06-20|2007-06-21|Estimate|||||||2014-01-09|2014-01-10|Estimate|May 2007||2007-05-31|July 2009|2009-07-31||||December 2012|Anticipated|2012-12-31||Interventional|||Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma|A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma|Unknown status|Recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:08:29.371694|2018-06-01 03:08:29.371694
NCT00489931|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-06-30|2007-06-20|2007-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 18, 2007||2007-06-18|April 15, 2009|2009-04-15|April 15, 2009||2009-04-15|||||Interventional|||Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally|A Phase I Open-Label Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for the Influenza Virus H5 Hemagglutinin Protein Administered Intradermally in Healthy Adults|Completed||Phase 1|44||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:08:29.505942|2018-06-01 03:08:29.505942
NCT00489918|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2009-05-07|2007-06-20|2007-06-21|Estimate|||||||2009-05-07|2009-05-08|Estimate|June 2007||2007-06-30|May 2009|2009-05-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Dose Ranging Study - Macroflux PTH in Postmenopausal Women With Osteoporosis|A Dose Ranging Study of the Effects of Macroflux® PTH Compared With Macroflux® Placebo and FORTEO® in Postmenopausal Women With Osteoporosis|Completed||Phase 2|165|Actual|Zosano Pharma Corporation||5|||f||||f||||||||||2018-06-01 03:08:29.606374|2018-06-01 03:08:29.606374
NCT00489905|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2013-10-22|2007-06-20|2007-06-21|Estimate|||||||2013-10-22|2013-10-23|Estimate|April 2005||2005-04-30|October 2013|2013-10-31|May 2008|Actual|2008-05-31|||||Interventional|||Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer|Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer|Completed||N/A|24|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:08:29.714667|2018-06-01 03:08:29.714667
NCT00489892|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-07-23|2007-06-20|2007-06-21|Estimate|||||||2007-07-23|2007-07-25|Estimate|August 2003||2003-08-31|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI|Efficacy of Pharmacological Treatment of Working Memory Impairment After Traumatic Brain Injury: Evaluation With fMRI|Unknown status|Recruiting|N/A|20|Anticipated|Kessler Foundation|||||f||||f||||||||||2018-06-01 03:08:29.843561|2018-06-01 03:08:29.843561
NCT00489879|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2008-05-19|2007-06-20|2007-06-21|Estimate|||||||2008-05-19|2008-05-20|Estimate|July 2007||2007-07-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Management of Patients With Type 2 Diabetes and Hypertension Using Mobile Health Care System|Efficacy of Mobile Health Care System in Patients With Type 2 Diabets and Hypertension|Completed||N/A|140|Anticipated|Korea University|||||f||||t||||||||||2018-06-01 03:08:30.080066|2018-06-01 03:08:30.080066
NCT00489866|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2011-09-16||2015-03-12|2007-06-20|2007-06-21|Estimate|2012-02-28|2012-03-28|Estimate||||2015-03-12|2015-03-31|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|September 2008|Actual|2008-09-30||Interventional|||Aripiprazole Augmentation of Antidepressants in PTSD|Aripiprazole Augmentation of Antidepressants in PTSD|Completed||Phase 2|14|Actual|Durham VA Medical Center|One of the primary limitations of this pilot clinical trial is small sample size. Results of this study will clearly need to be replicated in a larger cohort.|2|||f||||||||||||||2018-06-01 03:08:30.19259|2018-06-01 03:08:30.19259
NCT00489853|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2009-08-06||2012-07-27|2007-06-19|2007-06-21|Estimate|2012-07-27|2012-08-30|Estimate||||2012-07-27|2012-08-30|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|CODEX||Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD|A Multi-centre, Randomised, Double-blind, Cross-over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort ®(Budesonide/Formoterol) 320/9μg One Inhalation Twice Daily Compared With Placebo and Oxis® 9μg One Inhalation Twice Daily in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 4|137|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 03:08:30.641544|2018-06-01 03:08:30.641544
NCT00489840|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2012-10-24|2007-06-20|2007-06-21|Estimate|||||||2012-10-24|2012-10-25|Estimate|May 2007||2007-05-31|October 2012|2012-10-31||||July 2010|Actual|2010-07-31||Interventional|CSC-AA||Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate|Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate|Completed||Phase 1/Phase 2|5|Actual|Manhattan Eye, Ear & Throat Hospital||1|||f||||f||||||||||2018-06-01 03:08:31.741349|2018-06-01 03:08:31.741349
NCT00489827|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2013-01-16|2007-06-20|2007-06-21|Estimate|||||||2013-01-16|2013-01-18|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2009|Actual|2009-12-31||Interventional|GLUTAMICS||Glutamate for Metabolic Intervention in Coronary Surgery|Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease|Unknown status|Active, not recruiting|Phase 3|800|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-06-01 03:08:31.886616|2018-06-01 03:08:31.886616
NCT00489814|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2017-10-04|2007-06-19|2007-06-21|Estimate|||||||2017-10-04|2017-10-05|Actual|May 2006|Actual|2006-05-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Study of Quality of Life for Prostate Proton Therapy|Prospective Evaluation of Quality of Life After Proton Therapy for Prostate Cancer|Active, not recruiting|||1084|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:08:32.056831|2018-06-01 03:08:32.056831
NCT00489801|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2009-11-09|2007-06-20|2007-06-21|Estimate|||||||2009-11-09|2009-11-10|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|HOME-BASE||Trial Comparing Home-based Cardiac Rehabilitation With Comprehensive Centre-based Cardiac Rehabilitation in Patients Older Than 65 Years With Coronary Heart Disease. The HOMEBASE Trial|RCT Comparing Home-based Cardiac Rehabilitation With Comprehensive Centre-based Cardiac Rehabilitation and Usual Care in Patients Older Than 65 Years With Coronary Heart Disease. The HOMEBASE Trial.|Unknown status|Active, not recruiting|N/A|115|Actual|Bispebjerg Hospital||1|||f||||f||||||||||2018-06-01 03:08:32.13159|2018-06-01 03:08:32.13159
NCT00489788|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2013-12-10|2007-06-20|2007-06-21|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|March 2009|Actual|2009-03-31|||||Observational|||Predictors for Pulmonary Valve Replacement - Anatomic and Hemodynamic Using MRI|MRI Assessment of Right and Left Ventricular Strain, Associated Function, Volume and ECG Parameters as Predictors of Optimal Timing for Pulmonary Valve Replacement in Patients Post Repair for Tetralogy of Fallot|Completed|||101|Actual|Emory University|||||f||||f||||||||||2018-06-01 03:08:32.204456|2018-06-01 03:08:32.204456
NCT00489749|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-19|2007-06-19|2007-06-21|Estimate|||||||2007-06-19|2007-06-21|Estimate|October 2003||2003-10-31|June 2007|2007-06-30|May 2006|Actual|2006-05-31|||||Interventional|||A Study Comparing Protected Early Weightbearing Versus Non-Weightbearing After Surgery for Achilles Tendon Rupture|The Influence of Protected Early Weightbearing Versus Nonweightbearing After Surgical Repair of the Achilles Tendon|Completed||N/A|110|Actual|University of Alberta|||||f||||f||||||||||2018-06-01 03:08:32.531075|2018-06-01 03:08:32.531075
NCT00489736|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2009-09-30||2010-02-15|2007-06-20|2007-06-21|Estimate|2009-09-30|2009-11-09|Estimate||||2010-02-15|2010-02-18|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|DIONYSOS||Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation|Randomized Double Blind Trial to Evaluate the Efficacy and Safety of Dronedarone (400mg BID) Versus Amiodarone (600mg Daily for 28 Days, Then 200mg Daily Thereafter) for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation (AF)|Completed||Phase 3|504|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:08:32.639255|2018-06-01 03:08:32.639255
NCT00489723|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|May 2007||2007-05-31|June 2007|2007-06-30||||||||Observational|||Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?||Unknown status|Recruiting||||HaEmek Medical Center, Israel|||||f||||t||||||||||2018-06-01 03:08:33.235958|2018-06-01 03:08:33.235958
NCT00489710|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2018-02-22|2007-06-20|2007-06-21|Estimate|||||||2018-02-22|2018-02-26|Actual|December 2006||2006-12-31|February 2018|2018-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Talabostat in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Talabostat in Patients With Metastatic Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|University of Nebraska||1||Terminated for safety reasons|f||||t||||||||||2018-06-01 03:08:33.31477|2018-06-01 03:08:33.31477
NCT00489697|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-01-02|2007-06-20|2007-06-21|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases|Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases|Completed||N/A|200|Anticipated|University Hospital, Tours||1|||f||||f||||||||||2018-06-01 03:08:33.408072|2018-06-01 03:08:33.408072
NCT00489684|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2008-06-13|2007-06-20|2007-06-21|Estimate|||||||2008-06-13|2008-06-17|Estimate|August 2007||2007-08-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|||||Observational|AEO-2007-01||Effect of Opioids on Experimental Hyperalgesia in Oesophagus, Skin and Muscles|Investigation of the Effect of Opioids on Experimental Hyperalgesia in Oesophagus and Skin, and in an Ischemic Model of Musclepain. Including an Explorative Study of the Effect of Morphine on the Pain Processing in the Brain|Completed|||24|Actual|University of Aarhus|||||f||||t||||||Samples With DNA|"~     Blood samples are collected to study the pharmacokinetic of the drugs~   "|||2018-06-01 03:08:33.519432|2018-06-01 03:08:33.519432
NCT00489671|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-01-17|2007-06-20|2007-06-21|Estimate|||||||2017-01-17|2017-01-19|Estimate|June 2003||2003-06-30|October 2015|2015-10-31|August 2007|Actual|2007-08-31|October 2006|Actual|2006-10-31||Observational|||Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis|Differential Diagnosis Between Pancreatic Cancer and Chronic Pancreatitis: Value of the Detection of Urinary Cadmium|Completed|||32|Actual|Wake Forest University Health Sciences|||1||f||||f||||||||||2018-06-01 03:08:33.580917|2018-06-01 03:08:33.580917
NCT00489658|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|October 2002||2002-10-31|June 2007|2007-06-30||||||||Interventional|NECS||Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda|Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda|Terminated||Phase 2/Phase 3|31|Actual|Epicentre||||"Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was~   taken to terminate recruitment in March 2003."|f||||f||||||||||2018-06-01 03:08:33.640898|2018-06-01 03:08:33.640898
NCT00489645|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2008-01-15|2007-06-19|2007-06-21|Estimate|||||||2008-01-15|2008-01-16|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide|The Influence of Ambient Glycemia on the Effect of Pramlintide on Gastric Emptying in Patients With Type 1 Diabetes and Healthy Subjects|Completed||N/A|27|Actual|Ludwig-Maximilians - University of Munich||4|||f||||t||||||||||2018-06-01 03:08:33.74534|2018-06-01 03:08:33.74534
NCT00489632|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2012-02-17|2007-06-20|2007-06-21|Estimate|||||||2012-02-17|2012-02-20|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Children's Resiliency, Adjustment, and Coping|Children's Resiliency, Adjustment, and Coping: Cancer-Related, Family Context, and Within-Child Factors|Completed|||66|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:08:33.839313|2018-06-01 03:08:33.839313
NCT00489619|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2014-07-29|2007-06-19|2007-06-21|Estimate|||||||2014-07-29|2014-07-31|Estimate|April 2004||2004-04-30|July 2014|2014-07-31|March 2005|Actual|2005-03-31|||||Observational|||Safe Pregnancy by Infectious Disease Control|Safe Pregnancy by Infectious Disease Control in the Democratic Republic of Congo - Pilot Study|Completed|||2008|Actual|NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 03:08:33.912568|2018-06-01 03:08:33.912568
NCT00489606|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|April 2007||2007-04-30|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530|Clinical Trial to Investigate the Influence of Drug Interaction After Oral Administration of Tamsulosin and SK3530 in Healthy Male Volunteers|Completed||Phase 1|16|Actual|SK Chemicals Co.,Ltd.|||||f||||t||||||||||2018-06-01 03:08:33.98088|2018-06-01 03:08:33.98088
NCT00489593|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2015-01-07|2007-06-20|2007-06-21|Estimate|||||||2015-01-07|2015-01-08|Estimate|October 2006||2006-10-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Olanzapine in Patients With Advanced Cancer and Weight Loss|Phase I Dose-Finding Pilot Study of the Safety and Tolerability of Olanzapine in Patients With Advanced Cancer and Weight Loss|Completed||Phase 1|57|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:08:34.045269|2018-06-01 03:08:34.045269
NCT00489580|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-07-23|2007-06-20|2007-06-21|Estimate|||||||2007-07-23|2007-07-25|Estimate|August 2005||2005-08-31|July 2007|2007-07-31|May 2006|Actual|2006-05-31|||||Interventional|||A Pilot Study Investigating the Feasibility of the Saebo Arm Training Program on an Inpatient Population|A Pilot Study Investigating the Feasibility of Using a Functional Tone Management (F.T.M.) Arm Training Program With the SaeboFlex Dynamic Hand Orthosis on an Inpatient Population|Completed||N/A|24|Actual|Kessler Foundation|||||f||||f||||||||||2018-06-01 03:08:34.14216|2018-06-01 03:08:34.14216
NCT00489567|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2011-01-27|2007-06-20|2007-06-21|Estimate|||||||2011-01-27|2011-01-31|Estimate|October 2007||2007-10-31|January 2011|2011-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden|A Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE, Its Complications and Diversity of Co-circulating Rotavirus Strains in Children < 5 Years of Age in Sweden|Completed|||642|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Stool sample, Blood sample~   "|||2018-06-01 03:08:34.213502|2018-06-01 03:08:34.213502
NCT00489554|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2012-03-15||2016-11-03|2007-06-20|2007-06-21|Estimate|2012-04-12|2012-05-10|Estimate||||2016-11-03|2016-12-16|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age|Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix|Completed||Phase 3|230|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:08:34.31351|2018-06-01 03:08:34.31351
NCT00489541|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2011-04-28|2010-08-18|2014-04-24|2007-06-20|2007-06-21|Estimate|2011-06-02|2011-06-28|Estimate|2010-08-18|2010-08-20|Estimate|2014-04-24|2014-05-08|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|June 2009|Actual|2009-06-30||Interventional|PERSEUS SV||TAXUS PERSEUS Small Vessel|A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels|Completed||Phase 3|224|Actual|Boston Scientific Corporation|There were no commercially available dedicated small vessel paclitaxel-eluting stents at the time of study enrollment, thus, the PERSEUS Small Vessel comparator group does not represent the most recently available paclitaxel-eluting stents.|1|||f||||t||||||||||2018-06-01 03:08:34.875611|2018-06-01 03:08:34.875611
NCT00489528|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2013-10-21|2007-06-20|2007-06-21|Estimate|||||||2013-10-21|2013-10-22|Estimate|July 1997||1997-07-31|October 2013|2013-10-31|March 2002|Actual|2002-03-31|||||Interventional|||Growth Hormone in the Treatment of HIV-Associated Wasting|A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting|Completed||Phase 3|||EMD Serono|||||f||||||||||||||2018-06-01 03:08:36.13438|2018-06-01 03:08:36.13438
NCT00489515|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-05-25|2007-06-20|2007-06-21|Estimate|||||||2017-05-25|2017-05-30|Actual|February 1999||1999-02-28|February 2017|2017-02-28|August 2010|Actual|2010-08-31|June 2009|Actual|2009-06-30||Observational|||Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder|Visceral Lymphatic Mapping Project: A Pilot Study|Completed|||115|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-06-01 03:08:36.196957|2018-06-01 03:08:36.196957
NCT00489502|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|June 2007||2007-06-30|June 2007|2007-06-30||||||||Observational|||Clinical Observation of Implementing the MedGem Into a Medical Specialty Practice|Phase I: Clinical Observation of Implementing the MedGem Into a Medical Specialty (i.e. Cardiology) Practice|Unknown status|Recruiting||30|Anticipated|Microlife|||||f||||f||||||||||2018-06-01 03:08:36.26861|2018-06-01 03:08:36.26861
NCT00489489|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2012-10-03|2010-09-30|2012-11-05|2007-06-20|2007-06-21|Estimate|2012-10-03|2012-11-02|Estimate|2010-09-30|2010-10-05|Estimate|2012-11-05|2012-11-06|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis|A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Interferon-beta in Subjects With Multiple Sclerosis.|Completed||Phase 2|118|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 03:08:36.356639|2018-06-01 03:08:36.356639
NCT00489476|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2017-03-13||2017-06-13|2007-06-20|2007-06-21|Estimate|2017-03-13|2017-04-24|Actual||||2017-06-13|2017-07-06|Actual|June 2007||2007-06-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional||Safety Population|Staccato Loxapine in Migraine (in Clinic)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Migraine Headache|Completed||Phase 2|168|Actual|Alexza Pharmaceuticals, Inc.||4|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 03:08:37.009593|2018-06-01 03:08:37.009593
NCT00489463|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|January 2004||2004-01-31|January 2006|2006-01-31|November 2006|Actual|2006-11-30|||||Interventional|||IUD Uterine Vascularization and Side Effects|The Effect of the Levonorgestrel-Releasing Intrauterine System and the Copper-Intrauterine Device (TCu 380A) on Subendometrial Microvascularization and Uterine Artery Blood Flow.|Completed||N/A|63|Actual|Hospital de Clinicas de Porto Alegre|||||f||||t||||||||||2018-06-01 03:08:37.389663|2018-06-01 03:08:37.389663
NCT00489450|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|May 2007|Actual|2007-05-31|||||Interventional|||Phase I Study to Investigate the Alcohol Interaction of SK3530|Clinical Trial to Investigate the Influence of Alcohol on the Pharmacokinetics and Safety of SK3530 in Healthy Male Volunteers|Completed||Phase 1|18|Actual|SK Chemicals Co.,Ltd.|||||f||||t||||||||||2018-06-01 03:08:37.524867|2018-06-01 03:08:37.524867
NCT00489437|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2013-09-09|2007-06-19|2007-06-21|Estimate|||||||2013-09-09|2013-09-10|Estimate|December 2007||2007-12-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Heparin-Induced Thrombocytopenia Score Card Study|Improving the Diagnosis of Heparin-Induced Thrombocytopenia: Utility of the 4T's Score and Evaluation of New Rapid Assays|Completed||Phase 1|536|Actual|McMaster University|||||f||||t||||||||||2018-06-01 03:08:37.588961|2018-06-01 03:08:37.588961
NCT00489424|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2009-08-06||2011-02-15|2007-06-20|2007-06-21|Estimate|2009-08-06|2009-09-14|Estimate||||2011-02-15|2011-02-18|Estimate|June 2007||2007-06-30|February 2011|2011-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass|A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group Study of Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an i.v. Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass|Completed||Phase 4|793|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:08:37.664672|2018-06-01 03:08:37.664672
NCT00489411|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2016-12-02||2017-03-16|2007-06-20|2007-06-21|Estimate|2017-03-16|2017-04-26|Actual||||2017-03-16|2017-04-26|Actual|April 2008||2008-04-30|March 2017|2017-03-31|March 2013|Actual|2013-03-31|January 2012|Actual|2012-01-31||Interventional||All patients who received duloxetine/placebo as randomized were included in the analysis population.|Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer|A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy|Completed||Phase 3|231|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 03:08:38.201828|2018-06-01 03:08:38.201828
NCT00489398|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2010-10-05|2007-06-20|2007-06-21|Estimate|||||||2010-10-05|2010-10-07|Estimate|July 2007||2007-07-31|October 2010|2010-10-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Comparison of CL Wear Between Two Allergy Drops|Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride|Withdrawn||Phase 4|25|Anticipated|Hom, Milton M., OD, FAAO||||Protocol changes|f||||t||||||||||2018-06-01 03:08:39.586432|2018-06-01 03:08:39.586432
NCT00489385|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-06-30|2007-06-20|2007-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 18, 2007||2007-06-18|January 25, 2012|2012-01-25|March 15, 2011|Actual|2011-03-15|March 15, 2011|Actual|2011-03-15||Interventional|||An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals|An Open Label Non-Randomized Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals|Completed||Phase 1|41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:08:39.642158|2018-06-01 03:08:39.642158
NCT00489372|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2014-11-13|2007-06-20|2007-06-21|Estimate|||||||2014-11-13|2014-11-14|Estimate|July 2007||2007-07-31|September 2014|2014-09-30|July 2009|Actual|2009-07-31|March 2008|Actual|2008-03-31||Interventional|||Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients|Phase I Study of Single Oral Dose of Se-Methyl-Seleno-L-Cysteine (MSC) in Adult Men|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 03:08:39.709594|2018-06-01 03:08:39.709594
NCT00489359|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2011-02-17||2011-05-17|2007-06-19|2007-06-21|Estimate|2011-05-17|2011-06-16|Estimate||||2011-05-17|2011-06-16|Estimate|July 2005||2005-07-31|May 2011|2011-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer|A Phase 1 and 2 Clinical Trial of ALIMTA® (Pemetrexed) in Combination With Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer|Completed||Phase 1/Phase 2|86|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:08:39.847868|2018-06-01 03:08:39.847868
NCT00489346|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-03-03|2007-06-20|2007-06-21|Estimate|||||||2017-03-03|2017-03-06|Actual|October 2001||2001-10-31|March 2017|2017-03-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)|A Double-Blind, Randomized, Double-Dummy, Multicenter Study to Evaluate and Compare Oral Montelukast and Inhaled Fluticasone in the Control of Asthma for 6- to 14-Year-Olds With Mild Persistent Asthma|Completed||Phase 3|994|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:08:41.025657|2018-06-01 03:08:41.025657
NCT00489333|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-19|2007-06-19|2007-06-21|Estimate|||||||2007-06-19|2007-06-21|Estimate|May 2006||2006-05-31|June 2007|2007-06-30|September 2006|Actual|2006-09-30|||||Interventional|||ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome|The Effects of ProAlgaZyme Novel Algae Infusion vs. Placebo on Metabolic Syndrome and Markers of Cardiovascular Health|Completed||N/A|52|Actual|Health Enhancement Products, Inc.|||||f||||f||||||||||2018-06-01 03:08:41.084914|2018-06-01 03:08:41.084914
NCT00489320|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-08-01|2007-06-20|2007-06-21|Estimate|||||||2007-08-01|2007-08-02|Estimate|December 2004||2004-12-31|August 2007|2007-08-31|July 2006|Actual|2006-07-31|||||Observational|DESCOVER||An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).|An Observational Registry Using Drug Eluting Stents (DES) in Patients in a Real-World Setting (DEScover Registry).|Completed|||7759|Actual|Cordis Corporation|||||f||||f||||||||||2018-06-01 03:08:41.20571|2018-06-01 03:08:41.20571
NCT00489307|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2017-11-09|2007-06-19|2007-06-21|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2006|Actual|2006-02-28|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Dexamethasone for Symptom Burden in Advanced Cancer Patients|The Effect of Dexamethasone on Symptoms in Patients With Advanced Cancer|Active, not recruiting||Phase 2|160|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 03:08:41.318735|2018-06-01 03:08:41.318735
NCT00489294|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2012-03-09|2007-06-19|2007-06-21|Estimate|||||||2012-03-09|2012-03-12|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency|An Open-Label Study of the Pharmacokinetics and Pharmacodynamics of Syntropin (a Human Growth Hormone) in Growth Hormone-Suppressed Healthy Volunteers|Completed||Phase 1|20|Actual|Phage Pharmaceuticals, Inc.|||||f||||t||||||||||2018-06-01 03:08:41.398631|2018-06-01 03:08:41.398631
NCT00489281|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-01-26|2007-06-20|2007-06-21|Estimate|||||||2017-01-26|2017-01-30|Estimate|May 2007||2007-05-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders|A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies|Active, not recruiting||Phase 2|42|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:08:41.470173|2018-06-01 03:08:41.470173
NCT00489268|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2011-03-07||2017-01-31|2007-06-20|2007-06-21|Estimate|2011-06-06|2011-06-30|Estimate||||2017-01-31|2017-03-13|Actual|November 2003||2003-11-30|January 2017|2017-01-31|October 2009|Actual|2009-10-31|February 2007|Actual|2007-02-28||Interventional|AIM||Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years|Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years|Completed||N/A|102|Actual|Medtronic - MITG|Study had no concurrent control arm, biopsy forceps were not standardized for all cases, the original patient group comprised 70 patients, whereas 69 and 61 patients were available at 1 and 2.5 years, respectively, 60 eligible patients at 5 years.|5|||f||||f||||||||||2018-06-01 03:08:41.582724|2018-06-01 03:08:41.582724
NCT00489099|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-03-15|2007-06-20|2007-06-21|Estimate|||||||2017-03-15|2017-03-16|Actual|June 2005||2005-06-30|March 2017|2017-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)|A Study in Healthy Young Adults To Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade|Completed||Phase 3|860|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 03:08:44.092777|2018-06-01 03:08:44.092777
NCT00489255|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2012-12-24||2014-05-22|2007-06-20|2007-06-21|Estimate|2013-04-09|2013-05-20|Estimate||||2014-05-22|2014-05-23|Estimate|May 2007||2007-05-31|May 2014|2014-05-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment|"A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Trimethobenzamide (Tigan®) in the Control of Nausea and Vomiting During Initiation and Continued Treatment With Subcutaneous Apomorphine (Apokyn®) in Apomorphine-naïve Subjects With Parkinson's Disease Suffering From Acute Intermittent Off Episodes, With Phased Withdrawal of Subjects From Tigan® to Placebo"|Completed||Phase 4|117|Actual|Ipsen||2|||f||||f||||||||||2018-06-01 03:08:42.091047|2018-06-01 03:08:42.091047
NCT00489242|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|August 2003||2003-08-31|June 2007|2007-06-30|September 2005|Actual|2005-09-30|||||Interventional|PREDICT||Prediction of CK-MB Release During Otherwise Successful Stenting Procedure|PREDICT Trial: Prediction of CK-MB Release During Otherwise Successful Stenting Procedure Correlating With Indicators of Microvascular Obstruction|Completed||N/A|72|Actual|Icahn School of Medicine at Mount Sinai|||||f||||||||||||||2018-06-01 03:08:42.867966|2018-06-01 03:08:42.867966
NCT00489229|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2009-07-15|2007-06-20|2007-06-21|Estimate|||||||2009-07-15|2009-07-16|Estimate|October 2002||2002-10-31|March 2007|2007-03-31|December 2005|Actual|2005-12-31|||||Interventional|||To Investigate the Effect of Rosiglitazone and Ramipril on Pre-clinical Vasculopathy in Diabetes and IGT Patients|Studies on Diabetic and Pre Diabetic Vascular Disease and the Effect of Selected Therapeutic Modalities on Associated Vasculopathy|Completed||Phase 3|66|Actual|University of Science Malaysia|||||f||||t||||||||||2018-06-01 03:08:42.921001|2018-06-01 03:08:42.921001
NCT00489216|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2017-02-21||2017-04-12|2007-06-20|2007-06-21|Estimate|2017-02-21|2017-04-06|Actual||||2017-04-12|2017-05-23|Actual|December 2006||2006-12-31|April 2017|2017-04-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|NRR|Patients with evidence of an inflammatory, erythematous rash and skin biopsy consistent with cutaneous Graft-Versus-Host disease who had failed to improve after at least 4 weeks of methylprednisolone at 0.5mg/kg were eligible for enrollment. Two patients were enrolled in the study.|Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids|Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Versus-Host Disease of the Skin and Liver|Terminated||N/A|2|Actual|UNC Lineberger Comprehensive Cancer Center|The study was terminated early due to funding withdrawal/insufficient accrual limiting the data to be analyzed.|1||insufficient accrual/funding withdrawn|f||||t||||||||||2018-06-01 03:08:43.009915|2018-06-01 03:08:43.009915
NCT00489203|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20||2011-09-21|2015-03-05|2007-06-20|2007-06-21|Estimate||||2011-09-21|2011-10-05|Estimate|2015-03-05|2015-03-26|Estimate|April 2007||2007-04-30|March 2015|2015-03-31||||November 2010|Actual|2010-11-30||Interventional|||Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens|Completed||Phase 2|140|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-06-01 03:08:43.201628|2018-06-01 03:08:43.201628
NCT00489190|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2009-03-13|2007-06-20|2007-06-21|Estimate|||||||2009-03-13|2009-03-16|Estimate|August 2005||2005-08-31|March 2009|2009-03-31||||||||Interventional|||APIDRA Registration Study|Local, Open, Non-Randomized, Phase IV Clinical Study for the Collection of Data Regarding the Drug Portability Received During the Treatment With Subcutaneous Injection of Apidra Glulisine (HMR1964) to Patients With Diabetes Mellitus 1st Type|Completed||Phase 4|45|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:08:43.450433|2018-06-01 03:08:43.450433
NCT00489177|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2015-11-17|2007-06-20|2007-06-21|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2007||2007-06-30|November 2015|2015-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|OPTIMISE-CRT||Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.|Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.|Completed||Phase 4|461|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 03:08:43.552444|2018-06-01 03:08:43.552444
NCT00489164|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2008-11-10|2007-06-20|2007-06-21|Estimate|||||||2008-11-10|2008-11-11|Estimate|August 2002||2002-08-31|November 2008|2008-11-30|May 2004|Actual|2004-05-31|||||Interventional|DECODE||Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions|A Randomized Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions (DECODE)|Terminated||Phase 1/Phase 2|83|Actual|Cordis Corporation|||||f||||t||||||||||2018-06-01 03:08:43.654138|2018-06-01 03:08:43.654138
NCT00489151|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2010-07-06|2007-06-20|2007-06-21|Estimate|||||||2010-07-06|2010-07-07|Estimate|June 2005||2005-06-30|July 2010|2010-07-31|December 2007|Anticipated|2007-12-31|||||Interventional|||A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy|A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy|Unknown status|Recruiting|N/A|70|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:08:43.733439|2018-06-01 03:08:43.733439
NCT00489138|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2014-02-24|2007-06-20|2007-06-21|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2007||2007-04-30|February 2014|2014-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Prospective, Open-label Study of Pharmacokinetics of Ertapenem in the Muscle Using Microdialysis in Mechanically Ventilated Intensive Care Unit Patients, Treated or Not by Norepinephrine||Terminated||Phase 4|9|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||||||||||||2018-06-01 03:08:43.826054|2018-06-01 03:08:43.826054
NCT00489125|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-10-26|2007-06-20|2007-06-21|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2005||2005-03-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer|Breast Clinic Strength and Range of Motion Study|Active, not recruiting|||275|Anticipated|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 03:08:43.893304|2018-06-01 03:08:43.893304
NCT00489112|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-25|2007-06-20|2007-06-21|Estimate|||||||2007-06-25|2007-06-26|Estimate||||June 2007|2007-06-30||||||||Interventional|||The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study||Unknown status|Recruiting|Phase 4|||HaEmek Medical Center, Israel|||||f||||t||||||||||2018-06-01 03:08:43.953472|2018-06-01 03:08:43.953472
NCT00488384|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2015-06-10|2007-06-19|2007-06-20|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|June 2018|Anticipated|2018-06-30|December 2014|Actual|2014-12-31||Interventional|||Acitretin Plasma Levels Under Hemodialysis|Acitretin Plasma Levels Under Hemodialysis|Suspended||Phase 4|2009|Anticipated|University of Zurich||1||lack of subjects|f||||f||||||||||2018-06-01 03:09:07.076381|2018-06-01 03:09:07.076381
NCT00489086|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|2013-07-31||2016-01-13|2007-06-20|2007-06-21|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|July 2004||2004-07-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face|A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome|Completed||Phase 2|36|Actual|Children's Hospital & Research Center Oakland|34 pts. were included in the analysis of the primary endpoint. 23 pts. completed 18 months (68%). Only 2 of 34 patients achieved complete resolution (CR = 5.9%). 13 pts. completed 36 month trial (first 18 months tazarotene, months 19-36 observation).|1|||f||||f||||||||||2018-06-01 03:08:44.189789|2018-06-01 03:08:44.189789
NCT00489073|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-19|2007-06-19|2007-06-21|Estimate|||||||2007-06-19|2007-06-21|Estimate|November 2002||2002-11-30|June 2007|2007-06-30|December 2003|Actual|2003-12-31|||||Interventional|||Duloxetine Versus Placebo for Fibromyalgia|Duloxetine Versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder|Completed||Phase 3|345||Eli Lilly and Company|||||||||f||||||||||2018-06-01 03:08:44.383042|2018-06-01 03:08:44.383042
NCT00489060|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2008-07-16|2007-06-20|2007-06-21|Estimate|||||||2008-07-16|2008-07-17|Estimate|December 1997||1997-12-31|July 2008|2008-07-31|April 2007|Actual|2007-04-30|||||Interventional|||A Randomized Trial of External Beam Radiotherapy Versus Cryoablation in Patients With Localized Prostate Cancer|A Randomized Trial of External Beam Radiotherapy Versus Cryoablation in Patients With Clinically Localized Prostate Cancer|Completed||Phase 3|244|Actual|University of Calgary|||||f||||t||||||||||2018-06-01 03:08:44.455674|2018-06-01 03:08:44.455674
NCT00489034|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2017-03-02|2007-06-19|2007-06-21|Estimate|||||||2017-03-02|2017-03-06|Actual|July 2003||2003-07-31|August 2016|2016-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Engaging Care for HIV-infected Adolescent Females.|Drug Use and HIV-Infected Female Adolescents' Care Use|Completed|||178|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||No||2018-06-01 03:08:44.541177|2018-06-01 03:08:44.541177
NCT00489021|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2007-06-20|2007-06-20|2007-06-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|July 2007||2007-07-31|June 2007|2007-06-30|August 2007|Anticipated|2007-08-31|||||Interventional|||Feasibility and Outcomes of Older Patients Hospitalization||Unknown status|Not yet recruiting|N/A|300|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-06-01 03:08:44.640351|2018-06-01 03:08:44.640351
NCT00489008|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-20|||2017-06-08|2007-06-20|2007-06-21|Estimate|||||||2017-06-08|2017-06-09|Actual|November 21, 2005|Actual|2005-11-21|June 2017|2017-06-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||SRS Study in Patients With Non-Small Cell Lung Cancer|Phase II Stereotactic Body Radiotherapy for Stage I (T1-T2, N0, M0), Selective Stage II (Chest Wall T3, N0M0) or Isolated Peripheral Lung Recurrent Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|141|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 03:08:44.703631|2018-06-01 03:08:44.703631
NCT00488995|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2015-03-10|2007-06-19|2007-06-20|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2007||2007-07-31|March 2015|2015-03-31||||||||Interventional|||Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients|A Phase 2 Study To Evaluate The Safety, Tolerability, Virologic And Immunologic Effect Of Single-Dose CP-675,206 In Patients Infected With Human Immunodeficiency Virus|Withdrawn||Phase 2|0|Actual|Pfizer|||||||||||||||||||2018-06-01 03:08:44.79033|2018-06-01 03:08:44.79033
NCT00488982|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2016-10-26|2007-06-19|2007-06-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC|A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy With Maintenance GM-CSF in Patients With Previously Untreated Hormone Refractory Prostate Cancer|Completed||Phase 2|125|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 03:08:44.866616|2018-06-01 03:08:44.866616
NCT00488969|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2016-03-18|2007-06-19|2007-06-20|Estimate|||||||2016-03-18|2016-03-22|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury|Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury|Completed||Phase 2|17|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 03:08:44.953489|2018-06-01 03:08:44.953489
NCT00488956|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2014-03-14|2007-06-18|2007-06-20|Estimate|||||||2014-03-14|2014-03-18|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Foot and Ankle Edema Post-Cesarean Delivery|Foot and Ankle Edema Post-Cesarean Delivery|Completed|||35|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:08:45.062128|2018-06-01 03:08:45.062128
NCT00488943|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2012-06-28|2007-06-19|2007-06-20|Estimate|||||||2012-06-28|2012-07-02|Estimate|January 2005||2005-01-31|June 2012|2012-06-30||||December 2009|Actual|2009-12-31||Observational|||Follow-up After Endovascular Repair of Abdominal Aortic Aneurysm|Follow-up After Endovascular Repair of Abdominal Aortic Aneurysm|Completed|||300|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:08:45.120875|2018-06-01 03:08:45.120875
NCT00488930|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2016-10-24|2007-06-18|2007-06-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Characteristics of Dendritic Cells Before and After Gastric Banding|Characteristics of Dendritic Cells Before and After Gastric Banding|Terminated|||7|Actual|University of California, San Diego||||Terminated due to a lack of recruitment and decision by the PI not to continue.|f||||f||||||||||2018-06-01 03:08:45.188633|2018-06-01 03:08:45.188633
NCT00488917|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2009-09-02|2007-06-19|2007-06-20|Estimate|||||||2009-09-02|2009-09-03|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|SELLIFA||Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)|Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)|Completed|||167|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||t||||||Samples Without DNA|"~     plasma, urine, ascites fluid.~   "|||2018-06-01 03:08:45.262875|2018-06-01 03:08:45.262875
NCT00488904|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2010-04-09|2007-06-19|2007-06-20|Estimate|||||||2010-04-09|2010-04-12|Estimate|June 2007||2007-06-30|April 2010|2010-04-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|omega3||Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery|Omega-3 Fatty Acids and Postoperative Complication After Colorectal Surgery|Completed||Phase 4|148|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-06-01 03:08:45.330737|2018-06-01 03:08:45.330737
NCT00488371|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2007-12-16|2007-06-19|2007-06-20|Estimate|||||||2007-12-16|2007-12-20|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Observational|||Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®|Evaluation of Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Pneumococcal Conjugated Vaccine (Prevnar®) Under the Auspices of the Taipei City Government Vaccination Program|Completed|||250||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 03:09:07.164495|2018-06-01 03:09:07.164495
NCT00488891|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2012-08-28|2007-06-19|2007-06-20|Estimate|||||||2012-08-28|2012-08-29|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|POST||The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia|The Paliperidone ER Outcomes Study of Schizophrenia Patients in Typical Clinical Practice|Terminated|||43|Actual|Ortho-McNeil Janssen Scientific Affairs, LLC|||2|The study was terminated because it was not enrolling at the expected rate|f||||f||||||Samples With DNA|"~     10 mL blood sample is collected from patients who consent to the pharmacogenomic component of~     the study.~   "|||2018-06-01 03:08:45.407384|2018-06-01 03:08:45.407384
NCT00488878|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2017-08-16|2007-06-19|2007-06-20|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2006|Actual|2006-05-31|August 2017|2017-08-31|May 2034|Anticipated|2034-05-31|May 2034|Anticipated|2034-05-31||Observational|||Data Collection for Patients With Low Grade Ovarian Carcinoma|Data Collection for Patients With Low Grade Ovarian Carcinoma|Recruiting|||2000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     If patient gives consent, tumor tissue left over from earlier surgery or surgeries that is~     preserved in wax or on glass slides will be stored in a research tissue bank.~   "|||2018-06-01 03:08:45.48243|2018-06-01 03:08:45.48243
NCT00488865|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2010-05-03||2010-08-04|2007-06-19|2007-06-20|Estimate|2010-07-07|2010-08-05|Estimate||||2010-08-04|2010-08-10|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||RexMedical- Option* Vena Cava Filter IDE Study|RexMedical- Option* Vena Cava Filter IDE Study|Completed||N/A|100|Actual|Rex Medical||1|||f||||t||||||||||2018-06-01 03:08:45.563079|2018-06-01 03:08:45.563079
NCT00488839|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18||2013-09-27|2017-02-09|2007-06-19|2007-06-20|Estimate||||2015-09-08|2015-09-22|Estimate|2017-02-09|2017-02-13|Actual|June 2007||2007-06-30|February 2017|2017-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis|A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the PK and PD of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis|Completed||Phase 3|173|Actual|IMPAX Laboratories, Inc.||4|||f||||f||||||||No||2018-06-01 03:08:45.702997|2018-06-01 03:08:45.702997
NCT00488826|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2009-03-31||2010-01-15|2007-06-18|2007-06-20|Estimate|2009-03-31|2009-05-27|Estimate||||2010-01-15|2010-01-20|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants|An Open-Label Controlled Phase I/III Study to Evaluate the Safety and Immunogenicity of Pneumococcal 7-Valent Conjugate Vaccine [DIPHTHERIA CRM197 PROTEIN] (PrevenarTM) in Healthy Infants|Completed||Phase 1|800|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:08:45.942248|2018-06-01 03:08:45.942248
NCT00488813|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2009-09-04|2007-06-19|2007-06-20|Estimate|||||||2009-09-04|2009-09-09|Estimate|July 2004||2004-07-31|September 2009|2009-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Study of Antibiotic Utilization Measures and Control of ESBLs in China|Association of Antibiotic Utilization Measures and Control of Extended-spectrum β-lactamases (ESBLs) in MICU1 and MICU2 at Buddhist Tzu Chi General Hospital.|Completed||Phase 4|300||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:08:46.25026|2018-06-01 03:08:46.25026
NCT00488800|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2007-12-20|2007-06-19|2007-06-20|Estimate|||||||2007-12-20|2007-12-28|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Safety and Local Tolerability of Prevenar in Indian Children|A Postmarketing Surveillance Study Evaluating the Safety and Local Tolerance of PREVENAR in Indian Children|Completed|||1000||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:08:46.295158|2018-06-01 03:08:46.295158
NCT00488787|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2008-02-05|2007-06-19|2007-06-20|Estimate|||||||2008-02-05|2008-02-07|Estimate|March 2001||2001-03-31|February 2008|2008-02-29|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Safety and Efficacy of 10 mg, 30 mg, and 50 mg of Transnasal Ketamine Hydrochloride (PMI-100) for the Treatment of Postoperative Dental Pain|Completed||Phase 2|40|Actual|Javelin Pharmaceuticals||4|||f||||f||||||||||2018-06-01 03:08:46.337386|2018-06-01 03:08:46.337386
NCT00488774|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2013-04-29|2009-12-03|2013-04-29|2007-06-18|2007-06-20|Estimate|2013-04-29|2013-06-14|Estimate|2009-12-03|2010-03-04|Estimate|2013-04-29|2013-06-14|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis|A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis|Terminated||Phase 2/Phase 3|291|Actual|Janssen Research & Development, LLC|Data collection was not considered complete for primary outcome measure because study was terminated prematurely.|4||Protocol was cancelled by company based on overall efficacy, no safety concern|f||||t||||||||||2018-06-01 03:08:46.422576|2018-06-01 03:08:46.422576
NCT00488761|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2007-12-21|2007-06-18|2007-06-20|Estimate|||||||2007-12-21|2007-12-28|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI|A Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Tigecycline to Treat Complicated Skin and Skin Structure Infections (cSSSI) in Hospitalized Patients|Completed||Phase 4|50|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:08:48.04005|2018-06-01 03:08:48.04005
NCT00488748|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18||2014-11-10|2015-01-16|2007-06-19|2007-06-20|Estimate||||2015-01-16|2015-01-28|Estimate|2015-01-16|2015-01-28|Estimate|June 2007||2007-06-30|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Magnetic Seizure Therapy (MST) for Severe Mood Disorder|Magnetic Seizure Therapy (MST) for the Treatment of Severe Mood Disorder|Completed||Phase 3|75|Actual|Duke University||2|||f||||f||||||||||2018-06-01 03:08:48.117357|2018-06-01 03:08:48.117357
NCT00488735|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2010-05-06|2007-06-19|2007-06-20|Estimate|||||||2010-05-06|2010-05-07|Estimate|August 2000||2000-08-31|June 2007|2007-06-30|July 2005|Actual|2005-07-31|||||Interventional|||Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation vs. Traditional Primary Care|Subacute and Chronic, Non-specific Back and Neck Pain: Cognitive-behavioral Rehabilitation Compared With Traditional Primary Care Concerning Sick-listing and Health-care Visits. A Randomized Controlled Trial, 18-month Follow-up|Completed||N/A|125|Actual|Karolinska Institutet|||||f||||f||||||||||2018-06-01 03:08:48.207751|2018-06-01 03:08:48.207751
NCT00488358|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2013-10-08|2007-06-19|2007-06-20|Estimate|||||||2013-10-08|2013-10-09|Estimate|November 2005||2005-11-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|January 2010|Actual|2010-01-31||Observational|||Hemodynamic Changes After Aortic Aneurysm Treatment With Stent-Graft|Hemodynamic Changes After Aortic Aneurysm Treatment With Stent-Graft|Completed|||10|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:09:07.235045|2018-06-01 03:09:07.235045
NCT00488722|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2007-06-25|2007-06-19|2007-06-20|Estimate|||||||2007-06-25|2007-06-26|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|March 2009||2009-03-31|||||Interventional|||A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer|A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer|Unknown status|Recruiting|N/A|||Tianjin Medical University|||||f||||t||||||||||2018-06-01 03:08:48.324759|2018-06-01 03:08:48.324759
NCT00488709|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2008-11-17|2007-06-19|2007-06-20|Estimate|||||||2008-11-17|2008-11-18|Estimate|May 2003||2003-05-31|November 2008|2008-11-30|April 2007|Actual|2007-04-30|||||Interventional|FLAT||Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia|Completed||Phase 4|47|Actual|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:08:48.443898|2018-06-01 03:08:48.443898
NCT00488696|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2018-01-12|2007-06-18|2007-06-20|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2006||2006-10-31|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||Branched Aortic Arch Study|Branched Stent-Graft Repair for Endo Repair of Aneurysms Involving the Proximal Aortic Arch|Recruiting||Phase 1/Phase 2|25|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 03:08:48.562808|2018-06-01 03:08:48.562808
NCT00488683|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2013-05-30|2010-04-16|2014-09-18|2007-06-19|2007-06-20|Estimate|2014-07-24|2014-08-15|Estimate|2010-04-16|2010-04-20|Estimate|2014-09-18|2014-10-01|Estimate|July 2007||2007-07-31|September 2014|2014-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional||Analysis was done on all enrolled subjects.|B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants|A Phase II, Single Center, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants|Completed||Phase 2|216|Actual|Novartis||3|||f||||f||||||||||2018-06-01 03:08:49.669869|2018-06-01 03:08:49.669869
NCT00488670|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2011-06-02|2007-06-19|2007-06-20|Estimate|||||||2011-06-02|2011-06-06|Estimate|December 2010||2010-12-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Escitalopram and Depression in Elderly Alzheimer's Patients|An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease|Terminated||Phase 3|50|Anticipated|University of British Columbia||||"Dr. Rabheru left VCH last year and the study was cancelled according to his research~   coordinator."|f||||f||||||||||2018-06-01 03:08:52.243455|2018-06-01 03:08:52.243455
NCT00488657|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2013-01-17|2007-06-18|2007-06-20|Estimate|||||||2013-01-17|2013-01-18|Estimate|June 2006||2006-06-30|January 2013|2013-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|MJFFSpeech||Improve Speech Using an In-the-ear Device in Parkinson's Disease|Treating Speech Disorders in Patients With Parkinson's Disease Using Altered Auditory Feedback|Completed||Phase 1|40|Actual|Rush University Medical Center||1|||f||||f||||||||||2018-06-01 03:08:52.301009|2018-06-01 03:08:52.301009
NCT00488644|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2012-03-22||2013-06-14|2007-06-19|2007-06-20|Estimate|2012-06-13|2012-07-17|Estimate||||2013-06-14|2013-06-24|Estimate|February 2006||2006-02-28|June 2013|2013-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors|Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors|Terminated||N/A|12|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 03:08:52.375429|2018-06-01 03:08:52.375429
NCT00488631|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2013-05-01|2012-03-12|2016-03-24|2007-06-18|2007-06-20|Estimate|2013-10-14|2013-11-11|Estimate|2012-03-12|2012-03-14|Estimate|2016-03-24|2016-04-26|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|October 2011|Actual|2011-10-31||Interventional|||An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 3|1228|Actual|Janssen Research & Development, LLC||6|||f||||t||||||||||2018-06-01 03:08:52.817105|2018-06-01 03:08:52.817105
NCT00488618|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2017-03-01|2012-03-02|2017-03-01|2007-06-19|2007-06-20|Estimate|2017-03-01|2017-04-14|Actual|2012-03-02|2012-03-06|Estimate|2017-03-01|2017-04-14|Actual|June 2007||2007-06-30|March 2017|2017-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Safety population included all participants who received at least 1 dose of study drug.|Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in Patients With Acute Mania Associated With Bipolar I Disorder|Completed||Phase 2|238|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 03:08:59.677158|2018-06-01 03:08:59.677158
NCT00488605|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2016-05-10|2007-06-18|2007-06-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2004||2004-02-29|May 2016|2016-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis|H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis|Completed||Phase 3|476|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-06-01 03:09:00.043113|2018-06-01 03:09:00.043113
NCT00488592|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|2013-04-30||2014-06-05|2007-06-19|2007-06-20|Estimate|2014-06-05|2014-07-09|Estimate||||2014-06-05|2014-07-09|Estimate|June 2007||2007-06-30|June 2014|2014-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers|Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)|"Although not tested or described formally, no clinically meaningful hematological responses were seen.~Despite boosting, cellular immune responses were only transient."|1|||f||||t||||||||||2018-06-01 03:09:00.12636|2018-06-01 03:09:00.12636
NCT00488579|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2017-11-29|2007-06-19|2007-06-20|Estimate|||||||2017-11-29|2017-11-30|Actual|May 2007||2007-05-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|December 2007|Actual|2007-12-31||Interventional|PROFEG||Routine Iron Prophylaxis During Pregnancy|Routine Iron Prophylaxis During Pregnancy - Effects on Maternal and Child Health in Maputo City and Province (Mozambique)|Completed||Phase 4|4326|Actual|National Istitute For Health and Welfare, Finland||2|||f||||f||||||||No||2018-06-01 03:09:00.339818|2018-06-01 03:09:00.339818
NCT00488566|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2017-10-25|2007-06-19|2007-06-20|Estimate|||||||2017-10-25|2017-10-26|Actual|May 31, 2007|Actual|2007-05-31|October 2017|2017-10-31|May 31, 2008|Actual|2008-05-31|May 31, 2008|Actual|2008-05-31||Interventional|||GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers|Double Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of GSK Drug and the Effect of Single Doses of GSK Drug or Lamotrigine on Resting Motor Threshold in Healthy Volunteers|Completed||Phase 1|50|Actual|Biogen||2|||f||||f||||||||||2018-06-01 03:09:00.590416|2018-06-01 03:09:00.590416
NCT00488553|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2012-02-23|2007-06-19|2007-06-20|Estimate|||||||2012-02-23|2012-02-24|Estimate|August 2006||2006-08-31|February 2012|2012-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Molecular Epidemiology of Lymphoma Patients|Molecular Epidemiology of Lymphoma Patients|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||2|No participants recruited, study discontinued.|f||||f||||||Samples With DNA|"~     Subjects will also provide 30 cc of blood. The blood will be genotyped, and the genotype and~     epidemiological data will be used to evaluate the role of genomic instability (baseline and~     induced) in the development of lymphomas.~   "|||2018-06-01 03:09:00.687932|2018-06-01 03:09:00.687932
NCT00488540|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2017-02-07|2007-06-19|2007-06-20|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2007||2007-06-30|February 2017|2017-02-28|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||Is Paracetamol an Effective Treatment for Chronic Moderate Pain in the Newborn After Operative Vaginal Delivery?|Is Paracetamol an Effective Treatment for Chronic Moderate Pain in the Newborn After Operative Vaginal Delivery?|Completed||Phase 4|280|Anticipated|Basel Women’s University Hospital||2|||f||||f||||||||||2018-06-01 03:09:00.764718|2018-06-01 03:09:00.764718
NCT00488527|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2010-09-10|2007-06-19|2007-06-20|Estimate|||||||2010-09-10|2010-09-13|Estimate|April 2007||2007-04-30|September 2010|2010-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|DOMME||DOMME Dose Optimization Multicentric Mexican Evaluation|Multicentric, Open Label Clinical Trial. Use of Optimal Method to Initiate and Maintain Lantus Therapy (Insulin Glargine) in Combination With Hypoglycemic Agents, Assessing the Resulting Metabolic Control and the Safety in T2 Diabetes Mellitus Patients.|Completed||Phase 4|371|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:09:00.856977|2018-06-01 03:09:00.856977
NCT00488514|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2010-08-06||2017-04-17|2007-06-19|2007-06-20|Estimate|2010-08-06|2010-09-06|Estimate||||2017-04-17|2017-05-18|Actual|July 13, 2007||2007-07-13|October 2016|2016-10-31|August 20, 2009|Actual|2009-08-20|August 1, 2009|Actual|2009-08-01||Interventional|||Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents|Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents|Completed||Phase 3|656|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:09:01.096716|2018-06-01 03:09:01.096716
NCT00488501|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2009-11-09|2007-06-19|2007-06-20|Estimate|||||||2009-11-09|2009-11-10|Estimate|July 2007||2007-07-31|November 2009|2009-11-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Clinical Usefulness and Efficacy of Intrathoracic Impedance Monitoring Using the OptiVol Patient Alert(TM)|Clinical Usefulness and Efficacy of Intrathoracic Impedance Monitoring Using the OptiVol Patient Alert(TM) in Medtronic(R) ICD's for Early Detection of Decompensated Heart Failure|Completed|||29|Actual|Catharina Ziekenhuis Eindhoven|||||f||||f||||||||||2018-06-01 03:09:02.827176|2018-06-01 03:09:02.827176
NCT00488488|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2011-03-29||2011-07-20|2007-06-19|2007-06-20|Estimate|2011-06-17|2011-07-18|Estimate||||2011-07-20|2011-07-22|Estimate|November 2006||2006-11-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting|A Non-Interventional Study To Evaluate The Safety And Effectiveness Of Tygacil In The Treatment Of Patients With Complicated Intra-Abdominal Infections Or Complicated Skin And Skin Structure Infections|Completed|||1028|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:09:03.010415|2018-06-01 03:09:03.010415
NCT00488475|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2014-04-16||2014-07-25|2007-06-19|2007-06-20|Estimate|2014-04-16|2014-05-15|Estimate||||2014-07-25|2014-08-01|Estimate|September 2006||2006-09-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational||Safety population included all participants with available documentations.|Observational Trial With Enbrel|A 1 Year Observational Study of the Use of Etanercept in Routine German Clinical Practice to Treat Rheumatoid Arthritis Patients: a Health Economic, Safety and Effectiveness Evaluation|Completed|||4945|Actual|Pfizer|Prioritization of endpoints as primary or secondary was not specified in protocol and was based on study team's inputs.||1||f||||f||||||||||2018-06-01 03:09:04.000931|2018-06-01 03:09:04.000931
NCT00488462|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2015-01-16|2007-06-19|2007-06-20|Estimate|||||||2015-01-16|2015-01-21|Estimate|October 2007||2007-10-31|January 2015|2015-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|NASG||Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe|Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe|Completed||N/A|887|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 03:09:06.482506|2018-06-01 03:09:06.482506
NCT00488449|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2012-05-31|2007-06-19|2007-06-20|Estimate|||||||2012-05-31|2012-06-04|Estimate|June 2007||2007-06-30|February 2011|2011-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers|A Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK256073A, in a Randomized, Single-Blind, Dose Escalation Study in Healthy Adult Subjects|Completed||Phase 1|56|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:09:06.584215|2018-06-01 03:09:06.584215
NCT00488436|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2008-11-17|2007-06-19|2007-06-20|Estimate|||||||2008-11-17|2008-11-19|Estimate|May 2002||2002-05-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome|SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome|Completed||Phase 4|25|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:09:06.677042|2018-06-01 03:09:06.677042
NCT00488423|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2011-06-21|2007-06-19|2007-06-20|Estimate|||||||2011-06-21|2011-06-22|Estimate|November 2006||2006-11-30|June 2011|2011-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|MIDAS||Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery|Glucose Metabolism in the Immediate and Short Term Follow up From Bariatric Surgery|Completed||Phase 1|21|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 03:09:06.785474|2018-06-01 03:09:06.785474
NCT00488410|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2010-09-06|2007-06-19|2007-06-20|Estimate|||||||2010-09-06|2010-09-08|Estimate|November 2006||2006-11-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||SYNCHRO. Evaluation of the Forecasts Parameters of Real Time-three-dimensional Doppler Echocardiography in Selecting Patients With Chronic Heart Failure for Cardiac Resynchronisation Therapy|Evaluation of the Forecasts Parameters of Real Time Three-dimensional Doppler Echocardiography in Selecting Patients With Chronic Heart Failure for Cardiac Resynchronisation Therapy|Completed||N/A|||University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:09:06.929793|2018-06-01 03:09:06.929793
NCT00488397|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2011-03-21|2007-06-18|2007-06-20|Estimate|||||||2011-03-21|2011-03-22|Estimate|August 2006||2006-08-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Tigecycline In-Vitro Surveillance Study In Taiwan|Tigecycline In-Vitro Surveillance Study In Taiwan|Completed|||7902|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 03:09:07.001265|2018-06-01 03:09:07.001265
NCT00488345|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2010-09-01||2012-09-12|2007-06-18|2007-06-20|Estimate|2012-09-12|2012-10-24|Estimate||||2012-09-12|2012-10-24|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age|A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections|Completed||Phase 2|59|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 03:09:07.309097|2018-06-01 03:09:07.309097
NCT00488332|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2012-07-18|2007-06-19|2007-06-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|March 2006||2006-03-31|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||An Exploratory Study on Optical Assessment of Oral Mucositis|An Exploratory Study on Optical Assessment of Oral Mucositis|Terminated|||2|Actual|M.D. Anderson Cancer Center|||1|Terminated due to slow accrual.|f||||f||||||||||2018-06-01 03:09:07.877849|2018-06-01 03:09:07.877849
NCT00488319|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2013-07-12||2016-12-19|2007-06-19|2007-06-20|Estimate|2013-11-12|2014-01-06|Estimate||||2016-12-19|2017-02-10|Actual|June 2007||2007-06-30|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.|A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia|Completed||Phase 3|400|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-06-01 03:09:08.016661|2018-06-01 03:09:08.016661
NCT00488306|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2009-07-06|2007-06-18|2007-06-20|Estimate|||||||2009-07-06|2009-07-07|Estimate|August 2006||2006-08-31|July 2009|2009-07-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI|A Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Tigecycline to Treat Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Patients|Completed||Phase 4|50|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:09:09.212945|2018-06-01 03:09:09.212945
NCT00488293|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2014-11-03||2015-05-11|2007-06-19|2007-06-20|Estimate|2014-12-05|2014-12-15|Estimate||||2015-05-11|2015-06-08|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional||One patient assigned to teledermatology was misrandomized and not included in the analysis.|Impact of Teledermatology on Health Services Outcomes in the Department of Veterans Affairs|Impact of Teledermatology on Health Services Outcomes in the VA|Completed||N/A|392|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:09:09.462802|2018-06-01 03:09:09.462802
NCT00488280|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2013-01-07|2007-06-19|2007-06-20|Estimate|||||||2013-01-07|2013-01-08|Estimate|February 2007||2007-02-28|January 2010|2010-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Restoring Walking in Non-ambulatory Children With Severe Chronic Spinal Cord Injury (SCI) (Kids STEP Study)|Restoring Walking in Non-ambulatory Children With Severe Chronic SCI (Kids STEP Study)|Completed||Phase 1|7|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 03:09:09.912004|2018-06-01 03:09:09.912004
NCT00488267|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18||2012-03-14|2012-05-17|2007-06-18|2007-06-20|Estimate||||2012-05-17|2012-05-30|Estimate|2012-05-17|2012-05-30|Estimate|June 2007||2007-06-30|May 2012|2012-05-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee|A Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy of ThermoProfen™ in the Treatment of Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee (ZMK-301)|Completed||Phase 3|679|Actual|ZARS Pharma Inc.||3|||f||||f||||||||||2018-06-01 03:09:10.008104|2018-06-01 03:09:10.008104
NCT00488254|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2011-04-12|2007-06-19|2007-06-20|Estimate|||||||2011-04-12|2011-04-14|Estimate|June 2007||2007-06-30|April 2011|2011-04-30|April 2008|Actual|2008-04-30|||||Observational|||The Long QT Syndrome in Pregnancy|The Long QT Syndrome in Pregnancy|Completed|||12|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:09:10.241912|2018-06-01 03:09:10.241912
NCT00488241|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2014-02-25|2007-06-19|2007-06-20|Estimate|||||||2014-02-25|2014-02-26|Estimate|June 2007||2007-06-30|February 2014|2014-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema|A Multicenter, Open Uncontrolled Clinical Study to Examine the Efficacy and Safety of Zarzenda in the Management of Hand Eczema|Completed||Phase 4|40|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:09:10.329235|2018-06-01 03:09:10.329235
NCT00488228|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2012-04-12|2007-06-18|2007-06-20|Estimate|||||||2012-04-12|2012-04-13|Estimate|April 2007||2007-04-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Behavioral Self-Regulation|Behavioral Self-Regulation for Weight Loss in Young Adults|Completed||N/A|41|Anticipated|The Miriam Hospital||2|||f||||||||||||||2018-06-01 03:09:10.420706|2018-06-01 03:09:10.420706
NCT00488215|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2008-05-28|2007-06-19|2007-06-20|Estimate|||||||2008-05-28|2008-05-29|Estimate|January 2000||2000-01-31|June 2007|2007-06-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of Prucalopride|A Double-Blind, Placebo-Controlled, 2-Way Cross-Over Trial in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Oral Prucalopride at Steady State, After up-Titration to a Maximum of 20 mg.|Completed||Phase 1|32|Actual|Movetis||2|||f||||f||||||||||2018-06-01 03:09:10.497096|2018-06-01 03:09:10.497096
NCT00488202|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2017-05-30|2007-06-19|2007-06-20|Estimate|||||||2017-05-30|2017-06-01|Actual|May 2007||2007-05-31|May 2017|2017-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|ANOVA1||Advanced Ovarian Cancer and Sexuality Phase 1|Advanced Ovarian Cancer and Sexuality Phase 1|Completed|||26|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:09:10.589749|2018-06-01 03:09:10.589749
NCT00488189|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2011-04-14|2007-06-18|2007-06-20|Estimate|||||||2011-04-14|2011-04-15|Estimate|May 2007||2007-05-31|June 2010|2010-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study Evaluation Tazocin Intervention|Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria|Completed||Phase 4|134|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:09:10.654555|2018-06-01 03:09:10.654555
NCT00488176|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-19|||2013-02-06|2007-06-19|2007-06-20|Estimate|||||||2013-02-06|2013-02-07|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis|Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation Measured by Exhaled Nitric Oxide Concentration in Children With Seasonal Allergic Rhinitis|Unknown status|Recruiting|Phase 4|116|Anticipated|Medical Universtity of Lodz||4|||f||||t||||||||||2018-06-01 03:09:10.738278|2018-06-01 03:09:10.738278
NCT00488163|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2017-10-03|2007-06-18|2007-06-20|Estimate|||||||2017-10-03|2017-10-05|Actual|January 2005||2005-01-31|October 2017|2017-10-31|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia|Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia|Completed||Phase 4|20|Actual|Research Foundation for Mental Hygiene, Inc.||2|||f||||f||||||||No||2018-06-01 03:09:10.87238|2018-06-01 03:09:10.87238
NCT00488137|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2013-09-25|2007-06-18|2007-06-19|Estimate|||||||2013-09-25|2013-09-26|Estimate|March 1998||1998-03-31|September 2013|2013-09-30|July 1999|Actual|1999-07-31|July 1999|Actual|1999-07-31||Interventional|||Efficacy and Safety Study of Prucalopride to Treat Chronic Constipation|A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation|Completed||Phase 3|716|Actual|Movetis||3|||f||||f||||||||||2018-06-01 03:09:10.963814|2018-06-01 03:09:10.963814
NCT00488124|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2011-03-29|2007-06-18|2007-06-19|Estimate|||||||2011-03-29|2011-03-30|Estimate|November 2005||2005-11-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|ISS||Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin|Evaluation of Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin: A Prospective, Longitudinal Non-randomised, Open, Phase II Study|Completed||Phase 2|120|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 03:09:11.046283|2018-06-01 03:09:11.046283
NCT00488111|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2008-08-12|2007-06-18|2007-06-19|Estimate|||||||2008-08-12|2008-08-14|Estimate|May 2007||2007-05-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|FMCS||Fluid Management for Cesarean Section|Fluid Management With Ringer's and 6% Starch for Cesarean Section After Epidural or Spinal Anesthesia|Completed||N/A|850|Actual|Nanjing Medical University||2|||f||||f||||||||||2018-06-01 03:09:11.137015|2018-06-01 03:09:11.137015
NCT00488098|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2012-05-31|2007-06-15|2007-06-19|Estimate|||||||2012-05-31|2012-06-04|Estimate|July 2007||2007-07-31|February 2011|2011-02-28||||||||Interventional|||GSK372475 Bioequivalence Study|An Open Label, Randomized, Parallel Groups, Bioequivalence Study to Compare a Single Oral Dose of GSK372475B or GSK372475C in Male and Female Healthy Volunteers.|Completed||Phase 1|66|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:09:11.206155|2018-06-01 03:09:11.206155
NCT00488085|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-17|||2007-06-18|2007-06-18|2007-06-19|Estimate|||||||2007-06-18|2007-06-19|Estimate|June 2007||2007-06-30|March 2007|2007-03-31|December 2007|Anticipated|2007-12-31|||||Observational|CROHN_OBESE||Crohn’s Disease, Obesity and Disease Severity|Crohn’s Disease, Obesity and Disease Severity|Unknown status|Recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 03:09:11.269373|2018-06-01 03:09:11.269373
NCT00488072|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2017-11-27|2007-06-18|2007-06-19|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2007|Actual|2007-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Effects of Mirtazapine on Appetite in Advanced Cancer Patients|Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients|Active, not recruiting||Phase 2|98|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 03:09:11.328326|2018-06-01 03:09:11.328326
NCT00488059|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2009-11-11||2011-07-18|2007-06-18|2007-06-19|Estimate|2011-06-01|2011-06-29|Estimate||||2011-07-18|2011-07-22|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|AMICI||A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients|A Multicenter, Open-label Study Evaluating the Antiviral Activity and Safety of Enfuvirtide (ENF) Once Daily (QD) or Twice Daily (BID) in Triple-class Experienced HIV-1 Infected Patients Changing Their Therapy to a Standard of Care (SOC) Regimen That Includes Initiating Raltegravir Plus an Optimized Background (OB) Antiviral Regimen|Terminated||Phase 4|29|Actual|Hoffmann-La Roche||2||This study was terminated early due to poor enrollment.|f||||||||||||||2018-06-01 03:09:11.438916|2018-06-01 03:09:11.438916
NCT00488046|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2007-11-19|2007-06-18|2007-06-19|Estimate|||||||2007-11-19|2007-11-20|Estimate|June 2007||2007-06-30|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults|Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine Modified H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic|Completed||Phase 1|16|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 03:09:11.836498|2018-06-01 03:09:11.836498
NCT00488033|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|2016-12-09||2017-02-10|2007-06-18|2007-06-19|Estimate|2017-02-10|2017-03-15|Actual||||2017-02-10|2017-03-15|Actual|June 2007||2007-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|faCTor-64||Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64|Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64: A Randomized Control Study (The faCTor-64 Study)|Completed||N/A|900|Actual|Intermountain Health Care, Inc.||2|||f||||t||||||||||2018-06-01 03:09:11.923765|2018-06-01 03:09:11.923765
NCT00488020|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2008-06-12|2007-06-18|2007-06-19|Estimate|||||||2008-06-12|2008-06-13|Estimate|April 2006||2006-04-30|June 2007|2007-06-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Stem Cells for Treating Critical Ischemia|the Use of Autogenous Adult Stem Cells in the Treatment of Critical Ischemia|Unknown status|Recruiting|Phase 1|10|Anticipated|Instituto de Molestias Cardiovasculares|||||f||||t||||||||||2018-06-01 03:09:12.632854|2018-06-01 03:09:12.632854
NCT00488007|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2016-08-29|2007-06-18|2007-06-19|Estimate|||||||2016-08-29|2016-08-30|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial on Alzheimer Disease, Presbycusis and Hearing Aids|Clinical Trial on Cognitive, Behavioural, Quality of Life and Medico-economic Benefits of Hearing Aids in Alzheimer Disease Patients Suffering From Presbycusis|Completed||N/A|51|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 03:09:12.772223|2018-06-01 03:09:12.772223
NCT00487994|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2012-05-23|2007-06-15|2007-06-19|Estimate|||||||2012-05-23|2012-05-24|Estimate|November 2004||2004-11-30|May 2012|2012-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia|A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of Lapaquistat Acetate Alone or Coadministered With Atorvastatin in Subjects With Primary Dyslipidemia|Completed||Phase 3|2130|Actual|Takeda||3|||f||||t||||||||||2018-06-01 03:09:12.89169|2018-06-01 03:09:12.89169
NCT00487981|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|2012-02-13||2012-02-21|2007-06-15|2007-06-19|Estimate|2012-02-21|2012-03-13|Estimate||||2012-02-21|2012-03-13|Estimate|February 2007||2007-02-28|February 2012|2012-02-29|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|DPN||Spinal Cord Stimulation for Painful Diabetic Neuropathy|Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy|Terminated||Phase 4|1|Actual|Boston Scientific Corporation|One subject enrolled.|1||Insufficient Data Collected|f||||f||||||||||2018-06-01 03:09:13.144746|2018-06-01 03:09:13.144746
NCT00487955|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2007-06-18|2007-06-18|2007-06-19|Estimate|||||||2007-06-18|2007-06-19|Estimate|June 2007||2007-06-30|March 2007|2007-03-31|December 2007|Anticipated|2007-12-31|||||Observational|A-P-REE||The Metabolic Contribution of the Human Microbiota to Resting Energy Expenditure|The Metabolic Contribution of the Human Microbiota to Resting Energy Expenditure|Unknown status|Recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 03:09:13.475619|2018-06-01 03:09:13.475619
NCT00487942|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|2010-04-30||2013-07-12|2007-06-15|2007-06-19|Estimate|2010-11-23|2010-12-20|Estimate||||2013-07-12|2013-07-19|Estimate|July 2007||2007-07-31|July 2013|2013-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits|A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia|Completed||Phase 2|60|Actual|Teva Pharmaceutical Industries||4|||f||||||||||||||2018-06-01 03:09:14.683345|2018-06-01 03:09:14.683345
NCT00487929|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2013-04-01|2007-06-18|2007-06-19|Estimate|||||||2013-04-01|2013-04-02|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|OSCAMSA||Oxidative Stress and Cardiovascular Morbidity in Sleep Apnea-Hypopnea Syndrome (SAHS)|Phase 4 Study of the Relationship Between the Oxidative Stress and the Development of Cardiovascular Complications in the Sleep Apnea-hypopnea Syndrome (SAHS). Effect of the Treatment With CPAP|Completed||Phase 4|100|Actual|Hospital Universitario La Paz||2|||f||||f||||||||||2018-06-01 03:09:19.303468|2018-06-01 03:09:19.303468
NCT00487916|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-16|||2017-06-30|2007-06-16|2007-06-19|Estimate|||||||2017-06-30|2017-07-02|Actual|June 13, 2007||2007-06-13|September 22, 2009|2009-09-22|February 5, 2009|Actual|2009-02-05|February 5, 2009|Actual|2009-02-05||Interventional|||Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum|Phase 1 Study of the Safety, Reactogenicity and Immunogenicity of AMA1-C1/ISA 720: A Blood Stage Vaccine for Plasmodium Falciparum|Completed||Phase 1|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:09:19.397273|2018-06-01 03:09:19.397273
NCT00487903|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2008-07-01|2007-06-18|2007-06-19|Estimate|||||||2008-07-01|2008-07-03|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems|A Phase 2 Trial of PB127 Myocardial Perfusion Echocardiography to Evaluate and Optimize Additional Ultrasound Imaging Systems|Terminated||Phase 2|40|Anticipated|Point Biomedical||||Discontinued PB127 development program for business reasons|f||||f||||||||||2018-06-01 03:09:19.473963|2018-06-01 03:09:19.473963
NCT00487890|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2008-12-31|2007-06-18|2007-06-19|Estimate|||||||2008-12-31|2009-01-01|Estimate|April 2004||2004-04-30|December 2008|2008-12-31|September 2009|Anticipated|2009-09-30|||||Observational|PERFORM||Performance Evaluation and Research for Older Adults Requiring Major Surgery|Performance Evaluation and Research for Older Adults Requiring Major Surgery|Unknown status|Active, not recruiting||400|Anticipated|University of Washington|||||f||||f||||||||||2018-06-01 03:09:19.541981|2018-06-01 03:09:19.541981
NCT00487877|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2007-06-18|2007-06-18|2007-06-19|Estimate|||||||2007-06-18|2007-06-19|Estimate|June 2007||2007-06-30|December 2006|2006-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|TEMP||Measurements of Skin Physiological Parameters as Mean of Metabolic Assessment|Measurements of Skin Physiological Parameters as Mean of Metabolic Assessment|Unknown status|Recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 03:09:19.615224|2018-06-01 03:09:19.615224
NCT00487864|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2007-06-18|2007-06-18|2007-06-19|Estimate|||||||2007-06-18|2007-06-19|Estimate|September 2006||2006-09-30|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Observational|CSLM-nevi||In Vivo Confocal Scanning Laser Microscopy of Benign Nevi|In Vivo Confocal Scanning Laser Microscopy of Benign Globular, Homogeneous and Reticular Nevi; Comparison With Dermoscopy and Histopathology|Completed|||30|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 03:09:19.689668|2018-06-01 03:09:19.689668
NCT00487851|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2013-04-11|2007-06-18|2007-06-19|Estimate|||||||2013-04-11|2013-04-12|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|March 2012|Anticipated|2012-03-31||Interventional|||Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer|Endoscopic Strategy Versus Surgical by Pass in Nonresectable Periampullary Cancer|Withdrawn||Phase 2|0|Actual|Karolinska Institutet||2||Withdrawn|f||||t||||||||||2018-06-01 03:09:19.740004|2018-06-01 03:09:19.740004
NCT00487838|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-16|||2017-06-30|2007-06-16|2007-06-19|Estimate|||||||2017-06-30|2017-07-02|Actual|June 14, 2007||2007-06-14|May 4, 2012|2012-05-04|May 4, 2012||2012-05-04|||||Observational|||Effects of Sun Filters on Age-related Macular Degeneration in People With Lens Implants|Noninvasive Optical Imaging of the Effects of External Spectral Filters on Macular Autofluorescence in Pseudophakic Eyes|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:09:19.818135|2018-06-01 03:09:19.818135
NCT00487825|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2011-01-24||2012-07-24|2007-06-18|2007-06-19|Estimate|2011-04-12|2011-05-06|Estimate||||2012-07-24|2012-08-01|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis|A 26-week, Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Response to Treatment (ACR50) and to Determine a Biomarker Profile in Responders to ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) Plus MTX as Compared to MTX Alone in Early Rheumatoid Arthritis Patients|Completed||Phase 2|78|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:09:19.995487|2018-06-01 03:09:19.995487
NCT00487812|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2008-10-06|2007-06-18|2007-06-19|Estimate|||||||2008-10-06|2008-10-07|Estimate|December 2004||2004-12-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|August 2006|Actual|2006-08-31||Interventional|||Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT to Predict Left Ventricular Remodelling in Patients Reperfused in the Acute Phase of MI|Prediction of Left Ventricular Remodelling in Patients Treated by Angioplasty in the Acute of Phase of a First Myocardial Infarction by Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT|Completed||N/A|50|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:09:20.367464|2018-06-01 03:09:20.367464
NCT00487799|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2009-07-17|2007-06-15|2007-06-19|Estimate|||||||2009-07-17|2009-07-20|Estimate||||July 2009|2009-07-31||||||||Interventional|||A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure|Withdrawn||Phase 1|32|Anticipated|Facet Biotech||||Facet no longer has ownership of ularitide.|f||||t||||||||||2018-06-01 03:09:20.437595|2018-06-01 03:09:20.437595
NCT00487786|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2016-01-14|2007-06-15|2007-06-19|Estimate|||||||2016-01-14|2016-01-18|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer|A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27|Completed||Phase 1|64|Actual|Achieve Life Sciences||1|||f||||t||||||||||2018-06-01 03:09:20.516525|2018-06-01 03:09:20.516525
NCT00487773|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2010-04-12|2007-06-18|2007-06-19|Estimate|||||||2010-04-12|2010-04-13|Estimate|September 2007||2007-09-30|April 2010|2010-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma|Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma - Randomized, Controlled Trial.|Completed||Phase 4|96|Actual|Medical Universtity of Lodz||4|||f||||t||||||||||2018-06-01 03:09:20.580223|2018-06-01 03:09:20.580223
NCT00487760|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-16|||2017-06-30|2007-06-16|2007-06-19|Estimate|||||||2017-06-30|2017-07-02|Actual|June 11, 2007||2007-06-11|August 2, 2011|2011-08-02|August 2, 2011||2011-08-02|||||Observational|||African American Families and Lung Cancer Study|African American Families and Lung Cancer Study|Completed|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:09:20.646113|2018-06-01 03:09:20.646113
NCT00487747|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2016-11-02||2017-02-21|2007-06-18|2007-06-19|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|August 2006||2006-08-31|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||All participants who received at least one dose of the study drug were included.|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.|PEGASYS® (Peginterferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B|Completed||Phase 4|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:09:20.739983|2018-06-01 03:09:20.739983
NCT00487734|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2012-10-22|2007-06-18|2007-06-19|Estimate|||||||2012-10-22|2012-10-23|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Effect of Testosterone Replacement on Insulin Resistance|Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome|Completed||Phase 4|19|Actual|McGuire Research Institute||2|||f||||f||||||||||2018-06-01 03:09:21.150957|2018-06-01 03:09:21.150957
NCT00487721|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-16|2014-01-15||2014-03-03|2007-06-16|2007-06-19|Estimate|2014-01-15|2014-02-28|Estimate||||2014-03-03|2014-03-31|Estimate|August 2006||2006-08-31|March 2014|2014-03-31|November 2010|Actual|2010-11-30|September 2007|Actual|2007-09-30||Interventional||Since this was a pilot study, the number of patients was selected based on the feasibility of accrual and support, rather than statistical calculations. The results of this study will be considered in the planning of future trials with silibinin.|The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer|A Pilot Biomarker Study of Oral Silybin-Phytosome Followed by Prostatectomy in Patients With Localized Prostate Cancer|Completed||Phase 2|12|Actual|University of Colorado, Denver|Some end of study blood samples were not obtained due to the timing of surgery, tissue was successfully obtained in all participants.|2|||f||||f||||||||||2018-06-01 03:09:21.247848|2018-06-01 03:09:21.247848
NCT00487708|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|||2009-02-16|2007-06-18|2007-06-19|Estimate|||||||2009-02-16|2009-02-17|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms|An Open-Label, Phase II Dose Titration Study of ACZ885 (Human Anti-IL-1β Monoclonal Antibody) to Assess the Clinical Efficacy, Safety, Pharmacokinetics and Pharmacodynamics in Patients With NALP3 Mutations|Completed||Phase 2|34|Actual|Novartis||1|||f||||t||||||||||2018-06-01 03:09:21.593587|2018-06-01 03:09:21.593587
NCT00487695|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-18|2011-06-21||2018-02-12|2007-06-18|2007-06-19|Estimate|2011-08-16|2011-08-17|Estimate||||2018-02-12|2018-03-12|Actual|April 2007||2007-04-30|February 2018|2018-02-28|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|CEBE||Confocal Endomicroscopy for Barrett's Esophagus|Confocal Laser Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Associated Neoplasia|Completed||Phase 3|46|Actual|Johns Hopkins University|Relatively small study (39 patients) and performed at a tertiary care, referral center, which can reduce generalizability.|2|||f||||t||||||||||2018-06-01 03:09:21.687836|2018-06-01 03:09:21.687836
NCT00487682|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2011-12-19|2007-06-15|2007-06-18|Estimate|||||||2011-12-19|2011-12-21|Estimate|August 2007||2007-08-31|December 2011|2011-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dose-finding Study of ASP2151 in Subjects With Herpes Zoster|Dose-finding Study of ASP2151 in Subjects With Herpes Zoster- A Multicenter, Randomized, Double-blind, Valacyclovir Hydrochloride-controlled, Parallel-group, Comparative Study|Completed||Phase 2|403|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 03:09:21.999355|2018-06-01 03:09:21.999355
NCT00487669|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2013-11-21||2013-11-21|2007-06-15|2007-06-18|Estimate|2013-11-21|2014-01-09|Estimate||||2013-11-21|2014-01-09|Estimate|October 2006||2006-10-31|November 2013|2013-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)|Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-small Cell Lung Cancer.|Completed||Phase 2|14|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 03:09:22.106795|2018-06-01 03:09:22.106795
NCT00487656|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15||2011-05-06|2011-05-13|2007-06-15|2007-06-18|Estimate||||2011-05-06|2011-05-13|Estimate|2011-05-13|2011-05-18|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation|A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects With Sepsis and Disseminated Intravascular Coagulation|Completed||Phase 2|750|Actual|Artisan Pharma, Inc.||2|||f||||t||||||||||2018-06-01 03:09:22.377692|2018-06-01 03:09:22.377692
NCT00487643|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2014-07-10|2007-06-15|2007-06-18|Estimate|||||||2014-07-10|2014-07-11|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|October 2010|Actual|2010-10-31||Observational|||Normal Lacritin Levels in Human Tears- Development of a New Clinical Assay|Normal Lacritin Levels in Human Tears- Development of a New Clinical Assay|Completed|||100|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:09:22.508336|2018-06-01 03:09:22.508336
NCT00487630|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2007-06-15|2007-06-15|2007-06-18|Estimate|||||||2007-06-15|2007-06-18|Estimate|June 2005||2005-06-30|June 2007|2007-06-30|June 2009|Anticipated|2009-06-30|||||Interventional|HEART||Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease|A Multicenter, Phase 4, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Recombinant Alpha-Galactosidase A (Agalsidase Beta, FABRAZYME) in Heterozygous Females for Fabry Disease|Unknown status|Recruiting|Phase 4|34|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 03:09:22.559571|2018-06-01 03:09:22.559571
NCT00487617|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2009-02-24|2007-06-15|2007-06-18|Estimate|||||||2009-02-24|2009-02-25|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|April 2012|Anticipated|2012-04-30|October 2011|Anticipated|2011-10-31||Interventional|||Arteriopathy and Endothelial Function|Endothelial Dysfunction Reversibility in Patients With Peripheral Arterial Disease|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 03:09:22.624744|2018-06-01 03:09:22.624744
NCT00487604|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2007-08-01|2007-06-15|2007-06-18|Estimate|||||||2007-08-01|2007-08-02|Estimate|May 2007||2007-05-31|April 2007|2007-04-30|May 2008|Anticipated|2008-05-31|||||Observational|||Retrospective Study of the Impact of Drug Eluting Stents|Retrospective Study of the Impact of Drug Eluting Stents on Intermediate Term Survival, Cardiovascular Outcomes Including Revascularization, Bleeding Rates and Economic Costs|Unknown status|Recruiting||9800|Anticipated|Providence Health & Services|||||f||||f||||||||||2018-06-01 03:09:22.716136|2018-06-01 03:09:22.716136
NCT00487591|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2008-04-28|2007-06-15|2007-06-18|Estimate|||||||2008-04-28|2008-05-07|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia|An Evaluation of Simvastatin 20 mg Plus Omacor 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia|Completed|||40|Actual|Provident Clinical Research|||2||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-06-01 03:09:22.782044|2018-06-01 03:09:22.782044
NCT00487578|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2009-11-16||2013-02-04|2007-06-14|2007-06-18|Estimate|2010-01-12|2010-02-02|Estimate||||2013-02-04|2013-02-11|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction|Evaluation of the Efficacy of Naratriptan for the Treatment and Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction|Terminated||Phase 4|12|Actual|Cady, Roger, M.D.|"Study terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration November 2009 (study drug had previously been re-supplied at expiration of 1st batch November 2007).~No analysis performed."|2||"Terminated October 2009 (in 4th year) due to low enrollment and anticipated drug expiration~   November 2009."|f||||t||||||||||2018-06-01 03:09:22.860061|2018-06-01 03:09:22.860061
NCT00487565|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2012-02-21||2013-08-06|2007-06-15|2007-06-18|Estimate|2012-02-21|2012-03-23|Estimate||||2013-08-06|2013-08-14|Estimate|September 2006||2006-09-30|August 2013|2013-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System|LCS® PS: A Prospective, Multi-center Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System|Completed||N/A|210|Actual|DePuy Orthopaedics||1|||f||||f||||||||||2018-06-01 03:09:23.152662|2018-06-01 03:09:23.152662
NCT00487552|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|2012-01-16||2017-07-20|2007-06-15|2007-06-18|Estimate|2012-06-21|2012-07-27|Estimate||||2017-07-20|2017-08-23|Actual|January 2008||2008-01-31|July 2017|2017-07-31|April 2011|Actual|2011-04-30|January 2009|Actual|2009-01-31||Interventional|MAD||Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction|Endoscopic Gastroenteric Anastomosis Formed by Magnetic Compression and Stent Placement for Palliation of Malignant Gastric Outlet Obstruction|Terminated||N/A|18|Actual|Cook Group Incorporated|Enrollment was stopped in Feb 2009, due to the death of a patient after distal stent migration.|1||Failure to achieve one of the primary endpoints.|f||||f||||||||||2018-06-01 03:09:23.307323|2018-06-01 03:09:23.307323
NCT00487539|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2013-04-29|2011-03-03|2014-01-14|2007-06-14|2007-06-18|Estimate|2014-01-14|2014-02-17|Estimate|2011-03-03|2011-03-16|Estimate|2014-01-14|2014-02-17|Estimate|August 2007||2007-08-31|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 2/Phase 3|1065|Actual|Janssen Research & Development, LLC||4|||f||||t||||||||||2018-06-01 03:09:23.678261|2018-06-01 03:09:23.678261
NCT00487526|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-07-10|2007-06-15|2007-06-18|Estimate|||||||2007-07-10|2007-07-11|Estimate|June 2007||2007-06-30|July 2007|2007-07-31||||||||Interventional|DJBD||Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)|Clinical Evaluation of the Effect of Duodenal Jejunal Bypass on Type Two Diabetes in Non Obese Adults|Unknown status|Recruiting|Phase 1|50|Anticipated|Ferzli, George S., M.D. F.A.C.S.|||||f||||t||||||||||2018-06-01 03:09:24.661727|2018-06-01 03:09:24.661727
NCT00487513|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2017-03-08|2007-06-15|2007-06-18|Estimate|||||||2017-03-08|2017-03-09|Actual|June 2007||2007-06-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials|Procurement of Follicular B Cell Lymphoma Cells From Blood, Tissue or Malignant Effusion for the Purpose of Possible Use in Future Clinical Trials: A Minimal Risk Protocol|Completed|||40|Anticipated|Dana-Farber Cancer Institute|||||f||||f||||||Samples With DNA|"~     Whole Blood Lymph node biopsy Drainage of an effusion Bone marrow biopsy~   "|||2018-06-01 03:09:24.737385|2018-06-01 03:09:24.737385
NCT00487500|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2014-08-15|2007-06-15|2007-06-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|December 1998||1998-12-31|June 2007|2007-06-30|May 2005|Actual|2005-05-31|December 2002|Actual|2002-12-31||Interventional|||Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression|Affective and Cognitive Consequences of ECT|Completed||Phase 4|180|Actual|New York State Psychiatric Institute||4|||f||||t||||||||||2018-06-01 03:09:24.809847|2018-06-01 03:09:24.809847
NCT00487487|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2007-06-15|2007-06-15|2007-06-18|Estimate|||||||2007-06-15|2007-06-18|Estimate||||March 2007|2007-03-31||||||||Observational|||Study of Mental Fatigue in Polio Survivors||Unknown status|Recruiting||||Uniformed Services University of the Health Sciences|||||f||||f||||||||||2018-06-01 03:09:24.918014|2018-06-01 03:09:24.918014
NCT00487474|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2009-03-12|2007-06-15|2007-06-18|Estimate|||||||2009-03-12|2009-03-13|Estimate|June 2007||2007-06-30|March 2009|2009-03-31|February 2008|Actual|2008-02-29|||||Interventional|||A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of SCULPTRA Measured by Three Dimensional Digital Surface Imaging|A Single-Center, Open-Label, Exploratory Study of the Volumizing Effect of Sculptra (Poly-L-Lactic Acid) Measured by Three Dimensional Digital Surface Imaging|Completed||Phase 4|20|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:09:24.984219|2018-06-01 03:09:24.984219
NCT00487461|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|2015-07-22||2015-10-22|2007-06-15|2007-06-18|Estimate|2015-10-22|2015-11-25|Estimate||||2015-10-22|2015-11-25|Estimate|May 2007||2007-05-31|October 2015|2015-10-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage|Randomized Double Blind Study Using Simvastatin for the PRevention Aof Vasospasm in Aneurysmal Subarachnoid Hemorrhage|Terminated||N/A|25|Actual|University of Illinois at Chicago|Early termination leading to small numbers of subjects analyzed and Primary Physician leaving institution before study completion.|3||Study PI left the institution and study was stopped at that time.|f||||f||||||||||2018-06-01 03:09:25.07109|2018-06-01 03:09:25.07109
NCT00487266|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2013-11-04|2007-06-15|2007-06-18|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2006||2006-09-30|November 2013|2013-11-30|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|||Soft Tissue Biomechanical Behavior During Acupuncture in Low Back Pain|Soft Tissue Biomechanical Behavior During Acupuncture in Low Back Pain|Completed||N/A|180|Actual|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 03:09:27.560784|2018-06-01 03:09:27.560784
NCT00487448|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2008-11-17|2007-06-15|2007-06-18|Estimate|||||||2008-11-17|2008-11-19|Estimate|July 1998||1998-07-31|November 2008|2008-11-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|FLAG-IDA||SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia|FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia.|Completed||Phase 4|200|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:09:25.421794|2018-06-01 03:09:25.421794
NCT00487435|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2010-06-24||2014-04-24|2007-06-14|2007-06-18|Estimate|2010-06-24|2010-07-23|Estimate||||2014-04-24|2014-05-09|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain|Open-Label Extension, Single-Arm, Flexible-Dosing, Phase 3 Trial With CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain|Completed||Phase 3|1166|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 03:09:25.524202|2018-06-01 03:09:25.524202
NCT00487422|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2008-05-28|2007-06-15|2007-06-18|Estimate|||||||2008-05-28|2008-05-29|Estimate|October 1998||1998-10-31|June 2007|2007-06-30|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Efficacy and Safety Study of Prucalopride for the Treatment of Elderly Patients With Chronic Constipation|A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Quality-of-Life of R108512 Tablets in Elderly Subjects With Chronic Constipation|Completed||Phase 3|303|Actual|Movetis||3|||f||||f||||||||||2018-06-01 03:09:26.201925|2018-06-01 03:09:26.201925
NCT00487409|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2014-12-12|2007-06-15|2007-06-18|Estimate|||||||2014-12-12|2014-12-15|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Random Comparison of LigaSure and Disposable Staples for Laparoscopic Surgery|A Randomized Trial Comparing Outcomes for the LigaSure and Disposable Stapling Instruments for Laparoscopic Surgery|Completed||N/A|100|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-06-01 03:09:26.302814|2018-06-01 03:09:26.302814
NCT00487396|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2012-03-20||2012-04-17|2007-06-15|2007-06-18|Estimate|2012-04-17|2012-05-16|Estimate||||2012-04-17|2012-05-16|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|MA-51||Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease|Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease|Completed||N/A|98|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-06-01 03:09:26.390467|2018-06-01 03:09:26.390467
NCT00487383|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2018-04-27|2007-06-15|2007-06-18|Estimate|||||||2018-04-27|2018-04-30|Actual|June 12, 2007||2007-06-12|June 29, 2012|2012-06-29|June 29, 2012||2012-06-29|||||Observational|||Brain Changes in Blepharospasm|Suppression and Facilitation of the Motor Cortex by Stimulation of the Cerebellum in Patients With Dystonia and Healthy Controls|Terminated|||47|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:09:26.627019|2018-06-01 03:09:26.627019
NCT00487370|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2007-06-15|2007-06-15|2007-06-18|Estimate|||||||2007-06-15|2007-06-18|Estimate|March 1997||1997-03-31|June 2007|2007-06-30|December 1998|Actual|1998-12-31|||||Interventional|||Implantation of Gold Beads to Relieve Discomfort From Knee Osteoarthritis|Extraarticular Gold Implantation for Treatment of Knee Osteoarthritis.|Completed||N/A|43|Actual|Research Unit Of General Practice, Copenhagen|||||f||||f||||||||||2018-06-01 03:09:26.691473|2018-06-01 03:09:26.691473
NCT00487357|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2016-02-17|2007-06-15|2007-06-18|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||MATCh Parents' Supplemental Survey|MATCh Parents' Supplemental Survey: Predictors of Smoking in Mexican American Youth|Completed|||1215|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:09:26.755843|2018-06-01 03:09:26.755843
NCT00487344|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2007-07-02|2007-06-15|2007-06-18|Estimate|||||||2007-07-02|2007-07-03|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|November 2007|Anticipated|2007-11-30|||||Interventional|||Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations|Comparison of Body Fat Reduction in Overweight and Obese Subjects Utilizing Personalized Low-Fat Meal Plans vs. Non-Personalized Low-Fat Meal Plans.|Unknown status|Recruiting|Phase 1|32|Anticipated|Central FITT, Inc|||||f||||f||||||||||2018-06-01 03:09:26.851878|2018-06-01 03:09:26.851878
NCT00487331|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2015-01-07|2007-06-15|2007-06-18|Estimate|||||||2015-01-07|2015-01-09|Estimate|June 2007||2007-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study|Acupuncture for Treatment of Uncontrolled Pain: A Feasibility Study|Completed||N/A|52|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:09:26.943471|2018-06-01 03:09:26.943471
NCT00487318|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2012-08-20|2007-06-15|2007-06-18|Estimate|||||||2012-08-20|2012-08-21|Estimate|June 2007||2007-06-30|August 2012|2012-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin|A Randomized Controlled Trial of Adding Fluvastatin to Standard Medical Treatment (SMT) and a Pilot Trial of Rosuvastatin and Other Statins With SMT, for Patients Infected With Chronic Hepatitis C Who Are Naive to Therapy.|Completed||Phase 2|40|Actual|Bader, Ted, M.D.||2|||f||||f||||||||||2018-06-01 03:09:27.020968|2018-06-01 03:09:27.020968
NCT00487305|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2018-05-07|2007-06-15|2007-06-18|Estimate|||||||2018-05-07|2018-05-08|Actual|June 2007||2007-06-30|May 2018|2018-05-31|October 2024|Anticipated|2024-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma|A Phase I Trial of Vaccination With Lethally Irradiated Lymphoma Cells Admixed With Granulocyte-Macrophage Colony Stimulating Factor Secreting K562 Cells for the Treatment of Previously Untreated or Relapses Follicular Lymphoma|Active, not recruiting||Phase 1|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:09:27.094272|2018-06-01 03:09:27.094272
NCT00487292|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2007-06-18|2007-06-15|2007-06-18|Estimate|||||||2007-06-18|2007-06-19|Estimate|April 2003||2003-04-30|June 2007|2007-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Naps and Pulses of Bright Light in Shift Workers|The Effects of a Combination of Napping and Bright Light Pulses on Shift Workers Sleepiness at the Wheel A Pilot Study|Completed||N/A|9|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 03:09:27.179072|2018-06-01 03:09:27.179072
NCT00487279|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2012-01-04||2012-03-25|2007-06-15|2007-06-18|Estimate|2012-02-22|2012-03-26|Estimate||||2012-03-25|2012-03-27|Estimate|June 2007||2007-06-30|March 2012|2012-03-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|DETERMINE||DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation|DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation|Terminated||N/A|81|Actual|St. Jude Medical||2||Study terminated early due to inability to enroll.|f||||t||||||||||2018-06-01 03:09:27.258614|2018-06-01 03:09:27.258614
NCT00487253|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2010-02-13|2007-06-15|2007-06-18|Estimate|||||||2010-02-13|2010-02-17|Estimate|July 2007||2007-07-31|February 2010|2010-02-28|December 2010|Anticipated|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia|Randomized Clinical Trial of the Efficacy and Tolerability of Oral Miltefosine Versus Parenteral Antimony for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|Centro Internacional de Entrenamiento e Investigaciones Médicas||2|||f||||t||||||||||2018-06-01 03:09:27.624902|2018-06-01 03:09:27.624902
NCT00487240|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2009-08-17||2010-10-20|2007-06-14|2007-06-18|Estimate|2009-08-17|2009-09-25|Estimate||||2010-10-20|2010-11-04|Estimate|June 2007||2007-06-30|October 2010|2010-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|IOOZ||Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes|Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients With Type 1 Diabetes|Completed||Phase 3|387|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:09:27.772616|2018-06-01 03:09:27.772616
NCT00487227|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-15|||2015-10-06|2007-06-15|2007-06-18|Estimate|||||||2015-10-06|2015-10-08|Estimate|June 2005||2005-06-30|October 2015|2015-10-31|November 2005|Actual|2005-11-30|||||Interventional|||Effects of Low Doses of Caffeine on Mood, Physiology and Mental Function|Levels of Caffeine Lower Than Those Found in Decaffeinated Beverages Exert Effects on Cognition, Mood, and Autonomic Activity|Completed||N/A|20|Actual|Northumbria University||4|||f||||f||||||||||2018-06-01 03:09:28.832397|2018-06-01 03:09:28.832397
NCT00487214|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2011-05-31|2007-06-14|2007-06-15|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2002||2002-06-30|May 2011|2011-05-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Observational|||Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma||Completed|||361|Actual|Allergan|||||f||||||||||||||2018-06-01 03:09:28.917221|2018-06-01 03:09:28.917221
NCT00487201|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-15|2007-06-13|2007-06-15|Estimate|||||||2007-06-15|2007-06-18|Estimate|April 2006||2006-04-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Endoscopic Treatment of Biliary Strictures After LTX: Balloon Dilatation Versus Stent Placement||Completed||N/A|22|Actual|University of Ulm|||||f||||f||||||||||2018-06-01 03:09:28.961221|2018-06-01 03:09:28.961221
NCT00487188|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2011-03-22||2015-07-22|2007-06-14|2007-06-15|Estimate|2011-08-02|2011-09-02|Estimate||||2015-07-22|2015-08-13|Estimate|November 2005||2005-11-30|July 2015|2015-07-31|April 2008|Actual|2008-04-30|November 2007|Actual|2007-11-30||Interventional|INTENSE||A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience|Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients|Completed||Phase 4|47|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:09:29.070343|2018-06-01 03:09:29.070343
NCT00487175|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2009-03-16|2007-06-14|2007-06-15|Estimate|||||||2009-03-16|2009-03-17|Estimate|September 2007||2007-09-30|March 2009|2009-03-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|TRAMADOL||Tramadol and Pain Sensitization|Tramadol and Pain Sensitization|Completed||Phase 1|12|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:09:30.787267|2018-06-01 03:09:30.787267
NCT00487162|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2010-12-03||2016-10-04|2007-06-13|2007-06-15|Estimate|2014-02-20|2014-04-03|Estimate||||2016-10-04|2016-11-08|Estimate|June 2007||2007-06-30|September 2016|2016-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||males and females between the ages of 18 and 89.|The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality|The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality|Terminated||N/A|56|Actual|Rutgers, The State University of New Jersey|Study was terminated. No final conclusion drawn. A sentinel article was published in Feb 2009 issue of Anesthesiology which questioned the safety of intense insulin therapy/strict glycemic control.|2||potential harm of insulin infusion outweights the benefit.|f||||f||||||||No||2018-06-01 03:09:30.948116|2018-06-01 03:09:30.948116
NCT00487149|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2009-01-13|2007-06-13|2007-06-15|Estimate|||||||2009-01-13|2009-01-14|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|||||Observational|||Respiratory Muscle Strength in Bronchiectasis: Repeatability and Reliability||Completed|||40|Actual|University of Ulster|||||f||||t||||||||||2018-06-01 03:09:31.169048|2018-06-01 03:09:31.169048
NCT00487136|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2012-09-27|2007-06-13|2007-06-15|Estimate|||||||2012-09-27|2012-09-28|Estimate|June 2007||2007-06-30|September 2012|2012-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Interaction Between ABT-335, Rosuvastatin and Warfarin|Multiple-Dose Pharmacokinetic and Pharmacodynamic Interaction Between ABT-335, Rosuvastatin and Warfarin|Completed||Phase 1|45|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 03:09:31.242177|2018-06-01 03:09:31.242177
NCT00487123|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2008-06-13|2007-06-13|2007-06-15|Estimate|||||||2008-06-13|2008-06-17|Estimate||||June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months|A Multi-Center, Randomized, Proof-of-Concept, Parallel Control Study With Remind Cap® in Patients With Essential Hypertension and Newly Treated With Valsartan+/-Hydrochlorothiazide (HCTZ)|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 03:09:31.329578|2018-06-01 03:09:31.329578
NCT00487110|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2010-03-26|2007-06-14|2007-06-15|Estimate|||||||2010-03-26|2010-03-29|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|Tropisétron||Clinical Confirmation of a Pharmacodynamic Interaction Between Tropisetron and Paracetamol||Completed||Phase 4|40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:09:31.39197|2018-06-01 03:09:31.39197
NCT00487097|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2013-02-15|2007-06-14|2007-06-15|Estimate|||||||2013-02-15|2013-02-18|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Effect of Antioxidants on the Immune Response and Wound Healing in Critically Ill Patients|Effect of EPA, GLA and Antioxidants on the Immune Response - Cellular and Molecular Mechanisms of Wound Healing in Critically Ill Patients.|Completed||N/A|40|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-06-01 03:09:31.454611|2018-06-01 03:09:31.454611
NCT00487084|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2011-02-09||2014-03-17|2007-06-14|2007-06-15|Estimate|2011-03-14|2011-04-18|Estimate||||2014-03-17|2014-04-14|Estimate|August 2004||2004-08-31|March 2014|2014-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia|Interaction Between Epidural 2-chloroprocaine and Epidural Morphine: Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia|Completed||N/A|136|Actual|Northwestern University|We used a single 30-minute interval between morphine and 2-chloroprocaine administration and additional investigation is warranted to determine the optimum interval for administration.|3|||f||||f||||||||||2018-06-01 03:09:31.546186|2018-06-01 03:09:31.546186
NCT00487071|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2014-02-12|2007-06-13|2007-06-15|Estimate|||||||2014-02-12|2014-02-13|Estimate|August 2006||2006-08-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Anal Fistula Plug for High-type Anal Fistulae|Efficacy of Anal Fistula Plug in the Management of High-type Anal Fistulae: a Pilot Study|Terminated||N/A|10|Actual|Chinese University of Hong Kong||1||No financial support|f||||t||||||||||2018-06-01 03:09:31.986349|2018-06-01 03:09:31.986349
NCT00487058|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2009-11-18|2007-06-14|2007-06-15|Estimate|||||||2009-11-18|2009-11-19|Estimate|May 2007||2007-05-31|November 2009|2009-11-30||||June 2008|Actual|2008-06-30||Interventional|||A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors.|Completed||Phase 1|28|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:09:32.059146|2018-06-01 03:09:32.059146
NCT00487045|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2009-07-23|2007-06-14|2007-06-15|Estimate|||||||2009-07-23|2009-07-24|Estimate|December 2007||2007-12-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|HEM-AVERT||Prevention and/or Reduction of Hemorrhoids and/or Thrombosed External Hemorrhoids Using the HEM-AVERT Perianal Stabilizer Instrument|Prevention and/or Reduction of Hemorrhoids and/or Thrombosed External Hemorrhoids (TEH) Using the HEM-AVERT Perianal Stabilizer Instrument|Completed||Phase 1|176|Actual|Plexus Biomedical, Inc.||2|||f||||t||||||||||2018-06-01 03:09:32.117683|2018-06-01 03:09:32.117683
NCT00487032|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2016-10-24|2007-06-14|2007-06-15|Estimate|||||||2016-10-24|2016-10-25|Estimate|May 2008||2008-05-31|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation|A Proof of Concept Study to Evaluate Differential Tachyphylaxis of Alpha 1 and Alpha 2 Adrenoreceptor Mediated Decongestant Response to Oxymetazoline and Its Acute Reversal by Corticosteroid in Healthy Volunteers|Completed||Phase 4|19|Actual|University of Dundee||2|||f||||f||||||||||2018-06-01 03:09:32.199036|2018-06-01 03:09:32.199036
NCT00487019|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2008-05-27|2007-06-14|2007-06-15|Estimate|||||||2008-05-27|2008-05-29|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|||||Observational|||Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment|Comparative Study of Two Antibiotic Regimen - Penicillin G/Gentamicin Versus Ampicillin/Gentamicin in Empirical Treatment of Early Onset Neonatal Septicaemia|Completed|||281|Actual|University of Tartu|||2||f||||f||||||||||2018-06-01 03:09:32.38398|2018-06-01 03:09:32.38398
NCT00487006|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2015-06-12|2007-06-13|2007-06-15|Estimate|||||||2015-06-12|2015-06-16|Estimate|October 2006||2006-10-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|July 2011|Actual|2011-07-31||Interventional|CIH||Study of High Blood Sugars and Insulin in Hospitalized, Critically Ill Children|Insulin Resistance Versus Absolute Insulin Deficiency: Evaluating the Mechanism of Hyperglycemia in Pediatric Critical Illness|Completed||N/A|209|Actual|Children's Healthcare of Atlanta||3|||f||||f||||||||||2018-06-01 03:09:32.456838|2018-06-01 03:09:32.456838
NCT00486993|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2016-11-05|2007-06-14|2007-06-15|Estimate|||||||2016-11-05|2016-11-08|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|AsuRiesgo||Cardiovascular Risk Factors in an Ambulatory Urban Patient Population|Estimation of Prevalence and Assessment of the Effects of Modification of Cardiovascular Risk Factors in an Ambulatory Urban Patient Population|Completed|||18287|Actual|Heidelberg University|||1||f||||t||||||||||2018-06-01 03:09:32.535871|2018-06-01 03:09:32.535871
NCT00486980|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2008-01-28|2007-06-14|2007-06-15|Estimate|||||||2008-01-28|2008-01-30|Estimate||||January 2008|2008-01-31||||||||Interventional|||Intramuscular Peramivir for the Treatment of Uncomplicated Influenza|A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR PERAMIVIR IN SUBJECTS WITH UNCOMPLICATED ACUTE INFLUENZA|Withdrawn||Phase 3|||BioCryst Pharmaceuticals||||"This study was withdrawn for administrative reasons. The dose ranging plan for the program was~   revised."|||||||||||||||2018-06-01 03:09:32.632712|2018-06-01 03:09:32.632712
NCT00486967|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-13|2007-06-13|2007-06-15|Estimate|||||||2007-06-13|2007-06-15|Estimate|August 2006||2006-08-31|June 2007|2007-06-30||||||||Observational|||Insulin Resistance : Heart Failure|Insulin Resistance: A New Target in Heart Failure|Unknown status|Recruiting||||University of Dundee|||||f||||t||||||||||2018-06-01 03:09:32.68994|2018-06-01 03:09:32.68994
NCT00486954|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2012-12-20||2013-06-12|2007-06-13|2007-06-15|Estimate|2013-01-04|2013-02-07|Estimate||||2013-06-12|2013-06-20|Estimate|July 2007||2007-07-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|January 2012|Actual|2012-01-31||Interventional|||Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer|A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination With Weekly Paclitaxel Versus Weekly Paclitaxel Alone in the Second Line Treatment of ErbB2 Amplified Advanced Gastric Cancer|Completed||Phase 3|273|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:09:32.86023|2018-06-01 03:09:32.86023
NCT00486941|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2007-07-18|2007-06-14|2007-06-15|Estimate|||||||2007-07-18|2007-07-20|Estimate|February 2003||2003-02-28|July 2007|2007-07-31|March 2006|Actual|2006-03-31|||||Interventional|||Lifestyle Intervention in Primary Health Care - the Björknäs Study|A Randomized Trial of Lifestyle Intervention in Primary Health Care for the Modification of Cardiovascular Risk Factors - the Björknäs Study|Completed||Phase 3|151|Actual|Umeå University|||||f||||f||||||||||2018-06-01 03:09:34.631276|2018-06-01 03:09:34.631276
NCT00486928|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2011-07-22|2007-06-14|2007-06-15|Estimate|||||||2011-07-22|2011-07-25|Estimate|May 2004||2004-05-31|July 2011|2011-07-31|May 2005|Actual|2005-05-31|||||Observational|Hall-Kaster||Twenty-five-year Experience With the Medtronic-Hall Valve Prosthesis|Twenty-five-year Experience With the Medtronic-Hall Valve Prosthesis|Completed|||816|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-06-01 03:09:34.701151|2018-06-01 03:09:34.701151
NCT00486915|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2011-06-22|2007-06-14|2007-06-15|Estimate|||||||2011-06-22|2011-06-23|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|December 2011|Anticipated|2011-12-31|||||Interventional|||Impact of Left Atrial Appendage Exclusion on Short-Term Clinical Outcomes and Long-Term Stroke Incidence|Concurrent Prophylactic Left Atrial Appendage Exclusion: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|London Health Sciences Centre||2|||f||||f||||||||||2018-06-01 03:09:34.762248|2018-06-01 03:09:34.762248
NCT00486902|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2011-03-15||2014-03-17|2007-06-14|2007-06-15|Estimate|2011-04-11|2011-05-06|Estimate||||2014-03-17|2014-04-14|Estimate|July 2006||2006-07-31|March 2014|2014-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?|Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?|Completed||N/A|188|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 03:09:34.856147|2018-06-01 03:09:34.856147
NCT00486551|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2007-06-13|2007-06-13|2007-06-14|Estimate|||||||2007-06-13|2007-06-14|Estimate|August 2001||2001-08-31|June 2007|2007-06-30|January 2006|Actual|2006-01-31|||||Interventional|||Anger Control Training for Youth With Tourette Syndrome|Anger Control Training for Youth With Tourette Syndrome|Completed||N/A|26|Actual|Yale University|||||f||||t||||||||||2018-06-01 03:09:42.79599|2018-06-01 03:09:42.79599
NCT00486889|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2017-01-18|2007-06-13|2007-06-15|Estimate|||||||2017-01-18|2017-01-20|Estimate|August 2008||2008-08-31|January 2017|2017-01-31|January 2026|Anticipated|2026-01-31|December 2025|Anticipated|2025-12-31||Interventional|||Growth and Development Study of Alglucosidase Alfa.|A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.|Active, not recruiting||Phase 4|30|Anticipated|Sanofi||1|||f||||f||||||||||2018-06-01 03:09:35.407281|2018-06-01 03:09:35.407281
NCT00486876|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2011-08-01|2007-06-14|2007-06-15|Estimate|||||||2011-08-01|2011-08-02|Estimate|June 2007||2007-06-30|August 2011|2011-08-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome|A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of 100, 200, and 300 mg BID Dextofisopam in Female Outpatients With Irritable Bowel Syndrome|Completed||Phase 2|324|Actual|Pharmos||4|||f||||t||||||||||2018-06-01 03:09:35.535841|2018-06-01 03:09:35.535841
NCT00486863|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2013-10-31||2015-12-17|2007-06-14|2007-06-15|Estimate|2014-01-09|2014-02-07|Estimate||||2015-12-17|2016-01-26|Estimate|August 2007||2007-08-31|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||S. Japonicum and Pregnancy Outcomes|S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)|Completed||Phase 2|370|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:09:35.751752|2018-06-01 03:09:35.751752
NCT00486850|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2009-07-09|2007-06-13|2007-06-15|Estimate|||||||2009-07-09|2009-07-10|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress|Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress|Completed||Phase 4|110|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 03:09:36.465394|2018-06-01 03:09:36.465394
NCT00486837|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2009-09-24||2014-08-05|2007-06-13|2007-06-15|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|December 2003||2003-12-31|August 2014|2014-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|CF2||Deposition of Inhaled Prolastin in Cystic Fibrosis Patients|Multicenter, Randomized, Parallel Group Study to Investigate the Optimal Deposition Site for Inhaled Prolastin® in Patients With Cystic Fibrosis (CF)|Completed||Phase 2|72|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-06-01 03:09:36.548603|2018-06-01 03:09:36.548603
NCT00486824|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2018-04-19|2007-06-13|2007-06-15|Estimate|||||||2018-04-19|2018-04-20|Actual|April 2007|Actual|2007-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Indomethacin Versus Nifedipine for Preterm Labor Tocolysis|Indocin Versus Nifedipine for Preterm Labor Tocolysis - A Randomized Double-Blinded Clinical Trial|Active, not recruiting||Phase 1/Phase 2|29|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 03:09:36.896451|2018-06-01 03:09:36.896451
NCT00486811|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2010-10-25|2009-12-09|2012-04-16|2007-06-14|2007-06-15|Estimate|2011-01-10|2011-01-11|Estimate|2009-12-09|2009-12-10|Estimate|2012-04-16|2012-04-18|Estimate|June 2007||2007-06-30|April 2012|2012-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|A Randomized Double-blind, Placebo- and Active-control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee.|Completed||Phase 3|990|Actual|Grünenthal GmbH||3|||f||||f||||||||||2018-06-01 03:09:37.030023|2018-06-01 03:09:37.030023
NCT00486798|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2010-12-08|2007-06-14|2007-06-15|Estimate|||||||2010-12-08|2010-12-10|Estimate|May 2007||2007-05-31|April 2009|2009-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|FAST||FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis||Terminated||Phase 3|||AstraZeneca||||study was not ethically acceptable to continue and therefore it was finally stopped|f||||||||||||||2018-06-01 03:09:38.194572|2018-06-01 03:09:38.194572
NCT00486785|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2009-09-29|2007-06-14|2007-06-15|Estimate|||||||2009-09-29|2009-09-30|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin|Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study|Completed||Phase 4|431|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:09:38.309246|2018-06-01 03:09:38.309246
NCT00486772|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-18|2007-06-14|2007-06-15|Estimate|||||||2007-06-18|2007-06-19|Estimate||||June 2007|2007-06-30||||||||Interventional|||Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD||Completed||Phase 4|||Gulhane School of Medicine|||||f||||f||||||||||2018-06-01 03:09:38.435103|2018-06-01 03:09:38.435103
NCT00486759|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2012-11-28||2017-06-26|2007-06-14|2007-06-15|Estimate|2012-11-28|2012-12-31|Estimate||||2017-06-26|2017-07-25|Actual|July 26, 2007|Actual|2007-07-26|June 2017|2017-06-30|November 30, 2011|Actual|2011-11-30|November 30, 2011|Actual|2011-11-30||Interventional|||A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Comparing the Efficacy of Bevacizumab in Combination With Rituximab and CHOP (R-CHOP + Bevacizumab) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)|Terminated||Phase 3|787|Actual|Hoffmann-La Roche|Due to premature termination of the study, the efficacy results should be interpreted with caution.|2||Due to an unfavorable benefit/risk ratio.|f||||||||||||||2018-06-01 03:09:38.603556|2018-06-01 03:09:38.603556
NCT00486746|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2018-04-26|2007-06-14|2007-06-15|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2004||2004-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2007|Actual|2007-12-31||Interventional|||Lifestyle Intervention Treatment for Patients With Mild Obstructive Sleep Apnea|Lifestyle Intervention Treatment for Patients With Mild Obstructive Sleep Apnea|Active, not recruiting||N/A|81|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-06-01 03:09:40.053075|2018-06-01 03:09:40.053075
NCT00486733|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2012-12-18|2007-06-13|2007-06-15|Estimate|||||||2012-12-18|2012-12-20|Estimate|April 2007||2007-04-30|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|CWI||Study to Determine if Shock Wave Therapy Applied to Traumatic Wounds of the Extremity Improves Healing Time|Prospective Randomized Trial of Standard Wound Care Versus Standard Wound Care Plus Shock Wave Therapy for Traumatic Wounds of the Extremity|Unknown status|Recruiting|Phase 3|213|Anticipated|Walter Reed Army Medical Center||2|||f||||t||||||||||2018-06-01 03:09:40.158002|2018-06-01 03:09:40.158002
NCT00001333|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1993||1993-02-28|January 2000|2000-01-31|December 2000||2000-12-31|||||Interventional|||Phase I Study of Intrathecal Topotecan|Phase I Study of Intrathecal Topotecan|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.081247|2018-06-01 05:29:57.081247
NCT00486720|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|2010-04-19||2015-06-08|2007-06-14|2007-06-15|Estimate|2010-05-24|2010-06-22|Estimate||||2015-06-08|2015-07-03|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)|A Randomized Phase IIa Study of Vorinostat in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome|Terminated||Phase 2|22|Actual|Merck Sharp & Dohme Corp.|This trial was terminated because the pre-specified futility criterion was met.|2|||f||||||||||||||2018-06-01 03:09:40.291408|2018-06-01 03:09:40.291408
NCT00486707|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2012-07-31|2007-06-13|2007-06-15|Estimate|||||||2012-07-31|2012-08-01|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Ovarian Cancer Patient Questionnaire on Genetic Testing|Questionnaire for Ovarian Cancer Patients Regarding Acceptance and Willingness to Undergo Genetic Testing|Completed|||237|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:09:40.815192|2018-06-01 03:09:40.815192
NCT00486694|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-13|2007-06-13|2007-06-15|Estimate|||||||2007-06-13|2007-06-15|Estimate|March 2004||2004-03-31|June 2007|2007-06-30|August 2004|Actual|2004-08-31|||||Interventional|||Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria|A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan.|Completed||Phase 2|190|Actual|London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-06-01 03:09:40.880866|2018-06-01 03:09:40.880866
NCT00486681|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-14|||2008-02-26|2007-06-14|2007-06-15|Estimate|||||||2008-02-26|2008-03-04|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|January 2008|Actual|2008-01-31|July 2007|Actual|2007-07-31||Observational|COBAS||Clinical Assessment of an in-Patient Glucose Monitoring System (Accu-Chek Inform Cobas IT 1000)|Evaluation of the Implementation of the Accu-Chek Inform Cobas IT 1000 System in Three Medical Hospital Departments: Impact on the Management of Diabetes|Completed|||949|Actual|University Hospital, Grenoble|||2||f||||f||||||||||2018-06-01 03:09:40.942258|2018-06-01 03:09:40.942258
NCT00486668|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2016-06-03|2007-06-13|2007-06-15|Estimate|||||||2016-06-03|2016-06-06|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|June 2012|Actual|2012-06-30||Interventional|||A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer|A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response|Active, not recruiting||Phase 3|529|Actual|NSABP Foundation Inc||3|||f||||t||||||||||2018-06-01 03:09:41.036006|2018-06-01 03:09:41.036006
NCT00486655|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2012-08-07|2007-06-13|2007-06-14|Estimate|||||||2012-08-07|2012-08-08|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|June 2007|Actual|2007-06-30|||||Interventional|||NOTES-Assisted Laparoscopic Cholecystectomy Surgery|Assisted Laparoscopic Cholecystectomy Surgery|Terminated||N/A|25|Anticipated|USGI Medical||||Change of Focus for the company|f||||f||||||||||2018-06-01 03:09:41.282204|2018-06-01 03:09:41.282204
NCT00486642|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2015-10-14||2017-04-17|2007-06-13|2007-06-14|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|September 2007||2007-09-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase 2 Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:09:41.397098|2018-06-01 03:09:41.397098
NCT00486629|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2016-02-18|2007-06-13|2007-06-14|Estimate|||||||2016-02-18|2016-02-22|Estimate|July 2004||2004-07-31|February 2016|2016-02-29|July 2020|Anticipated|2020-07-31|June 2019|Anticipated|2019-06-30||Interventional|IDEA||Impact of Diet and Exercise Activity on Pregnancy Outcomes|Impact of a Community-based Obesity and Diabetes Prevention Program on Pregnant Outcomes in Pregnant Women|Recruiting||Phase 2|1000|Anticipated|University of Manitoba||2|||f||||t||||||||Yes|"Hui A, Back L, Ludwig S, Gardiner P, Sevenhuysen G, Dean H, Sellers E, McGavock J, Morris M, Bruce S, Murray R, Shen GX. Lifestyle intervention on diet and exercise reduced excessive gestational weight gain in pregnant women under a randomized controlled trial. Br J Obstetr Gynecol 2012;119:70-77~Hui AL, Back L, Ludwig S, Gardiner P, Sevenhuysen G, Dean HJ, Sellers E, McGavock J, Morris M, Jiang D, Shen GX. Effects of lifestyle intervention on dietary intake, physical activity level, and gestational weight gain in pregnant women with different pre-pregnancy Body Mass Index in a randomized control trial. BMC Pregnancy Childbirth. 2014;14:331. PMID:25248797"|2018-06-01 03:09:42.138909|2018-06-01 03:09:42.138909
NCT00486616|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2008-02-11|2007-06-13|2007-06-14|Estimate|||||||2008-02-11|2008-02-18|Estimate|May 2007||2007-05-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Examination of Double-Lumen Tube Placement by Functional Electrical Impedance Tomography|Examination of Double-Lumen Tube Placement: Functional Electrical Impedance Tomography Versus Fibreoptic Bronchoscopy|Completed|||||University Hospital Freiburg|||||f||||f||||||||||2018-06-01 03:09:42.281044|2018-06-01 03:09:42.281044
NCT00486603|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2012-05-01|2007-06-13|2007-06-14|Estimate|||||||2012-05-01|2012-05-02|Estimate|October 2007||2007-10-31|May 2012|2012-05-31||||January 2013|Anticipated|2013-01-31||Interventional|||Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Hydroxychloroquine in Conjunction With Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Unknown status|Active, not recruiting|Phase 1/Phase 2|94|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:09:42.394877|2018-06-01 03:09:42.394877
NCT00486590|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2008-02-27|2007-06-12|2007-06-14|Estimate|||||||2008-02-27|2008-03-03|Estimate|August 2006||2006-08-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Evaluation of Prolact-Plus Human Milk Fortifier|The Evaluation of Prolact-Plus, Human Milk Fortifier (Human, Pasteurized) for Pre-Term Infants Receiving Human Milk|Completed||N/A|105|Actual|Prolacta Bioscience|||||f||||f||||||||||2018-06-01 03:09:42.52312|2018-06-01 03:09:42.52312
NCT00486577|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2011-01-27|2007-06-13|2007-06-14|Estimate|||||||2011-01-27|2011-01-28|Estimate|June 2007||2007-06-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ACOUSCO||Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus|Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus|Completed||Phase 2/Phase 3|10|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 03:09:42.606231|2018-06-01 03:09:42.606231
NCT00486564|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2009-10-22|2007-06-13|2007-06-14|Estimate|||||||2009-10-22|2009-10-23|Estimate|November 2006||2006-11-30|October 2009|2009-10-31|June 2009|Actual|2009-06-30|November 2007|Actual|2007-11-30||Interventional|||Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma|A Phase I Trial of Nifurtimox for Relapsed or Refractory Neuroblastoma|Completed||Phase 1|20|Anticipated|University of Vermont|||||f||||t||||||||||2018-06-01 03:09:42.713311|2018-06-01 03:09:42.713311
NCT00486538|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12||2012-06-29|2013-01-02|2007-06-12|2007-06-14|Estimate||||2012-06-29|2012-07-03|Estimate|2013-01-02|2013-01-04|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib|An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib|Completed||Phase 2|53|Actual|AbbVie||1|||f||||f||||||||||2018-06-01 03:09:42.866157|2018-06-01 03:09:42.866157
NCT00486525|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2013-11-14||2014-04-17|2007-06-13|2007-06-14|Estimate|2014-03-04|2014-04-10|Estimate||||2014-04-17|2014-05-05|Estimate|August 2007||2007-08-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors|Breast Cancer Survivors: Physical Activity, Inflammation, Fatigue, and Distress|Completed||N/A|200|Actual|Ohio State University Comprehensive Cancer Center|We did not compare yoga to an active control group; Fatigue and depressive symptoms were not used as part of the inclusion criteria. Accordingly, our data may underestimate yoga's potential benefit.|2|||f||||t||||||||||2018-06-01 03:09:42.993953|2018-06-01 03:09:42.993953
NCT00486512|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2011-02-04|2007-06-13|2007-06-14|Estimate|||||||2011-02-04|2011-02-08|Estimate|June 2007||2007-06-30|February 2011|2011-02-28|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Chemoprevention of Colorectal Adenomas|A Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal Adenomas|Terminated||Phase 3|1000|Anticipated|Colotech A/S||2||Planned Interim Analysis failed to show difference between the active and placebo groups|f||||f||||||||||2018-06-01 03:09:44.009663|2018-06-01 03:09:44.009663
NCT00486499|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2007-06-12|2007-06-12|2007-06-14|Estimate|||||||2007-06-12|2007-06-14|Estimate|March 2003||2003-03-31|June 2007|2007-06-30||||||||Interventional|||I-125 Versus Pd-103 for Medium Risk Prostate Cancer||Unknown status|Recruiting|Phase 3|660|Anticipated|VA Puget Sound Health Care System|||||f||||||||||||||2018-06-01 03:09:44.456089|2018-06-01 03:09:44.456089
NCT00486486|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2014-05-09|2007-06-13|2007-06-14|Estimate|||||||2014-05-09|2014-05-12|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|BTFC||24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination|A 3-month, 4-centre, Crossover, Double-masked Study Investigating the 24-hour Intraocular Pressure Control With the Bimatoprost/Timolol Fixed Combination Dosed Morning, or Evening in Subjects With Exfoliative Glaucoma|Completed||Phase 4|60|Actual|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-06-01 03:09:44.744823|2018-06-01 03:09:44.744823
NCT00486473|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2010-07-14|2007-06-13|2007-06-14|Estimate|||||||2010-07-14|2010-07-15|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|DETECT||Multihance Versus Magnevist in Breast MRI|Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast|Completed||Phase 3|130|Anticipated|Bracco Diagnostics, Inc|||||f||||f||||||||||2018-06-01 03:09:45.051625|2018-06-01 03:09:45.051625
NCT00486460|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-13|2007-06-13|2007-06-14|Estimate|||||||2007-06-13|2007-06-14|Estimate|June 2005||2005-06-30|June 2007|2007-06-30||||||||Interventional|||Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer||Unknown status|Recruiting|Phase 3|||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 03:09:45.2744|2018-06-01 03:09:45.2744
NCT00486447|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2017-05-03||2017-07-24|2007-06-13|2007-06-14|Estimate|2017-07-24|2017-08-23|Actual||||2017-07-24|2017-08-23|Actual|June 2007||2007-06-30|July 2017|2017-07-31|December 2009|Actual|2009-12-31|April 2008|Actual|2008-04-30||Interventional|PICTURE|All subjects|Perfusion Imaging and CT -Understanding Relative Efficacy|A Prospective Multi-center Study Comparing Cardiac Computed Tomography (CT) Using a 64-detector Row Volumetric Computed Tomography (VCT) Scanner for the Detection of Coronary Artery Disease With Cardiac Radionuclide Imaging.|Terminated||N/A|249|Actual|GE Healthcare||1||Accrual|f||||t||||||||||2018-06-01 03:09:45.550636|2018-06-01 03:09:45.550636
NCT00486434|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2012-03-28||2012-10-22|2007-06-13|2007-06-14|Estimate|2012-05-25|2012-06-28|Estimate||||2012-10-22|2012-10-29|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis|A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis|Completed||Phase 3|1176|Actual|Nordic Bioscience A/S||2|||f||||||||||||||2018-06-01 03:09:45.86269|2018-06-01 03:09:45.86269
NCT00486421|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2014-10-15|2007-06-13|2007-06-14|Estimate|||||||2014-10-15|2014-10-17|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura|A Pilot Study of Rituximab in Combination With Corticosteroids for the Initial Treatment of Immune Thrombocytopenic Purpura|Completed||Early Phase 1|22|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:09:46.827592|2018-06-01 03:09:46.827592
NCT00486408|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2015-06-02|2007-06-12|2007-06-14|Estimate|||||||2015-06-02|2015-06-04|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|November 2012|Actual|2012-11-30|September 2008|Actual|2008-09-30||Interventional|||Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults|A Phase 1B Open-label Clinical Trial to Expand the Characterization of the Immune Responses to the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy, HIV-1-uninfected Adult Participants|Completed||Phase 1|35|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 03:09:46.927549|2018-06-01 03:09:46.927549
NCT00486395|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2012-02-08|2007-06-13|2007-06-14|Estimate|||||||2012-02-08|2012-02-10|Estimate|September 2007||2007-09-30|February 2012|2012-02-29|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|OLIVIA||Will CPAP Reduce Length Of Respiratory Support In Premature Infants?|Offering Less Invasive Ventilation in Infants Born 28 to 32 Weeks Gestation: A Randomized Controlled Trial.|Terminated||Phase 3|126|Actual|Children's & Women's Health Centre of British Columbia||2||Decreasing recruitment|f||||t||||||||||2018-06-01 03:09:47.036537|2018-06-01 03:09:47.036537
NCT00486382|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2015-04-01|2007-06-12|2007-06-14|Estimate|||||||2015-04-01|2015-04-03|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India|A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India|Completed||Phase 1|36|Actual|IDRI||3|||f||||t||||||||||2018-06-01 03:09:47.144705|2018-06-01 03:09:47.144705
NCT00486369|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-13|2007-06-13|2007-06-14|Estimate|||||||2007-06-13|2007-06-14|Estimate|January 2007||2007-01-31|June 2007|2007-06-30||||||||Interventional|||SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study|SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.|Completed||Phase 1|||Nordic Bioscience A/S|||||f||||||||||||||2018-06-01 03:09:47.25124|2018-06-01 03:09:47.25124
NCT00486356|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2018-01-24|2007-06-13|2007-06-14|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2004||2004-10-31|January 2018|2018-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer|A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients|Completed||Phase 1|46|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 03:09:47.337265|2018-06-01 03:09:47.337265
NCT00486343|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2008-04-01|2007-06-13|2007-06-14|Estimate|||||||2008-04-01|2008-04-03|Estimate|July 2007||2007-07-31|April 2008|2008-04-30|June 2008|Anticipated|2008-06-30|May 2008|Anticipated|2008-05-31||Interventional|||Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS|A Randomized, Double-Blind, Placebo Controlled Study of Zileuton CR Tablets Versus Placebo in Adult Patients With Poorly Controlled Asthma Patients on Moderate Dose Inhaled Corticosteroids (ICS)|Terminated||Phase 4|400|Anticipated|Critical Therapeutics||2||Slower than anticipated enrollment|f||||f||||||||||2018-06-01 03:09:47.460295|2018-06-01 03:09:47.460295
NCT00486330|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2010-02-25||2012-10-19|2007-06-13|2007-06-14|Estimate|2012-10-19|2012-11-21|Estimate||||2012-10-19|2012-11-21|Estimate|May 2006||2006-05-31|October 2012|2012-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|BUTI||Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir|Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Tipranavir/Ritonavir in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone|Completed||N/A|12|Actual|Yale University|First, the sample size was small. Second, this study utilized a within-subject design with patients acting as their own controls and thereby resulting in less intra-patient variability in the analysis of BUP/NLX.|1|||f||||f||||||||||2018-06-01 03:09:47.563654|2018-06-01 03:09:47.563654
NCT00486317|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-13|2007-06-13|2007-06-14|Estimate|||||||2007-06-13|2007-06-14|Estimate|October 2005||2005-10-31|June 2007|2007-06-30||||||||Interventional|||Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis|SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study.|Completed||Phase 1|||Nordic Bioscience A/S|||||f||||||||||||||2018-06-01 03:09:47.735602|2018-06-01 03:09:47.735602
NCT00486304|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2012-04-16|2007-06-13|2007-06-14|Estimate|||||||2012-04-16|2012-04-18|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|May 2008|Actual|2008-05-31|February 2007|Actual|2007-02-28||Interventional|||Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy|Phase I Randomized, Double-blind, Placebo-controlled Trial of the Effect of Temporary Dietary Antioxidant Depletion on Tumor Growth and Cachexia in Head and Neck Cancer Patients Receiving Chemoradiation Therapy|Completed||Phase 1|4|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 03:09:47.805311|2018-06-01 03:09:47.805311
NCT00486291|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2012-07-31|2009-11-30|2012-09-05|2007-06-12|2007-06-14|Estimate|2012-07-31|2012-09-03|Estimate|2009-11-30|2009-12-02|Estimate|2012-09-05|2012-09-10|Estimate|June 2007||2007-06-30|September 2012|2012-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics|A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults|Completed||Phase 2|210|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-06-01 03:09:47.903295|2018-06-01 03:09:47.903295
NCT00486278|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2013-09-27|2010-11-05|2017-01-23|2007-06-13|2007-06-14|Estimate|2014-12-15|2014-12-25|Estimate|2011-03-18|2011-03-28|Estimate|2017-01-23|2017-03-07|Actual|June 2007||2007-06-30|January 2017|2017-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds|A Multi-centre, Randomised, Double-blinded, Controlled, Dose-escalation Trial on Safety and Efficacy of Activated Recombinant FVII Analogue (NN1731) in the Treatment of Joint Bleeds in Congenital Haemophilia Patients With Inhibitors|Completed||Phase 2|51|Actual|Novo Nordisk A/S||6|||f||||t||||||||||2018-06-01 03:09:48.246636|2018-06-01 03:09:48.246636
NCT00486265|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2010-07-20||2010-12-07|2007-06-13|2007-06-14|Estimate|2010-07-20|2010-08-17|Estimate||||2010-12-07|2010-12-21|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|July 2009|Actual|2009-07-31|||||Interventional|||Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)|A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients With Recurrent or Refractory Acute Myelogenous Leukemia (AML) Excluding Promyelocytic Leukemia|Terminated||Phase 1|47|Actual|AstraZeneca|On 16 June 2009, the study was terminated for a lack of efficacy. None of the 8 patients had experienced CR or CRi. The secondary efficacy outcome measures were not evaluated due to early termination and small number of participants.|||"AML assess. of response in Part B patients find treatment failure in all 8 evaluable for marrow~   response following a maximum of 2 induction courses of therapy"|f||||||||||||||2018-06-01 03:09:49.713747|2018-06-01 03:09:49.713747
NCT00486252|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2009-03-31||2009-11-04|2007-06-12|2007-06-14|Estimate|2009-05-27|2009-07-16|Estimate||||2009-11-04|2009-11-11|Estimate|June 2007||2007-06-30|November 2009|2009-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®|Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN® (Latanoprost) as First-Line Monotherapy and as Second-Line Monotherapy After Beta-Blockers Therapy Failure|Completed|||996|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:09:51.429795|2018-06-01 03:09:51.429795
NCT00486239|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2007-06-13|2007-06-13|2007-06-14|Estimate|||||||2007-06-13|2007-06-14|Estimate|October 2006||2006-10-31|June 2007|2007-06-30||||||||Interventional|||Emotional Processing and Memory Evaluation in Epilepsy Patients|Emotional Processing and Memory Evaluation in Epilepsy Patients|Unknown status|Recruiting|Early Phase 1|36|Anticipated|University Hospitals Cleveland Medical Center|||||f||||f||||||||||2018-06-01 03:09:51.708163|2018-06-01 03:09:51.708163
NCT00486226|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|2014-01-08||2014-03-19|2007-06-13|2007-06-14|Estimate|2014-03-19|2014-04-21|Estimate||||2014-03-19|2014-04-21|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|SUNRISE||The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System|The SUNRISE Registry - A Multicenter Post-Market Surveillance With the CORDIS ENTERPRISE™ Vascular Reconstruction Device and Delivery System|Completed||Phase 4|109|Actual|Codman & Shurtleff|This study was powered to have a total of 250 subjects, but was stopped early due to slow enrollment. Hence, this study ended up having only 105 total subjects, making it underpowered.|1|||f||||t||||||||||2018-06-01 03:09:51.791112|2018-06-01 03:09:51.791112
NCT00486213|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-13|||2015-09-22|2007-06-13|2007-06-14|Estimate|||||||2015-09-22|2015-09-24|Estimate|June 2007||2007-06-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer|Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS)|Terminated||Phase 3|210|Actual|National Cancer Centre, Singapore||2||Slow accrual|f||||t||||||||||2018-06-01 03:09:52.038079|2018-06-01 03:09:52.038079
NCT00486200|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12||2010-01-04|2017-12-01|2007-06-12|2007-06-14|Estimate||||2010-01-04|2010-01-06|Estimate|2017-12-01|2017-12-07|Actual|June 21, 2007|Actual|2007-06-21|December 2017|2017-12-31|August 12, 2008|Actual|2008-08-12|August 12, 2008|Actual|2008-08-12||Interventional|||A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes|A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes|Completed||Phase 2|695|Actual|Astellas Pharma Inc||6|||f||||f||||||||Undecided||2018-06-01 03:09:52.223619|2018-06-01 03:09:52.223619
NCT00486187|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2016-01-27|2007-06-12|2007-06-14|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study|Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study|Completed||N/A|103|Actual|Canadian Collaborative Research Network||2|||f||||f||||||||||2018-06-01 03:09:52.350756|2018-06-01 03:09:52.350756
NCT00486174|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2008-05-26|2007-06-12|2007-06-14|Estimate|||||||2008-05-26|2008-05-29|Estimate|June 2007||2007-06-30|May 2008|2008-05-31||||||||Interventional|SMURF||Methylene Blue in Sepsis: A Randomized Controlled Trial|Intermittent Bolus Infusion of Methylene Blue to Reduce Norepinephrine Requirements in Sepsis: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Queen's University||2||primary site withdrew due to competing study: never enrolled any subjects.|f||||t||||||||||2018-06-01 03:09:52.430022|2018-06-01 03:09:52.430022
NCT00486161|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-12|2007-06-12|2007-06-13|Estimate|||||||2007-06-12|2007-06-13|Estimate|March 2004||2004-03-31|June 2007|2007-06-30|December 2006|Actual|2006-12-31|||||Observational|aeroghre||Acylated Ghrelin Response to Acute Exercise in Obesity|Evaluation of Acylated Ghrelin Response Following Acute Exercise in Relation to Adiposity, Metabolic Homeostasis and Growth Hormone Secretion|Completed|||16|Actual|Istituto Auxologico Italiano|||||f||||t||||||||||2018-06-01 03:09:52.519655|2018-06-01 03:09:52.519655
NCT00486148|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2015-03-17|2007-06-12|2007-06-13|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2006||2006-02-28|March 2015|2015-03-31|June 2013|Actual|2013-06-30|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of an Infant Formula Supplemented With Galacto-oligosaccharides (GOS)|Randomized, Double Blind Study to Evaluate the Safety and Efficacy of an Infant Formula Supplemented With Galacto-oligosaccharides (GOS) in Healthy, Full Term Infants|Completed||N/A|360|Actual|Heinz Italia SpA||3|||f||||f||||||||||2018-06-01 03:09:52.60504|2018-06-01 03:09:52.60504
NCT00486135|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2013-01-31|2007-06-11|2007-06-13|Estimate|||||||2013-01-31|2013-02-01|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 Administered Orally Daily to Subjects With Solid Tumors or Lymphoma|Completed||Phase 1|118|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:09:52.718427|2018-06-01 03:09:52.718427
NCT00486122|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|September 2003||2003-09-30|June 2007|2007-06-30|June 2004|Actual|2004-06-30|||||Interventional|||Evaluation of Continuous Symptom Treatment of ADHD|Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera|Completed||Phase 4|282|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:09:52.817872|2018-06-01 03:09:52.817872
NCT00486109|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2008-03-10|2007-06-12|2007-06-13|Estimate|||||||2008-03-10|2008-03-11|Estimate|October 2006||2006-10-31|March 2008|2008-03-31|January 2007|Actual|2007-01-31|||||Interventional|||A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port|A Study Assessing an Injection Port for Administration of Insulin|Completed||N/A|74|Actual|Patton Medical Devices|||||f||||f||||||||||2018-06-01 03:09:52.895928|2018-06-01 03:09:52.895928
NCT00486096|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2012-03-14|2007-06-12|2007-06-13|Estimate|||||||2012-03-14|2012-03-16|Estimate|February 2007||2007-02-28|June 2007|2007-06-30|August 2007|Actual|2007-08-31|||||Observational|||Femoral Arterial Cannulation|Femoral Arterial Cannulation in Infants Following Complicated Sternal Re-entry|Terminated|||1|Actual|Children's Healthcare of Atlanta||||sufficient data collected.|f||||f||||||||||2018-06-01 03:09:52.970039|2018-06-01 03:09:52.970039
NCT00486083|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|December 2003||2003-12-31|June 2007|2007-06-30|October 2004|Actual|2004-10-31|||||Interventional|||Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD|A Randomized, Double-Blind Comparison, Safety and Efficacy Trial of Atomoxetine Hydrochloride and Methylphenidate Hydrochloride in Pediatric Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|330|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:09:53.03014|2018-06-01 03:09:53.03014
NCT00486070|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2012-03-14|2007-06-12|2007-06-13|Estimate|||||||2012-03-14|2012-03-16|Estimate|December 2006||2006-12-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Observational|||Review of Descending Aortic Flow Reversal in Total Anomalous Pulmonary Venous Connection|Proposal for Retrospective Review of Descending Aortic Flow Reversal in Total Anomalous Pulmonary Venous Connection|Terminated|||40||Children's Healthcare of Atlanta||||conclusions drawn, manuscript written|f||||f||||||||||2018-06-01 03:09:53.18697|2018-06-01 03:09:53.18697
NCT00486057|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2011-11-18|2007-06-12|2007-06-13|Estimate|||||||2011-11-18|2011-11-21|Estimate|August 2004||2004-08-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||Daclizumab Experience in Pediatric Heart Transplant|A Retrospective Review of Daclizumab Experience in Pediatric Heart Transplant|Terminated|||30|Actual|Children's Healthcare of Atlanta||||sufficient data collected for conclusion of retrospective study|f||||f||||||||||2018-06-01 03:09:53.416257|2018-06-01 03:09:53.416257
NCT00486044|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2012-11-16||2015-10-01|2007-06-12|2007-06-13|Estimate|2015-10-01|2015-11-05|Estimate||||2015-10-01|2015-11-05|Estimate|February 2005||2005-02-28|March 2014|2014-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ESPRIT||Evaluating Simvastatin's Potential Role in Therapy|Effect of Statins on Pathobiology of Alzheimer's Disease|Completed||Phase 2|103|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 03:09:53.682739|2018-06-01 03:09:53.682739
NCT00486031|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2017-12-19||2018-02-06|2007-06-11|2007-06-13|Estimate|2017-12-19|2018-01-19|Actual||||2018-02-06|2018-03-07|Actual|October 2006||2006-10-31|February 2018|2018-02-28|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study|A Multicenter, Open-label Trials to Evaluate the Long-term Safety and Tolerability of a New Balsalazide Disodium Tablet Formulation in Patients With Ulcerative Colitis|Completed||Phase 3|500|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||||2018-06-01 03:09:55.098609|2018-06-01 03:09:55.098609
NCT00486018|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2010-08-16|2010-05-05|2017-04-04|2007-06-11|2007-06-13|Estimate|2011-02-01|2011-02-25|Estimate|2010-05-05|2010-05-07|Estimate|2017-04-04|2017-05-10|Actual|July 2007||2007-07-31|April 2017|2017-04-30|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|BRAVO||A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)|A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion|Completed||Phase 3|397|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 03:09:55.669517|2018-06-01 03:09:55.669517
NCT00486005|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|February 2003||2003-02-28|June 2007|2007-06-30|October 2003|Actual|2003-10-31|||||Interventional|||Weight Gain Management in Patients With Schizophrenia|Weight Gain Management in Patients With Schizophrenia During Treatment With Olanzapine in Association With Nizatidine|Completed||Phase 4|74|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:09:56.29228|2018-06-01 03:09:56.29228
NCT00485992|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2011-11-18|2007-06-12|2007-06-13|Estimate|||||||2011-11-18|2011-11-21|Estimate|August 2006||2006-08-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Observational|||Chlorhexidine Swabs Effectiveness in Reducing Blood Stream Infections|Effectiveness of Utilizing Chlorhexidine Swabs for Accessing Lines and Results Impact on Catheter Related Blood Stream Infections in the Cardiac Intensive Care Unit|Terminated|||352|Actual|Children's Healthcare of Atlanta||||sufficient data has been collected for significant conclusion|f||||t||||||||||2018-06-01 03:09:56.341837|2018-06-01 03:09:56.341837
NCT00485979|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2011-06-27|2007-06-12|2007-06-13|Estimate|||||||2011-06-27|2011-06-28|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|SATIN||Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients|A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized Breast Cancer.|Completed||Phase 2|330|Actual|Sanofi||4|||f||||||||||||||2018-06-01 03:09:56.397721|2018-06-01 03:09:56.397721
NCT00485966|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2008-11-03|2007-06-12|2007-06-13|Estimate|||||||2008-11-03|2008-11-05|Estimate|June 2007||2007-06-30|November 2008|2008-11-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase 2, Multi-Center, Open Label Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of Quarfloxacin (CX-3543) in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Withdrawn||Phase 2|25|Anticipated|Cylene Pharmaceuticals||||This study was withdrawn prior to patient enrollment|f||||f||||||||||2018-06-01 03:09:56.558762|2018-06-01 03:09:56.558762
NCT00485953|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2014-06-02||2017-09-12|2007-06-11|2007-06-13|Estimate|2014-06-02|2014-07-03|Estimate||||2017-09-12|2017-10-13|Actual|September 2007||2007-09-30|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|REBBeCA II||Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy|The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy|Completed||Phase 4|109|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:09:56.649738|2018-06-01 03:09:56.649738
NCT00485940|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2013-09-24|2007-06-12|2007-06-13|Estimate|||||||2013-09-24|2013-09-25|Estimate|March 1998||1998-03-31|September 2013|2013-09-30|May 1999|Actual|1999-05-31|May 1999|Actual|1999-05-31||Interventional|||Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic Constipation|A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of R108512 Tablets in Subjects With Chronic Constipation|Completed||Phase 3|641|Actual|Movetis||3|||f||||f||||||||||2018-06-01 03:09:57.265365|2018-06-01 03:09:57.265365
NCT00485927|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|April 2007||2007-04-30|June 2007|2007-06-30||||||||Interventional|||The Effects of Stress on the Clinical Performance of Residents in Simulated Trauma Scenarios|The Effects of Stress on the Clinical Performance of Residents in Simulated Trauma Scenarios|Unknown status|Recruiting|N/A|20|Anticipated|University of Toronto|||||f||||f||||||||||2018-06-01 03:09:57.365325|2018-06-01 03:09:57.365325
NCT00485914|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2016-10-03|2007-06-12|2007-06-13|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2003||2003-10-31|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Work Interventions to Improve Employment Outcomes for Persons With Rheumatoid Arthritis and Osteoarthritis|Worksite Vocational Rehabilitation Intervention to Improve Employment Outcomes for Persons With Arthritis?|Completed||N/A|89|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 03:09:57.431082|2018-06-01 03:09:57.431082
NCT00485901|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|July 2004||2004-07-31|June 2007|2007-06-30|January 2005|Actual|2005-01-31|||||Interventional|||Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia|A Double-Blind Randomized Comparison of the Efficacy and Safety of Intramuscular Olanzapine and Intramuscular Haloperidol in Acutely Agitated Patients With Schizophrenia|Completed||Phase 3|50|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:09:57.516427|2018-06-01 03:09:57.516427
NCT00485888|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2013-10-29|2007-06-12|2007-06-13|Estimate|||||||2013-10-29|2013-10-30|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Flushing in Social Anxiety Disorder on Cipralex|Changes in the Vasodilatory Response to Methyl-nicotinate in Response to S-citalopram Treatment in Social Phobia Patients|Completed||Phase 2|71|Actual|START Clinic for Mood and Anxiety Disorders||2|||f||||f||||||||||2018-06-01 03:09:57.611652|2018-06-01 03:09:57.611652
NCT00485875|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|June 2004||2004-06-30|June 2007|2007-06-30|January 2005|Actual|2005-01-31|||||Interventional|||Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD|An Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 4|62|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:09:57.701092|2018-06-01 03:09:57.701092
NCT00485862|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|June 2003||2003-06-30|June 2007|2007-06-30|January 2005|Actual|2005-01-31|||||Interventional|||Combination Therapy in Patients With Depression|Noradrenergic Augmentation of SSRI Therapy in Patients With Depression Unresponsive or Incompletely Responsive to SSRI Monotherapy|Completed||Phase 4|214|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:09:57.768042|2018-06-01 03:09:57.768042
NCT00043537|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2013-07-31|2002-08-09|2002-08-12|Estimate|||||||2013-07-31|2013-08-01|Estimate|April 2001||2001-04-30|July 2013|2013-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Treatment of Childhood Social Phobia|Treatment of Childhood Social Phobia|Completed||Phase 3|139|Actual|University of Central Florida||3|||f||||t||||||||||2018-06-01 05:31:43.167305|2018-06-01 05:31:43.167305
NCT00485849|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|February 2004||2004-02-29|June 2007|2007-06-30|October 2004|Actual|2004-10-31|||||Interventional|||A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD|An Open Label Pilot Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behavior Problems in Children and Adolescents With Autistic Spectrum Disorders|Completed||Phase 4|12|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:09:57.837526|2018-06-01 03:09:57.837526
NCT00485836|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2010-08-16|2010-05-05|2017-06-29|2007-06-11|2007-06-13|Estimate|2011-02-01|2011-02-25|Estimate|2010-05-05|2010-05-07|Estimate|2017-06-29|2017-07-28|Actual|July 2007||2007-07-31|June 2017|2017-06-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|CRUISE||A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)|A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion|Completed||Phase 3|392|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 03:09:57.953611|2018-06-01 03:09:57.953611
NCT00485823|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|December 2002||2002-12-31|June 2007|2007-06-30|September 2003|Actual|2003-09-30|||||Interventional|||Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia|The Assessment of a Weight Management Program for Treatment-Emergent Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, and Schizoaffective Disorder During Olanzapine Therapy|Completed||Phase 4|48|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:09:58.619233|2018-06-01 03:09:58.619233
NCT00485810|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|June 2004||2004-06-30|June 2007|2007-06-30|November 2004|Actual|2004-11-30|||||Interventional|||Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia|A Study Examining Clinical Therapeutic Dose of Rapid Acting Intra-Muscular Olanzapine in Japanese Agitated Patients With Schizophrenia|Completed||Phase 1/Phase 2|31|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:09:58.675817|2018-06-01 03:09:58.675817
NCT00485797|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2011-02-17|2007-06-12|2007-06-13|Estimate|||||||2011-02-17|2011-02-18|Estimate|October 2007||2007-10-31|May 2007|2007-05-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Effects of Ritalin on Postural Stability of Hyper Active Children|Effects of Methylphenidate on Postural Stability of Children Suffer From Attention Deficit Hyperactivity Disorder (ADHD) Under Single and Dual Task Conditions.|Completed||N/A|30|Actual|Soroka University Medical Center|||||f||||t||||||||||2018-06-01 03:09:58.739273|2018-06-01 03:09:58.739273
NCT00485784|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2014-08-27|2007-06-12|2007-06-13|Estimate|||||||2014-08-27|2014-08-28|Estimate|July 2007||2007-07-31|August 2014|2014-08-31||||July 2012|Actual|2012-07-31||Interventional|||Interest of Circulating Endothelial Biomarkers in Vascular Pregnancy Complications|Interest of Circulating Endothelial Biomarkers in Vascular Pregnancy Complications|Completed||N/A|280|Actual|Assistance Publique Hopitaux De Marseille||4|||f||||||||||||||2018-06-01 03:09:58.80016|2018-06-01 03:09:58.80016
NCT00485771|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|November 2003||2003-11-30|June 2007|2007-06-30|January 2005|Actual|2005-01-31|||||Interventional|||Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression|Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression|Completed||Phase 4|403|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:09:58.868414|2018-06-01 03:09:58.868414
NCT00485758|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2009-08-04||2015-10-09|2007-06-12|2007-06-13|Estimate|2009-08-04|2009-09-11|Estimate||||2015-10-09|2015-10-12|Estimate|July 2007||2007-07-31|October 2015|2015-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)|A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes|Completed||Phase 3|796|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:09:59.035662|2018-06-01 03:09:59.035662
NCT00485745|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2014-11-25|2007-06-12|2007-06-13|Estimate|||||||2014-11-25|2014-12-02|Estimate|January 2002||2002-01-31|November 2014|2014-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Repeat Sternotomy for Pediatrics|Repeat Sternotomy for Pediatric Cardiac Surgery: Indications, Risks and Results|Completed|||1281|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 03:09:59.456061|2018-06-01 03:09:59.456061
NCT00485732|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2009-11-12||2016-11-03|2007-06-12|2007-06-13|Estimate|2009-11-12|2009-12-17|Estimate||||2016-11-03|2016-12-16|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years|A Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly in Healthy Female Subjects Aged 15 - 25 Years|Completed||Phase 3|225|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:09:59.546085|2018-06-01 03:09:59.546085
NCT00485719|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2013-05-29|2007-06-11|2007-06-13|Estimate|||||||2013-05-29|2013-05-30|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL765 Administered Orally Daily to Subjects With Solid Tumors|Completed||Phase 1|83|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:10:00.065913|2018-06-01 03:10:00.065913
NCT00485706|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2010-01-15|2007-06-12|2007-06-13|Estimate|||||||2010-01-15|2010-01-18|Estimate|June 2007||2007-06-30|June 2007|2007-06-30||||||||Interventional|||Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients|Arterial Stiffness and Decreased Bone Buffering Capacity in Hemodialysis Patients|Completed||N/A|||Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-06-01 03:10:00.172899|2018-06-01 03:10:00.172899
NCT00485693|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2011-11-23|2010-08-25|2013-07-03|2007-06-11|2007-06-13|Estimate|2013-07-03|2013-08-06|Estimate|2010-09-01|2010-09-06|Estimate|2013-07-03|2013-08-06|Estimate|June 2007||2007-06-30|July 2013|2013-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|TKA||Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty|A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 Via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty.|Completed||Phase 2|138|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 03:10:00.292919|2018-06-01 03:10:00.292919
NCT00040638|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-02|||2011-07-21|2002-07-03|2002-07-04|Estimate|||||||2011-07-21|2011-07-25|Estimate|July 2002||2002-07-31|June 2011|2011-06-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer||Completed||Phase 2|40||Telik|||||f||||||||||||||2018-06-01 05:32:05.466434|2018-06-01 05:32:05.466434
NCT00485680|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|December 2003||2003-12-31|June 2007|2007-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Olanzapine Versus Comparator in the Treatment of Bipolar Disorder|Olanzapine Versus Lithium Carbonate in the Treatment of Bipolar Disorder, Manic or Mixed Episodes|Completed||Phase 3|140|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:10:00.681033|2018-06-01 03:10:00.681033
NCT00485667|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11||2010-08-30|2010-09-07|2007-06-11|2007-06-13|Estimate||||2010-08-30|2010-09-03|Estimate|2010-09-07|2010-10-04|Estimate|June 2007||2007-06-30|September 2010|2010-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|TQT||Phase 1 Thorough QT Study in Young Healthy Volunteers|Evaluation of the Effects of Therapeutic and Supra-therapeutic Single Doses of SKY0402 Given as Subcutaneous Injection on the QT/QTc Interval in Young Healthy Volunteers. A Prospective, Randomized, Placebo- and Positive-controlled, Double Blind, Single-centre, Crossover Phase 1 Study.|Completed||Phase 1|48|Actual|Pacira Pharmaceuticals, Inc||5|||f||||f||||||||||2018-06-01 03:10:00.779543|2018-06-01 03:10:00.779543
NCT00485654|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2012-03-14|2007-06-12|2007-06-13|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 1990||1990-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|January 2005|Actual|2005-01-31||Observational|||Racial Distribution of Heterotaxy Syndrome|Racial Distribution of Heterotaxy Syndrome and Effects on Clinical Outcomes Protocol|Terminated|||65|Actual|Children's Healthcare of Atlanta||||study was terminated because study conclusions varied.|f||||f||||||||||2018-06-01 03:10:00.867739|2018-06-01 03:10:00.867739
NCT00485641|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-12|2007-06-12|2007-06-13|Estimate|||||||2007-06-12|2007-06-13|Estimate|August 2005||2005-08-31|June 2007|2007-06-30|January 2007|Actual|2007-01-31|||||Observational|||Saeboflex Dynamic Hand Orthosis for Inpatient Rehabilitation Stroke Patients|Screening of Inpatient Rehabilitation Stroke Patients for Their Potential to Qualify to Use the Saeboflex Dynamic Hand Orthosis|Completed|||222|Actual|Kessler Foundation|||||f||||f||||||||||2018-06-01 03:10:00.918918|2018-06-01 03:10:00.918918
NCT00485628|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|April 2003||2003-04-30|June 2007|2007-06-30|October 2003|Actual|2003-10-31|||||Interventional|||Safety Study in Outpatient Japanese Children With ADHD|An Open-Label, Dose Titration Safety Study of Atomoxetine Hydrochloride in Outpatient Japanese Children With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 2|37|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:10:00.981089|2018-06-01 03:10:00.981089
NCT00485615|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2013-10-29|2007-06-11|2007-06-13|Estimate|||||||2013-10-29|2013-10-30|Estimate|October 2008||2008-10-31|June 2010|2010-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|OMEGA3SP||An Open Label Trial of Omega 3(o3mega+Joy)in the Treatment of Social Phobia|An Open-label, Pilot Study Evaluating the Efficacy of Enteric-coated Eicosapentaenoic Acid (o3mega+Joy) in the Treatment of Social Phobia|Completed||Phase 2|8|Actual|START Clinic for Mood and Anxiety Disorders||1|||f||||f||||||||||2018-06-01 03:10:01.049396|2018-06-01 03:10:01.049396
NCT00485602|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2007-06-12|2007-06-12|2007-06-13|Estimate|||||||2007-06-12|2007-06-13|Estimate|December 2007||2007-12-31|June 2007|2007-06-30||||||||Interventional|||Orthodontic Treatment With a Part-Time Wearing Esthetic Removable Appliance||Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:10:01.190519|2018-06-01 03:10:01.190519
NCT00485589|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11||2013-06-28|2017-05-10|2007-06-11|2007-06-13|Estimate||||2013-06-28|2013-07-04|Estimate|2017-05-10|2017-05-11|Actual|June 2007|Actual|2007-06-30|May 2017|2017-05-31|August 2013|Actual|2013-08-31|January 2010|Actual|2010-01-31||Interventional|FILM||A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)|A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab in Combination With Methotrexate (MTX) Compared to MTX Alone in Methotrexate- Naive Patients With Active Rheumatoid Arthritis|Terminated||Phase 3|613|Actual|Genentech, Inc.||2||"Based on analysis of results and consideration of available treatments, the overall benefit to~   risk profile of ocrelizumab was not favorable in RA."|f||||||||||||||2018-06-01 03:10:01.35398|2018-06-01 03:10:01.35398
NCT00485576|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2009-01-14|2007-06-12|2007-06-13|Estimate|||||||2009-01-14|2009-01-15|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma|A Randomized, Double Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Mild Allergic Asthma.|Completed||Phase 2|21|Actual|Alexion Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:10:01.500306|2018-06-01 03:10:01.500306
NCT00485563|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11||2010-08-20|2012-03-05|2007-06-11|2007-06-13|Estimate||||2010-08-20|2010-08-24|Estimate|2012-03-05|2012-03-08|Estimate|June 2007||2007-06-30|March 2012|2012-03-31|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|||A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma|A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma|Terminated||Phase 2|12|Actual|Endocyte||||Changes in treatment paradigm resulted in a lower than expected rate of accrual.|f||||f||||||||||2018-06-01 03:10:01.592211|2018-06-01 03:10:01.592211
NCT00485550|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|January 2004||2004-01-31|June 2007|2007-06-30|March 2005|Actual|2005-03-31|||||Interventional|||Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy|A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride Augmented With Either Extended-Release Methylphenidate Hydrochloride (Concerta-TM) or Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Not Responded to Stimulant Mono Therapy|Completed||Phase 3|14|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:10:01.710826|2018-06-01 03:10:01.710826
NCT00485537|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|September 2005||2005-09-30|June 2007|2007-06-30|December 2006|Actual|2006-12-31|||||Interventional|||Pregnancy Outcomes With a GnRH Antagonist Protocol Versus GnRH-Agonist Protocol in ICSI Cycles|Pregnancy Outcomes With a Gonadotropin-Releasing Hormone (GnRH) Antagonist (Cetrorelix) Protocol Versus GnRH-Agonist Protocol in Ovarian Stimulation for ICSI Cycles-a Prospective Study|Completed||N/A|2005|Actual|Clinic and Research Center in Human Reproduction Roger Abdelmassih|||||f||||t||||||||||2018-06-01 03:10:01.790073|2018-06-01 03:10:01.790073
NCT00485524|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2012-03-14|2007-06-12|2007-06-13|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2002||2002-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Comparison of NIRS and Serum Lactate to Predict Poor Post-operative Outcomes|A Retrospective Evaluation of the Utility of NIRS Compared With Serum Lactate Levels in Predicting Poor Post-Operative Outcome After Repair of Complex Congenital Heart Disease|Completed|||12|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 03:10:01.857538|2018-06-01 03:10:01.857538
NCT00485511|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2010-02-11|2007-06-12|2007-06-13|Estimate|||||||2010-02-11|2010-02-15|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Trial of Hydroxyurea in Spinal Muscular Atrophy|A Randomized, Double-Blind, Placebo-Controlled Trial of Hydroxyurea in Spinal Muscular Atrophy|Completed||Phase 2/Phase 3|||Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-06-01 03:10:01.932481|2018-06-01 03:10:01.932481
NCT00485498|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|April 2003||2003-04-30|June 2007|2007-06-30|December 2003|Actual|2003-12-31|||||Interventional|||Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics|Managing Acute Schizophrenia, a Double Blind Comparison Between Two Atypical Antipsychotics - Olanzapine and Risperidone|Completed||Phase 4|122|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:10:02.08379|2018-06-01 03:10:02.08379
NCT00485485|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2011-07-28||2012-08-01|2007-06-12|2007-06-13|Estimate|2011-07-28|2011-08-29|Estimate||||2012-08-01|2012-08-07|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer|Phase II Study of Imatinib Mesylate and Docetaxel in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer|Completed||Phase 2|7|Actual|M.D. Anderson Cancer Center|Study was closed to enrollment early due to low enrollment. Study enrolled 7 participants over approximately 2 years with a planned enrollment of up to 58.|1|||f||||f||||||||||2018-06-01 03:10:02.164126|2018-06-01 03:10:02.164126
NCT00485472|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|2009-08-12||2017-07-28|2007-06-12|2007-06-13|Estimate|2009-08-12|2009-09-22|Estimate||||2017-07-28|2017-08-28|Actual|March 2007||2007-03-31|July 2017|2017-07-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Osteoarthritis of the Knee|Terminated||Phase 2|194|Actual|UCB Pharma||2||"Based on the outcome of the planned first interim analysis, it was decided not to continue the~   trial. No safety concerns were identified."|f||||f||||||||||2018-06-01 03:10:02.374785|2018-06-01 03:10:02.374785
NCT00485459|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-13|Estimate|||||||2007-06-11|2007-06-13|Estimate|February 2004||2004-02-29|June 2007|2007-06-30|November 2004|Actual|2004-11-30|||||Interventional|||Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD|Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|106|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:10:03.088129|2018-06-01 03:10:03.088129
NCT00485446|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-12|||2007-06-12|2007-06-12|2007-06-13|Estimate|||||||2007-06-12|2007-06-13|Estimate||||June 2007|2007-06-30||||||||Observational|||Thrombophilia and Thyroid Autoimmunity in Implantation Failure and Recurrent Miscarriage||Completed|||||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||||||||||||2018-06-01 03:10:03.198619|2018-06-01 03:10:03.198619
NCT00485433|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2011-11-23|2010-08-25|2013-07-03|2007-06-11|2007-06-13|Estimate|2013-07-03|2013-08-06|Estimate|2010-09-03|2010-09-08|Estimate|2013-07-03|2013-08-06|Estimate|June 2007||2007-06-30|July 2013|2013-07-31|August 2008|Actual|2008-08-31|December 2007|Actual|2007-12-31||Interventional|||Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair|A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair.|Completed||Phase 2|98|Actual|Pacira Pharmaceuticals, Inc||4|||f||||f||||||||||2018-06-01 03:10:03.296559|2018-06-01 03:10:03.296559
NCT00485420|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2012-04-18|2007-06-11|2007-06-13|Estimate|||||||2012-04-18|2012-04-19|Estimate|September 2002||2002-09-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||eCare for Moods: An Internet-based Management Program|Using the Internet to Provide Disease Management and Improve Compliance Among Bipolar and Depressed Patients|Completed||N/A|404|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 03:10:03.766807|2018-06-01 03:10:03.766807
NCT00485407|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-10-31|2007-06-11|2007-06-13|Estimate|||||||2007-10-31|2007-11-01|Estimate|July 2003||2003-07-31|June 2007|2007-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine|Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study|Completed||Phase 3|377|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:10:03.911704|2018-06-01 03:10:03.911704
NCT00485394|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2008-03-31|2007-06-11|2007-06-13|Estimate|||||||2008-03-31|2008-04-02|Estimate|June 2007||2007-06-30|March 2008|2008-03-31||||February 2010|Anticipated|2010-02-28||Interventional|OMEGA||The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)|A Randomized, Double-Masked, Dose-Ranging, Multi-Center, Phase II Study Comparing the Safety and Efficacy of OT-551 With Placebo to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration|Unknown status|Active, not recruiting|Phase 2|198|Anticipated|Othera Pharmaceuticals||3|||f||||t||||||||||2018-06-01 03:10:04.039139|2018-06-01 03:10:04.039139
NCT00485368|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-12|2007-06-12|2007-06-13|Estimate|||||||2007-06-12|2007-06-13|Estimate|January 2004||2004-01-31|June 2007|2007-06-30|September 2006|Actual|2006-09-30|||||Interventional|||Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome|The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.|Completed||Phase 3|17|Actual|Bayside Health|||||f||||f||||||||||2018-06-01 03:10:04.158403|2018-06-01 03:10:04.158403
NCT00485355|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2014-02-18|2007-06-11|2007-06-12|Estimate|||||||2014-02-18|2014-02-19|Estimate|June 2007||2007-06-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy|A Prospective Randomized Trial Comparing Conventional vs. Robotic Assisted Laparoscopic Hysterectomy|Completed||N/A|27|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 03:10:04.243495|2018-06-01 03:10:04.243495
NCT00485342|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2012-01-06|2007-06-08|2007-06-12|Estimate|||||||2012-01-06|2012-01-09|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|RIBAJUSTE||RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin|Multicentric, Controlled and Randomised Open Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin Using Pharmacologic Measures of Ribavirin Exposition During Combination Peginterferon Alfa-2 and Ribavirin Treatment in Naive Patients With Chronic Hepatitis C of Genotype 1 on a First Combination Therapy|Unknown status|Recruiting|Phase 3|236|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 03:10:04.350282|2018-06-01 03:10:04.350282
NCT00485329|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-10|||2010-05-24|2007-06-11|2007-06-12|Estimate|||||||2010-05-24|2010-05-25|Estimate|July 2007||2007-07-31|May 2010|2010-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|ENZ-DER-002-IL||Assessment of the Safety and Efficacy of DERMASTREAM™ - ENZYSTREAM™ System for the Treatment of Chronic Venous Ulcers|A Phase I/II Randomized, Double Blind, Placebo-Controlled Dose- Escalating Study, to Assess The Safety and Efficacy of Enzystream™ Debriding Solution (Papain) Applied by Dermastream™ Device for the Treatment of Lower Extremity Chronic Venous Ulcers|Completed||Phase 1/Phase 2|48|Actual|EnzySurge||3|||f||||t||||||||||2018-06-01 03:10:04.502987|2018-06-01 03:10:04.502987
NCT00485316|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2009-03-30|2007-06-11|2007-06-12|Estimate|||||||2009-03-30|2009-03-31|Estimate|September 1993||1993-09-30|March 2009|2009-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma|Prospective Randomized Trial Comparing Laparoscopic Assisted and Open Resection for Colonic and Rectal Carcinoma|Completed||Phase 3|||Chinese University of Hong Kong|||||f||||t||||||||||2018-06-01 03:10:04.646849|2018-06-01 03:10:04.646849
NCT00485303|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|2013-04-23||2013-06-25|2007-06-08|2007-06-12|Estimate|2013-04-23|2013-06-17|Estimate||||2013-06-25|2013-07-02|Estimate|June 2007||2007-06-30|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy|A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy|Completed||Phase 2|58|Actual|Cougar Biotechnology, Inc.||1|||f||||f||||||||||2018-06-01 03:10:04.763022|2018-06-01 03:10:04.763022
NCT00485290|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2008-08-06|2007-06-11|2007-06-12|Estimate|||||||2008-08-06|2008-08-07|Estimate|June 2007||2007-06-30|November 2007|2007-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|VIPE||Effect of Meal on Portal and Esophagus Variceal Pressure|Effect of Meal on Portal and Esophagus Variceal Pressure|Terminated||N/A|0|Actual|Hvidovre University Hospital||||No eligible patients were found, the study stopped without including any patients|f||||f||||||||||2018-06-01 03:10:05.221821|2018-06-01 03:10:05.221821
NCT00485277|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2012-01-25|2007-06-11|2007-06-12|Estimate|||||||2012-01-25|2012-01-26|Estimate|June 2007||2007-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer|A Phase I Trial of a Fixed Dose of MVA-BN-HER2 Following 1st- or 2nd-Line Chemotherapy for HER-2-Positive Metastatic Breast Cancer|Completed||Phase 1|9|Actual|Bavarian Nordic, Inc.|||||f||||t||||||||||2018-06-01 03:10:05.292882|2018-06-01 03:10:05.292882
NCT00485264|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2014-02-28||2018-02-26|2007-06-11|2007-06-12|Estimate|2014-12-18|2014-12-22|Estimate||||2018-02-26|2018-03-29|Actual|September 17, 2007|Actual|2007-09-17|February 2018|2018-02-28|May 18, 2017|Actual|2017-05-18|June 3, 2013|Actual|2013-06-03||Interventional||All Treated Population: All patients exposed to raltegravir (at any dose)|Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents|A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents|Completed||Phase 1/Phase 2|153|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 03:10:05.511018|2018-06-01 03:10:05.511018
NCT00485251|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2009-11-23|2007-06-11|2007-06-12|Estimate|||||||2009-11-23|2009-11-25|Estimate|February 2007||2007-02-28|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Prospective Randomized Trial of Hand-assisted Laparoscopic Right Hemicolectomy vs Total Laparoscopic Right Hemicolectomy||Completed||Phase 4|60|Anticipated|Pamela Youde Nethersole Eastern Hospital||2|||f||||t||||||||||2018-06-01 03:10:11.575565|2018-06-01 03:10:11.575565
NCT00485238|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2008-05-13|2007-06-11|2007-06-12|Estimate|||||||2008-05-13|2008-05-15|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|||||Interventional|Iridoplasty||ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function|EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES|Unknown status|Recruiting|Phase 4|60|Anticipated|National University Hospital, Singapore|||||f||||f||||||||||2018-06-01 03:10:11.681218|2018-06-01 03:10:11.681218
NCT00485225|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08||2012-02-21|2012-02-21|2007-06-11|2007-06-12|Estimate||||2012-02-21|2012-02-23|Estimate|2012-02-21|2012-02-23|Estimate|June 2007||2007-06-30|December 2011|2011-12-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain|An Open-Label, Two-Stage, Phase II Study to Explore the Titration Schedule for Transitioning Opioid-Experienced Patients With Non-Malignant Moderate to Severe Chronic Pain From Current Opioid Therapy to EN3270.|Completed||Phase 2|77|Actual|Durect||4|||f||||f||||||||||2018-06-01 03:10:11.763872|2018-06-01 03:10:11.763872
NCT00485212|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-12|Estimate|||||||2007-06-11|2007-06-12|Estimate|January 2007||2007-01-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Compression Bandage in Local Infiltration Analgesia Afte Total Knee Arthroplasty|The Effect of a Compression Bandage in Local Infiltration Analgesia After Total Knee Arthroplasty|Completed||Phase 4|48|Actual|Hvidovre University Hospital|||||f||||f||||||||||2018-06-01 03:10:11.83328|2018-06-01 03:10:11.83328
NCT00485199|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-12|Estimate|||||||2007-06-11|2007-06-12|Estimate|January 2005||2005-01-31|June 2007|2007-06-30|December 2006|Actual|2006-12-31|||||Interventional|RDMH||Pneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole|Pneumatic Retinopexy Versus Vitrectomy With Gas for Retinal Detachment Due to Myopic Macular Hole|Completed||N/A|231|Actual|Peking University|||||f||||t||||||||||2018-06-01 03:10:11.912495|2018-06-01 03:10:11.912495
NCT00485186|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2013-09-04|2007-06-08|2007-06-12|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Gene Polymorphisms Influencing Steroid Synthesis and Action|Investigation of Gene Polymorphisms Influencing Steroid Synthesis and Action in Patients With Deficient Steroid Biosynthesis and Disorders of Sex Development|Withdrawn|||0|Actual|University of Schleswig-Holstein|||2||f||||f||||||||||2018-06-01 03:10:11.999296|2018-06-01 03:10:11.999296
NCT00485173|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|2012-12-14||2013-02-14|2007-06-08|2007-06-12|Estimate|2013-02-14|2013-03-19|Estimate||||2013-02-14|2013-03-19|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|ACDF||INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial|A Pivotal Clinical Investigation of INFUSE® Bone Graft With a PEEK Interbody Spacer and an Anterior Cervical Plate in Patients With Cervical Degenerative Disc Disease at a Single Level.|Completed||N/A|224|Actual|Medtronic Spinal and Biologics||1|||f||||t||||||||||2018-06-01 03:10:12.294344|2018-06-01 03:10:12.294344
NCT00485160|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2011-07-20|2007-06-11|2007-06-12|Estimate|||||||2011-07-20|2011-07-21|Estimate|February 2002||2002-02-28|June 2007|2007-06-30|September 2006|Actual|2006-09-30|||||Interventional|||Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA|Comparison of Intravenous Ibuprofen vs. Continuous Indomethacin in the Treatment of Patent Ductus Arteriosus|Completed||Phase 3|70|Anticipated|Shaare Zedek Medical Center|||||f||||f||||||||||2018-06-01 03:10:14.827408|2018-06-01 03:10:14.827408
NCT00485147|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2012-06-28|2007-06-11|2007-06-12|Estimate|||||||2012-06-28|2012-07-02|Estimate|March 2006||2006-03-31|April 2010|2010-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Starter-GPS||Locomotion and Global Positioning System in Arterial Disease|Study of Human Locomotion With Global Positioning System. Application to Patients With Peripheral Arterial Disease|Completed||N/A|140|Actual|University Hospital, Angers|||||f||||f||||||||||2018-06-01 03:10:14.89283|2018-06-01 03:10:14.89283
NCT00485134|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2016-10-24||2017-08-08|2007-06-11|2007-06-12|Estimate|2017-08-08|2017-09-11|Actual||||2017-08-08|2017-09-11|Actual|May 2007||2007-05-31|August 2017|2017-08-31|September 2010|Actual|2010-09-30|July 2009|Actual|2009-07-31||Interventional|||Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection|Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection|Completed||Phase 1/Phase 2|113|Actual|U.S. Army Medical Research and Materiel Command||6|||f||||f||||||||||2018-06-01 03:10:14.992579|2018-06-01 03:10:14.992579
NCT00485121|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2010-11-24|2007-06-08|2007-06-12|Estimate|||||||2010-11-24|2010-11-25|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis|Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis|Completed||N/A|50|Anticipated|Canadian Collaborative Research Network|||||f||||f||||||||||2018-06-01 03:10:15.761877|2018-06-01 03:10:15.761877
NCT00485108|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-09|||2015-09-21|2007-06-09|2007-06-12|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|June 2009|Actual|2009-06-30||Interventional|||Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty|Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study|Completed||N/A|120|Actual|Queen's University||3|||f||||f||||||||||2018-06-01 03:10:15.845483|2018-06-01 03:10:15.845483
NCT00485095|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2011-06-30|2007-06-11|2007-06-12|Estimate|||||||2011-06-30|2011-07-01|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The Effect of Plant Sterol Supplement on Blood Cholesterol|A Single Centre, Randomized Crossover Double-Blind Placebo-Controlled Study to Measure the Effect of Plant Sterol Supplement on Blood Cholesterol|Completed||Phase 4|41|Actual|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:10:16.013651|2018-06-01 03:10:16.013651
NCT00485082|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-09|||2017-06-30|2007-06-09|2007-06-12|Estimate|||||||2017-06-30|2017-07-02|Actual|June 5, 2007||2007-06-05|August 25, 2009|2009-08-25||||March 21, 2008|Actual|2008-03-21||Observational|||Disclosing a Cystic Fibrosis Diagnosis to a Dating Partner|Disclosure of a Cystic Fibrosis Diagnosis to a Dating Partner|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:10:16.065857|2018-06-01 03:10:16.065857
NCT00485069|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2010-09-20|2010-08-12|2010-11-18|2007-06-11|2007-06-12|Estimate|2010-11-18|2010-12-15|Estimate|2010-08-12|2010-08-17|Estimate|2010-11-18|2010-12-15|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study|Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety -|Completed||Phase 4|123|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:10:16.149797|2018-06-01 03:10:16.149797
NCT00485056|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2016-08-08|2007-06-11|2007-06-12|Estimate|||||||2016-08-08|2016-08-09|Estimate|April 2008||2008-04-30|August 2009|2009-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|PICCOLA||Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study)|Pioglitazone on Cardiac Function and Large Arteries (PICCOLA)|Completed||Phase 4|24|Actual|Imperial College London||2|||f||||t||||||||No||2018-06-01 03:10:16.893229|2018-06-01 03:10:16.893229
NCT00485043|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-12|Estimate|||||||2007-06-11|2007-06-12|Estimate|January 2006||2006-01-31|June 2007|2007-06-30|April 2006|Actual|2006-04-30|||||Interventional|||Effects of Modified T'ai Chi on Symptoms in Older Adults With Osteoarthritis|Effects of Modified T’ai Chi Exercise on Physical Function, Pain, and Stiffness in Older Adults With Lower Extremity Osteoarthritis|Completed||Phase 1|30|Actual|University of Kansas|||||f||||f||||||||||2018-06-01 03:10:17.181051|2018-06-01 03:10:17.181051
NCT00485030|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2012-08-06|2007-06-11|2007-06-12|Estimate|||||||2012-08-06|2012-08-08|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|DES-ISR||Diffuse Type In-Stent Restenosis After Drug-Eluting Stent|Comparison Between Drug-Eluting Stents for the Treatment of the Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation: Sirolimus-Eluting vs. Paclitaxel-Eluting Stents|Completed||Phase 4|60|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 03:10:17.237088|2018-06-01 03:10:17.237088
NCT00485017|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2008-06-30|2007-06-08|2007-06-12|Estimate|||||||2008-06-30|2008-07-02|Estimate|August 2007||2007-08-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety of THR-4109 in Obese Subjects|A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of THR-4109 in Obese Subjects|Completed||Phase 2|220|Anticipated|Theracos||4|||f||||f||||||||||2018-06-01 03:10:17.335432|2018-06-01 03:10:17.335432
NCT00485004|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2012-08-06|2007-06-11|2007-06-12|Estimate|||||||2012-08-06|2012-08-08|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|FOCUS||Focal In-stent Restenosis After Drug-Eluting Stent|FOcal Type In-stent Restenosis After Drug-Eluting Stent Implantation Treated by CUtting Balloon Angioplasty Versus Sirolimus-Eluting Stent|Completed||Phase 4|100|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 03:10:17.47093|2018-06-01 03:10:17.47093
NCT00484991|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2008-04-11|2007-06-08|2007-06-12|Estimate|||||||2008-04-11|2008-04-15|Estimate||||April 2008|2008-04-30||||||||Expanded Access|||Sapropterin Expanded Access Program|Sapropterin Expanded Access Program|Approved for marketing|||||BioMarin Pharmaceutical|||||||||||||||||||2018-06-01 03:10:17.569184|2018-06-01 03:10:17.569184
NCT00484978|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-12|Estimate|||||||2007-06-11|2007-06-12|Estimate|February 2007||2007-02-28|June 2007|2007-06-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Stereotactic Radiosurgery to the Resection Cavity Following Surgical Removal of Brain Metastasis|A Single Center Prospective Phase II Study: Stereotactic Radiosurgery to the Resection Cavity Following Surgical Removal of Brain Metastasis|Unknown status|Recruiting|Phase 2|35|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 03:10:17.754505|2018-06-01 03:10:17.754505
NCT00484965|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-06-11|2007-06-11|2007-06-12|Estimate|||||||2007-06-11|2007-06-12|Estimate|July 2007||2007-07-31|June 2007|2007-06-30|January 2009|Anticipated|2009-01-31|||||Interventional|TROY||Erythrocyte-Mediated Drug Delivery for the Prevention of Stent Restenosis|Erythrocyte-Mediated Drug Delivery for the Prevention of Restenosis After Coronary Artery Stent Implantation:TROY-Study|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Rome Tor Vergata|||||f||||t||||||||||2018-06-01 03:10:17.846171|2018-06-01 03:10:17.846171
NCT00484952|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2007-07-31|2007-06-11|2007-06-12|Estimate|||||||2007-07-31|2007-08-01|Estimate|September 2007||2007-09-30|June 2007|2007-06-30|September 2009|Anticipated|2009-09-30|||||Observational|||Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel|Multicenter Study for Surveillance of Hospitalizations Due to Rotavirus-Associated Diarrhea and Estimation of the Economic Burden of Rotavirus Hospitalizations|Unknown status|Not yet recruiting||2500|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-06-01 03:10:17.922691|2018-06-01 03:10:17.922691
NCT00484939|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|2014-03-07||2015-01-07|2007-06-11|2007-06-12|Estimate|2014-05-28|2014-06-10|Estimate||||2015-01-07|2015-01-08|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Intent-to-treat population: All participants randomized into the study.|A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer|A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer|Completed||Phase 3|280|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:10:18.053582|2018-06-01 03:10:18.053582
NCT00484926|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-11|||2012-08-09|2007-06-11|2007-06-12|Estimate|||||||2012-08-09|2012-08-10|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|REAL-LATE||Association of Clopidogrel Therapy and Stent Thrombosis|Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events|Completed||Phase 4|2000|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 03:10:18.742784|2018-06-01 03:10:18.742784
NCT00484913|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2007-06-08|2007-06-08|2007-06-12|Estimate|||||||2007-06-08|2007-06-12|Estimate|September 2003||2003-09-30|June 2007|2007-06-30|December 2003|Actual|2003-12-31|||||Interventional|||Effects of Abdominal Hot Compresses on Indocyanine Green Elimination in Healthy Subjects|Effects of Abdominal Hot Compresses on Indocyanine Green Elimination – a Randomized Cross Over Study in Healthy Subjects|Completed||Phase 1|14|Actual|University Hospital Freiburg|||||f||||f||||||||||2018-06-01 03:10:18.825339|2018-06-01 03:10:18.825339
NCT00484900|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2008-03-25|2007-06-08|2007-06-11|Estimate|||||||2008-03-25|2008-03-26|Estimate|May 2006||2006-05-31|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria|Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria|Completed||Phase 3|1390|Actual|Dafra Pharma|||||f||||f||||||||||2018-06-01 03:10:18.906175|2018-06-01 03:10:18.906175
NCT00484887|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2016-08-05|2007-06-07|2007-06-11|Estimate|||||||2016-08-05|2016-08-08|Estimate|April 2007||2007-04-30|May 2016|2016-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Characterization of Explanted Hernia Meshes From Human Subjects: A Multi-Center, Prospective Study|Characterization of Explanted Hernia Meshes From Human Subjects: A Multi-Center, Prospective Study|Terminated|||272|Actual|University of Missouri-Columbia||||PI left institution|f||||f||||||Samples Without DNA|"~     Explanted mesh from surgical procedures.~   "|No||2018-06-01 03:10:18.969399|2018-06-01 03:10:18.969399
NCT00484874|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2011-04-21|2007-06-08|2007-06-11|Estimate|||||||2011-04-21|2011-04-22|Estimate|June 2007||2007-06-30|April 2011|2011-04-30||||January 2014|Anticipated|2014-01-31||Interventional|||Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma|A Phase I/II Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||t||||||||||2018-06-01 03:10:19.057394|2018-06-01 03:10:19.057394
NCT00484861|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2018-05-09|2007-06-08|2007-06-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 7, 2007||2007-06-07|February 14, 2017|2017-02-14|February 14, 2017||2017-02-14|||||Observational|||Effect of Diet on Vascular Disease in Pre-Menopausal Women|The Effect of Diet on Vascular Disease: A Study of African American and Caucasian Women|Completed|||47|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:10:19.29496|2018-06-01 03:10:19.29496
NCT00484848|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2009-01-23|2007-06-07|2007-06-11|Estimate|||||||2009-01-23|2009-01-26|Estimate|September 2004||2004-09-30|January 2009|2009-01-31|March 2005|Actual|2005-03-31|December 2004|Actual|2004-12-31||Interventional|||Functional Evaluation of Two Types of Totally Implanted Venous Ports|Functional Evaluation of Conventional Venous Access Port (Celsite®) Versus Venous Access Port With Tangential Outlet (Vortex®) : a Prospective Randomized Pilot Study|Completed||N/A|200|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-06-01 03:10:19.356614|2018-06-01 03:10:19.356614
NCT00484835|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2007-08-07|2007-06-08|2007-06-11|Estimate|||||||2007-08-07|2007-08-08|Estimate|September 2007||2007-09-30|June 2007|2007-06-30|August 2008|Anticipated|2008-08-31|||||Interventional|||Are Sutures Required in Total Abdominal Hysterectomy? A Randomised Control Trial|Randomised Control Trial Comparing Hysterectomy Using Electrocoagulation Forceps With the Traditional Clamp & Suture Technique of Richardson Abdominal Hysterectomy|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Southern Health|||||f||||t||||||||||2018-06-01 03:10:19.43928|2018-06-01 03:10:19.43928
NCT00484822|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2010-02-03|2007-06-08|2007-06-11|Estimate|||||||2010-02-03|2010-02-04|Estimate|February 2007||2007-02-28|February 2010|2010-02-28|May 2009|Anticipated|2009-05-31|||||Interventional|BERTA||Bemiparin Randomized Trial on Bridging Oral Anticoagulants in Invasive Procedures (BERTA Study)|Multicentric, Randomized, Controlled, Double-blind Clinical Trial to Assess Perioperative Bridging Therapy With Sodium Bemiparin vs Calcium Unfractionated Heparin in Invasive Procedures, Outpatient Surgery and Laparoscopy Surgery in Patients Receiving Long-term Oral Anticoagulant Therapy|Terminated||Phase 3|206|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||The study has been halted prematurely due to a low recruitment.|f||||t||||||||||2018-06-01 03:10:19.530937|2018-06-01 03:10:19.530937
NCT00484809|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2007-12-11|2007-06-08|2007-06-11|Estimate|||||||2007-12-11|2007-12-14|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|February 2006|Actual|2006-02-28|||||Observational|||Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children|A Post-Marketing Surveillance Looking at Safety of Enbrel (Etanercept) in Adults With Active Rheumatoid Arthritis (RA) and Children With Juvenile Rheumatoid Arthritis (JRA).|Completed|||100||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:10:19.69617|2018-06-01 03:10:19.69617
NCT00484796|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2012-10-26|2007-06-08|2007-06-11|Estimate|||||||2012-10-26|2012-10-29|Estimate|October 2006||2006-10-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Observational|TRISEP||Trigeminus-evoked Somatosensory Potentials in Patients Undergoing Carotid Surgery|Comparison of Trigeminus-evoked Somatosensory Potentials (TRI-SEP) and Medianus-evoked Somatosensory Potentials (MED-SEP) in Patients Undergoing Carotid Surgery|Completed|||120|Actual|Klinikum St. Georg gGmbH|||1||f||||f||||||||||2018-06-01 03:10:19.794605|2018-06-01 03:10:19.794605
NCT00484783|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2014-12-12|2007-06-08|2007-06-11|Estimate|||||||2014-12-12|2014-12-16|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|NOTES||Transluminal Flexible Endoscopic Procedure in Foregut and Urologic Surgery|Prospective Evaluation of the Intraoperative Use of Translumenal Flexible Endoscopes During Combined Flexible and Laparoscopic Foregut and Urologic Surgery|Completed||N/A|11|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 03:10:19.937844|2018-06-01 03:10:19.937844
NCT00484770|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2014-08-20|2007-06-07|2007-06-11|Estimate|||||||2014-08-20|2014-08-22|Estimate|February 2003||2003-02-28|June 2007|2007-06-30|August 2005|Actual|2005-08-31|||||Interventional|STARBRITE||STARBRITE: A Randomized Pilot Trial of BNP-Guided Therapy in Patients With Advanced Heart Failure|Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: Brain Natriuretic Peptide Levels Versus the Clinical Congestion Score|Completed||Phase 2|135|Actual|Duke University||2|||f||||t||||||||||2018-06-01 03:10:20.047235|2018-06-01 03:10:20.047235
NCT00484757|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2009-04-02|2007-06-08|2007-06-11|Estimate|||||||2009-04-02|2009-04-03|Estimate|June 2007||2007-06-30|April 2009|2009-04-30|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|NARKOREX||Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition||Unknown status|Active, not recruiting|N/A|||Zentrum für Integrative Psychiatrie|||||f||||f||||||||||2018-06-01 03:10:20.163385|2018-06-01 03:10:20.163385
NCT00484744|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2013-04-24|2007-06-07|2007-06-11|Estimate|||||||2013-04-24|2013-04-25|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Acetaminophen Versus Ibuprofen for the Control of Immediate and Delayed Pain Following Orthodontic Separator Placement|Acetaminophen Versus Ibuprofen for the Control of Immediate and Delayed Pain Following Orthodontic Separator Placement|Completed||Phase 4|35|Actual|University of Missouri, Kansas City||3|||f||||f||||||||||2018-06-01 03:10:20.266484|2018-06-01 03:10:20.266484
NCT00484731|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2011-06-21|2007-06-08|2007-06-11|Estimate|||||||2011-06-21|2011-06-22|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|June 2012|Anticipated|2012-06-30|December 2011|Anticipated|2011-12-31||Interventional|||Effect of Intraoperative Infiltration With Bupivacain on the Development of Chronic Pain After Inguinal Hernia Repair|Investigating the Effect of Intra-operative Infiltration With Local Anaesthesia on the Development of Chronic Postoperative Pain After Inguinal Hernia Repair. A Randomized Placebo Controlled Triple Blinded and Group Sequential Study Design|Unknown status|Recruiting|Phase 4|404|Anticipated|Luzerner Kantonsspital||2|||f||||t||||||||||2018-06-01 03:10:20.3725|2018-06-01 03:10:20.3725
NCT00484718|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2012-01-26|2007-06-08|2007-06-11|Estimate|||||||2012-01-26|2012-01-31|Estimate|February 2008||2008-02-29|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.|Measures Of Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee: A Randomized, Single-Blind Washout, Double-Blind Treatment, Double Dummy Cross-Over Pilot Trial Using Placebo, Oxycodone And Celecoxib (A9011030)|Terminated||N/A|6|Actual|Pfizer||3||See termination reason in detailed description.|f||||f||||||||||2018-06-01 03:10:20.458225|2018-06-01 03:10:20.458225
NCT00484705|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2009-11-09|2007-06-08|2007-06-11|Estimate|||||||2009-11-09|2009-11-10|Estimate|October 2005||2005-10-31|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|PCOSNTS||Polycystic Ovary Syndrome (PCOS) - Effect Of Physical Exercise And Electroacupuncture|Polycystic Ovary Syndrome (PCOS) - The Female Metabolic Syndrome Genes And Processes In The Aetiology And Pathogenesis Of PCOS And Identification Of New Treatment Strategies|Completed||N/A|84|Actual|Göteborg University||3|||f||||t||||||||||2018-06-01 03:10:20.558191|2018-06-01 03:10:20.558191
NCT00484692|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2007-06-08|2007-06-08|2007-06-11|Estimate|||||||2007-06-08|2007-06-11|Estimate|July 2005||2005-07-31|June 2007|2007-06-30|January 2007|Actual|2007-01-31|||||Interventional|||Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation|Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training®|Completed||Phase 4|779|Actual|Medical University Innsbruck|||||f||||t||||||||||2018-06-01 03:10:20.652712|2018-06-01 03:10:20.652712
NCT00484679|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|2013-02-27||2017-04-17|2007-06-08|2007-06-11|Estimate|2014-05-20|2014-06-20|Estimate||||2017-04-17|2017-05-19|Actual|May 2007||2007-05-31|April 2017|2017-04-30|March 2011|Actual|2011-03-31|June 2009|Actual|2009-06-30||Interventional||15 completed the study and were used for analysis.|Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata|Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata|Completed||Phase 2|18|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-06-01 03:10:20.719824|2018-06-01 03:10:20.719824
NCT00484666|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2013-02-05|2007-06-08|2007-06-11|Estimate|||||||2013-02-05|2013-02-06|Estimate|May 2008||2008-05-31|February 2013|2013-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|Topo Txt||A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer|A Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer|Completed||Phase 2|46|Actual|Carilion Clinic||1|||f||||t||||||||||2018-06-01 03:10:20.891218|2018-06-01 03:10:20.891218
NCT00484653|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2014-08-27|2007-06-08|2007-06-11|Estimate|||||||2014-08-27|2014-08-28|Estimate|July 2007||2007-07-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman|Identification and Impact of Vaginal Flora Anomalies Among Pregnant Woman|Completed||N/A|1000|Actual|Assistance Publique Hopitaux De Marseille|||||f||||||||||||||2018-06-01 03:10:20.980466|2018-06-01 03:10:20.980466
NCT00484640|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2007-06-08|2007-06-08|2007-06-11|Estimate|||||||2007-06-08|2007-06-11|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|May 2008|Anticipated|2008-05-31|||||Interventional|||Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing|Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing|Unknown status|Not yet recruiting|N/A|260|Anticipated|Agency for Healthcare Research and Quality (AHRQ)|||||f||||t||||||||||2018-06-01 03:10:21.044577|2018-06-01 03:10:21.044577
NCT00484627|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2007-06-08|2007-06-08|2007-06-11|Estimate|||||||2007-06-08|2007-06-11|Estimate|August 2001||2001-08-31|June 2007|2007-06-30|October 2003|Actual|2003-10-31|||||Interventional|||Effects of Creatine and Resistance Exercise Training in People With HIV Infection|Ergogenic Effects of Creatine Supplementation in HIV Infection|Completed||Phase 2|43|Actual|National Center for Complementary and Integrative Health (NCCIH)|||||f||||f||||||||||2018-06-01 03:10:21.112296|2018-06-01 03:10:21.112296
NCT00484614|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2009-09-02|2007-06-08|2007-06-11|Estimate|||||||2009-09-02|2009-09-03|Estimate|September 2006||2006-09-30|December 2008|2008-12-31|March 2009|Anticipated|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer|Prospective Multicenter Study of the Role of Positron Emission Mammography (PEM) in Pre-Surgical Planning for Breast Cancer|Unknown status|Active, not recruiting|Phase 4|472|Actual|Naviscan PET Systems||2|||f||||t||||||||||2018-06-01 03:10:21.167728|2018-06-01 03:10:21.167728
NCT00484601|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2008-12-16|2007-06-08|2007-06-11|Estimate|||||||2008-12-16|2008-12-17|Estimate|October 2004||2004-10-31|December 2008|2008-12-31|September 2010|Anticipated|2010-09-30|||||Interventional|||Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma|Phase II Study of Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma|Terminated||Phase 2|35|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-06-01 03:10:21.247254|2018-06-01 03:10:21.247254
NCT00484575|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2010-05-19|2007-06-08|2007-06-11|Estimate|||||||2010-05-19|2010-05-20|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting|Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting|Completed||Phase 1/Phase 2|100|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 03:10:21.349564|2018-06-01 03:10:21.349564
NCT00484562|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2016-10-03|2007-06-08|2007-06-11|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Prospective Study Comparing Different Modalities of Oxygen Delivery During Assessment of Functional Exercise Capacity|A Randomized, Multi-arm Repeated Measures Prospective Study Comparing Different Modalities of Portable Oxygen Delivery During Assessment of Functional Exercise Capacity|Completed||N/A|39|Actual|University of Missouri-Columbia||4|||f||||f||||||||No||2018-06-01 03:10:21.42312|2018-06-01 03:10:21.42312
NCT00484549|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2009-12-18|2007-06-08|2007-06-11|Estimate|||||||2009-12-18|2009-12-21|Estimate|March 2007||2007-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|FIND||Fabry : National Initiative of Screening|National, Multicenter, Prospective Study of Screening of Fabry Disease in a Population of Men Over 28 Days Old and Less Than 55 Years, Hospitalized for an Ischemic Stroke.|Completed||N/A|889|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:10:21.495632|2018-06-01 03:10:21.495632
NCT00484536|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08||2011-01-20|2011-09-02|2007-06-08|2007-06-11|Estimate||||2011-01-20|2011-01-28|Estimate|2011-09-02|2011-09-12|Estimate|May 2007||2007-05-31|March 2011|2011-03-31|July 2010|Actual|2010-07-31|November 2009|Actual|2009-11-30||Interventional|||Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323|Double-blind, Placebo-controlled, Randomized, Parallel-group Phase II Study in Subjects With Relapsing Forms of Multiple Sclerosis (MS) to Evaluate the Safety, Tolerability, and Effects of CDP323.|Terminated||Phase 2|232|Actual|UCB Pharma||3||The study was discontinued due to unfavorable interim analysis|f||||t||||||||||2018-06-01 03:10:21.567762|2018-06-01 03:10:21.567762
NCT00484523|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2014-08-27|2007-06-08|2007-06-11|Estimate|||||||2014-08-27|2014-08-28|Estimate|July 2007||2007-07-31|August 2014|2014-08-31||||January 2010|Actual|2010-01-31||Interventional|||Constitution of a Standardized Neural Imaging Database in Healthy Subjects|Constitution of a Standardized Neural Imaging Database in Healthy Subjects|Completed||Early Phase 1|60|Actual|Assistance Publique Hopitaux De Marseille|||||f||||||||||||||2018-06-01 03:10:21.699593|2018-06-01 03:10:21.699593
NCT00484510|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2013-03-04|2007-06-08|2007-06-11|Estimate|||||||2013-03-04|2013-03-06|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||High Dose Ascorbic Acid Treatment of CMT1A|"A Randomized, Placebo-controlled, Double Masked 120 Subject Futility Design Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A."|Completed||Phase 2/Phase 3|110|Actual|Wayne State University||2|||f||||t||||||||||2018-06-01 03:10:21.867796|2018-06-01 03:10:21.867796
NCT00484497|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2007-06-08|2007-06-08|2007-06-11|Estimate|||||||2007-06-08|2007-06-11|Estimate|September 2006||2006-09-30|June 2007|2007-06-30||||||||Interventional|Cyclamax||Evaluation of a Food Supplement on Sleep Quality|A Randomized, Double-Blind, Placebo-Controlled Trial for the Evaluation of a Food Supplement on Sleep Quality in Primary Insomnia Patient|Completed||N/A|105|Actual|Persee Medica|||||f||||f||||||||||2018-06-01 03:10:21.940633|2018-06-01 03:10:21.940633
NCT00484484|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2011-05-03|2007-06-08|2007-06-11|Estimate|||||||2011-05-03|2011-05-04|Estimate|May 2007||2007-05-31|June 2007|2007-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|KETADOL||Ketamine Associated With Opioids in Refractory Cancer Pain Treatment|Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment|Completed||Phase 3|100|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:10:21.997606|2018-06-01 03:10:21.997606
NCT00484471|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2012-11-27|2007-06-08|2007-06-11|Estimate|||||||2012-11-27|2012-11-28|Estimate|October 2007||2007-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|ABLE||ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness|A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder|Completed||Phase 4|127|Actual|Korea Otsuka International Asia Arab||2|||f||||f||||||||||2018-06-01 03:10:22.06558|2018-06-01 03:10:22.06558
NCT00484458|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2011-10-03|2007-06-07|2007-06-11|Estimate|||||||2011-10-03|2011-10-04|Estimate|January 2007||2007-01-31|October 2011|2011-10-31|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Wallis Stabilization System for Low Back Pain|A Prospective, Multi-center, Randomized, Active-Controlled Study of the Wallis System for the Treatment of Mild to Moderate Degenerative Disc Disease of the Lumbar Spine|Unknown status|Active, not recruiting|Phase 3|340|Anticipated|Zimmer Spine||2|||f||||t||||||||||2018-06-01 03:10:22.156492|2018-06-01 03:10:22.156492
NCT00484445|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-08|||2013-09-04|2007-06-08|2007-06-11|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2003||2003-01-31|September 2013|2013-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Observational|||Transfer to Another Health Care Facility Following Critical Illness|Transfer to Another Health Care Facility Following Critical Illness|Completed|||548|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 03:10:22.229666|2018-06-01 03:10:22.229666
NCT00484432|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2015-10-08|2007-06-07|2007-06-08|Estimate|||||||2015-10-08|2015-10-09|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer|NGR012: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|37|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:10:22.382752|2018-06-01 03:10:22.382752
NCT00484419|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|2009-04-29||2016-08-23|2007-06-07|2007-06-08|Estimate|2009-04-29|2009-06-17|Estimate||||2016-08-23|2016-10-04|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin|Effects of Colesevelam HCl, Avandia® (Rosiglitazone Maleate), or JanuviaTM (Sitagliptin) on Glycemic Parameters and Lipid Profiles in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy|Completed||Phase 3|169|Actual|Daiichi Sankyo, Inc.||3|||f||||||||||||||2018-06-01 03:10:22.510633|2018-06-01 03:10:22.510633
NCT00484406|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate|February 2005||2005-02-28|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Observational|||MMP Polymorphisms and Acute Coronary Syndromes|Matrix Metalloproteinase Genetic Polymorphisms and Outcome of Non-ST Elevated Acute Coronary Syndromes|Completed|||||University of Trieste|||||f||||f||||||||||2018-06-01 03:10:23.365865|2018-06-01 03:10:23.365865
NCT00484393|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2015-03-05||2015-05-22|2007-06-06|2007-06-08|Estimate|2015-03-17|2015-03-18|Estimate||||2015-05-22|2015-06-19|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study|Tetracaine (Ametop®) Compared to Placebo for Reducing Pain Associated With Intramuscular Injection of Palivizumab (Synagis®) - A Pilot Study|Completed||Phase 4|7|Actual|Fraser Health||2|||f||||f||||||||||2018-06-01 03:10:23.42309|2018-06-01 03:10:23.42309
NCT00484380|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2011-03-15|2007-06-06|2007-06-08|Estimate|||||||2011-03-15|2011-03-16|Estimate|August 2007||2007-08-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Scanner in the Coronary Evaluation|Contribution of the Scanner in the Coronary Evaluation Before Valvular Replacement|Completed||N/A|66|Actual|French Cardiology Society|||||f||||t||||||||||2018-06-01 03:10:23.623488|2018-06-01 03:10:23.623488
NCT00484367|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2011-08-25|2007-06-07|2007-06-08|Estimate|||||||2011-08-25|2011-08-26|Estimate|July 1999||1999-07-31|November 2008|2008-11-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers|Family and Group Therapies for Adolescent Alcohol Abuse|Unknown status|Active, not recruiting|Phase 2/Phase 3|120|Actual|The Morton Center, Inc.||2|||f||||f||||||||||2018-06-01 03:10:23.683201|2018-06-01 03:10:23.683201
NCT00484354|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2017-11-02|2007-06-07|2007-06-08|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2006||2006-05-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery|Reduction of Acute Renal Failure Associated With Cardiovascular Surgery: A Randomized Study Comparing Sodium Bicarbonate to Normal Saline|Completed||N/A|123|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-06-01 03:10:23.75941|2018-06-01 03:10:23.75941
NCT00484341|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2015-10-08|2007-06-07|2007-06-08|Estimate|||||||2015-10-08|2015-10-09|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.|NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS)|Unknown status|Active, not recruiting|Phase 2|96|Anticipated|MolMed S.p.A.||4|||f||||f||||||||||2018-06-01 03:10:23.865512|2018-06-01 03:10:23.865512
NCT00484328|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2018-01-05|2007-06-07|2007-06-08|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2007||2007-07-31|July 2011|2011-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Ribados||Ribavirin, Its Dosing Regime|Ribavirin, Its Dosing Regime|Completed||Phase 4|15|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 03:10:24.159225|2018-06-01 03:10:24.159225
NCT00484315|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2011-04-28|2010-08-18|2014-04-24|2007-06-06|2007-06-08|Estimate|2011-06-02|2011-06-28|Estimate|2010-08-18|2010-08-20|Estimate|2014-04-24|2014-05-08|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|September 2009|Actual|2009-09-30||Interventional|PERSEUS WH||TAXUS PERSEUS Workhorse|A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions|Completed||Phase 3|1264|Actual|Boston Scientific Corporation|The comparator control for PERSEUS Workhorse study was chosen based on commercially available stent (TAXUS Express) at the time of study enrollment. Thus, the comparator group does not represent the most recently available paclitaxel-eluting stent.|2|||f||||t||||||||||2018-06-01 03:10:24.306839|2018-06-01 03:10:24.306839
NCT00484302|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2011-01-24|2007-06-06|2007-06-08|Estimate|||||||2011-01-24|2011-01-25|Estimate|September 2007||2007-09-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|CapOpus||Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis|Cannabis and Psychosis. Randomized Clinical Trial: Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis|Completed||N/A|103|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-06-01 03:10:26.812542|2018-06-01 03:10:26.812542
NCT00484289|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|2012-05-25||2013-06-18|2007-06-07|2007-06-08|Estimate|2012-07-02|2012-08-09|Estimate||||2013-06-18|2013-06-24|Estimate|December 2006||2006-12-31|June 2013|2013-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis|A Phase III, Multi-center, Open-label, Uncontrolled, Long-term Study to Evaluate the Safety of Abatacept (BMS-188667) in Japanese Subjects With Rheumatoid Arthritis Having Completed Clinical Studies IM101-071, IM101-034, and Also Special DMARD Failures|Completed||Phase 3|217|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 03:10:27.0422|2018-06-01 03:10:27.0422
NCT00484276|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2015-10-26|2007-06-07|2007-06-08|Estimate|||||||2015-10-26|2015-10-27|Estimate|May 2007||2007-05-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|September 2010|Actual|2010-09-30||Interventional|NGR010||Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma|NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen|Completed||Phase 2|57|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:10:29.398149|2018-06-01 03:10:29.398149
NCT00484263|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2011-06-22|2007-06-07|2007-06-08|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis|The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non-cystic Fibrosis Bronchiectasis.|Completed||Phase 3|40|Actual|The Alfred||1|||f||||t||||||||||2018-06-01 03:10:29.487372|2018-06-01 03:10:29.487372
NCT00484250|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-06-08|2007-06-07|2007-06-08|Estimate|||||||2007-06-08|2007-06-11|Estimate|September 2005||2005-09-30|June 2007|2007-06-30|May 2006|Actual|2006-05-31|||||Interventional|||Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other||Completed||Phase 2|20|Actual|Mashhad University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:10:29.570164|2018-06-01 03:10:29.570164
NCT00484237|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-12-03|2007-06-07|2007-06-08|Estimate|||||||2007-12-03|2007-12-05|Estimate|April 2007||2007-04-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Safety and Efficacy of Etanercept 10 mg Twice Weekly and 25 mg Once Weekly in Japanese Subjects With Active Rheumatoid Arthritis|Completed||Phase 3|80|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:10:29.630013|2018-06-01 03:10:29.630013
NCT00484224|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate||||May 2007|2007-05-31||||||||Observational|||Audiological Disturbances in Vitiligo||Unknown status|Not yet recruiting||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:10:29.708081|2018-06-01 03:10:29.708081
NCT00484211|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2014-05-29|2007-06-07|2007-06-08|Estimate|||||||2014-05-29|2014-05-30|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|November 2011|Actual|2011-11-30||Interventional|||Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC)|NGR008: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) Previously Treated With no More Than One Systemic Therapeutic Regimen|Completed||Phase 2|40|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:10:29.759772|2018-06-01 03:10:29.759772
NCT00484198|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07||2010-02-01|2010-02-01|2007-06-07|2007-06-08|Estimate||||2010-02-01|2010-02-03|Estimate|2010-02-01|2010-02-03|Estimate|April 2007||2007-04-30|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus|Completed||Phase 3|1820|Anticipated|Daiichi Sankyo, Inc.||4|||f||||t||||||||||2018-06-01 03:10:29.865106|2018-06-01 03:10:29.865106
NCT00484185|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|2013-05-15||2013-05-15|2007-06-07|2007-06-08|Estimate|2013-05-15|2013-08-12|Estimate||||2013-05-15|2013-08-12|Estimate|August 2007||2007-08-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B|Post Marketing Surveillance To Observe Safety And Efficacy Of BeneFIX In Patients With Hemophilia B|Completed|||183|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:10:30.354557|2018-06-01 03:10:30.354557
NCT00484172|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|June 2008|Anticipated|2008-06-30|||||Observational|||Genomic Search for Childhood Obesity Genes-A Pilot Study|Genomic Search for Childhood Obesity Genes-A Pilot Study|Unknown status|Not yet recruiting||500|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 03:10:30.72278|2018-06-01 03:10:30.72278
NCT00484159|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2011-06-22||2011-07-25|2007-06-07|2007-06-08|Estimate|2011-06-22|2011-07-21|Estimate||||2011-07-25|2011-07-26|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy and Cost: Benefit Ratio of 0, 1, and 2 Medial Branch Blocks for Lumbar Facet Joint Radiofrequency Denervation|Prospective Randomized Study Comparing 0, 1, and 2 Diagnostic Lumbar Medial Branch (Facet Joint) Blocks Before Radiofrequency Denervation in Patients With Chronic Low Back Pain: A Cost: Benefit Analysis.|Completed||N/A|151|Actual|Johns Hopkins University|This study only followed patients for 3 months, so we don't know if proceeding straight to radiofrequency is associated with the same duration of pain relief as when diagnostic facet blocks are performed.|3|||f||||t||||||||||2018-06-01 03:10:30.805179|2018-06-01 03:10:30.805179
NCT00484146|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2017-02-07|2007-06-07|2007-06-08|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2006||2006-06-30|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|LAVISS_01||Alterations of Immunologic Mediators During Severe Sepsis|Alterations of Immunologic Mediators During Severe Sepsis|Terminated|||20|Actual|Klinikum St. Georg gGmbH||||anticipated number of patients could not be reached|f||||f||||||Samples Without DNA|"~     Whole Blood Samples, Plasma Samples~   "|||2018-06-01 03:10:31.109344|2018-06-01 03:10:31.109344
NCT00484133|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2008-01-17|2007-06-06|2007-06-08|Estimate|||||||2008-01-17|2008-01-22|Estimate|June 2007||2007-06-30|January 2008|2008-01-31||||December 2008|Anticipated|2008-12-31||Interventional|||"Microcirculation Guided Therapy Versus Standard Treatment of Severe Sepsis"||Unknown status|Recruiting|Phase 4|80|Anticipated|Onze Lieve Vrouwe Gasthuis|||||f||||f||||||||||2018-06-01 03:10:31.198989|2018-06-01 03:10:31.198989
NCT00484120|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2011-08-01|2007-06-07|2007-06-08|Estimate|||||||2011-08-01|2011-08-02|Estimate|June 2007||2007-06-30|August 2011|2011-08-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Proof-of Concept Study of Topical 3%-Diclofenac-Nano-Emulsion Cream for Knee OA Pain|Proof-of Concept Study to Evaluate the Safety and Analgesic Efficacy of Topical 3%-Diclofenac-Nano-Emulsion Cream Versus Placebo for Knee Osteoarthritis|Completed||Phase 2|123|Actual|Pharmos||2|||f||||t||||||||||2018-06-01 03:10:31.316361|2018-06-01 03:10:31.316361
NCT00484107|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-12-20|2007-06-07|2007-06-08|Estimate|||||||2007-12-20|2007-12-28|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Observational|||Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women|A Postmarketing Surveillance Study Evaluating the Tolerability and Safety of PREMARIN VAGINAL CREAM in Indian Postmenopausal Women|Completed|||200||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:10:31.438452|2018-06-01 03:10:31.438452
NCT00484094|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|2016-06-02||2016-11-21|2007-06-07|2007-06-08|Estimate|2016-11-21|2017-01-16|Estimate||||2016-11-21|2017-01-16|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational||Safety Analysis Set: Participants who received Rapamune at least once and were evaluated on its related safety endpoints at least once.|Study Investigating Rapamune For Post-Marketing Surveillance|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Rapamune|Completed|||209|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:10:31.510494|2018-06-01 03:10:31.510494
NCT00484081|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate|June 2005||2005-06-30|June 2007|2007-06-30|October 2006|Actual|2006-10-31|||||Interventional|||Microdissection Testicular Sperm Extraction (MicroTESE) and IVF-ICSI Outcome in Non-Obstructive Azoospermia (NOA)|Prospective Evaluation of Microdissection Testicular Sperm Extraction in Non-Obstructive Azoospermic Men and Their IVF-ICSI Related Outcomes at ART Treatment.|Completed||N/A|53|Actual|Clinic and Research Center in Human Reproduction Roger Abdelmassih|||||f||||t||||||||||2018-06-01 03:10:31.858198|2018-06-01 03:10:31.858198
NCT00484068|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate|January 2003||2003-01-31|June 2007|2007-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Chicken-Diet vs. Enalapril to Reduce Albuminuria|Effect of Chicken-Based Diet Versus Enalapril on Albuminuria in Patients With Type 2 Diabetes and Microalbuminuria: a One-Year Randomized Controlled Study|Completed||N/A|28|Actual|Hospital de Clinicas de Porto Alegre|||||f||||f||||||||||2018-06-01 03:10:31.915291|2018-06-01 03:10:31.915291
NCT00484055|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2016-10-12|2007-06-06|2007-06-08|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|LOGIX||Local Collagen-Gentamicin and Extra Fixation of the Sternum for Prevention of Sternal Wound Infection in Cardiac Surgery|Local Application of Collagen-Gentamicin in Addition to Fixation of the Sternum With Extra Sternal Wires for Prevention of Sternal Wound Infection in Cardiac Surgery|Completed||N/A|1358|Actual|Region Örebro County||1|||f||||f||||||||||2018-06-01 03:10:31.986965|2018-06-01 03:10:31.986965
NCT00484042|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate|January 2006||2006-01-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Observational|||Activation of Polyamine Catabolism in Patients With Acute Pancreatitis||Completed|||||University of Tampere|||||f||||t||||||||||2018-06-01 03:10:32.069999|2018-06-01 03:10:32.069999
NCT00484029|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07||2010-08-17|2010-08-18|2007-06-07|2007-06-08|Estimate||||2010-08-18|2010-08-20|Estimate|2010-08-18|2010-08-20|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Nasal Carbon Dioxide (CO2)for the Treatment of Temporomandibular Disorders (TMD)Related Pain|A Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Nasal CO2 in the Symptomatic Treatment of Temporomandibular Disorders|Completed||Phase 2|100|Actual|Capnia, Inc.||2|||f||||f||||||||||2018-06-01 03:10:32.115566|2018-06-01 03:10:32.115566
NCT00484016|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2013-08-09|2007-06-06|2007-06-08|Estimate|||||||2013-08-09|2013-08-13|Estimate|February 2006||2006-02-28|August 2013|2013-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC|Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected Non Small Cell Lung Cancer|Completed|||45|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 03:10:32.185883|2018-06-01 03:10:32.185883
NCT00484003|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2008-02-13|2007-06-07|2007-06-08|Estimate|||||||2008-02-13|2008-02-15|Estimate|October 2004||2004-10-31|February 2008|2008-02-29|December 2004|Actual|2004-12-31|||||Interventional|||A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis|A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 03:10:32.417326|2018-06-01 03:10:32.417326
NCT00483990|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2010-07-14|2007-06-07|2007-06-08|Estimate|||||||2010-07-14|2010-07-15|Estimate|March 2007||2007-03-31|July 2010|2010-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers|A Phase I, Double-blind, Stratified, Parallel Group, Placeob-controlled Study of the Safety, Tolerability and Pharmacokinetics of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times Daily for 21 Days in Healthy Male Volunteers|Completed||Phase 1|16||Plethora Solutions Ltd|||||f||||f||||||||||2018-06-01 03:10:32.489951|2018-06-01 03:10:32.489951
NCT00483977|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06||2009-04-06|2011-04-22|2007-06-06|2007-06-08|Estimate||||2010-04-12|2010-04-14|Estimate|2011-04-22|2011-04-29|Estimate|June 2007||2007-06-30|April 2011|2011-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee|A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicentre Study To Assess The Efficacy And Tolerability Of PF-00592379 In Patients With Moderate To Severe Pain Due To Osteoarthritis|Terminated||Phase 2|113|Actual|Pfizer||3||Met criteria for study futility at interim analysis|f||||t||||||||||2018-06-01 03:10:32.555755|2018-06-01 03:10:32.555755
NCT00483964|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2007-10-09|2007-06-06|2007-06-08|Estimate|||||||2007-10-09|2007-10-10|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia|A Randomized, Controlled ,Clinical Trial of a Herbal Combination of Aqueous Extracts of Bacopa Monnieri and Nardostachys Jatamansi in the Treatment of Schizophrenia, Compared to Standard Anti-Psychotic Drugs|Completed||Phase 2|200|Actual|Q.Mundewadi Ayurvedic Research & Charitable Trust||2|||f||||f||||||||||2018-06-01 03:10:32.650362|2018-06-01 03:10:32.650362
NCT00483951|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2018-04-07|2007-06-07|2007-06-08|Estimate|||||||2018-04-07|2018-04-10|Actual|June 6, 2007||2007-06-06|April 6, 2018|2018-04-06||||||||Observational|||Cardiovascular Disease Screening|Suburban/NHLBI Cardiovascular Disease Screening Protocol|Suspended|||1325|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:10:32.719654|2018-06-01 03:10:32.719654
NCT00483938|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|2016-11-25||2016-11-25|2007-06-07|2007-06-08|Estimate|2016-11-25|2017-01-23|Estimate||||2016-11-25|2017-01-23|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|IMPROVE|The safety (SAF) population included participants who received at least one dose of study medication and had at least one post-baseline safety assessment.|The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)|The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial|Completed||Phase 3|236|Actual|Hoffmann-La Roche||7|||f||||||||||||||2018-06-01 03:10:32.819321|2018-06-01 03:10:32.819321
NCT00483925|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate|September 2005||2005-09-30|June 2007|2007-06-30||||||||Observational|||Cardiovascular Risk Factors and LCH in Adults|CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES|Unknown status|Recruiting||||Laikon General District Hospital, Athens|||||f||||f||||||||||2018-06-01 03:10:33.841613|2018-06-01 03:10:33.841613
NCT00483912|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-07|||2007-06-07|2007-06-07|2007-06-08|Estimate|||||||2007-06-07|2007-06-08|Estimate||||June 2007|2007-06-30||||||||Interventional|pancreatitis||Albumindialysis in Acute Pancreatitis|Molecular Adsorbent Recirculating System (MARS) in Severe Acute Pancreatitis|Suspended||N/A|||University of Tampere|||||f||||f||||||||||2018-06-01 03:10:33.916145|2018-06-01 03:10:33.916145
NCT00483899|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2017-09-27|2007-06-05|2007-06-07|Estimate|||||||2017-09-27|2017-09-29|Actual|October 7, 2005|Actual|2005-10-07|September 2017|2017-09-30|December 15, 2006|Actual|2006-12-15|December 15, 2006|Actual|2006-12-15||Interventional|||Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects|Double-blind, Placebo-controlled, 3-way Crossover Study to Investigate the Effect of 7-days Repeat Once Daily Inhaled Doses of GW870086X Administered Via DISKHALER on Airway Responsiveness to AMP in Mild Steroid-naive Male Asthmatics|Completed||Phase 1|20|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:10:33.993551|2018-06-01 03:10:33.993551
NCT00483886|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2013-04-10|2007-06-06|2007-06-07|Estimate|||||||2013-04-10|2013-04-11|Estimate|April 1998||1998-04-30|April 2013|2013-04-30|May 1999|Actual|1999-05-31|May 1999|Actual|1999-05-31||Interventional|||Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation|A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation.|Completed||Phase 3|620|Actual|Movetis||3|||f||||f||||||||||2018-06-01 03:10:34.080794|2018-06-01 03:10:34.080794
NCT00483873|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2009-01-28|2007-06-06|2007-06-07|Estimate|||||||2009-01-28|2009-01-29|Estimate|August 2007||2007-08-31|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|||||Observational|CARES||Cardiac Arrest Recovery EEG Study|Phase IIB Study of Novel Quantitative Neurodiagnostic Technology in the Early Period After Cardiac Arrest|Unknown status|Recruiting||100|Anticipated|Infinite Biomedical Technologies|||||f||||t||||||||||2018-06-01 03:10:34.155033|2018-06-01 03:10:34.155033
NCT00483860|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2017-11-08|2007-06-05|2007-06-07|Estimate|||||||2017-11-08|2017-11-13|Actual|June 20, 2007|Actual|2007-06-20|November 2017|2017-11-30|February 6, 2012|Actual|2012-02-06|February 6, 2012|Actual|2012-02-06||Interventional|||A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function|A Phase I Study of Oral Topotecan in Subjects With Cancer and Impaired Renal Function|Completed||Phase 1|59|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:10:34.228822|2018-06-01 03:10:34.228822
NCT00483847|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2015-04-09|2007-06-06|2007-06-07|Estimate|||||||2015-04-09|2015-04-13|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|TYGRIS - ROW||TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World|TYGRIS - ROW: TYSABRI® Global Observational Program in Safety - Rest of World|Completed|||4296|Actual|Biogen|||||f||||f||||||||||2018-06-01 03:10:34.299072|2018-06-01 03:10:34.299072
NCT00483834|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2012-03-19|2007-06-06|2007-06-07|Estimate|||||||2012-03-19|2012-03-20|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer|A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer|Completed||Phase 2|50|Actual|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 03:10:34.356156|2018-06-01 03:10:34.356156
NCT00483821|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2012-09-07|2007-06-06|2007-06-07|Estimate|||||||2012-09-07|2012-09-10|Estimate|May 2004||2004-05-31|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC|A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC|Completed|||165|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||||||2018-06-01 03:10:34.436924|2018-06-01 03:10:34.436924
NCT00483808|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2013-11-01|2007-06-05|2007-06-07|Estimate|||||||2013-11-01|2013-11-05|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Renal Denervation in Patients With Refractory Hypertension|Renal Denervation in Patients With Refractory Hypertension|Completed||Phase 1|73|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-06-01 03:10:34.606807|2018-06-01 03:10:34.606807
NCT00483795|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2007-07-23|2007-06-06|2007-06-07|Estimate|||||||2007-07-23|2007-07-25|Estimate||||July 2007|2007-07-31||||||||Interventional|||Pilot Evaluation of Two Multipurpose Solutions in Regards to Corneal Staining||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:10:34.674537|2018-06-01 03:10:34.674537
NCT00483782|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2013-08-09|2007-06-06|2007-06-07|Estimate|||||||2013-08-09|2013-08-12|Estimate|April 2006||2006-04-30|April 2012|2012-04-30||||||||Interventional|||Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer|Completed||Phase 3|1520|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:10:34.768218|2018-06-01 03:10:34.768218
NCT00483769|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2007-06-06|2007-06-06|2007-06-07|Estimate|||||||2007-06-06|2007-06-07|Estimate|February 2006||2006-02-28|February 2007|2007-02-28|January 2007|Actual|2007-01-31|||||Interventional|||One Year Glargine Treatment in CFRD Children and Adolescents|One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements|Completed||Phase 4|20|Actual|Federico II University|||||f||||t||||||||||2018-06-01 03:10:35.082997|2018-06-01 03:10:35.082997
NCT00483756|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2012-12-03|2011-03-24|2013-02-08|2007-06-06|2007-06-07|Estimate|2013-02-08|2013-03-14|Estimate|2011-03-24|2011-04-01|Estimate|2013-02-08|2013-03-14|Estimate|August 2007||2007-08-31|February 2013|2013-02-28|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|||Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients|A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients|Completed||Phase 2|338|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 03:10:35.241907|2018-06-01 03:10:35.241907
NCT00483743|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2012-11-30|2007-06-06|2007-06-07|Estimate|||||||2012-11-30|2012-12-03|Estimate|November 2007||2007-11-30|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety, Tolerability and PD Activity of Inhaled TPI 1020 Versus Inhaled Budesonide in COPD Patients|Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.|Completed||Phase 2|62|Actual|Pharmaxis||3|||f||||f||||||||||2018-06-01 03:10:37.761599|2018-06-01 03:10:37.761599
NCT00483730|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2012-05-04|2007-06-06|2007-06-07|Estimate|||||||2012-05-04|2012-05-07|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)|A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin® in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy|Completed||Phase 3|569|Actual|Nycomed|||||f||||t||||||||||2018-06-01 03:10:37.845067|2018-06-01 03:10:37.845067
NCT00483717|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2012-08-31||2016-09-22|2007-06-06|2007-06-07|Estimate|2016-09-22|2016-09-30|Estimate||||2016-09-22|2016-09-30|Estimate|July 2007||2007-07-31|September 2016|2016-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine|A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Analgesic Efficacy of Ketorolac Tromethamine Administered Intranasally for the Acute Treatment of Migraine|Completed||Phase 2|173|Actual|Egalet Ltd||2|||f||||f||||||||||2018-06-01 03:10:37.903702|2018-06-01 03:10:37.903702
NCT00483704|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2014-07-14||2017-04-06|2007-06-06|2007-06-07|Estimate|2014-08-27|2014-08-29|Estimate||||2017-04-06|2017-05-12|Actual|August 14, 2008|Actual|2008-08-14|April 2017|2017-04-30|March 25, 2009|Actual|2009-03-25|March 25, 2009|Actual|2009-03-25||Interventional|||Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura|Completed||Phase 3|1935|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 03:10:38.438086|2018-06-01 03:10:38.438086
NCT00483691|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2017-04-20|2007-06-05|2007-06-07|Estimate|||||||2017-04-20|2017-04-24|Actual|January 1989||1989-01-31|April 2017|2017-04-30|December 1995|Actual|1995-12-31|December 1995|Actual|1995-12-31||Interventional|FTT||Trial of Home Visitation Among Infants With Failure To Thrive|Growth and Development Longitudinal Follow-Up|Completed||N/A|130|Actual|University of Maryland|||||f||||t||||||||Yes|Participants have been enrolled into a study funded by the Office of Child Abuse and Neglect with Dr. Dubowitz as PI.|2018-06-01 03:10:39.069351|2018-06-01 03:10:39.069351
NCT00483678|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2018-03-05|2007-06-06|2007-06-07|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2007||2007-04-30|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners|A Pilot Study of an Intimacy-Enhancing Couples Therapy for Men With Advanced Prostate Cancer and Their Partners|Completed||N/A|64|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 03:10:39.251173|2018-06-01 03:10:39.251173
NCT00483652|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2010-11-22||2016-01-04|2007-06-06|2007-06-07|Estimate|2011-03-14|2011-04-14|Estimate||||2016-01-04|2016-02-04|Estimate|May 2007||2007-05-31|January 2016|2016-01-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Study of Fampridine-SR Tablets in Multiple Sclerosis Patients|Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis|Completed||Phase 3|240|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-06-01 03:10:39.504788|2018-06-01 03:10:39.504788
NCT00483639|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2013-03-13|2007-06-06|2007-06-07|Estimate|||||||2013-03-13|2013-03-15|Estimate|November 2003||2003-11-30|March 2013|2013-03-31|January 2008|Actual|2008-01-31|March 2006|Actual|2006-03-31||Observational|||Study of Anxiety and Avoidance of Others in Patients Previously Treated for Head and Neck Cancer|Social Anxiety and Avoidance in Head and Neck Cancer Patients|Completed|||100|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||||||2018-06-01 03:10:39.903382|2018-06-01 03:10:39.903382
NCT00483626|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2007-06-06|2007-06-06|2007-06-07|Estimate|||||||2007-06-06|2007-06-07|Estimate|August 2003||2003-08-31|April 2007|2007-04-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Hemodynamic Response After Six Months of Sildenafil|Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment|Unknown status|Recruiting|Phase 4|27|Anticipated|University of Chile|||||f||||f||||||||||2018-06-01 03:10:39.989005|2018-06-01 03:10:39.989005
NCT00483613|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2007-06-06|2007-06-06|2007-06-07|Estimate|||||||2007-06-06|2007-06-07|Estimate|December 2003||2003-12-31|June 2007|2007-06-30|July 2005|Actual|2005-07-31|||||Interventional|||Effects of Treatment of Chronic Stress in Patients With Lupus||Completed||N/A|45|Actual|University Hospital Virgen de las Nieves|||||f||||t||||||||||2018-06-01 03:10:40.069717|2018-06-01 03:10:40.069717
NCT00483600|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2014-07-25|2007-06-05|2007-06-07|Estimate|||||||2014-07-25|2014-07-29|Estimate|August 2007||2007-08-31|February 2011|2011-02-28|August 2008|Anticipated|2008-08-31|||||Interventional|||Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction|Studies of Fondaparinux in Patients With Renal Dysfunction: PK Study of Fondaparinux in Outpatients With Renal Dysfunction|Withdrawn||N/A|0|Actual|Duke University||1||unable to enroll|f||||f||||||||||2018-06-01 03:10:40.138183|2018-06-01 03:10:40.138183
NCT00483587|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2010-09-17|2007-06-06|2007-06-07|Estimate|||||||2010-09-17|2010-09-20|Estimate|July 2007||2007-07-31|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|HAEM||Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?|A Safety and Efficacy Study to Evaluate Intravenous Heme Arginate Infusion in Patients With an Acute Coronary Syndrome Without ST-elevation (NSTEMI)|Completed||Phase 1/Phase 2|15|Actual|University Medical Center Groningen|||||f||||f||||||||||2018-06-01 03:10:40.201093|2018-06-01 03:10:40.201093
NCT00483574|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2011-05-10|2010-03-31|2016-04-12|2007-06-06|2007-06-07|Estimate|2011-06-08|2011-07-06|Estimate|2010-03-31|2010-04-02|Estimate|2016-04-12|2016-05-16|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers|Safety Study of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers|Completed||Phase 3|1378|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:10:40.525878|2018-06-01 03:10:40.525878
NCT00483561|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2018-01-29|2007-06-06|2007-06-07|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2004||2004-01-31|January 2018|2018-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Study Evaluating the Efficacy of Iressa Plus Etoposide in Patients With Advanced Hormone Refractory Prostate Cancer|Terminated||Phase 2|23|Actual|University of Nebraska||1||PI left UNMC|f||||t||||||||||2018-06-01 03:10:41.218806|2018-06-01 03:10:41.218806
NCT00483548|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2009-12-22||2010-02-04|2007-06-05|2007-06-07|Estimate|2010-02-04|2010-02-23|Estimate||||2010-02-04|2010-02-23|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Adjunctive Ziprasidone in the Treatment of Bipolar I Depression|A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression|Completed||Phase 3|298|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:10:41.393438|2018-06-01 03:10:41.393438
NCT00483535|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2017-08-05|2007-06-06|2007-06-07|Estimate|||||||2017-08-05|2017-08-08|Actual|March 7, 2007|Actual|2007-03-07|August 2017|2017-08-31|November 16, 2007|Actual|2007-11-16|November 16, 2007|Actual|2007-11-16||Interventional|||Oral Contraceptive Interaction Study for GW273225|An Open, Repeat Dose Study to Investigate the Effect of Co-administration of the Combined Oral Contraceptive Pill (COC) and GW273225 on the Pharmacokinetics of the COC and to Investigate the Effects of the COC on the Pharmacokinetics of GW273225 in Healthy Female Subjects|Terminated||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:10:42.387943|2018-06-01 03:10:42.387943
NCT00483522|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2012-06-19|2007-06-05|2007-06-07|Estimate|||||||2012-06-19|2012-06-20|Estimate|December 2004||2004-12-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Telephone Intervention After Traumatic Brain Injury|The Effect of Scheduled Telephone Intervention on Outcomes After Traumatic Brain Injury|Completed||N/A|433|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:10:42.482854|2018-06-01 03:10:42.482854
NCT00483509|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2015-10-08|2007-06-06|2007-06-07|Estimate|||||||2015-10-08|2015-10-09|Estimate|December 2006||2006-12-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|NGR007||Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma|NGR007: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Small Cell Lung Carcinoma (SCLC) Previously Treated With at Least One Therapeutic Regimen|Unknown status|Active, not recruiting|Phase 2|28|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:10:42.556643|2018-06-01 03:10:42.556643
NCT00483496|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2013-12-19||2017-11-24|2007-06-06|2007-06-07|Estimate|2014-02-14|2014-03-31|Estimate||||2017-11-24|2017-12-22|Actual|September 2007||2007-09-30|November 2017|2017-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)|Evaluation of the Protection Activity of Microfine Ti02, Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With SU: Phase II Photoprovocation Test|Completed||Phase 2|16|Actual|Orfagen||1|||f||||||||||||||2018-06-01 03:10:42.645253|2018-06-01 03:10:42.645253
NCT00483483|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2017-07-19|2007-06-06|2007-06-07|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2007||2007-10-31|July 2017|2017-07-31|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Interventional|||Project HERMITAGE: HIV Prevention in Hospitalized Russian Drinkers|Maximizing Opportunity: HIV Prevention in Hospitalized Russian Drinkers|Completed||N/A|700|Actual|Boston Medical Center||2|||f||||f|f|f||||||||2018-06-01 03:10:42.871677|2018-06-01 03:10:42.871677
NCT00483457|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2012-08-31|2007-06-06|2007-06-07|Estimate|||||||2012-08-31|2012-09-03|Estimate|February 2006||2006-02-28|August 2012|2012-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients|Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on the EGFR in Skin Lesions|Completed|||33|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||||||2018-06-01 03:10:43.14113|2018-06-01 03:10:43.14113
NCT00483444|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2017-11-07|2007-06-05|2007-06-07|Estimate|||||||2017-11-07|2017-11-09|Actual|October 2003|Actual|2003-10-31|November 2017|2017-11-30|May 2006|Actual|2006-05-31|February 2006|Actual|2006-02-28||Interventional|TBI||Telephone Follow-Up on Outcome After Mild Traumatic Brain Injury|The Effect of Telephone Follow-Up on Outcome After Mild TBI|Completed||N/A|366|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:10:43.206571|2018-06-01 03:10:43.206571
NCT00483431|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2018-04-26|2007-06-06|2007-06-07|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2007||2007-05-31|March 2009|2009-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Dose-finding Study for Vitamin K2 in Human Volunteers|Dose-finding Study for Vitamin K2 in Human Volunteers|Completed||N/A|42|Actual|Maastricht University Medical Center||7|||f||||f||||||||||2018-06-01 03:10:43.282433|2018-06-01 03:10:43.282433
NCT00483418|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2011-03-10|2007-06-06|2007-06-07|Estimate|||||||2011-03-10|2011-03-11|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Survey of Testosterone Levels in Male Cancer Patients|Survey of Testosterone Levels in a Diverse Set of Male Patients With Hormone-Independent Cancers|Completed|||425|Actual|Beth Israel Medical Center|||||f||||f||||||||||2018-06-01 03:10:43.355314|2018-06-01 03:10:43.355314
NCT00483405|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2017-03-28||2017-06-13|2007-06-06|2007-06-07|Estimate|2017-03-28|2017-05-09|Actual||||2017-06-13|2017-07-12|Actual|October 2006||2006-10-31|June 2017|2017-06-30|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|NRR|29 patients received any protocol directed therapy, but only 28 patients were included in any efficacy analysis because one patient was found to have a sarcoma and was withdrawn from the study.|Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer|Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma|Completed||Phase 2|33|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||No||2018-06-01 03:10:43.434718|2018-06-01 03:10:43.434718
NCT00483392|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2007-06-05|2007-06-05|2007-06-07|Estimate|||||||2007-06-05|2007-06-07|Estimate||||June 2007|2007-06-30||||||||Interventional|||Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected Patients||Completed||N/A|||University Medical Centre Ljubljana|||||f||||f||||||||||2018-06-01 03:10:43.842485|2018-06-01 03:10:43.842485
NCT00483379|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|2011-02-07||2014-02-04|2007-06-06|2007-06-07|Estimate|2011-03-23|2011-04-22|Estimate||||2014-02-04|2014-03-07|Estimate|May 2007||2007-05-31|February 2014|2014-02-28|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||High Dose or High Dose Frequency Study of Alglucosidase Alfa|An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Alglucosidase Alfa Treatment in Patients With Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen|Completed||Phase 4|13|Actual|Sanofi|This small exploratory study lacked a parallel control arm at the standard dose for a longer period; decline in respiratory or motor function prior to study was not collected systematically, thus change from baseline observations are inconclusive.|2|||f||||t||||||||||2018-06-01 03:10:43.971326|2018-06-01 03:10:43.971326
NCT00483366|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2018-02-22|2007-06-06|2007-06-07|Estimate|||||||2018-02-22|2018-02-26|Actual|August 2006||2006-08-31|February 2018|2018-02-28|March 29, 2011|Actual|2011-03-29|January 30, 2009|Actual|2009-01-30||Interventional|||Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008)|Phase I Study of Imatinib, Gemcitabine and Capecitabine in Patients With Solid Tumors|Completed||Phase 1|13|Actual|University of Nebraska||1|||f||||||||||||||2018-06-01 03:10:44.892133|2018-06-01 03:10:44.892133
NCT00483353|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2008-06-12|2007-06-05|2007-06-07|Estimate|||||||2008-06-12|2008-06-17|Estimate|July 2007||2007-07-31|June 2008|2008-06-30||||||||Interventional|||Effect of a Nasal Bolus Allergen Challenge on Inflammatory Markers|A Pilot Study to Explore the Effect of a Nasal Bolus Allergen Challenge on Inflammatory Markers in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 1|6||Pfizer|||||f||||||||||||||2018-06-01 03:10:44.972302|2018-06-01 03:10:44.972302
NCT00483327|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2015-07-30||2018-03-06|2007-06-06|2007-06-07|Estimate|2016-05-24|2016-07-01|Estimate||||2018-03-06|2018-04-04|Actual|June 2007||2007-06-30|March 2018|2018-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All the patients enrolled to the study (including one who withdrew before the start of treatment)|Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate|Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate|Completed||Phase 2|31|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-06-01 03:10:45.048309|2018-06-01 03:10:45.048309
NCT00483314|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2009-02-16|2007-06-06|2007-06-07|Estimate|||||||2009-02-16|2009-02-18|Estimate|November 2007||2007-11-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Homocystinuria: Treatment With N-Acetylcysteine|Homocystinuria: Treatment With N-Acetylcysteine|Completed||Phase 2|5|Actual|McGill University Health Center||1|||f||||f||||||||||2018-06-01 03:10:45.455553|2018-06-01 03:10:45.455553
NCT00483301|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2012-05-02|2007-06-05|2007-06-07|Estimate|||||||2012-05-02|2012-05-03|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma|A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma|Completed||Phase 2|34|Actual|Mt. Sinai Medical Center, Miami|||||f||||t||||||||||2018-06-01 03:10:45.52847|2018-06-01 03:10:45.52847
NCT00483288|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2017-01-17|2007-06-06|2007-06-07|Estimate|||||||2017-01-17|2017-01-19|Estimate|May 2005||2005-05-31|June 2013|2013-06-30||||September 2006|Actual|2006-09-30||Interventional|||Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap Smears|Wake Forest University Cervical Screening and Follow Up System for Hispanic Women - A Pilot Study|Completed||N/A|238|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 03:10:45.621017|2018-06-01 03:10:45.621017
NCT00483275|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-06|||2011-07-20|2007-06-06|2007-06-07|Estimate|||||||2011-07-20|2011-07-21|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|September 2009|Anticipated|2009-09-30|||||Interventional|SPALT||Fall Prevention by Alfacalcidol and Training|Effects of a Multi-modal 12-month-intervention With Alfacalcidol Plus Calcium, Patient Education and a Mobility Program on the Number of Fallers Among Patients With an Impaired Kidney Function Aged 65 and Older.|Withdrawn||Phase 4|484|Anticipated|Ruhr University of Bochum||||No final agreement with sponsor|f||||f||||||||||2018-06-01 03:10:45.686513|2018-06-01 03:10:45.686513
NCT00040625|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-02|||2007-03-14|2002-07-03|2002-07-04|Estimate|||||||2007-03-14|2007-03-15|Estimate||||March 2007|2007-03-31||||||||Expanded Access|||ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.||Approved for marketing|||||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:32:05.529095|2018-06-01 05:32:05.529095
NCT00483262|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2011-06-27||2013-10-16|2007-06-05|2007-06-06|Estimate|2013-03-27|2013-05-10|Estimate||||2013-10-16|2013-11-11|Estimate|May 2007||2007-05-31|October 2013|2013-10-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|63|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:10:45.78843|2018-06-01 03:10:45.78843
NCT00483249|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2018-01-05|2007-06-05|2007-06-06|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2005||2005-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm|Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm|Recruiting||Phase 1/Phase 2|250|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 03:10:46.253852|2018-06-01 03:10:46.253852
NCT00483236|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2009-09-17|2007-06-05|2007-06-06|Estimate|||||||2009-09-17|2009-09-18|Estimate|December 2007||2007-12-31|September 2009|2009-09-30|June 2009|Anticipated|2009-06-30|||||Observational|||Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair|Quality of Life Measures After Mitral Valve Repair in Non-Ischaemic Cardiomyopathy|Suspended|||20|Anticipated|McGill University Health Center||||Lack of patient recruitment.|f||||f||||||||||2018-06-01 03:10:46.423636|2018-06-01 03:10:46.423636
NCT00483223|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2017-04-13||2017-07-25|2007-06-05|2007-06-06|Estimate|2017-05-25|2017-06-01|Actual||||2017-07-25|2017-08-25|Actual|June 2007||2007-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2014|Actual|2014-06-30||Interventional|||Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response|A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response|Completed||Phase 2|86|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 03:10:46.568358|2018-06-01 03:10:46.568358
NCT00483210|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2015-03-03|2007-06-04|2007-06-06|Estimate|||||||2015-03-03|2015-03-04|Estimate||||March 2015|2015-03-31||||||||Interventional|||Tissue Lipids and Insulin Resistance|Tissue Lipids and Insulin Resistance|Withdrawn||N/A|0|Actual|University of Arkansas||||The study goals were accomplished by a similar study at UAMS. (W.J. Evans)|f||||t||||||||||2018-06-01 03:10:47.061113|2018-06-01 03:10:47.061113
NCT00483197|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2009-09-04|2007-06-04|2007-06-06|Estimate|||||||2009-09-04|2009-09-09|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|June 2010|Anticipated|2010-06-30|||||Interventional|||VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial|Evaluation of the VentrAssistTM Left Ventricular Assist Device as a Bridge to Cardiac Transplantation - Pivotal Trial|Unknown status|Active, not recruiting|Phase 3|140|Anticipated|Ventracor|||||f||||t||||||||||2018-06-01 03:10:47.136088|2018-06-01 03:10:47.136088
NCT00483184|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2009-04-27||2009-04-27|2007-06-05|2007-06-06|Estimate|2009-04-27|2009-06-16|Estimate||||2009-04-27|2009-06-16|Estimate|April 2006||2006-04-30|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease|Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease|Completed||Phase 2|84|Actual|Nobel Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:10:47.257939|2018-06-01 03:10:47.257939
NCT00483171|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04||2009-08-11|2012-11-05|2007-06-04|2007-06-06|Estimate||||2009-08-11|2009-08-13|Estimate|2012-11-05|2012-11-07|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients|A 14-Month, Randomized, Double-Blind,Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety of CP-945,598 In Prevention Of Weight Regain In Obese Subjects|Terminated||Phase 3|699|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:10:47.640055|2018-06-01 03:10:47.640055
NCT00483158|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2008-07-25|2007-06-04|2007-06-06|Estimate|||||||2008-07-25|2008-07-29|Estimate|August 2007||2007-08-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||First Time in Man Study of Finafloxacin Hydrochloride|A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single and Multiple Oral Doses of Finafloxacin Hydrochloride in Healthy Subjects and a Study of H. Pylori Treatment in Healthy Carriers|Completed||Phase 1|95|Actual|MerLion Pharmaceuticals GmbH||3|||f||||f||||||||||2018-06-01 03:10:47.737255|2018-06-01 03:10:47.737255
NCT00483145|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2008-06-02|2007-06-04|2007-06-06|Estimate|||||||2008-06-02|2008-06-03|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|November 2007|Actual|2007-11-30|||||Interventional|||Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea|Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea|Completed||N/A|||Bispebjerg Hospital||2|||f||||||||||||||2018-06-01 03:10:47.809289|2018-06-01 03:10:47.809289
NCT00483132|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2007-06-05|2007-06-05|2007-06-06|Estimate|||||||2007-06-05|2007-06-06|Estimate|September 1994||1994-09-30|June 2007|2007-06-30|April 2002|Actual|2002-04-30|||||Interventional|||Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III|Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III|Completed||Phase 3|232|Actual|French Innovative Leukemia Organisation|||||f||||t||||||||||2018-06-01 03:10:47.884089|2018-06-01 03:10:47.884089
NCT00483119|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2015-10-05||2016-01-21|2007-06-05|2007-06-06|Estimate|2016-01-21|2016-02-18|Estimate||||2016-01-21|2016-02-18|Estimate|April 2007||2007-04-30|January 2016|2016-01-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional||This number is based only on the number of patients who passed screening and then were enrolled. Please note that this study was not evaluable due to the untimely death of the study Principal Investigator as noted previously.|Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus|Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus|Terminated||Phase 2|9|Actual|New York University School of Medicine|Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.|2||Study was terminated due to the death of the PI.|f||||t||||||||||2018-06-01 03:10:47.947229|2018-06-01 03:10:47.947229
NCT00483106|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2017-08-30|2007-06-04|2007-06-06|Estimate|||||||2017-08-30|2017-09-01|Actual|November 1999||1999-11-30|August 2017|2017-08-31|March 2025|Anticipated|2025-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)|Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)|Recruiting||Phase 4|1000|Anticipated|McGill University||2|||f||||f||||||||||2018-06-01 03:10:48.403201|2018-06-01 03:10:48.403201
NCT00483093|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2014-05-29|2007-06-05|2007-06-06|Estimate|||||||2014-05-29|2014-05-30|Estimate|July 2007||2007-07-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|June 2010|Actual|2010-06-30||Interventional|||Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor|NGR004:A Phase IB Study of NGR-hTNF in Combination With Cisplatin in Patient Affected by Advanced or Metastatic Solid Tumor|Completed||Phase 1|22|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:10:48.480971|2018-06-01 03:10:48.480971
NCT00483080|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2014-05-29|2007-06-05|2007-06-06|Estimate|||||||2014-05-29|2014-05-30|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|June 2009|Actual|2009-06-30||Interventional|||Study of NGR-hTNF as Single Agent in Patients Affected by Colorectal Cancer (CRC)|NGR006: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Colorectal Cancer (CRC), Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan Based Regimens|Completed||Phase 2|46|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:10:48.570436|2018-06-01 03:10:48.570436
NCT00483067|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2012-08-01|2007-06-05|2007-06-06|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 1998||1998-03-31|August 2012|2012-08-31|July 2008|Actual|2008-07-31|March 2006|Actual|2006-03-31||Interventional|||2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)|Phase II Study: 2-Chlorodeoxyadenosine (2-CdA) and Cytarabine (Ara-C) in Idiopathic Hypereosinophilic Syndrome (HES)|Completed||Phase 2|13|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:10:48.645387|2018-06-01 03:10:48.645387
NCT00483054|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2011-11-21|2007-06-05|2007-06-06|Estimate|||||||2011-11-21|2011-11-22|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|N2R||Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin|Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin|Completed||Phase 3|142|Actual|Bamrasnaradura Infectious Diseases Institute||2|||f||||t||||||||||2018-06-01 03:10:48.751649|2018-06-01 03:10:48.751649
NCT00483041|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2013-10-22||2014-02-04|2007-06-05|2007-06-06|Estimate|2014-02-04|2014-03-07|Estimate||||2014-02-04|2014-03-07|Estimate|July 2007||2007-07-31|February 2014|2014-02-28|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Interventional|||A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528|A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma|Terminated||Phase 2|11|Actual|MedImmune LLC||2||Study is replaced by MI-CP198 per CPM.|f||||||||||||||2018-06-01 03:10:48.856706|2018-06-01 03:10:48.856706
NCT00483028|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2008-02-01|2007-06-05|2007-06-06|Estimate|||||||2008-02-01|2008-02-05|Estimate|June 2004||2004-06-30|February 2008|2008-02-29|January 2007|Actual|2007-01-31|||||Interventional|||A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI|A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 Weeks) After Single Dose and Steady State Therapy (2 Weeks and 6 Weeks) in Subjects With Mild Cognitive Impairment|Completed||N/A|38||Pfizer|||||f||||||||||||||2018-06-01 03:10:49.213198|2018-06-01 03:10:49.213198
NCT00483015|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2013-08-09|2007-06-04|2007-06-06|Estimate|||||||2013-08-09|2013-08-13|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Differences in the Presentation Outcome and Response to Treatment Between Never- Smokers and Smokers With NSCLC|Differences in the Presentation, Outcome and Response to Treatment Between Never- Smokers and Smokers With Non- Small Cell Lung Cancer.|Completed|||280|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 03:10:49.276578|2018-06-01 03:10:49.276578
NCT00483002|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|2012-04-11||2012-04-11|2007-06-05|2007-06-06|Estimate|2012-04-11|2012-05-11|Estimate||||2012-04-11|2012-05-11|Estimate|June 2007||2007-06-30|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets|Completed|||3719|Actual|Pfizer|Planned observation time points at 4, 8 and 12 weeks were reported as from week 3 to less than week 7, from week 7 to less than week 11, at least week 11. As this is non-interventional study it is likely that adverse events had been under reported.||1||f||||t||||||||||2018-06-01 03:10:49.326793|2018-06-01 03:10:49.326793
NCT00482989|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2012-07-10|2007-06-05|2007-06-06|Estimate|||||||2012-07-10|2012-07-11|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus|A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus|Completed||Phase 1|183|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 03:10:49.50859|2018-06-01 03:10:49.50859
NCT00482976|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2016-07-25|2007-06-04|2007-06-06|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2003||2003-12-31|July 2016|2016-07-31|March 2005|Actual|2005-03-31|||||Interventional|||Effect of LY333531 on Vascular and Neural Functions|The Effects of a Protein Kinase C Beta Inhibitor, LY333531, on Vascular and Neural Functions in Type 2 Diabetes Mellitus - Study B7A-MC-MBDM|Completed||Phase 2|30|Actual|Chromaderm, Inc.|||||f||||f||||||||||2018-06-01 03:10:50.658352|2018-06-01 03:10:50.658352
NCT00482963|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-05|||2013-07-11|2007-06-05|2007-06-06|Estimate|||||||2013-07-11|2013-07-15|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication|A Pilot Study of the Pharmacokinetic Interactions Between the Hormonal Emergency Contraception, Plan B, and Efavirenz|Completed||Phase 1|24|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-06-01 03:10:50.730041|2018-06-01 03:10:50.730041
NCT00482950|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2009-06-04|2007-06-04|2007-06-06|Estimate|||||||2009-06-04|2009-06-08|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|February 2008|Anticipated|2008-02-29|||||Interventional|||A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 2|400|Anticipated|Phenomix|||||t||||f||||||||||2018-06-01 03:10:50.809179|2018-06-01 03:10:50.809179
NCT00482937|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2007-06-04|2007-06-04|2007-06-06|Estimate|||||||2007-06-04|2007-06-06|Estimate|January 2007||2007-01-31|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Safety and Pharmacodynamic Study of CD-NP|A Phase I, Single Ascending Dose Trial to Examine the Safety and Pharmacodynamic Effects of CD-NP|Completed||Phase 1|22|Actual|Nile Therapeutics|||||f||||f||||||||||2018-06-01 03:10:50.910079|2018-06-01 03:10:50.910079
NCT00482924|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2018-05-17|2007-06-05|2007-06-06|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2003||2003-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|STYJOBS||Observational Study of Early Metabolic and Vascular Changes in Obesity|Study for the Investigation of New Individual Risk Profiles and Therapeutic Strategies in Obesity Related Cardiovascular and Metabolic Disorders.|Recruiting|||1500|Anticipated|Medical University of Graz|||2||f||||f||||||Samples With DNA|"~     Collection of fasted blood samples between 9 and 12 AM.~   "|||2018-06-01 03:10:51.001744|2018-06-01 03:10:51.001744
NCT00482911|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2012-10-11||2017-02-06|2007-06-04|2007-06-05|Estimate|2012-10-11|2012-11-14|Estimate||||2017-02-06|2017-03-27|Actual|April 2007|Actual|2007-04-30|February 2017|2017-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma|A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma|Terminated||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||2||Investigator left the institute.|f||||f|t|f||||||No||2018-06-01 03:10:51.249724|2018-06-01 03:10:51.249724
NCT00482898|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2015-05-26|2007-06-01|2007-06-05|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2002||2002-09-30|May 2015|2015-05-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||A Study of MK0359 in Patients With Chronic Asthma (0359-013)|A Multicenter, Randomized, Double-Blind, Crossover Study Comparing the Effect of MK0359 and Placebo in Adult Patients With Chronic Asthma|Completed||Phase 2|56|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:10:51.931987|2018-06-01 03:10:51.931987
NCT00482885|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2011-06-24|2007-06-01|2007-06-05|Estimate|||||||2011-06-24|2011-06-27|Estimate|October 2007||2007-10-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Coordination Versus Pressure in Oesophageal Peristalsis|The Effect of Position on Oesophageal Peristalsis and LOS Pressures: a High Resolution Manometry Study|Completed|||25|Actual|Guy's and St Thomas' NHS Foundation Trust|||||f||||f||||||||||2018-06-01 03:10:52.008377|2018-06-01 03:10:52.008377
NCT00482872|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2017-03-10|2007-06-04|2007-06-05|Estimate|||||||2017-03-10|2017-03-14|Actual|March 2004|Actual|2004-03-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer|Familial HNSCC Syndrome and p16 Germline Mutations|Completed|||400|Anticipated|Vanderbilt University Medical Center|||||f|||||f|f||||||||2018-06-01 03:10:52.069371|2018-06-01 03:10:52.069371
NCT00482859|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-03|||2009-01-21|2007-06-04|2007-06-05|Estimate|||||||2009-01-21|2009-01-22|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Observational|||Sleep Disturbance and Sleep Quality in Women With Fibromyalgia Syndrome|Sleep Disturbance and Sleep Quality in Women With Fibromyalgia Syndrome|Completed|||57|Actual|University of Kentucky|||||f||||f||||||||||2018-06-01 03:10:52.171597|2018-06-01 03:10:52.171597
NCT00482846|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2014-04-14|2007-06-04|2007-06-05|Estimate|||||||2014-04-14|2014-04-15|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma|Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma|Completed||Phase 1|38|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 03:10:52.239287|2018-06-01 03:10:52.239287
NCT00482833|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2018-03-21|2007-06-04|2007-06-05|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2007||2007-08-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|September 2012|Actual|2012-09-30||Interventional|APL0406||Phase III Trial in Acute Promyelocytic Leukemia Patients|A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia|Active, not recruiting||Phase 3|276|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto||2|||f||||f||||||||||2018-06-01 03:10:52.370683|2018-06-01 03:10:52.370683
NCT00482820|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2013-02-06|2007-06-04|2007-06-05|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Clinical Research Studying a Method of Intervention for Children Diagnosed With Anxiety Disorder: Attentional Bias Intervention||Completed||N/A|80|Actual|Rabin Medical Center||2|||f||||||||||||||2018-06-01 03:10:52.695116|2018-06-01 03:10:52.695116
NCT00482807|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2018-02-22|2007-06-04|2007-06-05|Estimate|||||||2018-02-22|2018-02-26|Actual|August 2004||2004-08-31|February 2018|2018-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Intensity-Modulated Radiation Therapy, Docetaxel, and Hormone Therapy in Treating Patients With High-Risk Locally Advanced Prostate Cancer With Pelvic Lymph Node Metastasis|Phase I Study Evaluating Extended Field Intensity Modulated Radiation Therapy and Docetaxel in Patients With Prostate Cancer Associated With Pelvic Node Metastasis|Completed||Phase 1|9|Actual|University of Nebraska|||||f||||t||||||||||2018-06-01 03:10:52.756134|2018-06-01 03:10:52.756134
NCT00482794|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2017-11-02|2007-06-01|2007-06-05|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2006||2006-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|APS||Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome|Genetics of Antiphospholipid Antibody Syndrome|Recruiting|||2800|Anticipated|Duke University|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, and DNA samples~   "|No||2018-06-01 03:10:52.894682|2018-06-01 03:10:52.894682
NCT00482781|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2007-06-04|2007-06-04|2007-06-05|Estimate|||||||2007-06-04|2007-06-05|Estimate|September 2000||2000-09-30|June 2007|2007-06-30|September 2004|Actual|2004-09-30|||||Interventional|PIA||DTaP and Apnea/Bradycardia in Preterm Infants|Prolonged Apnea and Prolonged Bradycardia Following DTaP Immunization in Preterm Infants: A Randomized Multicenter Study|Completed||N/A|191|Actual|American SIDS Institute|||||f||||f||||||||||2018-06-01 03:10:52.974658|2018-06-01 03:10:52.974658
NCT00482768|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2018-03-15|2007-06-04|2007-06-05|Estimate|||||||2018-03-15|2018-03-19|Actual|June 2007||2007-06-30|March 2011|2011-03-31|May 2013|Actual|2013-05-31|April 2012|Actual|2012-04-30||Interventional|||Improving Risk Factors for Diabetes Complications in Primary Care|Improving Risk Factors for Diabetes Complications in Primary Care|Completed||N/A|2493|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-06-01 03:10:53.086472|2018-06-01 03:10:53.086472
NCT00482755|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2013-06-20|2007-06-04|2007-06-05|Estimate|||||||2013-06-20|2013-06-21|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery|A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients With T1c-T3 Operable Carcinoma of the Breast|Completed||Phase 2|4|Actual|Canadian Cancer Trials Group|||||f||||t||||||||||2018-06-01 03:10:53.244701|2018-06-01 03:10:53.244701
NCT00482742|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-03|||2013-07-06|2007-06-04|2007-06-05|Estimate|||||||2013-07-06|2013-07-09|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety & Performance Randomized Study of the CiTop™ Guidewire for Peripheral CTO|A Feasibility, Multi Center Multinational Randomized Open Label Study, to Evaluate the Safety and Performance of the CiTop™ Guidewire for Crossing Total Occlusion in Peripheral Arteries.|Terminated||N/A|50|Actual|Ovalum||2||product development was cancelled|f||||t||||||||||2018-06-01 03:10:53.369547|2018-06-01 03:10:53.369547
NCT00482729|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2009-12-09||2017-05-11|2007-06-01|2007-06-05|Estimate|2010-03-02|2010-03-15|Estimate||||2017-05-11|2017-06-09|Actual|June 19, 2007|Actual|2007-06-19|May 2017|2017-05-31|April 27, 2009|Actual|2009-04-27|November 3, 2008|Actual|2008-11-03||Interventional|||MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)|A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 3|1246|Actual|Merck Sharp & Dohme Corp.|Site 079011301 was non-compliant with Good Clinical Practice (GCP). Data from the 4 patients at this site are included in the Participant Flow summary, but are excluded from all other summaries and analyses.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:10:53.488482|2018-06-01 03:10:53.488482
NCT00482716|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2014-01-09|2007-06-04|2007-06-05|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2007||2007-01-31|August 2009|2009-08-31||||||||Interventional|||Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer|Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia|Unknown status|Active, not recruiting|Phase 3|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:10:54.201298|2018-06-01 03:10:54.201298
NCT00482703|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2010-07-23||2010-11-30|2007-06-04|2007-06-05|Estimate|2010-11-02|2010-11-30|Estimate||||2010-11-30|2010-12-17|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia|A Randomized, Multicenter, Open-label Phase II Study of Dasatinib (BMS-354825) Administered Orally at a Dose of 50mg Twice Daily or 100mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Imatinib|Completed||Phase 1/Phase 2|23|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:10:54.445776|2018-06-01 03:10:54.445776
NCT00482690|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2007-06-04|2007-06-04|2007-06-05|Estimate|||||||2007-06-04|2007-06-05|Estimate|March 2006||2006-03-31|June 2007|2007-06-30|July 2007|Anticipated|2007-07-31|||||Interventional|||Analysis of Aldehyde Biomarkers of Exposure and Host Response||Unknown status|Active, not recruiting|N/A|||University of Nebraska|||||f||||f||||||||||2018-06-01 03:10:55.640052|2018-06-01 03:10:55.640052
NCT00482677|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2017-02-14||2018-01-18|2007-06-04|2007-06-05|Estimate|2018-01-18|2018-01-23|Actual||||2018-01-18|2018-01-23|Actual|May 2007||2007-05-31|April 2016|2016-04-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme|A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients|Completed||Phase 3|562|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||Undecided||2018-06-01 03:10:55.745981|2018-06-01 03:10:55.745981
NCT00482664|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01||2009-03-24|2010-10-27|2007-06-01|2007-06-05|Estimate||||2010-10-27|2010-11-01|Estimate|2010-10-27|2010-11-01|Estimate|July 2007||2007-07-31|October 2010|2010-10-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.|A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).|Completed||Phase 2|84|Anticipated|Pfizer||4|||f||||||||||||||2018-06-01 03:10:56.580818|2018-06-01 03:10:56.580818
NCT00482651|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2012-01-20|2007-06-04|2007-06-05|Estimate|||||||2012-01-20|2012-01-23|Estimate|November 2007||2007-11-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Imaging of Vulnerable Plaques in Coronary Artery Disease by Multidetector Computed Tomography|Imaging of Vulnerable Plaques in Coronary Artery Disease by Multidetector Computed Tomography|Completed||N/A|60|Actual|University of Aarhus||1|||f||||t||||||||||2018-06-01 03:10:56.684626|2018-06-01 03:10:56.684626
NCT00482638|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2015-08-11|2007-06-01|2007-06-05|Estimate|||||||2015-08-11|2015-08-13|Estimate|May 2004||2004-05-31|August 2015|2015-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)||Completed||Phase 2|||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:10:56.751833|2018-06-01 03:10:56.751833
NCT00482625|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2014-04-18||2014-10-07|2007-06-04|2007-06-05|Estimate|2014-04-18|2014-05-19|Estimate||||2014-10-07|2014-10-16|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|February 2010|Actual|2010-02-28||Interventional|||Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|Phase IIA Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms|Terminated||Phase 2|6|Actual|National Cancer Institute (NCI)||1||"The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug~   supply, IND closure)."|f||||t||||||||||2018-06-01 03:10:56.808254|2018-06-01 03:10:56.808254
NCT00482612|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|2014-06-09|2009-04-29|2015-05-11|2007-06-04|2007-06-05|Estimate|2014-06-09|2014-07-10|Estimate|2009-10-02|2009-10-06|Estimate|2015-05-11|2015-06-04|Estimate|December 2006||2006-12-31|May 2015|2015-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|RUBY|Baseline characteristics were reported for the All-Subjects-Treated group. One participant who was randomized to receive MK-8265 4.5 mg did not receive double-blind study medication.|Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)|A Two-Week, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Efficacy and Safety Out-Patient Trial With Org 50081 in Patients With Chronic Primary Insomnia|Completed||Phase 3|526|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 03:10:57.042692|2018-06-01 03:10:57.042692
NCT00482599|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2017-06-15|2007-06-04|2007-06-05|Estimate|||||||2017-06-15|2017-06-16|Actual|June 1, 2005|Actual|2005-06-01|June 2017|2017-06-30|April 13, 2006|Actual|2006-04-13|April 13, 2006|Actual|2006-04-13||Interventional|||Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function (19.4.304)(P05948)(COMPLETED)|A Multicenter, Parallel Group, Comparative Trial Evaluating the Efficacy, Pharmacokinetics and Safety of Org 25969 in Subjects With Normal or Impaired Renal Function|Completed||Phase 3|30|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:10:57.477899|2018-06-01 03:10:57.477899
NCT00482586|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2015-06-03|2007-06-04|2007-06-05|Estimate|||||||2015-06-03|2015-06-08|Estimate|October 2003||2003-10-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy|Outcomes Following Image-Guided Therapy for Hepatic Malignancies|Completed|||137|Actual|Vanderbilt University|||1||f||||f||||||||||2018-06-01 03:10:57.543128|2018-06-01 03:10:57.543128
NCT00477555|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2015-10-28|2007-05-22|2007-05-23|Estimate|||||||2015-10-28|2015-10-29|Estimate|April 2006||2006-04-30|October 2015|2015-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Hemodynamic Assessment of Mosaic Ultra Stented Heart Valve in the Aortic Position|Mosaic Ultra Porcine Bioprosthesis - Hemodynamic Study|Completed|||43|Actual|Medtronic Cardiovascular|||||f||||f||||||||||2018-06-01 03:12:23.020368|2018-06-01 03:12:23.020368
NCT00482573|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2008-06-04|2007-06-04|2007-06-05|Estimate|||||||2008-06-04|2008-06-05|Estimate|April 2004||2004-04-30|June 2008|2008-06-30|January 2006|Actual|2006-01-31|July 2005|Actual|2005-07-31||Interventional|||Dental Anesthesia in Pregnant Women With Rheumatic Heart Disease|Maternal-Fetal Monitoring of Patients With Rheumatic Heart Disease During Dental Procedure Under Local Anesthesia|Completed||Phase 1|31|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-06-01 03:10:57.634497|2018-06-01 03:10:57.634497
NCT00482560|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2007-06-28|2007-06-04|2007-06-05|Estimate|||||||2007-06-28|2007-06-29|Estimate|January 2007||2007-01-31|June 2007|2007-06-30|April 2007|Actual|2007-04-30|||||Interventional|||Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening|Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening|Completed||Phase 3|100|Actual|University of Turin, Italy|||||f||||f||||||||||2018-06-01 03:10:57.810633|2018-06-01 03:10:57.810633
NCT00482547|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2009-04-06||2017-01-13|2007-06-04|2007-06-05|Estimate|2009-12-17|2010-01-21|Estimate||||2017-01-13|2017-02-28|Actual|June 2007||2007-06-30|January 2017|2017-01-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|SUCCESS||Study of a Urethral Catheter Coated With Eluting Silver Salts (SUCCESS)|Study of a Urethral Catheter Coated With Eluting Silver Salts|Terminated||Phase 4|1188|Actual|C. R. Bard|Sample size calculations required 1244 Efficacy Evaluable 48 subjects, only 854 Efficacy Evaluable 48 subjects were enrolled, which does not allow for a fully powered study and there is the threat of a type II error (false negative result).|2||Terminated for futility reasons.|f||||t||||||||||2018-06-01 03:10:57.908873|2018-06-01 03:10:57.908873
NCT00482521|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2012-08-27|2007-06-04|2007-06-05|Estimate|||||||2012-08-27|2012-08-28|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|September 2010|Actual|2010-09-30||Interventional|||CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment|A Phase I, Open-Label Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety Profile of CC-4047 in Subjects With Advanced Solid Tumors|Completed||Phase 1|42|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:10:58.399541|2018-06-01 03:10:58.399541
NCT00482508|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2011-10-24|2007-06-04|2007-06-05|Estimate|||||||2011-10-24|2011-10-25|Estimate|May 2003||2003-05-31|October 2011|2011-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients|A One Year Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Poorly Controlled Moderate to Severe Allergic Asthma Patients Who Participated in the 52-week CIGE24IA04E1 Study|Completed||Phase 3|95|Actual|Novartis|||||f||||||||||||||2018-06-01 03:10:58.47943|2018-06-01 03:10:58.47943
NCT00482495|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2011-05-10|2007-06-04|2007-06-05|Estimate|||||||2011-05-10|2011-05-11|Estimate|April 2006||2006-04-30|May 2011|2011-05-31|November 2009|Actual|2009-11-30|December 2006|Actual|2006-12-31||Interventional|||Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Trial of Bevacizumab in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|42|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 03:10:58.535856|2018-06-01 03:10:58.535856
NCT00482482|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2012-12-04|2007-06-01|2007-06-05|Estimate|||||||2012-12-04|2012-12-05|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Yoga in Unipolar and Bipolar Disorders|The Safety and Effectiveness of Yoga as Augmentation in Improving Residual Depressive Symptoms in Unipolar and Bipolar Disorders.|Completed||N/A|90|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 03:10:58.679924|2018-06-01 03:10:58.679924
NCT00482469|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2009-01-06|2007-06-04|2007-06-05|Estimate|||||||2009-01-06|2009-01-07|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|||||Observational|||The DIEP-Flap as a Model of Ischemia-Reperfusion|The DIEP-Flap as a Model of Ischemia-Reperfusion|Completed|||45|Actual|Maastricht University Medical Center|||||f||||t||||||Samples With DNA|"~     Frozen tissue.~   "|||2018-06-01 03:10:58.818089|2018-06-01 03:10:58.818089
NCT00482456|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2007-06-01|2007-06-01|2007-06-05|Estimate|||||||2007-06-01|2007-06-05|Estimate|January 2005||2005-01-31|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Homocysteine After Nitrous Oxide Anesthesia|Influence of the MTHFR 677C>T Mutation on Homocysteine Levels After Nitrous Oxide Anesthesia.|Completed||Phase 4|140|Actual|Medical University of Vienna|||||f||||f||||||||||2018-06-01 03:10:58.880752|2018-06-01 03:10:58.880752
NCT00482443|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2008-07-08|2007-06-04|2007-06-05|Estimate|||||||2008-07-08|2008-07-10|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|DID||Assessing the Effectiveness of Diabetes Interactive Diary (DID) in Diabetes Management|A Multinational, Randomised Study of the Efficacy of the Diabetes Interactive Diary (DID), a Carbohydrates/Insulin Bolus Calculator and a Telemedicine System Based on the Communication Between Physician or Dietitian and Patient by SMS|Completed||N/A|20|Actual|The Royal Bournemouth Hospital||2|||f||||f||||||||||2018-06-01 03:10:58.94716|2018-06-01 03:10:58.94716
NCT00482430|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2015-08-20|2007-06-01|2007-06-05|Estimate|||||||2015-08-20|2015-08-21|Estimate|September 2007||2007-09-30|August 2015|2015-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia|Completed||Phase 2|50|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:10:59.027654|2018-06-01 03:10:59.027654
NCT00482417|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2015-11-19|2007-06-01|2007-06-05|Estimate|||||||2015-11-19|2015-11-20|Estimate|December 2002||2002-12-31|November 2015|2015-11-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Efficacy and Safety Study of MK0359 in Patients With Arthritis (0359-017)||Completed||Phase 2|11|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:10:59.08999|2018-06-01 03:10:59.08999
NCT00482404|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2007-06-04|2007-06-04|2007-06-05|Estimate|||||||2007-06-04|2007-06-05|Estimate|February 2007||2007-02-28|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Effects of Romantic Affection on Blood Chemistry and Immune Parameters|Study of the Effects of Romantic Affection on Blood Lipids, Blood Glucose, C-Reactive Protein, and Antibodies to Latent Epstein-Barr Virus|Completed||Early Phase 1|||Arizona State University|||||f||||f||||||||||2018-06-01 03:10:59.135453|2018-06-01 03:10:59.135453
NCT00482391|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2015-12-22||2017-04-06|2007-06-04|2007-06-05|Estimate|2017-01-23|2017-03-13|Actual||||2017-04-06|2017-05-12|Actual|March 2007||2007-03-31|April 2017|2017-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer|Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/NEU-Overexpressed/Amplified Breast Cancer: Feasibility|Completed||Phase 2|95|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:10:59.206143|2018-06-01 03:10:59.206143
NCT00482378|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2017-08-28|2007-06-04|2007-06-05|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2005||2005-03-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain|An Open-Label, Pilot Study of Samarium - Sm 153 Lexidronam (Quadramet) in Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain|Active, not recruiting||Phase 1/Phase 2|39|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:10:59.453262|2018-06-01 03:10:59.453262
NCT00482365|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2013-08-16|2007-06-04|2007-06-05|Estimate|||||||2013-08-16|2013-08-19|Estimate|April 2002||2002-04-30|May 2013|2013-05-31|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Observational|||National Registry and Blood Bank of Patients With Liver Cancer|A National Registry of Patients With Hepatocellular Carcinoma|Completed|||151|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||||||2018-06-01 03:10:59.640488|2018-06-01 03:10:59.640488
NCT00482352|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2016-02-19|2007-06-04|2007-06-05|Estimate|||||||2016-02-19|2016-02-23|Estimate|December 2003||2003-12-31|February 2016|2016-02-29||||April 2012|Actual|2012-04-30||Observational|||Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Classification Of Acute Lymphoblastic Leukemia|Completed|||11196|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     marrow and blood samples~   "|||2018-06-01 03:10:59.802988|2018-06-01 03:10:59.802988
NCT00482339|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2007-06-04|2007-06-04|2007-06-05|Estimate|||||||2007-06-04|2007-06-05|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|July 2009|Anticipated|2009-07-31|||||Observational|||PCR-Based Detection of Bacterial Agents in Platelet Concentrates and Whole Blood|PCR-Based Detection of Bacterial Agents in Platelet Concentrates and Whole Blood (First Study)|Unknown status|Not yet recruiting||2000|Anticipated|University of Jena|||||f||||f||||||||||2018-06-01 03:11:00.21047|2018-06-01 03:11:00.21047
NCT00482313|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2010-05-07|2007-06-04|2007-06-05|Estimate|||||||2010-05-07|2010-05-10|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Effectiveness of Methylphenidate in Swedish Male Prison Inmates With Attention-deficit Hyperactivity Disorder (ADHD)|A Single Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy of PR OROS Methylphenidate Followed by Open-Label Extension, in Swedish Male Prison Inmates With ADHD|Completed||Phase 3|30|Actual|Psychiatry Karolinska||2|||f||||t||||||||||2018-06-01 03:11:00.363236|2018-06-01 03:11:00.363236
NCT00482300|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2007-06-04|2007-06-04|2007-06-05|Estimate|||||||2007-06-04|2007-06-05|Estimate||||March 2007|2007-03-31||||||||Interventional|||Systematic Pelvic Lymphadenectomy Versus no Lymphadenectomy in Clinical Stage I-II Endometrial Cancer||Completed||N/A|||University of Roma La Sapienza|||||f||||t||||||||||2018-06-01 03:11:00.494707|2018-06-01 03:11:00.494707
NCT00482287|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2015-04-06|2007-06-01|2007-06-05|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients|A Phase II, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study to Assess the Pharmacokinetics and Pharmacodynamics of MTR105 in Cardiac Surgery Induced Hypotension Patients During Weaning Off Cardiopulmonary Bypass|Withdrawn||Phase 2|0|Actual|Meditor Pharmaceuticals Ltd.||4||Site did not recruit any patients|f||||f||||||||||2018-06-01 03:11:00.567062|2018-06-01 03:11:00.567062
NCT00482274|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|2010-07-27||2017-04-26|2007-06-04|2007-06-05|Estimate|2010-07-27|2010-08-24|Estimate||||2017-04-26|2017-04-28|Actual|May 2007||2007-05-31|April 2017|2017-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Docetaxel in Treating Patients With Relapsed Prostate Cancer|Phase II Study of the Early Use of Docetaxel in Patients With Biochemical Relapse After Primary Therapy for Prostate Cancer and an Incomplete Response to Androgen Deprivation Therapy.|Terminated||Phase 2|3|Actual|OHSU Knight Cancer Institute|Due to withdrawal of sponsor support, this study was terminated after only 3 subjects were enrolled (of the planned 36 subjects). Sufficient data were not obtained to make statistically significant conclusions.|||Drug supplier stopped funding due to loss of study drug (docetaxel) patent.|f||||||||||||||2018-06-01 03:11:00.768451|2018-06-01 03:11:00.768451
NCT00482261|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-03|||2013-01-08|2007-06-04|2007-06-05|Estimate|||||||2013-01-08|2013-01-10|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|August 2010|Actual|2010-08-31||Interventional|||A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression|Phase II Trial of Low Dose Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (Rev-Lite) in Patients at High Risk for Myelosuppression|Unknown status|Active, not recruiting|Phase 2|150|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-06-01 03:11:00.987873|2018-06-01 03:11:00.987873
NCT00482248|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2016-11-16|2007-06-04|2007-06-05|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2003||2003-06-30|November 2016|2016-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma|An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study|Completed||Phase 3|132|Actual|Novartis|||||f||||||||||||||2018-06-01 03:11:01.089179|2018-06-01 03:11:01.089179
NCT00482235|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2015-11-30|2007-06-01|2007-06-05|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2002||2002-12-31|November 2015|2015-11-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)||Completed||Phase 2|45|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:11:01.145325|2018-06-01 03:11:01.145325
NCT00482222|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2013-01-22|2007-06-04|2007-06-05|Estimate|||||||2013-01-22|2013-01-23|Estimate|February 2007||2007-02-28|April 2008|2008-04-30||||December 2014|Anticipated|2014-12-31||Interventional|||Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer|A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy|Unknown status|Recruiting|Phase 3|340|Anticipated|University of Southampton||2|||f||||t||||||||||2018-06-01 03:11:01.210794|2018-06-01 03:11:01.210794
NCT00482209|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2009-10-09|2007-06-04|2007-06-05|Estimate|||||||2009-10-09|2009-10-12|Estimate|May 2007||2007-05-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of 400mcg Versus 800mcg Buccal Misoprostol Following Mifepristone 200mg for Abortion up to 63 Days Gestation||Completed||N/A|1220|Anticipated|Gynuity Health Projects||2|||f||||||||||||||2018-06-01 03:11:01.492602|2018-06-01 03:11:01.492602
NCT00482196|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2015-04-27|2007-06-01|2007-06-05|Estimate|||||||2015-04-27|2015-04-28|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)||Completed||Phase 2|173|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:11:01.626739|2018-06-01 03:11:01.626739
NCT00482183|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-04|||2007-06-04|2007-06-04|2007-06-05|Estimate|||||||2007-06-04|2007-06-05|Estimate|July 2003||2003-07-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Comparison Between Pioglitazone and SES With type2 DM|Comparison of Bare Metal Stent With Pioglitazone Versus Sirolimus-Eluting Stent for Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus.|Completed||Phase 2/Phase 3|38|Actual|Showa University|||||f||||f||||||||||2018-06-01 03:11:01.70493|2018-06-01 03:11:01.70493
NCT00482170|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|2012-03-01||2012-03-01|2007-06-01|2007-06-04|Estimate|2012-03-01|2012-03-30|Estimate||||2012-03-01|2012-03-30|Estimate|September 2007||2007-09-30|March 2012|2012-03-31|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept|A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-injector and the Etanercept Prefilled Syringe) in Patients With Psoriasis.|Completed||Phase 3|421|Actual|Pfizer||2|||f||||||||||||||2018-06-01 03:11:01.965958|2018-06-01 03:11:01.965958
NCT00482157|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-06-23|2007-05-31|2007-06-04|Estimate|||||||2009-06-23|2009-06-25|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|November 2008|Anticipated|2008-11-30|November 2007|Anticipated|2007-11-30||Interventional|||Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance|Calcitriol or Placebo in Men for Prostate Cancer Active Surveillance|Unknown status|Active, not recruiting|N/A|24|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 03:11:06.360227|2018-06-01 03:11:06.360227
NCT00482144|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2016-06-26|2007-06-01|2007-06-04|Estimate|||||||2016-06-26|2016-06-28|Estimate|July 2003||2003-07-31|June 2016|2016-06-30|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Study of the Effects of the Pulsed-dye Laser at 585nm and 595nm to Treat Post-operative Scars on Suture-removal Day|Comparison of the Effectiveness of the Pulsed Dye Laser 585nm Versus 595nm in the Treatment of New Surgical Scars|Completed||N/A|20|Actual|University of Miami||3|||f||||f||||||||||2018-06-01 03:11:06.431456|2018-06-01 03:11:06.431456
NCT00482118|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2018-04-04|2007-06-01|2007-06-04|Estimate|||||||2018-04-04|2018-04-05|Actual|March 1, 2006||2006-03-01|February 13, 2018|2018-02-13||||||||Observational|||Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China|A Hospital-Based Case-Control Study of Non-Smoking Women in Xuan Wei and Fu Yua, China: PAH Exposure, Genetic Susceptibility, and Lung Cancer|Completed|||3720|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:11:06.520118|2018-06-01 03:11:06.520118
NCT00482105|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2015-04-20|2007-06-01|2007-06-04|Estimate|||||||2015-04-20|2015-04-22|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|DermTech||Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells|Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells|Terminated||N/A|7|Actual|University of California, Davis||1||Withdrawn per sponsor and Investigator|f||||f||||||||||2018-06-01 03:11:06.581921|2018-06-01 03:11:06.581921
NCT00482092|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2017-12-06|2007-05-31|2007-06-04|Estimate|||||||2017-12-06|2017-12-08|Actual|May 2007||2007-05-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease|A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease|Active, not recruiting||Phase 3|330|Anticipated|Mesoblast, Ltd.||3|||f||||t||||||||||2018-06-01 03:11:06.66108|2018-06-01 03:11:06.66108
NCT00482079|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2017-03-24|2007-06-01|2007-06-04|Estimate|||||||2017-03-24|2017-03-28|Actual|May 13, 2003|Actual|2003-05-13|March 2017|2017-03-31|June 15, 2006|Actual|2006-06-15|August 25, 2004|Actual|2004-08-25||Interventional|||A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)|A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 2|743|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:11:06.910732|2018-06-01 03:11:06.910732
NCT00482066|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2015-05-28|2007-06-01|2007-06-04|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|ABAVAS||Abatacept in ANCA Associated Vasculitis|A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis|Terminated||Phase 2|7|Actual|Imperial College London||2||Funders withdrew funding due to slow recruitment|f||||t||||||||||2018-06-01 03:11:06.973796|2018-06-01 03:11:06.973796
NCT00482053|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2017-10-25||2018-05-11|2007-05-31|2007-06-04|Estimate|2018-05-11|2018-05-14|Actual||||2018-05-11|2018-05-14|Actual|October 2006||2006-10-31|May 2018|2018-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT|A Phase 2 Study in Poor Risk Diffuse Large B-cell Lymphoma of Total Lymphoid Irradiation & Antithymocyte Globulin Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation|Terminated||Phase 2|3|Actual|Stanford University||1||Low accrual|f||||t|t|f|||f|||No||2018-06-01 03:11:07.075315|2018-06-01 03:11:07.075315
NCT00482040|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2007-08-23|2007-06-01|2007-06-04|Estimate|||||||2007-08-23|2007-08-24|Estimate|March 2004||2004-03-31|May 2007|2007-05-31|January 2006|Actual|2006-01-31|||||Interventional|||Randomized Trial Investigating Four Nasal CPAP Systems in the Management of Apnea of Prematurity|Randomized Trial Investigating Four Nasal CPAP Systems in the Management of Apnea of Prematurity|Terminated||N/A|16|Actual|University Hospital Tuebingen||||"Recruiting took longer than expected due to a lack of eligible patients (very strong inclusion~   and exclusion criterias)"|f||||f||||||||||2018-06-01 03:11:07.391952|2018-06-01 03:11:07.391952
NCT00482027|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2013-01-14|2007-06-01|2007-06-04|Estimate|||||||2013-01-14|2013-01-16|Estimate|December 2003||2003-12-31|May 2007|2007-05-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|A001||Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine|A Phase 1 Randomized, Placebo-controlled, Double-blind Dose-escalation Trial to Evaluate the Safety and Immunogenicity of tgAAC09, a Gag-PR-RT AAV HIV Vaccine|Completed||Phase 1|80|Actual|International AIDS Vaccine Initiative||2|||f||||t||||||||||2018-06-01 03:11:07.468464|2018-06-01 03:11:07.468464
NCT00482014|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2012-10-26||2012-10-26|2007-05-31|2007-06-04|Estimate|2012-10-26|2012-11-27|Estimate||||2012-10-26|2012-11-27|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer|Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|120|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:11:07.758529|2018-06-01 03:11:07.758529
NCT00482001|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-02-05|2007-05-31|2007-06-04|Estimate|||||||2009-02-05|2009-02-06|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults|The Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults: A Pilot Study|Completed||Phase 4|22|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 03:11:09.132467|2018-06-01 03:11:09.132467
NCT00481988|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|2012-12-06||2013-05-17|2007-06-01|2007-06-04|Estimate|2013-05-17|2013-05-20|Estimate||||2013-05-17|2013-05-20|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|June 2009|Actual|2009-06-30||Interventional||One patient dropped out of study after 5 treatments due to One patient dropped out of study after 5 treatments to pursue other treatment options One patient dropped by investigator when patient had HDRS of 8 at baseline ratings One patient dropped out of study after 1 treatment to pursue other treatment options|Treating Depression With Transcranial Direct Current Stimulation (tDCS)|Randomized, Double Blind Crossover Study of the Treatment of Major Depressive Episode With Transcranial Direct Current Stimulation (tDCS)|Completed||Phase 1/Phase 2|20|Actual|New York State Psychiatric Institute|Data for the secondary outcome measure (Beck Depression Inventory) was incompletely collected and not analyzed.|2|||f||||t||||||||||2018-06-01 03:11:09.262241|2018-06-01 03:11:09.262241
NCT00481975|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2009-04-06|2007-06-01|2007-06-04|Estimate|||||||2009-04-06|2009-04-07|Estimate|August 2004||2004-08-31|April 2009|2009-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients|A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving|Completed||Phase 3|289|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:11:09.538178|2018-06-01 03:11:09.538178
NCT00481962|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-09-25|2007-06-01|2007-06-04|Estimate|||||||2009-09-25|2009-09-28|Estimate|February 2006||2006-02-28|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)|Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units|Completed|||180|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:11:09.638007|2018-06-01 03:11:09.638007
NCT00481949|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2011-06-24|2007-06-01|2007-06-04|Estimate|||||||2011-06-24|2011-06-27|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo|What is the Physiologic and Clinical Relevance of Oesophagogastric Junction Distensibility? Studies Using Endo-Flip and 96 Hour Wireless pH System|Completed|||50|Actual|Guy's and St Thomas' NHS Foundation Trust|||||f||||f||||||Samples Without DNA|"~     Biopsies taken at the gastro-oesophageal junction will be sent to histology lab and analysed~     as per routine histology specimens. These will be stored as all samples at our hospital are~     stored and only results reported by the appointed histologist will be used for analysis.~   "|||2018-06-01 03:11:09.702126|2018-06-01 03:11:09.702126
NCT00481936|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2015-12-22|2007-05-31|2007-06-04|Estimate|||||||2015-12-22|2015-12-23|Estimate|May 2007||2007-05-31|December 2015|2015-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin|A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin|Terminated||Phase 1|15|Actual|Viventia Bio||1||Corporate reasons unrelated to safety and efficacy|f||||f||||||||||2018-06-01 03:11:09.759226|2018-06-01 03:11:09.759226
NCT00481923|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2009-04-17|2007-06-01|2007-06-04|Estimate|||||||2009-04-17|2009-04-20|Estimate|May 2004||2004-05-31|April 2009|2009-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|REBA||Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients|A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 With or Without Hypocaloric Diet in Obese Patients|Completed||Phase 3|156|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:11:09.84091|2018-06-01 03:11:09.84091
NCT00481897|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2012-08-06|2007-05-31|2007-06-04|Estimate|||||||2012-08-06|2012-08-07|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Worksite Nutrition Study|Worksite Nutrition Study|Completed||N/A|113|Actual|Physicians Committee for Responsible Medicine|||||f||||t||||||||||2018-06-01 03:11:10.062125|2018-06-01 03:11:10.062125
NCT00481884|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2016-04-29|2007-05-31|2007-06-04|Estimate|||||||2016-04-29|2016-05-02|Estimate|May 2007||2007-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients|Phase III Trial to Compare RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients|Completed||Phase 3|80|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:11:10.134949|2018-06-01 03:11:10.134949
NCT00481871|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|2012-08-20||2013-05-08|2007-06-01|2007-06-04|Estimate|2012-08-20|2012-09-18|Estimate||||2013-05-08|2013-05-10|Estimate|May 2007||2007-05-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies|A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies|Completed||Phase 1/Phase 2|119|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||||||||||||2018-06-01 03:11:10.263127|2018-06-01 03:11:10.263127
NCT00481858|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2011-02-25|2007-05-31|2007-06-04|Estimate|||||||2011-02-25|2011-02-28|Estimate|July 2005||2005-07-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Observational|CRC011||Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis|A CLL Research Consortium (CRC) Phase II Study of Kinetic Biomarker for Chronic Lymphocytic Leukemia (CLL) Prognosis|Completed|||150|Anticipated|KineMed|||||f||||f||||||Samples With DNA|"~     CLL cells~   "|||2018-06-01 03:11:11.264668|2018-06-01 03:11:11.264668
NCT00481845|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2016-12-13||2016-12-13|2007-05-31|2007-06-04|Estimate|2016-12-13|2017-02-07|Estimate||||2016-12-13|2017-02-07|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer|Randomized Phase 2 Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer|Terminated||Phase 2|1|Actual|Stanford University||2||Low accrual|f||||t||||||||||2018-06-01 03:11:11.368486|2018-06-01 03:11:11.368486
NCT00468949|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2011-07-27|2007-05-02|2007-05-03|Estimate|||||||2011-07-27|2011-07-28|Estimate|May 2007||2007-05-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Health-Related Quality of Life in Patients With Dupuytren's Disease|Health-Related Quality of Life in Patients With Dupuytren's Disease: A Prospective Cohort Study.|Completed|||51|Actual|McMaster University|||2||f||||f||||||||||2018-06-01 03:15:08.754308|2018-06-01 03:15:08.754308
NCT00481832|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2017-10-23||2018-01-17|2007-05-31|2007-06-04|Estimate|2018-01-17|2018-02-14|Actual||||2018-01-17|2018-02-14|Actual|January 2007||2007-01-31|January 2018|2018-01-31|March 30, 2017|Actual|2017-03-30|October 27, 2014|Actual|2014-10-27||Interventional|||Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma|Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma|Terminated||Phase 2|50|Actual|Stanford University||1||Accrual Factor|f||||t||||||||||2018-06-01 03:11:11.739898|2018-06-01 03:11:11.739898
NCT00481819|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2016-02-23|2007-05-31|2007-06-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2007||2007-07-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With MMF and Steroids in Patients Undergoing Kidney Transplantation and a Pharmacokinetics Study.|Completed||Phase 3|240|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 03:11:12.054938|2018-06-01 03:11:12.054938
NCT00481806|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2013-05-08|2007-05-31|2007-06-04|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Observational|||Evaluating the Role of Thrombin in Saphenous Vein Graft Failure After Heart Bypass Surgery|Thrombin Dysregulation Leads to Early Saphenous Vein Graft Failure|Unknown status|Recruiting||450|Anticipated|University of Arizona|||||f||||||||||Samples With DNA|"~     Whole blood and vein samples~   "|||2018-06-01 03:11:12.134633|2018-06-01 03:11:12.134633
NCT00481793|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2018-05-23|2007-06-01|2007-06-04|Estimate|||||||2018-05-23|2018-05-24|Actual|June 9, 2004||2004-06-09|September 17, 2014|2014-09-17|September 17, 2014||2014-09-17|||||Observational|||Relationship of Genetic Differences to the Development of Chromosome Abnormalities|Germline Genetic Variation and Risk of Chromosome Aberrations Among Mayak Nuclear Workers|Terminated|||361|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:11:12.201028|2018-06-01 03:11:12.201028
NCT00481780|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2007-09-10|2007-06-01|2007-06-04|Estimate|||||||2007-09-10|2007-09-11|Estimate|November 2004||2004-11-30|May 2007|2007-05-31|April 2007||2007-04-30|||||Interventional|||PTA vs. CB-PTA for Treatment of Femoropopliteal Artery In-Stent Restenosis|Conventional Balloon Angioplasty vs. Cutting Balloon Angioplasty for Treatment of Femoropopliteal Artery In-Stent Restenosis - A Randomized Controlled Pilot Trial|Completed||N/A|40|Actual|Vienna General Hospital|||||f||||f||||||||||2018-06-01 03:11:12.295467|2018-06-01 03:11:12.295467
NCT00481767|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2011-02-24||2018-02-12|2007-06-01|2007-06-04|Estimate|2011-02-24|2011-03-24|Estimate||||2018-02-12|2018-03-15|Actual|October 1, 2007|Actual|2007-10-01|February 2018|2018-02-28|July 26, 2010|Actual|2010-07-26|February 25, 2010|Actual|2010-02-25||Interventional|||Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.|Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years.|Completed||Phase 3|676|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:11:12.419142|2018-06-01 03:11:12.419142
NCT00481754|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2017-10-18|2007-06-01|2007-06-04|Estimate|||||||2017-10-18|2017-10-19|Actual|March 2, 2006||2006-03-02|July 25, 2017|2017-07-25||||||||Observational|||Benign Reproductive Tissue Analysis for Endometrial Cancer Markers|Benign Reproductive Tissue Evaluation (BRTE) Study|Recruiting|||295|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:11:14.465385|2018-06-01 03:11:14.465385
NCT00481741|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2009-07-30|2007-06-01|2007-06-04|Estimate|||||||2009-07-30|2009-07-31|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions|A Prospective Randomized Controlled Efficacy and Safety Trial of the SafeSeal Hemostasis Patch Compared to Manual Compression for Achieving Vascular Hemostasis Following Percutaneous Coronary and Peripheral Intervention.|Completed||Phase 4|150|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 03:11:14.533087|2018-06-01 03:11:14.533087
NCT00481728|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2009-05-27|2007-06-01|2007-06-04|Estimate|||||||2009-05-27|2009-05-28|Estimate|June 2007||2007-06-30|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.|Evaluation of Sympathetic Skin Responses and Heart Rate Variability as Objective Measures of Bladder Sensation - a Double Blind Third Party Open Placebo Controlled Randomised Study Using a Single Dose of Tolterodine in Patients With Idiopathic Overactive Bladder and Healthy Volunteers|Completed||Phase 1|28|Anticipated|Pfizer||1|||f||||||||||||||2018-06-01 03:11:14.585206|2018-06-01 03:11:14.585206
NCT00481715|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2011-01-26|2007-05-31|2007-06-04|Estimate|||||||2011-01-26|2011-01-27|Estimate|September 2008||2008-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of Two Workplace-Sponsored Obesity Prevention Programs|Interventions to Control Obesity in Colleges|Completed||N/A|1020|Actual|University of North Carolina, Chapel Hill||4|||f||||t||||||||||2018-06-01 03:11:14.644458|2018-06-01 03:11:14.644458
NCT00481702|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2017-02-17|2007-06-01|2007-06-04|Estimate|||||||2017-02-17|2017-02-20|Actual|December 2001||2001-12-31|February 2017|2017-02-28|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)|A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults|Completed||Phase 3|300||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:11:14.70275|2018-06-01 03:11:14.70275
NCT00481689|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2009-06-25|2007-06-01|2007-06-04|Estimate|||||||2009-06-25|2009-06-26|Estimate|May 2004||2004-05-31|June 2009|2009-06-30|September 2005|Actual|2005-09-30|||||Interventional|||Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens|Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens|Completed||Phase 4|500|Actual|Bayer|||||||||||||||||||2018-06-01 03:11:14.937801|2018-06-01 03:11:14.937801
NCT00480974|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-09-03|2007-05-31|2007-06-01|Estimate|||||||2009-09-03|2009-09-04|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea|Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea.Observational Retrospective Study.|Completed|||20|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-06-01 03:11:27.188446|2018-06-01 03:11:27.188446
NCT00481676|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|2010-12-17||2011-09-14|2007-06-01|2007-06-04|Estimate|2011-09-14|2011-10-21|Estimate||||2011-09-14|2011-10-21|Estimate|May 2007||2007-05-31|September 2011|2011-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria|A Randomized, 24 Weeks, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Adult Patients With Chronic Urticaria Who Exhibit IgE Against Thyroperoxidase|Completed||Phase 2|49|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:11:15.118915|2018-06-01 03:11:15.118915
NCT00481663|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2017-03-31|2007-06-01|2007-06-04|Estimate|||||||2017-03-31|2017-04-04|Actual|August 19, 2003|Actual|2003-08-19|March 2017|2017-03-31|May 14, 2006|Actual|2006-05-14|July 21, 2004|Actual|2004-07-21||Interventional|||A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Finding Study of Once-Daily Dosing of Sitaglipin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 2|555|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 03:11:15.830267|2018-06-01 03:11:15.830267
NCT00481650|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2007-12-07|2007-06-01|2007-06-04|Estimate|||||||2007-12-07|2007-12-10|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Observational|||Observational Trial With Leios/Alesse|A Prospective Observation Study (Anwendungsbeobachtung [AWB]) of the Prescribing and Administration Practices of German Gynecologists With Leios® Dragées/Alesse|Completed|||||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:11:15.929697|2018-06-01 03:11:15.929697
NCT00481637|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2018-01-02|2007-06-01|2007-06-04|Estimate|||||||2018-01-02|2018-01-04|Actual|March 1998||1998-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients|Tumor Immunity in Neurologically Normal Patients|Recruiting|||10|Anticipated|Rockefeller University|||2||f||||f||||||||||2018-06-01 03:11:15.981711|2018-06-01 03:11:15.981711
NCT00481624|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2018-03-01|2007-06-01|2007-06-04|Estimate|||||||2018-03-01|2018-03-05|Actual|May 2007||2007-05-31|March 2018|2018-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|Procrit||Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia|A Phase II Trial Using Intravenous Iron in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia Treated With 120,000 Units Epoetin Alfa Every Three Weeks|Withdrawn||Phase 2|0|Actual|University of Louisville||1||The study was stopped because of lack of funding.|f||||t||||||||||2018-06-01 03:11:16.04449|2018-06-01 03:11:16.04449
NCT00481611|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2018-05-16|2007-06-01|2007-06-04|Estimate|||||||2018-05-16|2018-05-17|Actual|June 15, 2006||2006-06-15|October 18, 2017|2017-10-18||||||||Observational|||Cancer Markers Associated With Occupational Exposure to Trichloroethylene|A Cross-Sectional Study of Occupational Exposure to Trichloroethylene, Chromosomal Aberrations, and Related Biomarkers in Guangdong, China|Completed|||125|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:11:16.14741|2018-06-01 03:11:16.14741
NCT00481598|ClinicalTrials.gov processed this data on May 31, 2018|2007-06-01|||2008-09-11|2007-06-01|2007-06-04|Estimate|||||||2008-09-11|2008-09-12|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Non Invasive Assessment of Liver Glycogen Kinetics and ATP Synthesis in Type1 Diabetics|Non Invasive Assessment of Liver Glycogen Kinetics and ATP Synthesis in Type1 Diabetics|Completed||N/A|28|Anticipated|Landsteiner Institut|||||f||||t||||||||||2018-06-01 03:11:16.251405|2018-06-01 03:11:16.251405
NCT00481585|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2014-02-01|2007-05-30|2007-06-01|Estimate|||||||2014-02-01|2014-02-04|Estimate|May 2007||2007-05-31|February 2014|2014-02-28||||July 2009|Actual|2009-07-31||Observational|||The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture|The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture|Terminated|||13|Actual|Hackensack University Medical Center||||study team failed to complete timely reviews, study suspended|f||||t||||||||||2018-06-01 03:11:16.329803|2018-06-01 03:11:16.329803
NCT00481572|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2008-02-26|2007-05-30|2007-06-01|Estimate|||||||2008-02-26|2008-02-29|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Continuous Infusion of Terlipressin in Septic Shock|"Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock. A Randomized, Controlled, Pilot Trial. THE TERLIVAP STUDY"|Completed||Phase 2|45|Actual|University of Roma La Sapienza||3|||f||||f||||||||||2018-06-01 03:11:16.391816|2018-06-01 03:11:16.391816
NCT00481559|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2014-01-16|2007-05-30|2007-06-01|Estimate|||||||2014-01-16|2014-01-17|Estimate||||January 2014|2014-01-31||||||||Expanded Access|||Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity|An Open-Label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate Toxicity|Approved for marketing|||||BTG International Inc.|||||||||||||||||||2018-06-01 03:11:16.489401|2018-06-01 03:11:16.489401
NCT00481546|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2017-08-23|2007-05-31|2007-06-01|Estimate|||||||2017-08-23|2017-08-24|Actual|July 2007||2007-07-31|August 2017|2017-08-31|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30||Interventional|LCA||Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations|Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis)|Active, not recruiting||Phase 1|15|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 03:11:16.545558|2018-06-01 03:11:16.545558
NCT00481533|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-06-01|Estimate|||||||2007-05-30|2007-06-01|Estimate|June 2005||2005-06-30|May 2007|2007-05-31|January 2007|Actual|2007-01-31|||||Interventional|||Ergot and Oxytocin During Cesarean Delivery Following Failure to Progress in Labour|Prophylactic Ergonovine-Oxytocin Versus Oxytocin During Cesarean Delivery Following Failure to Progress in Labour|Completed||N/A|47|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||||f||||f||||||||||2018-06-01 03:11:16.650209|2018-06-01 03:11:16.650209
NCT00481520|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30||2009-09-28|2009-09-28|2007-05-30|2007-06-01|Estimate||||2009-09-28|2009-09-30|Estimate|2009-09-28|2009-09-30|Estimate|June 2007||2007-06-30|June 2008|2008-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.|Completed||Phase 2|72|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:11:16.721908|2018-06-01 03:11:16.721908
NCT00481169|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2009-08-20|2007-05-30|2007-06-01|Estimate|||||||2009-08-20|2009-08-21|Estimate|July 2001||2001-07-31|August 2009|2009-08-31|September 2004|Actual|2004-09-30|July 2004|Actual|2004-07-31||Interventional|||Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women|A Multicenter, Double Blind, Randomized, Placebo and Raloxifene Controlled Study to Assess Safety and Efficacy of TSE-424 (Bazedoxifene Acetate) in the Prevention of Postmenopausal Osteoporosis|Completed||Phase 3|1742|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:11:23.361624|2018-06-01 03:11:23.361624
NCT00481507|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|2011-05-09||2017-12-15|2007-05-30|2007-06-01|Estimate|2012-02-21|2012-03-26|Estimate||||2017-12-15|2018-01-16|Actual|July 2007||2007-07-31|December 2017|2017-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|MILK||Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)|Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)|Completed||N/A|125|Actual|Georgetown University|We did not assess or culture stools for the presence of pathogenic organisms. We did not independently examine children; we relied on parental/patient-oriented outcomes. Our population was generally very healthy. We did not assess probiotic dosages.|2|||f||||t|f|f|||t|||||2018-06-01 03:11:17.036418|2018-06-01 03:11:17.036418
NCT00481494|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2007-05-31|2007-05-31|2007-06-01|Estimate|||||||2007-05-31|2007-06-01|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|October 2007|Anticipated|2007-10-31|||||Observational|GDC||Personality Characteristics and Compliance With Antiglaucoma Medication|Personality Characteristics and Compliance With Antiglaucoma Medication|Unknown status|Recruiting||150|Anticipated|Yonsei University|||||f||||f||||||||||2018-06-01 03:11:17.270703|2018-06-01 03:11:17.270703
NCT00481481|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2014-07-17|2007-05-30|2007-06-01|Estimate|||||||2014-07-17|2014-07-18|Estimate|April 2007||2007-04-30|July 2014|2014-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|CONCERTO||Conversion Study From Cyclosporine to FK506MR Based Immunosuppression in Kidney Transplant Subjects|A Multicenter, Single-arm, Open, Conversion Study From a Cyclosporine (CyA) Based Immunosuppressive Regimen to a Tacrolimus Modified Release, FK506E (MR4), Based Immunosuppressive Regimen in Kidney Transplant Subjects (CONCERTO: Converting Cyclosporine to FK506E (MR4) in Renal Transplantation)|Completed||Phase 3|346|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 03:11:17.345484|2018-06-01 03:11:17.345484
NCT00481468|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2012-09-26|2007-05-31|2007-06-01|Estimate|||||||2012-09-26|2012-09-27|Estimate|June 2006||2006-06-30|September 2012|2012-09-30|March 2010|Actual|2010-03-31|June 2007|Actual|2007-06-30||Observational|SOMARIS||Validation of the Siemens System Somatom Definition and Operating Software for Cardiac CT Studies|Validation of the Siemens System Somatom Definition and Operating Software SYNGO CT2007 (Software Version SOMARIS/7 SYNGO® Software) for Cardiac CT Studies|Completed|||385|Actual|William Beaumont Hospitals|||||f||||t||||||||||2018-06-01 03:11:17.52705|2018-06-01 03:11:17.52705
NCT00481455|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2008-11-24|2007-05-30|2007-06-01|Estimate|||||||2008-11-24|2008-11-25|Estimate|April 2007||2007-04-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)|A Single-Center, Open-Label, Phase II, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With Protracted Oral Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|15|Actual|CASI Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 03:11:17.657277|2018-06-01 03:11:17.657277
NCT00481442|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-06-01|Estimate|||||||2007-05-30|2007-06-01|Estimate|January 2007||2007-01-31|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Phenylephrine Versus Norepinephrine in Septic Shock|Effects of Phenylephrine on Systemic and Regional Hemodynamics in Patients With Septic Shock: a Crossover Pilot Study|Completed||Phase 2|15|Actual|University of Roma La Sapienza|||||f||||f||||||||||2018-06-01 03:11:17.738454|2018-06-01 03:11:17.738454
NCT00481429|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-01-28|2007-05-31|2007-06-01|Estimate|||||||2009-01-28|2009-01-29|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study|Evaluation of Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study|Completed||N/A|12|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 03:11:17.821384|2018-06-01 03:11:17.821384
NCT00481416|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-06-01|Estimate|||||||2007-05-30|2007-06-01|Estimate|December 2004||2004-12-31|June 2006|2006-06-30|January 2005|Actual|2005-01-31|||||Observational|MA-37||“Evaluation of the PillCam™ESO Capsule in the Detection of Esophageal Varices|Evaluation of the PillCam™ Eso Capsule in the Detection of Esophageal Varices|Completed|||318|Actual|Given Imaging Ltd.|||||f||||f||||||||||2018-06-01 03:11:17.930822|2018-06-01 03:11:17.930822
NCT00481403|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2015-03-09|2007-05-31|2007-06-01|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2006||2006-05-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Study of Sperm Molecular Factors Implicated in Male Fertility|Microarray Analysis in Sperm From Fertile and Infertile Males Without Basic Sperm Analysis Abnormalities|Unknown status|Active, not recruiting||100|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||Samples Without DNA|"~     After sperm washing, sperm pellet was suspended in trizol and immediately frozen by direct~     immersion in liquid nitrogen and stored in a nitrogen tank until mRNA extraction.~   "|||2018-06-01 03:11:18.003212|2018-06-01 03:11:18.003212
NCT00481390|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2011-06-07|2007-05-31|2007-06-01|Estimate|||||||2011-06-07|2011-06-08|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients|Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected Patients|Completed|||1110|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 03:11:18.084195|2018-06-01 03:11:18.084195
NCT00481377|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2008-07-18|2007-05-31|2007-06-01|Estimate|||||||2008-07-18|2008-07-21|Estimate|May 2007||2007-05-31|July 2008|2008-07-31|May 2010|Anticipated|2010-05-31|||||Interventional|ABLATION 4 ICD||Ablation for ICD Intervention Reduction in Patients With CAD|Ablation for ICD Intervention Reduction in Patients With CAD - a Prospective Randomized Trial|Terminated||N/A|200|Anticipated|Institute of Cardiology, Warsaw, Poland|||||f||||f||||||||||2018-06-01 03:11:18.17767|2018-06-01 03:11:18.17767
NCT00481364|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2013-09-06|2007-05-30|2007-06-01|Estimate|||||||2013-09-06|2013-09-09|Estimate|November 2006||2006-11-30|September 2013|2013-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients|Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease: Prospective, Randomized, Controlled Study|Completed||Phase 3|446|Actual|Ege University||2|||f||||t||||||||||2018-06-01 03:11:18.243877|2018-06-01 03:11:18.243877
NCT00481351|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|2011-01-07||2011-01-07|2007-05-30|2007-06-01|Estimate|2011-01-07|2011-01-26|Estimate||||2011-01-07|2011-01-26|Estimate|June 2007||2007-06-30|January 2007|2007-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons|Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons in Men With Stable Coronary Heart Disease.|Completed||Phase 4|25|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-06-01 03:11:18.33534|2018-06-01 03:11:18.33534
NCT00481156|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2018-05-01|2007-05-30|2007-06-01|Estimate|||||||2018-05-01|2018-05-04|Actual|March 1, 2005|Actual|2005-03-01|May 2018|2018-05-31|February 28, 2007|Actual|2007-02-28|February 28, 2007|Actual|2007-02-28||Interventional|||Functional Neuroimaging Effects of Cognitive Remediation Training|Functional Neuroimaging Effects of Cognitive Remediation Training|Completed||Phase 3|30|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||||||||||No||2018-06-01 03:11:23.441911|2018-06-01 03:11:23.441911
NCT00481338|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2015-07-31|2007-05-31|2007-06-01|Estimate|||||||2015-07-31|2015-08-03|Estimate|April 2007||2007-04-30|July 2015|2015-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|KHOALA||Prevalence,Natural History,Prognosis Factor,QualityofLife,Health Care Consumption and Social Consequences of Symptomatic Knee and Hip Osteoarthritis in France|Knee and Hip OsteoArthritis Long Term Assessment. Prevalence, Natural History, Prognosis Factor, Quality of Life, Health Care Consumption and Social Consequences of Symptomatic Knee and Hip Osteoarthritis in France|Active, not recruiting||N/A|878|Actual|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-06-01 03:11:18.780346|2018-06-01 03:11:18.780346
NCT00481325|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31||2010-09-10|2015-09-23|2007-05-31|2007-06-01|Estimate||||2010-09-10|2010-09-14|Estimate|2015-09-23|2015-10-12|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder|A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder|Completed||Phase 2/Phase 3|260|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 03:11:18.872387|2018-06-01 03:11:18.872387
NCT00481312|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2012-05-04|2007-05-31|2007-06-01|Estimate|||||||2012-05-04|2012-05-07|Estimate|June 2007||2007-06-30|November 2009|2009-11-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|MIDEX||Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)|A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Midazolam for Continuous Sedation of Ventilated Patients in Intensive Care Unit|Completed||Phase 3|501|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-06-01 03:11:19.002571|2018-06-01 03:11:19.002571
NCT00481299|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-06-01|Estimate|||||||2007-05-30|2007-06-01|Estimate|October 2004||2004-10-31|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Observational|||Insulin Resistance in Women With Prolactinoma|Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists|Completed|||2004|Actual|Universidade Federal do Rio de Janeiro|||||f||||t||||||||||2018-06-01 03:11:19.10969|2018-06-01 03:11:19.10969
NCT00481286|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-10-20|2007-05-31|2007-06-01|Estimate|||||||2009-10-20|2009-10-21|Estimate|April 2007||2007-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|April 2008|Actual|2008-04-30||Interventional|EPIC||Improving Outcomes Using Collaborative Group Clinics to Empower Older Patients|Improving Outcomes for Multiple Morbidities Using Collaborative Group Clinics to Empower Older Patients|Completed||Phase 2|129|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 03:11:19.157526|2018-06-01 03:11:19.157526
NCT00481273|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2018-05-01|2007-05-31|2007-06-01|Estimate|||||||2018-05-01|2018-05-03|Actual|October 31, 2006|Actual|2006-10-31|May 2018|2018-05-31|August 31, 2010|Actual|2010-08-31|August 31, 2010|Actual|2010-08-31||Observational|AVIDA||AVIDA The Vidaza® (Azacitidine) Patient Registry|AVIDA The Vidaza® (Azacitidine) Patient Registry|Completed|||479|Actual|Celgene|||||f||||f||||||||||2018-06-01 03:11:19.358565|2018-06-01 03:11:19.358565
NCT00481260|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-09-03|2007-05-31|2007-06-01|Estimate|||||||2009-09-03|2009-09-04|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous|Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous|Completed|||100|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:11:19.431264|2018-06-01 03:11:19.431264
NCT00481247|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|2010-11-23||2016-12-22|2007-05-31|2007-06-01|Estimate|2011-02-18|2011-03-15|Estimate||||2016-12-22|2017-02-15|Actual|September 2007||2007-09-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2009|Actual|2009-12-31||Interventional|DASISION||A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia|An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia|Completed||Phase 3|547|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:11:19.567722|2018-06-01 03:11:19.567722
NCT00481234|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2007-05-31|2007-05-31|2007-06-01|Estimate|||||||2007-05-31|2007-06-01|Estimate|June 2002||2002-06-30|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Observational|||Heart Rate Variability for Prediction of Perioperative Events|Heart Rate Variability for Prediction of Incidence of Cardiac Ischemia and Cardiovascular Events After General Anesthesia in High Risk Patients|Completed|||2002|Actual|University of Schleswig-Holstein|||||f||||f||||||||||2018-06-01 03:11:20.934864|2018-06-01 03:11:20.934864
NCT00481221|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2017-08-08|2007-05-31|2007-06-01|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2007||2007-03-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter|Detection of β Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter. A Clinical Retrospective Study.|Enrolling by invitation|||300|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-06-01 03:11:20.989565|2018-06-01 03:11:20.989565
NCT00481208|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2007-05-31|2007-05-31|2007-06-01|Estimate|||||||2007-05-31|2007-06-01|Estimate|March 2006||2006-03-31|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Observational|IOPMG||Diurnal Intraocular Pressure and Peripapillary Retinal Blood Flow in Medically Controlled Open-Angle Glaucoma|Diurnal Intraocular Pressure and Peripapillary Retinal Blood Flow in Medically Controlled Open-Angle Glaucoma|Completed|||70|Actual|Yonsei University|||||f||||f||||||||||2018-06-01 03:11:21.055166|2018-06-01 03:11:21.055166
NCT00481195|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|2010-04-30||2013-07-12|2007-05-31|2007-06-01|Estimate|2010-11-23|2010-12-20|Estimate||||2013-07-12|2013-07-19|Estimate|June 2007||2007-06-30|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder|Completed||Phase 2|257|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 03:11:21.152172|2018-06-01 03:11:21.152172
NCT00481182|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2009-02-19|2007-05-30|2007-06-01|Estimate|||||||2009-02-19|2009-02-23|Estimate|February 2005||2005-02-28|February 2009|2009-02-28||||||||Interventional|||Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.|A Phase I, Open-Label, 2-Period, Single-Sequence, Drug Interaction Study to Assess Steady-State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD With Fosamprenavir 700mg BID + RTV 100mg BID in Opiate-Dependent, HIV Seronegative, Adult Subjects|Completed||Phase 1|20||GlaxoSmithKline|||||||||||||||||||2018-06-01 03:11:22.290183|2018-06-01 03:11:22.290183
NCT00480961|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2007-05-31|2007-05-31|2007-06-01|Estimate|||||||2007-05-31|2007-06-01|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Interventional|||Congestive Heart Failure Surgical Treatmment With Autologous Stem Cell Therapy||Unknown status|Recruiting|Phase 2|||The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|||||f||||t||||||||||2018-06-01 03:11:27.290342|2018-06-01 03:11:27.290342
NCT00481143|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2017-05-30|2007-05-31|2007-06-01|Estimate|||||||2017-05-30|2017-05-31|Actual|May 2007||2007-05-31|November 2016|2016-11-30||||November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload|A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload|Completed||Phase 4|63|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:11:23.508309|2018-06-01 03:11:23.508309
NCT00481130|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2018-04-30|2007-05-31|2007-06-01|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2007||2007-09-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31|15 Years|Observational [Patient Registry]|ASTOR||Alport Syndrome Treatments and Outcomes Registry|Alport Syndrome Treatments and Outcomes Registry|Recruiting|||1000|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 03:11:23.578076|2018-06-01 03:11:23.578076
NCT00481117|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2010-09-10|2007-05-31|2007-06-01|Estimate|||||||2010-09-10|2010-09-13|Estimate|August 2008||2008-08-31|September 2010|2010-09-30|December 2008|Actual|2008-12-31|||||Interventional|||Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes|Safety, Tolerability, PK and PD of LY2405319 After Multiple Subcutaneous Injections in Subjects With Type 2 Diabetes|Completed||Phase 1|37|Actual|Eli Lilly and Company|||||f||||t||||||||||2018-06-01 03:11:23.667109|2018-06-01 03:11:23.667109
NCT00481104|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2011-07-01|2007-05-31|2007-06-01|Estimate|||||||2011-07-01|2011-07-04|Estimate|May 2007||2007-05-31|March 2008|2008-03-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of Long Term Safety of Tesofensine in Patients With Obesity|Evaluation of Long Term Safety of Tesofensine in Patients With Obesity|Completed||Phase 2|140|Actual|NeuroSearch A/S|||||f||||f||||||||||2018-06-01 03:11:23.742139|2018-06-01 03:11:23.742139
NCT00481091|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2018-04-23|2007-05-30|2007-06-01|Estimate|||||||2018-04-23|2018-04-25|Actual|July 25, 2007|Actual|2007-07-25|April 2018|2018-04-30|September 4, 2020|Anticipated|2020-09-04|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1/Phase 2|60|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-06-01 03:11:23.806242|2018-06-01 03:11:23.806242
NCT00481078|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2014-10-24||2014-10-24|2007-05-31|2007-06-01|Estimate|2014-10-24|2014-10-30|Estimate||||2014-10-24|2014-10-30|Estimate|May 2007||2007-05-31|December 2012|2012-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Randomized Phase II Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|94|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:11:24.032041|2018-06-01 03:11:24.032041
NCT00481065|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|2011-08-26||2013-12-31|2007-05-31|2007-06-01|Estimate|2013-01-23|2013-02-28|Estimate||||2013-12-31|2014-02-03|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||The demographic characteristics of the randomized population are summarized in this section.|Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects|A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects|Completed||Phase 2|405|Actual|Novartis||8|||f||||||||||||||2018-06-01 03:11:24.734177|2018-06-01 03:11:24.734177
NCT00481052|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2017-12-15|2007-05-31|2007-06-01|Estimate|||||||2017-12-15|2017-12-18|Actual|June 2007||2007-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CML0307||Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase|The Protein Tyrosine Kinase Inhibitor Nilotinib as First-line Treatment of Ph+ Chronic Myeloid Leucemia (CML) in Early Chronic Phase: a Phase II Exploratory, Multicenter Study. GIMEMA Protocol CML 0307. EUDRACT 2007-000597-22.|Active, not recruiting||Phase 2|70|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||t||||||||||2018-06-01 03:11:26.454347|2018-06-01 03:11:26.454347
NCT00481039|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2009-09-03|2007-05-31|2007-06-01|Estimate|||||||2009-09-03|2009-09-04|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel|Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel- An Observational Study|Completed|||300|Anticipated|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-06-01 03:11:26.569073|2018-06-01 03:11:26.569073
NCT00481026|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2008-05-05|2007-05-31|2007-06-01|Estimate|||||||2008-05-05|2008-05-09|Estimate|July 2007||2007-07-31|May 2007|2007-05-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and Depression|A Double Blind Sham Controlled Trial of tDCS in Treating Schizophrenia and Depression|Unknown status|Recruiting|N/A|100|Anticipated|Bayside Health||2|||f||||f||||||||||2018-06-01 03:11:26.629623|2018-06-01 03:11:26.629623
NCT00481013|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2016-12-05|2007-05-30|2007-06-01|Estimate|||||||2016-12-05|2016-12-06|Estimate|July 2007||2007-07-31|December 2016|2016-12-31|November 2010|Actual|2010-11-30|December 2009|Actual|2009-12-31||Interventional|VALIANTSMA||Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy|Prospective Controlled Trial of Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy (VALIANTSMA) Study|Completed||Phase 2|33|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 03:11:26.730066|2018-06-01 03:11:26.730066
NCT00481000|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-31|||2010-04-20|2007-05-31|2007-06-01|Estimate|||||||2010-04-20|2010-04-21|Estimate|April 2007||2007-04-30|April 2010|2010-04-30|October 2010|Anticipated|2010-10-31|December 2008|Anticipated|2008-12-31||Interventional|PASA||Dialectical Cognitive Traumatherapy (DCT) on Patients With Severe PTSD Following Sexual Abuse|Dialectical Cognitive Traumatherapy (DCT) on Patients With Severe Posttraumatic Stress Disorder Following Sexual Abuse - A Randomised Controlled Trial|Unknown status|Active, not recruiting|Phase 2|64|Anticipated|Central Institute of Mental Health, Mannheim||1|||f||||f||||||||||2018-06-01 03:11:26.81245|2018-06-01 03:11:26.81245
NCT00480987|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|2011-06-06||2012-08-01|2007-05-31|2007-06-01|Estimate|2011-06-06|2011-06-30|Estimate||||2012-08-01|2012-08-07|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)|A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse With Complete Remission Duration < 1 Year|Terminated||Phase 1/Phase 2|27|Actual|M.D. Anderson Cancer Center||1||Lack of support.|f||||f||||||||||2018-06-01 03:11:26.90168|2018-06-01 03:11:26.90168
NCT00040027|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2008-01-08|2002-07-03|2002-07-04|Estimate|||||||2008-01-08|2008-01-15|Estimate|April 2002||2002-04-30|January 2008|2008-01-31||||||||Interventional|||Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin||Completed||Phase 3|500||SciClone Pharmaceuticals|||||||||||||||||||2018-06-01 05:32:05.58776|2018-06-01 05:32:05.58776
NCT00480948|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2011-06-06|2007-05-30|2007-05-31|Estimate|||||||2011-06-06|2011-06-07|Estimate|September 2008||2008-09-30|August 2008|2008-08-31|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Interventional|||Effects of InFat™ Product on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants|Effects of InFat™ Product (High Sn-2 Palmitic Acid) on Stool Biochemistry and Stool Characteristics in Formula-fed Term Chinese Infants: a Triple-blind, Randomized, Placebo-controlled Trial|Terminated||Phase 4|80|Anticipated|Enzymotec||2||"Study design changes were needed due to change of protocol to a multisite trial and updated set~   up"|f||||||||||||||2018-06-01 03:11:27.361447|2018-06-01 03:11:27.361447
NCT00480935|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2015-12-07|2007-05-29|2007-05-31|Estimate|||||||2015-12-07|2015-12-09|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma|A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma|Terminated||Phase 2|3|Actual|University Health Network, Toronto||1||poor recruitment|f||||t||||||||||2018-06-01 03:11:27.450106|2018-06-01 03:11:27.450106
NCT00480922|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2011-08-25|2007-05-29|2007-05-31|Estimate|||||||2011-08-25|2011-08-26|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|DELIVER||Effects of a Low Glycemic Load Diet on Fatty Liver in Children|Randomized Controlled Trial Comparing the Effects of a Low Glycemic Load Diet With a Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescents|Completed||N/A|40|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-06-01 03:11:27.531431|2018-06-01 03:11:27.531431
NCT00480896|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2014-09-17|2007-05-30|2007-05-31|Estimate|||||||2014-09-17|2014-09-18|Estimate|June 2004||2004-06-30|September 2014|2014-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment|"Clinical Study on Tacrolimus Ointment Over the Long-term. CONTROL Study - Children"|Completed||Phase 3|250|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:11:27.627219|2018-06-01 03:11:27.627219
NCT00480883|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2010-06-01|2007-05-30|2007-05-31|Estimate|||||||2010-06-01|2010-06-02|Estimate|January 2008||2008-01-31|May 2008|2008-05-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate Versus Meglumine Antimoniate and Allopurinol|Treatment of Cutaneous Leishmaniasis With Meglumine Antimoniate 20 Mg/Kg/Day Versus Meglumine Antimoniate 10 Mg/Kg/Day And Tablet Allopurinol 20 Mg/Kg/Day|Completed||N/A|400|Anticipated|Combined Military Hospital, Pakistan||2|||f||||f||||||||||2018-06-01 03:11:27.775459|2018-06-01 03:11:27.775459
NCT00480870|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-12-03|2007-05-30|2007-05-31|Estimate|||||||2007-12-03|2007-12-04|Estimate|April 1999||1999-04-30|December 2007|2007-12-31|January 2005|Actual|2005-01-31|||||Interventional|ACHALZSLEEP||The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients|The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients|Completed||Phase 4|65|Actual|Associacao Fundo de Incentivo a Psicofarmcologia||2|||f||||f||||||||||2018-06-01 03:11:27.884041|2018-06-01 03:11:27.884041
NCT00480857|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|2015-01-09||2017-09-07|2007-05-30|2007-05-31|Estimate|2015-01-09|2015-01-16|Estimate||||2017-09-07|2017-10-06|Actual|March 2007||2007-03-31|September 2017|2017-09-30|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional|||Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy|Salvage Radiation Therapy and Docetaxel (Taxotere) for Biochemical Failure After Radical Prostatectomy|Terminated||Phase 2|19|Actual|University of Michigan Cancer Center||1||Lack of funding.|f||||t||||||||||2018-06-01 03:11:27.985584|2018-06-01 03:11:27.985584
NCT00480844|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2009-03-24|2007-05-30|2007-05-31|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 2008||2008-10-31|March 2009|2009-03-31||||October 2011|Anticipated|2011-10-31||Interventional|||Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone|Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone|Unknown status|Recruiting|Phase 4|60|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 03:11:28.365228|2018-06-01 03:11:28.365228
NCT00480831|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30||2013-01-17|2017-05-16|2007-05-30|2007-05-31|Estimate||||2013-01-17|2013-01-28|Estimate|2017-05-16|2017-05-18|Actual|June 2007|Actual|2007-06-30|May 2017|2017-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g)|A Randomized, Double-Blind, Phase II Trial of Paclitaxel + Carboplatin + Bevacizumab With or Without PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer|Completed||Phase 2|128|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:11:28.457998|2018-06-01 03:11:28.457998
NCT00480818|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-12-09|2007-05-29|2007-05-31|Estimate|||||||2007-12-09|2007-12-11|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects|Completed||Phase 1|80||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:11:28.54562|2018-06-01 03:11:28.54562
NCT00480805|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2017-09-22|2007-05-30|2007-05-31|Estimate|||||||2017-09-22|2017-09-25|Actual|August 8, 2001|Actual|2001-08-08|September 2017|2017-09-30|October 16, 2002|Actual|2002-10-16|October 15, 2002|Actual|2002-10-15||Interventional|||HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)|HYZAAR Versus Ramipril Diabetic Patients|Completed||Phase 3|312|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:11:28.603276|2018-06-01 03:11:28.603276
NCT00480792|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2013-07-22|2007-05-30|2007-05-31|Estimate|||||||2013-07-22|2013-07-23|Estimate|June 2007||2007-06-30|July 2013|2013-07-31|September 2012|Actual|2012-09-30|December 2008|Actual|2008-12-31||Interventional|VIHVAC-B||Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients|Open-label, Randomized, and Multicentric Phase III Clinical Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV-1-infected Patients With CD4-positive T-lymphocytes Counts Above 200 permm3 ANRS HB 03 VIHVAC-B|Completed||Phase 3|437|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3|||f||||t||||||||||2018-06-01 03:11:28.667809|2018-06-01 03:11:28.667809
NCT00480779|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|2016-01-11||2016-05-19|2007-05-30|2007-05-31|Estimate|2016-05-19|2016-06-28|Estimate||||2016-05-19|2016-06-28|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|STEPUP||Evaluation of Group Lifestyle Balance DVD in Primary Care Practice|Screening, Training, Education and Prevention Service of the University of Pittsburgh, Phase 2|Completed||N/A|48|Actual|University of Pittsburgh|It should be noted that this was a small pilot study and should be tested in a larger sample.|2|||f||||f||||||||No||2018-06-01 03:11:28.774635|2018-06-01 03:11:28.774635
NCT00395668|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2007-09-06|2006-11-02|2006-11-03|Estimate|||||||2007-09-06|2007-09-10|Estimate|November 2006||2006-11-30|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||TETRA (Terrestrial Trunked Radio)|Assessment of Acute Changes in Cognitive Performance Arising From Exposure to TETRA Handset.|Completed||Phase 4|56|Anticipated|University of Aarhus|||||f||||||||||||||2018-06-01 03:39:38.257188|2018-06-01 03:39:38.257188
NCT00480766|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2017-03-03|2007-05-30|2007-05-31|Estimate|||||||2017-03-03|2017-03-06|Actual|July 2001||2001-07-31|March 2017|2017-03-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of Oral Alendronate Sodium Once Weekly for the Prevention and Treatment of Glucocorticoid-Induced Bone Loss|Completed||Phase 3|173|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:11:29.17446|2018-06-01 03:11:29.17446
NCT00480753|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-12-18|2007-05-30|2007-05-31|Estimate|||||||2007-12-18|2007-12-24|Estimate|May 2007||2007-05-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon|Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon|Completed||Phase 2|15|Anticipated|MediQuest Therapeutics|||||f||||||||||||||2018-06-01 03:11:29.248084|2018-06-01 03:11:29.248084
NCT00480740|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|2014-08-19||2015-06-17|2007-05-30|2007-05-31|Estimate|2015-06-17|2015-06-26|Estimate||||2015-06-17|2015-06-26|Estimate|December 2006||2006-12-31|June 2015|2015-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease|The Pharmacology of Dexmedetomidine in Children With Congenital Heart Disease|Completed||Phase 3|41|Actual|Children's Research Institute||3|||f||||f||||||||||2018-06-01 03:11:29.333211|2018-06-01 03:11:29.333211
NCT00480727|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2013-02-10|2007-05-29|2007-05-31|Estimate|||||||2013-02-10|2013-02-12|Estimate|April 2007||2007-04-30|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Determining Optimal Halo Pin Management Practises to Decrease Pin Complications|Determining Optimal Halo Pin Management Practises to Decrease Pin Complications|Completed||N/A|44|Actual|Bayside Health||2|||f||||f||||||||||2018-06-01 03:11:29.801056|2018-06-01 03:11:29.801056
NCT00480714|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-05-31|Estimate|||||||2007-05-30|2007-05-31|Estimate|March 2003||2003-03-31|May 2007|2007-05-31|September 2003|Actual|2003-09-30|||||Interventional|||A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers|A Study of the Immunogenicity of M. Bovis BCG (SSI Strain), Delivered Intradermally in Healthy Volunteers|Completed||N/A|10|Actual|University of Oxford|||||f||||t||||||||||2018-06-01 03:11:29.865775|2018-06-01 03:11:29.865775
NCT00480701|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30||2014-03-21|2014-04-16|2007-05-30|2007-05-31|Estimate||||2014-03-21|2014-04-17|Estimate|2014-04-16|2014-05-07|Estimate|February 2007||2007-02-28|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|IBVM001||Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease|Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT as a Marker of Acetylcholine Transporter Density in the Brain of Healthy Subjects and Patients With Alzheimer Disease|Completed||Phase 2|26|Actual|Institute for Neurodegenerative Disorders||1|||f||||t||||||||||2018-06-01 03:11:29.928189|2018-06-01 03:11:29.928189
NCT00480688|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-05-31|Estimate|||||||2007-05-30|2007-05-31|Estimate|November 2001||2001-11-30|May 2007|2007-05-31|May 2002|Actual|2002-05-31|||||Interventional|||A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers|A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers|Completed||Phase 1|11|Actual|University of Oxford|||||f||||t||||||||||2018-06-01 03:11:29.991732|2018-06-01 03:11:29.991732
NCT00480675|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2009-01-27|2007-05-30|2007-05-31|Estimate|||||||2009-01-27|2009-01-28|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Randomized Study Comparing Fluoroscopically-Guided Versus Blinded Trochanteric Bursa Injections||Completed||N/A|65|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 03:11:30.047833|2018-06-01 03:11:30.047833
NCT00480662|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2017-03-03|2007-05-30|2007-05-31|Estimate|||||||2017-03-03|2017-03-06|Actual|October 2001||2001-10-31|March 2017|2017-03-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)|A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone|Completed||Phase 3|60|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:11:30.140644|2018-06-01 03:11:30.140644
NCT00480649|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2012-11-08|2007-05-30|2007-05-31|Estimate|||||||2012-11-08|2012-11-12|Estimate|January 2004||2004-01-31|November 2012|2012-11-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)|SUccessful Control and Clinical Effectiveness of SERETIDE Study in aSthma, a Randomised Controlled Study to Investigate the Clinical Effectiveness and Health Outcome of SERETIDE in Patients With Moderate and Severe Persistent Asthma in Korea|Completed||Phase 4|424|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:11:30.223972|2018-06-01 03:11:30.223972
NCT00480636|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|2010-05-25||2010-07-14|2007-05-29|2007-05-31|Estimate|2010-07-14|2010-08-10|Estimate||||2010-07-14|2010-08-10|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients|Fragmin Safety And Efficacy In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism And Extended Thromboprophylaxis In Cancer Patients In Slovakia (An Open, Prospective, Non-Comparative Study)|Completed|||102|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:11:30.458519|2018-06-01 03:11:30.458519
NCT00480623|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2012-03-21|2007-05-29|2007-05-31|Estimate|||||||2012-03-21|2012-03-23|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence|A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence Following Radical Prostatectomy|Terminated||Phase 1|||Agennix||||Sponsor decided to discontinue study drug development|f||||f||||||||||2018-06-01 03:11:30.768202|2018-06-01 03:11:30.768202
NCT00480610|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2014-09-17|2007-05-30|2007-05-31|Estimate|||||||2014-09-17|2014-09-18|Estimate|April 2004||2004-04-30|September 2014|2014-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment|"Clinical Study on Tacrolimus Ointment Over the Long-term. CONTROL Study - Adults"|Completed||Phase 3|226|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:11:30.863727|2018-06-01 03:11:30.863727
NCT00480597|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2010-10-27|2007-05-30|2007-05-31|Estimate|||||||2010-10-27|2010-10-28|Estimate|October 2002||2002-10-31|May 2007|2007-05-31||||||||Interventional|||Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer|Randomised, Multicenter Phase II Study in Patients With Metastatic Breast Cancer With Gemcitabine Plus Vinorelbine Versus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Capecitabine|Completed||Phase 2|141|Actual|Ludwig-Maximilians - University of Munich|||||f||||t||||||||||2018-06-01 03:11:30.982151|2018-06-01 03:11:30.982151
NCT00480584|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2012-11-07|2007-05-30|2007-05-31|Estimate|||||||2012-11-07|2012-11-08|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer|A Phase I Trial of GemCap-T, Capecitabine in Combination With Gemcitabine and Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma|Completed||Phase 1|20|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 03:11:31.046432|2018-06-01 03:11:31.046432
NCT00480571|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2009-07-20|2007-05-30|2007-05-31|Estimate|||||||2009-07-20|2009-07-21|Estimate|June 2007||2007-06-30|August 2007|2007-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder|An Open-label, Multi-center, 6-week, Sequential Cohort Study Designed to Determine the Safety and Tolerability of Two Dose Ranges of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-affective Disorder|Completed||Phase 2|90|Anticipated|BioLineRx, Ltd.||2|||f||||t||||||||||2018-06-01 03:11:31.183063|2018-06-01 03:11:31.183063
NCT00480558|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2011-03-25|2007-05-30|2007-05-31|Estimate|||||||2011-03-25|2011-03-28|Estimate|July 2007||2007-07-31|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Asymptomatic Volunteers Who Are Infected With Either Mycobacterium Tuberculosis (M.tb.), Human Immunodeficiency Virus (HIV) or Both|Completed||Phase 1|48|Anticipated|University of Oxford||4|||f||||t||||||||||2018-06-01 03:11:31.258572|2018-06-01 03:11:31.258572
NCT00480545|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2014-12-03|2007-05-30|2007-05-31|Estimate|||||||2014-12-03|2014-12-05|Estimate|October 2005||2005-10-31|December 2014|2014-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Changes in Bleeding and Clotting During the Menstrual Cycle|Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle|Withdrawn|||0|Actual|The University of Texas Health Science Center, Houston||||IRB Approval lapsed|f||||f||||||Samples Without DNA|"~     Blood samples will be discarded when the study is completed.~   "|||2018-06-01 03:11:31.370007|2018-06-01 03:11:31.370007
NCT00480532|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|2012-05-21||2014-10-14|2007-05-30|2007-05-31|Estimate|2012-12-17|2013-01-28|Estimate||||2014-10-14|2014-10-22|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|May 2011|Actual|2011-05-31|January 2010|Actual|2010-01-31||Interventional|||A Study of Continuous Oral Contraceptives and Doxycycline|A Study of Continuous Oral Contraceptives and Doxycycline|Completed||N/A|131|Actual|Oregon Health and Science University|Treatment Arm: Subjects had difficulty understanding when to start and stop treatment.|4|||f||||f||||||||||2018-06-01 03:11:31.450948|2018-06-01 03:11:31.450948
NCT00480519|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-05-31|Estimate|||||||2007-05-30|2007-05-31|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|May 2008|Anticipated|2008-05-31|||||Interventional|||Use of Sedation and Local Anesthesia in Meatotomy: A Prospective Comparison Study|Use of Sedation and Local Anesthesia in Meatotomy: A Prospective Comparison Study|Unknown status|Recruiting|Phase 3|75|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:11:31.86933|2018-06-01 03:11:31.86933
NCT00480506|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2012-02-22|2007-05-30|2007-05-31|Estimate|||||||2012-02-22|2012-02-23|Estimate|April 2004||2004-04-30|February 2012|2012-02-29|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|||Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major|Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major|Completed|||40|Anticipated|Dana-Farber Cancer Institute|||||f||||f||||||||||2018-06-01 03:11:31.935577|2018-06-01 03:11:31.935577
NCT00480493|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|2011-11-03||2012-06-21|2007-05-30|2007-05-31|Estimate|2012-06-21|2012-07-30|Estimate||||2012-06-21|2012-07-30|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|STEP||STEP: Social Support To Empower Parents|STEP: Social Support To Empower Parents|Completed||Phase 3|60|Actual|University of Massachusetts, Worcester|We did not have enough parents recruited to look at structural equation modeling.|2|||f||||f||||||||||2018-06-01 03:11:32.011479|2018-06-01 03:11:32.011479
NCT00480480|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2007-05-30|2007-05-30|2007-05-31|Estimate|||||||2007-05-30|2007-05-31|Estimate|September 2000||2000-09-30|May 2007|2007-05-31|October 2001|Actual|2001-10-31|||||Interventional|||Randomized Controlled Trial of the Effectiveness of Group Treatment With War-Exposed Bosnian Adolescents|Long-Term Post- War Adjustment in Bosnian Adolescents, Their Parents and Teachers|Completed||N/A|144|Actual|Brigham Young University|||||f||||f||||||||||2018-06-01 03:11:32.287961|2018-06-01 03:11:32.287961
NCT00480467|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-12-03|2007-05-29|2007-05-31|Estimate|||||||2007-12-03|2007-12-05|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 Administered Orally to Healthy Japanese Male Subjects|Completed||Phase 1|32||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:11:32.371415|2018-06-01 03:11:32.371415
NCT00480454|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2010-02-08|2007-05-30|2007-05-31|Estimate|||||||2010-02-08|2010-02-09|Estimate|October 2006||2006-10-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines|An Open Randomized Dose Selection Study Evaluating the Safety, Immunogenicity, and Impact of a TB Vaccine, MVA85A, on the Immunogenicity of EPI Vaccines Administered Simultaneously to Healthy Infants Previously Vaccinated With BCG.|Completed||Phase 1|214|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 03:11:32.438999|2018-06-01 03:11:32.438999
NCT00480441|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2012-01-17|2007-05-30|2007-05-31|Estimate|||||||2012-01-17|2012-01-18|Estimate|August 2006||2006-08-31|January 2012|2012-01-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal|A Phase II Double-Blind Placebo-Controlled Trial of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal|Completed||Phase 2|61|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:11:32.512725|2018-06-01 03:11:32.512725
NCT00480428|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-30|||2018-05-23|2007-05-30|2007-05-31|Estimate|||||||2018-05-23|2018-05-24|Actual|May 17, 2007||2007-05-17|August 17, 2017|2017-08-17|August 17, 2017||2017-08-17|||||Observational|||Radiation Exposure and Thyroid Disease in Kazakhstan|Study to Improve Thyroid Doses From Fallout Exposure in Kazakhstan|Completed|||117|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:11:32.586931|2018-06-01 03:11:32.586931
NCT00480402|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2013-04-03|2007-05-29|2007-05-30|Estimate|||||||2013-04-03|2013-04-04|Estimate|January 2006||2006-01-31|April 2013|2013-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Natural Progesterone and Preterm Birth in Twins|Eficacia de Los Suplementos de Progesterona Natural en la prevención Del Parto pretérmino Gemelar|Completed||Phase 3|290|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||3|||f||||t||||||||||2018-06-01 03:11:32.642377|2018-06-01 03:11:32.642377
NCT00480389|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2015-12-07|2007-05-29|2007-05-30|Estimate|||||||2015-12-07|2015-12-09|Estimate|May 2007||2007-05-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal|Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy|Completed||Phase 2|19|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 03:11:32.702289|2018-06-01 03:11:32.702289
NCT00480376|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-05-29|2007-05-29|2007-05-30|Estimate|||||||2007-05-29|2007-05-30|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate|Ofloxacin vs. Gentamicin as Prophylaxis Prior Transrectal Biopsy of Prostate|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:11:32.766335|2018-06-01 03:11:32.766335
NCT00480363|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2013-07-30|2007-05-29|2007-05-30|Estimate|||||||2013-07-30|2013-07-31|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|December 2008|Actual|2008-12-31||Interventional|QUIREDEX||QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression|QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression|Completed||Phase 3|120|Actual|PETHEMA Foundation||2|||f||||t||||||||||2018-06-01 03:11:32.827787|2018-06-01 03:11:32.827787
NCT00480350|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2007-09-04|2007-05-29|2007-05-30|Estimate|||||||2007-09-04|2007-09-05|Estimate|September 2007||2007-09-30|March 2007|2007-03-31|January 2009|Anticipated|2009-01-31|||||Interventional|||RiSolubles™, the Soluble Fraction of Rice Bran for HIV-Infected Patients||Unknown status|Not yet recruiting|Phase 2|140|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:11:32.917176|2018-06-01 03:11:32.917176
NCT00480337|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2008-12-16|2007-05-29|2007-05-30|Estimate|||||||2008-12-16|2008-12-17|Estimate||||December 2008|2008-12-31||||||||Interventional|||In Vitro Maturation of Immature Oocytes||Completed||N/A|||Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:11:33.108295|2018-06-01 03:11:33.108295
NCT00480324|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|2010-03-30||2016-10-06|2007-05-29|2007-05-30|Estimate|2010-10-21|2010-11-17|Estimate||||2016-10-06|2016-11-09|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants|Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants|Completed||Phase 3|765|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:11:33.193535|2018-06-01 03:11:33.193535
NCT00480311|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2011-06-26|2007-05-28|2007-05-30|Estimate|||||||2011-06-26|2011-06-28|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||World Health Organization Disability Assessment Schedule II (WHODAS-II) for Patients With Symptomatic Lumbar Spinal Stenosis|WHODAS-II for Patients With Symptomatic Lumbar Spinal Stenosis|Terminated|||200|Anticipated|Kovacs Foundation|||1|"Recruitment was so slow, that it made the study impossible. Organizational changes made it~   impossible for recruiting centers to continue recruitment"|f||||t||||||||||2018-06-01 03:11:33.814359|2018-06-01 03:11:33.814359
NCT00480298|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-12-19|2007-05-26|2007-05-30|Estimate|||||||2007-12-19|2007-12-28|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|July 2006|Actual|2006-07-31|||||Interventional|||Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis|Double-Blind Randomized Placebo-Controlled Trial on Clinical and Biological Effects of Oral Corticosteroids or Doxycyclin in Patients With Nasal Polyposis|Completed||Phase 2|48||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:11:33.878721|2018-06-01 03:11:33.878721
NCT00480285|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-05-29|2007-05-29|2007-05-30|Estimate|||||||2007-05-29|2007-05-30|Estimate|November 2006||2006-11-30|May 2007|2007-05-31|November 2011|Anticipated|2011-11-30|||||Interventional|||A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients|A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients|Unknown status|Recruiting|Phase 3|100|Anticipated|Chinese University of Hong Kong|||||f||||t||||||||||2018-06-01 03:11:33.935166|2018-06-01 03:11:33.935166
NCT00480272|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2017-03-03|2007-05-29|2007-05-30|Estimate|||||||2017-03-03|2017-03-06|Actual|May 2007||2007-05-31|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|CURE||Prospective Study on Intensive Early Rheumatoid Arthritis Treatment|A Phase IV Multicenter, Randomized, Double-blind Study. prospeCtive Study on Intensive Early Rheumatoid Arthritis Treatment With adalimUmab: Induction of REmission and Maintenance|Completed||Phase 4|251|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||No||2018-06-01 03:11:34.008432|2018-06-01 03:11:34.008432
NCT00480259|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-05-29|2007-05-29|2007-05-30|Estimate|||||||2007-05-29|2007-05-30|Estimate||||May 2007|2007-05-31||||||||Interventional|||Hyperproteic Nutrition:Correlation of BUN to Nitrogen Balance|Hyperproteic Nutrition; Correlation of BUN to Nitrogen Balance and Associated Infection Rates With Bimodal Protein Administration|Unknown status|Not yet recruiting|N/A|||Penn State University|||||f||||f||||||||||2018-06-01 03:11:34.095818|2018-06-01 03:11:34.095818
NCT00480246|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2009-07-20|2007-05-29|2007-05-30|Estimate|||||||2009-07-20|2009-07-21|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Interventional|||A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer||Completed||Phase 1|||BioLineRx, Ltd.|||||f||||||||||||||2018-06-01 03:11:34.140778|2018-06-01 03:11:34.140778
NCT00480233|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2008-02-04|2007-05-29|2007-05-30|Estimate|||||||2008-02-04|2008-02-06|Estimate|January 2008||2008-01-31|February 2008|2008-02-29||||||||Observational|||Screening Questionnaire for Depression|Validation of a Hebrew Version of a Brief Screening Questionnaire for Depression in General Medicine|Unknown status|Recruiting||200|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:11:34.188396|2018-06-01 03:11:34.188396
NCT00480220|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2015-08-18|2007-05-29|2007-05-30|Estimate|||||||2015-08-18|2015-08-19|Estimate|August 2003||2003-08-31|August 2015|2015-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|PLASA||Specific Care and Assistance Plan for Alzheimer's Disease|Specific Care and Assistance Plan for Alzheimer's Disease: Impact Study on Disease Progression and Management Modalities|Completed||N/A|1200|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 03:11:34.255128|2018-06-01 03:11:34.255128
NCT00034970|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-08-17|2002-05-02|2002-05-03|Estimate|||||||2006-08-17|2006-08-18|Estimate|April 2002||2002-04-30|July 2006|2006-07-31|December 2003||2003-12-31|||||Interventional|||Mindfulness-Based Art Therapy for Cancer Patients|Mindfulness-Based Art Therapy for Cancer Patients|Completed||N/A|114||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:03.495587|2018-06-01 05:33:03.495587
NCT00480207|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2012-11-05|2007-05-28|2007-05-30|Estimate|||||||2012-11-05|2012-11-06|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Folic Acid and Omega -3 Fatty Acid Supplementation in Depressed Older Adults|Randomized Double-blind Controlled Clinical Trial to Assess the Impact of Folic Acid and Omega-3 Fatty Acids Supplementation on the Severity of Depressive Symptoms in Older Adults With Identified Depression|Completed||Phase 2/Phase 3|15|Actual|Beersheva Mental Health Center||4|||f||||t||||||||||2018-06-01 03:11:34.366723|2018-06-01 03:11:34.366723
NCT00480194|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2012-05-04|2007-05-29|2007-05-30|Estimate|||||||2012-05-04|2012-05-07|Estimate|December 2006||2006-12-31|February 2008|2008-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)|A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting|Completed|||1000|Anticipated|Nycomed|||||f||||t||||||||||2018-06-01 03:11:34.444178|2018-06-01 03:11:34.444178
NCT00480181|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2012-07-26|2007-05-29|2007-05-30|Estimate|||||||2012-07-26|2012-07-27|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis|A Comparative, Single Center, Randomized, Double-blinded, Parallel, Placebo-controlled Study to Evaluate the Efficacy of Nabilone (Cesamet) as Adjunctive Therapy to Gabapentin (Neurontin) in the Management of Neuropathic Pain (NPP) Symptoms in Subjects With Multiple Sclerosis (MS)|Completed||Phase 4|50|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-06-01 03:11:34.497386|2018-06-01 03:11:34.497386
NCT00480168|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2017-08-25|2007-05-25|2007-05-30|Estimate|||||||2017-08-25|2017-08-28|Actual|July 5, 2005|Actual|2005-07-05|August 2017|2017-08-31|August 31, 2012|Actual|2012-08-31|August 31, 2012|Actual|2012-08-31||Observational|||A Prospective Study to Assess Metabolic Changes in Children and Adolescents Treated With Atypical Antipsychotics|A Prospective Study to Assess Metabolic Changes in Children and Adolescents Aged 6-18 Treated With Atypical Antipsychotics|Completed|||50|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 03:11:34.567301|2018-06-01 03:11:34.567301
NCT00480155|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2008-12-19|2007-05-25|2007-05-30|Estimate|||||||2008-12-19|2008-12-22|Estimate|May 2007||2007-05-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety of A Monovalent Vaccine in Healthy Adults|Completed||Phase 2|300|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 03:11:34.632212|2018-06-01 03:11:34.632212
NCT00480142|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2007-06-05|2007-05-29|2007-05-30|Estimate|||||||2007-06-05|2007-06-06|Estimate|July 2007||2007-07-31|May 2007|2007-05-31|July 2008||2008-07-31|||||Interventional|||Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy|Controlled Release of Oxycodone 10 mg In Pre-Medication For The Post Operative Analgesia In Elective Laparoscopic Bilateral Inguinal Hernia And Elective Laparoscopic Cholecystectomy : Prospective Double Blind, Randomized, Placebo-Controlled Study|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Kaplan Medical Center|||||f||||t||||||||||2018-06-01 03:11:34.70066|2018-06-01 03:11:34.70066
NCT00480129|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2015-08-10|2007-05-25|2007-05-30|Estimate|||||||2015-08-10|2015-08-11|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|October 2007|Actual|2007-10-31|||||Interventional|||The Anti-allergic Effects of Specific Probiotics|The Anti-allergic Effects of Specific Probiotics - a Double Blind Clinical Study|Completed||Phase 1|36|Actual|Lawson Health Research Institute|||||f||||||||||||||2018-06-01 03:11:34.751376|2018-06-01 03:11:34.751376
NCT00480116|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2008-08-22|2007-05-29|2007-05-30|Estimate|||||||2008-08-22|2008-08-25|Estimate|January 2008||2008-01-31|August 2008|2008-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Consistency Study of Three Lots of Henogen's Adjuvanted Hepatitis B Vaccine When Given in 0, 1 Month Schedule|Phase III, Single Centre, Double Blind, Randomised Study Evaluating the Consistency of Three Lots of Henogen's New Adjuvanted Hepatitis B Vaccine, When Given at 0, 1 Month Schedule in Healthy Volunteers Aged 18 Years to 40 Years.|Completed||Phase 3|450|Actual|Henogen||3|||f||||f||||||||||2018-06-01 03:11:34.820187|2018-06-01 03:11:34.820187
NCT00480103|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2011-03-03|2007-05-29|2007-05-30|Estimate|||||||2011-03-03|2011-03-04|Estimate|August 2007||2007-08-31|March 2011|2011-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|ANECOVA||Intrauterine Embryo Development With ANECOVA Device|Multi-Center Evaluation Program NCVD1H Intrauterine Embryo'S Development Assisted by ANECOVA ACVd1 Device|Terminated||Phase 3|||Instituto Valenciano de Infertilidad, IVI VALENCIA||||INHERENT MODIFICATIONS NEEDED BEFORE PROCEEDING|f||||f||||||||||2018-06-01 03:11:34.892456|2018-06-01 03:11:34.892456
NCT00480090|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2013-01-10|2007-05-29|2007-05-30|Estimate|||||||2013-01-10|2013-01-11|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|SLAP||A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer|A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer|Completed||Phase 2|10|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 03:11:34.950118|2018-06-01 03:11:34.950118
NCT00480077|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2010-02-05|2007-05-29|2007-05-30|Estimate|||||||2010-02-05|2010-02-08|Estimate|March 2007||2007-03-31|February 2010|2010-02-28|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|DOT-HF||Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)|Diagnostic Outcome Trial in Heart Failure|Terminated||Phase 4|336|Actual|Medtronic Bakken Research Center||2||Low enrollment rates|f||||t||||||||||2018-06-01 03:11:35.014529|2018-06-01 03:11:35.014529
NCT00480064|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-05-29|2007-05-29|2007-05-30|Estimate|||||||2007-05-29|2007-05-30|Estimate|July 1995||1995-07-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Lomustine and Intermediate Dose Cytarabine in Older Patients With AML|Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction Chemotherapy and Adding Intermediate Dose Cytarabine to Consolidation in Older Patients With Acute Myeloid Leukaemia|Completed||Phase 3|360|Actual|French Innovative Leukemia Organisation|||||f||||t||||||||||2018-06-01 03:11:35.0854|2018-06-01 03:11:35.0854
NCT00480051|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2017-02-27|2007-05-29|2007-05-30|Estimate|||||||2017-02-27|2017-02-28|Actual|July 2007||2007-07-31|February 2017|2017-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|RESPOND||RESynchronisation in Patients With Heart Failure and a Normal QRS Duration|RESynchronisation in Patients With Heart Failure and a Normal QRS Duration|Completed||Phase 3|60|Actual|Heart of England NHS Trust|||||f||||t||||||||||2018-06-01 03:11:35.144114|2018-06-01 03:11:35.144114
NCT00479531|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-11-29|2007-05-25|2007-05-28|Estimate|||||||2007-11-29|2007-11-30|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Sequential Compression Devices for Treatment of Restless Legs Syndrome|Sequential Compression Devices for Treatment of Restless Legs Syndrome - a Prospective, Randomized, Sham-Controlled Study|Completed||Phase 3|40|Anticipated|Walter Reed Army Medical Center|||||f||||t||||||||||2018-06-01 03:11:46.458424|2018-06-01 03:11:46.458424
NCT00480038|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2011-06-26|2007-05-28|2007-05-30|Estimate|||||||2011-06-26|2011-06-28|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||World Health Organization Disability Assessment Schedule (WHODAS-II) for Patients With Symptomatic Lumbar Disc Herniation|WHODAS-II for Patients With Symptomatic Lumbar Disc Herniation|Terminated||N/A|200|Anticipated|Kovacs Foundation||1||"Recruitment was so slow, that it made the study impossible. Organizational changes made it~   impossible for recruiting centers to continue recruitment"|f||||t||||||||||2018-06-01 03:11:35.208666|2018-06-01 03:11:35.208666
NCT00480025|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29||2013-08-22|2015-11-19|2007-05-29|2007-05-30|Estimate||||2013-08-22|2013-08-30|Estimate|2015-11-19|2015-12-21|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|||GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer|GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer|Terminated||Phase 3|2278|Actual|GlaxoSmithKline||2||"The study was terminated following assessment of the lack of efficacy of the study product by~   the Independent Data monitoring Committee for the study."|f||||||||||||||2018-06-01 03:11:35.340066|2018-06-01 03:11:35.340066
NCT00480012|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2011-08-28|2007-05-29|2007-05-30|Estimate|||||||2011-08-28|2011-08-30|Estimate|May 2005||2005-05-31|August 2011|2011-08-31||||June 2007|Anticipated|2007-06-30||Interventional|||The Effects of TMS on Memory-consolidation in Human Primary Visual Cortex|The Effects of Transcranial Magnetic Stimulation of the Brain on Memory-consolidation in Human Primary Visual Cortex|Withdrawn||N/A|0|Anticipated|Sheba Medical Center||||Due to administrative issues, the study was withdrawn.|f||||||||||||||2018-06-01 03:11:36.471356|2018-06-01 03:11:36.471356
NCT00479999|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-26|||2018-05-23|2007-05-26|2007-05-30|Estimate|||||||2018-05-23|2018-05-24|Actual|May 24, 2007||2007-05-24|May 5, 2014|2014-05-05|May 5, 2014|Actual|2014-05-05|May 5, 2014|Actual|2014-05-05||Interventional|||Phase 1 Safety Study of Two Experimental HIV Vaccines|VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults|Completed||Phase 1|35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:11:36.51744|2018-06-01 03:11:36.51744
NCT00479986|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2015-03-31|2007-05-29|2007-05-30|Estimate|||||||2015-03-31|2015-04-01|Estimate|June 2005||2005-06-30|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Interventional|PIOcard||Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease|Effects of Pioglitazone in Patients With Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Vascular Complications : A Placebo-Controlled Study|Completed||Phase 4|92|Actual|IKFE Institute for Clinical Research and Development||2|||f||||t||||||||||2018-06-01 03:11:36.597626|2018-06-01 03:11:36.597626
NCT00479973|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2007-11-19|2007-05-29|2007-05-30|Estimate|||||||2007-11-19|2007-11-20|Estimate|September 2007||2007-09-30|November 2007|2007-11-30|May 2008|Anticipated|2008-05-31|||||Interventional|||The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark|The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark (Cinnamomum Verum and C. Aromaticum) (Cinnamonforce™) - Randomized Placebo-Controlled Clinical Trial|Unknown status|Recruiting|Phase 2|70|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 03:11:36.728644|2018-06-01 03:11:36.728644
NCT00479960|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-28|||2007-05-29|2007-05-29|2007-05-30|Estimate|||||||2007-05-29|2007-05-30|Estimate|June 2007||2007-06-30|November 2006|2006-11-30|June 2007|Anticipated|2007-06-30|||||Interventional|||A Preliminary Study on Effect of Omega-3 on Human Sperm|Effect of Dietary Supplementation With Omega-3 Fatty Acids on Human Sperm Characteristics, a Preliminary Study|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:11:36.80217|2018-06-01 03:11:36.80217
NCT00479947|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-05-29|2007-05-29|2007-05-30|Estimate|||||||2007-05-29|2007-05-30|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis|A Double-Blind,Randomized Placebo-Controlled Study Using Probiotic Lactobacillus GR-1 and RC-14 as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis|Unknown status|Recruiting|Phase 1|100|Anticipated|Faith Mediplex|||||f||||f||||||||||2018-06-01 03:11:36.87517|2018-06-01 03:11:36.87517
NCT00479934|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2011-03-03|2007-05-29|2007-05-30|Estimate|||||||2011-03-03|2011-03-04|Estimate|December 2007||2007-12-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|SCLEROGLIVEC||Efficacy and Safety of Imatinib in Scleroderma|Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.|Completed||Phase 2|28|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 03:11:36.95385|2018-06-01 03:11:36.95385
NCT00479921|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2009-01-29|2007-05-29|2007-05-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|June 2007||2007-06-30|January 2009|2009-01-31||||||||Interventional|||Annual Study to Investigate Influenza Vaccine Due to New Virus Strains for the 2007/2008 Influenza Season in Europe|Immunogenicity and Reactogenicity of Trivalent Influenza Subunit Vaccine Influvac® for the Season 2007/2008. An Open, Baseline-Controlled Multi-Center Study in Two Groups of Healthy Subjects: Adults and Elderly|Completed||Phase 3|120|Anticipated|Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 03:11:37.183637|2018-06-01 03:11:37.183637
NCT00479908|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-29|||2007-05-29|2007-05-29|2007-05-30|Estimate|||||||2007-05-29|2007-05-30|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|September 2005|Actual|2005-09-30|||||Interventional|||Blood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina|Investigation of the Time Course of the Interaction of the Hypotensive Effects of Sildenafil Citrate and Sublingual Glyceryl Trinitrate (GTN) in Men With Stable Angina Pectoris|Completed||Phase 4|20|Actual|University of Edinburgh|||||f||||f||||||||||2018-06-01 03:11:37.251044|2018-06-01 03:11:37.251044
NCT00479895|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2008-05-29|2007-05-25|2007-05-28|Estimate|||||||2008-05-29|2008-05-30|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization|Phase II, Open-Label Study in the Catheterization Laboratory Setting to Challenge the Concept That HBOC-201 Administration Might Improve Myocardial 'Oxygenation' and Myocardial Function at the Moment of (Brief) Coronary Occlusion|Completed||Phase 2|5|Actual|Biopure Corporation||2|||f||||f||||||||||2018-06-01 03:11:37.322485|2018-06-01 03:11:37.322485
NCT00479882|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2015-12-16||2017-03-03|2007-05-24|2007-05-28|Estimate|2016-03-02|2016-04-01|Estimate||||2017-03-03|2017-03-31|Actual|June 2007||2007-06-30|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||MK-0524B Lipid Study (MK-0524B-063)|"A Multicenter, Randomized, Double-Blind, Crossover Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia"|Completed||Phase 3|2414|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 03:11:37.441913|2018-06-01 03:11:37.441913
NCT00479856|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|2010-05-03||2012-05-31|2007-05-25|2007-05-28|Estimate|2010-05-03|2010-06-02|Estimate||||2012-05-31|2012-06-05|Estimate|November 2007||2007-11-30|June 2011|2011-06-30|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer|An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.|Terminated||Phase 2|9|Actual|GlaxoSmithKline||1||Study was terminated due to difficulty in identifying eligible subjects|f||||||||||||||2018-06-01 03:11:39.837119|2018-06-01 03:11:39.837119
NCT00479843|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2014-01-23|2007-05-25|2007-05-28|Estimate|||||||2014-01-23|2014-01-24|Estimate|July 2005||2005-07-31|January 2014|2014-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Nutritional Programme for Dementia Elderly Patient|Development of a Programme to Show the Positive Effect of a Nutritional Programme on Preventing Functional and Weight Losses in Patients With Dementia|Completed||N/A|946|Actual|Nestlé|||||f||||f||||||||||2018-06-01 03:11:40.171022|2018-06-01 03:11:40.171022
NCT00479830|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2016-04-11|2007-05-25|2007-05-28|Estimate|||||||2016-04-11|2016-04-13|Estimate|April 2007||2007-04-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Health and Cancer Issues in the South Asian Community|Health and Cancer Issues in the South Asian Community|Completed|||39|Actual|M.D. Anderson Cancer Center|||4||f||||f||||||||||2018-06-01 03:11:41.009008|2018-06-01 03:11:41.009008
NCT00479817|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2015-10-29|2018-03-26|2007-05-24|2007-05-28|Estimate||||2015-10-29|2015-11-25|Estimate|2018-03-26|2018-03-29|Actual|July 5, 2007|Actual|2007-07-05|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|August 11, 2009|Actual|2009-08-11||Interventional|||Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer|A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|161|Actual|Amgen||3|||f||||f||||||||||2018-06-01 03:11:41.099749|2018-06-01 03:11:41.099749
NCT00479804|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2008-06-04|2007-05-25|2007-05-28|Estimate|||||||2008-06-04|2008-06-05|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|NICO||Non-Invasive Determination of Cardiac Output by Inertgas Rebreathing Method|Non-Invasive Determination of Cardiac Output by the Inertgas Rebreathing Method Compared With Magnetic Resonance Tomography|Completed|||311|Actual|Universitätsmedizin Mannheim|||||f||||||||||||||2018-06-01 03:11:41.181082|2018-06-01 03:11:41.181082
NCT00479791|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-05-25|2007-05-25|2007-05-28|Estimate|||||||2007-05-25|2007-05-28|Estimate|April 1997||1997-04-30|May 2007|2007-05-31|June 1999|Actual|1999-06-30|||||Interventional|||Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids|Lipid, Glycemic, and Insulin Responses to Meals Rich in Saturated, Cis-Monounsaturated, and Polyunsaturated Fatty (n-3 and n-6)Acids in Subjects With Type 2 Diabetes Mellitus|Completed||N/A|11|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:11:41.23337|2018-06-01 03:11:41.23337
NCT00479778|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-12-19|2007-05-25|2007-05-28|Estimate|||||||2007-12-19|2007-12-28|Estimate|April 2007||2007-04-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms|An Open Label, Randomized, Multicenter Study To Compare Bazedoxifene Steady-State Exposures Obtained With 2 Bazedoxifene Acetate/Conjugated Estrogen Formulations In Postmenopausal Women|Completed||Phase 1|72||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:11:41.287756|2018-06-01 03:11:41.287756
NCT00479765|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2014-04-17||2014-04-17|2007-05-25|2007-05-28|Estimate|2014-04-17|2014-05-15|Estimate||||2014-04-17|2014-05-15|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Four subjects were dosed with 5% Oncogel prior to study termination.|A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma|A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma|Terminated||Phase 1/Phase 2|4|Actual|BTG International Inc.||1||Sponsor business decision, not based on safety or efficacy data|f||||t||||||||||2018-06-01 03:11:41.357209|2018-06-01 03:11:41.357209
NCT00479752|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2016-02-17|2007-05-25|2007-05-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|June 2010|Actual|2010-06-30||Interventional|CORE 2||Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer|A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX4 + Weekly Cetuximab Versus FOLFOX4+ Biweekly Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer.|Completed||Phase 2|151|Actual|Central European Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 03:11:41.550528|2018-06-01 03:11:41.550528
NCT00479739|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2016-09-13|2007-05-25|2007-05-28|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2002||2002-11-30|September 2016|2016-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.|Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/160 in Adult Asthmatics|Completed||Phase 4|700|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:11:41.760212|2018-06-01 03:11:41.760212
NCT00479726|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-05-25|2007-05-25|2007-05-28|Estimate|||||||2007-05-25|2007-05-28|Estimate|August 2004||2004-08-31|May 2007|2007-05-31|January 2005|Actual|2005-01-31|||||Interventional|LEAPS||Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)|Lilly's Emotional and Physical Symptoms of Depression Study|Completed||Phase 4|8000||Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:11:42.035012|2018-06-01 03:11:42.035012
NCT00479713|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2009-02-11||2017-03-31|2007-05-24|2007-05-28|Estimate|2009-04-16|2009-06-10|Estimate||||2017-03-31|2017-05-05|Actual|February 1, 2007|Actual|2007-02-01|March 2017|2017-03-31|March 1, 2008|Actual|2008-03-01|March 1, 2008|Actual|2008-03-01||Interventional|||A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)|A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients With Primary High Cholesterol and High Cardiovascular Risk Not Controlled With a Prior Statin Treatment|Completed||Phase 3|618|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:11:42.14318|2018-06-01 03:11:42.14318
NCT00479700|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-12-07|2007-05-24|2007-05-28|Estimate|||||||2007-12-07|2007-12-10|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|July 2006|Actual|2006-07-31|||||Interventional|||Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Subjects|Completed||Phase 1|80||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:11:42.732673|2018-06-01 03:11:42.732673
NCT00479687|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2015-03-17|2007-05-24|2007-05-28|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder|A Multi-center, Randomized, Double-blind, Placebo Controlled Trial of SUPARTZ (Sodium Hyaluronate) for the Treatment of Chronic Shoulder Pain|Completed||Phase 3|256|Actual|Bioventus LLC||2|||f||||f||||||||||2018-06-01 03:11:42.879117|2018-06-01 03:11:42.879117
NCT00479674|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|2014-12-09||2015-01-29|2007-05-25|2007-05-28|Estimate|2015-01-29|2015-02-18|Estimate||||2015-01-29|2015-02-18|Estimate|May 2007||2007-05-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ABC||Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer|"A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in Triple Negative (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer"|Completed||Phase 2|41|Actual|Duke University||1|||f||||f||||||||||2018-06-01 03:11:42.998942|2018-06-01 03:11:42.998942
NCT00479661|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2010-08-12|2007-05-25|2007-05-28|Estimate|||||||2010-08-12|2010-08-13|Estimate|May 2007||2007-05-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|Prodex||Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU)|A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Propofol for Continuous Sedation of Ventilated Patients in Intensive Care Unit|Completed||Phase 3|500|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-06-01 03:11:43.464221|2018-06-01 03:11:43.464221
NCT00479648|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2016-07-17|2007-05-25|2007-05-28|Estimate|||||||2016-07-17|2016-07-19|Estimate|May 2007||2007-05-31|November 2008|2008-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants|A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 Years) and Older Adults (≥ 60 Years)|Completed||Phase 2|612|Actual|Seqirus||4|||f||||||||||||||2018-06-01 03:11:43.597361|2018-06-01 03:11:43.597361
NCT00479635|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2012-07-16|2014-01-09|2007-05-25|2007-05-28|Estimate||||2012-07-24|2012-08-01|Estimate|2014-01-09|2014-01-22|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer|A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Taxane Regimen|Terminated||Phase 2|26|Actual|Cortice Biosciences, Inc.||1||Sponsor could no longer support; enrollment stopped August 2008.|f||||f||||||||||2018-06-01 03:11:43.682565|2018-06-01 03:11:43.682565
NCT00479622|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2008-05-07|2007-05-25|2007-05-28|Estimate|||||||2008-05-07|2008-05-08|Estimate|August 2007||2007-08-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus|A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus|Terminated||Phase 1|20|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:11:43.780192|2018-06-01 03:11:43.780192
NCT00479609|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2008-05-06|2007-05-25|2007-05-28|Estimate|||||||2008-05-06|2008-05-07|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|April 2009|Anticipated|2009-04-30|January 2009|Anticipated|2009-01-31||Interventional|||Testosterone Therapy in Men With Low Testosterone Levels and Metabolic Syndrome or Early Stages of Type 2 Diabetes|A Randomised Placebo Controlled Study of Transdermal Testosterone Therapy to Investigate the Efficacy and Safety in Men With Abdominal Obesity, Low Testosterone Levels and Early Stages of the Metabolic Cluster Syndrome.|Unknown status|Recruiting|Phase 3|176|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-06-01 03:11:43.860755|2018-06-01 03:11:43.860755
NCT00479596|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-05-29|2007-05-25|2007-05-28|Estimate|||||||2007-05-29|2007-05-30|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|May 2007|Anticipated|2007-05-31|||||Interventional|BTX0621||This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.|Safety and Efficacy Study of Intradetrusor Injections of Botox® for the Treatment of Urinary Incontinence Secondary to Benign Prostatic Obstruction (BTX0621)|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Urological Sciences Research Foundation|||||f||||f||||||||||2018-06-01 03:11:43.959864|2018-06-01 03:11:43.959864
NCT00479583|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2011-11-29|2007-05-25|2007-05-28|Estimate|||||||2011-11-29|2011-11-30|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-690514 in Combination With FOLFIRI and FOLFOX in Subjects With Advanced Metastatic Solid Tumors|Completed||Phase 1|25|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:11:44.036795|2018-06-01 03:11:44.036795
NCT00479570|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2009-04-07|2007-05-25|2007-05-28|Estimate|||||||2009-04-07|2009-04-08|Estimate|June 2007||2007-06-30|April 2009|2009-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.|Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).|Completed||Phase 2|23|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:11:44.146426|2018-06-01 03:11:44.146426
NCT00479557|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2014-05-06||2015-11-30|2007-05-24|2007-05-28|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|May 2007||2007-05-31|November 2015|2015-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||245 participants were randomized in both studies (86 participants in 3134K1-200-EU [B2571004] and 159 participants in 3134K1-2201-US [B2571005]) and included in the analysis below. One participant of the randomized participants did not receive treatment.|Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease|A Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease|Completed||Phase 2|86|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 03:11:44.326004|2018-06-01 03:11:44.326004
NCT00479518|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2017-02-23|2007-05-25|2007-05-28|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2007|Actual|2007-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|April 2014|Actual|2014-04-30||Observational|ABC-AVC||Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack|Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack :Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke|Completed|||159|Actual|University Hospital, Tours|||||f||||f||||||Samples Without DNA|"~     Blood Urine~   "|||2018-06-01 03:11:46.60892|2018-06-01 03:11:46.60892
NCT00479505|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2009-03-24|2011-03-11|2007-05-25|2007-05-28|Estimate||||2011-03-11|2011-03-23|Estimate|2011-03-11|2011-03-23|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder|A Multi-Center, Randomised, Parallel Group, Double-Blind, Placebo Controlled Estimation Study To Assess The Efficacy And Safety Of Modified Release UK-369,003 In The Treatment Of Men With Storage Lower Urinary Tract Symptoms (LUTS) With And Without Erectile Dysfunction (ED).|Completed||Phase 2|275|Anticipated|Pfizer||2|||f||||f||||||||||2018-06-01 03:11:46.674459|2018-06-01 03:11:46.674459
NCT00479492|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2009-09-29|2009-09-29|2007-05-24|2007-05-28|Estimate||||2009-09-29|2009-10-01|Estimate|2009-09-29|2009-10-01|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers|A 12-Week, Randomized, Subject And Investigator Blind, Placebo-Controlled Trial To Evaluate The Effect Of CP-866,087 On Weight Loss In Obese, Otherwise Healthy Adult Subjects|Completed||Phase 2|94|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 03:11:46.81974|2018-06-01 03:11:46.81974
NCT00479479|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2015-07-20|2007-05-25|2007-05-28|Estimate|||||||2015-07-20|2015-07-21|Estimate|December 2004||2004-12-31|July 2015|2015-07-31|December 2006|Actual|2006-12-31|August 2006|Actual|2006-08-31||Interventional|||Cobalamin Supplementation During Infancy; Effect on B-vitamin Status, Growth and Psychomotor Development|Cobalamin Supplementation During Infancy; Effect on B-vitamin Status, Growth and Psychomotor Development|Completed||N/A|107|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 03:11:46.908374|2018-06-01 03:11:46.908374
NCT00479466|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|2011-10-07||2015-09-08|2007-05-25|2007-05-28|Estimate|2011-10-07|2011-11-11|Estimate||||2015-09-08|2015-09-09|Estimate|July 2007||2007-07-31|September 2015|2015-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Dose-Range Finding Study for MK0893 (0893-008)|A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose-Range Finding Study of MK0893 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Terminated||Phase 2|342|Actual|Merck Sharp & Dohme Corp.|Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy, thus the study was discontinued.|6||"Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort~   of the study to assess the safety and efficacy"|f||||||||||||||2018-06-01 03:11:46.992437|2018-06-01 03:11:46.992437
NCT00479440|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-12-03|2007-05-24|2007-05-28|Estimate|||||||2007-12-03|2007-12-05|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 Administered Orally to Healthy Adult Subjects|Completed||Phase 1|56||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:11:47.499742|2018-06-01 03:11:47.499742
NCT00479427|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2009-07-22|2017-07-09|2007-05-24|2007-05-28|Estimate||||2009-07-22|2009-08-10|Estimate|2017-07-09|2017-07-11|Actual|July 6, 2007|Actual|2007-07-06|July 2017|2017-07-31|October 9, 2007|Actual|2007-10-09|October 9, 2007|Actual|2007-10-09||Interventional|||A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis|A Double-blind, Placebo Controlled Cross-over Study of the Effects of the CB2 Compound of GW842166 in Patients With Osteoarthritis|Completed||Phase 2|1|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:11:47.545882|2018-06-01 03:11:47.545882
NCT00479401|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|2009-11-20||2014-06-20|2007-05-25|2007-05-28|Estimate|2010-03-29|2010-04-15|Estimate||||2014-06-20|2014-07-17|Estimate|May 2007||2007-05-31|June 2014|2014-06-30||||November 2008|Actual|2008-11-30||Interventional|||Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients|A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).|Completed||Phase 3|539|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 03:11:47.851198|2018-06-01 03:11:47.851198
NCT00479388|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2009-06-09||2015-02-20|2007-05-24|2007-05-28|Estimate|2009-06-09|2009-07-31|Estimate||||2015-02-20|2015-03-10|Estimate|July 2007||2007-07-31|February 2015|2015-02-28|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)|A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.|Completed||Phase 3|1216|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:11:48.851298|2018-06-01 03:11:48.851298
NCT00479375|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-05-25|2007-05-25|2007-05-28|Estimate|||||||2007-05-25|2007-05-28|Estimate|May 1997||1997-05-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|SWEDESCREEN||Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening|Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Screening|Completed||N/A|12527|Actual|Skane University Hospital|||||f||||t||||||||||2018-06-01 03:11:49.554543|2018-06-01 03:11:49.554543
NCT00479362|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2012-09-14|2007-05-25|2007-05-28|Estimate|||||||2012-09-14|2012-09-17|Estimate|September 2005||2005-09-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|FINPAC||Anticoagulant Therapy During Pacemaker Implantation|Randomized Trial of Uninterrupted Versus Interrupted Anticoagulant Therapy in Patients Undergoing Cardiac Pacing Device Implantation|Completed||Phase 4|447|Actual|University of Turku||4|||f||||f||||||||||2018-06-01 03:11:49.60918|2018-06-01 03:11:49.60918
NCT00479349|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2009-07-06|2007-05-24|2007-05-28|Estimate|||||||2009-07-06|2009-07-07|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Young Male and Elderly Subjects|Completed||Phase 1|32|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||||||||||||2018-06-01 03:11:49.698851|2018-06-01 03:11:49.698851
NCT00468780|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2014-05-23|2007-05-02|2007-05-03|Estimate|||||||2014-05-23|2014-05-26|Estimate|February 2003||2003-02-28|May 2014|2014-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Standardized Comparison of Triage in EMS|Study to Evaluate the Safety and Efficacy of Redirecting Ambulance Patients to Destinations Based on Acuity|Completed|||928|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-06-01 03:15:16.95312|2018-06-01 03:15:16.95312
NCT00479336|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|2013-12-15||2014-01-30|2007-05-25|2007-05-28|Estimate|2014-01-30|2014-03-14|Estimate||||2014-01-30|2014-03-14|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||"2 subjects (1 of placebo and 1 of OPC-41061 30 mg) were excluded by GCP deviation.~1 subject (OPC-41061 7.5 mg) was excluded by receiving a dose 7 times higher than specified daily dose."|A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema|A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema|Completed||Phase 2|104|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 03:11:49.765469|2018-06-01 03:11:49.765469
NCT00479323|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2016-12-22|2007-05-24|2007-05-28|Estimate|||||||2016-12-22|2016-12-26|Estimate|June 2007||2007-06-30|April 2011|2011-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Pneumococcal Reference Standard|Stimulation of Donors for Pneumococcal Reference Serum|Completed||Phase 1|250|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 03:11:50.363694|2018-06-01 03:11:50.363694
NCT00479310|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-05-25|2007-05-25|2007-05-28|Estimate|||||||2007-05-25|2007-05-28|Estimate|January 2006||2006-01-31|May 2007|2007-05-31||||||||Interventional|||Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice|A Multi-Center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice.|Completed||Phase 3|120||Summers Laboratories|||||||||||||||||||2018-06-01 03:11:50.425406|2018-06-01 03:11:50.425406
NCT00479297|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2009-08-06|2007-05-24|2007-05-28|Estimate|||||||2009-08-06|2009-08-07|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Male Subjects|Completed||Phase 1|72||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:11:50.469095|2018-06-01 03:11:50.469095
NCT00479284|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2007-05-25|2007-05-25|2007-05-28|Estimate|||||||2007-05-25|2007-05-28|Estimate|June 2006||2006-06-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Efficacy of Average Volume Assured Pressure Support With Bi-Level Pressure Support Nocturnal Ventilation|Contribution of Average Volume Assured Pressure Support (AVAPS) to Efficacy of bi-Level Pressure Support Nocturnal Ventilation and Impact on Sleep Structure|Completed||N/A|14|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-06-01 03:11:50.510797|2018-06-01 03:11:50.510797
NCT00479271|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2015-03-31|2007-05-25|2007-05-28|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2003||2003-10-31|May 2007|2007-05-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Evaluating the Effectiveness of a Community Based Intervention for Persons With Dementia and Their Caregivers in a Developing Country|The Dementia Home Care Project: a Randomised Controlled Trial to Evaluate the Effectiveness of a Home Care Program for Supporting Caregivers of Persons With Dementia in Developing Countries: a Randomised Controlled Trial From Goa, India|Completed||N/A|||London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 03:11:50.564155|2018-06-01 03:11:50.564155
NCT00479258|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2008-10-29||2008-10-31|2007-05-24|2007-05-28|Estimate|2008-10-31|2008-11-03|Estimate||||2008-10-31|2008-11-03|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents|Safety And Efficacy Of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents Ages 6-17 Years With Type 1 Diabetes Mellitus: A 12 Month, Outpatient, Randomized, Open Label, Parallel Group Comparative Trial.|Terminated||Phase 3|554|Anticipated|Pfizer|Pfizer announced Oct07 it would stop marketing Exubera; recruitment placed on hold. Nektar, from which Pfizer licensed Exubera, announced April 9, 2008 it had stopped its search for a new marketing partner. Study terminated; no further recruitment.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 03:11:50.636926|2018-06-01 03:11:50.636926
NCT00479245|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2011-06-26|2007-05-25|2007-05-28|Estimate|||||||2011-06-26|2011-06-28|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||WHODAS-II for Patients With Nonspecific Low Back Pain|WHODAS-II for Patients With Nonspecific Low Back Pain|Terminated||N/A|200|Anticipated|Kovacs Foundation||1||"Recruitment rate, lower than expected. Organizational changes made it impossible for recruiting~   centers to continue"|f||||t||||||||||2018-06-01 03:11:50.864032|2018-06-01 03:11:50.864032
NCT00479232|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2011-04-28||2015-09-04|2007-05-25|2007-05-28|Estimate|2011-08-01|2011-08-31|Estimate||||2015-09-04|2015-09-21|Estimate|June 2007||2007-06-30|September 2015|2015-09-30|March 2012|Actual|2012-03-31|April 2010|Actual|2010-04-30||Interventional|||Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)|A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Completed||Phase 1|71|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:11:50.966265|2018-06-01 03:11:50.966265
NCT00479219|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2008-07-09|2007-05-25|2007-05-28|Estimate|||||||2008-07-09|2008-07-10|Estimate|May 2007||2007-05-31|July 2008|2008-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients|A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease|Completed||Phase 1|17|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:11:52.402371|2018-06-01 03:11:52.402371
NCT00479206|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2008-04-29|2007-05-25|2007-05-28|Estimate|||||||2008-04-29|2008-04-30|Estimate|October 2006||2006-10-31|April 2008|2008-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Artemisinin Resistance in Cambodia|Artemisinin Resistance in Cambodia|Completed||N/A|||Medical University of Vienna|||||f||||f||||||||||2018-06-01 03:11:52.462255|2018-06-01 03:11:52.462255
NCT00479193|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2017-09-07|2007-05-25|2007-05-28|Estimate|||||||2017-09-07|2017-09-11|Actual|October 2006|Anticipated|2006-10-31|August 2017|2017-08-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Polymem vs. Bacitracin/Xeroform in Treating Burn Wounds|Prospective Randomized Trial of Polymem vs. Bacitracin/Xeroform for Superficial Second Degree Burns|Withdrawn||Phase 1|0|Actual|MetroHealth Medical Center||1|||f||||f||||||||||2018-06-01 03:11:52.524023|2018-06-01 03:11:52.524023
NCT00479180|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2011-10-25|2007-05-25|2007-05-28|Estimate|||||||2011-10-25|2011-10-27|Estimate|July 2006||2006-07-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use|Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use|Completed||Phase 1/Phase 2|65|Actual|Pervasis Therapeutics, Inc||4|||f||||t||||||||||2018-06-01 03:11:52.610947|2018-06-01 03:11:52.610947
NCT00479167|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2009-02-04|2007-05-24|2007-05-28|Estimate|||||||2009-02-04|2009-02-06|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma|A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg|Completed||Phase 2|20|Anticipated|Rush University Medical Center|||||f||||f||||||||||2018-06-01 03:11:52.671813|2018-06-01 03:11:52.671813
NCT00479154|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|2011-03-14||2012-04-25|2007-05-25|2007-05-28|Estimate|2012-04-25|2012-04-26|Estimate||||2012-04-25|2012-04-26|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Botulinum Toxin to Treat Restless Legs Syndrome|Pilot Study of Botulinum Toxin Type A for the Treatment of Restless Legs Syndrome|Completed||Phase 1/Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 03:11:52.79045|2018-06-01 03:11:52.79045
NCT00479141|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-25|||2009-03-26|2007-05-25|2007-05-28|Estimate|||||||2009-03-26|2009-03-27|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|July 2007|Actual|2007-07-31||Interventional|||A Cluster-Randomized Intervention Trial to Improve Quality of Life for HIV-Infected Individuals in Anhui, China|A Cluster-Randomized Trail to Evaluate the Efficacy of a Combined Individual- and Community-Based Behavioral Intervention to Improve Quality of Life (QOL) For HIV-Positive Villagers in Rural China|Completed||N/A|3199|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:11:53.104352|2018-06-01 03:11:53.104352
NCT00479128|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2018-04-13|2007-05-24|2007-05-25|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2006|Actual|2006-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors|Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination With Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumors|Active, not recruiting||Phase 1|80|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:11:53.187118|2018-06-01 03:11:53.187118
NCT00479115|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2012-02-15|2007-05-23|2007-05-25|Estimate|||||||2012-02-15|2012-02-16|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100|AMD3100 in Combination With G-CSF to Mobilize Peripheral Blood Stem Cells in Patients With Fanconi Anemia(FA): A Phase I/II Study|Completed||Phase 1/Phase 2|1|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||||||2018-06-01 03:11:53.531809|2018-06-01 03:11:53.531809
NCT00479102|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-05-24|2007-05-24|2007-05-25|Estimate|||||||2007-05-24|2007-05-25|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Interventional|||Prevention of Iron Deficiency in 2nd Year of Life|Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency|Unknown status|Not yet recruiting|Phase 4|||Soroka University Medical Center|||||f||||f||||||||||2018-06-01 03:11:53.598055|2018-06-01 03:11:53.598055
NCT00479089|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2015-07-27||2015-10-08|2007-05-24|2007-05-25|Estimate|2015-09-02|2015-10-06|Estimate||||2015-10-08|2015-11-02|Estimate|February 2004||2004-02-29|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer|Phase II Trial of Weekly Docetaxel (Taxotere) Vs. Weekly Docetaxel in Combination With ZD1839 (Iressa®) As Consolidation Therapy For Metastatic Urothelial Cancer Following Maximal Response To Multi-Agent Chemotherapy|Terminated||Phase 2|50|Actual|M.D. Anderson Cancer Center|Early termination leading to small numbers of subjects analyzed.|2||Study halted due to drug sponsor decision to not continue.|f||||t||||||||||2018-06-01 03:11:53.701782|2018-06-01 03:11:53.701782
NCT00479076|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2011-01-25|2007-05-24|2007-05-25|Estimate|||||||2011-01-25|2011-01-26|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients|A Single Agent-combination Hybrid Phase I, Open-label, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous AVE0005 (VEGF Trap)Administered Every 2 Weeks in Combination With Oral S-1 in Patients With Advanced Solid Malignancies|Completed||Phase 1|22|Anticipated|Sanofi|||||f||||||||||||||2018-06-01 03:11:54.113442|2018-06-01 03:11:54.113442
NCT00479063|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2011-06-26|2007-05-24|2007-05-25|Estimate|||||||2011-06-26|2011-06-28|Estimate|February 2010||2010-02-28|June 2011|2011-06-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Observational|MODIC 2||Association of Lumbar MODIC Changes With Chronic Low Back Pain in Southern European Subjects|Modic Changes Are Not Associated With a Higher Risk of Chronic Low Back Pain Among Southern European Subjects. A Case Control Study|Completed|||304|Actual|Kovacs Foundation|||2||f||||t||||||||||2018-06-01 03:11:54.216325|2018-06-01 03:11:54.216325
NCT00479050|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-05-24|2007-05-24|2007-05-25|Estimate|||||||2007-05-24|2007-05-25|Estimate|January 2001||2001-01-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|TACE-RFA||Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm|Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm|Completed||Phase 1|291|Actual|Shandong University|||||f||||t||||||||||2018-06-01 03:11:54.284947|2018-06-01 03:11:54.284947
NCT00479037|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2011-03-31||2012-05-04|2007-05-24|2007-05-25|Estimate|2011-05-31|2011-06-28|Estimate||||2012-05-04|2012-05-08|Estimate|April 2007||2007-04-30|May 2012|2012-05-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)|A 24-week, International, Multi Centre, Randomised, Open Label, Parallel Group, Phase IV Clinical Trial Investigating Changes in Bone Formation Markers in Postmenopausal Women With Primary Osteoporosis Treated With Either PTH(1-84) or Strontium Ranelate|Completed||Phase 4|82|Actual|Nycomed|A limitation of the trial was the open label design, however this is not considered to affect the primary or secondary outcome of the trial.|2|||f||||t||||||||||2018-06-01 03:11:54.406582|2018-06-01 03:11:54.406582
NCT00479024|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2009-09-29|2007-05-24|2007-05-25|Estimate|||||||2009-09-29|2009-09-30|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Observational|||Follow-up Study to Previous CARE Trial|CARE (Visipaque 320 and Isovue 370 in Cardiac Angiography in REnally Impaired Patients); FOLLOW-UP STUDY|Completed|||294|Actual|Bracco Diagnostics, Inc|||1||f||||f||||||||||2018-06-01 03:11:54.642535|2018-06-01 03:11:54.642535
NCT00479011|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-05-24|2007-05-24|2007-05-25|Estimate|||||||2007-05-24|2007-05-25|Estimate|September 2005||2005-09-30|May 2007|2007-05-31|January 2006|Actual|2006-01-31|||||Interventional|||Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery|Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery|Terminated||N/A|33|Actual|Santa Casa de Passos||||significant reduction in length of hospital stay (primary endpoint)|f||||t||||||||||2018-06-01 03:11:54.712709|2018-06-01 03:11:54.712709
NCT00478998|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-05-24|2007-05-24|2007-05-25|Estimate|||||||2007-05-24|2007-05-25|Estimate||||May 2007|2007-05-31||||||||Interventional|||Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin|Phase II Study Comparing Two Groups of Patients Undergoing ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin|Unknown status|Not yet recruiting|Phase 2|||Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:11:54.783925|2018-06-01 03:11:54.783925
NCT00478985|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2013-07-01|2007-05-24|2007-05-25|Estimate|||||||2013-07-01|2013-07-02|Estimate|June 2007||2007-06-30|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|STIM||Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia|Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM)|Completed||N/A|100|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-06-01 03:11:54.854407|2018-06-01 03:11:54.854407
NCT00478972|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2016-06-01|2016-06-06|2007-05-24|2007-05-25|Estimate||||2016-06-01|2016-06-06|Estimate|2016-06-06|2016-06-08|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|SOLO||Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients Inadequately Controlled With Diet and Exercise Alone|Terminated||Phase 3|321|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 03:11:55.126576|2018-06-01 03:11:55.126576
NCT00478959|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2016-06-21|2007-05-24|2007-05-25|Estimate|||||||2016-06-21|2016-06-23|Estimate|December 2006||2006-12-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma|Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma|Completed||Phase 2|30|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 03:11:55.218878|2018-06-01 03:11:55.218878
NCT00478946|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2009-01-20|2007-05-23|2007-05-25|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||A Study of Picoplatin in Colorectal Cancer|A Phase I Open-Label Study of Picoplatin in Combination With 5-Fluorouracil and Leucovorin as Initial Therapy in Subjects With Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|43|Anticipated|Poniard Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:11:55.302581|2018-06-01 03:11:55.302581
NCT00478933|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2017-07-04||2017-07-04|2007-05-24|2007-05-25|Estimate|2017-07-04|2017-11-22|Actual||||2017-07-04|2017-11-22|Actual|February 2007||2007-02-28|July 2017|2017-07-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|DISCOVERY||DISCOVERY: Diagnostic Data and Genetic Polymorphisms in ICD Patients.|Diagnostic Data Influence on Disease Management and Relation of Genetic Polymorphisms to Tachy-arrhythmia in ICD Patients.|Completed||N/A|1223|Actual|Medtronic Bakken Research Center|"The following limitations can be noted:~• Patient follow-up was prematurely terminated after at least 12-month follow-up data on all enrolled patients but before the planned 24-month follow-up."|1|||f||||f|f|f||||||No|study is closed several years ago; this is not applicable for this study|2018-06-01 03:11:55.430673|2018-06-01 03:11:55.430673
NCT00478907|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-05-24|2007-05-24|2007-05-25|Estimate|||||||2007-05-24|2007-05-25|Estimate|March 2004||2004-03-31|May 2007|2007-05-31|March 2006|Actual|2006-03-31|||||Interventional|ocr||Prevention of Complications of Eye Surgery|phase2 Study of Prevention of Complications of Strabismus Surgery|Completed||Phase 2|300|Actual|Isfahan University of Medical Sciences|||||f||||f||||||||||2018-06-01 03:11:56.091208|2018-06-01 03:11:56.091208
NCT00478894|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2017-11-28|2007-05-24|2007-05-25|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2007||2007-08-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Observational|MOON-Onsite||Multicenter Orthopaedic Outcomes Network (MOON) ACL Reconstruction (ACLR): Onsite Follow-up|Multicenter Orthopaedic Outcomes Network (MOON) Anterior Cruciate Ligament (ACL) Reconstruction (ACLR): Onsite Follow-up|Enrolling by invitation|||432|Actual|Vanderbilt University Medical Center|||||f||||t||||||||||2018-06-01 03:11:56.191208|2018-06-01 03:11:56.191208
NCT00478881|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2009-11-16||2014-11-24|2007-05-24|2007-05-25|Estimate|2009-11-16|2009-12-24|Estimate||||2014-11-24|2014-12-11|Estimate|August 2007||2007-08-31|November 2014|2014-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function|Randomized, Double-blind, Placebo-controlled, Parallel Group Study of Vardenafil 10 mg Twice Daily to Assess the Effect on Urodynamics in Patients With Overactive Bladder (Detrusor Overactivity)|Completed||Phase 2|397|Actual|Bayer|635 participants were screened; 238 were not randomized because they did not fulfill the inclusion/exclusion criteria. Cystometric bladder compliance not presented since only relevant to characterization of detrusor overactivity, not to efficacy.|2|||f||||f||||||||||2018-06-01 03:11:56.301011|2018-06-01 03:11:56.301011
NCT00478868|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2011-06-26|2007-05-24|2007-05-25|Estimate|||||||2011-06-26|2011-06-28|Estimate|May 2008||2008-05-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Observational|MODIC||Modic Changes and Associated Features in Southern European Chronic Low Back Pain Patients|Modic Changes and Associated Features in Southern European Chronic Low Back Pain Patients|Completed|||487|Actual|Kovacs Foundation|||||f||||t||||||||||2018-06-01 03:11:56.77966|2018-06-01 03:11:56.77966
NCT00478855|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-12-07|2007-05-24|2007-05-25|Estimate|||||||2007-12-07|2007-12-10|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Tazocin Intervention Study|Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria|Completed||Phase 4|500||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:11:56.834252|2018-06-01 03:11:56.834252
NCT00478842|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2017-02-20|2007-05-24|2007-05-25|Estimate|||||||2017-02-20|2017-02-23|Actual|November 2007||2007-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|STIC||Pallidal Stimulation and Gilles de la Tourette Syndrome|Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS|Completed||Phase 3|20|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:11:56.884016|2018-06-01 03:11:56.884016
NCT00478829|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-12-04|2007-05-24|2007-05-25|Estimate|||||||2007-12-04|2007-12-06|Estimate|April 2007||2007-04-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Observational|||Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in China|Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in 5 Large Cities in China|Completed|||8000||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:11:56.95368|2018-06-01 03:11:56.95368
NCT00034957|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2012-02-14|2002-05-02|2002-05-03|Estimate|||||||2012-02-14|2012-02-16|Estimate||||February 2012|2012-02-29|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)||Completed||Phase 2|||Pfizer|||||f||||||||||||||2018-06-01 05:33:03.599214|2018-06-01 05:33:03.599214
NCT00478816|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2016-11-30|2007-05-24|2007-05-25|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines|A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines|Completed||Phase 2|58|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:11:57.02687|2018-06-01 03:11:57.02687
NCT00478803|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2015-03-06|2007-05-24|2007-05-25|Estimate|||||||2015-03-06|2015-03-10|Estimate|May 2007||2007-05-31|July 2012|2012-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|CAVIAAR||Conservative Aortic Valve Surgery for Aortic Insufficiency and Aneurysms of the Aortic Root. CAVIAAR|Conservative Aortic Valve Surgery for Aortic Insufficiency and Aneurysms of the Aortic Root|Completed||Phase 3|245|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:11:57.101579|2018-06-01 03:11:57.101579
NCT00478790|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2011-10-06|2007-05-24|2007-05-25|Estimate|||||||2011-10-06|2011-10-07|Estimate|February 2007||2007-02-28|June 2008|2008-06-30|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Ologen(Oculusgen)-Glaucoma and Pterygium Historical Control Study in China Shanghai Sixth People's Hospital|Study of the Safety and Effectiveness of the Ologen(OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery|Unknown status|Recruiting|Phase 3|60|Anticipated|Pro Top & Mediking Company Limited||1|||f||||t||||||||||2018-06-01 03:11:57.311579|2018-06-01 03:11:57.311579
NCT00478777|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2011-09-26||2011-09-26|2007-05-24|2007-05-25|Estimate|2011-09-26|2011-11-03|Estimate||||2011-09-26|2011-11-03|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|August 2009|Actual|2009-08-31|November 2007|Actual|2007-11-30||Interventional|||A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma|A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma|Completed||Phase 3|150|Actual|Celgene||1|||f||||t||||||||||2018-06-01 03:11:57.446823|2018-06-01 03:11:57.446823
NCT00478764|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2007-05-24|2007-05-24|2007-05-25|Estimate|||||||2007-05-24|2007-05-25|Estimate|March 2006||2006-03-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Intraocular Steroid After Cataract Surgery Study|Intracameral Use of Triamcinolone and Gatifloxacin Versus Standard Postoperative Steroid and Antibiotic Eye Drops After Cataract Surgery|Completed||N/A|41|Actual|Dean Health System|||||f||||f||||||||||2018-06-01 03:11:58.00431|2018-06-01 03:11:58.00431
NCT00478751|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2009-01-28|2007-05-24|2007-05-25|Estimate|||||||2009-01-28|2009-01-29|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Impact of Long Wavelength Ultraviolet (UVA) and Visible Light on Melanocompetent Skin|Impact of Long Wavelength UVA and Visible Light on Melanocompetent Skin|Completed|||22|Actual|Henry Ford Health System|||||f||||f||||||||||2018-06-01 03:11:58.115777|2018-06-01 03:11:58.115777
NCT00478738|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2009-07-22|2017-02-01|2007-05-24|2007-05-25|Estimate||||2009-07-22|2009-08-10|Estimate|2017-02-01|2017-02-02|Estimate|June 2007||2007-06-30|January 2017|2017-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients|A Study to Assess the Pharmacokinetics of Single Escalating Doses of Inhaled GSK961081 DPI (a Dual Pharmacophore) in Healthy Subjects (Part 1) and a Randomised, Double-blind, Double Dummy, Crossover (Incomplete Block) Study to Assess the Safety, Tolerability, Pharmacodynamics (Pulmonary and Systemic) and Pharmacokinetics of 14 Days Dosing With Inhaled GSK961081 DPI Compared With Placebo and Tiotropium Plus Salmeterol in Patients With COPD (Part 2)|Completed||Phase 2|82|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:11:58.225545|2018-06-01 03:11:58.225545
NCT00478725|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2017-11-13|2007-05-24|2007-05-25|Estimate|||||||2017-11-13|2017-11-17|Actual|July 18, 2007|Actual|2007-07-18|November 2017|2017-11-30|July 1, 2008|Actual|2008-07-01|July 1, 2008|Actual|2008-07-01||Interventional|||Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034|An Open-Label, Two-Part Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Pazopanib (GW786034) and the Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of Pazopanib in Subjects With Solid Tumor Malignancies|Completed||Phase 1|10|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:11:58.415134|2018-06-01 03:11:58.415134
NCT00478712|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2018-04-06|2007-05-24|2007-05-25|Estimate|||||||2018-04-06|2018-04-09|Actual|January 2001|Actual|2001-01-31|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|||Hirschsprung Disease Genetic Study|Genetic Analysis of Hirschsprung Disease|Recruiting|||3000|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||Samples With DNA|"~     Study volunteers are asked to provide blood or cheek swab/saliva samples. DNA is extracted~     from the samples for use in the study.~   "|||2018-06-01 03:11:58.52223|2018-06-01 03:11:58.52223
NCT00478699|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2015-07-03|2007-05-24|2007-05-25|Estimate|||||||2015-07-03|2015-07-07|Estimate|June 2007||2007-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|GECP-SCAT||Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)|Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients|Completed||Phase 3|500|Actual|Spanish Lung Cancer Group||2|||f||||t||||||||||2018-06-01 03:11:58.661583|2018-06-01 03:11:58.661583
NCT00478686|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2017-05-04|2007-05-24|2007-05-25|Estimate|||||||2017-05-04|2017-05-08|Actual|May 23, 2007|Actual|2007-05-23|May 2017|2017-05-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Observational|||Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine|A Retrospective Analysis of the Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine|Completed|||102|Actual|M.D. Anderson Cancer Center|||3||f||||f|f|f||||Samples With DNA|"~     5 to 7.5 milliliter (mL) sample of blood. Alternatively, DNA will be extracted from 10um~     slices of formalin-fixed paraffin-embedded tissue from previously collected tumor tissue~     (from the time of the breast cancer diagnosis).~   "|||2018-06-01 03:11:58.791088|2018-06-01 03:11:58.791088
NCT00478517|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2009-03-10|2007-05-23|2007-05-24|Estimate|||||||2009-03-10|2009-03-11|Estimate|May 2007||2007-05-31|March 2009|2009-03-31||||||||Interventional|TETRAM2||TETRAM 2. Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study|Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study. TETRAM2|Withdrawn||Phase 1|20||Hospices Civils de Lyon|||||f||||t||||||||||2018-06-01 03:12:04.614195|2018-06-01 03:12:04.614195
NCT00478673|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2010-12-20||2012-07-02|2007-05-24|2007-05-25|Estimate|2012-07-02|2012-08-07|Estimate||||2012-07-02|2012-08-07|Estimate|May 2007||2007-05-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|SONOMA||Post-Approval Study of the NexStent Carotid Stent System and the FilterWire EZ Embolic Protection System: SONOMA|The NexStent® Carotid Stent System: A Post Market Approval Evaluation Study In Conjunction With the FilterWire EZ™ Embolic Protection System|Terminated||Phase 4|298|Actual|Boston Scientific Corporation|Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent System. The early termination of enrollment led to a smaller than expected number of analyzable subjects (298 actual vs. 1500 anticipated).|||"Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent~   System."|f||||f||||||||||2018-06-01 03:11:58.922705|2018-06-01 03:11:58.922705
NCT00478660|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2007-10-04|2007-05-23|2007-05-25|Estimate|||||||2007-10-04|2007-10-10|Estimate|February 2006||2006-02-28|October 2007|2007-10-31||||||||Interventional|RHAPSODY||An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)|Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis - An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)|Completed||Phase 3|1250|Actual|Abbott|||||f||||||||||||||2018-06-01 03:11:59.826928|2018-06-01 03:11:59.826928
NCT00478647|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2010-08-04||2015-03-19|2007-05-23|2007-05-25|Estimate|2010-08-04|2010-09-02|Estimate||||2015-03-19|2015-04-09|Estimate|July 2007||2007-07-31|February 2014|2014-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase|A Multicenter Open-Label Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase|Completed||Phase 2/Phase 3|40|Actual|Shire||1|||f||||f||||||||||2018-06-01 03:12:01.064587|2018-06-01 03:12:01.064587
NCT00478634|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2012-11-01|2007-05-24|2007-05-25|Estimate|||||||2012-11-01|2012-11-02|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer|An Open-label, Multicenter Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patient With Metastatic Colorectal Adenocarcinoma|Completed||Phase 1|19|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:12:01.385995|2018-06-01 03:12:01.385995
NCT00478621|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2017-05-09|2007-05-24|2007-05-25|Estimate|||||||2017-05-09|2017-05-10|Actual|May 25, 2007|Actual|2007-05-25|May 2017|2017-05-31|October 13, 2008|Actual|2008-10-13|June 30, 2008|Actual|2008-06-30||Interventional|||Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)|A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.|Completed||Phase 1|540|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:12:02.322784|2018-06-01 03:12:02.322784
NCT00478608|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2009-11-30||2010-04-22|2007-05-24|2007-05-25|Estimate|2009-11-30|2010-01-07|Estimate||||2010-04-22|2010-04-28|Estimate|March 2007||2007-03-31|April 2010|2010-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study Evaluating Rapamune® Maintenance Regimen|A Clinical Study to Evaluate the Efficacy and Safety of Cyclosporine (CsA) and Sirolimus (SRL) Induction Followed by Cyclosporine Withdrawal in Korean Renal Allograft Recipients|Completed||Phase 3|79|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:12:02.466996|2018-06-01 03:12:02.466996
NCT00478595|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24||2016-06-01|2016-06-01|2007-05-24|2007-05-25|Estimate||||2016-06-01|2016-06-06|Estimate|2016-06-01|2016-06-06|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|SYMPHONY||Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Monotherapy Inadequately Controlled With Oral Anti-diabetic Drug|Terminated||Phase 3|458|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||||||||||||2018-06-01 03:12:03.068858|2018-06-01 03:12:03.068858
NCT00478582|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2011-01-12|2007-05-24|2007-05-25|Estimate|||||||2011-01-12|2011-01-13|Estimate|May 2007||2007-05-31|January 2011|2011-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Validation of a New Standardized Clinical Anemia Evaluation Score Using a Hb Visual Scale in Nephrological Patients|Validation of a New Standardized Clinical Anemia Evaluation Score Using a Hb Visual Scale in Nephrological Patients|Completed||N/A|||University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 03:12:03.213947|2018-06-01 03:12:03.213947
NCT00478569|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2014-04-29||2014-04-29|2007-05-23|2007-05-25|Estimate|2014-04-29|2014-05-28|Estimate||||2014-04-29|2014-05-28|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Adherence to PTH(1-84) Treatment (FP-002-IM)|Adherence to PTH(1-84) Treatment in Europe. A Non-interventional Cohort Study Collecting Safety Information and Examining Reasons and Predictors for Adherence to PTH(1-84) Treatment in Usual Clinical Settings|Completed|||1179|Actual|Takeda|||1||f||||t||||||||||2018-06-01 03:12:03.388533|2018-06-01 03:12:03.388533
NCT00478556|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|2010-02-09||2017-03-22|2007-05-24|2007-05-25|Estimate|2010-05-19|2010-06-11|Estimate||||2017-03-22|2017-04-18|Actual|August 2007||2007-08-31|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT|Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT|Completed||Phase 4|300|Actual|University of Alabama at Birmingham|Study was completed.|2|||f||||f||||||||||2018-06-01 03:12:04.113782|2018-06-01 03:12:04.113782
NCT00478543|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2009-02-03|2007-05-24|2007-05-25|Estimate|||||||2009-02-03|2009-02-04|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Loop Diuretics in Chronic Kidney Disease|Effect of Loop Diuretics Treatment on Blood Pressure Control in Phase 3-4 of Chronic Kidney Disease|Completed||Phase 4|40|Actual|"University of Campania Luigi Vanvitelli"||1|||f||||f||||||||||2018-06-01 03:12:04.360432|2018-06-01 03:12:04.360432
NCT00478530|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-24|||2009-02-04|2007-05-24|2007-05-25|Estimate|||||||2009-02-04|2009-02-05|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||The Effect of Intravitreal Avastin on the Retina Measured by Electroretinogram|The Effect of Intravitreal Avastin on the Retina Measured by Electroretinogram|Completed||N/A|20|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:12:04.535341|2018-06-01 03:12:04.535341
NCT00478504|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2016-10-26|2007-05-23|2007-05-24|Estimate|||||||2016-10-26|2016-10-28|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Letrozole Versus Clomifene Citrate for Ovulation Induction|Double Blind Cross-over Randomized Controlled Trial Comparing Letrozole Versus Clomifene Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome|Completed||Phase 4|159|Actual|University of Nottingham||2|||f||||t||||||||||2018-06-01 03:12:04.668245|2018-06-01 03:12:04.668245
NCT00478491|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2016-10-25|2007-05-22|2007-05-24|Estimate|||||||2016-10-25|2016-10-27|Estimate|January 2003||2003-01-31|October 2016|2016-10-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|ALZ||fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease|fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease|Completed|||390|Actual|University of Wisconsin, Madison|||4||f||||t||||||Samples Without DNA|"~     plasma and serum~   "|||2018-06-01 03:12:04.741786|2018-06-01 03:12:04.741786
NCT00478478|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2014-11-06|2007-05-23|2007-05-24|Estimate|||||||2014-11-06|2014-11-10|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Observational|||Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke|Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke|Completed|||1000|Actual|Stryker Neurovascular|||1||f||||f||||||||||2018-06-01 03:12:04.83688|2018-06-01 03:12:04.83688
NCT00478465|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2007-08-29|2007-05-23|2007-05-24|Estimate|||||||2007-08-29|2007-08-31|Estimate|May 2007||2007-05-31|August 2007|2007-08-31|August 2007|Anticipated|2007-08-31|||||Interventional|||Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV)|Unknown status|Active, not recruiting|Phase 1/Phase 2|0|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 03:12:04.915331|2018-06-01 03:12:04.915331
NCT00478452|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2017-08-15|2007-05-23|2007-05-24|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2005||2005-08-31|April 2017|2017-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|DC-Ova||Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients|Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Carcinoma|Completed||Phase 1/Phase 2|14|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:12:04.9904|2018-06-01 03:12:04.9904
NCT00478439|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2010-10-26|2007-05-22|2007-05-24|Estimate|||||||2010-10-26|2010-10-27|Estimate|December 2007||2007-12-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|September 2009|Actual|2009-09-30||Interventional|||Investigation of Macular Pigment Augmentation on Dark Adaptation|Investigation of Macular Pigment Augmentation on Dark Adaptation|Terminated||Phase 4|13|Actual|University of Alabama at Birmingham||1||Study terminated: Recruitment delay due to equipment malfunction|f||||f||||||||||2018-06-01 03:12:05.067435|2018-06-01 03:12:05.067435
NCT00478426|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2018-05-28|2007-05-23|2007-05-24|Estimate|||||||2018-05-28|2018-05-30|Actual|April 30, 2007|Actual|2007-04-30|May 2018|2018-05-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer|A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma|Active, not recruiting||Phase 2|30|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:12:05.175028|2018-06-01 03:12:05.175028
NCT00478400|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2017-12-21|2007-05-22|2007-05-24|Estimate|||||||2017-12-21|2017-12-22|Actual|October 1, 2007|Actual|2007-10-01|December 2017|2017-12-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Awareness of Deficit After Combat-related Brain Injury|Awareness of Deficit After Combat-related Brain Injury|Completed|||100|Actual|VA Office of Research and Development|||4||f||||f||||||||||2018-06-01 03:12:05.291048|2018-06-01 03:12:05.291048
NCT00478387|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2016-10-03|2007-05-23|2007-05-24|Estimate|||||||2016-10-03|2016-10-05|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Ovarian Cancer and Immune Response to Flu Vaccine|Study of the Immunogenicity of Killed Influenza Vaccine in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Remission|Completed|||37|Actual|University of Pennsylvania|||||f||||t||||||||||2018-06-01 03:12:05.368238|2018-06-01 03:12:05.368238
NCT00478374|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2010-11-01|2007-05-23|2007-05-24|Estimate|||||||2010-11-01|2010-11-02|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|S-TACE||Sorafenib With TACE to Treat Hepatocellular Carcinoma|Transarterial Chemoembolisation With Doxorubicin in Combination With Systemic Administration of Sorafenib for Patients With Hepatocellular Carcinoma|Completed||Phase 1|21|Actual|University of Bern||1|||f||||f||||||||||2018-06-01 03:12:05.432608|2018-06-01 03:12:05.432608
NCT00478361|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2015-06-19|2007-05-23|2007-05-24|Estimate|||||||2015-06-19|2015-06-22|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function|A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency|Completed||Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:12:05.527873|2018-06-01 03:12:05.527873
NCT00478348|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2017-11-14|2007-05-22|2007-05-24|Estimate|||||||2017-11-14|2017-11-17|Actual|May 2007|Actual|2007-05-31|November 2017|2017-11-30|November 10, 2017|Actual|2017-11-10|October 1, 2017|Actual|2017-10-01||Interventional|||Should Prosthetic Repair of Incisional Abdominal Hernias be Drain or Not?|Adequacy of Drainage During Prosthetic Repair of Incisional Abdominal Hernias: a Randomized Controlled Trial.|Completed||N/A|200|Actual|University of Lausanne Hospitals||2|||f||||t||||||||||2018-06-01 03:12:05.624709|2018-06-01 03:12:05.624709
NCT00478335|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2014-05-27||2018-02-08|2007-05-23|2007-05-24|Estimate|2018-02-08|2018-02-12|Actual||||2018-02-08|2018-02-12|Actual|May 2007||2007-05-31|February 2018|2018-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||crossover|Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus|Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus|Completed||N/A|4|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-06-01 03:12:05.712215|2018-06-01 03:12:05.712215
NCT00478322|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2016-12-02|2007-05-22|2007-05-24|Estimate|||||||2016-12-02|2016-12-06|Estimate|April 2007||2007-04-30|December 2016|2016-12-31|February 2008|Actual|2008-02-29|November 2007|Actual|2007-11-30||Interventional|||Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects||Completed||Phase 2|24|Actual|Incyte Corporation||2|||f||||f||||||||||2018-06-01 03:12:05.94432|2018-06-01 03:12:05.94432
NCT00478309|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2016-03-01|2007-05-23|2007-05-24|Estimate|||||||2016-03-01|2016-03-03|Estimate|March 2007||2007-03-31|March 2016|2016-03-31||||March 2014|Actual|2014-03-31||Interventional|||Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants|Gene Environment Risk Assessment and CRC Screening|Completed||N/A|697|Actual|Fox Chase Cancer Center||2|||f||||||||||||||2018-06-01 03:12:06.041212|2018-06-01 03:12:06.041212
NCT00478296|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2012-03-14|2007-05-23|2007-05-24|Estimate|||||||2012-03-14|2012-03-16|Estimate|October 2004||2004-10-31|January 2008|2008-01-31|March 2008|Actual|2008-03-31|February 2007|Actual|2007-02-28||Observational|||Pulmonary Hypertension in Trisomy 21 Patients|Case Report: Resolution of Pulmonary Hypertension With Sildenafil and Bosentan in Patients With Trisomy 21 and Atrial Septal Defect|Completed|||1|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 03:12:06.140463|2018-06-01 03:12:06.140463
NCT00478283|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2010-02-05|2007-05-23|2007-05-24|Estimate|||||||2010-02-05|2010-02-09|Estimate|December 2006||2006-12-31|February 2010|2010-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer|Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Hormonal Therapy in Older and/or Frail Women: A Survey of Oncologists and Geriatricians|Completed||N/A|300|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 03:12:06.262135|2018-06-01 03:12:06.262135
NCT00478270|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2017-08-14|2007-05-23|2007-05-24|Estimate|||||||2017-08-14|2017-08-16|Actual|June 2007||2007-06-30|August 2017|2017-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.|An Open Label Study to Assess the Effect of Intravenous Loading Doses of Bondronat on Metastatic Bone Pain in Patients With Breast Cancer and Skeletal Metastases.|Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:12:06.327381|2018-06-01 03:12:06.327381
NCT00478257|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2012-06-18||2016-05-10|2007-05-22|2007-05-24|Estimate|2016-05-10|2016-06-16|Estimate||||2016-05-10|2016-06-16|Estimate|November 2005||2005-11-30|May 2016|2016-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Increased Light Exposure on Fatigue in Breast Cancer|Effect of Increased Light Exposure on Fatigue in Breast Cancer|Completed||N/A|39|Actual|University of California, San Diego|Small sample size; only partial compliance data; light only administered in morning; only tested effect in patients with breast cancer.|2|||f||||f||||||||||2018-06-01 03:12:06.414246|2018-06-01 03:12:06.414246
NCT00478244|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2012-07-17||2017-12-03|2007-05-23|2007-05-24|Estimate|2013-01-04|2013-02-11|Estimate||||2017-12-03|2017-12-28|Actual|April 2007||2007-04-30|December 2017|2017-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa|Allogeneic Hematopoietic Cell Transplantation to Correct the Biochemical Defect and Create Tolerance to Donor Tissue in Subjects With Epidermolysis Bullosa|Terminated||N/A|7|Actual|Masonic Cancer Center, University of Minnesota||1||Competing studies|f||||t||||||||||2018-06-01 03:12:06.734494|2018-06-01 03:12:06.734494
NCT00478231|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2011-07-08||2011-09-01|2007-05-22|2007-05-24|Estimate|2011-07-12|2011-08-08|Estimate||||2011-09-01|2011-09-09|Estimate|July 2007||2007-07-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Multicenter, Safety Study Of Maraviroc|A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc|Completed||Phase 3|209|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-06-01 03:12:07.116799|2018-06-01 03:12:07.116799
NCT00478218|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2011-06-30||2011-08-29|2007-05-23|2007-05-24|Estimate|2011-06-30|2011-07-27|Estimate||||2011-08-29|2011-08-31|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|April 2011|Actual|2011-04-30|September 2008|Actual|2008-09-30||Interventional|||Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Trial of Revlimid, Cyclophosphamide, and Dexamethasone in Patients With > Newly Diagnosed Active Multiple Myeloma|Completed||Phase 2|53|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:12:08.11147|2018-06-01 03:12:08.11147
NCT00478205|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2012-11-12|2010-02-17|2014-06-26|2007-05-23|2007-05-24|Estimate|2013-01-02|2013-02-05|Estimate|2010-04-25|2010-04-27|Estimate|2014-06-26|2014-07-11|Estimate|June 2007||2007-06-30|January 2013|2013-01-31||||June 2009|Actual|2009-06-30||Interventional|||Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease|Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease|Completed||Phase 3|1467|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 03:12:08.958728|2018-06-01 03:12:08.958728
NCT00478192|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2010-03-31||2014-04-30|2007-05-22|2007-05-24|Estimate|2010-03-31|2010-04-21|Estimate||||2014-04-30|2014-05-15|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase IIIb, Randomized, Double-Blind, Parallel Group, Multi-Center, Study to Assess the Efficacy and Safety of Multiple 30 Minute Infusions of YM087 (Conivaptan) in Subjects With Euvolemic or Hypervolemic Hyponatremia|Completed||Phase 3|50|Actual|Cumberland Pharmaceuticals|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.|3|||f||||f||||||||||2018-06-01 03:12:09.727602|2018-06-01 03:12:09.727602
NCT00478179|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22||2009-09-09|2009-09-09|2007-05-23|2007-05-24|Estimate||||2009-09-09|2009-09-11|Estimate|2009-09-09|2009-09-11|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia|A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients With Post-Herpetic Neuralgia|Completed||Phase 2|60|Actual|Durect|||||f||||||||||||||2018-06-01 03:12:10.468538|2018-06-01 03:12:10.468538
NCT00478166|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2015-10-01|2007-05-22|2007-05-24|Estimate|||||||2015-10-01|2015-10-05|Estimate|July 2005||2005-07-31|April 2011|2011-04-30|October 2007|Actual|2007-10-31|||||Observational|PC||Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease|Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease|Completed|||206|Anticipated|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 03:12:10.541156|2018-06-01 03:12:10.541156
NCT00478140|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2013-09-17||2014-05-15|2007-05-23|2007-05-24|Estimate|2013-09-17|2013-11-19|Estimate||||2014-05-15|2014-05-28|Estimate|May 2007||2007-05-31|September 2013|2013-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery|A Phase II Study Trastuzumab (NSC 688097) in Her2/Neu Positive Cancer of the Gallbladder or Biliary Tract (NCI 7756)|Completed||Phase 2|4|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:12:10.598844|2018-06-01 03:12:10.598844
NCT00478127|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2007-05-23|2007-05-23|2007-05-24|Estimate|||||||2007-05-23|2007-05-24|Estimate||||May 2007|2007-05-31||||||||Observational|||Hepatocyte Growth Factor and Cardiovascular Autonomic Function||Completed|||||Oita Red Cross Hospital|||||f||||||||||||||2018-06-01 03:12:10.775151|2018-06-01 03:12:10.775151
NCT00477763|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2008-02-13|2007-05-22|2007-05-24|Estimate|||||||2008-02-13|2008-02-18|Estimate|May 2007||2007-05-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Oasys vs. Extreme H20 Xtra 59|Oasys vs. Extreme H20 Xtra 59|Completed||Phase 4|52|Actual|Innovative Medical||2|||f||||||||||||||2018-06-01 03:12:14.958796|2018-06-01 03:12:14.958796
NCT00478114|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2011-08-25|2007-05-23|2007-05-24|Estimate|||||||2011-08-25|2011-08-29|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)|An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 3|15|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 03:12:10.814335|2018-06-01 03:12:10.814335
NCT00478101|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2008-03-12|2007-05-22|2007-05-24|Estimate|||||||2008-03-12|2008-03-13|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain||Completed||Phase 2|2006|Actual|Gachon University Gil Medical Center|||||f||||f||||||||||2018-06-01 03:12:10.883338|2018-06-01 03:12:10.883338
NCT00478088|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22||2011-08-29|2012-05-30|2007-05-22|2007-05-24|Estimate||||2011-09-02|2011-09-12|Estimate|2012-05-30|2012-06-05|Estimate|September 2006||2006-09-30|May 2012|2012-05-31|March 2012|Actual|2012-03-31|August 2010|Actual|2010-08-31||Interventional|NeoDisc™||Evaluating The Safety and Effectiveness of The NeoDisc™ Versus ACDF in Subjects With Single-Level Cervical Disc Disease|A Pivotal, Multi-Center, Randomized, Controlled Trial Evaluating The Safety and Effectiveness of The NeoDisc™ Versus Instrumented Anterior Cervical Discectomy and Fusion (ACDF) in Subjects With Single-Level Cervical Disc Disease|Completed||N/A|488|Actual|NuVasive||2|||f||||t||||||||||2018-06-01 03:12:11.022981|2018-06-01 03:12:11.022981
NCT00478075|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2011-05-10|2007-05-23|2007-05-24|Estimate|||||||2011-05-10|2011-05-11|Estimate|September 2005||2005-09-30|May 2011|2011-05-31|June 2009|Actual|2009-06-30|November 2007|Actual|2007-11-30||Interventional|||Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Study of 153 Sm EDTMP (Quadramet™) and PS-341 (Velcade®) in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|50|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 03:12:11.137023|2018-06-01 03:12:11.137023
NCT00478062|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2018-01-31||2018-01-31|2007-05-23|2007-05-24|Estimate|2018-01-31|2018-02-28|Actual||||2018-01-31|2018-02-28|Actual|April 2007||2007-04-30|October 2016|2016-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma|KGEL Vaccine After Initial Therapy of Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||Poor accrual|f||||f||||||||||2018-06-01 03:12:11.211565|2018-06-01 03:12:11.211565
NCT00478049|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2012-06-05|2007-05-23|2007-05-24|Estimate|||||||2012-06-05|2012-06-06|Estimate|September 2005||2005-09-30|June 2012|2012-06-30|February 2009|Actual|2009-02-28|May 2007|Actual|2007-05-31||Interventional|ISTANA||Iressa as Second Line Therapy in Advanced NSCLC-Asia|A Randomized, Open Label, Parallel Group, Regional, Multicenter, Phase III Study of Oral Gefitinib (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non Small Cell Lung Cancer Who Have Previously Received Platinum Based Chemotherapy (ISTANA)|Completed||Phase 3|163|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:12:11.377075|2018-06-01 03:12:11.377075
NCT00478036|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2016-03-17||2016-08-15|2007-05-23|2007-05-24|Estimate|2016-08-15|2016-10-07|Estimate||||2016-08-15|2016-10-07|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells|A Randomized Prospective Double Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells.|Terminated||N/A|31|Actual|University of Colorado, Denver||3||insufficient enrollment|f||||f||||||||No||2018-06-01 03:12:11.488634|2018-06-01 03:12:11.488634
NCT00478023|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2009-12-16||2013-12-20|2007-05-23|2007-05-24|Estimate|2009-12-22|2010-01-27|Estimate||||2013-12-20|2014-01-28|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy|A Randomized, Double-blind, Parallel-arm, Placebo- and Comparator- Controlled Trial of the Efficacy and Safety of Multiple Doses of Immediate-release (IR) CG5503 for Postoperative Pain Following Abdominal Hysterectomy|Completed||Phase 3|854|Actual|Grünenthal GmbH|Approval to conduct the trial was obtained in Slovenia. No Slovenian subjects were exposed to study drug.|5|||f||||f||||||||||2018-06-01 03:12:11.940632|2018-06-01 03:12:11.940632
NCT00478010|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2010-08-05|2007-05-23|2007-05-24|Estimate|||||||2010-08-05|2010-08-09|Estimate|January 2007||2007-01-31|August 2010|2010-08-31||||December 2008|Anticipated|2008-12-31||Interventional|||Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer|Research Participation: Decision Making and Outcomes in Cancer Clinical Trials|Unknown status|Active, not recruiting|N/A|200|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:12:12.694853|2018-06-01 03:12:12.694853
NCT00477997|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2009-04-20|2007-05-23|2007-05-24|Estimate|||||||2009-04-20|2009-04-21|Estimate|May 2007||2007-05-31|April 2009|2009-04-30|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Effect of Growth Hormone on Insulin Signaling in Muscle Tissue|The Effect of a Physiological Bolus of Growth Hormone (GH) on Insulin Signaling Pathways in Muscle Tissue From Healthy Adults|Completed||N/A|8|Anticipated|University of Aarhus||3|||f||||f||||||||||2018-06-01 03:12:12.766154|2018-06-01 03:12:12.766154
NCT00477984|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2008-04-11|2007-05-23|2007-05-24|Estimate|||||||2008-04-11|2008-04-15|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effects of Alcohol on Simulated Driving|The Effects of Five Dosages of Ethanol on Simulated Driving Performance and Event-Related Potentials|Completed||N/A|32|Actual|Utrecht Institute for Pharmaceutical Sciences||1|||f||||f||||||||||2018-06-01 03:12:12.83928|2018-06-01 03:12:12.83928
NCT00477971|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2015-06-23||2016-04-13|2007-05-23|2007-05-24|Estimate|2015-06-23|2015-07-21|Estimate||||2016-04-13|2016-05-17|Estimate|October 2005||2005-10-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|July 2012|Actual|2012-07-31||Interventional|||Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis|Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL)|Completed||Phase 3|89|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:12:12.94054|2018-06-01 03:12:12.94054
NCT00477958|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2017-08-02|2007-05-23|2007-05-24|Estimate|||||||2017-08-02|2017-08-03|Actual|May 11, 2007|Actual|2007-05-11|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Assessment Tool for Older Patients With Cancer|Determining the Utility of an Assessment Tool for Older Patients With Cancer|Active, not recruiting||N/A|750|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 03:12:13.562136|2018-06-01 03:12:13.562136
NCT00477945|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2014-09-10|2007-05-23|2007-05-24|Estimate|||||||2014-09-10|2014-09-11|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL|A Phase I Trial of Clofarabine in Combination With High-Dose Etoposide and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation for Patients With High-Risk or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 1|18|Actual|Indiana University|||||f||||t||||||||||2018-06-01 03:12:13.658273|2018-06-01 03:12:13.658273
NCT00477932|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2014-12-16|2007-05-22|2007-05-24|Estimate|||||||2014-12-16|2014-12-17|Estimate|March 2006||2006-03-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Genes Mutation Pentalogy of Cantrell|Human Disease With Mutation of Nonmuscle Myosin Heavy Chain Genes|Withdrawn|||0|Actual|Children's Healthcare of Atlanta||||Physician's chose to not follow through with the study.|f||||f||||||||||2018-06-01 03:12:13.72519|2018-06-01 03:12:13.72519
NCT00477919|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2015-10-08|2007-05-23|2007-05-24|Estimate|||||||2015-10-08|2015-10-09|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||E-MOSAIC Electronic Tool to Monitor Symptoms|E-MOSAIC: A Multicenter Randomized Controlled Phase III Study of Longitudinal Electronic Monitoring of Symptoms and Syndromes Associated With Advanced Cancer in Patients Receiving Anticancer Treatment in Palliative Intention|Completed|||264|Actual|Swiss Group for Clinical Cancer Research|||2||f||||t||||||||||2018-06-01 03:12:13.807492|2018-06-01 03:12:13.807492
NCT00477906|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2015-12-02|2007-05-22|2007-05-24|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2016||2016-07-31|December 2015|2015-12-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma|Comparison of M-Vax Plus Low Dose Interleukin-2 Versus Placebo Vaccine Plus Low Dose Interleukin-2 in Patients With Stage IV Melanoma|Not yet recruiting||Phase 3|387|Anticipated|AVAX Technologies||2|||f||||f||||||||||2018-06-01 03:12:13.884706|2018-06-01 03:12:13.884706
NCT00477893|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2012-03-27|2007-05-23|2007-05-24|Estimate|||||||2012-03-27|2012-03-28|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|January 2013|Anticipated|2013-01-31|January 2009|Actual|2009-01-31||Interventional|DANISH||Danish Multicenter Study of Adalimumab in Spondyloarthritis|Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab|Unknown status|Active, not recruiting|Phase 4|52|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-06-01 03:12:13.94927|2018-06-01 03:12:13.94927
NCT00477880|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2017-01-06|2007-05-23|2007-05-24|Estimate|||||||2017-01-06|2017-01-10|Estimate|April 2001||2001-04-30|January 2017|2017-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer|Treatment of Ménétrier's Disease With EGF Receptor Blockade|Completed||Phase 1|9|Actual|Vanderbilt University Medical Center||1|||f||||t||||||||||2018-06-01 03:12:14.035011|2018-06-01 03:12:14.035011
NCT00477867|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2013-06-07|2007-05-23|2007-05-24|Estimate|||||||2013-06-07|2013-06-10|Estimate||||October 2007|2007-10-31||||||||Interventional|||Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172|Assessing Economic Outcomes in Women With Stage III Ovarian Cancer Treated With Intravenous Paclitaxel and Cisplatin v. Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel on GOG #172: A Feasibility Study of Assessing Costs and Medical Resource Use|Withdrawn||N/A|0|Actual|Gynecologic Oncology Group||||Trial was never activated|f||||||||||||||2018-06-01 03:12:14.14423|2018-06-01 03:12:14.14423
NCT00477854|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2016-02-11|2007-05-23|2007-05-24|Estimate|||||||2016-02-11|2016-02-12|Estimate|April 2005||2005-04-30|February 2016|2016-02-29|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effects of Chromium Picolinate on Food Intake|Effects of Chromium Picolinate on Food Intake, Satiety, and Eating Attitudes in Overweight Women With Food Cravings|Completed||N/A|42|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 03:12:14.266709|2018-06-01 03:12:14.266709
NCT00477841|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2008-04-17|2007-05-22|2007-05-24|Estimate|||||||2008-04-17|2008-04-18|Estimate|April 2004||2004-04-30|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Self-Expandable Esophageal Radiation Stent:a Randomized Controlled Trial in Patients With Advanced Esophageal Cancer||Completed||Phase 2|60|Actual|Southeast University, China|||||f||||f||||||||||2018-06-01 03:12:14.360624|2018-06-01 03:12:14.360624
NCT00477828|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2007-05-22|2007-05-22|2007-05-24|Estimate|||||||2007-05-22|2007-05-24|Estimate|April 2000||2000-04-30|May 2007|2007-05-31|January 2006|Actual|2006-01-31|||||Interventional|||Effect of Treating Sleep Apnea on Cognition in Patients With Dementia|Cognitive Benefits of Treating Apnea in Dementia|Completed||N/A|61|Actual|University of California, San Diego|||||f||||f||||||||||2018-06-01 03:12:14.426705|2018-06-01 03:12:14.426705
NCT00477815|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2018-05-08|2007-05-23|2007-05-24|Estimate|||||||2018-05-08|2018-05-14|Actual|May 31, 2005|Actual|2005-05-31|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|July 28, 2011|Actual|2011-07-28||Interventional|||Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma|A Phase I Trial of Zevalin Radioimmunotherapy With High-Dose Melphalan and Stem Cell Transplant for Multiple Myeloma|Completed||Phase 1|30|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:12:14.510723|2018-06-01 03:12:14.510723
NCT00477802|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2009-02-13|2007-05-22|2007-05-24|Estimate|||||||2009-02-13|2009-02-16|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease|Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study|Terminated||Phase 4|8|Actual|University of Cincinnati||2||Intervention did not appear to be effective in most enrolled patients.|f||||t||||||||||2018-06-01 03:12:14.632228|2018-06-01 03:12:14.632228
NCT00477789|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2007-05-23|2007-05-23|2007-05-24|Estimate|||||||2007-05-23|2007-05-24|Estimate||||May 2007|2007-05-31||||||||Interventional|||Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients|Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients|Completed||Phase 4|||Universita di Verona|||||f||||f||||||||||2018-06-01 03:12:14.755809|2018-06-01 03:12:14.755809
NCT00477776|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2009-09-18|2007-05-23|2007-05-24|Estimate|||||||2009-09-18|2009-09-21|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|Maxalon||Maxolon to Improve Breastmilk Supply in Diabetic Women: a Randomised Controlled Trial|Metoclopramide to Improve Lactogenesis II in Diabetic Women: a Randomized Controlled Trial|Completed||Phase 3|160|Anticipated|National University Hospital, Singapore||4|||f||||t||||||||||2018-06-01 03:12:14.819575|2018-06-01 03:12:14.819575
NCT00477750|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2010-11-08||2017-03-21|2007-05-23|2007-05-24|Estimate|2010-11-08|2010-12-13|Estimate||||2017-03-21|2017-04-18|Actual|June 2005||2005-06-30|October 2015|2015-10-31|August 5, 2013|Actual|2013-08-05|April 2008|Actual|2008-04-30||Interventional|||Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma|Phase I/II Trial of Melphalan, Prednisone Plus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Stem Cell Transplant|Completed||Phase 1/Phase 2|33|Actual|Mayo Clinic||1|||f||||||||||||||2018-06-01 03:12:15.049961|2018-06-01 03:12:15.049961
NCT00477737|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2007-05-23|2007-05-23|2007-05-24|Estimate|||||||2007-05-23|2007-05-24|Estimate|August 2006||2006-08-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Early Cardioprotective Effect of Sevoflurane|Early Cardioprotective Effect of Sevoflurane on Left Ventricular Performance During Coronary Artery Bypass Grafting on a Beating Heart|Completed||Phase 4|32|Actual|University Hospital Dubrava|||||f||||f||||||||||2018-06-01 03:12:15.368947|2018-06-01 03:12:15.368947
NCT00477724|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2014-07-01|2007-05-22|2007-05-24|Estimate|||||||2014-07-01|2014-07-02|Estimate|June 2007||2007-06-30|July 2014|2014-07-31||||June 2015|Anticipated|2015-06-30||Interventional|||Latent Pulmonary Hypertension (PH) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH )After Endarterectomy and Influence of Exercise and Respiratory Therapy|Incidence of Latent Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Hypertension After Endarterectomy and Influence of Exercise and Respiratory Therapy|Unknown status|Recruiting|N/A|35|Anticipated|Heidelberg University||2|||f||||||||||||||2018-06-01 03:12:15.440314|2018-06-01 03:12:15.440314
NCT00477711|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2015-05-17|2007-05-22|2007-05-24|Estimate|||||||2015-05-17|2015-05-19|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|EXTRA||A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer||Completed||Phase 2|41|Actual|Peking University||1|||f||||t||||||||||2018-06-01 03:12:15.552874|2018-06-01 03:12:15.552874
NCT00477685|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2011-10-24||2017-07-01|2007-05-23|2007-05-24|Estimate|2012-02-29|2012-03-29|Estimate||||2017-07-01|2017-08-14|Actual|May 2007||2007-05-31|July 2017|2017-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31|3 Months|Observational [Patient Registry]|||Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India|Study of the Safety and Effectiveness of the OculusGenTM Collagen Matrix Implant as an Aid in Phacotrabeculectomy Surgery|Completed|||10|Actual|Pro Top & Mediking Company Limited|Limited sample size.||1||f||||||||||||||2018-06-01 03:12:15.645367|2018-06-01 03:12:15.645367
NCT00477672|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2014-02-06||2017-04-18|2007-05-22|2007-05-24|Estimate|2014-02-06|2014-03-26|Estimate||||2017-04-18|2017-05-17|Actual|June 2007||2007-06-30|April 2017|2017-04-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional||Safety Analysis Set|A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis|A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease|Completed||Phase 3|298|Actual|ACADIA Pharmaceuticals Inc.||3|||f||||f|t|f||||||No||2018-06-01 03:12:15.862805|2018-06-01 03:12:15.862805
NCT00477659|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2009-05-06|2007-05-23|2007-05-24|Estimate|||||||2009-05-06|2009-05-07|Estimate|July 2007||2007-07-31|May 2009|2009-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Neural Correlates In Mild Alzheimer's Disease|A Single Center Study To Examine Neural Correlates Of Cognition In Subjects With Mild Alzheimer's Disease After Three Months Of Open Label Donepezil HCl (Aricept® ) Treatment|Completed||Phase 4|14|Actual|Eisai Inc.||1|||f||||f||||||||||2018-06-01 03:12:16.439543|2018-06-01 03:12:16.439543
NCT00477646|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2011-08-04|2007-05-23|2007-05-24|Estimate|||||||2011-08-04|2011-08-05|Estimate|July 2007||2007-07-31|August 2011|2011-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care|New York Prevention Care Manager Project / Medicaid Managed Care Organization Version|Completed||N/A|2241|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-06-01 03:12:16.51988|2018-06-01 03:12:16.51988
NCT00477633|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2010-10-13||2013-04-15|2007-05-23|2007-05-24|Estimate|2010-12-22|2011-01-24|Estimate||||2013-04-15|2013-04-22|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Study of Safety and Efficacy of an Oral Contraceptive|An Open Label Study of the Contraceptive Efficacy of Norethindrone and Ethinyl Estradiol.|Completed||Phase 3|1700|Actual|Warner Chilcott||1|||f||||f||||||||||2018-06-01 03:12:16.621281|2018-06-01 03:12:16.621281
NCT00477620|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|||2009-02-19|2007-05-23|2007-05-24|Estimate|||||||2009-02-19|2009-02-23|Estimate|April 2004||2004-04-30|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|SMART||Study of Myopia Acquisition and Prevention|Study of Myopia Acquisition and Prevention in a Randomised Trial|Completed||N/A|||University Hospital Freiburg|||||f||||f||||||||||2018-06-01 03:12:16.896428|2018-06-01 03:12:16.896428
NCT00477607|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-23|2013-10-04||2014-02-03|2007-05-23|2007-05-24|Estimate|2013-12-10|2014-01-29|Estimate||||2014-02-03|2014-03-07|Estimate|October 2007||2007-10-31|February 2014|2014-02-28|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin|Prevention of Cisplatin Ototoxicity With the Antioxidant Alpha-Lipoic Acid|Completed||Phase 2/Phase 3|39|Actual|VA Office of Research and Development|Missing data constraints have the number of subjects in the study being different for different outcomes.|2|||f||||t||||||||||2018-06-01 03:12:16.949966|2018-06-01 03:12:16.949966
NCT00477594|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2013-02-25|2012-01-18|2016-08-01|2007-05-22|2007-05-24|Estimate|2013-02-25|2013-04-05|Estimate|2012-01-18|2012-01-23|Estimate|2016-08-01|2016-09-09|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia|An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia|Completed||Phase 2|21|Actual|Kastle Therapeutics, LLC||2|||f||||f||||||||||2018-06-01 03:12:19.181784|2018-06-01 03:12:19.181784
NCT00477581|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2015-08-25|2007-05-21|2007-05-23|Estimate|||||||2015-08-25|2015-08-26|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Crossover Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|102|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:12:22.394378|2018-06-01 03:12:22.394378
NCT00477568|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2015-03-31|2007-05-22|2007-05-23|Estimate|||||||2015-03-31|2015-04-01|Estimate|November 2007||2007-11-30|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Observational|||Back Pain Prevalence in Wheelchair Users and Associated Risk Factors|Back Pain Prevalence in Wheelchair Users and Associated Risk Factors|Unknown status|Recruiting||350|Anticipated|Kovacs Foundation|||||f||||t||||||||||2018-06-01 03:12:22.749329|2018-06-01 03:12:22.749329
NCT00477542|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2014-09-17|2007-05-22|2007-05-23|Estimate|||||||2014-09-17|2014-09-18|Estimate|May 2007||2007-05-31|September 2014|2014-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT|A Phase I Trial of Myeloablative Conditioning Using Clofarabine and High-Dose Busulfan for Patients With Refractory Hematological Malignancies Undergoing Allogeneic HSCT|Completed||Phase 1|18|Actual|Indiana University|||||f||||t||||||||||2018-06-01 03:12:23.278121|2018-06-01 03:12:23.278121
NCT00477529|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2015-09-09|2007-05-22|2007-05-23|Estimate|||||||2015-09-09|2015-09-11|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer|A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer|Completed||Phase 1/Phase 2|102|Anticipated|Celgene||1|||f||||f||||||||||2018-06-01 03:12:23.55817|2018-06-01 03:12:23.55817
NCT00477516|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2012-06-13|2007-05-22|2007-05-23|Estimate|||||||2012-06-13|2012-06-15|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients|Determination of FDF-23 Levels in Non-suppressible PTH Secretion and the Influence of Inflammation on Fetuin A Levels During Hemodialysis Treatment|Completed||N/A|18|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 03:12:23.873519|2018-06-01 03:12:23.873519
NCT00477503|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2012-07-31|2007-05-21|2007-05-23|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2007||2007-05-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA|Phase 1 Study Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||3||One participant enrolled, study terminated .|f||||f||||||||||2018-06-01 03:12:24.178644|2018-06-01 03:12:24.178644
NCT00477490|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2015-06-16|2009-06-02|2015-09-29|2007-05-22|2007-05-23|Estimate|2015-09-29|2015-11-02|Estimate|2009-09-28|2009-09-30|Estimate|2015-09-29|2015-11-02|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||Demographic data offered from the Intent-to-Treat population|Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia|"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study With a Double Blind Extension Investigating the Efficacy and Safety of a Fast- Dissolving (Melt) Formulation of Desmopressin for the Treatment of Nocturia in Adults"|Completed||Phase 3|799|Actual|Ferring Pharmaceuticals||5|||f||||t||||||||||2018-06-01 03:12:24.723001|2018-06-01 03:12:24.723001
NCT00477477|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2014-10-24|2007-05-22|2007-05-23|Estimate|||||||2014-10-24|2014-10-27|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp)|Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors|Terminated||N/A|27|Actual|Boston Children’s Hospital||2||Inadequate enrollment and lack of funds.|f||||f||||||||||2018-06-01 03:12:28.64656|2018-06-01 03:12:28.64656
NCT00477464|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2011-08-04||2011-09-15|2007-05-22|2007-05-23|Estimate|2011-08-04|2011-09-05|Estimate||||2011-09-15|2011-09-19|Estimate|June 2007||2007-06-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer|Clinical Evaluation of Lapatinib Administered With Capecitabine in Japanese Patients With ErbB2 Overexpressing Advanced or Metastatic Breast Cancer|Completed||Phase 2|51|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-06-01 03:12:29.007973|2018-06-01 03:12:29.007973
NCT00477451|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2017-03-12||2017-06-15|2007-05-22|2007-05-23|Estimate|2017-06-15|2017-06-16|Actual||||2017-06-15|2017-06-16|Actual|May 2007|Actual|2007-05-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||Safety Population|Staccato Alprazolam in Panic Attack|Investigation of a Single Dose of Staccato™ Alprazolam for Inhalation on Doxapram-Induced Panic Attack in Patients With Panic Disorder|Completed||Phase 2|49|Actual|Alexza Pharmaceuticals, Inc.||4|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 03:12:29.716963|2018-06-01 03:12:29.716963
NCT00477425|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2017-05-11|2007-05-21|2007-05-23|Estimate|||||||2017-05-11|2017-05-15|Actual|June 2007|Actual|2007-06-30|May 2017|2017-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab|Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab|Withdrawn|||0|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 03:12:30.06175|2018-06-01 03:12:30.06175
NCT00477412|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2018-03-23|2007-05-21|2007-05-23|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 2007|Actual|2007-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma|Phase I Study of Bortezomib (Velcade) Plus Rituximab-HyperCVAD Alternating With Bortezomib Plus Rituximab-High Dose Methotrexate/Cytarabine in Patients With Untreated Aggressive Mantle Cell Lymphoma|Active, not recruiting||Phase 1|110|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:12:30.112088|2018-06-01 03:12:30.112088
NCT00477399|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2007-05-22|2007-05-22|2007-05-23|Estimate|||||||2007-05-22|2007-05-23|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|May 2012|Anticipated|2012-05-31|||||Interventional|||Long Term Follow up After 1 Year Initial Lifestyle Intervention|Effect of Four Years Intensive- Versus Regular Follow up, After a One Year Weight Loss Period, in Patients With Morbid Obesity.|Unknown status|Recruiting|N/A|100|Anticipated|Evjeklinikken|||||f||||t||||||||||2018-06-01 03:12:30.201501|2018-06-01 03:12:30.201501
NCT00477386|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|2014-09-19||2014-09-19|2007-05-21|2007-05-23|Estimate|2014-09-19|2014-09-25|Estimate||||2014-09-19|2014-09-25|Estimate|July 2007||2007-07-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|May 2011|Actual|2011-05-31||Interventional|||Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer|Phase I/II Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer|Completed||Phase 1/Phase 2|28|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 03:12:30.290043|2018-06-01 03:12:30.290043
NCT00477373|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2008-12-18|2007-05-22|2007-05-23|Estimate|||||||2008-12-18|2008-12-19|Estimate|December 2006||2006-12-31|December 2008|2008-12-31||||December 2007|Actual|2007-12-31||Interventional|GEVANS||Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study|Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study|Completed||Phase 4|70|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:12:30.790112|2018-06-01 03:12:30.790112
NCT00477360|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2011-08-10|2007-05-22|2007-05-23|Estimate|||||||2011-08-10|2011-08-11|Estimate|January 2007||2007-01-31|August 2011|2011-08-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|CAP||Humeral Resurfacing Hemiarthroplasty|Humeral Resurfacing Hemiarthroplasty. Phase 2: Prospective Cohort Study|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Calgary||1|||f||||f||||||||||2018-06-01 03:12:30.869108|2018-06-01 03:12:30.869108
NCT00477347|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2016-09-22|2007-05-22|2007-05-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Drone-TH||Closed-loop Anesthesia, Using Bispectral Index as the Control Variable, During Liver Transplantation|Comparison of Manual Propofol and Remifentanil Administration and Dual Closed-loop, Using Bispectral Index as the Control Variable, During Liver Transplantation|Terminated||Phase 4|5|Actual|Hopital Foch||2||lack of recrutment|f||||f||||||||||2018-06-01 03:12:30.948169|2018-06-01 03:12:30.948169
NCT00477334|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2010-12-15||2011-03-24|2007-05-22|2007-05-23|Estimate|2011-02-22|2011-03-16|Estimate||||2011-03-24|2011-03-28|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients|A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients|Completed||Phase 4|463|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:12:31.137194|2018-06-01 03:12:31.137194
NCT00477321|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2012-10-17|2007-05-22|2007-05-23|Estimate|||||||2012-10-17|2012-10-18|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Interventional|||Safety Study of IL-7 in HIV-infected Patients (Inspire)|A Ph I/IIa Rand Placebo Ctrl, S-Blind Multictr Dose-Esc Study of SC Intermittent Interleukin-7 CYT107 in Chronically HIV-Infected Pts With CD4 T Lymphocyte Counts 101-400 Cells-/mm(3) and Plasma HIV RNA Less Than 50 Copies/mL After at Least 12 M of HAART|Completed||Phase 1|30|Actual|Cytheris SA||1|||f||||t||||||||||2018-06-01 03:12:31.741935|2018-06-01 03:12:31.741935
NCT00477308|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2010-06-04|2007-05-22|2007-05-23|Estimate|||||||2010-06-04|2010-06-07|Estimate|January 2006||2006-01-31|June 2010|2010-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs|Clinical, Immunologic and Virological Outcomes of Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs|Completed||Phase 4|95|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||||f||||t||||||||||2018-06-01 03:12:31.844621|2018-06-01 03:12:31.844621
NCT00477295|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|2012-11-12||2015-12-21|2007-05-21|2007-05-23|Estimate|2013-02-06|2013-02-08|Estimate||||2015-12-21|2015-12-24|Estimate|May 2007||2007-05-31|November 2015|2015-11-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy|A Randomized, Multi-centre, Double-blind Study, to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy|Completed||Phase 3|583|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 03:12:31.960946|2018-06-01 03:12:31.960946
NCT00477282|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2017-09-19|2007-05-21|2007-05-23|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2007||2007-08-31|September 2017|2017-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer|A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer|Completed||Phase 3|509|Actual|BioNumerik Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 03:12:32.555553|2018-06-01 03:12:32.555553
NCT00477269|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|2015-01-26||2015-03-10|2007-05-22|2007-05-23|Estimate|2015-03-10|2015-03-23|Estimate||||2015-03-10|2015-03-23|Estimate|April 2006||2006-04-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)|Completed||Phase 2/Phase 3|59|Actual|Novartis||3|||f||||t||||||||||2018-06-01 03:12:32.746087|2018-06-01 03:12:32.746087
NCT00477256|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2012-07-27|2007-05-22|2007-05-23|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 2007||2007-05-31|July 2012|2012-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||School Reintegration Outcomes in Pediatric Cancer Patients|Psychosocial Predictors of Child Adjustment and School Reintegration Outcome in a Pediatric Cancer Population|Completed|||91|Actual|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-06-01 03:12:34.226599|2018-06-01 03:12:34.226599
NCT00477243|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2017-08-25|2007-05-22|2007-05-23|Estimate|||||||2017-08-25|2017-08-28|Actual|June 3, 2004|Actual|2004-06-03|August 2017|2017-08-31|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Observational|||Locus of Control and Spirituality in Palliative Care Patients|Locus of Control and Spirituality in Palliative Care Patients|Completed|||100|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-06-01 03:12:34.322474|2018-06-01 03:12:34.322474
NCT00477230|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|2012-06-26||2012-06-26|2007-05-21|2007-05-23|Estimate|2012-06-26|2012-06-27|Estimate||||2012-06-26|2012-06-27|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|ENABLE||Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs|Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic Atrial Fibrillation (AF)|Terminated||Phase 3|64|Actual|CardioFocus|This study was terminated early due to Sponsor decision. Therefore, full patient assignement to treatments post-randomziation did not occur. Results and other measures cannot be determined because most patients exited the study before completion.|2||Study terminated based on decision of Sponsor.|f||||t||||||||||2018-06-01 03:12:34.407397|2018-06-01 03:12:34.407397
NCT00477217|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-22|||2016-09-22|2007-05-22|2007-05-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee|A Randomized, Double-blind, Placebo-controlled, Proof of Concept Study of Zoledronic Acid in Spontaneous Osteonecrosis of the Knee (SONK)|Withdrawn||Phase 2|0|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:12:34.644714|2018-06-01 03:12:34.644714
NCT00477204|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|2013-01-23||2013-08-19|2007-05-21|2007-05-22|Estimate|2013-06-18|2013-06-21|Estimate||||2013-08-19|2013-08-28|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes|Clinical Trial of Zocor and Vytorin in Adolescents With Type 1 Diabetes|Completed||Phase 2|9|Actual|University of Colorado, Denver|Recruitment for this study failed to meet target and therefore it is difficult to make conclusions on the data obtained in these 9 subjects.|2|||f||||t||||||||||2018-06-01 03:12:34.737922|2018-06-01 03:12:34.737922
NCT00477009|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2013-01-17|2007-05-21|2007-05-22|Estimate|||||||2013-01-17|2013-01-18|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects From a Mandibular Repositioning Appliance in Patients With Obstructive Sleep Apnea and Snoring|A Randomized Controlled Trial of Effects From a Mandibular Advancement Device in Patients With Obstructive Sleep Apnea and Snoring|Completed||N/A|96|Actual|Umeå University||2|||f||||f||||||||||2018-06-01 03:12:36.664478|2018-06-01 03:12:36.664478
NCT00477191|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2015-09-16||2016-04-12|2007-05-18|2007-05-22|Estimate|2016-04-12|2016-05-16|Estimate||||2016-04-12|2016-05-16|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Psoriasis patients with MetS|Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis|Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis|Terminated||N/A|18|Actual|Massachusetts General Hospital|It was likely underpowered to detect small changes in laboratory and exam measures. Patients were only evaluated after a 6 month course of etanercept therapy.|1||Difficulty in recruitment.|f||||f||||||||||2018-06-01 03:12:34.976458|2018-06-01 03:12:34.976458
NCT00477178|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2011-08-09|2007-05-21|2007-05-22|Estimate|||||||2011-08-09|2011-08-10|Estimate|August 2004||2004-08-31|May 2007|2007-05-31|December 2005|Actual|2005-12-31|May 2005|Actual|2005-05-31||Observational|||The Effect of Codeine on Driving Abilities|The Effect of Codeine on Driving Abilities|Completed|||60|Actual|Norwegian University of Science and Technology|||3||f||||f||||||||||2018-06-01 03:12:35.170186|2018-06-01 03:12:35.170186
NCT00477165|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2015-04-10||2017-03-02|2007-05-21|2007-05-22|Estimate|2017-03-02|2017-04-17|Actual||||2017-03-02|2017-04-17|Actual|April 2001||2001-04-30|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Citalopram in Irritable Bowel Syndrome|Effect of Citalopram on Clinical Symptoms and Visceral Sensitivity in Patients With Irritable Bowel Syndrome|Completed||Phase 2|54|Actual|Stanford University|Results have been entered as available in the published manuscript; the PI is no longer at UCSF. This trial has the limitation of relatively small sample size. A potential limitation is that patients could have been unblinded based on side effects.|2|||f||||f||||||||||2018-06-01 03:12:35.233599|2018-06-01 03:12:35.233599
NCT00477152|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2011-09-12||2011-11-22|2007-05-18|2007-05-22|Estimate|2011-10-18|2011-11-23|Estimate||||2011-11-22|2011-12-01|Estimate|August 2007||2007-08-31|November 2011|2011-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|INFUSE-PR||Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children|INcreased Flow Utilizing Subcutaneously-Enabled Pediatric Rehydration (INFUSE-Pediatric Rehydration Study): Phase IV Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase (HYLENEX) for Infants and Children|Completed||Phase 4|52|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-06-01 03:12:35.506968|2018-06-01 03:12:35.506968
NCT00477139|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2011-04-11|2007-05-18|2007-05-22|Estimate|||||||2011-04-11|2011-04-13|Estimate|January 2009||2009-01-31|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer|A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer|Completed|||4|Actual|Stanford University|||||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 03:12:35.665618|2018-06-01 03:12:35.665618
NCT00477126|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2012-04-03|2007-05-21|2007-05-22|Estimate|||||||2012-04-03|2012-04-05|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Bioequivalence Study of Generic GPO Ritonavir Versus Norvir®|Bioequivalence Study of Generic GPO Ritonavir Versus Norvir® in Thai Healthy Volunteers|Completed||Phase 1|16|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-06-01 03:12:35.727798|2018-06-01 03:12:35.727798
NCT00477113|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2015-06-18|2007-05-21|2007-05-22|Estimate|||||||2015-06-18|2015-06-22|Estimate|January 2007||2007-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|TYGRIS||TYSABRI Global Observational Program in Safety|TYGRIS: TYSABRI® Global Observational Program in Safety|Completed|||2207|Actual|Biogen|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-06-01 03:12:35.789122|2018-06-01 03:12:35.789122
NCT00477100|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2018-03-05|2007-05-18|2007-05-22|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2007|Actual|2007-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|||Inflammatory Breast Cancer (IBC) Registry|Inflammatory Breast Cancer (IBC) Registry|Recruiting|||1200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples Without DNA|"~     The collection of serum and plasma from patients with inflammatory breast cancer.~   "|||2018-06-01 03:12:35.838511|2018-06-01 03:12:35.838511
NCT00477087|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2017-05-10||2017-10-23|2007-05-18|2007-05-22|Estimate|2017-10-23|2017-11-29|Actual||||2017-10-23|2017-11-29|Actual|July 2006||2006-07-31|October 2017|2017-10-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer|Phase II Study of Granulocyte-Macrophage Colony Stimulating Factor Plus Mitoxantrone for the Treatment of Hormone Refractory Prostate Cancer|Terminated||Phase 2|10|Actual|Stanford University||1||Low accrual|f||||t|t|f|||f|||No||2018-06-01 03:12:36.024253|2018-06-01 03:12:36.024253
NCT00477074|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2007-05-18|2007-05-18|2007-05-22|Estimate|||||||2007-05-18|2007-05-22|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|December 2005|Actual|2005-12-31|||||Observational|||Pulmonary and Systemic Hepatocyte Growth Factors in Patients With COPD|Pulmonary and Systemic Hepatocyte Anb Keratinocyte Growth Factors in Patients With Chronic Obstructive Pulmonary Disease|Completed|||44|Actual|Hospital Universitari Son Dureta|||||f||||f||||||||||2018-06-01 03:12:36.215447|2018-06-01 03:12:36.215447
NCT00477061|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2007-05-20|2007-05-20|2007-05-22|Estimate|||||||2007-05-20|2007-05-22|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|March 2005|Actual|2005-03-31|||||Interventional|||Morphine Analgesia in Patients With Acute Appendicitis|Double Blind Randomized Study of Morphine Analgesia in Patients With Acute Appendicitis|Completed||Phase 4|71|Actual|Tehran University of Medical Sciences|||||f||||f||||||||||2018-06-01 03:12:36.286869|2018-06-01 03:12:36.286869
NCT00477048|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2016-02-18|2007-05-21|2007-05-22|Estimate|||||||2016-02-18|2016-02-22|Estimate|May 2004||2004-05-31|February 2016|2016-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity|Efficacy and Safety of a Saquinavir Based Regimen in HIV-1 Infected Thai Patients Who Have Chronic IDV Associated Nephrotoxicity.|Completed||Phase 2|30|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||t||||||||||2018-06-01 03:12:36.352787|2018-06-01 03:12:36.352787
NCT00477035|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2017-01-09|2007-05-18|2007-05-22|Estimate|||||||2017-01-09|2017-01-11|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies|A Phase I Study of Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for the Treatment of High-risk Hematologic Malignancies|Completed||Phase 1|22|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 03:12:36.414998|2018-06-01 03:12:36.414998
NCT00477022|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2007-05-22|2007-05-21|2007-05-22|Estimate|||||||2007-05-22|2007-05-25|Estimate|February 2006||2006-02-28|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Interventional|VCT||The Effects of Vacuum-Compression Therapy on the Healing of Diabetic Foot Ulcers||Completed||N/A|20|Actual|Zahedan University of Medical Sciences|||||f||||f||||||||||2018-06-01 03:12:36.563987|2018-06-01 03:12:36.563987
NCT00476996|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18||2013-08-20|2018-05-16|2007-05-18|2007-05-22|Estimate||||2013-08-20|2013-08-28|Estimate|2018-05-16|2018-05-18|Actual|May 15, 2007|Actual|2007-05-15|May 2018|2018-05-31|October 20, 2018|Anticipated|2018-10-20|January 21, 2010|Actual|2010-01-21||Interventional|SCRIPT||A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)|A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One Anti-TNF-α Therapy|Active, not recruiting||Phase 3|840|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 03:12:36.757268|2018-06-01 03:12:36.757268
NCT00476983|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2015-03-27|2007-05-20|2007-05-22|Estimate|||||||2015-03-27|2015-03-30|Estimate||||March 2015|2015-03-31||||||||Interventional|||Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg|Pharmacokinetic and Efficacy of Saquinavir Mesylate Film Coated Tablet / Ritonavir 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg Once Daily in HIV Pretreated Patients|Withdrawn||Phase 2/Phase 3|0|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1||No funding|f||||t||||||||||2018-06-01 03:12:36.84252|2018-06-01 03:12:36.84252
NCT00476970|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2016-09-20|2007-05-21|2007-05-22|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2007||2007-09-30|September 2016|2016-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Colorectal Cancer Screening Navigator Program for Low Income and Non-English Speaking Populations|Improving Colorectal Cancer Screening Rates by Lowering Barriers in Low Income and Non-English Speaking Populations: The Chelsea Colorectal Cancer Screening Project|Completed||N/A|1223|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-06-01 03:12:36.914264|2018-06-01 03:12:36.914264
NCT00476957|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|2013-09-17||2014-11-03|2007-05-21|2007-05-22|Estimate|2014-02-03|2014-03-17|Estimate||||2014-11-03|2014-11-10|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|May 2012|Actual|2012-05-31||Interventional|PROTECT|Intention to treat analysis has been used.|Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)|PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial|Completed||Phase 4|8709|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-06-01 03:12:37.028486|2018-06-01 03:12:37.028486
NCT00476944|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2007-05-18|2007-05-18|2007-05-22|Estimate|||||||2007-05-18|2007-05-22|Estimate|September 2006||2006-09-30|May 2007|2007-05-31||||||||Interventional|||Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI|Minimizing Post-Procedural Vascular Complications: Comparing Bivalirudin Versus Heparin/GP IIB/IIA in Patients Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 4|||Gold, Herman K., MD|||||||||||||||||||2018-06-01 03:12:37.424563|2018-06-01 03:12:37.424563
NCT00476931|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18||2012-10-30|2012-10-30|2007-05-18|2007-05-22|Estimate||||2012-10-30|2012-11-01|Estimate|2012-10-30|2012-11-01|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy|A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity|Completed||Phase 2|91|Actual|Sangamo Therapeutics||2|||f||||f||||||||||2018-06-01 03:12:37.542005|2018-06-01 03:12:37.542005
NCT00476918|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2007-05-21|2007-05-21|2007-05-22|Estimate|||||||2007-05-21|2007-05-22|Estimate|July 2006||2006-07-31|May 2007|2007-05-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema|Dosage Dependency of Intravitreal Triamcinolone Acetonide for Treatment of Diabetic Macular Edema|Unknown status|Recruiting|Phase 1|60|Anticipated|Heidelberg University|||||f||||t||||||||||2018-06-01 03:12:37.659108|2018-06-01 03:12:37.659108
NCT00476905|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2017-05-30|2007-05-21|2007-05-22|Estimate|||||||2017-05-30|2017-06-01|Actual|April 2007|Actual|2007-04-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Spectral Diagnosis of Cutaneous Malignancy|Spectral Diagnosis of Cutaneous Malignancy|Active, not recruiting|||350|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:12:37.734475|2018-06-01 03:12:37.734475
NCT00476892|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2011-03-22|2007-05-18|2007-05-22|Estimate|||||||2011-03-22|2011-03-23|Estimate|June 2007||2007-06-30|February 2010|2010-02-28|March 2011|Actual|2011-03-31|July 2010|Actual|2010-07-31||Interventional|POPPY||Multi-centre Randomised Controlled Trial of Pelvic Floor Muscle Training for Prolapse|A Multi-centre Randomised Controlled Trial of a Pelvic Floor Muscle Training Intervention for Women With Pelvic Organ Prolapse|Completed||N/A|448|Actual|Glasgow Caledonian University||2|||f||||t||||||||||2018-06-01 03:12:37.817683|2018-06-01 03:12:37.817683
NCT00476879|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2008-08-11|2007-05-21|2007-05-22|Estimate|||||||2008-08-11|2008-08-12|Estimate|August 2006||2006-08-31|August 2008|2008-08-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content|Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning|Completed||N/A|10|Actual|University of Aarhus||4|||f||||f||||||||||2018-06-01 03:12:37.928334|2018-06-01 03:12:37.928334
NCT00476866|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2007-05-21|2007-05-21|2007-05-22|Estimate|||||||2007-05-21|2007-05-22|Estimate|December 2002||2002-12-31|May 2007|2007-05-31|March 2005|Actual|2005-03-31|||||Interventional|||Intermittent Positive-Pressure Breathing Effects in Patients With High Spinal Cord Injury|Intermittent Positive-Pressure Breathing Effects in Patients With High Spinal Cord Injury|Terminated||N/A|14|Actual|University of Versailles||||The number of patients desired has been reached|f||||f||||||||||2018-06-01 03:12:37.998788|2018-06-01 03:12:37.998788
NCT00476853|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2010-06-04|2007-05-21|2007-05-22|Estimate|||||||2010-06-04|2010-06-07|Estimate|October 2005||2005-10-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy|A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Antituberculous Therapy|Completed||Phase 2|42|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-06-01 03:12:38.06963|2018-06-01 03:12:38.06963
NCT00476827|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2012-12-10||2013-07-15|2007-05-21|2007-05-22|Estimate|2013-07-15|2013-07-17|Estimate||||2013-07-15|2013-07-17|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain|A Phase II Safety and Tolerability Study of Avastin When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain|Terminated||Phase 2|16|Actual|Duke University||6||Slow accrual|f||||f||||||||||2018-06-01 03:12:38.171283|2018-06-01 03:12:38.171283
NCT00476814|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2007-10-30|2007-05-21|2007-05-22|Estimate|||||||2007-10-30|2007-10-31|Estimate||||October 2007|2007-10-31||||||||Observational|||NPD Measurements in PSC Patients|Cystic Fibrosis Transmembrane Conductance Regulator Function as Measured by Nasal Potential Difference Measurements in Patients With Primary Sclerosing Cholangitis|Unknown status|Not yet recruiting||||Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:12:38.830396|2018-06-01 03:12:38.830396
NCT00476801|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2015-07-08|2007-05-18|2007-05-22|Estimate|||||||2015-07-08|2015-07-10|Estimate|July 2001||2001-07-31|July 2015|2015-07-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||UVA1 Light for Treatment of Scleroderma and Similar Conditions|The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study|Completed||N/A|27|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 03:12:38.892813|2018-06-01 03:12:38.892813
NCT00476788|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2010-10-12||2017-03-20|2007-05-18|2007-05-22|Estimate|2010-12-20|2011-01-24|Estimate||||2017-03-20|2017-04-17|Actual|April 2007||2007-04-30|March 2017|2017-03-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM|Fast Track Continuous Subcutaneous Insulin Infusion (CSII) in Children With Newly Diagnosed Type 1 Diabetes Mellitus: An Evaluation of a Novel CSII Device in the Immediate Period Following Diagnosis of Type 1 Diabetes (T1DM)|Completed||N/A|14|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 03:12:38.960066|2018-06-01 03:12:38.960066
NCT00476775|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2012-12-12|2007-05-18|2007-05-22|Estimate|||||||2012-12-12|2012-12-17|Estimate|May 2007||2007-05-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|March 2011|Actual|2011-03-31||Interventional|ECHALE||Ethnic Dance and Screen Time Reduction to Prevent Weight Gain in Latina Girls|Ethnic Dance and Screen Time Reduction to Prevent Weight Gain in Latina Girls|Completed||N/A|233|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 03:12:39.115065|2018-06-01 03:12:39.115065
NCT00476736|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2007-05-21|2007-05-21|2007-05-22|Estimate|||||||2007-05-21|2007-05-22|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|May 2007|Anticipated|2007-05-31|||||Interventional|NAC||The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise|Reassessment Study of The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise|Unknown status|Recruiting|Phase 4|30|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:12:39.206489|2018-06-01 03:12:39.206489
NCT00476723|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2010-06-04|2007-05-20|2007-05-22|Estimate|||||||2010-06-04|2010-06-07|Estimate|April 2005||2005-04-30|June 2010|2010-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection|Generation of HBV-specific T-cell Immunity in Individuals With HIV/HBV Co-infection Receiving HBV-active Antiretroviral Therapy|Completed|||36|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||t||||||Samples With DNA|"~     PBMC~   "|||2018-06-01 03:12:39.301413|2018-06-01 03:12:39.301413
NCT00476710|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2015-03-30|2007-05-18|2007-05-22|Estimate|||||||2015-03-30|2015-04-01|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Effects of Colesevelam HCl On Bile Acid Kinetics|Effects of Colesevelam HCl On Bile Acid Pools And Kinetic Parameters in Normal Subjects, Subjects With Impaired Glucose Tolerance, And Subjects With Type 2 Diabetes Mellitus|Completed|||36|Actual|KineMed|||3||f||||f||||||||||2018-06-01 03:12:39.358743|2018-06-01 03:12:39.358743
NCT00476697|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2015-07-24|2007-05-18|2007-05-22|Estimate|||||||2015-07-24|2015-07-27|Estimate|January 1997||1997-01-31|July 2015|2015-07-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||UVA1 Light for Scleroderma and Similar Conditions|The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study|Terminated||N/A|23|Actual|University of Michigan||1||inactivity|f||||f||||||||||2018-06-01 03:12:39.439571|2018-06-01 03:12:39.439571
NCT00476684|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2017-08-17|2007-05-21|2007-05-22|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2004|Actual|2004-08-31|August 2017|2017-08-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||The Effect of Radiofrequency-treatment on Patients With Facet-joint Pain in Cervical- and Lumbar-columna|The Effect of Radiofrequency-treatment on Patients With Facet-joint Pain in Cervical- and Lumbar-columna|Completed||N/A|28|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 03:12:39.526236|2018-06-01 03:12:39.526236
NCT00476671|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2008-10-19|2007-05-21|2007-05-22|Estimate|||||||2008-10-19|2008-10-21|Estimate|March 2007||2007-03-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Observational|||Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1|Prevalence and Risk Factors of HIV-Associated Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1 Infected Thai Individuals With Undetectable Viral Load in the HAART Era.|Completed|||100|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||t||||||Samples Without DNA|"~     PBMC and plasma~   "|||2018-06-01 03:12:39.58724|2018-06-01 03:12:39.58724
NCT00476658|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2011-12-06|2007-05-21|2007-05-22|Estimate|||||||2011-12-06|2011-12-07|Estimate|January 2007||2007-01-31|May 2007|2007-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Macrophage Infiltration in Human Adipose Tissue|Characterisation of Macrophage Infiltration in Obesity and Its Complications|Completed|||200|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     adipose tissue, visceral adipose tissue, muscle, liver, bowel and stomach~   "|||2018-06-01 03:12:39.650762|2018-06-01 03:12:39.650762
NCT00476645|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2014-06-30||2014-08-04|2007-05-18|2007-05-22|Estimate|2014-08-04|2014-08-05|Estimate||||2014-08-04|2014-08-05|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional||All participants were included in the analysis|Fulvestrant in Hormone Refractory Prostate Cancer|Fulvestrant in Hormone-refractory Prostate Cancer|Completed||Phase 2|10|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 03:12:39.724177|2018-06-01 03:12:39.724177
NCT00476632|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2017-10-04|2007-05-21|2007-05-22|Estimate|||||||2017-10-04|2017-10-05|Actual|June 2004|Actual|2004-06-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Epidemiology Controls Using Healthy Participants|Epidemiology Controls Using Healthy Participants|Active, not recruiting|||1500|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     2 ½ tablespoons of blood drawn.~   "|||2018-06-01 03:12:40.93914|2018-06-01 03:12:40.93914
NCT00476619|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2009-04-02|2007-05-21|2007-05-22|Estimate|||||||2009-04-02|2009-04-06|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|ERIN||Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial|Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial|Terminated||Phase 4|17|Actual|Brigham and Women's Hospital||1||The exclusion criteria were stringent and enrollment was slow.|f||||t||||||||||2018-06-01 03:12:41.0303|2018-06-01 03:12:41.0303
NCT00476606|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2017-02-22|2007-05-21|2007-05-22|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2003||2003-03-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||A Prospective Cohort of Children With HIV Infection|Treatment Outcome of Children With HIV Infection|Recruiting|||1000|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||t||||||Samples With DNA|"~     PBMC~   "|||2018-06-01 03:12:41.288608|2018-06-01 03:12:41.288608
NCT00029744|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-21|||2012-10-29|2002-01-21|2002-01-22|Estimate|||||||2012-10-29|2012-10-31|Estimate|April 2003||2003-04-30|October 2012|2012-10-31|May 2007|Actual|2007-05-31|||||Observational|||A Study to Prepare for Future HIV Vaccine Studies|An HIV Vaccine Preparedness Study|Completed|||||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:37.247915|2018-06-01 05:33:37.247915
NCT00476593|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|2011-05-24||2017-03-28|2007-05-21|2007-05-22|Estimate|2011-05-27|2011-06-22|Estimate||||2017-03-28|2017-05-01|Actual|September 2005|Actual|2005-09-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications|Retinal Optical Coherence Tomography and Multifocal Electroretinogram; Establishing Normal Ranges Related to Age and Reproductive Factors; With the Use of Anti-inflammatory Medications;In Uncomplicated Anterior Uveitis; Anatomy and Function.|Completed||N/A|218|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-06-01 03:12:41.450448|2018-06-01 03:12:41.450448
NCT00476580|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2015-08-27|2007-05-21|2007-05-22|Estimate|||||||2015-08-27|2015-08-28|Estimate|April 2007||2007-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Health Habits and Cancer Risk Comparison Among Migrant Sri Lankans and Sri Lankans|Health Habits and Cancer Risk Among a US Migrant Sri Lankan Population and a Comparison With Siblings Living in Sri Lanka|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||2|Study terminated.|f||||f||||||||||2018-06-01 03:12:41.866853|2018-06-01 03:12:41.866853
NCT00476567|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2015-08-18|2007-05-21|2007-05-22|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Regular Exercise During Pregnancy|Training During Pregnancy - Effects of Regular Exercise During Pregnancy in Prevention of Pregnancy-related Diseases and Complications During Labour. A Randomised Clinical Trial|Completed||N/A|855|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 03:12:42.088817|2018-06-01 03:12:42.088817
NCT00476554|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-19|||2011-11-07|2007-05-19|2007-05-22|Estimate|||||||2011-11-07|2011-11-09|Estimate|April 2007||2007-04-30|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma||Terminated||Phase 2|32|Anticipated|Cyclacel Pharmaceuticals, Inc.||2||slow accrual and financial resource limitation|f||||||||||||||2018-06-01 03:12:42.196706|2018-06-01 03:12:42.196706
NCT00476541|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2016-05-12|2007-05-21|2007-05-22|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2004||2004-01-31|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia|NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia|Completed||Phase 3|250|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 03:12:42.309276|2018-06-01 03:12:42.309276
NCT00476528|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2010-08-09|2007-05-21|2007-05-22|Estimate|||||||2010-08-09|2010-08-10|Estimate|September 2007||2007-09-30|August 2010|2010-08-31|September 2010|Anticipated|2010-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Early Rehabilitation of Patients With Posttraumatic Amnesia|Early Rehabilitation of Patients With Posttraumatic Amnesia. A Clinical Controlled Investigation of the Effect of a Nursing Programme in Patients With Traumatic Brain Injury in the Acute Care|Unknown status|Active, not recruiting|N/A|62|Anticipated|University of Aarhus|||||f||||t||||||||||2018-06-01 03:12:42.394925|2018-06-01 03:12:42.394925
NCT00476515|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2008-02-15|2007-05-21|2007-05-22|Estimate|||||||2008-02-15|2008-02-25|Estimate|March 2007||2007-03-31|February 2008|2008-02-29|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Rituximab Therapy for Patients on Kidney Transplant Waiting List With Positive Donor Specific Crossmatch to Living Donor|Multicenter Trial Using Multi-Dose Rituximab as Induction and Desensitization Therapy for Patients on the Waiting List for Kidney Transplant With a Positive Donor Specific Crossmatch to a Living Donor|Completed||Phase 1|0|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:12:42.462147|2018-06-01 03:12:42.462147
NCT00476502|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2012-04-03|2007-05-21|2007-05-22|Estimate|||||||2012-04-03|2012-04-05|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r|Study of Genetic Polymorphisms of CYP 3A and MDR-1 Genes in Thai HIV-1 Infected Patients on Saquinavir/Ritonavir|Completed|||250|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||t||||||Samples With DNA|"~     PBMC~   "|||2018-06-01 03:12:42.578602|2018-06-01 03:12:42.578602
NCT00476489|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2007-05-21|2007-05-21|2007-05-22|Estimate|||||||2007-05-21|2007-05-22|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Observational|||Does Topical Steroid Treatment Impair the Adrenal Function?|Low Dose (1mcg) ACTH Stimulation Test for Assessment of the Hypothalamo-Pituitary- Adrenal Axis in Patients Treated With Topical Corticosteroids|Unknown status|Recruiting||50|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:12:42.653026|2018-06-01 03:12:42.653026
NCT00476476|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2015-03-08||2015-04-13|2007-05-21|2007-05-22|Estimate|2015-03-08|2015-03-19|Estimate||||2015-04-13|2015-05-07|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||The analysis population is comprised of all enrolled patients.|Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar|A Phase II Trial of Tarceva (Erlotinib) in Women With Squamous Cell Carcinoma of the Vulvar|Completed||Phase 2|41|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:12:42.755562|2018-06-01 03:12:42.755562
NCT00476463|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2016-02-18|2007-05-21|2007-05-22|Estimate|||||||2016-02-18|2016-02-22|Estimate|April 2005||2005-04-30|February 2016|2016-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection|Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naive Patients With HIV/HBV Co-infection|Completed||Phase 2|24|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-06-01 03:12:43.14407|2018-06-01 03:12:43.14407
NCT00476450|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-19|||2017-10-05|2007-05-19|2007-05-22|Estimate|||||||2017-10-05|2017-10-06|Actual|May 16, 2007||2007-05-16|March 7, 2016|2016-03-07|March 7, 2016||2016-03-07|||||Observational|||Effects of Stem Cell Transplantation on Bacteria in the Mouth|Effects of Peripheral Blood Stem Cell Transplantation on the Microbial Flora of the Oral Cavity|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:12:43.22713|2018-06-01 03:12:43.22713
NCT00476437|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2014-11-03|2007-05-21|2007-05-22|Estimate|||||||2014-11-03|2014-11-04|Estimate|April 2007||2007-04-30|November 2014|2014-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.|Safety and Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Human Insulin 50 in Patients With Type 2 Diabetes Mellitus.|Completed||Phase 3|81|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:12:43.278435|2018-06-01 03:12:43.278435
NCT00476424|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2010-06-04|2007-05-21|2007-05-22|Estimate|||||||2010-06-04|2010-06-07|Estimate|June 2007||2007-06-30|June 2010|2010-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects|A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects|Completed||Phase 2|28|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-06-01 03:12:43.337788|2018-06-01 03:12:43.337788
NCT00476411|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2010-06-04|2007-05-21|2007-05-22|Estimate|||||||2010-06-04|2010-06-07|Estimate|December 2006||2006-12-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||A Study to Test the Efficacy of the HBV Vaccine and to Look at the Prevalence of HBV Infection|The Efficacy of HBV Vaccine Response and Prevalence of Occult HBV Infection in Isolated Anti HBc Between HIV Infected and HIV Un-infected Thai Patients|Completed||N/A|200|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||t||||||||||2018-06-01 03:12:43.505754|2018-06-01 03:12:43.505754
NCT00476398|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2009-09-08|2007-05-21|2007-05-22|Estimate|||||||2009-09-08|2009-09-10|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluation of Patients With Non-cardiac Chest Pain|Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus.|Completed||Phase 4|40|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-06-01 03:12:43.578411|2018-06-01 03:12:43.578411
NCT00476385|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2009-02-11|2007-05-21|2007-05-22|Estimate|||||||2009-02-11|2009-02-12|Estimate|June 2003||2003-06-30|February 2009|2009-02-28||||December 2005|Actual|2005-12-31||Interventional|||Practicability and Acceptability of Stylomax® in Children|Usability and Acceptability of Stylomax® in Growth Hormone Deficient Children.|Completed||Phase 3|12|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:12:43.649069|2018-06-01 03:12:43.649069
NCT00476372|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2013-01-11|2007-05-21|2007-05-22|Estimate|||||||2013-01-11|2013-01-14|Estimate|August 2007||2007-08-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Cognitive Impairment in Parkinson's Disease Categorised in Accordance to Motor Symptoms|Cognitive Impairment in Parkinson's Disease Categorised in Accordance to Motor Symptoms -the Relation Between Cognitive Deficits and Comorbid Psychiatric Disorders, Medication, and Age at Disease Onset|Completed|||107|Actual|University of Aarhus|||1||f||||f||||||||||2018-06-01 03:12:43.743486|2018-06-01 03:12:43.743486
NCT00476359|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-20|||2015-03-26|2007-05-21|2007-05-22|Estimate|||||||2015-03-26|2015-03-27|Estimate|October 2003||2003-10-31|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A PK and Salvage Study for Children With HIV-infection|Lopinavir/r Plus Saquinavir Salvage Therapy in HIV-infected Children With NRTI and/or NNRTI Failure: PK and Two-year Treatment Follow up|Completed||Phase 4|50|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||t||||||||||2018-06-01 03:12:43.815951|2018-06-01 03:12:43.815951
NCT00476346|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2015-03-24|2007-05-21|2007-05-22|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2002||2002-05-31|August 2008|2008-08-31|March 2006|Actual|2006-03-31|||||Interventional|||Calcium and Vitamin D Supplementation Decreases Incidence of Stress Fractures in Female Navy Recruits|Calcium and Vitamin D Supplementation Decreases Incidence of Stress Fractures in Female Navy Recruits|Completed||N/A|5201|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 03:12:43.902669|2018-06-01 03:12:43.902669
NCT00476333|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-19|||2007-05-21|2007-05-21|2007-05-22|Estimate|||||||2007-05-21|2007-05-22|Estimate||||April 2007|2007-04-30||||||||Interventional|||The Effect of Custom-Made Biomechanical Perturbation Platform on Kinetics, Kinematics and Electromyography in Healthy Subjects||Unknown status|Recruiting|N/A|||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:12:43.99053|2018-06-01 03:12:43.99053
NCT00476320|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2007-05-21|2007-05-21|2007-05-22|Estimate|||||||2007-05-21|2007-05-22|Estimate|August 2004||2004-08-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Observational|||The Use of Myocardial Deformation Imaging|The Use of Myocardial Deformation Imaging Based on Ultrasonic Pixel Tracking to Identify Reversible Myocardial Dysfunction|Completed|||||RWTH Aachen University|||||f||||f||||||||||2018-06-01 03:12:44.083573|2018-06-01 03:12:44.083573
NCT00476307|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-21|||2016-11-02|2007-05-21|2007-05-22|Estimate|||||||2016-11-02|2016-11-04|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People Aged 18 Years or Above|Completed||Phase 3|120|Anticipated|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:12:44.15193|2018-06-01 03:12:44.15193
NCT00476294|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2012-07-10|2007-05-18|2007-05-21|Estimate|||||||2012-07-10|2012-07-11|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Long-Term Follow Up Study for AMD3100 Patients|Long-Term Observational Follow-Up Study of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 MCG/KG) Plus G-CSF (10 MCG/KG) Versus G-CSF (10 MCG/KG) Plus Placebo to Mobilize and Collect >/= 6 x 10^6 CD34+ Cells/KG in Multiple Myeloma Patients for Autologous Transplantation|Completed|||7|Actual|M.D. Anderson Cancer Center|||2||f||||t||||||||||2018-06-01 03:12:44.229395|2018-06-01 03:12:44.229395
NCT00476281|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2016-04-08|2007-05-18|2007-05-21|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2008||2008-04-30|March 2016|2016-03-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Nutritional, Metabolic and Respiratory Status in Cystic Fibrosis|Multicenter Prospective Study of Abnormalies Tolerance Glucose by the Continuous Measurement of Glucose of Nutritional Status and Breathing in the Patient With Cystic Fibrosis|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||1|||f||||||||||||||2018-06-01 03:12:44.34753|2018-06-01 03:12:44.34753
NCT00476268|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2012-04-02|2007-05-18|2007-05-21|Estimate|||||||2012-04-02|2012-04-03|Estimate|February 2004||2004-02-29|April 2012|2012-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma|A 24-week Phase III Study to Evaluate the Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler HFA 134a-pMDI in Adult Patients With Moderate to Severe Persistent Asthma|Completed||Phase 3|824|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-06-01 03:12:44.455611|2018-06-01 03:12:44.455611
NCT00476255|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2014-11-05|2007-05-18|2007-05-21|Estimate|||||||2014-11-05|2014-11-07|Estimate|December 2011||2011-12-31|April 2010|2010-04-30||||November 2014|Actual|2014-11-30||Interventional|||Evaluating Models for Dissemination of Injury Prevention Information in the Pediatric Emergency Department Setting|Evaluating Models for Dissemination of Injury Prevention Information in the PED|Withdrawn||N/A|0|Actual|Rhode Island Hospital||2||Unfunded|f||||t||||||||||2018-06-01 03:12:44.539538|2018-06-01 03:12:44.539538
NCT00476242|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2014-04-09||2014-06-04|2007-05-18|2007-05-21|Estimate|2014-06-04|2014-07-04|Estimate||||2014-06-04|2014-07-04|Estimate|June 2008||2008-06-30|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|NAMHS||Memantine as a Supplement to Naltrexone in Treating Heroin Dependence|Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence|Completed||Phase 2/Phase 3|82|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 03:12:44.633812|2018-06-01 03:12:44.633812
NCT00476229|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2011-07-13||2012-08-01|2007-05-18|2007-05-21|Estimate|2011-07-13|2011-08-09|Estimate||||2012-08-01|2012-08-07|Estimate|June 2006||2006-06-30|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies|Total Lymphoid Irradiation, Thymoglobulin, and Rituximab for Allogeneic Transplantation in Lymphoid Malignancies|Completed||N/A|20|Actual|M.D. Anderson Cancer Center|Early termination due to financial support.|1|||f||||f||||||||||2018-06-01 03:12:44.879452|2018-06-01 03:12:44.879452
NCT00476216|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2014-03-03|2007-05-18|2007-05-21|Estimate|||||||2014-03-03|2014-03-05|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer|Phase I Feasibility Study of the Combination of Fondaparinux (Arixtra) With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|23|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 03:12:45.04061|2018-06-01 03:12:45.04061
NCT00476203|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2012-11-27|2007-05-17|2007-05-21|Estimate|||||||2012-11-27|2012-11-28|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|Yoga||Yoga Study in Breast Cancer Patients|Effect of Yoga on Weight and Fatigue in Breast Cancer Patients Study|Completed||N/A|63|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-06-01 03:12:45.153864|2018-06-01 03:12:45.153864
NCT00476190|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2017-10-06|2007-05-18|2007-05-21|Estimate|||||||2017-10-06|2017-10-09|Actual|April 2007||2007-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||ALL Adult Consortium Trial: Adult ALL Trial|ALL Adult Consortium Trial: Adult ALL Trial|Active, not recruiting||Phase 2|112|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 03:12:45.233664|2018-06-01 03:12:45.233664
NCT00476177|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2012-03-28|2007-05-18|2007-05-21|Estimate|||||||2012-03-28|2012-03-29|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|July 2009|Actual|2009-07-31|August 2007|Actual|2007-08-31||Interventional|||Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant|Infusion of Donor Dendritic Cells and Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogenic Transplant|Completed||Phase 1|25|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 03:12:45.449376|2018-06-01 03:12:45.449376
NCT00476164|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2017-08-15|2007-05-18|2007-05-21|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2007||2007-01-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|May 2015|Actual|2015-05-31||Interventional|RituxiCAN-C4||Study of Rituximab to Treat Chronic Renal Transplant Rejection|Randomised Trial of Anti-Cd20 in C4d+ Chronic Allograft Nephropathy|Completed||Phase 4|62|Actual|King's College London||2|||f||||t||||||||||2018-06-01 03:12:45.539072|2018-06-01 03:12:45.539072
NCT00476151|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2010-09-28||2011-04-19|2007-05-18|2007-05-21|Estimate|2011-04-19|2011-05-17|Estimate||||2011-04-19|2011-05-17|Estimate|July 2007||2007-07-31|April 2011|2011-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of EpiCept™ NP-1 Topical Cream in Patients With Pain From Diabetic Peripheral Neuropathy (DPN)|Completed||Phase 2|226|Actual|EpiCept Corporation||2|||f||||f||||||||||2018-06-01 03:12:45.650672|2018-06-01 03:12:45.650672
NCT00476138|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2007-05-18|2007-05-18|2007-05-21|Estimate|||||||2007-05-18|2007-05-21|Estimate|November 2006||2006-11-30|May 2007|2007-05-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma|Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Catholic University of the Sacred Heart|||||f||||t||||||||||2018-06-01 03:12:45.98694|2018-06-01 03:12:45.98694
NCT00476125|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2017-12-11|2007-05-18|2007-05-21|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2008|Actual|2008-03-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Effects of Dietary Manipulation on Metabolism in Healthy Adults|Effects of Dietary Manipulation on Metabolism in Healthy Adults|Active, not recruiting||N/A|20|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||f||||||||||2018-06-01 03:12:46.104832|2018-06-01 03:12:46.104832
NCT00476112|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2008-03-31|2007-05-18|2007-05-21|Estimate|||||||2008-03-31|2008-04-02|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|Scene 2||A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter|A Phase II/III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter|Completed||Phase 2/Phase 3|60|Actual|Cardiome Pharma||1|||f||||t||||||||||2018-06-01 03:12:46.191054|2018-06-01 03:12:46.191054
NCT00476099|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2017-03-28|2007-05-18|2007-05-21|Estimate|||||||2017-03-28|2017-03-30|Actual|December 2006||2006-12-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD|"A 48-week, Double Blind, Double Dummy, Randomised, Multinational, Multicentre, 3-arm Parallel Group Clinical Study of Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant Versus Fixed Combination Budesonide Plus Formoterol DPI Versus Formoterol DPI in Patients With Stable Severe Chronic Obstructive Pulmonary Disease (COPD)"|Completed||Phase 3|828|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||t||||||||||2018-06-01 03:12:46.323743|2018-06-01 03:12:46.323743
NCT00476086|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2016-03-10||2017-05-04|2007-05-17|2007-05-21|Estimate|2016-03-10|2016-04-13|Estimate||||2017-05-04|2017-06-05|Actual|August 2006||2006-08-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|March 2012|Actual|2012-03-31||Interventional||The baseline population is comprised of all enrolled patients.|Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus|A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus|Completed||Phase 2|20|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 03:12:46.418837|2018-06-01 03:12:46.418837
NCT00476073|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2016-02-08|2007-05-18|2007-05-21|Estimate|||||||2016-02-08|2016-02-09|Estimate|April 2007||2007-04-30|February 2016|2016-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma||Completed||Phase 3|228|Actual|Mundipharma Research Limited|||||f||||f||||||||||2018-06-01 03:12:46.686422|2018-06-01 03:12:46.686422
NCT00476060|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2011-01-10|2007-05-18|2007-05-21|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|August 2011|Anticipated|2011-08-31|August 2011|Anticipated|2011-08-31||Interventional|||Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis|Autologous Mesenchymal Stem Cell Transplantation in Patients With Decompensated Cirrhosis: A Randomized Placebo-controlled Trial|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|University of Tehran||2|||f||||t||||||||||2018-06-01 03:12:46.750883|2018-06-01 03:12:46.750883
NCT00476047|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2017-04-14||2017-10-10|2007-05-18|2007-05-21|Estimate|2017-10-10|2017-10-12|Actual||||2017-10-10|2017-10-12|Actual|February 2007||2007-02-28|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission|A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission|Completed||Phase 2|16|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 03:12:46.866416|2018-06-01 03:12:46.866416
NCT00476034|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2012-05-18|2007-05-18|2007-05-21|Estimate|||||||2012-05-18|2012-05-21|Estimate|December 2003||2003-12-31|May 2012|2012-05-31||||November 2004|Actual|2004-11-30||Interventional|||Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)|A 39-week, Double-blind, Active-controlled Extension to CCOX189A2361, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator|Completed||Phase 3|1312|Actual|Novartis|||||f||||||||||||||2018-06-01 03:12:47.149976|2018-06-01 03:12:47.149976
NCT00476021|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2014-12-01||2016-05-17|2007-05-17|2007-05-21|Estimate|2016-01-22|2016-02-19|Estimate||||2016-05-17|2016-06-24|Estimate|May 2007||2007-05-31|May 2016|2016-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|POPI||Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery|Randomized Trial of Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device After Vaginal Delivery|Completed||N/A|168|Actual|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-06-01 03:12:47.245425|2018-06-01 03:12:47.245425
NCT00476008|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2013-09-20||2014-08-07|2007-05-17|2007-05-21|Estimate|2014-05-05|2014-06-03|Estimate||||2014-08-07|2014-08-11|Estimate|July 2007||2007-07-31|August 2014|2014-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease|Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease|Completed||Phase 4|60|Actual|Florida Atlantic University||2|||f||||f||||||||||2018-06-01 03:12:47.557201|2018-06-01 03:12:47.557201
NCT00475982|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2016-03-22|2007-05-18|2007-05-21|Estimate|||||||2016-03-22|2016-03-23|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Weight Loss on Prostate Cancer Pathology|Effect of Weight Loss on Prostate Cancer Pathology|Completed||N/A|44|Actual|VA Office of Research and Development||2|||f||||||||||||||2018-06-01 03:12:48.065566|2018-06-01 03:12:48.065566
NCT00475969|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-17|2007-05-17|2007-05-21|Estimate|||||||2007-05-17|2007-05-21|Estimate|August 2004||2004-08-31|May 2007|2007-05-31|June 2005|Actual|2005-06-30|||||Interventional|||Duloxetine vs Placebo in the Treatment of General Anxiety|Duloxetine Hydrochloride Once Daily Compared With Placebo in the Treatment of Generalized Anxiety Disorder|Completed||Phase 3|327||Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:12:48.196764|2018-06-01 03:12:48.196764
NCT00475956|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2010-04-14|2007-05-18|2007-05-21|Estimate|||||||2010-04-14|2010-04-15|Estimate|May 2007||2007-05-31|April 2010|2010-04-30|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours|Phase I, Open-Label Study To Assess the Safety, Tolerability and Pharmacokinetics of Daily Oral Doses of Cediranib (RECENTIN™;AZD2171) (20, 30 or 45mg) When Co-Administered With Daily Oral Doses of AZD0530 (125mg or 175mg) in Patients With Advanced Solid Tumours|Completed||Phase 1|40|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:12:48.269919|2018-06-01 03:12:48.269919
NCT00475943|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2017-06-30|2007-05-18|2007-05-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 16, 2007||2007-05-16|September 1, 2009|2009-09-01||||September 1, 2009|Actual|2009-09-01||Observational|||Movement of Epiglottis During Swallowing|Biomechanics of Human Epiglottal Movement and Inversion|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:12:48.382468|2018-06-01 03:12:48.382468
NCT00475930|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2009-09-01|2007-05-18|2007-05-21|Estimate|||||||2009-09-01|2009-09-02|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates|Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||N/A|1563|Actual|Uniformed Services University of the Health Sciences||2|||f||||t||||||||||2018-06-01 03:12:48.470519|2018-06-01 03:12:48.470519
NCT00475917|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2015-08-19|2007-05-17|2007-05-21|Estimate|||||||2015-08-19|2015-08-21|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies|Terminated||Phase 1|28|Actual|Exelixis||1|||f||||||||||||||2018-06-01 03:12:48.54753|2018-06-01 03:12:48.54753
NCT00475904|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2011-04-20||2011-07-25|2007-05-18|2007-05-21|Estimate|2011-06-09|2011-07-06|Estimate||||2011-07-25|2011-07-27|Estimate|July 2007||2007-07-31|July 2011|2011-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)|A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)|Completed||Phase 2|360|Actual|EpiCept Corporation||3|||f||||f||||||||||2018-06-01 03:12:48.62602|2018-06-01 03:12:48.62602
NCT00475891|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2014-12-05|2007-05-18|2007-05-21|Estimate|||||||2014-12-05|2014-12-08|Estimate|April 2007||2007-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2010|Actual|2010-12-31||Observational|||Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures|Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures|Completed|||20|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:12:48.942281|2018-06-01 03:12:48.942281
NCT00475878|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2011-06-28||2012-03-05|2007-05-18|2007-05-21|Estimate|2012-03-05|2012-04-03|Estimate||||2012-03-05|2012-04-03|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||SSRI and Buprenorphine|Antidepressants During Office-Based Buprenorphine|Completed||Phase 3|147|Actual|Butler Hospital||2|||f||||t||||||||||2018-06-01 03:12:49.013141|2018-06-01 03:12:49.013141
NCT00475696|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-16|2007-05-16|2007-05-21|Estimate|||||||2007-05-16|2007-05-21|Estimate|November 2002||2002-11-30|May 2007|2007-05-31|March 2005|Actual|2005-03-31|||||Interventional|||Urge Incontinence Bladder Overactivity Study|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Bladder Overactivity|Completed||Phase 2|300||Eli Lilly and Company|||||||||||||||||||2018-06-01 03:12:53.892702|2018-06-01 03:12:53.892702
NCT00475865|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2012-10-03|2011-02-25|2012-11-05|2007-05-18|2007-05-21|Estimate|2012-10-03|2012-11-02|Estimate|2011-02-25|2011-03-08|Estimate|2012-11-05|2012-11-06|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis|A Randomized, Multinational, Double-blind, Placebo-controlled, Parallel-group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Glatiramer Acetate in Subjects With Multiple Sclerosis|Completed||Phase 2|123|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 03:12:49.305216|2018-06-01 03:12:49.305216
NCT00475852|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|2011-09-27||2013-03-01|2007-05-18|2007-05-21|Estimate|2012-04-12|2012-05-10|Estimate||||2013-03-01|2013-03-08|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure|Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)|Completed||Phase 3|7141|Actual|Scios, Inc.|Only summary counts of deaths by group are provided for other pre-specified endpoints “All-cause mortality through Day 30” and “All-cause mortality through Day 180.” Formal statistical comparisons were not planned.|2|||f||||f||||||||||2018-06-01 03:12:50.033073|2018-06-01 03:12:50.033073
NCT00475839|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2013-01-09|2007-05-17|2007-05-21|Estimate|||||||2013-01-09|2013-01-10|Estimate|December 2004||2004-12-31|January 2013|2013-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Comparing Tension-free Vaginal Tape With the Monarc Procedure for Stress Urinary Incontinence|A Randomized Trial Comparing the Monarc Subfascial Hammock Procedure With Tension-free Vaginal Tape Procedure for the Surgical Treatment of Stress Urinary Incontinence|Completed||Phase 3|180|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 03:12:51.744379|2018-06-01 03:12:51.744379
NCT00475826|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2008-03-20|2007-05-18|2007-05-21|Estimate|||||||2008-03-20|2008-03-21|Estimate|April 2007||2007-04-30|May 2007|2007-05-31||||||||Interventional|||Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe|Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe|Unknown status|Recruiting|N/A|||University of Sao Paulo|||||f||||t||||||||||2018-06-01 03:12:51.832366|2018-06-01 03:12:51.832366
NCT00475813|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2016-03-15|2007-05-18|2007-05-21|Estimate|||||||2016-03-15|2016-03-17|Estimate|March 2007||2007-03-31|March 2016|2016-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma||Completed||Phase 3|211|Actual|Mundipharma Research Limited|||||f||||f||||||||||2018-06-01 03:12:51.918531|2018-06-01 03:12:51.918531
NCT00475800|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2012-05-18|2007-05-18|2007-05-21|Estimate|||||||2012-05-18|2012-05-21|Estimate|January 2004||2004-01-31|May 2012|2012-05-31||||December 2004|Actual|2004-12-31||Interventional|||Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)|A 39-week, Open-label Extension to CCOX189A2360, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator|Completed||Phase 3|833|Actual|Novartis|||||f||||||||||||||2018-06-01 03:12:51.987272|2018-06-01 03:12:51.987272
NCT00475787|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2014-10-21||2014-12-16|2007-05-17|2007-05-21|Estimate|2014-12-16|2014-12-30|Estimate||||2014-12-16|2014-12-30|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Chiropractic Management of Chronic Lower Back Pain in Older Adults|Chiropractic Management of Chronic Lower Back Pain in Older Adults|Completed||N/A|136|Actual|VA Office of Research and Development|"Sham intervention was that it did involve some tactile stimulation~Only VA sites/predominantly male~Clinicians not blinded to invention delivered~All received educational booklet~Consideration of non-specific therapeutic effects"|2|||f||||t||||||||||2018-06-01 03:12:52.065483|2018-06-01 03:12:52.065483
NCT00475774|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2008-04-04|2007-05-18|2007-05-21|Estimate|||||||2008-04-04|2008-04-07|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|September 2007|Actual|2007-09-30|||||Interventional|||Body Fat Distribution and Fat Metabolism|The Effect of Body Fat Distribution on the Physiological Response to a Dietary Fat Intervention|Completed||N/A|12|Anticipated|TNO|||||f||||f||||||||||2018-06-01 03:12:52.343113|2018-06-01 03:12:52.343113
NCT00475761|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-18|||2018-04-04|2007-05-18|2007-05-21|Estimate|||||||2018-04-04|2018-04-05|Actual|May 12, 2007||2007-05-12|July 10, 2017|2017-07-10||||||||Observational|||Breast Mammogram and Tissue Study|Breast Radiology Evaluation and Study of Tissues (Breast) Stamp Project|Active, not recruiting|||466|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:12:52.400977|2018-06-01 03:12:52.400977
NCT00475748|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2009-06-23|2007-05-17|2007-05-21|Estimate|||||||2009-06-23|2009-06-24|Estimate|May 2007||2007-05-31|June 2009|2009-06-30|May 2010|Anticipated|2010-05-31|May 2009|Actual|2009-05-31||Interventional|CCSS||Surgical Management of Spinal Cord Injuries In Neck|ASIA Motor, Functional and Health Related Quality of Life Outcome in Traumatic Central Cord Syndrome, a Prospective Randomized Study|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Maryland Department of Health and Mental Hygiene|||||f||||f||||||||||2018-06-01 03:12:52.465619|2018-06-01 03:12:52.465619
NCT00475735|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2010-10-13||2015-07-21|2007-05-17|2007-05-21|Estimate|2010-11-11|2010-12-10|Estimate||||2015-07-21|2015-07-28|Estimate|July 2007||2007-07-31|July 2015|2015-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Incomplete Block, Two-period, Crossover Clinical Trial to Study the Safety and Efficacy of MK0249, 10 mg, for Adult Patients, Ages 18 to 55, With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|72|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 03:12:52.578591|2018-06-01 03:12:52.578591
NCT00475722|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2015-05-26||2016-08-18|2007-05-17|2007-05-21|Estimate|2015-06-13|2015-07-08|Estimate||||2016-08-18|2016-09-26|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional|||Healthy Eating for Colon Cancer Prevention|A Mediterranean Diet in Colon Cancer Prevention|Completed||N/A|120|Actual|University of Michigan||2|||f||||t||||||||Undecided||2018-06-01 03:12:53.238851|2018-06-01 03:12:53.238851
NCT00475709|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2012-09-19||2014-01-24|2007-05-17|2007-05-21|Estimate|2014-01-24|2014-03-11|Estimate||||2014-01-24|2014-03-11|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|January 2012|Actual|2012-01-31|July 2010|Actual|2010-07-31||Interventional|||Aortic Valve Replacement With Trifecta(TM)|An Observational, Prospective Evaluation of the Trifecta Valve|Completed||N/A|1022|Actual|St. Jude Medical|The SAEs reported are based on the Edmunds criteria noted in Edmunds LH, Clark RE, Cohn LH, Grunkemeier GL, Miller CM, Weisel RD. Guidelines for reporting Morbidity and Mortality after Cardiac Valvular Operations. Ann Thorac Surg 1996;62:932-5.|1|||f||||t||||||||||2018-06-01 03:12:53.513312|2018-06-01 03:12:53.513312
NCT00475683|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2015-08-17|2007-05-17|2007-05-21|Estimate|||||||2015-08-17|2015-08-18|Estimate|January 2009||2009-01-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Curcumin for Prevention of Oral Mucositis in Children Chemotherapy|Randomized Cross-over Study of Curcumin for Prevention of Oral Mucositis in Children Receiving Doxorubicin Based Chemotherapy.|Completed||Phase 3|8|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 03:12:53.999681|2018-06-01 03:12:53.999681
NCT00475670|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2014-07-15||2014-09-09|2007-05-17|2007-05-21|Estimate|2014-09-09|2014-09-15|Estimate||||2014-09-09|2014-09-15|Estimate|October 2005||2005-10-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Full analysis set (FAS) included all enrolled participants who received at least one dose of either trastuzumab or taxane.|A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer|An Open-label Study of the Effect of First-line Herceptin Alone or in Combination With a Taxane on Tumor Response and Disease Progression in Patients With Metastatic Breast Cancer Who Relapsed After Receiving Adjuvant Herceptin for HER2-positive Early Breast Cancer|Completed||Phase 2|44|Actual|Hoffmann-La Roche|Cohort A (trastuzumab monotherapy) was closed prematurely due to enrollment difficulties. Therefore, Cohort A included only 3 participants.|2|||f||||||||||||||2018-06-01 03:12:54.126226|2018-06-01 03:12:54.126226
NCT00475657|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2009-03-31||2009-05-22|2007-05-16|2007-05-21|Estimate|2009-03-31|2009-05-25|Estimate||||2009-05-22|2009-05-29|Estimate|October 2007||2007-10-31|May 2009|2009-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer|Phase II Study of Pemetrexed Plus Cisplatin in the Treatment of Patients With Extensive Small Cell Lung Cancer|Terminated||Phase 2|5|Actual|Eli Lilly and Company|On the advice of an independent monitoring board, this trial was stopped early due to lack of efficacy of the combination pemetrexed/carboplatin for small cell lung cancer.|1||Terminated due to lack of efficacy|f||||f||||||||||2018-06-01 03:12:54.641731|2018-06-01 03:12:54.641731
NCT00475644|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16||2011-05-09|2015-03-17|2007-05-16|2007-05-21|Estimate||||2011-05-09|2011-05-13|Estimate|2015-03-17|2015-04-03|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|April 2012|Actual|2012-04-30||Interventional|||A Study of Enzastaurin in Patients With Follicular Lymphoma|A Phase 2 Study of Enzastaurin in Patients With Follicular Lymphoma|Completed||Phase 2|66|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:12:55.01575|2018-06-01 03:12:55.01575
NCT00475631|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-03-08|2007-05-17|2007-05-21|Estimate|||||||2012-03-08|2012-03-12|Estimate|October 2003||2003-10-31|March 2012|2012-03-31||||||||Observational|||Economic Evaluation of Clubfoot Treatment: One Centre's Experience|Economic Evaluation of Clubfoot Treatment: One Centre's Experience|Withdrawn|||0|Actual|University of British Columbia||||The person who started the study joined medical school|f||||f||||||||||2018-06-01 03:12:55.140685|2018-06-01 03:12:55.140685
NCT00475618|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-05-29|2007-05-17|2007-05-21|Estimate|||||||2012-05-29|2012-05-31|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Therapeutic Measures in Dental Caries Reduction in Children With Primary Dentition From Medellín City|Effect of Therapeutic Measures in Dental Caries Reduction in Children With Primary Dentition From Metropolitan Area Sorrounded Medellín City. A Clinical Trial|Completed||Phase 3|180|Actual|CES University||3|||f||||f||||||||||2018-06-01 03:12:55.203092|2018-06-01 03:12:55.203092
NCT00475605|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2016-07-07|2007-05-17|2007-05-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2005||2005-05-31|July 2016|2016-07-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|APPLES||A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis|APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis|Active, not recruiting|||8037|Actual|LEO Pharma|||1||f||||t||||||||||2018-06-01 03:12:55.350119|2018-06-01 03:12:55.350119
NCT00475592|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2017-07-20|2007-05-16|2007-05-21|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2007|Actual|2007-01-31|July 2017|2017-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy|Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy|Withdrawn||N/A|0|Actual|Johns Hopkins University||2||study failed to recruit|f||||t||||||||||2018-06-01 03:12:55.794098|2018-06-01 03:12:55.794098
NCT00475579|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2007-05-17|2007-05-17|2007-05-21|Estimate|||||||2007-05-17|2007-05-21|Estimate|March 2006||2006-03-31|May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Interventional|A/N||Endotracheal Tube With Polyurethane Cuff and Subglottic Secretion Drainage|Influence of an Endotracheal Tube With Polyurethane Cuff and Subglottic Secretion Drainage on Ventilator-Associated Pneumonia|Completed||Phase 4|280|Actual|Hospital Universitario de Canarias|||||f||||t||||||||||2018-06-01 03:12:55.886685|2018-06-01 03:12:55.886685
NCT00475566|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2011-03-09|2007-05-16|2007-05-21|Estimate|||||||2011-03-09|2011-03-10|Estimate|May 2007||2007-05-31|March 2011|2011-03-31|February 2010|Actual|2010-02-28|July 2008|Actual|2008-07-31||Interventional|STRIDES||A Safety and Efficacy Study of the Dynalink®-E Everolimus Eluting Peripheral Stent System|A Study to Evaluate the Safety and Performance of the Dynalink®-E, Everolimus Eluting Peripheral Stent System for Treating Atherosclerotic de Novo or Restenotic Native Superficial Femoral and Proximal Popliteal Artery Lesions|Completed||N/A|104|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 03:12:55.933232|2018-06-01 03:12:55.933232
NCT00475553|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2009-12-17|2007-05-17|2007-05-21|Estimate|||||||2009-12-17|2009-12-18|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®|The Frequency and Management of Breakthrough Bleeding During Extended Therapy With the Transvaginal Contraceptive Ring|Completed||N/A|75|Actual|Scott and White Hospital & Clinic||2|||f||||f||||||||||2018-06-01 03:12:56.01399|2018-06-01 03:12:56.01399
NCT00475540|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2015-09-21|2007-05-17|2007-05-21|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|August 2013|Actual|2013-08-31|July 2009|Actual|2009-07-31||Interventional|VAMP||Efficacy Study of Vaginal Mesh for Prolapse|A Randomized Clinical Trial of Vaginal Mesh for Prolapse|Completed||Phase 4|65|Actual|Medstar Health Research Institute||2|||f||||t||||||||||2018-06-01 03:12:56.110473|2018-06-01 03:12:56.110473
NCT00475527|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2015-08-19|2007-05-17|2007-05-21|Estimate|||||||2015-08-19|2015-08-20|Estimate||||January 2009|2009-01-31||||||||Interventional|||Helicobacter Pylori and Iron Deficiency: Prevalence of Association and Effect of Therapy||Withdrawn||Phase 4|0|Actual|Hadassah Medical Organization||2||problem of accrual|f||||f||||||||||2018-06-01 03:12:56.193818|2018-06-01 03:12:56.193818
NCT00475514|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2014-02-14|2007-05-17|2007-05-21|Estimate|||||||2014-02-14|2014-02-19|Estimate|October 2004||2004-10-31|February 2014|2014-02-28|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine|A Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, and Safety of Oral Frovatriptan in the Prevention on Menstrually-related Migraine (MRM) Headaches in a 'Difficult to Treat' Population|Completed||Phase 3|500|Actual|Endo Pharmaceuticals|||||||||f||||||||||2018-06-01 03:12:57.124687|2018-06-01 03:12:57.124687
NCT00475501|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2013-11-20||2014-12-04|2007-05-16|2007-05-21|Estimate|2014-06-27|2014-07-31|Estimate||||2014-12-04|2014-12-24|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|March 2012|Actual|2012-03-31||Interventional||Men aged over 60 with serum testosterone 300 ng/dL or biotestosterone 70 ng/dL or less were recruited|5-Alpha Reductase and Anabolic Effects of Testosterone|5-Alpha Reductase and Anabolic Effects of Testosterone|Completed||Phase 2|60|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 03:12:57.223332|2018-06-01 03:12:57.223332
NCT00475488|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2016-05-10|2007-05-17|2007-05-21|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 1996||1996-06-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|April 2015|Actual|2015-04-30||Interventional|RAPCO||Radial Artery Patency and Clinical Outcomes Trial|Randomised Trial of Graft Patency and Clinical Outcomes, Comparing Radial Artery With Either the Right Internal Thoracic Artery or Saphenous Vein|Active, not recruiting||N/A|605|Anticipated|Austin Health||2|||f||||t||||||||No||2018-06-01 03:12:58.783918|2018-06-01 03:12:58.783918
NCT00475475|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-04-30|2007-05-17|2007-05-21|Estimate|||||||2012-04-30|2012-05-02|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Sweetened Beverages and Food Intake|Sweetened Beverages and Food Intake|Completed||N/A|10|Actual|University of Washington||3|||f||||f||||||||||2018-06-01 03:12:58.983396|2018-06-01 03:12:58.983396
NCT00475462|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2007-05-18|2007-05-18|2007-05-21|Estimate|||||||2007-05-18|2007-05-21|Estimate|July 2001||2001-07-31|May 2007|2007-05-31|December 2003|Actual|2003-12-31|||||Interventional|||The Effectiveness of Metoprolol in the Prevention of Syncope Recurrence in Children and Adolescents||Completed||N/A|28|Actual|Peking University First Hospital|||||f||||t||||||||||2018-06-01 03:12:59.221311|2018-06-01 03:12:59.221311
NCT00475449|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2007-05-17|2007-05-17|2007-05-21|Estimate|||||||2007-05-17|2007-05-21|Estimate|November 1996||1996-11-30|May 2007|2007-05-31|February 2006|Actual|2006-02-28|||||Interventional|||The Stent or Surgery (SoS) Trial|A Randomised Controlled Trial to Compare Coronary Artery Bypass Grafting With Percutaneous Transluminal Coronary Angioplasty and Primary Stent Implantation in Patients With Multi-Vessel Coronary Artery Disease|Completed||N/A|988|Actual|Royal Brompton & Harefield NHS Foundation Trust|||||f||||t||||||||||2018-06-01 03:12:59.347011|2018-06-01 03:12:59.347011
NCT00475436|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2017-08-02|2007-05-16|2007-05-21|Estimate|||||||2017-08-02|2017-08-04|Actual|May 14, 2007|Actual|2007-05-14|August 2017|2017-08-31|September 18, 2007|Actual|2007-09-18|September 18, 2007|Actual|2007-09-18||Interventional|||A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Dose-ascending, 3-cohort Parallel-group Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK573719 Administered as Singledoses (750 μg and 1000 μg) and Repeat Doses Over 14 Days (250 μg-1000 μg Once-daily) of GSK573719 in Healthy Male and Female Subjects.|Completed||Phase 1|36|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:12:59.48271|2018-06-01 03:12:59.48271
NCT00475423|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2014-10-06||2015-02-04|2007-05-17|2007-05-21|Estimate|2015-02-04|2015-02-23|Estimate||||2015-02-04|2015-02-23|Estimate|May 2007||2007-05-31|February 2015|2015-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||Safety population: all participants who received at least one dose of study medication and for whom follow-up safety information was available.|A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.|An Open Label Study of a Fixed Dose Regimen of MabThera on Overall Response Rate in Patients With Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura.|Completed||Phase 2|122|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:12:59.657479|2018-06-01 03:12:59.657479
NCT00475410|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2011-06-13|2007-05-17|2007-05-21|Estimate|||||||2011-06-13|2011-06-14|Estimate|February 2007||2007-02-28|June 2011|2011-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|FATT1||Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease|A Phase III Multicenter, Single Blind, Randomized, Comparative and add-on Clinical Trial, in Three Parallel Groups, to Evaluate Efficacy and Safety of a New Therapy With Adipose-derived Autologous Stem Cells for the Treatment of Complex Perianal Fistulas in Patients Without Inflammatory Bowel Disease|Completed||Phase 3|214|Actual|Cellerix||3|||f||||f||||||||||2018-06-01 03:13:00.239278|2018-06-01 03:13:00.239278
NCT00475397|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-16|2007-05-16|2007-05-21|Estimate|||||||2007-05-16|2007-05-21|Estimate|December 2003||2003-12-31|May 2007|2007-05-31|October 2004|Actual|2004-10-31|||||Interventional|||Duloxetine Stress Urinary Incontinence Efficacy and Safety Study|Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence|Completed||Phase 3|120||Eli Lilly and Company|||||||||||||||||||2018-06-01 03:13:00.331408|2018-06-01 03:13:00.331408
NCT00475384|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2014-11-07|2007-05-16|2007-05-21|Estimate|||||||2014-11-07|2014-11-10|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Haploidentical Transplantation in Patients With Acute Leukemia and Myelodysplasia|Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplant From A Haploidentical Donor For Patients With Acute Leukemia and Myelodysplasia|Completed||Phase 1|10|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:13:00.40744|2018-06-01 03:13:00.40744
NCT00475371|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-06-12|2007-05-17|2007-05-21|Estimate|||||||2012-06-12|2012-06-14|Estimate|April 2007||2007-04-30|June 2012|2012-06-30||||June 2007|Actual|2007-06-30||Interventional|||A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males|A Phase 1a, Single-Dose, Open-Label, Parallel, Ascending Dose, Controlled Safety and Tolerability Trial of Inhaled MKC253 in Healthy Adult Male Subjects|Completed||Phase 1|26|Actual|Mannkind Corporation||1|||f||||||||||||||2018-06-01 03:13:00.499956|2018-06-01 03:13:00.499956
NCT00475358|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-16|2007-05-16|2007-05-21|Estimate|||||||2007-05-16|2007-05-21|Estimate|April 2003||2003-04-30|May 2007|2007-05-31|February 2005|Actual|2005-02-28|||||Interventional|||Efficacy and Safety Stress Urinary Incontinence Study|Efficacy and Safety of Duloxetine Compared With Placebo in Subjects With Stress Urinary Incontinence|Completed||Phase 3|120||Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:13:00.560923|2018-06-01 03:13:00.560923
NCT00475345|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-17|2007-05-17|2007-05-21|Estimate|||||||2007-05-17|2007-05-21|Estimate|August 2000||2000-08-31|May 2007|2007-05-31|September 2001|Actual|2001-09-30|||||Interventional|||Impact of Optimized Titration and Delivery of Bedtime Insulin on Prevention of Nocturnal Hypoglycemia|Impact of Optimized Titration and Delivery of Bedtime Insulin on Prevention of Nocturnal Hypoglycemia in Adults With Type 1 Diabetes Undergoing Intensive Management|Completed||N/A|29|Actual|McGill University|||||f||||f||||||||||2018-06-01 03:13:00.628583|2018-06-01 03:13:00.628583
NCT00464217|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2010-01-03|2007-04-20|2007-04-23|Estimate|||||||2010-01-03|2010-01-05|Estimate|October 1998||1998-10-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years|PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years|Completed||Phase 4|100||PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:16:49.537159|2018-06-01 03:16:49.537159
NCT00475332|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2011-11-28||2012-01-09|2007-05-17|2007-05-21|Estimate|2012-01-09|2012-02-15|Estimate||||2012-01-09|2012-02-15|Estimate|September 2007||2007-09-30|January 2012|2012-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar|Feasibility Study of External Beam Radiotherapy and Iodine-131 Tositumomab (Bexxar) for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma|Terminated||Phase 2|2|Actual|University of Florida|The PI left our institution and the study was closed. There were only 2 patients enrolled on the study so no conclusions can be drawn regarding the objectives of the study.|||PI left our institution|f||||f||||||||||2018-06-01 03:13:00.702517|2018-06-01 03:13:00.702517
NCT00475319|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2013-01-31||2013-06-04|2007-05-16|2007-05-21|Estimate|2013-05-01|2013-06-05|Estimate||||2013-06-04|2013-06-13|Estimate|May 2007||2007-05-31|May 2013|2013-05-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Late Phase 2 Study of OPC-12759 Ophthalmic Suspension|Late Phase 2 Study of OPC-12759 Ophthalmic Suspension|Completed||Phase 2|308|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-06-01 03:13:00.997322|2018-06-01 03:13:00.997322
NCT00475306|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2011-07-11||2012-11-28|2007-05-16|2007-05-21|Estimate|2012-11-28|2012-12-31|Estimate||||2012-11-28|2012-12-31|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Montefiore Metoclopramide Study|A Randomized, Facorial Design Study to Optimize the Dose of Parenteral Metoclopramide|Completed||Phase 4|289|Actual|Montefiore Medical Center||4|||f||||f||||||||||2018-06-01 03:13:01.465408|2018-06-01 03:13:01.465408
NCT00475293|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2013-09-12|2007-05-17|2007-05-21|Estimate|||||||2013-09-12|2013-09-13|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC|A Phase 2 Clinical Trial of Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With Metastatic Colorectal Cancer|Completed||Phase 2|85|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-06-01 03:13:01.767167|2018-06-01 03:13:01.767167
NCT00475280|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2017-10-10|2007-05-18|2007-05-21|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2007|Actual|2007-11-30|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|December 2016|Actual|2016-12-31||Interventional|LAL1104||"Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients"|"Geriatric Assessment Adapted Therapy for Ph- ALL Elderly Patients. GIMEMA Protocol LAL1104. EudraCT Code 2005-002156-17"|Active, not recruiting||Phase 2|102|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-06-01 03:13:01.859313|2018-06-01 03:13:01.859313
NCT00475267|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-03-09|2007-05-16|2007-05-21|Estimate|||||||2012-03-09|2012-03-12|Estimate|May 2007||2007-05-31|November 2009|2009-11-30|January 2012|Actual|2012-01-31|July 2010|Actual|2010-07-31||Interventional|||Aortic Valve Replacement With Trifecta(TM)|An Observational, Prospective Evaluation of the Trifecta Valve|Completed||N/A|203|Actual|St. Jude Medical|||||f||||t||||||||||2018-06-01 03:13:01.993073|2018-06-01 03:13:01.993073
NCT00475254|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2011-04-05|2007-05-16|2007-05-21|Estimate|||||||2011-04-05|2011-04-06|Estimate|August 2007||2007-08-31|August 2008|2008-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Stress and Vision Fluctuations in Retinitis Pigmentosa|Stress and Vision Fluctuations in Retinitis Pigmentosa|Completed|||50|Anticipated|Johns Hopkins University|||||f||||f||||||||||2018-06-01 03:13:02.100217|2018-06-01 03:13:02.100217
NCT00475241|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2014-10-27||2014-11-03|2007-05-17|2007-05-21|Estimate|2014-11-03|2014-11-10|Estimate||||2014-11-03|2014-11-10|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms|Exposure Therapy for Chronic PTSD: Efficacy and Mechanisms|Completed||Phase 2/Phase 3|36|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:13:02.163925|2018-06-01 03:13:02.163925
NCT00475228|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2016-05-19||2017-03-28|2007-05-18|2007-05-21|Estimate|2017-03-28|2017-05-09|Actual||||2017-03-28|2017-05-09|Actual|March 2007||2007-03-31|March 2017|2017-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|ILIAD|After completion of the D&E, 88 of the 93 women who consented were randomized 1:1 to Arm 1 and Arm 2.|'Levonorgestrel IUD Insertion After D&E Procedure|Immediate Versus Delayed Insertion of the Levonorgestrel-Releasing Intrauterine Device Following Dilation and Evacuation: A Randomized Controlled Trial|Completed||Phase 4|93|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-06-01 03:13:02.498066|2018-06-01 03:13:02.498066
NCT00475215|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2017-08-18|2007-05-17|2007-05-21|Estimate|||||||2017-08-18|2017-08-22|Actual|October 27, 2005|Actual|2005-10-27|August 2017|2017-08-31|September 9, 2006|Actual|2006-09-09|August 21, 2006|Actual|2006-08-21||Interventional|||Evaluation of Safety and Efficacy of Org 25969 in Subjects With or Having a Past History of Pulmonary Disease (19.4.308)(P05932)|A Multicenter, Randomized, Parallel Group, Comparative, Safety-Assessor Blinded, Phase IIIa Trial in Adult Surgical Subjects Under General Anesthesia at Increased Risk for Pulmonary Complications|Completed||Phase 3|86|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:13:02.91762|2018-06-01 03:13:02.91762
NCT00475202|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-17|2007-05-17|2007-05-21|Estimate|||||||2007-05-17|2007-05-21|Estimate||||May 2007|2007-05-31||||||||Observational|||Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers||Unknown status|Recruiting||||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:13:03.069813|2018-06-01 03:13:03.069813
NCT00475189|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2011-07-22|2007-05-16|2007-05-21|Estimate|||||||2011-07-22|2011-07-25|Estimate|June 2007||2007-06-30|July 2011|2011-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||"Study of Loestrin 24(24 Days of Real Pills) Fe Versus Loestrin 1/20 (21 Real Pills)"|Prospective Comparison of Hormone Withdrawal Symptoms of a 24/4 Regimen With a 21/7 Regimen of OC|Completed||N/A|51|Actual|Scott and White Hospital & Clinic||2|||f||||f||||||||||2018-06-01 03:13:03.17244|2018-06-01 03:13:03.17244
NCT00475176|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|2012-05-01||2013-05-31|2007-05-17|2007-05-21|Estimate|2013-05-31|2013-07-05|Estimate||||2013-05-31|2013-07-05|Estimate|May 2007||2007-05-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C|Effects of S-Adenosyl Methionine (SAMe) on Viral and Cell Signaling Response to Combination Therapy for Chronic Hepatitis C|Completed||Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 03:13:03.267785|2018-06-01 03:13:03.267785
NCT00475163|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-17|||2009-03-03|2007-05-17|2007-05-21|Estimate|||||||2009-03-03|2009-03-04|Estimate|November 2004||2004-11-30|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|MIM||Mentors in Motion: A Physical Activity Intervention for Obese Adolescents|Mentors in Motion: A Physical Activity Intervention for Obese Adolescents|Completed||N/A|34|Actual|McGill University Health Center|||||f||||f||||||||||2018-06-01 03:13:03.526044|2018-06-01 03:13:03.526044
NCT00474812|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2013-07-31||2015-04-14|2007-05-16|2007-05-17|Estimate|2013-11-04|2013-12-23|Estimate||||2015-04-14|2015-05-05|Estimate|May 2007||2007-05-31|November 2013|2013-11-30|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional|||Dasatinib in Treating Patients With Metastatic Pancreatic Cancer|Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas|Completed||Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:13:11.640151|2018-06-01 03:13:11.640151
NCT00475150|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2013-03-22||2016-12-28|2007-05-16|2007-05-17|Estimate|2013-05-24|2013-07-10|Estimate||||2016-12-28|2017-02-15|Actual|May 2008||2008-05-31|December 2016|2016-12-31|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Interventional|||Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase II Study of AZD2171 in the Treatment of Patients With Acute Leukemia and Myelodysplastic Syndrome.|Completed||Phase 2|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:13:03.59491|2018-06-01 03:13:03.59491
NCT00475137|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2015-06-02|2007-05-16|2007-05-17|Estimate|||||||2015-06-02|2015-06-04|Estimate|December 2007||2007-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression|A Randomized, Single-Blind Comparison of Lamotrigine Add-on Versus Switch to Lamotrigine Monotherapy in the Treatment of Bipolar II Depression Unresponsive to Antidepressant Treatment|Completed||Phase 2|15|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:13:04.035051|2018-06-01 03:13:04.035051
NCT00475124|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2014-10-30|2007-05-16|2007-05-17|Estimate|||||||2014-10-30|2014-10-31|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|VIRTUE||Virtual Clinic Pacemaker Follow-up|VIRTUE: Virtual Clinic Pacemaker Follow-up|Terminated||Phase 4|123|Actual|Biotronik SE & Co. KG||2||"Redundant in-clinic visits increased the workload in virtual follow-up group. An interim~   analysis showed that the study would not support the primary hypothesis"|f||||f||||||||||2018-06-01 03:13:04.126337|2018-06-01 03:13:04.126337
NCT00475111|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2013-05-16|2007-05-16|2007-05-17|Estimate|||||||2013-05-16|2013-05-17|Estimate|March 2001||2001-03-31|May 2013|2013-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Cognitive Behavioral Therapy Treatments for Adults With Rheumatoid Arthritis (The SARA Study)|Stress and Adaptation in Rheumatoid Arthritis (SARA)|Completed||N/A|136|Actual|Arizona State University||3|||f||||f||||||||||2018-06-01 03:13:04.213964|2018-06-01 03:13:04.213964
NCT00475098|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2016-09-01|2007-05-16|2007-05-17|Estimate|||||||2016-09-01|2016-09-02|Estimate|June 2007||2007-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|TILT||Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)|Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.|Completed||Phase 3|553|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:13:04.316585|2018-06-01 03:13:04.316585
NCT00475085|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2013-07-12||2015-10-13|2007-05-16|2007-05-17|Estimate|2013-10-08|2013-11-04|Estimate||||2015-10-13|2015-11-10|Estimate|December 2006||2006-12-31|October 2015|2015-10-31||||December 2012|Actual|2012-12-31||Interventional|||Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial|Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial|Completed||Phase 3|1021|Actual|University of Rochester||4|||f||||t||||||||||2018-06-01 03:13:04.427994|2018-06-01 03:13:04.427994
NCT00475072|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2016-10-29|2007-05-16|2007-05-17|Estimate|||||||2016-10-29|2016-11-01|Estimate|June 2003||2003-06-30|October 2016|2016-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.|An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C|Completed||Phase 4|14|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:13:05.010541|2018-06-01 03:13:05.010541
NCT00475059|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2010-01-05|2007-05-16|2007-05-17|Estimate|||||||2010-01-05|2010-01-06|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients|Performance of Cimetidine-corrected MDRD Equation in Renal Transplant Patients|Completed||N/A|59|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-06-01 03:13:05.07249|2018-06-01 03:13:05.07249
NCT00475046|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-18|2007-05-16|2007-05-17|Estimate|||||||2007-05-18|2007-05-21|Estimate|October 2001||2001-10-31|May 2007|2007-05-31|May 2005|Actual|2005-05-31|||||Interventional|EARLINT-EP3||Smoking Cessation and Relapse Prevention in Women Postpartum|Smoking Cessation and Relapse Prevention in Women Postpartum|Completed||Phase 1|2790|Actual|University Medicine Greifswald|||||f||||f||||||||||2018-06-01 03:13:05.149698|2018-06-01 03:13:05.149698
NCT00475033|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2010-05-04||2011-04-18|2007-05-15|2007-05-17|Estimate|2010-05-04|2010-06-04|Estimate||||2011-04-18|2011-04-21|Estimate|June 2007||2007-06-30|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Canada|Completed||Phase 3|603|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:13:05.390267|2018-06-01 03:13:05.390267
NCT00475020|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2017-10-06|2007-05-15|2007-05-17|Estimate|||||||2017-10-06|2017-10-09|Actual|January 4, 2006|Actual|2006-01-04|October 2017|2017-10-31|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|||Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome|Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning|Completed||Phase 2|63|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:13:08.027442|2018-06-01 03:13:08.027442
NCT00475007|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2018-04-16|2007-05-16|2007-05-17|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2007|Actual|2007-09-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|February 2011|Actual|2011-02-28||Interventional|IBV®Valve||Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema|A Prospective, Randomized, Controlled Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema|Completed||N/A|277|Actual|Spiration, Inc.||2|||f||||t||||||||||2018-06-01 03:13:08.129064|2018-06-01 03:13:08.129064
NCT00474994|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2015-12-15||2015-12-15|2007-05-16|2007-05-17|Estimate|2015-12-15|2016-01-20|Estimate||||2015-12-15|2016-01-20|Estimate|April 2007||2007-04-30|December 2015|2015-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas|A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas|Completed||Phase 2|53|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 03:13:08.253523|2018-06-01 03:13:08.253523
NCT00474981|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-04-02|2007-05-16|2007-05-17|Estimate|||||||2012-04-02|2012-04-03|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|IMNCI-India||Impact of the Integrated Management of Neonatal and Childhood Illness Strategy on Neonatal and Infant Mortality|Impact of the Integrated Management of Neonatal and Childhood Illness Strategy on Neonatal and Infant Mortality in Haryana, India|Completed||N/A|66600|Actual|Society for Applied Studies||2|||f||||f||||||||||2018-06-01 03:13:08.470343|2018-06-01 03:13:08.470343
NCT00474968|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2009-05-04||2009-11-16|2007-05-16|2007-05-17|Estimate|2009-06-29|2009-08-13|Estimate||||2009-11-16|2009-11-20|Estimate|April 2007||2007-04-30|November 2009|2009-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Adequacy and Efficacy of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique.|Clinical Study Validating the Adequacy, Efficacy, and Safety of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique In Patients With Recent History of Abnormal Pap Test Returning for Colposcopy/Biopsy.|Completed|||737|Actual|CytoCore, Inc.|||2||f||||t||||||None Retained|"~     Cervical cells~   "|||2018-06-01 03:13:08.56931|2018-06-01 03:13:08.56931
NCT00474955|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2016-04-22||2016-06-14|2007-05-16|2007-05-17|Estimate|2016-06-14|2016-07-25|Estimate||||2016-06-14|2016-07-25|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Intent-to-treat (ITT) population included all enrolled participants who received at least one dose of study medication.|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.|Multicenter Open-label Observation Program in Patients With Chronic Hepatitis C and With Chronic Renal Failure (CRF) Receiving Peginterferon Alpha-2a (40 kDa) Pegasys|Completed||Phase 4|27|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:13:08.938467|2018-06-01 03:13:08.938467
NCT00474942|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2015-12-10|2007-05-16|2007-05-17|Estimate|||||||2015-12-10|2015-12-11|Estimate|April 2007||2007-04-30|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Natural History of Apparent Mineralocorticoid Excess Syndrome|Apparent Mineralocorticoid Excess Syndrome Natural History Clinical Protocol|Completed|||130|Actual|Icahn School of Medicine at Mount Sinai|||||f||||t||||||Samples With DNA|"~     Peripheral blood~   "|||2018-06-01 03:13:09.233358|2018-06-01 03:13:09.233358
NCT00474929|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2015-03-23||2018-02-05|2007-05-16|2007-05-17|Estimate|2016-05-26|2016-07-07|Estimate||||2018-02-05|2018-03-07|Actual|August 2007||2007-08-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|November 2011|Actual|2011-11-30||Interventional|||Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma|A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|103|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:13:09.336426|2018-06-01 03:13:09.336426
NCT00474916|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2010-08-13|2007-05-15|2007-05-17|Estimate|||||||2010-08-13|2010-08-16|Estimate|June 2006||2006-06-30|August 2010|2010-08-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Neuropathic Pain in Patients With Cancer|A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer|Completed||Phase 2|19|Actual|DARA Therapeutics||2|||f||||t||||||||||2018-06-01 03:13:10.283612|2018-06-01 03:13:10.283612
NCT00474903|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2014-01-08||2014-06-02|2007-05-16|2007-05-17|Estimate|2014-06-02|2014-07-02|Estimate||||2014-06-02|2014-07-02|Estimate|April 2007||2007-04-30|January 2014|2014-01-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional||Two patients from ARM II withdrew due to an inadequate number of biopsies and were not included in baseline measures.|Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus|Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients|Completed||Phase 2|122|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 03:13:10.386048|2018-06-01 03:13:10.386048
NCT00474890|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2008-02-12|2007-05-16|2007-05-17|Estimate|||||||2008-02-12|2008-02-13|Estimate|June 2007||2007-06-30|February 2008|2008-02-29|February 2008||2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Study to Compare the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Placebo on Symptoms in Patients With Allergic Rhinitis Within/Out of Season|A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy's Reproducibility of a Combination of Pseudoephedrine and Cetirizine on Symptom Scores and Rhinomanometry in Patients With Allergic Rhinitis Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC) in- and Outside the Grass Pollen Season|Completed||N/A|70|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||t||||||||||2018-06-01 03:13:10.796775|2018-06-01 03:13:10.796775
NCT00474877|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-16|2007-05-16|2007-05-17|Estimate|||||||2007-05-16|2007-05-17|Estimate|October 2001||2001-10-31|May 2007|2007-05-31|April 2004|Actual|2004-04-30|||||Interventional|||The Clinical Effectiveness of Static Resting Splints in Early Rheumatoid Arthritis|The Clinical Effectiveness of Static Resting Splints in Early Rheumatoid Arthritis: a Randomized Controlled Trial|Completed||N/A|120|Actual|University of Southampton|||||f||||f||||||||||2018-06-01 03:13:10.862544|2018-06-01 03:13:10.862544
NCT00474864|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15||2009-07-22|2012-05-31|2007-05-15|2007-05-17|Estimate||||2009-07-22|2009-08-10|Estimate|2012-05-31|2012-06-06|Estimate|July 2007||2007-07-31|February 2011|2011-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.|A Double-Blind, Placebo-Controlled, Parallel Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.|Completed||Phase 2|66|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:13:10.936841|2018-06-01 03:13:10.936841
NCT00474851|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2015-03-04||2015-03-17|2007-05-15|2007-05-17|Estimate|2015-03-17|2015-03-30|Estimate||||2015-03-17|2015-03-30|Estimate|August 2007||2007-08-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|October 2013|Actual|2013-10-31||Interventional|||The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial|The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial|Completed||Phase 2|53|Actual|Boston Children’s Hospital|Sample of skeletally mature young women; Measurements of aBMD are two-dimensional and do not yield information regarding skeletal strength or microarchitecture|2|||f||||t||||||||||2018-06-01 03:13:11.057384|2018-06-01 03:13:11.057384
NCT00474838|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2013-09-25|2007-05-16|2007-05-17|Estimate|||||||2013-09-25|2013-09-26|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|KIIT||Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy|The Effect of Intensive and Short-term Insulin Treatment on Long-term Pancreatic β-cell Function in Newly Diagnosed People With Type 2 Diabetes in Korea|Completed||Phase 4|112|Actual|Kyunghee University Medical Center||2|||f||||t||||||||||2018-06-01 03:13:11.435351|2018-06-01 03:13:11.435351
NCT00474825|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-02-03|2007-05-16|2007-05-17|Estimate|||||||2012-02-03|2012-02-06|Estimate|July 2007||2007-07-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|HBO-XRT||Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck|Phase I Clinical Trial of Hyperbaric Oxygen Combined With Radiation and Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|12|Actual|Baromedical Research Foundation||3|||f||||t||||||||||2018-06-01 03:13:11.536993|2018-06-01 03:13:11.536993
NCT00474799|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2008-01-11|2007-05-16|2007-05-17|Estimate|||||||2008-01-11|2008-01-14|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine)|An Open Label, Randomized, Single Center, Repeat Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of MNS075 (Intranasal Morphine) in Opioid naïve, Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Javelin Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:13:11.935173|2018-06-01 03:13:11.935173
NCT00474786|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2013-01-31||2013-10-28|2007-05-15|2007-05-17|Estimate|2013-01-31|2013-03-07|Estimate||||2013-10-28|2013-11-21|Estimate|September 2007||2007-09-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|INTORSECT||Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib|A Randomized Trial Of Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy|Completed||Phase 3|512|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:13:12.052844|2018-06-01 03:13:12.052844
NCT00474773|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2016-04-26|2007-05-15|2007-05-17|Estimate|||||||2016-04-26|2016-04-28|Estimate|June 2007||2007-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery|Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery: A Randomized Controlled Study|Completed|||107|Actual|St. Louis Joint Replacement Institute|||||f||||f||||||||||2018-06-01 03:13:13.088417|2018-06-01 03:13:13.088417
NCT00474760|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2013-10-25||2013-10-25|2007-05-16|2007-05-17|Estimate|2013-10-25|2013-12-17|Estimate||||2013-10-25|2013-12-17|Estimate|August 2005||2005-08-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|January 2011|Actual|2011-01-31||Interventional||All enrolled participants|Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors|Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors|Completed||Phase 1|65|Actual|Pfizer|The study was completed and 2 participants in figitumumab 20 mg/kg RP2D ESFT group were transitioned to compassionate figitumumab treatment as investigators judged they were receiving benefit from the protocol therapy.|1|||f||||f||||||||||2018-06-01 03:13:13.209516|2018-06-01 03:13:13.209516
NCT00474747|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2017-11-10|2007-05-16|2007-05-17|Estimate|||||||2017-11-10|2017-11-14|Actual|February 7, 2006|Actual|2006-02-07|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia|Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From HLA-Compatible Unrelated Donors in Severe Aplastic Anemia|Completed||Phase 1/Phase 2|5|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:13:15.721642|2018-06-01 03:13:15.721642
NCT00474734|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2007-05-16|2007-05-16|2007-05-17|Estimate|||||||2007-05-16|2007-05-17|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|September 2007|Anticipated|2007-09-30|||||Observational|||Intravascular Ultrasound for Hepatocellular Carcinoma Staging|Intravascular Ultrasound for the Staging of Hepatocellular Carcinoma: a Pilot Study|Unknown status|Recruiting||||University Hospital, Geneva|||||f||||t||||||||||2018-06-01 03:13:15.819809|2018-06-01 03:13:15.819809
NCT00474721|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-16|2007-05-16|2007-05-17|Estimate|||||||2007-05-16|2007-05-17|Estimate|November 2002||2002-11-30|May 2007|2007-05-31|February 2004|Actual|2004-02-29|||||Interventional|||Comparison of Acetaminophen With Codeine and Ibuprofen for Children With Injuries|A Randomized Blinded Comparison of Acetaminophen With Codeine and Ibuprofen for Treatment of Acute Pain in Children With Extremity Injuries|Completed||N/A|68|Actual|University of California, San Diego|||||f||||t||||||||||2018-06-01 03:13:15.885951|2018-06-01 03:13:15.885951
NCT00474708|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2009-03-31||2012-03-02|2007-05-15|2007-05-17|Estimate|2010-04-07|2010-04-30|Estimate||||2012-03-02|2012-03-05|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients|The Efficacy of Venlafaxine XR (Efexor XR®) Versus SSRIs & Conventional Antidepressants in Depressed Patients Switched From Prior Antidepressants in Psychiatric Outpatient Care Settings in China|Completed||Phase 4|1151|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|365 participants were assessed for safety. Certain demographic data (gender and age) is missing for one participant. Thereby resulting in the participant flow reflecting 364 participants.|2|||f||||t||||||||||2018-06-01 03:13:15.978683|2018-06-01 03:13:15.978683
NCT00474695|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2015-02-10|2007-05-16|2007-05-17|Estimate|||||||2015-02-10|2015-02-11|Estimate|May 2007||2007-05-31|February 2015|2015-02-28|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|SEAGUL||Study Evaluating Genotypes Using Lucentis|VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis|Terminated|||65|Actual|University of Utah|||1|IND holder relocated from the University of Utah|f||||f||||||||||2018-06-01 03:13:16.309672|2018-06-01 03:13:16.309672
NCT00474682|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2008-12-02|2007-05-16|2007-05-17|Estimate|||||||2008-12-02|2008-12-03|Estimate||||May 2007|2007-05-31||||||||Interventional|||Relative Bioavailability of Ferric Pyrophosphate From an Apple Juice Drink|Relative Bioavailability of Ferric Pyrophosphate From an Apple Juice Drink|Completed||N/A|16|Anticipated|Quadram Institute|||||f||||t||||||||||2018-06-01 03:13:16.377798|2018-06-01 03:13:16.377798
NCT00474669|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2018-01-05|2007-05-16|2007-05-17|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2007||2007-06-30|January 2018|2018-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|IP||A Phase I Study of Intraperitoneal Hyperthermic Docetaxel|A Phase I Study of Intraperitoneal Hyperthermic Docetaxel at the Time of Second Look Surgery Following Front-Line Normothermic Intraperitoneal and Intravenous Cisplatin/Paclitaxel for Patients With Stage II and III Ovarian Carcinoma|Completed||Phase 1|30|Anticipated|University of Louisville||1|||f||||t||||||||||2018-06-01 03:13:16.444328|2018-06-01 03:13:16.444328
NCT00474656|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2009-01-29|2007-05-16|2007-05-17|Estimate|||||||2009-01-29|2009-01-30|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|OSCILLATE||The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study|The Oscillation for ARDS Treated Early (OSCILLATE) Trial Pilot Study|Completed||N/A|94|Actual|Canadian Critical Care Trials Group|||||f||||t||||||||||2018-06-01 03:13:16.515541|2018-06-01 03:13:16.515541
NCT00474643|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-05-15|2007-05-15|2007-05-17|Estimate|||||||2007-05-15|2007-05-17|Estimate|August 2006||2006-08-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Observational|||Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi Syndrome||Completed|||51|Actual|Samsung Medical Center|||||f||||t||||||||||2018-06-01 03:13:16.577779|2018-06-01 03:13:16.577779
NCT00474448|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2015-07-30|2007-05-16|2007-05-17|Estimate|||||||2015-07-30|2015-08-03|Estimate|May 2007||2007-05-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses|The Health-Related Quality of Life in Patients With Hereditary Multiple Exostoses|Completed|||200|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:13:28.991303|2018-06-01 03:13:28.991303
NCT00474630|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2014-10-10|2012-10-25|2014-11-18|2007-05-15|2007-05-17|Estimate|2014-11-18|2014-11-21|Estimate|2012-10-25|2012-10-31|Estimate|2014-11-18|2014-11-21|Estimate|May 2007||2007-05-31|November 2014|2014-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||All randomized subjects|A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|505|Actual|Orexigen Therapeutics, Inc||2|||f||||t||||||||||2018-06-01 03:13:16.658946|2018-06-01 03:13:16.658946
NCT00474617|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2017-06-14|2007-05-15|2007-05-17|Estimate|||||||2017-06-14|2017-06-16|Actual|December 29, 2005|Actual|2005-12-29|June 2017|2017-06-30|October 20, 2006|Actual|2006-10-20|October 20, 2006|Actual|2006-10-20||Interventional|||Comparison of Org 25969 in Elderly Subjects With Adult Subjects (19.4.305)(P05950)|A Multicenter, Parallel Group, Comparative, Phase IIIa Trial to Compare the Efficacy, Safety, and Pharmacokinetics of Org 25969 in Elderly Subjects With Adult Subjects|Completed||Phase 3|162|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 03:13:19.498787|2018-06-01 03:13:19.498787
NCT00474604|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2017-08-25|2007-05-16|2007-05-17|Estimate|||||||2017-08-25|2017-08-28|Actual|March 2006||2006-03-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants|MRI Evaluation of Breast Tumor Growth and Treatment Response|Recruiting||N/A|250|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||f||||||||||2018-06-01 03:13:19.583705|2018-06-01 03:13:19.583705
NCT00474591|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-25|2007-05-16|2007-05-17|Estimate|||||||2007-05-25|2007-05-28|Estimate||||May 2007|2007-05-31||||||||Interventional|Fonda CABG||Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study|Fondaparinux Compared With Heparin to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 03:13:19.674154|2018-06-01 03:13:19.674154
NCT00474565|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2012-09-19|2007-05-16|2007-05-17|Estimate|||||||2012-09-19|2012-09-21|Estimate|February 2007||2007-02-28|September 2012|2012-09-30|December 2008|Anticipated|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Coronary Artery and Coronary Artery Bypass Graft Imaging Using a Specialized Catheter and Computed Tomography|Contrast-Enhanced Coronary Artery and Coronary Artery Bypass Graft Imaging Using Aortic Root Catheter Injection With Computed Tomographic Angiography (CTA)|Withdrawn||Phase 1|0|Actual|William Beaumont Hospitals||||Suspended failure to follow Conflict of Interest Management Plan|f||||t||||||||||2018-06-01 03:13:19.803526|2018-06-01 03:13:19.803526
NCT00474552|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2008-02-13|2007-05-15|2007-05-17|Estimate|||||||2008-02-13|2008-02-18|Estimate|June 2007||2007-06-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315|An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 Administered Orally to Healthy Young Adult and Elderly Subjects|Terminated||Phase 1|56|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||||||||||||2018-06-01 03:13:19.873026|2018-06-01 03:13:19.873026
NCT00474539|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2010-03-26||2013-01-22|2007-05-15|2007-05-17|Estimate|2013-01-22|2013-03-05|Estimate||||2013-01-22|2013-03-05|Estimate|July 2007||2007-07-31|January 2013|2013-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain|Completed||Phase 3|449|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:13:20.028558|2018-06-01 03:13:20.028558
NCT00474526|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2013-05-27|2010-04-16|2014-02-24|2007-05-16|2007-05-17|Estimate|2014-02-24|2014-03-24|Estimate|2010-04-16|2010-04-20|Estimate|2014-02-24|2014-03-24|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|November 2009|Actual|2009-11-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants|A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants|Completed||Phase 3|4545|Actual|Novartis||17|||f||||||||||||||2018-06-01 03:13:22.146111|2018-06-01 03:13:22.146111
NCT00474513|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2012-05-31|2007-05-15|2007-05-17|Estimate|||||||2012-05-31|2012-06-04|Estimate|March 2007||2007-03-31|February 2011|2011-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.|A PET Study Using [11C] GSK189254 to Establish the Dose, Plasma Concentration and Brain Receptor Occupancy Relationship of GSK239512, a Histamine H3 Antagonist, in Healthy Subjects|Completed||Phase 1|5|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:13:27.895127|2018-06-01 03:13:27.895127
NCT00474500|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2011-03-16|2007-05-16|2007-05-17|Estimate|||||||2011-03-16|2011-03-17|Estimate|May 2007||2007-05-31|March 2011|2011-03-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Coca-Cola on Iron Absorption|Effect of Coca-Cola on Iron Absorption|Completed||N/A|16|Actual|Quadram Institute|||||f||||t||||||||||2018-06-01 03:13:27.959748|2018-06-01 03:13:27.959748
NCT00474487|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|2010-03-19|2009-08-03|2014-04-01|2007-05-16|2007-05-17|Estimate|2010-07-05|2010-08-04|Estimate|2009-08-03|2009-08-10|Estimate|2014-04-01|2014-04-21|Estimate|May 2007||2007-05-31|April 2014|2014-04-30|February 2008|Actual|2008-02-29|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults|A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age.|Completed||Phase 3|2831|Actual|Novartis||4|||f||||t||||||||||2018-06-01 03:13:28.047416|2018-06-01 03:13:28.047416
NCT00474474|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2007-05-16|2007-05-16|2007-05-17|Estimate|||||||2007-05-16|2007-05-17|Estimate|February 2007||2007-02-28|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|VPtdl-rct1||Study of the Impact of Virtual Patient Designs on the Reasoning Pattern and Therapeutic Decision Making|Study of the Impact of How the Virtual Patient's Anamnesis is Designed on the Reasoning Pattern and Therapeutic Decision Making|Completed||N/A|58|Actual|Karolinska Institutet|||||f||||f||||||||||2018-06-01 03:13:28.8589|2018-06-01 03:13:28.8589
NCT00474461|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2017-04-08|2007-05-16|2007-05-17|Estimate|||||||2017-04-08|2017-04-11|Actual|February 2009||2009-02-28|April 2017|2017-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|SCIPIO||Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)|Myocardial Regeneration Using Cardiac Stem Cells Harvested From Right Atrial Appendages in Patients With Ischemic Cardiomyopathy.|Completed||Phase 1|33|Actual|University of Louisville||2|||f||||t||||||||Yes||2018-06-01 03:13:28.924311|2018-06-01 03:13:28.924311
NCT00474435|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-16|||2010-12-16|2007-05-16|2007-05-17|Estimate|||||||2010-12-16|2010-12-17|Estimate|November 2008||2008-11-30|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|PETE||Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis|The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania|Unknown status|Recruiting|Phase 2|30|Anticipated|African Poverty Related Infection Oriented Research Initiative|||||f||||t||||||||||2018-06-01 03:13:29.057001|2018-06-01 03:13:29.057001
NCT00474422|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2007-05-14|2007-05-14|2007-05-16|Estimate|||||||2007-05-14|2007-05-16|Estimate|December 2003||2003-12-31|May 2007|2007-05-31|February 2005|Actual|2005-02-28|||||Interventional|||Hospital-Based Paraprofessional Lactation Clinic|Hospital-Based Paraprofessional Lactation Clinic|Completed||N/A|522|Actual|Baylor College of Medicine|||||f||||f||||||||||2018-06-01 03:13:29.153816|2018-06-01 03:13:29.153816
NCT00474409|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2017-06-01|2007-05-14|2007-05-16|Estimate|||||||2017-06-01|2017-06-05|Actual|May 2007||2007-05-31|May 2017|2017-05-31||||||||Interventional|||A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation|A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation|Withdrawn||Phase 4|0|Actual|Eisai Inc.||||Due to poor enrollment, this study was withdrawn/ terminated.|f||||||||||||||2018-06-01 03:13:29.21018|2018-06-01 03:13:29.21018
NCT00474396|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2007-05-15|2007-05-15|2007-05-16|Estimate|||||||2007-05-15|2007-05-16|Estimate|April 2005||2005-04-30|May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Interventional|dietUAT||Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules|Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules|Completed||N/A|59|Actual|Icahn School of Medicine at Mount Sinai|||||f||||t||||||||||2018-06-01 03:13:29.270661|2018-06-01 03:13:29.270661
NCT00474383|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2013-05-13||2014-04-10|2007-05-14|2007-05-16|Estimate|2013-05-23|2013-08-15|Estimate||||2014-04-10|2014-05-12|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy|A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy|Completed||Phase 2|47|Actual|Cougar Biotechnology, Inc.||1|||f||||f||||||||||2018-06-01 03:13:29.331724|2018-06-01 03:13:29.331724
NCT00474370|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2015-12-18|2007-05-15|2007-05-16|Estimate|||||||2015-12-18|2015-12-21|Estimate|May 2007||2007-05-31|December 2015|2015-12-31|October 2010|Actual|2010-10-31|August 2009|Actual|2009-08-31||Interventional|||Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)|Vicriviroc in Combination Treatment With an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects (VICTOR-E4)|Completed||Phase 3|400|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 03:13:29.973475|2018-06-01 03:13:29.973475
NCT00474357|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2010-12-16|2007-05-15|2007-05-16|Estimate|||||||2010-12-16|2010-12-17|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|BAD||Myths About Bipolar Affective Disorder: The Role of Structured Group Psychoeducation Therapy|Myths About Bipolar Affective Disorder: The Role of Structured Group Psychoeducation Therapy|Unknown status|Recruiting|N/A|110|Anticipated|Lev-Hasharon Mental Healtlh Center||3|||f||||t||||||||||2018-06-01 03:13:30.059229|2018-06-01 03:13:30.059229
NCT00474344|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2014-03-27|2007-05-15|2007-05-16|Estimate|||||||2014-03-27|2014-03-28|Estimate|August 2004||2004-08-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|December 2010|Actual|2010-12-31||Observational|||Genetic Linkage Study of Idiopathic Talipes Equinovarus (ITEV) (Clubfoot)|Genetic Linkage Study of Idiopathic Talipes Equinovarus (ITEV) (Clubfoot)|Completed|||370|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:13:30.14222|2018-06-01 03:13:30.14222
NCT00474331|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2014-12-12|2007-05-15|2007-05-16|Estimate|||||||2014-12-12|2014-12-16|Estimate|June 2004||2004-06-30|December 2014|2014-12-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Observational|||Gene Mutations and Orthopaedic Symptoms Correlation of Multiple Hereditary Exostoses: Multicentre Project|Genotype-Phenotype Correlation of Multiple Hereditary Exostoses: Multicentre Project|Suspended|||2000|Anticipated|University of British Columbia||||Due to unavailability of testing for gene mutation|f||||f||||||||||2018-06-01 03:13:30.202299|2018-06-01 03:13:30.202299
NCT00474318|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2017-08-21|2007-05-15|2007-05-16|Estimate|||||||2017-08-21|2017-08-23|Actual|March 2007||2007-03-31|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|Teen-LABS||Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Adolescent Bariatrics: Assessing Health Benefits and Risk|Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS) Research Project|Enrolling by invitation|||200|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||t||||||Samples With DNA|"~     Serum, plasma and urine, as well as liver samples (if agreed upon as part of the study; may~     participate in the study without giving samples per Informed Consent)~   "|Yes|Data uploaded to NIH repository and available from publications|2018-06-01 03:13:30.344498|2018-06-01 03:13:30.344498
NCT00474305|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2010-12-15|2007-05-15|2007-05-16|Estimate|||||||2010-12-15|2010-12-16|Estimate|December 2007||2007-12-31|May 2010|2010-05-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|||Virtual Reality Prolonged Exposure (PE) for Bus Bomb Survivors|Effectiveness of Virtual Reality for Persons With PTSD Following a Bus Bombing|Unknown status|Recruiting|N/A|5|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 03:13:30.445644|2018-06-01 03:13:30.445644
NCT00474292|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2017-06-30|2007-05-15|2007-05-16|Estimate|||||||2017-06-30|2017-07-02|Actual|May 14, 2007||2007-05-14|April 8, 2011|2011-04-08|April 8, 2011||2011-04-08|||||Observational|||Influence of Area of Brain Damage on Brain Reorganization After Chronic Stroke|Influence of Lesion Location on Cortical Reorganization After Chronic Stroke|Completed|||4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:13:30.520207|2018-06-01 03:13:30.520207
NCT00474279|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2007-05-15|2007-05-15|2007-05-16|Estimate|||||||2007-05-15|2007-05-16|Estimate|July 1998||1998-07-31|May 2007|2007-05-31|June 2004|Actual|2004-06-30|||||Interventional|MOT089||Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults|Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults|Completed||Phase 1/Phase 2|72||University of Virginia|||||f||||t||||||||||2018-06-01 03:13:30.575575|2018-06-01 03:13:30.575575
NCT00474097|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2014-12-12|2007-05-15|2007-05-16|Estimate|||||||2014-12-12|2014-12-15|Estimate|February 2006||2006-02-28|December 2014|2014-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Follow-Up Phone Calls After Colorectal Surgery|Follow-Up Phone Calls After Colorectal Surgery to Assess Patient Satisfaction and Post-Operative Outcomes|Completed|||100|Actual|University Hospitals Cleveland Medical Center|||||f||||f||||||||||2018-06-01 03:13:35.044339|2018-06-01 03:13:35.044339
NCT00474266|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2017-05-17|2009-09-03|2017-05-17|2007-05-15|2007-05-16|Estimate|2017-05-17|2017-12-15|Actual|2009-09-03|2009-09-04|Estimate|2017-05-17|2017-12-15|Actual|June 5, 2007||2007-06-05|November 2016|2016-11-30|March 26, 2008|Actual|2008-03-26|February 26, 2008|Actual|2008-02-26||Interventional|||Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children|Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children|Completed||Phase 3|1000|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:13:30.745086|2018-06-01 03:13:30.745086
NCT00474253|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2017-08-18|2007-05-15|2007-05-16|Estimate|||||||2017-08-18|2017-08-22|Actual|February 10, 2006|Actual|2006-02-10|August 2017|2017-08-31|September 9, 2006|Actual|2006-09-09|August 22, 2006|Actual|2006-08-22||Interventional|||Comparison of Recovery From Rocuronium 1.2 mg/kg Followed By Org 25969 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)|A Multicenter, Randomized, Parallel Group, Comparative, Active-Controlled, Safety-Assessor Blinded, Phase IIIa, Trial, in Adult Subjects Comparing Recovery From 1.2 mg.Kg-1 Rocuronium Followed by 16 mg.Kg-1 Org 25969 at 3 Minutes With Recovery From 1.0 mg.Kg-1 Succinylcholine|Completed||Phase 3|115|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:13:32.242344|2018-06-01 03:13:32.242344
NCT00474240|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2013-01-18||2018-02-21|2007-05-14|2007-05-16|Estimate|2013-01-18|2013-02-21|Estimate||||2018-02-21|2018-03-20|Actual|April 2007||2007-04-30|January 2013|2013-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) and Atorvastatin 20 mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia|Completed||Phase 2|157|Actual|Aegerion Pharmaceuticals, Inc.|Study AEGR-733-003, initiated in May 2007, was halted, and restarted under an amended Protocol in November 2007.|6|||f||||f||||||||||2018-06-01 03:13:32.364769|2018-06-01 03:13:32.364769
NCT00474227|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2008-05-01|2007-05-15|2007-05-16|Estimate|||||||2008-05-01|2008-05-02|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Proper Nutrition, Physical Exercise and Appropriate Weight in Individuals With Long Term Mental Illness|Proper Nutrition, Physical Exercise and Appropriate Weight in Individuals With Long Term Mental Illness|Completed||N/A|50|Anticipated|Lev-Hasharon Mental Healtlh Center||2|||f||||t||||||||||2018-06-01 03:13:33.129074|2018-06-01 03:13:33.129074
NCT00474214|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2010-02-22|2007-05-15|2007-05-16|Estimate|||||||2010-02-22|2010-02-23|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|SAFE-DEPART||Safety And Feasibility of Early DischargE - a Prospective And Randomized Trial of Low-risk Primary Percutaneous Coronary Intervention (PCI) Patients|Safety And Feasibility of Early DischargE - a Prospective And Randomized Trial of Low-risk Primary PCI Patients (The SAFE-DEPART Trial)|Completed||N/A|54|Actual|McMaster University|||||f||||f||||||||||2018-06-01 03:13:33.209622|2018-06-01 03:13:33.209622
NCT00474201|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2010-03-23||2016-09-23|2007-05-15|2007-05-16|Estimate|2012-03-13|2012-04-09|Estimate||||2016-09-23|2016-09-26|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|GEM-PK||Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil|The Influence of Lopinavir/Ritonavir on Gemfibrozil Pharmacokinetics in Healthy Volunteers|Completed||N/A|15|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 03:13:33.347136|2018-06-01 03:13:33.347136
NCT00474188|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2009-06-30||2009-08-27|2007-05-15|2007-05-16|Estimate|2009-06-30|2009-08-13|Estimate||||2009-08-27|2009-09-02|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid ®) in Combination With Dexamethasone in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Terminated||Phase 2|26|Actual|Celgene|Study terminated prematurely as a business decision. Analyses of efficacy not conducted.|1||Business decision|f||||t||||||||||2018-06-01 03:13:33.530461|2018-06-01 03:13:33.530461
NCT00474175|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2011-12-09||2013-02-22|2007-05-15|2007-05-16|Estimate|2011-12-09|2012-01-18|Estimate||||2013-02-22|2013-02-28|Estimate|May 2007||2007-05-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Benzocaine Gel Toothache Dose-Response Study|Benzocaine Gel Toothache Dose-Response Study|Completed||Phase 4|577|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 03:13:33.826214|2018-06-01 03:13:33.826214
NCT00474162|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2008-02-20|2007-05-15|2007-05-16|Estimate|||||||2008-02-20|2008-02-21|Estimate|May 2007||2007-05-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Clotting Effects of Pentastarch and Normal Saline in Obstetric Patients|Observational Pilot Study of the Effect of Intravenous Saline or Pentastarch on Coagulation in Women Having an Elective Cesarean Section|Completed||N/A|30|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:13:34.494147|2018-06-01 03:13:34.494147
NCT00474136|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2007-12-27|2007-05-15|2007-05-16|Estimate|||||||2007-12-27|2008-01-04|Estimate|March 2007||2007-03-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium|Open-Label, Randomized, Single Center Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses) Versus Oral Diclofenac Potassium in Healthy Adult Volunteers Following Single- and Multiple-Dose Administration|Completed||Phase 1|36|Actual|Javelin Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:13:34.550277|2018-06-01 03:13:34.550277
NCT00474123|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2010-01-08||2010-06-18|2007-05-15|2007-05-16|Estimate|2010-06-18|2010-07-14|Estimate||||2010-06-18|2010-07-14|Estimate|January 2006||2006-01-31|February 2010|2010-02-28|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe|Comparison of Antiplatelet and Anti-inflammatory Effects of High Dose Statin Monotherapy Versus Moderate Dose Statin Plus Ezetimibe|Completed||N/A|78|Actual|University of Sao Paulo|Adverse Events were assessed, but none were observed.|2|||f||||f||||||||||2018-06-01 03:13:34.648794|2018-06-01 03:13:34.648794
NCT00474110|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2010-10-29|2007-05-15|2007-05-16|Estimate|||||||2010-10-29|2010-11-01|Estimate|August 2009||2009-08-31|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's Mucositis|Ketamine and Hydromorphone PCA Analgesia for Antineoplastic-Induced Pediatric Mucositis|Withdrawn||Phase 3|0|Actual|University of British Columbia||1||"Clinical practice had changed between time of initial protocol development and subject~   recruitment. We were not able to find eligible patients."|f||||f||||||||||2018-06-01 03:13:34.969803|2018-06-01 03:13:34.969803
NCT00474084|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2007-05-15|2007-05-15|2007-05-16|Estimate|||||||2007-05-15|2007-05-16|Estimate|July 2007||2007-07-31|May 2007|2007-05-31||||||||Interventional|HApFIM||Hydroxyapatite Active Pro Healing Clinical Trial Program|First In Man Evaluation of the Vesta™ & VestaCOR™ (Hydroxy-Apetite Coated genX™) Stent for Treatment of de Novo Native Coronary Artery Lesion(s)|Unknown status|Not yet recruiting|N/A|70|Anticipated|BioSync Scientific Pvt. Ltd.|||||f||||t||||||||||2018-06-01 03:13:35.250323|2018-06-01 03:13:35.250323
NCT00474071|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2008-09-24|2007-05-15|2007-05-16|Estimate|||||||2008-09-24|2008-09-25|Estimate|March 2007||2007-03-31|May 2007|2007-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Optimum Dose of Remifentanil for Intubation in Small Children|Investigation to Determine the Optimum Dose of Remifentanil for Tracheal Intubation in Children Using the Up/Down Method|Completed||Phase 3|60|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:13:35.31102|2018-06-01 03:13:35.31102
NCT00474058|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2010-02-25||2015-05-26|2007-05-15|2007-05-16|Estimate|2010-03-29|2010-04-12|Estimate||||2015-05-26|2015-06-22|Estimate|May 2007||2007-05-31|May 2015|2015-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|RECOVER||Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine|Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease|Completed||Phase 3|287|Actual|UCB Pharma|During the course of the trial, the manufacturing process for rotigotine was changed. At that time, the expiry date for trial medication was Apr 2009, recruitment for SP889 had to be stopped effective on 17 Nov 2008.|2|||f||||f||||||||||2018-06-01 03:13:35.401975|2018-06-01 03:13:35.401975
NCT00474045|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2011-08-05||2017-01-30|2007-05-15|2007-05-16|Estimate|2011-10-28|2011-12-05|Estimate||||2017-01-30|2017-03-10|Actual|May 2007||2007-05-31|January 2017|2017-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes|A Randomised, Parallel-group, Open-labelled, Multinational Trial Comparing the Efficacy and Safety of Insulin Detemir (Levemir®) Versus Human Insulin (NPH Insulin), Used in Combination With Insulin Aspart as Bolus Insulin, in the Treatment of Pregnant Women With Type 1 Diabetes|Completed||Phase 3|470|Actual|Novo Nordisk A/S||2|||f||||t||||||||||2018-06-01 03:13:36.047406|2018-06-01 03:13:36.047406
NCT00474032|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2016-05-30|2007-05-15|2007-05-16|Estimate|||||||2016-05-30|2016-06-01|Estimate|March 2003||2003-03-31|May 2016|2016-05-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Using Botox to Treat Patients With Idiopathic Clubfoot|Efficacy of Botox in Patients With Idiopathic Clubfoot|Recruiting||N/A|2000|Anticipated|University of British Columbia|||||f||||t||||||||||2018-06-01 03:13:37.789393|2018-06-01 03:13:37.789393
NCT00474019|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2010-12-02|2007-05-14|2007-05-16|Estimate|||||||2010-12-02|2010-12-03|Estimate|October 2007||2007-10-31|December 2010|2010-12-31|October 2009|Actual|2009-10-31|||||Interventional|||Phase 1 Pharmacokinetics of Intravenous Nexium in Children|A Phase I, Randomised, Open-label, Multi-National Study to Evaluate the Pharmacokinetics of Repeated Once-Daily Intravenous Doses of Esomeprazole in Paediatric Patients 0 to 17 Years Old, Inclusive.|Completed||Phase 1|42|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-06-01 03:13:37.863405|2018-06-01 03:13:37.863405
NCT00474006|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2011-06-08|2007-05-15|2007-05-16|Estimate|||||||2011-06-08|2011-06-10|Estimate|August 2001||2001-08-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|August 2008|Actual|2008-08-31||Interventional|ADcomparison||High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML|A RANDOMIZED COMPARISON OF TWO DIFFERENT DOSAGES OF DAUNORUBICIN IN INDUCTION TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA|Completed||Phase 3|398|Actual|Cooperative Study Group A for Hematology||1|||f||||f||||||||||2018-06-01 03:13:37.955623|2018-06-01 03:13:37.955623
NCT00473993|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2009-02-13|2007-05-15|2007-05-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|July 2007||2007-07-31|May 2007|2007-05-31|December 2007|Actual|2007-12-31|||||Observational|HepCOP||Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland|Hepatitis C Bei Opioidabhängigen in Der Praxis, Eine Querschnittsuntersuchung|Completed|||||Seidenberg, Arztpraxis A., M.D.|||||f||||t||||||||||2018-06-01 03:13:38.046041|2018-06-01 03:13:38.046041
NCT00473980|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2012-03-30|2007-05-15|2007-05-16|Estimate|||||||2012-03-30|2012-04-02|Estimate|December 1998||1998-12-31|March 2012|2012-03-31|May 2007|Actual|2007-05-31|||||Interventional|||Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients|Preoperative Treatment With NSAID in Colorectal Cancer Patients in Relationship to Tumor Host Reactions|Completed||Phase 4|28|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 03:13:38.10523|2018-06-01 03:13:38.10523
NCT00473967|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2012-07-06|2007-05-14|2007-05-16|Estimate|||||||2012-07-06|2012-07-09|Estimate|May 2007||2007-05-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults|Double-blind, Randomized, Controlled Phase 1 Study of the Safety and Immunogenicity of Na-ASP-2 Hookworm Vaccine in Previously-Infected Brazilian Adults|Terminated||Phase 1|9|Actual|Albert B. Sabin Vaccine Institute||2||Occurrence of unacceptable adverse events.|f||||t||||||||||2018-06-01 03:13:38.179372|2018-06-01 03:13:38.179372
NCT00473954|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2013-03-25|2007-05-15|2007-05-16|Estimate|||||||2013-03-25|2013-03-26|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer|A Phase 1, Open-Label, Dose Escalation Study of the Safety and Preliminary Efficacy of EGEN-001 in Combination With Carboplatin and Docetaxel in Women With Recurrent, Platinum-Sensitive, Epithelial Ovarian Cancer|Completed||Phase 1|13|Actual|EGEN, Inc.||1|||f||||t||||||||||2018-06-01 03:13:38.272292|2018-06-01 03:13:38.272292
NCT00473941|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2011-08-24|2007-05-15|2007-05-16|Estimate|||||||2011-08-24|2011-08-25|Estimate|September 2005||2005-09-30|September 2010|2010-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Life After Cancer Treatment Study|Expressive Writing and Adjustment to Colorectal Cancer|Completed||N/A|150|Anticipated|Temple University||2|||f||||t||||||||||2018-06-01 03:13:38.328014|2018-06-01 03:13:38.328014
NCT00473928|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2010-03-16|2007-05-14|2007-05-16|Estimate|||||||2010-03-16|2010-03-18|Estimate|May 2007||2007-05-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|ASaP||Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)|Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)|Completed||Phase 1|27|Actual|Potentia Pharmaceuticals, Inc.|||||f||||t||||||||||2018-06-01 03:13:38.386143|2018-06-01 03:13:38.386143
NCT00473915|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2013-05-30|2007-05-14|2007-05-16|Estimate|||||||2013-05-30|2013-06-03|Estimate|April 2007||2007-04-30|May 2013|2013-05-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Intranasal Steroids and the Nasal Ocular Response|Intranasal Steroids Prevent Antigen-Induced Hyperresponsiveness of the Nasal Ocular Response|Completed||Phase 4|20|Anticipated|University of Chicago|||||f||||f||||||||||2018-06-01 03:13:38.442921|2018-06-01 03:13:38.442921
NCT00473902|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2007-05-15|2007-05-15|2007-05-16|Estimate|||||||2007-05-15|2007-05-16|Estimate|August 2003||2003-08-31|May 2007|2007-05-31|September 2004|Actual|2004-09-30|||||Interventional|OTR||Older Adult Training Study With Creatine and CLA|Creatine Monohydrate and Conjugated Linoleic Acid Improve Strength and Body Composition Following Resistance Exercise in Older Adults|Completed||N/A|39|Actual|McMaster University|||||f||||f||||||||||2018-06-01 03:13:38.513965|2018-06-01 03:13:38.513965
NCT00473889|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2009-09-03||2015-06-08|2007-05-14|2007-05-16|Estimate|2009-09-03|2009-10-12|Estimate||||2015-06-08|2015-07-03|Estimate|May 2007||2007-05-31|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)|A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination With Vorinostat or Placebo in Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC)|Terminated||Phase 2/Phase 3|253|Actual|Merck Sharp & Dohme Corp.|The study was stopped following a pre-planned interim analysis because the goal for this study to continue was not met, based on 100 events, a reduction in the hazard ratio for progression-free survival by > 23% with a one-sided p-value < 0.1|2||"The study was terminated based on the recommendation by the DSMB following a pre-planned~   protocol interim analysis because the endpoint was not achieved."|f||||f||||||||||2018-06-01 03:13:38.583001|2018-06-01 03:13:38.583001
NCT00473876|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2013-01-14||2013-05-28|2007-05-15|2007-05-16|Estimate|2013-05-28|2013-06-06|Estimate||||2013-05-28|2013-06-06|Estimate|August 2007||2007-08-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|TAYSIDE||Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)|Metformin in Insulin Resistant LV Dysfunction, a Double-blind, Placebo-controlled Trial (TAYSIDE Trial)|Completed||Phase 4|62|Actual|University of Dundee||2|||f||||t||||||||||2018-06-01 03:13:40.216233|2018-06-01 03:13:40.216233
NCT00473863|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|||2007-11-19|2007-05-15|2007-05-16|Estimate|||||||2007-11-19|2007-11-20|Estimate|November 2007||2007-11-30|November 2007|2007-11-30|July 2008|Anticipated|2008-07-31|||||Interventional|CCTA||Coronary Computed Tomographic Angiography in Emergency Department Chest Pain Patients at Intermediate Risk of Acute Coronary Syndrome|Coronary Computed Tomographic Angiography in Emergency Department Chest Pain Patients at Intermediate Risk of Acute Coronary Syndrome|Unknown status|Recruiting|Phase 3|150|Anticipated|Vancouver General Hospital||2|||f||||f||||||||||2018-06-01 03:13:40.499489|2018-06-01 03:13:40.499489
NCT00473850|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2011-04-13|2007-05-15|2007-05-16|Estimate|||||||2011-04-13|2011-04-15|Estimate|December 1998||1998-12-31|April 2011|2011-04-30|March 2023|Anticipated|2023-03-31|||||Observational|||Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC|Establishing the Genetic Profile of Multiple Hereditary Exostoses (HME) in Families of BC|Terminated|||2000|Anticipated|University of British Columbia||||"This study is recruiting under a different title - Genotype-Phenotype Correlation of Multiple~   Hereditary Exostoses: Multicentre Project NCT00474331"|f||||||||||||||2018-06-01 03:13:40.676502|2018-06-01 03:13:40.676502
NCT00473837|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-15|2014-10-09||2014-10-09|2007-05-15|2007-05-16|Estimate|2014-10-09|2014-10-13|Estimate||||2014-10-09|2014-10-13|Estimate|July 2007||2007-07-31|October 2014|2014-10-31|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|CQ-PMA||Chloroquine and Post Malaria Anaemia Study|Chloroquine as a Therapeutic Option for Mild Post Malaria Anaemia|Completed||N/A|96|Actual|Medical Research Council Unit, The Gambia||2|||f||||f||||||||||2018-06-01 03:13:40.75013|2018-06-01 03:13:40.75013
NCT00473824|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2012-01-05||2017-01-30|2007-05-14|2007-05-16|Estimate|2012-01-05|2012-02-07|Estimate||||2017-01-30|2017-03-10|Actual|May 2007||2007-05-31|May 2012|2012-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation|A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients|Terminated||Phase 2|7|Actual|Biotest Pharmaceuticals Corporation|Early termination by sponsor due to data from the initial 7 patients of 36 planned for this study. Therefore, statistical analysis was not performed and no conclusion were reached regarding efficacy or drug safety.|2||New sponsor's decision to pursue a redesigned clinical study|f||||f||||||||||2018-06-01 03:13:41.03536|2018-06-01 03:13:41.03536
NCT00473811|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2012-08-28|2007-05-14|2007-05-16|Estimate|||||||2012-08-28|2012-08-30|Estimate|August 2005||2005-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|DEEP||Diabetic Educational Eating Plan|Applicability of a Low Glycemic Index Diet in Diabetes|Completed||Phase 1/Phase 2|40|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 03:13:41.426319|2018-06-01 03:13:41.426319
NCT00473798|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2018-03-13|2007-05-15|2007-05-16|Estimate|||||||2018-03-13|2018-03-15|Actual|July 1999|Actual|1999-07-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer|Patient Satisfaction and Psychological Distress Related to Emerging Technologies for Cervical Cancer Screening and Diagnosis|Active, not recruiting|||5885|Anticipated|M.D. Anderson Cancer Center|||5||f||||t|f|f||||||||2018-06-01 03:13:41.530993|2018-06-01 03:13:41.530993
NCT00473785|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2007-05-14|2007-05-14|2007-05-15|Estimate|||||||2007-05-14|2007-05-15|Estimate|January 2002||2002-01-31|May 2007|2007-05-31|December 2005|Actual|2005-12-31|||||Interventional|COHRT||CVD Risk Reduction Trial|Community Outreach Heart Health and Risk Reduction Trial|Completed||N/A|827|Actual|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 03:13:41.641458|2018-06-01 03:13:41.641458
NCT00473772|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2014-05-05|2007-05-14|2007-05-15|Estimate|||||||2014-05-05|2014-05-06|Estimate|July 2007||2007-07-31|May 2014|2014-05-31|January 2011|Actual|2011-01-31|October 2008|Actual|2008-10-31||Interventional|PEPCADIII||DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery Disease|Paclitaxel-Eluting PTCA-Balloon in Combination With the CoroflexTM Blue Stent vs the Sirolimus Coated CypherTM Stent in the Treatment of Advanced Coronary Artery Disease|Completed||Phase 1/Phase 2|643|Actual|University Hospital, Saarland||2|||f||||t||||||||||2018-06-01 03:13:41.734265|2018-06-01 03:13:41.734265
NCT00473746|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|2013-12-20||2014-03-27|2007-05-11|2007-05-15|Estimate|2014-03-27|2014-04-29|Estimate||||2014-03-27|2014-04-29|Estimate|June 2006||2006-06-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer|Phase I/II Open Label Dose Escalation Study of the 17α-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer|Completed||Phase 1/Phase 2|66|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-06-01 03:13:41.929211|2018-06-01 03:13:41.929211
NCT00473733|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-13|||2007-05-14|2007-05-14|2007-05-15|Estimate|||||||2007-05-14|2007-05-15|Estimate||||April 2007|2007-04-30||||||||Interventional|GLP||Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2||Unknown status|Not yet recruiting|Phase 4|||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:13:43.392827|2018-06-01 03:13:43.392827
NCT00473720|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2013-01-21|2007-05-11|2007-05-15|Estimate|||||||2013-01-21|2013-01-23|Estimate|May 2007||2007-05-31|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers|Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers|Completed||Phase 1|15|Actual|Yale University||1|||f||||f||||||||||2018-06-01 03:13:43.470983|2018-06-01 03:13:43.470983
NCT00473707|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2008-05-14|2007-05-14|2007-05-15|Estimate|||||||2008-05-14|2008-05-15|Estimate|August 2002||2002-08-31|May 2008|2008-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Active Versus Expectant Management of the Third Stage of Labor|A Randomized Trial of Active Versus Expectant Management of the Third Stage of Labor|Completed||N/A|218|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-06-01 03:13:43.546452|2018-06-01 03:13:43.546452
NCT00473694|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2017-08-18|2007-05-14|2007-05-15|Estimate|||||||2017-08-18|2017-08-22|Actual|November 28, 2005|Actual|2005-11-28|August 2017|2017-08-31|January 29, 2007|Actual|2007-01-29|November 6, 2006|Actual|2006-11-06||Interventional|||Comparison of Sugammadex With Neostigmine Administered at 1-2 PTCs After Administration of Rocuronium or Vecuronium (19.4.302)(P05945)|A Multicenter Randomized Parallel Group Comparative Active-Controlled Safety-Assessor Blinded Phase 3a, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a NMB Induced by Maintenance Dosing of Rocuronium or Vecuronium at 1-2 PTCs|Completed||Phase 3|182|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 03:13:43.613373|2018-06-01 03:13:43.613373
NCT00473681|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2008-05-05|2007-05-14|2007-05-15|Estimate|||||||2008-05-05|2008-05-07|Estimate|September 2003||2003-09-30|May 2008|2008-05-31|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Interventional|HBP||Intervention Study to Control High Blood Pressure for Korean American|High Blood Pressure Care for Korean Americans|Completed||N/A|445|Actual|Johns Hopkins University|||||f||||t||||||||||2018-06-01 03:13:43.674912|2018-06-01 03:13:43.674912
NCT00473668|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2017-03-21|2009-05-20|2017-08-17|2007-05-14|2007-05-15|Estimate|2017-08-17|2017-08-18|Actual|2009-09-28|2009-09-30|Estimate|2017-08-17|2017-08-18|Actual|June 1, 2007||2007-06-01|March 2017|2017-03-31|January 30, 2008|Actual|2008-01-30|January 30, 2008|Actual|2008-01-30||Interventional|||Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib|Non-inferiority of One Formulation of GSK Biologicals' DTPw-HBV/Hib to 2 Formulations of GSK Biologicals' DTPw-HBV/Hib With Respect to the Immune Response to the PRP Antigen, When Administered to Healthy Infants at 6, 10, 14 Weeks of Age|Completed||Phase 3|300|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:13:43.819285|2018-06-01 03:13:43.819285
NCT00473655|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2010-05-10||2010-11-30|2007-05-14|2007-05-15|Estimate|2010-05-10|2010-06-08|Estimate||||2010-11-30|2010-12-16|Estimate|January 2007||2007-01-31|November 2010|2010-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients|A Double-blind, Double Dummy, Phase IV, Randomized, Multicenter, Parallel Group, Placebo Controlled Trial to Evaluate the Effect of Rosuvastatin on Triglycerides Levels in Mexican Hypertriglyceridemic Patients|Completed||Phase 4|334|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:13:44.740228|2018-06-01 03:13:44.740228
NCT00473642|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2011-09-20||2012-10-09|2007-05-14|2007-05-15|Estimate|2012-10-09|2012-11-08|Estimate||||2012-10-09|2012-11-08|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|April 2010|Actual|2010-04-30|May 2009|Actual|2009-05-31||Interventional|||Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration|A Prospective Pilot Study of Reduced Fluence Photodynamic Therapy With Visudyne® (Verteporfin) in Combination With Lucentis™ (Ranibizumab) for the Treatment of Age-Related Macular Degeneration|Completed||Phase 4|31|Actual|Oklahoma State University Center for Health Sciences|This study was limited by a small number of subjects. Additionally, several subjects did not meet the 12 month study endpoint. These subjects were included in the final analysis if their last visit was within 2 months of the final endpoint.|3|||f||||f||||||||||2018-06-01 03:13:45.187751|2018-06-01 03:13:45.187751
NCT00473616|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2011-02-10|2007-05-14|2007-05-15|Estimate|||||||2011-02-10|2011-02-11|Estimate|May 2007||2007-05-31|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan|A Phase I Open-label, Multi-center, Dose-escalation and Safety Expansion Study to Assess Safety, Tolerability, and Pharmacokinectics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose of Irinotecan in Patients With Advanced Solid Malignancies.|Terminated||Phase 1|60|Anticipated|AstraZeneca||1||"Termination of the study was made after a full review of program data and assessment of the~   current risk-benefit profile."|f||||f||||||||||2018-06-01 03:13:45.447043|2018-06-01 03:13:45.447043
NCT00473603|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2018-01-23|2007-05-14|2007-05-15|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2006||2006-12-31|January 2018|2018-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Free Fatty Acids (FFA) on Androgen Precursors in Women|Effect of Free Fatty Acids on Androgen Precursors in Vivo in Healthy Young Women|Completed||N/A|13|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 03:13:45.5375|2018-06-01 03:13:45.5375
NCT00473590|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2011-03-31||2017-05-19|2007-05-14|2007-05-15|Estimate|2011-12-13|2012-01-19|Estimate||||2017-05-19|2017-06-14|Actual|June 2007|Actual|2007-06-30|May 2017|2017-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|AMBER||A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)|A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|102|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:13:45.65853|2018-06-01 03:13:45.65853
NCT00473577|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2010-08-24|2007-05-14|2007-05-15|Estimate|||||||2010-08-24|2010-08-25|Estimate|August 2005||2005-08-31|August 2010|2010-08-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients|Two Phase, Open-Label, Sequential, Ascending Dose Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients|Completed||Phase 1|40|Anticipated|Pharmacyclics LLC.|||||f||||t||||||||||2018-06-01 03:13:46.108945|2018-06-01 03:13:46.108945
NCT00473564|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2015-04-14||2016-02-05|2007-05-14|2007-05-15|Estimate|2015-04-14|2015-04-30|Estimate||||2016-02-05|2016-03-08|Estimate|February 2007||2007-02-28|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery|Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery|Completed||N/A|170|Actual|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-06-01 03:13:46.169369|2018-06-01 03:13:46.169369
NCT00473551|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2011-12-16|2007-05-11|2007-05-15|Estimate|||||||2011-12-16|2011-12-19|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies|Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Treatment of Indolent Lymphoid Malignancies|Terminated||Phase 1|4|Actual|M.D. Anderson Cancer Center||1||Terminated due to slow accrual.|f||||f||||||||||2018-06-01 03:13:46.481574|2018-06-01 03:13:46.481574
NCT00473538|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2007-11-13|2007-05-14|2007-05-15|Estimate|||||||2007-11-13|2007-11-14|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|August 2006||2006-08-31|||||Interventional|||Structured Exercise Training Program Versus Hypocaloric Hyperproteic Diet in Obese Anovulatory Infertile Patients With PCOS|Effects of Structured Exercise Program Versus Hypocaloric Hyperproteic Diet on the Reproductive Function in Obese Anovulatory Infertile Patients With Polycystic Ovary Syndrome: a 24-Week Prospective Study.|Completed||Phase 4|40|Actual|University Magna Graecia|||||f||||f||||||||||2018-06-01 03:13:46.575782|2018-06-01 03:13:46.575782
NCT00473525|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14||2009-03-20|2010-06-22|2007-05-14|2007-05-15|Estimate||||2009-09-24|2009-09-28|Estimate|2010-06-22|2010-06-24|Estimate|July 2007||2007-07-31|June 2010|2010-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin|A Phase 2a, Randomized, Placebo-Controlled, Parallel Group, Multiple-Dose Study To Evaluate The Efficacy, Safety, And Tolerability Of 12-Week Oral Administration Of PF-00734200 Tablets To Subjects With Type 2 Diabetes Mellitus On Stable Treatment With Metformin|Completed||Phase 2|303|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 03:13:46.653614|2018-06-01 03:13:46.653614
NCT00473512|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|2013-06-07||2014-02-27|2007-05-11|2007-05-15|Estimate|2013-06-07|2013-08-29|Estimate||||2014-02-27|2014-03-27|Estimate|November 2005||2005-11-30|February 2014|2014-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy|A Phase I/II Open Label Study of the 17α-Hydroxylase/ C17,20 Lyase Inhibitor, Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy|Completed||Phase 1/Phase 2|54|Actual|Cougar Biotechnology, Inc.||1|||f||||t||||||||||2018-06-01 03:13:46.852592|2018-06-01 03:13:46.852592
NCT00473499|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2010-06-29|2007-05-14|2007-05-15|Estimate|||||||2010-06-29|2010-06-30|Estimate|July 2007||2007-07-31|June 2010|2010-06-30|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|PEPCADIIIsub||PEPCAD III Substudy: Stem Cell Mobilization|Paclitaxel-Eluting PTCA-Balloon in Combination With the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease - Substudy Homburg/Saar|Completed||Phase 1/Phase 2|60|Anticipated|University Hospital, Saarland||3|||f||||t||||||||||2018-06-01 03:13:48.119561|2018-06-01 03:13:48.119561
NCT00473486|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2010-01-26|2007-05-14|2007-05-15|Estimate|||||||2010-01-26|2010-01-27|Estimate|May 2007||2007-05-31|June 2007|2007-06-30|January 2010|Actual|2010-01-31|August 2008|Actual|2008-08-31||Interventional|PECASO||Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib|A Randomized (PhaseII), Double-blind, Multicenter Phase I/II Trial of Pemetrexed, Carboplatin Plus or Minus Sorafenib in the First-line Treatment of Patients With Stage IIIb or IV Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|12|Actual|University Hospital Muenster||2||"Sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance~   thrombocytopenia compared to historical data."|f||||t||||||||||2018-06-01 03:13:48.203043|2018-06-01 03:13:48.203043
NCT00473473|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2012-02-19|2007-05-14|2007-05-15|Estimate|||||||2012-02-19|2012-02-22|Estimate|July 2008||2008-07-31|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effect of the Homeopathic Remedy Kalium Bichromicum (Potassium Dichromate) on Viscosity and Amount of Sputum and Time to Extubation in Mechanically Ventilated ICU Patients.|A Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Investigate the Efficacy and Safety of the Homeopathic Remedy Kalium Bichromicum (Potassium Dichromate) to Decrease Viscosity and Amount of Sputum as Well as Time to Extubation, in Intubated Mechanically Ventilated ICU Patients.|Unknown status|Recruiting|Phase 3|56|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-06-01 03:13:48.284587|2018-06-01 03:13:48.284587
NCT00473460|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2014-10-27|2007-05-14|2007-05-15|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2004||2004-10-31|October 2014|2014-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis|A Double-blind, Randomized, Placebo-controlled Study to Investigate Chronic Intermittent-pulse-therapy of Moxifloxacin as a Prevention of Acute in Exacerbation Out-patients With Chronic Bronchitis.|Completed||Phase 3|1404|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:13:48.374467|2018-06-01 03:13:48.374467
NCT00473447|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2007-05-14|2007-05-14|2007-05-15|Estimate|||||||2007-05-14|2007-05-15|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|April 2006|Actual|2006-04-30|||||Interventional|mCIT||A Modified Constraint-Induced Movement Therapy Program in Rehabilitation of Arm Paresis in Children With Cerebral Palsy|Phase1 Effectiveness of a Modified Constraint-Induced Movement Therapy Program in Rehabilitation of Arm Paresis in Children With Cerebral Palsy: a Cross-Over Study|Completed||Phase 1|10|Actual|Universita di Verona|||||f||||f||||||||||2018-06-01 03:13:48.63918|2018-06-01 03:13:48.63918
NCT00473434|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|2012-06-26||2012-12-04|2007-05-11|2007-05-15|Estimate|2012-09-05|2012-10-08|Estimate||||2012-12-04|2012-12-05|Estimate|April 2007||2007-04-30|December 2012|2012-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia|An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia|Completed||Phase 3|64|Actual|Janssen-Cilag Pty Ltd||1|||f||||f||||||||||2018-06-01 03:13:48.726065|2018-06-01 03:13:48.726065
NCT00473421|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2007-05-14|2007-05-14|2007-05-15|Estimate|||||||2007-05-14|2007-05-15|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Interventional|||"How do Contrast Medias in Bone Cement Affect DXA Measurements After THR"||Unknown status|Recruiting|Phase 1/Phase 2|||Ullevaal University Hospital|||||f||||f||||||||||2018-06-01 03:13:49.269515|2018-06-01 03:13:49.269515
NCT00473408|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2016-12-05|2007-05-14|2007-05-15|Estimate|||||||2016-12-05|2016-12-06|Estimate|March 2007||2007-03-31|December 2016|2016-12-31|November 2011|Actual|2011-11-30|May 2007|Actual|2007-05-31||Observational|Gliomstudien||The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas|The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas|Terminated|||1|Actual|Haukeland University Hospital||||Moved to another country, not possible to recruit from abroad.|f||||f||||||Samples With DNA|"~     Tumor samples and blood samples are collected and frozen for future analysis for tumor~     vascularization and tumor stem cells.~   "|No|Only one patient was included before the study was terminated.|2018-06-01 03:13:49.327422|2018-06-01 03:13:49.327422
NCT00473382|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-13|2012-11-30||2017-03-21|2007-05-13|2007-05-15|Estimate|2013-01-16|2013-01-17|Estimate||||2017-03-21|2017-04-17|Actual|June 2007||2007-06-30|March 2017|2017-03-31|September 2012|Actual|2012-09-30|January 2011|Actual|2011-01-31||Interventional|RIDE|The Baseline Characteristics of the patients enrolled in the open-label extension phase (N=88, 83, 84 patients originally randomized to the ranibizumab 0.3 mg, ranibizumab 0.5 mg, and sham injection groups, respectively) were similar to the Baseline Characteristics of the patients enrolled in the core study.|A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)|A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus|Completed||Phase 3|382|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 03:13:49.47822|2018-06-01 03:13:49.47822
NCT00473369|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2007-05-14|2007-05-14|2007-05-15|Estimate|||||||2007-05-14|2007-05-15|Estimate|January 2001||2001-01-31|May 2007|2007-05-31|May 2007|Anticipated|2007-05-31|||||Observational|||Prognosis of Atypical Pituitary Adenomas||Unknown status|Active, not recruiting||||Tohoku University|||||f||||t||||||||||2018-06-01 03:13:52.511768|2018-06-01 03:13:52.511768
NCT00473356|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2013-11-17|2007-05-14|2007-05-15|Estimate|||||||2013-11-17|2013-11-19|Estimate|June 2007||2007-06-30|November 2013|2013-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Nutritional Effect of an Amino Acid Mixture on Lean Body Mass (LBM) in Post-bariatric Surgery Patients|Nutritional Effect of an Amino Acid Mixture on Lean Body Mass (LBM) in Post-bariatric Surgery Patients|Completed||N/A|30|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 03:13:52.560788|2018-06-01 03:13:52.560788
NCT00473343|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2010-09-01|2007-05-14|2007-05-15|Estimate|||||||2010-09-01|2010-09-03|Estimate|September 2000||2000-09-30|September 2010|2010-09-30|June 2006|Actual|2006-06-30|||||Interventional|||"Metvix PDT in Patients With High Risk Basal Cell Carcinoma"|"An Open Multicenter, Phase III Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Patients With High Risk Basal Cell Carcinoma"|Completed||Phase 3|102|Actual|Galderma|||||f||||f||||||||||2018-06-01 03:13:52.642438|2018-06-01 03:13:52.642438
NCT00473330|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-13|2012-12-10||2017-03-21|2007-05-13|2007-05-15|Estimate|2012-12-10|2013-01-17|Estimate||||2017-03-21|2017-04-17|Actual|June 2007||2007-06-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2010|Actual|2010-11-30||Interventional|RISE|The Baseline Characteristics of the patients enrolled in the open-label extension phase (N=88, 83, 84 patients originally randomized to the ranibizumab 0.3 mg, ranibizumab 0.5 mg, and sham injection groups, respectively) were similar to the Baseline Characteristics of the patients enrolled in the core study.|A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)|A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus|Completed||Phase 3|377|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 03:13:52.855077|2018-06-01 03:13:52.855077
NCT00473317|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2008-03-30|2007-05-11|2007-05-15|Estimate|||||||2008-03-30|2008-04-01|Estimate|July 2007||2007-07-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Sunlight Exposures Effect on Serum Vitamin D Levels|Sunlight Exposures Effect on Serum Vitamin D Levels|Completed||N/A|6|Actual|Creighton University||1|||f||||f||||||||||2018-06-01 03:13:56.401407|2018-06-01 03:13:56.401407
NCT00473304|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2010-05-10|2007-05-14|2007-05-15|Estimate|||||||2010-05-10|2010-05-12|Estimate|December 2006||2006-12-31|May 2010|2010-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|CLIP||Contact Lens in Pediatrics (CLIP) in an Asian Population Study||Completed||N/A|60|Anticipated|Singapore National Eye Centre|||||f||||f||||||||||2018-06-01 03:13:56.47673|2018-06-01 03:13:56.47673
NCT00473291|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2009-06-15|2007-05-14|2007-05-15|Estimate|||||||2009-06-15|2009-06-16|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|December 2007|Actual|2007-12-31|||||Observational|||Vibration Response Imaging (VRI) in Management and Evaluation in Patients With Pleural Effusion|Vibration Response Imaging (VRI) in Management and Evaluation in Patients With Pleural Effusion|Completed|||80|Anticipated|Deep Breeze|||1||f||||f||||||||||2018-06-01 03:13:56.54502|2018-06-01 03:13:56.54502
NCT00473278|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2013-01-29|2007-05-11|2007-05-15|Estimate|||||||2013-01-29|2013-01-30|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Analysis of Human Tear Proteins in Children|Analysis of Human Tear Proteins in Children: A Pilot Study to Describe the Tear Film Proteome of Pediatric Patients Undergoing Ophthalmic Examination.|Completed|||2|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-06-01 03:13:56.611491|2018-06-01 03:13:56.611491
NCT00473265|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|2013-10-23||2015-07-14|2007-05-14|2007-05-15|Estimate|2015-07-14|2015-07-16|Estimate||||2015-07-14|2015-07-16|Estimate|May 2004||2004-05-31|July 2015|2015-07-31|June 2014|Actual|2014-06-30|January 2011|Actual|2011-01-31||Interventional||hypoparathyroidism patients who signed Consent to participate in the study|Bone Properties in Hypoparathyroidism: Effects of PTH|Bone Properties in Hypoparathyroidism: Effects of PTH|Completed||Phase 2/Phase 3|68|Actual|Columbia University|Only 16 subjects received a bone biopsy, which is why many of the measurements were only analyzed in 16 subjects. In total, data was only analyzed for the first 30 subjects analyzed for data.|1|||f||||f||||||||||2018-06-01 03:13:56.694634|2018-06-01 03:13:56.694634
NCT00473252|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-14|||2011-05-19|2007-05-14|2007-05-15|Estimate|||||||2011-05-19|2011-05-20|Estimate|May 2006||2006-05-31|May 2011|2011-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Surveillance of Fungal Infections During Construction Activity||Completed|||340|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-06-01 03:13:56.980437|2018-06-01 03:13:56.980437
NCT00473239|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2015-04-30|2007-05-11|2007-05-15|Estimate|||||||2015-04-30|2015-05-04|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|Stoss||The Pharmacokinetics of a Single Large Dose of Vitamin D3|The Pharmacokinetics of a Single Large Dose of Vitamin D3|Completed||N/A|40|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 03:13:57.04822|2018-06-01 03:13:57.04822
NCT00473213|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2007-05-11|2007-05-11|2007-05-14|Estimate|||||||2007-05-11|2007-05-14|Estimate|September 1999||1999-09-30|May 2007|2007-05-31|February 2004|Actual|2004-02-29|||||Interventional|Optims||Optimizing IFN Beta - 1B Dose|Optimizing IFN Beta - 1B Dose|Completed||Phase 3|217|Actual|University of Turin, Italy|||||f||||t||||||||||2018-06-01 03:13:57.127047|2018-06-01 03:13:57.127047
NCT00473200|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2018-03-13|2007-05-11|2007-05-14|Estimate|||||||2018-03-13|2018-03-14|Actual|August 2009||2009-08-31|March 2018|2018-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine|Effect of Oral S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine in Human Subjects|Completed||Phase 1|27|Actual|Baylor Research Institute||2|||f||||t||||||||||2018-06-01 03:13:57.322197|2018-06-01 03:13:57.322197
NCT00473187|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2007-05-11|2007-05-11|2007-05-14|Estimate|||||||2007-05-11|2007-05-14|Estimate|August 2004||2004-08-31|May 2007|2007-05-31|August 2009|Anticipated|2009-08-31|||||Interventional|||Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets|Effects of Growth Hormone Treatment on Body Proportions and Final Height Among Small Children With X-Linked Hypophosphatemic Rickets|Unknown status|Active, not recruiting|Phase 1|||University of Rostock|||||f||||||||||||||2018-06-01 03:13:57.440517|2018-06-01 03:13:57.440517
NCT00473174|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2009-09-01|2007-05-11|2007-05-14|Estimate|||||||2009-09-01|2009-09-02|Estimate|March 2007||2007-03-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|HYCCRA||Comparison of Awakening Versus Bedtime Dosing of Ramipril in Subjects With Essential Hypertension|A Prospective, Randomized, Open Label, Blinded-endpoint Study to Compare Awakening Versus Bedtime Administration of 5-10 mg Ramipril in Terms of Systolic Blood Pressure Lowering Determined by ABPM in Subjects With Mild-to-moderate Essential|Completed||Phase 4|120|Actual|University of Vigo||2|||f||||t||||||||||2018-06-01 03:13:57.501977|2018-06-01 03:13:57.501977
NCT00473161|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2014-05-21|2007-05-11|2007-05-14|Estimate|||||||2014-05-21|2014-05-23|Estimate|May 2007||2007-05-31|May 2014|2014-05-31||||January 2009|Actual|2009-01-31||Observational|||Use of Surface Electromyography Biofeedback to Improve Reaching in Children With Cerebral Palsy||Completed|||20|Anticipated|University of Southern California|||||f||||f||||||||||2018-06-01 03:13:57.583813|2018-06-01 03:13:57.583813
NCT00473148|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2010-04-29|2007-05-11|2007-05-14|Estimate|||||||2010-04-29|2010-04-30|Estimate|June 2007||2007-06-30|November 2008|2008-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|BMW||B-type Natriuretic Peptide for the Management of Weaning|Weaning of Mechanical Ventilation Guided by the Natriuretic Peptide of Type B|Completed||Phase 3|265|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:13:57.65313|2018-06-01 03:13:57.65313
NCT00473135|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2010-01-11|2007-05-11|2007-05-14|Estimate|||||||2010-01-11|2010-01-13|Estimate|May 2007||2007-05-31|January 2008|2008-01-31||||January 2010|Actual|2010-01-31||Interventional|||Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine|Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months|Completed||Phase 1|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 03:13:57.741078|2018-06-01 03:13:57.741078
NCT00473122|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2016-07-14|2007-05-10|2007-05-14|Estimate|||||||2016-07-14|2016-07-15|Estimate|April 2005||2005-04-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Delayed-Immediate Breast Reconstruction|Delayed-Immediate Breast Reconstruction|Completed||Phase 2|200|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:13:57.822857|2018-06-01 03:13:57.822857
NCT00473109|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2009-05-22|2007-05-11|2007-05-14|Estimate|||||||2009-05-22|2009-05-25|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|HDSH||Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study|Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study|Completed||Phase 3|75|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 03:13:57.901663|2018-06-01 03:13:57.901663
NCT00473096|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2015-09-18|2007-05-11|2007-05-14|Estimate|||||||2015-09-18|2015-09-22|Estimate|October 2000||2000-10-31|September 2015|2015-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|H-6019||Efficacy Study of an Educational Program for Decision Support for Breast Cancer|Assessing the Efficacy of a CDSS for Breast Cancer|Completed||N/A|100|Actual|Baylor College of Medicine|||||f||||f||||||||||2018-06-01 03:13:58.062138|2018-06-01 03:13:58.062138
NCT00473083|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2016-01-22||2017-02-16|2007-05-10|2007-05-14|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|January 2009||2009-01-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|LUTRAERL||Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer|A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer|Completed||Phase 2|150|Actual|British Columbia Cancer Agency||3|||f||||f||||||||||2018-06-01 03:13:58.157944|2018-06-01 03:13:58.157944
NCT00473070|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2008-07-28|2007-05-10|2007-05-14|Estimate|||||||2008-07-28|2008-07-29|Estimate|November 2006||2006-11-30|July 2008|2008-07-31||||February 2007|Actual|2007-02-28||Interventional|||A Clinical Study of Tobradex AF|A Clinical Study of Tobradex AF|Completed||Phase 3|900|Anticipated|Alcon Research|||||||||||||||||||2018-06-01 03:13:58.701367|2018-06-01 03:13:58.701367
NCT00473057|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2011-05-18|2007-05-10|2007-05-14|Estimate|||||||2011-05-18|2011-05-19|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Autologous Stem Cell Transplantation for Patients With Ischemic Stroke|Phase I Study of Autologous Bone Marrow Cell Transplantation in Patient With Ischemic Stroke|Completed||Phase 1|12|Actual|Universidade Federal do Rio de Janeiro|||||f||||t||||||||||2018-06-01 03:13:58.758549|2018-06-01 03:13:58.758549
NCT00473044|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2008-12-29|2007-05-10|2007-05-14|Estimate|||||||2008-12-29|2008-12-31|Estimate|April 2006||2006-04-30|December 2008|2008-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||An Intervention to Increase Physical Activity Among African American Women|An Intervention to Increase Physical Activity Among African American Women|Completed||N/A|104|Anticipated|National Institute on Aging (NIA)|||||f||||f||||||||||2018-06-01 03:13:59.179583|2018-06-01 03:13:59.179583
NCT00473031|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2012-07-02|2007-05-10|2007-05-14|Estimate|||||||2012-07-02|2012-07-03|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Effect of Weight Loss and Dietary Protein Intake on Bone|Nutritional Regulation of Bone - Aim 1|Completed||N/A|48|Actual|Rutgers University||2|||f||||t||||||||||2018-06-01 03:13:59.261955|2018-06-01 03:13:59.261955
NCT00473018|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2015-06-01|2007-05-11|2007-05-14|Estimate|||||||2015-06-01|2015-06-02|Estimate||||May 2007|2007-05-31||||||||Interventional|PEP-2||"Behavioral, Clinical and Basic Science Studies of Non-occupational Post-exposure Prophylaxis (PEP-2)"||Completed||N/A|||University of California, San Francisco|||||f||||f||||||||||2018-06-01 03:13:59.33119|2018-06-01 03:13:59.33119
NCT00473005|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2012-05-24|2007-05-11|2007-05-14|Estimate|||||||2012-05-24|2012-05-28|Estimate|August 2007||2007-08-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast|A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer|Terminated||Phase 1|18|Actual|Stanford University||||Principal Investigator (Dr. Guardino) left Stanford|f||||t||||||||||2018-06-01 03:13:59.388766|2018-06-01 03:13:59.388766
NCT00472992|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2014-08-07|2007-05-11|2007-05-14|Estimate|||||||2014-08-07|2014-08-11|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31|52 Weeks|Observational [Patient Registry]|||Pregnancy Exposure Registry for Tysabri®|TYSABRI® Pregnancy Exposure Registry|Completed|||376|Actual|Biogen|||||f||||f||||||||||2018-06-01 03:13:59.471661|2018-06-01 03:13:59.471661
NCT00024817|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-28|||2016-07-14|2001-09-27|2001-09-28|Estimate|||||||2016-07-14|2016-07-15|Estimate|September 1999||1999-09-30|August 2004|2004-08-31|August 2002|Actual|2002-08-31|||||Observational|||Energy Expenditure, Diet and Body Fat in Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:57.12129|2018-06-01 05:33:57.12129
NCT00472966|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2008-03-27|2007-05-11|2007-05-14|Estimate|||||||2008-03-27|2008-03-31|Estimate|November 2006||2006-11-30|March 2008|2008-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma|Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma|Completed||Phase 4|20|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-06-01 03:13:59.534347|2018-06-01 03:13:59.534347
NCT00472953|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2017-02-28|2007-05-11|2007-05-14|Estimate|||||||2017-02-28|2017-03-01|Actual|May 15, 2007|Actual|2007-05-15|February 2017|2017-02-28|March 5, 2008|Actual|2008-03-05|March 5, 2008|Actual|2008-03-05||Interventional|iINHALE 8||Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)|Inhaled Pre-prandial Human Insulin Versus Subcutaneous Injected Insulin Aspart in Subjects With Diabetes and Chronic Obstructive Pulmonary Disease: A 52-week Open Label, Multicentre, Randomized, Parallel Trial to Investigate Long-term Safety|Terminated||Phase 3|38|Actual|Novo Nordisk A/S||2||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:13:59.622282|2018-06-01 03:13:59.622282
NCT00472940|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2011-06-23|2007-05-11|2007-05-14|Estimate|||||||2011-06-23|2011-06-27|Estimate|November 2006||2006-11-30|June 2011|2011-06-30||||||||Observational|||Prevalence of Hypogonadism in Male Cancer Patients|Prevalence of Hypogonadism in Male Cancer Patients|Completed|||135|Anticipated|Baylor College of Medicine|||||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 03:13:59.834323|2018-06-01 03:13:59.834323
NCT00472927|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-12-04|2007-05-11|2007-05-14|Estimate|||||||2007-12-04|2007-12-06|Estimate|May 2007||2007-05-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of Three New Formulations of Premarin 0.45mg/Medroxyprogesterone Acetate (MPA) 1.5mg Compared With a Reference Formulation of Premarin/MPA (PremproTM) 0.45mg/1.5mg in Healthy Postmenopausal Women|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:13:59.920239|2018-06-01 03:13:59.920239
NCT00472914|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2014-05-21|2007-05-11|2007-05-14|Estimate|||||||2014-05-21|2014-05-23|Estimate|January 2007||2007-01-31|May 2014|2014-05-31|March 2007|Actual|2007-03-31|||||Observational|||Use of EMG to Assess Clinical Hypertonia|Initial Assessment of the Use of Surface Electromyography as a Tool for Clinical Evaluation of Hypertonia in Children|Completed|||14||University of Southern California|||||f||||f||||||||||2018-06-01 03:13:59.993506|2018-06-01 03:13:59.993506
NCT00472901|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2011-10-04|2007-05-10|2007-05-14|Estimate|||||||2011-10-04|2011-10-05|Estimate|May 2007||2007-05-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Observational|||Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)|A Phase III, Randomised, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of CUV1647 in Patients Suffering From Polymorphic Light Eruption (PLE).|Completed|||18|Actual|Clinuvel Pharmaceuticals Limited|||||f||||f||||||||||2018-06-01 03:14:00.069633|2018-06-01 03:14:00.069633
NCT00472888|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-05-10|2007-05-10|2007-05-14|Estimate|||||||2007-05-10|2007-05-14|Estimate|November 2005||2005-11-30|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Observational|||Clinical Factors Associated Floppy Iris|Clinical Factors Associated With Floppy Iris Signs: a Prospective Study From Two Centers|Completed|||500|Actual|Baskent University|||||f||||t||||||||||2018-06-01 03:14:00.143514|2018-06-01 03:14:00.143514
NCT00472875|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-05-10|2007-05-10|2007-05-14|Estimate|||||||2007-05-10|2007-05-14|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Interventional|||Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?||Unknown status|Recruiting|Phase 4|10|Anticipated|King's College Hospital NHS Trust|||||f||||f||||||||||2018-06-01 03:14:00.202524|2018-06-01 03:14:00.202524
NCT00472862|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2015-04-14|2007-05-11|2007-05-14|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|NEUROCOM||Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual|NEUROCOM: Cognitive Training for Patients With First Episode Schizophrenia|Completed||Phase 3|117|Actual|Neurocom||2|||f||||f||||||||||2018-06-01 03:14:00.283183|2018-06-01 03:14:00.283183
NCT00472849|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|2013-08-09||2013-11-01|2007-05-11|2007-05-14|Estimate|2013-11-01|2013-11-26|Estimate||||2013-11-01|2013-11-26|Estimate|May 2007||2007-05-31|November 2013|2013-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias|A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|92|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:14:00.381946|2018-06-01 03:14:00.381946
NCT00472836|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11||2009-08-11|2009-08-11|2007-05-11|2007-05-14|Estimate||||2009-08-11|2009-08-13|Estimate|2009-08-11|2009-08-13|Estimate|June 2007||2007-06-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug|A Phase 1, Open-Label, Parallel Group, Multiple-Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of CP-945,598 Administered To Subjects With Severely Impaired And Normal Renal Function|Completed||Phase 1|17|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:14:00.683648|2018-06-01 03:14:00.683648
NCT00472823|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2016-03-11|2007-05-10|2007-05-14|Estimate|||||||2016-03-11|2016-03-14|Estimate|April 2007||2007-04-30|March 2016|2016-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|VIDOS||Vitamin D Supplementation in Older Women|Determination of RDA for Vitamin D in Caucasian and African American Women|Completed||N/A|273|Actual|Creighton University||8|||f||||t||||||||No||2018-06-01 03:14:00.766178|2018-06-01 03:14:00.766178
NCT00472810|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2011-10-06|2007-05-11|2007-05-14|Estimate|||||||2011-10-06|2011-10-07|Estimate|March 2007||2007-03-31|October 2011|2011-10-31||||May 2008|Actual|2008-05-31||Interventional|||Ologen (OculusGen)-Glaucoma MMC Control in Pakistan|Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery|Completed||Phase 3|40|Actual|Pro Top & Mediking Company Limited||2|||f||||f||||||||||2018-06-01 03:14:00.860845|2018-06-01 03:14:00.860845
NCT00472797|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2009-02-18||2013-08-02|2007-05-10|2007-05-14|Estimate|2009-07-23|2009-09-02|Estimate||||2013-08-02|2013-08-07|Estimate|April 2007||2007-04-30|August 2013|2013-08-31|November 2009|Actual|2009-11-30|February 2009|Actual|2009-02-28||Interventional|RebiQoL||Rebif New Formulation (RNF) Quality of Life (QOL) Study|A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF)|Completed||Phase 3|232|Actual|EMD Serono||2|||f||||||||||||||2018-06-01 03:14:00.970182|2018-06-01 03:14:00.970182
NCT00472784|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2016-05-09|2007-05-11|2007-05-14|Estimate|||||||2016-05-09|2016-05-11|Estimate|October 1998||1998-10-31|May 2016|2016-05-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Quantitative and Qualitative Changes in Neural Efferent Receptors|Quantitative and Qualitative Changes in Neural Efferent Receptors, Collagen and Smooth Muscle Content in the Bladder, Following Spinal Cord Injury (SCI) in Humans|Withdrawn|||0|Actual|Baylor College of Medicine||||Study no longer being conducted.|f||||t||||||||||2018-06-01 03:14:01.739541|2018-06-01 03:14:01.739541
NCT00472771|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2012-02-08|2007-05-11|2007-05-14|Estimate|||||||2012-02-08|2012-02-09|Estimate|May 2008||2008-05-31|February 2012|2012-02-29|November 2008|Actual|2008-11-30|||||Interventional|||INNO-206 in Patients With Small Cell Lung Cancer (SCLC)|A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy|Withdrawn||Phase 2|0|Actual|CytRx||||Terminated due to clinical trial material production delays|f||||f||||||||||2018-06-01 03:14:01.801718|2018-06-01 03:14:01.801718
NCT00472758|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2011-11-16|2007-05-11|2007-05-14|Estimate|||||||2011-11-16|2011-11-17|Estimate|February 2007||2007-02-28|November 2011|2011-11-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|CP145||A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545|A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation, Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose, Intravenously Administered MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Chronic Plaque Psoriasis|Completed||Phase 1|40|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 03:14:01.928174|2018-06-01 03:14:01.928174
NCT00472745|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2014-07-12|2007-05-10|2007-05-14|Estimate|||||||2014-07-12|2014-07-15|Estimate|March 2007||2007-03-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Effect of Weight Loss on Bone in Men|Nutritional Regulation of Bone - Pilot Study|Completed||N/A|39|Actual|Rutgers University||2|||f||||t||||||||||2018-06-01 03:14:02.019065|2018-06-01 03:14:02.019065
NCT00472732|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|2015-04-22||2015-05-28|2007-05-11|2007-05-14|Estimate|2015-05-12|2015-05-29|Estimate||||2015-05-28|2015-06-24|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Observational||Half of the subjects were affected and half were normal controls age 18-60|Neurologic Injuries in Adults With Urea Cycle Disorders|Assessing Neural Mechanisms of Injury in Inborn Errors of Urea Metabolism Using Structural MRI, Functional MRI, and Magnetic Resonance Spectroscopy|Completed|||46|Actual|Children's Research Institute|This study examined the neurobiological differences between OTCD patients and controls. This was, however, not a clinical trial, since participants received no form of drug therapy or treatment as part of this study.||2||f||||t||||||||||2018-06-01 03:14:02.188314|2018-06-01 03:14:02.188314
NCT00472719|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2014-10-15|2007-05-11|2007-05-14|Estimate|||||||2014-10-15|2014-10-16|Estimate|August 2007||2007-08-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|July 2008|Actual|2008-07-31||Interventional|||Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults|A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Serotype 35 (rAd35) and Serotype 5 (rAd5) HIV-1 Vaccines When Given in Heterologous Prime-Boost Regimens or as a Boost to a Recombinant DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants With Pre-Existing Immunity to Adenovirus Serotype 5 Infection|Completed||Phase 1|17|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 03:14:02.619985|2018-06-01 03:14:02.619985
NCT00472706|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2010-05-12|2007-05-10|2007-05-14|Estimate|||||||2010-05-12|2010-05-13|Estimate|May 2007||2007-05-31|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Trial of Excision Versus Photodynamic Therapy in the Treatment of Bowen's Disease|A Randomized Clinical Trial of Excision Versus Photodynamic Therapy in Bowen's Disease|Terminated||Phase 4|65|Actual|Catharina Ziekenhuis Eindhoven||2||Study stopped because of disappointing inclusion rates|f||||t||||||||||2018-06-01 03:14:02.779824|2018-06-01 03:14:02.779824
NCT00472693|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2016-09-23|2007-05-11|2007-05-14|Estimate|||||||2016-09-23|2016-09-26|Estimate|May 2007||2007-05-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer|A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer|Completed||Phase 2|5|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-06-01 03:14:02.886712|2018-06-01 03:14:02.886712
NCT00472680|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2014-07-12|2007-05-10|2007-05-14|Estimate|||||||2014-07-12|2014-07-15|Estimate|March 2008||2008-03-31|July 2012|2012-07-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||The Effect of Severe Weight Loss and Protein Intake on Bone|Nutritional Regulation of Bone - Aim 2|Unknown status|Recruiting|N/A|38|Anticipated|Rutgers University||2|||f||||t||||||||||2018-06-01 03:14:02.974564|2018-06-01 03:14:02.974564
NCT00472667|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|||2008-11-24|2007-05-11|2007-05-14|Estimate|||||||2008-11-24|2008-11-25|Estimate|July 2007||2007-07-31|May 2007|2007-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|PRORATA||PROcalcitonin Reduce Antibiotic Treatments in Acute-Ill Patients (PRORATA)|Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients|Completed||N/A|630|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:14:03.134165|2018-06-01 03:14:03.134165
NCT00472654|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2014-10-11|2007-05-10|2007-05-14|Estimate|||||||2014-10-11|2014-10-15|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|||The Effect of Vitamin D Supplementation During Caloric Restriction on Intestinal Calcium Absorption|Nutritional Regulation of Bone - Aim 3|Completed||N/A|83|Actual|Rutgers University||4|||f||||t||||||||||2018-06-01 03:14:03.238981|2018-06-01 03:14:03.238981
NCT00472641|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-11|2016-12-09||2017-03-29|2007-05-11|2007-05-14|Estimate|2017-03-29|2017-05-09|Actual||||2017-03-29|2017-05-09|Actual|January 2007||2007-01-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Geodon in Weight Loss Study for Bipolar Disorders|Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder|Completed||Phase 4|25|Actual|Stanford University|The current study has noteworthy limitations, including a small sample size, short trial duration, and an open, uncontrolled design.|1|||f||||f||||||||No||2018-06-01 03:14:03.335081|2018-06-01 03:14:03.335081
NCT00472628|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2015-07-20|2007-05-11|2007-05-14|Estimate|||||||2015-07-20|2015-07-21|Estimate|May 2007||2007-05-31|July 2015|2015-07-31|August 2007|Actual|2007-08-31|||||Observational|MINDSET||Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET)|Multi-marker Index for the Risk Assessment of Sepsis in the Emergency Department|Withdrawn|||0|Actual|Biosite||||Change in company strategy|f||||f||||||||||2018-06-01 03:14:03.591475|2018-06-01 03:14:03.591475
NCT00472615|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2009-02-25|2007-05-11|2007-05-14|Estimate|||||||2009-02-25|2009-02-26|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Menstrual Effects On Mood Symptoms in Bipolar Disorder|Menstrual Effects On Mood Symptoms in Bipolar Disorder|Completed|||45|Anticipated|University of Pittsburgh|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-06-01 03:14:03.732522|2018-06-01 03:14:03.732522
NCT00472589|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2016-08-22|2007-05-09|2007-05-11|Estimate|||||||2016-08-22|2016-08-23|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||A Biological Sample Collection Protocol of Women With and Without Breast Cancer|A Biological Sample Collection Protocol of Women With and Without Breast Cancer: Hoosier Oncology Group Study BRE06-120 for the Analytical Proteomics Team|Completed|||400|Actual|Hoosier Cancer Research Network|||2||f||||t||||||Samples With DNA|"~     plasma, serum, whole blood and tissue samples~   "|||2018-06-01 03:14:03.870071|2018-06-01 03:14:03.870071
NCT00472576|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2011-03-14||2012-07-19|2007-05-10|2007-05-11|Estimate|2011-03-14|2011-04-07|Estimate||||2012-07-19|2012-08-03|Estimate|May 2007||2007-05-31|July 2012|2012-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Antidepressant Effects of NR2B in Major Depression|An Investigation of the Antidepressant Effects of the Selective NR2B Antagonist MK-0657 in Major Depression|Completed||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|The study was ended early due to recruitment problems.|2|||f||||f||||||||||2018-06-01 03:14:03.957653|2018-06-01 03:14:03.957653
NCT00472563|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2008-05-05|2007-05-10|2007-05-11|Estimate|||||||2008-05-05|2008-05-06|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|PROMEC||Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate|Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate|Completed||Phase 2/Phase 3|212|Actual|Universidad de Antioquia|||||f||||t||||||||||2018-06-01 03:14:04.317124|2018-06-01 03:14:04.317124
NCT00472550|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-05-10|2007-05-10|2007-05-11|Estimate|||||||2007-05-10|2007-05-11|Estimate|January 2006||2006-01-31|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Interventional|||Esomeprazole and Gastric Emptying of Beer|Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers|Completed||Phase 4|16|Actual|Heidelberg University|||||f||||t||||||||||2018-06-01 03:14:04.590503|2018-06-01 03:14:04.590503
NCT00472537|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2013-04-22|2007-05-10|2007-05-11|Estimate|||||||2013-04-22|2013-04-24|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|ProLOVE||ProLOVE - Prospective Randomized Study of Midline Incisional Hernia Treatment|Prospective Randomized Evaluation of Open vs. Laparoscopic Operation of Ventral Incisional Eventrations. A Swedish Multicenter Study|Completed|||157|Actual|Skane University Hospital|||||f||||f||||||||||2018-06-01 03:14:04.675586|2018-06-01 03:14:04.675586
NCT00472524|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2008-07-01|2007-05-10|2007-05-11|Estimate|||||||2008-07-01|2008-07-03|Estimate||||July 2008|2008-07-31||||||||Interventional|||Cycloplegic Delivery Investigation||Completed||N/A|50||Ohio State University|||||f||||||||||||||2018-06-01 03:14:04.772823|2018-06-01 03:14:04.772823
NCT00472511|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2008-07-01|2007-05-10|2007-05-11|Estimate|||||||2008-07-01|2008-07-03|Estimate||||July 2008|2008-07-31||||||||Observational|||Study of Eyes and Attention Deficit (SEAD)||Completed|||75||Ohio State University|||||f||||||||||||||2018-06-01 03:14:04.822054|2018-06-01 03:14:04.822054
NCT00472498|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2013-09-26|2007-05-10|2007-05-11|Estimate|||||||2013-09-26|2013-09-27|Estimate|June 2005||2005-06-30|September 2013|2013-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|AED||Comparison on the Efficacy of a Monophasic|Comparison on the Efficacy of a Monophasic, Manually Operated Defibrillator to That of a Biphasic Automatic External Defibrillator in the Hospital Setting.|Terminated|||95|Actual|Emory University|||2|Terminated: No longer recruiting.|f||||f||||||||||2018-06-01 03:14:04.884627|2018-06-01 03:14:04.884627
NCT00472485|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2008-07-01|2007-05-10|2007-05-11|Estimate|||||||2008-07-01|2008-07-03|Estimate||||July 2008|2008-07-31||||||||Interventional|||Study of Eye Movement Testing and Therapy||Completed||N/A|40||Ohio State University|||||f||||||||||||||2018-06-01 03:14:04.952913|2018-06-01 03:14:04.952913
NCT00472472|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2010-06-29|2007-05-10|2007-05-11|Estimate|||||||2010-06-29|2010-06-30|Estimate|April 2004||2004-04-30|May 2007|2007-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|PACCOCATH_F||Paclitaxel Coated Balloon Catheter for Prevention of Restenosis in Femoropopliteal Arteries|Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries (PACCOCATH - FEM I)|Completed||Phase 1/Phase 2|87|Actual|University Hospital, Saarland||2|||f||||t||||||||||2018-06-01 03:14:05.018402|2018-06-01 03:14:05.018402
NCT00472459|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2010-09-01|2007-05-10|2007-05-11|Estimate|||||||2010-09-01|2010-09-03|Estimate|July 2003||2003-07-31|September 2010|2010-09-30|July 2006|Actual|2006-07-31|||||Interventional|||PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer|A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer|Completed||Phase 3|81|Actual|Galderma|||||f||||f||||||||||2018-06-01 03:14:05.113338|2018-06-01 03:14:05.113338
NCT00472446|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2015-11-24||2016-07-27|2007-05-10|2007-05-11|Estimate|2016-07-27|2016-09-15|Estimate||||2016-07-27|2016-09-15|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Superficial, Cervical Block in Thyroid Surgery, a Randomized Controlled Trial|Impact and Cost Efficiency of Bilateral, Superficial Cervical Block in Thyroid Surgery Under General Anesthesia|Completed||Phase 2/Phase 3|183|Actual|Cantonal Hospital of St. Gallen||4|||f||||f||||||||No||2018-06-01 03:14:05.320166|2018-06-01 03:14:05.320166
NCT00472433|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2009-06-18|2007-05-10|2007-05-11|Estimate|||||||2009-06-18|2009-06-22|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias|A Phase II Study of Alemtuzumab in Autoimmune Cytopenias|Terminated||Phase 2|30|Anticipated|Phramongkutklao College of Medicine and Hospital||||no eligible patient|f||||f||||||||||2018-06-01 03:14:06.000968|2018-06-01 03:14:06.000968
NCT00472420|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2014-11-21||2017-07-06|2007-05-10|2007-05-11|Estimate|2014-11-21|2014-11-26|Estimate||||2017-07-06|2017-08-15|Actual|June 27, 2007|Actual|2007-06-27|June 2017|2017-06-30|May 25, 2011|Actual|2011-05-25|May 25, 2011|Actual|2011-05-25||Interventional||Intent-to-treat (ITT) population: all randomized participants who received at least 1 dose of study treatment.|A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.|An Open-label Study of the Effect of the Addition of MabThera to Standard Chemotherapy on Clinical Response in Patients With Previously Untreated Mantle Cell Lymphoma|Completed||Phase 2|48|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:14:06.090537|2018-06-01 03:14:06.090537
NCT00472407|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2008-07-01|2007-05-10|2007-05-11|Estimate|||||||2008-07-01|2008-07-03|Estimate||||July 2008|2008-07-31||||||||Interventional|||Eye Teaming Evaluation Study||Completed||N/A|72|Anticipated|Ohio State University|||||f||||||||||||||2018-06-01 03:14:06.379341|2018-06-01 03:14:06.379341
NCT00472394|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-08-17|2007-05-10|2007-05-11|Estimate|||||||2007-08-17|2007-08-21|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Observational|||Determining Women's Preferences for Medical Abortion Using Willingness to Pay||Completed|||||University of Pittsburgh|||||f||||f||||||||||2018-06-01 03:14:06.448609|2018-06-01 03:14:06.448609
NCT00472381|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2014-06-04|2007-05-10|2007-05-11|Estimate|||||||2014-06-04|2014-06-05|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|INSULINFARCT||Efficacy and Safety of Continuous Intravenous Versus Usual Subcutaneous Insulin in Acute Ischemic Stroke|Assessment of Continuous Intravenous Insulin Protocol Versus Subcutaneous Insulin in Acute Ischemic Stroke|Completed||Phase 2/Phase 3|180|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 03:14:06.5001|2018-06-01 03:14:06.5001
NCT00472368|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2012-04-27|2007-05-10|2007-05-11|Estimate|||||||2012-04-27|2012-05-01|Estimate|May 2007||2007-05-31|April 2012|2012-04-30||||June 2008|Actual|2008-06-30||Interventional|||A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589|An Open-label, Single Center, Study to Determine the Absorption, Distribution, Metabolism, and Excretion (ADME) of LBH589 After a Single Oral Administration of 20 mg (14C) LBH589 in Advanced Cancer Patients|Completed||Phase 1|4|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:14:06.584774|2018-06-01 03:14:06.584774
NCT00472355|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2009-09-03|2007-05-10|2007-05-11|Estimate|||||||2009-09-03|2009-09-04|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Low Dose Apomorphine and Parkinsonism|Does Presynaptic Dopamine Receptor Stimulation Transiently Worsen Parkinsonism?|Completed||Phase 2|14|Anticipated|Oregon Health and Science University|||||f||||||||||||||2018-06-01 03:14:06.678543|2018-06-01 03:14:06.678543
NCT00472342|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-05-10|2007-05-10|2007-05-11|Estimate|||||||2007-05-10|2007-05-11|Estimate|March 2007||2007-03-31|May 2007|2007-05-31|December 2007|Anticipated|2007-12-31|||||Interventional|||The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients|The Effects of Exercise on Adipokine in Impaired Fasting Glucose or Impaired Glucose Tolerance Patients|Unknown status|Recruiting|N/A|182|Anticipated|Yonsei University|||||f||||t||||||||||2018-06-01 03:14:06.792422|2018-06-01 03:14:06.792422
NCT00472329|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2014-06-26|2007-05-10|2007-05-11|Estimate|||||||2014-06-26|2014-06-30|Estimate|March 2007||2007-03-31|June 2014|2014-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant|Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant|Recruiting||Phase 2|20|Anticipated|Colorado Blood Cancer Institute||1|||f||||f||||||||||2018-06-01 03:14:06.907936|2018-06-01 03:14:06.907936
NCT00472316|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2017-08-15|2007-05-10|2007-05-11|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2007||2007-05-31|August 2017|2017-08-31|May 2011|Actual|2011-05-31|October 2009|Actual|2009-10-31||Observational|||Innovative Approaches to Tuberculosis Control|A Cluster Randomized Trial of DOTS vs DOTS Plus Active Case Finding|Completed|||1000|Actual|Johns Hopkins University|||||f||||t||||||||||2018-06-01 03:14:07.219494|2018-06-01 03:14:07.219494
NCT00472303|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2013-09-30||2016-06-10|2007-05-10|2007-05-11|Estimate|2014-04-04|2014-05-07|Estimate||||2016-06-10|2016-07-12|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||"Titration Phase:~Safety Analysis Set (N = 496) Full Analysis Set (N = 492)~Maintenance Phase:~Safety Analysis Set (N = 327) Full Analysis Set (N = 325)~Note:~One site was excluded from all analysis sets (efficacy and safety) due to GCP non-compliance. Thus 8 participants who were randomized and treated are not reported in the tables below."|A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine|A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain|Completed||Phase 3|622|Actual|Grünenthal GmbH||3|||f||||f||||||||||2018-06-01 03:14:07.40223|2018-06-01 03:14:07.40223
NCT00472290|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2012-12-05||2017-12-05|2007-05-10|2007-05-11|Estimate|2013-06-10|2013-07-15|Estimate||||2017-12-05|2017-12-29|Actual|April 1, 2007|Actual|2007-04-01|December 2017|2017-12-31|December 26, 2011|Actual|2011-12-26|July 18, 2011|Actual|2011-07-18||Interventional|||Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)|An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)|Completed||N/A|72|Actual|Amgen|Early termination leading to small number of subjects analyzed;|1|||f||||||||||||||2018-06-01 03:14:09.873397|2018-06-01 03:14:09.873397
NCT00472264|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2009-07-01|2007-05-09|2007-05-11|Estimate|||||||2009-07-01|2009-07-02|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Observational|||A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients|An Exploratory Study To Investigate The Reproducibility Of Lung 18Fluoro-Deoxyglucose Positron Emission Tomography In Patients With Chronic Obstructive Airways Disease (COPD) In The Absence Of Anti-Inflammatory Treatments|Terminated|||20|Actual|Pfizer|||1|"Study terminated on Nov 7, 2008 as a result of poor recruitment and changes in business~   priorities. The decision was not based on safety concerns."|f||||f||||||||||2018-06-01 03:14:10.308595|2018-06-01 03:14:10.308595
NCT00472251|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2011-07-20|2007-05-10|2007-05-11|Estimate|||||||2011-07-20|2011-07-21|Estimate|May 2006||2006-05-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Observational|||One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reductase Inhibitor in Korean BPH Patients|One-year Prospective Observational Study of BMI Change Effect of 5-alpha Reductase Inhibitor in Korean BPH Patients|Completed|||120|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 03:14:10.465684|2018-06-01 03:14:10.465684
NCT00472238|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2008-11-19|2007-05-10|2007-05-11|Estimate|||||||2008-11-19|2008-11-20|Estimate|August 2007||2007-08-31|May 2007|2007-05-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Effects of Endurance Training on Patients With Reduced Left Ventricular Ejection Fraction (LVEF) and Cardiac Resynchronisation Therapy Especially for Cardiac Arrhythmias|Effects of Endurance Training on Patients With Reduced LVEF and Cardiac Resynchronisation Therapy Especially for Cardiac Arrhythmias|Unknown status|Recruiting|N/A|30|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 03:14:10.558401|2018-06-01 03:14:10.558401
NCT00472225|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2009-02-20|2007-05-10|2007-05-11|Estimate|||||||2009-02-20|2009-02-24|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|May 2009|Anticipated|2009-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease|Open-Labelled, Multicenter Phase II Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease|Unknown status|Active, not recruiting|Phase 2|42|Anticipated|The Korean Society of Hematopoietic Stem Cell Transplantation||1|||f||||t||||||||||2018-06-01 03:14:10.633753|2018-06-01 03:14:10.633753
NCT00472199|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2009-07-02||2014-06-17|2007-05-10|2007-05-11|Estimate|2009-10-14|2009-11-17|Estimate||||2014-06-17|2014-06-27|Estimate|May 2007||2007-05-31|May 2012|2012-05-31||||July 2008|Actual|2008-07-31||Interventional|||Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)|A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period|Completed||Phase 4|331|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 03:14:10.924434|2018-06-01 03:14:10.924434
NCT00472186|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2017-09-19|2007-05-10|2007-05-11|Estimate|||||||2017-09-19|2017-09-21|Actual|June 2008|Actual|2008-06-30|September 2017|2017-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain|The Effects of Gastro-esophageal Acid Suppression on Post-tonsillectomy Pain|Terminated||Phase 4|2|Actual|Boston Children’s Hospital||2||"Poor compliance with returning of logbooks by families. Two patients were enrolled. Only one~   returned the logbook and therefore not analyzed"|f||||t||||||||||2018-06-01 03:14:11.972599|2018-06-01 03:14:11.972599
NCT00472173|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2011-11-09|2007-05-10|2007-05-11|Estimate|||||||2011-11-09|2011-11-10|Estimate|May 2007||2007-05-31|November 2011|2011-11-30|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|APEXMTA||Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth|Assessment of a New Apexification Method for Patients Presenting a Non Vital Immature Tooth|Completed||Phase 3|34|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:14:12.080704|2018-06-01 03:14:12.080704
NCT00472160|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2011-03-25|2007-05-10|2007-05-11|Estimate|||||||2011-03-25|2011-03-28|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|PREOXY||Preoxygenation Using NIV in Hypoxemic Patients|Preoxygenation Using Noninvasive Ventilation Prior Intubation in Hypoxemic Patients|Completed||Phase 4|200|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 03:14:12.157433|2018-06-01 03:14:12.157433
NCT00472147|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2007-05-10|2007-05-10|2007-05-11|Estimate|||||||2007-05-10|2007-05-11|Estimate||||May 2007|2007-05-31||||||||Interventional|||Selection of Shock Energy in Out-Of-Hospital Cardiac Arrest||Unknown status|Not yet recruiting|N/A|||Charite University, Berlin, Germany|||||f||||f||||||||||2018-06-01 03:14:12.307969|2018-06-01 03:14:12.307969
NCT00472134|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2015-06-04|2007-05-10|2007-05-11|Estimate|||||||2015-06-04|2015-06-08|Estimate|December 2005||2005-12-31|January 2012|2012-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Laparoscopic Ventral Hernia Repair With Elastomeric Pain Pump|Prospective, Randomized, Double-blind Trial of Continuous Infusion of 0.5% Bupivacaine be Elastomeric Pump for Prospective Pain Management After Laparoscopic Ventral Hernia Repair.|Completed||N/A|100|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 03:14:12.394124|2018-06-01 03:14:12.394124
NCT00472121|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2008-04-17|2007-05-10|2007-05-11|Estimate|||||||2008-04-17|2008-04-18|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||The Precision and Arm-to-Arm Variation of Mechanomyography and Acceleromyography for Monitoring of Neuromuscular Block|The Precision and Arm-to-Arm Variation og Mechanomyography and Acceleromyography for Monitoring the Neuromuscular Block During Anesthesia, A Randomized Controlled Study|Completed|||||Rigshospitalet, Denmark|||2||f||||t||||||||||2018-06-01 03:14:12.46997|2018-06-01 03:14:12.46997
NCT00472108|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2010-09-01|2007-05-10|2007-05-11|Estimate|||||||2010-09-01|2010-09-03|Estimate|December 2000||2000-12-31|September 2010|2010-09-30|April 2002|Actual|2002-04-30|||||Interventional|||Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma|A Multicenter, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma|Completed||Phase 3|65|Actual|Galderma|||||f||||f||||||||||2018-06-01 03:14:12.547141|2018-06-01 03:14:12.547141
NCT00472095|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2014-01-21|2007-05-10|2007-05-11|Estimate|||||||2014-01-21|2014-01-23|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Fotonovela for Type 2 Diabetes Mellitus|Utility of a Diabetes Themed Fotonovela to Encourage Glycemic Control: a Culturally Appropriate Tool for Education in Latinos|Unknown status|Recruiting|N/A|260|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 03:14:12.669265|2018-06-01 03:14:12.669265
NCT00472082|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|2012-11-09||2013-12-19|2007-05-10|2007-05-11|Estimate|2012-11-09|2012-12-06|Estimate||||2013-12-19|2014-01-27|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients|An Open Label, Single-Center Pilot Study of Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Primary Renal Transplant Recipients|Terminated||Phase 1/Phase 2|5|Actual|Emory University||1||This study was terminated at the request of the drug manufacturer.|f||||t||||||||||2018-06-01 03:14:12.800866|2018-06-01 03:14:12.800866
NCT00472069|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2011-05-04|2007-05-10|2007-05-11|Estimate|||||||2011-05-04|2011-05-05|Estimate|April 2007||2007-04-30|September 2007|2007-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A New Therapeutic Strategy for Urethral Sphincter Insufficiency|EVALUATION Of A NEW THERAPEUTIC STRATEGY FOR URETHRAL SPHINCTER INSUFFICIENCY BASED ON THE INTRA-URETHRAL IMPLANTATION OF AUTOLOGOUS MYOFIBERS WITH THEIR SATELLITE CELLS|Completed||Phase 1|10|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:14:13.03359|2018-06-01 03:14:13.03359
NCT00472056|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|2012-01-09||2016-02-17|2007-05-09|2007-05-11|Estimate|2012-01-09|2012-02-13|Estimate||||2016-02-17|2016-03-15|Estimate|March 2005||2005-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies|Randomized Trial Using Standard Dose Versus High Dose Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Diffuse Large B Cell Lymphomas|Completed||Phase 2|93|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:14:13.130659|2018-06-01 03:14:13.130659
NCT00472043|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-10|||2010-09-01|2007-05-10|2007-05-11|Estimate|||||||2010-09-01|2010-09-03|Estimate|October 2000||2000-10-31|September 2010|2010-09-30|September 2002|Actual|2002-09-30|||||Interventional|||PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma|A Multicentre, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma.|Completed||Phase 3|66|Actual|Galderma|||||f||||f||||||||||2018-06-01 03:14:13.610078|2018-06-01 03:14:13.610078
NCT00463125|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|March 2007||2007-03-31|April 2007|2007-04-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Platelet Gel in Systemic Sclerosis|Platelet Gel for Digital Ulcers in Patients With SSc: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|40||Università Politecnica delle Marche|||||f||||f||||||||||2018-06-01 03:17:09.949944|2018-06-01 03:17:09.949944
NCT00472030|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2012-06-26||2012-09-17|2007-05-08|2007-05-10|Estimate|2012-09-17|2012-10-16|Estimate||||2012-09-17|2012-10-16|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety of Omalizumab in Bullous Pemphigoid|An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid|Completed||Phase 4|2|Actual|University of Iowa|Limitations of this trial include low enrollment of research subjects and the need to withdraw a subject from the trial.|2|||f||||f||||||||||2018-06-01 03:14:13.697575|2018-06-01 03:14:13.697575
NCT00472017|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2012-10-11|2007-05-08|2007-05-10|Estimate|||||||2012-10-11|2012-10-15|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma|Phase I Trial of Vandetanib (ZD6474, ZACTIMA) With Concurrent Radiation in Treatment of Newly Diagnosed Brainstem Glioma|Completed||Phase 1|35|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 03:14:14.001528|2018-06-01 03:14:14.001528
NCT00472004|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2010-10-28|2007-05-08|2007-05-10|Estimate|||||||2010-10-28|2010-10-29|Estimate|February 2006||2006-02-28|October 2010|2010-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Comparing 17B Estradiol/TMG CC 1mg Vs. Tibolone In Postmenopausal Women|A Prospective, Randomized, Open Label Study To Compare The Efficacy, Safety And Tolerability Of 17-B Estradiol/Trimegestone CC 1 Mg (Totelle) And Tibolone (Livial) In Postmenopausal Women.|Completed||Phase 4|204|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:14:14.086541|2018-06-01 03:14:14.086541
NCT00471991|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2013-01-23|2007-05-09|2007-05-10|Estimate|||||||2013-01-23|2013-01-25|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition|Monocenter, Open-label, Randomized Study to Determine the Ovulation Inhibitory Effect of the Combined Oral Contraceptive SH T04769G and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), Applied for Two Treatment Cycles to 60 Healthy Female Volunteers|Completed||Phase 2|60|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:14:14.15941|2018-06-01 03:14:14.15941
NCT00471978|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2017-08-31|2007-05-08|2007-05-10|Estimate|||||||2017-08-31|2017-09-01|Actual|September 2005||2005-09-30|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|June 2022|Anticipated|2022-06-30||Observational|||DNA Analysis of Blood and Tissue From Patients With Lung Cancer|Molecular and Genetic Analysis of Lung Cancer|Recruiting|||6800|Anticipated|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     blood or tissue samples may be collected~   "|No||2018-06-01 03:14:14.323475|2018-06-01 03:14:14.323475
NCT00471965|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2010-09-17|2007-05-09|2007-05-10|Estimate|||||||2010-09-17|2010-09-20|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|EACH||Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients|Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment|Completed||Phase 3|371|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:14:14.400271|2018-06-01 03:14:14.400271
NCT00471952|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2012-04-24|2007-05-09|2007-05-10|Estimate|||||||2012-04-24|2012-04-25|Estimate|April 2007||2007-04-30|April 2012|2012-04-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache|Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache|Completed||Phase 3|50|Actual|Diamond Headache Clinic||3|||f||||f||||||||||2018-06-01 03:14:14.478488|2018-06-01 03:14:14.478488
NCT00471939|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2009-03-02|2007-05-09|2007-05-10|Estimate|||||||2009-03-02|2009-03-03|Estimate|April 2007||2007-04-30|March 2009|2009-03-31|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy of I-020502 in Meshed Skin Autografting|A Phase II, Multi-Centre, Controlled Study of the Safety and Efficacy of Wound Healing Gel I-020502 (KUR-212) in Patients Undergoing Autologous Meshed Skin Grafting.|Completed||Phase 2|10|Actual|Kuros Biosurgery AG|||||f||||f||||||||||2018-06-01 03:14:14.562453|2018-06-01 03:14:14.562453
NCT00471926|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2007-05-09|2007-05-09|2007-05-10|Estimate|||||||2007-05-09|2007-05-10|Estimate|April 2007||2007-04-30|May 2007|2007-05-31|April 2008|Anticipated|2008-04-30|||||Observational|DQIP-DCMP||Diabetes Quality Improvement Program on Diabetes Case Management Program 2001|Diabetes Quality Improvement Program on Diabetes Case Management Program 2001|Unknown status|Recruiting||20000|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-06-01 03:14:14.640309|2018-06-01 03:14:14.640309
NCT00471913|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2011-04-13|2007-05-09|2007-05-10|Estimate|||||||2011-04-13|2011-04-15|Estimate|April 2007||2007-04-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Functional Outcome and MRI of Muscle Damage Following Nailing Procedure in Femur (Thigh) Fractures Using Different Entry Points|Functional Outcome and MR Imaging of Abductor Damage Following Antegrade Femoral Nailing With Different Entry Points: A Prospective Randomized Trial|Completed||N/A|60|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:14:14.732714|2018-06-01 03:14:14.732714
NCT00471900|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2007-05-09|2007-05-09|2007-05-10|Estimate|||||||2007-05-09|2007-05-10|Estimate|October 2001||2001-10-31|May 2007|2007-05-31|February 2003|Actual|2003-02-28|||||Interventional|||Six Months DHEA Treatment in Female Adrenal Failure|Physiolocal Effects of 6 Months DHEA Substitutional Therapy in Female Adrenal Failure in a Randomised, Placebo Controlled and Overcrossed Study.|Completed||N/A|10|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 03:14:14.80754|2018-06-01 03:14:14.80754
NCT00471887|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2016-01-28|2007-05-08|2007-05-10|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2007||2007-01-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|July 2011|Actual|2011-07-31||Interventional|||Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma|A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients With In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies|Completed||Phase 2|34|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:14:14.863993|2018-06-01 03:14:14.863993
NCT00471874|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2007-12-11|2007-05-09|2007-05-10|Estimate|||||||2007-12-11|2007-12-13|Estimate|April 2007||2007-04-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Observational|||Study Evaluating Health Related Utility in Rheumatoid Arthritis|An Observational Study to Examine the Relationship Between Rheumatoid Arthritis Disease Severity and Health Related Utility|Completed|||250|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 03:14:14.974265|2018-06-01 03:14:14.974265
NCT00471861|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2011-08-05|2007-05-08|2007-05-10|Estimate|||||||2011-08-05|2011-08-08|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|||||Observational|||Inflammatory Markers in Patients With Active Migraine Headaches|Does Migraine As A Partly Inflammatory Disease Increase The Inflammatory Markers Of The Patient When Actively Having a Migraine?|Completed|||30|Actual|Westside Family Medical Center, P.C.|||||f||||f||||||||||2018-06-01 03:14:15.03536|2018-06-01 03:14:15.03536
NCT00471848|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2012-08-23|2007-05-09|2007-05-10|Estimate|||||||2012-08-23|2012-08-24|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|September 2010|Actual|2010-09-30||Interventional|RATGAA07||Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia|Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia and Comparison With Matched Historical Patients Treated With Horse ATG and Ciclosporin|Unknown status|Active, not recruiting|Phase 2|35|Actual|European Group for Blood and Marrow Transplantation||1|||f||||t||||||||||2018-06-01 03:14:15.106619|2018-06-01 03:14:15.106619
NCT00471835|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2017-01-17|2007-05-08|2007-05-10|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2007||2007-01-31|June 2013|2013-06-30||||||||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Phase I/II Study of Hypofractionated Stereotactic Body Radiotherapy for Stage I/II Non-small Cell Lung Cancer Within the Central Lung Region and the Prognostic Impact of FDG Positron Emission Tomography|Withdrawn||Phase 1/Phase 2|0|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 03:14:15.225774|2018-06-01 03:14:15.225774
NCT00471822|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2012-10-03||2013-09-18|2007-05-09|2007-05-10|Estimate|2013-09-18|2013-11-20|Estimate||||2013-09-18|2013-11-20|Estimate|July 2005||2005-07-31|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Nasopharyngeal Streptococcus Pneumoniae Carriage|An Evaluation of Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Taiwanese Children Attending Pediatric Clinics in Hospitals, Day Care Centers, or Kindergartens|Completed|||9707|Actual|Pfizer|||||f||||f||||||||||2018-06-01 03:14:15.318948|2018-06-01 03:14:15.318948
NCT00471809|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2016-07-28|2007-05-08|2007-05-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2006||2006-03-31|April 2012|2012-04-30|March 2007|Actual|2007-03-31|||||Interventional|MARS||Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)|Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)|Terminated||Phase 4|210||National Heart, Lung, and Blood Institute (NHLBI)||||"The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a~   futility analysis with 55 randomized children."|f||||t||||||||||2018-06-01 03:14:15.606959|2018-06-01 03:14:15.606959
NCT00471796|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2007-05-09|2007-05-09|2007-05-10|Estimate|||||||2007-05-09|2007-05-10|Estimate||||April 2007|2007-04-30||||||||Interventional|||A Comparison of Factors of Symptoms Generation and Evaluation of Role of Biofeedback in Patients With Different Types of Functional Esophageal Disorders (Functional Heartburn and Functional Chest Pain)||Unknown status|Not yet recruiting|N/A|||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:14:15.693413|2018-06-01 03:14:15.693413
NCT00471783|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2008-08-13|2007-05-08|2007-05-10|Estimate|||||||2008-08-13|2008-08-15|Estimate|April 2006||2006-04-30|August 2008|2008-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Flossing With Chlorhexidine|The Effects of Flossing With a Chlorhexidine Solution on Interproximal Gingivitis: a Randomized Controlled Trial|Completed||Phase 3|66|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:14:15.755236|2018-06-01 03:14:15.755236
NCT00471770|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2008-03-12|2007-05-08|2007-05-10|Estimate|||||||2008-03-12|2008-03-13|Estimate|February 2007||2007-02-28|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Pneumoniae Epidemiology Study in China|Epidemiological Study of Hospitalized Pediatric Pneumonia in China|Completed|||1000|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||3||f||||t||||||Samples Without DNA|"~     deep respiratory aspirate,pleural fluid,cerebrospinal fluid,serum~   "|||2018-06-01 03:14:15.85932|2018-06-01 03:14:15.85932
NCT00471757|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2017-06-23|2007-05-09|2007-05-10|Estimate|||||||2017-06-23|2017-06-26|Actual|May 2007|Actual|2007-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|CAP||Etiology of Community Acquired Pneumonia|Etiology of Community Acquired Pneumonia|Completed|||200|Actual|University of Pittsburgh|||||f||||t||||||||No|not sharing|2018-06-01 03:14:15.921106|2018-06-01 03:14:15.921106
NCT00471744|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2009-01-28|2007-05-08|2007-05-10|Estimate|||||||2009-01-28|2009-01-29|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|July 2008|Actual|2008-07-31|||||Interventional|HEAD||HEAD-Study Optimizing the Treatment of Children With BECTS|HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign Epilepsy With Centro-Temporal Spikes|Terminated||Phase 3|44|Actual|Ludwig-Maximilians - University of Munich||||low patient number after 2 years recruiting|f||||t||||||||||2018-06-01 03:14:15.993636|2018-06-01 03:14:15.993636
NCT00471731|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2018-02-13|2007-05-09|2007-05-10|Estimate|||||||2018-02-13|2018-02-14|Actual|May 7, 2007||2007-05-07|November 13, 2014|2014-11-13|November 13, 2014||2014-11-13|||||Observational|||Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure|Ocular Impact of X Chromosome Karyotype and Sex Hormones in Turner Syndrome|Completed|||72|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:14:16.058546|2018-06-01 03:14:16.058546
NCT00471718|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2011-10-26||2012-06-27|2007-05-08|2007-05-10|Estimate|2012-05-23|2012-06-27|Estimate||||2012-06-27|2012-07-11|Estimate|January 2004||2004-01-31|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase1/2 Trial of ABT-751 in Patients With Advanced, Androgen-Independent Prostate Cancer|Terminated||Phase 1/Phase 2|27|Actual|Vanderbilt-Ingram Cancer Center||1||pharmaceutical company closed study because the treatment was not effective|f||||t||||||||||2018-06-01 03:14:16.134004|2018-06-01 03:14:16.134004
NCT00471705|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2010-06-14||2010-07-15|2007-05-08|2007-05-10|Estimate|2010-06-14|2010-07-14|Estimate||||2010-07-15|2010-07-20|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.|Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.|Completed||Phase 3|437|Actual|Universidad de Antioquia||3|||f||||f||||||||||2018-06-01 03:14:16.416225|2018-06-01 03:14:16.416225
NCT00471692|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2015-10-26|2007-05-09|2007-05-10|Estimate|||||||2015-10-26|2015-10-28|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Local Anaesthetic Following Hernia Repair|A Randomised, Double Blind, Placebo Controlled Study to Compare Ilio Inguinal Nerve Block and Local Wound Irrigation|Terminated||Phase 1|12|Actual|Royal Hobart Hospital||2||Due to high incidence of neurological complication in those with ilioinguinal block|f||||f||||||||||2018-06-01 03:14:16.87339|2018-06-01 03:14:16.87339
NCT00471341|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2011-09-16|2007-05-08|2007-05-09|Estimate|||||||2011-09-16|2011-09-19|Estimate|July 2002||2002-07-31|May 2007|2007-05-31|December 2004|Actual|2004-12-31|||||Interventional|||Effect of Celecoxib on Markers of Vascular Inflammation|A Pilot Study to Determine the Effect of Celecoxib on Markers of Inflammation in Patients With Hypertension and Coronary Artery Disease|Completed||Phase 4|75||University of Florida|||||f||||f||||||||||2018-06-01 03:14:25.251435|2018-06-01 03:14:25.251435
NCT00471679|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2013-03-04|2007-05-08|2007-05-10|Estimate|||||||2013-03-04|2013-03-05|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma|Phase I Study of an Ethanol-Lock Strategy to Prevent Central Venous Catheter Infections Among Patients With High-Risk Neuroblastoma|Completed||Phase 1|12|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:14:16.953834|2018-06-01 03:14:16.953834
NCT00471666|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2017-06-30|2007-05-09|2007-05-10|Estimate|||||||2017-06-30|2017-07-02|Actual|May 7, 2007||2007-05-07|January 31, 2012|2012-01-31|January 31, 2012||2012-01-31|||||Observational|||Medical Implications of Coinfection With Malaria and Filariasis Parasites|Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications|Completed|||1039|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:14:17.063585|2018-06-01 03:14:17.063585
NCT00471653|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2009-11-06|2007-05-08|2007-05-10|Estimate|||||||2009-11-06|2009-11-09|Estimate|November 2006||2006-11-30|July 2009|2009-07-31||||December 2008|Anticipated|2008-12-31||Interventional|||Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy|A Pharmacokinetic and Pharmacogenomic Study of Patients With High-Grade Gliomas Receiving Daily Radiation Therapy and Temozolomide|Unknown status|Active, not recruiting|N/A|150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:14:17.119867|2018-06-01 03:14:17.119867
NCT00471640|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2010-09-24|2007-05-08|2007-05-10|Estimate|||||||2010-09-24|2010-09-27|Estimate|November 2007||2007-11-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Ovidius||Dexamethasone Infusion in Community-acquired Pneumonia|Dexamethasone Infusion in Community-acquired Pneumonia|Completed||N/A|300|Anticipated|St. Antonius Hospital||2|||f||||t||||||||||2018-06-01 03:14:17.209091|2018-06-01 03:14:17.209091
NCT00471627|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2008-06-09|2007-05-09|2007-05-10|Estimate|||||||2008-06-09|2008-06-10|Estimate|December 2006||2006-12-31|June 2008|2008-06-30||||December 2008|Anticipated|2008-12-31||Interventional|||New Type of a Pancreaticojejunostomy|New Type of a Pancreaticojejunostomy - a Pilot Study|Unknown status|Recruiting|Phase 1|30|Anticipated|University of Tampere|||||f||||f||||||||||2018-06-01 03:14:17.29693|2018-06-01 03:14:17.29693
NCT00471614|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2012-05-15|2007-05-08|2007-05-10|Estimate|||||||2012-05-15|2012-05-16|Estimate|April 2007||2007-04-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine|Uridine Supplementation, Mitochondrial Function, and Glucose Metabolism in HIV|Completed||Phase 2|3|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 03:14:17.381846|2018-06-01 03:14:17.381846
NCT00471601|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2018-05-21|2007-05-08|2007-05-10|Estimate|||||||2018-05-21|2018-05-22|Actual|March 2007||2007-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions|Measuring Patient Expectations for Breast Reconstruction: Development and Validation of a Patient-Reported Outcomes Instrument|Active, not recruiting||N/A|357|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:14:17.477554|2018-06-01 03:14:17.477554
NCT00471588|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2014-09-11|2007-05-08|2007-05-10|Estimate|||||||2014-09-11|2014-09-15|Estimate|August 2006||2006-08-31|September 2014|2014-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors|Dopamine D2/D3 Receptor Agonist and Antagonist Drug Effects on Fronto-striatal Systems Related to Compulsive Behaviour in Healthy Volunteers and Patients With Addictive and Compulsive Disorders|Completed||Phase 1|52|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:14:17.582029|2018-06-01 03:14:17.582029
NCT00471575|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2007-05-13|2007-05-09|2007-05-10|Estimate|||||||2007-05-13|2007-05-15|Estimate|June 2007||2007-06-30|April 2007|2007-04-30|December 2007|Anticipated|2007-12-31|||||Observational|||Fatty Liver in Pregnancy|Prospective Observational Study|Unknown status|Not yet recruiting||||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:14:17.66117|2018-06-01 03:14:17.66117
NCT00471562|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2017-07-31|2007-05-08|2007-05-10|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2007||2007-03-31|June 2012|2012-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors|Phase I Clinical Trial of Angiotensin 1-7 for Advanced Solid Tumors|Completed||Phase 1|18|Actual|Wake Forest University Health Sciences|||||f||||f|t|f||||||||2018-06-01 03:14:17.735652|2018-06-01 03:14:17.735652
NCT00471549|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2007-05-09|2007-05-09|2007-05-10|Estimate|||||||2007-05-09|2007-05-10|Estimate|June 1991||1991-06-30|May 2007|2007-05-31|December 1993|Actual|1993-12-31|||||Interventional|||Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes|Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria|Completed||Phase 4|18|Actual|University of Aarhus|||||f||||t||||||||||2018-06-01 03:14:17.810072|2018-06-01 03:14:17.810072
NCT00471536|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2013-02-13||2014-05-22|2007-05-08|2007-05-10|Estimate|2013-02-13|2013-03-21|Estimate||||2014-05-22|2014-05-30|Estimate|August 2008||2008-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|July 2010|Actual|2010-07-31||Interventional|||Pazopanib in Treating Patients With Metastatic Urothelial Cancer|A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:14:17.890746|2018-06-01 03:14:17.890746
NCT00471523|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2007-05-08|2007-05-08|2007-05-10|Estimate|||||||2007-05-08|2007-05-10|Estimate|May 2006||2006-05-31|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Treatment of Anovulatory Infertility in PCOS Patients|Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome|Completed||Phase 4|80|Actual|University Magna Graecia|||||f||||f||||||||||2018-06-01 03:14:18.180582|2018-06-01 03:14:18.180582
NCT00471510|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2008-05-16|2007-05-08|2007-05-10|Estimate|||||||2008-05-16|2008-05-20|Estimate|May 2007||2007-05-31|May 2008|2008-05-31||||February 2008|Actual|2008-02-29||Interventional|||Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss|A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men|Unknown status|Active, not recruiting|Phase 2|140|Actual|Neosil, Inc.||4|||f||||f||||||||||2018-06-01 03:14:18.249659|2018-06-01 03:14:18.249659
NCT00471146|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2012-02-25|2010-02-11|2012-06-14|2007-05-07|2007-05-09|Estimate|2012-06-14|2012-07-16|Estimate|2010-02-11|2010-02-15|Estimate|2012-06-14|2012-07-16|Estimate|July 2007||2007-07-31|June 2012|2012-06-30|November 2010|Actual|2010-11-30|January 2009|Actual|2009-01-31||Interventional|||Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.|A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.|Completed||Phase 3|630|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:14:31.347594|2018-06-01 03:14:31.347594
NCT00471497|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2013-04-10||2017-10-30|2007-05-09|2007-05-10|Estimate|2013-06-13|2013-06-17|Estimate||||2017-10-30|2017-12-05|Actual|July 31, 2007|Actual|2007-07-31|October 2017|2017-10-31|October 15, 2018|Anticipated|2018-10-15|September 2, 2009|Actual|2009-09-02||Interventional|ENESTnd|Patients in the Full Analysis Set (FAS) were analyzed according to the treatment they were randomized to regardless of actual treatment received.|A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Active, not recruiting||Phase 3|852|Actual|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 03:14:18.415739|2018-06-01 03:14:18.415739
NCT00471484|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2011-06-21|2007-05-08|2007-05-10|Estimate|||||||2011-06-21|2011-06-22|Estimate|March 2007||2007-03-31|November 2008|2008-11-30||||||||Interventional|||Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery|A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|54|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:14:20.813617|2018-06-01 03:14:20.813617
NCT00471471|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2017-06-21|2007-05-08|2007-05-10|Estimate|||||||2017-06-21|2017-06-22|Actual|October 2008||2008-10-31|June 2017|2017-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma|Completed||Phase 1|22|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:14:21.09891|2018-06-01 03:14:21.09891
NCT00471458|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-09|||2007-05-09|2007-05-09|2007-05-10|Estimate|||||||2007-05-09|2007-05-10|Estimate|January 1969||1969-01-31|May 2007|2007-05-31|December 2003|Actual|2003-12-31|||||Observational|||Follow-up Study of the RAI-Treated Hyperthyroid Patients|Follow-up Study of Hyperthyroid Patients Treated With RAI in 1965-2002: Morbidity in Long-Term Follow-up|Completed|||5222|Actual|University of Tampere|||||f||||f||||||||||2018-06-01 03:14:21.417484|2018-06-01 03:14:21.417484
NCT00471445|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2014-08-20||2015-10-13|2007-05-08|2007-05-10|Estimate|2015-06-08|2015-06-10|Estimate||||2015-10-13|2015-11-09|Estimate|October 2007||2007-10-31|October 2015|2015-10-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional||The number of 458 does not include 2 subjects from the Placebo cream and 2 subjects from the Amitriptyline and ketamine hydrochloride topical analgesic cream group who did not provide baseline data.|Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients|Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN)|Completed||Phase 3|462|Actual|University of Rochester|Since ketamine and amitriptyline are both analgesics, it is possible that the effects of the ketamine plus amitriptyline-containing creams may have been diluted when all three neuropathy symptoms were assessed together.|2|||f||||t||||||||||2018-06-01 03:14:21.715878|2018-06-01 03:14:21.715878
NCT00471432|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2010-11-07|2007-05-08|2007-05-10|Estimate|||||||2010-11-07|2010-11-09|Estimate|March 2003||2003-03-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|||||Interventional|||OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors|A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel|Completed||Phase 1|30|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 03:14:23.150625|2018-06-01 03:14:23.150625
NCT00471419|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2012-06-03|2007-05-07|2007-05-09|Estimate|||||||2012-06-03|2012-06-05|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye|Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye|Completed||Phase 3|750|Anticipated|Alcon Research|||||||||||||||||||2018-06-01 03:14:23.269073|2018-06-01 03:14:23.269073
NCT00471406|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2008-10-16|2007-05-08|2007-05-09|Estimate|||||||2008-10-16|2008-10-17|Estimate||||October 2008|2008-10-31||||||||Interventional|||Photodynamic Therapy With Verteporfin for Corneal Neovascularization||Completed||N/A|||Chonnam National University Hospital|||||f||||||||||||||2018-06-01 03:14:23.350485|2018-06-01 03:14:23.350485
NCT00471393|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2017-05-03|2007-05-07|2007-05-09|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2006||2006-05-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease|Double-blind Randomized Clinical Study on Topical Diclofenac Efficacy in Symptomatic Relief of Temporomandibular Degenerative Joint Disease in Women.|Completed||N/A|28|Actual|University of Alberta, Graduate Orthodontic Program|||||f||||t||||||||||2018-06-01 03:14:23.398114|2018-06-01 03:14:23.398114
NCT00471380|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2009-11-04||2010-03-10|2007-05-08|2007-05-09|Estimate|2010-02-24|2010-03-11|Estimate||||2010-03-10|2010-03-16|Estimate|March 2007||2007-03-31|March 2010|2010-03-31||||October 2008|Actual|2008-10-31||Interventional|||A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension|A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension|Completed||Phase 4|46|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 03:14:24.556265|2018-06-01 03:14:24.556265
NCT00471367|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2009-09-23|2007-05-07|2007-05-09|Estimate|||||||2009-09-23|2009-09-24|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|||||Interventional|||Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877|A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma|Terminated||Phase 1|44|Anticipated|AstraZeneca||||Part B of the study was terminated early due to a lack of enrollment.|f||||||||||||||2018-06-01 03:14:24.715196|2018-06-01 03:14:24.715196
NCT00471354|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2009-11-19||2010-01-04|2007-05-07|2007-05-09|Estimate|2009-11-19|2009-12-31|Estimate||||2010-01-04|2010-01-12|Estimate|April 2007||2007-04-30|January 2010|2010-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study for Patients With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine|Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride|Completed||Phase 4|228|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:14:24.820723|2018-06-01 03:14:24.820723
NCT00471328|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|2011-01-12||2012-06-05|2007-05-07|2007-05-09|Estimate|2011-04-19|2011-05-17|Estimate||||2012-06-05|2012-06-12|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|August 2008|Actual|2008-08-31||Interventional|ENEST||Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib|A Randomized, Open-label, Multi-center Study to Evaluate the Efficacy of Nilotinib Versus Best Supportive Care With or Without a Tyrosine Kinase Inhibitor (Investigator's Choice) in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Both Imatinib and Sunitinib|Completed||Phase 3|248|Actual|Novartis||2|||f||||t||||||||||2018-06-01 03:14:25.384268|2018-06-01 03:14:25.384268
NCT00471315|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2013-10-23||2013-12-18|2007-05-08|2007-05-09|Estimate|2013-12-18|2014-02-06|Estimate||||2013-12-18|2014-02-06|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|SOD||Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)|Pilot Study of the Efficacy and Tolerability of Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction).|Completed||Phase 3|18|Actual|Medical University of South Carolina|Most frequently reported adverse events included fatigue, nausea, headaches, constipation, decreased appetite and insomnia at primarily mild to moderate severity.|1|||f||||f||||||||||2018-06-01 03:14:26.413335|2018-06-01 03:14:26.413335
NCT00471302|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2018-05-18|2007-05-08|2007-05-09|Estimate|||||||2018-05-18|2018-05-21|Actual|May 7, 2007||2007-05-07|October 2, 2017|2017-10-02||||||||Observational|||Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali|Establishment of Normal Immunological Parameters Among Healthy Volunteers in Kambila, Tieneguebougou and Kalifabougou, Mali|Recruiting|||450|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:14:26.644326|2018-06-01 03:14:26.644326
NCT00471289|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2014-05-23|2007-05-07|2007-05-09|Estimate|||||||2014-05-23|2014-05-26|Estimate|August 2007||2007-08-31|May 2014|2014-05-31|March 2023|Anticipated|2023-03-31|September 2013|Actual|2013-09-30||Interventional|PADI||PTA and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia|Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia|Active, not recruiting||Phase 2/Phase 3|144|Actual|Netherlands Society for Interventional Radiology||2|||f||||f||||||||||2018-06-01 03:14:26.876785|2018-06-01 03:14:26.876785
NCT00471276|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2011-06-23||2011-07-21|2007-05-07|2007-05-09|Estimate|2011-06-23|2011-07-22|Estimate||||2011-07-21|2011-07-25|Estimate|August 2007||2007-08-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer|A Phase II Study Of Sunitinib Malate Single Agent For The Treatment Of Women With Advanced Breast Cancer|Completed||Phase 2|83|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 03:14:27.065143|2018-06-01 03:14:27.065143
NCT00471263|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2008-04-04|2007-05-08|2007-05-09|Estimate|||||||2008-04-04|2008-04-07|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|||||Interventional|||The Effects of Milk Proteins on Blood Pressure|The Effects of Casigold and Casimax on Blood Pressure in Subjects With Highnormal Blood Pressure or Mild Hypertension|Completed||N/A|84|Anticipated|TNO|||||f||||f||||||||||2018-06-01 03:14:28.005325|2018-06-01 03:14:28.005325
NCT00471250|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2018-04-25|2007-05-08|2007-05-09|Estimate|||||||2018-04-25|2018-04-26|Actual|May 7, 2007||2007-05-07|April 24, 2018|2018-04-24||||||||Observational|||Collection of Lung Fluid and Tissue Samples for Research|Research Respiratory Tract Procedures|Recruiting|||550|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:14:28.086617|2018-06-01 03:14:28.086617
NCT00471237|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2017-08-02|2010-10-13|2017-10-09|2007-05-07|2007-05-09|Estimate|2017-08-03|2017-09-05|Actual|2012-04-19|2012-04-24|Estimate|2017-10-09|2017-11-07|Actual|May 14, 2007|Actual|2007-05-14|September 2017|2017-09-30|December 26, 2008|Actual|2008-12-26|December 26, 2008|Actual|2008-12-26||Interventional|||A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.|Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis|Terminated||Phase 2|564|Actual|GlaxoSmithKline|The study was terminated for futility in a phased manner by the sponsor on 25-Sep-2008 once the results of a planned 6-month interim analysis were available.|4||Terminated for futility by sponsor after a pre-planned interim review of data|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:14:28.264728|2018-06-01 03:14:28.264728
NCT00471224|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2011-02-16|2007-05-07|2007-05-09|Estimate|||||||2011-02-16|2011-02-17|Estimate|June 2007||2007-06-30|February 2011|2011-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product|A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Formulated Drug Product (LOT 8716-098).|Completed|||16|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:14:30.757697|2018-06-01 03:14:30.757697
NCT00471211|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2008-01-13|2007-05-08|2007-05-09|Estimate|||||||2008-01-13|2008-01-16|Estimate|December 2006||2006-12-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease|A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease|Completed||Phase 2|80|Anticipated|Prana Biotechnology Limited|||||f||||t||||||||||2018-06-01 03:14:30.819662|2018-06-01 03:14:30.819662
NCT00471185|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2010-12-02|2007-05-08|2007-05-09|Estimate|||||||2010-12-02|2010-12-03|Estimate|June 2007||2007-06-30|December 2010|2010-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|ACY-6||ACY-6 Oral Administration of Acyline|Oral Administration of the GnRH Antagonist Acyline in Normal Men|Completed||Phase 1|9|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:14:30.879876|2018-06-01 03:14:30.879876
NCT00471172|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2008-09-12|2007-05-07|2007-05-09|Estimate|||||||2008-09-12|2008-09-15|Estimate|August 2004||2004-08-31|September 2008|2008-09-30|May 2005|Actual|2005-05-31|||||Interventional|||Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss|A 6-Month, Randomized Study To Evaluate The Efficacy Of Various Non-Pharmacologic, Disease Management Programs For The Treatment Of Obesity|Completed||N/A|350||Pfizer|||||f||||||||||||||2018-06-01 03:14:31.006103|2018-06-01 03:14:31.006103
NCT00471159|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2015-04-30|2007-05-07|2007-05-09|Estimate|||||||2015-04-30|2015-05-04|Estimate|August 2007||2007-08-31|April 2015|2015-04-30||||||||Interventional|||A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.|A Randomized Phase 2 Clinical Trial Of Docetaxel With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:14:31.086949|2018-06-01 03:14:31.086949
NCT00471133|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2011-06-03|2007-05-08|2007-05-09|Estimate|||||||2011-06-03|2011-06-07|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation|A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma|Completed||Phase 1|24|Actual|Ichor Medical Systems Incorporated||1|||f||||f||||||||||2018-06-01 03:14:35.30491|2018-06-01 03:14:35.30491
NCT00471120|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2015-08-03|2007-05-07|2007-05-09|Estimate|||||||2015-08-03|2015-08-05|Estimate|November 2006||2006-11-30|August 2015|2015-08-31|February 2008|Actual|2008-02-29|April 2007|Actual|2007-04-30||Interventional|||Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer|Feasibility Clinical Study: Accuracy of the P2X7 Biomarker in Detection of Endometrial Cancers in Women|Terminated||N/A|20|Actual|CytoCore, Inc.||1||Study terminated due to protocol deficiencies.|f||||t||||||||||2018-06-01 03:14:35.398412|2018-06-01 03:14:35.398412
NCT00471107|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2012-01-17||2016-03-23|2007-05-08|2007-05-09|Estimate|2013-03-20|2013-05-15|Estimate||||2016-03-23|2016-03-24|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of Electrical Stimulation (DC Polarization) to the Brain on Memory|Effect of Direct Current Brain Polarization on Verbal Memory|Completed||Phase 1/Phase 2|45|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||||2018-06-01 03:14:35.497465|2018-06-01 03:14:35.497465
NCT00471094|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2012-01-31|2007-05-07|2007-05-09|Estimate|||||||2012-01-31|2012-02-02|Estimate|May 2007||2007-05-31|January 2012|2012-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis|A Phase 2 Study to Evaluate the Safety and Efficacy of Ilaprazole (5 mg QD, 20 mg QD and 40 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis.|Completed||Phase 2|831|Actual|Takeda||4|||f||||f||||||||||2018-06-01 03:14:35.938419|2018-06-01 03:14:35.938419
NCT00471081|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08||2009-09-03|2016-10-18|2007-05-08|2007-05-09|Estimate||||2009-09-03|2009-09-04|Estimate|2016-10-18|2016-10-19|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.|Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age|Completed||Phase 2|385|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:14:36.225572|2018-06-01 03:14:36.225572
NCT00471068|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|2009-10-21||2012-04-07|2007-05-08|2007-05-09|Estimate|2009-12-07|2010-01-08|Estimate||||2012-04-07|2012-04-11|Estimate|March 2007||2007-03-31|February 2010|2010-02-28||||August 2008|Actual|2008-08-31||Interventional|||Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension|Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension|Terminated||Phase 4|46|Actual|Alcon Research|Sample size smaller than the one defined by the protocol|2||Question raised by Ethics Committee|f||||f||||||||||2018-06-01 03:14:36.412689|2018-06-01 03:14:36.412689
NCT00471055|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2008-07-08|2007-05-08|2007-05-09|Estimate|||||||2008-07-08|2008-07-09|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|OAknee||Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo|Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo|Completed||Phase 3|100|Actual|Khon Kaen University||2|||f||||t||||||||||2018-06-01 03:14:36.745912|2018-06-01 03:14:36.745912
NCT00471042|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2018-05-10|2007-05-07|2007-05-09|Estimate|||||||2018-05-10|2018-05-16|Actual|June 2006||2006-06-30|May 2018|2018-05-31|August 2012|Actual|2012-08-31|August 2008|Actual|2008-08-31||Observational|||Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care|Buprenorphine for Treatment of Opioid Dependence in Primary Care|Completed|||30|Actual|New York State Psychiatric Institute|||||f||||f||||||||||2018-06-01 03:14:36.857754|2018-06-01 03:14:36.857754
NCT00471029|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-08|||2007-05-08|2007-05-08|2007-05-09|Estimate|||||||2007-05-08|2007-05-09|Estimate|September 2005||2005-09-30|May 2007|2007-05-31|September 2007|Anticipated|2007-09-30|||||Interventional|NPH||Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer|Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial|Unknown status|Recruiting|Phase 4|20|Anticipated|Pamela Youde Nethersole Eastern Hospital|||||f||||t||||||||||2018-06-01 03:14:36.963311|2018-06-01 03:14:36.963311
NCT00471016|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2007-05-04|2007-05-04|2007-05-08|Estimate|||||||2007-05-04|2007-05-08|Estimate|June 2006||2006-06-30|May 2007|2007-05-31|September 2006|Actual|2006-09-30|||||Interventional|||An Intervention to Improve End of Life Decision Making Among Homeless Persons|An Intervention to Improve End of Life Decision Making Among Homeless Persons|Completed||N/A|59|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 03:14:37.038607|2018-06-01 03:14:37.038607
NCT00471003|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2010-01-19|2007-05-07|2007-05-08|Estimate|||||||2010-01-19|2010-01-20|Estimate|September 2006||2006-09-30|January 2010|2010-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|METABOLIC||The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension|A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients|Completed|||5448|Actual|Bayer|||1||f||||f||||||||||2018-06-01 03:14:37.093876|2018-06-01 03:14:37.093876
NCT00470990|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2011-04-18|2007-05-07|2007-05-08|Estimate|||||||2011-04-18|2011-04-20|Estimate|October 2002||2002-10-31|April 2011|2011-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men|Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men|Completed||N/A|40|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 03:14:37.199334|2018-06-01 03:14:37.199334
NCT00470977|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2012-10-24|2007-05-07|2007-05-08|Estimate|||||||2012-10-24|2012-10-25|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|FVF4140S||Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy|Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)|Completed||Phase 1/Phase 2|18|Actual|Manhattan Eye, Ear & Throat Hospital||1|||f||||f||||||||||2018-06-01 03:14:37.294941|2018-06-01 03:14:37.294941
NCT00470964|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-06|||2007-05-07|2007-05-07|2007-05-08|Estimate|||||||2007-05-07|2007-05-08|Estimate||||May 2007|2007-05-31||||||||Interventional|||Titanium-Sapphire Laser Trabeculoplasty in Glaucoma: A Randomized Study Comparing Titanium-Sapphire With Argon Laser Trabeculoplasty in Open-Angle Glaucoma Patients||Completed||N/A|||Goldschleger Eye Institute|||||t||||t||||||||||2018-06-01 03:14:37.421311|2018-06-01 03:14:37.421311
NCT00470951|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2012-08-16|2007-05-07|2007-05-08|Estimate|||||||2012-08-16|2012-08-17|Estimate|April 2006||2006-04-30|August 2012|2012-08-31|August 2014|Anticipated|2014-08-31|August 2012|Actual|2012-08-31||Interventional|CTS-179||Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer|A Comparison for Laparoscopically Assisted and Open Surgery for Advanced Rectal Cancer After Preoperative Chemoradiation- Randomized Prospective Trial|Unknown status|Active, not recruiting|Phase 3|340|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-06-01 03:14:37.495626|2018-06-01 03:14:37.495626
NCT00470938|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2008-02-19|2007-05-07|2007-05-08|Estimate|||||||2008-02-19|2008-02-29|Estimate|March 2007||2007-03-31|February 2008|2008-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Randomized Controlled Trial of the Effects of Reactive Neuromuscular Training on Balance||Completed||Phase 1/Phase 2|||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:14:37.592224|2018-06-01 03:14:37.592224
NCT00470925|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2010-12-28|2007-05-07|2007-05-08|Estimate|||||||2010-12-28|2010-12-29|Estimate|May 2007||2007-05-31|December 2010|2010-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|mZINT||Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects|Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects|Terminated||Phase 1|10|Anticipated|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 03:14:37.646917|2018-06-01 03:14:37.646917
NCT00470912|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2007-05-07|2007-05-07|2007-05-08|Estimate|||||||2007-05-07|2007-05-08|Estimate|May 2001||2001-05-31|May 2007|2007-05-31|February 2002|Actual|2002-02-28|||||Interventional|||Sunscreen RV 2457C in Photoinduced CLE|Photoprotective Effects of the RV 2457C Sunscreen Milk in Photoinduced Cutaneous Lupus Erythematosus|Completed||Phase 3|25|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-06-01 03:14:37.751652|2018-06-01 03:14:37.751652
NCT00470899|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2015-04-06|2007-05-07|2007-05-08|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2005||2005-01-31|May 2007|2007-05-31|January 2006|Actual|2006-01-31|||||Interventional|||Effect of Placental Drainage of Fetal Blood at Cesarean Section on the Incidence of Feto-Maternal Transfusion|Effect of Placental Drainage of Fetal Blood at Cesarean Section on the Incidence of Feto-Maternal Transfusion: A Randomized Controlled Trial|Completed||Phase 3|86|Actual|Lester E. Cox Medical Centers||2|||f||||t||||||||||2018-06-01 03:14:37.844767|2018-06-01 03:14:37.844767
NCT00470886|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2012-11-14|2007-05-07|2007-05-08|Estimate|||||||2012-11-14|2012-11-16|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|COAST||Assessment of Compliance With Antihypertensive Telmisartan Therapy|A Non-Interventional, Post-Marketing Surveillance, Phase IV Study to Assess Compliance With Antihypertensive Telmisartan Therapy|Completed|||3400|Actual|Bayer|||1||f||||f||||||||||2018-06-01 03:14:37.906899|2018-06-01 03:14:37.906899
NCT00470873|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2014-11-26|2007-05-07|2007-05-08|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2007||2007-01-31|November 2014|2014-11-30|February 2008|Actual|2008-02-29|||||Observational|||Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive Men|A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Obtain Data on Safety and Efficacy of Levitra® in Routine Treatment of Erectile Dysfunction in Depressive and Non-Depressive Men.|Completed|||2471|Actual|Bayer|||1||f||||f||||||||||2018-06-01 03:14:38.150508|2018-06-01 03:14:38.150508
NCT00470860|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2007-05-07|2007-05-07|2007-05-08|Estimate|||||||2007-05-07|2007-05-08|Estimate|December 2004||2004-12-31|May 2007|2007-05-31|August 2005|Actual|2005-08-31|||||Interventional|||Educational Technology to Enhance Diabetes Care - Retention Study||Completed||N/A|105|Actual|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 03:14:38.247683|2018-06-01 03:14:38.247683
NCT00470847|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2013-09-10||2014-04-28|2007-05-07|2007-05-08|Estimate|2013-12-03|2014-01-20|Estimate||||2014-04-28|2014-05-22|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|June 2012|Actual|2012-06-30|December 2009|Actual|2009-12-31||Interventional|||Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer|A Phase I Study of Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer|Completed||Phase 1|35|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:14:38.356314|2018-06-01 03:14:38.356314
NCT00470834|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2013-08-29||2017-01-12|2007-05-07|2007-05-08|Estimate|2013-08-29|2013-11-01|Estimate||||2017-01-12|2017-02-27|Actual|May 2007||2007-05-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy|A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase|Completed||Phase 4|127|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:14:38.766417|2018-06-01 03:14:38.766417
NCT00470821|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2010-07-26|2007-05-04|2007-05-08|Estimate|||||||2010-07-26|2010-07-28|Estimate|May 2007||2007-05-31|January 2010|2010-01-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Oral Melatonin in Critically Ill High-risk Patients|Randomized, Controlled, Double Blind Trial to Evaluate Sedation and Quality of Life in High-risk, Critically Ill Patients Treated With Oral Melatonin|Completed||Phase 4|96|Actual|University of Milan||2|||f||||f||||||||||2018-06-01 03:14:39.678324|2018-06-01 03:14:39.678324
NCT00470808|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2007-05-07|2007-05-07|2007-05-08|Estimate|||||||2007-05-07|2007-05-08|Estimate|May 2007||2007-05-31|April 2007|2007-04-30|August 2007|Anticipated|2007-08-31|||||Interventional|POMX||The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients||Unknown status|Not yet recruiting|Phase 4|||HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:14:39.785501|2018-06-01 03:14:39.785501
NCT00470795|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2008-12-14|2007-05-07|2007-05-08|Estimate|||||||2008-12-14|2008-12-16|Estimate|June 2009||2009-06-30|December 2008|2008-12-31|September 2010|Anticipated|2010-09-30|June 2010|Anticipated|2010-06-30||Interventional|||Acupuncture for Diabetic Gastroparesis|A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis.|Suspended||Phase 3|40|Anticipated|Shaare Zedek Medical Center||2||Protocol to be re-designed (primary outome still GCSI)|f||||f||||||||||2018-06-01 03:14:39.869934|2018-06-01 03:14:39.869934
NCT00470782|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2016-02-24|2007-05-07|2007-05-08|Estimate|||||||2016-02-24|2016-02-26|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Aerobic Capacity and Body Composition in Colon Cancer Patients|Changes in Aerobic Capacity and Body Composition in Colon Cancer Patients Receiving Chemotherapy|Completed|||40|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:14:39.943158|2018-06-01 03:14:39.943158
NCT00024791|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-27|||2008-03-03|2001-09-27|2001-09-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Eye-Hand Coordination in Children With Spastic Diplegia|Neurophysiology of Motor Disorders in Spastic Diplegia|Completed|||144||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:57.203168|2018-06-01 05:33:57.203168
NCT00470769|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2007-05-07|2007-05-07|2007-05-08|Estimate|||||||2007-05-07|2007-05-08|Estimate|September 2006||2006-09-30|May 2007|2007-05-31|May 2007|Anticipated|2007-05-31|||||Observational|||The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR|Color-Doppler Ultrasonography vs 99mTc-DTPA Scintigraphy to Assess the Renal Blood Flow|Unknown status|Recruiting||2006|Anticipated|University of Roma La Sapienza|||||f||||f||||||||||2018-06-01 03:14:40.059117|2018-06-01 03:14:40.059117
NCT00470756|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-06|||2011-05-11|2007-05-06|2007-05-08|Estimate|||||||2011-05-11|2011-05-12|Estimate|March 2008||2008-03-31|April 2011|2011-04-30||||March 2012|Anticipated|2012-03-31||Observational|||Forefoot Adduction (FFA) in Infants and Toddlers. Differences of Neuromuscular Activity.|Difference of Neuromuscular Activity in Infants and Toddlers With Foot Dorsiflexion Compare to Infants and Toddlers With Foot Plantarflexion|Suspended|||20|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-06-01 03:14:40.137008|2018-06-01 03:14:40.137008
NCT00470743|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2015-09-01|2007-05-07|2007-05-08|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2007||2007-05-31|June 2009|2009-06-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies|A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants|Withdrawn||Phase 4|0|Actual|KK Women's and Children's Hospital||2||Funding withdrawn|f||||f||||||||||2018-06-01 03:14:40.214393|2018-06-01 03:14:40.214393
NCT00470717|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2018-03-19|2007-05-07|2007-05-08|Estimate|||||||2018-03-19|2018-03-21|Actual|November 2008||2008-11-30|December 2010|2010-12-31|January 2010|Actual|2010-01-31|February 2009|Actual|2009-02-28||Interventional|||Feeding and Wellness Among Late Preterm Infants|Early Feeding and Wellness Among Late Preterm Infants Born at MacDonald Women's Hospital: A Feasibility Study for a Breastfeeding Intervention|Completed||N/A|38|Actual|University Hospitals Cleveland Medical Center|||||f||||f||||||||||2018-06-01 03:14:40.290636|2018-06-01 03:14:40.290636
NCT00470704|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2018-02-21|2007-05-07|2007-05-08|Estimate|||||||2018-02-21|2018-02-23|Actual|May 2007||2007-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer|A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer|Active, not recruiting||Phase 2|116|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||Undecided||2018-06-01 03:14:40.354442|2018-06-01 03:14:40.354442
NCT00470691|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2015-04-07|2007-05-07|2007-05-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|June 2004||2004-06-30|April 2015|2015-04-30|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Dorsal Splint or Circular Cast for Colles' Fracture?|Comparison of Dorsal Plaster Splint and Circular Plaster Cast for Colles' Fractures|Completed||N/A|72|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-06-01 03:14:40.494552|2018-06-01 03:14:40.494552
NCT00470678|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2016-11-16|2007-05-07|2007-05-08|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months|Completed||Phase 3|95|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:14:40.55519|2018-06-01 03:14:40.55519
NCT00470665|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2007-05-07|2007-05-07|2007-05-08|Estimate|||||||2007-05-07|2007-05-08|Estimate|August 2002||2002-08-31|May 2007|2007-05-31|July 2004||2004-07-31|||||Interventional|||Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients|An Open-Label, Concentration-Controlled, Randomized, 12-Month Study of Prograf + Rapamune + Corticosteroids Compared to Cyclosporine,USP (Modified) + Rapamune + Corticosteroids in High Risk Renal Allograft Recipients|Completed||Phase 3|460||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:14:40.640834|2018-06-01 03:14:40.640834
NCT00470652|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2009-01-26|2007-05-04|2007-05-08|Estimate|||||||2009-01-26|2009-01-27|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|||||Observational|||Management of Acute Pain in the Emergency Department|Management of Acute Pain in the Emergency Department:Impact of a Computer-Assisted Support|Completed|||631|Actual|Centre Hospitalier Universitaire Vaudois|||3||f||||f||||||||||2018-06-01 03:14:40.703265|2018-06-01 03:14:40.703265
NCT00470639|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2008-09-25|2007-05-07|2007-05-08|Estimate|||||||2008-09-25|2008-09-26|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|April 2010|Anticipated|2010-04-30|||||Interventional|||Transcranial Magnetic Stimulation for Bipolar Depression|A Comparison of Left vs. Right Prefrontal Cortex Transcranial Magnetic Stimulation as a Treatment for Bipolar Depression|Suspended||Phase 1/Phase 2|100|Anticipated|The University of New South Wales||||Poor recruitment|f||||f||||||||||2018-06-01 03:14:40.937434|2018-06-01 03:14:40.937434
NCT00470626|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2010-02-03||2015-12-21|2007-05-07|2007-05-08|Estimate|2010-03-16|2010-04-06|Estimate||||2015-12-21|2016-01-25|Estimate|November 2005||2005-11-30|December 2015|2015-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Celect Vena Cava Filter Clinical Trial|Prospective Study of the Cook Celect Filter, Including Permanent and Retrievable Use|Completed||N/A|129|Actual|Cook Group Incorporated||1|||f||||t||||||||||2018-06-01 03:14:41.025128|2018-06-01 03:14:41.025128
NCT00470613|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2017-04-24|2007-05-07|2007-05-08|Estimate|||||||2017-04-24|2017-04-26|Actual|February 2008||2008-02-29|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety Study of Infusion of SGT-53 to Treat Solid Tumors|A Phase I Open-Label Safety and Pharmacokinetic Study of Escalating Doses of SGT-53 for Infusion in Subjects With Advanced Solid Tumors|Completed||Phase 1|25|Actual|SynerGene Therapeutics, Inc.||1|||f||||t||||||||||2018-06-01 03:14:41.426457|2018-06-01 03:14:41.426457
NCT00470600|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|2011-04-07||2015-08-03|2007-05-07|2007-05-08|Estimate|2011-11-03|2011-12-08|Estimate||||2015-08-03|2015-08-21|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients|A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF IBUPROFEN INJECTION (IVIb) FOR TREATMENT OF PAIN IN POST-OPERATIVE ORTHOPEDIC ADULT PATIENTS|Completed||Phase 3|185|Actual|Cumberland Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:14:41.519752|2018-06-01 03:14:41.519752
NCT00470587|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-07|||2018-04-04|2007-05-07|2007-05-08|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2006||2006-04-30|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|September 2020|Anticipated|2020-09-30||Observational|APACE||Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study|Advantageous Predictors of Acute Coronary Syndromes Evaluation (APACE) Study|Recruiting|||9000|Anticipated|University Hospital, Basel, Switzerland|||||f||||t||||||Samples Without DNA|"~     EDTA plasma, Heparin, Serum, Citrate~   "|||2018-06-01 03:14:42.042559|2018-06-01 03:14:42.042559
NCT00470574|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2018-02-23|2007-05-03|2007-05-07|Estimate|||||||2018-02-23|2018-02-27|Actual|March 2007||2007-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer|Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21|Active, not recruiting||N/A|7|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:14:42.184753|2018-06-01 03:14:42.184753
NCT00470561|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-11-10|2007-05-03|2007-05-07|Estimate|||||||2010-11-10|2010-11-15|Estimate|November 2005||2005-11-30|November 2010|2010-11-30|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density|The Effect of Aspirin on Mammogram Density (TEAM)|Completed||N/A|144|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 03:14:42.33047|2018-06-01 03:14:42.33047
NCT00470548|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2017-01-17||2018-01-05|2007-05-03|2007-05-07|Estimate|2017-01-17|2017-03-08|Actual||||2018-01-05|2018-01-10|Actual|April 2007||2007-04-30|January 2018|2018-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Abraxane and Alimta in Advanced Solid Tumors|Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer|Terminated||Phase 1/Phase 2|49|Actual|University of California, Davis|The phase II portion accrued 37 patients before early closure due to increasing the first-line pemetrexed/platinum doublet use in non-squamous NSCLC.|2||Practice patterns with pemetrexed have evolved.|f||||t|t|f||||||||2018-06-01 03:14:42.51769|2018-06-01 03:14:42.51769
NCT00470535|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2014-12-03||2017-01-09|2007-05-03|2007-05-07|Estimate|2014-12-03|2014-12-10|Estimate||||2017-01-09|2017-02-23|Actual|January 2007||2007-01-31|January 2017|2017-01-31|September 2010|Actual|2010-09-30|January 2009|Actual|2009-01-31||Interventional|||Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer|Phase II Study of Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma|Terminated||Phase 2|18|Actual|Roswell Park Cancer Institute|This study was terminated earlier due to a phase III study that showed this drug was not better than sorafenib|1||"This study was terminated earlier due to a phase III study that showed this drug inferior to~   sorafenib"|f||||t||||||||||2018-06-01 03:14:43.071051|2018-06-01 03:14:43.071051
NCT00470522|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2007-05-04|2007-05-04|2007-05-07|Estimate|||||||2007-05-04|2007-05-07|Estimate|June 1995||1995-06-30|May 2007|2007-05-31|December 2001|Actual|2001-12-31|||||Interventional|SMILE||Study of Methotrexate in Lupus Erythematosus|A Canadian Multicenter, Randomized, Double-Blind Placebo-Controlled Study of Methotrexate and Folic Acid in Systemic Lupus Erythematosus: A Phase III Trial.|Completed||Phase 3|86|Actual|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 03:14:43.357184|2018-06-01 03:14:43.357184
NCT00470509|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2008-06-06|2007-05-04|2007-05-07|Estimate|||||||2008-06-06|2008-06-09|Estimate|May 2005||2005-05-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|ASAS||Adalimumab in Severe and Acute Sciatica|Adalimumab in Severe and Acute Sciatica|Completed||Phase 2|61|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-06-01 03:14:43.43518|2018-06-01 03:14:43.43518
NCT00470496|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2018-03-28|2007-05-03|2007-05-07|Estimate|||||||2018-03-28|2018-03-29|Actual|October 19, 2006|Actual|2006-10-19|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|October 28, 2011|Actual|2011-10-28||Interventional|||Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer|A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer|Active, not recruiting||Phase 1|15|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 03:14:43.536674|2018-06-01 03:14:43.536674
NCT00470483|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2017-07-13|2007-05-03|2007-05-07|Estimate|||||||2017-07-13|2017-07-18|Actual|January 22, 2007|Actual|2007-01-22|July 2017|2017-07-31|January 7, 2009|Actual|2009-01-07|January 7, 2009|Actual|2009-01-07||Interventional|||A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder|Completed||Phase 1|56|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:14:43.799808|2018-06-01 03:14:43.799808
NCT00470470|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2014-03-19||2014-12-15|2007-05-03|2007-05-07|Estimate|2014-12-15|2014-12-23|Estimate||||2014-12-15|2014-12-23|Estimate|April 2007||2007-04-30|January 2014|2014-01-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|||Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:14:43.943792|2018-06-01 03:14:43.943792
NCT00470457|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2015-12-02|2007-05-04|2007-05-07|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2001||2001-06-30|December 2015|2015-12-31|March 2005|Actual|2005-03-31|||||Interventional|||A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy|A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy in Grass and/or Tree Pollen Allergic Subjects by Intralymphatic Allergen Administration|Completed||Phase 2|156|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 03:14:44.437186|2018-06-01 03:14:44.437186
NCT00470444|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2015-07-30|2007-05-04|2007-05-07|Estimate|||||||2015-07-30|2015-07-31|Estimate|December 2006||2006-12-31|November 2008|2008-11-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|TTRICS||Transfusion Triggers in Cardiac Surgery|Transfusion Triggers in Cardiac Surgery|Completed||N/A|50|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-06-01 03:14:44.503605|2018-06-01 03:14:44.503605
NCT00470418|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|2014-01-16||2017-01-05|2007-05-04|2007-05-07|Estimate|2017-01-05|2017-01-09|Estimate||||2017-01-05|2017-01-09|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|March 2010|Actual|2010-03-31|August 2008|Actual|2008-08-31||Interventional|||Development of NIC5-15 in the Treatment of Alzheimer's Disease|Development of NIC5-15 in the Treatment of Alzheimer's Disease|Completed||Phase 2|15|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:14:44.614941|2018-06-01 03:14:44.614941
NCT00470405|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2011-04-14|2007-05-03|2007-05-07|Estimate|||||||2011-04-14|2011-04-18|Estimate|May 2004||2004-05-31|April 2011|2011-04-30|November 2007|Actual|2007-11-30|May 2007|Actual|2007-05-31||Interventional|||Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma|A Phase I Study of ALIMTA Plus Oxaliplatin Administered Every Other Week in the Treatment of Patients With Metastatic Cancer|Completed||Phase 1|25|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:14:44.972943|2018-06-01 03:14:44.972943
NCT00018590|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2001||2001-01-31|December 2004|2004-12-31||||||||Observational|||Center for the Study of Vascular Disease in Hispanic and Native Americans|Center for the Study of Vascular Disease in Hispanic and Native Americans|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.826984|2018-06-01 05:36:47.826984
NCT00470392|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|2013-09-26||2016-10-03|2007-05-04|2007-05-07|Estimate|2013-12-19|2014-02-12|Estimate||||2016-10-03|2016-10-05|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|July 2012|Actual|2012-07-31|July 2010|Actual|2010-07-31||Interventional|||Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis|Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis|Terminated||N/A|9|Actual|VA Office of Research and Development|No synchronized T cell reactivation was observed upon immunohistochemical analysis, nor upon analysis of T cell death associated gene (TDAG) mRNA by PCR, with Clobetasol treatment, so this arm was terminated.|2||Recruiting complete and administrative termination|f||||t||||||||||2018-06-01 03:14:45.087365|2018-06-01 03:14:45.087365
NCT00470379|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2014-10-30|2007-05-03|2007-05-07|Estimate|||||||2014-10-30|2014-10-31|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery|Transcutaneous (Topical) Peptide Immunization With NY-ESO-1b (SLLMWITQC) Peptide Using Resiquimod as an Immune Adjuvant: A Pilot Study|Completed||Early Phase 1|30|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:14:45.380112|2018-06-01 03:14:45.380112
NCT00470366|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2017-05-12||2017-10-23|2007-05-03|2007-05-07|Estimate|2017-09-22|2017-10-24|Actual||||2017-10-23|2017-11-28|Actual|March 2007||2007-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors|Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Previously Untreated Intermediate and Poor Risk Germ Cell Tumor Patients|Completed||Phase 2|60|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 03:14:45.473279|2018-06-01 03:14:45.473279
NCT00470353|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2013-01-31|2007-05-03|2007-05-07|Estimate|||||||2013-01-31|2013-02-01|Estimate|September 2006||2006-09-30|January 2013|2013-01-31|September 2009|Actual|2009-09-30|July 2008|Actual|2008-07-31||Interventional|||Cholecalciferol and Calcium Carbonate in Treating Patients With Colon Cancer That Has Been Removed by Surgery|A Pilot Study of Low and High Dose Vitamin Cholecalciferol (D3) With Pharmacokinetic and Pharmacodynamic Correlates in Patients With Resected Colon Cancer|Terminated||N/A|8|Actual|Roswell Park Cancer Institute||||Withdrawn due to poor accrual/lack of funding|f||||||||||||||2018-06-01 03:14:47.255085|2018-06-01 03:14:47.255085
NCT00470340|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2011-05-04|2007-05-04|2007-05-07|Estimate|||||||2011-05-04|2011-05-05|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|GEMOXIAL||Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients|Arterial LIPIODOLISED Chemotherapy Versus Systemic Chemotherapy With Gemcitabine Plus Oxaliplatin (GEMOX) Versus no Treatment Following Surgical Resection or Local Ablation of Hepatocellular Carcinoma in Cirrhotic Patients|Terminated||Phase 3|263|Actual|Assistance Publique - Hôpitaux de Paris||2||during the study|f||||t||||||||||2018-06-01 03:14:47.518947|2018-06-01 03:14:47.518947
NCT00470327|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2018-04-26|2007-05-04|2007-05-07|Estimate|||||||2018-04-26|2018-04-30|Actual|September 2005|Actual|2005-09-30|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||A Study of the Natural Progression of Interstitial Lung Disease (ILD)|A Study of the Natural Progression of Interstitial Lung Disease (ILD)|Recruiting|||4000|Anticipated|University of Chicago|||||f||||f|f|f||||Samples With DNA|"~     blood~   "|Yes|We will share coded data with no PHI|2018-06-01 03:14:47.827619|2018-06-01 03:14:47.827619
NCT00470314|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2008-01-04|2007-05-04|2007-05-07|Estimate|||||||2008-01-04|2008-01-07|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|May 2007|Anticipated|2007-05-31|||||Interventional|||Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure|Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure: A Double- Blind, Randomized, Placebo- Controlled Study|Unknown status|Active, not recruiting|Phase 2|150|Actual|All India Institute of Medical Sciences, New Delhi|||||f||||f||||||||||2018-06-01 03:14:48.127606|2018-06-01 03:14:48.127606
NCT00470301|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2015-05-06||2015-05-06|2007-05-03|2007-05-07|Estimate|2015-05-06|2015-05-22|Estimate||||2015-05-06|2015-05-22|Estimate|April 2007||2007-04-30|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer|A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer|Completed||Phase 1/Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:14:48.451174|2018-06-01 03:14:48.451174
NCT00470288|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2007-05-04|2007-05-04|2007-05-07|Estimate|||||||2007-05-04|2007-05-07|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Randomized Controlled Trial of Bladder Flap vs.None|Randomized Controlled Trial of Bladder Flap vs.None|Unknown status|Recruiting|N/A|123|Anticipated|Mountain Area Health Organization Center|||||f||||f||||||||||2018-06-01 03:14:49.079865|2018-06-01 03:14:49.079865
NCT00470275|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2013-08-29||2014-10-09|2007-05-03|2007-05-07|Estimate|2013-08-29|2013-11-01|Estimate||||2014-10-09|2014-10-20|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|August 2008|Actual|2008-08-31||Interventional|||Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma|Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma|Completed||Phase 2|10|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 03:14:49.237857|2018-06-01 03:14:49.237857
NCT00470262|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|2014-06-27||2016-06-09|2007-05-04|2007-05-07|Estimate|2016-06-09|2016-07-21|Estimate||||2016-06-09|2016-07-21|Estimate|January 2007||2007-01-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|December 2012|Actual|2012-12-31||Interventional|||Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation|Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation in Subjects With Impaired Glucose Tolerance|Completed||N/A|27|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:14:49.766048|2018-06-01 03:14:49.766048
NCT00470249|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2009-08-01|2007-05-03|2007-05-07|Estimate|||||||2009-08-01|2009-08-04|Estimate|February 2007||2007-02-28|July 2009|2009-07-31||||April 2008|Anticipated|2008-04-30||Interventional|||Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes|Unknown status|Recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:14:50.115325|2018-06-01 03:14:50.115325
NCT00470236|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2018-02-26|2007-05-04|2007-05-07|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2007||2007-06-30|February 2018|2018-02-28|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|DCIS||Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast|A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast|Active, not recruiting||Phase 3|1608|Actual|Trans-Tasman Radiation Oncology Group (TROG)||4|||f||||t||||||||||2018-06-01 03:14:50.248929|2018-06-01 03:14:50.248929
NCT00470223|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2016-06-21|2007-05-03|2007-05-07|Estimate|||||||2016-06-21|2016-06-22|Estimate|March 2007||2007-03-31|June 2016|2016-06-30|April 2025|Anticipated|2025-04-30|December 2015|Actual|2015-12-31||Interventional|OS2006||Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma|OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant|Terminated||Phase 3|318|Actual|UNICANCER||2||IDMC decision upon interim efficacy analysis|f||||t||||||||No|IPD will not be shared at an individual level, they will be part of the study database including all enrolled patients.|2018-06-01 03:14:50.641144|2018-06-01 03:14:50.641144
NCT00470210|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2010-04-15|2007-05-04|2007-05-07|Estimate|||||||2010-04-15|2010-04-16|Estimate|May 2007||2007-05-31|April 2010|2010-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens|Efficacy and Safety of High-dose Ribavirin (1600 mg/d) Boosted With Epoetin β (450 IU/kg/wk) in HIV/HCV Coinfected Patients Not Responding to Previous Treatment Regimens|Completed||Phase 4|10|Actual|Germans Trias i Pujol Hospital||1|||f||||f||||||||||2018-06-01 03:14:50.950033|2018-06-01 03:14:50.950033
NCT00470197|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2013-09-27|2007-05-03|2007-05-07|Estimate|||||||2013-09-27|2013-09-30|Estimate|April 2007||2007-04-30|September 2013|2013-09-30||||January 2011|Actual|2011-01-31||Interventional|||Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia|Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:14:51.064687|2018-06-01 03:14:51.064687
NCT00470184|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2013-09-19||2013-09-19|2007-05-03|2007-05-07|Estimate|2013-09-19|2013-11-25|Estimate||||2013-09-19|2013-11-25|Estimate|November 2006||2006-11-30|September 2013|2013-09-30||||October 2012|Actual|2012-10-31||Interventional||treated patients|Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer|Phase II Study of Capecitabine in Combination With Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer|Completed||Phase 2|41|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 03:14:51.221981|2018-06-01 03:14:51.221981
NCT00470171|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2009-02-02|2007-05-04|2007-05-07|Estimate|||||||2009-02-02|2009-02-03|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|URSONASH||Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis|Efficacy and Safety of Ursodesoxycholic Acid in the Management of Non-Alcoholic Steatohepatitis|Completed||Phase 2|98|Anticipated|Axcan Pharma|||||f||||f||||||||||2018-06-01 03:14:51.693772|2018-06-01 03:14:51.693772
NCT00470158|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2011-08-10||2018-04-18|2007-05-03|2007-05-07|Estimate|2011-08-10|2011-09-19|Estimate||||2018-04-18|2018-04-20|Actual|May 2007||2007-05-31|December 2009|2009-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes|Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes|Completed||Phase 4|1000|Actual|Johns Hopkins Bloomberg School of Public Health||5|||f||||t||||||||||2018-06-01 03:14:51.79317|2018-06-01 03:14:51.79317
NCT00470145|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2012-05-31|2007-05-03|2007-05-07|Estimate|||||||2012-05-31|2012-06-04|Estimate|April 2007||2007-04-30|February 2011|2011-02-28|July 2007|Actual|2007-07-31|||||Interventional|||Comparison Of Two Tablet Formulations Of SB-568859|A Randomised, Single Blind, 2 Period, Crossover Study to Compare the Single Dose Pharmacokinetics and Tolerability of Formulations Containing Unmilled and Micronised SB-568859 in Healthy Adults|Completed||Phase 1|28|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:14:52.272273|2018-06-01 03:14:52.272273
NCT00470132|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2012-08-23|2007-05-04|2007-05-07|Estimate|||||||2012-08-23|2012-08-24|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Ventricular Shunt and Drain Infections - Timing of Reimplantation|Ventricular Shunt and Drain Infections - Timing of Reimplantation|Completed|||400|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 03:14:52.372373|2018-06-01 03:14:52.372373
NCT00470119|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2012-09-07|2007-05-03|2007-05-07|Estimate|||||||2012-09-07|2012-09-10|Estimate|December 2004||2004-12-31|September 2012|2012-09-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women|Exercise Diet and Sex Hormones in Postmenopausal Women (NEW)|Completed||N/A|439|Actual|Fred Hutchinson Cancer Research Center||4|||f||||t||||||||||2018-06-01 03:14:52.452769|2018-06-01 03:14:52.452769
NCT00470106|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|2015-10-14||2016-03-22|2007-05-04|2007-05-07|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|IBASC||Improving Basic and Social Cognition in Veterans With Schizophrenia|Improving Basic and Social Cognition in Veterans With Schizophrenia|Completed||N/A|85|Actual|VA Office of Research and Development||4|||f||||t||||||||Undecided||2018-06-01 03:14:52.652342|2018-06-01 03:14:52.652342
NCT00470093|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2012-01-25|2007-05-03|2007-05-07|Estimate|||||||2012-01-25|2012-01-26|Estimate|August 2007||2007-08-31|January 2012|2012-01-31||||January 2010|Actual|2010-01-31||Interventional|||Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma|A Pilot Study of Differentiation Therapy in Multiple Myeloma Using Interleukin-6 and Interferon-a|Completed||N/A|4|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:14:53.078643|2018-06-01 03:14:53.078643
NCT00470080|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2011-05-03|2007-05-04|2007-05-07|Estimate|||||||2011-05-03|2011-05-04|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|VIEP||Randomised Trial of Eutectic Mixture of Local Anaesthetics Cream and Oral Sucrose Solution for Venepuncture|Randomised Trial of Eutectic Mixture of Local Anaesthetics Cream and Oral Sucrose Solution for Venepuncture in Preterm Infants|Completed||Phase 4|80|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 03:14:53.168336|2018-06-01 03:14:53.168336
NCT00470067|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2014-01-27||2014-08-08|2007-05-03|2007-05-07|Estimate|2014-08-08|2014-08-22|Estimate||||2014-08-08|2014-08-22|Estimate|February 2007||2007-02-28|August 2014|2014-08-31|December 2009|Actual|2009-12-31|May 2008|Actual|2008-05-31||Interventional||All treated and eligible patients|Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer|A Multi-center Phase II Study of Doxil®/Carboplatin in Patients With Advanced or Recurrent Endometrial Carcinoma|Terminated||Phase 2|9|Actual|Roswell Park Cancer Institute|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.|1||Due to low accrual|f||||t||||||||||2018-06-01 03:14:53.285049|2018-06-01 03:14:53.285049
NCT00390819|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2006-10-19|2006-10-19|2006-10-20|Estimate|||||||2006-10-19|2006-10-20|Estimate|November 2006||2006-11-30|October 2006|2006-10-31||||||||Observational|||Epidemiology of Community Acquired Pneumonia in North Israel|Epidemiology of Community Acquired Pneumonia in North Israel|Unknown status|Not yet recruiting||100|Anticipated|HaEmek Medical Center, Israel|||||f||||||||||||||2018-06-01 03:41:27.056812|2018-06-01 03:41:27.056812
NCT00470054|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2013-01-02||2015-04-14|2007-05-03|2007-05-07|Estimate|2013-03-13|2013-04-26|Estimate||||2015-04-14|2015-05-05|Estimate|April 2007||2007-04-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|February 2009|Actual|2009-02-28||Interventional||Only eligible participants (those who met the criteria for inclusion) were evaluated for baseline characteristics.|Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of Dasatinib (NSC #732517) in Patients With Chemo-Sensitive Relapsed Small Cell Lung Cancer|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:14:53.618958|2018-06-01 03:14:53.618958
NCT00470041|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2010-06-15|2007-05-04|2007-05-07|Estimate|||||||2010-06-15|2010-06-16|Estimate|June 2007||2007-06-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Bioavailability Study of a New Pediatric Formulation of Zidovudine/Lamivudine in Adult Volunteers|Bioavailability Study of a New Pediatric Formulation of Zidovudine/Lamivudine in Adult Volunteers|Completed||Phase 1|12|Anticipated|University Ghent|||||f||||f||||||||||2018-06-01 03:14:54.088018|2018-06-01 03:14:54.088018
NCT00470028|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-01-19|2007-05-03|2007-05-07|Estimate|||||||2010-01-19|2010-01-20|Estimate|April 2005||2005-04-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Transcranial Magnetic Stimulation: Treatment Trial for Depressed Adolescents|A Study of Transcranial Magnetic Stimulation (TMS) Treatment in Depressed Adolescents|Terminated||Phase 1/Phase 2|30|Anticipated|The University of New South Wales||||Low recruitment.|f||||f||||||||||2018-06-01 03:14:54.247855|2018-06-01 03:14:54.247855
NCT00470015|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2018-03-05|2007-05-03|2007-05-07|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2007|Actual|2007-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2009|Actual|2009-04-30||Interventional|||Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma|Melanoma Peptide Vaccines (MART1 Analog, gp100 and Survivin) With GM-CSF and Low-Dose IL-2 as Immune Adjuvants, A Pilot Study|Active, not recruiting||Phase 1|20|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:14:54.420722|2018-06-01 03:14:54.420722
NCT00470002|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2007-05-04|2007-05-04|2007-05-07|Estimate|||||||2007-05-04|2007-05-07|Estimate|May 2004||2004-05-31|May 2007|2007-05-31|January 2005|Actual|2005-01-31|||||Interventional|||Effects of Growth Hormone on the Nitric Oxide Pathway|Effects of Growth Hormone (GH) on Parameters of the Nitric Oxide (NO) Pathway|Completed||Phase 1|16|Actual|Hannover Medical School|||||f||||f||||||||||2018-06-01 03:14:54.51403|2018-06-01 03:14:54.51403
NCT00469989|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2008-01-02|2007-05-04|2007-05-07|Estimate|||||||2008-01-02|2008-01-11|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Randomised Placebo Controlled Study of Effects of Therapeutic Hookworm Infection in Asthma|Randomised Placebo Controlled Study of Effects of Therapeutic Hookworm Infection in Asthma|Completed||N/A|30|Anticipated|University of Nottingham|||||f||||t||||||||||2018-06-01 03:14:54.586752|2018-06-01 03:14:54.586752
NCT00469976|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2015-10-06|2007-05-03|2007-05-07|Estimate|||||||2015-10-06|2015-10-08|Estimate|June 2007||2007-06-30|October 2015|2015-10-31||||||||Interventional|||Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Enzastaurin Plus Carboplatin and Gemcitabine (ECoG) in Bevacizumab-Ineligible Patients and Enzastaurin Plus Carboplatin, Gemcitabine and Bevacizumab (B-ECoG) in Bevacizumab-Eligible Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|Eastern Cooperative Oncology Group||||ECOG will not proceed with activation|f||||f||||||||||2018-06-01 03:14:54.685609|2018-06-01 03:14:54.685609
NCT00469963|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2012-08-31|2007-05-03|2007-05-07|Estimate|||||||2012-08-31|2012-09-03|Estimate|December 2003||2003-12-31|August 2012|2012-08-31|April 2007|Actual|2007-04-30|October 2006|Actual|2006-10-31||Interventional|||Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery|Clinical Trial of Sir Spheres® in Patients With Primary Hepatocellular Carcinoma|Terminated||N/A|12|Actual|Vanderbilt-Ingram Cancer Center||1||slow accrual|f||||t||||||||||2018-06-01 03:14:54.768731|2018-06-01 03:14:54.768731
NCT00469950|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2015-04-13|2007-05-04|2007-05-07|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|EFECTOR||The Effect of Training on Endothelial Function, Progression of Disease,Inflammation, Heart Rate Variability and Mental Health After Percutaneous Coronary Intervention|Effect of Exercise Training After Percutaneous Coronary Intervention|Completed||Phase 4|40|Anticipated|Helse Stavanger HF|||||f||||f||||||||||2018-06-01 03:14:54.855505|2018-06-01 03:14:54.855505
NCT00469937|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2012-02-26|2007-05-03|2007-05-07|Estimate|||||||2012-02-26|2012-02-28|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases|A Phase I Study of Lithium During Whole Brain Radiotherapy for Patients With Brain Metastases|Terminated||Phase 1|9|Actual|Vanderbilt-Ingram Cancer Center||1||low accrual|f||||t||||||||||2018-06-01 03:14:54.984186|2018-06-01 03:14:54.984186
NCT00469924|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2016-05-16|2007-05-04|2007-05-07|Estimate|||||||2016-05-16|2016-05-17|Estimate|February 2006||2006-02-28|May 2016|2016-05-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Effect of an Automated Paging System on Response to Critical Laboratory Values|Effect of an Automated Paging System on Response to Critical Laboratory Values|Completed||N/A|271|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 03:14:55.130454|2018-06-01 03:14:55.130454
NCT00469911|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2014-05-02|2007-05-04|2007-05-07|Estimate|||||||2014-05-02|2014-05-05|Estimate|August 2005||2005-08-31|May 2014|2014-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|MRS||Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy|Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy|Completed||N/A|25|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 03:14:55.224585|2018-06-01 03:14:55.224585
NCT00469898|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2010-10-11||2012-07-20|2007-05-03|2007-05-07|Estimate|2011-02-24|2011-03-23|Estimate||||2012-07-20|2012-07-27|Estimate|December 2003||2003-12-31|July 2012|2012-07-31|July 2010|Actual|2010-07-31|July 2008|Actual|2008-07-31||Interventional|||Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase II Trial of Carboplatin and Irinotecan (CPT-11) as First-Line Therapy for Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|50|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:14:55.33672|2018-06-01 03:14:55.33672
NCT00469885|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2017-01-09|2007-05-04|2007-05-07|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2001||2001-01-31|June 2008|2008-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Reduction of Smoking in Cardiac Disease Patients|Harm Reduction Treatment for Smokers With Cardiovascular Disease {Reduction of Smoking in Cardiovascular Disease Patients (ROSCAP)}|Completed||Phase 2|152|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 03:14:55.702322|2018-06-01 03:14:55.702322
NCT00469872|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2014-09-23|2007-05-03|2007-05-07|Estimate|||||||2014-09-23|2014-09-25|Estimate|June 2006||2006-06-30|September 2014|2014-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Focus on Function Study for Children With Cerebral Palsy|Family Centred Functional Therapy for Children With Cerebral Palsy|Completed||N/A|128|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 03:14:55.800766|2018-06-01 03:14:55.800766
NCT00469859|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2013-08-29||2017-02-07|2007-05-03|2007-05-07|Estimate|2013-10-31|2013-12-20|Estimate||||2017-02-07|2017-03-15|Actual|June 2007||2007-06-30|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|14|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 03:14:55.892478|2018-06-01 03:14:55.892478
NCT00469846|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2007-05-07|2007-05-04|2007-05-07|Estimate|||||||2007-05-07|2007-05-08|Estimate|January 2001||2001-01-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|L-Arg||L-Arginine and Antioxidant Vitamins During Pregnancy to Reduce Preeclampsia|Supplementation With L-Arginine and Antioxidant Vitamins During Pregnancy in a Medical Food to Reduce the Risk of Preeclampsia in a High Risk Population|Terminated||Phase 2|585|Actual|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||||Recruitment and follow-up has been completed.|f||||t||||||||||2018-06-01 03:14:56.519663|2018-06-01 03:14:56.519663
NCT00469833|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|2013-10-17||2015-01-06|2007-05-04|2007-05-07|Estimate|2015-01-06|2015-01-15|Estimate||||2015-01-06|2015-01-15|Estimate|April 2008||2008-04-30|January 2015|2015-01-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Insulin Secretion in Diabetes Before and After Glycemic Control|Pathogenesis of the Impaired Incretin Effect in Type 2 Diabetes|Completed||N/A|17|Actual|VA Office of Research and Development|Two subjects could not complete the initial assessment due to poor IV access. All 15 subjects who completed the initial assessment and were started on insulin completed the study. There were no significant adverse events.|1|||f||||f||||||||||2018-06-01 03:14:56.622814|2018-06-01 03:14:56.622814
NCT00469820|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2014-03-20|2007-05-03|2007-05-07|Estimate|||||||2014-03-20|2014-03-21|Estimate|April 2007||2007-04-30|March 2014|2014-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant|Posttransplant Immunotherapy With Donor Lymphocyte Infusions and Autologous Tumor Vaccines After HLA-Matched Transplant|Terminated||Phase 1|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||low accrual|f||||||||||||||2018-06-01 03:14:56.83757|2018-06-01 03:14:56.83757
NCT00469807|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2017-04-27|2007-05-04|2007-05-07|Estimate|||||||2017-04-27|2017-04-28|Actual|June 2004||2004-06-30|April 2017|2017-04-30|May 2007|Actual|2007-05-31|||||Observational|||Ghrelin Levels in Early IVF Pregnancies|Maternal Serum Ghrelin Levels in Early IVF Pregnancies: Lack of Prognostic Value for Gestational Outcome and Altered Post-Prandial Responses|Completed|||||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-06-01 03:14:56.904931|2018-06-01 03:14:56.904931
NCT00469794|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2007-05-04|2007-05-04|2007-05-07|Estimate|||||||2007-05-04|2007-05-07|Estimate|May 2006||2006-05-31|May 2007|2007-05-31|May 2008|Anticipated|2008-05-31|||||Observational|Athlete||The Significance of Arrhythmias in Athletes|The Long Term Significance of Exercise Induced Ventricular Arrhythmias in Trained Athletes|Unknown status|Recruiting||300|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:14:56.968359|2018-06-01 03:14:56.968359
NCT00469781|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-04|||2008-09-23|2007-05-04|2007-05-07|Estimate|||||||2008-09-23|2008-09-25|Estimate|May 2007||2007-05-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening||Completed||Phase 4|95|Actual|Center For Excellence In Eye Care||2|||f||||||||||||||2018-06-01 03:14:57.035265|2018-06-01 03:14:57.035265
NCT00469768|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2009-08-31|2007-05-03|2007-05-04|Estimate|||||||2009-08-31|2009-09-01|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|August 2007|Actual|2007-08-31|||||Interventional|||A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium|A Double-blind, Randomized, Placebo-controlled Safety and Pharmacokinetic Study in Healthy HIV-negative Women to Assess the Delivery of Dapivirine From Matrix and Reservoir Intravaginal Rings Each Containing 25 mg of Dapivirine|Completed||Phase 1|24|Actual|International Partnership for Microbicides, Inc.||3|||f||||f||||||||||2018-06-01 03:14:57.114693|2018-06-01 03:14:57.114693
NCT00469755|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-03-28|2007-05-03|2007-05-04|Estimate|||||||2008-03-28|2008-03-31|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne|A Comparison of Differin® Gel, 0.1% vs. Tazorac® Cream, 0.1% vs. Differin® Gel, 0.1% 6-Week Treatment Switched to Tazorac® Cream, 0.1% 6-Week Treatment in Patients With Acne Vulgaris|Completed||Phase 4|302|Actual|Galderma Laboratories, L.P.||3|||f||||f||||||||||2018-06-01 03:14:57.183658|2018-06-01 03:14:57.183658
NCT00469742|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2012-03-14|2007-05-03|2007-05-04|Estimate|||||||2012-03-14|2012-03-16|Estimate|April 2007||2007-04-30|May 2010|2010-05-31|December 2008|Actual|2008-12-31|||||Observational|||Aprotinin in Neonates Undergoing Cardiopulmonary Bypass|Safety Profile of Aprotinin in Neonates Undergoing Cardiopulmonary Bypass: A Retrospective Chart Review|Completed|||290|Anticipated|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 03:14:57.266127|2018-06-01 03:14:57.266127
NCT00469729|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2015-07-09|2007-05-03|2007-05-04|Estimate|||||||2015-07-09|2015-07-10|Estimate|October 2007||2007-10-31|March 2013|2013-03-31|June 2015|Actual|2015-06-30|February 2013|Actual|2013-02-28||Interventional|ExCell||Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy|A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy|Completed||Phase 2/Phase 3|101|Actual|Gamida Cell -Teva Joint Venture Ltd.||1|||f||||t||||||||||2018-06-01 03:14:57.350921|2018-06-01 03:14:57.350921
NCT00469716|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2016-08-23|2007-05-03|2007-05-04|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2007||2007-04-30|August 2016|2016-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|HH||Hypertonic Saline-hetastarch in Cardiac Surgery|Infusion of Hypertonic Saline-hetastarch in Cardiac Surgery|Completed||Phase 4|50|Actual|Haukeland University Hospital|||||f||||t||||||||||2018-06-01 03:14:57.514174|2018-06-01 03:14:57.514174
NCT00469339|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2018-05-26|2007-05-03|2007-05-04|Estimate|||||||2018-05-26|2018-05-30|Actual|April 27, 2007||2007-04-27|May 22, 2018|2018-05-22|December 13, 2010|Actual|2010-12-13|December 13, 2010|Actual|2010-12-13||Interventional|||Risk Communication Within Mexican-American Families|The Role of Family History and Culture in Communal Coping Within Mexican-American Families|Completed||N/A|498|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:15:02.791417|2018-06-01 03:15:02.791417
NCT00469703|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2008-01-10|2007-05-03|2007-05-04|Estimate|||||||2008-01-10|2008-01-16|Estimate|August 2005||2005-08-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis|A Phase II, Open-Label, Single Center Pilot Study to Determine the Safety and Efficacy of THALOMID (Thalidomide) in Patients With Chronic Pancreatitis.|Terminated||Phase 2|10|Anticipated|Winthrop University Hospital||||Terminated|f||||||||||||||2018-06-01 03:14:57.698839|2018-06-01 03:14:57.698839
NCT00469690|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-05-19|2007-05-03|2007-05-04|Estimate|||||||2008-05-19|2008-05-20|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects|Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects|Completed||Phase 4|58|Actual|Innovative Medical||2|||f||||||||||||||2018-06-01 03:14:57.755354|2018-06-01 03:14:57.755354
NCT00469664|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-05-20|2007-05-03|2007-05-04|Estimate|||||||2008-05-20|2008-05-21|Estimate|February 2000||2000-02-29|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|August 2008|Anticipated|2008-08-31||Interventional|Guanfacine||Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia|A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Research Foundation for Mental Hygiene, Inc.|||||f||||f||||||||||2018-06-01 03:14:57.821004|2018-06-01 03:14:57.821004
NCT00469651|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2007-12-13|2007-05-03|2007-05-04|Estimate|||||||2007-12-13|2007-12-14|Estimate|October 2007||2007-10-31|December 2007|2007-12-31|August 2008|Anticipated|2008-08-31|||||Interventional|MSP3TN||Phase Ib Trial of MSP3 LSP in Children in Tanzania|A Double Blind, Randomized, Controlled Phase Ib Field Trial in 12 to 24 Month Old Children in Tanzania to Evaluate the Safety and Immunogenicity of Candidate Malaria Vaccine MSP 3 Versus Hepatitis B Vaccine|Unknown status|Recruiting|Phase 1|45|Anticipated|African Malaria Network Trust||4|||f||||t||||||||||2018-06-01 03:14:57.894985|2018-06-01 03:14:57.894985
NCT00469638|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-04-21|2007-05-03|2007-05-04|Estimate|||||||2010-04-21|2010-04-22|Estimate|May 2007||2007-05-31|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|AGILIS||Efficacy and Safety Study on Agilis NxT Introducer in AF Patients|Ablation Success With the Use of Steerable AGILIS NxT Introducer Compared With Conventionally Used Swartz SL0.|Completed||N/A|130|Anticipated|St. Jude Medical||2|||f||||f||||||||||2018-06-01 03:14:57.987454|2018-06-01 03:14:57.987454
NCT00469625|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2015-12-24|2007-05-03|2007-05-04|Estimate|||||||2015-12-24|2015-12-28|Estimate|July 2006||2006-07-31|December 2015|2015-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease|A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease|Withdrawn||N/A|0|Actual|Winthrop University Hospital||||Investigator left the Institution.|f||||f||||||||||2018-06-01 03:14:58.061929|2018-06-01 03:14:58.061929
NCT00469612|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-04-09|2007-05-03|2007-05-04|Estimate|||||||2010-04-09|2010-04-12|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment|Evaluating the Efficacy of NeuroVisions's NVC Treatment for Low Myopia|Completed||N/A|50|Anticipated|Ohio State University||2|||f||||f||||||||||2018-06-01 03:14:58.108534|2018-06-01 03:14:58.108534
NCT00469599|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2011-04-01|2007-05-03|2007-05-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|July 2007||2007-07-31|April 2011|2011-04-30|October 2010|Actual|2010-10-31|September 2010|Anticipated|2010-09-30||Interventional|||Treatment of Secondary Hyperparathyroidism in the Uremic Patient|Treatment of Secondary Hyperparathyroidism in the Uremic Patient. A Study Comparing Alfacalcidol and Paricalcitol|Terminated||N/A|86|Actual|Zealand University Hospital||2||Terminated after 86 pt included, because of recruitment problems|f||||t||||||||||2018-06-01 03:14:58.197571|2018-06-01 03:14:58.197571
NCT00469586|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2017-02-28|2007-05-03|2007-05-04|Estimate|||||||2017-02-28|2017-03-01|Actual|April 26, 2007|Actual|2007-04-26|February 2017|2017-02-28|April 24, 2008|Actual|2008-04-24|April 24, 2008|Actual|2008-04-24||Interventional|iINHALE 7||Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes|Efficacy and Safety of Inhaled Prandial Insulin Compared to Metformin Plus Glimepiride in Type 2 Diabetes|Terminated||Phase 3|174|Actual|Novo Nordisk A/S||3||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:14:58.360524|2018-06-01 03:14:58.360524
NCT00469573|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-03-31|2007-05-02|2007-05-04|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2007||2007-05-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes|Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes|Completed||Phase 4|36|Actual|Innovative Medical||1|||f||||||||||||||2018-06-01 03:14:58.550762|2018-06-01 03:14:58.550762
NCT00469560|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2016-11-21|2007-05-03|2007-05-04|Estimate|||||||2016-11-21|2016-11-22|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|March 2010|Actual|2010-03-31||Interventional|||Safety, Tolerability, and Efficacy of Deferasirox in MDS|Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.|Completed||Phase 3|158|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-06-01 03:14:58.642903|2018-06-01 03:14:58.642903
NCT00469547|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2009-04-28|2007-05-03|2007-05-04|Estimate|||||||2009-04-28|2009-04-30|Estimate|November 2007||2007-11-30|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||62% & 15% Ethanol in Emollient Gel as Topical Male Microbicides|Safety & Acceptance of 62% & 15% Ethanol in Emollient Gel as Topical Male Microbicides|Completed||Phase 1|30|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 03:14:58.816752|2018-06-01 03:14:58.816752
NCT00469534|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2011-09-21|2007-05-02|2007-05-04|Estimate|||||||2011-09-21|2011-09-22|Estimate||||September 2011|2011-09-30||||||||Interventional|||Minimized Time to Beam in Patients With High Grade Gliomas|A Pilot Study Evaluating Minimized Time to Beam Hypofractionated IMRT With PET-Assisted Target Definition in Patients With High Grade Gliomas|Withdrawn||N/A|0|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:14:58.905189|2018-06-01 03:14:58.905189
NCT00469521|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2007-09-05|2007-05-03|2007-05-04|Estimate|||||||2007-09-05|2007-09-10|Estimate||||September 2007|2007-09-30||||||||Interventional|||Pilot Study Evaluation of 2 Artificial Tears. Evaluation of TBUT, Tear Meniscus Height and Tear Thickness||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:14:58.966422|2018-06-01 03:14:58.966422
NCT00469326|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2009-01-26|2007-05-03|2007-05-04|Estimate|||||||2009-01-26|2009-01-27|Estimate|April 2005||2005-04-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|TIPS||Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study|Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study|Completed||Phase 3|200|Actual|University Hospital, Motol||2|||f||||f||||||||||2018-06-01 03:15:02.921091|2018-06-01 03:15:02.921091
NCT00469508|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2012-12-07||2013-02-13|2007-05-03|2007-05-04|Estimate|2013-02-13|2013-03-15|Estimate||||2013-02-13|2013-03-15|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|Modafinil||Modafinil vs Placebo for the Treatment of Methamphetamine Dependence|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Modafinil vs Placebo for the Treatment of Methamphetamine Dependence|Completed||Phase 2|71|Actual|University of California, Los Angeles|study is powered to detect at least a moderate effect for modafinil (d = 0.50) in the overall sample; subgroups may be more meaningful|2|||f||||t||||||||||2018-06-01 03:14:59.04729|2018-06-01 03:14:59.04729
NCT00469495|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2009-08-25|2007-05-02|2007-05-04|Estimate|||||||2009-08-25|2009-08-26|Estimate|February 2007||2007-02-28|August 2009|2009-08-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis|Empiric Antihelminthic Therapy Combined With Antimony in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Trial in Subjects Co-Infected With Helminths and Leishmania Brasiliensis|Completed||N/A|90|Anticipated|Hospital Universitário Professor Edgard Santos|||||f||||t||||||||||2018-06-01 03:14:59.518124|2018-06-01 03:14:59.518124
NCT00469482|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2018-03-06|2007-05-03|2007-05-04|Estimate|||||||2018-03-06|2018-03-08|Actual|June 2007||2007-06-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|October 2008|Actual|2008-10-31||Interventional|SOMNUS||The SOMNUS Study: Sedative Optimization Via Monitoring Neurological Status|A Randomized Control Trial Using the BIS Monitor to Avoid Over Sedation and Prolonged Neuropsychological Deficits in Mechanically Ventilated ICU Patients|Completed||N/A|28|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-06-01 03:14:59.590512|2018-06-01 03:14:59.590512
NCT00469469|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2015-04-21|2007-05-02|2007-05-04|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|September 2009|Anticipated|2009-09-30|||||Interventional|||Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma|A Phase II Study of Bevacizumab in Patients With Nonresectable Cancer of the Adrenal Cortex.|Withdrawn||Phase 2|0|Actual|Dartmouth-Hitchcock Medical Center||||unable to enroll subjects into the study|f||||t||||||||||2018-06-01 03:14:59.687178|2018-06-01 03:14:59.687178
NCT00469456|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|2009-11-03||2009-12-21|2007-05-03|2007-05-04|Estimate|2009-11-03|2009-12-07|Estimate||||2009-12-21|2009-12-24|Estimate|April 2007||2007-04-30|December 2009|2009-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD)|Completed||Phase 4|265|Actual|Forest Laboratories||2|||f||||||||||||||2018-06-01 03:14:59.783507|2018-06-01 03:14:59.783507
NCT00469443|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-08-18|2007-05-03|2007-05-04|Estimate|||||||2010-08-18|2010-08-19|Estimate|December 2006||2006-12-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC|A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer|Completed||Phase 3|330|Anticipated|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 03:15:00.198151|2018-06-01 03:15:00.198151
NCT00469430|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2009-04-20|2007-05-03|2007-05-04|Estimate|||||||2009-04-20|2009-04-21|Estimate|May 2006||2006-05-31|April 2009|2009-04-30|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Study of Conservative Versus Surgical Treatment of Appendicitis|Randomized Study of Conservative Versus Surgical Treatment of Appendicitis; Analyses of Result and Economics|Completed||Phase 2|360|Actual|Göteborg University||2|||f||||f||||||||||2018-06-01 03:15:00.327975|2018-06-01 03:15:00.327975
NCT00469417|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-09-01|2007-05-03|2007-05-04|Estimate|||||||2010-09-01|2010-09-03|Estimate|October 1999||1999-10-31|September 2010|2010-09-30|May 2005|Actual|2005-05-31|||||Interventional|||Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma|A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma|Completed||Phase 3|120|Actual|Galderma|||||f||||||||||||||2018-06-01 03:15:00.44794|2018-06-01 03:15:00.44794
NCT00469404|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-11-15|2007-05-03|2007-05-04|Estimate|||||||2007-11-15|2007-11-16|Estimate|May 2007||2007-05-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID 297307)|Single Dose Bioequivalence Trial Comparing a Down-Scaled New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch.|Terminated||Phase 1|24|Anticipated|Grünenthal GmbH||||The trial end was achieved according to the definition in the trial protocol|f||||||||||||||2018-06-01 03:15:00.549861|2018-06-01 03:15:00.549861
NCT00469391|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2016-11-01|2010-04-06|2016-12-29|2007-05-03|2007-05-04|Estimate|2016-11-01|2016-12-30|Estimate|2010-08-05|2010-08-09|Estimate|2016-12-29|2017-02-15|Actual|June 2007||2007-06-30|December 2016|2016-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||ITT population: All subjects who did not withdraw before the procedure and device subjects who had a successful implant procedure|Multi-Center Pre-Bariatric Weight Loss Study|A Multi-Center, Pilot Efficacy Study of the GI Sleeve for Pre-Surgical Weight Loss|Completed||Phase 2|56|Actual|GI Dynamics||2|||f||||f||||||||Undecided|De-identified individual patient data is on file at the Sponsor|2018-06-01 03:15:00.610738|2018-06-01 03:15:00.610738
NCT00469378|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2017-03-21|2007-05-02|2007-05-04|Estimate|||||||2017-03-21|2017-03-23|Actual|July 2007||2007-07-31|March 2017|2017-03-31|February 2010|Actual|2010-02-28|May 2009|Actual|2009-05-31||Interventional|||Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis|An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast|Completed||Phase 2|46|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-06-01 03:15:00.862414|2018-06-01 03:15:00.862414
NCT00469365|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2008-11-25|2007-05-03|2007-05-04|Estimate|||||||2008-11-25|2008-11-26|Estimate|January 2006||2006-01-31|May 2007|2007-05-31|August 2006|Actual|2006-08-31|||||Interventional|||Pharmacy Interventions to Improve Chronic Disease Medication Refill|A Randomized Controlled Trial of Two Pharmacy Interventions to Improve Refill Adherence for Chronic Disease Medications|Completed||Phase 3|3048|Actual|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 03:15:02.291016|2018-06-01 03:15:02.291016
NCT00469352|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2011-07-20|2007-05-03|2007-05-04|Estimate|||||||2011-07-20|2011-07-22|Estimate|May 2007||2007-05-31|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD|The Effect of Genotype and Environmental Risk Factors on Treatment Response to Intravitreal Lucentis (Ranibizumab) for Neovascular AMD|Completed||Phase 3|150|Anticipated|Oregon Health and Science University|||||f||||f||||||||||2018-06-01 03:15:02.503634|2018-06-01 03:15:02.503634
NCT00469300|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-01-31|2007-05-02|2007-05-04|Estimate|||||||2008-01-31|2008-02-04|Estimate|April 2007||2007-04-30|January 2008|2008-01-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Iontophoretic Application of Acyclovir Gel to Treat Cold Sores|A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of the Electrokinetic Transdermal System (ETS) With Acyclovir Gel for the Episodic Treatment of Herpes Labialis|Completed||Phase 2|810|Anticipated|Transport Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:15:03.334055|2018-06-01 03:15:03.334055
NCT00469287|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-04-04|2007-05-03|2007-05-04|Estimate|||||||2008-04-04|2008-04-07|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|June 2007|Actual|2007-06-30|||||Observational|7348||Early Diagnosis of Diabetes Mellitus Type 2 (DM2)|Exploration of Early Diagnosis of Diabetes Mellitus Type 2 Based on Traditional Chinese Medicine by MERID Diagnostics, Biophoton Measurements, Heart Rate Variability and Systems Biology|Completed|||50|Anticipated|TNO|||||f||||f||||||||||2018-06-01 03:15:03.471232|2018-06-01 03:15:03.471232
NCT00469274|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2011-08-04||2012-12-18|2007-05-03|2007-05-04|Estimate|2012-12-18|2013-01-29|Estimate||||2012-12-18|2013-01-29|Estimate|May 2007||2007-05-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|VPES||Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure|A Randomized Open-Label Non-Inferiority Study to Examine the Impact of Pertussis Vaccination of Healthcare Workers on Post-exposure Prophylaxis|Completed||N/A|1102|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 03:15:03.57786|2018-06-01 03:15:03.57786
NCT00469261|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2012-09-24|2007-05-03|2007-05-04|Estimate|||||||2012-09-24|2012-09-25|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TIPTOP||Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling|Tetracycline (Doxycycline) In Patients With Large Acute Myocardial Infarction TO Prevent Left Ventricular Remodeling. TIPTOP Study|Completed||Phase 2|110|Actual|Careggi Hospital||2|||f||||t||||||||||2018-06-01 03:15:04.126707|2018-06-01 03:15:04.126707
NCT00469248|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2007-05-03|2007-05-03|2007-05-04|Estimate|||||||2007-05-03|2007-05-04|Estimate|March 2003||2003-03-31|April 2007|2007-04-30|June 2004|Actual|2004-06-30|||||Interventional|IABPSHOCK||Aortic Balloon Counterpulastion in Myocardial Infarction Related Shock|Intra-Aortic Balloon Counterpulsation in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock - The Prospective, Randomised IABP SHOCK Trial for Attenuation of Multi-Organ Dysfunction Syndrome|Completed||N/A|45|Actual|Martin-Luther-Universität Halle-Wittenberg|||||f||||f||||||||||2018-06-01 03:15:04.229438|2018-06-01 03:15:04.229438
NCT00469235|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2009-09-15|2007-05-03|2007-05-04|Estimate|||||||2009-09-15|2009-09-16|Estimate|June 2007||2007-06-30|September 2009|2009-09-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars|A Single-centre, Double Blind, Randomised, Rising Dose Tolerance Study to Investigate the Safety of Juvista When Administered Following Excision of Ear Lobe Keloids.|Completed||Phase 1/Phase 2|20|Actual|Renovo||2|||f||||f||||||||||2018-06-01 03:15:04.345692|2018-06-01 03:15:04.345692
NCT00469222|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2016-02-24|2007-05-02|2007-05-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Hypofractionated Radiotherapy for Small Cell Lung Cancer|Phase I Dose Escalation Trial of Hypofractionated Limited-field External Beam Thoracic Radiotherapy for Limited Stage Small Cell Carcinoma of the Lung|Completed||Phase 1|24|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:15:04.450433|2018-06-01 03:15:04.450433
NCT00469209|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2010-03-23||2012-08-01|2007-05-03|2007-05-04|Estimate|2011-03-22|2011-04-25|Estimate||||2012-08-01|2012-08-07|Estimate|June 2006||2006-06-30|August 2012|2012-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients|Phase I/II Study of the Combination of Bortezomib With Arsenic Trioxide, Ascorbic Acid and High-Dose Melphalan for Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|60|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-06-01 03:15:04.58515|2018-06-01 03:15:04.58515
NCT00469196|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2016-04-05|2007-05-02|2007-05-04|Estimate|||||||2016-04-05|2016-04-06|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Tomotherapy Treatment for Mesothelioma|Tomotherapy Treatment for Mesothelioma|Completed||Phase 2|18|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:15:05.084868|2018-06-01 03:15:05.084868
NCT00469183|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-03-28|2007-05-03|2007-05-04|Estimate|||||||2008-03-28|2008-03-31|Estimate|May 2006||2006-05-31|March 2008|2008-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma|An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma|Completed||Phase 4|70|Actual|Galderma Laboratories, L.P.|||||f||||f||||||||||2018-06-01 03:15:05.196844|2018-06-01 03:15:05.196844
NCT00469170|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-11-10|2007-05-03|2007-05-04|Estimate|||||||2010-11-10|2010-11-15|Estimate|March 2007||2007-03-31|November 2010|2010-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method|A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method for the Prevention of HIV Infection in Women|Completed||Early Phase 1|220|Actual|International Partnership for Microbicides, Inc.||2|||f||||t||||||||||2018-06-01 03:15:05.324718|2018-06-01 03:15:05.324718
NCT00469157|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-04-16|2007-05-03|2007-05-04|Estimate|||||||2008-04-16|2008-04-17|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Refractive Surgery and Optive Compatibility Study|Refractive Surgery and Optive Compatibility Study|Completed||Phase 4|92|Actual|Innovative Medical||1|||f||||||||||||||2018-06-01 03:15:05.47297|2018-06-01 03:15:05.47297
NCT00469144|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2015-11-23|2007-05-03|2007-05-04|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2005||2005-06-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome|A Randomized Study of Once Daily IV Busulfan With Fludarabine With Hemopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Completed||Phase 3|233|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:15:05.550099|2018-06-01 03:15:05.550099
NCT00469131|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2011-09-13|2007-05-03|2007-05-04|Estimate|||||||2011-09-13|2011-09-14|Estimate|September 2003||2003-09-30|September 2011|2011-09-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid|Randomized Comparative Study on Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparison Between Tacrolimus + MMF and Tacrolimus + Steroid|Completed||Phase 3|79|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-06-01 03:15:05.66698|2018-06-01 03:15:05.66698
NCT00469118|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2015-10-07|2007-05-02|2007-05-04|Estimate|||||||2015-10-07|2015-10-12|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Clinical Efficacy and Safety of Axiom Worldwide DRX9000 Axial Decompression System for Treatment of Low Back Pain|Clinical Efficacy and Safety of Axiom Worldwide DRX9000 Axial Decompression|Withdrawn||Phase 2|0|Actual|NEMA Research, Inc.||2||Financial concerns with device manufacturer.|f||||f||||||||||2018-06-01 03:15:05.877683|2018-06-01 03:15:05.877683
NCT00469105|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2010-04-22|2007-05-03|2007-05-04|Estimate|||||||2010-04-22|2010-04-23|Estimate|December 2006||2006-12-31|April 2010|2010-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills|Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills|Completed||Phase 4|110|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 03:15:06.019018|2018-06-01 03:15:06.019018
NCT00469092|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2009-11-30||2017-01-05|2007-05-03|2007-05-04|Estimate|2009-11-30|2010-01-06|Estimate||||2017-01-05|2017-02-23|Actual|May 2007||2007-05-31|January 2017|2017-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes|A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin naïve Subjects With Type 2 Diabetes|Completed||Phase 4|480|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 03:15:06.179587|2018-06-01 03:15:06.179587
NCT00469079|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|2013-10-29||2014-10-03|2007-05-03|2007-05-04|Estimate|2014-03-04|2014-04-14|Estimate||||2014-10-03|2014-10-13|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|ANTS3||Health Effects of SLT, Cigarette Smoking, and New Tobacco Products|Comparing the Health Effects of Smokeless Tobacco, Cigarette Smoking, and New Tobacco Products Advertised as Safer Alternatives Part of Tobacco Exposure Reduction|Completed||Phase 2|130|Actual|University of Minnesota - Clinical and Translational Science Institute|Smokeless tobacco products commercially available have been introduced, withdrawn, or changed at a relatively rapid rate resulting in products that are no longer available and changes that occurred during the time period that the study occurred.|3|||f||||t||||||||||2018-06-01 03:15:07.230631|2018-06-01 03:15:07.230631
NCT00469066|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2016-02-23|2007-05-02|2007-05-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Observational|||Cone Beam CT Scanning in Lung and Bladder Cancer.|Improving the Accuracy of Radiotherapy Planning and Delivery Using Kilovoltage Cone Beam CT Imaging|Completed|||22|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:15:07.699287|2018-06-01 03:15:07.699287
NCT00469053|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-11-15|2007-05-03|2007-05-04|Estimate|||||||2007-11-15|2007-11-16|Estimate|May 2007||2007-05-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID: 855509)|Multiple Dose Bioequivalence Trial Comparing a Down-Scaled New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch (Protocol ID: 855509)|Terminated||Phase 1|36|Anticipated|Grünenthal GmbH||||The trail end was achived according to the definition in the trial protocol|f||||||||||||||2018-06-01 03:15:07.765443|2018-06-01 03:15:07.765443
NCT00469040|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2017-08-02|2007-05-03|2007-05-04|Estimate|||||||2017-08-02|2017-08-04|Actual|February 28, 2007|Actual|2007-02-28|August 2017|2017-08-31|April 16, 2007|Actual|2007-04-16|April 16, 2007|Actual|2007-04-16||Interventional|||Safety, Blood Levels and Effects of GW642444|A Randomised, Double-blind, Placebo-controlled, Parallel-group, 14 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Extra-pulmonary Pharmacodynamics of Inhaled Doses of GW642444M Formulated With Magnesium Stearate in Healthy Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:15:07.830709|2018-06-01 03:15:07.830709
NCT00469027|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2016-10-13|2007-05-03|2007-05-04|Estimate|||||||2016-10-13|2016-10-17|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|PHACeT||Pulmonary Hypertension: Assessment of Cell Therapy|Phase I Trial to Establish Safety of Autologous Progenitor Cell-based Gene Therapy Delivery of heNOS in Patients With Severe Pulmonary Arterial Hypertension(PAH)Refractory to Conventional Treatment|Completed||Phase 1|7|Actual|Northern Therapeutics||1|||f||||t||||||||||2018-06-01 03:15:07.948752|2018-06-01 03:15:07.948752
NCT00469014|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-03|||2013-04-01|2007-05-03|2007-05-04|Estimate|||||||2013-04-01|2013-04-04|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia|Busulfan-Fludarabine-Clofarabine With Allogeneic Stem Cell Transplantation for Advanced Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Advanced, Gleevec Refractory Chronic Myeloid Leukemia. A Randomized Phase II Study.|Completed||Phase 2|72|Actual|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-06-01 03:15:08.058375|2018-06-01 03:15:08.058375
NCT00469001|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2010-09-12|2007-05-02|2007-05-03|Estimate|||||||2010-09-12|2010-09-14|Estimate|June 2007||2007-06-30|September 2010|2010-09-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Observational|||Evaluation of NT PRO BNP Guided Therapy on Hospitalization Rate and Mortality in Patients With Chronic HF NYHA II-IY|Phase 1 Study of Using BNP as Guided Parameter in Treatment HF|Completed|||108|Actual|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-06-01 03:15:08.293861|2018-06-01 03:15:08.293861
NCT00468988|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2012-05-23|2007-05-02|2007-05-03|Estimate|||||||2012-05-23|2012-05-25|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers|Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers|Completed||Phase 4|30|Anticipated|Alcon Research|||||f||||||||||||||2018-06-01 03:15:08.473035|2018-06-01 03:15:08.473035
NCT00468975|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02||2009-03-24|2010-10-27|2007-05-02|2007-05-03|Estimate||||2010-10-27|2010-11-01|Estimate|2010-10-27|2010-11-01|Estimate|May 2007||2007-05-31|October 2010|2010-10-31||||||||Interventional|||A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.|A Phase IIA Randomised, Double-blind, Double Dummy, Placebo and Active Controlled 5-Way Cross-over Trial to Examine the Bronchodilator Effects of PF-610,355 and to Test for Superiority Versus Placebo in Reversible Asthmatic Patients|Completed||Phase 2|42||Pfizer|||||f||||||||||||||2018-06-01 03:15:08.584702|2018-06-01 03:15:08.584702
NCT00468962|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2007-05-02|2007-05-02|2007-05-03|Estimate|||||||2007-05-02|2007-05-03|Estimate||||May 2007|2007-05-31||||||||Interventional|||The Effct of Chitooligosaccharide on Immune Function in Healthy Adults||Completed||Phase 4|||Eulji University Hospital|||||f||||||||||||||2018-06-01 03:15:08.681694|2018-06-01 03:15:08.681694
NCT00468936|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2008-10-16|2007-05-01|2007-05-03|Estimate|||||||2008-10-16|2008-10-17|Estimate|May 2007||2007-05-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms|Open-Label, Randomized Study Comparing the Patient Reported Severity of GI Side Effects of MMF Versus EC-MPS in Maintenance Heart Transplant Patients.|Unknown status|Recruiting|Phase 3|100|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-06-01 03:15:08.838942|2018-06-01 03:15:08.838942
NCT00468923|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2017-10-23|2007-05-02|2007-05-03|Estimate|||||||2017-10-23|2017-10-25|Actual|May 2007||2007-05-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|HOPE-3||Heart Outcomes Prevention Evaluation-3|Heart Outcomes Prevention Evaluation-3|Completed||Phase 4|12705|Actual|Population Health Research Institute||2|||f||||t||||||||Yes|Data will be shared with participants in the study April/May 2016|2018-06-01 03:15:08.945783|2018-06-01 03:15:08.945783
NCT00468910|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|2015-12-15||2017-04-26|2007-05-02|2007-05-03|Estimate|2017-04-26|2017-05-31|Actual||||2017-04-26|2017-05-31|Actual|March 2007||2007-03-31|April 2017|2017-04-30|August 2011|Actual|2011-08-31|December 2009|Actual|2009-12-31||Interventional||72 of the 79 subjects who were randomized completed the primary endpoint (3-month tissue biopsy); 36 from each arm.|Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer|Spectral Markers in Aspirin Chemoprevention of Colonic Neoplasia|Completed||Phase 2|79|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||Yes||2018-06-01 03:15:09.082319|2018-06-01 03:15:09.082319
NCT00468897|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2017-08-03|2007-05-01|2007-05-03|Estimate|||||||2017-08-03|2017-08-07|Actual|March 21, 2007|Actual|2007-03-21|August 2017|2017-08-31|May 2, 2007|Actual|2007-05-02|May 2, 2007|Actual|2007-05-02||Interventional|||A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.|An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions|Completed||Phase 1|50|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:15:09.757796|2018-06-01 03:15:09.757796
NCT00468884|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2008-10-16|2007-05-02|2007-05-03|Estimate|||||||2008-10-16|2008-10-17|Estimate|October 2006||2006-10-31|October 2008|2008-10-31|February 2007|Actual|2007-02-28|||||Interventional|||Oral Administration of Peptides; Absorption From Gastrointestinal Tract|Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: a Proof of Concept Study in Healthy Subjects|Completed||Phase 1|12||University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:15:09.844787|2018-06-01 03:15:09.844787
NCT00468871|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2011-12-07|2007-05-02|2007-05-03|Estimate|||||||2011-12-07|2011-12-08|Estimate|April 2002||2002-04-30|December 2011|2011-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized Therapy|A Multicenter, Randomized, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide (0.5mg) Implant Compared to Standardized Therapy in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye|Completed||Phase 2/Phase 3|140|Actual|Bausch & Lomb Incorporated||2|||f||||t||||||||||2018-06-01 03:15:09.911948|2018-06-01 03:15:09.911948
NCT00468858|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|2017-02-08|2015-12-28|2017-06-05|2007-05-01|2007-05-03|Estimate|2017-05-08|2017-06-06|Actual|2015-12-28|2016-02-01|Estimate|2017-06-05|2017-07-02|Actual|July 2007||2007-07-31|June 2017|2017-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children|Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children|Completed||Phase 2|636|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||Yes|GlaxoSmithKline|2018-06-01 03:15:10.079247|2018-06-01 03:15:10.079247
NCT00468845|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|2011-04-29||2011-06-07|2007-05-01|2007-05-03|Estimate|2011-04-29|2011-05-26|Estimate||||2011-06-07|2011-06-09|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy|A Multiple Dose, Randomized, Double-Blind Multicenter Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Treatment Of Patients With Post-Surgical Pain From Hysterectomy|Completed||Phase 3|501|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 03:15:12.180709|2018-06-01 03:15:12.180709
NCT00468832|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2016-04-19|2007-05-01|2007-05-03|Estimate|||||||2016-04-19|2016-04-21|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)|Longitudinal Study of the Relationship Between Impairment, Activity Limitation, Participation and Quality of Life in Persons With Confirmed Duchenne Muscular Dystrophy (DMD)|Active, not recruiting|||551|Actual|Cooperative International Neuromuscular Research Group|||3||f||||t||||||Samples With DNA|"~     Blood samples are being collected for single-nucleotide polymorphism, Genome-wide Association~     Study, and biomarker analyses.~   "|||2018-06-01 03:15:15.488983|2018-06-01 03:15:15.488983
NCT00468819|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|2011-06-10||2015-06-29|2007-05-02|2007-05-03|Estimate|2011-08-04|2011-09-05|Estimate||||2015-06-29|2015-07-22|Estimate|May 2007||2007-05-31|June 2015|2015-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children|Open-label Multi-center Study of Magnetic Resonance Imaging (MRI) With 0.1 mmol/kg Body Weight (BW) Gadavist (1.0 M) to Assess Pharmacokinetics, Safety and Tolerability in Children.|Completed||Phase 1|140|Actual|Bayer|Originally, urine was collected up to 6 hours post injection in patients > 9 years. This was amended to patients of all age groups. As a result, urine was collected in 102 of 138 patients with gadobutrol injection (lowest rate in patients 2-6 years).|4|||f||||f||||||||||2018-06-01 03:15:15.685183|2018-06-01 03:15:15.685183
NCT00468806|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01||2010-10-14|2010-10-14|2007-05-01|2007-05-03|Estimate||||2010-10-14|2010-10-28|Estimate|2010-10-14|2010-10-28|Estimate|April 2007||2007-04-30|October 2010|2010-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.|An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Occupancy Kinetics, Pharmacokinetics and Safety of Single Oral Doses of GSK598809, Using [11C]-(+)-PHNO as PET Ligand.|Completed||Phase 1|25|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:15:16.762625|2018-06-01 03:15:16.762625
NCT00468793|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2009-06-05|2007-05-02|2007-05-03|Estimate|||||||2009-06-05|2009-06-10|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Traditional Versus ScvO2 Guided Perioperative Fluid Therapy|Randomized Clinical Study of Traditional Versus ScvO2 Guided Perioperative Fluid Therapy|Completed||Phase 4|240|Anticipated|Haukeland University Hospital||2|||f||||f||||||||||2018-06-01 03:15:16.841233|2018-06-01 03:15:16.841233
NCT00468767|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2008-03-31|2007-05-02|2007-05-03|Estimate|||||||2008-03-31|2008-04-02|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|ACT I||Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation|A Phase III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation|Completed||Phase 3|356|Actual|Cardiome Pharma||2|||f||||t||||||||||2018-06-01 03:15:17.02732|2018-06-01 03:15:17.02732
NCT00468754|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2016-03-01|2007-05-02|2007-05-03|Estimate|||||||2016-03-01|2016-03-03|Estimate|July 2003||2003-07-31|June 2010|2010-06-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine|A Study Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections With Insulin Lispro and Glargine|Completed||N/A|50|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:15:17.17366|2018-06-01 03:15:17.17366
NCT00468741|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2016-04-21|2007-05-02|2007-05-03|Estimate|||||||2016-04-21|2016-04-22|Estimate|September 2003||2003-09-30|April 2016|2016-04-30|June 2014|Actual|2014-06-30|December 2008|Actual|2008-12-31||Interventional|||Component and Couple Analysis of Cancer Communications|Component and Couple Analysis of Cancer Communications|Completed||N/A|338|Actual|University of Wisconsin, Madison||4|||f||||f||||||||||2018-06-01 03:15:17.282601|2018-06-01 03:15:17.282601
NCT00468728|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|2011-07-01|2010-08-27|2017-03-23|2007-05-01|2007-05-03|Estimate|2011-07-01|2011-07-29|Estimate|2010-08-27|2010-08-31|Estimate|2017-03-23|2017-04-21|Actual|October 4, 2006|Actual|2006-10-04|March 2017|2017-03-31|December 11, 2009|Actual|2009-12-11|December 11, 2009|Actual|2009-12-11||Interventional|||PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)|A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)|Completed||Phase 3|535|Actual|Optimer Pharmaceuticals LLC||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:15:17.417677|2018-06-01 03:15:17.417677
NCT00468715|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2018-04-03|2007-05-02|2007-05-03|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2007|Actual|2007-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Bicalutamide in Treating Patients With Metastatic Breast Cancer|Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study|Active, not recruiting||Phase 2|28|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:15:18.552223|2018-06-01 03:15:18.552223
NCT00468702|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2016-11-01|2007-05-02|2007-05-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2007||2007-09-30|November 2016|2016-11-30||||||||Interventional|||Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial|Postoperative Canadian Oral Anticoagulation Self-Management (Post-COAGS) Trial|Withdrawn||N/A|0|Actual|Hoffmann-La Roche|||||f||||||||||||||2018-06-01 03:15:18.646574|2018-06-01 03:15:18.646574
NCT00468689|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2008-10-09|2007-05-01|2007-05-03|Estimate|||||||2008-10-09|2008-10-13|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.|A Two-Part Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-751689 When Administered as an Oral Formulation at Supratherapeutic Dose Levels in Healthy Adult Subjects.|Completed||Phase 1|15|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:15:18.700781|2018-06-01 03:15:18.700781
NCT00468676|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|2013-12-13||2014-05-01|2007-05-01|2007-05-03|Estimate|2014-05-01|2014-05-02|Estimate||||2014-05-01|2014-05-02|Estimate|May 2007||2007-05-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|October 2010|Actual|2010-10-31||Interventional|||Nurse-led Case Management for Diabetes and Cardiovascular Disease Patients With Depression|Randomized Trial of Liaison Psychiatry in Primary Care|Completed||N/A|214|Actual|University of Washington|"Limitations include the study being completed in one health care system in one geographic area, inadequate power to determine cardiovascular events or rates of hospitalization, potential spill-over of intervention to usual care patients."|2|||f||||t||||||||||2018-06-01 03:15:18.786726|2018-06-01 03:15:18.786726
NCT00468663|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2015-04-13|2007-05-02|2007-05-03|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Ambient Air Pollution, Preeclampsia, and Preterm Delivery|Ambient Air Pollution, Preeclampsia, and Preterm Delivery|Completed|||4200|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||f||||||||||2018-06-01 03:15:19.237603|2018-06-01 03:15:19.237603
NCT00468650|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|2009-02-12||2015-04-21|2007-05-01|2007-05-03|Estimate|2009-02-12|2009-03-16|Estimate||||2015-04-21|2015-05-12|Estimate|June 2007||2007-06-30|April 2015|2015-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.|A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico.|Completed||Phase 4|117|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:15:19.384112|2018-06-01 03:15:19.384112
NCT00468637|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2009-02-13|2007-05-02|2007-05-03|Estimate|||||||2009-02-13|2009-02-16|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|September 2011|Anticipated|2011-09-30|||||Observational|AMORE-Eur||Association of Multiple CardiOvascular Risk Factors and Erectile Function Across Europe|Association of Multiple CardiOvascular Risk Factors and Erectile Function Across Europe|Unknown status|Recruiting||1200|Anticipated|University Hospital, Saarland|||||f||||f||||||||||2018-06-01 03:15:20.785932|2018-06-01 03:15:20.785932
NCT00468624|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2007-05-02|2007-05-02|2007-05-03|Estimate|||||||2007-05-02|2007-05-03|Estimate|December 2004||2004-12-31|May 2007|2007-05-31|July 2005|Actual|2005-07-31|||||Interventional|||Effect of Pegvisomant on GH/IGF-I Relationship in GHD|A Study of the Relationship Between Serum Growth Hormone (GH) and Insulin-Like Growth Factor One (IGF-I) in Patients With Severe Adult Growth Hormone Deficiency (AGHD)|Terminated||N/A|||The Christie NHS Foundation Trust||||recruitment completed|f||||f||||||||||2018-06-01 03:15:20.863455|2018-06-01 03:15:20.863455
NCT00468611|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2009-08-12|2007-05-01|2007-05-03|Estimate|||||||2009-08-12|2009-08-13|Estimate|June 2007||2007-06-30|August 2009|2009-08-31|September 2009|Anticipated|2009-09-30|July 2009|Actual|2009-07-31||Interventional|MAESTRO-03||Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis|A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis|Terminated||Phase 3|510|Actual|BioMS Technology Corp.||2||Negative efficacy results of the MAESTRO-01 study|f||||t||||||||||2018-06-01 03:15:20.970556|2018-06-01 03:15:20.970556
NCT00389246|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2017-09-27|2006-10-17|2006-10-18|Estimate|||||||2017-09-27|2017-10-02|Actual|September 2002||2002-09-30|September 2017|2017-09-30|June 2005||2005-06-30|||||Interventional|||Evaluation of Consultation Including Genetic Aspects of Obesity|Evaluation of Consultation Including Genetic Aspects of Obesity|Completed||Phase 3|420||Philipps University Marburg Medical Center|||||f||||||||||||||2018-06-01 03:41:54.369359|2018-06-01 03:41:54.369359
NCT00468598|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|||2015-03-09|2007-05-02|2007-05-03|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Observational|||The Prognostic Value of Troponin T for Long-term Outcome After Cardiac Surgery|The Prognostic Value of Troponin T for Long-term Outcome After Cardiac Surgery|Completed|||3000|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:15:21.028223|2018-06-01 03:15:21.028223
NCT00468585|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-02|2015-12-17||2015-12-17|2007-05-02|2007-05-03|Estimate|2015-12-17|2016-01-22|Estimate||||2015-12-17|2016-01-22|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model|A Multicenter, Phase I/II Study of Every Other Week Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model|Completed||Phase 1/Phase 2|62|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 03:15:21.165766|2018-06-01 03:15:21.165766
NCT00468572|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2012-01-06|2007-05-01|2007-05-02|Estimate|||||||2012-01-06|2012-01-10|Estimate|February 2007||2007-02-28|January 2012|2012-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Using Affectionate Communication as a Response to Acute Stress|Affectionate Communication as a Mechanism for Responding to Acute Stress|Completed||N/A|120|Anticipated|Arizona State University||2|||f||||f||||||||||2018-06-01 03:15:21.81041|2018-06-01 03:15:21.81041
NCT00468559|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2009-06-03||2014-05-06|2007-04-30|2007-05-02|Estimate|2014-05-06|2014-06-02|Estimate||||2014-05-06|2014-06-02|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Phase 3/Safety & Efficacy of Esomeprazole in Infants|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesophageal Reflux (GERD) in Infants Aged 1 to 11 Months, Inclusive|Completed||Phase 3|98|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 03:15:21.965823|2018-06-01 03:15:21.965823
NCT00468546|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2016-08-30||2016-08-30|2007-04-30|2007-05-02|Estimate|2016-08-30|2016-10-25|Estimate||||2016-08-30|2016-10-25|Estimate|May 2003||2003-05-31|August 2016|2016-08-31|July 2012|Actual|2012-07-31|January 2005|Actual|2005-01-31||Interventional||Safety population included participants who were randomized and received any part of an infusion of the study drug.|A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy|A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies|Completed||Phase 3|520|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:15:22.534373|2018-06-01 03:15:22.534373
NCT00468533|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2007-04-30|2007-04-30|2007-05-02|Estimate|||||||2007-04-30|2007-05-02|Estimate|May 2006||2006-05-31|April 2007|2007-04-30|July 2007|Anticipated|2007-07-31|||||Interventional|||The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial|The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial|Unknown status|Recruiting|Phase 4|50|Anticipated|Yu-Li Hospital|||||f||||t||||||||||2018-06-01 03:15:23.489049|2018-06-01 03:15:23.489049
NCT00468520|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2011-02-28|2007-05-01|2007-05-02|Estimate|||||||2011-02-28|2011-03-02|Estimate|November 2003||2003-11-30|February 2011|2011-02-28|October 2005|Actual|2005-10-31|||||Interventional|||Adjuvant Oxytocin for Preinduction Ripening With a Foley catheter--a Clinical Trial|A Prospective, Randomized Trial of Transcervical Foley Catheter With or Without Oxytocin for Preinduction Cervical Ripening|Completed||N/A|200|Actual|Columbia University|||||f||||f||||||||||2018-06-01 03:15:23.633273|2018-06-01 03:15:23.633273
NCT00468507|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2010-03-30|2007-05-01|2007-05-02|Estimate|||||||2010-03-30|2010-03-31|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application|The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application|Completed||Early Phase 1|18|Actual|Maastricht University Medical Center|||||f||||t||||||||||2018-06-01 03:15:23.721059|2018-06-01 03:15:23.721059
NCT00468494|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2013-01-24|2007-05-01|2007-05-02|Estimate|||||||2013-01-24|2013-01-25|Estimate|September 2006||2006-09-30|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia?|Can Blood Glucose Levels During the Perioperative Period Identify a Population at Risk for Hyperglycemia|Completed|||308|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 03:15:23.785316|2018-06-01 03:15:23.785316
NCT00468481|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2011-01-04|2009-11-19|2014-04-04|2007-05-01|2007-05-02|Estimate|2011-01-04|2011-01-25|Estimate|2009-11-19|2009-11-23|Estimate|2014-04-04|2014-04-23|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety Study for an Oral Contraceptive Containing Folate|Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone|Completed||Phase 3|385|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:15:24.96041|2018-06-01 03:15:24.96041
NCT00468468|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2016-02-03|2007-05-01|2007-05-02|Estimate|||||||2016-02-03|2016-02-05|Estimate|September 2003||2003-09-30|February 2016|2016-02-29|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Mentor Integration Study|Mentor Integration Study|Completed||N/A|126|Actual|University of Wisconsin, Madison||4|||f||||||||||||||2018-06-01 03:15:26.027035|2018-06-01 03:15:26.027035
NCT00468455|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2014-12-12|2007-05-01|2007-05-02|Estimate|||||||2014-12-12|2014-12-15|Estimate|October 2005||2005-10-31|December 2014|2014-12-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Observational|||Post-Op Quality of Life After Colorectal Surgery|Postoperative Quality of Life: Development and Assessment of a Novel Tool to Assess Quality of Life Following Colorectal Surgery|Completed|||100|Actual|University Hospitals Cleveland Medical Center|||||f||||f||||||||||2018-06-01 03:15:26.127728|2018-06-01 03:15:26.127728
NCT00468442|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01||2011-11-28|2016-02-21|2007-05-01|2007-05-02|Estimate||||2011-11-28|2011-12-02|Estimate|2016-02-21|2016-03-21|Estimate|November 2006||2006-11-30|February 2016|2016-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||B-Lymphocyte Immunotherapy in Islet Transplantation|B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression (CIT-05)|Terminated||Phase 2|2|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1||Lack of efficacy|f||||||||||||||2018-06-01 03:15:26.229429|2018-06-01 03:15:26.229429
NCT00468429|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2007-06-01|2007-04-30|2007-05-02|Estimate|||||||2007-06-01|2007-06-04|Estimate|May 2007||2007-05-31|June 2007|2007-06-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery|Comparative Study of the Safety and Effectiveness Between Off-Label Subconjunctival Bevacizumab and Mitomycin C in Glaucoma Filtering Surgery.|Unknown status|Recruiting|Phase 4|40|Anticipated|Grewal Eye Institute|||||f||||f||||||||||2018-06-01 03:15:26.355266|2018-06-01 03:15:26.355266
NCT00468416|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2007-05-03|2007-05-01|2007-05-02|Estimate|||||||2007-05-03|2007-05-04|Estimate|February 2007||2007-02-28|May 2007|2007-05-31|February 2008||2008-02-29|||||Interventional|||Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection|Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection|Unknown status|Recruiting|Phase 2|60||Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 03:15:26.434094|2018-06-01 03:15:26.434094
NCT00468403|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01||2012-12-27|2016-03-09|2007-05-01|2007-05-02|Estimate||||2013-01-03|2013-01-07|Estimate|2016-03-09|2016-04-07|Estimate|October 2008||2008-10-31|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|LEEP||LEA29Y (Belatacept) Emory Edmonton Protocol|Islet Transplantation in Type I Diabetes With LEA29Y (Belatacept) Maintenance Therapy (CIT-04)|Completed||Phase 2|10|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 03:15:26.504334|2018-06-01 03:15:26.504334
NCT00468390|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2008-10-10|2007-05-01|2007-05-02|Estimate|||||||2008-10-10|2008-10-13|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|||||Observational|||Capsaicin-Evoked Pain in Patients With CRPS|Capsaicin-Evoked Pain in Patients With Complex Regional Pain Syndrome|Completed|||40|Actual|Danish Pain Research Center|||||f||||f||||||||||2018-06-01 03:15:26.626529|2018-06-01 03:15:26.626529
NCT00468364|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2007-08-29|2007-04-30|2007-05-02|Estimate|||||||2007-08-29|2007-08-30|Estimate|July 2003||2003-07-31|August 2007|2007-08-31|March 2006|Actual|2006-03-31|||||Observational|ClampHOE901||Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes|Comparison of Carbohydrate Metabolism During the Night and at Hypoglycemia in Type-2 Diabetic Patients Either on Glargine or NPH Insulin|Completed|||12|Actual|University of Giessen|||||f||||f||||||||||2018-06-01 03:15:26.696832|2018-06-01 03:15:26.696832
NCT00468351|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2007-05-01|2007-05-01|2007-05-02|Estimate|||||||2007-05-01|2007-05-02|Estimate|April 2006||2006-04-30|April 2007|2007-04-30|April 2007||2007-04-30|||||Interventional|IBEME||Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)|Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide for Refractory Diabetic Macular Edema|Unknown status|Active, not recruiting|Phase 1|||University of Sao Paulo|||||f||||t||||||||||2018-06-01 03:15:26.764933|2018-06-01 03:15:26.764933
NCT00468338|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2016-10-28|2007-04-30|2007-05-02|Estimate|||||||2016-10-28|2016-11-01|Estimate|December 2006||2006-12-31|April 2015|2015-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Correlation BIS Scores Mentally Retarded Patients|Correlation Between the Severity of Mental Retardation and BIS in Mentally Retarded Patients Undergoing Dental Rehabilitation|Completed|||90|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||||No||2018-06-01 03:15:26.834724|2018-06-01 03:15:26.834724
NCT00468325|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2009-11-13|2007-04-30|2007-05-02|Estimate|||||||2009-11-13|2009-11-16|Estimate|May 2007||2007-05-31|November 2009|2009-11-30|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|CTSTAT||Coronary Computed Tomography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT)|Coronary Computed Tomography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT)|Completed||N/A|750|Actual|William Beaumont Hospitals||2|||f||||t||||||||||2018-06-01 03:15:26.902116|2018-06-01 03:15:26.902116
NCT00468312|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2010-05-21||2015-02-24|2007-04-30|2007-05-02|Estimate|2010-05-21|2010-06-22|Estimate||||2015-02-24|2015-03-13|Estimate|March 2007||2007-03-31|February 2015|2015-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 3|429|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:15:27.016548|2018-06-01 03:15:27.016548
NCT00468299|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|2011-04-12||2011-06-23|2007-05-01|2007-05-02|Estimate|2011-06-23|2011-07-21|Estimate||||2011-06-23|2011-07-21|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MiMi||MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure|Treatment of Early Pregnancy Failure|Terminated||N/A|16|Actual|Boston University|The study was terminated because of poor enrollment. Few eligible women were referred.|2||poor enrollment|f||||t||||||||||2018-06-01 03:15:27.435591|2018-06-01 03:15:27.435591
NCT00468286|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2011-02-08|2009-07-02|2011-03-21|2007-05-01|2007-05-02|Estimate|2011-03-02|2011-03-03|Estimate|2009-10-01|2009-10-02|Estimate|2011-03-21|2011-03-23|Estimate|May 2007||2007-05-31|March 2011|2011-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy|An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy|Completed||Phase 2|133|Actual|Ferring Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:15:27.768345|2018-06-01 03:15:27.768345
NCT00468273|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01||2014-02-26|2014-08-07|2007-05-01|2007-05-02|Estimate||||2014-08-04|2014-08-06|Estimate|2014-08-07|2014-08-11|Estimate|November 2006||2006-11-30|August 2014|2014-08-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|IGIV||A Clinical Study of Intravenous Immunoglobulin|A Clinical Study of Immune Globulin Intravenous (Human) Omr-IgG-am IGIV in Subjects With Primary Immune Deficiency Diseases|Completed||Phase 3|57|Actual|FFF Enterprises||1|||f||||t||||||||||2018-06-01 03:15:28.633508|2018-06-01 03:15:28.633508
NCT00468260|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01|||2009-11-18|2007-05-01|2007-05-02|Estimate|||||||2009-11-18|2009-11-19|Estimate|May 2007||2007-05-31|November 2009|2009-11-30||||||||Interventional|||The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies-extension Study|Terminated||Phase 1|12|Anticipated|Novartis||||pts. will be captured in core|f||||||||||||||2018-06-01 03:15:28.743259|2018-06-01 03:15:28.743259
NCT00468247|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2008-04-24|2007-04-30|2007-05-02|Estimate|||||||2008-04-24|2008-04-25|Estimate|March 2007||2007-03-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|NAV-1||Registration Enabling Study of the Safety and Efficacy of the Use of the Navigator Circulatory Management System|A Prospective,Open,Multicentre,RCT to Assess the Safety & Efficacy of Navigator v Conventional Care in Post-op Cardiac Surgery Patients Undergoing CABG &/or Heart Valve Repair/Replacement Utilising Heart Lung Perfusion Pump(The NAV-1 Study)|Completed||Phase 2|112|Actual|Applied Physiology Pty Ltd||2|||f||||f||||||||||2018-06-01 03:15:28.81584|2018-06-01 03:15:28.81584
NCT00468234|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2009-12-31|2007-05-01|2007-05-02|Estimate|||||||2009-12-31|2010-01-05|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Validation of Biomarkers of Exposure and Host Response|Validation of Biomarkers of Exposure and Host Response|Completed||N/A|60||University of Nebraska|||||f||||f||||||||||2018-06-01 03:15:28.901645|2018-06-01 03:15:28.901645
NCT00468221|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2015-05-27|2007-05-01|2007-05-02|Estimate|||||||2015-05-27|2015-05-29|Estimate|June 2009||2009-06-30|May 2015|2015-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|Lowoz||The Effect of Low Level Ozone Exposure on Healthy Volunteers|The Effect of Low Level Ozone Exposure on Healthy Volunteers|Withdrawn||Phase 1|0|Actual|University of North Carolina, Chapel Hill||||Lack of funding|f||||f||||||||||2018-06-01 03:15:28.964372|2018-06-01 03:15:28.964372
NCT00468208|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2013-09-20||2015-12-15|2007-04-30|2007-05-02|Estimate|2013-09-20|2013-11-26|Estimate||||2015-12-15|2016-01-18|Estimate|February 2008||2008-02-29|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis|A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis|Completed||Phase 1/Phase 2|20|Actual|University of Pennsylvania|The main limitation of this trial is the small sample size and the open-label, uncontrolled design.|1|||f||||t||||||||||2018-06-01 03:15:29.069529|2018-06-01 03:15:29.069529
NCT00468195|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2012-03-20|2007-04-30|2007-05-02|Estimate|||||||2012-03-20|2012-03-21|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|||||Observational|BMI40||Optimizing Image Quality in Obese Patients Undergoing Coronary Computed Tomography (CT) Angiography|Optimizing Image Quality in Obese Patients Undergoing Coronary CT Angiography|Completed|||175|Actual|William Beaumont Hospitals|||||f||||t||||||||||2018-06-01 03:15:29.423601|2018-06-01 03:15:29.423601
NCT00468182|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2015-05-05|2007-04-30|2007-05-02|Estimate|||||||2015-05-05|2015-05-07|Estimate|April 2007||2007-04-30|May 2015|2015-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis|Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis|Completed|||24|Actual|Rutgers, The State University of New Jersey|||2||f||||f||||||||||2018-06-01 03:15:29.488197|2018-06-01 03:15:29.488197
NCT00468169|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2012-10-05|2007-05-01|2007-05-02|Estimate|||||||2012-10-05|2012-10-10|Estimate|July 2006||2006-07-31|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|August 2012|Actual|2012-08-31||Interventional|EPIC||Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer|A Randomized Phase II Trial of Concurrent Chemoradiation With Cetuximab (ERBITUX®), 5 Fluorouracil, Hydroxyurea, and Twice-daily Radiation (CetuxFHX) Versus Cetuximab (ERBITUX®), Cisplatin, and Accelerated Radiation With Concomitant Boost (CetuxPX) After Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer|Unknown status|Active, not recruiting|Phase 2|110|Anticipated|University of Chicago||2|||f||||t||||||||||2018-06-01 03:15:29.600728|2018-06-01 03:15:29.600728
NCT00468156|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2012-12-19|2007-04-30|2007-05-02|Estimate|||||||2012-12-19|2012-12-20|Estimate|September 2006||2006-09-30|November 2008|2008-11-30|June 2008|Actual|2008-06-30|September 2007|Actual|2007-09-30||Interventional|||The Fruit and Vegetable Study|Implementation Intentions for Improving Fruit and Vegetable Intakes|Completed||N/A|97|Actual|University of Michigan||3|||f||||t||||||||||2018-06-01 03:15:29.684348|2018-06-01 03:15:29.684348
NCT00468143|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2013-04-17||2016-04-26|2007-05-01|2007-05-02|Estimate|2016-04-26|2016-06-02|Estimate||||2016-04-26|2016-06-02|Estimate|August 2007||2007-08-31|April 2016|2016-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall|A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall|Completed||Phase 4|62|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 03:15:29.803635|2018-06-01 03:15:29.803635
NCT00468130|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30||2013-09-03|2014-09-23|2007-04-30|2007-05-02|Estimate||||2014-09-23|2014-10-02|Estimate|2014-09-23|2014-10-02|Estimate|May 2006||2006-05-31|September 2014|2014-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|Abilify||Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children|Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children|Completed||N/A|15|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 03:15:30.099977|2018-06-01 03:15:30.099977
NCT00468117|ClinicalTrials.gov processed this data on May 31, 2018|2007-05-01||2016-10-07|2017-10-18|2007-05-01|2007-05-02|Estimate||||2016-10-07|2016-10-12|Estimate|2017-10-18|2017-10-20|Actual|January 2007||2007-01-31|October 2017|2017-10-31|July 5, 2017|Actual|2017-07-05|July 2015|Actual|2015-07-31||Interventional|||Efficacy of Islet After Kidney Transplantation|Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation (CIT-06)|Completed||Phase 3|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 03:15:30.189773|2018-06-01 03:15:30.189773
NCT00468104|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-29|2011-12-18||2012-04-25|2007-05-01|2007-05-02|Estimate|2012-04-07|2012-04-24|Estimate||||2012-04-25|2012-04-30|Estimate|April 2004||2004-04-30|April 2012|2012-04-30|August 2009|Actual|2009-08-31|October 2008|Actual|2008-10-31||Interventional|CPE||Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas|Response to Instillation of Activase in the Pleural Cavity vs Placebo in the Management of Complicated Pleural Effusion/Empyema|Completed||N/A|100|Actual|Midwest Pulmonary and Critical Care|The sample size for secondary outcomes in the Placebo group is small|2|||f||||t||||||||||2018-06-01 03:15:30.315707|2018-06-01 03:15:30.315707
NCT00468091|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2015-03-31|2007-04-30|2007-05-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 1999||1999-02-28|April 2007|2007-04-30|September 2000|Actual|2000-09-30|||||Interventional|||Effects of Exendin(9-39) on Gastroduodenal Motility|Regulation of Antro-pyloro-duodenal and Proximal Gastric Motility by GLP-1: Involvement of Cholinergic Pathways|Completed||Phase 1|10|Actual|Ludwig-Maximilians - University of Munich||4|||f||||||||||||||2018-06-01 03:15:30.615197|2018-06-01 03:15:30.615197
NCT00468078|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2016-01-11|2007-04-30|2007-05-01|Estimate|||||||2016-01-11|2016-01-13|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|FPCIT||Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients|The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients|Completed||Phase 3|78|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 03:15:30.714253|2018-06-01 03:15:30.714253
NCT00468065|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2008-05-05|2007-04-30|2007-05-01|Estimate|||||||2008-05-05|2008-05-07|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department|VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department|Unknown status|Recruiting|Phase 4|200|Anticipated|Lifespan||2|||f||||t||||||||||2018-06-01 03:15:30.817017|2018-06-01 03:15:30.817017
NCT00468052|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2013-09-13||2016-10-11|2007-04-30|2007-05-01|Estimate|2016-08-17|2016-10-11|Estimate||||2016-10-11|2016-12-05|Estimate|March 2007||2007-03-31|September 2015|2015-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Decrease Emergence Agitation and Provide Pain Relief for Children Undergoing Tonsillectomy & Adenoidectomy|Use of Dexmedetomidine Infusion for Analgesia and Emergence Agitation for Children Undergoing Tonsillectomy and Adenotonsillectomy|Completed||Phase 3|122|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 03:15:30.924731|2018-06-01 03:15:30.924731
NCT00468039|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2017-08-01|2007-04-27|2007-05-01|Estimate|||||||2017-08-01|2017-08-02|Actual|March 6, 2007|Actual|2007-03-06|August 2017|2017-08-31|June 6, 2008|Actual|2008-06-06|June 6, 2008|Actual|2008-06-06||Interventional|||A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin|A Multicenter, Open-label Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin 100mg qd Plus Metformin 1000mg Bid in Drug Naive Patients With Type 2 Diabetes With Very Poor Glycemic Control|Completed||Phase 3|94|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:15:31.301859|2018-06-01 03:15:31.301859
NCT00468026|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2007-04-30|2007-04-30|2007-05-01|Estimate|||||||2007-04-30|2007-05-01|Estimate||||March 2007|2007-03-31||||||||Interventional|||Evaluation of the ProstaPlant Prostate Stent Insertion in Ex Vivo Human Prostate||Unknown status|Not yet recruiting|Phase 1|||ProstaPlant Urology System Ltd.|||||f||||||||||||||2018-06-01 03:15:31.374391|2018-06-01 03:15:31.374391
NCT00468013|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2015-02-06|2007-04-27|2007-05-01|Estimate|||||||2015-02-06|2015-02-09|Estimate|March 2007||2007-03-31|February 2015|2015-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Computer-Based Intervention for Medically Unexplained Physical Symptoms||Completed||N/A|60|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 03:15:31.454037|2018-06-01 03:15:31.454037
NCT00468000|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30||2016-06-24|2016-06-29|2007-04-30|2007-05-01|Estimate||||2016-06-28|2016-06-30|Estimate|2016-06-29|2016-07-01|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|RESTORE-CLI||Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia|Use of Ixmyelocel-T (Formerly TRC Autologous Bone Marrow Cells) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia|Completed||Phase 2|86|Actual|Vericel Corporation||2|||f||||t||||||||||2018-06-01 03:15:31.689272|2018-06-01 03:15:31.689272
NCT00467987|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2017-11-02|2007-04-27|2007-05-01|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2007|Actual|2007-06-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism|Effect of Androgel on Atherogenesis, Inflammation, Cardiovascular Risk Factors And Adiposity in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism.: a Prospective, Randomized and Controlled-Study|Recruiting||N/A|80|Anticipated|University at Buffalo||3|||f||||f||||||||||2018-06-01 03:15:31.819368|2018-06-01 03:15:31.819368
NCT00467974|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2015-01-21|2007-04-30|2007-05-01|Estimate|||||||2015-01-21|2015-01-26|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma|A Randomized Controlled Trial of Transarterial Ethanol Ablation (TEA) With Lipiodol-Ethanol Mixture (LEM) Versus Transcatheter Arterial Chemoembolisation (TACE) for Unresectable Hepatocellular Carcinoma|Completed||Phase 3|98|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 03:15:31.930652|2018-06-01 03:15:31.930652
NCT00467961|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-28|2014-12-22||2018-04-11|2007-04-28|2007-05-01|Estimate|2014-12-22|2015-01-06|Estimate||||2018-04-11|2018-05-14|Actual|April 2007||2007-04-30|December 2014|2014-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Stem Cell Transplantation for Patients With Cancers of the Blood|Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies|Completed||Phase 2|61|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 03:15:32.018558|2018-06-01 03:15:32.018558
NCT00467948|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-29|||2007-04-30|2007-04-30|2007-05-01|Estimate|||||||2007-04-30|2007-05-01|Estimate|June 2004||2004-06-30|June 2003|2003-06-30|March 2006|Actual|2006-03-31|||||Interventional|||Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients|Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery|Completed||Phase 3|90|Actual|Tehran University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:15:32.232824|2018-06-01 03:15:32.232824
NCT00467935|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-29|||2011-07-28|2007-04-30|2007-05-01|Estimate|||||||2011-07-28|2011-07-29|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|SALVAGE||Scotoma Reduction in AMD Patients Treated With Ranibizumab|A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis|Completed||Phase 1/Phase 2|20|Anticipated|Retina Research Foundation|||||f||||t||||||||||2018-06-01 03:15:32.315005|2018-06-01 03:15:32.315005
NCT00467922|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2009-10-20|2007-04-30|2007-05-01|Estimate|||||||2009-10-20|2009-10-21|Estimate|May 2007||2007-05-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy|A Randomized Prospective Double Blind Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care Versus Either Colloid and Crystalloid|Completed||Phase 3|69|Anticipated|Spectrum Health Hospitals|||||f||||f||||||||||2018-06-01 03:15:32.40293|2018-06-01 03:15:32.40293
NCT00467909|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2007-04-30|2007-04-30|2007-05-01|Estimate|||||||2007-04-30|2007-05-01|Estimate|November 2005||2005-11-30|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|CHAMPION||Nutrition and Cognition in Indian Children|Efficacy of Fortified Products on Improving Long Term Cognitive Performance in School Children in India|Completed||N/A|600|Actual|St. John's Research Institute|||||f||||f||||||||||2018-06-01 03:15:32.472169|2018-06-01 03:15:32.472169
NCT00467896|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2012-09-27||2013-03-27|2007-04-27|2007-05-01|Estimate|2012-09-27|2012-10-26|Estimate||||2013-03-27|2013-04-04|Estimate|September 2006||2006-09-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||"The Power 15 Study: Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting"|"A Comparison of Safety and Inhalation Times of Ventavis (Iloprost) Inhalation Solution Delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 Power 15 Study"|Terminated||Phase 2|62|Actual|Actelion|Study was terminated early due to the discontinuation of the I-neb Power Disc-15 development program.|1||Sponsor's decision|f||||||||||||||2018-06-01 03:15:32.564618|2018-06-01 03:15:32.564618
NCT00467883|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2014-07-17|2007-04-30|2007-05-01|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|March 2013|Actual|2013-03-31|June 2011|Actual|2011-06-30||Interventional|AMBIZYGO||Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment|AMBIZYGO: Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial|Completed||Phase 2|40|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:15:33.084835|2018-06-01 03:15:33.084835
NCT00466999|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2012-03-28|2007-04-25|2007-04-27|Estimate|||||||2012-03-28|2012-03-30|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion|Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion|Completed||N/A|1000|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-06-01 03:15:56.887923|2018-06-01 03:15:56.887923
NCT00467870|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2016-11-07|2012-08-31|2017-09-07|2007-04-27|2007-05-01|Estimate|2017-01-16|2017-03-07|Actual|2012-08-31|2012-09-06|Estimate|2017-09-07|2017-10-05|Actual|March 2006||2006-03-31|September 2017|2017-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|TU|Includes all participants who were enrolled and received at least 1 injection|Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men|A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men|Completed||Phase 3|531|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:15:33.240519|2018-06-01 03:15:33.240519
NCT00467857|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2010-11-03||2012-09-13|2007-04-30|2007-05-01|Estimate|2011-01-17|2011-02-11|Estimate||||2012-09-13|2012-09-18|Estimate|April 2007||2007-04-30|January 2011|2011-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination|A Randomized, Controlled, Parallel Group, Multi-center, Open Label Study Comparing Common Surgical Skin Preparation Solutions in Combination With InteguSeal Versus Common Surgical Skin Preparation Solutions to Reduce Skin Flora Contamination.|Completed||Phase 4|293|Actual|Kimberly-Clark Corporation||2|||f||||f||||||||||2018-06-01 03:15:34.325946|2018-06-01 03:15:34.325946
NCT00467844|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2013-01-18||2014-06-26|2007-04-30|2007-05-01|Estimate|2013-01-18|2013-02-21|Estimate||||2014-06-26|2014-07-11|Estimate|May 2007||2007-05-31|June 2014|2014-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.|Double-Blind, Placebo-Controlled, Dose-Finding Study of the Effect of GTx-024 on Muscle Wasting (Cachexia) in Patients With Cancer|Completed||Phase 2|159|Actual|GTx||3|||f||||f||||||||||2018-06-01 03:15:35.240473|2018-06-01 03:15:35.240473
NCT00467831|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-28|2013-06-03||2013-06-03|2007-04-28|2007-05-01|Estimate|2013-06-03|2013-08-02|Estimate||||2013-06-03|2013-08-02|Estimate|April 2007||2007-04-30|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome|Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome|Terminated||Phase 1/Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated because enrollment was too low. The results shown are not statistically significant.|1||insufficient enrollment|f||||f||||||||||2018-06-01 03:15:36.010687|2018-06-01 03:15:36.010687
NCT00467818|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2010-11-23|2007-04-30|2007-05-01|Estimate|||||||2010-11-23|2010-11-24|Estimate|January 2007||2007-01-31|November 2010|2010-11-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders|Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders|Unknown status|Recruiting|N/A|60|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-06-01 03:15:36.198775|2018-06-01 03:15:36.198775
NCT00467805|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2010-04-08|2007-04-30|2007-05-01|Estimate|||||||2010-04-08|2010-04-09|Estimate|March 2009||2009-03-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|May 2009|Actual|2009-05-31||Interventional|||Immediate Effect of Light on Reproductive Hormones in Women: a Role of the Spectrum||Completed||N/A|16|Actual|Russian Academy of Medical Sciences|||||f||||f||||||||||2018-06-01 03:15:36.320509|2018-06-01 03:15:36.320509
NCT00467792|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2008-12-05|2007-04-30|2007-05-01|Estimate|||||||2008-12-05|2008-12-08|Estimate|January 2006||2006-01-31|December 2008|2008-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|UP||Natural History of Urticaria Pigmentosa in Children|Natural History of Urticaria Pigmentosa in Children|Completed|||47|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 03:15:36.394341|2018-06-01 03:15:36.394341
NCT00467779|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2016-06-10||2016-07-25|2007-04-30|2007-05-01|Estimate|2016-06-10|2016-07-22|Estimate||||2016-07-25|2016-08-26|Estimate|May 2007||2007-05-31|July 2016|2016-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Safety population consisted of all participants who received at least 1 dose of study drug.|Study of Cobimetinib in Participants With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors|Completed||Phase 1|119|Actual|Genentech, Inc.||5|||f||||||||||||||2018-06-01 03:15:36.701491|2018-06-01 03:15:36.701491
NCT00467766|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2007-05-03|2007-04-27|2007-05-01|Estimate|||||||2007-05-03|2007-05-07|Estimate|July 1999||1999-07-31|May 2007|2007-05-31|June 2003|Actual|2003-06-30|||||Interventional|||Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease|Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease|Completed||N/A|300|Actual|National Institute on Aging (NIA)|||||f||||t||||||||||2018-06-01 03:15:43.270653|2018-06-01 03:15:43.270653
NCT00467753|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2013-10-25||2013-10-25|2007-04-30|2007-05-01|Estimate|2013-10-25|2013-12-16|Estimate||||2013-10-25|2013-12-16|Estimate|April 2006||2006-04-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||5 patients started in the study, 2 dropped out after 1-2 weeks , 3 were lost to follow up.|Oxcarbazepine Versus Placebo in Childhood Autism|Oxcarbazepine Versus Placebo in Childhood Autism|Completed||N/A|5|Actual|Rutgers, The State University of New Jersey|Patients became more irritable coming off of previous medication and were unable to tolerate monotherapy with the medication.|2|||f||||t||||||||||2018-06-01 03:15:43.339489|2018-06-01 03:15:43.339489
NCT00467740|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|2014-03-28||2014-06-17|2007-04-30|2007-05-01|Estimate|2014-06-10|2014-06-11|Estimate||||2014-06-17|2014-06-27|Estimate|May 2007||2007-05-31|June 2014|2014-06-30||||October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma|Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (4 Doses) Delivered by the Respimat® Inhaler in Patients With Asthma|Completed||Phase 2|296|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:15:43.80657|2018-06-01 03:15:43.80657
NCT00467727|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-29|||2012-04-27|2007-04-30|2007-05-01|Estimate|||||||2012-04-27|2012-05-01|Estimate|April 2007||2007-04-30|April 2012|2012-04-30|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||Visibility of Lesion Characteristics With Phase Contrast Mammography|Lesion Characteristics' Visibility With Phase Contrast Mammography in Comparison to X-Ray Mammography for Women Undergoing X-Ray Diagnostic Mammography|Completed||N/A|53|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:15:45.864419|2018-06-01 03:15:45.864419
NCT00467714|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-29|||2008-11-17|2007-04-30|2007-05-01|Estimate|||||||2008-11-17|2008-11-18|Estimate|February 2007||2007-02-28|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluation Of Cloumella Strut Effect In Tip Rotation|Evaluation of Cloumella Strut in Maintenance of Tip Rotation|Completed||Phase 4|92|Actual|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 03:15:45.94516|2018-06-01 03:15:45.94516
NCT00466648|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-04-25|2007-04-25|2007-04-27|Estimate|||||||2007-04-25|2007-04-27|Estimate|March 2007||2007-03-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Randomized Controlled Trial Comparing Different Closure Methods for Laparoscopic Port Sites|Randomized Controlled Trial Comparing Two Different Methods of Laparoscopy Port Closure|Completed||N/A|20||New York Presbyterian Hospital|||||f||||t||||||||||2018-06-01 03:16:04.658541|2018-06-01 03:16:04.658541
NCT00467701|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2009-01-16|2007-04-30|2007-05-01|Estimate|||||||2009-01-16|2009-01-19|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|CAPITO||Community Acquired Pneumonia in Telemark and Ostfold|Prevalence of Legionella Infections, Bacterial Etiology in Pneumonia Among Patients Admitted to Hospital,- and Risk Factors/Characteristics for These Patients.(Translated From Norwegian)|Completed|||380|Actual|Sykehuset Telemark|||||f||||f||||||Samples Without DNA|"~     sputum~   "|||2018-06-01 03:15:46.024288|2018-06-01 03:15:46.024288
NCT00467688|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2007-10-30|2007-04-30|2007-05-01|Estimate|||||||2007-10-30|2007-10-31|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|||Effect of Continuous Glucose Monitoring on Course of Glucose in Type 1 Diabetes|The Effect of Continuous Glucose Monitoring With and Without Real Time Access to Glucose Values and Glucose Alerts on Course of Glucose and Satisfaction With CGMS in Type 1 Diabetic Patients|Completed||N/A|50|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||t||||||||||2018-06-01 03:15:46.090612|2018-06-01 03:15:46.090612
NCT00467675|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-30|||2015-12-02|2007-04-30|2007-05-01|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2006||2006-04-30|September 2007|2007-09-30|January 2007|Actual|2007-01-31|||||Observational|||Establishing Ambulatory Glucose Profiles for People Without Diabetes Using CGM Data|Observational Study of Interstitial Glucose Monitoring With the FreeStyle Navigator CGM System to Develop Novel Methods for Displaying, Reporting and Analyzing CGM Data for Clinical Decision-Making: Phase 2-Establishing Ambulatory Glucose Profiles for Individuals Without Diabetes|Completed|||35|Actual|HealthPartners Institute|||||f||||f||||||||||2018-06-01 03:15:46.172526|2018-06-01 03:15:46.172526
NCT00467662|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2007-04-30|2007-04-30|2007-05-01|Estimate|||||||2007-04-30|2007-05-01|Estimate||||April 2007|2007-04-30||||||||Interventional|||Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)|"The Safety, Efficacy and Convenience of Use of the Natural Agent Superlysin Gel as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%."|Unknown status|Not yet recruiting|Phase 4|75|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 03:15:46.232451|2018-06-01 03:15:46.232451
NCT00467649|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2009-04-10||2015-03-26|2007-04-30|2007-05-01|Estimate|2009-04-10|2009-06-04|Estimate||||2015-03-26|2015-04-14|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes|A Phase 4, Randomized, Open Label, Parallel Group, Multicenter Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes|Completed||Phase 4|112|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:15:46.327176|2018-06-01 03:15:46.327176
NCT00467636|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2009-10-01|2007-04-27|2007-04-30|Estimate|||||||2009-10-01|2009-10-02|Estimate|July 2007||2007-07-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Insulin Therapy in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Influence of Insulin Therapy in Patients Admitted to Hospital With Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Terminated||N/A|51|Actual|The Royal Bournemouth Hospital||2||Difficulty recruiting (early discharge scheme initiated)|f||||t||||||||||2018-06-01 03:15:47.297267|2018-06-01 03:15:47.297267
NCT00467623|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2008-10-16|2007-04-27|2007-04-30|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 1995||1995-01-31|April 2007|2007-04-30|December 1997|Actual|1997-12-31|||||Observational|||Holotranscobalamin Remains Unchanged During Pregnancy|Holotranscobalamin Remains Unchanged During Pregnancy. Longitudinal Changes of Cobalamins and Its Binding Proteins During Pregnancy and Postpartum|Completed|||150||University of Aarhus|||||f||||f||||||||||2018-06-01 03:15:47.400124|2018-06-01 03:15:47.400124
NCT00467610|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|2012-08-21||2014-10-23|2007-04-26|2007-04-30|Estimate|2014-10-23|2014-10-24|Estimate||||2014-10-23|2014-10-24|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS|A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome|Terminated||Phase 2|6|Actual|Rush University Medical Center||1||lack of efficacy.|f||||t||||||||||2018-06-01 03:15:47.468963|2018-06-01 03:15:47.468963
NCT00467597|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2014-10-30||2014-11-19|2007-04-27|2007-04-30|Estimate|2014-11-19|2014-11-26|Estimate||||2014-11-19|2014-11-26|Estimate|April 2006||2006-04-30|November 2014|2014-11-30|October 2013|Actual|2013-10-31|August 2008|Actual|2008-08-31||Observational|||Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)|Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One)|Completed|||36|Actual|VA Office of Research and Development|||1||f||||t||||||||||2018-06-01 03:15:47.67363|2018-06-01 03:15:47.67363
NCT00467584|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|2014-04-17||2014-05-15|2007-04-27|2007-04-30|Estimate|2014-04-17|2014-05-16|Estimate||||2014-05-15|2014-05-20|Estimate|July 2007||2007-07-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Aspirin for Treatment of Multiple Sclerosis-Related Fatigue|Aspirin for Treatment of Multiple Sclerosis-Related Fatigue|Terminated||Phase 3|62|Actual|Mayo Clinic|Early termination leading to smaller number of subjects analyzed.|3||Interim analysis indicated treatment unlikely effective;slow recruitment|f||||f||||||||||2018-06-01 03:15:48.064072|2018-06-01 03:15:48.064072
NCT00467571|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2013-05-01|2007-04-27|2007-04-30|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura|Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura|Completed||Phase 4|26|Actual|Mahidol University||1|||f||||t||||||||||2018-06-01 03:15:48.299939|2018-06-01 03:15:48.299939
NCT00467558|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2012-02-03||2012-04-18|2007-04-27|2007-04-30|Estimate|2012-04-18|2012-05-18|Estimate||||2012-04-18|2012-05-18|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Double-Blind Naltrexone in Compulsive Sexual Behavior|A Double-Blind, Placebo-Controlled Study of Naltrexone in Compulsive Sexual Behavior|Completed||Phase 2|7|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 03:15:48.384341|2018-06-01 03:15:48.384341
NCT00467545|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2017-06-21|2007-04-27|2007-04-30|Estimate|||||||2017-06-21|2017-06-23|Actual|April 2007||2007-04-30|May 2012|2012-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B|An Extension to A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Adults With HBeAg-positive, Compensated Chronic Hepatitis B (CHB) (An Open-label Multicenter, follow-on Trial of the Safety of Oral Administration of Telbivudine (LDT600) 600 mg Over 21 Months in Adults With HBeAg-positive Ompensated Chronic Hepatitis B (CHB))|Completed||Phase 4|44|Actual|Novartis|||||f||||||||||||||2018-06-01 03:15:48.647586|2018-06-01 03:15:48.647586
NCT00467532|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2013-01-16|2007-04-27|2007-04-30|Estimate|||||||2013-01-16|2013-01-17|Estimate|March 2007||2007-03-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients|A Prospective Longitudinal Study of the Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Patients Sustaining Significant Burn Injury|Completed|||60|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 03:15:48.744053|2018-06-01 03:15:48.744053
NCT00467519|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2010-11-04||2014-01-10|2007-04-27|2007-04-30|Estimate|2010-11-04|2010-12-03|Estimate||||2014-01-10|2014-02-07|Estimate|April 2007||2007-04-30|January 2014|2014-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age|Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine as Fifth Dose Booster in Children 4 to 6 Years of Age|Completed||Phase 3|1045|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:15:48.833548|2018-06-01 03:15:48.833548
NCT00467506|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2011-11-10|2007-04-27|2007-04-30|Estimate|||||||2011-11-10|2011-11-11|Estimate|May 2004||2004-05-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|RIT in MTC||Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma|Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma|Completed||Phase 2|||Nantes University Hospital|||||f||||t||||||||||2018-06-01 03:15:49.319477|2018-06-01 03:15:49.319477
NCT00467493|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2009-06-02|2007-04-27|2007-04-30|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers|A Partial Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Anastrozole, an Aromatase Inhibitor, on Endometrial Thickness in Healthy Premenopausal Women When Dosed at Various Times During the Menstrual Cycle (Protocol M-001)|Completed||Phase 2|64|Actual|Meditrina Pharmaceuticals||6|||f||||f||||||||||2018-06-01 03:15:49.381991|2018-06-01 03:15:49.381991
NCT00467467|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2013-05-28|2007-04-27|2007-04-30|Estimate|||||||2013-05-28|2013-05-30|Estimate|June 2006||2006-06-30|May 2013|2013-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort|Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort|Completed||Phase 3|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 03:15:49.438459|2018-06-01 03:15:49.438459
NCT00467454|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2011-12-13|2007-04-27|2007-04-30|Estimate|||||||2011-12-13|2011-12-14|Estimate|June 2007||2007-06-30|December 2011|2011-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Naltrexone in the Treatment of Pyromania|A Double-Blind, Placebo-Controlled Study of Naltrexone in Pyromania|Withdrawn||Phase 2|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Funding allocation to different clinical trials.|f||||t||||||||||2018-06-01 03:15:49.483806|2018-06-01 03:15:49.483806
NCT00467441|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2007-10-31|2007-04-26|2007-04-30|Estimate|||||||2007-10-31|2007-11-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VSF-173 and Matching Placebo in Healthy Male and Female Subjects With Induced Excessive Sleepiness|Completed||Phase 2|60|Anticipated|Vanda Pharmaceuticals|||||f||||||||||||||2018-06-01 03:15:49.54219|2018-06-01 03:15:49.54219
NCT00467428|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2007-04-27|2007-04-27|2007-04-30|Estimate|||||||2007-04-27|2007-04-30|Estimate|August 2003||2003-08-31|April 2007|2007-04-30|September 2004|Actual|2004-09-30|||||Interventional|||Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder|Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder. A Randomised, Double-Blind, Placebo-Controlled Study|Completed||Phase 2|126|Actual|NeuroSearch A/S|||||f||||||||||||||2018-06-01 03:15:49.594868|2018-06-01 03:15:49.594868
NCT00467415|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2009-06-26|2007-04-27|2007-04-30|Estimate|||||||2009-06-26|2009-06-29|Estimate|May 2007||2007-05-31|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|October 2009|Anticipated|2009-10-31||Interventional|SSTTEP||Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy|Multi-Center Project: Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy|Unknown status|Active, not recruiting|N/A|66|Anticipated|Shriners Hospitals for Children|||||f||||f||||||||||2018-06-01 03:15:49.647429|2018-06-01 03:15:49.647429
NCT00467402|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27||2012-05-02|2012-05-02|2007-04-27|2007-04-30|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|April 2007||2007-04-30|May 2012|2012-05-31||||September 2009|Actual|2009-09-30||Interventional|||Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder|A 52-week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of the Long-term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-label Treatment of 16-24 Weeks|Completed||Phase 3|644|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:15:49.842289|2018-06-01 03:15:49.842289
NCT00467389|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2013-12-18||2014-05-21|2007-04-27|2007-04-30|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|February 2007||2007-02-28|May 2014|2014-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||All participating subjects|Use of Donepezil for Treatment of Cocaine Dependence|Donepezil Effects on Cocaine Craving and Pharmacokinetics|Completed||Phase 2|12|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:15:50.015138|2018-06-01 03:15:50.015138
NCT00467376|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2009-09-14|2007-04-27|2007-04-30|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 2007||2007-01-31|September 2009|2009-09-30||||June 2008|Actual|2008-06-30||Interventional|||Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus|12-week, Multicenter, Controlled, Open, 3:1 Randomized, Parallel Clinical Trial Comparing Insulin Glulisine With Regular Human Insulin (Insulin Lispro) Injected Subcutaneously in Subjects With Type 1 or 2 Diabetes Mellitus Also Using Lantus (Insulin Glargine)|Completed||Phase 3|485|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:15:50.196279|2018-06-01 03:15:50.196279
NCT00467363|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2014-04-10||2016-12-09|2007-04-27|2007-04-30|Estimate|2014-04-10|2014-05-14|Estimate||||2016-12-09|2017-02-03|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|EAGeR|All women who consented and underwent randomization were included in baseline analyses.|The Effects of Aspirin in Gestation and Reproduction|The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.|Completed||N/A|1228|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 03:15:50.358617|2018-06-01 03:15:50.358617
NCT00386776|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|2013-03-20||2013-06-11|2006-10-11|2006-10-12|Estimate|2013-05-01|2013-06-10|Estimate||||2013-06-11|2013-06-20|Estimate|January 2005||2005-01-31|June 2013|2013-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Patient Computer Dialog in Primary Care|Cybermedicine for the Patient and Physician|Completed||Phase 3|45|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-06-01 03:42:39.252758|2018-06-01 03:42:39.252758
NCT00467350|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2013-02-13|2007-04-27|2007-04-30|Estimate|||||||2013-02-13|2013-02-15|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Comparison Trial of Enema vs. PEG 3350 for Constipation|Randomized Clinical Trial of Milk and Molasses Enema vs. PEG 3350 for Fecal Impaction in Childhood Constipation|Terminated||N/A|80|Actual|Children's Mercy Hospital Kansas City||2||concern patients in oral cleaout arm had worse outcome|f||||f||||||||||2018-06-01 03:15:50.92585|2018-06-01 03:15:50.92585
NCT00467337|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2007-04-27|2007-04-27|2007-04-30|Estimate|||||||2007-04-27|2007-04-30|Estimate|June 2004||2004-06-30|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Interventional|||Medial-Wedge Insole is Highly Effective in the Treatment of Valgus Knee Osteoarthritis|Medial-Wedge Insole is Highly Effective in the Treatment of Valgus Knee Osteoarthritis|Terminated||Phase 3|||University of Sao Paulo||||Terminated|f||||t||||||||||2018-06-01 03:15:50.998295|2018-06-01 03:15:50.998295
NCT00467324|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2008-10-13|2007-04-26|2007-04-30|Estimate|||||||2008-10-13|2008-10-15|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|October 2007|Actual|2007-10-31||Interventional|||The Advance Trial. Tongue Advancement for Obstructive Sleep Apnea: An Evaluation of the Aspire Medical Advance System|The Advance Trial. Tongue Advancement for Obstructive Sleep Apnea: An Evaluation of the Aspire Medical Advance System|Unknown status|Active, not recruiting|N/A|42|Actual|Aspire Medical|||||f||||t||||||||||2018-06-01 03:15:51.060023|2018-06-01 03:15:51.060023
NCT00467311|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2008-05-06|2007-04-27|2007-04-30|Estimate|||||||2008-05-06|2008-05-08|Estimate|December 2006||2006-12-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Observational|||Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients|Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization|Completed|||66|Actual|National Heart Institute, Mexico|||||f||||f||||||||||2018-06-01 03:15:51.145238|2018-06-01 03:15:51.145238
NCT00467298|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2015-06-18||2017-08-30|2007-04-27|2007-04-30|Estimate|2017-08-30|2018-04-02|Actual||||2017-08-30|2018-04-02|Actual|December 2007||2007-12-31|August 2017|2017-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||An Intervention to Improve Function in Severe Cardiopulmonary Illness|An Intervention to Enhance Function in Severe Cardiopulmonary Illness|Completed||N/A|90|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:15:51.228311|2018-06-01 03:15:51.228311
NCT00467285|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|2014-12-02||2015-01-13|2007-04-26|2007-04-30|Estimate|2015-01-13|2015-01-14|Estimate||||2015-01-13|2015-01-14|Estimate|October 2006||2006-10-31|January 2015|2015-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Effect of Diabetic Medications on Bone Metabolism|Effect of Thiazolidinediones on Skeletal Health|Completed|||96|Actual|VA Office of Research and Development|||2||f||||f||||||Samples Without DNA|"~     Urine and serum samples collected for the study will be spin and stored at -70 degree C and~     assays run intermittently~   "|||2018-06-01 03:15:51.421339|2018-06-01 03:15:51.421339
NCT00467272|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2012-09-18|2007-04-27|2007-04-30|Estimate|||||||2012-09-18|2012-09-19|Estimate|March 2007||2007-03-31|September 2012|2012-09-30||||September 2012|Actual|2012-09-30||Interventional|||Catheter Related - Gram Positive Bloodstream Infections|Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections|Completed||Phase 2|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:15:51.715678|2018-06-01 03:15:51.715678
NCT00467259|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|2011-08-03||2011-11-10|2007-04-27|2007-04-30|Estimate|2011-11-10|2011-12-15|Estimate||||2011-11-10|2011-12-15|Estimate|April 2007||2007-04-30|November 2011|2011-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women|A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.|Completed||Phase 3|1271|Actual|Warner Chilcott||2|||f||||t||||||||||2018-06-01 03:15:51.809849|2018-06-01 03:15:51.809849
NCT00467246|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2007-04-27|2007-04-27|2007-04-30|Estimate|||||||2007-04-27|2007-04-30|Estimate||||April 2007|2007-04-30||||||||Interventional|||Sub-Cutaneous Insulin in Hyperglycaemic Emergencies|The Use of a Long-Acting Sub-Cutaneous Insulin Analogue in the Management of Hyperglycaemic Emergencies|Withdrawn||N/A|||The Royal Bournemouth Hospital||||Ethics approval denied|f||||t||||||||||2018-06-01 03:15:52.58727|2018-06-01 03:15:52.58727
NCT00467233|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2012-09-14|2007-04-26|2007-04-30|Estimate|||||||2012-09-14|2012-09-17|Estimate|May 2007||2007-05-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of Acid Peel and Laser for the Treatment of Melasma|A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of 30 % Salicylic Acid Peel vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.|Completed||N/A|15|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 03:15:52.633981|2018-06-01 03:15:52.633981
NCT00467220|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2015-12-01|2007-04-27|2007-04-30|Estimate|||||||2015-12-01|2015-12-02|Estimate|April 2007||2007-04-30|December 2015|2015-12-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|1072||Effect of Daily Calorie or Alternate-day Calorie Reductions on Risk for Cardiovascular Disease and Cancer|Effect of Daily Calorie Restriction or Alternate-day Reductions in Calorie Intake on Risk for Cardiovascular Disease and Cancer|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-06-01 03:15:52.695918|2018-06-01 03:15:52.695918
NCT00467207|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-27|||2016-04-15|2007-04-27|2007-04-30|Estimate|||||||2016-04-15|2016-04-18|Estimate|September 2006||2006-09-30|April 2016|2016-04-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Intensive Strength Training in Children With Cerebral Palsy - Effect on Hand Function|Intensive Strength Training in Children With Cerebral Palsy - Effect on Hand Function|Completed||Phase 2|10|Actual|St. Olavs Hospital||2|||f||||f||||||||Undecided||2018-06-01 03:15:52.773206|2018-06-01 03:15:52.773206
NCT00467194|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2013-06-14|2007-04-25|2007-04-27|Estimate|||||||2013-06-14|2013-06-17|Estimate|December 2006||2006-12-31|June 2013|2013-06-30||||May 2011|Actual|2011-05-31||Interventional|||Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Phase I Study of Rapamycin in Combination With Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 1|27|Actual|National Cancer Centre, Singapore||1|||f||||||||||||||2018-06-01 03:15:52.842867|2018-06-01 03:15:52.842867
NCT00467181|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2008-01-28|2007-04-26|2007-04-27|Estimate|||||||2008-01-28|2008-01-30|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery||Completed||Phase 2|30|Anticipated|Summa Health System|||||f||||t||||||||||2018-06-01 03:15:52.909444|2018-06-01 03:15:52.909444
NCT00467168|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2007-04-26|2007-04-26|2007-04-27|Estimate|||||||2007-04-26|2007-04-27|Estimate|January 1998||1998-01-31|April 2007|2007-04-30|May 1998|Actual|1998-05-31|||||Interventional|||Optimal Dietary Fat Pattern to Prevent Cardiovascular Disease Among Type 2 Diabetes|Effects of Fatty Acid Composition Ratios of Oral Fatty Loads on the Dynamic Metabolism of Postprandial Lipid and Triglyceride-Rich Lipoproteins in Chinese NIDDM Out-Patients|Completed||Phase 1/Phase 2|30||Sun Yat-sen University|||||f||||t||||||||||2018-06-01 03:15:52.96053|2018-06-01 03:15:52.96053
NCT00467155|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2015-09-23|2007-04-26|2007-04-27|Estimate|||||||2015-09-23|2015-09-24|Estimate|June 2007||2007-06-30|April 2015|2015-04-30||||||||Observational|||Helicobacter in The Gambia (Part 2)|Genotypes of Helicobacter Pylori in West African Children and Adults: Part 2: The Application of a Minimally Invasive Technique for H. Pylori Isolation in a Population Study|Withdrawn|||0|Actual|Medical Research Council Unit, The Gambia|||||f||||f||||||||||2018-06-01 03:15:53.037205|2018-06-01 03:15:53.037205
NCT00467142|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2011-05-13|2007-04-25|2007-04-27|Estimate|||||||2011-05-13|2011-05-16|Estimate|January 2007||2007-01-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery|Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|61|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:15:54.197935|2018-06-01 03:15:54.197935
NCT00467129|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2013-12-17|2007-04-25|2007-04-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 2002||2002-07-31|May 2007|2007-05-31||||||||Observational|||Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer|The Role of Genetic Factors in Clinical Outcome for Colorectal Cancer|Unknown status|Active, not recruiting||800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:15:54.296512|2018-06-01 03:15:54.296512
NCT00467116|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2012-05-16|2007-04-25|2007-04-27|Estimate|||||||2012-05-16|2012-05-18|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca|A Phase I Study of Erbitux and Gemcitabine With Radiation Therapy for Locally Advanced Pancreas Cancer|Completed||Phase 1|9|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:15:54.352105|2018-06-01 03:15:54.352105
NCT00467103|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2018-02-08|2007-04-26|2007-04-27|Estimate|||||||2018-02-08|2018-02-12|Actual|October 1, 1999|Actual|1999-10-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2016|Actual|2016-12-01||Observational|||Neural Networks and Language Recovery in Aphasia From Stroke: fMRI Studies|Neural Networks and Language Recovery in Aphasia From Stroke: fMRI Studies|Active, not recruiting|||80|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|||No||2018-06-01 03:15:54.538741|2018-06-01 03:15:54.538741
NCT00467090|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2018-05-23|2007-04-26|2007-04-27|Estimate|||||||2018-05-23|2018-05-24|Actual|April 23, 2007||2007-04-23|February 3, 2014|2014-02-03|February 3, 2014||2014-02-03|||||Observational|||Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation|Expanding the Phenotype of the LRRK-2 Mutation in Individuals With History of Parkinson s Disease and Their Relatives: a Prospective Study|Terminated|||34|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:15:54.665781|2018-06-01 03:15:54.665781
NCT00467077|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2016-07-25||2017-01-30|2007-04-25|2007-04-27|Estimate|2017-01-30|2017-03-17|Actual||||2017-01-30|2017-03-17|Actual|September 2004||2004-09-30|January 2017|2017-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer|Phase II Trial of ZD1839 (IRESSA®) and Pegylated Interferon Alfa 2b (PEG-Intron™) in Unresectable or Metastatic Renal Cell Carcinoma|Terminated||Phase 2|21|Actual|California Cancer Consortium|Protocol was closed prior to the second stage of accrual (pegged at n = 24) due to slow accrual. The reason for the slow accrual was likely the availability of several new Food and Drug Administration approved targeted agents during the study period.|1||Protocol was closed due to slow accrual.|f||||||||||||||2018-06-01 03:15:54.76133|2018-06-01 03:15:54.76133
NCT00467064|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2010-01-27|2007-04-26|2007-04-27|Estimate|||||||2010-01-27|2010-01-28|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Arthritis Self-Management Education Program|Arthritis Self-Management Education -- Dose Response|Completed||N/A|690|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 03:15:55.897253|2018-06-01 03:15:55.897253
NCT00467051|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2015-03-11||2017-11-14|2007-04-25|2007-04-27|Estimate|2015-03-11|2015-03-20|Estimate||||2017-11-14|2017-12-12|Actual|November 2007||2007-11-30|November 2017|2017-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors|Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin|Completed||Phase 2|20|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 03:15:56.010064|2018-06-01 03:15:56.010064
NCT00467038|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2014-11-24||2015-08-20|2007-04-26|2007-04-27|Estimate|2015-08-20|2015-08-25|Estimate||||2015-08-20|2015-08-25|Estimate|November 2006||2006-11-30|August 2015|2015-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder|Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder|Completed||N/A|22|Actual|VA Office of Research and Development|Small community sample. Additionally, our emotional task was a “passive viewing task” which means that we did not examine “active” emotion regulation, per se which might be considered a study limitation by some. No comparison treatment group.|2|||f||||f||||||||||2018-06-01 03:15:56.424589|2018-06-01 03:15:56.424589
NCT00467025|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26||2015-04-06|2016-02-23|2007-04-26|2007-04-27|Estimate||||2015-04-06|2015-04-27|Estimate|2016-02-23|2016-03-23|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|April 2010|Actual|2010-04-30||Interventional|||AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib|A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney|Completed||Phase 2|152|Actual|Amgen||3|||f||||f||||||||||2018-06-01 03:15:56.706895|2018-06-01 03:15:56.706895
NCT00467012|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2012-04-25|2007-04-26|2007-04-27|Estimate|||||||2012-04-25|2012-04-26|Estimate|April 2007||2007-04-30|April 2012|2012-04-30|September 2011|Actual|2011-09-30|June 2009|Actual|2009-06-30||Interventional|||Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer|Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer|Completed||Phase 2|122|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 03:15:56.797079|2018-06-01 03:15:56.797079
NCT00466986|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2011-10-07|2007-04-26|2007-04-27|Estimate|||||||2011-10-07|2011-10-12|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer|A Phase II, Non-Randomized Study of Abraxane Plus Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer|Completed||Phase 2|40|Anticipated|Southeastern Gynecologic Oncology|||||f||||f||||||||||2018-06-01 03:15:56.984377|2018-06-01 03:15:56.984377
NCT00466973|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-04-26|2007-04-26|2007-04-27|Estimate|||||||2007-04-26|2007-04-27|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|May 2009|Anticipated|2009-05-31|||||Interventional|||Atrial Fibrillation Ablation Device Comparison Study|Randomized Comparison of Ablation Devices Used During Surgery for the Treatment of Atrial Fibrillation|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Maimonides Medical Center|||||f||||t||||||||||2018-06-01 03:15:57.066573|2018-06-01 03:15:57.066573
NCT00466960|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2017-04-17||2017-07-24|2007-04-25|2007-04-27|Estimate|2017-07-24|2017-08-28|Actual||||2017-07-24|2017-08-28|Actual|May 2006||2006-05-31|July 2017|2017-07-31||||July 2011|Actual|2011-07-31||Interventional|||Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy|A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer|Completed||Phase 2|21|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:15:57.164783|2018-06-01 03:15:57.164783
NCT00466947|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|2011-08-25||2016-11-25|2007-04-26|2007-04-27|Estimate|2013-06-20|2013-09-04|Estimate||||2016-11-25|2017-01-12|Estimate|June 2007||2007-06-30|September 2016|2016-09-30|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|||COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine|COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media|Completed||Phase 3|23802|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:15:57.604712|2018-06-01 03:15:57.604712
NCT00466934|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2017-06-30|2007-04-26|2007-04-27|Estimate|||||||2017-06-30|2017-07-02|Actual|April 24, 2007||2007-04-24|December 29, 2011|2011-12-29|December 29, 2011||2011-12-29|||||Observational|||Measuring Blood Flow in the Brain|Cross-Validating NIRS With fMRI|Completed|||31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:16:00.858098|2018-06-01 03:16:00.858098
NCT00466921|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2018-01-24|2007-04-25|2007-04-27|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2005||2005-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome|Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma|Active, not recruiting||Phase 2|35|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 03:16:00.916988|2018-06-01 03:16:00.916988
NCT00466908|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2010-10-01|2007-04-25|2007-04-27|Estimate|||||||2010-10-01|2010-10-04|Estimate|March 2007||2007-03-31|October 2010|2010-10-31|August 2007|Actual|2007-08-31|||||Observational|||Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery|Accuracy of the Pentacam and IOL Master to Calculate the Effective Corneal Power After Corneal Refractive Surgery|Completed|||0|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-06-01 03:16:01.004398|2018-06-01 03:16:01.004398
NCT00466895|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2017-11-09|2007-04-26|2007-04-27|Estimate|||||||2017-11-09|2017-11-14|Actual|April 2007|Actual|2007-04-30|November 2017|2017-11-30|July 2016|Actual|2016-07-31|December 2014|Actual|2014-12-31||Interventional|||Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.|Phase I Study of Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.|Completed||Phase 1|37|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 03:16:01.065167|2018-06-01 03:16:01.065167
NCT00466882|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|2013-05-30||2015-05-29|2007-04-26|2007-04-27|Estimate|2015-05-29|2015-06-01|Estimate||||2015-05-29|2015-06-01|Estimate|October 2005||2005-10-31|May 2015|2015-05-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Use of the INAMED LAPBAND System to Reduce BMI's in Obese Renal Failure Patients|Issues Related to the Use of the INAMED LAPBAND SYSTEM to Reduce BMI's in Obese Renal Failure Patients Needing Renal Transplantation: A Pilot Study|Completed||N/A|3|Actual|Summa Health System|There were no SAEs, the study had a small sample size and was not able to enroll enough participants to get quality data.|1|||f||||t||||||||||2018-06-01 03:16:01.144665|2018-06-01 03:16:01.144665
NCT00466869|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-09-24|2007-04-26|2007-04-27|Estimate|||||||2007-09-24|2007-09-26|Estimate|May 2007||2007-05-31|August 2007|2007-08-31|September 2007|Actual|2007-09-30|||||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin|Terminated||Phase 2|30|Anticipated|OBEcure Ltd.||||Sponsor decision|f||||f||||||||||2018-06-01 03:16:01.275282|2018-06-01 03:16:01.275282
NCT00466856|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2012-05-17|2007-04-25|2007-04-27|Estimate|||||||2012-05-17|2012-05-18|Estimate|December 2003||2003-12-31|May 2012|2012-05-31|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Interventional|||Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors|Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors|Terminated||Phase 2|10|Actual|Vanderbilt-Ingram Cancer Center||1||due to slow accrual|f||||t||||||||||2018-06-01 03:16:01.432517|2018-06-01 03:16:01.432517
NCT00466843|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2009-06-01|2007-04-25|2007-04-27|Estimate|||||||2009-06-01|2009-06-02|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome|Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)|Unknown status|Recruiting|Phase 2|54|Anticipated|Office of Rare Diseases (ORD)||1|||f||||t||||||||||2018-06-01 03:16:01.508842|2018-06-01 03:16:01.508842
NCT00466830|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2011-05-12|2007-04-25|2007-04-27|Estimate|||||||2011-05-12|2011-05-13|Estimate|September 2005||2005-09-30|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Observational|||Psychological and Social Factors That May Increase the Risk of Developing Chronic Pain After Surgery in Women With Breast Cancer|Study of Psychological and Sociological Predisposing the Development of Chronic Pain After Surgery in Women With Resectable Breast Cancer|Completed|||150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:16:01.592525|2018-06-01 03:16:01.592525
NCT00465296|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2008-05-21|2007-04-23|2007-04-25|Estimate|||||||2008-05-21|2008-05-22|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS|Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS|Terminated||Phase 3|200|Anticipated|Medstar Health Research Institute||||Funding Discontinued|f||||t||||||||||2018-06-01 03:16:21.333952|2018-06-01 03:16:21.333952
NCT00466817|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|2013-08-29|2013-01-30|2015-08-13|2007-04-26|2007-04-27|Estimate|2013-08-29|2013-11-13|Estimate|2013-01-30|2013-02-04|Estimate|2015-08-13|2015-08-26|Estimate|June 2008||2008-06-30|July 2015|2015-07-31|June 2013|Actual|2013-06-30|December 2011|Actual|2011-12-31||Interventional|||Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections|A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)|Completed||Phase 3|109|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:16:01.694093|2018-06-01 03:16:01.694093
NCT00466804|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2015-12-31|2007-04-25|2007-04-27|Estimate|||||||2015-12-31|2016-01-01|Estimate|June 2007||2007-06-30|December 2015|2015-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients|Observational Study of Alloimmunity in Cardiac Transplant Recipients|Completed|||263|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Blood samples may be retained~   "|||2018-06-01 03:16:02.801679|2018-06-01 03:16:02.801679
NCT00466791|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2015-06-23|2007-04-25|2007-04-27|Estimate|||||||2015-06-23|2015-06-25|Estimate|August 2004||2004-08-31|June 2015|2015-06-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD|A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Optimization, Analog Classroom, Crossover Study Designed to Assess the Time Course of Treatment Effect, Tolerability and Safety of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|93|Actual|Noven Therapeutics||2|||f||||f||||||||||2018-06-01 03:16:02.946393|2018-06-01 03:16:02.946393
NCT00466778|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-09-20|2007-04-26|2007-04-27|Estimate|||||||2007-09-20|2007-09-21|Estimate|April 2007||2007-04-30|September 2007|2007-09-30||||||||Observational|||Autonomic Nervous System Dysfunction and Peripheral Neuropathy in a Cohort of Asymptomatic Juvenile Diabetic Patients (Type I): A Case-Controlled Study|Autonomic Nervous System Dysfunction and Peripheral Neuropathy in a Cohort of Asymptomatic Juvenile Diabetic Patients (Type I): A Case-Controlled Study|Completed|||40|Anticipated|Weintraub, Michael I., MD, FACP, FAAN|||||f||||f||||||||||2018-06-01 03:16:03.061461|2018-06-01 03:16:03.061461
NCT00466765|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25||2015-04-13|2015-05-01|2007-04-26|2007-04-27|Estimate||||2015-05-01|2015-05-05|Estimate|2015-05-01|2015-05-05|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Breast Reconstruction and Augmentation With Brava Enhanced Autologous Fat Micro Grafting|Breast Reconstruction and Augmentation With Brava Enhanced Autologous Fat Micro Grafting|Completed||N/A|589|Actual|Brava||1|||f||||f||||||||||2018-06-01 03:16:03.146688|2018-06-01 03:16:03.146688
NCT00466752|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2017-04-14||2017-11-20|2007-04-25|2007-04-27|Estimate|2017-11-20|2017-11-22|Actual||||2017-11-20|2017-11-22|Actual|December 2006||2006-12-31|November 2017|2017-11-30|July 1, 2011|Actual|2011-07-01|April 2010|Actual|2010-04-30||Interventional|||Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer|A Phase II Study of Sorafenib (Nexavar®) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer|Completed||Phase 2|5|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:16:03.382361|2018-06-01 03:16:03.382361
NCT00466739|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2008-05-22|2007-04-26|2007-04-27|Estimate|||||||2008-05-22|2008-05-23|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|September 2007|Actual|2007-09-30|||||Observational|||European Compliance Study in Parkinson's Disease|European Study of Therapeutic Compliance in Parkinson's Disease|Completed|||144|Anticipated|South Glasgow University Hospitals NHS Trust|||||f||||||||||||||2018-06-01 03:16:03.841026|2018-06-01 03:16:03.841026
NCT00466726|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2015-02-17|2007-04-25|2007-04-27|Estimate|||||||2015-02-17|2015-02-18|Estimate|March 2007||2007-03-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CML 0206||Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia|Phase II Multicenter Study of P210-B3A2 Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Response With Persistent Molecular Residual Disease During Imatinib Treatment|Completed||Phase 2|44|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 03:16:03.896067|2018-06-01 03:16:03.896067
NCT00466713|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2014-05-12|2007-04-26|2007-04-27|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy|Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy|Terminated||N/A|||Stanford University||||concern over safety of rosiglitazone in heart failure|f||||f||||||||||2018-06-01 03:16:03.98307|2018-06-01 03:16:03.98307
NCT00466700|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2015-05-07|2007-04-26|2007-04-27|Estimate|||||||2015-05-07|2015-05-08|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|March 2009|Actual|2009-03-31|June 2008|Actual|2008-06-30||Observational|||Helicobacter in The Gambia (Part 1)|Genotypes of Helicobacter Pylori in West African Children and Adults: Part 1: The Development and Evaluation of Minimally Invasive Techniques for Obtaining H. Pylori Isolates From Adults and Children in The Gambia|Completed|||75|Actual|Medical Research Council Unit, The Gambia|||||f||||f||||||||||2018-06-01 03:16:04.052505|2018-06-01 03:16:04.052505
NCT00466687|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2011-06-02||2013-07-15|2007-04-25|2007-04-27|Estimate|2013-01-23|2013-02-28|Estimate||||2013-07-15|2013-07-22|Estimate|September 2004||2004-09-30|July 2013|2013-07-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma|A Phase II Trial of Tarceva (Erlotinib) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Melanoma|Completed||Phase 2|34|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:16:04.190114|2018-06-01 03:16:04.190114
NCT00466674|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2014-01-14|2007-04-26|2007-04-27|Estimate|||||||2014-01-14|2014-01-15|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|IFM 2005-03||Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning|Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning (IFM 2005-03)|Completed||Phase 2|13|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-06-01 03:16:04.484359|2018-06-01 03:16:04.484359
NCT00466661|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2010-03-25|2007-04-26|2007-04-27|Estimate|||||||2010-03-25|2010-03-26|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|March 2010|Anticipated|2010-03-31|February 2010|Anticipated|2010-02-28||Interventional|||Acamprosate vs. Placebo in Bipolar Alcoholics|A Double-Blind, Randomized, Placebo-Controlled Trial of Acamprosate in Alcohol-Dependent Individuals With Comorbid Bipolar Disorder|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 03:16:04.565391|2018-06-01 03:16:04.565391
NCT00466635|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2015-03-17|2007-04-26|2007-04-27|Estimate|||||||2015-03-17|2015-03-19|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|August 2007|Actual|2007-08-31|||||Interventional|||A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea|An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea|Terminated||Phase 3|65|Anticipated|Sanofi|||||||||||||||||||2018-06-01 03:16:04.716125|2018-06-01 03:16:04.716125
NCT00466622|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2016-07-19|2007-04-26|2007-04-27|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2007||2007-04-30|July 2016|2016-07-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|FlowMet||Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin|Uterine Artery Blood Flow in Pregnant Women With Polycystic Ovary Syndrome(PCOS)Treated With Metformin - a Substudy to The PregMet Study|Completed||Phase 3|48|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 03:16:04.800208|2018-06-01 03:16:04.800208
NCT00466609|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2017-10-26|2007-04-26|2007-04-27|Estimate|||||||2017-10-26|2017-10-30|Actual|May 2007||2007-05-31|October 2017|2017-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|EPMTOC||Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment|Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study|Completed||Phase 4|54|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-06-01 03:16:04.877554|2018-06-01 03:16:04.877554
NCT00466596|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2014-01-08|2007-04-26|2007-04-27|Estimate|||||||2014-01-08|2014-01-09|Estimate|March 2007||2007-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|MiteE||Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements|Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements|Completed||Phase 1|8|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 03:16:04.963721|2018-06-01 03:16:04.963721
NCT00466583|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2011-07-05|2007-04-25|2007-04-27|Estimate|||||||2011-07-05|2011-07-07|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma|A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia-Inducible Factor-1α, Administered as a Weekly 2-Hour Intravenous Infusion in Adult Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|52|Actual|Enzon Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:16:05.040386|2018-06-01 03:16:05.040386
NCT00466570|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2013-06-12|2007-04-26|2007-04-27|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2007||2007-04-30|June 2013|2013-06-30||||||||Interventional|||Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application|Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour|Withdrawn||N/A|0|Actual|Stanford University|||||f||||f||||||||||2018-06-01 03:16:05.103398|2018-06-01 03:16:05.103398
NCT00466557|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2010-08-26|2007-04-26|2007-04-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|June 2007||2007-06-30|April 2008|2008-04-30||||||||Observational|||Plasmodium Resistance in A. Gambiae|Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae|Unknown status|Recruiting||40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:16:05.157425|2018-06-01 03:16:05.157425
NCT00466544|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2007-04-26|2007-04-26|2007-04-27|Estimate|||||||2007-04-26|2007-04-27|Estimate|May 2007||2007-05-31|March 2007|2007-03-31||||||||Interventional|jPK||Randomized Controlled Study of Plasmaknife Tonsillectomy Versus Monopolar Tonsillectomy||Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Children's Hospital of Michigan|||||f||||t||||||||||2018-06-01 03:16:05.210284|2018-06-01 03:16:05.210284
NCT00466531|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2018-05-09|2007-04-25|2007-04-27|Estimate|||||||2018-05-09|2018-05-15|Actual|March 21, 2007||2007-03-21|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19|A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19|Active, not recruiting||Phase 1/Phase 2|50|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:16:05.274093|2018-06-01 03:16:05.274093
NCT00466518|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2017-06-02|2007-04-26|2007-04-27|Estimate|||||||2017-06-02|2017-06-05|Actual|April 2007||2007-04-30|June 2017|2017-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant|Sitagliptin Treatment in Patients With Type 2 Diabetes Mellitus After Kidney Transplant|Completed||N/A|16|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 03:16:05.351733|2018-06-01 03:16:05.351733
NCT00466505|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2011-08-15||2012-12-14|2007-04-25|2007-04-27|Estimate|2011-10-06|2011-11-16|Estimate||||2012-12-14|2012-12-19|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|||Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery|A Phase 2 Study of Cetuximab in Combination With Celecoxib in Colorectal Cancer|Completed||Phase 2|17|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:16:05.437531|2018-06-01 03:16:05.437531
NCT00466492|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2010-03-18|2007-04-26|2007-04-27|Estimate|||||||2010-03-18|2010-03-19|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Advantages and Disadvantages of Long Term Sedation in Intensive Care Unit Patients|Advantages and Disadvantages of Long Term Sedation in ICU Patients|Completed||N/A|140|Actual|Odense University Hospital||1|||f||||f||||||||||2018-06-01 03:16:05.94479|2018-06-01 03:16:05.94479
NCT00466479|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2007-04-26|2007-04-26|2007-04-27|Estimate|||||||2007-04-26|2007-04-27|Estimate|August 1999||1999-08-31|April 2007|2007-04-30|October 2002|Actual|2002-10-31|||||Interventional|||Brimonidine vs ALTP in Progressing Human Glaucoma|Topical Brimonidine vs Argon Laser Trabeculoplasty in Progressing Human Glaucoma. A Prospective Randomized Clinical Trial.|Completed||Phase 4|50||University of Parma|||||f||||f||||||||||2018-06-01 03:16:06.01985|2018-06-01 03:16:06.01985
NCT00466466|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-26|||2011-11-21|2007-04-26|2007-04-27|Estimate|||||||2011-11-21|2011-11-23|Estimate|April 2007||2007-04-30|November 2011|2011-11-30||||November 2010|Actual|2010-11-30||Interventional|||Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients|A Phase Ib Study Investigating the Combination of RAD001 With Cisplatin and Etoposide in Patients With Extensive-stage Small-cell Lung Cancer Not Previously Treated With Chemotherapy|Completed||Phase 1|20|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:16:06.084324|2018-06-01 03:16:06.084324
NCT00466453|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2010-01-14|2007-04-26|2007-04-27|Estimate|||||||2010-01-14|2010-01-15|Estimate|November 2005||2005-11-30|January 2010|2010-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Adapting Web-based Instruction to Baseline Knowledge of Physicians-in-training|Adapting Web-based Instruction to Learner Baseline Knowledge: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|144||Mayo Clinic|||||f||||||||||||||2018-06-01 03:16:06.158069|2018-06-01 03:16:06.158069
NCT00466440|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25||2010-08-06|2010-11-23|2007-04-25|2007-04-27|Estimate||||2010-08-06|2010-08-10|Estimate|2010-11-23|2010-11-29|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients|A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study With and Without Enzastaurin in Combination With Docetaxel and Prednisone, Followed By Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients|Completed||Phase 2|101|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:16:06.214216|2018-06-01 03:16:06.214216
NCT00466414|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2008-05-14|2007-04-25|2007-04-27|Estimate|||||||2008-05-14|2008-05-15|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|April 2007|Anticipated|2007-04-30|||||Interventional|||Alveolar Ridge Preservation With Polycaprolactone Scaffold for Implant Site Development|Alveolar Ridge Preservation With Polycaprolactone Scaffold for Implant Site Development|Unknown status|Recruiting|Phase 2|20|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-06-01 03:16:06.391429|2018-06-01 03:16:06.391429
NCT00466401|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2013-02-19|2007-04-25|2007-04-27|Estimate|||||||2013-02-19|2013-02-20|Estimate|February 2005||2005-02-28|February 2013|2013-02-28|August 2007|Actual|2007-08-31|||||Interventional|||Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation|Phase 4 Study on Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation In Hypercholesterolemic Patients on Simvastatin|Completed||Phase 4|20||Ziv Hospital|||||f||||||||||||||2018-06-01 03:16:06.478745|2018-06-01 03:16:06.478745
NCT00466375|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2017-08-28|2007-04-25|2007-04-27|Estimate|||||||2017-08-28|2017-08-29|Actual|April 2007||2007-04-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|November 2014|Actual|2014-11-30||Observational|||Genetic Basis of Hemangiomas|Genetic Basis of Hemangiomas|Terminated|||300|Actual|Medical College of Wisconsin|||2||f||||f||||||Samples With DNA|"~     Buccal smear (cheek cells)or small blood sample (4 mL or one teaspoon)~   "|||2018-06-01 03:16:06.54775|2018-06-01 03:16:06.54775
NCT00466362|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-05-22|2007-04-25|2007-04-27|Estimate|||||||2007-05-22|2007-05-23|Estimate|April 2007||2007-04-30|May 2007|2007-05-31|December 2008|Anticipated|2008-12-31|||||Observational|||Lifestyle Intervention in Obesity, Effect on Diabetes|One Year Observational Study on Effects of Lifestyle Intervention in Morbidly Obese Persons With Type 2 Diabetes.|Unknown status|Recruiting||50|Anticipated|Evjeklinikken|||||f||||t||||||||||2018-06-01 03:16:06.632819|2018-06-01 03:16:06.632819
NCT00466349|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2017-02-28|2007-04-25|2007-04-27|Estimate|||||||2017-02-28|2017-03-01|Actual|May 1986||1986-05-31|February 2017|2017-02-28||||December 2020|Anticipated|2020-12-31|50 Years|Observational [Patient Registry]|||International SMA Patient Registry|International Spinal Muscular Atrophy Patient Registry|Active, not recruiting|||3000|Actual|Indiana University|||||f||||t||||||||||2018-06-01 03:16:06.694946|2018-06-01 03:16:06.694946
NCT00466336|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2008-03-05|2007-04-25|2007-04-27|Estimate|||||||2008-03-05|2008-03-06|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Observational|||Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices|Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices|Completed|||503|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:16:06.777144|2018-06-01 03:16:06.777144
NCT00466323|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|2014-10-09||2015-04-06|2007-04-25|2007-04-27|Estimate|2014-10-16|2014-10-20|Estimate||||2015-04-06|2015-04-24|Estimate|September 2007||2007-09-30|August 2014|2014-08-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.|The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness|Completed||N/A|238|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:16:06.869448|2018-06-01 03:16:06.869448
NCT00466310|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2011-04-05||2014-07-11|2007-04-25|2007-04-27|Estimate|2012-11-29|2013-01-03|Estimate||||2014-07-11|2014-07-25|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2009|Actual|2009-01-31||Interventional|||Metabolic Signatures and Biomarkers in Schizophrenia|Metabolic Signatures and Biomarkers in First Episode and Recurrent Patients With Schizophrenia in Comparison to Healthy Controls|Completed||Phase 1|71|Actual|Duke University|Limited to patients admitted to Psychiatric facility|3|||f||||f||||||||||2018-06-01 03:16:07.203133|2018-06-01 03:16:07.203133
NCT00466297|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2009-02-06|2007-04-25|2007-04-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|December 2008|Actual|2008-12-31|||||Interventional|SCRIPT||Interprofessional Collaborative Communication in Acute Care Hospital Teams|The SCRIPT Programme (GIM): Structuring Communication Relationships for Interprofessional Teamwork to Achieve Interprofessional Education for Collaborative Patient-Centered Practice (IECPCP)|Completed||N/A|1000|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 03:16:07.597283|2018-06-01 03:16:07.597283
NCT00466284|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-04-25|2007-04-25|2007-04-27|Estimate|||||||2007-04-25|2007-04-27|Estimate|January 2006||2006-01-31|April 2007|2007-04-30||||||||Interventional|||Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer|Phase II Trial of Tarceva Following Concurrent Chemo-Radiotherapy as First Line Therapy in Patients With Unresectable Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|46||Grupo Gallego de Cancer de Pulmon|||||f||||t||||||||||2018-06-01 03:16:07.689025|2018-06-01 03:16:07.689025
NCT00466271|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2008-12-21|2007-04-25|2007-04-27|Estimate|||||||2008-12-21|2008-12-23|Estimate|April 2007||2007-04-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Observational|||Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study|Prediction of Significant Hepatic Fibrosis in HCV Carriers With Persistently Normal Alanine Aminotransferase Levels by Splenic Arterial Pulsatility Index- A Validation Study|Completed|||102|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:16:07.767104|2018-06-01 03:16:07.767104
NCT00466258|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2009-11-23|2007-04-25|2007-04-27|Estimate|||||||2009-11-23|2009-11-25|Estimate|October 2006||2006-10-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|LINFOTARGAM||LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)|LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)|Completed||Phase 4|50|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:16:07.8483|2018-06-01 03:16:07.8483
NCT00466245|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2014-01-17|2007-04-25|2007-04-27|Estimate|||||||2014-01-17|2014-01-22|Estimate|July 2005||2005-07-31|January 2014|2014-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine|Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination|Completed||Phase 2|590|Actual|Sanofi||8|||f||||t||||||||||2018-06-01 03:16:07.965882|2018-06-01 03:16:07.965882
NCT00466232|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2015-12-15|2007-04-25|2007-04-27|Estimate|||||||2015-12-15|2015-12-16|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer|Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer|Completed||Phase 1|16|Actual|HealthPartners Institute||1|||f||||f||||||||||2018-06-01 03:16:08.062863|2018-06-01 03:16:08.062863
NCT00466219|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-04-25|2007-04-25|2007-04-27|Estimate|||||||2007-04-25|2007-04-27|Estimate|May 2002||2002-05-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant||Completed||Phase 3|25||University Hospital, Geneva|||||f||||f||||||||||2018-06-01 03:16:08.140002|2018-06-01 03:16:08.140002
NCT00466206|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|2012-05-11||2015-12-02|2007-04-25|2007-04-27|Estimate|2012-08-01|2012-09-03|Estimate||||2015-12-02|2016-01-01|Estimate|April 2007||2007-04-30|December 2015|2015-12-31|April 2011|Actual|2011-04-30|May 2010|Actual|2010-05-31||Interventional|3MP||Magnetic Mini-Mover Procedure to Treat Pectus Excavatum|Phase II Magnetic Alteration of Pectus Excavatum|Completed||Phase 1/Phase 2|10|Actual|University of California, San Francisco|Technical problems with measurement of PSI. PSI is uninformative in assessing efficacy of treatment as it is a dynamic measure that varies with patient position and respiration at any given measurement.|1|||f||||t||||||||||2018-06-01 03:16:08.199992|2018-06-01 03:16:08.199992
NCT00466193|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|2011-12-15||2012-02-10|2007-04-24|2007-04-27|Estimate|2011-12-15|2012-01-20|Estimate||||2012-02-10|2012-02-14|Estimate|May 2007||2007-05-31|February 2012|2012-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of the Zolpidem Tartrate Sublingual Tablet in Adult Subjects With Insomnia Characterized by Difficulty Returning to Sleep After Awakening in the Middle-of-the-Night (MOTN)|Completed||Phase 3|295|Actual|Transcept Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:16:08.386808|2018-06-01 03:16:08.386808
NCT00466180|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2010-10-27|2007-04-25|2007-04-27|Estimate|||||||2010-10-27|2010-10-28|Estimate|June 2004||2004-06-30|October 2010|2010-10-31|November 2006|Actual|2006-11-30|||||Interventional|POSOVIR||Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients||Completed||Phase 4|62|Actual|University Hospital, Caen|||||f||||f||||||||||2018-06-01 03:16:08.915189|2018-06-01 03:16:08.915189
NCT00466167|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2009-11-17||2014-06-24|2007-04-25|2007-04-27|Estimate|2010-01-19|2010-02-08|Estimate||||2014-06-24|2014-07-08|Estimate|April 2007||2007-04-30|May 2014|2014-05-31||||November 2008|Actual|2008-11-30||Interventional|||Pivotal Study in Advanced Parkinsons Disease Patients|A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole Extended Release (ER) Versus Placebo and Versus Pramipexole Immediate Release (IR) Administered Orally Over a 26-week Maintenance Phase in L-Dopa+ Treated Patients With Advanced Parkinsons Disease (PD).|Completed||Phase 3|517|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 03:16:09.028647|2018-06-01 03:16:09.028647
NCT00466154|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2013-02-19|2007-04-25|2007-04-27|Estimate|||||||2013-02-19|2013-02-20|Estimate|July 2005||2005-07-31|February 2013|2013-02-28|January 2007|Actual|2007-01-31|||||Interventional|||The Effect of Serum LDL Lowering on Aspirin Resistance|The Effect of Serum LDL Lowering on Aspirin Resistance|Completed||N/A|40||Ziv Hospital|||||f||||t||||||||||2018-06-01 03:16:10.195256|2018-06-01 03:16:10.195256
NCT00466141|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2008-01-21|2007-04-24|2007-04-27|Estimate|||||||2008-01-21|2008-01-23|Estimate|June 2007||2007-06-30|April 2007|2007-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|STOPRegain||Weight Maintenance Study for 2007 Shape UP RI Participants|Evaluation of the 2007 Shape Up RI Campaign: Study 3 Maintenance|Completed||N/A|180|Anticipated|The Miriam Hospital|||||f||||t||||||||||2018-06-01 03:16:10.276093|2018-06-01 03:16:10.276093
NCT00466128|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2015-03-17|2007-04-25|2007-04-27|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)|A Double-blinded Randomized Controlled Trial With Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM) Between 24 and 32 Weeks Gestation|Unknown status|Recruiting|Phase 2|116|Anticipated|Thomas Jefferson University|||||f||||t||||||||||2018-06-01 03:16:10.331884|2018-06-01 03:16:10.331884
NCT00466102|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2012-08-29|2007-04-25|2007-04-27|Estimate|||||||2012-08-29|2012-08-30|Estimate|December 2006||2006-12-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2010|Actual|2010-12-31||Interventional|RADAR||Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases|RADAR: A Randomized Discontinuation Phase II Study to Determine the Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases|Unknown status|Active, not recruiting|Phase 2|130|Anticipated|German Breast Group||2|||f||||t||||||||||2018-06-01 03:16:10.426476|2018-06-01 03:16:10.426476
NCT00466089|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2008-01-09|2007-04-25|2007-04-27|Estimate|||||||2008-01-09|2008-01-10|Estimate|March 2006||2006-03-31|November 2007|2007-11-30||||||||Interventional|||Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer|Phase II Randomized Trial of 3D Radiotherapy Versus the Combination of 3D Radiotherapy and Erlotinib (Tarceva®) in Patients With Localized-Unresectable Non-Small Cell Lung Cancer Non Susceptible for Chemotherapy Treatment.|Unknown status|Recruiting|Phase 2|90|Anticipated|Hospital of Navarra||2|||f||||f||||||||||2018-06-01 03:16:10.517013|2018-06-01 03:16:10.517013
NCT00466076|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2007-04-25|2007-04-25|2007-04-27|Estimate|||||||2007-04-25|2007-04-27|Estimate|August 2006||2006-08-31|April 2007|2007-04-30|April 2007|Anticipated|2007-04-30|||||Interventional|||Copaxone in Age Related Macular Degeneration|Subcutaneous Copaxone as Treatment for Dry Age Related Macular Degeneration|Unknown status|Recruiting|Phase 2/Phase 3|30||Kaplan Medical Center|||||f||||f||||||||||2018-06-01 03:16:10.603708|2018-06-01 03:16:10.603708
NCT00466063|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2015-12-26|2007-04-25|2007-04-27|Estimate|||||||2015-12-26|2015-12-29|Estimate|May 2007||2007-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox|A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox|Completed|||108|Actual|Novartis|||1||f||||t||||||||||2018-06-01 03:16:10.671088|2018-06-01 03:16:10.671088
NCT00466050|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2009-08-23|2007-04-25|2007-04-27|Estimate|||||||2009-08-23|2009-08-25|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|May 2009|Actual|2009-05-31|April 2008|Actual|2008-04-30||Observational|IVUS||Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS|Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS|Completed|||30|Anticipated|Ziv Hospital|||||f||||t||||||||||2018-06-01 03:16:10.753717|2018-06-01 03:16:10.753717
NCT00466037|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2007-04-25|2007-04-25|2007-04-27|Estimate|||||||2007-04-25|2007-04-27|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|February 2006||2006-02-28|||||Interventional|||The Effect of Rituximab on the Humoral Response to Influenza Vaccine|Vaccination Against Influenza in Rheumatoid Arthritis Patients: The Effect of Rituximab on the Humoral Response|Terminated||N/A|64||Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 03:16:10.813896|2018-06-01 03:16:10.813896
NCT00466024|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2015-08-31|2007-04-25|2007-04-27|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|June 2010|Actual|2010-06-30|February 2009|Actual|2009-02-28||Interventional|PREACH||Particulate Reduction Education in City Homes|Particulate Reduction Education in City Homes (PREACH)|Completed||Phase 3|125|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-06-01 03:16:10.954778|2018-06-01 03:16:10.954778
NCT00466011|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2012-07-11|2007-04-25|2007-04-27|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Observational|Stardust||Validation of the Stardust Cardio-Respiratory Recorder|Validation of the Stardust Cardio-Respiratory Recorder|Completed|||80|Actual|Associação Fundo de Incentivo à Pesquisa|||||f||||t||||||||||2018-06-01 03:16:11.031618|2018-06-01 03:16:11.031618
NCT00465998|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2016-04-28||2016-06-07|2007-04-25|2007-04-27|Estimate|2016-06-07|2016-07-19|Estimate||||2016-06-07|2016-07-19|Estimate|January 2006||2006-01-31|June 2016|2016-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Study of Ultrasound Imaging to Predict Time and Outcome in Pregnancies With Induced Labor|Prediction of Labor and Delivery With the Use of Ultrasound in Pregnancies With Induced Labor|Completed|||250|Actual|Helse Stavanger HF|||||f||||f||||||||||2018-06-01 03:16:11.097881|2018-06-01 03:16:11.097881
NCT00465985|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2010-11-16||2017-07-28|2007-04-25|2007-04-27|Estimate|2011-01-17|2011-02-11|Estimate||||2017-07-28|2017-08-28|Actual|April 2007||2007-04-30|July 2017|2017-07-31||||October 2008|Actual|2008-10-31||Interventional|REMITTER||Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome|A Three-part,Multicenter Study,With a Randomized,Double-blind,Placebo Controlled,Withdrawal Design in Part II to Assess Efficacy,Safety,and Tolerability of ACZ885(Anti-interleukin-1beta Monoclonal Antibody)in Patients With Muckle-Wells Syndrome|Completed||Phase 3|35|Actual|Novartis|The outcomes for this study were reported in separate tables for each period. The SAE and AEs were reported in all in one table.|2|||f||||||||||||||2018-06-01 03:16:11.298662|2018-06-01 03:16:11.298662
NCT00465972|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|2012-12-12||2013-07-26|2007-04-25|2007-04-27|Estimate|2013-07-26|2013-07-30|Estimate||||2013-07-26|2013-07-30|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Treatment of Insomnia in Patients With HIV Disease|A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Doxepin and Temazepam in HIV Seropositive Patients With Insomnia.|Completed||Phase 4|44|Actual|Duke University||3|||f||||t||||||||||2018-06-01 03:16:11.854636|2018-06-01 03:16:11.854636
NCT00465959|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24||2013-12-03|2013-12-03|2007-04-25|2007-04-27|Estimate||||2013-12-03|2013-12-27|Estimate|2013-12-03|2013-12-27|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease|Safety, Tolerability, Pharmacokinetics, and Efficacy of Single Inhaled Administrations of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 1/Phase 2|24|Actual|Endo Pharmaceuticals||3|||f||||||||||||||2018-06-01 03:16:12.096352|2018-06-01 03:16:12.096352
NCT00465946|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2007-04-25|2007-04-25|2007-04-27|Estimate|||||||2007-04-25|2007-04-27|Estimate|June 2004||2004-06-30|April 2007|2007-04-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial|Effect of Dietary Salt Supplemantation in Vasovagal Syncope Prophylaxis: A Clinical Trial|Unknown status|Active, not recruiting|N/A|20||Hospital de Clinicas de Porto Alegre|||||f||||f||||||||||2018-06-01 03:16:12.154981|2018-06-01 03:16:12.154981
NCT00465933|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2008-03-27|2007-04-25|2007-04-27|Estimate|||||||2008-03-27|2008-03-31|Estimate|March 1999||1999-03-31|March 2008|2008-03-31|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)|Treatment of Acute Promyelocytic Leukemia: Remission Induction With ATRA + Idarubicin (AIDA) Risk Adapted Intensity of Consolidation and Addition of ATRA Maintenance With ATRA + Methotrexate + Mercaptopurine Salvage Therapy for Molecular and Haematological Relapses|Completed||Phase 4|||PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:16:12.206348|2018-06-01 03:16:12.206348
NCT00465920|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-25|||2009-02-19|2007-04-25|2007-04-27|Estimate|||||||2009-02-19|2009-02-20|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|April 2010|Anticipated|2010-04-30|||||Interventional|mCBT||Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis|Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis|Unknown status|Recruiting|Phase 2|42|Anticipated|University of Cologne|||||f||||t||||||||||2018-06-01 03:16:13.330913|2018-06-01 03:16:13.330913
NCT00465907|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2008-12-16|2007-04-23|2007-04-25|Estimate|||||||2008-12-16|2008-12-17|Estimate|May 2003||2003-05-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|November 2008|Anticipated|2008-11-30||Interventional|||Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer|Phase II Study of Weekly Paclitaxel, Carboplatin and Irinotecan in Patients With Advanced Non-Small Cell Lung Cancer Nad Malignant Plerual Effusion|Unknown status|Active, not recruiting|Phase 2|48|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-06-01 03:16:13.401353|2018-06-01 03:16:13.401353
NCT00465894|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2012-06-01||2017-10-24|2007-04-24|2007-04-25|Estimate|2012-09-21|2012-10-23|Estimate||||2017-10-24|2017-11-30|Actual|April 2007||2007-04-30|October 2017|2017-10-31|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31||Interventional|DRIVE||Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms|Randomized Controlled Trial of Tolterodine in Combination With or Without Low-Dose Intra-Vaginal Estradiol Cream for the Treatment of Overactive Bladder in Post-Menopausal Women|Completed||N/A|58|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 03:16:13.480641|2018-06-01 03:16:13.480641
NCT00465881|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2015-12-02|2007-04-24|2007-04-25|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2006||2006-01-31|September 2007|2007-09-30|April 2006|Actual|2006-04-30|||||Observational|||Develop Novel Methods to Display, Report and Analyze CGM Data for Clinical Decision-Making in People With Diabetes|Observational Study of Interstitial Glucose Monitoring With the FreeStyle Navigator Continuous Glucose Monitoring (CGM) System to Develop Novel Methods for Displaying, Reporting and Analyzing CGM Data for Clinical Decision-Making|Completed|||30||HealthPartners Institute|||||f||||f||||||||||2018-06-01 03:16:13.66913|2018-06-01 03:16:13.66913
NCT00465868|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2015-07-27|2007-04-24|2007-04-25|Estimate|||||||2015-07-27|2015-07-28|Estimate|December 2004||2004-12-31|June 2008|2008-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|KoMPiS||MR, Myocardial Infarct and Heart Failure|Magnetic Resonance Imaging, Myocardial Infarction and Development of Heart Failure.|Completed|||44|Actual|Helse Stavanger HF|||||f||||f||||||Samples Without DNA|"~     collagen markers, inflammatory markers and heart failure markers~   "|||2018-06-01 03:16:13.721932|2018-06-01 03:16:13.721932
NCT00465855|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2017-10-09|2007-04-23|2007-04-25|Estimate|||||||2017-10-09|2017-10-11|Actual|June 3, 2007|Actual|2007-06-03|October 2017|2017-10-31|January 28, 2017|Actual|2017-01-28|September 10, 2016|Actual|2016-09-10||Interventional|1V3CORCT||One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning|Randomized Trial of One Versus Three Hyperbaric Oxygen Treatments for Acute CO Poisoning|Completed||Phase 4|75|Actual|Intermountain Health Care, Inc.||2|||f||||t|t|t|f|f|f|||||2018-06-01 03:16:13.794761|2018-06-01 03:16:13.794761
NCT00465842|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2008-05-19|2007-04-23|2007-04-25|Estimate|||||||2008-05-19|2008-05-20|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|December 2010|Anticipated|2010-12-31|||||Observational|||Protein Biomarker in Hepatocellular Carcinoma|Protein Biomarkers for Early Detection and Prognostication in Hepatocellular Carcinoma (HCC)|Suspended|||1050|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:16:13.907185|2018-06-01 03:16:13.907185
NCT00465829|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2016-09-20|2007-04-24|2007-04-25|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2006||2006-03-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Observational|LABS-2||Long-term Effects of Bariatric Surgery|Longitudinal Assessment of Bariatric Surgery (LABS-2)|Completed|||2458|Actual|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Whole blood, serum, plasma, urine.~   "|Yes|Data deposited in NIDDK funded data repository|2018-06-01 03:16:14.024882|2018-06-01 03:16:14.024882
NCT00465816|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|2012-04-23|2009-04-27|2016-11-02|2007-04-24|2007-04-25|Estimate|2012-04-23|2012-05-22|Estimate|2009-10-01|2009-10-02|Estimate|2016-11-02|2016-12-15|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612|Non-inferiority of GSK Biologicals' Meningococcal Vaccine 134612 Given Concomitantly With GSK Biologicals' Twinrix™ Versus 134612 Alone and Twinrix™ Alone in Healthy Subjects Aged 11 Through 17 Years.|Completed||Phase 3|611|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:16:14.155555|2018-06-01 03:16:14.155555
NCT00465803|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23||2014-07-22|2014-07-22|2007-04-24|2007-04-25|Estimate||||2014-07-22|2014-07-24|Estimate|2014-07-22|2014-07-24|Estimate|March 2007||2007-03-31|May 2012|2012-05-31||||January 2009|Actual|2009-01-31||Interventional|||A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension|Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid|Completed||Phase 3|81|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 03:16:15.037374|2018-06-01 03:16:15.037374
NCT00465790|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2012-09-26|2007-04-24|2007-04-25|Estimate|||||||2012-09-26|2012-09-27|Estimate|October 2007||2007-10-31|December 2011|2011-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|Genepark||Research of Biomarkers in Parkinson Disease|GENomic Biomarkers for PARKinson's Disease|Completed|||219|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-06-01 03:16:15.103685|2018-06-01 03:16:15.103685
NCT00465777|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-04-23|2007-04-23|2007-04-25|Estimate|||||||2007-04-23|2007-04-25|Estimate|December 2004||2004-12-31|April 2007|2007-04-30|February 2006|Actual|2006-02-28|||||Interventional|MTV||Improved Management and in-Hospital Mortality|Reduced in-Hospital Mortality After Improved Management of Patients Hospitalised With Malaria. A Randomised Trial|Completed||N/A|950||Bandim Health Project|||||f||||f||||||||||2018-06-01 03:16:15.433245|2018-06-01 03:16:15.433245
NCT00465764|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2009-04-24|2007-04-24|2007-04-25|Estimate|||||||2009-04-24|2009-04-27|Estimate|April 2007||2007-04-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Tolerance and Development of Healthy, Term Infants|Pilot Tolerance and Bone Status of Healthy, Term Infants Fed Infant Formulas|Completed||Phase 2|115|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-06-01 03:16:15.519629|2018-06-01 03:16:15.519629
NCT00465751|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2012-03-08|2007-04-24|2007-04-25|Estimate|||||||2012-03-08|2012-03-09|Estimate|October 2004||2004-10-31|March 2012|2012-03-31||||||||Interventional|||Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism|Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia|Completed||Early Phase 1|30|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 03:16:15.589584|2018-06-01 03:16:15.589584
NCT00465738|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|2010-08-31||2010-12-21|2007-04-24|2007-04-25|Estimate|2010-11-05|2010-12-06|Estimate||||2010-12-21|2010-12-31|Estimate|February 2007||2007-02-28|December 2010|2010-12-31|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|NT-Spin||IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity|Prospective, Randomized, Observer-blind, Parallel-group, Multi-center Trial to Assess Efficacy and Safety of Two Different Dilutions of incobotulinumtoxinA (Xeomin) in Patients With Upper Limb Spasticity|Completed||Phase 3|216|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 03:16:15.732666|2018-06-01 03:16:15.732666
NCT00465725|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2009-09-23|2007-04-23|2007-04-25|Estimate|||||||2009-09-23|2009-09-24|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors|A Randomized Crossover Oral Bioavailability Study Comparing the Pharmacokinetics and Pharmacodynamics of Picoplatin Administered Orally With Picoplatin Administered Intravenously in Subjects With Advanced Non-Hematological Malignancies|Completed||Phase 1|18|Anticipated|Poniard Pharmaceuticals||1|||f||||t||||||||||2018-06-01 03:16:16.724444|2018-06-01 03:16:16.724444
NCT00465712|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2011-05-31|2007-04-24|2007-04-25|Estimate|||||||2011-05-31|2011-06-01|Estimate|July 2006||2006-07-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|AMNIO||Effect of Amnioinfusion on External Cephalic Version Successful Rate|Effect of Amnioinfusion on External Cephalic Version After Initial Failure a Prospective Multicentric Randomized Study|Terminated||N/A|240|Anticipated|University Hospital, Tours||2|||f||||t||||||||||2018-06-01 03:16:16.885963|2018-06-01 03:16:16.885963
NCT00465699|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-04-23|2007-04-23|2007-04-25|Estimate|||||||2007-04-23|2007-04-25|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|April 2007|Anticipated|2007-04-30|||||Interventional|||Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis|Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis|Unknown status|Recruiting|N/A|50||Spartanburg Regional Family Medicine|||||f||||t||||||||||2018-06-01 03:16:16.980151|2018-06-01 03:16:16.980151
NCT00465686|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2008-05-05|2007-04-23|2007-04-25|Estimate|||||||2008-05-05|2008-05-09|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Ergonomic Classroom Furniture on the Printing Legibility of Elementary Students With Cerebral Palsy|Ergonomic Classroom Furniture and the Printing Legibility of Elementary School Students With CP|Completed||Phase 1|30|Actual|Holland Bloorview Kids Rehabilitation Hospital||1|||f||||f||||||||||2018-06-01 03:16:17.101941|2018-06-01 03:16:17.101941
NCT00465673|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2009-08-04|2007-04-24|2007-04-25|Estimate|||||||2009-08-04|2009-08-06|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer|A Phase II Study of Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer|Terminated||Phase 2|2|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||Low recruitment|f||||t||||||||||2018-06-01 03:16:17.199173|2018-06-01 03:16:17.199173
NCT00465660|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2007-04-24|2007-04-24|2007-04-25|Estimate|||||||2007-04-24|2007-04-25|Estimate|April 2005||2005-04-30|December 2006|2006-12-31|July 2009||2009-07-31|||||Interventional|||Resistive Exercise for Arthritic Cartilage Health (REACH)|The Effect of 6 Month High Intensity Progressive Resistance Training on Knee Articular Cartilage Morphology in Female Osteoarthritic Patients|Unknown status|Active, not recruiting|Phase 2|60||University of Sydney|||||f||||||||||||||2018-06-01 03:16:17.272147|2018-06-01 03:16:17.272147
NCT00465647|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|2010-12-22|2010-04-29|2015-10-19|2007-04-24|2007-04-25|Estimate|2011-02-15|2011-03-11|Estimate|2010-05-06|2010-05-10|Estimate|2015-10-19|2015-11-18|Estimate|April 2007||2007-04-30|October 2015|2015-10-31|April 2010|Actual|2010-04-30|May 2009|Actual|2009-05-31||Interventional|Palladone||An Open-label Study of Hydromorphone Oral Solution in Subjects Aged 28 Days to 16 Years for Postoperative Pain|A Multi-center, Open-label, Dose Titration Study Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Hydromorphone Oral Solution in Subjects From 28 Days to 16 Years of Age, Who Require Opioid Analgesics for Postoperative Pain|Completed||Phase 4|116|Actual|Purdue Pharma LP||4|||f||||t||||||||||2018-06-01 03:16:17.385186|2018-06-01 03:16:17.385186
NCT00465634|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2013-08-06|2007-04-24|2007-04-25|Estimate|||||||2013-08-06|2013-08-09|Estimate|May 2003||2003-05-31|August 2013|2013-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|ARTULEP||Doppler and Biological Second Trimester Placental Insufficiency Screening|Screening for Placental Insufficiency by a Combination of Second Trimester Uterine Artery Doppler and Maternal Serum Leptin and Lipids|Completed|||235|Actual|University Hospital, Tours|||||f||||f||||||||||2018-06-01 03:16:18.140519|2018-06-01 03:16:18.140519
NCT00465621|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2008-07-28|2007-04-23|2007-04-25|Estimate|||||||2008-07-28|2008-07-29|Estimate|March 2007||2007-03-31|July 2008|2008-07-31||||July 2007|Actual|2007-07-31||Interventional|||Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|150|Anticipated|Alcon Research|||||||||||||||||||2018-06-01 03:16:18.193773|2018-06-01 03:16:18.193773
NCT00465608|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2009-01-06|2007-04-24|2007-04-25|Estimate|||||||2009-01-06|2009-01-07|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|Reductrauma||Propranolol in Post Traumatic Stress Disorder|Reduction of the Traumatic Memory by Reconsolidation Blockade: A Pilot Study|Completed||Phase 2|20|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||||2018-06-01 03:16:18.266102|2018-06-01 03:16:18.266102
NCT00465595|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2016-10-10|2007-04-23|2007-04-25|Estimate|||||||2016-10-10|2016-10-12|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Psychopharmacology of Psilocybin in Cancer Patients|Psychopharmacology of Psilocybin in Cancer Patients|Active, not recruiting||N/A|44|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4|||f||||t||||||||||2018-06-01 03:16:18.348256|2018-06-01 03:16:18.348256
NCT00465582|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2012-03-26|2007-04-24|2007-04-25|Estimate|||||||2012-03-26|2012-03-27|Estimate|January 2008||2008-01-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|||||Observational|||B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors|B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors|Terminated|||3296|Actual|University Hospital, Rouen|||||f||||t||||||Samples Without DNA|"~     pharynx ecouvillonnage~   "|||2018-06-01 03:16:18.437684|2018-06-01 03:16:18.437684
NCT00465569|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2017-02-17||2017-04-18|2007-04-23|2007-04-25|Estimate|2017-04-18|2017-04-20|Actual||||2017-04-18|2017-04-20|Actual|August 2006||2006-08-31|April 2017|2017-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy|A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy|Completed||Phase 1/Phase 2|20|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:16:18.488806|2018-06-01 03:16:18.488806
NCT00465556|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2015-03-31|2007-04-24|2007-04-25|Estimate|||||||2015-03-31|2015-04-03|Estimate|February 2006||2006-02-28|March 2015|2015-03-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Domestic Violence Enhanced Home Visitation Program (DOVE)|Domestic Violence Enhanced Home Visitation Program - DOVE|Completed||Phase 2|239|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:16:18.888139|2018-06-01 03:16:18.888139
NCT00465543|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2011-12-08|2007-04-23|2007-04-25|Estimate|||||||2011-12-08|2011-12-09|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Mint Tea for the Treatment of Nasal Polyps|A Double-blind,Placebo-controlled, Randomized, Crossover Trial of Mint Tea High in Rosmarinic Acid in Adults With Nasal Polyposis|Completed||Phase 2|22|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 03:16:19.025931|2018-06-01 03:16:19.025931
NCT00465530|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2012-12-11||2013-04-22|2007-04-23|2007-04-25|Estimate|2013-04-22|2013-05-29|Estimate||||2013-04-22|2013-05-29|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children|Safety and Efficacy of Once Daily Intranasal Gentamycin Irrigation Versus Saline in the Treatment of Pediatric Chronic Sinusitis|Completed||N/A|40|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 03:16:19.133505|2018-06-01 03:16:19.133505
NCT00465517|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24||2009-10-28|2009-10-28|2007-04-24|2007-04-25|Estimate||||2009-10-28|2009-10-30|Estimate|2009-10-28|2009-10-30|Estimate|February 2007||2007-02-28|October 2009|2009-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as add-on Therapy in Adult Subjects With Epilepsy Consisting of Uncontrolled Partial-onset Seizures.|Completed||Phase 2|147|Actual|Marinus Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:16:19.516614|2018-06-01 03:16:19.516614
NCT00465504|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2011-05-13|2007-04-24|2007-04-25|Estimate|||||||2011-05-13|2011-05-17|Estimate|July 2006||2006-07-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Two Different Methods of Delivering Local Analgesia During Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis|Comparison of Iontophoresis of Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA®) Cream Versus Subcutaneous Injections of Lidocaine and EMLA® for Pain Relief in Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis: A Randomized Clinical Trial|Completed||Phase 3|5|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:16:19.630208|2018-06-01 03:16:19.630208
NCT00465491|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2009-04-13|2007-04-23|2007-04-25|Estimate|||||||2009-04-13|2009-04-14|Estimate|April 2007||2007-04-30|April 2009|2009-04-30||||May 2009|Anticipated|2009-05-31||Interventional|SPEAR||Study of Picoplatin Efficacy After Relapse|A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.|Unknown status|Active, not recruiting|Phase 3|399|Anticipated|Poniard Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:16:19.753455|2018-06-01 03:16:19.753455
NCT00465478|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2007-04-24|2007-04-24|2007-04-25|Estimate|||||||2007-04-24|2007-04-25|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|March 2014|Anticipated|2014-03-31|||||Interventional|||Autologous Bone Marrow Mononuclear Cells Transplantation in Treating Diabetes Patients|Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Patients With Type 1 or 2 Diabetes Mellitus－a Phase 1/2 Study|Unknown status|Recruiting|Phase 1/Phase 2|200||Shandong University|||||f||||t||||||||||2018-06-01 03:16:20.133308|2018-06-01 03:16:20.133308
NCT00465465|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2008-04-02|2007-04-24|2007-04-25|Estimate|||||||2008-04-02|2008-04-04|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG|A Dose Selection Study Evaluating the Safety and Immunogenicity of 2 Different Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Have Previously Been Vaccinated With BCG|Completed||Phase 1|24|Actual|University of Oxford||2|||f||||f||||||||||2018-06-01 03:16:20.253965|2018-06-01 03:16:20.253965
NCT00465452|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2009-03-18|2007-04-24|2007-04-25|Estimate|||||||2009-03-18|2009-03-19|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Impact of Switching to Continuous Release Dopamine Agonists|The Impact of Switching to Continuous Release Dopamine Agonists on Non-Motor Side Effects|Completed||Phase 3|15|Anticipated|University of Toledo Health Science Campus|||||f||||f||||||||||2018-06-01 03:16:20.324132|2018-06-01 03:16:20.324132
NCT00465439|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2008-08-21|2007-04-24|2007-04-25|Estimate|||||||2008-08-21|2008-08-22|Estimate|May 2007||2007-05-31|August 2008|2008-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety/Efficacy Study of Local Anesthetic Prior to Femoral Artery Sheath Removal|Randomized Controlled Trial Examining the Effect of Subcutaneous Xylocaine 2% on the Incidence of Vasovagal Reactions and Pain Intensity During Femoral Artery Sheath Removal.|Completed||N/A|78|Actual|McMaster University|||||f||||f||||||||||2018-06-01 03:16:20.384186|2018-06-01 03:16:20.384186
NCT00465426|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2012-10-30|2007-04-24|2007-04-25|Estimate|||||||2012-10-30|2012-10-31|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||HIV and Cardiovascular Risk|Assessment of Cardiovascular Risk in HIV Patients|Completed|||129|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     blood will be frozen for end of study analysis for insulin, CRP, adiponectin, TNF-α, sTNFR2,~     IL-6, PAI-1, MCP-1~   "|||2018-06-01 03:16:20.443351|2018-06-01 03:16:20.443351
NCT00465413|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2007-11-13|2007-04-24|2007-04-25|Estimate|||||||2007-11-13|2007-11-14|Estimate|September 2004||2004-09-30|September 2007|2007-09-30||||||||Interventional|MDI||Bronchodilatation Effects of a Small Volume Spacer Used With a Metered-Dose Inhaler||Completed||Phase 2|300|Anticipated|Mackay Memorial Hospital|||||f||||t||||||||||2018-06-01 03:16:20.508283|2018-06-01 03:16:20.508283
NCT00465400|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2008-12-08|2007-04-24|2007-04-25|Estimate|||||||2008-12-08|2008-12-09|Estimate|November 2006||2006-11-30|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Oxidative Stress in Patients With Age-Related Macular Degeneration|Quantification of Oxidative Stress in Patients With Age-Related Macular Degeneration Prior to and After Photodynamic Therapy: a Comet Assay Analysis|Completed|||12|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||None Retained|"~     plasma~   "|||2018-06-01 03:16:20.579564|2018-06-01 03:16:20.579564
NCT00465387|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2007-04-24|2007-04-24|2007-04-25|Estimate|||||||2007-04-24|2007-04-25|Estimate|March 2003||2003-03-31|April 2007|2007-04-30|January 2006|Actual|2006-01-31|||||Interventional|||FORCE (Falls, Fracture, and Osteoporosis Risk Control Evaluation) Study|Falls, Fracture, and Osteoporosis Risk Control Evaluation (FORCE) Study: A Randomized Controlled Trial With Community Partnerships in Northern Ontario|Completed||N/A|400||Group Health Centre|||||f||||f||||||||||2018-06-01 03:16:20.629562|2018-06-01 03:16:20.629562
NCT00465374|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2007-04-24|2007-04-24|2007-04-25|Estimate|||||||2007-04-24|2007-04-25|Estimate|October 2002||2002-10-31|April 2007|2007-04-30||||||||Interventional|||A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients||Unknown status|Recruiting|Phase 3|||University of Turin, Italy|||||f||||||||||||||2018-06-01 03:16:20.748234|2018-06-01 03:16:20.748234
NCT00465361|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2011-02-08||2012-02-06|2007-04-23|2007-04-25|Estimate|2012-02-06|2012-02-09|Estimate||||2012-02-06|2012-02-09|Estimate|May 2007||2007-05-31|December 2011|2011-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit|Evaluation of Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit|Completed||N/A|7|Actual|Children's Mercy Hospital Kansas City|Long-term effects of intervention are unknown.|2|||f||||f||||||||||2018-06-01 03:16:20.852494|2018-06-01 03:16:20.852494
NCT00465348|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2012-10-24|2007-04-24|2007-04-25|Estimate|||||||2012-10-24|2012-10-25|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients|The Antioxidant Effect of Routine Vascular Therapy for Normal Tension Glaucoma Patients|Withdrawn|||0|Actual|University Hospital, Basel, Switzerland||||investigator withdrew|f||||f||||||None Retained|"~     plasma~   "|||2018-06-01 03:16:21.003301|2018-06-01 03:16:21.003301
NCT00465335|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2012-09-19|2007-04-24|2007-04-25|Estimate|||||||2012-09-19|2012-09-21|Estimate|March 2006||2006-03-31|September 2012|2012-09-30|February 2007|Actual|2007-02-28|||||Observational|IMPACCT||Usefulness of Coronary CT Angiography in Patients With Inconclusive Stress Test Results|Multi-Detector Computer Tomography(MDCT)in Patients With Equivocal/Intermediate Post Test Probability of Coronary Artery Disease|Completed|||200|Actual|William Beaumont Hospitals|||||f||||t||||||||||2018-06-01 03:16:21.077735|2018-06-01 03:16:21.077735
NCT00465322|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-04-23|2007-04-23|2007-04-25|Estimate|||||||2007-04-23|2007-04-25|Estimate||||April 2007|2007-04-30||||||||Observational|EFA-1||Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation|Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation|Completed|||100||University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 03:16:21.146929|2018-06-01 03:16:21.146929
NCT00465309|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2009-01-09|2007-04-24|2007-04-25|Estimate|||||||2009-01-09|2009-01-12|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|||||Interventional|||Protective Ventilation With Carbon Dioxide (CO2) -Removal Technique in Patients With Adult Respiratory Distress Syndrome (ARDS)||Completed||Phase 3|200|Anticipated|University of Turin, Italy|||||f||||||||||||||2018-06-01 03:16:21.231856|2018-06-01 03:16:21.231856
NCT00466388|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2014-05-21|2007-04-23|2007-04-24|Estimate|||||||2014-05-21|2014-05-22|Estimate|May 2007||2007-05-31|May 2014|2014-05-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|SMILE||Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia|An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma|Completed||Phase 4|54|Actual|American Academy of Otolaryngology-Head and Neck Surgery Foundation||2|||f||||f||||||||||2018-06-01 03:16:21.420578|2018-06-01 03:16:21.420578
NCT00465283|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-22|||2009-01-26|2007-04-22|2007-04-24|Estimate|||||||2009-01-26|2009-01-27|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Donepezil Double Blind Trial for ECT Memory Disfunction|Donepezil Double Blind Trial for ECT Memory Disfunction|Unknown status|Recruiting|Phase 4|40|Anticipated|BeerYaakov Mental Health Center||2|||f||||||||||||||2018-06-01 03:16:21.519055|2018-06-01 03:16:21.519055
NCT00465270|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2016-07-20|2007-04-23|2007-04-24|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2003||2003-08-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2011|Actual|2011-12-31||Interventional|||RESPECT PFO Clinical Trial|Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment|Active, not recruiting||Phase 2|980|Actual|St. Jude Medical||2|||t||||t||||||||||2018-06-01 03:16:21.641723|2018-06-01 03:16:21.641723
NCT00465257|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2008-05-16|2007-04-23|2007-04-24|Estimate|||||||2008-05-16|2008-05-20|Estimate|May 2007||2007-05-31|May 2008|2008-05-31||||||||Interventional|||Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar|Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction as New Treatment Policy for Uncomplicated Plasmodium Falciparum Malaria in Zanzibar|Suspended||Phase 4|110|Anticipated|Karolinska University Hospital||||Due to lack of malaria patients in Zanzibar the study has been suspended.|f||||||||||||||2018-06-01 03:16:21.86572|2018-06-01 03:16:21.86572
NCT00465244|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2012-10-30|2007-04-23|2007-04-24|Estimate|||||||2012-10-30|2012-11-01|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|STILL||Seizure Therapy With Intravenous Levetiracetam and Lorazepam|Seizure Therapy With Intravenous Levetiracetam and Lorazepam|Withdrawn||Phase 2/Phase 3|0|Actual|Massachusetts General Hospital||2||Inability to recruit subjects|f||||t||||||||||2018-06-01 03:16:21.950063|2018-06-01 03:16:21.950063
NCT00465231|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-12-12|2007-04-23|2007-04-24|Estimate|||||||2007-12-12|2007-12-17|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Preventive Analgesia in Multiparas Undergoing Induction of Labour|Preventive Analgesia in Labour:A Randomised, Placebo-Controlled Study in Multiparas Undergoing Induction of Labour|Completed||N/A|16|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 03:16:22.088015|2018-06-01 03:16:22.088015
NCT00465218|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2012-06-20|2007-04-20|2007-04-24|Estimate|||||||2012-06-20|2012-06-21|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|December 2007|Actual|2007-12-31||Observational|Tissue-Valve||Transcranial Doppler (TCD) Assessment During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement|"Transcranial Doppler Assessment of Cerebral Embolization During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement: Comparison of High-dose Aspirin Versus Warfarin Plus Low-dose Aspirin"|Completed|||56|Actual|Ottawa Heart Institute Research Corporation|||2||f||||f||||||||||2018-06-01 03:16:22.162708|2018-06-01 03:16:22.162708
NCT00465205|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2013-08-21|2007-04-23|2007-04-24|Estimate|||||||2013-08-21|2013-08-22|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|December 2007|Actual|2007-12-31|December 2005|Actual|2005-12-31||Interventional|||HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons|A Randomized,Double-Blind , Placebo-Controlled Crossover Trial of Antivirals for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Co-infected Persons|Completed||Phase 3|20|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:16:22.241931|2018-06-01 03:16:22.241931
NCT00465192|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2017-02-28|2007-04-23|2007-04-24|Estimate|||||||2017-02-28|2017-03-01|Actual|August 31, 1994|Actual|1994-08-31|February 2017|2017-02-28|November 30, 1995|Actual|1995-11-30|November 30, 1995|Actual|1995-11-30||Interventional|||Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Comparing the Efficacy and Safety of 17-Beta Estradiol 10 Micrograms and 25 Micrograms (Vagifem) Doses in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis|Completed||Phase 3|230|Anticipated|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:16:22.331151|2018-06-01 03:16:22.331151
NCT00465179|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|2016-03-31||2016-05-04|2007-04-23|2007-04-24|Estimate|2016-04-01|2016-05-04|Estimate||||2016-05-04|2016-06-07|Estimate|March 2007||2007-03-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer|Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma|Completed||Phase 2|61|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:16:22.408824|2018-06-01 03:16:22.408824
NCT00465166|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-12-12|2007-04-23|2007-04-24|Estimate|||||||2007-12-12|2007-12-17|Estimate|February 2007||2007-02-28|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Observational|||Lumbar Spine Ultrasound of Patients With Previous Accidental Dural Puncture During Labour Epidural|Lumbar Spine Ultrasound of Patients With Previous Accidental Dural Puncture During Labour Epidural|Completed|||56|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||1||f||||f||||||||||2018-06-01 03:16:22.824836|2018-06-01 03:16:22.824836
NCT00465153|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2007-11-01|2007-04-20|2007-04-24|Estimate|||||||2007-11-01|2007-11-05|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||The Combined Effects of Resistance Training and Flax Oil Supplementation Upon Inflammation in Older Adults|The Combined Effects of Resistance Training and Flax Oil Supplementation Upon Inflammation in Older Adults|Completed||Phase 3|60|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 03:16:22.89843|2018-06-01 03:16:22.89843
NCT00465140|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-04-23|2007-04-23|2007-04-24|Estimate|||||||2007-04-23|2007-04-24|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Effects of Creatine Supplementation on Renal Function|Effects of Creatine Supplementation on Renal Function in Sedentary Healthy Males Urdergoing Aerobic Training: a Randomized, Double-Blind, Placebo-Controlled Trial|Completed||N/A|18||University of Sao Paulo|||||f||||t||||||||||2018-06-01 03:16:22.975731|2018-06-01 03:16:22.975731
NCT00465114|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2018-02-05|2007-04-23|2007-04-24|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2007||2007-04-30|February 2018|2018-02-28|December 2007|Anticipated|2007-12-31|||||Observational|||Minimally-invasive Assessment of Cardiac Output in Severe Preeclampsia|Minimally-invasive Assessment of Cardiac Output in Severe Preeclampsia: Radial Artery Wave Form Analysis Versus Trans-thoracic Echocardiogram|Withdrawn|||0|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||||Feasibility issues, only 1 patient recruited.|f||||f||||||||||2018-06-01 03:16:23.035686|2018-06-01 03:16:23.035686
NCT00465101|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2015-07-21||2015-09-24|2007-04-23|2007-04-24|Estimate|2015-09-24|2015-10-28|Estimate||||2015-09-24|2015-10-28|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|PVP||A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization|A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH)|Completed||Phase 4|150|Actual|American Medical Systems|Follow-up of subjects was discontinued in August 2012 prior to most participants completing the assessment planned at 5 years. At the time of the discontinuation, all but five of the participants remaining on study had completed 3 years of follow-up.|1|||f||||f||||||||||2018-06-01 03:16:23.105464|2018-06-01 03:16:23.105464
NCT00465088|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2009-02-10||2011-06-09|2007-04-23|2007-04-24|Estimate|2009-03-27|2009-05-13|Estimate||||2011-06-09|2011-06-13|Estimate|April 2007||2007-04-30|June 2011|2011-06-30||||February 2008|Actual|2008-02-29||Interventional|SUPREME||An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)|SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia|Completed||Phase 3|199|Actual|Abbott||2|||f||||||||||||||2018-06-01 03:16:23.802639|2018-06-01 03:16:23.802639
NCT00465075|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-12-19|2007-04-23|2007-04-24|Estimate|||||||2007-12-19|2007-12-28|Estimate|March 2007||2007-03-31|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women|An Open-Label, Single-Dose, 3-Period, Crossover Study To Determine The Effect Of A High-Fat Meal On The Relative Bioavailability And Pharmacokinetics Of A Single Dose Of Bazedoxifene Acetate/Conjugated Estrogens (Premarin© New Process) Administered Orally To Healthy, Postmenopausal Women|Completed||Phase 1|24|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:16:24.551383|2018-06-01 03:16:24.551383
NCT00465062|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-21|||2017-06-30|2007-04-21|2007-04-24|Estimate|||||||2017-06-30|2017-07-02|Actual|April 19, 2007||2007-04-19|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease|A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:16:24.612561|2018-06-01 03:16:24.612561
NCT00465049|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2012-10-19|2007-04-23|2007-04-24|Estimate|||||||2012-10-19|2012-10-22|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Comparison of Suturing and Packing of Drained Abscesses|Primary vs. Secondary Closure of Cutaneous Abscesses After I&D: A RCT|Completed||Phase 2|100|Anticipated|Stony Brook University||2|||f||||f||||||||||2018-06-01 03:16:24.65942|2018-06-01 03:16:24.65942
NCT00465036|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2009-03-25|2007-04-23|2007-04-24|Estimate|||||||2009-03-25|2009-03-26|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Effect of Flaxseed on Lipid Uptake and Appetite|Effect of Whole Flaxseeds and Flaxseed Mucilage on Lipid Absorption, Glucose and Insulin Metabolism and Appetite Regulation|Completed||N/A|18||University of Copenhagen|||||f||||f||||||||||2018-06-01 03:16:24.736938|2018-06-01 03:16:24.736938
NCT00465023|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2017-01-19|2007-04-23|2007-04-24|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2003||2003-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|September 2013|Actual|2013-09-30||Interventional|||Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases|Phase I Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases|Completed||N/A|16|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:16:24.794785|2018-06-01 03:16:24.794785
NCT00465010|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2011-10-14|2007-04-23|2007-04-24|Estimate|||||||2011-10-14|2011-10-18|Estimate|April 2002||2002-04-30|October 2011|2011-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of a Worksite Parenting Program|Talking Parents, Healthy Teens: A Worksite-Based Parenting Program for Parents of Adolescents|Completed||N/A|1252|Actual|RAND|||||f||||f||||||||||2018-06-01 03:16:24.997825|2018-06-01 03:16:24.997825
NCT00464997|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-04-23|2007-04-23|2007-04-24|Estimate|||||||2007-04-23|2007-04-24|Estimate|June 2007||2007-06-30|April 2007|2007-04-30||||||||Observational|||The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate|The Effect of Low Dose Aspirin on the Pharmacokinetics of Methotrexate|Unknown status|Not yet recruiting||30||Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 03:16:25.058032|2018-06-01 03:16:25.058032
NCT00464984|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2018-04-18|2007-04-23|2007-04-24|Estimate|||||||2018-04-18|2018-04-19|Actual|August 2006||2006-08-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2017|Actual|2017-12-31||Interventional|||Lifestyle Intervention in Morbidly Obese Patients|Lifestyle Intervention in Morbidly Obese Patients|Active, not recruiting||N/A|100|Anticipated|The Hospital of Vestfold||2|||f||||f||||||||||2018-06-01 03:16:25.108131|2018-06-01 03:16:25.108131
NCT00464971|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2017-02-28|2007-04-23|2007-04-24|Estimate|||||||2017-02-28|2017-03-01|Actual|January 31, 1995|Actual|1995-01-31|February 2017|2017-02-28|November 30, 1996|Actual|1996-11-30|November 30, 1996|Actual|1996-11-30||Interventional|||Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial|Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Estrogen Deficiency-Derived Atrophic Vaginitis|Completed||Phase 3|102|Anticipated|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:16:25.171052|2018-06-01 03:16:25.171052
NCT00464958|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-22|||2009-02-17|2007-04-22|2007-04-24|Estimate|||||||2009-02-17|2009-02-19|Estimate|January 2008||2008-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||One Year Extension Study To Protocol C2/5/TZ:MS-05|Long Term Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in Patients With Multiple Sclerosis - Open Label Extension Study|Terminated||Phase 1/Phase 2|10|Actual|Teva GTC||1||Study was stopped as the sponsor is no longer funding this project|f||||f||||||||||2018-06-01 03:16:25.227444|2018-06-01 03:16:25.227444
NCT00464945|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2010-03-26|2009-02-26|2012-07-06|2007-04-23|2007-04-24|Estimate|2012-07-06|2012-08-15|Estimate|2009-09-30|2009-10-01|Estimate|2012-07-06|2012-08-15|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomised,Active-Controlled ,Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine|Completed||Phase 3|269|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:16:25.388123|2018-06-01 03:16:25.388123
NCT00464932|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-04-23|2007-04-23|2007-04-24|Estimate|||||||2007-04-23|2007-04-24|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Observational|VIPCOPD||Vasoactive Intestinal Peptide in COPD||Completed|||34||Medical University of Vienna|||||f||||t||||||||||2018-06-01 03:16:28.815723|2018-06-01 03:16:28.815723
NCT00464919|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2009-07-06|2007-04-23|2007-04-24|Estimate|||||||2009-07-06|2009-07-07|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|March 2009|Actual|2009-03-31|||||Interventional|||Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)|A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|50|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 03:16:29.041748|2018-06-01 03:16:29.041748
NCT00464893|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2013-12-03|2007-04-23|2007-04-24|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection|Multicenter, Open-label Phase II Study to Evaluate the Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients With Gastric Adenocarcinoma After Neoadjuvant Chemotherapy and Intended Curative Resection|Completed||Phase 2|70|Actual|Neovii Biotech||1|||f||||t||||||||||2018-06-01 03:16:29.336106|2018-06-01 03:16:29.336106
NCT00464880|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-21|||2007-11-28|2007-04-23|2007-04-24|Estimate|||||||2007-11-28|2007-11-29|Estimate|September 2005||2005-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy|A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipient/Overt Diabetic Nephropathy|Completed||Phase 1/Phase 2|24||Novartis|||||f||||f||||||||||2018-06-01 03:16:29.65964|2018-06-01 03:16:29.65964
NCT00464867|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2012-06-09|2007-04-23|2007-04-24|Estimate|||||||2012-06-09|2012-06-12|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|January 2006|Actual|2006-01-31||Interventional|||Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine||Completed||N/A|128|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||f||||||||||2018-06-01 03:16:29.921928|2018-06-01 03:16:29.921928
NCT00464854|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-22|||2007-04-23|2007-04-23|2007-04-24|Estimate|||||||2007-04-23|2007-04-24|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward|Feasiblity, Safety And Efficacy Of Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward|Terminated||N/A|100||Assaf-Harofeh Medical Center||||The study was started before the official request for protocol registration|f||||f||||||||||2018-06-01 03:16:30.238595|2018-06-01 03:16:30.238595
NCT00464841|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2011-09-02|2007-04-23|2007-04-24|Estimate|||||||2011-09-02|2011-09-05|Estimate|February 2007||2007-02-28|September 2011|2011-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Usefulness of the Tsui Test in Combined Spinal-Epidural Analgesia in Labour|Can the Tsui Test be Used to Test the Placement of Epidural Catheters Following the Intrathecal Component of a Combined Spinal-epidural Technique Used for Labor Analgesia?|Completed||N/A|14|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-06-01 03:16:30.705708|2018-06-01 03:16:30.705708
NCT00464828|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-11-13|2007-04-23|2007-04-24|Estimate|||||||2007-11-13|2007-11-15|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Observational|||Ultrasound Imaging of Neck Blood Vessels in Pregnant and Non-Pregnant Women|Internal Jugular Vein and Carotid Artery Anatomic Relation as Determined by Ultrasonography in Obstetric Patients|Completed|||156|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||||f||||f||||||||||2018-06-01 03:16:31.128724|2018-06-01 03:16:31.128724
NCT00464815|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2017-05-31|2009-09-03|2018-03-30|2007-04-23|2007-04-24|Estimate|2018-03-30|2018-04-02|Actual|2009-09-03|2009-09-04|Estimate|2018-03-30|2018-04-02|Actual|May 2, 2007|Actual|2007-05-02|March 2018|2018-03-31|September 10, 2008|Actual|2008-09-10|April 16, 2008|Actual|2008-04-16||Interventional|||Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects|Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax™ ACWY|Completed||Phase 3|1025|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:16:31.49677|2018-06-01 03:16:31.49677
NCT00464802|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2011-07-22|2007-04-23|2007-04-24|Estimate|||||||2011-07-22|2011-07-26|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects|A Double-Blind, Placebo-Controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Comparison With the Current Formulation in Healthy Subjects|Completed||Phase 1|36|Anticipated|Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:16:33.48306|2018-06-01 03:16:33.48306
NCT00464789|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2007-12-19|2007-04-23|2007-04-24|Estimate|||||||2007-12-19|2007-12-28|Estimate|March 2007||2007-03-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Bazedoxifene/Conjugated Estrogens (Premarin Current Process) And Bazedoxifene/Conjugated Estrogens (Premarin New Process) In Healthy Postmenopausal Women|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:16:33.592539|2018-06-01 03:16:33.592539
NCT00464776|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-21|||2011-02-03|2007-04-21|2007-04-24|Estimate|||||||2011-02-03|2011-02-04|Estimate|October 2005||2005-10-31|February 2011|2011-02-28||||April 2008|Actual|2008-04-30||Interventional|||Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy|A Randomized, Double-blind, Cross-over, 4-period, 4 Treatment, Within-subject Placebo-controlled Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Type 2 Diabetic Patients With Incipient or Overt Nephropathy|Completed||Phase 1/Phase 2|26|Actual|Novartis||4|||f||||t||||||||||2018-06-01 03:16:33.65696|2018-06-01 03:16:33.65696
NCT00464763|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2017-03-20|2007-04-23|2007-04-24|Estimate|||||||2017-03-20|2017-03-21|Actual|April 2007||2007-04-30|November 2015|2015-11-30|September 2007|Actual|2007-09-30|||||Interventional|||A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel, Multicenter Study Evaluating the Efficacy and Safety of Dexmedetomidine in the Prevention of Postoperative Delirium in Subjects Undergoing Heart Surgery With Cardiopulmonary Bypass|Withdrawn||Phase 3|0|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2||"The incidence of post-operative delirium observed from interim blinded data in DEX-06-09 was~   significantly lower than the current literature in this population."|f||||f||||||||||2018-06-01 03:16:33.767058|2018-06-01 03:16:33.767058
NCT00464750|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2016-07-15|2007-04-23|2007-04-24|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2006||2006-11-30|July 2016|2016-07-31|June 2007|Actual|2007-06-30|||||Observational|||Study on the Repeatability of Cardiac Output Measurements Dependence of Temperature of Injectate|The Impact of Temperature of the Injectate on the Precision (Repeatability) of Cardiac Output Measurements Synchronized With the Respiration (the Temperature Study)|Completed|||40|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 03:16:33.846725|2018-06-01 03:16:33.846725
NCT00464737|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2009-11-23||2015-05-26|2007-04-23|2007-04-24|Estimate|2009-11-23|2010-01-05|Estimate||||2015-05-26|2015-06-22|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|SP888||The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.|A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Doses of Rotigotine in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome|Completed||Phase 2|230|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 03:16:33.939059|2018-06-01 03:16:33.939059
NCT00464724|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|||2018-02-19|2007-04-23|2007-04-24|Estimate|||||||2018-02-19|2018-02-21|Estimate|March 2007|Actual|2007-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate|3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate|Recruiting||N/A|80|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-06-01 03:16:34.672838|2018-06-01 03:16:34.672838
NCT00464711|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2014-09-15||2016-11-04|2007-04-23|2007-04-24|Estimate|2016-11-04|2017-01-04|Estimate||||2016-11-04|2017-01-04|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Brain GABA Levels and Treatment Response in Major Depressive Disorder|Brain GABA Levels and Treatment Response in Major Depressive Disorder|Completed||Phase 4|40|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-06-01 03:16:34.849031|2018-06-01 03:16:34.849031
NCT00464698|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2016-03-15||2017-01-17|2007-04-23|2007-04-24|Estimate|2017-01-17|2017-03-07|Actual||||2017-01-17|2017-03-07|Actual|December 2005||2005-12-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|FIJ-MC-1003||Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)|Duloxetine for the Treatment of Obsessive Compulsive Disorder|Completed||Phase 4|20|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:16:35.051397|2018-06-01 03:16:35.051397
NCT00464685|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|2014-07-10|2011-01-10|2014-07-10|2007-04-20|2007-04-24|Estimate|2014-07-10|2014-08-04|Estimate|2011-01-10|2011-01-20|Estimate|2014-07-10|2014-08-04|Estimate|May 2007||2007-05-31|July 2014|2014-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema||Completed||Phase 2|253|Actual|Allergan||2|||f||||f||||||||||2018-06-01 03:16:35.354304|2018-06-01 03:16:35.354304
NCT00464672|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-23|2010-01-25|2009-08-03|2015-09-16|2007-04-23|2007-04-24|Estimate|2010-04-09|2010-05-05|Estimate|2009-08-03|2009-08-10|Estimate|2015-09-16|2015-10-01|Estimate|April 2007||2007-04-30|September 2015|2015-09-30|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old|A Phase III, Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines in Healthy Children Aged 3 to 8 Years, in Healthy Children/Adolescents Aged 9 to 17 Years,and in Healthy Adults Aged 18 to 64 Years|Completed||Phase 3|1893|Actual|Novartis||2|||f||||t||||||||||2018-06-01 03:16:35.839933|2018-06-01 03:16:35.839933
NCT00464659|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2015-12-29|2007-04-20|2007-04-23|Estimate|||||||2015-12-29|2015-12-30|Estimate|April 2007||2007-04-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Protocol Memory Deficit in Patients With Obstructive Sleep Apnea Syndrome|"Comparison of the Evolution of Memory Deficit in Patients With Sleep Apnea Obstructive Syndrome (SAOS) Before and After Effective Versus Sham Treatment by Positive Pression Continues (PPC)"|Completed||N/A|40|Actual|University Hospital, Grenoble||2|||f||||t||||||||Yes|All individual patient data are anonymized|2018-06-01 03:16:37.070123|2018-06-01 03:16:37.070123
NCT00464646|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2012-08-24||2014-07-17|2007-04-19|2007-04-23|Estimate|2012-08-24|2012-09-26|Estimate||||2014-07-17|2014-07-25|Estimate|May 2007||2007-05-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|December 2009|Actual|2009-12-31||Interventional|||Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer|A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer|Completed||Phase 2|105|Actual|NSABP Foundation Inc||1|||f||||f||||||||||2018-06-01 03:16:37.198931|2018-06-01 03:16:37.198931
NCT00464633|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20||2013-02-08|2013-02-08|2007-04-20|2007-04-23|Estimate||||2013-02-08|2013-02-12|Estimate|2013-02-08|2013-02-12|Estimate|March 2007||2007-03-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)|A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL|Completed||Phase 2|165|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 03:16:40.118914|2018-06-01 03:16:40.118914
NCT00464620|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2017-03-20|2007-04-20|2007-04-23|Estimate|||||||2017-03-20|2017-03-22|Actual|May 2007||2007-05-31|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Trial of Dasatinib in Advanced Sarcomas|A Phase II Trial of Dasatinib in Advanced Sarcomas|Active, not recruiting||Phase 2|386|Actual|Sarcoma Alliance for Research through Collaboration||1|||f||||t||||||||||2018-06-01 03:16:40.433052|2018-06-01 03:16:40.433052
NCT00464607|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2007-04-20|2007-04-20|2007-04-23|Estimate|||||||2007-04-20|2007-04-23|Estimate|December 2001||2001-12-31|April 2007|2007-04-30|April 2005|Actual|2005-04-30|||||Interventional|||Prospective, Randomized, Controlled, Clinical Study on Tolerability and Efficacy of hMG-IBSA|A Prospective, Randomized, Controlled Clinical Study on the Assessment of Tolerability and of Clinical Efficacy of MERIONAL® (hMG-IBSA) Administered Subcutaneously Versus MERIONALâ Administered Intramuscularly in Women Undergoing Controlled Ovarian Hyperstimulation (COH) in an ART Programme (IVF)|Completed||Phase 3|160||IBSA Institut Biochimique SA|||||f||||f||||||||||2018-06-01 03:16:40.581587|2018-06-01 03:16:40.581587
NCT00464594|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-22|2007-04-19|2007-04-23|Estimate|||||||2007-04-22|2007-04-24|Estimate|April 2007||2007-04-30|April 2007|2007-04-30||||||||Interventional|JEDIS||Japan Early Diabetes Intervention Study|A Randomized Comparative Clinical Study on Suppression of Progression From Early Diabetes, Diet/Exercise Standard Intervention vs. Concurrent Pharmacological Standard Intervention|Unknown status|Recruiting|N/A|2560||Japan Early Diabetes Intervention Study Group|||||f||||||||||||||2018-06-01 03:16:40.702312|2018-06-01 03:16:40.702312
NCT00464581|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2012-05-24|2007-04-20|2007-04-23|Estimate|||||||2012-05-24|2012-05-28|Estimate|May 2007||2007-05-31|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|FVF4153s||Lucentis for Treatment of Macular Edema|A Single-center Phase 2 Trial of Intravitreous Injections of Lucentis (Ranibizumab) in Subjects With Cystoid Macular Edema Secondary to Non-ischemic Retinopathy|Completed|||30|Actual|Retina Institute of Hawaii|||||f||||f||||||||||2018-06-01 03:16:40.773002|2018-06-01 03:16:40.773002
NCT00464568|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|2017-05-02||2017-09-20|2007-04-20|2007-04-23|Estimate|2017-05-02|2017-08-21|Actual||||2017-09-20|2017-10-23|Actual|March 28, 2007||2007-03-28|May 2017|2017-05-31|May 16, 2007|Actual|2007-05-16|||||Interventional|||A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis|A Randomised, Open, Placebo-controlled 5-way Crossover Trial of Single Doses of Intranasal GSK256066 in Subjects With Seasonal Allergic Rhinitis (SAR).|Completed||Phase 2|32|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:16:40.893352|2018-06-01 03:16:40.893352
NCT00464555|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20||2014-03-27|2016-03-24|2007-04-20|2007-04-23|Estimate||||2014-06-10|2014-06-19|Estimate|2016-03-24|2016-04-26|Estimate|December 2006||2006-12-31|March 2016|2016-03-31|February 2014|Actual|2014-02-28|November 2011|Actual|2011-11-30||Interventional|||Strategies to Improve Islet Survival|Strategies to Improve Long Term Islet Graft Survival|Completed||Phase 2|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 03:16:41.886198|2018-06-01 03:16:41.886198
NCT00464542|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2011-03-22||2017-04-05|2007-04-19|2007-04-23|Estimate|2011-08-31|2011-10-04|Estimate||||2017-04-05|2017-05-11|Actual|December 2007||2007-12-31|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|MASH||Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study|Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding|Completed||Phase 4|12|Actual|University of Pittsburgh|Inadequate controls (study would have been improved by inclusion of women without herpes simplex virus type 2 infection) to better determine the strength of the association between recalcitrance of BV and HSV-2 infection.|1|||f||||f||||||||No||2018-06-01 03:16:41.96542|2018-06-01 03:16:41.96542
NCT00464529|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2007-11-06|2007-04-20|2007-04-23|Estimate|||||||2007-11-06|2007-11-07|Estimate|May 2007||2007-05-31|May 2007|2007-05-31|October 2007|Actual|2007-10-31|||||Observational|GluContinu||Accuracy and Safety of Real Time Continuous Glucose Monitoring Before, During and After Surgery|Peri-Operative Accuracy and Safety of Real Time Continuous Glucose Monitoring System in Cardiac Surgical Patients. A Pilot Study|Completed|||30|Actual|Medical Research Foundation, The Netherlands|||||f||||f||||||||||2018-06-01 03:16:42.113782|2018-06-01 03:16:42.113782
NCT00464516|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2012-06-28|2007-04-20|2007-04-23|Estimate|||||||2012-06-28|2012-07-02|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|March 2010|Actual|2010-03-31|February 2009|Actual|2009-02-28||Interventional|||Preoperative Estetrol in Breast Cancer|Preoperative Hormone Therapy for Pre- and Postmenopausal Women With ER Positive Breast Cancer: A Double Blind Randomized Parallel Group Phase II Trial, Comparing the Effect of 2 Weeks of Preoperative Estetrol With Placebo|Completed||Phase 2|30|Actual|Pantarhei Bioscience||2|||f||||f||||||||||2018-06-01 03:16:42.17216|2018-06-01 03:16:42.17216
NCT00464503|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2008-04-03|2007-04-20|2007-04-23|Estimate|||||||2008-04-03|2008-04-08|Estimate|September 2007||2007-09-30|April 2008|2008-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Statins and the Urinary Proteome|The Effect of Statins on the Urinary Proteome|Completed||N/A|7|Actual|Universiteit Antwerpen|||||f||||t||||||||||2018-06-01 03:16:42.236597|2018-06-01 03:16:42.236597
NCT00464490|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2014-10-25||2014-10-29|2007-04-20|2007-04-23|Estimate|2014-10-29|2014-10-31|Estimate||||2014-10-29|2014-10-31|Estimate|November 2007||2007-11-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts|A Prospective, Randomized, Controlled Study on the Use of Dexmedetomidine to Facilitate Extubation in Surgical Intensive-Care-Unit Patients Who Failed Previous Weaning Attempts|Terminated||N/A|42|Actual|University of California, San Francisco|Lower than anticipated enrollment due to unwillingness of providers to assign patients to the control group led to smaller-than-planned samples for analysis|2||Lack of eligible participants|f||||f||||||||||2018-06-01 03:16:42.302302|2018-06-01 03:16:42.302302
NCT00464477|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2007-11-06|2007-04-20|2007-04-23|Estimate|||||||2007-11-06|2007-11-07|Estimate|June 2007||2007-06-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Observational|||Advanced Grandparental Age as a Risk Factor for Autism|Advanced Grandparental Age as a Risk Factor for Autism and Other Pervasive Developmental Disorders|Completed|||100|Actual|University of Mississippi Medical Center|||||f||||f||||||||||2018-06-01 03:16:42.557279|2018-06-01 03:16:42.557279
NCT00464464|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|2014-03-10||2014-11-04|2007-04-20|2007-04-23|Estimate|2014-11-04|2014-11-05|Estimate||||2014-11-04|2014-11-05|Estimate|April 2007||2007-04-30|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Coping With Depression in Parkinson's Disease|Treating Depression in Parkinson's Disease: A New Method|Completed||N/A|80|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 03:16:42.631773|2018-06-01 03:16:42.631773
NCT00464451|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2016-11-01|2007-04-20|2007-04-23|Estimate|||||||2016-11-01|2016-11-03|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Dexmedetomidine Versus Chloral Hydrate for Pediatric Sedation During EEG|Prospective, Double Blinded,Randomized Controlled Trial of Dexmedetomidine Versus Chloral Hydrate for Pediatric Sedation During EEG|Withdrawn||Phase 2|0|Actual|Wesley Medical Center||2||Unable to obtain approval from FDA for use of chloral hydrate|f||||t||||||||||2018-06-01 03:16:43.038916|2018-06-01 03:16:43.038916
NCT00464438|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2010-06-15|2009-09-22|2011-08-17|2007-04-19|2007-04-23|Estimate|2011-08-17|2011-09-21|Estimate|2009-09-22|2009-09-24|Estimate|2011-08-17|2011-09-21|Estimate|June 2007||2007-06-30|August 2011|2011-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis||Completed||Phase 4|171|Actual|Allergan||2|||f||||||||||||||2018-06-01 03:16:43.128726|2018-06-01 03:16:43.128726
NCT00464425|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2011-04-20|2007-04-20|2007-04-23|Estimate|||||||2011-04-20|2011-04-21|Estimate|October 2008||2008-10-31|April 2011|2011-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Electroacupuncture for Postoperative Ileus After Laparoscopic Colorectal Surgery|Electroacupuncture for Postoperative Ileus After Laparoscopic Colorectal Surgery: a Randomised Sham-controlled Pilot Study|Completed||Phase 3|165|Anticipated|Chinese University of Hong Kong||3|||f||||t||||||||||2018-06-01 03:16:43.36574|2018-06-01 03:16:43.36574
NCT00464412|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-05-08|2007-04-19|2007-04-23|Estimate|||||||2007-05-08|2007-05-09|Estimate|January 2006||2006-01-31|May 2007|2007-05-31|February 2006|Actual|2006-02-28|||||Interventional|||The Effect of a Short Educational Program on Young Women's Knowledge and Beliefs About Osteoporosis|The Effect of a Short Educational Program on Young Women's Knowledge and Beliefs About Osteoporosis|Completed||Phase 1|135|Actual|Valdosta State University|||||f||||f||||||||||2018-06-01 03:16:43.451179|2018-06-01 03:16:43.451179
NCT00464399|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2016-11-15|2007-04-20|2007-04-23|Estimate|||||||2016-11-15|2016-11-16|Estimate|September 2006||2006-09-30|November 2016|2016-11-30||||December 2012|Actual|2012-12-31||Interventional|||Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients|A Pilot Study to Evaluate Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant|Completed||Phase 3|20||Novartis|||||f||||||||||||||2018-06-01 03:16:43.504975|2018-06-01 03:16:43.504975
NCT00464386|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2016-04-28|2007-04-20|2007-04-23|Estimate|||||||2016-04-28|2016-05-02|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|February 2009|Actual|2009-02-28||Interventional|POC||Continuous Glucose Monitoring (POC) in the ICU|Continuous Glucose Monitors (CGM) Versus Point-of-Care (POC) Glucometers in the Intensive Care Unit (ICU)|Terminated||N/A|23|Actual|United States Army Institute of Surgical Research||2||Study device required infeasible modifications. No patients received device.|f||||f||||||||No||2018-06-01 03:16:43.590172|2018-06-01 03:16:43.590172
NCT00464373|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2014-01-31|2007-04-20|2007-04-23|Estimate|||||||2014-01-31|2014-02-03|Estimate|April 2007||2007-04-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|BTX-URO-01||Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome|Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial|Terminated||Phase 3|11|Actual|Cantonal Hospital of St. Gallen||2||Slow accrual.|f||||t||||||||||2018-06-01 03:16:43.679673|2018-06-01 03:16:43.679673
NCT00464347|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2010-03-23|2007-04-19|2007-04-23|Estimate|||||||2010-03-23|2010-03-24|Estimate|January 2007||2007-01-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|VERTACL||TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration|Multi-Center, Randomized, Phase II Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide and Avastin® in Combination With Photodynamic Therapy in Participants With Neovascular Age Related Macular Degeneration|Terminated||Phase 2|100|Anticipated|National Eye Institute (NEI)||||Study was terminated because of poor enrollment.|f||||t||||||||||2018-06-01 03:16:43.769804|2018-06-01 03:16:43.769804
NCT00464334|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|2012-11-19||2015-09-24|2007-04-20|2007-04-23|Estimate|2012-11-19|2012-12-18|Estimate||||2015-09-24|2015-09-25|Estimate|March 2007||2007-03-31|September 2015|2015-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study of V950 in People With Alzheimer Disease (V950-001 AM7)|A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease|Completed||Phase 1|86|Actual|Merck Sharp & Dohme Corp.||11|||f||||f||||||||||2018-06-01 03:16:43.923298|2018-06-01 03:16:43.923298
NCT00464321|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2014-03-17|2007-04-20|2007-04-23|Estimate|||||||2014-03-17|2014-03-19|Estimate|May 2007||2007-05-31|March 2014|2014-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS|A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)|Completed||Phase 1|16|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 03:16:46.448546|2018-06-01 03:16:46.448546
NCT00464308|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|2009-06-09||2014-04-02|2007-04-20|2007-04-23|Estimate|2010-08-26|2010-08-30|Estimate||||2014-04-02|2014-04-21|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg|The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)|Completed||Phase 4|1392|Actual|Janssen-Cilag Pty Ltd|The MCID of 7.5% was amended to 9% to maintain power with smaller sample size.The proportion of patients without heartburn symptoms at baseline was not evenly distributed between treatment arms. This was a significant predictor of symptom resolution.|3|||f||||f||||||||||2018-06-01 03:16:46.562101|2018-06-01 03:16:46.562101
NCT00464295|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2007-12-13|2007-04-20|2007-04-23|Estimate|||||||2007-12-13|2007-12-14|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|HCC-CAP||Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)|Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)|Completed||Phase 2|15|Actual|Aga Khan University|||||f||||f||||||||||2018-06-01 03:16:47.032426|2018-06-01 03:16:47.032426
NCT00464282|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2007-04-20|2007-04-20|2007-04-23|Estimate|||||||2007-04-20|2007-04-23|Estimate||||April 2007|2007-04-30||||||||Observational|||Fluorine-18-α–Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer||Completed|||||Gunma University|||||f||||||||||||||2018-06-01 03:16:47.152253|2018-06-01 03:16:47.152253
NCT00464269|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2016-03-14|2010-02-01|2018-04-23|2007-04-20|2007-04-23|Estimate|2016-03-14|2016-04-13|Estimate|2009-08-26|2009-08-27|Estimate|2018-04-23|2018-05-22|Actual|September 2007||2007-09-30|December 2017|2017-12-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional||Baseline Characteristics refer to Randomized Set.|Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures|An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures|Completed||Phase 3|400|Actual|UCB Pharma||4|||f||||f||||||||||2018-06-01 03:16:47.266262|2018-06-01 03:16:47.266262
NCT00464256|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2010-12-09|2007-04-20|2007-04-23|Estimate|||||||2010-12-09|2010-12-10|Estimate|April 2004||2004-04-30|December 2010|2010-12-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|STRATUS-META||Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation|Comparison of the Efficacy and Safety of a 20 mg/Day Oral Dose of Rimonabant Versus Placebo as an Aid to Smoking Cessation - a US, Randomized, Double-blind, 2 Arm, Placebo-controlled, Parallel-group, Fixed Dose, 12-week Study|Completed||Phase 3|533|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:16:49.227223|2018-06-01 03:16:49.227223
NCT00464243|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20||2017-08-04|2017-08-04|2007-04-20|2007-04-23|Estimate||||2017-08-04|2017-08-08|Actual|2017-08-04|2017-08-08|Actual|April 2007||2007-04-30|August 2017|2017-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|NOCTURNE907||Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study|Efficacy and Safety of 2 mg/Day M100907 on Sleep Maintenance Insomnia: a 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Polysomnographic Study|Completed||Phase 3|604|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:16:49.283911|2018-06-01 03:16:49.283911
NCT00464230|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2011-06-30|2007-04-20|2007-04-23|Estimate|||||||2011-06-30|2011-07-01|Estimate|September 2002||2002-09-30|April 2007|2007-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Hemiarthroplasty or Internal Fixation for Displaced Femoral Neck Fractures|The Management of Intracapsular Fractures of the Proximal Femur. A Prospective, Randomized Trial of Two Parallel Screws and Hemiarthroplasty|Completed||Phase 4|220||Oslo University Hospital|||||f||||f||||||||||2018-06-01 03:16:49.363897|2018-06-01 03:16:49.363897
NCT00464204|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|2011-05-30||2012-01-09|2007-04-20|2007-04-23|Estimate|2011-07-04|2011-08-02|Estimate||||2012-01-09|2012-01-11|Estimate|July 2007||2007-07-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|CRYSTMAS||Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis|Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis|Completed||Phase 3|196|Actual|Fresenius Kabi||2|||f||||t||||||||||2018-06-01 03:16:49.711138|2018-06-01 03:16:49.711138
NCT00464191|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2009-09-19|2007-04-20|2007-04-23|Estimate|||||||2009-09-19|2009-09-21|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment|Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment|Terminated||Phase 4|150|Anticipated|Nordfjord Psychiatric Centre||||The study has been terminated because too few patients have been recruited|f||||||||||||||2018-06-01 03:16:50.623844|2018-06-01 03:16:50.623844
NCT00464178|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2013-09-04|2007-04-19|2007-04-23|Estimate|||||||2013-09-04|2013-09-05|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma|A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed Refractory Multiple Myeloma|Completed||Phase 2|7|Actual|Hackensack University Medical Center||1|||f||||f||||||||||2018-06-01 03:16:50.694924|2018-06-01 03:16:50.694924
NCT00464165|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-20|||2010-12-09|2007-04-20|2007-04-23|Estimate|||||||2010-12-09|2010-12-10|Estimate|November 2002||2002-11-30|December 2010|2010-12-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|STRATUS-EU||Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation|Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5mg/Day or 20mg/Day, Versus Placebo, as an Aid to Smoking Cessation; Multiple Country, Randomized, Double-blind, 3-arm, 10-week Treatment, 40-week Follow-up|Completed||Phase 3|789|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:16:50.869667|2018-06-01 03:16:50.869667
NCT00464139|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2009-02-19|2007-04-18|2007-04-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Prevalence of Endometriosis in a Well Defined Group of Infertile Women|High Prevalence of Endometriosis in Infertile Women With Normal Ovulation and Normospermic Partners|Completed|||221|Actual|University Hospital, Gasthuisberg|||1||f||||f||||||Samples Without DNA|"~     The diagnosis of endometriosis was always confirmed by histological examination of the~     lesions excised.~   "|||2018-06-01 03:16:50.93998|2018-06-01 03:16:50.93998
NCT00464126|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2017-03-30|2007-04-19|2007-04-20|Estimate|||||||2017-03-30|2017-04-04|Actual|August 2006||2006-08-31|March 2017|2017-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation|The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation|Completed||N/A|32|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 03:16:51.028118|2018-06-01 03:16:51.028118
NCT00464113|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2015-08-19|2007-04-18|2007-04-20|Estimate|||||||2015-08-19|2015-08-21|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL)|Terminated||Phase 1|49|Actual|Exelixis||2||Sponsor decision|f||||t||||||||||2018-06-01 03:16:51.104514|2018-06-01 03:16:51.104514
NCT00464100|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2015-09-21|2007-04-18|2007-04-20|Estimate|||||||2015-09-21|2015-09-23|Estimate|August 2006||2006-08-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Observational|NIRS ND||Near-infrared Spectroscopy (NIRS) Neurodevelopmental Outcomes|Neurodevelopmental Outcomes and Postoperative Hemodynamics in Children With Hypoplastic Left Heart Syndrome|Unknown status|Active, not recruiting||48|Anticipated|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 03:16:51.176565|2018-06-01 03:16:51.176565
NCT00464087|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2013-04-16||2013-07-30|2007-04-19|2007-04-20|Estimate|2013-07-30|2013-08-01|Estimate||||2013-07-30|2013-08-01|Estimate|June 2007||2007-06-30|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|SWITCHIII||Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI|Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III|Completed||Phase 3|100|Actual|Medstar Health Research Institute|This trial included only small number of patients and is not powered to detect intergroup differences|2|||f||||t||||||||||2018-06-01 03:16:51.254423|2018-06-01 03:16:51.254423
NCT00464074|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2011-07-07|2007-04-19|2007-04-20|Estimate|||||||2011-07-07|2011-07-08|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|ENER-G||Evaluation of Natalizumab for thE Relief of MS Associated FatiGue|Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS|Completed|||200|Actual|Biogen|||||f||||f||||||||||2018-06-01 03:16:51.612816|2018-06-01 03:16:51.612816
NCT00464061|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19||2016-04-26|2016-04-26|2007-04-19|2007-04-20|Estimate||||2016-04-26|2016-05-26|Estimate|2016-04-26|2016-05-26|Estimate|April 2007||2007-04-30|April 2016|2016-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|SAMS||Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus|Efficacy and Safety of 2mg/Day of M100907 on Sleep Maintenance Insomnia With a Sub-study of the Effect of M100907 on Stable Type II Diabetes Mellitus: a One Year, Multi-center, Randomized, Double-blind, Placebo-controlled Study|Terminated||Phase 3|1847|Actual|Sanofi||2||"Sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary~   insomnia with predominant sleep maintenance problems"|f||||||||||||||2018-06-01 03:16:51.719021|2018-06-01 03:16:51.719021
NCT00464048|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|May 2007||2007-05-31|April 2007|2007-04-30|May 2009|Anticipated|2009-05-31|||||Interventional|||A Controlled Study to Assess the Effectiveness of Aerobic Exercise as an Augmentation Therapy for Inpatients With Major Depressive Disorder|A Controlled Study to Assess the Effectiveness of Aerobic Exercise as an Augmentation Therapy for Inpatients With Major Depressive Disorder|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:16:51.842867|2018-06-01 03:16:51.842867
NCT00464035|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2009-01-20|2007-04-19|2007-04-20|Estimate|||||||2009-01-20|2009-01-21|Estimate|February 2005||2005-02-28|December 2004|2004-12-31|October 2005||2005-10-31|||||Interventional|||The Effect of Calcium on Postprandial Lipid Profile and Appetite||Completed||N/A|18||University of Copenhagen|||||f||||||||||||||2018-06-01 03:16:51.910749|2018-06-01 03:16:51.910749
NCT00464022|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-10-16|2007-04-19|2007-04-20|Estimate|||||||2007-10-16|2007-10-17|Estimate|November 2006||2006-11-30|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|||CO2 Insufflation During Double Balloon Enteroscopy|Carbon Dioxide Versus Air Insufflation in Double-Balloon Endoscopy -a Randomised Controlled Multicentre Trial|Completed||Phase 4|100|Anticipated|Rikshospitalet University Hospital|||||f||||f||||||||||2018-06-01 03:16:51.970422|2018-06-01 03:16:51.970422
NCT00464009|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2010-01-28|2007-04-19|2007-04-20|Estimate|||||||2010-01-28|2010-01-29|Estimate|February 2001||2001-02-28|September 2009|2009-09-30|November 2007|Actual|2007-11-30|April 2002|Actual|2002-04-30||Interventional|IMB-RCT||Development and Evaluation of a Medical Intervention for Early Childhood Caries|Development and Evaluation of a Medical Intervention for Early Childhood Caries|Completed||N/A|120|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-06-01 03:16:52.030596|2018-06-01 03:16:52.030596
NCT00463996|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-04-18|2007-04-18|2007-04-20|Estimate|||||||2007-04-18|2007-04-20|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|April 2008|Anticipated|2008-04-30|||||Observational|||MRI in Staging Ovarian Cancer Using MRI Contrast Agent|Værdien af MRI Til Staging af c.Ovarii-et Prospektivt Studie|Unknown status|Not yet recruiting||50||University of Aarhus|||||f||||f||||||||||2018-06-01 03:16:52.106536|2018-06-01 03:16:52.106536
NCT00463983|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2012-09-20|2007-04-18|2007-04-20|Estimate|||||||2012-09-20|2012-09-21|Estimate|October 2006||2006-10-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2010|Actual|2010-01-31||Interventional|FIBROSAND||Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide|Phase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary Fibrosis|Completed||Phase 1/Phase 2|25|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-06-01 03:16:52.164121|2018-06-01 03:16:52.164121
NCT00463970|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2017-02-20|2007-04-19|2007-04-20|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2008||2008-02-29|February 2017|2017-02-28|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Interventional|CINS||Cognitive Interventions and Nutritional Supplementation for Patients With Long-lasting Back Pain|A Randomized Controlled Multicentre Trial of a Brief Intervention (BI) Versus a BI Plus Cognitive Behavioural Treatment (CBT) Versus Nutritional Supplementation for Patients With Long-lasting Back Pain.|Completed||Phase 1|414|Actual|Uni Research||4|||f||||t||||||||||2018-06-01 03:16:52.223792|2018-06-01 03:16:52.223792
NCT00463957|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2010-01-11|2007-04-19|2007-04-20|Estimate|||||||2010-01-11|2010-01-12|Estimate|August 2006||2006-08-31|April 2007|2007-04-30||||||||Interventional|||The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil|The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil|Unknown status|Active, not recruiting|N/A|12||University of Cambridge|||||f||||f||||||||||2018-06-01 03:16:52.349674|2018-06-01 03:16:52.349674
NCT00463944|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|January 2001||2001-01-31|June 2005|2005-06-30|December 2001||2001-12-31|||||Observational|||Assessment of an Electronic Voting System Within the Tutorial Setting. A Randomised Controlled Trial|Assessment of an Electronic Voting System Within the Tutorial Setting. A Randomised Controlled Trial|Completed|||130||University of Adelaide|||||f||||||||||||||2018-06-01 03:16:52.403717|2018-06-01 03:16:52.403717
NCT00463931|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Observational|||Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana|Using Community-Based Volunteers to Reach Non-Enrolled School-Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana|Completed|||916||DBL -Institute for Health Research and Development|||||f||||f||||||||||2018-06-01 03:16:52.452195|2018-06-01 03:16:52.452195
NCT00463918|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2008-11-18|2007-04-18|2007-04-20|Estimate|||||||2008-11-18|2008-11-19|Estimate|May 2007||2007-05-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|||||Interventional|||A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers|Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics, Safety and Tolerability of Varenicline in Healthy Adolescent Smokers|Completed||Phase 1|73|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:16:52.564797|2018-06-01 03:16:52.564797
NCT00463905|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2014-12-03|2007-04-19|2007-04-20|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2007||2007-10-31|December 2014|2014-12-31|August 2011|Actual|2011-08-31|June 2009|Actual|2009-06-30||Interventional|COSHIBA||Evaluation of the Impact of a Case-finding Strategy for Vertebral Fractures|Evaluation of the Impact of a Case-finding Strategy for Vertebral Fractures on Bisphosphonate and Other Drug Prescribing in Primary Care, Using the Cohort for Skeletal Health in Bristol and Avon (COSHIBA)|Completed||N/A|3200|Actual|University of Bristol||2|||f||||t||||||||||2018-06-01 03:16:52.647589|2018-06-01 03:16:52.647589
NCT00463892|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2014-11-08|2007-04-19|2007-04-20|Estimate|||||||2014-11-08|2014-11-11|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|November 2011|Actual|2011-11-30||Interventional|||High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes|A Phase II Study of High-resolution Contrast-enhanced MRI of Regional Lymph Nodes in Patients With Clinically Localized Invasive Melanoma|Completed||Phase 2|200|Anticipated|Redwood Regional Medical Group|||||f||||f||||||||||2018-06-01 03:16:52.730008|2018-06-01 03:16:52.730008
NCT00463879|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-12-11|2007-04-19|2007-04-20|Estimate|||||||2007-12-11|2007-12-12|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Galantamine for Cognitive Deficits in Schizophrenia|Galantamine for Cognitive Deficits in Schizophrenia|Completed||Phase 2/Phase 3|21|Actual|Yale University|||||f||||f||||||||||2018-06-01 03:16:52.793604|2018-06-01 03:16:52.793604
NCT00463866|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2009-12-22||2010-03-08|2007-04-19|2007-04-20|Estimate|2010-03-08|2010-03-22|Estimate||||2010-03-08|2010-03-22|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|||||Interventional|||Local Phase 4 Pan-European SMART Study||Completed||Phase 4|8424|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:16:52.976089|2018-06-01 03:16:52.976089
NCT00463853|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2014-06-10|2007-04-18|2007-04-20|Estimate|||||||2014-06-10|2014-06-11|Estimate|August 2007||2007-08-31|June 2014|2014-06-30|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|STAR||Stem Cell Therapy as Adjunct to Revascularization|Stem Cell Therapy as Adjunct to Revascularization: STAR|Withdrawn||Phase 1|0|Actual|VA Office of Research and Development||1||inability to recruit due to administrative difficulties at the site|f||||t||||||||||2018-06-01 03:16:54.980363|2018-06-01 03:16:54.980363
NCT00463840|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2012-03-05||2017-10-30|2007-04-18|2007-04-20|Estimate|2012-04-04|2012-05-01|Estimate||||2017-10-30|2017-12-05|Actual|June 2004||2004-06-30|October 2017|2017-10-31|October 2015|Actual|2015-10-31|July 2010|Actual|2010-07-31||Interventional|||Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer|A Phase I/II Study of Chemoradiation With Oxaliplatin and 5FU for Locally Advanced Pancreatic Cancer|Terminated||Phase 1/Phase 2|24|Actual|New York University School of Medicine|This study did not reach its target accrual due to slow accrual. Small number of patients were analyzed.|1||Due to slow accrual|f||||t||||||||||2018-06-01 03:16:55.048091|2018-06-01 03:16:55.048091
NCT00463827|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2017-03-27|2007-04-18|2007-04-20|Estimate|||||||2017-03-27|2017-03-28|Actual|August 2007||2007-08-31|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Statins on Asthma Control in Smokers With Asthma|Effect of Statins on Asthma Control and Airway Inflammation in Smokers With Asthma: a Randomised Controlled Double-blind Parallel Group Study|Completed||Phase 2|71|Actual|NHS Greater Clyde and Glasgow||2|||f||||t||||||||No||2018-06-01 03:16:55.341372|2018-06-01 03:16:55.341372
NCT00463814|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2018-05-18|2007-04-19|2007-04-20|Estimate|||||||2018-05-18|2018-05-21|Actual|March 8, 2007|Actual|2007-03-08|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 17, 2008|Actual|2008-06-17||Interventional|||AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies|A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies|Active, not recruiting||Phase 1|58|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 03:16:55.418613|2018-06-01 03:16:55.418613
NCT00463801|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2010-12-09||2011-03-22|2007-04-19|2007-04-20|Estimate|2010-12-09|2010-12-23|Estimate||||2011-03-22|2011-03-24|Estimate|January 2007||2007-01-31|March 2011|2011-03-31||||November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections|A Multicentre, Open Label, Uncontrolled Clinical Trial to Evaluate Efficacy and Safety of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections (cSSTI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)|Terminated||Phase 4|52|Actual|Novartis|Inadequate accrual caused the premature study termination and the insufficient sample size, therefore none of the planned study analyses were performed; nor were any tabulations with descriptive statistics were provided.|1||Because of inadequate accrual.|f||||||||||||||2018-06-01 03:16:55.507045|2018-06-01 03:16:55.507045
NCT00463788|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2012-06-05||2014-01-20|2007-04-19|2007-04-20|Estimate|2012-09-07|2012-10-10|Estimate||||2014-01-20|2014-02-13|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|February 2011|Actual|2011-02-28|July 2009|Actual|2009-07-31||Interventional|BALI-1||"Cetuximab and Cisplatin in the Treatment of Triple Negative (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer"|"Randomized Phase II Trial With Cetuximab and Cisplatin in the Treatment of ER-negative, PgR-negative, HER2-negative Metastatic Breast Carcinoma (Basal Like)"|Completed||Phase 2|181|Actual|Merck KGaA|Participants were randomized to 2 groups in a 2:1 ratio.|2|||f||||f||||||||||2018-06-01 03:16:55.655606|2018-06-01 03:16:55.655606
NCT00463775|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2012-01-26|2007-04-19|2007-04-20|Estimate|||||||2012-01-26|2012-01-31|Estimate|March 2007||2007-03-31|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence|Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence|Withdrawn||Phase 3|0|Actual|Yale University||||Recruitment not progressing as planned.|f||||f||||||||||2018-06-01 03:16:56.664054|2018-06-01 03:16:56.664054
NCT00463762|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2011-04-21|2007-04-19|2007-04-20|Estimate|||||||2011-04-21|2011-04-22|Estimate|May 2007||2007-05-31|April 2011|2011-04-30||||||||Observational|||Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.|Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.|Withdrawn|||0|Actual|Pfizer|||||||||||||||||||2018-06-01 03:16:56.723412|2018-06-01 03:16:56.723412
NCT00463749|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2008-07-07|2007-04-18|2007-04-20|Estimate|||||||2008-07-07|2008-07-08|Estimate|December 2006||2006-12-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|LIPSIA-N-ACC||Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein|Trial to Compare Infarct Size and Occurrence of Contrast Dye Induced Nephropathy in Patients With Primary Percutaneous PCI in STEMI|Completed||Phase 3|251|Actual|University of Leipzig||2|||f||||t||||||||||2018-06-01 03:16:56.771355|2018-06-01 03:16:56.771355
NCT00463736|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2016-08-17|2007-04-19|2007-04-20|Estimate|||||||2016-08-17|2016-08-19|Estimate|April 2007||2007-04-30|August 2016|2016-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Magnesium Sulfate Versus Placebo for Tocolysis in PPROM|Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes|Terminated||N/A|4|Actual|Regional Obstetrical Consultants||2||enrollment proceeding too slowly|f||||t||||||||Undecided||2018-06-01 03:16:56.837121|2018-06-01 03:16:56.837121
NCT00463723|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-04-18|2007-04-18|2007-04-20|Estimate|||||||2007-04-18|2007-04-20|Estimate||||August 1999|1999-08-31||||||||Interventional|||Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty||Terminated||Phase 2/Phase 3|||University Hospital Freiburg|||||f||||f||||||||||2018-06-01 03:16:56.904804|2018-06-01 03:16:56.904804
NCT00463710|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|June 2005||2005-06-30|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Observational|||Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS|Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis|Completed|||150||State University of New York at Buffalo|||||f||||f||||||||||2018-06-01 03:16:56.962114|2018-06-01 03:16:56.962114
NCT00463697|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2017-08-03|2007-04-18|2007-04-20|Estimate|||||||2017-08-03|2017-08-07|Actual|April 2, 2007|Actual|2007-04-02|August 2017|2017-08-31|August 4, 2007|Actual|2007-08-04|August 4, 2007|Actual|2007-08-04||Interventional|||A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients|A Randomized, Single-dose, Dose-ascending, Double Blind, Placebo-controlled, 5-way Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With Magnesium Stearate in Asthmatic Patients|Completed||Phase 1|20|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:16:57.019021|2018-06-01 03:16:57.019021
NCT00463684|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2009-05-04|2007-04-18|2007-04-20|Estimate|||||||2009-05-04|2009-05-06|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional|JEV03||Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age|Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka|Completed||Phase 3|277|Anticipated|PATH|||||f||||f||||||||||2018-06-01 03:16:57.110118|2018-06-01 03:16:57.110118
NCT00463671|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2008-10-16|2007-04-18|2007-04-20|Estimate|||||||2008-10-16|2008-10-17|Estimate|December 2003||2003-12-31|May 2007|2007-05-31|September 2005|Actual|2005-09-30|||||Interventional|||Hyperbaric Oxygen, Oxidative Stress, NO Bioavailability and Tissue Oxygenation|The Relation Between Hyperbaric Oxygen, Oxidative Stress, NO Bioavailability and Tissue Oxygenation in Diabetic Patients Suffering From Foot Ulcers|Completed||N/A|50||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:16:57.249479|2018-06-01 03:16:57.249479
NCT00463658|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2008-05-05|2007-04-18|2007-04-20|Estimate|||||||2008-05-05|2008-05-07|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Interdisciplinary Falls Prevention for Seniors|The Comparative Effects and Expenses of a Proactive Nurse-Led, Multifactorial and Interdisciplinary Team Approach to Falls Prevention for Older At-Risk Home Care Clients|Completed||Phase 1|109|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 03:16:57.301754|2018-06-01 03:16:57.301754
NCT00463645|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-06-05|2007-04-19|2007-04-20|Estimate|||||||2007-06-05|2007-06-06|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|January 2006|Actual|2006-01-31|||||Observational|||Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients|An Open, Mono-Centre Trial to Investigate the Correlation Between the Interstitial and Arterial Blood Concentrations of Glucose During Subcutaneous Glucose Monitoring in Patients With Severe Sepsis at the Medical Intensive Care Unit|Completed|||10||Medical University of Graz|||||f||||f||||||||||2018-06-01 03:16:57.368748|2018-06-01 03:16:57.368748
NCT00463632|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2010-01-11|2007-04-19|2007-04-20|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2007||2007-01-31|January 2010|2010-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control|Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control|Completed|||200|Anticipated|DBL -Institute for Health Research and Development|||||f||||f||||||None Retained|"~     urine faeces blood~   "|||2018-06-01 03:16:57.414269|2018-06-01 03:16:57.414269
NCT00463619|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2011-08-15|2007-04-18|2007-04-20|Estimate|||||||2011-08-15|2011-08-16|Estimate|April 2000||2000-04-30|April 2010|2010-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Follow-up Study With Retarded Release Phosphatidylcholine in Ulcerative Colitis||Completed|||132|Actual|Heidelberg University|||||f||||f||||||||||2018-06-01 03:16:57.464104|2018-06-01 03:16:57.464104
NCT00463606|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2012-04-25|2010-08-27|2012-09-27|2007-04-19|2007-04-20|Estimate|2012-06-13|2012-08-01|Estimate|2010-09-13|2010-09-15|Estimate|2012-09-27|2012-10-03|Estimate|April 2007||2007-04-30|September 2012|2012-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia|A 12-week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to ABT-335 and Rosuvastatin Monotherapy in Subjects With Type IIa and IIb Dyslipidemia|Completed||Phase 3|760|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 03:16:57.553926|2018-06-01 03:16:57.553926
NCT00463593|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2008-01-23|2007-04-19|2007-04-20|Estimate|||||||2008-01-23|2008-01-25|Estimate|December 2006||2006-12-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|||||Observational|||Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes|Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control|Completed|||1293|Actual|DBL -Institute for Health Research and Development|||1||f||||f||||||None Retained|"~     faeces blood~   "|||2018-06-01 03:16:59.225804|2018-06-01 03:16:59.225804
NCT00463580|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2013-08-13||2018-02-28|2007-04-19|2007-04-20|Estimate|2014-04-14|2014-05-12|Estimate||||2018-02-28|2018-03-29|Actual|November 2008||2008-11-30|February 2018|2018-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Infliximab||A Study of Infliximab for Treatment Resistant Major Depression|An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators|Completed||Phase 4|60|Actual|Emory University|Our study was underpowered to adequately test placebo response typically reported for TRD. Also, no direct measures of the effect of either infliximab or placebo on the CNS were obtained.|2|||f||||t||||||||||2018-06-01 03:16:59.33475|2018-06-01 03:16:59.33475
NCT00463567|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2011-07-22||2011-07-22|2007-04-19|2007-04-20|Estimate|2011-07-22|2011-08-18|Estimate||||2011-07-22|2011-08-18|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 26-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (Selected From 75, 150, 300 & 600 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease Using Blinded Formoterol (12 µg b.i.d.) and Open Label Tiotropium (18 µg o.d.) as Active Controls|Completed||Phase 2/Phase 3|2059|Actual|Novartis||7|||f||||||||||||||2018-06-01 03:16:59.959075|2018-06-01 03:16:59.959075
NCT00463554|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2009-01-26|2007-04-18|2007-04-20|Estimate|||||||2009-01-26|2009-01-27|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|December 2007|Actual|2007-12-31|January 2007|Actual|2007-01-31||Observational|||TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence|An Evaluation of the GYNECARE TVT-SECUR* System (Tension-Free Support for Incontinence) for the Treatment of Stress Urinary Incontinence *Trademark|Completed|||72|Actual|Ethicon, Inc.|||||f||||f||||||||||2018-06-01 03:17:02.156661|2018-06-01 03:17:02.156661
NCT00463541|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2014-09-17|2007-04-19|2007-04-20|Estimate|||||||2014-09-17|2014-09-18|Estimate|June 2004||2004-06-30|September 2014|2014-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|VOLT||Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms|An Open-label Study of the Efficacy and Safety of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients With Overactive Bladder Symptoms VOLT: VESIcare® Open-Label Trial|Completed||Phase 3|2225|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 03:17:02.390448|2018-06-01 03:17:02.390448
NCT00463528|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-07-02|2007-04-19|2007-04-20|Estimate|||||||2007-07-02|2007-07-03|Estimate|December 2006||2006-12-31|July 2007|2007-07-31|February 2007|Actual|2007-02-28|||||Observational|||Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso|Women and Childres at the Focal Point for the Schistosomiasis Control and Sustainability and Effectiveness in the Hydro Agricultural Zone of Sourou, Burkina Faso|Completed|||360|Actual|DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 03:17:02.782354|2018-06-01 03:17:02.782354
NCT00463515|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-07-11|2007-04-19|2007-04-20|Estimate|||||||2013-07-11|2013-07-12|Estimate|January 2003||2003-01-31|July 2013|2013-07-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|CHER@NOS||Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC|A Multicenter Phase II Study of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation in Patients With Non-resectable Stage III Non-Small-Cell-Lung Cancer|Completed||Phase 2|77||University Hospital, Antwerp|||||f||||||||||||||2018-06-01 03:17:02.998902|2018-06-01 03:17:02.998902
NCT00463502|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate||||March 2007|2007-03-31||||||||Interventional|||The Effect of Metformin Treatment on Thyroid Hormone Metabolism in Euthyroid Patients With Type 2 Diabetes Mellitus||Completed||Phase 4|||Haydarpasa Numune State Hospital|||||f||||f||||||||||2018-06-01 03:17:03.089128|2018-06-01 03:17:03.089128
NCT00463489|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2018-03-22|2007-04-19|2007-04-20|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2007||2007-08-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|LISA||Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer|Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer|Active, not recruiting||Phase 3|2150|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||f||||||||||2018-06-01 03:17:03.158549|2018-06-01 03:17:03.158549
NCT00463476|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2009-05-04|2007-04-18|2007-04-20|Estimate|||||||2009-05-04|2009-05-06|Estimate|July 2007||2007-07-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional|||Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine|Assessment of the Immunogenicity and Safety of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine in Children in Sri Lanka|Completed||Phase 3|306|Anticipated|PATH|||||f||||f||||||||||2018-06-01 03:17:03.313441|2018-06-01 03:17:03.313441
NCT00463463|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2012-07-11|2007-04-19|2007-04-20|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2007||2007-04-30|February 2007|2007-02-28||||||||Interventional|Zevalin||Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma|Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma|Unknown status|Recruiting|Phase 3|||Soroka University Medical Center|||||f||||f||||||||||2018-06-01 03:17:03.443713|2018-06-01 03:17:03.443713
NCT00463450|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2014-12-28|2007-04-19|2007-04-20|Estimate|||||||2014-12-28|2014-12-30|Estimate|May 2002||2002-05-31|December 2014|2014-12-31|April 2004|Actual|2004-04-30|||||Interventional|||Efficacy of Gynodian® Depot in Women With Impaired Well-being|A Multicenter, Double-blind, Randomized, Cross-over Study to Investigate the Efficacy of Gynodian® Depot i.m. Compared to 4 mg Estradiol Valerate i.m. Both Given Every Four Weeks for Five Months Combined With 5 mg Medroxyprogesterone Acetate Orally in Postmeno-pausal Women With Impaired Well-being, Mood and Sexuality|Completed||Phase 3|140|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:17:03.903642|2018-06-01 03:17:03.903642
NCT00463437|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2009-06-11||2016-10-27|2007-04-19|2007-04-20|Estimate|2009-06-11|2009-08-03|Estimate||||2016-10-27|2016-12-09|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines|Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines|Completed||Phase 3|1437|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:17:04.270494|2018-06-01 03:17:04.270494
NCT00463424|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|October 2000||2000-10-31|April 2007|2007-04-30|August 2005|Actual|2005-08-31|||||Interventional|||Comparison of NeuFlex and Swanson Metacarpophalangeal Implants for Rheumatoid Arthritis|NeuFlex and Swanson Metacarpophalangeal Implants for Rheumatoid Arthritis: a Prospective Randomized Controlled Clinical Trial|Completed||Phase 2|40||St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-06-01 03:17:05.798507|2018-06-01 03:17:05.798507
NCT00463411|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|December 2017|Anticipated|2017-12-31|||||Observational|||Study of Male Osteoporosis and Aging|Study on Male Osteoporosis and Aging|Unknown status|Recruiting||30000||Odense University Hospital|||||f||||||||||||||2018-06-01 03:17:05.950775|2018-06-01 03:17:05.950775
NCT00463398|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2010-08-31|2007-04-18|2007-04-20|Estimate|||||||2010-08-31|2010-09-01|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Observational|||Fertility Surgery, Prospective Analysis|Quality Control in Surgical Diagnosis and Treatment of Endometriosis.|Unknown status|Recruiting||600|Anticipated|University Hospital, Gasthuisberg|||1||f||||f||||||Samples Without DNA|"~     Endometriosis is confirmed by histologic examination of excised lesions~   "|||2018-06-01 03:17:06.03946|2018-06-01 03:17:06.03946
NCT00463385|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|2013-03-07|2011-01-04|2015-06-04|2007-04-19|2007-04-20|Estimate|2013-08-21|2013-10-28|Estimate|2012-04-11|2012-04-13|Estimate|2015-06-04|2015-07-03|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|May 2009|Actual|2009-05-31||Interventional|||A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia|A Phase 2, Prospective, Randomized, Multicenter, Double-blind, Active-control, Parallel-group Study to Determine the Safety of and to Select a Treatment Regimen of CC-4047 (Pomalidomide) Either as Single-agent or in Combination With Prednisone to Study Further in Subjects With Myelofibrosis With Myeloid Metaplasia|Completed||Phase 2|88|Actual|Celgene||4|||f||||t||||||||||2018-06-01 03:17:06.30714|2018-06-01 03:17:06.30714
NCT00463372|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-09-17|2007-04-19|2007-04-20|Estimate|||||||2007-09-17|2007-09-18|Estimate|October 2006||2006-10-31|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia|A Phase I, Investigator And Subject-Blind (Sponsor Unblinded), Placebo-Controlled Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-02545920 After Multiple Oral Dose Administration In Subjects With Stable Schizophrenia|Completed||Phase 1|40||Pfizer|||||f||||||||||||||2018-06-01 03:17:07.97205|2018-06-01 03:17:07.97205
NCT00463359|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate||||April 2007|2007-04-30||||||||Interventional|||A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base|A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base|Unknown status|Not yet recruiting|N/A|50||University of Glasgow|||||f||||t||||||||||2018-06-01 03:17:08.040896|2018-06-01 03:17:08.040896
NCT00463346|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2015-10-19||2015-12-11|2007-04-19|2007-04-20|Estimate|2015-12-11|2016-01-15|Estimate||||2015-12-11|2016-01-15|Estimate|September 2006||2006-09-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Individuals with schizophrenia, schizoaffective or psychotic disorder not otherwise specified and current alcohol dependence|Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism|Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism|Completed||Phase 3|23|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:17:08.119964|2018-06-01 03:17:08.119964
NCT00463333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|May 2005||2005-05-31|April 2007|2007-04-30||||||||Observational|||Postoperative Delirium at Heidelberg's Intensive Care Unit -New Diagnostic Markers||Completed|||||Heidelberg University|||||f||||f||||||||||2018-06-01 03:17:08.329897|2018-06-01 03:17:08.329897
NCT00462410|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2012-01-20|2007-04-18|2007-04-19|Estimate|||||||2012-01-20|2012-01-23|Estimate|March 2006||2006-03-31|May 2011|2011-05-31||||May 2011|Actual|2011-05-31||Interventional|||Effect of Advertisements on Treatment Compliance in Women With Breast Cancer|Socio-anthropological Study Evaluating the Impact of Observance or Treatment in Patients With Breast Cancer|Completed||N/A|65|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:23.813859|2018-06-01 03:17:23.813859
NCT00463320|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2012-03-15|2007-04-18|2007-04-20|Estimate|||||||2012-03-15|2012-03-19|Estimate|March 2007||2007-03-31|February 2011|2011-02-28|August 2007|Actual|2007-08-31|||||Interventional|||A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.|A Placebo-controlled, Randomized, Dose Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Ocular Doses of Pazopanib in Healthy Adult and Elderly Subjects.|Completed||Phase 1|29|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:17:08.385368|2018-06-01 03:17:08.385368
NCT00463307|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-10-30|2007-04-19|2007-04-20|Estimate|||||||2007-10-30|2007-10-31|Estimate|April 2006||2006-04-30|October 2007|2007-10-31|November 2006|Actual|2006-11-30|||||Observational|||Evaluation of the Use of a Urin Test Strip to Determine the Spread of Schistosoma Infections in Areas Where Schistosomiasis Infections Are Low in Kenya|Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya|Completed|||1100|Actual|DBL -Institute for Health Research and Development|||||f||||f||||||||||2018-06-01 03:17:08.442513|2018-06-01 03:17:08.442513
NCT00463294|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2016-09-15|2007-04-19|2007-04-20|Estimate|||||||2016-09-15|2016-09-16|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|March 2012|Actual|2012-03-31||Interventional|CORONARY||Coronary Artery Bypass Surgery (CABG) Off or On Pump Revascularization Study|CABG Off or On Pump Revascularization Study (CORONARY)|Completed||Phase 3|4752|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-06-01 03:17:08.517879|2018-06-01 03:17:08.517879
NCT00463281|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2009-05-13|2007-04-19|2007-04-20|Estimate|||||||2009-05-13|2009-05-14|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Observational|CT-DEFINE||CT Based Definition of a Tissue Window for Acute Stroke Thrombolysis|Observational Study of Multimodal CT in Acute Ischemic Stroke to Define a Tissue Window for Thrombolysis|Completed|||100|Anticipated|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 03:17:08.646089|2018-06-01 03:17:08.646089
NCT00463268|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2013-05-28|2007-04-19|2007-04-20|Estimate|||||||2013-05-28|2013-05-29|Estimate|September 2007||2007-09-30|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Osteoporosis Prevention With Low Dose Alendronate|Prevention of Postmenopausal Bone Loss in Osteopenic Women With Alendronate Given on a 70 mg Once-every Two Week Regimen: a 2-year, Double-blind, Placebo-controlled Clinical Trial.|Completed||Phase 3|83|Actual|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-06-01 03:17:08.707103|2018-06-01 03:17:08.707103
NCT00463255|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2011-11-07|2007-04-19|2007-04-20|Estimate|||||||2011-11-07|2011-11-08|Estimate|August 2006||2006-08-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|||||Interventional|||Diet and the Aging Brain|Phase IV Interventional Study: Effect of Diet on Brain Function in Elderly Healthy People|Completed||Phase 3|120|Anticipated|University Hospital Muenster|||||f||||t||||||||||2018-06-01 03:17:08.918818|2018-06-01 03:17:08.918818
NCT00463242|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19||2012-05-02|2012-05-02|2007-04-19|2007-04-20|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|March 2007||2007-03-31|May 2012|2012-05-31||||June 2008|Actual|2008-06-30||Interventional|||A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)|An 8-week, Multicenter, Randomized, Double-blind, Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine 25 or 50 mg Given Once Daily in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week Open-label Treatment With Agomelatine 25 or 50 mg|Completed||Phase 3|501|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:17:08.992625|2018-06-01 03:17:08.992625
NCT00463229|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2010-07-22||2010-09-28|2007-04-18|2007-04-20|Estimate|2010-09-28|2010-10-15|Estimate||||2010-09-28|2010-10-15|Estimate|February 2006||2006-02-28|August 2010|2010-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Interdisciplinary Team Approach to Stroke Rehabilitation in Home Care|The Comparative Acceptability, Safety, Effects and Expense of Specialized, Integrated, and Interdisciplinary Community Rehabilitation for Stroke Survivors and Their Caregivers|Completed||Phase 1|101|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 03:17:09.139086|2018-06-01 03:17:09.139086
NCT00463216|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2010-02-05|2007-04-18|2007-04-20|Estimate|||||||2010-02-05|2010-02-08|Estimate|April 2004||2004-04-30|March 2007|2007-03-31|April 2006||2006-04-30|||||Interventional|||A Coordinated Return to Work Program|A Coordinated Return to Work Program for Workers on Long-term Sickness Absence Due to Musculoskeletal Disorders: a Prospective Controlled Intervention Study|Completed||N/A|120||Vejle Hospital|||||f||||f||||||||||2018-06-01 03:17:09.46059|2018-06-01 03:17:09.46059
NCT00463203|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2011-06-27|2007-04-19|2007-04-20|Estimate|||||||2011-06-27|2011-06-29|Estimate|March 2007||2007-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy||Completed||Phase 2|54|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 03:17:09.584399|2018-06-01 03:17:09.584399
NCT00463190|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2008-09-18|2007-04-18|2007-04-20|Estimate|||||||2008-09-18|2008-09-19|Estimate|February 2006||2006-02-28|April 2007|2007-04-30|November 2007|Actual|2007-11-30|||||Interventional|||Effect of Probiotics (Bio-Three) in Children's Enterocolitis|Postmarketing Study of Probiotics Medication in Childhood Diarrhea|Completed||Phase 4|300|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||||||2018-06-01 03:17:09.647204|2018-06-01 03:17:09.647204
NCT00463177|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2008-09-03|2007-04-19|2007-04-20|Estimate|||||||2008-09-03|2008-09-04|Estimate|March 2007||2007-03-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Augmented Cerebral Pain Processing in Chronic, Unexplained Pain: a fMRI Study|Augmented Cerebral Pain Processing in Chronic, Unexplained Pain: a 3T Event-Related Functional MRI Study|Completed|||24|Actual|UMC Utrecht|||||f||||f||||||||||2018-06-01 03:17:09.705287|2018-06-01 03:17:09.705287
NCT00463164|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|December 2007||2007-12-31|April 2007|2007-04-30||||||||Observational|||Functional MRI of Cognitive Control in Autism|Functional MRI of Cognitive Control in Autism|Unknown status|Not yet recruiting||90||UMC Utrecht|||||f||||f||||||||||2018-06-01 03:17:09.757769|2018-06-01 03:17:09.757769
NCT00463151|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2011-02-09|2007-04-19|2007-04-20|Estimate|||||||2011-02-09|2011-02-10|Estimate|June 2007||2007-06-30|February 2011|2011-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis|An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis|Completed||Phase 2|120|Anticipated|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 03:17:09.819326|2018-06-01 03:17:09.819326
NCT00463138|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2013-09-03|2007-04-19|2007-04-20|Estimate|||||||2013-09-03|2013-09-04|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Follow-up Study on Recipients of Treatment at the Jerusalem Center for the Treatment of Psychotrauma|Follow-up Study on Recipients of Treatment at the Jerusalem Center for the Treatment of Psychotrauma|Completed|||100|Actual|Herzog Hospital|||||f||||t||||||||||2018-06-01 03:17:09.901416|2018-06-01 03:17:09.901416
NCT00463112|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2007-04-19|2007-04-19|2007-04-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|March 2004||2004-03-31|December 2003|2003-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS|Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS: a Randomized, 24-Week Study|Completed||Phase 4|80||Hippocration General Hospital|||||f||||f||||||||||2018-06-01 03:17:10.009469|2018-06-01 03:17:10.009469
NCT00463099|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2017-11-28|2007-04-19|2007-04-20|Estimate|||||||2017-11-28|2017-11-30|Actual|January 2002||2002-01-31|November 2017|2017-11-30|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Observational|||Multicenter Orthopaedics Outcomes Network for ACL Reconstructions|Prognosis and Predictors of ACL Reconstruction - A Multicenter Cohort Study|Active, not recruiting|||5000|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||No||2018-06-01 03:17:10.068523|2018-06-01 03:17:10.068523
NCT00463086|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2012-07-16|2007-04-19|2007-04-20|Estimate|||||||2012-07-16|2012-07-17|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|HAART-IPT||Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons|A Randomized-controlled Trial of Isoniazid Plus Highly Active Antiretroviral Therapy Against Placebo to Prevent Tuberculosis in HIV-infected Persons|Completed||N/A|1368|Actual|University of Cape Town||2|||f||||t||||||||||2018-06-01 03:17:10.149825|2018-06-01 03:17:10.149825
NCT00463073|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-19|||2008-12-10|2007-04-19|2007-04-20|Estimate|||||||2008-12-10|2008-12-11|Estimate|August 2006||2006-08-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas|A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide|Completed||Phase 2|32|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 03:17:10.469485|2018-06-01 03:17:10.469485
NCT00463060|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2008-06-17|2007-04-18|2007-04-19|Estimate|||||||2008-06-17|2008-06-19|Estimate|January 2007||2007-01-31|June 2008|2008-06-30||||||||Interventional|||Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer|Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease|Unknown status|Recruiting|Phase 1/Phase 2|65|Anticipated|Icahn School of Medicine at Mount Sinai|||||f||||t||||||||||2018-06-01 03:17:10.544349|2018-06-01 03:17:10.544349
NCT00463047|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2010-02-26||2012-05-22|2007-04-17|2007-04-19|Estimate|2010-11-16|2010-12-14|Estimate||||2012-05-22|2012-05-28|Estimate|July 2007||2007-07-31|May 2012|2012-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy and Safety of Fentanyl Buccal Tablets Compared With Oxycodone for the Management of Break Through Pain|A Randomized, Double-Blind, Active-Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Compared With Immediate-release Oxycodone for the Management of Breakthrough Pain in Opioid-Tolerant Patient With Chronic Pain|Completed||Phase 3|323|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 03:17:10.714186|2018-06-01 03:17:10.714186
NCT00463034|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-12-17|2007-04-18|2007-04-19|Estimate|||||||2013-12-17|2013-12-18|Estimate|April 2005||2005-04-30|November 2008|2008-11-30||||March 2008|Anticipated|2008-03-31||Observational|||Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer|Genetic Factors Affecting Breast Cancer Progression|Unknown status|Active, not recruiting||1800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:11.808218|2018-06-01 03:17:11.808218
NCT00463021|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2015-05-04|2007-04-18|2007-04-19|Estimate|||||||2015-05-04|2015-05-05|Estimate|April 2007||2007-04-30|May 2015|2015-05-31|December 2007|Actual|2007-12-31|||||Interventional|||A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection|A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis.|Completed||Phase 4|36|Anticipated|Sanofi|||||||||||||||||||2018-06-01 03:17:11.868707|2018-06-01 03:17:11.868707
NCT00463008|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-06-21|2007-04-18|2007-04-19|Estimate|||||||2013-06-21|2013-06-24|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma|A Pharmacokinetic Study of Methotrexate Using an Intratumoral Microdialysis Catheter|Completed||N/A|12|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:11.957371|2018-06-01 03:17:11.957371
NCT00462995|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2018-02-21|2007-04-18|2007-04-19|Estimate|||||||2018-02-21|2018-02-23|Actual|May 2006||2006-05-31|February 2018|2018-02-28|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|SELECT||Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)|Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial|Completed||Phase 2|25|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 03:17:12.038879|2018-06-01 03:17:12.038879
NCT00462982|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2015-10-21||2015-11-24|2007-04-18|2007-04-19|Estimate|2015-11-24|2015-12-30|Estimate||||2015-11-24|2015-12-30|Estimate|March 2007||2007-03-31|November 2015|2015-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma|A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain|Completed||Phase 2|8|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:17:12.145463|2018-06-01 03:17:12.145463
NCT00462969|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-01-30|2007-04-18|2007-04-19|Estimate|||||||2015-01-30|2015-02-02|Estimate|April 2007||2007-04-30|January 2015|2015-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Cytologic Analysis of Distention Media as a Screening Test for Endometrial Cancer|Cytologic Analysis of Distention Media as a Screening Test for Endometrial Cancer|Completed||N/A|40|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 03:17:12.451405|2018-06-01 03:17:12.451405
NCT00462956|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2017-11-08|2007-04-17|2007-04-19|Estimate|||||||2017-11-08|2017-11-13|Actual|June 30, 2004|Actual|2004-06-30|November 2017|2017-11-30|December 20, 2006|Actual|2006-12-20|December 20, 2006|Actual|2006-12-20||Interventional|||GW572016 In Patients With Advanced Or Metastatic Breast Cancer|Phase II Clinical Study of GW572016 in Patients With Advanced or Metastatic Breast Cancer|Completed||Phase 1|59|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:17:12.526158|2018-06-01 03:17:12.526158
NCT00462761|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-10-29|2007-04-17|2007-04-19|Estimate|||||||2015-10-29|2015-11-02|Estimate|January 2007||2007-01-31|October 2015|2015-10-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status|Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 1|76|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 03:17:17.710722|2018-06-01 03:17:17.710722
NCT00462943|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2014-05-05|2012-05-03|2014-06-27|2007-04-17|2007-04-19|Estimate|2014-06-27|2014-06-30|Estimate|2012-05-03|2012-05-08|Estimate|2014-06-27|2014-06-30|Estimate|March 2007||2007-03-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|December 2010|Actual|2010-12-31||Interventional||Intent to Treat Population: all participants who provided written informed consent and received at least 1 dose of study drug constitute the ITT population.|Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML|A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy|Completed||Phase 2|100|Actual|Teva Pharmaceutical Industries||1|||f||||t||||||||||2018-06-01 03:17:12.681943|2018-06-01 03:17:12.681943
NCT00462917|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2014-08-21||2014-09-09|2007-04-17|2007-04-19|Estimate|2014-09-09|2014-09-11|Estimate||||2014-09-09|2014-09-11|Estimate|March 2007||2007-03-31|September 2014|2014-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|REVEAL|Baseline population includes all participants who received genetic risk information, regardless of whether they completed follow-up time surveys.|REVEAL III: Risk Evaluation and Education for Alzheimer's Disease|Risk Evaluation and Education for Alzheimer's Disease|Completed||N/A|290|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-06-01 03:17:13.940757|2018-06-01 03:17:13.940757
NCT00462904|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2008-06-02|2007-04-17|2007-04-19|Estimate|||||||2008-06-02|2008-06-04|Estimate|April 2006||2006-04-30|April 2007|2007-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pharmacokinetic Response to BPI in Burns|Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-Increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury.|Completed||Phase 2|6|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:17:14.446537|2018-06-01 03:17:14.446537
NCT00462891|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-05-18|2007-04-18|2007-04-19|Estimate|||||||2013-05-18|2013-05-21|Estimate|March 2007||2007-03-31|May 2013|2013-05-31||||March 2008|Actual|2008-03-31||Interventional|||A Mammography FastTrack Program in Increasing the Number of Women Undergoing Breast Cancer Screening|Breast Cancer Screening and Follow-Up in a PBRN: The Mammography FastTrack Trial|Completed||N/A|6730|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:17:14.56827|2018-06-01 03:17:14.56827
NCT00462878|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2009-05-11|2007-04-18|2007-04-19|Estimate|||||||2009-05-11|2009-05-12|Estimate|November 2002||2002-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|||||Observational|MERONEM||Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation|MERONEM: Observational Study About Efficacy of Meropenem in Comparison of Meropenem and Glycopeptide in Treatment of Neutropenia Febrile in Allogenic Blood Stem Cell Transplantation Patients|Completed|||392|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:17:14.665113|2018-06-01 03:17:14.665113
NCT00462865|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2013-11-14||2015-04-07|2007-04-18|2007-04-19|Estimate|2015-04-07|2015-04-08|Estimate||||2015-04-07|2015-04-08|Estimate|November 2007||2007-11-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|March 2012|Actual|2012-03-31||Interventional|||Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse|A Phase II Study of Adjuvant Gemcitabine/Capecitabine and Bevacizumab for Patients Treated Neoadjuvantly Chemotherapy for Early Stage Breast Cancer With High Risk for Relapse|Terminated||Phase 2|18|Actual|Brown University||1||DSMB determined toxicity of regimen more than originally thought. Slow accrual.|f||||t||||||||||2018-06-01 03:17:14.907045|2018-06-01 03:17:14.907045
NCT00462852|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-08-09|2007-04-18|2007-04-19|Estimate|||||||2013-08-09|2013-08-12|Estimate|April 2003||2003-04-30|April 2007|2007-04-30|November 2011|Actual|2011-11-30|||||Interventional|||Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]|Completed||Phase 2|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:15.417044|2018-06-01 03:17:15.417044
NCT00462839|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2011-06-22||2014-03-17|2007-04-18|2007-04-19|Estimate|2011-11-06|2011-12-09|Estimate||||2014-03-17|2014-04-14|Estimate|July 2006||2006-07-31|March 2014|2014-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Accuracy of Blood Loss Estimation After Vaginal Delivery|The Accuracy of Blood Loss Estimation After Simulated Vaginal Delivery|Completed||N/A|106|Actual|Northwestern University|A limitation to our study is that we asked participants to estimate blood loss based on inspection of the conical drape only. We did not ask them to estimate blood loss in hidden places. In addition, this was not an actual delivery but a simulation.|2|||f||||f||||||||||2018-06-01 03:17:15.550914|2018-06-01 03:17:15.550914
NCT00462826|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2013-07-09||2018-03-27|2007-04-18|2007-04-19|Estimate|2013-07-09|2013-09-16|Estimate||||2018-03-27|2018-04-25|Actual|November 2007||2007-11-30|March 2018|2018-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Number of Eligible and Evaluable Participants|VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of VEGF-Trap (AFLIBERCEPT, NSC #724770, NCI-Supplied Agent) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|49|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:17:16.013585|2018-06-01 03:17:16.013585
NCT00462813|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-08-06|2007-04-18|2007-04-19|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|January 2010|Actual|2010-01-31|June 2008|Actual|2008-06-30||Interventional|||Diindolylmethane in Treating Patients With Abnormal Cervical Cells|An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1]|Completed||Phase 3|3000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:17.467151|2018-06-01 03:17:17.467151
NCT00462787|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-11-13|2007-04-18|2007-04-19|Estimate|||||||2013-11-13|2013-11-14|Estimate|April 2007||2007-04-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia|A Phase I Dose Escalation Trial of Clofarabine in Addition to Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients With Relapsed or Refractory Acute Leukemia|Completed||Phase 1|23|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:17:17.547044|2018-06-01 03:17:17.547044
NCT00462774|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-01-15|2007-04-18|2007-04-19|Estimate|||||||2013-01-15|2013-01-16|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Cardio133||Bypass Surgery and CD133 Marrow Cell Injection for Treatment of Ischemic Heart Failure|Evaluierung Eines Therapiemodells Der Autologen Knochenmark-Transplantation Bei Herzerkrankungen Mit Besonderem Schwerpunkt Der Prüfung Verschiedener Progenitorzellen|Completed||Phase 2/Phase 3|60|Actual|German Heart Institute|||||f||||t||||||||||2018-06-01 03:17:17.636124|2018-06-01 03:17:17.636124
NCT00018330|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|December 2004|2004-12-31|March 2004||2004-03-31|||||Interventional|||Genetics, Metabolism and Weight Loss in Older, Obese Veterans|Genetics, Metabolism and Weight Loss in Older, Obese Veterans|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.081142|2018-06-01 05:36:49.081142
NCT00462748|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2009-05-07||2017-03-17|2007-04-18|2007-04-19|Estimate|2009-07-06|2009-08-17|Estimate||||2017-03-17|2017-04-14|Actual|March 2007||2007-03-31|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)|A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C <2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/l|Completed||Phase 3|786|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:17:17.792249|2018-06-01 03:17:17.792249
NCT00462735|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2016-12-23||2018-02-13|2007-04-18|2007-04-19|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|February 2007||2007-02-28|February 2018|2018-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer|Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer|Completed||Phase 2|33|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-06-01 03:17:18.15346|2018-06-01 03:17:18.15346
NCT00462722|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2015-06-11||2015-10-07|2007-04-17|2007-04-19|Estimate|2015-07-10|2015-08-10|Estimate||||2015-10-07|2015-11-02|Estimate|July 2007||2007-07-31|October 2015|2015-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|MOXI||Myogenic and Osteogenic Responses to eXercise and Ibuprofen|COX Inhibition & Musculoskeletal Responses to Exercise|Completed||N/A|159|Actual|University of Colorado, Denver|"The study did not include a no-exercise control group. The variability in the BMD responses was greater than expected.~The results may be specific to ibuprofen and not to other NSAIDs."|3|||f||||t||||||||||2018-06-01 03:17:18.693498|2018-06-01 03:17:18.693498
NCT00462709|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2010-03-31||2014-03-19|2007-04-17|2007-04-19|Estimate|2010-04-09|2010-05-03|Estimate||||2014-03-19|2014-04-15|Estimate|June 2006||2006-06-30|March 2014|2014-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|CHANGE 3||Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks|LEVP2006-4 CHANGE 3 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Use of C1INH-nf (Human) for the Prophylactic Treatment to Prevent HAE Attacks and as Treatment in Acute HAE Attacks|Completed||Phase 3|146|Actual|Shire||1|||f||||||||||||||2018-06-01 03:17:19.201994|2018-06-01 03:17:19.201994
NCT00462696|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2011-05-12|2007-04-18|2007-04-19|Estimate|||||||2011-05-12|2011-05-13|Estimate|February 2006||2006-02-28|December 2008|2008-12-31||||May 2011|Actual|2011-05-31||Interventional|||MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer|Study Evaluating the Contribution of MRI for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Patients With Infiltrative Breast Cancer|Completed||N/A|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:19.518547|2018-06-01 03:17:19.518547
NCT00462683|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2012-01-04|2007-04-18|2007-04-19|Estimate|||||||2012-01-04|2012-01-06|Estimate|July 2007||2007-07-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Bone Loss, Fractures, and Management of Bone Health in People With Stroke in Managed Rehabilitation Settings|Bone Loss, Fractures, and Management of Bone Health in People With Stroke in Managed Rehabilitation Settings|Completed|||87|Actual|Northwestern University|||||f||||f||||||Samples Without DNA|"~     Two 10ml tubes of blood will be obtained from each participant. Serum will be separated and~     frozen to be saved for possible measurement of vitamin D levels and/or bone markers.~   "|||2018-06-01 03:17:19.579314|2018-06-01 03:17:19.579314
NCT00462670|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2013-10-31||2013-12-24|2007-04-17|2007-04-19|Estimate|2013-12-24|2014-02-04|Estimate||||2013-12-24|2014-02-04|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)|A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)|Completed||Phase 3|110|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-06-01 03:17:19.655864|2018-06-01 03:17:19.655864
NCT00462657|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-08-23|2007-04-18|2007-04-19|Estimate|||||||2013-08-23|2013-08-26|Estimate|July 2005||2005-07-31|September 2007|2007-09-30||||||||Interventional|||Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease|Early Diagnosis of Invasive Aspergillosis in a High Risk Group of Patients Using Serum and Bronchoalveolar Lavage Fluid Real Time PCR and Galactomannan ELISA|Unknown status|Recruiting|N/A|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:20.031306|2018-06-01 03:17:20.031306
NCT00462644|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2009-03-04||2010-02-17|2007-04-18|2007-04-19|Estimate|2009-10-10|2009-11-11|Estimate||||2010-02-17|2010-02-23|Estimate|February 2006||2006-02-28|February 2010|2010-02-28|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||Evaluation of Etomidate on Adrenal Function in Trauma Patients|A Single Dose of Etomidate During Rapid Sequence Induction in Trauma Patients Causes Significant Adrenocortical Insufficiency: A Prospective Randomized Study|Completed||N/A|30|Actual|University of Tennessee|Small trial most likely underpowered; large number of exclusions; other limitations discussed in published paper (PMID: 18784570).|2|||f||||f||||||||||2018-06-01 03:17:20.124583|2018-06-01 03:17:20.124583
NCT00462631|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2016-02-18|2007-04-18|2007-04-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|September 2011|Actual|2011-09-30||Interventional|PEPCAD IV||Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients|Paclitaxel-Eluting Balloon Angioplasty and Cobalt-Chromium Stents Versus Conventional Angioplasty and Paclitaxel-Eluting Stents in the Treatment of Native Coronary Artery Stenoses of Diabetic Patients|Completed||Phase 2/Phase 3|84|Actual|Heart Centre Rotenburg||2|||f||||t||||||||||2018-06-01 03:17:20.681169|2018-06-01 03:17:20.681169
NCT00462618|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-04-22|2007-04-18|2007-04-19|Estimate|||||||2013-04-22|2013-04-23|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Group Cognitive Behavioral Therapy (CBT I) Vs. Quetiapine for Residual Insomnia Impairing Recovery Among Elderly With Stable Major Affective Disorders||Completed||Phase 2/Phase 3|32|Actual|Michael Debakey Veterans Affairs Medical Center||1|||f||||f||||||||||2018-06-01 03:17:20.789217|2018-06-01 03:17:20.789217
NCT00462605|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2017-03-06||2017-06-16|2007-04-18|2007-04-19|Estimate|2017-03-06|2017-04-17|Actual||||2017-06-16|2017-07-18|Actual|April 2007||2007-04-30|June 2017|2017-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia|A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies|Completed||Phase 2|24|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:17:20.913373|2018-06-01 03:17:20.913373
NCT00462592|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2009-10-20|2007-04-18|2007-04-19|Estimate|||||||2009-10-20|2009-10-21|Estimate|March 2007||2007-03-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Comparison of Combination Therapy: Montelukast and Inhaled Steroid on Exercise Induced Bronchoconstriction|A Randomised Double Blind, Placebo Controlled 4-way Cross Over Study Comparing Montelukast, Inhaled Budesonide and Their Combination on Exercise-induced Bronchoconstriction|Completed||Phase 3|18|Actual|McMaster University||4|||f||||f||||||||||2018-06-01 03:17:21.16724|2018-06-01 03:17:21.16724
NCT00462579|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2017-06-23|2007-04-18|2007-04-19|Estimate|||||||2017-06-23|2017-06-26|Actual|April 2007|Actual|2007-04-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Risk Factors for Carbapenem-resistant Acinetobacter Baumannii|Risk Factors for Carbapenem-resistant Acinetobacter Baumannii|Completed|||100|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:17:21.292426|2018-06-01 03:17:21.292426
NCT00462566|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2016-10-17|2007-04-18|2007-04-19|Estimate|||||||2016-10-17|2016-10-18|Estimate|October 2005||2005-10-31|June 2016|2016-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||The Efficacy of Motor Cortex Stimulation for Pain Control|The Efficacy of Motor Cortex Stimulation for Pain Control|Completed||N/A|12|Actual|Nova Scotia Health Authority|||||f||||f||||||||||2018-06-01 03:17:21.37005|2018-06-01 03:17:21.37005
NCT00462553|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2014-02-21|2007-04-18|2007-04-19|Estimate|||||||2014-02-21|2014-02-24|Estimate|March 2007||2007-03-31|April 2013|2013-04-30||||June 2010|Actual|2010-06-30||Interventional|||Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors|A Phase I Study of Sunitinib Malate and Standard Infusion Gemcitabine in Solid Tumors|Completed||Phase 1|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:17:21.476243|2018-06-01 03:17:21.476243
NCT00462540|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2009-03-03|2007-04-17|2007-04-19|Estimate|||||||2009-03-03|2009-03-04|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||A Crossover Study in the Treatment of Patients With COPD||Completed||Phase 3|100|Anticipated|Dey|||||f||||||||||||||2018-06-01 03:17:21.59971|2018-06-01 03:17:21.59971
NCT00462527|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2011-06-27|2007-04-18|2007-04-19|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2007||2007-05-31|September 2007|2007-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|CARING||Cystatin C as a Marker for Detecting Early Renal Dysfunction in a Pediatric Emergency Department|Cystatin C as a Marker for Detecting Early Renal Dysfunction in a Pediatric Emergency Department|Completed|||464|Anticipated|Children's Hospital of Eastern Ontario|||||f||||f||||||||||2018-06-01 03:17:21.814413|2018-06-01 03:17:21.814413
NCT00462501|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2015-12-15||2015-12-15|2007-04-18|2007-04-19|Estimate|2015-12-15|2016-01-20|Estimate||||2015-12-15|2016-01-20|Estimate|March 2007||2007-03-31|December 2015|2015-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer|A Pilot Study of Neoadjuvant Chemotherapy With Selective Use of Radiation for Locally Advanced Rectal Cancer|Completed||N/A|35|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:17:21.953262|2018-06-01 03:17:21.953262
NCT00462488|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-05-12|2007-04-17|2007-04-19|Estimate|||||||2015-05-12|2015-05-14|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ|Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Patients With Non-Invasive Urothelial Carcinoma in Situ (CIS) Previously Treated With Bacille Calmette-Guérin (BCG)|Completed||Phase 2|46|Actual|Viventia Bio||2|||f||||f||||||||||2018-06-01 03:17:22.1453|2018-06-01 03:17:22.1453
NCT00462475|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-10-15|2007-04-18|2007-04-19|Estimate|||||||2007-10-15|2007-10-16|Estimate|January 1996||1996-01-31|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Observational|5yrGH||Effect of 5 Years of GH Replacement on Atherosclerosis|Phase 4 Study of Recombinant GH on Intima-Media Thickness at Common Carotids and on Cardiovascular Risk Factors in Hypopituitary Patients|Completed|||20|Actual|Federico II University|||||f||||f||||||||||2018-06-01 03:17:22.354401|2018-06-01 03:17:22.354401
NCT00462462|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2014-12-05|2013-03-29|2015-01-06|2007-04-18|2007-04-19|Estimate|2014-12-05|2014-12-12|Estimate|2013-03-29|2013-04-05|Estimate|2015-01-06|2015-01-15|Estimate|May 2007||2007-05-31|January 2015|2015-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Baseline characteristics of the patients who received the study product (L0122 gel or Absolute Ethanol), whichever the amount of product was infused . 32 patients were enrolled in the study, but 31 received the study product (1 patient not treated; inclusion mistake).|Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.|Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.|Completed||Phase 2|32|Actual|Orfagen||2|||f||||f||||||||||2018-06-01 03:17:22.695268|2018-06-01 03:17:22.695268
NCT00462449|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2011-08-11||2014-06-19|2007-04-17|2007-04-19|Estimate|2014-06-19|2014-06-20|Estimate||||2014-06-19|2014-06-20|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|Botox + FES||Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity|Single Blind, Randomized Study to Determine the Safety and the Efficacy of Using Functional Electrical Stimulation (FES) and Repetitive Task Practice vs. Repetitive Task Practice Alone in Persons Receiving Botulinum Neurotoxin Type A Injections for Upper Extremity Spasticity|Completed||N/A|23|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:17:23.295633|2018-06-01 03:17:23.295633
NCT00462436|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2010-07-21|2007-04-18|2007-04-19|Estimate|||||||2010-07-21|2010-07-22|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Innovative Strategies For Risk Reduction Following CABG|Do Innovative Strategies Complement Medical Management to Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?|Completed||Phase 2|35|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-06-01 03:17:23.542389|2018-06-01 03:17:23.542389
NCT00462423|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2013-07-06||2014-01-07|2007-04-18|2007-04-19|Estimate|2014-01-07|2014-01-08|Estimate||||2014-01-07|2014-01-08|Estimate|April 2007||2007-04-30|January 2014|2014-01-31|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|AbraxAvast||Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study|Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study|Completed||Phase 2|50|Actual|Northern California Melanoma Center|This was a single arm study. Follow-up trials to further explore this regimen are warranted.|1|||f||||t||||||||||2018-06-01 03:17:23.631215|2018-06-01 03:17:23.631215
NCT00386594|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-08|||2009-01-20|2006-10-08|2006-10-11|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2006||2006-10-31|December 2006|2006-12-31|October 2012|Anticipated|2012-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus||Terminated||N/A|10|Anticipated|Rogers, B.H. Gerald, M.D.|||||f||||||||||||||2018-06-01 03:42:41.226996|2018-06-01 03:42:41.226996
NCT00462397|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2013-08-23|2007-04-18|2007-04-19|Estimate|||||||2013-08-23|2013-08-26|Estimate|June 2005||2005-06-30|April 2007|2007-04-30||||||||Interventional|||Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer|Phase II Study of Weekly Neoadjuvant Chemotherapy Followed by Radical Chemoradiation for Locally Advanced Cervical Cancer|Unknown status|Recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:17:23.863748|2018-06-01 03:17:23.863748
NCT00462384|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2016-03-02||2016-03-02|2007-04-18|2007-04-19|Estimate|2016-03-02|2016-04-01|Estimate||||2016-03-02|2016-04-01|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Safety population: included all participants who were treated with at least one dose of the study medication.|A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.|An Open-label, Multi-center Study to Demonstrate Correction of Anemia and to Assess the Maintenance of Hemoglobin Levels Using Subcutaneous Once Monthly Injections of Mircera in Pre-dialysis Patients With Chronic Kidney Disease|Terminated||Phase 3|39|Actual|Hoffmann-La Roche|This study was terminated early due to strategic decision unrelated to safety or efficacy.|1||Strategic decision unrelated to safety or efficacy|f||||||||||||||2018-06-01 03:17:23.973211|2018-06-01 03:17:23.973211
NCT00462371|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-04-18|2007-04-18|2007-04-19|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2002||2002-01-31|April 2007|2007-04-30|February 2004|Actual|2004-02-29|||||Interventional|||Comparison Between Insulin Pump Treatment and Multiple Daily Insulin Injections in Diabetic Type 1 Children|Open-Label, Randomised Trial Comparing Efficacy of Continuous Subcutaneous Insulin Infusion(CSII) and Multiple Daily Insulin Injections (MDII) in Improving Glycemic Control and Quality of Life in Poorly Regulated Type 1 Diabetic Children.|Completed||Phase 4|38||Erasmus Medical Center|||||f||||t||||||||||2018-06-01 03:17:25.085315|2018-06-01 03:17:25.085315
NCT00462358|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2011-09-29|2007-04-18|2007-04-19|Estimate|||||||2011-09-29|2011-10-03|Estimate|April 2007||2007-04-30|September 2011|2011-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of ARRY-520 in Patients With Advanced Cancer||Completed||Phase 1|41|Actual|Array BioPharma||2|||f||||||||||||||2018-06-01 03:17:25.165876|2018-06-01 03:17:25.165876
NCT00462345|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2014-05-08||2014-10-30|2007-04-18|2007-04-19|Estimate|2014-10-30|2014-11-04|Estimate||||2014-10-30|2014-11-04|Estimate|June 2007||2007-06-30|October 2014|2014-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Intent to treat (ITT) population included all enrolled participants who received the investigational treatment.|A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.|An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Treatment Response in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies|Completed||Phase 4|40|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:17:25.27315|2018-06-01 03:17:25.27315
NCT00462332|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2012-08-20||2013-08-20|2007-04-18|2007-04-19|Estimate|2013-07-25|2013-07-30|Estimate||||2013-08-20|2013-09-06|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|LLC0405||Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia|Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features|Completed||Phase 2|86|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto||2|||f||||f||||||||||2018-06-01 03:17:26.533989|2018-06-01 03:17:26.533989
NCT00462319|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|||2007-04-18|2007-04-18|2007-04-19|Estimate|||||||2007-04-18|2007-04-19|Estimate|May 2005||2005-05-31|April 2007|2007-04-30||||||||Interventional|ARTIST||ARTIST: ARThrose Intervention STandardisée|Evaluation of Standardized Management of Knee Arthritis Patients|Completed||Phase 4|||Almirall, SAS|||||f||||f||||||||||2018-06-01 03:17:27.125722|2018-06-01 03:17:27.125722
NCT00462306|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2011-03-28||2014-03-17|2007-04-18|2007-04-19|Estimate|2011-04-25|2011-05-25|Estimate||||2014-03-17|2014-04-14|Estimate|September 2005||2005-09-30|March 2014|2014-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|OSA||Incidence of Obstructive Sleep Apnea in Pregnancy|Incidence of Obstructive Sleep Apnea in Pregnancy|Completed|||4577|Actual|Northwestern University|The Berlin questionnaire has not been validated as a screening tool in pregnancy.||2||f||||f||||||||||2018-06-01 03:17:27.321876|2018-06-01 03:17:27.321876
NCT00462280|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-18|2014-04-23||2014-10-24|2007-04-18|2007-04-19|Estimate|2014-10-24|2014-10-31|Estimate||||2014-10-24|2014-10-31|Estimate|May 2007||2007-05-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|April 2011|Actual|2011-04-30||Interventional|||Lovastatin in Treating Patients At High Risk of Melanoma|A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-06-01 03:17:27.776575|2018-06-01 03:17:27.776575
NCT00462267|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-04-02|2007-04-17|2007-04-19|Estimate|||||||2015-04-02|2015-04-06|Estimate|January 2005||2005-01-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SHINE-Garfield||Examining the Feasibility of Collaborative Care Treatment for Overweight Adolescents|Examining the Feasibility of Collaborative Care Treatment for Overweight Adolescents|Completed||Phase 2|215|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 03:17:28.849334|2018-06-01 03:17:28.849334
NCT00462254|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2010-11-10|2007-04-17|2007-04-18|Estimate|||||||2010-11-10|2010-11-11|Estimate|June 2007||2007-06-30|November 2010|2010-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease|Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease|Terminated||Phase 4|4|Actual|Southern California Institute for Research and Education||2||Study discontinued.|f||||f||||||||||2018-06-01 03:17:28.915035|2018-06-01 03:17:28.915035
NCT00462241|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2013-02-19|2007-04-17|2007-04-18|Estimate|||||||2013-02-19|2013-02-20|Estimate|August 2006||2006-08-31|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|CARPA||Treatment Study Comparing Manual Treatment or Advice in Acute, Musculoskeletal Chest Pain|Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 2: Treatment Study|Completed||N/A|115|Actual|Clinical Locomotion Science||2|||f||||t||||||||||2018-06-01 03:17:29.012406|2018-06-01 03:17:29.012406
NCT00462228|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|2012-05-18||2016-11-22|2007-04-17|2007-04-18|Estimate|2013-10-24|2013-11-18|Estimate||||2016-11-22|2017-01-23|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury|Double-blind Cross-over Study of the Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury, Protocol NAM-MD-44|Terminated||Phase 4|11|Actual|University of Missouri-Columbia|The enrollment goal for the study was 20 subjects. The study included 11 subjects but was terminated due to a lack of additional subjects.|2||The study was stopped due to a lack of additional subjects.|f||||f||||||||No||2018-06-01 03:17:29.211251|2018-06-01 03:17:29.211251
NCT00462215|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-10-07|2007-04-17|2007-04-18|Estimate|||||||2015-10-07|2015-10-09|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|February 2010|Actual|2010-02-28|June 2007|Actual|2007-06-30||Interventional|||Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)|An Open Label Phase III Study of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine to Assess the Immunogenicity and Safety and to Investigate the Need for and Timing of a Booster Vaccination|Completed||Phase 3|550|Anticipated|Ology Bioservices||6|||f||||t||||||||||2018-06-01 03:17:29.79939|2018-06-01 03:17:29.79939
NCT00462202|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16||2015-04-13|2017-03-02|2007-04-17|2007-04-18|Estimate||||2015-04-13|2015-05-05|Estimate|2017-03-02|2017-03-03|Actual|April 2007||2007-04-30|March 2017|2017-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong|An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients With Persistent Microalbuminuria in Australia, New Zealand, and Hong Kong|Terminated||Phase 3|200|Actual|Keryx Biopharmaceuticals||1||Interim analysis of efficacy trial showed no drug efficacy.|f||||t||||||||No||2018-06-01 03:17:29.881277|2018-06-01 03:17:29.881277
NCT00462189|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|April 2007||2007-04-30|April 2007|2007-04-30||||||||Interventional|||Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patient With Relapsed or Refractory Hairy Cell Leukemia (HCL)|Unknown status|Recruiting|Phase 1|40||Cambridge Antibody Technology|||||f||||f||||||||||2018-06-01 03:17:29.959553|2018-06-01 03:17:29.959553
NCT00462176|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2009-02-19|2007-04-17|2007-04-18|Estimate|||||||2009-02-19|2009-02-20|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Laparoscopic Segmental Bowel Resection for Deep Infiltrating Colorectal Endometriosis|A Retrospective Follow-up of Patients After Laparoscopic Segmental Bowel Resection for Deep Infiltrating Colorectal Endometriosis|Completed|||45|Actual|University Hospital, Gasthuisberg|||1||f||||f||||||Samples Without DNA|"~     The diagnosis of endometriosis was confirmed by histologic examination of resected lesions.~   "|||2018-06-01 03:17:30.047356|2018-06-01 03:17:30.047356
NCT00462150|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|September 2002||2002-09-30|April 2007|2007-04-30|June 2003|Actual|2003-06-30|||||Interventional|||Effects of Home-Based Emotional Disclosure in Rheumatoid Arthritis|Psychological, Physiological, and Clinical Consequences of Emotional Disclosure in Rheumatoid Arthritis (RA)|Completed||Phase 2|80||UMC Utrecht|||||f||||f||||||||||2018-06-01 03:17:30.108375|2018-06-01 03:17:30.108375
NCT00462137|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2008-10-08|2007-04-17|2007-04-18|Estimate|||||||2008-10-08|2008-10-09|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux|The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux|Completed|||8|Actual|Thomas Jefferson University|||2||f||||f||||||||||2018-06-01 03:17:30.191458|2018-06-01 03:17:30.191458
NCT00462124|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2009-06-09|2007-04-17|2007-04-18|Estimate|||||||2009-06-09|2009-06-12|Estimate|June 2007||2007-06-30|June 2009|2009-06-30|February 2010|Anticipated|2010-02-28|December 2009|Anticipated|2009-12-31||Interventional|||Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy|One-Arm, Multi-Center, Prospective Study to Assess the Safety and Efficacy of BioProtect Biodegradable Implantable Balloon in Prostate Cancer Subjects Undergoing Radiotherapy|Unknown status|Recruiting|Phase 1|15|Anticipated|BioProtect|||||f||||f||||||||||2018-06-01 03:17:30.253868|2018-06-01 03:17:30.253868
NCT00462111|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2012-02-13|2007-04-17|2007-04-18|Estimate|||||||2012-02-13|2012-02-14|Estimate|April 2007||2007-04-30|February 2012|2012-02-29|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Indomethacin and Mechanisms Underlying Risk of Falling|Effect of Indomethacin on Reaction Time, Postural Balance and the Ability to Avoid Suddenly Appearing Obstacles During Gait in Healthy Middle-aged Individuals.|Completed||Phase 4|20|Anticipated|Sint Maartenskliniek|||||f||||||||||||||2018-06-01 03:17:30.3282|2018-06-01 03:17:30.3282
NCT00462098|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2013-02-19|2007-04-17|2007-04-18|Estimate|||||||2013-02-19|2013-02-21|Estimate|August 2006||2006-08-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates|Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates|Completed||Phase 1|54|Actual|Duke University||2|||f||||t||||||||||2018-06-01 03:17:30.388156|2018-06-01 03:17:30.388156
NCT00462085|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Observational|||Muscle Activity With the Use of Ankle Foot Orthoses in Cerebral Palsy|Muscle Activity With the Use of Ankle Foot Orthoses in Cerebral Palsy|Completed|||24||University Children's Hospital Basel|||||f||||t||||||||||2018-06-01 03:17:30.457087|2018-06-01 03:17:30.457087
NCT00462072|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2011-08-02||2015-04-07|2007-04-17|2007-04-18|Estimate|2011-12-09|2012-01-16|Estimate||||2015-04-07|2015-04-29|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Centocor Microarray Study of Patients|Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases|Completed||Phase 4|31|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 03:17:30.519631|2018-06-01 03:17:30.519631
NCT00462059|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|June 2005||2005-06-30|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Assessment of a Medication Reconciliation Program on Transitional Care|Impact of a Medication Reconciliation Program on Patients Transitioning From an Inpatient Hospitalization to Primary Care|Completed||N/A|200||Kaiser Permanente|||||f||||f||||||||||2018-06-01 03:17:30.872864|2018-06-01 03:17:30.872864
NCT00462046|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Efficacy and Safety of Berberine in the Treatment of Diabetes With Dyslipidemia|The Efficacy and Safety of Berberine in the Treatment of Type 2 Diabetes With Dyslipidemia|Completed||Phase 3|120||Shanghai Jiao Tong University School of Medicine|||||f||||t||||||||||2018-06-01 03:17:30.944591|2018-06-01 03:17:30.944591
NCT00462020|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2011-12-12||2011-12-12|2007-04-17|2007-04-18|Estimate|2011-12-12|2012-01-16|Estimate||||2011-12-12|2012-01-16|Estimate|March 2007||2007-03-31|December 2011|2011-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis|Intravenous Versus Intravenous/Oral Antibiotics for Perforated Appendicitis|Completed||N/A|150|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 03:17:31.081006|2018-06-01 03:17:31.081006
NCT00459368|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2010-06-17||2010-08-10|2007-04-09|2007-04-11|Estimate|2010-07-14|2010-08-10|Estimate||||2010-08-10|2010-08-17|Estimate|May 2007||2007-05-31|June 2010|2010-06-30|November 2009|Actual|2009-11-30|August 2008|Actual|2008-08-31||Interventional|AFFIRM||Using Information Technology to Improve Asthma Adherence|Adherence Feedback for Improving Respiratory Medication Use|Completed||N/A|2698|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-06-01 03:18:29.53055|2018-06-01 03:18:29.53055
NCT00462007|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-04-20|2007-04-17|2007-04-18|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|SENSE||Study to Evaluate Initiation of Stalevo in Early Wearing-off|Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients|Completed||Phase 4|115|Actual|Orion Corporation, Orion Pharma||1|||f||||f||||||||||2018-06-01 03:17:31.316051|2018-06-01 03:17:31.316051
NCT00461994|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate|April 2004||2004-04-30|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||The Role of Exercise and Diet in Weight Loss in Obese Children|The Role of Exercise and/or Diet in Weight Loss, and Weight Maintenance in Obese Preadolescent Children|Completed||N/A|160||Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:17:31.408419|2018-06-01 03:17:31.408419
NCT00461981|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2009-05-29||2010-01-12|2007-04-17|2007-04-18|Estimate|2010-01-12|2010-02-02|Estimate||||2010-01-12|2010-02-02|Estimate|May 2007||2007-05-31|January 2010|2010-01-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||A Phase 2 Study to Evaluate Immune Responses of FluMist®|A Phase 2, Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of FluMist® Compared With Trivalent Inactivated Vaccine (TIV) in Children 12 to <36 Months of Age|Completed||Phase 2|101|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 03:17:31.544811|2018-06-01 03:17:31.544811
NCT00461968|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate|February 2005||2005-02-28|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both|Genetic Determinanats of Cardiovascular Risk Factors: Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both|Completed||N/A|240||University of Texas Southwestern Medical Center|||||f||||t||||||||||2018-06-01 03:17:33.354602|2018-06-01 03:17:33.354602
NCT00461955|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2010-11-03|2007-04-17|2007-04-18|Estimate|||||||2010-11-03|2010-11-04|Estimate|August 2007||2007-08-31|November 2010|2010-11-30|August 2009|Actual|2009-08-31|September 2008|Actual|2008-09-30||Interventional|Expansion||Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation|Pilot Clinical Trial of Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation in Adult Patients With Multiple Myeloma in First Response|Completed||Phase 2|13|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-06-01 03:17:33.411079|2018-06-01 03:17:33.411079
NCT00461942|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2011-08-15|2007-04-17|2007-04-18|Estimate|||||||2011-08-15|2011-08-16|Estimate|April 2006||2006-04-30|August 2011|2011-08-31|March 2009|Actual|2009-03-31|||||Interventional|||Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease Patients|Completed||Phase 2|480|Anticipated|Xuanwu Hospital, Beijing|||||f||||t||||||||||2018-06-01 03:17:33.501604|2018-06-01 03:17:33.501604
NCT00461929|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2009-02-12|2007-04-16|2007-04-18|Estimate|||||||2009-02-12|2009-02-13|Estimate|February 2005||2005-02-28|April 2007|2007-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|GIST||Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib|Are the Secondary Chromosome Abnormalities Seen in Chronic Myeloid Leukemia (CML) Cells Induced to Ph-Chromosome Negativity by Imatinib a Result of Chromosome Instability or a Side Effect of the Therapy - a Study in GIST (Gastrointestinal Stromal Cell Tumors) Patients Treated With Imatinib.|Terminated||Phase 4|68|Anticipated|University Health Network, Toronto||||study terminated 12Feb09 due to low recruitment|f||||f||||||||||2018-06-01 03:17:33.556519|2018-06-01 03:17:33.556519
NCT00461916|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate|May 2005||2005-05-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin|Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin in a Long Protocol of Controlled Ovarian Stimulation for ICSI/ET|Completed||Phase 4|182||Tehran University of Medical Sciences|||||f||||f||||||||||2018-06-01 03:17:33.695336|2018-06-01 03:17:33.695336
NCT00461903|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2015-12-11|2007-04-17|2007-04-18|Estimate|||||||2015-12-11|2015-12-14|Estimate|December 2007||2007-12-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|CTAF-2||Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension|A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension|Completed||Phase 3|316|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-06-01 03:17:33.764107|2018-06-01 03:17:33.764107
NCT00461890|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2011-10-21|2007-04-13|2007-04-18|Estimate|||||||2011-10-21|2011-10-24|Estimate|October 2006||2006-10-31|October 2011|2011-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial|Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial|Terminated||Phase 4|20|Anticipated|State University of New York - Upstate Medical University|||||f||||||||||||||2018-06-01 03:17:33.836759|2018-06-01 03:17:33.836759
NCT00461877|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2013-11-15|2007-04-17|2007-04-18|Estimate|||||||2013-11-15|2013-11-19|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||High-Risk HPV Infections in Women Aged 25 to 65|High-Risk HPV Infections in Women Aged 25 to 65|Completed|||303|Actual|University of Washington|||||f||||f||||||Samples With DNA|"~     Vaginal swab samples for HPV DNA testing~   "|||2018-06-01 03:17:33.958627|2018-06-01 03:17:33.958627
NCT00461864|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate|April 2007||2007-04-30|March 2007|2007-03-31||||||||Observational|||Diagnosis of Occult Hip Fractures With Ultrasound||Unknown status|Not yet recruiting||40||Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:17:34.014992|2018-06-01 03:17:34.014992
NCT00461851|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2016-09-12||2017-11-15|2007-04-17|2007-04-18|Estimate|2016-09-12|2016-11-01|Estimate||||2017-11-15|2017-12-14|Actual|March 2007||2007-03-31|September 2016|2016-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma|A Phase II, Multicenter Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma|Completed||Phase 2|17|Actual|Yale University||1|||f||||f||||||||||2018-06-01 03:17:34.072439|2018-06-01 03:17:34.072439
NCT00460980|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2015-04-02|2007-04-13|2007-04-17|Estimate|||||||2015-04-02|2015-04-06|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Virtual Reality Training by Novices on Laparoscopic Cholecystectomy in a Porcine Model|Effect of Virtual Reality Training by Novices on Laparoscopic Cholecystectomy in a Porcine Model|Withdrawn||N/A|0|Actual|Columbia University||1||Principal investigator left institution.|f||||f||||||||||2018-06-01 03:17:49.993684|2018-06-01 03:17:49.993684
NCT00461838|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2009-02-19|2007-04-17|2007-04-18|Estimate|||||||2009-02-19|2009-02-20|Estimate|September 1996||1996-09-30|February 2009|2009-02-28|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Observational|||Outcome After Multidisciplinary CO2 Laser Laparoscopic Excision of Deep Infiltrating Colorectal Endometriosis|Outcome After Multidisciplinary CO2 Laser Laparoscopic Excision of Deep Infiltrating Colorectal Endometriosis|Completed|||56|Actual|University Hospital, Gasthuisberg|||1||f||||f||||||Samples Without DNA|"~     Endometriosis was proven by histologic examination of excised lesions.~   "|||2018-06-01 03:17:34.274846|2018-06-01 03:17:34.274846
NCT00461825|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate|July 1998||1998-07-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Maintenance Neoral Monotherapy Compared to Bitherapy in Renal Transplantation|Efficacy and Safety of Maintenance Neoral Compared to Bitherapy Neoral-Imurel or Neoral-CellCept in Renal Transplantation|Completed||Phase 3|207||Poitiers University Hospital|||||f||||f||||||||||2018-06-01 03:17:34.350568|2018-06-01 03:17:34.350568
NCT00461812|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2017-08-14||2017-09-19|2007-04-16|2007-04-18|Estimate|2017-09-19|2017-09-20|Actual||||2017-09-19|2017-09-20|Actual|April 2007|Actual|2007-04-30|September 2017|2017-09-30|January 19, 2010|Actual|2010-01-19|January 19, 2010|Actual|2010-01-19||Interventional||The number of participants assigned/randomized to each Arm/Group is unknown|A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma|A Single-Blind, Randomized, Positive-controlled Study to Compare Monotherapy With an Inhaled Corticosteroid (Mometasone) to Combination Therapy With an Inhaled Corticosteroid + a Long-Acting Bronchodilator (Advair) in Patients With Milder Persistent Asthma|Terminated||Phase 4|33|Actual|Johns Hopkins University||2||"by sponsor due to failure to recruit patients who had mild persistent asthma who were not~   already on Advair 250/50 or 500/50."|f||||t||||||||||2018-06-01 03:17:34.45357|2018-06-01 03:17:34.45357
NCT00461799|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|September 2003||2003-09-30|April 2007|2007-04-30|January 2004|Actual|2004-01-31|||||Interventional|||Orlistat Treatment of Crigler-Najjar Disease|Orlistat Treatment of Unconjugated Hyperbilirubinemia in Crigler-Najjar Disease; A Randomized Controlled Trial|Completed||N/A|16||University Medical Center Groningen|||||f||||f||||||||||2018-06-01 03:17:34.580751|2018-06-01 03:17:34.580751
NCT00461786|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2008-10-13||2009-12-01|2007-04-16|2007-04-18|Estimate|2009-07-13|2009-08-24|Estimate||||2009-12-01|2009-12-04|Estimate|September 2004||2004-09-30|December 2009|2009-12-31|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer|A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|51|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 03:17:34.677156|2018-06-01 03:17:34.677156
NCT00461773|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2009-06-05|2007-04-16|2007-04-18|Estimate|||||||2009-06-05|2009-06-09|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer|Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer|Unknown status|Recruiting|Phase 2|40|Anticipated|Yale University||2|||f||||f||||||||||2018-06-01 03:17:35.233234|2018-06-01 03:17:35.233234
NCT00461760|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2017-05-01|2007-04-13|2007-04-18|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2007||2007-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 30, 2017|Actual|2017-04-30||Interventional|HPVFOCAL||HPV Testing for Cervical Cancer Screening Study|A Randomized Controlled Evaluation of HPV Testing for Cervical Cancer Screening|Active, not recruiting||N/A|28000|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:17:35.331269|2018-06-01 03:17:35.331269
NCT00461747|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2009-09-17|2007-04-17|2007-04-18|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|GEM05MENOS65||GEM05 for Patients With Multiple Myeloma Under 65 Years|A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autologous Hemopoietic Stem Cell Support and Maintenance Treatment With Interferon-a Versus Thalidomide Versus Thalidomide / Velcade in Untreated Patients With Multiple Myeloma Less Than 65 Yrs Old|Completed||Phase 3|390|Anticipated|PETHEMA Foundation||3|||f||||t||||||||||2018-06-01 03:17:35.428925|2018-06-01 03:17:35.428925
NCT00461734|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2016-09-15||2017-03-14|2007-04-17|2007-04-18|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|August 2007||2007-08-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|October 2013|Actual|2013-10-31||Interventional|PROTECT-PACE||PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing|PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing. Does Right Ventricular High-septal Pacing Improve Outcome Compared With Right Ventricular Apical Pacing?|Completed||N/A|248|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f|f|f||||||No||2018-06-01 03:17:35.612135|2018-06-01 03:17:35.612135
NCT00461721|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-12-02|2007-04-17|2007-04-18|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2006||2006-12-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|January 2007|Actual|2007-01-31||Observational|||Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis|Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis Due to Grass Pollen During Immunotherapy|Completed|||20|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 03:17:36.092844|2018-06-01 03:17:36.092844
NCT00461708|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2014-11-10||2015-09-14|2007-04-17|2007-04-18|Estimate|2015-09-14|2015-10-15|Estimate||||2015-09-14|2015-10-15|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Intent-to-treat (ITT) population: all participants included in the study.|A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival|An Open Label Study of Tarceva in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas : Relationship Between Skin Rash and Survival|Completed||Phase 2|153|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:17:36.205572|2018-06-01 03:17:36.205572
NCT00461695|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2013-08-26|2007-04-17|2007-04-18|Estimate|||||||2013-08-26|2013-08-27|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|August 2008|Actual|2008-08-31||Interventional|||Influence of Persistent CMV-infection on Immune Senescence|Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study)|Completed||Phase 4|183|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 03:17:37.062684|2018-06-01 03:17:37.062684
NCT00461682|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2017-03-27||2017-03-27|2007-04-17|2007-04-18|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|January 26, 2007||2007-01-26|May 2012|2012-05-31|September 1, 2007|Actual|2007-09-01|||||Interventional||Safety population included all participants who received at least one dose of the study drug.|Sb-705498 Rectal Pain Study|A Double-blind, Randomised, Placebo Controlled, Single Dose, Two-period Crossover Study to Investigate the Therapeutic Potential of the TRPV1 Antagonist SB-705498 in Treatment of Subjects With Rectal Hypersensitivity Including Irritable Bowel Syndrome.|Terminated||Phase 2|1|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:17:37.180132|2018-06-01 03:17:37.180132
NCT00461669|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|April 2007||2007-04-30|March 2007|2007-03-31||||||||Observational|||Hip Fracture Characterization With Ultrasound Exam||Unknown status|Not yet recruiting||100||Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:17:37.583102|2018-06-01 03:17:37.583102
NCT00461656|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2013-03-04|2007-04-17|2007-04-18|Estimate|||||||2013-03-04|2013-03-05|Estimate|September 2009||2009-09-30|July 2011|2011-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PASS||Povidone-iodine Antisepsis for Strabismus Surgery|Prospective, Randomized, Double-blind Comparison of 5 % Against 1.25 % Povidone-iodine Solution as Preoperative Antisepsis for Strabismus Surgery in Young Children|Completed||Phase 4|70|Actual|Erasmus Medical Center|||||f||||f||||||||||2018-06-01 03:17:37.663331|2018-06-01 03:17:37.663331
NCT00461643|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2013-04-05|2007-04-13|2007-04-18|Estimate|||||||2013-04-05|2013-04-09|Estimate|January 2007||2007-01-31|April 2013|2013-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS|Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|552|Anticipated|University Magna Graecia||3|||f||||f||||||||||2018-06-01 03:17:37.831682|2018-06-01 03:17:37.831682
NCT00461630|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2013-07-12||2014-01-27|2007-04-17|2007-04-18|Estimate|2013-12-09|2014-01-28|Estimate||||2014-01-27|2014-02-28|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|HPS2-THRIVE||Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE|A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant|Completed||Phase 3|25673|Actual|University of Oxford|Participants may have SAEs reported in >1 category hence total participants affected across reported categories is less than total given.|2|||f||||t||||||||||2018-06-01 03:17:37.991039|2018-06-01 03:17:37.991039
NCT00461617|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2008-10-20|2007-04-17|2007-04-18|Estimate|||||||2008-10-20|2008-10-21|Estimate|August 2006||2006-08-31|April 2007|2007-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients|Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes|Completed||Phase 3|291|Actual|Kissei Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-06-01 03:17:38.569828|2018-06-01 03:17:38.569828
NCT00461604|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2008-05-19|2007-04-16|2007-04-18|Estimate|||||||2008-05-19|2008-05-20|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|NEXBAC||High Dosage Esomeprazole and Baclofen for Therapy of Gastroesophageal Reflux Disease||Completed|||40|Anticipated|Technische Universität München|||||f||||t||||||||||2018-06-01 03:17:38.669978|2018-06-01 03:17:38.669978
NCT00461591|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2017-07-14|2013-12-18|2017-09-07|2007-04-17|2007-04-18|Estimate|2017-07-14|2017-08-15|Actual|2015-05-26|2015-06-19|Estimate|2017-09-07|2017-10-09|Actual|April 2007|Actual|2007-04-30|July 2017|2017-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Safety/ITT Population|Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-611)|Completed||Phase 3|802|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||f||||||||||2018-06-01 03:17:38.818899|2018-06-01 03:17:38.818899
NCT00461578|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|October 2006|Actual|2006-10-31|||||Interventional|||Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children|Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children|Completed||N/A|800||London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-06-01 03:17:40.89829|2018-06-01 03:17:40.89829
NCT00461565|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2015-03-18|2007-04-17|2007-04-18|Estimate|||||||2015-03-18|2015-03-19|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|October 2006|Actual|2006-10-31|||||Interventional|||FDA Phase IV - Commitment - Retinal Function Study|A Double Blind, Randomized, Placebo Controlled, Two Part, Two Session Balanced, Crossover Study to Evaluate Visual Changes in Healthy Male Subjects Aged 18 - 55 Years After Receiving: 1. at Least 15 Doses of 20 mg Vardenafil, Compared to Placebo and 2. Two Doses of Sildenafil, 200 mg Compared to Placebo|Completed||Phase 4|63|Actual|Bayer||4|||f||||f||||||||||2018-06-01 03:17:40.961675|2018-06-01 03:17:40.961675
NCT00461552|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2015-06-22|2007-04-17|2007-04-18|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2003||2003-01-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Therapeutic Approaches to HAART-Induced Lipodystrophy|Therapeutic Approaches to HAART-Induced Lipodystrophy|Completed||Phase 2|23|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 03:17:41.035632|2018-06-01 03:17:41.035632
NCT00461539|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2013-06-05|2007-04-16|2007-04-18|Estimate|||||||2013-06-05|2013-06-06|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Reducing Health Risk Behavior and Improving Health in Adolescents With Depression|Reducing Health Risk Behavior and Improving Health in Adolescent Depression|Completed||Phase 1/Phase 2|217|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 03:17:41.119405|2018-06-01 03:17:41.119405
NCT00461526|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2010-11-19|2007-04-13|2007-04-18|Estimate|||||||2010-11-19|2010-11-22|Estimate|October 2006||2006-10-31|November 2010|2010-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Diarrhea Predominant Irritable Bowel Syndrome in Females|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN-002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS) in Females|Completed||Phase 2|240|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||t||||||||||2018-06-01 03:17:41.20732|2018-06-01 03:17:41.20732
NCT00461513|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2014-11-19||2015-04-06|2007-04-17|2007-04-18|Estimate|2014-12-02|2014-12-08|Estimate||||2015-04-06|2015-04-27|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|PCDM||Patient-Centered Heart Failure Trial|Patient-Centered Disease Management for Heart Failure Trial|Completed|||392|Actual|VA Office of Research and Development|||2||f||||t||||||||||2018-06-01 03:17:41.42725|2018-06-01 03:17:41.42725
NCT00461500|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2008-12-19||2017-01-19|2007-04-17|2007-04-18|Estimate|2012-02-16|2012-03-23|Estimate||||2017-01-19|2017-03-03|Actual|March 2007||2007-03-31|January 2017|2017-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults|Seretide 100 DK vs Flixotide 100 DK in IMT in Moderate Asthma in Adults on Static Lung Volumes (Mechanistic Study)|Completed||Phase 4|81|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:17:41.685934|2018-06-01 03:17:41.685934
NCT00461487|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2013-07-09|2007-04-16|2007-04-18|Estimate|||||||2013-07-09|2013-07-11|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||A Parent-Based Intervention to Reduce Sexual Risk Behavior in Adolescents|Reducing Teen Sexual Behavior: A Clinic-Based Approach|Completed||N/A|530|Actual|Columbia University||3|||f||||f||||||||||2018-06-01 03:17:42.08503|2018-06-01 03:17:42.08503
NCT00461474|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-18|2007-04-16|2007-04-18|Estimate|||||||2007-04-18|2007-04-19|Estimate|March 2004||2004-03-31|April 2007|2007-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Study of Strengthening Exercises and Improving Movement for Painful Shoulders in Adults With Spinal Cord Injury|Strengthening and Optimal Movements for Painful Shoulders in Chronic Spinal Cord Injury (STOMPS)|Completed||Phase 1|80||University of Southern California|||||f||||t||||||||||2018-06-01 03:17:42.15104|2018-06-01 03:17:42.15104
NCT00461461|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2009-06-24|2007-04-17|2007-04-18|Estimate|||||||2009-06-24|2009-06-25|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||a Multifaceted Program for Improving Quality of Care in ICU|IATROREF III: a Multifaceted Program for Improving Quality of Care in Critically Ill Patients|Completed||N/A|2117|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-06-01 03:17:42.222269|2018-06-01 03:17:42.222269
NCT00461448|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2009-02-04|2007-04-17|2007-04-18|Estimate|||||||2009-02-04|2009-02-06|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Pilot Study of Potassium Supplementation for Adult Patients With Rheumatoid Arthritis|Pilot Study of Potassium Supplementation in the Treatment of Rheumatoid Arthritis: a 4-Week, Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 1|36|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 03:17:42.278819|2018-06-01 03:17:42.278819
NCT00461435|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate||||April 2007|2007-04-30||||||||Interventional|||Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa|Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa|Completed||N/A|||Azienda Policlinico Umberto I|||||f||||||||||||||2018-06-01 03:17:42.353714|2018-06-01 03:17:42.353714
NCT00461422|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2008-06-26|2007-04-17|2007-04-18|Estimate|||||||2008-06-26|2008-06-27|Estimate|January 2004||2004-01-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Early Follicular Supplementation of Ganirelix in IVF 2004|Early Follicular GnRH Antagonist Supplementation Improves Fertilization and Embryo Cleavage Rates in IVF-ET GnRH Antagonist Cycles|Completed||Phase 4|50|Actual|The Baruch Padeh Medical Center, Poriya||2|||f||||f||||||||||2018-06-01 03:17:42.400287|2018-06-01 03:17:42.400287
NCT00461409|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2015-10-07|2007-04-16|2007-04-18|Estimate|||||||2015-10-07|2015-10-12|Estimate|April 2007||2007-04-30|October 2015|2015-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||IV Levetiracetam for the Treatment of Neonatal Seizures: a Pharmacokinetic and Preliminary Efficacy and Safety Study|Phase I/II Study of IV Levetiracetam as an add-on Drug for Seizures in Term Neonates Assessing Pharmacokinetics, Safety and Efficacy.|Completed||Phase 1/Phase 2|18|Actual|University of California, San Diego||1|||f||||t||||||||||2018-06-01 03:17:42.553071|2018-06-01 03:17:42.553071
NCT00461396|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2011-04-07|2007-04-17|2007-04-18|Estimate|||||||2011-04-07|2011-04-08|Estimate|May 2007||2007-05-31|April 2011|2011-04-30|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Observational|START||Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron|Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 Months|Completed|||104|Actual|Bayer|||1||f||||f||||||||||2018-06-01 03:17:42.640713|2018-06-01 03:17:42.640713
NCT00461370|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2008-03-11|2007-04-17|2007-04-18|Estimate|||||||2008-03-11|2008-03-13|Estimate|April 2007||2007-04-30|August 2007|2007-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|AVN001||Safety Study of SRX251 Capsules in Healthy Female Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of SRX251 Capsules in Healthy Female Volunteers|Completed||Phase 1|77|Actual|Azevan Pharmaceuticals|||||f||||t||||||||||2018-06-01 03:17:42.752004|2018-06-01 03:17:42.752004
NCT00461357|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2007-04-17|2007-04-17|2007-04-18|Estimate|||||||2007-04-17|2007-04-18|Estimate|January 2003||2003-01-31|April 2007|2007-04-30|December 2007|Anticipated|2007-12-31|||||Observational|ESP||Sirolimus Based Immunosuppression for Patients Undergoing Kidney Transplantation in the Eurotransplant Senior Program|Outcome After Renal Transplantation of a Randomized Prospective Trial in the Eurotransplant Senior Program|Unknown status|Active, not recruiting||48||Medical University of Vienna|||||f||||f||||||||||2018-06-01 03:17:42.813624|2018-06-01 03:17:42.813624
NCT00461344|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|||2008-04-01|2007-04-17|2007-04-18|Estimate|||||||2008-04-01|2008-04-03|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|June 2005|Actual|2005-06-30||Interventional|||Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer|A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed ≥ 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere®- Based Chemotherapy|Terminated||Phase 2|20|Actual|Sanofi||||due to slow recruitment of patients|f||||f||||||||||2018-06-01 03:17:42.8507|2018-06-01 03:17:42.8507
NCT00461331|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2009-05-12||2016-12-01|2007-04-17|2007-04-18|Estimate|2011-04-19|2011-05-19|Estimate||||2016-12-01|2017-01-30|Estimate|October 2004||2004-10-31|December 2016|2016-12-31|August 2008|Actual|2008-08-31|June 2007|Actual|2007-06-30||Interventional|||Comparison of Insulins Aspart and Lispro in Insulin Pumps|A Comparison of the Efficacy Beyond 48 Hours of Insulin Aspart (Novolog) and Lispro (Humalog) in Insulin Pumps|Completed||Phase 4|20|Actual|Tulane University||2|||f||||t||||||||||2018-06-01 03:17:42.912027|2018-06-01 03:17:42.912027
NCT00461318|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-18|Estimate|||||||2007-04-16|2007-04-18|Estimate|April 2003||2003-04-30|April 2007|2007-04-30|November 2005|Actual|2005-11-30|||||Interventional|EQOLISE||The Effectiveness of Supported Employment for People With Severe Mental Illness: an RCT in Six European Countries|Enhancing the Quality of Life and Independence of Persons Disabled by Severe Mental Illness Through Supported Employment|Completed||N/A|300||University of Oxford|||||f||||f||||||||||2018-06-01 03:17:43.129387|2018-06-01 03:17:43.129387
NCT00461305|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-17|2010-09-10||2013-01-22|2007-04-17|2007-04-18|Estimate|2010-09-10|2010-10-01|Estimate||||2013-01-22|2013-01-24|Estimate|February 2007||2007-02-28|January 2013|2013-01-31|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea|A Multicenter, Single-blind, Randomized Study, to Investigate Efficacy of Ethinylestradiol for Intracyclic Bleeding Profile During 24 Weeks (6 Cycles) by Oral Administration of Drospirenone 3 mg/Ethinylestradiol 20 µg and Drospirenone 3 mg/ Ethinylestradiol 30 µg in Patients With Dysmenorrheal and to Investigate the Long Term Safety Oral Administration of Drospirenone 3 mg/Ethinylestradiol 20 µg Administered for 52 Weeks (13 Cycles)|Completed||Phase 2/Phase 3|420|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:17:43.289982|2018-06-01 03:17:43.289982
NCT00461292|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2011-09-09|2011-03-31|2015-09-17|2007-04-13|2007-04-17|Estimate|2011-09-09|2011-10-17|Estimate|2011-03-31|2011-04-07|Estimate|2015-09-17|2015-10-02|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder||Completed||Phase 3|275|Actual|Allergan||4|||f||||||||||||||2018-06-01 03:17:44.991958|2018-06-01 03:17:44.991958
NCT00461279|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2011-12-02|2007-04-13|2007-04-17|Estimate|||||||2011-12-02|2011-12-06|Estimate|August 2006||2006-08-31|December 2011|2011-12-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Attachment Security as Mediator and Moderator of Outcome in Major Depression|Attachment Security as Mediator and Moderator of Outcome in Major Depression Following Interpersonal Therapy and Cognitive Behavior Therapy|Completed||N/A|134|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 03:17:45.57208|2018-06-01 03:17:45.57208
NCT00461266|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2016-08-23|2007-04-16|2007-04-17|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2007||2007-04-30|August 2016|2016-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.|A Randomized, Open Label Study to Determine the Immunological Benefits of Adding Fuzeon to an Antiretroviral Regimen in HIV-infected Fuzeon-naïve Patients With Sustained HIV Viral Suppression|Withdrawn||Phase 4|0|Actual|Hoffmann-La Roche||2||Slow recruitment|f||||||||||||||2018-06-01 03:17:45.641743|2018-06-01 03:17:45.641743
NCT00461253|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2015-12-17||2015-12-17|2007-04-16|2007-04-17|Estimate|2015-12-17|2016-01-25|Estimate||||2015-12-17|2016-01-25|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Definitions: cases were defined as women who were diagnised with breast cancer (invasive carcinoma or carcinoma in situ) between 1/2000 and 12/2007 and aged <50 years at diagnosis. Controls were selected randomly from the national population registry (Finland) or via neighborhood controls by a controlled random route method (Germany).|Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs|Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs|Completed|||25565|Actual|Center for Epidemiology and Health Research, Germany|Limitations include information-bias, which cannot be entirely eliminated in retrospective studies. However, in this study recall is likely not to be differential between cases and controls.||2||f||||t||||||||||2018-06-01 03:17:45.723584|2018-06-01 03:17:45.723584
NCT00461240|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2012-07-24|2007-04-16|2007-04-17|Estimate|||||||2012-07-24|2012-07-26|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|||||Observational|||Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States|Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States|Completed|||25|Actual|Barts & The London NHS Trust|||2||f||||f||||||Samples With DNA|"~     blood samples will be retained~   "|||2018-06-01 03:17:45.974203|2018-06-01 03:17:45.974203
NCT00461227|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2012-12-18|2007-04-13|2007-04-17|Estimate|||||||2012-12-18|2012-12-19|Estimate|August 2006||2006-08-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Effect of Heredity and Environment on Asthma Development and Severity in Puerto Rican Children|Genes, Home Allergens, and Asthma in Puerto Rican Children|Completed|||1127|Actual|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 03:17:46.035301|2018-06-01 03:17:46.035301
NCT00461214|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2012-11-19|2007-04-16|2007-04-17|Estimate|||||||2012-11-19|2012-11-21|Estimate|October 2006||2006-10-31|November 2012|2012-11-30||||August 2008|Actual|2008-08-31||Observational|||General Surgery Training Outcomes Project|General Surgery Training Outcomes Project: Evaluating the Impact of the Curriculum on General Surgery Resident Training and Evaluation|Terminated|||35|Actual|Columbia University|||||f||||f||||||||||2018-06-01 03:17:46.117314|2018-06-01 03:17:46.117314
NCT00461201|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-04-16|2007-04-16|2007-04-17|Estimate|||||||2007-04-16|2007-04-17|Estimate|January 2009||2009-01-31|April 2007|2007-04-30||||||||Interventional|||Nurse vs General Practitioner Care for Patients Requesting Same Day Consultations in Primary Care|Effectiveness of an Intervention in Primary Care: Randomized Controlled Trial Comparing Care for Patients Requesting Same Day Consultations by Nurse Practitioner vs General Practitioners|Unknown status|Not yet recruiting|N/A|1640||Catalan Institute of Health|||||f||||f||||||||||2018-06-01 03:17:46.251157|2018-06-01 03:17:46.251157
NCT00461188|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2018-01-17|2007-04-16|2007-04-17|Estimate|||||||2018-01-17|2018-01-18|Actual|March 2007||2007-03-31|July 2016|2016-07-31|April 2099|Anticipated|2099-04-30|April 2099|Anticipated|2099-04-30||Observational|||Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA|Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA|Recruiting|||150|Anticipated|Barts & The London NHS Trust|||||f||||f||||||Samples With DNA|"~     DNA sample, tissue sample~   "|||2018-06-01 03:17:46.323079|2018-06-01 03:17:46.323079
NCT00461175|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2014-10-16||2015-06-24|2007-04-16|2007-04-17|Estimate|2014-10-16|2014-10-22|Estimate||||2015-06-24|2015-07-17|Estimate|November 2006||2006-11-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|May 2012|Actual|2012-05-31||Observational|EURAS-IUD||European Active Surveillance Study for Intrauterine Devices|European Active Surveillance Study for Intrauterine Devices|Completed|||63194|Actual|Center for Epidemiology and Health Research, Germany|In observational studies like EURAS-IUD, the possibility of bias and residual confounding can never be entirely eliminated. Thus, for risk estimates smaller than 2-fold, causality cannot be inferred confidently in view of alternative explanations.||2||f||||t||||||||||2018-06-01 03:17:46.424173|2018-06-01 03:17:46.424173
NCT00461162|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2014-08-14|2007-04-13|2007-04-17|Estimate|||||||2014-08-14|2014-08-18|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Dyspnea Self-Management: Internet or Face-to-Face|Dyspnea Self-Management: Internet or Face-to-Face|Completed||Phase 1/Phase 2|125|Actual|University of California, San Francisco||3|||f||||||||||||||2018-06-01 03:17:46.715538|2018-06-01 03:17:46.715538
NCT00461149|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2007-04-13|2007-04-13|2007-04-17|Estimate|||||||2007-04-13|2007-04-17|Estimate|January 1995||1995-01-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|HDacro||Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly|Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly|Completed||Phase 4|50||Federico II University|||||f||||f||||||||||2018-06-01 03:17:46.854538|2018-06-01 03:17:46.854538
NCT00461136|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2016-09-22|2007-04-16|2007-04-17|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2005||2005-08-31|September 2016|2016-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes|An Open-label, One-period, One-treatment Study to Evaluate the Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes Suffering From Incipient and/or Established Nephropathy|Completed||Phase 1/Phase 2|18||Novartis|||||f||||f||||||||||2018-06-01 03:17:46.939821|2018-06-01 03:17:46.939821
NCT00461123|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2009-09-29||2014-12-04|2007-04-16|2007-04-17|Estimate|2009-12-14|2010-01-21|Estimate||||2014-12-04|2014-12-19|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate Hypertrophy|A Randomized, Double-blind, Parallel Group Prospective Pilot Study to Assess the Effect of Vardenafil on Clinical Outcome and on Procedure Duration After Green Light Laser-ablation of the Prostate Gland for Therapy of Benign Prostate Hypertrophy (BPH)|Completed||Phase 2|50|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:17:47.020636|2018-06-01 03:17:47.020636
NCT00461110|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2009-09-03|2007-04-13|2007-04-17|Estimate|||||||2009-09-03|2009-09-04|Estimate|January 2008||2008-01-31|September 2009|2009-09-30|April 2009|Anticipated|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)|A Phase 1 Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)|Terminated||Phase 1|35|Anticipated|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:17:47.397726|2018-06-01 03:17:47.397726
NCT00461097|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2011-12-29||2017-11-15|2007-04-16|2007-04-17|Estimate|2012-03-29|2012-05-01|Estimate||||2017-11-15|2017-12-13|Actual|May 2007||2007-05-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|December 2010|Actual|2010-12-31||Interventional|||Oral Immunotherapy for Childhood Egg Allergy|Oral Desensitization to Egg With Subsequent Induction of Tolerance for Egg-Allergic Children (CoFAR 3)|Completed||Phase 2|55|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 03:17:47.503952|2018-06-01 03:17:47.503952
NCT00461084|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2014-09-17|2007-04-16|2007-04-17|Estimate|||||||2014-09-17|2014-09-18|Estimate|April 2007||2007-04-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma|Biaxin(Clarithromycin)Based Antibiotic Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma|Completed|||36|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||t||||||Samples Without DNA|"~     tissue and whole blood~   "|||2018-06-01 03:17:48.252906|2018-06-01 03:17:48.252906
NCT00461071|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2017-09-28|2007-04-16|2007-04-17|Estimate|||||||2017-09-28|2017-10-02|Actual|April 2007||2007-04-30|September 2017|2017-09-30|April 2010|Actual|2010-04-30|February 2008|Actual|2008-02-29||Interventional|||Randomised Controlled Study on the Use of Psychoeducation for Bulimia Nervosa in Young Women|RCT on the Use of Psychoeducation for Bulimia Nervosa in Young Women|Completed||N/A|150|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 03:17:48.345947|2018-06-01 03:17:48.345947
NCT00461058|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2016-08-03|2007-04-16|2007-04-17|Estimate|||||||2016-08-03|2016-08-05|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.|A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos in Patients With Type 2 Diabetes and NYHA Class II Heart Failure.|Completed||Phase 2|14|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:17:48.42291|2018-06-01 03:17:48.42291
NCT00461045|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2017-03-29||2017-11-20|2007-04-13|2007-04-17|Estimate|2017-08-14|2017-09-13|Actual||||2017-11-20|2017-12-19|Actual|March 2007||2007-03-31|November 2017|2017-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|15|Actual|Celgene||1|||f||||f||||||||Yes||2018-06-01 03:17:48.627429|2018-06-01 03:17:48.627429
NCT00461032|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2010-01-12||2017-01-19|2007-04-13|2007-04-17|Estimate|2010-01-12|2010-02-04|Estimate||||2017-01-19|2017-03-03|Actual|June 2006||2006-06-30|January 2017|2017-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Montelukast Back to School Asthma Study (0476-340)|A Multicenter, Randomized, Double-blind, Placebo-Controlled Parallel Group 8-week Study to Evaluate the Efficacy and Safety of Chewable Montelukast When Initiated at the Start of the School Year in Pediatric Patients With Chronic Asthma|Completed||Phase 3|1162|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:17:49.063984|2018-06-01 03:17:49.063984
NCT00461019|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2011-03-04|2007-04-16|2007-04-17|Estimate|||||||2011-03-04|2011-03-07|Estimate|February 2007||2007-02-28|March 2011|2011-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||CardioFit™ for the Treatment of Heart Failure|CardioFiT™ for Heart Failure - Safety and Efficacy Study Protocol|Completed||Phase 2|32|Actual|BioControl Medical||1|||f||||f||||||||||2018-06-01 03:17:49.512643|2018-06-01 03:17:49.512643
NCT00461006|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16||2016-07-28|2016-07-28|2007-04-16|2007-04-17|Estimate||||2016-07-28|2016-08-01|Estimate|2016-07-28|2016-08-01|Estimate|June 2007||2007-06-30|July 2016|2016-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.|A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.|Completed||Phase 2|176|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:17:49.616734|2018-06-01 03:17:49.616734
NCT00460993|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|2013-11-06||2014-06-16|2007-04-16|2007-04-17|Estimate|2014-06-16|2014-07-15|Estimate||||2014-06-16|2014-07-15|Estimate|June 2005||2005-06-30|June 2014|2014-06-30|December 2010|Actual|2010-12-31|June 2008|Actual|2008-06-30||Interventional||71 subjects were in baseline. But only 31 subjects enrolled into the study intervention portion used for analysis.|Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients|Efficacy and Safety of Eszopiclone (Lunesta) in Nursing Home Patients|Completed||Phase 4|71|Actual|Emory University|Low power to detect statistically significant effects of the interventions on outcomes; Inability to examine predictors of responsiveness because of the small sample size and the large number of predictors of response.|2|||f||||t||||||||||2018-06-01 03:17:49.764569|2018-06-01 03:17:49.764569
NCT00458783|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2018-04-05|2007-04-10|2007-04-11|Estimate|||||||2018-04-05|2018-04-06|Actual|April 2007||2007-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Red Cell Storage Duration and Outcomes in Cardiac Surgery|Red Cell Storage Duration and Outcomes in Cardiac Surgery|Active, not recruiting||N/A|2800|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-06-01 03:18:38.25861|2018-06-01 03:18:38.25861
NCT00460967|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2007-11-06|2007-04-16|2007-04-17|Estimate|||||||2007-11-06|2007-11-07|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|December 2009|Anticipated|2009-12-31|||||Interventional|RHEO-AMD||Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis|Safety and Effectiveness, in a Multi-Center, Randomized, Sham Controlled Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD)Using Rheopheresis|Suspended||Phase 3|325|Anticipated|OccuLogix||2||"In light of the company's current financial position we have indefinately suspended the~   Rheo-AMD trial."|f||||f||||||||||2018-06-01 03:17:50.066719|2018-06-01 03:17:50.066719
NCT00460954|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2008-08-13|2007-04-16|2007-04-17|Estimate|||||||2008-08-13|2008-08-14|Estimate|June 2007||2007-06-30|August 2008|2008-08-31|August 2007|Actual|2007-08-31|||||Observational|||A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects|An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects|Completed|||20|Anticipated|Bristol-Myers Squibb|||||||||||||||||||2018-06-01 03:17:50.17715|2018-06-01 03:17:50.17715
NCT00460941|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16||2016-06-28|2016-11-01|2007-04-16|2007-04-17|Estimate||||2016-06-28|2016-06-30|Estimate|2016-11-01|2016-11-02|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.|A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.|Completed||Phase 2|133|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 03:17:50.304232|2018-06-01 03:17:50.304232
NCT00460928|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2018-01-10|2007-04-13|2007-04-17|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2007||2007-04-30|January 2018|2018-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PITCH||Preventive IVIG Therapy for Congenital Heart Block|Preventive IVIG Therapy for Congenital Heart Block (The PITCH Study)|Completed||Phase 2/Phase 3|54|Actual|New York University School of Medicine||1|||f||||f|t|f|||f|||||2018-06-01 03:17:50.402571|2018-06-01 03:17:50.402571
NCT00460915|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2010-03-01|2007-04-16|2007-04-17|Estimate|||||||2010-03-01|2010-03-02|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|ELDER||Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years|Korea University Guro Hospital|Completed||Phase 4|204|Anticipated|Korea University Guro Hospital|||||f||||||||||||||2018-06-01 03:17:50.480628|2018-06-01 03:17:50.480628
NCT00460902|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-15|||2015-03-18|2007-04-15|2007-04-17|Estimate|||||||2015-03-18|2015-03-20|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Evaluation of the Deep TMS H-Coil in the Treatment of Major Depression- Augmentation of Antidepressant Medication|Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression|Completed||Phase 1/Phase 2|57|Actual|Hadassah Medical Organization||3|||f||||f||||||||||2018-06-01 03:17:50.534742|2018-06-01 03:17:50.534742
NCT00460889|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2015-04-02|2007-04-13|2007-04-17|Estimate|||||||2015-04-02|2015-04-06|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Renal Donor Comparison of Outcomes: Hand Assist Versus Laparoscopic Nephrectomy|Renal Donor Comparison of Outcomes: Hand Assist Versus Laparoscopic Nephrectomy|Withdrawn|||0|Actual|Columbia University||||Principal Investigator left institution|f||||f||||||||||2018-06-01 03:17:50.593833|2018-06-01 03:17:50.593833
NCT00460876|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2008-04-30|2007-04-13|2007-04-17|Estimate|||||||2008-04-30|2008-05-02|Estimate|March 2007||2007-03-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Phase I Trial of Periocular Topotecan in Retinoblastoma|Toxicity and Activity of Periocular Topotecan in Children With Retinoblastoma|Completed||Phase 1|5|Actual|Hospital JP Garrahan|||||f||||t||||||||||2018-06-01 03:17:50.701966|2018-06-01 03:17:50.701966
NCT00460863|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2014-04-22|2007-04-16|2007-04-17|Estimate|||||||2014-04-22|2014-04-24|Estimate|April 2003||2003-04-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Hemodialysis on the Sleep/Wake Cycle|Effects of Hemodialysis on the Slee/Wake Cycle of Patients on Chronic Hemodialysis|Completed||Phase 1|58|Actual|Emory University|||||f||||t||||||||||2018-06-01 03:17:50.789912|2018-06-01 03:17:50.789912
NCT00460850|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2008-06-27|2007-04-16|2007-04-17|Estimate|||||||2008-06-27|2008-06-30|Estimate|September 2007||2007-09-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|||||Interventional|||A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.|An Open Label Study to Evaluate the Effect of PEGASYS on ALT and HBV DNA Levels in Patients With Lamivudine-Resistant HbeAg-Negative Chronic Hepatitis B|Terminated||Phase 4|60|Anticipated|Hoffmann-La Roche||1||Low recruitment rate due to treatment regimen change|f||||||||||||||2018-06-01 03:17:50.926239|2018-06-01 03:17:50.926239
NCT00460837|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2010-07-23|2007-04-16|2007-04-17|Estimate|||||||2010-07-23|2010-07-26|Estimate|November 2007||2007-11-30|July 2010|2010-07-31|March 2009|Anticipated|2009-03-31|||||Interventional|||Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience|Virtual Colonoscopy: Comparison of Reduced Laxative Virtual Colonoscopy Regimens With Standard Preparation on Patient Experience and Compliance - a Questionnaire Based Study|Withdrawn||Phase 4|150|Anticipated|London North West Healthcare NHS Trust||2||Supply of adequate label was not provided to the MHRA|f||||t||||||||||2018-06-01 03:17:51.113997|2018-06-01 03:17:51.113997
NCT00460824|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-16|||2013-12-29|2007-04-16|2007-04-17|Estimate|||||||2013-12-29|2013-12-31|Estimate|July 1988||1988-07-31|December 2013|2013-12-31||||||||Observational|||A Retrospective Review - Anti-HLA Antibodies|A Retrospective Review of Anti-HLA Antibodies and Donor Crossmatch Results as a Predictor of Pediatric Heart Transplant Outcomes|Withdrawn|||0|Actual|Emory University||||Not a Clinical trial. Retrospective Data review only.|f||||f||||||||||2018-06-01 03:17:51.240068|2018-06-01 03:17:51.240068
NCT00460811|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2012-09-28||2013-01-29|2007-04-13|2007-04-16|Estimate|2012-12-19|2013-01-30|Estimate||||2013-01-29|2013-02-04|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-design, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Irritable Bowel Syndrome With Constipation|Completed||Phase 2|420|Actual|Ironwood Pharmaceuticals, Inc.||5|||f||||||||||||||2018-06-01 03:17:51.425118|2018-06-01 03:17:51.425118
NCT00460616|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2008-04-14|2007-04-13|2007-04-16|Estimate|||||||2008-04-14|2008-04-16|Estimate|January 2007||2007-01-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Observational|ValveCab||Cardiac Valve Complications in Prolactinomas Treated With Cabergoline|Observational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With Cabergoline|Completed|||50|Actual|Federico II University|||2||f||||f||||||||||2018-06-01 03:17:56.686479|2018-06-01 03:17:56.686479
NCT00460798|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2010-09-30||2010-11-03|2007-04-13|2007-04-16|Estimate|2010-09-30|2010-11-04|Estimate||||2010-11-03|2010-11-16|Estimate|February 2007||2007-02-28|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|SUNIKA||SUTENT® In The First Line Treatment Of Renal Cell Carcinoma|A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Cancer|Completed|||356|Actual|Pfizer|Owing to extent of missing data, the planned TTP analyses derived from standardized lesion measurement was not reported. An additional TTP analysis using Investigator Disease Status and Overall Objective Tumor Assessments at 12 months was reported.||1||f||||f||||||||||2018-06-01 03:17:53.190466|2018-06-01 03:17:53.190466
NCT00460785|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-07-05|2007-04-13|2007-04-16|Estimate|||||||2007-07-05|2007-07-06|Estimate|February 2007||2007-02-28|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Bioequivalence Trial of a New Opioid Combination Compared to Reference|Phase 1 Single Center Trial to Demonstrate the Bioequivalence of a New Combination Analgesic Formulation as Compared to an Equimolar Marketed Formulation|Completed||Phase 1|32||Grünenthal GmbH|||||f||||||||||||||2018-06-01 03:17:54.121051|2018-06-01 03:17:54.121051
NCT00460759|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2017-12-05|2007-04-12|2007-04-16|Estimate|||||||2017-12-05|2017-12-07|Actual|June 2007|Actual|2007-06-30|December 2017|2017-12-31|August 24, 2008|Actual|2008-08-24|August 24, 2008|Actual|2008-08-24||Interventional|||Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine|Pharmacokinetic Issues in the Use of Moxifloxacin Plus Rifapentine|Terminated||Phase 1|15|Actual|Johns Hopkins University||1||||||||t|f||||||||2018-06-01 03:17:54.212999|2018-06-01 03:17:54.212999
NCT00460746|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2009-10-02||2013-07-24|2007-04-13|2007-04-16|Estimate|2009-10-02|2009-11-10|Estimate||||2013-07-24|2013-07-31|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.|Open Label Phase 3b, 48 wk Pilot Study of the Antiviral Efficacy and Tolerability of Combination of PREZISTA/r and TMC125 When Substituted for Enfuvirtide, Current Protease Inhibitor(s) and NNRTI(s) in Antiretroviral Resistant Patients With Viral Suppression But Who Are Intolerant of Enfuvirtide.|Completed||Phase 3|10|Actual|Tibotec, Inc|Conclusions on efficacy and safety are limited as the target enrollment of 40 subjects was not reached due to a shortage of eligible subjects.|1|||f||||f||||||||||2018-06-01 03:17:54.297029|2018-06-01 03:17:54.297029
NCT00460733|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2011-10-03|2007-04-13|2007-04-16|Estimate|||||||2011-10-03|2011-10-04|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SOLID||SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.|Local (Brazil) Study, Multicenter, Opened, Comparative, Randomized, With Parallel Groups, Phase IV, in Post Menopausal Woman With Colles' Fracture of the Risedronate Sodium Usage in the Consolidation and in the Callus of the Colles'Fracture.|Completed||Phase 4|141|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:17:54.840312|2018-06-01 03:17:54.840312
NCT00460720|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2010-04-26|2007-04-13|2007-04-16|Estimate|||||||2010-04-26|2010-04-28|Estimate||||April 2010|2010-04-30|February 2006|Actual|2006-02-28|||||Observational|||Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)|Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)|Completed|||591|Actual|Johnson & Johnson Taiwan Ltd|||1||f||||||||||||||2018-06-01 03:17:54.915868|2018-06-01 03:17:54.915868
NCT00460707|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2017-08-02|2007-04-12|2007-04-16|Estimate|||||||2017-08-02|2017-08-03|Actual|April 16, 2007|Actual|2007-04-16|August 2017|2017-08-31|August 27, 2007|Actual|2007-08-27|August 27, 2007|Actual|2007-08-27||Interventional|||A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults|A Phase I, Randomized, Double-Blind Study to Assess the Effects of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of Repeat Oral Dosing of Casopitant in Healthy Subjects|Completed||Phase 1|85|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:17:54.977328|2018-06-01 03:17:54.977328
NCT00460694|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2017-02-09|2007-04-13|2007-04-16|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2006||2006-08-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|alloCIK||Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies|A Phase II Trial on Allogeneic Cytokine-induced Killer Cell Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies|Completed||Phase 1/Phase 2|24|Actual|Singapore General Hospital|||||f||||t||||||||||2018-06-01 03:17:55.105377|2018-06-01 03:17:55.105377
NCT00460681|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2007-10-30|2007-04-13|2007-04-16|Estimate|||||||2007-10-30|2007-10-31|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|February 2012|Anticipated|2012-02-29|||||Interventional|||Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma|Phase III Study of Thymopentin in Patients After Curative Resection of Small|Unknown status|Recruiting|Phase 3|220|Anticipated|Fudan University|||||f||||t||||||||||2018-06-01 03:17:55.169256|2018-06-01 03:17:55.169256
NCT00460668|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2013-04-05|2007-04-13|2007-04-16|Estimate|||||||2013-04-05|2013-04-08|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Post-thoracotomy Pulmonary Rehabilitation on Quality of Life|A Prospective Single Centre Open Randomized Trial on the Effect of Post-thoracotomy Pulmonary Rehabilitation on Quality of Life|Completed||N/A|57|Actual|Isala||2|||f||||t||||||||||2018-06-01 03:17:55.324996|2018-06-01 03:17:55.324996
NCT00460655|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2009-09-02||2010-08-30|2007-04-13|2007-04-16|Estimate|2009-12-21|2010-01-26|Estimate||||2010-08-30|2010-09-08|Estimate|May 2007||2007-05-31|August 2010|2010-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity|A Multicenter Study to Evaluate the Efficacy and Safety in Patients With Post-Stroke Lower Limb Spasticity Receiving a Double-Blind, Placebo-Controlled GSK1358820 Treatment Followed by an Open-Label GSK1358820 Treatment|Completed||Phase 3|120|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:17:55.459468|2018-06-01 03:17:55.459468
NCT00460642|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2010-05-24|2007-04-13|2007-04-16|Estimate|||||||2010-05-24|2010-05-26|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||GnRH Antagonist to Prepare Recipients for Embryo Transfer|Use of GnRH Antagonist (Cetrotide) Protocol, Instead of Agonist, to Prepare Recipients for Embryo Transfer|Completed||N/A|130|Anticipated|Institute for Human Reproduction (IHR)|||||f||||t||||||||||2018-06-01 03:17:56.5267|2018-06-01 03:17:56.5267
NCT00460629|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2013-06-19|2007-04-12|2007-04-16|Estimate|||||||2013-06-19|2013-06-20|Estimate|March 2005||2005-03-31|June 2013|2013-06-30||||December 2011|Actual|2011-12-31||Interventional|||Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation|Specific Cellular Immunotherapy in Patients With Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation|Completed||Phase 1/Phase 2|20|Anticipated|University Hospital Carl Gustav Carus|||||f||||f||||||||||2018-06-01 03:17:56.60119|2018-06-01 03:17:56.60119
NCT00460603|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2013-03-28||2013-11-07|2007-04-13|2007-04-16|Estimate|2013-06-03|2013-06-04|Estimate||||2013-11-07|2013-12-06|Estimate|January 2006||2006-01-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|April 2012|Actual|2012-04-30||Interventional|||Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer|A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion|Completed||Phase 1/Phase 2|187|Actual|Pfizer|Time to Treatment Failure (TTF) was included as a secondary endpoint of the study after change in analysis plan.|3|||f||||f||||||||||2018-06-01 03:17:57.03859|2018-06-01 03:17:57.03859
NCT00460590|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2008-08-06|2007-04-13|2007-04-16|Estimate|||||||2008-08-06|2008-08-07|Estimate|October 2005||2005-10-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine MVA85A, in Healthy Volunteers With no Evidence of Infection With Mycobacterium Tuberculosis, in Cape Town|Completed||Phase 1|36|Actual|University of Oxford||3|||f||||t||||||||||2018-06-01 03:18:03.610363|2018-06-01 03:18:03.610363
NCT00460577|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2010-12-13||2011-03-23|2007-04-13|2007-04-16|Estimate|2011-03-23|2011-04-19|Estimate||||2011-03-23|2011-04-19|Estimate|March 2007||2007-03-31|March 2011|2011-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction|Randomized, Double Blind, Double Dummy, Placebo Controlled Trial to Compare the Effectiveness of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Asthmatic Children (5-<12 Years) With Acute Bronchial Obstruction Attending Emergency Services|Completed||Phase 4|60|Actual|Novartis|Secondary Outcome Measure 2: Safety Assessed by Pulse Oxymetry, Clinical Assessments, Adverse Events has not been posted. Analysis of Pulse Oxymetry and Clinical Assessment was not performed. Adverse events are reported in the Adverse Event section.|2|||f||||||||||||||2018-06-01 03:18:03.726778|2018-06-01 03:18:03.726778
NCT00460564|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2009-09-02||2017-05-25|2007-04-13|2007-04-16|Estimate|2009-12-21|2010-02-10|Estimate||||2017-05-25|2017-05-30|Actual|May 2007||2007-05-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity|A Multicenter Study to Evaluate the Efficacy and Safety in Patients With Post-Stroke Upper Limb Spasticity Receiving a Double-Blind, Placebo-Controlled GSK1358820 Treatment Followed by an Open-Label GSK1358820 Treatment|Completed||Phase 3|109|Actual|GlaxoSmithKline|The frequency threshold (5%) for reporting other adverse events is based on the result of the double-blind phase for the first four arms listed in the table and on the open-label phase for the last four arms listed in the table.|4|||f||||f||||||||||2018-06-01 03:18:04.235369|2018-06-01 03:18:04.235369
NCT00460551|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|2011-09-12||2011-12-05|2007-04-13|2007-04-16|Estimate|2011-10-28|2011-12-05|Estimate||||2011-12-05|2011-12-06|Estimate|April 2007||2007-04-30|December 2011|2011-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer|A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients|Terminated||Phase 2|13|Actual|Genmab|The trial was prematurely closed. The original protocol contained Part 1A, followed by Part 1B and Part 2. The trial was terminated when 13 patients were enrolled in Part 1A. Scans for efficacy were planned for Part 1B and Part 2.|1||Due to considerations regarding the appropriate therapeutic regimen for these patients.|f||||t||||||||||2018-06-01 03:18:06.694772|2018-06-01 03:18:06.694772
NCT00460538|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2010-04-02|2007-04-13|2007-04-16|Estimate|||||||2010-04-02|2010-04-05|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms|Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms|Completed||Phase 4|48|Actual|Milsing d.o.o.||2|||f||||t||||||||||2018-06-01 03:18:07.088653|2018-06-01 03:18:07.088653
NCT00460525|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|2010-07-02||2015-05-18|2007-04-12|2007-04-16|Estimate|2010-08-04|2010-08-10|Estimate||||2015-05-18|2015-06-12|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali|Randomized, Controlled Phase II Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali|Completed||Phase 2|400|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-06-01 03:18:07.235549|2018-06-01 03:18:07.235549
NCT00460512|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2017-10-23|2007-04-13|2007-04-16|Estimate|||||||2017-10-23|2017-10-24|Actual|April 25, 2007|Actual|2007-04-25|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|January 22, 2009|Actual|2009-01-22||Interventional|PERFlexS||An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia|Active, not recruiting||Phase 3|1815|Actual|Janssen-Cilag International NV||1|||f||||f||f||||||||2018-06-01 03:18:08.425618|2018-06-01 03:18:08.425618
NCT00460499|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2015-06-22|2007-04-12|2007-04-16|Estimate|||||||2015-06-22|2015-06-23|Estimate|July 2004||2004-07-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control||Completed||Phase 1|250|Actual|American Heart Association||3|||f||||t||||||||||2018-06-01 03:18:08.911641|2018-06-01 03:18:08.911641
NCT00460486|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2015-05-20|2007-04-13|2007-04-16|Estimate|||||||2015-05-20|2015-05-21|Estimate|September 2006||2006-09-30|May 2015|2015-05-31||||November 2007|Actual|2007-11-30||Interventional|||Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule|Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older|Completed||Phase 3|330||Pfizer|||||f||||t||||||||||2018-06-01 03:18:09.23654|2018-06-01 03:18:09.23654
NCT00460473|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|||2015-07-23|2007-04-13|2007-04-16|Estimate|||||||2015-07-23|2015-07-24|Estimate|April 2007||2007-04-30|July 2015|2015-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery|A Phase III,Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel, Multicenter Study Evaluating the Efficacy and Safety of Dexmedetomidine in the Prevention of Postoperative Delirium in Subjects Undergoing Surgery for Fractured Hip With General Anesthesia|Terminated||Phase 3|52|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2||"The incidence of post-operative delirium observed from interim blinded data was significantly~   lower than the current literature in this population."|f||||f||||||||||2018-06-01 03:18:09.313581|2018-06-01 03:18:09.313581
NCT00460460|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2011-01-24|2007-04-12|2007-04-16|Estimate|||||||2011-01-24|2011-01-25|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|August 2007|Actual|2007-08-31|||||Interventional|||Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies|A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN|Terminated||Phase 1|75|Anticipated|AstraZeneca||||Study was terminated due to low enrollment|f||||||||||||||2018-06-01 03:18:09.441024|2018-06-01 03:18:09.441024
NCT00460447|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2007-04-12|2007-04-12|2007-04-16|Estimate|||||||2007-04-12|2007-04-16|Estimate|October 2004||2004-10-31|April 2007|2007-04-30||||||||Interventional|||Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation|Gentuzumab Ozogamicin Berfore Allogeneic Stem Cell Transplantation in Patients With Relapsed CD33+ Acute Myeloid Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|30||University Hospital Carl Gustav Carus|||||f||||f||||||||||2018-06-01 03:18:09.513189|2018-06-01 03:18:09.513189
NCT00460434|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2017-04-18||2018-04-30|2007-04-13|2007-04-16|Estimate|2017-08-08|2017-09-11|Actual||||2018-04-30|2018-05-30|Actual|May 2007||2007-05-31|April 2018|2018-04-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|OPUS||Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial|Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling (OPUS) Trial|Completed||Phase 2|337|Actual|NICHD Pelvic Floor Disorders Network||2|||f||||t||||||||||2018-06-01 03:18:09.690515|2018-06-01 03:18:09.690515
NCT00460421|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|2012-05-30||2014-11-04|2007-04-12|2007-04-16|Estimate|2012-05-30|2012-07-03|Estimate||||2014-11-04|2014-12-05|Estimate|August 2006||2006-08-31|November 2014|2014-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT|A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects With Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Completed||Phase 1|27|Actual|Swedish Orphan Biovitrum|The original protocol included a long term follow-up (LTFU) phase up to 10 years. This was reduced in a protocol amendment to up to the time when the last enrolled subject had completed the day +100 follow-up.|1|||f||||t||||||||||2018-06-01 03:18:10.572924|2018-06-01 03:18:10.572924
NCT00460408|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-13|2012-09-24||2012-11-14|2007-04-13|2007-04-16|Estimate|2012-11-14|2012-12-11|Estimate||||2012-11-14|2012-12-11|Estimate|August 2006||2006-08-31|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration|European Epidemiologic COHORT Study: A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration (AMD) In Europe|Completed|||501|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:18:11.204061|2018-06-01 03:18:11.204061
NCT00460395|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2012-02-22|2007-04-13|2007-04-16|Estimate|||||||2012-02-22|2012-02-24|Estimate|January 1998||1998-01-31|February 2012|2012-02-29|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial|Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial|Completed||Phase 3|64|Actual|M.D. Anderson Cancer Center|||||f||||t||||||||||2018-06-01 03:18:12.43279|2018-06-01 03:18:12.43279
NCT00460382|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2010-09-16|2007-04-12|2007-04-13|Estimate|||||||2010-09-16|2010-09-17|Estimate|May 2007||2007-05-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|March 2008|Actual|2008-03-31||Interventional|ANRS139 TRIO||Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses|Prospective Clinical Trial to Assess Safety and Efficacy of DRV/r(TMC 114/r), ETV(TMC 125) and MK-0518 in Addition to OBT in HIV-1 Infected Patients With Limited to No Treatment Options ANRS 139 TRIO|Completed||Phase 2|103|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 03:18:12.57288|2018-06-01 03:18:12.57288
NCT00460369|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2008-04-11|2007-04-12|2007-04-13|Estimate|||||||2008-04-11|2008-04-14|Estimate|April 2007||2007-04-30|April 2008|2008-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Treatment of Uncomplicated Malaria in Benin|Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study|Completed||N/A|240|Actual|Institut de Recherche pour le Developpement||3|||f||||t||||||||||2018-06-01 03:18:13.009408|2018-06-01 03:18:13.009408
NCT00460356|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2017-08-23|2007-04-11|2007-04-13|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2, 2007|Actual|2007-04-02|August 2017|2017-08-31|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Observational|||Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes|Glycoprotein and Glycan Profiling in Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA &gt; 4 CM, IIB to IVA) Undergoing Pelvic and Para-aortic (Abdominal) Lymphadenectomy|Completed|||159|Actual|Gynecologic Oncology Group|||1||f||||||||||||||2018-06-01 03:18:13.19618|2018-06-01 03:18:13.19618
NCT00460343|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-07-09|2007-04-11|2007-04-13|Estimate|||||||2008-07-09|2008-07-10|Estimate|April 2007||2007-04-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Pharmacy Implementation Trial: Adherence to Antihypertensive Therapy|Implementation of a Pharmacy-Intervention to Establish and if Necessary Improve Adherence to Antihypertensive Therapy. A Cluster Randomized Trial.|Completed||N/A|57|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 03:18:13.33219|2018-06-01 03:18:13.33219
NCT00460330|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2007-04-12|2007-04-12|2007-04-13|Estimate|||||||2007-04-12|2007-04-13|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|December 2008|Anticipated|2008-12-31|||||Observational|||Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT|The Value of Real-Time Polymerase Chain Reaction (RT-PCR) Assay, Galactomannan and β-D-Glucan Detection (GM/G-Test) for Diagnosis of Invasive Fungal Infection (IFI) in Chinese Patients After Hematopoietic Stem Cell Transplantation (HSCT)|Unknown status|Recruiting||120||Peking University|||||f||||t||||||||||2018-06-01 03:18:13.409846|2018-06-01 03:18:13.409846
NCT00460317|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12||2015-07-13|2015-08-24|2007-04-12|2007-04-13|Estimate||||2015-07-13|2015-08-03|Estimate|2015-08-24|2015-09-07|Estimate|July 2007||2007-07-31|August 2015|2015-08-31|August 2013|Actual|2013-08-31|March 2011|Actual|2011-03-31||Interventional|||MONET1-MOtesanib NSCLC Efficacy and Tolerability Study|A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer.|Terminated||Phase 3|1450|Actual|Amgen||2||"Amgen discontinued the development of AMG706 because 20050201 did not meet its primary~   objective."|f||||t||||||||||2018-06-01 03:18:13.529674|2018-06-01 03:18:13.529674
NCT00460304|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2009-04-02|2007-04-12|2007-04-13|Estimate|||||||2009-04-02|2009-04-03|Estimate|September 2007||2007-09-30|April 2009|2009-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||The Effect of Pramlintide on Meal Time Insulin Bolus|The Effect of Pramlintide on Meal Time Insulin Bolus|Completed||N/A|12|Anticipated|Diabetes Care Center|||||f||||f||||||||||2018-06-01 03:18:13.644929|2018-06-01 03:18:13.644929
NCT00460291|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2007-10-02|2007-04-12|2007-04-13|Estimate|||||||2007-10-02|2007-10-03|Estimate|June 2005||2005-06-30|October 2007|2007-10-31|December 2008|Anticipated|2008-12-31|||||Interventional|PROVENA||Pilot Study to Asses the Function and Patency of Polyester-Coated Composite Bypasses From Autologous Varicose Veins|Pilot Study to Asses the Function and Patency of Polyester-Coated Composite Bypasses From Autologous Varicose Veins|Unknown status|Recruiting|N/A|50|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-06-01 03:18:13.723134|2018-06-01 03:18:13.723134
NCT00460278|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2008-06-02|2007-04-11|2007-04-13|Estimate|||||||2008-06-02|2008-06-04|Estimate|April 2007||2007-04-30|June 2008|2008-06-30||||||||Interventional|||Study of XL418 in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL418 Administered Orally Daily to Subjects With Solid Tumors|Suspended||Phase 1|63|Anticipated|Exelixis||||Enrollment suspended due to low drug exposure.|||||t||||||||||2018-06-01 03:18:13.863625|2018-06-01 03:18:13.863625
NCT00460265|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|2011-05-13||2014-02-03|2007-04-12|2007-04-13|Estimate|2011-05-13|2011-06-14|Estimate||||2014-02-03|2014-03-07|Estimate|May 2007||2007-05-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2010|Actual|2010-05-31||Interventional|SPECTRUM||Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 3|658|Actual|Amgen||2|||f||||t||||||||||2018-06-01 03:18:13.961168|2018-06-01 03:18:13.961168
NCT00460252|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2007-04-12|2007-04-12|2007-04-13|Estimate|||||||2007-04-12|2007-04-13|Estimate|May 2006||2006-05-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Tight Glycemic Control by eMPC Algorithm in Medical ICU Patients.|An Open, Mono-Centre Randomised Controlled Trial to Investigate the Feasibility of Blood Glucose Control With the Software-Algorithm eMPC (Enhanced Model Predictive Control) Via the Arterial-Intravenous Route in Patients at the Medical Intensive Care Unit.|Completed||N/A|50||Medical University of Graz|||||f||||f||||||||||2018-06-01 03:18:15.179432|2018-06-01 03:18:15.179432
NCT00460239|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2012-08-18||2017-01-11|2007-04-11|2007-04-13|Estimate|2017-01-11|2017-03-03|Actual||||2017-01-11|2017-03-03|Actual|January 2007||2007-01-31|January 2017|2017-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Buprenorphine's Dose Response Curve|Evaluation of Opioid Antagonist Activity in Humans|Completed||Phase 2|12|Actual|Johns Hopkins University||8|||f||||f||||||||||2018-06-01 03:18:15.356769|2018-06-01 03:18:15.356769
NCT00460226|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2012-03-15|2007-04-12|2007-04-13|Estimate|||||||2012-03-15|2012-03-19|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Lamictal Bipolar Observational Study|A Multi-centre, Observational Study to Evaluate the Incidence of Non-serious Rash in Korean Bipolar I Patients With Lamotrigine Therapy in Real World Setting|Completed|||238|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 03:18:16.111652|2018-06-01 03:18:16.111652
NCT00460213|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2013-12-05|2007-04-12|2007-04-13|Estimate|||||||2013-12-05|2013-12-09|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|December 2008|Actual|2008-12-31||Interventional|||Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study|Study on Optimal Anti-hypertensive Therapy With Valsartan by Using Home Blood Pressure Measurement|Completed||Phase 4|103|Actual|Kitakyushu-Tsuyazaki Hospital||1|||f||||t||||||||||2018-06-01 03:18:16.189248|2018-06-01 03:18:16.189248
NCT00460200|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2012-10-03|2007-04-11|2007-04-13|Estimate|||||||2012-10-03|2012-10-04|Estimate|December 2003||2003-12-31|October 2012|2012-10-31||||||||Observational|||Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer|Depression and IL-6 in Epithelial Ovarian Cancer: Genetic Diathesis and Psychological Stress|Withdrawn|||0|Actual|Jonsson Comprehensive Cancer Center||||no patient accrual|f||||f||||||||||2018-06-01 03:18:16.283921|2018-06-01 03:18:16.283921
NCT00460187|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2008-10-20|2007-04-11|2007-04-13|Estimate|||||||2008-10-20|2008-10-21|Estimate|March 2007||2007-03-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|||||Interventional|EPIC||EPIC US Pivotal Study|Evaluating the Use of the FiberNet Embolic Protection System in Carotid Artery Stenting: The EPIC US Pivotal Study.|Completed||N/A|237|Actual|Lumen Biomedical|||||f||||t||||||||||2018-06-01 03:18:16.356596|2018-06-01 03:18:16.356596
NCT00460174|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2017-03-15|2007-04-11|2007-04-13|Estimate|||||||2017-03-15|2017-03-17|Actual|October 2005||2005-10-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer|A Phase II Trial of Weekly Gemcitabine Hydrochloride and Bevacizumab in Combination With Abdominal Radiation Therapy in Patients With Localized Pancreatic Cancer|Active, not recruiting||Phase 2|31|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 03:18:16.414139|2018-06-01 03:18:16.414139
NCT00460161|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2009-02-17|2007-04-12|2007-04-13|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2009||2009-02-28|August 2008|2008-08-31||||August 2009|Anticipated|2009-08-31||Interventional|||Acupuncture for Phantom Limb Pain|Acupuncture for Phantom Limb Pain: A Randomized, Double-Blind, Placebo/Sham - Controlled Study|Suspended||Phase 3|40|Anticipated|Shaare Zedek Medical Center||2||Lack of patients|f||||f||||||||||2018-06-01 03:18:16.538529|2018-06-01 03:18:16.538529
NCT00460148|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2016-10-27|2007-04-11|2007-04-13|Estimate|||||||2016-10-27|2016-10-28|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole|An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets.|Completed||Phase 2|28|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:18:16.620277|2018-06-01 03:18:16.620277
NCT00460135|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2009-03-03|2007-04-12|2007-04-13|Estimate|||||||2009-03-03|2009-03-04|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Impact of Resistance Exercise Training On Metabolic Dysregulation in Obese Children.|The Impact of Resistance Exercise Training On Metabolic Dysregulation in Obese Children.|Completed||N/A|20|Actual|McGill University Health Center||2|||f||||f||||||||||2018-06-01 03:18:16.724662|2018-06-01 03:18:16.724662
NCT00460122|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2018-05-19|2007-04-12|2007-04-13|Estimate|||||||2018-05-19|2018-05-22|Actual|April 10, 2007||2007-04-10|August 10, 2012|2012-08-10|August 10, 2012||2012-08-10|||||Observational|||Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients|Pilot Study of the Incidence of HLA Class I and Class II Antibodies in Platelet Donors and Their Effects on the Transfusion Recipient|Completed|||135|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:18:16.789971|2018-06-01 03:18:16.789971
NCT00459589|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2012-06-19|2007-04-11|2007-04-12|Estimate|||||||2012-06-19|2012-06-20|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|INOGAD||Nutritional Intervention in Geriatric Oncology|Nutritional Intervention in Geriatric Oncology in Patients at Risk of Undernutrition|Completed||N/A|341|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 03:18:27.606421|2018-06-01 03:18:27.606421
NCT00460109|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2017-01-18||2017-03-07|2007-04-11|2007-04-13|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|April 2008||2008-04-30|March 2017|2017-03-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma|A Phase II Clinical Trial of Denileukin Diftitox in Combination With Rituximab in Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|24|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 03:18:16.89245|2018-06-01 03:18:16.89245
NCT00460096|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2007-10-16|2007-04-12|2007-04-13|Estimate|||||||2007-10-16|2007-10-17|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|Kamada API||Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency|Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency|Completed||Phase 2/Phase 3|50|Anticipated|Kamada, Ltd.|||||f||||t||||||||||2018-06-01 03:18:17.523515|2018-06-01 03:18:17.523515
NCT00460083|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2008-02-05|2007-04-11|2007-04-13|Estimate|||||||2008-02-05|2008-02-06|Estimate|April 2007||2007-04-30|February 2008|2008-02-29|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis|A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis|Completed||Phase 4|35|Actual|Ceragenix Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:18:17.594472|2018-06-01 03:18:17.594472
NCT00460070|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2011-07-26|2007-04-12|2007-04-13|Estimate|||||||2011-07-26|2011-07-27|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|||||Observational|||Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine or Lamotrigine for Epilepsy|Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females.|Completed|||240|Actual|Rikshospitalet University Hospital|||||f||||f||||||||||2018-06-01 03:18:17.695984|2018-06-01 03:18:17.695984
NCT00460057|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2014-08-02|2007-04-12|2007-04-13|Estimate|||||||2014-08-02|2014-08-05|Estimate|March 2006||2006-03-31|August 2014|2014-08-31|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|||The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss|The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women|Completed||Phase 4|63|Actual|Eulji University Hospital||1|||f||||f||||||||||2018-06-01 03:18:17.795999|2018-06-01 03:18:17.795999
NCT00460044|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2007-04-12|2007-04-12|2007-04-13|Estimate|||||||2007-04-12|2007-04-13|Estimate|January 2002||2002-01-31|April 2007|2007-04-30|July 2003|Actual|2003-07-31|||||Observational|||ADMA and Mechanical Ventilation in Preterm Infants|Plasma ADMA Concentrations at Birth and Mechanical Ventilation in Preterm Infants|Completed|||35||VU University Medical Center|||||f||||f||||||||||2018-06-01 03:18:17.887845|2018-06-01 03:18:17.887845
NCT00460031|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2014-07-14||2017-03-16|2007-04-11|2007-04-13|Estimate|2015-11-05|2015-12-09|Estimate||||2017-03-16|2017-04-13|Actual|September 1, 2006|Actual|2006-09-01|March 2017|2017-03-31|March 20, 2018|Anticipated|2018-03-20|August 31, 2010|Actual|2010-08-31||Interventional|||Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation|Active, not recruiting||Phase 2|34|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:18:19.058909|2018-06-01 03:18:19.058909
NCT00460018|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2009-06-18|2007-04-11|2007-04-13|Estimate|||||||2009-06-18|2009-06-19|Estimate|September 2005||2005-09-30|January 2009|2009-01-31||||||||Interventional|DEBI||Diet, Exercise, and Breastfeeding Intervention Program for Women With Gestational Diabetes (DEBI Trial)|Diet, Exercise and Breastfeeding Intervention (DEBI) Program for Women With Gestational Diabetes|Completed||Phase 2|180|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 03:18:19.457381|2018-06-01 03:18:19.457381
NCT00460005|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2008-04-14|2007-04-12|2007-04-13|Estimate|||||||2008-04-14|2008-04-15|Estimate|January 2006||2006-01-31|April 2008|2008-04-30||||||||Observational|||Clinical Study Of Migraine Evolution|A Multicenter Study to Determine the Clinical Characteristics of the Temporal Aspects of Migraine in a Canadian Population: Clinical Study Of Migraine Evolution (C-SOME)|Completed|||250||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:18:19.606331|2018-06-01 03:18:19.606331
NCT00459992|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2018-05-19|2007-04-12|2007-04-13|Estimate|||||||2018-05-19|2018-05-22|Actual|April 10, 2007||2007-04-10|December 11, 2014|2014-12-11|February 14, 2011|Actual|2011-02-14|February 14, 2011|Actual|2011-02-14||Interventional|||Effects of Betahistine Hydrochloride in Overweight Women|Pilot Study of the Metabolic Effects of Betahistine Hydrochloride in Overweight Women|Completed||Phase 1|150|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:18:19.772798|2018-06-01 03:18:19.772798
NCT00459979|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2013-11-19||2014-02-04|2007-04-11|2007-04-13|Estimate|2013-11-19|2014-01-07|Estimate||||2014-02-04|2014-03-07|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|March 2011|Actual|2011-03-31||Interventional|||Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery|A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors|Completed||Phase 2|30|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:18:19.88245|2018-06-01 03:18:19.88245
NCT00459966|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2007-04-12|2007-04-12|2007-04-13|Estimate|||||||2007-04-12|2007-04-13|Estimate|February 2005||2005-02-28|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Preoperative Prevention and Early Rehabilitation for Patients Undergoing Elective Spine Surgery||Completed||N/A|60||Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 03:18:20.366707|2018-06-01 03:18:20.366707
NCT00459953|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2016-03-02||2016-05-22|2007-04-11|2007-04-13|Estimate|2016-05-22|2016-05-30|Estimate||||2016-05-22|2016-05-30|Estimate|September 2006||2006-09-30|May 2016|2016-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|Nicoteens|Adolescent smokers were recruited from 10 continuation high schools in the San Francisco Bay Area over a period of 3 years. Recruitment was conducted on a nonrolling basis, with a new cohort participating each academic school year|Extended Cessation Treatment for Teen Smokers|Extended Cessation Treatment for Teen Smokers|Completed||Phase 2/Phase 3|141|Actual|Stanford University||2|||f||||t||||||||No||2018-06-01 03:18:20.466652|2018-06-01 03:18:20.466652
NCT00459940|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2007-04-12|2007-04-12|2007-04-13|Estimate|||||||2007-04-12|2007-04-13|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|March 2006|Actual|2006-03-31|||||Interventional|||The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients|"Can Growth Hormone's Lipolytic and Insulin-Antagonistic Effects be Modified by Peroxisome Proliferator-Activated Gamma Agonists?"|Completed||N/A|20||University of Aarhus|||||f||||t||||||||||2018-06-01 03:18:20.838028|2018-06-01 03:18:20.838028
NCT00459927|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2014-03-18|2007-04-11|2007-04-13|Estimate|||||||2014-03-18|2014-03-19|Estimate|July 2009||2009-07-31|March 2014|2014-03-31||||||||Interventional|||Comparison of Floseal Hemostasis Tonsillectomy With Coblation Tonsillectomy and Cautery Hemostasis Tonsillectomy|Prospective, Controlled Clinical Trial of a Novel Hemostatic Sealant Versus Electrocautery Hemostasis and Coblation Dissection in Patients Undergoing Tonsillectomy|Withdrawn||Phase 2/Phase 3|0|Actual|Kaiser Permanente|||||f||||f||||||||||2018-06-01 03:18:20.917052|2018-06-01 03:18:20.917052
NCT00459914|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2009-01-27|2007-04-11|2007-04-13|Estimate|||||||2009-01-27|2009-01-29|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Sleep Apnea and Refractory Hypertension: Prevalence and Effect of CPAP Treatment|Sleep Apnea in Patients With Refractory Hypertension: Study of the Prevalence and the Effect of CPAP Treatment on Blood Pressure Control, Endothelial Dysfunction and Angiogenesis.|Completed||Phase 2|130|Actual|Fundacio Catalana de Pneumologia||2|||f||||f||||||||||2018-06-01 03:18:21.038791|2018-06-01 03:18:21.038791
NCT00459901|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2015-04-28|2007-04-12|2007-04-13|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2004||2004-06-30|April 2015|2015-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer|Phase II Trial of OSI-774 (Erlotinib, Tarceva™,) and Capecitabine for Patients With Previously Untreated Metastatic Colorectal Cancer|Terminated||Phase 2|13|Actual|Beth Israel Medical Center||||Study halted by drug manufacturer|f||||||||||||||2018-06-01 03:18:21.104044|2018-06-01 03:18:21.104044
NCT00459888|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2010-07-02|2007-04-12|2007-04-13|Estimate|||||||2010-07-02|2010-07-05|Estimate|May 2007||2007-05-31|July 2010|2010-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|CLIMB||Cryoplasty CLIMB-registry|CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5).|Completed||Phase 4|100|Anticipated|Flanders Medical Research Program|||||f||||f||||||||||2018-06-01 03:18:21.198102|2018-06-01 03:18:21.198102
NCT00459875|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2015-09-24||2015-10-26|2007-04-11|2007-04-13|Estimate|2015-10-26|2015-11-26|Estimate||||2015-10-26|2015-11-26|Estimate|March 2007||2007-03-31|October 2015|2015-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer|Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma|Completed||Phase 2|24|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:18:21.393234|2018-06-01 03:18:21.393234
NCT00459862|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2013-10-07||2015-01-28|2007-04-11|2007-04-13|Estimate|2013-10-07|2013-12-05|Estimate||||2015-01-28|2015-02-24|Estimate|March 2007||2007-03-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|April 2009|Actual|2009-04-30||Interventional|||Pazopanib in Treating Patients With Malignant Pleural Mesothelioma|Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|34|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:18:21.772066|2018-06-01 03:18:21.772066
NCT00459849|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2008-05-06|2007-04-11|2007-04-13|Estimate|||||||2008-05-06|2008-05-09|Estimate|July 2000||2000-07-31|May 2008|2008-05-31|July 2007|Anticipated|2007-07-31|July 2007|Anticipated|2007-07-31||Interventional|||Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma|Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma|Unknown status|Active, not recruiting|N/A|175|Anticipated|Barnes Retina Institute|||||f||||f||||||||||2018-06-01 03:18:22.097278|2018-06-01 03:18:22.097278
NCT00459836|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2011-02-28|2007-04-11|2007-04-13|Estimate|||||||2011-02-28|2011-03-02|Estimate|February 2007||2007-02-28|February 2011|2011-02-28||||October 2009|Actual|2009-10-31||Interventional|||PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors|A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors|Completed||Phase 1|42|Actual|Proacta, Incorporated|||||f||||||||||||||2018-06-01 03:18:22.174758|2018-06-01 03:18:22.174758
NCT00459823|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2009-03-23|2007-04-11|2007-04-13|Estimate|||||||2009-03-23|2009-03-24|Estimate|May 2007||2007-05-31|March 2009|2009-03-31||||June 2009|Anticipated|2009-06-30||Interventional|||A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours|A Phase I Open-Label, Single-Arm, Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours|Suspended||Phase 1|40|Anticipated|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:18:22.265897|2018-06-01 03:18:22.265897
NCT00459810|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2010-05-25||2017-04-26|2007-04-11|2007-04-13|Estimate|2010-05-25|2010-06-23|Estimate||||2017-04-26|2017-04-28|Actual|February 2007||2007-02-28|April 2017|2017-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer|A Phase II Study of Paclitaxel Poliglumex (PPX) in Combination With Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer After Docetaxel Chemotherapy|Terminated||Phase 2|21|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 03:18:22.354753|2018-06-01 03:18:22.354753
NCT00459797|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2009-04-20|2007-04-12|2007-04-13|Estimate|||||||2009-04-20|2009-04-21|Estimate|April 2007||2007-04-30|April 2009|2009-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Conventional GlideScope to Single-Use GlideScope Cobalt for Orotracheal Intubation|Comparison of Conventional GlideScope to Single-Use GlideScope Cobalt for Orotracheal Intubation|Completed||N/A|100|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 03:18:22.545917|2018-06-01 03:18:22.545917
NCT00459784|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-12|||2007-04-12|2007-04-12|2007-04-13|Estimate|||||||2007-04-12|2007-04-13|Estimate|November 2006||2006-11-30|April 2007|2007-04-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Implementation Study of Dementia Guidelines in Primary Care|How to Reach Evidence Based Practice in Diagnostic Assessment and Management of Dementia by General Practitioners and Primary Care Nurses? The Effectiveness of an EASYcare Based Educational Program.|Unknown status|Recruiting|N/A|200||Radboud University|||||f||||f||||||||||2018-06-01 03:18:22.618876|2018-06-01 03:18:22.618876
NCT00459771|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2014-12-01|2007-04-11|2007-04-12|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity|Prospective, Randomized, Pharmacological Intervention Study; Evaluating Effect of the Angiotensin II-receptor (AT1) Blocker Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity in Patients Treated With Trastuzumab|Completed||Phase 3|210|Actual|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-06-01 03:18:22.698525|2018-06-01 03:18:22.698525
NCT00459758|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2007-07-31|2007-04-11|2007-04-12|Estimate|||||||2007-07-31|2007-08-01|Estimate|January 2007||2007-01-31|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Effect of Electrical Stimulation at Acupoints on Blood Pressure|Pilot Study Using Electrical Stimulation on Hypertension|Completed||Phase 1|40|Anticipated|Logan College of Chiropractic|||||f||||t||||||||||2018-06-01 03:18:22.797562|2018-06-01 03:18:22.797562
NCT00459576|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2013-04-16|2007-04-11|2007-04-12|Estimate|||||||2013-04-16|2013-04-17|Estimate|May 2005||2005-05-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Observational|||Risk of Asthma in Infants With Atopic Dermatitis|Risk of Asthma in Infants With Atopic Dermatitis|Completed|||120|Actual|Indiana University|||||f||||t||||||Samples With DNA|"~     We have retained nasal cell samples, whole blood cells, and serum.~   "|||2018-06-01 03:18:27.674901|2018-06-01 03:18:27.674901
NCT00459745|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09||2018-04-20|2018-04-20|2007-04-11|2007-04-12|Estimate||||2018-04-20|2018-04-24|Actual|2018-04-20|2018-04-24|Actual|April 2007||2007-04-30|August 2010|2010-08-31|July 2009|Actual|2009-07-31|April 2008|Actual|2008-04-30||Interventional|||A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia|A Multi-Center, Prospective, Longitudinal, Randomized, Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of Daily Administration of Pravastatin 40 mg or Fenofibrate 160 mg or Pravafen (the Combination of Pravastatin and Fenofibrate 40/160 mg) for 12 Weeks Followed by a 52-Week Open-Label Safety Phase of the Pravafen Alone in the Treatment of Combined Hyperlipidemia.|Completed||Phase 3|481|Actual|Shionogi Inc.||3|||f||||||||||||||2018-06-01 03:18:22.862678|2018-06-01 03:18:22.862678
NCT00459732|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2010-11-04||2011-10-04|2007-04-11|2007-04-12|Estimate|2011-08-25|2011-09-30|Estimate||||2011-10-04|2011-10-07|Estimate|April 2006||2006-04-30|October 2011|2011-10-31|February 2011|Actual|2011-02-28|October 2009|Actual|2009-10-31||Interventional|ThinkZn||Zinc & Bone Health in Thalassemia: The Think Zinc Study|Zinc and Bone Metabolism in Thalassemia|Completed||Phase 2|45|Actual|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-06-01 03:18:22.99508|2018-06-01 03:18:22.99508
NCT00459719|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2016-02-23|2007-04-11|2007-04-12|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With Steroids in Patients Undergoing Liver Transplantation and a Pharmacokinetics Study.|Completed||Phase 3|42|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-06-01 03:18:23.349481|2018-06-01 03:18:23.349481
NCT00459706|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2011-09-07||2013-02-20|2007-04-11|2007-04-12|Estimate|2013-02-20|2013-03-28|Estimate||||2013-02-20|2013-03-28|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept|A 3-Month, Randomised, Open-Label, Parallel-Group, Descriptive Study To Explore And Compare Perceptions and Satisfaction For Two Different Delivery Mechanisms For Etanercept (Etanercept Autoinjector And The Etanercept Prefilled Syringe) In Patients With Rheumatoid Arthritis|Completed||Phase 3|640|Actual|Pfizer||2|||f||||||||||||||2018-06-01 03:18:23.547652|2018-06-01 03:18:23.547652
NCT00459693|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2018-05-15|2007-04-11|2007-04-12|Estimate|||||||2018-05-15|2018-05-16|Actual|April 9, 2007||2007-04-09|August 28, 2014|2014-08-28|April 6, 2014|Actual|2014-04-06|April 6, 2014|Actual|2014-04-06||Interventional|||PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using (11C)PBR28 in HIV-Seropositive Patients With (MCMD)|Terminated||N/A|40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:18:25.86795|2018-06-01 03:18:25.86795
NCT00459680|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2010-01-20|2007-04-11|2007-04-12|Estimate|||||||2010-01-20|2010-01-21|Estimate|February 2008||2008-02-29|October 2008|2008-10-31|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Interventional|||Acupuncture and Laser Acupoint Treatment on Hypertension|Acupuncture and Laser Acupoint Treatment on Hypertension|Unknown status|Recruiting|Phase 1|30|Anticipated|Logan College of Chiropractic||2|||f||||f||||||||||2018-06-01 03:18:25.941166|2018-06-01 03:18:25.941166
NCT00459667|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|2009-03-16||2015-04-03|2007-04-11|2007-04-12|Estimate|2009-07-03|2009-08-17|Estimate||||2015-04-03|2015-04-23|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Beyond||BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose|International, Multicenter, Phase IIIb Study of Subcutaneous Every-other-day Treatment of Patients With Relapsing Multiple Sclerosis With (Phase A): Double-blind Betaseron/Betaferon 250µg or 500µg or Open-label Betaseron/Betaferon 250µg and (Phase B): Open-label Betaseron/Betaferon 500µg|Completed||Phase 3|1420|Actual|Bayer|Due to the termination of the study before start of Phase B according to protocol defined stopping rules, functional assessments of multiple sclerosis (FAMS) and EuroQoL (EQ-5D) were not performed.|3|||f||||f||||||||||2018-06-01 03:18:26.10205|2018-06-01 03:18:26.10205
NCT00459654|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2014-06-24|2007-04-11|2007-04-12|Estimate|||||||2014-06-24|2014-06-25|Estimate|February 2004||2004-02-29|June 2014|2014-06-30|May 2007|Actual|2007-05-31|May 2006|Actual|2006-05-31||Interventional|||A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer|A Phase II Randomised, Placebo-controlled, Multicentre Study in Prostate Cancer Patients With Painful Bone Metastases to Evaluate the Efficacy of Repeated Radium-223 Injections|Completed||Phase 2|64|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:18:27.252341|2018-06-01 03:18:27.252341
NCT00459641|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2012-07-16|2007-04-11|2007-04-12|Estimate|||||||2012-07-16|2012-07-17|Estimate|December 2012||2012-12-31|July 2012|2012-07-31|July 2019|Anticipated|2019-07-31|June 2014|Anticipated|2014-06-30||Interventional|||Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts|A Phase 2 Randomised, Open-label, Multi-centre Ascending Dose Study of the Efficacy, Safety and Tolerability of I-040302 Versus Control Injection (Bone Marrow Aspirate or Steroids) in Children and Young Adults With Solitary Bone Cysts|Withdrawn||Phase 2|0|Actual|Kuros Biosurgery AG||2||"Stopped before any site initiation or any recruitment due to change in overall product~   development plan"|f||||t||||||||||2018-06-01 03:18:27.3375|2018-06-01 03:18:27.3375
NCT00459628|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2017-05-12|2007-04-11|2007-04-12|Estimate|||||||2017-05-12|2017-05-16|Actual|May 2007||2007-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|August 2011|Actual|2011-08-31||Interventional|TomoBreast||Trial of Tomotherapy in Breast Cancer|Randomized Trial Comparing Conventional vs Short-course Reduced Volume Conformal Post-surgery Radiation Treatment in Women With Stage I or II Breast Cancer|Active, not recruiting||N/A|118|Anticipated|Vrije Universiteit Brussel||2|||f||||t||||||||||2018-06-01 03:18:27.403163|2018-06-01 03:18:27.403163
NCT00459615|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2008-09-23|2007-04-10|2007-04-12|Estimate|||||||2008-09-23|2008-09-25|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Phase II Dose Ranging Study of Artesunate|A Phase II, Randomized, Open-Label, Dose-Ranging Study of Intravenous Artesunate Therapy for the Treatment of Acute, Uncomplicated Plasmodium Falciparum Malaria.|Completed||Phase 2|120|Anticipated|Walter Reed Army Institute of Research (WRAIR)|||||||||||||||||||2018-06-01 03:18:27.479208|2018-06-01 03:18:27.479208
NCT00459602|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2015-03-25|2007-04-10|2007-04-12|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2004||2004-08-31|March 2015|2015-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Incisional Hernia Outcomes Study Using Parietex Composite Mesh|A Multi-Center, Laparoscopic Abdominal-Wall Hernia Repair Outcomes Study Using Parietex Composite Mesh|Terminated|||22|Actual|Columbia University|||1|Principal Investigator left institution.|f||||f||||||||||2018-06-01 03:18:27.550937|2018-06-01 03:18:27.550937
NCT00459563|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2014-01-07|2007-04-11|2007-04-12|Estimate|||||||2014-01-07|2014-01-08|Estimate|March 2007||2007-03-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Vitamin D and Blood Pressure|A Randomized Placebo-controlled Double Blinded Trial to Evaluate Cholecalciferol (Vitamin D3) and Calcitriol Treatment on Reducing Blood Pressure in Middle Aged Adults With Stage I Hypertension and Vitamin D Deficiency|Withdrawn||N/A|0|Actual|Atlanta VA Medical Center||3||Inadequate enrollment|f||||f||||||||||2018-06-01 03:18:27.738491|2018-06-01 03:18:27.738491
NCT00459550|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2017-07-18|2007-04-11|2007-04-12|Estimate|||||||2017-07-18|2017-07-21|Actual|March 12, 2007|Actual|2007-03-12|July 2017|2017-07-31|May 30, 2011|Actual|2011-05-30|May 30, 2011|Actual|2011-05-30||Interventional|||A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease|A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients With Alzheimer's Disease.|Completed||Phase 1|50|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:18:27.833171|2018-06-01 03:18:27.833171
NCT00459537|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|2011-01-19||2011-05-03|2007-04-11|2007-04-12|Estimate|2011-03-23|2011-04-20|Estimate||||2011-05-03|2011-05-06|Estimate|March 2007||2007-03-31|May 2011|2011-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis|A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis|Completed||Phase 3|1029|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:18:28.150576|2018-06-01 03:18:28.150576
NCT00459524|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2012-07-31|2007-04-11|2007-04-12|Estimate|||||||2012-07-31|2012-08-01|Estimate|April 2004||2004-04-30|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)|Longitudinal Assessment of Neurocognitive Function and Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Treatment|Completed|||104|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:18:28.519645|2018-06-01 03:18:28.519645
NCT00459511|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2007-04-11|2007-04-11|2007-04-12|Estimate|||||||2007-04-11|2007-04-12|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|October 2006|Actual|2006-10-31|||||Observational|AM||The Importance of Adrenomedullin (AM) on ACTH-Cortisol-Glucose Axis|The Importance of Adrenomedullin (AM) on Pituitary-Adrenal Axis and Glucose Kinetics in Pediatric Patients With Systemic Inflammatory Response Syndrome|Completed|||20||University of Sao Paulo|||||f||||t||||||||||2018-06-01 03:18:28.595765|2018-06-01 03:18:28.595765
NCT00459498|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2007-04-10|2007-04-10|2007-04-12|Estimate|||||||2007-04-10|2007-04-12|Estimate|April 2002||2002-04-30|April 2007|2007-04-30|October 2006|Actual|2006-10-31|||||Observational|||Expression of NIS Protein and mRNA in Thyroid Tumors|Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors|Completed|||30||University of Sao Paulo|||||f||||f||||||||||2018-06-01 03:18:28.653363|2018-06-01 03:18:28.653363
NCT00459485|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2010-02-18|2007-04-11|2007-04-12|Estimate|||||||2010-02-18|2010-02-19|Estimate|April 2007||2007-04-30|February 2010|2010-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on Plasma Zinc Concentration|Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on the Magnitude and Velocity of Change in Plasma Zinc Concentration|Completed||Phase 4|58|Actual|University of California, Davis||3|||f||||f||||||||||2018-06-01 03:18:28.700425|2018-06-01 03:18:28.700425
NCT00459472|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2015-04-03|2007-04-10|2007-04-12|Estimate|||||||2015-04-03|2015-04-06|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Operating Room Outcomes After Resident Training on a Virtual Reality Simulator|Operating Room Outcomes After Resident Training on a Virtual Reality Simulator|Terminated||N/A|100|Actual|Columbia University||1||Principal investigator left institution.|f||||f||||||||||2018-06-01 03:18:28.834097|2018-06-01 03:18:28.834097
NCT00459459|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2007-04-11|2007-04-11|2007-04-12|Estimate|||||||2007-04-11|2007-04-12|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Observational|||Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma||Completed|||100||National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:18:28.89909|2018-06-01 03:18:28.89909
NCT00459446|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2017-06-30|2007-04-11|2007-04-12|Estimate|||||||2017-06-30|2017-07-02|Actual|April 5, 2007||2007-04-05|November 25, 2008|2008-11-25||||November 25, 2008|Actual|2008-11-25||Interventional|||Imaging of Totally Blocked Arteries|Gadofosveset Imaging of Chronic Total Peripheral Artery Occlusion (CTO)|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:18:28.949589|2018-06-01 03:18:28.949589
NCT00459433|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2009-05-28|2007-04-10|2007-04-12|Estimate|||||||2009-05-28|2009-05-29|Estimate|October 2006||2006-10-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Right Intervention for the Right Patient|The Right Intervention for the Right Patient|Completed||N/A|300|Anticipated|The Back Research Center, Denmark||2|||f||||f||||||||||2018-06-01 03:18:29.022403|2018-06-01 03:18:29.022403
NCT00459420|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-11|||2015-04-15|2007-04-11|2007-04-12|Estimate|||||||2015-04-15|2015-04-16|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Caffeine for Excessive Daytime Somnolence in Parkinson's Disease|Caffeine for Excessive Daytime Somnolence in Parkinson's Disease|Completed||Phase 2/Phase 3|58|Actual|McGill University Health Center||2|||f||||t||||||||||2018-06-01 03:18:29.105936|2018-06-01 03:18:29.105936
NCT00459407|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2014-10-07|2007-04-09|2007-04-11|Estimate|||||||2014-10-07|2014-10-08|Estimate|March 2007||2007-03-31|February 2013|2013-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate|Phase Ib Study of Polyphenon E in a Pre-prostatectomy Prostate Cancer Cohort|Completed||Phase 1|50|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:18:29.175801|2018-06-01 03:18:29.175801
NCT00459381|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2016-10-12||2017-01-25|2007-04-09|2007-04-11|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|May 2007||2007-05-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pazopanib in Treating Patients With Recurrent Glioblastoma|A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||No||2018-06-01 03:18:29.268615|2018-06-01 03:18:29.268615
NCT00018304|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate||||December 2004|2004-12-31||||||||Observational|||Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow|Insulin Action: Role of Skeletal Muscle and Insulin-Mediated Blood Flow|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.201406|2018-06-01 05:36:49.201406
NCT00459355|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|2014-08-21||2015-04-06|2007-04-10|2007-04-11|Estimate|2014-09-26|2014-09-29|Estimate||||2015-04-06|2015-04-28|Estimate|July 2007||2007-07-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|May 2010|Actual|2010-05-31||Interventional||Sample size calculations indicated that 216 total participants was sufficient for all calculations|Home Safety Clinical Trial for Alzheimer's Disease|Clinical Trial of a Home Safety Intervention for Alzheimer's Disease|Completed||Phase 1|254|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:18:29.779431|2018-06-01 03:18:29.779431
NCT00459342|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2013-11-01||2014-04-29|2007-04-09|2007-04-11|Estimate|2013-11-01|2013-12-24|Estimate||||2014-04-29|2014-05-15|Estimate|March 2007||2007-03-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Phase II Study of Dasatinib in Non Small Cell Lung Cancer|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:18:30.095938|2018-06-01 03:18:30.095938
NCT00459329|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2008-06-02|2007-04-09|2007-04-11|Estimate|||||||2008-06-02|2008-06-04|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|March 2009|Anticipated|2009-03-31|March 2009|Anticipated|2009-03-31||Interventional|PEARL||PEARL Intervention to Reduce Depression Among Adults With Epilepsy|PEARL Intervention to Reduce Depression Among Adults With Epilepsy|Unknown status|Active, not recruiting|N/A|80|Actual|University of Washington|||||f||||f||||||||||2018-06-01 03:18:30.342366|2018-06-01 03:18:30.342366
NCT00459316|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|2014-03-03||2016-01-12|2007-04-10|2007-04-11|Estimate|2014-04-14|2014-05-12|Estimate||||2016-01-12|2016-01-14|Estimate|June 2007||2007-06-30|January 2016|2016-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All participants who started study treatment.|Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth|Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in HIV-Infected Children and Youth And Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth|Completed||Phase 1/Phase 2|384|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 03:18:30.582206|2018-06-01 03:18:30.582206
NCT00459303|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|2009-10-05||2013-12-29|2007-04-10|2007-04-11|Estimate|2013-12-29|2014-02-17|Estimate||||2013-12-29|2014-02-17|Estimate|October 2005||2005-10-31|December 2013|2013-12-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof|Intraidivisual Comparison of Functional Vision Provided by AMO Tecnis Z9000 and ALcon SA60AT Acrysof Posterior Chamber Intraocular Lenses|Completed||Phase 4|20|Actual|National Taiwan University Hospital|small sample size|1|||f||||t||||||||||2018-06-01 03:18:31.887837|2018-06-01 03:18:31.887837
NCT00459290|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2014-01-31||2014-06-16|2007-04-09|2007-04-11|Estimate|2014-06-16|2014-06-18|Estimate||||2014-06-16|2014-06-18|Estimate|May 2007||2007-05-31|June 2014|2014-06-30||||July 2010|Actual|2010-07-31||Interventional||Eligible and treated participants|Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase II Evaluation of Mifepristone in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|24|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 03:18:32.111093|2018-06-01 03:18:32.111093
NCT00459277|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10||2010-01-20|2012-01-20|2007-04-10|2007-04-11|Estimate||||2010-01-20|2010-01-22|Estimate|2012-01-20|2012-01-25|Estimate|December 2006||2006-12-31|January 2010|2010-01-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids|A Multicenter, Placebo-Controlled, Double-Blind, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy|Completed||Phase 3|73|Actual|Archimedes Development Ltd||2|||f||||f||||||||||2018-06-01 03:18:32.431413|2018-06-01 03:18:32.431413
NCT00459264|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2016-11-21|2007-04-10|2007-04-11|Estimate|||||||2016-11-21|2016-11-23|Estimate|December 2005||2005-12-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|PRE-EMPT||Prevention of Mood Disorders by Folic Acid Supplementation|Prevention of Mood Disorders by Folic Acid Supplementation|Completed||N/A|112|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 03:18:32.507988|2018-06-01 03:18:32.507988
NCT00459251|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2007-04-10|2007-04-10|2007-04-11|Estimate|||||||2007-04-10|2007-04-11|Estimate|December 2006||2006-12-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Observational|||Pharmacogenetics Study in Taiwan's Ethnic Groups|The Pharmacogenetics Study of Drug-Metabolising Enzyme Genetic Polymorphisms in Aboriginal and Minnan/Hakka Ethnic Groups in Taiwan|Completed|||350||Mackay Memorial Hospital|||||f||||f||||||||||2018-06-01 03:18:32.581874|2018-06-01 03:18:32.581874
NCT00459238|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2017-05-16|2007-04-09|2007-04-11|Estimate|||||||2017-05-16|2017-05-17|Actual|October 2006|Actual|2006-10-31|February 2017|2017-02-28|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants|A Telephone-Based Education and Prevention Intervention for Teens and Young Adults|Completed||N/A|104|Actual|Georgetown University|||||f||||f||||||||||2018-06-01 03:18:32.632506|2018-06-01 03:18:32.632506
NCT00459225|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2014-12-08|2007-04-10|2007-04-11|Estimate|||||||2014-12-08|2014-12-09|Estimate|April 2007||2007-04-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease|Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease: An Open Label Trial|Withdrawn||N/A|0|Actual|Emory University||2||Difficulty recruiting subjects|f||||f||||||||||2018-06-01 03:18:32.692387|2018-06-01 03:18:32.692387
NCT00459212|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2015-12-03|2007-04-09|2007-04-11|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2007||2007-03-31|April 2013|2013-04-30||||December 2010|Actual|2010-12-31||Interventional|||GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia|Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:18:32.765635|2018-06-01 03:18:32.765635
NCT00459186|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2013-12-13||2016-04-13|2007-04-10|2007-04-11|Estimate|2014-01-20|2014-03-03|Estimate||||2016-04-13|2016-05-16|Estimate|November 2005||2005-11-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Number of baseline participants represents the number who received at least one dose of investigational agent (did not withdraw before treatment).|The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer|A Phase I/II Study of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer|Completed||Phase 1/Phase 2|19|Actual|Dana-Farber Cancer Institute||1|||f||||f||||||||||2018-06-01 03:18:32.901876|2018-06-01 03:18:32.901876
NCT00458770|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2014-02-24|2007-04-10|2007-04-11|Estimate|||||||2014-02-24|2014-02-25|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks|Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks|Terminated||N/A|1|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-06-01 03:18:38.370532|2018-06-01 03:18:38.370532
NCT00459173|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2009-04-06|2007-04-10|2007-04-11|Estimate|||||||2009-04-06|2009-04-07|Estimate|November 2002||2002-11-30|April 2009|2009-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|STRATUS-WW||Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation|Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Maintenance of Smoking Cessation (1-Year Treatment, 1-Year Follow-up)|Completed||Phase 3|4850|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:18:33.109853|2018-06-01 03:18:33.109853
NCT00459160|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2010-11-30|2007-04-09|2007-04-11|Estimate|||||||2010-11-30|2010-12-01|Estimate|July 2007||2007-07-31|November 2010|2010-11-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients|A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients Undergoing Laparotomy or Thoracotomy for Trauma: A Prospective Randomized Controlled Clinical Trial|Unknown status|Recruiting|N/A|271|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 03:18:33.171204|2018-06-01 03:18:33.171204
NCT00459134|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2015-01-12||2017-05-25|2007-04-09|2007-04-11|Estimate|2015-01-12|2015-01-19|Estimate||||2017-05-25|2017-06-20|Actual|May 2007||2007-05-31|July 2015|2015-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||All randomized participants|L-Arginine Supplements in Treating Women Who Are Cancer Survivors|A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors|Completed||N/A|186|Actual|Wake Forest University Health Sciences||2|||f||||t|f|f||||||Undecided||2018-06-01 03:18:33.397818|2018-06-01 03:18:33.397818
NCT00459121|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2012-11-12||2017-11-15|2007-04-09|2007-04-11|Estimate|2012-11-12|2012-12-07|Estimate||||2017-11-15|2017-12-12|Actual|July 2007||2007-07-31|February 2013|2013-02-28|October 2008|Actual|2008-10-31|January 2008|Actual|2008-01-31||Interventional|||Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery|Assessment of Feasibility and Safety of the Addition of ZD6474 (Zactima) to Carboplatin and Paclitaxel Administered Neo-Adjuvantly in Stage IB, II and T3, N1 Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|2|Actual|Barbara Ann Karmanos Cancer Institute|This was a single center study. We did not accrue enough particpants in a timely fashion and a joint decision was made with AstraZeneca to terminate the study.|1|||f||||t||||||||||2018-06-01 03:18:33.845568|2018-06-01 03:18:33.845568
NCT00459108|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2014-06-19||2018-03-20|2007-04-09|2007-04-11|Estimate|2015-03-19|2015-03-20|Estimate||||2018-03-20|2018-04-19|Actual|April 2007||2007-04-30|March 2018|2018-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery|A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.|1||Halted early for futility.|f||||||||||||||2018-06-01 03:18:34.109525|2018-06-01 03:18:34.109525
NCT00459082|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2007-04-10|2007-04-10|2007-04-11|Estimate|||||||2007-04-10|2007-04-11|Estimate|May 2004||2004-05-31|April 2007|2007-04-30|November 2006||2006-11-30|||||Interventional|||A Pharmacokinetic Study of Dexmedetomine in Infants|A Pharmacokinetic Study of Dexmedetomine in Infants|Completed||Phase 1|36||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:18:34.595393|2018-06-01 03:18:34.595393
NCT00459069|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2010-01-11|2007-04-10|2007-04-11|Estimate|||||||2010-01-11|2010-01-12|Estimate|July 2004||2004-07-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Interventional|||The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma|The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma|Completed||Phase 1|18|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 03:18:34.665209|2018-06-01 03:18:34.665209
NCT00459056|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|2012-04-23||2013-11-13|2007-04-10|2007-04-11|Estimate|2013-09-05|2013-11-08|Estimate||||2013-11-13|2013-12-06|Estimate|April 2007||2007-04-30|November 2013|2013-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients|The Vascular Effects of Carvedilol Controlle Release (CR) + Lisinopril Versus Lisinopril + Hydrochlorothiazide (HCTZ) in Abdominally Obese Hypertensive Patients|Completed||Phase 3|25|Actual|St. Paul Heart Clinic|crossover study design|2|||f||||f||||||||||2018-06-01 03:18:34.74985|2018-06-01 03:18:34.74985
NCT00459043|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|2013-02-28||2013-07-01|2007-04-10|2007-04-11|Estimate|2013-07-01|2013-07-03|Estimate||||2013-07-01|2013-07-03|Estimate|March 2007||2007-03-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|March 2010|Actual|2010-03-31||Interventional||One patient withdrew consent after being randomized to docetaxel alone arm and did not receive any treatment, therefore, 29 patients were analyzable.|Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck|Randomized Phase II Study of Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|30|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 03:18:35.009401|2018-06-01 03:18:35.009401
NCT00459030|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2013-08-16|2007-04-09|2007-04-11|Estimate|||||||2013-08-16|2013-08-19|Estimate|October 2005||2005-10-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Traditional Print Communication Methods, Simple Electronic Communication Methods, or Usual Care in Increasing How Often Older Women Undergo Colorectal Cancer Screening|Two Delivery Channels to Improve CRC Screening|Completed||N/A|904|Actual|Fox Chase Cancer Center||3|||f||||f||||||||||2018-06-01 03:18:35.28347|2018-06-01 03:18:35.28347
NCT00459017|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2007-04-10|2007-04-10|2007-04-11|Estimate|||||||2007-04-10|2007-04-11|Estimate|December 2002||2002-12-31|April 2007|2007-04-30|June 2005|Actual|2005-06-30|||||Interventional|||The Effect of Frequent Self Measurements of Blood Pressure on the Control of Hypertension|The Effect of Frequent Self Measurements of Blood Pressure on the Control of Hypertension|Completed||Phase 3|150||Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:18:35.355065|2018-06-01 03:18:35.355065
NCT00459004|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2009-04-06|2007-04-10|2007-04-11|Estimate|||||||2009-04-06|2009-04-07|Estimate|October 2004||2004-10-31|April 2009|2009-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Japanese Dose-Response Study of Rimonabant in Obese Patients|A Dose-Response Relationship Study of SR141716 in Obese Patients|Completed||Phase 2|527|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:18:35.406681|2018-06-01 03:18:35.406681
NCT00458991|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2017-04-25|2007-04-10|2007-04-11|Estimate|||||||2017-04-25|2017-04-27|Actual|June 2001||2001-06-30|April 2017|2017-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||rhGH Therapy on Hepatic Drug Metabolism|Recombinant Human Growth Hormone Therapy and Drug Metabolism|Completed|||9|Actual|University of Louisville|||||f||||f||||||||||2018-06-01 03:18:35.461567|2018-06-01 03:18:35.461567
NCT00458978|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09||2013-09-04|2015-04-14|2007-04-09|2007-04-11|Estimate||||2013-09-04|2013-09-16|Estimate|2015-04-14|2015-05-05|Estimate|February 2007||2007-02-28|April 2014|2014-04-30|July 2014|Actual|2014-07-31|May 2013|Actual|2013-05-31||Interventional|||Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer|Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients|Completed||Phase 2|6|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:18:35.522374|2018-06-01 03:18:35.522374
NCT00458952|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2015-12-15||2016-06-13|2007-04-09|2007-04-11|Estimate|2016-03-21|2016-04-20|Estimate||||2016-06-13|2016-07-13|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|June 2011|Actual|2011-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma|A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma|Completed||Phase 1/Phase 2|24|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 03:18:35.598102|2018-06-01 03:18:35.598102
NCT00458926|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2012-05-30|2007-04-09|2007-04-11|Estimate|||||||2012-05-30|2012-06-01|Estimate|November 2003||2003-11-30|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|||||Observational|||Enhancing Utilization of Non-Invasive Positive Pressure Ventilation in Critical Care|Enhancing Utilization of Non-Invasive Positive Pressure Ventilation in Critical Care|Unknown status|Active, not recruiting||800|Anticipated|Tufts Medical Center|||||f||||f||||||||||2018-06-01 03:18:35.980467|2018-06-01 03:18:35.980467
NCT00458913|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2013-04-19|2007-04-09|2007-04-11|Estimate|||||||2013-04-19|2013-04-22|Estimate|February 2007||2007-02-28|April 2013|2013-04-30|March 2012|Actual|2012-03-31|April 2010|Actual|2010-04-30||Interventional|||Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma|Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma|Completed||Phase 2|82|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 03:18:36.038362|2018-06-01 03:18:36.038362
NCT00458900|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2012-12-07|2007-04-10|2007-04-11|Estimate|||||||2012-12-07|2012-12-10|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients|Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients|Completed||Phase 2|4|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 03:18:36.102765|2018-06-01 03:18:36.102765
NCT00458887|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2017-03-09|2007-04-09|2007-04-11|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2007||2007-05-31|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|January 2015|Actual|2015-01-31||Observational|||Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin|A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy|Completed|||301|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 03:18:36.182835|2018-06-01 03:18:36.182835
NCT00458874|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2016-05-17|2007-04-09|2007-04-11|Estimate|||||||2016-05-17|2016-05-18|Estimate|November 2007||2007-11-30|May 2016|2016-05-31|April 2011|Actual|2011-04-30|July 2010|Actual|2010-07-31||Interventional|BATTLE||Better Adherence to Therapeutic Lifestyle Change Efforts Trial|Better Adherence to Therapeutic Lifestyle Change Efforts (BATTLE) Trial|Completed||N/A|166|Actual|Walter Reed National Military Medical Center||2|||f||||f||||||||No||2018-06-01 03:18:36.34029|2018-06-01 03:18:36.34029
NCT00458861|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22||2015-12-17|2015-12-17|2007-04-09|2007-04-11|Estimate||||2015-12-17|2016-01-21|Estimate|2015-12-17|2016-01-21|Estimate|March 2007||2007-03-31|December 2015|2015-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, PK, and PD of BG9924 When Given in Combo With MTX to Subjects With Active RA Who Have Had an Inadequate Response to Anti-TNF|Terminated||Phase 2|115|Actual|Biogen||2||Interim analysis of data failed to meet primary endpoint.|f||||t||||||||||2018-06-01 03:18:36.406225|2018-06-01 03:18:36.406225
NCT00458848|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2015-05-26|2007-04-09|2007-04-11|Estimate|||||||2015-05-26|2015-05-28|Estimate|October 2004||2004-10-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|LAL0904||Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia|Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring.|Completed||Phase 2|470|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 03:18:36.47127|2018-06-01 03:18:36.47127
NCT00458835|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2016-12-01|2007-04-10|2007-04-11|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)|A Randomized, Open-label, Single-dose, 3-period Crossover, Pharmacokinetic Study Designed to Compare the Systemic Des-ciclesonide Exposure of OMNARIS™ (Ciclesonide) Nasal Spray, Ciclesonide HFA Nasal Aerosol, and Orally Inhaled Ciclesonide|Completed||Phase 4|30|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 03:18:37.592627|2018-06-01 03:18:37.592627
NCT00458822|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2016-01-04||2016-06-29|2007-04-09|2007-04-11|Estimate|2016-06-29|2016-08-10|Estimate||||2016-06-29|2016-08-10|Estimate|February 2007||2007-02-28|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis|Risk-Adapted Intravenous Melphalan With Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients With Systemic Light-Chain (AL) Amyloidosis|Completed||Phase 2|40|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:18:37.670555|2018-06-01 03:18:37.670555
NCT00458809|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2017-02-21|2007-04-09|2007-04-11|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2007||2007-03-31|April 2012|2012-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer|A Phase I Evaluation of Intraperitoneal Hyperthermic Chemoperfusion With Oxaliplatin for Peritoneal Surface Disemmination of Appendiceal and Colorectal Cancer|Completed||Phase 1|16|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-06-01 03:18:37.871776|2018-06-01 03:18:37.871776
NCT00458796|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2013-08-23|2007-04-09|2007-04-11|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2006||2006-03-31|November 2007|2007-11-30||||||||Interventional|||Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone|Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule|Unknown status|Recruiting|N/A|1500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:18:37.960324|2018-06-01 03:18:37.960324
NCT00458757|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2017-11-29|2007-04-10|2007-04-11|Estimate|||||||2017-11-29|2017-11-30|Actual|November 2007||2007-11-30|March 2007|2007-03-31||||||||Observational|||The Effect of Amputation on Spatial Visual Representation in Peripersonal Space|The Effect of Upper Arm Amputation and the Use of Prosthetics on Spatial Visual Representation in Peripersonal Space - a Behavioural Study|Unknown status|Not yet recruiting||40|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:18:38.531564|2018-06-01 03:18:38.531564
NCT00458744|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2014-08-07|2007-04-09|2007-04-11|Estimate|||||||2014-08-07|2014-08-08|Estimate|February 2007||2007-02-28|August 2014|2014-08-31||||July 2008|Anticipated|2008-07-31||Interventional|||Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment|A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias|Withdrawn||Phase 1|0|Actual|Children's Oncology Group||||Study withdrawn because of toxicity reported on the adult phase 1 trial.|||||f||||||||||2018-06-01 03:18:38.603364|2018-06-01 03:18:38.603364
NCT00458731|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2014-02-14|2007-04-09|2007-04-11|Estimate|||||||2014-02-14|2014-02-19|Estimate|May 2007||2007-05-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Interventional|||Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma|Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies|Completed||Phase 1|57|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:18:38.732895|2018-06-01 03:18:38.732895
NCT00458718|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2009-04-17|2007-04-10|2007-04-11|Estimate|||||||2009-04-17|2009-04-20|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|CIRRUS||Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch|Single Country, Double-Blind, Randomized, 2-Arm, Parallel-Group Study, Evaluating Efficacy and Safety of Rimonabant 20 mg OD, With/Without Association of Nicotine Patch, as Aid to Smoking Cessation During 9-Week Period|Completed||Phase 3|755|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:18:38.838028|2018-06-01 03:18:38.838028
NCT00458705|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2015-12-16||2015-12-16|2007-04-09|2007-04-11|Estimate|2015-12-16|2016-01-22|Estimate||||2015-12-16|2016-01-22|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma|Bortezomib + Pegylated Liposomal Doxorubicin (Doxil) + Dexamethasone Followed by Thalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone for Patients With Symptomatic Untreated High-Risk or Primary Resistant Multiple Myeloma|Completed||Phase 2|45|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:18:38.939122|2018-06-01 03:18:38.939122
NCT00458679|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2014-01-30|2007-04-09|2007-04-11|Estimate|||||||2014-01-30|2014-02-03|Estimate|December 2006||2006-12-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|October 2008|Actual|2008-10-31||Interventional|PRIMAL||Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells|Prolonged Immunization With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells for Treatment of B-Chronic Lymphocytic Leukemia (B-CLL)|Completed||Phase 1|6|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 03:18:39.2344|2018-06-01 03:18:39.2344
NCT00458666|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2007-04-10|2007-04-10|2007-04-11|Estimate|||||||2007-04-10|2007-04-11|Estimate|June 2006||2006-06-30|March 2007|2007-03-31||||||||Observational|||Coagulation Parameters During Pregnancy in Amniotic Fluid|Coagulation Parameters During Pregnancy in Amniotic Fluid|Unknown status|Recruiting||170||Rambam Health Care Campus|||||f||||t||||||||||2018-06-01 03:18:39.300603|2018-06-01 03:18:39.300603
NCT00458653|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2018-01-30|2007-04-10|2007-04-11|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2005||2005-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2012|Actual|2012-04-30||Interventional|||Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma|Vaccination With Dendritic Cell/Tumor Fusions in Conjunction With Autologous Stem Cell Transplant in Patients With Multiple Myeloma|Active, not recruiting||Phase 1|45|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 03:18:39.35416|2018-06-01 03:18:39.35416
NCT00458627|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2007-04-10|2007-04-10|2007-04-11|Estimate|||||||2007-04-10|2007-04-11|Estimate|February 2006||2006-02-28|April 2007|2007-04-30|September 2006||2006-09-30|||||Observational|||Body Plethysmograph Measurements Before and After Methacholine Challenge in Early Childhood|Body Plethysmograph Measurements Before and After Methacholine Challenge in Early Childhood|Completed|||50||Rambam Health Care Campus|||||f||||t||||||||||2018-06-01 03:18:39.423096|2018-06-01 03:18:39.423096
NCT00458614|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2011-01-10|2007-04-10|2007-04-11|Estimate|||||||2011-01-10|2011-01-11|Estimate|June 2006||2006-06-30|January 2011|2011-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pharmacokinetic Study of Lansoprazole in Cystic Fibrosis|Lansoprazole Disposition in Young Children With Cystic Fibrosis|Completed||Phase 1|18||Arkansas Children's Hospital Research Institute|||||f||||||||||||||2018-06-01 03:18:39.561563|2018-06-01 03:18:39.561563
NCT00458601|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10||2010-06-24|2018-01-11|2007-04-10|2007-04-11|Estimate||||2010-07-16|2010-07-20|Estimate|2018-01-11|2018-01-16|Actual|August 2007||2007-08-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|November 2010|Actual|2010-11-30||Interventional|ACT III||Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme|A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|82|Actual|Celldex Therapeutics||1|||f||||f||||||||||2018-06-01 03:18:39.651035|2018-06-01 03:18:39.651035
NCT00458588|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2017-04-05|2007-04-09|2007-04-11|Estimate|||||||2017-04-05|2017-04-06|Actual|September 2006|Actual|2006-09-30|April 2017|2017-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Long-Term Effect of Adolescent Diet on Hormones and Breast Cancer Risk in Women Previously Enrolled in the Dietary Intervention Study in Children|Adolescent Diet, Hormones and Breast Cancer Susceptibility|Completed|||301|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 03:18:39.789912|2018-06-01 03:18:39.789912
NCT00458575|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2014-06-25|2007-04-10|2007-04-11|Estimate|||||||2014-06-25|2014-06-26|Estimate|April 2007||2007-04-30|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa|A Phase I Open Label Non-comparative Study Evaluating the Safety of a Single, Unilateral, Subretinal Administration of CNTO 2476 in Advanced Retinitis Pigmentosa|Terminated||Phase 1|7|Actual|Centocor, Inc.||1||Internal Business Decision|f||||t||||||||||2018-06-01 03:18:39.898586|2018-06-01 03:18:39.898586
NCT00458393|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|2016-12-27||2018-01-19|2007-04-06|2007-04-10|Estimate|2018-01-19|2018-01-24|Actual||||2018-01-19|2018-01-24|Actual|June 2007||2007-06-30|December 2016|2016-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|iPrEx||Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men|Chemoprophylaxis for HIV Prevention in Men|Completed||Phase 3|2499|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 03:18:41.971624|2018-06-01 03:18:41.971624
NCT00458562|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2013-11-15|2007-04-09|2007-04-11|Estimate|||||||2013-11-15|2013-11-19|Estimate|January 2006||2006-01-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Identifying Genes That Predict Risk of Developing Cervical Intraepithelial Neoplasia or Invasive Cervical Cancer|HIV-Associated DNA Hypermethylation in Cervical Cancer|Completed|||1680|Actual|University of Washington|||3||f||||f||||||Samples With DNA|"~     Cervical brush in PreservCyt, cervical swab in STM, cervical swab in Roche media, whole~     blood, void urine, cervical tissue biopsy.~   "|||2018-06-01 03:18:39.981802|2018-06-01 03:18:39.981802
NCT00458549|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2009-02-06|2007-04-09|2007-04-11|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2006||2006-07-31|July 2008|2008-07-31||||||||Interventional|||Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery|Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids|Unknown status|Recruiting|N/A|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:18:40.055929|2018-06-01 03:18:40.055929
NCT00458536|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|2016-01-20||2017-06-30|2007-04-10|2007-04-11|Estimate|2016-01-20|2016-02-17|Estimate||||2017-06-30|2017-07-28|Actual|October 2004||2004-10-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2014|Actual|2014-12-31||Interventional|||Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF|Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF|Active, not recruiting||Phase 1/Phase 2|38|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 03:18:40.177339|2018-06-01 03:18:40.177339
NCT00458523|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2013-08-09|2007-04-09|2007-04-11|Estimate|||||||2013-08-09|2013-08-12|Estimate|December 2006||2006-12-31|April 2007|2007-04-30|February 2008|Actual|2008-02-29|||||Interventional|||Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission|Eradication of Minimal Residual Disease (MRD) in Patients With Chronic Lymphocytic Leukaemia (CLL) With Alemtuzumab: A Phase II Study|Completed||Phase 2|54|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:18:40.402799|2018-06-01 03:18:40.402799
NCT00458510|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-10|||2013-07-10|2007-04-10|2007-04-11|Estimate|||||||2013-07-10|2013-07-11|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|October 2011|Actual|2011-10-31||Interventional|||Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain|An Open-Label Study Investigating Long-Term Safety and Tolerability of Fentanyl Citrate Nasal Spray in the Treatment of BTCP in Subjects Taking Regular Opioid Therapy|Completed||Phase 3|403|Actual|Archimedes Development Ltd||1|||f||||f||||||||||2018-06-01 03:18:40.556478|2018-06-01 03:18:40.556478
NCT00458497|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2010-06-02|2007-04-09|2007-04-11|Estimate|||||||2010-06-02|2010-06-04|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Holofiber Socks and Bedding on Pain and Quality of Sleep in Subjects With Chronic Foot Pain|Effect of Holofiber Socks and Bedding on Pain and Quality of Sleep in Subjects With Chronic Foot Pain|Terminated||N/A|60|Actual|Southern California Institute for Research and Education||2||Low enrollment|f||||f||||||||||2018-06-01 03:18:40.679616|2018-06-01 03:18:40.679616
NCT00458484|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2018-01-22|2007-04-09|2007-04-11|Estimate|||||||2018-01-22|2018-01-24|Actual|February 20, 2007|Actual|2007-02-20|January 2018|2018-01-31|July 17, 2018|Anticipated|2018-07-17|July 17, 2018|Anticipated|2018-07-17||Interventional|||Radiosurgery in Treating Patients With Kidney Tumors|Evaluation of a Radio-Surgical Approach for the Treatment of Kidney Tumors in Poor Surgical Candidates|Active, not recruiting||N/A|32|Actual|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-06-01 03:18:40.813942|2018-06-01 03:18:40.813942
NCT00458471|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2007-04-09|2007-04-09|2007-04-10|Estimate|||||||2007-04-09|2007-04-10|Estimate|November 2003||2003-11-30|April 2007|2007-04-30|July 2005||2005-07-31|||||Interventional|||E. Coli for Prevention of Catheter UTI in SCI Patients|Evaluate the Safety in Human Subjects of Using Bladder Catheters That Are Pre-Coated With a Biofilm That Contains Living Bacteria Escherichia Coli 83972.|Completed||Phase 1|12||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:18:40.944383|2018-06-01 03:18:40.944383
NCT00458458|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2012-10-24|2007-04-09|2007-04-10|Estimate|||||||2012-10-24|2012-10-25|Estimate|August 2004||2004-08-31|October 2012|2012-10-31||||December 2012|Anticipated|2012-12-31||Interventional|||Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)|Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)|Unknown status|Active, not recruiting|Phase 3|112|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 03:18:41.066964|2018-06-01 03:18:41.066964
NCT00458445|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2015-03-03|2007-04-09|2007-04-10|Estimate|||||||2015-03-03|2015-03-05|Estimate|April 2007||2007-04-30|April 2008|2008-04-30||||||||Interventional|||A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators|A Phase IIIb Study to Evaluate the Efficacy and Time Course of Treatment With SPD465 Compared to Placebo on Simulated Driving Safety and Performance in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|Withdrawn||Phase 3|0|Actual|Shire||||"This study was stopped by the sponsor before enrollment based on a non-safety related corporate~   decision."|f||||||||||||||2018-06-01 03:18:41.217193|2018-06-01 03:18:41.217193
NCT00458432|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-07|||2017-06-30|2007-04-07|2007-04-10|Estimate|||||||2017-06-30|2017-07-02|Actual|April 5, 2007||2007-04-05|June 8, 2009|2009-06-08|August 31, 2009|Actual|2009-08-31|August 31, 2009|Actual|2009-08-31||Observational|||Functional Neuroanatomy of Emotion Perception, Recognition, Learning, and Memory|Functional Neuroanatomy of Emotion Perception, Recognition, Learning, and Memory|Completed|||180||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:18:41.272244|2018-06-01 03:18:41.272244
NCT00458419|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-08|||2007-10-31|2007-04-09|2007-04-10|Estimate|||||||2007-10-31|2007-11-02|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease|Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|17|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||||2018-06-01 03:18:41.369425|2018-06-01 03:18:41.369425
NCT00458406|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|2013-01-10||2014-03-31|2007-04-06|2007-04-10|Estimate|2014-03-31|2014-04-01|Estimate||||2014-03-31|2014-04-01|Estimate|May 2007||2007-05-31|March 2014|2014-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluation of Adherence and Therapeutic Effectiveness of Bi-Flex Versus CPAP in Children With OSA|Evaluation of Adherence and Therapeutic Effectiveness of BiPAP With Bi-Flex Versus CPAP in Children With Obstructive Sleep Apnea|Completed||N/A|60|Actual|Children's Hospital of Philadelphia|Limitations of the study include the relatively small sample size in the CPAP arm.|2|||f||||f||||||||||2018-06-01 03:18:41.502447|2018-06-01 03:18:41.502447
NCT00458380|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2007-04-09|2007-04-09|2007-04-10|Estimate|||||||2007-04-09|2007-04-10|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|February 2005||2005-02-28|||||Interventional|||Perifollicular Vascularity Assessment in in-Vitro Fertilization|Clinical Use of the Perifollicular Vascularity Assessment in in-Vitro Fertilization Cycles: a Pilot Study|Completed||Phase 4|116||University Magna Graecia|||||f||||f||||||||||2018-06-01 03:18:42.745168|2018-06-01 03:18:42.745168
NCT00458367|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2010-10-15|2007-04-06|2007-04-10|Estimate|||||||2010-10-15|2010-10-18|Estimate|June 2002||2002-06-30|October 2010|2010-10-31|October 2006|Actual|2006-10-31|||||Observational|||RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice|Risperdal Safety Protocol Evaluation Consta Treatment; A Post Authorization Safety Survey With RISPERDAL CONSTA TM|Completed|||5296|Actual|Janssen Pharmaceutica N.V., Belgium|||1||f||||||||||||||2018-06-01 03:18:42.807921|2018-06-01 03:18:42.807921
NCT00458354|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2011-10-10|2007-04-09|2007-04-10|Estimate|||||||2011-10-10|2011-10-12|Estimate|January 2006||2006-01-31|October 2011|2011-10-31|December 2008|Actual|2008-12-31|November 2007|Actual|2007-11-30||Interventional|||Use of Spinal Sealant System During Spinal Surgery|A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery|Completed||Phase 3|3|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:18:42.88131|2018-06-01 03:18:42.88131
NCT00458341|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2009-04-01|2007-04-06|2007-04-10|Estimate|||||||2009-04-01|2009-04-02|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||PTC124 for Pediatric Patients With Cystic Fibrosis|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis|Completed||Phase 2|30|Anticipated|PTC Therapeutics|||||f||||f||||||||||2018-06-01 03:18:42.967447|2018-06-01 03:18:42.967447
NCT00458328|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|||2010-11-21|2007-04-09|2007-04-10|Estimate|||||||2010-11-21|2010-11-23|Estimate|April 2007||2007-04-30|November 2010|2010-11-30|July 2010|Actual|2010-07-31|September 2009|Actual|2009-09-30||Interventional|||The Effect of Z-338 in Subjects With Functional Dyspepsia|The Effect of Z-338 in Subjects With Functional Dyspepsia, Evaluate the Function of Gastro-duodenum by Ultrasound|Completed||Phase 2|40|Anticipated|Zeria Pharmaceutical|||||f||||t||||||||||2018-06-01 03:18:43.044423|2018-06-01 03:18:43.044423
NCT00458315|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2015-05-06|2007-04-06|2007-04-10|Estimate|||||||2015-05-06|2015-05-08|Estimate|May 2007||2007-05-31|September 2009|2009-09-30|May 2012|Anticipated|2012-05-31|August 2007|Actual|2007-08-31||Interventional|||Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor|Randomized Fase II Trial: Comparing Cisplatin, Paclitaxel and Gemcitabine Versus Cisplatin, Paclitaxel, Gemcitabine and Avastin in Patients With Unknown Primary Tumors|Withdrawn||Phase 2|0|Actual|Rigshospitalet, Denmark||||never been started|f||||t||||||||||2018-06-01 03:18:43.103004|2018-06-01 03:18:43.103004
NCT00458302|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|2010-02-04||2012-12-14|2007-04-06|2007-04-10|Estimate|2010-02-04|2010-02-26|Estimate||||2012-12-14|2012-12-19|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|January 2011|Actual|2011-01-31|February 2009|Actual|2009-02-28||Interventional|MONET||Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir|A Randomised, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg O.D. vs a Triple Combination Therapy With DRV/r in HIV-1 Infected Patients With Undetectable Plasma HIV-RNA on Their Current Treatments.|Completed||Phase 3|256|Actual|Janssen-Cilag International NV|This study was not blinded and not designed to demonstrate a safety benefit to stopping nucleoside analogues.|2|||f||||t||||||||||2018-06-01 03:18:43.213924|2018-06-01 03:18:43.213924
NCT00458289|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2009-03-11|2007-04-06|2007-04-10|Estimate|||||||2009-03-11|2009-03-12|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate||Completed||Phase 1|12|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-06-01 03:18:44.076492|2018-06-01 03:18:44.076492
NCT00458276|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06||2010-02-11|2010-02-11|2007-04-06|2007-04-10|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|April 2007||2007-04-30|February 2010|2010-02-28|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery|Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Cardiac Surgery|Terminated||Phase 3|274|Actual|Actelion||2||"6 month vital status report not collected after 28 day follow up analysis indicated no~   difference between placebo & tezosentan"|f||||t||||||||||2018-06-01 03:18:44.160546|2018-06-01 03:18:44.160546
NCT00458263|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-08|||2013-01-01|2007-04-08|2007-04-10|Estimate|||||||2013-01-01|2013-01-03|Estimate|April 2006||2006-04-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ISS||Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature|One Arm, Open Study to Assess Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature|Completed||Phase 4|21|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-06-01 03:18:44.28253|2018-06-01 03:18:44.28253
NCT00458250|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-07|||2008-11-15|2007-04-07|2007-04-10|Estimate|||||||2008-11-15|2008-11-18|Estimate|September 2006||2006-09-30|November 2008|2008-11-30|February 2008|Actual|2008-02-29|||||Interventional|||Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H|Haploidentical Hematopoietic Stem Cell Transplantation in the Treatment of Hematological Malignancies Using CAMPATH-1H|Completed||Phase 1|10|Anticipated|Tehran University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:18:44.359047|2018-06-01 03:18:44.359047
NCT00458237|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-09|2015-12-04||2016-10-18|2007-04-09|2007-04-10|Estimate|2016-02-12|2016-03-10|Estimate||||2016-10-18|2016-10-20|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer|A Brief Dose Escalation Followed by a Phase 2 Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer|Completed||Phase 1/Phase 2|11|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||No||2018-06-01 03:18:44.451252|2018-06-01 03:18:44.451252
NCT00458224|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-07|||2015-06-02|2007-04-09|2007-04-10|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Prevention of Permanent Obesity in Children|Prevention of Permanent Obesity in Children|Completed||N/A|48|Actual|Sykehuset Innlandet HF||1|||f||||f||||||||||2018-06-01 03:18:44.900302|2018-06-01 03:18:44.900302
NCT00458211|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|2012-04-25||2015-07-20|2007-04-09|2007-04-10|Estimate|2013-03-22|2013-05-06|Estimate||||2015-07-20|2015-08-10|Estimate|May 2005||2005-05-31|July 2015|2015-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||The four Rochester subjects were dropped. The 17 Buffalo subjects were all out patients and 20 years older than the 19 Bronx subjects who were all in-patients. Buffalo subjects were 88% white (Bronx 5%), 12% African American (Bronx 39%), 0% Hispanic (Bronx 50%), 24% with Substance abuse (Bronx 68%)|Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics|Evaluation of Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotic Medications|Completed||Phase 4|40|Actual|Bronx Psychiatric Center||1|||f||||f||||||||||2018-06-01 03:18:45.007415|2018-06-01 03:18:45.007415
NCT00458198|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2016-11-23|2007-04-05|2007-04-09|Estimate|||||||2016-11-23|2016-11-28|Estimate|January 2006||2006-01-31|November 2016|2016-11-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||Integrated Behavioral Therapy for Treating Children With Selective Mutism|Integrated Behavioral Treatment for Selective Mutism|Completed||N/A|21|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-06-01 03:18:45.321421|2018-06-01 03:18:45.321421
NCT00458185|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2008-03-11|2007-04-05|2007-04-09|Estimate|||||||2008-03-11|2008-03-13|Estimate|August 2006||2006-08-31|March 2008|2008-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Study Evaluating Etanercept in Patients With Ankylosing Spondylitis|Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis|Completed||Phase 4|40|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 03:18:45.406167|2018-06-01 03:18:45.406167
NCT00458172|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2016-07-28|2007-04-06|2007-04-09|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2007||2007-04-30|July 2016|2016-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Lay Theories of Health in Young and Middle Aged American Adults|Study 1 of Lay Theories of Health: Conceptualizations of Physical, Mental, and Social Health in Young and Middle-Aged Adults|Completed|||302|Actual|University of Michigan|||||f||||f||||||||No||2018-06-01 03:18:45.457295|2018-06-01 03:18:45.457295
NCT00458159|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2009-08-28|2007-04-06|2007-04-09|Estimate|||||||2009-08-28|2009-08-31|Estimate|May 2007||2007-05-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes|A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes|Terminated||Phase 1|34|Actual|Celgene||1||"The compound has a benign safety profile with short-term use, clinically sig efficacy responses~   have not been demonstrated, or if so, have not been sustained."|f||||f||||||||||2018-06-01 03:18:45.512057|2018-06-01 03:18:45.512057
NCT00458146|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2008-03-24|2007-04-06|2007-04-09|Estimate|||||||2008-03-24|2008-03-27|Estimate|February 2007||2007-02-28|March 2008|2008-03-31||||||||Interventional|||A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis|A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate|Completed||Phase 2|100|Anticipated|Merrimack Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:18:45.584297|2018-06-01 03:18:45.584297
NCT00458133|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2012-11-02|2007-04-05|2007-04-09|Estimate|||||||2012-11-02|2012-11-06|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|HART-D||Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes|Health Benefits of Aerobic and Resistance Training in Individuals With Type 2 Diabetes|Completed||N/A|262|Actual|Pennington Biomedical Research Center||4|||f||||t||||||||||2018-06-01 03:18:45.667208|2018-06-01 03:18:45.667208
NCT00458120|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2010-12-13|2007-04-06|2007-04-09|Estimate|||||||2010-12-13|2010-12-14|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus|Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals|Completed||Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-06-01 03:18:45.75485|2018-06-01 03:18:45.75485
NCT00458107|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-12-03|2007-04-05|2007-04-09|Estimate|||||||2007-12-03|2007-12-05|Estimate|April 2007||2007-04-30|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects|An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SCA-136 Administered Orally to Healthy Japanese and Non-Japanese Female Subjects|Completed||Phase 1|64|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:18:45.838039|2018-06-01 03:18:45.838039
NCT00458094|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2017-12-04|2007-04-05|2007-04-09|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2007||2007-03-31|December 2017|2017-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses|Activating Consumers to Exercise in Community Psychiatry Through Peer Support|Completed||N/A|100|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:18:45.891186|2018-06-01 03:18:45.891186
NCT00458081|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2010-12-09|2007-04-06|2007-04-09|Estimate|||||||2010-12-09|2010-12-10|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|RIALTO||Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors|A 12-month Multicentre, Randomised, Double-blind, Placebo-controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors.|Terminated||Phase 3|174|Actual|Sanofi||2||"Company decision has been taken in light of recent demands by certain national health~   authorities"|f||||f||||||||||2018-06-01 03:18:45.966484|2018-06-01 03:18:45.966484
NCT00458068|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2007-04-06|2007-04-06|2007-04-09|Estimate|||||||2007-04-06|2007-04-09|Estimate|June 1996||1996-06-30|April 2007|2007-04-30|September 1999|Actual|1999-09-30|||||Interventional|||Early Versus Late Enteral Iron in Infants Less Than 1301 Grams|Prospective Randomized Trial of Early Versus Late Enteral Iron Supplementation in Infants With a Birth Weight of Less Than 1301 Grams|Completed||N/A|126||University of Ulm|||||f||||f||||||||||2018-06-01 03:18:46.031998|2018-06-01 03:18:46.031998
NCT00458055|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2008-06-02|2007-04-06|2007-04-09|Estimate|||||||2008-06-02|2008-06-04|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||High-Density Lipoprotein (HDL) Treatment Study|Treatment Study for Severe High-Density Lipoprotein Deficiency|Completed||N/A|19|Actual|McGill University Health Center|||||f||||t||||||||||2018-06-01 03:18:46.091175|2018-06-01 03:18:46.091175
NCT00458042|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-11-09|2007-04-06|2007-04-09|Estimate|||||||2007-11-09|2007-11-12|Estimate|March 2007||2007-03-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction|Transitioning To Intravenous Remodulin® (Treprostinil Sodium) From Inhaled Iloprost (Ventavis®) in Patients With Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction|Terminated||Phase 4|10|Anticipated|United Therapeutics||||Low Enrollment|f||||f||||||||||2018-06-01 03:18:46.167758|2018-06-01 03:18:46.167758
NCT00458029|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2011-05-31|2007-04-05|2007-04-09|Estimate|||||||2011-05-31|2011-06-01|Estimate|August 2006||2006-08-31|May 2011|2011-05-31|February 2011|Actual|2011-02-28|June 2009|Actual|2009-06-30||Interventional|HEALTHY||Middle-School Based Primary Prevention Trial of Type 2 Diabetes|Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)|Completed||Phase 3|4603|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 03:18:46.313647|2018-06-01 03:18:46.313647
NCT00458016|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2011-09-29|2007-04-05|2007-04-09|Estimate|||||||2011-09-29|2011-10-03|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus|A Phase 2, 28-day, Multicenter, Double-Blind,Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of MB07803 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|105|Actual|Ligand Pharmaceuticals||5|||f||||f||||||||||2018-06-01 03:18:46.416339|2018-06-01 03:18:46.416339
NCT00458003|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-01-31|2007-04-06|2007-04-09|Estimate|||||||2017-01-31|2017-02-02|Estimate|July 2006||2006-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phenylephrine in Spinal Anesthesia in Preeclamptic Patients|Phenylephrine Versus Ephedrine to Treat Spinal Anesthesia-Induced Hypotension in Preeclamptic Patients During Cesarean Delivery|Completed||N/A|110|Actual|Northwestern University||2|||f||||f||||||||No||2018-06-01 03:18:46.524014|2018-06-01 03:18:46.524014
NCT00457990|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2007-04-06|2007-04-06|2007-04-09|Estimate|||||||2007-04-06|2007-04-09|Estimate|April 2002||2002-04-30|April 2007|2007-04-30|December 2005|Actual|2005-12-31|||||Interventional|||Neurodevelopment After Early Iron Supplementation|Early Versus Late Enteral Iron Supplementation in Infants With a Birth Weight of Less Than 1301g – Neurocognitive Development at 5.3 Years Corrected Age|Completed||N/A|204||University of Ulm|||||f||||f||||||||||2018-06-01 03:18:46.613378|2018-06-01 03:18:46.613378
NCT00457977|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|2014-03-27||2015-04-22|2007-04-05|2007-04-09|Estimate|2015-04-22|2015-05-12|Estimate||||2015-04-22|2015-05-12|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PNEUMO||Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease|Pneumococcal Vaccine Response in COPD|Completed||Phase 3|181|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 03:18:46.720735|2018-06-01 03:18:46.720735
NCT00457964|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2013-09-23|2007-04-06|2007-04-09|Estimate|||||||2013-09-23|2013-09-25|Estimate|August 2005||2005-08-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM|RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis|Completed||Phase 1/Phase 2|36|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 03:18:47.374486|2018-06-01 03:18:47.374486
NCT00457951|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|2016-01-26||2016-10-25|2007-04-06|2007-04-09|Estimate|2016-10-25|2016-12-16|Estimate||||2016-10-25|2016-12-16|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|COPD|Open-Label followed by multi-center, randomized, double-blind, placebo-controlled trial in hospitalized subjects with exacerbations of COPD. In the double-blind phase, 145 subjects consented and 138 met criteria and were randomized.|A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD|An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Subjects With Exacerbations of Chronic Obstructive Pulmonary Disease|Terminated||Phase 2|158|Actual|Cantex Pharmaceuticals|PGX-ODSH-2006, Ph II in patients with exacerbation of COPD. There were no safety issues. An interim analysis demonstrated lack of efficacy for the primary and secondary endpoints; therefore, Cantex terminated the study on August 11, 2009.|3||Interim analysis: safety without efficacy ODSH in patients with acute COPD.|f||||t||||||||||2018-06-01 03:18:47.487252|2018-06-01 03:18:47.487252
NCT00457938|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2013-06-19|2007-04-06|2007-04-09|Estimate|||||||2013-06-19|2013-06-21|Estimate|April 2006||2006-04-30|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Novel Therapies for Metabolic Complications of Lipodystrophies|Novel Therapies for Metabolic Complications in Patients With Lipodystrophies|Unknown status|Recruiting|Phase 2/Phase 3|72|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 03:18:47.799817|2018-06-01 03:18:47.799817
NCT00457925|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2012-03-15|2007-04-06|2007-04-09|Estimate|||||||2012-03-15|2012-03-19|Estimate|October 2006||2006-10-31|February 2011|2011-02-28||||||||Interventional|||Absorption, Distribution, Metabolism And Excretion Study For GSK221149A|An Open-label, Two Period Study to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK221149A, Administered as Single Doses of an Oral Solution and an Intravenous Infusion to Healthy Female Volunteers|Completed||Phase 1|6||GlaxoSmithKline|||||||||||||||||||2018-06-01 03:18:47.882171|2018-06-01 03:18:47.882171
NCT00457912|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2018-01-23|2007-04-06|2007-04-09|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2005||2005-06-30|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy|Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy|Completed|||277|Actual|Nationwide Children's Hospital|||||f||||f||||||Samples With DNA|"~     whole blood, muscle tissue~   "|||2018-06-01 03:18:47.941753|2018-06-01 03:18:47.941753
NCT00457899|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-11-26|2007-04-05|2007-04-09|Estimate|||||||2007-11-26|2007-11-27|Estimate|July 2007||2007-07-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|RAPID||Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder|RAPID-An Open-Label Randomized, Multicenter Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immediate Release), Over 14 Days, in Acute Schizophrenia/Schizoaffective Disorder (Rapid Versus Conventional Titration)|Terminated||Phase 3|234|Anticipated|AstraZeneca||||Study terminated due to poor recruitment|f||||||||||||||2018-06-01 03:18:47.998343|2018-06-01 03:18:47.998343
NCT00457886|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2017-03-07|2007-04-06|2007-04-09|Estimate|||||||2017-03-07|2017-03-09|Actual|July 2005||2005-07-31|March 2017|2017-03-31|June 2007||2007-06-30|||||Observational|||Measurement of Hormone Levels in Patients Receiving 17-HPC for Preterm Delivery|Serum Levels of Hormones Known to Affect Parturition in Patients Receiving 17 Alpha-Hydroxyprogesterone Caproate (17-P) for the Prevention of Preterm Delivery|Completed|||20||Georgetown University|||||f||||||||||||||2018-06-01 03:18:48.090494|2018-06-01 03:18:48.090494
NCT00457873|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2008-05-20|2007-04-05|2007-04-09|Estimate|||||||2008-05-20|2008-05-22|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy|Isotonic Versus Hypotonic Saline for Maintenance Intravenous Fluid Therapy: A Pilot Randomized Trial|Completed||Phase 3|38|Actual|McGill University Health Center||2|||f||||||||||||||2018-06-01 03:18:48.166282|2018-06-01 03:18:48.166282
NCT00457860|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-04-16|2007-04-05|2007-04-09|Estimate|||||||2007-04-16|2007-04-17|Estimate|March 2007||2007-03-31|April 2007|2007-04-30||||||||Interventional|||Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease|A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)|Unknown status|Recruiting|Phase 1|50||Cambridge Antibody Technology|||||f||||f||||||||||2018-06-01 03:18:48.260107|2018-06-01 03:18:48.260107
NCT00457847|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2017-07-10|2007-04-05|2007-04-09|Estimate|||||||2017-07-10|2017-07-11|Actual|February 2007||2007-02-28|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Identifying Genetic Characteristics That Increase the Risk of Developing Primary Graft Dysfunction Following Lung Transplantation|Genetics of Primary Graft Dysfunction|Recruiting|||1150|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 03:18:48.333722|2018-06-01 03:18:48.333722
NCT00457834|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-01-08|2007-04-06|2007-04-09|Estimate|||||||2008-01-08|2008-01-15|Estimate|November 2003||2003-11-30|January 2008|2008-01-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|BIFF||Bi-Ventricular Pacing in Patients With Atrial Fibrillation and Heart Failure (BIFF-Study)|Study on the Efficacy of bi-Ventricular Pacing of Patients With Severe Heart Failure and Chronic Atrial Fibrillation|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Umeå University|||||f||||||||||||||2018-06-01 03:18:48.395783|2018-06-01 03:18:48.395783
NCT00457821|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|2012-02-27|2010-08-31|2012-10-03|2007-04-05|2007-04-09|Estimate|2012-10-03|2012-10-05|Estimate|2010-08-31|2010-09-06|Estimate|2012-10-03|2012-10-05|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety Study of Ivacaftor in Subjects With Cystic Fibrosis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D|Completed||Phase 2|39|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-06-01 03:18:48.490843|2018-06-01 03:18:48.490843
NCT00457808|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|||2007-04-06|2007-04-06|2007-04-09|Estimate|||||||2007-04-06|2007-04-09|Estimate|December 2002||2002-12-31|April 2007|2007-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM|Rapamycin Therapy of Angiomyolipomas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis|Completed||Phase 2|25||Children's Hospital Medical Center, Cincinnati|||||f||||t||||||||||2018-06-01 03:18:49.81964|2018-06-01 03:18:49.81964
NCT00457795|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-06|2011-10-18||2011-10-18|2007-04-06|2007-04-09|Estimate|2011-10-18|2011-11-24|Estimate||||2011-10-18|2011-11-24|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||24-hour IOP-lowering Effect of Brimonidine 0.1%||Completed||Phase 4|15|Actual|Allergan||1|||f||||||||||||||2018-06-01 03:18:49.907422|2018-06-01 03:18:49.907422
NCT00457782|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2011-01-31|2007-04-05|2007-04-06|Estimate|||||||2011-01-31|2011-02-01|Estimate|April 2007||2007-04-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma|A Phase I, Open-Label, Dose-escalation, Multicentre Study of KW-2478 Administered as a Single Agent Intravenously in a Consecutive Dosing Schedule in Patients With Relapsed/Refractory Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma|Completed||Phase 1|27|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||t||||||||||2018-06-01 03:18:50.093368|2018-06-01 03:18:50.093368
NCT00457769|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2016-02-22|2007-04-05|2007-04-06|Estimate|||||||2016-02-22|2016-02-24|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Aricept to Improve Functional Tasks in Vascular Dementia|Phase 1 Study of Aricept Plus a Behavioral Strategy to Improve Functional Tasks in Vascular Dementia|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-06-01 03:18:50.20977|2018-06-01 03:18:50.20977
NCT00457756|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-05-05|2007-04-05|2007-04-06|Estimate|||||||2008-05-05|2008-05-08|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The Effect of BiosLife on Serum Lipids|The Effect of an Integrative Dietary Supplement on the Lipid Profile of Subjects With Hypercholesterolemia|Completed||N/A|100|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 03:18:50.345682|2018-06-01 03:18:50.345682
NCT00457743|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2009-07-16||2009-10-02|2007-04-04|2007-04-06|Estimate|2009-10-02|2009-11-13|Estimate||||2009-10-02|2009-11-13|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)|A Phase I/II Study of Sunitinib Malate (SU011248) In The Treatment of Patients With Malignant Gastrointestinal Stromal Tumor (GIST) Previously Treated by Imatinib Mesylate.|Completed||Phase 1/Phase 2|36|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 03:18:50.517576|2018-06-01 03:18:50.517576
NCT00457730|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2014-08-27||2015-04-08|2007-04-05|2007-04-06|Estimate|2015-03-25|2015-04-06|Estimate||||2015-04-08|2015-04-27|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Test the Use of Duloxetine for Pain in MS|A Randomized Placebo Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis|Completed||Phase 2/Phase 3|38|Actual|Brown, Theodore R., M.D., MPH||2|||f||||f||||||||||2018-06-01 03:18:51.659574|2018-06-01 03:18:51.659574
NCT00457717|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Interventional|||Myopia Control by Combining Auricular Acupoint and Atropine Eyedrops||Completed||Phase 1|60||China Medical University, China|||||f||||t||||||||||2018-06-01 03:18:51.859393|2018-06-01 03:18:51.859393
NCT00457704|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-06|Estimate|||||||2007-04-04|2007-04-06|Estimate||||April 2007|2007-04-30||||||||Observational|||Carriage and Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Patients Admitted to Home Care.||Terminated|||||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:18:51.92693|2018-06-01 03:18:51.92693
NCT00457691|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2011-03-09||2015-03-10|2007-04-05|2007-04-06|Estimate|2011-05-02|2011-06-03|Estimate||||2015-03-10|2015-03-30|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer|A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment|Completed||Phase 3|768|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:18:52.048567|2018-06-01 03:18:52.048567
NCT00457678|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-08-21|2007-04-05|2007-04-06|Estimate|||||||2017-08-21|2017-08-23|Actual|January 2007|Anticipated|2007-01-31|August 2017|2017-08-31|December 4, 2007|Actual|2007-12-04|December 4, 2007|Actual|2007-12-04||Interventional|||Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself|A Multicenter, Randomized, Single-Masked Comparison of Lucentis™ Monotherapy With Triple Therapy of Reduced Fluence Visudyne-Lucentis-Dexamethasone (V-L-D) in Patients With CNV Secondary to AMD as Second Line Therapy After Lucentis Monotherapy|Withdrawn||Phase 2|0|Actual|Vitreous -Retina- Macula Consultants of New York||||Site did not enroll any patients to the study.|||||||||||||||2018-06-01 03:18:54.314652|2018-06-01 03:18:54.314652
NCT00457652|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-04-14|2007-04-04|2007-04-06|Estimate|||||||2008-04-14|2008-04-15|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?|Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?|Completed||Phase 4|24|Actual|Radboud University||2|||f||||t||||||||||2018-06-01 03:18:54.566729|2018-06-01 03:18:54.566729
NCT00457639|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2011-08-02|2007-04-04|2007-04-06|Estimate|||||||2011-08-02|2011-08-03|Estimate|April 2006||2006-04-30|August 2011|2011-08-31|October 2013|Anticipated|2013-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Cholic Acid for Hepatic Steatosis in Lipodystrophy|Phase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy Patients|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 03:18:54.642495|2018-06-01 03:18:54.642495
NCT00457626|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2016-11-16|2007-04-05|2007-04-06|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||An Open Label Extension Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension|An Open Label Extension Study to Evaluate Safety, Tolerability, and Efficacy of 18 Weeks of Valsartan Treatment in Children 6 Months-5 Years Old With Hypertension|Completed||Phase 3|66|Actual|Novartis||1|||f||||f||||||||||2018-06-01 03:18:54.735179|2018-06-01 03:18:54.735179
NCT00457613|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate|November 2004||2004-11-30|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Effects of Alkaline Phosphatase on Renal Function in Septic Patients|Effects of Alkaline Phosphatase on Renal Function in Patients With Severe Sepsis or Septic Shock.|Completed||Phase 2|15||Radboud University|||||f||||||||||||||2018-06-01 03:18:54.870336|2018-06-01 03:18:54.870336
NCT00457600|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate|June 2005||2005-06-30|January 2007|2007-01-31|July 2006||2006-07-31|||||Observational|||ParentLink: Better and Safer Emergency Care for Children|ParentLink: Better and Safer Emergency Care for Children|Completed|||3000||Boston Children’s Hospital|||||f||||||||||||||2018-06-01 03:18:54.926586|2018-06-01 03:18:54.926586
NCT00457587|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-05-07|2007-04-04|2007-04-06|Estimate|||||||2017-05-07|2017-05-09|Actual|September 2005||2005-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2011|Actual|2011-12-31|2 Years|Observational [Patient Registry]|||Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma|Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma|Active, not recruiting|||70|Actual|University of Wuerzburg|||||f||||f||||||Samples With DNA|"~     whole blood for monocytes isolation serum urine~   "|||2018-06-01 03:18:54.983233|2018-06-01 03:18:54.983233
NCT00457574|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2013-08-27|2007-04-05|2007-04-06|Estimate|||||||2013-08-27|2013-08-28|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas|A Single-Center, Open-Label, Phase I Study of Single-Agent GMX1777 Administered as a 24-Hour Infusion Every 3 Weeks to Patients With Refractory Solid Tumors or Lymphomas|Withdrawn||Phase 1|0|Actual|Teva Pharmaceutical Industries||||Study terminated prematurely due to financial constraints.|f||||f||||||||||2018-06-01 03:18:55.046684|2018-06-01 03:18:55.046684
NCT00457561|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate||||April 2007|2007-04-30||||||||Observational|||Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis||Completed|||||Hamamatsu University|||||f||||||||||||||2018-06-01 03:18:55.105138|2018-06-01 03:18:55.105138
NCT00457548|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2011-03-29|2007-04-05|2007-04-06|Estimate|||||||2011-03-29|2011-03-30|Estimate||||February 2009|2009-02-28||||||||Expanded Access|DIAL||Phone Intervention for Alcohol (ETOH) Use in Emergency Department Motor Vehicle Crash (ED MVC) Patients|Study of Effectiveness of BI Given to Injured MVC ED Patients Who Use Alcohol Harmfully and Hazardously|Available|||||Rhode Island Hospital|||||f||||||||||||||2018-06-01 03:18:55.15205|2018-06-01 03:18:55.15205
NCT00457535|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate|August 2000||2000-08-31|April 2007|2007-04-30|July 2004||2004-07-31|||||Observational|||Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning HD|Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis|Terminated|||||Hamamatsu University|||||f||||||||||||||2018-06-01 03:18:55.213369|2018-06-01 03:18:55.213369
NCT00457522|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2018-01-16|2007-04-05|2007-04-06|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2006||2006-04-30|January 2018|2018-01-31|December 2006|Actual|2006-12-31|||||Interventional|||Telephone Intervention to Increase Safety in Abused Women|Phone Intervention to Increase Safety in Abused Women: Pilot|Completed||N/A|40||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:18:55.267658|2018-06-01 03:18:55.267658
NCT00457509|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2014-01-10|2007-04-05|2007-04-06|Estimate|||||||2014-01-10|2014-01-14|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|September 2010|Actual|2010-09-30|November 2009|Actual|2009-11-30||Interventional|||Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults||Completed||Phase 1|251|Actual|Sanofi||5|||f||||f||||||||||2018-06-01 03:18:55.467539|2018-06-01 03:18:55.467539
NCT00457496|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2008-07-11|2007-04-05|2007-04-06|Estimate|||||||2008-07-11|2008-07-14|Estimate|March 2005||2005-03-31|July 2008|2008-07-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Effectiveness of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in Working Communities|Effectiveness of a Cognitive and Physical Program in Reducing Headache, Neck and Shoulder Pain: a Workplace Controlled Trial|Completed||Phase 3|300|Actual|University of Turin, Italy||1|||f||||f||||||||||2018-06-01 03:18:55.558405|2018-06-01 03:18:55.558405
NCT00457483|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2012-02-13|2007-04-04|2007-04-06|Estimate|||||||2012-02-13|2012-02-14|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|NAMIS||Nijmegen Antihypertensive Management Improvement Study|A Cross-over Trial to Identify Patient Characteristics That Predict Blood Pressure Response to Antihypertensive Therapy in General Practice|Completed||Phase 4|120|Actual|Radboud University|||||f||||f||||||||||2018-06-01 03:18:55.639255|2018-06-01 03:18:55.639255
NCT00457470|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2015-04-30|2007-04-05|2007-04-06|Estimate|||||||2015-04-30|2015-05-04|Estimate|June 2007||2007-06-30|April 2015|2015-04-30||||||||Interventional|||A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)|A Phase 2, Multi-Stage, Multi-Center Trial Exploring The Safety And Efficacy Of AG-014699 In Subjects With Diffuse Diabetic Macular Edema (DME) Involving The Center Of The Retina|Withdrawn||Phase 2|0|Actual|Pfizer||||Cancelled before first patient enrolled|f||||||||||||||2018-06-01 03:18:55.705777|2018-06-01 03:18:55.705777
NCT00456716|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2010-03-02|2007-04-04|2007-04-05|Estimate|||||||2010-03-02|2010-03-04|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma|A Phase II Trial of Sorafenib in BAC or Never-Smokers With Any Lung Adenocarcinoma|Completed||Phase 2|5|Actual|Swedish Medical Center|||||f||||f||||||||||2018-06-01 03:19:09.249272|2018-06-01 03:19:09.249272
NCT00457457|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05||2009-03-24|2010-10-27|2007-04-05|2007-04-06|Estimate||||2010-10-27|2010-11-01|Estimate|2010-10-27|2010-11-01|Estimate|May 2007||2007-05-31|October 2010|2010-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.|A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)|Completed||Phase 2|609|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:18:55.777338|2018-06-01 03:18:55.777338
NCT00457444|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate|December 2005||2005-12-31|April 2007|2007-04-30|November 2006||2006-11-30|||||Interventional|||Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration|ZU-SkinSIT-001 Single Center Phase I/IIa, Placebo Controlled, Randomized, Double Blind Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration|Completed||Phase 1|35||University of Zurich|||||f||||f||||||||||2018-06-01 03:18:55.918839|2018-06-01 03:18:55.918839
NCT00457431|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2015-06-12|2007-04-04|2007-04-06|Estimate|||||||2015-06-12|2015-06-15|Estimate|April 2007||2007-04-30|June 2015|2015-06-30||||April 2016|Anticipated|2016-04-30||Interventional|HACAinhospital||Hypothermia After In-hospital Cardiac Arrest|Hypothermia After In-hospital Cardiac Arrest|Unknown status|Recruiting|N/A|440|Anticipated|University of Schleswig-Holstein||2|||f||||t||||||||||2018-06-01 03:18:55.972033|2018-06-01 03:18:55.972033
NCT00457418|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|2013-05-28||2017-05-15|2007-04-05|2007-04-06|Estimate|2013-05-28|2013-07-31|Estimate||||2017-05-15|2017-06-07|Actual|February 20, 2007|Actual|2007-02-20|May 2017|2017-05-31|July 11, 2012|Actual|2012-07-11|May 27, 2008|Actual|2008-05-27||Interventional|||High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)|A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma|Completed||Phase 1|32|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:18:56.085486|2018-06-01 03:18:56.085486
NCT00457405|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-04-14|2007-04-04|2007-04-06|Estimate|||||||2008-04-14|2008-04-15|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?|Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?|Completed||Phase 4|10|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 03:18:56.357377|2018-06-01 03:18:56.357377
NCT00457392|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2011-07-06||2013-09-24|2007-04-04|2007-04-06|Estimate|2011-07-06|2011-08-02|Estimate||||2013-09-24|2013-10-29|Estimate|July 2007||2007-07-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|July 2010|Actual|2010-07-31||Interventional|||A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone|A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib|Completed||Phase 3|960|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:18:56.611435|2018-06-01 03:18:56.611435
NCT00457379|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-08-14|2007-04-04|2007-04-06|Estimate|||||||2007-08-14|2007-08-15|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|April 2008|Anticipated|2008-04-30|||||Interventional|HERCET||Effect of Exercise Training on the Function of HDL-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Coronary Artery Disease (HERCET-Study)|Randomized, Clinical Trial to Study the Effect of Exercise Training on the Function of HDL-Cholesterol, Endothelial Function, Oxidative Stress and Regenerative Capacity of Endothelial Progenitor Cells in Patients With Coronary Artery Disease|Unknown status|Recruiting|N/A|30|Anticipated|Hannover Medical School|||||f||||||||||||||2018-06-01 03:18:59.028123|2018-06-01 03:18:59.028123
NCT00457366|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2014-01-29|2007-04-05|2007-04-06|Estimate|||||||2014-01-29|2014-01-31|Estimate|May 2006||2006-05-31|January 2014|2014-01-31|May 2009|Actual|2009-05-31|August 2008|Actual|2008-08-31||Interventional|||A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room|A Comparison Study of the Efficacy of a Rapid Titration of Quetiapine and Haloperidol in Agitated Adults in an Emergency Setting.|Completed||Phase 4|72|Actual|University of Southern California||2|||f||||t||||||||||2018-06-01 03:18:59.102196|2018-06-01 03:18:59.102196
NCT00457353|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2009-01-20|2007-04-05|2007-04-06|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2007||2007-03-31|January 2009|2009-01-31||||December 2007|Actual|2007-12-31||Interventional|ENIGMA||ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children|Phase III Comparative Study to Assess the Efficacy and Safety of Oral Rehydration Therapy (ORT) in Combination With Spores of Bacillus Clausii (Enterogermina)Versus ORT Alone, Administered for 5 Days With the Treatment of Acute Diarrhea in Children.|Completed||Phase 3|264|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:18:59.175109|2018-06-01 03:18:59.175109
NCT00457340|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2009-06-17|2007-04-05|2007-04-06|Estimate|||||||2009-06-17|2009-06-19|Estimate|February 2000||2000-02-29|June 2009|2009-06-30|September 2004|Actual|2004-09-30|||||Interventional|CLARIDI||Atorvastatin For The Reduction Of Ventricular Arrhythmias|Cholesterol Lowering and Arrhythmia Recurrences After Internal Defibrillator Implantation (CLARIDI)|Completed||Phase 4|220||Pfizer|||||f||||||||||||||2018-06-01 03:18:59.252395|2018-06-01 03:18:59.252395
NCT00457327|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-06-04|2007-04-04|2007-04-06|Estimate|||||||2008-06-04|2008-06-05|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Pilot Study for Evaluation of the Need for Protective Ileostomy After Low Anterior Resection Due to Rectal Cancer|Pilot Study for Evaluation of the Need for Protective Ileostomy After Low Anterior Resection Due to Rectal Cancer|Terminated||Phase 2|40|Anticipated|Heidelberg University||||"RCT with same hypothesis ended and showed a superiority for protective ileostomy after lower~   anterior rectum resection."|f||||f||||||||||2018-06-01 03:18:59.32238|2018-06-01 03:18:59.32238
NCT00457314|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2009-05-18|2007-04-05|2007-04-06|Estimate|||||||2009-05-18|2009-05-19|Estimate|June 2007||2007-06-30|May 2009|2009-05-31|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||The Effects of Exercise Versus Inactivity on People With Mitochondrial Muscle Disease|Exercise Training and Deconditions: Implications for Therapy in Mitochondrial Myopathy|Unknown status|Recruiting|Phase 2|50|Anticipated|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||2|||f||||t||||||||||2018-06-01 03:18:59.386571|2018-06-01 03:18:59.386571
NCT00456937|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-03|||2009-01-26|2007-04-04|2007-04-05|Estimate|||||||2009-01-26|2009-01-27|Estimate|July 2006||2006-07-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Escitalopram in Schizophrenia in OCD- Open Label Study|Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study|Completed||Phase 4|15|Anticipated|BeerYaakov Mental Health Center|||||f||||f||||||||||2018-06-01 03:19:06.604406|2018-06-01 03:19:06.604406
NCT00457301|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2009-04-15||2009-09-21|2007-04-05|2007-04-06|Estimate|2009-09-21|2009-09-22|Estimate||||2009-09-21|2009-09-22|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|May 2008|Actual|2008-05-31|April 2007|Actual|2007-04-30||Interventional|||Using Health-related Quality of Life (HRQL) in Routine Clinical Care|An Assessment of the Effects of the Use of Measures of Health-related Quality of Life in Routine Clinical Care:an Application to Lung Transplantation.|Completed||N/A|213|Actual|University of Alberta|Randomizing patients instead of clinicians lead to sensitizing effects. EQ-5D is a generic preference-based measure, a specific measure should have been used to maximize responsiveness.|1|||f||||t||||||||||2018-06-01 03:18:59.480486|2018-06-01 03:18:59.480486
NCT00457288|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-11-09|2007-04-04|2007-04-06|Estimate|||||||2007-11-09|2007-11-12|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Efficacy and Safety of TF002 in Cutaneous Mastocytosis|Efficacy and Safety of TF002 in Cutaneous Mastocytosis|Completed||Phase 2|30|Anticipated|JADO Technologies GmbH|||||f||||t||||||||||2018-06-01 03:18:59.723025|2018-06-01 03:18:59.723025
NCT00457275|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2017-03-07|2007-04-05|2007-04-06|Estimate|||||||2017-03-07|2017-03-10|Actual|April 2005||2005-04-30|March 2017|2017-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)|A Multicentre, Open-Label, Observational Local Study to Evaluate the LDL-C Lowering Effect of Ezetimibe as Prescribed in Daily Routine Practice in the South African Population|Completed||Phase 3|440||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:18:59.795086|2018-06-01 03:18:59.795086
NCT00457262|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-06|Estimate|||||||2007-04-04|2007-04-06|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|August 2006|Actual|2006-08-31|||||Interventional|||Effects of Soy Protein on Serum paraoxonase1 Activity and Lipoproteins in Postmenopausal Women|Effects of Soy Protein on Serum paraoxonase1 Activity and Lipoproteins in Postmenopausal Women|Completed||N/A|42||Iran University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:18:59.849093|2018-06-01 03:18:59.849093
NCT00457249|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|2012-09-17|2010-04-28|2012-09-17|2007-04-05|2007-04-06|Estimate|2012-09-17|2012-10-19|Estimate|2010-04-28|2010-04-30|Estimate|2012-09-17|2012-10-19|Estimate|March 2007||2007-03-31|September 2012|2012-09-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older|Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age|Completed||Phase 4|1564|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:18:59.943669|2018-06-01 03:18:59.943669
NCT00457236|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate|March 2003||2003-03-31|April 2007|2007-04-30|December 2007|Anticipated|2007-12-31|||||Observational|EXCELSIOR||Effect of Clopidogrel Loading and Risk of PCI|Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement|Unknown status|Active, not recruiting||800||Heart Center Bad Krozingen|||||f||||||||||||||2018-06-01 03:19:00.530194|2018-06-01 03:19:00.530194
NCT00457223|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-02-12|2007-04-04|2007-04-06|Estimate|||||||2008-02-12|2008-02-13|Estimate|April 2007||2007-04-30|February 2008|2008-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||To Compare Fibrin Glue and Suture in Primary Pterygium Excision With Amniotic Membrane Transplantation|Randomized Controlled Trial to Compare Fibrin Glue and Suture in Primary Pterygium Excision With Amniotic Membrane Transplantation|Completed||Phase 2/Phase 3|32|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-06-01 03:19:00.583928|2018-06-01 03:19:00.583928
NCT00457210|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-05|||2007-04-05|2007-04-05|2007-04-06|Estimate|||||||2007-04-05|2007-04-06|Estimate|April 2007||2007-04-30|April 2007|2007-04-30||||||||Observational|||The Influence of Radiotherapy on Cognitive Function|The Influence of the Radiotherapy or Stereotactic Radiosurgery on the Cognitive Function of the Patients With the Neurotrax Assessment System and a Cognitive Questionnaire.|Unknown status|Not yet recruiting||150||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 03:19:00.652338|2018-06-01 03:19:00.652338
NCT00457197|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2015-10-23|2013-04-22|2016-04-01|2007-04-05|2007-04-06|Estimate|2015-12-21|2016-01-28|Estimate|2013-05-01|2013-05-08|Estimate|2016-04-01|2016-04-05|Estimate|March 2007||2007-03-31|April 2016|2016-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Quetiapine for Bipolar Disorder and Alcohol Dependence|Quetiapine for Bipolar Disorder and Alcohol Dependence|Completed||Phase 4|90|Actual|University of Texas Southwestern Medical Center|Larger sample size possibly needed for between-group differences in outcome measures. Pill counts not an optimum measure of medication adherence.|2|||f||||t||||||||||2018-06-01 03:19:00.723108|2018-06-01 03:19:00.723108
NCT00457184|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-08-27|2007-04-04|2007-04-05|Estimate|||||||2007-08-27|2007-08-28|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|June 2007|Actual|2007-06-30|||||Observational|||Thrombophilia and Migraine, Are They Related?|Thrombophilia and Migraine, Are They Related? - A Clinical Study|Completed|||50|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:19:01.509612|2018-06-01 03:19:01.509612
NCT00457171|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2009-05-15|2007-04-04|2007-04-05|Estimate|||||||2009-05-15|2009-05-18|Estimate|December 2004||2004-12-31|May 2009|2009-05-31||||||||Interventional|||GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis|A Double-Blind, Placebo-Controlled Phase I/II Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X, an Oral ICAM-1 and E-Selectin Inhibitor|Terminated||Phase 1|16||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:19:01.591236|2018-06-01 03:19:01.591236
NCT00457158|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2012-11-22|2007-04-04|2007-04-05|Estimate|||||||2012-11-22|2012-11-27|Estimate|July 2006||2006-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PREPIC2||PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption|PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study|Completed||Phase 4|399|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t||||||||||2018-06-01 03:19:01.674404|2018-06-01 03:19:01.674404
NCT00457145|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-06-30|2007-04-04|2007-04-05|Estimate|||||||2017-06-30|2017-07-02|Actual|March 27, 2007||2007-03-27|October 24, 2007|2007-10-24|October 24, 2007||2007-10-24|||||Interventional|||Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia Without Neovascularization|Completed||Phase 1|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:19:01.767026|2018-06-01 03:19:01.767026
NCT00457132|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-06-26|2007-04-04|2007-04-05|Estimate|||||||2007-06-26|2007-06-27|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|February 2006|Actual|2006-02-28|||||Interventional|||The Effect of Neuromuscular Training on Osteoarthritis: A Comparative Prospective Randomized Study|Dynamic Wedging: A Novel Treatment for Knee Osteoarthritis|Completed||N/A|60||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:19:01.893472|2018-06-01 03:19:01.893472
NCT00456742|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2012-04-30|2007-04-04|2007-04-05|Estimate|||||||2012-04-30|2012-05-01|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|||||Observational|||Efficacy of Treatment for Generalized Anxiety Disorder|Efficacy of Treatment for Generalized Anxiety Disorder|Completed|||250|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:19:09.144198|2018-06-01 03:19:09.144198
NCT00457119|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2013-02-09|2007-04-04|2007-04-05|Estimate|||||||2013-02-09|2013-02-12|Estimate|February 2007||2007-02-28|February 2013|2013-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients|A Two-step Phase 1 Study Investigating the Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients Not Treated Previously With Systemic Therapy|Completed||Phase 1|69|Actual|Novartis||4|||f||||t||||||||||2018-06-01 03:19:02.003458|2018-06-01 03:19:02.003458
NCT00457106|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2010-11-30|2007-04-04|2007-04-05|Estimate|||||||2010-11-30|2010-12-01|Estimate|June 2002||2002-06-30|November 2010|2010-11-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks|A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks|Completed||N/A|90|Anticipated|Beth Israel Medical Center|||||f||||||||||||||2018-06-01 03:19:02.126062|2018-06-01 03:19:02.126062
NCT00457093|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2010-11-17|2007-04-04|2007-04-05|Estimate|||||||2010-11-17|2010-11-18|Estimate|October 2006||2006-10-31|April 2007|2007-04-30|May 2007|Actual|2007-05-31|||||Interventional|||A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes|A Double Blind, Randomized, Parallel, Cross-Over Comparision of Glycemic Control Achieved With Once a Day Insulin Glargine Versus Detemir in Type 2 Diabetes|Completed||N/A|35|Anticipated|Diabetes Care Center|||||f||||f||||||||||2018-06-01 03:19:02.198857|2018-06-01 03:19:02.198857
NCT00457080|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2008-07-08|2007-04-04|2007-04-05|Estimate|||||||2008-07-08|2008-07-09|Estimate|October 2006||2006-10-31|July 2008|2008-07-31|February 2007|Actual|2007-02-28|||||Interventional|ETCO2||Application of Capnography Monitoring on the General Care Nursing Unit|Application of Capnography Monitoring on the General Care Nursing Unit|Completed||N/A|60||Texas Health Resources|||||f||||t||||||||||2018-06-01 03:19:02.289408|2018-06-01 03:19:02.289408
NCT00457067|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-06-30|2007-04-04|2007-04-05|Estimate|||||||2017-06-30|2017-07-02|Actual|March 27, 2007||2007-03-27|October 24, 2007|2007-10-24|October 24, 2007||2007-10-24|||||Interventional|||Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation|Pilot Study of Intravitreal Injection of Ranibizumab for Macular Telangiectasia With Neovascularization|Completed||Phase 1|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:19:02.360288|2018-06-01 03:19:02.360288
NCT00457054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-09-27|2007-04-04|2007-04-05|Estimate|||||||2011-09-27|2011-09-28|Estimate|July 2003||2003-07-31|September 2011|2011-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania|Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania Before and After Lithium Treatment: An Brain fMRI Study|Completed||Phase 4|60|Anticipated|Indiana University|||||f||||f||||||||||2018-06-01 03:19:02.423576|2018-06-01 03:19:02.423576
NCT00457041|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-06-30|2007-04-04|2007-04-05|Estimate|||||||2017-06-30|2017-07-02|Actual|January 17, 2007||2007-01-17|September 8, 2010|2010-09-08|September 8, 2010||2010-09-08|||||Observational|||Research Participants' Views on the Ethics of Clinical Research|Pilot Study Investigating Research Participants' Views on the Ethics of Clinical Research|Completed|||11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:19:02.50413|2018-06-01 03:19:02.50413
NCT00457028|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2011-06-07|2007-04-04|2007-04-05|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2003||2003-05-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|||||Observational|||Efficacy of Treatment for Obsessive Compulsive Disorder|Efficacy of Treatment for Obsessive Compulsive Disorder|Completed|||250|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:19:02.557761|2018-06-01 03:19:02.557761
NCT00457015|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2009-12-30|2009-12-30|2018-01-22|2007-04-04|2007-04-05|Estimate|2010-04-09|2010-05-04|Estimate|2010-04-09|2010-05-04|Estimate|2018-01-22|2018-02-20|Actual|April 1, 2007||2007-04-01|January 2018|2018-01-31|June 1, 2008|Actual|2008-06-01|June 1, 2008|Actual|2008-06-01||Interventional|||Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)|EDEMA4: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema|Completed||Phase 3|96|Actual|Shire||2|||f||||t||||||||||2018-06-01 03:19:02.635498|2018-06-01 03:19:02.635498
NCT00457002|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2014-04-14||2015-12-07|2007-04-04|2007-04-05|Estimate|2014-05-14|2014-05-20|Estimate||||2015-12-07|2015-12-08|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|ADOPT|Randomized Participants|Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness|A Phase 3 Randomized, Double-Blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization.|Completed||Phase 3|6758|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:19:03.248722|2018-06-01 03:19:03.248722
NCT00456989|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2014-10-06||2014-10-06|2007-04-04|2007-04-05|Estimate|2014-10-06|2014-10-09|Estimate||||2014-10-06|2014-10-09|Estimate|January 2004||2004-01-31|October 2014|2014-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer|Phase I/II Study of Docetaxel (Taxotere) in Combination With Doxorubicin HCI Liposome Injection (Doxil) in Advanced Androgen-Independent Prostate Cancer (AIPC)|Completed||Phase 1/Phase 2|39|Actual|James Graham Brown Cancer Center||1|||f||||f||||||||||2018-06-01 03:19:06.150556|2018-06-01 03:19:06.150556
NCT00456976|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2008-07-22|2007-04-04|2007-04-05|Estimate|||||||2008-07-22|2008-07-23|Estimate|April 2007||2007-04-30|July 2008|2008-07-31|September 2007||2007-09-30|||||Interventional|||Efficacy of Selegiline in Negative Symptoms of Schizophrenia|Efficacy of Selegiline Augmentation of Antipsychotic Medication to Treat Negative Symptoms in Inpatients With Chronic Schizophrenia|Completed||Early Phase 1|70||Tabriz University|||||f||||t||||||||||2018-06-01 03:19:06.342123|2018-06-01 03:19:06.342123
NCT00456963|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2011-07-04|2007-04-04|2007-04-05|Estimate|||||||2011-07-04|2011-07-06|Estimate|September 2007||2007-09-30|July 2011|2011-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|PHIDIAS||Prevention of Diabetes and Hypertension|Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.|Terminated||Phase 4|3000|Anticipated|Istituto Auxologico Italiano||3||"Because of delay in approval of the protocol by a number of Ethics Commitees the trial was~   terminated on March 4, 2010. No patient had received any study drug."|f||||t||||||||||2018-06-01 03:19:06.424238|2018-06-01 03:19:06.424238
NCT00456950|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2009-09-23|2007-04-04|2007-04-05|Estimate|||||||2009-09-23|2009-09-24|Estimate|October 2005||2005-10-31|September 2009|2009-09-30||||June 2008|Actual|2008-06-30||Observational|||Magnetic Resonance Imaging of the Coronary Vessel Wall|Detection of Vulnerable Plaque With Coronary Vessel Wall Magnetic Resonance Imaging|Completed|||75|Actual|Maastricht University Medical Center|||||f||||f||||||||||2018-06-01 03:19:06.549108|2018-06-01 03:19:06.549108
NCT00456924|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2010-06-16|2007-04-04|2007-04-05|Estimate|||||||2010-06-16|2010-06-17|Estimate|January 2004||2004-01-31|June 2010|2010-06-30|December 2004|Actual|2004-12-31|||||Interventional|||Low Dose Continuous Administration of the Progesterone Receptor Modulator VA2914|Prospective Randomized Multicenter Phase II Study of the Dose-Response Effects of Continuous Administration of Low-Dose VA2914 on Parameters of the Hypothalamic-Pituitary-Gonadal Axis and the Endometrium|Completed||Phase 2|48||HRA Pharma|||||f||||f||||||||||2018-06-01 03:19:06.672296|2018-06-01 03:19:06.672296
NCT00456911|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2008-02-12|2007-04-04|2007-04-05|Estimate|||||||2008-02-12|2008-02-13|Estimate|March 2005||2005-03-31|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Interventional|ELPAS||Family Dietary Coaching to Improve Nutritional Intakes and Body Weight Control|Prospective Longitudinal Study on Health and Diet (Etude Longitudinale Prospective Alimentation et Santé)|Completed||N/A|2020||Centre d'Etudes et de Documentation du Sucre|||||f||||t||||||||||2018-06-01 03:19:06.758509|2018-06-01 03:19:06.758509
NCT00456898|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-12-19|2007-04-04|2007-04-05|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway|A Randomized, Open-Label, 3-Period Crossover Study to Evaluate the Effect of Multiple Doses of DVS SR and Paroxetine on the CYP2D6 Biotransformation of Codeine to Morphine in Healthy Subjects.|Completed||Phase 1|40||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:19:06.836638|2018-06-01 03:19:06.836638
NCT00456885|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2017-03-30||2017-08-09|2007-04-04|2007-04-05|Estimate|2017-08-09|2017-09-11|Actual||||2017-08-09|2017-09-11|Actual|April 2007||2007-04-30|August 2017|2017-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women|The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus|Completed||Phase 4|41|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 03:19:06.925795|2018-06-01 03:19:06.925795
NCT00456872|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2017-03-30|2007-04-04|2007-04-05|Estimate|||||||2017-03-30|2017-04-04|Actual|December 2004||2004-12-31|March 2017|2017-03-31|September 2007|Actual|2007-09-30|May 2006|Actual|2006-05-31||Interventional|||Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies|A Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies|Completed||N/A|49|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 03:19:07.31811|2018-06-01 03:19:07.31811
NCT00456859|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-10-17|2007-04-04|2007-04-05|Estimate|||||||2007-10-17|2007-10-18|Estimate|April 2004||2004-04-30|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|CAP-KD||Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease|Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease (CAP-KD)|Completed||Phase 4|450||Institute for Health Outcomes and Process Evaluation Reseach|||||f||||t||||||||||2018-06-01 03:19:07.386781|2018-06-01 03:19:07.386781
NCT00456846|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2014-06-19||2016-04-27|2007-04-03|2007-04-05|Estimate|2014-06-19|2014-07-18|Estimate||||2016-04-27|2016-05-27|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional||Treated Population|First Line Therapy for Patients With Metastatic Breast Cancer|An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer|Terminated||Phase 2|123|Actual|Celgene Corporation||1|||f||||f||||||||||2018-06-01 03:19:07.484828|2018-06-01 03:19:07.484828
NCT00456833|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2012-04-12|2007-04-04|2007-04-05|Estimate|||||||2012-04-12|2012-04-13|Estimate|June 2005||2005-06-30|April 2012|2012-04-30||||March 2011|Actual|2011-03-31||Interventional|||Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy|A Combined Phase 1 and 2 Study Investigating the Combination of RAD001 and Erlotinib in Patients With Advanced NSCLC Previously Treated Only With Chemotherapy|Completed||Phase 1|248|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:19:08.144532|2018-06-01 03:19:08.144532
NCT00456820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-10-15|2007-04-04|2007-04-05|Estimate|||||||2007-10-15|2007-10-16|Estimate|July 2004||2004-07-31|April 2007|2007-04-30|November 2007||2007-11-30|||||Interventional|||Wellbutrin XL Effects on SSRIs Induced Changes|Wellbutrin XL Effects on SSRIs Induced Changes in the Reactivity of the Frontal Cortex and Limbic System to Emotional Stimuli: An fMRI Study|Completed||Phase 4|15||Indiana University|||||f||||||||||||||2018-06-01 03:19:08.35364|2018-06-01 03:19:08.35364
NCT00456807|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2009-11-12||2016-11-03|2007-04-04|2007-04-05|Estimate|2010-06-29|2010-07-30|Estimate||||2016-11-03|2016-12-16|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years|Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820.|Completed||Phase 3|100|Actual|GlaxoSmithKline|No safety data were collected in the framework of this ancillary study.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:19:08.429759|2018-06-01 03:19:08.429759
NCT00456794|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2016-07-13|2007-04-03|2007-04-05|Estimate|||||||2016-07-13|2016-07-14|Estimate|March 2002||2002-03-31|July 2016|2016-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa|A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/Day Istradefylline as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa|Completed||Phase 2|325||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 03:19:08.724911|2018-06-01 03:19:08.724911
NCT00456781|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2014-07-02|2007-04-04|2007-04-05|Estimate|||||||2014-07-02|2014-07-03|Estimate|April 2007||2007-04-30|July 2014|2014-07-31|March 2011|Actual|2011-03-31|April 2009|Actual|2009-04-30||Interventional|||Use of Graft Jacket for Rotator Cuff Repair|GraftJacket® Rotator Cuff Tendon Reinforcement Scaffold: A Randomized Prospective Clinical Evaluation|Completed||N/A|79|Actual|Wright Medical Technology||2|||f||||f||||||||||2018-06-01 03:19:08.789384|2018-06-01 03:19:08.789384
NCT00456768|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2011-04-28|2007-04-04|2007-04-05|Estimate|||||||2011-04-28|2011-04-29|Estimate|May 2003||2003-05-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Efficacy of Treatment for Panic Disorder|Efficacy of Treatment for Panic Disorder|Completed|||250|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:19:08.88|2018-06-01 03:19:08.88
NCT00456755|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2009-11-23||2009-11-23|2007-04-04|2007-04-05|Estimate|2009-11-23|2010-01-06|Estimate||||2009-11-23|2010-01-06|Estimate|March 2004||2004-03-31|November 2009|2009-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Herbal Treatment for Perennial Allergic Rhinitis|A Herbal Formula (SBL) for the Treatment of Perennial Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 2|126|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 03:19:08.940792|2018-06-01 03:19:08.940792
NCT00456703|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-03-03|2007-04-04|2007-04-05|Estimate|||||||2017-03-03|2017-03-06|Actual|July 2008||2008-07-31|March 2017|2017-03-31|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Interventional|||Restricted Fluid Regimen in Open Abdominal Bowel Surgery|Safety and Efficacy of Restricted Fluid Regimen in Open Abdominal Bowel Surgery|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center||1||Lack of funding|f||||f||||||||||2018-06-01 03:19:09.321941|2018-06-01 03:19:09.321941
NCT00456690|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2015-08-30|2007-04-04|2007-04-05|Estimate|||||||2015-08-30|2015-09-01|Estimate|May 2007||2007-05-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Endocrine and Nutritional Assessment in B Thalassemia Major|Endocrine and Nutritional Assessment in B Thalassemia Major - A Clinical Trial|Completed||N/A|133|Actual|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-06-01 03:19:09.385053|2018-06-01 03:19:09.385053
NCT00456677|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2017-04-14|2007-04-04|2007-04-05|Estimate|||||||2017-04-14|2017-04-18|Actual|June 1996||1996-06-30|April 2017|2017-04-30|October 1, 2007|Actual|2007-10-01|October 1, 2007|Actual|2007-10-01||Interventional|Mino||Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma|Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma|Completed||Phase 2|20|Actual|State University of New York - Downstate Medical Center||2|||f||||f||||||||No||2018-06-01 03:19:09.441765|2018-06-01 03:19:09.441765
NCT00456664|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2009-02-01|2007-04-04|2007-04-05|Estimate|||||||2009-02-01|2009-02-03|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||CMV Disease and IRIS in HIV-1 Infected Persons|Molecular Diagnostics for CMV Disease and IRIS in HIV-1 Infected Persons, and the Mechanism Study for CMV Alternative Gene Splicing in Immediate Early Protein|Completed|||200|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-06-01 03:19:10.445665|2018-06-01 03:19:10.445665
NCT00456651|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-05|Estimate|||||||2007-04-04|2007-04-05|Estimate|February 2007||2007-02-28|April 2007|2007-04-30||||||||Interventional|||Sleep Apnea-Hypopnea Syndrome and the Pathogenesis of Obesity|Sleep Apnea-Hypopnea Syndrome and the Pathogenesis of Obesity|Unknown status|Recruiting|N/A|40||Sociedad Española de Neumología y Cirugía Torácica|||||f||||t||||||||||2018-06-01 03:19:10.501213|2018-06-01 03:19:10.501213
NCT00456638|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2014-08-13|2007-04-04|2007-04-05|Estimate|||||||2014-08-13|2014-08-15|Estimate|April 2008||2008-04-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Clinical Study of Depodur Efficacy in Decreasing Post Operative Pain After Off Pump Coronary Artery Bypass Grafting (OP-CABG)|Clinical Study of Depodur Efficacy in Decreasing Post Operative Pain After Off Pump Coronary Artery Bypass Grafting (OP-CABG)|Withdrawn||N/A|0|Actual|Drexel University||2||Difficulty aquiring investigational drug|f||||f||||||||||2018-06-01 03:19:10.572108|2018-06-01 03:19:10.572108
NCT00456625|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2009-01-15||2016-11-03|2007-04-04|2007-04-05|Estimate|2009-04-01|2009-05-15|Estimate||||2016-11-03|2016-12-16|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.|To Evaluate Immune Response to a Hepatitis B Vaccine (Engerix™-B ) Challenge Dose in Healthy Subjects Who Received GSK Biologicals' Hepatitis B Vaccine (Engerix™-B ) Approximately 20 Years Ago as Primary Vaccination at 0, 1, 2 and 12 Months.|Completed||Phase 4|76|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:19:10.654566|2018-06-01 03:19:10.654566
NCT00456612|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2011-06-22||2017-01-23|2007-04-04|2007-04-05|Estimate|2015-09-03|2015-10-05|Estimate||||2017-01-23|2017-03-06|Actual|February 2007||2007-02-28|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Radiosurgery for Glioblastoma Multiforme|Phase I/II Study of Fractionated CyberKnife Stereotactic Radiosurgery for High Grade Gliomas in Elderly Patients With Poor Performance Status|Terminated||Phase 1/Phase 2|4|Actual|Beth Israel Deaconess Medical Center|Early termination due to difficulty in recruitment and retaining due to extremely bad prognosis of disease|1||Poor accrual|f||||f||||||||||2018-06-01 03:19:10.838875|2018-06-01 03:19:10.838875
NCT00456599|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2014-03-04||2015-11-04|2007-04-04|2007-04-05|Estimate|2014-03-04|2014-04-15|Estimate||||2015-11-04|2015-12-03|Estimate|April 2007||2007-04-30|November 2015|2015-11-30|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Interventional||68 patients were evaluable. 71 patients were enrolled however 1 was removed from study during cycle 1 due to non-compliance and 2 additional patients withdrew for reasons not related to toxicity or progression.|Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer|A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer|Completed||Phase 2|71|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 03:19:11.72151|2018-06-01 03:19:11.72151
NCT00456586|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2016-07-12|2007-04-03|2007-04-05|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|June 2003|Actual|2003-06-30|May 2003|Actual|2003-05-31||Interventional|||12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa|A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy|Completed||Phase 2|180||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 03:19:11.965596|2018-06-01 03:19:11.965596
NCT00456573|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2008-06-02|2007-04-04|2007-04-05|Estimate|||||||2008-06-02|2008-06-03|Estimate|April 2006||2006-04-30|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|September 2008|Anticipated|2008-09-30||Interventional|||Cytokine Profiles in Children With Obstructive Sleep Apnea|Local and Systemic Cytokine Profiles in Children With Obstructive Sleep Apnea and Controls|Unknown status|Recruiting|N/A|40|Anticipated|University of Chicago|||||f||||f||||||||||2018-06-01 03:19:12.027608|2018-06-01 03:19:12.027608
NCT00456560|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-09-13|2007-04-04|2007-04-05|Estimate|||||||2007-09-13|2007-09-17|Estimate|April 2007||2007-04-30|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||AV650 Drug-Drug Interaction Study|A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects|Completed||Phase 1|30|Anticipated|Avigen|||||f||||f||||||||||2018-06-01 03:19:12.094047|2018-06-01 03:19:12.094047
NCT00456547|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2011-11-06||2014-03-17|2007-04-04|2007-04-05|Estimate|2012-01-16|2012-02-20|Estimate||||2014-03-17|2014-04-14|Estimate|December 2003||2003-12-31|March 2014|2014-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Coagulation Factor Changes Associated With Postpartum Hysterectomies|Coagulation Factor Changes Associated With Postpartum Hysterectomies|Completed|||24|Actual|Northwestern University|||2||f||||f||||||||||2018-06-01 03:19:12.158176|2018-06-01 03:19:12.158176
NCT00456534|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-05|Estimate|||||||2007-04-03|2007-04-05|Estimate|November 2006||2006-11-30|April 2007|2007-04-30|June 2007|Anticipated|2007-06-30|||||Observational|||The Effect of Smoking on Perception||Unknown status|Recruiting||130||American University|||||f||||f||||||||||2018-06-01 03:19:12.503556|2018-06-01 03:19:12.503556
NCT00456521|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2014-10-08|2012-10-30|2014-12-02|2007-04-03|2007-04-05|Estimate|2014-11-18|2014-11-21|Estimate|2012-10-30|2012-11-01|Estimate|2014-12-02|2014-12-17|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||All randomized subjects|A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program|Completed||Phase 3|793|Actual|Orexigen Therapeutics, Inc||2|||f||||t||||||||||2018-06-01 03:19:12.611866|2018-06-01 03:19:12.611866
NCT00456508|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|2011-06-29||2018-01-22|2007-04-04|2007-04-05|Estimate|2012-11-27|2012-12-28|Estimate||||2018-01-22|2018-02-20|Actual|April 1, 2007||2007-04-01|January 2018|2018-01-31|September 1, 2010|Actual|2010-09-01|June 1, 2010|Actual|2010-06-01||Interventional|||Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)|Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks|Completed||Phase 3|147|Actual|Shire||1|||f||||f||||||||||2018-06-01 03:19:13.326881|2018-06-01 03:19:13.326881
NCT00456495|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2011-04-12||2017-06-21|2007-04-03|2007-04-05|Estimate|2013-05-03|2013-06-06|Estimate||||2017-06-21|2017-07-21|Actual|March 2007||2007-03-31|June 2017|2017-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effect of Ranibizumab on Malignant Conjunctival Neoplasia|Effect of Ranibizumab on Malignant Conjunctival Neoplasia|Completed||Phase 1|5|Actual|The New York Eye Cancer Center|This was a small case series involving a small number of subjects. Further investigations for dose, drug delivery and case selection are warranted.|1|||f||||f||||||||No||2018-06-01 03:19:13.721318|2018-06-01 03:19:13.721318
NCT00456482|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2011-12-07|2007-04-04|2007-04-05|Estimate|||||||2011-12-07|2011-12-08|Estimate|May 2002||2002-05-31|December 2011|2011-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant|A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye|Terminated||Phase 2/Phase 3|239|Actual|Bausch & Lomb Incorporated||3||SARS epidemic in Asia and Canada|f||||t||||||||||2018-06-01 03:19:13.875798|2018-06-01 03:19:13.875798
NCT00456469|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-05|Estimate|||||||2007-04-04|2007-04-05|Estimate|May 2007||2007-05-31|April 2007|2007-04-30|October 2009|Anticipated|2009-10-31|||||Observational|ALTAC||Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children|Diagnosis of Active and Latent TB Infection With IFN-y Assays in African Children|Unknown status|Not yet recruiting||500||Liverpool School of Tropical Medicine|||||f||||t||||||||||2018-06-01 03:19:13.951639|2018-06-01 03:19:13.951639
NCT00456456|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-05|Estimate|||||||2007-04-03|2007-04-05|Estimate|October 2006||2006-10-31|April 2007|2007-04-30||||||||Observational|||The Daily Habits Survey|The Daily Habits Survey|Unknown status|Recruiting||300||American University|||||f||||||||||||||2018-06-01 03:19:14.024349|2018-06-01 03:19:14.024349
NCT00456443|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-05|Estimate|||||||2007-04-04|2007-04-05|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Observational|||Invasive Infections in Children With Hemoglobinopathies|Invasive Infections in Children With Hemoglobinopathies. A Clinical Descriptive Retrospective Study.|Completed|||200||HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:19:14.080168|2018-06-01 03:19:14.080168
NCT00456430|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-11-11|2007-04-04|2007-04-05|Estimate|||||||2011-11-11|2011-11-15|Estimate|July 2003||2003-07-31|January 2010|2010-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response|Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response|Completed||Phase 4|80|Anticipated|Indiana University|||||f||||f||||||||||2018-06-01 03:19:14.134455|2018-06-01 03:19:14.134455
NCT00456417|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2008-01-17|2007-04-03|2007-04-05|Estimate|||||||2008-01-17|2008-01-18|Estimate|April 2007||2007-04-30|January 2008|2008-01-31||||December 2007|Actual|2007-12-31||Interventional|||Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects|Evaluation of [123I] MNI-187 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Completed||Phase 1|30|Anticipated|Institute for Neurodegenerative Disorders|||||t||||f||||||||||2018-06-01 03:19:14.200229|2018-06-01 03:19:14.200229
NCT00456404|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-05|Estimate|||||||2007-04-04|2007-04-05|Estimate|February 2005||2005-02-28|March 2004|2004-03-31|June 2005|Actual|2005-06-30|||||Interventional|||Effect of Peppermint Water on Breast Crack|Effect of Peppermint Water on Prevention of Nipple Crack in Lactating Primiparous Women: a Randomized Controlled Trial|Completed||N/A|196||Tabriz University|||||f||||t||||||||||2018-06-01 03:19:14.258502|2018-06-01 03:19:14.258502
NCT00456391|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-04|||2007-04-04|2007-04-04|2007-04-05|Estimate|||||||2007-04-04|2007-04-05|Estimate|October 2006||2006-10-31|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Observational|||The Utility of Performing Brain CT Scan in Non Trauma Patients at the Pediatric Emergency Unit|The Utility of Performing Brain CT Scan in Non Trauma Patients at the Pediatric Emergency Unit. A Retrospective Observational Study.|Completed|||||HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:19:14.308237|2018-06-01 03:19:14.308237
NCT00456378|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29||2018-04-17|2018-04-17|2007-04-02|2007-04-04|Estimate||||2018-04-17|2018-04-19|Actual|2018-04-17|2018-04-19|Actual|December 2006||2006-12-31|December 2017|2017-12-31|March 2022|Anticipated|2022-03-31|October 8, 2015|Actual|2015-10-08||Interventional|||Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care|A Prospective, Randomized, Controlled Pivotal Clinical Investigation of DIAM™ Spinal Stabilization System in Patients With Lumbar Degenerative Disc Disease.|Active, not recruiting||N/A|311|Anticipated|Medtronic Spinal and Biologics||2|||f||||t||t|f|||||||2018-06-01 03:19:14.370465|2018-06-01 03:19:14.370465
NCT00456365|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2014-05-27||2018-02-08|2007-04-02|2007-04-04|Estimate|2018-02-08|2018-03-09|Actual||||2018-02-08|2018-03-09|Actual|November 2006||2006-11-30|February 2018|2018-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||A total of 111 participants were screened with 110 enrolled in this clinical trial, including 56 randomized to pravastatin and 54 randomized to placebo.|Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 3|110|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-06-01 03:19:14.479147|2018-06-01 03:19:14.479147
NCT00456352|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2014-08-21|2007-04-02|2007-04-04|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2007||2007-04-30|August 2014|2014-08-31|October 2010|Actual|2010-10-31|April 2009|Actual|2009-04-30||Interventional|||Duodenal Exclusion for the Treatment of T2DM|Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 4|37|Actual|Medtronic - MITG|||||f||||||||||||||2018-06-01 03:19:14.766511|2018-06-01 03:19:14.766511
NCT00456339|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2013-09-04|2007-04-03|2007-04-04|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2006||2006-07-31|September 2013|2013-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Systemic Steroids Plus Antibiotics in Sleep Apnea Syndrome in Children|The Effect of a Combination of Systemic Steroids and Antibiotics on Obstructive Sleep Apnea Syndrome in Children|Terminated||Phase 4|4|Actual|University of Chicago||||Problems recruiting; patient relapse following treatment|f||||f||||||||||2018-06-01 03:19:14.814929|2018-06-01 03:19:14.814929
NCT00456326|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2008-02-12|2007-04-03|2007-04-04|Estimate|||||||2008-02-12|2008-02-18|Estimate|October 2005||2005-10-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|||||Observational|HIT||Heparin-Induced Thrombocytopenia Registry|A 3 Year Retrospective Heparin Induced Thrombocytopenia Registry (HIT) at Brigham and Women's Hospital.|Completed|||242|Actual|Brigham and Women's Hospital|||1||f||||t||||||||||2018-06-01 03:19:14.881974|2018-06-01 03:19:14.881974
NCT00456313|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2015-04-15|2007-04-03|2007-04-04|Estimate|||||||2015-04-15|2015-04-17|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|December 2007|Anticipated|2007-12-31|December 2007|Anticipated|2007-12-31||Interventional|||No Resistance After Long Term Treatment SERETIDE|Rationale for Therapy With Low Dose Steroids Combined With Long-acting beta2-agonists in Patients With Allergic Asthma: Redirecting Innate Immune Responses by Long-term Treatment With High Doses of Inhaled Steroids|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||1||lack of data|f||||||||||||||2018-06-01 03:19:14.940237|2018-06-01 03:19:14.940237
NCT00456300|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2010-11-30|2007-04-03|2007-04-04|Estimate|||||||2010-11-30|2010-12-01|Estimate|March 2007||2007-03-31|November 2010|2010-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Role of Exenatide in Type 1 Diabetes|The Role of Exenatide in Type 1 Mellitus|Completed||Phase 4|17|Anticipated|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 03:19:15.003925|2018-06-01 03:19:15.003925
NCT00456287|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2007-04-02|2007-04-02|2007-04-04|Estimate|||||||2007-04-02|2007-04-04|Estimate|February 2007||2007-02-28|April 2007|2007-04-30||||||||Interventional|||Platelet Activation and Circadian Rhythms of Clotting-Fibrinolysis Factors in Patients With Sleep Apnea Syndrome|Platelet Activation and Circadian Rhythms of Clotting-Fibrinolysis Factors in Patients With Sleep Apnea Syndrome. Implications in the Precipitation of Cardiovascular Events|Unknown status|Recruiting|N/A|40||Sociedad Española de Neumología y Cirugía Torácica|||||f||||t||||||||||2018-06-01 03:19:15.161899|2018-06-01 03:19:15.161899
NCT00456274|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2014-07-31|2007-04-02|2007-04-04|Estimate|||||||2014-07-31|2014-08-04|Estimate|September 1999||1999-09-30|July 2014|2014-07-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Baselines in Reproductive Disorders|Baselines in Reproductive Disorders|Recruiting||N/A|180|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:19:15.224867|2018-06-01 03:19:15.224867
NCT00456261|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2013-01-23||2013-01-23|2007-04-03|2007-04-04|Estimate|2013-01-23|2013-02-27|Estimate||||2013-01-23|2013-02-27|Estimate|March 2007||2007-03-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|February 2010|Actual|2010-02-28||Interventional|||First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC|A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|110|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 03:19:15.334112|2018-06-01 03:19:15.334112
NCT00456248|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2012-10-11|2007-04-02|2007-04-04|Estimate|||||||2012-10-11|2012-10-15|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|ENHANCE||Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin|Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy|Terminated||Phase 4|5|Actual|Kadmon Pharmaceuticals||3||slow enrollment|f||||t||||||||||2018-06-01 03:19:15.883494|2018-06-01 03:19:15.883494
NCT00456235|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2013-04-16|2007-04-03|2007-04-04|Estimate|||||||2013-04-16|2013-04-17|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Interventional|MONOCEPT||Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors|Interruption of the Calcineurine Inhibitors (ICN) and Introduction of Mycophenolate Mofetil (MMF) in Liver Transplant Patients With Side Effects Due to ICN: Study of the Reduction of the Risks of Rejection by Mycophenolate Mofetil Therapeutic Drug Monitoring|Completed||Phase 4|92|Actual|University Hospital, Limoges||2|||f||||||||||||||2018-06-01 03:19:15.977921|2018-06-01 03:19:15.977921
NCT00456222|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2009-08-20|2007-04-03|2007-04-04|Estimate|||||||2009-08-20|2009-08-21|Estimate|June 2003||2003-06-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|July 2007|Actual|2007-07-31||Observational|||Impact of Sleep Disruption on the Menstrual Cycle|Impact of Sleep Disruption on the Menstrual Cycle|Completed|||18|Actual|Brigham and Women's Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood/plasma~   "|||2018-06-01 03:19:16.066356|2018-06-01 03:19:16.066356
NCT00456209|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2014-02-01|2007-04-03|2007-04-04|Estimate|||||||2014-02-01|2014-02-04|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|June 2011|Actual|2011-06-30|December 2008|Actual|2008-12-31||Observational|||Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact on Occupations|Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact of Occupations|Completed|||4|Actual|Hackensack University Medical Center|||||f||||f||||||||||2018-06-01 03:19:16.131301|2018-06-01 03:19:16.131301
NCT00456196|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2009-07-09|2007-04-03|2007-04-04|Estimate|||||||2009-07-09|2009-07-13|Estimate|April 2006||2006-04-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Epidemiology of Venous Thromboembolism|Epidemiology of Venous Thromboembolism: Analyses and Publications From the DVT FREE Database|Completed|||5451|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 03:19:16.197628|2018-06-01 03:19:16.197628
NCT00456183|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-05-30|2007-04-03|2007-04-04|Estimate|||||||2007-05-30|2007-05-31|Estimate|August 2005||2005-08-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis.|Completed||Phase 1|12|Actual|University of Oxford|||||f||||t||||||||||2018-06-01 03:19:16.277421|2018-06-01 03:19:16.277421
NCT00456170|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate|April 2007||2007-04-30|April 2007|2007-04-30||||||||Interventional|HAVE||Are Sutures Required for Vaginal Hysterectomy: A Randomized Controlled Trial|Randomized Controlled Trial Comparing Traditional Vaginal Hysterectomy to Harmonic Scalpel Hysterectomy|Unknown status|Not yet recruiting|Phase 1|60||Southern Health|||||f||||t||||||||||2018-06-01 03:19:16.34482|2018-06-01 03:19:16.34482
NCT00455273|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2017-05-01|2007-03-30|2007-04-03|Estimate|||||||2017-05-01|2017-05-03|Actual|November 2006||2006-11-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer|Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer|Recruiting|||5|Anticipated|Sunnybrook Health Sciences Centre|||||f||||t||||||||||2018-06-01 03:19:30.798392|2018-06-01 03:19:30.798392
NCT00456157|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2010-06-16|2007-04-03|2007-04-04|Estimate|||||||2010-06-16|2010-06-17|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|November 2008|Actual|2008-11-30|||||Interventional|Knee OA||A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee|A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular Osteogenic Protein-1 OP-1 in Subjects With Osteoarthritis of the Knee|Completed||Phase 1|33|Anticipated|Stryker Biotech|||||f||||f||||||||||2018-06-01 03:19:16.410902|2018-06-01 03:19:16.410902
NCT00456144|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2013-07-09|2007-04-02|2007-04-04|Estimate|||||||2013-07-09|2013-07-11|Estimate|August 2006||2006-08-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer|Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone (GnRH) Agonist Therapy for Prostate Cancer|Completed|||36|Actual|Massachusetts General Hospital|||2||f||||||||||Samples With DNA|"~     Whole blood Urine~   "|||2018-06-01 03:19:16.486388|2018-06-01 03:19:16.486388
NCT00456131|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2012-08-16|2007-04-02|2007-04-04|Estimate|||||||2012-08-16|2012-08-17|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|Healthy Start||Prevention of Obesity at Universities: A Randomized Trial||Completed||N/A|330|Actual|Drexel University||1|||f||||t||||||||||2018-06-01 03:19:16.55048|2018-06-01 03:19:16.55048
NCT00456118|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate|September 2006||2006-09-30|April 2007|2007-04-30||||||||Observational|||Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies|Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies|Unknown status|Recruiting||150||University Hospital, Limoges|||||f||||||||||||||2018-06-01 03:19:16.607298|2018-06-01 03:19:16.607298
NCT00456105|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2018-01-16|2007-04-03|2007-04-04|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2006||2006-07-31|January 2018|2018-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of a Diabetes Action Team in Patients Post Infrainguinal Bypass Surgery With and Without Diabetes|Early Post-Operative Dysglycemia in Patients With and Without Diabetes Post-Infrainguinal Bypass Surgery and the Effectiveness of a Diabetes Action Team in the Management of Diabetes Post Infrainguinal Bypass Surgery on Glycemic Control, Length of Stay, and Infection Rates: A Pilot Study|Terminated||N/A|10|Actual|University of British Columbia||3||The study was stopped due to lack of resources of the study coordinator's time|f||||f||||||||||2018-06-01 03:19:16.674538|2018-06-01 03:19:16.674538
NCT00456092|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02||2013-03-28|2013-11-22|2007-04-02|2007-04-04|Estimate||||2013-07-26|2013-08-02|Estimate|2013-11-22|2013-12-17|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Phase II Study With CC-10004 in Psoriatic Arthritis|A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of CC-10004 in Subjects With Active Psoriatic Arthritis|Completed||Phase 2|204|Actual|Celgene||3|||f||||t||||||||||2018-06-01 03:19:16.749399|2018-06-01 03:19:16.749399
NCT00456066|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2008-10-07|2007-04-03|2007-04-04|Estimate|||||||2008-10-07|2008-10-08|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Coronary Thromboaspiration and Infarct Size|Assessment of Efficacity of Coronary Thromboaspiration (Export System) Performed Before Angioplasty on Infarct Size in Patients Treated by Coronary Percutaneous Interventions During Acute Phase.|Terminated||N/A|50|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:19:16.977498|2018-06-01 03:19:16.977498
NCT00456053|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2007-11-02|2007-04-02|2007-04-04|Estimate|||||||2007-11-02|2007-11-06|Estimate|December 2005||2005-12-31|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Interventional|||A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin|A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin|Completed||Phase 2|145|Actual|FibroGen|||||f||||f||||||||||2018-06-01 03:19:17.053878|2018-06-01 03:19:17.053878
NCT00456040|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate|March 2007||2007-03-31|April 2007|2007-04-30|March 2007||2007-03-31|||||Observational|||Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant|Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation|Completed|||25||Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 03:19:17.169546|2018-06-01 03:19:17.169546
NCT00456027|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2011-06-09|2007-04-03|2007-04-04|Estimate|||||||2011-06-09|2011-06-10|Estimate|December 2004||2004-12-31|April 2007|2007-04-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)|A Placebo-Controlled Study to Investigate the Impact of Diamyd® on the Diabetes Status of Patients With LADA (Latent Autoimmune Diabetes in Adult)|Completed||Phase 2|160|Actual|Diamyd Therapeutics AB|||||f||||t||||||||||2018-06-01 03:19:17.218867|2018-06-01 03:19:17.218867
NCT00456014|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|2014-11-26||2017-06-20|2007-04-02|2007-04-04|Estimate|2017-05-15|2017-06-14|Actual||||2017-06-20|2017-07-18|Actual|September 2006||2006-09-30|June 2017|2017-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||6 subjects who started on a TCA were also enrolled in the SSRI group (switched groups due to non-remission or side effects). We analyzed data from subjects completing either 6 or 8 weeks of SSRI treatment. Reasons remaining subjects were dropped from analysis included early withdrawal, insufficient PET data and later determination of ineligibility.|Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment|Biological Predictors of Response to Antidepressants|Completed||N/A|37|Actual|New York State Psychiatric Institute|small sample size, homogeneity of sample size|1|||f||||f||||||||No||2018-06-01 03:19:17.303344|2018-06-01 03:19:17.303344
NCT00456001|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2009-02-26|2007-04-03|2007-04-04|Estimate|||||||2009-02-26|2009-03-02|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Observational|||Heparin Induced Thrombocytopenia: Pharmacoeconomics|Study to Compare the Heparin Induced Thrombocytopenia Rates Associated With Heparin and Low Molecular Weight Heparin Usage as Well as Evaluate the Economic and Long-Term Clinical Burden of Heparin Induced Thrombocytopenia.|Completed|||200|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 03:19:17.49444|2018-06-01 03:19:17.49444
NCT00455988|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|December 2007|Anticipated|2007-12-31|||||Observational|||Developement of Questionnaire to Evaluate a Regularity of Lifestyle in Type 2 Diabetic Patients||Unknown status|Recruiting||360||Eulji University Hospital|||||f||||f||||||||||2018-06-01 03:19:17.570935|2018-06-01 03:19:17.570935
NCT00454545|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2007-10-18|2007-03-29|2007-03-30|Estimate|||||||2007-10-18|2007-10-22|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Atorvastatin in Moderate Active Crohns Disease||Completed||Phase 2|12|Anticipated|Skane University Hospital|||||f||||t||||||||||2018-06-01 03:19:55.574402|2018-06-01 03:19:55.574402
NCT00455975|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2014-12-12||2014-12-12|2007-04-03|2007-04-04|Estimate|2014-12-12|2014-12-22|Estimate||||2014-12-12|2014-12-22|Estimate|February 2007||2007-02-28|December 2014|2014-12-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||High-dose Bevacizumab in Advanced Renal Carcinoma Patients|Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma|Completed||Phase 2|119|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 03:19:17.654993|2018-06-01 03:19:17.654993
NCT00455962|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|2017-03-16||2017-06-28|2007-04-02|2007-04-04|Estimate|2017-03-16|2017-04-27|Actual||||2017-06-28|2017-07-27|Actual|January 2005||2005-01-31|June 2017|2017-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Race on Gonadotropin Responses|Effect of Race on Gonadotropin Responses to Short Term Negative and Positive Feedback Effects of Gonadal Steroids|Completed||Phase 1/Phase 2|23|Actual|Massachusetts General Hospital||2|||f||||t|t|f||||||Undecided|Coded individual level data with all identifiers removed will be available on request to the PI.|2018-06-01 03:19:18.150717|2018-06-01 03:19:18.150717
NCT00455949|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate||||April 2007|2007-04-30||||||||Observational|||Effect of Premature Luteinization on the Oocyte Quality in Oocyte Donation Program.||Completed|||||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-06-01 03:19:18.472805|2018-06-01 03:19:18.472805
NCT00455936|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2010-10-22|2007-04-03|2007-04-04|Estimate|||||||2010-10-22|2010-10-25|Estimate|October 2005||2005-10-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker|A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung|Completed||Phase 3|315|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 03:19:18.521563|2018-06-01 03:19:18.521563
NCT00455923|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2017-07-23||2018-01-09|2007-04-03|2007-04-04|Estimate|2017-07-23|2018-01-04|Actual||||2018-01-09|2018-02-05|Actual|May 3, 2005|Actual|2005-05-03|January 2018|2018-01-31|July 31, 2007|Actual|2007-07-31|July 31, 2007|Actual|2007-07-31||Interventional|||SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)|SERETIDE vs FLIXOTIDE in Mild Persistent Asthma (GINAII)|Completed||Phase 4|100|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:19:18.614529|2018-06-01 03:19:18.614529
NCT00455910|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate|January 2003||2003-01-31|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200|Thalidomide for the Treatment of Cytopenias of Patients With Low Risk Myelodysplastic Syndromes|Completed||Phase 2|112||Groupe Francophone des Myelodysplasies|||||f||||t||||||||||2018-06-01 03:19:18.916298|2018-06-01 03:19:18.916298
NCT00455897|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2018-01-16|2007-04-03|2007-04-04|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2006||2006-12-31|January 2018|2018-01-31|July 2011|Actual|2011-07-31|November 2007|Actual|2007-11-30||Interventional|||CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma|Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma|Terminated||Phase 2|3|Actual|Massachusetts General Hospital||1||Accrual was too slow. Trial terminated|f||||t||||||||||2018-06-01 03:19:18.989425|2018-06-01 03:19:18.989425
NCT00455884|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2012-04-03|2007-04-03|2007-04-04|Estimate|||||||2012-04-03|2012-04-04|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|||||Observational|||A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency|International Cooperative Metabolic Study (iNCMS) of NutropinAq® [Somatropin (rDNA Origin) Injection] Replacement Therapy in Adults With Growth Hormone Deficiency|Completed|||546|Actual|Ipsen|||||f||||f||||||||||2018-06-01 03:19:19.055506|2018-06-01 03:19:19.055506
NCT00455871|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2008-05-06|2007-04-03|2007-04-04|Estimate|||||||2008-05-06|2008-05-09|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Study of Treatment Effects of Combination Therapy of Lucentis Plus Reduced Fluence PDT With Visudyne in Patients With Exudative AMD|An Open-Label, Single-Site, Comparative, Pilot Study of the Treatment Effects of Combination Therapy of Lucentis (Ranibizumab) Plus Reduced Fluence Photodynamic Therapy With Visudyne in Patients With Exudative Age-Related Macular Degeneration (AMD)|Unknown status|Recruiting|N/A|30|Anticipated|Barnes Retina Institute||2|||f||||t||||||||||2018-06-01 03:19:19.103582|2018-06-01 03:19:19.103582
NCT00455858|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|2009-12-16||2014-11-25|2007-04-03|2007-04-04|Estimate|2010-02-04|2010-02-23|Estimate||||2014-11-25|2014-12-12|Estimate|November 2007||2007-11-30|November 2014|2014-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea|A 20-week, Multi-centre, Open-labelled, Non-comparative Evaluation of the Safety and Efficacy of Insulin Detemir in Combination With Oral Anti-diabetic Drug(s), in Subjects With Type 2 Diabetes Mellitus Who Were Inadequately Controlled on Current Therapy in Korea|Completed||Phase 4|87|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 03:19:19.262543|2018-06-01 03:19:19.262543
NCT00455845|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2011-03-01|2007-04-03|2007-04-04|Estimate|||||||2011-03-01|2011-03-02|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effectiveness of Lng IUD for Treatment of the Patient Undergone Conservative Surgery for Pelvic Endometriosis|A Double Blind Randomized Controlled Trial to Study the Effectiveness of a Levonorgestrel Releasing Intrauterine Device for the Treatment of Pelvic Pain or Dysmenorrhea in the Patients Undergone Conservative Surgery for Pelvic Endometriosis|Completed||Phase 3|54|Anticipated|Mahidol University||2|||f||||f||||||||||2018-06-01 03:19:19.479016|2018-06-01 03:19:19.479016
NCT00455832|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2012-02-28|2007-04-03|2007-04-04|Estimate|||||||2012-02-28|2012-02-29|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|IRIS||Influence of Ribavirin and Interferon on Semen Quality, IRIS Study|Influence of Ribavirin and Interferon on Semen Quality, IRIS Study|Completed|||23|Actual|Foundation for Liver Research|||||f||||f||||||||||2018-06-01 03:19:19.560983|2018-06-01 03:19:19.560983
NCT00455819|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2009-03-30|2007-04-03|2007-04-04|Estimate|||||||2009-03-30|2009-03-31|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Home Treatment of Patients With Pulmonary Embolism Based on Pro-Brain Natriuretic Peptide (BNP) Levels|Home Treatment of Patients With Pulmonary Embolism Based on Pro-BNP Levels|Completed||N/A|150|Actual|St. Antonius Hospital|||||f||||t||||||||||2018-06-01 03:19:19.638845|2018-06-01 03:19:19.638845
NCT00455637|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2008-06-18|2007-04-03|2007-04-04|Estimate|||||||2008-06-18|2008-06-19|Estimate|March 2007||2007-03-31|June 2008|2008-06-30||||||||Interventional|||Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?|A Phase II, Randomised, Double-Blind, Dose-Ranging Study in Children and Young People to Determine the Optimal Dose of Botulinum Toxin Type-A (Dysport®) in Managing the Symptoms of Hip Muscle Spasticity Due to Cerebral Palsy|Terminated||Phase 2|40|Anticipated|Ipsen||||Low levels of recruitment|f||||f||||||||||2018-06-01 03:19:22.058806|2018-06-01 03:19:22.058806
NCT00455806|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate|January 2007||2007-01-31|March 2007|2007-03-31|February 2008|Anticipated|2008-02-29|||||Interventional|ESAMOX||Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection|Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection|Unknown status|Recruiting|Phase 3|132||Technische Universität Dresden|||||f||||t||||||||||2018-06-01 03:19:19.7458|2018-06-01 03:19:19.7458
NCT00455793|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2013-11-27|2007-04-03|2007-04-04|Estimate|||||||2013-11-27|2013-12-02|Estimate|June 2006||2006-06-30|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Subclinical Atherosclerosis in HIV-infected Patients|Subclinical Atherosclerosis in HIV-infected Patients|Completed|||263|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-06-01 03:19:19.851818|2018-06-01 03:19:19.851818
NCT00455780|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2011-05-24|2007-04-03|2007-04-04|Estimate|||||||2011-05-24|2011-05-25|Estimate|January 2005||2005-01-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|PrimaryCare||Weight Loss Maintenance in Primary Care|Weight Loss Maintenance in Primary Care|Completed||N/A|238|Actual|Drexel University||4|||f||||f||||||||||2018-06-01 03:19:19.913638|2018-06-01 03:19:19.913638
NCT00455767|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2008-06-23|2007-04-03|2007-04-04|Estimate|||||||2008-06-23|2008-06-24|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients|Phase IIA Multicenter 1 Week Treatment, Randomised, Double-Blind, Placebo Controlled Study of Depelestat in Patients Suffering From Acute Respiratory Distress Syndrome|Completed||Phase 2|84|Actual|Debiopharm International SA||2|||f||||t||||||||||2018-06-01 03:19:19.987511|2018-06-01 03:19:19.987511
NCT00455754|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2007-04-03|2007-04-03|2007-04-04|Estimate|||||||2007-04-03|2007-04-04|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|December 2009|Anticipated|2009-12-31|||||Interventional|LYNEX||Esomeprazole Treatment for Patients With Lymphocytic Gastritis|Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on the Efficacy of Esomeprazole Treatment for Patients With Lymphocytic Gastritis|Unknown status|Recruiting|Phase 3|40||Technische Universität Dresden|||||f||||t||||||||||2018-06-01 03:19:20.081055|2018-06-01 03:19:20.081055
NCT00455741|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|2014-04-18||2018-04-19|2007-04-02|2007-04-04|Estimate|2018-04-19|2018-05-18|Actual||||2018-04-19|2018-05-18|Actual|November 2000||2000-11-30|April 2018|2018-04-30|August 22, 2015|Actual|2015-08-22|February 2007|Actual|2007-02-28||Interventional||All subjects were healthy and had experienced their last menstrual period 18 mo previously. Subjects were not on any medications known to interact with the neuroendocrine reproductive axis, including over-the-counter medications or herbal remedies. Factor V Leiden mutations were absent in all patients.|Postmenopausal Women Estrogen and Progesterone Infusion|Effect of Age on Gonadotropin Responses to Short-Term Negative and Positive Feedback Effects of Gonadal Steroids Using PET Scanning|Completed||Phase 1/Phase 2|20|Actual|Massachusetts General Hospital|PET scan data addresses hypothalamic vs pituitary sites of negative and positive estrogen feedback on LH, but there was insufficient power to address the effect of aging on these secondary measures..|2|||f||||t||||||||Undecided|Requests for sharing coded results without patient identifiers can be made directly to the PI.|2018-06-01 03:19:20.163815|2018-06-01 03:19:20.163815
NCT00455728|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2017-12-04|2007-04-03|2007-04-04|Estimate|||||||2017-12-04|2017-12-05|Actual|June 2006|Actual|2006-06-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|iNCGS||A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders|International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program for NutropinAq® [Somatropin (rDNA Origin) Injection]|Completed|||3690|Actual|Ipsen|||||f||||f||||||||||2018-06-01 03:19:20.96734|2018-06-01 03:19:20.96734
NCT00455715|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2011-06-27|2007-04-03|2007-04-04|Estimate|||||||2011-06-27|2011-06-29|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Interventional|||A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia|A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia|Completed||Phase 4|18|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 03:19:21.015798|2018-06-01 03:19:21.015798
NCT00455702|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|2014-06-11||2014-07-14|2007-04-03|2007-04-04|Estimate|2014-07-14|2014-08-07|Estimate||||2014-07-14|2014-08-07|Estimate|July 2004||2004-07-31|July 2014|2014-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia|Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals|Completed||Phase 4|38|Actual|Massachusetts General Hospital|As the first study of once-weekly dosing in Schizophrenia, this study was exploratory and so results must be considered preliminary. Additional studies are needed to replicate these findings.|2|||f||||f||||||||||2018-06-01 03:19:21.082761|2018-06-01 03:19:21.082761
NCT00455689|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2012-04-25|2007-04-02|2007-04-04|Estimate|||||||2012-04-25|2012-04-26|Estimate|November 2005||2005-11-30|April 2012|2012-04-30|October 2012|Anticipated|2012-10-31|September 2007|Actual|2007-09-30||Interventional|||Understanding Experimentally Induced Hot Flushes|Understanding Experimentally Induced Hot Flushes|Unknown status|Active, not recruiting|Phase 2/Phase 3|33|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:19:21.307703|2018-06-01 03:19:21.307703
NCT00455676|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-03|||2008-12-29|2007-04-03|2007-04-04|Estimate|||||||2008-12-29|2008-12-30|Estimate|June 2006||2006-06-30|December 2008|2008-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Chevron Osteotomy Versus SCARF Osteotomy in the Treatment of Hallux Valgus|Chevron Osteotomy Versus SCARF Osteotomy in the Treatment of Hallux Valgus|Completed||N/A|74||University Hospital, Limoges|||||f||||f||||||||||2018-06-01 03:19:21.382843|2018-06-01 03:19:21.382843
NCT00455663|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|2013-08-08||2015-05-29|2007-04-03|2007-04-04|Estimate|2015-05-29|2015-06-15|Estimate||||2015-05-29|2015-06-15|Estimate|November 2000||2000-11-30|May 2015|2015-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia|Medication Adherence and Outcomes in Schizophrenia|Completed||N/A|105|Actual|The University of Texas Health Science Center at San Antonio|Subjects were ill for a long-period of time|3|||f||||t||||||||||2018-06-01 03:19:21.472835|2018-06-01 03:19:21.472835
NCT00455650|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|2016-09-22||2017-02-07|2007-04-02|2007-04-04|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|March 2007||2007-03-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Eighty-nine participants were enrolled, and 71 participants (30 patients, 41 controls) completed at least one medication visit and were included in the analyses. Four participants (3 with schizophrenia, 1 control) missed one and 5 participants (3 with schizophrenia, 2 controls) missed two of the three medication visits.|Study of the Effects of Mecamylamine and Varenicline in Schizophrenia|Cognitive Effects of Mecamylamine and Varenicline in Schizophrenia|Completed||N/A|89|Actual|Massachusetts General Hospital||6|||f||||f||||||||||2018-06-01 03:19:21.722676|2018-06-01 03:19:21.722676
NCT00455624|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2013-07-09|2007-04-02|2007-04-04|Estimate|||||||2013-07-09|2013-07-11|Estimate|November 2002||2002-11-30|July 2013|2013-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer|Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer|Completed|||60|Actual|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 03:19:22.109092|2018-06-01 03:19:22.109092
NCT00455611|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2013-03-07|2007-04-02|2007-04-03|Estimate|||||||2013-03-07|2013-03-08|Estimate|May 2006||2006-05-31|April 2007|2007-04-30||||December 2012|Anticipated|2012-12-31||Interventional|||Effects of CPAP on Ventricular Function Modifications|Evaluation of the Effects of Intra-thoracic Positive Pressure Applicated With CPAP (Continuous Positive Airway Pressure) on Ventricular Function in Patients With Chronic Heart Failure: Modification Induced on Baroreflex Sensitivity|Withdrawn||N/A|0|Actual|Ospedale S. Giovanni Bosco||||No patients enrolled in the study|f||||t||||||||||2018-06-01 03:19:22.164127|2018-06-01 03:19:22.164127
NCT00455598|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2009-08-26|2007-04-02|2007-04-03|Estimate|||||||2009-08-26|2009-08-28|Estimate|February 2007||2007-02-28|August 2009|2009-08-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea|A Phase 2, Multi Center, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, PK, & Activity of ISIS 113715 Administered Weekly in Subjects With Type 2 DM Treated w/ Sulfonylurea|Completed||Phase 2|88|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 03:19:22.220002|2018-06-01 03:19:22.220002
NCT00455585|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2008-02-07|2007-04-02|2007-04-03|Estimate|||||||2008-02-07|2008-02-08|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|November 2007|Actual|2007-11-30|May 2007|Actual|2007-05-31||Interventional|||Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products|Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products.|Completed||Phase 4|18||Makerere University|||||f||||f||||||||||2018-06-01 03:19:22.312768|2018-06-01 03:19:22.312768
NCT00455572|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2017-05-12|2007-04-02|2007-04-03|Estimate|||||||2017-05-12|2017-05-15|Actual|May 11, 2007|Actual|2007-05-11|May 2017|2017-05-31|August 8, 2013|Actual|2013-08-08|August 4, 2013|Actual|2013-08-04||Interventional|||Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer|Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer|Terminated||Phase 1|71|Actual|GlaxoSmithKline||4||"Study early termination was due to slow recruitment and difficulties at achieving the required~   enrolment for the study."|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:19:22.43431|2018-06-01 03:19:22.43431
NCT00455559|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30||2018-02-06|2018-02-20|2007-03-30|2007-04-03|Estimate||||2018-02-06|2018-02-09|Actual|2018-02-20|2018-02-21|Estimate|August 2006||2006-08-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|November 2010|Actual|2010-11-30||Interventional|||Ph II Study of Perifosine Plus Gleevec for Patients With GIST|A Phase II Study of Perifosine Plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor|Completed||Phase 2|40|Actual|AEterna Zentaris||2|||f||||f||||||||||2018-06-01 03:19:22.654111|2018-06-01 03:19:22.654111
NCT00455546|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2010-02-01|2007-03-30|2007-04-03|Estimate|||||||2010-02-01|2010-02-02|Estimate|April 2007||2007-04-30|January 2008|2008-01-31|September 2007||2007-09-30|||||Interventional|PLASMA||PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease|PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease|Completed||Phase 2|400|Actual|Anthera Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:19:22.936601|2018-06-01 03:19:22.936601
NCT00455533|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|2011-03-04||2016-01-25|2007-04-02|2007-04-03|Estimate|2011-03-04|2011-04-04|Estimate||||2016-01-25|2016-02-24|Estimate|October 2007||2007-10-31|January 2016|2016-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer|A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer|Completed||Phase 2|384|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:19:23.231777|2018-06-01 03:19:23.231777
NCT00455520|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-01|2009-08-19||2013-07-12|2007-04-01|2007-04-03|Estimate|2009-12-10|2010-01-13|Estimate||||2013-07-12|2013-07-19|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy|A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects With Painful Diabetic Peripheral Neuropathy|Completed||Phase 3|395|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 03:19:26.798705|2018-06-01 03:19:26.798705
NCT00455507|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2012-08-28|2007-04-02|2007-04-03|Estimate|||||||2012-08-28|2012-08-29|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study)|Completed||Phase 2|363|Actual|Kyowa Hakko Kirin Co., Ltd||3|||f||||f||||||||||2018-06-01 03:19:27.155981|2018-06-01 03:19:27.155981
NCT00455494|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2007-04-02|2007-04-02|2007-04-03|Estimate|||||||2007-04-02|2007-04-03|Estimate|March 2007||2007-03-31|April 2007|2007-04-30||||||||Interventional|||Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial|Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial|Unknown status|Recruiting|Phase 1|14||Tulane University Health Sciences Center|||||f||||t||||||||||2018-06-01 03:19:27.243978|2018-06-01 03:19:27.243978
NCT00455468|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-01|||2011-07-11|2007-04-02|2007-04-03|Estimate|||||||2011-07-11|2011-07-12|Estimate|December 2005||2005-12-31|March 2007|2007-03-31|April 2009|Actual|2009-04-30|December 2007|Actual|2007-12-31||Interventional|||Randomized Controlled Trial (RCT) in Children With Severe Pneumonia||Completed||N/A|368|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||t||||||||||2018-06-01 03:19:27.327493|2018-06-01 03:19:27.327493
NCT00455455|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|2010-01-05||2010-06-09|2007-04-02|2007-04-03|Estimate|2010-06-09|2010-07-12|Estimate||||2010-06-09|2010-07-12|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Corneal and Conjunctival Sensitivity and Staining Study|Corneal and Conjunctival Sensitivity and Staining Study|Completed||Phase 4|50|Actual|University of Waterloo|Sample size completed as anticipated.|2|||f||||f||||||||||2018-06-01 03:19:27.402756|2018-06-01 03:19:27.402756
NCT00455442|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2008-09-18|2007-03-30|2007-04-03|Estimate|||||||2008-09-18|2008-09-19|Estimate|March 2007||2007-03-31|September 2008|2008-09-30|July 2007|Actual|2007-07-31|||||Interventional|||A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain|A Two-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain in Healthy Male Volunteers|Completed||Phase 2|57|Actual|Corcept Therapeutics|||||f||||t||||||||||2018-06-01 03:19:27.612003|2018-06-01 03:19:27.612003
NCT00455429|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-01|2013-02-28||2014-02-11|2007-04-01|2007-04-03|Estimate|2013-05-27|2013-07-01|Estimate||||2014-02-11|2014-03-12|Estimate|April 2007||2007-04-30|February 2014|2014-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis|A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis That is Moderate in Severity|Terminated||Phase 2|84|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Participants were not enrolled into JNJ-26113100(250 mg) twice daily dose because the study was stopped during 100mg twice daily dose due to preclinical finding of retinal atrophy in high dose group(150 mg/kg) of 6-month, albino rat toxicology study.|5||The study was stopped due to a non-clinical safety finding.|f||||t||||||||||2018-06-01 03:19:27.82513|2018-06-01 03:19:27.82513
NCT00455416|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2008-05-20|2007-04-02|2007-04-03|Estimate|||||||2008-05-20|2008-05-21|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|December 2009|Anticipated|2009-12-31|April 2009|Anticipated|2009-04-30||Interventional|KLYMF||Dietary Intervention in Follicular Lymphoma|Dietary Intervention in Stage III/IV Follicular Lymphoma. Impact on Markers of Cell Proliferation, Apoptosis, Host Immune Cell Infiltrate and Oxidative Stress.|Unknown status|Recruiting|Phase 2|45|Anticipated|Oslo University Hospital|||||f||||f||||||||||2018-06-01 03:19:28.855304|2018-06-01 03:19:28.855304
NCT00455403|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2018-02-02|2007-03-30|2007-04-03|Estimate|||||||2018-02-02|2018-02-05|Actual|April 2006||2006-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|ARCH-MS||Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)|Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome- Aim 3|Active, not recruiting||N/A|150|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 03:19:28.952902|2018-06-01 03:19:28.952902
NCT00455390|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2007-04-02|2007-04-02|2007-04-03|Estimate|||||||2007-04-02|2007-04-03|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|April 2009|Anticipated|2009-04-30|||||Interventional|IPPI A||Evaluation of the Effects of Post-Immediate Psychotherapeutic Interventions in Secondary Prevention of Psychotraumatic Disorders|Evaluation of the Effects of Post-Immediate Psychotherapeutic Interventions in Secondary Prevention of Psychotraumatic Disorders|Unknown status|Recruiting|Phase 3|330||Groupe Francais d'Epidemiologie Psychiatrique|||||f||||f||||||||||2018-06-01 03:19:29.156704|2018-06-01 03:19:29.156704
NCT00455377|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2013-06-12|2007-04-02|2007-04-03|Estimate|||||||2013-06-12|2013-06-13|Estimate|March 2007||2007-03-31|June 2013|2013-06-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|SPUTUM||Lung Function and Airway Inflammation in Portland Cement Workers|Airway Inflammation in Cement Dust Exposed Workers|Completed|||72|Actual|Sykehuset Telemark|||||f||||f||||||Samples Without DNA|"~     Induced sputum samples and blood samples~   "|||2018-06-01 03:19:29.221416|2018-06-01 03:19:29.221416
NCT00455364|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2013-02-05|2007-04-02|2007-04-03|Estimate|||||||2013-02-05|2013-02-06|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|VORI||Voriconazole as Prophylactic Therapy in Lung Transplant Recipients|Assessment of Safety and Efficacy of Voriconazole as Prophylactic Antifungal Therapy for Lung Transplant Recipients|Terminated||Phase 4|20|Anticipated|University of Chicago||||Protocol never received funding.|f||||f||||||||||2018-06-01 03:19:29.276815|2018-06-01 03:19:29.276815
NCT00455351|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2011-07-21|2007-04-02|2007-04-03|Estimate|||||||2011-07-21|2011-07-22|Estimate|February 2007||2007-02-28|July 2011|2011-07-31|August 2009|Actual|2009-08-31|||||Interventional|PRAVO||Vorinostat and Palliative Radiotherapy|Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.|Completed||Phase 1|20|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-06-01 03:19:29.332085|2018-06-01 03:19:29.332085
NCT00455338|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2007-04-02|2007-04-02|2007-04-03|Estimate|||||||2007-04-02|2007-04-03|Estimate|May 2005||2005-05-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Effect of Meal Composition on Postprandial Testosterone Concentration in Women With Polycystic Ovary Syndrome|The Effect of Meals of Varying Fat and Fiber Content on Postprandial Testosterone Concentration in Women With Polycystic Ovary Syndrome|Completed||N/A|16||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 03:19:29.444938|2018-06-01 03:19:29.444938
NCT00455325|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2018-02-02|2007-03-30|2007-04-03|Estimate|||||||2018-02-02|2018-02-05|Actual|March 2007||2007-03-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ARCH-MS||Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)|Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2|Active, not recruiting||Phase 2|35|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 03:19:29.527508|2018-06-01 03:19:29.527508
NCT00455312|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|2017-02-06||2017-12-03|2007-03-30|2007-04-03|Estimate|2017-05-01|2017-05-31|Actual||||2017-12-03|2017-12-05|Actual|August 2007||2007-08-31|December 2017|2017-12-31|June 2016|Actual|2016-06-30|March 2015|Actual|2015-03-31||Interventional|||Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA|Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia|Completed||Phase 2/Phase 3|36|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 03:19:29.71511|2018-06-01 03:19:29.71511
NCT00455299|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2014-10-14|2007-04-02|2007-04-03|Estimate|||||||2014-10-14|2014-10-16|Estimate|March 2007||2007-03-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||LVHR Multicenter Study|Randomized Controlled National Multicenter Study for Evaluation of Two Different Ways of Fixation of Mesh-implants and Differences With or Without Approximation of Herniadefects at Laparoscopic Operation for Incisional and Ventral Hernia|Completed||Phase 3|156|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-06-01 03:19:30.58142|2018-06-01 03:19:30.58142
NCT00455286|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2007-04-03|2007-04-02|2007-04-03|Estimate|||||||2007-04-03|2007-04-04|Estimate|November 2006||2006-11-30|April 2007|2007-04-30|November 2011|Anticipated|2011-11-30|||||Interventional|||a Phase II Study in Primary Central Nervous System Lymphoma|High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma – a Phase II Study|Unknown status|Recruiting|Phase 2|25||National Health Research Institutes, Taiwan|||||f||||t||||||||||2018-06-01 03:19:30.674923|2018-06-01 03:19:30.674923
NCT00018291|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2001||2001-01-31|December 2004|2004-12-31|January 2005||2005-01-31|||||Interventional|||Specific Interventions for Agitation in Alzheimer's Disease|Specific Interventions for Agitation in Alzheimer's Disease|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.245601|2018-06-01 05:36:49.245601
NCT00455260|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2013-08-30|2007-04-02|2007-04-03|Estimate|||||||2013-08-30|2013-09-02|Estimate|April 2007||2007-04-30|April 2009|2009-04-30||||October 2007|Actual|2007-10-31||Interventional|||A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study, to Assess Tolerability, Safety, Pharmacokinetic and Pharmacodynamic Profiles of hGH-ViaDerm™ System in Adult Subjects With Growth Hormone Deficiency|Completed||Phase 1|60|Actual|Teva Pharmaceutical Industries|||||f||||f||||||||||2018-06-01 03:19:30.85427|2018-06-01 03:19:30.85427
NCT00455247|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2013-06-04|2007-03-30|2007-04-03|Estimate|||||||2013-06-04|2013-06-05|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects||Completed||Phase 3|||Nestlé|||||f||||||||||||||2018-06-01 03:19:30.912847|2018-06-01 03:19:30.912847
NCT00455234|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2007-04-02|2007-04-02|2007-04-03|Estimate|||||||2007-04-02|2007-04-03|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|July 2006|Actual|2006-07-31|||||Interventional|TRECIndia-II||Rapid Tranquillization Trial: TREC-India II|Rapid Tranquilization of Violent or Agitated People in Psychiatric Emergency Settings- A Pragmatic Randomized Controlled Trial of Intramuscular Olanzepine Vs. Intramuscular Haloperidol + Promethazine.|Completed||Phase 3|300||Christian Medical College, Vellore, India|||||f||||f||||||||||2018-06-01 03:19:30.967989|2018-06-01 03:19:30.967989
NCT00455221|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-31|||2012-05-31|2007-03-31|2007-04-03|Estimate|||||||2012-05-31|2012-06-04|Estimate|February 2008||2008-02-29|May 2012|2012-05-31|November 2011|Actual|2011-11-30|December 2010|Actual|2010-12-31||Interventional|||Safety Assessment of a Multipeptide-gene Vaccine in CML|Safety Assessment of a Peptide Vaccine Derived From Bcr-abl Along With Cytokine Genes in CML Patients Undergoing Imatinib Treatment|Completed||Phase 1|12|Actual|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-06-01 03:19:31.045224|2018-06-01 03:19:31.045224
NCT00455208|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2009-02-18|2007-03-30|2007-04-03|Estimate|||||||2009-02-18|2009-02-19|Estimate|May 2007||2007-05-31|March 2007|2007-03-31|December 2008|Anticipated|2008-12-31|||||Interventional|||A Study Evaluating the Safety and Efficacy of Cura-100 in Subjects With Rheumatoid Arthritis and Osteoarthritis|Study Evaluating Cura-100 in Rheumatoid Arthritis and Osteoarthritis|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Cura Biotech LLC|||||f||||t||||||||||2018-06-01 03:19:31.125323|2018-06-01 03:19:31.125323
NCT00455195|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|2011-11-23||2014-02-04|2007-03-30|2007-04-03|Estimate|2011-11-23|2012-01-05|Estimate||||2014-02-04|2014-03-07|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Late-Onset Treatment Study Extension Protocol|An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704|Completed||Phase 4|81|Actual|Sanofi||2|||t||||t||||||||||2018-06-01 03:19:31.238837|2018-06-01 03:19:31.238837
NCT00455182|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2015-03-17|2007-04-02|2007-04-03|Estimate|||||||2015-03-17|2015-03-19|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Acupuncture for Pain Management After Hip or Knee Arthroplasty|Acupuncture for Pain Management After Hip or Knee Arthroplasty|Withdrawn||N/A|0|Actual|HealthEast Care System||3||Inability to enroll subjects who were willing to be randomized to control group|f||||f||||||||||2018-06-01 03:19:32.802098|2018-06-01 03:19:32.802098
NCT00455169|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2015-09-15|2007-03-30|2007-04-03|Estimate|||||||2015-09-15|2015-09-17|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Influenza Vaccine in Premature Infants|Influenza Vaccine Immunogenicity in Extremely Premature Infants|Completed|||66|Actual|University of Rochester|||2||f||||f||||||None Retained|"~     No retention~   "|||2018-06-01 03:19:32.91711|2018-06-01 03:19:32.91711
NCT00455156|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2012-10-26|2007-04-02|2007-04-03|Estimate|||||||2012-10-26|2012-10-29|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|September 2009|Actual|2009-09-30|January 2009|Actual|2009-01-31||Interventional|||Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring|A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150µg of Nestorone® and 15µg of Ethinyl Estradiol (150/15 NES/EE CVR)|Completed||Phase 3|1143|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||t||||||||||2018-06-01 03:19:33.004048|2018-06-01 03:19:33.004048
NCT00455143|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2016-03-16|2007-04-02|2007-04-03|Estimate|||||||2016-03-16|2016-03-17|Estimate|September 2006||2006-09-30|March 2016|2016-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Cognitive Protection - Dexmedetomidine and Cognitive Reserve|Cognitive Protection - Dexmedetomidine and Cognitive Reserve|Terminated||Phase 4|27|Actual|Icahn School of Medicine at Mount Sinai||2||"Pilot study initiated to provide support data for main grant GCO 06-0217 funded before this~   pilot collected significant data. no results for this study."|f||||f||||||||||2018-06-01 03:19:33.117086|2018-06-01 03:19:33.117086
NCT00455130|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2010-01-31|2007-04-02|2007-04-03|Estimate|||||||2010-01-31|2010-02-02|Estimate|March 2004||2004-03-31|January 2010|2010-01-31|August 2005|Actual|2005-08-31|||||Interventional|||A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis||Completed||Phase 2|||Pharmaxis|||||f||||||||||||||2018-06-01 03:19:33.196542|2018-06-01 03:19:33.196542
NCT00455117|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-01|||2013-05-28|2007-04-02|2007-04-03|Estimate|||||||2013-05-28|2013-05-30|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Parecoxib on Post-craniotomy Pain|Phase Four Study of Intravenous Parecoxib on Post-craniotomy Pain|Completed||Phase 4|130|Actual|Melbourne Health||2|||f||||f||||||||||2018-06-01 03:19:33.28455|2018-06-01 03:19:33.28455
NCT00455104|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2017-07-31|2007-03-30|2007-04-03|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2007|Actual|2007-01-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31|10 Years|Observational [Patient Registry]|CFDI-NR||Canadian Fabry Disease Initiative (CFDI) National Registry|Canadian Fabry Disease Initiative National Registry: Outcomes of Rare Disease Therapeutics and Cardiovascular Risk Factor Modification|Recruiting|||600|Anticipated|Canadian Fabry Research Consortium|||1||f||||t||||||Samples Without DNA|"~     Biomarker samples~   "|||2018-06-01 03:19:33.528015|2018-06-01 03:19:33.528015
NCT00455091|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2017-04-26|2007-04-02|2007-04-03|Estimate|||||||2017-04-26|2017-04-28|Actual|May 2007||2007-05-31|June 2009|2009-06-30|April 2018|Anticipated|2018-04-30|April 2012|Actual|2012-04-30||Observational|||A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma|A Randomization Trial of Adjuvant Lamivudine/ Adefovir Dipivoxil Against Recurrence in Post-operative HBV-related Hepatocellular Carcinoma|Terminated|||117|Actual|National Health Research Institutes, Taiwan||||No cases enrollment|f||||t||||||Samples With DNA|"~     HBVDNA~   "|||2018-06-01 03:19:33.652347|2018-06-01 03:19:33.652347
NCT00455078|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-02|||2013-09-04|2007-04-02|2007-04-03|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|LTXGERD||GI Reflux in Lung Transplant and Its Relationship to Chronic Rejection|The Role of Reflux in Innate Immunity Activation After Lung Transplantation.|Completed|||20|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 03:19:33.746132|2018-06-01 03:19:33.746132
NCT00455065|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2017-12-07|2007-03-30|2007-04-03|Estimate|||||||2017-12-07|2017-12-11|Actual|August 2005||2005-08-31|December 2017|2017-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Weight Loss and Cardiovascular Disease (CVD) Prevention Via a Whole Grain Diet in Men and Women With Metabolic Syndrome|Weight Loss and Cardiovascular Disease (CVD) Prevention Via a Whole Grain Diet in Men and Women With Metabolic Syndrome|Completed||N/A|50||Penn State University|||||f||||f||||||||||2018-06-01 03:19:33.811699|2018-06-01 03:19:33.811699
NCT00455052|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-01|||2018-01-29|2007-04-01|2007-04-03|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2011|Actual|2011-03-31|January 2017|2017-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors|A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors|Completed||Phase 1|30|Actual|Mersana Therapeutics||1|||f||||f||||||||No||2018-06-01 03:19:33.893766|2018-06-01 03:19:33.893766
NCT00455039|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2016-05-10|2007-03-30|2007-04-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2005||2005-07-31|May 2016|2016-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients|INST 0514C- A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study|Completed||Phase 1/Phase 2|55|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 03:19:34.064745|2018-06-01 03:19:34.064745
NCT00455026|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-01|||2013-05-28|2007-04-02|2007-04-03|Estimate|||||||2013-05-28|2013-05-30|Estimate|March 2006||2006-03-31|March 2007|2007-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia|Effect of Remifentanil on Electroencephalographic BAR Index During Propofol Anaesthesia|Completed||Phase 1|45|Actual|Melbourne Health||3|||f||||f||||||||||2018-06-01 03:19:34.214711|2018-06-01 03:19:34.214711
NCT00455013|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|2013-07-16|2010-04-29|2014-05-27|2007-03-30|2007-04-02|Estimate|2013-09-23|2013-11-21|Estimate|2010-04-29|2010-05-03|Estimate|2014-05-27|2014-06-09|Estimate|July 2007||2007-07-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|October 2008|Actual|2008-10-31||Interventional||All participants who received transplant and were treated with drug were analyzed up to Month 12 post transplant.|A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation|A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept (BMS-224818)-Based Corticosteroid-Free Regimens in Renal Transplant|Completed||Phase 2|93|Actual|Bristol-Myers Squibb|Main limitations of this study include: small size (small number of participants in each treatment arm), the open-label nature of the trial, its exploratory nature, and the high rate of switches from sirolimus to MMF in one of the belatacept groups.|3|||f||||t||||||||||2018-06-01 03:19:34.394584|2018-06-01 03:19:34.394584
NCT00455000|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2009-10-12|2007-03-30|2007-04-02|Estimate|||||||2009-10-12|2009-10-14|Estimate|March 2007||2007-03-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease|A Phase I, Randomized, Placebo Controlled, Double Blind Dose Escalation Study Of The Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease|Completed||Phase 1|37|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:19:36.329618|2018-06-01 03:19:36.329618
NCT00454987|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|2015-11-12|2012-01-23|2015-11-12|2007-03-30|2007-04-02|Estimate|2015-11-12|2015-12-16|Estimate|2012-01-23|2012-01-25|Estimate|2015-11-12|2015-12-16|Estimate|May 2007||2007-05-31|October 2015|2015-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine|Assessment of Long-term Antibody Persistence After a Booster Dose of GSK Biologicals' Hib & Meningococcal C Vaccine (Menitorix™) 811936 Given at 12-15 Months of Age to Subjects Primed With 3 Doses of Menitorix™ at 2, 3, 4 Months of Age|Completed||Phase 4|288|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:19:36.493164|2018-06-01 03:19:36.493164
NCT00454974|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2007-03-30|2007-03-30|2007-04-02|Estimate|||||||2007-03-30|2007-04-02|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|WAK||Pilot Study of Wearable Artificial Kidney|Preliminary Study to Assess the Safety and Efficacy of a Wearable Artificial Kidney Device for the Treatment of Patients With Endstage Renal Failure|Completed||Phase 1|8||Royal Free Hampstead NHS Trust|||||f||||t||||||||||2018-06-01 03:19:38.129727|2018-06-01 03:19:38.129727
NCT00454961|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2007-10-24|2007-03-30|2007-04-02|Estimate|||||||2007-10-24|2007-10-25|Estimate|April 2007||2007-04-30|October 2007|2007-10-31||||||||Interventional|C3||Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania|Effectiveness of Artemether-Lumefantrine Treatment Provided by Community Health Worker Against Uncomplicated Malaria in Children Under 5 Years of Age in Tanzania|Completed||Phase 4|200|Anticipated|Karolinska University Hospital|||||f||||||||||||||2018-06-01 03:19:38.20265|2018-06-01 03:19:38.20265
NCT00454948|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2007-03-30|2007-03-30|2007-04-02|Estimate|||||||2007-03-30|2007-04-02|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|August 2009|Anticipated|2009-08-31|||||Interventional|CHICOS||Nutrition Intervention and Play Group Exercise for Low-Income Latinas|Home Based Nutrition Intervention Nad Play Group Exercise for Low-Income Latinas|Unknown status|Recruiting|Phase 1|250||Stanford University|||||f||||t||||||||||2018-06-01 03:19:38.308801|2018-06-01 03:19:38.308801
NCT00454935|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2008-06-06|2007-03-30|2007-04-02|Estimate|||||||2008-06-06|2008-06-09|Estimate|April 2007||2007-04-30|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|||||Observational|||Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy|Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy|Unknown status|Recruiting||40|Anticipated|VU University Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood Tumor tissue~   "|||2018-06-01 03:19:38.384782|2018-06-01 03:19:38.384782
NCT00454922|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2012-12-04|2007-03-29|2007-04-02|Estimate|||||||2012-12-04|2012-12-06|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients|Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients|Completed||N/A|44|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 03:19:38.490557|2018-06-01 03:19:38.490557
NCT00454909|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|2017-03-01|2009-09-03|2017-04-25|2007-03-30|2007-04-02|Estimate|2017-03-01|2017-04-12|Actual|2009-09-03|2009-09-04|Estimate|2017-04-25|2017-05-30|Actual|April 23, 2007||2007-04-23|March 2017|2017-03-31|April 11, 2008|Actual|2008-04-11|October 31, 2007|Actual|2007-10-31||Interventional|||Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.|Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.|Completed||Phase 2|873|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:19:38.669478|2018-06-01 03:19:38.669478
NCT00454896|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2014-09-17|2007-03-29|2007-04-02|Estimate|||||||2014-09-17|2014-09-18|Estimate|May 2004||2004-05-31|September 2014|2014-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|VENUS||A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5mg and 10mg VESIcare® for the Treatment of Urgency Associated With Overactive Bladder|Completed||Phase 3|739|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:19:39.627476|2018-06-01 03:19:39.627476
NCT00454883|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2015-06-30|2007-03-30|2007-04-02|Estimate|||||||2015-06-30|2015-07-02|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.|Treatment Of Manic Or Mixed Episodes Of Up To Moderate Severity In Patients With Bipolar Disorder And Schizoaffective Disorder|Completed|||379|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:19:39.915442|2018-06-01 03:19:39.915442
NCT00454870|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2008-05-05|2007-03-30|2007-04-02|Estimate|||||||2008-05-05|2008-05-06|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|80|Anticipated|Memory Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:19:39.983448|2018-06-01 03:19:39.983448
NCT00454857|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|2009-10-16||2013-10-23|2007-03-29|2007-04-02|Estimate|2010-04-23|2010-05-12|Estimate||||2013-10-23|2013-11-26|Estimate|May 2006||2006-05-31|October 2013|2013-10-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Observational|||Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|A Prospective Observational Descriptive Study and Retrospective Chart Review of Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Completed|||326|Actual|Amgen|||1||f||||||||||None Retained|"~     None retained.~   "|||2018-06-01 03:19:40.116237|2018-06-01 03:19:40.116237
NCT00454831|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2007-11-14|2007-03-30|2007-04-02|Estimate|||||||2007-11-14|2007-11-16|Estimate|February 2006||2006-02-28|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|HEP-40||Efficacy and Safety of HEP-40 Chitosan for Mild to Moderately Elevated Cholesterol|A 16 Week With 12 Week Active Treatment Multi-Center, Placebo-Controlled, Randomized Study Evaluating the Efficacy of HEP-40 Chitosan in Managing Moderate Hypercholesterolemia|Completed||Phase 2|207|Actual|DNP Canada||5|||f||||f||||||||||2018-06-01 03:19:40.55087|2018-06-01 03:19:40.55087
NCT00454818|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|2014-06-25||2014-08-19|2007-03-30|2007-04-02|Estimate|2014-08-19|2014-08-20|Estimate||||2014-08-19|2014-08-20|Estimate|March 2007||2007-03-31|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Interventional|CUPID|Baseline data are provided for subjects enrolled in the Phase 1 or Phase 2 trials.|Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure|A Phase 1/2 Trial of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure in Two Stages (Open-Label, Sequential Dose-Escalation Cohorts and Randomized, Double-Blind, Placebo-Controlled, Parallel Cohorts)|Completed||Phase 1/Phase 2|51|Actual|Celladon Corporation|Limitations of this study include its small sample size and the inability to conclusively prove that the delivered gene was responsible for the observed clinical effects. Larger confirmatory trials are needed.|5|||f||||t||||||||||2018-06-01 03:19:40.731235|2018-06-01 03:19:40.731235
NCT00454805|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|2012-04-25|2011-04-06|2016-07-06|2007-03-30|2007-04-02|Estimate|2012-10-29|2012-11-28|Estimate|2011-04-06|2011-04-12|Estimate|2016-07-06|2016-08-03|Estimate|March 2007||2007-03-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|December 2008|Actual|2008-12-31||Interventional|||AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.|A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients|Completed||Phase 2|75|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:19:42.60835|2018-06-01 03:19:42.60835
NCT00454792|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2011-09-23|2007-03-30|2007-04-02|Estimate|||||||2011-09-23|2011-09-26|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Rehabilitation of Patients With Modic Changes in the Lumbar Spine|Rehabilitation of Patients With Modic Changes in the Lumbar Spine - a Randomized Controlled Trial|Completed||N/A|100|Actual|The Back Research Center, Denmark||2|||f||||f||||||||||2018-06-01 03:19:43.134323|2018-06-01 03:19:43.134323
NCT00454779|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|2013-10-11|2011-08-16|2016-12-15|2007-03-29|2007-04-02|Estimate|2014-01-08|2014-02-07|Estimate|2011-08-16|2011-08-23|Estimate|2016-12-15|2017-02-08|Estimate|January 2007||2007-01-31|December 2016|2016-12-31|May 2014|Actual|2014-05-31|August 2012|Actual|2012-08-31||Interventional|||PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response|A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy…|Completed||Phase 2|113|Actual|Amgen||2|||f||||t||||||||||2018-06-01 03:19:43.282137|2018-06-01 03:19:43.282137
NCT00454766|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2017-09-12|2007-03-30|2007-04-02|Estimate|||||||2017-09-12|2017-09-13|Actual|February 2007|Actual|2007-02-28|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Evaluating Materials to Educate Patients About Cervical Dysplasia|Evaluating Materials to Educate Patients About Cervical Dysplasia|Active, not recruiting|||80|Anticipated|M.D. Anderson Cancer Center|||1||f||||t||||||||||2018-06-01 03:19:45.36607|2018-06-01 03:19:45.36607
NCT00454753|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2010-05-07|2007-03-30|2007-04-02|Estimate|||||||2010-05-07|2010-05-12|Estimate|May 2007||2007-05-31|May 2010|2010-05-31||||||||Expanded Access|||Korean Early Access Program|Study of Dasatinib (BMS-354825) in Subjects With Chronic Phase or Advanced Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant to or Intolerant of Imatinib Mesylate|Approved for marketing|||||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 03:19:45.452987|2018-06-01 03:19:45.452987
NCT00454740|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2014-09-17|2007-03-30|2007-04-02|Estimate|||||||2014-09-17|2014-09-18|Estimate|June 2004||2004-06-30|September 2014|2014-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|VERSUS||Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder|An Open-Label Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients Who Wish to Switch From Detrol LA® (Tolterodine Tartrate Extended Release) for the Treatment of Overactive Bladder Symptoms Versus: VESIcare® Efficacy and Research Study US|Completed||Phase 3|441|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 03:19:45.667736|2018-06-01 03:19:45.667736
NCT00454714|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2017-04-10|2007-03-30|2007-04-02|Estimate|||||||2017-04-10|2017-04-12|Actual|March 1, 2007||2007-03-01|April 2017|2017-04-30|December 31, 2009|Actual|2009-12-31|December 31, 2009|Actual|2009-12-31||Interventional|||Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm|Application of Sildenafil in Patients With Documented Coronary Vasospasm to Explore the Pathophysiology of Coronary Vasospasm and the Therapeutic Effect of Sildenafil in Patients Suffering From Coronary Vasospasm|Withdrawn||Phase 3|0|Actual|Robert Bosch Gesellschaft für Medizinische Forschung mbH||2||Study not started|f||||f||||||||||2018-06-01 03:19:45.899126|2018-06-01 03:19:45.899126
NCT00454701|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2013-12-10|2007-03-30|2007-04-02|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2003||2003-06-30|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|ATLAS||Assessment and Tracking of Long-term Alefacept Safety|Assessment and Tracking of Long-term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS)|Terminated|||1897|Actual|Astellas Pharma Inc|||1|"The Sponsor has made a decision, driven by business needs, to cease promotion, manufacturing,~   distribution and sales of Amevive"|f||||t||||||||||2018-06-01 03:19:46.045423|2018-06-01 03:19:46.045423
NCT00454688|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2011-10-17|2007-03-29|2007-04-02|Estimate|||||||2011-10-17|2011-10-18|Estimate|August 2006||2006-08-31|October 2011|2011-10-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome|A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of Asimadoline in Subjects With Irritable Bowel Syndrome|Completed||Phase 2|596|Actual|Tioga Pharmaceuticals||4|||f||||f||||||||||2018-06-01 03:19:46.704071|2018-06-01 03:19:46.704071
NCT00454675|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2008-08-13|2007-03-30|2007-04-02|Estimate|||||||2008-08-13|2008-08-15|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|August 2008|Actual|2008-08-31|||||Observational|||Pulmonary Function Changes in 10 Pack Year Smokers With Chronic Bronchitis|Pulmonary Function Changes in 10 Pack Year Smokers With Chronic Bronchitis|Completed|||100|Anticipated|Westside Family Medical Center, P.C.|||||f||||||||||||||2018-06-01 03:19:46.924792|2018-06-01 03:19:46.924792
NCT00454662|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2013-01-22|2007-03-30|2007-04-02|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)|Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)|Completed||Phase 4|5141|Actual|COLM Study Research Organization||2|||f||||t||||||||||2018-06-01 03:19:46.986379|2018-06-01 03:19:46.986379
NCT00454649|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|2012-02-25||2012-03-30|2007-03-30|2007-04-02|Estimate|2012-02-25|2012-03-27|Estimate||||2012-03-30|2012-04-04|Estimate|December 2005||2005-12-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|August 2009|Actual|2009-08-31||Interventional|||Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor|A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors|Completed||Phase 1|102|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:19:47.270932|2018-06-01 03:19:47.270932
NCT00454636|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|2016-07-12||2016-08-23|2007-03-30|2007-04-02|Estimate|2016-07-12|2016-08-19|Estimate||||2016-08-23|2016-09-29|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.|Open Label, Phase II Study of Capecitabine (Xeloda®) as Fluoropyrimidine of Choice in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-Based Regimen|Completed||Phase 2|158|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 03:19:51.561579|2018-06-01 03:19:51.561579
NCT00454623|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2007-03-30|2007-03-30|2007-04-02|Estimate|||||||2007-03-30|2007-04-02|Estimate|March 2006||2006-03-31|March 2007|2007-03-31|June 2007|Anticipated|2007-06-30|||||Interventional|||Normal Serum Adiponectin Levels in Females|Normal Serum Adiponectin Levels in Females During the Childbearing Ages and Normal Serum Adiponectin Levels in Pregnancy|Unknown status|Active, not recruiting|N/A|300||The Cooper Health System|||||f||||f||||||||||2018-06-01 03:19:52.605286|2018-06-01 03:19:52.605286
NCT00454610|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-30|||2017-02-23|2007-03-30|2007-04-02|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2005||2005-01-31|February 2017|2017-02-28|March 2007||2007-03-31|||||Interventional|FLOW||Family Lifestyle Overweight Prevention Program|Family Lifestyle Overweight Prevention Program: Evaluation of a Weight Management Program for Mexican American Youth|Completed||Phase 3|100||Baylor College of Medicine|||||f||||f||||||||||2018-06-01 03:19:52.687015|2018-06-01 03:19:52.687015
NCT00454597|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2008-05-30|2007-03-30|2007-04-02|Estimate|||||||2008-05-30|2008-06-04|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|December 2007|Actual|2007-12-31|March 2007|Actual|2007-03-31||Interventional|omentectomy||Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity|PHASE 1 The Effect of the Omentectomy on the Hyperglycemia and the Resistance to the Insulin in Patients With Morbid Obesity|Completed||Early Phase 1|21|Actual|Universidad de Guanajuato|||||f||||t||||||||||2018-06-01 03:19:52.851614|2018-06-01 03:19:52.851614
NCT00454584|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|2009-10-23||2012-10-19|2007-03-28|2007-03-30|Estimate|2012-10-19|2012-11-21|Estimate||||2012-10-19|2012-11-21|Estimate|March 2007||2007-03-31|October 2012|2012-10-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis|A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis|Completed||Phase 3|903|Actual|Centocor, Inc.||3|||f||||t||||||||||2018-06-01 03:19:52.984746|2018-06-01 03:19:52.984746
NCT00454571|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2015-05-29||2016-01-08|2007-03-27|2007-03-30|Estimate|2016-01-08|2016-02-10|Estimate||||2016-01-08|2016-02-10|Estimate|June 2006||2006-06-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Baseline demographics data for this multi-center trial are only available for participants at The University of Chicago with known study arm assignment.|Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer|A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 03:19:54.239249|2018-06-01 03:19:54.239249
NCT00454558|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2015-10-14|2007-03-29|2007-03-30|Estimate|||||||2015-10-14|2015-10-16|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension|A Multicenter, Non-randomized, Non-blinded, Noncontrolled Study to Investigate the Impact of Multiple Doses of BAY 63-2521 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Pulmonary Hypertension in a 12-week 3 Times a Day Individual Dose Titration Scheme|Completed||Phase 2|75|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:19:55.421348|2018-06-01 03:19:55.421348
NCT00454532|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2012-02-27||2012-02-27|2007-03-29|2007-03-30|Estimate|2012-02-27|2012-03-16|Estimate||||2012-02-27|2012-03-16|Estimate|March 2007||2007-03-31|February 2012|2012-02-29||||December 2009|Actual|2009-12-31||Interventional|||A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer|A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 For Metastatic Breast Cancer.|Completed||Phase 1/Phase 2|27|Actual|Bionovo|||||f||||t||||||||||2018-06-01 03:19:55.717882|2018-06-01 03:19:55.717882
NCT00454519|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2009-02-12|2007-03-29|2007-03-30|Estimate|||||||2009-02-12|2009-02-13|Estimate|March 2007||2007-03-31|February 2009|2009-02-28||||December 2009|Anticipated|2009-12-31||Interventional|IPHC||Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis|Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Wuhan University||2|||f||||t||||||||||2018-06-01 03:19:57.006252|2018-06-01 03:19:57.006252
NCT00454506|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2018-05-24|2007-03-29|2007-03-30|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2007||2007-04-30|May 2018|2018-05-31|April 2027|Anticipated|2027-04-30|April 2027|Anticipated|2027-04-30||Observational|||Hospital for Special Surgery Hip Arthroplasty Cohort|Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: HSS Hip Arthroplasty Cohort|Active, not recruiting|||3000|Anticipated|Hospital for Special Surgery, New York|||||f||||t||||||||||2018-06-01 03:19:57.283736|2018-06-01 03:19:57.283736
NCT00454493|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2007-03-29|2007-03-29|2007-03-30|Estimate|||||||2007-03-29|2007-03-30|Estimate|August 2006||2006-08-31|March 2007|2007-03-31|July 2008|Anticipated|2008-07-31|||||Interventional|||The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease|The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease|Unknown status|Recruiting|N/A|100||University of California, Los Angeles|||||f||||||||||||||2018-06-01 03:19:57.349141|2018-06-01 03:19:57.349141
NCT00454480|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2013-08-23|2007-03-27|2007-03-30|Estimate|||||||2013-08-23|2013-08-26|Estimate|August 2006||2006-08-31|August 2008|2008-08-31||||August 2012|Actual|2012-08-31||Interventional|||Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome|Completed||Phase 2/Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:19:57.460811|2018-06-01 03:19:57.460811
NCT00454467|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2018-05-24|2007-03-29|2007-03-30|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2007||2007-04-30|May 2018|2018-05-31|April 2027|Anticipated|2027-04-30|April 2027|Anticipated|2027-04-30||Observational|||Hospital for Special Surgery Knee Arthroplasty Cohort|Prospective Evaluation of the Clinical and Economic Outcomes of Total Joint Replacement: The HSS Knee Arthroplasty Cohort|Active, not recruiting|||3000|Anticipated|Hospital for Special Surgery, New York|||||f||||t||||||||||2018-06-01 03:19:57.679972|2018-06-01 03:19:57.679972
NCT00454454|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2013-07-27|2007-03-29|2007-03-30|Estimate|||||||2013-07-27|2013-07-30|Estimate|March 2007||2007-03-31|July 2013|2013-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|DETECT||Virtual Reality Helmet to Test for Problems With Memory|Display Enhanced TEsting for Cognitive Impairment and Traumatic Brain Injury|Completed|||425|Actual|Emory University|||1||f||||f||||||||||2018-06-01 03:19:57.74747|2018-06-01 03:19:57.74747
NCT00454441|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-03-29|2007-03-29|2007-03-30|Estimate|||||||2007-03-29|2007-03-30|Estimate|February 2006||2006-02-28|March 2007|2007-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Sleep Quality in CHIMES (MF101)|Sleep Quality in CHIMES (MF101)|Completed||Phase 2|180||Bionovo|||||f||||||||||||||2018-06-01 03:19:57.827984|2018-06-01 03:19:57.827984
NCT00454428|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2007-03-29|2007-03-29|2007-03-30|Estimate|||||||2007-03-29|2007-03-30|Estimate||||March 2006|2006-03-31||||||||Interventional|||Randomized Trial of Pulsatile vs Non Pulsatile Perfusion on Short Term Changes in Kidney Function Using an Intra-Aortic Ballooon Pump During Cardioplegic Arrest in Patients Undergoing Myocardial Reperfusion||Completed||Phase 4|||University of Cantanzaro|||||f||||f||||||||||2018-06-01 03:19:58.143416|2018-06-01 03:19:58.143416
NCT00454415|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2012-12-24|2007-03-29|2007-03-30|Estimate|||||||2012-12-24|2012-12-27|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children|Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children|Completed|||16000|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 03:19:58.199139|2018-06-01 03:19:58.199139
NCT00454402|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2007-09-21|2007-03-29|2007-03-30|Estimate|||||||2007-09-21|2007-09-24|Estimate|August 2006||2006-08-31|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||ALF-STONE: Alfuzosin in Uretheric Stones|Alfuzosin in Uretheric Stones|Terminated||Phase 3|220|Anticipated|Sanofi||||Discontinued due to incomplete recruitment|f||||f||||||||||2018-06-01 03:19:58.27587|2018-06-01 03:19:58.27587
NCT00454389|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2011-07-26|2007-03-29|2007-03-30|Estimate|||||||2011-07-26|2011-07-27|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|August 2012|Anticipated|2012-08-31|September 2011|Anticipated|2011-09-30||Interventional|CABERNET||A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration|A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration|Unknown status|Active, not recruiting|Phase 3|494|Actual|NeoVista||2|||f||||t||||||||||2018-06-01 03:19:58.350569|2018-06-01 03:19:58.350569
NCT00454376|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2013-10-28|2007-03-27|2007-03-30|Estimate|||||||2013-10-28|2013-10-29|Estimate|October 2006||2006-10-31|November 2008|2008-11-30||||||||Observational|||Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors|Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients With G.I.-Related Neuroendocrine Tumours|Unknown status|Active, not recruiting||408|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:19:58.483663|2018-06-01 03:19:58.483663
NCT00454363|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2015-01-22||2015-10-15|2007-03-27|2007-03-30|Estimate|2015-03-18|2015-04-01|Estimate||||2015-10-15|2015-11-18|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer|A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma|Completed||Phase 2|52|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:19:58.661687|2018-06-01 03:19:58.661687
NCT00454350|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2015-05-04|2007-03-28|2007-03-30|Estimate|||||||2015-05-04|2015-05-05|Estimate|February 2007||2007-02-28|May 2015|2015-05-31|July 2007|Actual|2007-07-31|||||Interventional|||A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis|A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis|Completed||Phase 4|12|Anticipated|Sanofi|||||||||||||||||||2018-06-01 03:19:59.152099|2018-06-01 03:19:59.152099
NCT00454337|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2012-11-06|2007-03-29|2007-03-30|Estimate|||||||2012-11-06|2012-11-07|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|EASIER||Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load|Randomized Non-inferiority Study Comparing a Strategy Maintaining Current Enfuvirtide-based Antiretroviral Therapy to a Strategy Replacing Enfuvirtide by an Integrase Inhibitor (Raltegravir) in HIV-1 Infected Subjects With Plasma Hiv-1 RNA Levels Below 400 Copies Per ml.ANRS 138 EASIER|Completed||Phase 3|170|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 03:19:59.219222|2018-06-01 03:19:59.219222
NCT00454324|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|2017-03-23||2017-06-09|2007-03-29|2007-03-30|Estimate|2017-05-09|2017-06-12|Actual||||2017-06-09|2017-07-11|Actual|April 2006||2006-04-30|June 2017|2017-06-30|December 2014|Actual|2014-12-31|July 2010|Actual|2010-07-31||Interventional|NRR||Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer|Phase II Clinical Trial of Carboplatin and Abraxane in Patients With Extensive Stage Small Cell Lung Cancer|Terminated||Phase 2|30|Actual|UNC Lineberger Comprehensive Cancer Center|The trial was closed prematurely because of slow accrual before the impact of the dose reduction on toxicity and treatment compliance could be assessed. In arm A, 6 patients required a dose reduction. In arm B, 3 patients required a dose reduction.|2||slow accrual|f||||t||||||||||2018-06-01 03:19:59.325317|2018-06-01 03:19:59.325317
NCT00454311|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2011-03-03|2007-03-29|2007-03-30|Estimate|||||||2011-03-03|2011-03-04|Estimate|November 2007||2007-11-30|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Impact of the Biopsy of 1-2 Cells in a PGD Program for Anueploidy Screening|Prospective and Randomized Study of the Impact of the Biopsy of 1-2 Cells in a PGD Program for Aneuploidy Screening|Completed||N/A|||Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-06-01 03:19:59.758816|2018-06-01 03:19:59.758816
NCT00454298|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2009-07-28|2007-03-29|2007-03-30|Estimate|||||||2009-07-28|2009-07-29|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Regimen, Parallel-Group Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGG-523 Administered Orally to Subjects With Severe Osteoarthritis|Completed||Phase 1|2|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||||||||||||2018-06-01 03:19:59.820676|2018-06-01 03:19:59.820676
NCT00454285|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2009-12-02|2007-03-29|2007-03-30|Estimate|||||||2009-12-02|2009-12-03|Estimate|January 2003||2003-01-31|December 2009|2009-12-31|June 2006|Actual|2006-06-30|November 2005|Actual|2005-11-30||Interventional|||Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing|Bacteremia From Dental Extractions vs. Oral Hygiene|Completed||Phase 2|290|Actual|Carolinas Healthcare System|||||f||||t||||||||||2018-06-01 03:19:59.956583|2018-06-01 03:19:59.956583
NCT00454272|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2009-03-05|2007-03-29|2007-03-30|Estimate|||||||2009-03-05|2009-03-06|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients|Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients|Completed||Phase 4|197|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:20:00.149588|2018-06-01 03:20:00.149588
NCT00454259|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2015-06-02|2007-03-29|2007-03-30|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|FENTANULD||Fentanyl Ultra Low Doses Effects on the Nociceptive Threshold|Fentanyl Ultra Low Doses Effects on Human Volunteer's Nociceptive Threshold. Towards a Simple Pharmacological Test Able to Predict Pain Vulnerability, Post Operative Hyperalgesia Development Risk?|Completed||Phase 4|48|Actual|University Hospital, Bordeaux||4|||f||||t||||||||||2018-06-01 03:20:00.319254|2018-06-01 03:20:00.319254
NCT00454246|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|2011-03-29||2011-11-14|2007-03-29|2007-03-30|Estimate|2011-11-14|2011-12-16|Estimate||||2011-11-14|2011-12-16|Estimate|April 2007||2007-04-30|November 2011|2011-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.|A Randomized, Open Label Study of the Effect of Intravenous Mircera on Hemoglobin Control in Patients Transitioning From Chronic Kidney Disease Stage 4 Through Dialysis|Terminated||Phase 3|111|Actual|Hoffmann-La Roche||3||Strategic decision unrelated to safety or efficacy|f||||||||||||||2018-06-01 03:20:00.430177|2018-06-01 03:20:00.430177
NCT00454233|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2008-10-14|2007-03-29|2007-03-30|Estimate|||||||2008-10-14|2008-10-16|Estimate|February 2007||2007-02-28|October 2008|2008-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Safety and Efficacy Study With YM543 in Type 2 Diabetes Mellitus Subjects|A Randomized, Double Blind, Placebo and Active Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Potential Efficacy of a 12-Week Treatment With YM543 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|97|Actual|Astellas Pharma Inc||6|||f||||t||||||||||2018-06-01 03:20:00.980873|2018-06-01 03:20:00.980873
NCT00454220|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28||2011-12-16|2014-10-27|2007-03-28|2007-03-30|Estimate||||2011-12-16|2011-12-22|Estimate|2014-10-27|2014-11-03|Estimate|July 2007||2007-07-31|October 2014|2014-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter|Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction With Radioiodine for the Treatment of Multinodular Goiter.|Completed||Phase 2|96|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:20:01.065328|2018-06-01 03:20:01.065328
NCT00454207|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|2010-02-18||2013-08-19|2007-03-28|2007-03-30|Estimate|2010-08-18|2010-09-09|Estimate||||2013-08-19|2013-08-27|Estimate|April 2007||2007-04-30|August 2010|2010-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension|A Phase 3, Multi-Center, Open-Label Study to Assess Safety and Efficacy of Sildenafil Citrate 20 mg TID in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 3|44|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:20:01.206764|2018-06-01 03:20:01.206764
NCT00454194|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2016-12-07||2017-02-16|2007-03-27|2007-03-30|Estimate|2016-12-07|2017-01-31|Estimate||||2017-02-16|2017-03-21|Actual|September 2007||2007-09-30|February 2017|2017-02-28|May 2013|Actual|2013-05-31|July 2010|Actual|2010-07-31||Interventional||All participants who met the eligibility criteria and started the treatment.|Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|110|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 03:20:02.038256|2018-06-01 03:20:02.038256
NCT00454181|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|2010-11-09||2011-09-12|2007-03-29|2007-03-30|Estimate|2010-12-14|2011-01-13|Estimate||||2011-09-12|2011-09-16|Estimate|February 2007||2007-02-28|September 2011|2011-09-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Treatment of Oral Warts in HIV+ Patients|Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial|Completed||Phase 2|59|Actual|Amarillo Biosciences, Inc.|Only 59 of 80 planned subjects were randomized, so statistical power of the study was limited.|2|||f||||f||||||||||2018-06-01 03:20:03.137847|2018-06-01 03:20:03.137847
NCT00454168|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2014-01-03|2007-03-27|2007-03-30|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 2005||2005-05-31|February 2009|2009-02-28||||April 2009|Anticipated|2009-04-30||Interventional|||Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission|A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study|Unknown status|Active, not recruiting|Phase 3|244|Anticipated|National Cancer Institute (NCI)||2|||||||||||||||||2018-06-01 03:20:03.647262|2018-06-01 03:20:03.647262
NCT00454155|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2012-07-27|2007-03-28|2007-03-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|HSCT||Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|A Phase I/II Study of the Safety and Pharmacokinetics of Opebacan (rBPI21) in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Terminated||Phase 1/Phase 2|6|Actual|XOMA (US) LLC||1||Lack of enrollment|f||||t||||||||||2018-06-01 03:20:03.798334|2018-06-01 03:20:03.798334
NCT00454142|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2014-12-12||2015-11-16|2007-03-27|2007-03-30|Estimate|2015-11-16|2015-12-17|Estimate||||2015-11-16|2015-12-17|Estimate|August 2007||2007-08-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer|A Phase 2 Study of GW786034 (Pazopanib) in Asian Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|33|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:20:03.927008|2018-06-01 03:20:03.927008
NCT00454129|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-29|||2013-01-25|2007-03-29|2007-03-30|Estimate|||||||2013-01-25|2013-01-28|Estimate|March 2007||2007-03-31|March 2007|2007-03-31||||||||Interventional|DBE ERC||ERC Via Double-Balloon-Enteroscopy in Patients With Biliodigestive Anastomosis|ERC Via Double-Balloon-Enteroscopy in Patients With Biliodigestive Anastomosis|Unknown status|Recruiting|N/A|||Heidelberg University|||||f||||f||||||||||2018-06-01 03:20:04.262524|2018-06-01 03:20:04.262524
NCT00454116|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|2011-04-27||2016-08-25|2007-03-29|2007-03-30|Estimate|2011-04-27|2011-05-24|Estimate||||2016-08-25|2016-10-07|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|November 2009|Actual|2009-11-30|March 2008|Actual|2008-03-31||Interventional|||A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients|A Phase II, Double Blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Oxaliplatin and Fluoropyrimidine Containing Regimen|Completed||Phase 2|106|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:20:04.345162|2018-06-01 03:20:04.345162
NCT00454103|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2010-08-17|2007-03-28|2007-03-30|Estimate|||||||2010-08-17|2010-08-18|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy||Completed||Phase 1/Phase 2|||University of Wuerzburg|||||f||||t||||||||||2018-06-01 03:20:04.773757|2018-06-01 03:20:04.773757
NCT00454090|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2011-08-23|2007-03-27|2007-03-29|Estimate|||||||2011-08-23|2011-08-24|Estimate|March 2007||2007-03-31|August 2011|2011-08-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||AZD8330 First Time in Man in Patients With Advanced Malignancies|A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of AZD8330 in Patients With Advanced Malignancies|Completed||Phase 1|83|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:20:04.82981|2018-06-01 03:20:04.82981
NCT00454077|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-03-28|2007-03-28|2007-03-29|Estimate|||||||2007-03-28|2007-03-29|Estimate|December 2004||2004-12-31|October 2006|2006-10-31|September 2006|Actual|2006-09-30|||||Observational|||rhTSH-Thyroid Ablation With 1850 MBq of 131I|Recombinant Human TSH (rhTSH)-Aided Radioiodine (131) Therapy for Thyroid Remnant Ablation in Differentiated Thyroid Cancer Patients: a Comparison Between 1850 MBq and 3700 MBq Activities|Completed|||72||University of Siena|||||f||||f||||||||||2018-06-01 03:20:05.060698|2018-06-01 03:20:05.060698
NCT00454064|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2017-09-27|2007-03-28|2007-03-29|Estimate|||||||2017-09-27|2017-10-02|Actual|September 2004||2004-09-30|September 2017|2017-09-30|February 2008|Actual|2008-02-29|September 2007|Actual|2007-09-30||Interventional|||Cognitive-behavioural Treatment of Chronic Back Pain|Study to Compare a Cognitive-behavioral Treatment With a Cognitive-behavioral Treatment With Biofeedback Elements to Patients With Chronic (Low) Back Pain|Completed||Phase 3|128|Actual|Philipps University Marburg Medical Center||2|||f||||t||||||||||2018-06-01 03:20:05.128546|2018-06-01 03:20:05.128546
NCT00454051|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|2010-12-03||2011-08-02|2007-03-28|2007-03-29|Estimate|2011-07-01|2011-08-01|Estimate||||2011-08-02|2011-08-08|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma|Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment.|Completed||Phase 4|31|Actual|Novartis||2|||f||||t||||||||||2018-06-01 03:20:05.238526|2018-06-01 03:20:05.238526
NCT00454038|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2009-07-09|2007-03-28|2007-03-29|Estimate|||||||2009-07-09|2009-07-10|Estimate|June 2007||2007-06-30|January 2009|2009-01-31|May 2009|Anticipated|2009-05-31|January 2008|Anticipated|2008-01-31||Interventional|GBR||Study of Collagen Membrane in Guided Bone Regeneration|Preliminary Study of Hypro-Sorb® F Bilayer Bioabsorbable Membrane for Guided Tissue and Bone Regeneration|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||||||||||||2018-06-01 03:20:05.916904|2018-06-01 03:20:05.916904
NCT00454025|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2013-01-29|2007-03-28|2007-03-29|Estimate|||||||2013-01-29|2013-01-30|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Intraocular Pressure (IOP) Changes Associated With Muslim Prayer Postural Changes|Intraocular Pressure Changes Associated With Muslim Prayer Postural Changes|Terminated|||5|Actual|University of Colorado, Denver|||2|Stopped due to low enrollment|f||||f||||||||||2018-06-01 03:20:05.994022|2018-06-01 03:20:05.994022
NCT00454012|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2009-11-07|2007-03-27|2007-03-29|Estimate|||||||2009-11-07|2009-11-10|Estimate|April 2005||2005-04-30|March 2009|2009-03-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Use of Intrapartum Biophysical Profile When Fetal Heart Rate Monitoring is Non-reassuring in Labor|Use of Intrapartum Biophysical Profile When Fetal Heart Rate Monitoring is Non-reassuring in Labor|Terminated||N/A|100|Anticipated|The Cooper Health System||||poor enrolment|f||||f||||||||||2018-06-01 03:20:06.04766|2018-06-01 03:20:06.04766
NCT00453999|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2015-01-16|2011-12-09|2015-01-28|2007-03-28|2007-03-29|Estimate|2015-01-28|2015-02-12|Estimate|2011-12-21|2011-12-26|Estimate|2015-01-28|2015-02-12|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|August 2009|Actual|2009-08-31|September 2008|Actual|2008-09-30||Interventional||ITT Population|Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza|Phase II, Multicenter, Randomized, Double-Mask, Double-Dummy Study Comparing Efficacy and Safety of Intravenous Peramivir Once Daily Versus Oral Oseltamivir Twice Daily in Adults With Acute Serious or Potentially Life-Threatening Influenza|Completed||Phase 2|137|Actual|BioCryst Pharmaceuticals||3|||f||||t||||||||||2018-06-01 03:20:06.140273|2018-06-01 03:20:06.140273
NCT00453986|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|2012-04-23|2009-09-03|2016-11-02|2007-03-28|2007-03-29|Estimate|2012-04-23|2012-05-22|Estimate|2009-09-03|2009-09-04|Estimate|2016-11-02|2016-12-16|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional|||Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults|Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the Co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age|Completed||Phase 3|1352|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:20:08.559803|2018-06-01 03:20:08.559803
NCT00453973|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2012-04-26|2012-03-13|2012-06-22|2007-03-28|2007-03-29|Estimate|2012-04-26|2012-05-28|Estimate|2012-03-13|2012-03-15|Estimate|2012-06-22|2012-06-29|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU)|An Open-Label, Multi-Center, Extension Study to Evaluate the Safety and Tolerability of Peginesatide for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease|Terminated||Phase 2|114|Actual|Affymax|Early termination of study due to generation of controlled long-term data in Phase 3 studies. Amended dosing guidelines during the trial to reflect label changes for ESAs; the primary outcome was assessed after the dosing guideline change.|2||Due to more robust long-term data generated in other active-controlled studies|f||||f||||||||||2018-06-01 03:20:10.294591|2018-06-01 03:20:10.294591
NCT00453960|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2008-12-18|2007-03-28|2007-03-29|Estimate|||||||2008-12-18|2008-12-19|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Genistein and Endometrial Hyperplasia|Effect of Genistein on Endometrial Hyperplasia|Completed||Phase 2|59|Actual|University of Messina||3|||f||||t||||||||||2018-06-01 03:20:10.852298|2018-06-01 03:20:10.852298
NCT00453947|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-03-28|2007-03-28|2007-03-29|Estimate|||||||2007-03-28|2007-03-29|Estimate|July 2002||2002-07-31|March 2007|2007-03-31|May 2005|Actual|2005-05-31|||||Interventional|||Non-Invasive Ventilation in Pulmonary Edema|Non Invasive Positive Airway Pressure And Risk Of Myocardial Infarction In Acute Cardiogenic Pulmonary Edema: Continuous Positive Airway Pressure Vs Non Invasive Positive Pressure Ventilation|Completed||Phase 4|60||Ospedale S. Giovanni Bosco|||||f||||t||||||||||2018-06-01 03:20:10.950461|2018-06-01 03:20:10.950461
NCT00453934|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2007-12-05|2007-03-28|2007-03-29|Estimate|||||||2007-12-05|2007-12-06|Estimate|May 2007||2007-05-31|March 2007|2007-03-31|September 2007|Actual|2007-09-30|||||Interventional|||Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device|h-Patch vs. Pen or Needle and Syringe as Insulin Administration Device in Type 1 or 2 Diabetes Patients Using MDI: Patient Preference and Glycemic Control After Switch in an Open-Label, Randomized Cross-Over Study|Terminated||Phase 4|11|Actual|Valeritas, Inc.||||Endpoint no longer deemed meaningful|f||||f||||||||||2018-06-01 03:20:11.005624|2018-06-01 03:20:11.005624
NCT00453921|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2013-06-19|2007-03-28|2007-03-29|Estimate|||||||2013-06-19|2013-06-20|Estimate|February 2007||2007-02-28|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)|Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)|Completed||N/A|160|Actual|Dartmouth-Hitchcock Medical Center||4|||f||||t||||||||||2018-06-01 03:20:11.072214|2018-06-01 03:20:11.072214
NCT00453908|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-08-17|2007-03-28|2007-03-29|Estimate|||||||2007-08-17|2007-08-20|Estimate|May 2004||2004-05-31|August 2007|2007-08-31||||||||Interventional|ALF-RIK||Alfuzosin Versus Placebo in Acute Urinary Retention|Does Alfuzosin OD vs. Placebo in Male Patients Facilitate Spontaneous Voiding During Clean Intermittent Self-Catheterization Following Acute Urinary Retention?|Terminated||Phase 3|160||Sanofi||||The study was early terminated due to slow and difficult recruitment|f||||f||||||||||2018-06-01 03:20:11.165838|2018-06-01 03:20:11.165838
NCT00453895|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2010-07-06|2007-03-28|2007-03-29|Estimate|||||||2010-07-06|2010-07-07|Estimate|July 2007||2007-07-31|July 2010|2010-07-31|June 2011|Anticipated|2011-06-30|October 2010|Anticipated|2010-10-31||Interventional|SIRAC||Sunitinib in Refractory Adrenocortical Carcinoma|Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|University of Wuerzburg|||||f||||f||||||||||2018-06-01 03:20:11.223966|2018-06-01 03:20:11.223966
NCT00453882|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2012-01-26|2007-03-28|2007-03-29|Estimate|||||||2012-01-26|2012-01-30|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Uretal Flow Assessment During Gynecological Procedures|An Evaluation of Ureteral Flow After Temporary Bilateral Uterine Artery Occlusion During Conservative Gynecological Procedures|Completed||N/A|7|Actual|Ethicon, Inc.|||||f||||f||||||||||2018-06-01 03:20:11.296594|2018-06-01 03:20:11.296594
NCT00453869|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2014-12-11|2007-03-28|2007-03-29|Estimate|||||||2014-12-11|2014-12-12|Estimate|April 2007||2007-04-30|December 2014|2014-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|SNIFF11||Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail|Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail|Terminated|||240|Actual|University Hospital, Angers||||Few prevalence of liver fibrosis in subjects|f||||f||||||||||2018-06-01 03:20:11.435062|2018-06-01 03:20:11.435062
NCT00453856|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-08-08|2007-03-28|2007-03-29|Estimate|||||||2007-08-08|2007-08-10|Estimate|March 2007||2007-03-31|August 2007|2007-08-31||||||||Interventional|||Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children|Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné|Terminated||Phase 4|139|Anticipated|Albert Schweitzer Hospital||||"The study was terminated because of Early Treatment Failure in child.The justification for this~   decision are concerns about safety of children."|f||||||||||||||2018-06-01 03:20:11.499063|2018-06-01 03:20:11.499063
NCT00453843|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2012-10-28|2007-03-28|2007-03-29|Estimate|||||||2012-10-28|2012-10-30|Estimate|June 2004||2004-06-30|March 2007|2007-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Shoulder, or Elbow, or Wrist: What Should we Train First After a Stroke?|The Effect of Proximal and Distal Training on Stroke Recovery|Completed||Phase 2|190|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||4|||f||||f||||||||||2018-06-01 03:20:11.568664|2018-06-01 03:20:11.568664
NCT00453830|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2009-02-17|2007-03-28|2007-03-29|Estimate|||||||2009-02-17|2009-02-18|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Laparoscopic Versus Open Sigmoid Colectomy for Diverticular Disease|Laparoscopic Versus Open Sigmoid Colectomy for Diverticular Disease: A Prospective Randomized Single-Blind Trial|Completed||Phase 4|100|Anticipated|University Hospital, Geneva|||||f||||f||||||||||2018-06-01 03:20:11.649897|2018-06-01 03:20:11.649897
NCT00453817|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2014-12-01|2007-03-28|2007-03-29|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2005||2005-06-30|December 2014|2014-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Islet of Langerhans Graft Monitoring by Magnetic Resonance Imaging|Suivi Par résonance magnétique après Transplantation d'îlots de Langerhans|Terminated||Phase 1|5|Actual|University Hospital, Geneva||1||Feasibility issues|f||||f||||||||||2018-06-01 03:20:11.709156|2018-06-01 03:20:11.709156
NCT00453804|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2008-03-17|2007-03-28|2007-03-29|Estimate|||||||2008-03-17|2008-03-18|Estimate|July 2006||2006-07-31|March 2008|2008-03-31|June 2007|Actual|2007-06-30|||||Interventional|vivitrol||Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)|Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study|Completed||Phase 4|15||State University of New York - Upstate Medical University|||||f||||t||||||||||2018-06-01 03:20:11.772064|2018-06-01 03:20:11.772064
NCT00453791|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2017-09-27|2007-03-28|2007-03-29|Estimate|||||||2017-09-27|2017-09-29|Actual|February 7, 2006|Actual|2006-02-07|September 2017|2017-09-30|April 10, 2006|Actual|2006-04-10|April 10, 2006|Actual|2006-04-10||Interventional|||The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics|A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics|Terminated||Phase 1|31|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 03:20:11.835598|2018-06-01 03:20:11.835598
NCT00453778|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2013-02-11|2007-03-28|2007-03-29|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2002||2002-11-30|February 2013|2013-02-28|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients|A Study to Investigate the Effect of Inhaled Fluticasone Propionate on the Bronchial Responsiveness to Leukotriene D4 in Asthmatics Patients|Completed||Phase 4|14||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:20:11.914928|2018-06-01 03:20:11.914928
NCT00453765|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2013-04-05|2007-03-28|2007-03-29|Estimate|||||||2013-04-05|2013-04-08|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|montelukast||The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity|Prospective Single-centre, Double Blind Randomised Trial of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity|Completed||Phase 4|89|Actual|Isala||2|||f||||t||||||||||2018-06-01 03:20:12.002066|2018-06-01 03:20:12.002066
NCT00453752|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-03-28|2007-03-28|2007-03-29|Estimate|||||||2007-03-28|2007-03-29|Estimate|April 2006||2006-04-30|March 2006|2006-03-31|April 2010|Anticipated|2010-04-30|||||Observational|||Non-Invasive Diagnostic and Functional Evaluation of Cardiac Involvement in Patients With Systemic Sclerosis||Unknown status|Recruiting||100||Medical University of Warsaw|||||f||||t||||||||||2018-06-01 03:20:12.086625|2018-06-01 03:20:12.086625
NCT00453739|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2014-05-05|2007-03-28|2007-03-29|Estimate|||||||2014-05-05|2014-05-06|Estimate|February 2007||2007-02-28|May 2014|2014-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||TVT Worldwide Registry|TVT-World Wide Observational Registry for Long-Term Data|Completed|||1407|Actual|Ethicon, Inc.|||||f||||f||||||||||2018-06-01 03:20:12.144848|2018-06-01 03:20:12.144848
NCT00453726|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2009-10-02|2007-03-28|2007-03-29|Estimate|||||||2009-10-02|2009-10-05|Estimate|May 2006||2006-05-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|||||Observational|||Brain Natriuretic Peptide (BNP) Levels in Patients in Non Invasive Mechanical Ventilation|Evaluation of BNP in Patients With Severe Acute Respiratory Failure Requiring Non Invasive Mechanical Ventilation|Completed|||40|Anticipated|Ospedale S. Giovanni Bosco|||||f||||t||||||||||2018-06-01 03:20:12.426928|2018-06-01 03:20:12.426928
NCT00453713|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2015-04-20|2007-03-27|2007-03-29|Estimate|||||||2015-04-20|2015-04-21|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Race, Ethnicity, and Diffuse Parenchymal Lung Disease|Determinants of Outcome in Diffuse Parenchymal Lung Disease|Completed|||565|Actual|Columbia University|||||f||||f||||||Samples With DNA|"~     Plasma/serum, DNA, and circulating cells and endothelial microparticles will be collected and~     processed.~   "|||2018-06-01 03:20:12.537782|2018-06-01 03:20:12.537782
NCT00453700|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-03-28|2007-03-28|2007-03-29|Estimate|||||||2007-03-28|2007-03-29|Estimate|February 2007||2007-02-28|March 2007|2007-03-31||||||||Interventional|||Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram|Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram|Unknown status|Recruiting|N/A|300||University of California, Los Angeles|||||f||||f||||||||||2018-06-01 03:20:12.703445|2018-06-01 03:20:12.703445
NCT00453687|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2017-08-03|2007-03-28|2007-03-29|Estimate|||||||2017-08-03|2017-08-07|Actual|March 9, 2007|Actual|2007-03-09|August 2017|2017-08-31|May 16, 2007|Actual|2007-05-16|May 16, 2007|Actual|2007-05-16||Interventional|||A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.|A Single-centre, Randomized, Double-blind Placebo-controlled, Dose-ascending, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705, Formulated With the Excipient Magnesium Stearate, in Healthy Volunteers|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:20:12.852808|2018-06-01 03:20:12.852808
NCT00453674|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2016-10-28|2007-03-28|2007-03-29|Estimate|||||||2016-10-28|2016-11-01|Estimate|January 2003||2003-01-31|October 2016|2016-10-31|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Observational|||German Adrenocortical Carcinoma Registry|Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry|Recruiting|||1000|Anticipated|University of Wuerzburg|||1||f||||f||||||||||2018-06-01 03:20:13.041605|2018-06-01 03:20:13.041605
NCT00453661|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2017-10-04|2007-03-27|2007-03-29|Estimate|||||||2017-10-04|2017-10-05|Actual|March 2007|Actual|2007-03-31|October 2017|2017-10-31|March 2020||2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities|Cancer Prevention and Treatment Demonstration for Hispanic Medicare Eligible Beneficiaries - CMS|Active, not recruiting|||2812|Anticipated|M.D. Anderson Cancer Center|||2||f||||t||||||||||2018-06-01 03:20:13.142171|2018-06-01 03:20:13.142171
NCT00453453|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2015-02-06|2007-03-28|2007-03-29|Estimate|||||||2015-02-06|2015-02-09|Estimate|March 2007||2007-03-31|February 2015|2015-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|BOOST||BNP Therapy Observation Unit Outcomes STudy (BOOST)|BNP Therapy Observation Unit Outcomes STudy|Terminated||Phase 4|17|Actual|Emory University||2|||f||||t||||||||||2018-06-01 03:20:17.062598|2018-06-01 03:20:17.062598
NCT00453648|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2017-05-24|2007-03-28|2007-03-29|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2006||2006-03-31|May 2017|2017-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Impact of Consumption of Orange-fleshed Sweet Potatoes on the Vitamin A Status of Bangladeshi Women of Reproductive Age|Efficacy of Daily Consumption of Sweet Potatoes for Increasing Total Body Vitamin A Pool Size, and the Effect of Consumption of Sweet Potatoes on Iron and Zinc Absorption in Bangladeshi Women of Reproductive Age|Completed||N/A|130|Actual|University of California, Davis||4|||f||||f||||||||||2018-06-01 03:20:13.281401|2018-06-01 03:20:13.281401
NCT00453635|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2012-03-12|2007-03-28|2007-03-29|Estimate|||||||2012-03-12|2012-03-13|Estimate|December 2003||2003-12-31|March 2012|2012-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients|A Multicenter Randomized Phase II Study of First Line Treatment With Sequential Administration of Docetaxel, Carboplatin and Herceptin Versus the Administration of Vinorelbine and Herceptin Combination in HER-2 Positive Patients With Metastatic Breast Cancer|Terminated||Phase 2|88|Actual|Hellenic Oncology Research Group||2||Due to poor accrual|f||||f||||||||||2018-06-01 03:20:13.431905|2018-06-01 03:20:13.431905
NCT00453622|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2013-07-17|2007-03-28|2007-03-29|Estimate|||||||2013-07-17|2013-07-19|Estimate|November 2005||2005-11-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|RISK||RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D|RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D|Completed|||222|Actual|St. Jude Medical|||||f||||t||||||Samples Without DNA|"~     Blood samples will be collected~   "|||2018-06-01 03:20:13.55605|2018-06-01 03:20:13.55605
NCT00453609|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2008-12-10|2007-03-28|2007-03-29|Estimate|||||||2008-12-10|2008-12-11|Estimate|April 2007||2007-04-30|December 2008|2008-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|vivitrol||Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)|Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI): An Open Prospective Pilot Trial|Completed||Phase 4|15|Actual|State University of New York - Upstate Medical University|||||f||||t||||||||||2018-06-01 03:20:13.699873|2018-06-01 03:20:13.699873
NCT00453596|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2007-03-28|2007-03-28|2007-03-29|Estimate|||||||2007-03-28|2007-03-29|Estimate||||March 2007|2007-03-31||||||||Observational|||Analysis of Implantation Failure and Establishment of Therapy for Implantation Failure||Unknown status|Recruiting||||Yamaguchi University Hospital|||||f||||||||||||||2018-06-01 03:20:13.781095|2018-06-01 03:20:13.781095
NCT00453583|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2013-12-13|2007-03-28|2007-03-29|Estimate|||||||2013-12-13|2013-12-16|Estimate|March 2007||2007-03-31|May 2012|2012-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine|Evaluation of the Treatment Satisfaction in Children Suffering From an Allergy and Who Received an Antihistamine Treatment|Completed|||4581|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 03:20:13.990339|2018-06-01 03:20:13.990339
NCT00453570|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2012-04-13|2007-03-28|2007-03-29|Estimate|||||||2012-04-13|2012-04-17|Estimate|March 2007||2007-03-31|April 2012|2012-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months||Completed||Phase 3|792|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:20:14.154193|2018-06-01 03:20:14.154193
NCT00453557|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2016-12-06|2007-03-28|2007-03-29|Estimate|||||||2016-12-06|2016-12-08|Estimate|April 1999||1999-04-30|December 2016|2016-12-31|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|GH||Mechanism of Growth Hormone Effects on Adipose Tissue||Completed||Phase 4|30||Pennington Biomedical Research Center|||||f||||t||||||||||2018-06-01 03:20:14.304585|2018-06-01 03:20:14.304585
NCT00453544|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2016-10-26|2007-03-28|2007-03-29|Estimate|||||||2016-10-26|2016-10-28|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|BWP-AD||Enhancing Consent for Alzheimer's Research|Enhancing Consent for Alzheimer's Research|Completed||N/A|252|Actual|University of California, San Diego||4|||f||||t||||||||||2018-06-01 03:20:14.460186|2018-06-01 03:20:14.460186
NCT00453531|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2017-06-30|2007-03-28|2007-03-29|Estimate|||||||2017-06-30|2017-07-02|Actual|March 26, 2007||2007-03-26|February 11, 2009|2009-02-11||||February 11, 2009|Actual|2009-02-11||Interventional|||Model System for Transient Forearm Blood Vessel Dysfunction|Pilot Study for the Development of Transient Forearm Endothelial Dysfunction|Completed||N/A|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:20:14.566336|2018-06-01 03:20:14.566336
NCT00453518|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2009-08-17|2007-03-28|2007-03-29|Estimate|||||||2009-08-17|2009-08-18|Estimate|March 2007||2007-03-31|August 2009|2009-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|RETRIEVE||The RETRIEVE Study: Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts|Evaluating the Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts: The RETRIEVE Study|Completed||N/A|29|Actual|Lumen Biomedical|||||f||||t||||||||||2018-06-01 03:20:14.633434|2018-06-01 03:20:14.633434
NCT00453505|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2018-05-23|2007-03-28|2007-03-29|Estimate|||||||2018-05-23|2018-05-24|Actual|March 27, 2007||2007-03-27|January 29, 2018|2018-01-29||||||||Observational|||Modulation of Motor Function by Stimulation of the Central and Peripheral Nervous System|Modulation of Motor Function by Stimulation of the Central and Peripheral Nervous System|Recruiting|||1200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:20:14.831632|2018-06-01 03:20:14.831632
NCT00453492|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2008-03-10|2007-03-28|2007-03-29|Estimate|||||||2008-03-10|2008-03-11|Estimate|January 2004||2004-01-31|March 2008|2008-03-31||||||||Interventional|||Risedronate Sodium in Post Menopausal Osteoporosis|A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily|Completed||Phase 4|246||Sanofi|||||f||||||||||||||2018-06-01 03:20:14.913752|2018-06-01 03:20:14.913752
NCT00453479|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2017-07-19||2018-02-13|2007-03-28|2007-03-29|Estimate|2017-07-24|2018-02-08|Actual||||2018-02-13|2018-03-12|Actual|March 28, 2007|Actual|2007-03-28|July 2017|2017-07-31|October 11, 2007|Actual|2007-10-11|October 11, 2007|Actual|2007-10-11||Interventional|||A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.|A Randomised, Double-blind, Placebo-controlled, Dose Ascending, 2-cohort, Parallel Group Study to Examine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Twice-daily Inhaled Doses of GSK233705B Formulated With the Excipient Magnesium Stearate in COPD Subjects for 7-days.|Completed||Phase 2|23|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:20:15.055592|2018-06-01 03:20:15.055592
NCT00453466|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2007-03-28|2007-03-28|2007-03-29|Estimate|||||||2007-03-28|2007-03-29|Estimate|December 2001||2001-12-31|March 2007|2007-03-31|December 2004|Actual|2004-12-31|||||Interventional|EBW||Group Empowerment of Battered Women as a Tool for Violence Prevention||Completed||N/A|||Ben-Gurion University of the Negev|||||f||||t||||||||||2018-06-01 03:20:17.01877|2018-06-01 03:20:17.01877
NCT00453440|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-28|||2017-09-09|2007-03-28|2007-03-29|Estimate|||||||2017-09-09|2017-09-12|Actual|March 20, 2007|Actual|2007-03-20|September 2017|2017-09-30|August 10, 2007|Actual|2007-08-10|August 10, 2007|Actual|2007-08-10||Observational|||Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701|Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected UK Patients|Completed|||1502|Actual|ViiV Healthcare|||||f||||f||||||||||2018-06-01 03:20:17.134571|2018-06-01 03:20:17.134571
NCT00453427|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2015-06-01|2007-03-28|2007-03-29|Estimate|||||||2015-06-01|2015-06-03|Estimate|September 2006||2006-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|June 2013|Actual|2013-06-30||Interventional|ACCAPELA||Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas|Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study|Completed||Phase 1/Phase 2|20|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||t||||||||||2018-06-01 03:20:17.200754|2018-06-01 03:20:17.200754
NCT00453414|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-02-12|2007-03-27|2007-03-29|Estimate|||||||2010-02-12|2010-02-15|Estimate|July 2006||2006-07-31|February 2010|2010-02-28|October 2006|Anticipated|2006-10-31|October 2006|Anticipated|2006-10-31||Interventional|||Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension|Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension|Withdrawn||Phase 2|0|Actual|Actelion||||Withdrawn due to lack of enrollment|f||||||||||||||2018-06-01 03:20:17.267003|2018-06-01 03:20:17.267003
NCT00453401|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2008-05-28|2007-03-27|2007-03-28|Estimate|||||||2008-05-28|2008-05-30|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis|The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis|Completed||Phase 2|1000|Anticipated|NanoBio Corporation|||||f||||f||||||||||2018-06-01 03:20:17.455393|2018-06-01 03:20:17.455393
NCT00453388|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2017-04-10||2017-04-18|2007-03-27|2007-03-28|Estimate|2017-04-18|2017-05-24|Actual||||2017-04-18|2017-05-24|Actual|February 2007||2007-02-28|April 2017|2017-04-30||||June 2013|Actual|2013-06-30||Interventional|||Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia|Nonmyeloablative Hematopoietic Cell Transplantation for Patients With Fanconi Anemia Using Alternative Marrow Donors: A Phase II Dose-Finding Study|Active, not recruiting||Phase 2|6|Actual|Fred Hutchinson Cancer Research Center||4|||f||||t||||||||||2018-06-01 03:20:17.585038|2018-06-01 03:20:17.585038
NCT00453375|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2011-06-27|2007-03-26|2007-03-28|Estimate|||||||2011-06-27|2011-06-28|Estimate|October 2006||2006-10-31|January 2011|2011-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus|A Randomized, Blinded, Placebo Controlled, Safety and Pharmacodynamic Study of BHT-3021 With Open Label Cross-Over in Subjects With Type I Diabetes Mellitus|Completed||Phase 1|80|Actual|Bayhill Therapeutics||2|||f||||t||||||||||2018-06-01 03:20:18.028184|2018-06-01 03:20:18.028184
NCT00453362|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2011-03-31||2017-03-02|2007-03-26|2007-03-28|Estimate|2011-08-26|2011-10-03|Estimate||||2017-03-02|2017-03-31|Actual|December 2006||2006-12-31|October 2011|2011-10-31|April 23, 2010|Actual|2010-04-23|April 2010|Actual|2010-04-30||Interventional|||A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib|Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib|Completed||Phase 1/Phase 2|88|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:20:18.201227|2018-06-01 03:20:18.201227
NCT00453349|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2009-09-01||2014-09-02|2007-03-27|2007-03-28|Estimate|2009-10-26|2009-11-30|Estimate||||2014-09-02|2014-09-08|Estimate|January 2007||2007-01-31|September 2014|2014-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease|A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 Days in Subjects With an Uncomplicated Pelvic Inflammatory Disease (PID). Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study)|Completed||Phase 3|460|Actual|Bayer|Out of the 460 randomized subjects, 5 subjects (3 moxifloxacin subjects, 2 placebo subjects) did not receive any study medication. Only one of these patients had an adverse event (stomachache, randomized to Moxifloxacin).|2|||f||||f||||||||||2018-06-01 03:20:18.710148|2018-06-01 03:20:18.710148
NCT00453336|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2013-08-14||2016-12-14|2007-03-27|2007-03-28|Estimate|2013-08-14|2013-10-18|Estimate||||2016-12-14|2017-02-08|Estimate|June 2003||2003-06-30|December 2016|2016-12-31|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional|||Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract|A Phase II Clinical Trial on the Efficacy of Photodynamic Therapy With Porfimer Sodium (Photofrin®) for Malignant and Pre-Malignant Lesions and Condemned Mucosa Syndrome in the Upper Aerodigestive Tract|Completed||Phase 2|45|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 03:20:19.209478|2018-06-01 03:20:19.209478
NCT00453323|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-07-09|2007-03-27|2007-03-28|Estimate|||||||2010-07-09|2010-07-12|Estimate|June 2006||2006-06-30|July 2010|2010-07-31|December 2010|Anticipated|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer|A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer|Unknown status|Active, not recruiting|Phase 2|33|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 03:20:19.401825|2018-06-01 03:20:19.401825
NCT00453310|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2015-09-24||2015-09-24|2007-03-27|2007-03-28|Estimate|2015-09-24|2015-10-27|Estimate||||2015-09-24|2015-10-27|Estimate|March 2007||2007-03-31|September 2015|2015-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment|A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors|Completed||Phase 2|10|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:20:19.657002|2018-06-01 03:20:19.657002
NCT00453297|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2008-08-27|2007-03-27|2007-03-28|Estimate|||||||2008-08-27|2008-08-29|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components|A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women.|Terminated||Phase 1|32|Anticipated|Bionovo|||||t||||||||||||||2018-06-01 03:20:19.861375|2018-06-01 03:20:19.861375
NCT00452894|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2008-03-28|2007-03-27|2007-03-28|Estimate|||||||2008-03-28|2008-04-01|Estimate|March 2007||2007-03-31|March 2008|2008-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Phase 1 Clinical Trial of Varenicline in Chinese Healthy Smoking Volunteers|A Pharmacokinetic, Toleration And Safety Study Of Single And Multiple Oral Doses Of Varenicline In Chinese Healthy Volunteers|Completed||Phase 1|14||Pfizer|||||f||||||||||||||2018-06-01 03:20:24.605931|2018-06-01 03:20:24.605931
NCT00453271|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26||2013-05-15|2013-05-15|2007-03-26|2007-03-28|Estimate||||2013-05-15|2013-05-23|Estimate|2013-05-15|2013-05-23|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail|A Randomized, Double-Blind, Parallel-Group,Multicenter, Dose-Response, Vehicle-Controlled Study of the Safety and Efficacy of NB-002 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail|Completed||Phase 2|443|Actual|NanoBio Corporation||4|||f||||f||||||||||2018-06-01 03:20:19.932873|2018-06-01 03:20:19.932873
NCT00453258|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2013-01-15|2007-03-27|2007-03-28|Estimate|||||||2013-01-15|2013-01-17|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Pilot Study of Human Tear Proteins|Analysis of Human Tear Proteins: A Pilot Study to Describe the Tear Film Proteome of Patients Undergoing Ophthalmic Examination.|Terminated|||63|Actual|University of Colorado, Denver|||1|Stopped due to low enrollment|f||||f||||||||||2018-06-01 03:20:20.044396|2018-06-01 03:20:20.044396
NCT00453245|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2007-03-27|2007-03-27|2007-03-28|Estimate|||||||2007-03-27|2007-03-28|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|January 2006|Actual|2006-01-31|||||Observational|||Molecular Basis of the Growth Axis in Short Stature|Study of the Molecular Basis of the Growth Axis Among Short Stature Children|Completed|||||HaEmek Medical Center, Israel|||||f||||t||||||||||2018-06-01 03:20:20.108633|2018-06-01 03:20:20.108633
NCT00453232|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2013-08-06|2007-03-27|2007-03-28|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2004||2004-08-31|August 2007|2007-08-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors|Accelerated BEP Chemotherapy for Intermediate and High Risk Metastatic Germ Cell Tumor|Completed||Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:20:20.153748|2018-06-01 03:20:20.153748
NCT00453219|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2013-10-29|2007-03-27|2007-03-28|Estimate|||||||2013-10-29|2013-10-30|Estimate|July 2011||2011-07-31|October 2013|2013-10-31||||||||Observational|||FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity|Functional Hypothalamic Amenorrhea: Characterization of Metabolic Status, Brain Circuitry, and Stress-reactivity|Withdrawn|||0|Actual|Emory University|||3|prior to participant recruitment, PI left Emory, study stopped|f||||t||||||Samples With DNA|"~     Blood samples will be collected, processed, and stored for the evaluation of genetic markers~     assocaited with stress vulnerability. Serum and plasma specimens will be collected and stored~     for the evaluation of factors associated with the regulation of reproduction.~   "|||2018-06-01 03:20:20.303933|2018-06-01 03:20:20.303933
NCT00453206|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2014-05-28||2017-07-31|2007-03-27|2007-03-28|Estimate|2014-06-30|2014-07-02|Estimate||||2017-07-31|2017-08-30|Actual|February 2007||2007-02-28|February 2017|2017-02-28|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases|Reduced Intensity Allogeneic Hematopoietic Cell Transplantation for Patients With Hematological Diseases|Completed||N/A|66|Actual|Wake Forest University Health Sciences|By the time the primary objective of this trial was completed, the treatment approach of the trial had become standard of care. Analysis was therefore limited.||||f||||t|f|f||||||||2018-06-01 03:20:20.391374|2018-06-01 03:20:20.391374
NCT00453193|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2011-03-01||2012-08-01|2007-03-27|2007-03-28|Estimate|2011-03-01|2011-03-28|Estimate||||2012-08-01|2012-08-07|Estimate|September 2004||2004-09-30|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Alemtuzumab and Pentostatin In T-cell Neoplasms|A Phase II Study of Alemtuzumab and Pentostatin In T-Cell Neoplasms|Terminated||Phase 2|26|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 03:20:20.666067|2018-06-01 03:20:20.666067
NCT00453180|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2017-03-29|2013-04-23|2017-05-19|2007-03-27|2007-03-28|Estimate|2017-05-19|2017-06-14|Actual|2013-04-23|2013-05-01|Estimate|2017-05-19|2017-06-14|Actual|March 2007||2007-03-31|May 2017|2017-05-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders|A Pilot Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders|Completed||Phase 2|31|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 03:20:20.869679|2018-06-01 03:20:20.869679
NCT00453167|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-07-09|2007-03-27|2007-03-28|Estimate|||||||2010-07-09|2010-07-12|Estimate|December 2005||2005-12-31|July 2010|2010-07-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer|A Phase II Study of Weekly Paclitaxel and Gemcitabine as Second-line Therapy in Patients With Metastatic or Recurrence Small Cell Lung Cancer|Completed||Phase 2|35|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 03:20:21.311787|2018-06-01 03:20:21.311787
NCT00453154|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2015-03-24||2018-04-26|2007-03-27|2007-03-28|Estimate|2015-04-10|2015-04-14|Estimate||||2018-04-26|2018-05-24|Actual|March 15, 2007|Actual|2007-03-15|March 2018|2018-03-31||||June 30, 2013|Actual|2013-06-30||Interventional||Per protocol, participants who were randomized and received treatment were analyzed.|Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study|Active, not recruiting||Phase 1/Phase 2|156|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:20:21.442631|2018-06-01 03:20:21.442631
NCT00453141|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2009-11-07|2007-03-27|2007-03-28|Estimate|||||||2009-11-07|2009-11-10|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Betamethasone Dosing Interval - 12 or 24 Hours?|Betamethasone Dosing Interval - 12 or 24 Hours?|Completed||N/A|200|Anticipated|The Cooper Health System|||||f||||f||||||||||2018-06-01 03:20:22.575691|2018-06-01 03:20:22.575691
NCT00453128|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-03-27|2007-03-27|2007-03-28|Estimate|||||||2007-03-27|2007-03-28|Estimate|January 1997||1997-01-31|March 2007|2007-03-31|December 2006|Actual|2006-12-31|||||Observational|||Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients|Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease|Completed|||240||Sociedade Galega de Reumatoloxía|||||f||||f||||||||||2018-06-01 03:20:22.646621|2018-06-01 03:20:22.646621
NCT00453115|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-10-22|2007-03-27|2007-03-28|Estimate|||||||2010-10-22|2010-10-25|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|May 2011|Anticipated|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|A Phase II Study of Gemcitabine Plus Oxaliplatin for Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|43|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 03:20:22.785376|2018-06-01 03:20:22.785376
NCT00451854|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2017-01-10|2007-03-23|2007-03-26|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 1999||1999-09-30|March 2007|2007-03-31|October 2002|Actual|2002-10-31|||||Interventional|SATURN||Student Athlete Testing Using Random Notification|Student Athlete Drug Surveillance Trail|Completed||N/A|14000||National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 03:20:48.740737|2018-06-01 03:20:48.740737
NCT00453102|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2015-10-23||2015-11-30|2007-03-27|2007-03-28|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|February 2006||2006-02-28|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Data reported for only 16 of 18 participants due to 2 participants withdrawing consent.|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma|Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma|Completed||Phase 2|18|Actual|University of Miami|Data reported for only 16 of 18 enrolled participants due to 2 participants withdrawing consent.|1|||f||||t||||||||||2018-06-01 03:20:22.951457|2018-06-01 03:20:22.951457
NCT00453089|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2012-02-06|2007-03-27|2007-03-28|Estimate|||||||2012-02-06|2012-02-08|Estimate|June 2012||2012-06-30|February 2012|2012-02-29|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women|A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women|Unknown status|Not yet recruiting|Phase 1/Phase 2|40|Anticipated|Bionovo|||||f||||||||||||||2018-06-01 03:20:23.433635|2018-06-01 03:20:23.433635
NCT00453076|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-06-10|2007-03-27|2007-03-28|Estimate|||||||2010-06-10|2010-06-11|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction|Randomized Trial of Conventional Covered Self Expandable Metallic Stent Versus Paclitaxel Eluting Covered Self Expandable Metallic Stent in Unresectable Malignant Bile Duct Obstruction|Completed||Phase 3|52|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 03:20:23.517604|2018-06-01 03:20:23.517604
NCT00453063|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2010-02-03||2015-03-17|2007-03-26|2007-03-28|Estimate|2010-04-01|2010-05-17|Estimate||||2015-03-17|2015-04-03|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)|Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 3|426|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:20:23.600474|2018-06-01 03:20:23.600474
NCT00453050|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2015-05-05|2007-03-27|2007-03-28|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2006||2006-03-31|November 2008|2008-11-30||||March 2009|Actual|2009-03-31||Interventional|||Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin|Laser and TLR-Agonist Immunotherapy: A Novel Autologous Melanoma Vaccine Study|Completed||Phase 1|11|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:20:23.943704|2018-06-01 03:20:23.943704
NCT00453037|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2011-01-14|2007-03-27|2007-03-28|Estimate|||||||2011-01-14|2011-01-17|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|herzleben||Effects of a Structured Education Program on Blood Pressure in Essential Hypertensive Patients|Effects of a Structured Education Program on Blood Pressure in Essential Hypertensive Patients and Effects of a Reminder Program for Physicians to Guide Optimal Therapy|Completed||N/A|256|Actual|Medical University of Graz||2|||f||||f||||||||||2018-06-01 03:20:24.020321|2018-06-01 03:20:24.020321
NCT00453024|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2008-05-12|2007-03-27|2007-03-28|Estimate|||||||2008-05-12|2008-05-14|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Imaging Ahmed Glaucoma Tubes With a Pericardial Graft and Tissue Glue or Partial-Thickness Scleral Flap and Sutures|Anterior Segment Optical Coherence Tomography Findings in Patients With Ahmed Glaucoma Drainage Implants With Either a Pericardial Patch Graft and Fibrin Tissue Glue or a Partial-Thickness Scleral Flap and Conventional Sutures|Unknown status|Recruiting|Phase 2|40|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-06-01 03:20:24.10641|2018-06-01 03:20:24.10641
NCT00453011|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2015-10-19|2007-03-27|2007-03-28|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 1992||1992-02-29|October 2015|2015-10-31|February 1998||1998-02-28|||||Interventional|||Comparison of AC and PC Lenses After Vitreous Loss During ECCE|CSP #338 - Comparison of Anterior and Posterior Chamber Lens Implants After Vitreous Loss in Attempted Extracapsular Cataract Extraction|Completed||Phase 3|1202||VA Office of Research and Development|||||f||||||||||||||2018-06-01 03:20:24.200985|2018-06-01 03:20:24.200985
NCT00452998|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2008-05-12|2007-03-27|2007-03-28|Estimate|||||||2008-05-12|2008-05-14|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study|Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot Study|Completed||N/A|10|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-06-01 03:20:24.249392|2018-06-01 03:20:24.249392
NCT00452985|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2012-08-13|2007-03-27|2007-03-28|Estimate|||||||2012-08-13|2012-08-14|Estimate|February 2002||2002-02-28|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|OCSTUD||Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer|Randomised Study With Docetaxel, Cisplatin and Cyclophosphamide vs Docetaxel and Carboplatin as First Line Chemotherapy With Advanced or Metastatic Ovarian Cancer|Completed|||30|Actual|Sanofi|||1||f||||||||||||||2018-06-01 03:20:24.343192|2018-06-01 03:20:24.343192
NCT00452972|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-03-26|2007-03-26|2007-03-28|Estimate|||||||2007-03-26|2007-03-28|Estimate|April 2004||2004-04-30|March 2007|2007-03-31|December 2004|Actual|2004-12-31|||||Interventional|||Exteriorized Versus In Situ Uterine Repair at Cesarean Delivery|Complications of Exteriorized Versus In Situ Uterine Repair at Cesarean Delivery Under Spinal Anesthesia|Completed||N/A|80||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||||f||||f||||||||||2018-06-01 03:20:24.413299|2018-06-01 03:20:24.413299
NCT00452920|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2016-12-14|2007-03-27|2007-03-28|Estimate|||||||2016-12-14|2016-12-15|Estimate|September 2003||2003-09-30|December 2016|2016-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer|A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026)|Withdrawn||Phase 1/Phase 2|0|Actual|University of Miami|||||f||||t||||||||||2018-06-01 03:20:24.481046|2018-06-01 03:20:24.481046
NCT00452907|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-02-16|2007-03-27|2007-03-28|Estimate|||||||2010-02-16|2010-02-17|Estimate|July 2005||2005-07-31|February 2010|2010-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||ACT MALI: Treatment of Malaria Based on Combination Therapies|Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali|Completed||Phase 4|780|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:20:24.548428|2018-06-01 03:20:24.548428
NCT00451438|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-03-21|2007-03-21|2007-03-23|Estimate|||||||2007-03-21|2007-03-23|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|March 2007||2007-03-31|||||Observational|||Investigation of Muscle Activity Pattern of Gluteus Medius and Tensor Fascia Lata in Patients With PFPS||Completed|||30||National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 03:20:53.451415|2018-06-01 03:20:53.451415
NCT00452881|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-10-22|2007-03-27|2007-03-28|Estimate|||||||2010-10-22|2010-10-25|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|December 2014|Anticipated|2014-12-31|October 2009|Actual|2009-10-31||Interventional|||Adjuvant Gemcitabine Plus Oxaliplatin Versus Gemcitabine Plus Cisplatin for Completely Resected Stage IB/II/IIIA NSCLC|A Randomized Phase II Study Adjuvant Gemcitabine And Oxaliplatin Versus Gemcitabine and Cisplatin for Completely Resected Stage IB, II or IIIA Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|151|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 03:20:24.658952|2018-06-01 03:20:24.658952
NCT00452868|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|2012-08-31||2017-07-31|2007-03-27|2007-03-28|Estimate|2013-01-24|2013-02-28|Estimate||||2017-07-31|2017-08-30|Actual|June 2006|Actual|2006-06-30|July 2016|2016-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain|A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation|Completed||Early Phase 1|14|Actual|Wake Forest University Health Sciences|small number (11) analyzed|1|||f||||t|t|f||||||||2018-06-01 03:20:24.73607|2018-06-01 03:20:24.73607
NCT00452855|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-03-28|2007-03-27|2007-03-28|Estimate|||||||2007-03-28|2007-03-29|Estimate|January 2002||2002-01-31|March 2007|2007-03-31|May 2005|Actual|2005-05-31|||||Interventional|||Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea|Postoperative Nausea and Vomiting Are Similar When Propofol or Sevoflurane Are Used as Adjuvant to Remifentanil During Anaesthesia for Gynaecological Surgery|Completed||N/A|160||Central Jutland Regional Hospital|||||f||||f||||||||||2018-06-01 03:20:24.901217|2018-06-01 03:20:24.901217
NCT00452842|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2008-02-21|2007-03-27|2007-03-28|Estimate|||||||2008-02-21|2008-02-22|Estimate|October 2007||2007-10-31|December 2007|2007-12-31||||||||Observational|||Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies|An Observational Safety Follow Up Trial Of The Occurrence Of Major Cardiovascular Events And All Cause Mortality In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Clinical Trials.|Terminated|||26784||Pfizer||||See termination reason in detailed description.|f||||||||||||||2018-06-01 03:20:24.961778|2018-06-01 03:20:24.961778
NCT00452829|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2015-06-23|2007-03-27|2007-03-28|Estimate|||||||2015-06-23|2015-06-24|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Prevention of Neural Tube Defects by Inositol in Conjunction With Folic Acid (PONTI Study)|Prevention of Neural Tube Defects by Inositol in Conjunction With Folic Acid (PONTI Study)|Completed||Phase 1|100|Actual|Institute of Child Health||2|||f||||f||||||||||2018-06-01 03:20:25.013954|2018-06-01 03:20:25.013954
NCT00452816|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2009-11-18|2007-03-26|2007-03-28|Estimate|||||||2009-11-18|2009-11-20|Estimate|April 2007||2007-04-30|November 2009|2009-11-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Marketing Workplace Chronic Disease Prevention|Marketing Workplace Chronic Disease Prevention|Completed||N/A|48|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:20:25.09228|2018-06-01 03:20:25.09228
NCT00452803|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-27|||2010-07-09|2007-03-27|2007-03-28|Estimate|||||||2010-07-09|2010-07-12|Estimate|April 2006||2006-04-30|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study Preoperative Chemotherapy Versus Preoperative Concurrent Chemoradiotherapy for Patients With Biopsy-Proven N2 Stage IIIA Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|102|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 03:20:25.163947|2018-06-01 03:20:25.163947
NCT00452790|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|2010-10-13||2011-03-22|2007-03-26|2007-03-27|Estimate|2010-10-13|2010-11-15|Estimate||||2011-03-22|2011-03-24|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India|A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India|Completed||Phase 3|708|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Geometric Mean Concentration Outcome Measures were identified as secondary analysis in the study protocol, but are included to maintain consistency with other postings for this program.|2|||f||||||||||||||2018-06-01 03:20:25.430511|2018-06-01 03:20:25.430511
NCT00452777|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2014-10-31|2007-03-26|2007-03-27|Estimate|||||||2014-10-31|2014-11-03|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study Evaluating the Efficacy and Tolerability of Oral BVT.115959, a Novel A2A Agonist, Versus Placebo in the Treatment of Diabetic Neuropathic Pain|Completed||Phase 2|193|Actual|Swedish Orphan Biovitrum||2|||f||||t||||||||||2018-06-01 03:20:27.265713|2018-06-01 03:20:27.265713
NCT00452764|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-11-07|2007-03-26|2007-03-27|Estimate|||||||2007-11-07|2007-11-08|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||Regulatory T Cells in COPD|Phenotype and Number of Regulatory T Cells Present in Peripheral Blood of COPD Patients Versus Healthy Controls|Completed|||50|Anticipated|Groningen Research Institute for Asthma and COPD|||||f||||t||||||||||2018-06-01 03:20:27.444565|2018-06-01 03:20:27.444565
NCT00452751|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2010-09-20|2007-03-26|2007-03-27|Estimate|||||||2010-09-20|2010-09-21|Estimate|February 2006||2006-02-28|September 2010|2010-09-30|May 2014|Anticipated|2014-05-31|||||Interventional|KLASS||Comparison of Laparoscopic Versus Open Gastrectomy for Gastric Cancer: A Prospective Randomized Trial|Multi-institutional Prospective Randomized Trial on the Assessment of Laparoscopic Surgery for Gastric Cancer|Unknown status|Recruiting|Phase 3|1400|Anticipated|National Cancer Center, Korea|||||f||||t||||||||||2018-06-01 03:20:27.510978|2018-06-01 03:20:27.510978
NCT00452738|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2015-04-20|2007-03-26|2007-03-27|Estimate|||||||2015-04-20|2015-04-21|Estimate|April 2007||2007-04-30|January 2008|2008-01-31|February 2008|Anticipated|2008-02-29|||||Interventional|Dog||The Effect of Pre Surgery Dog Visits on Post Surgery Consumption of Pain Medication|The Effect of Pre Surgery Dog Visits on Post Surgery Consumption of Pain Medication|Withdrawn||N/A|0|Actual|Oklahoma State University Center for Health Sciences||||PI left university. Did not start study|f||||f||||||||||2018-06-01 03:20:27.642773|2018-06-01 03:20:27.642773
NCT00452725|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2010-10-04|2007-03-26|2007-03-27|Estimate|||||||2010-10-04|2010-10-05|Estimate|October 1997||1997-10-31|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome|Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome|Completed||Phase 3|36|Actual|Sanofi|||||f||||f||||||||||2018-06-01 03:20:27.734701|2018-06-01 03:20:27.734701
NCT00452712|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-05-02|2007-03-26|2007-03-27|Estimate|||||||2007-05-02|2007-05-03|Estimate|November 2006||2006-11-30|May 2007|2007-05-31||||||||Observational|||Orthostatic Hypotension in Children With Acute Febrile Illness||Unknown status|Recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:20:27.800132|2018-06-01 03:20:27.800132
NCT00452699|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2010-01-14||2016-10-26|2007-03-26|2007-03-27|Estimate|2010-01-25|2010-02-15|Estimate||||2016-10-26|2016-12-08|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma|A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma|Completed||Phase 4|621|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:20:27.927154|2018-06-01 03:20:27.927154
NCT00452686|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2016-10-27|2007-03-26|2007-03-27|Estimate|||||||2016-10-27|2016-10-28|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine|Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix (dTpa) Vaccine and the Chinese DT Vaccine, When Administered as Booster Vaccination in Healthy Children Aged 6-8 Years|Completed||Phase 3|660||GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:20:28.60672|2018-06-01 03:20:28.60672
NCT00452673|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2013-10-09||2015-03-04|2007-03-26|2007-03-27|Estimate|2013-10-09|2013-12-06|Estimate||||2015-03-04|2015-03-24|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer|Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer|Completed||Phase 1|52|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 03:20:29.7889|2018-06-01 03:20:29.7889
NCT00452660|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2014-06-13|2007-03-26|2007-03-27|Estimate|||||||2014-06-13|2014-06-16|Estimate|May 2007||2007-05-31|June 2014|2014-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load|A Phase IV , Multicenter ,Open Label ,Non Comparative ,Investigator Initiated Study , Evaluating the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load|Completed||Phase 4|21|Actual|Wolfson Medical Center||1|||f||||t||||||||||2018-06-01 03:20:31.828298|2018-06-01 03:20:31.828298
NCT00452647|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2013-09-05|2007-03-26|2007-03-27|Estimate|||||||2013-09-05|2013-09-09|Estimate|February 2007||2007-02-28|September 2013|2013-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Comparison of Blood Pressure Throughout Pregnancy|Comparison of Blood Pressure Throughout Pregnancy|Terminated|||200|Actual|Drexel University||||data did not indicate any meaningful information|f||||||||||||||2018-06-01 03:20:32.025289|2018-06-01 03:20:32.025289
NCT00452634|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2013-06-17|2007-03-26|2007-03-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|April 2006||2006-04-30|June 2013|2013-06-30|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)|A Phase II Study of Irinotecan/Cisplatin Plus Simvastatin in Chemo-naive Patients With Extensive Disease-Small Cell Lung Cancer|Completed||Phase 2|62|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 03:20:32.186908|2018-06-01 03:20:32.186908
NCT00452621|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2008-04-22|2007-03-26|2007-03-27|Estimate|||||||2008-04-22|2008-04-23|Estimate|February 2007||2007-02-28|April 2008|2008-04-30||||||||Interventional|||Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years|A Phase IV, Uncontrolled, Open-Label, Multi-Center Study in Children and Adolescents: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New Pediatric TBE Vaccine (Free of Protein-Derived Stabilizer) in Study V48P4E1, Five Years After First Booster Immunization|Completed||Phase 4|235|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:20:32.276148|2018-06-01 03:20:32.276148
NCT00452608|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2009-06-25|2007-03-26|2007-03-27|Estimate|||||||2009-06-25|2009-06-26|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Statin for Immunomudulation in Sepsis|Use of Statins in Modulation of Inflammatory Answer in Septic Patients|Unknown status|Recruiting|Phase 2|80|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 03:20:32.352022|2018-06-01 03:20:32.352022
NCT00452595|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2007-03-23|2007-03-23|2007-03-27|Estimate|||||||2007-03-23|2007-03-27|Estimate|January 2004||2004-01-31|March 2007|2007-03-31|May 2005||2005-05-31|||||Interventional|||Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder|A 12-Month Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Outpatients With Major Depressive Disorder|Completed||Phase 3|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:20:32.444819|2018-06-01 03:20:32.444819
NCT00452582|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2011-03-15|2007-03-26|2007-03-27|Estimate|||||||2011-03-15|2011-03-16|Estimate|April 2005||2005-04-30|March 2011|2011-03-31||||||||Interventional|||Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke|Phase 1 Study of Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke|Terminated||Phase 1|20|Actual|Henry Ford Health System||2||Failure to recruit in expected time period.|f||||t||||||||||2018-06-01 03:20:32.506771|2018-06-01 03:20:32.506771
NCT00452569|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2016-11-22|2007-03-26|2007-03-27|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|OPTIMUM||Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma|Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma|Completed||Phase 3|499|Actual|Celgene Corporation||4|||f||||t||||||||||2018-06-01 03:20:32.6936|2018-06-01 03:20:32.6936
NCT00452556|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2014-03-18|2007-03-26|2007-03-27|Estimate|||||||2014-03-18|2014-03-19|Estimate|May 2007||2007-05-31|March 2014|2014-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study|The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study: A Phase II Study of Chemo - Hormonal Therapy and Radiation in High Risk Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|86|Anticipated|Nova Scotia Cancer Centre||2|||f||||t||||||||||2018-06-01 03:20:32.968492|2018-06-01 03:20:32.968492
NCT00452543|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2011-05-24||2012-06-04|2007-03-26|2007-03-27|Estimate|2012-06-04|2012-07-09|Estimate||||2012-06-04|2012-07-09|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism|A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence|Completed||Phase 4|23|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:20:33.078378|2018-06-01 03:20:33.078378
NCT00452530|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|2014-04-14||2014-07-08|2007-03-26|2007-03-27|Estimate|2014-04-14|2014-05-13|Estimate||||2014-07-08|2014-07-09|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|ADVANCE-2|All participants randomized to treatment|Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery|A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)|Completed||Phase 3|3221|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:20:33.465664|2018-06-01 03:20:33.465664
NCT00452517|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-03-26|2007-03-26|2007-03-27|Estimate|||||||2007-03-26|2007-03-27|Estimate|March 2004||2004-03-31|March 2007|2007-03-31|November 2004|Actual|2004-11-30|||||Interventional|||Comparison of Stent Graft, Sirolimus Stent, and Bare Metal Stent Implanted in Patients With Acute Coronary Syndrome|Comparison of Stent Graft, Sirolimus Stent, and Bare Metal Stent Implanted in Patients With Acute Coronary Syndrome: Clinical and Angiographic Follow-up|Completed||Phase 4|100||University of Zagreb|||||f||||f||||||||||2018-06-01 03:20:34.891998|2018-06-01 03:20:34.891998
NCT00452504|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2007-12-03|2007-03-23|2007-03-27|Estimate|||||||2007-12-03|2007-12-05|Estimate|February 2007||2007-02-28|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Single Ascending Dose Study of SRA-444 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRA-444 Administered Orally to Healthy Adult Subjects|Completed||Phase 1|64|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:20:34.950012|2018-06-01 03:20:34.950012
NCT00452491|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2010-10-04|2007-03-26|2007-03-27|Estimate|||||||2010-10-04|2010-10-05|Estimate|May 1993||1993-05-31|October 2010|2010-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children|A Cohort of Pre-pubertal Children for the Study of Optimization of Methods of Administration of the Biosynthetic Growth Hormone MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation|Completed||Phase 3|306|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:20:35.000011|2018-06-01 03:20:35.000011
NCT00452478|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2014-06-06|2007-03-26|2007-03-27|Estimate|||||||2014-06-06|2014-06-09|Estimate|May 2007||2007-05-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5|A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion From Standard Phosphate Binder Therapy to Fosrenol® in Chronic Kidney Disease Stage 5 Patients on Haemodialysis|Terminated||Phase 4|68|Actual|Shire||1||This study was stopped by the sponsor based on a non-safety related corporate decision|f||||||||||||||2018-06-01 03:20:35.076114|2018-06-01 03:20:35.076114
NCT00452465|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2016-03-14|2007-03-26|2007-03-27|Estimate|||||||2016-03-14|2016-03-16|Estimate|February 2007||2007-02-28|March 2016|2016-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Primary Healthcare for Community Living Old Elderly|The ElderCare Project: Primary Healthcare for Community Living Old Elderly|Completed||N/A|236|Actual|Memorial University of Newfoundland||2|||f||||f||||||||||2018-06-01 03:20:35.180791|2018-06-01 03:20:35.180791
NCT00452452|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|2010-03-26|2009-01-21|2012-07-06|2007-03-26|2007-03-27|Estimate|2012-07-06|2012-08-15|Estimate|2009-09-30|2009-10-01|Estimate|2012-07-06|2012-08-15|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children|A Phase 3 Open-label Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Older Infants and Children Who Are Naive to Previous Vaccination With Pneumococcal Conjugate Vaccine.|Completed||Phase 3|355|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||||||||||||2018-06-01 03:20:35.272742|2018-06-01 03:20:35.272742
NCT00452439|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2014-08-19|2007-03-26|2007-03-27|Estimate|||||||2014-08-19|2014-08-21|Estimate|February 2004||2004-02-29|August 2014|2014-08-31||||August 2014|Actual|2014-08-31||Interventional|||A Study of Actonel for the Prevention of Bone Loss|A Randomized, Double Blinded Study of Actonel for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)|Completed||Phase 3|95|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:20:36.03061|2018-06-01 03:20:36.03061
NCT00452426|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2010-10-06|2008-10-16|2010-12-30|2007-03-26|2007-03-27|Estimate|2010-12-30|2011-01-25|Estimate|2009-09-30|2009-10-02|Estimate|2010-12-30|2011-01-25|Estimate|March 2007||2007-03-31|December 2010|2010-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Effectiveness of a Computer-Assisted Personalized Sedation (CAPS) Device for Propofol Delivery During Endoscopy|Multi-center Pivotal Clinical Trial to Compare the Safety and Effectiveness of Procedural Sedation in GI Endoscopy: A Computer-Assisted Personalized Sedation (CAPS) Device Versus Current Standard of Care|Completed||Phase 3|1000|Actual|Ethicon Endo-Surgery||2|||f||||t||||||||||2018-06-01 03:20:36.348923|2018-06-01 03:20:36.348923
NCT00452413|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23||2010-05-27|2016-11-30|2007-03-26|2007-03-27|Estimate||||2010-05-27|2010-06-02|Estimate|2016-11-30|2016-12-01|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|July 2009|Actual|2009-07-31||Interventional|||A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer|A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy|Completed||Phase 1/Phase 2|65|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:20:36.612383|2018-06-01 03:20:36.612383
NCT00452400|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2014-03-28||2014-06-17|2007-03-26|2007-03-27|Estimate|2014-05-02|2014-06-03|Estimate||||2014-06-17|2014-06-27|Estimate|March 2007||2007-03-31|May 2014|2014-05-31||||January 2008|Actual|2008-01-31||Interventional||Treated set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.|Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Treatment of Orally Inhaled BI 1744 CL (3 - 4 Doses) Delivered by the Respimat® Inhaler in Patients With COPD|Completed||Phase 2|409|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:20:36.821907|2018-06-01 03:20:36.821907
NCT00452387|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2009-08-17||2011-09-13|2007-03-26|2007-03-27|Estimate|2010-05-03|2010-05-26|Estimate||||2011-09-13|2011-09-16|Estimate|May 2007||2007-05-31|September 2011|2011-09-30|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|||Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)|Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)|Terminated||Phase 2|22|Actual|Accelerated Community Oncology Research Network|Early termination, according to the stopping rule included in the protocol, leading to a small number of subjects analyzed|||Early stopping rule|f||||f||||||||||2018-06-01 03:20:39.020144|2018-06-01 03:20:39.020144
NCT00452374|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|2011-07-28||2011-10-25|2007-03-26|2007-03-27|Estimate|2011-07-28|2011-08-29|Estimate||||2011-10-25|2011-11-02|Estimate|November 2004||2004-11-30|October 2011|2011-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL|A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|48|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:20:39.512413|2018-06-01 03:20:39.512413
NCT00452361|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|2009-09-24||2012-07-27|2007-03-26|2007-03-27|Estimate|2012-07-27|2012-09-03|Estimate||||2012-07-27|2012-09-03|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient|A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipient|Terminated||Phase 4|31|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Study terminated early due to difficulties in enrolling qualified patients. No patients completed 104 weeks (primary outcome); a few completed 60 weeks. Insufficient data were available for efficacy analyses.|2|||f||||f||||||||||2018-06-01 03:20:39.788824|2018-06-01 03:20:39.788824
NCT00452348|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2010-01-20||2016-10-27|2007-03-26|2007-03-27|Estimate|2010-01-20|2010-02-15|Estimate||||2016-10-27|2016-12-09|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma|A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma|Completed||Phase 4|628|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:20:40.237224|2018-06-01 03:20:40.237224
NCT00452335|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|2016-02-16|2009-10-21|2016-07-12|2007-03-26|2007-03-27|Estimate|2016-07-12|2016-08-22|Estimate|2009-10-21|2010-02-19|Estimate|2016-07-12|2016-08-22|Estimate|January 2007||2007-01-31|July 2016|2016-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation|A Multi-center, Open-labeled Study of the Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients With Constipation|Completed||Phase 4|127|Actual|Sucampo Pharma Americas, LLC||3|||f||||f||||||||||2018-06-01 03:20:40.802073|2018-06-01 03:20:40.802073
NCT00452322|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-03-26|2007-03-26|2007-03-27|Estimate|||||||2007-03-26|2007-03-27|Estimate|April 1997||1997-04-30|March 2007|2007-03-31|January 2007|Actual|2007-01-31|||||Interventional|||Safety of Testosterone Undecanoate i.m. in Hypogonadal Men|Long-Term Intervention Phase 2 Study of Safety Aspects of Testosterone Undecanoate i.m. in Hypogonadal Men|Completed||Phase 2|60||University Hospital Muenster|||||f||||t||||||||||2018-06-01 03:20:42.14419|2018-06-01 03:20:42.14419
NCT00452309|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-25|||2007-09-25|2007-03-26|2007-03-27|Estimate|||||||2007-09-25|2007-09-26|Estimate|March 2007||2007-03-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Observational|||Validation of a Correction Factor for Measurement of an Accurate Ankle-Brachial Index in the Seated Position|Validation of a Correction Factor for Measurement of an Accurate Ankle-Brachial Index in the Seated Position|Completed|||50|Anticipated|The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:20:42.201031|2018-06-01 03:20:42.201031
NCT00452296|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-25|||2012-06-25|2007-03-26|2007-03-27|Estimate|||||||2012-06-25|2012-06-26|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|May 2010|Actual|2010-05-31||Interventional|||Tight Glycemic Control in Acute Exacerbations of COPD|Tight Glycemic Control in Acute Exacerbations of COPD|Unknown status|Active, not recruiting|N/A|84|Anticipated|Soroka University Medical Center|||||f||||f||||||||||2018-06-01 03:20:42.254883|2018-06-01 03:20:42.254883
NCT00452283|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2013-01-29|2007-03-26|2007-03-27|Estimate|||||||2013-01-29|2013-01-31|Estimate|March 2007||2007-03-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy|The Effect of a Systemic Non-selective Endothelin Antagonist on Intraocular Pressure and Anterior Depth in Pulmonary Hypertension Patients.|Completed|||23|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-06-01 03:20:42.311629|2018-06-01 03:20:42.311629
NCT00452270|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-05-02|2007-03-26|2007-03-27|Estimate|||||||2007-05-02|2007-05-03|Estimate|March 2007||2007-03-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold|A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study, Evaluating the Decongestant Effect, Time to Onset, Duration of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold|Completed||Phase 3|60||Novartis|||||f||||f||||||||||2018-06-01 03:20:42.362137|2018-06-01 03:20:42.362137
NCT00452257|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2009-03-18|2007-03-23|2007-03-27|Estimate|||||||2009-03-18|2009-03-19|Estimate|May 2007||2007-05-31|March 2009|2009-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of Enzastaurin in Patients With Leukemia|A Phase 1b Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Completed||Phase 1|18|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:20:42.420966|2018-06-01 03:20:42.420966
NCT00452244|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2017-08-24|2007-03-26|2007-03-27|Estimate|||||||2017-08-24|2017-08-25|Actual|May 2006||2006-05-31|August 2017|2017-08-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)|Randomized Phase II Trail Comparing Gefitinib Plus Simvastatin and Gefitinib Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|110|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 03:20:42.580823|2018-06-01 03:20:42.580823
NCT00452231|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2007-03-26|2007-03-26|2007-03-27|Estimate|||||||2007-03-26|2007-03-27|Estimate|February 2007||2007-02-28|March 2007|2007-03-31|July 2008|Anticipated|2008-07-31|||||Interventional|||RCT of CBT Combined With D-Cycloserine for Treating PTSD|Comparative Study of the Efficacy of a Cognitive-Behavioral Therapy for Post-Traumatic Stress Disorder With or Without D-Cycloserine|Unknown status|Recruiting|Phase 2/Phase 3|20||Université de Montréal|||||f||||t||||||||||2018-06-01 03:20:42.659001|2018-06-01 03:20:42.659001
NCT00452218|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2016-08-23|2007-03-26|2007-03-27|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)|Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 1|12|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 03:20:42.733228|2018-06-01 03:20:42.733228
NCT00452205|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2009-08-03|2007-03-26|2007-03-27|Estimate|||||||2009-08-03|2009-08-04|Estimate|April 2007||2007-04-30|August 2009|2009-08-31|March 2017|Anticipated|2017-03-31|||||Observational|||Bone Marrow-derived Cells' Contribution to Tumor Formation and Inflammation|Bone Marrow-derived Cells' Contribution to Tumor Formation and Epithelial Cells Regeneration in the Gastrointestinal Tract|Unknown status|Recruiting||300|Anticipated|Komagome Hospital|||||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-06-01 03:20:42.814932|2018-06-01 03:20:42.814932
NCT00452192|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2012-07-06|2007-03-26|2007-03-27|Estimate|||||||2012-07-06|2012-07-10|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome|Detailed Analysis of the Effects of Telmisartan on Renal Perfusion in Patients With Metabolic Syndrome|Completed||Phase 3|30|Actual|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 03:20:42.896163|2018-06-01 03:20:42.896163
NCT00452179|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2007-09-06|2007-03-26|2007-03-27|Estimate|||||||2007-09-06|2007-09-10|Estimate|February 2007||2007-02-28|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|||Safety and Efficacy Study of APD125 in Patient With Insomnia|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Effects of APD125 in Patients With Chronic Primary Insomnia|Completed||Phase 2|173|Actual|Arena Pharmaceuticals|||||||||||||||||||2018-06-01 03:20:42.971745|2018-06-01 03:20:42.971745
NCT00452166|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2008-09-30|2007-03-26|2007-03-27|Estimate|||||||2008-09-30|2008-10-02|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Rosiglitazone and Insulin Resistance in Renally Impaired Patients|Rosiglitazone and Insulin Resistance in Renally Impaired Patients|Terminated||Phase 3|30|Anticipated|Leiden University Medical Center||||it was not possible to recruit new patients anymore|f||||t||||||||||2018-06-01 03:20:43.062717|2018-06-01 03:20:43.062717
NCT00452153|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2015-07-28|2007-03-26|2007-03-27|Estimate|||||||2015-07-28|2015-07-29|Estimate|March 2007||2007-03-31|July 2015|2015-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis|Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis|Terminated||N/A|200|Actual|Centre Hospitalier Universitaire de Saint Etienne||1||Too much difficulties to includ patient|f||||f||||||||||2018-06-01 03:20:43.13349|2018-06-01 03:20:43.13349
NCT00452140|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-26|||2009-05-18|2007-03-26|2007-03-27|Estimate|||||||2009-05-18|2009-05-19|Estimate|March 2007||2007-03-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|||||Interventional|||Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment|Phase II Study for Repeated Dosing of the Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab in Patients With HER-2/Neu 1+ or 2+/FISH Negative Expressing Advanced or Metastatic Breast Cancer (Stage IIIb/IV) Progressing After Endocrine Treatment|Terminated||Phase 2|40|Anticipated|Neovii Biotech||||company focus on other projects|f||||t||||||||||2018-06-01 03:20:43.228037|2018-06-01 03:20:43.228037
NCT00452127|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23||2013-01-18|2013-01-18|2007-03-23|2007-03-27|Estimate||||2013-01-18|2013-01-28|Estimate|2013-01-18|2013-01-28|Estimate|May 2007||2007-05-31|January 2013|2013-01-31||||May 2009|Actual|2009-05-31||Interventional|||A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Have Been Treated With a Prior Rituximab-Containing Regimen|Terminated||Phase 1/Phase 2|26|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:20:43.306091|2018-06-01 03:20:43.306091
NCT00452114|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|2013-01-30||2018-03-15|2007-03-22|2007-03-26|Estimate|2013-01-30|2013-03-06|Estimate||||2018-03-15|2018-04-12|Actual|April 2004||2004-04-30|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||In-exsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis|A Randomized, Controlled Study Evaluating the Effectiveness of the Inexsufflator Cough Assist Device in Patients With Symptomatic Bronchiectasis|Terminated||N/A|28|Actual|University of Massachusetts, Worcester||2||interim analysis indicates statistical futility for primary outcomes|f||||f||||||||||2018-06-01 03:20:43.371409|2018-06-01 03:20:43.371409
NCT00452101|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-26|Estimate|||||||2007-03-22|2007-03-26|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|December 2006|Actual|2006-12-31|||||Interventional|||Effects of Aquamin F on Osteoarthritis of the Knee|Randomized, Placebo Controlled Trial: Effects of Aquamin F Alone or in Combination With Glucosamine Sulfate on Joint Mobility and Pain in Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|70||Marigot Ltd.|||||f||||f||||||||||2018-06-01 03:20:43.60184|2018-06-01 03:20:43.60184
NCT00452088|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2008-05-06|2007-03-23|2007-03-26|Estimate|||||||2008-05-06|2008-05-07|Estimate|April 2007||2007-04-30|November 2007|2007-11-30|May 2008|Anticipated|2008-05-31|May 2008|Anticipated|2008-05-31||Interventional|MSP3LSP||A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso|Randomized, Controlled, Dose Escalation Phase Ib Trial of MSP 3 LSP Adjuvanted in Aluminium Hydroxide Versus Hepatitis Bin 12 to 24 Month Old Children in Burkina Faso.|Unknown status|Recruiting|Phase 1|45|Anticipated|African Malaria Network Trust||4|||f||||t||||||||||2018-06-01 03:20:43.658493|2018-06-01 03:20:43.658493
NCT00452075|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2014-12-10|2007-03-23|2007-03-26|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional|||Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy|A Phase II Study of Erlotinib and Predictive Markers as First-line Treatment of Advanced Non-small Cell Lung Cancer for Patients Unfit for Chemotherapy|Terminated||Phase 2|24|Actual|Rigshospitalet, Denmark||1||Poor recruitment|f||||t||||||||||2018-06-01 03:20:43.752565|2018-06-01 03:20:43.752565
NCT00452062|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2007-03-23|2007-03-23|2007-03-26|Estimate|||||||2007-03-23|2007-03-26|Estimate|October 2004||2004-10-31|March 2007|2007-03-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Dexamethasone and the Prevention of Post-Extubation Airway Obstruction in Adults|Mackay Memorial Hospital|Unknown status|Recruiting|Phase 2|70||Mackay Memorial Hospital|||||f||||t||||||||||2018-06-01 03:20:43.917855|2018-06-01 03:20:43.917855
NCT00452049|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2012-05-28|2007-03-23|2007-03-26|Estimate|||||||2012-05-28|2012-05-30|Estimate|April 2005||2005-04-30|May 2012|2012-05-31||||||||Observational|||The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure|Observational Study to Evaluate the Effect of Parathyroidectomy on Renal Function, Endothelial Function and Blood Pressure|Unknown status|Recruiting||20|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-06-01 03:20:43.998371|2018-06-01 03:20:43.998371
NCT00452036|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2010-07-26|2007-03-23|2007-03-26|Estimate|||||||2010-07-26|2010-07-27|Estimate|December 2004||2004-12-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|||||Observational|||Diagnostic Algorithm in Patients With Minor Head Injury|Prospective Study to Find a Diagnostic Algorithm for Diagnosis of Minor Head Injury|Completed|||12500|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-06-01 03:20:44.060535|2018-06-01 03:20:44.060535
NCT00452023|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2018-01-05|2007-03-22|2007-03-26|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2005|Actual|2005-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pegasys® in Patients With Myeloproliferative Diseases|PEG IFN-alpha2a (Pegasys®) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia)|Active, not recruiting||Phase 2|280|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:20:44.131626|2018-06-01 03:20:44.131626
NCT00452010|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2012-07-03|2007-03-23|2007-03-26|Estimate|||||||2012-07-03|2012-07-04|Estimate|September 2006||2006-09-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|LOBOTENS||Pain Reducing Effect of Transcutaneous Electrical Nerve Stimulation in Patients With Chronic Low Back Pain or Lumbo-radiculalgia|Pain Reducing Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Chronic Low Back Pain or Chronic Lumbo-radiculalgia and Followed in Pain Treatment Centers|Completed||Phase 4|236|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-06-01 03:20:44.216921|2018-06-01 03:20:44.216921
NCT00451997|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2012-07-31|2007-03-23|2007-03-26|Estimate|||||||2012-07-31|2012-08-01|Estimate|March 2004||2004-03-31|July 2012|2012-07-31|April 2007|Actual|2007-04-30|August 2005|Actual|2005-08-31||Interventional|||Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes|Phase II Trial of Gleevec and Low-Dose Ara-C for Elderly Patients With C-Kit Positive Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes|Completed||Phase 2|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:20:44.312329|2018-06-01 03:20:44.312329
NCT00451984|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2007-10-31|2007-03-23|2007-03-26|Estimate|||||||2007-10-31|2007-11-01|Estimate|March 2007||2007-03-31|October 2007|2007-10-31||||||||Interventional|HEPVACHIV||Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2||Unknown status|Recruiting|Phase 3|80|Anticipated|Aalborg Universitetshospital|||||f||||f||||||||||2018-06-01 03:20:44.402419|2018-06-01 03:20:44.402419
NCT00451971|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2008-09-04|2007-03-23|2007-03-26|Estimate|||||||2008-09-04|2008-09-05|Estimate|March 2002||2002-03-31|September 2008|2008-09-30||||||||Interventional|OSRA||Objective Study in Rheumatoid Arthritis|Objective Study in Rheumatoid Arthritis|Completed||Phase 4|249|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:20:44.481507|2018-06-01 03:20:44.481507
NCT00451958|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|2012-10-10||2013-03-20|2007-03-23|2007-03-26|Estimate|2013-03-20|2013-03-21|Estimate||||2013-03-20|2013-03-21|Estimate|March 2007||2007-03-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional||CS21A intention-to-treat (ITT) population.|A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy|An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients With Prostate Cancer Requiring Androgen Ablation Therapy|Completed||Phase 3|386|Actual|Ferring Pharmaceuticals||4|||f||||t||||||||||2018-06-01 03:20:44.624195|2018-06-01 03:20:44.624195
NCT00451945|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2008-06-17|2007-03-23|2007-03-26|Estimate|||||||2008-06-17|2008-06-18|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|March 2008||2008-03-31|||||Interventional|||New Indications for Ultrasound in the Staging of Cervical Cancer|New Indications for Ultrasound in the Staging of Cervical Cancer|Withdrawn||N/A|||Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 03:20:46.656479|2018-06-01 03:20:46.656479
NCT00451932|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2008-04-15|2007-03-23|2007-03-26|Estimate|||||||2008-04-15|2008-04-17|Estimate|October 2002||2002-10-31|April 2008|2008-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study to Evaluate the Safety and Effectiveness of FK778 in Liver Transplant Patients|A Multicentre, Randomised, Double-Blind, Tacrolimus Dual Therapy-Controlled, Parallel Group, Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of FK778 in Liver Transplant Patients Receiving Standard Tacrolimus (FK506) and Steroids Therapy|Completed||Phase 2|303|Actual|Astellas Pharma Inc|||||f||||t||||||||||2018-06-01 03:20:46.721967|2018-06-01 03:20:46.721967
NCT00451919|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2016-08-18|2007-03-23|2007-03-26|Estimate|||||||2016-08-18|2016-08-19|Estimate|July 2006||2006-07-31|October 2013|2013-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||The Link Between Anemia and Deficits in Memory and Attention in Individuals With Sickle Cell Disease|Sickle-Cell Disease: Neuroimaging and Cognitive Decline|Completed|||120|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:20:46.816843|2018-06-01 03:20:46.816843
NCT00451906|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|2016-03-23||2016-04-25|2007-03-22|2007-03-26|Estimate|2016-03-23|2016-04-25|Estimate||||2016-04-25|2016-05-24|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Baseline characteristics were described for the intent-to-treat (ITT) population, which included all participants with at least one valid post-baseline (Day -28 to -1) assessment.|A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.|Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer|Completed||Phase 4|2252|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:20:46.979567|2018-06-01 03:20:46.979567
NCT00451893|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2016-05-31|2007-03-23|2007-03-26|Estimate|||||||2016-05-31|2016-06-01|Estimate|December 2006||2006-12-31|May 2016|2016-05-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Interventional|LJUNO||The Significance of the Mesh Thickness in the Operation of Inguinal Hernia|An Expertise-based Multicentre Randomized Controlled Trial Comparing a Heavy-weight and a Light-weight Mesh in the Operation of Inguinal Hernia|Unknown status|Active, not recruiting|Phase 2/Phase 3|400|Anticipated|Umeå University||2|||f||||f||||||||||2018-06-01 03:20:48.506226|2018-06-01 03:20:48.506226
NCT00451880|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2011-10-11|2007-03-23|2007-03-26|Estimate|||||||2011-10-11|2011-10-13|Estimate|February 2007||2007-02-28|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of XL281 in Adults With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors|Completed||Phase 1|180|Anticipated|Exelixis||3|||f||||||||||||||2018-06-01 03:20:48.574682|2018-06-01 03:20:48.574682
NCT00451867|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2010-01-12|2007-03-23|2007-03-26|Estimate|||||||2010-01-12|2010-01-14|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|April 2008|Anticipated|2008-04-30|February 2008|Actual|2008-02-29||Interventional|ICCRN RCT2||A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .|A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Mycophenolate Mofetil (CellCept) for the Treatment of Refractory Interstitial Cystitis (IC)|Terminated||Phase 3|210|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||"The major and primary reason for the study termination is the observed reduced efficacy of~   CellCept compared to placebo."|f||||t||||||||||2018-06-01 03:20:48.650495|2018-06-01 03:20:48.650495
NCT00451841|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2018-02-14|2007-03-23|2007-03-26|Estimate|||||||2018-02-14|2018-02-16|Estimate|March 2007||2007-03-31|February 2018|2018-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux|Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux|Terminated|||30|Anticipated|University of Massachusetts, Worcester|||2|"IRB approval not renewed/approval lapsed. Prior status: insufficient enrollment; study~   suspended pending analysis"|f||||f||||||Samples Without DNA|"~     frozen sputum supernatant and exhaled breath condensate fixed sputum cell preparations~   "|||2018-06-01 03:20:48.803581|2018-06-01 03:20:48.803581
NCT00451828|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2011-10-04|2007-03-23|2007-03-26|Estimate|||||||2011-10-04|2011-10-05|Estimate|March 2002||2002-03-31|October 2011|2011-10-31||||October 2004|Actual|2004-10-31||Interventional|CAP||Cholesterol and Pharmacogenetic Study|Cholesterol and Pharmacogenetic Study|Completed||Phase 4|1000|Anticipated|Children's Hospital & Research Center Oakland|||||f||||t||||||||||2018-06-01 03:20:48.865253|2018-06-01 03:20:48.865253
NCT00451815|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2007-03-23|2007-03-23|2007-03-26|Estimate|||||||2007-03-23|2007-03-26|Estimate||||March 2007|2007-03-31||||||||Interventional|||BIIB014 Phase 2a Monotherapy|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson’s Disease|Withdrawn||Phase 2|||Biogen|||||f||||||||||||||2018-06-01 03:20:49.071436|2018-06-01 03:20:49.071436
NCT00451802|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-23|2007-03-23|2007-03-26|Estimate|||||||2007-03-23|2007-03-26|Estimate|January 2003||2003-01-31|January 2005|2005-01-31|December 2005||2005-12-31|||||Observational|||A Pilot Scheme - Specimen Collection of Health Management Center|A Pilot Scheme - Specimen Collection of Health Management Center|Completed|||7000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:20:49.137907|2018-06-01 03:20:49.137907
NCT00451789|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-23|||2007-03-23|2007-03-23|2007-03-26|Estimate|||||||2007-03-23|2007-03-26|Estimate|December 2004||2004-12-31|March 2007|2007-03-31|April 2006|Actual|2006-04-30|||||Observational|||Risk Factors of Minor Head Injury|Risk Factors of Minor Head Injury in Traumatological Patients|Completed|||12500||Medical University of Vienna|||||f||||f||||||||||2018-06-01 03:20:49.189273|2018-06-01 03:20:49.189273
NCT00451776|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2008-10-29|2007-03-22|2007-03-23|Estimate|||||||2008-10-29|2008-10-31|Estimate|June 2007||2007-06-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC|Post Operative Hemodynamic Function After Anesthetic Induction With Etomidate for Cardiac Surgery With ECC. A Prospective, Monocentric, Randomised Double Blind Study|Completed||Phase 4|100|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t||||||||||2018-06-01 03:20:49.246316|2018-06-01 03:20:49.246316
NCT00451763|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2008-07-21|2007-03-21|2007-03-23|Estimate|||||||2008-07-21|2008-07-23|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia|Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia|Completed||Phase 3|31|Actual|University of Sao Paulo|||||f||||t||||||||||2018-06-01 03:20:49.320988|2018-06-01 03:20:49.320988
NCT00451750|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2010-01-11|2007-03-21|2007-03-23|Estimate|||||||2010-01-11|2010-01-12|Estimate|May 2007||2007-05-31|January 2010|2010-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Cortisol in the Treatment of Phobias|The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias|Completed||N/A|40|Anticipated|University of Zurich|||||f||||||||||||||2018-06-01 03:20:49.387195|2018-06-01 03:20:49.387195
NCT00451737|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate|November 2006||2006-11-30|January 2006|2006-01-31|March 2007|Anticipated|2007-03-31|||||Interventional|||Correlation of 6-Minute Walk Test and Neuromuscular Parameters in the Elderly|Correlation of 6-Minute Walk Test and Neuromuscular Parameters in the Elderly: Knee Proprioception, Standing Balance, Quadriceps Muscle Strength, Endurance, and Torque Acceleration Energy|Unknown status|Recruiting|Phase 1|100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:20:49.447369|2018-06-01 03:20:49.447369
NCT00451724|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2010-07-21|2007-03-21|2007-03-23|Estimate|||||||2010-07-21|2010-07-22|Estimate|May 2007||2007-05-31|July 2010|2010-07-31|February 2010|Actual|2010-02-28|||||Interventional|||Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair|Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair|Completed||Phase 2|45|Anticipated|Rhode Island Hospital|||||f||||t||||||||||2018-06-01 03:20:49.506468|2018-06-01 03:20:49.506468
NCT00451711|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2013-12-12|2007-03-21|2007-03-23|Estimate|||||||2013-12-12|2013-12-16|Estimate|May 2007||2007-05-31|March 2007|2007-03-31|October 2014|Anticipated|2014-10-31|||||Interventional|||Intermittent Liposomal Amphotericin B Primary Prophylaxis|A Randomised, Stratified, Open Label, Phase II Pilot Study on the Safety of a Daily, Intermittent, or Weekly Administration of 1, 3 or 10mg/kg of AmBisome® in Antifungal Primary Prophylaxis of High-Risk Patients With Acute Myeloid Leukaemia|Unknown status|Recruiting|Phase 2|60|Anticipated|Bayside Health|||||f||||t||||||||||2018-06-01 03:20:49.643086|2018-06-01 03:20:49.643086
NCT00451698|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|2013-03-21||2013-07-25|2007-03-22|2007-03-23|Estimate|2013-06-11|2013-07-16|Estimate||||2013-07-25|2013-07-31|Estimate|October 2007||2007-10-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|EPO||Erythropoietin and Pediatric Cardiac Surgery|Erythropoietin and Pediatric Cardiac Surgery|Terminated||N/A|9|Actual|Medical College of Wisconsin|Data for all recruited patients was included with available results. The number of participants fell far short of study goals and the study was terminated prematurely due to inadequate enrollment.|2||Inadequate patient enrollment|f||||t||||||||||2018-06-01 03:20:49.737791|2018-06-01 03:20:49.737791
NCT00451672|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate|January 2007||2007-01-31|December 2006|2006-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|||The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism||Unknown status|Recruiting|Phase 4|25||National Taiwan University Hospital|||||t||||f||||||||||2018-06-01 03:20:49.970806|2018-06-01 03:20:49.970806
NCT00451659|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-03-21|2007-03-21|2007-03-23|Estimate|||||||2007-03-21|2007-03-23|Estimate|February 2005||2005-02-28|March 2007|2007-03-31|February 2007|Actual|2007-02-28|||||Observational|||Characterization of Recently Deployed Veterans|Characterization of Recently Deployed Veterans|Completed|||500||Tuscaloosa Research & Education Advancement Corporation|||||f||||f||||||||||2018-06-01 03:20:50.034967|2018-06-01 03:20:50.034967
NCT00451646|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2010-08-26|2007-03-22|2007-03-23|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition|A Double-blind, Randomised Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition|Completed||Phase 3|75|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 03:20:50.089127|2018-06-01 03:20:50.089127
NCT00013858|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-30|||2015-04-13|2001-04-02|2001-04-03|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 1997||1997-01-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Environmental Contaminants and Infant Development||Completed|||280|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:01.207674|2018-06-01 05:37:01.207674
NCT00451633|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2013-10-30|2007-03-21|2007-03-23|Estimate|||||||2013-10-30|2013-10-31|Estimate|March 2007||2007-03-31|October 2013|2013-10-31||||||||Interventional|||The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations|A Randomized, Double Blind, Placebo-Controlled Study To Investigate The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations|Withdrawn||Phase 2|0|Actual|Eisai Inc.||||"The study group changed from patients to a healthy volunteers. A healthy-volunteer study is~   being planned to replace 213."|f||||||||||||||2018-06-01 03:20:50.156291|2018-06-01 03:20:50.156291
NCT00451620|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2018-01-16|2007-03-22|2007-03-23|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2003||2003-11-30|January 2018|2018-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes|Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes|Completed||Phase 2|30|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:20:50.250474|2018-06-01 03:20:50.250474
NCT00451607|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2009-06-10|2007-03-22|2007-03-23|Estimate|||||||2009-06-10|2009-06-11|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Observational|||Environmental Stress and Individualized Sensorimotor Care on Autonomic Nervous System Activity in Premature Population|Evaluation of Environmental Stress and Individualized Sensorimotor Care on Autonomic Nervous System Activity in a Premature Population : a Prospective Study|Completed|||39|Actual|Centre Hospitalier Universitaire de Saint Etienne|||||f||||f||||||||||2018-06-01 03:20:50.33463|2018-06-01 03:20:50.33463
NCT00451594|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2011-01-12|2007-03-22|2007-03-23|Estimate|||||||2011-01-12|2011-01-13|Estimate|September 2005||2005-09-30|January 2011|2011-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP|A Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic Purpura|Completed||Phase 3|157|Actual|Cooperative Study Group A for Hematology|||||f||||t||||||||||2018-06-01 03:20:50.389448|2018-06-01 03:20:50.389448
NCT00451581|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate|January 2007||2007-01-31|October 2006|2006-10-31|January 2008|Anticipated|2008-01-31|||||Interventional|||A Prospective Randomized Study Comparing Different Dilation Durations for Endoscopic Papillary Balloon Dilatation|A Prospective Randomized Multicenter Study Comparing Different Dilation Durations During Endoscopic Papillary Balloon Dilatation for Bile Duct Stones.|Unknown status|Recruiting|N/A|160||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:20:50.452275|2018-06-01 03:20:50.452275
NCT00451568|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2015-04-10|2007-03-22|2007-03-23|Estimate|||||||2015-04-10|2015-04-13|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|January 2012|Actual|2012-01-31||Interventional|||Metformin and Oral Contraceptives in PCOS|Metformin and Oral Contraceptives in PCOS|Completed||Phase 4|90|Actual|Odense University Hospital||3|||f||||t||||||||||2018-06-01 03:20:50.521983|2018-06-01 03:20:50.521983
NCT00451555|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21||2011-04-05|2017-08-25|2007-03-21|2007-03-23|Estimate||||2011-04-05|2011-04-13|Estimate|2017-08-25|2017-08-29|Actual|March 2007||2007-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2010|Actual|2010-12-31||Interventional|||Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer|A Randomized, Double-Blind, Phase II Trial of Fulvestrant Plus Enzastaurin Versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer|Active, not recruiting||Phase 2|160|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:20:50.662839|2018-06-01 03:20:50.662839
NCT00451542|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2017-04-25|2007-03-21|2007-03-23|Estimate|||||||2017-04-25|2017-04-27|Actual|February 1, 2006|Actual|2006-02-01|April 2017|2017-04-30|February 1, 2008|Actual|2008-02-01|May 1, 2007|Actual|2007-05-01||Observational|||Divalproex vs. Lamotrigine for Bipolar Disorder|Time to Relapse During Treatment With Divalproex vs. Lamotrigine for Bipolar Disorder|Terminated|||1000|Actual|Tuscaloosa Research & Education Advancement Corporation||||Sample too small in retrospective chart review to conduct analysis|f||||f|f|f||||||No||2018-06-01 03:20:50.837603|2018-06-01 03:20:50.837603
NCT00451529|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2011-04-18|2007-03-22|2007-03-23|Estimate|||||||2011-04-18|2011-04-19|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|September 2011|Anticipated|2011-09-30|||||Observational|||Predictive Value for Stroke|Predictive Value of Magnetic Resonance Imaging (MRI), 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), and Microemboli Detection for Stroke|Unknown status|Recruiting||200|Anticipated|Dutch Heart Foundation|||||f||||t||||||||||2018-06-01 03:20:50.883146|2018-06-01 03:20:50.883146
NCT00451516|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2008-05-16|2007-03-22|2007-03-23|Estimate|||||||2008-05-16|2008-05-19|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety|St. John's Wort And Kava In The Treatment Of Major Depressive Disorder With Comorbid Anxiety|Completed||Phase 2|50|Anticipated|The University of Queensland|||||f||||f||||||||||2018-06-01 03:20:50.994955|2018-06-01 03:20:50.994955
NCT00451503|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2012-07-06|2007-03-22|2007-03-23|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|January 2011|Actual|2011-01-31||Interventional|||Evaluation of Middle Ear Implantation|Evaluation of Middle Ear Implants in the Therapeutic Strategy of Auditory Rehabilitation in Case of Failure of Conventional Hearing Aid|Completed||N/A|69|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:20:51.050173|2018-06-01 03:20:51.050173
NCT00451490|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-12-24|2007-03-22|2007-03-23|Estimate|||||||2007-12-24|2008-01-08|Estimate|October 2006||2006-10-31|January 2007|2007-01-31|December 2007|Anticipated|2007-12-31|||||Interventional|||The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder|The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder|Withdrawn||N/A|24|Anticipated|National Taiwan University Hospital||||This study not get the approval by the drug company|f||||t||||||||||2018-06-01 03:20:51.296752|2018-06-01 03:20:51.296752
NCT00451464|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate|January 2002||2002-01-31|July 2005|2005-07-31|January 2005||2005-01-31|||||Observational|||Studies of Apolipoprotein Genotyping on the Drug Treatment of Hyperlipidemic Patients|Studies of Apolipoprotein Genotyping on the Drug Treatment of Hyperlipidemic Patients|Completed|||600||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:20:51.515113|2018-06-01 03:20:51.515113
NCT00451451|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2014-05-05|2012-11-01|2015-01-13|2007-03-22|2007-03-23|Estimate|2014-05-05|2014-06-02|Estimate|2012-11-01|2012-11-05|Estimate|2015-01-13|2015-01-26|Estimate|June 2007||2007-06-30|January 2015|2015-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|CONFIRM||Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis|A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|1417|Actual|Biogen||4|||f||||t||||||||||2018-06-01 03:20:51.738783|2018-06-01 03:20:51.738783
NCT00451425|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2009-05-28|2007-03-22|2007-03-23|Estimate|||||||2009-05-28|2009-05-29|Estimate|May 2007||2007-05-31|May 2009|2009-05-31|October 2010|Anticipated|2010-10-31|December 2009|Anticipated|2009-12-31||Interventional|VIGA||Weight Gain During Pregnancy - a Randomized Controlled Trial of Intervention to Prevent Excessive Gestational Weight Gain|Weight Gain During Pregnancy - a Randomized Controlled Trial of Intervention to Prevent Excessive Gestational Weight Gain.|Unknown status|Recruiting|N/A|430|Anticipated|Region Örebro County||1|||f||||f||||||||||2018-06-01 03:20:53.517432|2018-06-01 03:20:53.517432
NCT00451412|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2012-07-24|2007-03-22|2007-03-23|Estimate|||||||2012-07-24|2012-07-25|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients|A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients|Completed||Phase 3|3254|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:20:53.703455|2018-06-01 03:20:53.703455
NCT00451399|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-10-30|2007-03-22|2007-03-23|Estimate|||||||2007-10-30|2007-10-31|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain|Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison|Completed||Phase 4|128||Central South University|||||t||||t||||||||||2018-06-01 03:20:53.819754|2018-06-01 03:20:53.819754
NCT00451386|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2017-02-16|2007-03-21|2007-03-23|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2002||2002-01-31|February 2017|2017-02-28|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)|A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Local Tolerability, and Clinical Outcome of Ertapenem Versus Ceftriaxone in Pediatric Patients With Complicated Urinary Tract Infection, Skin and Soft Tissue Infection, or Community-Acquired Pneumonia|Completed||Phase 2|400||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:20:53.882196|2018-06-01 03:20:53.882196
NCT00451373|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate|July 2006||2006-07-31|January 2007|2007-01-31|December 2012|Anticipated|2012-12-31|||||Interventional|||Acute Renal Failure in the Surgical Intense Care Units - NTUH-SICU-ARF (NSARF) Study||Unknown status|Recruiting|N/A|300||National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:20:54.080005|2018-06-01 03:20:54.080005
NCT00451360|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2008-07-24|2007-03-22|2007-03-23|Estimate|||||||2008-07-24|2008-07-25|Estimate|March 1993||1993-03-31|March 2007|2007-03-31|April 1997|Actual|1997-04-30|||||Interventional|ECHODIAH||Chondromodulating Effect of Diacerein in Osteoarthritis of the Hip|Evaluation of the CHOndromodulating Effect of DIAcerein in Osteoarthritis of the Hip. ECHODIAH.|Completed||Phase 3|500||Laboratoires NEGMA|||||f||||f||||||||||2018-06-01 03:20:54.22982|2018-06-01 03:20:54.22982
NCT00451347|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-03-21|2007-03-21|2007-03-23|Estimate|||||||2007-03-21|2007-03-23|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|August 2008|Anticipated|2008-08-31|||||Interventional|||Comparison of The Clinical Effects Between Different Physical Therapy Tools in Patellofemoral Pain Patients||Unknown status|Recruiting|Phase 1/Phase 2|90||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:20:54.43986|2018-06-01 03:20:54.43986
NCT00451334|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate||||November 2006|2006-11-30||||||||Observational|GS||Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement|Safety and Efficacy of Using GlucoSat Technology For Non-Invasive Glucose Measurement|Unknown status|Not yet recruiting||40||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:20:54.596769|2018-06-01 03:20:54.596769
NCT00451321|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2017-07-18|2012-11-15|2017-10-11|2007-03-22|2007-03-23|Estimate|2017-10-11|2017-11-13|Actual|2012-11-15|2012-11-20|Estimate|2017-10-11|2017-11-13|Actual|July 31, 2006|Actual|2006-07-31|October 2017|2017-10-31|December 1, 2011|Actual|2011-12-01|December 1, 2011|Actual|2011-12-01||Interventional|TTEDD|Participants from all 7 cohorts who had received a total dose <3.0 mg were analyzed as a separate treatment group. All other participants were analyzed according to the planned dose based on the cohort they belonged to.|TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)|TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD)|Terminated||Phase 2|88|Actual|GlaxoSmithKline|This study was terminated on 15 December 2011|1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:20:54.986754|2018-06-01 03:20:54.986754
NCT00451308|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2013-07-31|2007-03-22|2007-03-23|Estimate|||||||2013-07-31|2013-08-02|Estimate|November 2006||2006-11-30|July 2013|2013-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Induction of Labor With a Foley Balloon Catheter: Inflation With 30ml Compared to 60ml|Induction of Labor With a Foley Catheter Balloon: A Randomized Trial Comparing Inflation With 30ml and 60ml|Completed||Phase 4|192|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 03:20:59.297118|2018-06-01 03:20:59.297118
NCT00451295|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2011-11-13|2007-03-22|2007-03-23|Estimate|||||||2011-11-13|2011-11-15|Estimate|May 2007||2007-05-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia|A Phase III, Double-Blind, Multi-Centre, Randomised, Parallel Group Design, Placebo-Controlled, Flexible Dose Study of MCI-196 in Combination With a Ca-Based Phosphate Binder in CKD Stage V Subjects on Dialysis With Hyperphosphatemia.|Terminated||Phase 3|6|Actual|Mitsubishi Tanabe Pharma Corporation||2||This study was stopped because of insufficient enrollment.|f||||f||||||||||2018-06-01 03:20:59.38212|2018-06-01 03:20:59.38212
NCT00451282|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|2010-12-23||2015-04-02|2007-03-22|2007-03-23|Estimate|2015-04-02|2015-04-20|Estimate||||2015-04-02|2015-04-20|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Stepped Preventive Care to Reduce the Impact of Acute Pediatric Injury|Stepped Preventive Care to Reduce the Impact of Acute Pediatric Injury|Completed||Phase 3|290|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-06-01 03:20:59.493958|2018-06-01 03:20:59.493958
NCT00451269|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2011-02-18|2007-03-22|2007-03-23|Estimate|||||||2011-02-18|2011-02-21|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|TDR-PALU||Evaluation of Rapid Diagnosis Tests in Imported Malaria|Multicentric Evaluation of Rapid Diagnosis Tests for the Diagnosis of Imported Malaria.|Completed|||1297|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 03:20:59.806676|2018-06-01 03:20:59.806676
NCT00450710|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2014-08-21|2007-03-21|2007-03-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|March 2006||2006-03-31|August 2014|2014-08-31|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Neuroendocrine Brake for Type 2 Diabetes Mellitus|Phase IV Study of Neuroendocrine Brake Surgical Procedure for Type 2 Diabetes Mellitus|Completed||Phase 4|40||Medtronic - MITG|||||f||||||||||||||2018-06-01 03:21:05.520545|2018-06-01 03:21:05.520545
NCT00451256|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2009-07-06|2007-03-21|2007-03-23|Estimate|||||||2009-07-06|2009-07-08|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)|Clinical Study to Assess the Safety and Efficacy of ex-Vivo Vein Graft Exposure to AVI-5126 in Coronary Artery By-Pass Grafting to Reduce Clinical Graft Failure|Terminated||Phase 2|600|Anticipated|Sarepta Therapeutics||||Protocol-defined outcome in terms of efficacy would not be achieved.|f||||t||||||||||2018-06-01 03:20:59.860299|2018-06-01 03:20:59.860299
NCT00451243|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate|January 2005||2005-01-31|December 2004|2004-12-31|June 2005||2005-06-30|||||Observational|||Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment|Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatmen|Completed|||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:20:59.913384|2018-06-01 03:20:59.913384
NCT00451230|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2017-01-17|2007-03-22|2007-03-23|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2005||2005-06-30|October 2002|2002-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Metabolic Effects of Cocaine|Elucidating the Role of the Hypothalamic-Pituitary-Adrenal (HPA) Axis in the Mechanisms Underlying Cocaine Dependence|Completed||N/A|15||National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 03:20:59.950238|2018-06-01 03:20:59.950238
NCT00451217|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2017-06-14|2007-03-22|2007-03-23|Estimate|||||||2017-06-14|2017-06-16|Actual|November 17, 2005|Actual|2005-11-17|June 2017|2017-06-30|March 6, 2006|Actual|2006-03-06|March 6, 2006|Actual|2006-03-06||Interventional|||Comparison of Org 25969 With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (19.4.301)(P05960)|A Multi -Center Randomized Parallel Group Comparative Active Controlled Safety Assessor Blinded Phase 3a Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agents of a Neuromuscular Block Induced by Rocuronium or Vecuronium at Reappearance of T2|Completed||Phase 3|198|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:21:00.000025|2018-06-01 03:21:00.000025
NCT00451204|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|2016-01-20||2016-05-10|2007-03-22|2007-03-23|Estimate|2016-05-10|2016-06-16|Estimate||||2016-05-10|2016-06-16|Estimate|March 2007||2007-03-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Estriol-MS|Relapsing remitting multiple sclerosis women aged 18 to 50 years.|A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)|A Combination Trial of Copaxone Plus Estriol in RRMS|Completed||Phase 2|158|Actual|University of California, Los Angeles||2|||f||||t||||||||Yes|Investigators interested in further research using the data should contact Dr. Voskuhl with proposed plans and request.|2018-06-01 03:21:00.110491|2018-06-01 03:21:00.110491
NCT00451191|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2013-06-20||2013-06-20|2007-03-22|2007-03-23|Estimate|2013-06-20|2013-06-24|Estimate||||2013-06-20|2013-06-24|Estimate|October 2006||2006-10-31|June 2013|2013-06-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|MIST2||Botulinum Toxin Injection for the Management of BPH|Intraprostatic Injection of Botulinum Toxin for the Management of Benign Prostatic Hyperplasia: A Randomized Phase II Trial|Completed||Phase 2|134|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|First, this study was not designed to compare the effect of onabotulinum toxin A to placebo. Second, we assessed our primary outcome, treatment efficacy, at 3 months post-injection. The long-term safety of this product should also be evaluated.|2|||f||||t||||||||||2018-06-01 03:21:00.792442|2018-06-01 03:21:00.792442
NCT00451178|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21||2012-05-24|2013-03-26|2007-03-21|2007-03-23|Estimate||||2012-05-24|2012-06-01|Estimate|2013-03-26|2013-04-02|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|||An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only|An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma|Completed||Phase 2|100|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:21:01.04148|2018-06-01 03:21:01.04148
NCT00451165|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2010-04-14|2007-03-22|2007-03-23|Estimate|||||||2010-04-14|2010-04-15|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Bowel, Urinary and Sexual Function After Laparoscopic Colorectal Surgery|Outcome Study of Bowel, Urinary and Sexual Function After Laparoscopic Colorectal Surgery, Using Questionnaire and Function Tests|Completed|||36|Actual|Kyoto University|||2||f||||f||||||||||2018-06-01 03:21:01.217879|2018-06-01 03:21:01.217879
NCT00451152|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21||2012-11-27|2012-11-27|2007-03-21|2007-03-23|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|March 2007||2007-03-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma|A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma|Completed||Phase 2|89|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 03:21:01.293827|2018-06-01 03:21:01.293827
NCT00451139|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate||||March 2007|2007-03-31||||||||Interventional|||Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials||Completed||Phase 4|||Jimma University|||||f||||||||||||||2018-06-01 03:21:01.365645|2018-06-01 03:21:01.365645
NCT00451126|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2007-03-22|2007-03-22|2007-03-23|Estimate|||||||2007-03-22|2007-03-23|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|January 2006|Actual|2006-01-31|||||Observational|cortpersonal||Moderating Impact of Various Emotion Personality Factors on Salivary Cortisol Response to a TSST|Moderating Impact of Various Emotion Personality Factors on Salivary Cortisol|Completed|||58||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||t||||||||||2018-06-01 03:21:01.425278|2018-06-01 03:21:01.425278
NCT00451113|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2018-01-16|2007-03-21|2007-03-23|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2006||2006-11-30|January 2018|2018-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Sitagliptin in the Elderly|Sitagliptin in the Elderly|Completed||Phase 2|12|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:21:01.48438|2018-06-01 03:21:01.48438
NCT00451100|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2017-08-18|2007-03-22|2007-03-23|Estimate|||||||2017-08-18|2017-08-22|Actual|November 10, 2005|Actual|2005-11-10|August 2017|2017-08-31|August 29, 2006|Actual|2006-08-29|May 22, 2006|Actual|2006-05-22||Interventional|||Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)|Comparison of Rocuronium and Org25969 With Cisatracurium and Neostigmine When Neuromuscular Block is Reversed at Reappearance of T2|Completed||Phase 3|84|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:21:01.560196|2018-06-01 03:21:01.560196
NCT00451087|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-22|||2008-01-28|2007-03-22|2007-03-23|Estimate|||||||2008-01-28|2008-01-30|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|September 2009|Anticipated|2009-09-30|March 2007|Actual|2007-03-31||Interventional|||Comparisons of Mechanical Properties of Tendon Structures|Phase 1 Study: Comparison of Electromechanical Delay Phase 2 Study: Research in Viscoelasticity of Tendon Structures Phase 3 Study: Effects of Exercise Training in the Mechanical Properties|Unknown status|Recruiting|Phase 1|120|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 03:21:01.637453|2018-06-01 03:21:01.637453
NCT00451074|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2012-03-22|2007-03-21|2007-03-23|Estimate|||||||2012-03-22|2012-03-23|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons|A Six Month Randomized, Clinical Trial of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon Mutations|Completed||Phase 1|12|Actual|Nationwide Children's Hospital|||||f||||t||||||||||2018-06-01 03:21:01.718991|2018-06-01 03:21:01.718991
NCT00451061|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2012-07-11|2007-03-21|2007-03-22|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2007||2007-04-30|February 2007|2007-02-28||||||||Interventional|||The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones||Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Soroka University Medical Center|||||f||||f||||||||||2018-06-01 03:21:01.797217|2018-06-01 03:21:01.797217
NCT00451048|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2014-08-20||2015-12-03|2007-03-20|2007-03-22|Estimate|2014-08-20|2014-09-01|Estimate||||2015-12-03|2015-12-07|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|October 2012|Actual|2012-10-31|September 2011|Actual|2011-09-30||Interventional|||Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia|A Phase II Study of Sunitinib Malate (Sutent®; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|Completed||Phase 2|10|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:21:01.880467|2018-06-01 03:21:01.880467
NCT00451035|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-11-16|2007-03-20|2007-03-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2007||2007-01-31|November 2016|2016-11-30||||September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase|A Phase II, Multicentre Study of Oral LBH589 in Patients With Chronic Phase Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors|Completed||Phase 2/Phase 3|29|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:21:02.061935|2018-06-01 03:21:02.061935
NCT00451022|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2017-11-07|2007-03-20|2007-03-22|Estimate|||||||2017-11-07|2017-11-08|Actual|September 1, 2004||2004-09-01|October 30, 2017|2017-10-30||||||||Observational|||Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies|Follow-Up of Study Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:21:02.151011|2018-06-01 03:21:02.151011
NCT00451009|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2014-05-28|2007-03-20|2007-03-22|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|April 2009|Anticipated|2009-04-30|||||Interventional|||Safety and Efficacy of Freezing and Thawing of Human Eggs in Assisted Reproductive Technology|Safety and Effectiveness of Freeze and Thaw Media Kits for the Manufacturing of Oocytes for Future Use in Assisted Reproductive Technology|Withdrawn||N/A|0|Actual|ViaCell|||||f||||t||||||||||2018-06-01 03:21:02.211552|2018-06-01 03:21:02.211552
NCT00450996|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2015-06-03|2007-03-20|2007-03-22|Estimate|||||||2015-06-03|2015-06-04|Estimate|January 1999||1999-01-31|June 2015|2015-06-30|March 2007|Actual|2007-03-31|||||Interventional|||Analysis of a Beneficial Effect of Prolonges Topical Steroid Treatment After Low-risk Penetrating Keratoplasty|Phase 3: Analysis of a Beneficial Effect of Prolonges Topical Steroid Treatment After Low-risk Penetrating Keratoplasty|Completed||N/A|400||University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 03:21:02.274896|2018-06-01 03:21:02.274896
NCT00450983|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2017-04-17||2017-04-17|2007-03-20|2007-03-22|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|December 2006||2006-12-31|April 2017|2017-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases|Transplantation of Haploidentical CD34+ Purified Peripheral Blood Stem Cells With NK-Cell Add-Back Following Conditioning With Total Body Irradiation, Thiotepa, Fludarabine and OKT3|Terminated||Phase 2|1|Actual|Fred Hutchinson Cancer Research Center|||||f||||f||||||||||2018-06-01 03:21:02.35783|2018-06-01 03:21:02.35783
NCT00450970|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20||2012-08-09|2012-08-09|2007-03-21|2007-03-22|Estimate||||2012-08-09|2012-08-17|Estimate|2012-08-09|2012-08-17|Estimate|February 2007||2007-02-28|August 2012|2012-08-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|SPERA||Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)|Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) Previously Treated With Unlimited Cytotoxic Chemotherapy Regimen (SPERA)|Terminated||Phase 3|344|Actual|Agennix||2||Sponsor decided to discontinue study drug development.|f||||f||||||||||2018-06-01 03:21:02.585295|2018-06-01 03:21:02.585295
NCT00450957|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2015-04-14|2007-03-20|2007-03-22|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2006||2006-10-31|April 2013|2013-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Lycopene in Healthy Male Participants|Phase I Multiple Dose Pharmacokinetic Study of the Dietary Supplement Lycopene Delivered in Capsule Form to Healthy Male Volunteers Between 18 and 55 Years of Age|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:21:02.982405|2018-06-01 03:21:02.982405
NCT00450944|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2009-02-06|2007-03-20|2007-03-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2005||2005-11-30|June 2007|2007-06-30||||||||Interventional|||Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia|A Phase I Study of Combination Therapy With Anti-CD19 and Anti-CD22 Immunotoxins (Combotox) in Adults With Refractory/Relapse Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:21:03.094967|2018-06-01 03:21:03.094967
NCT00450931|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2014-01-03|2007-03-20|2007-03-22|Estimate|||||||2014-01-03|2014-01-06|Estimate||||September 2008|2008-09-30||||||||Interventional|||Drug Facts Page or a Short Drug Summary in Helping Patients and Doctors Understand Medical Information|Helping Patients and Physicians Make Sense of Medical Data|Unknown status|Active, not recruiting|N/A|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:21:03.16879|2018-06-01 03:21:03.16879
NCT00450918|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2018-01-24|2007-03-20|2007-03-22|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2006||2006-08-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and Adolescents|Longitudinal Study of Primary Ciliary Dyskinesia: Participants 5-18 Years of Age|Active, not recruiting|||150|Anticipated|University of North Carolina, Chapel Hill|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 03:21:03.248002|2018-06-01 03:21:03.248002
NCT00450905|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2008-10-03|2007-03-21|2007-03-22|Estimate|||||||2008-10-03|2008-10-06|Estimate|March 2007||2007-03-31|February 2008|2008-02-29|December 2008|Anticipated|2008-12-31|||||Interventional|||Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population|Randomized Evaluation of a Low-Frequency Investigational Device Employing Neuromodulation Therapy in Patients With Fibromyalgia|Terminated||Phase 3|200|Anticipated|Fralex Therapeutics|||||f||||t||||||||||2018-06-01 03:21:03.419206|2018-06-01 03:21:03.419206
NCT00450892|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-07-06|2007-03-20|2007-03-22|Estimate|||||||2016-07-06|2016-07-07|Estimate|February 2007||2007-02-28|July 2016|2016-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer|A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer|Completed||Phase 1/Phase 2|129|Actual|European Organisation for Research and Treatment of Cancer - EORTC||3|||f||||t||||||||||2018-06-01 03:21:03.542656|2018-06-01 03:21:03.542656
NCT00450879|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2015-03-24|2007-03-20|2007-03-22|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2007||2007-01-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|November 2010|Actual|2010-11-30||Interventional|||Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery|Pilot Study of GW786034 (Pazopanib), a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Operable Breast Cancer|Terminated||Phase 1|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:21:03.672287|2018-06-01 03:21:03.672287
NCT00450866|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2013-07-26||2014-01-28|2007-03-20|2007-03-22|Estimate|2013-07-26|2013-10-09|Estimate||||2014-01-28|2014-02-28|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|May 2012|Actual|2012-05-31|June 2011|Actual|2011-06-30||Interventional|||Epothilone B in Treating Patients With CNS Metastases From Breast Cancer|Phase II Trial of Patupilone in Patients With Brain Metastases From Breast Cancer|Completed||Phase 2|55|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:21:03.797041|2018-06-01 03:21:03.797041
NCT00450853|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2015-01-26|2007-03-21|2007-03-22|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2005||2005-04-30|January 2015|2015-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients|Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated With Platinum Based Chemotherapy|Completed||Phase 2|31|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-06-01 03:21:04.181974|2018-06-01 03:21:04.181974
NCT00450840|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-09-14|2007-03-21|2007-03-22|Estimate|||||||2007-09-14|2007-09-17|Estimate||||September 2007|2007-09-30||||||||Interventional|||Simvastatin in Patients With Septic Shock||Unknown status|Recruiting|Phase 4|||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:21:04.240396|2018-06-01 03:21:04.240396
NCT00450827|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2015-09-25|2007-03-20|2007-03-22|Estimate|||||||2015-09-25|2015-09-28|Estimate|August 2006||2006-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma|Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study|Completed||Phase 1|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:21:04.296122|2018-06-01 03:21:04.296122
NCT00450814|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2018-05-02|2007-03-20|2007-03-22|Estimate|||||||2018-05-02|2018-05-03|Actual|November 30, 2006|Actual|2006-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma|Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|73|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:21:04.362147|2018-06-01 03:21:04.362147
NCT00450801|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2015-08-07||2015-10-12|2007-03-20|2007-03-22|Estimate|2015-10-12|2015-11-10|Estimate||||2015-10-12|2015-11-10|Estimate|April 2004||2004-04-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma|Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma|Completed||Phase 2|22|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 03:21:04.469375|2018-06-01 03:21:04.469375
NCT00450788|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-17|||2018-05-18|2007-03-17|2007-03-22|Estimate|||||||2018-05-18|2018-05-21|Actual|March 15, 2007||2007-03-15|March 26, 2018|2018-03-26||||||||Observational|||Esophageal Cancer in Northeastern Iran|The Golestan Cohort Study of Esophageal Cancer|Active, not recruiting|||50000|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:21:04.912483|2018-06-01 03:21:04.912483
NCT00450775|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2008-09-23|2007-03-21|2007-03-22|Estimate|||||||2008-09-23|2008-09-25|Estimate|March 2007||2007-03-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars|Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars|Completed||Phase 4|12|Anticipated|Innovative Medical||1|||f||||||||||||||2018-06-01 03:21:04.970807|2018-06-01 03:21:04.970807
NCT00450762|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2007-03-21|2007-03-21|2007-03-22|Estimate|||||||2007-03-21|2007-03-22|Estimate|March 2004||2004-03-31|March 2007|2007-03-31|October 2006||2006-10-31|||||Interventional|||Gemcitabine + Carboplatin in Breast Cancer|Gemcitabine Plus Carboplatin in Patients With Pretreated Metastatic Breast Cancer|Completed||Phase 2|||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:21:05.025552|2018-06-01 03:21:05.025552
NCT00450749|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2012-03-30||2014-04-23|2007-03-20|2007-03-22|Estimate|2012-06-14|2012-07-16|Estimate||||2014-04-23|2014-05-12|Estimate|February 2008||2008-02-29|April 2013|2013-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer|Phase II Placebo Controlled Trial of Preoperative Lycopene Supplementation in Prostate Cancer Patients|Completed||Phase 2|10|Actual|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-06-01 03:21:05.085958|2018-06-01 03:21:05.085958
NCT00450736|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-12-14|2007-03-20|2007-03-22|Estimate|||||||2016-12-14|2016-12-15|Estimate|March 2004||2004-03-31|December 2016|2016-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery|A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity|Completed||Phase 1|3|Actual|University of Miami||1|||f||||||||||||||2018-06-01 03:21:05.311489|2018-06-01 03:21:05.311489
NCT00450723|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2013-01-22||2016-12-14|2007-03-20|2007-03-22|Estimate|2013-02-26|2013-04-05|Estimate||||2016-12-14|2017-02-07|Estimate|May 2004||2004-05-31|December 2016|2016-12-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer|Thoracoscopic Internal Mammary Sentinel Node Biopsy|Completed||N/A|39|Actual|University of Miami|A total of 39 subjects were enrolled however; only 34 of the subjects had identifiable internal mammary sentinel lymph nodes. As a result, the data of 34 subjects were analyzed.|1|||f||||t||||||||||2018-06-01 03:21:05.381964|2018-06-01 03:21:05.381964
NCT00450697|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2010-11-04|2007-03-21|2007-03-22|Estimate|||||||2010-11-04|2010-11-05|Estimate|February 2007||2007-02-28|November 2010|2010-11-30|November 2008|Anticipated|2008-11-30|||||Observational|||Feeding Tolerance in Preterm Infants|Feeding Tolerance in Preterm Infants: Randomized Trial of Bolus Feeding Every 4 Hours Versus Every 3 Hours|Unknown status|Recruiting||160|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 03:21:05.569793|2018-06-01 03:21:05.569793
NCT00450684|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2014-10-09|2007-03-21|2007-03-22|Estimate|||||||2014-10-09|2014-10-10|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|February 2012|Actual|2012-02-29||Interventional|CARE-CHD||Cardiac Resynchronization Therapy in Congenital Heart Defects|Cardiac Resynchronization Therapy in Heart Failure Patients With Congenital Heart Defects|Completed||Phase 2/Phase 3|55|Actual|Competence Network for Congenital Heart Defects||2|||f||||||||||||||2018-06-01 03:21:05.63145|2018-06-01 03:21:05.63145
NCT00450671|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2017-03-15|2007-03-20|2007-03-22|Estimate|||||||2017-03-15|2017-03-17|Actual|February 2007||2007-02-28|March 2017|2017-03-31|May 9, 2013|Actual|2013-05-09|||||Interventional|||Treatment of Perirectal Fistula With Cutting Seton vs. Collagen Plug|Seton Placement vs. Surgisis Anal Fistula Plug Insertion for Perirectal Fistula: A Prospective Randomized Study|Completed||Phase 3|300|Anticipated|University of Southern California|||||f||||t|f|f||||||||2018-06-01 03:21:05.721483|2018-06-01 03:21:05.721483
NCT00450658|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|2011-05-17||2013-04-22|2007-03-21|2007-03-22|Estimate|2011-05-17|2011-06-21|Estimate||||2013-04-22|2013-04-29|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers|A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment|Completed||Phase 3|627|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||t||||||||||2018-06-01 03:21:05.800693|2018-06-01 03:21:05.800693
NCT00450645|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2009-03-03|2007-03-20|2007-03-22|Estimate|||||||2009-03-03|2009-03-04|Estimate|March 2005||2005-03-31|March 2009|2009-03-31|March 2011|Anticipated|2011-03-31|March 2009|Anticipated|2009-03-31||Interventional|Cancer-DACUS||Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis|Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs|Unknown status|Recruiting|Phase 4|300|Anticipated|Azienda Ospedaliera Universitaria Policlinico|||||f||||t||||||||||2018-06-01 03:21:07.162941|2018-06-01 03:21:07.162941
NCT00450632|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2012-03-26|2007-03-21|2007-03-22|Estimate|||||||2012-03-26|2012-03-27|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection|CONSTITUTION D'UNE BIOTHEQUE DE PATIENTS DE SEINE-MARITIME AUX ANTECEDENTS D'INFECTION INVASIVE A MENINGOCOQUES|Completed|||101|Actual|University Hospital, Rouen|||||f||||t||||||||||2018-06-01 03:21:07.239035|2018-06-01 03:21:07.239035
NCT00450619|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2013-05-10||2016-11-08|2007-03-20|2007-03-22|Estimate|2013-05-10|2013-07-01|Estimate||||2016-11-08|2017-01-04|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer|A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer|Completed||Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)|This study was stopped before full accrual(after about two-thirds of the subjects were enrolled) due to a significant decrease in enrollment despite making this a multicenter study.|2|||f||||t||||||||No||2018-06-01 03:21:07.362902|2018-06-01 03:21:07.362902
NCT00450606|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2008-05-20|2007-03-21|2007-03-22|Estimate|||||||2008-05-20|2008-05-21|Estimate|March 2007||2007-03-31|May 2008|2008-05-31||||December 2007|Actual|2007-12-31||Interventional|||The Effects of Ambulatory Treatment at the Dead Sea on Osteoarthritis of the Knees||Completed||N/A|50|Anticipated|Soroka University Medical Center|||||f||||f||||||||||2018-06-01 03:21:08.464768|2018-06-01 03:21:08.464768
NCT00450593|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2013-08-09|2007-03-20|2007-03-22|Estimate|||||||2013-08-09|2013-08-12|Estimate|January 1989||1989-01-31|April 2008|2008-04-30||||December 2020|Anticipated|2020-12-31||Observational|||Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma|Studies of Familial Melanoma|Recruiting|||5000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:21:08.528863|2018-06-01 03:21:08.528863
NCT00450580|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2009-07-24||2012-05-31|2007-03-21|2007-03-22|Estimate|2009-07-24|2009-09-02|Estimate||||2012-05-31|2012-06-07|Estimate|March 2007||2007-03-31|April 2012|2012-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults|Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.|Completed||Phase 3|212|Actual|ViiV Healthcare||2|||f||||||||||||||2018-06-01 03:21:08.636812|2018-06-01 03:21:08.636812
NCT00450567|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2015-10-28|2007-03-20|2007-03-22|Estimate|||||||2015-10-28|2015-10-30|Estimate|December 2004||2004-12-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy|Monitoring Targeted Lung Cancer Treatments With FDG-PET/CT|Completed|||36|Actual|Jonsson Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 03:21:09.27266|2018-06-01 03:21:09.27266
NCT00450554|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2012-03-26|2007-03-21|2007-03-22|Estimate|||||||2012-03-26|2012-03-27|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Immunogenicity After Two Doses of Meningococcal Outer Membrane Vesicle Vaccine MenBVac|EVALUATION DE LA REPONSE IMMUNITAIRE CONTRE LA SOUCHE DE NEISSERIA MENINGITIDIS B:14,P1.7,16|Completed|||236|Actual|University Hospital, Rouen|||||f||||t||||||||||2018-06-01 03:21:09.337883|2018-06-01 03:21:09.337883
NCT00450541|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2012-07-26|2007-03-20|2007-03-22|Estimate|||||||2012-07-26|2012-07-30|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Fatigue Experience in Cancer Patients|The Experience of Fatigue for Patients With Cancer|Completed|||73|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:21:09.387877|2018-06-01 03:21:09.387877
NCT00450528|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-10-23|2007-03-21|2007-03-22|Estimate|||||||2007-10-23|2007-10-24|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Observational|||Kinetics of D-Dimers After Abdominal Surgery|The Kinetics of D-Dimers After Abdominal Surgery as a Function of the Invasiveness of Surgery|Completed|||90|Anticipated|University of Zurich|||||f||||f||||||||||2018-06-01 03:21:09.464961|2018-06-01 03:21:09.464961
NCT00450515|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-12-02|2007-03-20|2007-03-22|Estimate|||||||2016-12-02|2016-12-06|Estimate|March 2007||2007-03-31|December 2016|2016-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer|Phase II Trial of Vinfluinine and Capecitabine in Previously Treated Metastatic Breast Cancer|Withdrawn||Phase 2|0|Actual|Alliance for Clinical Trials in Oncology||1||Study was dropped prior to opening.|f||||f||||||||||2018-06-01 03:21:09.517242|2018-06-01 03:21:09.517242
NCT00450502|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2018-05-18|2007-03-20|2007-03-22|Estimate|||||||2018-05-18|2018-05-21|Actual|February 24, 2007||2007-02-24|August 14, 2013|2013-08-14|April 24, 2011|Actual|2011-04-24|April 24, 2011|Actual|2011-04-24||Interventional|||Safety of Batracylin in Patients With Solid Tumors and Lymphomas|A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas|Completed||Phase 1|33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:21:09.588657|2018-06-01 03:21:09.588657
NCT00450489|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2010-03-03|2007-03-20|2007-03-22|Estimate|||||||2010-03-03|2010-03-05|Estimate|June 2008||2008-06-30|March 2010|2010-03-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Observational|||Assessment of Quality of Life and Satisfaction With Medical Care of Pediatric Type 1 Diabetes Mellitus Patients|Assessment of Quality of Life and Satisfaction With Medical Care of Pediatric Type 1 Diabetes Mellitus Patients|Withdrawn|||120|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 03:21:09.687301|2018-06-01 03:21:09.687301
NCT00450476|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-03-21|2007-03-21|2007-03-22|Estimate|||||||2007-03-21|2007-03-22|Estimate|January 2007||2007-01-31|March 2007|2007-03-31||||||||Observational|||Aspiration of Subglottic Secretions Using Hi-Lo Evac Endotracheal Tube: Tube Size and Incidence of Suction Lumen Dysfunction|Aspiration of Subglottic Secretions in Intubated Critically Ill Patients Using Hi-Lo Evac Endotracheal Tube: Correlation Between Tube Size and Incidence of Suction Lumen Dysfunction|Unknown status|Recruiting||60||University Hospital, Alexandroupolis|||||f||||f||||||||||2018-06-01 03:21:09.763572|2018-06-01 03:21:09.763572
NCT00450463|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2017-12-06|2007-03-20|2007-03-22|Estimate|||||||2017-12-06|2017-12-07|Actual|February 23, 2007||2007-02-23|June 7, 2017|2017-06-07|June 8, 2017|Actual|2017-06-08|April 27, 2017|Actual|2017-04-27||Interventional|||Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer|A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer|Completed||Phase 2|53|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:21:09.830272|2018-06-01 03:21:09.830272
NCT00450450|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2016-11-10||2017-03-29|2007-03-20|2007-03-22|Estimate|2017-03-29|2017-05-09|Actual||||2017-03-29|2017-05-09|Actual|December 2007||2007-12-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Group 2 enrollment total is 14, patient 774353 enrolled on study, but was not randomized and didn’t contribute any data. Group 2 AE total is 13.|Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases|A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation|Terminated||Phase 3|27|Actual|Children's Oncology Group|ASCT0631 is closed to further patient entry as of 11/25/2011 due to poor accrual.|2||Poor accrual|f||||t||||||||||2018-06-01 03:21:09.955443|2018-06-01 03:21:09.955443
NCT00450437|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2010-03-19|2009-08-03|2015-01-15|2007-03-21|2007-03-22|Estimate|2010-08-31|2010-09-24|Estimate|2009-08-03|2009-08-10|Estimate|2015-01-15|2015-01-28|Estimate|March 2007||2007-03-31|January 2015|2015-01-31|January 2008|Actual|2008-01-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults|A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine|Completed||Phase 3|3539|Actual|Novartis||2|||f||||t||||||||||2018-06-01 03:21:10.51054|2018-06-01 03:21:10.51054
NCT00450424|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2014-08-05||2014-09-04|2007-03-20|2007-03-22|Estimate|2014-09-04|2014-09-05|Estimate||||2014-09-04|2014-09-05|Estimate|June 2007||2007-06-30|September 2014|2014-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer|Facilitating Informed Decisions for MSI Testing|Completed||N/A|239|Actual|Fox Chase Cancer Center||1|||f||||f||||||||||2018-06-01 03:21:11.567062|2018-06-01 03:21:11.567062
NCT00450411|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2017-10-10||2017-11-07|2007-03-20|2007-03-22|Estimate|2017-10-10|2017-11-07|Actual||||2017-11-07|2017-12-11|Actual|May 2007||2007-05-31|November 2017|2017-11-30||||June 2016|Actual|2016-06-30||Interventional||Eligible patients who received protocol treatment|Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy|A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy|Active, not recruiting||Phase 2|100|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 03:21:11.84346|2018-06-01 03:21:11.84346
NCT00450398|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2008-01-24|2007-03-20|2007-03-22|Estimate|||||||2008-01-24|2008-01-29|Estimate|March 2007||2007-03-31|January 2008|2008-01-31|February 2008|Anticipated|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation|A Controlled, Prospective, Blinded, Randomized, Single-Center, Study of YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation|Unknown status|Active, not recruiting|Phase 2|12|Anticipated|Y's Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 03:21:12.059322|2018-06-01 03:21:12.059322
NCT00450385|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2017-03-13||2017-06-02|2007-03-20|2007-03-22|Estimate|2017-06-02|2017-06-23|Actual||||2017-06-02|2017-06-23|Actual|April 24, 2007|Actual|2007-04-24|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|R-CHOP||Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)|Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP|Terminated||Phase 2|57|Actual|University of Miami||1||Investigator Decision due to insufficient accrual.|f||||t||||||||||2018-06-01 03:21:12.138414|2018-06-01 03:21:12.138414
NCT00450372|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2013-02-01||2016-12-14|2007-03-20|2007-03-22|Estimate|2013-03-14|2013-05-01|Estimate||||2016-12-14|2017-02-08|Estimate|June 2004||2004-06-30|December 2016|2016-12-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery|Clinical Protocol for Phase II Testing of ADI-PEG 20 in Patients With Metastatic Melanoma|Completed||Phase 2|38|Actual|University of Miami|Of the 38 subjects enrolled, only 10 were ASS-positive and 17 were ASS-negative. The remaining 11 subjects, who declined pre-treatment biopsies, were not assessed.|1|||f||||t||||||||||2018-06-01 03:21:12.351351|2018-06-01 03:21:12.351351
NCT00450359|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2013-08-01|2007-03-20|2007-03-22|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|||||Interventional|||Computer-Aided Breast Cancer Detection in Women Undergoing Screening Mammography|A Prospective Evaluation of Computer Aided Detection (CAD) in the NHS Breast Screening Programme [CADET II]|Completed||N/A|30000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:21:12.502157|2018-06-01 03:21:12.502157
NCT00450333|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2009-08-18||2014-06-06|2007-03-21|2007-03-22|Estimate|2009-09-29|2009-11-10|Estimate||||2014-06-06|2014-06-12|Estimate|October 2006||2006-10-31|November 2009|2009-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Dynepo Infrequent Dosing Study|An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease Who Are Pre-Dialysis or Require Peritoneal Dialysis or Haemodialysis|Terminated||Phase 3|407|Actual|Shire|This study terminated early due to a decision by Shire Pharmaceuticals to permanently cease marketing Dynepo due to commercial reasons, it was not the result of any safety signal. Not enough subjects completed the study to do any efficacy analyses.|4||"The termination of the study is not linked to a product recall or result of any safety signal.~   Rather it was sponsor's commercial decision to withdraw the MA"|f||||f||||||||||2018-06-01 03:21:12.66762|2018-06-01 03:21:12.66762
NCT00450320|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2014-08-27|2007-03-20|2007-03-22|Estimate|||||||2014-08-27|2014-08-29|Estimate|October 2007||2007-10-31|August 2014|2014-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma|A Pilot Study of Rapamycin in Patients With HIV-Related Kaposi's Sarcoma|Completed||Phase 1|7|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 03:21:13.604593|2018-06-01 03:21:13.604593
NCT00450307|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2013-10-14|2007-03-20|2007-03-22|Estimate|||||||2013-10-14|2013-10-16|Estimate|June 2005||2005-06-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma|3F8 Antibody Dose Escalation Plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma: A Phase I Trial|Completed||Phase 1|32|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:21:13.689917|2018-06-01 03:21:13.689917
NCT00450294|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2009-08-26||2014-02-12|2007-03-21|2007-03-22|Estimate|2014-02-12|2014-03-31|Estimate||||2014-02-12|2014-03-31|Estimate|March 2007||2007-03-31|February 2014|2014-02-28|August 2007|Actual|2007-08-31|||||Observational|||Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair|The Effect of Aortic Infrarenal Clamping and Unclamping On Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair|Completed|||10|Actual|University of Manitoba|There were no limitations to trial during course of study.||||f||||t||||||||||2018-06-01 03:21:13.824378|2018-06-01 03:21:13.824378
NCT00450281|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2015-10-23|2007-03-20|2007-03-22|Estimate|||||||2015-10-23|2015-10-26|Estimate|October 2005||2005-10-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men|Completed|||981|Actual|Southwest Oncology Group|||4||f||||t||||||||||2018-06-01 03:21:14.445756|2018-06-01 03:21:14.445756
NCT00450268|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2007-03-21|2007-03-21|2007-03-22|Estimate|||||||2007-03-21|2007-03-22|Estimate|January 2005||2005-01-31|March 2007|2007-03-31|January 2010|Anticipated|2010-01-31|||||Observational|DCalloTX||Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation|Analysis of Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting||50||Technische Universität Dresden|||||f||||t||||||||||2018-06-01 03:21:15.117355|2018-06-01 03:21:15.117355
NCT00450255|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2014-04-22||2018-04-26|2007-03-20|2007-03-22|Estimate|2015-02-02|2015-02-04|Estimate||||2018-04-26|2018-05-24|Actual|June 2007||2007-06-30|April 2018|2018-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Phase 2 Study Evaluating the Efficacy of VEGF Trap in Patients With Recurrent Inoperable Stage III or Stage IV Melanoma|Completed||Phase 2|41|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:21:15.244558|2018-06-01 03:21:15.244558
NCT00450242|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|2012-02-27||2012-06-12|2007-03-21|2007-03-22|Estimate|2012-06-12|2012-07-16|Estimate||||2012-06-12|2012-07-16|Estimate|December 2006||2006-12-31|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis|Use of 5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis|Terminated||Phase 2|14|Actual|University of North Carolina, Chapel Hill|The study terminated due to lack of funding and difficulties with recruitment. More extensive data analysis to include secondary outcome measures was not performed due to inability to fund statistical programming and analysis efforts.|2||lack of funding|f||||f||||||||||2018-06-01 03:21:15.650006|2018-06-01 03:21:15.650006
NCT00450229|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2015-12-03|2007-03-20|2007-03-22|Estimate|||||||2015-12-03|2015-12-04|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer|Phase Ib Placebo-Controlled Trial of Diindolylmethane (BR-DIM) in the Study of the Modulation of Intermediate Endpoint Markers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 03:21:16.105535|2018-06-01 03:21:16.105535
NCT00450216|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|2011-05-17||2013-04-22|2007-03-21|2007-03-22|Estimate|2011-05-17|2011-06-21|Estimate||||2013-04-22|2013-04-29|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment|A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment|Completed||Phase 3|906|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||t||||||||||2018-06-01 03:21:16.241825|2018-06-01 03:21:16.241825
NCT00450203|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-11-30|2007-03-20|2007-03-22|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ST03||Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer|A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies|Recruiting||Phase 2/Phase 3|1103|Anticipated|Medical Research Council||3|||f||||t||||||||||2018-06-01 03:21:16.724474|2018-06-01 03:21:16.724474
NCT00450190|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-21|||2014-02-17|2007-03-21|2007-03-22|Estimate|||||||2014-02-17|2014-02-19|Estimate|February 2006||2006-02-28|February 2014|2014-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Saizen® E-Device User Trial|User Trial on the Use in Common Practice of a New Electronic Auto-injector of Saizen®, the E-Device (Electronic Device), in Children Treated by Recombinant Human Growth Hormone Over a Period of 2 Months|Completed||Phase 3|20|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 03:21:16.926075|2018-06-01 03:21:16.926075
NCT00450177|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2008-03-31|2007-03-20|2007-03-21|Estimate|||||||2008-03-31|2008-04-03|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy of Enteral Iron Supplementation in Critical Illness|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Enteral Iron Supplementation on Anemia and Risk of Infection in Critical Illness|Completed||Phase 2|200|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 03:21:16.992128|2018-06-01 03:21:16.992128
NCT00450164|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2007-03-20|2007-03-20|2007-03-21|Estimate|||||||2007-03-20|2007-03-21|Estimate|November 2000||2000-11-30|March 2007|2007-03-31|June 2004|Actual|2004-06-30|||||Interventional|KT-2000||Secondary Prophylaxis After Variceal Bleeding in Non-Responders|Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response.|Completed||Phase 4|50||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t||||||||||2018-06-01 03:21:17.045165|2018-06-01 03:21:17.045165
NCT00450151|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2012-02-29|2007-03-20|2007-03-21|Estimate|||||||2012-02-29|2012-03-01|Estimate|February 2007||2007-02-28|February 2012|2012-02-29|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Platelet Activation Markers in Pediatric Cardiac Surgery|Effect of Cardiopulmonary Bypass on Platelet Activation Markers Such as Platelet Factor 4 and Transforming Growth Factor B, in Pediatric Cardiac Surgery|Completed|||10|Actual|Weill Medical College of Cornell University|||||f||||f||||||Samples Without DNA|"~     For all patients, after obtaining written consent, 3.15ml of blood will be collected in CTAD~     tubes, from arterial line pre cardiopulmonary bypass and post cardiopulmonary bypass. Blood~     sample will be cooled in ice bath, centrifuged at 2500 rpm for 30 minutes, and supernatant~     plasma sample will be collected. This plasma will be stored at -20 degrees celcius or below.~     Enzyme-linked immunosorbent assay (ELISA) will be performed using the plasma to make~     quantitative assessment of platelet factor 4 and transforming growth factor beta.~   "|||2018-06-01 03:21:17.114062|2018-06-01 03:21:17.114062
NCT00450138|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-08-26|2007-03-20|2007-03-21|Estimate|||||||2016-08-26|2016-08-29|Estimate|December 2006||2006-12-31|August 2016|2016-08-31|November 2011|Actual|2011-11-30|November 2009|Actual|2009-11-30||Interventional|||Open Label, Phase I ZD6474 Head and Neck Cancer Study|An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma|Completed||Phase 1|48|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:21:17.16593|2018-06-01 03:21:17.16593
NCT00450125|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2017-09-21|2007-03-19|2007-03-21|Estimate|||||||2017-09-21|2017-09-25|Actual|February 2007|Actual|2007-02-28|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection|Six-Minute Walk Test in the Evaluation of Patients at High Risk for Complications From Lung Resection|Active, not recruiting|||101|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:21:17.27944|2018-06-01 03:21:17.27944
NCT00450112|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2011-04-15|2010-06-28|2011-07-25|2007-03-20|2007-03-21|Estimate|2011-07-25|2011-08-22|Estimate|2010-06-28|2010-07-01|Estimate|2011-07-25|2011-08-22|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee|A Multi-Center Extension and Open-Label Study of a Single or Repeat Intra-Articular Injection of Gel-200 in Osteoarthritis of the Knee.|Completed||Phase 3|202|Actual|Seikagaku Corporation|||||f||||f||||||||||2018-06-01 03:21:17.443114|2018-06-01 03:21:17.443114
NCT00450099|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-12-12|2007-03-19|2007-03-21|Estimate|||||||2007-12-12|2007-12-17|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Minimum Local Anesthetic Volume of Bupivacaine in Labour Epidurals|Determination of the Minimum Local Anesthetic Volume of 0.125% Bupivacaine in Labour Epidurals|Completed||N/A|50|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||1|||f||||f||||||||||2018-06-01 03:21:17.972764|2018-06-01 03:21:17.972764
NCT00450086|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2014-05-16|2007-03-20|2007-03-21|Estimate|||||||2014-05-16|2014-05-19|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis|Double-blind, Double-dummy, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules vs. Mesalazine Granules vs. Placebo for Patients With Collagenous Colitis.|Completed||Phase 3|92|Actual|Dr. Falk Pharma GmbH||3|||f||||t||||||||||2018-06-01 03:21:18.067783|2018-06-01 03:21:18.067783
NCT00450073|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|2013-01-28||2014-01-07|2007-03-19|2007-03-21|Estimate|2014-01-07|2014-02-21|Estimate||||2014-01-07|2014-02-21|Estimate|November 2006||2006-11-30|January 2014|2014-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Improving Vitamin D Status In Cystic Fibrosis|Desktop Tanning Unit to Improve Vitamin D Status in Patients With Cystic Fibrosis and Short Bowel Syndrome: A Pilot Study|Completed||N/A|30|Actual|Atlanta VA Medical Center||3|||f||||f||||||||||2018-06-01 03:21:18.179455|2018-06-01 03:21:18.179455
NCT00450060|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-03-19|2007-03-19|2007-03-21|Estimate|||||||2007-03-19|2007-03-21|Estimate|January 2007||2007-01-31|March 2007|2007-03-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Juvenile Postlumbar Puncture Headache After Puncture With Needles With Quincke Tip or With Sprotte Tip|Postlumbar Puncture Complaints After Lumbar Punctures in Children and Adolescents: Frequency and Impact by Compariosn of Two Needle Designs|Unknown status|Recruiting|N/A|150||Heidelberg University|||||f||||f||||||||||2018-06-01 03:21:18.53312|2018-06-01 03:21:18.53312
NCT00450047|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2007-03-20|2007-03-20|2007-03-21|Estimate|||||||2007-03-20|2007-03-21|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|December 2006|Actual|2006-12-31|||||Interventional|||Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia|Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia: a Randomized Controlled Trial|Completed||Phase 4|120||Hiroshima University|||||f||||f||||||||||2018-06-01 03:21:18.620958|2018-06-01 03:21:18.620958
NCT00450034|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2011-11-30|2007-03-19|2007-03-21|Estimate|||||||2011-11-30|2011-12-01|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|OMAGE||Optimization of Drug Treatment in Hospitalized Elderly (OMAGE)|Impact of Optimization of Drug Treatment of Elderly Admitted in 4 Acute Geriatric Wards : Randomized Trial|Completed||N/A|665|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:21:18.672665|2018-06-01 03:21:18.672665
NCT00450021|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2017-06-30|2007-03-20|2007-03-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 19, 2007||2007-03-19|February 6, 2008|2008-02-06||||February 6, 2008|Actual|2008-02-06||Interventional|||Imaging of Cannabinoid Receptors Using New Radioactive Tracer|Imaging of Cannabinoid CB(1) Receptors Using [11C] MePPEP|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:21:18.768594|2018-06-01 03:21:18.768594
NCT00450008|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2016-03-15|2007-03-19|2007-03-21|Estimate|||||||2016-03-15|2016-03-17|Estimate|December 2006||2006-12-31|March 2016|2016-03-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer|Phase II Study of Patients With Hormone-Naïve Prostate Cancer With a Rising Prostate Specific Antigen: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Thalidomide Plus Docetaxel|Terminated||Phase 2|9|Actual|The Methodist Hospital System||1||PI decision|f||||f||||||||No||2018-06-01 03:21:18.83281|2018-06-01 03:21:18.83281
NCT00449995|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2008-12-23|2007-03-20|2007-03-21|Estimate|||||||2008-12-23|2008-12-24|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|||Confocal Laserscanning Microscopy for Detection of Barretts Esophagus|Confocal Laserscanning Microscopy for Detection of Barretts Esophagus. A Blinded Multi-Center Study.|Completed||N/A|73|Anticipated|Technische Universität München|||||f||||||||||||||2018-06-01 03:21:18.919668|2018-06-01 03:21:18.919668
NCT00449982|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2007-03-20|2007-03-20|2007-03-21|Estimate|||||||2007-03-20|2007-03-21|Estimate|July 2003||2003-07-31|March 2007|2007-03-31|August 2004||2004-08-31|||||Interventional|||Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts|A Randomized, Double-Blind, Three-Arm Parallel-Group, Placebo-Controlled Phase 3 Trial to Investigate the Clinical Efficacy and Safety of Polyphenon E in the Treatment of External Genital Warts|Completed||Phase 3|480||MediGene|||||f||||f||||||||||2018-06-01 03:21:18.997303|2018-06-01 03:21:18.997303
NCT00449969|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2011-04-21|2007-03-20|2007-03-21|Estimate|||||||2011-04-21|2011-04-22|Estimate|April 2007||2007-04-30|April 2011|2011-04-30|December 2010|Actual|2010-12-31|April 2009|Actual|2009-04-30||Interventional|||Out-of-hospital Cardiopulmonary Resuscitation and AED Feedback|Quality of Out-of-hospital Cardiopulmonary Resuscitation (CPR) With Real Time Automated Feedback: a Prospective Randomized Study|Completed||N/A|312|Actual|University Hospital Muenster||2|||f||||f||||||||||2018-06-01 03:21:19.069828|2018-06-01 03:21:19.069828
NCT00449956|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|2009-01-23||2017-05-25|2007-03-19|2007-03-21|Estimate|2009-04-06|2009-05-29|Estimate||||2017-05-25|2017-06-20|Actual|March 12, 2007|Actual|2007-03-12|May 2017|2017-05-31|February 16, 2008|Actual|2008-02-16|February 16, 2008|Actual|2008-02-16||Interventional|||MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)|Multicenter, Double-Blind, Active Comparator-controlled Study to Evaluate the Safety and Efficacy of MK0507A in Patients With Glaucoma and Ocular Hypertension Who Are Inadequately Controlled on Beta-Blockers|Completed||Phase 3|474|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:21:19.148198|2018-06-01 03:21:19.148198
NCT00449943|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2012-01-25|2007-03-20|2007-03-21|Estimate|||||||2012-01-25|2012-01-26|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Cardiac Computed Tomographic Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)|Comparison of Cardiac Computed Tomographic Angiography (CTA) to Tc-99m Single Photon Emission Computed Tomography (SPECT)|Completed||N/A|107|Actual|Ottawa Heart Institute Research Corporation|||||f||||||||||||||2018-06-01 03:21:19.512322|2018-06-01 03:21:19.512322
NCT00449930|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|2009-06-23||2017-04-05|2007-03-19|2007-03-21|Estimate|2009-06-23|2009-08-11|Estimate||||2017-04-05|2017-05-11|Actual|March 1, 2007|Actual|2007-03-01|April 2017|2017-04-30|July 25, 2008|Actual|2008-07-25|July 25, 2008|Actual|2008-07-25||Interventional|||Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)|A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control|Completed||Phase 3|1050|Actual|Merck Sharp & Dohme Corp.|Site 0490125 was non-compliant with Good Clinical Practice (GCP). Data from the 8 patients at this site were removed from all analyses.|2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:21:19.585205|2018-06-01 03:21:19.585205
NCT00449917|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2011-10-05|2007-03-20|2007-03-21|Estimate|||||||2011-10-05|2011-10-06|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||"Visiobiane Anti-age Effects on Vision Parameters"|"Study of the Effects of Visiobiane Anti-age Dietary Supplement on Macular Pigment Optical Density, Contrast Sensibility and Visual Acuity"|Completed||Phase 4|30||Pileje|||||f||||f||||||||||2018-06-01 03:21:19.990676|2018-06-01 03:21:19.990676
NCT00449904|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19||2010-12-13|2014-10-15|2007-03-20|2007-03-21|Estimate||||2010-12-13|2010-12-16|Estimate|2014-10-15|2014-10-24|Estimate|June 2007||2007-06-30|October 2014|2014-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|DIGEST||Open-Label Phase III Long-Term Safety Trial of Liprotamase|An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|Completed||Phase 3|214|Actual|Anthera Pharmaceuticals||1|||f||||t||||||||||2018-06-01 03:21:20.051845|2018-06-01 03:21:20.051845
NCT00449891|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2016-04-13|2007-03-20|2007-03-21|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2007||2007-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Neuropsychological and Neuroanatomical Studies of Young Children With and Without Type 1 Diabetes Mellitus|Neuropsychological and Neuroanatomical Studies of Young Children With and Without Type 1 Diabetes Mellitus|Completed|||30|Anticipated|Stanford University|||||f||||t||||||||||2018-06-01 03:21:20.144723|2018-06-01 03:21:20.144723
NCT00449878|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19||2010-12-13|2014-10-15|2007-03-20|2007-03-21|Estimate||||2010-12-13|2010-12-16|Estimate|2014-10-15|2014-10-24|Estimate|May 2007||2007-05-31|October 2014|2014-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|DIGEST||Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|Completed||Phase 3|163|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:21:20.209651|2018-06-01 03:21:20.209651
NCT00449865|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2015-02-19||2015-03-23|2007-03-20|2007-03-21|Estimate|2015-03-23|2015-04-02|Estimate||||2015-03-23|2015-04-02|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional|||NET-PD LS-1 Creatine in Parkinson's Disease|A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study of Creatine in Subjects With Treated Parkinson's Disease (PD) Long Term Study (LS-1)|Terminated||Phase 3|1741|Actual|University of Rochester||2||Futility|f||||t||||||||||2018-06-01 03:21:21.350541|2018-06-01 03:21:21.350541
NCT00449852|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2011-04-27|2007-03-20|2007-03-21|Estimate|||||||2011-04-27|2011-04-29|Estimate|July 2006||2006-07-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|IVR||Interactive Voice Response Telephone Technology for the Treatment of Smoking in Patients With Heart Disease|An Interactive, Voice Response-Mediated, Follow-up and Triage System for Smoking Cessation in Smokers With Coronary Heart Disease|Completed||Phase 2|442|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-06-01 03:21:23.336512|2018-06-01 03:21:23.336512
NCT00449839|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2009-06-30|2007-03-20|2007-03-21|Estimate|||||||2009-06-30|2009-07-02|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Changes of the Infusion Rate in Insulin Pump Treatment|Changes of the Infusion Rate in Insulin Pump Treatment. A Randomized, Unblinded Cross-Over Study.|Completed||Phase 4|10|Actual|University of Aarhus||3|||f||||t||||||||||2018-06-01 03:21:23.658751|2018-06-01 03:21:23.658751
NCT00449826|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2012-01-25|2007-03-20|2007-03-21|Estimate|||||||2012-01-25|2012-01-26|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Risk Stratification of Non ST Elevation ACS With Computed Tomographic Angiography (REACT)|Risk Stratification of Non ST Elevation ACS With Computed Tomographic Angiography (REACT)|Completed||N/A|107|Actual|Ottawa Heart Institute Research Corporation|||||f||||||||||||||2018-06-01 03:21:23.795517|2018-06-01 03:21:23.795517
NCT00449813|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2012-05-04|2007-03-20|2007-03-21|Estimate|||||||2012-05-04|2012-05-07|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|November 2008|Actual|2008-11-30|October 2007|Actual|2007-10-31||Interventional|||The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)|The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms|Terminated||Phase 4|40|Actual|Takeda||1||"Inclusion-rate does not seem feasible anymore to obtain te required number of patients before~   the end of the trial."|f||||f||||||||||2018-06-01 03:21:24.04151|2018-06-01 03:21:24.04151
NCT00449800|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-03-20|2007-03-20|2007-03-21|Estimate|||||||2007-03-20|2007-03-21|Estimate|July 2006||2006-07-31|March 2007|2007-03-31|March 2007|Anticipated|2007-03-31|||||Interventional|PORTHOS||Pharmacokinetic of Ceftriaxone in Septic ICU Patients|Pharmacokinetics Variability of Ceftriaxone in Septic ICU Patients|Unknown status|Recruiting|Phase 4|70||Association Pour La Promotion A Tours De La Reanimation Medicale|||||f||||f||||||||||2018-06-01 03:21:24.347313|2018-06-01 03:21:24.347313
NCT00449787|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|2011-07-13||2018-05-01|2007-03-19|2007-03-21|Estimate|2012-10-29|2012-11-29|Estimate||||2018-05-01|2018-05-31|Estimate|March 2007||2007-03-31|May 2018|2018-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|HEDNet2||Comparing Naproxen to Sumatriptan for Emergency Headache Patients|A Randomized Clinical Trial to Compare Naproxen and Sumatriptan for Headache Patients Discharged From the Emergency Department (ED)|Completed||Phase 4|401|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-06-01 03:21:24.56823|2018-06-01 03:21:24.56823
NCT00449774|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2017-08-05|2007-03-20|2007-03-21|Estimate|||||||2017-08-05|2017-08-08|Actual|May 7, 2007|Actual|2007-05-07|August 2017|2017-08-31|June 19, 2007|Actual|2007-06-19|June 19, 2007|Actual|2007-06-19||Interventional|||Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers|An Open-label, Randomised, Single-dose, Parallel-group Study to Demonstrate Bioequivalence of Two Formulations and the Effect of Food and Water on One Formulation of Lamotrigine in Healthy Male and Female Volunteers|Completed||Phase 1|220|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:21:24.872555|2018-06-01 03:21:24.872555
NCT00449761|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-11-16|2007-03-20|2007-03-21|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2007||2007-02-28|November 2016|2016-11-30||||August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Accelerated Phase or Blast Phase (Blast Crisis)|A Phase II, Multicentre Study of Oral LBH589 in Patients With Accelerated Phase or Blast Phase (Blast Crisis) Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two BCR-ABL Tyrosine Kinase Inhibitors|Completed||Phase 2/Phase 3|27|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:21:25.015555|2018-06-01 03:21:25.015555
NCT00449748|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|2011-04-04||2012-08-01|2007-03-20|2007-03-21|Estimate|2011-04-04|2011-04-29|Estimate||||2012-08-01|2012-08-07|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis|Evaluation of RAD001 as Therapy for Patients With Systemic Mastocytosis|Completed||Phase 2|10|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:21:25.37119|2018-06-01 03:21:25.37119
NCT00449735|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2017-06-23|2007-03-20|2007-03-21|Estimate|||||||2017-06-23|2017-06-26|Actual|March 2007|Actual|2007-03-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Quinolone Resistance in Bloodstream Isolates of Escherichia Coli|Quinolone Resistance in Bloodstream Isolates of Escherichia Coli|Completed|||500|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:21:25.635148|2018-06-01 03:21:25.635148
NCT00449722|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|||2016-01-20|2007-03-20|2007-03-21|Estimate|||||||2016-01-20|2016-01-21|Estimate|July 2005||2005-07-31|January 2016|2016-01-31|June 2006|Actual|2006-06-30|||||Interventional|||OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis|Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis|Completed||Phase 3|380||Dr. Falk Pharma GmbH|||||f||||t||||||||||2018-06-01 03:21:25.772315|2018-06-01 03:21:25.772315
NCT00449709|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2012-03-15|2007-03-19|2007-03-21|Estimate|||||||2012-03-15|2012-03-19|Estimate|March 2007||2007-03-31|February 2011|2011-02-28||||||||Interventional|||A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects|A Two-part, Open-label, Cross-over Study to Assess the Pharmacokinetics of GSK221149 Following Single Oral Doses of Various Modified Release Formulations and a Solution in Healthy Adult Subjects|Terminated||Phase 1|36|Anticipated|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:21:26.011795|2018-06-01 03:21:26.011795
NCT00449696|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-20|2011-04-15|2009-04-08|2011-10-03|2007-03-20|2007-03-21|Estimate|2011-08-10|2011-09-15|Estimate|2009-10-20|2009-10-22|Estimate|2011-10-03|2011-10-07|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Gel-200 Versus Placebo in Osteoarthritis of the Knee|A Multi-Center, Randomized, Double-Blind, Controlled, Parallel-Group Study of a Single Intra-Articular Injection of Gel-200 With a Single Intra-Articular Injection of Phosphate Buffered Saline (PBS) in Osteoarthritis of the Knee.|Completed||Phase 3|379|Actual|Seikagaku Corporation||2|||f||||f||||||||||2018-06-01 03:21:26.217084|2018-06-01 03:21:26.217084
NCT00449683|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2016-08-24|2007-03-19|2007-03-20|Estimate|||||||2016-08-24|2016-08-25|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|ADIES||Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin|Antidepressant Induced Excessive Sweating: Measurement and Treatment With Terazosin|Completed||Phase 4|23|Actual|Thomas Jefferson University||1|||f||||f||||||||Undecided||2018-06-01 03:21:26.942009|2018-06-01 03:21:26.942009
NCT00449124|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2010-08-26|2007-03-15|2007-03-19|Estimate|||||||2010-08-26|2010-08-27|Estimate||||June 2008|2008-06-30|September 2007|Anticipated|2007-09-30|September 2007|Anticipated|2007-09-30||Interventional|||TG4040 in Patients With Chronic HCV|A Phase I, Randomized, Double-Blind, Dose-Ranging, Crossover Trial of HCV Vaccine (TG4040) in Patients With Chronic Hepatitis C to be Conducted in Two Parts|Withdrawn||Phase 1|85|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 03:21:33.126837|2018-06-01 03:21:33.126837
NCT00449670|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2016-10-26|2007-03-19|2007-03-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|June 2008|Actual|2008-06-30|July 2007|Actual|2007-07-31||Interventional|||Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults|Assess the Consistency of the Immunogenicity of a GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults Aged Between 18 and 60 Years|Completed||Phase 3|1206|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:21:27.011874|2018-06-01 03:21:27.011874
NCT00449657|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2018-03-13|2007-03-19|2007-03-20|Estimate|||||||2018-03-13|2018-03-14|Actual|February 2007||2007-02-28|March 2018|2018-03-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC|Phase II Trial of Pulsed Paclitaxel With Concurrent Radiotherapy,and Adjuvant Chemotherapy in Stage III Non-Small Cell Lung Cancer|Terminated||Phase 2|24|Actual|Leo W. Jenkins Cancer Center||||Poor accrual, change in standard of care.|f||||f||||||||||2018-06-01 03:21:27.146216|2018-06-01 03:21:27.146216
NCT00449644|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|2013-01-29|2011-06-20|2014-04-10|2007-03-16|2007-03-20|Estimate|2013-06-24|2013-06-25|Estimate|2011-06-20|2011-06-28|Estimate|2014-04-10|2014-04-29|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|March 2010|Actual|2010-03-31||Interventional|||TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).|A Phase II, Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Subjects With Newly Diagnosed Sputum Smear-positive Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).|Completed||Phase 2|208|Actual|Janssen Infectious Diseases BVBA|In Participant Flow, deaths occurring during the trial are reported. In addition, 1 TMC207 and 2 placebo subjects in stage 1 and 4 TMC207 and 1 placebo subject in stage 2 died after discontinuation during long-term survival follow-up.|4|||f||||t||||||||||2018-06-01 03:21:27.256908|2018-06-01 03:21:27.256908
NCT00449631|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-03-23|2007-03-19|2007-03-20|Estimate|||||||2007-03-23|2007-03-26|Estimate||||March 2007|2007-03-31||||||||Observational|||Multidrug Resistance After Trabeculectomy With Mitomycin C|Multidrug Resistance After Trabeculectomy With Mitomycin C|Completed|||30||University of Cologne|||||f||||f||||||||||2018-06-01 03:21:28.249351|2018-06-01 03:21:28.249351
NCT00449618|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2008-12-31|2007-03-19|2007-03-20|Estimate|||||||2008-12-31|2009-01-05|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Awakening Versus Bedtime Dosing of Aspirin in Pre-Hypertension or Mild Essential Hypertension|A Prospective, Randomized, Multi-Center, Double-Blind Crossover Study to Compare Awakening Versus Bedtime Administration of 100 mg Aspirin or Placebo in Subjects With High-Normal Blood Pressure or Mild Essential Hypertension|Terminated||Phase 4|23|Actual|University of Vigo||4||Not enough recruitment during the proposed period.|f||||t||||||||||2018-06-01 03:21:28.3393|2018-06-01 03:21:28.3393
NCT00449605|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19||2016-04-13|2016-04-13|2007-03-19|2007-03-20|Estimate||||2016-04-13|2016-05-16|Estimate|2016-04-13|2016-05-16|Estimate|March 2007||2007-03-31|April 2016|2016-04-30|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|ALLEGRO||A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes|A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control With Rimonabant in Comparison With Glimepiride Over 1 Year in Overweight/Obese Type2 Diabetic Patients Not Adequately Controlled With Metformin|Terminated||Phase 3|508|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 03:21:28.451262|2018-06-01 03:21:28.451262
NCT00449592|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-18|||2008-10-02|2007-03-18|2007-03-20|Estimate|||||||2008-10-02|2008-10-03|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Oral Zinc Therapy for the Prevention of Mucositis|A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support|Completed||Phase 4|40|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 03:21:28.632705|2018-06-01 03:21:28.632705
NCT00449579|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2015-04-16|2007-03-19|2007-03-20|Estimate|||||||2015-04-16|2015-04-17|Estimate|August 2006||2006-08-31|October 2006|2006-10-31|October 2007||2007-10-31|||||Interventional|||The Diagnostic Benefits of the HyperQTM System in ECG Stress Testing|The Diagnostic Benefits of the HyperQTM System in ECG Stress Testing|Unknown status|Recruiting|Phase 3|1200|Anticipated|Assuta Hospital Systems|||||f||||||||||||||2018-06-01 03:21:28.719234|2018-06-01 03:21:28.719234
NCT00449566|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-18|||2007-03-18|2007-03-18|2007-03-20|Estimate|||||||2007-03-18|2007-03-20|Estimate|January 2006||2006-01-31|March 2007|2007-03-31||||||||Observational|||Magnetic Resonance Imaging of Brain Development in Autism|Magnetic Resonance Imaging of Brain Development in Autism|Unknown status|Recruiting||300||UMC Utrecht|||||f||||f||||||||||2018-06-01 03:21:28.783356|2018-06-01 03:21:28.783356
NCT00449553|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-02-27|2007-03-16|2007-03-20|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2001||2001-06-30|February 2012|2012-02-29|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Observational|||Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.|A Prospective Study of Associations of Changes in HbA1C and Fasting Blood Lipids Due to Treatment With Pioglitazone for 6 Months and Genetic Polymorphism's in PPAR-gamma|Completed|||326|Actual|Takeda|||4||f||||f||||||Samples With DNA|"~     Whole blood for DNA-analyses~   "|||2018-06-01 03:21:28.838006|2018-06-01 03:21:28.838006
NCT00449540|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-18|2009-01-07||2011-08-09|2007-03-19|2007-03-20|Estimate|2011-07-14|2011-08-10|Estimate||||2011-08-09|2011-08-15|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura|Phase III Randomized Double-Blind Parallel Group Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive Non-repetitive Transcranial Magnetic Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache|Completed||Phase 3|201|Actual|Neuralieve||2|||f||||f||||||||||2018-06-01 03:21:28.957061|2018-06-01 03:21:28.957061
NCT00449527|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2011-01-21|2007-03-19|2007-03-20|Estimate|||||||2011-01-21|2011-01-24|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|August 2007|Actual|2007-08-31|||||Interventional|||A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects|A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Daily Versus Weekly in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Actuations Twice Daily|Completed||Phase 3|123|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:21:29.387673|2018-06-01 03:21:29.387673
NCT00449514|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-18|||2007-09-19|2007-03-19|2007-03-20|Estimate|||||||2007-09-19|2007-09-20|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Interventional|||Tamoxifen Compared With Clomiphene Citrate for Women Who Had Thin Endometrium Women Under Clomiphene in a Previous Cycle|Prospective Randomized Study of Ovulation Induction Using Either Tamoxifen or Clomiphene Citrate for Women Who Had Thin Endometrium During Previous Treatment With Clomiphene Citrate|Unknown status|Recruiting|N/A|100|Anticipated|Shaare Zedek Medical Center|||||f||||f||||||||||2018-06-01 03:21:29.490341|2018-06-01 03:21:29.490341
NCT00449501|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2011-01-21|2007-03-16|2007-03-20|Estimate|||||||2011-01-21|2011-01-24|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|November 2007|Actual|2007-11-30|||||Interventional|||A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects|A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Act. Twice Daily|Completed||Phase 3|134|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:21:29.616227|2018-06-01 03:21:29.616227
NCT00449488|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-18|||2009-12-14|2007-03-18|2007-03-20|Estimate|||||||2009-12-14|2009-12-15|Estimate|January 2007||2007-01-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|HEBEIII||Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction|A Prospective, Randomised, Clinical Study to Examine the Effects of a Single Bolus Erythropoietin on Left Ventricular Function in Patients With an Acute Myocardial Infarction|Completed||Phase 2|529|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-06-01 03:21:29.731614|2018-06-01 03:21:29.731614
NCT00449462|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-07-05|2007-03-19|2007-03-20|Estimate|||||||2007-07-05|2007-07-06|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|June 2007|Actual|2007-06-30|||||Interventional|||Effect of Conjugated Linoleic Acid Intake on Liver and Kidney Function|The Effect of Conjugated Linoleic Acid Intake on Liver and Kidney Function in Healthy Volunteers (CLAxon-Study)|Completed||N/A|20|Anticipated|Wageningen University|||||f||||f||||||||||2018-06-01 03:21:29.810204|2018-06-01 03:21:29.810204
NCT00449449|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-17|||2007-03-19|2007-03-19|2007-03-20|Estimate|||||||2007-03-19|2007-03-20|Estimate|September 2003||2003-09-30|March 2007|2007-03-31|September 2006|Actual|2006-09-30|||||Interventional|||A Phase II Clinical Study of Lidocain Pertubation as Treatment for Couples With Unexplained Infertility|A Randomised, Open, Controlled, Parallel Group, Multi-Centre Phase II Clinical Study of Lidocain Pertubation as Treatment for Couples With Unexplained Infertility|Completed||Phase 2|330||Isifer AB|||||f||||t||||||||||2018-06-01 03:21:29.872147|2018-06-01 03:21:29.872147
NCT00449436|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2008-02-26|2007-03-19|2007-03-20|Estimate|||||||2008-02-26|2008-02-29|Estimate|October 2004||2004-10-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults|A Randomized, Open Label Study to Compare the Safety and Efficacy of a Long Term Maintenance With TRIZIVIR After a Switch From a Boosted PI or a NNRTI as First Line Therapy for 96 Weeks.|Completed||Phase 1|152|Anticipated|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:21:29.937683|2018-06-01 03:21:29.937683
NCT00449423|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-10-24|2007-03-19|2007-03-20|Estimate|||||||2007-10-24|2007-10-25|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|MEMO||Metabolic Modulation as Treatment in Acute Heart Failure|Metabolic Modulation as Treatment in Acute Heart Failure|Terminated||Phase 2|32|Anticipated|University of Aarhus||||due to slow recruitment|f||||f||||||||||2018-06-01 03:21:30.030508|2018-06-01 03:21:30.030508
NCT00449410|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-03-19|2007-03-19|2007-03-20|Estimate|||||||2007-03-19|2007-03-20|Estimate|May 2005||2005-05-31|March 2007|2007-03-31|October 2006||2006-10-31|||||Interventional|SPACE||Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients|Silent Cerebrovascular Lesion and Cognitive Decline Prevention in Atrial Fibrillation by Intensive Cholesterol Lowering in Elderly Patients|Completed||Phase 4|35||Radboud University|||||f||||f||||||||||2018-06-01 03:21:30.093192|2018-06-01 03:21:30.093192
NCT00449397|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2011-01-25|2007-03-19|2007-03-20|Estimate|||||||2011-01-25|2011-01-27|Estimate|July 2003||2003-07-31|January 2011|2011-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis|A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years.|Completed||Phase 3|150||AstraZeneca|||||f||||f||||||||||2018-06-01 03:21:30.159269|2018-06-01 03:21:30.159269
NCT00449384|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-07-02|2007-03-19|2007-03-20|Estimate|||||||2007-07-02|2007-07-03|Estimate|February 2007||2007-02-28|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Observational|||SIB-Norwegian Version, Validation and Reliability Study|Severe Impairment Study - Norwegian Version. A Validation and Reliability Study.|Completed|||59|Actual|Sykehuset Innlandet HF|||||f||||f||||||||||2018-06-01 03:21:30.254054|2018-06-01 03:21:30.254054
NCT00449358|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2013-04-14|2007-03-19|2007-03-20|Estimate|||||||2013-04-14|2013-04-16|Estimate|February 2006||2006-02-28|January 2006|2006-01-31|April 2013|Anticipated|2013-04-30|||||Interventional|||Checking Wether the m-ALA Cream Could Mark Correctly the Borders of BCC's Tumors|Correlation Between Mohs Surgery and Microscopic Fluorescence Photometry in Determination of Histological Borders in Basal Cell Carcinoma .|Unknown status|Active, not recruiting|N/A|32||Assuta Hospital Systems|||||f||||||||||||||2018-06-01 03:21:30.476392|2018-06-01 03:21:30.476392
NCT00449345|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-05-28|2007-03-19|2007-03-20|Estimate|||||||2007-05-28|2007-05-30|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Observational|||Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis||Unknown status|Recruiting||150|Anticipated|Assuta Hospital Systems|||||f||||f||||||||||2018-06-01 03:21:30.54268|2018-06-01 03:21:30.54268
NCT00449332|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2016-09-19|2007-03-16|2007-03-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2006||2006-03-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|BOS||Early Indicators of Chronic Rejection in Lung Transplant|Role of Inflammatory and Fibroproliferative Cytokines in the Pathogenesis of Bronchiolitis Obliterans Syndrome-OP in Lung Transplant Recipients.|Terminated|||120|Actual|University of Chicago||||PI left University|f||||f||||||Samples With DNA|"~     lung tissues, bal, blood~   "|||2018-06-01 03:21:30.599533|2018-06-01 03:21:30.599533
NCT00449319|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2017-11-14|2007-03-19|2007-03-20|Estimate|||||||2017-11-14|2017-11-17|Actual|November 1998|Actual|1998-11-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|LAM99P||AML Treatment in Untreated Adult Patients|AML Treatment in Untreated Adult Patients According to EORTC-GIMEMA Protocols AML8 and AML10|Recruiting||N/A|||Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||||2018-06-01 03:21:30.665622|2018-06-01 03:21:30.665622
NCT00449306|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2016-10-23|2007-03-19|2007-03-20|Estimate|||||||2016-10-23|2016-10-25|Estimate|March 2001||2001-03-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Observational|||Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques|Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques|Active, not recruiting|||120|Anticipated|Sheba Medical Center|||||f||||f||||||Samples Without DNA|"~     Tissue for RNA extraction (frozen); Tissue for histological analysis (formalin fixation);~     Plasma for CV biomarkers (frozen)~   "|||2018-06-01 03:21:30.78773|2018-06-01 03:21:30.78773
NCT00449293|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2017-05-26|2007-03-16|2007-03-20|Estimate|||||||2017-05-26|2017-05-31|Actual|October 2006||2006-10-31|January 2008|2008-01-31|May 2008|Actual|2008-05-31|June 2007|Actual|2007-06-30||Interventional|||Behavioral Therapy for Reduction in Smoking Craving|Behavioral Therapy for Reduction in Smoking Craving|Completed||N/A|40|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 03:21:30.867662|2018-06-01 03:21:30.867662
NCT00449280|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2013-06-11|2007-03-16|2007-03-20|Estimate|||||||2013-06-11|2013-06-12|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies|A Drug Interaction Study of Sorafenib (BAY 43-9006 Tosylate) and Rapamycin in Patients With Advanced Malignancies|Completed||Phase 1|34|Actual|University of Chicago||4|||f||||t||||||||||2018-06-01 03:21:31.068456|2018-06-01 03:21:31.068456
NCT00449267|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-17|||2009-02-10|2007-03-19|2007-03-20|Estimate|||||||2009-02-10|2009-02-11|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Aurolab Hydrophobic Foldable Intraocular Lens Study|Clinical Evaluation of Hydrophobic Foldable Intraocular Lenses|Completed||Phase 4|120|Actual|Aurolab||1|||f||||t||||||||||2018-06-01 03:21:31.146031|2018-06-01 03:21:31.146031
NCT00449254|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2007-06-04|2007-03-16|2007-03-20|Estimate|||||||2007-06-04|2007-06-05|Estimate|October 2006||2006-10-31|June 2007|2007-06-30||||||||Interventional|||Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults|A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults.|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|Manhattan Pharmaceuticals|||||t||||f||||||||||2018-06-01 03:21:31.223082|2018-06-01 03:21:31.223082
NCT00449241|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-19|||2007-03-19|2007-03-19|2007-03-20|Estimate|||||||2007-03-19|2007-03-20|Estimate|November 2006||2006-11-30|March 2007|2007-03-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Acupuncture Treatment in Adults Undergoing Diagnostic OGD : A Double-Blind Placebo Controlled Randomized Trial|Acupuncture Treatment in Adults Undergoing Diagnostic Upper Gastrintestinal Endoscopy: A Double-Blind Placebo Controlled Randomized Trial|Unknown status|Recruiting|N/A|210||Chinese University of Hong Kong|||||f||||t||||||||||2018-06-01 03:21:31.279088|2018-06-01 03:21:31.279088
NCT00449228|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-18|||2012-06-04|2007-03-18|2007-03-20|Estimate|||||||2012-06-04|2012-06-05|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|ANRACT||Efficacy of Preoperative Education and Mini-invasive Surgery for Total Hip Replacement|Evaluation of Preoperative Education and Mini-invasive Total Hip Replacement in Regard to the Attainment of Functional Independency and Reduction of Hospital Stay|Unknown status|Recruiting|Phase 3|215|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 03:21:31.351304|2018-06-01 03:21:31.351304
NCT00449215|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-18|||2007-03-18|2007-03-18|2007-03-20|Estimate|||||||2007-03-18|2007-03-20|Estimate|October 2004||2004-10-31|March 2007|2007-03-31|December 2006|Actual|2006-12-31|||||Observational|||The Genetic and Life Style Determinants of Bone Mass of Young Greek Males||Completed|||301||University of Athens|||||f||||f||||||||||2018-06-01 03:21:31.435754|2018-06-01 03:21:31.435754
NCT00449202|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2007-03-16|2007-03-16|2007-03-20|Estimate|||||||2007-03-16|2007-03-20|Estimate|June 2006||2006-06-30|March 2007|2007-03-31||||||||Interventional|||Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)|A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects|Unknown status|Active, not recruiting|Phase 2|100||Manhattan Pharmaceuticals|||||t||||f||||||||||2018-06-01 03:21:31.502012|2018-06-01 03:21:31.502012
NCT00449176|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|2009-04-17||2012-04-26|2007-03-16|2007-03-20|Estimate|2010-05-28|2010-06-24|Estimate||||2012-04-26|2012-04-30|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain|A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Subjects With Moderate to Severe Chronic Low Back Pain|Completed||Phase 3|981|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 03:21:31.584234|2018-06-01 03:21:31.584234
NCT00449163|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2013-01-23||2017-04-05|2007-03-15|2007-03-19|Estimate|2013-01-23|2013-02-28|Estimate||||2017-04-05|2017-05-11|Actual|March 1, 2006|Actual|2006-03-01|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer|Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer|Terminated||Phase 2|25|Actual|University of Miami|A total of 25 subjects were enrolled however; data were analyzed for 22 subjects only. Study was terminated early by the University of Miami Institutional Review Board.|1||Study terminated by University of Miami Institutional Review Board|f||||t||||||||||2018-06-01 03:21:32.072922|2018-06-01 03:21:32.072922
NCT00449150|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2010-10-05||2018-02-20|2007-03-15|2007-03-19|Estimate|2010-12-15|2011-01-19|Estimate||||2018-02-20|2018-03-15|Actual|March 2007||2007-03-31|June 2011|2011-06-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)|Cetrorelix Pamoate Intermittent IM Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment|Terminated||Phase 3|667|Actual|AEterna Zentaris||3||Trial did not meet primary efficacy endpoint for double blind phase.|f||||f||||||||||2018-06-01 03:21:32.287016|2018-06-01 03:21:32.287016
NCT00449137|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2016-12-14|2007-03-15|2007-03-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2005||2005-06-30|December 2016|2016-12-31|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|||Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment|A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma|Completed||Phase 1|13|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 03:21:33.05129|2018-06-01 03:21:33.05129
NCT00448968|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2007-09-26|2007-03-16|2007-03-19|Estimate|||||||2007-09-26|2007-09-27|Estimate|March 2007||2007-03-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Observational|||The Utility of Ischemia Modified Albumin (IMA) in Sepsis|The Utility of Ischemia Modified Albumin (IMA) in Sepsis|Completed|||150|Actual|Inverness Medical Innovations|||||f||||f||||||||||2018-06-01 03:21:36.015182|2018-06-01 03:21:36.015182
NCT00449111|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2017-04-27|2007-03-16|2007-03-19|Estimate|||||||2017-04-27|2017-04-28|Actual|March 13, 2006|Actual|2006-03-13|April 2017|2017-04-30|September 30, 2006|Actual|2006-09-30|September 30, 2006|Actual|2006-09-30||Interventional|||An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)|An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension|Terminated||Phase 3|11|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:21:33.252915|2018-06-01 03:21:33.252915
NCT00449098|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2011-10-06|2007-03-15|2007-03-19|Estimate|||||||2011-10-06|2011-10-07|Estimate|January 2007||2007-01-31|October 2011|2011-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|||Ologen (OculusGen)-Glaucoma MMC Control Trial in India|Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery|Unknown status|Recruiting|Phase 4|40|Anticipated|Pro Top & Mediking Company Limited||2|||f||||||||||||||2018-06-01 03:21:33.308979|2018-06-01 03:21:33.308979
NCT00449085|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2015-01-05|2007-03-16|2007-03-19|Estimate|||||||2015-01-05|2015-01-06|Estimate|April 2007||2007-04-30|January 2015|2015-01-31||||July 2012|Anticipated|2012-07-31||Interventional|||Clinical Evaluation of the CARTO™ XP EP Navigation System v9 and Biosense Webster SOUNDSTAR 3D Diagnostic Ultrasound. A Feasibility Study|Clinical Evaluation of the CARTO™ XP EP Navigation System v9 and Biosense Webster SOUNDSTAR 3D Diagnostic Ultrasound. A Feasibility Study|Withdrawn||Phase 2|0|Actual|Biosense Webster, Inc.|||||f||||f||||||||||2018-06-01 03:21:33.42384|2018-06-01 03:21:33.42384
NCT00449072|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2012-06-29||2012-08-07|2007-03-16|2007-03-19|Estimate|2012-06-29|2012-08-07|Estimate||||2012-08-07|2012-08-10|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the 12 Month Effect of Treatment With Once Daily Triamcinolone Acetonide (NASACORT® AQ Nasal Spray 110 μg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR)|Completed||Phase 4|299|Actual|Sanofi|Two study sites with significant GCP noncompliance were reported to the U.S. Food and Drug Administration (FDA) by the Sponsor. A total of 5 treated participants (1 placebo and 4 TAA-AQ) from these 2 study sites were excluded from the analysis.|2|||f||||||||||||||2018-06-01 03:21:33.505304|2018-06-01 03:21:33.505304
NCT00449059|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2007-03-15|2007-03-15|2007-03-19|Estimate|||||||2007-03-15|2007-03-19|Estimate|January 2003||2003-01-31|March 2007|2007-03-31|December 2004|Actual|2004-12-31|||||Interventional|||Nitrate and Hypertension in Heart Transplanted Patients|Acute Effect of Nitroglycerin on Cyclosporine-Induced Hypertension After Cardiac Transplantation|Completed||Phase 4|20||University of Zurich|||||f||||f||||||||||2018-06-01 03:21:34.101779|2018-06-01 03:21:34.101779
NCT00449046|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|2008-11-21||2015-04-16|2007-03-16|2007-03-19|Estimate|2009-06-18|2009-08-04|Estimate||||2015-04-16|2015-05-06|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-|Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-|Completed||Phase 3|40|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:21:34.177597|2018-06-01 03:21:34.177597
NCT00449033|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|2011-04-20||2015-04-03|2007-03-16|2007-03-19|Estimate|2011-08-08|2011-09-09|Estimate||||2015-04-03|2015-04-23|Estimate|February 2007||2007-02-28|April 2015|2015-04-30|June 2011|Actual|2011-06-30|April 2010|Actual|2010-04-30||Interventional|NEXUS||A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)|A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|904|Actual|Bayer|Inclusion of squamous patients stopped in FEB 2008, as 11961 (NCT00558636) trial reported higher mortality for this subgroup. Squamous patients in 12006 (NCT00449033) trial discontinued drug as a precaution endorsed by Data Monitoring Committee.|2|||f||||t||||||||||2018-06-01 03:21:34.426312|2018-06-01 03:21:34.426312
NCT00449020|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2016-12-14|2007-03-15|2007-03-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2004||2004-01-31|December 2016|2016-12-31|January 2008|Actual|2008-01-31|May 2007|Actual|2007-05-31||Interventional|||Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer|Carboplatin and Irinotecan Concomitantly With Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel for Locally Advanced Non-Small Cell Lung Cancer (GIA 12177).|Completed||Phase 2|32|Actual|University of Miami|||||f||||t||||||||||2018-06-01 03:21:35.686363|2018-06-01 03:21:35.686363
NCT00449007|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2008-09-26|2007-03-15|2007-03-19|Estimate|||||||2008-09-26|2008-09-29|Estimate|February 2006||2006-02-28|September 2008|2008-09-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism|A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence)|Unknown status|Active, not recruiting|Phase 4|42|Anticipated|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||t||||||||||2018-06-01 03:21:35.77793|2018-06-01 03:21:35.77793
NCT00448994|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2014-12-08|2007-03-15|2007-03-19|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Adenovirus and Fungal Load in Pediatric Stem Cell Transplant Patients|Serial Monitoring of Adenovirus and Fungal Load by Real-Time, Quantitative Polymerase Chain Reaction (PCR) Assay and Correlation With Outcomes in Pediatric Hematopoietic Stem Cell Transplant Patients|Withdrawn|||0|Actual|ViraCor Laboratories||||Method development/validation|f||||f||||||||||2018-06-01 03:21:35.875097|2018-06-01 03:21:35.875097
NCT00448981|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2012-10-01|2007-03-16|2007-03-19|Estimate|||||||2012-10-01|2012-10-02|Estimate|November 2006||2006-11-30|October 2012|2012-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|STUFFY||Stopping Upper Respiratory Infections and Flu in the Family: The Stuffy Trial|Stopping URIs and Flu in the Family: The Stuffy Trial|Completed||N/A|2788|Actual|Centers for Disease Control and Prevention|||||f||||t||||||||||2018-06-01 03:21:35.933099|2018-06-01 03:21:35.933099
NCT00448955|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2008-04-17|2007-03-16|2007-03-19|Estimate|||||||2008-04-17|2008-04-18|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Open-Label Study of ARD-0403 in Testosterone Deficient Men|A Phase III Open-Label Study of the Efficacy and Safety of ARD-0403, a Testosterone Cream, in Testosterone Deficient Men|Completed||Phase 3|150|Anticipated|Ardana Bioscience Ltd|||||f||||||||||||||2018-06-01 03:21:36.091322|2018-06-01 03:21:36.091322
NCT00448942|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2007-03-15|2007-03-15|2007-03-19|Estimate|||||||2007-03-15|2007-03-19|Estimate|November 2004||2004-11-30|March 2007|2007-03-31|January 2006|Actual|2006-01-31|||||Observational|||The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections|The Impact of the Use of Chlorhexidine-Based Bathing System in the Hospital to Reduce the Incidence of MRSA/VRE Infection or Colonization and Nosocomial Bloodstream Infections (BSI)|Completed|||5300||Hunter Holmes Mcguire Veteran Affairs Medical Center|||||f||||f||||||||||2018-06-01 03:21:36.168074|2018-06-01 03:21:36.168074
NCT00448929|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2017-06-26|2007-03-15|2007-03-19|Estimate|||||||2017-06-26|2017-06-27|Actual|January 2007|Actual|2007-01-31|June 2017|2017-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Ologen (OculusGen)-Glaucoma Case Control Trial in India|Comparative Study of the Safety and Effectiveness Between Trabeculectomy and Trabeculectomy With Ologen (OculusGen) Collagen Matrix Implant|Completed||Phase 3|40|Actual|Pro Top & Mediking Company Limited||2|||f||||||||||||||2018-06-01 03:21:36.246175|2018-06-01 03:21:36.246175
NCT00448916|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2014-10-06||2014-11-24|2007-03-15|2007-03-19|Estimate|2014-11-24|2014-12-02|Estimate||||2014-11-24|2014-12-02|Estimate|May 2007||2007-05-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures|A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures|Completed||Phase 3|54|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:21:36.396077|2018-06-01 03:21:36.396077
NCT00448903|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2011-03-16|2007-03-16|2007-03-19|Estimate|||||||2011-03-16|2011-03-17|Estimate|March 2007||2007-03-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers|Multicentric, Randomized, Double-blind, Controlled Clinical Trial to Assess the Efficacy and Safety of Bemiparin Sodium as Treatment of Diabetic Foot Ulcers|Completed||Phase 3|329|Actual|Rovi Pharmaceuticals Laboratories||2|||f||||t||||||||||2018-06-01 03:21:37.84191|2018-06-01 03:21:37.84191
NCT00448890|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15||2010-10-14|2010-10-14|2007-03-15|2007-03-19|Estimate||||2010-10-14|2010-10-15|Estimate|2010-10-14|2010-10-15|Estimate|November 2006||2006-11-30|October 2010|2010-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers|Single-Blind, Randomised, Placebo-Controlled Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Escalating Doses and Repeat Doses of GSK729327 in Healthy Volunteers|Completed||Phase 1|79|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:21:37.942784|2018-06-01 03:21:37.942784
NCT00448877|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2009-04-06|2007-03-16|2007-03-19|Estimate|||||||2009-04-06|2009-04-07|Estimate|December 2006||2006-12-31|April 2008|2008-04-30||||July 2007|Actual|2007-07-31||Interventional|||Deployment of Functional Optical Brain Monitor [fNIR] in Clinical Anesthesia|Deployment of Functional Optical Brain Monitor [fNIR] in Clinical Anesthesia|Completed||N/A|50|Actual|Drexel University|||||f||||||||||||||2018-06-01 03:21:38.0428|2018-06-01 03:21:38.0428
NCT00448864|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|2015-04-22||2016-01-05|2007-03-16|2007-03-19|Estimate|2015-06-12|2015-07-08|Estimate||||2016-01-05|2016-02-03|Estimate|May 2007||2007-05-31|November 2015|2015-11-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional||Randomized participants who received at least 1 dose of study drug.|Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement|KALAHARI-1: Kallikrein Antagonist (DX-88 [Ecallantide]) Effect on Blood Loss Associated With Heart Surgery Requiring Institution of Bypass|Terminated||Phase 2|75|Actual|Cubist Pharmaceuticals LLC||3||Experience gained from this study is sufficient to design and facilitate the follow-on study.|f||||t||||||||||2018-06-01 03:21:38.143865|2018-06-01 03:21:38.143865
NCT00448851|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2013-12-09|2007-03-15|2007-03-19|Estimate|||||||2013-12-09|2013-12-10|Estimate|February 2007||2007-02-28|December 2013|2013-12-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Study of Dust Mite Inhalation in Humans|Phase 1 Study of Dermatophagoides Farinae Inhalation in Humans|Completed||Phase 1|13|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 03:21:38.868212|2018-06-01 03:21:38.868212
NCT00448838|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2016-12-14|2007-03-15|2007-03-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|May 2006||2006-05-31|December 2016|2016-12-31|March 2011|Actual|2011-03-31|August 2007|Actual|2007-08-31||Interventional|||Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Pilot Study of Gemcitabine, Oxaliplatin, and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer|Completed||N/A|42|Actual|University of Miami|||||f||||t||||||||||2018-06-01 03:21:38.926311|2018-06-01 03:21:38.926311
NCT00448825|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2013-03-14|2007-03-15|2007-03-19|Estimate|||||||2013-03-14|2013-03-15|Estimate|March 2007||2007-03-31|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Novel Pharmacotherapy for Dual Dependence|Novel Pharmacotherapy for Dual Dependence|Unknown status|Recruiting|Phase 3|180|Anticipated|University of Virginia||2|||f||||t||||||||||2018-06-01 03:21:38.989491|2018-06-01 03:21:38.989491
NCT00448812|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2010-02-11|2007-03-16|2007-03-19|Estimate|||||||2010-02-11|2010-02-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 03:21:40.037847|2018-06-01 03:21:40.037847
NCT00448799|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2008-05-09|2007-03-16|2007-03-19|Estimate|||||||2008-05-09|2008-05-13|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls|Evaluation of [123I] AV83 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Completed||Phase 1|30|Anticipated|Molecular NeuroImaging|||||f||||f||||||||||2018-06-01 03:21:40.114295|2018-06-01 03:21:40.114295
NCT00448786|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2011-01-20|2007-03-15|2007-03-19|Estimate|||||||2011-01-20|2011-01-21|Estimate|February 2007||2007-02-28|January 2011|2011-01-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors|An Open-Label, Randomized, Phase 1b Study Evaluating the Effect of Different Doses of AMG 706 on the Gallbladder in Subjects With Advanced Solid Tumors|Completed||Phase 1|49|Actual|Amgen||3|||f||||||||||||||2018-06-01 03:21:40.174038|2018-06-01 03:21:40.174038
NCT00386217|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2012-07-31|2006-10-10|2006-10-11|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2004||2004-12-31|July 2012|2012-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Psychosocial Impact of Cancer-Related Female Infertility|Psychosocial Impact of Cancer-Related Female Infertility|Completed|||239|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:42:51.602944|2018-06-01 03:42:51.602944
NCT00448773|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2010-01-06|2007-03-16|2007-03-19|Estimate|||||||2010-01-06|2010-01-07|Estimate|February 2007||2007-02-28|January 2010|2010-01-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|REDI-US||REDucing Influenza Among University Students, University of California at Berkeley|Effectiveness of Selected Non-pharmaceutical Interventions in Reducing Influenza-like Illness Among University Students|Completed||Phase 4|3000|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 03:21:40.247258|2018-06-01 03:21:40.247258
NCT00448760|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2013-01-16||2016-12-14|2007-03-15|2007-03-19|Estimate|2013-01-16|2013-02-18|Estimate||||2016-12-14|2017-02-07|Estimate|October 2004||2004-10-31|December 2016|2016-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery|A Nonrandomized Phase II Study: Feasibility and Outcome of Neo Adjuvant Chemotherapy With Oxaliplatin, Fluorodeoxyuridine (FUdR), Taxotere and Leucovorin in the Treatment of Previously Untreated Advanced Esophago-Gastric Carcinoma|Completed||Phase 2|29|Actual|University of Miami||1|||f||||||||||||||2018-06-01 03:21:40.312962|2018-06-01 03:21:40.312962
NCT00448747|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2017-06-28|2007-03-16|2007-03-19|Estimate|||||||2017-06-28|2017-07-02|Actual|June 2007||2007-06-30|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Investigation of a New, Oral Growth Hormone Secretagogue, Macimorelin (AEZS-130) as a Growth Hormone Stimulation Test.|A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy|Completed||Phase 3|100|Actual|AEterna Zentaris||2|||f||||f||||||||No|To share IPD is not planned as subjects were not informed about this possibility and thus, no related patient consent is available (data protection issue).|2018-06-01 03:21:40.537747|2018-06-01 03:21:40.537747
NCT00448734|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2009-01-20|2007-03-15|2007-03-19|Estimate|||||||2009-01-20|2009-01-21|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|July 2010|Anticipated|2010-07-31|December 2009|Anticipated|2009-12-31||Interventional|||A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer|A Phase 1/2 Study of Picoplatin and Docetaxel (With Prednisone) in Subjects With Chemotherapy-Naive Metastatic Hormone-Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|95|Anticipated|Poniard Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:21:40.732051|2018-06-01 03:21:40.732051
NCT00448721|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15||2018-02-27|2018-02-27|2007-03-15|2007-03-19|Estimate||||2018-02-27|2018-03-01|Actual|2018-02-27|2018-03-01|Actual|March 2007||2007-03-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer|A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|24|Actual|AEterna Zentaris||1|||f||||t||||||||||2018-06-01 03:21:40.838093|2018-06-01 03:21:40.838093
NCT00448708|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2011-06-08||2011-10-13|2007-03-15|2007-03-19|Estimate|2011-10-13|2011-11-17|Estimate||||2011-10-13|2011-11-17|Estimate|March 2007||2007-03-31|October 2011|2011-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access|Trial to Assess the Effectiveness of Maintaining Patency and Safety of the Vascular Wrap Paclitaxel-Eluting Mesh After Surgical Implantation With the Lifespan® ePTFE Vascular Graft in the Upper Extremity for Hemodialysis Vascular Access|Terminated||N/A|222|Actual|Angiotech Pharmaceuticals|Due to an observed imbalance in the number of graft infections, enrollment in the 1-year study 012-VWAV06 was suspended at the recommendation of the DSMC. Many of the planned efficacy analyses did not occur as a result of this suspension.|2||Due to an imbalance in graft infections between groups.|f||||t||||||||||2018-06-01 03:21:40.96815|2018-06-01 03:21:40.96815
NCT00448695|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2012-06-14|2007-03-16|2007-03-19|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer|Phase 1 Study of MRI Targeted Focal Laser Thermal Therapy of Biopsy Confirmed Prostate Cancer|Completed||Phase 1|12|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 03:21:41.449485|2018-06-01 03:21:41.449485
NCT00448682|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2013-02-21||2016-12-14|2007-03-15|2007-03-19|Estimate|2013-03-29|2013-05-13|Estimate||||2016-12-14|2017-02-07|Estimate|June 2005||2005-06-30|December 2016|2016-12-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery|A Phase II Study of Weekly 24-hour Infusion 5-fluoro-deoxyuridine (FUdR)/Leucovorin With Oxaliplatin and Docetaxel (Taxotere) as First-line Treatment in Patients With Metastatic Gastric Adenocarcinoma (IIT# 14065)|Terminated||Phase 2|25|Actual|University of Miami|The study was terminated prematurely by the University of Miami Institutional Review Board. The results have not been analyzed.|1|||f||||t||||||||||2018-06-01 03:21:41.523853|2018-06-01 03:21:41.523853
NCT00448669|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2012-10-01|2007-03-16|2007-03-19|Estimate|||||||2012-10-01|2012-10-02|Estimate|March 2007||2007-03-31|October 2012|2012-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|TDF2||Botswana TDF/FTC Oral HIV Prophylaxis Trial|Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana|Completed||Phase 2/Phase 3|1219|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 03:21:41.694373|2018-06-01 03:21:41.694373
NCT00448656|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2012-06-18|2007-03-15|2007-03-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ABOLISH-AF||Treatment of Atrial Fibrillation by Minimal Invasive Surgery|Treatment of Atrial Fibrillation by Minimal Invasive Epicardial Pulmonary Vein Isolation: The ABOLISH-AF Study|Completed||Phase 2|15|Actual|University Medical Center Groningen|||||f||||t||||||||||2018-06-01 03:21:41.780719|2018-06-01 03:21:41.780719
NCT00448643|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2016-12-14|2007-03-15|2007-03-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|May 2002||2002-05-31|December 2016|2016-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery|A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium|Completed||Phase 1|12|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 03:21:41.85901|2018-06-01 03:21:41.85901
NCT00448630|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|2009-07-27||2010-06-04|2007-03-16|2007-03-19|Estimate|2010-06-04|2010-07-07|Estimate||||2010-06-04|2010-07-07|Estimate|October 2007||2007-10-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|MESSAGE||An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics|A Multi-Center, Non-Interventional, Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics|Completed|||328|Actual|Pfizer|||1||f||||f||||||Samples With DNA|"~     Whole blood (fasting blood glucose, total cholesterol, LDL cholesterol, HDL cholesterol,~     triglyceride levels)~   "|||2018-06-01 03:21:42.074617|2018-06-01 03:21:42.074617
NCT00448617|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2015-05-28|2007-03-16|2007-03-19|Estimate|||||||2015-05-28|2015-05-29|Estimate|July 2006||2006-07-31|May 2015|2015-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Cigarette Smoke and Susceptibility to Influenza Infection|Cigarette Smoke and Susceptibility to Influenza Infection|Completed|||138|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     nasal lavage fluid, urine, blood, nasal epithelial tissue from subjects who consent to have~     excess samples stored in our repository~   "|||2018-06-01 03:21:43.135269|2018-06-01 03:21:43.135269
NCT00448604|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2010-11-03|2007-03-16|2007-03-19|Estimate|||||||2010-11-03|2010-11-04|Estimate|May 2007||2007-05-31|February 2009|2009-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|VICE||Viral Infections in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Impact of Viral Infections in Patients With Chronic Obstructive Pulmonary Diseases: Virological Work-up During Exacerbations and 1-year Follow-up|Completed|||86|Actual|University Hospital, Geneva|||||f||||f||||||Samples Without DNA|"~     Naso-pharyngeal swaps~   "|||2018-06-01 03:21:43.190356|2018-06-01 03:21:43.190356
NCT00448591|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|2014-12-22||2015-05-21|2007-03-16|2007-03-19|Estimate|2015-05-21|2015-05-25|Estimate||||2015-05-21|2015-05-25|Estimate|September 2006||2006-09-30|May 2015|2015-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||The safety/intent-to-treat (ITT) population was defined as all participants who had signed informed consent, with at least one valid post-baseline assessment and who received at least one dose of bevacizumab.|A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.|An Open-label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-based Chemotherapy in Patients With Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 3|2296|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:21:43.331457|2018-06-01 03:21:43.331457
NCT00448578|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2010-12-07|2007-03-16|2007-03-19|Estimate|||||||2010-12-07|2010-12-09|Estimate|August 2005||2005-08-31|December 2010|2010-12-31|June 2006|Actual|2006-06-30|||||Interventional|STAR||Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients|A Double Dummy & Double Blind, Multicenter, Randomized Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania in Patients With Bipolar Disorder|Completed||Phase 3|150||AstraZeneca|||||f||||||||||||||2018-06-01 03:21:45.579179|2018-06-01 03:21:45.579179
NCT00448565|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2009-01-30|2007-03-15|2007-03-19|Estimate|||||||2009-01-30|2009-02-02|Estimate|January 2007||2007-01-31|January 2009|2009-01-31||||||||Observational|||Prediction of Extubation Success by the Patient||Completed|||200|Actual|Ospedale Regionale Bellinzona e Valli|||||f||||||||||||||2018-06-01 03:21:45.838249|2018-06-01 03:21:45.838249
NCT00448552|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2016-12-14|2007-03-15|2007-03-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|February 2004||2004-02-29|December 2016|2016-12-31|June 2008|Actual|2008-06-30|April 2007|Actual|2007-04-30||Interventional|||Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer|Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine|Completed||Phase 2|30|Anticipated|University of Miami|||||f||||t||||||||||2018-06-01 03:21:45.972826|2018-06-01 03:21:45.972826
NCT00448539|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2012-04-16||2012-11-12|2007-03-15|2007-03-19|Estimate|2012-11-12|2012-12-10|Estimate||||2012-11-12|2012-12-10|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|Completed||Phase 3|286|Actual|Eisai Inc.|This study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.|2|||f||||f||||||||||2018-06-01 03:21:46.191323|2018-06-01 03:21:46.191323
NCT00448526|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2007-03-16|2007-03-16|2007-03-19|Estimate|||||||2007-03-16|2007-03-19|Estimate|December 1997||1997-12-31|March 2007|2007-03-31|August 2006||2006-08-31|||||Interventional|LPD||Effect of Low Protein Diet in Preventing the Progression of Diabetic Nephropathy||Terminated||N/A|||Kanazawa Medical University||||"Terminated: recruiting or enrolling participants has halted and will not resume because low~   protein diet is not feasible nor efficious."|f||||t||||||||||2018-06-01 03:21:47.699252|2018-06-01 03:21:47.699252
NCT00448513|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-16|||2013-07-14|2007-03-16|2007-03-19|Estimate|||||||2013-07-14|2013-07-16|Estimate|June 2007||2007-06-30|April 2009|2009-04-30|April 2012|Actual|2012-04-30|August 2009|Actual|2009-08-31||Interventional|||Effects of Tea Catechin Extracts on Oxidative Damage|Effects of Tea Catechin Extracts on the Frequency Changes of Micronuclei in Peripheral Lymphocytes in Late Middle Aged Healthy Volunteers|Completed||N/A|40|Actual|University of Shizuoka||1|||f||||f||||||||||2018-06-01 03:21:47.777416|2018-06-01 03:21:47.777416
NCT00448500|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2008-05-06|2007-03-14|2007-03-16|Estimate|||||||2008-05-06|2008-05-09|Estimate|February 2006||2006-02-28|May 2008|2008-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Exhaled Breath Condensate (EBC) Assessment in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Measurement of Biomarkers in the Exhaled Breath Condensate in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Completed|||80|Actual|Chinese University of Hong Kong|||||f||||f||||||None Retained|"~     Exhaled breath condensate~   "|||2018-06-01 03:21:47.846287|2018-06-01 03:21:47.846287
NCT00448487|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2015-06-10|2007-03-15|2007-03-16|Estimate|||||||2015-06-10|2015-06-12|Estimate|April 2005||2005-04-30|June 2015|2015-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|ICARER||Haptoglobin Phenotype and Cardiovascular Complications in Diabetic Patients|Prospective Observational Study to Asses the Incidence of CVD Complications in Diabetic Patients Pre-stratified by Haptoglobin Phenotype From the I CARE Registry|Completed|||3054|Actual|Technion, Israel Institute of Technology|||||f||||f||||||||||2018-06-01 03:21:48.039246|2018-06-01 03:21:48.039246
NCT00448474|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-03-15|2007-03-15|2007-03-16|Estimate|||||||2007-03-15|2007-03-16|Estimate|November 2005||2005-11-30|March 2007|2007-03-31|July 2006||2006-07-31|||||Interventional|||Development and Evaluation of A Mailed Arthritis Self-Management Program|Mail-Delivered Arthritis Self-Management Education -- Years 1, 2, Carryover|Completed||N/A|900||University of North Carolina, Chapel Hill|||||f||||t||||||||||2018-06-01 03:21:48.131773|2018-06-01 03:21:48.131773
NCT00448461|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2009-02-09|2007-03-14|2007-03-16|Estimate|||||||2009-02-09|2009-02-10|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|ARNO||Antithrombotic Regimens and Outcome|Comparison of Bivalirudin and Unfractioned Heparin in Elective Percutaneous Coronary Interventions|Completed||Phase 4|850|Actual|Careggi Hospital||2|||f||||t||||||||||2018-06-01 03:21:48.276268|2018-06-01 03:21:48.276268
NCT00448448|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2014-05-19||2017-07-12|2007-03-14|2007-03-16|Estimate|2014-06-23|2014-07-23|Estimate||||2017-07-12|2017-08-11|Actual|February 2007||2007-02-28|July 2017|2017-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|BrAIST|Age, gender, race, height, Scoliosis Research Society curve classification, Cobb angle, Risser grade|Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)|Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)|Terminated||N/A|383|Actual|University of Iowa|Study was terminated early due to efficacy. 119 subjects were still on protocol.|2||Stopped for efficacy|f||||t||||||||||2018-06-01 03:21:48.519204|2018-06-01 03:21:48.519204
NCT00448435|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2009-01-19||2010-06-03|2007-03-15|2007-03-16|Estimate|2009-06-25|2009-08-11|Estimate||||2010-06-03|2010-06-08|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma|A Study to Compare GW815SF HFA MDI With Concomitant Treatment With Salmeterol Xinafoate DPI Plus Fluticasone Propionate DPI and to Assess Long-term Safety of GW815SF HFA MDI|Completed||Phase 3|51|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:21:49.738242|2018-06-01 03:21:49.738242
NCT00448422|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15||2010-08-27|2010-09-22|2007-03-15|2007-03-16|Estimate||||2010-08-27|2010-08-31|Estimate|2010-09-22|2010-09-27|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers|A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers|Completed||Phase 3|268|Actual|Optimer Pharmaceuticals LLC||2|||f||||f||||||||||2018-06-01 03:21:50.239956|2018-06-01 03:21:50.239956
NCT00448409|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2016-03-15|2007-03-14|2007-03-16|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2006||2006-05-31|March 2016|2016-03-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer|A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer|Completed||Phase 2|27|Actual|The Methodist Hospital System||2|||f||||f||||||||No||2018-06-01 03:21:50.380959|2018-06-01 03:21:50.380959
NCT00448396|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2009-11-18|2007-03-15|2007-03-16|Estimate|||||||2009-11-18|2009-11-19|Estimate|March 2007||2007-03-31|November 2009|2009-11-30||||February 2008|Actual|2008-02-29||Interventional|||Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies|Completed||Phase 1|17|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:21:50.568965|2018-06-01 03:21:50.568965
NCT00448383|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2008-07-31|2007-03-14|2007-03-16|Estimate|||||||2008-07-31|2008-08-04|Estimate|September 2002||2002-09-30|July 2008|2008-07-31||||November 2004|Actual|2004-11-30||Interventional|ReAct||A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis|An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|6610|Actual|Abbott||1|||f||||||||||||||2018-06-01 03:21:50.648438|2018-06-01 03:21:50.648438
NCT00448370|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2017-12-19|2007-03-14|2007-03-16|Estimate|||||||2017-12-19|2017-12-21|Actual|March 2007||2007-03-31|December 2017|2017-12-31||||December 2012|Actual|2012-12-31||Observational|||Role of Placenta Growth Factor in Sickle Acute Chest Syndrome|Role of Placenta Growth Factor in Sickle Acute Chest Syndrome|Completed|||136|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 03:21:50.72579|2018-06-01 03:21:50.72579
NCT00448357|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2017-04-17||2017-06-16|2007-03-15|2007-03-16|Estimate|2017-06-16|2017-07-17|Actual||||2017-06-16|2017-07-17|Actual|October 2005||2005-10-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|LCCC0510||Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen|Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen|Completed||Phase 1/Phase 2|54|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||No||2018-06-01 03:21:50.821427|2018-06-01 03:21:50.821427
NCT00448344|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2014-08-13||2015-04-06|2007-03-15|2007-03-16|Estimate|2014-08-13|2014-08-27|Estimate||||2015-04-06|2015-04-24|Estimate|February 2008||2008-02-29|August 2014|2014-08-31|July 2012|Actual|2012-07-31|September 2010|Actual|2010-09-30||Interventional|||Family-supported Smoking Cessation for Chronically Ill Veterans|Family-Supported Smoking Cessation for Chronically Ill Veterans|Completed||N/A|471|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:21:51.226745|2018-06-01 03:21:51.226745
NCT00448331|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-10-31|2007-03-14|2007-03-16|Estimate|||||||2007-10-31|2007-11-02|Estimate|June 2004||2004-06-30|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Observational|MI||Facilitated Referral for Children Screening Positive for Mental Illness|Facilitated Referral for Children Screening Positive for Mental Illness in the Pediatric Emergency Department and Readiness to Seek Care|Completed|||551|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-06-01 03:21:51.491356|2018-06-01 03:21:51.491356
NCT00448318|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-03-14|2007-03-14|2007-03-16|Estimate|||||||2007-03-14|2007-03-16|Estimate|March 2007||2007-03-31|February 2007|2007-02-28|October 2008||2008-10-31|||||Interventional|||Evaluating the Effects of Music Interventions on Hospitalised People With Dementia|Evaluating the Effects of Music Interventions on Hospitalised People With Dementia|Unknown status|Not yet recruiting|Phase 2/Phase 3|180||National Ageing Research Institute, Australia|||||f||||f||||||||||2018-06-01 03:21:51.553447|2018-06-01 03:21:51.553447
NCT00448305|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2012-01-03|2007-03-15|2007-03-16|Estimate|||||||2012-01-03|2012-01-05|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|March 2011|Actual|2011-03-31|February 2010|Actual|2010-02-28||Interventional|||EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients|An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients|Completed||Phase 2|143|Actual|MediGene||3|||f||||t||||||||||2018-06-01 03:21:51.666835|2018-06-01 03:21:51.666835
NCT00448292|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-11-09|2007-03-15|2007-03-16|Estimate|||||||2007-11-09|2007-11-14|Estimate|March 2007||2007-03-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of PRX-00023 in Patients With Major Depressive Disorder.|Completed||Phase 2|330|Anticipated|Epix Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 03:21:51.801919|2018-06-01 03:21:51.801919
NCT00448279|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2014-10-21||2014-10-21|2007-03-15|2007-03-16|Estimate|2014-10-21|2014-10-24|Estimate||||2014-10-21|2014-10-24|Estimate|April 2007||2007-04-30|October 2014|2014-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||Intent-to-treat (ITT) population: all randomized participants.|THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.|A Randomized, Open-label Study to Compare Progression-free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin|Completed||Phase 3|58|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:21:51.943293|2018-06-01 03:21:51.943293
NCT00448266|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2010-10-25|2007-03-15|2007-03-16|Estimate|||||||2010-10-25|2010-10-26|Estimate|May 2007||2007-05-31|October 2010|2010-10-31||||February 2010|Actual|2010-02-28||Interventional|||Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD|Randomized Phase II/III Study of Intensified Alkylating Agent Chemotherapy With Peripheral Blood Progenitor Cell Support in the Preoperative Chemotherapy of Breast Tumors That Are Deficient for Homologous Recombination.|Terminated||Phase 2/Phase 3|237|Anticipated|The Netherlands Cancer Institute||2||Activation of a similar multicenter study for same population|f||||f||||||||||2018-06-01 03:21:52.284506|2018-06-01 03:21:52.284506
NCT00448253|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2011-03-25|2007-03-14|2007-03-16|Estimate|||||||2011-03-25|2011-03-29|Estimate|July 2007||2007-07-31|March 2011|2011-03-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum|Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers.|Completed||Phase 1|92|Actual|Cangene Corporation||2|||f||||t||||||||||2018-06-01 03:21:52.34643|2018-06-01 03:21:52.34643
NCT00448240|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2010-02-01|2007-03-14|2007-03-16|Estimate|||||||2010-02-01|2010-02-02|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|January 2015|Anticipated|2015-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer|Erlotinib (Tarceva) Given Intermittently During First Line Standard Platinum Containing Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2/Phase 3|6|Actual|Henry Ford Health System||||Low Accrual, Funding|f||||f||||||||||2018-06-01 03:21:52.418438|2018-06-01 03:21:52.418438
NCT00448227|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2010-11-12||2011-02-09|2007-03-15|2007-03-16|Estimate|2010-11-12|2010-12-14|Estimate||||2011-02-09|2011-02-11|Estimate|October 2007||2007-10-31|February 2011|2011-02-28||||November 2008|Actual|2008-11-30||Interventional|||Pharmacokinetics, Acceptability and Safety of Famciclovir in Infants (1 Month to Less Than 12 Months) With Herpes Simplex Infection|A Multicenter, Open-label, Single-arm Study to Evaluate the Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections|Completed||Phase 2|18|Actual|Novartis||1|||f||||f||||||||||2018-06-01 03:21:52.585135|2018-06-01 03:21:52.585135
NCT00448214|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2011-12-15|2007-03-15|2007-03-16|Estimate|||||||2011-12-15|2011-12-19|Estimate|March 2007||2007-03-31|December 2011|2011-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation|Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin|Completed||Phase 2|448|Actual|Astellas Pharma Inc||4|||f||||t||||||||||2018-06-01 03:21:52.905472|2018-06-01 03:21:52.905472
NCT00448201|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2017-04-17||2017-05-23|2007-03-15|2007-03-16|Estimate|2017-05-23|2017-05-30|Actual||||2017-05-23|2017-05-30|Actual|January 7, 2011|Actual|2011-01-07|May 2017|2017-05-31|May 23, 2012|Actual|2012-05-23|January 11, 2011|Actual|2011-01-11||Interventional|||Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease|Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen|Completed||Phase 2|71|Actual|UNC Lineberger Comprehensive Cancer Center|Per the protocol, non-serious adverse events were not captured as this was a high-dose transplant study and grades 1,2, and 3 adverse events were expected. No unexpected toxicities were seen beyond those reported in the Serious Adverse Event section.|4|||f||||t||||||||||2018-06-01 03:21:53.001478|2018-06-01 03:21:53.001478
NCT00448188|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2013-01-25|2007-03-15|2007-03-16|Estimate|||||||2013-01-25|2013-01-28|Estimate|November 2005||2005-11-30|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Bleeding Risk in CVCs|Thrombocytes and International Normalized Ratio Are no Predictors for Bleeding in Application of Central Veneous Catheters|Completed||N/A|200|Anticipated|Heidelberg University|||||f||||t||||||||||2018-06-01 03:21:53.414015|2018-06-01 03:21:53.414015
NCT00448175|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2013-01-24||2013-04-04|2007-03-15|2007-03-16|Estimate|2013-04-04|2013-05-16|Estimate||||2013-04-04|2013-05-16|Estimate|June 2006||2006-06-30|April 2013|2013-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|OrBIT||Overactive Bladder Innovative Therapy Trial (OrBIT)|Overactive Bladder Innovative Therapy Trial|Completed||Phase 4|100|Actual|Uroplasty, Inc||1|||f||||||||||||||2018-06-01 03:21:53.49743|2018-06-01 03:21:53.49743
NCT00448162|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2011-03-30|2007-03-15|2007-03-16|Estimate|||||||2011-03-30|2011-03-31|Estimate|May 2005||2005-05-31|May 2009|2009-05-31|December 2009||2009-12-31|||||Observational|||The Chinese Mutation Hotspot of ENaC Causing Liddle's Syndrome and the Association of ENaC Variations and Hypertension||Suspended|||2000|Anticipated|Peking Union Medical College||||no enough fund|f||||t||||||||||2018-06-01 03:21:53.797408|2018-06-01 03:21:53.797408
NCT00448149|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|||2016-03-15|2007-03-15|2007-03-16|Estimate|||||||2016-03-15|2016-03-17|Estimate|December 2006||2006-12-31|March 2016|2016-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer|Phase I/II Trial of RAD001 Plus Nexavar® For Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|55|Actual|The Methodist Hospital System||1|||f||||f||||||||No||2018-06-01 03:21:53.877027|2018-06-01 03:21:53.877027
NCT00448136|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-15|2014-10-31||2015-01-20|2007-03-15|2007-03-16|Estimate|2015-01-20|2015-01-22|Estimate||||2015-01-20|2015-01-22|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Intent-to-treat (ITT) population: all participants who received at least 1 dose of treatment.|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.|An Open Label Study to Evaluate the Effect of Avastin in Association With Chemotherapy on Progression-free Survival in Patients With Progressive Advanced/Metastatic Well-differentiated Digestive Endocrine Tumors of the Gastrointestinal Tract|Completed||Phase 2|83|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:21:54.1458|2018-06-01 03:21:54.1458
NCT00448123|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|2013-12-24||2016-10-11|2007-03-13|2007-03-15|Estimate|2016-10-11|2016-10-12|Estimate||||2016-10-11|2016-10-12|Estimate|February 2007||2007-02-28|October 2016|2016-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients|The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients|Completed||N/A|127|Actual|William Beaumont Hospitals|Limitations of this study include non-consecutive enrollment and small sample size.|2|||f||||f||||||||No||2018-06-01 03:21:55.429378|2018-06-01 03:21:55.429378
NCT00447941|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2009-08-06|2007-03-14|2007-03-15|Estimate|||||||2009-08-06|2009-08-07|Estimate|June 2006||2006-06-30|August 2009|2009-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Safety, PK and PD Study in Healthy Male Japanese Subjects|Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sca-136 Administered Orally to Healthy Male Japanese Subjects|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:21:57.854747|2018-06-01 03:21:57.854747
NCT00448110|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2009-05-21|2007-03-13|2007-03-15|Estimate|||||||2009-05-21|2009-05-22|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery|Randomized, Double-Blind, Active- and Placebo-Controlled Study of the Efficacy and Safety of Repeated Dosing of DIC075V Relative To Parenteral Ketorolac and Placebo in Patients With Acute Post-Op Pain After Abdominal or Pelvic Surgery|Completed||Phase 3|331|Actual|Javelin Pharmaceuticals||4|||f||||f||||||||||2018-06-01 03:21:55.639851|2018-06-01 03:21:55.639851
NCT00448097|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2016-03-15|2007-03-14|2007-03-15|Estimate|||||||2016-03-15|2016-03-17|Estimate|February 2007||2007-02-28|March 2016|2016-03-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy|A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate|Terminated||Phase 2|7|Actual|The Methodist Hospital System||1||lack of patient population - slow accrual|f||||f||||||||No||2018-06-01 03:21:55.735227|2018-06-01 03:21:55.735227
NCT00448084|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2017-06-30|2007-03-14|2007-03-15|Estimate|||||||2017-06-30|2017-07-02|Actual|March 8, 2007||2007-03-08|August 5, 2008|2008-08-05|August 5, 2008||2008-08-05|||||Observational|||Brain Activity in People With Functional Movement Disorders|BOLD-fMRI of the Perception of Volition in Functional Movement Disorders|Completed|||65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:21:55.807985|2018-06-01 03:21:55.807985
NCT00448071|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-03-14|2007-03-14|2007-03-15|Estimate|||||||2007-03-14|2007-03-15|Estimate|May 2006||2006-05-31|December 2006|2006-12-31|March 2007||2007-03-31|||||Interventional|||Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients|A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients|Unknown status|Recruiting|Phase 2|12||Wolfson Medical Center|||||f||||t||||||||||2018-06-01 03:21:55.853932|2018-06-01 03:21:55.853932
NCT00448058|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13||2009-11-30|2014-10-02|2007-03-13|2007-03-15|Estimate||||2009-11-30|2009-12-02|Estimate|2014-10-02|2014-10-10|Estimate|April 2007||2007-04-30|November 2011|2011-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study Of New Medicine (GSK 372475) For The Treatment Of Depression|A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/Day to 2.0 mg/Day) or Extended Release Venlafaxine XR (150 mg/Day to 225 mg/Day) Compared to Placebo in Adult s|Completed||Phase 2|396|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:21:55.928198|2018-06-01 03:21:55.928198
NCT00448045|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2013-01-14|2007-03-13|2007-03-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|June 2007||2007-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Preventing Pneumonia and Other Respiratory Problems in Persons With Spinal Cord Injury|Prevention of Long-Term Respiratory Complications of Spinal Cord Injury: a Randomized Controlled Trial|Completed||Phase 2|120|Actual|Kessler Foundation||2|||f||||t||||||||||2018-06-01 03:21:56.039845|2018-06-01 03:21:56.039845
NCT00448032|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-12-03|2007-03-14|2007-03-15|Estimate|||||||2007-12-03|2007-12-05|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating Multiple Oral Doses of PPM-204 in Healthy Japanese Male Subjects|A Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Ppm-204 Administered Orally to Healthy Male Japanese Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:21:56.116716|2018-06-01 03:21:56.116716
NCT00448019|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|2015-07-13||2015-10-05|2007-03-14|2007-03-15|Estimate|2015-10-05|2015-11-02|Estimate||||2015-10-05|2015-11-02|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Two participants included in the study demographics were registered but withdrew prior to receiving treatment.|FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)|Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 2|64|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:21:56.168245|2018-06-01 03:21:56.168245
NCT00448006|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-03-14|2007-03-14|2007-03-15|Estimate|||||||2007-03-14|2007-03-15|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|December 2008||2008-12-31|||||Interventional|||Clinical Feasibility Study of Allium's Biliary Stent|A Clinical Feasibility Study to Evaluate the New Allium Biliary Stent, in Patients Suffering From “Malignant Biliary Duct Obstruction” (Endoscopic Insertion)|Unknown status|Not yet recruiting|N/A|30||Allium, Ltd.|||||f||||f||||||||||2018-06-01 03:21:57.315681|2018-06-01 03:21:57.315681
NCT00447993|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09||2016-11-15|2016-11-15|2007-03-14|2007-03-15|Estimate||||2016-11-15|2016-11-16|Estimate|2016-11-15|2016-11-16|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa|A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome|Completed||Phase 2|65|Actual|Neurotech Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:21:57.38367|2018-06-01 03:21:57.38367
NCT00447980|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09||2016-11-15|2016-11-15|2007-03-14|2007-03-15|Estimate||||2016-11-15|2016-11-16|Estimate|2016-11-15|2016-11-16|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa|A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome|Completed||Phase 2|68|Actual|Neurotech Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:21:57.474652|2018-06-01 03:21:57.474652
NCT00447967|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2009-09-25|2007-03-14|2007-03-15|Estimate|||||||2009-09-25|2009-09-28|Estimate|July 2004||2004-07-31|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients|A Randomized Phase II Study of Irinotecan and Oxaliplatin Versus the Combination of 5-FU/LV and Oxaliplatin, as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer|Completed||Phase 2|110|Anticipated|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 03:21:57.56076|2018-06-01 03:21:57.56076
NCT00447954|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09||2016-11-15|2016-11-15|2007-03-14|2007-03-15|Estimate||||2016-11-15|2016-11-16|Estimate|2016-11-15|2016-11-16|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration|A Phase II Study of Implants of Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Participants With Visual Acuity Impairment Associated With Atrophic Macular Degeneration|Completed||Phase 2|51|Actual|Neurotech Pharmaceuticals||3|||f||||t||||||||||2018-06-01 03:21:57.755646|2018-06-01 03:21:57.755646
NCT00447928|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-03-13|2007-03-13|2007-03-15|Estimate|||||||2007-03-13|2007-03-15|Estimate|April 2007||2007-04-30|March 2007|2007-03-31|November 2007||2007-11-30|||||Interventional|||Phase II Dose-Ranging Study of OrthoDerm Patch for Patients With Tennis Elbow|A Randomized, Double-Blind, Placebo-Controlled Phase II Dose-Ranging Study of the OrthoDerm Transdermal Nitroglycerin Patch for Patients With Chronic Lateral Epicondylitis|Unknown status|Not yet recruiting|Phase 2|164||Cure Therapeutics|||||f||||f||||||||||2018-06-01 03:21:57.907142|2018-06-01 03:21:57.907142
NCT00447915|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2012-07-31|2007-03-14|2007-03-15|Estimate|||||||2012-07-31|2012-08-02|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis|Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index -|Completed||Phase 3|1265|Actual|Chugai Pharmaceutical||3|||f||||f||||||||||2018-06-01 03:21:57.988465|2018-06-01 03:21:57.988465
NCT00447902|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2009-09-25||2014-04-25|2007-03-14|2007-03-15|Estimate|2009-11-18|2009-12-23|Estimate||||2014-04-25|2014-05-14|Estimate|March 2007||2007-03-31|April 2014|2014-04-30||||October 2008|Actual|2008-10-31||Interventional|||Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation|Safety and Antiviral Activity of TPV in Hepatitis C or Hepatitis B HIV Coinfected Patients - TDM Randomised Pilot Evaluation|Terminated||Phase 3|11|Actual|Boehringer Ingelheim|Due to an early termination of the trial no analysis has been performed for primary and secondary endpoints||||f||||||||||||||2018-06-01 03:21:58.144618|2018-06-01 03:21:58.144618
NCT00447889|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2008-11-25|2007-03-14|2007-03-15|Estimate|||||||2008-11-25|2008-11-26|Estimate|March 2006||2006-03-31|November 2008|2008-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography|A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR)|Completed||Phase 4|||Guerbet|||||f||||f||||||||||2018-06-01 03:21:58.658732|2018-06-01 03:21:58.658732
NCT00447876|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|2017-04-06||2017-07-13|2007-03-13|2007-03-15|Estimate|2017-04-06|2017-06-23|Actual||||2017-07-13|2017-08-21|Actual|July 2005||2005-07-31|July 2017|2017-07-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional||Baseline characteristics are presented for all patients randomized in the study.|Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis|Double-blind, Placebo-controlled, Randomised, Multicentre Study on the Efficacy and Safety of a Single Injection of Botulinum Toxin A (200 Units Dysport®) in the Treatment of Chronic Plantar Fasciitis|Completed||Phase 2/Phase 3|40|Actual|Ipsen||2|||f||||f||||||||||2018-06-01 03:21:58.758198|2018-06-01 03:21:58.758198
NCT00447863|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2010-08-21|2007-03-14|2007-03-15|Estimate|||||||2010-08-21|2010-08-24|Estimate|August 2007||2007-08-31|August 2010|2010-08-31|August 2007||2007-08-31|||||Interventional|||Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women|An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study to Compare Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg in 2 Dosage Forms With Different Dissolution Characteristics in Healthy, Cycling Women|Withdrawn||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:21:59.500638|2018-06-01 03:21:59.500638
NCT00447850|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2009-09-18|2007-03-13|2007-03-15|Estimate|||||||2009-09-18|2009-09-21|Estimate|April 2007||2007-04-30|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization|Endometrial Gene Expression Profile in Controlled Ovarian Stimulation Cycles With Premature Luteinization|Completed||N/A|||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||||||||||||2018-06-01 03:21:59.555678|2018-06-01 03:21:59.555678
NCT00447837|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2008-03-13|2007-03-13|2007-03-15|Estimate|||||||2008-03-13|2008-03-17|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Evaluating SPRC-AB01 in Post-Surgical Subjects With Chronic Sinusitis|A Phase 2, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating the Safety and Efficacy of SPRC-AB01, Tobramycin Solution for Nasal Inhalation, in Post-Surgical Subjects With Chronic Sinusitis|Completed||Phase 2|180|Actual|Naryx Pharma||3|||f||||f||||||||||2018-06-01 03:21:59.655539|2018-06-01 03:21:59.655539
NCT00447824|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-03-13|2007-03-13|2007-03-15|Estimate|||||||2007-03-13|2007-03-15|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|November 2009||2009-11-30|||||Interventional|||Pain Detection and Interception in Neonates|Pain Detection and Interception in Neonates During Blood Sampling|Unknown status|Recruiting|N/A|160||Sorlandet Hospital HF|||||f||||t||||||||||2018-06-01 03:21:59.784536|2018-06-01 03:21:59.784536
NCT00447811|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2011-07-22|2007-03-13|2007-03-15|Estimate|||||||2011-07-22|2011-07-25|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|May 2007|Actual|2007-05-31|||||Interventional|||Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance|Two Ascending Single Doses Crossover, Placebo Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MOA-728 Administered Orally to Subjects on Stable Methadone Maintenance|Completed||Phase 1|||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:21:59.85253|2018-06-01 03:21:59.85253
NCT00447798|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2015-03-31|2007-03-14|2007-03-15|Estimate|||||||2015-03-31|2015-04-01|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users|Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users|Completed||N/A|413|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 03:21:59.910968|2018-06-01 03:21:59.910968
NCT00447785|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-03-14|2007-03-14|2007-03-15|Estimate|||||||2007-03-14|2007-03-15|Estimate|September 2004||2004-09-30|March 2007|2007-03-31||||||||Observational|||Endocrine Regulation of Energy and Fluid Supplies in Alcoholic Patients|Etude Des déterminants Endocrinologiques Des Apports énergétiques et Fluides Des Patients Alcooliques en Cours de Sevrage|Unknown status|Recruiting||300||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-06-01 03:21:59.981023|2018-06-01 03:21:59.981023
NCT00447772|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2009-07-23|2007-03-13|2007-03-15|Estimate|||||||2009-07-23|2009-07-24|Estimate|October 2004||2004-10-31|July 2009|2009-07-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia|Open Multicentre Study to Demonstrate the Efficacy and Safety of Botulinum Toxin A (500 Units Dysport®) in the Treatment of Heterogeneous Forms of Cervical Dystonia|Completed||Phase 3|516|Actual|Ipsen||1|||f||||f||||||||||2018-06-01 03:22:00.102546|2018-06-01 03:22:00.102546
NCT00447759|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2016-01-07|2007-03-14|2007-03-15|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2007||2007-06-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SCOTLSSS||The Standard Care Versus Celecoxib Outcome Trial|Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's|Completed||Phase 4|7300|Actual|University of Dundee||2|||f||||t||||||||||2018-06-01 03:22:00.405305|2018-06-01 03:22:00.405305
NCT00447746|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-03-14|2007-03-14|2007-03-15|Estimate|||||||2007-03-14|2007-03-15|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|March 2014||2014-03-31|||||Interventional|||A Comparison Between D1 and D2 Lymphadenectomy in Gastric Cancer : A Prospective Randomized Controlled Trial|A Comparison Between D1 and D2 Lymphadenectomy in Gastric Cancer : A Prospective Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|600||Tata Memorial Hospital|||||f||||t||||||||||2018-06-01 03:22:00.552226|2018-06-01 03:22:00.552226
NCT00447733|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2012-03-23|2007-03-14|2007-03-15|Estimate|||||||2012-03-23|2012-03-26|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ROP||Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders|Effects of Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders|Completed||N/A|76|Actual|University of Oslo||2|||f||||t||||||||||2018-06-01 03:22:00.637154|2018-06-01 03:22:00.637154
NCT00447720|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2015-12-01|2007-03-14|2007-03-15|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2004||2004-06-30|December 2015|2015-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||HIV Prevention Among Substance Abusing SMI|Translation of CDC and NIDA Programs to Prevent HIV/AIDS Among Persons With Serious Mental Illness|Completed||Phase 3|238|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:22:00.728488|2018-06-01 03:22:00.728488
NCT00447707|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2017-01-11|2007-03-14|2007-03-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2003||2003-12-31|March 2007|2007-03-31|September 2006||2006-09-30|||||Interventional|||Positive Choice: Prevention for Positive Health|Positive Choice: Prevention for Positive Health|Completed||N/A|497||National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 03:22:00.803992|2018-06-01 03:22:00.803992
NCT00447694|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2016-09-22|2007-03-13|2007-03-15|Estimate|||||||2016-09-22|2016-09-23|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment|An Open Label Trial Evaluating Cardiac T2* in Beta-thalassemia Patients on Deferasirox (ICL670) Treatment for 18 Months|Completed||Phase 2|30|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:22:00.87078|2018-06-01 03:22:00.87078
NCT00447681|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-12-11|2007-03-14|2007-03-15|Estimate|||||||2007-12-11|2007-12-13|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetiks, and Pharmacodynamics of ILV-094 Administered Intravenously and One Dose of ILV-094 Administered Subcutaneously to Healthy Subjects|Completed||Phase 1|56|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:22:00.951666|2018-06-01 03:22:00.951666
NCT00447668|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2017-10-11|2007-03-13|2007-03-15|Estimate|||||||2017-10-11|2017-10-13|Actual|March 2007||2007-03-31|October 2017|2017-10-31|August 2011|Actual|2011-08-31|August 2009|Actual|2009-08-31||Interventional|YES||Effect of Yoga Vs. Stretching on Chronic Back Pain|Effect of Yoga Vs. Stretching on Chronic Back Pain|Completed||Phase 2|210|Anticipated|Kaiser Permanente||3|||f||||t||||||||||2018-06-01 03:22:01.012922|2018-06-01 03:22:01.012922
NCT00447655|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2017-12-12|2007-03-14|2007-03-15|Estimate|||||||2017-12-12|2017-12-13|Actual|March 2007||2007-03-31|December 2017|2017-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PALS-PLUS||Improving Outcomes Following Limb Loss: PALS Plus|Improving Outcomes Following Limb Loss: PALS Plus|Completed||Phase 1/Phase 2|400|Actual|Johns Hopkins University|||||f||||t||||||||||2018-06-01 03:22:01.093763|2018-06-01 03:22:01.093763
NCT00447642|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2012-10-09|2007-03-13|2007-03-15|Estimate|||||||2012-10-09|2012-10-11|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|January 2010|Actual|2010-01-31|August 2008|Actual|2008-08-31||Interventional|||Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty|A Multi-center, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 Implantation for the Prevention of Corneal Allograft Rejection Episodes or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty|Terminated||Phase 3|122|Actual|Lux Biosciences, Inc.||3||The primary efficacy endpoint was not met|f||||t||||||||||2018-06-01 03:22:01.191701|2018-06-01 03:22:01.191701
NCT00447629|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|||2007-12-03|2007-03-14|2007-03-15|Estimate|||||||2007-12-03|2007-12-05|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart|A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)- Controlled, 4-Period Crossover Study of the Effects of Single Oral Doses of PPM 204 on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:22:01.342827|2018-06-01 03:22:01.342827
NCT00447616|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2017-12-21|2007-03-13|2007-03-15|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2003||2003-10-31|December 2017|2017-12-31|April 7, 2015|Actual|2015-04-07|April 7, 2015|Actual|2015-04-07||Observational|||Prostatectomy Prospective Database|Prostatectomy Database|Terminated|||896|Actual|William Beaumont Hospitals||||Lack of funding|f||||f||||||||No||2018-06-01 03:22:01.419299|2018-06-01 03:22:01.419299
NCT00447603|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2014-01-23||2017-02-15|2007-03-14|2007-03-15|Estimate|2014-01-23|2014-03-05|Estimate||||2017-02-15|2017-03-21|Actual|May 2007||2007-05-31|February 2017|2017-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional||All enrolled population which included all participants who provided consent and entered screening period of study.|A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)|A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Essential Hypertension|Terminated||Phase 3|40|Actual|Merck Sharp & Dohme Corp.|The study was discontinued early (during screening) due to limited availability of sites and readiness of sites to enroll participants within the predefined time.|4||Achieving site readiness and enrolling the trial within a reasonable time|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:22:01.506485|2018-06-01 03:22:01.506485
NCT00447590|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-14|2014-09-16||2014-09-22|2007-03-14|2007-03-15|Estimate|2014-09-16|2014-09-23|Estimate||||2014-09-22|2014-10-02|Estimate|March 2007||2007-03-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|January 2009|Actual|2009-01-31||Interventional||The baseline population consisted of all subjects who were implanted with the LAP-BAND System.|Effectiveness and Safety Study of LAP-BAND Treatment for Obese Adolescents||Completed||N/A|153|Actual|Apollo Endosurgery, Inc.||1|||f||||||||||||||2018-06-01 03:22:01.849234|2018-06-01 03:22:01.849234
NCT00447395|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2015-10-21|2007-03-13|2007-03-14|Estimate|||||||2015-10-21|2015-10-22|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Genetic Abnormalities and Oxidative Stress in Sperm as Cause of Recurrent Miscarriage.|Genetic Abnormalities and Oxidative Stress in Sperm as Cause of Recurrent Miscarriage.|Completed|||90|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA|||4||f||||f||||||||||2018-06-01 03:22:04.061516|2018-06-01 03:22:04.061516
NCT00447577|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2011-12-07|2007-03-12|2007-03-14|Estimate|||||||2011-12-07|2011-12-09|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Zylet vs TobraDex in Blepharokeratoconjunctivitis|A Clinical Safety and Efficacy Evaluation of Zylet (Loteprednol Etabonate and Tobramycin Ophthalmic Suspension) vs. Tobradex (Tobramycin and Dexamethasone Ophthalmic Suspension) in the Treatment of Blepharokeratoconjunctivitis|Completed||Phase 4|276|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:22:02.112062|2018-06-01 03:22:02.112062
NCT00447564|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12||2011-01-05|2017-06-12|2007-03-12|2007-03-14|Estimate||||2012-10-18|2012-10-23|Estimate|2017-06-12|2017-06-14|Actual|October 2006||2006-10-31|June 2017|2017-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence|Completed||Phase 3|163|Actual|Braeburn Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:22:02.17103|2018-06-01 03:22:02.17103
NCT00447551|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2009-11-12|2007-03-13|2007-03-14|Estimate|||||||2009-11-12|2009-11-13|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Canadian Aesthetic Experience With Sculptra Therapy|Canadian Study of the Use of Injectable POLY-L-LACTIC Acid (Sculptra Therapy) in Aesthetic Medicine|Completed||Phase 4|76|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:22:02.248381|2018-06-01 03:22:02.248381
NCT00447538|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2013-04-29|2007-03-13|2007-03-14|Estimate|||||||2013-04-29|2013-04-30|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|January 2007||2007-01-31|||||Observational|||Posttraumatic Symptoms Among Toddlers and Their Parents Following Exposure to Terrorism|Identifying Distress, Developmental and Behavioral Problems Among Toddlers, and Posttraumatic Distress Among Their Parents Following Continuous Exposure to Terrorism|Completed|||300||Herzog Hospital|||||f||||t||||||||||2018-06-01 03:22:02.392502|2018-06-01 03:22:02.392502
NCT00447525|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2017-09-08|2007-03-13|2007-03-14|Estimate|||||||2017-09-08|2017-09-11|Actual|February 2007|Actual|2007-02-28|September 2017|2017-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children|Comparison of the Immunogenicity and Safety of a Combined Adsorbed Low Dose Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (REVAXIS®) With a Combined Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (DT Polio®) When Given as a Booster Dose at 6 Years of Age|Completed||Phase 3|760|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:22:02.467859|2018-06-01 03:22:02.467859
NCT00447512|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-10-29|2007-03-13|2007-03-14|Estimate|||||||2007-10-29|2007-10-31|Estimate|March 2004||2004-03-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones|Effects of Ghrelin on the Sleep-EEG and Nocturnal Secretion of Hormones|Completed||N/A|80|Anticipated|Max-Planck-Institute of Psychiatry|||||f||||f||||||||||2018-06-01 03:22:02.633316|2018-06-01 03:22:02.633316
NCT00447499|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2010-03-23||2012-06-18|2007-03-12|2007-03-14|Estimate|2010-11-23|2010-12-20|Estimate||||2012-06-18|2012-06-25|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|SALSA||Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel|A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel|Completed||Phase 3|59|Actual|Ipsen||1|||f||||||||||||||2018-06-01 03:22:02.703989|2018-06-01 03:22:02.703989
NCT00447486|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2009-05-15|2007-03-12|2007-03-14|Estimate|||||||2009-05-15|2009-05-18|Estimate|April 2007||2007-04-30|May 2009|2009-05-31||||||||Interventional|||A Study of GW842166 in Adults With Osteoarthritis Pain|A Multicentre, Randomised, Double-Blind, Placebo and Naproxen (500mg) BID Controlled, Phase II Proof of Concept, Parallel Group Study to Assess the Efficacy and Safety of Oral GW842166 at Two Dose Levels Administered for 4 Weeks in Adults With Osteoarthritis of the Knee|Completed||Phase 2|308|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:22:03.097622|2018-06-01 03:22:03.097622
NCT00447473|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2016-03-15|2007-03-12|2007-03-14|Estimate|||||||2016-03-15|2016-03-17|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer|Phase II Trial to Assess the Activity of Ketoconazole and Mitoxantrone Plus GM-CSF in Patients With Progressive Hormone Refractory Prostate Cancer|Terminated||Phase 2|31|Actual|The Methodist Hospital System||1||PI decision|f||||f||||||||No||2018-06-01 03:22:03.209352|2018-06-01 03:22:03.209352
NCT00447460|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-03-20|2007-03-13|2007-03-14|Estimate|||||||2007-03-20|2007-03-22|Estimate|January 2007||2007-01-31|March 2007|2007-03-31|August 2009|Anticipated|2009-08-31|||||Interventional|||Treatment of Refractory (Acute or Chronic) Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell|A Phase I/II Trial in Treating Patients With Graft-Versus-Host Disease by the Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell|Unknown status|Recruiting|Phase 1/Phase 2|15||University of Salamanca|||||f||||t||||||||||2018-06-01 03:22:03.32034|2018-06-01 03:22:03.32034
NCT00447434|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-03-13|2007-03-13|2007-03-14|Estimate|||||||2007-03-13|2007-03-14|Estimate|June 2005||2005-06-30|March 2007|2007-03-31|October 2005||2005-10-31|||||Interventional|||Efficacy and Safety of Natto Extract|An Open-Label, Parallel Comparison Study to Evaluate the Effect of Oral Administration of Nattokinase Taken by Normal Subjects, Patients Under Dialysis, and Patients of Cardiovascular High Risk Groups|Completed||Phase 4|45||Changhua Christian Hospital|||||f||||f||||||||||2018-06-01 03:22:03.454684|2018-06-01 03:22:03.454684
NCT00447421|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2009-05-28||2009-10-24|2007-03-12|2007-03-14|Estimate|2009-07-17|2009-08-26|Estimate||||2009-10-24|2009-10-28|Estimate|February 2007||2007-02-28|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy|Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|9|Actual|Eli Lilly and Company|The Study Phase 1 was stopped early based on interim results of another trial, showing inferior activity of pemetrexed/carboplatin compared to etoposide/carboplatin in extensive small cell lung cancer. The Study did not progress to Phase 2.|1||Interim results of another trial showed inferior activity of treatment|f||||f||||||||||2018-06-01 03:22:03.608946|2018-06-01 03:22:03.608946
NCT00447408|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2010-06-24|2007-03-12|2007-03-14|Estimate|||||||2010-06-24|2010-06-28|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|BalanceWise-HD||Impact of a Personal Digital Assistant (PDA) - Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients|Impact of a PDA-Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients|Completed||N/A|22|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:22:03.987476|2018-06-01 03:22:03.987476
NCT00447382|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|2010-11-24|2010-10-29|2014-10-08|2007-03-13|2007-03-14|Estimate|2011-05-11|2011-05-12|Estimate|2010-10-29|2010-11-02|Estimate|2014-10-08|2014-10-09|Estimate|March 2007||2007-03-31|October 2014|2014-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes|A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bolus Regimen With Insulin Aspart as the Bolus Insulin|Completed||Phase 3|330|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 03:22:04.157708|2018-06-01 03:22:04.157708
NCT00447369|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2008-05-06|2007-03-13|2007-03-14|Estimate|||||||2008-05-06|2008-05-09|Estimate|May 2007||2007-05-31|May 2008|2008-05-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Efficacy of Pregabalin in Migraine Prevention||Withdrawn||Phase 3|70|Anticipated|Hospital Militar del General Luis Felipe Brieba Aran||||Because we did not find funds to do it|f||||t||||||||||2018-06-01 03:22:05.324083|2018-06-01 03:22:05.324083
NCT00447356|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2013-05-09|2007-03-12|2007-03-14|Estimate|||||||2013-05-09|2013-05-13|Estimate|January 2000||2000-01-31|May 2013|2013-05-31||||||||Interventional|||High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma|Phase III Randomized Study of Four Weeks High Dose IFN-2b in StageT3-T4 or N1 (Microscopic) Melanoma|Withdrawn||Phase 3|0|Actual|Hackensack University Medical Center||||There were no patient enrolled in this study at this site|f||||t||||||||||2018-06-01 03:22:05.521754|2018-06-01 03:22:05.521754
NCT00447343|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2017-08-25|2007-03-13|2007-03-14|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2008|Actual|2008-09-30|August 2017|2017-08-31|August 2012|Actual|2012-08-31|January 2011|Actual|2011-01-31||Observational|||Reorganization of Brain Functions in Patients With Cervical Myelopathy Using fMRI and MRS|Mapping of the Sensorimotor Cortex in Cervical Myelopathy Using Functional Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy|Completed|||35|Actual|Lawson Health Research Institute|||2||f||||f||||||||||2018-06-01 03:22:05.618392|2018-06-01 03:22:05.618392
NCT00447330|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|2015-01-20||2015-01-28|2007-03-13|2007-03-14|Estimate|2015-01-20|2015-01-28|Estimate||||2015-01-28|2015-02-13|Estimate|February 2007||2007-02-28|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|XAGastric|Number of subjects receiving study drug|Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma|A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas|Completed||Phase 2|60|Actual|Duke University||1|||f||||t||||||||||2018-06-01 03:22:05.90113|2018-06-01 03:22:05.90113
NCT00447317|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2010-05-14|2007-03-12|2007-03-14|Estimate|||||||2010-05-14|2010-05-17|Estimate|November 2007||2007-11-30|May 2010|2010-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|BalanceWise-PD||Dietary Adherence Enhancement in Peritoneal Dialysis: BalanceWise-PD|Dietary Adherence Enhancement in Peritoneal Dialysis|Completed||N/A|60|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:22:06.510529|2018-06-01 03:22:06.510529
NCT00447304|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2012-07-20|2007-03-13|2007-03-14|Estimate|||||||2012-07-20|2012-07-23|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|ACDC||Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy|Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy = ACDC-study|Completed||Phase 3|644|Anticipated|Heidelberg University|||||f||||t||||||||||2018-06-01 03:22:06.718622|2018-06-01 03:22:06.718622
NCT00447291|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2011-01-26|2007-03-12|2007-03-14|Estimate|||||||2011-01-26|2011-01-27|Estimate|December 2006||2006-12-31|September 2006|2006-09-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Safety & Efficacy of Omega-3 Fish Oil in Overweight Children & Adolescents|Evaluation of the Safety and Efficacy of Omega-3 Fish Oil Dietary Supplementation in Biometric Measurement, Lipid Profile, Serum Markers for Inflammation, and Insulin Resistance in Overweight Children and Adolescents|Terminated||Phase 3|60|Actual|Children's Heart Center||||Zone Labs, Inc discontinue utilizing their fish oil supplement and frozen foods|f||||f||||||||||2018-06-01 03:22:06.826646|2018-06-01 03:22:06.826646
NCT00447278|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2010-02-24||2010-04-22|2007-03-12|2007-03-14|Estimate|2010-04-01|2010-04-20|Estimate||||2010-04-22|2010-04-27|Estimate|March 2007||2007-03-31|April 2010|2010-04-30|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|ADHD LIFE||A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents|A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naïve Children and Adolescents|Completed||Phase 3|399|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:22:06.976794|2018-06-01 03:22:06.976794
NCT00447265|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2011-10-07||2013-02-06|2007-03-12|2007-03-14|Estimate|2011-12-16|2011-12-19|Estimate||||2013-02-06|2013-02-12|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Etanercept for the Treatment of Lupus Nephritis|A Randomized, Double-Blind, Placebo-Controlled, Phase II, Multi-Center Study for Treatment of Lupus Nephritis by Inhibition of Tumor Necrosis Factor-alpha Using Etanercept|Terminated||Phase 2|1|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study terminated early with 1 subject enrolled. Based on safety info from other trials, the protocol chairs decided possible risks to patients outweighed the potential benefits. Analysis of groups is not possible. Study objectives cannot be met.|2||The perceived risk-benefit ratio for individuals with early active RA|f||||||||||||||2018-06-01 03:22:08.261767|2018-06-01 03:22:08.261767
NCT00447252|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-03-13|2007-03-13|2007-03-14|Estimate|||||||2007-03-13|2007-03-14|Estimate|January 2007||2007-01-31|March 2007|2007-03-31||||||||Observational|NABF||Needs Assessment for Bereaved Families|Needs Assessment for Bereaved Families|Unknown status|Recruiting||100||Herzog Hospital|||||f||||t||||||||||2018-06-01 03:22:09.383836|2018-06-01 03:22:09.383836
NCT00447239|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2008-10-23|2007-03-13|2007-03-14|Estimate|||||||2008-10-23|2008-10-24|Estimate|September 2004||2004-09-30|March 2007|2007-03-31|July 2006||2006-07-31|||||Interventional|||The Effect of Intensive Insulin Therapy|The Effect of Intensive Insulin Therapy on the Incidence of Ventilator-Associated Pneumonia in Surgical Critically Ill Patients|Completed||N/A|117||University Medical Centre Ljubljana|||||t||||t||||||||||2018-06-01 03:22:09.44463|2018-06-01 03:22:09.44463
NCT00447057|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2011-06-17||2011-09-12|2007-03-09|2007-03-13|Estimate|2011-09-12|2011-10-13|Estimate||||2011-09-12|2011-10-13|Estimate|March 2007||2007-03-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|||Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)|A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC|Completed||Phase 2|204|Actual|Eli Lilly and Company|Baseline Characteristics are presented by histology (nonsquamous/squamous) for each arm. Per the protocol amendment of August 2008, study entry criteria were changed to exclude participants with predominantly squamous cell histology.|4|||f||||f||||||||||2018-06-01 03:22:11.149513|2018-06-01 03:22:11.149513
NCT00447226|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|2010-01-11||2012-06-07|2007-03-13|2007-03-14|Estimate|2010-01-11|2010-02-04|Estimate||||2012-06-07|2012-06-12|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists|A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer|Terminated||Phase 2|32|Actual|GlaxoSmithKline|Study terminated prematurely: preliminary assessment (prompted by low screening/enrollment rates) showed primary objective of tumor response rate not met. Also unable to test primary treatment comparison after randomization following SD at 12 wks.|2||"The study had failed to meet the primary objective of tumor response rate at 12 weeks from~   first dose."|f||||f||||||||||2018-06-01 03:22:09.534015|2018-06-01 03:22:09.534015
NCT00447213|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2010-10-12|2007-03-12|2007-03-14|Estimate|||||||2010-10-12|2010-10-13|Estimate|April 2007||2007-04-30|October 2010|2010-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study for Patients With Type 1 Diabetes Mellitus|A Crossover Study to Evaluate the Efficacy and Safety of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus|Completed||Phase 2/Phase 3|70|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:22:09.828155|2018-06-01 03:22:09.828155
NCT00447200|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-10-12|2007-03-13|2007-03-14|Estimate|||||||2007-10-12|2007-10-15|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Observational|||Study of the Natural Variation in Strokevolume|Study of the Natural Variation in Strokevolume, and Investigation in the Number of Cycles Necessary to Find a 10% Strokevolume Variation Using Esophageal Doppler|Completed|||20|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 03:22:10.007225|2018-06-01 03:22:10.007225
NCT00447187|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2012-10-09|2007-03-12|2007-03-14|Estimate|||||||2012-10-09|2012-10-11|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|November 2010|Actual|2010-11-30|March 2009|Actual|2009-03-31||Interventional|||Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk|A Multi-center, Placebo-Controlled, Randomized, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure Following Penetrating Keratoplasty With LX201 Implantation in Subjects Who Are at Increased Immunological Risk|Terminated||Phase 3|368|Actual|Lux Biosciences, Inc.||3||The primary efficacy endpoint was not met|f||||t||||||||||2018-06-01 03:22:10.079784|2018-06-01 03:22:10.079784
NCT00447174|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2016-11-02|2007-03-13|2007-03-14|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|PBS||Parental Bereavement Study Among Couples Coping Traumatic Loss of a Child|Dyadic Therapy Assessment Among Couples Coping With Traumatic Loss of a Child|Completed||N/A|64|Actual|Herzog Hospital||2|||f||||t||||||||||2018-06-01 03:22:10.222787|2018-06-01 03:22:10.222787
NCT00447161|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2008-09-04|2007-03-13|2007-03-14|Estimate|||||||2008-09-04|2008-09-05|Estimate|July 2006||2006-07-31|September 2008|2008-09-30||||October 2007|Actual|2007-10-31||Interventional|PADRE||Preventing Antibiotic-Associated DiarRhea Using Erceflora|Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Efficacy and Safety|Completed||Phase 4|323|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:22:10.295429|2018-06-01 03:22:10.295429
NCT00447148|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2007-10-29|2007-03-13|2007-03-14|Estimate|||||||2007-10-29|2007-10-31|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|3-DCA||Standard vs. 3-Dimensional Coronary Angiography: a Paired Comparison|"Standard vs. 3-Dimensional Coronary Angiography: a Paired Comparison Using Intra-Coronary Marker Wires as Matched-Comparison Gold Standard"|Completed||Phase 4|36|Actual|Antwerp Cardiovascular Institute Middelheim||1|||f||||f||||||||||2018-06-01 03:22:10.371171|2018-06-01 03:22:10.371171
NCT00447135|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2008-01-28|2007-03-13|2007-03-14|Estimate|||||||2008-01-28|2008-01-30|Estimate|March 2005||2005-03-31|January 2008|2008-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Immunologic Function in the Elderly After Injury|Immunologic Function in the Elderly After Injury: the Polymorphonuclear Leukocyte (PMN) and Innate Immunity|Completed|||55|Actual|Summa Health System|||||f||||f||||||||||2018-06-01 03:22:10.440752|2018-06-01 03:22:10.440752
NCT00447122|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2013-05-21||2018-03-29|2007-03-13|2007-03-14|Estimate|2014-04-17|2014-05-19|Estimate||||2018-03-29|2018-04-27|Actual|March 2007||2007-03-31|March 2018|2018-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer|BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer: A Phase II Study #108181|Terminated||Phase 2|31|Actual|Brown University||1|||f||||t||||||||||2018-06-01 03:22:10.548254|2018-06-01 03:22:10.548254
NCT00447109|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2007-03-13|2007-03-13|2007-03-14|Estimate|||||||2007-03-13|2007-03-14|Estimate|September 2003||2003-09-30|March 2007|2007-03-31|April 2004||2004-04-30|||||Interventional|||Time Interval for Changing Closed System Suction Catheters, Effect on Ventilator Associated Pneumonia|Endotracheal Suction With or Without Daily Changes of Closed System Suction. Effect on Ventilator Associated Pneumonia and Cost|Completed||N/A|344||Bayside Health|||||f||||f||||||||||2018-06-01 03:22:10.743336|2018-06-01 03:22:10.743336
NCT00447096|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2016-06-08|2007-03-12|2007-03-14|Estimate|||||||2016-06-08|2016-06-09|Estimate|February 2007||2007-02-28|June 2016|2016-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|rTMS||rTMS for Treatment of Depressed Phase of Bipolar Disorder Type II|rTMS (Repetitive Transcranial Magnetic Stimulation) for Acute Treatment of Depressed Phase of Bipolar Disorder Type II|Withdrawn||Phase 2|0|Actual|University of Texas Southwestern Medical Center||2||No results, funding terminated and PI no longer at institution|f||||f||||||||||2018-06-01 03:22:10.81643|2018-06-01 03:22:10.81643
NCT00447083|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-13|||2009-02-12|2007-03-13|2007-03-14|Estimate|||||||2009-02-12|2009-02-16|Estimate|May 2005||2005-05-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Benefits of Tanning in Fibromyalgia Patients|A Pilot Study of the Effect of Ultraviolet Light on Pain in Persons With Fibromyalgia Syndrome|Completed||N/A|19|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 03:22:10.946343|2018-06-01 03:22:10.946343
NCT00447070|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2009-05-26|2007-03-13|2007-03-14|Estimate|||||||2009-05-26|2009-05-27|Estimate|August 2004||2004-08-31|March 2007|2007-03-31|May 2006||2006-05-31|||||Interventional|ENDOPACT||Effect of Atazanavir on Endothelial Function in HIV-Infected Patients|Effect of Atazanavir on Endothelial Function in HIV-Infected Patients Compared to Standard Proteinase Inhibitors on Top of Potent Antiviral Combination Therapy|Completed||Phase 4|50||Foundation for Cardiovascular Research, Zurich|||||f||||f||||||||||2018-06-01 03:22:11.015342|2018-06-01 03:22:11.015342
NCT00447031|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2010-02-05|2007-03-12|2007-03-13|Estimate|||||||2010-02-05|2010-02-09|Estimate|March 2007||2007-03-31|March 2009|2009-03-31|November 2007|Anticipated|2007-11-30|||||Interventional|||Combination Therapy for Neovascular Age Related Macular Degeneration|Intravitreal Bevacizumab Combined With Intravitreal Triamcinolone Acetonide Injection Versus Intravitreal Bevacizumab for Age Related Macular Degeneration|Withdrawn||N/A|0|Actual|Yonsei University||||Insufficient patients who met inclusion criteria|f||||f||||||||||2018-06-01 03:22:15.486392|2018-06-01 03:22:15.486392
NCT00447018|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2007-03-12|2007-03-12|2007-03-13|Estimate|||||||2007-03-12|2007-03-13|Estimate|October 2002||2002-10-31|March 2007|2007-03-31|June 2005||2005-06-30|||||Interventional|||Mannitol Versus Hypertonic Saline Solution in the Treatment of Elevated Intracranial Pressure|Equimolar Doses of Mannitol and Hypertonic Saline in the Treatment of Elevated Intracranial Pressure|Completed||Phase 4|20||University Hospital, Grenoble|||||f||||f||||||||||2018-06-01 03:22:15.59445|2018-06-01 03:22:15.59445
NCT00447005|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2012-02-25||2012-05-17|2007-03-12|2007-03-13|Estimate|2012-02-25|2012-03-26|Estimate||||2012-05-17|2012-05-23|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors|A Phase 1 Study Of AG-013736 (Axitinib) In Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 03:22:15.683098|2018-06-01 03:22:15.683098
NCT00446992|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2014-10-22||2014-11-06|2007-03-12|2007-03-13|Estimate|2014-10-30|2014-11-06|Estimate||||2014-11-06|2014-11-19|Estimate|April 2006||2006-04-30|November 2014|2014-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Diabetes in Neuropsychiatric Disorders|Metabolic Effects of Olanzapine in Patients With Newly Diagnosed Psychosis|Completed||Phase 1/Phase 2|30|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The most important limitations in our study were sample size and duration. With a larger sample, some of these measures may have a significant change within this time frame.|1|||f||||t||||||||||2018-06-01 03:22:16.197907|2018-06-01 03:22:16.197907
NCT00446979|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2013-04-18|2007-03-12|2007-03-13|Estimate|||||||2013-04-18|2013-04-19|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Safety Study of UC-781 Vaginal Microbicide|Phase I Study of the Safety and Acceptability of UC-781 Topical Vaginal Microbicide in Women and Acceptability in Their Male Partners,Chiang Rai, Thailand|Completed||Phase 1|90|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-06-01 03:22:16.592285|2018-06-01 03:22:16.592285
NCT00446966|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2010-05-10|2007-03-12|2007-03-13|Estimate|||||||2010-05-10|2010-05-12|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|FISH||Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery|Fish Oil to Inhibit Supraventricular Arrhythmias After Cardiac Surgery: The Fish Trial|Completed||Phase 4|260|Actual|University of Iowa||1|||f||||t||||||||||2018-06-01 03:22:16.682208|2018-06-01 03:22:16.682208
NCT00446953|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2015-10-13|2007-03-12|2007-03-13|Estimate|||||||2015-10-13|2015-10-14|Estimate|February 2007||2007-02-28|September 2013|2013-09-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Caesarean and Corticotherapy|Interest in Programming Caesarean Section at 38 Weeks of Pregnancy With Antenatal Betamethasone to Prevent Neonatal Respiratory Distress and to Avoid Emergency Caesarean Section Before Planned Date.|Completed||Phase 4|200|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 03:22:16.775386|2018-06-01 03:22:16.775386
NCT00446940|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-11|||2008-09-08|2007-03-12|2007-03-13|Estimate|||||||2008-09-08|2008-09-09|Estimate|December 2006||2006-12-31|September 2008|2008-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C|Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C|Completed||Phase 2|16|Anticipated|Bader, Ted, M.D.|||||f||||f||||||||||2018-06-01 03:22:16.89626|2018-06-01 03:22:16.89626
NCT00446927|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2012-05-22|2007-03-09|2007-03-13|Estimate|||||||2012-05-22|2012-05-24|Estimate|April 2007||2007-04-30|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||SPY Imaging System: Its Role in Pediatric Cardiac Surgery|SPY Imaging System: Its Role in Pediatric Cardiac Surgery|Completed|||40|Actual|Emory University|||||f||||f||||||||||2018-06-01 03:22:16.968401|2018-06-01 03:22:16.968401
NCT00446914|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2008-08-18|2007-03-12|2007-03-13|Estimate|||||||2008-08-18|2008-08-19|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||High Blood Pressure Strategy (HBPS)|High Blood Pressure Strategy: Hypertension Management Initiative Study|Unknown status|Recruiting|N/A|5000|Anticipated|Heart and Stroke Foundation of Ontario|||||f||||||||||||||2018-06-01 03:22:17.090785|2018-06-01 03:22:17.090785
NCT00446901|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2011-03-11|2007-03-12|2007-03-13|Estimate|||||||2011-03-11|2011-03-14|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SePros||Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression|Selenium and Prostate Cancer: Clinical Trial on Availability to Prostate Tissue and Effects on Gene Expression|Completed||N/A|60|Anticipated|Wageningen University||2|||f||||f||||||||||2018-06-01 03:22:17.159385|2018-06-01 03:22:17.159385
NCT00446888|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2009-06-17|2007-03-12|2007-03-13|Estimate|||||||2009-06-17|2009-06-19|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients|Effects of Nutritional Supplementation (Product 4808) on Acute Skeletal Muscle Protein Synthesis in Cancer Patients|Completed||N/A|35|Actual|University of Arkansas||2|||f||||||||||||||2018-06-01 03:22:17.317108|2018-06-01 03:22:17.317108
NCT00446875|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2007-03-09|2007-03-09|2007-03-13|Estimate|||||||2007-03-09|2007-03-13|Estimate|January 2007||2007-01-31|March 2007|2007-03-31||||||||Interventional|||Analgesic Properties of Oral Sucrose During Immunizations|Efficacy of Oral Sucrose and Maternal Contact During Routine Immunizations in Postnatal Infants|Unknown status|Recruiting|N/A|141||Penn State University|||||f||||t||||||||||2018-06-01 03:22:17.389421|2018-06-01 03:22:17.389421
NCT00446862|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-11|||2013-11-17|2007-03-12|2007-03-13|Estimate|||||||2013-11-17|2013-11-19|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|FAACET||The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study|Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study|Completed|||36|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 03:22:17.467679|2018-06-01 03:22:17.467679
NCT00446849|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2010-04-09||2011-10-19|2007-03-12|2007-03-13|Estimate|2010-06-07|2010-07-08|Estimate||||2011-10-19|2011-10-24|Estimate|May 2007||2007-05-31|October 2011|2011-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)|A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)|Completed||Phase 4|290|Actual|Shire||1|||f||||||||||||||2018-06-01 03:22:17.596302|2018-06-01 03:22:17.596302
NCT00446836|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2016-03-15|2007-03-12|2007-03-13|Estimate|||||||2016-03-15|2016-03-17|Estimate|March 2005||2005-03-31|March 2016|2016-03-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety Study of Xyotax to Treat Prostate Cancer|Phase II Study of Xyotax in Advanced Hormone Refractory Prostate Cancer|Completed||Phase 2|29|Actual|The Methodist Hospital System||1|||f||||f||||||||No||2018-06-01 03:22:18.041191|2018-06-01 03:22:18.041191
NCT00446823|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2007-03-12|2007-03-12|2007-03-13|Estimate|||||||2007-03-12|2007-03-13|Estimate|June 2002||2002-06-30|March 2007|2007-03-31|December 2003||2003-12-31|||||Interventional|XCell||Effectiveness of XCell on Autolytic Debridement of Venous Ulcers|A Prospective, Randomized, Controlled Clinical Study to Evaluate the Effectiveness of a Cellulose Matrix Wound Dressing for Autolytic Debridement and Healing of Chronic Venous Ulcers|Completed||N/A|50||Xylos Corporation|||||f||||f||||||||||2018-06-01 03:22:18.120622|2018-06-01 03:22:18.120622
NCT00446810|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2007-09-25|2007-03-12|2007-03-13|Estimate|||||||2007-09-25|2007-09-27|Estimate|September 2007||2007-09-30|September 2007|2007-09-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus|Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System|Unknown status|Recruiting|Phase 4|30|Anticipated|Ruhr University of Bochum||2|||f||||t||||||||||2018-06-01 03:22:18.203541|2018-06-01 03:22:18.203541
NCT00446797|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2009-04-21||2009-06-12|2007-03-09|2007-03-13|Estimate|2009-04-21|2009-06-10|Estimate||||2009-06-12|2009-06-25|Estimate|May 2007||2007-05-31|June 2009|2009-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain|An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain|Completed||Phase 4|278|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:22:18.336151|2018-06-01 03:22:18.336151
NCT00446784|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2011-05-19|2007-03-09|2007-03-13|Estimate|||||||2011-05-19|2011-05-23|Estimate|April 2007||2007-04-30|May 2011|2011-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis|A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate|Completed||Phase 1|20||Pfizer|||||f||||||||||||||2018-06-01 03:22:19.134804|2018-06-01 03:22:19.134804
NCT00446771|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2007-03-12|2007-03-12|2007-03-13|Estimate|||||||2007-03-12|2007-03-13|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|November 2006||2006-11-30|||||Interventional|||A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects||Completed||Phase 1|18||Pharmaxis|||||f||||||||||||||2018-06-01 03:22:19.191727|2018-06-01 03:22:19.191727
NCT00446758|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2012-09-13|2007-03-12|2007-03-13|Estimate|||||||2012-09-13|2012-09-14|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Trial of Zinc and HIV Progression in Children|Trial of Zinc and HIV Progression in Children|Completed||Phase 3|440|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-06-01 03:22:19.305087|2018-06-01 03:22:19.305087
NCT00446745|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2012-09-18|2007-03-09|2007-03-13|Estimate|||||||2012-09-18|2012-09-19|Estimate|April 2006||2006-04-30|September 2012|2012-09-30|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Observational|Mithycal||Abdominal Adiposity and Muscle Mitochondrial Functions|Study of Interaction Between Adipose and Muscle Tissues in the Control of Muscle Mitochondrial Functions|Completed|||60|Actual|Institut National de la Recherche Agronomique|||1||f||||f||||||||||2018-06-01 03:22:19.375333|2018-06-01 03:22:19.375333
NCT00446732|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-11|||2009-03-24|2007-03-12|2007-03-13|Estimate|||||||2009-03-24|2009-03-25|Estimate|March 2007||2007-03-31|March 2009|2009-03-31|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Interventional|CAUTI||The Use of the UroShield Device in Patients With Indwelling Urinary Catheters|Catheter Associated Urinary Tract Infections|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|Nanovibronix||2|||f||||t||||||||||2018-06-01 03:22:19.442651|2018-06-01 03:22:19.442651
NCT00446719|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2011-01-04|2007-03-12|2007-03-13|Estimate|||||||2011-01-04|2011-01-05|Estimate|August 2007||2007-08-31|January 2011|2011-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder|An Open-Label Pilot Study Evaluating the Safety and Antidepressant Effects of Rellidep (BI= Biological Isolate) in Major Depressive Disorder|Completed||Phase 2/Phase 3|23|Actual|Mount Sinai Hospital, Canada|||||f||||f||||||||||2018-06-01 03:22:19.516773|2018-06-01 03:22:19.516773
NCT00446706|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2017-05-05|2007-03-12|2007-03-13|Estimate|||||||2017-05-05|2017-05-09|Actual|January 2004||2004-01-31|May 2017|2017-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)|Estimation of Intrinsic Positive End-Expiratory Pressure (PEEP) in Acute Respiratory Distress Syndrome (ARDS)|Completed|||6|Actual|Texas Tech University Health Sciences Center, El Paso|||||f||||f||||||||No||2018-06-01 03:22:19.577419|2018-06-01 03:22:19.577419
NCT00446693|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2009-11-18|2007-03-12|2007-03-13|Estimate|||||||2009-11-18|2009-11-19|Estimate|February 2007||2007-02-28|November 2009|2009-11-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement|A Single Arm, Multi-center, Prospective Clinical Investigation to Evaluate Safety and Performance of the EndoFast Reliant™ System in Vaginal Wall Reinforcement|Completed||N/A|20|Actual|Endogun Medical Systems Ltd.||1|||f||||t||||||||||2018-06-01 03:22:19.630653|2018-06-01 03:22:19.630653
NCT00446680|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2010-06-23|2007-03-12|2007-03-13|Estimate|||||||2010-06-23|2010-06-25|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study|Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study|Completed||Phase 3|340|Anticipated|Pharmaxis||2|||f||||t||||||||||2018-06-01 03:22:19.763103|2018-06-01 03:22:19.763103
NCT00446667|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2016-09-26|2007-03-12|2007-03-13|Estimate|||||||2016-09-26|2016-09-28|Estimate|October 2006||2006-10-31|September 2016|2016-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD|A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD|Withdrawn||Phase 1/Phase 2|0|Actual|Pharmaxis||1||Failed to recruit|f||||f||||||||||2018-06-01 03:22:19.865164|2018-06-01 03:22:19.865164
NCT00446498|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2007-04-02|2007-03-12|2007-03-13|Estimate|||||||2007-04-02|2007-04-03|Estimate|July 2002||2002-07-31|April 2007|2007-04-30|May 2005|Actual|2005-05-31|||||Interventional|||CPAP Versus NPPV in ACPE|Continuous Positive Airway Pressure Versus Non-Invasive Positive Pressure Support Ventilation in Acute Cardiogenic Pulmonary Oedema: a Prospective Randomised Multicentre Trial.|Completed||Phase 4|80||Ospedale S. Giovanni Bosco|||||f||||||||||||||2018-06-01 03:22:21.950217|2018-06-01 03:22:21.950217
NCT00446654|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2012-05-29||2012-06-28|2007-03-09|2007-03-13|Estimate|2012-06-28|2012-08-06|Estimate||||2012-06-28|2012-08-06|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD|A Phase Ib Randomized Open Label Study Between Once-every-two-weeks and Once-every-four-weeks Treatment of CGC-11047 in Patients With CNV Due to Age Related Macular Degeneration|Completed||Phase 1|43|Actual|Progen Pharmaceuticals|Early termination leading to small numbers of subjects analyzed: 100 patients were planned; 43 patients were recruited.|2|||f||||f||||||||||2018-06-01 03:22:19.92684|2018-06-01 03:22:19.92684
NCT00446641|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2009-01-22||2009-12-10|2007-03-12|2007-03-13|Estimate|2009-12-10|2010-01-18|Estimate||||2009-12-10|2010-01-18|Estimate|March 2007||2007-03-31|November 2009|2009-11-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|ARCC||Overcome Biochemical Aspirin Resistance Through Cilostazol Combination|Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients|Completed||Phase 4|244|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 03:22:20.193205|2018-06-01 03:22:20.193205
NCT00446628|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2016-01-26|2007-03-12|2007-03-13|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2007||2007-01-31|January 2016|2016-01-31|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|PIPP||Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With Children|Pittsburgh Influenza Prevention Project|Completed||N/A|3360|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||No||2018-06-01 03:22:20.534046|2018-06-01 03:22:20.534046
NCT00446615|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2007-03-09|2007-03-09|2007-03-13|Estimate|||||||2007-03-09|2007-03-13|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|March 2007||2007-03-31|||||Interventional|||Multifaceted Intervention to Improve Prescribing in Patients With Chronic Kidney Disease|Multifaceted Intervention to Improve Prescribing of Medications Requiring Dose Adjustment in Patients With Chronic Kidney Disease|Unknown status|Not yet recruiting|N/A|||McMaster University|||||f||||f||||||||||2018-06-01 03:22:20.602195|2018-06-01 03:22:20.602195
NCT00446602|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2016-09-19|2007-03-12|2007-03-13|Estimate|||||||2016-09-19|2016-09-20|Estimate||||June 2011|2011-06-30|August 2009|Anticipated|2009-08-31|||||Interventional|||A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)|A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)|Withdrawn||Phase 2|0|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1||"Due to company decision to focus resources on a larger, controlled study in this patient~   population."|||||t||||||||||2018-06-01 03:22:20.683272|2018-06-01 03:22:20.683272
NCT00446589|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2014-10-28|2007-03-12|2007-03-13|Estimate|||||||2014-10-28|2014-10-29|Estimate|July 2006||2006-07-31|October 2014|2014-10-31||||||||Interventional|||The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density||Terminated||Phase 4|19|Actual|Papageorgiou General Hospital||2||due to financial problems|f||||||||||||||2018-06-01 03:22:20.746264|2018-06-01 03:22:20.746264
NCT00446576|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2011-01-31|2007-03-12|2007-03-13|Estimate|||||||2011-01-31|2011-02-01|Estimate|November 1999||1999-11-30|January 2011|2011-01-31|April 2003|Actual|2003-04-30|||||Interventional|||The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease|"A Study in Early Renal Insufficiency Patients to Assess the Effect of Maintaining Three Different Hemoglobin Levels With the Use of Erythropoetin Alpha on Left Ventricular Hypertrophy and Dilation and Quality if Life; The Cardiac Results of Early Treatment of Anaemia (CRETA) Study"|Completed||Phase 3|176|Actual|Janssen-Cilag B.V.|||||f||||||||||||||2018-06-01 03:22:20.845243|2018-06-01 03:22:20.845243
NCT00446563|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|2011-03-31||2011-05-06|2007-03-12|2007-03-13|Estimate|2011-03-31|2011-04-27|Estimate||||2011-05-06|2011-05-11|Estimate|March 2007||2007-03-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy|An Open-label, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Amlodipine in Combination With Valsartan Compared to Losartan in Combination With Hydrochlorothiazide Given for 52 Weeks on the Regression of Left Ventricular Hypertrophy in Patients With Mild to Moderate Hypertension|Completed||Phase 3|90|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:22:20.943331|2018-06-01 03:22:20.943331
NCT00446550|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09||2011-05-12|2011-05-12|2007-03-09|2007-03-13|Estimate||||2011-05-12|2011-05-18|Estimate|2011-05-12|2011-05-18|Estimate|December 2007||2007-12-31|May 2011|2011-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study of Oral AT2101 in Treatment-naive Patients With Gaucher Disease|A Randomized, Open-label Study To Assess the Safety and Tolerability of AT2101 in Treatment-naive Adult Patients With Type I Gaucher Disease|Completed||Phase 2|19|Actual|Amicus Therapeutics||2|||f||||t||||||||||2018-06-01 03:22:21.32018|2018-06-01 03:22:21.32018
NCT00446537|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-11|||2007-03-12|2007-03-12|2007-03-13|Estimate|||||||2007-03-12|2007-03-13|Estimate||||January 2007|2007-01-31||||||||Interventional|||Procedural Learning in Participants With ADHD||Unknown status|Not yet recruiting|Early Phase 1|||Shaare Zedek Medical Center|||||f||||t||||||||||2018-06-01 03:22:21.40852|2018-06-01 03:22:21.40852
NCT00446524|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2017-03-24|2007-03-09|2007-03-13|Estimate|||||||2017-03-24|2017-03-28|Actual|February 2007||2007-02-28|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)|A 54-week Extension to the Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of VAA489 (Valsartan and Amlodipine Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAA489 in Patients With Essential Hypertension (Extension From A1301 Study)|Completed||Phase 3|403|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:22:21.469407|2018-06-01 03:22:21.469407
NCT00446511|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2011-01-11||2011-06-30|2007-03-09|2007-03-13|Estimate|2011-05-02|2011-06-06|Estimate||||2011-06-30|2011-07-12|Estimate|June 2007||2007-06-30|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension|An Extension to Study Protocol CVAL489K2302 to Evaluate the Long Term Safety, Tolerability and Efficacy of Valsartan in Children 6 to 17 Years of Age With Hypertension, Versus Enalapril Treatment for 14 Weeks, or Combined With Enalapril Versus Enalapril for 66 Weeks in Chronic Kidney Disease Patients.|Completed||Phase 3|250|Actual|Novartis|Study was prolonged from 14 to 66 wks for CKD patients only. Most CKD patients completed the initial 14 wk extension period prior to amendment approval and the study was terminated prematurely with 3 CKD patients progressing to a maximum of Visit 13.|4|||f||||f||||||||||2018-06-01 03:22:21.545623|2018-06-01 03:22:21.545623
NCT00446485|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-12|||2015-09-24|2007-03-12|2007-03-13|Estimate|||||||2015-09-24|2015-09-28|Estimate|May 2007||2007-05-31|September 2015|2015-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency|Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment|Completed||Phase 4|90|Actual|Milsing d.o.o.||2|||f||||t||||||||||2018-06-01 03:22:22.091633|2018-06-01 03:22:22.091633
NCT00446472|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2010-06-02|2007-03-08|2007-03-12|Estimate|||||||2010-06-02|2010-06-04|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|September 2010|Anticipated|2010-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers|Evaluation of Windowed Casts With and Without Regranex® Gel for Healing|Unknown status|Recruiting|N/A|60|Anticipated|Southern California Institute for Research and Education||2|||f||||f||||||||||2018-06-01 03:22:22.177619|2018-06-01 03:22:22.177619
NCT00446459|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2009-12-29||2010-04-05|2007-03-09|2007-03-12|Estimate|2010-03-12|2010-03-30|Estimate||||2010-04-05|2010-04-15|Estimate|April 2006||2006-04-30|April 2010|2010-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.|The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant|Completed||Phase 2|45|Actual|University of Washington|The treatment of highly sensitized patients on dialysis with single agent therapy of mycophenolate was hampered by gastrointestinal side effects that reduced anticipated maximum tolerated doses and duration of treatment.||||f||||t||||||||||2018-06-01 03:22:22.286373|2018-06-01 03:22:22.286373
NCT00446446|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|2016-02-01|2014-09-16|2017-12-15|2007-03-08|2007-03-12|Estimate|2016-02-01|2016-03-07|Estimate|2014-10-14|2014-10-22|Estimate|2017-12-15|2018-01-16|Actual|October 30, 2007|Actual|2007-10-30|December 2017|2017-12-31|November 29, 2017|Actual|2017-11-29|December 15, 2010|Actual|2010-12-15||Interventional|||PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)|Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|52|Actual|Amgen||1|||f||||f||||||||||2018-06-01 03:22:22.549607|2018-06-01 03:22:22.549607
NCT00446433|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2016-11-30|2007-03-08|2007-03-12|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2002||2002-03-31|November 2016|2016-11-30|December 2003||2003-12-31|||||Interventional|||A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease|Completed||Phase 2|90||Celgene Corporation|||||f||||||||||||||2018-06-01 03:22:22.958499|2018-06-01 03:22:22.958499
NCT00446420|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2013-05-28|2007-03-08|2007-03-12|Estimate|||||||2013-05-28|2013-05-30|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations|Cognitive Impairment Following Sedation for Colonoscopy With Propofol, Midazolam and Fentanyl Combinations|Completed||Phase 4|200|Actual|Melbourne Health||2|||f||||f||||||||||2018-06-01 03:22:23.079848|2018-06-01 03:22:23.079848
NCT00446407|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2015-03-31|2007-03-09|2007-03-12|Estimate|||||||2015-03-31|2015-04-01|Estimate|April 2007||2007-04-30|July 2009|2009-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|MANAS||Evaluating the Benefits and Affordability of a Program to Improve the Care of Common Mental Disorders in Primary Care|The Effectiveness and Cost-effectiveness of a Collaborative Stepped Care Intervention for the Treatment of Common Mental Disorders in Primary Care Settings in Goa, India|Completed||N/A|2796|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 03:22:23.170496|2018-06-01 03:22:23.170496
NCT00446394|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2012-10-18|2007-03-08|2007-03-12|Estimate|||||||2012-10-18|2012-10-19|Estimate|June 2007||2007-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Exercise and Activities for Independent Living With Mild Cognitive Impairment (MCI)|Exercise & Health Promotion for MCI: A Controlled Trial|Completed||N/A|181|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:22:23.257769|2018-06-01 03:22:23.257769
NCT00446381|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2012-04-17|2007-03-09|2007-03-12|Estimate|||||||2012-04-17|2012-04-19|Estimate|October 2006||2006-10-31|April 2012|2012-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|PEGAP001||Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)|Effect of Macugen (Pegaptanib) on Surgical Outcomes and Growth Factors Including Vascular Endothelial Growth Factor (VEGF) Levels in Patients With Proliferative Diabetic Retinopathy (PDR) and Clinically Significant Diabetic Macular Edema (CSDME)|Completed||N/A|28|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 03:22:23.346549|2018-06-01 03:22:23.346549
NCT00446368|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2016-03-15|2007-03-09|2007-03-12|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|RAD001||Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer|Phase II Study of RAD001 (Everolimus) in Patient's With Metastatic Renal Cell Cancer|Completed||Phase 2|66|Actual|The Methodist Hospital System||1|||f||||f||||||||No||2018-06-01 03:22:23.423978|2018-06-01 03:22:23.423978
NCT00446355|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2009-04-12|2007-03-09|2007-03-12|Estimate|||||||2009-04-12|2009-04-14|Estimate|February 2007||2007-02-28|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes|Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes|Completed|||1000|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:22:23.504258|2018-06-01 03:22:23.504258
NCT00446342|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2017-04-07|2007-03-08|2007-03-12|Estimate|||||||2017-04-07|2017-04-11|Actual|February 2007||2007-02-28|April 2017|2017-04-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies|Phase 1 Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Advanced B-Lymphoid Malignancies|Completed||Phase 1|21|Actual|Sunesis Pharmaceuticals||1|||f||||f|t|f||||||No||2018-06-01 03:22:23.557369|2018-06-01 03:22:23.557369
NCT00446329|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2014-10-28|2007-03-09|2007-03-12|Estimate|||||||2014-10-28|2014-10-29|Estimate|July 2006||2006-07-31|October 2014|2014-10-31||||||||Interventional|||Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis||Terminated||Phase 4|15|Actual|Papageorgiou General Hospital||||due to financial problems|f||||||||||||||2018-06-01 03:22:23.632687|2018-06-01 03:22:23.632687
NCT00446316|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2016-06-21|2007-03-09|2007-03-12|Estimate|||||||2016-06-21|2016-06-22|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effect of Antacids on Gleevec® in Healthy Volunteers|Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)|Completed||Phase 1|12|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:22:23.688587|2018-06-01 03:22:23.688587
NCT00446303|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2012-01-18|2007-03-09|2007-03-12|Estimate|||||||2012-01-18|2012-01-19|Estimate|July 2006||2006-07-31|June 2010|2010-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Phase II Study of Maintenance With Azacitidine in MDS Patients|A Phase II Study of Maintenance With Azacitidine in MDS Patients Achieving Complete or Partial Remission (CR or PR) After Intensive Chemotherapy|Terminated||Phase 2|39|Actual|Groupe Francophone des Myelodysplasies|||||f||||t||||||||||2018-06-01 03:22:23.78284|2018-06-01 03:22:23.78284
NCT00446290|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2013-12-15||2017-07-13|2007-03-09|2007-03-12|Estimate|2015-06-30|2015-07-28|Estimate||||2017-07-13|2017-08-21|Actual|March 2006||2006-03-31|July 2017|2017-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|DXO||Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer|A Phase I Study of Docetaxel, Capecitabine and Oxaliplatin (DXO) in Patients With Advanced Stomach Cancer|Completed||Phase 1|22|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 03:22:23.882002|2018-06-01 03:22:23.882002
NCT00446277|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2008-05-09|2007-03-09|2007-03-12|Estimate|||||||2008-05-09|2008-05-12|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|June 2007|Anticipated|2007-06-30|June 2007|Anticipated|2007-06-30||Observational|||Corneal Endothelial Cell Loss in Diabetes Type II During Cataract Surgery|Corneal Endothelial Cell Loss in Diabetes Type II During Cataract Surgery|Suspended|||30|Anticipated|Frederiksberg University Hospital||||The present study was joining 2005-41-4933 into one study|f||||t||||||||||2018-06-01 03:22:24.06407|2018-06-01 03:22:24.06407
NCT00446264|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2009-05-18||2012-04-23|2007-03-09|2007-03-12|Estimate|2010-04-08|2010-05-12|Estimate||||2012-04-23|2012-04-27|Estimate|May 2003||2003-05-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|October 2007|Actual|2007-10-31||Interventional|||Islet Allotransplantation With Steroid Free Immunosuppression|Sequential Islet Transplantation With Steroid Free Immunosuppression for Type 1 Diabetes|Completed||Phase 2|14|Actual|University Hospital, Lille||1|||f||||t||||||||||2018-06-01 03:22:24.131384|2018-06-01 03:22:24.131384
NCT00446251|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2009-12-29||2010-03-30|2007-03-09|2007-03-12|Estimate|2010-03-12|2010-03-29|Estimate||||2010-03-30|2010-04-06|Estimate|December 2006||2006-12-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant|The Highly Sensitized Patients: Effects of Rituximab and Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.|Completed||Phase 2|14|Actual|University of Washington|||||t||||t||||||||||2018-06-01 03:22:24.318756|2018-06-01 03:22:24.318756
NCT00446238|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2014-05-19|2007-03-08|2007-03-12|Estimate|||||||2014-05-19|2014-05-20|Estimate|September 2002||2002-09-30|May 2014|2014-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Treatment of Depressed Adolescents With Physical Illness|Treatment of Depressed Adolescents With Physical Illness|Completed||N/A|41|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:22:24.557175|2018-06-01 03:22:24.557175
NCT00446225|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2013-03-08|2007-03-09|2007-03-12|Estimate|||||||2013-03-08|2013-03-11|Estimate|February 2007||2007-02-28|October 2008|2008-10-31|December 2012|Actual|2012-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR|Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR|Completed||Phase 3|174|Actual|Spanish Lung Cancer Group||2|||f||||t||||||||||2018-06-01 03:22:24.650815|2018-06-01 03:22:24.650815
NCT00446212|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2013-05-28|2007-03-08|2007-03-12|Estimate|||||||2013-05-28|2013-05-30|Estimate|August 2006||2006-08-31|May 2013|2013-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Dreaming and EEG Changes During Anaesthesia Maintained With Propofol or Desflurane|Dreaming and EEG Changes During Anaesthesia Maintained With Propofol or Desflurane|Completed||Phase 4|300|Actual|Melbourne Health||2|||f||||f||||||||||2018-06-01 03:22:24.798795|2018-06-01 03:22:24.798795
NCT00446199|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2012-03-23|2009-12-10|2015-04-16|2007-03-09|2007-03-12|Estimate|2012-03-23|2012-04-18|Estimate|2009-12-10|2009-12-14|Estimate|2015-04-16|2015-05-06|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Low-dose Hormone Therapy for Relief of Vasomotor Symptoms|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Lowest Effective Dose of Combinations of Oral Drospirenone and 17 Beta-Estradiol for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Over a Treatment Period of 12 Weeks|Completed||Phase 3|735|Actual|Bayer||4|||f||||f||||||||||2018-06-01 03:22:24.896677|2018-06-01 03:22:24.896677
NCT00446186|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2017-03-17|2007-03-09|2007-03-12|Estimate|||||||2017-03-17|2017-03-21|Actual|February 2004||2004-02-29|March 2017|2017-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)|Mk0476 Phase II Dose Finding Study -Allergic Rhinitis-|Completed||Phase 2|945|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:22:27.048326|2018-06-01 03:22:27.048326
NCT00446173|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2015-08-21|2007-03-09|2007-03-12|Estimate|||||||2015-08-21|2015-08-25|Estimate|March 2007||2007-03-31|August 2015|2015-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia|Autologous Purged Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Terminated due to low accrual.|f||||t||||||||||2018-06-01 03:22:27.117506|2018-06-01 03:22:27.117506
NCT00446160|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2018-02-22|2007-03-09|2007-03-12|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2000||2000-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Adult Congenital Heart Disease Surgery|Proposal for Retrospective Review of an Adult Congenital Heart Surgery Program|Active, not recruiting|||350|Anticipated|Emory University|||||f||||f||||||||||2018-06-01 03:22:27.206758|2018-06-01 03:22:27.206758
NCT00446147|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|2014-01-13||2014-01-13|2007-03-09|2007-03-12|Estimate|2014-01-13|2014-02-25|Estimate||||2014-01-13|2014-02-25|Estimate|June 2004||2004-06-30|January 2014|2014-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of Pyridoxine for Hand-Foot Syndrome|Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome|Completed||Phase 3|389|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 03:22:27.281692|2018-06-01 03:22:27.281692
NCT00445952|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2018-01-31|2007-03-07|2007-03-09|Estimate|||||||2018-01-31|2018-02-01|Actual|February 2005||2005-02-28|January 2018|2018-01-31|May 12, 2016|Actual|2016-05-12|November 2009|Actual|2009-11-30||Observational|||Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant|Fungemia Survey in Cancer Patients|Completed|||304|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 03:22:31.952482|2018-06-01 03:22:31.952482
NCT00446134|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|2011-09-20||2012-06-20|2007-03-09|2007-03-12|Estimate|2012-06-20|2012-07-27|Estimate||||2012-06-20|2012-07-27|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)|Phase 2 Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection|Completed||Phase 2|278|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||t||||||||||2018-06-01 03:22:27.515921|2018-06-01 03:22:27.515921
NCT00446121|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2007-03-09|2007-03-09|2007-03-12|Estimate|||||||2007-03-09|2007-03-12|Estimate||||March 2007|2007-03-31||||||||Observational|||Inhaled Mannitol and Ciliary Beat Frequency in COPD Patients|The Effect of Inhaled Mannitol on Ciliary Beat Frequency in COPD Patients|Unknown status|Recruiting||||Imperial College London|||||f||||||||||||||2018-06-01 03:22:28.60179|2018-06-01 03:22:28.60179
NCT00446108|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2013-11-25|2007-03-09|2007-03-12|Estimate|||||||2013-11-25|2013-11-26|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Retrospective Pulmonary Valve Replacement Imaging|Proposal for Retrospective Review of Imaging Pre- and Post - Pulmonary Valve Replacement|Completed|||153|Actual|Emory University|||||f||||f||||||||||2018-06-01 03:22:28.670716|2018-06-01 03:22:28.670716
NCT00446095|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|2014-05-14||2016-08-09|2007-03-08|2007-03-12|Estimate|2014-12-17|2014-12-18|Estimate||||2016-08-09|2016-09-19|Estimate|April 2007||2007-04-30|August 2016|2016-08-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma|A Phase I/II Multi-Center, Open Label Trial of the Safety and Efficacy of Fostamatinib in Patients With Relapsed/Refractory B-Cell Lymphoma|Completed||Phase 1/Phase 2|81|Actual|Rigel Pharmaceuticals|This is a small, non-randomized study. Comparisons between the 3 groups cannot be reliably made and should be interpreted with caution.|1|||f||||t||||||||No||2018-06-01 03:22:28.819583|2018-06-01 03:22:28.819583
NCT00446082|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2016-11-07|2007-03-09|2007-03-12|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease|A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease|Completed||Phase 1|85|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:22:30.675356|2018-06-01 03:22:30.675356
NCT00446069|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2016-08-26|2007-03-09|2007-03-12|Estimate|||||||2016-08-26|2016-08-29|Estimate|August 2007||2007-08-31|August 2016|2016-08-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients|A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment|Completed||Phase 2|36|Actual|Egalet Ltd||2|||f||||f||||||||||2018-06-01 03:22:30.783487|2018-06-01 03:22:30.783487
NCT00446056|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2017-09-14|2007-03-09|2007-03-12|Estimate|||||||2017-09-14|2017-09-15|Actual|September 25, 2003|Actual|2003-09-25|September 2017|2017-09-30|June 16, 2004|Actual|2004-06-16|June 16, 2004|Actual|2004-06-16||Interventional|||Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)|Montelukast, on Pediatric Bronchial Asthma in Multicenter Comparative Double-Blind Clinical Study (Phase IV) With Ketotifen Fumarate|Completed||Phase 4|188|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:22:30.847091|2018-06-01 03:22:30.847091
NCT00446043|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2007-03-08|2007-03-08|2007-03-12|Estimate|||||||2007-03-08|2007-03-12|Estimate|February 2004||2004-02-29|March 2007|2007-03-31|May 2004||2004-05-31|||||Interventional|||A Long-Term Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris|A Long-Term Safety and Efficacy Study of a Fixed Combination of Adapalene 0.1% and Benzoyl Peroxide 2.5% (Adapalene and Benzoyl Peroxide Topical Gel) Gel in Subjects With Acne Vulgaris|Completed||Phase 3|452||Galderma|||||f||||||||||||||2018-06-01 03:22:30.902619|2018-06-01 03:22:30.902619
NCT00446030|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|2011-08-18||2012-06-21|2007-03-08|2007-03-12|Estimate|2011-09-28|2011-11-04|Estimate||||2012-06-21|2012-06-26|Estimate|March 2007||2007-03-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer|A Phase II, Open-Label, Multicenter, Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer|Completed||Phase 2|127|Actual|Sanofi|The number of participants enrolled into the TCH with bevacizumab arm was reduced to half of the originally intended number. Therefore, all conclusions related to the safety of TCH with bevacizumab must be interpreted with caution.|2|||f||||t||||||||||2018-06-01 03:22:30.982716|2018-06-01 03:22:30.982716
NCT00446017|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-09|||2015-06-02|2007-03-09|2007-03-12|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|April 2007|Actual|2007-04-30|August 2004|Actual|2004-08-31||Interventional|AMORI||The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG|Phase 3 Study of Adrenaline and Milrinone in Patients With Myocardial Dysfunction|Completed||Phase 3|60||University of Luebeck|||||f||||f||||||||||2018-06-01 03:22:31.5746|2018-06-01 03:22:31.5746
NCT00446004|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2016-06-21|2007-03-09|2007-03-12|Estimate|||||||2016-06-21|2016-06-22|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers|Effect of a Proton Pump Inhibitor (Omeprazole, Prilosec®) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS258)|Completed||Phase 1|15|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:22:31.63931|2018-06-01 03:22:31.63931
NCT00445978|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2014-09-04|2007-03-07|2007-03-09|Estimate|||||||2014-09-04|2014-09-08|Estimate|April 2007||2007-04-30|September 2014|2014-09-30|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease|A Phase 2a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Efficacy of 6R-BH4 in Subjects With Sickle Cell Disease|Completed||Phase 2|40|Anticipated|BioMarin Pharmaceutical||1|||f||||f||||||||||2018-06-01 03:22:31.733286|2018-06-01 03:22:31.733286
NCT00445965|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2018-05-07|2007-03-07|2007-03-09|Estimate|||||||2018-05-07|2018-05-08|Actual|January 2006|Actual|2006-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer|Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms|Active, not recruiting||Phase 2|78|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:22:31.838107|2018-06-01 03:22:31.838107
NCT00445939|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2008-12-23||2011-06-20|2007-03-07|2007-03-09|Estimate|2009-03-20|2009-03-23|Estimate||||2011-06-20|2011-06-27|Estimate|February 2007||2007-02-28|June 2011|2011-06-30||||December 2007|Actual|2007-12-31||Interventional|||A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease|A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease|Completed||Phase 2/Phase 3|90|Actual|Abbott|Small population, therefore no statistical tests were performed|3|||f||||||||||||||2018-06-01 03:22:32.111257|2018-06-01 03:22:32.111257
NCT00445926|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2010-05-05|2007-03-08|2007-03-09|Estimate|||||||2010-05-05|2010-05-06|Estimate|July 2006||2006-07-31|May 2010|2010-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in Schizophrenia|Deep TMS With the H Coils as a Novel Strategy for the Treatment of Negative Symptoms of Schizophrenia|Completed||Phase 1|||Shalvata Mental Health Center|||||f||||t||||||||||2018-06-01 03:22:32.633469|2018-06-01 03:22:32.633469
NCT00445913|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2016-02-12|2007-03-08|2007-03-09|Estimate|||||||2016-02-12|2016-02-15|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2012|Actual|2012-01-31||Interventional|||Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study|Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study|Completed||Phase 1|10|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:22:32.720349|2018-06-01 03:22:32.720349
NCT00445900|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2011-03-16|2007-03-07|2007-03-09|Estimate|||||||2011-03-16|2011-03-17|Estimate|October 2004||2004-10-31|March 2011|2011-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia|"Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC) in the Therapy of Myelofibrosis With Myeloid Metaplasia (MMM)"|Completed||Phase 2|22|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 03:22:32.858092|2018-06-01 03:22:32.858092
NCT00445887|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2017-01-09||2017-12-13|2007-03-07|2007-03-09|Estimate|2017-12-13|2018-01-11|Actual||||2017-12-13|2018-01-11|Actual|March 2008||2008-03-31|January 2017|2017-01-31||||December 2012|Actual|2012-12-31||Interventional|||Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer|Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer|Completed||Phase 2|64|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 03:22:32.958236|2018-06-01 03:22:32.958236
NCT00445874|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-04-08|2007-03-08|2007-03-09|Estimate|||||||2009-04-08|2009-04-09|Estimate|February 2007||2007-02-28|April 2009|2009-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens Wearers|Completed||Phase 3|120|Anticipated|Vistakon Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:22:33.551209|2018-06-01 03:22:33.551209
NCT00445861|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2012-06-08|2007-03-07|2007-03-09|Estimate|||||||2012-06-08|2012-06-11|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery|Cetuximab in Combination With Radiation Therapy and Chemotherapy Prior to Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma. A Multicenter Phase IB-II Trial|Completed||Phase 1/Phase 2|27|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 03:22:33.615092|2018-06-01 03:22:33.615092
NCT00445848|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2016-05-06||2017-10-03|2007-03-07|2007-03-09|Estimate|2016-07-21|2016-09-07|Estimate||||2017-10-03|2017-11-06|Actual|July 2007||2007-07-31|October 2017|2017-10-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional||85 patients were eligible and analyzable.|S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer|A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas|Completed||Phase 2|89|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 03:22:33.709991|2018-06-01 03:22:33.709991
NCT00445835|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2010-09-30|2007-03-08|2007-03-09|Estimate|||||||2010-09-30|2010-10-01|Estimate|September 2007||2007-09-30|September 2010|2010-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|AMERICA||Active Detection of the Extension of Atherothrombosis in High Risk Coronary Patients|Active Detection and Management of the Extension of Atherothrombosis in High Risk Coronary Patients In Comparison With Standard of Care for Coronary Atherosclerosis: The AMERICA Study|Unknown status|Active, not recruiting|N/A|526|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:22:34.299488|2018-06-01 03:22:34.299488
NCT00445822|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2012-02-28|2007-03-08|2007-03-09|Estimate|||||||2012-02-28|2012-02-29|Estimate|March 2007||2007-03-31|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|July 2012|Anticipated|2012-07-31||Observational|CML-paed II||Registration of Children With CML and Treatment With Imatinib|Protocol for Standardized Diagnostic Procedures, Registration, and Treatment Recommendations in Children and Adolescents With Philadelphia Chromosome-positive Chronic Myeloid Leukemia (CML)|Unknown status|Recruiting||150|Anticipated|Technische Universität Dresden|||||f||||t||||||Samples With DNA|"~     Bone Marrow and blood smears~   "|||2018-06-01 03:22:34.3731|2018-06-01 03:22:34.3731
NCT00445809|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2009-08-03|2007-03-07|2007-03-09|Estimate|||||||2009-08-03|2009-08-04|Estimate|February 2007||2007-02-28|August 2009|2009-08-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Observational|EVOLVE||Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury|EValuation Of NGAL in Early and eVolving Acute kidnEy Injury|Completed|||355|Actual|Biosite|||2||f||||t||||||Samples Without DNA|"~     Blood Samples (3 10ml, 7 5ml) at ten timepoints over 5 days.~   "|||2018-06-01 03:22:34.443022|2018-06-01 03:22:34.443022
NCT00445796|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2008-04-08|2007-03-08|2007-03-09|Estimate|||||||2008-04-08|2008-04-10|Estimate|June 2005||2005-06-30|April 2008|2008-04-30||||||||Interventional|ATOL||Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance|Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack|Completed||Phase 4|300||Sanofi|||||f||||||||||||||2018-06-01 03:22:34.56259|2018-06-01 03:22:34.56259
NCT00445783|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2013-08-09|2007-03-07|2007-03-09|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2000||2000-07-31|April 2008|2008-04-30||||December 2020|Anticipated|2020-12-31||Observational|||Study of Families With Melanoma|Melanoma Family Case-Control Study Protocol|Recruiting|||3700|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:22:34.620488|2018-06-01 03:22:34.620488
NCT00445770|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|2011-07-12||2011-08-10|2007-03-08|2007-03-09|Estimate|2011-07-12|2011-08-05|Estimate||||2011-08-10|2011-08-15|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Multicenter, Comparative Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Active Rheumatoid Arthritis|Completed||Phase 3|550|Actual|Pfizer|Total Sharp Score and modified total Sharp Score were used interchangeably in the protocol and meant the same thing. In the statistical analysis plan and study results, mTSS was used consistently.|3|||f||||f||||||||||2018-06-01 03:22:34.876868|2018-06-01 03:22:34.876868
NCT00445757|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2012-03-16|2007-03-07|2007-03-09|Estimate|||||||2012-03-16|2012-03-20|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors|Evaluation of a Radio-Surgical Approach for the Treatment of Kidney Tumors|Withdrawn||Phase 1|0|Actual|Case Comprehensive Cancer Center||||slow accrual|f||||t||||||||||2018-06-01 03:22:38.207372|2018-06-01 03:22:38.207372
NCT00445744|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2017-04-05||2017-12-01|2007-03-07|2007-03-09|Estimate|2017-12-01|2018-01-02|Actual||||2017-12-01|2018-01-02|Actual|December 2006||2006-12-31|December 2017|2017-12-31|June 2013|Actual|2013-06-30|June 2011|Actual|2011-06-30||Interventional|||Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome|Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.|Completed||N/A|52|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 03:22:38.297804|2018-06-01 03:22:38.297804
NCT00445731|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2014-09-05|2007-03-07|2007-03-09|Estimate|||||||2014-09-05|2014-09-08|Estimate|May 2002||2002-05-31|September 2014|2014-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant|A Randomized Trial of the Effect of a Walking Regimen on the Functional Status of Adult Allogeneic Donor Bone Marrow Transplant Patients|Completed||N/A|115|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 03:22:38.454742|2018-06-01 03:22:38.454742
NCT00445718|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2017-02-07|2007-03-07|2007-03-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|July 2001||2001-07-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging|Perinatal Neuroblastoma: Expectant Observation A Children's Oncology Group Pilot Study|Completed|||97|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Urine, Tumor tissue~   "|||2018-06-01 03:22:38.521077|2018-06-01 03:22:38.521077
NCT00445705|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2011-12-16||2015-08-25|2007-03-07|2007-03-09|Estimate|2011-12-16|2012-01-20|Estimate||||2015-08-25|2015-09-07|Estimate|March 2007||2007-03-31|August 2015|2015-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome||Terminated||Phase 2|211|Actual|Allergan|This study was terminated early due to company decision. Only Part A results are presented; Part B was never conducted.|4||This study was terminated early due to company decision. Part B was never conducted.|f||||||||||||||2018-06-01 03:22:38.629312|2018-06-01 03:22:38.629312
NCT00445692|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2018-02-22||2018-02-22|2007-03-07|2007-03-09|Estimate|2018-02-22|2018-03-21|Actual||||2018-02-22|2018-03-21|Actual|January 10, 2007|Actual|2007-01-10|November 2017|2017-11-30|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma|Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma|Completed||Phase 2|32|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 03:22:38.97967|2018-06-01 03:22:38.97967
NCT00445679|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2010-02-26||2013-10-08|2007-03-08|2007-03-09|Estimate|2013-10-08|2013-11-04|Estimate||||2013-10-08|2013-11-04|Estimate|July 2007||2007-07-31|October 2013|2013-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD|A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|807|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||||||||||||2018-06-01 03:22:40.177349|2018-06-01 03:22:40.177349
NCT00445653|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2017-01-13|2007-03-07|2007-03-09|Estimate|||||||2017-01-13|2017-01-18|Estimate|August 2005||2005-08-31|January 2017|2017-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Risk Factors for Barrett's Esophagus in Patients With BE, Gastroesophageal Reflux, or Gastrointestinal Bleeding|Molecular Epidemiology of Barrett's Esophagus|Completed|||170|Actual|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     Blood samples only were collected~   "|No||2018-06-01 03:22:40.736024|2018-06-01 03:22:40.736024
NCT00445627|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2018-03-27|2007-03-08|2007-03-09|Estimate|||||||2018-03-27|2018-03-29|Actual|March 6, 2007||2007-03-06|June 27, 2017|2017-06-27||||||||Observational|||Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus|Natural History of Type 2 Diabetes Mellitus in Children and Young Adults|Recruiting|||430|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:22:40.884259|2018-06-01 03:22:40.884259
NCT00445614|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2008-08-12|2007-03-08|2007-03-09|Estimate|||||||2008-08-12|2008-08-14|Estimate|March 2007||2007-03-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effects of Trout Fed With a Vegetable Based Feed on Cardiovascular Risk Markers and Plasma Proteome|Healthy, Nutritious and Tasty Fish for the Future|Completed||N/A|72|Anticipated|University of Copenhagen||3|||f||||f||||||||||2018-06-01 03:22:40.960054|2018-06-01 03:22:40.960054
NCT00445601|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2017-12-21||2018-04-18|2007-03-07|2007-03-09|Estimate|2018-04-18|2018-04-24|Actual||||2018-04-18|2018-04-24|Actual|September 2007||2007-09-30|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional||All eligible patients|S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer|A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer|Completed||Phase 3|406|Actual|Southwest Oncology Group||2|||f||||t|t|f||||||||2018-06-01 03:22:41.13116|2018-06-01 03:22:41.13116
NCT00445419|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2010-02-05|2007-03-08|2007-03-09|Estimate|||||||2010-02-05|2010-02-08|Estimate|December 2006||2006-12-31|February 2010|2010-02-28|June 2008|Actual|2008-06-30|||||Interventional|||Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides|A Phase I Single-blind Randomised Placebo Controlled Dose Escalating Study of One Virosome Formulated CD4 and Two Virosomes Formulated CD8 Hepatitis C Virus (HCV) Vaccine Components (PEV2A and PEV2B) Administered to Healthy Adult Volunteers|Completed||Phase 1|30|Anticipated|Pevion Biotech Ltd|||||f||||t||||||||||2018-06-01 03:22:45.325295|2018-06-01 03:22:45.325295
NCT00445588|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2016-03-25||2016-03-25|2007-03-07|2007-03-09|Estimate|2016-03-25|2016-04-27|Estimate||||2016-03-25|2016-04-27|Estimate|January 2007||2007-01-31|March 2016|2016-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||histologically confirmed GBM, progressed or recurred following RT and 0-2 prior chemotherapy regimens|Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:22:41.922382|2018-06-01 03:22:41.922382
NCT00445575|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2011-12-29|2007-03-08|2007-03-09|Estimate|||||||2011-12-29|2012-01-02|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|PROFIDYS||Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone|Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone|Unknown status|Recruiting|Phase 2/Phase 3|156|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||t||||||||||2018-06-01 03:22:42.119306|2018-06-01 03:22:42.119306
NCT00445562|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2013-07-09|2007-03-07|2007-03-09|Estimate|||||||2013-07-09|2013-07-10|Estimate|January 2001||2001-01-31|July 2009|2009-07-31||||December 2004|Actual|2004-12-31||Observational|||Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters|Breast Cancer Siblings Database|Unknown status|Recruiting||1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:22:42.226064|2018-06-01 03:22:42.226064
NCT00445549|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2011-06-30||2012-05-22|2007-03-07|2007-03-09|Estimate|2012-05-22|2012-06-26|Estimate||||2012-05-22|2012-06-26|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Phase II Study of Clinical Activity and Proteomic Pathway Profiling of the Vascular Endothelial Growth Factor 2 (VEGFR2) Inhibitor, ZD6474 (Vandetanib) in Women With Relapsed or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Terminated||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)|The study closed after the first stage of accrual because of inadequate early activity with 32 cycles of administered treatment.|1||The study closed because of inadequate early activity.|f||||f||||||||||2018-06-01 03:22:42.301463|2018-06-01 03:22:42.301463
NCT00445523|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2016-03-15|2007-03-08|2007-03-09|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2006||2006-05-31|March 2016|2016-03-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer|A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer|Completed||Phase 2|28|Actual|The Methodist Hospital System||2|||f||||f||||||||No||2018-06-01 03:22:42.667244|2018-06-01 03:22:42.667244
NCT00445510|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2012-05-31|2007-03-07|2007-03-09|Estimate|||||||2012-05-31|2012-06-04|Estimate|June 2006||2006-06-30|February 2011|2011-02-28||||||||Interventional|||This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge|A Double Blind, Placebo Controlled, Repeat Dose Study to Determine the Effect of GSK256066 87.5 Mcg to Protect Against AMP Challenge in the Lung in Mild Steroid-naive Asthmatics.|Completed||Phase 2|24||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:22:42.764214|2018-06-01 03:22:42.764214
NCT00445497|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2013-08-09|2007-03-07|2007-03-09|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2007||2007-07-31|May 2007|2007-05-31||||July 2010|Anticipated|2010-07-31||Interventional|||Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia|A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE]|Unknown status|Recruiting|Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:22:42.838607|2018-06-01 03:22:42.838607
NCT00445484|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2015-06-26||2015-08-05|2007-03-07|2007-03-09|Estimate|2015-06-26|2015-07-24|Estimate||||2015-08-05|2015-08-24|Estimate|January 2007||2007-01-31|August 2015|2015-08-31|September 2010|Actual|2010-09-30|April 2009|Actual|2009-04-30||Interventional||A total of 22 patients were enrolled, 11 in each cohort. Patients who showed evidence of disease progression while on study were not included in subsequent analysis.|Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma|Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma|Completed||Phase 2|22|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-06-01 03:22:42.994721|2018-06-01 03:22:42.994721
NCT00445471|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2014-12-24|2007-03-08|2007-03-09|Estimate|||||||2014-12-24|2014-12-25|Estimate|April 2007||2007-04-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Prospective Study Comparing the Mifne Approach of Treating Childhood Autism With Routine Standard Treatment||Terminated||N/A|45|Actual|Rabin Medical Center||2||"Mifne began treating younger patients who could not be diagnosed with the ADOS used in the~   study"|f||||f||||||||||2018-06-01 03:22:43.290722|2018-06-01 03:22:43.290722
NCT00445458|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|2017-08-10|2013-01-29|2018-04-06|2007-03-08|2007-03-09|Estimate|2018-04-06|2018-05-09|Actual|2013-01-29|2013-01-31|Estimate|2018-04-06|2018-05-09|Actual|September 2007||2007-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2011|Actual|2011-05-31||Interventional||Safety population|A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer|A Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer|Active, not recruiting||Phase 1/Phase 2|115|Actual|Puma Biotechnology, Inc.||4|||f||||f||||||||||2018-06-01 03:22:43.4119|2018-06-01 03:22:43.4119
NCT00445445|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2018-01-29|2007-03-07|2007-03-09|Estimate|||||||2018-01-29|2018-01-31|Actual|January 10, 2007|Actual|2007-01-10|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women|Longitudinal Changes in Mammographic Density and Risk of Breast Cancer|Recruiting|||3000|Anticipated|Case Comprehensive Cancer Center|||2||f||||t|f|f||||Samples With DNA|"~     Time perspective: Prospective and retrospective. Blood and urine samples will be processed in~     our lab and stored in a -80 degree freezer until needed. Urine samples will be assessed for~     levels of bisphenol-A and remaining samples of urine and blood will be stored for future~     projects.~   "|||2018-06-01 03:22:44.221|2018-06-01 03:22:44.221
NCT00445432|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2010-03-31||2012-02-01|2007-03-07|2007-03-09|Estimate|2010-05-17|2010-06-09|Estimate||||2012-02-01|2012-02-02|Estimate|March 2007||2007-03-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|March 2009|Actual|2009-03-31||Interventional|||A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease|A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease|Completed||Phase 2/Phase 3|82|Actual|Abbott||3|||f||||||||||||||2018-06-01 03:22:44.357569|2018-06-01 03:22:44.357569
NCT00445406|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2012-06-26|2007-03-07|2007-03-09|Estimate|||||||2012-06-26|2012-06-28|Estimate|December 2006||2006-12-31|June 2012|2012-06-30|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer|Bevacizumab and Pegylated Liposomal Doxorubicin as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. A Multicenter, Single-Arm Phase II Trial|Completed||Phase 2|43|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 03:22:45.394284|2018-06-01 03:22:45.394284
NCT00445393|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-01-05|2007-03-08|2007-03-09|Estimate|||||||2009-01-05|2009-01-06|Estimate|October 2006||2006-10-31|January 2009|2009-01-31|October 2008|Actual|2008-10-31|||||Observational|||Adolescent Idiopathic Scoliosis and Mental Health|Prevalence of Psychiatric Disorders in Adolescents With Idiopathic Scoliosis: A Pilot Study of a Validated Screening Tool|Completed|||100|Anticipated|University of British Columbia|||||f||||t||||||||||2018-06-01 03:22:45.463211|2018-06-01 03:22:45.463211
NCT00445367|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-08|||2018-01-13|2007-03-08|2007-03-09|Estimate|||||||2018-01-13|2018-01-17|Actual|May 2006||2006-05-31|January 2018|2018-01-31||||October 2026|Anticipated|2026-10-31||Observational|||Biobank For MS And Other Demyelinating Diseases|Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases|Active, not recruiting|||3226|Actual|Accelerated Cure Project for Multiple Sclerosis|||2||f||||f||||||||||2018-06-01 03:22:45.539353|2018-06-01 03:22:45.539353
NCT00445354|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2007-03-07|2007-03-07|2007-03-09|Estimate|||||||2007-03-07|2007-03-09|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|August 2007||2007-08-31|||||Interventional|||Randomized Controlled Clinical Trial of Cinnamon to Lower Hemoglobin A1c|A Randomized Controlled Clinical Trial Comparing the Effect of 1g of Daily Cinnamon Plus Usual Care to Usual Cre on the Hemoglobin A1c of Uncontrolled Type 2 Diabetics|Unknown status|Recruiting|Phase 3|140||Eglin AFB Regional Hospital|||||f||||t||||||||||2018-06-01 03:22:45.611389|2018-06-01 03:22:45.611389
NCT00445341|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2012-09-05||2018-01-02|2007-03-07|2007-03-09|Estimate|2012-09-05|2012-10-05|Estimate||||2018-01-02|2018-01-30|Actual|November 27, 2006|Actual|2006-11-27|January 2018|2018-01-31|October 18, 2012|Actual|2012-10-18|April 30, 2012|Actual|2012-04-30||Interventional|||Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma|A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 1/Phase 2|28|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 03:22:45.700295|2018-06-01 03:22:45.700295
NCT00445328|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2009-07-20||2009-10-05|2007-03-07|2007-03-08|Estimate|2009-08-28|2009-10-02|Estimate||||2009-10-05|2009-10-15|Estimate|June 2007||2007-06-30|October 2009|2009-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients|Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients.|Terminated||Phase 4|84|Actual|Pfizer|Study terminated prematurely due to delay in overall study start-up and inability to meet predefined protocol recruitment milestones; sample size too small to permit meaningful statistical analyses. No statistical analyses for all but 2 endpoints.|2||See Detailed Description|f||||f||||||||||2018-06-01 03:22:46.036422|2018-06-01 03:22:46.036422
NCT00445315|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2013-12-09||2014-01-02|2007-03-07|2007-03-08|Estimate|2014-01-02|2014-02-17|Estimate||||2014-01-02|2014-02-17|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients|A Phase 1, Randomized, Double Blind (3rd Party Open), Placebo-controlled, Sequential Group, Multicentre Study To Evaluate The Multiple Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics, of PF-00868554 in Hepatitis C Virus (HCV) Positive Otherwise Healthy Patient Volunteers|Completed||Phase 1|32|Actual|Pfizer|Designation of outcomes as primary, secondary based on team’s input. Results for relationship analyses of baseline susceptibility to PF-00868554 and/or non-structural 5B genotype and change in HCV RNA was not done, as per change in planned analysis.|5|||f||||f||||||||||2018-06-01 03:22:46.428474|2018-06-01 03:22:46.428474
NCT00445302|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2010-12-12||2014-02-10|2007-03-07|2007-03-08|Estimate|2010-12-12|2011-01-12|Estimate||||2014-02-10|2014-03-13|Estimate|January 2006||2006-01-31|February 2014|2014-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment|A Phase I Study Of The Safety, Pharmacokinetics, And Hematological Activity Of AMD3100 (240 µg/kg) In Subjects With Renal Impairment|Completed||Phase 1|23|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 03:22:47.942563|2018-06-01 03:22:47.942563
NCT00445289|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2008-08-15|2007-03-07|2007-03-08|Estimate|||||||2008-08-15|2008-08-18|Estimate|March 2007||2007-03-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|ASOPI||Automatic Control of Pressure Support Ventilation in Surgical Intensive Care Units|Automatic Control of Pressure Support Ventilation in Surgical Intensive Care Units - a Bicentric, Prospective, Randomized, Controlled Trial|Completed||N/A|300|Anticipated|University of Schleswig-Holstein|||||f||||t||||||||||2018-06-01 03:22:48.882208|2018-06-01 03:22:48.882208
NCT00445276|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2010-03-03|2007-03-06|2007-03-08|Estimate|||||||2010-03-03|2010-03-04|Estimate|November 2005||2005-11-30|March 2010|2010-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Symptomatic Efficacy of Diacerein in Knee Osteoarthritis|Efficacy Study of Diacerein in the Symptomatic Treatment of Knee Osteoarthritis|Completed||Phase 4|500||Laboratoires NEGMA|||||f||||f||||||||||2018-06-01 03:22:48.971805|2018-06-01 03:22:48.971805
NCT00445263|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2015-01-26||2015-02-09|2007-03-07|2007-03-08|Estimate|2015-01-26|2015-02-09|Estimate||||2015-02-09|2015-02-27|Estimate|March 2007||2007-03-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|December 2010|Actual|2010-12-31||Interventional|SISCA||Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation|Treatment by Anti GP IIb/IIIa in the Setting of a Strategy of Early Coronarography to Patients With an Acute Coronary Syndrome Without ST Elevation|Terminated||Phase 4|170|Actual|Hospital Avicenne||2||Because of inclusion delay|f||||t||||||||||2018-06-01 03:22:49.047068|2018-06-01 03:22:49.047068
NCT00445250|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2007-03-07|2007-03-07|2007-03-08|Estimate|||||||2007-03-07|2007-03-08|Estimate||||January 2007|2007-01-31||||||||Interventional|||The Role of Calcipotriol as Radioprotector of Skin|Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.|Unknown status|Not yet recruiting|Phase 2|50||Rabin Medical Center|||||f||||t||||||||||2018-06-01 03:22:49.662706|2018-06-01 03:22:49.662706
NCT00445237|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-02-04|2007-03-07|2007-03-08|Estimate|||||||2009-02-04|2009-02-05|Estimate|May 2006||2006-05-31|March 2007|2007-03-31|March 2008|Actual|2008-03-31|||||Interventional|||Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression|Evaluation of the H1 Coil and H2 Coil TMS Device - Safety and Feasibility in Major Depression Episode|Completed||Phase 1|||Shalvata Mental Health Center|||||f||||f||||||||||2018-06-01 03:22:49.98502|2018-06-01 03:22:49.98502
NCT00445224|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2010-01-28||2017-02-25|2007-03-07|2007-03-08|Estimate|2010-08-04|2010-08-05|Estimate||||2017-02-25|2017-03-28|Actual|January 2008||2008-01-31|February 2017|2017-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparing Rehabilitation Programs for Patellofemoral Pain Syndrome|Comparison of Early Hip Strengthening to Early Quadriceps Strengthening in the Treatment of Females With Patellofemoral Pain|Completed||N/A|33|Actual|University of Kentucky|Early termination leading to small number of subjects analyzed. Intention to treat analysis, last score carried forward, was used to analyze all outcome data.|2|||f||||f||||||||Undecided|willing to share strength and patient reported outcome data at pre, mid, and post testing time points.|2018-06-01 03:22:50.043493|2018-06-01 03:22:50.043493
NCT00445211|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2017-04-11||2017-04-11|2007-03-07|2007-03-08|Estimate|2017-04-11|2017-05-19|Actual||||2017-04-11|2017-05-19|Actual|January 2006||2006-01-31|April 2017|2017-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|HEROIC||HEROIC (Heparin Requirement in Counterpulsation)|Heparin Requirement in Counterpulsation|Terminated||Phase 2|46|Actual|William Beaumont Hospitals|Early termination leading to small number of subjects analyzed.|2||lack of enrollment|f||||f|t|f||||||No||2018-06-01 03:22:50.43939|2018-06-01 03:22:50.43939
NCT00445198|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06||2011-12-22|2013-01-17|2007-03-06|2007-03-08|Estimate||||2011-12-22|2011-12-26|Estimate|2013-01-17|2013-01-25|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies|A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Small Cell Lung Cancer or Other Non-Hematological Malignancies|Completed||Phase 1/Phase 2|86|Actual|AbbVie||1|||f||||||||||||||2018-06-01 03:22:50.896715|2018-06-01 03:22:50.896715
NCT00445185|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-11-18|2007-03-07|2007-03-08|Estimate|||||||2009-11-18|2009-11-19|Estimate|March 2007||2007-03-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™|A Study to Evaluate the Persistence of Anti-HBs Antibodies at Months 12, 24 and 36 in Pre-dialysis or Dialysis Patients Who Have Received a Primary Vaccination Course of Either Henogen's HBV Vaccine, HB-AS02V or GSK Biological's Fendrix™|Completed||Phase 3|102|Anticipated|Henogen||2|||f||||f||||||||||2018-06-01 03:22:51.03441|2018-06-01 03:22:51.03441
NCT00445172|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2017-08-21|2007-03-07|2007-03-08|Estimate|||||||2017-08-21|2017-08-23|Actual|February 2008|Actual|2008-02-29|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2/Phase 3|135|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:22:51.135926|2018-06-01 03:22:51.135926
NCT00445159|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2007-03-07|2007-03-07|2007-03-08|Estimate|||||||2007-03-07|2007-03-08|Estimate|November 2006||2006-11-30|March 2007|2007-03-31||||||||Interventional|||UT-15C SR in the Treatment of Critical Limb Ischemia|An Investigator Initiated Eight Week Two Center Open-Label Pilot Study of the Tolerability and Safety of Oral UT-15C (Treprostinil Diethanolamine)SR Tablets in Patients With Critical Limb Ischemia (CLI) and Ischemic Rest Pain|Unknown status|Recruiting|Phase 2|20||Southern Arizona Vascular Institute|||||f||||t||||||||||2018-06-01 03:22:51.502463|2018-06-01 03:22:51.502463
NCT00445146|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2016-03-23||2016-03-23|2007-03-07|2007-03-08|Estimate|2016-03-23|2016-04-25|Estimate||||2016-03-23|2016-04-25|Estimate|February 2007||2007-02-28|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety Analysis Set: enrolled participants who received at least 1 dose of EVG|Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection|A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects|Completed||Phase 2|192|Actual|Gilead Sciences||1|||f||||f||||||||||2018-06-01 03:22:51.642998|2018-06-01 03:22:51.642998
NCT00445133|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-09-26|2007-03-07|2007-03-08|Estimate|||||||2007-09-26|2007-09-27|Estimate|February 2007||2007-02-28|September 2007|2007-09-30|December 2007||2007-12-31|||||Interventional|SLEEP/MAG||Study on Magnetic Field Therapy to Improve Quality of Sleep and Reduction of Chronic Spine Pain|A Double-Blind, Randomized, Placebo-Controlled Study on Magnetic Field Therapy to Improve Quality of Sleep and Reduction of Chronic Spine Pain (Sleep/Mag)|Unknown status|Recruiting|Phase 4|80|Anticipated|Weintraub, Michael I., MD, FACP, FAAN|||||f||||f||||||||||2018-06-01 03:22:53.12472|2018-06-01 03:22:53.12472
NCT00445120|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-01-28|2007-03-07|2007-03-08|Estimate|||||||2009-01-28|2009-01-29|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment|Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Lactobacillus Rhamnosus GG Treatment in Preventing Vernal Keratoconjunctivitis VKC) Relapses.|Completed||Phase 2/Phase 3|48|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||||2018-06-01 03:22:53.217969|2018-06-01 03:22:53.217969
NCT00445107|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2017-03-24|2007-03-06|2007-03-08|Estimate|||||||2017-03-24|2017-03-28|Actual|November 1, 2005|Actual|2005-11-01|March 2017|2017-03-31|May 17, 2006|Actual|2006-05-17|May 1, 2006|Actual|2006-05-01||Interventional|STAR||SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)|An Open Label, Observational Study to Assess The Efficacy, Safety and Tolerability of Added Singulair in Persistent Asthma Patients With or Without Allergic Rhinitis and Long Acting B-Agonist|Completed||Phase 3|198|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:22:53.398739|2018-06-01 03:22:53.398739
NCT00445094|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2017-02-15|2007-03-06|2007-03-08|Estimate|||||||2017-02-15|2017-02-17|Actual|November 2006||2006-11-30|February 2017|2017-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)|A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit|Completed||Phase 4|120|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:22:53.483182|2018-06-01 03:22:53.483182
NCT00445081|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2010-10-28|2007-03-07|2007-03-08|Estimate|||||||2010-10-28|2010-10-29|Estimate|March 2007||2007-03-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|PROVE||Prednisolone vs. Ciclosporine in Severe Atopic Eczema|Prednisolone vs. Ciclosporine in Severe Atopic Eczema|Completed||Phase 4|66|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-06-01 03:22:53.549264|2018-06-01 03:22:53.549264
NCT00445068|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2013-05-08|2007-03-07|2007-03-08|Estimate|||||||2013-05-08|2013-05-10|Estimate|April 2007||2007-04-30|May 2013|2013-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma|A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy|Terminated||Phase 2|38|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:22:53.760156|2018-06-01 03:22:53.760156
NCT00445055|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2011-12-12|2007-03-07|2007-03-08|Estimate|||||||2011-12-12|2011-12-13|Estimate|April 2007||2007-04-30|December 2011|2011-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|DIPAVO||Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea|Study of Evaluation of the Profile of Efficiency / Tolerance of 2 Doses of Intravenous Droperidol in the Prevention of the Postoperative Nausea and Vomits Related to the Surgery of the Thyroid|Terminated||Phase 4|71|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-06-01 03:22:54.014693|2018-06-01 03:22:54.014693
NCT00445042|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2016-03-15|2007-03-07|2007-03-08|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2005||2005-11-30|March 2016|2016-03-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer|A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|71|Actual|The Methodist Hospital System||1|||f||||f||||||||No||2018-06-01 03:22:54.128402|2018-06-01 03:22:54.128402
NCT00445029|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2007-10-03|2007-03-07|2007-03-08|Estimate|||||||2007-10-03|2007-10-04|Estimate|March 2007||2007-03-31|October 2007|2007-10-31||||||||Observational|||Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation|Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation|Unknown status|Recruiting||36|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:22:54.245751|2018-06-01 03:22:54.245751
NCT00445016|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2008-05-05|2007-03-07|2007-03-08|Estimate|||||||2008-05-05|2008-05-09|Estimate|May 2008||2008-05-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|||||Observational|||Neurologic Complications in Peripheral Regional Anesthesia - An Evaluation Based on a Standardized Protocol|Neurologic Complications in Peripheral Regional Anesthesia - A Clinical Follow Up Study to Evaluate the Incidence of Neurologic Complications Defined According to a Standardized Protocol Considering Motoric and Sensory Function and Pain|Unknown status|Active, not recruiting||1000|Anticipated|BG Unfallklinik|||||f||||||||||||||2018-06-01 03:22:54.307349|2018-06-01 03:22:54.307349
NCT00445003|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2011-04-14|2011-01-14|2016-08-25|2007-03-06|2007-03-08|Estimate|2011-06-14|2011-07-13|Estimate|2011-03-15|2011-03-16|Estimate|2016-08-25|2016-08-26|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|July 2010|Actual|2010-07-31|October 2009|Actual|2009-10-31||Interventional|LRTforDME+PRP||Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy|Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Completed||Phase 3|333|Actual|Jaeb Center for Health Research||3|||f||||t||||||||||2018-06-01 03:22:54.456474|2018-06-01 03:22:54.456474
NCT00444990|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-09-20|2007-03-07|2007-03-08|Estimate|||||||2007-09-20|2007-09-21|Estimate|February 2007||2007-02-28|September 2007|2007-09-30|December 2007||2007-12-31|||||Interventional|LBP||Study on Magnetic Field Therapy to Improve Chronic Lumbar Pain|A Double-Blind, Randomized, Placebo-Controlled Study on Magnetic Field Therapy to Improve Chronic Lumbar Pain (Lbp)|Unknown status|Recruiting|Phase 4|60|Anticipated|Weintraub, Michael I., MD, FACP, FAAN|||||f||||||||||||||2018-06-01 03:22:56.27397|2018-06-01 03:22:56.27397
NCT00444977|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2013-07-03|2007-03-07|2007-03-08|Estimate|||||||2013-07-03|2013-07-08|Estimate|April 2005||2005-04-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Enhancing Oral Health Care Use by HIV Positive Individuals|Enhancing Oral Health Care Use by HIV-Positives|Completed||N/A|600|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 03:22:56.461279|2018-06-01 03:22:56.461279
NCT00444964|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-03-07|2007-03-07|2007-03-08|Estimate|||||||2007-03-07|2007-03-08|Estimate|April 2005||2005-04-30|March 2007|2007-03-31|February 2007||2007-02-28|||||Interventional|||Growth Hormone Use in Adults With Prader-Willi Syndrome|Growth Hormone Use in Adults With Prader-Willi Syndrome|Unknown status|Recruiting|Phase 3|10||Children's Mercy Hospital Kansas City|||||f||||t||||||||||2018-06-01 03:22:56.533578|2018-06-01 03:22:56.533578
NCT00444951|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2011-02-09||2015-06-16|2007-03-07|2007-03-08|Estimate|2011-02-09|2011-03-04|Estimate||||2015-06-16|2015-07-14|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia|Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia.|Completed||Phase 3|450|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:22:56.625099|2018-06-01 03:22:56.625099
NCT00444938|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-02-04|2007-03-07|2007-03-08|Estimate|||||||2009-02-04|2009-02-05|Estimate|June 2006||2006-06-30|March 2007|2007-03-31|March 2008|Actual|2008-03-31|||||Interventional|||Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device in the Treatment of Bipolar Depression|Evaluation of the H-Coil (TMS) Device - Safety and Feasibility in Bipolar Depression|Completed||Phase 1|||Shalvata Mental Health Center|||||f||||t||||||||||2018-06-01 03:22:57.254442|2018-06-01 03:22:57.254442
NCT00444925|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2009-07-14||2015-03-04|2007-03-07|2007-03-08|Estimate|2009-07-27|2009-09-03|Estimate||||2015-03-04|2015-03-24|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)|12-Week, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (OAB)|Completed||Phase 3|1712|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 03:22:57.451103|2018-06-01 03:22:57.451103
NCT00444912|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2010-06-25||2014-02-10|2007-03-07|2007-03-08|Estimate|2010-06-25|2010-07-29|Estimate||||2014-02-10|2014-03-13|Estimate|February 2006||2006-02-28|February 2014|2014-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)|A Pilot Cohort Study of AMD3100 in Combination With G-CSF and Rituximab Compared With AMD3100 in Combination With G-CSF Alone for Mobilization of BPCs in Patients With Relapsed or Refractory NHL or HD Prior to Autologous HPC Transplant|Completed||Phase 2|30|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:22:59.442743|2018-06-01 03:22:59.442743
NCT00444899|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2018-05-02|2007-03-07|2007-03-08|Estimate|||||||2018-05-02|2018-05-08|Actual|March 2007||2007-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Interventional|GRC||Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients|Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Diabetic Patients|Active, not recruiting||N/A|80|Anticipated|Université de Sherbrooke||2|||f||||f||||||||No||2018-06-01 03:23:00.242681|2018-06-01 03:23:00.242681
NCT00444886|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2011-02-09|2007-03-07|2007-03-08|Estimate|||||||2011-02-09|2011-02-10|Estimate|May 2007||2007-05-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Treatment of Thoracic Outlet Syndrome (TOS) With Botox|Treatment of Thoracic Outlet Syndrome With Botulinum Toxin Injection: A Double-Blind, Randomized Controlled Trial|Completed||Phase 2|40|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:23:00.359035|2018-06-01 03:23:00.359035
NCT00444873|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2012-06-18|2007-03-07|2007-03-08|Estimate|||||||2012-06-18|2012-06-19|Estimate|January 2005||2005-01-31|June 2012|2012-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly|A Phase III, Multicentre, Open Label, Comparative, Dose-interval Titration Study Evaluating the Efficacy and Safety of Six Repeated Deep Subcutaneous Administrations of Lanreotide Autogel 120mg, in Acromegalic Patients Previously Treated With Octreotide LAR|Completed||Phase 3|38|Actual|Ipsen||3|||f||||f||||||||||2018-06-01 03:23:00.557872|2018-06-01 03:23:00.557872
NCT00444860|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2015-06-03|2007-03-07|2007-03-08|Estimate|||||||2015-06-03|2015-06-04|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||ZOSTAVAX(R) Local Registration Trial (V211-019)|A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX(R) in Healthy Adults in Taiwan|Completed||Phase 3|150|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 03:23:00.723681|2018-06-01 03:23:00.723681
NCT00444847|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2017-07-26|2007-03-07|2007-03-08|Estimate|||||||2017-07-26|2017-07-27|Actual|July 2005||2005-07-31|March 2007|2007-03-31||||||||Interventional|DANET1||Effect of Repeated Exposures to Compressed Air on Patients With AIDS|Effect of Repeated Exposure to Compressed Air on Patients With AIDS (Acquired Immunodeficiency Syndrome)|Withdrawn||Phase 2|0|Actual|Designed Altobaric Technology, Incorporated|||||f||||t||||||||||2018-06-01 03:23:00.987979|2018-06-01 03:23:00.987979
NCT00444834|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2016-08-26|2007-03-07|2007-03-08|Estimate|||||||2016-08-26|2016-08-29|Estimate|April 2007||2007-04-30|August 2016|2016-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension|A Phase II, Multi-center, Multiple-dose, Double-blind, Randomized, Crossover Study Comparing the Pharmacodynamic Effects of a Once-daily Controlled-Release Carvedilol (CRC; Egalet® Formulation) and an Immediate-Release Carvedilol (IRC) Formulation in Patients With Primary Hypertension|Terminated||Phase 2|14|Actual|Egalet Ltd||2||IMP supply|f||||f||||||||||2018-06-01 03:23:01.109868|2018-06-01 03:23:01.109868
NCT00444821|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2017-12-21||2018-04-30|2007-03-07|2007-03-08|Estimate|2018-03-23|2018-04-23|Actual||||2018-04-30|2018-05-30|Actual|March 2005||2005-03-31|April 2018|2018-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The (PIVOTAL) Study|Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL)|Terminated||N/A|728|Actual|Medtronic Endovascular|Terminated before subjects enrolled & completed follow-up, leading to small numbers. Crossover from the Surveillance Group to Early Endovascular Group led to subjects treated endovascularly being included in the Surveillance Group results.|2||Interim analysis of Primary Endpoint completed|f||||||||||||||2018-06-01 03:23:01.248314|2018-06-01 03:23:01.248314
NCT00444808|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2008-06-02|2007-03-07|2007-03-08|Estimate|||||||2008-06-02|2008-06-04|Estimate|February 2007||2007-02-28|June 2008|2008-06-30|January 2008|Actual|2008-01-31|||||Interventional|||Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs|Analgesic Effect of Intranasal Calcitonin on Patients With Fractured Ribs|Terminated||Phase 4|19|Actual|Université de Montréal||||Medication expired|f||||f||||||||||2018-06-01 03:23:02.591984|2018-06-01 03:23:02.591984
NCT00444795|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2016-02-19||2016-12-06|2007-03-07|2007-03-08|Estimate|2016-03-23|2016-04-26|Estimate||||2016-12-06|2017-02-01|Estimate|May 2007||2007-05-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||Safety Analysis Set: Participants who administered Sutene at least once and were evaluated upon its related safety endpoints at least once.|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene|Completed|||520|Actual|Pfizer|||3||f||||f||||||||||2018-06-01 03:23:02.686883|2018-06-01 03:23:02.686883
NCT00444782|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2008-12-17|2007-03-07|2007-03-08|Estimate|||||||2008-12-17|2008-12-18|Estimate|November 2006||2006-11-30|December 2008|2008-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.|"Heptovax - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma."|Completed||Phase 2|41|Anticipated|Pharmexa A/S|||||f||||||||||||||2018-06-01 03:23:03.282445|2018-06-01 03:23:03.282445
NCT00444769|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2009-05-15|2007-03-06|2007-03-08|Estimate|||||||2009-05-15|2009-05-18|Estimate|October 2006||2006-10-31|May 2009|2009-05-31||||||||Interventional|||Dental Pain 3rd Molar Tooth Extraction GW842166|A Multi-Centre, Randomised, Single-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy of Single Pre-Emptive Doses of GW842166X, a Non-Cannabinoid CB2 Receptor Agonist, on Pain Following Third Molar Tooth Extraction.|Completed||Phase 2|112|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:23:03.372024|2018-06-01 03:23:03.372024
NCT00444756|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2007-03-07|2007-03-07|2007-03-08|Estimate|||||||2007-03-07|2007-03-08|Estimate|April 2005||2005-04-30|March 2007|2007-03-31|April 2006||2006-04-30|||||Interventional|||Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Intravenous (IV) Catheterization in Children|Jet Injection of 1% Buffered Lidocaine Versus Topical ELA-Max for Anesthesia Prior to Peripheral Intravenous Catheterization in Children|Completed||Phase 4|70||Norton Healthcare|||||f||||t||||||||||2018-06-01 03:23:03.611582|2018-06-01 03:23:03.611582
NCT00444743|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2008-12-16|2007-03-07|2007-03-08|Estimate|||||||2008-12-16|2008-12-18|Estimate|February 2007||2007-02-28|December 2008|2008-12-31||||November 2008|Actual|2008-11-30||Interventional|||Phase 2 Study of MM-093 to Treat Patients With Uveitis|A Phase 2, Double - Blind, Placebo - Controlled, Randomized Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Uveitis|Completed||Phase 2|20|Anticipated|Merrimack Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:23:03.688578|2018-06-01 03:23:03.688578
NCT00444730|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2014-08-26|2007-03-07|2007-03-08|Estimate|||||||2014-08-26|2014-08-28|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Urology Database for Outcomes Research|Urology Database for Outcomes Research|Completed|||860|Actual|William Beaumont Hospitals|||||f||||f||||||||||2018-06-01 03:23:03.812064|2018-06-01 03:23:03.812064
NCT00444717|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2011-07-12|2007-03-07|2007-03-08|Estimate|||||||2011-07-12|2011-07-13|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Impact of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome|Multicenter Study for Anti-oxidative and Anti-inflammatory Effects of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome|Completed||Phase 4|100|Actual|Aichi Gakuin University|||||f||||t||||||||||2018-06-01 03:23:03.924608|2018-06-01 03:23:03.924608
NCT00444704|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-07-08|2007-03-07|2007-03-08|Estimate|||||||2009-07-08|2009-07-10|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|December 2007|Actual|2007-12-31|||||Interventional|||Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Japanese Females|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:23:04.120601|2018-06-01 03:23:04.120601
NCT00444691|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-08-25|2007-03-07|2007-03-08|Estimate|||||||2009-08-25|2009-08-26|Estimate|March 2007||2007-03-31|August 2009|2009-08-31|April 2010|Anticipated|2010-04-30|August 2008|Actual|2008-08-31||Interventional|SEA||Sensitivity of Echography in Arthritis|Sensitivity of Echography in Arthritis|Unknown status|Active, not recruiting|N/A|120|Anticipated|Association de Recherche Clinique en Rhumatologie|||||f||||f||||||||||2018-06-01 03:23:04.310061|2018-06-01 03:23:04.310061
NCT00444678|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2018-02-23|2007-03-07|2007-03-08|Estimate|||||||2018-02-23|2018-02-27|Actual|June 1, 2004||2004-06-01|February 2018|2018-02-28|June 1, 2015|Actual|2015-06-01|August 1, 2012|Actual|2012-08-01||Interventional|||Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer|A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With EGFR-Expressing Metastatic Colorectal Cancer|Completed||Phase 2|38|Actual|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-06-01 03:23:04.53673|2018-06-01 03:23:04.53673
NCT00444665|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2016-11-18|2007-03-07|2007-03-08|Estimate|||||||2016-11-18|2016-11-21|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy|Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy|Completed||Phase 4|750|Anticipated|Alcon Research|||||f||||f||||||||||2018-06-01 03:23:04.715029|2018-06-01 03:23:04.715029
NCT00444652|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2012-06-28|2007-03-07|2007-03-08|Estimate|||||||2012-06-28|2012-07-02|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Thromboprophylaxis and Bariatric Surgery|Thromboprophylaxis During Bariatric Surgery|Unknown status|Recruiting|Phase 4|300|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 03:23:04.826849|2018-06-01 03:23:04.826849
NCT00444639|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|||2009-12-10|2007-03-07|2007-03-08|Estimate|||||||2009-12-10|2009-12-11|Estimate|February 2007||2007-02-28|December 2009|2009-12-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)|Phase II Multi-Centric, Randomised, Open-label, Parallel-Group Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer|Terminated||Phase 2|25|Actual|Ipsen||2||Low recruitment|f||||||||||||||2018-06-01 03:23:04.936713|2018-06-01 03:23:04.936713
NCT00444626|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2015-04-07|2009-12-10|2015-04-07|2007-03-07|2007-03-08|Estimate|2015-04-07|2015-04-22|Estimate|2009-12-10|2009-12-14|Estimate|2015-04-07|2015-04-22|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|||A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)|A Subject- and Evaluator-Blinded, Randomized, Multi-Center Study to Evaluate the Safety and Effectiveness of Injection With DGE Injectable Gel as Compared to an FDA-Approved Dermal Filler in Subjects Undergoing Cutaneous Correction of Nasolabial Folds|Completed||Phase 3|140|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:23:05.049789|2018-06-01 03:23:05.049789
NCT00444613|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2014-12-04|2007-03-06|2007-03-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|April 2007||2007-04-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2/Phase 3|373|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 03:23:05.896881|2018-06-01 03:23:05.896881
NCT00444600|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2011-01-14||2016-08-25|2007-03-06|2007-03-08|Estimate|2011-06-14|2011-07-12|Estimate||||2016-08-25|2016-08-26|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|February 2014|Actual|2014-02-28|December 2009|Actual|2009-12-31||Interventional|LRT for DME||Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema|Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination With Laser Photocoagulation for Diabetic Macular Edema|Completed||Phase 3|691|Actual|Jaeb Center for Health Research||4|||f||||t||||||||||2018-06-01 03:23:06.130189|2018-06-01 03:23:06.130189
NCT00444587|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-07|2016-03-16||2016-05-12|2007-03-07|2007-03-08|Estimate|2016-05-12|2016-06-21|Estimate||||2016-05-12|2016-06-21|Estimate|March 2007||2007-03-31|May 2016|2016-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||The Safety Population included all participants who entered the trial and received at least one dose of trial medication.|A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.|A Multicenter Phase II Trial of Trastuzumab (Herceptin) Continuation in Combination With 2nd-line Chemotherapies After Progression on a 1st-line Chemotherapy Combined With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer (Treatment Beyond Progression, TBP)|Completed||Phase 2|114|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:23:10.122199|2018-06-01 03:23:10.122199
NCT00444574|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2015-06-23|2007-03-07|2007-03-08|Estimate|||||||2015-06-23|2015-06-25|Estimate|September 2004||2004-09-30|June 2015|2015-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD|A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA® in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|282|Actual|Noven Therapeutics||3|||f||||f||||||||||2018-06-01 03:23:10.820215|2018-06-01 03:23:10.820215
NCT00444561|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2015-06-10|2007-03-06|2007-03-08|Estimate|||||||2015-06-10|2015-06-11|Estimate|August 2004||2004-08-31|May 2015|2015-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects|A Phase 2, Randomized, Double‑Blind, Placebo‑Controlled, Multicenter Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects|Completed||Phase 2|184|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 03:23:10.885434|2018-06-01 03:23:10.885434
NCT00444548|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2011-05-31|2007-03-07|2007-03-08|Estimate|||||||2011-05-31|2011-06-01|Estimate|May 2007||2007-05-31|May 2011|2011-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers|Measurement Of Urethral Function In Healthy Female Volunteers - Evaluation Of The Sensitivity of Urethral Reflectometry Compared To Urethral Pressure Profilometry, Using [S,S]-Reboxetine.|Completed||N/A|12|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:23:11.00122|2018-06-01 03:23:11.00122
NCT00444197|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-03-05|2007-03-05|2007-03-07|Estimate|||||||2007-03-05|2007-03-07|Estimate|August 2001||2001-08-31|March 2007|2007-03-31|January 2006||2006-01-31|||||Interventional|||Community-Based Violence Prevention for High-Risk Youth||Completed||Phase 2|198||Johns Hopkins University|||||f||||f||||||||||2018-06-01 03:23:21.581788|2018-06-01 03:23:21.581788
NCT00444535|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2009-07-09||2017-06-06|2007-03-06|2007-03-08|Estimate|2009-07-09|2009-08-20|Estimate||||2017-06-06|2017-07-07|Actual|February 27, 2007|Actual|2007-02-27|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|July 22, 2008|Actual|2008-07-22||Interventional|||Lapatinib and Bevacizumab for Metastatic Breast Cancer|A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer|Active, not recruiting||Phase 2|50|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 03:23:11.064251|2018-06-01 03:23:11.064251
NCT00444522|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2017-03-10|2007-03-07|2007-03-08|Estimate|||||||2017-03-10|2017-03-14|Actual|June 2005|Actual|2005-06-30|March 2007|2007-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Staccato Alprazolam Single Dose PK|Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoTM Alprazolam for Inhalation in Normal, Healthy Volunteers|Completed||Phase 1|50||Alexza Pharmaceuticals, Inc.|||||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 03:23:11.472808|2018-06-01 03:23:11.472808
NCT00444509|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2017-08-03|2007-03-06|2007-03-07|Estimate|||||||2017-08-03|2017-08-04|Actual|February 17, 2007|Actual|2007-02-17|August 2017|2017-08-31|April 9, 2007|Actual|2007-04-09|April 9, 2007|Actual|2007-04-09||Interventional|||Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.|A Double-blind, Placebo-controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Dose Dry Powder GW685698X Containing Magnesium Stearate in Subjects With Mild to Moderate Asthmatic Patients|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:23:11.536016|2018-06-01 03:23:11.536016
NCT00444496|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2008-02-12|2007-03-06|2007-03-07|Estimate|||||||2008-02-12|2008-02-15|Estimate|February 2007||2007-02-28|February 2008|2008-02-29|July 2007|Actual|2007-07-31|||||Observational|||SPHERE Hypertension Baseline Data Study|SPHERE Hypertension Baseline Data Study|Completed|||470|Actual|University of Washington|||||f||||t||||||||||2018-06-01 03:23:11.704871|2018-06-01 03:23:11.704871
NCT00444483|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-03-06|2007-03-06|2007-03-07|Estimate|||||||2007-03-06|2007-03-07|Estimate||||March 2007|2007-03-31||||||||Interventional|||Structured Patient Education and Quality of Life of Elderly Patients With Diabetes Mellitus- a Prospective Study|Structured Treatment and Teaching of Elderly Patients With Type 2 Diabetes Mellitus|Completed||N/A|50||Heidelberg University|||||f||||f||||||||||2018-06-01 03:23:11.764828|2018-06-01 03:23:11.764828
NCT00444470|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-11-29|2007-03-05|2007-03-07|Estimate|||||||2007-11-29|2007-11-30|Estimate|February 2003||2003-02-28|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||Safety of Tranexamic Acid in Reducing Bleeding in Adults Undergoing Spinal Surgery|Efficacy of Tranexamic Acid in Reducing Blood Loss in Adult Patients Having Major Spine Surgery|Completed||Phase 3|151|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 03:23:11.830333|2018-06-01 03:23:11.830333
NCT00444457|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|2010-06-11||2012-10-10|2007-03-06|2007-03-07|Estimate|2010-06-11|2010-07-14|Estimate||||2012-10-10|2012-10-15|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States|Completed||Phase 3|1712|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella) was not available as planned; the alternate of a commercially available MMR and a commercially available varicella vaccine was administered in separate injections.|4|||f||||||||||||||2018-06-01 03:23:12.116223|2018-06-01 03:23:12.116223
NCT00444444|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-06-25|2007-03-06|2007-03-07|Estimate|||||||2007-06-25|2007-06-26|Estimate|February 2002||2002-02-28|March 2007|2007-03-31|June 2007|Actual|2007-06-30|||||Observational|||Genetic Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP)|Clinical Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP) in Korean Population Based on the HLA Analysis by Using a High Resolution (Sequence Based) Techniques|Completed|||40|Actual|Asan Medical Center|||||f||||f||||||||||2018-06-01 03:23:19.271536|2018-06-01 03:23:19.271536
NCT00444431|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-03-05|2007-03-05|2007-03-07|Estimate|||||||2007-03-05|2007-03-07|Estimate|March 2007||2007-03-31|March 2007|2007-03-31||||||||Interventional|TOKU||Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance. A Prospective, Randomized, Controlled Multi-Center Study|Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance in Children With Scintigraphically Prooved Obstruction. A Prospective, Randomized, Controlled Multi-Center Study|Unknown status|Not yet recruiting|N/A|240||University Hospital, Essen|||||f||||t||||||||||2018-06-01 03:23:19.35191|2018-06-01 03:23:19.35191
NCT00444418|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2013-04-30|2007-03-06|2007-03-07|Estimate|||||||2013-04-30|2013-05-01|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Medication and Counseling for Controlled Drinking (Project SMART)|Naltrexone and CBT for Problem-drinking MSM|Completed||Phase 3|200|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||4|||f||||t||||||||||2018-06-01 03:23:19.417361|2018-06-01 03:23:19.417361
NCT00444405|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2018-03-22|2007-03-06|2007-03-07|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 2007||2007-03-31|March 2018|2018-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Surgical Treatment Comparison for Recurrent Lumbar Disc Herniation|Surgical Treatment Comparison for Recurrent Lumbar Disc Herniation|Withdrawn|||0|Actual|Mercy Research||||PI left Health System|f||||t||||||||||2018-06-01 03:23:19.507203|2018-06-01 03:23:19.507203
NCT00444392|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2016-11-17|2007-03-06|2007-03-07|Estimate|||||||2016-11-17|2016-11-21|Estimate|March 2007||2007-03-31|November 2016|2016-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus|Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus|Completed||Phase 3|9|Actual|Vanderbilt University|||||f||||t||||||||||2018-06-01 03:23:19.568854|2018-06-01 03:23:19.568854
NCT00443365|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2008-05-27|2007-03-02|2007-03-06|Estimate|||||||2008-05-27|2008-05-30|Estimate|March 2007||2007-03-31|May 2008|2008-05-31||||||||Interventional|||Should we Repair Ischemic Mitral Regurgitation?||Unknown status|Recruiting|N/A|100|Anticipated|Medical University of Silesia||2|||f||||||||||||||2018-06-01 03:23:35.361031|2018-06-01 03:23:35.361031
NCT00444379|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2014-08-19|2007-03-06|2007-03-07|Estimate|||||||2014-08-19|2014-08-20|Estimate|April 2007||2007-04-30|August 2014|2014-08-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|ARKS||Anti-Retrovirals for Kaposi's Sarcoma|A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa|Completed||Phase 4|224|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 03:23:19.642466|2018-06-01 03:23:19.642466
NCT00444353|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2008-04-22|2007-03-05|2007-03-07|Estimate|||||||2008-04-22|2008-04-23|Estimate|August 2004||2004-08-31|April 2008|2008-04-30|January 2007|Actual|2007-01-31|||||Interventional|||DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up|A Randomized Study of the Safety and Effectiveness of DL6049 (Injectable Poly-l-Lactic Acid) Versus Cosmoplast Collagen Implant in the Treatment of Nasolabial Fold Wrinkles (Long Term Follow-up)|Completed||Phase 3|240||Sanofi|||||f||||f||||||||||2018-06-01 03:23:19.736647|2018-06-01 03:23:19.736647
NCT00444340|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-12-05|2007-03-06|2007-03-07|Estimate|||||||2007-12-05|2007-12-07|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis|An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis|Completed||Phase 4|70||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:23:20.001448|2018-06-01 03:23:20.001448
NCT00444327|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2009-05-13|2007-03-06|2007-03-07|Estimate|||||||2009-05-13|2009-05-14|Estimate|March 2007||2007-03-31|May 2009|2009-05-31||||||||Observational|||Use Cord Blood Single Nucleotide Polymorphism to Predict the Later Development of Atopy and Allergy|Observational Study of Cord Blood Single Nucleotide Polymorphisms of Genes Related to Atopy and Allergic Diseases|Unknown status|Recruiting||900|Anticipated|Min-Sheng General Hospital|||||f||||t||||||||||2018-06-01 03:23:20.071331|2018-06-01 03:23:20.071331
NCT00444314|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2011-08-03|2007-03-06|2007-03-07|Estimate|||||||2011-08-03|2011-08-04|Estimate|February 2007||2007-02-28|August 2011|2011-08-31|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma|Phase II Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion Alone and in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma Progressing on Sunitinib Malate|Completed||Phase 2|82|Anticipated|CASI Pharmaceuticals, Inc.||2|||f||||||||||||||2018-06-01 03:23:20.147419|2018-06-01 03:23:20.147419
NCT00444301|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2008-06-08|2007-03-06|2007-03-07|Estimate|||||||2008-06-08|2008-06-11|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|PAIN-HF||Pain Assessment, Incidence & Nature in Heart Failure|Investigating Pain in Heart Failure Patients|Completed|||349|Actual|PC-HEART|||||f||||f||||||||||2018-06-01 03:23:20.223781|2018-06-01 03:23:20.223781
NCT00444288|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2017-06-30|2007-03-06|2007-03-07|Estimate|||||||2017-06-30|2017-07-02|Actual|February 27, 2007||2007-02-27|March 1, 2010|2010-03-01|March 1, 2010||2010-03-01|||||Observational|||PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2|PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:23:20.296142|2018-06-01 03:23:20.296142
NCT00444275|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|2010-03-29||2012-11-14|2007-03-05|2007-03-07|Estimate|2012-11-14|2012-12-11|Estimate||||2012-11-14|2012-12-11|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|MAESTRO||Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients|A Randomized, Open, Parallel-group Study to Evaluate the Efficacy of Three Different Patient Management Strategies During a 12 Weeks Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related|Completed||Phase 4|3029|Actual|AstraZeneca|"Planned number of patients not reached: statistical analysis plan revised,comparisons between treatment arms performed globally (No stratified analysis).~Safety pop=3032-3 incorrect enrolments (withdrawals at V2) with no information on ttmt received"|5|||f||||f||||||||||2018-06-01 03:23:20.375339|2018-06-01 03:23:20.375339
NCT00444262|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2011-10-06|2007-03-06|2007-03-07|Estimate|||||||2011-10-06|2011-10-07|Estimate|April 2007||2007-04-30|June 2011|2011-06-30|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|FRACTALE||Stroke Volume Optimisation in Patients With Hip Fracture|"Study Multicentric, Randomised, in Duplicate Blind Person of the Impact of a Per Operatory Strategy of Optimization of the Cardiac Output on the Forecast of the Old Subjects Operated for Fracture of the Upper End of the Femur  FRACTALE "|Terminated||Phase 3|215|Actual|Assistance Publique - Hôpitaux de Paris||2||termination of the study due to difficulties to include patients|f||||t||||||||||2018-06-01 03:23:21.101802|2018-06-01 03:23:21.101802
NCT00444249|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2009-04-20|2007-03-05|2007-03-07|Estimate|||||||2009-04-20|2009-04-22|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|BluMel||Influence of Blue Light Filtering Intraocular Lenses on Daytime Levels of Melatonin|Influence of Blue Light Filtering Intra Ocular Lenses on Daytime Levels of Melatonin in Patients With Non-Exudative Age-Related Macular Degeneration|Terminated||N/A|136|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery||4||Because only a few patients follow the inclusion and exclusion criteria.|f||||f||||||||||2018-06-01 03:23:21.249487|2018-06-01 03:23:21.249487
NCT00444236|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2016-01-19|2007-03-06|2007-03-07|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 2007||2007-04-30|January 2016|2016-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression|Effect of Acid Reflux on Respiratory Physiology During Exercise in Athletes With GER-Response to Acid Suppression|Terminated||Phase 1|31|Actual|University of Utah||2||The sponsor decided to terminate the study due to slow enrollment.|f||||t||||||||||2018-06-01 03:23:21.330745|2018-06-01 03:23:21.330745
NCT00444223|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2017-02-15|2007-03-05|2007-03-07|Estimate|||||||2017-02-15|2017-02-17|Actual|May 4, 2004|Actual|2004-05-04|February 2016|2016-02-29|May 15, 2008|Actual|2008-05-15|May 15, 2008|Actual|2008-05-15||Interventional|||Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants|The Biodistribution of N-{4-[3'-[F-18] Fluoroethylphenyl)Amino]-6-quinazolinyl}-Acrylamide ([F-F18]FEQA) in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and in Healthy Subjects: A Pilot Study|Terminated||N/A|30|Anticipated|Jonsson Comprehensive Cancer Center||1||poor recruitment|f||||f||||||||||2018-06-01 03:23:21.447916|2018-06-01 03:23:21.447916
NCT00444210|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2008-04-08|2007-03-05|2007-03-07|Estimate|||||||2008-04-08|2008-04-10|Estimate|June 2004||2004-06-30|April 2008|2008-04-30|April 2006||2006-04-30|||||Interventional|||DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles|A Randomized Study of the Safety and Effectiveness of DL6049 (Injectable Poly-L-Lactic Acid) Versus CosmoPlast Collagen Implant in the Treatment of Nasolabial Fold Wrinkles|Completed||Phase 3|240||Sanofi|||||f||||f||||||||||2018-06-01 03:23:21.5313|2018-06-01 03:23:21.5313
NCT00444184|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2014-05-09|2007-03-05|2007-03-07|Estimate|||||||2014-05-09|2014-05-12|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost|A Crossover, Double-Masked Comparison Investigating the 24-Hour Intraocular Pressure Control With the Travoprost/Timolol Fixed Combination Versus Travoprost, When Both Are Given in the Evening, in Subjects With Primary Open-Angle Glaucoma|Completed||Phase 4|32|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-06-01 03:23:21.637777|2018-06-01 03:23:21.637777
NCT00444171|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-03-05|2007-03-05|2007-03-07|Estimate|||||||2007-03-05|2007-03-07|Estimate|September 2006||2006-09-30|March 2007|2007-03-31|February 2007||2007-02-28|||||Interventional|||Glucose Control by eMPC Algorithm in Peri- and Postoperative Period in Cardiac Surgery Patients|Randomized Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm With Variable Sampling Rate (eMPC) vs. Routine Glucose Management Protocol in Peri- and Postoperative Period in Cardiac Surgery Patients|Completed||N/A|60||Charles University, Czech Republic|||||f||||f||||||||||2018-06-01 03:23:21.703895|2018-06-01 03:23:21.703895
NCT00444158|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2011-07-22|2007-03-05|2007-03-07|Estimate|||||||2011-07-22|2011-07-26|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects|A Randomized, Double-Blind, Double-Dummy, 2-Period Crossover Study to Characterize the PK/PD Relationship of a 20-Minute Versus a 4-hour Intravenous Infusion of MOA-728 in Subjects on Stable Methadone Maintenance|Completed||Phase 1|24|Anticipated|Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:23:21.781854|2018-06-01 03:23:21.781854
NCT00444145|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|2014-12-11||2017-02-21|2007-03-06|2007-03-07|Estimate|2017-02-21|2017-03-29|Actual||||2017-02-21|2017-03-29|Actual|March 2007|Actual|2007-03-31|February 2017|2017-02-28|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional||Patients diagnosed with GERD as evidenced by erosive esophagitis and patients diagnosed with laryngopharyngeal reflux (LPR)|Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment?|Do Laryngeal Biopsy Findings Predict Treatment Response in Suspected Laryngopharyngeal Reflux|Completed||Phase 4|38|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 03:23:21.837561|2018-06-01 03:23:21.837561
NCT00444132|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-09-19|2007-03-06|2007-03-07|Estimate|||||||2007-09-19|2007-09-20|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|||Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS|Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS|Completed||Phase 3|50|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-06-01 03:23:22.151667|2018-06-01 03:23:22.151667
NCT00444119|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-03-05|2007-03-05|2007-03-07|Estimate|||||||2007-03-05|2007-03-07|Estimate|May 2004||2004-05-31|March 2007|2007-03-31|April 2005||2005-04-30|||||Observational|||Survey in Patients With Chronic Adrenal Insufficiency in Germany||Completed|||||University of Wuerzburg|||||f||||||||||||||2018-06-01 03:23:22.214493|2018-06-01 03:23:22.214493
NCT00444106|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2010-12-08||2011-04-01|2007-03-06|2007-03-07|Estimate|2011-02-22|2011-03-16|Estimate||||2011-04-01|2011-04-05|Estimate|May 2007||2007-05-31|April 2011|2011-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function|An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older|Completed||Phase 4|265|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:23:22.292375|2018-06-01 03:23:22.292375
NCT00444093|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2018-04-11|2007-03-06|2007-03-07|Estimate|||||||2018-04-11|2018-04-12|Actual|March 5, 2007|Actual|2007-03-05|April 2018|2018-04-30|February 29, 2008|Actual|2008-02-29|February 29, 2008|Actual|2008-02-29||Interventional|Loop||Prospective Randomized Open Label Study of the Treatment of Therapy-associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium -|Prospective Randomized Open Label Study of the Treatment of Therapy-associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium|Terminated||Phase 3|1|Actual|Philipps University Marburg Medical Center||2||bad recruitment|f||||t||||||||||2018-06-01 03:23:22.655933|2018-06-01 03:23:22.655933
NCT00444080|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2013-02-01|2007-03-05|2007-03-07|Estimate|||||||2013-02-01|2013-02-04|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma|A Multi Center Study Comparing the Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma|Completed||Phase 4|120|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 03:23:22.739305|2018-06-01 03:23:22.739305
NCT00444067|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|2012-07-17||2017-08-07|2007-03-06|2007-03-07|Estimate|2012-07-17|2012-08-21|Estimate||||2017-08-07|2017-09-07|Actual|May 2007||2007-05-31|September 2014|2014-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Evaluate Safety & Effectiveness of Spinal Sealant|A Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair With Standard of Care Methods During Spinal Surgery|Completed||N/A|98|Actual|Integra LifeSciences Corporation||2|||f||||t||||||||||2018-06-01 03:23:22.939314|2018-06-01 03:23:22.939314
NCT00444054|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2012-09-24|2007-03-05|2007-03-07|Estimate|||||||2012-09-24|2012-09-26|Estimate|February 2006||2006-02-28|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2010|Actual|2010-05-31||Interventional|RECHARGE||The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer|Pilot Feasibility Study Of A Low Carbohydrate Diet In Patients With Advanced Cancer|Completed||N/A|10|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-06-01 03:23:23.250946|2018-06-01 03:23:23.250946
NCT00444041|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2013-01-29|2007-03-06|2007-03-07|Estimate|||||||2013-01-29|2013-01-30|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ASSO-LM1||Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer|Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer (mCRC). A Multicenter, Single Arm Phase I/II Academic Trial|Completed||Phase 1/Phase 2|43|Actual|Austrian Society Of Surgical Oncology||1|||f||||t||||||||||2018-06-01 03:23:23.33682|2018-06-01 03:23:23.33682
NCT00444028|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-03-05|2007-03-05|2007-03-07|Estimate|||||||2007-03-05|2007-03-07|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|November 2005||2005-11-30|||||Interventional|||Staccato® Loxapine for Inhalation in Schizophrenia|Safety, Tolerability, and Pharmacokinetics of a Single Dose of Staccato™ Loxapine for Inhalation in Normal, Healthy Volunteers|Completed||Phase 1|50||Alexza Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:23:23.407011|2018-06-01 03:23:23.407011
NCT00444015|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2017-02-20|2007-03-06|2007-03-07|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2007||2007-03-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)|Phase I Trial Evaluating the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Recurrent Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|34|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 03:23:23.479308|2018-06-01 03:23:23.479308
NCT00444002|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2014-01-09|2007-03-06|2007-03-07|Estimate|||||||2014-01-09|2014-01-10|Estimate|July 2005||2005-07-31|January 2014|2014-01-31|July 2010|Actual|2010-07-31|July 2008|Actual|2008-07-31||Observational|||Oxidative Stress and Fatty Acids in Hepatitis C|Hepatitis C Infection With Liver Steatosis Compared to Hepatitis C Infection Without Liver Steatosis: Is There a Difference in Lipid Peroxidation and Indicators of Inflammation?|Completed|||105|Actual|University Health Network, Toronto|||2||f||||f||||||||||2018-06-01 03:23:23.564067|2018-06-01 03:23:23.564067
NCT00443989|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2008-05-27|2007-03-06|2007-03-07|Estimate|||||||2008-05-27|2008-05-30|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Observational|VISION-pilot||Troponin-T for Detection of Perioperative Cardiovascular Events|"A Pilot for the:Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study"|Completed|||100|Actual|Rigshospitalet, Denmark|||||f||||f||||||Samples Without DNA|"~     Troponin-T~   "|||2018-06-01 03:23:23.64415|2018-06-01 03:23:23.64415
NCT00443976|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2016-11-25|2007-03-05|2007-03-07|Estimate|||||||2016-11-25|2016-11-28|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma|A Phase I Study of AT9283 Given As a 24 Hour Infusion on Days 1 and 8 Every Three Weeks in Patients With Advanced Incurable Malignancy|Completed||Phase 1|35|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-06-01 03:23:23.712492|2018-06-01 03:23:23.712492
NCT00443963|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-12-17|2007-03-06|2007-03-07|Estimate|||||||2007-12-17|2007-12-21|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-Steroidal Anti-Inflammatory Drugs|Effects of Esomeprazole Magnesium on Gastric Free Radical Production and Total Antioxidant Capacity in Dyspeptic Patients Receiving Non-Steroidal Anti-Inflammatory Drugs|Terminated||Phase 4|20|Anticipated|Medstar Health Research Institute||||The Principal Investigator is no longer affiliated with the Study Site.|||||f||||||||||2018-06-01 03:23:23.804834|2018-06-01 03:23:23.804834
NCT00443950|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-12-11|2007-03-05|2007-03-07|Estimate|||||||2007-12-11|2007-12-13|Estimate|June 2006||2006-06-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Etanercept in Chinese Subjects With Active Rheumatoid Arthritis Receiving Methotrexate|Completed||Phase 3|150|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:23:23.89284|2018-06-01 03:23:23.89284
NCT00443937|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-06|||2007-10-31|2007-03-06|2007-03-07|Estimate|||||||2007-10-31|2007-11-02|Estimate|January 2004||2004-01-31|October 2007|2007-10-31|March 2006|Actual|2006-03-31|||||Interventional|||Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients|Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Stable Renal Transplant Patients|Completed||Phase 4|15|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 03:23:24.009762|2018-06-01 03:23:24.009762
NCT00443924|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2015-01-19|2007-03-06|2007-03-07|Estimate|||||||2015-01-19|2015-01-21|Estimate|March 2007||2007-03-31|January 2015|2015-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Ascending Dose Study of INS115644 Ophthalmic Solution in Subjects With Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma|Completed||Phase 1|56|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-06-01 03:23:24.139053|2018-06-01 03:23:24.139053
NCT00443911|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2011-06-23|2007-03-05|2007-03-07|Estimate|||||||2011-06-23|2011-06-27|Estimate|March 2007||2007-03-31|June 2011|2011-06-30|May 2012|Anticipated|2012-05-31|||||Observational|ReLux-AMD||Rheohemapheresis and Lutein Supplementation in the Non-Exsudative Form of Age-Related Macular Degeneration|Rheohemapheresis and Lutein Supplementation (Xantophyll Carotenoid) in the Non-Exsudative Form of Age-Related Macular Degeneration|Unknown status|Active, not recruiting||20|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 03:23:24.242529|2018-06-01 03:23:24.242529
NCT00443898|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|2011-01-19||2012-05-01|2007-03-06|2007-03-07|Estimate|2011-03-23|2011-04-20|Estimate||||2012-05-01|2012-05-03|Estimate|December 2006||2006-12-31|May 2012|2012-05-31||||June 2008|Actual|2008-06-30||Interventional|||Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail|A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis|Completed||Phase 3|518|Actual|Novartis||4|||f||||f||||||||||2018-06-01 03:23:24.315337|2018-06-01 03:23:24.315337
NCT00443885|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2017-06-09|2007-03-06|2007-03-07|Estimate|||||||2017-06-09|2017-06-12|Actual|February 2007||2007-02-28|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC|Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC to Problematic Gram-negative Organisms|Recruiting|||1000|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:23:24.787955|2018-06-01 03:23:24.787955
NCT00443872|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-03|2012-05-23||2014-10-30|2007-03-03|2007-03-06|Estimate|2014-10-30|2014-10-31|Estimate||||2014-10-30|2014-10-31|Estimate|March 2007||2007-03-31|October 2014|2014-10-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|AtoZ||Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists|Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications|Completed||Phase 4|77|Actual|Parkinson's Disease and Movement Disorder Center of Boca Raton||1|||f||||f||||||||||2018-06-01 03:23:24.858335|2018-06-01 03:23:24.858335
NCT00443859|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2016-07-07|2007-03-02|2007-03-06|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2007||2007-02-28|May 2009|2009-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension|Clinical Significance of N-Terminal Pro-Brain Natriuretic Peptide Levels in Persistent Pulmonary Hypertension|Terminated|||10|Actual|Christiana Care Health Services|||1|Interim analysis showed greater variablility in NT-proBNP findings than anticipated.|f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 03:23:25.282013|2018-06-01 03:23:25.282013
NCT00443846|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2017-03-14|2007-03-05|2007-03-06|Estimate|||||||2017-03-14|2017-03-16|Actual|February 2007||2007-02-28|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||RotaTeq® and Meningococcus C Vaccine in Healthy Infants|An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants|Completed||Phase 3|246|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:23:25.339094|2018-06-01 03:23:25.339094
NCT00443833|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2007-03-05|2007-03-05|2007-03-06|Estimate|||||||2007-03-05|2007-03-06|Estimate|January 2004||2004-01-31|March 2007|2007-03-31|December 2005||2005-12-31|||||Observational|||Genetic Analysis of Thyrotoxic Periodic Paralysis|Genetic Analysis of Thai Patients With Thyrotoxic Periodic Paralysis|Completed|||80||Ramathibodi Hospital|||||f||||f||||||||||2018-06-01 03:23:25.416331|2018-06-01 03:23:25.416331
NCT00443820|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2011-01-19||2011-03-22|2007-03-05|2007-03-06|Estimate|2011-03-22|2011-04-19|Estimate||||2011-03-22|2011-04-19|Estimate|December 2006||2006-12-31|March 2011|2011-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail|A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis|Completed||Phase 3|526|Actual|Novartis||4|||f||||f||||||||||2018-06-01 03:23:25.564796|2018-06-01 03:23:25.564796
NCT00443807|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2008-04-15|2007-03-05|2007-03-06|Estimate|||||||2008-04-15|2008-04-16|Estimate|August 2007||2007-08-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||EEG Monitoring to Assess Emergence From Neuroanesthesia|A Comparison of the EEGo and BIS Monitors to Assess Emergence From Neuroanesthesia|Completed||N/A|21|Actual|University of Manitoba|||||f||||f||||||||||2018-06-01 03:23:26.293904|2018-06-01 03:23:26.293904
NCT00443794|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2010-09-22|2007-03-05|2007-03-06|Estimate|||||||2010-09-22|2010-09-23|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||The Indian POLYCAP Study (TIPS)|A Randomized Double Blind Controlled Trial of the Efficacy and Safety of POLYCAP (Quintapill)Versus Its Components in Subjects With at Least One Additional Cardiovascular Risk Factor|Completed||N/A|2050|Actual|St. John's Research Institute||9|||f||||t||||||||||2018-06-01 03:23:26.374254|2018-06-01 03:23:26.374254
NCT00443781|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2010-06-23|2010-03-10|2017-12-06|2007-03-02|2007-03-06|Estimate|2010-07-20|2010-08-23|Estimate|2010-07-20|2010-08-23|Estimate|2017-12-06|2017-12-08|Actual|March 2007||2007-03-31|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|SODA||Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain|Study Of Disc Anaesthesia For The Preoperative Diagnosis Of Chronic Lower Back Pain|Completed||Phase 4|62|Actual|Medtronic Spinal and Biologics|There were 12 subjects which did not undergo both PD (Provocative Discography) and F.A.D. (Functional Anesthetic Discography) and therefore could not be included in the primary endpoint analysis (analyzable population for primary endpoint = 50/62).|1|||f||||f||||||||||2018-06-01 03:23:26.576073|2018-06-01 03:23:26.576073
NCT00443768|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2013-02-01|2007-03-02|2007-03-06|Estimate|||||||2013-02-01|2013-02-04|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|PDCom||Medication Review in Patients on Anti-parkinson Therapy|Medication Review in Patients on Anti-parkinson Therapy|Completed|||120|Anticipated|South Glasgow University Hospitals NHS Trust|||2||f||||f||||||||||2018-06-01 03:23:26.744923|2018-06-01 03:23:26.744923
NCT00443755|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2013-04-22||2013-10-07|2007-03-05|2007-03-06|Estimate|2013-04-22|2013-06-06|Estimate||||2013-10-07|2013-10-31|Estimate|August 2005||2005-08-31|October 2013|2013-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||The baseline characteristics are reported for the subjects who completed the study.|Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance|Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance|Completed||Phase 2|28|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:23:26.83395|2018-06-01 03:23:26.83395
NCT00443742|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-03|||2009-02-17|2007-03-05|2007-03-06|Estimate|||||||2009-02-17|2009-02-18|Estimate||||February 2009|2009-02-28||||||||Observational|||Diagnosis of Depression Among Adolescents|Diagnosis of Depression Among Adolescents - a Clinical Validation Study of Key Questions and Questionnaire|Completed|||323|Anticipated|University of Oslo|||||f||||f||||||||||2018-06-01 03:23:27.513268|2018-06-01 03:23:27.513268
NCT00443729|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2009-10-12||2017-02-14|2007-03-05|2007-03-06|Estimate|2009-10-12|2009-11-19|Estimate||||2017-02-14|2017-03-21|Actual|May 2007||2007-05-31|February 2017|2017-02-28|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional|||MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study B|Terminated||Phase 3|355|Actual|Merck Sharp & Dohme Corp.|Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™.|2||"Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus~   lopinavir (+) ritonavir"|f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:23:27.633744|2018-06-01 03:23:27.633744
NCT00443716|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2010-01-14|2007-03-05|2007-03-06|Estimate|||||||2010-01-14|2010-01-15|Estimate|April 1985||1985-04-30|January 2010|2010-01-31|April 1989|Actual|1989-04-30|April 1989|Actual|1989-04-30||Interventional|||Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women|Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women|Completed||N/A|60||Mayo Clinic|||||f||||t||||||||||2018-06-01 03:23:28.269495|2018-06-01 03:23:28.269495
NCT00443703|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2009-10-16||2017-02-14|2007-03-05|2007-03-06|Estimate|2009-10-16|2009-12-01|Estimate||||2017-02-14|2017-03-21|Actual|May 2007||2007-05-31|February 2017|2017-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A|Terminated||Phase 3|352|Actual|Merck Sharp & Dohme Corp.|The reason for early termination: Study was terminated after the primary efficacy analysis at Week 24 did not demonstrate non-inferiority of MK0518 versus KALETRA™.|2||"primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus~   lopinavir (+) ritonavir"|f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:23:28.356733|2018-06-01 03:23:28.356733
NCT00443690|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2009-02-19|2007-03-02|2007-03-06|Estimate|||||||2009-02-19|2009-02-20|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|REACH UP||Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms, Diuresis, Renal Function, and Clinical Outcomes in Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring Intravenous Therapy|Completed||Phase 3|480|Anticipated|NovaCardia, Inc.||2|||f||||t||||||||||2018-06-01 03:23:30.135575|2018-06-01 03:23:30.135575
NCT00443677|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2009-03-19|2007-03-05|2007-03-06|Estimate|||||||2009-03-19|2009-03-20|Estimate|April 2000||2000-04-30|March 2009|2009-03-31|June 2007|Actual|2007-06-30|||||Interventional|HD2000||Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)|Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)|Completed||Phase 3|307|Actual|Gruppo Italiano Studio Linfomi||3|||f||||f||||||||||2018-06-01 03:23:30.223836|2018-06-01 03:23:30.223836
NCT00443664|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2008-05-13|2007-03-05|2007-03-06|Estimate|||||||2008-05-13|2008-05-15|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|||||Interventional|EMDLT||External Micropulse Diode Laser Transscleral Trabeculoplasty (EMDLT) for Severe Open Angle Glaucoma|External Micropulse Diode Laser Transscleral Trabeculoplasty(EMDLT) For Severe Open Angle Glaucoma|Unknown status|Recruiting|Early Phase 1|30|Anticipated|National University Hospital, Singapore|||||f||||f||||||||||2018-06-01 03:23:30.34455|2018-06-01 03:23:30.34455
NCT00443651|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2012-04-18||2017-03-21|2007-03-02|2007-03-06|Estimate|2012-07-31|2012-08-31|Estimate||||2017-03-21|2017-04-17|Actual|January 2007||2007-01-31|March 2017|2017-03-31|February 2013|Actual|2013-02-28|May 2011|Actual|2011-05-31||Interventional|SUNDIAL||A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis|An Open-Label, Prospective Study of the Safety of Rituximab in Combination With Other Disease-Modifying Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis|Completed||Phase 3|578|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:23:30.540146|2018-06-01 03:23:30.540146
NCT00443638|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2013-01-29|2007-03-05|2007-03-06|Estimate|||||||2013-01-29|2013-01-31|Estimate|May 1998||1998-05-31|January 2013|2013-01-31|April 2000|Actual|2000-04-30|||||Interventional|ElmiraY19||Longitudinal Follow Up of Subjects Enrolled in Randomized Trial of Prenatal and Infancy Home Visitation|Longitudinal Follow Up of Subjects Enrolled in Randomized Trials of Prenatal and Infancy Home Visitation|Completed||N/A|320|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-06-01 03:23:31.142069|2018-06-01 03:23:31.142069
NCT00443625|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2013-04-16|2007-03-05|2007-03-06|Estimate|||||||2013-04-16|2013-04-18|Estimate|December 2006||2006-12-31|April 2013|2013-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Phase 1 Study of SK3530 to Investigate of the Effect of Food|Clinical Trials to Investigate the Influence of Food on Pharmacokinetics of SK3530 in Healthy Male Volunteers.|Completed||Phase 1|15||SK Chemicals Co.,Ltd.|||||f||||||||||||||2018-06-01 03:23:31.226989|2018-06-01 03:23:31.226989
NCT00443612|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2009-09-30|2007-03-05|2007-03-06|Estimate|||||||2009-09-30|2009-10-01|Estimate|September 2006||2006-09-30|September 2009|2009-09-30||||October 2008|Actual|2008-10-31||Interventional|||Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing|A Randomized, Open Label, Cross-over Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension|Completed||Phase 4|60|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:23:31.283836|2018-06-01 03:23:31.283836
NCT00443599|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|2014-01-28||2018-03-09|2007-03-05|2007-03-06|Estimate|2014-01-28|2014-03-10|Estimate||||2018-03-09|2018-04-04|Actual|November 2006||2006-11-30|March 2018|2018-03-31|January 2014|Actual|2014-01-31|June 2012|Actual|2012-06-30||Interventional|SPECS||SPECS: Safe Pediatric Euglycemia in Cardiac Surgery|Maintaining Normal Blood Sugar Levels in Children Undergoing Heart Surgery to Reduce the Risk of Infections and Improve Recovery (The SPECS Study)|Completed||N/A|989|Actual|Boston Children’s Hospital||2|||f||||t||||||||Yes|Will share with investigators based upon specific requests|2018-06-01 03:23:31.37086|2018-06-01 03:23:31.37086
NCT00443586|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2018-05-08|2007-03-05|2007-03-06|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2004|Actual|2004-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Follow-up Evaluation of Home Nurse Visitation Program for Socially Disadvantaged Women and Their Children|Age-27 Follow-up of Early Preventive Intervention|Active, not recruiting||N/A|345|Anticipated|University of Colorado, Denver||4|||f||||t|f|f||||||Yes|We plan to share individual participant data once the primary reports on this phase of the trial are published. This includes baseline data on maternal characteristics at registration during pregnancy and outcome data on primary outcomes for offspring participants at the 27-year follow-up. Data will be made available through the University of Michigan Inter-University Consortium for Political and Social Research (ICPSR). We anticipate archiving the data from this study with ICPSR by March 2018|2018-06-01 03:23:31.848371|2018-06-01 03:23:31.848371
NCT00443573|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2008-05-05|2007-03-02|2007-03-06|Estimate|||||||2008-05-05|2008-05-07|Estimate|December 2006||2006-12-31|May 2008|2008-05-31||||August 2007|Anticipated|2007-08-31||Interventional|||Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer|Multicenter, Two-Stage Study to Evaluate the Safety and Efficacy of Second-Line Metastatic Colorectal Carcinoma Treatment With Recombinant NAPc2|Suspended||Phase 1/Phase 2|100|Anticipated|ARCA Biopharma, Inc.||||Company suspended development of product.|f||||t||||||||||2018-06-01 03:23:31.933722|2018-06-01 03:23:31.933722
NCT00443560|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2011-05-09||2014-03-17|2007-03-05|2007-03-06|Estimate|2011-06-22|2011-07-21|Estimate||||2014-03-17|2014-04-14|Estimate|January 2006||2006-01-31|March 2014|2014-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||The Association Between Decreasing Labor Analgesia Epidural Infusion and Forceps Delivery|A Retrospective Case-controlled Study of the Association Between Request to Discontinue Second Stage Labor Epidural Analgesia and Risk of Instrumental Vaginal Delivery|Completed|||2162|Actual|Northwestern University|The retrospective design incurs the risk of unrecorded or unobserved data. The sample selected included all patients with neuraxial analgesia who underwent IVD, but a limited sample of SVD.||2||f||||f||||||||||2018-06-01 03:23:32.01522|2018-06-01 03:23:32.01522
NCT00443547|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2011-07-01|2007-03-05|2007-03-06|Estimate|||||||2011-07-01|2011-07-06|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Outcome Study of Patients Treated With Translational Cervical Plate Used to Treat Degenerative Disc Disease|Prospective Multi-Center Clinical Study of Patients With Degenerative Disc Disease Treated With Anterior Cervical Decompression and Fusion Using the Vectra-T Translational Cervical Plate.|Completed||N/A|231|Actual|Synthes USA HQ, Inc.||4|||f||||f||||||||||2018-06-01 03:23:32.303351|2018-06-01 03:23:32.303351
NCT00382746|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2016-07-17|2006-09-28|2006-09-29|Estimate|||||||2016-07-17|2016-07-19|Estimate|October 2006||2006-10-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Observational|||EarlySense Monitoring Device Evaluation on CHF Patients|EarlySense Monitoring Device Evaluation on CHF Patients|Withdrawn|||0|Actual|EarlySense Ltd.||||No need|f||||||||||||||2018-06-01 03:44:08.360815|2018-06-01 03:44:08.360815
NCT00443534|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2012-12-15||2013-04-02|2007-03-05|2007-03-06|Estimate|2013-04-02|2013-05-24|Estimate||||2013-04-02|2013-05-24|Estimate|May 2006||2006-05-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.|A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.|Completed||N/A|123|Actual|Pfizer|The reason for not completed ‘Study Terminated by Sponsor’ in participant flow table indicates the termination of study at few sites as captured in case report forms at those sites and does not reflect overall status of study.|1|||f||||f||||||||||2018-06-01 03:23:32.44666|2018-06-01 03:23:32.44666
NCT00443521|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2007-03-02|2007-03-02|2007-03-06|Estimate|||||||2007-03-02|2007-03-06|Estimate|March 2005||2005-03-31|March 2007|2007-03-31|July 2006||2006-07-31|||||Interventional|||Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Completed||Phase 2/Phase 3|30||University of Sao Paulo|||||f||||t||||||||||2018-06-01 03:23:32.890716|2018-06-01 03:23:32.890716
NCT00443508|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-04|||2007-03-05|2007-03-05|2007-03-06|Estimate|||||||2007-03-05|2007-03-06|Estimate|February 2007||2007-02-28|September 2005|2005-09-30|February 2010||2010-02-28|||||Interventional|||Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion|Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study|Unknown status|Recruiting|Phase 4|60||Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:23:32.965836|2018-06-01 03:23:32.965836
NCT00443495|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2007-03-02|2007-03-02|2007-03-06|Estimate|||||||2007-03-02|2007-03-06|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|March 2007||2007-03-31|||||Interventional|||Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis|First Into Man Administration of Chitin Microparticles: a Randomised,Double Blind,Placebo Controlled Parallel Group Upward Titration Evaluation of 3 Dose Levels Given Intr-Nasally Over 24 Hours,Followed by a Placebo Controlled,Randomised Parallel Group Evaluation of Safety and Biological Activity Over 7 Days in Subjects Suffering From Allergic Rhinitis|Completed||Phase 1/Phase 2|24||CMP Therapeutics Ltd|||||f||||f||||||||||2018-06-01 03:23:33.062302|2018-06-01 03:23:33.062302
NCT00443482|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2017-03-24|2007-03-05|2007-03-06|Estimate|||||||2017-03-24|2017-03-28|Actual|February 2007||2007-02-28|March 2017|2017-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)|A Randomized, Multi-centre, Double-blind, Double Dummy Placebo Controlled Single-dose Cross-over Study to Demonstrate That 12 and 24 µg of Formoterol Delivered by Concept1 Has a Bronchodilator Efficacy Which is Equivalent to the Same Dose of Formoterol Delivered by Aerolizer in Adult Patients With Persistent Asthma|Completed||Phase 2|50|Actual|Novartis|||||f||||||||||||||2018-06-01 03:23:33.11391|2018-06-01 03:23:33.11391
NCT00443469|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-04|||2010-03-30|2007-03-04|2007-03-06|Estimate|||||||2010-03-30|2010-03-31|Estimate|August 2006||2006-08-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Spinal Magnetic Stimulation in Neuropathic Pain|A Randomized Placebo-controlled Trial on the Use of Repetitive Spinal Magnetic Stimulation as a Therapeutic Option in Patients With Intractable Neuropathic Pain of the Lower Limbs|Completed||Phase 3|20|Actual|Singapore General Hospital||2|||f||||t||||||||||2018-06-01 03:23:33.183019|2018-06-01 03:23:33.183019
NCT00443456|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2009-06-10||2009-10-19|2007-03-02|2007-03-06|Estimate|2009-09-08|2009-10-09|Estimate||||2009-10-19|2009-10-28|Estimate|May 2007||2007-05-31|October 2009|2009-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient|Long-Term Study For Amlodipine 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective|Completed||Phase 3|134|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:23:33.306126|2018-06-01 03:23:33.306126
NCT00443443|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2015-03-26|2007-03-02|2007-03-06|Estimate|||||||2015-03-26|2015-03-30|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|SUNSTONE||A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)|A Long-Term Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)|Completed|||1026|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 03:23:34.296758|2018-06-01 03:23:34.296758
NCT00443430|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2013-03-13||2013-05-30|2007-03-02|2007-03-06|Estimate|2013-05-30|2013-05-31|Estimate||||2013-05-30|2013-05-31|Estimate|May 2007||2007-05-31|May 2013|2013-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||2 patients were ineligible|Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis|Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis (TREAT in JIA)|Completed||Phase 4|85|Actual|Seattle Children's Hospital|small number of participants with recent onset poly JIA|2|||f||||t||||||||||2018-06-01 03:23:34.612614|2018-06-01 03:23:34.612614
NCT00443417|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2009-12-08|2007-03-05|2007-03-06|Estimate|||||||2009-12-08|2009-12-09|Estimate|April 2007||2007-04-30|January 2008|2008-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease|Dose Finding Study to Assess the Efficacy and Safety of SK-PC-B70M in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|188|Anticipated|SK Chemicals Co.,Ltd.||4|||f||||||||||||||2018-06-01 03:23:34.884029|2018-06-01 03:23:34.884029
NCT00443404|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2011-11-04|2007-03-05|2007-03-06|Estimate|||||||2011-11-04|2011-11-07|Estimate|December 2003||2003-12-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Optimized Perioperative Analgesia Reduces the Prevalence and the Intensity of Phantom Pain in Lower Limb Amputation|Double Blind, Placebo Controlled Study for the Study of the Effectiveness of Perioperative Analgesia in Phantom and Stump Pain|Completed||Phase 2/Phase 3|60|Actual|University of Patras||5|||f||||t||||||||||2018-06-01 03:23:35.038434|2018-06-01 03:23:35.038434
NCT00443391|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02||2011-08-18|2013-01-10|2007-03-02|2007-03-06|Estimate||||2011-08-18|2011-08-23|Estimate|2013-01-10|2013-01-18|Estimate|February 2007||2007-02-28|January 2013|2013-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)|The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study|Completed||Phase 2|141|Actual|AbbVie||1|||f||||||||||||||2018-06-01 03:23:35.153834|2018-06-01 03:23:35.153834
NCT00443378|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|||2008-01-22|2007-03-05|2007-03-06|Estimate|||||||2008-01-22|2008-01-29|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|CARE+||Computer Assisted Rx Education for HIV-Positives: CARE+|Computer Assisted Rx Education for HIV-Positives: CARE+|Completed||N/A|240|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:23:35.274674|2018-06-01 03:23:35.274674
NCT00443352|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-05|2014-02-19||2014-04-25|2007-03-05|2007-03-06|Estimate|2014-04-25|2014-05-26|Estimate||||2014-04-25|2014-05-26|Estimate|August 2007||2007-08-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache|A Single-Center, Open Label Pilot Study Examining The Use Of Duloxetine In The Prevention Of Episodic Migraine|Completed||Phase 4|27|Actual|Thomas Jefferson University|This trial was uncontrolled. Five of the 27 subjects did not complete.|1|||f||||t||||||||||2018-06-01 03:23:35.43922|2018-06-01 03:23:35.43922
NCT00443339|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-04|||2007-05-15|2007-03-04|2007-03-06|Estimate|||||||2007-05-15|2007-05-17|Estimate|December 2006||2006-12-31|March 2007|2007-03-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)|A Phase II Study of Darbepoetin Alpha in Myelodysplastic Syndromes (MSD)|Unknown status|Recruiting|Phase 2|99|Anticipated|Groupe Francophone des Myelodysplasies|||||f||||t||||||||||2018-06-01 03:23:35.634089|2018-06-01 03:23:35.634089
NCT00020475|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2013-08-14|2007-03-02|2007-03-06|Estimate|||||||2013-08-14|2013-08-16|Estimate|February 2001||2001-02-28|July 2002|2002-07-31|March 2007|Actual|2007-03-31|||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye|Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:35.838255|2018-06-01 03:23:35.838255
NCT00020371|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2015-04-27|2007-03-02|2007-03-06|Estimate|||||||2015-04-27|2015-04-28|Estimate|September 2000||2000-09-30|May 2005|2005-05-31||||||||Interventional|||BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy|Phase I Study of BMS-247550 in Patients With Refractory Neoplasms|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:35.896637|2018-06-01 03:23:35.896637
NCT00020345|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2012-03-07|2007-03-02|2007-03-06|Estimate|||||||2012-03-07|2012-03-08|Estimate|September 2000||2000-09-30|March 2012|2012-03-31|March 2002|Actual|2002-03-31|||||Interventional|||Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas|Phase II Study of Neoadjuvant Intraperitoneal Gemcitabine and Intravenous Gemcitabine With Radiotherapy Followed by Surgery and Adjuvant Intraperitoneal Gemcitabine, Intravenous Gemcitabine, and Fluorouracil in Patients With Advanced Adenocarcinoma of the Pancreas|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:23:35.945309|2018-06-01 03:23:35.945309
NCT00020267|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2015-04-27|2007-03-02|2007-03-06|Estimate|||||||2015-04-27|2015-04-28|Estimate|July 2000||2000-07-31|May 2002|2002-05-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Cancer|Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:36.164374|2018-06-01 03:23:36.164374
NCT00019643|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2012-03-28|2007-03-02|2007-03-06|Estimate|||||||2012-03-28|2012-03-29|Estimate|August 1999||1999-08-31|March 2012|2012-03-31|April 2007|Actual|2007-04-30|||||Observational|||Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer|Prospective Study of Potential Factors Affecting Weight in Breast Cancer Patients Receiving Adjuvant Chemotherapy|Terminated|||26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:23:36.238451|2018-06-01 03:23:36.238451
NCT00443326|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01||2015-12-16|2015-12-16|2007-03-01|2007-03-05|Estimate||||2015-12-16|2016-01-20|Estimate|2015-12-16|2016-01-20|Estimate|March 2007||2007-03-31|December 2015|2015-12-31|May 2010|Actual|2010-05-31|December 2008|Actual|2008-12-31||Interventional|||AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects|A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of AMG 714 After Multiple Dose Administration in Subjects With Moderate to Severe Psoriasis|Completed||Phase 2|22|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:23:36.313748|2018-06-01 03:23:36.313748
NCT00443313|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2018-04-04|2007-03-02|2007-03-05|Estimate|||||||2018-04-04|2018-04-05|Actual|January 24, 2007||2007-01-24|June 25, 2015|2015-06-25|June 25, 2015||2015-06-25|||||Observational|||Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta|HPV Testing to Improve Cervical Cancer Screening in the Mississippi Delta (Mississippi Delta Project)|Completed|||664|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:23:36.380171|2018-06-01 03:23:36.380171
NCT00443300|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-08-01|2007-03-01|2007-03-05|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Effectiveness of Protected Environment Rooms for AML and MDS|"Effectiveness of HEPA-filtered Rooms (Protected Environment) to Prevent Morbidity and Mortality in Patients Age >/ = 60 Receiving Lower Intensity (Targeted) Therapy for Untreated AML and High-risk Myelodysplasia (MDS)"|Terminated|||3|Actual|M.D. Anderson Cancer Center|||2|Terminated due to low accrual.|f||||t||||||||||2018-06-01 03:23:36.439027|2018-06-01 03:23:36.439027
NCT00443287|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02||2018-05-03|2018-05-15|2007-03-02|2007-03-05|Estimate||||2018-05-03|2018-05-08|Actual|2018-05-15|2018-05-17|Actual|February 2007||2007-02-28|May 2018|2018-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ACCELA||Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease|A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of HMR1766 Assessing the Efficacy and Safety of 3 Doses of HMR1766 Versus Placebo With Cilostazol as a Calibrator, Administered for 26 Weeks in Patients With Peripheral Arterial Disease (PAD) Fontaine Stage II|Completed||Phase 2|553|Actual|Sanofi||5|||f||||||||||||||2018-06-01 03:23:36.500221|2018-06-01 03:23:36.500221
NCT00443274|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2018-04-05|2007-03-02|2007-03-05|Estimate|||||||2018-04-05|2018-04-06|Actual|November 1, 2006|Actual|2006-11-01|April 2018|2018-04-30|October 31, 2028|Anticipated|2028-10-31|October 31, 2028|Anticipated|2028-10-31||Observational|BIFS||Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms|Breast Implant Follow-up Study: A 10- Year Observational Study of the Safety of Allergan Silicone Gel-filled Breast Implants as Compared Both to Saline-Filled Breast Implants and to National Norms|Recruiting|||57000|Anticipated|Allergan|||3||f|||||f|t|f|||||||2018-06-01 03:23:37.145976|2018-06-01 03:23:37.145976
NCT00443261|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2016-01-08||2017-01-08|2007-03-02|2007-03-05|Estimate|2017-01-08|2017-02-27|Actual||||2017-01-08|2017-02-27|Actual|February 2007||2007-02-28|January 2017|2017-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase I Study of Azacitidine in Combination With Cisplatin Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1|1|Actual|University of Kansas Medical Center||1||Accrual problems|f||||t||||||||No||2018-06-01 03:23:40.03046|2018-06-01 03:23:40.03046
NCT00443066|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2017-02-06|2007-03-01|2007-03-05|Estimate|||||||2017-02-06|2017-02-07|Estimate|May 2005||2005-05-31|February 2017|2017-02-28|December 2022|Anticipated|2022-12-31|October 2020|Anticipated|2020-10-31||Observational|||Clinical Study of Spinal Muscular Atrophy|Clinical Study of Spinal Muscular Atrophy|Active, not recruiting|||120|Actual|Columbia University|||||f||||f||||||Samples With DNA|"~     blood and skin tissue~   "|No||2018-06-01 03:23:43.532222|2018-06-01 03:23:43.532222
NCT00443248|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2009-02-06|2007-03-02|2007-03-05|Estimate|||||||2009-02-06|2009-02-10|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|FSAD HWO VBF||Vaginal Heat Wash-Out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)).|A 2-Way Repeatability Study To Investigate Vaginal Blood Flow Before, During And After Visual Sexual Stimulation In Pre- And Post-Menopausal Women With And Without Female Sexual Arousal Disorder, Using The Heat Wash-Out Technique.|Completed||Phase 1|64|Anticipated|Pfizer||1|||f||||f||||||||||2018-06-01 03:23:41.190831|2018-06-01 03:23:41.190831
NCT00443235|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2011-09-16|2007-03-02|2007-03-05|Estimate|||||||2011-09-16|2011-09-19|Estimate|March 2005||2005-03-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|March 2007|Actual|2007-03-31||Interventional|||GEM05 for Patients With Multiple Myeloma More Than 65 Years Old|A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old.|Completed||Phase 3|260|Anticipated|PETHEMA Foundation||2|||f||||t||||||||||2018-06-01 03:23:41.290022|2018-06-01 03:23:41.290022
NCT00443222|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2007-03-02|2007-03-02|2007-03-05|Estimate|||||||2007-03-02|2007-03-05|Estimate||||March 2007|2007-03-31||||||||Interventional|||Treatment With TNF Blockade, Infliximab, in Patients With Myositis|An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies|Completed||Phase 2/Phase 3|||Karolinska Institutet|||||f||||f||||||||||2018-06-01 03:23:41.48429|2018-06-01 03:23:41.48429
NCT00443209|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2014-07-29||2017-04-06|2007-03-02|2007-03-05|Estimate|2014-07-29|2014-08-18|Estimate||||2017-04-06|2017-05-12|Actual|February 21, 2007|Actual|2007-02-21|April 2017|2017-04-30|January 22, 2009|Actual|2009-01-22|January 22, 2009|Actual|2009-01-22||Interventional||Baseline Analyis Population consisted of All Treated Participants.|Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)|A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura|Completed||Phase 3|1068|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 03:23:41.644094|2018-06-01 03:23:41.644094
NCT00443196|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2018-03-09|2007-03-01|2007-03-05|Estimate|||||||2018-03-09|2018-03-12|Actual|March 2006||2006-03-31|March 2011|2011-03-31|September 2010|Actual|2010-09-30|||||Interventional|||Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas|Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas|Completed||Phase 2/Phase 3|150|Anticipated|Pierian Biosciences||1|||f||||||||||||||2018-06-01 03:23:42.075577|2018-06-01 03:23:42.075577
NCT00443183|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2016-08-04|2007-03-02|2007-03-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|May 2002||2002-05-31|August 2016|2016-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Emergency Physician Brief Interventions for Alcohol|Emergency Physician Brief Interventions for Alcohol|Completed||N/A|500|Actual|Yale University||2|||f||||||||||||||2018-06-01 03:23:42.151213|2018-06-01 03:23:42.151213
NCT00443170|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-03-15|2007-03-01|2007-03-05|Estimate|||||||2012-03-15|2012-03-19|Estimate|November 2006||2006-11-30|February 2011|2011-02-28||||||||Interventional|||A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects|A Randomized, Blinded, Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Single and Repeat Dose Escalation of the Oral YAK3/DYRK3 Inhibitor GSK626616AC in Healthy Subjects|Completed||Phase 1|90|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:23:42.233759|2018-06-01 03:23:42.233759
NCT00443157|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2008-12-04|2007-03-02|2007-03-05|Estimate|||||||2008-12-04|2008-12-05|Estimate|February 2006||2006-02-28|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|MNB3||Meningococcal B Vaccination in University Students|A Phase II, Open Label, Randomised, Single Centre Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three or Four Doses of Meningococcal Serogroup B Outer Membrane Vesicle (OMV) Vaccine MENZBTM When Administered to Healthy Adults (University Students)|Completed||Phase 2|50||Public Health England|||||f||||||||||||||2018-06-01 03:23:42.304126|2018-06-01 03:23:42.304126
NCT00443144|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2015-12-02|2007-03-02|2007-03-05|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2005||2005-05-31|December 2015|2015-12-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Observational|||D3-GHR Polymorphism and Turner Syndrome|D3-Growth Hormone Receptor Polymorphism and Total Effect of Recombinant Human Growth Hormone on Growth in Girls With Turner Syndrome|Completed|||||University Hospital Tuebingen|||||f||||f||||||||||2018-06-01 03:23:42.358019|2018-06-01 03:23:42.358019
NCT00443131|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2017-04-24|2007-03-02|2007-03-05|Estimate|||||||2017-04-24|2017-04-25|Actual|March 26, 2007||2007-03-26|April 2017|2017-04-30|July 13, 2007|Actual|2007-07-13|July 1, 2007|Actual|2007-07-01||Interventional|||Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines|Adjuvant Justification Study of Candidate Malaria Vaccines (257049), Administered According to a 0, 1, 2 Months Schedule .|Completed||Phase 2|36|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:23:42.424079|2018-06-01 03:23:42.424079
NCT00443118|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2014-02-22||2015-03-30|2007-03-02|2007-03-05|Estimate|2015-03-30|2015-03-31|Estimate||||2015-03-30|2015-03-31|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Newborn Ventilation in the Delivery Room: Could it be Improved With a T-piece Resuscitator?|NEWBORN VENTILATION IN THE DELIVERY ROOM: CAN IT BE IMPROVED WITH A T-PIECE RESUSCITATOR? Multicenter Cross-over Cluster Randomized Controlled Trial|Completed||Phase 3|1032|Actual|Fundacion para la Salud Materno Infantil||3|||f||||t||||||||||2018-06-01 03:23:42.570516|2018-06-01 03:23:42.570516
NCT00443105|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2007-03-02|2007-03-02|2007-03-05|Estimate|||||||2007-03-02|2007-03-05|Estimate||||December 2006|2006-12-31||||||||Interventional|||Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study||Unknown status|Active, not recruiting|Phase 2|||Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-06-01 03:23:43.279225|2018-06-01 03:23:43.279225
NCT00443092|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2012-08-01|2007-03-02|2007-03-05|Estimate|||||||2012-08-01|2012-08-03|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee|A Double Blind Cross-over Study of the Efficacy of a Proprietary Cherry Juice Blend in Osteoarthritis of the Knee.|Completed||Phase 4|59|Actual|CherryPharm||2|||f||||f||||||||||2018-06-01 03:23:43.351789|2018-06-01 03:23:43.351789
NCT00443079|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2010-06-24|2007-03-02|2007-03-05|Estimate|||||||2010-06-24|2010-06-25|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)|A Single-center, Single-blinded, Placebo-controlled Pilot Study of IdB 1016 (Siliphos) in Adult Patients With Non-alcoholic Steatohepatitis (NASH)|Completed||Phase 2|10|Anticipated|University of California, San Diego|||||f||||||||||||||2018-06-01 03:23:43.44759|2018-06-01 03:23:43.44759
NCT00443053|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2010-07-02||2017-01-20|2007-03-02|2007-03-05|Estimate|2010-07-02|2010-08-02|Estimate||||2017-01-20|2017-03-06|Actual|March 2007||2007-03-31|January 2017|2017-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)|An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg Subcutaneously) for the Treatment of Patients With Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to Prevent Thromboembolic Complications|Completed||Phase 3|3002|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:23:43.684749|2018-06-01 03:23:43.684749
NCT00443040|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2011-10-14|2011-08-23|2011-11-30|2007-03-01|2007-03-05|Estimate|2011-11-30|2012-01-06|Estimate|2011-08-23|2011-08-25|Estimate|2011-11-30|2012-01-06|Estimate|January 2007||2007-01-31|November 2011|2011-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Asimadoline for the Treatment of Post-Operative Ileus|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Asimadoline on the Duration of POI in Subjects Undergoing Laparoscopic/Hand-Assisted Lap Segmental Colonic Resection Secondary to Colon Cancer, Polypectomy or Diverticulitis|Terminated||Phase 2|35|Actual|Tioga Pharmaceuticals|Early termination leading to small numbers of subjects analyzed; no efficacy analysis was completed.|3||poor enrollment (31 of a planned 114 subjects were randomized and evaluable)|f||||f||||||||||2018-06-01 03:23:44.631983|2018-06-01 03:23:44.631983
NCT00443027|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2009-02-06|2007-03-02|2007-03-05|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|HWO VBF||Effect Of Menstrual Cycle On Vaginal Blood Flow In Pre-Menopausal Healthy Women.|Effect Of Menstrual Cycle On Vaginal Blood Flow (As Determined By The Heat Wash-Out Technique) Before, During And After Visual Sexual Stimulation In Pre-Menopausal Healthy Women.|Completed||Phase 1|12|Anticipated|Pfizer||1|||f||||f||||||||||2018-06-01 03:23:45.085276|2018-06-01 03:23:45.085276
NCT00443014|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2011-11-09|2007-03-02|2007-03-05|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 2003||2003-06-30|November 2011|2011-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Dementia Study in Northern Norway|Phase 4 Study of Cognitive Therapy and Donepezil in Alzheimers Disease.|Completed||Phase 4|187|Actual|University Hospital of North Norway||2|||f||||t||||||||||2018-06-01 03:23:45.148979|2018-06-01 03:23:45.148979
NCT00443001|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2018-05-17|2007-03-02|2007-03-05|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2001||2001-11-30|May 2018|2018-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Noninvasive Blood Pressure Monitor Evaluation Including Performance During Dysrhythmias|Noninvasive Blood Pressure Monitor Evaluation Including Performance During Dysrhythmias|Completed||N/A|40|Anticipated|GE Healthcare|||||f||||t||||||||||2018-06-01 03:23:45.239895|2018-06-01 03:23:45.239895
NCT00442988|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2007-03-02|2007-03-02|2007-03-05|Estimate|||||||2007-03-02|2007-03-05|Estimate|October 2000||2000-10-31|March 2007|2007-03-31|October 2005||2005-10-31|||||Observational|||Prediction of NODAT After Renal Transplantation|Early Prediction of New Onset Diabetes Mellitus After Transplantation (NODAT) in Renal Transplantation: Use of Oral Glucose Tolerance Test (OGTT) and Fasting Plasma Glucose (FPG).|Completed|||360||Katholieke Universiteit Leuven|||||f||||f||||||||||2018-06-01 03:23:45.364372|2018-06-01 03:23:45.364372
NCT00442975|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2008-07-09|2007-03-02|2007-03-05|Estimate|||||||2008-07-09|2008-07-10|Estimate|March 2007||2007-03-31|February 2008|2008-02-29|September 2007|Actual|2007-09-30|||||Interventional|CMVflu||Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status|A Phase IV, Single Group Study to Evaluate the Immune Response to Licensed Seasonal Influenza Vaccine and Relationship of This to Cytomegalovirus-Associated Immunosenescence in UK Older Adults Aged 50-80 Years|Completed||Phase 4|100|Actual|Public Health England|||||f||||f||||||||||2018-06-01 03:23:45.416297|2018-06-01 03:23:45.416297
NCT00442962|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|2011-07-13||2015-06-01|2007-03-02|2007-03-05|Estimate|2011-07-13|2011-08-09|Estimate||||2015-06-01|2015-06-26|Estimate|May 2007||2007-05-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|Nearly Naive||HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV|"The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-Nearly Naive Participants"|Completed||Phase 4|54|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-06-01 03:23:45.513793|2018-06-01 03:23:45.513793
NCT00442949|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2009-02-11|2007-03-02|2007-03-05|Estimate|||||||2009-02-11|2009-02-12|Estimate|August 2006||2006-08-31|April 2008|2008-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|ABOARD||Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndrome (ACS)|Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention (The ABOARD Study)|Completed||N/A|400|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:23:45.95946|2018-06-01 03:23:45.95946
NCT00442936|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2014-06-17||2017-04-06|2007-03-02|2007-03-05|Estimate|2014-07-31|2014-08-04|Estimate||||2017-04-06|2017-05-12|Actual|February 15, 2007|Actual|2007-02-15|April 2017|2017-04-30|October 2, 2007|Actual|2007-10-02|October 2, 2007|Actual|2007-10-02||Interventional|||Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura|Completed||Phase 3|1380|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 03:23:46.057967|2018-06-01 03:23:46.057967
NCT00442923|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2013-05-24|2007-03-02|2007-03-05|Estimate|||||||2013-05-24|2013-05-29|Estimate||||May 2013|2013-05-31||||||||Interventional|MARC||"The Evaluation of Stimulant Withdrawal"|Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse|Withdrawn||Phase 2|0|Actual|Oregon Health and Science University||||This study was withdrawn for lack of progress. No subjects were recruited.|f||||t||||||||||2018-06-01 03:23:46.686718|2018-06-01 03:23:46.686718
NCT00442910|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2010-06-22|2007-03-02|2007-03-05|Estimate|||||||2010-06-22|2010-06-24|Estimate|July 2007||2007-07-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women|Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel™) Applied Vaginally in Sexually Active Young Women|Completed||Phase 1|61|Actual|Starpharma Pty Ltd||3|||f||||t||||||||||2018-06-01 03:23:46.786776|2018-06-01 03:23:46.786776
NCT00019097|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2013-06-19|2007-03-01|2007-03-05|Estimate|||||||2013-06-19|2013-06-20|Estimate|July 1995||1995-07-31|May 2006|2006-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Vaccine Therapy in Treating Patients With Multiple Myeloma|Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.844809|2018-06-01 03:23:48.844809
NCT00442897|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2009-10-01||2017-03-17|2007-03-01|2007-03-05|Estimate|2009-10-01|2009-11-09|Estimate||||2017-03-17|2017-04-14|Actual|September 2006||2006-09-30|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)|Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery Disease|Completed||Phase 4|229|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:23:46.920457|2018-06-01 03:23:46.920457
NCT00442884|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2007-03-02|2007-03-02|2007-03-05|Estimate|||||||2007-03-02|2007-03-05|Estimate|February 2006||2006-02-28|March 2007|2007-03-31|August 2006||2006-08-31|||||Interventional|||Effect of Acute Psychological Stress on Glucose Concentrations in Patients With Type 2 Diabetes|Effect of Acute Psychological Stress on Glucose Concentrations in Patients With Type 2 Diabetes|Completed||N/A|30||University of Zurich|||||f||||f||||||||||2018-06-01 03:23:47.514626|2018-06-01 03:23:47.514626
NCT00442871|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2017-11-08|2007-03-01|2007-03-05|Estimate|||||||2017-11-08|2017-11-13|Actual|September 28, 2006|Actual|2006-09-28|November 2017|2017-11-30|January 3, 2008|Actual|2008-01-03|January 3, 2008|Actual|2008-01-03||Interventional|||Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment|An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50 mg Eltrombopag in Healthy Subjects and in Subjects With Mild, Moderate, or Severe Renal Impairment|Completed||Phase 1|29|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:23:47.60332|2018-06-01 03:23:47.60332
NCT00442858|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2007-03-01|2007-03-01|2007-03-05|Estimate|||||||2007-03-01|2007-03-05|Estimate|January 1999||1999-01-31|March 2007|2007-03-31|December 2002||2002-12-31|||||Observational|||Incidence of Cardiovascular Diseases in Patients With Hypopituitarims||Completed|||800||Lund University Hospital|||||f||||f||||||||||2018-06-01 03:23:47.726796|2018-06-01 03:23:47.726796
NCT00020202|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2013-08-14|2007-03-02|2007-03-05|Estimate|||||||2013-08-14|2013-08-16|Estimate|June 2000||2000-06-30|June 2006|2006-06-30|March 2007|Actual|2007-03-31|||||Interventional|||FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer|Phase II Study of FR901228 in Patients With Refractory or Progressive Small Cell or Non-Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:47.797834|2018-06-01 03:23:47.797834
NCT00020046|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2012-03-14|2007-03-02|2007-03-05|Estimate|||||||2012-03-14|2012-03-15|Estimate|December 1999||1999-12-31|March 2012|2012-03-31|September 2003|Actual|2003-09-30|||||Interventional|||Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer|Phase II Randomized Study of Docetaxel With or Without Thalidomide in Patients With Androgen-Independent Metastatic Prostate Cancer|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:23:47.902734|2018-06-01 03:23:47.902734
NCT00019968|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2012-03-14|2007-03-02|2007-03-05|Estimate|||||||2012-03-14|2012-03-15|Estimate|August 1999||1999-08-31|March 2012|2012-03-31|March 2002|Actual|2002-03-31|||||Interventional|||Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg|Phase II Randomized Study of Isolated Limb Perfusion Using Melphalan With or Without Tumor Necrosis Factor in Patients With Unresectable High Grade Soft Tissue Sarcomas of the Extremity|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:23:47.988088|2018-06-01 03:23:47.988088
NCT00019890|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2013-06-19|2007-03-02|2007-03-05|Estimate|||||||2013-06-19|2013-06-20|Estimate||||June 2001|2001-06-30|March 2007|Actual|2007-03-31|||||Interventional|||Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma|Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.076994|2018-06-01 03:23:48.076994
NCT00019760|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-02|||2012-03-21|2007-03-02|2007-03-05|Estimate|||||||2012-03-21|2012-03-23|Estimate|April 1999||1999-04-30|March 2012|2012-03-31|March 2002|Actual|2002-03-31|||||Interventional|||Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver|Phase II Study of Isolated Hepatic Perfusion With Melphalan Followed By Postoperative Hepatic Arterial Chemotherapy in Patients With Unresectable Colorectal Cancer Metastatic to the Liver|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:23:48.132506|2018-06-01 03:23:48.132506
NCT00019695|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2014-04-21|2007-03-01|2007-03-05|Estimate|||||||2014-04-21|2014-04-22|Estimate|March 1999||1999-03-31|March 2004|2004-03-31|March 2005|Actual|2005-03-31|||||Interventional|||Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer|Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate|Terminated||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.195982|2018-06-01 03:23:48.195982
NCT00019630|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2015-04-27|2007-03-01|2007-03-05|Estimate|||||||2015-04-27|2015-04-28|Estimate|July 1999||1999-07-31|June 2002|2002-06-30||||||||Interventional|||Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors|Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.322729|2018-06-01 03:23:48.322729
NCT00019448|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2013-06-19|2007-03-01|2007-03-05|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 1998||1998-09-30|September 2001|2001-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.561984|2018-06-01 03:23:48.561984
NCT00019396|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2013-06-19|2007-03-01|2007-03-05|Estimate|||||||2013-06-19|2013-06-20|Estimate|February 1998||1998-02-28|May 2006|2006-05-31|March 2007|Actual|2007-03-31|||||Interventional|||flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer|Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.658563|2018-06-01 03:23:48.658563
NCT00019188|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2013-06-19|2007-03-01|2007-03-05|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 1997||1997-01-31|April 2004|2004-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma|Phase I/II Pilot Study of Interleukin-12 in Patients With AIDS-Associated Kaposi's Sarcoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.773999|2018-06-01 03:23:48.773999
NCT00003552|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2015-04-27|2007-03-01|2007-03-05|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 1999||1999-01-31|December 2001|2001-12-31|October 2002|Actual|2002-10-31|||||Interventional|||Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma|Phase I/II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation Followed by Allogeneic T-cell Infusion as Adoptive Immunotherapy in Patients With Metastatic Melanoma|Terminated||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:23:48.911444|2018-06-01 03:23:48.911444
NCT00442845|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2015-04-21|2007-02-28|2007-03-02|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2003||2003-01-31|April 2015|2015-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|ACTFAST||Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)|ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg|Completed||Phase 4|2080||Pfizer|||||f||||||||||||||2018-06-01 03:23:48.99738|2018-06-01 03:23:48.99738
NCT00442832|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2009-08-15|2007-02-28|2007-03-02|Estimate|||||||2009-08-15|2009-08-18|Estimate|December 2006||2006-12-31|August 2009|2009-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection|A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections|Completed||Phase 2|203|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||f||||||||||2018-06-01 03:23:49.222669|2018-06-01 03:23:49.222669
NCT00442819|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2007-03-01|2007-03-01|2007-03-02|Estimate|||||||2007-03-01|2007-03-02|Estimate|July 2006||2006-07-31|March 2007|2007-03-31|September 2006||2006-09-30|||||Interventional|||Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney||Completed||Phase 4|30||China Medical University Hospital|||||f||||t||||||||||2018-06-01 03:23:49.299372|2018-06-01 03:23:49.299372
NCT00442806|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2013-11-25|2007-03-01|2007-03-02|Estimate|||||||2013-11-25|2013-11-26|Estimate|November 2007||2007-11-30|November 2013|2013-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction|A Randomized Clinical Trial of AdiPOse-derived Stem ceLLs in the Treatment of Patients With ST-elevation myOcardial Infarction - The APOLLO Trial|Completed||Phase 1|14|Actual|Cytori Therapeutics||2|||f||||t||||||||||2018-06-01 03:23:49.358656|2018-06-01 03:23:49.358656
NCT00442793|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2016-11-01|2007-03-01|2007-03-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.|A Randomized, Open Label Study Comparing the Effect of Mircera and Epoetin Beta on Hemoglobin Response in Patients With Chronic Kidney Disease Who Are on Dialysis|Completed||Phase 3|265|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:23:49.430371|2018-06-01 03:23:49.430371
NCT00442780|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2009-01-08|2007-03-01|2007-03-02|Estimate|||||||2009-01-08|2009-01-09|Estimate|August 2007||2007-08-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MOBILE||Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease|Completed||Phase 2|36|Actual|Biogen||4|||f||||t||||||||||2018-06-01 03:23:49.529953|2018-06-01 03:23:49.529953
NCT00442767|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2010-11-30|2007-03-01|2007-03-02|Estimate|||||||2010-11-30|2010-12-02|Estimate|February 2007||2007-02-28|November 2010|2010-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus|Reducing Postprandial Hyperglycemia With Adjuvant Premeal Pramlintide and Postmeal Insulin in Children With Type 1 Diabetes Mellitus.|Completed||Phase 4|8|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 03:23:49.622166|2018-06-01 03:23:49.622166
NCT00442754|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-03-19|2007-03-01|2007-03-02|Estimate|||||||2012-03-19|2012-03-20|Estimate|December 2006||2006-12-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Dendritic Cells in Lung Cancer|Vaccination With Autologous Dendritic Cells Pulsed With Allogeneic Tumour Lysate (MelCancerVac) for the Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. A Phase II Study|Completed||Phase 2|50|Anticipated|Herlev Hospital|||||f||||f||||||||||2018-06-01 03:23:49.68486|2018-06-01 03:23:49.68486
NCT00442741|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-04-23|2007-03-01|2007-03-02|Estimate|||||||2012-04-23|2012-04-25|Estimate|July 2007||2007-07-31|April 2012|2012-04-30||||July 2007|Actual|2007-07-31||Interventional|||Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)|Withdrawn||Phase 1|0|Actual|Novartis||2||pts. will be captured in core|f||||||||||||||2018-06-01 03:23:49.862906|2018-06-01 03:23:49.862906
NCT00442728|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|||2007-03-01|2007-03-01|2007-03-02|Estimate|||||||2007-03-01|2007-03-02|Estimate|January 2003||2003-01-31|March 2007|2007-03-31|June 2003||2003-06-30|||||Interventional|||The Effect of Neuromuscular Electrical Stimulation|on Muscle Wasting in Artificially Ventilated and Sedated Patients at the Intensive Care Unit: a Pilot Study|Completed||N/A|21||Provinciale Hogeschool Limburg|||||f||||||||||||||2018-06-01 03:23:49.949841|2018-06-01 03:23:49.949841
NCT00442715|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2007-03-05|2007-03-01|2007-03-02|Estimate|||||||2007-03-05|2007-03-06|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|December 2006||2006-12-31|||||Observational|||Exercise Challenge Test in 3-6 Years Old Asthmatic Children|Exercise Challenge Test in 3-6 Years Old Asthmatic Children|Completed|||100||Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:23:50.008252|2018-06-01 03:23:50.008252
NCT00442702|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|2011-08-29||2011-12-13|2007-03-01|2007-03-02|Estimate|2011-08-29|2011-10-03|Estimate||||2011-12-13|2011-12-19|Estimate|September 2007||2007-09-30|December 2011|2011-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.|An Open-label, Randomized, Multi-center, Parallel Group Non-inferiority Study of Subcutaneous Injections of RO0503821 Given Once Monthly vs. Darbepoetin Alfa Given According to Local Label in Patients With Chronic Kidney Disease Who Are Not on Dialysis.|Completed||Phase 3|228|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:23:50.109881|2018-06-01 03:23:50.109881
NCT00442689|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2014-04-09||2014-05-09|2007-03-01|2007-03-02|Estimate|2014-05-09|2014-06-06|Estimate||||2014-05-09|2014-06-06|Estimate|July 2006||2006-07-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Metabolic Syndrome in PCOS: Precursors and Interventions|Metabolic Syndrome in PCOS: Precursors and Interventions|Completed||N/A|97|Actual|Northwestern University|Please note there were 2 additional arms at the start of the study: Metformin alone (n=8) and Metformin+Flutamide (n=6), which were discontinued. These arms are therefore not included in these results data.|3|||f||||t||||||||||2018-06-01 03:23:50.872736|2018-06-01 03:23:50.872736
NCT00442676|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2012-03-12|2007-02-28|2007-03-02|Estimate|||||||2012-03-12|2012-03-13|Estimate|June 2009||2009-06-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia|Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia|Withdrawn||Phase 2|0|Actual|Virginia Commonwealth University||2||No patients were recruited. Treatment drug expired.|f||||t||||||||||2018-06-01 03:23:51.288438|2018-06-01 03:23:51.288438
NCT00442663|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-04-23|2007-02-28|2007-03-02|Estimate|||||||2007-04-23|2007-04-24|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|December 2005|Actual|2005-12-31|||||Interventional|FOLEYEASI||Trial of Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction|Randomized Trial of Transcervical Foley Catheter With and Without Extra-Amniotic Saline Infusion for Labor Induction|Completed||N/A|170||University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 03:23:51.401241|2018-06-01 03:23:51.401241
NCT00442650|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2016-11-18|2007-03-01|2007-03-02|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2004||2004-01-31|March 2009|2009-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis||Completed||Phase 3|||Merck KGaA|||||f||||||||||||||2018-06-01 03:23:51.470034|2018-06-01 03:23:51.470034
NCT00442637|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2013-12-11|2007-02-28|2007-03-02|Estimate|||||||2013-12-11|2013-12-12|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|September 2013|Actual|2013-09-30||Interventional|CAIRO3||Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma|Maintenance Treatment With Capecitabine and Bevacizumab Versus Observation After Induction Treatment With Chemotherapy and Bevacizumab as First-line Treatment in Patients With Advanced Colorectal Carcinoma|Unknown status|Active, not recruiting|Phase 3|635|Anticipated|Dutch Colorectal Cancer Group||2|||f||||t||||||||||2018-06-01 03:23:51.52797|2018-06-01 03:23:51.52797
NCT00442624|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-03-08|2007-03-01|2007-03-02|Estimate|||||||2012-03-08|2012-03-09|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|December 2008||2008-12-31|||||Observational|||Effects of Chronic Insomnia on the Neuroendocrine Regulation of Glucose and Lipid Metabolism|Effects of Chronic Insomnia on the Neuroendocrine Regulation of Glucose and Lipid Metabolism|Completed|||25|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||Samples Without DNA|"~     plasma and serum samples~   "|||2018-06-01 03:23:51.612652|2018-06-01 03:23:51.612652
NCT00442611|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|2015-01-26||2017-09-28|2007-03-01|2007-03-02|Estimate|2015-04-23|2015-04-24|Estimate||||2017-09-28|2017-10-31|Actual|November 2008||2008-11-30|September 2017|2017-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)|A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis|Completed||Phase 1/Phase 2|10|Actual|Stanford University||2|||f||||||||||||||2018-06-01 03:23:51.670071|2018-06-01 03:23:51.670071
NCT00442598|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2015-02-20||2015-03-06|2007-03-01|2007-03-02|Estimate|2015-03-06|2015-03-10|Estimate||||2015-03-06|2015-03-10|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy Study of Glufosfamide in Ovarian Cancer|An Open-Label Phase 2 Study of the Safety and Efficacy of Glufosfamide in Ovarian Cancer|Terminated||Phase 2|17|Actual|Eleison Pharmaceuticals LLC.||3|||f||||f||||||||||2018-06-01 03:23:51.917759|2018-06-01 03:23:51.917759
NCT00442585|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-03-12|2007-03-01|2007-03-02|Estimate|||||||2012-03-12|2012-03-13|Estimate|September 2006||2006-09-30|March 2012|2012-03-31|October 2007|Actual|2007-10-31|||||Interventional|||S(+)-Ibuprofen Effects on Asprin Treated Volunteers|Double Blind, Randomised, Parallel Group, Placebo Controlled Clinical Trial of S(+)-Ibuprofen Effects on TxB2 Concentrations and Platelet Aggregation in Aspirin-treated Healthy Adult Volunteers|Completed||Phase 1|72||Gebro Pharma GmbH|||||f||||f||||||||||2018-06-01 03:23:52.485509|2018-06-01 03:23:52.485509
NCT00442572|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2015-12-08||2017-03-09|2007-03-01|2007-03-02|Estimate|2016-03-10|2016-04-11|Estimate||||2017-03-09|2017-04-06|Actual|July 3, 2006|Actual|2006-07-03|March 2017|2017-03-31|April 23, 2012|Actual|2012-04-23|April 23, 2012|Actual|2012-04-23||Interventional||Safety population included all the randomized participants who passed during at least one treatment period, and had at least one efficacy and safety evaluation.|SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).|Stop Progression of Fibrosis by Administration of Intermittent Continuous Treatment With Peginterferon Alfa-2a. Open-label, Randomized Efficacy and Safety Clinical Trial of Intermittent Continuous Treatment With Peginterferon Alfa-2a (PEGASYS) in Patients With HBeAg Negative Hepatitis B Responding to Prior Treatment With Interferon Alfa (SOFIA -LTT)|Completed||Phase 2|21|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:23:52.562487|2018-06-01 03:23:52.562487
NCT00442559|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2008-10-12||2017-03-13|2007-02-28|2007-03-02|Estimate|2008-11-10|2008-11-18|Estimate||||2017-03-13|2017-04-11|Actual|January 2005||2005-01-31|March 2017|2017-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Montelukast in Mild Asthmatic Children With Allergic Rhinitis (0476-367)|"Korean Study of Real-World Montelukast Use in Mild Asthmatic Children With Concomitant Allergic Rhinitis"|Completed||Phase 4|191|Actual|Merck Sharp & Dohme Corp.|This was an open-label study. Only 53 patients had diary information with daytime asthma symptom score - thus, 138 cases were dropped from analysis due to lack of daytime asthma symptom score.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:23:53.064302|2018-06-01 03:23:53.064302
NCT00442546|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|2009-12-15||2011-02-15|2007-03-01|2007-03-02|Estimate|2010-07-20|2010-08-18|Estimate||||2011-02-15|2011-02-18|Estimate|May 2007||2007-05-31|February 2011|2011-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement|A Multicenter, Double-Blind Randomized, Placebo-Controlled Study Of The Efficacy And Safety Of Pregabalin In The Treatment Of Subjects With Post-Operative Pain Following Total Knee Arthroplasty (TKA)|Completed||Phase 3|307|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 03:23:53.513094|2018-06-01 03:23:53.513094
NCT00442533|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2017-04-27|2007-03-01|2007-03-02|Estimate|||||||2017-04-27|2017-04-28|Actual|August 2005||2005-08-31|April 2017|2017-04-30|December 29, 2015|Actual|2015-12-29|August 30, 2014|Actual|2014-08-30||Interventional|||Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors|High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms.|Completed||Phase 2/Phase 3|200|Actual|Radio Isotope Therapy of America||1|||f||||t||||||||Undecided||2018-06-01 03:23:56.955743|2018-06-01 03:23:56.955743
NCT00442520|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2016-11-23|2007-03-01|2007-03-02|Estimate|||||||2016-11-23|2016-11-28|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy|Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy|Completed|||70|Actual|University of Kansas Medical Center|||3||f||||t||||||||||2018-06-01 03:23:57.028796|2018-06-01 03:23:57.028796
NCT00442507|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|2015-06-10||2015-07-02|2007-03-01|2007-03-02|Estimate|2015-06-10|2015-07-03|Estimate||||2015-07-02|2015-07-24|Estimate|March 2007||2007-03-31|July 2015|2015-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|OSI3650||Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Trial of Erlotinib and Avastin in Previously Treated Patients With Cancer of the Esophagus or Gastroesophageal Junction|Terminated||Phase 2|6|Actual|Washington University School of Medicine||1||Slow accrual|f||||f||||||||||2018-06-01 03:23:57.088804|2018-06-01 03:23:57.088804
NCT00442494|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-11-15|2007-03-01|2007-03-02|Estimate|||||||2012-11-15|2012-11-16|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Corticosteroids for the Prevention of Atrial Fibrillation After Cardiac Surgery|Feasibility of Corticosteroid in the Prevention of Atrial Fibrillation After Cardiac Surgery: A Prospective, Double-Blind Randomized Multicenter Trial|Terminated||N/A|1|Actual|Kuopio University Hospital||1||Study has been completed as planned|f||||f||||||||||2018-06-01 03:23:57.283829|2018-06-01 03:23:57.283829
NCT00442481|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2007-03-01|2007-03-01|2007-03-02|Estimate|||||||2007-03-01|2007-03-02|Estimate|February 2007||2007-02-28|March 2007|2007-03-31||||||||Interventional|||Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder|Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder|Unknown status|Recruiting|Phase 4|25||Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:23:57.343811|2018-06-01 03:23:57.343811
NCT00442468|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|2009-12-02||2013-01-04|2007-03-01|2007-03-02|Estimate|2009-12-03|2010-01-07|Estimate||||2013-01-04|2013-01-10|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath|An Evaluation of the Prevalence of Airway Obstruction Consistent With Chronic Obstructive Pulmonary Disease (COPD) in Subjects With a History of Cigarette Smoking and Symptoms of Chronic Bronchitis in a Primary Care Setting|Completed|||1283|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 03:23:57.440166|2018-06-01 03:23:57.440166
NCT00442455|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2016-09-23|2007-03-01|2007-03-02|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2006||2006-01-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck|Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|53|Actual|Grupo de Investigación Clínica en Oncología Radioterapia||1|||f||||t||||||||||2018-06-01 03:23:59.720381|2018-06-01 03:23:59.720381
NCT00442442|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2007-10-30|2007-03-01|2007-03-02|Estimate|||||||2007-10-30|2007-10-31|Estimate|April 2007||2007-04-30|October 2007|2007-10-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Clinical Evaluation of Mosquito Coils to Control Malaria in China|Clinical Evaluation of Mosquito Coils to Control Malaria in China|Unknown status|Active, not recruiting|Phase 3|8000|Anticipated|London School of Hygiene and Tropical Medicine||4|||f||||f||||||||||2018-06-01 03:23:59.806522|2018-06-01 03:23:59.806522
NCT00442429|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2007-03-01|2007-03-01|2007-03-02|Estimate|||||||2007-03-01|2007-03-02|Estimate|July 2004||2004-07-31|March 2007|2007-03-31|June 2010||2010-06-30|||||Observational|||Morbidity and Mortality Among Dialysis Patients After Treatment for Depression|Morbidity and Mortality Among Dialysis Patients After Treatment for Depression|Unknown status|Recruiting||350||Portland VA Medical Center|||||f||||||||||||||2018-06-01 03:23:59.871543|2018-06-01 03:23:59.871543
NCT00442416|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|2016-07-05||2016-07-05|2007-03-01|2007-03-02|Estimate|2016-07-05|2016-08-17|Estimate||||2016-07-05|2016-08-17|Estimate|February 2007||2007-02-28|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||Safety population included all participants who received at least one dose of the study drug and had at least one post-baseline safety assessment.|A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.|A Two-arm, Randomized, Open-label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 Versus Epoetin Alfa in Peritoneal Dialysis Patients Who Self Inject or Receive In-center Injections.|Terminated||Phase 3|80|Actual|Hoffmann-La Roche|The study was prematurely terminated during enrollment period due to legal reasons. Therefore, the planned statistical analysis of the primary endpoint was not performed.|2||Strategic decision unrelated to safety or efficacy|f||||||||||||||2018-06-01 03:23:59.987616|2018-06-01 03:23:59.987616
NCT00019578|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2012-03-21|2007-03-01|2007-03-02|Estimate|||||||2012-03-21|2012-03-23|Estimate|November 1998||1998-11-30|March 2012|2012-03-31|May 2002|Actual|2002-05-31|||||Interventional|||Stereotactic Radiosurgery in Treating Patients With Brain Tumors|Phase I Pilot Study of Stereotaxic Radiosurgery in Patients With Intracranial Neoplasms|Completed||Phase 1|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:24:00.767302|2018-06-01 03:24:00.767302
NCT00019006|ClinicalTrials.gov processed this data on May 31, 2018|2007-03-01|||2015-04-27|2007-03-01|2007-03-02|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 1995||1995-03-31|May 2005|2005-05-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer|Phase I Pilot Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in the Adjuvant Setting in Patients With Colorectal, Pancreatic, or Lung Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:24:00.837417|2018-06-01 03:24:00.837417
NCT00442403|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|April 2002||2002-04-30|February 2007|2007-02-28|September 2002||2002-09-30|||||Interventional|||Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria|Etude de l’Activite (Efficacite et Tolerance) de l’Association de la Chloroquine Avec la Dehydroepiandrosterone-Sulfate (Dheas) Dans le Traitement de l’Acces Palustre Simple A Plasmodium Falciparum|Suspended||Phase 3|200||Université Victor Segalen Bordeaux 2||||"At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line~   therapy for of uncomplicated malaria."|f||||f||||||||||2018-06-01 03:24:00.904729|2018-06-01 03:24:00.904729
NCT00442390|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|January 2002||2002-01-31|February 2007|2007-02-28|January 2003||2003-01-31|||||Interventional|||Metabolic Effects of Acute Cortisol Withdrawal in Adrenal Failure|Effects of Cortisol on Carbohydrate, Lipid, and Protein Metabolism; Studies of Acute Cortisol Withdrawal in Adrenocortical Failure.|Completed||N/A|10||University of Aarhus|||||f||||f||||||||||2018-06-01 03:24:00.97402|2018-06-01 03:24:00.97402
NCT00442377|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-08-15|2007-02-28|2007-03-01|Estimate|||||||2007-08-15|2007-08-16|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Study to Investigate the Induction of an Protective Immune Response to Malaria|Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis|Completed||N/A|15|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 03:24:01.030108|2018-06-01 03:24:01.030108
NCT00442364|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2014-01-07|2011-09-14|2015-02-19|2007-02-28|2007-03-01|Estimate|2014-01-07|2014-02-26|Estimate|2011-09-14|2011-09-21|Estimate|2015-02-19|2015-03-10|Estimate|March 2007||2007-03-31|February 2015|2015-02-28|August 2009|Actual|2009-08-31|June 2008|Actual|2008-06-30||Interventional|MRI|Patients with bubbles detected on MRI|Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt|An Open Label Multicenter Safety Study of the Varisolve® Procedure for the Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt|Completed||Phase 2|60|Actual|BTG International Inc.||1|||f||||t||||||||||2018-06-01 03:24:01.099194|2018-06-01 03:24:01.099194
NCT00442351|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2010-03-26||2015-09-28|2007-02-28|2007-03-01|Estimate|2010-03-26|2010-04-16|Estimate||||2015-09-28|2015-09-30|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)|"A Comparative Study of The Efficacy and Tolerability of Maintenance Treatment of Patients With Mild/Moderate Persistent Asthma With Asmanex Twisthaler 220 mcg QD PM Versus Asmanex Placebo QD PM"|Terminated||Phase 4|26|Actual|Merck Sharp & Dohme Corp.|This study was terminated early due to a high screening failure rate and poor enrollment that resulted from stringent inclusion and exclusion criteria. Efficacy data were not evaluated.|2||Slow Enrollment|f||||f||||||||||2018-06-01 03:24:01.373675|2018-06-01 03:24:01.373675
NCT00442338|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2009-05-22||2016-09-07|2007-02-27|2007-03-01|Estimate|2009-05-22|2009-07-14|Estimate||||2016-09-07|2016-10-20|Estimate|March 2007||2007-03-31|September 2016|2016-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)|MK-476 IV Formulation Phase III Open Label Exploratory Comparative Study - Acute Exacerbations of Asthma -|Completed||Phase 3|91|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 03:24:01.619526|2018-06-01 03:24:01.619526
NCT00442325|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-10-24|2007-02-28|2007-03-01|Estimate|||||||2007-10-24|2007-10-25|Estimate|January 2003||2003-01-31|April 2007|2007-04-30|February 2004||2004-02-29|||||Interventional|ACTFAST 2||Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets|ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg.|Completed||Phase 4|595||Pfizer|||||f||||||||||||||2018-06-01 03:24:01.970365|2018-06-01 03:24:01.970365
NCT00442312|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|May 2006||2006-05-31|February 2007|2007-02-28|November 2006||2006-11-30|||||Interventional|||Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy|An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension.|Unknown status|Active, not recruiting|Phase 4|43||Genovate Biotechnology Co., Ltd.,|||||f||||f||||||||||2018-06-01 03:24:02.080823|2018-06-01 03:24:02.080823
NCT00442299|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|April 2005||2005-04-30|February 2007|2007-02-28|December 2009||2009-12-31|||||Interventional|||Albumin Dialysis in End-Stage Renal Disease: Detoxification Capacity and Impact on Vascular Endothelial Function|Phase 1 Study of Albumin Dialysis Using Prometheus in End Stage Renal Disease: Detoxification Capacity and Impact on Vascular Endothelial Function|Suspended||Phase 1/Phase 2|10||Universitaire Ziekenhuizen Leuven||||Major side-effects|f||||t||||||||||2018-06-01 03:24:02.15088|2018-06-01 03:24:02.15088
NCT00442286|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2016-11-18||2017-01-30|2007-02-28|2007-03-01|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|October 2006||2006-10-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Rheos® Pivotal Trial|Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System|Completed||N/A|591|Actual|CVRx, Inc.||2|||f||||t||||||||||2018-06-01 03:24:02.299578|2018-06-01 03:24:02.299578
NCT00442273|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate||||February 2007|2007-02-28||||||||Interventional|||Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome|Comparison of Autologous Serum and Umbilical Cord Serum Eyedrops for Dry Eye Syndrome|Completed||N/A|||Chonnam National University Hospital|||||f||||||||||||||2018-06-01 03:24:03.164506|2018-06-01 03:24:03.164506
NCT00442260|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2018-05-25|2007-02-28|2007-03-01|Estimate|||||||2018-05-25|2018-05-30|Actual|February 2007||2007-02-28|May 2018|2018-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer|Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination With Abraxane (Abraxane) in Patients With Metastatic Breast Cancer (MBC) [Phase I and II]|Completed||Phase 1/Phase 2|2|Actual|West Virginia University||1|||f||||t||||||||||2018-06-01 03:24:03.232044|2018-06-01 03:24:03.232044
NCT00442247|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|September 2004||2004-09-30|February 2007|2007-02-28|December 2008||2008-12-31|||||Interventional|||A Randomised, Controlled Study of Bimesh, Pelvicol for Vaginal Wall Prolapse|A Randomised, Controlled Study of Bimesh, Pelvicol for Vaginal Wall Prolapse|Unknown status|Active, not recruiting|N/A|60||Zealand University Hospital|||||f||||t||||||||||2018-06-01 03:24:03.296743|2018-06-01 03:24:03.296743
NCT00442234|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2010-01-27|2007-02-28|2007-03-01|Estimate|||||||2010-01-27|2010-01-28|Estimate|May 2007||2007-05-31|January 2010|2010-01-31||||April 2008|Actual|2008-04-30||Interventional|||"Post-marketing Study of Monteplase (Cleactor) in Patients With Acute Pulmonary Embolism"|"Pharmacokinetic/Pharmacodynamic Study of Monteplase (Cleactor) in Acute Pulmonary Embolism"|Completed||Phase 4|4||Eisai Inc.|||||f||||||||||||||2018-06-01 03:24:03.359384|2018-06-01 03:24:03.359384
NCT00442221|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|May 2004||2004-05-31|February 2007|2007-02-28|August 2004||2004-08-31|||||Interventional|||The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months|An Open-Label, Repeat Dose Study Of The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months|Completed||Phase 3|500||POZEN|||||t||||t||||||||||2018-06-01 03:24:03.42592|2018-06-01 03:24:03.42592
NCT00442208|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2008-04-21|2007-02-28|2007-03-01|Estimate|||||||2008-04-21|2008-04-22|Estimate|January 2007||2007-01-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers||Completed||Phase 1|24||POZEN|||||t||||t||||||||||2018-06-01 03:24:03.487066|2018-06-01 03:24:03.487066
NCT00442195|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2018-05-26|2007-02-28|2007-03-01|Estimate|||||||2018-05-26|2018-05-30|Actual|February 27, 2007||2007-02-27|May 22, 2018|2018-05-22||||||||Observational|||Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers|Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:24:03.548712|2018-06-01 03:24:03.548712
NCT00442169|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2011-01-21||2016-04-12|2007-02-28|2007-03-01|Estimate|2011-01-21|2011-02-14|Estimate||||2016-04-12|2016-04-14|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|April 2009|Actual|2009-04-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults|Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults|Completed||Phase 2|208|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 03:24:03.692176|2018-06-01 03:24:03.692176
NCT00442156|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2016-08-25|2007-02-28|2007-03-01|Estimate|||||||2016-08-25|2016-08-26|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|Laser Resp||The Course of Response to Focal Photocoagulation for DME|The Course of Response to Focal Photocoagulation for Diabetic Macular Edema|Completed|||122|Actual|Jaeb Center for Health Research|||1||f||||f||||||||||2018-06-01 03:24:04.587339|2018-06-01 03:24:04.587339
NCT00442143|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2010-07-22|2007-02-28|2007-03-01|Estimate|||||||2010-07-22|2010-07-23|Estimate|January 2007||2007-01-31|March 2007|2007-03-31|December 2007|Anticipated|2007-12-31|||||Interventional|DANCELL-CLI||Treatment of Severe Limb Ischemia With Autologous Bonemarrow Derived Mononuclear Cells|Treatment of Severe Limb Ischemia With Autologous Bonemarrow Derived Mononuclear Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|Odense University Hospital|||||f||||f||||||||||2018-06-01 03:24:04.706356|2018-06-01 03:24:04.706356
NCT00442130|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2017-07-25|2007-02-27|2007-03-01|Estimate|||||||2017-07-25|2017-07-27|Actual|February 2007||2007-02-28|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|February 2014|Actual|2014-02-28||Interventional|||Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination|Reduced Intensity Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia Followed by Vaccination With Lethally Irradiated Autologous Tumor Cells Admixed With Granulocyte Macrophage-colony Stimulating Factor Secreting K562 Cells|Active, not recruiting||Phase 1|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:24:04.776701|2018-06-01 03:24:04.776701
NCT00442117|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2011-01-12||2017-03-15|2007-02-28|2007-03-01|Estimate|2011-02-02|2011-02-10|Estimate||||2017-03-15|2017-04-12|Actual|June 2007||2007-06-30|March 2017|2017-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)|A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Mild Persistent and Moderate Persistent Asthmatic Patients|Completed||Phase 3|180|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:24:04.869317|2018-06-01 03:24:04.869317
NCT00442104|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27||2009-10-28|2009-10-28|2007-02-28|2007-03-01|Estimate||||2009-10-28|2009-11-02|Estimate|2009-10-28|2009-11-02|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Open-label Extension to Protocol 1042-0500|An Open-label Clinical Study to Evaluate the Safety and Antiepileptic Activity of Ganaxolone in Treatment of Patients Diagnosed With Infantile Spasms.|Terminated||Phase 2|54|Actual|Marinus Pharmaceuticals||1||ganaxolone did not significantly reduce spasms after an 8-day placebo control period|f||||f||||||||||2018-06-01 03:24:05.105577|2018-06-01 03:24:05.105577
NCT00442091|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2017-09-19|2007-02-28|2007-03-01|Estimate|||||||2017-09-19|2017-09-20|Actual|December 2010||2010-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dandelion Juice in the Treatment of Dyshidrotic Hand Eczema|Dandelion Juice in the Treatment of Dyshidrotic Hand Eczema|Recruiting||N/A|4|Anticipated|Odense University Hospital||1|||f||||f||||||||No||2018-06-01 03:24:05.191217|2018-06-01 03:24:05.191217
NCT00442078|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2012-09-08|2007-02-28|2007-03-01|Estimate|||||||2012-09-08|2012-09-11|Estimate|May 2006||2006-05-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|May 2007|Actual|2007-05-31||Interventional|||I-STOP TOMS - Trans Obturator Male Sling|Evaluation of the Efficacy on Urinary Continence and Quality of Life of the Sub-urethral Tape I-STOP® Using the Transobturator and Perineal Route on Male Incontinent After Radical Prostatectomy.|Completed||Phase 4|50|Actual|CL Medical|||||f||||f||||||||||2018-06-01 03:24:05.261257|2018-06-01 03:24:05.261257
NCT00442065|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2012-10-15|2007-02-28|2007-03-01|Estimate|||||||2012-10-15|2012-10-17|Estimate|October 2006||2006-10-31|October 2012|2012-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ARBITER-II||ARBITER-II: Aorfix™ Bifurcated Safety and Performance Trial: Phase II, Angulated Vessels|A Study to Assess the Acute Technical Success of Aorfix™ Stent Grafts in the Treatment of Abdominal Aortic and Aorto-Iliac Aneurysm Where a Significant Degree of Vessel Angulation Exists at the Neck of the Aneurysm|Completed||Phase 2/Phase 3|30|Actual|Lombard Medical||1|||f||||f||||||||||2018-06-01 03:24:05.407494|2018-06-01 03:24:05.407494
NCT00442052|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|November 2006||2006-11-30|February 2007|2007-02-28|January 2007||2007-01-31|||||Interventional|||To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin|An Open-Label, Investigator-Blinded, Randomized, Parellel Group Study to Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA 325 Versus Enteric-Coated Aspirin.|Completed||Phase 1|80||POZEN|||||f||||t||||||||||2018-06-01 03:24:05.50486|2018-06-01 03:24:05.50486
NCT00442039|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27||2011-02-13|2012-02-24|2007-02-27|2007-03-01|Estimate||||2011-03-10|2011-03-18|Estimate|2012-02-24|2012-02-28|Estimate|December 2006||2006-12-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||Lithium for the Treatment of Pediatric Mania|Pediatric Pharmacokinetic and Tolerability Study of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long Term Safety Period, Discontinuation Phase, and Restabilization Period.|Completed||Phase 2|61|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||4|||f||||t||||||||||2018-06-01 03:24:05.568063|2018-06-01 03:24:05.568063
NCT00442026|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2012-06-26|2007-02-28|2007-03-01|Estimate|||||||2012-06-26|2012-06-27|Estimate|December 2006||2006-12-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC|A Multicenter Randomized Phase III Study of the Docetaxel and Gemcitabine Combination Versus Monotherapy With Gemcitabine as First-line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)|Terminated||Phase 3|106|Actual|Hellenic Oncology Research Group||2||Due to poor accrual|f||||f||||||||||2018-06-01 03:24:05.661769|2018-06-01 03:24:05.661769
NCT00442013|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2012-07-23||2012-12-05|2007-02-28|2007-03-01|Estimate|2012-12-05|2012-12-06|Estimate||||2012-12-05|2012-12-06|Estimate|March 2007||2007-03-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|SARCA||Lansoprazole to Treat Children With Asthma|Phase III: The Study of Acid Reflux in Children With Asthma|Completed||Phase 4|306|Actual|Johns Hopkins University|Results limited to patients without overt Gastroesophageal reflux disease(GERD). Did not conduct on-treatment potential hydrogen(pH) probe studies to confirm treatment effect. Protein-pump inhibitors(PPI) dose may not induce maximal acid suppression.|2|||f||||t||||||||||2018-06-01 03:24:05.793061|2018-06-01 03:24:05.793061
NCT00442000|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2012-03-19|2007-02-28|2007-03-01|Estimate|||||||2012-03-19|2012-03-21|Estimate|January 2005||2005-01-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Outcomes Comparison of Robotic, Retropubic, and Perineal Prostatectomy|Outcomes Comparison of Robotic, Retropubic, and Perineal Prostatectomy|Completed|||700|Actual|William Beaumont Hospitals|||||f||||f||||||||||2018-06-01 03:24:06.154696|2018-06-01 03:24:06.154696
NCT00441987|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2010-06-17|2007-02-28|2007-03-01|Estimate|||||||2010-06-17|2010-06-22|Estimate|February 2007||2007-02-28|June 2010|2010-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953|A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 Administered Orally to Healthy Japanese Male Subjects and Healthy Elderly Male Japanese Subjects.|Completed||Phase 1|96|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:24:06.212158|2018-06-01 03:24:06.212158
NCT00441974|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2009-08-26||2009-10-15|2007-02-28|2007-03-01|Estimate|2009-08-26|2009-10-02|Estimate||||2009-10-15|2009-10-20|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients|A 48-week Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B|Completed||Phase 4|1470|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:24:06.282991|2018-06-01 03:24:06.282991
NCT00441961|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2011-08-10|2007-02-28|2007-03-01|Estimate|||||||2011-08-10|2011-08-11|Estimate|October 2006||2006-10-31|July 2010|2010-07-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis|Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis|Completed||N/A|6|Actual|Radboud University|||||f||||f||||||||||2018-06-01 03:24:06.537069|2018-06-01 03:24:06.537069
NCT00441948|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-02-27|2007-02-27|2007-03-01|Estimate|||||||2007-02-27|2007-03-01|Estimate|May 2007||2007-05-31|February 2007|2007-02-28|April 2008||2008-04-30|||||Interventional|||Enhanced Safety Laser Hair Removal System|Peterio™ – an Add-on Device for Enhanced Safety of Aesthetic Laser Treatments.|Unknown status|Not yet recruiting|N/A|10||Scilex Ltd.|||||f||||f||||||||||2018-06-01 03:24:06.605005|2018-06-01 03:24:06.605005
NCT00441935|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2017-12-21|2007-02-28|2007-03-01|Estimate|||||||2017-12-21|2017-12-26|Actual|April 2004||2004-04-30|December 2017|2017-12-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Observational|||InterStim Prospective Database|InterStim Prospective Database for Outcomes Research|Terminated|||736|Actual|William Beaumont Hospitals|||1|Shift in department's research interest|f||||f||||||||||2018-06-01 03:24:06.670978|2018-06-01 03:24:06.670978
NCT00441922|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2008-10-28|2007-02-28|2007-03-01|Estimate|||||||2008-10-28|2008-10-29|Estimate|January 2003||2003-01-31|October 2008|2008-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase II Study of Docetaxel Versus Vinorelbine as First-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 3|166|Anticipated|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 03:24:06.855772|2018-06-01 03:24:06.855772
NCT00441909|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2009-03-03|2007-02-27|2007-03-01|Estimate|||||||2009-03-03|2009-03-05|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide|Phase I Study of the Safety and Persistence of 0.1% UC-781 Vaginal Gel in HIV-1 Seronegative Women|Completed||Phase 1|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||||||||||||2018-06-01 03:24:06.946241|2018-06-01 03:24:06.946241
NCT00441896|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27||2009-10-28|2009-10-29|2007-02-28|2007-03-01|Estimate||||2009-10-28|2009-10-30|Estimate|2009-10-29|2009-11-03|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms|A Double-blind, Placebo-controlled, Dose-ranging Clinical Study to Evaluate the Safety, Tolerability, and Antiepileptic Activity of Ganaxolone in Treatment of Patients With Infantile Spasms|Completed||Phase 2|56|Actual|Marinus Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:24:07.049579|2018-06-01 03:24:07.049579
NCT00441883|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27||2013-11-20|2013-11-20|2007-02-27|2007-03-01|Estimate||||2013-11-20|2013-12-13|Estimate|2013-11-20|2013-12-13|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|||Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma|A Phase 2, 28 Day Parallel-Group, Double-Masked, Dose-Finding Study Comparing the Safety and Efficacy of PF-03187207 to Latanoprost|Completed||Phase 2|242|Actual|Bausch & Lomb Incorporated||2|||f||||t||||||||||2018-06-01 03:24:07.150122|2018-06-01 03:24:07.150122
NCT00441870|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2012-03-08|2007-02-27|2007-03-01|Estimate|||||||2012-03-08|2012-03-09|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of EC0225 for the Treatment of Refractory or Metastatic Tumors|Protocol EC-0225-01: A Phase 1 Study of EC0225 Administered Weeks 1 and 3 of a 4-Week Cycle|Completed||Phase 1|77|Actual|Endocyte|||||f||||f||||||||||2018-06-01 03:24:07.256894|2018-06-01 03:24:07.256894
NCT00441857|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-07-04|2007-02-28|2007-03-01|Estimate|||||||2007-07-04|2007-07-06|Estimate|March 2007||2007-03-31|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Interventional|DOSE||Effect of Plant Stanols on Cholesterol Absorption|The Effect of Three Different Stanol Ester Doses in Margarines on Cholesterol Absorption Efficiency|Completed||Phase 4|60||Oy Foodfiles Ltd|||||f||||f||||||||||2018-06-01 03:24:07.330004|2018-06-01 03:24:07.330004
NCT00441844|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|October 2002||2002-10-31|February 2007|2007-02-28|July 2005||2005-07-31|||||Interventional|||Monocyte Function and Inflammation in Type 1 Diabetes and Its Modulation|Phase 2 Study Examining the Effect of Simvastatin vs Placebo on Monocyte Function and Inflammation in Patients With Type 1 Diabetes|Completed||Phase 2|50||University of California, Davis|||||f||||t||||||||||2018-06-01 03:24:07.45315|2018-06-01 03:24:07.45315
NCT00441831|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2009-02-04|2007-02-27|2007-03-01|Estimate|||||||2009-02-04|2009-02-05|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|February 2008|Anticipated|2008-02-29|||||Observational|||The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy||Unknown status|Recruiting||65|Anticipated|Mackay Memorial Hospital|||||f||||t||||||||||2018-06-01 03:24:07.521224|2018-06-01 03:24:07.521224
NCT00441818|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2008-05-08|2007-02-27|2007-03-01|Estimate|||||||2008-05-08|2008-05-09|Estimate|May 2006||2006-05-31|February 2007|2007-02-28|June 2007|Anticipated|2007-06-30|||||Interventional|||Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma|A Phase I/II, Non-Randomized,Multiple-Dose,Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TNX-650 in Patients With Refractory Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|59|Anticipated|Tanox|||||f||||f||||||||||2018-06-01 03:24:07.596082|2018-06-01 03:24:07.596082
NCT00441792|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2012-02-07||2012-04-08|2007-02-28|2007-03-01|Estimate|2012-03-11|2012-04-06|Estimate||||2012-04-08|2012-04-11|Estimate|October 2007||2007-10-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of Etomidate on Patient Outcomes After Single Bolus Doses|A Randomized Trial of Etomidate Versus Midazolam for Intubation of Patients With Sepsis.|Completed||N/A|122|Actual|Advocate Hospital System|Because of limitations in the availability of study investigators and pharmacists, we were unable to enroll all potentially eligible patients, raising the possibility that our study sample was not representative of our entire patient population.|2|||f||||f||||||||||2018-06-01 03:24:07.750579|2018-06-01 03:24:07.750579
NCT00441779|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2016-07-11|2007-02-28|2007-03-01|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2008||2008-08-31|October 2014|2014-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Transfusion-Associated Microchimerism in Previously Injured Individuals Who Received a Blood Transfusion|Retrospective Study of the Prevalence of Transfusion-Associated Microchimerism Following Traumatic Injury, Burns, and Elective Orthopedic Procedures|Terminated|||59|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||3|"A separate study (similar subjects) identified transfusion-associated microchimerism only~   rarely, making this observational study impractical to conduct."|f||||f||||||Samples With DNA|"~     Whole blood, plasma, peripheral blood mononuclear cells~   "|||2018-06-01 03:24:07.952983|2018-06-01 03:24:07.952983
NCT00441766|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2011-12-16||2011-12-16|2007-02-27|2007-03-01|Estimate|2011-12-16|2012-01-20|Estimate||||2011-12-16|2012-01-20|Estimate|March 2007||2007-03-31|December 2011|2011-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain||Terminated||Phase 2|213|Actual|Allergan|Only Part A results are presented; Due to termination of the study, Part B was never conducted.|4||Study was terminated due to company decision after Part A. Part B was never conducted|f||||||||||||||2018-06-01 03:24:08.050719|2018-06-01 03:24:08.050719
NCT00441753|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2009-02-05|2007-02-28|2007-03-01|Estimate|||||||2009-02-05|2009-02-06|Estimate|September 2006||2006-09-30|February 2009|2009-02-28||||||||Observational|||Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest|Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest|Unknown status|Recruiting||10|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 03:24:08.553896|2018-06-01 03:24:08.553896
NCT00441740|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2008-10-29|2007-02-28|2007-03-01|Estimate|||||||2008-10-29|2008-10-31|Estimate|April 2004||2004-04-30|October 2008|2008-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer|Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine as First Line Treatment in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC). A Prospective , Multicenter, Randomized, Phase III Trial|Completed||Phase 3|419|Actual|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 03:24:08.620035|2018-06-01 03:24:08.620035
NCT00441727|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2009-08-28||2012-07-12|2007-02-27|2007-03-01|Estimate|2012-01-10|2012-02-13|Estimate||||2012-07-12|2012-07-16|Estimate|February 2007||2007-02-28|July 2012|2012-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Oberon||Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)|A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)|Completed||Phase 3|2426|Actual|AstraZeneca|Not enough patients had peptic ulcer, gastric ulcer, or duodenal ulcer to report the intended primary endpoint of time to peptic ulcer and two secondary endpoints, time to gastric ulcer and time to duodenal ulcer. Percentage used instead.|3|||f||||||||||||||2018-06-01 03:24:08.758271|2018-06-01 03:24:08.758271
NCT00441714|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2015-11-09|2007-02-28|2007-03-01|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise|Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise|Withdrawn||N/A|0|Actual|Radboud University||||"new insights have let us to expect marginal annexin targeting with a 10 minutes delay between~   reperfusion and administration of Annexin A5"|f||||f||||||||||2018-06-01 03:24:09.741329|2018-06-01 03:24:09.741329
NCT00441701|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2014-08-11||2017-03-10|2007-02-28|2007-03-01|Estimate|2014-09-15|2014-09-17|Estimate||||2017-03-10|2017-04-10|Actual|December 2006||2006-12-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)|Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD|Terminated||Phase 2|99|Actual|Merck Sharp & Dohme Corp.||10|||f||||t||||||||||2018-06-01 03:24:09.88128|2018-06-01 03:24:09.88128
NCT00441688|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2017-08-17|2007-02-28|2007-03-01|Estimate|||||||2017-08-17|2017-08-22|Actual|March 15, 2007|Actual|2007-03-15|August 2017|2017-08-31|June 1, 2007|Actual|2007-06-01|June 1, 2007|Actual|2007-06-01||Interventional|||Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients|Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients|Completed||Phase 4|974|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-06-01 03:24:10.725092|2018-06-01 03:24:10.725092
NCT00441675|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2012-03-15|2007-02-28|2007-03-01|Estimate|||||||2012-03-15|2012-03-19|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||A Long Term Prospective Follow Up Study For The CATO Study (SAS30018/SER9702)|A Long Term Follow up Study for a Comparison of Stepwise Treatment of Asthmatic Children With Salmeterol/Fluticasone Propionate Combination Product (SERETIDE®) and/or Fluticasone Propionate (FLIXOTIDE (TM)) Based on PD20 Methacholine and Symptoms or Based on Symptoms Only.|Completed|||137|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-06-01 03:24:10.796837|2018-06-01 03:24:10.796837
NCT00441662|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2007-02-28|2007-02-28|2007-03-01|Estimate|||||||2007-02-28|2007-03-01|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|May 2007||2007-05-31|||||Interventional|||Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema|Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema Following Plaque Radiotherapy for Uveal Melanoma|Completed||N/A|170||Wills Eye|||||f||||||||||||||2018-06-01 03:24:10.889067|2018-06-01 03:24:10.889067
NCT00441649|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2013-10-29|2007-02-28|2007-03-01|Estimate|||||||2013-10-29|2013-10-31|Estimate|February 2000||2000-02-29|October 2013|2013-10-31|January 2007|Actual|2007-01-31|June 2004|Actual|2004-06-30||Interventional|||Methylphenidate for Treating Children With ADHD and Tourette Syndrome|Methylphenidate Treatment of ADHD in Children With Tourette Syndrome|Completed||N/A|71||Stony Brook University|||||f||||||||||||||2018-06-01 03:24:10.953497|2018-06-01 03:24:10.953497
NCT00441636|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2018-04-27|2007-02-28|2007-03-01|Estimate|||||||2018-04-27|2018-04-30|Actual|March 2007||2007-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Treatment Resistant Depression and Obstructive Sleep Apnea, Effect of Continuous Positive Airway Pressure (CPAP)|Treatment Resistant Depression and Obstructive Sleep Apnea: Effect of Treatment With CPAP on Mood, Anxiety and Quality of Life|Recruiting||N/A|120|Anticipated|Queen's University||3|||f||||t||||||||||2018-06-01 03:24:11.016098|2018-06-01 03:24:11.016098
NCT00441623|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2016-05-12|2007-02-28|2007-03-01|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2005||2005-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Role of P-cresol and Related Protein Fermentation Metabolites in Chronic Kidney Disease Patients|A Single Centre Observational Cohort Study on the Prognostic Relevance of P-cresol and Related Uremic Retention Solutes in the Development and/or Progression of Renal Failure and Cardiovascular Disease in Chronic Kidney Disease Patients|Completed|||499|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples Without DNA|"~     Serum, plasma Urine (if provided by patient)~   "|No||2018-06-01 03:24:11.092776|2018-06-01 03:24:11.092776
NCT00441610|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2012-04-27|2007-02-28|2007-03-01|Estimate|||||||2012-04-27|2012-05-01|Estimate|January 2007||2007-01-31|April 2012|2012-04-30||||September 2009|Actual|2009-09-30||Interventional|||An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor|An Extension Trial to a Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor|Completed||Phase 1|4|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:24:11.145024|2018-06-01 03:24:11.145024
NCT00441597|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2009-03-16|2007-02-28|2007-03-01|Estimate|||||||2009-03-16|2009-03-17|Estimate|February 2007||2007-02-28|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?|Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?|Completed||Phase 4|30|Anticipated|Radboud University||3|||f||||f||||||||||2018-06-01 03:24:11.323307|2018-06-01 03:24:11.323307
NCT00441584|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2009-06-18||2017-03-08|2007-02-28|2007-03-01|Estimate|2009-06-18|2009-08-04|Estimate||||2017-03-08|2017-04-05|Actual|July 2005||2005-07-31|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)|Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys|Terminated||Phase 3|117|Actual|Merck Sharp & Dohme Corp.|Due to slow enrollment, an unplanned interim analysis was conducted: 75 of 93 (80.6%) subjects who had reached treatment Week 12 did not achieve early virologic response. Given the low likelihood of response, a decision was made to stop enrollment.|1||Subject accrual was prematurely terminated due slow enrollment.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:24:11.413303|2018-06-01 03:24:11.413303
NCT00441571|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-09-06|2007-02-28|2007-03-01|Estimate|||||||2007-09-06|2007-09-10|Estimate|February 2007||2007-02-28|September 2007|2007-09-30||||||||Interventional|CYT-500||Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer|A Phase 1 Study of Radiolabeled Monoclonal Antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) in Patients With Progressive Androgen-Independent Prostate Cancer|Unknown status|Recruiting|Phase 1|30|Anticipated|Cytogen Corporation|||||f||||f||||||||||2018-06-01 03:24:11.581299|2018-06-01 03:24:11.581299
NCT00441558|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2014-05-14||2014-05-14|2007-02-28|2007-03-01|Estimate|2014-05-14|2014-06-13|Estimate||||2014-05-14|2014-06-13|Estimate|February 2007||2007-02-28|May 2014|2014-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).|Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD|Terminated||Phase 3|1723|Actual|Sprout Pharmaceuticals, Inc||1||terminated for administrative reasons|f||||t||||||||||2018-06-01 03:24:11.677543|2018-06-01 03:24:11.677543
NCT00441545|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2009-06-29||2014-06-06|2007-02-27|2007-03-01|Estimate|2009-06-29|2009-08-13|Estimate||||2014-06-06|2014-06-12|Estimate|February 2007||2007-02-28|August 2011|2011-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Head to Head Study Against Sevelamer Hydrochloride|A Prospective, Multicenter, Open-label, Randomized, Cross-over Study to Compare the Efficacy and Safety of Fosrenol® and Sevelamer Hydrochloride in Patients Receiving Hemodialysis for End Stage Renal Disease|Completed||Phase 3|182|Actual|Shire||2|||f||||||||||||||2018-06-01 03:24:13.009294|2018-06-01 03:24:13.009294
NCT00441532|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2011-11-22|2007-02-28|2007-03-01|Estimate|||||||2011-11-22|2011-11-23|Estimate|August 2005||2005-08-31|October 2010|2010-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy|A Double-Blind Randomized Study On Lidocaine Vs. Placebo Pain Control During Transrectal Ultrasound Guided Prostate Biopsy|Completed||N/A|50||William Beaumont Hospitals|||||f||||f||||||||||2018-06-01 03:24:13.47051|2018-06-01 03:24:13.47051
NCT00441519|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2009-01-09|2007-02-28|2007-03-01|Estimate|||||||2009-01-09|2009-01-12|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin|An Open-Label, Investigator-Blinded, Stratified, Randomized, Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin|Completed||Phase 1|80|Anticipated|POZEN|||||f||||t||||||||||2018-06-01 03:24:13.542293|2018-06-01 03:24:13.542293
NCT00441506|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2010-08-23|2007-02-28|2007-03-01|Estimate|||||||2010-08-23|2010-08-24|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Effects of Daily Interruption of Sedatives in Critically Ill Children|Effects of Daily Interruption of Sedatives in Critically Ill Children|Completed||N/A|30|Actual|Radboud University|||||f||||f||||||||||2018-06-01 03:24:13.618993|2018-06-01 03:24:13.618993
NCT00441493|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2012-07-26|2007-02-28|2007-03-01|Estimate|||||||2012-07-26|2012-07-27|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|September 2007|Actual|2007-09-30|March 2007|Actual|2007-03-31||Interventional|||Fluvastatin Versus Hepatitis C Virus|A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C With Special Attention to the African-American Population.|Completed||N/A|32||Bader, Ted, M.D.|||||||||||||||||||2018-06-01 03:24:13.681557|2018-06-01 03:24:13.681557
NCT00441480|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2009-07-01||2012-01-12|2007-02-28|2007-03-01|Estimate|2009-08-13|2009-08-14|Estimate||||2012-01-12|2012-01-13|Estimate|March 2007||2007-03-31|January 2012|2012-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels|Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels in Healthy, Hyperlipidemic Subjects|Completed||Phase 4|91|Actual|Enzymotec||2|||f||||t||||||||||2018-06-01 03:24:13.958111|2018-06-01 03:24:13.958111
NCT00441467|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2015-02-16||2015-03-03|2007-02-27|2007-03-01|Estimate|2015-02-16|2015-03-02|Estimate||||2015-03-03|2015-03-25|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma|An Open-Label Phase 2 Study of the Efficacy and Safety of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma|Completed||Phase 2|22|Actual|Eleison Pharmaceuticals LLC.||1|||f||||||||||||||2018-06-01 03:24:14.387234|2018-06-01 03:24:14.387234
NCT00441454|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|||2012-12-09|2007-02-28|2007-03-01|Estimate|||||||2012-12-09|2012-12-11|Estimate|September 2004||2004-09-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Retropubic vs. Transobturator Tension-free Vaginal Tape|Retropubic vs. Transobturator Tension-free Vaginal Tape (TVT vs. TVT-O): A Randomized Trial|Completed||N/A|564|Actual|Austrian Urogynecology Working Group (AUWG)||2|||f||||||||||||||2018-06-01 03:24:14.621462|2018-06-01 03:24:14.621462
NCT00441441|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-28|2009-01-23||2016-11-02|2007-02-28|2007-03-01|Estimate|2010-08-30|2010-09-23|Estimate||||2016-11-02|2016-12-16|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma|A Randomized, Double-blind, Parallel Group Study Evaluating the Safety of Fluticasone Propionate/Salmeterol 100/50mcg HFA (2 Inhalations of 50/25mcg) Twice Daily Compared With Fluticasone Propionate 100mcg HFA (2 Inhalations of 50mcg) Twice Daily in Subjects 4-11 Years of Age With Persistent Asthma|Completed||Phase 3|351|Actual|GlaxoSmithKline|A post-hoc evaluation confirmed that no clinically relevant ECG abnormalities were present. Differences in the primary and post-hoc analyses were associated with variation in the method of ECG interpretation and are not fully interpretable.|2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:24:14.760258|2018-06-01 03:24:14.760258
NCT00441428|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2008-06-02|2007-02-27|2007-02-28|Estimate|||||||2008-06-02|2008-06-04|Estimate|February 2006||2006-02-28|June 2008|2008-06-30||||January 2007||2007-01-31||Observational|||Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity||Completed|||||University of L'Aquila|||||f||||t||||||||||2018-06-01 03:24:15.815147|2018-06-01 03:24:15.815147
NCT00441415|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2008-08-05|2007-02-27|2007-02-28|Estimate|||||||2008-08-05|2008-08-06|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris|Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 0.1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris|Completed||Phase 3|272|Actual|Galderma|||||||||||||||||||2018-06-01 03:24:15.902533|2018-06-01 03:24:15.902533
NCT00441402|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2010-03-01|2007-02-27|2007-02-28|Estimate|||||||2010-03-01|2010-03-02|Estimate||||March 2010|2010-03-31||||||||Observational|||Exercise Amenorrhea Stress and Bone Health in Adolescents||Completed|||||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:24:15.97806|2018-06-01 03:24:15.97806
NCT00441389|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-02-27|2007-02-27|2007-02-28|Estimate|||||||2007-02-27|2007-02-28|Estimate|May 2004||2004-05-31|February 2007|2007-02-28|December 2007||2007-12-31|||||Observational|||Infectious Etiology of Acute Exacerbations of COPD|Infectious Etiology of Acute Exacerbations of COPD in Hong Kong|Completed|||500||Chinese University of Hong Kong|||||f||||f||||||||||2018-06-01 03:24:16.038716|2018-06-01 03:24:16.038716
NCT00441376|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2016-03-04|2007-02-27|2007-02-28|Estimate|||||||2016-03-04|2016-03-07|Estimate|February 2007||2007-02-28|March 2016|2016-03-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver|A Phase I Dose Escalation Tolerability Study of ThermoDox™ (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) of Primary and Metastatic Tumors of the Liver|Completed||Phase 1|30|Actual|Celsion|||||f||||f||||||||||2018-06-01 03:24:16.088965|2018-06-01 03:24:16.088965
NCT00441363|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2010-11-08||2016-04-26|2007-02-27|2007-02-28|Estimate|2016-04-26|2016-05-09|Estimate||||2016-04-26|2016-05-09|Estimate|February 2005||2005-02-28|April 2016|2016-04-30|March 2006|Actual|2006-03-31|February 2006|Actual|2006-02-28||Interventional|||Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin|A Randomized, Double-Blind, Parallel-Group Trial to Assess the Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|66|Actual|VeroScience||2||Failure to Recruit in a Timely manner|f||||f||||||||||2018-06-01 03:24:16.169136|2018-06-01 03:24:16.169136
NCT00441350|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2009-06-03|2007-02-27|2007-02-28|Estimate|||||||2009-06-03|2009-06-04|Estimate|July 2007||2007-07-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension|Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Patients With Essential Hypertension|Completed||Phase 3|1004|Actual|Menarini Group||2|||f||||f||||||||||2018-06-01 03:24:16.42212|2018-06-01 03:24:16.42212
NCT00441337|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2015-01-21||2015-02-05|2007-02-27|2007-02-28|Estimate|2015-02-05|2015-02-20|Estimate||||2015-02-05|2015-02-20|Estimate|August 2006||2006-08-31|February 2015|2015-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|MDX1106-01|All participants who received at least 1 dose or any partial dose of study drug.|A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies|A Phase 1, Open Label, Dose-escalation, Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies|Completed||Phase 1|39|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 03:24:16.595804|2018-06-01 03:24:16.595804
NCT00441324|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-02-27|2007-02-27|2007-02-28|Estimate|||||||2007-02-27|2007-02-28|Estimate|March 2003||2003-03-31|February 2007|2007-02-28|February 2006||2006-02-28|||||Interventional|||Efficacy and Safety of R-hLH (Luveris ®) Priming Prior to R-HFSH Treatment in Infertile Women Undergoing IVF-ET|Efficacy and Safety of R-hLH (Luveris ®) Priming Prior to R-HFSH Treatment in Infertile Women Undergoing IVF-ET|Completed||Phase 4|160||NHS Greater Clyde and Glasgow|||||f||||f||||||||||2018-06-01 03:24:18.681064|2018-06-01 03:24:18.681064
NCT00441311|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2011-01-28|2007-02-27|2007-02-28|Estimate|||||||2011-01-28|2011-02-01|Estimate|May 2003||2003-05-31|January 2011|2011-01-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Dissemination of Colorectal Cancer Screening to Primary Care Physicians|Dissemination of Colorectal Cancer Screening to Primary Care Physicians|Completed||Phase 4|264|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 03:24:18.734179|2018-06-01 03:24:18.734179
NCT00438828|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2014-11-17|2007-02-20|2007-02-22|Estimate|||||||2014-11-17|2014-11-19|Estimate|February 2007||2007-02-28|November 2014|2014-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dexamethasone for the Prophylaxis of Pain Flare Study|Dexamethasone for the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases|Completed||Phase 1|61|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-06-01 03:25:19.636211|2018-06-01 03:25:19.636211
NCT00441298|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2016-01-29|2007-02-27|2007-02-28|Estimate|||||||2016-01-29|2016-02-01|Estimate|May 2007||2007-05-31|January 2016|2016-01-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV|Phase IIb Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel for the Prevention of HIV Infection in Women in South Africa|Completed||Phase 2|889|Actual|Centre for the AIDS Programme of Research in South Africa||2|||f||||t||||||||||2018-06-01 03:24:18.80594|2018-06-01 03:24:18.80594
NCT00441285|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2010-01-28||2015-05-15|2007-02-27|2007-02-28|Estimate|2013-07-03|2013-08-07|Estimate||||2015-05-15|2015-06-11|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional||The population involves 32 patients in the Phase II substudy and 124 patients in the Phase III main study|Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)|Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole|Completed||Phase 2/Phase 3|156|Actual|Universidad Peruana Cayetano Heredia||3|||f||||t||||||||||2018-06-01 03:24:18.893783|2018-06-01 03:24:18.893783
NCT00441272|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2009-04-08||2010-01-29|2007-02-27|2007-02-28|Estimate|2010-01-29|2010-02-19|Estimate||||2010-01-29|2010-02-19|Estimate|February 2007||2007-02-28|October 2008|2008-10-31||||October 2008|Actual|2008-10-31||Interventional|||Pioglitazone to Treat Fatty Liver in People With HIV Infection|Pioglitazone for Hepatic Steatosis in HIV|Completed||Phase 2|100|Actual|National Institutes of Health Clinical Center (CC)|Early termination prior to enrollment leading to no analysis of enrolled participants receiving Pioglitazone or placebo.||||f||||||||||||||2018-06-01 03:24:19.47871|2018-06-01 03:24:19.47871
NCT00441259|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2012-06-06||2012-07-24|2007-02-27|2007-02-28|Estimate|2012-07-24|2012-08-27|Estimate||||2012-07-24|2012-08-27|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age|Randomised, Double Blind, Controlled, Safety, Tolerability and Immunogenicity Phase II Trial of ChimeriVax™-JE and Japanese Encephalitis Inactivated Mouse Brain Vaccine in Children of Descending Age.|Completed||Phase 2|96|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:24:19.72957|2018-06-01 03:24:19.72957
NCT00441246|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2008-02-05|2007-02-27|2007-02-28|Estimate|||||||2008-02-05|2008-02-06|Estimate|February 2007||2007-02-28|February 2008|2008-02-29|July 2007|Actual|2007-07-31|May 2007|Actual|2007-05-31||Interventional|||Phase 4 Study - Mucinex D as Adjunct Therapy|A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Mucinex D as Adjunct Therapy to Antibiotic Treatment of Acute Respiratory Infection|Completed||Phase 4|600|Anticipated|Adams Respiratory Therapeutics|||||f||||t||||||||||2018-06-01 03:24:20.429389|2018-06-01 03:24:20.429389
NCT00441233|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-12-27|2007-02-27|2007-02-28|Estimate|||||||2007-12-27|2008-01-09|Estimate|March 2007||2007-03-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Clinical Performance of Extended Wear Silicone Hydrogel Lenses||Completed||N/A|||University of Melbourne|||||f||||||||||||||2018-06-01 03:24:20.564225|2018-06-01 03:24:20.564225
NCT00441220|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2009-03-04|2007-02-27|2007-02-28|Estimate|||||||2009-03-04|2009-03-05|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|October 2010|Anticipated|2010-10-31|||||Observational|||Cyclophosphamide in Lupus Nephritis|Failure of Cyclophosphamide Therapy in Lupus Nephritis Patients: the Role of Bioactivation Phenotype and Genotype|Unknown status|Recruiting||60|Anticipated|University of Auckland, New Zealand|||2||f||||f||||||||||2018-06-01 03:24:20.661329|2018-06-01 03:24:20.661329
NCT00441207|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2013-04-22|2007-02-26|2007-02-28|Estimate|||||||2013-04-22|2013-04-23|Estimate|August 2006||2006-08-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors|A Phase I Study of High-Dose IV Vitamin C Treatment in Patients With Solid Tumors|Completed||Phase 1|18|Actual|Midwestern Regional Medical Center|||||f||||t||||||||||2018-06-01 03:24:20.786958|2018-06-01 03:24:20.786958
NCT00441194|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2012-03-02|2007-02-27|2007-02-28|Estimate|||||||2012-03-02|2012-03-05|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|May 2007|Actual|2007-05-31|||||Observational|||To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series|To Compare the Octopus 311 and the Humphrey Field Analyzer 700 Series With Respect to Reliability, Reproducibility, Test Duration, Patient Preference, Technician Preference.|Terminated|||80|Anticipated|Haag Streit USA||||Study terminated due to resources|f||||t||||||||||2018-06-01 03:24:20.85142|2018-06-01 03:24:20.85142
NCT00441181|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2011-06-21|2007-02-27|2007-02-28|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2008||2008-01-31|February 2007|2007-02-28|December 2008|Anticipated|2008-12-31|||||Interventional|||Effects of Travoprost on Neovascular Glaucoma|Effects of Travoprost on Neovascular Glaucoma|Withdrawn||N/A|40|Anticipated|Federal University of São Paulo|||||f||||f||||||||||2018-06-01 03:24:21.119406|2018-06-01 03:24:21.119406
NCT00441168|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2009-12-03||2014-02-20|2007-02-27|2007-02-28|Estimate|2014-02-20|2014-03-21|Estimate||||2014-02-20|2014-03-21|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma|A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed After Primary Therapy for Multiple Myeloma|Terminated||Phase 2|30|Actual|Janssen-Cilag International NV|Due to a substantial decline in the use of the VAD regimen as standard of care, recruitment of the study was halted at 30 subjects. It was not possible to statistically evaluate any long term efficacy parameter.|2||"TRIAL STOPPED due to a change in standard of care and the required patient numbers could no~   longer be achieved"|f||||f||||||||||2018-06-01 03:24:21.357937|2018-06-01 03:24:21.357937
NCT00441155|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2013-05-09|2007-02-27|2007-02-28|Estimate|||||||2013-05-09|2013-05-13|Estimate|November 2006||2006-11-30|May 2013|2013-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib|An Extension to a Phase I Multicenter, Dose Escalation Study of Nilotinib in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST)|Completed||Phase 1|14|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:24:22.546505|2018-06-01 03:24:22.546505
NCT00441142|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2015-02-05||2017-11-15|2007-02-27|2007-02-28|Estimate|2015-02-27|2015-03-02|Estimate||||2017-11-15|2017-12-13|Actual|May 2007||2007-05-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|August 2013|Actual|2013-08-31||Interventional|Zactima||Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors|Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma|Active, not recruiting||Phase 1/Phase 2|119|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 03:24:23.037165|2018-06-01 03:24:23.037165
NCT00441129|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-03-05|2007-02-27|2007-02-28|Estimate|||||||2007-03-05|2007-03-06|Estimate|June 2006||2006-06-30|December 2006|2006-12-31|October 2007||2007-10-31|||||Interventional|RTD||Obtain a Good Blood Glucose Control With the Paradigm Real Time System|To Assess Whether Type 1 Diabetic Patients Treated With M D I and in Poor Metabolic Control Can Improve Using the Paradigm® Real Time System Compared to Self-Monitoring Blood Glucose and Continuous Subcutaneous Insulin Infusion|Unknown status|Recruiting|Phase 4|120||Medtronic|||||f||||f||||||||||2018-06-01 03:24:24.905829|2018-06-01 03:24:24.905829
NCT00441116|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2009-01-20||2017-05-30|2007-02-27|2007-02-28|Estimate|2009-03-13|2009-04-22|Estimate||||2017-05-30|2017-06-23|Actual|December 15, 2006||2006-12-15|March 2017|2017-03-31|January 21, 2008|Actual|2008-01-21|January 1, 2008|Actual|2008-01-01||Interventional|||A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia|An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)|Completed||Phase 3|150|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:24:25.168757|2018-06-01 03:24:25.168757
NCT00441103|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2010-05-20||2014-06-06|2007-02-26|2007-02-28|Estimate|2010-05-27|2010-07-05|Estimate||||2014-06-06|2014-07-09|Estimate|December 2006||2006-12-31|June 2014|2014-06-30|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|IMPROVE|Intent to treat (ITT) population included all randomized participants who received at least one dose of study drug.|A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis|A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis|Completed||Phase 3|180|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 03:24:28.22106|2018-06-01 03:24:28.22106
NCT00441090|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|2017-12-04|2013-05-21|2018-02-06|2007-02-27|2007-02-28|Estimate|2017-12-04|2018-01-04|Actual|2013-05-21|2013-05-29|Estimate|2018-02-06|2018-03-07|Actual|February 2007||2007-02-28|February 2018|2018-02-28|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional||Randomized (Intent-to-Treat) population included all participants who were randomly assigned to treatment.|Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).|Completed||Phase 2|64|Actual|Eisai Inc.||2|||f||||f||||||||||2018-06-01 03:24:28.807949|2018-06-01 03:24:28.807949
NCT00441077|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2017-06-30|2007-02-27|2007-02-28|Estimate|||||||2017-06-30|2017-07-02|Actual|February 19, 2007||2007-02-19|August 25, 2009|2009-08-25|December 12, 2007|Actual|2007-12-12|December 12, 2007|Actual|2007-12-12||Interventional|||Interventions to Educate An Underserved Population About Inherited Disease Risks|Using a Communication Intervention to Provide Information About Inherited Risk to Underserved Latino Communities|Completed||N/A|550||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:24:30.052618|2018-06-01 03:24:30.052618
NCT00441064|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2010-12-15||2011-02-28|2007-02-27|2007-02-28|Estimate|2011-02-28|2011-03-25|Estimate||||2011-02-28|2011-03-25|Estimate|January 2007||2007-01-31|February 2011|2011-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren|A Randomized, Open-label, Blinded Endpoint, Multi-center, Cross-over Study to Evaluate the Effect of High and Low Sodium Diets on Reduction in Mean 24-hour Ambulatory Blood Pressure in Systolic Hypertensive Patients Treated With Aliskiren (300 mg)|Completed||Phase 4|132|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:24:30.150251|2018-06-01 03:24:30.150251
NCT00441051|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-27|||2007-02-27|2007-02-27|2007-02-28|Estimate|||||||2007-02-27|2007-02-28|Estimate|November 2006||2006-11-30|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||Efficacy and Safety of Diclofenac Sodium (0.1%) Gel in Patients With UV Induced Painful Sunburn|A Randomized, Double-Blind, Vehicle-Controlled, Single Center, Intra-Individual Comparative Study of the Efficacy and Safety of Diclofenac Sodium 1 mg/g (0.1%) Gel in Subjects With Painful UV-Induced Erythema|Completed||Phase 3|45||Novartis|||||f||||f||||||||||2018-06-01 03:24:30.530949|2018-06-01 03:24:30.530949
NCT00441038|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2011-08-23|2007-02-27|2007-02-28|Estimate|||||||2011-08-23|2011-08-24|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|September 2008|Anticipated|2008-09-30|July 2008|Anticipated|2008-07-31||Interventional|||A Trial on the Effect on Low Back Pain Related Disability of Different Health Education Programs for Retired Persons|Controlled Randomized Clinical Trial on the Effect on Low Back Pain Related Disability of Different Health Education Programs for Retired Persons|Withdrawn||Phase 2|1100|Actual|Kovacs Foundation||3||"Pilot study showed recruitment rates were lower than expected,and number of losses to~   follow-up, much higher."|f||||t||||||||||2018-06-01 03:24:30.589626|2018-06-01 03:24:30.589626
NCT00441025|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2009-06-24|2007-02-26|2007-02-27|Estimate|||||||2009-06-24|2009-06-25|Estimate|September 2006||2006-09-30|February 2007|2007-02-28|August 2009|Anticipated|2009-08-31|||||Interventional|||The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL|A Phase II Study of Alemtuzumab in Combination With CHOP as First-Line Treatment in Peripheral T-Cell Lymphoma|Terminated||Phase 2|4|Actual|Mahidol University||1||a lack of a potential patient.|f||||||||||||||2018-06-01 03:24:30.666959|2018-06-01 03:24:30.666959
NCT00441012|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2009-05-11||2015-03-02|2007-02-26|2007-02-27|Estimate|2009-05-19|2009-07-10|Estimate||||2015-03-02|2015-03-19|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)|A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus Influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process|Completed||Phase 3|546|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:24:30.736857|2018-06-01 03:24:30.736857
NCT00440999|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2009-01-21|2007-02-26|2007-02-27|Estimate|||||||2009-01-21|2009-01-22|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|||Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria|A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-Dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients With Acute Plasmodium Vivax Malaria|Completed||Phase 3|456|Anticipated|Medicines for Malaria Venture|||||f||||t||||||||||2018-06-01 03:24:31.0587|2018-06-01 03:24:31.0587
NCT00440986|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2007-02-28|2007-02-26|2007-02-27|Estimate|||||||2007-02-28|2007-03-01|Estimate|April 2003||2003-04-30|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis|Clinical Management of Hereditary Hemochromatosis: Phlebotomy vs. Erythrocytoapheresis|Completed||Phase 2/Phase 3|25||San Filippo Neri General Hospital|||||f||||f||||||||||2018-06-01 03:24:31.123951|2018-06-01 03:24:31.123951
NCT00440973|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2016-03-15|2007-02-26|2007-02-27|Estimate|||||||2016-03-15|2016-03-17|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer|Phase II Study of Interleukin- 2 and Bevacizumab in Patients With Progressive Metastatic Renal Cell Carcinoma|Terminated||Phase 2|6|Actual|The Methodist Hospital System||1||contract issues|f||||f||||||||No||2018-06-01 03:24:31.194327|2018-06-01 03:24:31.194327
NCT00440960|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2007-02-26|2007-02-26|2007-02-27|Estimate|||||||2007-02-26|2007-02-27|Estimate||||February 2007|2007-02-28||||||||Interventional|||Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic||Completed||Phase 4|||Hospital Pompeia|||||f||||f||||||||||2018-06-01 03:24:31.261702|2018-06-01 03:24:31.261702
NCT00440947|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2011-05-19|2010-05-14|2012-03-15|2007-02-26|2007-02-27|Estimate|2011-07-21|2011-08-17|Estimate|2010-11-18|2010-11-25|Estimate|2012-03-15|2012-03-22|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection|See Detailed Description|Completed||Phase 3|515|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-06-01 03:24:31.377118|2018-06-01 03:24:31.377118
NCT00440934|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-24|||2008-05-02|2007-02-26|2007-02-27|Estimate|||||||2008-05-02|2008-05-06|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Anticipated|2007-12-31||Interventional|THBC002||A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma|Étude de Phase II Pour déterminer l'efficacité Des Ondes électromagnétiques de Basse intensité administrées Par Voie Buccale Dans le Traitement du Cancer du Foie avancé|Terminated||Phase 2|0|Actual|Pasche, Boris, M.D.||||Poor patient accrual|f||||f||||||||||2018-06-01 03:24:33.943595|2018-06-01 03:24:33.943595
NCT00440921|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2015-06-01|2007-02-26|2007-02-27|Estimate|||||||2015-06-01|2015-06-02|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|||Clinical Trial for Fibrin Sealant in Knee Surgery|Randomized Clinical Trial for Fibrin Sealant in Knee Surgery|Withdrawn||N/A|0|Actual|Sanquin Research & Blood Bank Divisions||||No agreement between investigator and sponsor|f||||t||||||||||2018-06-01 03:24:34.011432|2018-06-01 03:24:34.011432
NCT00440908|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2008-05-06|2007-02-26|2007-02-27|Estimate|||||||2008-05-06|2008-05-07|Estimate|March 2007||2007-03-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers|A Prospective Observational Cohort Study Tracking Laboratory Markers for Changes Over Time, After Converting Dialyzer Practice From Reuse to Single Use in Outpatient Dialysis Units|Completed|||2500|Actual|Fresenius Medical Care North America|||||f||||f||||||||||2018-06-01 03:24:34.115852|2018-06-01 03:24:34.115852
NCT00440895|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2013-05-07|2007-02-23|2007-02-27|Estimate|||||||2013-05-07|2013-05-08|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|EASY-RESCUE||A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI|A Randomized Trial of Early Discharge After Trans-Radial Stenting of Coronary Arteries in Acute Myocardial Infarction and RESCUE-PCI: The EASY-RESCUE Pilot Study|Completed||Phase 4|74|Actual|Laval University||3|||f||||t||||||||||2018-06-01 03:24:34.188041|2018-06-01 03:24:34.188041
NCT00440882|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2008-10-08|2007-02-26|2007-02-27|Estimate|||||||2008-10-08|2008-10-09|Estimate|September 2004||2004-09-30|October 2008|2008-10-31||||||||Observational|||Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome|Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome|Completed|||80|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||t||||||||||2018-06-01 03:24:34.374794|2018-06-01 03:24:34.374794
NCT00440869|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2010-03-02|2007-02-26|2007-02-27|Estimate|||||||2010-03-02|2010-03-03|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|NAC||Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis|Effects of N-acetylcysteine on Muscle Fatigue in ESRD|Completed||Phase 1|30|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 03:24:34.460407|2018-06-01 03:24:34.460407
NCT00440856|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2015-06-08|2007-02-26|2007-02-27|Estimate|||||||2015-06-08|2015-06-09|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|POLDAROS||Presentation of Lumbar Disc and Reduction of Symptoms|Reduction in Leg and Back Pain Following Lumbar Microdiscetomy in Those Shown the Removed Disc Fragments After the Operation: a Double Blind Randomized Control Trial.|Completed||N/A|100|Actual|St George's, University of London||2|||f||||f||||||||||2018-06-01 03:24:34.547554|2018-06-01 03:24:34.547554
NCT00440843|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-25|||2013-12-19|2007-02-26|2007-02-27|Estimate|||||||2013-12-19|2013-12-23|Estimate|February 2007||2007-02-28|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Zyprexa and Task Engagement in Schizophrenia|Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia|Withdrawn||Phase 3|0|Actual|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-06-01 03:24:34.675397|2018-06-01 03:24:34.675397
NCT00440830|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2010-10-01||2010-10-29|2007-02-26|2007-02-27|Estimate|2010-10-01|2010-10-27|Estimate||||2010-10-29|2010-11-11|Estimate|December 2005||2005-12-31|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Nicotine Patch as an Analgesic Adjuvant After Surgery|Study to Determine Whether the Use of a Nicotine Patch During the Day of Surgery Improves Postoperative Pain and Reduces Opioid Requirement.|Completed||Phase 4|68|Actual|Columbia University||4|||f||||f||||||||||2018-06-01 03:24:34.781816|2018-06-01 03:24:34.781816
NCT00440817|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2014-04-09|2007-02-26|2007-02-27|Estimate|||||||2014-04-09|2014-04-10|Estimate|February 2006||2006-02-28|April 2014|2014-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.|A Review of Reports of Lymphoma Occurring in Patients With Rheumatoid Arthritis or Crohn's Disease in Centocor-Sponsored and Centocor-Supported Disease Registries|Completed|||120|Actual|Centocor Ortho Biotech Services, L.L.C.|||1||f||||f||||||||||2018-06-01 03:24:35.253822|2018-06-01 03:24:35.253822
NCT00440804|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-02-23|2007-02-23|2007-02-27|Estimate|||||||2007-02-23|2007-02-27|Estimate|December 2002||2002-12-31|February 2007|2007-02-28|August 2005||2005-08-31|||||Interventional|||Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA|Randomized, Double-Blind Study of Ibuprofen L-Lysine Intravenous Solution in Premature Infants for the Early Treatment of Patent Ductus Arteriosus|Completed||Phase 3|||Farmacon|||||f||||t||||||||||2018-06-01 03:24:35.335962|2018-06-01 03:24:35.335962
NCT00440791|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2007-08-01|2007-02-26|2007-02-27|Estimate|||||||2007-08-01|2007-08-03|Estimate|June 2006||2006-06-30|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Observational|||Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon|Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon|Terminated|||40|Actual|Given Imaging Ltd.||||Interim analysis|f||||f||||||||||2018-06-01 03:24:35.430237|2018-06-01 03:24:35.430237
NCT00440778|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2011-11-23|2007-02-26|2007-02-27|Estimate|||||||2011-11-23|2011-11-24|Estimate|February 2007||2007-02-28|November 2011|2011-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|EASY-MI||A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI|A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute Myocardial Infarction: The EASY-MI Pilot Study.|Completed||Phase 4|105|Actual|Laval University||4|||f||||t||||||||||2018-06-01 03:24:35.540585|2018-06-01 03:24:35.540585
NCT00440765|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2014-01-13|2007-02-26|2007-02-27|Estimate|||||||2014-01-13|2014-01-14|Estimate|November 2004||2004-11-30|January 2014|2014-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands|A Post Authorization Study, Designed to Learn More About the Safety and Efficacy of the Use of VELCADE (Bortezomib) in the Netherlands|Completed|||331|Actual|Janssen-Cilag B.V.|||1||f||||f||||||||||2018-06-01 03:24:35.623952|2018-06-01 03:24:35.623952
NCT00440752|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2008-03-25|2007-02-26|2007-02-27|Estimate|||||||2008-03-25|2008-03-26|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Observational|||The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance|The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance in an Area of Seasonal Transmission|Completed|||100|Actual|Tropical Medicine Research Institute|||1||f||||f||||||Samples With DNA|"~     Blood spots on glass fibre membranes. 0.5ml of whole blood preserved in TRI reagent.~   "|||2018-06-01 03:24:35.882075|2018-06-01 03:24:35.882075
NCT00440739|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2009-02-04|2007-02-26|2007-02-27|Estimate|||||||2009-02-04|2009-02-05|Estimate|September 2005||2005-09-30|February 2007|2007-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)|Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy: A Factorial Randomized Controlled Trial|Completed||Phase 4|128|Actual|Mahidol University||4|||f||||f||||||||||2018-06-01 03:24:35.98924|2018-06-01 03:24:35.98924
NCT00440726|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2012-06-29|2007-02-26|2007-02-27|Estimate|||||||2012-06-29|2012-07-03|Estimate|June 2006||2006-06-30|June 2012|2012-06-30||||February 2011|Actual|2011-02-28||Interventional|||Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)|A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia|Completed||Phase 1/Phase 2|31|Actual|Therapeutic Advances in Childhood Leukemia Consortium|||||f||||t||||||||||2018-06-01 03:24:36.113186|2018-06-01 03:24:36.113186
NCT00440713|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-02-23|2007-02-23|2007-02-27|Estimate|||||||2007-02-23|2007-02-27|Estimate|January 2004||2004-01-31|February 2007|2007-02-28|March 2006||2006-03-31|||||Interventional|AripipPTSD||Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms|Phase 3 Study of Aripriprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms|Completed||Phase 3|40||Federal University of São Paulo|||||f||||t||||||||||2018-06-01 03:24:36.242602|2018-06-01 03:24:36.242602
NCT00440700|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2012-05-23||2013-04-24|2007-02-23|2007-02-27|Estimate|2013-04-24|2013-04-26|Estimate||||2013-04-24|2013-04-26|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation|Reducing Sedative Exposure in Ventilated ICU Patients|Completed||Phase 2|364|Actual|University of Minnesota - Clinical and Translational Science Institute|Overall limitations of the trial include the challenges of obtaining informed consent from patients' themselves. Many times patients were too sedated or not alert enough to participate in the consent process.|3|||f||||t||||||||||2018-06-01 03:24:36.385486|2018-06-01 03:24:36.385486
NCT00440687|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2007-02-26|2007-02-26|2007-02-27|Estimate|||||||2007-02-26|2007-02-27|Estimate|January 2001||2001-01-31|February 2007|2007-02-28|March 2004||2004-03-31|||||Interventional|||Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care|Phase 4 Withdrawal of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease in Primary Care: a Randomised Controlled Trial|Completed||Phase 4|256||Queen Mary University of London|||||f||||t||||||||||2018-06-01 03:24:36.850968|2018-06-01 03:24:36.850968
NCT00440674|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2009-10-29|2007-02-26|2007-02-27|Estimate|||||||2009-10-29|2009-10-30|Estimate|February 2007||2007-02-28|October 2009|2009-10-31|July 2009|Actual|2009-07-31|June 2007|Actual|2007-06-30||Interventional|DECIDE||Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)|The DECIDE Trial: Prospective, Multi-center, Randomized Study to Evaluate the CoStar Paclitaxel-Eluting Coronary Stent System Using a Direct Stenting Technique Compared to Conventional Stenting With Pre-dilatation Strategy|Terminated||Phase 4|18|Actual|Conor Medsystems||2|||f||||f||||||||||2018-06-01 03:24:36.988412|2018-06-01 03:24:36.988412
NCT00440661|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2010-03-03|2007-02-26|2007-02-27|Estimate|||||||2010-03-03|2010-03-04|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Exploration of the Synovial Fluid Inflammation Mediators Under Diacerhein in Knee Osteoarthritis|Exploratory Study of Some Synovial Fluid Inflammation Mediatorsunder Diacerhein in Knee Osteoarthritis Patients. Phase IV Study.|Completed||Phase 4|96|Anticipated|Laboratoires NEGMA|||||f||||f||||||||||2018-06-01 03:24:37.109451|2018-06-01 03:24:37.109451
NCT00440648|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-24|||2014-03-17|2007-02-24|2007-02-27|Estimate|||||||2014-03-17|2014-03-19|Estimate|March 2005||2005-03-31|March 2014|2014-03-31|July 2006|Actual|2006-07-31|March 2006|Actual|2006-03-31||Interventional|||Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate|A Double-Blind, Cross-Over Design Study of Sevelamer Hydrochloride (Renagel®) and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis|Completed||Phase 2|80|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:24:37.178278|2018-06-01 03:24:37.178278
NCT00440635|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2013-04-15|2007-02-26|2007-02-27|Estimate|||||||2013-04-15|2013-04-16|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|October 2006|Actual|2006-10-31|||||Observational|||Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma|International Single-Arm Protocol to Provide Expanded Access to Bortezomib for Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma|Completed|||641|Actual|Janssen-Cilag International NV|||||f||||||||||||||2018-06-01 03:24:37.313788|2018-06-01 03:24:37.313788
NCT00440622|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2013-02-12|2007-02-26|2007-02-27|Estimate|||||||2013-02-12|2013-02-13|Estimate|April 2003||2003-04-30|February 2013|2013-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients|A Multicenter Randomized Phase III Study of Gemcitabine Plus Herceptin Combination Versus the Capecitabine Plus Herceptin Combination in Pretreated Patients With HER-2 Positive Metastatic Breast Cancer|Terminated||Phase 3|90|Actual|Hellenic Oncology Research Group||2||Due to poor accrual|f||||f||||||||||2018-06-01 03:24:37.386625|2018-06-01 03:24:37.386625
NCT00440609|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2013-08-01|2007-02-23|2007-02-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema|A Phase I/II Study Comparing the Treatment of Clinically Significant Diabetic Macular Edema (CSDME) With 0.5mg Ranibizumab, 1.0mg Ranibizumab and 2.0mg Ranibizumab|Completed||Phase 1/Phase 2|50|Actual|Long Island Vitreoretinal Consultants||2|||f||||t||||||||||2018-06-01 03:24:37.508574|2018-06-01 03:24:37.508574
NCT00440596|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2009-05-18|2007-02-26|2007-02-27|Estimate|||||||2009-05-18|2009-05-19|Estimate|September 2006||2006-09-30|May 2009|2009-05-31||||May 2010|Anticipated|2010-05-31||Interventional|||Mindfulness Based Stress Reduction for High Blood Pressure|Mindfulness Based Stress Reduction for High Blood Pressure|Unknown status|Recruiting|N/A|84|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 03:24:37.66876|2018-06-01 03:24:37.66876
NCT00440583|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2015-01-28|2007-02-26|2007-02-27|Estimate|||||||2015-01-28|2015-01-30|Estimate|September 2006||2006-09-30|January 2015|2015-01-31|May 2012|Actual|2012-05-31|September 2011|Actual|2011-09-30||Interventional|||The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP|Yt90 Zevalin & Combination Chemotherapy in Treating Patients With Stage II,Stage III,or Stage IV Diffuse Large B-cell Lymphoma|Completed||Phase 2|15|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 03:24:37.815341|2018-06-01 03:24:37.815341
NCT00440570|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-24|||2011-06-28|2007-02-26|2007-02-27|Estimate|||||||2011-06-28|2011-06-29|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|September 2006|Actual|2006-09-30||Interventional|THBC001||A Study of Therapeutic Amplitude-modulated Electromagnetic Fields in Advanced Tumors|Treatment of Advanced Cancer With Amplitude-modulated Electromagnetic Fields of Low Intensity by Means of an Intrabuccal Probe|Completed||Early Phase 1|2||Pasche, Boris, M.D.|||||f||||f||||||||||2018-06-01 03:24:37.928591|2018-06-01 03:24:37.928591
NCT00440557|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2009-02-23||2014-04-22|2007-02-26|2007-02-27|Estimate|2010-02-02|2010-02-08|Estimate||||2014-04-22|2014-05-07|Estimate|September 2006||2006-09-30|April 2014|2014-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease|A Randomized, Open Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens, Once-Weekly and Every-Two-Weeks, With the Three-Times-Weekly Dosing Regimen for Initiation and Maintenance Treatment in Anemic Subjects With Chronic Kidney Disease|Completed||Phase 3|375|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||t||||||||||2018-06-01 03:24:38.045132|2018-06-01 03:24:38.045132
NCT00440544|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2008-10-31|2007-02-26|2007-02-27|Estimate|||||||2008-10-31|2008-11-03|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|February 2008|Actual|2008-02-29|November 2007|Actual|2007-11-30||Interventional|TMUVA-01||A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)|A Phase I Trial of the Safety and Immunogenicity of an Adjuvated TB Subunit Vaccine (Ag85B-ESAT6 + LTK63) Administered at 0 and 2 Months|Terminated||Phase 1|9|Actual|St George's, University of London||6||Safety Issues|f||||t||||||||||2018-06-01 03:24:39.314952|2018-06-01 03:24:39.314952
NCT00440531|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2008-11-11||2017-03-16|2007-02-26|2007-02-27|Estimate|2009-02-27|2009-03-31|Estimate||||2017-03-16|2017-04-13|Actual|November 2006||2006-11-30|March 2017|2017-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)|A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process|Completed||Phase 3|540|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:24:39.498898|2018-06-01 03:24:39.498898
NCT00440518|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2009-08-03||2017-07-28|2007-02-26|2007-02-27|Estimate|2009-08-03|2009-09-11|Estimate||||2017-07-28|2017-08-28|Actual|February 2007||2007-02-28|July 2017|2017-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|SP906||A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.|Completed||Phase 2|218|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 03:24:39.968131|2018-06-01 03:24:39.968131
NCT00440505|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2010-10-01||2011-01-12|2007-02-26|2007-02-27|Estimate|2011-01-12|2011-02-09|Estimate||||2011-01-12|2011-02-09|Estimate|February 2004||2004-02-29|January 2011|2011-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of Nicotine on Chronic Pelvic Pain|Effect of Nicotine on Chronic Pelvic Pain|Completed||Phase 4|20|Actual|Columbia University||3|||f||||f||||||||||2018-06-01 03:24:40.642523|2018-06-01 03:24:40.642523
NCT00440492|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-12-11|2007-02-26|2007-02-27|Estimate|||||||2007-12-11|2007-12-13|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis|An Open-Label Study To Evaluate The Potential Pharmacokinetic Interaction Between PLA-695 And Methotrexate When Coadministered Orally To Adult Subjects With Rheumatoid Arthritis|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:24:40.980356|2018-06-01 03:24:40.980356
NCT00440479|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2015-04-15|2007-02-26|2007-02-27|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.|An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)|Completed|||11|Actual|Janssen-Cilag B.V.|||1||f||||f||||||||||2018-06-01 03:24:41.04424|2018-06-01 03:24:41.04424
NCT00440466|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2010-05-13||2014-04-02|2007-02-26|2007-02-27|Estimate|2011-03-14|2011-04-14|Estimate||||2014-04-02|2014-04-21|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients|A Randomized, Open-label, Multicenter Study of Epoetin Alfa Comparing Two Extended Dosing Regimens, Once-every-two-weeks and Once-every-four-weeks, With the Once-weekly Dosing Regimen for Maintenance Treatment in Anemic Subjects With Chronic Kidney Disease|Completed||Phase 3|430|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||t||||||||||2018-06-01 03:24:41.163447|2018-06-01 03:24:41.163447
NCT00440453|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2011-09-22|2007-02-23|2007-02-27|Estimate|||||||2011-09-22|2011-09-23|Estimate|February 2007||2007-02-28|September 2011|2011-09-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|EMS||Feeding the Patient at Nutritional Risk: Does the Clinical Outcome Improve?|Feeding the Patient at Nutritional Risk: Does the Clinical Outcome Improve?|Completed||Phase 4|200|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-06-01 03:24:42.492657|2018-06-01 03:24:42.492657
NCT00440440|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2015-08-06|2007-02-26|2007-02-27|Estimate|||||||2015-08-06|2015-08-10|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|July 2012|Anticipated|2012-07-31|November 2011|Anticipated|2011-11-30||Interventional|||Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes|Effect of Androgel on Total and Regional Adipose Tissue and Lean Body Mass in Type 2 Diabetic Patients With Hypogonadism|Withdrawn||Phase 4|0|Actual|Diabetes Center of the Southwest||2||study merged with another study|f||||f||||||||||2018-06-01 03:24:42.573896|2018-06-01 03:24:42.573896
NCT00440427|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-12-03|2007-02-23|2007-02-27|Estimate|||||||2007-12-03|2007-12-05|Estimate|February 2007||2007-02-28|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)|A Randomized, Open-Label, Single-Dose Parallel Group Study of the Pharmacokinetic Profile, Safety, and Tolerability of 25- and 50-mg Desvenlafaxine Sustained Release (DVS SR) in Healthy Subjects|Completed||Phase 1|12||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:24:42.66078|2018-06-01 03:24:42.66078
NCT00440414|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2010-08-18|2007-02-26|2007-02-27|Estimate|||||||2010-08-18|2010-08-19|Estimate|April 2006||2006-04-30|August 2010|2010-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 3|320|Anticipated|Hellenic Oncology Research Group||2|||f||||f||||||||||2018-06-01 03:24:42.778054|2018-06-01 03:24:42.778054
NCT00440401|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2010-05-07||2012-05-04|2007-02-26|2007-02-27|Estimate|2010-05-07|2010-06-04|Estimate||||2012-05-04|2012-05-08|Estimate|February 2007||2007-02-28|July 2010|2010-07-31|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||TachoSil® Versus Standard Haemostatic Treatment of Haemorrhage in Cardiovascular Surgery (TC-023-IM)|A Randomised, Open Label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety of TachoSil® Versus Standard Haemostatic Treatment in Cardiovascular Surgery|Completed||Phase 4|120|Actual|Nycomed||2|||f||||t||||||||||2018-06-01 03:24:42.927497|2018-06-01 03:24:42.927497
NCT00440388|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23||2010-08-12|2010-08-24|2007-02-26|2007-02-27|Estimate||||2010-08-12|2010-08-17|Estimate|2010-08-24|2010-08-27|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma|An Open-label, Multicenter, Phase II Study of AT-101 in Combination With Rituximab in Patients With Untreated, Grade I-II, Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|23|Actual|Ascenta Therapeutics|||||f||||||||||||||2018-06-01 03:24:43.500379|2018-06-01 03:24:43.500379
NCT00440375|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|||2007-02-26|2007-02-26|2007-02-27|Estimate|||||||2007-02-26|2007-02-27|Estimate|June 2005||2005-06-30|February 2007|2007-02-28|March 2006||2006-03-31|||||Interventional|||Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women||Completed||Phase 4|82||Baskent University|||||f||||t||||||||||2018-06-01 03:24:43.673414|2018-06-01 03:24:43.673414
NCT00440362|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2008-11-07|2007-02-26|2007-02-27|Estimate|||||||2008-11-07|2008-11-10|Estimate|April 2007||2007-04-30|November 2008|2008-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza|A Single-Site, Phase 1/2, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Healthy Volunteers|Completed||Phase 1/Phase 2|216|Actual|AlphaVax, Inc.||12|||f||||t||||||||||2018-06-01 03:24:43.727734|2018-06-01 03:24:43.727734
NCT00440349|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-02-23|2007-02-23|2007-02-27|Estimate|||||||2007-02-23|2007-02-27|Estimate|October 2000||2000-10-31|February 2007|2007-02-28|April 2007||2007-04-30|||||Interventional|||Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis|A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis|Unknown status|Active, not recruiting|Phase 2|38||University of Parma|||||f||||f||||||||||2018-06-01 03:24:43.823111|2018-06-01 03:24:43.823111
NCT00440336|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-24|||2007-02-28|2007-02-26|2007-02-27|Estimate|||||||2007-02-28|2007-03-01|Estimate|October 2006||2006-10-31|February 2007|2007-02-28||||||||Interventional|||Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.|Comparison of Efficacy of Prostaglandin Analogues (Xalatan) and Aqueous Suppressants (Cosopt) in Reducing Intraocular Pressure Following Selective Laser Trabeculoplasty in the Management of Open-Angle Glaucoma.|Unknown status|Recruiting|N/A|30||Advanced Glaucoma Specialists|||||f||||f||||||||||2018-06-01 03:24:43.902493|2018-06-01 03:24:43.902493
NCT00440323|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2017-08-15|2007-02-26|2007-02-27|Estimate|||||||2017-08-15|2017-08-17|Actual|January 5, 2007|Actual|2007-01-05|August 2017|2017-08-31|July 3, 2007|Actual|2007-07-03|July 3, 2007|Actual|2007-07-03||Interventional|||Disturbed Sleep Model Study.|A Double-blind, Double-dummy, Randomised, Placebo-controlled,Four-way Crossover Study to Investigate the Effect of Single Oral Doses of SB-649868 and of Zolpidem in a Model of Noise Induced Situational Insomnia in Healthy Male Volunteers.|Completed||Phase 1|52|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:24:44.014848|2018-06-01 03:24:44.014848
NCT00440310|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2015-07-28|2015-01-09|2015-07-28|2007-02-23|2007-02-27|Estimate|2015-07-28|2015-08-25|Estimate|2015-01-09|2015-01-22|Estimate|2015-07-28|2015-08-25|Estimate|February 2007||2007-02-28|July 2015|2015-07-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional||All patients randomized/enrolled|Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases|A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Treating Colorectal Cancer Patients With Recurrent Liver Metastases Using the Litx™ System Plus Chemotherapy as Compared to Chemotherapy Only|Completed||Phase 3|483|Actual|Light Sciences Oncology||2|||f||||t||||||||||2018-06-01 03:24:44.125083|2018-06-01 03:24:44.125083
NCT00440297|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2009-03-24||2017-03-16|2007-02-26|2007-02-27|Estimate|2009-05-18|2009-07-08|Estimate||||2017-03-16|2017-04-13|Actual|December 2006||2006-12-31|March 2017|2017-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||All vaccinated participants|Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)|A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process|Completed||Phase 3|277|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:24:44.762113|2018-06-01 03:24:44.762113
NCT00440284|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2007-02-23|2007-02-23|2007-02-27|Estimate|||||||2007-02-23|2007-02-27|Estimate|January 2004||2004-01-31|February 2007|2007-02-28|December 2004||2004-12-31|||||Interventional|||Flexible, Intensive vs. Conventional Insulin Therapy in Insulin-Naive Adults With Type 2 Diabetes|Flexible, Intensive vs. Conventional Insulin Therapy in Insulin-Naive Adults With Type 2 Diabetes - a Non-Blinded, Randomized Controlled Cross-Over Clinical Trial of Metabolic Control and Patient Preference|Unknown status|Active, not recruiting|Phase 3|38||University of Jena|||||f||||f||||||||||2018-06-01 03:24:45.266406|2018-06-01 03:24:45.266406
NCT00440271|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-26|2009-10-20||2014-06-17|2007-02-26|2007-02-27|Estimate|2009-10-20|2009-11-26|Estimate||||2014-06-17|2014-06-27|Estimate|February 2007||2007-02-28|January 2014|2014-01-31||||October 2008|Actual|2008-10-31||Interventional|||SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC|SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care|Terminated||Phase 3|33|Actual|Boehringer Ingelheim|The study was terminated early due to low patient enrollment, and, therefore, no analysis was performed on the primary and secondary endpoints|2|||f||||||||||||||2018-06-01 03:24:45.367757|2018-06-01 03:24:45.367757
NCT00440258|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-02-26|2007-02-23|2007-02-26|Estimate|||||||2007-02-26|2007-02-27|Estimate|April 2004||2004-04-30|February 2007|2007-02-28|July 2006||2006-07-31|||||Interventional|||Cabergoline Reduces OHSS|Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction.|Completed||Phase 3|60||Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-06-01 03:24:45.885668|2018-06-01 03:24:45.885668
NCT00440245|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-06-12|2007-02-22|2007-02-26|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2007||2007-02-28|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease|Bronchoprotection of Salbutamol in Asthma and COPD|Recruiting||Phase 4|20|Anticipated|University of Saskatchewan||1|||f||||f||||||||No||2018-06-01 03:24:45.947717|2018-06-01 03:24:45.947717
NCT00440232|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2010-10-26||2011-05-23|2007-02-23|2007-02-26|Estimate|2010-10-27|2010-11-18|Estimate||||2011-05-23|2011-05-26|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting|A Pilot Trial Examining the Safety and Efficacy of Frovatriptan as a Preemptive Treatment for Fasting-Induced Migraine Headache|Completed||N/A|74|Actual|Thomas Jefferson University||2|||f||||||||||||||2018-06-01 03:24:46.06647|2018-06-01 03:24:46.06647
NCT00440219|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2014-01-08|2007-02-22|2007-02-26|Estimate|||||||2014-01-08|2014-01-10|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy.|The Effect of Preoperative Oral Prednisone on the Operative Field During Nasal Polypectomy.|Completed||Phase 3|34|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||t||||||||||2018-06-01 03:24:46.361271|2018-06-01 03:24:46.361271
NCT00440206|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-02-26|2007-02-23|2007-02-26|Estimate|||||||2007-02-26|2007-02-27|Estimate|September 2001||2001-09-30|February 2007|2007-02-28|December 2001||2001-12-31|||||Observational|||Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes|Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes|Completed|||50||Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 03:24:46.450303|2018-06-01 03:24:46.450303
NCT00440193|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2012-11-22|2011-12-21|2014-01-26|2007-02-23|2007-02-26|Estimate|2013-01-22|2013-01-24|Estimate|2011-12-21|2011-12-22|Estimate|2014-01-26|2014-02-27|Estimate|March 2007||2007-03-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study|Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism|Completed||Phase 3|3449|Actual|Bayer||2|||f||||t||||||||||2018-06-01 03:24:46.637787|2018-06-01 03:24:46.637787
NCT00440180|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2016-02-05||2016-03-08|2007-02-23|2007-02-26|Estimate|2016-02-05|2016-03-07|Estimate||||2016-03-08|2016-04-06|Estimate|March 2007||2007-03-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Aromatase Inhibitors in the Treatment of Male Infertility|The Role of Aromatase Inhibitors in the Treatment of Infertility in Obese Male|Terminated||Phase 3|20|Actual|University of Utah||2||Not able meet target enrollment.|f||||t||||||||||2018-06-01 03:24:49.868871|2018-06-01 03:24:49.868871
NCT00440167|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2012-07-05|2007-02-22|2007-02-26|Estimate|||||||2012-07-05|2012-07-09|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine|Randomized Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 3|280|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||||||||||||2018-06-01 03:24:50.187214|2018-06-01 03:24:50.187214
NCT00440154|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2008-12-15|2007-02-23|2007-02-26|Estimate|||||||2008-12-15|2008-12-16|Estimate|February 2007||2007-02-28|December 2008|2008-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Ezetimibe-Calibrated, Multicenter Study Evaluating the Safety and Efficacy of Four Doses and Two Dose-Regimens of AVE5530 Over 4 Weeks in Patients With Mild to Moderate Primary Hypercholesterolemia|Completed||Phase 2|206|Actual|Sanofi||7|||f||||||||||||||2018-06-01 03:24:50.306796|2018-06-01 03:24:50.306796
NCT00440141|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-12-26|2007-02-22|2007-02-26|Estimate|||||||2007-12-26|2008-01-02|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%||Completed||Phase 4|40|Actual|Allergan||2|||f||||||||||||||2018-06-01 03:24:50.434047|2018-06-01 03:24:50.434047
NCT00440128|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-08-02|2007-02-22|2007-02-26|Estimate|||||||2017-08-02|2017-08-04|Actual|May 4, 2007|Actual|2007-05-04|August 2017|2017-08-31|July 17, 2008|Actual|2008-07-17|July 17, 2008|Actual|2008-07-17||Interventional|||The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer|A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:24:50.51483|2018-06-01 03:24:50.51483
NCT00440115|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2017-03-23||2017-05-08|2007-02-23|2007-02-26|Estimate|2017-05-08|2017-06-07|Actual||||2017-05-08|2017-06-07|Actual|June 2009||2009-06-30|May 2017|2017-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Disease Management for Smoking Cessation|Disease Management for Smokers in Rural Primary Care|Completed||Phase 3|750|Actual|University of Kansas Medical Center||3|||f||||f|t|f|||f|||||2018-06-01 03:24:50.684316|2018-06-01 03:24:50.684316
NCT00440102|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2011-09-21|2007-02-23|2007-02-26|Estimate|||||||2011-09-21|2011-09-22|Estimate|April 2007||2007-04-30|May 2007|2007-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|KETASED||Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity|Ketamine Versus Etomidate During Rapid Sequence Intubation: Consequences on Hospital Morbidity|Completed||Phase 4|655|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:24:51.571126|2018-06-01 03:24:51.571126
NCT00440089|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2010-05-24|2007-02-23|2007-02-26|Estimate|||||||2010-05-24|2010-05-25|Estimate|October 2005||2005-10-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effects of Hands-on-Healing vs. Touch for Fatigued Breast Cancer Survivors|Effects of Hands-on-Healing vs. Touch for Fatigue and Inflammation in Breast Cancer Survivors|Completed||Phase 2/Phase 3|76|Actual|University of California, San Diego|||||f||||||||||||||2018-06-01 03:24:51.694709|2018-06-01 03:24:51.694709
NCT00440076|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2015-04-21|2007-02-23|2007-02-26|Estimate|||||||2015-04-21|2015-04-23|Estimate|August 2006||2006-08-31|April 2015|2015-04-30|March 2008|Actual|2008-03-31|||||Interventional|||Velcade in Myelodysplastic Syndrome - Pilot Study|Phase II Study of PS341 (VELCADE) in Myelodysplastic Syndromes (MDS). EudraCT Number 2004-002935-23|Terminated||Phase 2|28|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto||||Low accrual|f||||||||||||||2018-06-01 03:24:51.81539|2018-06-01 03:24:51.81539
NCT00440063|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-12-18|2007-02-23|2007-02-26|Estimate|||||||2007-12-18|2007-12-20|Estimate||||December 2007|2007-12-31||||||||Interventional|||A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.|A Randomized Study to Compare the Safety and Effectiveness of Two Monitoring Schedules to Maintain Hemoglobin Levels and Iron Parameters in Patients With Renal Anemia Receiving NeoRecormon|Terminated||Phase 4|||Hoffmann-La Roche|||||f||||||||||||||2018-06-01 03:24:51.887|2018-06-01 03:24:51.887
NCT00440050|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2010-05-28||2014-09-15|2007-02-22|2007-02-26|Estimate|2010-07-28|2010-08-30|Estimate||||2014-09-15|2014-09-25|Estimate|February 2007||2007-02-28|September 2014|2014-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|DHA||DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease|A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease|Completed||Phase 3|402|Actual|Alzheimer's Disease Cooperative Study (ADCS)||2|||f||||t||||||||||2018-06-01 03:24:51.971229|2018-06-01 03:24:51.971229
NCT00440037|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2014-09-11|2007-02-22|2007-02-26|Estimate|||||||2014-09-11|2014-09-12|Estimate|November 2006||2006-11-30|September 2014|2014-09-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Open Label Extension Study of AMG 531 in Japanese Subjects With ITP|An Open Label Extension Study Evaluating the Safety and Efficacy of Long Term Dosing of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura|Completed||Phase 2/Phase 3|44|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 03:24:52.37759|2018-06-01 03:24:52.37759
NCT00440024|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-02-25|2007-02-23|2007-02-26|Estimate|||||||2017-02-25|2017-02-28|Actual|February 2007||2007-02-28|February 2017|2017-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance|A Single-Blind Study to Assess Benefits of a Controlled Daily Skin Care Regimen on Retinoid Intolerant Patients (Derm 570)|Completed||N/A|40|Actual|University of Michigan||2|||f||||f|f|f||||||||2018-06-01 03:24:52.476349|2018-06-01 03:24:52.476349
NCT00440011|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2008-09-25||2013-07-16|2007-02-22|2007-02-26|Estimate|2008-09-25|2008-09-26|Estimate||||2013-07-16|2013-07-22|Estimate|August 2006||2006-08-31|July 2013|2013-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%||Completed||Phase 4|266|Actual|Allergan||2|||f||||||||||||||2018-06-01 03:24:52.59193|2018-06-01 03:24:52.59193
NCT00439998|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2009-07-29|2007-02-22|2007-02-26|Estimate|||||||2009-07-29|2009-07-30|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Ultrasound Imaging For Facilitating Labour Epidurals in Obese Parturients|Ultrasound Imaging For Facilitating Labour Epidurals in Obese Parturients|Completed||N/A|54|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||||f||||f||||||||||2018-06-01 03:24:52.855153|2018-06-01 03:24:52.855153
NCT00439985|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2011-06-06|2007-02-23|2007-02-26|Estimate|||||||2011-06-06|2011-06-08|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Improving Metabolic Control in Diabetic Young Children|Improving Metabolic Control in Diabetic Young Children|Terminated||N/A|23|Actual|Icahn School of Medicine at Mount Sinai||1||decreased enrollment. (there are no data results for this study)|f||||f||||||||||2018-06-01 03:24:52.943393|2018-06-01 03:24:52.943393
NCT00439972|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2011-02-10|2007-02-23|2007-02-26|Estimate|||||||2011-02-10|2011-02-14|Estimate|February 2007||2007-02-28|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity|Comparison of Oral and Patch Forms of Hormonal Contraception on Plasma Lipoproteins, Glycemia, Clotting Factors, Indices of Inflammation and Vascular Reactivity|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|University of Washington||6|||f||||t||||||||||2018-06-01 03:24:53.106267|2018-06-01 03:24:53.106267
NCT00439959|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2012-05-31|2007-02-22|2007-02-26|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2006||2006-10-31|March 2011|2011-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults|A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK625433 in Healthy Subjects and in Subjects Who Are Chronically Infected With Hepatitis C.|Terminated||Phase 1|48|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:24:53.209766|2018-06-01 03:24:53.209766
NCT00439946|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2013-03-26||2013-06-12|2007-02-22|2007-02-26|Estimate|2013-06-12|2013-07-17|Estimate||||2013-06-12|2013-07-17|Estimate|February 2007||2007-02-28|June 2013|2013-06-30|March 2011|Actual|2011-03-31|September 2009|Actual|2009-09-30||Interventional|||Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH|Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) Using the Crono Five Ambulatory Infusion Pump in Patients With Stable Pulmonary Arterial Hypertension (PAH): Safety, Efficacy and Treatment Satisfaction|Terminated||Phase 4|8|Actual|United Therapeutics|The main limitations of this study are the modest sample size and relatively short duration of follow-up.|1||"Study closed due to limited availability of eligible subjects and competition by for enrollment~   by other studies"|f||||f||||||||||2018-06-01 03:24:53.317771|2018-06-01 03:24:53.317771
NCT00439933|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-05-08|2007-02-22|2007-02-26|Estimate|||||||2007-05-08|2007-05-09|Estimate|April 2007||2007-04-30|March 2007|2007-03-31||||||||Interventional|||Weight Loss in Obese Children and Adolescents and Its Effect on Improvement of Destructive Changes in Blood Vessels|Weight Loss in Obese Children and Adolescents and Its Effect on Improvement of Endothelial Dysfunction|Unknown status|Recruiting|N/A|180|Anticipated|Heidelberg University|||||f||||||||||||||2018-06-01 03:24:53.811226|2018-06-01 03:24:53.811226
NCT00439582|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2009-03-13|2007-02-21|2007-02-23|Estimate|||||||2009-03-13|2009-03-16|Estimate|August 2005||2005-08-31|March 2009|2009-03-31|December 2005||2005-12-31|||||Interventional|TRANSFACT1||Trans Fatty Acids and Cardiovascular Risk Factors|Comparative Effect of 2 Different Sources of Trans Fatty Acid (Milk Fat vs Hydrogenated Oil)on Cardiovascular Risk Factors in Healthy Humans|Completed||N/A|46||Institut National de la Recherche Agronomique||2|||f||||||||||||||2018-06-01 03:25:04.803311|2018-06-01 03:25:04.803311
NCT00439920|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2018-02-20|2007-02-23|2007-02-26|Estimate|||||||2018-02-20|2018-02-22|Actual|October 1996|Actual|1996-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.|GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult Acute Lymphoblastic Leukemia. A Prospective Multicentric GIMEMA Trial.|Active, not recruiting||Phase 2|||Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f|f|f||||||||2018-06-01 03:24:53.902551|2018-06-01 03:24:53.902551
NCT00439907|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2015-07-27|2007-02-23|2007-02-26|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2005||2005-02-28|August 2010|2010-08-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Comparison of Overlap and End-to-end Repair in Anal Sphincter Rupture During Delivery|A Prospective, Randomized Study Comparing the Outcome of Overlap and End-to-end Repair in Anal Sphincter Rupture During Delivery|Completed||N/A|160|Actual|Helse Stavanger HF||2|||f||||f||||||||||2018-06-01 03:24:54.020216|2018-06-01 03:24:54.020216
NCT00439894|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2008-03-20|2007-02-22|2007-02-26|Estimate|||||||2008-03-20|2008-03-21|Estimate|December 2006||2006-12-31|March 2008|2008-03-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Observational|||Ancillary Study to Protocol 20060104|Protein Phosphorylation Ancillary Study to Amgen Protocol 20060104: Open Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis|Completed|||50|Actual|Amgen|||1||f||||||||||None Retained|"~     no biospecimens will be retained.~   "|||2018-06-01 03:24:54.109634|2018-06-01 03:24:54.109634
NCT00439881|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2012-05-31|2007-02-23|2007-02-26|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2006||2006-10-31|February 2011|2011-02-28||||||||Interventional|||A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose|A Study to Assess the Safety and Tolerability of SB-681323 Administered Via the Intravenous Route|Completed||Phase 1|16||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:24:54.316685|2018-06-01 03:24:54.316685
NCT00439868|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-08-09|2007-02-22|2007-02-26|Estimate|||||||2017-08-09|2017-08-10|Actual|February 16, 2007|Actual|2007-02-16|August 2017|2017-08-31|June 8, 2007|Actual|2007-06-08|June 8, 2007|Actual|2007-06-08||Interventional|||A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure|A Cross-over Study to Evaluate the Effect of WELLBUTRIN XL on Intraocular Pressure in Healthy Volunteers|Completed||Phase 1|33|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:24:54.446163|2018-06-01 03:24:54.446163
NCT00439855|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-02-23|2007-02-23|2007-02-26|Estimate|||||||2007-02-23|2007-02-26|Estimate|September 2003||2003-09-30|February 2007|2007-02-28|February 2006||2006-02-28|||||Interventional|||Enoxaparin Versus Unfractionated Heparin in PCI|Enoxaparin Versus Unfractionated Heparin in PCI|Completed||Phase 4|2100||Triemli Hospital|||||f||||||||||||||2018-06-01 03:24:54.548171|2018-06-01 03:24:54.548171
NCT00439842|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2015-04-16|2007-02-22|2007-02-26|Estimate|||||||2015-04-16|2015-04-17|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|May 2013|Actual|2013-05-31||Interventional|||Self-Management and Care of Heart Failure With Group Clinics (SMAC-HF)|HF Group Clinic Appointments: Rehospitalization Prevention|Completed||N/A|198|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 03:24:54.616745|2018-06-01 03:24:54.616745
NCT00439829|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2010-05-21|2007-02-23|2007-02-26|Estimate|||||||2010-05-21|2010-05-25|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Synchronization of Follicle Wave Emergence and Ovarian Stimulation|Synchronization of Follicle Wave Emergence and Ovarian Stimulation in Women With a History of Poor Ovarian Response to Treatment|Completed||Phase 4|80|Anticipated|University of Saskatchewan||2|||f||||||||||||||2018-06-01 03:24:54.718654|2018-06-01 03:24:54.718654
NCT00439816|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2015-04-06|2007-02-23|2007-02-26|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Veteran Preference For Group Visits and Its Effect on Hypertension Outcomes|Veteran Preference For Group Visits and Its Effect on Hypertension Outcomes|Completed||N/A|160|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 03:24:54.836071|2018-06-01 03:24:54.836071
NCT00439803|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2008-11-07|2007-02-23|2007-02-26|Estimate|||||||2008-11-07|2008-11-10|Estimate|April 2007||2007-04-30|November 2008|2008-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|CMV||A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)|A Single-Site, Phase 1, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Cytomegalovirus Genes (AVX601) in Healthy Volunteers|Completed||Phase 1|40|Actual|AlphaVax, Inc.||8|||f||||t||||||||||2018-06-01 03:24:54.905349|2018-06-01 03:24:54.905349
NCT00439790|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2012-06-12|2007-02-23|2007-02-26|Estimate|||||||2012-06-12|2012-06-13|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|||||Observational|||Sympathetic Nerve Activity and an Implantable Cardioverter Defibrillator in Heart Failure Patients|Validation of a Prognostic Score to Identify Heart Failure Patients Who Might Need an Implantable Cardioverter Defibrillator Using Muscle Sympathetic Nerve Activity and Autonomic Testing|Completed|||109|Actual|University Hospital, Toulouse|||||f||||f||||||||||2018-06-01 03:24:54.98856|2018-06-01 03:24:54.98856
NCT00439777|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2012-11-22|2011-12-21|2014-01-25|2007-02-23|2007-02-26|Estimate|2013-01-22|2013-01-24|Estimate|2011-12-21|2011-12-22|Estimate|2014-01-25|2014-02-27|Estimate|March 2007||2007-03-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study|Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism|Completed||Phase 3|4833|Actual|Bayer||2|||f||||t||||||||||2018-06-01 03:24:55.168164|2018-06-01 03:24:55.168164
NCT00439764|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2009-05-27|2007-02-23|2007-02-26|Estimate|||||||2009-05-27|2009-05-28|Estimate|March 2007||2007-03-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Health Education vs. Health Education Plus Physical Therapy for Low Back Pain Patients|Health Education vs. Health Education Plus Physical Therapy for Low Back Pain Patients|Completed||Phase 2|680|Anticipated|Kovacs Foundation||3|||f||||t||||||||||2018-06-01 03:24:58.218091|2018-06-01 03:24:58.218091
NCT00439751|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2016-07-08|2007-02-22|2007-02-26|Estimate|||||||2016-07-08|2016-07-12|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|ELAAT||Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy|A Randomized Comparison of Immediate Versus Deferred Androgen Deprivation Therapy Using Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy.|Completed||Phase 3|79|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 03:24:58.364943|2018-06-01 03:24:58.364943
NCT00439387|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-10-05|2007-02-22|2007-02-23|Estimate|||||||2017-10-05|2017-10-06|Actual|February 20, 2007||2007-02-20|June 5, 2015|2015-06-05|June 5, 2015||2015-06-05|||||Observational|||The Role of Serotonin in Seizures|Imaging Serotoninergic Neurotransmission in Epilepsy|Terminated|||46|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:25:08.033078|2018-06-01 03:25:08.033078
NCT00439738|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2008-11-05||2017-04-19|2007-02-23|2007-02-26|Estimate|2009-02-09|2009-02-10|Estimate||||2017-04-19|2017-05-16|Actual|December 2006||2006-12-31|April 2017|2017-04-30||||November 2007|Actual|2007-11-30||Interventional|||Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults|A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients|Completed||Phase 4|412|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:24:58.494398|2018-06-01 03:24:58.494398
NCT00439725|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|2012-01-31||2014-10-28|2007-02-23|2007-02-26|Estimate|2012-03-14|2012-04-12|Estimate||||2014-10-28|2014-11-04|Estimate|February 2007||2007-02-28|October 2014|2014-10-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study|Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study|Completed||Phase 3|1197|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:24:59.111593|2018-06-01 03:24:59.111593
NCT00439712|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2008-01-12|2007-02-23|2007-02-26|Estimate|||||||2008-01-12|2008-01-15|Estimate|February 2007||2007-02-28|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis|Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis|Completed||Phase 4|60|Actual|Institut für Atemwegsforschung GmbH||2|||f||||f||||||||||2018-06-01 03:25:01.976478|2018-06-01 03:25:01.976478
NCT00439699|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2012-06-20|2007-02-22|2007-02-26|Estimate|||||||2012-06-20|2012-06-22|Estimate|February 2007||2007-02-28|June 2012|2012-06-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||A Pilot Clinical Trial Of Memantine for Essential Tremor|A Pilot Clinical Trial of Memantine for Essential Tremor|Completed||Phase 4|16|Actual|VA Greater Los Angeles Healthcare System||1|||f||||||||||||||2018-06-01 03:25:02.130579|2018-06-01 03:25:02.130579
NCT00439686|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2014-01-29|2007-02-22|2007-02-26|Estimate|||||||2014-01-29|2014-01-31|Estimate|February 2006||2006-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|June 2008|Actual|2008-06-30||Interventional|||Study of ZIO-201 in Advanced Sarcoma|A Phase IB/IIA Study of the Saftey and Activity of Intravenous Isophosporamide Mustard (ZIO-201) in Patients With Advanced Sarcoma|Completed||Phase 1/Phase 2|53|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 03:25:02.262857|2018-06-01 03:25:02.262857
NCT00439673|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2010-11-24|2007-02-23|2007-02-26|Estimate|||||||2010-11-24|2010-11-25|Estimate|May 2007||2007-05-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS|A Open Label, Phase II, Non Randomized, Clinical Trial of Chemotherapy Treatment With 5-Azacytidine Plus Valproic Acid and Eventually Atra for Patients Diagnosed With Intermediate II and High Risk Myelodysplastic Syndrome (MDS). EudraCT Number 2005-004811-31. GIMEMA Protocol MDS0205|Completed||Phase 2|56|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||||||||||||2018-06-01 03:25:02.373953|2018-06-01 03:25:02.373953
NCT00439660|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-23|||2007-03-21|2007-02-23|2007-02-26|Estimate|||||||2007-03-21|2007-03-22|Estimate|December 2006||2006-12-31|February 2007|2007-02-28|November 2008|Anticipated|2008-11-30|||||Interventional|||Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old|Double-Blind Randomized Placebo-Controlled Dose Escalating Phase Ib/IIa Study to Evaluate the Safety and Immunogenicity of Live Attenuated Oral Rotavirus Vaccine 116E in Healthy Non-Malnourished Infants 8 to 20 Weeks of Age|Unknown status|Active, not recruiting|Phase 1/Phase 2|540||Bharat Biotech International Limited|||||f||||||||||||||2018-06-01 03:25:02.485614|2018-06-01 03:25:02.485614
NCT00439647|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2011-10-10||2017-04-19|2007-02-22|2007-02-23|Estimate|2011-10-10|2011-11-16|Estimate||||2017-04-19|2017-04-21|Actual|December 2006||2006-12-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis|A Two Year Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Fracture Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Annually for the Treatment of Osteoporosis in Men|Completed||Phase 3|1199|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:25:02.774481|2018-06-01 03:25:02.774481
NCT00439634|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22||2016-04-18|2016-04-18|2007-02-22|2007-02-23|Estimate||||2016-04-18|2016-05-18|Estimate|2016-04-18|2016-05-18|Estimate|February 2007||2007-02-28|April 2016|2016-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|CONNECT||Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia|A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia.|Terminated||Phase 2|873|Actual|Sanofi||4||"Following a pre-specified interim analysis and Data Monitoring Committee recommendation due to~   insufficient level of efficacy"|f||||||||||||||2018-06-01 03:25:04.277296|2018-06-01 03:25:04.277296
NCT00439621|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2008-08-13|2007-02-22|2007-02-23|Estimate|||||||2008-08-13|2008-08-18|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|August 2008|Actual|2008-08-31|March 2008|Actual|2008-03-31||Interventional|||Safety Study of Anti-IgE Immunotherapy in Allergic Patients|A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients|Completed||Phase 2|42|Actual|Resistentia Pharmaceuticals AB||4|||f||||t||||||||||2018-06-01 03:25:04.345774|2018-06-01 03:25:04.345774
NCT00439608|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2013-05-09||2018-03-29|2007-02-22|2007-02-23|Estimate|2013-05-13|2013-07-01|Estimate||||2018-03-29|2018-04-27|Actual|October 2004||2004-10-31|March 2018|2018-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Patients received cetuximab, 400 mg/mg2 over 2 h on Day 1 then 250 mg/m2/week over 1 h, for 5 additional weeks. Patients also received paclitaxel, 50 mg/m2/week, over 1 h and carboplatin AUC (area under the curve) = 2/week, over 30 min, for 6 weeks. Cetuximab was administered first.|BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer|BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer BMS#CA225091|Completed||Phase 2|60|Actual|Brown University||1|||f||||t||||||||||2018-06-01 03:25:04.526031|2018-06-01 03:25:04.526031
NCT00439595|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2010-05-26|2007-02-22|2007-02-23|Estimate|||||||2010-05-26|2010-05-27|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|EARS||A Trial of 2 'Point of Care' Diagnostic Methods to Improve Detection and Treatment of Anaemia in African Children|A Cluster Randomised Trial of Different Methods of Haemoglobin Measurement to Improve Recognition and Treatment of Childhood and Pregnancy-related Anaemia in a Malaria Endemic Area of North East Tanzania.|Completed||N/A|450|Anticipated|London School of Hygiene and Tropical Medicine||3|||f||||f||||||||||2018-06-01 03:25:04.720175|2018-06-01 03:25:04.720175
NCT00439569|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|2010-01-19||2010-08-30|2007-02-22|2007-02-23|Estimate|2010-01-19|2010-02-12|Estimate||||2010-08-30|2010-09-08|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|NPTUNE01||Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III|Phase I/IIa Clinical Trial of Sodium Phenylbutyrate in Pediatric Subjects With Type II/III Spinal Muscular Atrophy|Terminated||Phase 1/Phase 2|9|Actual|Westat|The study was closed early due to poor study drug compliance. The sample size is therefore extremely limited.|1||Due to poor compliance with study drug administration.|f||||t||||||||||2018-06-01 03:25:04.913708|2018-06-01 03:25:04.913708
NCT00439556|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2018-02-21|2007-02-22|2007-02-23|Estimate|||||||2018-02-21|2018-02-22|Actual|February 2007||2007-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies|Bortezomib (Velcade) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies|Active, not recruiting||Phase 2|52|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:25:05.178252|2018-06-01 03:25:05.178252
NCT00439543|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-02-22|2007-02-22|2007-02-23|Estimate|||||||2007-02-22|2007-02-23|Estimate|March 2007||2007-03-31|February 2007|2007-02-28|August 2007||2007-08-31|||||Interventional|||Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis|Inhaled Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis|Unknown status|Not yet recruiting|Phase 2/Phase 3|15||Interstitial Lung Disease Study Group, Korea|||||f||||||||||||||2018-06-01 03:25:05.287977|2018-06-01 03:25:05.287977
NCT00439530|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2009-07-24|2007-02-21|2007-02-23|Estimate|||||||2009-07-24|2009-07-28|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|SEA002||Pharmacologic Study of Oseltamivir in Healthy Volunteers|Pharmacologic Study of Oseltamivir in Healthy Volunteers|Completed||Phase 1|21|Actual|Mahidol University|||||f||||t||||||||||2018-06-01 03:25:05.365831|2018-06-01 03:25:05.365831
NCT00439517|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2011-03-31||2014-06-18|2007-02-22|2007-02-23|Estimate|2011-05-13|2011-06-14|Estimate||||2014-06-18|2014-06-27|Estimate|February 2007||2007-02-28|June 2014|2014-06-30|May 2012|Actual|2012-05-31|June 2009|Actual|2009-06-30||Interventional|FUTURE||Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.|A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer.|Completed||Phase 2|302|Actual|Merck KGaA|Dosing of UFT/ folinic acid in the experimental arm were not directly recorded, so dosing data is not fully available in the UFOX plus cetuximab arm (36/151). Comparative conclusions on drug exposure might be impacted by a bias due to missing data.|2|||f||||t||||||||||2018-06-01 03:25:05.480608|2018-06-01 03:25:05.480608
NCT00439504|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-01-10|2007-02-22|2007-02-23|Estimate|||||||2017-01-10|2017-01-11|Estimate||||February 2007|2007-02-28||||||||Interventional|||Ph1 Lobeline Interaction Study - 1|Double-Blind, Placebo-Controlled, Cross-Over Assessment of Intravenous Methamphetamine and Sublingual Lobeline Interactions|Unknown status|Recruiting|Phase 1|10||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 03:25:06.726527|2018-06-01 03:25:06.726527
NCT00439491|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2007-02-21|2007-02-21|2007-02-23|Estimate|||||||2007-02-21|2007-02-23|Estimate|January 2004||2004-01-31|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||Role of Adipose Tissue in Pathogenesis of Insulin Resistance|Role of Adipose Tissue in Pathogenesis of Insulin Resistance|Completed||N/A|35||Charles University, Czech Republic|||||f||||||||||||||2018-06-01 03:25:06.802676|2018-06-01 03:25:06.802676
NCT00439478|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-11-13|2007-02-22|2007-02-23|Estimate|||||||2007-11-13|2007-11-14|Estimate|September 2004||2004-09-30|October 2007|2007-10-31|September 2006|Actual|2006-09-30|||||Observational|||Dental Safety Profile of High-Dose Radioiodine Therapy|The Dental Safety Profile of High-Dose Radioiodine Therapy for Thyroid Cancer|Completed|||202||University Hospital, Basel, Switzerland|||||f||||||||||||||2018-06-01 03:25:06.872863|2018-06-01 03:25:06.872863
NCT00439465|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2018-03-06|2007-02-22|2007-02-23|Estimate|||||||2018-03-06|2018-03-08|Actual|January 2007||2007-01-31|January 2018|2018-01-31|November 30, 2012|Actual|2012-11-30|October 15, 2012|Actual|2012-10-15||Interventional|||Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma|Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma|Completed||Phase 2|22|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 03:25:06.953308|2018-06-01 03:25:06.953308
NCT00439452|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2011-08-31|2007-02-22|2007-02-23|Estimate|||||||2011-08-31|2011-09-02|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Telemedicine-Based Collaborative Care to Reduce Rural Disparities|Telemedicine-Based Collaborative Care to Reduce Rural Disparities|Completed||N/A|500|Anticipated|University of Arkansas||2|||f||||f||||||||||2018-06-01 03:25:07.091351|2018-06-01 03:25:07.091351
NCT00439439|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2008-05-19|2007-02-21|2007-02-23|Estimate|||||||2008-05-19|2008-05-20|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||ACHAT-STUDY, Alternative Treatment of Chronic Globus Sensations|"ACHAT-STUDY: Argon-Beamer-Ablation of Cervical Heterotopic Gastral Mucosa, an Alternative Treatment of Chronic Globus Sensations - Sham-Controlled Multicenter Study"|Completed||N/A|40|Anticipated|Technische Universität München||2|||f||||||||||||||2018-06-01 03:25:07.201298|2018-06-01 03:25:07.201298
NCT00439426|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2016-11-01|2007-02-22|2007-02-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2007||2007-04-30|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.|An Open Label Study of First Line Chemotherapy With Xeloda in Combination With Cisplatin on Treatment Response in Patients With Metastatic Nasopharyngeal Cancer|Completed||Phase 2|25|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:25:07.297986|2018-06-01 03:25:07.297986
NCT00439413|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2016-08-17||2016-12-07|2007-02-22|2007-02-23|Estimate|2016-08-17|2016-10-13|Estimate||||2016-12-07|2017-02-02|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Selegiline for Smoking Cessation - 1|Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation.|Completed||Phase 2|246|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 03:25:07.395957|2018-06-01 03:25:07.395957
NCT00439400|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-10-01|2007-02-22|2007-02-23|Estimate|||||||2007-10-01|2007-10-02|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period|A Double-Masked, Randomized, Placebo-Controlled Study of ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution) for the Treatment of Dry Eye Administered QID for a 56 Day Period Utilizing the Controlled Adverse Environment Model|Completed||Phase 2|160|Actual|Alacrity Biosciences, Inc.||2|||||||||||||||||2018-06-01 03:25:07.933374|2018-06-01 03:25:07.933374
NCT00439374|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2012-10-26|2007-02-21|2007-02-23|Estimate|||||||2012-10-26|2012-10-29|Estimate|April 2007||2007-04-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|SCAN||RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix|A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Nulliparous Women With a Short Cervix|Terminated||Phase 3|657|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1||Halted by NICHD after recommendation by DSMC to stop for futility|f||||t||||||||||2018-06-01 03:25:08.127254|2018-06-01 03:25:08.127254
NCT00439361|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2012-07-05|2007-02-22|2007-02-23|Estimate|||||||2012-07-05|2012-07-09|Estimate|February 2007||2007-02-28|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma|Phase-I Study of Bortezomib (VELCADE) Plus ICE (Ifosfamide, Carboplatin, Etoposide) for Patients With Relapsed Classical Hodgkin Lymphoma|Completed||Phase 1|14|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:25:08.336432|2018-06-01 03:25:08.336432
NCT00439348|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2009-11-20|2007-02-21|2007-02-23|Estimate|||||||2009-11-20|2009-11-23|Estimate|February 2007||2007-02-28|November 2009|2009-11-30|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Over-the-Counter Medication Usage|Improving Over-the-counter Medication Compliance.|Completed||N/A|246|Actual|Florida Hospital||2|||f||||||||||||||2018-06-01 03:25:08.469736|2018-06-01 03:25:08.469736
NCT00439335|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2009-03-24||2013-03-28|2007-02-22|2007-02-23|Estimate|2009-03-24|2009-05-08|Estimate||||2013-03-28|2013-04-09|Estimate|March 2007||2007-03-31|August 2009|2009-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Higher Dose Intradermal H5 Vaccine|A Phase I/II Randomized, Double-Blinded Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Immunization With Inactivated Subvirion Influenza A/H5N1 Vaccine Administered by the Intradermal or the Intramuscular Route Among Healthy Adults|Completed||Phase 1/Phase 2|227|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:25:08.612811|2018-06-01 03:25:08.612811
NCT00439322|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2015-04-06|2007-02-21|2007-02-23|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2000|Actual|2000-09-30|||||Observational|||Post Traumatic Stress Disorder Among VA Ambulatory Care Patients|Post Traumatic Stress Disorder Among VA Ambulatory Care Patients|Completed|||473|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 03:25:09.57741|2018-06-01 03:25:09.57741
NCT00439309|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|2013-11-07||2017-08-07|2007-02-22|2007-02-23|Estimate|2014-02-17|2014-04-01|Estimate||||2017-08-07|2017-09-07|Actual|April 2007||2007-04-30|August 2017|2017-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study to Evaluate Safety & Effectiveness of Vascular Sealant System|Randomized Study to Evaluate Safety & Effectiveness of Vascular Sealant to Control Suture Line Bleeding|Terminated||N/A|69|Actual|Integra LifeSciences Corporation||2||Business Decision|f||||t||||||||||2018-06-01 03:25:09.818327|2018-06-01 03:25:09.818327
NCT00439296|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2012-11-28|2007-02-21|2007-02-23|Estimate|||||||2012-11-28|2012-11-30|Estimate|May 2006||2006-05-31|November 2012|2012-11-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||ABT-751 With Chemotherapy for Relapsed Pediatric ALL|A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL)|Terminated||Phase 1|9|Actual|Therapeutic Advances in Childhood Leukemia Consortium||||The study was stopped due to poor accrual and lack of funding.|f||||t||||||||||2018-06-01 03:25:10.350907|2018-06-01 03:25:10.350907
NCT00439283|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-02-26|2007-02-22|2007-02-23|Estimate|||||||2007-02-26|2007-02-27|Estimate|April 2003||2003-04-30|February 2007|2007-02-28|December 2004||2004-12-31|||||Interventional|||Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis|Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis: Comparison of Infusion Every 6 Weeks Versus Infusion on Demand|Completed||Phase 3|240||Association de Recherche Clinique en Rhumatologie|||||f||||f||||||||||2018-06-01 03:25:10.480121|2018-06-01 03:25:10.480121
NCT00439270|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2013-06-25||2014-02-28|2007-02-22|2007-02-23|Estimate|2013-09-26|2013-11-27|Estimate||||2014-02-28|2014-03-28|Estimate|July 2007||2007-07-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional||All patients who received at least 1 dose of dasatinib|Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer|Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 1/Phase 2|49|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-06-01 03:25:10.721081|2018-06-01 03:25:10.721081
NCT00439257|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2015-04-06|2007-02-22|2007-02-23|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|June 2000|Actual|2000-06-30|||||Observational|||Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)|Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)|Completed|||124|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 03:25:12.289758|2018-06-01 03:25:12.289758
NCT00439244|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2011-01-05||2011-03-23|2007-02-22|2007-02-23|Estimate|2011-03-23|2011-04-20|Estimate||||2011-03-23|2011-04-20|Estimate|December 2006||2006-12-31|March 2011|2011-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis|A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis|Completed||Phase 3|412|Actual|Novartis|No teriparatide placebo available, Short study duration, Only bone mineral data, No bone strength or bone stucture assessment, No bone turnover markers data between 8 and 26 weeks, Study not powered for fracture outcomes.|3|||f||||||||||||||2018-06-01 03:25:12.36818|2018-06-01 03:25:12.36818
NCT00439231|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2011-09-19||2013-11-14|2007-02-22|2007-02-23|Estimate|2013-11-14|2014-01-13|Estimate||||2013-11-14|2014-01-13|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase II Study of Lenalidomide Revlimid(Registered Trademark) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Completed||Phase 2|33|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 03:25:13.131076|2018-06-01 03:25:13.131076
NCT00439218|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2010-04-16||2010-10-27|2007-02-22|2007-02-23|Estimate|2010-06-18|2010-07-20|Estimate||||2010-10-27|2010-11-09|Estimate|January 2008||2008-01-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|NPTUNE 02||Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I|Phase I/IIa Clinical Trial of Sodium Phenylbutyrate in Pediatric Subjects With Type I Spinal Muscular Atrophy|Terminated||Phase 1/Phase 2|5|Actual|Westat|This study was closed early due to slow accrual. The sample size is therefore extremely limited.|1||Extremely slow enrollment|f||||t||||||||||2018-06-01 03:25:14.435182|2018-06-01 03:25:14.435182
NCT00439205|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2017-10-18|2007-02-21|2007-02-23|Estimate|||||||2017-10-18|2017-10-20|Actual|February 7, 2007|Actual|2007-02-07|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Observational|||Oral Margin Spectroscopy Detection Using Optical Spectroscopy|Oral Tumor Margin Detection Using Optical Spectroscopy|Completed|||58|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Tissue removal and study biopsies to be done so that researchers can better compare the~     appearance and diagnosis at these sites to the images that were taken.~   "|||2018-06-01 03:25:14.680493|2018-06-01 03:25:14.680493
NCT00439192|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-08-07|2007-02-22|2007-02-23|Estimate|||||||2007-08-07|2007-08-08|Estimate|February 2007||2007-02-28|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)|A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)|Terminated||Phase 2|275|Anticipated|elbion AG||||side effect profile did not match expectations|f||||||||||||||2018-06-01 03:25:14.783806|2018-06-01 03:25:14.783806
NCT00439179|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|2013-05-13||2014-07-15|2007-02-22|2007-02-23|Estimate|2014-04-03|2014-05-05|Estimate||||2014-07-15|2014-07-24|Estimate|July 2006||2006-07-31|July 2014|2014-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|BrUOG-PA205|participant number correlates to all enrolled patients treated on this study as a whole which is the way in which the abstract was written and therefore how these results are entered|A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema|BrUOG-PA-205 A Phase I Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema GSK Study ProtocolGSK #103556|Completed||Phase 1|27|Actual|Brown University||4|||f||||t||||||||||2018-06-01 03:25:15.01149|2018-06-01 03:25:15.01149
NCT00439166|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2018-03-15|2007-02-21|2007-02-23|Estimate|||||||2018-03-15|2018-03-19|Actual|February 2007||2007-02-28|March 2017|2017-03-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid|Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid|Completed||Phase 3|100|Actual|McMaster University||4|||f||||f||||||||||2018-06-01 03:25:15.433668|2018-06-01 03:25:15.433668
NCT00439153|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2011-10-12|2007-02-22|2007-02-23|Estimate|||||||2011-10-12|2011-10-14|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Minimizing Tourniquet Pressures in Paediatric Orthopaedic Knee Surgery|Quality of Surgical Field in Reconstructive Anterior Cruciate Ligament Surgery: Comparison of Tourniquet Cuff Pressure Determined by an Automated Limb Occlusion Pressure Measurement to a Standard Pressure of 300 mm Hg.|Completed||N/A|41|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 03:25:15.532799|2018-06-01 03:25:15.532799
NCT00439140|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|2013-12-09||2013-12-09|2007-02-21|2007-02-23|Estimate|2013-12-09|2014-01-24|Estimate||||2013-12-09|2014-01-24|Estimate|June 2007||2007-06-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder||Terminated||Phase 3|41|Actual|Allergan||4||In agreement with FDA the study was terminated based on data available.|f||||t||||||||||2018-06-01 03:25:15.638882|2018-06-01 03:25:15.638882
NCT00439127|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-02-27|2007-02-22|2007-02-23|Estimate|||||||2007-02-27|2007-02-28|Estimate|January 2005||2005-01-31|February 2007|2007-02-28|January 2007||2007-01-31|||||Observational|||OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation|Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma?|Completed|||28||Oncology Institute of Southern Switzerland|||||f||||||||||||||2018-06-01 03:25:16.412908|2018-06-01 03:25:16.412908
NCT00439114|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2007-02-21|2007-02-21|2007-02-23|Estimate|||||||2007-02-21|2007-02-23|Estimate|July 2005||2005-07-31|February 2007|2007-02-28|June 2006||2006-06-30|||||Observational|||Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze|Comparison of Ultrasonic Pachymetry With Orbscan in Corneal Haze|Completed|||40||Baskent University|||||f||||||||||||||2018-06-01 03:25:16.553991|2018-06-01 03:25:16.553991
NCT00439101|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2012-07-11|2007-02-22|2007-02-23|Estimate|||||||2012-07-11|2012-07-13|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Randomized Clinical Trial of Megestrol Acetate as an Appetite Stimulant in Malnourished Children With Cancer|A Randomized, Double Blind, Placebo-Controlled Trial of Megestrol Acetate as an Appetite Stimulant in Malnourished Children With Cancer|Completed||N/A|26|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:25:16.619836|2018-06-01 03:25:16.619836
NCT00439088|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2007-03-07|2007-02-22|2007-02-23|Estimate|||||||2007-03-07|2007-03-08|Estimate|July 2005||2005-07-31|March 2007|2007-03-31|August 2005||2005-08-31|||||Observational|PamPed||Try Walking a Mile in These Shoes: Activity Level of Lower Extremity Amputees|Comparison of the Patient Activity Monitor to a Pedometer During Ambulation Monitoring of Transtibial Amputees|Completed|||20||University of Ottawa|||||f||||||||||||||2018-06-01 03:25:16.70664|2018-06-01 03:25:16.70664
NCT00439075|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-22|||2017-05-10|2007-02-22|2007-02-23|Estimate|||||||2017-05-10|2017-05-12|Actual|October 2006|Actual|2006-10-31|May 2017|2017-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||OUT-OF-HOSPITAL CPAP STUDY|Randomised Controlled Comparison of Continuous Positive Airway Pressure (CPAP) With Standard Treatment in Out-of-hospital Patients With Acute Cardiogenic Pulmonary Edema.|Completed||Phase 4|124|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 03:25:16.782109|2018-06-01 03:25:16.782109
NCT00439062|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-20|2007-02-20|2007-02-22|Estimate|||||||2007-02-20|2007-02-22|Estimate|June 2006||2006-06-30|February 2007|2007-02-28|June 2006||2006-06-30|||||Interventional|||Treatment of Rheumatoid Arthritis With Roxithromycin|Treatment of Rheumatoid Arthritis With Roxithromycin|Completed||Phase 4|100||Nazilli State Hospital|||||f||||||||||||||2018-06-01 03:25:16.856523|2018-06-01 03:25:16.856523
NCT00439049|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2017-04-04|2007-02-21|2007-02-22|Estimate|||||||2017-04-04|2017-04-05|Actual|October 2005||2005-10-31|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Substance Abuse Pre-Treatment Screening Study|General Evaluation of Eligibility for Substance Abuse/Dependence Research|Recruiting|||7500|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells~   "|||2018-06-01 03:25:16.918294|2018-06-01 03:25:16.918294
NCT00439036|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2013-05-03|2007-02-21|2007-02-22|Estimate|||||||2013-05-03|2013-05-06|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|August 2010|Actual|2010-08-31||Interventional|||Acceptance Therapy During Methadone Detoxification|Acceptance Therapy During Methadone Detoxification|Completed||Phase 1|56|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 03:25:17.010316|2018-06-01 03:25:17.010316
NCT00439010|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2008-04-22|2007-02-20|2007-02-22|Estimate|||||||2008-04-22|2008-04-24|Estimate|February 2007||2007-02-28|April 2008|2008-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects|Evaluation of [123I] AV39 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects|Completed||Phase 1|30|Anticipated|Molecular NeuroImaging|||||f||||f||||||||||2018-06-01 03:25:17.210258|2018-06-01 03:25:17.210258
NCT00438984|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2012-03-14|2007-02-20|2007-02-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma|Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma|Completed||Phase 1|11|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 03:25:17.319736|2018-06-01 03:25:17.319736
NCT00438971|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2013-07-19||2016-03-24|2007-02-21|2007-02-22|Estimate|2013-10-29|2013-12-19|Estimate||||2016-03-24|2016-04-27|Estimate|August 2006||2006-08-31|March 2016|2016-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder|The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder|Completed||Phase 4|15|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 03:25:17.442746|2018-06-01 03:25:17.442746
NCT00438958|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2014-03-04|2007-02-20|2007-02-22|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2007||2007-03-31|July 2009|2009-07-31||||||||Interventional|||Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases|A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies|Completed||Phase 3|230|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:25:17.78378|2018-06-01 03:25:17.78378
NCT00438945|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2008-05-05|2007-02-21|2007-02-22|Estimate|||||||2008-05-05|2008-05-09|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|January 2008|Actual|2008-01-31|||||Interventional|||The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension|The Effect of Eprosartan in Patients With Essential Hypertension on Renal Tubular Function and Vasoactive Hormones During Baseline Conditions and After Activation of the Sympathetic Nervous System.|Completed||Phase 4|18|Anticipated|Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:25:17.897592|2018-06-01 03:25:17.897592
NCT00438932|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2011-07-25||2011-09-23|2007-02-21|2007-02-22|Estimate|2011-09-23|2011-09-27|Estimate||||2011-09-23|2011-09-27|Estimate|January 2007||2007-01-31|September 2011|2011-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease|"Reduced Phosphate Intake in Normo-Phosphatemic Chronic Kidney Disease Patients"|Completed||N/A|16|Actual|Massachusetts General Hospital|In addition to limited power, the small sample size led to imbalances in baseline laboratory tests, which added further variability to the analyses. .|4|||f||||t||||||||||2018-06-01 03:25:17.96305|2018-06-01 03:25:17.96305
NCT00438919|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2009-12-02|2007-02-21|2007-02-22|Estimate|||||||2009-12-02|2009-12-03|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|||||Interventional|E-SELECT||A Multi-center Post-Market Surveillance Registry|The e-SELECT Registry a MULTICENTER POST-MARKET SURVEILLANCE|Completed||Phase 4|15000|Anticipated|Cordis Corporation||1|||f||||t||||||||||2018-06-01 03:25:18.364115|2018-06-01 03:25:18.364115
NCT00438906|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2018-02-12|2007-02-20|2007-02-22|Estimate|||||||2018-02-12|2018-02-14|Actual|December 2006||2006-12-31|February 2018|2018-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|CAPS 3||Cancer of the Pancreas Screening Study (CAPS 3)|Screening for Early Pancreatic Neoplasia|Completed|||200|Actual|Johns Hopkins University|||||f||||t||||||Samples With DNA|"~     approx 40 ml of blood, approx 10 ml pancreatic juice, pancreatic cells if fine needle~     aspirate is clinically recommended~   "|||2018-06-01 03:25:18.466293|2018-06-01 03:25:18.466293
NCT00438893|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2013-07-22|2007-02-20|2007-02-22|Estimate|||||||2013-07-22|2013-07-23|Estimate|January 2004||2004-01-31|July 2013|2013-07-31||||April 2010|Actual|2010-04-30||Interventional|||Effects of a Long Term Dietary Portfolio and of Sequential Removal of Food Components From the Diet|The Long-Term Effect of Viscous Fibers, Soy Protein, and Plant Sterol Foods in Combination on Serum Cholesterol and Other Risk Factors for Cardiovascular Disease|Unknown status|Active, not recruiting|Phase 2|66|Anticipated|University of Toronto||1|||f||||f||||||||||2018-06-01 03:25:18.534787|2018-06-01 03:25:18.534787
NCT00438880|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2014-05-20||2016-01-04|2007-02-20|2007-02-22|Estimate|2014-08-20|2014-09-01|Estimate||||2016-01-04|2016-02-04|Estimate|October 2004||2004-10-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|October 2010|Actual|2010-10-31||Interventional||All participants accrued to this study were analyzed for baseline characteristics|Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma|A Phase I/II Trial of CpG 7909, Rituximab Immunotherapy, and Y-90 Zevalin Radioimmunotherapy for Patients With Previously Treated CD20+ Non-Hodgkin Lymphoma|Completed||Phase 1/Phase 2|38|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 03:25:18.687223|2018-06-01 03:25:18.687223
NCT00438867|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2013-02-11|2007-02-21|2007-02-22|Estimate|||||||2013-02-11|2013-02-13|Estimate|May 2007||2007-05-31|November 2008|2008-11-30||||November 2009|Actual|2009-11-30||Interventional|AWARE||Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Female Patients With Stable Angina Pectoris Who Are Not Candidates for Revascularization|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|Cardium Therapeutics||3|||f||||t||||||||||2018-06-01 03:25:19.085184|2018-06-01 03:25:19.085184
NCT00438854|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2012-04-25||2017-11-15|2007-02-20|2007-02-22|Estimate|2012-09-12|2012-10-12|Estimate||||2017-11-15|2017-12-13|Actual|December 2006||2006-12-31|November 2017|2017-11-30|March 2013|Actual|2013-03-31|October 2010|Actual|2010-10-31||Interventional|||Dasatinib in Relapsed Chronic Lymphocytic Leukemia|Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 2|15|Actual|Massachusetts General Hospital||1|||f||||||||||||||2018-06-01 03:25:19.288696|2018-06-01 03:25:19.288696
NCT00438841|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2009-03-12|2007-02-20|2007-02-22|Estimate|||||||2009-03-12|2009-03-13|Estimate|August 2006||2006-08-31|March 2009|2009-03-31||||December 2008|Anticipated|2008-12-31||Interventional|||Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma|A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients|Unknown status|Active, not recruiting|Phase 2|43|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:25:19.547926|2018-06-01 03:25:19.547926
NCT00438815|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|2010-03-31||2014-03-19|2007-02-21|2007-02-22|Estimate|2010-05-18|2010-06-09|Estimate||||2014-03-19|2014-04-15|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|CHANGE 2||Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks|LEVP2006-1 CHANGE 2 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Safety/Efficacy Repeat Exposure Study of C1INH-nf (Human) in the Treatment of Acute HAE Attacks|Completed||Phase 3|113|Actual|Shire||1|||f||||||||||||||2018-06-01 03:25:19.760608|2018-06-01 03:25:19.760608
NCT00438802|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2016-09-12||2017-08-11|2007-02-20|2007-02-22|Estimate|2017-08-11|2017-10-02|Actual||||2017-08-11|2017-10-02|Actual|March 2006||2006-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|July 2010|Actual|2010-07-31||Interventional|||Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma|A Phase I Study of Alefacept (AmeviveTM) in the Treatment of Cutaneous T-cell Lymphoma and Peripheral T-cell NHL|Completed||Phase 1|23|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:25:20.08012|2018-06-01 03:25:20.08012
NCT00438789|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2014-05-05|2007-02-21|2007-02-22|Estimate|||||||2014-05-05|2014-05-06|Estimate||||September 2011|2011-09-30||||||||Expanded Access|EMBRACE||The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol||Approved for marketing|||||Alexion Pharmaceuticals|||||||||||||||||||2018-06-01 03:25:20.442748|2018-06-01 03:25:20.442748
NCT00438776|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2011-12-12|2007-02-21|2007-02-22|Estimate|||||||2011-12-12|2011-12-13|Estimate|February 2007||2007-02-28|December 2011|2011-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling||Completed||Phase 3|42|Actual|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 03:25:20.501099|2018-06-01 03:25:20.501099
NCT00438763|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2013-09-25|2007-02-20|2007-02-22|Estimate|||||||2013-09-25|2013-09-27|Estimate|December 2005||2005-12-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational|||CMC Arthritis - Neoprene Vs. Thermoplast Short Opponens Splinting|Prospective Randomized Comparison: Neoprene Vs. Thermoplast Short Opponens Splinting. Outcomes After a Five-week to Sixteen-week Treatment Trial.|Completed|||120|Actual|Massachusetts General Hospital|||2||f||||||||||||||2018-06-01 03:25:20.571589|2018-06-01 03:25:20.571589
NCT00438750|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2012-03-27||2012-06-01|2007-02-21|2007-02-22|Estimate|2012-04-25|2012-05-28|Estimate||||2012-06-01|2012-06-08|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Comparison of Occupational Therapy and Home Exercises for Adults With Operatively Treated Distal Radius Fractures|Prospective Randomized Comparison of Occupational Therapy vs Home Exercises After Volar Plate Fixation of a Fracture of the Distal Radius|Completed||N/A|94|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 03:25:20.705894|2018-06-01 03:25:20.705894
NCT00438737|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2011-09-01|2007-02-20|2007-02-22|Estimate|||||||2011-09-01|2011-09-02|Estimate|January 2007||2007-01-31|September 2007|2007-09-30||||||||Interventional|||Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer|Randomized Phase II Trial Evaluating the Feasibility and Tolerance of the Combination of FOLFOX With Cetuximab and the Combination of FOLFOX With Cetuximab and Bevacizumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:25:21.057488|2018-06-01 03:25:21.057488
NCT00438724|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2007-09-19|2007-02-21|2007-02-22|Estimate|||||||2007-09-19|2007-09-20|Estimate|November 2004||2004-11-30|September 2007|2007-09-30|November 2007|Anticipated|2007-11-30|||||Interventional|||Couples Coping With Alzheimer's Disease|A Randomized Control Trial of an Intervention for Couples Coping With Alzheimer's Disease|Unknown status|Recruiting|N/A|200|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 03:25:21.19781|2018-06-01 03:25:21.19781
NCT00438711|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-11-14|2007-02-21|2007-02-22|Estimate|||||||2017-11-14|2017-11-17|Actual|September 2005||2005-09-30|July 2011|2011-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Surgical Decision Making Among People With Inflammatory Bowel Disease|Surgical Decision Making Among People With Inflammatory Bowel Disease|Completed|||91|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 03:25:21.265128|2018-06-01 03:25:21.265128
NCT00438698|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2015-12-15|2007-02-21|2007-02-22|Estimate|||||||2015-12-15|2015-12-16|Estimate|September 2004||2004-09-30|December 2015|2015-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Low Glycemic Index Diets vs. High Cereal Fibre Diets in Type 2 Diabetes|Effect of Low Glycemic Index Diets on Glucose Control in Non-Insulin Dependent Diabetics|Completed||N/A|210|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 03:25:21.322033|2018-06-01 03:25:21.322033
NCT00438685|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2015-04-10|2007-02-21|2007-02-22|Estimate|||||||2015-04-10|2015-04-13|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|September 2010|Actual|2010-09-30|August 2007|Actual|2007-08-31||Interventional|||Outpatient Adolescent Treatment for Comorbid Substance Use and Internalizing Disorders|Development of Outpatient MST for Dually Diagnosed Youth|Completed||Phase 1|40|Anticipated|Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:25:21.399034|2018-06-01 03:25:21.399034
NCT00438672|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2012-03-22||2012-04-25|2007-02-21|2007-02-22|Estimate|2012-04-25|2012-05-28|Estimate||||2012-04-25|2012-05-28|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Corticosteroid Injection for Common Upper Extremity Problems|Corticosteroid Injection for Common Upper Extremity Problems|Completed||N/A|64|Actual|Massachusetts General Hospital||3|||f||||||||||||||2018-06-01 03:25:21.492666|2018-06-01 03:25:21.492666
NCT00438659|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2014-06-12||2016-07-01|2007-02-20|2007-02-22|Estimate|2015-02-11|2015-02-12|Estimate||||2016-07-01|2016-08-01|Estimate|August 2007||2007-08-31|July 2016|2016-07-31|June 2014|Actual|2014-06-30|January 2010|Actual|2010-01-31||Interventional||All (169) eligible patients are included in the baseline analysis. There were 5 cancels in Arm I and 2 in Arm II.|Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ|Phase III Randomized Double-Blind Study of Mometasone Furoate Versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy|Completed||Phase 3|176|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 03:25:21.810258|2018-06-01 03:25:21.810258
NCT00438646|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2009-08-24|2007-02-21|2007-02-22|Estimate|||||||2009-08-24|2009-08-25|Estimate|February 2007||2007-02-28|November 2008|2008-11-30||||December 2008|Actual|2008-12-31||Observational|||Oral Bacteria and Allergic Disease in Children|Oral Bacteria and History of Allergic Disease in Children: A Pilot Study|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:25:22.669701|2018-06-01 03:25:22.669701
NCT00438061|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-23|2007-02-20|2007-02-21|Estimate|||||||2007-02-23|2007-02-26|Estimate|January 1995||1995-01-31|February 2007|2007-02-28|December 1998||1998-12-31|||||Interventional|||Effect of Abdominal Obesity on Lipoprotein Metabolism|Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity|Completed||Phase 3|40||The University of Western Australia|||||f||||||||||||||2018-06-01 03:25:31.908867|2018-06-01 03:25:31.908867
NCT00438633|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-02-08|2007-02-20|2007-02-22|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2005||2005-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Comparison of Early and Late Therapy for Adults With Non-Operatively Treated Proximal Humerus Fractures|Early vs Delayed Physical Therapy (Exercises) for Non-Operatively-Treated Proximal Humerus Fractures: A Prospective Randomized Trial|Active, not recruiting|||60|Anticipated|Massachusetts General Hospital|||2||f||||||||||||||2018-06-01 03:25:22.72815|2018-06-01 03:25:22.72815
NCT00438620|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2016-02-24|2007-02-21|2007-02-22|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2006||2006-10-31|January 2012|2012-01-31||||November 2011|Actual|2011-11-30||Observational|||The Feasibility of Physical Activity in Advanced Cancer Patients|A Pilot Study to Explore the Role of Physical Activity as a Quality of Life Intervention in Advanced Cancer Patients|Completed|||30|Actual|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 03:25:22.79323|2018-06-01 03:25:22.79323
NCT00438607|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2009-07-10|2007-02-20|2007-02-22|Estimate|||||||2009-07-10|2009-07-13|Estimate|April 2007||2007-04-30|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects With Moderate to Late Stage Parkinson's Disease Who Are Also Receiving Treatment With Levodopa|Completed||Phase 2|83|Actual|Biogen||3|||f||||t||||||||||2018-06-01 03:25:22.851815|2018-06-01 03:25:22.851815
NCT00438594|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2013-01-29|2007-02-21|2007-02-22|Estimate|||||||2013-01-29|2013-01-31|Estimate|February 2004||2004-02-29|January 2013|2013-01-31|April 2006|Actual|2006-04-30|||||Interventional|DenverY09||Age 9 Follow-up of Preventive Intervention (Denver)|Age 9 Follow-up of Preventive Intervention|Completed||N/A|584|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-06-01 03:25:22.950814|2018-06-01 03:25:22.950814
NCT00438581|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-26|2007-02-20|2007-02-22|Estimate|||||||2007-02-26|2007-02-27|Estimate|March 2007||2007-03-31|February 2007|2007-02-28||||||||Interventional|Zevalin||Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma|Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma|Unknown status|Not yet recruiting|Phase 2|40||McGill University|||||f||||||||||||||2018-06-01 03:25:23.032256|2018-06-01 03:25:23.032256
NCT00438568|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2012-09-12|2007-02-21|2007-02-22|Estimate|||||||2012-09-12|2012-09-14|Estimate|June 2006||2006-06-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SNIFF 120||SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)|Therapeutic Effects of Intranasal Insulin Administration in AD|Completed||Phase 2|173|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 03:25:23.098248|2018-06-01 03:25:23.098248
NCT00438555|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2015-03-18|2007-02-21|2007-02-22|Estimate|||||||2015-03-18|2015-03-19|Estimate|October 2006||2006-10-31|July 2014|2014-07-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|4055obesityprv||Randomized, Controlled, Open, Comparative Intervention Study for Obesity Prevention in Children|Randomized, Controlled, Open, Comparative Intervention Study for Obesity Prevention in Children|Completed||N/A|248|Actual|Rabin Medical Center||3|||f||||||||||||||2018-06-01 03:25:23.170355|2018-06-01 03:25:23.170355
NCT00438542|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2007-02-21|2007-02-21|2007-02-22|Estimate|||||||2007-02-21|2007-02-22|Estimate|July 2003||2003-07-31|February 2007|2007-02-28|July 2006||2006-07-31|||||Observational|||HMW-Adiponectin is Raised in Newborns||Completed|||||University of Oslo|||||f||||||||||||||2018-06-01 03:25:23.235573|2018-06-01 03:25:23.235573
NCT00438516|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2008-01-09|2007-02-21|2007-02-22|Estimate|||||||2008-01-09|2008-01-15|Estimate|June 2000||2000-06-30|December 2007|2007-12-31|March 2003|Actual|2003-03-31|||||Interventional|MemphisYear9||Follow-up of Families in Early Preventive Intervention|Follow-up of Families in Early Preventive Intervention|Completed||N/A|627|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 03:25:23.294269|2018-06-01 03:25:23.294269
NCT00438503|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2015-09-14|2007-02-21|2007-02-22|Estimate|||||||2015-09-14|2015-09-15|Estimate|May 2006||2006-05-31|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Glucose in Dialysis Water in Diabetics With Chronic Renal Failure|Effect of Glucose in Dialysis Water in Diabetics With Chronic Renal Failure on Blood Pressure, Pulse Rate, Plasma Glucose, Plasma Concentrations of Insulin, Growth Hormone, Renin, Angiotensin II, Endothelin and Body Temperature|Completed||Phase 4|18|Actual|Regional Hospital Holstebro|||||f||||f||||||||||2018-06-01 03:25:23.370112|2018-06-01 03:25:23.370112
NCT00438490|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2013-02-05||2017-12-31|2007-02-21|2007-02-22|Estimate|2013-03-10|2013-04-18|Estimate||||2017-12-31|2018-01-03|Actual|April 2002||2002-04-30|December 2017|2017-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Safety and Efficacy of Recombinant Human Prolactin|Phase 2 Study of Recombinant Human Prolactin Efficacy and Safety|Completed||Phase 2|21|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 03:25:23.427701|2018-06-01 03:25:23.427701
NCT00438477|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2012-07-27|2007-02-20|2007-02-22|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 2005||2005-06-30|July 2012|2012-07-31|April 2008|Actual|2008-04-30|August 2006|Actual|2006-08-31||Interventional|||Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer|A Preliminary Study To Explore Subareolar Injection As The Site For Lymphatic Mapping And Sentinel Lymph Node Biopsy In Patients With Breast Cancer|Completed||N/A|74|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:25:23.773386|2018-06-01 03:25:23.773386
NCT00438464|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2015-10-20||2016-02-10|2007-02-20|2007-02-22|Estimate|2016-02-10|2016-03-09|Estimate||||2016-02-10|2016-03-09|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Baseline includes participants who were randomized to arms and received assigned treatment.|Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery|A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride Versus Placebo for Patients With Clinically Organ-Confined Prostate Cancer|Completed||Phase 2|204|Actual|National Cancer Institute (NCI)|Predefined molecular signature could not easily distinguish GG 4 from GG 3 tumor areas in the placebo arm.|2|||f||||f||||||||||2018-06-01 03:25:23.918402|2018-06-01 03:25:23.918402
NCT00438451|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|2012-09-24||2013-01-24|2007-02-21|2007-02-22|Estimate|2013-01-24|2013-02-28|Estimate||||2013-01-24|2013-02-28|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|July 2010|Actual|2010-07-31||Interventional|STEP-ONE||Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs|A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy.|Completed||Phase 4|361|Actual|Johannes Gutenberg University Mainz||3|||f||||f||||||||||2018-06-01 03:25:25.244054|2018-06-01 03:25:25.244054
NCT00438438|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2011-08-31|2007-02-21|2007-02-22|Estimate|||||||2011-08-31|2011-09-02|Estimate|April 2006||2006-04-30|August 2011|2011-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Interaction of Chronic Sleep Restriction and Circadian Misalignment on Sleep and Neuro-cognitive Performance|"Interaction of Chronic Sleep Restriction and Circadian Misalignment on Sleep and Neuro-cognitive Performance"|Completed||N/A|9|Anticipated|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 03:25:26.672351|2018-06-01 03:25:26.672351
NCT00438425|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2015-12-03|2007-02-21|2007-02-22|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2011|Actual|2011-01-31||Interventional|||Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia|Assessment of the Practical Application, Acceptability and Effectiveness of a Portfolio Diet in Reducing Serum Cholesterol|Unknown status|Active, not recruiting|Phase 2|351|Actual|University of Toronto||3|||f||||f||||||||||2018-06-01 03:25:26.73956|2018-06-01 03:25:26.73956
NCT00438412|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2008-04-17|2007-02-20|2007-02-22|Estimate|||||||2008-04-17|2008-04-22|Estimate|October 2006||2006-10-31|April 2008|2008-04-30||||||||Observational|||Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea||Suspended|||40|Anticipated|Regional Hospital Holstebro||||It was not possible to recruit enough patients with obstructive sleep apnea.|f||||||||||||||2018-06-01 03:25:26.861981|2018-06-01 03:25:26.861981
NCT00438399|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|2011-06-22||2011-11-21|2007-02-21|2007-02-22|Estimate|2011-11-21|2011-12-23|Estimate||||2011-11-21|2011-12-23|Estimate|February 2007||2007-02-28|November 2011|2011-11-30|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Subject Preference for Scalp Psoriasis Treatment|Subject Preference Comparison Between Clobetasol Propionate Shampoo, 0.05% and Three Other Topical Corticosteroids in the Treatment of Moderate to Severe Scalp Psoriasis|Completed||Phase 3|219|Actual|Galderma||6|||f||||f||||||||||2018-06-01 03:25:26.932498|2018-06-01 03:25:26.932498
NCT00438386|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2009-08-07|2007-02-20|2007-02-22|Estimate|||||||2009-08-07|2009-08-10|Estimate|April 2005||2005-04-30|August 2009|2009-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Aripiprazole for the Treatment of Refractory Anxiety|Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters|Completed||Phase 4|||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 03:25:28.453534|2018-06-01 03:25:28.453534
NCT00438373|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2015-02-25|2007-02-21|2007-02-22|Estimate|||||||2015-02-25|2015-02-26|Estimate|January 2007||2007-01-31|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||LH/HCG Receptor Expression and Retrieval Rates|Association of LH/HCG Receptor Expression and Retrieval Rates at Oocyte Pick up.|Suspended|||100|Anticipated|Aristotle University Of Thessaloniki|||||f||||||||||||||2018-06-01 03:25:28.519684|2018-06-01 03:25:28.519684
NCT00438360|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|2010-12-15||2011-07-13|2007-02-21|2007-02-22|Estimate|2011-07-13|2011-08-09|Estimate||||2011-07-13|2011-08-09|Estimate|May 2006||2006-05-31|July 2011|2011-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis|A 24-week, Double-blind, Randomized, Placebo-controlled, Multicenter Study, to Evaluate the Effectiveness of Cyclosporine 2,5 mg/kg/Day Bid Twice a Week on Reducing Relapse Rate, in Maintenance Patients With Chronic Plaque Psoriasis|Completed||Phase 3|243|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:25:28.59956|2018-06-01 03:25:28.59956
NCT00438347|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2016-11-04|2007-02-21|2007-02-22|Estimate|||||||2016-11-04|2016-11-08|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Influence of Fitness on Brain and Cognition|Influence of Fitness on Brain and Cognition|Completed|||179|Actual|University of Illinois at Urbana-Champaign|||2||f||||t||||||||No||2018-06-01 03:25:28.854537|2018-06-01 03:25:28.854537
NCT00438334|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2016-11-18|2007-02-21|2007-02-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|April 2001||2001-04-30|November 2016|2016-11-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Real-World Benefit From Directional Hearing Aids|Real-World Benefit From Directional Microphone Hearing Aids|Completed||N/A|105|Actual|Vanderbilt University|||||f||||||||||||||2018-06-01 03:25:29.034654|2018-06-01 03:25:29.034654
NCT00438321|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-04-14|2007-02-20|2007-02-22|Estimate|||||||2017-04-14|2017-04-18|Actual|September 2006||2006-09-30|April 2017|2017-04-30|February 26, 2010|Actual|2010-02-26|February 26, 2010|Actual|2010-02-26||Interventional|||Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome|Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome|Terminated||Phase 1|66|Actual|Massachusetts General Hospital||3||PI relocated|f||||f||||||||No||2018-06-01 03:25:29.103135|2018-06-01 03:25:29.103135
NCT00438308|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2010-08-11|2007-02-21|2007-02-22|Estimate|||||||2010-08-11|2010-08-12|Estimate|December 2004||2004-12-31|August 2010|2010-08-31|May 2007|Actual|2007-05-31|||||Observational|||Comparison of Early and Late Therapy for Adults With Operatively Treated Distal Radius Fractures|Prospective Randomized Comparison of Early and Late Wrist Mobilization After Volar Plate Fixation of a Fracture of the Distal Radius|Completed|||60|Actual|Massachusetts General Hospital|||2||f||||||||||||||2018-06-01 03:25:29.196152|2018-06-01 03:25:29.196152
NCT00438295|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2015-09-14|2007-02-21|2007-02-22|Estimate|||||||2015-09-14|2015-09-15|Estimate|August 2006||2006-08-31|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Temperature Control During Dialysis Treatment|Effect of Temperature Control During Dialysis Treatment With Glucose in Dialysis Water in Patients With Chronic Renal Failure|Completed||Phase 4|18|Actual|Regional Hospital Holstebro|||||f||||f||||||||||2018-06-01 03:25:29.255409|2018-06-01 03:25:29.255409
NCT00438282|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2013-04-30|2007-02-21|2007-02-22|Estimate|||||||2013-04-30|2013-05-01|Estimate|March 2001||2001-03-31|February 2013|2013-02-28|December 2007|Actual|2007-12-31|July 2005|Actual|2005-07-31||Interventional|DenverY06||Age 6 Test of Home Visits by Nurses vs Paraprofessionals|Age 6 Test of Home Visits by Nurses vs Paraprofessionals|Completed||N/A|604|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-06-01 03:25:29.312958|2018-06-01 03:25:29.312958
NCT00438269|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-17|||2007-02-21|2007-02-21|2007-02-22|Estimate|||||||2007-02-21|2007-02-22|Estimate|February 2003||2003-02-28|February 2007|2007-02-28|March 2005||2005-03-31|||||Interventional|||Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection|Appropriate Antimicrobial Therapy in Critical Care: A Pilot Randomized Controlled Trial|Completed||Phase 2|80||Canadian Critical Care Trials Group|||||f||||||||||||||2018-06-01 03:25:29.390686|2018-06-01 03:25:29.390686
NCT00438256|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-12-27|2007-02-20|2007-02-22|Estimate|||||||2017-12-27|2017-12-29|Actual|December 2007||2007-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer|Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer|Completed||Phase 1/Phase 2|50|Actual|Massachusetts General Hospital||4|||f||||t||||||||||2018-06-01 03:25:29.468697|2018-06-01 03:25:29.468697
NCT00438243|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2016-07-01|2007-02-21|2007-02-22|Estimate|||||||2016-07-01|2016-07-04|Estimate|May 2008||2008-05-31|July 2016|2016-07-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.|Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||2||Principal Investigator left institution|f||||||||||||||2018-06-01 03:25:29.571388|2018-06-01 03:25:29.571388
NCT00438230|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-21|2007-02-21|2007-02-22|Estimate|||||||2007-02-21|2007-02-22|Estimate|November 2003||2003-11-30|February 2007|2007-02-28|September 2006||2006-09-30|||||Interventional|DACUS||Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants|Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs|Completed||Phase 4|250||Azienda Ospedaliera Universitaria Policlinico|||||f||||||||||||||2018-06-01 03:25:29.673483|2018-06-01 03:25:29.673483
NCT00438217|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2007-02-21|2007-02-21|2007-02-22|Estimate|||||||2007-02-21|2007-02-22|Estimate||||February 2007|2007-02-28||||||||Interventional|CPP-EDG 01||Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children|Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children|Unknown status|Recruiting|Phase 4|100||University of Pisa|||||f||||||||||||||2018-06-01 03:25:29.781649|2018-06-01 03:25:29.781649
NCT00438204|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2014-06-04||2016-07-15|2007-02-20|2007-02-22|Estimate|2014-06-04|2014-07-04|Estimate||||2016-07-15|2016-08-16|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2013|Actual|2013-03-31||Interventional|||Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients With Stages IIIB/IV Non- Squamous, Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|39|Actual|Barbara Ann Karmanos Cancer Institute|There were no significant limitations of the trial.|1||All data collection has completed.|f||||t||||||||||2018-06-01 03:25:29.862471|2018-06-01 03:25:29.862471
NCT00438191|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2017-02-02||2017-04-06|2007-02-20|2007-02-22|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|December 2005||2005-12-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Clinical Trial of Splinting for DeQuervain's Tenosynovitis|A Clinical Trial of Full Time vs. As Needed Splint Wear for DeQuervain's Tenosynovitis|Completed|||83|Actual|Massachusetts General Hospital|||2||f||||||||||||||2018-06-01 03:25:30.169521|2018-06-01 03:25:30.169521
NCT00438178|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-21|||2014-05-09|2007-02-21|2007-02-22|Estimate|||||||2014-05-09|2014-05-12|Estimate|October 2005||2005-10-31|May 2014|2014-05-31||||October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies|A Phase I Study of Obatoclax Mesylate (GX15-070MS) in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myeloid Leukemia (CML)in Myeloid Blast Phase, Myelofibrosis, Previously-Treated Chronic Lymphocytic Leukemia (CLL), or Aplastic Anemia|Completed||Phase 1|44|Actual|Teva Pharmaceutical Industries|||||f||||f||||||||||2018-06-01 03:25:30.510031|2018-06-01 03:25:30.510031
NCT00438165|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2016-02-18|2007-02-21|2007-02-22|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2003||2003-09-30|February 2016|2016-02-29|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|MemphisY12||Age 12 Follow-up of Early Preventive Intervention (Memphis)|Age 12 Follow-up of Early Preventive Intervention|Completed||N/A|609|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 03:25:30.595956|2018-06-01 03:25:30.595956
NCT00438152|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2011-07-15|2007-02-20|2007-02-21|Estimate|||||||2011-07-15|2011-07-18|Estimate|September 2006||2006-09-30|February 2007|2007-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|LoCKIT||Lopinavir Capsules to Kaletra or Invirase Tablets|A 24-week, Randomized, Open-label, 2-arm Study to Compare the Safety, Efficacy and Tolerability of Invirase® Tablets With Ritonavir Versus Kaletra® Tablets in HIV 1 Infected Adults on a Kaletra® Based Regimen With 2 Nucleosides/Nucleotides|Completed||Phase 4|53|Actual|Royal Free Hampstead NHS Trust||2|||f||||t||||||||||2018-06-01 03:25:30.690343|2018-06-01 03:25:30.690343
NCT00438139|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-01-13|2007-02-20|2007-02-21|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2007||2007-03-31|February 2007|2007-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Ph1 Marinol Interaction Study - Part 1 - 1|Phase 1, Pilot Study to Examine the Cardiovascular Effects of Smoked Marijuana, Interactions With Oral Dronabinol, and Effects of Dronabinol on Withdrawal in Marijuana Dependent Volunteers|Terminated||Phase 1|6||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 03:25:30.801711|2018-06-01 03:25:30.801711
NCT00438126|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2010-03-01|2007-02-20|2007-02-21|Estimate|||||||2010-03-01|2010-03-02|Estimate|January 2002||2002-01-31|March 2010|2010-03-31|May 2006||2006-05-31|||||Interventional|||Family-Centered Diabetes Project - Sharing Wisdom||Completed||N/A|200||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 03:25:30.867899|2018-06-01 03:25:30.867899
NCT00438113|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2017-06-19|2007-02-20|2007-02-21|Estimate|||||||2017-06-19|2017-06-20|Actual|December 2009||2009-12-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SMAC AF||Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF|Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF|Completed||Phase 4|184|Actual|Nova Scotia Health Authority||2|||f||||f||||||||No||2018-06-01 03:25:31.02096|2018-06-01 03:25:31.02096
NCT00438100|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-18|2015-05-14||2015-05-14|2007-02-20|2007-02-21|Estimate|2015-05-14|2015-05-29|Estimate||||2015-05-14|2015-05-29|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Interventional|||Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer|Randomized Control Study of Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer Patients|Completed||Phase 2|142|Actual|Japan Breast Cancer Research Network||2|||f||||t||||||||||2018-06-01 03:25:31.193965|2018-06-01 03:25:31.193965
NCT00438087|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2012-07-06|2007-02-20|2007-02-21|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Interventional|||Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery|Assessment of Corticosteroid Effect in the Prevention of Facial Palsy After Cerebella-pontine Angle Surgery|Completed||Phase 3|313|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:25:31.668841|2018-06-01 03:25:31.668841
NCT00438074|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-05-01|2007-02-20|2007-02-21|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2007||2007-02-28|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer|A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer|Recruiting|||40|Anticipated|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 03:25:31.779877|2018-06-01 03:25:31.779877
NCT00438048|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2008-05-21|2007-02-20|2007-02-21|Estimate|||||||2008-05-21|2008-05-22|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment|Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva|Completed||Phase 4|76|Actual|Pontificia Universidad Catolica de Chile||1|||f||||t||||||||||2018-06-01 03:25:32.048783|2018-06-01 03:25:32.048783
NCT00438035|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2008-08-11|2007-02-19|2007-02-21|Estimate|||||||2008-08-11|2008-08-12|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|ECG-Spectral||Heart Rate Variability and Postoperative Pain|Evaluation of Postoperative Pain by Spectral Analysis of ECG R-R Intervals|Completed||N/A|106|Actual|University Hospital, Bordeaux|||||f||||f||||||||||2018-06-01 03:25:32.187609|2018-06-01 03:25:32.187609
NCT00438022|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2016-10-04|2007-02-20|2007-02-21|Estimate|||||||2016-10-04|2016-10-06|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis|Risk Factors in Atopic Dermatitis for the Development of Eczema Herpeticum|Completed|||240|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||t||||||Samples With DNA|"~     Blood and skin samples will be retained~   "|Yes|Participant level data access is available to the public in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 03:25:32.330145|2018-06-01 03:25:32.330145
NCT00438009|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2018-01-10|2007-02-20|2007-02-21|Estimate|||||||2018-01-10|2018-01-12|Actual|February 2007||2007-02-28|January 2018|2018-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)|A Phase I, Open Label, Cohort Study of Two Doses of Cavatak (Coxsackievirus Type A21) Given Intratumourally in Stage IV Melanoma Patients.|Completed||Phase 1|9|Actual|Viralytics||1|||f||||t||||||||||2018-06-01 03:25:32.437446|2018-06-01 03:25:32.437446
NCT00437996|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2009-06-26|2007-02-19|2007-02-21|Estimate|||||||2009-06-26|2009-06-30|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|January 2008|Actual|2008-01-31|||||Interventional|||Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial|Epidural Analgesia During Labour. Impact of Clonidine Addition to Levobupivacaine and Sufentanil|Completed||Phase 3|85|Actual|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:25:32.523661|2018-06-01 03:25:32.523661
NCT00437983|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2009-06-30||2010-01-03|2007-02-20|2007-02-21|Estimate|2009-10-19|2009-11-25|Estimate||||2010-01-03|2010-01-05|Estimate|April 2007||2007-04-30|January 2010|2010-01-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||The Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of Phosphatidylserine-Omega3 in Elderly With Age Associated Memory Impairment|Completed||Phase 4|157|Actual|Enzymotec||2|||f||||||||||||||2018-06-01 03:25:32.587596|2018-06-01 03:25:32.587596
NCT00437970|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-18|||2016-05-26|2007-02-20|2007-02-21|Estimate|||||||2016-05-26|2016-05-27|Estimate|April 2008||2008-04-30|April 2009|2009-04-30|February 2009|Anticipated|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Medication in Early Diabetes (MED) Study|Drug naïve Indigenous Australians With Type 2 Diabetes, Enrolled in a Randomised Controlled Trial of Rosiglitazone Versus Metformin Monotherapy to Assess the Effects on Metabolic and Cardiovascular Parameters|Withdrawn||Phase 4|0|Actual|Menzies School of Health Research||2||Unable to secure supply of the study medication|f||||t||||||||||2018-06-01 03:25:32.800837|2018-06-01 03:25:32.800837
NCT00437957|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2017-02-20|2007-02-20|2007-02-21|Estimate|||||||2017-02-20|2017-02-23|Actual|December 2006||2006-12-31|June 2011|2011-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases|Phase I Trial Of Temozolomide Combined With The Histone Deacetylase Inhibitor Valproic Acid (VPA) And Whole Brain Radiation Therapy (WBR) For Brain Metastases From Solid Tumors In Adults|Terminated||Phase 1|10|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||Lack of enrollment|f||||f||||||||||2018-06-01 03:25:32.891311|2018-06-01 03:25:32.891311
NCT00437944|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2007-02-19|2007-02-19|2007-02-21|Estimate|||||||2007-02-19|2007-02-21|Estimate|May 2006||2006-05-31|February 2007|2007-02-28|July 2006||2006-07-31|||||Observational|||Relation Between Polymorphism in Genes Related to Kidney Disease and Renal Manifistations in Fabry Disease||Completed|||||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:25:33.105445|2018-06-01 03:25:33.105445
NCT00437931|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2016-09-07|2007-02-19|2007-02-21|Estimate|||||||2016-09-07|2016-09-08|Estimate|February 2007||2007-02-28|September 2016|2016-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction||Completed|||60|Actual|HaEmek Medical Center, Israel|||3||f||||||||||||||2018-06-01 03:25:33.158997|2018-06-01 03:25:33.158997
NCT00437918|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2008-03-21|2007-02-20|2007-02-21|Estimate|||||||2008-03-21|2008-03-24|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients|Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy|Completed||Phase 4|85|Actual|Inje University|||||f||||t||||||||||2018-06-01 03:25:33.249277|2018-06-01 03:25:33.249277
NCT00437905|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate|June 2003||2003-06-30|February 2007|2007-02-28|January 2007||2007-01-31|||||Interventional|||Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial|Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial|Terminated||Phase 4|40||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:25:33.333262|2018-06-01 03:25:33.333262
NCT00437892|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2011-08-18|2007-02-20|2007-02-21|Estimate|||||||2011-08-18|2011-08-19|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis|The Effect of Statins on D-dimer Levels in Patients With a Previous Venous Thromboembolic Event|Terminated||Phase 2|10|Actual|Università degli Studi dell'Insubria||2||Competitive trials and slow recruitment rate|f||||f||||||||||2018-06-01 03:25:33.424133|2018-06-01 03:25:33.424133
NCT00437879|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-05-01|2007-02-20|2007-02-21|Estimate|||||||2017-05-01|2017-05-03|Actual|January 2007||2007-01-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment|Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment|Recruiting|||100|Anticipated|Sunnybrook Health Sciences Centre|||||f||||t||||||||||2018-06-01 03:25:33.508674|2018-06-01 03:25:33.508674
NCT00437866|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2012-12-05|2007-02-20|2007-02-21|Estimate|||||||2012-12-05|2012-12-06|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|July 2010|Actual|2010-07-31|February 2008|Actual|2008-02-29||Observational|||Hepcidin in Anemic Chronic Heart Failure (CHF) Patients|Hepcidin in the Pathogenesis of Anemia in Patients With Chronic Heart Failure|Completed|||100|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 03:25:33.582865|2018-06-01 03:25:33.582865
NCT00437853|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate|June 2003||2003-06-30|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer||Completed||N/A|30||Instituto Nacional de Cancerologia de Mexico|||||f||||||||||||||2018-06-01 03:25:33.657579|2018-06-01 03:25:33.657579
NCT00437840|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2017-08-03|2007-02-20|2007-02-21|Estimate|||||||2017-08-03|2017-08-07|Actual|March 20, 2007|Actual|2007-03-20|August 2017|2017-08-31|June 20, 2007|Actual|2007-06-20|June 20, 2007|Actual|2007-06-20||Interventional|||A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809|A Placebo-controlled, Single-blind, Randomised, Human Volunteer Study Investigating the Tolerability and Pharmacokinetics of Escalating Single Oral Doses of GSK598809 in Smokers|Completed||Phase 1|12|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:25:33.720207|2018-06-01 03:25:33.720207
NCT00437827|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2009-10-23|2007-02-20|2007-02-21|Estimate|||||||2009-10-23|2009-10-27|Estimate|August 2006||2006-08-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure|A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure|Completed||N/A|120|Anticipated|CNS Response||2|||f||||f||||||||||2018-06-01 03:25:33.806275|2018-06-01 03:25:33.806275
NCT00437814|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate|September 2005||2005-09-30|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Effect of Ketamine (Ketalar) on Intracranial Pressure|Effect of Ketamine (Ketalar) on Intracranial Pressure|Unknown status|Recruiting|N/A|30||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:25:33.908643|2018-06-01 03:25:33.908643
NCT00437788|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate||||January 2007|2007-01-31||||||||Observational|||The Effect of a Digital Photograph of the Patient in a CT Scan Examination on the Quality of Diagnosis by the Radiologist||Unknown status|Not yet recruiting||10000||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:25:33.999974|2018-06-01 03:25:33.999974
NCT00437775|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|March 2007||2007-03-31|||||Observational|||ACEIs and ARBs Treatment in Diabetic Patients -Drug Interactions and Adverse Drug Effects|Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.|Unknown status|Recruiting||300||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:25:34.052651|2018-06-01 03:25:34.052651
NCT00437762|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2013-02-27|2007-02-20|2007-02-21|Estimate|||||||2013-02-27|2013-02-28|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|TBA||Effectiveness of Botulinum Toxin Injection in the Tennis Elbow Treatment|Effectiveness of Botulinum Toxin A Injection for the Treatment of Lateral Epicondylitis Unrelieved by Usual Medical Cares : A Double Blind Randomized Controlled Trial Versus Placebo|Completed||Phase 3|61|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 03:25:34.127479|2018-06-01 03:25:34.127479
NCT00437749|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2011-09-08|2007-02-20|2007-02-21|Estimate|||||||2011-09-08|2011-09-09|Estimate|August 2001||2001-08-31|September 2011|2011-09-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer|Phase 3, Randomized, Double-Blind, Placebo-controlled Study of CBT-1 and Paclitaxel/Carboplatin in Patients With Inoperable Non-Small Cell Lung Cancer|Terminated||Phase 3|214|Actual|CBA Research||2||slow accrual rate; interim accrual objective met|f||||||||||||||2018-06-01 03:25:34.23351|2018-06-01 03:25:34.23351
NCT00437736|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2015-09-16|2007-02-20|2007-02-21|Estimate|||||||2015-09-16|2015-09-17|Estimate|February 2007||2007-02-28|September 2015|2015-09-30|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|AP1001||A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors|Phase I Dose Finding and Pharmacokinetic Study of Intravenous APO010, a Recombinant Form of Human Fas Ligand, in Patients With Solid Tumors|Completed||Phase 1|26|Actual|Onxeo||1|||f||||t||||||||||2018-06-01 03:25:34.302316|2018-06-01 03:25:34.302316
NCT00437723|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2009-05-13|2007-02-19|2007-02-21|Estimate|||||||2009-05-13|2009-05-14|Estimate||||May 2009|2009-05-31|April 2008|Actual|2008-04-30|||||Interventional|||A Study of NeoRecormon in Patients With Chronic Kidney Disease.|An Open-Label Study to Investigate the Effect of NeoRecormon on Hemoglobin Level and Renal Function in Patients With Chronic Kidney Disease, Stage 2-4|Completed||Phase 4|90|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:25:34.373023|2018-06-01 03:25:34.373023
NCT00437710|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2010-03-23|2007-02-20|2007-02-21|Estimate|||||||2010-03-23|2010-03-24|Estimate|July 2005||2005-07-31|February 2007|2007-02-28|February 2007|Anticipated|2007-02-28|||||Interventional|CARDIAC||Safety and Efficacy of Bone Marrow Cell Transplantation in Humans Myocardial Infarction|Cardiac Study. Cellular Cardiomyoplasty of Infarcted Failed Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Azienda Unità Sanitaria Locale di Piacenza|||||f||||||||||||||2018-06-01 03:25:34.435004|2018-06-01 03:25:34.435004
NCT00437697|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate|April 2003||2003-04-30|February 2007|2007-02-28|April 2005||2005-04-30|||||Interventional|||Thromboprophylaxis in Critically Ill Patients|Thromboprophylaxis in Critically Ill Patients: a Prospective, Randomized Study Comparing Anti-Xa Activities Following Subcutaneous Administration of 5000 IU and 7500 IU Dalteparin|Terminated||Phase 4|90||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:25:34.503257|2018-06-01 03:25:34.503257
NCT00437684|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2009-02-05|2007-02-20|2007-02-21|Estimate|||||||2009-02-05|2009-02-06|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy|A Pilot, Open Label, Multicenter, Randomized Clinical Trial on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin and Pegylated Interferon|Unknown status|Recruiting|Phase 3|50|Anticipated|IRCCS San Raffaele||2|||f||||||||||||||2018-06-01 03:25:34.584307|2018-06-01 03:25:34.584307
NCT00437333|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate|December 2003||2003-12-31|February 2007|2007-02-28|April 2006||2006-04-30|||||Interventional|||Metformin Suspension and Insulin Sensitivity|Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome|Completed||Phase 4|30||University Magna Graecia|||||f||||||||||||||2018-06-01 03:25:37.769815|2018-06-01 03:25:37.769815
NCT00437671|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2016-01-18|2007-02-20|2007-02-21|Estimate|||||||2016-01-18|2016-01-20|Estimate|March 2007||2007-03-31|January 2016|2016-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels|Pharmacokinetics Of Active And Passive Tetanus Immunization Given Concurrently In Subjects With No Known Primary Immunization History Or In Subjects With Tetanus Antibody Levels Below Protective Levels|Terminated||Phase 4|6|Actual|Grifols Therapeutics LLC||1||Study terminated for cGCP non-compliance. Analyses could not be performed.|f||||f||||||||||2018-06-01 03:25:34.66922|2018-06-01 03:25:34.66922
NCT00437658|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16||2012-02-24|2013-01-02|2007-02-16|2007-02-21|Estimate||||2012-02-24|2012-02-28|Estimate|2013-01-02|2013-01-08|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy Study of NBI-56418 in Endometriosis|A Phase II, Randomized, Double Blind, Active-controlled Study to Access the Safety and Efficacy of NBI-56418 in Subjects With Endometriosis|Completed||Phase 2|252|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 03:25:34.753836|2018-06-01 03:25:34.753836
NCT00437645|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|2009-08-17||2014-11-03|2007-02-20|2007-02-21|Estimate|2011-01-17|2011-02-14|Estimate||||2014-11-03|2014-11-11|Estimate|January 2007||2007-01-31|November 2014|2014-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension|A Double-blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of Treatment With the Combination of Valsartan/Amlodipine 160/5 mg Compared to Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Alone|Completed||Phase 3|1183|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:25:34.929923|2018-06-01 03:25:34.929923
NCT00437632|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2017-07-27|2007-02-20|2007-02-21|Estimate|||||||2017-07-27|2017-07-31|Actual|March 1, 2007|Actual|2007-03-01|July 2017|2017-07-31|August 22, 2008|Actual|2008-08-22|August 22, 2008|Actual|2008-08-22||Interventional|||Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809|A Placebo Controlled, Single Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses of GSK598809 in Healthy Male and Female Volunteers for 28 Days.|Completed||Phase 1|104|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 03:25:35.413286|2018-06-01 03:25:35.413286
NCT00437619|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2015-12-01|2007-02-19|2007-02-21|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2007||2007-02-28|December 2015|2015-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.|An Open Label Study to Evaluate the Clinical Response to Sequential Treatment With Daivobet and Daivonex in Patients With Mild to Moderate Psoriasis|Completed||Phase 4|200|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:25:35.525808|2018-06-01 03:25:35.525808
NCT00437606|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2016-08-23|2007-02-19|2007-02-21|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.|A Nonrandomized, Open Label Study to Examine the Effect of Hepatic Impairment on the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.'|Terminated||Phase 1|2|Actual|Hoffmann-La Roche||3||poor recruitment|f||||||||||||||2018-06-01 03:25:35.604563|2018-06-01 03:25:35.604563
NCT00437593|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2008-09-21|2007-02-20|2007-02-21|Estimate|||||||2008-09-21|2008-09-23|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue|UHR-OCT and HD-OCT for Preretinal Membranes: Is There a Difference Between ICG and Membrane Blue? A Randomized Clinical Trial|Completed||N/A|20|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||||f||||f||||||||||2018-06-01 03:25:35.6863|2018-06-01 03:25:35.6863
NCT00437580|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2011-01-18|2007-02-20|2007-02-21|Estimate|||||||2011-01-18|2011-01-19|Estimate|February 2007||2007-02-28|January 2011|2011-01-31|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus Intestinal Carriage|Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus (VRE) Intestinal Carriage : a Double Blind Randomized Pilot Study|Unknown status|Recruiting|Phase 4|24|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:25:35.763309|2018-06-01 03:25:35.763309
NCT00437567|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2014-01-02|2007-02-19|2007-02-21|Estimate|||||||2014-01-02|2014-01-03|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Prebiotics in the Prevention of Necrotizing Enterocolitis|Prebiotics vs. Placebo in the Prevention of Necrotizing Enterocolitis in Premature Neonates|Unknown status|Recruiting|Phase 2|260|Anticipated|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-06-01 03:25:35.851774|2018-06-01 03:25:35.851774
NCT00437554|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-11-28|2007-02-20|2007-02-21|Estimate|||||||2007-11-28|2007-11-29|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Phase III Study for Glimepiride + Metformin Hydrochloride (Amaryl M) Slow Release (SR)|A 16-Week Controlled, Double Blind, Double Dummy, Randomized, Two Arm Parallel-Group Study to Compare the Efficacy and Safety of Amaryl M 1/250 mg b.i.d vs. Amaryl M SR 2/500 mg od. in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|188|Anticipated|Handok Pharmaceuticals Co., Ltd.|||||f||||f||||||||||2018-06-01 03:25:35.969576|2018-06-01 03:25:35.969576
NCT00437541|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2007-02-20|2007-02-20|2007-02-21|Estimate|||||||2007-02-20|2007-02-21|Estimate|July 2001||2001-07-31|February 2007|2007-02-28|December 2002||2002-12-31|||||Interventional|HIHS||Housing, Insulation and Health Study|The Impact of Insulating Domestic Houses on the Health of Occupants: an Intervention Study|Completed||N/A|4000||University of Otago|||||f||||||||||||||2018-06-01 03:25:36.096429|2018-06-01 03:25:36.096429
NCT00437528|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2007-05-16|2007-02-20|2007-02-21|Estimate|||||||2007-05-16|2007-05-17|Estimate|November 2006||2006-11-30|February 2007|2007-02-28|December 2007||2007-12-31|||||Observational|||Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity|Phase I Study for Evaluating the Safety and Applicability of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity|Unknown status|Recruiting||10|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-06-01 03:25:36.233355|2018-06-01 03:25:36.233355
NCT00437502|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2012-11-15|2007-02-19|2007-02-21|Estimate|||||||2012-11-15|2012-11-19|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer|A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA-51) as Consolidation Following Optimal Debulking and Systemic Chemotherapy for Women With Advanced Stage Ovarian, Tubal, or Peritoneal Cancer|Completed||Phase 1|8|Actual|Duke University||1|||f||||t||||||||||2018-06-01 03:25:36.298733|2018-06-01 03:25:36.298733
NCT00437489|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2008-12-11||2009-04-13|2007-02-20|2007-02-21|Estimate|2009-02-04|2009-03-06|Estimate||||2009-04-13|2009-05-11|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Clinical Trial Comparing The Efficacy And Safety Of 2 Different Initial Dose Prescriptions For Exubera.|A 16 Week Open-Label Outpatient, Randomized, Parallel Study Assessing The Impact Of Two Different Initial Dose Prescriptions For Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents.|Terminated||Phase 4|49|Actual|Pfizer|As a result of Pfizer's decision (18Oct2007) to return the worldwide rights for Exubera (insulin human [rDNA origin]) Inhalation Powder) to Nektar, from which Pfizer licensed inhaled insulin technology, it was decided to terminate this study.|2||"This protocol was terminated not for safety reasons, but because Pfizer decided to return the~   worldwide rights for Exubera to Nektar, on 18 October 2007."|f||||f||||||||||2018-06-01 03:25:36.413322|2018-06-01 03:25:36.413322
NCT00437476|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2009-02-05|2007-02-20|2007-02-21|Estimate|||||||2009-02-05|2009-02-06|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|July 2010|Anticipated|2010-07-31||Interventional|||Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy|Pilot, Multicenter, Randomized Study on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV ARV-Naive Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin and Pegylated Interferon|Unknown status|Recruiting|Phase 3|60|Anticipated|IRCCS San Raffaele||2|||f||||||||||||||2018-06-01 03:25:36.728045|2018-06-01 03:25:36.728045
NCT00437463|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2010-11-17|2007-02-20|2007-02-21|Estimate|||||||2010-11-17|2010-11-18|Estimate|July 2004||2004-07-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor|Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial|Completed||Phase 3|60|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:25:36.824106|2018-06-01 03:25:36.824106
NCT00437450|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2009-11-17|2007-02-19|2007-02-21|Estimate|||||||2009-11-17|2009-11-18|Estimate|October 2004||2004-10-31|February 2007|2007-02-28|September 2005||2005-09-30|||||Interventional|||Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid|Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid|Unknown status|Active, not recruiting|Phase 2|99||Groupe Francophone des Myelodysplasies|||||f||||t||||||||||2018-06-01 03:25:36.899902|2018-06-01 03:25:36.899902
NCT00437437|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2013-06-20|2007-02-20|2007-02-21|Estimate|||||||2013-06-20|2013-06-21|Estimate|May 2000||2000-05-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|May 2008|Actual|2008-05-31||Interventional|||A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)|Phase I Study to Determine the Effect of a High Fat Meal on the Pharmacokinetics of BMS-540215, the Active Metabolite of Brivanib Alaninate in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|29|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:25:36.996209|2018-06-01 03:25:36.996209
NCT00437424|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2011-05-03|2007-02-20|2007-02-21|Estimate|||||||2011-05-03|2011-05-04|Estimate|July 2007||2007-07-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction|A Pharmacokinetic Study of Brivanib (BMS-582664) in Subjects With Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma With Impaired Hepatic Function|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:25:37.06219|2018-06-01 03:25:37.06219
NCT00437411|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2016-10-20|2007-02-20|2007-02-21|Estimate|||||||2016-10-20|2016-10-24|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Healing Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial|Healing Through Affective Self-Awareness in Fibromyalgia: a Randomized Controlled Trial|Completed||N/A|66|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 03:25:37.136941|2018-06-01 03:25:37.136941
NCT00437398|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|2013-03-05||2013-04-18|2007-02-20|2007-02-21|Estimate|2013-03-05|2013-04-16|Estimate||||2013-04-18|2013-04-25|Estimate|July 2006||2006-07-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Islet Transplantation for Type 1 Diabetes Mellitus|Islet Transplantation for Type 1 Diabetes Mellitus|Terminated||Phase 1/Phase 2|2|Actual|Mayo Clinic|The study was terminated early due to difficulty in recruiting subjects, and ran short of funds. The sample size (n=2) was too small to perform a meaningful analysis.|1||"The study was terminated early due to difficulty in recruiting subjects, and ran short of~   funds."|f||||t||||||||||2018-06-01 03:25:37.214295|2018-06-01 03:25:37.214295
NCT00437385|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2011-11-08|2007-02-20|2007-02-21|Estimate|||||||2011-11-08|2011-11-10|Estimate|March 2005||2005-03-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|EffECT||Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients|Phase 1 Study: Evaluation of Three Continuation Therapies After Acute Electroconvusive Therapy (ECT) Concerning Efficacy and Cognition in Severly Depressed Patients|Completed||Phase 1|90|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-06-01 03:25:37.344594|2018-06-01 03:25:37.344594
NCT00437372|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-20|||2016-10-19|2007-02-20|2007-02-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients|A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer|Completed||Phase 1|39|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:25:37.428703|2018-06-01 03:25:37.428703
NCT00437359|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-18|||2012-03-28|2007-02-20|2007-02-21|Estimate|||||||2012-03-28|2012-03-30|Estimate|May 2007||2007-05-31|March 2012|2012-03-31|May 2020|Anticipated|2020-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer|Antiestrogen vs Aromatase Inhibitor After Chemotherapy for Adjuvant Setting: Efficacy of Endocrine Therapy After Chemotherapy in Postoperative Adjuvant Therapy for Breast Cancer|Terminated||Phase 2|240|Anticipated|Japan Breast Cancer Research Network||2|||f||||t||||||||||2018-06-01 03:25:37.503149|2018-06-01 03:25:37.503149
NCT00437346|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2015-01-22|2007-02-18|2007-02-21|Estimate|||||||2015-01-22|2015-01-26|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Functional Dyspepsia - Effect of Acid-Reducing Treatment and Information.|Study of Gastroscopy Negative Dyspepsia - Effect of Acid-reducing Treatment and Information on Various Types of Dysmotility.|Unknown status|Active, not recruiting|N/A|200|Anticipated|Helse Fonna||2|||f||||||||||||||2018-06-01 03:25:37.597186|2018-06-01 03:25:37.597186
NCT00437320|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2009-01-06|2007-02-19|2007-02-21|Estimate|||||||2009-01-06|2009-01-07|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin|Comparison of Metvix PDT With Its Vehicle in the Treatment of Photoaged Skin|Completed||Phase 2|45|Anticipated|Galderma||2|||f||||f||||||||||2018-06-01 03:25:37.847028|2018-06-01 03:25:37.847028
NCT00437307|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-19|||2016-09-21|2007-02-20|2007-02-21|Estimate|||||||2016-09-21|2016-09-22|Estimate|March 2007||2007-03-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|July 2013|Actual|2013-07-31||Interventional|HECTOR||Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse|Topotecan Plus Carboplatin im Vergleich Zur Standardtherapie (Paclitaxel Plus Carboplatin Oder Gemcitabin Plus Carboplatin) in Der Therapie Von Patientinnen Mit Platin-sensitivem Rezidivierten Epithelialen Ovarialkarzinom, Peritonealkarzinom Oder Tubenkarzinom|Completed||Phase 3|550|Actual|North Eastern Germany Society of Gynaecologic Oncology||2|||f||||||||||||No||2018-06-01 03:25:37.930307|2018-06-01 03:25:37.930307
NCT00437294|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16||2010-02-16|2010-02-16|2007-02-16|2007-02-19|Estimate||||2010-02-16|2010-02-18|Estimate|2010-02-16|2010-02-18|Estimate|March 2007||2007-03-31|February 2010|2010-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Enzastaurin in Combination of Capecitabine to Treat Breast Cancer|A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane|Terminated||Phase 2|86|Actual|Eli Lilly and Company||2||Lack of efficacy|f||||t||||||||||2018-06-01 03:25:38.047532|2018-06-01 03:25:38.047532
NCT00437281|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|2013-09-16||2014-01-29|2007-02-16|2007-02-19|Estimate|2014-01-29|2014-03-17|Estimate||||2014-01-29|2014-03-17|Estimate|April 2007||2007-04-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures|A Placebo-Controlled, Escalating Dose, Multiple Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pregabalin In Pediatric Patients With Partial Onset Seizures|Completed||Phase 1/Phase 2|65|Actual|Pfizer|Results are reported for AUCtau for multiple-dose PK analysis and AUC (0-∞) for single-dose PK analysis, instead of AUC (0-24), as per change in planned analysis.|2|||f||||f||||||||||2018-06-01 03:25:38.340518|2018-06-01 03:25:38.340518
NCT00437268|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16||2010-04-16|2010-04-16|2007-02-16|2007-02-19|Estimate||||2010-04-16|2010-04-20|Estimate|2010-04-16|2010-04-20|Estimate|March 2007||2007-03-31|April 2010|2010-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer|A Randomized Phase 2 Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Recurrent Colorectal Cancer|Completed||Phase 2|26|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:25:41.310922|2018-06-01 03:25:41.310922
NCT00437255|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-04-03|2007-02-17|2007-02-19|Estimate|||||||2008-04-03|2008-04-07|Estimate|August 2006||2006-08-31|April 2008|2008-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis|An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis|Completed||Phase 4|122|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 03:25:41.434057|2018-06-01 03:25:41.434057
NCT00437242|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2012-05-31|2007-02-16|2007-02-19|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2006||2006-10-31|March 2011|2011-03-31||||||||Interventional|||Odiparcil QT Definitive Study|A Study to Evaluate the Effect of Repeat Oral Doses of Odiparcil on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin.|Terminated||Phase 1|54||GlaxoSmithKline|||||||||||||||||||2018-06-01 03:25:41.505646|2018-06-01 03:25:41.505646
NCT00437229|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2017-11-08|2007-02-17|2007-02-19|Estimate|||||||2017-11-08|2017-11-13|Actual|February 19, 2007|Actual|2007-02-19|November 2017|2017-11-30|May 15, 2007|Actual|2007-05-15|May 15, 2007|Actual|2007-05-15||Interventional|||A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults|An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects|Completed||Phase 1|37|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:25:41.567804|2018-06-01 03:25:41.567804
NCT00437216|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-03-27|2007-02-17|2007-02-19|Estimate|||||||2008-03-27|2008-03-31|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis|Phase 4 Open-Label Multicenter Community-Based 4-Wk Trial to Assess Efficacy, Tolerance to Tx & Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis|Completed|||2488|Actual|Galderma Laboratories, L.P.|||2||f||||f||||||||||2018-06-01 03:25:42.589639|2018-06-01 03:25:42.589639
NCT00437203|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|2012-03-06||2012-03-06|2007-02-16|2007-02-19|Estimate|2012-03-06|2012-04-03|Estimate||||2012-03-06|2012-04-03|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine|Phase I Study of PF-00477736 With Gemcitabine In Patients With Advanced Solid Malignancies|Terminated||Phase 1|43|Actual|Pfizer|The study was prematurely terminated due to business reasons.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 03:25:42.792123|2018-06-01 03:25:42.792123
NCT00437190|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2016-05-11|2007-02-16|2007-02-19|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2003||2003-06-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2006|Actual|2006-12-31||Interventional|||Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF|Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of Degenerative Disc Disease|Completed||N/A|494|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 03:25:45.267162|2018-06-01 03:25:45.267162
NCT00437177|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2009-04-28|2007-02-17|2007-02-19|Estimate|||||||2009-04-28|2009-04-29|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|June 2010|Anticipated|2010-06-30|December 2009|Anticipated|2009-12-31||Interventional|ALC-DRD2-APO||Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)|Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence: Predictive Value for Relapse|Unknown status|Recruiting|Phase 2|50|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||||f||||||||||||||2018-06-01 03:25:45.388439|2018-06-01 03:25:45.388439
NCT00429234|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2013-04-01|2007-01-29|2007-01-31|Estimate|||||||2013-04-01|2013-04-04|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Gemcitabine and Dasatinib in Advanced Solid Tumors|Phase I Open-Labeled Trial of Gemcitabine and Dasatinib in Advanced Solid Tumors|Completed||Phase 1|54|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:20.253306|2018-06-01 03:28:20.253306
NCT00437164|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2012-05-31|2007-02-16|2007-02-19|Estimate|||||||2012-05-31|2012-06-04|Estimate|September 2006||2006-09-30|May 2011|2011-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus|A Randomized, Double-blind, Parallel, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of Oral GW677954 Capsules (15 mg) in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|1|Actual|GlaxoSmithKline||||Company decision not related to safety.|||||f||||||||||2018-06-01 03:25:45.507268|2018-06-01 03:25:45.507268
NCT00437151|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-03-27|2007-02-17|2007-02-19|Estimate|||||||2008-03-27|2008-03-31|Estimate|June 2006||2006-06-30|March 2008|2008-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%|An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris.|Completed||Phase 4|61|Actual|Galderma Laboratories, L.P.||4|||f||||f||||||||||2018-06-01 03:25:45.644989|2018-06-01 03:25:45.644989
NCT00437138|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2007-02-16|2007-02-16|2007-02-19|Estimate|||||||2007-02-16|2007-02-19|Estimate|April 2006||2006-04-30|February 2007|2007-02-28|June 2006||2006-06-30|||||Interventional|||Controlled Exposures to Air Pollution in Patients With Coronary Heart Disease|The Effects of Air Pollution on Vascular and Endogenous Fibrinolytic Function in Patients With Coronary Heart Disease|Completed||Early Phase 1|20||University of Edinburgh|||||f||||||||||||||2018-06-01 03:25:45.735104|2018-06-01 03:25:45.735104
NCT00437125|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|2010-07-16||2010-09-01|2007-02-16|2007-02-19|Estimate|2010-07-16|2010-08-16|Estimate||||2010-09-01|2010-09-08|Estimate|March 2007||2007-03-31|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease|An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease|Completed||Phase 4|151|Actual|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 03:25:45.834934|2018-06-01 03:25:45.834934
NCT00437112|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16||2018-03-07|2018-03-07|2007-02-16|2007-02-19|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|February 2007||2007-02-28|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared With Once-Daily Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes Mellitus on Oral Agents|Completed||Phase 3|142|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:25:46.532703|2018-06-01 03:25:46.532703
NCT00437099|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2010-05-26|2007-02-16|2007-02-19|Estimate|||||||2010-05-26|2010-05-27|Estimate|February 2009||2009-02-28|May 2010|2010-05-31|September 2011|Anticipated|2011-09-30|February 2011|Anticipated|2011-02-28||Interventional|||Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder|Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial.|Unknown status|Recruiting|Phase 4|102|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||||||||||||2018-06-01 03:25:46.655276|2018-06-01 03:25:46.655276
NCT00437086|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2014-10-15|2007-02-15|2007-02-19|Estimate|||||||2014-10-15|2014-10-17|Estimate|September 2005||2005-09-30|October 2014|2014-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders|A Prospective Open-Label Pilot Trial of PS-341 (Bortezomib; VELCADE) for the Therapy of Symptomatic Advanced Myeloproliferative Disorders|Completed||Early Phase 1|30|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:25:46.754208|2018-06-01 03:25:46.754208
NCT00437073|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2012-09-13||2015-09-24|2007-02-16|2007-02-19|Estimate|2012-09-13|2012-10-15|Estimate||||2015-09-24|2015-10-15|Estimate|May 2007||2007-05-31|October 2012|2012-10-31|February 2010|Actual|2010-02-28|January 2009|Actual|2009-01-31||Interventional|||Brain Metastases In ErbB2-Positive Breast Cancer|Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy|Terminated||Phase 2|22|Actual|GlaxoSmithKline||2||"Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into~   remaining arm terminated due to operational issues."|f||||||||||||||2018-06-01 03:25:46.908364|2018-06-01 03:25:46.908364
NCT00437060|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2017-07-19|2007-02-15|2007-02-19|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2007||2007-01-31|July 2017|2017-07-31||||September 2015|Actual|2015-09-30||Observational|||Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia|A Study of Neurocognitive Function in Children Treated for ALL|Completed|||233|Actual|Children's Oncology Group|||1||f||||||||||Samples Without DNA|"~     blood and cerebrospinal fluid~   "|||2018-06-01 03:25:47.681154|2018-06-01 03:25:47.681154
NCT00437034|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2015-05-07||2015-07-28|2007-02-15|2007-02-19|Estimate|2015-07-28|2015-07-29|Estimate||||2015-07-28|2015-07-29|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||Aflibercept for Relapsed Multiple Myeloma|A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma|Terminated||Phase 2|6|Actual|National Cancer Institute (NCI)||1||Poor accrual|f||||t||||||||||2018-06-01 03:25:47.904628|2018-06-01 03:25:47.904628
NCT00437021|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16||2011-07-20|2013-10-24|2007-02-16|2007-02-19|Estimate||||2011-07-20|2011-07-22|Estimate|2013-10-24|2013-11-18|Estimate|April 2007||2007-04-30|March 2010|2010-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||MVA Post-Event: Administration Timing and Boost Study|Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults|Completed||Phase 1/Phase 2|206|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 03:25:48.225434|2018-06-01 03:25:48.225434
NCT00437008|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2007-02-15|2007-02-15|2007-02-19|Estimate|||||||2007-02-15|2007-02-19|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|January 2006||2006-01-31|||||Interventional|AGE-Benfo||Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes|Acute Effects of a Low-AGE vs. High-AGE Meal on Postprandial Endothelial Function in People With Type 2 Diabetes Mellitus. Protective Effects of Benfotiamine|Completed||Phase 4|21||Ruhr University of Bochum|||||f||||||||||||||2018-06-01 03:25:48.32657|2018-06-01 03:25:48.32657
NCT00436995|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2011-01-20|2007-02-15|2007-02-19|Estimate|||||||2011-01-20|2011-01-21|Estimate|April 2006||2006-04-30|January 2011|2011-01-31|December 2008|Actual|2008-12-31|January 2007|Actual|2007-01-31||Interventional|||Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis|A Multicentre, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis.|Completed||Phase 3|114|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:25:48.42925|2018-06-01 03:25:48.42925
NCT00012610|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||April 2015|2015-04-30|September 2000|Actual|2000-09-30|||||Interventional|||Efficacy of Telepsychiatry in the Treatment of Depression|Efficacy of Telepsychiatry in the Treatment of Depression|Completed||N/A|119|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:17.407982|2018-06-01 05:37:17.407982
NCT00436982|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|2015-09-29||2018-01-23|2007-02-16|2007-02-19|Estimate|2015-11-03|2015-12-08|Estimate||||2018-01-23|2018-02-21|Estimate|February 2006||2006-02-28|December 2017|2017-12-31|January 4, 2017|Actual|2017-01-04|November 2008|Actual|2008-11-30||Interventional||With an alpha of 0.05 and a beta of 0.20 the required sample size in each group is 25 patients to detect a difference of 0.3 mm. Patients with inadequate marking will be excluded from the study. Taking the latter into account and to compensate for possible lost to follow up, 30 patients will be recruited per study group.|Evaluation of Triathlon - a New Total Knee Prosthesis System - Triathlon vs. Duracon|Evaluation of Triathlon - a New Total Knee Prosthesis System. Prospective, Comparative, Randomised, Roentgen Stereophotogrammetric Analysis (RSA) Series|Completed||N/A|60|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-06-01 03:25:48.563097|2018-06-01 03:25:48.563097
NCT00436969|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|2013-08-13|2013-02-26|2017-01-27|2007-02-16|2007-02-19|Estimate|2014-03-06|2014-04-11|Estimate|2013-02-26|2013-03-04|Estimate|2017-01-27|2017-03-09|Actual|December 2006||2006-12-31|November 2016|2016-11-30|August 2011|Actual|2011-08-31|February 2010|Actual|2010-02-28||Interventional||The number of partipants analyzed were all 270 subjects that received treatment (87 control, 183 investigational).|ORTHOVISC Shoulder Osteoarthritis Study|A Comparison of Orthovisc® to Corticosteroid Injection in Shoulder Osteoarthritis: Orthovisc Randomized Clinical Trial|Completed||Phase 3|274|Actual|DePuy Mitek||2|||f||||t||||||||No|We will not submit the data to FDA, and as such will not be making IPD available.|2018-06-01 03:25:49.112176|2018-06-01 03:25:49.112176
NCT00436956|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2014-03-07||2014-07-07|2007-02-15|2007-02-19|Estimate|2014-05-28|2014-07-01|Estimate||||2014-07-07|2014-07-17|Estimate|January 2007||2007-01-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|October 2010|Actual|2010-10-31||Interventional||The cohorts are grouped together because the second cohort added prednisone to minimize toxicity/side effects.|AZD2171 to Treat Prostate Cancer|A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|59|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 03:25:49.828643|2018-06-01 03:25:49.828643
NCT00436943|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2010-07-09|2007-02-16|2007-02-19|Estimate|||||||2010-07-09|2010-07-12|Estimate|January 2007||2007-01-31|July 2010|2010-07-31|January 2008|Anticipated|2008-01-31|||||Observational|||Smoking Cessation Program: A Quality Improvement Trial in a Resident-Based Outpatient Clinic|Smoking Cessation Program: A Quality Improvement Trial in a Resident Based Outpatient Clinic|Terminated|||900|Anticipated|Atlantic Health System|||1||f||||||||||||||2018-06-01 03:25:50.311306|2018-06-01 03:25:50.311306
NCT00436930|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2014-01-09|2007-02-15|2007-02-19|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma|Randomized Phase II Trial of Autologous Vaccines Consisting of Adjuvant GM-CSF Plus Proliferating Tumor Cells Versus GM-CSF Plus Dendritic Cells Loaded With Proliferating Tumor Cells in Patients With Metastatic Melanoma (MAC-VAC)|Completed||Phase 2|200|Anticipated|National Cancer Institute (NCI)||2|||||||||||||||||2018-06-01 03:25:50.377449|2018-06-01 03:25:50.377449
NCT00436917|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2011-07-19||2017-03-21|2007-02-15|2007-02-19|Estimate|2011-07-19|2011-08-12|Estimate||||2017-03-21|2017-04-18|Actual|April 2006|Actual|2006-04-30|April 2016|2016-04-30|May 9, 2016|Actual|2016-05-09|June 2008|Actual|2008-06-30||Interventional|||Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer|Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy|Completed||N/A|60|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:25:50.617668|2018-06-01 03:25:50.617668
NCT00436904|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2011-09-16||2011-11-21|2007-02-15|2007-02-19|Estimate|2011-09-16|2011-10-26|Estimate||||2011-11-21|2011-12-01|Estimate|December 2004||2004-12-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|July 2008|Actual|2008-07-31||Interventional|||Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia|Antibody Therapy With Alemtuzumab and Rituximab for Initial Treatment of High Risk Chronic Lymphocytic Leukemia|Completed||Phase 2|30|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:25:50.887905|2018-06-01 03:25:50.887905
NCT00436891|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-05-01|2007-02-16|2007-02-19|Estimate|||||||2008-05-01|2008-05-02|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|April 2007||2007-04-30|||||Observational|||Streptococcal Infections in Fiji - Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 4 -The Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji|Completed|||550||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:25:51.102705|2018-06-01 03:25:51.102705
NCT00436878|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2011-02-04|2007-02-16|2007-02-19|Estimate|||||||2011-02-04|2011-02-08|Estimate|October 2005||2005-10-31|June 2010|2010-06-30||||July 2010|Anticipated|2010-07-31||Interventional|||Intake Promoting Effects of Large Portions in Children||Unknown status|Recruiting|N/A|160|Anticipated|Temple University|||||f||||||||||||||2018-06-01 03:25:51.209616|2018-06-01 03:25:51.209616
NCT00436865|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2018-03-29|2007-02-16|2007-02-19|Estimate|||||||2018-03-29|2018-03-30|Actual|February 2007||2007-02-28|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study|Insulin and the Polycystic Ovary Syndrome|Completed||N/A|79|Actual|Virginia Commonwealth University||2|||f||||||||||||||2018-06-01 03:25:51.269862|2018-06-01 03:25:51.269862
NCT00436852|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2013-11-19||2017-01-30|2007-02-15|2007-02-19|Estimate|2014-01-13|2014-02-28|Estimate||||2017-01-30|2017-03-10|Actual|January 2007||2007-01-31|January 2017|2017-01-31||||September 2010|Actual|2010-09-30||Interventional||The protocol-specified definition of evaluability was applied. This was not an intention-to-treat analysis because patients who did not receive study drug were excluded (inevaluable).|ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment|A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma|Active, not recruiting||Phase 2|92|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 03:25:51.355216|2018-06-01 03:25:51.355216
NCT00436839|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2012-07-05|2007-02-16|2007-02-19|Estimate|||||||2012-07-05|2012-07-09|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Taxotere Prostate Cancer New Indication Registration Trial in China|An Multicenter, Randomized Study of Comparison of Docetaxel Plus Prednisone With Mitoxantrone Plus Prednisone in the Patients With Hormone-refractory (Androgen-independent) Metastatic Prostate Cancer|Completed||Phase 3|228|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:25:51.966945|2018-06-01 03:25:51.966945
NCT00436644|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2012-02-17||2014-03-20|2007-02-15|2007-02-19|Estimate|2012-02-17|2012-03-22|Estimate||||2014-03-20|2014-04-16|Estimate|March 2007||2007-03-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|March 2009|Actual|2009-03-31||Interventional|||Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin|A Phase II Trial of Lapatinib in Combination With Weekly Topotecan in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma|Completed||Phase 2|18|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:25:55.335085|2018-06-01 03:25:55.335085
NCT00436826|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2013-03-28||2013-08-04|2007-02-16|2007-02-19|Estimate|2013-05-27|2013-07-01|Estimate||||2013-08-04|2013-08-07|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|ONWARD||A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)|A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-β) Treatment in Multiple Sclerosis Subjects With Active Disease|Completed||Phase 2|214|Actual|EMD Serono|The 96-week DB treatment period of study was completed as planned, and safety and exploratory efficacy results are presented here. The duration of OL Ext. period was reduced for some participants, following termination of the development program.|2|||f||||||||||||||2018-06-01 03:25:52.08416|2018-06-01 03:25:52.08416
NCT00436800|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2009-09-17|2007-02-16|2007-02-19|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2005||2005-03-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma|Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC)|Completed||Phase 2|41|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:25:52.844265|2018-06-01 03:25:52.844265
NCT00436787|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-05-15|2007-02-16|2007-02-19|Estimate|||||||2008-05-15|2008-05-16|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers|Pharmacokinetic Properties of Fondaparinux Sodium in Morbidly Obese Volunteers|Completed||Phase 2|21|Anticipated|University of Pittsburgh|||||t||||||||||||||2018-06-01 03:25:52.906097|2018-06-01 03:25:52.906097
NCT00436774|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2013-08-09|2007-02-15|2007-02-19|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2006||2006-06-30|June 2009|2009-06-30||||September 2010|Anticipated|2010-09-30||Observational|||Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01|Cross-Sectional Evaluation of Outcome Following Extra-Cranial Germ Cell Tumors Treated According to UKCCSG GC 7901 (GC I) and GC 8901 (GC II) Protocols|Unknown status|Recruiting||60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:25:52.966578|2018-06-01 03:25:52.966578
NCT00436761|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2013-12-17|2007-02-15|2007-02-19|Estimate|||||||2013-12-17|2013-12-18|Estimate|May 2004||2004-05-31|June 2007|2007-06-30||||||||Interventional|||Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors|A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:25:53.06675|2018-06-01 03:25:53.06675
NCT00436748|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2015-03-04||2018-01-05|2007-02-15|2007-02-19|Estimate|2015-03-26|2015-03-31|Estimate||||2018-01-05|2018-01-30|Actual|September 16, 2008|Actual|2008-09-16|January 2018|2018-01-31|March 3, 2014|Actual|2014-03-03|March 3, 2014|Actual|2014-03-03||Interventional||Efficacy analysis set, including all participants who received ≥ 1 dose of investigational product.|Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease|A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis|Terminated||Phase 3|116|Actual|Amgen||2||"FDA and EMA agreed that the information that had been submitted to date was acceptable to meet~   the requirements of the post-marketing commitment."|f||||f||||||||||2018-06-01 03:25:53.169182|2018-06-01 03:25:53.169182
NCT00436722|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2009-05-19|2007-02-16|2007-02-19|Estimate|||||||2009-05-19|2009-05-20|Estimate|June 2006||2006-06-30|May 2009|2009-05-31||||July 2009|Anticipated|2009-07-31||Interventional|ATEGE-LIVER||Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial|Study of ATEGE-Fresenius Induction in Liver Transplantation Followed by Tacrolimus Weaning.|Terminated||Phase 2|72|Anticipated|Hospital Clinic of Barcelona||||Experimental arm (induction + low dose tacrolimus) not effective.|f||||f||||||||||2018-06-01 03:25:54.809106|2018-06-01 03:25:54.809106
NCT00436709|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2014-01-03|2007-02-15|2007-02-19|Estimate|||||||2014-01-03|2014-01-06|Estimate|July 2006||2006-07-31|June 2007|2007-06-30||||||||Interventional|||Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer|A Pilot Study of Bevacizumab With Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Dose Dense Nanoparticle Albumin Bound Paclitaxel for the Treatment of Early Stage Breast Cancer|Unknown status|Active, not recruiting|N/A|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:25:54.890296|2018-06-01 03:25:54.890296
NCT00436696|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2017-10-05|2007-02-15|2007-02-19|Estimate|||||||2017-10-05|2017-10-09|Actual|December 2006||2006-12-31|October 2017|2017-10-31||||January 2100|Anticipated|2100-01-31||Observational|||Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions|Genetic Basis of Neuroblastoma Tumorigenesis|Active, not recruiting|||9350|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     Blood, Bone Marrow~   "|||2018-06-01 03:25:54.975933|2018-06-01 03:25:54.975933
NCT00436683|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16||2009-07-21|2009-07-21|2007-02-16|2007-02-19|Estimate||||2009-07-21|2009-08-10|Estimate|2009-07-21|2009-08-10|Estimate|February 2007||2007-02-28|July 2009|2009-07-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|ACT3||Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia|An Open Label, Dose-Ranging Study to Establish the Tolerability of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia.|Completed||Phase 2|64|Actual|Ineos Healthcare Limited||2|||f||||t||||||||||2018-06-01 03:25:55.076007|2018-06-01 03:25:55.076007
NCT00436670|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15||2016-02-23|2016-02-23|2007-02-15|2007-02-19|Estimate||||2016-02-23|2016-03-23|Estimate|2016-02-23|2016-03-23|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional|||Phase II Study to Evaluate the Efficacy of AMG 317|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma|Completed||Phase 2|294|Actual|Amgen||4|||f||||||||||||||2018-06-01 03:25:55.169982|2018-06-01 03:25:55.169982
NCT00436657|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2012-03-29|2007-02-15|2007-02-19|Estimate|||||||2012-03-29|2012-04-02|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer|A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease|Completed||Phase 1|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:25:55.249337|2018-06-01 03:25:55.249337
NCT00436631|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2015-08-31|2007-02-16|2007-02-19|Estimate|||||||2015-08-31|2015-09-02|Estimate|February 2007||2007-02-28|August 2015|2015-08-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|||Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy|Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy|Completed||Phase 3|30|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 03:25:55.542084|2018-06-01 03:25:55.542084
NCT00436618|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2013-05-01||2013-07-24|2007-02-15|2007-02-19|Estimate|2013-07-24|2013-07-30|Estimate||||2013-07-24|2013-07-30|Estimate|August 2005||2005-08-31|July 2013|2013-07-31||||December 2010|Actual|2010-12-31||Interventional|||Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment|Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma|Completed||Phase 2|277|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 03:25:55.771116|2018-06-01 03:25:55.771116
NCT00436605|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2013-12-05||2014-04-29|2007-02-15|2007-02-19|Estimate|2013-12-05|2014-01-20|Estimate||||2014-04-29|2014-05-15|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|November 2010|Actual|2010-11-30|March 2010|Actual|2010-03-31||Interventional|||Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma|A Phase 2 Study of Dasatinib in Advanced Melanoma|Completed||Phase 2|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:25:56.584234|2018-06-01 03:25:56.584234
NCT00436592|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2009-02-03|2007-02-16|2007-02-19|Estimate|||||||2009-02-03|2009-02-05|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|Flo 24||Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients|Safety and Efficacy of NeuroFlo in 8-24 Hour Stroke Patients|Completed||Phase 1|26|Actual|CoAxia||1|||f||||t||||||||||2018-06-01 03:25:56.715956|2018-06-01 03:25:56.715956
NCT00436579|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2014-02-21|2007-02-15|2007-02-19|Estimate|||||||2014-02-21|2014-02-24|Estimate|January 2007||2007-01-31|October 2011|2011-10-31||||September 2011|Actual|2011-09-30||Interventional|||Sorafenib in Treating Patients With Advanced Solid Tumors|A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Nomotensive Patients With Advanced Malignancies|Terminated||Phase 1|110|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 03:25:56.792897|2018-06-01 03:25:56.792897
NCT00436566|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2012-10-22||2012-11-20|2007-02-15|2007-02-19|Estimate|2012-10-22|2012-11-21|Estimate||||2012-11-20|2012-11-22|Estimate|March 2007||2007-03-31|November 2012|2012-11-30||||April 2009|Actual|2009-04-30||Interventional|||Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery|Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer|Completed||Phase 2|122|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 03:25:56.877267|2018-06-01 03:25:56.877267
NCT00436553|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|2011-01-06||2011-03-23|2007-02-16|2007-02-19|Estimate|2011-03-23|2011-04-19|Estimate||||2011-03-23|2011-04-19|Estimate|February 2007||2007-02-28|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization|A 24-month Randomized, Double-masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Completed||Phase 3|321|Actual|Novartis|Shorten the study duration from 24 months to 12 months based on results of the European combination study MONT BLANC (CBPD952A2309).|3|||f||||||||||||||2018-06-01 03:25:58.344991|2018-06-01 03:25:58.344991
NCT00436540|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-03-27|2007-02-16|2007-02-19|Estimate|||||||2008-03-27|2008-03-31|Estimate|March 2006||2006-03-31|March 2008|2008-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam|A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis|Completed||Phase 4|78|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||||2018-06-01 03:25:59.396275|2018-06-01 03:25:59.396275
NCT00436527|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-04-11|2007-02-16|2007-02-19|Estimate|||||||2008-04-11|2008-04-14|Estimate|August 2006||2006-08-31|April 2008|2008-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application|MetroGel 1% Hydration Study: A Kinetic Regression Study|Completed||Phase 4|26|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-06-01 03:25:59.465193|2018-06-01 03:25:59.465193
NCT00436514|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2009-07-21|2007-02-16|2007-02-19|Estimate|||||||2009-07-21|2009-07-23|Estimate|April 2007||2007-04-30|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Colonoscopy by Videocapsuls Versus Standard Colonoscopy. Intra-individual Comparison for the Subject With a Medium or High Risk of Colorectal Cancer.|Colonoscopy by Videocapsuls Versus Standard Colonoscopy. Intra-individual Comparison for the Subject With a Medium or High Risk of Colorectal Cancer.|Completed||N/A|550|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 03:25:59.536582|2018-06-01 03:25:59.536582
NCT00436501|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2015-01-29||2015-03-11|2007-02-15|2007-02-19|Estimate|2015-03-09|2015-03-11|Estimate||||2015-03-11|2015-03-31|Estimate|January 2007||2007-01-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|March 2011|Actual|2011-03-31||Interventional|||VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|Completed||Phase 1/Phase 2|58|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 03:25:59.620122|2018-06-01 03:25:59.620122
NCT00436488|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2007-02-16|2007-02-16|2007-02-19|Estimate|||||||2007-02-16|2007-02-19|Estimate|January 2005||2005-01-31|February 2007|2007-02-28|July 2006||2006-07-31|||||Observational|||Frequency of ICAM-1 Polymorphisms in Obese Subjects|Study of the Association Between ICAM-1 Polymorphisms and Severe Obesity|Completed|||200||Istituto Auxologico Italiano|||||f||||||||||||||2018-06-01 03:26:00.172187|2018-06-01 03:26:00.172187
NCT00436475|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2011-03-15|2007-02-16|2007-02-19|Estimate|||||||2011-03-15|2011-03-16|Estimate|September 2007||2007-09-30|March 2011|2011-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|CaDDM||Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes|Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes|Completed||Phase 1/Phase 2|112|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||t||||||||||2018-06-01 03:26:00.227333|2018-06-01 03:26:00.227333
NCT00436462|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2009-11-06|2007-02-16|2007-02-19|Estimate|||||||2009-11-06|2009-11-09|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Expression of Steroid Receptors in Endometrium|Expression of Steroid Receptors in Endometrium During the Early Follicular Phase in Stimulated Cycles|Completed|||30|Anticipated|Aristotle University Of Thessaloniki|||||f||||f||||||Samples Without DNA|"~     endometrial tissue~   "|||2018-06-01 03:26:00.330542|2018-06-01 03:26:00.330542
NCT00436449|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2008-08-13|2007-02-16|2007-02-19|Estimate|||||||2008-08-13|2008-08-14|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||RN1001(Avotermin) in Scar Improvement Following Breast Augmentation|A Double Blind, Within Subject, Placebo Controlled Randomised Trial to Investigate the Scar Improvement Efficacy of a Single Intradermal Application of RN1001 (Avotermin) in Female Subjects Undergoing Bilateral Breast Augmentation|Completed||Phase 2|63|Actual|Renovo|||||f||||f||||||||||2018-06-01 03:26:00.38992|2018-06-01 03:26:00.38992
NCT00436436|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2016-11-25||2017-02-07|2007-02-15|2007-02-19|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|November 13, 2006|Actual|2006-11-13|February 2017|2017-02-28|April 14, 2010|Actual|2010-04-14|March 15, 2010|Actual|2010-03-15||Interventional|||O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy|A Phase 2 Study of O-Benzylguanine (O-BG) and Temozolomide in Patients With Glioblastoma Progressing at Least 3 Months After Completion of Primary Treatment With Radiation Therapy and Temozolomide|Terminated||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)|Dr. Howard A. Fine is no longer with the National Cancer Institute (NCI). For historical reasons, he is listed as the (original principal investigator) study official for this study.|1||Study closed to accrual after the company chose to stop development of the drug.|f||||f|t|f||||||No||2018-06-01 03:26:00.465964|2018-06-01 03:26:00.465964
NCT00436423|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2007-10-31|2007-02-16|2007-02-19|Estimate|||||||2007-10-31|2007-11-01|Estimate|March 2006||2006-03-31|October 2007|2007-10-31||||||||Interventional|||A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer||Completed||Phase 2|38|Actual|Korea University Anam Hospital||1|||f||||||||||||||2018-06-01 03:26:00.714177|2018-06-01 03:26:00.714177
NCT00436410|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2012-05-01|2007-02-15|2007-02-19|Estimate|||||||2012-05-01|2012-05-02|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|August 2009|Actual|2009-08-31|||||Interventional|||Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer|An Evaluation of the Tissue Distribution and the Selective Tumor Trafficking of TNF-Bound Colloidal Gold (CYT-6091) Following Intravenous Administration in Subjects With Primary and Metastatic Cancer Undergoing Surgical Resection|Completed||Early Phase 1|108|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:26:00.784145|2018-06-01 03:26:00.784145
NCT00436397|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2010-02-11|2007-02-15|2007-02-19|Estimate|||||||2010-02-11|2010-02-12|Estimate|June 2002||2002-06-30|February 2010|2010-02-28|August 2005|Actual|2005-08-31|||||Interventional|||A New Radiation Therapy Planning System in Patients Undergoing Radiation Therapy for Cancer|Evaluation of the Radionics Body Localizer System and XPLAN/IMRT for Extra-Cranial Sites: A Pilot Study|Completed||N/A|60|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 03:26:00.858088|2018-06-01 03:26:00.858088
NCT00436384|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2008-04-15|2007-02-16|2007-02-19|Estimate|||||||2008-04-15|2008-04-16|Estimate|November 2005||2005-11-30|February 2007|2007-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients|Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients|Completed|||150||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:26:00.91011|2018-06-01 03:26:00.91011
NCT00436371|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2008-09-04|2007-02-15|2007-02-19|Estimate|||||||2008-09-04|2008-09-05|Estimate|May 2005||2005-05-31|September 2008|2008-09-30||||November 2006|Actual|2006-11-30||Interventional|ASAP||Amisulpride in Schizophrenic Acute Phase Patients|The Use of Amisulpride in Schizophrenic Acute Phase Patients.|Completed||Phase 4|50||Sanofi||1|||f||||||||||||||2018-06-01 03:26:01.09288|2018-06-01 03:26:01.09288
NCT00436358|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2011-01-27|2007-02-16|2007-02-19|Estimate|||||||2011-01-27|2011-01-31|Estimate|April 2007||2007-04-30|January 2011|2011-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals in Mexico|Implementation of Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals With Pediatric Medical Care in Mexico|Completed|||134|Actual|GlaxoSmithKline|||5||f||||||||||||||2018-06-01 03:26:01.161487|2018-06-01 03:26:01.161487
NCT00436345|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2009-08-07||2017-05-25|2007-02-15|2007-02-19|Estimate|2010-05-14|2010-05-18|Estimate||||2017-05-25|2017-05-30|Actual|November 2007||2007-11-30|May 2017|2017-05-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)|A Randomized, Open Label, Multicentre Study to Compare the Pharmaco-economic Implications of an Analgesia Based Regimen With Remifentanil and a Conventional Sedation Based Regimen Using Propofol in Medical and Post-surgical ICU Subjects Requiring Mechanical Ventilation for at Least 2 Days.|Terminated||Phase 3|39|Actual|GlaxoSmithKline||2||recruitment issues|f||||||||||||||2018-06-01 03:26:01.277564|2018-06-01 03:26:01.277564
NCT00436332|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2016-10-28||2018-01-31|2007-02-15|2007-02-19|Estimate|2016-10-28|2016-12-22|Estimate||||2018-01-31|2018-03-01|Actual|July 2007||2007-07-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2016|Actual|2016-08-31||Interventional|||S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma|A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC)|Active, not recruiting||Phase 2|84|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 03:26:02.082415|2018-06-01 03:26:02.082415
NCT00436319|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2016-02-11|2007-02-16|2007-02-19|Estimate|||||||2016-02-11|2016-02-12|Estimate|May 2006||2006-05-31|February 2016|2016-02-29||||June 2015|Actual|2015-06-30||Interventional|||Duration of GnRH-analogue Downregulation and Pregnancy Rates|Effect of the Duration of GnRH-analogue Downregulation on Pregnancy Rates in IVF|Terminated||Phase 4|300|Actual|Aristotle University Of Thessaloniki||2|||f||||||||||||||2018-06-01 03:26:02.724767|2018-06-01 03:26:02.724767
NCT00436306|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2015-10-06|2007-02-16|2007-02-19|Estimate|||||||2015-10-06|2015-10-08|Estimate|October 1999||1999-10-31|October 2015|2015-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|PROTECT||Stage Matched Intervention to Increase Dual Method Use|Stage Matched Intervention to Increase Dual Method Use|Completed||Phase 4|550|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-06-01 03:26:02.790527|2018-06-01 03:26:02.790527
NCT00436293|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2010-11-16|2007-02-16|2007-02-19|Estimate|||||||2010-11-16|2010-11-17|Estimate|December 2002||2002-12-31|November 2010|2010-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Taxotere + Cisplatin in Nasopharyngeal Carcinoma|A Randomized Phase II Study of Concurrent Cisplatin-radiotherapy With or Without Neoadjuvant Chemotherapy Using Taxotere and Cisplatin in Advanced Nasopharyngeal Carcinoma (NPC)|Completed||Phase 2|61|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:26:02.867612|2018-06-01 03:26:02.867612
NCT00436085|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2007-02-15|2007-02-15|2007-02-16|Estimate|||||||2007-02-15|2007-02-16|Estimate|December 2003||2003-12-31|February 2007|2007-02-28|December 2005||2005-12-31|||||Interventional|SWISSIT||Randomized Controlled Trial of Stress Management Training in HIV|Randomized Controlled Trial of Stress Management Training in Individuals With HIV Infection|Completed||Phase 3|100||University of Zurich|||||f||||||||||||||2018-06-01 03:26:04.85772|2018-06-01 03:26:04.85772
NCT00436280|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16||2010-10-25|2012-11-28|2007-02-16|2007-02-19|Estimate||||2010-10-25|2010-10-27|Estimate|2012-11-28|2012-11-30|Estimate|February 2007||2007-02-28|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2009|Actual|2009-11-30||Interventional|||Chemotherapy for Patients With Lymphoma|An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine and Oxaliplatin Plus Enzastaurin as Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma|Completed||Phase 2|61|Anticipated|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 03:26:03.056565|2018-06-01 03:26:03.056565
NCT00436267|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2013-12-18|2007-02-15|2007-02-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|November 2006||2006-11-30|November 2009|2009-11-30||||October 2009|Anticipated|2009-10-31||Interventional|||Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery|Phase II Study of SIRT and SERT With Chemotherapy in Patients With Recurrent /Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:26:03.160716|2018-06-01 03:26:03.160716
NCT00436254|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2018-05-01|2007-02-15|2007-02-19|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2001||2001-10-31|May 2018|2018-05-31||||March 2010|Actual|2010-03-31||Interventional|||Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer|A Phase I Study of a DNA Plasmid Based Vaccine Encoding the HER-2/Neu Intracellular Domain in Subjects With HER-2/Neu (HER2) Overexpressing Tumors|Active, not recruiting||Phase 1|66|Anticipated|University of Washington||1|||f||||t||||||||||2018-06-01 03:26:03.23014|2018-06-01 03:26:03.23014
NCT00436241|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-16|||2016-11-01|2007-02-16|2007-02-19|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2007||2007-03-31|November 2016|2016-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.|A Open Label Study of the Effect of First-line Therapy With Xeloda in Combination With Oxaliplatin on Overall Response Rate in Patients With Locally Advanced and/or Metastatic Gastric Cancer|Completed||Phase 2|45|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:26:03.32358|2018-06-01 03:26:03.32358
NCT00436228|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2008-10-09|2007-02-16|2007-02-19|Estimate|||||||2008-10-09|2008-10-13|Estimate|November 2006||2006-11-30|October 2008|2008-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug|An Open-Label, Randomized, Crossover Study to Estimate the Formulation Effect on the Relative Bioavailability of Single Dose Oral SB-742510 in Healthy Subjects|Completed|||32|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:26:03.395848|2018-06-01 03:26:03.395848
NCT00436215|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2015-03-16||2017-07-31|2007-02-15|2007-02-19|Estimate|2015-03-16|2015-03-26|Estimate||||2017-07-31|2017-08-29|Actual|December 12, 2006|Actual|2006-12-12|July 2017|2017-07-31|September 27, 2014|Actual|2014-09-27|June 26, 2014|Actual|2014-06-26||Interventional|||Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer|A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer|Completed||Phase 2|55|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 03:26:03.551297|2018-06-01 03:26:03.551297
NCT00436202|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2010-09-12|2007-02-15|2007-02-16|Estimate|||||||2010-09-12|2010-09-14|Estimate||||September 2010|2010-09-30||||||||Interventional|||Evaluation of an Intervention Program for the Prevention of Anemia||Unknown status|Active, not recruiting|N/A|||Wolfson Medical Center|||||f||||||||||||||2018-06-01 03:26:04.005235|2018-06-01 03:26:04.005235
NCT00436189|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2008-04-25|2007-02-15|2007-02-16|Estimate|||||||2008-04-25|2008-04-30|Estimate|February 2007||2007-02-28|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008||2008-04-30||Interventional|||Assess Cancer in Ovarian Tumors With Biomarkers.|Whole Blood Collection Protocol For Ovarian Assay Clinical Trial In Women With Ovarian Tumors|Completed||N/A|1000|Anticipated|Ciphergen Biosystems|||||f||||||||||||||2018-06-01 03:26:04.095549|2018-06-01 03:26:04.095549
NCT00436176|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2009-03-20|2007-02-14|2007-02-16|Estimate|||||||2009-03-20|2009-03-23|Estimate|June 2007||2007-06-30|March 2009|2009-03-31|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Improving Diabetes Care for African Americans|The Expanded Chronic Care Model: Targeting Disparities in Diabetes Care|Completed||Phase 3|6000|Anticipated|Harvard Vanguard Medical Associates||2|||f||||f||||||||||2018-06-01 03:26:04.203668|2018-06-01 03:26:04.203668
NCT00436163|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2016-08-31||2016-08-31|2007-02-15|2007-02-16|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|March 2007||2007-03-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||All enrolled participants who received at least 1 dose of peginterferon alfa-2a.|A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B|Baltic Post-marketing Program of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B|Completed||Phase 4|39|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:26:04.305759|2018-06-01 03:26:04.305759
NCT00436150|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2013-03-08|2007-02-14|2007-02-16|Estimate|||||||2013-03-08|2013-03-12|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Interpersonal Therapy-Based Treatment to Prevent Postpartum Depression in Adolescent Mothers|Preventing Postpartum Depression in Adolescent Mothers|Completed||N/A|106|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-06-01 03:26:04.523035|2018-06-01 03:26:04.523035
NCT00436137|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2008-11-05|2007-02-14|2007-02-16|Estimate|||||||2008-11-05|2008-11-06|Estimate|June 2007||2007-06-30|November 2008|2008-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Improving Followup of Abnormal Colon Cancer Screening Tests|Improving Followup of Positive Fecal Occult Blood Tests|Completed||N/A|70|Actual|Harvard Vanguard Medical Associates||1|||f||||f||||||||||2018-06-01 03:26:04.602279|2018-06-01 03:26:04.602279
NCT00436124|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2017-02-16|2007-02-15|2007-02-16|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2007|Actual|2007-01-31|February 2017|2017-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.|A Randomized, Open Label Study to Evaluate the Effect of Tamiflu on Viral Shedding and on Serum and Cytoplasmic Inflammatory Cytokine Concentrations in Patients With Laboratory-confirmed Influenza|Terminated||Phase 4|||Hoffmann-La Roche||||poor recruitment, no patients were enrolled|f||||||||||||||2018-06-01 03:26:04.666754|2018-06-01 03:26:04.666754
NCT00436111|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2007-02-15|2007-02-15|2007-02-16|Estimate|||||||2007-02-15|2007-02-16|Estimate|January 2005||2005-01-31|February 2007|2007-02-28|December 2006||2006-12-31|||||Observational|||Characterization of Macroprolactinemia||Completed|||||Kansai Medical University|||||f||||||||||||||2018-06-01 03:26:04.717674|2018-06-01 03:26:04.717674
NCT00436098|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2008-08-26|2007-02-15|2007-02-16|Estimate|||||||2008-08-26|2008-08-27|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|May 2010|Anticipated|2010-05-31|November 2009|Anticipated|2009-11-30||Interventional|||Pediatric Exercise With Congenital Heart Defects (Kinderturnen Mit Angeborenem Herzfehler)|Pediatric Exercise With Congenital Heart Defects (Kinderturnen Mit Angeborenem Herzfehler)|Unknown status|Recruiting|N/A|60|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 03:26:04.766445|2018-06-01 03:26:04.766445
NCT00436072|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2012-10-03|2007-02-15|2007-02-16|Estimate|||||||2012-10-03|2012-10-04|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer|Phase I Study of ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer|Completed||Phase 1|46|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 03:26:04.913053|2018-06-01 03:26:04.913053
NCT00436059|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2009-07-07|2007-02-15|2007-02-16|Estimate|||||||2009-07-07|2009-07-08|Estimate|February 2007||2007-02-28|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)|The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)|Completed||Phase 2|20|Anticipated|Vejle Hospital|||||f||||||||||||||2018-06-01 03:26:04.97698|2018-06-01 03:26:04.97698
NCT00436046|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2008-10-09||2011-06-09|2007-02-15|2007-02-16|Estimate|2008-11-12|2008-11-18|Estimate||||2011-06-09|2011-06-13|Estimate|March 2007||2007-03-31|October 2009|2009-10-31|October 2007|Actual|2007-10-31|April 2007|Actual|2007-04-30||Interventional|||Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally|Type 1 Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally|Completed||Phase 1|95|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 03:26:05.053814|2018-06-01 03:26:05.053814
NCT00436033|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2013-07-10|2007-02-15|2007-02-16|Estimate|||||||2013-07-10|2013-07-11|Estimate|February 2006||2006-02-28|July 2013|2013-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome|A European Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia Syndrome|Completed||Phase 3|1429|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-06-01 03:26:05.924341|2018-06-01 03:26:05.924341
NCT00436020|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2008-05-05|2007-02-15|2007-02-16|Estimate|||||||2008-05-05|2008-05-09|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|November 2008|Anticipated|2008-11-30||Interventional|||rTMS in the Treatment of Bipolar Depression|A Double-Blind Sham Controlled Trial of rTMS in the Treatment of Bipolar Depression|Unknown status|Recruiting|Phase 2|120|Anticipated|Bayside Health||2|||f||||||||||||||2018-06-01 03:26:06.013011|2018-06-01 03:26:06.013011
NCT00436007|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2012-12-19|2012-02-02|2017-04-24|2007-02-15|2007-02-16|Estimate|2013-05-23|2013-05-27|Estimate|2012-02-02|2012-02-07|Estimate|2017-04-24|2017-04-25|Actual|April 30, 2007||2007-04-30|April 2017|2017-04-30|October 7, 2009|Actual|2009-10-07|September 15, 2008|Actual|2008-09-15||Interventional|||Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen|Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants|Completed||Phase 2|511|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:26:06.1183|2018-06-01 03:26:06.1183
NCT00435994|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2015-11-12||2016-05-23|2007-02-15|2007-02-16|Estimate|2016-05-23|2016-06-01|Estimate||||2016-05-23|2016-06-01|Estimate|December 2003||2003-12-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|March 2009|Actual|2009-03-31||Interventional|||Assessment of Airway Obstruction in Infants With Lower Respiratory Infections|Assessment of Airway Obstruction in Infants With Lower Respiratory Infections|Completed||N/A|59|Actual|Indiana University|More than half of our infants woke up before completion of the protocol therefore limiting our analysis.|3|||f||||t||||||||||2018-06-01 03:26:07.213069|2018-06-01 03:26:07.213069
NCT00435981|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2008-01-29|2007-02-15|2007-02-16|Estimate|||||||2008-01-29|2008-01-30|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes|A Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Investigate the Impact of Diamyd® on the Progression of Diabetes in Patients Newly Diagnosed With Type 1 Diabetes Mellitus|Completed||Phase 2|70||Diamyd Therapeutics AB|||||f||||||||||||||2018-06-01 03:26:07.465286|2018-06-01 03:26:07.465286
NCT00435968|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-07-16|2007-02-15|2007-02-16|Estimate|||||||2007-07-16|2007-07-17|Estimate|March 2007||2007-03-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults|Safety and Immune Enhancing Effects of Acute Dosing of COLD-fX in Healthy Adults|Completed||Phase 2|50|Anticipated|Afexa Life Sciences Inc|||||f||||||||||||||2018-06-01 03:26:07.566138|2018-06-01 03:26:07.566138
NCT00435955|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2007-02-15|2007-02-15|2007-02-16|Estimate|||||||2007-02-15|2007-02-16|Estimate|March 2000||2000-03-31|February 2007|2007-02-28||||||||Interventional|||Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma|MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA|Unknown status|Active, not recruiting|Phase 3|240||Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-06-01 03:26:07.62831|2018-06-01 03:26:07.62831
NCT00435942|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|2013-09-23||2017-12-18|2007-02-14|2007-02-16|Estimate|2017-08-03|2017-09-05|Actual||||2017-12-18|2018-01-16|Actual|January 2007||2007-01-31|August 2017|2017-08-31|May 15, 2017|Actual|2017-05-15|April 2011|Actual|2011-04-30||Interventional|||Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft|Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients With Thoracic Aortic Pathologies|Completed||N/A|180|Actual|Bolton Medical|Many subjects experienced more than one type of event.|2|||t||||t||||||||||2018-06-01 03:26:07.837601|2018-06-01 03:26:07.837601
NCT00435929|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2015-12-02||2018-02-28|2007-02-15|2007-02-16|Estimate|2015-12-02|2016-01-08|Estimate||||2018-02-28|2018-03-29|Actual|September 2006||2006-09-30|February 2018|2018-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.|Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients|Completed||Phase 1|16|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:26:08.219581|2018-06-01 03:26:08.219581
NCT00435916|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14||2011-05-24|2014-12-17|2007-02-15|2007-02-16|Estimate||||2011-05-24|2011-06-02|Estimate|2014-12-17|2015-01-07|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma|A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 2|46|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 03:26:08.715293|2018-06-01 03:26:08.715293
NCT00435175|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2007-02-13|2007-02-13|2007-02-14|Estimate|||||||2007-02-13|2007-02-14|Estimate|June 2005||2005-06-30|February 2007|2007-02-28|July 2006||2006-07-31|||||Interventional|||Acute Metabolic Effects of Estradiol|Acute Effects of Estradiol on Lipolysis in Subcutaneous Adipose Tissue and Muscle Assessed by Microdialysis and Tissue Biopsies|Completed||N/A|8||University of Aarhus|||||f||||||||||||||2018-06-01 03:26:28.211866|2018-06-01 03:26:28.211866
NCT00435903|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2009-05-14|2007-02-15|2007-02-16|Estimate|||||||2009-05-14|2009-05-18|Estimate|June 2005||2005-06-30|February 2007|2007-02-28|October 2005||2005-10-31|||||Interventional|||Pilot Study of the Feasibility of Palm Pilots in Monitoring Smoking Behavior in Individuals With Chronic Mental Illness|Pilot Study of the Feasibility of Palm Pilots in Monitoring Smoking Behavior in Individuals With Chronic Mental Illness|Unknown status|Active, not recruiting|Early Phase 1|11||North Suffolk Mental Health Association|||||f||||||||||||||2018-06-01 03:26:08.792773|2018-06-01 03:26:08.792773
NCT00435890|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2008-09-11|2007-02-15|2007-02-16|Estimate|||||||2008-09-11|2008-09-12|Estimate|December 2005||2005-12-31|September 2008|2008-09-30|June 2006|Actual|2006-06-30|February 2006|Actual|2006-02-28||Interventional|||Triage Liaison Physician - Evaluation of a Novel Approach to Address Emergency Department Overcrowding|Randomized Controlled Trial of a Liaison Physician at the Triage Desk to Reduce Emergency Department Overcrowding and Improve Patient Flow.|Completed||Phase 4|5718|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 03:26:08.86022|2018-06-01 03:26:08.86022
NCT00435877|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2018-05-12|2007-02-15|2007-02-16|Estimate|||||||2018-05-12|2018-05-15|Actual|January 29, 2007||2007-01-29|November 5, 2012|2012-11-05|November 5, 2012||2012-11-05|||||Observational|||Procurement of Tissue Samples for Cell Cultures and Analyses|Procurement of Normal Bone, Dermis, Spleen, Thymus and Adipose Tissue for Establishment of Cell Cultures and Tissue Analyses|Terminated|||2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:26:09.933082|2018-06-01 03:26:09.933082
NCT00435864|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2014-04-29|2007-02-15|2007-02-16|Estimate|||||||2014-04-29|2014-04-30|Estimate|April 2007||2007-04-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Natural Killer Index From Hematopoietic Stem Cell Graft|Pilot, Multicenter and Prospective Study of the Natural Killer Index From Hematopoietic Stem Cell Graft at a Genotypic, Phenotypic and Functional Level|Completed||N/A|92|Actual|Nantes University Hospital||3|||f||||f||||||||||2018-06-01 03:26:10.025902|2018-06-01 03:26:10.025902
NCT00435851|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2007-02-16|2007-02-15|2007-02-16|Estimate|||||||2007-02-16|2007-02-19|Estimate|February 2007||2007-02-28|February 2007|2007-02-28||||||||Interventional|Estimabl||Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients|Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl|Unknown status|Not yet recruiting|Phase 3|950||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 03:26:10.118391|2018-06-01 03:26:10.118391
NCT00435838|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|||2008-10-13|2007-02-15|2007-02-16|Estimate|||||||2008-10-13|2008-10-15|Estimate|March 2007||2007-03-31|October 2008|2008-10-31||||||||Observational|||A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701|A Retrospective, Multi-Centre Observational Study to Evaluate Disease Management and Adverse Events in Adult Subjects With HIV-1 Infection Who Were Withdrawn From CNA106030 Due to a Positive HLA-B*5701 Test Result|Completed|||35||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:26:10.203938|2018-06-01 03:26:10.203938
NCT00435825|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-15|2013-03-20||2013-06-19|2007-02-15|2007-02-16|Estimate|2013-06-19|2013-06-25|Estimate||||2013-06-19|2013-06-25|Estimate|March 2007||2007-03-31|June 2013|2013-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||Baseline Measures are based on participants from the Intent-to-treat population who received study drug.|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).|A Randomized, Double-blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.|Completed||Phase 4|551|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 03:26:10.375897|2018-06-01 03:26:10.375897
NCT00435812|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2017-12-08|2014-06-16|2018-01-15|2007-02-14|2007-02-15|Estimate|2018-01-15|2018-02-13|Actual|2014-06-16|2014-06-19|Estimate|2018-01-15|2018-02-13|Actual|December 2006||2006-12-31|January 2018|2018-01-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional||"Safety Analysis Population: All participants who received at least 1 study injection and had any post-baseline safety data.~NOTE: One (1) subject randomized to the Engerix-B group received HEPLISAV in error and was analyzed in the HEPLSAV group for the Safety Analysis Population"|Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine|A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®|Completed||Phase 3|2428|Actual|Dynavax Technologies Corporation||2|||f||||t|t|f||||||No||2018-06-01 03:26:12.231518|2018-06-01 03:26:12.231518
NCT00435799|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2008-06-09|2007-02-14|2007-02-15|Estimate|||||||2008-06-09|2008-06-10|Estimate|February 2007||2007-02-28|January 2007|2007-01-31|January 2010|Anticipated|2010-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Evaluating Collagen Cross-Linking (CCL) Treatment in Norway|Treatment of Keratectasia With Collagen Cross-Linking (CCL) at the Eye Departments of the University Hospital, North Norway in Tromsø and Ullevål University Hospital in Oslo|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Ullevaal University Hospital||1|||f||||||||||||||2018-06-01 03:26:12.864167|2018-06-01 03:26:12.864167
NCT00435786|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-02-14|2007-02-14|2007-02-15|Estimate|||||||2007-02-14|2007-02-15|Estimate||||February 2007|2007-02-28||||||||Observational|||Diabetic Patients With End-Stage Renal Disease||Completed|||||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:26:13.070758|2018-06-01 03:26:13.070758
NCT00435773|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-04-06|2007-02-14|2007-02-15|Estimate|||||||2007-04-06|2007-04-09|Estimate|February 2004||2004-02-29|April 2007|2007-04-30|December 2004||2004-12-31|||||Interventional|||Leeches for the Treatment of Knee Osteoarthritis|Single and Repeated Leech Therapy for the Treatment of Late Stage Knee Osteoarthritis. A Randomized, Placebo Controlled Comparative Trial|Completed||Phase 2|118||RWTH Aachen University|||||f||||||||||||||2018-06-01 03:26:13.238431|2018-06-01 03:26:13.238431
NCT00435760|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2016-11-16|2007-02-14|2007-02-15|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients|Single Dose, Double-blind, Double-dummy, 3 Period Cross-over, Placebo Controlled Clinical Trial to Assess the Reate of Onset of Action of Inhaled Aclidinium Bromide 200µg Compared to Placebo and Tiotropium 18µg in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|115|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 03:26:13.345909|2018-06-01 03:26:13.345909
NCT00435747|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2012-03-13|2007-02-13|2007-02-15|Estimate|||||||2012-03-13|2012-03-14|Estimate||||March 2012|2012-03-31||||||||Interventional|||Efficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo Following Sub Muscular Breast Augmentation|A Double-Blind Comparative Multicenter Study Of The Efficacy And Safety Of Parecoxib IV/IM 40 Mg Vs Placebo On Reducing Opioids Consumption Following Sub Muscular Breast Augmentation Surgery|Withdrawn||Phase 4|0|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:26:13.492032|2018-06-01 03:26:13.492032
NCT00433810|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2010-12-23|2007-02-09|2007-02-12|Estimate|||||||2010-12-23|2010-12-24|Estimate|March 2005||2005-03-31|December 2010|2010-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|LABS-1||Longitudinal Assessment of Bariatric Surgery|Longitudinal Assessment of Bariatric Surgery (LABS-1)|Completed|||5102|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:26:53.04018|2018-06-01 03:26:53.04018
NCT00435734|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2018-05-01|2007-02-14|2007-02-15|Estimate|||||||2018-05-01|2018-05-02|Actual|July 1999||1999-07-31|May 2018|2018-05-31|December 2035|Anticipated|2035-12-31|December 2034|Anticipated|2034-12-31||Observational|Obeldicks||"Obesity Intervention Obeldicks for Obese Children, Adolescents and Their Parents"|"Evaluation of the Intervention Program Obeldicks for Obese Children and Adolescents"|Recruiting|||6000|Anticipated|University of Witten/Herdecke|||||f||||||||||||||2018-06-01 03:26:13.550566|2018-06-01 03:26:13.550566
NCT00435721|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-02-14|2007-02-14|2007-02-15|Estimate|||||||2007-02-14|2007-02-15|Estimate|June 2002||2002-06-30|January 2007|2007-01-31|August 2005||2005-08-31|||||Interventional|||Families Coping With Mental Illness Program|The Families Coping With Mental Illness Program|Unknown status|Active, not recruiting|Phase 1|50||North Suffolk Mental Health Association|||||f||||||||||||||2018-06-01 03:26:13.975965|2018-06-01 03:26:13.975965
NCT00435708|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2015-09-28|2007-02-14|2007-02-15|Estimate|||||||2015-09-28|2015-09-29|Estimate|February 2007||2007-02-28|September 2015|2015-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|DISCO||Effect of Increased Fruit and Vegetable Intake on Chronic Obstructive Pulmonary Disease (COPD)|Effect of Increased Fruit and Vegetable Intake on Airway Inflammation and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|81|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-06-01 03:26:14.162329|2018-06-01 03:26:14.162329
NCT00435695|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2012-05-31|2007-02-13|2007-02-15|Estimate|||||||2012-05-31|2012-06-04|Estimate|November 2006||2006-11-30|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males|An Open Label, Non-randomized Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain 5-HT1A Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK163090, Using the Ligand [11C]-WAY100635.|Completed||Phase 1|13|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:26:14.298174|2018-06-01 03:26:14.298174
NCT00435682|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2008-02-05|2007-02-14|2007-02-15|Estimate|||||||2008-02-05|2008-02-08|Estimate|March 2007||2007-03-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||To Study the Peripheral Effect of Botulinum Toxin-A (Botox-A) on Experimentally Induced Cutaneous Pain in Healthy Subjects||Completed||N/A|||Aalborg University|||||f||||||||||||||2018-06-01 03:26:14.534562|2018-06-01 03:26:14.534562
NCT00435669|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2009-01-21|2007-02-14|2007-02-15|Estimate|||||||2009-01-21|2009-01-22|Estimate|September 2007||2007-09-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)|Mass Balance, Pharmacokinetics and Metabolism of [14C]BMS-582664 Prodrug of BMS-540215, in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|4|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-06-01 03:26:14.616196|2018-06-01 03:26:14.616196
NCT00435656|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2011-08-24|2007-02-14|2007-02-15|Estimate|||||||2011-08-24|2011-08-25|Estimate|September 2007||2007-09-30|August 2011|2011-08-31||||||||Observational|||Pharmacogenetics of Antiretroviral Drugs||Completed|||200|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||||||||||||2018-06-01 03:26:14.69091|2018-06-01 03:26:14.69091
NCT00435643|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-11-19|2007-02-14|2007-02-15|Estimate|||||||2007-11-19|2007-11-20|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Influence of nCPAP on Metabolic Consequences Associated With OSAS|Improvement in Hypothalamic-Pituitary-Adrenal Axis Function After Continuous Positive Airway Pressure Therapy in Obstructive Sleep Apnea Syndrome|Completed||N/A|45|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-06-01 03:26:14.763438|2018-06-01 03:26:14.763438
NCT00435630|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2012-11-19|2007-02-14|2007-02-15|Estimate|||||||2012-11-19|2012-11-21|Estimate|July 2004||2004-07-31|November 2012|2012-11-30|August 2008|Actual|2008-08-31|January 2005|Actual|2005-01-31||Interventional|||Documenting a Learning Curve and Test-retest Reliability of a Virtual Reality Training Simulator in Laparoscopic Surgery|Documenting a Learning Curve and Test-retest Reliability of a Virtual Reality Training Simulator in Laparoscopic Surgery|Completed||N/A|29|Actual|Columbia University||1|||f||||f||||||||||2018-06-01 03:26:14.841325|2018-06-01 03:26:14.841325
NCT00435617|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2012-07-18|2007-02-14|2007-02-15|Estimate|||||||2012-07-18|2012-07-20|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of Hand Therapy 3 to 24 Months After Stroke|Clinical Assessment of a Massed Practice Therapy Device|Completed||N/A|78|Actual|Kinetic Muscles||1|||f||||f||||||||||2018-06-01 03:26:14.937483|2018-06-01 03:26:14.937483
NCT00435604|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2011-10-13|2007-02-14|2007-02-15|Estimate|||||||2011-10-13|2011-10-17|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|May 2007|Actual|2007-05-31|||||Interventional|||A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase|Phase I Dose-Ranging Randomized Double-Blinded Controlled Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase|Completed||Phase 1|15|Anticipated|Halozyme Therapeutics|||||f||||||||||||||2018-06-01 03:26:15.088628|2018-06-01 03:26:15.088628
NCT00435591|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|2010-04-28||2014-04-30|2007-02-14|2007-02-15|Estimate|2010-04-28|2010-05-26|Estimate||||2014-04-30|2014-05-15|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase 4, Randomized, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia|Completed||Phase 4|121|Actual|Cumberland Pharmaceuticals|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.|4|||f||||f||||||||||2018-06-01 03:26:15.311515|2018-06-01 03:26:15.311515
NCT00435578|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2009-04-28|2007-02-14|2007-02-15|Estimate|||||||2009-04-28|2009-04-30|Estimate|February 2007||2007-02-28|April 2009|2009-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma|An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma|Terminated||Phase 2|50|Anticipated|Threshold Pharmaceuticals|||||||||||||||||||2018-06-01 03:26:16.618846|2018-06-01 03:26:16.618846
NCT00435565|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-02-14|2007-02-14|2007-02-15|Estimate|||||||2007-02-14|2007-02-15|Estimate||||February 2007|2007-02-28||||||||Observational|||Severe Hypoglycemia in Pregnant Women With Type 1 Diabetes|Severe Hypoglycemia in Pregnant Women With Type 1 Diabetes. Incidence, Risk Markers and Possibilities for Prevention|Completed|||||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:26:16.73413|2018-06-01 03:26:16.73413
NCT00435552|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-02-14|2007-02-14|2007-02-15|Estimate|||||||2007-02-14|2007-02-15|Estimate|February 2007||2007-02-28|January 2007|2007-01-31||||||||Interventional|||Ease-it Spray for the Treatment of Fire Ant Stings||Completed||Phase 1|||C.R.Darnall Army Medical Center|||||f||||||||||||||2018-06-01 03:26:16.793321|2018-06-01 03:26:16.793321
NCT00435539|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|2013-07-04||2014-12-02|2007-02-14|2007-02-15|Estimate|2013-07-04|2013-09-13|Estimate||||2014-12-02|2014-12-17|Estimate|February 2007||2007-02-28|April 2014|2014-04-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)|A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of Vitreomacular Traction (VMT).|Completed||Phase 2|60|Actual|ThromboGenics||5|||f||||t||||||||||2018-06-01 03:26:16.891008|2018-06-01 03:26:16.891008
NCT00435526|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2007-02-14|2007-02-14|2007-02-15|Estimate|||||||2007-02-14|2007-02-15|Estimate|March 2006||2006-03-31|February 2007|2007-02-28|October 2006||2006-10-31|||||Interventional|BIgGI||Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I|Protective Efficacy of Orally Delivered Bovine Milk Immunoglobulin (BIgG) Specific for the Minor CFA/I Fimbrial Adhesin CfaE Against Challenge With H10407 Enterotoxigenic E. Coli (ETEC) Strain Expressing CFA/I|Completed||Phase 1|30||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 03:26:17.654091|2018-06-01 03:26:17.654091
NCT00435513|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2015-05-03|2007-02-14|2007-02-15|Estimate|||||||2015-05-03|2015-05-05|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Observational|||A Common Polymorphism of the SRD5A2 Gene is Not Associated With Male-to-Female and Female-to-Male Transsexualism|Association Study of a SRD5A2 SNP and Transsexualism.|Completed|||1770|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-06-01 03:26:17.74702|2018-06-01 03:26:17.74702
NCT00435500|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2009-08-21|2007-02-14|2007-02-15|Estimate|||||||2009-08-21|2009-08-25|Estimate|June 2003||2003-06-30|August 2009|2009-08-31|January 2006||2006-01-31|||||Interventional|||Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children|Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children|Unknown status|Active, not recruiting|Phase 3|1320||University of Toronto|||||f||||||||||||||2018-06-01 03:26:17.802409|2018-06-01 03:26:17.802409
NCT00435487|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2009-12-22||2011-10-07|2007-02-14|2007-02-15|Estimate|2009-12-22|2010-01-27|Estimate||||2011-10-07|2011-10-17|Estimate|June 2007||2007-06-30|October 2011|2011-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome|Prospective Randomized Phase IV Open Label Comparative Study Of Dalteparin vs Unfractionated Heparin In High Risk Patients Of Non-ST Elevation Acute Coronary Syndromes Intended For Early Invasive Strategy|Terminated||Phase 4|173|Actual|Pfizer|This study was terminated due to insufficient recruitment of subjects.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 03:26:18.019512|2018-06-01 03:26:18.019512
NCT00435474|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2009-06-08|2007-02-14|2007-02-15|Estimate|||||||2009-06-08|2009-06-09|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Malignant Wounds, Wound Treatment, Psycho-Social Support and Relaxation Therapy|Malignant Wounds: A Randomized Clinical Trial Investigating a Complementary Multidimensional Intervention|Completed||Phase 3|70|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 03:26:18.700179|2018-06-01 03:26:18.700179
NCT00435461|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|2017-02-21||2018-02-06|2007-02-14|2007-02-15|Estimate|2017-07-17|2018-02-05|Actual||||2018-02-06|2018-03-07|Actual|December 20, 2006||2006-12-20|July 2017|2017-07-31|February 28, 2007|Actual|2007-02-28|February 1, 2007|Actual|2007-02-01||Interventional|||Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine|A Comparison of Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 4|1000|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:26:18.864758|2018-06-01 03:26:18.864758
NCT00435448|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2009-04-28|2007-02-14|2007-02-15|Estimate|||||||2009-04-28|2009-04-29|Estimate|June 2005||2005-06-30|April 2009|2009-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia|A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia|Terminated||Phase 3|480||Threshold Pharmaceuticals|||||f||||||||||||||2018-06-01 03:26:20.125297|2018-06-01 03:26:20.125297
NCT00435435|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2007-02-15|2007-02-14|2007-02-15|Estimate|||||||2007-02-15|2007-02-16|Estimate|September 2000||2000-09-30|February 2000|2000-02-29|April 2005||2005-04-30|||||Interventional|DNA||Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence|Phase Four Randomized, Multicentre, Open-Label, Comparative Trial Of Disulfiram, Nalterexone And Acamprosate In The Treatment Of Alcohol Dependence|Completed||Phase 4|243||National Institute for Health and Welfare, Finland|||||f||||||||||||||2018-06-01 03:26:20.27339|2018-06-01 03:26:20.27339
NCT00435422|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2010-03-24|2007-02-14|2007-02-15|Estimate|||||||2010-03-24|2010-03-25|Estimate|January 2010||2010-01-31|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Neuroaxial Blokade and Blood Pressure|Neuroaxial Blokade and the Effect of Fluid Optimization|Unknown status|Recruiting|N/A|16|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:26:20.342649|2018-06-01 03:26:20.342649
NCT00435409|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2010-12-14||2012-06-15|2007-02-13|2007-02-15|Estimate|2010-12-14|2011-01-13|Estimate||||2012-06-15|2012-06-26|Estimate|February 2007||2007-02-28|June 2012|2012-06-30|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|||A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer|A Randomized, Phase 3 Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Previously Treated Breast Cancer|Completed||Phase 3|442|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:26:20.542521|2018-06-01 03:26:20.542521
NCT00435396|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-14|||2017-05-24|2007-02-14|2007-02-15|Estimate|||||||2017-05-24|2017-05-30|Actual|February 22, 2007|Actual|2007-02-22|May 2017|2017-05-31|August 27, 2008|Actual|2008-08-27|August 27, 2008|Actual|2008-08-27||Interventional|||Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects|A Phase I, Open-label, Vaccination Study to Evaluate the Safety and Immunogenicity of the GSK Biologicals Recombinant CMV gB Sub-unit Vaccine GSK1492903A in CMV-seronegative Healthy Male Adult Subjects|Completed||Phase 1|40|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:26:22.476159|2018-06-01 03:26:22.476159
NCT00435383|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2015-12-11|2007-02-14|2007-02-15|Estimate|||||||2015-12-11|2015-12-14|Estimate|March 2003||2003-03-31|December 2015|2015-12-31|October 2008|Actual|2008-10-31|February 2007|Actual|2007-02-28||Observational|||Comparing Oxygen Saturation in Post Anesthesia Care Unit After Different Methods of Pain Relief|Oxygen Saturation During Transfer From Operating Room to Post Anesthesia Care Unit After Current Anesthesia Care|Completed|||42|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||||||||||||2018-06-01 03:26:22.653588|2018-06-01 03:26:22.653588
NCT00012597|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||April 2015|2015-04-30|September 2000|Actual|2000-09-30|||||Interventional|||Pressure Ulcer Assessment Via Telemedicine|Pressure Ulcer Assessment Via Telemedicine|Completed||N/A|128|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:17.494952|2018-06-01 05:37:17.494952
NCT00435370|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2013-08-01||2017-02-04|2007-02-13|2007-02-14|Estimate|2014-08-12|2014-09-08|Estimate||||2017-02-04|2017-03-15|Actual|November 2006||2006-11-30|February 2017|2017-02-28|August 2011|Actual|2011-08-31|February 2011|Actual|2011-02-28||Interventional|||Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia|Tropisetron With Risperidone for Schizophrenia|Completed||Phase 3|179|Actual|Baylor College of Medicine|Since all participants were the first episode and drug naive patients, some participants quit before the completion of the entire clinical trial|2|||f||||f||||||||No||2018-06-01 03:26:22.723105|2018-06-01 03:26:22.723105
NCT00435357|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2013-06-20|2007-02-13|2007-02-14|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2007||2007-02-28|June 2013|2013-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Comparison Between Fixed- Versus Mobile-bearing TKA|Comparison Between Fixed- Versus Mobile-bearing TKA : a Randomized Prospective Study|Completed||N/A|160|Actual|Hospices Civils de Lyon||2|||f||||||||||||||2018-06-01 03:26:23.133803|2018-06-01 03:26:23.133803
NCT00435344|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2007-02-12|2007-02-12|2007-02-14|Estimate|||||||2007-02-12|2007-02-14|Estimate|February 1999||1999-02-28|February 2007|2007-02-28|January 2004||2004-01-31|||||Interventional|||Provider and Peer Delivered Youth Smoking Intervention|Provider and Peer Delivered Youth Smoking Intervention|Completed||Phase 2|2711||University of Massachusetts, Worcester|||||f||||||||||||||2018-06-01 03:26:23.289346|2018-06-01 03:26:23.289346
NCT00435331|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2013-06-17|2007-02-12|2007-02-14|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||6R-BH4 Pulmonary Arterial Hypertension Study|A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of 6R-BH4 in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 1|14|Actual|Vanderbilt University||1|||f||||t||||||||||2018-06-01 03:26:23.418765|2018-06-01 03:26:23.418765
NCT00435318|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2015-12-07|2007-02-12|2007-02-14|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2007||2007-02-28|December 2015|2015-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Lateral Epicondylitis Iontophoresis Randomized Control Trial (LERCT)|Lateral Epicondylitis Iontophoresis Randomized Control Trial (LERCT)|Withdrawn||N/A|0|Actual|Vanderbilt University||||Study approval deferred by the IRB.|f||||||||||||||2018-06-01 03:26:23.572646|2018-06-01 03:26:23.572646
NCT00435305|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2008-06-06|2007-02-13|2007-02-14|Estimate|||||||2008-06-06|2008-06-09|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|November 2007|Anticipated|2007-11-30|||||Observational|||Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion|Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion|Terminated|||40|Anticipated|University Hospital Tuebingen||||"difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to~   continue enrolling patients,"|f||||t||||||||||2018-06-01 03:26:23.718977|2018-06-01 03:26:23.718977
NCT00435292|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2015-10-19|2007-02-13|2007-02-14|Estimate|||||||2015-10-19|2015-10-21|Estimate|April 2006||2006-04-30|November 2008|2008-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee|A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multi Center Study of Flavocoxid ( Limbrel) vs Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee|Completed||N/A|350|Actual|Primus Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:26:23.882004|2018-06-01 03:26:23.882004
NCT00435279|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2012-02-21|2007-02-13|2007-02-14|Estimate|||||||2012-02-21|2012-02-22|Estimate|June 2007||2007-06-30|February 2012|2012-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia|A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-existing Insomnia|Completed||Phase 3|678|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 03:26:24.008149|2018-06-01 03:26:24.008149
NCT00435266|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2009-02-16|2007-02-13|2007-02-14|Estimate|||||||2009-02-16|2009-02-17|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Remote Ischemic Preconditioning in Primary PCI|The Effect of Remote Preconditioning in Primary Percutaneous Intervention of Acute ST Elevation Myocardial Infarction|Completed||Phase 2/Phase 3|250|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-06-01 03:26:24.338661|2018-06-01 03:26:24.338661
NCT00435253|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2011-10-21|2007-02-12|2007-02-14|Estimate|||||||2011-10-21|2011-10-24|Estimate|February 2007||2007-02-28|October 2011|2011-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study|Phase 2 Study of the Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema|Completed||Phase 2|20|Actual|Aeris Therapeutics||1|||f||||t||||||||||2018-06-01 03:26:24.621165|2018-06-01 03:26:24.621165
NCT00435240|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2008-05-13|2007-02-13|2007-02-14|Estimate|||||||2008-05-13|2008-05-15|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Paleolithic Diet in the Treatment of Diabetes Type 2 in Primary Health Care||Completed||Phase 2|13|Actual|Lund University Hospital|||||f||||||||||||||2018-06-01 03:26:24.721808|2018-06-01 03:26:24.721808
NCT00435227|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13||2012-07-02|2012-07-02|2007-02-13|2007-02-14|Estimate||||2012-07-02|2012-07-04|Estimate|2012-07-02|2012-07-04|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Evaluate a Single IM Dose of Motavizumab Treatment of Children With RSV (Respiratory Syncytial Virus) Illness|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children With RSV Illness|Completed||Phase 2|12|Actual|MedImmune LLC||2|||f||||||||||||||2018-06-01 03:26:24.808356|2018-06-01 03:26:24.808356
NCT00435214|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2018-04-03|2007-02-13|2007-02-14|Estimate|||||||2018-04-03|2018-04-04|Actual|January 29, 2007||2007-01-29|March 19, 2018|2018-03-19||||||||Observational|||Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer|The HPV Persistence and Progression (PaP) Cohort at Kaiser Permanente Northern California|Recruiting|||135600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:26:25.034733|2018-06-01 03:26:25.034733
NCT00435201|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2013-08-06|2007-02-13|2007-02-14|Estimate|||||||2013-08-06|2013-08-09|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Characterization of Clonal B Cell Populations in HCV Infection|Characterization of Clonal B Cell Populations in HCV Infection|Completed|||14|Actual|Rockefeller University|||||f||||t||||||Samples With DNA|"~     white blood cells~   "|||2018-06-01 03:26:25.343734|2018-06-01 03:26:25.343734
NCT00435188|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|2014-10-07||2015-01-08|2007-02-13|2007-02-14|Estimate|2015-01-08|2015-01-09|Estimate||||2015-01-08|2015-01-09|Estimate|November 2004||2004-11-30|January 2015|2015-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|Project LIFE||Life 2: Improving Fitness and Function in Elders|Life 2: Improving Fitness and Function in Elders|Completed||N/A|400|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:26:25.736771|2018-06-01 03:26:25.736771
NCT00435162|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2010-12-17|2010-12-17|2011-04-15|2007-02-13|2007-02-14|Estimate|2011-04-15|2011-05-09|Estimate|2011-04-15|2011-05-09|Estimate|2011-04-15|2011-05-09|Estimate|March 2007||2007-03-31|April 2011|2011-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure|A Randomized, Multicenter, Double-blind, 6 Week Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 6 Months - 5 Years Old With Hypertension, Followed by a 2 Week Placebo Withdrawal Period.|Completed||Phase 3|74|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:26:28.495159|2018-06-01 03:26:28.495159
NCT00435149|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2011-02-17|2007-02-12|2007-02-14|Estimate|||||||2011-02-17|2011-02-18|Estimate|December 2006||2006-12-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Post-operative Mobilization for Carpal Tunnel Syndrome|Post-operative Mobilization for Carpal Tunnel|Completed||N/A|100|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 03:26:29.773461|2018-06-01 03:26:29.773461
NCT00435123|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2008-02-12|2007-02-12|2007-02-14|Estimate|||||||2008-02-12|2008-02-21|Estimate|July 2007||2007-07-31|February 2008|2008-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||ProStat Supplementation in Dialysis Patients|A Randomized, Placebo Controlled, Double Blind Study of the Use of a Nutritional Supplement, ProStat-64, in Chronic Hemodialysis Patients With Poor Nutritional Status.|Terminated||N/A|16|Actual|Fresenius Medical Care North America||2||Increased use of commercial product; less eligible patients & poor enrollment.|f||||f||||||||||2018-06-01 03:26:29.859976|2018-06-01 03:26:29.859976
NCT00435110|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2007-02-13|2007-02-13|2007-02-14|Estimate|||||||2007-02-13|2007-02-14|Estimate|May 2004||2004-05-31|February 2006|2006-02-28|October 2005||2005-10-31|||||Observational|HELP||Effects of PEEP and FIO2 in ALI and ARDS|Effects of PEEP and FiO2 in the Evaluation of Severity of ALI and ARDS|Completed|||170||Instituto Canario de Investigacion Biomedica|||||f||||||||||||||2018-06-01 03:26:29.94765|2018-06-01 03:26:29.94765
NCT00435097|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2007-02-13|2007-02-13|2007-02-14|Estimate|||||||2007-02-13|2007-02-14|Estimate||||February 2007|2007-02-28||||||||Observational|||Computer Assisted Early Detection of Liver Metastases From fMRI Maps|Computer Assisted Early Detection of Liver Metastases From fMRI Maps|Unknown status|Not yet recruiting||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:26:30.007573|2018-06-01 03:26:30.007573
NCT00435084|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2015-09-22|2007-02-13|2007-02-14|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|April 2009|Actual|2009-04-30|February 2008|Actual|2008-02-29||Interventional|||A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL|An Open Phase I/II Clinical Study Assessing the Safety and Tolerability of APO866 in Patients With Refractory B-cell Lymphocytic Leukaemia Not Amenable to Allogeneic Hemopoietic Stem Cell Transplantation|Completed||Phase 1/Phase 2|10|Actual|Onxeo||1|||f||||f||||||||||2018-06-01 03:26:30.131955|2018-06-01 03:26:30.131955
NCT00435071|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2011-02-17|2007-02-12|2007-02-14|Estimate|||||||2011-02-17|2011-02-18|Estimate|December 2006||2006-12-31|February 2011|2011-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Effect of Surgical Incision Size on Carpal Tunnel Surgery|The Effect of Surgical Incision Size on Carpal Tunnel Surgery|Terminated||N/A|100|Anticipated|Vanderbilt University||2||Investigator initiated suspension to focus on other studies.|f||||f||||||||||2018-06-01 03:26:30.251586|2018-06-01 03:26:30.251586
NCT00435058|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2007-02-16|2007-02-12|2007-02-14|Estimate|||||||2007-02-16|2007-02-19|Estimate|September 2005||2005-09-30|February 2007|2007-02-28|April 2006||2006-04-30|||||Interventional|||Visual Function Changes After Intraocular Pressure Reduction|Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial|Completed||N/A|54||University of Sao Paulo|||||f||||||||||||||2018-06-01 03:26:30.315787|2018-06-01 03:26:30.315787
NCT00435045|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2008-10-22||2016-12-02|2007-02-13|2007-02-14|Estimate|2009-03-31|2009-05-12|Estimate||||2016-12-02|2017-02-02|Estimate|February 2007||2007-02-28|December 2016|2016-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia|A Randomized, Double-Blind, Placebo-Controlled, Forced Titration Study to Assess the Efficacy and Safety of Omacor, Co-Administered With Open-Label Atorvastatin Therapy, in Hypertriglyceridemic Subjects|Completed||Phase 3|245|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:26:30.402412|2018-06-01 03:26:30.402412
NCT00435032|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2010-01-11|2007-02-13|2007-02-14|Estimate|||||||2010-01-11|2010-01-12|Estimate|October 2006||2006-10-31|January 2010|2010-01-31||||September 2009|Actual|2009-09-30||Interventional|RAPTOR||Early Versus Interval Appendectomy for Ruptured Appendicitis in Children|Early Versus Interval Appendectomy for Ruptured Appendicitis in Children. Ruptured Appendicitis Pilot Trial (RAPTOR)|Completed||Phase 3|128|Anticipated|University of Tennessee||2|||f||||||||||||||2018-06-01 03:26:31.187712|2018-06-01 03:26:31.187712
NCT00435019|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2009-11-03||2017-01-30|2007-02-13|2007-02-14|Estimate|2009-11-03|2009-12-08|Estimate||||2017-01-30|2017-03-10|Actual|February 2007||2007-02-28|January 2017|2017-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes|An Efficacy and Safety Comparison of Insulin Detemir vs. NPH Insulin in Children and Adolescents Diagnosed With Type 1 Diabetes|Completed||Phase 3|348|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 03:26:31.345845|2018-06-01 03:26:31.345845
NCT00435006|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2007-02-13|2007-02-13|2007-02-14|Estimate|||||||2007-02-13|2007-02-14|Estimate|August 2003||2003-08-31|February 2007|2007-02-28|June 2006||2006-06-30|||||Observational|||Hypopituitarism Following Traumatic Brain Injury or Spontaneous Subarachnoidal Haemorrhages||Completed|||||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:26:31.771628|2018-06-01 03:26:31.771628
NCT00434993|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2012-12-04||2016-12-21|2007-02-12|2007-02-14|Estimate|2013-06-07|2013-07-15|Estimate||||2016-12-21|2017-02-10|Actual|August 2007||2007-08-31|December 2016|2016-12-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|ALTA|All randomized patients were analyzed.|Drug Study of Albuterol to Treat Acute Lung Injury|Prospective, Randomized, Multicenter Trial of Aerosolized Albuterol Versus Placebo in Acute Lung Injury|Terminated||Phase 2/Phase 3|282|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2||Stopped for futility by DSMB|f||||t||||||||Yes|a deidentified database of the ALVEOLI study is available through BioLINCC|2018-06-01 03:26:31.885285|2018-06-01 03:26:31.885285
NCT00434980|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2017-03-10|2007-02-13|2007-02-14|Estimate|||||||2017-03-10|2017-03-14|Actual|February 2005||2005-02-28|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia|Pilot Study of the Feasibility of a Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia|Completed||N/A|11|Actual|Beth Israel Deaconess Medical Center||1|||f||||||||||||||2018-06-01 03:26:32.428281|2018-06-01 03:26:32.428281
NCT00434967|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|2009-01-09||2010-11-30|2007-02-13|2007-02-14|Estimate|2009-04-29|2009-06-17|Estimate||||2010-11-30|2010-12-16|Estimate|January 2007||2007-01-31|November 2010|2010-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo|A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults|Completed||Phase 3|2207|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 03:26:32.571612|2018-06-01 03:26:32.571612
NCT00434954|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|2010-06-25||2015-03-19|2007-02-12|2007-02-14|Estimate|2010-07-30|2010-08-23|Estimate||||2015-03-19|2015-04-07|Estimate|February 2007||2007-02-28|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes|Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment|Completed||Phase 3|494|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:26:32.954476|2018-06-01 03:26:32.954476
NCT00434941|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2018-01-30|2007-02-13|2007-02-14|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2007||2007-09-30|January 2018|2018-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours|Multicenter Phase IV.II Trial, for the Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours|Terminated||Phase 2|1|Actual|Spanish Breast Cancer Research Group||1||Due to the slow rate of recruitment the study was stopped.|f||||||||||||||2018-06-01 03:26:33.863068|2018-06-01 03:26:33.863068
NCT00434928|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2007-02-13|2007-02-13|2007-02-14|Estimate|||||||2007-02-13|2007-02-14|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|January 2007||2007-01-31|||||Observational|||Dietary Intake and Nutrient Status of Children With ADHD|Dietary Intake and Nutrient Status of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed|||60||University of British Columbia|||||f||||||||||||||2018-06-01 03:26:33.959558|2018-06-01 03:26:33.959558
NCT00434915|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2011-03-22|2007-02-13|2007-02-14|Estimate|||||||2011-03-22|2011-03-23|Estimate|April 2003||2003-04-30|March 2011|2011-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?|Does DHEA Enhance the Effects of Exercise in Postmenopausal Women?|Completed||N/A|32||Mayo Clinic|||||f||||||||||||||2018-06-01 03:26:34.025204|2018-06-01 03:26:34.025204
NCT00434902|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2012-12-18|2007-02-13|2007-02-14|Estimate|||||||2012-12-18|2012-12-19|Estimate|February 2007||2007-02-28|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|March 2009|Actual|2009-03-31||Observational|ETENDARD||Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease|Evaluation of the Characteristics, Prevalence and Prognosis of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease: Study ETENDARD.|Unknown status|Active, not recruiting||700|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 03:26:34.096105|2018-06-01 03:26:34.096105
NCT00434889|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-13|||2010-01-08|2007-02-13|2007-02-14|Estimate|||||||2010-01-08|2010-01-11|Estimate|August 2007||2007-08-31|January 2010|2010-01-31|December 2009|Anticipated|2009-12-31|||||Observational|||A Study of Why People With Early Memory Problems Fall or Almost Fall|Factors Associated With Falls and Near-Falls in Community Dwelling Older Adults With Early-Stage Dementia|Unknown status|Recruiting||200|Anticipated|University of Saskatchewan|||2||f||||f||||||||||2018-06-01 03:26:34.197966|2018-06-01 03:26:34.197966
NCT00434876|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|2013-05-16||2013-07-09|2007-02-13|2007-02-14|Estimate|2013-07-09|2013-08-09|Estimate||||2013-07-09|2013-08-09|Estimate|August 2007||2007-08-31|July 2013|2013-07-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence|The Effects of Quetiapine on Sleep During Alcohol Abstinence|Completed||Phase 3|22|Actual|Corporal Michael J. Crescenz VA Medical Center|The limitations of this study include the small sample size, and assessment of PSQI, PHQ-9, BAI, and SF-12 at week 9 (immediately after washout from the study drug). The corruption of stored online actigraphic sleep data prevented its interpretation.|2|||f||||t||||||||||2018-06-01 03:26:34.288008|2018-06-01 03:26:34.288008
NCT00434863|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2007-02-12|2007-02-12|2007-02-13|Estimate|||||||2007-02-12|2007-02-13|Estimate|October 2005||2005-10-31|February 2007|2007-02-28|March 2006||2006-03-31|||||Interventional|||Comparative Study of the Effect of Dysport and Botox|A Comparative Randomized Double-Blinded Study of the Effect of Dysport and Botox on Forehead Wrinkles and EMG Activity|Completed||Phase 4|24||Laserklinik Karlsruhe|||||f||||||||||||||2018-06-01 03:26:34.585093|2018-06-01 03:26:34.585093
NCT00434850|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09||2011-11-28|2016-02-17|2007-02-09|2007-02-13|Estimate||||2011-11-28|2011-12-02|Estimate|2016-02-17|2016-03-16|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|November 2013|Actual|2013-11-30|September 2011|Actual|2011-09-30||Interventional|||Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes|Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03)|Completed||Phase 2|14|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 03:26:34.650037|2018-06-01 03:26:34.650037
NCT00434837|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2017-12-05|2007-02-09|2007-02-13|Estimate|||||||2017-12-05|2017-12-08|Actual|February 2004|Actual|2004-02-29|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Initial Graft Tension and ACL Surgery|Effects of Initial Graft Tension on Anterior Cruciate Ligament Reconstruction|Active, not recruiting||N/A|168|Actual|Rhode Island Hospital||3|||f||||t|f|f||||||Yes|Data are available upon request. Once the study is complete, the data records will be made available through a data repository|2018-06-01 03:26:34.746449|2018-06-01 03:26:34.746449
NCT00434824|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2015-04-15|2007-02-12|2007-02-13|Estimate|||||||2015-04-15|2015-04-16|Estimate|November 2001||2001-11-30|April 2015|2015-04-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Oral Administration of Different Doses of Org 538 in Symptomatic Aging Men With Androgen Deficiency|Completed||Phase 2|322|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:26:34.821798|2018-06-01 03:26:34.821798
NCT00434811|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09||2011-11-28|2016-08-29|2007-02-09|2007-02-13|Estimate||||2011-11-28|2011-12-02|Estimate|2016-08-29|2016-08-31|Estimate|October 2006||2006-10-31|August 2016|2016-08-31|May 2014|Actual|2014-05-31|September 2012|Actual|2012-09-30||Interventional|||Islet Transplantation in Type 1 Diabetes|Islet Transplantation in Type 1 Diabetes|Completed||Phase 3|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 03:26:34.978691|2018-06-01 03:26:34.978691
NCT00429221|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2013-04-22|2007-01-30|2007-01-31|Estimate|||||||2013-04-22|2013-04-23|Estimate|January 2006||2006-01-31|April 2013|2013-04-30||||||||Interventional|||Parent-Provider Intervention for Improving Medication Adherence in Children With Attention Deficit Hyperactivity Disorder|ADHD Medication Adherence: A Parent-Provider Intervention Modeled From HIV|Withdrawn||N/A|0|Actual|New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 03:28:20.324536|2018-06-01 03:28:20.324536
NCT00434798|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2008-06-04|2007-02-12|2007-02-13|Estimate|||||||2008-06-04|2008-06-05|Estimate|February 2007||2007-02-28|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Campylobacter Jejuni Challenge Model Development: Dose Ranging Study|Campylobacter Jejuni Challenge Model Development: Dose Ranging Study|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|University of Vermont|||||f||||||||||||||2018-06-01 03:26:35.097492|2018-06-01 03:26:35.097492
NCT00434785|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2007-12-03|2007-02-12|2007-02-13|Estimate|||||||2007-12-03|2007-12-05|Estimate|February 2007||2007-02-28|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||A Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 in Healthy Japanese Males|An Ascending, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Healthy Male Japanese Subjects.|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:26:35.153925|2018-06-01 03:26:35.153925
NCT00434772|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|||2009-05-27|2007-02-11|2007-02-13|Estimate|||||||2009-05-27|2009-05-28|Estimate|December 2007||2007-12-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers|Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers|Completed||Phase 2|||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:26:35.20332|2018-06-01 03:26:35.20332
NCT00434759|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2011-11-29||2012-10-28|2007-02-09|2007-02-13|Estimate|2012-10-28|2012-11-28|Estimate||||2012-10-28|2012-11-28|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|December 2011|Actual|2011-12-31|May 2009|Actual|2009-05-31||Interventional|||Social Phobia Intervention Study of Mannheim|Evaluation of the Efficacy, Mechanisms of Change and Efficiency of a Stepped-care Program With a Computer-based Self-help Module and Minimal Therapist Contact in Comparison to a Standard Cognitive Therapy for Patients With Social Phobia|Completed||N/A|89|Actual|Central Institute of Mental Health, Mannheim||2|||f||||t||||||||||2018-06-01 03:26:35.2745|2018-06-01 03:26:35.2745
NCT00434746|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-07-08|2007-02-12|2007-02-13|Estimate|||||||2009-07-08|2009-07-10|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects|Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-094 Administered IV and One Dose of SC Administered to Healthy Subjects|Completed||Phase 1|56|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:26:35.656667|2018-06-01 03:26:35.656667
NCT00434733|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2008-04-23|2007-02-12|2007-02-13|Estimate|||||||2008-04-23|2008-04-24|Estimate|January 2007||2007-01-31|April 2008|2008-04-30||||||||Interventional|||Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects|A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects|Completed||Phase 3|4400|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:26:35.715877|2018-06-01 03:26:35.715877
NCT00434720|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2008-10-15|2007-02-09|2007-02-13|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Comparison of GlideScope Specific Stylet to Malleable Stylet for GlideScope Intubation|Comparison of GlideScope Specific Stylet to Malleable Stylet for GlideScope Intubation|Completed||N/A|70|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 03:26:35.796436|2018-06-01 03:26:35.796436
NCT00434707|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-10|||2007-02-12|2007-02-12|2007-02-13|Estimate|||||||2007-02-12|2007-02-13|Estimate|March 2007||2007-03-31|February 2007|2007-02-28|December 2007||2007-12-31|||||Observational|||Outcome of Small Pupil Phacotrabeculectomy in Persons With Glaucoma and Cataract||Unknown status|Not yet recruiting||70||Aravind Medical Research Foundation|||||f||||||||||||||2018-06-01 03:26:35.847604|2018-06-01 03:26:35.847604
NCT00434694|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2015-11-24|2007-02-12|2007-02-13|Estimate|||||||2015-11-24|2015-11-25|Estimate|July 2003||2003-07-31|November 2015|2015-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study of Strategies for Electrical Isolation of Pulmonic Veins for Curative Treatment of Atrial Fibrillation|Electrical Isolation of Pulmonic Veins for Curative Treatment of Atrial Fibrillation: Efficacy of Isolating All Veins Vs Arrhythmogenic Veins Only Using Standard 4-mm or 8-mm Ablation Catheter Vs Saline Irrigated Cooled Tip Catheter|Completed||N/A|300|Actual|University of Pennsylvania|||||f||||t||||||||||2018-06-01 03:26:35.894721|2018-06-01 03:26:35.894721
NCT00434681|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2008-07-18|2007-02-12|2007-02-13|Estimate|||||||2008-07-18|2008-07-21|Estimate|October 2006||2006-10-31|July 2008|2008-07-31|April 2007|Actual|2007-04-30|||||Interventional|||Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.|Multicentre, Open, Non-Comparative Study of the Acceptability and Safety of Paracetamol Oral Paediatric Suspension at 4.8%.|Completed||Phase 3|48||Sanofi|||||f||||f||||||||||2018-06-01 03:26:35.959538|2018-06-01 03:26:35.959538
NCT00434668|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2010-11-29|2007-02-12|2007-02-13|Estimate|||||||2010-11-29|2010-11-30|Estimate|December 2005||2005-12-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|TOLEDO||Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer|Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial|Completed||Phase 2|99|Anticipated|University Hospital, Antwerp|||||f||||||||||||||2018-06-01 03:26:36.012372|2018-06-01 03:26:36.012372
NCT00434655|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-12-14|2007-02-09|2007-02-13|Estimate|||||||2009-12-14|2009-12-15|Estimate|January 2008||2008-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy|Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy: A Prospective Trial|Completed||Phase 3|40|Anticipated|North Texas Veterans Healthcare System||2|||f||||||||||||||2018-06-01 03:26:36.084604|2018-06-01 03:26:36.084604
NCT00434642|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2011-09-26||2017-07-10|2007-02-09|2007-02-13|Estimate|2011-09-26|2011-11-03|Estimate||||2017-07-10|2017-08-09|Actual|April 2007||2007-04-30|July 2017|2017-07-31|July 2013|Actual|2013-07-31|September 2010|Actual|2010-09-30||Interventional|OCEANS||A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma|A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma|Completed||Phase 3|484|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:26:37.213587|2018-06-01 03:26:37.213587
NCT00434629|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2016-08-15|2007-02-12|2007-02-13|Estimate|||||||2016-08-15|2016-08-17|Estimate|February 2007||2007-02-28|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant|A Phase I Study of Bexxar® (Tositumomab and 131I-Tositumomab) Radioimmunotherapy in Patients With Relapsed or Residual CD20 Antigen-Expressing B-Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation|Completed||Phase 1|16|Actual|University of Pennsylvania|||||f||||t||||||||||2018-06-01 03:26:38.079268|2018-06-01 03:26:38.079268
NCT00434616|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2011-04-05|2007-02-12|2007-02-13|Estimate|||||||2011-04-05|2011-04-06|Estimate|April 2007||2007-04-30|April 2011|2011-04-30|July 2011|Anticipated|2011-07-31|April 2011|Actual|2011-04-30||Interventional|BONMOT||Autologous Bone Marrow Stem Cell Transplantation for Critical, Limb-threatening Ischemia|Security and Effectiveness of Autologous Bone Marrow Stem Cell Transplantation to Avoid Amputations in Patients With Limb-threatening Ischemia: A Multicentric Randomized Placebo-controlled Double-blind Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|90|Anticipated|Franziskus-Krankenhaus||2|||f||||f||||||||||2018-06-01 03:26:38.169946|2018-06-01 03:26:38.169946
NCT00434603|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2009-02-26|2007-02-12|2007-02-13|Estimate|||||||2009-02-26|2009-02-27|Estimate|July 2007||2007-07-31|February 2009|2009-02-28|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Observational|||Expressive Arts as a Social and Community Integration Tool for Youth Recovering From Brain Injury|"Expressive Arts as a Social and Community Integration Tool for Adolescents With Acquired Brain Injury: I Want to Thrive, Not Just Survive!"|Unknown status|Active, not recruiting||8|Actual|University of Toronto|||||f||||f||||||||||2018-06-01 03:26:38.269578|2018-06-01 03:26:38.269578
NCT00434590|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|2010-12-13||2011-03-08|2007-02-12|2007-02-13|Estimate|2011-03-08|2011-04-07|Estimate||||2011-03-08|2011-04-07|Estimate|March 2007||2007-03-31|March 2011|2011-03-31|May 2008||2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients|Controlled, Randomized, Parallel Group Study to Assess Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients|Terminated||Phase 4|10|Actual|Novartis||2||The study has been stopped because of the lack of enrollment|f||||||||||||||2018-06-01 03:26:38.327563|2018-06-01 03:26:38.327563
NCT00434577|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12||2012-03-09|2012-03-22|2007-02-12|2007-02-13|Estimate||||2012-03-09|2012-03-14|Estimate|2012-03-22|2012-03-28|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|July 2010|Actual|2010-07-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects|A Vaccination Study to Evaluate the Safety and Immune Response of the GSK Biologicals Zoster Vaccine, GSK1437173A, and to Compare 3 Dosages of GSK1437173A in Healthy Elderly Subjects, Aged 60 Years and Above|Completed||Phase 2|715|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 03:26:38.55097|2018-06-01 03:26:38.55097
NCT00434564|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2017-02-09|2007-02-12|2007-02-13|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2000||2000-08-31|February 2017|2017-02-28|May 2002||2002-05-31|||||Interventional|||Acute Chest Pain Treatment and Evaluation (ACTION) Study|A Randomised Trial on Early Stress Nuclear Scan for Patients Presented to the Emergency Department (ED) With Chest Pain But Non-diagnostic Electrocardiography-Acute Chest Pain Treatment and Evaluation (ACTION) Study|Completed||Phase 4|1690||Singapore General Hospital|||||f||||||||||||||2018-06-01 03:26:38.643402|2018-06-01 03:26:38.643402
NCT00434551|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|||2009-03-25|2007-02-12|2007-02-13|Estimate|||||||2009-03-25|2009-03-26|Estimate|February 2005||2005-02-28|February 2007|2007-02-28|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Observational|MACCS||MACCS: Multicenter Australian CE in Patients With Suspected Crohn's Disease Study|Evaluation of Capsule Endoscopy in Patients With Suspected Small Bowel Crohn's Disease|Completed|||119|Actual|Given Imaging Ltd.|||1||f||||f||||||||||2018-06-01 03:26:38.711423|2018-06-01 03:26:38.711423
NCT00434538|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-02-03|2007-02-09|2007-02-13|Estimate|||||||2009-02-03|2009-02-05|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers|A Multicenter, Prospective, Randomized Comparison Study of BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers|Terminated||Phase 3|40|Actual|BioSyntech Canada Inc.||||Due to Sponsor's financial reasons|f||||f||||||||||2018-06-01 03:26:38.785647|2018-06-01 03:26:38.785647
NCT00434525|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-12-14|2007-02-09|2007-02-13|Estimate|||||||2009-12-14|2009-12-15|Estimate|January 2008||2008-01-31|August 2009|2009-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Laparoscopic Sleeve Gastrectomy With and Without Omentectomy|Metabolic Effects of Laparoscopic Sleeve Gastrectomy With or Without Omentectomy: Prospective Randomized Trial|Completed||Phase 3|30|Anticipated|North Texas Veterans Healthcare System||2|||f||||f||||||||||2018-06-01 03:26:38.9548|2018-06-01 03:26:38.9548
NCT00434512|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12||2009-06-08|2017-10-30|2007-02-12|2007-02-13|Estimate||||2009-09-28|2009-09-30|Estimate|2017-10-30|2017-11-01|Actual|February 20, 2007|Actual|2007-02-20|October 2017|2017-10-31|June 13, 2008|Actual|2008-06-13|June 13, 2008|Actual|2008-06-13||Interventional|||Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers|A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.|Completed||Phase 2|180|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 03:26:39.062793|2018-06-01 03:26:39.062793
NCT00434499|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-10|||2016-01-28|2007-02-10|2007-02-13|Estimate|||||||2016-01-28|2016-01-29|Estimate|February 2007||2007-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of EGCG on the Body's Response to Insulin|An Exploratory Study to Evaluate the Ability of Epigallocatechin Gallate to Simultaneously Improve Metabolic and Cardiovascular Actions of Insulin in Healthy and Obese Subjects|Withdrawn||Phase 2|0|Actual|University of Maryland||2||Not funded|f||||t||||||||||2018-06-01 03:26:39.135502|2018-06-01 03:26:39.135502
NCT00434486|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2007-09-10|2007-02-12|2007-02-13|Estimate|||||||2007-09-10|2007-09-12|Estimate|March 2007||2007-03-31|September 2007|2007-09-30|March 2007||2007-03-31|||||Interventional|||Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606|An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606 Administered Orally to Healthy Subjects|Completed||Phase 1|24|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:26:39.227265|2018-06-01 03:26:39.227265
NCT00434473|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09||2012-01-31|2014-01-30|2007-02-09|2007-02-13|Estimate||||2012-01-31|2012-02-02|Estimate|2014-01-30|2014-03-04|Estimate|December 2006||2006-12-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome|IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients With Sickle Cell Disease and Vaso-occlusive Crisis)|Completed||Phase 2|30|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:26:39.327434|2018-06-01 03:26:39.327434
NCT00434460|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2010-08-31|2007-02-12|2007-02-13|Estimate|||||||2010-08-31|2010-09-01|Estimate|April 2007||2007-04-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|||||Observational|ABATEVAP||Study of Knowledge Translation of Clinical Practice Guidelines for Ventilator Associated Pneumonia|Active Observational Study of the Adoption and Transfer of Clinical Practice Guidelines Through Education, for Ventilator Associated Pneumonia (ABATE VAP Study)|Completed|||1320|Actual|Canadian Critical Care Trials Group|||1||f||||f||||||||||2018-06-01 03:26:39.421129|2018-06-01 03:26:39.421129
NCT00434447|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2017-02-23|2007-02-12|2007-02-13|Estimate|||||||2017-02-23|2017-02-27|Actual|December 2006||2006-12-31|October 2010|2010-10-31||||September 2009|Actual|2009-09-30||Interventional|||Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases|A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety|Completed||Phase 4|73|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:26:39.552967|2018-06-01 03:26:39.552967
NCT00434434|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|2010-02-17||2010-04-30|2007-02-11|2007-02-13|Estimate|2010-04-30|2010-05-26|Estimate||||2010-04-30|2010-05-26|Estimate|October 2007||2007-10-31|April 2010|2010-04-30|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|AQUA||A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lyophilized and Aged Liquid Omalizumab in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma|Completed||Phase 2|61|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 03:26:39.750192|2018-06-01 03:26:39.750192
NCT00434421|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|2015-04-27||2015-06-05|2007-02-12|2007-02-13|Estimate|2015-04-27|2015-05-12|Estimate||||2015-06-05|2015-06-11|Estimate|February 2007||2007-02-28|June 2015|2015-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|SCSS|All study participants who were initiated onto the initial placebo study treatment during the Preliminary Dosing Visit.|Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma|A Safety and Pilot Dosing Study for Sublingual-Oral Administration of Glycerinated German Cockroach Allergenic Extract in Pediatric and Adult Subjects With Cockroach Allergy and Perennial Allergic Rhinitis With or Without Asthma|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 03:26:40.12705|2018-06-01 03:26:40.12705
NCT00434408|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2011-08-09|2007-02-09|2007-02-13|Estimate|||||||2011-08-09|2011-08-10|Estimate|May 2007||2007-05-31|July 2007|2007-07-31|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|CHX||Impact of Umbilical Cord Cleansing With 4.0% Chlorhexidine on Neonatal Mortality|Impact of Umbilical Cord Cleansing With Chlorhexidine on Neonatal Mortality and Omphalitis in Rural Sylhet District of Bangladesh|Completed||Phase 3|28797|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||||2018-06-01 03:26:40.387489|2018-06-01 03:26:40.387489
NCT00434395|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2011-07-22|2007-02-12|2007-02-13|Estimate|||||||2011-07-22|2011-07-26|Estimate|March 2007||2007-03-31|July 2011|2011-07-31|October 2007|Actual|2007-10-31|||||Interventional|||Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects|A Randomized, Double-Blind, Placebo- and Moxifloxacin (Open-Label)-Controlled, 4-Period Crossover Study of the Effects of a Single Dose of MOA-728 Infused Intravenously on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:26:40.475483|2018-06-01 03:26:40.475483
NCT00434382|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2010-07-29|2007-02-12|2007-02-13|Estimate|||||||2010-07-29|2010-07-30|Estimate|October 2002||2002-10-31|February 2007|2007-02-28|December 2003||2003-12-31|||||Interventional|BEO||Neuronal Mechanisms of Sensory Processing During General Anesthesia|Neuronale Mechanismen Der Sensorischen Reizverarbeitung in Der Narkose|Unknown status|Active, not recruiting|N/A|768||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:26:40.531832|2018-06-01 03:26:40.531832
NCT00434369|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2008-04-18|2007-02-09|2007-02-13|Estimate|||||||2008-04-18|2008-04-22|Estimate|February 2006||2006-02-28|April 2008|2008-04-30||||||||Interventional|||5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients|A Multi-Center, Open-Label, Single-Arm Phase II Trial Assessing the Efficacy and Safety of Weekly Bolus Infusions of 5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Advanced Breast Cancer Patients Who Failed Anthracycline and Taxane Chemotherapy Regimens|Unknown status|Active, not recruiting|Phase 2|31|Anticipated|Mast Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:26:40.60891|2018-06-01 03:26:40.60891
NCT00434356|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2009-09-01||2009-11-17|2007-02-09|2007-02-13|Estimate|2009-11-17|2009-12-03|Estimate||||2009-11-17|2009-12-03|Estimate|March 2007||2007-03-31|November 2009|2009-11-30||||May 2008|Actual|2008-05-31||Interventional|||A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)|A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer|Terminated||Phase 2|46|Actual|Genentech, Inc.|Based on the early safety results from this study, further recruitment and treatment was halted. Insufficient efficacy data were available to perform all protocol-specified analyses and limited the interpretation of the analyses performed.|2||Based on data collected, the combination appeared to be poorly tolearated.|f||||||||||||||2018-06-01 03:26:40.706216|2018-06-01 03:26:40.706216
NCT00434343|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2010-03-02|2007-02-12|2007-02-13|Estimate|||||||2010-03-02|2010-03-03|Estimate|November 2006||2006-11-30|March 2010|2010-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|UPPCRN-RCT#1||Physical Therapy Trial for Pelvic Pain|A Pilot Feasibility Study of Physical Therapy for the Treatment of Urologic Pelvic Pain Syndromes|Completed||N/A|48|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:26:41.54962|2018-06-01 03:26:41.54962
NCT00434330|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|2012-04-26|2012-03-13|2012-06-22|2007-02-12|2007-02-13|Estimate|2012-04-26|2012-05-28|Estimate|2012-03-13|2012-03-15|Estimate|2012-06-22|2012-06-29|Estimate|December 2006||2006-12-31|June 2012|2012-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis|A Phase 2, Open-Label, Multi-Center, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin|Completed||Phase 2|91|Actual|Affymax|Notable issues with some documentation occurred at some of the study sites. In general, overall results excluding the sites with issues were comparable to results based on the full population.|6|||f||||f||||||||||2018-06-01 03:26:41.677123|2018-06-01 03:26:41.677123
NCT00434317|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2017-02-21|2007-02-09|2007-02-13|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2005||2005-08-31|February 2017|2017-02-28||||April 2008|Actual|2008-04-30||Interventional|||Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases|A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer|Completed||Phase 4|80|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:26:42.419591|2018-06-01 03:26:42.419591
NCT00433797|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2013-12-18|2007-02-09|2007-02-12|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 2007||2007-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|March 2012|Actual|2012-03-31||Interventional|||Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients|Prostate Phytochemical & PUFA Intervention - a Phase I/II Study|Completed||Phase 1/Phase 2|86|Actual|University of Oslo||3|||f||||f||||||||||2018-06-01 03:26:53.110374|2018-06-01 03:26:53.110374
NCT00434304|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2009-11-16||2017-10-26|2007-02-09|2007-02-13|Estimate|2009-11-16|2009-12-23|Estimate||||2017-10-26|2017-12-02|Actual|April 9, 2007||2007-04-09|October 2017|2017-10-31|March 10, 2009|Actual|2009-03-10|March 1, 2009|Actual|2009-03-01||Interventional|||Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)|Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease - an Open-Label, Uncontrolled Study -|Completed||Phase 2|62|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:26:42.62609|2018-06-01 03:26:42.62609
NCT00434291|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2009-11-23|2007-02-12|2007-02-13|Estimate|||||||2009-11-23|2009-11-25|Estimate|December 2006||2006-12-31|November 2009|2009-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Safety and Efficacy Comparison of TG-873870(Nemonoxacin) to Levofloxacin in Community-Acquired Pneumonia|A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)|Completed||Phase 2|264|Anticipated|TaiGen Biotechnology Co., Ltd.|||||f||||||||||||||2018-06-01 03:26:44.068325|2018-06-01 03:26:44.068325
NCT00434278|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|2010-10-18||2017-05-12|2007-02-11|2007-02-13|Estimate|2010-10-18|2010-11-16|Estimate||||2017-05-12|2017-05-16|Actual|March 2007||2007-03-31|May 2017|2017-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease|Terminated||Phase 4|27|Actual|Genentech, Inc.|Because the study was terminated (for administrative reasons and infeasibility of enrollment), no conclusions can be made about the effect of Pulmozyme on exercise tolerance in this population.|2||This study was terminated for administrative reasons. There were no safety concerns.|f||||||||||||||2018-06-01 03:26:44.190549|2018-06-01 03:26:44.190549
NCT00434265|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|||2011-08-29|2007-02-12|2007-02-13|Estimate|||||||2011-08-29|2011-08-30|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|August 2011|Actual|2011-08-31|||||Interventional|||Obesity, Physical Inactivity or Dietary Fat ?|OBESITY, PHYSICAL INACTIVITY OR DIETARY FAT ? Role of Physical Activity in the Trafficking of Dietary Fatty Acids Varying in Length and Saturation Degree.|Completed||N/A|12|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:26:44.47738|2018-06-01 03:26:44.47738
NCT00434252|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|2011-03-29||2017-06-20|2007-02-11|2007-02-13|Estimate|2011-08-22|2011-09-28|Estimate||||2017-06-20|2017-07-18|Actual|February 2007|Actual|2007-02-28|June 2017|2017-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|BEAM||A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma|Completed||Phase 2|214|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:26:44.565802|2018-06-01 03:26:44.565802
NCT00434239|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|||2013-01-08|2007-02-11|2007-02-13|Estimate|||||||2013-01-08|2013-01-10|Estimate|February 2007||2007-02-28|January 2013|2013-01-31|May 2014|Anticipated|2014-05-31|May 2011|Actual|2011-05-31||Interventional|||Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia|A Pilot Study of the Combination of Lenalidomide (Revlimid®) With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor (rhSCF; Ancestim) for Myelodysplasia.|Unknown status|Active, not recruiting|Early Phase 1|25|Actual|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-06-01 03:26:45.189834|2018-06-01 03:26:45.189834
NCT00434226|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-11|2009-07-09||2009-07-09|2007-02-11|2007-02-13|Estimate|2009-07-09|2009-08-21|Estimate||||2009-07-09|2009-08-21|Estimate|March 2007||2007-03-31|July 2009|2009-07-31||||April 2008|Actual|2008-04-30||Interventional|||A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)|A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|56|Actual|Genentech, Inc.|Based on the early safety results from this study, Genentech halted further recruitment and discontinued treatment. Insufficient efficacy data was available to perform additional analyses and limited the interpretation of the analyses performed.|2||Based on data collected, the combination appeared to be poorly tolearated.|f||||||||||||||2018-06-01 03:26:45.309533|2018-06-01 03:26:45.309533
NCT00434213|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-12|2009-02-04||2017-03-27|2007-02-12|2007-02-13|Estimate|2009-02-04|2009-03-06|Estimate||||2017-03-27|2017-04-26|Actual|January 2007||2007-01-31|March 2017|2017-03-31|July 2008|Actual|2008-07-31|August 2007|Actual|2007-08-31||Interventional|||Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA|A Phase IV, Multi-center, Open-label Study of DAYTRANA (Methylphenidate Transdermal System [MTS]) to Characterize the Dermal Reactions in Pediatric Patients Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD).|Completed||Phase 4|309|Actual|Noven Therapeutics||1|||f||||f||||||||No||2018-06-01 03:26:45.933618|2018-06-01 03:26:45.933618
NCT00434200|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2007-02-09|2007-02-09|2007-02-13|Estimate|||||||2007-02-09|2007-02-13|Estimate|January 1998||1998-01-31|February 2007|2007-02-28|June 2000||2000-06-30|||||Interventional|RAPIT||Rheumatoid Arthritis Patients in Training|Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA|Unknown status|Active, not recruiting|Phase 4|300||Leiden University Medical Center|||||f||||||||||||||2018-06-01 03:26:46.179985|2018-06-01 03:26:46.179985
NCT00434187|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-07-08|2007-02-12|2007-02-13|Estimate|||||||2009-07-08|2009-07-10|Estimate|August 2006||2006-08-31|July 2009|2009-07-31|October 2006||2006-10-31|||||Interventional|||Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects|An Ascending Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics of ERB-041 Administered Orally to Healthy, Female Japanese Subjects|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:26:46.279003|2018-06-01 03:26:46.279003
NCT00434174|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2012-12-18|2007-02-09|2007-02-13|Estimate|||||||2012-12-18|2012-12-19|Estimate|December 2006||2006-12-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety of Everolimus and Pemetrexed in Lung Cancer Patients|A Phase I Study Investigating the Combination of Everolimus With Pemetrexed in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy|Completed||Phase 1|48|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:26:46.369102|2018-06-01 03:26:46.369102
NCT00434161|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2010-03-02||2015-03-10|2007-02-08|2007-02-12|Estimate|2015-02-24|2015-03-10|Estimate||||2015-03-10|2015-03-30|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma|A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation|Completed||Phase 3|281|Actual|Swedish Orphan Biovitrum||3|||f||||f||||||||||2018-06-01 03:26:46.505659|2018-06-01 03:26:46.505659
NCT00434148|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2013-01-03||2016-02-05|2007-02-09|2007-02-12|Estimate|2013-01-03|2013-02-06|Estimate||||2016-02-05|2016-03-08|Estimate|December 2006||2006-12-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease|A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease|Completed||Phase 3|162|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:26:47.664741|2018-06-01 03:26:47.664741
NCT00434135|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-02-04|2007-02-09|2007-02-12|Estimate|||||||2009-02-04|2009-02-05|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|ANGEL||Alimta and Gemcitabine in Non-Small Cell Lung Cancer|A Phase II Randomized Trial Assessing the Combination of Gemcitabine and Pemetrexed in the First Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|180|Anticipated|Southern Italy Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 03:26:48.877467|2018-06-01 03:26:48.877467
NCT00434122|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2009-01-19||2011-05-18|2007-02-09|2007-02-12|Estimate|2009-03-09|2009-04-10|Estimate||||2011-05-18|2011-06-02|Estimate|March 2007||2007-03-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix|A Randomised, Assessor-blind, Parallel Groups, Multi-centre, Exploratory Study Assessing the Impact of Subcutaneous Administration of Degarelix 2.5 mg on Synchronisation of Follicle Cohort Compared to Placebo and Evaluating the Effects of Degarelix 2.5 mg Started in the Mid-luteal or Early Follicular Phase on Endometrial Receptivity Compared to a Fixed Gonadotrophin Releasing Hormone Antagonist Protocol in Oocyte Donors Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproductive Technologies|Completed||Phase 2|85|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:26:48.983538|2018-06-01 03:26:48.983538
NCT00434109|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2012-08-08||2012-09-07|2007-02-09|2007-02-12|Estimate|2012-08-08|2012-09-07|Estimate||||2012-09-07|2012-09-14|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization|Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors|Completed||Phase 2|39|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 03:26:49.277646|2018-06-01 03:26:49.277646
NCT00434096|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-07-17|2007-02-09|2007-02-12|Estimate|||||||2009-07-17|2009-07-20|Estimate|February 2007||2007-02-28|July 2009|2009-07-31|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)|A Randomized Double-blind, Placebo-controlled, Parallel-group, Fixed Single-dose Regimen (SR141716 20 mg), Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Patients With Dyslipidemia.|Terminated||Phase 3|915|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||||||||||||2018-06-01 03:26:49.534646|2018-06-01 03:26:49.534646
NCT00434083|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2007-02-09|2007-02-09|2007-02-12|Estimate|||||||2007-02-09|2007-02-12|Estimate|July 2004||2004-07-31|February 2007|2007-02-28|January 2005||2005-01-31|||||Interventional|||To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches|A Double-Blind Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches|Completed||Phase 3|1200||POZEN|||||f||||||||||||||2018-06-01 03:26:49.610312|2018-06-01 03:26:49.610312
NCT00434070|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2018-05-23|2007-02-09|2007-02-12|Estimate|||||||2018-05-23|2018-05-24|Actual|February 7, 2007||2007-02-07|February 7, 2013|2013-02-07|February 7, 2013||2013-02-07|||||Observational|||Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load Monitoring|Comparison of the Development of Thymidine Analogue Mutations With CD4 Monitoring Alone Versus CD4 Monitoring Plus Viral Load Monitoring in Naive HIV-1 Individuals on First-Line Antiretroviral Therapy in Africa|Completed|||1012|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:26:49.676662|2018-06-01 03:26:49.676662
NCT00434057|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2009-05-26||2012-02-10|2007-02-08|2007-02-12|Estimate|2009-11-10|2009-11-11|Estimate||||2012-02-10|2012-02-14|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Pigmented Skin Lesions With MelaFind(R) System|Evaluation of Pigmented Skin Lesions With MelaFind(R) System|Completed||Phase 3|1383|Actual|MELA Sciences, Inc.||1|||f||||f||||||||||2018-06-01 03:26:49.758563|2018-06-01 03:26:49.758563
NCT00434044|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2007-12-11|2007-02-09|2007-02-12|Estimate|||||||2007-12-11|2007-12-13|Estimate|February 2007||2007-02-28|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Study Evaluating Etanercept in the Treatment of Subjects With Ankylosing Spondylitis|Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase III Study of Etanercept in the Treatment of Subjects With Ankylosing Spondylitis|Completed||Phase 3|150||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:26:49.929674|2018-06-01 03:26:49.929674
NCT00434031|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2012-07-27|2007-02-09|2007-02-12|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 2007||2007-09-30|July 2012|2012-07-31||||||||Interventional|CETRA||CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer|Neoadjuvant Therapy With Trastuzumab and Docetaxel Followed by Trastuzumab, Caelyx (Liposomal Doxorubicin) and Cyclophosphamide in Operable or Locally Advanced Her-2 Positive Breast Cancer|Withdrawn||Phase 2|0|Actual|National Cancer Institute, Naples||||lack of enrollment|f||||||||||||||2018-06-01 03:26:49.978249|2018-06-01 03:26:49.978249
NCT00434018|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2014-09-16||2015-04-24|2007-02-09|2007-02-12|Estimate|2014-09-29|2014-10-06|Estimate||||2015-04-24|2015-05-12|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional||One hundred thirty-eight veterans were recruited and randomly selected for group assignments.|Enhancing Indoor, Community, and Advanced Wheelchair Skills in Spinal Cord Injury (SCI)|Enhancing Indoor, Community, and Advanced Wheelchair Skills in SCI|Completed||Phase 2/Phase 3|138|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:26:50.046652|2018-06-01 03:26:50.046652
NCT00434005|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2013-01-14|2007-02-09|2007-02-12|Estimate|||||||2013-01-14|2013-01-16|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans|Effect of Diesel Exhaust Particulate Exposures on Endothelial Function in Humans - the Role of Oxidative Stress|Completed||N/A|24|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:26:50.43713|2018-06-01 03:26:50.43713
NCT00433992|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2017-03-28||2017-09-01|2007-02-09|2007-02-12|Estimate|2017-06-16|2017-07-31|Actual||||2017-09-01|2017-09-05|Actual|April 2006||2006-04-30|September 2017|2017-09-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications|Effects of Thymidine Sparing Regimens on Mitochondrial Metabolism and Adipocyte Apoptosis|Completed|||56|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Limitations included small sample size and premature study discontinuation before week 96||2||f||||t||||||Samples With DNA|"~     Blood collection~   "|No||2018-06-01 03:26:50.52483|2018-06-01 03:26:50.52483
NCT00433979|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2012-07-27|2007-02-09|2007-02-12|Estimate|||||||2012-07-27|2012-07-30|Estimate|February 2007||2007-02-28|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Study of Pharmacokinetics in HIV-infected Women|Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression on Combination Antiretroviral Therapy|Completed|||88|Actual|Women's College Hospital|||||f||||f||||||Samples Without DNA|"~     Blood samples will be drawn before and after antiretroviral drugs are taken for visits 1-3.~   "|||2018-06-01 03:26:50.842214|2018-06-01 03:26:50.842214
NCT00433966|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2017-09-12||2017-11-30|2007-02-09|2007-02-12|Estimate|2017-11-30|2017-12-04|Actual||||2017-11-30|2017-12-04|Actual|March 2005||2005-03-31|November 2017|2017-11-30|November 2010|Actual|2010-11-30|June 2008|Actual|2008-06-30||Interventional||Baseline data is presented by first randomization (pharmacology).|Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction|Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty With Stent Implantation With Either a Slow Rate-release Paclitaxel-eluting Stent (TAXUS™) or Uncoated Bare Metal Stent (EXPRESS2™)|Completed||Phase 3|3602|Actual|Cardiovascular Research Foundation, New York||2|||f||||t||||||||||2018-06-01 03:26:50.960947|2018-06-01 03:26:50.960947
NCT00433953|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2013-02-18|2007-02-08|2007-02-12|Estimate|||||||2013-02-18|2013-02-20|Estimate|February 2007||2007-02-28|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Genetic Drug Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients|Pharmacogenetics of Mycophenolic Acid in Kidney Transplant Patients|Terminated||Phase 1|44|Actual|Children's Hospital Medical Center, Cincinnati||||No longer following patient and no plans to publish.|f||||||||||||||2018-06-01 03:26:51.356015|2018-06-01 03:26:51.356015
NCT00433940|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2013-01-23|2007-02-09|2007-02-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2006||2006-10-31|January 2013|2013-01-31|July 2010|Actual|2010-07-31|April 2008|Actual|2008-04-30||Observational|||Immune Suppression Of Infants Treated With Steroids|Immune Suppression of Infants Treated With Oral Corticosteroids for Infantile Hemangiomas: A Pilot Study|Completed|||16|Actual|Medical College of Wisconsin|||1||f||||f||||||None Retained|"~     Collection of blood samples at each visit. Following laboratory testing, no samples were~     retained.~   "|||2018-06-01 03:26:51.489203|2018-06-01 03:26:51.489203
NCT00433927|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2014-03-13|2007-02-09|2007-02-12|Estimate|||||||2014-03-13|2014-03-14|Estimate|January 2007||2007-01-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|April 2014|Anticipated|2014-04-30||Interventional|||5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)|Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.|Unknown status|Active, not recruiting|Phase 3|568|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||||||||||||2018-06-01 03:26:51.583332|2018-06-01 03:26:51.583332
NCT00433914|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2015-02-18||2015-03-05|2007-02-09|2007-02-12|Estimate|2015-03-05|2015-03-06|Estimate||||2015-03-05|2015-03-06|Estimate|February 2007||2007-02-28|March 2015|2015-03-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional||Analysis was performed on all enrolled subjects.|Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants|A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, When Administered to Healthy Infants 6-8 Months Old|Completed||Phase 2|60|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:26:51.722456|2018-06-01 03:26:51.722456
NCT00433901|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2010-07-16|2007-02-09|2007-02-12|Estimate|||||||2010-07-16|2010-07-20|Estimate|November 2004||2004-11-30|July 2010|2010-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Family Connections Weight Management|Managing Weight in Overweight and At-Risk Children|Completed||N/A|220||Kaiser Permanente|||||f||||||||||||||2018-06-01 03:26:52.369673|2018-06-01 03:26:52.369673
NCT00433888|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-01-29|2007-02-09|2007-02-12|Estimate|||||||2009-01-29|2009-02-02|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)|Clinical Study of Switching From rHuEPO to R744 and Maintenance Treatment With R744 in Renal Anemia Patients on Hemodialysis (Phase Ⅲ Study)|Completed||Phase 3|179|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 03:26:52.431715|2018-06-01 03:26:52.431715
NCT00433875|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2007-12-20|2007-02-08|2007-02-12|Estimate|||||||2007-12-20|2007-12-28|Estimate|December 2002||2002-12-31|December 2007|2007-12-31||||||||Interventional|||Phase 2 AMG 714 in Rheumatoid Arthritis|A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs|Completed||Phase 2|180||Amgen|||||||||||||||||||2018-06-01 03:26:52.50078|2018-06-01 03:26:52.50078
NCT00433862|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2017-06-30|2007-02-09|2007-02-12|Estimate|||||||2017-06-30|2017-07-02|Actual|February 6, 2007||2007-02-06|May 19, 2010|2010-05-19|May 19, 2010||2010-05-19|||||Observational|||Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders|Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders|Completed|||8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:26:52.544019|2018-06-01 03:26:52.544019
NCT00433849|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2009-01-29|2007-02-09|2007-02-12|Estimate|||||||2009-01-29|2009-02-02|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Clinical Study of R744 to Peritoneal Dialysis Patients|Switch and Maintenance Study of Subcutaneous or Intravenous Injections of R744 to Peritoneal Dialysis Patients (Phase Ⅲ Study)|Completed||Phase 3|72|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 03:26:52.600505|2018-06-01 03:26:52.600505
NCT00433836|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2010-12-08||2011-04-19|2007-02-09|2007-02-12|Estimate|2011-04-19|2011-05-19|Estimate||||2011-04-19|2011-05-19|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure|A Multicenter, Randomized, Double-blind, Parallel-group, Evaluation of 12 Weeks of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children 6 to 17 Years of Age With Hypertension|Completed||Phase 3|300|Actual|Novartis||6|||f||||||||||||||2018-06-01 03:26:52.708301|2018-06-01 03:26:52.708301
NCT00433823|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2007-02-09|2007-02-09|2007-02-12|Estimate|||||||2007-02-09|2007-02-12|Estimate|January 2007||2007-01-31|February 2007|2007-02-28|January 2008||2008-01-31|||||Interventional|||A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis|A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis|Unknown status|Recruiting|Phase 4|||Abant Izzet Baysal University|||||f||||||||||||||2018-06-01 03:26:52.955924|2018-06-01 03:26:52.955924
NCT00433784|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2012-08-20|2007-02-08|2007-02-12|Estimate|||||||2012-08-20|2012-08-21|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|April 2006||2006-04-30|||||Interventional|||H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel|Evaluation of the Effect of the H2 Haplotype and CYP3As Polymorphisms on the Antiplatelet Response to Clopidogrel Given Before Elective Percutaneous Coronary Intervention|Completed||Phase 4|120||Hopital du Sacre-Coeur de Montreal|||||f||||||||||||||2018-06-01 03:26:53.184194|2018-06-01 03:26:53.184194
NCT00433771|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2009-09-25||2010-06-21|2007-02-08|2007-02-12|Estimate|2010-01-14|2010-02-09|Estimate||||2010-06-21|2010-06-29|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction|A Multi-Center, Single Arm, Prospective Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction|Completed||Phase 3|74|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 03:26:53.248814|2018-06-01 03:26:53.248814
NCT00433758|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2008-03-17|2007-02-09|2007-02-12|Estimate|||||||2008-03-17|2008-03-18|Estimate|December 2006||2006-12-31|September 2007|2007-09-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Evaluation of the GlucoTrack, Non-Invasive Glucose Monitoring Device|Evaluation of the Performance and Use of the GlucoTrack(TM), Non-Invasive Glucose Monitoring Device|Unknown status|Active, not recruiting|N/A|142|Anticipated|Integrity Applications Ltd.|||||f||||t||||||||||2018-06-01 03:26:54.717268|2018-06-01 03:26:54.717268
NCT00433745|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|2013-04-30||2014-06-05|2007-02-09|2007-02-12|Estimate|2014-06-05|2014-07-08|Estimate||||2014-06-05|2014-07-08|Estimate|February 2007||2007-02-28|June 2014|2014-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy|Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies|Completed||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)|"Although there was one partial response at 7 weeks, this patient went on to relapse as well.~Consequently, all 4 patients had rapid relapses despite vaccination. Accrual was stopped at 4."|1|||f||||t||||||||||2018-06-01 03:26:54.781805|2018-06-01 03:26:54.781805
NCT00433732|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2007-02-09|2007-02-09|2007-02-12|Estimate|||||||2007-02-09|2007-02-12|Estimate|August 2004||2004-08-31|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches|A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches|Completed||Phase 3|1400||POZEN|||||f||||||||||||||2018-06-01 03:26:55.037114|2018-06-01 03:26:55.037114
NCT00433719|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-08-06|2007-02-09|2007-02-12|Estimate|||||||2008-08-06|2008-08-07|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis|Randomised Controlled Trial of Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis|Unknown status|Active, not recruiting|N/A|253|Actual|University of Oxford||2|||f||||t||||||||||2018-06-01 03:26:55.106622|2018-06-01 03:26:55.106622
NCT00433706|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2016-12-12|2007-02-09|2007-02-12|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Image Guided Radiation Therapy For Prostate Cancer|Economic Evaluation of Image Guided Radiation Therapy For Prostate Cancer|Completed||Phase 3|470|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||||||||||||2018-06-01 03:26:55.20547|2018-06-01 03:26:55.20547
NCT00433693|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-01-29|2007-02-09|2007-02-12|Estimate|||||||2009-01-29|2009-02-02|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|October 2008|Actual|2008-10-31|March 2008|Actual|2008-03-31||Interventional|||Correction Study of R744 in Renal Anemia Patients on Hemodialysis|Correction Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase Ⅲ Study ).|Completed||Phase 3|50|Actual|Chugai Pharmaceutical||1|||f||||f||||||||||2018-06-01 03:26:55.280576|2018-06-01 03:26:55.280576
NCT00433680|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2014-04-07|2007-02-09|2007-02-12|Estimate|||||||2014-04-07|2014-04-08|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Targeted Obesity Prevention Program for Adolescent Females|Targeted Obesity Prevention Program for Adolescent Females|Completed||N/A|405|Anticipated|Oregon Research Institute|||||f||||t||||||||||2018-06-01 03:26:55.356253|2018-06-01 03:26:55.356253
NCT00433667|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2012-06-15|2007-02-09|2007-02-12|Estimate|||||||2012-06-15|2012-06-18|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.|Epilepsy Phase III Trial|Completed||Phase 3|563|Actual|SK Life Science|||||||||||||||||||2018-06-01 03:26:55.428569|2018-06-01 03:26:55.428569
NCT00433654|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2011-01-11|2009-09-29|2011-10-17|2007-02-09|2007-02-12|Estimate|2011-07-18|2011-08-11|Estimate|2009-09-29|2009-10-01|Estimate|2011-10-17|2011-10-24|Estimate|February 2007||2007-02-28|July 2011|2011-07-31|August 2010|Actual|2010-08-31|November 2008|Actual|2008-11-30||Interventional|||EMRI SureScan™ Clinical Study|EnRhythm MRI™ SureScan™ Pacing System Clinical Investigation|Completed||N/A|484|Actual|Medtronic Cardiac Rhythm and Heart Failure|Comparisons with a historical control (5076 Lead) were performed for secondary objectives #11-#16, however the results database is currently only designed to allow for reporting of participants specifically enrolled as part of this protocol.|2|||f||||t||||||||||2018-06-01 03:26:55.578648|2018-06-01 03:26:55.578648
NCT00433641|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2011-03-10|2007-02-09|2007-02-12|Estimate|||||||2011-03-10|2011-03-14|Estimate|July 2006||2006-07-31|March 2011|2011-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes|Pharmacogenomics of Weight Loss With Sibutramine in Obese and Overweight Patients|Completed||Phase 4|181|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 03:26:56.789346|2018-06-01 03:26:56.789346
NCT00433628|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2017-06-30|2007-02-09|2007-02-12|Estimate|||||||2017-06-30|2017-07-02|Actual|February 7, 2007||2007-02-07|August 25, 2009|2009-08-25||||November 12, 2008|Actual|2008-11-12||Observational|||Accuracy of Hemoglobin A1C to Predict Glycemia in HIV|Accuracy of Hemoglobin A1C to Predict Glycemia in HIV|Completed|||175||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:26:56.875709|2018-06-01 03:26:56.875709
NCT00433615|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2009-01-29|2007-02-09|2007-02-12|Estimate|||||||2009-01-29|2009-02-02|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Clinical Study of R744 to Predialysis Patients|Switch and Maintenance Study of Subcutaneous or Intravenous Injections of R744 to Predialysis Patients ( Phase Ⅲ Study ).|Completed||Phase 3|124|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 03:26:56.960534|2018-06-01 03:26:56.960534
NCT00433238|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2007-02-07|2007-02-07|2007-02-09|Estimate|||||||2007-02-07|2007-02-09|Estimate|March 2007||2007-03-31|February 2007|2007-02-28||||||||Interventional|||Screening for Mental Health Concerns for at-Risk Community Living Chinese Seniors|Screening for Mental Health Concerns for at-Risk Community Living Chinese Seniors - a Feasibility Study|Unknown status|Not yet recruiting|Phase 1|100||Mount Sinai Hospital, Canada|||||f||||||||||||||2018-06-01 03:27:05.597038|2018-06-01 03:27:05.597038
NCT00433602|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2013-06-11|2007-02-08|2007-02-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|November 2006||2006-11-30|June 2013|2013-06-30||||March 2007|Actual|2007-03-31||Observational|||Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors|TEACH Survey (Thrombo-Embolism And Chemotherapy) A Prospective Survey on the Incidence of Venous Thromboembolic Events During Chemotherapy for Solid Tumors|Completed|||64|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 03:26:57.079319|2018-06-01 03:26:57.079319
NCT00433589|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2017-09-07|2007-02-08|2007-02-12|Estimate|||||||2017-09-07|2017-09-08|Actual|December 2006||2006-12-31|September 2017|2017-09-30||||March 2020|Anticipated|2020-03-31||Interventional|MINDACT||Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes|MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes|Active, not recruiting||Phase 3|6600|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 03:26:57.227281|2018-06-01 03:26:57.227281
NCT00433576|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2014-09-12|2007-02-08|2007-02-12|Estimate|||||||2014-09-12|2014-09-15|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery|Phase I Repeat-Dose Study of Resveratrol in Colorectal Cancer Patients: Tolerability, Target Tissue Levels and Pharmacodynamics|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:26:57.335133|2018-06-01 03:26:57.335133
NCT00433563|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2018-02-22|2007-02-08|2007-02-12|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2008||2008-04-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2016|Actual|2016-02-29||Interventional|CONVERT||Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer|A 2-Arm Randomized Controlled Trial of Concurrent Chemo-Radiotherapy Comparing Twice-Daily and Once-Daily Radiotherapy Schedules in Patients With Limited Stage Small Cell Lung Cancer (SCLC) and Good Performance Status [CONVERT]|Active, not recruiting||N/A|547|Actual|The Christie NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 03:26:57.406213|2018-06-01 03:26:57.406213
NCT00433550|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2017-02-15||2017-07-25|2007-02-08|2007-02-12|Estimate|2017-07-25|2017-08-24|Actual||||2017-07-25|2017-08-24|Actual|May 2007||2007-05-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional||All patients registered were analyzed for baseline characteristics.|Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer|A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma|Completed||Phase 2|33|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-06-01 03:26:57.577834|2018-06-01 03:26:57.577834
NCT00433537|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2014-10-24||2014-10-24|2007-02-08|2007-02-12|Estimate|2014-10-24|2014-10-30|Estimate||||2014-10-24|2014-10-30|Estimate|May 2007||2007-05-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All eligible patients who received VcR-CVAD induction.|Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma|A Phase II Study of VcR-CVAD With Rituximab Maintenance for Untreated Mantle Cell Lymphoma|Completed||Phase 2|77|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 03:26:58.346592|2018-06-01 03:26:58.346592
NCT00433524|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2010-02-11|2007-02-08|2007-02-12|Estimate|||||||2010-02-11|2010-02-12|Estimate|April 2003||2003-04-30|February 2010|2010-02-28|September 2007|Actual|2007-09-30|||||Interventional|||Computed Tomography in Detecting Movement of the Esophagus in Patients Undergoing Radiation Therapy to the Chest|Evaluation of Esophageal Motion by Computed Tomography (CT) During the Course of Thoracic Radiotherapy|Completed||N/A|30|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 03:26:58.813631|2018-06-01 03:26:58.813631
NCT00433511|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2017-10-10|2007-02-08|2007-02-12|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2, 2007|Actual|2007-11-02|September 2017|2017-09-30||||September 30, 2016|Actual|2016-09-30||Interventional|||Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer|A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer|Active, not recruiting||Phase 3|4890|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 03:26:59.040743|2018-06-01 03:26:59.040743
NCT00433498|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2014-12-01|2007-02-08|2007-02-12|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|November 2013|Actual|2013-11-30|January 2012|Actual|2012-01-31||Interventional|||Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer|A Multicentre Phase III Randomized Double Blind Placebo Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Patients With Small Lung Cancer|Completed||Phase 3|846|Actual|University College, London||2|||f||||t||||||||||2018-06-01 03:27:00.539312|2018-06-01 03:27:00.539312
NCT00433485|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2016-09-21|2007-02-08|2007-02-12|Estimate|||||||2016-09-21|2016-09-23|Estimate||||September 2016|2016-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants|In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome|Completed||Phase 1|16|Anticipated|Yale University|||||f||||||||||||||2018-06-01 03:27:00.6952|2018-06-01 03:27:00.6952
NCT00433472|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2015-07-27|2007-02-08|2007-02-12|Estimate|||||||2015-07-27|2015-07-29|Estimate||||July 2015|2015-07-31||||||||Interventional|||MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806|Effect of RSR13 on T2 and T2* Cranial MRI Images: An Imaging Companion Study to NABTT 9806|Withdrawn||N/A|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||not enough interest|f||||||||||||||2018-06-01 03:27:00.87323|2018-06-01 03:27:00.87323
NCT00433459|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2015-11-17|2007-02-08|2007-02-12|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma|First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents|Completed||Phase 3|2134|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-06-01 03:27:00.944371|2018-06-01 03:27:00.944371
NCT00433446|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2012-11-09||2013-01-02|2007-02-08|2007-02-12|Estimate|2013-01-02|2013-02-05|Estimate||||2013-01-02|2013-02-05|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|May 2009|Actual|2009-05-31||Interventional|||S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|62|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 03:27:01.0714|2018-06-01 03:27:01.0714
NCT00433433|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2014-06-13|2007-02-08|2007-02-12|Estimate|||||||2014-06-13|2014-06-16|Estimate|October 2006||2006-10-31|June 2014|2014-06-30||||December 2011|Actual|2011-12-31||Interventional|H10||Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma|The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma|Completed||Phase 3|1952|Actual|European Organisation for Research and Treatment of Cancer - EORTC||6|||f||||t||||||||||2018-06-01 03:27:01.666687|2018-06-01 03:27:01.666687
NCT00433420|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2013-08-01|2007-02-08|2007-02-12|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2003||2003-04-30|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer|A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:27:01.774915|2018-06-01 03:27:01.774915
NCT00433407|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2012-10-03|2007-02-08|2007-02-12|Estimate|||||||2012-10-03|2012-10-04|Estimate|August 2005||2005-08-31|October 2012|2012-10-31||||February 2006|Actual|2006-02-28||Interventional|||T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors|A Study to Assess HER2-Specific T Cell Responses in Patients Receiving Trastuzumab for Solid Tumor Treatment|Completed||N/A|12|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 03:27:01.838812|2018-06-01 03:27:01.838812
NCT00433394|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-09|||2013-06-26|2007-02-09|2007-02-12|Estimate|||||||2013-06-26|2013-06-27|Estimate|May 2001||2001-05-31|June 2013|2013-06-30|January 2011|Actual|2011-01-31|January 2007|Actual|2007-01-31||Interventional|||Registration and Informed Consent Study for the Childhood Cancer Research Network|Protocol for Registration and Consent to the Childhood Cancer Research Network - A Limited Institution Pilot|Completed||N/A|2242|Actual|Children's Oncology Group||3|||f||||f||||||||||2018-06-01 03:27:01.93561|2018-06-01 03:27:01.93561
NCT00433381|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2013-03-14||2014-05-07|2007-02-08|2007-02-12|Estimate|2013-03-14|2013-05-01|Estimate||||2014-05-07|2014-05-23|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|February 2011|Actual|2011-02-28|January 2010|Actual|2010-01-31||Interventional|||Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma|A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma|Completed||Phase 2|123|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:27:02.099229|2018-06-01 03:27:02.099229
NCT00433368|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2007-02-08|2007-02-08|2007-02-09|Estimate|||||||2007-02-08|2007-02-09|Estimate|October 2003||2003-10-31|February 2007|2007-02-28|September 2004||2004-09-30|||||Interventional|||Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy|Efficacy of a Three Days’ Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study|Completed||Phase 3|108||Aga Khan University|||||f||||||||||||||2018-06-01 03:27:03.138214|2018-06-01 03:27:03.138214
NCT00433355|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2009-03-18|2007-02-08|2007-02-09|Estimate|||||||2009-03-18|2009-03-19|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Observational|||Epstein-Barr Virus as a Possible Cause for Chronic Fatigue Syndrome|Studies on Epstein-Barr Virus as a Possible Etiological Agent for Chronic Fatigue Syndrome|Completed|||15|Actual|University of Mississippi Medical Center|||||f||||t||||||||||2018-06-01 03:27:03.262956|2018-06-01 03:27:03.262956
NCT00433342|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2011-09-14|2007-02-08|2007-02-09|Estimate|||||||2011-09-14|2011-09-15|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients|Study on the Effect of Flucloxacillin on the Serum Level of P-cresol in Peritoneal Dialysis Patients|Suspended||Phase 1|10|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-06-01 03:27:03.413831|2018-06-01 03:27:03.413831
NCT00433329|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|2013-03-27||2013-05-30|2007-02-08|2007-02-09|Estimate|2013-03-27|2013-05-17|Estimate||||2013-05-30|2013-06-05|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|COMPASS 3||Combination Therapy in Pulmonary Arterial Hypertension|COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling|Completed||Phase 4|100|Actual|Actelion||1|||f||||||||||||||2018-06-01 03:27:03.574188|2018-06-01 03:27:03.574188
NCT00433316|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2008-06-19|2007-02-08|2007-02-09|Estimate|||||||2008-06-19|2008-06-20|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Pain Relief by Intra-Peritoneal Ropivacaine During Gynecological Laparoscopy|Pain Relief by Continuous Intra-Peritoneal Nebulization of Ropivacaine During Gynecological Laparoscopic Surgery|Completed||Phase 3|40|Actual|Carmel Medical Center||2|||f||||f||||||||||2018-06-01 03:27:03.962647|2018-06-01 03:27:03.962647
NCT00433303|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2007-02-08|2007-02-08|2007-02-09|Estimate|||||||2007-02-08|2007-02-09|Estimate||||February 2007|2007-02-28||||||||Observational|||Correlation Between Coital Activity During Pregnancy and Premature Delivery Related to Prostanoid Receptor Polymorphisms|Correlation Between Coital Activity During Pregnancy and Premature Delivery Related to Prostanoid Receptor Polymorphisms|Unknown status|Not yet recruiting||||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:27:04.062247|2018-06-01 03:27:04.062247
NCT00433290|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|2009-04-30||2009-08-26|2007-02-07|2007-02-09|Estimate|2009-07-13|2009-08-24|Estimate||||2009-08-26|2009-09-02|Estimate|February 2007||2007-02-28|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain|Protocol F1J-MC-HMFG Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain|Completed||Phase 3|256|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:27:04.217463|2018-06-01 03:27:04.217463
NCT00433277|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-02-08|2007-02-08|2007-02-09|Estimate|||||||2007-02-08|2007-02-09|Estimate||||February 2007|2007-02-28||||||||Interventional|||Autoimmunity in Retinitis Pigmentosa||Unknown status|Active, not recruiting|N/A|||Semmelweis University|||||f||||||||||||||2018-06-01 03:27:05.472699|2018-06-01 03:27:05.472699
NCT00433264|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2009-03-04|2007-02-07|2007-02-09|Estimate|||||||2009-03-04|2009-03-05|Estimate|February 2007||2007-02-28|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|INVEST-PD||The Interrelation of the Vasculature, Endothelium, Bone Metabolism and Uremic Toxins in Peritoneal Dialysis|The Interrelation of the Vasculature, Endothelium, Bone Metabolism and Uremic Toxins in Peritoneal Dialysis|Completed|||62|Actual|Universitaire Ziekenhuizen Leuven|||||f||||t||||||Samples With DNA|"~     serum, plasma, DNA~   "|||2018-06-01 03:27:05.53878|2018-06-01 03:27:05.53878
NCT00433225|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2007-09-05|2007-02-08|2007-02-09|Estimate|||||||2007-09-05|2007-09-10|Estimate||||September 2007|2007-09-30||||||||Interventional|||Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:27:05.655337|2018-06-01 03:27:05.655337
NCT00433212|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2014-12-03|2007-02-08|2007-02-09|Estimate|||||||2014-12-03|2014-12-05|Estimate|April 2007||2007-04-30|December 2014|2014-12-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|NIPPV||Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV)|Efficacy and Safety of NIPPV to Increase Survival Without Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants|Completed||Phase 3|1011|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 03:27:05.775531|2018-06-01 03:27:05.775531
NCT00433199|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2011-05-27||2015-01-15|2007-02-08|2007-02-09|Estimate|2011-11-03|2011-12-08|Estimate||||2015-01-15|2015-01-27|Estimate|February 2007||2007-02-28|November 2011|2011-11-30|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Interventional|||Testosterone Treatment for Hypogonadal Men|A Multi-Center, Randomized, Double-Blind,Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men|Completed||Phase 3|274|Actual|Abbott||2|||f||||||||||||||2018-06-01 03:27:05.958581|2018-06-01 03:27:05.958581
NCT00433186|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2011-03-29|2007-02-07|2007-02-09|Estimate|||||||2011-03-29|2011-03-31|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Mycophenolate Mofetil in Systemic Sclerosis|Phase I, Open-label Study of Mycophenolate Mofetil In Systemic Sclerosis|Completed||Phase 1|30|Anticipated|Boston University||1|||f||||||||||||||2018-06-01 03:27:06.335989|2018-06-01 03:27:06.335989
NCT00433173|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2010-03-01|2007-02-08|2007-02-09|Estimate|||||||2010-03-01|2010-03-02|Estimate|May 2006||2006-05-31|March 2010|2010-03-31|March 2011|Anticipated|2011-03-31|February 2011|Anticipated|2011-02-28||Interventional|||Insulin Sensitivity in Men With the Metabolic Syndrome|Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome|Suspended||N/A|72|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3||Primary investigator is taking a leave of absence|f||||t||||||||||2018-06-01 03:27:06.4487|2018-06-01 03:27:06.4487
NCT00433160|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|2009-08-17||2010-09-14|2007-02-07|2007-02-09|Estimate|2009-08-21|2009-09-30|Estimate||||2010-09-14|2010-09-21|Estimate|January 2007||2007-01-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Phase 3 Clinical Trial of Teriparatide in Japan|Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis|Completed||Phase 3|207|Actual|Eli Lilly and Company|Original data presented were for the 52-week double-blinded treatment phase; results of the open label phases at 76 weeks and 104 weeks have now been added|2|||f||||||||||||||2018-06-01 03:27:06.637712|2018-06-01 03:27:06.637712
NCT00433147|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07||2010-08-17|2010-08-17|2007-02-07|2007-02-09|Estimate||||2010-08-17|2010-08-19|Estimate|2010-08-17|2010-08-19|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Safety Study of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy|A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving ERT|Completed||Phase 2|32|Anticipated|Amicus Therapeutics||4|||f||||f||||||||||2018-06-01 03:27:07.796068|2018-06-01 03:27:07.796068
NCT00433134|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2009-04-23|2007-02-08|2007-02-09|Estimate|||||||2009-04-23|2009-04-24|Estimate|June 2006||2006-06-30|April 2009|2009-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Survey of Adherence to Immunosuppression and Other Medications in Kidney Transplant Patients|Survey Investigation of Adherence to Immunosuppression and Other Medications Among Kidney Transplant Recipients at SUNY Downstate|Completed|||100|Anticipated|State University of New York - Downstate Medical Center|||||f||||f||||||||||2018-06-01 03:27:07.869122|2018-06-01 03:27:07.869122
NCT00433121|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-08-23|2007-02-08|2007-02-09|Estimate|||||||2007-08-23|2007-08-24|Estimate|September 2006||2006-09-30|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD|Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - an Open Study.|Completed||Phase 4|24|Actual|Sykehuset Innlandet HF||1|||f||||f||||||||||2018-06-01 03:27:07.918733|2018-06-01 03:27:07.918733
NCT00433108|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2008-08-12|2007-02-07|2007-02-09|Estimate|||||||2008-08-12|2008-08-14|Estimate|March 2007||2007-03-31|August 2008|2008-08-31|November 2007|Actual|2007-11-30|||||Interventional|||Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C|A Double-Blind, Parallel, Randomized Comparison of Two Doses of MitoQ and Placebo for the Treatment of Patients With Raised Liver Enzymes Due to Hepatitis C|Completed||Phase 2|30|Actual|Antipodean Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:27:08.000181|2018-06-01 03:27:08.000181
NCT00433095|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2011-03-11|2007-02-07|2007-02-09|Estimate|||||||2011-03-11|2011-03-14|Estimate||||February 2007|2007-02-28||||||||Interventional|||Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer||Completed||Phase 2|||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:27:08.231483|2018-06-01 03:27:08.231483
NCT00433082|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2007-02-08|2007-02-08|2007-02-09|Estimate|||||||2007-02-08|2007-02-09|Estimate|August 2006||2006-08-31|February 2007|2007-02-28|November 2006||2006-11-30|||||Interventional|||Metabolic Syndrome and Inflammatory Markers|Effect of Fasting With Two Meals on Inflammatory Markers of Metabolic Syndrome|Completed||N/A|||Free Islamic University of Medical Sciences|||||f||||||||||||||2018-06-01 03:27:08.325657|2018-06-01 03:27:08.325657
NCT00433069|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2015-05-27|2007-02-08|2007-02-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2007||2007-01-31|May 2015|2015-05-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone|A Pilot Study of Treatment With Pegylated Interferon-Alpha2a, Ribavirin and Insulin Sensitizer Pioglitazone of Insulin Resistance (With the Exception of Diabetes) in Hepatitis C Virus Infection (The INSPIRED HCV Study)|Completed||Phase 2|5|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-06-01 03:27:08.37923|2018-06-01 03:27:08.37923
NCT00433056|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2008-04-24|2007-02-08|2007-02-09|Estimate|||||||2008-04-24|2008-04-25|Estimate|January 2004||2004-01-31|April 2008|2008-04-30||||||||Interventional|||Long Term Treatment Interruptions|Strategic, Long Term, Immunologically Driven Treatment Interruptions in Patients on Effective HAART: A Controlled, Randomized Study|Completed||Phase 3|320|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||||||||||||2018-06-01 03:27:08.455678|2018-06-01 03:27:08.455678
NCT00433043|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2015-10-28|2007-02-08|2007-02-09|Estimate|||||||2015-10-28|2015-10-30|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)|Beta-blocker Uptitration in Heart Failure Patients Receiving Cardiac Resynchronization Therapy With Optivol Fluid Status Monitoring System|Terminated||Phase 4|2|Actual|St. Luke's-Roosevelt Hospital Center||2||Insufficient enrollment|f||||f||||||||||2018-06-01 03:27:08.523357|2018-06-01 03:27:08.523357
NCT00432510|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2014-03-19|2007-02-07|2007-02-08|Estimate|||||||2014-03-19|2014-03-20|Estimate|October 2006||2006-10-31|March 2014|2014-03-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects|Protocol LEVP2006-5: Pharmacokinetics of C1INH-nf in Hereditary Angioedema Subjects|Completed||Phase 1|27|Actual|Shire||2|||f||||f||||||||||2018-06-01 03:27:19.900915|2018-06-01 03:27:19.900915
NCT00433030|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|||2018-03-16|2007-02-08|2007-02-09|Estimate|||||||2018-03-16|2018-03-20|Actual|January 2007||2007-01-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand|Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand|Completed|||2816|Actual|Institut de Recherche pour le Developpement|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 03:27:08.641754|2018-06-01 03:27:08.641754
NCT00433017|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2011-01-12||2011-04-18|2007-02-08|2007-02-09|Estimate|2011-01-12|2011-02-04|Estimate||||2011-04-18|2011-04-21|Estimate|May 2007||2007-05-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)|24-month Randomized, Double-masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.|Terminated||Phase 2/Phase 3|255|Actual|Novartis||2||Study was terminated based on the results of analyses performed as planned at Month 12.|f||||||||||||||2018-06-01 03:27:08.865771|2018-06-01 03:27:08.865771
NCT00433004|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-08|2017-05-11||2017-08-17|2007-02-08|2007-02-09|Estimate|2017-08-17|2017-09-15|Actual||||2017-08-17|2017-09-15|Actual|February 2007||2007-02-28|August 2017|2017-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens|A Pilot Randomized Control Trial of Advanced Supply of Levonorgestrel Emergency Contraception vs. Routine Postpartum Contraceptive Care in the Teenage Population|Completed||Phase 4|50|Actual|University of Pennsylvania||2|||f||||||||||||||2018-06-01 03:27:09.44807|2018-06-01 03:27:09.44807
NCT00432991|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|2017-02-16||2017-04-14|2007-02-08|2007-02-09|Estimate|2017-04-14|2017-05-22|Actual||||2017-04-14|2017-05-22|Actual|February 2007||2007-02-28|April 2017|2017-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of the Effect of Intramuscular Ephedrine on the Incidence of Nausea and Vomiting During Elective Cesarean Section|A Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Intramuscular Ephedrine on the Incidence of Perioperative Nausea and Vomiting During Elective Cesarean Section|Completed||Phase 2|53|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-06-01 03:27:09.690259|2018-06-01 03:27:09.690259
NCT00432978|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-04-17|2007-02-06|2007-02-08|Estimate|||||||2007-04-17|2007-04-18|Estimate|July 2006||2006-07-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Effect of Bosentan on Exercise Capacity at High Altitude|Effect of Bosentan on Exercise Capacity at High Altitude|Completed||Phase 1|20||VA Loma Linda Health Care System|||||f||||f||||||||||2018-06-01 03:27:09.927037|2018-06-01 03:27:09.927037
NCT00432965|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|2017-10-13||2017-12-29|2007-02-06|2007-02-08|Estimate|2017-10-13|2017-11-13|Actual||||2017-12-29|2018-01-23|Actual|May 2002||2002-05-31|December 2017|2017-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in Diabetic Foot Ulcers|"KCI VAC Protocol VAC2001-08, A Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure Therapy™ in the Treatment and Blinded Evaluation of Diabetic Foot Ulcers"|Completed||N/A|335|Actual|KCI USA, Inc.||2|||f||||||||||||||2018-06-01 03:27:10.018207|2018-06-01 03:27:10.018207
NCT00432952|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2008-08-12|2007-02-07|2007-02-08|Estimate|||||||2008-08-12|2008-08-13|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|January 2009|Anticipated|2009-01-31|March 2007|Actual|2007-03-31||Interventional|||Acute Single Meal Effects of Trout on Cardiovascular Risk Markers and Plasma Proteome||Unknown status|Active, not recruiting|N/A|6||University of Copenhagen|||||f||||||||||||||2018-06-01 03:27:10.491492|2018-06-01 03:27:10.491492
NCT00432939|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2015-03-06|2007-02-06|2007-02-08|Estimate|||||||2015-03-06|2015-03-09|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|November 2009|Actual|2009-11-30||Observational|||Primary Hyperparathyroidism: Non-classical Manifestations|Primary Hyperparathyroidism: Non-classical Manifestations|Completed|||58|Actual|Columbia University|||||f||||t||||||Samples Without DNA|"~     Specimens of frozen serum will be retained for possible future analyses.~   "|||2018-06-01 03:27:10.549339|2018-06-01 03:27:10.549339
NCT00432926|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2012-09-27|2007-02-06|2007-02-08|Estimate|||||||2012-09-27|2012-09-28|Estimate|February 2007||2007-02-28|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users|Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users|Completed||Phase 2|429|Actual|University of California, San Diego||3|||f||||t||||||||||2018-06-01 03:27:10.608754|2018-06-01 03:27:10.608754
NCT00432913|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2008-10-16|2007-02-07|2007-02-08|Estimate|||||||2008-10-16|2008-10-17|Estimate|October 2006||2006-10-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa|The Effect of Two Dose Levels of Eicosapentaenoic Acid (EPA) on Apoptosis and Cell Proliferation in the Colonic Mucosa of Patients With a History of Colonic Polyps.|Completed||Phase 2/Phase 3|120|Anticipated|S.L.A. Pharma AG||3|||f||||f||||||||||2018-06-01 03:27:10.804818|2018-06-01 03:27:10.804818
NCT00432900|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2018-05-15|2007-02-07|2007-02-08|Estimate|||||||2018-05-15|2018-05-16|Actual|February 5, 2007||2007-02-05|April 22, 2014|2014-04-22|May 29, 2013|Actual|2013-05-29|May 23, 2013|Actual|2013-05-23||Interventional|||Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis|PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [(11)C]PBR28 in Patients With Multiple Sclerosis (MS)|Completed||Phase 1|21|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:27:10.907621|2018-06-01 03:27:10.907621
NCT00432887|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2010-03-01|2007-02-07|2007-02-08|Estimate|||||||2010-03-01|2010-03-02|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|February 2007||2007-02-28|||||Interventional|||Experimental Studies of the Effects of Caffeine on Glucose Regulation|Caffeine and Glucose Regulation|Completed||Early Phase 1|150||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:27:10.986154|2018-06-01 03:27:10.986154
NCT00432874|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2010-10-15|2007-02-07|2007-02-08|Estimate|||||||2010-10-15|2010-10-19|Estimate|February 2007||2007-02-28|October 2010|2010-10-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Prospective Evaluation of Safety and Efficacy of Two Forms of Corneal Stromal Hydration|A Prospective Evaluation of the Safety and Efficacy of Two Forms of Corneal Stromal Hydration|Completed||N/A|60|Anticipated|University of Utah||2|||f||||f||||||||||2018-06-01 03:27:11.068235|2018-06-01 03:27:11.068235
NCT00432861|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2012-02-21|2007-02-07|2007-02-08|Estimate|||||||2012-02-21|2012-02-22|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Crossover Study to Evaluate the Effectiveness and Safety of PANCRECARB® MS-16 (Pancrelipase) in Reducing Steatorrhea in Children and Adults With Cystic Fibrosis|Completed||Phase 3|29|Actual|Digestive Care, Inc.||2|||f||||t||||||||||2018-06-01 03:27:11.132431|2018-06-01 03:27:11.132431
NCT00432835|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|2012-04-11||2012-11-01|2007-02-07|2007-02-08|Estimate|2012-11-01|2012-12-03|Estimate||||2012-11-01|2012-12-03|Estimate|August 2005||2005-08-31|November 2012|2012-11-30|November 2007|Actual|2007-11-30|October 2006|Actual|2006-10-31||Interventional|||Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis|Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis|Completed||Phase 3|58|Actual|University of Mississippi Medical Center|New lead implantation techniques now minimize dislodgment (only adverse effect); Parallel, non-crossover protocol will address any carry-over effect after tGES activation OFF; stratification for baseline mucosal EGG and medications may be useful.|2|||f||||t||||||||||2018-06-01 03:27:11.216296|2018-06-01 03:27:11.216296
NCT00432822|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2007-09-19|2007-02-07|2007-02-08|Estimate|||||||2007-09-19|2007-09-20|Estimate||||September 2007|2007-09-30||||||||Interventional|||Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety|Double-Blind, Placebo Controlled, Multicentre Study With an Open Label Extension to Evaluate the Efficacy and Safety of Tetrahydrobiopterin (BH4) in Children and Adolescents With Hyperphenylalaninemia Caused by Phenylalanine Hydroxylase Deficiency|Terminated||Phase 2/Phase 3|50|Anticipated|Orphanetics Pharma Entwicklungs GmbH|||||f||||||||||||||2018-06-01 03:27:11.557631|2018-06-01 03:27:11.557631
NCT00432809|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|2012-11-09||2017-07-18|2007-02-06|2007-02-08|Estimate|2013-06-07|2013-06-11|Estimate||||2017-07-18|2017-08-23|Actual|February 2007||2007-02-28|July 2017|2017-07-31|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes|STAMPEDE: Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently|Completed||N/A|150|Actual|The Cleveland Clinic|Important limitations in the primary endpoint and 1 year outcomes are the short duration of follow-up (12 months), the study occurred at a single-center and the open-label nature of the study (subjects were not blinded to treatment).|3|||f||||t||||||||||2018-06-01 03:27:11.639736|2018-06-01 03:27:11.639736
NCT00432796|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2018-03-05|2007-02-07|2007-02-08|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2006||2006-12-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.|A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)|Active, not recruiting||Phase 3|1473|Actual|Lawson Health Research Institute||2|||f||||t|f|f||||||No||2018-06-01 03:27:14.319524|2018-06-01 03:27:14.319524
NCT00432783|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2018-04-25|2007-02-07|2007-02-08|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2006|Actual|2006-06-30|April 2018|2018-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor|A Comparison of Adherence Rates to Ritonavir (Soft-gel Capsules) and Its Accompanying Protease Inhibitor (PI) in Patients Receiving Ritonavir Boosted PI Regimens|Completed|||45|Anticipated|Montefiore Medical Center|||||f||||||||||||||2018-06-01 03:27:14.450036|2018-06-01 03:27:14.450036
NCT00432770|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-04-19|2007-02-06|2007-02-08|Estimate|||||||2007-04-19|2007-04-20|Estimate|December 2006||2006-12-31|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers|A Phase 1, Single-Site, Double-Blind,Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779 Compared to Placebo in Healthy Volunteers|Completed||Phase 1|42||Archemix Corp.|||||f||||||||||||||2018-06-01 03:27:14.526238|2018-06-01 03:27:14.526238
NCT00432757|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-04|||2009-04-08|2007-02-07|2007-02-08|Estimate|||||||2009-04-08|2009-04-09|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens Wearers|Completed||Phase 3|120|Anticipated|Vistakon Pharmaceuticals|||||||||||||||||||2018-06-01 03:27:14.588792|2018-06-01 03:27:14.588792
NCT00432744|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|2014-04-11||2017-09-07|2007-02-06|2007-02-08|Estimate|2014-04-30|2014-05-01|Estimate||||2017-09-07|2017-09-11|Actual|January 2007||2007-01-31|September 2017|2017-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||This is the set of subjects that met all eligibility requirements|Phase III Trial of Coenzyme Q10 in Mitochondrial Disease|Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease|Completed||Phase 3|24|Actual|University of Florida|The trial intended to accrual 40 subjects, but accrual was below expectations and the granting agency turned down a request for extended accrual.|2|||f||||t||||||||||2018-06-01 03:27:14.710241|2018-06-01 03:27:14.710241
NCT00432731|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2017-03-10|2007-02-07|2007-02-08|Estimate|||||||2017-03-10|2017-03-14|Actual|December 2004||2004-12-31|March 2017|2017-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety Study of a Refrigerator-stable Formulation of VARIVAX®|A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants.|Completed||Phase 4|500||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:27:15.051802|2018-06-01 03:27:15.051802
NCT00432718|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2007-02-07|2007-02-07|2007-02-08|Estimate|||||||2007-02-07|2007-02-08|Estimate|August 2001||2001-08-31|February 2007|2007-02-28||||||||Interventional|||Saline Instillation Before Tracheal Suctioning and the Incidence of Ventilator Associated Pneumonia||Completed||N/A|260||Hospital do Cancer, Sao Paulo|||||f||||||||||||||2018-06-01 03:27:15.131275|2018-06-01 03:27:15.131275
NCT00432705|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2009-07-21|2007-02-06|2007-02-08|Estimate|||||||2009-07-21|2009-07-22|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Changes in Unstable Ankles After Balance Training|Modulation of Sensorimotor Measures in Chronically Unstable Ankles|Completed||Phase 1|70|Actual|University of North Carolina, Charlotte|||||f||||f||||||||||2018-06-01 03:27:15.183436|2018-06-01 03:27:15.183436
NCT00432692|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2010-02-24|2007-02-07|2007-02-08|Estimate|||||||2010-02-24|2010-02-25|Estimate|December 2005||2005-12-31|April 2007|2007-04-30|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Falls Prevention in Osteoporosis|Falls Prevention for People With Increased Risk of Fractures as a Result of Osteoporosis: a Randomized Controlled Study on the Effects of a Modified Program|Completed||N/A|96|Actual|Sint Maartenskliniek|||||f||||||||||||||2018-06-01 03:27:15.250356|2018-06-01 03:27:15.250356
NCT00432484|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2008-05-06|2007-02-06|2007-02-07|Estimate|||||||2008-05-06|2008-05-09|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Lingzhi and Sen Miao San for the Treatment of Rheumatoid Arthritis|Lingzhi (Ganoderma Lucidum) and Sen Miao San Supplementation in Rheumatoid Arthritis(RA): An Animal Model and A Phase I Study|Completed||Phase 2|70|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-06-01 03:27:19.986824|2018-06-01 03:27:19.986824
NCT00432679|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2017-01-16|2007-02-06|2007-02-08|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study|Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Combination Therapy With Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study -|Completed||Phase 3|140|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:27:15.403644|2018-06-01 03:27:15.403644
NCT00432666|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|2010-08-31|2009-05-05|2010-11-25|2007-02-07|2007-02-08|Estimate|2010-08-31|2010-09-28|Estimate|2010-08-31|2010-09-28|Estimate|2010-11-25|2010-12-15|Estimate|June 2006||2006-06-30|November 2010|2010-11-30|May 2008|Actual|2008-05-31|November 2006|Actual|2006-11-30||Interventional|||IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Post-stroke Spasticity of the Upper Limb|Completed||Phase 3|148|Actual|Merz Pharmaceuticals GmbH||2|||f||||||||||||||2018-06-01 03:27:15.694169|2018-06-01 03:27:15.694169
NCT00432653|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-02-07|2007-02-07|2007-02-08|Estimate|||||||2007-02-07|2007-02-08|Estimate|March 2007||2007-03-31|February 2007|2007-02-28|November 2009||2009-11-30|||||Interventional|||Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis|Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis|Unknown status|Not yet recruiting|Phase 2/Phase 3|20||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 03:27:18.294491|2018-06-01 03:27:18.294491
NCT00432640|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2010-12-15|2007-02-07|2007-02-08|Estimate|||||||2010-12-15|2010-12-16|Estimate|January 2007||2007-01-31|December 2010|2010-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Assessment of Surgical sTaging vs Endoscopic Ultrasound in Lung Cancer: a Randomized Clinical Trial (ASTER Study)|Complete Echo-Endoscopic Staging of Lung Cancer vs Surgical Staging: a Randomized Clinical Trial|Completed||N/A|240|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 03:27:18.412824|2018-06-01 03:27:18.412824
NCT00432627|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2016-04-20|2007-02-07|2007-02-08|Estimate|||||||2016-04-20|2016-04-21|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.|An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of 20 mg/kg Oral Deferasirox in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Novartis||4|||f||||f||||||||||2018-06-01 03:27:18.498242|2018-06-01 03:27:18.498242
NCT00432614|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2009-03-24|2007-02-07|2007-02-08|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|ALBERIO||Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder|A Multi-National, Multi-Center, DB, Placebo-Controlled, Parallel Group, Fixed Dose Efficacy & Safety Study of SR58611A 350 mg Twice Daily vs. Placebo in Adults With Major Depressive Disorder on Concomitant Treatment With Escitalopram 10mg/d|Completed||Phase 3|510|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:27:18.577454|2018-06-01 03:27:18.577454
NCT00432601|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|2015-03-19||2016-03-07|2007-02-06|2007-02-08|Estimate|2016-03-07|2016-03-22|Estimate||||2016-03-07|2016-03-22|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Testing the Helpfulness of 2 Decision Aids for Prostate Cancer|Impact of a Plain Language Prostate Cancer Decision Aid on Decision Making|Completed||N/A|1028|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:27:18.717999|2018-06-01 03:27:18.717999
NCT00432588|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-05-31|2007-02-06|2007-02-08|Estimate|||||||2007-05-31|2007-06-01|Estimate||||February 2007|2007-02-28||||||||Interventional|||Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies||Unknown status|Not yet recruiting|Phase 1/Phase 2|||Hormozgan University of Medical Sciences|||||||||||||||||||2018-06-01 03:27:18.993682|2018-06-01 03:27:18.993682
NCT00432575|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2009-04-14|2007-02-07|2007-02-08|Estimate|||||||2009-04-14|2009-04-15|Estimate|January 2007||2007-01-31|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of Surinabant Treatment as an Aid to Smoking Cessation (SURSMOKE)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Fixed-Dose, 8-Week Treatment, Multi-Center Trial Evaluating the Efficacy and the Safety of 3 Oral Doses of Surinabant as an Aid to Smoking Cessation in Cigarette Smokers|Completed||Phase 2|810|Actual|Sanofi||4|||f||||||||||||||2018-06-01 03:27:19.06218|2018-06-01 03:27:19.06218
NCT00432562|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|2012-01-19||2012-01-19|2007-02-06|2007-02-08|Estimate|2012-01-19|2012-02-23|Estimate||||2012-01-19|2012-02-23|Estimate|February 2007||2007-02-28|January 2012|2012-01-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.|A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.|Completed||Phase 1|31|Actual|Mast Therapeutics, Inc.|||||f||||f||||||||||2018-06-01 03:27:19.177317|2018-06-01 03:27:19.177317
NCT00432549|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-02-07|2007-02-07|2007-02-08|Estimate|||||||2007-02-07|2007-02-08|Estimate|January 2007||2007-01-31|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Detoxification and Treatment of Subjects With Medication Overuse Headache|Evaluation of Almotriptan and Topiramate in the Detoxification and Treatment of Subjects With Medication Overuse Headache|Unknown status|Recruiting|Phase 4|60||The New England Center for Headache, P.C.|||||f||||||||||||||2018-06-01 03:27:19.619469|2018-06-01 03:27:19.619469
NCT00432536|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2013-05-14|2007-02-07|2007-02-08|Estimate|||||||2013-05-14|2013-05-16|Estimate|October 2002||2002-10-31|May 2013|2013-05-31|February 2012|Actual|2012-02-29|August 2011|Actual|2011-08-31||Observational|||Redesigning Cardiac Surgery to Reduce Neurologic Injury|Redesigning Cardiac Surgery to Reduce Neurologic Injury|Completed|||469|Actual|Dartmouth-Hitchcock Medical Center|||||f||||f||||||Samples Without DNA|"~     Serum to study neurologic biomarker, Sb100.~   "|||2018-06-01 03:27:19.698528|2018-06-01 03:27:19.698528
NCT00432523|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-07|||2017-03-07|2007-02-07|2007-02-08|Estimate|||||||2017-03-07|2017-03-10|Actual|January 2005||2005-01-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2006|Actual|2006-07-31||Interventional|||Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route|An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of M-M-R™II Manufactured With Recombinant Human Albumin (rHA) and VARIVAX® When Administered Concomitantly by Intramuscular (IM) Route or Subcutaneous (SC) Route at Two Separate Injection Sites in Healthy Subjects 12 to 18 Months of Age|Completed||Phase 3|752||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:27:19.819259|2018-06-01 03:27:19.819259
NCT00427284|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2011-12-22|2007-01-26|2007-01-29|Estimate|||||||2011-12-22|2011-12-23|Estimate|July 2004||2004-07-31|December 2011|2011-12-31||||||||Observational|||Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease||Completed|||42|Actual|University of Zurich|||||f||||||||||||||2018-06-01 03:28:59.087534|2018-06-01 03:28:59.087534
NCT00432471|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2017-06-27|2007-02-05|2007-02-07|Estimate|||||||2017-06-27|2017-06-28|Actual|January 30, 2007|Actual|2007-01-30|June 2017|2017-06-30|June 25, 2017|Actual|2017-06-25|June 25, 2017|Actual|2017-06-25||Interventional|||Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers|Evaluation of Optical Imaging for Margin Delineation of Non-Melanoma Skin Cancers|Completed||N/A|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:27:20.2416|2018-06-01 03:27:20.2416
NCT00432458|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2012-04-11||2012-06-04|2007-02-05|2007-02-07|Estimate|2012-06-04|2012-07-04|Estimate||||2012-06-04|2012-07-04|Estimate|July 2003||2003-07-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Interventional|||Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma|A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma|Completed||Phase 3|68|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:27:20.347668|2018-06-01 03:27:20.347668
NCT00432445|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2015-02-12||2015-02-12|2007-02-05|2007-02-07|Estimate|2015-02-12|2015-02-27|Estimate||||2015-02-12|2015-02-27|Estimate|January 2007||2007-01-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||No analysis performed as a result of small study population.|Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma|A Phase II Trial of Proton Beam Radiation Therapy for Intra- and Periocular Retinoblastoma|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Low accrual.|f||||f||||||||||2018-06-01 03:27:20.893028|2018-06-01 03:27:20.893028
NCT00432432|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2012-02-10|2007-02-06|2007-02-07|Estimate|||||||2012-02-10|2012-02-13|Estimate|February 2005||2005-02-28|February 2012|2012-02-29|October 2006|Actual|2006-10-31|August 2006|Actual|2006-08-31||Interventional|||Combination Methotrexate and Infliximab|The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation|Completed||Phase 4|38|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-06-01 03:27:21.03091|2018-06-01 03:27:21.03091
NCT00432419|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2011-12-21|2007-02-05|2007-02-07|Estimate|||||||2011-12-21|2011-12-22|Estimate|February 2007||2007-02-28|December 2011|2011-12-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy.|Therapeutic Intensification for HIV-associated Non-Hodgkin's Lymphoma by Autologous Transplantation of Either Unselected or CD34+-Selected Peripheral Blood Stem Cells, in Patients in First or Second Complete Remission. ANRS 131|Terminated||Phase 1/Phase 2|1|Actual|French National Agency for Research on AIDS and Viral Hepatitis||||only one patient enrolled|f||||t||||||||||2018-06-01 03:27:21.181163|2018-06-01 03:27:21.181163
NCT00432406|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2009-03-10|2007-02-06|2007-02-07|Estimate|||||||2009-03-10|2009-03-11|Estimate|May 2006||2006-05-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis|TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile|Completed||Phase 4|40|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 03:27:21.257416|2018-06-01 03:27:21.257416
NCT00432393|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2008-10-17|2007-02-06|2007-02-07|Estimate|||||||2008-10-17|2008-10-20|Estimate|June 2002||2002-06-30|February 2007|2007-02-28|April 2003||2003-04-30|||||Interventional|||Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy|Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy|Completed||Phase 4|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:27:21.340313|2018-06-01 03:27:21.340313
NCT00432380|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|2017-03-23||2017-09-05|2007-02-06|2007-02-07|Estimate|2017-09-05|2017-09-11|Actual||||2017-09-05|2017-09-11|Actual|March 1, 2007||2007-03-01|March 2017|2017-03-31|September 4, 2007|Actual|2007-09-04|September 1, 2007|Actual|2007-09-01||Interventional|||A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.|Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine (GSK 357941A) in Healthy Infants.|Completed||Phase 2|375|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:27:21.420086|2018-06-01 03:27:21.420086
NCT00432367|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2016-10-19|2007-02-05|2007-02-07|Estimate|||||||2016-10-19|2016-10-20|Estimate|February 2007||2007-02-28|February 2014|2014-02-28|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|||Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy|The Effectiveness, Cost and Cost Effectiveness of Intermittent Preventive Treatment or Screening and Treatment of Malaria in Pregnancy Among Women Using Long Lasting Insecticide Treated Bed Net: a Randomised Controlled Trial.|Completed||Phase 3|3333|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-06-01 03:27:22.071422|2018-06-01 03:27:22.071422
NCT00432354|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-03-19|2007-02-06|2007-02-07|Estimate|||||||2007-03-19|2007-03-20|Estimate|March 2007||2007-03-31|March 2007|2007-03-31|March 2009|Anticipated|2009-03-31|||||Interventional|||An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus||Unknown status|Recruiting|Phase 2/Phase 3|40||Buddhist Tzu Chi General Hospital|||||f||||||||||||||2018-06-01 03:27:22.142616|2018-06-01 03:27:22.142616
NCT00432341|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2011-11-14||2011-11-14|2007-02-05|2007-02-07|Estimate|2011-11-14|2011-12-16|Estimate||||2011-11-14|2011-12-16|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia||Terminated||Phase 4|54|Actual|Allergan|The study was terminated early due to difficulties with patient recruitment.|2||Study was terminated early due to difficulties with patient recruitment|f||||||||||||||2018-06-01 03:27:22.239678|2018-06-01 03:27:22.239678
NCT00432328|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2009-01-12|2007-02-06|2007-02-07|Estimate|||||||2009-01-12|2009-01-13|Estimate|October 2006||2006-10-31|January 2009|2009-01-31||||||||Interventional|||Juvista (Avotermin) in Breast Reduction Surgery Scars|A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Improvement of Scar Appearance in Patients Undergoing Bilateral Reduction Mammaplasty.|Terminated||Phase 2|39|Anticipated|Renovo||||Futility analysis undertaken, determined that study was underpowered.|f||||||||||||||2018-06-01 03:27:22.730461|2018-06-01 03:27:22.730461
NCT00432315|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2010-09-13|2007-02-06|2007-02-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|May 2001||2001-05-31|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Docetaxel in Non Small Cell Lung Cancer (NSCLC)|Multicenter Phase II Study Evaluating Docetaxel and CDDP as Induction Regimen Prior to Surgery or Radiochemotherapy With Docetaxel, Followed by Adjuvant Docetaxel Therapy in Chemonaive Patients With NSCLC Stage II, IIIa and IIIb|Completed||Phase 2|80|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:27:22.797638|2018-06-01 03:27:22.797638
NCT00432302|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2015-12-10|2007-02-06|2007-02-07|Estimate|||||||2015-12-10|2015-12-14|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Investigation of Mass Balance of the Test Drug and Major Metabolites|Investigation of Mass Balance and Major Metabolites After Administration of 28 mg Radiolabeled ZK 219477 in Patients With Solid Tumor in an Open-label, Non Randomized Design|Completed||Phase 1|7|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:27:22.870434|2018-06-01 03:27:22.870434
NCT00432289|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2010-06-10|2007-02-05|2007-02-07|Estimate|||||||2010-06-10|2010-06-11|Estimate|November 2006||2006-11-30|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Acupuncture for Treatment of Acute Spinal Cord Injury: an Exploratory/Developmental Study|Acupuncture for Treatment of Acute Spinal Cord Injury|Completed||Phase 1/Phase 2|30|Anticipated|Craig Hospital|||||f||||t||||||||||2018-06-01 03:27:22.955045|2018-06-01 03:27:22.955045
NCT00432276|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2013-02-19|2010-04-08|2013-04-01|2007-02-05|2007-02-07|Estimate|2013-04-01|2013-04-04|Estimate|2010-04-08|2010-04-12|Estimate|2013-04-01|2013-04-04|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg Versus Dose Titration From 30 mg to 45 mg of Pioglitazone HCl (ACTOS®) in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Control on a Combination of Metformin and 30 mg of Pioglitazone HCl Therapy|Completed||Phase 3|803|Actual|Takeda||2|||f||||f||||||||||2018-06-01 03:27:23.17827|2018-06-01 03:27:23.17827
NCT00432263|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2015-04-21|2007-02-06|2007-02-07|Estimate|||||||2015-04-21|2015-04-22|Estimate|April 2007||2007-04-30|April 2015|2015-04-30||||||||Interventional|||Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury.|Placebo-Controlled Trial On The Efficacy Of Growth Hormone Replacement Therapy In Patients With Growth Hormone Deficiency After Traumatic Brain Injury|Withdrawn||Phase 4|0|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:27:25.020421|2018-06-01 03:27:25.020421
NCT00432250|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-02-06|2007-02-06|2007-02-07|Estimate|||||||2007-02-06|2007-02-07|Estimate|January 2002||2002-01-31|February 2007|2007-02-28|April 2005||2005-04-30|||||Interventional|||The Use of Cervical Length to Reduce Hospital Stay in Women Admitted Because of Preterm Labor.||Completed||Phase 4|150||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:27:25.076664|2018-06-01 03:27:25.076664
NCT00432237|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2010-07-19||2015-06-08|2007-02-05|2007-02-07|Estimate|2010-11-03|2010-12-06|Estimate||||2015-06-08|2015-07-03|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)|A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 in the Acute Treatment of Migraine With or Without Aura|Completed||Phase 3|1703|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 03:27:25.139696|2018-06-01 03:27:25.139696
NCT00432224|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2007-02-06|2007-02-06|2007-02-07|Estimate|||||||2007-02-06|2007-02-07|Estimate|May 2006||2006-05-31|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Treatment of Actinic Keratoses With Photodynamic Therapy Using Sunlight Versus Red Light||Completed||N/A|28||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 03:27:25.911706|2018-06-01 03:27:25.911706
NCT00432211|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2009-02-03|2007-02-06|2007-02-07|Estimate|||||||2009-02-03|2009-02-04|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|September 2012|Anticipated|2012-09-30|July 2008|Anticipated|2008-07-31||Interventional|||Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.|A Double Blind, Placebo Controlled, Randomised Trial to Investigate the Efficacy of Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Renovo||2|||f||||||||||||||2018-06-01 03:27:25.965641|2018-06-01 03:27:25.965641
NCT00432198|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2017-02-15|2007-02-06|2007-02-07|Estimate|||||||2017-02-15|2017-02-17|Actual|February 2007||2007-02-28|February 2017|2017-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Zolpidem Postmarketing Study in Adolescent Patients With Insomnia|Zolpidem Postmarketing Clinical Study: A Double Blind, Placebo Controlled Group Comparative Trial in the Adolescent Patients With Insomnia|Completed||Phase 4|122|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 03:27:26.030039|2018-06-01 03:27:26.030039
NCT00432185|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06||2016-01-22|2016-01-22|2007-02-06|2007-02-07|Estimate||||2010-09-22|2010-09-27|Estimate|2016-01-22|2016-02-15|Estimate|February 2007||2007-02-28|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC|An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk.|Completed||Phase 2|117|Actual|Peplin||2|||f||||f||||||||||2018-06-01 03:27:26.114576|2018-06-01 03:27:26.114576
NCT00432172|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2012-11-21|2007-02-06|2007-02-07|Estimate|||||||2012-11-21|2012-11-22|Estimate|September 2007||2007-09-30|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients|"A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients"|Unknown status|Active, not recruiting|Phase 2|189|Actual|Spanish Breast Cancer Research Group||4|||f||||||||||||||2018-06-01 03:27:26.336589|2018-06-01 03:27:26.336589
NCT00432159|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2014-05-27||2017-09-19|2007-02-05|2007-02-07|Estimate|2014-07-15|2014-08-07|Estimate||||2017-09-19|2017-10-20|Actual|July 1, 2006|Actual|2006-07-01|September 2017|2017-09-30|May 1, 2016|Actual|2016-05-01|May 1, 2013|Actual|2013-05-01||Interventional||Intent-to-treat|Comparison of DISCOVER™ Artificial Cervical Disc and ACDF for Treatment of Cervical DDD (IDE Study)|A Multi-Center, Prospective, Randomized Controlled Trial Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion for the Treatment of Cervical Degenerative Disc Disease|Completed||N/A|500|Actual|DePuy Spine|Enrollment terminated early, and beginning in March 2013, follow-up visits beyond 24 months were limited to Discover subjects only.|5|||f||||t|f|t|t|f||||||2018-06-01 03:27:26.545902|2018-06-01 03:27:26.545902
NCT00432146|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-10-17|2007-02-06|2007-02-07|Estimate|||||||2008-10-17|2008-10-20|Estimate|September 2005||2005-09-30|February 2007|2007-02-28|September 2006||2006-09-30|||||Observational|||Effect of Lugol's Solution in the Patients With Graves' Disease|Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease|Completed|||36||Istanbul University|||||f||||||||||||||2018-06-01 03:27:30.390915|2018-06-01 03:27:30.390915
NCT00432133|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2012-04-26|2007-02-05|2007-02-07|Estimate|||||||2012-04-26|2012-04-27|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Individual and Environmental Mechanisms of PA Change|Behavioral 2X2 Randomized Controlled Trial to Determine Individual and Environmental Mechanisms of Physical Activity Behavior Change|Completed||N/A|452|Actual|Kaiser Permanente||3|||f||||t||||||||||2018-06-01 03:27:30.450876|2018-06-01 03:27:30.450876
NCT00432120|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-01-28|2007-02-05|2007-02-07|Estimate|||||||2008-01-28|2008-01-29|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Clopidogrel Only Before Percutaneous Coronary Intervention or Before Every Coronarography?|Clopidogrel Loading Dose for ad-Hoc Percutaneous Coronary Intervention Immediately Following Elective Coronary Angiography: Randomized Multicenter Trial Comparing Pre-Treatment > 6 Hours Before Every Angiography vs. Cath-Lab Administration After Angiography (Just Before Intervention): the PRAGUE-8 Trial.|Completed||Phase 3|||Charles University, Czech Republic||2|||f||||||||||||||2018-06-01 03:27:30.522055|2018-06-01 03:27:30.522055
NCT00432107|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-06|||2015-09-28|2007-02-06|2007-02-07|Estimate|||||||2015-09-28|2015-09-29|Estimate|July 2006||2006-07-31|November 2013|2013-11-30|March 2009|Actual|2009-03-31|February 2008|Actual|2008-02-29||Interventional|||A Study to Assess APO866 for the Treatment of Advanced Melanoma|A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.|Completed||Phase 2|25|Actual|Onxeo||1|||f||||f||||||||||2018-06-01 03:27:30.610084|2018-06-01 03:27:30.610084
NCT00432094|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2018-02-12|2007-02-05|2007-02-07|Estimate|||||||2018-02-12|2018-02-13|Actual|December 19, 2006|Actual|2006-12-19|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors|Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors|Recruiting||Phase 2|25|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 03:27:30.687652|2018-06-01 03:27:30.687652
NCT00432081|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2007-02-05|2007-02-05|2007-02-06|Estimate|||||||2007-02-05|2007-02-06|Estimate|May 2000||2000-05-31|February 2007|2007-02-28|August 2005||2005-08-31|||||Interventional|||Effect of Indomethacin on the Progression of Alzheimer's Disease|Effect of Indomethacin on the Progression of Alzheimer's Disease|Completed||Phase 3|160||Radboud University|||||f||||||||||||||2018-06-01 03:27:31.772478|2018-06-01 03:27:31.772478
NCT00432068|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2015-12-02|2007-02-05|2007-02-06|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers|A Phase I , Open Label, Single Center, Dose Escalation Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of a New Extended Long-acting Formulation of Octreotide Pamoate Administered i.m. in Healthy Cholecystectomized Volunteers|Completed||Phase 1|48|Actual|Novartis||1|||f||||f||||||||No||2018-06-01 03:27:31.848538|2018-06-01 03:27:31.848538
NCT00432055|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2009-02-23|2007-02-05|2007-02-06|Estimate|||||||2009-02-23|2009-02-24|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy|A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy|Completed||Phase 4|66|Anticipated|Sunnaas Rehabilitation Hospital||2|||f||||f||||||||||2018-06-01 03:27:31.930379|2018-06-01 03:27:31.930379
NCT00432042|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|2017-09-01||2018-02-19|2007-02-05|2007-02-06|Estimate|2018-02-19|2018-03-19|Actual||||2018-02-19|2018-03-19|Actual|January 12, 2007|Actual|2007-01-12|February 2018|2018-02-28|March 27, 2008|Actual|2008-03-27|March 27, 2008|Actual|2008-03-27||Interventional|||Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)|An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age|Completed||Phase 3|955|Actual|Merck Sharp & Dohme Corp.||3|||f||||f|t|f|||t|||No||2018-06-01 03:27:32.05002|2018-06-01 03:27:32.05002
NCT00432029|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-07-01|2007-02-05|2007-02-06|Estimate|||||||2008-07-01|2008-07-04|Estimate|December 2006||2006-12-31|June 2008|2008-06-30|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers.|Correlation of Flicker Induced and Flow Mediated Vasodilatation in Patients With Endothelial Dysfunction and Healthy Volunteers|Completed||N/A|80|Actual|Medical University of Vienna||3|||f||||||||||||||2018-06-01 03:27:32.63616|2018-06-01 03:27:32.63616
NCT00432016|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2007-05-10|2007-02-05|2007-02-06|Estimate|||||||2007-05-10|2007-05-11|Estimate|February 2007||2007-02-28|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV|A Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerance, Pharmacokinetics and Antiviral Activity of Amdoxovir and Zidovudine in Untreated HIV-1 Infected Subjects Currently Untreated|Completed||Phase 1/Phase 2|24||RFS Pharma, LLC|||||f||||f||||||||||2018-06-01 03:27:32.723281|2018-06-01 03:27:32.723281
NCT00432003|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2014-04-16|2007-02-05|2007-02-06|Estimate|||||||2014-04-16|2014-04-17|Estimate|March 2005||2005-03-31|April 2014|2014-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Effects of Anti-HIV Therapy on Nervous System Function|Neurology: A Substudy of a Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (SMART) to Determine the Impact of the Strategies Upon Central and Peripheral Nervous System Function|Completed|||297|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:27:32.833407|2018-06-01 03:27:32.833407
NCT00431990|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-04|||2011-08-11|2007-02-04|2007-02-06|Estimate|||||||2011-08-11|2011-08-12|Estimate|November 2006||2006-11-30|August 2011|2011-08-31|January 2012|Anticipated|2012-01-31|December 2011|Anticipated|2011-12-31||Interventional|||A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma|A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Peter MacCallum Cancer Centre, Australia|||||f||||t||||||||||2018-06-01 03:27:32.960404|2018-06-01 03:27:32.960404
NCT00431977|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2011-06-20|2007-02-05|2007-02-06|Estimate|||||||2011-06-20|2011-06-21|Estimate|November 2006||2006-11-30|October 2006|2006-10-31|December 2012||2012-12-31|||||Interventional|||Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes|DEtection of Subclinical Coronary AtheRosclerosis in diabeTES Using Coronary CT Angiography (DESCARTES Trial)|Completed||N/A|1000|Anticipated|Seoul National University Bundang Hospital|||||f||||||||||||||2018-06-01 03:27:33.05198|2018-06-01 03:27:33.05198
NCT00431964|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2015-07-24||2015-07-24|2007-02-02|2007-02-06|Estimate|2015-07-24|2015-08-19|Estimate||||2015-07-24|2015-08-19|Estimate|February 2007||2007-02-28|July 2015|2015-07-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional||3 participants in the Placebo arm were randomized but did not receive drug due to withdrawal of consent and unstable health.|Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa|Multi-center, Multi-national, Randomized, Placebo-Controlled Trial of Azithromycin in Subjects With Cystic Fibrosis 6-18 Years Old, Culture Negative for Pseudomonas Aeruginosa|Completed||Phase 4|263|Actual|CF Therapeutics Development Network Coordinating Center||2|||f||||t||||||||||2018-06-01 03:27:33.137208|2018-06-01 03:27:33.137208
NCT00431951|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2009-05-29||2017-07-25|2007-02-05|2007-02-06|Estimate|2010-04-16|2010-05-07|Estimate||||2017-07-25|2017-07-27|Actual|February 2007||2007-02-28|September 2010|2010-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|SIGA-246-002||Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers|Double-blind, Randomized, Placebo-controlled, Escalating, Multiple-dose, Phase I Trial to Assess Safety, Tolerability and Pharmacokinetics of ST-246 Administered as a Single Daily Dose for 21 Days in Healthy, Non-fasted Volunteers|Completed||Phase 1|30|Actual|SIGA Technologies||2|||f||||t||||||||||2018-06-01 03:27:34.237276|2018-06-01 03:27:34.237276
NCT00431925|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2007-08-09|2007-02-05|2007-02-06|Estimate|||||||2007-08-09|2007-08-10|Estimate||||February 2007|2007-02-28|May 2011|Anticipated|2011-05-31|||||Observational|||Can Cytokines Predict the Severity of Acute Mucositis and the Need for Gastrostomy Tubes (PEG)?|Can Cytokines Predict the Severity of Acute Mucositis and the Need for PEG During Chemo-Radiation Treatment to Head and Neck Cancer?|Unknown status|Not yet recruiting||35|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:27:35.639414|2018-06-01 03:27:35.639414
NCT00431912|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2015-07-07|2007-02-05|2007-02-06|Estimate|||||||2015-07-07|2015-07-08|Estimate|February 2007||2007-02-28|July 2015|2015-07-31|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma|A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma|Completed||Phase 2|25|Actual|Onxeo||1|||f||||f||||||||||2018-06-01 03:27:35.757367|2018-06-01 03:27:35.757367
NCT00431899|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-03|||2016-03-02|2007-02-03|2007-02-06|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2003||2003-05-31|February 2007|2007-02-28|November 2003||2003-11-30|||||Interventional|||Effects of Omega 3 in Hemodialysis Patients|Effets of Fish Oil on Metabolic Fate of an Oral Glucose Load in Patients With End Stage Renal Disease Undergoing Hemodialysis|Completed||N/A|8||Laboratoire Régional de Nutrition Humaine|||||f||||||||||||||2018-06-01 03:27:35.84163|2018-06-01 03:27:35.84163
NCT00431886|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2011-06-20|2007-02-05|2007-02-06|Estimate|||||||2011-06-20|2011-06-21|Estimate|April 2006||2006-04-30|February 2007|2007-02-28|December 2007|Actual|2007-12-31|||||Interventional|||Usefulness of 64 Slice Multi-Detector Computed Tomography as a First Diagnostic Approach in Acute Chest Pain Patients|Usefulness of 64 Slice Multi-Detector Computed Tomography as a First Diagnostic Approach in Acute Chest Pain Patients|Completed||N/A|400|Anticipated|Seoul National University Bundang Hospital|||||f||||f||||||||||2018-06-01 03:27:35.9146|2018-06-01 03:27:35.9146
NCT00431873|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02||2015-06-04|2015-06-04|2007-02-02|2007-02-06|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|January 2007||2007-01-31|June 2015|2015-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia|A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia|Completed||Phase 2|21|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 03:27:35.986614|2018-06-01 03:27:35.986614
NCT00431860|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2007-05-02|2007-02-05|2007-02-06|Estimate|||||||2007-05-02|2007-05-03|Estimate|December 2005||2005-12-31|May 2007|2007-05-31|November 2011|Anticipated|2011-11-30|||||Observational|||Subclinical COronary Atheroscleorosis Updated With Coronary cT Angiography (SCOUT Study)|Subclinical COronary Atheroscleorosis Updated With Coronary cT Angiography (SCOUT Study)|Unknown status|Recruiting||3000|Anticipated|Seoul National University Bundang Hospital|||||f||||t||||||||||2018-06-01 03:27:36.091933|2018-06-01 03:27:36.091933
NCT00431847|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2016-02-08||2017-05-04|2007-02-05|2007-02-06|Estimate|2017-05-04|2017-05-15|Actual||||2017-05-04|2017-05-15|Actual|October 2007||2007-10-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|September 2013|Actual|2013-09-30||Observational|RAMBPOS||Regional Anesthesia Military Battlefield Pain Outcomes Study|Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes|Completed|||386|Actual|VA Office of Research and Development|||2||f||||f||||||||No||2018-06-01 03:27:36.228389|2018-06-01 03:27:36.228389
NCT00431834|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2013-08-09|2012-05-17|2013-11-03|2007-02-05|2007-02-06|Estimate|2013-08-09|2013-10-16|Estimate|2012-10-01|2012-10-05|Estimate|2013-11-03|2013-11-27|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study|Medtronic Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF)/Permanent Study|Completed||Phase 3|75|Actual|Medtronic Cardiovascular|"Slow/delayed enrollment~Medical management of subjects by non-investigators leading to medication washout protocol deviations~Missing endpoint data (attrition) due to cohort demographics (old age, dementia, relocation, etc.)"||||f||||t||||||||||2018-06-01 03:27:37.821261|2018-06-01 03:27:37.821261
NCT00431821|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2013-07-18|2007-02-05|2007-02-06|Estimate|||||||2013-07-18|2013-07-22|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|February 2011|Actual|2011-02-28||Interventional|REHAB||Reshaping Exercise Habits and Beliefs (REHAB)|Reshaping Exercise Habits and Beliefs (REHAB): Pilot Testing of a Behavioral Intervention to Improve Mobility After Stroke|Completed||N/A|90|Anticipated|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:27:38.354753|2018-06-01 03:27:38.354753
NCT00431808|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-04-01|2007-02-05|2007-02-06|Estimate|||||||2008-04-01|2008-04-03|Estimate|May 2007||2007-05-31|April 2008|2008-04-30|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])|Randomized Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Pichia Pastoris-Expressed P. Falciparum Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) Versus Tetanus Toxoid, in Healthy Malian Adult in Bandiagara|Unknown status|Recruiting|Phase 1|40|Anticipated|African Malaria Network Trust||1|||f||||t||||||||||2018-06-01 03:27:38.496217|2018-06-01 03:27:38.496217
NCT00431795|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2013-02-12|2007-02-05|2007-02-06|Estimate|||||||2013-02-12|2013-02-13|Estimate|June 2003||2003-06-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer|A Multicenter Randomized Phase II Study of Second Line Chemotherapy With Epirubicin( Farmorubicin) Versus the Pegylated Liposomal Doxorubicin in Advanced Breast Cancer Patients|Terminated||Phase 2|100|Actual|Hellenic Oncology Research Group||2||Due to poor accrual|f||||||||||||||2018-06-01 03:27:38.631302|2018-06-01 03:27:38.631302
NCT00431782|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2007-11-07|2007-02-02|2007-02-06|Estimate|||||||2007-11-07|2007-11-08|Estimate|December 2006||2006-12-31|May 2007|2007-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation|An Open-Label Multi-Center Study of ATI-5923 for Anticoagulation in Patients With Atrial Fibrillation|Completed||Phase 2|60|Anticipated|ARYx Therapeutics|||||f||||||||||||||2018-06-01 03:27:38.746816|2018-06-01 03:27:38.746816
NCT00431769|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2014-05-09|2007-02-02|2007-02-06|Estimate|||||||2014-05-09|2014-05-12|Estimate|June 2006||2006-06-30|May 2014|2014-05-31|January 2010|Actual|2010-01-31|February 2009|Actual|2009-02-28||Interventional|||An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma|A Phase II, Open-Label Trial Using Velcade for ReTreatment of Multiple Myeloma Subjects Following an Initial Response to Velcade|Completed||Phase 2|130|Actual|Janssen-Cilag International NV||1|||f||||f||||||||||2018-06-01 03:27:38.835843|2018-06-01 03:27:38.835843
NCT00431756|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2017-12-05|2007-02-02|2007-02-06|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2002||2002-01-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|BE||Predicting Risk of Cancer in Barrett's Esophagus|Methylation in Cancer Progression of Barrett's Esophagus|Recruiting|||540|Anticipated|Johns Hopkins University|||||f||||f||||||Samples With DNA|"~     approx. 24 ml blood, 1-8 esophageal mucosal pinch specimens and or esophageal brushings~   "|||2018-06-01 03:27:39.12925|2018-06-01 03:27:39.12925
NCT00431743|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2009-02-27|2007-02-05|2007-02-06|Estimate|||||||2009-02-27|2009-03-03|Estimate|April 2009||2009-04-30|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Fluid Infusion During Breast Surgery|Phase 4 Study of Fluid Infusion During Breast Surgery.|Unknown status|Not yet recruiting|Phase 4|32|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:27:39.231807|2018-06-01 03:27:39.231807
NCT00431730|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-07-01|2007-02-05|2007-02-06|Estimate|||||||2008-07-01|2008-07-04|Estimate|December 2006||2006-12-31|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?|Is There a Difference in Flicker Induced Vasodilatation Between Smokers and Non-Smokers?|Completed||N/A|||Medical University of Vienna|||||f||||t||||||||||2018-06-01 03:27:39.31633|2018-06-01 03:27:39.31633
NCT00431717|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-08-22|2007-02-05|2007-02-06|Estimate|||||||2008-08-22|2008-08-25|Estimate|November 2006||2006-11-30|August 2008|2008-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes|Study Comparing Coronary Computed Tomography Angiography and SPECT to Detect Subclinical Coronary Atherosclerosis in Asymptomatic Diabetes|Completed|||116|Actual|Seoul National University Bundang Hospital|||||f||||t||||||||||2018-06-01 03:27:39.373944|2018-06-01 03:27:39.373944
NCT00431704|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2015-11-27|2007-02-05|2007-02-06|Estimate|||||||2015-11-27|2015-11-30|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|VinCaT||VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer|Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase 2 Study|Unknown status|Active, not recruiting|Phase 2|39|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-06-01 03:27:39.610784|2018-06-01 03:27:39.610784
NCT00431691|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-07-01|2007-02-05|2007-02-06|Estimate|||||||2008-07-01|2008-07-04|Estimate|September 2006||2006-09-30|July 2008|2008-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.|Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.|Completed||Phase 4|22|Actual|Medical University of Vienna||2|||f||||||||||||||2018-06-01 03:27:39.688487|2018-06-01 03:27:39.688487
NCT00431678|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2014-12-16|2007-02-05|2007-02-06|Estimate|||||||2014-12-16|2014-12-17|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia|A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Treatment of Patients With Severe Community-acquired Pneumonia|Completed||Phase 3|738|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:27:39.780746|2018-06-01 03:27:39.780746
NCT00431665|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2007-02-05|2007-02-05|2007-02-06|Estimate|||||||2007-02-05|2007-02-06|Estimate|July 1999||1999-07-31|February 2007|2007-02-28|June 2000||2000-06-30|||||Interventional|||Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters|Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters|Completed||N/A|9||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:27:40.029788|2018-06-01 03:27:40.029788
NCT00431639|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-03|||2018-03-27|2007-02-03|2007-02-06|Estimate|||||||2018-03-27|2018-03-29|Actual|February 4, 2005||2005-02-04|September 11, 2017|2017-09-11|January 22, 2009|Actual|2009-01-22|January 22, 2009|Actual|2009-01-22||Interventional|||Effects of Pet Therapy on Pain in Cancer Patients|The Effect of Animal-Assisted Therapy on Distress in Oncology Patients Being Treated for Pain|Completed||Phase 2|36|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:27:40.093539|2018-06-01 03:27:40.093539
NCT00431626|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2014-12-19||2015-10-06|2007-02-05|2007-02-06|Estimate|2014-12-19|2015-01-01|Estimate||||2015-10-06|2015-10-28|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Clinical Trial Comparing Laser TURP With and Without Dutasteride.|A Randomized, Placebo-Controlled, Double-Masked Clinical Trial Comparing Laser TURP With and Without Neo-Adjuvant Dutasteride|Terminated||Phase 3|4|Actual|Northwestern University|Difficulty in recruitment forced the closing of this trial.|2||Low enrollment|f||||t||||||||||2018-06-01 03:27:40.161147|2018-06-01 03:27:40.161147
NCT00431613|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2015-05-28|2007-02-05|2007-02-06|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2006||2006-03-31|May 2015|2015-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)|Sequential Administration of Docetaxel/Gemcitabine Followed by Concurrent Chemo-radiotherapy, With or Without Consolidation Chemotherapy, as First Line Treatment in Patients With Unresectable Stage IIIA/IIIB NSCLC. A Randomized Phase II Study|Terminated||Phase 2|38|Actual|Hellenic Oncology Research Group||2||Due to Poor Accrual|f||||||||||||||2018-06-01 03:27:40.445583|2018-06-01 03:27:40.445583
NCT00431600|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2012-09-20|2007-02-05|2007-02-06|Estimate|||||||2012-09-20|2012-09-21|Estimate|September 2010||2010-09-30|July 2008|2008-07-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||The Validity of Retinal Blood Flow Measurements During Hyperoxia in Humans Using Fourier Domain Color Doppler Optical Coherence Tomography (CDOCT)|The Validity of Retinal Blood Flow Measurements During Hyperoxia in Humans Using Fourier Domain CDOCT|Completed||N/A|12|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 03:27:40.583741|2018-06-01 03:27:40.583741
NCT00431587|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2008-04-16|2007-02-05|2007-02-06|Estimate|||||||2008-04-16|2008-04-17|Estimate|June 2007||2007-06-30|January 2007|2007-01-31||||||||Observational|||Changes in Different Fat Compartments and Their Effect on Particular Manifestations of Metabolic Syndrome After Bariatric Procedures.|Changes in Different Fat Compartments During Weight Loss and Their Effect on Particular Manifestations of Metabolic Syndrome After Bariatric Procedures.|Unknown status|Recruiting||1000|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:27:40.769112|2018-06-01 03:27:40.769112
NCT00431574|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2008-02-25|2007-02-02|2007-02-06|Estimate|||||||2008-02-25|2008-02-26|Estimate|August 2002||2002-08-31|February 2008|2008-02-29|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||Antipsychotic Medication Extended Dosing Study|Antipsychotic Medication Extended Dosing Study|Completed||N/A|40||Centre for Addiction and Mental Health|||||f||||||||||||||2018-06-01 03:27:40.886091|2018-06-01 03:27:40.886091
NCT00431561|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2013-12-02|2007-02-05|2007-02-06|Estimate|||||||2013-12-02|2013-12-03|Estimate|April 2003||2003-04-30|December 2013|2013-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma|Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week|Completed||Phase 2|141|Actual|Isarna Therapeutics GmbH||3|||f||||t||||||||||2018-06-01 03:27:41.000568|2018-06-01 03:27:41.000568
NCT00431548|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2007-02-05|2007-02-05|2007-02-06|Estimate|||||||2007-02-05|2007-02-06|Estimate||||February 2007|2007-02-28||||||||Interventional|||Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV)|Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV).|Completed||N/A|30||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:27:41.201739|2018-06-01 03:27:41.201739
NCT00431535|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-05|||2013-06-14|2007-02-05|2007-02-06|Estimate|||||||2013-06-14|2013-06-17|Estimate|February 2007||2007-02-28|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Observational|||Study Concerning Relationship Between Mixed Venous Saturation (SvO2) and Balance|Descriptive Study Concerning the Connection Between SvO2 and Orthostatic Function Post Operatively|Completed|||17|Actual|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:27:41.292392|2018-06-01 03:27:41.292392
NCT00431522|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2009-05-28|2007-02-02|2007-02-05|Estimate|||||||2009-05-28|2009-05-29|Estimate|December 2004||2004-12-31|May 2009|2009-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Valproic Acid Sodium Salt in Bipolar Disorder|Protective Effect of Valproate on Brain Cells:A Magnetic Resonance Imaging and Spectroscopy Study in Patients With Bipolar Disorder Diagnosis|Completed||Phase 4|58|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:27:41.44656|2018-06-01 03:27:41.44656
NCT00431509|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2007-04-23|2007-02-02|2007-02-05|Estimate|||||||2007-04-23|2007-04-24|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|June 2009|Anticipated|2009-06-30|||||Interventional|||Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery|A Randomized Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery. Influence on Operative Result, Health-Related Quality of Life, and Coordinative Abilities.|Unknown status|Recruiting|Phase 4|477||University of Schleswig-Holstein|||||f||||||||||||||2018-06-01 03:27:41.588918|2018-06-01 03:27:41.588918
NCT00431496|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2010-09-24||2013-04-18|2007-02-02|2007-02-05|Estimate|2011-06-16|2011-07-13|Estimate||||2013-04-18|2013-04-24|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)|A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management|Completed||Phase 4|71|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:27:41.745244|2018-06-01 03:27:41.745244
NCT00431483|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2013-09-25|2007-02-01|2007-02-05|Estimate|||||||2013-09-25|2013-09-26|Estimate|February 2007||2007-02-28|September 2013|2013-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Clinical and Economic Impact of Interventions by a Clinical Pharmacist on Antibiotic Use on Surgical Wards|Clinical and Economic Impact of Interventions by a Clinical Pharmacist on Antibiotic Use on Surgical Wards|Completed||N/A|779|Actual|Ludwig-Maximilians - University of Munich||1|||f||||f||||||||||2018-06-01 03:27:42.391678|2018-06-01 03:27:42.391678
NCT00431470|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2009-02-04|2007-02-02|2007-02-05|Estimate|||||||2009-02-04|2009-02-05|Estimate|February 2007||2007-02-28|October 2006|2006-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Are Character Building Lessons Effective in Decreasing Bullying Behaviors?|Is the Classroom Education Program Intervention Effective in Increasing Positive Self Esteem, Enhancing Leadership Behaviors, While Decreasing the Prevalence of Bullying Behaviors in Fifth Grade Elementary Students?|Completed||N/A|175|Anticipated|Maimonides Medical Center|||||f||||||||||||||2018-06-01 03:27:42.570554|2018-06-01 03:27:42.570554
NCT00431457|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2014-12-04|2007-02-02|2007-02-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Controlled Randomized Stimulation Versus Resection (CoRaStiR)|Prospective Randomized Controlled Study of Neurostimulation in the Medial Temporal Lobe for Patients With Medically Refractory Medial Temporal Lobe Epilepsy; Controlled Randomized Stimulation Versus Resection (CoRaStiR)|Unknown status|Recruiting|N/A|45|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-06-01 03:27:42.708683|2018-06-01 03:27:42.708683
NCT00431444|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2010-11-12||2011-03-25|2007-02-02|2007-02-05|Estimate|2011-02-15|2011-03-11|Estimate||||2011-03-25|2011-03-29|Estimate|January 2007||2007-01-31|March 2011|2011-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density|A Multi-center, Randomized, Double-blind, Double-dummy Study in Postmenopausal Women With Low Bone Mineral Density to Compare the Effects of a Single Dose of i.v. Zoledronic Acid 5 mg, With Daily Oral Raloxifene 60 mg OD on Bone Turnover Markers|Completed||Phase 4|110|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:27:42.847141|2018-06-01 03:27:42.847141
NCT00431431|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2017-06-23|2007-02-02|2007-02-05|Estimate|||||||2017-06-23|2017-06-26|Actual|July 31, 2000|Actual|2000-07-31|June 2017|2017-06-30|February 15, 2005|Actual|2005-02-15|February 15, 2005|Actual|2005-02-15||Interventional|STEP||Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)|A Multinational, Randomized, Double-Blind, Parallel Group Comparative Trial on the Effects of 2 Years Treatment With Tibolone (1.25 mg Org OD 14) and Raloxifene (60 mg) on Bone Mineral Density in Osteopenic Postmenopausal Women|Completed||Phase 4|324|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:27:43.938246|2018-06-01 03:27:43.938246
NCT00431418|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2015-09-21|2007-02-02|2007-02-05|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|June 2012|Actual|2012-06-30|July 2010|Actual|2010-07-31||Interventional|||The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease|The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease (SPICE Trial): a Pilot Study|Completed||Phase 3|20|Actual|Mercy Hospital for Women, Australia||2|||f||||||||||||||2018-06-01 03:27:44.046115|2018-06-01 03:27:44.046115
NCT00431405|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-02-01|2007-02-01|2007-02-05|Estimate|||||||2007-02-01|2007-02-05|Estimate|August 2006||2006-08-31|February 2007|2007-02-28|January 2007||2007-01-31|||||Observational|||Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population|Assessing Risk of Cardiovascular Events in RA Patients Using a Retrospective Cohort From the VARA Registry|Unknown status|Active, not recruiting||450||Dallas VA Medical Center|||||f||||||||||||||2018-06-01 03:27:44.18249|2018-06-01 03:27:44.18249
NCT00431392|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2007-02-02|2007-02-02|2007-02-05|Estimate|||||||2007-02-02|2007-02-05|Estimate|September 2001||2001-09-30|January 2007|2007-01-31||||||||Interventional|||Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions|Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions|Completed||Phase 2|42||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:27:44.248905|2018-06-01 03:27:44.248905
NCT00431379|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2013-11-04|2007-02-02|2007-02-05|Estimate|||||||2013-11-04|2013-11-06|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study|Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study: Phase I|Withdrawn||Phase 1|0|Actual|Medical Center of Central Georgia||||drug has expired, no enrollments in study. Company pulled funding|f||||||||||||||2018-06-01 03:27:44.330059|2018-06-01 03:27:44.330059
NCT00431366|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2017-06-30|2007-02-02|2007-02-05|Estimate|||||||2017-06-30|2017-07-02|Actual|February 1, 2007||2007-02-01|December 24, 2008|2008-12-24|December 24, 2008||2008-12-24|||||Observational|||Sequence Effect in Parkinson's Disease|The Characteristics of Sequence Effect in de Novo and Advanced Parkinson's Disease|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:27:44.408709|2018-06-01 03:27:44.408709
NCT00431353|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2016-11-01|2007-02-02|2007-02-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2004||2004-04-30|November 2016|2016-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients|A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients|Completed||Phase 4|325|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:27:44.475209|2018-06-01 03:27:44.475209
NCT00431340|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2015-07-07|2007-02-02|2007-02-05|Estimate|||||||2015-07-07|2015-07-08|Estimate|March 2007||2007-03-31|July 2015|2015-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma|A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma|Terminated||Phase 2|4|Actual|Onxeo||||Terminated due to dose limiting toxicity|||||||||||||||2018-06-01 03:27:44.631994|2018-06-01 03:27:44.631994
NCT00431327|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-02-02|2007-02-02|2007-02-05|Estimate|||||||2007-02-02|2007-02-05|Estimate|February 2005||2005-02-28|February 2007|2007-02-28|October 2006||2006-10-31|||||Interventional|||Facilitators to Keeping Colonoscopy Appointments|Peer Coach Intervention to Improve Attendance to Scheduled Colonoscopy|Completed||Early Phase 1|140||University of Pennsylvania|||||f||||||||||||||2018-06-01 03:27:44.697947|2018-06-01 03:27:44.697947
NCT00431314|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2008-07-08|2007-02-02|2007-02-05|Estimate|||||||2008-07-08|2008-07-09|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|March 2007|Actual|2007-03-31|||||Observational|||Effect of Hemodialysis on Toe Pressure- and Finger Pressure and Skin Autofluorescence in Hemodialysis Patients|The Effect of Hemodialysis on Toe Pressure- and Finger Pressure Measurements and Measurement of Skin Autofluorescence; a Pilot Study in the Assessment of Critical Limb Ischemia in Hemodialysis Patients.|Completed|||82|Actual|Isala|||||f||||f||||||||||2018-06-01 03:27:44.762876|2018-06-01 03:27:44.762876
NCT00431301|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2017-04-06|2007-02-02|2007-02-05|Estimate|||||||2017-04-06|2017-04-10|Actual|August 2006||2006-08-31|April 2017|2017-04-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|||Risk Factors for Progressive Supranuclear Palsy (PSP)|Genetic and Environmental Risk Factors for PSP|Completed|||942|Actual|University of Louisville|||2||f||||||||||Samples With DNA|"~     DNA will be used for genotyping specific genes of interest related to the disease.~   "|||2018-06-01 03:27:44.820877|2018-06-01 03:27:44.820877
NCT00431288|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-02-01|2007-02-01|2007-02-05|Estimate|||||||2007-02-01|2007-02-05|Estimate|August 2003||2003-08-31|February 2007|2007-02-28|June 2006||2006-06-30|||||Interventional|||A Nutrition Intervention to Lower Blood Pressure in Adolescents|Efficacy of a Nutrition Intervention Emphasizing Fruits, Vegetables and Dairy to Lower Blood Pressure in Adolescents|Completed||N/A|54||University of Cincinnati|||||f||||||||||||||2018-06-01 03:27:44.892385|2018-06-01 03:27:44.892385
NCT00431275|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2012-06-05|2007-02-02|2007-02-05|Estimate|||||||2012-06-05|2012-06-06|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody|An Open Label, Randomized Clinical Comparability Study Of The Current Liquid And Commercial Liquid Formulations|Completed||Phase 1|85|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:27:44.950775|2018-06-01 03:27:44.950775
NCT00431262|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-03-02|2007-02-01|2007-02-05|Estimate|||||||2007-03-02|2007-03-05|Estimate|February 2007||2007-02-28|March 2007|2007-03-31|June 2009||2009-06-30|||||Interventional|||Antabuse in Severe Alcoholism: an Open Controlled Study|Antabuse in Severe Alcoholism: an Open Controlled Study|Unknown status|Recruiting|Phase 4|60||Psykiatrisk Center Gentofte|||||f||||||||||||||2018-06-01 03:27:45.033849|2018-06-01 03:27:45.033849
NCT00431249|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2015-05-11|2007-02-02|2007-02-05|Estimate|||||||2015-05-11|2015-05-12|Estimate|February 2007||2007-02-28|May 2015|2015-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease|Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease.|Completed||Phase 4|40|Actual|Tungs’ Taichung Metroharbour Hospital||1|||f||||f||||||||||2018-06-01 03:27:45.086553|2018-06-01 03:27:45.086553
NCT00431236|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2017-08-21|2007-02-02|2007-02-05|Estimate|||||||2017-08-21|2017-08-22|Actual|November 6, 2006|Actual|2006-11-06|August 2017|2017-08-31|October 9, 2007|Actual|2007-10-09|October 9, 2007|Actual|2007-10-09||Interventional|||A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy|A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, Administered in Combination With ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy|Completed||Phase 3|810|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:27:45.159645|2018-06-01 03:27:45.159645
NCT00431223|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2015-04-14|2007-02-02|2007-02-05|Estimate|||||||2015-04-14|2015-04-16|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|fMRI||Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training|Does Computerized Cognitive Skills Training Change Brain Activation Patterns in Schizophrenia?|Completed||N/A|11|Actual|Manhattan Psychiatric Center||2|||f||||t||||||||||2018-06-01 03:27:45.464226|2018-06-01 03:27:45.464226
NCT00431210|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2017-04-14|2007-02-02|2007-02-05|Estimate|||||||2017-04-14|2017-04-18|Actual|February 2007||2007-02-28|April 2017|2017-04-30|January 26, 2016|Actual|2016-01-26|June 30, 2015|Actual|2015-06-30||Interventional|||Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma|A Pilot Feasibility Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma|Completed||Phase 1|28|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No|There are no plans to share IPD. Cumulative results will be posted and published.|2018-06-01 03:27:45.624281|2018-06-01 03:27:45.624281
NCT00431197|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2010-01-26|2007-02-02|2007-02-05|Estimate|||||||2010-01-26|2010-01-28|Estimate|February 2004||2004-02-29|January 2010|2010-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men|Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men|Completed||Phase 1|40|Anticipated|Mayo Clinic|||||||||||||||||||2018-06-01 03:27:45.717748|2018-06-01 03:27:45.717748
NCT00431184|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2014-06-19||2014-08-05|2007-02-02|2007-02-05|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Pentazocine Versus Lorazepam on Manic Symptoms|Effects of Pentazocine Versus Lorazepam on Manic Symptoms|Completed||Phase 2|19|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 03:27:45.809926|2018-06-01 03:27:45.809926
NCT00431171|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2012-01-13|2007-02-01|2007-02-05|Estimate|||||||2012-01-13|2012-01-16|Estimate|September 2007||2007-09-30|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Pharmacokinetics Study of Oral Lithium in Patients With Chronic Spinal Cord Injury|A Three Month, Open-label, Single-arm Trial Evaluating the Safety and Pharmacokinetics of Oral Lithium in Patients Diagnosed With Chronic Spinal Cord Injury|Completed||Phase 1|20|Anticipated|The University of Hong Kong|||||f||||||||||||||2018-06-01 03:27:46.114128|2018-06-01 03:27:46.114128
NCT00431158|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2014-09-17|2007-02-01|2007-02-05|Estimate|||||||2014-09-17|2014-09-18|Estimate|January 2007||2007-01-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||ARDSnet Protocol vs. Open Lung Approach in ARDS|ARDSnet Protocol vs. the Open Lung Approach for the Ventilatory Management of Severe, Established ARDS: A Global Randomized Controlled Trial|Completed||N/A|224|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:27:46.225463|2018-06-01 03:27:46.225463
NCT00431145|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-02-01|2007-02-01|2007-02-05|Estimate|||||||2007-02-01|2007-02-05|Estimate|October 2006||2006-10-31|February 2007|2007-02-28||||||||Interventional|||Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)|Influence of Combined Therapy of Niacin and Statins on Stem Cell Mobilization and Inflammatory Parameters in Patients Suffering From Coronary Artery Disease – Randomized Clinical Study -|Unknown status|Recruiting|Phase 2|80||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:27:46.323525|2018-06-01 03:27:46.323525
NCT00431132|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2011-02-07||2017-02-06|2007-02-02|2007-02-05|Estimate|2011-03-07|2011-04-07|Estimate||||2017-02-06|2017-03-15|Actual|January 2007||2007-01-31|February 2017|2017-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis|A 12 Month, Open-label, Multi-center Trial to Investigate the Endometrial Safety of Vagifem Low Dose (10ug 17beta-estradiol Vaginal Tablet) in Postmenopausal Women With Atrophic Vaginitis Symptoms|Completed||Phase 3|336|Actual|Novo Nordisk A/S|This was a single-arm, 12-month, open label, multicentre trial; therefore there were no comparator results available.|1|||f||||f||||||||||2018-06-01 03:27:46.427459|2018-06-01 03:27:46.427459
NCT00431119|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2007-02-02|2007-02-02|2007-02-05|Estimate|||||||2007-02-02|2007-02-05|Estimate|October 1997||1997-10-31|February 2007|2007-02-28|October 2000||2000-10-31|||||Interventional|||Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid|A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid|Completed||Phase 2|70||University Hospital Muenster|||||f||||||||||||||2018-06-01 03:27:46.710096|2018-06-01 03:27:46.710096
NCT00431106|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2009-09-25|2007-02-02|2007-02-05|Estimate|||||||2009-09-25|2009-09-28|Estimate|April 2002||2002-04-30|September 2009|2009-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer|A Multicenter Randomized Phase III Study of Combination Treatment With Vinorelbine and Gemcitabine Versus Capecitabine Monotherapy in Metastatic Breast Cancer Patients Following Treatment Failure With the Combination of a Taxane and an Anthracycline|Completed||Phase 3|144|Anticipated|Hellenic Oncology Research Group||2|||f||||||||||||||2018-06-01 03:27:46.787863|2018-06-01 03:27:46.787863
NCT00431093|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2015-06-03|2007-02-02|2007-02-05|Estimate|||||||2015-06-03|2015-06-04|Estimate|November 2002||2002-11-30|June 2015|2015-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|TOTAL||Trial to Compare the Effects of Tibolone (Livial®) and Continuous Combined Low-Dose Estradiol/Noresterone (Activelle®)|A Multicenter, Randomized, Double-Blind, Double Dummy, Group-Comparative Trial to Compare the Effects of Livial® and Activelle ® on the Vaginal Bleeding Pattern, Vasomotor Complaints, Vaginal Atrophy, QoL and Sexual Function|Completed||Phase 4|570|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:27:46.903505|2018-06-01 03:27:46.903505
NCT00431080|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2008-01-18|2007-02-02|2007-02-05|Estimate|||||||2008-01-18|2008-01-21|Estimate|August 2004||2004-08-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer|A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-Supported Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Women With Axillary Lymph Node Positive Breast Cancer|Completed||Phase 3|478|Actual|Hellenic Oncology Research Group||2|||f||||||||||||||2018-06-01 03:27:46.963433|2018-06-01 03:27:46.963433
NCT00431067|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|2013-08-08||2014-06-03|2007-02-02|2007-02-05|Estimate|2013-11-06|2013-12-23|Estimate||||2014-06-03|2014-06-09|Estimate|September 2006||2006-09-30|November 2013|2013-11-30||||August 2009|Actual|2009-08-31||Interventional|||Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy|Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy|Completed||Phase 2|41|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 03:27:47.069373|2018-06-01 03:27:47.069373
NCT00431054|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-02|||2016-02-17|2007-02-02|2007-02-05|Estimate|||||||2016-02-17|2016-02-19|Estimate|February 2007||2007-02-28|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer|Pharmacodynamic Trial: Molecular Marker & Imaging Studies as Primary Endpoints to Determine Optimal Biological Dosage of Perifosine, Orally Avail AKT PH Domain Inhibitor Combined w/ Docetaxel in Patients w/Relapsed Epithelial Ovarian Cancer|Completed||Phase 1|22|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:27:47.307185|2018-06-01 03:27:47.307185
NCT00430859|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2012-03-30|2007-02-01|2007-02-02|Estimate|||||||2012-03-30|2012-04-02|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis|A Pilot, Double-blind, Randomised, Placebo-controlled, Exploratory Study to Investigate the Safety and Effect of Bovine Intestinal Alkaline Phosphatase in Patients With Sepsis|Completed||Phase 2|37|Actual|AM-Pharma||2|||f||||t||||||||||2018-06-01 03:27:50.626445|2018-06-01 03:27:50.626445
NCT00431041|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2009-10-05||2010-06-01|2007-02-01|2007-02-02|Estimate|2009-12-08|2010-01-11|Estimate||||2010-06-01|2010-06-08|Estimate|December 2006||2006-12-31|June 2010|2010-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|VECTOR||Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)|VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients|Completed||Phase 4|132|Actual|Astellas Pharma Inc|The relatively high incidence of AEs, specifically dry mouth, in both groups may be a result of the direct questioning methodology used. Subjects were also informed the primary objectives were the relative frequency and severity of dry mouth.|2|||f||||f||||||||||2018-06-01 03:27:47.388554|2018-06-01 03:27:47.388554
NCT00431028|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2008-03-06|2007-02-01|2007-02-02|Estimate|||||||2008-03-06|2008-03-07|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery|Phase I/II Comparative Study of a Single Intraoperative Sub-Tenon's Capsule Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System Versus 1% Prednisolone and 0.3% Ciprofloxacin Eyedrops for Cataract Surgery|Terminated||Phase 1/Phase 2|140|Actual|Federal University of São Paulo||1||Terminated|f||||t||||||||||2018-06-01 03:27:47.723372|2018-06-01 03:27:47.723372
NCT00431015|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31||2012-12-06|2012-12-06|2007-01-31|2007-02-02|Estimate||||2012-12-06|2012-12-10|Estimate|2012-12-06|2012-12-10|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)|A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients|Completed||Phase 1/Phase 2|88|Actual|Infinity Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:27:47.7996|2018-06-01 03:27:47.7996
NCT00431002|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2017-05-13|2007-02-01|2007-02-02|Estimate|||||||2017-05-13|2017-05-16|Actual||||May 2017|2017-05-31|September 2008||2008-09-30|||||Interventional|||Provincial Roll-Out Bone Health Strategy||Withdrawn||N/A|0|Actual|University of British Columbia||||Withdrawn|f||||f||||||||||2018-06-01 03:27:48.882067|2018-06-01 03:27:48.882067
NCT00430989|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2013-09-24|2007-02-01|2007-02-02|Estimate|||||||2013-09-24|2013-09-26|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial|Large, Randomised, Parallel-group, Controlled Trial, With Patients Randomly Allocated to Either N2O-containing (70% N2O in Oxygen [FiO2 0.3]) or N2O-free (70% Nitrogen in Oxygen [FiO2 0.3]).|Completed||Phase 4|7103|Actual|Bayside Health||2|||f||||t||||||||||2018-06-01 03:27:48.94096|2018-06-01 03:27:48.94096
NCT00430976|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2009-12-10|2007-01-31|2007-02-02|Estimate|||||||2009-12-10|2009-12-11|Estimate|December 2006||2006-12-31|August 2008|2008-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Exercise, Executive Processes and the Aging Brain|Exercise, Executive Processes and the Aging Brain|Completed||Phase 3|100||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 03:27:49.03759|2018-06-01 03:27:49.03759
NCT00430963|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2011-10-25|2007-02-01|2007-02-02|Estimate|||||||2011-10-25|2011-10-26|Estimate|October 2006||2006-10-31|October 2011|2011-10-31|November 2007|Actual|2007-11-30|April 2007|Actual|2007-04-30||Interventional|||IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines|Completed||Phase 3|256|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-06-01 03:27:49.113027|2018-06-01 03:27:49.113027
NCT00430950|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2009-02-09||2017-10-11|2007-02-01|2007-02-02|Estimate|2009-03-13|2009-04-20|Estimate||||2017-10-11|2017-10-12|Actual|February 2007||2007-02-28|October 2017|2017-10-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension|Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy|Completed||Phase 3|1011|Actual|Daiichi Sankyo, Inc.||2|||f||||||||||||||2018-06-01 03:27:49.208228|2018-06-01 03:27:49.208228
NCT00430937|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2010-12-07||2012-07-10|2007-02-01|2007-02-02|Estimate|2010-12-07|2011-01-05|Estimate||||2012-07-10|2012-07-16|Estimate|April 2006||2006-04-30|July 2012|2012-07-31||||March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections|A Multicenter, Randomized, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)|Terminated||Phase 3|194|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:27:49.726207|2018-06-01 03:27:49.726207
NCT00430924|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2012-02-07|2007-02-01|2007-02-02|Estimate|||||||2012-02-07|2012-02-08|Estimate|March 2007||2007-03-31|February 2012|2012-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Inhibition of Aldosterone in Patients With Chronic Renal Disease|The Effect of Aldosterone Inhibition on Proteinuria in Patients With Progressive Renal Disease|Completed||Phase 4|42|Actual|Herlev Hospital||2|||f||||t||||||||||2018-06-01 03:27:50.076849|2018-06-01 03:27:50.076849
NCT00430911|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2007-01-31|2007-01-31|2007-02-02|Estimate|||||||2007-01-31|2007-02-02|Estimate|February 2001||2001-02-28|January 2007|2007-01-31||||||||Interventional|||Radiotherapy for Malignant Astrocytomas in the Elderly||Completed||Phase 3|||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:27:50.149817|2018-06-01 03:27:50.149817
NCT00430898|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2008-12-17|2007-01-31|2007-02-02|Estimate|||||||2008-12-17|2008-12-18|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Basiliximab in Moderate to Severe Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, With Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis|Completed||Phase 2|181|Anticipated|Cerimon Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:27:50.220167|2018-06-01 03:27:50.220167
NCT00430885|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2014-01-24|2007-02-01|2007-02-02|Estimate|||||||2014-01-24|2014-01-27|Estimate|February 2007||2007-02-28|January 2014|2014-01-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction|Phase III Study of Intravenous Immunglobulin (IVIG) in Patients With Heart Failure After Myocardial Infarction|Completed||Phase 3|62|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-06-01 03:27:50.451953|2018-06-01 03:27:50.451953
NCT00430872|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2012-07-31|2007-02-01|2007-02-02|Estimate|||||||2012-07-31|2012-08-01|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Development of the MDASI-Spine Tumor Module|Validation of the M.D. Anderson Symptom Inventory-Spine Tumor Module|Completed|||128|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:27:50.538765|2018-06-01 03:27:50.538765
NCT00430846|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2014-12-17|2007-02-01|2007-02-02|Estimate|||||||2014-12-17|2014-12-18|Estimate|November 2006||2006-11-30|December 2014|2014-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies|A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.|Completed||Phase 1|45|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 03:27:50.743047|2018-06-01 03:27:50.743047
NCT00430833|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2007-01-31|2007-01-31|2007-02-02|Estimate|||||||2007-01-31|2007-02-02|Estimate||||January 2007|2007-01-31||||||||Interventional|||CHANCE - Candesartan in Hypertrophic Cardiomyopathy|Candesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter Study|Unknown status|Active, not recruiting|Phase 2|||Charles University, Czech Republic|||||f||||||||||||||2018-06-01 03:27:50.832488|2018-06-01 03:27:50.832488
NCT00430820|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2010-12-02|2007-02-01|2007-02-02|Estimate|||||||2010-12-02|2010-12-03|Estimate|March 2007||2007-03-31|April 2009|2009-04-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Observational|||Discovery of New Circulating Biomarkers of Coronary Atherosclerosis|Discovery of New Circulating Biomarkers of Coronary Atherosclerosis Using Differential Proteomics: the BIOmarkers of CORonary Events (BIOCORE) Study|Completed|||124|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||Samples With DNA|"~     biomarqueurs~   "|||2018-06-01 03:27:50.895703|2018-06-01 03:27:50.895703
NCT00430807|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2015-10-04|2007-02-01|2007-02-02|Estimate|||||||2015-10-04|2015-10-06|Estimate|January 2002||2002-01-31|October 2015|2015-10-31|December 2006|Actual|2006-12-31|January 2005|Actual|2005-01-31||Interventional|||Hydroxychloroquine in Giant Cell Arteritis|Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis.|Completed||Phase 3|75|Actual|University Hospital, Toulouse|||||f||||f||||||||||2018-06-01 03:27:50.978363|2018-06-01 03:27:50.978363
NCT00430794|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2010-12-03|2007-02-01|2007-02-02|Estimate|||||||2010-12-03|2010-12-06|Estimate|March 2007||2007-03-31|February 2007|2007-02-28|December 2008|Actual|2008-12-31|||||Interventional|||The Efficacy of Spironolactone in Patients With Resistant Hypertension|A Randomised, Placebo Controlled Trial of the Efficacy of the Addition of Spironolactone to Modern Antihypertensive Treatment Regimens in Patients With Resistant Hypertension|Terminated||Phase 2|40|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||||Difficulties with recruitment.|f||||||||||||||2018-06-01 03:27:51.085171|2018-06-01 03:27:51.085171
NCT00430781|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2009-11-19||2015-04-15|2007-02-01|2007-02-02|Estimate|2011-02-17|2011-03-14|Estimate||||2015-04-15|2015-05-08|Estimate|November 2006||2006-11-30|April 2015|2015-04-30|July 2011|Actual|2011-07-31|July 2008|Actual|2008-07-31||Interventional|||Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer|A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen|Completed||Phase 2|228|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:27:51.213792|2018-06-01 03:27:51.213792
NCT00430768|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2016-09-21||2016-12-13|2007-01-31|2007-02-02|Estimate|2016-12-13|2016-12-15|Estimate||||2016-12-13|2016-12-15|Estimate|February 2006||2006-02-28|December 2016|2016-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|AAT||Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency|Preclinical & Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV1-CB-hAAT) Gene Vector to AAT-Deficient Adults|Completed||Phase 1|9|Actual|University of Massachusetts, Worcester|Study results based on small number of subjects No statistical analysis.|3|||f||||t||||||||Yes|Laboratory information shared as received; copy of manuscript given to patients; at 5 year follow up Principal investigator explained results to patients|2018-06-01 03:27:52.596227|2018-06-01 03:27:52.596227
NCT00430755|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2010-09-24||2015-11-15|2007-01-31|2007-02-02|Estimate|2015-11-15|2015-12-18|Estimate||||2015-11-15|2015-12-18|Estimate|August 2005||2005-08-31|November 2015|2015-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CLEOS||Improving the Quality of Patient Care by Using a Clinical Expert System.|Quality Assessment for History Taking With or Without an Knowledge Based Interview System.|Completed||N/A|98|Actual|Robert Bosch Gesellschaft für Medizinische Forschung mbH||1|||f||||f||||||||||2018-06-01 03:27:53.277413|2018-06-01 03:27:53.277413
NCT00430742|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2015-02-12|2007-02-01|2007-02-02|Estimate|||||||2015-02-12|2015-02-13|Estimate|November 2006||2006-11-30|February 2015|2015-02-28|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|||An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM) Followed by a 1-Year Extension|Terminated||Phase 3|600|Actual|Merck Sharp & Dohme Corp.||4||The overall profile does not support development for obesity|f||||||||||||||2018-06-01 03:27:53.415751|2018-06-01 03:27:53.415751
NCT00430729|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2016-11-29|2007-02-01|2007-02-02|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2003||2003-01-31|September 2016|2016-09-30||||||||Interventional|||Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)|Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52 Weeks Double Blind Study With 500mcg Roflumilast Once Daily Versus Placebo. Ratio-Study.|Completed||Phase 3|1100||AstraZeneca|||||f||||||||||||||2018-06-01 03:27:53.489386|2018-06-01 03:27:53.489386
NCT00430716|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2011-04-22||2011-05-25|2007-01-31|2007-02-02|Estimate|2011-04-22|2011-05-17|Estimate||||2011-05-25|2011-05-30|Estimate|April 2008||2008-04-30|May 2011|2011-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.|A Multinational, Multicentre, Randomized, Parallel Group, Double-Blind Study To Assess The Efficacy and Safety Of 1 mg, 5 mg and 20 mg TID of Oral Sildenafil in the Treatment of Subjects Aged 18 Years and Over With Pulmonary Arterial Hypertension (PAH)|Terminated||Phase 4|130|Actual|Pfizer|The trial was not designed to demonstrate the equivalence of doses and due to premature study termination, the resulting sample size was not adequately powered to show superiority.|4||"This study was terminated at the recommendation of an independent Data Monitoring Committee.~   The decision was not based on any safety concerns."|f||||t||||||||||2018-06-01 03:27:53.645957|2018-06-01 03:27:53.645957
NCT00430703|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2008-11-05|2007-02-01|2007-02-02|Estimate|||||||2008-11-05|2008-11-06|Estimate|August 2006||2006-08-31|November 2008|2008-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Passive Gait Training on the Cortical Activity in Patients With Severe Traumatic Brain Injury.|Effect of Massive Proprioceptive Stimulation With Passive Gait Training on the Cortical Activity in Patients With Impaired States of Consciousness After Severe Traumatic Brain Injury.|Completed||Early Phase 1|26|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 03:27:55.431809|2018-06-01 03:27:55.431809
NCT00430690|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2018-01-19|2007-02-01|2007-02-02|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2006|Actual|2006-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2012|Actual|2012-08-31||Observational|||Acoustic Startle Reduction In Cocaine Dependence|Acoustic Startle Reduction In Cocaine Dependence|Active, not recruiting|||135|Anticipated|Emory University|||3||f||||f||||||Samples With DNA|"~     Blood and extracted DNA~   "|No||2018-06-01 03:27:55.513119|2018-06-01 03:27:55.513119
NCT00430677|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2012-02-13||2015-03-03|2007-02-01|2007-02-02|Estimate|2012-04-13|2012-05-11|Estimate||||2015-03-03|2015-03-20|Estimate|June 2007||2007-06-30|March 2015|2015-03-31|August 2011|Actual|2011-08-31|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis|A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects With Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)|Terminated||Phase 2/Phase 3|423|Actual|Bristol-Myers Squibb||4||Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period|f||||t||||||||||2018-06-01 03:27:55.723218|2018-06-01 03:27:55.723218
NCT00430664|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-02-01|2007-02-01|2007-02-02|Estimate|||||||2007-02-01|2007-02-02|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|December 2007||2007-12-31|||||Interventional|||A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis|A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis|Unknown status|Recruiting|N/A|100||Postgraduate Institute of Medical Education and Research|||||f||||||||||||||2018-06-01 03:27:58.407299|2018-06-01 03:27:58.407299
NCT00430651|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2009-01-27|2007-02-01|2007-02-02|Estimate|||||||2009-01-27|2009-01-28|Estimate|July 2004||2004-07-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)|Multicenter Randomized Phase III Study Comparing Docetaxel With Carboplatin Versus Docetaxel Single Agent as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (NSCLC).|Completed||Phase 3|135|Actual|Hellenic Oncology Research Group||2|||f||||||||||||||2018-06-01 03:27:58.473386|2018-06-01 03:27:58.473386
NCT00430638|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2008-10-03||2010-01-27|2007-02-01|2007-02-02|Estimate|2009-12-15|2010-01-22|Estimate||||2010-01-27|2010-02-02|Estimate|December 2006||2006-12-31|January 2010|2010-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension|A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension|Completed||Phase 4|278|Actual|Daiichi Sankyo, Inc.||2|||f||||||||||||||2018-06-01 03:27:58.58256|2018-06-01 03:27:58.58256
NCT00430625|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2010-06-03||2014-02-19|2007-02-01|2007-02-02|Estimate|2010-08-19|2010-09-10|Estimate||||2014-02-19|2014-03-17|Estimate|January 2007||2007-01-31|February 2014|2014-02-28|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease|A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease|Completed||Phase 3|25|Actual|Shire|Due to small sample sizes no conclusions could be drawn on Quality of life (QOL).|2|||f||||f||||||||||2018-06-01 03:27:59.149085|2018-06-01 03:27:59.149085
NCT00430612|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2015-04-30|2007-01-31|2007-02-02|Estimate|||||||2015-04-30|2015-05-01|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|December 2013|Actual|2013-12-31|2 Years|Observational [Patient Registry]|OBTAIN||The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)|The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)|Unknown status|Active, not recruiting||6830|Anticipated|Northwestern University|||1||f||||t||||||||||2018-06-01 03:27:59.548749|2018-06-01 03:27:59.548749
NCT00430599|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2015-10-07|2007-02-01|2007-02-02|Estimate|||||||2015-10-07|2015-10-12|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|September 2009|Actual|2009-09-30|||||Observational|||The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis||Completed|||20|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||||f||||||||||||||2018-06-01 03:27:59.65356|2018-06-01 03:27:59.65356
NCT00430586|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2011-08-02|2007-02-01|2007-02-02|Estimate|||||||2011-08-02|2011-08-03|Estimate|November 2006||2006-11-30|August 2011|2011-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Determine the Optimal Dose of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines|Completed||Phase 2|191|Actual|Merz Pharmaceuticals GmbH||4|||f||||||||||||||2018-06-01 03:27:59.702517|2018-06-01 03:27:59.702517
NCT00430573|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2018-02-07||2018-05-14|2007-02-01|2007-02-02|Estimate|2018-05-14|2018-05-17|Actual||||2018-05-14|2018-05-17|Actual|February 2007|Actual|2007-02-28|May 2018|2018-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||10 participants were randomized out of the initial15 who consented to the study|Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use|Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use|Terminated||Phase 2|15|Actual|Boston University Charles River Campus|Study was terminated due to low enrollment/adherence with the study drug. 10 participants were randomized, 5 dropped out before taking study drug. The blind was never broken so results can only be presented aggregated for all randomized participants.|2||The investigators failed to recruit participants as originally projected.|f||||t|t|f|||t|||No||2018-06-01 03:27:59.770472|2018-06-01 03:27:59.770472
NCT00430560|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2017-09-07|2007-01-31|2007-02-02|Estimate|||||||2017-09-07|2017-09-11|Actual|October 2000||2000-10-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2005|Actual|2005-10-31||Interventional|||Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia|Work Activity Augmented by Cognitive Rehabilitation: Continuation and Follow-up|Completed||Phase 2/Phase 3|150|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:27:59.950742|2018-06-01 03:27:59.950742
NCT00430547|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-02-01|2007-02-01|2007-02-02|Estimate|||||||2007-02-01|2007-02-02|Estimate|August 2003||2003-08-31|August 2003|2003-08-31|January 2006||2006-01-31|||||Interventional|||Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies|Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies|Completed||N/A|60||Barwon Health|||||f||||||||||||||2018-06-01 03:28:00.024778|2018-06-01 03:28:00.024778
NCT00430534|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2007-02-01|2007-02-01|2007-02-02|Estimate|||||||2007-02-01|2007-02-02|Estimate||||February 2007|2007-02-28||||||||Interventional|||Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals’ EBV (Epstein Barr Virus) Vaccine (268664).|To Evaluate the Safety, Immunogenicity and Efficacy of GSK Biologicals’ EBV Vaccine (268664) in Healthy Seronegative Adolescents/Adults When Injected Intramuscularly According to a 0-1-5 Month Schedule in Belgium.|Completed||Phase 2|200||Henogen|||||f||||||||||||||2018-06-01 03:28:00.072622|2018-06-01 03:28:00.072622
NCT00430521|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01||2009-05-20|2016-10-18|2007-02-01|2007-02-02|Estimate||||2009-09-28|2009-09-30|Estimate|2016-10-18|2016-10-19|Estimate|February 2007||2007-02-28|October 2016|2016-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)|Reactogenicity and Immunogenicity Study of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1119711A) Administered According to Different Vaccination Schedules|Completed||Phase 2|512|Actual|GlaxoSmithKline||8|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:28:00.323293|2018-06-01 03:28:00.323293
NCT00430508|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|2009-02-09||2009-06-17|2007-02-01|2007-02-02|Estimate|2009-04-29|2009-06-17|Estimate||||2009-06-17|2009-06-25|Estimate|February 2007||2007-02-28|June 2009|2009-06-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension|Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy|Completed||Phase 3|972|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-06-01 03:28:00.495649|2018-06-01 03:28:00.495649
NCT00430495|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|2016-01-19||2016-01-19|2007-02-01|2007-02-02|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|December 2006||2006-12-31|January 2016|2016-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|AUGUST I|Intention-to-treat (ITT) population included all randomized participants who received at least one treatment dose.|A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)|A Randomized, Double-blind, Placebo-controlled, Multicentre, Phase II Dose-finding Study of Atacicept Given Subcutaneously in Subjects With Rheumatoid Arthritis and Inadequate Response to TNFa Antagonist Therapy|Completed||Phase 2|256|Actual|EMD Serono||4|||f||||f||||||||||2018-06-01 03:28:01.173614|2018-06-01 03:28:01.173614
NCT00430482|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2017-04-28|2007-01-31|2007-02-02|Estimate|||||||2017-04-28|2017-05-01|Actual|June 2005|Actual|2005-06-30|April 2017|2017-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Stress, Distress Intolerance, and Drug Dependence|Stress, Distress Intolerance, and Drug Dependence|Completed||N/A|133|Actual|Boston University Charles River Campus||2|||f||||t||||||||||2018-06-01 03:28:01.728449|2018-06-01 03:28:01.728449
NCT00430469|ClinicalTrials.gov processed this data on May 31, 2018|2007-02-01|||2015-06-29|2007-02-01|2007-02-02|Estimate|||||||2015-06-29|2015-06-30|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|June 2009|Anticipated|2009-06-30|March 2009|Anticipated|2009-03-31||Interventional|||Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients|Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients|Withdrawn||Phase 1/Phase 2|0|Actual|AM-Pharma||||Strategic company decision|f||||t||||||||||2018-06-01 03:28:01.82119|2018-06-01 03:28:01.82119
NCT00430456|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2012-06-11|2007-02-01|2007-02-02|Estimate|||||||2012-06-11|2012-06-12|Estimate|August 2006||2006-08-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional|STEPs||Treadmill Exercise Prescriptions to Improve Fitness Versus Ambulatory Function After Stroke.|Treadmill Exercise Prescriptions to Improve Fitness Versus Ambulatory Function After Stroke|Completed||Phase 1|120|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:28:01.8876|2018-06-01 03:28:01.8876
NCT00430443|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2011-08-30|2007-01-30|2007-02-01|Estimate|||||||2011-08-30|2011-08-31|Estimate|February 2007||2007-02-28|August 2011|2011-08-31|January 2009|Actual|2009-01-31|||||Interventional|||Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML|Phase I Study of Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed Acute Lymphocytic Leukemia and Acute Myelogeneous Leukemia|Terminated||Phase 1|3|Actual|Callisto Pharmaceuticals||||Participants are no longer being examined or treated.|f||||f||||||||||2018-06-01 03:28:01.955613|2018-06-01 03:28:01.955613
NCT00430430|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2016-10-25|2007-01-30|2007-02-01|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets|Lipoprotein Turnover on Low- and High-MUFA Portfolio Diets|Completed||Phase 2|24|Actual|University of Toronto||2|||f||||||||||||||2018-06-01 03:28:02.023552|2018-06-01 03:28:02.023552
NCT00430417|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2013-10-30|2007-01-31|2007-02-01|Estimate|||||||2013-10-30|2013-10-31|Estimate|January 2007||2007-01-31|October 2013|2013-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Bone Metabolism and Parathyroid Hormone-related Protein (PTHrP) Lactation Study|A Prospective Cohort Pilot Study of Bone Metabolism in Lactating and Non-lactating Postpartum Women and Healthy Non-pregnant Women|Completed|||49|Actual|University of Pittsburgh|||3||f||||t||||||Samples Without DNA|"~     archival blood serum and plasma~   "|||2018-06-01 03:28:02.083404|2018-06-01 03:28:02.083404
NCT00430404|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2014-01-02|2007-01-31|2007-02-01|Estimate|||||||2014-01-02|2014-01-03|Estimate|August 2004||2004-08-31|January 2014|2014-01-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Screening and Treatment of Depression in the Community|Randomized Controlled Trial of a Community-based Early Psychiatric Intervention Strategy to Screen and Manage Depression in the Elderly|Completed||Phase 4|214|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-06-01 03:28:02.164305|2018-06-01 03:28:02.164305
NCT00430391|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2013-06-18|2007-01-31|2007-02-01|Estimate|||||||2013-06-18|2013-06-19|Estimate|December 2003||2003-12-31|January 2011|2011-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Comparison of Video Consent Versus Routine Consent for Participation in Research Studies|Comparison of Video Consent and Routine Consent for Research|Completed||N/A|382|Actual|University of California, San Diego||8|||f||||t||||||||||2018-06-01 03:28:02.223346|2018-06-01 03:28:02.223346
NCT00430378|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2018-01-08|2007-01-31|2007-02-01|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2007|Actual|2007-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Acupuncture for Prevention of Radiation-Induced Xerostomia|Acupuncture for Prevention of Radiation-Induced Xerostomia|Active, not recruiting||N/A|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-06-01 03:28:02.290254|2018-06-01 03:28:02.290254
NCT00430365|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2018-01-03|2007-01-31|2007-02-01|Estimate|||||||2018-01-03|2018-01-05|Actual|June 2006|Actual|2006-06-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2017|Actual|2017-09-30||Interventional|IFM2005-02||Maintenance Therapy Using Lenalidomide in Myeloma|Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).|Active, not recruiting||Phase 3|614|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||||2018-06-01 03:28:02.368029|2018-06-01 03:28:02.368029
NCT00430144|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2012-04-25|2007-01-31|2007-02-01|Estimate|||||||2012-04-25|2012-04-26|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|October 2010|Actual|2010-10-31|August 2009|Actual|2009-08-31||Interventional|||Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix|A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix|Completed||Phase 2|16|Actual|National Cancer Center, Korea||1|||f||||f||||||||||2018-06-01 03:28:10.191074|2018-06-01 03:28:10.191074
NCT00430352|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2014-09-04||2017-07-05|2007-01-31|2007-02-01|Estimate|2015-06-03|2015-06-08|Estimate||||2017-07-05|2017-08-14|Actual|September 4, 2006|Actual|2006-09-04|July 2017|2017-07-31|May 26, 2011|Actual|2011-05-26|May 26, 2011|Actual|2011-05-26||Interventional||Intent-to-treat (ITT) population: all participants who completed a baseline visit and at least 1 further assessment.|MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.|A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.|Completed||Phase 4|545|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:28:02.725731|2018-06-01 03:28:02.725731
NCT00430326|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2010-03-08|2007-01-31|2007-02-01|Estimate|||||||2010-03-08|2010-03-09|Estimate|November 2006||2006-11-30|March 2010|2010-03-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Juvista (Avotermin) in Scars Following Varicose Vein Removal|A Dose Response Trial to Investigate the Efficacy of Juvista (Avotermin) in the Improvement of Scar Appearance When Applied to Approximated Wound Margins Following Bilateral Varicose Vein Removal.|Completed||Phase 2|156|Anticipated|Renovo|||||f||||f||||||||||2018-06-01 03:28:03.462828|2018-06-01 03:28:03.462828
NCT00430313|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2018-02-19|2007-01-31|2007-02-01|Estimate|||||||2018-02-19|2018-02-21|Estimate|January 2007|Actual|2007-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin|Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by Cisplatin or Oxaliplatin|Active, not recruiting||N/A|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-06-01 03:28:03.542552|2018-06-01 03:28:03.542552
NCT00430300|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|2013-05-17|2011-03-16|2013-05-17|2007-01-31|2007-02-01|Estimate|2013-05-17|2013-07-08|Estimate|2011-03-16|2011-03-28|Estimate|2013-05-17|2013-07-08|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.|A Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Evaluate the Efficacy And Safety of UK-432,097 Dry Powder For Inhalation In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease.|Terminated||Phase 2|87|Actual|Pfizer|Study was terminated prematurely due to futility based on results of interim analysis.|2|||f||||t||||||||||2018-06-01 03:28:03.895186|2018-06-01 03:28:03.895186
NCT00430287|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2016-11-08|2007-01-30|2007-02-01|Estimate|||||||2016-11-08|2016-11-10|Estimate|March 2007||2007-03-31|November 2016|2016-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines?|Correlation of DDLS Grading to OCT, HRT, and HVF|Completed|||101|Actual|Wills Eye|||2||f||||f||||||||Yes|A manuscript has been published.|2018-06-01 03:28:06.355992|2018-06-01 03:28:06.355992
NCT00430274|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2017-08-24|2007-01-31|2007-02-01|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2006||2006-01-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|August 2009|Actual|2009-08-31||Observational|||Photographic Imaging of the Retina and Optic Nerve Head of Glaucoma Patients and Normal Controls|Photographic Imaging of the Retina and Optic Nerve Head of Glaucoma Patients and Normal Controls|Completed|||120|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||No||2018-06-01 03:28:06.41049|2018-06-01 03:28:06.41049
NCT00430261|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2010-10-05|2007-01-31|2007-02-01|Estimate|||||||2010-10-05|2010-10-06|Estimate|January 2007||2007-01-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma|Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma|Completed||Phase 2|20|Anticipated|Swedish Medical Center|||||f||||f||||||||||2018-06-01 03:28:06.532428|2018-06-01 03:28:06.532428
NCT00430248|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2009-03-12||2012-01-31|2007-01-31|2007-02-01|Estimate|2009-05-26|2009-07-16|Estimate||||2012-01-31|2012-02-02|Estimate|February 2007||2007-02-28|January 2012|2012-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|CONFIRMS||Efficacy and Safety of Oral Febuxostat in Participants With Gout|A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.|Completed||Phase 3|2269|Actual|Takeda||3|||f||||t||||||||||2018-06-01 03:28:06.671795|2018-06-01 03:28:06.671795
NCT00430235|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2010-08-04|2007-01-31|2007-02-01|Estimate|||||||2010-08-04|2010-08-05|Estimate|March 2007||2007-03-31|August 2010|2010-08-31||||August 2010|Actual|2010-08-31||Interventional|||A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer|A Phase II Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer|Completed||Phase 2|39|Actual|British Columbia Cancer Agency|||||f||||||||||||||2018-06-01 03:28:08.321959|2018-06-01 03:28:08.321959
NCT00430209|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2013-12-10|2007-01-31|2007-02-01|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2006||2006-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Neurovascular Coupling in Eyes of Glaucoma Patients|Neurovascular Coupling in Eyes of Glaucoma Patients|Completed|||150|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:28:08.389599|2018-06-01 03:28:08.389599
NCT00430196|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2007-01-31|2007-01-31|2007-02-01|Estimate|||||||2007-01-31|2007-02-01|Estimate|December 2003||2003-12-31|January 2007|2007-01-31|September 2006||2006-09-30|||||Interventional|||BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity|Placebo-Controlled Trial of BOTOX® Versus Zanaflex® for the Treatment of Subjects With Post Stroke Upper Limb Spasticity|Completed||Phase 4|135||Icahn School of Medicine at Mount Sinai|||||f||||||||||||||2018-06-01 03:28:08.44375|2018-06-01 03:28:08.44375
NCT00430183|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2017-06-26|2007-01-30|2007-02-01|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2006||2006-12-31|June 2017|2017-06-30||||June 2018|Anticipated|2018-06-30||Interventional|||Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer|A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer|Active, not recruiting||Phase 3|788|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 03:28:08.521251|2018-06-01 03:28:08.521251
NCT00430170|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2008-07-28|2007-01-31|2007-02-01|Estimate|||||||2008-07-28|2008-07-29|Estimate|January 2007||2007-01-31|July 2008|2008-07-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?|Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?|Completed||Phase 4|20|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 03:28:10.04505|2018-06-01 03:28:10.04505
NCT00430157|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-05-31|2007-01-30|2007-02-01|Estimate|||||||2012-05-31|2012-06-04|Estimate|January 2007||2007-01-31|February 2011|2011-02-28||||||||Interventional|||Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber|An 8 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|45|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:28:10.123001|2018-06-01 03:28:10.123001
NCT00430131|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2009-08-12|2007-01-30|2007-02-01|Estimate|||||||2009-08-12|2009-08-13|Estimate|December 2006||2006-12-31|August 2009|2009-08-31|September 2009|Anticipated|2009-09-30|||||Interventional|||Investigating Best Practices for Children With Cerebral Palsy: A Pilot Study of Two Approaches|Investigating Best Practices for Children With Cerebral Palsy: A Pilot Study of Two Approaches|Unknown status|Active, not recruiting|N/A|18|Actual|University of Toronto|||||f||||f||||||||||2018-06-01 03:28:10.253594|2018-06-01 03:28:10.253594
NCT00430118|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2013-05-28|2007-01-30|2007-02-01|Estimate|||||||2013-05-28|2013-05-29|Estimate|July 2000||2000-07-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia|ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia|Completed||Phase 3|4559|Actual|University of Schleswig-Holstein||10|||f||||||||||||||2018-06-01 03:28:10.333176|2018-06-01 03:28:10.333176
NCT00430105|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2007-01-31|2007-01-31|2007-02-01|Estimate|||||||2007-01-31|2007-02-01|Estimate|February 1998||1998-02-28|January 2007|2007-01-31|April 2004||2004-04-30|||||Interventional|||Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides|Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides|Completed||Phase 2/Phase 3|160||Cambridge University Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 03:28:10.682072|2018-06-01 03:28:10.682072
NCT00430092|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|2009-05-12||2009-05-12|2007-01-31|2007-02-01|Estimate|2009-05-12|2009-07-02|Estimate||||2009-05-12|2009-07-02|Estimate||||May 2009|2009-05-31||||||||Interventional|||Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)|A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery|Completed||Phase 3|219|Actual|Sirion Therapeutics, Inc.||3|||f||||||||||||||2018-06-01 03:28:10.755141|2018-06-01 03:28:10.755141
NCT00430079|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2013-01-15|2007-01-30|2007-02-01|Estimate|||||||2013-01-15|2013-01-16|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||September 2007|Actual|2007-09-30||Interventional|||Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma|Assessment of Hypoxia in Malignant Gliomas Using EF5|Terminated||N/A|48|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 03:28:10.989199|2018-06-01 03:28:10.989199
NCT00430066|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2014-10-07|2007-01-31|2007-02-01|Estimate|||||||2014-10-07|2014-10-08|Estimate|February 2007||2007-02-28|October 2014|2014-10-31|September 2012|Actual|2012-09-30|November 2009|Actual|2009-11-30||Interventional|||Effects of Imatinib Mesylate in Polycythemia Vera|Glivec (Imatinib Mesylate) in the Treatment of Polycythemia Vera|Completed||Phase 2|9|Actual|Niguarda Hospital||1|||f||||t||||||||||2018-06-01 03:28:11.091841|2018-06-01 03:28:11.091841
NCT00430053|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-03-14|2007-01-30|2007-02-01|Estimate|||||||2012-03-14|2012-03-15|Estimate|January 2004||2004-01-31|March 2012|2012-03-31|June 2010|Actual|2010-06-30|||||Observational|||Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma|Pathogenesis And Course Of Cutaneous T-Cell Lymphoma|Completed|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:28:11.170056|2018-06-01 03:28:11.170056
NCT00430040|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-12-17|2007-01-30|2007-02-01|Estimate|||||||2012-12-17|2012-12-18|Estimate|February 2007||2007-02-28|December 2012|2012-12-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.|Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI:Effects on Oxidative Stress and Inflammation.|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Kaleida Health||2|||f||||f||||||||||2018-06-01 03:28:11.242481|2018-06-01 03:28:11.242481
NCT00430027|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|2013-10-22||2013-10-22|2007-01-31|2007-02-01|Estimate|2013-10-22|2013-12-12|Estimate||||2013-10-22|2013-12-12|Estimate|November 2006||2006-11-30|October 2013|2013-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma|Pilot Feasibility Trial of Preoperative Capecitabine, Oxaliplatin, Cetuximab and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma|Terminated||N/A|8|Actual|University of Colorado, Denver|This study was terminated due slow accrual.|1||This study was terminated due slow accrual.|f||||t||||||||||2018-06-01 03:28:11.32781|2018-06-01 03:28:11.32781
NCT00430014|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2012-02-14|2007-01-31|2007-02-01|Estimate|||||||2012-02-14|2012-02-15|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of Atiprimod Treatment for Patients With Advanced Cancer|An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer|Terminated||Phase 1|28|Actual|M.D. Anderson Cancer Center||1||Sponsor Withdrew|f||||f||||||||||2018-06-01 03:28:11.485847|2018-06-01 03:28:11.485847
NCT00430001|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2008-05-06|2007-01-31|2007-02-01|Estimate|||||||2008-05-06|2008-05-09|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer|A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer|Unknown status|Recruiting|Phase 3|300|Anticipated|Danish Breast Cancer Cooperative Group|||||f||||||||||||||2018-06-01 03:28:11.55858|2018-06-01 03:28:11.55858
NCT00429988|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-09-25|2007-01-30|2007-02-01|Estimate|||||||2012-09-25|2012-09-26|Estimate|August 2002||2002-08-31|September 2012|2012-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Observational|||Study of Ductal Lavage in Women at High Risk for Breast Cancer|Ductal Lavage to Monitor and Treat High Risk Women|Completed|||30|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 03:28:11.634842|2018-06-01 03:28:11.634842
NCT00429975|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2007-01-31|2007-01-31|2007-02-01|Estimate|||||||2007-01-31|2007-02-01|Estimate|August 2004||2004-08-31|January 2007|2007-01-31|September 2005||2005-09-30|||||Interventional|||Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia|Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia|Terminated||Phase 4|45||Hospital Mutua de Terrassa|||||f||||||||||||||2018-06-01 03:28:11.697474|2018-06-01 03:28:11.697474
NCT00429962|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2009-04-06|2007-01-31|2007-02-01|Estimate|||||||2009-04-06|2009-04-07|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV|Randomized, Phase IIIb Study Comparing Safety, Tolerability and Efficacy Between Lucentis® Administered in Conjunction With PDT With Visudyne® and Lucentis® in Patients With Subfoveal CNV Secondary to Age-Related Macular Degeneration|Completed||Phase 3|40|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 03:28:11.761033|2018-06-01 03:28:11.761033
NCT00429949|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2014-07-28||2014-08-15|2007-01-31|2007-02-01|Estimate|2014-08-15|2014-08-29|Estimate||||2014-08-15|2014-08-29|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma|A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma|Completed||Phase 2|21|Actual|Washington University School of Medicine||1|||f||||||||||||||2018-06-01 03:28:11.86663|2018-06-01 03:28:11.86663
NCT00429936|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2010-06-21|2007-01-31|2007-02-01|Estimate|||||||2010-06-21|2010-06-22|Estimate|December 2006||2006-12-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration|A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration|Completed||Phase 2|245|Actual|Sirion Therapeutics, Inc.||3|||f||||t||||||||||2018-06-01 03:28:12.385819|2018-06-01 03:28:12.385819
NCT00429923|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2009-05-12||2009-05-12|2007-01-31|2007-02-01|Estimate|2009-05-12|2009-07-02|Estimate||||2009-05-12|2009-07-02|Estimate||||May 2009|2009-05-31||||||||Interventional|||Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)|A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery|Completed||Phase 3|219|Actual|Sirion Therapeutics, Inc.||3|||f||||||||||||||2018-06-01 03:28:12.469232|2018-06-01 03:28:12.469232
NCT00429910|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2016-12-30|2007-01-30|2007-02-01|Estimate|||||||2016-12-30|2017-01-02|Estimate|February 2003||2003-02-28|December 2016|2016-12-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||Natural History Study of Patients With Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia (CML) Cohort|Completed|||48|Actual|Dana-Farber Cancer Institute|||||f||||f||||||||No||2018-06-01 03:28:12.678324|2018-06-01 03:28:12.678324
NCT00429897|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2007-01-31|2007-01-31|2007-02-01|Estimate|||||||2007-01-31|2007-02-01|Estimate|August 2006||2006-08-31|January 2007|2007-01-31|July 2007||2007-07-31|||||Interventional|||Double Blind Crossover Comparison of Diuretics in the Young|Double Blind Crossover Comparison od Diuretics in Young Patients With Low Renin Hypertension|Unknown status|Recruiting|N/A|30||University of Cambridge|||||f||||||||||||||2018-06-01 03:28:12.740391|2018-06-01 03:28:12.740391
NCT00429884|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2008-07-01|2007-01-31|2007-02-01|Estimate|||||||2008-07-01|2008-07-02|Estimate|January 2007||2007-01-31|June 2008|2008-06-30||||||||Observational|||Studies of Disorders and Mechanisms Related to Atrial Fibrillation Before and After DC-Conversion.|Studies of Disorders and Mechanisms Related to Atrial Fibrillation Before and After DC-Conversion: Polysomnography, Heart Rate Variability and 24h Holter.|Unknown status|Recruiting||||Umeå University|||||f||||||||||||||2018-06-01 03:28:12.815432|2018-06-01 03:28:12.815432
NCT00429871|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2009-05-28|2007-01-31|2007-02-01|Estimate|||||||2009-05-28|2009-05-29|Estimate|May 2002||2002-05-31|May 2009|2009-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer|A Multicenter Randomized Comparative Study of Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine Combinations as First Line Treatment of Metastatic Breast Cancer|Completed||Phase 3|272|Actual|Hellenic Oncology Research Group||2|||f||||||||||||||2018-06-01 03:28:12.877201|2018-06-01 03:28:12.877201
NCT00429858|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2013-10-14|2007-01-30|2007-02-01|Estimate|||||||2013-10-14|2013-10-16|Estimate|January 2007||2007-01-31|October 2013|2013-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer|Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial|Terminated||Phase 2|21|Actual|University of California, San Francisco||||Study accrual rate is very slow, it was mandated by NCI to be terminated.|f||||t||||||||||2018-06-01 03:28:12.969109|2018-06-01 03:28:12.969109
NCT00429845|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2007-01-31|2007-01-31|2007-02-01|Estimate|||||||2007-01-31|2007-02-01|Estimate|March 2004||2004-03-31|January 2007|2007-01-31|February 2007||2007-02-28|||||Interventional|||Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial|Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start on Highly Active Antiretroviral Therapy: a Randomized Trial|Completed||N/A|80||Hospital de Clinicas de Porto Alegre|||||f||||||||||||||2018-06-01 03:28:13.055941|2018-06-01 03:28:13.055941
NCT00429832|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2007-01-31|2007-01-31|2007-02-01|Estimate|||||||2007-01-31|2007-02-01|Estimate|October 2003||2003-10-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department|A Randomized Controlled Trial of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department|Completed||Phase 4|120||University of New Mexico|||||f||||||||||||||2018-06-01 03:28:13.114979|2018-06-01 03:28:13.114979
NCT00429819|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2014-12-15|2007-01-31|2007-02-01|Estimate|||||||2014-12-15|2014-12-16|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Neurovascular Coupling in Eyes of Glaucoma Patients|Neurovascular Coupling in Eyes of Glaucoma Patients|Completed|||100|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:28:13.184297|2018-06-01 03:28:13.184297
NCT00429806|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2017-04-06|2007-01-31|2007-02-01|Estimate|||||||2017-04-06|2017-04-07|Actual|November 2006||2006-11-30|April 2017|2017-04-30|July 2007|Actual|2007-07-31|March 2007|Actual|2007-03-31||Interventional|||DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy|DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy-Phase I Randomized,Placebo-Controlled, Double-Blind Study.|Completed||Phase 1|40|Actual|CHU de Quebec-Universite Laval||4|||f||||f||||||||No||2018-06-01 03:28:13.241035|2018-06-01 03:28:13.241035
NCT00429793|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|2013-07-09||2017-10-27|2007-01-30|2007-02-01|Estimate|2013-09-17|2013-11-20|Estimate||||2017-10-27|2017-12-04|Actual|February 2007||2007-02-28|October 2017|2017-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Number of eligible and evaluable participants|Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Evaluation of CCI-779 (Temsirolimus, NCI-Supplied Agent, NSC #683864, IND #61010) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:28:13.346673|2018-06-01 03:28:13.346673
NCT00429780|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2009-11-17|2007-01-31|2007-02-01|Estimate|||||||2009-11-17|2009-11-18|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0)|A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With Positive Response to Leishmanin (LST>0)|Completed||Phase 2/Phase 3|100|Anticipated|Tehran University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:28:13.8751|2018-06-01 03:28:13.8751
NCT00429767|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-06-01|2007-01-30|2007-02-01|Estimate|||||||2012-06-01|2012-06-05|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals|Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine: Study 1|Completed|||16|Anticipated|Wayne State University|||||f||||t||||||||||2018-06-01 03:28:13.948818|2018-06-01 03:28:13.948818
NCT00429754|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2016-01-25|2007-01-31|2007-02-01|Estimate|||||||2016-01-25|2016-01-26|Estimate||||January 2016|2016-01-31|September 2008||2008-09-30|||||Interventional|||Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)|A Pharmacokinetic Evaluation of the Addition of Aprepitant to the Bleomycin -Etoposide - Cisplatin (BEP) Treatment of Patients With Testis Carcinoma (A-BEP)|Withdrawn||Phase 4|0|Actual|Radboud University||1||change of study population and chemotherapeutic regimen|f||||f||||||||||2018-06-01 03:28:14.004103|2018-06-01 03:28:14.004103
NCT00429728|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2009-05-15|2007-01-31|2007-02-01|Estimate|||||||2009-05-15|2009-05-18|Estimate|November 2006||2006-11-30|May 2009|2009-05-31||||||||Interventional|||A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.|An Open-Label, Parallel Group, Single Session Study Comparing the Pharmacokinetics of a Single Oral Dose of GW876008 Administered to Healthy Volunteer Smokers and Healthy Volunteer Non-Smokers.|Completed||Phase 1|26|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:28:14.067898|2018-06-01 03:28:14.067898
NCT00429715|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2011-02-16|2007-01-31|2007-02-01|Estimate|||||||2011-02-16|2011-02-17|Estimate|January 2007||2007-01-31|February 2011|2011-02-28|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Interventional|||Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin|A Randomized, Safety, Immunogenicity & Efficacy Study of Autoclaved Leishmania Major Plus BCG vs. BCG (Double Blind) or Placebo (Open), in Healthy High Risk Iranian Volunteers With no Response to Leishmanin|Completed||Phase 2/Phase 3|150|Anticipated|Tehran University of Medical Sciences||3|||f||||||||||||||2018-06-01 03:28:14.126241|2018-06-01 03:28:14.126241
NCT00429702|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|2014-03-24||2014-06-26|2007-01-31|2007-02-01|Estimate|2014-06-26|2014-07-25|Estimate||||2014-06-26|2014-07-25|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional||Baseline number of participants was determined by the number of participants that completed their Baseline Study visit.|Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy|Phase II Randomized, Double-Blinded Study of an Antiemetic Pump, Using Benadryl®, Avitan® and Decadron® (BAD), for Children Receiving Moderately or Highly Emetogenic Chemotherapy|Terminated||Phase 2|7|Actual|University of South Florida|The study was closed prior to completing enrollment based on the recommendation by the SunCoast CCOP Research Base Data Safety Monitoring Board for a lack of feasibility and poor enrollment.|2||Closed due to poor accrual and lack of feasibility to finish study per DSMB|f||||t||||||||||2018-06-01 03:28:14.215026|2018-06-01 03:28:14.215026
NCT00429689|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2011-08-28|2007-01-31|2007-02-01|Estimate|||||||2011-08-28|2011-08-30|Estimate||||August 2011|2011-08-31||||||||Observational|||Hormonal Levels in Men With Major Depressive Disorder|Hormonal Levels in Men With Major Depressive Disorder|Withdrawn|||2000|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-06-01 03:28:14.44185|2018-06-01 03:28:14.44185
NCT00429676|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-11-13|2007-01-31|2007-02-01|Estimate|||||||2012-11-13|2012-11-14|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Pilot Study of Haloperidol to Treat Critical Illness Delirium|A Randomized Prospective Pilot Study Of Haloperidol In Addition To Standard Sedation In Mechanically Ventilated Patients With Delirium|Completed||Phase 2|20|Anticipated|University of Colorado, Denver|||||f||||||||||||||2018-06-01 03:28:14.496315|2018-06-01 03:28:14.496315
NCT00429663|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|2016-12-18||2017-04-05|2007-01-30|2007-02-01|Estimate|2016-12-18|2017-02-09|Estimate||||2017-04-05|2017-05-11|Actual|February 2007||2007-02-28|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional||156 Patients were randomized to locked plate (80) or IM nail (76). Data for only 126 participants were captured due to patient withdrawal or incomplete data from sites|A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Distal Femur Fractures|Study of Locked Plates Versus Intramedullary Nails in Distal Femur Fractures: A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation (S.O.L.V.E.D)|Completed||N/A|160|Actual|Boston Medical Center||2|||f||||t||||||||No||2018-06-01 03:28:14.594122|2018-06-01 03:28:14.594122
NCT00429650|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2018-05-08|2007-01-31|2007-02-01|Estimate|||||||2018-05-08|2018-05-10|Estimate|July 2007||2007-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Interventional|Lose-It||Using the Energy Gap to Prevent Weight Regain|Using the Energy Gap to Prevent Weight Regain|Active, not recruiting||N/A|120|Anticipated|University of Colorado, Denver||3|||f||||t||||||||||2018-06-01 03:28:14.921566|2018-06-01 03:28:14.921566
NCT00429637|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2008-08-06|2007-01-30|2007-02-01|Estimate|||||||2008-08-06|2008-08-07|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|January 2009|Anticipated|2009-01-31|||||Observational|||Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients|Phase 2 Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients|Unknown status|Recruiting||120|Anticipated|University of Virginia|||||f||||||||||||||2018-06-01 03:28:14.982954|2018-06-01 03:28:14.982954
NCT00429624|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2013-02-04|2007-01-31|2007-02-01|Estimate|||||||2013-02-04|2013-02-05|Estimate|September 1994||1994-09-30|January 2007|2007-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Randomized Controlled Trial of Chiropractic Manipulation Versus Medical Therapy for Chronic Neck Pain|Randomized Controlled Trial of Chiropractic Manipulation Versus Medical Therapy for Chronic Neck Pain|Completed||N/A|70||University of Colorado, Denver|||||f||||||||||||||2018-06-01 03:28:15.05086|2018-06-01 03:28:15.05086
NCT00429611|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-31|||2009-06-30|2007-01-31|2007-02-01|Estimate|||||||2009-06-30|2009-07-02|Estimate|November 2004||2004-11-30|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||High Low Biphasic Energy Defibrillation (HiLoBED)|A Multicentre Prospective Randomised Study Comparing the Efficacy of High Versus Low Biphasic Energy Defibrillation in Patients With Cardiac Arrest|Unknown status|Active, not recruiting|Phase 3|600|Anticipated|Singapore General Hospital|||||f||||t||||||||||2018-06-01 03:28:15.117164|2018-06-01 03:28:15.117164
NCT00429585|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2017-12-18|2007-01-30|2007-02-01|Estimate|||||||2017-12-18|2017-12-19|Actual|February 2007||2007-02-28|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation in Proximal Tibial Fractures|Intramedullary Nail Versus Plate Fixation Re-Evaluation Study in Proximal Tibial Fractures: A Multicenter Randomized Trial Comparing IM Nails and Plate Fixation (IMPRESS)|Recruiting||N/A|160|Anticipated|Boston Medical Center||2|||f||||t||||||||||2018-06-01 03:28:15.196322|2018-06-01 03:28:15.196322
NCT00011141|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-12|||2005-06-23|2001-02-13|2001-02-14|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency|Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency|Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:22.355632|2018-06-01 05:37:22.355632
NCT00429572|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2009-09-25||2012-08-01|2007-01-30|2007-01-31|Estimate|2011-06-14|2011-07-13|Estimate||||2012-08-01|2012-08-07|Estimate|January 1998||1998-01-31|August 2012|2012-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer|Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer|Completed||Phase 2|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:15.325429|2018-06-01 03:28:15.325429
NCT00429559|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2011-07-21|2007-01-30|2007-01-31|Estimate|||||||2011-07-21|2011-07-22|Estimate|June 2006||2006-06-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma|Weekly Administration of Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer|Completed||Phase 1/Phase 2|31|Actual|Hellenic Oncology Research Group||1|||f||||||||||||||2018-06-01 03:28:15.511668|2018-06-01 03:28:15.511668
NCT00429546|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2013-06-24|2007-01-29|2007-01-31|Estimate|||||||2013-06-24|2013-06-26|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|TRACK||Assisting HIV-infected Mothers in Disclosing Their Serostatus to Their Children|Maternal HIV: Intervention to Assist Disclosure to Children|Completed||Phase 1|160|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 03:28:15.583168|2018-06-01 03:28:15.583168
NCT00429533|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-02-01|2007-01-30|2007-01-31|Estimate|||||||2007-02-01|2007-02-05|Estimate|November 1996||1996-11-30|February 2007|2007-02-28|February 2004||2004-02-29|||||Interventional|||Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris|A Prospective Randomized Placebo-Controlled Clinical Trial of Dapsone as a Glucocorticoid-Sparing Agent in Maintenance Phase Pemphigus Vulgaris|Terminated||Phase 2|48||Jacobus Pharmaceutical|||||f||||||||||||||2018-06-01 03:28:15.645309|2018-06-01 03:28:15.645309
NCT00429520|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2008-02-05|2007-01-30|2007-01-31|Estimate|||||||2008-02-05|2008-02-07|Estimate|December 2005||2005-12-31|February 2008|2008-02-29|December 2006||2006-12-31|||||Interventional|||Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds|Prospective, Multicentre, Not Controlled Clinical Study to Investigate Efficacy and Tolerability of the Hyaluronic Acid Filler IMD1 Basic After Single Bilateral Injection for Correction of Nasolabial Folds (NLF)|Completed||Phase 4|114||Merz Pharmaceuticals GmbH|||||f||||||||||||||2018-06-01 03:28:15.701363|2018-06-01 03:28:15.701363
NCT00429507|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2015-10-22||2015-10-22|2007-01-30|2007-01-31|Estimate|2015-10-22|2015-11-24|Estimate||||2015-10-22|2015-11-24|Estimate|March 2007||2007-03-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases|Phase 2 Study of 153 Sm-EDTMP Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases|Completed||Phase 2|12|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:15.746687|2018-06-01 03:28:15.746687
NCT00429494|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2013-05-20||2013-05-20|2007-01-30|2007-01-31|Estimate|2013-05-20|2013-07-09|Estimate||||2013-05-20|2013-07-09|Estimate|November 2002||2002-11-30|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients|Phase II Study of GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:15.961987|2018-06-01 03:28:15.961987
NCT00429481|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2016-09-15|2007-01-30|2007-01-31|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2001||2001-01-31|September 2016|2016-09-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants|Study to Assess Efficacy, Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine at Different Viral Concentrations in Healthy Infants Previously Uninfected With Human Rotavirus and Approximately 3 Months of Age.|Completed||Phase 2|2464|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:28:16.115494|2018-06-01 03:28:16.115494
NCT00429468|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-10-24|2007-01-29|2007-01-31|Estimate|||||||2007-10-24|2007-10-26|Estimate|January 2007||2007-01-31|October 2007|2007-10-31||||||||Interventional|||A Study to Evaluate the Interaction Between Vicodin® CR and Ethanol in Healthy Male and Female Moderate Alcohol Drinkers|A Single-Centre, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Interaction Between Vicodin® CR and Ethanol in Healthy Male and Female Moderate Alcohol Drinkers|Completed||Phase 1|25||Abbott|||||||||||||||||||2018-06-01 03:28:16.208271|2018-06-01 03:28:16.208271
NCT00429455|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2012-07-31|2007-01-29|2007-01-31|Estimate|||||||2012-07-31|2012-08-01|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among HSCT Patients|Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among Young Women Who Underwent Hematopoietic Stem Cell Transplantation|Completed|||196|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:28:16.271417|2018-06-01 03:28:16.271417
NCT00429442|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2014-02-19|2007-01-30|2007-01-31|Estimate|||||||2014-02-19|2014-02-20|Estimate|March 2008||2008-03-31|February 2014|2014-02-28|March 2011|Anticipated|2011-03-31|||||Interventional|||Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis|A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in Patients Treated With Copaxone for at Least 3 Months|Withdrawn||Phase 3|0|Actual|Glostrup University Hospital, Copenhagen||2|||f||||||||||||||2018-06-01 03:28:16.338321|2018-06-01 03:28:16.338321
NCT00429429|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30||2012-09-14|2016-06-16|2007-01-30|2007-01-31|Estimate||||2012-09-14|2012-09-21|Estimate|2016-06-16|2016-06-20|Estimate|April 2006||2006-04-30|June 2016|2016-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Immunotherapy for Peanut Allergy|Immunotherapy for Peanut Allergy|Completed||N/A|7|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-06-01 03:28:16.406615|2018-06-01 03:28:16.406615
NCT00429416|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2013-07-19||2016-10-19|2007-01-30|2007-01-31|Estimate|2013-10-14|2013-12-10|Estimate||||2016-10-19|2016-11-29|Estimate|March 2004||2004-03-31|October 2016|2016-10-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation|A Phase I/II Study of Llme Treated Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematological Malignancies|Completed||Phase 1/Phase 2|14|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:28:16.487381|2018-06-01 03:28:16.487381
NCT00429403|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2011-06-27||2016-04-05|2007-01-30|2007-01-31|Estimate|2011-06-27|2011-07-26|Estimate||||2016-04-05|2016-05-09|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer|Phase III Randomized Study of a Goserelin Acetate for Preservation of Ovarian Function in Patients With Primary Breast Cancer (PBC)|Terminated||Phase 3|1|Actual|M.D. Anderson Cancer Center||2||Study stopped due to low accrual.|f||||t||||||||||2018-06-01 03:28:16.732254|2018-06-01 03:28:16.732254
NCT00429390|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-30|2007-01-30|2007-01-31|Estimate|||||||2007-01-30|2007-01-31|Estimate|August 2006||2006-08-31|January 2007|2007-01-31|November 2006||2006-11-30|||||Interventional|||Effect of Fasting With Two Meals on Insulin Resistance Indices of Metabolic Syndrome||Completed||N/A|55||Free Islamic University of Medical Sciences|||||f||||||||||||||2018-06-01 03:28:16.901958|2018-06-01 03:28:16.901958
NCT00429377|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-31|Estimate|||||||2007-01-29|2007-01-31|Estimate|June 2003||2003-06-30|January 2007|2007-01-31||||||||Interventional|||Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study|Phase 3 Study of Tacrolimus(FK506)for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study|Completed||Phase 3|64||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 03:28:16.951004|2018-06-01 03:28:16.951004
NCT00429364|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2015-02-25||2015-03-17|2007-01-29|2007-01-31|Estimate|2015-03-17|2015-04-01|Estimate||||2015-03-17|2015-04-01|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network|Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)|Completed||Phase 3|608|Actual|New England Research Institutes|"The effect of losartan on TGF-β was not assessed. The study results do not apply to Marfan subjects whose BSA–adj. aortic-root z score is ≤3.~Subjects may find their treatment based on the appearance of the drug."|2|||f||||t||||||||||2018-06-01 03:28:17.080974|2018-06-01 03:28:17.080974
NCT00429351|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2010-12-21|2007-01-30|2007-01-31|Estimate|||||||2010-12-21|2010-12-22|Estimate|September 2006||2006-09-30|December 2010|2010-12-31|June 2010|Actual|2010-06-30|||||Observational|||Aromatic Amino Acid Metabolism in the Pathogenesis of Kwashiorkor||Completed|||82|Anticipated|Baylor College of Medicine|||||f||||||||||Samples Without DNA|"~     plasma, expired breath~   "|||2018-06-01 03:28:18.476921|2018-06-01 03:28:18.476921
NCT00429338|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2015-01-07|2007-01-29|2007-01-31|Estimate|||||||2015-01-07|2015-01-09|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate|Feasibility Study of 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate|Terminated||N/A|8|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||f||||||||||2018-06-01 03:28:18.515616|2018-06-01 03:28:18.515616
NCT00429325|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2007-07-16|2007-01-30|2007-01-31|Estimate|||||||2007-07-16|2007-07-17|Estimate|January 2004||2004-01-31|February 2007|2007-02-28|January 2007||2007-01-31|||||Observational|||Fecal Calprotectin: Cheap Marker for Diagnosing Acute Infectious Diarrhea|Comparative Evaluation of Accuracy of Fecal Calprotectin, Lactoferrin and Occult Blood Testing (FOBT) in Predicting Microbiological Diagnosis for Acute Infectious Diarrhea: A Prospective Multicentre Double Blind Randomized Controlled Trial.|Completed|||400||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 03:28:18.688954|2018-06-01 03:28:18.688954
NCT00429312|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2015-01-13|2007-01-29|2007-01-31|Estimate|||||||2015-01-13|2015-01-15|Estimate|March 2007||2007-03-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|February 2008|Actual|2008-02-29||Interventional|||A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma|A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma|Completed||Phase 1/Phase 2|10|Actual|Jennerex Biotherapeutics||1|||f||||t||||||||||2018-06-01 03:28:18.760797|2018-06-01 03:28:18.760797
NCT00429299|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2014-07-21|2012-05-17|2016-02-22|2007-01-29|2007-01-31|Estimate|2016-02-22|2016-03-22|Estimate|2012-05-17|2012-05-22|Estimate|2016-02-22|2016-03-22|Estimate|August 2006||2006-08-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CHERLOB||Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer|Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation.|Completed||Phase 2|121|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:28:18.896479|2018-06-01 03:28:18.896479
NCT00429286|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2011-10-24|2007-01-30|2007-01-31|Estimate|||||||2011-10-24|2011-10-26|Estimate|May 2007||2007-05-31|October 2011|2011-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Preserving Function in Breast Cancer Patients|Preserving Function in Rural Breast Cancer Patients Undergoing Chemotherapy|Completed|||30|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 03:28:19.714964|2018-06-01 03:28:19.714964
NCT00429273|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2017-01-18||2017-05-12|2007-01-29|2007-01-31|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|January 2007||2007-01-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|Project1||Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder|An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years|Completed||Phase 4|212|Actual|University of California, Los Angeles|Larger group sizes would enable more conclusive tests of treatment differences; Study design began with guanfacine first and addition of a stimulant second, making difficult to compare to those study designs adding guanfacine to ongoing stimulants.|3|||f||||t||||||||||2018-06-01 03:28:19.790736|2018-06-01 03:28:19.790736
NCT00429260|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-02-15|2007-01-30|2007-01-31|Estimate|||||||2012-02-15|2012-02-17|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression|A 1-week, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Outpatients With Depression Who Completed 8 Weeks of Treatment With Saredutant 100 mg Once Daily|Completed||Phase 3|125|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:28:20.122066|2018-06-01 03:28:20.122066
NCT00429247|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2011-07-20|2007-01-30|2007-01-31|Estimate|||||||2011-07-20|2011-07-21|Estimate|February 2003||2003-02-28|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients|A Pilot Randomized Phase II Study of Adjuvant Administration of Trastuzumab (HERCEPTIN) Versus Observation After the Completion of Adjuvant Chemotherapy and Radiotherapy in Patients With Stage I-III Breast Cancer Who Have Detectable Disseminated and/or Circulating Tumor Cells (DTCs and/or CTCs) in the Bone Marrow or/and the Peripheral Blood Before or/and After the Completion of Adjuvant Treatment|Completed||Phase 2|75|Actual|University Hospital of Crete||2|||f||||f||||||||||2018-06-01 03:28:20.186556|2018-06-01 03:28:20.186556
NCT00429208|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2007-01-30|2007-01-30|2007-01-31|Estimate|||||||2007-01-30|2007-01-31|Estimate|February 2007||2007-02-28|January 2007|2007-01-31|April 2007|Anticipated|2007-04-30|||||Interventional|||Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers|Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers: A Double-Blind, Within-Subjects, Placebo-Controlled Study|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:28:20.377951|2018-06-01 03:28:20.377951
NCT00429195|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2013-01-18|2007-01-30|2007-01-31|Estimate|||||||2013-01-18|2013-01-21|Estimate|February 2004||2004-02-29|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||The Effect of Dietary Fat Modification on Risk Factors Associated With the Metabolic Syndrome|LIPGENE Dietary Intervention Study|Completed||N/A|480||University College Dublin|||||f||||||||||||||2018-06-01 03:28:20.440214|2018-06-01 03:28:20.440214
NCT00429182|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2013-02-28||2013-02-28|2007-01-30|2007-01-31|Estimate|2013-02-28|2013-04-10|Estimate||||2013-02-28|2013-04-10|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer|Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients|Completed||Phase 2|32|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:20.507219|2018-06-01 03:28:20.507219
NCT00429169|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2012-12-11||2017-10-19|2007-01-29|2007-01-31|Estimate|2012-12-18|2013-01-24|Estimate||||2017-10-19|2017-11-21|Actual|June 2004||2004-06-30|October 2017|2017-10-31|January 2013|Actual|2013-01-31|January 2010|Actual|2010-01-31||Interventional|||Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression|Paroxetine Versus Bupropion for Suicide Ideators or Attempters With Major Depressive Disorder|Terminated||Phase 4|101|Actual|New York State Psychiatric Institute|"Significant dropout meant the number of subjects with analyzable data was smaller than the number enrolled.~An interim analysis of this pilot study showed differential treatment effects so a decision was made to stop enrollment early."|2||Interim analysis showed differential treatment effects.|f||||f||||||||||2018-06-01 03:28:20.669623|2018-06-01 03:28:20.669623
NCT00429156|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2009-10-22|2007-01-30|2007-01-31|Estimate|||||||2009-10-22|2009-10-23|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Non-invasive Ventilation Versus Sham Ventilation in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Controlled Trial of Continuation of Home Non-invasive Ventilation vs Sham Ventilation in Survivors of Acute Hypercapnic Respiratory Failure in Chronic Obstructive Pulmonary Disease|Completed||Phase 3|46|Actual|United Christian Hospital||2|||f||||t||||||||||2018-06-01 03:28:20.895791|2018-06-01 03:28:20.895791
NCT00429143|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2012-06-04||2016-10-19|2007-01-30|2007-01-31|Estimate|2013-05-30|2013-05-31|Estimate||||2016-10-19|2016-11-29|Estimate|January 2006||2006-01-31|October 2016|2016-10-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative|A Two Step Approach To Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies From HLA Partially-Matched Related Donors|Completed||Phase 1/Phase 2|27|Actual|Thomas Jefferson University|Limitations of the trial include small sample size and single institution|1|||f||||t||||||||||2018-06-01 03:28:20.970096|2018-06-01 03:28:20.970096
NCT00429117|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2011-11-17|2007-01-30|2007-01-31|Estimate|||||||2011-11-17|2011-11-18|Estimate|January 2007||2007-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Interest in Spirituality and Oncology: Is It An International Phenomenon?|Interest in Spirituality and Oncology: Is It An International Phenomenon?|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:28:21.149153|2018-06-01 03:28:21.149153
NCT00429104|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2011-03-25||2012-12-04|2007-01-30|2007-01-31|Estimate|2011-03-25|2011-04-15|Estimate||||2012-12-04|2012-12-06|Estimate|August 2002||2002-08-31|December 2012|2012-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Herceptin and GM-CSF for Metastatic Breast Cancer|Phase II Study of GM-CSF to Overcome Herceptin-Resistant HER-2/Neu-Overexpressing Metastatic Breast Cancer|Completed||Phase 2|18|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:21.214195|2018-06-01 03:28:21.214195
NCT00429091|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2010-11-01|2007-01-29|2007-01-31|Estimate|||||||2010-11-01|2010-11-02|Estimate|January 2007||2007-01-31|September 2010|2010-09-30||||August 2007|Actual|2007-08-31||Interventional|||A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|243|Actual|Abbott||3|||f||||||||||||||2018-06-01 03:28:22.308134|2018-06-01 03:28:22.308134
NCT00429078|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-03-01|2007-01-30|2007-01-31|Estimate|||||||2012-03-01|2012-03-02|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer|Phase I Trial of 2nd Generation Anti-CEA Designer T Cells in Gastric Cancer|Withdrawn||Phase 1|0|Actual|Roger Williams Medical Center||||low accrual|f||||t||||||||||2018-06-01 03:28:22.424637|2018-06-01 03:28:22.424637
NCT00429065|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2007-01-30|2007-01-30|2007-01-31|Estimate|||||||2007-01-30|2007-01-31|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Observational|||Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.|Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.|Unknown status|Recruiting||30||Instituto Nacional de Cancerologia de Mexico|||||f||||||||||||||2018-06-01 03:28:22.476461|2018-06-01 03:28:22.476461
NCT00429052|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-30|||2012-03-06|2007-01-30|2007-01-31|Estimate|||||||2012-03-06|2012-03-07|Estimate|November 2006||2006-11-30|January 2007|2007-01-31|September 2008|Actual|2008-09-30|||||Observational|||Mechanism of Percutaneous Revascularization for Coronary Bifurcation Disease|Insights Into the Mechanism of Percutaneous Revascularization of Coronary Bifurcation Disease in the Drug-eluting Stent Era. An Angiographic and Intravascular Ultrasound Study. The INSIGHT Trial|Terminated|||24|Actual|University of Florida||||"PI left institution,inability to enroll and analyze data due to software/technical limitations,~   pt enrollment terminated early with no data generated"|f||||f||||||||||2018-06-01 03:28:22.534698|2018-06-01 03:28:22.534698
NCT00429039|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2016-10-19|2007-01-29|2007-01-31|Estimate|||||||2016-10-19|2016-10-21|Estimate|September 2000||2000-09-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation|LLME Treated Cellular Immunotherapy Following T-cell Depleted Allogeneic Heamtopoietic Stem Cell Transplantation for Acceleration of Immune Reconstitution|Terminated||Phase 2|21|Actual|Thomas Jefferson University||||Low accrual.|f||||t||||||||||2018-06-01 03:28:22.596216|2018-06-01 03:28:22.596216
NCT00379444|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2012-03-08|2006-09-19|2006-09-21|Estimate|||||||2012-03-08|2012-03-09|Estimate|November 2006||2006-11-30|September 2006|2006-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Tobacco Cessation Treatment for Pregnant Alaska Natives|Tobacco Cessation Treatment for Pregnant Alaska Natives|Completed||Phase 1/Phase 2|35|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 03:45:20.041665|2018-06-01 03:45:20.041665
NCT00429026|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2009-02-26||2013-02-26|2007-01-29|2007-01-31|Estimate|2009-05-21|2009-07-13|Estimate||||2013-02-26|2013-03-04|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Adaptive Randomization of Fludarabine-Melphalan Versus Fludarabine-Cyclophosphamide Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor for Metastatic Renal Cell Carcinoma|Terminated||Phase 2|40|Actual|M.D. Anderson Cancer Center|Primary outcome measure was not assessed due to early study termination, e.g. patients did not receive assigned treatment.|2||Slow accrual, study terminated.|f||||t||||||||||2018-06-01 03:28:22.75228|2018-06-01 03:28:22.75228
NCT00429013|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2016-09-14|2007-01-29|2007-01-30|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2006||2006-09-30|September 2016|2016-09-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue.|A Prospective, Randomised, Controlled, Open Study. Phase II Treatment Equivalent.|Terminated||Phase 2|12|Actual|University Hospital, Grenoble||2||principal criteria was achieved with the intermediate statistical analysis|f||||t||||||||||2018-06-01 03:28:22.91337|2018-06-01 03:28:22.91337
NCT00429000|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|October 2007||2007-10-31|||||Interventional|||Perinatal Hypothermia, Risk Factors and Long-Term Consequences in Guinea-Bissau, Westafrica|Reducing the Prevalence of Hypothermia Among Newborns by Means of Continuous Temperature Monitoring Using Thermospot.|Unknown status|Not yet recruiting|N/A|788||Bandim Health Project|||||f||||||||||||||2018-06-01 03:28:23.000005|2018-06-01 03:28:23.000005
NCT00428987|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-27|||2018-03-28|2007-01-29|2007-01-30|Estimate|||||||2018-03-28|2018-03-29|Actual|January 26, 2007||2007-01-26|February 22, 2018|2018-02-22||||||||Observational|||Physical and Behavioral Traits of Overweight and Obese Adults|Study of the Phenotype of Overweight and Obese Adults|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:28:23.094089|2018-06-01 03:28:23.094089
NCT00428974|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2011-06-20||2018-01-23|2007-01-29|2007-01-30|Estimate|2011-08-18|2011-09-26|Estimate||||2018-01-23|2018-01-25|Actual|June 2007||2007-06-30|August 2011|2011-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety and Efficacy Study of CF101 to Treat Psoriasis|A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 2|76|Actual|Can-Fite BioPharma||4|||f||||f||||||||||2018-06-01 03:28:23.185532|2018-06-01 03:28:23.185532
NCT00428961|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2013-01-08|2007-01-29|2007-01-30|Estimate|||||||2013-01-08|2013-01-10|Estimate|July 2002||2002-07-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|DGP||Diabetes Genome Project: A Prospective Registry to Identify Genetic Variation Among Diabetic Patients|Diabetic Genome Project: A Multi-Phase Prospective Registry to Identify Genetic Variation Among Diabetic Patients Undergoing Coronary Revascularization|Completed|||1607|Actual|Saint Luke's Health System|||||f||||t||||||Samples With DNA|"~     Whole blood separated into 12 x1000µL, 10x500µL EDTA plasma, 2x1,000 µL and 20x200 µL of~     buffy coat (baseline only) and 2x1,000 µL of RBCs (baseline only)~   "|||2018-06-01 03:28:23.54907|2018-06-01 03:28:23.54907
NCT00428948|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2017-03-29|2013-02-01|2017-05-30|2007-01-29|2007-01-30|Estimate|2017-05-30|2017-07-02|Actual|2013-02-01|2013-02-04|Estimate|2017-05-30|2017-07-02|Actual|January 2007||2007-01-31|May 2017|2017-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|TEMPO3:4|Intent-to-treat population: All randomized participants.|Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 3|1445|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-06-01 03:28:23.687963|2018-06-01 03:28:23.687963
NCT00428935|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2013-02-04|2007-01-26|2007-01-30|Estimate|||||||2013-02-04|2013-02-05|Estimate|March 2006||2006-03-31|February 2013|2013-02-28|July 2010|Actual|2010-07-31|March 2009|Actual|2009-03-31||Interventional|||Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy|Phase 1 Clinical Trial of rAAV2.5-CMV-mini-Dystrophin Gene Vector in Duchenne Muscular Dystrophy|Completed||Phase 1|6|Actual|Nationwide Children's Hospital||2|||f||||||||||||||2018-06-01 03:28:24.90544|2018-06-01 03:28:24.90544
NCT00428922|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2015-11-10||2017-04-04|2007-01-29|2007-01-30|Estimate|2016-01-14|2016-02-12|Estimate||||2017-04-04|2017-05-10|Actual|June 14, 2007|Actual|2007-06-14|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|November 1, 2012|Actual|2012-11-01||Interventional|||Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients|Phase II Trial of Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients|Active, not recruiting||Phase 2|26|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:28:25.006789|2018-06-01 03:28:25.006789
NCT00428909|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2016-04-20|2007-01-29|2007-01-30|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2006||2006-11-30|April 2016|2016-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)|A Non-randomized, Open-label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)|Completed||Phase 1|12|Actual|Novartis||1|||f||||f||||||||||2018-06-01 03:28:25.179944|2018-06-01 03:28:25.179944
NCT00428896|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2008-07-18|2007-01-29|2007-01-30|Estimate|||||||2008-07-18|2008-07-21|Estimate|April 2005||2005-04-30|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer|A Pilot Feasibility Study to Evaluate the Efficacy of ZD1839 (IRESSA) in Eliminating Chemo- and Hormone- Resistant Cytokeratin-Positive Tumour Cells Circulating in the Blood of Women With Breast Cancer|Completed||Phase 2|24|Actual|University Hospital of Crete||1|||f||||||||||||||2018-06-01 03:28:25.240028|2018-06-01 03:28:25.240028
NCT00428883|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|February 2009||2009-02-28|||||Interventional|||High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis|Rare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis|Unknown status|Recruiting|Phase 2/Phase 3|45||Università Politecnica delle Marche|||||f||||||||||||||2018-06-01 03:28:25.405332|2018-06-01 03:28:25.405332
NCT00428870|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2017-02-06|2007-01-29|2007-01-30|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2005||2005-02-28|February 2017|2017-02-28|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Operative or Conservative Treatment for Subacromial Impingement Syndrome?|Arthroscopic Decompression Versus Diagnostic Arthroscopy Without Subacromial Decompression Versus Supervised Exercise Therapy in Treatment of Subacromial Impingement Syndrome. A Blinded Randomized Controlled Trail.|Active, not recruiting||N/A|210|Actual|Helsinki University||3|||f||||||||||||||2018-06-01 03:28:25.50828|2018-06-01 03:28:25.50828
NCT00428857|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2011-02-23|2007-01-29|2007-01-30|Estimate|||||||2011-02-23|2011-02-24|Estimate|June 2008||2008-06-30|January 2007|2007-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|POPVNI||Noninvasive Ventilatory Support After Lung Surgery in COPD Patients|Noninvasive Ventilatory Support After Lung Surgery to Prevent Pulmonary Complications in COPD Patients|Completed||N/A|360|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:28:25.579506|2018-06-01 03:28:25.579506
NCT00428844|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2011-03-16||2018-01-07|2007-01-29|2007-01-30|Estimate|2011-05-13|2011-06-14|Estimate||||2018-01-07|2018-01-31|Actual|June 26, 2007|Actual|2007-06-26|January 2018|2018-01-31|June 23, 2010|Actual|2010-06-23|March 26, 2010|Actual|2010-03-26||Interventional|||Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci|A Phase 2 Randomized Study Investigating the Safety, Efficacy and Pharmacokinetics of Daptomycin 6 mg/kg and 8 mg/kg Versus Comparator in the Treatment of Subjects Undergoing Surgical Standard of Care for Osteomyelitis Associated With an Infected Prosthetic Hip or Knee Joint Caused by Staphylococci|Completed||Phase 2|75|Actual|Cubist Pharmaceuticals LLC||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:28:25.673217|2018-06-01 03:28:25.673217
NCT00428831|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2013-12-19|2007-01-26|2007-01-30|Estimate|||||||2013-12-19|2013-12-20|Estimate|February 2007||2007-02-28|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Clinical IGSP-CHOP Boston|Clinical Correlates to Influenza Genomic Data|Completed|||500|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||||||2018-06-01 03:28:26.334896|2018-06-01 03:28:26.334896
NCT00428818|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|August 2005||2005-08-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Trimethoprim-Sulfamethoxazole or Doxycycline for Skin and Soft Tissue Infections|Empiric Therapy With Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High MRSA Prevalence: A Prospective Randomized Trial|Completed||N/A|75||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 03:28:26.408284|2018-06-01 03:28:26.408284
NCT00428805|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2015-11-30|2007-01-29|2007-01-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|CHILE||Child Health Initiative for Lifelong Eating and Exercise (CHILE)|Site Specific Approaches to Prevention or Management of Pediatric Obesity: Child Health Initiative for Lifelong Eating and Exercise--CHILE|Completed||N/A|980|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 03:28:26.463015|2018-06-01 03:28:26.463015
NCT00428792|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2011-01-06||2011-04-11|2007-01-29|2007-01-30|Estimate|2011-04-11|2011-05-06|Estimate||||2011-04-11|2011-05-06|Estimate|April 2007||2007-04-30|April 2011|2011-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)|An Open-label, Randomized, Rater-blinded, Cross-over, Multicenter Study Comparing the Clinical Efficacy of Methylphenidate (Immediate Release/Extended Release) Treatment (20 or 40 mg Orally od) in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Under Different Breakfast Conditions Over Two Weeks|Completed||Phase 3|150|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:28:26.565028|2018-06-01 03:28:26.565028
NCT00428779|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2009-06-10|2007-01-29|2007-01-30|Estimate|||||||2009-06-10|2009-06-11|Estimate|September 2007||2007-09-30|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Neuromuscular and Cognitive Fatigue During a 24 Hour Treadmill Running Exercise|Neuromuscular and Cognitive Fatigue During a 24h Treadmill Running Exercise.|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-06-01 03:28:26.865326|2018-06-01 03:28:26.865326
NCT00428766|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-28|||2013-11-05|2007-01-28|2007-01-30|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2005||2005-06-30|November 2013|2013-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer|A Study of the Safety, Tolerability, and Pharamcokinetics of MORAb-003, a Humanized Monoclonal Antibody, in Subjects With Advanced Ovarian Cancer|Completed||Phase 1|24|Anticipated|Morphotek|||||f||||||||||||||2018-06-01 03:28:26.933933|2018-06-01 03:28:26.933933
NCT00428753|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-05-29|2007-01-26|2007-01-30|Estimate|||||||2008-05-29|2008-05-30|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|January 2008||2008-01-31|||||Observational|||China Case Control Avian Influenza|Matched Case-Control Study of Risk Factors for Human Infection With Avian Influenza A (H5N1) Virus, China|Completed|||100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:28:26.989649|2018-06-01 03:28:26.989649
NCT00428740|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|October 2005||2005-10-31|January 2007|2007-01-31|December 2005||2005-12-31|||||Observational|||Long-Term IOP Fluctuation and VF Progression After Triple Procedure|Long-Term Intraocular Pressure Fluctuation and Visual Field Progression in Glaucoma Patients With Low Intraocular Pressure After Triple Procedure|Completed|||300||Yonsei University|||||f||||||||||||||2018-06-01 03:28:27.037436|2018-06-01 03:28:27.037436
NCT00428727|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2012-11-02|2007-01-26|2007-01-30|Estimate|||||||2012-11-02|2012-11-06|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON|Double Blind, Randomized, Placebo Controlled Clinical Trial for the Treatment of Diabetic Foot Ulcers, Using a Nitric Oxide Releasing Patch: PATHON|Completed||Phase 3|100|Actual|Fundación Cardiovascular de Colombia||2|||f||||t||||||||||2018-06-01 03:28:27.088478|2018-06-01 03:28:27.088478
NCT00428714|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26||2010-05-27|2011-08-01|2007-01-26|2007-01-30|Estimate||||2010-05-27|2010-06-02|Estimate|2011-08-01|2011-08-08|Estimate|January 2007||2007-01-31|August 2011|2011-08-31|January 2011|Actual|2011-01-31|June 2009|Actual|2009-06-30||Interventional|||Phase 2 Trial of Enzastaurin in Prostate Cancer in Patients Who Have Had Hormonal and Chemotherapy|Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy|Completed||Phase 2|72|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:28:27.165698|2018-06-01 03:28:27.165698
NCT00428701|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2011-01-21|2007-01-29|2007-01-30|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2006||2006-10-31|January 2011|2011-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium|An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours|Completed||Phase 4|40|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:28:27.352561|2018-06-01 03:28:27.352561
NCT00428688|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-28|||2012-12-12|2007-01-29|2007-01-30|Estimate|||||||2012-12-12|2012-12-13|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma|Assessment of Endothelial Function and IMT in Survivors Hodgkin's Lymphoma Patients|Unknown status|Enrolling by invitation||40|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:28:27.427291|2018-06-01 03:28:27.427291
NCT00428675|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2011-11-29|2007-01-26|2007-01-30|Estimate|||||||2011-11-29|2011-11-30|Estimate|October 2005||2005-10-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2007|Actual|2007-10-31||Observational|||A New Tool for Assessing Fatigue in Individuals With Advanced Cancer|Development of a Rapid Assessment Tool for Fatigue in Palliative Care|Completed|||221|Actual|University of Alberta|||||f||||f||||||||||2018-06-01 03:28:27.499282|2018-06-01 03:28:27.499282
NCT00428662|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|October 2007||2007-10-31|||||Interventional|||Evaluation of a New Nanotechnology Based Drug-Eluting Stent for Opening of Narrowed Arteries of the Heart|Clinical and Angiographic Evaluation of Paclitaxel Eluting, Non-Polymeric, Nanoporous Carbon-Carbon Coated, Cobalt-Chromium Stent|Unknown status|Recruiting|N/A|200||All India Institute of Medical Sciences, New Delhi|||||f||||||||||||||2018-06-01 03:28:27.566775|2018-06-01 03:28:27.566775
NCT00428649|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-03-06|2007-01-25|2007-01-30|Estimate|||||||2012-03-06|2012-03-07|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|October 2008|Actual|2008-10-31|December 2007|Actual|2007-12-31||Interventional|||Optimization of Selenoprotein P in Chinese Subjects|Optimization of Selenoprotein P in Chinese Subjects|Completed||N/A|98|Actual|Vanderbilt University||7|||f||||||||||||||2018-06-01 03:28:27.657977|2018-06-01 03:28:27.657977
NCT00428636|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2007-01-26|2007-01-26|2007-01-30|Estimate|||||||2007-01-26|2007-01-30|Estimate|May 2001||2001-05-31|January 2007|2007-01-31|July 2005||2005-07-31|||||Interventional|||Early Temporary Stoma Closure After Proctectomy|Study of Early Closure of Temporary Loop Ileostomy After Elective Rectal Resection With Low Pelvic Anastomoses|Completed||N/A|270||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:28:27.76494|2018-06-01 03:28:27.76494
NCT00428623|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|January 2004||2004-01-31|January 2007|2007-01-31|January 2006||2006-01-31|||||Observational|||Aquacel Compared to Traditional Post Surgical Wound Dressing in Vascular Surgery Patients||Completed|||160||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:28:27.83287|2018-06-01 03:28:27.83287
NCT00428610|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2018-03-17|2011-06-13|2018-03-17|2007-01-26|2007-01-30|Estimate|2018-03-17|2018-04-19|Actual|2011-06-13|2011-06-27|Estimate|2018-03-17|2018-04-19|Actual|February 2007||2007-02-28|March 2018|2018-03-31|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional||All enrolled participants who had at least one dose of study drug.|A Study of Chemotherapy Treatment for Patients With Ovarian Cancer|A Phase 2 Study of LY573636-Sodium as Treatment for Patients With Platinum-Resistant Ovarian Cancer|Completed||Phase 2|103|Actual|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 03:28:27.93117|2018-06-01 03:28:27.93117
NCT00428597|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2010-04-15||2010-09-16|2007-01-29|2007-01-30|Estimate|2010-09-16|2010-10-11|Estimate||||2010-09-16|2010-10-11|Estimate|June 2007||2007-06-30|September 2010|2010-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors|A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors|Terminated||Phase 3|171|Actual|Pfizer||2||Refer to Detailed Description.|f||||t||||||||||2018-06-01 03:28:28.959134|2018-06-01 03:28:28.959134
NCT00428584|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2008-11-26||2013-08-01|2007-01-29|2007-01-30|Estimate|2010-02-18|2010-03-04|Estimate||||2013-08-01|2013-08-07|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|September 2009|Actual|2009-09-30|November 2007|Actual|2007-11-30||Interventional|REFORMS||RNF and Betaseron® Tolerability Study|A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension|Completed||Phase 3|129|Actual|EMD Serono||2|||f||||||||||||||2018-06-01 03:28:30.408531|2018-06-01 03:28:30.408531
NCT00428571|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2016-04-13|2007-01-29|2007-01-30|Estimate|||||||2016-04-13|2016-04-14|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients|Laparoscopic Bariatric Surgery for Treatment of Type 2 Diabetes in Obese Patients With End Organ Damage: A Prospective Randomized Controlled Pilot Study|Terminated||N/A|20|Actual|McMaster University||3|||f||||||||||||||2018-06-01 03:28:30.876537|2018-06-01 03:28:30.876537
NCT00428558|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2013-12-19|2007-01-29|2007-01-30|Estimate|||||||2013-12-19|2013-12-20|Estimate|July 2007||2007-07-31|July 2007|2007-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Timed-Sequential Induction in CBF-AML|A Phase 3 Trial of Systematic Versus Response-adapted Timed-Sequential Induction in Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)|Completed||Phase 3|200|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:28:30.949036|2018-06-01 03:28:30.949036
NCT00428545|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2013-02-11|2007-01-29|2007-01-30|Estimate|||||||2013-02-11|2013-02-12|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Bevacizumab and Bortezomib in Patients With Advanced Malignancy|A Phase I Trial of Bevacizumab and Bortezomib in Patients With Advanced Malignancy|Completed||Phase 1|104|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:31.050018|2018-06-01 03:28:31.050018
NCT00428532|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-27|||2007-05-07|2007-01-29|2007-01-30|Estimate|||||||2007-05-07|2007-05-08|Estimate|March 2007||2007-03-31|January 2007|2007-01-31|August 2007|Anticipated|2007-08-31|||||Interventional|||The Effect of Licorice Root Extract and Pomegranate Juice on Atherosclerotic Parameters in Diabetic Patients||Unknown status|Recruiting|N/A|10|Anticipated|HaEmek Medical Center, Israel|||||f||||||||||||||2018-06-01 03:28:31.129252|2018-06-01 03:28:31.129252
NCT00428519|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2017-03-28|2007-01-29|2007-01-30|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2007||2007-01-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals|A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals|Completed||Phase 1|30|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 03:28:31.187195|2018-06-01 03:28:31.187195
NCT00428506|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2008-04-09|2007-01-29|2007-01-30|Estimate|||||||2008-04-09|2008-04-11|Estimate|February 2007||2007-02-28|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction|Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction in Cirrhotic Patients With Ascites|Unknown status|Recruiting|Phase 2|70|Anticipated|University of Turin, Italy|||||f||||t||||||||||2018-06-01 03:28:31.268321|2018-06-01 03:28:31.268321
NCT00428493|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-05-29|2007-01-26|2007-01-30|Estimate|||||||2008-05-29|2008-05-30|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|January 2008||2008-01-31|||||Observational|||Prospective Study of AI H5N1 in China|Prospective Study of Individuals Exposed to Confirmed Cases of Human Influenza A (H5N1) Infection in China|Completed|||4000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:28:31.340757|2018-06-01 03:28:31.340757
NCT00428480|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2011-11-10|2007-01-29|2007-01-30|Estimate|||||||2011-11-10|2011-11-11|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|SIRROWS||Walking Study for Stroke Rehabilitation|Stroke Inpatient Rehabilitation Reinforcement of Walking Speed|Completed||Phase 1|216|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 03:28:31.4031|2018-06-01 03:28:31.4031
NCT00428467|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|May 2004||2004-05-31|January 2007|2007-01-31|April 2007||2007-04-30|||||Interventional|||Apical Compression Stitch - a New Option for LV Remodelling|Pronounced Apical Dilatation in Failing Left Ventricles – a New Option for Surgical Remodelling Techniques|Unknown status|Active, not recruiting|N/A|||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 03:28:31.5299|2018-06-01 03:28:31.5299
NCT00428454|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2015-06-03|2007-01-29|2007-01-30|Estimate|||||||2015-06-03|2015-06-04|Estimate|January 2007||2007-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|December 2010|Actual|2010-12-31||Interventional|||Sirolimus-eluting vs Zotarolimus-eluting Stents for Chronic Total Coronary Occlusions|A Randomized Comparison of Sirolimus-eluting Stent Implantation With Zotarolimus-eluting Stent Implantation for the Treatment of Chronic Total Coronary Occlusions. The PRISON III Trial.|Completed||Phase 3|301|Actual|R&D Cardiologie||2|||f||||||||||||||2018-06-01 03:28:31.590298|2018-06-01 03:28:31.590298
NCT00428441|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2011-08-18||2011-08-18|2007-01-29|2007-01-30|Estimate|2011-08-18|2011-09-26|Estimate||||2011-08-18|2011-09-26|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|June 2010|Actual|2010-06-30||Interventional|||D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism|The Negative Predictive Value of D-dimer on the Risk of Recurrent Venous Thromboembolism in Patients With Multiple Previous Events: a Prospective Cohort Study|Terminated||N/A|73|Actual|Università degli Studi dell'Insubria||||Enrolment was halted prematurely because of the observed excess in recurrences|f||||f||||||||||2018-06-01 03:28:31.688404|2018-06-01 03:28:31.688404
NCT00428428|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-11-15|2007-01-29|2007-01-30|Estimate|||||||2007-11-15|2007-11-16|Estimate|February 2007||2007-02-28|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract|Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract|Completed||Phase 2/Phase 3|12|Actual|Fredericia Hosptial||2|||f||||t||||||||||2018-06-01 03:28:31.818129|2018-06-01 03:28:31.818129
NCT00428415|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2008-03-03|2007-01-29|2007-01-30|Estimate|||||||2008-03-03|2008-03-05|Estimate|March 2007||2007-03-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Tesofensine on Energy Balance in Humans.|The Effect of Tesofensine on Energy Balance in Humans. A Randomised, Double-Blind, Placebo-Controlled, Parallel- Group, Single Centre Study.|Completed||Phase 1/Phase 2|32|Anticipated|NeuroSearch A/S|||||f||||||||||||||2018-06-01 03:28:31.873779|2018-06-01 03:28:31.873779
NCT00428402|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2012-02-27|2007-01-29|2007-01-30|Estimate|||||||2012-02-27|2012-02-28|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Using Focus Groups to Assess the Impact of Environmental Health Science Programs for K-12 Educational Community|Using Focus Groups to Assess the Impact of Environmental Health Science Programs for K-12 Educational Community|Completed|||6|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:28:32.018559|2018-06-01 03:28:32.018559
NCT00428389|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2010-12-22||2014-06-05|2007-01-26|2007-01-30|Estimate|2011-05-27|2011-06-27|Estimate||||2014-06-05|2014-06-11|Estimate|January 2007||2007-01-31|June 2014|2014-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease|A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease|Completed||Phase 3|262|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:28:32.10315|2018-06-01 03:28:32.10315
NCT00428376|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2008-09-25|2007-01-29|2007-01-30|Estimate|||||||2008-09-25|2008-09-29|Estimate|September 2005||2005-09-30|September 2008|2008-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Does Block Play Improve Language Acquisition: A Randomized Trial|Clinical Trial of Building Block Distribution in Children|Completed||N/A|200||University of Washington|||||f||||||||||||||2018-06-01 03:28:32.513014|2018-06-01 03:28:32.513014
NCT00428363|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-29|2007-01-29|2007-01-30|Estimate|||||||2007-01-29|2007-01-30|Estimate|June 2001||2001-06-30|January 2007|2007-01-31|March 2006||2006-03-31|||||Interventional|||Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification||Completed||Phase 4|52||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:28:32.567579|2018-06-01 03:28:32.567579
NCT00428350|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2009-03-24|2007-01-29|2007-01-30|Estimate|||||||2009-03-24|2009-03-25|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study of Efficacy and Safety of Seroquel (Quetiapine Fumarate) as Mono-Therapy for Acute Schizophrenic|A 24-Week, Multi-Centre, Open-Label, Single-Arm, Phase IV Study of the Efficacy and Safety of Seroquel (Quetiapine Fumarate) With Daily Dose 600mg-750mg as Mono-Therapy in the Treatment of Acute Schizophrenic Patients|Completed||Phase 4|120|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:28:32.629417|2018-06-01 03:28:32.629417
NCT00428337|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2015-03-03|2007-01-29|2007-01-30|Estimate|||||||2015-03-03|2015-03-04|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|August 2008|Actual|2008-08-31|||||Interventional|||Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of DNA Vaccine EP-1233 and Recombinant MVA-HIV Polytope Vaccine MVA-mBN32, Separately and in a Combined Prime-boost Regimen, When Given to Healthy, Vaccinia-naive, HIV-1-uninfected Adults|Completed||Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 03:28:32.70017|2018-06-01 03:28:32.70017
NCT00428311|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|||2007-01-30|2007-01-29|2007-01-30|Estimate|||||||2007-01-30|2007-01-31|Estimate|April 2004||2004-04-30|January 2007|2007-01-31|October 2006||2006-10-31|||||Interventional|||Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS|The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives|Completed||Phase 4|50||Hospital Universitario Ramon y Cajal|||||f||||||||||||||2018-06-01 03:28:32.78068|2018-06-01 03:28:32.78068
NCT00428298|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-29|2016-09-20||2017-02-28|2007-01-29|2007-01-30|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|March 2007||2007-03-31|February 2017|2017-02-28|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Research Study of Bipolar Mood Symptoms and Cognitive Problems|A Double Blind Placebo Controlled Study of Valacyclovir in Cognitive Impairment and Mood Symptoms of Bipolar Disorder|Completed||Phase 2|60|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-06-01 03:28:32.844416|2018-06-01 03:28:32.844416
NCT00428285|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2016-07-29|2007-01-25|2007-01-29|Estimate|||||||2016-07-29|2016-08-01|Estimate|February 2007||2007-02-28|July 2016|2016-07-31|July 2016|Actual|2016-07-31|February 2010|Actual|2010-02-28||Interventional|||Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men|A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men|Completed||Phase 2|20|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-06-01 03:28:33.104179|2018-06-01 03:28:33.104179
NCT00428272|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2018-05-24|2007-01-25|2007-01-29|Estimate|||||||2018-05-24|2018-05-25|Actual|December 4, 2006||2006-12-04|October 9, 2015|2015-10-09|October 9, 2015|Actual|2015-10-09|April 28, 2011|Actual|2011-04-28||Interventional|||HGS-ETR2 to Treat Children With Solid Tumors|A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients With Refractory Pediatric Solid Tumors|Terminated||Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 03:28:33.179681|2018-06-01 03:28:33.179681
NCT00428246|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2009-04-06||2009-04-06|2007-01-26|2007-01-29|Estimate|2009-04-06|2009-06-03|Estimate||||2009-04-06|2009-06-03|Estimate|November 2006||2006-11-30|April 2009|2009-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation|Anti-Inflammatory and Endothelial Protectant Effects of Paricalcitol|Completed||N/A|24|Actual|Indiana University||3|||f||||f||||||||||2018-06-01 03:28:33.270981|2018-06-01 03:28:33.270981
NCT00428233|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2017-11-17|2007-01-25|2007-01-29|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2006|Actual|2006-11-30|November 2017|2017-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation|Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation|Completed||Phase 1|65|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:28:33.697406|2018-06-01 03:28:33.697406
NCT00428220|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2015-07-26||2015-10-07|2007-01-26|2007-01-29|Estimate|2015-10-07|2015-11-06|Estimate||||2015-10-07|2015-11-06|Estimate|July 2007||2007-07-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional||The safety population was defined as all participants enrolled in the study who received at least one dose of study drug in this study.|A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.|An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment|Completed||N/A|226|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:28:33.825131|2018-06-01 03:28:33.825131
NCT00428207|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2013-04-17||2017-04-25|2007-01-25|2007-01-29|Estimate|2017-04-25|2017-05-30|Actual||||2017-04-25|2017-05-30|Actual|February 2007||2007-02-28|April 2017|2017-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||All study participants received both interventions.|Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy|Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy|Terminated||N/A|4|Actual|Joslin Diabetes Center|The 7 point fingerstick blood glucose profile was not sensitive enough to detect differences in the treatments.|2||Treatment differences not detected with 7 point fingerstick monitoring|f||||f||||||||No||2018-06-01 03:28:34.46672|2018-06-01 03:28:34.46672
NCT00428194|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2017-11-27|2007-01-25|2007-01-29|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2007||2007-01-31|November 2017|2017-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer|Erlotinib in Combination With Cisplatin as Radiosensitizing Agents in Women Receiving Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Cervix; A Phase I Trial|Withdrawn||Phase 1|0|Actual|Masonic Cancer Center, University of Minnesota||3||Withdrawn due to lack of accrual|f||||t||||||||||2018-06-01 03:28:34.650649|2018-06-01 03:28:34.650649
NCT00428181|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-04-05|2007-01-25|2007-01-29|Estimate|||||||2012-04-05|2012-04-06|Estimate|September 2007||2007-09-30|April 2012|2012-04-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Multidisciplinary Approach to Reduce Injury and Alcohol|Multidisciplinary Approach to Reduce Injury and Alcohol|Completed||Phase 3|605|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-06-01 03:28:34.756121|2018-06-01 03:28:34.756121
NCT00428168|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2015-10-13|2007-01-26|2007-01-29|Estimate|||||||2015-10-13|2015-10-15|Estimate|March 2007||2007-03-31|October 2008|2008-10-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment|Terminated||Phase 2|36|Actual|OBEcure Ltd.||2||"Interim Analysis result indicated the study will not show a significant benefit of the study~   medication on the primary endpoint."|f||||f||||||||||2018-06-01 03:28:34.832078|2018-06-01 03:28:34.832078
NCT00428155|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-01-26|2007-01-26|2007-01-29|Estimate|||||||2007-01-26|2007-01-29|Estimate|January 2007||2007-01-31|January 2007|2007-01-31||||||||Interventional|||Arterial Closure Device Comparison Trial II – ACDC Trial II|A Randomized Trial of Angioseal and Starclose for Hemostasis After PCI|Unknown status|Recruiting|N/A|448||St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 03:28:34.928545|2018-06-01 03:28:34.928545
NCT00428142|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-11-26|2007-01-25|2007-01-29|Estimate|||||||2012-11-26|2012-11-27|Estimate|December 2006||2006-12-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|||Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma|A Multi-Centre Phase II Trial Investigating the Efficacy and Tolerability of Bortezomib Added to Cyclophosphamide, Vincristine, Prednisone, and Rituximab (BCVP-R) for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma Requiring Systemic First-Line Treatment|Completed||Phase 2|95|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-06-01 03:28:35.010189|2018-06-01 03:28:35.010189
NCT00428129|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2014-04-04|2007-01-26|2007-01-29|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|MAX-DVT||Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT|An Open Label Clinical Trial of Microplasmin Administered Via the Trellis-8 Infusion System for the Treatment of Acute Iliofemoral Deep Vein Thrombosis|Terminated||Phase 2|6|Actual|ThromboGenics||1||Sponsor's decision to not pursue uPLi for vascular conditions including DVT.|f||||t||||||||||2018-06-01 03:28:35.122358|2018-06-01 03:28:35.122358
NCT00428116|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2015-06-08||2017-05-01|2007-01-26|2007-01-29|Estimate|2015-07-24|2015-08-20|Estimate||||2017-05-01|2017-05-03|Actual|September 2007||2007-09-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional||following 24 months of HAART|Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya|Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (0-4.5 Month Randomized Controlled Trial)|Terminated||N/A|140|Actual|University of Washington||2||DSMB recommended termination because TI was safe but not durable.|f||||t||||||||||2018-06-01 03:28:35.217278|2018-06-01 03:28:35.217278
NCT00428103|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2013-02-26|2007-01-26|2007-01-29|Estimate|||||||2013-02-26|2013-02-28|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy|Destiny Trial: Effects of Mitral Valve Annuloplasty With the Geoform Ring on Left Ventricular Geometry and Function in Patients With Cardiomyopathy|Withdrawn||N/A|0|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 03:28:35.506509|2018-06-01 03:28:35.506509
NCT00428090|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2017-02-16|2010-10-13|2017-04-13|2007-01-25|2007-01-29|Estimate|2017-04-13|2017-05-19|Actual|2010-10-13|2010-11-18|Estimate|2017-04-13|2017-05-19|Actual|February 27, 2007||2007-02-27|April 2017|2017-04-30|September 5, 2008|Actual|2008-09-05|September 1, 2008|Actual|2008-09-01||Interventional||The intent-to-treat (ITT) population was used and consist of all par. randomized to treatment, who have taken at least one dose of study medication and who have at least one post baseline efficacy assessment. The ITT population included 553 participants.|Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease|A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease. (REFLECT-1)|Completed||Phase 3|862|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:28:35.648219|2018-06-01 03:28:35.648219
NCT00428077|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2011-05-26||2011-08-31|2007-01-25|2007-01-29|Estimate|2011-08-01|2011-08-31|Estimate||||2011-08-31|2011-09-02|Estimate|October 2005||2005-10-31|August 2011|2011-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|A Multi-Center Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease|Terminated||Phase 2|4|Actual|OHSU Knight Cancer Institute||||"Withdrawn because there were no dramatic changes in the main endpoint, as well as low~   enrollment numbers. The data are not interpretable in terms of efficacy."|f||||t||||||||||2018-06-01 03:28:39.117845|2018-06-01 03:28:39.117845
NCT00428064|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-01-26|2007-01-26|2007-01-29|Estimate|||||||2007-01-26|2007-01-29|Estimate|May 1998||1998-05-31|January 2007|2007-01-31|June 2004||2004-06-30|||||Interventional|||Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients|A Randomized, Open-Label Study of Continuous Therapy With Cyclosporine and Sirolimus Versus Induction With Cyclosporine and Sirolimus Followed by Continuous Therapy With Sirolimus in Renal Allograft Recipients|Completed||Phase 3|408||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:28:39.336764|2018-06-01 03:28:39.336764
NCT00428051|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2011-10-26|2007-01-26|2007-01-29|Estimate|||||||2011-10-26|2011-10-27|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|February 2011|Actual|2011-02-28||Observational|LEAP II||Colombia Epidemiologic Surveillance Study|Multinational Latin American Epidemiologic Surveillance For Invasive Pneumococcal Disease|Terminated|||32867|Actual|Pfizer|||1|See termination reason in detailed description.|f||||f||||||Samples With DNA|"~     Cerebral Spinal Fluid Pleural Fluid S. pneumoniae isolates~   "|||2018-06-01 03:28:39.383096|2018-06-01 03:28:39.383096
NCT00428038|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-03-29|2007-01-25|2007-01-29|Estimate|||||||2012-03-29|2012-03-30|Estimate|February 2004||2004-02-29|March 2012|2012-03-31|December 2008|Actual|2008-12-31|||||Observational|||Assessment of the Pulmonary Diffusion Capacity in Healthy Infants and Infants With Chronic Lung Disease|Assessment of the Pulmonary Diffusion Capacity in Healthy Infants and Infants With Chronic Lung Disease|Completed|||68|Actual|Indiana University|||3||f||||t||||||||||2018-06-01 03:28:39.455395|2018-06-01 03:28:39.455395
NCT00428025|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2015-09-18|2007-01-26|2007-01-29|Estimate|||||||2015-09-18|2015-09-22|Estimate|October 2006||2006-10-31|September 2015|2015-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients|Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients: A Prospective, Randomized, Double Blind, Placebo Controlled Trial.|Terminated||Phase 4|23|Actual|Queen's University||2||slow recruitment|f||||f||||||||||2018-06-01 03:28:39.51098|2018-06-01 03:28:39.51098
NCT00428012|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-01-05|2007-01-25|2007-01-29|Estimate|||||||2012-01-05|2012-01-06|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|April 2011|Actual|2011-04-30|July 2009|Actual|2009-07-31||Interventional|||Quality of Life Therapy for Adults With ESRD Awaiting Renal Transplantation|Quality of Life Therapy for Adults With ESRD Awaiting Renal Transplantation|Completed||Phase 2/Phase 3|65|Actual|Beth Israel Deaconess Medical Center||3|||f||||t||||||||||2018-06-01 03:28:39.570169|2018-06-01 03:28:39.570169
NCT00427999|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2016-08-10||2016-10-06|2007-01-25|2007-01-29|Estimate|2016-08-10|2016-10-06|Estimate||||2016-10-06|2016-11-21|Estimate|February 2007||2007-02-28|October 2016|2016-10-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|INV342||Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer|A Single Stage Phase II, Multi-centre, Open Label Study of Imatinib in Combination With Pioglitazone, Etoricoxib, Dexamethasone and Low-dose Treosulfane for Anti-inflammatory and Angiostatic Treatment in Patients With Hormone-refractory Prostate Cancer|Completed||Phase 2|67|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:28:39.64047|2018-06-01 03:28:39.64047
NCT00427986|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-06-25|2007-01-25|2007-01-29|Estimate|||||||2007-06-25|2007-06-26|Estimate|January 2007||2007-01-31|June 2007|2007-06-30|March 2007|Actual|2007-03-31|||||Interventional|||Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema|Diabetic Macular Oedema: Quantification of the Effect of Rising the Intracapillary Osmotic Pressure With Intravenous Galactose on the Retinal Thickness|Terminated||N/A|1|Actual|Glostrup University Hospital, Copenhagen||||No sufficient increase in plasma osmolarity by galactose (one patient included)|f||||||||||||||2018-06-01 03:28:41.240647|2018-06-01 03:28:41.240647
NCT00427973|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2015-07-01||2016-09-13|2007-01-25|2007-01-29|Estimate|2016-09-13|2016-10-31|Estimate||||2016-09-13|2016-10-31|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|March 2012|Actual|2012-03-31|April 2010|Actual|2010-04-30||Interventional|||AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer|A Phase II Study of AZD2171 in Hepatocellular Carcinoma|Terminated||Phase 2|17|Actual|National Cancer Institute (NCI)|Despite reaching the prespecified goal for the first stage of the trial, the study was stopped and did not proceed to the second stage after reviewing the development program of cediranib by AstraZeneca for reasons unrelated to this study.|1||The study was stopped prior to 2nd stage.|f||||t||||||||||2018-06-01 03:28:41.349068|2018-06-01 03:28:41.349068
NCT00427960|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2009-03-25||2010-11-30|2007-01-25|2007-01-29|Estimate|2010-03-08|2010-03-22|Estimate||||2010-11-30|2010-12-16|Estimate|December 2006||2006-12-31|November 2010|2010-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg|A Phase IV, 6-week, Randomised, Double-blind, Multicentre, Parallel Group, Comparative Study to Evaluate the Efficacy of Rosuvastatin 5mg and Atorvastatin 10mg in UK Asian Subjects With Primary Hypercholesterolaemia|Terminated||Phase 4|55|Actual|AstraZeneca|The study achieved only 8% of the randomised target number of patients and for this reason alone was terminated early. Planned statistical analyses could not be performed. No scientifically valid conclusions can be drawn from the limited study data.|2||Due to inadequate recruitment|f||||||||||||||2018-06-01 03:28:41.711516|2018-06-01 03:28:41.711516
NCT00427947|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2009-12-28|2007-01-26|2007-01-29|Estimate|||||||2009-12-28|2009-12-29|Estimate|December 2006||2006-12-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|CAPDAF||Leg Amputation and Continuous Sciatic Nerve Block|Continuous Popliteal Sciatic Nerve Block Interest in Postoperative Pain Management for Patients With Leg Amputation|Terminated||Phase 3|6|Actual|University Hospital, Bordeaux||2||lack of patients|f||||t||||||||||2018-06-01 03:28:42.162488|2018-06-01 03:28:42.162488
NCT00427934|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2009-10-06||2014-10-30|2007-01-25|2007-01-29|Estimate|2010-01-13|2010-02-05|Estimate||||2014-10-30|2014-11-05|Estimate|February 2007||2007-02-28|October 2014|2014-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Maraviroc in Rheumatoid Arthritis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate|Terminated||Phase 2|128|Actual|Pfizer||2||See Detailed Description.|f||||f||||||||||2018-06-01 03:28:42.343901|2018-06-01 03:28:42.343901
NCT00427921|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2009-01-09||2009-11-12|2007-01-26|2007-01-29|Estimate|2009-09-22|2009-10-23|Estimate||||2009-11-12|2009-11-20|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|ACCESS||Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)|A Multicentre, Open Label, Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)|Completed||Phase 3|304|Actual|Abbott|Subjects who failed prior infliximab therapy were eligible to enter study after minimum 8 week wash-out since last dose. Includes subjects who previously used infliximab & never responded or responded & developed intolerance/lost efficacy.|1|||f||||f||||||||||2018-06-01 03:28:44.051242|2018-06-01 03:28:44.051242
NCT00427908|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26||2012-08-02|2016-10-18|2007-01-26|2007-01-29|Estimate||||2012-08-02|2012-08-07|Estimate|2016-10-18|2016-10-19|Estimate|February 2007||2007-02-28|October 2016|2016-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612|Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age)|Completed||Phase 2|612|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:28:44.978551|2018-06-01 03:28:44.978551
NCT00427895|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2012-08-01||2012-08-01|2007-01-26|2007-01-29|Estimate|2012-08-01|2012-09-05|Estimate||||2012-08-01|2012-09-05|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults|A Phase 3, Randomized, Active-Controlled, Modified Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Compared to a 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) in Adults 60 to 64 Years Old Who Are Naive to 23vPS and the Safety, Tolerability, and Immunogenicity of 13vPnC in Adults 18 to 59 Years Old Who Are Naïve to 23vPS|Completed||Phase 3|2141|Actual|Pfizer||7|||f||||f||||||||||2018-06-01 03:28:45.423583|2018-06-01 03:28:45.423583
NCT00427882|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-11-28|2007-01-25|2007-01-29|Estimate|||||||2007-11-28|2007-11-29|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study|An Open, Non-Comparative, Multicenter Study on the Sexual Function Improvement Following Treatment With Alfuzosin in Patients With Benign Prostate Hyperplasia|Completed||Phase 4|125|Anticipated|Handok Pharmaceuticals Co., Ltd.|||||f||||||||||||||2018-06-01 03:28:51.619003|2018-06-01 03:28:51.619003
NCT00427856|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25||2013-08-16|2016-07-20|2007-01-26|2007-01-29|Estimate||||2013-08-16|2013-08-26|Estimate|2016-07-20|2016-07-22|Estimate|March 2007||2007-03-31|July 2016|2016-07-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)|A Multi-Center, Open-Label, Phase II Study of Sequential, Single-Agent Obatoclax Mesylate (GX15-070MS)Followed by a Combination With Rituximab to Patients With Previously-Untreated Follicular Lymphoma (FL)|Completed||Phase 2|7|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 03:28:51.694807|2018-06-01 03:28:51.694807
NCT00427843|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-10-14|2007-01-26|2007-01-29|Estimate|||||||2008-10-14|2008-10-15|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||The Influence of Hip Strengthening Exercises on Walking Patterns and Muscle Strength in Persons With Knee Osteoarthritis|The Influence of a Home Program of Hip Abductor Exercises on Gait Parameters and Muscle Strength in Persons With Knee Osteoarthritis|Completed||N/A|80|Actual|Queen's University||1|||f||||t||||||||||2018-06-01 03:28:51.854598|2018-06-01 03:28:51.854598
NCT00427830|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-01-26|2007-01-26|2007-01-29|Estimate|||||||2007-01-26|2007-01-29|Estimate|May 2003||2003-05-31|December 2006|2006-12-31|January 2005||2005-01-31|||||Interventional|||A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG|Completed||Phase 1|16||University of Oxford|||||f||||||||||||||2018-06-01 03:28:51.958843|2018-06-01 03:28:51.958843
NCT00427817|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2011-10-05|2007-01-26|2007-01-29|Estimate|||||||2011-10-05|2011-10-06|Estimate|August 2006||2006-08-31|October 2011|2011-10-31|January 2011|Actual|2011-01-31|January 2009|Actual|2009-01-31||Observational|||PRO-STATE:Search for a Protein Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins in Prostate Carcinoma|PRO-STATE: Prognostic Interest of Serum Protein Profiles of Patients Undergoing a Prostate Biopsy: Search for a Profile Corresponding to Fast-developing Lesions and Characterization of Implicated Proteins.|Completed|||300|Anticipated|University Hospital, Grenoble|||||f||||||||||||||2018-06-01 03:28:52.037013|2018-06-01 03:28:52.037013
NCT00427804|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2011-08-03||2013-01-30|2007-01-25|2007-01-29|Estimate|2011-08-03|2011-09-02|Estimate||||2013-01-30|2013-02-04|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption|Tumor Necrosis Factor-α Induces Vitamin D Resistance in Small Intestinal Calcium Absorption|Completed||N/A|9|Actual|Atlanta VA Medical Center||1|||f||||f||||||||||2018-06-01 03:28:52.172267|2018-06-01 03:28:52.172267
NCT00427791|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2012-01-19||2016-04-05|2007-01-25|2007-01-29|Estimate|2012-04-10|2012-05-07|Estimate||||2016-04-05|2016-05-09|Estimate|July 2005||2005-07-31|April 2012|2012-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia|Phase II Randomized Study Evaluating the Addition of Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia|Completed||Phase 2|23|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:28:52.828604|2018-06-01 03:28:52.828604
NCT00427778|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2016-11-29||2017-09-25|2007-01-25|2007-01-29|Estimate|2017-09-25|2017-09-27|Actual||||2017-09-25|2017-09-27|Actual|June 2006|Actual|2006-06-30|September 2017|2017-09-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional||all patients who were recruited and for whom a pessary was fitted, successfully or not.|Incontinence Ring on Stress Urinary Incontinence|The Treatment of Stress Urinary Incontinence Using an Incontinence Ring: A Randomized, Cross-over Trial|Terminated||N/A|29|Actual|Queen's University|small sample size. slow recruitment|2||Slow recruitment|f||||f||||||||Undecided||2018-06-01 03:28:53.257868|2018-06-01 03:28:53.257868
NCT00427765|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2011-11-14||2011-12-15|2007-01-25|2007-01-29|Estimate|2011-12-15|2012-01-19|Estimate||||2011-12-15|2012-01-19|Estimate|December 2004||2004-12-31|December 2011|2011-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma|A Phase II Study of High-Dose Intravenous Busulfan Plus Melphalan With Allogeneic or Autologous Marrow or Peripheral Blood Progenitor Cell Transplantation for Lymphoid Malignancies or Multiple Myeloma|Completed||Phase 2|168|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:53.690197|2018-06-01 03:28:53.690197
NCT00427752|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-05-03|2007-01-26|2007-01-29|Estimate|||||||2012-05-03|2012-05-07|Estimate|October 2006||2006-10-31|May 2012|2012-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Abdominal Exploration Without Incisions|Diagnostic Transluminal Endoscopic Peritoneoscopy|Completed||Early Phase 1|20|Actual|Ohio State University||1|||f||||f||||||||||2018-06-01 03:28:53.98955|2018-06-01 03:28:53.98955
NCT00427739|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2017-03-29|2007-01-26|2007-01-29|Estimate|||||||2017-03-29|2017-03-31|Actual|June 2006||2006-06-30|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Data Collection During CT for Axial Flow VADs|Pilot Study of Data Collection During Computerized Tomography (CT) to Determine Accurate Flow Rates for Axial Flow Ventricular Assist Device (VAD) Patients|Completed|||9|Actual|Ohio State University|||1||f||||f||||||||||2018-06-01 03:28:54.179977|2018-06-01 03:28:54.179977
NCT00427726|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2018-05-19|2007-01-26|2007-01-29|Estimate|||||||2018-05-19|2018-05-22|Actual|March 6, 2003||2003-03-06|May 20, 2014|2014-05-20|May 20, 2014||2014-05-20|||||Observational|||Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies|Follow-Up Study of Breast Cancer and Multiple Myeloma Subjects Previously Enrolled in Retroviral Gene Transfer Studies|Completed|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:28:54.267469|2018-06-01 03:28:54.267469
NCT00427713|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2013-08-23|2007-01-25|2007-01-29|Estimate|||||||2013-08-23|2013-08-26|Estimate|November 2004||2004-11-30|June 2007|2007-06-30||||March 2008|Actual|2008-03-31||Interventional|||Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer|Chemotherapy or No Chemotherapy in Clear Margins After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. A Randomised Phase III Trial of Control Vs Capecitabine Plus Oxaliplatin [CHRONICLE]|Completed||Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:28:54.363042|2018-06-01 03:28:54.363042
NCT00427700|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|2014-11-21||2016-08-15|2007-01-26|2007-01-29|Estimate|2016-08-15|2016-10-06|Estimate||||2016-08-15|2016-10-06|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Age, body mass index (BMI), hormone levels, waist-hip ratio, degree os hirsutism by the Ferriman-Gallwey(FG) score, and fasting glycemia were compared between both groups. The FG represents hair growth in 11 parts in the body, ranging from 0 (no excessive terminal hair growth) to 4 (extensive terminal hair growth) adding up maximum count of 36.|Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome|Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome|Completed||Phase 3|82|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-06-01 03:28:54.938954|2018-06-01 03:28:54.938954
NCT00427687|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-08-01|2007-01-25|2007-01-29|Estimate|||||||2008-08-01|2008-08-05|Estimate|February 2007||2007-02-28|August 2008|2008-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Study Evaluating AGG-523 in Subjects With Osteoarthritis|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:28:55.245581|2018-06-01 03:28:55.245581
NCT00427674|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2010-10-05|2007-01-25|2007-01-29|Estimate|||||||2010-10-05|2010-10-06|Estimate|January 2007||2007-01-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients|Phase I Evaluation of (123-I)MZINT as a Brain SPECT Tracer of Serotonin Transporters in Healthy Human Subjects|Terminated||Phase 1|28|Actual|Institute for Neurodegenerative Disorders||1||Scan results to date did not show reason to continue with study|f||||t||||||||||2018-06-01 03:28:55.305149|2018-06-01 03:28:55.305149
NCT00427661|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2016-02-19||2016-07-08|2007-01-26|2007-01-29|Estimate|2016-07-08|2016-08-18|Estimate||||2016-07-08|2016-08-18|Estimate|June 2002||2002-06-30|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen|A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism|Completed||N/A|8|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:28:55.378715|2018-06-01 03:28:55.378715
NCT00427648|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2014-03-14|2007-01-26|2007-01-29|Estimate|||||||2014-03-14|2014-03-17|Estimate|March 2006||2006-03-31|March 2014|2014-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Local Anesthetic Treatments for Overactive Bladder|Intravesical Alkalized Lidocaine for the Treatment of Overactive Bladder (OAB), a Randomized, Double-blinded Controlled Trial|Terminated||Phase 3|22|Actual|NorthShore University HealthSystem Research Institute||2||Data collection complete; analysis to take place|f||||f||||||||||2018-06-01 03:28:55.56562|2018-06-01 03:28:55.56562
NCT00427635|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2010-04-19||2010-12-02|2007-01-25|2007-01-29|Estimate|2010-04-19|2010-05-19|Estimate||||2010-12-02|2010-12-20|Estimate|October 2006||2006-10-31|December 2010|2010-12-31|April 2009|Actual|2009-04-30|||||Interventional|||Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients|A Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of Esomeprazole Once Daily for the Treatment of Gastroesophageal Reflux Disease (GERD) in Neonatal Patients, Including Premature and up to 1 Month Corrected Age|Completed||Phase 3|32|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:28:55.761664|2018-06-01 03:28:55.761664
NCT00427622|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2014-04-07|2007-01-25|2007-01-29|Estimate|||||||2014-04-07|2014-04-09|Estimate|May 2006||2006-05-31|June 2007|2007-06-30||||June 2007|Actual|2007-06-30||Interventional|||Skin Conduction Device for Measuring Hot Flashes in Postmenopausal Women With Hot Flashes|A Trial to Examine the Accuracy of an Ambulatory Sternal Skin Conductance Recording Tool to Measure Hot Flashes|Completed||N/A|25|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 03:28:56.155545|2018-06-01 03:28:56.155545
NCT00427609|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2015-04-20|2007-01-26|2007-01-29|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications|Efficacy of Bicillin LA for the Treatment of Chronic, Plaque-type Psoriasis Unresponsive to Topical Medications.|Terminated||Phase 2|5|Actual|University of Tennessee||2||Not enough enrollees to obtain a valid conclusion|f||||f||||||||||2018-06-01 03:28:56.246015|2018-06-01 03:28:56.246015
NCT00427596|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-10-06|2007-01-25|2007-01-29|Estimate|||||||2008-10-06|2008-10-07|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Two-Part Study to Determine: Best Medication Formulation and Food Effect|A Two-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Four MR Formulations and Food Effect of GW427353 (Solabegron) in Healthy Adult Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:28:56.324498|2018-06-01 03:28:56.324498
NCT00427583|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2012-08-06|2007-01-26|2007-01-29|Estimate|||||||2012-08-06|2012-08-07|Estimate|May 2006||2006-05-31|August 2012|2012-08-31||||April 2009|Actual|2009-04-30||Interventional|||Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors|An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors|Terminated||Phase 2/Phase 3|11|Actual|Novartis||1||stopped due to slow recruitment and no effect|f||||||||||||||2018-06-01 03:28:56.382299|2018-06-01 03:28:56.382299
NCT00427570|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2013-06-21|2007-01-18|2007-01-29|Estimate|||||||2013-06-21|2013-06-24|Estimate|September 1977||1977-09-30|August 2010|2010-08-31|May 2006|Actual|2006-05-31|||||Interventional|||Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery|A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:28:56.465718|2018-06-01 03:28:56.465718
NCT00427557|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2012-04-19||2012-05-23|2007-01-25|2007-01-29|Estimate|2012-04-19|2012-05-17|Estimate||||2012-05-23|2012-05-28|Estimate|October 2006||2006-10-31|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Cellular Therapy With Cord Blood Cells|Use of Umbilical Cord Blood Cell in the Preparative Regimen of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|31|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:56.543515|2018-06-01 03:28:56.543515
NCT00427544|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-12-03|2007-01-26|2007-01-29|Estimate|||||||2007-12-03|2007-12-05|Estimate|February 2007||2007-02-28|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Women of Nonchildbearing Potential|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:28:56.774743|2018-06-01 03:28:56.774743
NCT00427531|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2011-03-16|2007-01-26|2007-01-29|Estimate|||||||2011-03-16|2011-03-17|Estimate|June 2006||2006-06-30|March 2011|2011-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Skin Conduction Device and Patient Diary for Measuring Hot Flashes in Postmenopausal Women With Hot Flashes|An Exploratory Trial to Examine the Accuracy of Various Hot Flash Variables With an Ambulatory Sternal Skin Conductance Recording Tool|Completed||N/A|3|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 03:28:56.832766|2018-06-01 03:28:56.832766
NCT00427505|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2009-11-18|2007-01-26|2007-01-29|Estimate|||||||2009-11-18|2009-11-19|Estimate|July 2006||2006-07-31|November 2009|2009-11-30||||||||Interventional|||Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam|An Open-label, One-sequence Cross-over Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam in Healthy Volunteers|Completed||Phase 1|22||Novartis|||||f||||||||||||||2018-06-01 03:28:57.053477|2018-06-01 03:28:57.053477
NCT00427492|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2009-02-10|2007-01-26|2007-01-29|Estimate|||||||2009-02-10|2009-02-11|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effect of Postoperative Laxative on Bowel Function After Colonic Surgery|Effect of Postoperative Laxative on Bowel Function After Colonic Surgery|Completed||Phase 4|56|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-06-01 03:28:57.107415|2018-06-01 03:28:57.107415
NCT00427479|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2007-01-26|2007-01-26|2007-01-29|Estimate|||||||2007-01-26|2007-01-29|Estimate|July 2002||2002-07-31|January 2007|2007-01-31|December 2003||2003-12-31|||||Observational|||Oral Allergy Syndrome (OAS): a Pilot Study to Evaluate a Clinical Questionnaire as a Diagnostic Tool|The Prevalence of Oral Allergy Syndrome and Types of Food Commonly Causing Reactions in Birch Pollen Sensitive Patients Who Have Springtime Hayfever|Completed|||40||Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 03:28:57.173448|2018-06-01 03:28:57.173448
NCT00427466|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2009-02-13|2007-01-26|2007-01-29|Estimate|||||||2009-02-13|2009-02-16|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pemetrexed in Patients With Soft Tissue Sarcoma|Multicenter Phase II Study With Pemetrexed in Patients With Pre-Treated Metastatic Soft Tissue Sarcomas|Completed||Phase 2|54|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 03:28:57.225363|2018-06-01 03:28:57.225363
NCT00427453|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-01-26|2007-01-26|2007-01-29|Estimate|||||||2007-01-26|2007-01-29|Estimate|June 2003||2003-06-30|December 2006|2006-12-31|March 2005||2005-03-31|||||Interventional|||A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously|Completed||Phase 1|12||University of Oxford|||||f||||||||||||||2018-06-01 03:28:57.289827|2018-06-01 03:28:57.289827
NCT00427440|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25||2015-04-06|2015-04-06|2007-01-25|2007-01-29|Estimate||||2015-04-06|2015-04-27|Estimate|2015-04-06|2015-04-27|Estimate|November 2006||2006-11-30|April 2015|2015-04-30|April 2013|Actual|2013-04-30|December 2008|Actual|2008-12-31||Interventional|||A Phase II Study to Treat Advanced Malignant Glioma|A Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Malignant Glioma|Completed||Phase 2|61|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:28:57.383989|2018-06-01 03:28:57.383989
NCT00427427|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2016-07-28|2007-01-26|2007-01-29|Estimate|||||||2016-07-28|2016-08-01|Estimate|January 2007||2007-01-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer|A Phase II Trial of Delayed Adjuvant Herceptin® in Patients With HER-2 Positive Breast Cancer|Terminated||Phase 2|75|Anticipated|Jonsson Comprehensive Cancer Center||||lack of accrual|f||||||||||||||2018-06-01 03:28:57.485245|2018-06-01 03:28:57.485245
NCT00427414|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2015-04-28|2007-01-25|2007-01-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma|Pilot Study of Viral Load and Transcription in Kaposi's Sarcoma Patients Treated With Liposomal Anthracyclines|Terminated||Phase 1|14|Actual|AIDS Malignancy Consortium||1||Terminated due to slow accrual.|f||||f||||||||||2018-06-01 03:28:57.551369|2018-06-01 03:28:57.551369
NCT00427401|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-09-25|2007-01-25|2007-01-29|Estimate|||||||2008-09-25|2008-09-29|Estimate|February 2007||2007-02-28|September 2008|2008-09-30|June 2007|Actual|2007-06-30|||||Interventional|||A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks|A Double Blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-00915275 After Oral Administration To Subjects With Type 2 Diabetes Mellitus For 4-Weeks|Terminated||Phase 2|40||Pfizer||||"This study was terminated May 7, 2007. The study stopped due to tablet formulation issues. No~   safety issues were involved in the termination decision."|f||||||||||||||2018-06-01 03:28:57.715168|2018-06-01 03:28:57.715168
NCT00427388|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2014-07-31|2007-01-26|2007-01-29|Estimate|||||||2014-07-31|2014-08-04|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Steroids In caRdiac Surgery Trial (SIRS Trial)|Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass|Unknown status|Active, not recruiting|Phase 4|7507|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 03:28:57.803721|2018-06-01 03:28:57.803721
NCT00427375|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2018-03-12|2007-01-26|2007-01-29|Estimate|||||||2018-03-12|2018-03-14|Actual|March 5, 2007|Actual|2007-03-05|March 2018|2018-03-31|February 8, 2018|Actual|2018-02-08|December 2014|Actual|2014-12-31||Interventional|GRECCAR 2||Local Excision in Downstaged Rectal Cancer|Phase III Randomized Trial of Local Excision Versus Total Mesorectal Excision in Downstaged T2T3 Low Rectal Cancer After Radiochemotherapy|Completed||Phase 3|148|Actual|University Hospital, Bordeaux||2|||f||||t||||||||No||2018-06-01 03:28:57.909272|2018-06-01 03:28:57.909272
NCT00427362|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2008-04-30|2007-01-26|2007-01-29|Estimate|||||||2008-04-30|2008-05-02|Estimate|May 2006||2006-05-31|April 2008|2008-04-30||||May 2007|Actual|2007-05-31||Interventional|||A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)|A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)|Completed||Phase 3|127|Actual|Abbott|||||f||||f||||||||||2018-06-01 03:28:58.044028|2018-06-01 03:28:58.044028
NCT00427349|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2015-05-19||2016-07-12|2007-01-25|2007-01-29|Estimate|2015-05-19|2015-06-04|Estimate||||2016-07-12|2016-08-12|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional||Per protocol, the primary population for all efficacy analysis is all eligible and treated patients|AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors|A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors|Completed||Phase 2|46|Actual|Eastern Cooperative Oncology Group||1|||f||||t||||||||||2018-06-01 03:28:58.169216|2018-06-01 03:28:58.169216
NCT00427336|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|2011-09-20||2011-09-20|2007-01-26|2007-01-29|Estimate|2011-09-20|2011-10-27|Estimate||||2011-09-20|2011-10-27|Estimate|December 2000||2000-12-31|September 2011|2011-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia|Purine Analog-Based Conditioning for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia|Completed||N/A|9|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:28:58.596927|2018-06-01 03:28:58.596927
NCT00427323|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2009-12-10|2007-01-25|2007-01-29|Estimate|||||||2009-12-10|2009-12-11|Estimate|June 2006||2006-06-30|September 2007|2007-09-30|September 2007|Anticipated|2007-09-30|September 2007|Anticipated|2007-09-30||Interventional|||Light Exposure to Treat Sleep Disruption in Older People|Disrupted Sleep in the Elderly: Light Exposure Studies|Suspended||N/A|60|Anticipated|National Institute on Aging (NIA)||||recruitment has been put on hold until a future date|f||||||||||||||2018-06-01 03:28:58.743032|2018-06-01 03:28:58.743032
NCT00427310|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2012-12-31|2007-01-18|2007-01-29|Estimate|||||||2012-12-31|2013-01-03|Estimate|March 1984||1984-03-31|December 2012|2012-12-31|February 2001|Actual|2001-02-28|September 1989|Actual|1989-09-30||Interventional|||Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery|A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon|Completed||Phase 3|1158|Actual|NSABP Foundation Inc||2|||f||||||||||||||2018-06-01 03:28:58.799631|2018-06-01 03:28:58.799631
NCT00427297|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2010-03-16|2007-01-26|2007-01-29|Estimate|||||||2010-03-16|2010-03-17|Estimate|September 2007||2007-09-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya|Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT)|Terminated||Phase 3|34|Actual|University of Washington||2||There is no longer equipoise.|f||||t||||||||||2018-06-01 03:28:59.002185|2018-06-01 03:28:59.002185
NCT00427271|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-26|||2007-01-26|2007-01-26|2007-01-29|Estimate|||||||2007-01-26|2007-01-29|Estimate|March 2003||2003-03-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients|Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study|Unknown status|Recruiting|Phase 4|20||Hospital de Clinicas de Porto Alegre|||||f||||||||||||||2018-06-01 03:28:59.141214|2018-06-01 03:28:59.141214
NCT00427258|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2011-07-22|2007-01-26|2007-01-29|Estimate|||||||2011-07-22|2011-07-25|Estimate|January 2010||2010-01-31|July 2011|2011-07-31||||||||Interventional|||Study Evaluating MOA-728 Administered in Healthy Men|An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]MOA-728 in Healthy Men|Withdrawn||Phase 1|6|Anticipated|Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:28:59.212645|2018-06-01 03:28:59.212645
NCT00427245|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2013-08-06|2007-01-25|2007-01-29|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2004||2004-08-31|May 2007|2007-05-31||||||||Interventional|||Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer|Ovarian Protection Trial In Premenopausal Breast Cancer Patients [OPTION]|Completed||Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:28:59.278487|2018-06-01 03:28:59.278487
NCT00427232|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-01-25|2007-01-25|2007-01-26|Estimate|||||||2007-01-25|2007-01-26|Estimate|May 2003||2003-05-31|January 2007|2007-01-31|August 2006||2006-08-31|||||Interventional|||Endothelin-Receptor Blockade in Coronary Heart Disease|Selective and Non-Selective Endothelin-Receptor Blockade in Coronary Artey Disease|Completed||Phase 1|26||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:28:59.503383|2018-06-01 03:28:59.503383
NCT00427219|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2012-06-06|2007-01-24|2007-01-26|Estimate|||||||2012-06-06|2012-06-08|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate|A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS)Due to Benign Prostatic Hypertrophy (BPH)|Completed||Phase 2/Phase 3|76|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||||||||||||2018-06-01 03:28:59.573036|2018-06-01 03:28:59.573036
NCT00427206|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2009-02-06|2007-01-25|2007-01-26|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing|Hepatic Function Following Five Days of Therapeutic Dosing of Acetaminophen in Alcoholics|Completed||Phase 4|181|Actual|Denver Health and Hospital Authority||2|||f||||t||||||||||2018-06-01 03:28:59.658239|2018-06-01 03:28:59.658239
NCT00427193|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2015-03-25|2007-01-25|2007-01-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy|Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy (CALERIE)|Completed||N/A|238|Actual|Duke University||2|||f||||t||||||||||2018-06-01 03:28:59.732294|2018-06-01 03:28:59.732294
NCT00427180|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2010-03-02|2007-01-25|2007-01-26|Estimate|||||||2010-03-02|2010-03-03|Estimate|December 2006||2006-12-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||IRIS PILOT - Extended Pilot Study With a Retinal Implant System|Extended Pilot Study to Evaluate Pattern Recognition With a Chronic Retinal Implant System|Unknown status|Active, not recruiting|N/A|20|Anticipated|Intelligent Medical Implants GmbH|||||f||||f||||||||||2018-06-01 03:28:59.817346|2018-06-01 03:28:59.817346
NCT00427167|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2017-06-30|2007-01-25|2007-01-26|Estimate|||||||2017-06-30|2017-07-02|Actual|January 23, 2007||2007-01-23|August 3, 2009|2009-08-03|November 5, 2008|Actual|2008-11-05|November 5, 2008|Actual|2008-11-05||Interventional|||Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine|Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria|Completed||Phase 1|300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:28:59.888535|2018-06-01 03:28:59.888535
NCT00427154|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2017-02-28|2007-01-25|2007-01-26|Estimate|||||||2017-02-28|2017-03-01|Actual|January 10, 2007|Actual|2007-01-10|February 2017|2017-02-28|March 11, 2008|Actual|2008-03-11|March 11, 2008|Actual|2008-03-11||Interventional|||Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes|Effect of Inhaled Pre-Prandial Human Insulin Plus Metformin & Glimepiride Versus Rosiglitazone Plus Metformin & Glimepiride on HbA1c in Subjects With Type 2 Diabetes|Terminated||Phase 3|227|Actual|Novo Nordisk A/S||2||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:28:59.979476|2018-06-01 03:28:59.979476
NCT00427141|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2012-05-31|2007-01-24|2007-01-26|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2006||2006-10-31|February 2011|2011-02-28||||||||Interventional|||A Three-Part Study Of GSK580416 In Healthy Subjects|A Three-part First Time in Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Food Effect of Single Oral Doses of GSK580416 in Healthy Adult Subjects|Completed||Phase 1|48|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:29:00.189599|2018-06-01 03:29:00.189599
NCT00427128|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2011-12-14|2007-01-25|2007-01-26|Estimate|||||||2011-12-14|2011-12-15|Estimate|November 1995||1995-11-30|December 2011|2011-12-31|March 2003|Actual|2003-03-31|||||Interventional|||Prozac Treatment of Major Depression: Discontinuation Study|Prozac Treatment of Major Depression: Discontinuation Study|Completed||Phase 4|627|Actual|New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 03:29:00.242571|2018-06-01 03:29:00.242571
NCT00427115|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-05-20|2007-01-25|2007-01-26|Estimate|||||||2008-05-20|2008-05-21|Estimate|August 2005||2005-08-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Multimodal Intervention in Allogeneic Stem Cell Transplantation|Pilot Study of an Exercise an Psycho-Educational Intervention During Allogeneic Stem Cell Transplantation|Completed||Phase 3|42|Actual|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:29:00.310866|2018-06-01 03:29:00.310866
NCT00427102|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2012-11-13|2007-01-25|2007-01-26|Estimate|||||||2012-11-13|2012-11-14|Estimate|January 2007||2007-01-31|November 2012|2012-11-30|July 2007|Actual|2007-07-31|||||Interventional|||MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck|A Phase 1 Study of Oral MRX-1024 in Combination With Standard Fractionation Radiation Therapy and High-Dose Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Following Surgical Resection|Terminated||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||No subjects enrolled and PI went to another facility|f||||||||||||||2018-06-01 03:29:00.355909|2018-06-01 03:29:00.355909
NCT00427089|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2008-04-15|2007-01-25|2007-01-26|Estimate|||||||2008-04-15|2008-04-16|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|May 2005||2005-05-31|||||Interventional|||Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening|Parallel Group Comparison of the New 2 Liter Gut Cleansing Solution NRL 994 Versus Sodium Phosphate Preparation in Routine Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening.|Completed||Phase 3|360|Actual|Norgine||2|||f||||f||||||||||2018-06-01 03:29:00.41265|2018-06-01 03:29:00.41265
NCT00427076|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2015-09-23|2007-01-25|2007-01-26|Estimate|||||||2015-09-23|2015-09-25|Estimate|June 2007||2007-06-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections|Treatment With Cotrimoxazole vs. Vancomycin for Infections Caused by Methicillin-resistant Staphylococcus Aureus: Randomized Controlled Trial|Completed||Phase 3|252|Actual|Rabin Medical Center||2|||f||||t||||||||||2018-06-01 03:29:00.487842|2018-06-01 03:29:00.487842
NCT00427063|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-01-25|2007-01-25|2007-01-26|Estimate|||||||2007-01-25|2007-01-26|Estimate|January 1998||1998-01-31|January 2007|2007-01-31|December 1998||1998-12-31|||||Observational|||Heredity of Retinal Vessel Tortuosity|Heredity of Retinal Vessel Tortuosity - A Twin Study|Completed|||218||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 03:29:00.563638|2018-06-01 03:29:00.563638
NCT00427050|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2015-09-11|2007-01-24|2007-01-26|Estimate|||||||2015-09-11|2015-09-14|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel|An Open-label, Multi-centre, Dose-escalation, Cohort Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel When Applied to a 25 cm2 Contiguous Actinic Keratoses Treatment Area on the Face or Face and Scalp.|Completed||Phase 2|50|Anticipated|Peplin|||||f||||||||||||||2018-06-01 03:29:00.606412|2018-06-01 03:29:00.606412
NCT00427037|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|2009-01-14||2015-07-20|2007-01-25|2007-01-26|Estimate|2009-02-11|2009-03-12|Estimate||||2015-07-20|2015-07-22|Estimate|December 2005||2005-12-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|July 2006|Actual|2006-07-31||Interventional|||Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects|Efficacy of Cholecalciferol (Vitamin D3) Therapy in Correcting Vitamin D Insufficiency and Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease: A Randomized, Placebo Controlled Pilot Study|Completed||N/A|34|Actual|Atlanta VA Medical Center||2|||f||||f||||||||||2018-06-01 03:29:00.68504|2018-06-01 03:29:00.68504
NCT00427024|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-25|||2007-02-05|2007-01-25|2007-01-26|Estimate|||||||2007-02-05|2007-02-06|Estimate|February 2007||2007-02-28|February 2007|2007-02-28|February 2009||2009-02-28|||||Observational|||Renal Transporters After Renal Transplantation|Study of Renal Transporters and Their Regulators After Renal Transplantation|Unknown status|Not yet recruiting||200||University Hospital Muenster|||||f||||||||||||||2018-06-01 03:29:00.865764|2018-06-01 03:29:00.865764
NCT00427011|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|2012-11-20|2012-08-23|2013-02-05|2007-01-25|2007-01-26|Estimate|2013-01-02|2013-02-05|Estimate|2012-08-23|2012-08-30|Estimate|2013-02-05|2013-02-11|Estimate|February 2007||2007-02-28|February 2013|2013-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of E2007 In Patients With Parkinson's Disease|"A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing-Off Motor Fluctuations"|Terminated||Phase 2|25|Actual|Eisai Inc.|Due to early termination, a limited number of subjects (n=26) were screened for inclusion in the study and only 25 subjects were analyzed. The majority of subjects did not reach the scheduled Week 56 assessment.|1||Study stopped due to lack of efficacy.|f||||||||||||||2018-06-01 03:29:01.052618|2018-06-01 03:29:01.052618
NCT00426998|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2007-01-25|2007-01-25|2007-01-26|Estimate|||||||2007-01-25|2007-01-26|Estimate|April 2006||2006-04-30|January 2007|2007-01-31||||||||Interventional|||Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD|A 24 Month Randomized, Double-Masked, Single Center, Phase II Study Comparing Photodynamic Therapy With Verteporfin (Visudyne)Plus Two Different Timing Regimens of Intravitreal Bevacizumab (Avastin) Given 1 Week Prior to or 1 Week Following Photodynamic Therapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.|Completed||Phase 2|30||Retinal Consultants Medical Group|||||f||||||||||||||2018-06-01 03:29:01.293069|2018-06-01 03:29:01.293069
NCT00426985|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2008-08-13|2007-01-24|2007-01-26|Estimate|||||||2008-08-13|2008-08-14|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|October 2008|Anticipated|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee|Terminated||Phase 3|330|Anticipated|Endo Pharmaceuticals||||Sufficient number of subjects accrued to conduct analysis|f||||||||||||||2018-06-01 03:29:01.35191|2018-06-01 03:29:01.35191
NCT00426972|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2009-08-27|2007-01-24|2007-01-25|Estimate|||||||2009-08-27|2009-08-28|Estimate|January 2007||2007-01-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites|A Double Blind, Placebo Controlled Trial to Investigate the Efficacy of Zesteem (Estradiol) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites.|Completed||Phase 3|148|Anticipated|Renovo|||||f||||f||||||||||2018-06-01 03:29:01.426438|2018-06-01 03:29:01.426438
NCT00426959|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2012-11-13|2007-01-24|2007-01-25|Estimate|||||||2012-11-13|2012-11-14|Estimate|February 2005||2005-02-28|November 2012|2012-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy|Feasibility Study of Image-guided, Dynamic Dosimetry for Permanent Interstitial Prostate Brachytherapy|Completed||Phase 1|6|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:29:01.595916|2018-06-01 03:29:01.595916
NCT00426946|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2007-01-24|2007-01-24|2007-01-25|Estimate|||||||2007-01-24|2007-01-25|Estimate|January 2005||2005-01-31|September 2004|2004-09-30||||||||Interventional|||Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study|Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study|Unknown status|Recruiting|Phase 4|60||Geha Mental Health Center|||||f||||||||||||||2018-06-01 03:29:01.677275|2018-06-01 03:29:01.677275
NCT00426933|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2010-09-13|2007-01-24|2007-01-25|Estimate|||||||2010-09-13|2010-09-14|Estimate|January 2007||2007-01-31|September 2010|2010-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections|Phase 2 Multicenter Randomized Semi-Single Blind Study to Compare Efficacy and Safety of High-dose Short Duration Daptomycin With Conventional Therapy in Complicated Skin and Skin Structure Infections Due to Gram-positive Bacteria|Completed||Phase 2|100|Actual|Cubist Pharmaceuticals LLC|||||f||||f||||||||||2018-06-01 03:29:01.752878|2018-06-01 03:29:01.752878
NCT00426920|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2007-01-24|2007-01-24|2007-01-25|Estimate|||||||2007-01-24|2007-01-25|Estimate|February 2007||2007-02-28|January 2007|2007-01-31||||||||Interventional|||Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler|Evaluation of the Pharmacokinetics and Pharmacodynamics of Spray-Dried Recombinant Human Insulin Powder for Inhalation Administered Via a Dry Powder Inhalation Device Relative to SC Recombinant Human Insulin in Healthy Male Volunteers|Unknown status|Not yet recruiting|Phase 1|14||QDose Limited|||||f||||||||||||||2018-06-01 03:29:01.830828|2018-06-01 03:29:01.830828
NCT00426907|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2015-04-09|2007-01-23|2007-01-25|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Weightbearing After High Tibial Osteotomy|Weightbearing After Proximal Open-wedge Tibial Osteotomy - a Clinical, Randomized RSA-study.|Completed||Phase 4|20|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-06-01 03:29:01.959196|2018-06-01 03:29:01.959196
NCT00426894|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2007-01-24|2007-01-24|2007-01-25|Estimate|||||||2007-01-24|2007-01-25|Estimate|January 2007||2007-01-31|January 2007|2007-01-31||||||||Interventional|||Microbial Surveillance in Children Hospitalized for Cardiovascular Surgery|Longitudinal Microbial Surveillance in Children Hospitalized for Cardiac Surgery Before the Operation and During Hospitalization|Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:29:02.067849|2018-06-01 03:29:02.067849
NCT00426881|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2017-10-02|2007-01-24|2007-01-25|Estimate|||||||2017-10-02|2017-10-04|Actual|January 2007||2007-01-31|October 2017|2017-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Brain Power: Resistance Training and Cognitive Function|The Effect of Resistance Training on Cognitive Performance, Cortical Plasticity, and Fall Risk in Women Aged 65-75 Years Old: A 12-Month RCT|Completed||N/A|155|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 03:29:02.147829|2018-06-01 03:29:02.147829
NCT00426868|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2013-08-27|2007-01-24|2007-01-25|Estimate|||||||2013-08-27|2013-08-28|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Randomized Clinical Trial of Adipose-derived Stem Cells in Treatment of Non Revascularizable Ischemic Myocardium|A Randomized Clinical Trial of adiPose-deRived stEm & Regenerative Cells In the Treatment of Patients With Non revaScularizable ischEmic Myocardium - The PRECISE Trial|Completed||Phase 1|27|Actual|Cytori Therapeutics||2|||f||||t||||||||||2018-06-01 03:29:02.242761|2018-06-01 03:29:02.242761
NCT00426855|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|2011-06-27||2015-04-02|2007-01-24|2007-01-25|Estimate|2015-04-02|2015-04-03|Estimate||||2015-04-02|2015-04-03|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)|Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study|Completed||Phase 1/Phase 2|12|Actual|Kantonsspital Aarau||1|||f||||f||||||||||2018-06-01 03:29:02.332446|2018-06-01 03:29:02.332446
NCT00426842|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|2013-09-17||2016-08-29|2007-01-24|2007-01-25|Estimate|2015-05-08|2015-05-12|Estimate||||2016-08-29|2016-10-10|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride|A Dose Response Trial Using 5 and 10 mg. of Midodrine Hydrochloride to Treat Orthostatic Hypotension in Persons With SCI|Completed||Phase 2|11|Actual|James J. Peters Veterans Affairs Medical Center|A matching placebo tablet was not used and the order of testing was not randomized. The total number of subjects recruited was relatively small and extrapolation to a broader group of individuals with chronic SCI may not be appropriate.|1|||f||||f||||||||||2018-06-01 03:29:02.521292|2018-06-01 03:29:02.521292
NCT00426829|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2012-07-31|2007-01-24|2007-01-25|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2007||2007-05-31|July 2012|2012-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Proton Therapy and Bevacizumab for Primary Liver Tumors|Phase I Study of Proton Radiotherapy and Bevacizumab for Primary Liver Tumors|Terminated||Phase 1|3|Actual|M.D. Anderson Cancer Center||1||Low Accural|f||||f||||||||||2018-06-01 03:29:02.708013|2018-06-01 03:29:02.708013
NCT00426816|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2012-08-09|2007-01-23|2007-01-25|Estimate|||||||2012-08-09|2012-08-13|Estimate|December 2006||2006-12-31|August 2012|2012-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia|A Multi-centre, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of SB-649868 (10, 30 mg and 60 mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects With Primary Insomnia|Completed||Phase 2|48|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:29:02.798226|2018-06-01 03:29:02.798226
NCT00426803|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2017-01-17|2007-01-24|2007-01-25|Estimate|||||||2017-01-17|2017-01-18|Estimate|August 2002||2002-08-31|January 2017|2017-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Recombinant Factor VIIa in Acute Intracerebral Haemorrhage|Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Parallel Groups, Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (NovoSeven®) in Acute Intracerebral Haemorrhage|Completed||Phase 2|400|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:29:02.915864|2018-06-01 03:29:02.915864
NCT00426790|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2007-01-24|2007-01-24|2007-01-25|Estimate|||||||2007-01-24|2007-01-25|Estimate||||January 2007|2007-01-31||||||||Interventional|||Open Lung Approach During General Anaesthesia to Prevent Post-Operative Pulmonary Complications||Unknown status|Recruiting|N/A|||Università degli Studi dell'Insubria|||||f||||||||||||||2018-06-01 03:29:02.991024|2018-06-01 03:29:02.991024
NCT00426777|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2012-02-02|2007-01-24|2007-01-25|Estimate|||||||2012-02-02|2012-02-03|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer|A Randomized, Single-blind, Placebo-controlled, Multicentre Study to Evaluate the Effect of Risedronate and Placebo on Bone Mineral Density in Men Undergoing Androgen Deprivation Therapy With Leuprolide Acetate|Completed||Phase 3|160|Actual|CMX Research||2|||f||||f||||||||||2018-06-01 03:29:03.080022|2018-06-01 03:29:03.080022
NCT00426764|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|2012-07-05||2018-04-06|2007-01-23|2007-01-25|Estimate|2012-07-05|2012-08-13|Estimate||||2018-04-06|2018-05-02|Actual|June 21, 2007|Actual|2007-06-21|April 2018|2018-04-30|May 17, 2018|Anticipated|2018-05-17|November 11, 2010|Actual|2010-11-11||Interventional|||A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma|A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)|Active, not recruiting||Phase 2|131|Actual|Celgene||1|||f||||t||||||||||2018-06-01 03:29:03.388639|2018-06-01 03:29:03.388639
NCT00426751|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|2010-04-06||2012-11-21|2007-01-24|2007-01-25|Estimate|2010-04-06|2010-04-26|Estimate||||2012-11-21|2012-11-27|Estimate|October 2006||2006-10-31|November 2012|2012-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)|Eptifibatide Versus Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction|Completed||Phase 3|429|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:29:03.990871|2018-06-01 03:29:03.990871
NCT00426725|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2008-07-30|2007-01-23|2007-01-25|Estimate|||||||2008-07-30|2008-08-01|Estimate|February 2007||2007-02-28|July 2008|2008-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Testing the Efficiency of a Device Meant to Relieve Labour Pain|Protocol for Testing the Efficiency of a Device Meant to Relieve Labour Pain|Completed||N/A|64|Actual|ACU Medical Technologies Ltd||2|||f||||f||||||||||2018-06-01 03:29:05.579584|2018-06-01 03:29:05.579584
NCT00426712|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2018-02-27|2007-01-24|2007-01-25|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2006||2006-01-31|February 2018|2018-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients|A Phase 1, Randomized, Observer-blind, Dose-escalating Study in Adult End-stage Renal Failure Patients to Explore the Safety, Tolerability, Pharmacokinetics and Immune Response to Recombinant Hepatitis B Virus Surface Antigen (rHBsAg) Co-administered With Dynavax Immunostimulatory Phosphorothioate Oligodeoxyribonucleotide (1018 ISS)|Completed||Phase 1|42|Actual|Dynavax Technologies Corporation||4|||f||||t||||||||Undecided|3/2017 No change to status of this study|2018-06-01 03:29:05.646083|2018-06-01 03:29:05.646083
NCT00426699|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2011-05-18|2007-01-24|2007-01-25|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Urinary Excretion of Enteroviruses From Children With a Presumed Enteroviral Infection||Completed|||82|Actual|University Hospital Inselspital, Berne|||||f||||||||||||||2018-06-01 03:29:05.727648|2018-06-01 03:29:05.727648
NCT00426686|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2012-12-11|2007-01-24|2007-01-25|Estimate|||||||2012-12-11|2012-12-12|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|April 2011|Actual|2011-04-30|March 2009|Actual|2009-03-31||Observational|ADAMTS13||ADAMTS13 in Thrombotic Thrombocytopenic Purpura|ADAMTS13-related Prognostic Factors in Adult and Pediatric Thrombotic Thrombocytopenic Purpura|Completed|||153|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     March 2010~   "|||2018-06-01 03:29:05.798465|2018-06-01 03:29:05.798465
NCT00426673|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2008-03-07|2007-01-23|2007-01-25|Estimate|||||||2008-03-07|2008-03-10|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.|A Multi-Center, Open-Label, Unilateral Interaction Study of Ucb 34714 on Stable Phenytoin Monotherapy During a 45 Day b.i.d. Administration Period in 15 Adult Subjects Suffering From Epilepsy|Completed||Phase 1|15||UCB Pharma|||||f||||||||||||||2018-06-01 03:29:05.993|2018-06-01 03:29:05.993
NCT00426660|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2011-06-02||2016-05-23|2007-01-23|2007-01-25|Estimate|2011-09-12|2011-10-17|Estimate||||2016-05-23|2016-06-29|Estimate|February 2007||2007-02-28|May 2016|2016-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Expanded Access Program for Maraviroc At Multiple Centers|A Multicenter, Open Label, Expanded Access Trial Of Maraviroc|Completed||Phase 3|1047|Actual|ViiV Healthcare|Viral loads were not available for subjects uniformly as this expanded access study followed local country guidelines and practices that could vary significantly between countries, and testing frequency may have been affected by insurance status.|1|||f||||t||||||||||2018-06-01 03:29:06.292086|2018-06-01 03:29:06.292086
NCT00426647|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2010-01-29|2007-01-24|2007-01-25|Estimate|||||||2010-01-29|2010-02-01|Estimate|February 2007||2007-02-28|January 2010|2010-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar Spine|A Randomised Double-blind Multicentre Equivalence Study With Active Parallel Comparator Group to Evaluate the Efficacy and Safety of Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip, Knee &/or Lumbar Spine.|Completed||Phase 4|120|Anticipated|Norpharma A/S||2|||f||||f||||||||||2018-06-01 03:29:08.583639|2018-06-01 03:29:08.583639
NCT00426634|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2018-05-22|2007-01-24|2007-01-25|Estimate|||||||2018-05-22|2018-05-23|Actual|January 19, 2007||2007-01-19|August 30, 2016|2016-08-30|August 30, 2016||2016-08-30|||||Observational|||Children With Asthma in New Orleans After Hurricane Katrina|Head-Off Environmental Asthma in Louisiana|Completed|||200|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:29:08.654126|2018-06-01 03:29:08.654126
NCT00426621|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2007-12-13|2007-01-24|2007-01-25|Estimate|||||||2007-12-13|2007-12-18|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis|A 12-Week, Randomized, Double-Blind, Multi-Center, Vehicle-Controlled, Parallel Group Study to Assess the Efficacy and Safety of the Diclofenac Sodium Gel 1% for the Relief of Signs and Symptoms in Patients With Osteoarthritis of the Knee.|Completed||Phase 3|420|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:29:08.728529|2018-06-01 03:29:08.728529
NCT00426608|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2017-09-07|2007-01-23|2007-01-25|Estimate|||||||2017-09-07|2017-09-11|Actual|October 6, 2006|Actual|2006-10-06|September 2017|2017-09-30|January 8, 2007|Actual|2007-01-08|January 8, 2007|Actual|2007-01-08||Interventional|||To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.|Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover Study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone With a Single Dose of GSK561679 or Alprazolam in Healthy Volunteers|Completed||Phase 1|20|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 03:29:08.868858|2018-06-01 03:29:08.868858
NCT00426595|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2009-04-09|2007-01-24|2007-01-25|Estimate|||||||2009-04-09|2009-04-10|Estimate|April 2007||2007-04-30|April 2009|2009-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation|Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation|Completed||Phase 2|14|Anticipated|University Hospital, Ghent|||||f||||||||||||||2018-06-01 03:29:09.031655|2018-06-01 03:29:09.031655
NCT00426582|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-24|||2011-03-24|2007-01-24|2007-01-25|Estimate|||||||2011-03-24|2011-03-25|Estimate|August 2006||2006-08-31|March 2011|2011-03-31||||August 2010|Actual|2010-08-31||Interventional|||Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors|A Phase Ib, Multicenter, Open-label, Dose-finding Study of Patupilone Administered Intravenously Every 3 Weeks in Combination With Carboplatin AUC 6 in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|48|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:29:09.093743|2018-06-01 03:29:09.093743
NCT00426569|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2015-05-22|2007-01-23|2007-01-24|Estimate|||||||2015-05-22|2015-05-25|Estimate|February 2007||2007-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|||Normal Paranasal Sinuses Microflora Study||Completed|||18|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:29:09.166351|2018-06-01 03:29:09.166351
NCT00426556|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|2015-03-20||2015-11-24|2007-01-23|2007-01-24|Estimate|2015-03-20|2015-03-31|Estimate||||2015-11-24|2015-12-28|Estimate|July 2007||2007-07-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||The Full Analysis Set (FAS) consisted of all patients who received a least one dose of any one compound of the study treatment. Patients were analyzed according to the everolimus dose level to which they enrolled.|Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer|A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer|Completed||Phase 1|88|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:29:09.345151|2018-06-01 03:29:09.345151
NCT00426543|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2017-03-11|2007-01-23|2007-01-24|Estimate|||||||2017-03-11|2017-03-14|Actual|January 2007||2007-01-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome|Phase 1 Study of B-cell Depletion With Rituximab on Oral, Ocular and General Disease Manifestations in Patients With Primary Sjögren's Syndrome|Completed||Phase 2|21|Actual|University of Copenhagen|||||f||||t||||||||||2018-06-01 03:29:10.745553|2018-06-01 03:29:10.745553
NCT00426530|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2016-04-20|2007-01-23|2007-01-24|Estimate|||||||2016-04-20|2016-04-21|Estimate|February 2007||2007-02-28|April 2016|2016-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer|A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-overexpressing Metastatic Breast Cancer|Completed||Phase 1|50|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:29:10.818087|2018-06-01 03:29:10.818087
NCT00426517|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2018-03-27|2007-01-23|2007-01-24|Estimate|||||||2018-03-27|2018-03-29|Actual|January 19, 2007||2007-01-19|January 30, 2018|2018-01-30|December 1, 2023|Anticipated|2023-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Donor Stem Cell Transplantation for Congenital Immunodeficiencies|Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients With Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning With Campath- 1H or h-ATG, Radiation, and Sirolimus|Recruiting||Early Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 03:29:10.897064|2018-06-01 03:29:10.897064
NCT00426504|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2013-06-04|2007-01-23|2007-01-24|Estimate|||||||2013-06-04|2013-06-05|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Radiation Therapy Using Helical Tomotherapy IMRT for Head and Neck Cancer|Helical Tomotherapy Intensity Modulated Radiotherapy:A Phase I/II Pilot Study to Determine the Toxicity Profile, Pattern of Failures and Quality of Life of Patients With Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1/Phase 2|89|Actual|Ottawa Hospital Research Institute||1|||f||||||||||||||2018-06-01 03:29:10.978102|2018-06-01 03:29:10.978102
NCT00426491|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2008-02-01|2007-01-22|2007-01-24|Estimate|||||||2008-02-01|2008-02-08|Estimate|March 1999||1999-03-31|February 2008|2008-02-29|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Misoprostol for Non-Viable Pregnancies|Misoprostol for the Medical Management of Non-Viable First Trimester Pregnancies|Completed||Phase 3|30|Actual|Madigan Army Medical Center||2|||f||||f||||||||||2018-06-01 03:29:11.044983|2018-06-01 03:29:11.044983
NCT00426478|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2008-08-20|2007-01-23|2007-01-24|Estimate|||||||2008-08-20|2008-08-22|Estimate|November 2006||2006-11-30|August 2008|2008-08-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients|The Comparison of the Antihypertensive Efficacy and Tolerability Between Valsartan Plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5mg in the Essential Hypertensive Patients|Completed||Phase 4|80|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:29:11.112613|2018-06-01 03:29:11.112613
NCT00426465|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2018-05-18|2007-01-23|2007-01-24|Estimate|||||||2018-05-18|2018-05-21|Actual|January 17, 2007||2007-01-17|December 16, 2013|2013-12-16|December 16, 2013||2013-12-16|||||Observational|||Spaced Versus Massed Skill Learning|Neural Substrates of Lasting Motor Skill Learning by Spacing Effect|Completed|||213|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:29:11.222869|2018-06-01 03:29:11.222869
NCT00426452|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2009-11-18|2007-01-23|2007-01-24|Estimate|||||||2009-11-18|2009-11-19|Estimate|July 2006||2006-07-31|November 2009|2009-11-30||||||||Interventional|||A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers|A Phase IB, Open Label, Single Center, Drug-drug Interaction Study of Oral 1250 mg of PTK787/ZK 222584 Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor (Omeprazole) in Healthy Sterile or Postmenopausal Female Volunteers|Completed||Phase 1|24||Novartis|||||f||||||||||||||2018-06-01 03:29:11.27933|2018-06-01 03:29:11.27933
NCT00426439|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2011-01-02|2007-01-23|2007-01-24|Estimate|||||||2011-01-02|2011-01-04|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau|Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau.|Completed||Phase 4|300|Anticipated|Bandim Health Project||2|||f||||t||||||||||2018-06-01 03:29:11.342537|2018-06-01 03:29:11.342537
NCT00426426|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2017-06-27|2007-01-23|2007-01-24|Estimate|||||||2017-06-27|2017-06-28|Actual|January 2007|Actual|2007-01-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparing Cognitive Behaviour Therapy (CBT) With Metacognitive Therapy (MCT) in the Treatment of GAD|A Randomised Controlled Trial Comparing the Effectiveness of Cognitive Behaviour Therapy (CBT) With Metacognitive Therapy (MCT) in the Treatment of Patients With Generalised Anxiety Disorder (GAD)|Completed||N/A|68|Actual|Norwegian University of Science and Technology||3|||f||||f|f|f||||||||2018-06-01 03:29:11.414688|2018-06-01 03:29:11.414688
NCT00426413|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2013-11-12|2007-01-23|2007-01-24|Estimate|||||||2013-11-12|2013-11-13|Estimate|May 2007||2007-05-31|November 2013|2013-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Ketosis Prone Diabetes in African-Americans|Ketosis Prone Diabetes Mellitus in African-Americans: Insulin Signaling, Proteomics, and Outcomes|Completed|||44|Anticipated|Emory University|||3||f||||t||||||Samples With DNA|"~     The study has IRB approval for blood sample collection for future DNA analyses and HLA~     typing.~   "|||2018-06-01 03:29:11.559209|2018-06-01 03:29:11.559209
NCT00426400|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2007-01-23|2007-01-23|2007-01-24|Estimate|||||||2007-01-23|2007-01-24|Estimate|March 2006||2006-03-31|January 2007|2007-01-31||||||||Interventional|||Anti-Aggregative Therapy and Laser Iridectomy||Unknown status|Recruiting|Phase 4|||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:29:11.639333|2018-06-01 03:29:11.639333
NCT00426374|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-01-31|2007-01-23|2007-01-24|Estimate|||||||2007-01-31|2007-02-01|Estimate|January 2007||2007-01-31|January 2007|2007-01-31||||||||Interventional|||Assessment of Asymptomatic Heart Disease in Children With HIV|Evaluation of the Cardiac Complications in Congenitally HIV-1 Infected Children in Israel by the Echocardiography and Measurement of N-Terminal Pro-B-Type Natriuretic Peptide (N-BNP).|Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:29:11.706692|2018-06-01 03:29:11.706692
NCT00426179|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-11-16|2007-01-23|2007-01-24|Estimate|||||||2007-11-16|2007-11-19|Estimate|December 2006||2006-12-31|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Effects of Imatinib in Subjects With Seasonal Allergic Rhinitis and Who Are Sensitive to Timothy Grass Pollen|An Exploratory Study of the Effects of Imatinib on Allergic Inflammation Following Out of Allergy Season Repeated Nasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis Sensitive to Timothy Grass Pollen - an Exploratory Study of c-Kit Inhibition in Allergic Respiratory Diseases|Completed||Phase 1/Phase 2|30|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:29:14.458387|2018-06-01 03:29:14.458387
NCT00426361|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|2009-11-12|2009-08-20|2017-04-20|2007-01-23|2007-01-24|Estimate|2010-07-30|2010-08-23|Estimate|2009-08-20|2009-08-21|Estimate|2017-04-20|2017-05-17|Actual|February 13, 2007||2007-02-13|April 2017|2017-04-30|July 25, 2008|Actual|2008-07-25|March 17, 2008|Actual|2008-03-17||Interventional|||Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects|A Multicentre Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) Co-administered With Boostrix Polio (dTpa-IPV) in Healthy Female Subjects Aged 10-18 Years|Completed||Phase 3|751|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:29:11.818151|2018-06-01 03:29:11.818151
NCT00426348|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2013-08-27|2007-01-23|2007-01-24|Estimate|||||||2013-08-27|2013-08-28|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy|A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy|Completed||Phase 4|75|Actual|Guangdong General Hospital||2|||f||||t||||||||||2018-06-01 03:29:12.480939|2018-06-01 03:29:12.480939
NCT00426335|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2010-01-12|2007-01-23|2007-01-24|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2007||2007-01-31|January 2010|2010-01-31||||||||Observational|||Evaluation of Group CBT Programme With Breast Cancer Patients|An Evaluation of a Group CBT Programme for Women With Primary Breast Cancer.|Unknown status|Recruiting||78|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 03:29:12.552197|2018-06-01 03:29:12.552197
NCT00426322|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2013-09-09|2007-01-23|2007-01-24|Estimate|||||||2013-09-09|2013-09-10|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy of Sinus Floor Augmentation Using Large or Small Bovine Bone Mineral.|Efficacy of Sinus Floor Augmentation Using Large (1-2mm) or Small (0.25-1mm) Bovine Bone Mineral Particles (Bio-Oss®): A Comparative Histomorphometric Clinical Study|Completed||N/A|10|Actual|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 03:29:12.620467|2018-06-01 03:29:12.620467
NCT00426296|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-10-30|2007-01-23|2007-01-24|Estimate|||||||2007-10-30|2007-11-01|Estimate|August 2006||2006-08-31|October 2007|2007-10-31||||||||Interventional|||SHARE: Simple HAART With Abacavir, Reyataz, and Epivir|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks|Unknown status|Recruiting|Phase 4|||Clinical Alliance for Research & Education - Infectious Diseases, LLC.|||||f||||||||||||||2018-06-01 03:29:12.687254|2018-06-01 03:29:12.687254
NCT00426283|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2013-12-16||2014-09-10|2007-01-22|2007-01-24|Estimate|2013-12-16|2014-02-03|Estimate||||2014-09-10|2014-09-19|Estimate|January 2007||2007-01-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||A Study of Flovent in Patients With Eosinophilic Esophagitis|A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis|Completed||Phase 2|42|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 03:29:12.76723|2018-06-01 03:29:12.76723
NCT00426270|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2014-04-07||2014-07-28|2007-01-22|2007-01-24|Estimate|2014-04-07|2014-05-08|Estimate||||2014-07-28|2014-08-01|Estimate|June 2006||2006-06-30|July 2014|2014-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Safety population: All participants who received at least 1 dose of study medication.|Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults|Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults|Completed||Phase 3|116|Actual|Octapharma||1|||f||||t||||||||||2018-06-01 03:29:13.168356|2018-06-01 03:29:13.168356
NCT00426257|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2017-08-18|2007-01-23|2007-01-24|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2007||2007-02-28|August 2017|2017-08-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer|Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy|Completed||Phase 3|242|Actual|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-06-01 03:29:13.35938|2018-06-01 03:29:13.35938
NCT00426244|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2015-04-19|2007-01-22|2007-01-24|Estimate|||||||2015-04-19|2015-04-21|Estimate|April 2006||2006-04-30|April 2015|2015-04-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects|Osteopathic Manipulative Medicine in Pregnancy: Physiologic and Clinical Effects|Completed||Phase 2|400|Actual|University of North Texas Health Science Center||3|||f||||t||||||||||2018-06-01 03:29:13.436348|2018-06-01 03:29:13.436348
NCT00426231|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|2014-01-13||2014-01-13|2007-01-23|2007-01-24|Estimate|2014-01-13|2014-02-24|Estimate||||2014-01-13|2014-02-24|Estimate|March 2006||2006-03-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Culturally-Tailored Approach to Improve Medication Use in Patients With Heart Attacks|Culturally-Tailored Hospital-based Model to Improve Statin Use and Outcomes in Patients With Coronary Disease|Completed||N/A|140|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 03:29:13.611842|2018-06-01 03:29:13.611842
NCT00426218|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2011-08-08|2007-01-23|2007-01-24|Estimate|||||||2011-08-08|2011-08-09|Estimate|December 2006||2006-12-31|August 2011|2011-08-31||||March 2010|Actual|2010-03-31||Interventional|||Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)|Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)|Completed||Phase 1/Phase 2|26|Anticipated|Novartis||1|||f||||||||||||||2018-06-01 03:29:13.838514|2018-06-01 03:29:13.838514
NCT00426205|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2014-03-03|2007-01-23|2007-01-24|Estimate|||||||2014-03-03|2014-03-04|Estimate|June 2004||2004-06-30|March 2014|2014-03-31|September 2009|Actual|2009-09-30|September 2007|Actual|2007-09-30||Interventional|||GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies|GM-CSF Secreting Leukemia Cell Vaccinations After Allogeneic Non-myeloablative Peripheral Blood Stem Cell Transplantation in Patients With Advanced Myelodysplastic Syndrome or Refractory Acute or Advanced Chronic Myeloid Leukemia|Completed||N/A|24|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 03:29:13.918063|2018-06-01 03:29:13.918063
NCT00426192|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-23|2007-01-23|2007-01-24|Estimate|||||||2007-01-23|2007-01-24|Estimate|October 2003||2003-10-31|January 2007|2007-01-31|November 2004||2004-11-30|||||Interventional|||Effects of Hemofiltration and Mannitol Treatment on Cardiopulmonary-Bypass Induced Immunosuppression|Mechanisms of Endotoxin-Tolerance of Human Monocytes After CABG-Sugery - Effects of Hemofiltration and Mannitol Treatment|Unknown status|Active, not recruiting|Phase 4|52||University Hospital, Saarland|||||f||||||||||||||2018-06-01 03:29:13.987134|2018-06-01 03:29:13.987134
NCT00426153|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2012-10-22||2012-10-22|2007-01-23|2007-01-24|Estimate|2012-10-22|2012-11-21|Estimate||||2012-10-22|2012-11-21|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Octreotide in Severe Polycystic Liver Disease|Pilot Study Of Long-Acting Octreotide (Octreotide LAR® Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease|Completed||Phase 2/Phase 3|42|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 03:29:14.604311|2018-06-01 03:29:14.604311
NCT00426140|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2010-04-22|2007-01-23|2007-01-24|Estimate|||||||2010-04-22|2010-04-23|Estimate|August 2006||2006-08-31|April 2010|2010-04-30||||November 2006|Actual|2006-11-30||Interventional|||Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.|An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Elimination (ADME) of Patupilone (EPO906) After a Single Intravenous Administration of 10 mg/m2 [14C] Patupilone in Patients With Advanced Solid Tumor Malignancies.|Completed||Phase 1|5|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:29:15.030761|2018-06-01 03:29:15.030761
NCT00426127|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|2017-03-01||2017-12-05|2007-01-23|2007-01-24|Estimate|2017-04-26|2017-06-02|Actual||||2017-12-05|2017-12-29|Actual|November 2006||2006-11-30|December 2017|2017-12-31|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer|Phase II Trial of Docetaxel and Liposomal Doxorubicin (Doxil) Chemotherapy Combined With Enoxaparin in Patients With Advanced Pancreatic Cancer|Terminated||Phase 2|2|Actual|University of Iowa|Study closed early due to slow accrual. No analysis done, 2 subjects received study treatment. Both subjects went off study due to progression and complications from cancer.|1||Inadequate number of eligible patients|f||||t||||||||No||2018-06-01 03:29:15.166169|2018-06-01 03:29:15.166169
NCT00426114|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2009-04-09|2007-01-23|2007-01-24|Estimate|||||||2009-04-09|2009-04-10|Estimate||||April 2009|2009-04-30||||||||Interventional|||Acute Haemodynamic Impact of an IV Glucose-Injection|Acute Haemodynamic Impact of an IV Glucose-Injection|Withdrawn||Phase 2|20|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:29:15.364408|2018-06-01 03:29:15.364408
NCT00426101|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2017-03-12|2007-01-23|2007-01-24|Estimate|||||||2017-03-12|2017-03-14|Actual|January 2004||2004-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2011|Actual|2011-12-31||Interventional|||Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004|HLH-2004 Treatment Protocol|Active, not recruiting||Phase 3|300|Anticipated|Karolinska University Hospital||1|||f||||t||||||||Undecided||2018-06-01 03:29:15.415662|2018-06-01 03:29:15.415662
NCT00426075|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2008-06-09|2007-01-23|2007-01-24|Estimate|||||||2008-06-09|2008-06-10|Estimate|January 2006||2006-01-31|June 2008|2008-06-30||||November 2007|Actual|2007-11-30||Interventional|||Full-Leg vs Below-Knee Elastic Stockings for Prevention of the Post-Thrombotic Syndrome||Completed||Phase 3|||University of Padova|||||f||||||||||||||2018-06-01 03:29:15.491478|2018-06-01 03:29:15.491478
NCT00426062|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-02-18|2007-01-23|2007-01-24|Estimate|||||||2007-02-18|2007-02-21|Estimate||||February 2007|2007-02-28||||||||Observational|||Free Radical Level in SCC of Tongue Patients Tumor, Serum and Saliva||Unknown status|Recruiting||||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:29:15.551502|2018-06-01 03:29:15.551502
NCT00426049|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-01-23|2007-01-23|2007-01-24|Estimate|||||||2007-01-23|2007-01-24|Estimate|October 2006||2006-10-31|January 2007|2007-01-31||||||||Interventional|||Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation|Monocenter, Double Blinded, Prospective, Randomized Placebo Controlled Study Investigating Prevention of Major Adverse Cardiac Events (MACEs) Within 6 Months by Systemic Treatment With Everolimus After Coronary Intervention With Bare Metal Stents in Patients With Significant Coronary Artery Disease|Unknown status|Recruiting|Phase 3|484||German Heart Institute|||||f||||||||||||||2018-06-01 03:29:15.607025|2018-06-01 03:29:15.607025
NCT00426036|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-06-21|2007-01-23|2007-01-24|Estimate|||||||2007-06-21|2007-06-22|Estimate|June 2006||2006-06-30|June 2007|2007-06-30||||||||Interventional|||Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine|An Open-Label Study in Healthy Subjects and in Patients With Stable Impaired Renal Function to Assess the Effect of Severe Renal Impairment on Licarbazepine Pharmacokinetics and Metabolism After the Single Administration of a 500 mg Licarbazepine Immediate Release (IR) Tablet|Completed||Phase 1|12||Novartis|||||f||||||||||||||2018-06-01 03:29:15.670689|2018-06-01 03:29:15.670689
NCT00426023|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2009-01-27|2007-01-23|2007-01-24|Estimate|||||||2009-01-27|2009-01-28|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis|Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Cyclosporine Eye Drop Treatment in Preventing Vernal Keratoconjunctivitis (VKC) Relapses and in Treating the Acute Phase.|Completed||Phase 3|48|Anticipated|Campus Bio-Medico University||2|||f||||||||||||||2018-06-01 03:29:15.723104|2018-06-01 03:29:15.723104
NCT00426010|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2011-12-11|2007-01-23|2007-01-24|Estimate|||||||2011-12-11|2011-12-13|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Measuring Placebo Effect by Elimination and Investigating Mechanism of Action|Measuring Placebo Effect by Elimination and Investigating Its Mechanism of Action|Completed||N/A|180|Anticipated|King Faisal Specialist Hospital & Research Center||4|||f||||||||||||||2018-06-01 03:29:15.793652|2018-06-01 03:29:15.793652
NCT00425997|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2011-06-07|2007-01-23|2007-01-24|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension|A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hypertension|Completed||Phase 4|480|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:29:15.855759|2018-06-01 03:29:15.855759
NCT00425984|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-08-23|2007-01-23|2007-01-24|Estimate|||||||2007-08-23|2007-08-24|Estimate|August 2002||2002-08-31|August 2007|2007-08-31|December 2006||2006-12-31|||||Interventional|||Male Circumcision for HIV Prevention in Rakai, Uganda|Randomized Trial of Male Circumcision for HIV Prevention, Rakai, Uganda|Completed||Phase 3|5000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:29:15.909542|2018-06-01 03:29:15.909542
NCT00425971|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2008-09-03|2007-01-23|2007-01-24|Estimate|||||||2008-09-03|2008-09-04|Estimate|July 2008||2008-07-31|September 2008|2008-09-30||||||||Interventional|||Safety Study of Anti-Asthma Agent BMEC-1217B|A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Safety Study of BMEC-1217B, in Healthy Volunteers|Unknown status|Recruiting|Phase 1|32|Anticipated|Medigreen Biotechnology Corp.|||||f||||||||||||||2018-06-01 03:29:16.112339|2018-06-01 03:29:16.112339
NCT00425958|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|||2007-09-23|2007-01-23|2007-01-24|Estimate|||||||2007-09-23|2007-09-26|Estimate|April 2006||2006-04-30|September 2007|2007-09-30|September 2006|Actual|2006-09-30|||||Observational|||Examination of Virtual Supermarket (Vmall) as an Assessment of Executive Functions in Children and Adolescents With Acquired Brain Injury||Completed|||40|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:29:16.167972|2018-06-01 03:29:16.167972
NCT00425945|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-23|2013-03-29||2014-02-19|2007-01-23|2007-01-24|Estimate|2014-02-19|2014-04-02|Estimate||||2014-02-19|2014-04-02|Estimate|October 2006||2006-10-31|February 2014|2014-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study|Cardiovascular Effects of Pine Bark Extract|Completed||N/A|130|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 03:29:16.25725|2018-06-01 03:29:16.25725
NCT00425932|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2013-08-21|2007-01-22|2007-01-24|Estimate|||||||2013-08-21|2013-08-22|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis|Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis|Completed||Phase 2|60|Actual|Gaylis, Norman B., M.D.||2|||f||||||||||||||2018-06-01 03:29:16.780393|2018-06-01 03:29:16.780393
NCT00425919|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2007-12-18|2007-01-19|2007-01-23|Estimate|||||||2007-12-18|2007-12-27|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Study Evaluating PPM-204 In Subjects With Type 2 Diabetes|A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of The Safety And Efficacy Of PPM-204 In Subjects With Type 2 Diabetes|Terminated||Phase 2|500||Wyeth is now a wholly owned subsidiary of Pfizer||||Study terminated as a result of interim analysis not meeting predetermined criteria.|f||||||||||||||2018-06-01 03:29:16.887762|2018-06-01 03:29:16.887762
NCT00425906|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2016-01-11|2007-01-19|2007-01-23|Estimate|||||||2016-01-11|2016-01-12|Estimate|December 2003||2003-12-31|July 2011|2011-07-31||||||||Interventional|||"Nicotine in Treating Hunger Pain in Patients With Malignant Bowel Obstruction Caused By Cancer"|"A Pilot Study of Nicotine for Hunger Pain in Patients With Bowel Obstruction From Incurable Cancer"|Withdrawn||N/A|0|Actual|Mayo Clinic||2||No patient enrollment occurred.|f||||t||||||||||2018-06-01 03:29:17.139614|2018-06-01 03:29:17.139614
NCT00425893|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2012-04-12|2007-01-22|2007-01-23|Estimate|||||||2012-04-12|2012-04-13|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households|A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households|Completed||N/A|6069|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-06-01 03:29:17.222055|2018-06-01 03:29:17.222055
NCT00425880|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2013-08-07|2007-01-22|2007-01-23|Estimate|||||||2013-08-07|2013-08-09|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Monitoring and Outcome Measures in Asthmatics and Smokers During Pregnancy|GCRC: Monitoring and Outcome Measures in Asthmatics and Smokers (MOMAS) During Pregnancy|Withdrawn|||0|Actual|University of Kentucky|||3||f||||||||||||||2018-06-01 03:29:17.306199|2018-06-01 03:29:17.306199
NCT00425867|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2007-01-25|2007-01-22|2007-01-23|Estimate|||||||2007-01-25|2007-01-26|Estimate|March 2007||2007-03-31|January 2007|2007-01-31|November 2007||2007-11-30|||||Observational|||PAR Family Polymorphisms and Placental Invasion Disorders||Unknown status|Not yet recruiting||100||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:29:17.405847|2018-06-01 03:29:17.405847
NCT00425854|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2013-08-08||2013-12-05|2007-01-22|2007-01-23|Estimate|2013-08-08|2013-10-14|Estimate||||2013-12-05|2013-12-31|Estimate|November 2006||2006-11-30|August 2013|2013-08-31||||May 2009|Actual|2009-05-31||Interventional|||An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer|An Open Label Phase II Trial to Assess the Efficacy and Safety of a Once Daily Oral Dose of 50 mg BIBW 2992 in Two Cohorts of Patients With HER2-negative Metastatic Breast Cancer After Failure of no More Than Two Chemotherapy Regimen|Completed||Phase 2|50|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-06-01 03:29:17.492769|2018-06-01 03:29:17.492769
NCT00425841|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2012-12-11|2007-01-19|2007-01-23|Estimate|||||||2012-12-11|2012-12-12|Estimate|May 2006||2006-05-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|||||Interventional|||Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer|Lokal Fortgeschrittenes Pankreas-Karzinom: Stereotaktische Radiotherapie Gefolfgt Von Gemox-Chemotherapie|Completed||Phase 2|29|Anticipated|Technische Universität München|||||f||||||||||||||2018-06-01 03:29:18.505646|2018-06-01 03:29:18.505646
NCT00425815|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2016-02-05|2007-01-22|2007-01-23|Estimate|||||||2016-02-05|2016-02-09|Estimate|April 2009||2009-04-30|February 2016|2016-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia|A Placebo-Controlled Trial of Org 24448 (Ampakine) Added to Atypical Antipsychotics in Patients With Schizophrenia|Withdrawn||Phase 2|0|Actual|University of California, Los Angeles||3||Study terminated at Sponsor's request.|f||||f||||||||||2018-06-01 03:29:18.613365|2018-06-01 03:29:18.613365
NCT00425802|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2017-08-11||2017-10-24|2007-01-19|2007-01-23|Estimate|2017-10-24|2017-10-31|Actual||||2017-10-24|2017-10-31|Actual|November 28, 2006|Actual|2006-11-28|February 2017|2017-02-28|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional|||Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-Compatible Related or Unrelated Donors in Patients With B Cell Lymphoid Malignancies|Completed||Phase 2|61|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:29:18.720403|2018-06-01 03:29:18.720403
NCT00425789|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2011-04-04|2007-01-22|2007-01-23|Estimate|||||||2011-04-04|2011-04-05|Estimate|January 2007||2007-01-31|December 2005|2005-12-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Hyperbaric Therapy and Deep Chemical Peeling|Hyperbaric Therapy and Healing From Deep Chemical Peel|Unknown status|Recruiting|Phase 1|40|Anticipated|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:29:19.183874|2018-06-01 03:29:19.183874
NCT00425776|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2015-08-20|2007-01-22|2007-01-23|Estimate|||||||2015-08-20|2015-08-21|Estimate|February 2007||2007-02-28|August 2015|2015-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Treatment of Hot Flushes in Breast Cancer Patients With Acupuncture||Completed||Phase 1|94|Actual|Vejle Hospital||3|||f||||f||||||||||2018-06-01 03:29:19.271862|2018-06-01 03:29:19.271862
NCT00425763|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2012-04-04|2007-01-19|2007-01-23|Estimate|||||||2012-04-04|2012-04-05|Estimate|May 2007||2007-05-31|April 2012|2012-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|IPTi DRWG||Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria|Efficacy of Amodiaquine-artesunate in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children at an IPTi Site in Rural Western Kenya|Completed||Phase 4|110|Actual|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-06-01 03:29:19.341043|2018-06-01 03:29:19.341043
NCT00424710|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2014-11-03|2007-01-18|2007-01-19|Estimate|||||||2014-11-03|2014-11-05|Estimate|January 2007||2007-01-31|November 2014|2014-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PEARL||Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)|Phase I Study of Ranibizumab Injection for Polypoidal Choroidal Vasculopathy (PEARL)|Completed||Phase 1|17|Actual|Hawaii Pacific Health||1|||f||||f||||||||||2018-06-01 03:29:36.708688|2018-06-01 03:29:36.708688
NCT00425750|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2011-03-07||2011-11-07|2007-01-19|2007-01-23|Estimate|2011-03-07|2011-04-04|Estimate||||2011-11-07|2011-11-16|Estimate|August 2005||2005-08-31|November 2011|2011-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Trial of Combination Weekly Bortezomib (VELCADE) and Docetaxel (TAXOTERE) in Patients With Recurrent and/ or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|Completed||Phase 2|25|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:29:19.427319|2018-06-01 03:29:19.427319
NCT00425737|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2016-09-15|2007-01-22|2007-01-23|Estimate|||||||2016-09-15|2016-09-16|Estimate|August 2000||2000-08-31|September 2016|2016-09-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants|A Study to Assess the Efficacy, Immunogenicity and Safety of Two Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in Healthy Infants.|Completed||Phase 2|405|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:29:19.758481|2018-06-01 03:29:19.758481
NCT00425724|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2011-08-05|2007-01-22|2007-01-23|Estimate|||||||2011-08-05|2011-08-08|Estimate|January 2000||2000-01-31|August 2011|2011-08-31|February 2011|Actual|2011-02-28|February 2007|Actual|2007-02-28||Interventional|||HSP-glomerulonephritis Trial: MP vs CyA||Completed||Phase 4|20|Anticipated|Oulu University Hospital|||||f||||||||||||||2018-06-01 03:29:19.925576|2018-06-01 03:29:19.925576
NCT00425711|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2012-07-26|2007-01-22|2007-01-23|Estimate|||||||2012-07-26|2012-07-27|Estimate|February 2007||2007-02-28|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of Acamprosate in Driving Under the Influence (DUI) Court Participants|An Open-Label Study of Acamprosate in DUI Court Participants|Terminated||N/A|4|Actual|University of Oklahoma||1||Recruitment barriers.|f||||f||||||||||2018-06-01 03:29:20.017849|2018-06-01 03:29:20.017849
NCT00425698|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2010-08-04||2010-09-23|2007-01-22|2007-01-23|Estimate|2010-09-01|2010-09-23|Estimate||||2010-09-23|2010-09-28|Estimate|February 2007||2007-02-28|September 2010|2010-09-30|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation|Effect of Erythropoietin on Renal Function After Kidney Transplantation|Completed||Phase 2/Phase 3|88|Actual|Hannover Medical School||2|||f||||t||||||||||2018-06-01 03:29:20.11156|2018-06-01 03:29:20.11156
NCT00425685|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2007-01-22|2007-01-22|2007-01-23|Estimate|||||||2007-01-22|2007-01-23|Estimate|January 2003||2003-01-31|January 2007|2007-01-31|December 2006||2006-12-31|||||Observational|||Use of ECMO in Acute MI|Use of Extracorporeal Membrane Oxygenation in Treatment of Acute Myocardial Infarction Following Cardiac Surgery Procedures|Unknown status|Active, not recruiting||60||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 03:29:20.395456|2018-06-01 03:29:20.395456
NCT00425672|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2017-04-17||2017-08-01|2007-01-19|2007-01-23|Estimate|2017-08-01|2017-08-04|Actual||||2017-08-01|2017-08-04|Actual|September 2005||2005-09-30|August 2017|2017-08-31||||April 2010|Actual|2010-04-30||Interventional|||ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment|Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients With Advanced Refractory Breast Cancer|Active, not recruiting||Phase 1/Phase 2|15|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:29:20.457568|2018-06-01 03:29:20.457568
NCT00425659|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2009-07-09|2007-01-22|2007-01-23|Estimate|||||||2009-07-09|2009-07-10|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||Evaluation of New Diagnostic and Treatment Algorithm for Obstructive Sleep Apnea|Evaluation of New Diagnostic and Treatment Algorithm for Obstructive Sleep Apnea in High Risk Population in Hong Kong|Completed||N/A|150|Anticipated|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 03:29:20.74539|2018-06-01 03:29:20.74539
NCT00425646|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2013-05-02|2007-01-19|2007-01-23|Estimate|||||||2013-05-02|2013-05-06|Estimate|November 2006||2006-11-30|May 2013|2013-05-31|July 2009|Actual|2009-07-31|October 2007|Actual|2007-10-31||Interventional|||Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study Evaluating a Maintenance Strategy of Gleevce® (Imatinib Mesylate) and Bevacizumab in Patients With Advanced, Non-squamous, Non-small Cell Lung Cancer, Following Completion of First-line Chemotherapy With Bevacizumab|Completed||Phase 2|50|Anticipated|University of Washington|||||f||||||||||||||2018-06-01 03:29:20.807652|2018-06-01 03:29:20.807652
NCT00425633|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2011-03-24|2007-01-22|2007-01-23|Estimate|||||||2011-03-24|2011-03-25|Estimate|January 2007||2007-01-31|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy Study of Homeopathic Potassium Dichromate to Treat Tracheal Secretions in Critically Ill Patients|A Study To Evaluate The Effect Of Homeopathic Concentrations Of Potassium Dichromate On Tracheal Secretions In Critically Ill Patients.|Terminated||Phase 2|16|Actual|Sunnybrook Health Sciences Centre||||slow recruitment|f||||f||||||||||2018-06-01 03:29:20.865509|2018-06-01 03:29:20.865509
NCT00425620|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2007-11-29|2007-01-22|2007-01-23|Estimate|||||||2007-11-29|2007-11-30|Estimate|December 2006||2006-12-31|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Amphotericin B Suspension in Refractory Chronic Sinusitis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Intranasal Amphotericin B Suspension in Patients With Refractory, Postsurgical Chronic Sinusitis (CS)|Completed||Phase 3|300|Actual|Accentia Biopharmaceuticals||1|||f||||f||||||||||2018-06-01 03:29:20.948308|2018-06-01 03:29:20.948308
NCT00425607|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2015-09-25||2018-04-08|2007-01-22|2007-01-23|Estimate|2017-04-14|2017-05-24|Actual||||2018-04-08|2018-04-10|Actual|May 2007||2007-05-31|April 2018|2018-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||The analysis population represents the 25 patients with classic HGPS who received the farnesyltransferase inhibitor lonafarnib for a minimum of 2 y. The analysis population does not include 1 patient (with prior history of strokes) who died of a stroke after 5 mo on study, or 2 additional patients who had nonclassic mutations.|Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria|An Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies|Completed||Phase 2|29|Actual|Boston Children’s Hospital|This was an open label clinical trial on a very rare disease population. Patient numbers are small, though 26 participants represents a significant portion of the world's population of children with HGPS|1|||f||||t||||||||||2018-06-01 03:29:21.647676|2018-06-01 03:29:21.647676
NCT00425594|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2007-12-20|2007-01-22|2007-01-23|Estimate|||||||2007-12-20|2007-12-27|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population|A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population|Completed||Phase 4|150||Braintree Laboratories|||||f||||f||||||||||2018-06-01 03:29:22.218125|2018-06-01 03:29:22.218125
NCT00425581|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2008-01-22|2007-01-22|2007-01-23|Estimate|||||||2008-01-22|2008-01-24|Estimate|February 2007||2007-02-28|January 2008|2008-01-31||||||||Observational|||N-Terminal Pro-B-Type Natriuretic Peptide and Troponin Levels as Markers of Hemodynamic Stability in Very Low Birth Weight Infants During the First Days of Life|N-Terminal Pro-B-Type and Cardiac Troponin T Levels for Monitoring Effectiveness of Treatment in Very Low Birth Weight Infants With Hemodynamic Instability|Withdrawn|||100|Anticipated|Sheba Medical Center||||Did not receive budget needed.|f||||f||||||||||2018-06-01 03:29:22.514522|2018-06-01 03:29:22.514522
NCT00425568|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-20|||2007-01-22|2007-01-22|2007-01-23|Estimate|||||||2007-01-22|2007-01-23|Estimate|December 2005||2005-12-31|January 2007|2007-01-31||||||||Observational|||Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR|Phase I Study of Transdermal Testosterone Gel and Its Effect on Erection Quality as Measured by a Digital Inflection Rigidometer (DIR)|Unknown status|Recruiting||30||Lamm, Steven, M.D.|||||f||||||||||||||2018-06-01 03:29:22.639902|2018-06-01 03:29:22.639902
NCT00425555|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2016-11-16|2007-01-22|2007-01-23|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma|A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma|Completed||Phase 2/Phase 3|139|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:29:22.714818|2018-06-01 03:29:22.714818
NCT00425542|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2010-06-10|2007-01-22|2007-01-23|Estimate|||||||2010-06-10|2010-06-11|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|OTPE||Safety Study of Outpatient Treatment for Pulmonary Embolism|Outpatient Treatment of Low-risk Patients With Pulmonary Embolism: a Randomized-controlled Trial|Completed||Phase 3|343|Actual|University of Lausanne Hospitals||2|||f||||t||||||||||2018-06-01 03:29:22.823261|2018-06-01 03:29:22.823261
NCT00425529|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2007-01-22|2007-01-22|2007-01-23|Estimate|||||||2007-01-22|2007-01-23|Estimate|February 2002||2002-02-28|January 2007|2007-01-31|May 2003||2003-05-31|||||Interventional|||Tolerance and Practicality of Module AOX|Tolerance and Practicality of Module AOX - a Modular Device for Supplementation of Enteral Nutrition|Completed||Early Phase 1|20||VU University Medical Center|||||f||||||||||||||2018-06-01 03:29:22.911012|2018-06-01 03:29:22.911012
NCT00425516|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2014-09-30|2007-01-22|2007-01-23|Estimate|||||||2014-09-30|2014-10-01|Estimate|January 2007||2007-01-31|February 2007|2007-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Breast Cancer Treated by Neoadjuvant Chemotherapy|Clinical Trial of the Neoadjuvant Standard Chemotherapy 3 FEC 100 + 3 TAXOTERE Protocol Versus the Same Protocol Adapted as a Function of Clinical Response|Completed||Phase 2|264|Actual|Centre Jean Perrin||2|||f||||||||||||||2018-06-01 03:29:22.958154|2018-06-01 03:29:22.958154
NCT00425503|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2014-02-15||2014-04-03|2007-01-22|2007-01-23|Estimate|2014-02-15|2014-04-01|Estimate||||2014-04-03|2014-04-21|Estimate|December 2001||2001-12-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Interventional|||PS-341 Followed by Removal of Prostate for Those With Prostate Cancer|H-11047: A Study of PS-341 Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate (Spore #: 11-01-30-13)|Completed||Phase 2|40|Actual|Baylor College of Medicine|||||f||||||||||||||2018-06-01 03:29:23.974815|2018-06-01 03:29:23.974815
NCT00425490|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2009-09-22|2007-01-22|2007-01-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Januvia on Beta Cell Function in Patients With Diabetes Mellitus|Phase III Study on the Effect of Sitagliptin on Maximal Beta Cell Stimulation|Completed||Phase 3|30|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:29:24.212687|2018-06-01 03:29:24.212687
NCT00425477|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2015-10-30|2007-01-19|2007-01-23|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2006||2006-11-30|October 2015|2015-10-31||||July 2016|Anticipated|2016-07-31||Interventional|||Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML|Unknown status|Active, not recruiting|Phase 2|26|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:29:24.286184|2018-06-01 03:29:24.286184
NCT00425464|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19||2013-04-11|2013-09-16|2007-01-19|2007-01-23|Estimate||||2013-04-11|2013-04-17|Estimate|2013-09-16|2013-09-19|Estimate|November 2005||2005-11-30|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Synchrony Dual Optic Intraocular Lens in Patients Undergoing Cataract Extraction|A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Synchrony Dual Optic Intraocular Lens in Patients Undergoing Cataract Extraction|Terminated||Phase 3|410|Actual|Abbott Medical Optics||2|||f||||||||||||||2018-06-01 03:29:24.382589|2018-06-01 03:29:24.382589
NCT00425451|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-21|||2011-06-13|2007-01-21|2007-01-23|Estimate|||||||2011-06-13|2011-06-14|Estimate|August 2008||2008-08-31|June 2011|2011-06-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis|The Efficacy and Safety of PerioChip Plus (Flurbiprofen/Chlorhexidine) Formulation in the Therapy of Adult Periodontitis|Completed||Phase 2|80|Actual|Dexcel Pharma Technologies Ltd.||4|||f||||||||||||||2018-06-01 03:29:24.467449|2018-06-01 03:29:24.467449
NCT00425438|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2014-08-14||2014-09-22|2007-01-22|2007-01-23|Estimate|2014-09-22|2014-09-25|Estimate||||2014-09-22|2014-09-25|Estimate|March 2007||2007-03-31|September 2014|2014-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||Safety population: all participants who recieved at least one dose of study drug.|A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.|A Randomized, Open-label Study to Compare the Effect of CellCept Plus Corticosteroids, and Cyclophosphamide Plus Corticosteroids Followed by Azathioprine, on Remission Rate in Patients With Lupus Nephritis|Terminated||Phase 3|52|Actual|Hoffmann-La Roche|The study was terminated early due to administrative reasons.|2||Study was terminated early for administrative reasons.|f||||||||||||||2018-06-01 03:29:25.285432|2018-06-01 03:29:25.285432
NCT00425425|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2014-04-30|2007-01-19|2007-01-23|Estimate|||||||2014-04-30|2014-05-01|Estimate|July 2006||2006-07-31|April 2014|2014-04-30|May 2015|Anticipated|2015-05-31|May 2010|Actual|2010-05-31||Interventional|||Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer|Neoadjuvant Radiochemotherapy in Local Advanced Squamous Cell Carcinoma of the Esophagus With Weekly Cetuximab Plus Oxaliplatin Plus Continuous IV. 5-FU and Conventional Fractionated External Multi-Field Irradiation up to 45 Gray. A Phase I/II Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|43|Anticipated|Technische Universität München|||||f||||f||||||||||2018-06-01 03:29:25.600512|2018-06-01 03:29:25.600512
NCT00425399|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|||2014-05-21|2007-01-22|2007-01-23|Estimate|||||||2014-05-21|2014-05-22|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|||||Interventional|||Shiatsu Adjuvant Therapy For Schizophrenia|Shiatsu Adjuvant Therapy for Hospitalized Psychiatric Patients: an Open Pilot Study|Completed||N/A|20|Anticipated|Herzog Hospital|||||f||||||||||||||2018-06-01 03:29:25.667165|2018-06-01 03:29:25.667165
NCT00425386|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2012-01-12||2017-05-01|2007-01-19|2007-01-23|Estimate|2012-01-12|2012-02-16|Estimate||||2017-05-01|2017-05-03|Actual|August 2006||2006-08-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|August 2010|Actual|2010-08-31||Interventional||The discrepancy between the number of participants enrolled (60) and the number of participants Started in the Participant Flow module (46) is due to screen failures and consent withdrawals.|Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Dose Escalation Phase II Study of Sunitinib Plus Erlotinib in Advanced Renal Carcinoma|Completed||Phase 2|60|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 03:29:25.743694|2018-06-01 03:29:25.743694
NCT00425373|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-22|2011-01-12||2011-04-20|2007-01-22|2007-01-23|Estimate|2011-01-12|2011-02-04|Estimate||||2011-04-20|2011-04-29|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients|Completed||Phase 2/Phase 3|1474|Actual|Novartis||9|||f||||||||||||||2018-06-01 03:29:26.103796|2018-06-01 03:29:26.103796
NCT00425360|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2013-08-23|2007-01-19|2007-01-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2006||2006-09-30|May 2009|2009-05-31|March 2013|Actual|2013-03-31|||||Interventional|||Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC]|Completed||Phase 3|1110|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:29:27.085291|2018-06-01 03:29:27.085291
NCT00425347|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2009-09-21|2007-01-18|2007-01-22|Estimate|||||||2009-09-21|2009-09-23|Estimate|December 2006||2006-12-31|September 2009|2009-09-30|July 2009|Actual|2009-07-31|August 2008|Actual|2008-08-31||Interventional|||Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma|Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma|Completed||Phase 1|35|Actual|Facet Biotech|||||f||||t||||||||||2018-06-01 03:29:27.458955|2018-06-01 03:29:27.458955
NCT00425334|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2013-08-15|2007-01-18|2007-01-22|Estimate|||||||2013-08-15|2013-08-19|Estimate|July 2005||2005-07-31|August 2013|2013-08-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Safety Study of Hemospan® in Prostatectomy Patients|A Clinical Safety (Phase II) Increasing Dose Study of MP4 (Hemospan®) in Total Prostatectomy Surgical Patients|Completed||Phase 2|20|Actual|Sangart||2|||f||||t||||||||||2018-06-01 03:29:27.526562|2018-06-01 03:29:27.526562
NCT00425321|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19||2011-05-27|2014-05-06|2007-01-19|2007-01-22|Estimate||||2011-05-27|2011-06-03|Estimate|2014-05-06|2014-05-21|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 2|259|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||t||||||||||2018-06-01 03:29:27.711635|2018-06-01 03:29:27.711635
NCT00425308|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2011-01-06||2017-02-28|2007-01-19|2007-01-22|Estimate|2011-03-23|2011-04-19|Estimate||||2017-02-28|2017-03-30|Actual|October 2006||2006-10-31|February 2017|2017-02-28||||May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.|A Prospective Multicenter Open-label Randomized Study to Assess Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus Without Calcineurine Inhibitor in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.|Completed||Phase 3|30|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:29:27.916509|2018-06-01 03:29:27.916509
NCT00425295|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2014-12-02|2007-01-19|2007-01-22|Estimate|||||||2014-12-02|2014-12-04|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effectiveness of Human Simulation Training for Medical Crisis Management Skills|Effectiveness of Human Simulation Training for Medical Crisis Management Skills|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||2||too much cross over bias between small numbers of participants|f||||t||||||||||2018-06-01 03:29:28.62868|2018-06-01 03:29:28.62868
NCT00425282|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2012-06-19|2007-01-19|2007-01-22|Estimate|||||||2012-06-19|2012-06-20|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.|Completed||Phase 3|566|Actual|SK Life Science|||||f||||||||||||||2018-06-01 03:29:28.701929|2018-06-01 03:29:28.701929
NCT00425269|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2014-04-11||2014-06-24|2007-01-19|2007-01-22|Estimate|2014-06-24|2014-07-21|Estimate||||2014-06-24|2014-07-21|Estimate|April 2006||2006-04-30|April 2014|2014-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|InnvaDiab|Women, aged 18-65 years, more than 50 percent rated their command of the Norwegian language as poor, and mean number of years of education was 9.|Lifestyle Intervention for Pakistani Women in Oslo|Evaluation of a Lifestyle Intervention to Prevent Type 2 Diabetes/Metabolic Syndrome Among Pakistani Immigrants - Focusing on Changes in Diet and Physical Activity|Completed||N/A|198|Actual|University of Oslo||2|||f||||f||||||||||2018-06-01 03:29:28.809125|2018-06-01 03:29:28.809125
NCT00425256|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2011-02-22|2007-01-19|2007-01-22|Estimate|||||||2011-02-22|2011-02-23|Estimate|February 2006||2006-02-28|February 2011|2011-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)||Completed||Phase 2|||Palatin Technologies|||||f||||||||||||||2018-06-01 03:29:29.637487|2018-06-01 03:29:29.637487
NCT00425243|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2009-04-03|2007-01-19|2007-01-22|Estimate|||||||2009-04-03|2009-04-06|Estimate|August 2004||2004-08-31|April 2009|2009-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Efficacy and Safety of Zolpidem-MR Administered Over a Long Term Period as Needed for Insomnia (ZOLONG)|"Evaluation of the Long-Term Efficacy and Safety of Zolpidem-MR 12.5 mg Compared to Placebo, When Both Are Administered Over a Long-Term Period as Needed, in Patients With Chronic Primary Insomnia"|Completed||Phase 3|1025|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:29:29.834667|2018-06-01 03:29:29.834667
NCT00425230|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2010-12-21|2007-01-19|2007-01-22|Estimate|||||||2010-12-21|2010-12-22|Estimate|January 2007||2007-01-31|December 2010|2010-12-31|June 2007||2007-06-30|||||Interventional|||Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain|Pilot Study of Use of Duloxetine for the Treatment of Phantom Limb Pain|Terminated||N/A|15|Anticipated|Baylor College of Medicine||||"No patients were enrolled in this study. The study onset was delayed due to problems with drug~   acquisition."|f||||||||||||||2018-06-01 03:29:29.939483|2018-06-01 03:29:29.939483
NCT00425217|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2011-02-23|2007-01-19|2007-01-22|Estimate|||||||2011-02-23|2011-02-25|Estimate|August 2004||2004-08-31|February 2011|2011-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Rituximab in Membranous Nephropathy|The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy|Completed||Phase 2/Phase 3|15|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:29:30.016166|2018-06-01 03:29:30.016166
NCT00425204|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2008-09-11|2007-01-18|2007-01-22|Estimate|||||||2008-09-11|2008-09-15|Estimate|March 2004||2004-03-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|September 2007|Actual|2007-09-30||Interventional|||Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment|A Multi-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment|Completed||Phase 2|31|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:29:30.120966|2018-06-01 03:29:30.120966
NCT00425191|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2009-12-04|2007-01-19|2007-01-22|Estimate|||||||2009-12-04|2009-12-07|Estimate|July 2002||2002-07-31|December 2009|2009-12-31||||April 2005|Actual|2005-04-30||Interventional|||Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.|A Multicenter, Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.|Completed||Phase 2|165|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:29:30.208833|2018-06-01 03:29:30.208833
NCT00425178|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2008-01-07|2007-01-18|2007-01-22|Estimate|||||||2008-01-07|2008-01-08|Estimate|September 2005||2005-09-30|November 2007|2007-11-30||||||||Interventional|||FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers|A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Patients With Diabetic or Venous Stasis Ulcers|Completed||Phase 1|8|Actual|CardioVascular BioTherapeutics, Inc.|||||f||||||||||||||2018-06-01 03:29:30.350728|2018-06-01 03:29:30.350728
NCT00425165|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19||2011-03-31|2015-03-17|2007-01-19|2007-01-22|Estimate||||2011-03-31|2011-04-07|Estimate|2015-03-17|2015-04-03|Estimate|August 2007||2007-08-31|March 2015|2015-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of Denufosol Inhalation Solution in Patients With Mild to Moderate Cystic Fibrosis Lung Disease|A Randomized, Double-Blind, Two Way Crossover Evaluation of the Effects of a Single Dose of Denufosol Tetrasodium (INS37217) Inhalation Solution Versus Placebo (0.9% Sodium Chloride Solution) on Mucociliary Clearance in Patients With Mild to Moderate Cystic Fibrosis Lung Disease|Terminated||Phase 2|6|Actual|Merck Sharp & Dohme Corp.|||||f||||f||||||||||2018-06-01 03:29:30.475124|2018-06-01 03:29:30.475124
NCT00425152|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2010-02-05|2007-01-18|2007-01-22|Estimate|||||||2010-02-05|2010-02-08|Estimate|July 1989||1989-07-31|February 2010|2010-02-28|April 2004|Actual|2004-04-30|June 1998|Actual|1998-06-30||Interventional|||Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer|A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon|Completed||Phase 3|2151|Actual|NSABP Foundation Inc|||||f||||t||||||||||2018-06-01 03:29:30.551781|2018-06-01 03:29:30.551781
NCT00425139|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2015-03-19|2007-01-19|2007-01-22|Estimate|||||||2015-03-19|2015-03-20|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Evaluation of a Video Game for Adolescents and Young Adults With Cancer|Multi-site Evaluation of a Video Game for Adolescents and Young Adults With Cancer|Completed||N/A|375||HopeLab Foundation|||||f||||||||||||||2018-06-01 03:29:30.641203|2018-06-01 03:29:30.641203
NCT00425126|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2010-05-25|2007-01-18|2007-01-22|Estimate|||||||2010-05-25|2010-05-27|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation|Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation|Completed||Phase 4|76|Actual|West Penn Allegheny Health System|||||f||||||||||||||2018-06-01 03:29:30.770874|2018-06-01 03:29:30.770874
NCT00425113|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2013-02-07||2013-05-10|2007-01-19|2007-01-22|Estimate|2013-05-10|2013-07-10|Estimate||||2013-05-10|2013-07-10|Estimate|December 2006||2006-12-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional||2 subjects excluded: 1 for uncontrolled diabetes mellitus and 1 for diagnosis of extrapulmonary TB. 2 additional subjects withdrew: 1 self- withdrew and the other was withdrawn for missing >14 days of study drug.|Metronidazole for Pulmonary Tuberculosis (South Korea)|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Metronidazole Combined With Antituberculous Chemotherapy vs. Antituberculous Chemotherapy With Placebo in Subjects With Multi-Drug Resistant Pulmonary Tuberculosis|Completed||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)|Major limitation of our study was the small sample size. Planned enrollment was 80 subjects but DSMB recommended closing the study to new enrollment after 35 subjects due to increased peripheral neuropathy in the metronidazole arm.|2|||f||||t||||||||||2018-06-01 03:29:30.850763|2018-06-01 03:29:30.850763
NCT00425100|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2008-10-10||2009-02-24|2007-01-19|2007-01-22|Estimate|2009-01-13|2009-02-10|Estimate||||2009-02-24|2009-03-23|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients|A 12-Week, Multicenter, Open-Label, Single-Arm Study To Evaluate The Effects Of Fesoterodine On Treatment Satisfaction And Symptom Relief In Overactive Bladder Patients.|Completed||Phase 3|516|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:29:31.241093|2018-06-01 03:29:31.241093
NCT00425074|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2011-06-07|2007-01-19|2007-01-22|Estimate|||||||2011-06-07|2011-06-08|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Pharmacodynamic-pharmacokinetic Trial, of Slow Release ASA, in the Platelet Functionalism.|Pharmacodynamic- Pharmacokinetic Trial, Comparative Double Blind, of the Chronic Administration of 150 mg of Slow Release ASA Versus 150 mg of Normal Release ASA, in the Platelet Functionalism.|Completed||Phase 1|50|Actual|Rottapharm Spain||2|||f||||||||||||||2018-06-01 03:29:31.961176|2018-06-01 03:29:31.961176
NCT00424372|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2009-08-19||2009-10-30|2007-01-18|2007-01-19|Estimate|2009-08-19|2009-09-28|Estimate||||2009-10-30|2009-11-11|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia|A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In The Treatment Of Postherpetic Neuralgia|Completed||Phase 3|126|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:29:50.071567|2018-06-01 03:29:50.071567
NCT00425061|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2014-11-06|2014-04-11|2015-01-12|2007-01-19|2007-01-22|Estimate|2015-01-12|2015-01-14|Estimate|2014-04-11|2014-05-06|Estimate|2015-01-12|2015-01-14|Estimate|February 2007||2007-02-28|January 2015|2015-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||Modified intent-to-treat (mITT) population included all randomized participants who received at least 1 dose administration of the test article.|Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma|Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study Conducted Sequentially With 3 Doses Of Ima-638 Administered Sc.|Completed||Phase 2|159|Actual|Pfizer|The study was stopped early due to futility of the interim efficacy analysis results. Hence, only safety results and key efficacy results were presented for this study.|3|||f||||f||||||||||2018-06-01 03:29:32.101766|2018-06-01 03:29:32.101766
NCT00425048|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2009-02-09|2007-01-19|2007-01-22|Estimate|||||||2009-02-09|2009-02-10|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|||||Observational|||Does Gloved Medical Personnel Scratch Less Often?||Completed|||40|Anticipated|Medical University Innsbruck|||||f||||||||||||||2018-06-01 03:29:34.04477|2018-06-01 03:29:34.04477
NCT00425035|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2013-05-10|2007-01-18|2007-01-22|Estimate|||||||2013-05-10|2013-05-13|Estimate|February 2003||2003-02-28|May 2013|2013-05-31||||||||Interventional|||Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2|A Two-part, Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of ABX-EGF in Patients With Renal Carcinoma|Completed||Phase 2|115||Amgen|||||||||||||||||||2018-06-01 03:29:34.084238|2018-06-01 03:29:34.084238
NCT00425022|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2007-01-29|2007-01-19|2007-01-22|Estimate|||||||2007-01-29|2007-01-30|Estimate|January 2007||2007-01-31|January 2007|2007-01-31||||||||Interventional|||VATS Lobectomy for Clinical Stage IB or II Lung Cancer|Feasibility of VATS(Video-Assisted Thoracoscopic Surgery) Lobectomy for Clinical Stage IB or II Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|40||National Cancer Center, Korea|||||f||||||||||||||2018-06-01 03:29:34.153247|2018-06-01 03:29:34.153247
NCT00425009|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2007-01-18|2007-01-18|2007-01-22|Estimate|||||||2007-01-18|2007-01-22|Estimate|January 2004||2004-01-31|January 2007|2007-01-31|December 2004||2004-12-31|||||Interventional|||Therapeutic Effects of Berberine in Patients With Type 2 Diabetes|Effects of Berberine on Improvement of Glucose and Lipid Metabolism in Patients With Type 2 Diabetes|Completed||Phase 1/Phase 2|70||Shanghai Jiao Tong University School of Medicine|||||f||||||||||||||2018-06-01 03:29:34.282244|2018-06-01 03:29:34.282244
NCT00424996|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2014-05-20|2007-01-19|2007-01-22|Estimate|||||||2014-05-20|2014-05-21|Estimate|August 2006||2006-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Utility of Heidelberg Retina Tomograph in Monitoring Glaucoma Progression|Utility of Heidelberg Retina Tomograph in Monitoring Glaucoma Progression|Completed|||74|Actual|University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:29:34.336089|2018-06-01 03:29:34.336089
NCT00424983|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2014-09-08|2007-01-19|2007-01-22|Estimate|||||||2014-09-08|2014-09-09|Estimate|November 2006||2006-11-30|September 2014|2014-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year|A Stratified, Randomized, Open-label, Multi-center Comparative 2-arm Trial of PK, PD, and Safety of Zoledronic Acid Infusions Administered Monthly vs. Every 3-month, in Multiple Myeloma Patients With Malignant Bone Lesions, and Breast Cancer Patients With Bone Metastasis, Who Have Received 9-12* Doses of Zoledronic Acid Over the Prior Year. (*Amendment 1 Changed the Required Doses to 9-20 But Due to FDA Guidelines, the Title Has Not Been Changed)|Completed||Phase 1|18|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:29:34.388304|2018-06-01 03:29:34.388304
NCT00424970|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2013-01-23|2007-01-19|2007-01-22|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|November 2007|Actual|2007-11-30|||||Interventional|||Treatment of High Altitude Polycythemia by Acetazolamide|Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment|Completed||Phase 4|55|Anticipated|Association pour la Recherche en Physiologie de l'Environnement||1|||f||||||||||||||2018-06-01 03:29:34.462848|2018-06-01 03:29:34.462848
NCT00424957|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2009-02-04|2007-01-19|2007-01-22|Estimate|||||||2009-02-04|2009-02-05|Estimate|November 2006||2006-11-30|February 2009|2009-02-28|October 2008|Actual|2008-10-31|April 2007|Actual|2007-04-30||Observational|||Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System|Brain Energy Metabolism in Patients With Acute Hepatic Encephalopathy Measured With PET|Completed|||18|Anticipated|University of Aarhus|||||f||||t||||||||||2018-06-01 03:29:34.526792|2018-06-01 03:29:34.526792
NCT00424944|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2008-04-01|2007-01-19|2007-01-22|Estimate|||||||2008-04-01|2008-04-03|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|August 2008|Anticipated|2008-08-31|July 2008|Anticipated|2008-07-31||Interventional|||Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine|A Single Centre, Randomised Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Lactococcus Lactis Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine Versus Rabies Vaccine in Healthy Gabonese Adult Volunteers|Unknown status|Recruiting|Phase 1|40|Anticipated|African Malaria Network Trust||2|||f||||t||||||||||2018-06-01 03:29:34.634572|2018-06-01 03:29:34.634572
NCT00424931|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2014-05-21|2007-01-19|2007-01-22|Estimate|||||||2014-05-21|2014-05-23|Estimate|January 2007||2007-01-31|May 2014|2014-05-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy|A Phase II Randomized, Double-blind, Double-dummy, Placebo and Comparator-controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of a Single Dose of JNJ-17216498 Administered to Subjects With Narcolepsy.|Completed||Phase 2|16|Actual|Alza Corporation, DE, USA||3|||f||||||||||||||2018-06-01 03:29:34.722593|2018-06-01 03:29:34.722593
NCT00424918|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2017-05-16|2007-01-18|2007-01-22|Estimate|||||||2017-05-16|2017-05-18|Actual|September 2006|Actual|2006-09-30|May 2017|2017-05-31|September 2009|Actual|2009-09-30|September 2007|Actual|2007-09-30||Interventional|||"Generation Fit and Exerlearning With In the Groove"|"Generation-Fit, a Pilot Study of Youth in Maine Middle Schools Using an Exerlearning Dance Video Game to Promote Physical Activity During School"|Completed||N/A|85|Anticipated|Maine Medical Center|||||f||||||||||||||2018-06-01 03:29:34.816326|2018-06-01 03:29:34.816326
NCT00424905|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2008-11-28|2007-01-19|2007-01-22|Estimate|||||||2008-11-28|2008-12-01|Estimate|December 2006||2006-12-31|November 2008|2008-11-30||||December 2007|Actual|2007-12-31||Interventional|||DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect|Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study.|Completed||Phase 4|60|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:29:34.877745|2018-06-01 03:29:34.877745
NCT00424892|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2007-12-04|2007-01-18|2007-01-22|Estimate|||||||2007-12-04|2007-12-06|Estimate||||December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome|A 6-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Fibromyalgia Syndrome.|Completed||Phase 2/Phase 3|600||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:29:34.954077|2018-06-01 03:29:34.954077
NCT00424866|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2018-01-25|2007-01-18|2007-01-22|Estimate|||||||2018-01-25|2018-01-26|Actual|June 1, 2019|Anticipated|2019-06-01|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|December 15, 2019|Anticipated|2019-12-15||Interventional|||FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease|A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication|Not yet recruiting||Phase 1/Phase 2|24|Anticipated|CardioVascular BioTherapeutics, Inc.||2|||f||||f|t|f||||||||2018-06-01 03:29:35.084281|2018-06-01 03:29:35.084281
NCT00424853|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2009-12-04|2007-01-19|2007-01-22|Estimate|||||||2009-12-04|2009-12-07|Estimate|May 2005||2005-05-31|December 2009|2009-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)|Randomized Phase II Trial of Two Sequential Schedules of Docetaxel and Cisplatin Followed by Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer.|Completed||Phase 2|88|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:29:35.15982|2018-06-01 03:29:35.15982
NCT00424840|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2014-11-18|2007-01-19|2007-01-22|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy|Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 1/Phase 2|19|Actual|University of Massachusetts, Worcester||1|||f||||f||||||||||2018-06-01 03:29:35.23301|2018-06-01 03:29:35.23301
NCT00424827|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2016-03-14||2017-05-01|2007-01-19|2007-01-22|Estimate|2017-05-01|2017-06-01|Actual||||2017-05-01|2017-06-01|Actual|June 2006||2006-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Subjects with non-metastatic, locally advanced pancreatic adenocarcinoma. Following neoadjuvant treatment, subjects were re-evaluated for response and surgical candidacy with restaging scans.|A Trial of Chemo & Radiation Therapy for Pancreatic Cancer|A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil and Radiation Therapy in Locally Advanced Non-metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|11|Actual|University of Massachusetts, Worcester||1|||f||||f||||||||||2018-06-01 03:29:35.342391|2018-06-01 03:29:35.342391
NCT00424814|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2013-07-17|2007-01-19|2007-01-22|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2007||2007-03-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Interventional|||Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva|Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. A Multicenter Randomised Phase II/III Open Label Study With a Group of 100 Pregnant Women Receiving Lopinavir/Ritonavir and a Group of 50 Receiving Lopinavir/Ritonavir Plus Zidovudine and Lamivudine. ANRS 135 Primeva|Completed||Phase 2/Phase 3|105|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 03:29:35.534555|2018-06-01 03:29:35.534555
NCT00424801|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|||2009-05-05|2007-01-19|2007-01-22|Estimate|||||||2009-05-05|2009-05-06|Estimate|January 2007||2007-01-31|May 2009|2009-05-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris|Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris|Terminated||N/A|10|Actual|University of Aarhus||1||Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis|f||||t||||||||||2018-06-01 03:29:35.618064|2018-06-01 03:29:35.618064
NCT00424788|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2009-09-03|2007-01-18|2007-01-22|Estimate|||||||2009-09-03|2009-09-04|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)|A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)|Completed||Early Phase 1|12|Anticipated|Biogen|||||f||||||||||||||2018-06-01 03:29:35.847621|2018-06-01 03:29:35.847621
NCT00424775|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2009-04-03||2015-03-31|2007-01-19|2007-01-22|Estimate|2009-04-03|2009-06-01|Estimate||||2015-03-31|2015-04-20|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)|A Phase I Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|3|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:29:35.920117|2018-06-01 03:29:35.920117
NCT00424762|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2011-08-10||2012-04-02|2007-01-18|2007-01-22|Estimate|2012-03-05|2012-03-30|Estimate||||2012-04-02|2012-04-04|Estimate|February 2005||2005-02-28|April 2012|2012-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride|Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride|Completed||Phase 4|150|Actual|University of Texas Southwestern Medical Center|Larger than anticipated study discontinuation-72% with complete primary data analysis with lower numbers analyzed for imaging endpoints|2|||f||||f||||||||||2018-06-01 03:29:36.087713|2018-06-01 03:29:36.087713
NCT00424749|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-19|2011-09-12||2011-11-03|2007-01-19|2007-01-22|Estimate|2011-11-03|2011-12-08|Estimate||||2011-11-03|2011-12-08|Estimate|June 2007||2007-06-30|November 2011|2011-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Rituxan in Churg Strauss Syndrome With Renal Involvement|A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement|Terminated||Phase 2|4|Actual|Mayo Clinic|The limited number of individuals enrolled into the study makes it difficult to draw firm conclusions that are more than hypothesis generating. The company providing study drug terminated study due to lack of funds.|1||Company providing study drug terminated study due to lack of funds|f||||t||||||||||2018-06-01 03:29:36.374178|2018-06-01 03:29:36.374178
NCT00424736|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-01-18|2007-01-18|2007-01-19|Estimate|||||||2007-01-18|2007-01-19|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2008||2008-01-31|||||Observational|||the Role of Total Body Imaging in Asymptomatic Pediatric Trauma Patients|Role of Whole Body Imaging in Asymptomatic Pediatric Trauma Patients|Unknown status|Not yet recruiting||100||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:29:36.58279|2018-06-01 03:29:36.58279
NCT00424723|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2010-08-10|2007-01-18|2007-01-19|Estimate|||||||2010-08-10|2010-08-12|Estimate|December 2005||2005-12-31|August 2010|2010-08-31|March 2010|Actual|2010-03-31|January 2007|Actual|2007-01-31||Interventional|||Pemetrexed in Patients With Advanced Neuroendocrine Tumors|A Phase II Study of Pemetrexed in Patients With Advanced Neuroendocrine Tumors|Completed||Phase 2|32|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 03:29:36.636044|2018-06-01 03:29:36.636044
NCT00424697|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17||2010-10-13|2010-10-13|2007-01-18|2007-01-19|Estimate||||2010-10-13|2010-10-15|Estimate|2010-10-13|2010-10-15|Estimate|March 2007||2007-03-31|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.|A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.|Completed||Phase 1|26|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:29:36.784069|2018-06-01 03:29:36.784069
NCT00424684|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2015-12-16|2007-01-18|2007-01-19|Estimate|||||||2015-12-16|2015-12-17|Estimate|January 2007||2007-01-31|December 2015|2015-12-31||||||||Interventional|||Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation|Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation|Withdrawn||N/A|0|Actual|University of Pittsburgh||||unable to obtain contract with sponsor|f||||||||||||||2018-06-01 03:29:36.860931|2018-06-01 03:29:36.860931
NCT00424671|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2007-06-21|2007-01-18|2007-01-19|Estimate|||||||2007-06-21|2007-06-22|Estimate|November 2006||2006-11-30|June 2007|2007-06-30||||||||Interventional|||Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine|An Open-Label Study in Healthy Subjects and in Subjects With Stable Impaired Hepatic Function to Assess the Effect of Moderate Hepatic Impairment on Licarbazepine Pharmacokinetics and Metabolism After a Single Dose of 1000 mg Licarbazepine IR Tablets|Completed||Phase 1|16||Novartis|||||f||||||||||||||2018-06-01 03:29:36.920641|2018-06-01 03:29:36.920641
NCT00424658|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2015-03-31|2007-01-17|2007-01-19|Estimate|||||||2015-03-31|2015-04-01|Estimate|January 2000||2000-01-31|January 2007|2007-01-31|April 2004||2004-04-30|||||Interventional|||Sleep Apnea. Concordance Between Non-reference and Reference Centres||Completed||Phase 4|90||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:29:36.973146|2018-06-01 03:29:36.973146
NCT00424645|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2010-11-09||2012-12-04|2007-01-17|2007-01-19|Estimate|2010-12-10|2011-01-07|Estimate||||2012-12-04|2012-12-06|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Voraxaze for Delayed Methotrexate Clearance|Randomized, Double-Blind, Placebo Controlled Trial of Voraxaze™ in Patients With a Delayed MTX Clearance|Terminated||Phase 1/Phase 2|3|Actual|M.D. Anderson Cancer Center||2||Sponsor terminated due to low accrual.|f||||t||||||||||2018-06-01 03:29:37.043579|2018-06-01 03:29:37.043579
NCT00424632|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2012-03-21||2012-06-14|2007-01-18|2007-01-19|Estimate|2012-05-07|2012-06-12|Estimate||||2012-06-14|2012-06-25|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors|A Phase 1, Open Label, Multi-Center, Accelerated Dose-Escalation, Pharmacokinetic And Pharmacodynamic Trial Of The Oral Single Agent Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors For Whom No Standard Therapy Is Available|Completed||Phase 1|57|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:29:37.313873|2018-06-01 03:29:37.313873
NCT00424619|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2011-07-25||2012-05-11|2007-01-17|2007-01-19|Estimate|2012-05-11|2012-06-14|Estimate||||2012-05-11|2012-06-14|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients|A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients|Completed||Phase 4|64|Actual|McMaster University||3|||f||||f||||||||||2018-06-01 03:29:39.243553|2018-06-01 03:29:39.243553
NCT00424606|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2015-05-19|2007-01-18|2007-01-19|Estimate|||||||2015-05-19|2015-05-20|Estimate|June 2001||2001-06-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients|A Multicenter Randomized Phase III Study of Adjuvant Treatment With Epirubicin Followed by Docetaxel (E/T) Versus Epirubicin and Docetaxel Combination (ET) in High Risk Lymph Node Negative Breast Cancer Patients|Completed||Phase 3|658|Actual|Hellenic Oncology Research Group||2|||f||||||||||||||2018-06-01 03:29:39.629973|2018-06-01 03:29:39.629973
NCT00424593|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2009-10-16||2009-11-18|2007-01-17|2007-01-19|Estimate|2009-10-16|2009-11-18|Estimate||||2009-11-18|2009-11-20|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|October 2008|Actual|2008-10-31|December 2007|Actual|2007-12-31||Interventional|||Duloxetine Versus Placebo in Chronic Low Back Pain|Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain|Completed||Phase 3|236|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:29:39.793702|2018-06-01 03:29:39.793702
NCT00424580|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2008-01-18|2007-01-18|2007-01-19|Estimate|||||||2008-01-18|2008-01-23|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Airway Responses to Montelukast and Desloratadine.|Airway Responses to Montelukast and Desloratadine.|Completed||N/A|12||University of Saskatchewan|||||f||||||||||||||2018-06-01 03:29:41.238168|2018-06-01 03:29:41.238168
NCT00424567|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2017-03-08|2007-01-18|2007-01-19|Estimate|||||||2017-03-08|2017-03-13|Actual|October 2003||2003-10-31|March 2017|2017-03-31|June 2007||2007-06-30|||||Interventional|||Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.|TRC Autologous Bone Marrow Cells for the Treatment of Appendicular Skeletal Fracture Non-Union|Terminated||Phase 1/Phase 2|36||Vericel Corporation||||Closed early for business reasons (not safety reasons)|t||||||||||||||2018-06-01 03:29:41.334592|2018-06-01 03:29:41.334592
NCT00424554|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2011-06-03||2017-05-15|2007-01-18|2007-01-19|Estimate|2011-06-03|2011-06-29|Estimate||||2017-05-15|2017-06-07|Actual|September 26, 2006|Actual|2006-09-26|May 2017|2017-05-31|February 16, 2011|Actual|2011-02-16|January 11, 2010|Actual|2010-01-11||Interventional|||Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)|A Phase II Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.|Completed||Phase 2|40|Actual|Merck Sharp & Dohme Corp.|"The assay developed to measure MGMT activity had high variability.~The TMZ assay was unable to detect the low levels of the drug due to the relatively low dose and short half life of TMZ."|2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:29:41.443905|2018-06-01 03:29:41.443905
NCT00424541|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2007-11-28|2007-01-18|2007-01-19|Estimate|||||||2007-11-28|2007-11-29|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension|A Multiple Center, Randomized, Double Blind, Parallel Group, Multiple Oral Doses Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profiles of 150 mg and 300 mg of SPP100 in Japanese Patients With Mild to Moderate Essential Hypertension|Completed||Phase 1|34|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:29:41.805075|2018-06-01 03:29:41.805075
NCT00424528|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2008-10-24||2012-05-29|2007-01-18|2007-01-19|Estimate|2009-04-01|2009-04-02|Estimate||||2012-05-29|2012-06-04|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)|A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Once Daily in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|235|Actual|Sunovion|As of October 24, 2008, Sepracor is unaware of any limitations or caveats associated with this study.|3|||f||||f||||||||||2018-06-01 03:29:41.901959|2018-06-01 03:29:41.901959
NCT00424515|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2016-08-22||2016-10-16|2007-01-18|2007-01-19|Estimate|2016-10-16|2016-12-08|Estimate||||2016-10-16|2016-12-08|Estimate|July 2006||2006-07-31|June 2016|2016-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|BUS255|The analysis dataset is comprised of enrolled and treated patients.|Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma|A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin.|Completed||Phase 2|24|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 03:29:45.083256|2018-06-01 03:29:45.083256
NCT00424502|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2014-06-12||2016-04-04|2007-01-18|2007-01-19|Estimate|2014-06-12|2014-07-14|Estimate||||2016-04-04|2016-05-09|Estimate|January 2007||2007-01-31|April 2016|2016-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||All enrolled participants|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.|An Open-label Study to Evaluate the Effect of MabThera on Treatment Response in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Previous TNF Inhibition.|Completed||Phase 4|20|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:29:45.886956|2018-06-01 03:29:45.886956
NCT00424489|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2016-07-11|2007-01-18|2007-01-19|Estimate|||||||2016-07-11|2016-07-12|Estimate|February 2002||2002-02-28|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis|Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis|Terminated||Phase 1|9|Actual|Northwestern University||1||No participants enrolled for more than two years. No plan to continue study.|f||||f||||||||No||2018-06-01 03:29:46.26919|2018-06-01 03:29:46.26919
NCT00424476|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2011-04-07|2009-09-22|2016-10-28|2007-01-17|2007-01-19|Estimate|2011-04-07|2011-05-05|Estimate|2009-09-22|2009-09-24|Estimate|2016-10-28|2016-12-12|Estimate|May 2007||2007-05-31|October 2016|2016-10-31|March 2010|Actual|2010-03-31|May 2009|Actual|2009-05-31||Interventional|BLISS-52||A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 3|865|Actual|Human Genome Sciences Inc.||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:29:46.463446|2018-06-01 03:29:46.463446
NCT00424463|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2013-02-27|2007-01-17|2007-01-19|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)|An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3)|Completed||Phase 3|181|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 03:29:47.69009|2018-06-01 03:29:47.69009
NCT00424450|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2008-06-05|2007-01-18|2007-01-19|Estimate|||||||2008-06-05|2008-06-06|Estimate|October 2006||2006-10-31|June 2008|2008-06-30|July 2008|Anticipated|2008-07-31|January 2008|Actual|2008-01-31||Observational|||Assessment of Bypass Surgery and Balloon Angioplasty Effects in Peripheral Arterial Disease Using Contrast Ultrasound|Assessment of Revascularization Effects in Peripheral Arterial Disease Using Contrast Ultrasound Tissue Perfusion Imaging (REVASC-PI)|Unknown status|Active, not recruiting||30|Actual|University Hospital Freiburg|||1||f||||f||||||||||2018-06-01 03:29:47.75612|2018-06-01 03:29:47.75612
NCT00424437|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-02-09|2007-01-17|2007-01-19|Estimate|||||||2007-02-09|2007-02-13|Estimate|September 1999||1999-09-30|February 2007|2007-02-28|September 2000||2000-09-30|||||Interventional|||Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.|Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial|Completed||Phase 3|320||Pfizer|||||||||||||||||||2018-06-01 03:29:47.830122|2018-06-01 03:29:47.830122
NCT00424424|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2015-10-30|2007-01-18|2007-01-19|Estimate|||||||2015-10-30|2015-11-02|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002)|Proprietary Information - Exploratory (Non-Confirmatory) Trial|Terminated||Phase 2|81|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 03:29:47.935161|2018-06-01 03:29:47.935161
NCT00424411|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-02-09|2007-01-17|2007-01-19|Estimate|||||||2007-02-09|2007-02-13|Estimate|September 1999||1999-09-30|February 2007|2007-02-28|December 2000||2000-12-31|||||Interventional|||Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 2 Diabetes|Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial|Completed||Phase 3|300||Pfizer|||||||||||||||||||2018-06-01 03:29:47.996001|2018-06-01 03:29:47.996001
NCT00424398|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2009-10-08|2009-10-08|2013-02-13|2007-01-17|2007-01-19|Estimate|2012-02-22|2012-03-26|Estimate|2012-02-22|2012-03-26|Estimate|2013-02-13|2013-02-15|Estimate|February 2007||2007-02-28|February 2013|2013-02-28||||July 2007|Actual|2007-07-31||Interventional|||Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis|A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis|Completed||Phase 2/Phase 3|107|Actual|Bausch & Lomb Incorporated||3|||f||||||||||||||2018-06-01 03:29:48.149051|2018-06-01 03:29:48.149051
NCT00424385|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2013-05-24||2014-06-19|2007-01-18|2007-01-19|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|January 2007||2007-01-31|June 2014|2014-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)|Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-Independent Chemotherapy-Failure Prostate Cancer.|Completed||Phase 1|17|Actual|Oncology Specialists, S.C.||1|||f||||f||||||||||2018-06-01 03:29:49.82172|2018-06-01 03:29:49.82172
NCT00424346|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2013-04-02||2014-01-14|2007-01-17|2007-01-19|Estimate|2013-06-11|2013-06-19|Estimate||||2014-01-14|2014-02-10|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|October 2009|Actual|2009-10-31|September 2008|Actual|2008-09-30||Interventional|||Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis|A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of ACZ885 (Anti-interleukin-1beta Monoclonal Antibody) With Three Different Dose Regimens in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate Including 76-week and 96-week Extensions|Completed||Phase 2|274|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:29:50.563716|2018-06-01 03:29:50.563716
NCT00424333|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-02-09|2007-01-17|2007-01-19|Estimate|||||||2007-02-09|2007-02-13|Estimate|May 1999||1999-05-31|February 2007|2007-02-28|October 2000||2000-10-31|||||Interventional|||Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes|Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin in an Intensive Insulin Regimen for Subjects With Type 1 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial|Completed||Phase 3|320||Pfizer|||||||||||||||||||2018-06-01 03:29:52.601793|2018-06-01 03:29:52.601793
NCT00424320|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|||2007-01-18|2007-01-18|2007-01-19|Estimate|||||||2007-01-18|2007-01-19|Estimate|October 2006||2006-10-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Clinical Trial of Sodium Bicarbonate to Prevent Contrast-Induced Nephropathy|Clinical Controlled Trial to Determinate the Role of Sodium Bicarbonate in the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing to Diagnostic Coronariography and/or Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 3|100||Instituto Nacional de Cardiologia Ignacio Chavez|||||f||||||||||||||2018-06-01 03:29:52.711417|2018-06-01 03:29:52.711417
NCT00424307|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2011-06-24|2007-01-18|2007-01-19|Estimate|||||||2011-06-24|2011-06-27|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||Bilateral Cochlear Implant Benefit in Young Children|Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Advanced Bionics|||||f||||f||||||||||2018-06-01 03:29:52.791703|2018-06-01 03:29:52.791703
NCT00424294|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2014-09-10|2009-04-06|2014-09-10|2007-01-18|2007-01-19|Estimate|2014-09-10|2014-09-25|Estimate|2011-03-24|2011-04-01|Estimate|2014-09-10|2014-09-25|Estimate|June 2006||2006-06-30|September 2014|2014-09-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional||Full analysis set (FAS) was an intent-to-treat analysis set including all participants randomized to treatment who had taken at least 1 dose of study drug.|A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CP-195543 And Celecoxib Dual Therapy In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate|Terminated||Phase 2|70|Actual|Pfizer|The study was terminated early because it was determined that the dual therapy with CP-195543 and celecoxib had poor tolerability and a high discontinuation rate.|3||See Detailed Description field|f||||t||||||||||2018-06-01 03:29:52.926162|2018-06-01 03:29:52.926162
NCT00424281|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-01-17|2007-01-17|2007-01-19|Estimate|||||||2007-01-17|2007-01-19|Estimate|February 2007||2007-02-28|January 2007|2007-01-31|January 2010||2010-01-31|||||Observational|||Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication|Pharmacokinetics of Fondaparinux (Arixtra) to Critically Ill Patients on Vasopressor Therapy|Unknown status|Not yet recruiting||40||Wayne State University|||||f||||||||||||||2018-06-01 03:29:54.001011|2018-06-01 03:29:54.001011
NCT00424268|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-18|2011-03-17||2016-10-24|2007-01-18|2007-01-19|Estimate|2011-04-20|2011-05-19|Estimate||||2016-10-24|2016-12-05|Estimate|January 2007||2007-01-31|September 2016|2016-09-30|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|HELIOS||Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)|Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study|Completed||Phase 3|743|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:29:54.229854|2018-06-01 03:29:54.229854
NCT00424255|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2013-11-27||2014-07-10|2007-01-17|2007-01-19|Estimate|2013-12-19|2014-02-11|Estimate||||2014-07-10|2014-07-18|Estimate|December 2006||2006-12-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Interventional|||Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery|A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects With Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 3|688|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:29:55.010226|2018-06-01 03:29:55.010226
NCT00424242|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2017-03-15|2007-01-16|2007-01-18|Estimate|||||||2017-03-15|2017-03-17|Actual|January 2007||2007-01-31|March 2017|2017-03-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases|A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases|Active, not recruiting||Early Phase 1|15|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 03:29:57.039443|2018-06-01 03:29:57.039443
NCT00424229|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2007-03-09|2007-01-17|2007-01-18|Estimate|||||||2007-03-09|2007-03-12|Estimate|October 2006||2006-10-31|January 2007|2007-01-31|October 2008||2008-10-31|||||Interventional|||Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]|Phase II Study of the Efficacy and Safety of Lenalidomide in Adult Subjects With Intermediate-2-or Higt Risk Myelodysplastic Syndrome(MDS) Associated With a Deletion (DEL) 5q [31]|Unknown status|Recruiting|Phase 2|49||Groupe Francophone des Myelodysplasies|||||f||||f||||||||||2018-06-01 03:29:57.13632|2018-06-01 03:29:57.13632
NCT00424216|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2017-06-30|2007-01-17|2007-01-18|Estimate|||||||2017-06-30|2017-07-02|Actual|January 11, 2007||2007-01-11|December 23, 2008|2008-12-23|December 23, 2008||2008-12-23|||||Interventional|||Direct Current Brain Polarization of the Frontal Lobes|Direct Current Brain Polarization of Bilateral Prefrontal Cortex|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:29:57.241338|2018-06-01 03:29:57.241338
NCT00424203|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2013-09-02|2007-01-16|2007-01-18|Estimate|||||||2013-09-02|2013-09-04|Estimate|January 2006||2006-01-31|September 2013|2013-09-30|November 2011|Actual|2011-11-30|January 2008|Actual|2008-01-31||Interventional|||Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery|Multicenter Pilot Clinical Study of Adjuvant Chemotherapy for Subjects Over 70 Years: Impact on the Independence and Quality of Life of the Administration of Anthracycline-Based Chemotherapy in Adjuvant Setting for Patients Presenting With Immediately Operable Breast Cancer, Hormone Receptor Negative (RH-), and Lymph Node Positive (pN+) or pN0 But of Scarff-Bloom-Richardson* Grade III and ≥ 2cm [GERICO]|Completed||Phase 2|40|Actual|UNICANCER||1|||f||||f||||||||||2018-06-01 03:29:57.298367|2018-06-01 03:29:57.298367
NCT00424190|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2010-10-12||2017-02-02|2007-01-16|2007-01-18|Estimate|2010-10-12|2010-11-08|Estimate||||2017-02-02|2017-03-14|Actual|February 2007||2007-02-28|February 2017|2017-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|cSSSI||Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection|Completed||Phase 3|698|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 03:29:57.420299|2018-06-01 03:29:57.420299
NCT00424177|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2009-06-23||2013-07-25|2007-01-17|2007-01-18|Estimate|2009-06-23|2009-08-11|Estimate||||2013-07-25|2013-07-30|Estimate|March 2007||2007-03-31|May 2012|2012-05-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)|An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Completed||Phase 2|66|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:29:57.89149|2018-06-01 03:29:57.89149
NCT00424164|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2013-06-18|2007-01-16|2007-01-18|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 2006||2006-11-30|June 2013|2013-06-30||||June 2009|Actual|2009-06-30||Interventional|LAPATAM||Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer|Pharmacokinetics Study of Combined Treatment Lapatinib and Tamoxifen in Advanced/Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 03:29:58.846137|2018-06-01 03:29:58.846137
NCT00424151|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2010-10-04|2007-01-17|2007-01-18|Estimate|||||||2010-10-04|2010-10-06|Estimate|December 2006||2006-12-31|October 2010|2010-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy|Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Phase I/II|Completed||Phase 1/Phase 2|12|Actual|Silkiss, Rona Z., M.D., FACS|||||f||||||||||||||2018-06-01 03:29:58.915289|2018-06-01 03:29:58.915289
NCT00424138|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2017-06-26|2007-01-16|2007-01-18|Estimate|||||||2017-06-26|2017-06-28|Actual|March 30, 2007|Actual|2007-03-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ACRIN6678||FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy|[18F]FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer|Terminated||N/A|96|Actual|American College of Radiology Imaging Network||3||Recruitment obstacles; data to be combined with other resources for analysis|f||||t||||||||Yes|"See ACRIN data sharing policy:~https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx"|2018-06-01 03:29:58.979871|2018-06-01 03:29:58.979871
NCT00424125|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2015-08-21|2007-01-17|2007-01-18|Estimate|||||||2015-08-21|2015-08-25|Estimate|July 2006||2006-07-31|August 2015|2015-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Involving Community Pharmacies in Improving Asthma Outcomes in an Urban Pediatric Population|Improving Pediatric Asthma Care in the District of Columbia (IMPACT DC)-Community Pharmacy Intervention|Completed||N/A|125|Actual|Children's Research Institute||1|||f||||||||||||||2018-06-01 03:29:59.198982|2018-06-01 03:29:59.198982
NCT00424112|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-01-17|2007-01-17|2007-01-18|Estimate|||||||2007-01-17|2007-01-18|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|September 2006||2006-09-30|||||Observational|||Motivation in Alcohol Treatment Facilities|Stages an Processes of Change in Help-Seeking and Drinking Behavior|Completed|||450||University Medicine Greifswald|||||f||||||||||||||2018-06-01 03:29:59.268149|2018-06-01 03:29:59.268149
NCT00424099|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2011-12-06|2007-01-16|2007-01-18|Estimate|||||||2011-12-06|2011-12-07|Estimate|January 2007||2007-01-31|December 2011|2011-12-31||||December 2012|Anticipated|2012-12-31||Interventional|||Methylphenidate and a Nursing Telephone Intervention for Fatigue|A Randomized Controlled Trial of Methylphenidate and a Nursing Telephone Intervention (NTI) for Fatigue in Advanced Cancer Patients|Unknown status|Active, not recruiting|N/A|212|Anticipated|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-06-01 03:29:59.318113|2018-06-01 03:29:59.318113
NCT00424086|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2015-10-07|2007-01-17|2007-01-18|Estimate|||||||2015-10-07|2015-10-09|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)|Single Blind, Randomized, Actively Controlled Phase 1/2 Study to Compare the Safety and Immunogenicity of a Split Virus, Vero Cell Derived, Seasonal Influenza Vaccine (VCIC) With a Licensed, Egg Derived, Split Virus, Seasonal Influenza Vaccine (EIV)|Completed||Phase 1/Phase 2|1000|Anticipated|Ology Bioservices|||||f||||t||||||||||2018-06-01 03:29:59.403327|2018-06-01 03:29:59.403327
NCT00424060|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2012-09-20|2007-01-16|2007-01-18|Estimate|||||||2012-09-20|2012-09-24|Estimate|December 2006||2006-12-31|September 2012|2012-09-30||||August 2007|Actual|2007-08-31||Interventional|||Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma|Phase II Study of ZK 219477 in Patients With Recurrent Glioblastoma|Completed||Phase 2|38|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 03:29:59.463897|2018-06-01 03:29:59.463897
NCT00424047|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2015-02-13||2017-09-18|2007-01-17|2007-01-18|Estimate|2015-03-03|2015-03-04|Estimate||||2017-09-18|2017-10-19|Actual|January 1, 2003|Actual|2003-01-01|September 2017|2017-09-30|November 12, 2013|Actual|2013-11-12|November 1, 2005|Actual|2005-11-01||Interventional||Intent to treat population included all participants who were randomized|A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma|The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.|Completed||Phase 3|351|Actual|Celgene||2|||f||||t||||||||||2018-06-01 03:29:59.648461|2018-06-01 03:29:59.648461
NCT00424034|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2017-01-18|2007-01-17|2007-01-18|Estimate|||||||2017-01-18|2017-01-19|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study of GSK1325760A in Healthy Japanese Subjects|Phase I Study of Ambrisentan - Single Dose Study in Healthy Japanese Male Subjects|Completed||Phase 1|32|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:30:01.007955|2018-06-01 03:30:01.007955
NCT00424021|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2011-07-12||2011-12-21|2007-01-17|2007-01-18|Estimate|2011-12-21|2012-01-27|Estimate||||2011-12-21|2012-01-27|Estimate|April 2003||2003-04-30|December 2011|2011-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension|An Open-Label, Long-Term Study of Ambrisentan in Pulmonary Hypertension Subjects Having Completed Myogen Study AMB-220|Completed||Phase 2|54|Actual|Gilead Sciences|The small sample size, nonrandomized dose group assignments, and the potential for dose adjustments precluded meaningful comparisons between the dose groups. Therefore, efficacy results are only presented for the combined ambrisentan group.||||f||||||||||||||2018-06-01 03:30:01.158052|2018-06-01 03:30:01.158052
NCT00424008|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2010-06-30|2009-04-17|2017-03-15|2007-01-17|2007-01-18|Estimate|2010-10-07|2010-11-01|Estimate|2009-09-30|2009-10-02|Estimate|2017-03-15|2017-04-12|Actual|April 2007||2007-04-30|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)|A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50mcg BID Delivered by Dry Powder Inhaler (Diskus) Versus Mometasone Furoate/Formoterol Fumarate 200/10mcg BID Delivered by Pressurized Metered-Dose Inhaler in Persistent Asthmatics Previously Treated With Medium Doses of Inhaled Glucocorticosteroids|Completed||Phase 3|722|Actual|Merck Sharp & Dohme Corp.|The sponsor closed the study early, at 12 weeks treatment, for reasons that were not safety related. No efficacy analysis of data collected beyond 12 weeks of treatment was performed. All safety data were examined regardless of treatment duration.|2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:30:06.602832|2018-06-01 03:30:06.602832
NCT00423995|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2017-03-22|2007-01-17|2007-01-18|Estimate|||||||2017-03-22|2017-03-24|Actual|November 1, 2006|Actual|2006-11-01|March 2017|2017-03-31|March 10, 2007|Actual|2007-03-10|March 1, 2007|Actual|2007-03-01||Interventional|||Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)|Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit|Completed||Phase 3|379|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:30:07.106017|2018-06-01 03:30:07.106017
NCT00423982|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2013-06-26|2007-01-17|2007-01-18|Estimate|||||||2013-06-26|2013-06-27|Estimate|April 2006||2006-04-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty|Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 03:30:07.176915|2018-06-01 03:30:07.176915
NCT00423969|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-01-17|2007-01-17|2007-01-18|Estimate|||||||2007-01-17|2007-01-18|Estimate|November 2003||2003-11-30|January 2007|2007-01-31|September 2005||2005-09-30|||||Interventional|||Galantamine Augmentation of Escitalopram for Treatment of Depression|Galantamine Augmentation of Escitalopram for Treatment of Depression Associated Cognitive Impairment in Outpatients - A Randomized Single Blind Clinical Trial|Terminated||Phase 4|20||Indiana University|||||f||||||||||||||2018-06-01 03:30:07.276448|2018-06-01 03:30:07.276448
NCT00423956|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2013-01-20|2007-01-16|2007-01-18|Estimate|||||||2013-01-20|2013-01-23|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Repair of Orthodontically-induced Tooth Root Resorption by Ultrasound|Repair of Orthodontically-induced Tooth Root Resorption by Ultrasound in Human Subjects|Unknown status|Recruiting|Phase 1/Phase 2|72|Anticipated|University of Alberta, Graduate Orthodontic Program||1|||f||||t||||||||||2018-06-01 03:30:07.372786|2018-06-01 03:30:07.372786
NCT00423943|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2017-01-18||2017-08-31|2007-01-16|2007-01-18|Estimate|2017-08-31|2017-09-29|Actual||||2017-08-31|2017-09-29|Actual|September 2005||2005-09-30|August 2017|2017-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia|Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia|Completed||Phase 4|33|Actual|University of California, Los Angeles||2|||f||||f||||||||Undecided||2018-06-01 03:30:07.517256|2018-06-01 03:30:07.517256
NCT00423930|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2017-06-20||2017-07-19|2007-01-16|2007-01-18|Estimate|2017-07-19|2017-08-18|Actual||||2017-07-19|2017-08-18|Actual|October 2006||2006-10-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Forty-four patients were enrolled on the study between November 20, 2006 and October 22, 2008. Two patients withdrew consent before receiving any treatment on the study.|Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers|Completed||Phase 2|44|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:30:08.281327|2018-06-01 03:30:08.281327
NCT00423917|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2016-12-05||2018-04-06|2007-01-16|2007-01-18|Estimate|2017-03-28|2017-04-04|Actual||||2018-04-06|2018-05-08|Actual|August 2007||2007-08-31|April 2018|2018-04-30|January 15, 2017|Actual|2017-01-15|February 2009|Actual|2009-02-28||Interventional|||Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor|Completed||Phase 2|36|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 03:30:09.079919|2018-06-01 03:30:09.079919
NCT00423904|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-01-17|2007-01-17|2007-01-18|Estimate|||||||2007-01-17|2007-01-18|Estimate|October 2001||2001-10-31|January 2007|2007-01-31|August 2005||2005-08-31|||||Interventional|||Brief Alcohol Intervention in General Hospitals|Implementing Early Intervention for Alcohol Use Disorders in the General Hospital|Completed||Phase 2|1035||University Medicine Greifswald|||||f||||||||||||||2018-06-01 03:30:10.010996|2018-06-01 03:30:10.010996
NCT00423891|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2014-07-15||2018-03-30|2007-01-16|2007-01-18|Estimate|2014-07-15|2014-08-07|Estimate||||2018-03-30|2018-05-02|Actual|June 30, 2007|Actual|2007-06-30|March 2018|2018-03-31|September 4, 2017|Actual|2017-09-04|August 31, 2013|Actual|2013-08-31||Interventional||All participants who received at least one dose of study drug.|A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection|Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive|Completed||Phase 1/Phase 2|64|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-06-01 03:30:10.215864|2018-06-01 03:30:10.215864
NCT00423878|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2012-11-16||2016-09-27|2007-01-16|2007-01-18|Estimate|2012-11-16|2012-12-19|Estimate||||2016-09-27|2016-11-02|Estimate|January 2007||2007-01-31|November 2010|2010-11-30|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional|CAMP||Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder|Clinical Management of Metabolic Problems in Patients With Schizophrenia|Completed||Phase 4|215|Actual|National Institute of Mental Health (NIMH)|Open-label treatment is a limitation of this study, particularly for outcomes not measured in the laboratory but instead subject to clinical judgment.|2|||f||||t||||||||||2018-06-01 03:30:12.161721|2018-06-01 03:30:12.161721
NCT00423865|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2015-05-22|2007-01-16|2007-01-18|Estimate|||||||2015-05-22|2015-05-25|Estimate|November 2006||2006-11-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors|A Phase I Study of Weekly Low-Dose Cisplatin Plus Escalating Doses of Oral RAD001(Everolimus) for Patients With Advanced Solid Tumors|Completed||Phase 1|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:30:12.716878|2018-06-01 03:30:12.716878
NCT00423852|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2015-12-17||2016-04-12|2007-01-16|2007-01-18|Estimate|2016-04-12|2016-05-18|Estimate||||2016-04-12|2016-05-18|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin|Phase I/II Trial of Sequential Paclitaxel/Ifosfamide Followed by Dose-Escalated, Dose-Intensive Carboplatin, Paclitaxel and Ifosfamide With Stem Cell Support in Cisplatin-Resistant Germ Cell Tumor Patients|Completed||Phase 1/Phase 2|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:30:12.83329|2018-06-01 03:30:12.83329
NCT00423839|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-01-17|2007-01-17|2007-01-18|Estimate|||||||2007-01-17|2007-01-18|Estimate|March 2003||2003-03-31|December 2006|2006-12-31|July 2005||2005-07-31|||||Interventional|||A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers|A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers|Completed||Phase 1|12||University of Oxford|||||f||||||||||||||2018-06-01 03:30:13.111131|2018-06-01 03:30:13.111131
NCT00423826|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2016-02-26|2007-01-16|2007-01-18|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Expanded Access|||Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease|A Pilot Study of Double Cord Blood Stem Cell Transplantation in Patients With Hematologic Malignancies|No longer available|||||Barbara Ann Karmanos Cancer Institute|||||f||||||||||||||2018-06-01 03:30:13.209721|2018-06-01 03:30:13.209721
NCT00423813|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2011-09-08||2012-01-20|2007-01-17|2007-01-18|Estimate|2011-12-05|2012-01-10|Estimate||||2012-01-20|2012-01-24|Estimate|December 2006||2006-12-31|December 2011|2011-12-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.|A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.|Completed||Phase 3|573|Actual|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:30:13.349435|2018-06-01 03:30:13.349435
NCT00423800|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2011-01-27||2017-03-09|2007-01-17|2007-01-18|Estimate|2011-01-27|2011-02-23|Estimate||||2017-03-09|2017-04-07|Actual|December 2006||2006-12-31|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)|Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) Therapy (1.5 mcg/kg/Week + 800-1200 mg/Day) in Naïve Genotype 1 Hepatitis C Patients With High Baseline Viral Load Who Are HCV-RNA Negative at Week 4 and Week 12|Terminated||Phase 3|56|Actual|Merck Sharp & Dohme Corp.|Due to the small sample size (n=5), no conclusions should be drawn.|2||The study was terminated due to difficulty in recruiting participants.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:30:14.783093|2018-06-01 03:30:14.783093
NCT00423787|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2010-06-16|2007-01-17|2007-01-18|Estimate|||||||2010-06-16|2010-06-17|Estimate|March 2007||2007-03-31|June 2010|2010-06-30|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety/Tolerability of Ragweed MATA MPL|Efficacy and Safety/Tolerability of Ragweed MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study|Completed||Phase 3|993|Actual|Allergy Therapeutics||2|||f||||t||||||||||2018-06-01 03:30:15.222354|2018-06-01 03:30:15.222354
NCT00423774|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2017-06-30|2007-01-17|2007-01-18|Estimate|||||||2017-06-30|2017-07-02|Actual|January 11, 2007||2007-01-11|September 28, 2010|2010-09-28|December 1, 2008|Actual|2008-12-01|December 1, 2008|Actual|2008-12-01||Interventional|||Education Program to Manage Emotional Stress of Stem Cell Transplant Recipients and Their Caregivers|A Feasibility Study to Test an Individualized Dyadic Problem-Solving Education Intervention to Improve Problem-Solving Skills of Patients and Family Caregivers During Allogeneic HSCT|Completed||Phase 1|20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:30:15.619182|2018-06-01 03:30:15.619182
NCT00423761|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2009-05-15|2007-01-17|2007-01-18|Estimate|||||||2009-05-15|2009-05-18|Estimate|December 2006||2006-12-31|May 2009|2009-05-31||||||||Interventional|||An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam.|An Open-Label, Single-Sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of GW876008 in Healthy Subjects|Completed||Phase 1|25|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:30:16.3187|2018-06-01 03:30:16.3187
NCT00423748|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2009-04-15|2007-01-17|2007-01-18|Estimate|||||||2009-04-15|2009-04-16|Estimate|December 2003||2003-12-31|April 2009|2009-04-30|February 2006||2006-02-28|||||Interventional|||Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.|Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 3|186||Gilead Sciences|||||||||||||||||||2018-06-01 03:30:16.454819|2018-06-01 03:30:16.454819
NCT00423735|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2014-06-19||2018-04-20|2007-01-16|2007-01-18|Estimate|2014-12-18|2015-01-06|Estimate||||2018-04-20|2018-05-21|Actual|January 24, 2007|Actual|2007-01-24|April 2018|2018-04-30||||March 9, 2011|Actual|2011-03-09||Interventional||Eligible patients who started protocol treatment.|Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme|Active, not recruiting||Phase 2|64|Actual|National Cancer Institute (NCI)|Designed as a 2-stage study. The protocol was amended after Stage 1 to add Stage 1B allowing intra-patient escalation. Per protocol criteria, the study did not continue to Stage 2.|1|||f||||f||||||||||2018-06-01 03:30:16.604074|2018-06-01 03:30:16.604074
NCT00423722|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2012-07-05||2015-11-16|2007-01-17|2007-01-18|Estimate|2015-11-16|2015-12-17|Estimate||||2015-11-16|2015-12-17|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Parenteral Hydration in Advanced Cancer Patients|Parenteral Hydration in Advanced Cancer Patients - A Randomized Controlled Trial|Completed||N/A|262|Actual|M.D. Anderson Cancer Center|Study had a planned sample size of 150 participants but due to funding issues recruitment was halted after 129 patients; additionally, participants with delirium or severe dehydration were excluded for logistic purposes.|2|||f||||t||||||||||2018-06-01 03:30:17.929509|2018-06-01 03:30:17.929509
NCT00423709|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2012-01-20|2007-01-16|2007-01-18|Estimate|||||||2012-01-20|2012-01-24|Estimate|January 1998||1998-01-31|January 2012|2012-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Allogeneic Blood Stem Cell Transplantation|A Study of Allogeneic Blood Stem Cell Transplantation With Purine Analog-Based Conditioning For Patients With Advanced Hodgkin's Disease|Completed||N/A|46|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 03:30:18.581445|2018-06-01 03:30:18.581445
NCT00423540|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2008-12-09|2007-01-17|2007-01-18|Estimate|||||||2008-12-09|2008-12-10|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Exploring the Role of Magnesium in Rest Cramps|Magnesium Status & Effect of Magnesium Infusions on Rest Cramps|Completed||N/A|54|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:30:25.804739|2018-06-01 03:30:25.804739
NCT00423696|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2011-09-28|2007-01-16|2007-01-18|Estimate|||||||2011-09-28|2011-09-29|Estimate|January 2006||2006-01-31|September 2011|2011-09-30||||||||Interventional|||Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Metastatic Colorectal Cancer [ACCORD]|Unknown status|Active, not recruiting|Phase 2|144|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:30:18.718364|2018-06-01 03:30:18.718364
NCT00423683|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2012-10-24||2016-05-06|2007-01-17|2007-01-18|Estimate|2016-03-30|2016-05-03|Estimate||||2016-05-06|2016-06-08|Estimate|January 2007||2007-01-31|May 2016|2016-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism|A Randomized Control Trial of Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With A Venous Thromboembolism|Terminated||Phase 3|64|Actual|Northwell Health||2||Study accrual stopped due to poor accrual.|f||||t||||||||No||2018-06-01 03:30:18.847573|2018-06-01 03:30:18.847573
NCT00423670|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2011-05-13|2009-04-17|2017-03-08|2007-01-17|2007-01-18|Estimate|2011-05-13|2011-06-15|Estimate|2009-10-01|2009-10-05|Estimate|2017-03-08|2017-04-05|Actual|January 2007||2007-01-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)|A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1|Completed||Phase 2|765|Actual|Merck Sharp & Dohme Corp.||8|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:30:19.264596|2018-06-01 03:30:19.264596
NCT00423657|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2010-10-12||2017-02-02|2007-01-16|2007-01-18|Estimate|2010-10-12|2010-11-18|Estimate||||2017-02-02|2017-03-14|Actual|March 2007||2007-03-31|February 2017|2017-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections|A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI)|Completed||Phase 3|680|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 03:30:21.985966|2018-06-01 03:30:21.985966
NCT00423644|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2013-11-13|2007-01-17|2007-01-18|Estimate|||||||2013-11-13|2013-11-14|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b|A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b|Unknown status|Active, not recruiting|Phase 2|17|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 03:30:22.87194|2018-06-01 03:30:22.87194
NCT00423631|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2011-10-06|2007-01-17|2007-01-18|Estimate|||||||2011-10-06|2011-10-10|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Web-based Education to Enhance Fibromyalgia Management|Internet-Enhanced Management of Fibromyalgia|Completed||N/A|118|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 03:30:23.026522|2018-06-01 03:30:23.026522
NCT00423618|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2018-05-14|2007-01-17|2007-01-18|Estimate|||||||2018-05-14|2018-05-15|Actual|March 2006||2006-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VORTEX||Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma|Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX]|Active, not recruiting||Phase 3|216|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||No||2018-06-01 03:30:23.19944|2018-06-01 03:30:23.19944
NCT00423605|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2011-09-12||2012-03-28|2007-01-16|2007-01-18|Estimate|2011-09-12|2011-10-20|Estimate||||2012-03-28|2012-03-30|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.|A Long-Term, Open-Label, Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.|Completed||Phase 3|560|Actual|Jazz Pharmaceuticals||1|||f||||f||||||||||2018-06-01 03:30:23.434036|2018-06-01 03:30:23.434036
NCT00423592|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2010-05-14||2013-06-07|2007-01-17|2007-01-18|Estimate|2012-05-17|2012-06-20|Estimate||||2013-06-07|2013-06-17|Estimate|May 2005||2005-05-31|June 2013|2013-06-30|March 2009|Actual|2009-03-31|January 2006|Actual|2006-01-31||Interventional|||Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension|A Phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects With Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities|Completed||Phase 2|36|Actual|Gilead Sciences|Seven subjects were excluded from the change from baseline analysis of the SF-36 Health Survey because the incorrect version of the SF-36 questionnaire was used for evaluation at baseline, which made comparisons problematic.||||f||||||||||||||2018-06-01 03:30:24.07977|2018-06-01 03:30:24.07977
NCT00423579|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2009-03-19||2017-04-03|2007-01-17|2007-01-18|Estimate|2009-07-16|2009-08-25|Estimate||||2017-04-03|2017-05-09|Actual|July 1, 2006|Actual|2006-07-01|April 2017|2017-04-30|March 1, 2008|Actual|2008-03-01|March 1, 2008|Actual|2008-03-01||Interventional|||The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)|A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of Administration of Ezetimibe/Simvastatin Tablet 10/20 mg Versus Doubling the Dose of Simvastatin 20 mg [Simvastatin 40 mg] in Subjects With Primary Hypercholesterolemia and Coronary Heart Disease|Completed||Phase 4|120|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:30:25.210041|2018-06-01 03:30:25.210041
NCT00423566|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2007-01-17|2007-01-17|2007-01-18|Estimate|||||||2007-01-17|2007-01-18|Estimate|September 2002||2002-09-30|December 2006|2006-12-31|July 2003||2003-07-31|||||Interventional|||A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.|A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.|Completed||Phase 1|14||University of Oxford|||||f||||||||||||||2018-06-01 03:30:25.648478|2018-06-01 03:30:25.648478
NCT00423553|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2017-06-30|2007-01-17|2007-01-18|Estimate|||||||2017-06-30|2017-07-02|Actual|January 11, 2007||2007-01-11|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Collection of Heart Tissue Sample During Open Heart Surgery|Modifying Tolerance to Ischemic Injury in Human Atrial Tissue|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:30:25.729936|2018-06-01 03:30:25.729936
NCT00423527|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2009-12-17|2007-01-16|2007-01-18|Estimate|||||||2009-12-17|2009-12-18|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Levetiracetam in Central Pain in Multiple Sclerosis(MS)|Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis|Completed||Phase 4|30|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 03:30:25.951172|2018-06-01 03:30:25.951172
NCT00423514|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2018-05-02|2007-01-16|2007-01-18|Estimate|||||||2018-05-02|2018-05-07|Actual|November 2006|Actual|2006-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease|A Phase I/II Dose Escalation Trial of Clofarabine, in Addition to Melphalan and Thiotepa as Myeloablative Regimen Followed by an Allogeneic Unmodified Hematopoietic Stem Cell Transplant From HLA-Compatible Related or Unrelated Donors for the Treatment of High Risk and/or Advanced Hematologic Malignancies|Active, not recruiting||Phase 1/Phase 2|42|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:30:26.027368|2018-06-01 03:30:26.027368
NCT00423501|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2016-11-01|2007-01-17|2007-01-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.|A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.|Completed||Phase 2|306|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 03:30:26.233967|2018-06-01 03:30:26.233967
NCT00423488|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2010-02-17||2015-09-18|2007-01-17|2007-01-18|Estimate|2010-02-17|2010-03-09|Estimate||||2015-09-18|2015-09-21|Estimate|July 2005||2005-07-31|September 2015|2015-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)|A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing the Efficacy, Safety, and Tolerability of Co-administration of Ezetimibe 10 mg With Ongoing Treatment With Simvastatin 20 mg Versus Doubling the Dose of Simvastatin in Subjects With Primary Hypercholesterolemia Diabetes Mellitus Type 2 and Coronary Heart Disease|Completed||Phase 3|93|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:30:26.404553|2018-06-01 03:30:26.404553
NCT00423475|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2018-05-14|2007-01-16|2007-01-18|Estimate|||||||2018-05-14|2018-05-17|Actual|October 2006|Actual|2006-10-31|May 2018|2018-05-31||||March 2015|Actual|2015-03-31||Interventional|||Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer|Phase III Randomized Study of Adjuvant Radiotherapy With Versus Without Concurrent Goserelin in Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer|Completed||Phase 3|743|Actual|UNICANCER||2|||f||||t||||||||||2018-06-01 03:30:26.671574|2018-06-01 03:30:26.671574
NCT00423462|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-08-24|2007-01-16|2007-01-18|Estimate|||||||2007-08-24|2007-08-27|Estimate|January 1993||1993-01-31|August 2007|2007-08-31|December 2005||2005-12-31|||||Interventional|||First Experimental Study of Transference-Interpretations (FEST)|First Experimental Study of Transference Interpretations (FEST)|Completed||Phase 2/Phase 3|100||University of Oslo|||||f||||||||||||||2018-06-01 03:30:26.792129|2018-06-01 03:30:26.792129
NCT00423449|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2011-07-06||2016-02-03|2007-01-17|2007-01-18|Estimate|2011-07-06|2011-08-02|Estimate||||2016-02-03|2016-02-04|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)|A Phase I Clinical Trial of Vorinostat in Combination With Gemcitabine Plus Platinum in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|61|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 03:30:26.981407|2018-06-01 03:30:26.981407
NCT00423436|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2011-09-08||2011-11-14|2007-01-16|2007-01-18|Estimate|2011-11-14|2011-12-16|Estimate||||2011-11-14|2011-12-16|Estimate|April 2003||2003-04-30|November 2011|2011-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Interactive Voice Response (IVR) Symptom Assessment in Non-Small Cell Lung Cancer (NSCLC) Patients|Using an Interactive Voice Response Telephone System in the Assessment and Management of Symptoms in Advanced Lung Cancer Patients Receiving Chemotherapy|Completed||N/A|84|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:30:28.120546|2018-06-01 03:30:28.120546
NCT00423410|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2009-09-09|2007-01-16|2007-01-18|Estimate|||||||2009-09-09|2009-09-10|Estimate|December 2006||2006-12-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer|A First In Man Phase I Study Of EPC2407, A Microtubule Inhibitor Anti-Cancer Drug With Tumor Vascular Endothelial Disrupting Activity: Intravenous Administration Daily For Three Days In Patients With Advanced Solid Tumors And Lymphomas|Completed||Phase 1|30|Anticipated|EpiCept Corporation||1|||f||||f||||||||||2018-06-01 03:30:28.410317|2018-06-01 03:30:28.410317
NCT00423397|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2013-12-18|2007-01-16|2007-01-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2006||2006-09-30|March 2008|2008-03-31||||January 2008|Anticipated|2008-01-31||Interventional|||Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer|A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin|Unknown status|Active, not recruiting|Phase 1/Phase 2|16|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:30:28.62448|2018-06-01 03:30:28.62448
NCT00423384|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2010-03-22|2007-01-17|2007-01-18|Estimate|||||||2010-03-22|2010-03-24|Estimate|January 2007||2007-01-31|March 2010|2010-03-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Ibandronate Versus Placebo in the Prevention of Bone Loss After Renal Transplantation.|Ibandronate Versus Placebo as add-on to Active Vitamin D and Calcium in the Prevention of Bone Loss After Renal Transplantation.|Unknown status|Active, not recruiting|Phase 2/Phase 3|130|Anticipated|Smerud Medical Research International AS||2|||f||||f||||||||||2018-06-01 03:30:28.723724|2018-06-01 03:30:28.723724
NCT00423371|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2011-05-18|2007-01-17|2007-01-18|Estimate|||||||2011-05-18|2011-05-19|Estimate|December 2006||2006-12-31|May 2011|2011-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMC|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Osteoarthritis (OA) of the First Carpometacarpal (CMC) Joint|Completed||Phase 2/Phase 3|79|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:30:28.86886|2018-06-01 03:30:28.86886
NCT00423358|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2015-05-29||2015-07-27|2007-01-17|2007-01-18|Estimate|2015-07-27|2015-08-24|Estimate||||2015-07-27|2015-08-24|Estimate|February 2005||2005-02-28|July 2015|2015-07-31|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||Treatment of Hypovitaminosis D in Rheumatoid Arthritis|Treatment of Hypovitaminosis D in Rheumatoid Arthritis|Completed||N/A|22|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 03:30:29.022939|2018-06-01 03:30:29.022939
NCT00423345|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2012-08-24|2007-01-17|2007-01-18|Estimate|||||||2012-08-24|2012-08-27|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Colon Investigation - Factors Determining Choice of Procedure|Colon Investigation With Barium Enema, CT Colonography and Colonoscopy: A Prospective Registration of Indications, Delay and Procedure Results.|Unknown status|Active, not recruiting||750|Actual|Sykehuset Telemark|||||f||||t||||||||||2018-06-01 03:30:29.434872|2018-06-01 03:30:29.434872
NCT00423332|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2012-04-03|2011-04-06|2016-12-08|2007-01-16|2007-01-18|Estimate|2012-08-03|2012-09-06|Estimate|2011-04-06|2011-04-12|Estimate|2016-12-08|2017-02-02|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|March 2008|Actual|2008-03-31||Interventional|||Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma|A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib 45mg Versus Placebo Following 12 Weeks of Treatment in Patients With Metastatic or Recurrent Renal Cell Carcinoma Who Have Had no Previous Anti-VEGF Therapy.|Completed||Phase 2|105|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:30:29.569843|2018-06-01 03:30:29.569843
NCT00423319|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2014-04-14|2011-06-21|2014-04-14|2007-01-17|2007-01-18|Estimate|2014-04-14|2014-05-14|Estimate|2014-03-18|2014-03-19|Estimate|2014-04-14|2014-05-14|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)|A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery (The Advance-3 Study Apixaban Dosed Orally Versus Anticoagulation With Injectable Enoxaparin to Prevent Venous Thromboembolism)|Completed||Phase 3|5407|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:30:30.72278|2018-06-01 03:30:30.72278
NCT00423306|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2013-11-13|2007-01-17|2007-01-18|Estimate|||||||2013-11-13|2013-11-14|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma|A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 2|15|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 03:30:32.921003|2018-06-01 03:30:32.921003
NCT00423293|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2013-04-11||2016-12-30|2007-01-16|2007-01-18|Estimate|2013-04-11|2013-05-29|Estimate||||2016-12-30|2017-02-17|Actual|December 2006||2006-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|February 2009|Actual|2009-02-28||Interventional||All eligible patients|Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer|A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal|Completed||Phase 2|63|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 03:30:33.009912|2018-06-01 03:30:33.009912
NCT00423280|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2008-08-06|2007-01-17|2007-01-18|Estimate|||||||2008-08-06|2008-08-07|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)|A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects With Coronary Artery Disease|Unknown status|Recruiting|Phase 2|66|Anticipated|University of Oxford||3|||f||||t||||||||||2018-06-01 03:30:34.586655|2018-06-01 03:30:34.586655
NCT00423267|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2010-05-27||2017-03-13|2007-01-17|2007-01-18|Estimate|2010-05-27|2010-06-30|Estimate||||2017-03-13|2017-04-11|Actual|May 2007||2007-05-31|March 2017|2017-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)|A Multicenter, Randomized, Controlled, Double-Blind, Double-Dummy, Two-Arm Study of Posaconazole vs Fluconazole in the Treatment of Coccidioidomycosis|Completed||Phase 3|16|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:30:34.711849|2018-06-01 03:30:34.711849
NCT00423254|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2010-08-02|2007-01-12|2007-01-18|Estimate|||||||2010-08-02|2010-08-03|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.|A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies|Completed||Phase 1|12|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-06-01 03:30:35.153399|2018-06-01 03:30:35.153399
NCT00423241|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2010-08-20|2007-01-17|2007-01-18|Estimate|||||||2010-08-20|2010-08-23|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||SEMPERFLO* Pain Management System in Inguinal Hernia Repair|A Prospective, Randomized, Exploratory Comparison of the SEMPERFLO* Pain Management System to a Commercially Available Pain Relief System in Subjects Undergoing Open Inguinal Hernia Repair|Terminated||N/A|7|Actual|Ethicon, Inc.||2||Market dynamics including other technologies made the project not viable.|f||||f||||||||||2018-06-01 03:30:35.25702|2018-06-01 03:30:35.25702
NCT00423228|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2015-01-13|2007-01-17|2007-01-18|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2007||2007-02-28|January 2015|2015-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|BRAINz||Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease|A Randomised, Double-blind, Double-dummy, Oral Donepezil Controlled Study on the Safety and Efficacy of Repeated Monthly Subcutaneous Injections of a Sustained-release Implant of ZT 1 in Patients With Moderate Alzheimer's Disease|Completed||N/A|228|Actual|Debiopharm International SA||2|||f||||t||||||||||2018-06-01 03:30:35.338822|2018-06-01 03:30:35.338822
NCT00423215|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2009-06-12|2007-01-17|2007-01-18|Estimate|||||||2009-06-12|2009-06-15|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus|An Open Therapeutic Observational Evaluation of the Efficacy and Safety Profile of Lantus in Everyday Medical Practice in Type 2 Diabetes Mellitus Patients, Who Start Receiving Lantus - Treated With Any Other Insulin, With A1c>7%|Completed|||1007|Actual|Sanofi|||1||f||||f||||||||||2018-06-01 03:30:35.447861|2018-06-01 03:30:35.447861
NCT00376545|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2017-06-30|2006-09-14|2006-09-15|Estimate|||||||2017-06-30|2017-07-02|Actual|September 12, 2006||2006-09-12|November 13, 2009|2009-11-13||||November 13, 2008|Actual|2008-11-13||Observational|||Brain Connectivity Between Visual Input and Movement|Brain Connectivity Between Visual Input and Motor Output|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:46:20.25354|2018-06-01 03:46:20.25354
NCT00423202|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2009-04-15|2007-01-17|2007-01-18|Estimate|||||||2009-04-15|2009-04-16|Estimate|December 2003||2003-12-31|April 2009|2009-04-30|October 2005||2005-10-31|||||Interventional|||A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.|Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.|Completed||Phase 3|186||Gilead Sciences|||||||||||||||||||2018-06-01 03:30:35.503659|2018-06-01 03:30:35.503659
NCT00423189|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2012-10-17||2016-02-05|2007-01-16|2007-01-18|Estimate|2016-02-05|2016-03-04|Estimate||||2016-02-05|2016-03-04|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration|Lucentis Utilizing Visudyne (LUV Trial)-- Reduced Fluence Photodynamic Therapy With Visudyne Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration|Terminated||Phase 4|7|Actual|Greater Houston Retina Research|The trial was discontinued due to a lack of efficacy.|3||Lack of efficacy|f||||t||||||||||2018-06-01 03:30:35.585936|2018-06-01 03:30:35.585936
NCT00423176|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|2009-07-29||2017-03-15|2007-01-17|2007-01-18|Estimate|2010-05-21|2010-06-22|Estimate||||2017-03-15|2017-04-12|Actual|December 2006||2006-12-31|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)|Efficacy and Safety of 200mcg BID Mometasone Furoate Nasal Spray (MFNS) Versus Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis|Terminated||Phase 3|237|Actual|Merck Sharp & Dohme Corp.|The study was terminated early due to a very high screening failure rate (mainly caused by the necessity to demonstrate CT changes at baseline indicative of acute sinusitis), which limits any conclusions.|2||"Based on business priorities. Not related to any safety or efficacy issue & took place before~   data were unblinded or analyzed"|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:30:36.053416|2018-06-01 03:30:36.053416
NCT00423163|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17|||2015-08-31|2007-01-17|2007-01-18|Estimate|||||||2015-08-31|2015-09-02|Estimate|February 2007||2007-02-28|August 2015|2015-08-31||||||||Interventional|||A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis|A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis|Withdrawn||Phase 4|0|Actual|Astellas Pharma Inc||||"An alternative joint industry effort will provide information on combination versus single~   agent therapy for treatment of aspergillosis"|f||||t||||||||||2018-06-01 03:30:36.415064|2018-06-01 03:30:36.415064
NCT00423150|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2010-05-27||2017-05-12|2007-01-17|2007-01-18|Estimate|2010-05-27|2010-07-05|Estimate||||2017-05-12|2017-06-08|Actual|January 26, 2007|Actual|2007-01-26|May 2017|2017-05-31|June 11, 2009|Actual|2009-06-11|June 11, 2009|Actual|2009-06-11||Interventional|||Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)|A Phase 2 Study of Temozolomide (SCH 52365) in Subjects With Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter|Terminated||Phase 2|86|Actual|Merck Sharp & Dohme Corp.|Due to low response rate for colorectal cancer in interim analyses, low enrollment in head & neck and non-small cell lung cancer groups due to low methylation rates, and low overall response rate in esophageal cancer group, the study was terminated.|1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:30:36.539962|2018-06-01 03:30:36.539962
NCT00423137|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-17||2014-04-30|2014-04-30|2007-01-17|2007-01-18|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|January 2007||2007-01-31|April 2014|2014-04-30||||July 2008|Actual|2008-07-31||Interventional|||Effect of BIBW 2948 BS in COPD|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of a 4-week Treatment of 15 and 30 mg b.i.d BIBW2948 BS (Inhalation Powder, Hard Capsule for HandiHaler®) on Epithelial Mucin Stores and the Safety and Efficacy in COPD Patients With Symptoms Associated With Chronic Bronchitis|Completed||Phase 2|48|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:30:36.844916|2018-06-01 03:30:36.844916
NCT00423124|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2014-05-29|2007-01-16|2007-01-17|Estimate|||||||2014-05-29|2014-05-30|Estimate|July 2002||2002-07-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|December 2011|Actual|2011-12-31||Interventional|||Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies|A Phase I-II Study: Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK, After Transplantation of Allogeneic T-depleted Stem Cells From a Haploidentical Donor in Patients With Haematological Malignancies|Completed||Phase 1/Phase 2|57|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:30:36.928328|2018-06-01 03:30:36.928328
NCT00423111|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2007-09-20|2007-01-15|2007-01-17|Estimate|||||||2007-09-20|2007-09-21|Estimate|February 2007||2007-02-28|September 2007|2007-09-30|February 2009|Anticipated|2009-02-28|||||Observational|||Correlation Between Cognitive Functions and MRI in Multiple Sclerosis||Unknown status|Recruiting||100|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-06-01 03:30:37.021178|2018-06-01 03:30:37.021178
NCT00423098|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2010-12-14||2011-05-31|2007-01-16|2007-01-17|Estimate|2011-05-31|2011-06-28|Estimate||||2011-05-31|2011-06-28|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare|A Randomized, Multicenter, Open-label, 6-month Study to Explore the Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare|Completed||Phase 2|81|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:30:37.109879|2018-06-01 03:30:37.109879
NCT00423085|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|2011-04-27||2014-01-14|2007-01-12|2007-01-17|Estimate|2011-04-27|2011-05-25|Estimate||||2014-01-14|2014-02-10|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease|A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)|Completed||Phase 3|859|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:30:37.70232|2018-06-01 03:30:37.70232
NCT00423072|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2017-11-06|2007-01-12|2007-01-17|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2006||2006-08-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||Middle Ear Pressure Disregulation in Cleft Palate Patients|Middle Ear Pressure Disregulation in Cleft Palate Patients: Form-Function Correlates|Active, not recruiting|||82|Actual|University of Pittsburgh|||1||f||||f||||||||No||2018-06-01 03:30:38.731075|2018-06-01 03:30:38.731075
NCT00423059|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-03-12|2007-01-16|2007-01-17|Estimate|||||||2007-03-12|2007-03-13|Estimate|December 2006||2006-12-31|January 2007|2007-01-31|March 2007||2007-03-31|||||Interventional|||Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy|Histologic Changes of Fibrovascular Membrane Associated With Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab (Avastin®)|Completed||N/A|20||Yonsei University|||||f||||||||||||||2018-06-01 03:30:38.809682|2018-06-01 03:30:38.809682
NCT00423046|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2009-11-12||2016-08-29|2007-01-16|2007-01-17|Estimate|2010-07-29|2010-08-25|Estimate||||2016-08-29|2016-10-07|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|May 2012|Actual|2012-05-31|March 2008|Actual|2008-03-31||Interventional|||Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age|Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]|Completed||Phase 3|1106|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:30:39.00358|2018-06-01 03:30:39.00358
NCT00423033|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-14|||2008-12-25|2007-01-16|2007-01-17|Estimate|||||||2008-12-25|2008-12-29|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Qualitative Analysis on the Experiences of Employment Among Schizophrenic Patients||Completed|||50|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 03:30:40.997979|2018-06-01 03:30:40.997979
NCT00423020|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-01-16|2007-01-16|2007-01-17|Estimate|||||||2007-01-16|2007-01-17|Estimate||||January 2007|2007-01-31||||||||Interventional|||Anti-Restenosis After AMI by Erythropoietin|Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI)|Unknown status|Recruiting|Phase 4|72||Kyoto Prefectural University of Medicine|||||f||||||||||||||2018-06-01 03:30:41.037746|2018-06-01 03:30:41.037746
NCT00423007|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2013-03-13|2007-01-15|2007-01-17|Estimate|||||||2013-03-13|2013-03-14|Estimate|November 2006||2006-11-30|March 2013|2013-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis|Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With a History of Allergic Conjunctivitis|Completed||Phase 3|90||Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:30:41.130388|2018-06-01 03:30:41.130388
NCT00422994|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2016-10-24|2007-01-12|2007-01-17|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole|An Open-Label, Parallel-Group, Repeat-Dose Study to Investigate the Effects of End Stage Renal Disease and Haemodialysis on the Pharmacokinetics of Ropinirole (Study RRL103628)|Completed||Phase 1|48|Actual|GlaxoSmithKline|||||||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:30:41.19173|2018-06-01 03:30:41.19173
NCT00422981|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16||2012-07-11|2012-10-18|2007-01-16|2007-01-17|Estimate||||2012-10-10|2012-10-12|Estimate|2012-10-18|2012-10-24|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment|A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment|Completed||Phase 2|144|Actual|Allon Therapeutics||3|||f||||f||||||||||2018-06-01 03:30:41.454986|2018-06-01 03:30:41.454986
NCT00422968|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2014-04-29|2007-01-16|2007-01-17|Estimate|||||||2014-04-29|2014-05-01|Estimate|March 2005||2005-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|November 2009|Actual|2009-11-30||Interventional|PRECOMBAT||Bypass Surgery Versus Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease|PREmier of Randomized COMparison of Bypass Surgery Versus AngioplasTy Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease|Completed||Phase 3|1454|Actual|CardioVascular Research Foundation, Korea||2|||f||||t||||||||||2018-06-01 03:30:41.605198|2018-06-01 03:30:41.605198
NCT00422955|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2016-09-13|2007-01-15|2007-01-17|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2003||2003-11-30|September 2016|2016-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.|A 16-week, Randomised, Double-blind, Placebo-controlled, Single-centre Study to Investigate Fluid Retention in Insulin-treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4mg Twice Daily|Completed||Phase 3|36|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:30:41.712582|2018-06-01 03:30:41.712582
NCT00422942|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|2014-05-07||2014-07-14|2007-01-15|2007-01-17|Estimate|2014-07-14|2014-07-16|Estimate||||2014-07-14|2014-07-16|Estimate|January 2006||2006-01-31|July 2014|2014-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)|An Open-label, Exploratory Study of the Pharmacokinetic and Pharmacodynamic Activity of MabThera in Combination With Methotrexate in Synovial Tissue and in Peripheral Blood of Patients With Active Rheumatoid Arthritis.|Terminated||Phase 2|3|Actual|Hoffmann-La Roche|Study terminated after enrollment of 3 participants due to recruitment difficulties and since the objectives and data under study had been published from other, independent sources it was not appropriate to expose further participants to study drug.|1||Study was terminated after enrollment of 3 participants due to recruitment difficulties.|f||||||||||||||2018-06-01 03:30:41.83921|2018-06-01 03:30:41.83921
NCT00422929|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2017-11-10|2007-01-12|2007-01-17|Estimate|||||||2017-11-10|2017-11-14|Actual|August 2006||2006-08-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|July 2018|Anticipated|2018-07-31||Observational|||Eustachian Tube Growth and Development|Eustachian Tube Growth and Development: Anatomy/Function|Active, not recruiting|||150|Anticipated|University of Pittsburgh|||3||f||||f||||||Samples With DNA|"~     cells obtained from buccal brushing~   "|No||2018-06-01 03:30:42.02843|2018-06-01 03:30:42.02843
NCT00422916|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2016-10-24|2007-01-16|2007-01-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Treatment of Overweight Children and Adolescents|"Evaluation of the Intervention Program Obeldicks Light for Overweight Children and Adolescents"|Completed||N/A|66|Actual|University of Witten/Herdecke||2|||f||||||||||||||2018-06-01 03:30:42.112239|2018-06-01 03:30:42.112239
NCT00422903|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2012-04-06||2016-04-07|2007-01-16|2007-01-17|Estimate|2012-07-26|2012-08-29|Estimate||||2016-04-07|2016-05-12|Estimate|April 2007||2007-04-30|March 2016|2016-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer|Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation.|Completed||Phase 2|92|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:30:42.19615|2018-06-01 03:30:42.19615
NCT00422890|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2011-07-08|2007-01-16|2007-01-17|Estimate|||||||2011-07-08|2011-07-11|Estimate|January 2007||2007-01-31|July 2011|2011-07-31||||December 2009|Actual|2009-12-31||Interventional|||Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)||Completed||Phase 3|10|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 03:30:42.623714|2018-06-01 03:30:42.623714
NCT00422877|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2017-05-08|2007-01-15|2007-01-17|Estimate|||||||2017-05-08|2017-05-10|Actual|January 2007||2007-01-31|May 2017|2017-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Taxoprexin® Treatment for Advanced Primary Cancers of the Liver|Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Second Line Therapy for Patients With Advanced Primary Cancers of the Liver, Including Hepatocellular Carcinoma and Carcinoma of the Gallbladder or Biliary Tract|Terminated||Phase 2|13|Actual|Luitpold Pharmaceuticals||1||Sponsor suspended development of the drug on September 3, 2008.|f||||f||||||||No||2018-06-01 03:30:42.687345|2018-06-01 03:30:42.687345
NCT00422864|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2011-12-14|2007-01-15|2007-01-17|Estimate|||||||2011-12-14|2011-12-15|Estimate|October 2006||2006-10-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|June 2009|Actual|2009-06-30||Interventional|||A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer|A Single-Arm Prospective Trial Evaluating The Local And Systemic Benefits Of Oxaliplatin And 5FU With Concurrent Radiation In Patients With Metastatic Rectal Cancer|Completed||Phase 2|26|Actual|Peter MacCallum Cancer Centre, Australia|||||f||||||||||||||2018-06-01 03:30:42.758203|2018-06-01 03:30:42.758203
NCT00422851|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2017-11-08|2007-01-16|2007-01-17|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2007||2007-06-30|November 2017|2017-11-30|February 2009|Actual|2009-02-28|||||Observational|||Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3c|Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3c|Completed|||45||University of Pittsburgh|||3||f||||f||||||||||2018-06-01 03:30:42.821569|2018-06-01 03:30:42.821569
NCT00422838|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2017-01-26|2007-01-15|2007-01-17|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2007||2007-01-31|January 2017|2017-01-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Observational|CIRES||Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.|Impact of Immune Responses in Chronic Hepatitis C Genotype 1,2,3 Virus Infected Patients During Treatment With Pegylated Interferon-alpha-2b and Ribavirin (CIRES).|Completed|||20|Actual|Foundation for Liver Research|||2||f||||f||||||Samples With DNA|"~     PBMC Serum RNA Liver infiltrating lymphocytes~   "|||2018-06-01 03:30:42.87876|2018-06-01 03:30:42.87876
NCT00422825|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2016-04-04|2007-01-16|2007-01-17|Estimate|||||||2016-04-04|2016-04-05|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib|A Phase I, Open-label, Randomized, Crossover Study to Investigate the Effect of Food on the Bioavailability of a Single 800 mg Imatinib Dose in a Modified Release Formulation (MR2) and Compare the Bioavailability Between MR2 and Imatinib 400 mg Twice Daily Immediate Release Tablet (IR) in Healthy Subjects|Completed||Phase 1|16|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:30:42.942104|2018-06-01 03:30:42.942104
NCT00422812|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2017-03-10||2017-06-16|2007-01-16|2007-01-17|Estimate|2017-06-16|2018-01-25|Actual||||2017-06-16|2018-01-25|Actual|April 2006|Actual|2006-04-30|June 2008|2008-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional||Safety Population|Staccato Prochlorperazine in Migraine (Out Patient)|A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy and Safety Outpatient Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache|Completed||Phase 2|400|Actual|Alexza Pharmaceuticals, Inc.||4|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 03:30:43.014604|2018-06-01 03:30:43.014604
NCT00422799|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2017-12-27||2017-12-27|2007-01-12|2007-01-17|Estimate|2017-12-27|2018-01-26|Actual||||2017-12-27|2018-01-26|Actual|August 30, 2006|Actual|2006-08-30|December 2017|2017-12-31|October 9, 2015|Actual|2015-10-09|October 9, 2015|Actual|2015-10-09||Interventional|||Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia|Completed||Phase 2|63|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:30:43.522009|2018-06-01 03:30:43.522009
NCT00422786|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2008-07-10|2007-01-12|2007-01-17|Estimate|||||||2008-07-10|2008-07-15|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma|A Multi-Centre, Open Label, Phase II Study of the Safety, Efficacy and Pharmacokinetic (PK) Profile of CAP-232 Administered Through Continuous Intravenous Infusion in Patients With Metastatic Kidney Cancer|Completed||Phase 2|10|Actual|Thallion Pharmaceuticals||1|||f||||t||||||||||2018-06-01 03:30:43.700706|2018-06-01 03:30:43.700706
NCT00422773|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2009-02-26|2007-01-15|2007-01-17|Estimate|||||||2009-02-26|2009-02-27|Estimate|January 2007||2007-01-31|February 2009|2009-02-28||||June 2008|Actual|2008-06-30||Interventional|||Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer|Open Labeled, Multicenter Phase I/II Study Evaluating the Dose Escalation/Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan as First-Line Treatment of Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|21|Anticipated|Technische Universität Dresden||1|||f||||||||||||||2018-06-01 03:30:43.776508|2018-06-01 03:30:43.776508
NCT00422760|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-13|||2007-01-13|2007-01-13|2007-01-17|Estimate|||||||2007-01-13|2007-01-17|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|February 2007||2007-02-28|||||Observational|||A 75 Year Old With Dyspnea a Case Report.Observational Study||Completed|||1||Stanley Medical College|||||f||||||||||||||2018-06-01 03:30:43.924487|2018-06-01 03:30:43.924487
NCT00422747|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2013-06-17|2007-01-15|2007-01-17|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2007||2007-04-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|June 2011|Actual|2011-06-30||Interventional|||Early Diagnosis of Asthma in Young Children|Early Diagnosis of Asthma in Young Children|Completed||N/A|202|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-06-01 03:30:43.98544|2018-06-01 03:30:43.98544
NCT00421356|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2010-08-05|2007-01-10|2007-01-12|Estimate|||||||2010-08-05|2010-08-06|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|February 2009|Actual|2009-02-28|||||Observational|||Comparison of Prosthetic Knee Performance During Sitting and Standing|Kinetic and Kinematic Comparison of Power Assisted Versus Stance Control Artificial Knees During Sit To Stand|Completed|||35|Anticipated|University of South Florida|||||f||||||||||||||2018-06-01 03:31:11.914581|2018-06-01 03:31:11.914581
NCT00422734|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2008-12-23||2009-06-08|2007-01-16|2007-01-17|Estimate|2009-04-08|2009-06-02|Estimate||||2009-06-08|2009-06-10|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life|Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life|Completed||Phase 3|342|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:30:44.099595|2018-06-01 03:30:44.099595
NCT00422721|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2011-11-23|2007-01-12|2007-01-17|Estimate|||||||2011-11-23|2011-11-24|Estimate|April 2007||2007-04-30|November 2011|2011-11-30||||||||Interventional|||Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy|Genetical, Multi-center, Prospective Study of Phenotyping and Genotyping of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy in the Aim of the Realisation of a Clinical Trial of Gene Therapy|Completed||N/A|360|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-06-01 03:30:45.10747|2018-06-01 03:30:45.10747
NCT00422708|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2010-01-19|2007-01-15|2007-01-17|Estimate|||||||2010-01-19|2010-01-20|Estimate|June 2006||2006-06-30|January 2010|2010-01-31|June 2008|Actual|2008-06-30|June 2006|Actual|2006-06-30||Interventional|||Local Anesthesia for Prostate Biopsy|Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention|Completed||Phase 4|243|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:30:45.173524|2018-06-01 03:30:45.173524
NCT00422695|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|2016-03-09||2017-03-02|2007-01-16|2007-01-17|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|January 2007||2007-01-31|January 2017|2017-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Pain and Sensory Changes Assessment in HIV+ Patients|Pain and Sensory Changes Assessment in HIV+ Patients, A Model for Pain and Sensory Changes Related Compromised Immune System.|Completed|||143|Actual|Rutgers, The State University of New Jersey|||2||f||||f||||||Samples With DNA|"~     Saliva Samples~   "|No||2018-06-01 03:30:45.234902|2018-06-01 03:30:45.234902
NCT00422682|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2016-06-09|2007-01-16|2007-01-17|Estimate|||||||2016-06-09|2016-06-10|Estimate|January 2007||2007-01-31|June 2016|2016-06-30|October 2012|Actual|2012-10-31|January 2009|Actual|2009-01-31||Interventional|||A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors|A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors|Completed||Phase 1|136|Actual|Sanofi||4|||t||||||||||||||2018-06-01 03:30:45.515471|2018-06-01 03:30:45.515471
NCT00422669|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2011-06-09||2013-01-24|2007-01-12|2007-01-17|Estimate|2012-10-03|2012-11-01|Estimate||||2013-01-24|2013-01-31|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Optimize RV Selective Site Pacing Clinical Trial|Optimize RV Selective Site Pacing Clinical Trial|Terminated||N/A|205|Actual|Medtronic Cardiac Rhythm and Heart Failure|Early study termination due to enrollment rates significantly below protocol expectations.|2||Study enrollment significantly below protocol expectations|f||||f||||||||||2018-06-01 03:30:45.706198|2018-06-01 03:30:45.706198
NCT00422656|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2011-06-29||2017-11-21|2007-01-12|2007-01-17|Estimate|2012-02-15|2012-02-16|Estimate||||2017-11-21|2017-12-26|Actual|September 2006||2006-09-30|November 2017|2017-11-30|November 2012|Actual|2012-11-30|June 2009|Actual|2009-06-30||Interventional|||Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia|A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia|Completed||Phase 2|37|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:30:46.079638|2018-06-01 03:30:46.079638
NCT00422643|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2007-01-17|2007-01-16|2007-01-17|Estimate|||||||2007-01-17|2007-01-18|Estimate|March 2007||2007-03-31|January 2007|2007-01-31|October 2007||2007-10-31|||||Interventional|||The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator|The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator|Unknown status|Not yet recruiting|Phase 4|60||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:30:46.346217|2018-06-01 03:30:46.346217
NCT00422630|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2011-10-12|2007-01-16|2007-01-17|Estimate|||||||2011-10-12|2011-10-13|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Metabolic Effects of Different Weight Loss Diets|Dietary Interventions for Insulin Resistance and the Metabolic Syndrome|Completed||N/A|18|Anticipated|Rockefeller University||3|||f||||t||||||||||2018-06-01 03:30:46.402097|2018-06-01 03:30:46.402097
NCT00422617|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-01-16|2007-01-16|2007-01-17|Estimate|||||||2007-01-16|2007-01-17|Estimate|January 2005||2005-01-31|September 2004|2004-09-30|November 2005||2005-11-30|||||Interventional|||Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients||Completed||N/A|40||Uni-Pharma|||||f||||||||||||||2018-06-01 03:30:46.468056|2018-06-01 03:30:46.468056
NCT00422604|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2016-10-27|2007-01-16|2007-01-17|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Multicentre, Randomised, Partially Blinded, Placebo-controlled, Three-way Crossover, Incomplete Block Design Study to Investigate the Safety, Tolerability, Pharmacodynamics/ Efficacy and Pharmacokinetics of Dual Bronchodilator Therapy With Salmeterol 50µg Twice-daily Plus Two Different Doses of GSK233705B (20 and 50µg Twice-daily), Compared With Placebo, Salmeterol 50µg Twice-daily Alone, and Tiotropium 18µg Once-daily Alone, in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|60|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:30:46.514028|2018-06-01 03:30:46.514028
NCT00422591|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2017-01-17|2007-01-16|2007-01-17|Estimate|||||||2017-01-17|2017-01-19|Estimate|December 2006||2006-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)|Prospective Evaluation of Standard Chemotherapy Regimen of Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Completed||Phase 2|175|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:30:46.610132|2018-06-01 03:30:46.610132
NCT00422578|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-10-23|2007-01-16|2007-01-17|Estimate|||||||2007-10-23|2007-10-25|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|September 2005|Actual|2005-09-30|||||Interventional|||Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction|Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy|Completed||Phase 4|200||Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:30:47.685856|2018-06-01 03:30:47.685856
NCT00420433|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2016-02-17|2007-01-10|2007-01-11|Estimate|||||||2016-02-17|2016-02-19|Estimate|September 2004||2004-09-30|May 2012|2012-05-31|May 2012|Actual|2012-05-31|October 2008|Actual|2008-10-31||Observational|||Bone Response in Metastatic Breast Cancer Involving Bones|Prospective Study of Tumor Response Assessment in Metastatic Breast Cancer Involving Bones|Completed|||37|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:31:27.896319|2018-06-01 03:31:27.896319
NCT00422565|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2009-01-30|2007-01-16|2007-01-17|Estimate|||||||2009-01-30|2009-02-02|Estimate|October 2006||2006-10-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|ZEST-AMI||Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients|Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients|Terminated||Phase 4|328|Actual|CardioVascular Research Foundation, Korea||3||The recruitment rate was much slower than expected.|f||||t||||||||||2018-06-01 03:30:47.749256|2018-06-01 03:30:47.749256
NCT00422552|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-06-21|2007-01-16|2007-01-17|Estimate|||||||2007-06-21|2007-06-22|Estimate|September 2006||2006-09-30|June 2007|2007-06-30||||||||Interventional|||Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol|An Exploratory, Double-Blind Comparison of Inspiratory Capacity (IC) and FEV1 in COPD Patients Following Single Dose Administration of Indacaterol and Placebo and Open Label b.i.d. Administration of Formoterol|Completed||Phase 1/Phase 2|30||Novartis|||||f||||||||||||||2018-06-01 03:30:47.854473|2018-06-01 03:30:47.854473
NCT00422539|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2007-01-16|2007-01-16|2007-01-17|Estimate|||||||2007-01-16|2007-01-17|Estimate|March 2006||2006-03-31|January 2007|2007-01-31||||||||Interventional|||Efficacy of TCA Effect on Varicella Atrophic Scars|Evaluation of Tri Chloro Acetic Acid (TCA) Effect on Atrophic Varicella Scars|Unknown status|Recruiting|Phase 2|100||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:30:47.920441|2018-06-01 03:30:47.920441
NCT00422526|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2007-01-16|2007-01-16|2007-01-17|Estimate|||||||2007-01-16|2007-01-17|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|November 2006||2006-11-30|||||Interventional|||Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial|Randomised Study to Examine the Effectiveness of Progesterone in Preventing Severe Preterm Delivery|Completed||Phase 3|250||King's College Hospital NHS Trust|||||f||||||||||||||2018-06-01 03:30:47.977906|2018-06-01 03:30:47.977906
NCT00422513|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|2011-03-29||2011-11-09|2007-01-15|2007-01-17|Estimate|2011-11-09|2011-12-14|Estimate||||2011-11-09|2011-12-14|Estimate|March 2007||2007-03-31|November 2011|2011-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.|A Randomized, Open-label Study Comparing the Pharmacoeconomic (Time and Motion) Benefit of Mircera and Epoetin Alfa in Patients With Chronic Kidney Disease (Stage V) on Dialysis.|Terminated||Phase 3|260|Actual|Hoffmann-La Roche||2||Strategic decision unrelated to safety or efficacy|f||||||||||||||2018-06-01 03:30:48.084222|2018-06-01 03:30:48.084222
NCT00422500|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2012-08-01|2007-01-16|2007-01-17|Estimate|||||||2012-08-01|2012-08-02|Estimate|November 2003||2003-11-30|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer|Longitudinal Study of the Prevalence, Severity, and Interference of Multiple Symptoms in Advanced Lung Cancer|Completed|||204|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Study participants enrolled at M. D. Anderson will have additional serum drawn for cytokine~     analysis and DNA repair capacity. This blood will be drawn at the routine blood draws before~     treatment begins, and at the beginning of each treatment cycle.~   "|||2018-06-01 03:30:48.676597|2018-06-01 03:30:48.676597
NCT00422487|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2015-04-29|2007-01-15|2007-01-17|Estimate|||||||2015-04-29|2015-05-01|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes|Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of MBX-2044 to Evaluate the Multiple-dose Pharmacokinetics, Safety and Tolerability When Administered Orally in Patients With Type 2 Diabetes|Completed||Phase 2|60|Actual|CymaBay Therapeutics, Inc.||7|||f||||||||||||||2018-06-01 03:30:48.794454|2018-06-01 03:30:48.794454
NCT00422474|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-14|||2008-07-08|2007-01-14|2007-01-17|Estimate|||||||2008-07-08|2008-07-10|Estimate|January 2007||2007-01-31|July 2008|2008-07-31||||||||Observational|||Prognostic Significance of the Baroreflex Sensitivity Changes After Acute Ischemic Stroke|Noninvasive Study of the Time Course of Baroreflex Sensitivity 6-Month After Acute Ischemic Stroke and the Relation of Its Changes With Post Stroke Prognosis|Unknown status|Recruiting||100|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 03:30:48.886023|2018-06-01 03:30:48.886023
NCT00422461|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12||2009-04-06|2009-10-07|2007-01-12|2007-01-17|Estimate||||2009-10-07|2009-10-12|Estimate|2009-10-07|2009-10-12|Estimate|February 2007||2007-02-28|October 2009|2009-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure|A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study Of PF-00489791 In Subjects With Stage 1 And 2 Essential Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)|Completed||Phase 2|140|Anticipated|Pfizer||4|||f||||f||||||||||2018-06-01 03:30:49.004133|2018-06-01 03:30:49.004133
NCT00422448|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|2010-04-25||2010-12-14|2007-01-16|2007-01-17|Estimate|2010-12-14|2011-01-14|Estimate||||2010-12-14|2011-01-14|Estimate|September 2006||2006-09-30|December 2010|2010-12-31|April 2010|Actual|2010-04-30|March 2009|Actual|2009-03-31||Interventional|||Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.|BRAF and Nevi.Nevi Are Common Benign Pigmented Tumors of the Skin. Mutations in So-called BRAF and NRAS Genes Genes Appear to be Initiating Events Responsible for the Formation of Nevi.|Completed||N/A|43|Actual|Medical University of Graz|During first year of enrollment too few patients agreed to participate. Therefore a sample of 21 nevi were additionally retrospectively included.|1|||f||||t||||||||||2018-06-01 03:30:49.111842|2018-06-01 03:30:49.111842
NCT00422435|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|||2008-10-23|2007-01-15|2007-01-17|Estimate|||||||2008-10-23|2008-10-24|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2007|Actual|2007-05-31||Interventional|||CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation|The PreCiSE Trial: CoStar™ Paclitaxel-Eluting Coronary Stent Catheter System Evaluation|Completed||Phase 3|107|Actual|Conor Medsystems||1|||f||||f||||||||||2018-06-01 03:30:49.352129|2018-06-01 03:30:49.352129
NCT00422422|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2016-03-14|2014-03-18|2016-11-08|2007-01-12|2007-01-17|Estimate|2016-11-08|2017-01-09|Estimate|2014-03-18|2014-04-15|Estimate|2016-11-08|2017-01-09|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Baseline Characteristics consists of the Enrolled Subjects analysis set, which is comprised of all subjects enrolled into the study.|Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.|Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From ≥1 Month to <16 Years Old With Epilepsy|Completed||Phase 2|100|Actual|UCB Pharma||1|||f||||t||||||||||2018-06-01 03:30:49.478623|2018-06-01 03:30:49.478623
NCT00422409|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-16|||2011-07-03|2007-01-16|2007-01-17|Estimate|||||||2011-07-03|2011-07-06|Estimate|October 2006||2006-10-31|April 2007|2007-04-30|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||Endoscopic Stenting of Gastrointestinal Cancer|Palliative Endoscopic Treatment of Malignant GI-strictures With Self Expanding Metal Stents(SEMS)-a Prospective Multicenter Study|Completed||N/A|270|Actual|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:30:49.819432|2018-06-01 03:30:49.819432
NCT00422396|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2017-02-09|2007-01-12|2007-01-17|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2001|Actual|2001-01-31|February 2017|2017-02-28|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis|Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis|Completed||N/A|60||University of Michigan|||||f||||||||||||||2018-06-01 03:30:49.890409|2018-06-01 03:30:49.890409
NCT00422383|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-15|2014-12-09||2015-04-16|2007-01-15|2007-01-17|Estimate|2015-04-16|2015-05-04|Estimate||||2015-04-16|2015-05-04|Estimate|February 2006||2006-02-28|April 2015|2015-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The intent-to-treat-modified 2 (ITT-M2) population included all randomized participants who received at least 1 infusion of study treatment. Due to a UK protocol amendment error, 6 participants incorrectly received placebo. Due to medication list error, 25 participants received an incorrect dose of treatment. Participants were analyzed as treated.|A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)|A Randomized, Double-blind Study to Evaluate the Effect of Various Re-treatment Regimens of MabThera in Combination With Methotrexate on Treatment Response in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.|Completed||Phase 3|378|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:30:50.116625|2018-06-01 03:30:50.116625
NCT00422370|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2007-01-16|2007-01-16|2007-01-17|Estimate|||||||2007-01-16|2007-01-17|Estimate|January 2007||2007-01-31|December 2006|2006-12-31||||||||Interventional|||Lipid Based Food Additives for Treating Patients With Dry Mouth|Lipid Based Food Additives for Treating Patients With Dry Mouth|Unknown status|Not yet recruiting|N/A|20|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:30:52.966719|2018-06-01 03:30:52.966719
NCT00422357|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2007-04-17|2007-01-12|2007-01-15|Estimate|||||||2007-04-17|2007-04-18|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus|Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|56||Shahid Beheshti University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:30:53.034453|2018-06-01 03:30:53.034453
NCT00422344|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2010-02-25|2007-01-12|2007-01-15|Estimate|||||||2010-02-25|2010-02-26|Estimate|October 2006||2006-10-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma|A Phase I Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma Patients|Completed||Phase 1|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:30:53.107609|2018-06-01 03:30:53.107609
NCT00422331|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-08-13|2007-01-12|2007-01-15|Estimate|||||||2007-08-13|2007-08-14|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Safety and Efficacy Study of Lithium in Bipolar Disorder|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder|Unknown status|Active, not recruiting|Phase 3|206|Anticipated|JDS Pharmaceuticals|||||f||||||||||||||2018-06-01 03:30:53.213544|2018-06-01 03:30:53.213544
NCT00422318|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2007-01-12|2007-01-12|2007-01-15|Estimate|||||||2007-01-12|2007-01-15|Estimate|January 2004||2004-01-31|January 2007|2007-01-31|December 2005||2005-12-31|||||Interventional|||Treatment of Hyperuricemia in Patients With Heart Failure|Hyperuricemia and the Effects of the Uricosuric Agents Benzbromarone in Patients With Chronic Heart Failure|Completed||Phase 4|||Tottori University Hospital|||||f||||||||||||||2018-06-01 03:30:53.282217|2018-06-01 03:30:53.282217
NCT00422305|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2018-02-27|2007-01-11|2007-01-15|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2007||2007-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessment of Lung Structure and Function of Infants Born Prematurely|Assessment of Lung Structure and Function of Infants Born Prematurely|Recruiting|||129|Anticipated|Indiana University|||3||f||||t||||||||||2018-06-01 03:30:53.37792|2018-06-01 03:30:53.37792
NCT00422292|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2011-05-10|2010-03-31|2016-04-12|2007-01-12|2007-01-15|Estimate|2011-05-10|2011-06-02|Estimate|2010-03-31|2010-04-02|Estimate|2016-04-12|2016-04-14|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers|An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers|Completed||Phase 3|1664|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 03:30:53.470567|2018-06-01 03:30:53.470567
NCT00422279|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|2012-01-17||2016-03-22|2007-01-11|2007-01-15|Estimate|2015-05-11|2015-05-29|Estimate||||2016-03-22|2016-04-20|Estimate|November 2006||2006-11-30|March 2016|2016-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of Dental Implants Coated With Bone Morphogenetic Protein|Evaluation of Implant Stability and Local Bone Formation at Endosseous Dental Implants With a Titanium Porous Oxide Surface Adsorbed With rhBMP-2|Completed||N/A|4|Actual|Nobel Biocare||2|||f||||t||||||||No||2018-06-01 03:30:54.48083|2018-06-01 03:30:54.48083
NCT00422266|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2007-09-24|2007-01-12|2007-01-15|Estimate|||||||2007-09-24|2007-09-26|Estimate|December 2006||2006-12-31|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Effect of Omega -3 Fatty Acids Supplements and Plant Sterol Enriched Food in Dyslipidemic Adults|Effect of Omega -3 Fatty Acids Supplements and Plant Sterol Enriched Drink/Food on the Composite Risk Profile of Dyslipidemic Adults|Completed||Phase 3|178|Actual|Centre for Chronic Disease Control, India|||||f||||t||||||||||2018-06-01 03:30:54.83831|2018-06-01 03:30:54.83831
NCT00422253|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2013-12-12|2007-01-11|2007-01-15|Estimate|||||||2013-12-12|2013-12-16|Estimate|November 2006||2006-11-30|January 2007|2007-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Dietary Advanced Glycation End-products and Insulin Resistance in Overweight and Obese Humans|Will Reduction in Dietary Advanced Glycation End- Products Reduce Chronic Low Grade Inflammation and Improve Insulin Sensitivity in Overweight and Obese Humans|Completed||N/A|27|Actual|Bayside Health|||||f||||f||||||||||2018-06-01 03:30:54.895331|2018-06-01 03:30:54.895331
NCT00422240|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-09-10|2007-01-11|2007-01-15|Estimate|||||||2007-09-10|2007-09-11|Estimate|June 2006||2006-06-30|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris|Completed||Phase 3|1656|Anticipated|Galderma|||||f||||||||||||||2018-06-01 03:30:54.95131|2018-06-01 03:30:54.95131
NCT00421343|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2010-07-08||2011-05-11|2007-01-11|2007-01-12|Estimate|2011-05-11|2011-06-10|Estimate||||2011-05-11|2011-06-10|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Secondary Prevention of Osteoporosis|Secondary Prevention of Osteoporosis: A Window of Opportunity in the Acute Rehabilitation Setting|Completed||Phase 3|29|Actual|Hebrew Rehabilitation Center, Boston||1|||f||||f||||||||||2018-06-01 03:31:11.966051|2018-06-01 03:31:11.966051
NCT00422227|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|2010-03-31||2010-07-28|2007-01-11|2007-01-15|Estimate|2010-07-28|2010-08-30|Estimate||||2010-07-28|2010-08-30|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region|A Randomized, Open-Label Study in the Asia-Pacific Region Comparing the Safety and Efficacy of Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis|Completed||Phase 4|300|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:30:55.057852|2018-06-01 03:30:55.057852
NCT00422214|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2009-03-24|2007-01-12|2007-01-15|Estimate|||||||2009-03-24|2009-03-25|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|June 2007|Actual|2007-06-30|||||Interventional|||Phase III/Seroquel SR Bipolar Depression Monotherapy - US|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel SR®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Depression|Completed||Phase 3|400||AstraZeneca|||||f||||||||||||||2018-06-01 03:30:55.666536|2018-06-01 03:30:55.666536
NCT00422201|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2013-08-08||2013-10-14|2007-01-12|2007-01-15|Estimate|2013-08-08|2013-10-14|Estimate||||2013-10-14|2013-11-11|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion|Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion|Terminated||Phase 2|18|Actual|HRA Pharma|As a consequence of the premature study end, analyses performed were primarily descriptive due to the reduced number of enrolled and completed patients.||||f||||||||||||||2018-06-01 03:30:55.819664|2018-06-01 03:30:55.819664
NCT00422188|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2015-12-08|2007-01-12|2007-01-15|Estimate|||||||2015-12-08|2015-12-10|Estimate|January 2007||2007-01-31|December 2015|2015-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Deoxycholic Acid Injection for the Treatment of Superficial Lipomas|Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of the Pharmacokinetics, Safety, and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Intralipomal Injections for the Treatment of Superficial Lipomas|Completed||Phase 1|16|Actual|Kythera Biopharmaceuticals||5|||f||||f||||||||||2018-06-01 03:30:56.099684|2018-06-01 03:30:56.099684
NCT00422175|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-11-28|2007-01-12|2007-01-15|Estimate|||||||2007-11-28|2007-11-29|Estimate|October 2006||2006-10-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312|A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers|Completed||Phase 1|63||Novartis|||||f||||||||||||||2018-06-01 03:30:56.176522|2018-06-01 03:30:56.176522
NCT00422162|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|2009-08-25||2011-07-22|2007-01-11|2007-01-15|Estimate|2009-08-25|2009-10-02|Estimate||||2011-07-22|2011-07-26|Estimate|February 2007||2007-02-28|July 2011|2011-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression|An Eight-Week, Randomized, Double Blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 Per Day in Patients Hospitalized for Severe Depression|Completed||Phase 4|339|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:30:56.279178|2018-06-01 03:30:56.279178
NCT00422149|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2012-02-06|2007-01-12|2007-01-15|Estimate|||||||2012-02-06|2012-02-07|Estimate|September 2006||2006-09-30|February 2012|2012-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Twin SUBLIVAC® Grasses Clinical Efficacy Study|Twin SUBLIVAC® Grasses Clinical Efficacy Study|Completed||Phase 3|350|Actual|HAL Allergy||2|||f||||t||||||||||2018-06-01 03:30:57.361836|2018-06-01 03:30:57.361836
NCT00422136|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2017-11-10|2007-01-12|2007-01-15|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2002||2002-07-31|November 2017|2017-11-30|July 2009|Actual|2009-07-31|July 2007|Actual|2007-07-31||Observational|||Genetics of Middle Ear Disease|Genetic Epidemiology of Otitis Media|Completed|||2121|Actual|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     Blood samples, DNA~   "|||2018-06-01 03:30:57.489851|2018-06-01 03:30:57.489851
NCT00422123|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2009-03-24|2007-01-12|2007-01-15|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|July 2007|Actual|2007-07-31|||||Interventional|||Phase 3 /Seroquel SR Acute Mania Monotherapy - US|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Sustained-Release as Monotherapy in Adult Patients With Acute Bipolar Mania|Completed||Phase 3|447|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:30:57.629252|2018-06-01 03:30:57.629252
NCT00422110|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2012-05-25|2007-01-11|2007-01-15|Estimate|||||||2012-05-25|2012-05-28|Estimate|May 2008||2008-05-31|May 2012|2012-05-31||||||||Interventional|||A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures|A Phase IIb/III, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Seletracetam as Adjunctive Treatment in Subjects (≥16 to 70 Years Old) With Refractory Partial Onset Seizures.|Withdrawn||Phase 2/Phase 3|0|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 03:30:57.769667|2018-06-01 03:30:57.769667
NCT00422097|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2011-01-27||2016-02-09|2007-01-12|2007-01-15|Estimate|2011-03-24|2011-04-20|Estimate||||2016-02-09|2016-03-10|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|April 2011|Actual|2011-04-30|August 2009|Actual|2009-08-31||Interventional|||A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer|A Phase I Study of Ixabepilone Administered as a Daily Oral Dose on 5 Successive Days Every 21 Days in Subjects With Advanced Cancer|Completed||Phase 1|40|Actual|R-Pharm||8|||f||||||||||||||2018-06-01 03:30:57.905087|2018-06-01 03:30:57.905087
NCT00422084|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2008-05-19|2007-01-12|2007-01-15|Estimate|||||||2008-05-19|2008-05-20|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients|A Phase III Comparative, (Double-Blind, Double-Dummy), Randomised, Multi-Centre, Clinical Study to Assess the Safety and Efficacy of Fixed Dose Formulation of Oral Pyronaridine Artesunate Tablet (180:60 mg) Versus Coartem® (Artemether Lumefantrine) in Children and Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 3|1269|Anticipated|Medicines for Malaria Venture||2|||f||||||||||||||2018-06-01 03:30:59.558104|2018-06-01 03:30:59.558104
NCT00422071|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2018-05-18|2007-01-12|2007-01-15|Estimate|||||||2018-05-18|2018-05-21|Actual|January 8, 2007||2007-01-08|March 6, 2014|2014-03-06|March 6, 2014||2014-03-06|||||Observational|||Detecting a Reward Signal in the Motor Cortex|Detecting a Reward Signal in the Motor Cortex|Completed|||168|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:30:59.715213|2018-06-01 03:30:59.715213
NCT00422058|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2010-04-27||2017-09-29|2007-01-12|2007-01-15|Estimate|2010-10-05|2010-10-28|Estimate||||2017-09-29|2017-11-01|Actual|January 10, 2007|Actual|2007-01-10|September 2017|2017-09-30|April 30, 2009|Actual|2009-04-30|September 13, 2007|Actual|2007-09-13||Interventional|||The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes|Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period|Completed||Phase 2|564|Actual|Novo Nordisk A/S||6|||f||||f|f|f||||||||2018-06-01 03:30:59.832725|2018-06-01 03:30:59.832725
NCT00422045|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2014-12-09|2007-01-12|2007-01-15|Estimate|||||||2014-12-09|2014-12-10|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Assessment of Low Level Laser Therapy for Late Postoperative Pain After Lumbar Fusion Surgery|Assessment of Low Level Laser Therapy for Late Postoperative Pain After Lumbar Fusion Surgery|Withdrawn||N/A|0|Actual|University of Toledo Health Science Campus||2|||f||||f||||||||||2018-06-01 03:31:02.361248|2018-06-01 03:31:02.361248
NCT00422032|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|2012-06-22||2012-06-22|2007-01-12|2007-01-15|Estimate|2012-06-22|2012-07-27|Estimate||||2012-06-22|2012-07-27|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||2 Arm Study of Clofarabine IV in MDS Patients|Phase II Randomized Study of Two Different Schedules of Intravenous Clofarabine in Myelodysplastic Syndrome (MDS)|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:31:02.432125|2018-06-01 03:31:02.432125
NCT00422019|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11||2015-03-23|2015-03-23|2007-01-11|2007-01-15|Estimate||||2015-03-23|2015-04-10|Estimate|2015-03-23|2015-04-10|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma|A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma|Completed||Phase 2|61|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:31:02.655819|2018-06-01 03:31:02.655819
NCT00422006|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2014-04-02|2007-01-12|2007-01-15|Estimate|||||||2014-04-02|2014-04-03|Estimate|February 2008||2008-02-29|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance|Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance|Completed||N/A|111|Actual|Nantes University Hospital||4|||f||||t||||||||||2018-06-01 03:31:02.726354|2018-06-01 03:31:02.726354
NCT00421993|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|2009-01-15||2009-10-19|2007-01-11|2007-01-15|Estimate|2009-03-10|2009-03-11|Estimate||||2009-10-19|2009-10-20|Estimate|October 2006||2006-10-31|October 2009|2009-10-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris|Completed||Phase 3|1670|Actual|Galderma||4|||f||||||||||||||2018-06-01 03:31:02.839061|2018-06-01 03:31:02.839061
NCT00421980|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2007-01-12|2007-01-12|2007-01-15|Estimate|||||||2007-01-12|2007-01-15|Estimate|June 2002||2002-06-30|January 2007|2007-01-31|July 2004||2004-07-31|||||Interventional|||An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis|An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis|Completed||Phase 3|84||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:31:03.512423|2018-06-01 03:31:03.512423
NCT00421967|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2008-05-06|2007-01-12|2007-01-15|Estimate|||||||2008-05-06|2008-05-07|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Postoperative Analgesia After Total Knee Arthroplasty|Postoperative Analgesia After Total Knee Arthroplasty. A Comparison of Continuous Epidural Infusion and Wound Infiltration With Continuous Intraarticular Infusion|Terminated||Phase 4|80|Actual|University of Aarhus||2||Interim analysis|f||||t||||||||||2018-06-01 03:31:03.574929|2018-06-01 03:31:03.574929
NCT00421954|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2017-01-12||2017-01-12|2007-01-12|2007-01-15|Estimate|2017-01-12|2017-01-13|Estimate||||2017-01-12|2017-01-13|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional||P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.|Open-label Ziprasidone Study for Psychosis Treatment in Adolescents|Open-label Feasibility Study for the Treatment of Psychotic Adolescents With Ziprasidone in the Inpatient and Day Hospital Settings|Completed||Phase 3|8|Actual|New York State Psychiatric Institute||1|||f||||||||||||||2018-06-01 03:31:03.646062|2018-06-01 03:31:03.646062
NCT00421941|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2013-10-31|2007-01-12|2007-01-15|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2007||2007-01-31|October 2013|2013-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Enteral Feeding Study of Formula Containing Fish Oil in Critical Care Setting|Use of a High-protein Enteral Formula Containing Prebiotics and Fish Oil in Critical Care|Terminated||N/A|50|Anticipated|Nestlé||||Unable to meet enrollment goal|f||||||||||||||2018-06-01 03:31:03.754009|2018-06-01 03:31:03.754009
NCT00421928|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2009-07-08||2012-04-16|2007-01-12|2007-01-15|Estimate|2010-04-05|2010-04-23|Estimate||||2012-04-16|2012-04-18|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Tapentadol (CG5503)|A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|Completed||Phase 3|1030|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 03:31:03.834852|2018-06-01 03:31:03.834852
NCT00421915|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2007-01-12|2007-01-12|2007-01-15|Estimate|||||||2007-01-12|2007-01-15|Estimate|March 2002||2002-03-31|January 2007|2007-01-31|August 2002||2002-08-31|||||Interventional|||Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis|Multicenter, Double-Blind, Parallel, Placebo-Controlled, Randomised Phase 3 Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis: 12-Week Final Data|Completed||Phase 3|84||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:31:04.245936|2018-06-01 03:31:04.245936
NCT00421902|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2018-04-04|2007-01-12|2007-01-15|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2006|Actual|2006-01-31|April 2018|2018-04-30|June 2012|Actual|2012-06-30|June 2010|Actual|2010-06-30||Interventional|||Acupuncture Treatment for Hot Flashes Study|Acupuncture Treatment for Hot Flashes in Men With Prostate Cancer, A Phase I/II Study|Completed||N/A|50|Actual|New York Methodist Hospital||1|||f||||||||||||||2018-06-01 03:31:04.412837|2018-06-01 03:31:04.412837
NCT00419367|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2018-04-25|2007-01-05|2007-01-08|Estimate|||||||2018-04-25|2018-04-26|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)|Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma|No longer available|||||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:31:48.816044|2018-06-01 03:31:48.816044
NCT00421889|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|2014-07-01|2012-12-18|2015-07-07|2007-01-12|2007-01-15|Estimate|2014-12-05|2014-12-15|Estimate|2012-12-18|2012-12-21|Estimate|2015-07-07|2015-07-28|Estimate|August 2005||2005-08-31|July 2015|2015-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment|A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients With Advanced Solid Tumours|Completed||Phase 1/Phase 2|80|Actual|Onxeo||1|||f||||f||||||||||2018-06-01 03:31:04.551873|2018-06-01 03:31:04.551873
NCT00421876|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2007-01-12|2007-01-12|2007-01-15|Estimate|||||||2007-01-12|2007-01-15|Estimate|December 2000||2000-12-31|January 2007|2007-01-31|December 2005||2005-12-31|||||Interventional|||GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study|GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study|Completed||N/A|3200||Heart Care Foundation|||||f||||||||||||||2018-06-01 03:31:06.064439|2018-06-01 03:31:06.064439
NCT00421863|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-12|||2013-08-14|2007-01-12|2007-01-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|February 2005||2005-02-28|March 2013|2013-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study|Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study|Completed||Phase 4|1111|Actual|Heart Care Foundation||2|||f||||f||||||||||2018-06-01 03:31:06.227129|2018-06-01 03:31:06.227129
NCT00421850|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2011-05-20|2007-01-11|2007-01-12|Estimate|||||||2011-05-20|2011-05-23|Estimate|July 2001||2001-07-31|May 2011|2011-05-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Using Networks, Informatics, Technology, and Education in Care for People With Diabetes|UNITED Planned Care for People With Diabetes|Completed||N/A|3491||Mayo Clinic|||||f||||||||||||||2018-06-01 03:31:06.47155|2018-06-01 03:31:06.47155
NCT00421837|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2013-08-15|2007-01-11|2007-01-12|Estimate|||||||2013-08-15|2013-08-16|Estimate|May 2007||2007-05-31|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Pilot Study of Genotypic Analysis|Pilot Study of the Genotypic Analysis of Patients Infected With Influenza Virus Compared With Uninfected Spouse/Close Contact Controls|Completed|||6|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Sera and saliva~   "|||2018-06-01 03:31:06.527378|2018-06-01 03:31:06.527378
NCT00421824|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2011-01-03|2007-01-11|2007-01-12|Estimate|||||||2011-01-03|2011-01-04|Estimate|May 2006||2006-05-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer|Phase II Randomized Trial of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer|Completed||Phase 2|108|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:31:06.579897|2018-06-01 03:31:06.579897
NCT00421811|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2010-12-27|2007-01-10|2007-01-12|Estimate|||||||2010-12-27|2010-12-28|Estimate|April 2007||2007-04-30|December 2010|2010-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan|An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).|Completed||Phase 1/Phase 2|56|Anticipated|Adherex Technologies, Inc.|||||f||||||||||||||2018-06-01 03:31:06.655914|2018-06-01 03:31:06.655914
NCT00421798|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2009-07-08|2007-01-11|2007-01-12|Estimate|||||||2009-07-08|2009-07-09|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Observational|||Rapid Characterization of Paucibacillary TB Along Tex/Mex Border|Rapid Characterization of Mycobacteria and Drug Resistance In Paucibacillary TB|Completed|||780|Anticipated|The University of Texas Health Science Center, Houston|||||f||||f||||||Samples With DNA|"~     Blood from participants will be collected, and DNA extracted from white blood cells. These~     are expected to also contain DNA from M. tuberculosis- that will be the research question~   "|||2018-06-01 03:31:06.721241|2018-06-01 03:31:06.721241
NCT00421785|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-07-06|2007-01-11|2007-01-12|Estimate|||||||2007-07-06|2007-07-09|Estimate|February 2007||2007-02-28|July 2007|2007-07-31|January 2008|Anticipated|2008-01-31|||||Interventional|||Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients|Effect of N-Acetylcysteine on Peritoneal Membrane Function in Chronic Peritoneal Dialysis Patients.|Unknown status|Recruiting|N/A|20|Anticipated|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:31:06.787329|2018-06-01 03:31:06.787329
NCT00421772|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-01-11|2007-01-11|2007-01-12|Estimate|||||||2007-01-11|2007-01-12|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Observational|||Prospective Follow-up of a Multicentric Cohort of Children With Prenatal Discovery of Mild Isolated Cerebral Ventriculomegaly. Evaluation at 2 and 5 Years.|Prospective Follow-up of a Multicentric Cohort of Children With Prenatal Discovery of Mild Isolated Cerebral Ventriculomegaly. Evaluation at 2 and 5 Years.|Unknown status|Recruiting||245||University Hospital, Angers|||||f||||||||||||||2018-06-01 03:31:06.858799|2018-06-01 03:31:06.858799
NCT00421759|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2009-12-10|2007-01-10|2007-01-12|Estimate|||||||2009-12-10|2009-12-14|Estimate|April 2006||2006-04-30|August 2008|2008-08-31|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Noise-Enhanced Sensory Function in Elders at Risk for Falls|Noise-Enhanced Sensory Function in Elders at Risk for Falls|Unknown status|Recruiting|N/A|170|Anticipated|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 03:31:06.93121|2018-06-01 03:31:06.93121
NCT00421746|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-08-02|2007-01-11|2007-01-12|Estimate|||||||2007-08-02|2007-08-03|Estimate|January 2006||2006-01-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure|A Proof of Biological Efficacy Study Assessing the Potential of Piboserod, a Specific 5-HT4 Antagonist, for the Treatment of Symptomatic Congestive Heart Failure on Top of Usual Evidence Based Pharmacological Treatment|Completed||Phase 2|137|Actual|Bio-Medisinsk Innovasjon|||||f||||t||||||||||2018-06-01 03:31:07.039367|2018-06-01 03:31:07.039367
NCT00421733|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2010-06-09||2012-01-18|2007-01-11|2007-01-12|Estimate|2010-08-20|2010-09-14|Estimate||||2012-01-18|2012-01-20|Estimate|December 2006||2006-12-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|VITAL||The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors|VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With Renin-angiotensin System Inhibitors|Completed||Phase 2|281|Actual|Abbott||3|||f||||f||||||||||2018-06-01 03:31:07.158049|2018-06-01 03:31:07.158049
NCT00421720|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2018-03-30|2007-01-11|2007-01-12|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2007||2007-01-31|March 2018|2018-03-31||||||||Interventional|||A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus Sufentanil/Propofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.|A Randomized, Open-label, Multicenter, Parallel-group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days|Terminated||Phase 4|164||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:31:08.268706|2018-06-01 03:31:08.268706
NCT00421707|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2017-07-28|2009-07-22|2018-01-05|2007-01-10|2007-01-12|Estimate|2017-11-29|2017-12-26|Actual|2009-07-22|2009-08-10|Estimate|2018-01-05|2018-01-31|Actual|October 14, 2006|Actual|2006-10-14|November 2017|2017-11-30|June 25, 2008|Actual|2008-06-25|June 25, 2008|Actual|2008-06-25||Interventional|||Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome|A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008|Completed||Phase 2|133|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:31:08.421631|2018-06-01 03:31:08.421631
NCT00421694|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-10-05|2007-01-10|2007-01-12|Estimate|||||||2007-10-05|2007-10-08|Estimate||||October 2007|2007-10-31||||||||Interventional|||Positive Surgical Margins Rate and EGFR Family Members Expression in Prostate Cancer Treated With Bicalutamide||Completed||Phase 2/Phase 3|119||University of L'Aquila|||||f||||||||||||||2018-06-01 03:31:09.352417|2018-06-01 03:31:09.352417
NCT00421681|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2009-12-10|2007-01-10|2007-01-12|Estimate|||||||2009-12-10|2009-12-14|Estimate|October 2003||2003-10-31|January 2008|2008-01-31|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||Exercise Adherence Among Older Adults With Osteoarthritis|Exercise Adherence Among Older Adults With Osteoarthritis|Unknown status|Active, not recruiting|N/A|600|Anticipated|National Institute on Aging (NIA)||2|||f||||f||||||||||2018-06-01 03:31:09.534054|2018-06-01 03:31:09.534054
NCT00421668|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2017-03-01|2007-01-11|2007-01-12|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2007||2007-09-30|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Trial of Zinc and Micronutrients in Tanzanian Children|A Trial of Zinc and Micronutrients in Tanzanian Children|Completed||Phase 3|2400|Actual|Harvard School of Public Health||4|||f||||t||||||||||2018-06-01 03:31:09.61823|2018-06-01 03:31:09.61823
NCT00421655|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2015-06-23|2007-01-11|2007-01-12|Estimate|||||||2015-06-23|2015-06-24|Estimate|December 2006||2006-12-31|June 2015|2015-06-30|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||A Trial of Grazax in Subjects With Hayfever|A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma|Completed||Phase 3|329|Actual|ALK-Abelló A/S||2|||f||||t||||||||||2018-06-01 03:31:09.70108|2018-06-01 03:31:09.70108
NCT00421642|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2012-07-31|2007-01-11|2007-01-12|Estimate|||||||2012-07-31|2012-08-01|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Open-Label Adalimumab for Ulcerative Colitis Patients|An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Ulcerative Colitis Patients|Completed||Phase 1|20|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 03:31:09.757011|2018-06-01 03:31:09.757011
NCT00421629|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-01-11|2007-01-11|2007-01-12|Estimate|||||||2007-01-11|2007-01-12|Estimate|October 2003||2003-10-31|January 2007|2007-01-31|April 2006||2006-04-30|||||Interventional|||Experimental Study to Assess Interventions Aimed at Improving the Equity Impact of Community-Based Health Insurance|Experimental Study to Assess Interventions Aimed at Improving the Equity Impact of Community-Based Health Insurance|Completed||N/A|688||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 03:31:09.824784|2018-06-01 03:31:09.824784
NCT00421616|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-02-16|2007-01-11|2007-01-12|Estimate|||||||2007-02-16|2007-02-19|Estimate|February 2007||2007-02-28|February 2007|2007-02-28||||||||Interventional|||Effectiveness of High Protein Diets in Promoting Weight Loss in Overweight and Obese Subjects.|A Diet Higher in Animal-Based Protein is More Effective in Promoting Weight Loss in Overweight and Obese Individuals Than Other Protein Based Diets.|Unknown status|Not yet recruiting|N/A|45||University of Wollongong|||||f||||||||||||||2018-06-01 03:31:09.904858|2018-06-01 03:31:09.904858
NCT00421603|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2012-12-13||2018-05-10|2007-01-11|2007-01-12|Estimate|2013-01-23|2013-02-28|Estimate||||2018-05-10|2018-05-15|Actual|February 2007||2007-02-28|May 2018|2018-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|TACT||A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence|A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) and Topiramate for the Treatment of Cocaine Dependence|Completed||Phase 2|81|Actual|New York State Psychiatric Institute|The two-arm placebo controlled design does not allow us to address whether both medications are necessary for efficacy. Potential limited treatment masking that occurred when giving two medications with distinctive adverse effect profiles.|2|||f||||t||||||||||2018-06-01 03:31:09.982251|2018-06-01 03:31:09.982251
NCT00421590|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-06-21|2007-01-11|2007-01-12|Estimate|||||||2007-06-21|2007-06-22|Estimate|October 2006||2006-10-31|June 2007|2007-06-30||||||||Interventional|||Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).|A Randomized, Partially Blind, Placebo Controlled, Crossover, Single Oral Dose Study to Assess the Effect of Concomitant Antacid (Calcium Carbonate / Magnesium Hydroxide) on the Pharmacokinetics and Pharmacodynamics of SMC021 (0.8 mg Salmon Calcitonin/200 mg 5-CNAC) in Healthy Postmenopausal Women|Completed||Phase 2|38||Novartis|||||f||||||||||||||2018-06-01 03:31:10.273957|2018-06-01 03:31:10.273957
NCT00421577|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-01-11|2007-01-11|2007-01-12|Estimate|||||||2007-01-11|2007-01-12|Estimate||||January 2007|2007-01-31||||||||Observational|||Technique for Localization of Caries Associated Bacteria on Tooth Surfaces.|Usage of Laboratory Technique for Localization of Caries Associated Bacteria on Tooth Surfaces as Clinical Measurement to Caries Diagnosis and Treatment Efficiency.|Unknown status|Not yet recruiting||60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:31:10.329761|2018-06-01 03:31:10.329761
NCT00421564|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-01-11|2007-01-11|2007-01-12|Estimate|||||||2007-01-11|2007-01-12|Estimate|February 2003||2003-02-28|January 2007|2007-01-31|December 2004||2004-12-31|||||Interventional|||Study the Effect of Danggui Buxue Tang on Menopausal Symptoms|A Randomized, Double-Blind, Placebo Controlled Study of the Effect of Danggui Buxue Tang on Menopausal Symptoms and Quality of Life in Hong Kong Chinese Women|Completed||Phase 2|100||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 03:31:10.379226|2018-06-01 03:31:10.379226
NCT00421369|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2013-03-21|2007-01-11|2007-01-12|Estimate|||||||2013-03-21|2013-03-22|Estimate|September 2007||2007-09-30|January 2007|2007-01-31|August 2011|Actual|2011-08-31|||||Interventional|||Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.|Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.|Completed||N/A|35|Actual|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:31:11.854198|2018-06-01 03:31:11.854198
NCT00421551|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2013-07-17|2007-01-11|2007-01-12|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2007||2007-03-31|July 2013|2013-07-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136|A Randomized Multicenter Study With Non-inferiority Hypothesis, Comparing the Availability to Maintain a Complete Viral Suppression by a Monotherapy of Darunavir/r to a NRTI Containing Regimen Including Darunavir/r, in HIV-1 Infected Patients With Previous Prolonged Complete Viral Suppression. ANRS 136 MONOI|Completed||Phase 3|225|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 03:31:10.441516|2018-06-01 03:31:10.441516
NCT00421538|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2018-05-03|2007-01-11|2007-01-12|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2008|Actual|2008-01-31|May 2018|2018-05-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|CACTUS-PTS||Randomized Controlled Trial of Anticoagulation vs. Placebo for a First Symptomatic Isolated Distal Deep-vein Thrombosis (IDDVT)|Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography|Completed||Phase 3|260|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-06-01 03:31:10.559426|2018-06-01 03:31:10.559426
NCT00421525|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2012-10-03|2007-01-11|2007-01-12|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2007||2007-01-31|October 2012|2012-10-31||||August 2009|Actual|2009-08-31||Interventional|||Phase I/II Study of hLL1 in Multiple Myeloma|A Phase I/II Study of Immunotherapy With hLL1 Administered Twice Weekly for 4 Consecutive Weeks in Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|25|Actual|Immunomedics, Inc.||1|||f||||f||||||||||2018-06-01 03:31:10.64798|2018-06-01 03:31:10.64798
NCT00421512|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2008-11-10|2007-01-11|2007-01-12|Estimate|||||||2008-11-10|2008-11-11|Estimate|March 2006||2006-03-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients|A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients|Completed||Phase 1|28|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 03:31:10.73503|2018-06-01 03:31:10.73503
NCT00421499|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-01-11|2007-01-11|2007-01-12|Estimate|||||||2007-01-11|2007-01-12|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|May 2005||2005-05-31|||||Interventional|||Effects of Cocoa Intake on Blood Pressure in Elderly Individuals With Mild Hypertension|Randomized Controlled, Parallel Group, Single Blinded, Phase 1 Study That Investigates the Effects of Regular Daily Intake of Small Amounts of Dark or White Chocolate on Blood Pressure in Elderly Individuals With Mild Hypertension|Completed||Phase 1|44||University of Cologne|||||f||||||||||||||2018-06-01 03:31:10.803938|2018-06-01 03:31:10.803938
NCT00421486|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2016-01-20|2007-01-11|2007-01-12|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|||Oral Human Papillomavirus Infection in HIV-infected Men|Incidence, Prevalence, Spectrum of HPV-types, and Viral Load Determination of High-risk Human Papillomavirus Infection of the Oral Cavity in HIV-infected Men Who Have Sex With Men|Unknown status|Recruiting||500|Anticipated|Deutsche Luft und Raumfahrt|||||f||||||||||||||2018-06-01 03:31:10.856055|2018-06-01 03:31:10.856055
NCT00421473|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2009-02-24|2007-01-11|2007-01-12|Estimate|||||||2009-02-24|2009-02-25|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients|Drug Interactions Between ATOvaquone Used in MAlaria Prophylaxis and Antiretroviral Agents in HIV-1 Infected Patients (ATOMA)|Completed||Phase 4|79|Actual|Radboud University|||||f||||||||||||||2018-06-01 03:31:10.932093|2018-06-01 03:31:10.932093
NCT00421460|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2012-05-14|2007-01-11|2007-01-12|Estimate|||||||2012-05-14|2012-05-15|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction|Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction|Completed||Phase 4|30|Actual|Chulalongkorn University|||||f||||f||||||||||2018-06-01 03:31:10.989899|2018-06-01 03:31:10.989899
NCT00421447|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2015-09-22|2007-01-11|2007-01-12|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2007||2007-01-31|September 2015|2015-09-30|August 2009|Actual|2009-08-31|April 2009|Actual|2009-04-30||Observational|||Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole|Bone Geometry and Muscle Density Changes in Postmenopausal Women and Breast Cancer Patients Prescribed Anastrozole|Completed|||58|Actual|McMaster University|||2||f||||t||||||||||2018-06-01 03:31:11.052303|2018-06-01 03:31:11.052303
NCT00421434|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2008-09-23|2007-01-10|2007-01-12|Estimate|||||||2008-09-23|2008-09-25|Estimate|June 2006||2006-06-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|STEALTHC-1||Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C|Randomized Study of Nitazoxanide-Peginterferon, Nitazoxanide-Peginterferon-Ribavirin and Peginterferon-Ribavirin in the Treatment of Chronic Hepatitis C|Completed||Phase 2/Phase 3|121|Actual|Romark Laboratories L.C.||3|||f||||f||||||||||2018-06-01 03:31:11.117847|2018-06-01 03:31:11.117847
NCT00421421|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2007-11-26|2007-01-11|2007-01-12|Estimate|||||||2007-11-26|2007-11-27|Estimate|March 2007||2007-03-31|November 2007|2007-11-30||||||||Interventional|||Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter|A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 Weeks to Reduce The Risk of Acute Urinary Retention Relapse Following Successful Trial Without Catheter.|Terminated||Phase 4|276||GlaxoSmithKline||||Incomplete information|f||||||||||||||2018-06-01 03:31:11.196366|2018-06-01 03:31:11.196366
NCT00421408|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|2013-04-30||2013-08-26|2007-01-11|2007-01-12|Estimate|2013-08-26|2013-08-28|Estimate||||2013-08-26|2013-08-28|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional||Healthy older men and women with no known disorders that affect mineral metabolism and not taking drugs that alter skeletal metabolism.|The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women|Impact of a Protein Supplement on Bone Mass in Older Men and Women|Completed||Phase 1/Phase 2|208|Actual|Yale University|The limitations of this study include the large attrition rate due to the length of the intervention and the difficulty in adhering to 40 grams of protein or placebo powder as a daily supplement.|2|||f||||t||||||||||2018-06-01 03:31:11.290541|2018-06-01 03:31:11.290541
NCT00421395|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-11|||2008-01-16|2007-01-11|2007-01-12|Estimate|||||||2008-01-16|2008-01-18|Estimate|August 2002||2002-08-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety Study of NHL With 90Y-hLL2 IgG|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG|Completed||Phase 1/Phase 2|59|Actual|Immunomedics, Inc.||1|||f||||f||||||||||2018-06-01 03:31:11.760005|2018-06-01 03:31:11.760005
NCT00421330|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2008-06-03|2007-01-10|2007-01-11|Estimate|||||||2008-06-03|2008-06-04|Estimate|November 2000||2000-11-30|June 2008|2008-06-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Dutch Randomised Endovascular Aneurysm Management (DREAM-) Trial|Endovascular Versus Transabdominal Treatment of the Abdominal Aortic Aneurysm: the Dutch Randomised Endovascular Aneurysm Management (DREAM-) Trial|Unknown status|Active, not recruiting|N/A|392|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 03:31:12.18186|2018-06-01 03:31:12.18186
NCT00421317|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2016-01-05|2007-01-09|2007-01-11|Estimate|||||||2016-01-05|2016-01-06|Estimate|December 2005||2005-12-31|January 2016|2016-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|O-Mel-Inib||Imatinib in Adult Patients With Metastatic Ocular Melanoma|A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma|Terminated||Phase 2|13|Actual|Centre Oscar Lambret||||Study stopped at the end of the first step|f||||f||||||||||2018-06-01 03:31:12.310699|2018-06-01 03:31:12.310699
NCT00421304|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09||2012-06-27|2012-06-27|2007-01-09|2007-01-11|Estimate||||2012-06-27|2012-07-02|Estimate|2012-06-27|2012-07-02|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Treatment of Children Hospitalized With RSV Illness|Completed||Phase 2|118|Actual|MedImmune LLC||3|||f||||t||||||||||2018-06-01 03:31:12.394277|2018-06-01 03:31:12.394277
NCT00421291|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2007-01-09|2007-01-09|2007-01-11|Estimate|||||||2007-01-09|2007-01-11|Estimate|April 2004||2004-04-30|January 2007|2007-01-31|October 2005||2005-10-31|||||Interventional|||Effect of Information on Service Delivery in Rural India||Completed||N/A|||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:31:12.531256|2018-06-01 03:31:12.531256
NCT00421278|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2016-01-21|2007-01-09|2007-01-11|Estimate|||||||2016-01-21|2016-01-22|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)(COMPLETED)|A Clinical Study to Evaluate the Efficacy and Safety of MK0633 in Patients With Atherosclerosis|Completed||Phase 2|180|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 03:31:12.600422|2018-06-01 03:31:12.600422
NCT00421265|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-01-10|2007-01-10|2007-01-11|Estimate|||||||2007-01-10|2007-01-11|Estimate||||January 2007|2007-01-31||||||||Observational|||Active Surveillance for Prostate Cancer With Indolent Features|Prospective Cohort Study of Active Surveillance for Prostate Cancer With Indolent Linical Features|Unknown status|Not yet recruiting||150||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:31:12.755836|2018-06-01 03:31:12.755836
NCT00421252|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2017-04-12|2007-01-10|2007-01-11|Estimate|||||||2017-04-12|2017-04-14|Actual|January 2007|Actual|2007-01-31|April 2017|2017-04-30|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.|Impact of Pre-treatment With 600mg of Clopidogrel (Plavix) on the Incidence of Ischemic and Hemorrhagic Complications in Patients Undergoing Elective Percutaneous Coronary Revascularization.--Prospective Randomized Trial.|Terminated||Phase 4|18|Actual|Beth Israel Deaconess Medical Center||4||Difficult to enroll patients; limited resources available|f||||t||||||||No|No plans to share data|2018-06-01 03:31:12.836785|2018-06-01 03:31:12.836785
NCT00421239|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2008-12-08|2007-01-08|2007-01-11|Estimate|||||||2008-12-08|2008-12-09|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|||||Observational|OSADA||Risk Factors of Hypertensive Urgencies|Retrospective Study of Hypertensive Urgencies in Patients With Arterial Hypertension|Completed|||1200|Actual|Russian Cardiology Research and Production Center|||2||f||||f||||||||||2018-06-01 03:31:12.923922|2018-06-01 03:31:12.923922
NCT00421226|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2012-04-27|2007-01-10|2007-01-11|Estimate|||||||2012-04-27|2012-04-30|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Demonstrate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered as Intravenous Infusion and Subcutaneous Injection in Japanese Healthy Volunteers|Completed||Phase 1|48|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:31:13.02698|2018-06-01 03:31:13.02698
NCT00421213|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2012-07-18|2007-01-10|2007-01-11|Estimate|||||||2012-07-18|2012-07-19|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers|Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers|Completed||Phase 2|50|Actual|Ziopharm||1|||f||||||||||||||2018-06-01 03:31:13.105661|2018-06-01 03:31:13.105661
NCT00421200|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2013-08-15|2007-01-09|2007-01-11|Estimate|||||||2013-08-15|2013-08-19|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty|A Randomized, Double-blind, Phase III Study of the Efficacy and Safety of an Oxygen-carrying Plasma Expander, Hemospan®, Compared With Voluven® to Prevent Hypotension in Patients Undergoing Primary Hip Arthroplasty With Spinal Anesthesia|Completed||Phase 3|375|Actual|Sangart||2|||f||||t||||||||||2018-06-01 03:31:13.246869|2018-06-01 03:31:13.246869
NCT00421187|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2011-03-09|2007-01-10|2007-01-11|Estimate|||||||2011-03-09|2011-03-11|Estimate|March 2007||2007-03-31|April 2008|2008-04-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics|Phase III Study of 3 Sequential Doses (10 mg/kg, 5 mg/kg, and 5 mg/kg) vs 3 mg/kg/Day of AmBisome® in the Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics|Terminated||Phase 4|20|Actual|Gilead Sciences||2||Unable to recruit subjects in the Turkey site.|f||||f||||||||||2018-06-01 03:31:13.379816|2018-06-01 03:31:13.379816
NCT00421174|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2016-01-28||2017-08-24|2007-01-09|2007-01-11|Estimate|2016-04-08|2016-05-16|Estimate||||2017-08-24|2017-09-25|Actual|August 2007||2007-08-31|August 2017|2017-08-31|July 2013|Actual|2013-07-31|June 2010|Actual|2010-06-30||Interventional|||Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)|A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Cell Transplantation (BMT CTN #0403)|Completed||Phase 3|37|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-06-01 03:31:13.479633|2018-06-01 03:31:13.479633
NCT00421161|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-01-10|2007-01-10|2007-01-11|Estimate|||||||2007-01-10|2007-01-11|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|March 2007||2007-03-31|||||Interventional|||Olive Oil With Omega 3 to Treat Stasis Dermatitis|Phase 1 and 2 Study on the Efficacy and Side Effects of Olive Oil and Omega 3 Local Treatment in Stasis Dermatitis|Unknown status|Not yet recruiting|Phase 1/Phase 2|30||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:31:14.131545|2018-06-01 03:31:14.131545
NCT00421148|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2017-06-14|2007-01-08|2007-01-11|Estimate|||||||2017-06-14|2017-06-16|Actual|May 30, 2005|Actual|2005-05-30|June 2017|2017-06-30|June 2, 2006|Actual|2006-06-02|May 31, 2006|Actual|2006-05-31||Interventional|||Dose-Finding Pediatric Trial With Sugammadex (19.4.306)(P05961)(COMPLETED)|A Multi -Center, Randomized, Parallel Dose-Finding, Safety Assessor-Blinded Trial to Explore the Efficacy, Safety and Pharmacokinetics of Four Doses of Sugammadex and Placebo in Pediatric and Adult Subjects.|Completed||Phase 3|120|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-06-01 03:31:14.198642|2018-06-01 03:31:14.198642
NCT00421135|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2009-09-16|2007-01-10|2007-01-11|Estimate|||||||2009-09-16|2009-09-17|Estimate|February 2006||2006-02-28|September 2009|2009-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer|A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer|Completed||Phase 1|30|Anticipated|Ziopharm||1|||f||||||||||||||2018-06-01 03:31:14.270332|2018-06-01 03:31:14.270332
NCT00421122|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2009-03-26|2007-01-09|2007-01-11|Estimate|||||||2009-03-26|2009-03-27|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|November 2007|Actual|2007-11-30|||||Interventional|||Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD|A 6-Month, Phase IIIA, Multi-Center,Randomised,Double-Blind, Double-Dummy, Parallel-Group Study of the Efficacy and Safety of Symbicort® Turbuhaler®+ Bricasol® pMDI Compared With Pulmicort® Turbuhaler®+Bricasol® pMDI in Chinese Patients With COPD|Completed||Phase 3|315|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 03:31:14.345316|2018-06-01 03:31:14.345316
NCT00421109|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2012-04-04|2007-01-09|2007-01-11|Estimate|||||||2012-04-04|2012-04-05|Estimate|July 2006||2006-07-31|April 2012|2012-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria|Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria|Completed||Phase 3|522|Actual|Faes Farma, S.A.||3|||f||||f||||||||||2018-06-01 03:31:14.43359|2018-06-01 03:31:14.43359
NCT00421096|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2012-07-23|2007-01-10|2007-01-11|Estimate|||||||2012-07-23|2012-07-24|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|April 2008|Actual|2008-04-30||Interventional|GEMCOL||Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer|Stage IB2 to IVA Uterine Cervical Cancer: Phase 2 Study to Assess a New Therapeutic Sequence Associating a Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine|Terminated||Phase 2|19|Actual|Centre Oscar Lambret||1||Problems of recruitment|f||||f||||||||||2018-06-01 03:31:14.702382|2018-06-01 03:31:14.702382
NCT00421083|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2007-10-23|2007-01-09|2007-01-11|Estimate|||||||2007-10-23|2007-10-25|Estimate|September 2004||2004-09-30|October 2007|2007-10-31|June 2005|Actual|2005-06-30|||||Interventional|||Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess Efficacy and Safety of Tadalafil (LY450190) in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury|Completed||Phase 3|180||Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:31:14.870228|2018-06-01 03:31:14.870228
NCT00421070|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2015-04-26|2007-01-10|2007-01-11|Estimate|||||||2015-04-26|2015-04-28|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effect of Massage Therapy on Aggression in a Psychiatric Inpatient Unit|The Evaluation of Relaxation Massage Therapy as an Intervention Treatment for Reducing the Level of Arousal and Aggression on a Young Adult Psychiatric Inpatient Unit|Completed||N/A|47|Actual|Melbourne Health||2|||f||||f||||||||||2018-06-01 03:31:14.958377|2018-06-01 03:31:14.958377
NCT00421057|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2012-07-27|2007-01-09|2007-01-11|Estimate|||||||2012-07-27|2012-07-31|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Combined Strength Training and Functional Endurance Exercise Regimen on Cancer -Related Fatigue and Physical Performance|The Effects of Combined Strength Training and Functional Endurance Exercise Regimen on Cancer-Related Fatigue and Physical Performance|Completed|||25|Actual|M.D. Anderson Cancer Center|||2||f||||t||||||||||2018-06-01 03:31:15.100603|2018-06-01 03:31:15.100603
NCT00421044|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2012-01-09|2007-01-10|2007-01-11|Estimate|||||||2012-01-09|2012-01-11|Estimate|May 2006||2006-05-31|January 2012|2012-01-31||||February 2008|Actual|2008-02-29||Interventional|||A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function|An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function|Completed||Phase 1|14|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:31:15.177901|2018-06-01 03:31:15.177901
NCT00421031|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-01-10|2007-01-10|2007-01-11|Estimate|||||||2007-01-10|2007-01-11|Estimate|December 2003||2003-12-31|January 2007|2007-01-31|April 2004||2004-04-30|||||Interventional|||Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause|A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR For Relief of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|540||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:31:15.316907|2018-06-01 03:31:15.316907
NCT00421018|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2012-08-14|2007-01-10|2007-01-11|Estimate|||||||2012-08-14|2012-08-15|Estimate|November 2006||2006-11-30|August 2012|2012-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)|Optimization of the Anti-Inflammatory Treatment of Asthma Patients Through Exhaled NO Measurements for Increased Asthma-Related Quality of Life in Primary Health Care (NOAK)|Completed||N/A|187|Actual|Karolinska Institutet||2|||f||||||||||||||2018-06-01 03:31:15.431136|2018-06-01 03:31:15.431136
NCT00421005|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2009-04-28|2007-01-09|2007-01-11|Estimate|||||||2009-04-28|2009-04-29|Estimate|November 2004||2004-11-30|April 2009|2009-04-30|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Fluvastatin After Heart Transplantation|Safety and Efficacy of Fluvastatin in Heart Transplant Recipients|Unknown status|Active, not recruiting|Phase 4|56|Actual|University of Bologna||2|||f||||||||||||||2018-06-01 03:31:15.510095|2018-06-01 03:31:15.510095
NCT00420810|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2015-01-13|2007-01-10|2007-01-11|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2006||2006-09-30|January 2015|2015-01-31||||March 2007|Actual|2007-03-31||Interventional|||Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)|A Double-Blind, Placebo Controlled, Randomized, Cross-Over Polysomnographic Study of MK0928 15 mg in Adult Patients With Primary Insomnia|Terminated||Phase 3|138||H. Lundbeck A/S|||||f||||||||||||||2018-06-01 03:31:21.537573|2018-06-01 03:31:21.537573
NCT00420992|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2009-09-11|2009-03-09|2013-09-13|2007-01-10|2007-01-11|Estimate|2009-10-28|2009-10-30|Estimate|2009-10-28|2009-10-30|Estimate|2013-09-13|2013-09-20|Estimate|December 2006||2006-12-31|September 2013|2013-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Efficacy Study of Kadian NT (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee|Completed||Phase 3|547|Actual|Pfizer||2|||f||||||||||||||2018-06-01 03:31:15.617616|2018-06-01 03:31:15.617616
NCT00420966|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2018-04-13|2007-01-10|2007-01-11|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2005||2005-10-31|September 2017|2017-09-30|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Observational|||Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy|Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers|Completed|||25003|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 03:31:16.010102|2018-06-01 03:31:16.010102
NCT00420953|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2017-09-07|2007-01-09|2007-01-11|Estimate|||||||2017-09-07|2017-09-08|Actual|December 18, 2006|Actual|2006-12-18|September 2017|2017-09-30|April 23, 2007|Actual|2007-04-23|April 23, 2007|Actual|2007-04-23||Interventional|||Relative Bioavailability of PM101 IV and Cordarone IV|A Randomized, Double-blind, 2-period Crossover Trial to Determine the Relative Bioavailability of PM101 I.V. (Amiodarone HCl) and Cordarone I.V. in Healthy Adult Volunteers|Completed||Phase 1|||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 03:31:16.07716|2018-06-01 03:31:16.07716
NCT00420940|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2010-04-07|2007-01-09|2007-01-11|Estimate|||||||2010-04-07|2010-04-08|Estimate|November 2006||2006-11-30|October 2008|2008-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Influence of Vibration on Bone Mineral Density in Women Who Have Weak Bones After Menopause|The Effect of Daily Whole-Body Vibration on Tibial Trabecular Bone Mineral Density in Osteopenic Postmenopausal Women|Completed||Phase 3|202|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-06-01 03:31:16.129703|2018-06-01 03:31:16.129703
NCT00420927|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2011-07-01||2012-04-16|2007-01-10|2007-01-11|Estimate|2011-08-24|2011-09-29|Estimate||||2012-04-16|2012-04-18|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|OPTIMA||Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis|A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation With Methotrexate and Adalimumab Combination Therapy in Patients With Early Rheumatoid Arthritis (OPTIMA)|Completed||Phase 4|1032|Actual|Abbott||5|||f||||f||||||||||2018-06-01 03:31:16.30321|2018-06-01 03:31:16.30321
NCT00420914|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2008-05-27|2007-01-08|2007-01-11|Estimate|||||||2008-05-27|2008-05-28|Estimate|October 2003||2003-10-31|May 2008|2008-05-31||||||||Interventional|||Strategies for Transfusion of Platelets (SToP)|"Strategies for Transfusion of Platelets (SToP) [Formerly Titled Evaluation of the Hemostatic Efficacy and Platelet Utilization Rates of Low Versus Standard Dose Platelet Therapy]"|Terminated||Phase 3|130|Actual|McMaster University||||Stopped at the request of the Data Safety Monitoring Board for safety reasons.|f||||||||||||||2018-06-01 03:31:19.560038|2018-06-01 03:31:19.560038
NCT00420901|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2007-01-09|2007-01-09|2007-01-11|Estimate|||||||2007-01-09|2007-01-11|Estimate|January 1999||1999-01-31|January 2007|2007-01-31|February 2000||2000-02-29|||||Interventional|||Effect of Chronic PDE5-Inhibition on Endothelial Function in Diabetics|Effect of Chronic Administration of Sildenafil on Endothelial Function in Men With Diabetes|Completed||Phase 3|30||IRCCS San Raffaele|||||f||||||||||||||2018-06-01 03:31:19.637537|2018-06-01 03:31:19.637537
NCT00420888|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09||2014-06-02|2015-06-30|2007-01-09|2007-01-11|Estimate||||2014-07-01|2014-07-08|Estimate|2015-06-30|2015-07-22|Estimate|January 2007||2007-01-31|June 2014|2014-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma|A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.|Completed||Phase 2/Phase 3|526|Actual|Active Biotech AB||3|||f||||f||||||||||2018-06-01 03:31:19.711123|2018-06-01 03:31:19.711123
NCT00420875|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2015-08-25|2007-01-09|2007-01-11|Estimate|||||||2015-08-25|2015-08-26|Estimate|June 2007||2007-06-30|August 2015|2015-08-31||||||||Interventional|TOPAZ Registry||Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis|"Clinical Evaluation of Placement of Radiofrequency-based Plasma Microdebridement in the Treatment Algorithm for Foot and Ankle Tendinosis and Plantar Fasciosis"|Withdrawn||Phase 4|0|Actual|ArthroCare Corporation||||Did not meet enrollment goals|f||||||||||||||2018-06-01 03:31:19.950524|2018-06-01 03:31:19.950524
NCT00420862|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-01-10|2007-01-10|2007-01-11|Estimate|||||||2007-01-10|2007-01-11|Estimate|June 2001||2001-06-30|January 2007|2007-01-31|February 2010||2010-02-28|||||Interventional|||The DANTE Trial. A Randomized Study on Lung Cancer Screening With Low-Dose Spiral Computed Tomography||Terminated||Phase 3|2400||Istituto Clinico Humanitas|||||f||||||||||||||2018-06-01 03:31:20.041255|2018-06-01 03:31:20.041255
NCT00420849|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2012-02-10||2012-05-15|2007-01-09|2007-01-11|Estimate|2012-02-10|2012-03-14|Estimate||||2012-05-15|2012-05-21|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma|A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma|Completed||Phase 3|587|Actual|Celgene|This study was defined primarily as an expanded access program in the selected countries. Treatment was to continue until disease progression, study drug was discontinued for any reason, or lenalidomide became commercially available for indication.|1|||f||||||||||||||2018-06-01 03:31:20.193196|2018-06-01 03:31:20.193196
NCT00420836|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-01-10|2007-01-10|2007-01-11|Estimate|||||||2007-01-10|2007-01-11|Estimate|April 2006||2006-04-30|January 2007|2007-01-31||||||||Interventional|||Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study|Crossover Pharmacokinetic Study of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (no Compressor) vs. PARI LC PLUSTM Jet Nebulizer (With Compressor) in Cystic Fibrosis Subjects|Completed||Phase 1|20||Novartis|||||f||||||||||||||2018-06-01 03:31:21.406354|2018-06-01 03:31:21.406354
NCT00420823|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2015-11-18|2007-01-09|2007-01-11|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment|A 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.|Completed||Phase 2/Phase 3|121|Actual|Melbourne Health||2|||f||||||||||||||2018-06-01 03:31:21.462612|2018-06-01 03:31:21.462612
NCT00420797|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2015-05-18|2007-01-09|2007-01-11|Estimate|||||||2015-05-18|2015-05-19|Estimate|February 2007||2007-02-28|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence|A Double-blind, Randomised, Placebo-controlled Study to Evaluate Topical 10% Phenylephrine Gel in the Management of Ileal Pouch Anal Anastomosis (IPAA)-Related Faecal Incontinence|Withdrawn||Phase 3|0|Actual|S.L.A. Pharma AG||||Terminated, new protocol to be developed|f||||f||||||||||2018-06-01 03:31:21.591393|2018-06-01 03:31:21.591393
NCT00420784|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2011-06-22||2014-07-09|2007-01-08|2007-01-11|Estimate|2011-06-22|2011-07-21|Estimate||||2014-07-09|2014-08-05|Estimate|February 2007||2007-02-28|July 2014|2014-07-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional||Full Analysis Set = subjects who received at least 1 dose of study drug.|A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)|A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy|Completed||Phase 2|465|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-06-01 03:31:21.717261|2018-06-01 03:31:21.717261
NCT00420771|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2012-12-11|2007-01-08|2007-01-11|Estimate|||||||2012-12-11|2012-12-12|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients|A Randomized Controlled Pilot Trial of Gabapentin for the Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients|Completed||Phase 2|19|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 03:31:22.637489|2018-06-01 03:31:22.637489
NCT00420758|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2015-12-03|2007-01-10|2007-01-11|Estimate|||||||2015-12-03|2015-12-04|Estimate|November 2007||2007-11-30|December 2015|2015-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effectiveness Trial on Alleviation of Infant Malnutrition With Fortified Spread or Maize-Soy Flour Food Supplements|LCNI-7. A Three-centre Intervention Trial in Rural Malawi, Testing the Effectiveness of Fortified Spread or Maize-Soy Flour Supplementation to Alleviate Moderate Malnutrition Among 6-18 Month Old Children|Completed||Phase 3|299|Actual|University of Tampere||3|||f||||t||||||||||2018-06-01 03:31:22.71671|2018-06-01 03:31:22.71671
NCT00420745|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2009-03-13||2016-11-03|2007-01-09|2007-01-11|Estimate|2009-03-13|2009-05-04|Estimate||||2016-11-03|2016-12-16|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants|Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants|Completed||Phase 3|1009|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:31:22.803871|2018-06-01 03:31:22.803871
NCT00420732|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08||2014-05-28|2015-05-29|2007-01-08|2007-01-11|Estimate||||2014-05-28|2014-06-02|Estimate|2015-05-29|2015-06-26|Estimate|January 2007||2007-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2012|Actual|2012-11-30||Interventional|||Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer|A Phase II Study of Tergenpumatucel-L (HyperAcute Lung) Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment|Terminated||Phase 2|6|Actual|NewLink Genetics Corporation||1||Enrollment goals unable to be reached.|f||||t||||||||||2018-06-01 03:31:23.293333|2018-06-01 03:31:23.293333
NCT00420719|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2009-03-16|2007-01-09|2007-01-11|Estimate|||||||2009-03-16|2009-03-18|Estimate|October 2004||2004-10-31|March 2009|2009-03-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|||Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)|Multi-Center Pivotal Study of Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)|Unknown status|Active, not recruiting|N/A|100|Anticipated|Synapse Biomedical|||||f||||||||||||||2018-06-01 03:31:23.375644|2018-06-01 03:31:23.375644
NCT00420706|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2007-12-06|2007-01-09|2007-01-11|Estimate|||||||2007-12-06|2007-12-10|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Study Evaluating SCA-136 Tolerability With Dose Titration and Food|A Multi-Dose, Double-Blind, Parallel-Group Study of the Effects of Dose Titration and Administration With Food on the Tolerability of SCA-136 in Healthy Subjects|Terminated||Phase 1|120||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:31:23.466789|2018-06-01 03:31:23.466789
NCT00420693|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|||2009-01-14|2007-01-09|2007-01-11|Estimate|||||||2009-01-14|2009-01-15|Estimate|August 2006||2006-08-31|January 2009|2009-01-31||||May 2008|Actual|2008-05-31||Interventional|||Interest of Using the Sevoflurane in the Prevention of Newborns Pain|Interest of Using the Sevoflurane in the Prevention of Newborns Pain|Completed||Phase 2/Phase 3|60|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||||||||||||2018-06-01 03:31:23.515526|2018-06-01 03:31:23.515526
NCT00420680|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2017-08-18|2007-01-10|2007-01-11|Estimate|||||||2017-08-18|2017-08-22|Actual|November 7, 2005|Actual|2005-11-07|August 2017|2017-08-31|August 1, 2006|Actual|2006-08-01|August 1, 2006|Actual|2006-08-01||Interventional|||Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)|A Multi -Center, Randomized, Parallel-Group, Placebo-Controlled, Safety Assessor-Blinded Trial, Evaluating the Safety and Efficacy of Sugammadex in Cardiac Patients|Completed||Phase 3|120|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 03:31:23.567851|2018-06-01 03:31:23.567851
NCT00420667|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2007-01-08|2007-01-08|2007-01-11|Estimate|||||||2007-01-08|2007-01-11|Estimate|November 2004||2004-11-30|January 2007|2007-01-31|May 2005||2005-05-31|||||Interventional|||Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery|Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery|Completed||N/A|40||G. d'Annunzio University|||||f||||||||||||||2018-06-01 03:31:23.634875|2018-06-01 03:31:23.634875
NCT00420654|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2011-11-06|2007-01-10|2007-01-11|Estimate|||||||2011-11-06|2011-11-08|Estimate|August 2007||2007-08-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Growth Hormone Treatment of Women With Turner Syndrome|Growth Hormone Treatment of Women With Turner Syndrome: Body Composition and Heart Function.|Completed||N/A|24|Anticipated|University of Aarhus||3|||f||||t||||||||||2018-06-01 03:31:23.712244|2018-06-01 03:31:23.712244
NCT00420472|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2007-11-19|2007-01-10|2007-01-11|Estimate|||||||2007-11-19|2007-11-20|Estimate|March 2007||2007-03-31|November 2007|2007-11-30||||||||Interventional|||A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.|An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept|Terminated||Phase 4|||Hoffmann-La Roche|||||f||||||||||||||2018-06-01 03:31:27.504757|2018-06-01 03:31:27.504757
NCT00420641|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2017-07-17||2017-07-17|2007-01-10|2007-01-11|Estimate|2017-07-17|2018-02-05|Actual||||2017-07-17|2018-02-05|Actual|December 19, 2006||2006-12-19|October 2014|2014-10-31|October 15, 2008|Actual|2008-10-15|June 1, 2008|Actual|2008-06-01||Interventional||Intent-to-Treat (ITT) Population was defined as consisting of all participants who gave informed consent, were randomized, received at least one dose of double blind medication and for whom at least one post-randomization assessment was available.|MDD POC Study GSK372475 Subjects Depressive Disease|A Ten-week, Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled, Paralleled-Group, Flexible-Dose Study Evaluating the Efficacy, Safety and Tolerability of GSK372475 or Paroxetine Compared to Placebo in Adult Subjects Diagnosed With Major Depressive Disorder|Completed||Phase 2|492|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:31:23.921944|2018-06-01 03:31:23.921944
NCT00420628|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2010-03-19||2011-09-30|2007-01-08|2007-01-11|Estimate|2010-08-27|2010-09-22|Estimate||||2011-09-30|2011-10-07|Estimate|November 2006||2006-11-30|September 2011|2011-09-30|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||Pediatric Zylet Safety and Efficacy Study|A Safety and Efficacy Study of Zylet® (Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension) Compared to Vehicle in the Management of Lid Inflammation (Chalazion/Hordeolum) in Pediatric Subjects|Completed||Phase 4|108|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:31:26.081275|2018-06-01 03:31:26.081275
NCT00420615|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2012-04-23|2007-01-10|2007-01-11|Estimate|||||||2012-04-23|2012-04-25|Estimate|December 2006||2006-12-31|April 2012|2012-04-30||||August 2008|Actual|2008-08-31||Interventional|||Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies|An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies|Completed||Phase 1|34|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:31:26.344791|2018-06-01 03:31:26.344791
NCT00420602|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2018-05-08|2007-01-10|2007-01-11|Estimate|||||||2018-05-08|2018-05-09|Actual|September 21, 2007|Actual|2007-09-21|May 2018|2018-05-31|December 27, 2017|Actual|2017-12-27|December 27, 2017|Actual|2017-12-27||Interventional|||DHA Supplementation in Patients With STGD3|Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3|Completed||N/A|11|Actual|University of Utah||1|||f||||f||||||||||2018-06-01 03:31:26.409419|2018-06-01 03:31:26.409419
NCT00420589|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2015-02-04|2007-01-10|2007-01-11|Estimate|||||||2015-02-04|2015-02-05|Estimate|October 2006||2006-10-31|February 2015|2015-02-28|November 2008|Actual|2008-11-30|February 2008|Actual|2008-02-29||Interventional|||A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED)|A Study to Assess the Efficacy and Tolerability of Taranabant in Maintaining Weight Loss Induced by Diet in Obese Patients Followed by a 1-Year Extension|Terminated||Phase 3|1000|Actual|Merck Sharp & Dohme Corp.||4||The overall profile does not support development for obesity|f||||||||||||||2018-06-01 03:31:26.552922|2018-06-01 03:31:26.552922
NCT00420576|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2008-12-17|2007-01-10|2007-01-11|Estimate|||||||2008-12-17|2008-12-18|Estimate|June 2006||2006-06-30|January 2007|2007-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dose Finding Study of Danggui Buxue Tang (Herbal Formula)on the Treatment of Menopausal Symptoms|A Randomized, Double-Blind, Multiple-Dose Escalation Study of the Effect of Danggui Buxue Tang on Symptomatic Postmenopausal Hong Kong Chinese Women (Continuation of a Completed Study Using the Same Formula)|Completed||Phase 2|60|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 03:31:26.619915|2018-06-01 03:31:26.619915
NCT00420563|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2012-07-20|2007-01-09|2007-01-11|Estimate|||||||2012-07-20|2012-07-23|Estimate|September 2006||2006-09-30|July 2012|2012-07-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|PALANGI-0601||Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer|A Phase II Randomized Study to Assess the Benefit of a Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer|Completed||Phase 2|88|Actual|Centre Oscar Lambret||2|||f||||t||||||||||2018-06-01 03:31:26.70518|2018-06-01 03:31:26.70518
NCT00420550|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2012-03-19|2007-01-09|2007-01-11|Estimate|||||||2012-03-19|2012-03-21|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC|Pilot Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With Interstitial Cystitis|Completed||Phase 2|10|Anticipated|William Beaumont Hospitals|||||f||||||||||||||2018-06-01 03:31:26.779381|2018-06-01 03:31:26.779381
NCT00420537|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2010-01-11|2007-01-09|2007-01-11|Estimate|||||||2010-01-11|2010-01-12|Estimate|September 2006||2006-09-30|May 2009|2009-05-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Shift to Everolimus (RAD) Kidney Sparing Study|Safety and Efficacy of Low-dose Cyclosporine in Association With Everolimus to Minimize Renal Dysfunction in Heart Transplant Recipients|Terminated||Phase 4|34|Actual|University of Bologna||2||A cluster of adverse events in everolimus arm was noted.|f||||||||||||||2018-06-01 03:31:26.839983|2018-06-01 03:31:26.839983
NCT00420524|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2011-12-22|2007-01-10|2007-01-11|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2006||2006-01-31|December 2011|2011-12-31||||July 2010|Actual|2010-07-31||Interventional|||A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function|An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function|Completed||Phase 1|36|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:31:26.986724|2018-06-01 03:31:26.986724
NCT00420511|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2011-06-24||2011-12-28|2007-01-10|2007-01-11|Estimate|2011-12-20|2011-12-29|Estimate||||2011-12-28|2012-01-02|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|BEST||Beta-Cell Function and Sitagliptin Trial (BEST)|A Randomized Controlled Pilot Study Assessing the Effect of Sitagliptin on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes|Completed||Phase 2|21|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|The modest sample size of this pilot study may have lacked sufficient statistical power to detect an effect on preservation of beta-cell function.|2|||f||||f||||||||||2018-06-01 03:31:27.082656|2018-06-01 03:31:27.082656
NCT00420498|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2007-12-11|2007-01-09|2007-01-11|Estimate|||||||2007-12-11|2007-12-12|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Effects of Atomoxetine on Cognitive Function in Schizophrenia|Effects of Atomoxetine on Cognitive Function in Schizophrenia|Completed||Phase 2|12|Actual|Yale University|||||f||||f||||||||||2018-06-01 03:31:27.360374|2018-06-01 03:31:27.360374
NCT00420485|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2013-04-17|2007-01-08|2007-01-11|Estimate|||||||2013-04-17|2013-04-19|Estimate|March 2006||2006-03-31|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors|A Phase I Open-label, Multi-center Dose-escalation Study to Determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|120|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:31:27.424717|2018-06-01 03:31:27.424717
NCT00420420|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2010-10-25||2015-01-28|2007-01-10|2007-01-11|Estimate|2010-10-25|2010-11-18|Estimate||||2015-01-28|2015-02-12|Estimate|November 2006||2006-11-30|January 2015|2015-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease|Completed||Phase 2|144|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:31:27.972977|2018-06-01 03:31:27.972977
NCT00420407|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2012-09-11||2017-11-13|2007-01-09|2007-01-11|Estimate|2013-03-05|2013-04-16|Estimate||||2017-11-13|2017-12-12|Actual|February 2007||2007-02-28|April 2013|2013-04-30|February 2011|Actual|2011-02-28|April 2009|Actual|2009-04-30||Interventional||Vasopressin enrolled 40 and two withdrawn and never received drug (38) Normal saline enrolled 41 and one withdrawn and never received drug (40)|Low Dose Vasopressin in Traumatic Shock|Prospective, Randomized, Double-Blind, Multi-Center Trial of Low Dose Vasopressin Versus Placebo in Traumatic Shock Resuscitation|Terminated||N/A|81|Actual|The University of Texas Health Science Center at San Antonio||2||accrual rate|f||||t||||||||||2018-06-01 03:31:28.259348|2018-06-01 03:31:28.259348
NCT00420394|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2007-06-19|2007-01-09|2007-01-11|Estimate|||||||2007-06-19|2007-06-20|Estimate|April 2007||2007-04-30|January 2007|2007-01-31||||||||Interventional|||Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer|Phase II Study of Preoperative Chemotherapy and Postoperative Chemo-Radiation for Newly Diagnosed, Potentially Resectable Gastric Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|Soroka University Medical Center|||||f||||t||||||||||2018-06-01 03:31:29.170984|2018-06-01 03:31:29.170984
NCT00420381|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08||2009-12-11|2015-03-10|2007-01-08|2007-01-11|Estimate||||2009-12-11|2009-12-15|Estimate|2015-03-10|2015-03-30|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|May 2008|Actual|2008-05-31||Interventional|||Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer|A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|28|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 03:31:29.242032|2018-06-01 03:31:29.242032
NCT00420368|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2012-06-17|2007-01-10|2007-01-11|Estimate|||||||2012-06-17|2012-06-19|Estimate|February 2007||2007-02-28|June 2012|2012-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Efficacy Trial on Alleviation of Infant Malnutrition With Fortified Spread or Maize-soy Flour Food Supplements|LCNI-6. A Single-centre Intervention Trial in Rural Malawi, Testing the Efficacy of Fortified Spread or Maize-soy Flour Supplementation to Alleviate Moderate Malnutrition Among 6-18 Month Old Children|Completed||Phase 3|189||University of Tampere|||||f||||t||||||||||2018-06-01 03:31:29.308652|2018-06-01 03:31:29.308652
NCT00420355|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2009-02-05|2007-01-09|2007-01-11|Estimate|||||||2009-02-05|2009-02-06|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|September 2008|Actual|2008-09-30|October 2007|Actual|2007-10-31||Interventional|||Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients|The Pharmacokinetics of Lopinavir/Ritonavir in Combination With Atazanavir in HIV-Infected Subjects|Terminated||Phase 4|19|Actual|University of Oklahoma||2||Unexpected adverse event|f||||f||||||||||2018-06-01 03:31:29.375814|2018-06-01 03:31:29.375814
NCT00420342|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|2009-10-28||2015-05-11|2007-01-09|2007-01-11|Estimate|2010-01-18|2010-01-20|Estimate||||2015-05-11|2015-06-02|Estimate|January 2007||2007-01-31|May 2015|2015-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension|A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension|Completed||Phase 2|92|Actual|Bayer|Small sample size, as this was a pilot study.|3|||f||||f||||||||||2018-06-01 03:31:29.476144|2018-06-01 03:31:29.476144
NCT00420316|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2017-01-05||2017-01-05|2007-01-10|2007-01-11|Estimate|2017-01-05|2017-02-23|Actual||||2017-01-05|2017-02-23|Actual|February 2007||2007-02-28|January 2017|2017-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.|To Assess Long-term Efficacy & Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in the Primary Vaccination Study (102247).|Completed||Phase 3|2601|Actual|GlaxoSmithKline|None reported.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:31:30.172007|2018-06-01 03:31:30.172007
NCT00420303|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2009-09-30||2010-07-15|2007-01-08|2007-01-11|Estimate|2009-10-05|2009-11-10|Estimate||||2010-07-15|2010-07-20|Estimate|January 2007||2007-01-31|July 2010|2010-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study Evaluating Etanercept for the Treatment of Refractory Heel Enthesitis in Spondylarthropathy|A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy|Completed||Phase 4|24|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:31:30.548974|2018-06-01 03:31:30.548974
NCT00420290|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|2011-07-11||2011-10-10|2007-01-10|2007-01-11|Estimate|2011-10-10|2011-11-17|Estimate||||2011-10-10|2011-11-17|Estimate|January 2008||2008-01-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients|Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients|Completed||N/A|31|Actual|Vanderbilt University|The sample size is small and the intervention is of short duration. Also, the results cannot be generalized to all CHD patients because our inclusion criteria were stringent.|2|||f||||t||||||||||2018-06-01 03:31:30.859447|2018-06-01 03:31:30.859447
NCT00420277|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2013-08-15|2007-01-09|2007-01-11|Estimate|||||||2013-08-15|2013-08-19|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty|A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of an Oxygen-Carrying Plasma Expander, Hemospan®, Compared With Voluven® toTreat Hypotension in Patients Undergoing Primary Hip Arthroplasty With Spinal Anesthesia|Completed||Phase 3|462|Actual|Sangart||2|||f||||t||||||||||2018-06-01 03:31:31.15138|2018-06-01 03:31:31.15138
NCT00420264|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-10|||2013-08-13|2007-01-10|2007-01-11|Estimate|||||||2013-08-13|2013-08-14|Estimate|November 2005||2005-11-30|August 2013|2013-08-31|May 2009|Actual|2009-05-31|June 2008|Actual|2008-06-30||Interventional|||ThermaChoice III Under Local Sedation in the Office Setting|Feasibility of Using Gynecare Thermachoice III in the Office Setting Without Conscious Sedation|Completed||N/A|21|Actual|Female Pelvic Medicine & Urogynecology Institute of Michigan|||||f||||||||||||||2018-06-01 03:31:31.252647|2018-06-01 03:31:31.252647
NCT00420251|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2007-01-09|2007-01-09|2007-01-11|Estimate|||||||2007-01-09|2007-01-11|Estimate|March 1996||1996-03-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis|Recombinant Human Growth Hormone Treatment in Juvenile Idiopathic Arthritis: Controlled Study on the Effect on Growth and Bone Development|Completed||Phase 3|50||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:31:31.302734|2018-06-01 03:31:31.302734
NCT00420238|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2010-05-13||2010-06-24|2007-01-08|2007-01-11|Estimate|2010-05-14|2010-06-15|Estimate||||2010-06-24|2010-06-29|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis|A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis|Completed||Phase 4|82|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:31:31.626332|2018-06-01 03:31:31.626332
NCT00420225|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-09|||2007-01-09|2007-01-09|2007-01-11|Estimate|||||||2007-01-09|2007-01-11|Estimate|April 2003||2003-04-30|January 2007|2007-01-31|May 2008||2008-05-31|||||Interventional|||Mesh Repair of Anterior Vaginal Wall Prolapse|Low-Weight Polypropylene Mesh for Anterior Vaginal Wall Prolapse: A Prospective Randomized Study|Completed||Phase 3|202||University of Tampere|||||f||||||||||||||2018-06-01 03:31:33.900676|2018-06-01 03:31:33.900676
NCT00420212|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2014-05-05|2012-10-31|2015-01-13|2007-01-09|2007-01-11|Estimate|2014-05-05|2014-06-02|Estimate|2012-10-31|2012-11-02|Estimate|2015-01-13|2015-01-26|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|DEFINE||Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|1234|Actual|Biogen||3|||f||||t||||||||||2018-06-01 03:31:33.989863|2018-06-01 03:31:33.989863
NCT00420199|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2011-02-08||2012-01-13|2007-01-08|2007-01-09|Estimate|2011-04-19|2011-05-17|Estimate||||2012-01-13|2012-01-18|Estimate|May 2007||2007-05-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional|||A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate|Completed||Phase 3|50|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:31:35.790812|2018-06-01 03:31:35.790812
NCT00420186|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2016-09-28|2007-01-08|2007-01-09|Estimate|||||||2016-09-28|2016-09-30|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-690514 in Combination With Paclitaxel and Carboplatin for Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|37|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:31:36.975965|2018-06-01 03:31:36.975965
NCT00420173|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2013-12-11|2007-01-08|2007-01-09|Estimate|||||||2013-12-11|2013-12-12|Estimate|September 2004||2004-09-30|December 2013|2013-12-31|June 2008|Actual|2008-06-30|July 2005|Actual|2005-07-31||Observational|||Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)|Interdisciplinary Study Group of Lupus Erythematosus|Completed|||45|Actual|European Society of Cutaneous Lupus Erythematosus e.V.|||1||f||||f||||||||||2018-06-01 03:31:37.18935|2018-06-01 03:31:37.18935
NCT00420160|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2015-04-10|2007-01-08|2007-01-09|Estimate|||||||2015-04-10|2015-04-14|Estimate|February 2007||2007-02-28|April 2015|2015-04-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?|Does Moderate Intensity Exercise Help Prevent Smoking Relapse Among Women?|Completed||Phase 2/Phase 3|59|Actual|The Miriam Hospital||2|||f||||||||||||||2018-06-01 03:31:37.284882|2018-06-01 03:31:37.284882
NCT00420147|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2013-12-19||2017-04-03|2007-01-05|2007-01-09|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|February 2002||2002-02-28|April 2017|2017-04-30|November 2007|Actual|2007-11-30|February 2006|Actual|2006-02-28||Interventional|||Wedged Orthoses and Knee Osteoarthritis|Effect of In-shoe Wedges on Knee Osteoarthritis|Completed||N/A|38|Actual|University of Delaware|Compliance with the wedged orthoses was self reported by the subjects. There was difficulty with the larger degrees of wedging (10-15 degrees) fitting into the footwear.|2|||f||||f|f|f||||||No||2018-06-01 03:31:37.371729|2018-06-01 03:31:37.371729
NCT00420134|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2009-09-15|2007-01-08|2007-01-09|Estimate|||||||2009-09-15|2009-09-17|Estimate|February 2006||2006-02-28|September 2009|2009-09-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial|A Phase One/Two Clinical Trial on the Use of Autograft Mesenchymal Stem Cells Differentiated Into Progenitor of Hepatocytes for the Salvage Treatment of Patients With End-stage Liver Disease|Completed||Phase 1/Phase 2|30|Anticipated|Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:31:37.562724|2018-06-01 03:31:37.562724
NCT00420121|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2017-02-07|2007-01-08|2007-01-09|Estimate|||||||2017-02-07|2017-02-08|Estimate|January 2007||2007-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Observational|||European Society of Cutaneous Lupus Erythematosus (EUSCLE)|European Society of Cutaneous Lupus Erythematosus|Enrolling by invitation|||300|Anticipated|European Society of Cutaneous Lupus Erythematosus e.V.|||||f||||f||||||||||2018-06-01 03:31:37.627766|2018-06-01 03:31:37.627766
NCT00420108|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2010-08-18|2007-01-08|2007-01-09|Estimate|||||||2010-08-18|2010-08-20|Estimate|December 2006||2006-12-31|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|3DHF||Optivol Diagnostic Data for Discharge in Heart Failure|Comparing ICD Device Diagnostics to Hospitalized Heart Failure Patient Symptoms and Physician Opinion on Discharge Readiness|Completed|||23|Actual|Thomas Jefferson University|||||f||||f||||||None Retained|"~     No biospecimens to be retained~   "|||2018-06-01 03:31:37.727706|2018-06-01 03:31:37.727706
NCT00420095|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2009-01-07||2009-06-09|2007-01-05|2007-01-09|Estimate|2009-04-15|2009-06-05|Estimate||||2009-06-09|2009-06-17|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|IOPA||A Study for Patients With Diabetes Mellitus (IOPA)|Comparison of HbA1c in Type 1 or Type 2 Diabetic Patients Using Insulin Treated Twice Daily With Either Insulin Lispro Low Mixture or Human Insulin Mix 30/70|Completed||Phase 4|117|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:31:37.822276|2018-06-01 03:31:37.822276
NCT00419588|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2018-02-27|2007-01-05|2007-01-08|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2006||2006-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Growth of Airways and Lung Tissues in Premature and Healthy Infants|Growth of Airways and Lung Parenchyma|Recruiting|||215|Anticipated|Indiana University|||3||f||||t||||||Samples With DNA|"~     Buccal Cells are being obtained.~   "|||2018-06-01 03:31:46.828246|2018-06-01 03:31:46.828246
NCT00420082|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2012-04-04|2007-01-08|2007-01-09|Estimate|||||||2012-04-04|2012-04-05|Estimate|October 2006||2006-10-31|April 2012|2012-04-30|December 2006|Actual|2006-12-31|||||Interventional|||A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber|A Randomized, Double-Blind, 4 Way Cross-over, Placebo Controlled Trial to Evaluate the Onset of Action of Bilastine 20 mg vs. Placebo, Cetirizine 10 mg, and Fexofenadine 120 mg in the Vienna Challenge Chamber|Completed||Phase 2|75|Actual|Faes Farma, S.A.||4|||f||||f||||||||||2018-06-01 03:31:39.431507|2018-06-01 03:31:39.431507
NCT00420069|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-07|||2008-05-19|2007-01-08|2007-01-09|Estimate|||||||2008-05-19|2008-05-20|Estimate|July 2008||2008-07-31|January 2007|2007-01-31|December 2009|Anticipated|2009-12-31|||||Observational|||Biphasic Extrathoracic Cuirass Ventilation During Dental Treatment|Biphasic Extrathoracic Cuirass Ventilation During Dental Treatment Under Deep Sedation|Withdrawn|||20|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:31:39.515318|2018-06-01 03:31:39.515318
NCT00420056|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2015-03-04||2015-10-06|2007-01-05|2007-01-09|Estimate|2015-05-25|2015-06-09|Estimate||||2015-10-06|2015-10-28|Estimate|May 2007||2007-05-31|October 2015|2015-10-31|March 2012|Actual|2012-03-31|March 2010|Actual|2010-03-31||Interventional||Full analysis set (FAS) included all participants enrolled in the study who received at least 1 dose of study medication.|An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.|A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma|Completed||Phase 1|17|Actual|Pfizer|Results are reported for change from baseline in maximum standard uptake value (SUVmax) instead of percent change from baseline in SUVmax.|1|||f||||f||||||||||2018-06-01 03:31:39.613425|2018-06-01 03:31:39.613425
NCT00420043|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2016-04-04|2007-01-08|2007-01-09|Estimate|||||||2016-04-04|2016-04-05|Estimate|September 2006||2006-09-30|February 2016|2016-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Effect of Food on Bioavailability of Modified Release Formulations of Imatinib|A Phase I, Two Arm, Open-label, Randomized, Study to Investigate the Effect of Food on the Bioavailability of a Single 800 mg Imatinib Dose in Modified Release Formulations (MR3 and MR4) and Compare the Bioavailability Between MR3, MR4 and Imatinib 400 mg Twice Daily Immediate Release Tablet (IR) in Healthy Subjects|Completed||Phase 1|32|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:31:40.170148|2018-06-01 03:31:40.170148
NCT00420030|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2009-06-22|2007-01-08|2007-01-09|Estimate|||||||2009-06-22|2009-06-23|Estimate|September 2006||2006-09-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock|Routine Upfront Abciximab Versus Standard Peri-Procedural Therapy in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock PRAGUE-7 Trial.|Completed||Phase 4|80|Anticipated|Charles University, Czech Republic||2|||f||||t||||||||||2018-06-01 03:31:40.241644|2018-06-01 03:31:40.241644
NCT00420017|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2010-07-27||2013-09-06|2007-01-08|2007-01-09|Estimate|2013-01-02|2013-02-06|Estimate||||2013-09-06|2013-09-18|Estimate|September 2005||2005-09-30|September 2013|2013-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Prevention of Atrial Fibrillation Following Esophagectomy|Prevention of Atrial Fibrillation Following Thoracoabdominal Esophagectomy Surgery|Completed||Phase 4|80|Actual|Indiana University|Design not double-blind placebo-control Atrial fibrillation was left to discretion of treating MD Larger study necessary to determine differences in length of hospital stay and cost and identify infrequently occurring amiodarone adverse effects|2|||f||||t||||||||||2018-06-01 03:31:40.350306|2018-06-01 03:31:40.350306
NCT00420004|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2018-02-17|2009-03-26|2018-03-26|2007-01-05|2007-01-09|Estimate|2018-03-26|2018-04-27|Actual|2009-10-05|2009-10-07|Estimate|2018-03-26|2018-04-27|Actual|December 2006||2006-12-31|March 2018|2018-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||All randomized participants.|A Study for Participants With Major Depression|A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression|Completed||Phase 2|469|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 03:31:40.6575|2018-06-01 03:31:40.6575
NCT00419991|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2011-06-21|2007-01-08|2007-01-09|Estimate|||||||2011-06-21|2011-06-22|Estimate|January 2007||2007-01-31|June 2011|2011-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection|An Open-Label Noncomparative, Multicenter, Clinical Trail Measuring Time Related Clinical Response Factors in Relation to Time to Bacterial Eradication With Tigecycline Treatment in Patients With Catheter Infection|Completed||Phase 4|10|Actual|CPL Associates||1|||f||||||||||||||2018-06-01 03:31:41.446821|2018-06-01 03:31:41.446821
NCT00419978|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2008-06-27|2007-01-05|2007-01-09|Estimate|||||||2008-06-27|2008-07-04|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|||||Interventional|||The Significance of Sentinel Node Analysis in Colon Cancer|The Significance of Sentinel Node Analysis in Colon Cancer|Terminated||N/A|24|Actual|Legacy Health System||||Slow accrural to study.|f||||||||||||||2018-06-01 03:31:41.536695|2018-06-01 03:31:41.536695
NCT00419965|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2010-08-18|2007-01-08|2007-01-09|Estimate|||||||2010-08-18|2010-08-20|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Measuring G Protein-coupled Receptor Kinase-2 (GRK2) in the Blood to Diagnose and Treat Patients With Heart Failure|Measuring GRK2 in the Blood to Diagnose and Treat Patients With Heart Failure|Completed|||582|Actual|Thomas Jefferson University|||||f||||t||||||Samples With DNA|"~     Frozen serum/plasma - coded samples~   "|||2018-06-01 03:31:41.592786|2018-06-01 03:31:41.592786
NCT00419952|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2010-11-30||2012-09-28|2007-01-05|2007-01-09|Estimate|2012-09-28|2012-10-30|Estimate||||2012-09-28|2012-10-30|Estimate|February 2007||2007-02-28|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.|A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (≥12 Years) African American Subjects With Asthma|Completed||Phase 3|742|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:31:41.689058|2018-06-01 03:31:41.689058
NCT00419939|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2011-06-20|2007-01-08|2007-01-09|Estimate|||||||2011-06-20|2011-06-21|Estimate|February 2007||2007-02-28|June 2011|2011-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Intensive Rehabilitation of Patients With Severe Traumatic Brain Injury - Development of a Didactic Model|Improvement of the Interaction Between Motivation, Involvement and Re-learning of Daily Life Competences During the Intensive Neurorehabilitation of Patients With Severe TBI. Development of a Research-based Didactic Model.|Completed|||11|Actual|University of Aarhus|||1||f||||f||||||||||2018-06-01 03:31:42.249932|2018-06-01 03:31:42.249932
NCT00419575|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2008-06-04|2007-01-05|2007-01-08|Estimate|||||||2008-06-04|2008-06-05|Estimate|October 2006||2006-10-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|||||Observational|||Renal Transplantation With Immune Monitoring|Renal Transplantation With Immune Monitoring|Completed|||60|Anticipated|Washington University School of Medicine|||||f||||||||||||||2018-06-01 03:31:46.893268|2018-06-01 03:31:46.893268
NCT00419926|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|2010-12-14||2011-02-25|2007-01-08|2007-01-09|Estimate|2010-12-14|2011-01-11|Estimate||||2011-02-25|2011-03-01|Estimate|December 2006||2006-12-31|February 2011|2011-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients|A Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Therapeutic Benefit of an Initially Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Dosing Regimen, in Combination With Cyclosporine and Corticosteroids in de Novo Renal Transplant Patients|Completed||Phase 4|313|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:31:42.346678|2018-06-01 03:31:42.346678
NCT00419913|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-07|||2008-03-31|2007-01-07|2007-01-09|Estimate|||||||2008-03-31|2008-04-02|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|July 2007|Actual|2007-07-31||Interventional|||A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)|A Randomized Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) Treatment for Two Months Before Starting Ovulation Induction for in Vitro Fertilization (IVF)|Terminated||Phase 2/Phase 3|8|Actual|Center for Human Reproduction||2||Failure to recruit sufficient participants.|f||||||||||||||2018-06-01 03:31:43.129021|2018-06-01 03:31:43.129021
NCT00419900|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-07|||2007-01-07|2007-01-07|2007-01-09|Estimate|||||||2007-01-07|2007-01-09|Estimate|December 2006||2006-12-31|January 2007|2007-01-31||||||||Interventional|||Use of Hair to Diagnose the Presence of Breast Cancer||Unknown status|Recruiting|Phase 1/Phase 2|2000||Fermiscan Ltd|||||f||||||||||||||2018-06-01 03:31:43.209595|2018-06-01 03:31:43.209595
NCT00419887|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2007-06-21|2007-01-08|2007-01-09|Estimate|||||||2007-06-21|2007-06-22|Estimate|September 2006||2006-09-30|June 2007|2007-06-30||||||||Interventional|||Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Time-Lagged, Parallel-Group, Ascending Single and Multiple Oral Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LAF237 in Chinese Healthy Subjects|Completed||Phase 1|60||Novartis|||||f||||||||||||||2018-06-01 03:31:43.281982|2018-06-01 03:31:43.281982
NCT00419874|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-07|||2007-01-07|2007-01-07|2007-01-09|Estimate|||||||2007-01-07|2007-01-09|Estimate||||November 2006|2006-11-30||||||||Observational|||Characteristics of Blood- Brain Barrier Permeability in Neurological Patients|Blood- Brain Barrier Permeability in Neurological Patients: Anatomical, Neurophysiological, and Clinical Characteristics|Unknown status|Recruiting||100||Soroka University Medical Center|||||f||||||||||||||2018-06-01 03:31:43.342933|2018-06-01 03:31:43.342933
NCT00419861|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2013-08-22|2007-01-05|2007-01-09|Estimate|||||||2013-08-22|2013-08-23|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Inpatient Influenza Surveillance|Inpatient Surveillance for Influenza Infections in Adults|Completed|||350|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Nasal and throat swabs will be obtained and combined for viral culture, rapid antigen~     testing, and PCR. Specimens obtained from hospitalized subjects will be tested for influenza~     A & B viruses by viral culture, rapid antigen testing and Real-Time Reverse-Transcriptase PCR~     (RTrtPCR) analysis.~   "|||2018-06-01 03:31:43.409913|2018-06-01 03:31:43.409913
NCT00419848|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2008-01-28|2007-01-08|2007-01-09|Estimate|||||||2008-01-28|2008-01-29|Estimate|August 2006||2006-08-31|January 2008|2008-01-31|February 2008|Anticipated|2008-02-29|January 2008|Anticipated|2008-01-31||Interventional|||the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris|the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris|Unknown status|Recruiting|Phase 2|100|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:31:43.473507|2018-06-01 03:31:43.473507
NCT00419835|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2011-08-03|2007-01-08|2007-01-09|Estimate|||||||2011-08-03|2011-08-04|Estimate|May 2005||2005-05-31|January 2007|2007-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus|Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus|Completed||Phase 4|80|Actual|University of Sao Paulo|||||f||||||||||||||2018-06-01 03:31:43.552341|2018-06-01 03:31:43.552341
NCT00419822|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2011-06-30|2007-01-08|2007-01-09|Estimate|||||||2011-06-30|2011-07-04|Estimate|September 2006||2006-09-30|May 2010|2010-05-31||||March 2011|Actual|2011-03-31||Interventional|||Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients|A Randomized, Intent to Treat, Controlled Study of the Efficacy of Verum Acupuncture Compared to Sham Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Subjects That Have Undergone Axillary Surgery|Completed||N/A|30|Anticipated|Legacy Health System||3|||f||||||||||||||2018-06-01 03:31:43.620352|2018-06-01 03:31:43.620352
NCT00419809|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2012-05-31|2007-01-05|2007-01-09|Estimate|||||||2012-05-31|2012-06-04|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||SB-681323-Methotrexate Interaction Study|A Placebo Controlled Study to Evaluate the Safety and Tolerability of Repeat Doses of SB-681323 in Patients Receiving Methotrexate for Rheumatoid Arthritis.|Completed||Phase 1|18|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:31:43.691017|2018-06-01 03:31:43.691017
NCT00419796|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2007-11-28|2007-01-08|2007-01-09|Estimate|||||||2007-11-28|2007-11-29|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension|A 4-Week, Multicentre, Randomized, Double-Blind, Placebo Controlled, Double Dummy, Parallel Group Study, to Assess the Effect of Lumiracoxib 100 mg o.d. and Ibuprofen 600 mg t.i.d on 24-Hour Blood Pressure Profile and on Urinary Excretions of Eicosanoids, in Osteoarthritis Patients With Controlled Hypertension|Completed||Phase 4|78|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:31:43.760785|2018-06-01 03:31:43.760785
NCT00419783|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2012-04-04|2007-01-08|2007-01-09|Estimate|||||||2012-04-04|2012-04-05|Estimate|August 2006||2006-08-31|April 2012|2012-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine|A Phase 1, Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic Effects of Bilastine in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Faes Farma, S.A.||5|||f||||f||||||||||2018-06-01 03:31:43.868121|2018-06-01 03:31:43.868121
NCT00419770|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2011-06-29||2011-09-02|2007-01-08|2007-01-09|Estimate|2011-09-02|2011-10-06|Estimate||||2011-09-02|2011-10-06|Estimate|October 2007||2007-10-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study|The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study|Completed||Phase 2|20|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-06-01 03:31:43.994077|2018-06-01 03:31:43.994077
NCT00419757|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2009-05-20||2012-08-24|2007-01-05|2007-01-09|Estimate|2012-08-24|2012-08-27|Estimate||||2012-08-24|2012-08-27|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma|A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma|Completed||Phase 3|558|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:31:44.34469|2018-06-01 03:31:44.34469
NCT00419744|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|2010-08-18||2010-08-18|2007-01-05|2007-01-09|Estimate|2010-08-18|2010-09-16|Estimate||||2010-08-18|2010-09-16|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD|A Phase IIIB, 12-Month, Double-blind, Double-dummy,Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 μg x 2 Actuations Twice-daily and 80/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler® 4.5 μg x 2 Inhalations Twice-daily in COPD Subjects|Completed||Phase 3|1200|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:31:44.966238|2018-06-01 03:31:44.966238
NCT00419731|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2009-12-02|2007-01-08|2007-01-09|Estimate|||||||2009-12-02|2009-12-03|Estimate|November 2006||2006-11-30|December 2009|2009-12-31|July 2010|Anticipated|2010-07-31|February 2010|Anticipated|2010-02-28||Interventional|||Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation|Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 03:31:45.928064|2018-06-01 03:31:45.928064
NCT00419718|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2017-01-23|2007-01-08|2007-01-09|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes|Effect of Exercise on the Pharmacokinetics and Pharmacodynamics of Inhaled Human Insulin in Subjects With Type 1 Diabetes|Completed||Phase 1|23|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:31:46.02618|2018-06-01 03:31:46.02618
NCT00419705|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2011-06-07|2007-01-05|2007-01-09|Estimate|||||||2011-06-07|2011-06-09|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)|NeuroThera® Effectiveness and Safety Trial - 2 (NEST-2) A Double Blind, Randomized, Controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Effectiveness of the Treatment of Acute Ischemic Stroke With the NeuroThera® Laser System Within 24 Hours From Stroke Onset|Completed||Phase 3|660|Actual|PhotoThera, Inc||2|||f||||t||||||||||2018-06-01 03:31:46.104698|2018-06-01 03:31:46.104698
NCT00419692|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2017-10-11|2007-01-05|2007-01-09|Estimate|||||||2017-10-11|2017-10-13|Actual|August 24, 2006|Actual|2006-08-24|October 2017|2017-10-31|December 12, 2006|Actual|2006-12-12|December 12, 2006|Actual|2006-12-12||Interventional|||Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food|An Open Label, Repeat Dose, Dose Escalation Study Conducted in RLS Patients to Characterize Pharmacokinetics and Food Effect of Ropinirole Controlled Release for RLS|Completed||Phase 1|32|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-06-01 03:31:46.235722|2018-06-01 03:31:46.235722
NCT00419679|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-07|||2007-01-07|2007-01-07|2007-01-09|Estimate|||||||2007-01-07|2007-01-09|Estimate|December 2006||2006-12-31|January 2007|2007-01-31||||||||Interventional|||Use of Hair to Diagnose Breast Cancer|A Prospective Blinded Study to Evaluate and Characterise an Assay for the Diagnosis of Breast Cancer Using Synchrotron-Derived X-Ray Diffraction of Hair Fibres.|Unknown status|Recruiting|Phase 1/Phase 2|3600||Fermiscan Ltd|||||f||||||||||||||2018-06-01 03:31:46.305245|2018-06-01 03:31:46.305245
NCT00419666|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2012-03-08|2007-01-05|2007-01-09|Estimate|||||||2012-03-08|2012-03-09|Estimate|August 2006||2006-08-31|April 2011|2011-04-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis|PK and PD of Calcitriol Following Twice Daily Application of Calcitriol 3 µg/g Ointment Under Conditions of Maximal Use in Adolescents With Plaque Psoriasis|Completed||Phase 2|25|Actual|Galderma||1|||f||||||||||||||2018-06-01 03:31:46.364465|2018-06-01 03:31:46.364465
NCT00419653|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2008-09-15|2007-01-08|2007-01-09|Estimate|||||||2008-09-15|2008-09-16|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy|Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy With Amisulpride, Olanzapine or Haloperidol. A Study With Functional Magnetic Resonance Imaging (fMRI) and Diffusion Tensor Imaging (DTI)|Terminated||Phase 4|19|Actual|University of Jena||3||Recruitment issues|f||||f||||||||||2018-06-01 03:31:46.511564|2018-06-01 03:31:46.511564
NCT00419640|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-08|||2012-12-12|2007-01-08|2007-01-09|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|February 2012|Actual|2012-02-29||Interventional|SAFE||SAFE Study - Septal Pacing for Atrial Fibrillation Suppression Evaluation|Septal Pacing for Atrial Fibrillation Suppression Evaluation|Completed||N/A|385|Actual|St. Jude Medical||4|||f||||t||||||||||2018-06-01 03:31:46.576824|2018-06-01 03:31:46.576824
NCT00419627|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2007-01-05|2007-01-05|2007-01-08|Estimate|||||||2007-01-05|2007-01-08|Estimate|February 2007||2007-02-28|January 2007|2007-01-31||||||||Observational|||Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas|Proteomic Analysis of Serology and Peptides Presented on the HLA Complex of Breast, Ovarian, Colon, Rectal, Gastric and Pancreatic Adenocarcinoma.|Unknown status|Not yet recruiting||160||Hillel Yaffe Medical Center|||||f||||||||||||||2018-06-01 03:31:46.648735|2018-06-01 03:31:46.648735
NCT00419614|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2007-01-05|2007-01-05|2007-01-08|Estimate|||||||2007-01-05|2007-01-08|Estimate||||January 2007|2007-01-31||||||||Observational|||Outcome of Pancreatic Stump Closure Following Resection of Tumors of the Head of the Pancreas.|Retrospective Chart Review on the Association of Pancreaticoduodenectomy Without Pancreatic-Gastrointestinal Anastomosis to Perioperative Morbidity and Mortality|Unknown status|Not yet recruiting||||Hillel Yaffe Medical Center|||||f||||||||||||||2018-06-01 03:31:46.712524|2018-06-01 03:31:46.712524
NCT00419601|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2010-06-24|2007-01-05|2007-01-08|Estimate|||||||2010-06-24|2010-06-25|Estimate|November 2006||2006-11-30|May 2010|2010-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants|Prospective Randomized, Double-blinded Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants|Completed||Phase 3|24|Actual|University of Cologne||2|||f||||f||||||||||2018-06-01 03:31:46.75467|2018-06-01 03:31:46.75467
NCT00419562|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2017-03-27|2007-01-04|2007-01-08|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2007||2007-02-28|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus|Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus|Active, not recruiting||Phase 3|400|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 03:31:46.94715|2018-06-01 03:31:46.94715
NCT00419549|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2009-01-28|2007-01-05|2007-01-08|Estimate|||||||2009-01-28|2009-01-29|Estimate|October 2003||2003-10-31|January 2009|2009-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)|Effect of Transdermal Glyceryl-Trinitrate and Parecoxib (Valdecoxib) for the Prevention of Post -ERCP Pancreatitis|Terminated||Phase 2/Phase 3|371|Actual|All India Institute of Medical Sciences, New Delhi||3||Because one of the drugs Valdecoxib was withdrawn due to safety concerns.|f||||f||||||||||2018-06-01 03:31:47.060729|2018-06-01 03:31:47.060729
NCT00419536|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2010-04-07|2007-01-05|2007-01-08|Estimate|||||||2010-04-07|2010-04-08|Estimate|May 2006||2006-05-31|April 2010|2010-04-30||||||||Interventional|||Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone|A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC)|Terminated||Phase 1|108||Novartis|||||f||||||||||||||2018-06-01 03:31:47.135153|2018-06-01 03:31:47.135153
NCT00419510|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2016-08-15|2007-01-05|2007-01-08|Estimate|||||||2016-08-15|2016-08-17|Estimate|February 2003||2003-02-28|August 2016|2016-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Genetic Counseling in African American Women|Genetic Counseling for Breast Cancer Susceptibility in African American Women|Completed||N/A|204|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 03:31:47.194682|2018-06-01 03:31:47.194682
NCT00419497|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2016-09-18|2007-01-04|2007-01-08|Estimate|||||||2016-09-18|2016-09-20|Estimate|January 2003||2003-01-31|September 2016|2016-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Paleolithic Diet in the Treatment of Glucose Intolerance|Paleolithic Diet in the Treatment of Glucose Intolerance|Completed||Phase 2/Phase 3|29|Actual|Lund University Hospital||1|||f||||f||||||||No||2018-06-01 03:31:47.270974|2018-06-01 03:31:47.270974
NCT00419484|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2007-01-05|2007-01-05|2007-01-08|Estimate|||||||2007-01-05|2007-01-08|Estimate|March 2004||2004-03-31|January 2007|2007-01-31|July 2008||2008-07-31|||||Observational|||Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes||Completed|||1000||Dokkyo Medical University|||||f||||||||||||||2018-06-01 03:31:47.346257|2018-06-01 03:31:47.346257
NCT00419471|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2013-06-11|2007-01-05|2007-01-08|Estimate|||||||2013-06-11|2013-06-13|Estimate|May 2007||2007-05-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome|Efficacy and Safety of Escitalopram in the Treatment of Depressive Patients With Acute Coronary Artery Syndrome: A Double-blind Placebo-controlled Trial|Completed||Phase 4|300|Actual|Chonnam National University Hospital||2|||f||||t||||||||||2018-06-01 03:31:47.398797|2018-06-01 03:31:47.398797
NCT00419458|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2009-11-06|2007-01-04|2007-01-08|Estimate|||||||2009-11-06|2009-11-09|Estimate|February 2004||2004-02-29|November 2009|2009-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Inspiratory Muscle Training in Ventilator Dependent Patients|Respiratory Muscle Training in Ventilator Dependent Patients|Completed||Phase 1|150|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:31:47.471555|2018-06-01 03:31:47.471555
NCT00419445|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2010-08-16||2010-08-16|2007-01-05|2007-01-08|Estimate|2010-08-16|2010-09-10|Estimate||||2010-08-16|2010-09-10|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder|A Double-Blind, Randomized, Proof-of-Concept Crossover Trial to Assess the Effects of GTS21 on Cognitive Function, Clinical Symptoms, and Adverse Events in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder|Completed||Phase 1/Phase 2|37|Actual|CoMentis||3|||f||||f||||||||||2018-06-01 03:31:47.539446|2018-06-01 03:31:47.539446
NCT00419432|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2017-11-14|2007-01-05|2007-01-08|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2007||2007-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Outcomes of Orthopaedic Surgery Using Gait Laboratory Versus Observational Gait Analysis in Children With Cerebral Palsy|Functional Outcomes Following Orthopaedic Surgery Based on Gait Laboratory Versus Observational Gait Analysis in Ambulatory Children With Cerebral Palsy: A Multi-center Randomized Controlled Trial.|Active, not recruiting||Phase 1/Phase 2|60|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 03:31:47.806772|2018-06-01 03:31:47.806772
NCT00419419|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2007-05-29|2007-01-04|2007-01-08|Estimate|||||||2007-05-29|2007-05-30|Estimate|December 2006||2006-12-31|May 2007|2007-05-31||||||||Interventional|||Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon|"Phase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon"|Completed||Phase 3|80||MediQuest Therapeutics|||||f||||||||||||||2018-06-01 03:31:47.881715|2018-06-01 03:31:47.881715
NCT00419406|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2009-01-21|2007-01-04|2007-01-08|Estimate|||||||2009-01-21|2009-01-22|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Medium-Dose UVA1 Versus Narrow-Band UVB in Atopic Dermatitis|Medium-Dose UVA1 Versus Narrow-Band UVB Phototherapy: A Randomized Double-Blind Controlled Cross-Over-Study|Completed||N/A|28|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-06-01 03:31:47.970319|2018-06-01 03:31:47.970319
NCT00419393|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2011-03-25||2014-08-26|2007-01-04|2007-01-08|Estimate|2011-06-15|2011-07-13|Estimate||||2014-08-26|2014-09-05|Estimate|December 2007||2007-12-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures|An Open-label, Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Treatment of Partial-onset Seizures|Completed||Phase 3|190|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:31:48.160648|2018-06-01 03:31:48.160648
NCT00419380|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2015-02-24||2015-03-11|2007-01-04|2007-01-08|Estimate|2015-03-11|2015-03-27|Estimate||||2015-03-11|2015-03-27|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)|Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)|Completed||Phase 4|40|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 03:31:48.427384|2018-06-01 03:31:48.427384
NCT00419354|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2009-04-20|2007-01-05|2007-01-08|Estimate|||||||2009-04-20|2009-04-21|Estimate|March 2007||2007-03-31|July 2006|2006-07-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Observational|||The Impact of Right Ventricular Pacing on Tricuspid Regurgitation||Unknown status|Recruiting||50|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-06-01 03:31:48.875619|2018-06-01 03:31:48.875619
NCT00419341|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|2012-12-16||2012-12-16|2007-01-05|2007-01-08|Estimate|2012-12-16|2013-01-25|Estimate||||2012-12-16|2013-01-25|Estimate|November 2006||2006-11-30|December 2012|2012-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy|A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID)|Completed||Phase 3|49|Actual|CSL Behring||1|||f||||||||||||||2018-06-01 03:31:48.974846|2018-06-01 03:31:48.974846
NCT00419328|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2013-01-28|2007-01-05|2007-01-08|Estimate|||||||2013-01-28|2013-01-29|Estimate|March 2005||2005-03-31|January 2013|2013-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors|NGR002: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors: Definition of an Optimal Biological Dose|Completed||Phase 1|16|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 03:31:49.429633|2018-06-01 03:31:49.429633
NCT00419315|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2014-10-01||2015-04-24|2007-01-05|2007-01-08|Estimate|2014-11-03|2014-11-11|Estimate||||2015-04-24|2015-05-12|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||A Randomized Clinical Trial of Alcohol Care Management|Primary Care Based Disease Management for Alcohol Dependence|Completed||Phase 4|163|Actual|VA Office of Research and Development|The data presented in the results does not provide a true measure of the longitudinal effects done with GEE modeling.|2|||f||||t||||||||||2018-06-01 03:31:49.520789|2018-06-01 03:31:49.520789
NCT00419302|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2009-10-12|2007-01-04|2007-01-08|Estimate|||||||2009-10-12|2009-10-14|Estimate|October 2003||2003-10-31|October 2009|2009-10-31|April 2004||2004-04-30|||||Interventional|||To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.||Completed||Phase 2|16||Mannkind Corporation|||||f||||||||||||||2018-06-01 03:31:49.817947|2018-06-01 03:31:49.817947
NCT00419289|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2007-01-04|2007-01-04|2007-01-08|Estimate|||||||2007-01-04|2007-01-08|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|June 2008||2008-06-30|||||Interventional|||Optimizing the Effect of COPD Rehabilitation|Rehabilitation of COPD Patients: Can the Effect be Prolonged by Follow-up and Continued Rehabilitation|Unknown status|Not yet recruiting|N/A|120||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 03:31:49.870086|2018-06-01 03:31:49.870086
NCT00419276|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2016-09-27|2007-01-05|2007-01-08|Estimate|||||||2016-09-27|2016-09-28|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Replacement|Effect of Ambulatory Continuous Femoral Nerve Blocks on Readiness-for-Discharge Following Total Knee Arthroplasty: A Multicenter, Randomized, Triple-Masked, Placebo-Controlled Investigation|Completed||N/A|81|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 03:31:49.940082|2018-06-01 03:31:49.940082
NCT00419263|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2015-01-16||2015-01-28|2007-01-05|2007-01-08|Estimate|2015-01-28|2015-02-12|Estimate||||2015-01-28|2015-02-12|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional||The safety population included all subjects who received any dose of study drug. Subjects were analyzed according to the treatment received.|Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.|A Phase II, Multicenter, Randomized, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza.|Completed||Phase 2|344|Actual|BioCryst Pharmaceuticals||3|||f||||t||||||||||2018-06-01 03:31:50.039175|2018-06-01 03:31:50.039175
NCT00419250|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2016-10-27|2007-01-05|2007-01-08|Estimate|||||||2016-10-27|2016-10-31|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia|A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia|Completed||Phase 1|52|Actual|Celgene Corporation||5|||f||||t||||||||||2018-06-01 03:31:50.949183|2018-06-01 03:31:50.949183
NCT00419237|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2017-10-31|2007-01-05|2007-01-08|Estimate|||||||2017-10-31|2017-11-06|Actual|January 13, 2005|Actual|2005-01-13|October 2017|2017-10-31|April 15, 2005|Actual|2005-04-15|April 15, 2005|Actual|2005-04-15||Interventional|||Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function|A Study to Investigate the Pharmacokinetics of a Single Inhaled Dose (400mcg) of GW685698X and Its Effect on Serum Cortisol in Patients With Impaired Liver Function and Matched Control Subjects.|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:31:51.057632|2018-06-01 03:31:51.057632
NCT00419224|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2007-01-09|2007-01-05|2007-01-08|Estimate|||||||2007-01-09|2007-01-11|Estimate|October 2002||2002-10-31|January 2007|2007-01-31|April 2003||2003-04-30|||||Interventional|||Influenza Vaccination in Bone Marrow Transplantation|Immunogenicity of Influenza Vaccination (Flu Vac) in Patients Receiving Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NM Allo PBSCT) Compared to Healthy Controls|Completed||Phase 4|36||The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:31:51.130802|2018-06-01 03:31:51.130802
NCT00419211|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2012-05-23|2007-01-04|2007-01-08|Estimate|||||||2012-05-23|2012-05-25|Estimate|January 2007||2007-01-31|May 2012|2012-05-31||||December 2011|Actual|2011-12-31||Interventional|||An Intervention Study to Increase Physical Activity and Maternal Well-being During Pregnancy|"Fit Pregnancy: A Transtheoretical-Model Based Intervention Designed To Increase Physical Activity and Maternal Well-Being During Pregnancy"|Completed||Early Phase 1|76|Actual|McGill University||2|||f||||||||||||||2018-06-01 03:31:51.180337|2018-06-01 03:31:51.180337
NCT00419198|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2010-03-08|2007-01-05|2007-01-08|Estimate|||||||2010-03-08|2010-03-09|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|||Clinical Outcomes of Angioplasty Postconditioning|Postconditioning and Functional Recovery After Acute Myocardial Infarction|Completed||N/A|91|Actual|Hospices Civils de Lyon||2|||f||||||||||||||2018-06-01 03:31:51.245593|2018-06-01 03:31:51.245593
NCT00419185|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2007-01-05|2007-01-05|2007-01-08|Estimate|||||||2007-01-05|2007-01-08|Estimate|April 2003||2003-04-30|January 2007|2007-01-31|January 2005||2005-01-31|||||Interventional|||Indocyanine Green or Trypan Blue for Delamination of the Internal Limiting Membrane in Macular Hole Surgery|Internal Limiting Membrane (ILM)- Peeling With Indocyanine Green or Trypan Blue in Macular Hole Surgery: A Prospective Randomized Trial|Completed||N/A|40||University of Luebeck|||||f||||||||||||||2018-06-01 03:31:51.315426|2018-06-01 03:31:51.315426
NCT00413452|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2009-02-12|2006-12-15|2006-12-19|Estimate|||||||2009-02-12|2009-02-13|Estimate|December 2006||2006-12-31|February 2009|2009-02-28|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Etanercept SFP in RA Patients|Open-Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis.|Completed||Phase 3|224|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:33:38.35695|2018-06-01 03:33:38.35695
NCT00419172|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2009-11-18|2007-01-05|2007-01-08|Estimate|||||||2009-11-18|2009-11-19|Estimate|January 2007||2007-01-31|November 2009|2009-11-30||||||||Interventional|||Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers|A Phase I, Single Center, Open-label, One-sequence Cross-over Study to Investigate the Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers|Completed||Phase 1|22|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:31:51.378791|2018-06-01 03:31:51.378791
NCT00419159|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2010-12-17||2011-11-04|2007-01-04|2007-01-08|Estimate|2011-04-20|2011-05-16|Estimate||||2011-11-04|2011-11-16|Estimate|December 2006||2006-12-31|November 2011|2011-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy|A Single Arm, Multicenter Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Whose Cancer Has Progressed Despite Prior Therapy With an Anti-EGFR Antibody (if Appropriate), Bevacizumab, Fluoropyrimidine, Oxaliplatin, and Irinotecan-based Regimens|Completed||Phase 2|199|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:31:52.348279|2018-06-01 03:31:52.348279
NCT00419146|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2011-01-03|2007-01-05|2007-01-08|Estimate|||||||2011-01-03|2011-01-04|Estimate|September 2001||2001-09-30|August 2010|2010-08-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants|A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders|Completed||Phase 2/Phase 3|99|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-06-01 03:31:52.882105|2018-06-01 03:31:52.882105
NCT00419133|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2009-12-04|2007-01-04|2007-01-08|Estimate|||||||2009-12-04|2009-12-07|Estimate|June 2007||2007-06-30|December 2009|2009-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine|Immune Responses Following One Versus Two Doses of Killed Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India|Completed||Phase 2|160|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-06-01 03:31:53.086544|2018-06-01 03:31:53.086544
NCT00419120|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2009-12-08||2015-11-02|2007-01-04|2007-01-08|Estimate|2010-05-12|2010-06-07|Estimate||||2015-11-02|2015-11-30|Estimate|December 2006||2006-12-31|November 2015|2015-11-30|April 2011|Actual|2011-04-30|October 2008|Actual|2008-10-31||Interventional|||Augmentation Cystoplasty Using an Autologous Neo-Bladder|An Open-Label Multicenter Study of Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct in Subjects With Spina Bifida|Terminated||Phase 2|10|Actual|Tengion||1||36 months follow up without change to profile. No further studies planned.|f||||t||||||||||2018-06-01 03:31:53.176343|2018-06-01 03:31:53.176343
NCT00419107|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2011-11-07|2007-01-05|2007-01-08|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2004||2004-11-30|November 2011|2011-11-30|January 2007|Actual|2007-01-31|||||Observational|||Beta Cell Function in Women With Turner Syndrome|Beta Cell Function in Women With Turner Syndrome|Terminated|||25|Actual|University of Aarhus||||Completed|f||||||||||Samples With DNA|"~     Blood samples.~   "|||2018-06-01 03:31:53.382492|2018-06-01 03:31:53.382492
NCT00419094|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2010-09-13||2014-08-26|2007-01-04|2007-01-08|Estimate|2010-11-23|2010-12-20|Estimate||||2014-08-26|2014-09-05|Estimate|August 2007||2007-08-31|January 2011|2011-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Conversion to Monotherapy Study With Keppra XR for Partial Seizures|A Multi-center, Double-blind, Historical Control, Randomized Conversion to Monotherapy Study With Keppra XR for Treatment of Partial Onset Seizures|Completed||Phase 3|228|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 03:31:53.464353|2018-06-01 03:31:53.464353
NCT00419081|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05||2012-01-18|2012-01-18|2007-01-05|2007-01-08|Estimate||||2012-01-18|2012-01-23|Estimate|2012-01-18|2012-01-23|Estimate|July 2006||2006-07-31|January 2012|2012-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens|A Phase IIb, Multicenter, Open-Label, Nonrandomized, Repeat-Dose Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens.|Terminated||Phase 2|100||BioCryst Pharmaceuticals||||Issues with Manufacturing|f||||||||||||||2018-06-01 03:31:53.918347|2018-06-01 03:31:53.918347
NCT00419068|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-05|||2009-09-29|2007-01-05|2007-01-08|Estimate|||||||2009-09-29|2009-09-30|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Trial of Adjunctive Vitamin D in Tuberculosis Treatment|Trial of Adjunctive Vitamin D in Tuberculosis Treatment|Completed||Phase 3|146|Anticipated|Barts & The London NHS Trust|||||f||||||||||||||2018-06-01 03:31:54.045219|2018-06-01 03:31:54.045219
NCT00419055|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2012-03-29|2007-01-04|2007-01-08|Estimate|||||||2012-03-29|2012-04-02|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|August 2006|Actual|2006-08-31|||||Observational|||Outpatient Percutaneous Coronary Intervention|Outpatient Percutaneous Coronary Intervention in a Selected, Stable Patient Population|Terminated|||100|Anticipated|University of Pennsylvania|||2|Stopped early due to inability to recruit full 100 subjects over 2 years|f||||t||||||||||2018-06-01 03:31:54.215862|2018-06-01 03:31:54.215862
NCT00419042|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2013-09-29|2007-01-04|2007-01-05|Estimate|||||||2013-09-29|2013-10-01|Estimate|July 2006||2006-07-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|September 2006|Actual|2006-09-30||Observational|||Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase II Trial in NSCLC Stage IV et IIIB in Elderly Dependent Patients With Evaluation of the Sequence Gemcitabine First Line Followed by Erlotinib When Progression Versus Erlotinib First Line Followed by Gemcitabine When Progression.|Completed|||100|Actual|Groupe Francais De Pneumo-Cancerologie|||||f||||t||||||||||2018-06-01 03:31:54.295372|2018-06-01 03:31:54.295372
NCT00419029|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2014-08-25|2007-01-04|2007-01-05|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2007||2007-09-30|August 2014|2014-08-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment|Motivational Interviewing to Engage OEF/OIF Veterans in Mental Health Treatment|Completed||N/A|400|Actual|San Francisco Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 03:31:54.495667|2018-06-01 03:31:54.495667
NCT00419016|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2007-01-04|2007-01-04|2007-01-05|Estimate|||||||2007-01-04|2007-01-05|Estimate||||January 2007|2007-01-31||||||||Observational|||Association Between Schizophrenia and Cancer||Completed|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:31:54.564048|2018-06-01 03:31:54.564048
NCT00419003|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2013-09-05||2016-02-19|2007-01-04|2007-01-05|Estimate|2016-02-19|2016-03-21|Estimate||||2016-02-19|2016-03-21|Estimate|December 2006||2006-12-31|February 2016|2016-02-29|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Research Study for Major Depressive Disorder: Investigation of Glutamate Medications|Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression|Completed||Phase 4|26|Actual|Baylor College of Medicine|The open-label administration of ketamine limits interpretation of phase 1 results. The sample size was too small to detect moderators and mediators of response. Third,lack of placebo-controlled efficacy data supporting riluzole's use in depression.|2|||f||||f||||||||No||2018-06-01 03:31:54.619841|2018-06-01 03:31:54.619841
NCT00418990|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-04|2007-01-04|2007-01-05|Estimate|||||||2007-01-04|2007-01-05|Estimate|August 2003||2003-08-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Effect of Vitamins on Academic Performance of School Children|Effect of a Randomized Trial of Multivitamin-Mineral Supplementation on Standardized Assessment of Academic Performance in Elementary School Children|Completed||N/A|1600||Rutgers, The State University of New Jersey|||||f||||||||||||||2018-06-01 03:31:54.852567|2018-06-01 03:31:54.852567
NCT00418977|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2014-03-10||2015-11-19|2007-01-03|2007-01-05|Estimate|2014-03-10|2014-04-28|Estimate||||2015-11-19|2015-12-23|Estimate|September 2005||2005-09-30|November 2015|2015-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents|Early Identification and Treatment of Anorexia Nervosa|Completed||N/A|59|Actual|Icahn School of Medicine at Mount Sinai|Limitations include a small sample size and attrition leading to missing end-of-intervention data. In addition, participation with follow-up evaluations was poor.|2|||f||||f||||||||||2018-06-01 03:31:54.923095|2018-06-01 03:31:54.923095
NCT00418964|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2011-06-22||2012-03-22|2007-01-04|2007-01-05|Estimate|2012-02-16|2012-03-20|Estimate||||2012-03-22|2012-03-27|Estimate|December 2006||2006-12-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Clinical Trial Comparing Three Anterior Cruciate Ligament Reconstructive Procedures|Functional, Clinical & Radiological Outcome of Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Control Clinical Trial Studies Comparing Bone Patella Bone, Single Bundle and Double Bundle Method.|Completed||N/A|62|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 03:31:55.203939|2018-06-01 03:31:55.203939
NCT00418951|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2011-04-15||2012-08-01|2007-01-03|2007-01-05|Estimate|2011-04-15|2011-05-13|Estimate||||2012-08-01|2012-08-07|Estimate|November 2006||2006-11-30|August 2012|2012-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections|Open, Randomized Comparative Trial of Two Different Schedules of Liposomal Amphotericin B Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections|Completed||Phase 2|120|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-06-01 03:31:55.472584|2018-06-01 03:31:55.472584
NCT00418938|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2013-10-04|2010-07-20|2017-02-07|2007-01-04|2007-01-05|Estimate|2014-02-13|2014-03-28|Estimate|2010-07-20|2010-07-22|Estimate|2017-02-07|2017-03-15|Actual|November 2006||2006-11-30|February 2017|2017-02-28|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial|A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors|Completed||Phase 2|266|Actual|Amgen||2|||f||||t||||||||||2018-06-01 03:31:55.771519|2018-06-01 03:31:55.771519
NCT00418925|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2008-09-08|2007-01-04|2007-01-05|Estimate|||||||2008-09-08|2008-09-09|Estimate|September 2006||2006-09-30|August 2007|2007-08-31|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Efficacy of Dronabinol for the Treatment of Cervical Dystonia|Phase II, Double Blind, Randomized, Placebo Controlled Trial of Dronabinol for the Treatment of Cervical Dystonia|Unknown status|Recruiting|Phase 2|38|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 03:31:56.579077|2018-06-01 03:31:56.579077
NCT00418912|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2008-02-13|2007-01-04|2007-01-05|Estimate|||||||2008-02-13|2008-02-15|Estimate|March 2007||2007-03-31|February 2008|2008-02-29|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Observational|||Family Study in Schizophrenia||Unknown status|Recruiting||100|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-06-01 03:31:56.664244|2018-06-01 03:31:56.664244
NCT00418899|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2017-10-05|2007-01-04|2007-01-05|Estimate|||||||2017-10-05|2017-10-06|Actual|February 2004|Actual|2004-02-29|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|||Gliogene: Brain Tumor Linkage Study|Gliogene: Brain Tumor Linkage Study|Active, not recruiting|||17080|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     About 3 tablespoons of blood will be drawn and if unable to donate blood, researchers will~     collect a saliva sample.~   "|||2018-06-01 03:31:56.738238|2018-06-01 03:31:56.738238
NCT00418886|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2011-04-27||2017-01-25|2007-01-04|2007-01-05|Estimate|2012-02-22|2012-03-26|Estimate||||2017-01-25|2017-03-08|Actual|January 2007||2007-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|September 2008|Actual|2008-09-30||Interventional|ZEAL||Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients|A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC|Active, not recruiting||Phase 3|698|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:31:56.904854|2018-06-01 03:31:56.904854
NCT00418873|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2010-04-15|2007-01-04|2007-01-05|Estimate|||||||2010-04-15|2010-04-16|Estimate|March 2007||2007-03-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward|A Multi-centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward|Terminated||Phase 4|39|Actual|Astellas Pharma Inc||2||Study was stopped due to difficulty in patient enrollment|f||||f||||||||||2018-06-01 03:31:57.704935|2018-06-01 03:31:57.704935
NCT00418860|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2011-08-10|2007-01-04|2007-01-05|Estimate|||||||2011-08-10|2011-08-11|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|DATE||The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent|The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent in the Patients With Coronary Artery Disease (DATE Registry)|Completed||N/A|1200|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-06-01 03:31:57.773344|2018-06-01 03:31:57.773344
NCT00418847|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2016-05-18|2007-01-04|2007-01-05|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2004||2004-07-31|May 2016|2016-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis|Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis: Single and Multiple Oral Doses|Completed||Phase 2|5|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 03:31:57.843053|2018-06-01 03:31:57.843053
NCT00418678|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2010-11-30|2007-01-04|2007-01-05|Estimate|||||||2010-11-30|2010-12-02|Estimate|August 2006||2006-08-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting|A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting|Terminated||Phase 4|16|Actual|Veeda Oncology||||Enrollment was too slow|f||||f||||||||||2018-06-01 03:32:00.249852|2018-06-01 03:32:00.249852
NCT00418834|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2009-08-25||2017-03-09|2007-01-04|2007-01-05|Estimate|2009-08-31|2009-10-06|Estimate||||2017-03-09|2017-04-06|Actual|January 2007||2007-01-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)|A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHD|Completed||Phase 3|1053|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:31:57.966873|2018-06-01 03:31:57.966873
NCT00418821|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2017-08-17|2007-01-04|2007-01-05|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2010||2010-10-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants|A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme (Laronidase) Treatment on Lactation in Women With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants|Recruiting||Phase 4|10|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 03:31:58.985808|2018-06-01 03:31:58.985808
NCT00418808|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2007-01-22|2007-01-04|2007-01-05|Estimate|||||||2007-01-22|2007-01-23|Estimate|August 2006||2006-08-31|January 2007|2007-01-31|August 2009||2009-08-31|||||Observational|||Early Movements as a Predictor of Future Developmental Delay|Analysis of Movements of Singletons and Infants of Multiple Fetus Pregnancy as a Predictor of Developmental Delay|Unknown status|Recruiting||50||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:31:59.045629|2018-06-01 03:31:59.045629
NCT00418795|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2018-03-07|2007-01-04|2007-01-05|Estimate|||||||2018-03-07|2018-03-09|Actual|June 11, 2003|Actual|2003-06-11|March 2018|2018-03-31|June 20, 2006|Actual|2006-06-20|June 20, 2006|Actual|2006-06-20||Interventional|||Porphozym in the Treatment of Acute Attacks in AIP|A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP|Completed||Phase 2/Phase 3|36||Chiesi Farmaceutici S.p.A.|||||t||||||||||||||2018-06-01 03:31:59.107248|2018-06-01 03:31:59.107248
NCT00418782|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2008-02-29|2007-01-04|2007-01-05|Estimate|||||||2008-02-29|2008-03-03|Estimate|January 2007||2007-01-31|February 2008|2008-02-29|August 2007|Anticipated|2007-08-31|||||Interventional|||A Study Of The Effect Of CE-224535 On Knee OA (Osteoarthritis) Pain|A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicenter Study Of CE-224,535 In Subjects With Osteoarthritic Pain Of The Knee|Terminated||Phase 2|212|Anticipated|Pfizer||3||Results of interim analysis indicate lack of efficacy when compared to placebo.|f||||t||||||||||2018-06-01 03:31:59.183224|2018-06-01 03:31:59.183224
NCT00418769|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2012-04-23|2007-01-04|2007-01-05|Estimate|||||||2012-04-23|2012-04-24|Estimate|June 2006||2006-06-30|April 2012|2012-04-30||||August 2006|Actual|2006-08-31||Interventional|||Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers|A Randomized, Open Label, Two-arm, Three Period Crossover Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers|Completed||Phase 1|24|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:31:59.344332|2018-06-01 03:31:59.344332
NCT00418756|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2010-03-18|2007-01-04|2007-01-05|Estimate|||||||2010-03-18|2010-03-19|Estimate|October 2006||2006-10-31|March 2010|2010-03-31||||November 2006|Actual|2006-11-30||Interventional|||Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects|A Phase I Open-label, Two Period, Single Center Study to Assess the Effect of 600 mg Daily Oral Dose of Rifampin (CYP3A4 Inducer) on the Pharmacokinetics of a Single 400 mg Oral Dose of Nilotinib in Healthy Subjects|Completed||Phase 1|12|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:31:59.398242|2018-06-01 03:31:59.398242
NCT00418743|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2010-03-08|2007-01-04|2007-01-05|Estimate|||||||2010-03-08|2010-03-09|Estimate|December 2005||2005-12-31|March 2010|2010-03-31|May 2010|Anticipated|2010-05-31|||||Observational|||Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)|A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC), Comparing Oral Combination Chemotherapy (CCNU, Cyclophosphamide, Etoposide) With Intravenous Association Chemotherapy.|Unknown status|Recruiting||138|Anticipated|Groupe Francais De Pneumo-Cancerologie|||||f||||t||||||||||2018-06-01 03:31:59.468522|2018-06-01 03:31:59.468522
NCT00418730|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2008-05-16|2007-01-04|2007-01-05|Estimate|||||||2008-05-16|2008-05-20|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Interventional|||Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss|A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men|Completed||Phase 2|180|Actual|Neosil, Inc.||3|||f||||||||||||||2018-06-01 03:31:59.608289|2018-06-01 03:31:59.608289
NCT00418717|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2008-12-19||2012-03-01|2007-01-04|2007-01-05|Estimate|2010-04-08|2010-05-04|Estimate||||2012-03-01|2012-03-02|Estimate|February 2007||2007-02-28|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA|An Open-label, Multicenter, Dose-regimen Study Evaluating the Efficacy and Safety of Etanercept 50 mg Once-weekly Dose in Japanese Subjects With Rheumatoid Arthritis|Completed||Phase 3|42|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 03:31:59.678594|2018-06-01 03:31:59.678594
NCT00418704|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2013-09-29|2007-01-04|2007-01-05|Estimate|||||||2013-09-29|2013-10-01|Estimate|May 2006||2006-05-31|September 2013|2013-09-30|June 2009|Actual|2009-06-30|June 2006|Actual|2006-06-30||Observational|||Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)|A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression.|Completed|||100|Actual|Groupe Francais De Pneumo-Cancerologie|||||f||||f||||||||||2018-06-01 03:31:59.929294|2018-06-01 03:31:59.929294
NCT00418691|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2011-01-10||2012-08-01|2007-01-04|2007-01-05|Estimate|2011-04-12|2011-05-06|Estimate||||2012-08-01|2012-08-07|Estimate|February 2004||2004-02-29|August 2012|2012-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning|Assessing the Efficacy of Immediate Release Methylphenidate, Sustained Release Methylphenidate and Modafinil for Patients With Brain Tumors|Terminated||Phase 3|34|Actual|M.D. Anderson Cancer Center|Early termination lead to limited analysis.|3||Closed early due to slow accrual.|f||||f||||||||||2018-06-01 03:32:00.024284|2018-06-01 03:32:00.024284
NCT00418665|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2010-11-24||2011-01-20|2007-01-04|2007-01-05|Estimate|2010-11-24|2010-12-22|Estimate||||2011-01-20|2011-01-24|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|October 2010|Actual|2010-10-31|March 2009|Actual|2009-03-31||Interventional|||A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.|Completed||Phase 2|39|Actual|Amgen||5|||f||||||||||||||2018-06-01 03:32:00.332579|2018-06-01 03:32:00.332579
NCT00418652|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2011-08-03|2007-01-04|2007-01-05|Estimate|||||||2011-08-03|2011-08-04|Estimate|January 2006||2006-01-31|August 2011|2011-08-31||||July 2010|Actual|2010-07-31||Interventional|||Interruption of Dorsal Visual Stream Using TMS|Interruption of Dorsal Visual Stream Using TMS in Normal Controls|Completed||N/A|12|Actual|Sheba Medical Center||3|||f||||||||||||||2018-06-01 03:32:01.224711|2018-06-01 03:32:01.224711
NCT00418639|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-03|2007-01-03|2007-01-05|Estimate|||||||2007-01-03|2007-01-05|Estimate|February 2005||2005-02-28|January 2007|2007-01-31||||||||Interventional|||Study of Nitazoxanide in the Treatment of Chronic Hepatitis C|Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide in the Treatment of Chronic Hepatitis C|Completed||Phase 2|50||Romark Laboratories L.C.|||||f||||||||||||||2018-06-01 03:32:01.316597|2018-06-01 03:32:01.316597
NCT00418626|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2012-03-07|2007-01-04|2007-01-05|Estimate|||||||2012-03-07|2012-03-08|Estimate|November 2006||2006-11-30|March 2012|2012-03-31||||September 2007|Actual|2007-09-30||Interventional|||Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function|A Phase I, Single Center, Open-label, Single Oral Dose, Study to Assess the Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|27|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:32:01.38763|2018-06-01 03:32:01.38763
NCT00418613|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2015-09-02|2007-01-03|2007-01-05|Estimate|||||||2015-09-02|2015-09-03|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MK0633 in Patients With COPD|Completed||Phase 2|266|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:32:01.461232|2018-06-01 03:32:01.461232
NCT00418600|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2015-03-17|2007-01-03|2007-01-05|Estimate|||||||2015-03-17|2015-03-19|Estimate|November 2006||2006-11-30|March 2015|2015-03-31|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|||A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis|A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® Capsules When Converting From Hectorol® Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis|Completed||Phase 4|36|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:32:01.532797|2018-06-01 03:32:01.532797
NCT00418587|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2016-08-14|2007-01-04|2007-01-05|Estimate|||||||2016-08-14|2016-08-16|Estimate|December 2006||2006-12-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2008|Actual|2008-08-31||Interventional|||Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)|Phase 1 Study of Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)|Completed||Phase 1|18|Anticipated|Medical University of South Carolina||3|||f||||t||||||||||2018-06-01 03:32:01.629706|2018-06-01 03:32:01.629706
NCT00418574|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2011-07-01||2011-11-17|2007-01-04|2007-01-05|Estimate|2011-10-12|2011-11-18|Estimate||||2011-11-17|2011-11-24|Estimate|December 2006||2006-12-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|MIMOSA||Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients|A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy|Terminated||Phase 2/Phase 3|888|Actual|Menarini Group||2||No benefit on primary end point (RFS); no rationale to collect survival data|f||||t||||||||||2018-06-01 03:32:01.790956|2018-06-01 03:32:01.790956
NCT00418561|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|2015-07-16||2016-03-24|2007-01-04|2007-01-05|Estimate|2015-07-16|2015-08-13|Estimate||||2016-03-24|2016-04-27|Estimate|January 2007||2007-01-31|March 2016|2016-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||Intent-to-treat (ITT) population included all participants who received at least 1 dose of study drug.|Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)|A Single Center, Open-label, Non-randomized, Uncontrolled, Multiple-dose, Dose Escalation Study of the Safety, Pharmacokinetics and Efficacy of Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)|Completed||Phase 1|13|Actual|Shire|ASA activity in leukocytes could not be included in basic results format as the results were presented graphically. Due to quick disappearance of rhASA from plasma, rhASA levels were not possible to report.|1|||f||||t||||||||||2018-06-01 03:32:03.119561|2018-06-01 03:32:03.119561
NCT00418548|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2007-01-04|2007-01-04|2007-01-05|Estimate|||||||2007-01-04|2007-01-05|Estimate|June 2004||2004-06-30|January 2007|2007-01-31|February 2005||2005-02-28|||||Interventional|||Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing Spondylitis|A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly Compared With 25 mg Twice Weekly in Subjects With Ankylosing Spondylitis|Completed||Phase 3|350||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:32:04.646072|2018-06-01 03:32:04.646072
NCT00418535|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2009-10-20|2007-01-03|2007-01-05|Estimate|||||||2009-10-20|2009-10-21|Estimate|April 2006||2006-04-30|January 2007|2007-01-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|||Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma|A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma|Completed||Phase 2|||Samsung Medical Center|||||f||||||||||||||2018-06-01 03:32:04.716211|2018-06-01 03:32:04.716211
NCT00418522|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2009-07-30||2009-09-08|2007-01-04|2007-01-05|Estimate|2009-07-30|2009-09-04|Estimate||||2009-09-08|2009-09-10|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus|A Six Month, Open Label, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents|Completed||Phase 4|413|Actual|Pfizer|Due to cancellation of the EXUBERA program, the collected Patient Reported Outcome (PRO) data were not summarized, and no statistical analyses were performed.|2|||f||||f||||||||||2018-06-01 03:32:04.812243|2018-06-01 03:32:04.812243
NCT00371969|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2015-10-28|2006-08-31|2006-09-04|Estimate|||||||2015-10-28|2015-10-30|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Reducing Unsafe Alcohol Use in HIV-Positive Individuals|Reducing Unsafe Drinking in HIV Primary Care|Completed||N/A|254|Actual|Research Foundation for Mental Hygiene, Inc.||2|||f||||||||||||||2018-06-01 03:47:49.019112|2018-06-01 03:47:49.019112
NCT00418509|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-04|||2007-06-21|2007-01-04|2007-01-05|Estimate|||||||2007-06-21|2007-06-22|Estimate|November 2006||2006-11-30|June 2007|2007-06-30||||||||Interventional|||Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers|A Randomized, Single Dose, 3-Period Crossover Study to Evaluate the Dosage Form Proportionality, Dose Proportionality and Pharmacokinetics of Mometasone Furoate and Formoterol Fumarate From Three Combination MDI Formulations|Completed||Phase 1|24||Novartis|||||f||||||||||||||2018-06-01 03:32:06.024881|2018-06-01 03:32:06.024881
NCT00418496|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2017-02-17|2007-01-03|2007-01-04|Estimate|||||||2017-02-17|2017-02-20|Actual|November 8, 2006|Actual|2006-11-08|February 2017|2017-02-28|October 2013|Actual|2013-10-31|February 28, 2013|Actual|2013-02-28||Interventional|||Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma|A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma|Completed||Phase 1|17|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:32:06.090568|2018-06-01 03:32:06.090568
NCT00418483|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2016-10-28|2007-01-02|2007-01-04|Estimate|||||||2016-10-28|2016-10-31|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|PRIORITY||A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion|A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion|Completed||Phase 1|83|Actual|Grifols Therapeutics LLC||7|||f||||t||||||||||2018-06-01 03:32:06.215097|2018-06-01 03:32:06.215097
NCT00418470|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2015-10-28|2007-01-03|2007-01-04|Estimate|||||||2015-10-28|2015-10-29|Estimate|March 2007||2007-03-31|October 2015|2015-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People|Prolonging the Duration on Site of Short Peripheral Venous Catheters Used to Administer Intravenous Antibiotics in Cystic Fibrosis Adults. Randomized Controlled Trial on the Effect of Different Concentrations of Antibiotic in Normal Saline|Terminated||Phase 4|60|Anticipated|University of Florence||2||impossibility to find volunteers|f||||f||||||||||2018-06-01 03:32:06.330133|2018-06-01 03:32:06.330133
NCT00418457|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2018-01-24|2007-01-03|2007-01-04|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2007||2007-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Regional Anesthesia and Breast Cancer Recurrence|Regional Anesthesia and Breast Cancer Recurrence|Recruiting||Phase 3|2076|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-06-01 03:32:06.448913|2018-06-01 03:32:06.448913
NCT00418444|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2015-06-30|2007-01-02|2007-01-04|Estimate|||||||2015-06-30|2015-07-02|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Body Image and Psychosocial Functioning in Women With Breast Cancer: Can We Fix What We've Broken?|Randomized Control Trial of a Group Therapy Intervention Addressing Body Image and Psychosocial Functioning for Women With Breast Cancer|Completed||N/A|180|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:32:06.553737|2018-06-01 03:32:06.553737
NCT00418431|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|April 2006||2006-04-30|June 2006|2006-06-30|August 2006||2006-08-31|||||Interventional|||Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy||Unknown status|Recruiting|Phase 2/Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:32:06.619575|2018-06-01 03:32:06.619575
NCT00418418|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2008-08-18|2007-01-03|2007-01-04|Estimate|||||||2008-08-18|2008-08-19|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Combined CABG and Stem-Cell Transplantation for Heart Failure|Combined CABG and Stem-Cell Transplantation for Heart Failure|Unknown status|Recruiting|Phase 2|60|Anticipated|Helsinki University||2|||f||||t||||||||||2018-06-01 03:32:06.687877|2018-06-01 03:32:06.687877
NCT00418405|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2012||2012-01-31|||||Observational|||Hanyang University Medical Center Arthritis Network|Hanyang University Medical Center Arthritis Network|Unknown status|Not yet recruiting||1500||Hanyang University|||||f||||||||||||||2018-06-01 03:32:06.830654|2018-06-01 03:32:06.830654
NCT00418392|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-31|||2012-12-13|2007-01-03|2007-01-04|Estimate|||||||2012-12-13|2012-12-17|Estimate|November 2006||2006-11-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax|Intrapleural Minocycline After Simple Aspiration for the Prevention of Primary Spontaneous Pneumothorax: A Randomized Trial|Unknown status|Recruiting|Phase 3|300|Anticipated|National Taiwan University Hospital||2|||f||||||||||||||2018-06-01 03:32:06.889867|2018-06-01 03:32:06.889867
NCT00418379|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2016-01-25||2016-04-18|2007-01-03|2007-01-04|Estimate|2016-04-18|2016-05-25|Estimate||||2016-04-18|2016-05-25|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|September 2011|Actual|2011-09-30|August 2010|Actual|2010-08-31||Interventional||Full Analysis Set Year 1 (FASY1). FASY1 included all patients who received at least one dose of the investigational product and had at least one Adjusted Symptom Score (ASS) during the pollen period while on treatment during the Year 1.|Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets|A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of Two Dosing Regimens of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis|Completed||Phase 3|633|Actual|Stallergenes Greer||3|||f||||t||||||||||2018-06-01 03:32:07.011199|2018-06-01 03:32:07.011199
NCT00418366|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2015-08-18|2007-01-03|2007-01-04|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2003||2003-01-31|August 2015|2015-08-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)|An Open- Label, 2 Part Study to Investigate the Pharmacokinetics, Safety, and Tolerability of MK0431(Sitagliptin Phosphate) in Patients With Varying Degrees of Renal Insufficiency|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 03:32:07.521791|2018-06-01 03:32:07.521791
NCT00418353|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2007-01-02|2007-01-02|2007-01-04|Estimate|||||||2007-01-02|2007-01-04|Estimate|August 2002||2002-08-31|January 2007|2007-01-31|April 2005||2005-04-30|||||Interventional|||"Antenatal Betamethasone Compared to Dexamethasone - BETACODE TRIAL"||Completed||N/A|||University of Oklahoma|||||f||||||||||||||2018-06-01 03:32:07.581684|2018-06-01 03:32:07.581684
NCT00418340|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2007-11-15|2007-01-03|2007-01-04|Estimate|||||||2007-11-15|2007-11-16|Estimate|December 2007||2007-12-31|November 2007|2007-11-30||||||||Interventional|||Manipulation of Visceral Sensitivity and Immune System in IBS|Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity|Unknown status|Not yet recruiting|Phase 4|10|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 03:32:07.644185|2018-06-01 03:32:07.644185
NCT00418327|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2009-08-06|2007-01-03|2007-01-04|Estimate|||||||2009-08-06|2009-08-07|Estimate|June 2005||2005-06-30|August 2009|2009-08-31||||||||Interventional|||Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma|Phase I Studies of TarcevaTM (Erlotinib Hydrochloride, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma|Completed||Phase 1|48|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 03:32:07.719136|2018-06-01 03:32:07.719136
NCT00418314|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2014-05-14||2017-06-15|2007-01-03|2007-01-04|Estimate|2016-01-05|2016-02-04|Estimate||||2017-06-15|2017-07-12|Actual|October 2006||2006-10-31|June 2017|2017-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||Date of birth missing for 1 treatment patient and 1 control patient.|FREEDOM - A Frequent Optimization Study Using the QuickOpt Method|FREEDOM - A Frequent Optimization Study Using the QuickOpt Method|Completed||N/A|1647|Actual|St. Jude Medical||2|||f||||f||||||||No||2018-06-01 03:32:07.800661|2018-06-01 03:32:07.800661
NCT00418301|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2009-07-21|2007-01-02|2007-01-04|Estimate|||||||2009-07-21|2009-07-22|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain|Changes in Regional Cerebral Blood Flow as an Indicator of Neuronal Activity in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain|Completed||Phase 4|15|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 03:32:08.162536|2018-06-01 03:32:08.162536
NCT00418288|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2008-06-09|2007-01-03|2007-01-04|Estimate|||||||2008-06-09|2008-06-10|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia|The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Subjects During Hypoglycemia Assessed by Positron Emission Tomography|Completed||N/A|10|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 03:32:08.286243|2018-06-01 03:32:08.286243
NCT00418275|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|April 2001||2001-04-30|December 2006|2006-12-31|June 2004||2004-06-30|||||Interventional|||Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.|A Dose Finding, Pharmacokinetic and Safety Study of a Recombinant Human Plasminogen Activator (HTU-PA) in Patients With Acute Ischemic Stroke|Completed||Phase 1/Phase 2|30||Global Biotech|||||f||||||||||||||2018-06-01 03:32:08.355219|2018-06-01 03:32:08.355219
NCT00418262|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2017-06-02||2017-06-02|2007-01-03|2007-01-04|Estimate|2017-06-02|2017-07-02|Actual||||2017-06-02|2017-07-02|Actual|August 2005||2005-08-31|June 2017|2017-06-30|April 22, 2015|Actual|2015-04-22|April 22, 2015|Actual|2015-04-22||Interventional|B4Z-US-050||Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD|An Open-label Study of the Long Term Tolerability and Safety of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal-Alcohol Syndrome or Effects.|Completed||Phase 3|27|Actual|University of Oklahoma|There were a limited number of subjects because of difficulties in recruiting children with FAS and ADHD within the age group studied. We were only able to obtain a small number of teacher rating scales.|1|||f||||t||||||||No||2018-06-01 03:32:08.441398|2018-06-01 03:32:08.441398
NCT00418249|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate||||December 2006|2006-12-31||||||||Interventional|||Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women|Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women|Unknown status|Not yet recruiting|Phase 2|40||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:32:08.893045|2018-06-01 03:32:08.893045
NCT00418236|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02||2009-03-02|2010-08-17|2007-01-02|2007-01-04|Estimate||||2009-09-28|2009-09-30|Estimate|2010-08-17|2010-08-19|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|April 2010|Actual|2010-04-30|||||Observational|||Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density|Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW|Completed|||400||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:32:08.966532|2018-06-01 03:32:08.966532
NCT00418223|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2011-04-18|2007-01-03|2007-01-04|Estimate|||||||2011-04-18|2011-04-19|Estimate|November 2005||2005-11-30|April 2011|2011-04-30|February 2007||2007-02-28|||||Observational|||Detecting Urinary Retention After Child Birth With a Ultrasound Scanner|Detecting Urinary Retention After Child Birth With a Ultrasound Scanner|Completed|||100|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:32:09.071243|2018-06-01 03:32:09.071243
NCT00418210|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2017-07-10|2007-01-03|2007-01-04|Estimate|||||||2017-07-10|2017-07-12|Actual|August 2007||2007-08-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Accelerated Partial Breast Irradiation for Early Breast Cancer|A Multicentre Feasibility Study of Accelerated Partial Breast Irradiation Using Three-dimensional Conformal Radiation Therapy for Early Breast Cancer.|Active, not recruiting||N/A|48|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||t||||||||||2018-06-01 03:32:09.12534|2018-06-01 03:32:09.12534
NCT00418197|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2009-02-04|2007-01-02|2007-01-04|Estimate|||||||2009-02-04|2009-02-05|Estimate|August 2005||2005-08-31|February 2009|2009-02-28||||||||Interventional|||Total Facet Arthroplasty System®(TFAS®) Clinical Trial|A Prospective and Randomized Controlled Trial to Evaluate the Safety and Effectiveness of Total Facet Arthroplasty in the Treatment of Degenerative Spinal Stenosis|Unknown status|Active, not recruiting|Phase 3|450|Anticipated|Archus Orthopedics, Inc.|||||f||||||||||||||2018-06-01 03:32:09.21523|2018-06-01 03:32:09.21523
NCT00418184|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-31|2009-11-30||2014-02-12|2007-01-03|2007-01-04|Estimate|2010-02-03|2010-02-26|Estimate||||2014-02-12|2014-03-12|Estimate|March 2007||2007-03-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder|Completed||Phase 2|200|Actual|Enzymotec||2|||f||||||||||||||2018-06-01 03:32:09.275391|2018-06-01 03:32:09.275391
NCT00418171|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2009-10-23|2007-01-03|2007-01-04|Estimate|||||||2009-10-23|2009-10-26|Estimate|February 2002||2002-02-28|October 2009|2009-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)|An International, Multicenter, Large Simple Trial (LST) To Compare The Cardiovascular Safety Of Ziprasidone And Olanzapine|Completed||Phase 4|18239|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:32:09.61002|2018-06-01 03:32:09.61002
NCT00418158|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2009-11-09|2007-01-03|2007-01-04|Estimate|||||||2009-11-09|2009-11-10|Estimate|December 2005||2005-12-31|November 2009|2009-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Pulmonary Complications After Heart Surgery.|Pulmonary Complications After Heart Surgery|Completed||N/A|120|Anticipated|Catharina Ziekenhuis Eindhoven|||||f||||||||||||||2018-06-01 03:32:09.706653|2018-06-01 03:32:09.706653
NCT00418145|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2015-08-05||2017-04-10|2007-01-03|2007-01-04|Estimate|2017-04-10|2017-05-18|Actual||||2017-04-10|2017-05-18|Actual|September 2003||2003-09-30|April 2017|2017-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||16 participants were enrolled into the study. Data not available separated by arm. Data is also no longer accessible. Data was with biostatistician who no longer has data.|Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks|Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)|Terminated||Phase 3|16|Actual|Icahn School of Medicine at Mount Sinai|The trial was terminated due to difficulties obtaining drug and matching placebo and the inability to meet recruitment. There was no data analysis done for this trial due to low enrollment and data will not be meaningful.|2||low enrollment - data was not analyzed for this study|f||||f||||||||||2018-06-01 03:32:09.770465|2018-06-01 03:32:09.770465
NCT00418132|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2016-03-10|2007-01-03|2007-01-04|Estimate|||||||2016-03-10|2016-03-11|Estimate|August 2000||2000-08-31|March 2016|2016-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis|T Cell Immunity in Collagen Biosynthesis of Scleroderma|Terminated||Phase 1|30|Actual|New York University School of Medicine||2||Study terminated early due to difficulties in subject recruitment|f||||t||||||||||2018-06-01 03:32:09.977365|2018-06-01 03:32:09.977365
NCT00418119|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|January 2007||2007-01-31|December 2006|2006-12-31|January 2008||2008-01-31|||||Interventional|||Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function|Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function|Unknown status|Not yet recruiting|Phase 4|10||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:32:10.041519|2018-06-01 03:32:10.041519
NCT00418106|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2008-01-16|2007-01-02|2007-01-04|Estimate|||||||2008-01-16|2008-01-18|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Kangaroo Holding Effects on Breast Milk|Early Kangaroo Holding Effects on Breast Milk Composition|Completed|||20|Actual|Christiana Care Health Services|||1||f||||f||||||||||2018-06-01 03:32:10.218225|2018-06-01 03:32:10.218225
NCT00418093|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2012-04-27||2014-06-18|2007-01-02|2007-01-04|Estimate|2014-06-18|2014-06-19|Estimate||||2014-06-18|2014-06-19|Estimate|September 2006||2006-09-30|June 2014|2014-06-30|October 2011|Actual|2011-10-31|January 2011|Actual|2011-01-31||Interventional|||Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma|A Phase II Evaluation of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma|Terminated||Phase 2|19|Actual|Dana-Farber Cancer Institute|The trial was closed after enrolling 19 of the 53 projected patient accrual.|1||THe study was terminated early due to a lack of accural|f||||||||||||||2018-06-01 03:32:10.304351|2018-06-01 03:32:10.304351
NCT00418080|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-10-05|2007-01-03|2007-01-04|Estimate|||||||2007-10-05|2007-10-08|Estimate|April 2002||2002-04-30|October 2007|2007-10-31|December 2006||2006-12-31|||||Interventional|||Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy|The Role of HER Receptor Family as Indicator of Prognosis and Drug Responsiveness in Locally Advanced Prostate Cancer|Completed||Phase 2|86||University of L'Aquila|||||f||||||||||||||2018-06-01 03:32:10.515729|2018-06-01 03:32:10.515729
NCT00418067|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2012-08-20|2007-01-03|2007-01-04|Estimate|||||||2012-08-20|2012-08-21|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|ZEST||Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions|Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions|Completed||Phase 4|2645|Actual|CardioVascular Research Foundation, Korea||3|||f||||t||||||||||2018-06-01 03:32:10.58417|2018-06-01 03:32:10.58417
NCT00418054|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|December 2005||2005-12-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C|Phase II, Multi-Center, Randomized, Double-Blind Study of Nitazoxanide Tablets Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Chronic Hepatitis C|Completed||Phase 2|40||Romark Laboratories L.C.|||||f||||||||||||||2018-06-01 03:32:10.699977|2018-06-01 03:32:10.699977
NCT00418041|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2015-05-11|2007-01-03|2007-01-04|Estimate|||||||2015-05-11|2015-05-12|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|||Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)|Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)|Active, not recruiting|||10000|Anticipated|Tohoku University|||||f||||t||||||||||2018-06-01 03:32:10.824342|2018-06-01 03:32:10.824342
NCT00418028|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|2017-01-09||2017-05-18|2007-01-03|2007-01-04|Estimate|2017-05-18|2017-12-18|Actual||||2017-05-18|2017-12-18|Actual|September 2005||2005-09-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|December 2011|Actual|2011-12-31||Interventional|||Standard Versus Continuous Capecitabine in Advanced Breast Cancer|Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.|Completed||Phase 2/Phase 3|195|Actual|Hospital San Carlos, Madrid||2|||f||||f||||||||||2018-06-01 03:32:10.909577|2018-06-01 03:32:10.909577
NCT00418015|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-31|2011-02-15||2014-03-17|2006-12-31|2007-01-04|Estimate|2011-03-14|2011-04-18|Estimate||||2014-03-17|2014-04-14|Estimate|October 2005||2005-10-31|March 2014|2014-03-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Observational|||Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia|Mu-Opioid Receptor Genetic Polymorphism and the Duration of Intrathecal Fentanyl Labor Analgesia. Mu-Opioid Receptor Genetic Polymorphism and the Efficacy of Postoperative Intrathecal Morphine Analgesia|Completed|||293|Actual|Northwestern University|A limitation to the finding of this study was the relatively low number of OPRM1 heterozygous subjects.||2||f||||f||||||Samples With DNA|"~     Blood Samples~   "|||2018-06-01 03:32:11.344275|2018-06-01 03:32:11.344275
NCT00418002|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-06-21|2007-01-03|2007-01-04|Estimate|||||||2007-06-21|2007-06-22|Estimate|May 2006||2006-05-31|June 2007|2007-06-30||||||||Interventional|||Safety and Tolerability of AQW051 in Elderly Healthy Volunteers.|A Randomized, Double-Blind, Ascending Dose, Placebo-Controlled Single Dose Study in Non-Smoking Healthy Elderly Subjects Interleaved With a 2-Week Multiple Once Daily Dose Study to Explore Safety, Tolerability, Pharmacokinetics and Cognitive Effects After Oral Administration of AQW051|Completed||Phase 1|72|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:32:11.817822|2018-06-01 03:32:11.817822
NCT00417989|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2010-12-24||2018-05-22|2007-01-02|2007-01-04|Estimate|2011-02-09|2011-03-10|Estimate||||2018-05-22|2018-05-23|Actual|January 2007||2007-01-31|May 2018|2018-05-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|STAR3||Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy|The STAR 3 Study - A Prospective, Randomized, Two-Arm Study to Compare the Efficacy of the MiniMed Paradigm REAL-Time System Versus Multiple Daily Injections (MDI) in Subjects Naïve to Insulin Pump Therapy|Completed||N/A|485|Actual|Medtronic Diabetes||2|||f||||t||||||||||2018-06-01 03:32:11.910101|2018-06-01 03:32:11.910101
NCT00417976|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2014-05-19||2015-09-15|2007-01-03|2007-01-04|Estimate|2014-10-30|2014-11-03|Estimate||||2015-09-15|2015-10-01|Estimate|December 2006||2006-12-31|September 2015|2015-09-30|February 2011|Actual|2011-02-28|March 2010|Actual|2010-03-31||Interventional||42 patients enrolled in study; of which, 39 were evaluable for primary end point.|Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer|A Phase II Study of the Combination of Fixed Dose Rate Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer|Completed||Phase 2|42|Actual|Ohio State University Comprehensive Cancer Center|42 patients enrolled, 39 were evaluable for the primary end point.|1|||f||||t||||||||||2018-06-01 03:32:12.313303|2018-06-01 03:32:12.313303
NCT00417963|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2011-04-16||2017-01-17|2007-01-03|2007-01-04|Estimate|2011-06-21|2011-07-20|Estimate||||2017-01-17|2017-03-01|Actual|October 2005||2005-10-31|January 2017|2017-01-31|March 2010|Actual|2010-03-31|January 2009|Actual|2009-01-31||Interventional|||ViVEXX Carotid Revascularization Trial (VIVA)|The ViVEXX Carotid Revascularization Trial (VIVA) for High Surgical Risk Patients With Extracranial Carotid Artery Stenosis Using the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System|Completed||Phase 3|407|Actual|C. R. Bard||1|||f||||t||||||||||2018-06-01 03:32:12.66173|2018-06-01 03:32:12.66173
NCT00417950|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-01|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|January 2007||2007-01-31|January 2007|2007-01-31||||||||Interventional|||Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes||Unknown status|Recruiting|N/A|30||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 03:32:13.216317|2018-06-01 03:32:13.216317
NCT00417937|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2014-02-20|2007-01-02|2007-01-04|Estimate|||||||2014-02-20|2014-02-21|Estimate|January 2007||2007-01-31|February 2014|2014-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily|A Multicenter, Double-Blind Clinical Trial to Assess the Efficacy and Tolerability of Topical Azelaic Acid 15% Gel Once Daily Compared to Topical Azelaic Acid 15% gelTwice Daily in Subjects With Papulopustular Rosacea|Completed||Phase 4|98|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:32:13.275591|2018-06-01 03:32:13.275591
NCT00417924|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2007-01-02|2007-01-02|2007-01-04|Estimate|||||||2007-01-02|2007-01-04|Estimate|October 2004||2004-10-31|December 2006|2006-12-31|October 2005||2005-10-31|||||Interventional|||Eye on Diabetes: A Multidisciplinary Patient Education Intervention|Eye Health and Vision Care for Patients With Diabetes: Comparing Usual Care to a Targeted Intervention in a Randomized Controlled Trial|Completed||Early Phase 1|90||Nova Southeastern University|||||f||||||||||||||2018-06-01 03:32:13.335287|2018-06-01 03:32:13.335287
NCT00417911|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2010-06-17|2007-01-03|2007-01-04|Estimate|||||||2010-06-17|2010-06-22|Estimate|December 2005||2005-12-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients|Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05)|Completed||Phase 3|400|Anticipated|Nordic Myeloma Study Group||2|||f||||||||||||||2018-06-01 03:32:13.389333|2018-06-01 03:32:13.389333
NCT00417898|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2016-09-01|2007-01-03|2007-01-04|Estimate|||||||2016-09-01|2016-09-02|Estimate|March 2007||2007-03-31|January 2007|2007-01-31|December 2012|Anticipated|2012-12-31|||||Interventional|||Study of Aspirin and TPA in Acute Ischemic Stroke|Phase 1 Study to Assess the Safety of 500mg of Aspirin Added to IV TPA at Standard Doses to Prevent Re-occlusion of Cerebral Vessels After Successful Reperfusion.|Withdrawn||Phase 1|0|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:32:14.425573|2018-06-01 03:32:14.425573
NCT00417885|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|2010-07-09||2010-09-16|2007-01-02|2007-01-04|Estimate|2010-08-10|2010-08-30|Estimate||||2010-09-16|2010-09-21|Estimate|June 2007||2007-06-30|September 2010|2010-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer|Phase 1/2 Open-Label Trial Of Sutent (Sunitinib Malate) And Aromasin(Exemestane) In The First-Line Treatment Of Hormone Receptor-Positive Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|6|Actual|Pfizer||1||See Detailed Description for Termination Reason|f||||f||||||||||2018-06-01 03:32:14.519159|2018-06-01 03:32:14.519159
NCT00417872|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|January 2004||2004-01-31|October 2005|2005-10-31|September 2005||2005-09-30|||||Interventional|||Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis|Multicenter, Double Blind, Metronidazole Controlled, Dose Range Finding Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis|Completed||Phase 2|114||Romark Laboratories L.C.|||||f||||||||||||||2018-06-01 03:32:14.815101|2018-06-01 03:32:14.815101
NCT00417859|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2015-12-01|2007-01-03|2007-01-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2004||2004-02-29|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Total Knee Arthroplasty: Comparison of Fixed and Mobile Bearings|Total Knee Arthroplasty: Comparison of Fixed and Mobile Bearings|Completed||Phase 4|64|Actual|University of Lausanne Hospitals||2|||f||||||||||||||2018-06-01 03:32:14.886382|2018-06-01 03:32:14.886382
NCT00417846|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2009-10-02|2007-01-03|2007-01-04|Estimate|||||||2009-10-02|2009-10-05|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)|Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)|Completed|||98|Actual|Johns Hopkins University|||||f||||t||||||||||2018-06-01 03:32:14.946147|2018-06-01 03:32:14.946147
NCT00417833|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2008-10-17|2007-01-03|2007-01-04|Estimate|||||||2008-10-17|2008-10-20|Estimate|December 2005||2005-12-31|October 2008|2008-10-31|July 2006||2006-07-31|||||Interventional|||Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment||Completed||Phase 2/Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:32:15.104458|2018-06-01 03:32:15.104458
NCT00417820|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-11-28|2007-01-03|2007-01-04|Estimate|||||||2007-11-28|2007-11-29|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.|A Multicenter, Double-Blind, Placebo Controlled Exploratory Study to Evaluate the Safety, Tolerability and Pharmacodynamics of a Single Administration of BCT194 in Healthy Volunteers and Multiple Administrations in Patients With Psoriasis.|Completed||Phase 1|35|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:32:15.160303|2018-06-01 03:32:15.160303
NCT00417807|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2010-12-23|2007-01-03|2007-01-04|Estimate|||||||2010-12-23|2010-12-24|Estimate|August 2005||2005-08-31|December 2010|2010-12-31||||June 2009|Actual|2009-06-30||Interventional|||Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors|Open-label Trial of Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors (DSRCT) Expressing PDGF-R|Completed||Phase 1/Phase 2|9|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:32:15.230911|2018-06-01 03:32:15.230911
NCT00417794|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2017-04-06|2007-01-03|2007-01-04|Estimate|||||||2017-04-06|2017-04-10|Actual|August 2005||2005-08-31|April 2017|2017-04-30|April 22, 2015|Actual|2015-04-22|April 22, 2015|Actual|2015-04-22||Interventional|B4Z-MC-X017||Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD|A Study of the Efficacy of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal Alcohol Syndrome or Effects|Completed||Phase 1|38|Actual|University of Oklahoma||2|||f||||t||||||||||2018-06-01 03:32:15.314026|2018-06-01 03:32:15.314026
NCT00417781|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-31|||2012-11-12|2007-01-03|2007-01-04|Estimate|||||||2012-11-12|2012-11-14|Estimate|January 2005||2005-01-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|||||Observational|||A Follow-up, Family Study on Attention-deficit Hyperactivity Disorder|A Follow-up, Family Study on Attention-deficit Hyperactivity Disorder|Completed|||1800|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:32:15.406425|2018-06-01 03:32:15.406425
NCT00417768|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2014-01-13|2007-01-03|2007-01-04|Estimate|||||||2014-01-13|2014-01-14|Estimate|July 2005||2005-07-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|July 2012|Actual|2012-07-31||Interventional|||Safety and Effectiveness of tPA in Intra-abdominal Abscesses|Safety and Effectiveness of Local Instillation of tPA in the Management of Complex Intra-abdominal Fluid Collections: a Randomized, Double Blinded Controlled Clinical Trial|Terminated||Phase 2/Phase 3|35|Actual|University Health Network, Toronto||2||Change in patient population no longer fit study criteria.|f||||f||||||||||2018-06-01 03:32:15.464434|2018-06-01 03:32:15.464434
NCT00417755|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|January 2007||2007-01-31|December 2006|2006-12-31|December 2007||2007-12-31|||||Observational|||Effect of Invasive and Non Invasive Mechanical Ventilation on Feeding Delivery in COPD Elderly Patients|Effect of Invasive and Non Invasive Mechanical Ventilation on the Nutritional Status of COPD Elderly Patients|Unknown status|Not yet recruiting||40||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:32:15.551419|2018-06-01 03:32:15.551419
NCT00417742|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2014-08-20|2007-01-02|2007-01-04|Estimate|||||||2014-08-20|2014-08-22|Estimate|June 2002||2002-06-30|January 2007|2007-01-31|December 2004||2004-12-31|||||Interventional|||Project CHEER (Comprehensive Headache Evaluation, Education, Relief)|A Randomized Trial of Headache Management Programs|Completed||N/A|828||Duke University|||||f||||||||||||||2018-06-01 03:32:15.613424|2018-06-01 03:32:15.613424
NCT00417729|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-01|||2010-05-11|2007-01-01|2007-01-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|January 2007||2007-01-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM|Phase 4 Study Evaluation of the Effects of Acarbose Versus Glibenclamide on Mean Amplitude of Glycemic Excursions and Oxidative Stress in Patients With Type 2 Diabetes Insufficiently Controlled by Metformin|Completed||Phase 4|51|Actual|Taichung Veterans General Hospital||1|||f||||f||||||||||2018-06-01 03:32:15.684797|2018-06-01 03:32:15.684797
NCT00417716|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|September 2005||2005-09-30|June 2006|2006-06-30|May 2006||2006-05-31|||||Interventional|||Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema|The Efficacy of a Single Intravitreal Injection of Bevacizumab in Patients With Diffuse Diabetic Macular Edema|Unknown status|Active, not recruiting|Phase 3|45||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:32:15.755802|2018-06-01 03:32:15.755802
NCT00417703|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2008-01-22|2007-01-03|2007-01-04|Estimate|||||||2008-01-22|2008-01-24|Estimate|January 2007||2007-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab|A Prospective Investigation of the Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab|Completed|||75|Anticipated|Oklahoma State University Center for Health Sciences|||||f||||||||||||||2018-06-01 03:32:15.817065|2018-06-01 03:32:15.817065
NCT00417690|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2008-10-14|2007-01-02|2007-01-04|Estimate|||||||2008-10-14|2008-10-15|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|December 2007|Actual|2007-12-31||Interventional|||High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease|A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease|Terminated||Phase 2|54|Anticipated|Jacobus Pharmaceutical||2||Efforts at recruitment have halted as recruitment was poor.|f||||||||||||||2018-06-01 03:32:15.871983|2018-06-01 03:32:15.871983
NCT00417677|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2007-12-19|2007-01-03|2007-01-04|Estimate|||||||2007-12-19|2007-12-28|Estimate|March 2007||2007-03-31|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma|A Phase I/II Study of Temsirolimus and Sunitinib in Subjects With Advanced Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|124||Wyeth is now a wholly owned subsidiary of Pfizer||||Decision was made not to attempt a lower dose|f||||||||||||||2018-06-01 03:32:15.9552|2018-06-01 03:32:15.9552
NCT00417664|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-03|||2007-01-03|2007-01-03|2007-01-04|Estimate|||||||2007-01-03|2007-01-04|Estimate|April 2002||2002-04-30|January 2007|2007-01-31|December 2003||2003-12-31|||||Interventional|||Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients|ICU Delirium: Can Dexmedetomidine Reduce Its Incidence?|Unknown status|Active, not recruiting|Phase 4|90||Stanford University|||||f||||||||||||||2018-06-01 03:32:16.015954|2018-06-01 03:32:16.015954
NCT00417651|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2011-12-13|2007-01-02|2007-01-04|Estimate|||||||2011-12-13|2011-12-14|Estimate|July 2006||2006-07-31|December 2011|2011-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Testing for Bacterial Contamination During Gastric Surgeries|Transgastric Bacterial Contamination of the Abdomen|Completed|||50|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 03:32:16.165027|2018-06-01 03:32:16.165027
NCT00417638|ClinicalTrials.gov processed this data on May 31, 2018|2007-01-02|||2010-01-14|2007-01-02|2007-01-04|Estimate|||||||2010-01-14|2010-01-18|Estimate|January 2007||2007-01-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention|A Randomized, Controlled Study of the Use of Central Venous Catheter Core Cooling Combined With Cold Saline, and Rewarming as an Adjunct to Percutaneous Coronary Intervention For the Treatment of Acute Myocardial Infarction|Completed||N/A|20|Actual|Philips Healthcare||2|||f||||f||||||||||2018-06-01 03:32:16.232834|2018-06-01 03:32:16.232834
NCT00417625|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-30|||2017-06-30|2007-01-03|2007-01-04|Estimate|||||||2017-06-30|2017-07-02|Actual|December 29, 2006||2006-12-29|July 19, 2010|2010-07-19|July 19, 2010||2010-07-19|||||Observational|||Validation of MRI Measurement of Cardiac Blood Flow|Validation of Cardiac MR Perfusion With Cardiac Catheterization Physiological Assessment|Completed|||34|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:32:16.322565|2018-06-01 03:32:16.322565
NCT00411489|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2008-03-17|2006-12-12|2006-12-14|Estimate|||||||2008-03-17|2008-03-18|Estimate||||June 2007|2007-06-30||||||||Interventional|||Endoscopic Stomach and Pouch Reduction in Patients With Weight Regain Following Roux-En-Y Bypass Surgery|Use of a New Endosurgical Operating System for Endoscopic Stoma and Pouch Reduction in Patients With Weight Regain Following Roux-En-Y Bypass Surgery|Completed||N/A|||USGI Medical|||||f||||||||||||||2018-06-01 03:34:26.59114|2018-06-01 03:34:26.59114
NCT00417612|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|2014-08-02||2014-10-22|2006-12-28|2007-01-01|Estimate|2014-10-22|2014-10-28|Estimate||||2014-10-22|2014-10-28|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets|The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH)|Completed||Phase 3|33|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:32:16.405795|2018-06-01 03:32:16.405795
NCT00417599|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2016-06-22|2006-12-28|2007-01-01|Estimate|||||||2016-06-22|2016-06-24|Estimate|December 2001||2001-12-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Preventing Overweight in USAF Personnel: Minimal Contact Program|Preventing Overweight in USAF Personnel: Minimal Contact Program|Completed||N/A|500|Actual|Baylor College of Medicine||2|||f||||f||||||||Yes|See publication: Hunter CM et al Weight management using the internet: a randomized clinical trial. Am J Prev Med 2998;34:119-126|2018-06-01 03:32:16.795378|2018-06-01 03:32:16.795378
NCT00417586|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2013-12-09|2006-12-28|2007-01-01|Estimate|||||||2013-12-09|2013-12-11|Estimate|June 2007||2007-06-30|December 2013|2013-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Observational|||Cost-Effectiveness of a Specialized Ultrasound Instrument to Diagnose Carotid Stenosis as a Way to Reduce the Risk of Stroke|New Ultrasound Instrument for Carotid Screening|Completed|||984|Actual|DVX, LLC|||||f||||t||||||||||2018-06-01 03:32:16.871221|2018-06-01 03:32:16.871221
NCT00417573|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2006-12-29|2006-12-29|2007-01-01|Estimate|||||||2006-12-29|2007-01-01|Estimate|December 2004||2004-12-31|December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections|Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections|Completed||Phase 2|10||The Center for Rheumatic Disease, Allergy, & Immunology|||||f||||||||||||||2018-06-01 03:32:16.935169|2018-06-01 03:32:16.935169
NCT00417560|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2012-09-06|2006-12-29|2007-01-01|Estimate|||||||2012-09-06|2012-09-07|Estimate|January 2007||2007-01-31|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|December 2007|Actual|2007-12-31||Interventional|||Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses|A Single Center, Open-label, Phase I/II Study of Two 90 Microgram Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses|Unknown status|Active, not recruiting|Phase 1/Phase 2|55|Actual|Centers for Disease Control and Prevention||1|||f||||||||||||||2018-06-01 03:32:17.008124|2018-06-01 03:32:17.008124
NCT00417547|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|||2009-02-04|2006-12-29|2007-01-01|Estimate|||||||2009-02-04|2009-02-05|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|September 2006||2006-09-30|||||Observational|||Comparison of Body Dissatisfaction Among Islamic Veil Practicing (IVP), Non-Complete IVP, and Inconsiderate to IVP Women|Comparison of Body Dissatisfaction Among Islamic Veil Practicing (IVP), Non-Complete IVP, and Inconsiderate to IVP Women|Completed|||3000||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:32:17.081354|2018-06-01 03:32:17.081354
NCT00417534|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|||2007-07-02|2006-12-29|2007-01-01|Estimate|||||||2007-07-02|2007-07-03|Estimate|June 2006||2006-06-30|December 2006|2006-12-31|December 2009|Anticipated|2009-12-31|||||Observational|||Genetic Predisposition of Coronary Artery Disease -- The COROGENE-Study|Genetic Predisposition of Coronary Artery Disease in Patients Verified With Coronary Angiogram The COROGENE-Study|Unknown status|Recruiting||5000|Anticipated|Helsinki University|||||f||||||||||||||2018-06-01 03:32:17.141518|2018-06-01 03:32:17.141518
NCT00417521|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2013-09-25|2006-12-28|2007-01-01|Estimate|||||||2013-09-25|2013-09-26|Estimate|July 2004||2004-07-31|December 2006|2006-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Open Trial of Family-Based Treatment for Anorexia Nervosa|Pilot Study of Manualized Family Therapy for Adolescents With Anorexia Nervosa|Completed||N/A|20|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 03:32:17.210356|2018-06-01 03:32:17.210356
NCT00417508|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|||2012-06-13|2006-12-29|2007-01-01|Estimate|||||||2012-06-13|2012-06-14|Estimate|December 2006||2006-12-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Nutritional Intervention in Malnourished Elderly Patients|Effectiveness of Nutritional Intervention in Malnourished Elderly Patients|Completed||Phase 4|23|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 03:32:17.266355|2018-06-01 03:32:17.266355
NCT00417495|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|||2016-01-05|2006-12-29|2007-01-01|Estimate|||||||2016-01-05|2016-01-06|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Sentinel Lymph Node Technique in Multifocal Breast Cancer|Interest of Sentinel Lymph Node Technique in Women With a Multifocal Breast Cancer - IGASSU-0502|Completed||Phase 2|216|Actual|Centre Oscar Lambret|||||f||||||||||||||2018-06-01 03:32:17.339021|2018-06-01 03:32:17.339021
NCT00417482|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|2013-02-11||2013-03-14|2006-12-28|2007-01-01|Estimate|2013-03-14|2013-04-24|Estimate||||2013-03-14|2013-04-24|Estimate|August 2004||2004-08-31|March 2013|2013-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|ADAD||Antipsychotic Discontinuation in Alzheimer's Disease|Antipsychotic Discontinuation in Alzheimer's Disease|Completed||Phase 4|180|Actual|New York State Psychiatric Institute|Comparisons of adverse events in Phase B were limited by the small sample & the truncated observation period for relapsed subjects. Identification of predictors of relapse after discontinuation of treatment was limited by the small sample.|3|||f||||t||||||||||2018-06-01 03:32:17.441998|2018-06-01 03:32:17.441998
NCT00417469|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2015-03-04|2006-12-29|2007-01-01|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|February 2007|Actual|2007-02-28|||||Interventional|||A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)|A Single-Blind, Randomized, Single-Center Evaluation of Procedural and Post Procedural Pain Experienced With Injections of NADG With Lidocaine Injectable Gel as Compared to Captique® Injectable Gel in Subjects Undergoing Cutaneous Correction of Nasolabial Folds|Completed||Phase 3|45||Sanofi|||||||||||||||||||2018-06-01 03:32:18.018765|2018-06-01 03:32:18.018765
NCT00417456|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|||2012-03-14|2006-12-29|2007-01-01|Estimate|||||||2012-03-14|2012-03-16|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||"The Development and Evaluation of an E-Visit Program for the Management of Acne"|"The Development and Evaluation of an E-Visit Program for the Management of Acne"|Completed||N/A|151|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:32:18.092586|2018-06-01 03:32:18.092586
NCT00417443|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2014-01-07|2006-12-28|2007-01-01|Estimate|||||||2014-01-07|2014-01-08|Estimate|December 2007||2007-12-31|December 2006|2006-12-31|December 2009||2009-12-31|||||Interventional|||Epidural Clonidine for Postoperative Hyperalgesia|A Study of Effect of Epidural Clonidine on Postoperative Pain Relief, Hyperalgesia and Chronic Pain in Patients Undergoing Colorectal Surgery|Withdrawn||Phase 3|0|Actual|Cambridge University Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 03:32:18.174575|2018-06-01 03:32:18.174575
NCT00417430|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2009-09-18|2006-12-29|2007-01-01|Estimate|||||||2009-09-18|2009-09-22|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies|Phase II Study of Efficacy of ICI 182,780 (Faslodex) in the Treatment of Systemic Lupus Erythematosus: Clinical, Serologic, Molecular|Completed||Phase 2|20||The Center for Rheumatic Disease, Allergy, & Immunology|||||f||||||||||||||2018-06-01 03:32:18.249552|2018-06-01 03:32:18.249552
NCT00417417|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|2009-09-14||2012-04-25|2006-12-29|2007-01-01|Estimate|2010-03-23|2010-04-13|Estimate||||2012-04-25|2012-04-30|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Rilonacept to Improve Artery Function in Patients With Atherosclerosis|Effects of Interleukin-1 Inhibition on C-Reactive Protein Levels, Endothelial Progenitor Cell Mobilization and Endothelial Function in Patients With Coronary Artery Disease|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 03:32:18.328152|2018-06-01 03:32:18.328152
NCT00417404|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|||2010-06-24|2006-12-29|2007-01-01|Estimate|||||||2010-06-24|2010-06-25|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Vitamin A and Very Low Birthweight Babies (VitAL)|Does Additional Vitamin A Supplementation Improve Retinal Function and Conjunctival Health in Very Low Birthweight Infants?|Completed||Phase 4|94|Actual|Glasgow Royal Infirmary||2|||f||||t||||||||||2018-06-01 03:32:18.572495|2018-06-01 03:32:18.572495
NCT00417391|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2008-05-25|2006-12-28|2007-01-01|Estimate|||||||2008-05-25|2008-05-29|Estimate|December 2006||2006-12-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Phase II Study of RR110 in Patients With Active Crohn's Disease|Phase II Study of RR110 in Patients With Active Crohn's Disease|Completed||Phase 2|24|Anticipated|R&R Inc.||2|||f||||||||||||||2018-06-01 03:32:18.656126|2018-06-01 03:32:18.656126
NCT00417378|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29|||2007-11-27|2006-12-29|2007-01-01|Estimate|||||||2007-11-27|2007-11-28|Estimate|August 2004||2004-08-31|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK)|Left Ventricular Assist Device (Impella LP 2.5) vs. Intraaortic Balloon Counterpulsation (IABP) in Patients With Cardiogenic Shock and Acute Coronary Syndromes|Completed||Phase 4|26|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 03:32:18.73302|2018-06-01 03:32:18.73302
NCT00417365|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2007-08-13|2006-12-29|2007-01-01|Estimate|||||||2007-08-13|2007-08-15|Estimate|August 2006||2006-08-31|August 2007|2007-08-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Efficacy of (WaterWorks®)Douching Device for Elimination of Perceived Vaginal Odor Not Caused by BV or Vaginitis|"A Comparison Study of the WaterWorks® Douching Device vs. Commercial OTC Douching Device for the Reduction or Abatement of Perceived Vaginal Odor With or Without Complaints of Discharge in Women With no Infectious Causes of Vaginitis"|Unknown status|Recruiting|N/A|100|Anticipated|Abbott Research Group|||||f||||||||||||||2018-06-01 03:32:18.808628|2018-06-01 03:32:18.808628
NCT00417352|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2010-08-05|2006-12-29|2007-01-01|Estimate|||||||2010-08-05|2010-08-06|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||Study of Compensatory Motion While Using an Upper Limb Prosthesis|Kinematic and Kinetic Profile of Common Tasks for the Development of Design Parameters of an Upper Limb Prosthesis|Completed||N/A|17|Actual|University of South Florida|||||f||||||||||||||2018-06-01 03:32:18.896821|2018-06-01 03:32:18.896821
NCT00417339|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2016-05-12|2006-12-28|2007-01-01|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 2006||2006-12-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Protein-bound Uremic Retention Solutes and Long Nocturnal Hemodialysis: a Longitudinal Analysis|A Multicentric Observational Trial on Protein Bound Uremic Toxins in Nocturnal Hemodialysis|Completed|||38|Actual|Universitaire Ziekenhuizen Leuven|||4||f||||f||||||Samples Without DNA|"~     serum, urine, dialysate~   "|No||2018-06-01 03:32:18.964238|2018-06-01 03:32:18.964238
NCT00417326|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2012-06-12|2006-12-28|2007-01-01|Estimate|||||||2012-06-12|2012-06-13|Estimate|December 2006||2006-12-31|June 2012|2012-06-30||||August 2009|Actual|2009-08-31||Interventional|||Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia|ONO-5046Na Phase II Study - A Pilot Study for Patients With Acute Respiratory Failure|Completed||Phase 2|174|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 03:32:19.040254|2018-06-01 03:32:19.040254
NCT00417313|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2006-12-28|2006-12-28|2007-01-01|Estimate|||||||2006-12-28|2007-01-01|Estimate|October 2004||2004-10-31|December 2006|2006-12-31|August 2006||2006-08-31|||||Interventional|||Osteopuncture for Osteoarthritis-Associated Knee Pain & Disability|Osteopuncture for Osteoarthritis-Associated Knee Pain & Disability|Completed||Phase 2|88||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 03:32:19.12355|2018-06-01 03:32:19.12355
NCT00417300|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2013-06-26|2006-12-28|2007-01-01|Estimate|||||||2013-06-26|2013-06-27|Estimate|February 2006||2006-02-28|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse|Treating Adolescents With CSA Related PTSD|Completed||Phase 2|90|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:32:19.175256|2018-06-01 03:32:19.175256
NCT00417287|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-29||2015-04-30|2018-05-14|2006-12-29|2007-01-01|Estimate||||2015-04-30|2015-05-19|Estimate|2018-05-14|2018-05-16|Actual|December 2006||2006-12-31|April 2015|2015-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer|A Randomized Phase II Open-Label Study of Two Different Dose Levels of PX-12 in Patients With Advanced Carcinoma of the Pancreas Whose Tumors Have Progressed on Gemcitabine or on a Gemcitabine-Containing Combination|Terminated||Phase 2|17|Actual|Seattle Genetics, Inc.||2||Investigator decision|f||||t||||||||||2018-06-01 03:32:19.245654|2018-06-01 03:32:19.245654
NCT00417274|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2011-06-28||2013-03-06|2006-12-28|2006-12-29|Estimate|2013-03-06|2013-04-11|Estimate||||2013-03-06|2013-04-11|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer|An Open-Label, Phase II Safety, Tolerability, Drug Level and Efficacy Trial of Quinacrine in Patients With Androgen-Independent Metastatic Prostate Cancer|Completed||Phase 2|31|Actual|Cleveland BioLabs||1|||f||||f||||||||||2018-06-01 03:32:19.31551|2018-06-01 03:32:19.31551
NCT00417261|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2008-06-20|2006-12-28|2006-12-29|Estimate|||||||2008-06-20|2008-06-23|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|April 2008|Actual|2008-04-30|||||Interventional|||Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.|A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Ascending Single and Multiple Dose, Seamless Design Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Orally Administered Compounds, ATF936 and AXT914, in Healthy Male and Female Subjects|Completed||Phase 1|65|Anticipated|Novartis||3|||f||||f||||||||||2018-06-01 03:32:19.467399|2018-06-01 03:32:19.467399
NCT00417248|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|2016-05-04||2016-06-13|2006-12-28|2006-12-29|Estimate|2016-06-13|2016-07-25|Estimate||||2016-06-13|2016-07-25|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer|A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107|Terminated||Phase 1/Phase 2|8|Actual|Hoosier Cancer Research Network||1||Negative sorafenib results from ESCAPE trial and safety concerns of regimen|f||||t||||||||Yes||2018-06-01 03:32:19.527432|2018-06-01 03:32:19.527432
NCT00417235|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2016-05-23|2006-12-28|2006-12-29|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|DRESSING||Dressing: Frequency of Change and Evaluation of an Antiseptic-Impregnated Catheter Dressing in ICU Patients|Dressing: Comparison of 3-day and 7-day Catheter Dressing Frequency and Efficacy of Antiseptic Impregnated Dressing in Preventing Catheter-related Infection in ICU|Completed||Phase 4|1600|Actual|University Hospital, Grenoble||4|||f||||t||||||||||2018-06-01 03:32:19.772272|2018-06-01 03:32:19.772272
NCT00417222|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2014-05-16|2006-12-28|2006-12-29|Estimate|||||||2014-05-16|2014-05-19|Estimate|November 2006||2006-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|SUPPORT||Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan|Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)|Completed||Phase 3|1145|Actual|Tohoku University||2|||f||||t||||||||||2018-06-01 03:32:19.853444|2018-06-01 03:32:19.853444
NCT00417209|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28||2016-04-06|2016-05-03|2006-12-28|2006-12-29|Estimate||||2016-04-06|2016-05-04|Estimate|2016-05-03|2016-06-03|Estimate|December 2006||2006-12-31|May 2016|2016-05-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|PAPRIKA||Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen|A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen|Completed||Phase 3|408|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:32:19.920871|2018-06-01 03:32:19.920871
NCT00417196|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2010-09-30|2006-12-28|2006-12-29|Estimate|||||||2010-09-30|2010-10-01|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of Intravenous QAX576|Completed||Phase 1|32|Actual|Novartis|||||f||||f||||||||||2018-06-01 03:32:20.027715|2018-06-01 03:32:20.027715
NCT00417183|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2006-12-28|2006-12-28|2006-12-29|Estimate|||||||2006-12-28|2006-12-29|Estimate|September 2005||2005-09-30|December 2006|2006-12-31|June 2007||2007-06-30|||||Interventional|||Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation|Randomized Controlled Trial Comparing the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation in Normal Responders|Unknown status|Recruiting|Phase 4|300||Eugonia|||||f||||||||||||||2018-06-01 03:32:20.121085|2018-06-01 03:32:20.121085
NCT00417170|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|2011-07-15||2011-09-22|2006-12-28|2006-12-29|Estimate|2011-07-15|2011-08-11|Estimate||||2011-09-22|2011-09-26|Estimate|October 2007||2007-10-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome|A Double-blind, Double Dummy, Randomized Parallel Design Trial to Study the Effects of 12 Weeks of Treatment With 300mg Aliskiren vs. 5mg Amlodipine on Insulin Resistance and Endothelial Dysfunction in Hypertensive Patients With Metabolic Syndrome|Completed||Phase 2|48|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:32:20.20388|2018-06-01 03:32:20.20388
NCT00417157|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2013-12-13|2006-12-28|2006-12-29|Estimate|||||||2013-12-13|2013-12-16|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Modified Natural Cycle Offers a Chance of Pregnancy in Patients With Poor Response and High Basal FSH|Successful Application of Modified Natural Cycle in Poor Responders With High Basal FSH Prior to Oocyte Donation|Completed|||135|Actual|Eugonia|||||f||||||||||||||2018-06-01 03:32:20.506939|2018-06-01 03:32:20.506939
NCT00417144|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2006-12-28|2006-12-28|2006-12-29|Estimate|||||||2006-12-28|2006-12-29|Estimate|November 2003||2003-11-30|December 2006|2006-12-31|May 2007||2007-05-31|||||Interventional|||Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients|Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients|Unknown status|Recruiting|Phase 4|200||Eugonia|||||f||||||||||||||2018-06-01 03:32:20.574457|2018-06-01 03:32:20.574457
NCT00417131|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2011-08-03|2006-12-28|2006-12-29|Estimate|||||||2011-08-03|2011-08-04|Estimate|October 2006||2006-10-31|July 2008|2008-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Imaging of Islet Transplantation With PET and MRT|Imaging of Islet Transplantation With PET and MRT|Completed|||8|Actual|Uppsala University Hospital|||||f||||f||||||||||2018-06-01 03:32:20.641717|2018-06-01 03:32:20.641717
NCT00417118|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28||2016-04-25|2016-04-25|2006-12-28|2006-12-29|Estimate||||2016-04-25|2016-05-24|Estimate|2016-04-25|2016-05-24|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder|An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder|Completed||Phase 3|365|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 03:32:20.695488|2018-06-01 03:32:20.695488
NCT00417105|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2009-03-04|2006-12-28|2006-12-29|Estimate|||||||2009-03-04|2009-03-05|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Protein-Bound Uremic Retention Solutes in Long Nocturnal Hemodialysis|A Multicentric Observational Study on the Removal of Protein-Bound Uremic Retention Solutes in Nocturnal Hemodialysis: A Cross-Sectional Analysis|Completed|||120|Actual|Universitaire Ziekenhuizen Leuven|||4||f||||t||||||Samples Without DNA|"~     serum, urine, dialysate~   "|||2018-06-01 03:32:20.776567|2018-06-01 03:32:20.776567
NCT00417092|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|||2007-09-21|2006-12-28|2006-12-29|Estimate|||||||2007-09-21|2007-09-24|Estimate|December 2006||2006-12-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Biventricular Pacing After Coronary Artery Bypass Grafting (BIVAC)||Completed||N/A|100|Anticipated|University of Schleswig-Holstein|||||f||||||||||||||2018-06-01 03:32:20.852883|2018-06-01 03:32:20.852883
NCT00417079|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-28|2010-09-20||2011-03-04|2006-12-28|2006-12-29|Estimate|2010-12-22|2010-12-23|Estimate||||2011-03-04|2011-03-10|Estimate|January 2007||2007-01-31|March 2011|2011-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|TROPIC||XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer|A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated With A Taxotere®-Containing Regimen|Completed||Phase 3|755|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:32:20.979151|2018-06-01 03:32:20.979151
NCT00417066|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2013-12-13|2006-12-28|2006-12-29|Estimate|||||||2013-12-13|2013-12-16|Estimate|September 2003||2003-09-30|January 2009|2009-01-31|July 2006|Actual|2006-07-31|||||Interventional|||Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders|The Flexible GnRH Antagonist Protocol Provides Better Results (IVF Outcomes) Than Flare up GnRH Agonist Protocol in Poor Responders|Completed||Phase 4|270||Eugonia|||||f||||||||||||||2018-06-01 03:32:22.073326|2018-06-01 03:32:22.073326
NCT00417053|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-08-01|2006-12-27|2006-12-28|Estimate|||||||2013-08-01|2013-08-02|Estimate||||December 2006|2006-12-31||||||||Interventional|||Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant|European Infant Neuroblastoma Study Final Protocol|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:22.130278|2018-06-01 03:32:22.130278
NCT00417040|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2017-06-26|2006-12-27|2006-12-28|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2006|Actual|2006-12-31|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|March 2013|Actual|2013-03-31||Interventional|||Collection of Patient-Reported Symptoms and Performance Status Via the Internet|Collection of Patient-Reported Symptoms and Performance Status Via the Internet|Completed||N/A|325|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 03:32:22.189471|2018-06-01 03:32:22.189471
NCT00417027|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2011-06-28||2014-03-17|2006-12-27|2006-12-28|Estimate|2011-11-06|2011-12-09|Estimate||||2014-03-17|2014-04-14|Estimate|August 2006||2006-08-31|March 2014|2014-03-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Programmed Intermittent Epidural Bolus Time Interval and Injection Volume|Effect of Manipulation of the Programmed Intermittent Bolus Time Interval and Injection Volume on Total Drug Use for Labor Epidural Analgesia: a Randomized Controlled Trial|Completed||N/A|190|Actual|Northwestern University|No group that received a continuous infusion or PCEA without a background infusion was included. Conclusions are limited to our patient population, drug concentrations, and mode of initiation of labor analgesia.|3|||f||||f||||||||||2018-06-01 03:32:22.462746|2018-06-01 03:32:22.462746
NCT00417014|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-08-01|2006-12-27|2006-12-28|Estimate|||||||2013-08-01|2013-08-02|Estimate||||December 2006|2006-12-31||||||||Interventional|||Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma|Hodgkins Disease Study|Unknown status|Active, not recruiting|N/A|358|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:22.907337|2018-06-01 03:32:22.907337
NCT00417001|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2009-01-20|2006-12-27|2006-12-28|Estimate|||||||2009-01-20|2009-01-22|Estimate|October 2006||2006-10-31|January 2009|2009-01-31|October 2008|Actual|2008-10-31|January 2008|Actual|2008-01-31||Interventional|||Reduction of Conscious Sedation Requirements by Olfactory Stimulation|Reduction of Conscious Sedation Requirements by Olfactory Stimulation|Completed||N/A|284|Anticipated|United States Naval Medical Center, Portsmouth|||||f||||f||||||||||2018-06-01 03:32:22.969098|2018-06-01 03:32:22.969098
NCT00416988|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-06-19|2006-12-27|2006-12-28|Estimate|||||||2013-06-19|2013-06-20|Estimate||||July 2008|2008-07-31||||||||Interventional|||Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants|Skin Self-Examination for Early Detection of Melanoma: Intervention and Consequence|Completed||N/A|1135|Anticipated|Rhode Island Hospital|||||f||||||||||||||2018-06-01 03:32:23.040656|2018-06-01 03:32:23.040656
NCT00416975|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-04-23|2006-12-27|2006-12-28|Estimate|||||||2013-04-23|2013-04-24|Estimate|May 2000||2000-05-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2005|Actual|2005-12-31||Interventional|||Individualized Risk-Based Education in Promoting Breast Cancer Screening in Healthy Women|Breast Cancer Risk-Tailored Messages for More Women|Completed||N/A|899|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-06-01 03:32:23.092369|2018-06-01 03:32:23.092369
NCT00416962|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2007-11-29|2006-12-27|2006-12-28|Estimate|||||||2007-11-29|2007-11-30|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine|An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.|Completed||Phase 1|18||Novartis|||||f||||||||||||||2018-06-01 03:32:23.153631|2018-06-01 03:32:23.153631
NCT00416949|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2014-08-06|2006-12-27|2006-12-28|Estimate|||||||2014-08-06|2014-08-07|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Iodine I 131 in Treating Patients With Thyroid Cancer|Dose-Response in Radionuclide Therapy of Thyroid Cancer|Completed||N/A|9|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 03:32:23.211962|2018-06-01 03:32:23.211962
NCT00416936|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2009-02-09|2006-12-27|2006-12-28|Estimate|||||||2009-02-09|2009-02-10|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|November 2007|Actual|2007-11-30|||||Observational|||Bacterial Contamination of Anaesthetists' Hands by Personal Mobile Phones Used in the Operating Theatre||Completed|||40||Medical University Innsbruck|||||f||||||||||||||2018-06-01 03:32:23.292137|2018-06-01 03:32:23.292137
NCT00416923|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2015-02-12|2006-12-27|2006-12-28|Estimate|||||||2015-02-12|2015-02-16|Estimate|August 2002||2002-08-31|February 2015|2015-02-28|April 2007|Actual|2007-04-30|November 2005|Actual|2005-11-30||Interventional|||Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma|Phase I Study of Intrathecal Rituximab in Patients With Recurrent CNS Lymphoma|Completed||Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||||||||||||2018-06-01 03:32:23.336488|2018-06-01 03:32:23.336488
NCT00416910|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2016-09-23|2006-12-27|2006-12-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 1999||1999-07-31|September 2016|2016-09-30|September 2007|Actual|2007-09-30|September 2003|Actual|2003-09-30||Interventional|||Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|Treatment of Advanced Chronic Lymphocytic Leukemia (CLL) Fludarabine, Mitoxantrone and Cyclophosphamide With or Without G-CSF|Terminated||Phase 3|83|Actual|German CLL Study Group||2||low recruitment|f||||f||||||||No||2018-06-01 03:32:23.402945|2018-06-01 03:32:23.402945
NCT00416715|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2017-04-14||2017-06-10|2006-12-27|2006-12-28|Estimate|2017-06-10|2017-07-11|Actual||||2017-06-10|2017-07-11|Actual|October 2006||2006-10-31|June 2017|2017-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer|A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness Associated With Letrozole (Femara® )|Completed||Phase 2|100|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:32:24.779614|2018-06-01 03:32:24.779614
NCT00416897|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-08-23|2006-12-27|2006-12-28|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2003||2003-03-31|June 2007|2007-06-30|December 2008|Actual|2008-12-31|||||Interventional|||Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure|A Randomised Controlled Trial of Adjunctive Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Renal Failure [MERIT] MyEloma Renal Impairment Trial|Completed||Phase 3|280|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:23.486125|2018-06-01 03:32:23.486125
NCT00416884|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2011-05-31||2017-09-25|2006-12-27|2006-12-28|Estimate|2011-07-06|2011-08-02|Estimate||||2017-09-25|2017-09-27|Actual|May 2003||2003-05-31|July 2011|2011-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML|Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571)|Terminated||Phase 2|1|Actual|OHSU Knight Cancer Institute|Study was terminated early due to low enrollment, hence the study did not have any treatment-related mortalities to report.|1||Low enrollment|f||||t||||||||||2018-06-01 03:32:23.582817|2018-06-01 03:32:23.582817
NCT00416871|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2012-09-25|2006-12-27|2006-12-28|Estimate|||||||2012-09-25|2012-09-26|Estimate||||September 2012|2012-09-30|February 2006|Actual|2006-02-28|||||Interventional|||Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer|Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO]|Completed||Phase 3|220|Anticipated|Centre Leon Berard|||||f||||||||||||||2018-06-01 03:32:23.717194|2018-06-01 03:32:23.717194
NCT00416858|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2014-03-03|2006-12-27|2006-12-28|Estimate|||||||2014-03-03|2014-03-04|Estimate||||April 2007|2007-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery|Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer|Completed||Phase 3|40|Anticipated|Federation Francophone de Cancerologie Digestive|||||f||||||||||||||2018-06-01 03:32:23.772705|2018-06-01 03:32:23.772705
NCT00416845|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2010-06-03|2006-12-27|2006-12-28|Estimate|||||||2010-06-03|2010-06-04|Estimate|October 2006||2006-10-31|June 2010|2010-06-30||||March 2007|Actual|2007-03-31||Interventional|||Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers|A Randomized, Parallel Group, Double-blind, Placebo Controlled, 14 Days Multiple-dose Treatment to Assess the Pulmonary and Cardiac Pharmacodynamics of FTY720 (0.5 and 1.25 mg) in Healthy Volunteers|Completed||Phase 1|39|Actual|Novartis|||||f||||||||||||||2018-06-01 03:32:23.833959|2018-06-01 03:32:23.833959
NCT00416832|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2015-11-17|2006-12-27|2006-12-28|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2002||2002-11-30|November 2015|2015-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma|Optimising Therapy for Boys With Hodgkin's Lymphoma and Quality Assurance of Therapy for Girls With Hodgkin's Lymphoma Until Start of a New Prospective Trial for Hodgkin's Lymphoma in Childhood and Adolescence|Completed||Phase 2|648|Anticipated|Martin-Luther-Universität Halle-Wittenberg|||||f||||||||||||||2018-06-01 03:32:23.888668|2018-06-01 03:32:23.888668
NCT00416819|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2015-08-18|2006-12-27|2006-12-28|Estimate|||||||2015-08-18|2015-08-20|Estimate|September 2003||2003-09-30|August 2015|2015-08-31|February 2012|Actual|2012-02-29|December 2005|Actual|2005-12-31||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma|Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: A Pilot Study|Completed||N/A|10|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 03:32:23.948011|2018-06-01 03:32:23.948011
NCT00416793|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2011-06-14||2014-05-12|2006-12-27|2006-12-28|Estimate|2011-06-14|2011-07-15|Estimate||||2014-05-12|2014-05-28|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|9|Actual|National Cancer Institute (NCI)|Given the toxicity and lack of objective responses observed with this regimen, the protocol met prospective criteria for early stopping and was terminated.|1|||f||||||||||||||2018-06-01 03:32:24.064966|2018-06-01 03:32:24.064966
NCT00416780|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-05-29|2006-12-27|2006-12-28|Estimate|||||||2013-05-29|2013-05-30|Estimate||||March 2006|2006-03-31|March 2006|Actual|2006-03-31|||||Interventional|||Psychosocial Support in Treating Women With Recurrent Breast Cancer or Stage I, Stage II, or Stage IV Breast Cancer|Psychobiological Pathways: Breast Cancer Interventions|Completed||N/A|350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:24.291234|2018-06-01 03:32:24.291234
NCT00416767|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2016-05-27|2006-12-27|2006-12-28|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2004||2004-05-31|May 2016|2016-05-31|July 2007|Actual|2007-07-31|January 2006|Actual|2006-01-31||Interventional|||Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery|Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors|Completed||Phase 2|20|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||||||||||||2018-06-01 03:32:24.410359|2018-06-01 03:32:24.410359
NCT00416754|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2017-04-05|2006-12-27|2006-12-28|Estimate|||||||2017-04-05|2017-04-07|Actual|December 2000||2000-12-31|February 2017|2017-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Genetic Counseling in Women at Risk for BRCA1 or BRCA2 Mutations|Improving the Long-Term Outcomes of BRCA1/BRCA2 Mutation Testing|Completed||N/A|1109|Actual|Georgetown University|||||f||||f||||||||No||2018-06-01 03:32:24.510973|2018-06-01 03:32:24.510973
NCT00416741|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2011-06-23|2006-12-27|2006-12-28|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2005||2005-02-28|June 2011|2011-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Observational|ATTEMPT||Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)|Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT)|Completed|||2000|Actual|Hellenic Atherosclerosis Society|||2||f||||t||||||||||2018-06-01 03:32:24.577491|2018-06-01 03:32:24.577491
NCT00416728|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2007-06-21|2006-12-27|2006-12-28|Estimate|||||||2007-06-21|2007-06-22|Estimate|November 2006||2006-11-30|June 2007|2007-06-30||||||||Interventional|||Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.|An Open-Label, Randomized, Two-Treatment, Two Period Crossover, Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image (FMI) Aliskiren/Valsartan 150/80 mg Tablets and the Free Combination of Aliskiren 150 mg and Valsartan 80 mg in Healthy Subjects|Completed||Phase 1|32||Novartis|||||f||||||||||||||2018-06-01 03:32:24.713114|2018-06-01 03:32:24.713114
NCT00416702|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2008-06-09|2006-12-27|2006-12-28|Estimate|||||||2008-06-09|2008-06-10|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|March 2008|Actual|2008-03-31|||||Interventional|||Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics of 600 µg Indacaterol in Subjects With Impaired Hepatic Function in Comparison With Healthy Control Subjects|Completed||Phase 1|32|Anticipated|Novartis||1|||f||||||||||||||2018-06-01 03:32:25.015199|2018-06-01 03:32:25.015199
NCT00416689|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2016-06-28|2006-12-27|2006-12-28|Estimate|||||||2016-06-28|2016-06-29|Estimate|April 2000||2000-04-30|June 2016|2016-06-30|January 2006|Actual|2006-01-31|March 2003|Actual|2003-03-31||Observational|||Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer|Determination of Utilities for Control of Chemotherapy-Induced Nausea or Vomiting|Completed|||99|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 03:32:25.097584|2018-06-01 03:32:25.097584
NCT00416676|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-08-01|2006-12-27|2006-12-28|Estimate|||||||2013-08-01|2013-08-02|Estimate||||December 2006|2006-12-31||||||||Interventional|||Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma|UKCCSG Stage IIB/3 (INSS) Neuroblastoma Pilot Study [ENSG VI (Pilot 2B/3)]|Unknown status|Active, not recruiting|Phase 3|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:25.181065|2018-06-01 03:32:25.181065
NCT00416663|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2007-08-30|2006-12-27|2006-12-28|Estimate|||||||2007-08-30|2007-09-03|Estimate|August 2007||2007-08-31|December 2006|2006-12-31|August 2007|Anticipated|2007-08-31|||||Interventional|||Vescell(TM) for the Treatment of Patients With Severe Anginal Syndrome With or Without Heart Failure|A Study for Testing Efficacy and Safety of the Administration of Vescell(TM) (Blood-Borne Autologous Angiogenic Cell Precursors) to Alleviate Anginal Symptoms and Myocardial Ischemia in Severe Anginal Syndrome +/- Heart Failure|Unknown status|Not yet recruiting|Phase 1/Phase 2|10|Anticipated|TheraVitae Ltd.||1|||f||||t||||||||||2018-06-01 03:32:25.241942|2018-06-01 03:32:25.241942
NCT00416650|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-04-02|2006-12-27|2006-12-28|Estimate|||||||2013-04-02|2013-04-04|Estimate|July 2002||2002-07-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|October 2007|Actual|2007-10-31||Interventional|||Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer|Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) in Patients With Advanced Bronchioalveolar Cell Lung Cancer.|Completed||Phase 2|16|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:32:25.329033|2018-06-01 03:32:25.329033
NCT00416637|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2016-07-05|2006-12-27|2006-12-28|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Bevacizumab in Treating Patients With Advanced Solid Tumors|Biomarker and Clinical Evaluation of Bevacizumab (Avastin) to Determine the Role of Nitric Oxide in Anti-VEGF Therapy|Completed||Phase 1|27|Anticipated|Duke University||1|||f||||||||||||||2018-06-01 03:32:25.416175|2018-06-01 03:32:25.416175
NCT00416624|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2015-09-10||2016-12-19|2006-12-27|2006-12-28|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|May 2007||2007-05-31|September 2015|2015-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||All patients that were evaluable per protocol.|Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy|RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa|Completed||Phase 2|239|Actual|Mayo Clinic||4|||f||||t||||||||||2018-06-01 03:32:25.53326|2018-06-01 03:32:25.53326
NCT00416611|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-23|||2009-01-28|2006-12-27|2006-12-28|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 2006||2006-11-30|January 2009|2009-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|IMPULSION||IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study|IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study|Completed|||1000|Anticipated|Hellenic Atherosclerosis Society|||||f||||t||||||||||2018-06-01 03:32:26.72846|2018-06-01 03:32:26.72846
NCT00416598|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2014-01-06||2018-05-23|2006-12-27|2006-12-28|Estimate|2014-01-06|2014-02-20|Estimate||||2018-05-23|2018-05-24|Actual|November 15, 2006|Actual|2006-11-15|May 2018|2018-05-31||||January 31, 2011|Actual|2011-01-31||Interventional||Participants who received investigational decatibine maitenance were analyzed.|Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia|Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML &lt; 60 Years|Active, not recruiting||Phase 2|546|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:32:26.824367|2018-06-01 03:32:26.824367
NCT00416585|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2008-01-22|2006-12-27|2006-12-28|Estimate|||||||2008-01-22|2008-01-23|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|November 2006||2006-11-30|||||Interventional|||Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne|Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment|Completed||Phase 1|30||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:32:27.279577|2018-06-01 03:32:27.279577
NCT00416572|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2015-08-25||2016-09-21|2006-12-27|2006-12-28|Estimate|2016-09-21|2016-11-07|Estimate||||2016-09-21|2016-11-07|Estimate|January 1997||1997-01-31|September 2016|2016-09-30|April 2006|Actual|2006-04-30|May 2001|Actual|2001-05-31||Interventional|||Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer|Adjustment to Breast Cancer Among Younger Women|Completed||N/A|252|Actual|Carnegie Mellon University||3|||f||||t||||||||||2018-06-01 03:32:27.336837|2018-06-01 03:32:27.336837
NCT00416559|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-09-19|2006-12-27|2006-12-28|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 2004||2004-12-31|May 2007|2007-05-31||||||||Interventional|||Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only|Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma|Unknown status|Active, not recruiting|Phase 2|140|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:27.613344|2018-06-01 03:32:27.613344
NCT00416546|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2008-08-08|2006-12-27|2006-12-28|Estimate|||||||2008-08-08|2008-08-11|Estimate|October 2006||2006-10-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects|A Double Blind, Randomized, Placebo-Controlled Study of AEB071 in Healthy Volunteers to Evaluate the Safety/Tolerability of 14 Day Multiple-Dose AEB071 and Measure the Effect of Ethnicity on Pharmacokinetics, Pharmacodynamics and Safety/Tolerability in Caucasian and Japanese Subjects Receiving Single and Multiple Doses of AEB071|Completed||Phase 1|96|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:32:27.656777|2018-06-01 03:32:27.656777
NCT00416533|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2017-01-17|2006-12-27|2006-12-28|Estimate|||||||2017-01-17|2017-01-19|Estimate|August 2004||2004-08-31|June 2013|2013-06-30||||October 2006|Actual|2006-10-31||Interventional|||Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of Taxotere (Docetaxel) Plus Adriamycin (Doxorubicin) and Prednisone (TAP) in Hormone-Refractory Prostate Cancer|Completed||Phase 2|47|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 03:32:27.703211|2018-06-01 03:32:27.703211
NCT00416520|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2014-08-22||2014-10-28|2006-12-27|2006-12-28|Estimate|2014-10-20|2014-10-23|Estimate||||2014-10-28|2014-11-04|Estimate|June 2007||2007-06-30|October 2014|2014-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia|A Phase III, Randomised, Double-Blind, Multi-centre, Withdrawal Study Comparing MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia|Completed||Phase 3|336|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-06-01 03:32:28.797343|2018-06-01 03:32:28.797343
NCT00416507|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2016-05-27|2006-12-27|2006-12-28|Estimate|||||||2016-05-27|2016-05-30|Estimate|March 2000||2000-03-31|May 2016|2016-05-31|January 2007|Actual|2007-01-31|July 2005|Actual|2005-07-31||Interventional|||Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Non Resectable But Non Metastatic Adenocarcinoma of the Exocrine Pancreas Non Resecables. Randomised Phase III: Initial Radiochimiotherapy (5-FU, Cisplatine, 60 GY Radiotherapy) Followed by Gemcitabine Versus Gemcitabine Alone|Completed||Phase 3|190|Anticipated|Federation Francophone de Cancerologie Digestive|||||f||||||||||||||2018-06-01 03:32:29.815214|2018-06-01 03:32:29.815214
NCT00416494|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2013-02-12||2014-08-25|2006-12-27|2006-12-28|Estimate|2013-02-12|2013-03-14|Estimate||||2014-08-25|2014-09-03|Estimate|September 2003||2003-09-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|January 2008|Actual|2008-01-31||Interventional|||Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer|Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Colorectal Cancer|Completed||Phase 2|50|Actual|Duke University||2|||f||||||||||||||2018-06-01 03:32:29.895216|2018-06-01 03:32:29.895216
NCT00416481|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2016-07-12|2006-12-27|2006-12-28|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 2006||2006-12-31|July 2016|2016-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Assessing Older Patients With Cancer|Development of a Geriatric Assessment Measure for Older Patients With Cancer|Completed|||93|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 03:32:30.213173|2018-06-01 03:32:30.213173
NCT00416468|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2007-06-21|2006-12-27|2006-12-28|Estimate|||||||2007-06-21|2007-06-22|Estimate|November 2006||2006-11-30|June 2007|2007-06-30||||||||Interventional|||Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.|An Open-Label, Randomized, Two-Treatment, Two Period Crossover, Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image (FMI) Aliskiren/Valsartan 75/160 mg Tablets and the Free Combination of Aliskiren 75 mg and Valsartan 160 mg in Healthy Subjects|Completed||Phase 1|32||Novartis|||||f||||||||||||||2018-06-01 03:32:30.285808|2018-06-01 03:32:30.285808
NCT00416455|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|2015-11-09||2016-11-14|2006-12-27|2006-12-28|Estimate|2015-11-09|2015-12-14|Estimate||||2016-11-14|2017-01-02|Estimate|September 2007||2007-09-30|November 2016|2016-11-30||||September 2014|Actual|2014-09-30||Interventional||Adequate imaging and pathologically eligible patients (N =360)|Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer|Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage|Active, not recruiting||Phase 1/Phase 2|384|Actual|National Cancer Institute (NCI)|Relatively small number of patients with abdominal metastasis in both cervical and endometrial cancer cohorts|1|||f||||||||||||||2018-06-01 03:32:30.477213|2018-06-01 03:32:30.477213
NCT00416442|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2011-11-01|2006-12-27|2006-12-28|Estimate|||||||2011-11-01|2011-11-02|Estimate|October 2006||2006-10-31|November 2011|2011-11-30||||November 2006|Actual|2006-11-30||Interventional|||Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.|A Randomized, Double-blind Placebo-controlled Single- to Multiple-dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of RSV604 Intravenous Formulation in Healthy Subjects|Completed||Phase 1|48||Novartis|||||f||||f||||||||||2018-06-01 03:32:31.043525|2018-06-01 03:32:31.043525
NCT00416429|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2012-09-25|2006-12-27|2006-12-28|Estimate|||||||2012-09-25|2012-09-26|Estimate||||September 2012|2012-09-30|February 2005|Actual|2005-02-28|||||Interventional|||Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer|Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO]|Completed||Phase 3|456|Anticipated|Centre Leon Berard|||||f||||||||||||||2018-06-01 03:32:31.10509|2018-06-01 03:32:31.10509
NCT00416403|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2012-12-12|2006-12-27|2006-12-28|Estimate|||||||2012-12-12|2012-12-13|Estimate|July 2006||2006-07-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|September 2007|Actual|2007-09-30||Interventional|||Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer|Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer|Completed||Phase 2|35|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-06-01 03:32:31.174927|2018-06-01 03:32:31.174927
NCT00416390|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-09-19|2006-12-27|2006-12-28|Estimate|||||||2013-09-19|2013-09-20|Estimate||||October 2007|2007-10-31|March 2011|Actual|2011-03-31|||||Interventional|||Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia|The Effect of Lycopene on DNA Damage in Human Prostate|Completed||N/A|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:31.261313|2018-06-01 03:32:31.261313
NCT00416377|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-08-01|2006-12-27|2006-12-28|Estimate|||||||2013-08-01|2013-08-02|Estimate||||December 2006|2006-12-31||||||||Interventional|||Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma|Hodgkin's Disease Study|Unknown status|Active, not recruiting|N/A|353|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:31.420573|2018-06-01 03:32:31.420573
NCT00416364|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2007-12-04|2006-12-27|2006-12-28|Estimate|||||||2007-12-04|2007-12-05|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Observational|||The Economic Impact of Four Varieties of Mesh Inguinal Hernia Repair- a Double-Blinded, Prospective, Randomized Trial|The Economic Impact of Four Varieties of Mesh Inguinal Hernia Repair- a Double-Blinded, Prospective, Randomized Trial|Terminated|||23|Actual|United States Naval Medical Center, Portsmouth|||4|Inadequate accrural rates|f||||f||||||||||2018-06-01 03:32:31.510407|2018-06-01 03:32:31.510407
NCT00415961|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2009-01-08|2006-12-22|2006-12-27|Estimate|||||||2009-01-08|2009-01-09|Estimate|November 2006||2006-11-30|January 2009|2009-01-31|May 2012|Anticipated|2012-05-31|||||Interventional|||Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety|Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety|Terminated||N/A|120|Anticipated|Conor Medsystems||1|||f||||||||||||||2018-06-01 03:32:38.979442|2018-06-01 03:32:38.979442
NCT00416351|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2017-08-03|2006-12-27|2006-12-28|Estimate|||||||2017-08-03|2017-08-04|Actual|June 2006||2006-06-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment|A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas|Active, not recruiting||Phase 1/Phase 2|29|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:32:31.575695|2018-06-01 03:32:31.575695
NCT00416338|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2007-05-09|2006-12-27|2006-12-28|Estimate|||||||2007-05-09|2007-05-10|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Method of Exit Site Care in Chronic Peritoneal Dialysis Patients|Comparison of Two Exit-Site Care Methods, Film Dressing (F) Method and Simple Gauze Dressing (G) Method, in Chronic Peritoneal Dialysis (CPD) Patients|Terminated||Phase 4|11|Actual|Chinese University of Hong Kong||||"We encounter technical problems to continue with the study. (Notably difficulty in teaching the~   patients to use the dressing set involved in the study.)"|f||||||||||||||2018-06-01 03:32:31.64753|2018-06-01 03:32:31.64753
NCT00416325|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-06-25|2006-12-27|2006-12-28|Estimate|||||||2013-06-25|2013-06-26|Estimate||||September 2006|2006-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer|Phase I Multiple Dose Pharmacokinetic Study of Lycopene Delivered in a Well-Defined Food-Based Lycopene Delivery System (Tomato Paste-Oil Mixture) in Patients at Increased Risk for Developing Prostate Cancer|Completed||Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:31.694873|2018-06-01 03:32:31.694873
NCT00416312|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-27|||2013-05-15|2006-12-27|2006-12-28|Estimate|||||||2013-05-15|2013-05-17|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma|Dose-Response in Radioimmunotherapy of Lymphoma|Completed||N/A|9|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-06-01 03:32:31.751669|2018-06-01 03:32:31.751669
NCT00416299|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2009-01-29|2006-12-26|2006-12-27|Estimate|||||||2009-01-29|2009-01-30|Estimate|May 2007||2007-05-31|January 2009|2009-01-31|August 2007|Actual|2007-08-31|||||Observational|||Prognostic Value of New Cardiac Biomarkers in Elderly Patients Undergoing Cardiac Surgery|Observational Cohort Study on the Prognostic Value of New Cardiac Biomarkers in Elderly Patients Undergoing Cardiac Surgery|Completed|||100|Actual|Klinikum Ludwigshafen|||||f||||f||||||||||2018-06-01 03:32:31.935585|2018-06-01 03:32:31.935585
NCT00416286|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-25|||2006-12-26|2006-12-26|2006-12-27|Estimate|||||||2006-12-26|2006-12-27|Estimate||||December 2006|2006-12-31||||||||Observational|||Effect of Sustained-Release Cetylpyridinium Chloride Varnish on Streptococcus Mutans and Lactobacillus in Orthodontic Patients|Phase 1: To Evaluate the Antibacterial Efficacy of Sustained Release Cetylpyridinium Chloride Varnish in Orthodontic Patients|Unknown status|Not yet recruiting||30|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:32:31.989209|2018-06-01 03:32:31.989209
NCT00416273|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2015-03-05|2006-12-22|2006-12-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma|Consolidation Therapy With Bortezomib <= 60 Year Old Patients With Multiple Myeloma|Completed||Phase 3|217|Actual|Janssen-Cilag G.m.b.H||2|||f||||f||||||||||2018-06-01 03:32:32.05035|2018-06-01 03:32:32.05035
NCT00416260|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2014-06-21|2006-12-26|2006-12-27|Estimate|||||||2014-06-21|2014-06-24|Estimate|July 2006||2006-07-31|June 2014|2014-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Combined High Frequency Oscillation and Tracheal Gas Insufflation for Severe Acute Respiratory Distress Syndrome|Phase 1/Phase 2, Single-Center, Controlled Study of the Effectiveness of Combined High Frequency Oscillation and Tracheal Gas Insufflation in Improving the Clinical Course of Patients With Severe Acute Respiratory Distress Syndrome|Completed||Phase 1/Phase 2|54|Actual|University of Athens||2|||f||||t||||||||||2018-06-01 03:32:32.190185|2018-06-01 03:32:32.190185
NCT00416247|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2010-08-04|2006-12-26|2006-12-27|Estimate|||||||2010-08-04|2010-08-05|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|June 2009|Actual|2009-06-30|December 2007|Actual|2007-12-31||Interventional|||Effect of Hypnosis on Motor Cortex Excitability|Effect of Hypnosis on Motor Cortex Excitability|Completed||N/A|20|Actual|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:32:32.568263|2018-06-01 03:32:32.568263
NCT00416234|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2010-01-13|2006-12-26|2006-12-27|Estimate|||||||2010-01-13|2010-01-14|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Laparoendoscopic Rendez Vous Versus Standard Two Stage Approach for the Management of Cholelithiasis/Choledocholithiasis|Laparoendoscopic Rendez Vous (Intraoperative ERCP) vs Two Stage Approach (Preoperative ERCP Followed by Laparoscopic Cholecystectomy) for the Management of Cholelithiasis/Choledocholithiasis|Unknown status|Recruiting|N/A|300|Anticipated|University of Thessaly||2|||f||||t||||||||||2018-06-01 03:32:33.584214|2018-06-01 03:32:33.584214
NCT00416221|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2011-08-17|2006-12-26|2006-12-27|Estimate|||||||2011-08-17|2011-08-18|Estimate|April 2006||2006-04-30|August 2011|2011-08-31|January 2007|Actual|2007-01-31|||||Interventional|||PACEPro - Mood Management Pilot|Development and a Pilot Study of the PACEPRO Exercise and Mood Management Program in Depressed Patients on Escitalopram Oxalate (Lexapro)|Completed||N/A|40|Actual|University of California, San Diego|||||f||||||||||||||2018-06-01 03:32:33.865311|2018-06-01 03:32:33.865311
NCT00416208|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2015-03-04|2006-12-22|2006-12-27|Estimate|||||||2015-03-04|2015-03-05|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma|Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75|Completed||Phase 3|154|Actual|Janssen-Cilag G.m.b.H||2|||f||||f||||||||||2018-06-01 03:32:34.007281|2018-06-01 03:32:34.007281
NCT00416195|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|2012-10-23||2014-06-26|2006-12-26|2006-12-27|Estimate|2012-10-23|2012-11-22|Estimate||||2014-06-26|2014-07-11|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures|Completed||Phase 2|48|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 03:32:35.692117|2018-06-01 03:32:35.692117
NCT00416182|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|2012-10-02||2014-11-12|2006-12-26|2006-12-27|Estimate|2014-11-12|2014-11-14|Estimate||||2014-11-12|2014-11-14|Estimate|December 2006||2006-12-31|November 2014|2014-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis|The Use of Nasally Delivered Pulmozyme in the Treatment of Sinusitis in Cystic Fibrosis Patients: A Pilot Study|Completed||Phase 2|16|Actual|University of Vermont|recruitment for a long trial was difficult so enrollment was truncated.|2|||f||||t||||||||||2018-06-01 03:32:36.04878|2018-06-01 03:32:36.04878
NCT00416169|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2011-06-06|2006-12-22|2006-12-27|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2003||2003-05-31|January 2011|2011-01-31|July 2004|Actual|2004-07-31|||||Interventional|||A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia|An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex|Completed||Phase 2|41|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 03:32:36.503652|2018-06-01 03:32:36.503652
NCT00416156|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-25|||2006-12-26|2006-12-26|2006-12-27|Estimate|||||||2006-12-26|2006-12-27|Estimate|May 2005||2005-05-31|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||Effect of Weight Reduction on Inflammatory Markers and Genes Expression in Obese Individuals||Completed||N/A|25||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 03:32:36.629315|2018-06-01 03:32:36.629315
NCT00416143|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-24|||2006-12-24|2006-12-24|2006-12-27|Estimate|||||||2006-12-24|2006-12-27|Estimate|June 2006||2006-06-30|December 2006|2006-12-31|December 2008||2008-12-31|||||Interventional|||Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss|Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss|Unknown status|Recruiting|Phase 2/Phase 3|60||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:32:36.758069|2018-06-01 03:32:36.758069
NCT00416130|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2013-12-08|2006-12-26|2006-12-27|Estimate|||||||2013-12-08|2013-12-10|Estimate|January 2007||2007-01-31|December 2013|2013-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Clinical Trial of SAHA in Patients With Breast Cancer|Phase I/II Clinical Trial of Vorinostat in Patients With Recurrent and/or Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|49|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-06-01 03:32:36.994764|2018-06-01 03:32:36.994764
NCT00416117|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2006-12-26|2006-12-26|2006-12-27|Estimate|||||||2006-12-26|2006-12-27|Estimate|July 2001||2001-07-31|December 2006|2006-12-31|June 2004||2004-06-30|||||Interventional|||Manual Physical Therapy and Exercise for Mechanical Neck Disorders|The Effectiveness of Manual Physical Therapy and Exercise for Mechanical Neck Disorders: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|100||Brooke Army Medical Center|||||f||||||||||||||2018-06-01 03:32:37.121953|2018-06-01 03:32:37.121953
NCT00416104|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2006-12-26|2006-12-26|2006-12-27|Estimate|||||||2006-12-26|2006-12-27|Estimate|December 2006||2006-12-31|July 2006|2006-07-31|February 2007||2007-02-28|||||Observational|||Postcesarean Section Pain: Possible Demographic and Medical Predictors|Postcesarean Section Pain: Possible Demographic and Medical Predictors|Unknown status|Not yet recruiting||600||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:32:37.211027|2018-06-01 03:32:37.211027
NCT00416091|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2012-11-12|2006-12-26|2006-12-27|Estimate|||||||2012-11-12|2012-11-14|Estimate|January 2007||2007-01-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|||||Observational|||Neuropsychological Functioning Among Children With Tourret's Disorder and ADHD|Neuropsychological Functioning, Symptomatology, and Social Adjustment Among Children With Tourret's Disorder, Attention-Deficit/Hyperactivity Disorder, and Comorbid Conditions.|Completed|||120|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 03:32:37.314909|2018-06-01 03:32:37.314909
NCT00416078|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|2014-12-16||2015-04-07|2006-12-26|2006-12-27|Estimate|2015-04-07|2015-04-29|Estimate||||2015-04-07|2015-04-29|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Online Caregiver Psychoeducation and Support for Alzheimer's|Caregiver Psychoeducation and Support: Improving Outcomes in AD/ADRD|Completed||Phase 2/Phase 3|53|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:32:37.417557|2018-06-01 03:32:37.417557
NCT00416065|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2006-12-26|2006-12-26|2006-12-27|Estimate|||||||2006-12-26|2006-12-27|Estimate|April 2004||2004-04-30|November 2006|2006-11-30||||||||Interventional|||"PET/CT to Identify Vulnerable Arterial Plaque"|"PET/CT to Identify Vulnerable Arterial Plaque"|Unknown status|Recruiting|N/A|800||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:32:38.122781|2018-06-01 03:32:38.122781
NCT00416052|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2011-05-18|2006-12-26|2006-12-27|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2004||2004-03-31|May 2011|2011-05-31|June 2006||2006-06-30|||||Observational|||Relation Between Bone Density and the Regulation of Mineral Metabolism in Renal Stone Formers|Relation Between Bone Mineral Density and the Regulation of Mineral Metabolism in Renal Stone Formers|Completed|||90||University Hospital Inselspital, Berne|||||f||||||||||||||2018-06-01 03:32:38.28002|2018-06-01 03:32:38.28002
NCT00416039|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2013-08-27|2006-12-26|2006-12-27|Estimate|||||||2013-08-27|2013-08-28|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|MIDAZODOL||Efficacy of Sublingual Midazolam in Association With Oral Morphine in Children Analgesia After Bone Fracture|Clinical Randomized Study of Sublingual Midazolam in Association With Morphine by Oral Route in Arm Fracture in Children at the Emergency Children Care|Completed||Phase 3|60|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:32:38.426366|2018-06-01 03:32:38.426366
NCT00416026|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2006-12-26|2006-12-26|2006-12-27|Estimate|||||||2006-12-26|2006-12-27|Estimate|January 2002||2002-01-31|December 2006|2006-12-31|October 2004||2004-10-31|||||Interventional|||Translating Research: Patient Decision Support/Coaching||Completed||N/A|304||Michigan State University|||||f||||||||||||||2018-06-01 03:32:38.542717|2018-06-01 03:32:38.542717
NCT00416013|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2010-10-06|2006-12-26|2006-12-27|Estimate|||||||2010-10-06|2010-10-07|Estimate|December 2005||2005-12-31|October 2010|2010-10-31|December 2010|Anticipated|2010-12-31|||||Observational|||Correlations Between BNP & Dry Weight, and Between Troponin & Mortality, in Hemodialysis Patients|Correlations Between BNP and Dry Weight, and Between Troponin and Mortality, in Hemodialysis Patients|Unknown status|Active, not recruiting||151|Actual|Eastern Virginia Medical School|||||f||||f||||||||||2018-06-01 03:32:38.66242|2018-06-01 03:32:38.66242
NCT00416000|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2014-05-20|2006-12-26|2006-12-27|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2006||2006-01-31|May 2014|2014-05-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Mechanism and Prevention of Remote Organ Injury Following Ruptured Aortic Aneurysm|Phase 1 Study of Complement Activation Following Ruptured Abdominal Aortic Aneurysm: Combining Human Observation With Animal Experimentation to Establish a Framework for Human Therapy|Completed|||24|Actual|University Health Network, Toronto|||||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 03:32:38.714371|2018-06-01 03:32:38.714371
NCT00415987|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2008-06-19|2006-12-26|2006-12-27|Estimate|||||||2008-06-19|2008-06-20|Estimate||||June 2008|2008-06-30|September 2006||2006-09-30|||||Interventional|||Hematopoietic Stem Cell Transplantation in Myeloma||Unknown status|Active, not recruiting|Phase 2/Phase 3|||Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-06-01 03:32:38.766137|2018-06-01 03:32:38.766137
NCT00415974|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-26|||2012-08-15|2006-12-26|2006-12-27|Estimate|||||||2012-08-15|2012-08-16|Estimate|February 2008||2008-02-29|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||PACE-PC: Primary Care Management of Adolescent Obesity|PACE-PC: Primary Care Management of Adolescent Obesity|Completed||N/A|106|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 03:32:38.894212|2018-06-01 03:32:38.894212
NCT00415948|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2009-12-17|2006-12-23|2006-12-25|Estimate|||||||2009-12-17|2009-12-18|Estimate|December 2006||2006-12-31|December 2009|2009-12-31|June 2008|Actual|2008-06-30|||||Observational|||Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement|Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement|Completed|||300|Anticipated|Biosite|||||f||||||||||Samples Without DNA|"~     Plasma Specimens~   "|||2018-06-01 03:32:39.047929|2018-06-01 03:32:39.047929
NCT00415935|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2006-12-23|2006-12-23|2006-12-25|Estimate|||||||2006-12-23|2006-12-25|Estimate||||December 2006|2006-12-31|December 2006||2006-12-31|||||Observational|||PRINTO (the Paediatric Rheumatology International Trials Organisation)||Unknown status|Recruiting||||Institute of Child Health|||||f||||||||||||||2018-06-01 03:32:39.127716|2018-06-01 03:32:39.127716
NCT00415922|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2007-06-21|2006-12-23|2006-12-25|Estimate|||||||2007-06-21|2007-06-22|Estimate|July 2006||2006-07-31|June 2007|2007-06-30||||||||Interventional|||Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 37.5 mg Carbidopa, 150 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 37.5 mg Carbidopa and 150 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions|Completed||Phase 1|42||Novartis|||||f||||||||||||||2018-06-01 03:32:39.184077|2018-06-01 03:32:39.184077
NCT00415909|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|2014-05-29||2014-05-29|2006-12-23|2006-12-25|Estimate|2014-05-29|2014-06-30|Estimate||||2014-05-29|2014-06-30|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Two participants withdrew from the study, and one died of a second, unrelated malignancy.|TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients|"Phase II Proof of Concept Study of TALL-104 (MHC Non-Restricted Cytotoxic T-Cell Line) and Imatinib Mesylate (Gleevec) in Chronic Myelogenous Leukemia in Chronic Phase"|Terminated||Phase 2|3|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-06-01 03:32:39.249412|2018-06-01 03:32:39.249412
NCT00415896|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2006-12-22|2006-12-22|2006-12-25|Estimate|||||||2006-12-22|2006-12-25|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|June 2007||2007-06-30|||||Interventional|||Impact of Respiratory Muscle Unloading on Respiratory Muscle Endurance|Impact of Respiratory Muscle Unloading on Respiratory Muscle Endurance|Unknown status|Recruiting|N/A|10||Krankenhaus Kloster Grafschaft|||||f||||||||||||||2018-06-01 03:32:39.444116|2018-06-01 03:32:39.444116
NCT00415883|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2007-06-21|2006-12-22|2006-12-25|Estimate|||||||2007-06-21|2007-06-22|Estimate|July 2006||2006-07-31|June 2007|2007-06-30||||||||Interventional|||To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers|An Open-Label, Randomized, Single Dose, Two Period, Crossover Study to Determine the Relative Bioavailability of Valsartan 160 mg Japanese Formulation and Valsartan 160 mg Global Formulation in Healthy Adult Volunteers|Completed||Phase 1|40||Novartis|||||f||||f||||||||||2018-06-01 03:32:39.528505|2018-06-01 03:32:39.528505
NCT00415870|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|2013-06-20||2017-11-15|2006-12-23|2006-12-25|Estimate|2013-06-20|2013-09-04|Estimate||||2017-11-15|2017-12-13|Actual|June 2007||2007-06-30|November 2017|2017-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||mDiet - Ecological Momentary Intervention of Diet Via Mobile Technology|Ecological Momentary Intervention of Diet Via Mobile Technology|Completed||N/A|65|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 03:32:39.589273|2018-06-01 03:32:39.589273
NCT00415857|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|2014-03-28||2014-03-28|2006-12-23|2006-12-25|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|December 2006||2006-12-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)|Potential of Immunotherapy to Convert a Complete Cytogenetic Remission in Chronic Myelogenous Leukemia to a Molecular Complete Remission: Randomized Phase II Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and Peginterferon Alfa-2b [PEG-INTRON(R), Schering Corporation]|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center||2||Vaccine sponsor ceased operations.|f||||t||||||||||2018-06-01 03:32:39.832313|2018-06-01 03:32:39.832313
NCT00415844|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2007-06-21|2006-12-23|2006-12-25|Estimate|||||||2007-06-21|2007-06-22|Estimate|June 2006||2006-06-30|June 2007|2007-06-30||||||||Interventional|||Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 25 mg Carbidopa, 100 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 25 mg Carbidopa and 100 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions|Completed||Phase 1|42||Novartis|||||f||||||||||||||2018-06-01 03:32:40.031006|2018-06-01 03:32:40.031006
NCT00415831|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2007-06-21|2006-12-23|2006-12-25|Estimate|||||||2007-06-21|2007-06-22|Estimate|June 2006||2006-06-30|June 2007|2007-06-30||||||||Interventional|||Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 12.5 mg Carbidopa, 50 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 12.5 mg Carbidopa and 50 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fed Conditions|Completed||Phase 1|42||Novartis|||||f||||||||||||||2018-06-01 03:32:40.1852|2018-06-01 03:32:40.1852
NCT00415818|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2014-07-15|2006-12-23|2006-12-25|Estimate|||||||2014-07-15|2014-07-16|Estimate|December 2005||2005-12-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer|A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010(MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer|Completed||Phase 2/Phase 3|148|Actual|Transgene||2|||f||||||||||||||2018-06-01 03:32:40.244735|2018-06-01 03:32:40.244735
NCT00415805|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2009-03-12|2006-12-23|2006-12-25|Estimate|||||||2009-03-12|2009-03-13|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent|A Pilot, Open-Label, Multicenter Intra-Individual Comparison of Multihance and Vasovist for Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) of Renal Arteries|Completed||Phase 3|39|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-06-01 03:32:40.336257|2018-06-01 03:32:40.336257
NCT00415792|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2007-01-04|2006-12-23|2006-12-25|Estimate|||||||2007-01-04|2007-01-05|Estimate|November 2003||2003-11-30|January 2007|2007-01-31|July 2005||2005-07-31|||||Interventional|||Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs|Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients|Unknown status|Active, not recruiting|Phase 4|60||Eugonia|||||f||||||||||||||2018-06-01 03:32:40.412806|2018-06-01 03:32:40.412806
NCT00415779|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2010-02-23|2006-12-22|2006-12-25|Estimate|||||||2010-02-23|2010-02-24|Estimate|July 2006||2006-07-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|ZANTE||ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer|Phase I Study of the Combination of Zoledronic Acid and Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer|Completed||Phase 1|36|Anticipated|National Cancer Institute, Naples|||||f||||f||||||||||2018-06-01 03:32:40.561614|2018-06-01 03:32:40.561614
NCT00415766|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2016-01-18|2006-12-23|2006-12-25|Estimate|||||||2016-01-18|2016-01-20|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders|Recombinant hCG (Ovitrelle) Vesrus Urinary hCG (Pregnyl) for Triggering Final Oocyte Maturation in High Responders|Unknown status|Active, not recruiting|Phase 4|150|Actual|Eugonia||3|||f||||f||||||||||2018-06-01 03:32:40.634773|2018-06-01 03:32:40.634773
NCT00415753|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2008-05-22|2006-12-22|2006-12-25|Estimate|||||||2008-05-22|2008-05-23|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Procalcitonin as a Marker of Bacterial Pneumonia||Completed||N/A|223|Actual|Aarhus University Hospital Skejby|||||f||||f||||||||||2018-06-01 03:32:40.723844|2018-06-01 03:32:40.723844
NCT00415740|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2007-06-21|2006-12-23|2006-12-25|Estimate|||||||2007-06-21|2007-06-22|Estimate|May 2006||2006-05-31|June 2007|2007-06-30||||||||Interventional|||Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers|A Randomized, Two-Way Crossover Study to Investigate the Bioavailability of a Single Oral Dose of 12.5 mg Carbidopa, 50 mg Levodopa and 200 mg Entacapone Compared to a Single Oral Combined Dose of Both 12.5 mg Carbidopa and 50 mg Levodopa and 200 mg Entacapone in Healthy Volunteers Under Fasting Conditions|Completed||Phase 1|42||Novartis|||||f||||||||||||||2018-06-01 03:32:40.784413|2018-06-01 03:32:40.784413
NCT00415727|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2006-12-23|2006-12-23|2006-12-25|Estimate|||||||2006-12-23|2006-12-25|Estimate|November 2006||2006-11-30|December 2006|2006-12-31||||||||Interventional|||Prevention Of Morbidity In Sickle Cell Disease Pilot Phase||Unknown status|Recruiting|Phase 2|22||Institute of Child Health|||||f||||||||||||||2018-06-01 03:32:40.862381|2018-06-01 03:32:40.862381
NCT00415714|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2007-01-26|2006-12-22|2006-12-25|Estimate|||||||2007-01-26|2007-01-29|Estimate|September 2006||2006-09-30|December 2006|2006-12-31|October 2007||2007-10-31|||||Interventional|||Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia|A Randomized Controlled Pilot Trial Testing the Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia|Unknown status|Recruiting|N/A|132||Helicor|||||f||||||||||||||2018-06-01 03:32:40.94105|2018-06-01 03:32:40.94105
NCT00415701|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2010-03-03|2006-12-22|2006-12-25|Estimate|||||||2010-03-03|2010-03-04|Estimate|November 2006||2006-11-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery|Effect of an Anesthetic Induction Dose of Etomidate on Hemodynamics and Adrenocortical Function After Cardiac Surgery|Completed||Phase 4|130|Anticipated|University Hospital Inselspital, Berne||3|||f||||f||||||||||2018-06-01 03:32:41.018147|2018-06-01 03:32:41.018147
NCT00415688|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2006-12-21|2006-12-21|2006-12-25|Estimate|||||||2006-12-21|2006-12-25|Estimate|July 2004||2004-07-31|December 2006|2006-12-31|January 2006||2006-01-31|||||Interventional|||Lifestyle Modification for Obesity-Related Type 2 Diabetes|A Randomized, Controlled Trial of a Low-Carbohydrate, Ketogenic Diet Versus a Low-Glycemic Index Diet for Obesity-Related Type 2 Diabetes|Completed||Phase 4|90||Robert C. Atkins Foundation|||||f||||||||||||||2018-06-01 03:32:41.157574|2018-06-01 03:32:41.157574
NCT00415675|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2012-10-22|2006-12-22|2006-12-25|Estimate|||||||2012-10-22|2012-10-23|Estimate|November 2004||2004-11-30|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Observational|||Respiratory Tumor and Normal Tissue Motion|Assessing the Magnitude and Potential Impact of Respiration-Induced Three-Dimensional Motion of Tumors and Normal Tissues Using Four-Dimensional CT Technology|Completed|||86|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:32:41.223072|2018-06-01 03:32:41.223072
NCT00415662|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2006-12-22|2006-12-22|2006-12-25|Estimate|||||||2006-12-22|2006-12-25|Estimate|June 2002||2002-06-30|December 2006|2006-12-31|June 2006||2006-06-30|||||Interventional|||Effect of Biomagnetic Therapy on Gonarthrosis||Terminated||N/A|||University of Lausanne Hospitals|||||f||||||||||||||2018-06-01 03:32:41.307896|2018-06-01 03:32:41.307896
NCT00415649|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2012-03-20|2006-12-21|2006-12-25|Estimate|||||||2012-03-20|2012-03-21|Estimate||||March 2012|2012-03-31||||||||Interventional|||Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults|A Phase II, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine in Healthy Adult Volunteers at Risk for HIV Infection|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:32:41.370109|2018-06-01 03:32:41.370109
NCT00415636|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2010-08-30|2006-12-21|2006-12-25|Estimate|||||||2010-08-30|2010-08-31|Estimate|December 2006||2006-12-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer|A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer|Completed||Phase 1|31|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 03:32:41.454986|2018-06-01 03:32:41.454986
NCT00415623|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2008-10-16||2008-12-05|2006-12-22|2006-12-25|Estimate|2008-12-05|2008-12-09|Estimate||||2008-12-05|2008-12-09|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient|A Double-Blind, Comparative Study Between Amlodipine 5mg And 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective|Completed||Phase 3|305|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:32:41.572729|2018-06-01 03:32:41.572729
NCT00415610|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2015-03-03||2017-11-17|2006-12-21|2006-12-25|Estimate|2015-08-10|2015-09-07|Estimate||||2017-11-17|2017-11-21|Actual|July 2005||2005-07-31|November 2017|2017-11-30|March 2008|Actual|2008-03-31|September 2007|Actual|2007-09-30||Interventional|ATACH|Group numbers were adjusted as adequate safety parameters were met in each successive treatment tier. A larger number of subjects were therefore evaluated in the final tier where safety is of greatest concern and SBP parameter is also of greatest challenge to meet.|Antihypertensive Treatment in Acute Cerebral Hemorrhage|Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)|Completed||Phase 1|60|Actual|University of Minnesota - Clinical and Translational Science Institute|Limited by small sample size and likelihood of imbalances in subject characteristics among the three tiers. Clinical measures may be insensitive. Not designed to provide comparative event rates and not powered toward prediction of clinical outcomes.|3|||f||||t||||||||Undecided|consult investigator for options|2018-06-01 03:32:42.024603|2018-06-01 03:32:42.024603
NCT00415597|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2009-09-11|2009-03-09|2013-09-13|2006-12-21|2006-12-25|Estimate|2009-10-28|2009-10-29|Estimate|2009-10-28|2009-10-29|Estimate|2013-09-13|2013-09-20|Estimate|December 2006||2006-12-31|September 2013|2013-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain|A Long-Term, Open-Label Safety Study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Chronic Moderate to Severe Nonmalignant Pain|Completed||Phase 3|467|Actual|Pfizer||1|||f||||||||||||||2018-06-01 03:32:42.650186|2018-06-01 03:32:42.650186
NCT00415584|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2009-11-03|2006-12-21|2006-12-25|Estimate|||||||2009-11-03|2009-11-05|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|November 2009||2009-11-30|||||Interventional|||Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients|Cinacalcet for Treatment of Persistent Secondary Hyperparathyroidism in Renal Transplant Recipients: Effect on Renal Function, Serum Calcium and Bone Histomorphometry|Withdrawn||N/A|18|Anticipated|Montefiore Medical Center||||low enrollment|f||||||||||||||2018-06-01 03:32:43.040059|2018-06-01 03:32:43.040059
NCT00415571|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2010-02-02|2006-12-22|2006-12-25|Estimate|||||||2010-02-02|2010-02-03|Estimate|December 2006||2006-12-31|February 2010|2010-02-28|August 2008|Actual|2008-08-31|||||Interventional|||Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors|Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 2|72|Anticipated|QuatRx Pharmaceuticals Company|||||f||||||||||||||2018-06-01 03:32:43.116877|2018-06-01 03:32:43.116877
NCT00415558|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2009-06-05|2006-12-20|2006-12-25|Estimate|||||||2009-06-05|2009-06-09|Estimate|May 2007||2007-05-31|June 2009|2009-06-30||||||||Interventional|||Prospective Clinical Study of the Guidant Microwave Ablation System for the Treatment of PAF in the MIS Procedure|Prospective, Multicenter, Un-Blinded, Single Arm, Clinical Study Using the Guidant Microwave Ablation System Comprised of the Flex 10 Ablation Probe and Microwave Generator for Patients With Symptomatic Paroxysmal Atrial Fibrillation|Terminated||N/A|||Maquet Cardiovascular||||Low enrollment|f||||||||||||||2018-06-01 03:32:43.183301|2018-06-01 03:32:43.183301
NCT00415545|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2013-06-06|2006-12-21|2006-12-25|Estimate|||||||2013-06-06|2013-06-07|Estimate|January 2007||2007-01-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|REMOTE-HF||Educational Program to Improve Heart Failure Outcomes in Adults Living in Rural Areas|Improving Self Care Behavior and Outcomes in Rural Patients With Heart Failure|Completed||Phase 3|614|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-06-01 03:32:43.241419|2018-06-01 03:32:43.241419
NCT00415532|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2010-10-01||2014-07-18|2006-12-21|2006-12-25|Estimate|2013-05-31|2013-07-08|Estimate||||2014-07-18|2014-07-25|Estimate|December 2006||2006-12-31|July 2014|2014-07-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura|A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura|Completed||Phase 3|234|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:32:43.331809|2018-06-01 03:32:43.331809
NCT00415519|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|2017-09-06||2017-11-20|2006-12-22|2006-12-25|Estimate|2017-11-20|2017-12-20|Actual||||2017-11-20|2017-12-20|Actual|December 2006||2006-12-31|November 2017|2017-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III|An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner|Completed||Phase 3|25|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 03:32:44.287434|2018-06-01 03:32:44.287434
NCT00415506|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2013-05-20||2013-08-08|2006-12-21|2006-12-25|Estimate|2013-05-20|2013-08-08|Estimate||||2013-08-08|2013-08-16|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation|A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation|Completed||Phase 1/Phase 2|20|Actual|Oregon Health and Science University||2|||f||||||||||||||2018-06-01 03:32:44.842666|2018-06-01 03:32:44.842666
NCT00415493|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2012-07-20||2017-01-23|2006-12-22|2006-12-25|Estimate|2012-09-26|2012-10-26|Estimate||||2017-01-23|2017-03-06|Actual|December 2006||2006-12-31|January 2017|2017-01-31|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation|Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation|Completed||N/A|24|Actual|Associated Scientists to Help Minimize Allergies||2|||f||||f||||||||No||2018-06-01 03:32:45.061486|2018-06-01 03:32:45.061486
NCT00415467|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-22|||2012-08-01|2006-12-22|2006-12-25|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2005||2005-01-31|August 2012|2012-08-31|July 2008|Actual|2008-07-31|November 2007|Actual|2007-11-30||Interventional|||Treatment of Resectable Malignant Brain Tumors|Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors|Terminated||Phase 4|13|Actual|M.D. Anderson Cancer Center||1||Sponsor decision to terminate study.|f||||f||||||||||2018-06-01 03:32:45.262567|2018-06-01 03:32:45.262567
NCT00415454|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2011-06-21|2006-12-21|2006-12-25|Estimate|||||||2011-06-21|2011-06-23|Estimate|November 2006||2006-11-30|June 2011|2011-06-30||||||||Interventional|||Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma|Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Chemoradiotherapy for the Treatment of Non-Metastatic Pancreatic Adenocarcinoma|Terminated||Phase 1|8|Actual|Henry Ford Health System||1||Poor enrollment|f||||t||||||||||2018-06-01 03:32:45.326742|2018-06-01 03:32:45.326742
NCT00415441|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2013-01-15|2006-12-21|2006-12-22|Estimate|||||||2013-01-15|2013-01-17|Estimate|March 2004||2004-03-31|January 2013|2013-01-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Effectiveness of Physiotherapy for Chronic Shoulder Pain|Efficacy and Cost-effectiveness of Physiotherapy for Chronic Rotator Cuff Pathology|Completed||Phase 3|120|Actual|University of Melbourne||2|||f||||f||||||||||2018-06-01 03:32:45.400843|2018-06-01 03:32:45.400843
NCT00415428|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2015-04-21|2006-12-20|2006-12-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||A Quality Ensuring Project With Focus On Patients With Cardiovascular Diseases As Well As Type 2 Diabetes.|Patient And Physician Alliance -Guideline Education Treatment Optimization|Completed|||2776|Actual|Pfizer|||1||f||||||||||||||2018-06-01 03:32:45.503165|2018-06-01 03:32:45.503165
NCT00415415|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2016-07-28|2006-12-20|2006-12-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2000||2000-09-30|December 2006|2006-12-31|March 2004|Actual|2004-03-31|||||Observational|||Factors Associated With Coronary Heart Disease in African Americans in the Jackson Heart Study|Disparities in CHD in the Jackson Heart Study|Completed|||5302||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:32:45.561875|2018-06-01 03:32:45.561875
NCT00415402|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2012-08-21|2006-12-21|2006-12-22|Estimate|||||||2012-08-21|2012-08-22|Estimate|March 2007||2007-03-31|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|DIVIDS||Effect of Vitamin D Supplementation on Health of Low Birth Weight Infants|Randomised Controlled Trial to Evaluate the Preventive Effect on Mortality and Serious Morbidity/ Hospitalisations of Daily Vitamin D Supplements in Small for Gestational Age Term Infants|Completed||N/A|2000|Actual|Delhi University||2|||f||||t||||||||||2018-06-01 03:32:45.616167|2018-06-01 03:32:45.616167
NCT00415389|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2013-02-15|2006-12-21|2006-12-22|Estimate|||||||2013-02-15|2013-02-18|Estimate|February 2005||2005-02-28|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Stroke Warning Information and Faster Treatment Study (SWIFT)|The Stroke Warning Information and Faster Treatment Study (SWIFT)|Terminated||Phase 2|1635|Actual|Columbia University||2||Approval lapse|f||||f||||||||||2018-06-01 03:32:45.71044|2018-06-01 03:32:45.71044
NCT00415376|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2012-05-17|2006-12-20|2006-12-22|Estimate|||||||2012-05-17|2012-05-18|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|July 2007||2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases|A Pilot Study of the Efficacy of Levetiracetam in Patients With Seizures From Brain Metastases|Withdrawn||N/A|0|Actual|Northwestern University||||Unable to accrue subjects|f||||||||||||||2018-06-01 03:32:45.853067|2018-06-01 03:32:45.853067
NCT00415363|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20||2011-04-05|2011-04-05|2006-12-20|2006-12-22|Estimate||||2011-04-05|2011-04-13|Estimate|2011-04-05|2011-04-13|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy|A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer|Completed||Phase 2|107|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:32:45.93282|2018-06-01 03:32:45.93282
NCT00415350|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2010-03-16|2006-12-21|2006-12-22|Estimate|||||||2010-03-16|2010-03-17|Estimate|April 2008||2008-04-30|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|BAT||Bronchiectasis and Long Term Azithromycin Treatment|Bronchiectasis and Long Term Azithromycin Treatment: A Randomised Placebo-controlled Trial Studying Disease Modifying Effects of Immunomodulating Treatment|Unknown status|Active, not recruiting|Phase 3|72|Anticipated|Medical Center Alkmaar||2|||f||||f||||||||||2018-06-01 03:32:46.06192|2018-06-01 03:32:46.06192
NCT00415337|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2011-12-13|2006-12-21|2006-12-22|Estimate|||||||2011-12-13|2011-12-14|Estimate|April 2007||2007-04-30|December 2011|2011-12-31||||||||Observational|||Endobronchial Ultrasound Guided Transbronchial Lung Biopsy With or Without Guide Sheath in Lung Tumors and the Analysis of Echoic Patterns of Lung Tumors and Mediastinal Lymph Nodes, and the Association Between Diagnostic Yield of Transbronchial Lung Biopsy and EBUS Echoic Features.||Unknown status|Active, not recruiting||200|Anticipated|Chang Gung Memorial Hospital|||||f||||||||||||||2018-06-01 03:32:47.06718|2018-06-01 03:32:47.06718
NCT00415324|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2014-05-19|2006-12-20|2006-12-22|Estimate|||||||2014-05-19|2014-05-20|Estimate|December 2006||2006-12-31|April 2014|2014-04-30||||May 2014|Actual|2014-05-31||Interventional|||Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of Halichondrin B Analog (E7389) in Combination With Cisplatin in Advanced Solid Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:32:47.153522|2018-06-01 03:32:47.153522
NCT00415311|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2011-08-08|2006-12-20|2006-12-22|Estimate|||||||2011-08-08|2011-08-09|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.|A Multicenter, Open-Label, Randomized, Phase 1B Study Evaluating the Safety and Tolerability of Intravenous Recombinant Human Mannose‑Binding Lectin (rhMBL) in Liver Transplant Recipients|Terminated||Phase 1|24|Actual|Enzon Pharmaceuticals, Inc.||3||Sponsor decision to terminate the study|f||||t||||||||||2018-06-01 03:32:47.368815|2018-06-01 03:32:47.368815
NCT00415298|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2014-01-09|2006-12-20|2006-12-22|Estimate|||||||2014-01-09|2014-01-10|Estimate|May 2006||2006-05-31|May 2007|2007-05-31||||||||Interventional|||AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer|AP5346 for Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck: A Pilot Study With Clinical and Biological Endpoints|Unknown status|Active, not recruiting|N/A|12|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:32:47.474158|2018-06-01 03:32:47.474158
NCT00415285|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2007-02-12|2006-12-20|2006-12-22|Estimate|||||||2007-02-12|2007-02-13|Estimate|December 2006||2006-12-31|February 2007|2007-02-28||||||||Interventional|||Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer|Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer|Unknown status|Recruiting|Phase 2|100||Georgia Center for Oncology Research & Education|||||f||||||||||||||2018-06-01 03:32:47.583413|2018-06-01 03:32:47.583413
NCT00415272|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2008-01-11|2006-12-21|2006-12-22|Estimate|||||||2008-01-11|2008-01-15|Estimate||||January 2008|2008-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease||Terminated||N/A|||University of California, San Francisco||||Inadequate enrollment.|f||||||||||||||2018-06-01 03:32:47.69302|2018-06-01 03:32:47.69302
NCT00415259|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2013-01-15|2006-12-21|2006-12-22|Estimate|||||||2013-01-15|2013-01-17|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Shoes Insoles on Symptoms and Disease Progression in Knee Osteoarthritis|Effects of Shoes Insoles on Symptoms and Disease Progression in Knee Osteoarthritis|Completed||N/A|200|Actual|University of Melbourne||2|||f||||t||||||||||2018-06-01 03:32:47.937499|2018-06-01 03:32:47.937499
NCT00415246|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2007-11-15|2006-12-21|2006-12-22|Estimate|||||||2007-11-15|2007-11-16|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer|A Phase III, Single Arm, Multicentre Study to Evaluate the Efficacy and Safety of a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin, a Gonadotrophin Releasing Hormone Analogue in Patients With Prostate Cancer|Terminated||Phase 3|100|Anticipated|Ipsen||||"The preliminary data do not support the expected sustainable blood levels of triptorelin for a~   duration of 4 months in all patients."|f||||||||||||||2018-06-01 03:32:48.204779|2018-06-01 03:32:48.204779
NCT00415064|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2012-07-03|2006-12-20|2006-12-22|Estimate|||||||2012-07-03|2012-07-06|Estimate|December 2006||2006-12-31|November 2011|2011-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma|An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|32|Actual|AEterna Zentaris|||||f||||f||||||||||2018-06-01 03:32:51.560306|2018-06-01 03:32:51.560306
NCT00415233|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2017-10-10|2006-12-20|2006-12-22|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2006||2006-11-30|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|June 2011|Actual|2011-06-30||Interventional|HiLo||Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer|Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO]|Active, not recruiting||Phase 3|438|Actual|University College, London||4|||f||||t||||||||||2018-06-01 03:32:48.354811|2018-06-01 03:32:48.354811
NCT00415220|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2006-12-21|2006-12-21|2006-12-22|Estimate|||||||2006-12-21|2006-12-22|Estimate|January 2000||2000-01-31|December 2006|2006-12-31|May 2004||2004-05-31|||||Interventional|||Manipulation or Microdiscectomy For Sciatica? A Prospective Randomized Controlled Trial.|Comparison of Treatment Outcomes Between Chiropractic and Back Surgery for the Treatment of Sciatica Secondary to Lumbar Herniated Disc: A Prospective Randomized Controlled Trial.|Completed||Phase 2|40||McMorland, Gordon, D.C.|||||f||||||||||||||2018-06-01 03:32:48.516831|2018-06-01 03:32:48.516831
NCT00415207|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2011-08-04|2006-12-21|2006-12-22|Estimate|||||||2011-08-04|2011-08-08|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|December 2010|Actual|2010-12-31|August 2008|Actual|2008-08-31||Observational|||Pharmacogenomics of Paclitaxel in Ovarian Cancer|Pharmacogenomics of Paclitaxel in Ovarian Cancer: Predictors of Toxicity and Response|Completed|||300|Anticipated|University of Southern Denmark|||||f||||||||||Samples With DNA|"~     paraffin embedded biopsies~   "|||2018-06-01 03:32:48.653693|2018-06-01 03:32:48.653693
NCT00415194|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2011-03-10||2011-06-23|2006-12-21|2006-12-22|Estimate|2011-03-10|2011-04-06|Estimate||||2011-06-23|2011-06-28|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study for Patients With Head and Neck Cancer|A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer|Completed||Phase 3|795|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:32:48.838107|2018-06-01 03:32:48.838107
NCT00415181|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2015-01-12|2006-12-21|2006-12-22|Estimate|||||||2015-01-12|2015-01-13|Estimate|September 2006||2006-09-30|December 2006|2006-12-31|March 2013|Actual|2013-03-31|January 2009|Actual|2009-01-31||Observational|||Pharmacogenomics of Paclitaxel in Ovarian Cancer|The Pharmacogenomics of Paclitaxel in Patients With Ovarian Cancer: Predictors of Toxicity and Response|Completed|||93|Actual|University of Southern Denmark|||||f||||||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:32:50.588824|2018-06-01 03:32:50.588824
NCT00415168|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2010-07-13||2010-08-11|2006-12-20|2006-12-22|Estimate|2010-07-13|2010-08-10|Estimate||||2010-08-11|2010-08-17|Estimate|December 2006||2006-12-31|August 2010|2010-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer|Phase 2 Study of ALIMTA® (Pemetrexed) Plus Cisplatin as First-Line Treatment of Gastric Cancer|Completed||Phase 2|53|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:32:50.674629|2018-06-01 03:32:50.674629
NCT00415155|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2008-08-27|2006-12-20|2006-12-22|Estimate|||||||2008-08-27|2008-08-29|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma|An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma|Withdrawn||Phase 1/Phase 2|60|Anticipated|Eli Lilly and Company||1||Trial cancelled|f||||||||||||||2018-06-01 03:32:50.928212|2018-06-01 03:32:50.928212
NCT00415142|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21||2016-04-25|2016-04-25|2006-12-21|2006-12-22|Estimate||||2016-04-25|2016-05-24|Estimate|2016-04-25|2016-05-24|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder|An Eight-week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients With Major Depressive Disorder|Completed||Phase 3|393|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 03:32:51.001985|2018-06-01 03:32:51.001985
NCT00415129|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2014-01-10|2006-12-21|2006-12-22|Estimate|||||||2014-01-10|2014-01-14|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly||Completed||Phase 2|600|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:32:51.172768|2018-06-01 03:32:51.172768
NCT00415116|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2011-07-06|2006-12-21|2006-12-22|Estimate|||||||2011-07-06|2011-07-08|Estimate|August 2004||2004-08-31|November 2006|2006-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors|Phase I Trial of Three-Weekly Docetaxel, Carboplatin and Oral CC-5013 in Patients With Advanced Solid Tumors|Completed||Phase 1|14|Actual|The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:32:51.245548|2018-06-01 03:32:51.245548
NCT00415103|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2009-09-17|2006-12-21|2006-12-22|Estimate|||||||2009-09-17|2009-09-18|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|AMENO-2||AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors|AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors|Completed||Phase 4|196|Anticipated|PETHEMA Foundation||2|||f||||t||||||||||2018-06-01 03:32:51.305731|2018-06-01 03:32:51.305731
NCT00415090|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2008-10-30|2006-12-21|2006-12-22|Estimate|||||||2008-10-30|2008-10-31|Estimate|August 2004||2004-08-31|October 2008|2008-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study to Evaluate the Replacement of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors by Nevirapine in Patients on Triple Treatment With Analogues Only|Substitution by Nevirapine in HIV-1 Infected Patients on Triple Treatment of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors|Completed||Phase 4|28|Actual|Hospital de Calella||2|||f||||f||||||||||2018-06-01 03:32:51.405348|2018-06-01 03:32:51.405348
NCT00415077|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2010-07-15|2006-12-21|2006-12-22|Estimate|||||||2010-07-15|2010-07-16|Estimate|June 2004||2004-06-30|July 2010|2010-07-31||||||||Interventional|||A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia|A Prospective Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia|Terminated||N/A|960|Anticipated|Walter Reed Army Medical Center||3||Change in excimer laser systems prior to completion of study|f||||||||||||||2018-06-01 03:32:51.495805|2018-06-01 03:32:51.495805
NCT00415051|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2016-12-06|2015-06-08|2017-04-14|2006-12-21|2006-12-22|Estimate|2016-12-06|2017-02-01|Estimate|2015-06-08|2015-07-07|Estimate|2017-04-14|2017-05-19|Actual|August 2006||2006-08-31|April 2017|2017-04-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|MP-12||Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine|Safety and Immunogenicity of Live-Attenuated MP-12 Rift Valley Fever Vaccine in Humans, and Genetic Characterization of Virus Isolates Recovered From the Blood of Vaccinated Volunteers: A Phase II Study|Completed||Phase 2|20|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||Undecided||2018-06-01 03:32:51.64545|2018-06-01 03:32:51.64545
NCT00415038|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2011-06-16|2006-12-21|2006-12-22|Estimate|||||||2011-06-16|2011-06-17|Estimate|February 2005||2005-02-28|June 2011|2011-06-30|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Efficacy of Rostafuroxin in the Treatment of Essential Hypertension|A Double Blind, Dose Range, Placebo Controlled Study of the Effects of Rostafuroxin vs Placebo in Patients With Stable, Uncomplicated, Essential Hypertension.|Completed||Phase 2|438|Actual|sigma-tau i.f.r. S.p.A.||5|||f||||t||||||||||2018-06-01 03:32:51.963516|2018-06-01 03:32:51.963516
NCT00415025|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2015-10-15|2006-12-21|2006-12-22|Estimate|||||||2015-10-15|2015-10-16|Estimate|June 2004||2004-06-30|October 2015|2015-10-31|July 2007|Actual|2007-07-31|||||Observational|||Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer|Evaluation of Normal Tissue Toxicities in Head and Neck Cancer Patients Receiving Intensity Modulated Radiotherapy (IMRT)|Completed|||20|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 03:32:52.047404|2018-06-01 03:32:52.047404
NCT00414999|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2007-07-27|2006-12-20|2006-12-22|Estimate|||||||2007-07-27|2007-07-30|Estimate|November 2006||2006-11-30|July 2007|2007-07-31|February 2007|Actual|2007-02-28|||||Interventional|||A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers|A Phase 1, Double-Masked, Placebo-Controlled, Dose-Escalation Study (in Two Parts) of TG100801 and a Colored Vehicle in Adult Healthy Volunteers|Completed||Phase 1|44|Actual|TargeGen|||||f||||||||||||||2018-06-01 03:32:52.220245|2018-06-01 03:32:52.220245
NCT00414986|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2012-11-21|2006-12-21|2006-12-22|Estimate|||||||2012-11-21|2012-11-22|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ULTRA-DM/MDD||Using Learning Teams for Reflective Adaptation for Diabetes and Depression|Using Learning Teams for Reflective Adaptation|Completed||N/A|1565|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-06-01 03:32:52.280014|2018-06-01 03:32:52.280014
NCT00414973|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2009-07-16||2009-10-22|2006-12-20|2006-12-22|Estimate|2009-07-16|2009-08-26|Estimate||||2009-10-22|2009-10-28|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study for Patients With Osteoporosis|Comparison of Teriparatide and Calcitonin in the Treatment of Men and Postmenopausal Women With Osteoporosis|Completed||Phase 3|364|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:32:52.377791|2018-06-01 03:32:52.377791
NCT00414960|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21||2011-02-25|2011-02-25|2006-12-21|2006-12-22|Estimate||||2011-02-25|2011-03-11|Estimate|2011-02-25|2011-03-11|Estimate|November 2006||2006-11-30|October 2010|2010-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers|Phase IIB Randomized, Placebo-Controlled, Double-Blind Study of Enzastaurin HCL (LY317615) for Lung Cancer Prevention in Former Smokers|Completed||Phase 2|39|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:32:52.926911|2018-06-01 03:32:52.926911
NCT00414947|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2007-06-21|2006-12-21|2006-12-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|December 2006||2006-12-31|June 2007|2007-06-30||||||||Interventional|||Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers|A Single Center, Randomized, Open-Label, Crossover, Single Oral Dose Study to Assess the Bioequivalence of LAF237 Tablet Manufactured by Beijing Novartis Pharma Ltd. to Imported LAF237 Tablet in Chinese Healthy Subjects|Completed||Phase 1|30||Novartis|||||f||||||||||||||2018-06-01 03:32:53.000827|2018-06-01 03:32:53.000827
NCT00414934|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2009-08-13|2006-12-21|2006-12-22|Estimate|||||||2009-08-13|2009-08-17|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer.|The Effectiveness of Whole-body 18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer: A Comparison Study With 99mTc-MDP Bone Scintigraphy.|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-06-01 03:32:53.072575|2018-06-01 03:32:53.072575
NCT00414921|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2009-05-20|2006-12-21|2006-12-22|Estimate|||||||2009-05-20|2009-05-21|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|kiddie-CAT||Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)|Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)|Completed||Phase 2|30|Actual|University of Cincinnati||4|||f||||t||||||||||2018-06-01 03:32:53.14877|2018-06-01 03:32:53.14877
NCT00414908|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2009-08-07||2011-08-08|2006-12-21|2006-12-22|Estimate|2009-08-07|2009-09-16|Estimate||||2011-08-08|2011-08-10|Estimate|October 2007||2007-10-31|August 2011|2011-08-31|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional|||A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy|A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy|Completed||Phase 3|52|Actual|Solvay Pharmaceuticals|Only treatment emergent events have been presented. They are defined as events started at or after the 1st administration of study medication and includes events started prior to the 1st administration but which worsened after the 1st intake.|2|||f||||||||||||||2018-06-01 03:32:53.258721|2018-06-01 03:32:53.258721
NCT00414895|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2010-10-25|2006-12-21|2006-12-22|Estimate|||||||2010-10-25|2010-10-26|Estimate|December 2006||2006-12-31|October 2010|2010-10-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Observational|||Absolute Myocardial Perfusion Measurement in the Transplanted Heart|Absolute Myocardial Perfusion Measurement in the Transplanted Heart: a New Method for Accurate Detection of Allograft Rejection. A Pilot Study|Completed|||90|Actual|University Hospital Inselspital, Berne|||||f||||||||||||||2018-06-01 03:32:53.743727|2018-06-01 03:32:53.743727
NCT00414882|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2010-08-26|2006-12-21|2006-12-22|Estimate|||||||2010-08-26|2010-08-27|Estimate|June 2007||2007-06-30|September 2007|2007-09-30|June 2012||2012-06-30|||||Observational|||A Cluster-Randomized Trial of DOTS vs DOTS Plus Active Case Finding|A Cluster-Randomized Trial of DOTS Versus DOTS Plus Active Case Finding to Reduce Tuberculosis Incidence in Rio de Janeiro, Brazil|Unknown status|Recruiting||200000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:32:53.801898|2018-06-01 03:32:53.801898
NCT00412789|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2010-05-28|2006-12-15|2006-12-18|Estimate|||||||2010-05-28|2010-05-31|Estimate|August 2006||2006-08-31|May 2010|2010-05-31||||January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan|A Phase IA, Open-label, Dose Escalation Study of Patupilone Administered Intravenously Every 3 Weeks in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|15|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:34:05.265252|2018-06-01 03:34:05.265252
NCT00414869|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2017-02-07|2006-12-21|2006-12-22|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 2005||2005-11-30|February 2017|2017-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure|Preliminary Efficacy And Tolerability Of Oral NCX-1000 After Repeated Administrations In Patients With Portal Hypertension: A Double-Blind Dose Escalating Study|Terminated||Phase 2|11|Actual|Forest Laboratories||2||Preliminary analysis of 11 patients did not demonstrate the efficacy required.|f||||f||||||||||2018-06-01 03:32:53.86914|2018-06-01 03:32:53.86914
NCT00414856|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2007-06-21|2006-12-21|2006-12-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|August 2006||2006-08-31|June 2007|2007-06-30||||||||Interventional|||Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux|A Multi-Center, Randomized, Double-Blind, Placebo- and Positive-Control, Double-Dummy, 3 Parallel Cohort, Two-Way Crossover Single Oral Dose Study in GERD (Gastro Esophageal Reflux Disease) Patients to Evaluate the Effects of AFQ056 and Baclofen (Positive Control) on the Incidence of Meal-Induced Gastro Esophageal Reflux Events|Completed||Phase 1|34|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:32:53.984823|2018-06-01 03:32:53.984823
NCT00414843|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2016-02-22|2006-12-21|2006-12-22|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2006||2006-12-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Storage of Bile From Routine Procedures to Study Risk Factors|A Prospective Study of Human Bile and Molecular Predictors of Biliary Malignancy Risk|Terminated|||390|Actual|Indiana University||||Decreasing interest in using samples; department infrastructure waned|f||||||||||Samples Without DNA|"~     Bile, plasma~   "|||2018-06-01 03:32:54.039854|2018-06-01 03:32:54.039854
NCT00414830|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2008-04-29|2006-12-21|2006-12-22|Estimate|||||||2008-04-29|2008-05-07|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|September 2009|Anticipated|2009-09-30|||||Observational|||Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.||Unknown status|Active, not recruiting||600|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 03:32:54.098993|2018-06-01 03:32:54.098993
NCT00414817|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2015-07-23||2016-12-06|2006-12-20|2006-12-22|Estimate|2016-12-06|2017-01-30|Estimate||||2016-12-06|2017-01-30|Estimate|June 2007||2007-06-30|December 2016|2016-12-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional||individuals who met our inclusion/exclusion criteria|Telephone-Based Program to Promote Inhaled Corticosteroid Adherence Among Individuals With Asthma|Phone Calls to Promote Adherence With Inhaled Corticosteroids|Completed||N/A|14064|Actual|Kaiser Permanente||2|||f||||f||||||||No||2018-06-01 03:32:54.171959|2018-06-01 03:32:54.171959
NCT00414804|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2012-02-13|2006-12-20|2006-12-22|Estimate|||||||2012-02-13|2012-02-15|Estimate|December 2006||2006-12-31|February 2012|2012-02-29||||||||Interventional|||Spinal Cord Stimulation Versus Nerve Blocks and Physical Therapy|Spinal Cord Stimulation (SCS) Versus Nerve Blocks and Physical Therapy for Complex Regional Pain Syndrome|Withdrawn||N/A|0|Actual|Boston Scientific Corporation||2||Investigator decided to withdraw participation in the study|f||||f||||||||||2018-06-01 03:32:54.687243|2018-06-01 03:32:54.687243
NCT00414778|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2011-01-12|2006-12-21|2006-12-22|Estimate|||||||2011-01-12|2011-01-13|Estimate|October 2006||2006-10-31|January 2011|2011-01-31||||October 2006|Actual|2006-10-31||Interventional|||Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects|A Single-center, Open-label, Single and Multiple Oral Dose Study to Assess Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects|Completed||Phase 1|12|Actual|Novartis|||||f||||||||||||||2018-06-01 03:32:54.802783|2018-06-01 03:32:54.802783
NCT00414765|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21||2013-02-09|2013-02-09|2006-12-21|2006-12-22|Estimate||||2013-02-09|2013-02-12|Estimate|2013-02-09|2013-02-12|Estimate|January 2006||2006-01-31|February 2013|2013-02-28||||March 2010|Actual|2010-03-31||Interventional|||Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma|Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma and Metastatic Melanoma With Immunologic Correlative Studies|Completed||Phase 1/Phase 2|26|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:32:54.96102|2018-06-01 03:32:54.96102
NCT00414752|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2007-06-21|2006-12-21|2006-12-22|Estimate|||||||2007-06-21|2007-06-22|Estimate|September 2006||2006-09-30|June 2007|2007-06-30||||||||Interventional|||Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking|A Randomized, Double Blind, Multiple Dose, Cross-Over, Placebo- and Active-Controlled Proof of Concept Study to Explore the Effects of AFQ056 and Nicotine (Active Comparator) on Craving and Withdrawal During Voluntary Smoking Abstinence in Healthy Smokers|Completed||Phase 1|36||Novartis|||||f||||||||||||||2018-06-01 03:32:55.060544|2018-06-01 03:32:55.060544
NCT00414739|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2006-12-21|2006-12-21|2006-12-22|Estimate|||||||2006-12-21|2006-12-22|Estimate||||December 2006|2006-12-31||||||||Interventional|||Testing of Innocuousness of Benzalkonium Chloride on the Eye Concerning Possible Growth of Langerhans Cells||Unknown status|Recruiting|Phase 1|20||University of Rostock|||||f||||||||||||||2018-06-01 03:32:55.116387|2018-06-01 03:32:55.116387
NCT00414726|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2010-07-01||2017-10-18|2006-12-21|2006-12-22|Estimate|2010-08-24|2010-09-16|Estimate||||2017-10-18|2017-10-20|Actual|January 2007||2007-01-31|October 2017|2017-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Normobaric Oxygen Therapy in Acute Ischemic Stroke Trial|Clinical Trial of Normobaric Oxygen Therapy in Acute Ischemic Stroke|Terminated||Phase 2|85|Actual|Massachusetts General Hospital|Early termination leading to small numbers of subjects analyzed.|2||"Imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded~   external medical monitor."|f||||t||||||||||2018-06-01 03:32:55.207162|2018-06-01 03:32:55.207162
NCT00414713|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|||2010-12-28|2006-12-21|2006-12-22|Estimate|||||||2010-12-28|2010-12-29|Estimate|October 2002||2002-10-31|December 2010|2010-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Transfusion Requirements in Gastrointestinal (GI) Bleeding|Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding.|Unknown status|Recruiting|Phase 4|860|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-06-01 03:32:55.551926|2018-06-01 03:32:55.551926
NCT00414700|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-21|2009-05-06||2011-09-22|2006-12-21|2006-12-22|Estimate|2009-12-14|2010-01-18|Estimate||||2011-09-22|2011-09-26|Estimate|February 2002||2002-02-28|September 2011|2011-09-30|January 2010|Actual|2010-01-31|July 2006|Actual|2006-07-31||Interventional|TIGACT01||RCT of ChondroCelect® (in an ACI Procedure) vs Microfracture in the Repair of Cartilage Defects of the Knee|Prospective Multicenter Randomized Controlled Trial of ChondroCelect® (Via Autologous Chondrocyte Implantation) vs Microfracture (as Procedure) in the Repair of Symptomatic Cartilaginous Defects of the Femoral Condyles|Completed||Phase 3|118|Actual|TiGenix n.v.||2|||f||||f||||||||||2018-06-01 03:32:55.705642|2018-06-01 03:32:55.705642
NCT00414531|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2014-12-02|2006-12-20|2006-12-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2005||2005-05-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity|Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity|Completed||Phase 4|53|Actual|University of Oslo School of Pharmacy||1|||f||||||||||||||2018-06-01 03:32:59.43872|2018-06-01 03:32:59.43872
NCT00414687|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2009-05-14|2006-12-20|2006-12-21|Estimate|||||||2009-05-14|2009-05-15|Estimate|July 1998||1998-07-31|May 2009|2009-05-31|May 2001|Actual|2001-05-31|||||Interventional|||Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension|An Explorative, Open-Label, Multicenter, Randomized, Parallel-Group Comparative Study of Safety, Tolerability, and the Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension Over 2 Years|Completed||Phase 2|63|Actual|Bayer||1|||f||||||||||||||2018-06-01 03:32:56.305827|2018-06-01 03:32:56.305827
NCT00414661|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2012-11-28||2012-11-28|2006-12-20|2006-12-21|Estimate|2012-11-28|2013-01-01|Estimate||||2012-11-28|2013-01-01|Estimate|April 2007||2007-04-30|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550|A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550|Completed|||162|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:32:56.410662|2018-06-01 03:32:56.410662
NCT00414648|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2009-08-27|2006-12-20|2006-12-21|Estimate|||||||2009-08-27|2009-08-28|Estimate|December 2006||2006-12-31|August 2009|2009-08-31|September 2011|Anticipated|2011-09-30|September 2010|Anticipated|2010-09-30||Interventional|||Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)|Lymphangioleiomyomatosis Efficacy and Safety Trial|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|Office of Rare Diseases (ORD)||2|||f||||t||||||||||2018-06-01 03:32:56.893566|2018-06-01 03:32:56.893566
NCT00414635|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2010-07-22||2017-08-24|2006-12-20|2006-12-21|Estimate|2010-12-06|2011-01-04|Estimate||||2017-08-24|2017-09-25|Actual|August 2006||2006-08-31|July 2017|2017-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment|A Randomized Controlled Trial of a Weekly Schedule of Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment (5/2 Intermittent Treatment Schedule) Versus Continuous Treatment in Individuals With Virologic Suppression on This Combination|Completed||Phase 4|60|Actual|Community Research Initiative of New England|"Conclusions are limited by the small n studied. The results are only applicable to the specific drug regimen studied and thus can not be generalized to all ART. We only studied individuals already virologically undetectable."|2|||f||||||||||||||2018-06-01 03:32:57.001899|2018-06-01 03:32:57.001899
NCT00414622|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2007-04-18|2006-12-20|2006-12-21|Estimate|||||||2007-04-18|2007-04-19|Estimate|November 2006||2006-11-30|December 2006|2006-12-31|April 2007|Actual|2007-04-30|||||Interventional|||GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease|A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease|Completed||Phase 2|60||CoMentis|||||t||||||||||||||2018-06-01 03:32:57.310129|2018-06-01 03:32:57.310129
NCT00414609|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2010-12-20||2012-07-05|2006-12-20|2006-12-21|Estimate|2011-06-14|2011-07-13|Estimate||||2012-07-05|2012-07-13|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|September 2009|Actual|2009-09-30||Interventional|||Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)|A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized Standard Therapy|Completed||Phase 3|820|Actual|Novartis||2|||f||||t||||||||||2018-06-01 03:32:57.403159|2018-06-01 03:32:57.403159
NCT00414596|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2009-04-28||2016-05-04|2006-12-19|2006-12-21|Estimate|2016-05-04|2016-06-06|Estimate||||2016-05-04|2016-06-06|Estimate|December 2006||2006-12-31|May 2016|2016-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System|Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System For Treatment of Low Back Pain|Completed||Phase 2|20|Actual|NEMA Research, Inc.||1|||f||||f||||||||||2018-06-01 03:32:58.702427|2018-06-01 03:32:58.702427
NCT00414583|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2016-05-18|2006-12-19|2006-12-21|Estimate|||||||2016-05-18|2016-05-19|Estimate|January 2008||2008-01-31|May 2016|2016-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|sifap1||Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke Patients|Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in an Unselected Group of Young Stroke Patients: an International, Multicentre Prevalence Study|Completed|||5000|Actual|University of Rostock|||1||f||||t||||||Samples With DNA|"~     Fabry diagnostic will be done centrally: blood samples will be retained for analysis of~     a-galactosidase in blood to diagnose an a-galactosidase deficit; in females direct analysis~     of the gene has to be done since due to the Lyonisation effect a-galactosidase activity might~     be normal in blood although the patient might suffer from Fabry disease.~   "|||2018-06-01 03:32:58.938064|2018-06-01 03:32:58.938064
NCT00414570|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2016-03-14|2006-12-19|2006-12-21|Estimate|||||||2016-03-14|2016-03-16|Estimate|November 2006||2006-11-30|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine|An Imaging Pilot Study of 18F-fluoro-3'-Deoxy-3'-L-fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine|Unknown status|Recruiting|N/A|30|Anticipated|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:32:59.109381|2018-06-01 03:32:59.109381
NCT00414557|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2006-12-21|2006-12-20|2006-12-21|Estimate|||||||2006-12-21|2006-12-22|Estimate|May 2004||2004-05-31|December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Knee Malalignment and Thigh Muscle Strengthening in Individuals With Medial Knee Arthritis|The Effects of Knee Malalignment and Quadriceps Strengthening on the Adduction Moment in Individuals With Medial Knee Osteoarthritis|Completed||Phase 2/Phase 3|107||University of Melbourne|||||f||||||||||||||2018-06-01 03:32:59.185866|2018-06-01 03:32:59.185866
NCT00414544|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2011-03-04||2011-06-22|2006-12-20|2006-12-21|Estimate|2011-06-08|2011-06-10|Estimate||||2011-06-22|2011-06-27|Estimate|October 2006||2006-10-31|June 2011|2011-06-30|March 2008|Actual|2008-03-31|September 2007|Actual|2007-09-30||Interventional|||Evaluation of the Safety and Efficacy of CosmetaLife™ for the Correction of Nasolabial Folds|A Randomized, Double-Blind, Multicenter Comparison of the Safety and Efficacy of CosmetaLife™ Versus Control for the Correction of Nasolabial Folds|Completed||Phase 2|145|Actual|Cosmeta||2|||f||||t||||||||||2018-06-01 03:32:59.262552|2018-06-01 03:32:59.262552
NCT00412438|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2006-12-15|2006-12-15|2006-12-18|Estimate|||||||2006-12-15|2006-12-18|Estimate|October 2006||2006-10-31|December 2006|2006-12-31||||||||Observational|||Investigation of Genetic Risk of Atrial Fibrillation|Investigation of Genetic Risk of Atrial Fibrillation|Unknown status|Recruiting||1000||Nagoya University|||||f||||||||||||||2018-06-01 03:34:12.232817|2018-06-01 03:34:12.232817
NCT00414518|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2012-09-06||2013-01-16|2006-12-19|2006-12-21|Estimate|2013-01-16|2013-02-20|Estimate||||2013-01-16|2013-02-20|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection|An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States|Completed||N/A|16|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 03:32:59.516705|2018-06-01 03:32:59.516705
NCT00414505|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2014-05-29|2006-12-20|2006-12-21|Estimate|||||||2014-05-29|2014-06-02|Estimate|August 2006||2006-08-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|||||Interventional|||A Randomized Controlled Double Blinding Study of Intradermal Acupuncture Treatment on Obesity|Korea Institute of Oriental Medicine|Unknown status|Recruiting|Phase 3|180|Anticipated|Wonkwang University|||||f||||||||||||||2018-06-01 03:32:59.799162|2018-06-01 03:32:59.799162
NCT00414492|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2010-09-15|2006-12-20|2006-12-21|Estimate|||||||2010-09-15|2010-09-16|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|June 2010|Actual|2010-06-30|||||Observational|||Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer|Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer|Completed|||100|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||Samples With DNA|"~     liver tissue from surgical specimen~   "|||2018-06-01 03:32:59.850239|2018-06-01 03:32:59.850239
NCT00414479|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2010-01-13|2006-12-20|2006-12-21|Estimate|||||||2010-01-13|2010-01-14|Estimate|July 2006||2006-07-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment|Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment|Completed|||1500|Actual|DBL -Institute for Health Research and Development|||1||f||||||||||||||2018-06-01 03:32:59.897839|2018-06-01 03:32:59.897839
NCT00414466|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2010-12-22||2013-08-19|2006-12-20|2006-12-21|Estimate|2011-05-06|2011-06-08|Estimate||||2013-08-19|2013-08-23|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional|||A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain|A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.|Terminated||Phase 2|254|Actual|MedtronicNeuro||4||Study closed and subject follow-up completed following analysis of blinded study data.|f||||t||||||||||2018-06-01 03:32:59.967924|2018-06-01 03:32:59.967924
NCT00414453|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2015-03-11||2015-06-23|2006-12-20|2006-12-21|Estimate|2015-06-23|2015-07-17|Estimate||||2015-06-23|2015-07-17|Estimate|January 2007||2007-01-31|June 2015|2015-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis|Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (TALENT-MS)|Terminated||Phase 4|19|Actual|University of Rochester||1||Did not reach enrollment goals|f||||f||||||||||2018-06-01 03:33:00.52848|2018-06-01 03:33:00.52848
NCT00414440|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2014-10-07||2015-01-13|2006-12-20|2006-12-21|Estimate|2015-01-13|2015-01-14|Estimate||||2015-01-13|2015-01-14|Estimate|December 2006||2006-12-31|January 2015|2015-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease|A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Completed||Phase 4|431|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:33:00.889523|2018-06-01 03:33:00.889523
NCT00414427|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2010-07-07|2006-12-20|2006-12-21|Estimate|||||||2010-07-07|2010-07-08|Estimate|December 2005||2005-12-31|December 2006|2006-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Using Ultrasonography to Predict Clinical Response to Intraarticular Corticosteroids in Knee Osteoarthritis|Using Ultrasonography to Predict Clinical Response to Intraarticular Corticosteroids in Knee Osteoarthritis|Completed||N/A|120|Anticipated|University of California, San Diego|||||f||||||||||||||2018-06-01 03:33:01.691657|2018-06-01 03:33:01.691657
NCT00414414|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-03-31|2006-12-20|2006-12-21|Estimate|||||||2017-03-31|2017-04-04|Actual|February 2007||2007-02-28|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection|A Randomized, Prospective Double Blind Placebo Control Clinical Trial of Prednisone as Adjunctive Therapy for the Treatment of Hospitalized Patients With Pulmonary TB and HIV Co-infection|Withdrawn||Phase 3|0|Actual|Ottawa Hospital Research Institute||2||Funding not awarded|f||||||||||||||2018-06-01 03:33:02.919608|2018-06-01 03:33:02.919608
NCT00414401|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2015-04-06|2006-12-20|2006-12-21|Estimate|||||||2015-04-06|2015-04-07|Estimate|May 2001||2001-05-31|December 2006|2006-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Clinical Reminders in Test Reports to Improve Guideline Compliance|Clinical Reminders in Test Reports to Improve Guideline Compliance|Completed||N/A|1500|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 03:33:03.101425|2018-06-01 03:33:03.101425
NCT00414388|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2013-05-03||2014-02-28|2006-12-19|2006-12-21|Estimate|2014-02-28|2014-04-07|Estimate||||2014-02-28|2014-04-07|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional||Recruitment was from our clinic population. Eligible patients were those who progressed while receiving chemotherapy (docetaxel or mitoxantrone)or within 12 weeks of stopping chemo|Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer|Phase I/II Study to Evaluate the Ability of Sorafenib in Overcoming Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer (AIPC)|Completed||Phase 1/Phase 2|22|Actual|Oncology Specialists, S.C.||1|||f||||f||||||||||2018-06-01 03:33:03.301413|2018-06-01 03:33:03.301413
NCT00414375|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2009-03-02|2006-12-20|2006-12-21|Estimate|||||||2009-03-02|2009-03-03|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Early Versus Delayed Operation for Perforated Appendicitis|Early Versus Delayed Operation for Perforated Appendicitis With Abscess, a Pilot Study|Completed||N/A|30|Actual|Children's Mercy Hospital Kansas City||2|||f||||||||||||||2018-06-01 03:33:03.577953|2018-06-01 03:33:03.577953
NCT00414037|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2015-10-23|2006-12-19|2006-12-21|Estimate|||||||2015-10-23|2015-10-26|Estimate|December 2006||2006-12-31|October 2015|2015-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||How do Sleeping Pills Affect Pain in the Brain?|Subchronic Effects of Eszopiclone (Lunesta) on Pain Behavior and Circuitry in Primary Insomnia|Terminated||Phase 4|40|Actual|University of California, San Diego||2||Funding terminated by sponsor, insufficient data collection|f||||f||||||||||2018-06-01 03:33:11.200957|2018-06-01 03:33:11.200957
NCT00414362|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-06-23|2006-12-20|2006-12-21|Estimate|||||||2017-06-23|2017-06-26|Actual|February 2007|Actual|2007-02-28|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin|Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin|Completed|||1000|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:33:03.730578|2018-06-01 03:33:03.730578
NCT00414349|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2009-06-15|2006-12-20|2006-12-21|Estimate|||||||2009-06-15|2009-06-16|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of Topical Versus Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain|Safety and Efficacy of Lidocaine 5% Medicated Plaster in Comparison to Systemic Treatment in Postherpetic Neuralgia and Diabetic Polyneuropathic Pain.|Completed||Phase 3|350|Anticipated|Grünenthal GmbH||3|||f||||||||||||||2018-06-01 03:33:03.959387|2018-06-01 03:33:03.959387
NCT00414336|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2017-06-30|2006-12-20|2006-12-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 15, 2006||2006-12-15|August 4, 2009|2009-08-04|December 15, 2006|Actual|2006-12-15|December 15, 2006|Actual|2006-12-15||Interventional|||Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria|Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults|Completed||Phase 1|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:33:04.049645|2018-06-01 03:33:04.049645
NCT00414323|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2007-06-11|2006-12-19|2006-12-21|Estimate|||||||2007-06-11|2007-06-12|Estimate|November 2006||2006-11-30|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Evaluation of the Effects of Duloxetine on Norepinephrine|Evaluation of the Effects of Duloxetine on Norepinephrine Transporter Inhibition in Healthy Subjects|Completed||Phase 1|35|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:33:04.232086|2018-06-01 03:33:04.232086
NCT00414310|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2015-07-15||2015-07-15|2006-12-20|2006-12-21|Estimate|2015-07-15|2015-08-13|Estimate||||2015-07-15|2015-08-13|Estimate|December 2006||2006-12-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)|"Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -SPORE"|Completed||Phase 2|153|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:33:04.38343|2018-06-01 03:33:04.38343
NCT00414297|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2010-10-25|2006-12-20|2006-12-21|Estimate|||||||2010-10-25|2010-10-26|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||External Counterpulsation (ECP) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease|External Counterpulsation (ECP) for the Promotion of Collateral Growth in Patients With Coronary Artery Disease|Completed||N/A|30|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-06-01 03:33:05.027013|2018-06-01 03:33:05.027013
NCT00414284|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2010-12-06|2006-12-20|2006-12-21|Estimate|||||||2010-12-06|2010-12-08|Estimate|June 2006||2006-06-30|December 2010|2010-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)|Evaluation of the Pharmacokinetics and Tolerability of Increased Dosage of Lopinavir/Ritonavir(LPV/r) in Individuals Experiencing Viremia on Standard Dose LPV/r Using LPV/r Tablet Formulation|Terminated||Phase 4|||Community Research Initiative of New England||||"One subject's HIV RNA rebounded at week 12. A repeat PhenoSense GT combination resistance assay~   at week 12 revealed evolution in protease inhibitor resistance."|f||||||||||||||2018-06-01 03:33:05.122491|2018-06-01 03:33:05.122491
NCT00414271|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2008-12-16|2006-12-20|2006-12-21|Estimate|||||||2008-12-16|2008-12-17|Estimate|January 2006||2006-01-31|December 2008|2008-12-31||||||||Interventional|||Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer|A Phase II Study of Neo-Adjuvant Chemotherapy in Locally Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:33:05.277961|2018-06-01 03:33:05.277961
NCT00414258|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2011-04-12|2006-12-20|2006-12-21|Estimate|||||||2011-04-12|2011-04-14|Estimate|September 2006||2006-09-30|April 2011|2011-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Holding Study: Feeding Analgesia in Preterm Infants|The Holding Pilot Study: Feeding Analgesia in Preterm Infants|Completed||N/A|15|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:33:05.423737|2018-06-01 03:33:05.423737
NCT00414245|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2006-12-20|2006-12-20|2006-12-21|Estimate|||||||2006-12-20|2006-12-21|Estimate|January 2007||2007-01-31|December 2006|2006-12-31||||||||Interventional|||Metformin for the Treatment of Diabetes in Pregnancy|Metformin for the Treatment of Diabetes in Pregnancy|Unknown status|Not yet recruiting|Phase 3|200||Soroka University Medical Center|||||f||||||||||||||2018-06-01 03:33:05.49365|2018-06-01 03:33:05.49365
NCT00414232|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2013-01-07|2006-12-20|2006-12-21|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 2006||2006-11-30|January 2013|2013-01-31||||October 2010|Actual|2010-10-31||Observational|||Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy|Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy|Completed|||13|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-06-01 03:33:05.653003|2018-06-01 03:33:05.653003
NCT00414219|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2010-12-29|2006-12-20|2006-12-21|Estimate|||||||2010-12-29|2010-12-30|Estimate|November 2004||2004-11-30|December 2010|2010-12-31|May 2007|Actual|2007-05-31|||||Observational|||Visual Prognosis in Non-Penetrating Corneal Blast Injuries|Visual Prognosis in Non-Penetrating Corneal Blast Injuries|Completed|||40|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:33:05.802776|2018-06-01 03:33:05.802776
NCT00414206|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2010-08-16||2010-10-26|2006-12-20|2006-12-21|Estimate|2010-10-26|2010-11-23|Estimate||||2010-10-26|2010-11-23|Estimate|March 2007||2007-03-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)|"A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular (Wet) Age-Related Macular Degeneration (NV-AMD)"|Terminated||Phase 2|343|Actual|CoMentis||3||Sponsor decision|f||||t||||||||||2018-06-01 03:33:06.179112|2018-06-01 03:33:06.179112
NCT00414193|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-06-08|2006-12-20|2006-12-21|Estimate|||||||2017-06-08|2017-06-09|Actual|February 2007||2007-02-28|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase|Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase|Active, not recruiting|||1000|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:33:07.432495|2018-06-01 03:33:07.432495
NCT00414180|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2011-03-10|2006-12-20|2006-12-21|Estimate|||||||2011-03-10|2011-03-14|Estimate|August 2003||2003-08-31|March 2011|2011-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Bupropion SR for Treating Smokeless Tobacco Use|Bupropion SR for Treating Smokeless Tobacco Use|Completed||Phase 3|225||Mayo Clinic|||||f||||||||||||||2018-06-01 03:33:08.046762|2018-06-01 03:33:08.046762
NCT00414167|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2012-10-22||2014-02-12|2006-12-20|2006-12-21|Estimate|2014-02-12|2014-03-28|Estimate||||2014-02-12|2014-03-28|Estimate|December 2005||2005-12-31|February 2014|2014-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Craving, Binge Eating and Obesity|Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder|Completed||Phase 2/Phase 3|61|Actual|Yale University||2|||f||||||||||||||2018-06-01 03:33:08.245933|2018-06-01 03:33:08.245933
NCT00414154|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2011-02-23|2006-12-20|2006-12-21|Estimate|||||||2011-02-23|2011-02-24|Estimate|May 2002||2002-05-31|March 2007|2007-03-31|May 2007||2007-05-31|||||Interventional|||The Importance of Patient Education - A Randomised Controlled Trial|The Effect of a Group Based Multidisciplinary Patient Education Programme for Patients With Osteoporosis - a Controlled Randomised Trial|Completed||Early Phase 1|300||Odense University Hospital|||||f||||||||||||||2018-06-01 03:33:08.797632|2018-06-01 03:33:08.797632
NCT00414141|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2010-06-16|2006-12-20|2006-12-21|Estimate|||||||2010-06-16|2010-06-17|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety/Tolerability of Grass MATA MPL|Efficacy and Safety/Tolerability of Grass MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study|Completed||Phase 3|1028|Actual|Allergy Therapeutics||2|||f||||||||||||||2018-06-01 03:33:09.023246|2018-06-01 03:33:09.023246
NCT00414128|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2013-12-05|2006-12-19|2006-12-21|Estimate|||||||2013-12-05|2013-12-06|Estimate|March 2007||2007-03-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|July 2011|Actual|2011-07-31||Interventional|MYCYC||Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis|A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis.|Completed||Phase 2/Phase 3|140|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 03:33:09.3358|2018-06-01 03:33:09.3358
NCT00414115|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-11-02|2006-12-20|2006-12-21|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2005||2005-08-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children|Canadian Pharmacogenomics Network for Drug Safety|Recruiting|||7000|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:33:09.48625|2018-06-01 03:33:09.48625
NCT00414102|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2016-06-27|2006-12-20|2006-12-21|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2006||2006-10-31|May 2010|2010-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.|"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of Ramelteon on Sleep Using a Post Sleep Questionnaire - Interactive Voice Response System (PSQ-IVRS) in an At-Home Setting in an Adult Population With Chronic Insomnia"|Completed||Phase 4|552|Actual|Takeda||2|||f||||f||||||||||2018-06-01 03:33:09.729659|2018-06-01 03:33:09.729659
NCT00414089|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2016-02-12|2006-12-20|2006-12-21|Estimate|||||||2016-02-12|2016-02-15|Estimate||||July 2007|2007-07-31||||||||Interventional|||Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL|Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|Withdrawn||Phase 2|0|Actual|AHS Cancer Control Alberta||||Funding will not be provided for the drug|f||||||||||||||2018-06-01 03:33:10.061235|2018-06-01 03:33:10.061235
NCT00414076|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-07-25|2006-12-19|2006-12-21|Estimate|||||||2017-07-25|2017-07-28|Actual|December 19, 2006|Actual|2006-12-19|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma|A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma|Terminated||Phase 2|9|Actual|M.D. Anderson Cancer Center||2||Low accrual|f||||t||||||||||2018-06-01 03:33:10.152115|2018-06-01 03:33:10.152115
NCT00414063|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|||2018-05-23|2006-12-20|2006-12-21|Estimate|||||||2018-05-23|2018-05-24|Actual|December 15, 2006||2006-12-15|March 19, 2013|2013-03-19|March 19, 2013||2013-03-19|||||Observational|||Energy Metabolism and Nutrient Absorption in Lean and Obese Individuals|Investigation of Differences in Energy Metabolism and Nutrient Absorption Between Lean and Obese Individuals|Completed|||28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:33:10.330013|2018-06-01 03:33:10.330013
NCT00414050|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-20|2008-10-15||2017-04-12|2006-12-20|2006-12-21|Estimate|2009-03-10|2009-04-14|Estimate||||2017-04-12|2017-05-23|Actual|October 6, 2006|Actual|2006-10-06|April 2017|2017-04-30|October 24, 2007|Actual|2007-10-24|October 22, 2007|Actual|2007-10-22||Interventional|||A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)|A Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age|Completed||Phase 3|1718|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:33:10.471338|2018-06-01 03:33:10.471338
NCT00413842|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-06-30|2006-12-19|2006-12-20|Estimate|||||||2017-06-30|2017-07-02|Actual|December 14, 2006||2006-12-14|August 20, 2008|2008-08-20|August 20, 2008||2008-08-20|||||Observational|||Effects of tDCS Over the Cerebellum on Motor Function|Effects of tDCS Over the Cerebellum on Motor Function|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:33:16.263834|2018-06-01 03:33:16.263834
NCT00414024|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2012-04-19|2006-12-19|2006-12-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.|An Open Label 52-week Study to Evaluate the Safety and Efficacy of Tegaserod Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain|Terminated||Phase 3|11|Actual|Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in~   2007"|||||||||||||||2018-06-01 03:33:11.397242|2018-06-01 03:33:11.397242
NCT00414011|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2013-04-01||2013-06-26|2006-12-19|2006-12-20|Estimate|2013-05-17|2013-06-26|Estimate||||2013-06-26|2013-07-17|Estimate||||June 2013|2013-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional||35 out of 40 participants had complete data for analysis.|Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)||Completed||N/A|40|Actual|Walter Reed Army Medical Center||2|||f||||||||||||||2018-06-01 03:33:11.549771|2018-06-01 03:33:11.549771
NCT00413998|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2015-06-03|2006-12-19|2006-12-20|Estimate|||||||2015-06-03|2015-06-04|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|RIME||Randomised Ischaemic Mitral Evaluation (RIME) Trial|Randomized Evaluation of Mitral Annuloplasty During Coronary Artery Bypass Grafting for Moderate Functional Ischaemic Mitral Regurgitation.|Completed||Phase 3|73|Actual|Imperial College London||2|||f||||t||||||||||2018-06-01 03:33:11.778269|2018-06-01 03:33:11.778269
NCT00413985|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2013-12-30|2006-12-19|2006-12-20|Estimate|||||||2013-12-30|2013-12-31|Estimate|January 2004||2004-01-31|December 2013|2013-12-31||||November 2007|Actual|2007-11-30||Interventional|||Post Discharge Human Milk Fortifier in Preterm Infants|Growth and Development in Preterm Infants Fed Human Milk Containing a Powdered Human Milk Fortifier (HMF) Post Hospital Discharge|Completed||Phase 2|40||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 03:33:11.93335|2018-06-01 03:33:11.93335
NCT00413972|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2010-04-28||2015-06-16|2006-12-19|2006-12-20|Estimate|2010-04-28|2010-05-25|Estimate||||2015-06-16|2015-07-14|Estimate|April 2006||2006-04-30|June 2015|2015-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)|A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Groups Study Comparing the Efficacy and Safety of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia|Completed||Phase 3|392|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 03:33:12.081285|2018-06-01 03:33:12.081285
NCT00413959|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2013-05-07||2013-10-17|2006-12-19|2006-12-20|Estimate|2013-08-06|2013-09-27|Estimate||||2013-10-17|2013-11-11|Estimate|August 2006||2006-08-31|October 2013|2013-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|VRCD||VELCADE®,Rituximab,Cyclophosphamide and Decadron (VRCD Regimen)|Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma|Terminated||Phase 2|12|Actual|Oncology Specialists, S.C.||1|||f||||f||||||||||2018-06-01 03:33:12.608946|2018-06-01 03:33:12.608946
NCT00413946|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2015-02-23|2006-12-19|2006-12-20|Estimate|||||||2015-02-23|2015-02-25|Estimate|January 2006||2006-01-31|February 2015|2015-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Does Erythropoietin Improve Outcome in Very Preterm Infants?|Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants|Completed||Phase 2|420|Actual|Swiss Neonatal Network||2|||f||||t||||||||||2018-06-01 03:33:12.965163|2018-06-01 03:33:12.965163
NCT00413933|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2016-04-20|2006-12-19|2006-12-20|Estimate|||||||2016-04-20|2016-04-21|Estimate|April 2008||2008-04-30|December 2006|2006-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comprehensive Intervention for Falls Prevention in the Elderly||Terminated||N/A|8|Actual|Soroka University Medical Center||2||The study was stopped due to lack of funding|f||||||||||||||2018-06-01 03:33:13.090719|2018-06-01 03:33:13.090719
NCT00413920|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2011-01-12||2011-04-19|2006-12-19|2006-12-20|Estimate|2011-01-12|2011-02-07|Estimate||||2011-04-19|2011-04-21|Estimate|April 2007||2007-04-30|April 2011|2011-04-30||||March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients|A Multicenter Randomized Open Label Study to Assess Efficacy and Safety of a Steroid Avoidance Regimen in Comparison to a Treatment With Steroids, in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS) 2.16 g/d for 6 Weeks and Cyclosporine Microemulsion, in de Novo Adult Renal Transplant Recipients|Completed||Phase 3|222|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:33:13.265557|2018-06-01 03:33:13.265557
NCT00413894|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2016-01-17||2016-01-17|2006-12-19|2006-12-20|Estimate|2016-01-17|2016-02-15|Estimate||||2016-01-17|2016-02-15|Estimate|March 2007||2007-03-31|January 2016|2016-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Safety Population included all participants who received at least one dose of study medication independent of whether they completed the study or not.|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.|An Open Label Study of the Effect of Intravenous Mircera on Hemoglobin Levels in Anemic Patients With Chronic Kidney Disease Who Are on Dialysis, and Who Have Previously Received Epoetin Alfa or Beta or Darbepoetin Alfa Treatment.|Completed||Phase 3|424|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:33:14.913937|2018-06-01 03:33:14.913937
NCT00413881|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2010-01-13|2006-12-19|2006-12-20|Estimate|||||||2010-01-13|2010-01-14|Estimate|July 2004||2004-07-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|||||Interventional|||A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures|A Prospective Comparison of Alcon LADARVision Wavefront-guided LASIK Enhancement and Conventional LASIK Enhancement for the Correction of Residual Refractive Errors Following LASIK Procedures|Completed||N/A|50|Anticipated|Walter Reed Army Medical Center||2|||f||||||||||||||2018-06-01 03:33:15.913155|2018-06-01 03:33:15.913155
NCT00413868|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2008-03-31|2006-12-19|2006-12-20|Estimate|||||||2008-03-31|2008-04-01|Estimate||||March 2008|2008-03-31||||||||Interventional|||A Prospective Evaluation of Contrast Sensitivity and Disability Glare in Refractive Surgery, a Sub-Study of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)||Completed||N/A|50||Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:33:16.057259|2018-06-01 03:33:16.057259
NCT00413855|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2006-12-19|2006-12-19|2006-12-20|Estimate|||||||2006-12-19|2006-12-20|Estimate|September 1994||1994-09-30|December 2006|2006-12-31|June 2005||2005-06-30|||||Interventional|||Laparoscopic Appendectomy for Chronic Right Lower Abdominal Pain|Elective Laparoscopic Appendectomy for Chronic Right Lower Abdominal Pain; Outcome of a Prospective Randomized Double-Blind Controlled Surgical Trial|Completed||Phase 3|40||Maxima Medical Center|||||f||||||||||||||2018-06-01 03:33:16.120012|2018-06-01 03:33:16.120012
NCT00413829|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2010-01-13|2006-12-19|2006-12-20|Estimate|||||||2010-01-13|2010-01-14|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|March 2008|Actual|2008-03-31|May 2007|Actual|2007-05-31||Interventional|||Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)|Open-label, Phase II Study Assessing Immediate Effects of Lucentis®(Ranibizumab) Administered in Conjunction With Photodynamic Therapy With Visudyne® in Patients With Choroidal Neovascularization Secondary to AMD|Completed||Phase 2|20|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 03:33:16.318368|2018-06-01 03:33:16.318368
NCT00413816|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2006-12-19|2006-12-19|2006-12-20|Estimate|||||||2006-12-19|2006-12-20|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|December 2006||2006-12-31|||||Observational|||The Israeli Trigger for Blood Transfusions in the ICU|A Multicenter Study of Anemia in the ICU Patient: Determination of the Israeli Trigger and Post ICU Course|Unknown status|Recruiting||500||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:33:16.443057|2018-06-01 03:33:16.443057
NCT00413803|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2009-08-03|2006-12-19|2006-12-20|Estimate|||||||2009-08-03|2009-08-04|Estimate|December 2006||2006-12-31|August 2009|2009-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis|Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis: Long Dialysis Study|Completed||Phase 4|410|Actual|Ege University||2|||f||||t||||||||||2018-06-01 03:33:16.531732|2018-06-01 03:33:16.531732
NCT00413790|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2008-01-14|2006-12-19|2006-12-20|Estimate|||||||2008-01-14|2008-01-15|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Interventional|||Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects|A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older|Completed||Phase 4|162|Actual|Novartis||3|||||||||||||||||2018-06-01 03:33:16.656588|2018-06-01 03:33:16.656588
NCT00413777|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2017-03-29|2012-05-22|2017-05-30|2006-12-18|2006-12-20|Estimate|2017-05-30|2017-07-02|Actual|2012-05-30|2012-06-05|Estimate|2017-05-30|2017-07-02|Actual|December 2005||2005-12-31|May 2017|2017-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|TEMPO 2:4||Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|A Phase 2, Multi-center, Open-label Study to Determine Long-term Safety, Tolerability and Efficacy of Split-dose Oral Regimens of Tolvaptan Tablets in a Range of 30 to 120 mg/d in Patients With Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 2|46|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 03:33:16.908963|2018-06-01 03:33:16.908963
NCT00413764|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-04-07|2006-12-19|2006-12-20|Estimate|||||||2017-04-07|2017-04-10|Actual|March 23, 2004|Actual|2004-03-23|April 2017|2017-04-30|November 15, 2005|Actual|2005-11-15|November 15, 2005|Actual|2005-11-15||Interventional|||Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)|A Multicenter, Randomized, Double-Blind, Double Dummy Trial to Compare the Effects Tibolone and Transdermal Continuous Combined Estradiol/Norethisterone on Sexual Desire and Arousal in Postmenopausal Women With Sexual Dysfunction|Completed||Phase 3|358|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:33:18.398551|2018-06-01 03:33:18.398551
NCT00413751|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2006-12-19|2006-12-19|2006-12-20|Estimate|||||||2006-12-19|2006-12-20|Estimate||||December 2006|2006-12-31||||||||Observational|||Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes||Completed|||20||Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:33:18.524967|2018-06-01 03:33:18.524967
NCT00413738|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2009-01-26|2006-12-19|2006-12-20|Estimate|||||||2009-01-26|2009-01-27|Estimate|December 2006||2006-12-31|January 2009|2009-01-31|January 2009||2009-01-31|||||Interventional|||Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease|Prevention of Catheter-Related Bloodstream Infection in Patients With Hemato-Oncological Disease.A Randomized Controlled Trial:Heparin-Coated Central Venous Catheters Versus Antiseptic-Coated Central Venous Catheters|Completed||Phase 3|||Centre National de Greffe de Moelle Osseuse|||||f||||||||||||||2018-06-01 03:33:18.623201|2018-06-01 03:33:18.623201
NCT00413725|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18||2015-05-28|2015-07-02|2006-12-18|2006-12-20|Estimate||||2015-07-02|2015-07-24|Estimate|2015-07-02|2015-07-24|Estimate|January 2007||2007-01-31|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults|A Multicenter Double-Blind Randomized Placebo-Controlled Phase IIB Test-of-Concept Study to Evaluate the Safety and Efficacy of a Three-Dose Regimen of the Clade B-based Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in HIV-1 Uninfected Adults in South Africa|Completed||Phase 2|801|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:33:18.75677|2018-06-01 03:33:18.75677
NCT00413712|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-02-09|2006-12-19|2006-12-20|Estimate|||||||2017-02-09|2017-02-10|Actual|January 1997||1997-01-31|February 2017|2017-02-28|March 2001||2001-03-31|||||Interventional|||Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT|Comparism Between Efficacy and Effectiveness Between Slow Infusion of Calcium Channel Blockers and Intravenous Bolus Adenosine in the Management of Supraventricular Tachycardia in the Emergency Department.|Completed||Phase 4|206||Singapore General Hospital|||||f||||||||||||||2018-06-01 03:33:18.945631|2018-06-01 03:33:18.945631
NCT00413699|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2017-11-17||2018-02-27|2006-12-18|2006-12-20|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|February 5, 2007|Actual|2007-02-05|February 2018|2018-02-28|October 26, 2017|Actual|2017-10-26|November 30, 2016|Actual|2016-11-30||Interventional|||Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis|A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis|Completed||Phase 3|4481|Actual|Pfizer|"All information is based on protocol Amendment 25 with a database release date of 02 March 2017.~One serious adverse event in the Tofacitinib 5mg BID group could not be coded (septic shock and pneumonia) and has not been included."|2|||f||||t||||||||||2018-06-01 03:33:19.550312|2018-06-01 03:33:19.550312
NCT00413686|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2010-12-03|2006-12-19|2006-12-20|Estimate|||||||2010-12-03|2010-12-06|Estimate|December 2006||2006-12-31|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies|A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies|Completed||Phase 1|42|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 03:33:27.95922|2018-06-01 03:33:27.95922
NCT00413673|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2008-03-31|2006-12-19|2006-12-20|Estimate|||||||2008-03-31|2008-04-01|Estimate|August 2001||2001-08-31|November 2007|2007-11-30|March 2008||2008-03-31|||||Interventional|||Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel|Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel|Completed||N/A|100|Anticipated|Walter Reed Army Medical Center||1|||f||||||||||||||2018-06-01 03:33:28.092308|2018-06-01 03:33:28.092308
NCT00413660|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2012-12-04|2009-04-06|2013-01-14|2006-12-18|2006-12-20|Estimate|2012-12-04|2013-01-08|Estimate|2009-10-07|2009-10-12|Estimate|2013-01-14|2013-01-18|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis|A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone|Completed||Phase 2|509|Actual|Pfizer||7|||f||||f||||||||||2018-06-01 03:33:28.469083|2018-06-01 03:33:28.469083
NCT00413647|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2013-06-10|2006-12-18|2006-12-20|Estimate|||||||2013-06-10|2013-06-12|Estimate|September 2006||2006-09-30|June 2013|2013-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Phase I Study in Healthy Volunteers to Evaluate the Safety of CardioPET™ in Detection of Coronary Artery Disease|A Phase I Study to Evaluate the Safety, Biodistribution and Radiation Dosimetry of CardioPET™ as a PET Tracer for Detection of Coronary Artery Disease|Completed||Phase 1|21|Actual|Fluoropharma, Inc.||1|||f||||f||||||||||2018-06-01 03:33:36.123384|2018-06-01 03:33:36.123384
NCT00413634|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|2009-03-05||2014-06-06|2006-12-19|2006-12-20|Estimate|2009-04-08|2009-06-02|Estimate||||2014-06-06|2014-06-12|Estimate|August 2006||2006-08-31|July 2010|2010-07-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)|A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia.|Completed||Phase 2|24|Actual|Shire||1|||f||||||||||||||2018-06-01 03:33:36.222699|2018-06-01 03:33:36.222699
NCT00413621|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-06-30|2006-12-19|2006-12-20|Estimate|||||||2017-06-30|2017-07-02|Actual|December 14, 2006||2006-12-14|October 7, 2009|2009-10-07||||October 7, 2009|Actual|2009-10-07||Observational|||MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems|MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:33:36.799657|2018-06-01 03:33:36.799657
NCT00413608|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2011-05-04|2006-12-19|2006-12-20|Estimate|||||||2011-05-04|2011-05-05|Estimate|January 2007||2007-01-31|July 2007|2007-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects|Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects|Completed||Phase 1|140|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:33:36.922791|2018-06-01 03:33:36.922791
NCT00413595|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-19|||2017-07-24|2006-12-19|2006-12-20|Estimate|||||||2017-07-24|2017-07-26|Actual|July 2007||2007-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|sifap2||Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation|Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study|Recruiting|||100|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     EDTA-blood and urine sample for central laboratory analysis of agalsidase antibodies and Gb3~     for safety issues.~      There will be a proteomic analysis in blood to check whether there will be the possibility to~     characterize a biomarker for Fabry disease.~   "|Undecided||2018-06-01 03:33:37.014169|2018-06-01 03:33:37.014169
NCT00413582|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2011-12-12||2011-12-12|2006-12-19|2006-12-20|Estimate|2011-12-12|2012-01-16|Estimate||||2011-12-12|2012-01-16|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|October 2010|Actual|2010-10-31|May 2010|Actual|2010-05-31||Interventional|||Pain Management for Pectus Excavatum Repair|Prospective Randomized Trial: Pain Management Strategy After Pectus Excavatum Repair|Completed||N/A|110|Actual|Children's Mercy Hospital Kansas City||2|||f||||||||||||||2018-06-01 03:33:37.17872|2018-06-01 03:33:37.17872
NCT00413569|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2006-12-18|2006-12-18|2006-12-19|Estimate|||||||2006-12-18|2006-12-19|Estimate||||December 2006|2006-12-31||||||||Observational|||The Effect of Intubation Method on Outcome of Cervical Spine Surgery||Completed|||||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 03:33:37.375064|2018-06-01 03:33:37.375064
NCT00413556|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2008-03-04|2006-12-18|2006-12-19|Estimate|||||||2008-03-04|2008-03-06|Estimate|January 2007||2007-01-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Changes in the Immune Response and Skin Reactivity of Grass Pollen Allergic Patients Treated With ALK Grass Tablets|Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study Investigating Changes in Immunological Parameters and Cutaneous Reactivity Induced by a Short Course Immunotherapy With ALK Grass Tablets|Completed||Phase 3|76|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-06-01 03:33:37.425636|2018-06-01 03:33:37.425636
NCT00413543|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2015-09-17|2006-12-18|2006-12-19|Estimate|||||||2015-09-17|2015-09-18|Estimate|October 2006||2006-10-31|September 2015|2015-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|Early Pulmonary Rehabilitation After Hospitalisation for Acute Exacerbation COPD|Terminated||N/A|17|Actual|Isala||2||enrollment insufficient: lack of motivated patients|f||||t||||||||||2018-06-01 03:33:37.486936|2018-06-01 03:33:37.486936
NCT00413517|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2010-07-15|2006-12-18|2006-12-19|Estimate|||||||2010-07-15|2010-07-16|Estimate|November 2006||2006-11-30|July 2010|2010-07-31|September 2009|Actual|2009-09-30|||||Interventional|||Evaluation of Epi-lasik in U.S. Army Personnel|Evaluation of Epi-lasik in U.S. Army Personnel|Completed||N/A|150|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:33:37.549757|2018-06-01 03:33:37.549757
NCT00413504|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2009-02-02|2006-12-15|2006-12-19|Estimate|||||||2009-02-02|2009-02-04|Estimate|April 2006||2006-04-30|February 2009|2009-02-28|July 2007|Actual|2007-07-31|||||Interventional|||Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism|Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study)|Completed||N/A|30|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 03:33:37.601442|2018-06-01 03:33:37.601442
NCT00413491|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2014-05-19|2006-12-18|2006-12-19|Estimate|||||||2014-05-19|2014-05-20|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|MR BRCA||National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations|National Screening i Danmark Med MR-scanning af Brystet Kontra Klinisk Mammografi Hos Kvinder Der er bærere af Risikogivende BRCA1 Eller BRCA2 Mutationer|Unknown status|Recruiting|Phase 4|300|Anticipated|Danish Breast Cancer Cooperative Group||1|||f||||||||||||||2018-06-01 03:33:37.678304|2018-06-01 03:33:37.678304
NCT00413478|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2015-06-03||2015-06-26|2006-12-18|2006-12-19|Estimate|2015-06-26|2015-06-30|Estimate||||2015-06-26|2015-06-30|Estimate|September 2006||2006-09-30|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia|Phase II Study of 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia|Terminated||Phase 2|9|Actual|M.D. Anderson Cancer Center|Early termination led to small numbers of subjects analyzed.|1||Slow accrual.|f||||f||||||||||2018-06-01 03:33:38.101333|2018-06-01 03:33:38.101333
NCT00413439|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2017-03-08|2006-12-18|2006-12-19|Estimate|||||||2017-03-08|2017-03-10|Actual|May 2006||2006-05-31|March 2017|2017-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy|Open Label, Multi-center, Sequential Group Clinical Study to Determine the Safety and Efficacy of Escalating Dosing Regimens of Intravenous BAL8557 in the Prophylaxis of Patients Undergoing Chemotherapy for Acute Myeloid Leukemia|Completed||Phase 2/Phase 3|18|Actual|Basilea Pharmaceutica||2|||f||||f||||||||||2018-06-01 03:33:38.474259|2018-06-01 03:33:38.474259
NCT00413426|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2016-04-08|2006-12-18|2006-12-19|Estimate|||||||2016-04-08|2016-04-12|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|September 2007|Actual|2007-09-30|||||Interventional|||Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects|An Open-labeled, Randomized, Single Dose, Three Period, 2-sequence Crossover Study to Investigate the Pharmacokinetics of Darifenacin When Given as 7.5 mg Oral Doses of a Modified Release Suspension, as Compared to the Commercial Modified Release Tablet in Healthy Adult|Completed||Phase 1|28||Novartis|||||f||||||||||||||2018-06-01 03:33:38.549466|2018-06-01 03:33:38.549466
NCT00413413|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2009-08-06||2011-04-26|2006-12-18|2006-12-19|Estimate|2009-08-06|2009-09-14|Estimate||||2011-04-26|2011-04-28|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension|A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy.|Completed||Phase 3|1134|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:33:38.641075|2018-06-01 03:33:38.641075
NCT00413400|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2010-08-31||2010-11-03|2006-12-18|2006-12-19|Estimate|2010-11-03|2010-12-02|Estimate||||2010-11-03|2010-12-02|Estimate|December 2006||2006-12-31|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of TNF-Antagonism in the Metabolic Syndrome (II)|Effects of Etanercept in Patients With the Metabolic Syndrome (II)|Completed||N/A|40|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:33:39.185099|2018-06-01 03:33:39.185099
NCT00413387|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2008-04-21|2006-12-18|2006-12-19|Estimate|||||||2008-04-21|2008-04-22|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|October 2005|Actual|2005-10-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)|Double Blind, Double Dummy, Multinational, Multicentre, Parallel-Group Design Clinical Trial of the Efficacy and Tolerability of CHF 1535 (Beclomethasone Dipropionate 100 µg + Formoterol 6 µg) pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler® (Symbicort®) in the 12-Week Treatment of Adult Patients With Moderate to Severe Persistent Asthma|Completed||Phase 3|219|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-06-01 03:33:39.704754|2018-06-01 03:33:39.704754
NCT00413374|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2011-06-22||2012-04-27|2006-12-15|2006-12-19|Estimate|2012-04-27|2012-04-30|Estimate||||2012-04-27|2012-04-30|Estimate|May 2006||2006-05-31|April 2012|2012-04-30|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism|Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism|Completed||N/A|40|Actual|Brigham and Women's Hospital||1|||f||||t||||||||||2018-06-01 03:33:39.829975|2018-06-01 03:33:39.829975
NCT00413361|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2011-01-26|2006-12-18|2006-12-19|Estimate|||||||2011-01-26|2011-01-27|Estimate|June 2007||2007-06-30|May 2007|2007-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS|Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study|Completed||Phase 4|543|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:33:40.021345|2018-06-01 03:33:40.021345
NCT00413348|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2006-12-18|2006-12-18|2006-12-19|Estimate|||||||2006-12-18|2006-12-19|Estimate|November 2006||2006-11-30|December 2006|2006-12-31|December 2007||2007-12-31|||||Interventional|||Type 2 Diabetes and the Effect of Probiotics|Effect of Probiotics on Systemic Inflammation and Insulin Resistance in Type 2 Diabetics and Healthy Controls|Unknown status|Recruiting|N/A|48||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:33:40.094528|2018-06-01 03:33:40.094528
NCT00413335|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2012-11-07||2013-07-15|2006-12-18|2006-12-19|Estimate|2013-03-07|2013-04-19|Estimate||||2013-07-15|2013-07-22|Estimate|November 2005||2005-11-30|July 2013|2013-07-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth|Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth|Completed||N/A|21|Actual|Yale University||2|||f||||f||||||||||2018-06-01 03:33:40.206036|2018-06-01 03:33:40.206036
NCT00413322|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2015-07-07|2006-12-18|2006-12-19|Estimate|||||||2015-07-07|2015-07-08|Estimate|September 2005||2005-09-30|July 2015|2015-07-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors|A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors|Completed||Phase 1|35|Actual|Onxeo||1|||f||||f||||||||||2018-06-01 03:33:40.473194|2018-06-01 03:33:40.473194
NCT00413309|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2009-02-02|2006-12-15|2006-12-19|Estimate|||||||2009-02-02|2009-02-04|Estimate|April 2006||2006-04-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention|Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention|Completed||N/A|30|Anticipated|Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 03:33:40.780977|2018-06-01 03:33:40.780977
NCT00413296|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2014-07-18|2006-12-18|2006-12-19|Estimate|||||||2014-07-18|2014-07-21|Estimate|November 2005||2005-11-30|June 2010|2010-06-30|March 2008|Actual|2008-03-31|September 2007|Actual|2007-09-30||Interventional|PTSD||Levetiracetam in Post-Traumatic Stress Disorder|A Double-Blind Discontinuation Study of Levetiracetam in Post- Traumatic Stress Disorder|Completed||Phase 2/Phase 3|16|Actual|Duke University||2|||f||||t||||||||||2018-06-01 03:33:40.896099|2018-06-01 03:33:40.896099
NCT00413283|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2010-09-24||2013-09-18|2006-12-15|2006-12-19|Estimate|2010-09-24|2010-10-21|Estimate||||2013-09-18|2013-10-24|Estimate|December 2006||2006-12-31|September 2013|2013-09-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)|Phase 2, Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 For Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Advanced Non-Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum.|Completed||Phase 2|63|Actual|Amgen||4|||f||||||||||||||2018-06-01 03:33:41.090182|2018-06-01 03:33:41.090182
NCT00413270|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2011-07-12|2006-12-18|2006-12-19|Estimate|||||||2011-07-12|2011-07-13|Estimate|December 2006||2006-12-31|July 2011|2011-07-31||||||||Expanded Access|||Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant|A Canadian Open-label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase|No longer available|||||Novartis|||||f||||||||||||||2018-06-01 03:33:42.339342|2018-06-01 03:33:42.339342
NCT00413257|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2010-05-27|2006-12-18|2006-12-19|Estimate|||||||2010-05-27|2010-05-28|Estimate|December 2006||2006-12-31|May 2010|2010-05-31|November 2008|Actual|2008-11-30|December 2007|Actual|2007-12-31||Interventional|NefalCard||Effects of Nefopam on Hyperalgesia After Cardiac Surgery|Study of the Effects of Nefopam on Hyperalgesia Following Sternotomy in Cardiac Surgery|Completed||Phase 2/Phase 3|90|Actual|University Hospital, Bordeaux||3|||f||||t||||||||||2018-06-01 03:33:42.432775|2018-06-01 03:33:42.432775
NCT00413244|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2016-05-25||2016-11-07|2006-12-18|2006-12-19|Estimate|2016-11-07|2017-01-05|Estimate||||2016-11-07|2017-01-05|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Interventional|||The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery|The Cardiac Benefit of Androgen Replacement in Hypogonadal Males With Coronary Artery Disease Following Successful Percutaneous Coronary Intervention (PCI).|Completed||Phase 3|51|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 03:33:42.51475|2018-06-01 03:33:42.51475
NCT00413231|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2011-12-23||2015-11-25|2006-12-15|2006-12-19|Estimate|2012-03-08|2012-04-05|Estimate||||2015-11-25|2015-12-30|Estimate|December 2006||2006-12-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|August 2010|Actual|2010-08-31||Interventional|||Valor II: The Valiant Thoracic Stent Graft System Clinical Study|The Valiant Thoracic Stent Graft System. The Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System in the Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in Subjects Who Are Candidates for Endovascular Repair.|Completed||N/A|160|Actual|Medtronic Endovascular|Adverse Events and Serious Adverse Events listed in ClinicalTrials.gov were re-coded, using MedDRA 13.1. To do so, events were reclassified. As a result, data in listings may not match those in Clinical Update reports, SSEDs, or Instructions for Use.|1|||f||||t||||||||||2018-06-01 03:33:43.428337|2018-06-01 03:33:43.428337
NCT00413218|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2017-07-05|2015-08-17|2017-08-22|2006-12-18|2006-12-19|Estimate|2017-07-05|2017-08-01|Actual|2015-08-17|2015-09-02|Estimate|2017-08-22|2017-09-19|Actual|March 8, 2007|Actual|2007-03-08|August 2017|2017-08-31|March 3, 2015|Actual|2015-03-03|March 3, 2015|Actual|2015-03-03||Interventional|||Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections|A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections|Completed||Phase 3|450|Actual|Astellas Pharma Inc|Enrollment in the clinical study was suspended in January 2009 pending further characterization of newly identified impurities. After successful completion of the studies, regulatory notifications and transfer of sponsorship from Basilea to Astellas,|2|||f||||t||||||||||2018-06-01 03:33:44.280266|2018-06-01 03:33:44.280266
NCT00413205|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18||2016-07-06|2016-11-01|2006-12-18|2006-12-19|Estimate||||2016-07-06|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)|A Double-blind, Placebo-controlled Efficacy (as Assessed by Post-bronchodilator FEV1) and Safety Study of RAR Gamma in Subjects With Smoking-related, Moderate to Severe COPD With Emphysema Receiving Concurrent Optimised COPD Drug Therapy.|Completed||Phase 2|491|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:33:45.724531|2018-06-01 03:33:45.724531
NCT00413192|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2017-02-02||2017-03-27|2006-12-15|2006-12-19|Estimate|2017-02-02|2017-03-22|Actual||||2017-03-27|2017-04-26|Actual|January 2007||2007-01-31|January 2017|2017-01-31|February 2013|Actual|2013-02-28|June 2012|Actual|2012-06-30||Interventional||Full analysis set consisted of all enrolled subjects who received at least one dose of study drug, regardless of their eligibility to enter the study.|E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma|Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma|Completed||Phase 2|128|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:33:45.959948|2018-06-01 03:33:45.959948
NCT00413179|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2006-12-18|2006-12-18|2006-12-19|Estimate|||||||2006-12-18|2006-12-19|Estimate|December 1997||1997-12-31|December 2006|2006-12-31|April 2003||2003-04-30|||||Interventional|||The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women|The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial|Completed||Phase 3|56||Wilford Hall Medical Center|||||f||||||||||||||2018-06-01 03:33:46.881519|2018-06-01 03:33:46.881519
NCT00413166|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2016-02-15|2006-12-18|2006-12-19|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2006||2006-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab|Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Gemtuzumab|Completed||Phase 2|78|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:33:46.953461|2018-06-01 03:33:46.953461
NCT00413153|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2009-11-04||2010-03-05|2006-12-18|2006-12-19|Estimate|2010-01-26|2010-03-03|Estimate||||2010-03-05|2010-03-09|Estimate|May 2006||2006-05-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Metabolic Effects of Switching Kaletra to Boosted Reyataz|Metabolic Effects of Switching Kaletra to Boosted Reyataz|Completed||N/A|15|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:33:47.065328|2018-06-01 03:33:47.065328
NCT00413140|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2006-12-18|2006-12-18|2006-12-19|Estimate|||||||2006-12-18|2006-12-19|Estimate|June 2004||2004-06-30|November 2003|2003-11-30|May 2005||2005-05-31|||||Observational|||Non-Invasive Biomarkers in Cystic Fibrosis|Biomarkers in Exhaled Breath Indicate Presence, Control and Severity of Cystic Fibrosis|Completed|||100||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:33:47.571444|2018-06-01 03:33:47.571444
NCT00413127|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2015-06-25|2006-12-18|2006-12-19|Estimate|||||||2015-06-25|2015-06-26|Estimate|September 2007||2007-09-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Perioperative Protective Effects of Lidocaine|Perioperative Protective Effects of Lidocaine - Clinical Study on the Route and Timing of Administration|Terminated||Phase 2/Phase 3|78|Actual|University Hospital Muenster||5||Less patients than expected for inclusion, therefore patient recruitment is to low|f||||f||||||||||2018-06-01 03:33:47.629178|2018-06-01 03:33:47.629178
NCT00011206|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-13|||2014-03-14|2001-02-12|2001-02-13|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2001||2001-01-31|March 2014|2014-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Mortality Follow-Up and Analyses of Men in the MRFIT||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 05:37:22.409089|2018-06-01 05:37:22.409089
NCT00413114|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18||2013-08-16|2013-08-16|2006-12-18|2006-12-19|Estimate||||2013-08-16|2013-08-26|Estimate|2013-08-16|2013-08-26|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|November 2009|Actual|2009-11-30|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)|A Phase II Study of Obatoclax Mesylate (GX15-070MS) in Patients With Previously-Untreated Myelodysplastic Syndromes (MDS) With Anemia and/or Thrombocytopenia|Completed||Phase 2|24|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 03:33:47.708781|2018-06-01 03:33:47.708781
NCT00413101|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2009-05-13|2006-12-18|2006-12-19|Estimate|||||||2009-05-13|2009-05-14|Estimate||||May 2009|2009-05-31|March 2008|Actual|2008-03-31|||||Interventional|||A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.|An Open-Label Study to Investigate Improvement in Heart Function After Complete Anemia Correction With NeoRecormon in Patients With End-Stage Renal Disease Already Receiving Sub-Optimal Doses of NeoRecormon|Completed||Phase 4|50|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:33:47.79957|2018-06-01 03:33:47.79957
NCT00413088|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2011-03-17|2006-12-18|2006-12-19|Estimate|||||||2011-03-17|2011-03-18|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly|Clinical Trial to Assess Bemiparin Pharmacokinetics at Therapeutic (115 IU/kg) and Prophylactic Doses (3500 IU) Administered Subcutaneously in Single or Multiple Doses in Renal Insufficiency and in the Elderly|Completed||Phase 1|60|Anticipated|Rovi Pharmaceuticals Laboratories|||||f||||||||||||||2018-06-01 03:33:47.908916|2018-06-01 03:33:47.908916
NCT00413075|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2015-07-07|2006-12-18|2006-12-19|Estimate|||||||2015-07-07|2015-07-08|Estimate|June 2006||2006-06-30|July 2015|2015-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma|Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors|Completed||Phase 1|121|Actual|Onxeo||1|||f||||f||||||||||2018-06-01 03:33:48.032567|2018-06-01 03:33:48.032567
NCT00413062|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2011-04-27|2009-04-29|2015-08-26|2006-12-18|2006-12-19|Estimate|2011-07-28|2011-08-29|Estimate|2009-09-25|2009-09-30|Estimate|2015-08-26|2015-08-27|Estimate|June 2006||2006-06-30|August 2015|2015-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)|A Randomized, Open-Label, Comparative, Multi -Center Trial to Evaluate Contraceptive Efficacy, Cycle Control, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 µg Ethinyl Estradiol (EE)|Completed||Phase 3|2281|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:33:48.220313|2018-06-01 03:33:48.220313
NCT00413049|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2011-01-11||2011-04-26|2006-12-18|2006-12-19|Estimate|2011-01-11|2011-02-08|Estimate||||2011-04-26|2011-04-29|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension|A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Amlodipine 5 mg Monotherapy|Completed||Phase 3|698|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:33:48.917767|2018-06-01 03:33:48.917767
NCT00413036|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2013-01-09||2017-01-17|2006-12-18|2006-12-19|Estimate|2013-03-06|2013-04-11|Estimate||||2017-01-17|2017-03-01|Actual|June 2006||2006-06-30|January 2017|2017-01-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|217|Actual|Celgene||1|||f||||t||||||||||2018-06-01 03:33:49.184138|2018-06-01 03:33:49.184138
NCT00413023|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2016-10-26|2006-12-18|2006-12-19|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 2005||2005-06-30|October 2016|2016-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)|A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Major Depressive Disorder (MDD)|Completed||Phase 2|348|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:33:49.629114|2018-06-01 03:33:49.629114
NCT00413010|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2009-02-27||2009-12-03|2006-12-18|2006-12-19|Estimate|2009-10-21|2009-12-02|Estimate||||2009-12-03|2009-12-09|Estimate|December 2006||2006-12-31|December 2009|2009-12-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).|An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD)|Completed||Phase 3|356|Actual|Pfizer|Further enrollment in this study was stopped based on the recommendation of an independent Data Monitoring Committee (DMC). An interim data analysis did not suggest the potential for robust efficacy. The study was not stopped for any safety findings.|2|||f||||t||||||||||2018-06-01 03:33:49.90603|2018-06-01 03:33:49.90603
NCT00412997|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2012-11-26|2006-12-18|2006-12-19|Estimate|||||||2012-11-26|2012-11-27|Estimate|November 2006||2006-11-30|November 2012|2012-11-30||||May 2008|Actual|2008-05-31||Interventional|||LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma|A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma|Completed||Phase 1|14|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:33:50.863151|2018-06-01 03:33:50.863151
NCT00412984|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2013-01-25||2013-09-27|2006-12-18|2006-12-19|Estimate|2013-03-15|2013-04-29|Estimate||||2013-09-27|2013-11-07|Estimate|December 2006||2006-12-31|September 2013|2013-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|ARISTOTLE|Randomized participants|Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation|A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation|Completed||Phase 3|18201|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:33:51.279029|2018-06-01 03:33:51.279029
NCT00412971|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2013-08-05||2013-08-05|2006-12-18|2006-12-19|Estimate|2013-08-05|2013-10-11|Estimate||||2013-08-05|2013-10-11|Estimate|April 2005||2005-04-30|August 2013|2013-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer|A Randomized, Comparative Phase III, 2-center Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer|Completed||Phase 3|233|Actual|Photocure||2|||f||||||||||||||2018-06-01 03:34:00.08241|2018-06-01 03:34:00.08241
NCT00412958|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2012-12-20||2014-12-02|2006-12-18|2006-12-19|Estimate|2012-12-20|2013-01-30|Estimate||||2014-12-02|2014-12-17|Estimate|December 2006||2006-12-31|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)|A Multicenter, Randomized, Placebo-Controlled, Double-Masked, Parallel Group, Dose-Ranging Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial|Completed||Phase 2|125|Actual|ThromboGenics||4|||f||||t||||||||||2018-06-01 03:34:00.401523|2018-06-01 03:34:00.401523
NCT00412932|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2009-04-28||2009-09-15|2006-12-18|2006-12-19|Estimate|2009-08-05|2009-09-11|Estimate||||2009-09-15|2009-09-22|Estimate|December 2006||2006-12-31|September 2009|2009-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension|A Prospective, Open Label, Single Arm Study to Evaluation the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Elderly Patients With Hypertension|Completed||Phase 4|178|Actual|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 03:34:00.883633|2018-06-01 03:34:00.883633
NCT00412919|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-17|||2013-12-12|2006-12-17|2006-12-19|Estimate|||||||2013-12-12|2013-12-16|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma|A Prospective, Single-Arm, 2-Stage, Open-label, Phase II Trial of Azacitidine in Relapsed and Refractory Multiple Myeloma.|Terminated||Phase 2|7|Actual|Bayside Health||||Lack of efficacy|f||||||||||||||2018-06-01 03:34:01.380839|2018-06-01 03:34:01.380839
NCT00412906|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|||2008-05-20|2006-12-18|2006-12-19|Estimate|||||||2008-05-20|2008-05-21|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls|Study of Gene Expression in Fat and Muscle Tissue in Type 2 Diabetics and Healthy Controls During Experimental Endotoxemia|Completed||N/A|48|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||||||2018-06-01 03:34:01.447971|2018-06-01 03:34:01.447971
NCT00412893|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2015-03-19|2014-03-12|2017-12-07|2006-12-18|2006-12-19|Estimate|2015-03-19|2015-03-31|Estimate|2014-03-12|2014-04-09|Estimate|2017-12-07|2018-01-02|Actual|March 7, 2007|Actual|2007-03-07|December 2017|2017-12-31|March 28, 2013|Actual|2013-03-28|March 28, 2013|Actual|2013-03-28||Interventional||Intent-to-treat (ITT) population consisted of all randomized participants who received at least one administration of study drug.|Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis|A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.|Completed||Phase 3|527|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||t||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-06-01 03:34:01.582052|2018-06-01 03:34:01.582052
NCT00412880|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18||2014-04-30|2014-04-30|2006-12-18|2006-12-19|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|January 2007||2007-01-31|April 2014|2014-04-30||||June 2008|Actual|2008-06-30||Interventional|||BI 2536 Second Line Monotherapy in SCLC|An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer|Completed||Phase 2|23|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:34:03.441626|2018-06-01 03:34:03.441626
NCT00412867|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-17|2012-01-19||2017-12-20|2006-12-18|2006-12-19|Estimate|2012-01-19|2012-02-24|Estimate||||2017-12-20|2018-01-19|Actual|December 2006||2006-12-31|December 2017|2017-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）|Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Phase 4)|Completed||Phase 4|58|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-06-01 03:34:03.543213|2018-06-01 03:34:03.543213
NCT00412854|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2016-12-20||2016-12-20|2006-12-18|2006-12-19|Estimate|2016-12-20|2017-02-10|Actual||||2016-12-20|2017-02-10|Actual|January 2007||2007-01-31|November 2016|2016-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.|Phase IIIb, Multicentre Study to Assess Safety & Immunogenicity of GSK Biologicals' Combined DTPa/Hib (Infanrix/Hib) Vaccine vs Separate Administration of DTPa (Infanrix) & Hib (Hiberix) Vaccines in Healthy Infants 3,4,&5 Months of Age as Compared With the Separate Administration of DTPa and Hib Vaccines at Different Injection Sites.|Completed||Phase 3|660|Actual|GlaxoSmithKline|None reported.||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:34:04.053326|2018-06-01 03:34:04.053326
NCT00412841|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18|2014-05-28||2017-11-06|2006-12-18|2006-12-19|Estimate|2016-02-03|2016-03-03|Estimate||||2017-11-06|2017-12-08|Actual|November 2002||2002-11-30|November 2017|2017-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus|AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial|Terminated||Phase 2|43|Actual|New York University School of Medicine||2|||f||||t|t|f||||||||2018-06-01 03:34:04.758862|2018-06-01 03:34:04.758862
NCT00412828|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-18||2015-02-02|2015-02-02|2006-12-18|2006-12-19|Estimate||||2015-02-02|2015-02-19|Estimate|2015-02-02|2015-02-19|Estimate|June 2006||2006-06-30|February 2015|2015-02-28|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma|A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma|Completed||Phase 1/Phase 2|117|Actual|Celldex Therapeutics|||||f||||t||||||||||2018-06-01 03:34:05.043508|2018-06-01 03:34:05.043508
NCT00412815|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2017-08-25|2006-12-14|2006-12-18|Estimate|||||||2017-08-25|2017-08-28|Actual|November 25, 1998|Actual|1998-11-25|August 2017|2017-08-31|June 9, 2000|Actual|2000-06-09|June 9, 2000|Actual|2000-06-09||Interventional|||Exercise Training, Insulin Resistance and Coronary Artery Disease|The Effects of Exercise Training on Insulin Resistance in Patients With Coronary Artery Disease and Insulin Resistance, the Exercise, Coronary Artery Disease and Insulin Resistance (EXCADIR) Randomized Controlled Trial|Completed||Phase 3|60||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 03:34:05.113471|2018-06-01 03:34:05.113471
NCT00412802|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2011-07-19|2006-12-15|2006-12-18|Estimate|||||||2011-07-19|2011-07-21|Estimate|December 2006||2006-12-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome|Validation of Enoxaparin Dose Adaptation in Patients With Moderate Renal Failure Hospitalized for an Acute Coronary Syndrome, the VALIDE Study|Completed||Phase 4|67|Actual|French Cardiology Society||2|||f||||t||||||||||2018-06-01 03:34:05.187232|2018-06-01 03:34:05.187232
NCT00412776|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2015-12-22|2006-12-14|2006-12-18|Estimate|||||||2015-12-22|2015-12-23|Estimate|December 2005||2005-12-31|December 2015|2015-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer|A Randomized, Multicentre Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Proxinium Plus Best Supportive Care Versus Best Supportive Care Alone in Patients With Advanced SCCHN Who Have Received at Least One Anti-cancer Treatment Regimen for Advanced Disease|Terminated||Phase 2/Phase 3|165|Actual|Viventia Bio||2||Corporate reasons unrelated to safety and efficacy|f||||t||||||||||2018-06-01 03:34:05.354635|2018-06-01 03:34:05.354635
NCT00412763|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2006-12-15|2006-12-15|2006-12-18|Estimate|||||||2006-12-15|2006-12-18|Estimate|July 2003||2003-07-31|December 2006|2006-12-31|October 2005||2005-10-31|||||Interventional|||Efficacy of Silymarin for Acute Hepatitis|Efficacy of Silymarin for Treatment of Acute Hepatitis In Egypt: A Randomized, Double-Blinded, Controlled Trial|Completed||Phase 4|200||University of Maryland|||||f||||||||||||||2018-06-01 03:34:05.721432|2018-06-01 03:34:05.721432
NCT00412750|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2010-12-02||2011-06-14|2006-12-15|2006-12-18|Estimate|2011-06-14|2011-07-13|Estimate||||2011-06-14|2011-07-13|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)|A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq 180 µg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Treatment naïve Patients With HBeAg-positive CHB.|Terminated||Phase 3|159|Actual|Novartis||3||Enrollment stopped for safety issues|f||||||||||||||2018-06-01 03:34:05.818479|2018-06-01 03:34:05.818479
NCT00412737|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2009-08-03||2016-05-04|2006-12-15|2006-12-18|Estimate|2009-08-03|2009-09-09|Estimate||||2016-05-04|2016-06-10|Estimate|January 2007||2007-01-31|May 2016|2016-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||The safety population included all participants who received at least 1 dose of study drug and had at least 1 post baseline safety assessment. Participants were analyzed as per actual treatment received.|A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants|A Double-blind, Randomized, Placebo Controlled, Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients|Completed||Phase 4|477|Actual|Hoffmann-La Roche|There were no overall limitations and caveats.|2|||f||||||||||||||2018-06-01 03:34:06.423725|2018-06-01 03:34:06.423725
NCT00412724|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2012-08-06|2006-12-15|2006-12-18|Estimate|||||||2012-08-06|2012-08-07|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Development and Validation of the Food Acceptability Questionnaire|Development and Validation of the Food Acceptability Questionnaire|Completed|||189|Actual|Physicians Committee for Responsible Medicine|||||f||||t||||||||||2018-06-01 03:34:06.997801|2018-06-01 03:34:06.997801
NCT00412698|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2010-12-09|2006-12-15|2006-12-18|Estimate|||||||2010-12-09|2010-12-10|Estimate|December 2006||2006-12-31|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|ETERNAL||European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia|A European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Dyslipidemia With or Without Other Comorbidities|Terminated||Phase 3|645|Actual|Sanofi||2||"Company decision has been taken in light of recent demands by certain national health~   authorities"|f||||||||||||||2018-06-01 03:34:07.052354|2018-06-01 03:34:07.052354
NCT00412685|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2015-06-15|2006-12-15|2006-12-18|Estimate|||||||2015-06-15|2015-06-16|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Myocardial Contrast Echocardiography in Congenital Heart Disease|Quantification of the Myocardial Microcirculation by Contrast Echocardiography In Adult Patients With Congenital Heart Disease|Completed|||45|Actual|University Hospital Inselspital, Berne|||3||f||||||||||||||2018-06-01 03:34:07.132809|2018-06-01 03:34:07.132809
NCT00412672|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2015-06-15|2006-12-15|2006-12-18|Estimate|||||||2015-06-15|2015-06-16|Estimate|July 2010||2010-07-31|June 2015|2015-06-30||||||||Observational|||Protective Effect of Coronary Collaterals on Infarct Size in Patients With Acute Myocardial Infarction|Protective Effect of Coronary Collaterals on Infarct Size in Patients With Acute Myocardial Infarction|Withdrawn|||0|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-06-01 03:34:07.185966|2018-06-01 03:34:07.185966
NCT00412659|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2016-05-31|2006-12-15|2006-12-18|Estimate|||||||2016-05-31|2016-06-01|Estimate|March 2006||2006-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Mid-line Excision Versus Karydakis Operation for Pilonidal Sinus|An Expertise-based Randomized Controlled Trial Comparing Midline Excision Versus Karydakis Operation at Surgery for Pilonidal Sinus|Completed||Phase 2/Phase 3|125|Actual|Umeå University||2|||f||||||||||||||2018-06-01 03:34:07.236054|2018-06-01 03:34:07.236054
NCT00412646|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2010-04-26|2006-12-15|2006-12-18|Estimate|||||||2010-04-26|2010-04-28|Estimate|June 2002||2002-06-30|April 2010|2010-04-30|November 2006|Actual|2006-11-30|||||Interventional|||TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients|A Randomized, Placebo-controlled Phase II Trial in HIV-1-infected, NRTI-, PI and NNRTI-experienced Subjects to Evaluate the Safety, Tolerability and Efficacy of Different Doses of TMC125 b.i.d. on Top of an Individually Optimized Antiretroviral Therapy by Means of a 2-stage Dose-escalating Design|Completed||Phase 2|260|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 03:34:07.31721|2018-06-01 03:34:07.31721
NCT00412633|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2012-06-08|2006-12-15|2006-12-18|Estimate|||||||2012-06-08|2012-06-11|Estimate|February 2004||2004-02-29|June 2012|2012-06-30|October 2010|Actual|2010-10-31|July 2007|Actual|2007-07-31||Interventional|||Clinical & Web-based Diet & Activity Counseling for Men|Clinical & Web-based Diet & Activity Counseling for Men|Completed||N/A|442|Actual|University of California, San Diego|||||f||||||||||||||2018-06-01 03:34:07.539149|2018-06-01 03:34:07.539149
NCT00412620|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2011-04-25|2006-12-15|2006-12-18|Estimate|||||||2011-04-25|2011-04-27|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia|Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia|Terminated||Phase 2|156|Actual|Abbott||4|||f||||t||||||||||2018-06-01 03:34:07.609363|2018-06-01 03:34:07.609363
NCT00412425|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2012-02-07||2012-04-09|2006-12-15|2006-12-18|Estimate|2012-04-09|2012-05-04|Estimate||||2012-04-09|2012-05-04|Estimate|November 2006||2006-11-30|April 2012|2012-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting|Evaluation of Two Different Schedules of Palonosetron for the Prevention of Nausea and Vomiting in Patients With Metastatic Melanoma Receiving Concurrent Biochemotherapy|Completed||Phase 1/Phase 2|30|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:34:12.312634|2018-06-01 03:34:12.312634
NCT00412607|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2014-09-23||2014-10-29|2006-12-14|2006-12-18|Estimate|2014-10-14|2014-10-16|Estimate||||2014-10-29|2014-11-05|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|VT-CoA|All enrolled subjects who signed the informed consent form and were eligible for inclusion in the clinical study|Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia|NaviStar ThermoCool Catheter for Endocardial RF Ablation in Patients With Ventricular Tachycardia|Completed||Phase 4|249|Actual|Biosense Webster, Inc.||1|||f||||||||||||||2018-06-01 03:34:07.744908|2018-06-01 03:34:07.744908
NCT00412594|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2017-12-06|2006-12-15|2006-12-18|Estimate|||||||2017-12-06|2017-12-08|Actual|June 10, 2004|Actual|2004-06-10|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||2CDA With Rituximab in Hairy Cell Leukemia|Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed By Rituximab in Hairy Cell Leukemia|Recruiting||Phase 2|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:34:08.149208|2018-06-01 03:34:08.149208
NCT00412581|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2016-04-28|2006-12-14|2006-12-18|Estimate|||||||2016-04-28|2016-04-29|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma|Phase I Safety Study of the Combination of Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy (CC-5013-MEL-003)|Completed||Phase 1|28|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:34:08.226008|2018-06-01 03:34:08.226008
NCT00412568|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2008-03-31|2006-12-15|2006-12-18|Estimate|||||||2008-03-31|2008-04-01|Estimate|May 2004||2004-05-31|November 2007|2007-11-30|March 2008||2008-03-31|||||Interventional|||Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel|Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel|Completed||N/A|150|Anticipated|Walter Reed Army Medical Center||1|||f||||||||||||||2018-06-01 03:34:08.297018|2018-06-01 03:34:08.297018
NCT00412555|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2016-11-01|2006-12-15|2006-12-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2006||2006-12-31|November 2016|2016-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.|An Open-label Multi-center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Children.|Completed||Phase 4|52|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:34:08.348016|2018-06-01 03:34:08.348016
NCT00412542|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2012-02-08||2012-02-08|2006-12-15|2006-12-18|Estimate|2012-02-08|2012-02-28|Estimate||||2012-02-08|2012-02-28|Estimate|October 2003||2003-10-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas|A Phase II Trial of Combination Therapy With Thalidomide and CPT-11 in Patients With Recurrent Anaplastic Gliomas or Glioblastoma Multiforme|Completed||Phase 2|78|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:34:08.426678|2018-06-01 03:34:08.426678
NCT00412529|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2010-12-02||2015-02-23|2006-12-15|2006-12-18|Estimate|2011-07-18|2011-08-12|Estimate||||2015-02-23|2015-03-13|Estimate|December 2006||2006-12-31|February 2015|2015-02-28||||February 2008|Actual|2008-02-29||Interventional|||Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B|A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Adults With HBeAg-positive, Compensated Chronic Hepatitis B (CHB)|Completed||Phase 3|44|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:34:09.759707|2018-06-01 03:34:09.759707
NCT00412516|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2014-09-30||2014-10-03|2006-12-14|2006-12-18|Estimate|2014-09-30|2014-10-06|Estimate||||2014-10-03|2014-10-13|Estimate|December 2006||2006-12-31|October 2014|2014-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||The baseline analysis population includes all subjects enrolled in the study|Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine|Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone|Completed||Phase 3|519|Actual|PATH||3|||f||||f||||||||||2018-06-01 03:34:10.103701|2018-06-01 03:34:10.103701
NCT00412503|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2009-08-06|2006-12-15|2006-12-18|Estimate|||||||2009-08-06|2009-08-07|Estimate||||August 2009|2009-08-31||||||||Interventional|||Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents|Phase 1 Study of Temozolomide Associated With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents|Completed||Phase 1|||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 03:34:11.228846|2018-06-01 03:34:11.228846
NCT00412490|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2016-01-27|2006-12-15|2006-12-18|Estimate|||||||2016-01-27|2016-01-29|Estimate|December 2005||2005-12-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Smoking Status and Body Image in Oral Cancer Patients|A Prospective Examination of Smoking Status and Body Image in Surgical Patients With Cancer of the Oral Cavity|Completed|||75|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:34:11.285398|2018-06-01 03:34:11.285398
NCT00412477|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2017-06-19|2006-12-15|2006-12-18|Estimate|||||||2017-06-19|2017-06-21|Actual|August 20, 2004|Actual|2004-08-20|June 2017|2017-06-30|November 1, 2006|Actual|2006-11-01|March 13, 2006|Actual|2006-03-13||Interventional|||A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine|RV 151: A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults, WRAIR #984, HSRRB Log # A-11905.|Completed||Phase 1|18|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f|t|f||||||No||2018-06-01 03:34:11.387798|2018-06-01 03:34:11.387798
NCT00412464|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2011-07-28||2015-04-14|2006-12-15|2006-12-18|Estimate|2011-10-28|2011-12-06|Estimate||||2015-04-14|2015-04-15|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis|A Pilot Dose-finding and Pharmacokinetic Study of Fondaparinux in Children With Deep Vein Thrombosis or Heparin-induced Thrombocytopenia|Completed||Phase 1|24|Actual|FDA Office of Orphan Products Development|||||f||||t||||||||||2018-06-01 03:34:11.47055|2018-06-01 03:34:11.47055
NCT00412451|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2013-07-04||2014-12-02|2006-12-14|2006-12-18|Estimate|2013-07-04|2013-09-13|Estimate||||2014-12-02|2014-12-17|Estimate|December 2006||2006-12-31|April 2014|2014-04-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|MIVI-II||A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)|A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME.|Completed||Phase 2|51|Actual|ThromboGenics||4|||f||||t||||||||||2018-06-01 03:34:11.679143|2018-06-01 03:34:11.679143
NCT00412412|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2012-06-07|2006-12-15|2006-12-18|Estimate|||||||2012-06-07|2012-06-08|Estimate|December 2007||2007-12-31|December 2011|2011-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study|A Ph1 Open-Label,Dose-Escalation,Safety,PK & PD Study of CNF2024 as a Single-Agent Treatment in Subjects w/HER2- Adv Breast Cancer or in Combo w/Trastuzumab in Subjects w/HER2+ Advanced Breast Cancer|Completed||Phase 1|34|Actual|Biogen||2|||f||||f||||||||||2018-06-01 03:34:12.527455|2018-06-01 03:34:12.527455
NCT00412399|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2006-12-15|2006-12-15|2006-12-18|Estimate|||||||2006-12-15|2006-12-18|Estimate|June 1999||1999-06-30|December 2006|2006-12-31|October 2001||2001-10-31|||||Observational|||Job Adaptation in Patients With Rheumatoid Arthritis|Job Adaptation in Patients With Rheumatoid Arthritis|Completed|||244||Hospital for Special Surgery, New York|||||f||||||||||||||2018-06-01 03:34:12.623904|2018-06-01 03:34:12.623904
NCT00412386|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2013-12-02|2006-12-14|2006-12-18|Estimate|||||||2013-12-02|2013-12-03|Estimate|December 2006||2006-12-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|||||Observational|||Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve|Abnormal 3-dimensional MRI Flow Patterns and Plasma Matrix Metalloproteinase Levels Predict Dilatation of Ascending Aorta in Adolescent Patients With Bicuspid Aortic Valve|Completed|||45|Actual|Emory University|||2||f||||f||||||||||2018-06-01 03:34:12.685386|2018-06-01 03:34:12.685386
NCT00412373|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2009-07-01||2014-04-24|2006-12-15|2006-12-18|Estimate|2009-11-05|2009-12-09|Estimate||||2014-04-24|2014-05-09|Estimate|December 2006||2006-12-31|April 2014|2014-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.|A Randomized, Double-blind, Placebo-controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Flexible-dose Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.|Completed||Phase 3|307|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 03:34:12.816173|2018-06-01 03:34:12.816173
NCT00412360|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2015-08-28||2018-05-01|2006-12-14|2006-12-18|Estimate|2015-11-17|2015-12-21|Estimate||||2018-05-01|2018-05-03|Actual|December 2006||2006-12-31|May 2018|2018-05-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional||Analysis based on intent-to-treat.|Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)|Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501)|Completed||Phase 3|224|Actual|Medical College of Wisconsin||2|||f||||t||||||||Yes|Findings were published in a manuscript.|2018-06-01 03:34:13.733372|2018-06-01 03:34:13.733372
NCT00412347|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2014-02-07|2006-12-15|2006-12-18|Estimate|||||||2014-02-07|2014-02-11|Estimate|August 2006||2006-08-31|February 2014|2014-02-28|December 2006||2006-12-31|||||Observational|||Insulin Infusion in the Hospital Wards|Insulin Infusion and Outcomes for Non-Critical Wards|Completed|||200|Actual|Emory University|||||f||||||||||||||2018-06-01 03:34:14.784602|2018-06-01 03:34:14.784602
NCT00412334|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2016-04-02|2006-12-15|2006-12-18|Estimate|||||||2016-04-02|2016-04-05|Estimate|January 2007||2007-01-31|April 2016|2016-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.|Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy|Completed||Phase 4|104|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 03:34:14.844182|2018-06-01 03:34:14.844182
NCT00412321|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2014-06-30|2006-12-15|2006-12-18|Estimate|||||||2014-06-30|2014-07-01|Estimate|May 2005||2005-05-31|June 2014|2014-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease|A Phase 1 Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease|Completed||Phase 1|67|Actual|Centocor, Inc.||8|||f||||f||||||||||2018-06-01 03:34:15.035166|2018-06-01 03:34:15.035166
NCT00412308|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2011-06-27|2006-12-14|2006-12-18|Estimate|||||||2011-06-27|2011-06-28|Estimate|December 2006||2006-12-31|June 2011|2011-06-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||A Comparison of High vs. Low Tidal Volumes in Ventilator Weaning for Individuals With Cervical Spinal Cord Injuries|A Comparison of High vs. Low Tidal Volumes in Ventilator Weaning for Individuals With Sub-Acute Cervical Spinal Cord Injuries|Completed||N/A|34|Actual|Craig Hospital|||||f||||||||||||||2018-06-01 03:34:15.13896|2018-06-01 03:34:15.13896
NCT00412295|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2015-01-12|2006-12-15|2006-12-18|Estimate|||||||2015-01-12|2015-01-13|Estimate||||December 2014|2014-12-31||||||||Interventional|||Evaluation of Alcon Ladarvision Wavefront-Guided PRK|Evaluation of Alcon Ladarvision Wavefront-Guided PRK|Withdrawn||N/A|0|Actual|Walter Reed Army Medical Center||||"Lack of resources and not because of any concern with the safety or effectiveness of the~   procedures studied."|f||||||||||||||2018-06-01 03:34:15.210848|2018-06-01 03:34:15.210848
NCT00412269|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2016-01-22|2006-12-14|2006-12-18|Estimate|||||||2016-01-22|2016-01-25|Estimate|February 1998||1998-02-28|January 2016|2016-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Healthy Transitions: Menopause Effect on Obesity, Energy Balance, and Insulin|Healthy Transitions: Menopause Effect on Obesity, Energy Balance, and Insulin|Completed|||160|Actual|Pennington Biomedical Research Center|||||f||||t||||||||||2018-06-01 03:34:15.279859|2018-06-01 03:34:15.279859
NCT00412256|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2006-12-15|2006-12-15|2006-12-18|Estimate|||||||2006-12-15|2006-12-18|Estimate|September 2004||2004-09-30|December 2006|2006-12-31|November 2006||2006-11-30|||||Interventional|||Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)|Clinical Trial to Evaluate the Effect of Parenteral Supplementation With Omega-3-Fatty Acids in Patients With Rheumatoid Arthritis|Completed||Phase 3|60||Humanis Klinikum Niederosterreich|||||f||||||||||||||2018-06-01 03:34:15.360203|2018-06-01 03:34:15.360203
NCT00412243|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2013-01-25||2013-03-08|2006-12-15|2006-12-18|Estimate|2013-01-25|2013-03-04|Estimate||||2013-03-08|2013-03-12|Estimate|March 2006||2006-03-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients|Phase I/II Study of Clofarabine Plus Cyclophosphamide for Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 1/Phase 2|51|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:34:15.437684|2018-06-01 03:34:15.437684
NCT00412230|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|||2009-02-17|2006-12-15|2006-12-18|Estimate|||||||2009-02-17|2009-02-18|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|||||Observational|||Insulin Resistance and Hypertensive Disorders in Pregnancy|The Role of Insulin Resistance in Gestational Hypertension and in Preeclampsia.|Completed|||100|Anticipated|University of Messina|||2||f||||f||||||||||2018-06-01 03:34:15.656841|2018-06-01 03:34:15.656841
NCT00412217|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-15|2016-08-02||2016-10-11|2006-12-15|2006-12-18|Estimate|2016-08-02|2016-09-26|Estimate||||2016-10-11|2016-11-25|Estimate|November 2006||2006-11-30|October 2016|2016-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||Intent-to-Treat (ITT) Population: All participants who were randomized in the study.|A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer|Phase III Randomized, Controlled Trial of Erlotinib (Tarceva) as Maintenance Therapy in Patients With Squamous Cell Carcinoma of the Head and Neck Treated With Resection and Radiotherapy With or Without Concomitant Chemotherapy With Curative Aim|Terminated||Phase 3|94|Actual|Hoffmann-La Roche|The Study was terminated early as a result of slow recruitment. Results should be interpreted with consideration of the small sample size.|2||The study was terminated because recruitment was too slow.|f||||||||||||||2018-06-01 03:34:15.765321|2018-06-01 03:34:15.765321
NCT00412204|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2009-10-20|2006-12-14|2006-12-15|Estimate|||||||2009-10-20|2009-10-21|Estimate|June 2006||2006-06-30|October 2009|2009-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise|A Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Tiotropium Bromide on Gas Exchange in Subjects With COPD During Exercise|Completed||Phase 4|20|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 03:34:16.103333|2018-06-01 03:34:16.103333
NCT00412191|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2017-08-03|2006-12-14|2006-12-15|Estimate|||||||2017-08-03|2017-08-07|Actual|February 6, 2007|Actual|2007-02-06|August 2017|2017-08-31|April 27, 2007|Actual|2007-04-27|April 27, 2007|Actual|2007-04-27||Interventional|||Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR|A Pivotal Single-dose Randomised, Parallel-group, Open-label Study to Demonstrate Bioequivalence of 300mg Lamotrigine XR Relative to 100mg + 200mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 300mg Lamotrigine XR in Healthy Male and Female Volunteers|Completed||Phase 1|180|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:34:16.183916|2018-06-01 03:34:16.183916
NCT00412178|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2006-12-14|2006-12-14|2006-12-15|Estimate|||||||2006-12-14|2006-12-15|Estimate|December 2004||2004-12-31|December 2006|2006-12-31|April 2005||2005-04-30|||||Interventional|||Effect of Mobile Communication With a Cellular Phone With a Glucometer on Glucose Control in Type 2 Diabetic Patients||Terminated||N/A|80||The Catholic University of Korea|||||f||||||||||||||2018-06-01 03:34:16.36178|2018-06-01 03:34:16.36178
NCT00412165|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2012-08-15|2006-12-14|2006-12-15|Estimate|||||||2012-08-15|2012-08-16|Estimate|February 2006||2006-02-28|August 2012|2012-08-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||PACE-iDP: An Intervention for Youth at Risk for Diabetes|PACE-iDP: An Intervention for Youth at Risk for Diabetes|Completed||N/A|101|Actual|University of California, San Diego||4|||f||||||||||||||2018-06-01 03:34:16.447309|2018-06-01 03:34:16.447309
NCT00412152|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2012-08-09|2006-12-14|2006-12-15|Estimate|||||||2012-08-09|2012-08-10|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Oxycodone-naloxone in Relieving Opioid-related Constipation|A Randomised, Double-blind, Parallel-group, Multicentre Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Non-malignant Pain Taking Oxycodone Equivalent of >20 mg/Day and <50 mg/Day as Oxycodone/Naloxone Prolonged Release Compared to Subjects Taking Oxycodone Prolonged Release Tablets Alone.|Completed||Phase 3|||Mundipharma Research GmbH & Co KG|||||f||||f||||||||||2018-06-01 03:34:16.516771|2018-06-01 03:34:16.516771
NCT00412139|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-02-08|2006-12-14|2006-12-15|Estimate|||||||2010-02-08|2010-02-09|Estimate|December 2006||2006-12-31|December 2008|2008-12-31|January 2010|Actual|2010-01-31|November 2008|Actual|2008-11-30||Observational|||Serum Uremic Toxins and Histological Findings of the Blood Vessels in Dialysis Patients|A Correlation Between Histological Findings of the Blood Vessels in Patients With Chronic Renal Failure and Serum Uremic Toxins and Its Diagnostic Performance in the Assessment of the Cardiovascular Morbidity and Mortality|Completed|||100|Actual|University of Skopje|||||f||||t||||||None Retained|"~     3 aliquots of 2-3 ml sera are retained for various uremic markers determination~   "|||2018-06-01 03:34:16.573284|2018-06-01 03:34:16.573284
NCT00412126|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2006-12-13|2006-12-13|2006-12-15|Estimate|||||||2006-12-13|2006-12-15|Estimate|July 2002||2002-07-31|December 2006|2006-12-31|September 2005||2005-09-30|||||Interventional|||Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCI|Does Reduction of Hyperglycemia With Insulin Impact Restenosis and Improve Clinical Outcomes Following PCI?|Completed||N/A|240||McMaster University|||||f||||||||||||||2018-06-01 03:34:16.688933|2018-06-01 03:34:16.688933
NCT00412113|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|2009-04-13||2009-11-12|2006-12-13|2006-12-15|Estimate|2009-09-29|2009-11-06|Estimate||||2009-11-12|2009-11-20|Estimate|January 2007||2007-01-31|March 2009|2009-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|TOGETHER||A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk|A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.|Completed||Phase 4|245|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 03:34:16.792475|2018-06-01 03:34:16.792475
NCT00412100|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2012-08-09|2006-12-14|2006-12-15|Estimate|||||||2012-08-09|2012-08-10|Estimate|April 2006||2006-04-30|August 2012|2012-08-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation|A Randomsied, Double-blind, Double-dummy, Parallel-group Multicentre Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Non-malignant Pain Taking Oxycodone Equivalent of 60-80 mg/Day as Oxycodone/Naloxone Prolonged Release Compared to Subjects Taking Oxycodone Prolonged Release Tablets Alone|Completed||Phase 3|||Mundipharma Research GmbH & Co KG|||||f||||||||||||||2018-06-01 03:34:17.552386|2018-06-01 03:34:17.552386
NCT00412087|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|2016-05-04||2016-06-16|2006-12-14|2006-12-15|Estimate|2016-05-04|2016-06-10|Estimate||||2016-06-16|2016-07-29|Estimate|January 2007||2007-01-31|June 2016|2016-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina|Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina: A Prevalence and Supplementation Model for Community Health Care Centers in the U.S.|Completed||Phase 3|564|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 03:34:17.638485|2018-06-01 03:34:17.638485
NCT00412074|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|2016-04-27||2016-07-26|2006-12-14|2006-12-15|Estimate|2016-04-27|2016-06-03|Estimate||||2016-07-26|2016-09-12|Estimate|August 2006||2006-08-31|July 2016|2016-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Establishing the Vitamin D Requirements During Lactation|Establishing the Vitamin D Requirements During Lactation|Completed||Phase 3|460|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-06-01 03:34:17.861745|2018-06-01 03:34:17.861745
NCT00412061|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|2011-10-25||2014-11-11|2006-12-14|2006-12-15|Estimate|2012-02-07|2012-03-12|Estimate||||2014-11-11|2014-11-21|Estimate|December 2006||2006-12-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|April 2010|Actual|2010-04-30||Interventional|RADIANT-2||Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor|A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo|Completed||Phase 3|429|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:34:18.261245|2018-06-01 03:34:18.261245
NCT00412048|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2012-11-12|2006-12-14|2006-12-15|Estimate|||||||2012-11-12|2012-11-14|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease|Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.|Withdrawn||N/A|0|Actual|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-06-01 03:34:20.000744|2018-06-01 03:34:20.000744
NCT00412035|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2014-12-22|2006-12-13|2006-12-15|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BOLLD||Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery|Safety and Efficacy of Botox Injection in Alleviating Post-Operative Pain and Improving Quality of Life in Lower Extremity Limb Lengthening and Deformity Correction|Completed||Phase 3|125|Actual|Shriners Hospitals for Children||2|||f||||t||||||||||2018-06-01 03:34:20.09733|2018-06-01 03:34:20.09733
NCT00412022|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2017-07-14|2006-12-14|2006-12-15|Estimate|||||||2017-07-14|2017-07-17|Actual|March 2004||2004-03-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|HOBOE||HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.|Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.|Active, not recruiting||Phase 3|1294|Actual|National Cancer Institute, Naples||3|||f||||f||||||||||2018-06-01 03:34:20.207832|2018-06-01 03:34:20.207832
NCT00412009|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2006-12-14|2006-12-14|2006-12-15|Estimate|||||||2006-12-14|2006-12-15|Estimate|May 2003||2003-05-31|December 2006|2006-12-31|January 2005||2005-01-31|||||Interventional|||Investigation of a Novel Approach to Improve Treatment Success Rates for Tuberculosis Patients in Senegal|Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal|Completed||Phase 4|1500||Institut de Recherche pour le Developpement|||||f||||||||||||||2018-06-01 03:34:20.35407|2018-06-01 03:34:20.35407
NCT00411996|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2010-06-04|2006-12-14|2006-12-15|Estimate|||||||2010-06-04|2010-06-07|Estimate|December 2006||2006-12-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin|The Pharmacokinetics and Safety of Ritonavir-boosted Indinavir 600/100mg Bid Combined With NRTIs in ARV naïve HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy|Completed||Phase 1/Phase 2|20|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||t||||||||||2018-06-01 03:34:20.423334|2018-06-01 03:34:20.423334
NCT00411983|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2017-02-22|2006-12-14|2006-12-15|Estimate|||||||2017-02-22|2017-02-24|Actual|November 2002||2002-11-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||A Long-term Follow-up of the HIV-NAT Cohort|A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols|Recruiting|||10000|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration|||||f||||t||||||Samples With DNA|"~     PBMC collection once a year~   "|||2018-06-01 03:34:20.518308|2018-06-01 03:34:20.518308
NCT00411970|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2007-10-24|2006-12-14|2006-12-15|Estimate|||||||2007-10-24|2007-10-25|Estimate|September 2004||2004-09-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||20- Versus 23- Gauge System for Pars Plana Vitrectomy|20- Versus 23- Gauge System for Pars Plana Vitrectomy: A Prospective Randomized Clinical Study|Completed||Phase 4|60|Actual|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||||f||||||||||||||2018-06-01 03:34:20.645558|2018-06-01 03:34:20.645558
NCT00411957|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2010-06-04|2006-12-14|2006-12-15|Estimate|||||||2010-06-04|2010-06-07|Estimate|January 2007||2007-01-31|June 2010|2010-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients|The Pharmacokinetics of Atazanavir / Ritonavir 200/100 OD Versus 300/100 mg OD in Combination With 2 NRTIs in HIV Pre-treated Patients|Completed||Phase 1/Phase 2|22|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||t||||||||||2018-06-01 03:34:20.752448|2018-06-01 03:34:20.752448
NCT00411944|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2006-12-13|2006-12-13|2006-12-15|Estimate|||||||2006-12-13|2006-12-15|Estimate|August 1999||1999-08-31|December 2006|2006-12-31|September 2005||2005-09-30|||||Observational|||Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients|Prospective Study of the Influence of CYP3A4/CYP3A5 and MDR1 Gene Single Nucleotide Polymorphisms on Long-Term Tacrolimus Disposition in Renal Allograft Recipients: a Five Year Follow-up Study Using Abbreviated Concentration-Time Measurements.|Completed|||100||Katholieke Universiteit Leuven|||||f||||||||||||||2018-06-01 03:34:20.83006|2018-06-01 03:34:20.83006
NCT00411931|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2008-01-10|2006-12-14|2006-12-15|Estimate|||||||2008-01-10|2008-01-11|Estimate|September 2006||2006-09-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Pharmacokinetics Study of MultiHance in Pediatric Patients|A Clinical Investigation of the Pharmacokinetics and Safety of MultiHance in Patients From 2-5 Years of Age Undergoing A Clinical Indicated MRI of the CNS|Completed||Phase 1|15|Actual|Bracco Diagnostics, Inc|||||f||||||||||||||2018-06-01 03:34:20.884005|2018-06-01 03:34:20.884005
NCT00411905|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2007-03-09|2006-12-14|2006-12-15|Estimate|||||||2007-03-09|2007-03-12|Estimate|June 2006||2006-06-30|December 2006|2006-12-31|June 2006||2006-06-30|||||Interventional|||Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes|Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes|Unknown status|Recruiting|Phase 1/Phase 2|39||Groupe Francophone des Myelodysplasies|||||f||||f||||||||||2018-06-01 03:34:20.94804|2018-06-01 03:34:20.94804
NCT00411892|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2017-02-28|2006-12-14|2006-12-15|Estimate|||||||2017-02-28|2017-03-01|Actual|November 29, 2006|Actual|2006-11-29|February 2017|2017-02-28|March 18, 2008|Actual|2008-03-18|March 18, 2008|Actual|2008-03-18||Interventional|||Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes|Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes|Terminated||Phase 3|196|Actual|Novo Nordisk A/S||2||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:34:21.086645|2018-06-01 03:34:21.086645
NCT00411879|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2016-01-08|2006-12-14|2006-12-15|Estimate|||||||2016-01-08|2016-01-12|Estimate|June 2006||2006-06-30|January 2016|2016-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Combined Vasopressin, Methylprednisolone, and Epinephrine for Inhospital Cardiac Arrest|Phase 2, Single-Center, Placebo-Controlled Study of the Effects of Combined Administration of Vasopressin, Methylprednisolone, and Epinephrine During Cardiopulmonary Resuscitation on Survival After Cardiac Arrest|Completed||Phase 2|100|Actual|University of Athens||2|||f||||t||||||||||2018-06-01 03:34:21.350342|2018-06-01 03:34:21.350342
NCT00411866|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2017-08-02|2006-12-14|2006-12-15|Estimate|||||||2017-08-02|2017-08-03|Actual|October 13, 2006|Actual|2006-10-13|August 2017|2017-08-31|October 10, 2007|Actual|2007-10-10|October 10, 2007|Actual|2007-10-10||Interventional|||Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812|Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:34:21.450727|2018-06-01 03:34:21.450727
NCT00411853|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2009-07-30|2006-12-14|2006-12-15|Estimate|||||||2009-07-30|2009-07-31|Estimate|June 2007||2007-06-30|July 2009|2009-07-31|June 2012|Anticipated|2012-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients|An Open Phase II Clinical Trial of Fermented Wheat Germ Extract in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients|Unknown status|Recruiting|Phase 2|60|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:34:21.626172|2018-06-01 03:34:21.626172
NCT00411840|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2006-12-13|2006-12-13|2006-12-15|Estimate|||||||2006-12-13|2006-12-15|Estimate|July 2004||2004-07-31|December 2006|2006-12-31||||||||Interventional|||Novel Therapy of PAD by Combined Transplantation of BMCs|Transplantation of Autologous Mononuclear Bone Marrow Stem Cells in Patients With Peripheral Arterial Disease (TAM-PAD Study)|Unknown status|Recruiting|Phase 1|100||Heinrich-Heine University, Duesseldorf|||||f||||||||||||||2018-06-01 03:34:21.698992|2018-06-01 03:34:21.698992
NCT00411827|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2014-07-16|2006-12-14|2006-12-15|Estimate|||||||2014-07-16|2014-07-17|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|February 2011|Actual|2011-02-28||Interventional|||Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK|Goblet Cell Response and Dry Eye Symptoms After PRK and LASIK|Unknown status|Active, not recruiting|N/A|146|Anticipated|Walter Reed National Military Medical Center||2|||f||||||||||||||2018-06-01 03:34:21.781721|2018-06-01 03:34:21.781721
NCT00411814|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2012-03-15|2006-12-14|2006-12-15|Estimate|||||||2012-03-15|2012-03-19|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers|A Dose-escalating Study of the Safety and Pharmacokinetics of GSK679586A in Healthy Volunteers and Mild Asthmatics.|Completed||Phase 1|56|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:34:21.862902|2018-06-01 03:34:21.862902
NCT00411801|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13||2015-07-07|2017-06-19|2006-12-14|2006-12-15|Estimate||||2015-10-24|2015-11-20|Estimate|2017-06-19|2017-06-21|Actual|May 2007||2007-05-31|June 2017|2017-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)|A Blinded Non-inferiority Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)|Terminated||Phase 3|8|Actual|Octapharma||2||Insufficient enrollment|f||||t||||||||||2018-06-01 03:34:21.966367|2018-06-01 03:34:21.966367
NCT00411788|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2016-06-17||2016-08-01|2006-12-14|2006-12-15|Estimate|2016-08-01|2016-09-21|Estimate||||2016-08-01|2016-09-21|Estimate|December 2006||2006-12-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Eleven patients were enrolled from study start date until February 2010.|A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer|A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer|Completed||Phase 2|11|Actual|Yale University||1|||f||||f||||||||||2018-06-01 03:34:22.056445|2018-06-01 03:34:22.056445
NCT00411762|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|2015-03-10||2015-03-19|2006-12-13|2006-12-15|Estimate|2015-03-19|2015-03-27|Estimate||||2015-03-19|2015-03-27|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma|A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma|Completed||Phase 1/Phase 2|25|Actual|Yale University||1|||f||||f||||||||||2018-06-01 03:34:22.258392|2018-06-01 03:34:22.258392
NCT00411749|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|2010-07-19||2017-03-23|2006-12-14|2006-12-15|Estimate|2010-07-19|2010-08-18|Estimate||||2017-03-23|2017-04-21|Actual|December 11, 2006|Actual|2006-12-11|March 2017|2017-03-31|September 18, 2009|Actual|2009-09-18|September 18, 2009|Actual|2009-09-18||Interventional|||V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)|V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years|Completed||Phase 2|107|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:34:22.651169|2018-06-01 03:34:22.651169
NCT00411736|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-14|||2014-03-13|2006-12-14|2006-12-15|Estimate|||||||2014-03-13|2014-03-14|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Scandinavian Cystic Fibrosis Azithromycin Study|Supplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double-blinded, Placebo-controlled Scandinavian Multi-centre Study.|Completed||Phase 4|45|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-06-01 03:34:22.968778|2018-06-01 03:34:22.968778
NCT00411723|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2009-02-19|2006-12-12|2006-12-14|Estimate|||||||2009-02-19|2009-02-20|Estimate|December 2006||2006-12-31|February 2009|2009-02-28|May 2009|Anticipated|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis|Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis|Unknown status|Active, not recruiting|Phase 1|34|Actual|Artielle ImmunoTherapeutics||2|||f||||||||||||||2018-06-01 03:34:23.075511|2018-06-01 03:34:23.075511
NCT00411697|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2016-10-27|2006-12-13|2006-12-14|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge|Assess Long-term Persistence of Hepatitis B Antibodies & Immune Response to a Hepatitis B Vaccine (Engerix-B Kinder) Challenge in Children Aged 4-5 Years (Previously Primed & Boosted in the 1st 2 Years of Life With DTPa-HBV-IPV/Hib Vaccine)|Completed||Phase 4|301|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:34:23.162815|2018-06-01 03:34:23.162815
NCT00411684|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2010-06-16|2006-12-13|2006-12-14|Estimate|||||||2010-06-16|2010-06-17|Estimate|November 2006||2006-11-30|June 2010|2010-06-30||||||||Interventional|||Safety and Efficacy of CDB-2914 for Emergency Contraception|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Sex|Completed||Phase 3|1320|Anticipated|HRA Pharma|||||f||||||||||||||2018-06-01 03:34:23.373903|2018-06-01 03:34:23.373903
NCT00411671|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2015-11-05||2016-01-13|2006-12-13|2006-12-14|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||BATTLE Program: Sorafenib in Patients With NSCLC|A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|105|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:34:23.499511|2018-06-01 03:34:23.499511
NCT00411658|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2015-04-03|2006-12-13|2006-12-14|Estimate|||||||2015-04-03|2015-04-07|Estimate||||April 2015|2015-04-30||||||||Interventional|||Devitalized Non-valved Pulmonary Artery Allograft Implant for the Repair of Congenital Cardiac Abnormalities||Withdrawn||N/A|0|Actual|LifeNet Health||2||Submission converted to 510(k)|f||||||||||||||2018-06-01 03:34:23.97763|2018-06-01 03:34:23.97763
NCT00411645|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2015-05-15|2014-07-21|2015-06-03|2006-12-12|2006-12-14|Estimate|2015-05-15|2015-06-03|Estimate|2014-07-21|2014-07-24|Estimate|2015-06-03|2015-07-01|Estimate|December 2006||2006-12-31|March 2014|2014-03-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|||Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients|A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.|Completed||Phase 3|681|Actual|Shire||2|||f||||t||||||||||2018-06-01 03:34:24.118913|2018-06-01 03:34:24.118913
NCT00411632|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2018-02-28|2006-12-13|2006-12-14|Estimate|||||||2018-02-28|2018-03-01|Actual|November 29, 2006|Actual|2006-11-29|February 2018|2018-02-28|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|37|Actual|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-06-01 03:34:25.409085|2018-06-01 03:34:25.409085
NCT00411619|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2014-09-18||2014-10-17|2006-12-13|2006-12-14|Estimate|2014-10-17|2014-10-20|Estimate||||2014-10-17|2014-10-20|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex|Everolimus (RAD001)Therapy of Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex|Completed||Phase 1/Phase 2|28|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 03:34:25.506967|2018-06-01 03:34:25.506967
NCT00411606|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2009-04-03|2006-12-12|2006-12-14|Estimate|||||||2009-04-03|2009-04-06|Estimate|December 2006||2006-12-31|April 2009|2009-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Normal Values of Facial Thermography|Normal Values of Facial Thermography|Completed|||300|Anticipated|West Penn Allegheny Health System|||1||f||||||||||||||2018-06-01 03:34:25.746082|2018-06-01 03:34:25.746082
NCT00411593|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2012-02-07|2006-12-12|2006-12-14|Estimate|||||||2012-02-07|2012-02-08|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)|Phase I-II Study of Avastin®+ Bortezomib for Patients With Recurrent or Refractory Non-Squamous NSCLC|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Lack of Patient Accrual|f||||f||||||||||2018-06-01 03:34:25.806692|2018-06-01 03:34:25.806692
NCT00411580|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2013-03-27|2006-12-13|2006-12-14|Estimate|||||||2013-03-27|2013-03-29|Estimate|June 2005||2005-06-30|March 2013|2013-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)|A 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Time-lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Aß-specific Antibody Response Following Three Subcutaneous Injections of CAD106|Completed||Phase 1|58|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:34:25.887267|2018-06-01 03:34:25.887267
NCT00411567|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2007-06-21|2006-12-13|2006-12-14|Estimate|||||||2007-06-21|2007-06-22|Estimate|July 2006||2006-07-31|June 2007|2007-06-30||||||||Interventional|||A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma|An Open Label Study to Assess the Utility of Measuring Markers of Inflammation, to Detect Transition From Optimal to Sub-Optimal Inhaled Corticosteroid Therapy in Moderate-Severe Bronchial Asthma|Completed||Phase 1/Phase 2|26||Novartis|||||f||||f||||||||||2018-06-01 03:34:25.995631|2018-06-01 03:34:25.995631
NCT00411554|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|2009-08-19||2016-02-03|2006-12-13|2006-12-14|Estimate|2009-09-24|2009-09-25|Estimate||||2016-02-03|2016-02-05|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)|Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus -|Completed||Phase 3|319|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:34:26.080421|2018-06-01 03:34:26.080421
NCT00411541|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2006-12-13|2006-12-13|2006-12-14|Estimate|||||||2006-12-13|2006-12-14|Estimate|April 1995||1995-04-30|December 2006|2006-12-31|January 2004||2004-01-31|||||Interventional|||Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia|Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia|Completed||Phase 4|2600||International BFM Study Group|||||f||||||||||||||2018-06-01 03:34:26.334014|2018-06-01 03:34:26.334014
NCT00411528|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2013-03-07|2006-12-12|2006-12-14|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 2006||2006-09-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer|A Randomized Multicenter Phase II Trial of Patupilone (EPO906) Plus Prednisone Versus Docetaxel Plus Prednisone in Patients With Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|185|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:34:26.418878|2018-06-01 03:34:26.418878
NCT00411515|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2006-12-14|2006-12-12|2006-12-14|Estimate|||||||2006-12-14|2006-12-15|Estimate||||December 2006|2006-12-31||||||||Interventional|||A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty||Completed||Phase 4|||University Hospital Freiburg|||||f||||||||||||||2018-06-01 03:34:26.508524|2018-06-01 03:34:26.508524
NCT00010517|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-05|2001-02-02|2001-02-05|Estimate|||||||2008-03-05|2008-03-07|Estimate|September 1997||1997-09-30|March 2008|2008-03-31|April 2002||2002-04-30|||||Interventional|||Acupuncture in the Treatment of Depression|Acupuncture in the Treatment of Depression|Completed||Phase 3|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.512477|2018-06-01 05:37:25.512477
NCT00411463|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2016-01-05||2017-04-21|2006-12-13|2006-12-14|Estimate|2017-03-07|2017-04-19|Actual||||2017-04-21|2017-05-30|Actual|December 2006||2006-12-31|April 2017|2017-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Psychotherapy for Bipolar II Depression, Pilot Study, Phase II|Psychotherapy for Bipolar II Depression, Pilot Study, Phase II|Completed||Phase 2/Phase 3|25|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-06-01 03:34:26.660818|2018-06-01 03:34:26.660818
NCT00411450|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2016-01-15|2010-07-20|2016-01-15|2006-12-13|2006-12-14|Estimate|2016-01-15|2016-02-15|Estimate|2010-07-20|2010-07-22|Estimate|2016-01-15|2016-02-15|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|October 2010|Actual|2010-10-31|January 2009|Actual|2009-01-31||Interventional|PRECEPT||Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment|Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer|Completed||Phase 2|116|Actual|Amgen||1|||f||||f||||||||||2018-06-01 03:34:27.176503|2018-06-01 03:34:27.176503
NCT00411437|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2008-06-10|2006-12-13|2006-12-14|Estimate|||||||2008-06-10|2008-06-11|Estimate|December 2006||2006-12-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effects Of Detrol LA On Memory And Cognition In Elderly Population|A Randomized, Double-Blind, Placebo-Controlled, Three Arm Study To Evaluate The Effects Of Tolterodine ER 4 mg Vs. Placebo Vs. Oxybutynin ER On Memory And Other Cognitive Abilities In Elderly Subjects|Completed||Phase 4|220||Pfizer|||||||||||||||||||2018-06-01 03:34:27.801122|2018-06-01 03:34:27.801122
NCT00411424|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2013-03-19|2006-12-12|2006-12-14|Estimate|||||||2013-03-19|2013-03-21|Estimate|September 2007||2007-09-30|March 2013|2013-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety, Tolerability and Efficacy Study of the New Medication ASK8007 to Treat Patients With Rheumatoid Arthritis|Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Initial Efficacy of ASK8007 in Comparison With Placebo in Patients With Active Rheumatoid Arthritis - a Randomized, Double Blind, Placebo-controlled, Combined Single Dose Escalation and Multiple Dose Study|Completed||Phase 1/Phase 2|54|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:34:27.865474|2018-06-01 03:34:27.865474
NCT00411411|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|2014-05-19||2014-07-21|2006-12-13|2006-12-14|Estimate|2014-07-21|2014-08-13|Estimate||||2014-07-21|2014-08-13|Estimate|February 2007||2007-02-28|July 2014|2014-07-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes|Phase 3, Double Blinded, Placebo Controlled Study of the Effects of 12 Weeks DPP-IV Inhibitor Treatment on Secretion and Action of the Incretin Hormones in Patients With Type 2 Diabetes|Completed||Phase 3|49|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-06-01 03:34:27.94784|2018-06-01 03:34:27.94784
NCT00411398|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2012-09-06||2014-12-09|2006-12-12|2006-12-14|Estimate|2014-12-09|2014-12-10|Estimate||||2014-12-09|2014-12-10|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder|A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD), Who Are Only Partial Responders to Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's) or Selective Serotonin Reuptake Inhibitors (SSRI's).|Completed||Phase 3|15|Actual|State University of New York - Upstate Medical University||1|||f||||||||||||||2018-06-01 03:34:28.259057|2018-06-01 03:34:28.259057
NCT00411385|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13||2009-09-17|2013-08-01|2006-12-13|2006-12-14|Estimate||||2009-09-17|2009-09-22|Estimate|2013-08-01|2013-08-08|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3|Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3.|Completed||Phase 3|933|Actual|Human Genome Sciences Inc.||3|||f||||||||||||||2018-06-01 03:34:28.452557|2018-06-01 03:34:28.452557
NCT00411372|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2015-02-19|2006-12-13|2006-12-14|Estimate|||||||2015-02-19|2015-02-23|Estimate|November 2006||2006-11-30|February 2015|2015-02-28||||||||Interventional|||Shortness Of Breath Questionnaire Validation Study|A Randomized, Double-blind, Parallel-group Study of Fluticasone Propionate/Salmeterol Combination (FSC 250/50mcg) Twice Daily and Salmeterol (SAL 50mcg) Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||||No subjects enrolled. Study was canceled before active|||||||||||||||2018-06-01 03:34:28.759308|2018-06-01 03:34:28.759308
NCT00411359|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2015-04-21|2006-12-12|2006-12-14|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2006||2006-12-31|April 2015|2015-04-30|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Cardiac Rehabilitation for the Treatment of Refractory Angina|Cardiac Rehabilitation for the Treatment of Refractory Angina|Completed||Phase 3|42|Actual|National Heart and Lung Institute||2|||f||||f||||||||||2018-06-01 03:34:28.835024|2018-06-01 03:34:28.835024
NCT00411346|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2006-12-13|2006-12-13|2006-12-14|Estimate|||||||2006-12-13|2006-12-14|Estimate|January 2003||2003-01-31|December 2006|2006-12-31|November 2004||2004-11-30|||||Interventional|||Patient Research In Self-Management of Asthma (PRISMA)|Nurse-Led Telemonitoring Programme in Asthmatic Outpatients: a Randomized Controlled Trial|Completed||Phase 4|112||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:34:28.917092|2018-06-01 03:34:28.917092
NCT00411333|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-13|||2010-11-09|2006-12-13|2006-12-14|Estimate|||||||2010-11-09|2010-11-11|Estimate|July 2006||2006-07-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy|Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy|Completed||Early Phase 1|100|Anticipated|National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 03:34:28.967742|2018-06-01 03:34:28.967742
NCT00411320|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2011-08-03|2006-12-12|2006-12-14|Estimate|||||||2011-08-03|2011-08-04|Estimate|January 2007||2007-01-31|September 2008|2008-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Determinants of Corticosteroid Insensitivity in Smokers With Asthma|Determinants of Corticosteroid Insensitivity in Smokers With Asthma|Completed||N/A|53|Actual|University of Glasgow||5|||f||||t||||||||||2018-06-01 03:34:29.039566|2018-06-01 03:34:29.039566
NCT00411307|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-14|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|October 2001|Actual|2001-10-31|||||Interventional|||A Randomized, Open-Label, Single-Dose, Small Study to Evaluate the Safety and Effectiveness of Hydromorphone in Patients With Short Term, Moderate to Severe Postoperative Pain|A Randomized, Open-Label, Single-Dose, Pilot Study to Evaluate the Safety and Efficacy of OROS Hydromorphone in Patients With Acute, Moderate-to-Severe Postoperative Pain|Completed||Phase 2|50|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:29.105826|2018-06-01 03:34:29.105826
NCT00411281|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2015-09-28|2006-12-11|2006-12-13|Estimate|||||||2015-09-28|2015-09-30|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder|Treatment of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)|Withdrawn||Phase 3|0|Actual|Children's Oncology Group||2||Per Group Chair: This study will not move forward.|f||||t||||||||||2018-06-01 03:34:29.215797|2018-06-01 03:34:29.215797
NCT00411268|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-13|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|June 2001|Actual|2001-06-30|||||Interventional|||Safety, Effectiveness, and Impact on Quality of Life on Long-Term Administration of OROS Hydromorphone Slow-Release in Patients With Chronic Low Back Pain|Safety, Efficacy and Impact on Quality of Life of Long-Term Administration of Dilaudid CR (Hydromorphone HCI) in Patients With Chronic Low Back Pain|Completed||Phase 3|207|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:29.27767|2018-06-01 03:34:29.27767
NCT00411255|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2017-06-30|2006-12-12|2006-12-13|Estimate|||||||2017-06-30|2017-07-02|Actual|June 22, 2006||2006-06-22|February 19, 2010|2010-02-19|April 7, 2009|Actual|2009-04-07|April 7, 2009|Actual|2009-04-07||Interventional|||Brain Stimulation to Treat Blepharospasm or Meige Syndrome|Blepharospasm and the Experimental Modulation of Cortical Excitability in Primary and Secondary Motor Areas. A Pilot Study.|Completed||Phase 2|22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:34:29.323337|2018-06-01 03:34:29.323337
NCT00411242|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11||2012-05-02|2012-05-02|2006-12-11|2006-12-13|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|December 2006||2006-12-31|May 2012|2012-05-31||||January 2008|Actual|2008-01-31||Interventional|||Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder|An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-label Extension (CAGO178A2302E)|Completed||Phase 3|503|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:34:29.522954|2018-06-01 03:34:29.522954
NCT00411229|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2013-02-18|2006-12-12|2006-12-13|Estimate|||||||2013-02-18|2013-02-20|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CLASSIC||Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer|A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma|Completed||Phase 3|1035|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:34:29.660733|2018-06-01 03:34:29.660733
NCT00411216|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2013-12-20||2015-07-16|2006-12-12|2006-12-13|Estimate|2014-06-24|2014-07-21|Estimate||||2015-07-16|2015-08-07|Estimate|August 2000||2000-08-31|July 2015|2015-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Recovery of Visual Acuity in People With Vestibular Deficits|Recovery of Visual Acuity in Vestibular Deficits|Completed||N/A|23|Actual|Emory University||2|||f||||f||||||||||2018-06-01 03:34:29.74235|2018-06-01 03:34:29.74235
NCT00411203|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2014-07-30|2006-12-12|2006-12-13|Estimate|||||||2014-07-30|2014-07-31|Estimate|April 2003||2003-04-30|July 2014|2014-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Tamoxifen in Treatment of Acute Mania|Double Blind Placebo Controlled Trial of a Protein Kinase C Inhibitor: Tamoxifen Citrate in Treatment of Acute Mania|Completed||Phase 3|66|Actual|Stanley Medical Research Institute||2|||f||||||||||||||2018-06-01 03:34:30.065373|2018-06-01 03:34:30.065373
NCT00411190|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2017-10-02|2006-12-11|2006-12-13|Estimate|||||||2017-10-02|2017-10-04|Actual|October 19, 2006|Actual|2006-10-19|October 2017|2017-10-31|December 15, 2006|Actual|2006-12-15|December 15, 2006|Actual|2006-12-15||Interventional|||Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin|A Study to Evaluate the Potential for Pharmacokinetic Interaction Between SB 462795 and SSRIs in Healthy Subjects [3A]|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:34:30.152448|2018-06-01 03:34:30.152448
NCT00411177|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2013-09-06|2006-12-12|2006-12-13|Estimate|||||||2013-09-06|2013-09-09|Estimate|January 2007||2007-01-31|September 2013|2013-09-30|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis|Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis (TURKISH HDF STUDY)|Completed||Phase 4|782|Actual|Ege University||2|||f||||t||||||||||2018-06-01 03:34:30.245491|2018-06-01 03:34:30.245491
NCT00411164|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2013-07-04|2006-12-12|2006-12-13|Estimate|||||||2013-07-04|2013-07-08|Estimate|November 2003||2003-11-30|July 2013|2013-07-31|May 2005|Actual|2005-05-31|||||Interventional|||A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis|A Phase 3, Randomized, Double-Blind, Fixed-Dose, Parallel Group Comparison of Controlled-Release Hydromorphone HCI vs Placebo in Subjects With Osteoarthritis|Completed||Phase 3|990|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 03:34:30.347135|2018-06-01 03:34:30.347135
NCT00411151|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2010-11-29||2011-01-19|2006-12-11|2006-12-13|Estimate|2010-12-15|2011-01-14|Estimate||||2011-01-19|2011-01-20|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer|An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer|Completed||Phase 2|52|Actual|Johannes Gutenberg University Mainz|||||f||||t||||||||||2018-06-01 03:34:30.469406|2018-06-01 03:34:30.469406
NCT00411138|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2018-02-26|2006-12-11|2006-12-13|Estimate|||||||2018-02-26|2018-02-28|Actual|November 23, 2006|Actual|2006-11-23|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|April 1, 2017|Actual|2017-04-01||Interventional|PORTEC-3||Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer|Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy With Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3|Active, not recruiting||Phase 3|670|Anticipated|Leiden University Medical Center||2|||f||||t||||||||Undecided|Will be decided with international participating groups at time of final analysis|2018-06-01 03:34:30.875033|2018-06-01 03:34:30.875033
NCT00411125|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-13|Estimate|||||||2006-12-11|2006-12-13|Estimate|August 2006||2006-08-31|December 2006|2006-12-31|November 2006||2006-11-30|||||Interventional|||Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women|A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Crossover Phase I Study Assessing Pharmacokinetics and Pharmacodynamics of Two Different SMC021 0.8 mg Variants and the Effect of Timing of Drug Intake in Healthy Postmenopausal Women|Completed||Phase 1|86||Novartis|||||f||||||||||||||2018-06-01 03:34:30.97498|2018-06-01 03:34:30.97498
NCT00411112|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2009-01-09|2006-12-12|2006-12-13|Estimate|||||||2009-01-09|2009-01-12|Estimate|March 2007||2007-03-31|January 2009|2009-01-31||||March 2013|Anticipated|2013-03-31||Interventional|||Sentinel Node in Colon Cancer|Sentinel Node Study in Colon Cancer Surgery|Unknown status|Recruiting|N/A|140|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:34:31.037088|2018-06-01 03:34:31.037088
NCT00411099|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11||2012-05-02|2012-05-02|2006-12-11|2006-12-13|Estimate||||2012-05-02|2012-05-04|Estimate|2012-05-02|2012-05-04|Estimate|December 2006||2006-12-31|May 2012|2012-05-31||||January 2008|Actual|2008-01-31||Interventional|||Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder|An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-label Extension (CAGO178A2301E)|Completed||Phase 3|508|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:34:31.116692|2018-06-01 03:34:31.116692
NCT00411086|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2017-11-03||2017-11-03|2006-12-11|2006-12-13|Estimate|2017-11-03|2017-12-05|Actual||||2017-11-03|2017-12-05|Actual|November 2006||2006-11-30|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma|Single-Arm, Open-Label, Phase II Trial of Rituximab Plus Sargramostim for the Treatment of Newly Diagnosed Follicular B-Cell Lymphoma in Adults|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:34:31.242898|2018-06-01 03:34:31.242898
NCT00411073|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2016-10-27|2006-12-12|2006-12-13|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2006||2006-12-31|October 2016|2016-10-31||||||||Interventional|||Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart|A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin|Completed||Phase 1|72|Anticipated|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:34:31.577569|2018-06-01 03:34:31.577569
NCT00411060|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2017-12-06|2006-12-12|2006-12-13|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2007||2007-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Clinical Orthopaedic Data Bank (Acute and Chronic)|Orthopaedic Data Bank; Collection and Storage of Data Relating to Orthopaedic Disorders|Recruiting|||10000|Anticipated|University of Florida|||||f||||f|f|f||||||||2018-06-01 03:34:31.650458|2018-06-01 03:34:31.650458
NCT00411047|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2013-05-12|2006-12-11|2006-12-13|Estimate|||||||2013-05-12|2013-05-14|Estimate|September 2005||2005-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|January 2007|Actual|2007-01-31||Interventional|||Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor|Completed||Phase 2|34|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 03:34:31.853662|2018-06-01 03:34:31.853662
NCT00411034|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-13|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|September 1999|Actual|1999-09-30|||||Interventional|||A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain|A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR( Hydromorphone HCI) in Patients With Chronic Cancer Pain|Completed||Phase 3|463|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:31.926265|2018-06-01 03:34:31.926265
NCT00411021|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2006-12-12|2006-12-12|2006-12-13|Estimate|||||||2006-12-12|2006-12-13|Estimate||||December 2006|2006-12-31||||||||Interventional|||Endometrial Sampling (Pipelle)in IVF Patients|Endometrial Sampling (Pipelle)in IVF Patients|Unknown status|Recruiting|N/A|70||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:34:31.983417|2018-06-01 03:34:31.983417
NCT00410995|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2007-10-10|2006-12-12|2006-12-13|Estimate|||||||2007-10-10|2007-10-11|Estimate|May 2004||2004-05-31|October 2007|2007-10-31|August 2006|Actual|2006-08-31|||||Interventional|||Effects of Naproxen on Physical Performance|Effects of Naproxen on Physical Performance|Terminated||Phase 4|40||University of Oklahoma||||Study never initiated.|f||||||||||||||2018-06-01 03:34:32.04376|2018-06-01 03:34:32.04376
NCT00410982|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2016-06-01|2006-12-12|2006-12-13|Estimate|||||||2016-06-01|2016-06-03|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies|Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies|Completed||Phase 1|145|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:34:32.105799|2018-06-01 03:34:32.105799
NCT00410969|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2008-09-25|2006-12-12|2006-12-13|Estimate|||||||2008-09-25|2008-09-29|Estimate|December 2006||2006-12-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|February 2008|Actual|2008-02-29||Interventional|||Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients|Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients|Completed||Phase 1|27|Anticipated|Life Recovery Systems|||||f||||t||||||||||2018-06-01 03:34:32.248677|2018-06-01 03:34:32.248677
NCT00410956|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2017-09-06|2006-12-11|2006-12-13|Estimate|||||||2017-09-06|2017-09-07|Actual|May 2007||2007-05-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery|A Phase II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Bevacizumab (A Monoclonal Antibody to Vascular Endothelial Growth Factor-A), in Patients With Unresectable Primary Hepatic Malignancy|Active, not recruiting||Phase 2|55|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:34:32.318066|2018-06-01 03:34:32.318066
NCT00410943|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-13|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|June 1999|Actual|1999-06-30|||||Interventional|||Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain|A Randomized, Double-Blind, Repeated Dose, Parallel-Group Comparison of the Efficacy & Tolerability of Dilaudid SR Tablets and Immediate Release Dilaudid Tablets (Hydromorphone HCI) in Patients With Chronic Pain|Completed||Phase 3|169|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:32.408131|2018-06-01 03:34:32.408131
NCT00410930|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2006-12-15|2006-12-12|2006-12-13|Estimate|||||||2006-12-15|2006-12-19|Estimate|November 2002||2002-11-30|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients|Double-Blind Placebo-Controlled Study of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients|Terminated||Phase 2|160||Stallergenes Greer|||||f||||||||||||||2018-06-01 03:34:32.459993|2018-06-01 03:34:32.459993
NCT00410735|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2012-06-12|2006-12-12|2006-12-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|December 2006||2006-12-31|June 2012|2012-06-30||||June 2008|Actual|2008-06-30||Interventional|||Study of ONO-1078 in Patients With Chronic Sinusitis|Study of ONO-1078 in Patients With Chronic Sinusitis, a Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-center Study|Completed||Phase 3|495|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 03:34:36.72148|2018-06-01 03:34:36.72148
NCT00410904|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2013-12-23||2018-03-15|2006-12-11|2006-12-13|Estimate|2014-09-19|2014-09-22|Estimate||||2018-03-15|2018-04-13|Actual|October 2006||2006-10-31|March 2018|2018-03-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer|Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)|Pemetrexed was approved for front line therapy based on the results of a phase III study; it became known that pemetrexed is ineffective in pts.with squamous cell lung ca. It was also challenging to combine VEGF-TKIS with chemo this pt. population.|1|||f||||||||||||||2018-06-01 03:34:32.525257|2018-06-01 03:34:32.525257
NCT00410891|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|2014-05-13||2017-10-04|2006-12-11|2006-12-13|Estimate|2014-05-13|2014-06-12|Estimate||||2017-10-04|2017-11-06|Actual|July 2008||2008-07-31|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||patient undergoing IVT|Topical Antibiotics and Intravitreous Injections||Completed||Phase 4|129|Actual|Stanford University||1|||f||||||||||||||2018-06-01 03:34:32.855613|2018-06-01 03:34:32.855613
NCT00410878|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2017-02-15|2006-12-12|2006-12-13|Estimate|||||||2017-02-15|2017-02-17|Actual||||April 2010|2010-04-30|August 1999|Actual|1999-08-31|||||Interventional|||A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain|A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain|Completed||Phase 1|22|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:33.976593|2018-06-01 03:34:33.976593
NCT00410865|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2011-12-06|2006-12-11|2006-12-13|Estimate|||||||2011-12-06|2011-12-07|Estimate|June 2003||2003-06-30|December 2011|2011-12-31|November 2010|Actual|2010-11-30|March 2008|Actual|2008-03-31||Interventional|||Wild Type p53 Adenovirus for Oral Premalignancies|Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]|Terminated||Phase 1|4|Actual|M.D. Anderson Cancer Center||1||Sponsor withdrawl prior to study completion.|f||||t||||||||||2018-06-01 03:34:34.032977|2018-06-01 03:34:34.032977
NCT00410852|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2007-10-31|2006-12-12|2006-12-13|Estimate|||||||2007-10-31|2007-11-02|Estimate|May 2005||2005-05-31|October 2007|2007-10-31|March 2007|Actual|2007-03-31|||||Interventional|||Efficacy and Safety of Three Insulin Protocols in Medical Intensive Care Unit Patients|Randomized Study to Evaluate the Efficacy and Safety of Two Endovenous Insulin Protocols and a Subcutaneous Insulin Protocol in Critically Ill Patients|Completed||N/A|168|Actual|Hospital Israelita Albert Einstein||3|||f||||f||||||||||2018-06-01 03:34:34.109152|2018-06-01 03:34:34.109152
NCT00410839|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2006-12-12|2006-12-12|2006-12-13|Estimate|||||||2006-12-12|2006-12-13|Estimate|June 1999||1999-06-30|August 2004|2004-08-31|June 2003||2003-06-30|||||Interventional|||Studies of the Prevention of Atrial Fibrillation by ALA|Prevention of Atrial Fibrillation Recurrence By An Alpha-Linolenic Enriched Diet - A Pilot Study|Unknown status|Active, not recruiting|Phase 2|130||University of Toronto|||||f||||||||||||||2018-06-01 03:34:34.187871|2018-06-01 03:34:34.187871
NCT00410826|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2012-12-14||2013-05-08|2006-12-11|2006-12-13|Estimate|2013-02-20|2013-04-02|Estimate||||2013-05-08|2013-05-10|Estimate|June 2006||2006-06-30|May 2013|2013-05-31||||May 2012|Actual|2012-05-31||Interventional||204 patients were randomized. However, after completing study therapy, it became apparent that one participant had metastatic disease and was therefore, ineligible for study. This participant was excluded from subsequent results presented here.|Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|204|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:34:34.265096|2018-06-01 03:34:34.265096
NCT00410813|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2014-01-13||2017-05-31|2006-12-11|2006-12-13|Estimate|2017-05-31|2017-07-02|Actual||||2017-05-31|2017-07-02|Actual|March 2007||2007-03-31|May 2017|2017-05-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional||All eligible participants|S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone|Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer|Completed||Phase 2|85|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 03:34:34.730779|2018-06-01 03:34:34.730779
NCT00410800|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2017-06-30|2006-12-12|2006-12-13|Estimate|||||||2017-06-30|2017-07-02|Actual|August 19, 1996||1996-08-19|August 16, 2011|2011-08-16|August 16, 2011||2011-08-16|||||Observational|||Insulin Secretory Defects in Pima Indians at High Risk for NIDDM|Insulin Secretory Defects in Pima Indians at High Risk for NIDDM|Completed|||310|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:34:35.588944|2018-06-01 03:34:35.588944
NCT00410787|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-13|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|April 2002|Actual|2002-04-30|||||Interventional|||Safety and Tolerability of Long-term Administration of OROS Hydromorphone HCI (Slow Release) in Cancer Pain|Safety and Tolerability of Long-Term Administration of Dilaudid SR (Hydromorphone HCI) in Cancer Pain|Completed||Phase 3|68|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:35.71923|2018-06-01 03:34:35.71923
NCT00410774|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2012-09-13|2006-12-11|2006-12-13|Estimate|||||||2012-09-13|2012-09-17|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery|A Phase I/II Study of Fixed-Dose Rate Gemcitabine and Bevacizumab for Postoperative Adjuvant Treatment of Patients With Resected Pancreatic Cancer|Terminated||Phase 1/Phase 2|20|Anticipated|University of California, San Francisco||||low accrual-no data available|f||||t||||||||||2018-06-01 03:34:35.791586|2018-06-01 03:34:35.791586
NCT00410761|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2011-04-27|2011-03-28|2017-11-02|2006-12-12|2006-12-13|Estimate|2012-02-22|2012-03-26|Estimate|2011-03-28|2011-04-06|Estimate|2017-11-02|2017-12-07|Actual|November 30, 2006|Actual|2006-11-30|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|July 2009|Actual|2009-07-31||Interventional|||An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer|An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer|Active, not recruiting||Phase 3|437|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:34:35.912865|2018-06-01 03:34:35.912865
NCT00410748|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-13|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|June 2000|Actual|2000-06-30|||||Interventional|||Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)|Safety and Tolerability of Long-term Administration of Dilaudid CR (Hydromorphone HCI)|Completed||Phase 3|388|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:36.662768|2018-06-01 03:34:36.662768
NCT00410722|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2013-01-08|2006-12-12|2006-12-13|Estimate|||||||2013-01-08|2013-01-09|Estimate|December 2006||2006-12-31|January 2013|2013-01-31||||December 2008|Actual|2008-12-31||Interventional|||Effect of Nuts vs. a Wheat Bran Muffin in Type 2 Diabetes|Effect of Nuts on Glycemic Control and Cardiovascular Disease Risk in Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|University of Toronto||3|||f||||||||||||||2018-06-01 03:34:36.801465|2018-06-01 03:34:36.801465
NCT00410709|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2008-07-31|2006-12-12|2006-12-13|Estimate|||||||2008-07-31|2008-08-01|Estimate|December 2006||2006-12-31|July 2008|2008-07-31|January 2007|Actual|2007-01-31|||||Interventional|||A Pharmacokinetic (PK) Study of NatrOVA Topical Creme (1%) in Pediatric Subjects 6 to 24 Months of Age|A Phase 1B Single Treatment, Pharmacokinetic and Tolerance Study of NatroVA Topical Creme (1%) i Pediatric Subjects 6 to 24 Months of Age|Completed||Phase 1|6|Actual|ParaPRO LLC|||||f||||f||||||||||2018-06-01 03:34:36.881915|2018-06-01 03:34:36.881915
NCT00410696|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2013-06-28|2006-12-12|2006-12-13|Estimate|||||||2013-06-28|2013-07-01|Estimate|September 2006||2006-09-30|June 2013|2013-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy|Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy With Peripheral Autologous Stem Cell Reinfusion in Patients With Hematological Neoplasms and Solid Tumors: Phase II Randomised Trial|Completed||Phase 2|80|Actual|Istituto Clinico Humanitas||2|||f||||t||||||||||2018-06-01 03:34:36.936135|2018-06-01 03:34:36.936135
NCT00410683|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2017-08-07|2006-12-11|2006-12-13|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2007||2007-02-28|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2018|Anticipated|2018-02-28||Interventional|LUNG ART||Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery|Phase III Study Comparing Post-Operative Conformal Radiotherapy to No Post-Operative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement [Lung ART]|Recruiting||Phase 3|500|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-06-01 03:34:37.009789|2018-06-01 03:34:37.009789
NCT00410670|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2018-05-24|2006-12-12|2006-12-13|Estimate|||||||2018-05-24|2018-05-25|Actual|August 1, 2003||2003-08-01|December 29, 2017|2017-12-29|December 29, 2017||2017-12-29|||||Observational|||Chordoma Family Study|The Chordoma Family Study: A Pilot Collaboration Between NCI and Massachusetts General Hospital (MGH) to Identify Chordoma Families|Completed|||55|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:34:37.088642|2018-06-01 03:34:37.088642
NCT00410657|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2010-05-12|2006-12-11|2006-12-13|Estimate|||||||2010-05-12|2010-05-14|Estimate|July 2006||2006-07-31|May 2010|2010-05-31||||November 2006|Actual|2006-11-30||Interventional|||Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant|A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease|Completed||Phase 2|53|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 03:34:37.145714|2018-06-01 03:34:37.145714
NCT00410644|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-13|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|February 1999|Actual|1999-02-28|||||Interventional|||A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain|A Repeated-Dose Evaluation of Analgesic Use and Safety of Dilaudid SR (Hydromorphone HCI) in Patients With Chronic Non-Malignant Pain|Completed||Phase 3|463|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:37.316306|2018-06-01 03:34:37.316306
NCT00410631|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2013-08-06|2006-12-11|2006-12-13|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2004||2004-10-31|January 2008|2008-01-31||||December 2010|Anticipated|2010-12-31||Interventional|||Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma|NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma|Unknown status|Recruiting|Phase 3|642|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:34:37.412339|2018-06-01 03:34:37.412339
NCT00410618|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2015-12-02|2006-12-11|2006-12-13|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2003||2003-04-30|August 2012|2012-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer|Neurological Effects of Chemotherapy and Radiation Treatment: Colon Cancer|Completed|||42|Anticipated|University of Arizona|||||f||||||||||||||2018-06-01 03:34:37.71468|2018-06-01 03:34:37.71468
NCT00410605|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2016-06-13||2017-08-02|2006-12-11|2006-12-13|Estimate|2017-08-02|2017-09-01|Actual||||2017-08-02|2017-09-01|Actual|November 2006||2006-11-30|August 2017|2017-08-31|June 2014|Actual|2014-06-30|December 2011|Actual|2011-12-31||Interventional|||Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma|Phase II Trial of Bevacizumab Combined With Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|39|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:34:37.833172|2018-06-01 03:34:37.833172
NCT00410592|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2009-03-10|2006-12-12|2006-12-13|Estimate|||||||2009-03-10|2009-03-11|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|May 2007|Actual|2007-05-31|||||Interventional|||Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD|A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD|Completed||Phase 4|90|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:34:38.199708|2018-06-01 03:34:38.199708
NCT00410579|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2010-12-15|2006-12-11|2006-12-13|Estimate|||||||2010-12-15|2010-12-17|Estimate|November 2006||2006-11-30|December 2010|2010-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers|Patient Reported Outcomes in Long Term Survivors With Colon and Rectal Cancer|Completed|||744|Actual|NSABP Foundation Inc|||1||f||||f||||||||||2018-06-01 03:34:38.31177|2018-06-01 03:34:38.31177
NCT00410566|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2015-03-17|2006-12-11|2006-12-13|Estimate|||||||2015-03-17|2015-03-19|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)|A Phase I, Single-Center, Single Dose, Dose Escalation Study of Recombinant Human Acid Sphingomyelinase (rhASM) in Adults With Acid Sphingomyelinase Deficiency (ASMD)|Terminated||Phase 1|11|Actual|Sanofi||5||Terminated by sponsor - Single dose safety objective achieved.|f||||t||||||||||2018-06-01 03:34:38.724843|2018-06-01 03:34:38.724843
NCT00410553|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2017-09-19|2006-12-11|2006-12-13|Estimate|||||||2017-09-19|2017-09-20|Actual|November 14, 2006|Actual|2006-11-14|September 2017|2017-09-30||||October 24, 2012|Actual|2012-10-24||Interventional|||Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery|A Phase I Study of Halichondrin B Analog E7389 in Combination With Gemcitabine in Patients With Refractory or Advanced Solid Tumors|Active, not recruiting||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:34:38.806075|2018-06-01 03:34:38.806075
NCT00410540|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2010-04-26|2006-12-12|2006-12-13|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|May 2001|Actual|2001-05-31|||||Interventional|||A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.|A Randomized, Double-Blind, Controlled Trial of Hydromorphone (Immediate and Sustained- Release) vs Morphine (Immediate and Sustained-release) in Cancer Pain|Completed||Phase 3|202|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:34:38.964683|2018-06-01 03:34:38.964683
NCT00410527|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2017-06-30|2006-12-12|2006-12-13|Estimate|||||||2017-06-30|2017-07-02|Actual|August 11, 2006||2006-08-11|May 22, 2007|2007-05-22|May 22, 2007||2007-05-22|||||Interventional|||Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients|Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU)|Completed||Phase 4|0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:34:39.021521|2018-06-01 03:34:39.021521
NCT00410514|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|2012-08-02|2009-08-24|2014-03-07|2006-12-12|2006-12-13|Estimate|2012-08-02|2012-09-05|Estimate|2009-08-24|2009-08-26|Estimate|2014-03-07|2014-04-04|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)|A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)|Completed||Phase 2|200|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||f||||||||||2018-06-01 03:34:39.144087|2018-06-01 03:34:39.144087
NCT00410501|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2007-06-18|2006-12-12|2006-12-13|Estimate|||||||2007-06-18|2007-06-19|Estimate|December 2006||2006-12-31|June 2007|2007-06-30||||||||Interventional|||Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects|An Open Label, Single Dose, Two Period, Single Sequence Crossover Study to Assess the Pharmacokinetic Interaction of QAB149 (300 Mcg Via Inhalation) With Ketoconazole (200 mg Tablet b.i.d.) in Healthy Adult Subjects|Completed||Phase 1|20|Anticipated|Novartis|||||f||||f||||||||||2018-06-01 03:34:40.139537|2018-06-01 03:34:40.139537
NCT00410488|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2012-06-28||2013-02-19|2006-12-12|2006-12-13|Estimate|2013-02-19|2013-03-22|Estimate||||2013-02-19|2013-03-22|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)|Dose/Schedule Finding Study of Palonosetron in Sarcoma Patients Receiving Multi-Day Chemotherapy With Adriamycin and Ifosfamide (AI)|Completed||N/A|51|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:34:40.22804|2018-06-01 03:34:40.22804
NCT00410475|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-12|||2018-05-17|2006-12-12|2006-12-13|Estimate|||||||2018-05-17|2018-05-18|Actual|September 17, 1997||1997-09-17|April 11, 2018|2018-04-11||||||||Observational|||Cancer Risk in X-Ray Technologists: Second Survey|Cancer Risk in X-Ray Technologists|Completed|||146022|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:34:40.438432|2018-06-01 03:34:40.438432
NCT00410462|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2014-08-07|2006-12-11|2006-12-13|Estimate|||||||2014-08-07|2014-08-08|Estimate|October 2006||2006-10-31|July 2010|2010-07-31||||September 2008|Actual|2008-09-30||Interventional|||Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma|Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma|Unknown status|Active, not recruiting|Phase 2|118|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 03:34:40.510545|2018-06-01 03:34:40.510545
NCT00410449|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2015-10-05|2006-12-11|2006-12-12|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2001||2001-05-31|December 2006|2006-12-31|May 2004||2004-05-31|||||Observational|||Oxidative Stress and Hemodialysis Access Failure|Study of the Effect of Oral Supplementation With Vitamin E on Circulating Oxidative Markers, Hemodialysis Vascular Access Occlusion, and Clinical Events in Patients With End Stage Renal Failure Treated by Hemodialysis|Completed|||35||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 03:34:40.577416|2018-06-01 03:34:40.577416
NCT00410436|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2013-02-25|2006-12-08|2006-12-12|Estimate|||||||2013-02-25|2013-02-27|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Resistance Exercise in Already-active Diabetic Individuals (READI) Trial|Resistance Exercise in Already-active Diabetic Individuals (READI) Trial|Completed||Phase 4|131|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 03:34:40.634962|2018-06-01 03:34:40.634962
NCT00410423|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2016-09-08||2018-04-23|2006-12-11|2006-12-12|Estimate|2018-03-16|2018-04-17|Actual||||2018-04-23|2018-04-25|Actual|January 2006||2006-01-31|April 2018|2018-04-30|September 2014|Actual|2014-09-30|May 2013|Actual|2013-05-31||Interventional|||Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias|Phase I/II Trial of VELCADE® (Bortezomib) in Combination With Mitoxantrone and Etoposide for Relapsed or Refractory Acute Leukemias|Completed||Phase 1/Phase 2|55|Actual|Thomas Jefferson University||3|||f||||t||||||||||2018-06-01 03:34:40.716583|2018-06-01 03:34:40.716583
NCT00410410|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2010-08-12||2015-03-04|2006-12-11|2006-12-12|Estimate|2010-11-04|2010-12-02|Estimate||||2015-03-04|2015-03-24|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||A Study of Abatacept in Patients With Active Ulcerative Colitis|A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Ulcerative Colitis (UC) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy|Completed||Phase 3|591|Actual|Bristol-Myers Squibb|This study was terminated after review of the IP1C results due to lack of efficacy. Enrollment for the MP and for IP2C was not completed. Participants in MP, IP2C, and OL were early terminated at the time of study termination.|3|||f||||t||||||||||2018-06-01 03:34:41.252562|2018-06-01 03:34:41.252562
NCT00410397|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2008-01-08|2006-12-11|2006-12-12|Estimate|||||||2008-01-08|2008-01-15|Estimate|December 2006||2006-12-31|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||The Use of Manual Therapy to Treat Low-Back and Hip Pain|The Use of Myofascial Release in Lumbopelvic Pain|Completed||N/A|27|Actual|Oklahoma State University Center for Health Sciences||2|||f||||f||||||||||2018-06-01 03:34:44.722395|2018-06-01 03:34:44.722395
NCT00410215|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2015-09-18|2006-12-08|2006-12-12|Estimate|||||||2015-09-18|2015-09-22|Estimate|February 2006||2006-02-28|September 2015|2015-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy|A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy|Completed||Phase 4|315|Actual|Queen's University||3|||f||||f||||||||||2018-06-01 03:34:47.975179|2018-06-01 03:34:47.975179
NCT00410384|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2011-04-07|2010-10-21|2016-12-02|2006-12-08|2006-12-12|Estimate|2011-04-07|2011-05-05|Estimate|2010-10-21|2010-10-25|Estimate|2016-12-02|2017-02-01|Estimate|December 2006||2006-12-31|December 2016|2016-12-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|BLISS-76||A Study of Belimumab in Subjects With Systemic Lupus Erythematosus|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 3|819|Actual|Human Genome Sciences Inc.||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:34:44.878204|2018-06-01 03:34:44.878204
NCT00410371|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2017-09-11|2006-12-11|2006-12-12|Estimate|||||||2017-09-11|2017-09-12|Actual|December 28, 2006|Actual|2006-12-28|September 2017|2017-09-30|January 25, 2007|Actual|2007-01-25|January 25, 2007|Actual|2007-01-25||Interventional|||Study to Compare Two Formulations of Lamotrigine in Healthy Subjects|An Open-label, Randomised, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Characteristics, Safety and Tolerability of up to Two Formulations (With Different Taste Masking Approaches) of an Orally Disintegrating Tablet (ODT) of Lamotrigine at 25mg and 200mg Versus the Immediate Release (IR) Lamotrigine in Healthy Subjects|Completed||Phase 1|96|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:34:46.380829|2018-06-01 03:34:46.380829
NCT00410358|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2012-10-15|2006-12-11|2006-12-12|Estimate|||||||2012-10-15|2012-10-16|Estimate|June 2006||2006-06-30|October 2012|2012-10-31||||February 2008|Actual|2008-02-29||Interventional|||A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.|A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor.|Completed||Phase 1|19|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:34:46.461392|2018-06-01 03:34:46.461392
NCT00410345|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2017-02-28|2006-12-11|2006-12-12|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2004||2004-08-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Cervical Rippening With Antiprogesterone in Midtrimester Abortions|Cervical Rippening With Antiprogesterone in Midtrimester Abortions|Completed||Phase 4|145|Actual|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 03:34:46.571115|2018-06-01 03:34:46.571115
NCT00410332|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2012-02-19|2006-12-11|2006-12-12|Estimate|||||||2012-02-19|2012-02-22|Estimate|March 2011||2011-03-31|February 2012|2012-02-29||||December 2012|Anticipated|2012-12-31||Interventional|||Traumeel for Post-Tonsillectomy Pain|A Randomized, Double-Blind, Placebo-Controlled Pilot Study for Evaluating the Efficacy of the Homeopathic Remedy Traumeel S on Pain Reduction Following Tonsillectomy in Adult Patients.|Unknown status|Recruiting|Phase 3|20|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-06-01 03:34:46.647826|2018-06-01 03:34:46.647826
NCT00410319|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2007-04-25|2006-12-11|2006-12-12|Estimate|||||||2007-04-25|2007-04-27|Estimate||||April 2007|2007-04-30||||||||Interventional|||Information or Physical Activity for Chronic LBP||Unknown status|Active, not recruiting|N/A|||University of Southern Denmark|||||f||||||||||||||2018-06-01 03:34:46.789559|2018-06-01 03:34:46.789559
NCT00410306|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2010-09-23|2006-12-11|2006-12-12|Estimate|||||||2010-09-23|2010-09-24|Estimate|October 2006||2006-10-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|IPASS Nebido||Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice|International, Multi-center Post Authorization Surveillance Study on the Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido)|Completed|||1493|Actual|Bayer|||1||f||||f||||||||||2018-06-01 03:34:46.84688|2018-06-01 03:34:46.84688
NCT00410293|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|December 2004||2004-12-31|December 2006|2006-12-31|August 2006||2006-08-31|||||Interventional|||NT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs|NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs|Completed||N/A|500||Erasmus Medical Center|||||f||||||||||||||2018-06-01 03:34:47.015785|2018-06-01 03:34:47.015785
NCT00410280|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2014-11-07|2014-04-11|2014-11-07|2006-12-11|2006-12-12|Estimate|2014-11-07|2014-11-18|Estimate|2014-04-11|2014-05-06|Estimate|2014-11-07|2014-11-18|Estimate|March 2007||2007-03-31|November 2014|2014-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Intent-to-treat population (ITT) included all randomized participants who received at least 1 dose administration of the test article.|Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma|Allergen Challenge|Completed||Phase 2|30|Actual|Pfizer|The study was stopped early due to futility of the interim efficacy analysis results. Hence, only safety results and key efficacy results were presented for this study.|1|||f||||f||||||||||2018-06-01 03:34:47.11305|2018-06-01 03:34:47.11305
NCT00410267|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2016-08-08|2006-12-11|2006-12-12|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells|A Randomized Prospective Double - Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-Selective Laser Trabeculoplasty Anterior Chamber Flare and Cells|Terminated|||1|Actual|University of Pittsburgh||||low recruitment|f||||f||||||||No||2018-06-01 03:34:47.710621|2018-06-01 03:34:47.710621
NCT00410254|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2007-12-03|2006-12-11|2006-12-12|Estimate|||||||2007-12-03|2007-12-05|Estimate|June 2007||2007-06-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects|An Open Label, Single-Dose Midazolam, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Midazolam|Completed||Phase 1|38|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:34:47.781195|2018-06-01 03:34:47.781195
NCT00410241|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-09|||2018-05-26|2006-12-09|2006-12-12|Estimate|||||||2018-05-26|2018-05-30|Actual|December 8, 2006||2006-12-08|May 23, 2018|2018-05-23||||||||Observational|||ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study|ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:34:47.842021|2018-06-01 03:34:47.842021
NCT00410228|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2007-06-21|2006-12-11|2006-12-12|Estimate|||||||2007-06-21|2007-06-22|Estimate|June 2006||2006-06-30|June 2007|2007-06-30||||||||Interventional|||Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects|A Single Center, Randomized, Double-Blind, Placebo-and Positive-Controlled, Interleaved, Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHTT956 in Healthy Subjects|Completed||Phase 1|42||Novartis|||||f||||||||||||||2018-06-01 03:34:47.914143|2018-06-01 03:34:47.914143
NCT00410202|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2012-04-24||2013-10-29|2006-12-11|2006-12-12|Estimate|2012-06-01|2012-07-04|Estimate||||2013-10-29|2013-11-21|Estimate|March 2008||2008-03-31|October 2013|2013-10-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|DEFINE||Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus|A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-resistant Chronic Hepatitis B Subjects: The DEFINE Study|Completed||Phase 3|629|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 03:34:48.163294|2018-06-01 03:34:48.163294
NCT00410189|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2015-03-17||2015-03-17|2006-12-08|2006-12-12|Estimate|2015-03-17|2015-03-23|Estimate||||2015-03-17|2015-03-23|Estimate|November 2006||2006-11-30|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC|A Phase II, Open Label Study of ZD6474 in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|54|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:34:49.764205|2018-06-01 03:34:49.764205
NCT00410176|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|January 2007||2007-01-31|December 2006|2006-12-31||||||||Interventional|||A Randomized, Controlled, Unblinded, Clinical Trial of the Acceptability and Efficacy of Non-Pharmaceutical Methods in Preventing Spread of Influenza Within the Family||Unknown status|Not yet recruiting|N/A|400||Ministry of Health, Israel|||||f||||||||||||||2018-06-01 03:34:50.156813|2018-06-01 03:34:50.156813
NCT00410163|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2011-07-28||2013-12-19|2006-12-11|2006-12-12|Estimate|2011-09-08|2011-10-17|Estimate||||2013-12-19|2014-02-10|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|March 2009|Actual|2009-03-31||Interventional|BIFROST||Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients|An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With Fludarabine and Cyclophosphamide, in Patients With Previously Untreated B-cell CLL|Completed||Phase 2|61|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 03:34:50.226677|2018-06-01 03:34:50.226677
NCT00410150|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2010-09-15||2010-10-22|2006-12-11|2006-12-12|Estimate|2010-09-15|2010-10-13|Estimate||||2010-10-22|2010-11-08|Estimate|April 2006||2006-04-30|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation|A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus|Terminated||Phase 2|42|Actual|Children's Hospital Medical Center, Cincinnati||2||Study was stopped after interim analysis and slow enrollment.|f||||t||||||||||2018-06-01 03:34:52.083636|2018-06-01 03:34:52.083636
NCT00410137|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-10|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|March 2006||2006-03-31|December 2006|2006-12-31|April 2008||2008-04-30|||||Observational|||Influence of Nutritional and Inflammational Status on Survival of Hemodialysis Patients||Unknown status|Recruiting||100||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:34:53.149212|2018-06-01 03:34:53.149212
NCT00410124|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2012-10-23||2012-12-07|2006-12-11|2006-12-12|Estimate|2012-12-07|2013-01-15|Estimate||||2012-12-07|2013-01-15|Estimate|November 2006||2006-11-30|December 2012|2012-12-31|October 2011|Actual|2011-10-31|February 2008|Actual|2008-02-29||Interventional|RECORD-1||RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor|Completed||Phase 3|416|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:34:53.293287|2018-06-01 03:34:53.293287
NCT00410111|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2008-10-15|2006-12-11|2006-12-12|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|July 2007|Actual|2007-07-31|||||Observational|||Pathogenesis and Cerebrovascular Manifestations of Septic Encephalopathy|A Pilotstudy on Pathogenesis and Cerebrovascular Manifestations of Septic Encephalopathy|Completed|||23|Actual|University Hospital, Basel, Switzerland|||||f||||||||||||||2018-06-01 03:34:55.312178|2018-06-01 03:34:55.312178
NCT00410098|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-10|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|June 2007||2007-06-30|December 2006|2006-12-31||||||||Interventional|||Bikram Yoga and Asthma|The Influence of Bikram Yoga (39 Degree Celsius Heat and 60% Humidity) on Basic Lung Function Tests,Bronchial Challenges and Pulmonary-Heart Endurance in Young Asthmatic Adults.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:34:55.374531|2018-06-01 03:34:55.374531
NCT00410085|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-10|||2008-04-17|2006-12-11|2006-12-12|Estimate|||||||2008-04-17|2008-04-22|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|November 2005||2005-11-30|||||Interventional|||Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls||Completed||Phase 4|40||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:34:55.443347|2018-06-01 03:34:55.443347
NCT00410072|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|2011-11-04||2013-03-13|2006-12-11|2006-12-12|Estimate|2012-01-03|2012-02-03|Estimate||||2013-03-13|2013-03-15|Estimate|April 2007||2007-04-30|March 2013|2013-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B|A Comparative Study of Chronic Hepatitis B Subjects Treated With Entecavir Plus Tenofovir Combination Therapy vs. Entecavir Monotherapy in Adults Who Are Treatment-Naive to Nucleosides and Nucleotides: The BE-LOW Study|Completed||Phase 3|669|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:34:55.581007|2018-06-01 03:34:55.581007
NCT00410059|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2017-07-06||2017-07-06|2006-12-11|2006-12-12|Estimate|2017-07-06|2017-08-02|Actual||||2017-07-06|2017-08-02|Actual|November 2006||2006-11-30|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC|A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|59|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 03:34:56.61743|2018-06-01 03:34:56.61743
NCT00410046|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2009-10-30||2012-04-09|2006-12-11|2006-12-12|Estimate|2012-04-09|2012-05-11|Estimate||||2012-04-09|2012-05-11|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Extension Study Evaluating Etanercept in Ankylosing Spondylitis|An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis|Completed||Phase 4|84|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||||||||||||2018-06-01 03:34:56.954911|2018-06-01 03:34:56.954911
NCT00410033|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2016-12-21|2006-12-11|2006-12-12|Estimate|||||||2016-12-21|2016-12-22|Estimate|December 1989||1989-12-31|December 2016|2016-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin|Safety/Efficacy Trial Using Stored Serum Samples to Investigate the Immunogenicity of Insulin Aspart and Soluble Human Insulin in Children and Adolescents From Onset of Type 1 Diabetes|Completed||N/A|74|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:34:57.396915|2018-06-01 03:34:57.396915
NCT00410020|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|June 1999||1999-06-30|December 2006|2006-12-31|June 2003||2003-06-30|||||Interventional|||Arrhythmia Prevention With an Alpha-Linolenic Enriched Diet|Secondary Prevention of Atrial Fibrillation With an Alpha-Linolenic Enriched Diet : a Randomized Study|Completed||Phase 2|130||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:34:57.478453|2018-06-01 03:34:57.478453
NCT00410007|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-10|||2018-03-16|2006-12-11|2006-12-12|Estimate|||||||2018-03-16|2018-03-20|Actual|October 2006||2006-10-31|March 2018|2018-03-31|November 2011|Actual|2011-11-30|October 2010|Actual|2010-10-31||Interventional|||The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease|The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease, During Basal Conditions and After Hypertonic Saline Infusion.|Completed||N/A|29|Actual|Regional Hospital Holstebro||4|||f||||f||||||||||2018-06-01 03:34:57.560497|2018-06-01 03:34:57.560497
NCT00409994|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2017-03-21|2006-12-11|2006-12-12|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2006||2006-09-30|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer|A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study|Active, not recruiting||Phase 1/Phase 2|65|Anticipated|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-06-01 03:34:57.647715|2018-06-01 03:34:57.647715
NCT00409981|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|July 2004||2004-07-31|December 2006|2006-12-31|June 2006||2006-06-30|||||Interventional|||Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II)|Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR II)|Completed||Phase 1/Phase 2|56||University Hospital, Saarland|||||f||||||||||||||2018-06-01 03:34:57.749073|2018-06-01 03:34:57.749073
NCT00409968|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2018-03-15|2006-12-11|2006-12-12|Estimate|||||||2018-03-15|2018-03-19|Actual|November 2006|Actual|2006-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)|A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting|||250|Anticipated|M.D. Anderson Cancer Center|||1||f||||t|f|f||||Samples With DNA|"~     A sample of your tumor tissue will be collected for biomarker analysis, and based on the~     results, you will be assigned to one of four phase II studies.~   "|||2018-06-01 03:34:57.825841|2018-06-01 03:34:57.825841
NCT00409955|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|December 2005||2005-12-31|December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Lamellar Transplant With Lyophilized Corneas|Randomized Clinical Trial for Lamellar Transplants Using Lyophilized and Optisol Corneas|Completed||Phase 2|20||Federal University of São Paulo|||||f||||||||||||||2018-06-01 03:34:57.89553|2018-06-01 03:34:57.89553
NCT00409942|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2009-07-14|2006-12-11|2006-12-12|Estimate|||||||2009-07-14|2009-07-15|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TORAFIC||Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.|Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure|Completed||Phase 4|142|Actual|Ferrer Internacional S.A.||2|||f||||f||||||||||2018-06-01 03:34:58.002434|2018-06-01 03:34:58.002434
NCT00409929|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2010-10-18|2006-12-11|2006-12-12|Estimate|||||||2010-10-18|2010-10-19|Estimate|June 2006||2006-06-30|October 2010|2010-10-31||||July 2006|Actual|2006-07-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071|A Randomized, Double-blind, Placebo-controlled, Time Lagged, Parallel Group, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AEB071 Doses Greater Than 500 mg in Healthy Subjects|Completed||Phase 1|16|Actual|Novartis|||||f||||||||||||||2018-06-01 03:34:58.140707|2018-06-01 03:34:58.140707
NCT00409916|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2009-06-01|2006-12-08|2006-12-12|Estimate|||||||2009-06-01|2009-06-03|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||PREVENT-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing|Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF)|Unknown status|Recruiting|Phase 4|500|Anticipated|CardioDynamics||2|||f||||t||||||||||2018-06-01 03:34:58.191702|2018-06-01 03:34:58.191702
NCT00409903|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-10|||2007-09-13|2006-12-11|2006-12-12|Estimate|||||||2007-09-13|2007-09-14|Estimate|November 2006||2006-11-30|September 2007|2007-09-30||||||||Interventional|||The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.|The Effect of Eprosartan on Vasoactive Hormones and Renal Tubular Function in Healthy Humans.|Completed||Phase 4|18|Anticipated|Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:34:58.274874|2018-06-01 03:34:58.274874
NCT00409890|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-11|||2006-12-11|2006-12-11|2006-12-12|Estimate|||||||2006-12-11|2006-12-12|Estimate|June 2005||2005-06-30|December 2006|2006-12-31|October 2005||2005-10-31|||||Interventional|||The Effect of Hyoscine Butyl Bromide on the First Stage of Labor in Term Pregnancies|The Effect of Hyoscine Butyl Bromide on the First Stage of Labor in Term Pregnancies|Completed||Phase 2|120||University Hospital of the West Indies|||||f||||||||||||||2018-06-01 03:34:58.322333|2018-06-01 03:34:58.322333
NCT00409864|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2010-05-25|2006-12-08|2006-12-11|Estimate|||||||2010-05-25|2010-05-26|Estimate|October 2003||2003-10-31|December 2006|2006-12-31|December 2005|Actual|2005-12-31|July 2005|Actual|2005-07-31||Interventional|||Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer|Endoscopic Versus Percutaneous Biliary Drainage For Hilar Block Due to Carcinoma Gall Bladder: A Randomized Prospective Trial and Quality Of Life Assessment|Completed||N/A|182|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||||||||||||2018-06-01 03:34:58.395725|2018-06-01 03:34:58.395725
NCT00409851|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2011-11-07|2006-12-07|2006-12-11|Estimate|||||||2011-11-07|2011-11-08|Estimate|April 2003||2003-04-30|November 2011|2011-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||One Year Study to Evaluate the Safety of the Combination of Valsartan and Amlodipine in Patients With Hypertension|A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.|Completed||Phase 3|1293|Actual|Novartis|||||f||||||||||||||2018-06-01 03:34:58.498752|2018-06-01 03:34:58.498752
NCT00409838|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2009-11-16||2013-08-06|2006-12-08|2006-12-11|Estimate|2009-12-20|2010-01-26|Estimate||||2013-08-06|2013-08-08|Estimate|April 2007||2007-04-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|July 2008|Actual|2008-07-31||Interventional|||A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept Administered Intravenously in Korean Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate|Completed||Phase 3|113|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 03:34:58.599588|2018-06-01 03:34:58.599588
NCT00409825|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2015-01-13||2015-02-09|2006-12-08|2006-12-11|Estimate|2015-01-22|2015-02-09|Estimate||||2015-02-09|2015-02-27|Estimate|March 2006||2006-03-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|April 2008|Actual|2008-04-30||Interventional|||Study of Pharmacology of 17-OHPC in Pregnancy|A Study of the Pharmacology of 17-Hydroxyprogesterone Caproate in Pregnancy|Completed||Phase 2|61|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:34:59.777918|2018-06-01 03:34:59.777918
NCT00409812|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2007-01-18|2006-12-08|2006-12-11|Estimate|||||||2007-01-18|2007-01-19|Estimate|February 2007||2007-02-28|January 2007|2007-01-31||||||||Observational|||A Study of the Effects of Sodium Citrate on Olfactory Thresholds|A Double Blinded Randomised Controlled Trial of the Effects of Sodium Citrate on Olfactory Thresholds|Unknown status|Not yet recruiting||||University Hospitals, Leicester|||||f||||||||||||||2018-06-01 03:34:59.971806|2018-06-01 03:34:59.971806
NCT00409799|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2012-03-15|2006-12-08|2006-12-11|Estimate|||||||2012-03-15|2012-03-16|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy of I 0401 in the Treatment of Tibial Plateau Fractures Requiring Grafting|A Phase 2 Randomized, Controlled, Open-label (Dose-blinded), Multi-center, Dose-finding Study of the Safety and Efficacy of I-0401 in the Treatment of Patients With Fractures of the Tibial Plateau Requiring Grafting.|Completed||Phase 2|208|Actual|Kuros Biosurgery AG||3|||f||||f||||||||||2018-06-01 03:35:00.02962|2018-06-01 03:35:00.02962
NCT00409786|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2011-02-23||2011-03-23|2006-12-08|2006-12-11|Estimate|2011-03-23|2011-04-22|Estimate||||2011-03-23|2011-04-22|Estimate|November 2006||2006-11-30|March 2011|2011-03-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal|Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal|Completed||N/A|50|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 03:35:00.152548|2018-06-01 03:35:00.152548
NCT00409773|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2009-06-16||2017-03-17|2006-12-08|2006-12-11|Estimate|2009-06-17|2009-08-04|Estimate||||2017-03-17|2017-04-14|Actual|January 2007||2007-01-31|March 2017|2017-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease|Completed||Phase 3|1143|Actual|Merck Sharp & Dohme Corp.|15 patients were randomized but not treated. Since these patients were not treated no Adverse Event Data was collected.|5|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:35:00.355243|2018-06-01 03:35:00.355243
NCT00409760|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2011-11-22|2006-12-07|2006-12-11|Estimate|||||||2011-11-22|2011-11-23|Estimate|January 2003||2003-01-31|November 2011|2011-11-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.|A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.|Completed||Phase 3|1930|Actual|Novartis|||||f||||||||||||||2018-06-01 03:35:01.57705|2018-06-01 03:35:01.57705
NCT00409747|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2012-10-22||2015-11-05|2006-12-08|2006-12-11|Estimate|2015-11-05|2015-12-11|Estimate||||2015-11-05|2015-12-11|Estimate|November 2006||2006-11-30|November 2015|2015-11-30|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional||10 subjects completed the trial and had analyzable data at the 6 month mark. One child had csf collected after 3 months.|Minocycline to Treat Childhood Regressive Autism|Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS|Completed||Phase 4|11|Actual|National Institutes of Health Clinical Center (CC)|Small, uncontrolled pilot.|1|||f||||f||||||||||2018-06-01 03:35:01.718852|2018-06-01 03:35:01.718852
NCT00409734|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2006-12-08|2006-12-08|2006-12-11|Estimate|||||||2006-12-08|2006-12-11|Estimate|October 2006||2006-10-31|November 2006|2006-11-30||||||||Observational|||Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis|Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis|Unknown status|Recruiting||100||Maimonides Medical Center|||||f||||||||||||||2018-06-01 03:35:02.056202|2018-06-01 03:35:02.056202
NCT00409721|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2011-03-01|2006-12-08|2006-12-11|Estimate|||||||2011-03-01|2011-03-02|Estimate|March 2007||2007-03-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis (ALS)|A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS|Completed||Phase 2|42|Anticipated|University of Alberta||2|||f||||t||||||||||2018-06-01 03:35:02.142223|2018-06-01 03:35:02.142223
NCT00409708|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2010-12-06||2011-04-19|2006-12-08|2006-12-11|Estimate|2011-04-19|2011-05-17|Estimate||||2011-04-19|2011-05-17|Estimate|November 2006||2006-11-30|April 2011|2011-04-30||||March 2008|Actual|2008-03-31||Interventional|||Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)|An Open-label, Behavioral-treatment-controlled Evaluation of the Effects of Extended Release Methylphenidate on the Frequency of Cytogenetic Abnormalities in Children 6 - 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|142|Actual|Novartis|Since no cytogenetic effects were observed, blood samples were not analyzed for pharmacokinetics/pharmacodynamics.|2|||f||||||||||||||2018-06-01 03:35:02.280925|2018-06-01 03:35:02.280925
NCT00409695|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2012-01-19|2006-12-08|2006-12-11|Estimate|||||||2012-01-19|2012-01-23|Estimate|December 2006||2006-12-31|January 2012|2012-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Thymoglobulin (ATG) Dose Finding Study|Dose Finding Study of Thymoglobulin (ATG) in Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)|Terminated||Phase 1/Phase 2|1|Actual|M.D. Anderson Cancer Center||2||Lack of Accrual|f||||t||||||||||2018-06-01 03:35:02.88096|2018-06-01 03:35:02.88096
NCT00409682|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2011-05-18||2011-07-11|2006-12-08|2006-12-11|Estimate|2011-07-11|2011-08-04|Estimate||||2011-07-11|2011-08-04|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease|A Multi-Center, Double-Blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease|Completed||Phase 3|192|Actual|Abbott|Absence of placebo group comparative data.|3|||f||||t||||||||||2018-06-01 03:35:03.120615|2018-06-01 03:35:03.120615
NCT00409669|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2008-05-06|2006-12-08|2006-12-11|Estimate|||||||2008-05-06|2008-05-09|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Intraocular Pressure Accuracy and Variability of the Barraquer Tonometer|Study to Compare the Accuracy and Variability of the Barraquer Tonometer With Other Methods of Tonometry|Unknown status|Recruiting|N/A|300|Anticipated|Barnes Retina Institute|||||f||||||||||||||2018-06-01 03:35:04.02287|2018-06-01 03:35:04.02287
NCT00409656|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2006-12-12|2006-12-08|2006-12-11|Estimate|||||||2006-12-12|2006-12-13|Estimate|December 2003||2003-12-31|December 2006|2006-12-31|December 2005||2005-12-31|||||Interventional|||Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients|Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty Patients|Completed||Phase 2|||University Hospital Freiburg|||||f||||||||||||||2018-06-01 03:35:04.100097|2018-06-01 03:35:04.100097
NCT00409643|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2011-11-07|2006-12-07|2006-12-11|Estimate|||||||2011-11-07|2011-11-08|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients|A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients|Completed||Phase 3|1259|Actual|Novartis|||||f||||||||||||||2018-06-01 03:35:04.16395|2018-06-01 03:35:04.16395
NCT00409630|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2012-04-11|2006-12-08|2006-12-11|Estimate|||||||2012-04-11|2012-04-12|Estimate||||April 2012|2012-04-30||||||||Interventional|||Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma|Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||||Sponsor decided against going forward with the study.|f||||||||||||||2018-06-01 03:35:04.298577|2018-06-01 03:35:04.298577
NCT00409617|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2009-07-24||2011-10-06|2006-12-08|2006-12-11|Estimate|2009-07-24|2009-09-02|Estimate||||2011-10-06|2011-10-10|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease|A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease|Completed||Phase 3|945|Actual|Abbott||1|||f||||f||||||||||2018-06-01 03:35:04.426044|2018-06-01 03:35:04.426044
NCT00409604|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2010-08-30|2006-12-08|2006-12-11|Estimate|||||||2010-08-30|2010-08-31|Estimate|December 2006||2006-12-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||PROTECT : Pacing to Protect Heart for Damage From Blocked Heart Vessel and From Re-opening Blocked Vessel(s)|Clinical Evaluation of Pacing During the Onset of Revascularization / Feasibility Study|Completed||Phase 2|60|Actual|Guidant Corporation||2|||f||||||||||||||2018-06-01 03:35:05.482704|2018-06-01 03:35:05.482704
NCT00409591|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2016-01-26|2006-12-08|2006-12-11|Estimate|||||||2016-01-26|2016-01-28|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|November 2010|Actual|2010-11-30||Interventional|PHPT-5||Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand|Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.|Terminated||Phase 3|435|Actual|Institut de Recherche pour le Developpement||3||Change in National PMTCT guidelines in Thailand|f||||t||||||||||2018-06-01 03:35:05.568601|2018-06-01 03:35:05.568601
NCT00409578|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2011-01-11||2011-04-15|2006-12-08|2006-12-11|Estimate|2011-01-11|2011-02-02|Estimate||||2011-04-15|2011-04-19|Estimate|February 2007||2007-02-28|April 2011|2011-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational Clinical Trial to Evaluate the Efficacy of Aliskiren and Valsartan Versus Placebo in Lowering Levels on NT-proBNP in Stabilized Patients Post Acute Coronary Syndromes|Completed||Phase 2|1101|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:35:05.748641|2018-06-01 03:35:05.748641
NCT00409565|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2014-02-12||2017-09-19|2006-12-08|2006-12-11|Estimate|2016-06-01|2016-07-12|Estimate||||2017-09-19|2017-10-20|Actual|September 2006||2006-09-30|September 2017|2017-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||STARTED 46; Overall Response Rate 7; COMPLETED 45; Not Completed 1|A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer|Completed||Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:35:06.760493|2018-06-01 03:35:06.760493
NCT00409552|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2017-01-11|2006-12-08|2006-12-11|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2009||2009-11-30|September 2009|2009-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Human Factors Analysis in VR for Burn Treatment|Phase 1 and 2 Study of Human Factors Analysis in VR for Burn Treatment|Completed||Phase 1/Phase 2|10|Actual|National Institute on Drug Abuse (NIDA)||5|||f||||||||||||||2018-06-01 03:35:07.365878|2018-06-01 03:35:07.365878
NCT00409539|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|2014-09-26|2014-05-24|2014-12-05|2006-12-08|2006-12-11|Estimate|2014-12-05|2014-12-10|Estimate|2014-05-24|2014-05-30|Estimate|2014-12-05|2014-12-10|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)|A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome|Completed||Phase 2|550|Actual|Sunovion||6|||f||||f||||||||||2018-06-01 03:35:07.47642|2018-06-01 03:35:07.47642
NCT00409526|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2014-05-30|2006-12-08|2006-12-11|Estimate|||||||2014-05-30|2014-06-02|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.|Pilot Study: The Effect of Inhaled Iloprost on Oxygenation in Term and Near Term Infants With Pulmonary Hypertension. Testing Two Doses.|Terminated||Phase 4|1|Actual|University of Chicago||||Sub-Investigator left U of C|f||||||||||||||2018-06-01 03:35:08.41997|2018-06-01 03:35:08.41997
NCT00409500|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2007-06-21|2006-12-08|2006-12-11|Estimate|||||||2007-06-21|2007-06-22|Estimate|October 2006||2006-10-31|June 2007|2007-06-30||||||||Interventional|||Effect of Food on the Pharmacokinetics of AQW051 in Japanese Healthy Male Subjects|A Randomized, Double-Blind, Placebo-Controlled, Interleaved, Ascending Dose Study, to Evaluate Safety, Tolerability and Pharmacokinetics of Single Oral Doses of AQW051; to Evaluate the Effect of Food on the Pharmacokinetics of AQW051, in Japanese Healthy Male Subjects|Completed||Phase 1|54||Novartis|||||f||||||||||||||2018-06-01 03:35:08.490132|2018-06-01 03:35:08.490132
NCT00409487|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2010-09-07|2006-12-08|2006-12-11|Estimate|||||||2010-09-07|2010-09-08|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|December 2006|Actual|2006-12-31||Interventional|VALSAS||Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients|Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.|Completed||Phase 4|60|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 03:35:08.54619|2018-06-01 03:35:08.54619
NCT00409461|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-08|||2006-12-08|2006-12-08|2006-12-11|Estimate|||||||2006-12-08|2006-12-11|Estimate||||December 2006|2006-12-31||||||||Interventional|||Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts|Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts|Terminated||N/A|||AZ-VUB|||||f||||||||||||||2018-06-01 03:35:08.63455|2018-06-01 03:35:08.63455
NCT00409448|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2014-09-18|2006-12-07|2006-12-08|Estimate|||||||2014-09-18|2014-09-19|Estimate|March 2007||2007-03-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|CAPS||Internet-Based Treatment for Children With Traumatic Brain Injuries & Their Families: Counselor Assisted Problem Solving|Improving Mental Health Outcomes of Child Brain Injury|Completed||N/A|132|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 03:35:08.705473|2018-06-01 03:35:08.705473
NCT00409435|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2018-04-12|2006-12-06|2006-12-08|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2006||2006-10-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study of Pyridostigmine in Postural Tachycardia Syndrome|Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome|Recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:35:08.79914|2018-06-01 03:35:08.79914
NCT00409422|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2008-06-20|2006-12-06|2006-12-08|Estimate|||||||2008-06-20|2008-06-24|Estimate|May 2002||2002-05-31|June 2008|2008-06-30|February 2007|Actual|2007-02-28|October 2006|Actual|2006-10-31||Interventional|||Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children|Effects of a Comprehensive Weight Management Program on Obese Adolescents and Children|Completed||N/A|200||Yale University|||||f||||f||||||||||2018-06-01 03:35:08.910629|2018-06-01 03:35:08.910629
NCT00409409|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2016-01-25||2016-04-18|2006-12-07|2006-12-08|Estimate|2016-04-18|2016-05-26|Estimate||||2016-04-18|2016-05-26|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional||The Intent-to-treat (ITT) population included all patients who received at least one dose of the investigational product and had a Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS) and at least one Rhinoconjunctivitis Total Symptom Score (RTSS) during the pollen period while on treatment.|Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis|A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis|Completed||Phase 3|278|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-06-01 03:35:08.987188|2018-06-01 03:35:08.987188
NCT00409396|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2015-06-05|2006-12-07|2006-12-08|Estimate|||||||2015-06-05|2015-06-09|Estimate|November 2006||2006-11-30|November 2014|2014-11-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||A Study to Determine Whether Urinary PGE-M Levels Correlate With Ulcerative Colitis Disease|Urinary PGE-M, A Metabolite of PGE2: A Novel Biomarker of Ulcerative Colitis Disease|Completed||N/A|35|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 03:35:09.237191|2018-06-01 03:35:09.237191
NCT00409383|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2011-11-04|2006-12-07|2006-12-08|Estimate|||||||2011-11-04|2011-11-07|Estimate|November 2006||2006-11-30|July 2010|2010-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Abraxane and Temodar Plus Genasense in Advanced Melanoma|"A Pilot Study of Abraxane® (Albumin-bound Paclitaxel) and Temodar® (Temozolomide) Plus Genasense® (Oblimersen Sodium) in Subjects With Advanced Melanoma (The ATG Study)."|Unknown status|Active, not recruiting|Phase 1|28|Anticipated|Genta Incorporated|||||f||||f||||||||||2018-06-01 03:35:09.347508|2018-06-01 03:35:09.347508
NCT00409370|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2006-12-07|2006-12-07|2006-12-08|Estimate|||||||2006-12-07|2006-12-08|Estimate|April 2003||2003-04-30|December 2006|2006-12-31|February 2005||2005-02-28|||||Interventional|||Trial of Safety Nets In Hospitalized Patients|A Randomized Clinical Trial to Compare The Use Of Safety Net Enclosures With Standard Restraints in Agitated Hospitalized Patients|Completed||Phase 3|60||Griffin Hospital|||||f||||||||||||||2018-06-01 03:35:09.653327|2018-06-01 03:35:09.653327
NCT00409357|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2009-10-01|2006-12-07|2006-12-08|Estimate|||||||2009-10-01|2009-10-02|Estimate|November 2004||2004-11-30|October 2009|2009-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of SL77.0499-10 Once Daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH)|Completed||Phase 2|473|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:35:09.745535|2018-06-01 03:35:09.745535
NCT00409344|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2009-02-26||2009-09-16|2006-12-07|2006-12-08|Estimate|2009-08-07|2009-09-16|Estimate||||2009-09-16|2009-09-22|Estimate|January 2007||2007-01-31|September 2009|2009-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms|Phase 4 Study of Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms|Terminated||Phase 4|0|Actual|Massachusetts General Hospital|Unable to enroll participants into the study|2||Surgical approach changed therefore subject enrollment not possible.|f||||t||||||||||2018-06-01 03:35:09.867636|2018-06-01 03:35:09.867636
NCT00409331|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2009-12-11||2012-07-31|2006-12-07|2006-12-08|Estimate|2009-12-11|2010-01-18|Estimate||||2012-07-31|2012-08-07|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment|A Phase II Study To Assess The Efficacy of Amifostine for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment With Intensity- Modulated Radiation Therapy (IMRT) for Parotid Salivary Sparing|Terminated||Phase 2|3|Actual|M.D. Anderson Cancer Center||1||Study terminated by Principal Investigator; no patients completed study.|f||||f||||||||||2018-06-01 03:35:10.145509|2018-06-01 03:35:10.145509
NCT00409318|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2008-05-23|2006-12-07|2006-12-08|Estimate|||||||2008-05-23|2008-05-28|Estimate|April 2004||2004-04-30|May 2008|2008-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study of TNF-Antagonism in Metabolic Syndrome|Effects of TNF-Alpha Antagonism in Patients With the Metabolic Syndrome (I)|Completed||N/A|56|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:35:10.286572|2018-06-01 03:35:10.286572
NCT00409305|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2015-04-20|2006-12-06|2006-12-08|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||The Effect of Betahistine on Body Weight in Obese Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Subjects|Completed||Phase 2|280||OBEcure Ltd.|||||f||||||||||||||2018-06-01 03:35:10.383399|2018-06-01 03:35:10.383399
NCT00371202|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-01-12|2006-08-31|2006-09-01|Estimate|||||||2007-01-12|2007-01-15|Estimate|July 2006||2006-07-31|January 2007|2007-01-31|August 2006||2006-08-31|||||Interventional|||Comparison of Penetrating Keratoplasty and Deep Lamellar Keratoplasty With the Big Bubble Technique for Keratoconus||Unknown status|Active, not recruiting|Phase 3|50||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:09.047941|2018-06-01 03:48:09.047941
NCT00409292|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2014-04-30||2014-07-23|2006-12-06|2006-12-08|Estimate|2014-07-23|2014-08-11|Estimate||||2014-07-23|2014-08-11|Estimate|January 2007||2007-01-31|July 2014|2014-07-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional||Our study design used a one-stage design with a target accrual of 35 eligible patients, with the assumption that an improvement in PFS at 2 months from 50% to 71% would warrant further study in this patient population.|RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer|Phase II Study of RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|33|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 03:35:10.564014|2018-06-01 03:35:10.564014
NCT00409279|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2008-02-28|2006-12-07|2006-12-08|Estimate|||||||2008-02-28|2008-03-03|Estimate|September 2003||2003-09-30|February 2008|2008-02-29|April 2008|Anticipated|2008-04-30|April 2008|Anticipated|2008-04-30||Interventional|||An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease|An Innovative Psychosocial Intervention for Adult-Child Caregivers of Parents With Alzheimer's Disease|Unknown status|Recruiting|N/A|100|Anticipated|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 03:35:10.803965|2018-06-01 03:35:10.803965
NCT00409266|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2006-12-07|2006-12-07|2006-12-08|Estimate|||||||2006-12-07|2006-12-08|Estimate||||December 2006|2006-12-31||||||||Interventional|||CT Assessment of Minimally Invasive Surgery and Computer Assisted Navigation in Total Knee Arthroplasty||Unknown status|Not yet recruiting|Phase 4|||Stryker Instruments|||||f||||||||||||||2018-06-01 03:35:10.88491|2018-06-01 03:35:10.88491
NCT00409253|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2009-02-24|2006-12-07|2006-12-08|Estimate|||||||2009-02-24|2009-02-25|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|August 2010|Anticipated|2010-08-31|June 2010|Anticipated|2010-06-30||Interventional|||Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine|Treatment of Severe Hypertension During Pre-Eclampsia.A Preliminary Equivalence Study Between URAPIDIL and NICARDIPINE|Unknown status|Recruiting|Phase 3|72|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-06-01 03:35:10.955437|2018-06-01 03:35:10.955437
NCT00409240|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2014-01-14||2014-03-06|2006-12-07|2006-12-08|Estimate|2014-03-06|2014-04-11|Estimate||||2014-03-06|2014-04-11|Estimate|October 2006||2006-10-31|March 2014|2014-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes|Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes|Completed||Phase 3|103|Actual|Providence VA Medical Center|Only 1 in 5 patients responded to the invitation to join the study and was willing to participate, participants were mostly male veterans, and pharmacists had prescribing privileges in the VA and in this study.|2|||f||||t||||||||||2018-06-01 03:35:11.069654|2018-06-01 03:35:11.069654
NCT00409227|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2008-06-17|2006-12-07|2006-12-08|Estimate|||||||2008-06-17|2008-06-18|Estimate|December 2006||2006-12-31|June 2008|2008-06-30||||July 2009|Anticipated|2009-07-31||Interventional|||Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy|Prospective Randomized Placebo Controlled Blinded Study to Evaluate the Efficacy of Alfuzosin (Alpha Blocker) on the Success Rates Following SWL.|Unknown status|Recruiting|Phase 2|150|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 03:35:11.305269|2018-06-01 03:35:11.305269
NCT00409214|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2012-11-14|2006-12-07|2006-12-08|Estimate|||||||2012-11-14|2012-11-16|Estimate|November 2006||2006-11-30|November 2012|2012-11-30||||February 2008|Actual|2008-02-29||Interventional|||Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma|A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma|Completed||Phase 2|18|Anticipated|Light Sciences Oncology|||||f||||||||||||||2018-06-01 03:35:11.405403|2018-06-01 03:35:11.405403
NCT00409201|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2006-12-07|2006-12-07|2006-12-08|Estimate|||||||2006-12-07|2006-12-08|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|November 2006||2006-11-30|||||Interventional|||Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia|Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures|Unknown status|Recruiting|Phase 1|30||Abarbanel Mental Health Center|||||f||||||||||||||2018-06-01 03:35:11.474449|2018-06-01 03:35:11.474449
NCT00409188|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|2015-07-23||2015-10-19|2006-12-07|2006-12-08|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|January 2007||2007-01-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2012|Actual|2012-04-30||Interventional|START|ITT population included all the subject who were randomized.|Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)|A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.|Completed||Phase 3|1513|Actual|EMD Serono||2|||f||||t||||||||||2018-06-01 03:35:11.627247|2018-06-01 03:35:11.627247
NCT00409175|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2012-11-16|2010-03-09|2012-11-16|2006-12-06|2006-12-08|Estimate|2012-11-16|2012-12-17|Estimate|2010-03-09|2010-03-11|Estimate|2012-11-16|2012-12-17|Estimate|January 2007||2007-01-31|November 2012|2012-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis|Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 2/Phase 3|128|Actual|Pfizer|Instead of the intended endpoint 'heat pain and cooling threshold', results of 'summated 3 score for small nerve fiber function' were reported.|2|||f||||t||||||||||2018-06-01 03:35:13.269642|2018-06-01 03:35:13.269642
NCT00409162|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2006-12-07|2006-12-07|2006-12-08|Estimate|||||||2006-12-07|2006-12-08|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|October 2007||2007-10-31|||||Interventional|||Safety and Efficacy Study of a New Device for Tattoo Removal|A Prospective, Open Label, Non Randomized, First-In-Man (Feasibility) Study to Evaluate the Safety and Effectiveness of the Eraser Tattoo Removal Device|Unknown status|Not yet recruiting|N/A|30||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:35:13.873114|2018-06-01 03:35:13.873114
NCT00409149|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2011-01-16|2006-12-07|2006-12-08|Estimate|||||||2011-01-16|2011-01-19|Estimate|December 2006||2006-12-31|April 2007|2007-04-30|November 2009|Actual|2009-11-30|October 2008|Actual|2008-10-31||Interventional|||The Effect of a Complementary Multi Disciplinary Program on Blood Pressure in Hypertensive Patients|Comprehensive Approach to Lower Measured Blood Pressure (CALM-BP) - Results From a Randomized Controlled Trial|Completed||Phase 3|113|Actual|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-06-01 03:35:13.942323|2018-06-01 03:35:13.942323
NCT00409136|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2009-01-29|2006-12-07|2006-12-08|Estimate|||||||2009-01-29|2009-02-02|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Multi-Center Human Alert Trial to Prevent DVT and PE|Physician Alerts to Prevent DVT and Pulmonary Embolism in Hospitalized Patients|Completed|||2496|Actual|Brigham and Women's Hospital|||2||f||||t||||||||||2018-06-01 03:35:14.026975|2018-06-01 03:35:14.026975
NCT00409123|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2008-09-25|2006-12-07|2006-12-08|Estimate|||||||2008-09-25|2008-09-26|Estimate|September 2004||2004-09-30|September 2008|2008-09-30|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Observational|||Effect of Systemic Cooling in Vasospasms|Effect of Systemic Cooling in Vasospasms (Kühleffekte Beim Vasospastischen Syndrom)|Completed|||28|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:35:14.147446|2018-06-01 03:35:14.147446
NCT00409110|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2011-08-08|2006-12-07|2006-12-08|Estimate|||||||2011-08-08|2011-08-09|Estimate|January 2006||2006-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry|Relationship Between Ocular Pulse Amplitude And Choroidal Laser Doppler Flowmetry In Healthy Subjects|Terminated|||10|Actual|University Hospital, Basel, Switzerland||||methodological problems|f||||f||||||||||2018-06-01 03:35:14.205329|2018-06-01 03:35:14.205329
NCT00409097|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2006-12-07|2006-12-07|2006-12-08|Estimate|||||||2006-12-07|2006-12-08|Estimate|April 2006||2006-04-30|December 2006|2006-12-31|December 2007||2007-12-31|||||Interventional|||Effect of Rosiglitazone on ADMA in Critical Illness||Unknown status|Recruiting|Phase 3|30||VU University Medical Center|||||f||||||||||||||2018-06-01 03:35:14.261335|2018-06-01 03:35:14.261335
NCT00409084|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2010-07-02|2006-12-06|2006-12-08|Estimate|||||||2010-07-02|2010-07-05|Estimate|December 2006||2006-12-31|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding|Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding|Terminated||Phase 3|2|Actual|Virginia Commonwealth University||2||Lack of enrollment|f||||t||||||||||2018-06-01 03:35:14.407409|2018-06-01 03:35:14.407409
NCT00409071|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2010-02-04|2006-12-07|2006-12-08|Estimate|||||||2010-02-04|2010-02-05|Estimate|September 2005||2005-09-30|February 2010|2010-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Placebo-controlled Evaluation of Cocculine® Efficacy in the Management of Nausea After Chemotherapy in Breast Cancer.|Placebo-controlled Evaluation of Homeopathic Remedy (Cocculine®) Efficacy in the Management of Nausea After Adjuvant Chemotherapy in Non Metastatic Breast Cancer.|Completed||Phase 3|431|Actual|Centre Leon Berard||2|||f||||f||||||||||2018-06-01 03:35:14.482272|2018-06-01 03:35:14.482272
NCT00409058|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2014-10-27|2006-12-07|2006-12-08|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2005||2005-10-31|September 2014|2014-09-30|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|TOPS||Teen Online Problem Solving (TOPS) - An Online Intervention Following TBI|An Online Intervention for Families Following Adolescent TBI - Teen Online Problem Solving (TOPS)|Completed||N/A|42|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-06-01 03:35:14.562101|2018-06-01 03:35:14.562101
NCT00409045|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2007-11-02|2006-12-07|2006-12-08|Estimate|||||||2007-11-02|2007-11-05|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Observational|||Evaluation of Obstructive Sleep Apnea as a Risk Factor for Pulmonary Embolism|Evaluation of Obstructive Sleep Apnea as a Risk Factor for Pulmonary Embolism|Completed|||300|Anticipated|Atlantic Health System|||||f||||||||||||||2018-06-01 03:35:14.630343|2018-06-01 03:35:14.630343
NCT00409032|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2009-10-22|2006-12-07|2006-12-08|Estimate|||||||2009-10-22|2009-10-23|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||A Dose-response Study With Strontium Malonate in Postmenopausal Women|A Dose-response Study With Strontium Malonate in Postmenopausal Women. A 12 Week, Multi National, Double Blind, Randomized, 5 Arms, Parallel Group Placebo Controlled Open Label Active Controlled, Phase II Study With 3 Dose Levels of Strontium Malonate and Protelos Within Post Menopausal Women With a BMDT-score Below -1|Completed||Phase 2|275||Osteologix|||||f||||||||||||||2018-06-01 03:35:14.68808|2018-06-01 03:35:14.68808
NCT00409019|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2015-03-05|2006-12-07|2006-12-08|Estimate|||||||2015-03-05|2015-03-09|Estimate||||March 2015|2015-03-31||||March 2011|Actual|2011-03-31||Interventional|||Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy|A Prospective, Randomized, Trial to Investigate the Effect of Continued Adefovir Versus Combination Regimens of Telbivudine Plus Adefovir, and Telbivudine Plus Tenofovir in Patients With Chronic Hepatitis B and Suboptimal Viral Suppression (PROACTIV Study)|Withdrawn||Phase 4|0|Actual|Novartis||3||Study cancelled: Withdrawn before enrollment of any participants|f||||||||||||||2018-06-01 03:35:14.764554|2018-06-01 03:35:14.764554
NCT00409006|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2010-08-13||2010-08-13|2006-12-06|2006-12-08|Estimate|2010-08-13|2010-09-09|Estimate||||2010-08-13|2010-09-09|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Interventional|||Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers|"A Phase 2 Trial of Pemetrexed and Cisplatin Followed Sequentially by Gefitinib Versus Pemetrexed and Cisplatin in Asian Never Smoker Patients With Advanced Non-Small Cell Lung Cancer"|Completed||Phase 2|70|Actual|Eli Lilly and Company|Median overall survival cannot be estimated due to the high censor rate (25 participants per treatment group were censored). Most participants were still living at the end of the study.|2|||f||||f||||||||||2018-06-01 03:35:14.850282|2018-06-01 03:35:14.850282
NCT00408993|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2009-02-05||2011-07-22|2006-12-06|2006-12-08|Estimate|2009-04-09|2009-06-02|Estimate||||2011-07-22|2011-07-26|Estimate|December 2006||2006-12-31|July 2011|2011-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China|Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China|Completed||Phase 3|215|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:35:15.532842|2018-06-01 03:35:15.532842
NCT00408980|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2006-12-07|2006-12-07|2006-12-08|Estimate|||||||2006-12-07|2006-12-08|Estimate|January 2007||2007-01-31|November 2006|2006-11-30||||||||Interventional|||is Dietary Manipulation of Human Milk Total Fat and Caloric Content Feasible?|is Dietary Manipulation of Human Milk Total Fat and Caloric Content Feasible?|Unknown status|Not yet recruiting|N/A|20||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:35:16.462997|2018-06-01 03:35:16.462997
NCT00408967|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2017-08-15|2006-12-07|2006-12-08|Estimate|||||||2017-08-15|2017-08-18|Actual|December 31, 2006|Actual|2006-12-31|August 2017|2017-08-31|May 31, 2008|Actual|2008-05-31|May 31, 2008|Actual|2008-05-31||Interventional|||Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.|An Open-label Phase II Study of Two Dose Levels of EMD 273066 Administered With Low-dose Cyclophosphamide Following Objective Response to Second-line Chemotherapy in Women With Recurrent Ovarian Carcinoma|Withdrawn||Phase 2|0|Actual|EMD Serono||1||"Th trial got cancelled and no subjects signed informed consent form (ICF); study design not~   appropriate any longer."|||||||||||||||2018-06-01 03:35:16.519744|2018-06-01 03:35:16.519744
NCT00010504|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-05|2001-02-02|2001-02-05|Estimate|||||||2008-03-05|2008-03-07|Estimate|August 2000||2000-08-31|March 2008|2008-03-31|July 2003||2003-07-31|||||Interventional|||Acupuncture in Fibromyalgia|Pilot Study of Acupuncture in Fibromyalgia|Completed||Phase 3|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.587909|2018-06-01 05:37:25.587909
NCT00408954|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06||2009-03-24|2010-11-12|2006-12-07|2006-12-08|Estimate||||2010-11-12|2010-11-23|Estimate|2010-11-12|2010-11-23|Estimate|March 2007||2007-03-31|November 2010|2010-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms|A Multi Center Randomized Cross Over Double Blind Third Party Open Placebo Controlled Pilot Study to Assess the Urodynamic Effects of Modified Release UK-369,003 in Men With Lower Urinary Tract Symptoms.|Completed||Phase 2|27|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:35:16.605483|2018-06-01 03:35:16.605483
NCT00408941|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-07|||2006-12-07|2006-12-07|2006-12-08|Estimate|||||||2006-12-07|2006-12-08|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||EEG and Auditory Evoked Potentials During Local Anesthesia|EEG and Auditory Evoked Potentials During Local Anesthesia|Unknown status|Not yet recruiting|Phase 4|15||Technische Universität München|||||f||||||||||||||2018-06-01 03:35:16.867514|2018-06-01 03:35:16.867514
NCT00408928|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2013-07-18||2016-10-19|2006-12-07|2006-12-08|Estimate|2013-09-27|2013-11-28|Estimate||||2016-10-19|2016-11-29|Estimate|November 2005||2005-11-30|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease|Phase II Trial of VELCADE® (Bortezomib) for Steroid Refractory Acute GVHD|Completed||Phase 2|11|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:35:16.994967|2018-06-01 03:35:16.994967
NCT00408915|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2012-03-06|2006-12-06|2006-12-07|Estimate|||||||2012-03-06|2012-03-07|Estimate|July 2006||2006-07-31|March 2012|2012-03-31||||||||Interventional|||Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion|Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy|Completed||Phase 3|60|Anticipated|Axxonis Pharma AG|||||f||||||||||||||2018-06-01 03:35:17.213242|2018-06-01 03:35:17.213242
NCT00408902|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2015-01-26||2017-10-19|2006-12-06|2006-12-07|Estimate|2015-01-26|2015-02-04|Estimate||||2017-10-19|2017-11-22|Actual|November 2006||2006-11-30|October 2017|2017-10-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer|Phase II Study of MLN518 in Patients With Metastatic Clear Cell Renal Cell Carcinoma|Completed||Phase 2|10|Actual|National Cancer Institute (NCI)|Principal Investigator closed this study due to lack of response and toxicities of drug, therefore overall survival analysis was not done.|1|||f||||||||||||||2018-06-01 03:35:17.281283|2018-06-01 03:35:17.281283
NCT00408889|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2010-04-08|2006-12-06|2006-12-07|Estimate|||||||2010-04-08|2010-04-09|Estimate|December 2006||2006-12-31|December 2008|2008-12-31||||||||Observational|||Prospective Evaluation of Predictors for Organ Failure Following Liver Transplantation|Prospective Evaluation of Predictors for Organ Failure Following Liver Transplantation|Completed|||150|Anticipated|Heidelberg University|||||f||||||||||||||2018-06-01 03:35:17.538982|2018-06-01 03:35:17.538982
NCT00408876|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2008-11-07||2009-11-19|2006-12-06|2006-12-07|Estimate|2009-11-19|2009-12-29|Estimate||||2009-11-19|2009-12-29|Estimate|December 2006||2006-12-31|November 2009|2009-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Duloxetine Versus Placebo in Chronic Low Back Pain|Protocol F1J-MC-HMEO Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain|Completed||Phase 3|404|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 03:35:17.70155|2018-06-01 03:35:17.70155
NCT00408863|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2015-07-13|2006-12-06|2006-12-07|Estimate|||||||2015-07-13|2015-07-14|Estimate|May 2002||2002-05-31|July 2015|2015-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Investigate Safety and Efficacy of Tibolone (Org OD14) in Women With Climacteric Symptoms and a History of Breast Cancer|Completed||Phase 3|3148|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 03:35:24.209012|2018-06-01 03:35:24.209012
NCT00408850|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2013-01-16|2006-12-06|2006-12-07|Estimate|||||||2013-01-16|2013-01-17|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity|Mechanisms of Sympathetic Overactivity in the Metabolic Syndrome: Effects of Reversing Insulin Resistance by Drug Treatment|Unknown status|Recruiting|Phase 3|44|Anticipated|Baker Heart Research Institute||2|||f||||f||||||||||2018-06-01 03:35:24.308329|2018-06-01 03:35:24.308329
NCT00408824|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2007-09-19|2006-12-06|2006-12-07|Estimate|||||||2007-09-19|2007-09-20|Estimate|September 2006||2006-09-30|September 2007|2007-09-30||||||||Observational|||Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)|Assessment of Genetic Risk of Metabolic Syndrome in Company Employee and Making New Health Guidance Program (NGK Study)|Unknown status|Recruiting||4000|Anticipated|Nagoya University|||||f||||||||||||||2018-06-01 03:35:24.421348|2018-06-01 03:35:24.421348
NCT00408798|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2017-03-01|2006-12-06|2006-12-07|Estimate|||||||2017-03-01|2017-03-03|Actual|October 2007||2007-10-31|March 2017|2017-03-31|October 30, 2009|Actual|2009-10-30|October 30, 2009|Actual|2009-10-30||Interventional|||Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin|Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin|Completed||N/A|20|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:35:24.505537|2018-06-01 03:35:24.505537
NCT00408785|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2017-05-30|2006-12-06|2006-12-07|Estimate|||||||2017-05-30|2017-05-31|Actual|November 1, 2006|Actual|2006-11-01|November 2011|2011-11-30|May 9, 2007|Actual|2007-05-09|May 9, 2007|Actual|2007-05-09||Interventional|||A Study Of BOTOX For The Treatment Of Glabellar Lines|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of BOTOX? (Botulinum Toxin Type A) in Subjects With Glabellar Lines|Completed||Phase 3|256||GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:35:24.621043|2018-06-01 03:35:24.621043
NCT00408772|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2017-06-07|2006-12-06|2006-12-07|Estimate|||||||2017-06-07|2017-06-09|Actual|June 2007||2007-06-30|June 2017|2017-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer|Efficacy of Neoadjuvant XELOX/AVASTIN Therapy for Nonresectable Colorectal Liver Metastases With Secondary Hepatic Resection/Radiofrequency|Withdrawn||Phase 2|0|Actual|University of California, Davis||1||Lack of accrual|f||||t||||||||||2018-06-01 03:35:24.771404|2018-06-01 03:35:24.771404
NCT00408759|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2006-12-06|2006-12-06|2006-12-07|Estimate|||||||2006-12-06|2006-12-07|Estimate|November 2006||2006-11-30|December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients|Phase 2 Study of Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients|Unknown status|Recruiting|Phase 2|10||Bnai Zion Medical Center|||||f||||||||||||||2018-06-01 03:35:24.926224|2018-06-01 03:35:24.926224
NCT00408746|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2009-03-23|2006-12-06|2006-12-07|Estimate|||||||2009-03-23|2009-03-24|Estimate|January 2003||2003-01-31|February 2007|2007-02-28|August 2013|Anticipated|2013-08-31|January 2012|Anticipated|2012-01-31||Observational|||Orofacial Development of Preterm and Low Birthweight Infants Versus Term Infants|Prospective (Multicentre) Epidemiologic Longitudinal Study of Orofacial Development of Preterm and Low Birthweight Infants Compared to Term Infants in Consideration of Perinatal, Biometrical, Nutritional, Functional and Parental Parameters|Unknown status|Recruiting||80|Anticipated|University Hospital Muenster|||||f||||f||||||||||2018-06-01 03:35:25.037945|2018-06-01 03:35:25.037945
NCT00408733|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2008-01-24|2006-12-06|2006-12-07|Estimate|||||||2008-01-24|2008-01-25|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||Evaluating a Low-Literacy Discharge Medication Education Tool|Evaluating a Low-Literacy Discharge Medication Education Tool|Completed||N/A|287|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 03:35:25.166714|2018-06-01 03:35:25.166714
NCT00408720|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2006-12-06|2006-12-06|2006-12-07|Estimate|||||||2006-12-06|2006-12-07|Estimate|October 2006||2006-10-31|December 2006|2006-12-31|December 2006||2006-12-31|||||Observational|||Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies|Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies|Completed|||25||The New York Eye & Ear Infirmary|||||f||||||||||||||2018-06-01 03:35:25.388493|2018-06-01 03:35:25.388493
NCT00408707|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2008-02-28|2006-12-06|2006-12-07|Estimate|||||||2008-02-28|2008-02-29|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|||||Interventional|||Local Infiltration Analgesia With Ropivacaine Versus Placebo in Bilateral Knee Arthroplasty|Local Infiltration Analgesia With Ropivacaine Versus Placebo in Bilateral Knee Arthroplasty: a Placebo Controlled, Randomized, Double-Blinded Study.|Completed||Phase 4|16|Anticipated|Hvidovre University Hospital|||||f||||||||||||||2018-06-01 03:35:25.464705|2018-06-01 03:35:25.464705
NCT00408694|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2013-03-01||2018-01-04|2006-12-06|2006-12-07|Estimate|2013-03-01|2013-04-18|Estimate||||2018-01-04|2018-01-30|Actual|December 13, 2006|Actual|2006-12-13|January 2018|2018-01-31|December 15, 2011|Actual|2011-12-15|December 15, 2011|Actual|2011-12-15||Interventional|||Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer|A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer|Completed||Phase 2|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:35:25.640846|2018-06-01 03:35:25.640846
NCT00408681|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2016-11-23||2017-01-24|2006-12-06|2006-12-07|Estimate|2016-11-23|2017-01-20|Estimate||||2017-01-24|2017-03-07|Actual|June 2006||2006-06-30|January 2017|2017-01-31|May 1, 2015|Actual|2015-05-01|November 2010|Actual|2010-11-30||Interventional|GVHD||Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant|A Pilot Study to Evaluate the Potential Efficacy of Lithium Carbonate for Stimulation of Intestinal Recovery In Patients With Acute Graft-versus-host Disease (GVHD)|Completed||N/A|20|Actual|Fred Hutchinson Cancer Research Center|This trial was not controlled in any scientifically valid sense of the term. Clinical management included many changes of treatment other than the use of the study product. The trial had no validated external benchmark for comparisons.|1|||f||||f||||||||||2018-06-01 03:35:26.596738|2018-06-01 03:35:26.596738
NCT00408668|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2006-12-05|2006-12-05|2006-12-07|Estimate|||||||2006-12-05|2006-12-07|Estimate|August 2005||2005-08-31|October 2006|2006-10-31|February 2006||2006-02-28|||||Interventional|||Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen|Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Virosomal Vaccine PEV3A and FP9-MVA ME-TRAP. A Phase I / IIa Controlled Challenge Trial|Completed||Phase 1/Phase 2|30||University of Oxford|||||f||||||||||||||2018-06-01 03:35:27.378781|2018-06-01 03:35:27.378781
NCT00408655|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2014-06-18|2006-12-06|2006-12-07|Estimate|||||||2014-06-18|2014-06-19|Estimate|February 2007||2007-02-28|June 2014|2014-06-30||||January 2012|Actual|2012-01-31||Interventional|||Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors|Phase I Study of CCI-779 (NSC 683864) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumours|Completed||Phase 1|38|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:35:27.463254|2018-06-01 03:35:27.463254
NCT00408642|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2016-01-29|2006-12-06|2006-12-07|Estimate|||||||2016-01-29|2016-02-01|Estimate|August 2007||2007-08-31|January 2016|2016-01-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|eASP||An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)|An Enhanced Adherence Support Programme for HAART|Completed||Phase 3|297|Actual|Centre for the AIDS Programme of Research in South Africa||2|||f||||f||||||||||2018-06-01 03:35:27.559832|2018-06-01 03:35:27.559832
NCT00408629|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|2011-03-03||2011-04-28|2006-12-05|2006-12-07|Estimate|2011-03-03|2011-03-31|Estimate||||2011-04-28|2011-05-03|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 3|518|Actual|Abbott||2|||f||||t||||||||||2018-06-01 03:35:27.919333|2018-06-01 03:35:27.919333
NCT00408616|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2009-03-06|2006-12-06|2006-12-07|Estimate|||||||2009-03-06|2009-03-09|Estimate|November 2006||2006-11-30|March 2009|2009-03-31|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety of Grazax in Children|A Phase III Trial Investigating the Efficacy and Safety of Grazax in Children Aged 5-16 Years With Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma|Completed||Phase 3|253|Actual|ALK-Abelló A/S||2|||f||||t||||||||||2018-06-01 03:35:29.358008|2018-06-01 03:35:29.358008
NCT00408603|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|2017-04-07||2017-06-28|2006-12-05|2006-12-07|Estimate|2017-05-25|2017-06-28|Actual||||2017-06-28|2017-07-27|Actual|December 20, 2006|Actual|2006-12-20|June 2017|2017-06-30|June 9, 2010|Actual|2010-06-09|June 9, 2010|Actual|2010-06-09||Interventional||Safety population|Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer|A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer|Completed||Phase 2|183|Actual|Sunesis Pharmaceuticals|No statistical testings were performed to compare any of the treatment groups. No p-values or odds ratios were reported.|1|||f||||t|t|f||||||Yes|De-identified data of individual participants experiencing Serious Adverse Events, post trial completion|2018-06-01 03:35:29.54182|2018-06-01 03:35:29.54182
NCT00407901|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2008-01-16|2006-12-01|2006-12-05|Estimate|||||||2008-01-16|2008-01-18|Estimate|April 2006||2006-04-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Functional Assessment Questionnaire for the Visually Challenged|Functional Assessment Questionnaire for the Visually Challenged: Proposed Model to Quantitatively Measure the Functional Level of Individuals Who Are Legally Blind|Completed|||31|Actual|George Washington University|||1||f||||f||||||||||2018-06-01 03:35:42.284109|2018-06-01 03:35:42.284109
NCT00408590|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2016-05-04||2018-02-05|2006-12-06|2006-12-07|Estimate|2017-08-11|2017-10-02|Actual||||2018-02-05|2018-03-07|Actual|April 19, 2004|Actual|2004-04-19|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2012|Actual|2012-08-31||Interventional|||Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer|Active, not recruiting||Phase 1|37|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:35:31.123978|2018-06-01 03:35:31.123978
NCT00408577|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2006-12-11|2006-12-06|2006-12-07|Estimate|||||||2006-12-11|2006-12-12|Estimate|November 2004||2004-11-30|December 2006|2006-12-31|November 2006||2006-11-30|||||Interventional|||Prevention of Cardiac and Vascular Events in Patients With NGT/IGT.|Prevention of Cardiovascular Relapses by L-Arginine Oral Administration in Patients With CAD and IGT and/or Insulin Resistance.|Completed||Phase 3|150||IRCCS San Raffaele|||||f||||||||||||||2018-06-01 03:35:31.833463|2018-06-01 03:35:31.833463
NCT00408564|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2018-04-06|2006-12-06|2006-12-07|Estimate|||||||2018-04-06|2018-04-10|Actual|January 2006||2006-01-31|April 2018|2018-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Phase II Study of Neoadjuvant Gemcitabine/Oxaliplatin and Cetuximab Followed by Surgery or Concurrent External Beam Radiation With Capecitabine for Patients With Locally Advanced Unresectable Nonmetastatic Pancreatic Cancer|Completed||Phase 2|39|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 03:35:31.972347|2018-06-01 03:35:31.972347
NCT00408551|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2013-12-18|2006-12-06|2006-12-07|Estimate|||||||2013-12-18|2013-12-19|Estimate|November 2005||2005-11-30|June 2009|2009-06-30||||June 2009|Anticipated|2009-06-30||Interventional|||Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver|A Phase II Multi-Institutional Efficacy and Safety Study of Chemotherapy With Selective Internal Radiation Treatment Using Y-90 Microspheres (CHEMO-SIRT) in Patients With Colorectal Cancer Liver Metastasis|Unknown status|Recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 03:35:32.106981|2018-06-01 03:35:32.106981
NCT00408538|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2009-05-01|2006-12-06|2006-12-07|Estimate|||||||2009-05-01|2009-05-04|Estimate|December 2006||2006-12-31|May 2009|2009-05-31|April 2008|Actual|2008-04-30|||||Interventional|||Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally|A Phase 1 Randomized, Blinded, Placebo-Controlled Safety and Acceptability Study of the UC-781 Vaginal Microbicide Gel Formulation Applied Rectally in HIV-1 Seronegative Adults|Completed||Phase 1|36|Anticipated|University of California, Los Angeles|||||f||||||||||||||2018-06-01 03:35:32.252782|2018-06-01 03:35:32.252782
NCT00408525|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2018-02-01|2006-12-06|2006-12-07|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2006||2006-12-31|February 2018|2018-02-28|August 24, 2012|Actual|2012-08-24|August 24, 2012|Actual|2012-08-24||Interventional|||Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease|Efficacy of Donepezil in Normalizing Brain Activation Patterns in People Genetically at Risk for Alzheimer's Disease|Completed||Phase 1|41|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-06-01 03:35:32.35156|2018-06-01 03:35:32.35156
NCT00408512|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2011-06-24|2006-12-06|2006-12-07|Estimate|||||||2011-06-24|2011-06-27|Estimate|December 2006||2006-12-31|November 2009|2009-11-30|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|stayondiur||Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study|Increasing Stay-on-therapy in Hypertensive Patients Treated With First-line Diuretics: An Active Pharmacosurveillance and Pharmacogenetic Study.|Completed||Phase 4|2500|Anticipated|Federico II University||2|||f||||||||||||||2018-06-01 03:35:32.465383|2018-06-01 03:35:32.465383
NCT00408499|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2017-01-19||2017-03-27|2006-12-06|2006-12-07|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|August 2006||2006-08-31|January 2017|2017-01-31|January 2013|Actual|2013-01-31|April 2009|Actual|2009-04-30||Interventional|||Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer|Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|64|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 03:35:32.606596|2018-06-01 03:35:32.606596
NCT00408473|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2007-02-21|2006-12-06|2006-12-07|Estimate|||||||2007-02-21|2007-02-22|Estimate||||February 2007|2007-02-28||||||||Interventional|||Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.|A Randomised Double-Blind Pilot Study Comparing Flecainide CR and Placebo in the Early Treatment of Patients With a Documented First Episode of Atrial Fibrillation.|Terminated||Phase 4|256||MEDA Pharma GmbH & Co. KG|||||f||||||||||||||2018-06-01 03:35:32.997046|2018-06-01 03:35:32.997046
NCT00408460|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2017-01-17||2017-03-13|2006-12-06|2006-12-07|Estimate|2017-03-13|2017-04-25|Actual||||2017-03-13|2017-04-25|Actual|February 2006||2006-02-28|January 2017|2017-01-31|October 2012|Actual|2012-10-31|August 2010|Actual|2010-08-31||Interventional|||Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Intermittent Gleevec® (Imatinib Mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|34|Actual|University of Washington||1|||f||||f||||||||No||2018-06-01 03:35:33.121043|2018-06-01 03:35:33.121043
NCT00408447|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2018-01-23|2006-12-06|2006-12-07|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2004||2004-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stem Cell Transplant in Sickle Cell Disease and Thalassemia|Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia|Recruiting||Phase 2|60|Anticipated|Columbia University||2|||f||||t|t|f||||||||2018-06-01 03:35:33.371808|2018-06-01 03:35:33.371808
NCT00408434|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|||2010-02-12|2006-12-06|2006-12-07|Estimate|||||||2010-02-12|2010-02-15|Estimate|November 2006||2006-11-30|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study of an Experimental New Drug, PPAR Agonist Taken by Mouth by Patients With Advanced or Metastatic Cancer|A Phase I Dose Finding Study of an Experimental New Drug, PPAR Agonist Taken by Mouth by Patients With Advanced or Metastatic Cancer|Completed||Phase 1|32|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 03:35:33.477466|2018-06-01 03:35:33.477466
NCT00408421|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2008-10-02||2009-07-07|2006-12-06|2006-12-07|Estimate|2009-07-07|2009-08-19|Estimate||||2009-07-07|2009-08-19|Estimate|November 2006||2006-11-30|July 2009|2009-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Duloxetine Versus Placebo for Osteoarthritis Knee Pain|Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain|Completed||Phase 3|231|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:35:33.639513|2018-06-01 03:35:33.639513
NCT00408408|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-06|2017-03-23||2017-09-12|2006-12-06|2006-12-07|Estimate|2017-09-12|2017-09-18|Actual||||2017-09-12|2017-09-18|Actual|November 2006||2006-11-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2011|Actual|2011-03-31||Interventional|||Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery|A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens|Active, not recruiting||Phase 3|1206|Actual|NSABP Foundation Inc||6|||f||||t||||||||||2018-06-01 03:35:35.412291|2018-06-01 03:35:35.412291
NCT00408395|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2016-11-30|2006-12-05|2006-12-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2006||2006-11-30|December 2011|2011-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children|A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children|Completed||Phase 2|281|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:35:37.254686|2018-06-01 03:35:37.254686
NCT00408382|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2011-11-15|2006-12-05|2006-12-06|Estimate|||||||2011-11-15|2011-11-17|Estimate||||December 2006|2006-12-31||||||||Interventional|||Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque||Completed||Phase 4|50||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 03:35:37.333763|2018-06-01 03:35:37.333763
NCT00408369|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2008-01-25|2006-12-04|2006-12-06|Estimate|||||||2008-01-25|2008-01-29|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Prophylactic Antimalarial Activity of DB289 in Volunteers|Prophylactic Antimalarial Activity of DB289 in Volunteers Challenged With Plasmodium Falciparum|Completed||Phase 1/Phase 2|19|Anticipated|Immtech Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 03:35:37.408748|2018-06-01 03:35:37.408748
NCT00408356|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2009-02-19|2006-12-05|2006-12-06|Estimate|||||||2009-02-19|2009-02-20|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|November 2006|Actual|2006-11-30|August 2006|Actual|2006-08-31||Interventional|||Immunological and Clinical Responses to Zinc in Children With Diarrhoea|Immunological and Clinical Responses to Zinc: A Randomized, Double-Blind Trial of Zinc Treatment vs. Zinc Treatment Plus Daily Supplementation for 3 Months Among Children Under 2 Years of Age With an Acute Diarrheal Illness.|Completed||Phase 3|338|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||t||||||||||2018-06-01 03:35:37.489467|2018-06-01 03:35:37.489467
NCT00408330|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2015-03-18|2006-12-05|2006-12-06|Estimate|||||||2015-03-18|2015-03-19|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face|A Double-Blind, Randomized, Vehicle-Controlled, Six-Week Exploratory Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Seborrheic Dermatitis of the Face|Completed||Phase 2|48|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:35:37.633429|2018-06-01 03:35:37.633429
NCT00408317|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2014-01-27||2017-02-07|2006-12-04|2006-12-06|Estimate|2014-01-27|2014-03-12|Estimate||||2017-02-07|2017-03-16|Actual|November 2006||2006-11-30|February 2017|2017-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional||Intent-to-treat (ITT) population included all randomized participants.|Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)|A Multicenter, Randomized, Double-Blind, Crossover Study to Compare the Safety and Efficacy of Ultrase® MT20 to Placebo for the Correction of Steatorrhea in Patients With Cystic Fibrosis (CF)|Completed||Phase 3|36|Actual|Forest Laboratories||2|||f||||t||||||||||2018-06-01 03:35:37.745361|2018-06-01 03:35:37.745361
NCT00408304|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2006-12-05|2006-12-05|2006-12-06|Estimate|||||||2006-12-05|2006-12-06|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|December 2007||2007-12-31|||||Interventional|||Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.|Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.|Unknown status|Recruiting|Phase 2|60||Bnai Zion Medical Center|||||f||||||||||||||2018-06-01 03:35:38.008568|2018-06-01 03:35:38.008568
NCT00408291|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2015-05-19|2006-12-05|2006-12-06|Estimate|||||||2015-05-19|2015-05-20|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Evaluation of Treatment of Fractures of the Humerus With a Plate.|Evaluation of the Winsta PH Osteosynthesis Device in the Treatment of Three- and Four-Part Fractures of the Proximal Humerus A Prospective Migration and Bone Density Study|Unknown status|Recruiting||30|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-06-01 03:35:38.08666|2018-06-01 03:35:38.08666
NCT00408278|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2014-10-27|2006-12-05|2006-12-06|Estimate|||||||2014-10-27|2014-10-28|Estimate|July 2005||2005-07-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|April 2012|Actual|2012-04-30||Interventional|||Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)|Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients. Maintenance Therapy With ATRA + Low Dose Chemotherapy (Methotrexate + Mercaptopurine).|Completed||Phase 4|300|Anticipated|PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:35:38.159735|2018-06-01 03:35:38.159735
NCT00408265|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2011-11-17|2006-12-04|2006-12-06|Estimate|||||||2011-11-17|2011-11-21|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study|Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study|Completed||Phase 3|80|Actual|UConn Health|||||f||||t||||||||||2018-06-01 03:35:38.267526|2018-06-01 03:35:38.267526
NCT00408252|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2018-04-19|2006-12-05|2006-12-06|Estimate|||||||2018-04-19|2018-04-20|Actual|February 2007||2007-02-28|April 2018|2018-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy of SU 011248 in Head And Neck Carcinoma|A Phase II Study Of Su011248 In Patients With Recurrent And/Or Metastatic Squamous Head And Neck Carcinoma.|Terminated||Phase 2|54|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1||Too frequent grade 3-4 toxicities|f||||f||||||||||2018-06-01 03:35:38.446188|2018-06-01 03:35:38.446188
NCT00407706|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|December 2010||2010-12-31|||||Observational|||Using Test of SCM for Detection Breast Cancer|Breast Cancer- Early Detection of Cancer Disease and Pre-Cancer Disease, and in Women That Are at High Risk for Developing Breast Cancer by Identifying Lymphocytes Previously Exposed to Specific Cancer Antigen.|Unknown status|Recruiting||180||Ziv Hospital|||||f||||||||||||||2018-06-01 03:35:47.824822|2018-06-01 03:35:47.824822
NCT00408239|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2011-12-15|2006-12-04|2006-12-06|Estimate|||||||2011-12-15|2011-12-19|Estimate|December 2006||2006-12-31|December 2011|2011-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|PEARL-1||Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement|Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement: A Randomized, Enoxaparin-controlled, Open Label, Dose-escalation Study|Completed||Phase 2|367|Actual|Astellas Pharma Inc||3|||f||||||||||||||2018-06-01 03:35:38.529773|2018-06-01 03:35:38.529773
NCT00408226|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2012-01-19|2006-12-05|2006-12-06|Estimate|||||||2012-01-19|2012-01-20|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|June 2009|Actual|2009-06-30||Interventional|||Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer|Phase 1/2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 3 Weeks in Combination With Pemetrexed|Completed||Phase 1/Phase 2|27|Actual|CASI Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 03:35:38.62078|2018-06-01 03:35:38.62078
NCT00408213|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2008-05-22|2006-12-05|2006-12-06|Estimate|||||||2008-05-22|2008-05-23|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|September 2007|Actual|2007-09-30|||||Interventional|||A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.|A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone|Completed||Phase 3|136|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:35:38.702252|2018-06-01 03:35:38.702252
NCT00408200|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2012-09-12||2013-01-31|2006-12-05|2006-12-06|Estimate|2013-01-31|2013-03-07|Estimate||||2013-01-31|2013-03-07|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation|A Randomized Trial to Assess the Utility of Empirical Anti-Arrhythmic Drug Therapy to Prevent Atrial Arrhythmia During the 6 Weeks Following Pulmonary Vein Isolation to Treat Paroxysmal Atrial Fibrillation|Completed||N/A|110|Actual|University of Pennsylvania||2|||f||||||||||||||2018-06-01 03:35:38.784569|2018-06-01 03:35:38.784569
NCT00408187|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2009-07-29|2006-12-04|2006-12-06|Estimate|||||||2009-07-29|2009-07-30|Estimate|December 2006||2006-12-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ESSENCE||Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients|A Phase III, Randomized, Multicentre, Double-Blind, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients|Completed||Phase 3|642|Actual|Aurinia Pharmaceuticals Inc.||3|||f||||t||||||||||2018-06-01 03:35:39.049632|2018-06-01 03:35:39.049632
NCT00408174|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2009-12-21|2006-12-04|2006-12-06|Estimate|||||||2009-12-21|2009-12-23|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Actively-Controlled Trial to Evaluate the Safety and Efficacy of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium 3.3 g Bid Versus Mesalamine (5-ASA) as Asacol® 0.8 g Tid in Mildly to Moderately Active Ulcerative Colitis|Completed||Phase 3|400|Anticipated|Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:35:39.191543|2018-06-01 03:35:39.191543
NCT00408161|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2012-03-26|2006-12-04|2006-12-06|Estimate|||||||2012-03-26|2012-03-27|Estimate|August 2003||2003-08-31|March 2012|2012-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Contingency Management for Chronic Recidivist Alcohol-Dependent Patients|Contingency Management for Chronic Recidivist Alcohol-Dependent Patients|Completed||Phase 1/Phase 2|104|Actual|UConn Health||2|||f||||t||||||||||2018-06-01 03:35:39.369164|2018-06-01 03:35:39.369164
NCT00408148|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2010-12-09|2006-12-05|2006-12-06|Estimate|||||||2010-12-09|2010-12-10|Estimate|October 2006||2006-10-31|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||High Density Lipoprotein Turnover|A Randomized, Double-blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in Patients With Abdominal Obesity and Additional Cardiometabolic Risk Factors|Terminated||Phase 3|64|Actual|Sanofi||2||"Company decision has been taken in light of recent demands by certain national health~   authorities"|f||||||||||||||2018-06-01 03:35:39.713115|2018-06-01 03:35:39.713115
NCT00408135|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2009-04-02|2006-12-05|2006-12-06|Estimate|||||||2009-04-02|2009-04-03|Estimate|August 2004||2004-08-31|April 2009|2009-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Japanese Study Evaluating Safety, Efficacy and Acceptability of Telithromycin in Children With Infections|Evaluation of the Safety, Efficacy and Acceptability of HMR 3647 (20％ Fine Granules 1 g Sachet) in Children With Infections|Completed||Phase 3|111|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:35:39.824972|2018-06-01 03:35:39.824972
NCT00408122|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2014-10-15|2006-12-05|2006-12-06|Estimate|||||||2014-10-15|2014-10-16|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Evaluation of Preoperative Investigations in Patients With Liver Cancer|Evaluation of Positron Emission Tomography/ CT Scan, Endoscopic Ultrasono¬Graphy, and Laparoscopic Ultrasonography in the Preoperative Assess¬Ment of Resectability in Patients With Primary and Secondary Liver Cancer|Completed|||77|Actual|Odense University Hospital|||||f||||||||||||||2018-06-01 03:35:39.896153|2018-06-01 03:35:39.896153
NCT00408109|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2017-06-30|2006-12-05|2006-12-06|Estimate|||||||2017-06-30|2017-07-02|Actual|December 4, 2006||2006-12-04|August 28, 2008|2008-08-28|August 28, 2008||2008-08-28|||||Interventional|||Safety Study of Avian Flu Vaccine|VRC 304: A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP), Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults|Completed||Phase 1|45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:35:39.952999|2018-06-01 03:35:39.952999
NCT00408096|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|||2014-10-21|2006-12-05|2006-12-06|Estimate|||||||2014-10-21|2014-10-22|Estimate|December 2006||2006-12-31|October 2014|2014-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Comparison of Two Resurfacing Prostheses in the Treatment of Osteoarthritis of the Shoulder|Comparison of Two Resurfacing Prostheses in the Treatment of Osteoarthritis of the Shoulder A Prospective, Randomized Migration and Bone Density Study|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 03:35:40.016793|2018-06-01 03:35:40.016793
NCT00408083|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2009-03-25|2006-12-04|2006-12-06|Estimate|||||||2009-03-25|2009-03-27|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Crossover Study With MultiHance vs a Comparator for Peripheral MRA|A Phase IIIB, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.1 Mmol/kg of Multihance With 0.1 Mmol/kg of Magnevist for Contrast-Enhanced Magnetic Resonance Angiography(CE-MRA) of Peripheral Arteries|Completed||Phase 3|100|Anticipated|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-06-01 03:35:40.096596|2018-06-01 03:35:40.096596
NCT00408070|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-05|2010-10-14||2018-02-06|2006-12-05|2006-12-06|Estimate|2010-10-14|2010-11-16|Estimate||||2018-02-06|2018-03-08|Actual|October 2006||2006-10-31|February 2018|2018-02-28|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Phase 2 Study of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Terminated||Phase 2|5|Actual|UConn Health|This trial ended early after enrolling only 5 of 100 patients. Due to the small enrollment number and incomplete data set, no data analyses were performed.|1||Did not meet accrual goals.|f||||t||||||||||2018-06-01 03:35:40.18107|2018-06-01 03:35:40.18107
NCT00408057|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2008-05-12|2006-12-05|2006-12-06|Estimate|||||||2008-05-12|2008-05-14|Estimate|December 2005||2005-12-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|GUIDE||Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE )|Quality Enhancement Research Initiative (QERI) in the Dyslipidemia Management Strategy Involving Ezetimibe With Statin in High Risk Patients Who Have Not Achieved Recommended LDL Targets|Completed|||2500|Actual|Canadian Heart Research Centre|||||f||||f||||||||||2018-06-01 03:35:40.520336|2018-06-01 03:35:40.520336
NCT00408044|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2008-05-19|2006-12-04|2006-12-05|Estimate|||||||2008-05-19|2008-05-20|Estimate|December 2006||2006-12-31|May 2008|2008-05-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Observational|||Dysesthesia Study After Sternotomy|Pain After Sternotomy|Completed|||100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||||||||||||2018-06-01 03:35:40.584486|2018-06-01 03:35:40.584486
NCT00408031|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-03|||2012-08-02|2006-12-03|2006-12-05|Estimate|||||||2012-08-02|2012-08-03|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||D-cycloserine for Major Depressive Disorder|N-methyl-D-aspartate Receptor (NMDAR)-Based Pharmacotherapy With D-cycloserine for Treatment-resistant Major Depressive Disorder|Completed||Phase 2|26|Actual|Herzog Hospital||1|||f||||||||||||||2018-06-01 03:35:40.646437|2018-06-01 03:35:40.646437
NCT00408018|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2008-12-31|2006-12-04|2006-12-05|Estimate|||||||2008-12-31|2009-01-01|Estimate|March 2006||2006-03-31|December 2008|2008-12-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms|An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms|Terminated||Phase 1|28|Actual|Piramal Enterprises Limited||||"The decision to terminate this study after 202 mg/m2 cohort was taken as MTD achieved in other~   study at 185 mg/m2"|f||||f||||||||||2018-06-01 03:35:40.726186|2018-06-01 03:35:40.726186
NCT00408005|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2018-01-24|2006-12-04|2006-12-05|Estimate|||||||2018-01-24|2018-01-25|Actual|January 22, 2007|Actual|2007-01-22|December 2017|2017-12-31||||September 30, 2017|Actual|2017-09-30||Interventional|||Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma|Active, not recruiting||Phase 3|1895|Actual|National Cancer Institute (NCI)||16|||f||||||||||||||2018-06-01 03:35:40.876848|2018-06-01 03:35:40.876848
NCT00407992|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2011-08-29|2006-12-04|2006-12-05|Estimate|||||||2011-08-29|2011-08-30|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|Migraine||An Italian Randomized Open-label Study of Occipital Nerve Stimulation in the Treatment of Chronic Migraine Headache|An Italian, Randomized, Single-centre, Open-label Study of Occipital Nerve Stimulation in the Treatment of Chronic Migraine Headache|Completed||Phase 3|34|Anticipated|Ospedale Sacro Cuore - Don Calabria||2|||f||||||||||||||2018-06-01 03:35:41.586329|2018-06-01 03:35:41.586329
NCT00407979|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2017-01-10|2006-12-04|2006-12-05|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2005||2005-07-31|January 2017|2017-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis|Analysis and Correlation of Cathelicidin Expression in Skin and Saliva of Subjects With Atopic Dermatitis and Psoriasis|Completed|||80|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||||||||Samples With DNA|"~     Blood, skin, and saliva samples will be retained~   "|Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 03:35:41.671473|2018-06-01 03:35:41.671473
NCT00407966|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2012-05-01||2015-07-14|2006-12-04|2006-12-05|Estimate|2013-01-08|2013-02-11|Estimate||||2015-07-14|2015-08-04|Estimate|October 2006||2006-10-31|December 2012|2012-12-31|November 2009|Actual|2009-11-30|July 2008|Actual|2008-07-31||Interventional|||Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:35:41.77557|2018-06-01 03:35:41.77557
NCT00407940|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|December 2006||2006-12-31|December 2006|2006-12-31|December 2008||2008-12-31|||||Interventional|||ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion|ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion. A Prospective Randomized Trial Comparing Silverhawk™ Atherectomy to CryoPlasty® Therapy for Lower Extremity Claudication|Unknown status|Recruiting|Phase 4|100||University of California, San Diego|||||f||||||||||||||2018-06-01 03:35:42.050043|2018-06-01 03:35:42.050043
NCT00407927|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2015-10-09|2006-12-04|2006-12-05|Estimate|||||||2015-10-09|2015-10-12|Estimate|December 2006||2006-12-31|October 2015|2015-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Safety, Efficacy, and Tolerability Study of Two Doses of Epinastine Nasal Spray (0.05% and 0.1%) vs. Placebo in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 2|571|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:35:42.135524|2018-06-01 03:35:42.135524
NCT00407914|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04||2009-07-01|2009-10-06|2006-12-04|2006-12-05|Estimate||||2009-10-06|2009-10-08|Estimate|2009-10-06|2009-10-08|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Effectiveness of Aquamid as Compared to Restylane for the Aesthetic Treatment of Nasolabial Folds|A Double-Masked, Randomized, Multi-Center, 2-Arm Parallel Study Comparing the Safety and Effectiveness of Aquamid and Restylane for the Aesthetic Treatment of Nasolabial Folds|Completed||N/A|315|Actual|Contura||2|||f||||||||||||||2018-06-01 03:35:42.208432|2018-06-01 03:35:42.208432
NCT00407888|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2017-04-17||2017-08-30|2006-12-04|2006-12-05|Estimate|2017-08-30|2017-08-31|Actual||||2017-08-30|2017-08-31|Actual|May 2006||2006-05-31|August 2017|2017-08-31|July 2012|Actual|2012-07-31|May 2009|Actual|2009-05-31||Interventional|||Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery|Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II|Completed||Phase 2|60|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:35:42.360806|2018-06-01 03:35:42.360806
NCT00407875|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2009-10-14|2006-12-01|2006-12-05|Estimate|||||||2009-10-14|2009-10-15|Estimate|March 2007||2007-03-31|October 2009|2009-10-31|November 2016||2016-11-30|||||Interventional|||Intensity Modulated Versus Interstitial - Radiation Therapy|A Randomized Phase II Study Comparing Intensity Modulated External Beam Radiation Therapy (IMRT) Versus Permanent Interstitial Prostate Brachytherapy (PIPB) for Low Risk and Low-tier Intermediate Risk Prostate Cancer|Suspended||Phase 2|50|Anticipated|British Columbia Cancer Agency||||"Accrual has been very slow. We are currently determining whether or not to keep the trial going~   as is or to close the trial and write a new protocol."|f||||||||||||||2018-06-01 03:35:42.681019|2018-06-01 03:35:42.681019
NCT00407862|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|January 2005||2005-01-31|December 2006|2006-12-31|June 2006||2006-06-30|||||Interventional|||Telmisartan and Losartan in Hypertensive IGT|Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects|Completed||Phase 4|24||Medical University of Graz|||||f||||||||||||||2018-06-01 03:35:42.754974|2018-06-01 03:35:42.754974
NCT00407849|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2008-05-06|2006-12-04|2006-12-05|Estimate|||||||2008-05-06|2008-05-07|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|August 2008|Anticipated|2008-08-31|December 2007|Actual|2007-12-31||Interventional|||Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema|Phase I/II Study of Intravitreal Triamcinolone Acetonide Microspheres for Treatment of Diffuse Diabetic Macular Edema Unresponsive to Conventional Laser Photocoagulation Treatment.|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|Federal University of São Paulo|||||f||||||||||||||2018-06-01 03:35:42.821433|2018-06-01 03:35:42.821433
NCT00407836|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-03|||2009-12-01|2006-12-03|2006-12-05|Estimate|||||||2009-12-01|2009-12-02|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy Study of T Cell Vaccination in HIV Infection|Phase II Study of Efficacy, Tolerability and Safety of CD4-Specific T-cell Vaccine in HIV Infection|Completed||Phase 2|40|Anticipated|Soroka University Medical Center||1|||f||||f||||||||||2018-06-01 03:35:42.884641|2018-06-01 03:35:42.884641
NCT00407823|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|January 2004||2004-01-31|December 2006|2006-12-31|August 2005||2005-08-31|||||Interventional|||Comparison of Pediatric Septic Shock Treatment With and Without Central Venous Oxygen Saturation Monitoring|An Outcomes Comparison of ACCM/PALS Guidelines For Pediatric Septic Shock With and Without Central Venous Oxygen Saturation Monitoring|Completed||N/A|268||University of Sao Paulo|||||f||||||||||||||2018-06-01 03:35:42.959684|2018-06-01 03:35:42.959684
NCT00407797|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2010-08-12||2011-02-04|2006-12-01|2006-12-05|Estimate|2010-08-12|2010-09-09|Estimate||||2011-02-04|2011-02-08|Estimate|March 2007||2007-03-31|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PREPS MEXICO||Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial|Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin|Terminated||Phase 4|136|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:35:43.074429|2018-06-01 03:35:43.074429
NCT00407784|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2007-03-06|2006-12-04|2006-12-05|Estimate|||||||2007-03-06|2007-03-07|Estimate|January 2007||2007-01-31|March 2007|2007-03-31|November 2009||2009-11-30|||||Observational|||Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.|Aldosterone-Renin Ratio to Diagnose Primary Aldosteronism in a Population of Patients With Therapy-Resistant Hypertension: Test Characteristics, Diagnostic Value and Predictive Value for Antihypertensive Treatment. The Dutch ARRAT Study.|Unknown status|Recruiting||500||Erasmus Medical Center|||||f||||||||||||||2018-06-01 03:35:44.152661|2018-06-01 03:35:44.152661
NCT00407771|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2007-10-30|2006-12-04|2006-12-05|Estimate|||||||2007-10-30|2007-10-31|Estimate|November 2007||2007-11-30|October 2007|2007-10-31|December 2008|Anticipated|2008-12-31|||||Interventional|||The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention|A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention|Unknown status|Not yet recruiting|Phase 4|44|Anticipated|Jordan Hospital|||||f||||||||||||||2018-06-01 03:35:44.791076|2018-06-01 03:35:44.791076
NCT00407758|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2017-08-01||2017-11-20|2006-12-04|2006-12-05|Estimate|2017-11-20|2017-11-21|Actual||||2017-11-20|2017-11-21|Actual|November 2006||2006-11-30|August 2017|2017-08-31||||August 1, 2016|Actual|2016-08-01||Interventional||Eligible and treated patients|Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Enzastaurin (Lilly IND # 60, 933) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|28|Actual|Gynecologic Oncology Group|||||||||||||||||||2018-06-01 03:35:45.167682|2018-06-01 03:35:45.167682
NCT00407745|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2011-11-03||2012-02-23|2006-12-04|2006-12-05|Estimate|2011-11-03|2011-12-08|Estimate||||2012-02-23|2012-02-27|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury|A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury|Completed||Phase 3|220|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:35:46.327738|2018-06-01 03:35:46.327738
NCT00407732|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2012-01-24|2006-12-04|2006-12-05|Estimate|||||||2012-01-24|2012-01-25|Estimate|January 2007||2007-01-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|February 2010|Actual|2010-02-28||Interventional|||Overcoming Psychiatric Barriers to the Treatment of Hepatitis C|Overcoming Neuropsychiatric Barriers to the Treatment of Hepatitis C|Completed||N/A|101|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 03:35:47.687075|2018-06-01 03:35:47.687075
NCT00407719|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2009-02-02|2006-12-01|2006-12-05|Estimate|||||||2009-02-02|2009-02-03|Estimate|June 2005||2005-06-30|January 2009|2009-01-31|May 2008|Actual|2008-05-31|April 2007|Actual|2007-04-30||Interventional|||Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD)|An Open-Label, Pilot Study of Bevacizumab in Subjects With Choroidal Neovascularization Secondary to Diseases Other Than Age-Related Macular Degeneration|Completed||Phase 1|10||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:35:47.764589|2018-06-01 03:35:47.764589
NCT00407693|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-02|||2018-05-22|2006-12-02|2006-12-05|Estimate|||||||2018-05-22|2018-05-23|Actual|November 28, 2006||2006-11-28|July 21, 2016|2016-07-21|July 21, 2016|Actual|2016-07-21|||||Interventional|||PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28|PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28|Completed||Phase 1|51|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:35:47.896389|2018-06-01 03:35:47.896389
NCT00407680|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2007-10-21|2006-12-04|2006-12-05|Estimate|||||||2007-10-21|2007-10-23|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|March 2009|Anticipated|2009-03-31|||||Interventional|||Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension|Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension|Unknown status|Recruiting|Phase 4|80|Anticipated|Kitasato University|||||f||||||||||||||2018-06-01 03:35:47.958595|2018-06-01 03:35:47.958595
NCT00407667|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2011-03-18|2006-12-01|2006-12-05|Estimate|||||||2011-03-18|2011-03-21|Estimate|December 2006||2006-12-31|November 2006|2006-11-30|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|TraGAT||Transcranial Galvanic Stimulation After Stroke|Transcranial Direct Current Stimulation (tDCS) of the Lesioned or Non-lesioned Hemisphere Plus Computer-assisted Arm Trainer: a Randomized, Placebo-controlled Double-blind Multi-centre Study in Patients With Severe Arm Paresis Early After Stroke|Completed||N/A|96|Anticipated|Charite University, Berlin, Germany||3|||f||||||||||||||2018-06-01 03:35:48.054587|2018-06-01 03:35:48.054587
NCT00407654|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2015-03-27||2015-07-22|2006-12-04|2006-12-05|Estimate|2015-07-22|2015-08-18|Estimate||||2015-07-22|2015-08-18|Estimate|October 2006||2006-10-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer|Phase II Trial of VEGF Trap in Patients With Previously Treated Metastatic Colorectal Cancer|Completed||Phase 2|75|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:35:48.143572|2018-06-01 03:35:48.143572
NCT00407641|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2017-12-21|2006-12-04|2006-12-05|Estimate|||||||2017-12-21|2017-12-22|Actual|March 2009|Actual|2009-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis|"Effects of Tinzaparin Sodium on Cardio-vascular OUtcomes and on Blood Lipids in Diabetic Patients on Chronic HEmodialysis: A Long-term, Prospective Study (The Tinzaparin COULD HELP Study)."|Withdrawn||Phase 4|0|Actual|Anemia Working Group Romania||2||Financial and administrative matters did not allow collaboration among centers.|f||||||||||||||2018-06-01 03:35:48.37075|2018-06-01 03:35:48.37075
NCT00407628|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-03|||2013-07-04|2006-12-03|2006-12-05|Estimate|||||||2013-07-04|2013-07-08|Estimate|August 2006||2006-08-31|January 2013|2013-01-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||Neural Correlates of Lower Extremity Motor Recovery in Stroke Patients: Longitudinal Diffusion Spectrum Imaging Studies|Neural Correlates of Lower Extremity Motor Recovery in Stroke Patients: Longitudinal Diffusion Spectrum Imaging Studies|Completed|||24|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:35:48.444647|2018-06-01 03:35:48.444647
NCT00407615|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2007-09-20|2006-12-04|2006-12-05|Estimate|||||||2007-09-20|2007-09-21|Estimate|December 2006||2006-12-31|September 2007|2007-09-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Double-Blind Placebo Study on Magnetic Field Therapy in Chronic Lumbar Pain|A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ON MAGNETIC FIELD THERAPY TO IMPROVE CHRONIC LUMBAR PAIN|Unknown status|Recruiting|Phase 4|40|Anticipated|Weintraub, Michael I., MD, FACP, FAAN|||||f||||||||||||||2018-06-01 03:35:48.50064|2018-06-01 03:35:48.50064
NCT00407602|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2015-05-28|2006-12-01|2006-12-05|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2006||2006-09-30|May 2015|2015-05-31|August 2019|Anticipated|2019-08-31|March 2012|Actual|2012-03-31||Interventional|||Argus® II Retinal Stimulation System Feasibility Protocol|Argus® II Retinal Stimulation System Feasibility Protocol|Active, not recruiting||Phase 2|30|Actual|Second Sight Medical Products||1|||f||||t||||||||||2018-06-01 03:35:48.56565|2018-06-01 03:35:48.56565
NCT00407589|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2011-12-07|2006-12-01|2006-12-05|Estimate|||||||2011-12-07|2011-12-09|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Systemic Pharmacokinetics of BOL-303224-A|Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis|Completed||Phase 1|24|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 03:35:49.655908|2018-06-01 03:35:49.655908
NCT00407576|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-02|||2017-06-30|2006-12-02|2006-12-05|Estimate|||||||2017-06-30|2017-07-02|Actual|December 1, 2006||2006-12-01|November 7, 2008|2008-11-07||||November 7, 2008|Actual|2008-11-07||Interventional|||PET Imaging of Brain Amyloid Using [11C]MeS-IMPY|PET Imaging of Brain Amyloid Using [11C]MeS-IMPY|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:35:49.716764|2018-06-01 03:35:49.716764
NCT00407563|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2011-09-28||2012-03-08|2006-12-04|2006-12-05|Estimate|2012-03-08|2012-04-05|Estimate||||2012-03-08|2012-04-05|Estimate|January 2007||2007-01-31|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer|A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|48|Actual|Accelerated Community Oncology Research Network|||||f||||f||||||||||2018-06-01 03:35:49.809415|2018-06-01 03:35:49.809415
NCT00407550|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2012-02-17||2017-03-21|2006-12-04|2006-12-05|Estimate|2012-05-11|2012-06-13|Estimate||||2017-03-21|2017-04-18|Actual|November 2006|Actual|2006-11-30|April 2016|2016-04-30|May 12, 2010|Actual|2010-05-12|January 2008|Actual|2008-01-31||Interventional|||Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|19|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:35:50.336873|2018-06-01 03:35:50.336873
NCT00407537|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2010-10-06||2015-06-30|2006-12-04|2006-12-05|Estimate|2011-10-05|2011-11-11|Estimate||||2015-06-30|2015-07-23|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|CRUCIAL||Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors|A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice|Completed||Phase 4|1531|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:35:50.86042|2018-06-01 03:35:50.86042
NCT00407524|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|October 2003||2003-10-31|December 2006|2006-12-31|March 2005||2005-03-31|||||Interventional|||AKL 1 Asthma Study|AKL1 Asthma Study - Randomised, Double-Blind, Placebo Controlled, Cross Over Study to Determine Safety and Efficacy of Oral AKL1 in Treating Patients With Asthma|Completed||Phase 2|40||University of Aberdeen|||||f||||||||||||||2018-06-01 03:35:52.512102|2018-06-01 03:35:52.512102
NCT00407511|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2009-06-18||2009-10-08|2006-12-01|2006-12-05|Estimate|2009-07-07|2009-08-19|Estimate||||2009-10-08|2009-10-15|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP|A Prospective, Open Label, Multi-Center, Study Of Pregabalin In The Treatment Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, HIV-Related Peripheral Neuropathic Pain And Chemotherapy Induced Peripheral Neuropathic Pain|Completed||Phase 4|121|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:35:52.68652|2018-06-01 03:35:52.68652
NCT00407498|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2008-12-31|2006-12-04|2006-12-05|Estimate|||||||2008-12-31|2009-01-01|Estimate|May 2005||2005-05-31|December 2008|2008-12-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms|An Open Label Multicentric Phase 1 Study of Selective Cyclin Dependent Kinase Inhibitor P276-00 in Patients With Advanced Refractory Neoplasms|Completed||Phase 1|50|Actual|Piramal Enterprises Limited|||||f||||f||||||||||2018-06-01 03:35:53.18033|2018-06-01 03:35:53.18033
NCT00407485|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|2014-08-27||2014-10-10|2006-12-04|2006-12-05|Estimate|2014-10-01|2014-10-03|Estimate||||2014-10-10|2014-10-20|Estimate|November 2006||2006-11-30|October 2013|2013-10-31|April 2014|Actual|2014-04-30|April 2010|Actual|2010-04-30||Interventional|||VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium|A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:35:53.266265|2018-06-01 03:35:53.266265
NCT00407472|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2013-10-21|2006-12-04|2006-12-05|Estimate|||||||2013-10-21|2013-10-22|Estimate|September 2005||2005-09-30|October 2013|2013-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency||Completed||Phase 1|38||EMD Serono|||||f||||||||||||||2018-06-01 03:35:53.489304|2018-06-01 03:35:53.489304
NCT00407459|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2011-08-31|2006-12-04|2006-12-05|Estimate|||||||2011-08-31|2011-09-02|Estimate|September 2007||2007-09-30|August 2011|2011-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma|Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|77|Actual|Istituto Clinico Humanitas|||||f||||f||||||||||2018-06-01 03:35:53.537229|2018-06-01 03:35:53.537229
NCT00407446|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2006-12-12|2006-12-01|2006-12-05|Estimate|||||||2006-12-12|2006-12-14|Estimate|January 2004||2004-01-31|December 2006|2006-12-31|February 2005||2005-02-28|||||Interventional|||PDE5-Inhibition With Sildenafil in Chronic Heart Failure|Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure|Completed||Phase 3|40||University of Milan|||||f||||||||||||||2018-06-01 03:35:53.616301|2018-06-01 03:35:53.616301
NCT00407433|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2009-08-06|2006-12-04|2006-12-05|Estimate|||||||2009-08-06|2009-08-07|Estimate||||August 2009|2009-08-31||||||||Interventional|||Clinical Studies of Gemcitabine-Oxaliplatin|Phase 2 Single-Arm Studies of Gemcitabine in Combination With Oxaliplatin Refractory and Relapsed Pediatric Solid Tumors|Completed||Phase 2|156|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 03:35:53.677963|2018-06-01 03:35:53.677963
NCT00407420|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate||||December 2006|2006-12-31||||||||Interventional|||"Can a Novel Treatment Using Mandometer® Technology Improve Weight Loss in a Childhood Obesity Clinic?"||Completed||N/A|90||University of Bristol|||||f||||||||||||||2018-06-01 03:35:53.735399|2018-06-01 03:35:53.735399
NCT00407407|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2012-04-06|2006-12-01|2006-12-05|Estimate|||||||2012-04-06|2012-04-09|Estimate|November 2006||2006-11-30|August 2008|2008-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma|A Phase I Dose Escalation Study of ABI-007 With Carboplatin TM as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma|Terminated||Phase 1|6|Actual|Celgene||||MTD not determined|f||||f||||||||||2018-06-01 03:35:53.791825|2018-06-01 03:35:53.791825
NCT00407394|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-02|||2006-12-02|2006-12-02|2006-12-05|Estimate|||||||2006-12-02|2006-12-05|Estimate|April 2004||2004-04-30|December 2006|2006-12-31|April 2006||2006-04-30|||||Interventional|||Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze|Randomized Double Blind Placebo Controlled Trial of Amoxycillin in the Treatment of Non-Severe Pneumonia With Wheeze in Children Aged 2- 59 Months of Age: A Multi-Centric Study|Completed||Phase 3|2000||King George's Medical University|||||f||||||||||||||2018-06-01 03:35:53.852047|2018-06-01 03:35:53.852047
NCT00407381|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2016-08-30||2017-03-20|2006-12-01|2006-12-05|Estimate|2017-03-20|2017-03-31|Actual||||2017-03-20|2017-03-31|Actual|December 2006||2006-12-31|March 2017|2017-03-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study|Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)|Completed||Phase 2|126|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-06-01 03:35:53.918129|2018-06-01 03:35:53.918129
NCT00407368|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|September 2006||2006-09-30|November 2006|2006-11-30|December 2007||2007-12-31|||||Observational|||Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease||Unknown status|Recruiting||150||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:35:54.153797|2018-06-01 03:35:54.153797
NCT00407355|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2013-10-07||2013-10-07|2006-12-01|2006-12-05|Estimate|2013-10-07|2013-12-04|Estimate||||2013-10-07|2013-12-04|Estimate|January 2006||2006-01-31|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|LVO||Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions|A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects With Macular Edema Secondary to Vein Occlusions.|Completed||Phase 1/Phase 2|40|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 03:35:54.283835|2018-06-01 03:35:54.283835
NCT00407342|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-04|||2009-09-29|2006-12-04|2006-12-05|Estimate|||||||2009-09-29|2009-09-30|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|September 2004|Actual|2004-09-30|June 2004|Actual|2004-06-30||Interventional|||Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.|Prospective, Randomized Half-side Comparison of Alefacept (Amevive) With or Without UVB-311nm Phototherapy in Patients With Psoriasis (Translated From German)|Completed||N/A|14|Actual|Medical University of Graz|||||f||||f||||||||||2018-06-01 03:35:54.739725|2018-06-01 03:35:54.739725
NCT00407329|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2013-11-05|2006-12-04|2006-12-05|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 2006||2006-11-30|November 2013|2013-11-30|January 2012|Actual|2012-01-31|February 2008|Actual|2008-02-29||Observational|||Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia|Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia: A Possible Marker of Progression and Response to Medical Therapy|Completed|||30|Actual|Queen's University|||||f||||f||||||||||2018-06-01 03:35:54.817961|2018-06-01 03:35:54.817961
NCT00407303|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01||2013-08-16|2016-07-19|2006-12-04|2006-12-05|Estimate||||2013-08-16|2013-08-26|Estimate|2016-07-19|2016-07-21|Estimate|October 2006||2006-10-31|July 2016|2016-07-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)|A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination With Bortezomib to Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)|Completed||Phase 1/Phase 2|24|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 03:35:54.942674|2018-06-01 03:35:54.942674
NCT00407290|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2006-12-04|2006-12-04|2006-12-05|Estimate|||||||2006-12-04|2006-12-05|Estimate|March 2006||2006-03-31|December 2006|2006-12-31|October 2006||2006-10-31|||||Interventional|||The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor.|The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor, on Either Immediate Postpartum Perineal Pain or Development of Chronic Perineal Pain After Vaginal Delivery.|Unknown status|Recruiting|N/A|60||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||||||||||||2018-06-01 03:35:55.048605|2018-06-01 03:35:55.048605
NCT00407277|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2009-03-17|2006-11-30|2006-12-04|Estimate|||||||2009-03-17|2009-03-18|Estimate|February 2007||2007-02-28|March 2009|2009-03-31||||August 2008|Actual|2008-08-31||Interventional|||Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia|Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia|Completed||N/A|120|Anticipated|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 03:35:55.114097|2018-06-01 03:35:55.114097
NCT00407264|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-29|2006-11-29|2006-12-04|Estimate|||||||2006-11-29|2006-12-04|Estimate|February 2002||2002-02-28|November 2006|2006-11-30|December 2005||2005-12-31|||||Interventional|||Randomized Trial of Fluticasone in Bronchial Premalignancy|The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study|Completed||Phase 2|90||VU University Medical Center|||||f||||||||||||||2018-06-01 03:35:55.192731|2018-06-01 03:35:55.192731
NCT00407251|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2010-11-03|2006-11-30|2006-12-04|Estimate|||||||2010-11-03|2010-11-05|Estimate|February 2007||2007-02-28|November 2010|2010-11-30||||June 2010|Actual|2010-06-30||Interventional|||Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy|A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|73|Anticipated|British Columbia Cancer Agency|||||f||||||||||||||2018-06-01 03:35:55.249859|2018-06-01 03:35:55.249859
NCT00407238|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2007-10-21|2006-11-30|2006-12-04|Estimate|||||||2007-10-21|2007-10-23|Estimate|November 2006||2006-11-30|October 2007|2007-10-31|March 2007|Actual|2007-03-31|||||Interventional|||Corneal Barrier Function With Multi-Purpose Solutions|Comparison of Human Corneal Barrier Function With Three Marketed Multi-Purpose Solutions|Completed||N/A|25|Anticipated|Southern California College of Optometry|||||f||||||||||||||2018-06-01 03:35:55.322045|2018-06-01 03:35:55.322045
NCT00407225|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-12-05|2006-11-29|2006-12-04|Estimate|||||||2006-12-05|2006-12-06|Estimate|December 1999||1999-12-31|November 2006|2006-11-30|October 2000||2000-10-31|||||Interventional|||Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation|Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation After Cataract Surgery|Completed||Phase 2|24||Sirion Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:35:55.38486|2018-06-01 03:35:55.38486
NCT00407212|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2011-11-22|2006-11-30|2006-12-04|Estimate|||||||2011-11-22|2011-11-23|Estimate|January 2002||2002-01-31|November 2011|2011-11-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's Disease|Completed||Phase 1/Phase 2|301|Actual|Novartis|||||f||||||||||||||2018-06-01 03:35:55.441266|2018-06-01 03:35:55.441266
NCT00407199|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2011-10-26|2006-11-30|2006-12-04|Estimate|||||||2011-10-26|2011-10-27|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment|The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment|Completed||Phase 4|20|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 03:35:55.562321|2018-06-01 03:35:55.562321
NCT00407186|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2017-10-09|2006-12-01|2006-12-04|Estimate|||||||2017-10-09|2017-10-10|Actual|January 11, 2007|Actual|2007-01-11|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)|A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study)|Active, not recruiting||Phase 3|788|Actual|Dutch Colorectal Cancer Group||2|||f||||t||||||||||2018-06-01 03:35:55.634184|2018-06-01 03:35:55.634184
NCT00407173|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2008-04-10|2006-11-30|2006-12-04|Estimate|||||||2008-04-10|2008-04-14|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects|An Open-Label, Single-Dose, Parallel Group Study to Evaluate the Effects of Age and Gender on the Pharmacokinetics, Safety, and Tolerability of HCV-796 Administered Orally to Healthy Subjects|Completed||Phase 1|48|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 03:35:55.711225|2018-06-01 03:35:55.711225
NCT00407160|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2011-09-06|2006-11-30|2006-12-04|Estimate|||||||2011-09-06|2011-09-07|Estimate|August 2004||2004-08-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients|Comparison of Two Different Immunosuppression Protocols in Highly Sensitized Renal Transplant Recipients: Campath Induction With Tacrolimus Monotherapy vs Thymoglobulin Induction With Triple Drug Protocol.|Completed|||60|Anticipated|The University of Texas Medical Branch, Galveston|||2||f||||t||||||||||2018-06-01 03:35:55.772668|2018-06-01 03:35:55.772668
NCT00407147|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2012-01-16|2006-11-29|2006-12-04|Estimate|||||||2012-01-16|2012-01-18|Estimate|July 2008||2008-07-31|January 2012|2012-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection|ProBac - Use of Procalcitonin Level as Part of a Decision Tree to Discontinue Antibiotics When Started Empirically in the ICU in Hemodynamically Stable Patients With no Site of Infection Identified|Terminated||Phase 4|11|Actual|Brahms AG||2||termination due to futility (very slow patient enrollment)|f||||t||||||||||2018-06-01 03:35:55.851683|2018-06-01 03:35:55.851683
NCT00407134|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2007-12-19|2006-11-30|2006-12-04|Estimate|||||||2007-12-19|2007-12-28|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Acute Haemodynamic Effects of Peritoneal Dialysis as Evaluated by Sphygmocor Technology|Acute Haemodynamic Effects of Peritoneal Dialysis as Evaluated by Sphygmocor Technology|Completed||N/A|20||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:35:55.942736|2018-06-01 03:35:55.942736
NCT00407121|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2006-12-01|2006-12-01|2006-12-04|Estimate|||||||2006-12-01|2006-12-04|Estimate|August 2006||2006-08-31|December 2006|2006-12-31|November 2006||2006-11-30|||||Interventional|||Intravitreal Bevacizumab for Inflammatory Neovascular Membranes|Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation|Completed||Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:35:55.991995|2018-06-01 03:35:55.991995
NCT00407108|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-12-05|2006-11-30|2006-12-04|Estimate|||||||2006-12-05|2006-12-06|Estimate|March 2006||2006-03-31|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy||Unknown status|Recruiting|Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:35:56.050914|2018-06-01 03:35:56.050914
NCT00407095|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2010-09-10|2006-11-30|2006-12-04|Estimate|||||||2010-09-10|2010-09-13|Estimate|August 2007||2007-08-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.|An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.|Completed||Phase 3|140|Anticipated|Solvay Pharmaceuticals||1|||f||||t||||||||||2018-06-01 03:35:56.11987|2018-06-01 03:35:56.11987
NCT00407082|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2011-12-07|2006-12-01|2006-12-04|Estimate|||||||2011-12-07|2011-12-08|Estimate|December 2000||2000-12-31|December 2011|2011-12-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants|A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye|Completed||Phase 2/Phase 3|278|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 03:35:56.264257|2018-06-01 03:35:56.264257
NCT00407069|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2016-10-14|2006-11-30|2006-12-04|Estimate|||||||2016-10-14|2016-10-18|Estimate|June 2005||2005-06-30|October 2016|2016-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus|Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus (ADVN AMP01)|Completed|||286|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||6||f||||t||||||Samples With DNA|"~     Blood and skin samples will be retained~   "|Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 03:35:56.331985|2018-06-01 03:35:56.331985
NCT00407056|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-11-29|2006-11-29|2006-12-04|Estimate|||||||2006-11-29|2006-12-04|Estimate|August 2002||2002-08-31|November 2006|2006-11-30|June 2003||2003-06-30|||||Interventional|||Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis|Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis).|Completed||Phase 3|20||Sirion Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:35:56.450062|2018-06-01 03:35:56.450062
NCT00407043|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2011-07-20|2006-11-30|2006-12-04|Estimate|||||||2011-07-20|2011-07-21|Estimate|November 2006||2006-11-30|July 2011|2011-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis|A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine|Completed||Phase 4|5|Actual|Ophthalmic Consultants of Long Island|||||f||||t||||||||||2018-06-01 03:35:56.564134|2018-06-01 03:35:56.564134
NCT00407030|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2010-08-31||2013-07-12|2006-11-30|2006-12-04|Estimate|2010-12-01|2010-12-31|Estimate||||2013-07-12|2013-07-19|Estimate|July 2006||2006-07-31|July 2013|2013-07-31|June 2009|Actual|2009-06-30|January 2008|Actual|2008-01-31||Interventional|||IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With a Double-blind Parallel-group Extension Period to Investigate the Efficacy and Safety of Different Doses of IncobotulinumtoxinA (Xeomin) in the Treatment of Cervical Dystonia|Completed||Phase 3|233|Actual|Merz Pharmaceuticals GmbH||3|||f||||t||||||||||2018-06-01 03:35:56.656509|2018-06-01 03:35:56.656509
NCT00407017|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2007-08-17|2006-12-01|2006-12-04|Estimate|||||||2007-08-17|2007-08-21|Estimate||||August 2007|2007-08-31||||||||Interventional|||Therapeutic Variables in Cataract Surgery||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:35:57.177882|2018-06-01 03:35:57.177882
NCT00407004|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2006-12-01|2006-12-01|2006-12-04|Estimate|||||||2006-12-01|2006-12-04|Estimate|March 2003||2003-03-31|November 2006|2006-11-30|April 2004||2004-04-30|||||Interventional|||Elimination of Albumin-Bound Substances by MARS and Prometheus|Effect of Extracorporeal Liver Support by MARS and Prometheus on Albumin-Bound Substances in Acute-on-Chronic Liver Failure|Completed||N/A|10||Medical University of Graz|||||f||||||||||||||2018-06-01 03:35:57.247591|2018-06-01 03:35:57.247591
NCT00406991|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2015-10-28|2006-12-01|2006-12-04|Estimate|||||||2015-10-28|2015-10-30|Estimate|June 2003||2003-06-30|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Retinal Blood Flow and Microthrombi in Type 1 Diabetes|Retinal Blood Flow and Microthrombi in Type 1 Diabetes|Completed||Phase 2|100||Massachusetts Eye and Ear Infirmary|||||f||||||||||||||2018-06-01 03:35:57.313612|2018-06-01 03:35:57.313612
NCT00406978|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2016-05-09|2006-11-30|2006-12-04|Estimate|||||||2016-05-09|2016-05-10|Estimate|February 2006||2006-02-28|May 2016|2016-05-31|April 2014|Actual|2014-04-30|September 2010|Actual|2010-09-30||Interventional|MPTD||Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients|A Phase I/II, Multi-Center, Open Label Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Advanced and Refractory Multiple Myeloma Patients|Completed||Phase 1/Phase 2|24|Actual|University of Turin, Italy||1|||f||||f||||||||||2018-06-01 03:35:57.392961|2018-06-01 03:35:57.392961
NCT00406965|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2007-12-31|2006-11-30|2006-12-04|Estimate|||||||2007-12-31|2008-01-02|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of HAE1 (PRO98498) in Subjects With Moderate to Severe Allergic Asthma|Completed||Phase 2|50||Genentech, Inc.|||||f||||||||||||||2018-06-01 03:35:57.488131|2018-06-01 03:35:57.488131
NCT00405860|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2011-03-21|2006-11-29|2006-11-30|Estimate|||||||2011-03-21|2011-03-23|Estimate|December 2002||2002-12-31|March 2011|2011-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||CellCept in p-ANCA Vasculitis|A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction.|Completed||Phase 1|18|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:36:25.574734|2018-06-01 03:36:25.574734
NCT00406952|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2008-08-20|2006-11-30|2006-12-04|Estimate|||||||2008-08-20|2008-08-21|Estimate|November 2006||2006-11-30|August 2008|2008-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Study for Evaluating Different Methods of Measuring Depression Treatment Response|A Phase 4 Randomized, Double-Blind, Placebo Controlled Methodology Study to Evaluate the Time of Onset of AntiDepressant Response in Subjects With Major Depressive Disorder|Completed||N/A|165|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:35:57.541165|2018-06-01 03:35:57.541165
NCT00406939|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2008-07-08|2006-12-01|2006-12-04|Estimate|||||||2008-07-08|2008-07-10|Estimate|June 1998||1998-06-30|July 2008|2008-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Vector Delivery of the IL-12 Gene in Men With Prostate Cancer|Phase I Study of Adenoviral Vector Delivery of The IL-12 Gene in Men With Recurrence or Persistent Cancer of the Prostate After Primary Therapy With or Without Metastatic Disease (SPORE)|Completed||Phase 1|4|Actual|Baylor College of Medicine|||||f||||||||||||||2018-06-01 03:35:57.628736|2018-06-01 03:35:57.628736
NCT00406926|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-11-29|2006-11-29|2006-12-04|Estimate|||||||2006-11-29|2006-12-04|Estimate|August 1999||1999-08-31|November 2006|2006-11-30|August 2003||2003-08-31|||||Interventional|||The Effect of Growth Hormone in Very Young Girls With Turner Syndrome|The Effect of Recombinant Human Growth Hormone Treatment on the Growth of Infants and Toddlers With Turner Syndrome|Completed||Phase 3|100||Eli Lilly and Company|||||||||||||||||||2018-06-01 03:35:57.68979|2018-06-01 03:35:57.68979
NCT00406913|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2013-09-04|2006-11-30|2006-12-04|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2005||2005-10-31|September 2013|2013-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery|Assessment of Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery Using Intranasal Mupirocin Ointment|Completed||N/A|37|Actual|University of Chicago||2|||f||||||||||||||2018-06-01 03:35:57.753368|2018-06-01 03:35:57.753368
NCT00406900|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-12-05|2006-11-29|2006-12-04|Estimate|||||||2006-12-05|2006-12-06|Estimate|January 1999||1999-01-31|November 2006|2006-11-30|September 2006||2006-09-30|||||Observational|||Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma||Unknown status|Recruiting||560||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:35:57.831428|2018-06-01 03:35:57.831428
NCT00406887|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-11-29|2006-11-29|2006-12-04|Estimate|||||||2006-11-29|2006-12-04|Estimate|August 2002||2002-08-31|November 2006|2006-11-30|November 2003||2003-11-30|||||Interventional|||Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis|Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis).|Completed||Phase 3|140||Sirion Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:35:57.89229|2018-06-01 03:35:57.89229
NCT00406874|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2013-06-03|2006-12-01|2006-12-04|Estimate|||||||2013-06-03|2013-06-04|Estimate|January 2007||2007-01-31|June 2013|2013-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Omega 3 Fats on Sperm Quality and Sexual Function|Effect of Omega 3 Fats on Sperm Quality and Sexual Function in Infertile Men Age 35-55|Terminated||Phase 2|6|Actual|Reproductive Partners Medical Group||||reports indicating that increased folic acid intake may increase colin cancer|f||||f||||||||||2018-06-01 03:35:57.942965|2018-06-01 03:35:57.942965
NCT00406861|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2006-12-01|2006-12-01|2006-12-04|Estimate|||||||2006-12-01|2006-12-04|Estimate|December 2006||2006-12-31|November 2006|2006-11-30|June 2009||2009-06-30|||||Interventional|||Montelukast in ENL Reaction|Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy|Unknown status|Not yet recruiting|N/A|60||The Leprosy Mission Bangladesh|||||f||||||||||||||2018-06-01 03:35:58.006253|2018-06-01 03:35:58.006253
NCT00406848|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2010-07-22||2010-09-13|2006-11-29|2006-12-04|Estimate|2010-09-13|2010-09-29|Estimate||||2010-09-13|2010-09-29|Estimate|November 2006||2006-11-30|September 2010|2010-09-30|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients|Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression|Completed||Phase 4|370|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:35:58.219837|2018-06-01 03:35:58.219837
NCT00406835|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2006-11-30|2006-11-30|2006-12-04|Estimate|||||||2006-11-30|2006-12-04|Estimate|October 1999||1999-10-31|November 2006|2006-11-30|April 2005||2005-04-30|||||Observational|||Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases|Phase 3 Study of Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for 1-4 Brain Metastases|Completed|||180||Hokkaido University Hospital|||||f||||||||||||||2018-06-01 03:36:00.862898|2018-06-01 03:36:00.862898
NCT00406822|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2008-04-25|2006-11-30|2006-12-04|Estimate|||||||2008-04-25|2008-05-05|Estimate|December 2006||2006-12-31|June 2007|2007-06-30||||||||Interventional|||OculusGen-Glaucoma Historical Control Study in Taiwan|Study of the Safety and Effectiveness of the OculusGen Collagen Matrix Implant as an Aid in Glaucoma Surgery|Terminated||Phase 3|48|Anticipated|Pro Top & Mediking Company Limited||||Terminated due to the change of supplier and sponsor|f||||||||||||||2018-06-01 03:36:00.917157|2018-06-01 03:36:00.917157
NCT00406809|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30||2017-10-31|2017-11-01|2006-11-30|2006-12-04|Estimate||||2017-11-01|2017-11-06|Actual|2017-11-01|2017-11-06|Actual|November 2006||2006-11-30|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies|A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies|Completed||Phase 1/Phase 2|81|Actual|AbbVie||4|||f||||f||||||||||2018-06-01 03:36:00.991133|2018-06-01 03:36:00.991133
NCT00406796|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2013-12-10|2006-11-30|2006-12-04|Estimate|||||||2013-12-10|2013-12-12|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|October 2010|Actual|2010-10-31|September 2008|Actual|2008-09-30||Interventional|||Lucentis for Central Retinal Vein Occlusion (CRVO)|FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease|Completed||Phase 1|20|Actual|California Retina Consultants||2|||f||||t||||||||||2018-06-01 03:36:01.204511|2018-06-01 03:36:01.204511
NCT00406783|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2008-11-21||2017-03-15|2006-11-30|2006-12-04|Estimate|2009-03-05|2009-03-06|Estimate||||2017-03-15|2017-04-12|Actual|August 2006||2006-08-31|March 2017|2017-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Intermittent Allergic Rhinitis (IAR)|Completed||Phase 3|547|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:36:01.29299|2018-06-01 03:36:01.29299
NCT00406770|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2009-10-18|2006-11-30|2006-12-04|Estimate|||||||2009-10-18|2009-10-19|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Bright Light Therapy for Weight Loss||Completed||N/A|41|Actual|Russian Academy of Medical Sciences|||||f||||f||||||||||2018-06-01 03:36:01.532266|2018-06-01 03:36:01.532266
NCT00406757|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2017-11-08|2006-12-01|2006-12-04|Estimate|||||||2017-11-08|2017-11-13|Actual|August 30, 2006|Actual|2006-08-30|November 2017|2017-11-30|July 15, 2009|Actual|2009-07-15|July 15, 2009|Actual|2009-07-15||Interventional|||Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma|Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.|Completed||Phase 1|13|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 03:36:01.584769|2018-06-01 03:36:01.584769
NCT00406744|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2006-11-30|2006-11-30|2006-12-04|Estimate|||||||2006-11-30|2006-12-04|Estimate|May 2006||2006-05-31|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Efficacy of Retreatments With Intravitreal Bevacizumab|Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments|Unknown status|Recruiting|Phase 3|20||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:36:01.667043|2018-06-01 03:36:01.667043
NCT00406731|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2014-11-20|2006-11-30|2006-12-04|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure|Role of endothelin-and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure|Withdrawn||Phase 2|0|Actual|Medical University of Vienna|||||f||||t||||||||||2018-06-01 03:36:01.737504|2018-06-01 03:36:01.737504
NCT00406718|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2015-05-01||2015-09-01|2006-11-30|2006-12-04|Estimate|2015-09-01|2015-10-05|Estimate||||2015-09-01|2015-10-05|Estimate|November 2006||2006-11-30|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||X2 for categorical, and one way anova for continuous to examine differences in demographics for participants not making it to randomization versus those randomized to treatment.|Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia|Interventions for Adherence to Oral Antipsychotic Medications in Schizophrenia|Completed||N/A|197|Actual|The University of Texas Health Science Center at San Antonio|Patients had long-standing illness and results may not apply to patients with a more recent onset of schizophrenia/schizoaffective disorder|3|||f||||f||||||||||2018-06-01 03:36:01.814838|2018-06-01 03:36:01.814838
NCT00406705|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2007-05-03|2006-11-29|2006-12-04|Estimate|||||||2007-05-03|2007-05-04|Estimate|March 2005||2005-03-31|March 2007|2007-03-31|January 2007|Actual|2007-01-31|||||Interventional|||The Effect of Breathing Helium-Hyperoxia During Pulmonary Rehabilitation in Patients With COPD|A Randomized Controlled Trial to Study the Effect of Exercise Training Breathing Helium-Hyperoxia on The Exercise Tolerance and Quality of Life of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|38||University of Alberta|||||f||||||||||||||2018-06-01 03:36:02.091956|2018-06-01 03:36:02.091956
NCT00406692|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2010-02-08||2010-05-06|2006-11-30|2006-12-04|Estimate|2010-04-15|2010-05-06|Estimate||||2010-05-06|2010-05-11|Estimate|November 2006||2006-11-30|May 2010|2010-05-31|November 2009|Actual|2009-11-30|August 2008|Actual|2008-08-31||Interventional|||The Effects of Zonisamide on Alcohol Dependence|The Effects of Zonisamide on Alcohol Dependence|Completed||Phase 2|16|Actual|Boston University|Limitations of this trial include lack of a placebo controlled arm and small sample size.|1|||f||||t||||||||||2018-06-01 03:36:02.157546|2018-06-01 03:36:02.157546
NCT00406679|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2011-08-10|2006-11-29|2006-12-04|Estimate|||||||2011-08-10|2011-08-11|Estimate|November 2006||2006-11-30|August 2011|2011-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-containing Solutions in Post-Surgical Dental Pain|Single-Dose Comparison of the Analgesic Efficacy, Safety and Tolerability of Two Paracetamol 1%-Containing Solutions and Placebo in a Post-Surgical Dental Pain Model|Completed||Phase 3|135|Actual|Baxter Healthcare Corporation||3|||f||||f||||||||||2018-06-01 03:36:02.418532|2018-06-01 03:36:02.418532
NCT00406653|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|2010-07-30||2010-09-10|2006-12-01|2006-12-04|Estimate|2010-07-30|2010-08-31|Estimate||||2010-09-10|2010-09-14|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of Abatacept in Patients With Active Crohn's Disease|A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Crohn's Disease (CD) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy|Terminated||Phase 3|451|Actual|Bristol-Myers Squibb||3||Sponsor Decision|f||||t||||||||||2018-06-01 03:36:02.617131|2018-06-01 03:36:02.617131
NCT00406640|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2009-02-27||2010-05-26|2006-11-29|2006-12-04|Estimate|2010-05-26|2010-06-29|Estimate||||2010-05-26|2010-06-29|Estimate|December 2006||2006-12-31|May 2010|2010-05-31|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women|A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive Disorder|Completed||Phase 3|595|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:36:04.869573|2018-06-01 03:36:04.869573
NCT00406627|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2008-09-08|2006-11-30|2006-12-04|Estimate|||||||2008-09-08|2008-09-09|Estimate|December 2006||2006-12-31|September 2008|2008-09-30|December 2011||2011-12-31|||||Observational|||Research for Elimination of Lymphatic Filariasis (ICIDR)|Research for Elimination of Lymphatic Filariasis (ICIDR)|Completed|||117500||Washington University School of Medicine|||||f||||||||||||||2018-06-01 03:36:05.627227|2018-06-01 03:36:05.627227
NCT00406614|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2017-03-06|2006-11-30|2006-12-04|Estimate|||||||2017-03-06|2017-03-08|Actual|September 2007||2007-09-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|August 2009|Actual|2009-08-31||Interventional|||Health Literacy-Focused Program to Improve Blood Pressure Control in Korean Americans|Health Literacy Intervention for Korean Americans With High Blood Pressure (HBP)|Completed||N/A|360|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-06-01 03:36:05.68017|2018-06-01 03:36:05.68017
NCT00406601|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2010-09-01|2006-11-29|2006-12-04|Estimate|||||||2010-09-01|2010-09-02|Estimate|November 2006||2006-11-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|June 2010|Actual|2010-06-30||Interventional|||BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas|Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy|Completed||Phase 2|69|Actual|Istituto Clinico Humanitas|||||f||||f||||||||||2018-06-01 03:36:05.776645|2018-06-01 03:36:05.776645
NCT00406588|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30||2015-01-29|2015-02-09|2006-11-30|2006-12-04|Estimate||||2015-02-09|2015-02-27|Estimate|2015-02-09|2015-02-27|Estimate|March 2007||2007-03-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.|Completed||Phase 3|295|Actual|Solvay Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:36:05.86048|2018-06-01 03:36:05.86048
NCT00406575|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2014-05-06|2006-11-30|2006-12-04|Estimate|||||||2014-05-06|2014-05-07|Estimate|November 2006||2006-11-30|May 2014|2014-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Recombinant Human Relaxin for the Treatment of Decompensated CHF|A Phase II Randomized, Double Blind, Placebo-Controlled Study of Recombinant Human Relaxin in Patients With Decompensated Congestive Heart Failure|Terminated||Phase 2|11|Actual|Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies||3|||f||||||||||||||2018-06-01 03:36:06.052435|2018-06-01 03:36:06.052435
NCT00406562|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2016-10-26|2006-12-01|2006-12-04|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|February 2007|Actual|2007-02-28|||||Interventional|||Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.|Open, Booster Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Administered to Healthy Chinese Children 6-8 Years of Age.|Completed||Phase 3|30||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:36:06.134591|2018-06-01 03:36:06.134591
NCT00406549|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2007-03-07|2006-11-30|2006-12-04|Estimate|||||||2007-03-07|2007-03-08|Estimate|December 2006||2006-12-31|March 2007|2007-03-31|March 2007||2007-03-31|||||Observational|||Evaluation of a Diagnostic Device for Detection of Nasal Staphylococcus Aureus|Multi-Center Clinical Performance Evaluation of a Rapid In Vitro Diagnostic Device for Direct Detection of Staphylococcus Aureus Nasal Colonization: Comparative Analysis to Culture Screening Methods|Completed|||2000||3M|||||f||||||||||||||2018-06-01 03:36:06.222241|2018-06-01 03:36:06.222241
NCT00406536|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2013-01-11|2006-11-29|2006-12-04|Estimate|||||||2013-01-11|2013-01-14|Estimate|January 2007||2007-01-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI|Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF|Completed||Phase 2|110|Actual|Avanti Polar Lipids, Inc.||2|||f||||||||||||||2018-06-01 03:36:06.298516|2018-06-01 03:36:06.298516
NCT00406523|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2006-11-30|2006-11-30|2006-12-04|Estimate|||||||2006-11-30|2006-12-04|Estimate|February 2006||2006-02-28|November 2006|2006-11-30|September 2007||2007-09-30|||||Interventional|||A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery Disease||Completed||Phase 4|||Shenyang Northern Hospital|||||f||||||||||||||2018-06-01 03:36:06.561831|2018-06-01 03:36:06.561831
NCT00406510|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2007-05-30|2006-11-30|2006-12-04|Estimate|||||||2007-05-30|2007-06-01|Estimate||||May 2007|2007-05-31||||||||Interventional|||Comparison of Frequency of Use of Optive and Systane||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:36:06.606562|2018-06-01 03:36:06.606562
NCT00406497|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-11-29|2006-11-29|2006-12-04|Estimate|||||||2006-11-29|2006-12-04|Estimate|April 2003||2003-04-30|November 2006|2006-11-30|July 2003||2003-07-31|||||Interventional|||Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation|Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation|Completed||Phase 2|24||Sirion Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:36:06.655039|2018-06-01 03:36:06.655039
NCT00406484|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2014-01-15|2006-11-30|2006-12-04|Estimate|||||||2014-01-15|2014-01-16|Estimate|September 2004||2004-09-30|January 2014|2014-01-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Brief Introductory Therapy for Opioid Dependence|Brief Introductory Therapy for Opioid Dependence|Completed||Phase 2|51|Actual|Yale University||2|||f||||f||||||||||2018-06-01 03:36:06.716219|2018-06-01 03:36:06.716219
NCT00406471|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2013-03-12|2006-11-30|2006-12-04|Estimate|||||||2013-03-12|2013-03-14|Estimate|May 2005||2005-05-31|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion|Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion|Completed||Phase 1|20|Actual|Greater Houston Retina Research||2|||f||||||||||||||2018-06-01 03:36:06.79611|2018-06-01 03:36:06.79611
NCT00406458|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30||2012-10-30|2012-10-30|2006-11-30|2006-12-04|Estimate||||2012-10-30|2012-11-01|Estimate|2012-10-30|2012-11-01|Estimate|November 2006||2006-11-30|October 2012|2012-10-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy|A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy|Completed||Phase 2|110|Actual|Sangamo Therapeutics||2|||f||||f||||||||||2018-06-01 03:36:06.88635|2018-06-01 03:36:06.88635
NCT00406445|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-25|||2018-03-27|2006-12-01|2006-12-04|Estimate|||||||2018-03-27|2018-03-29|Actual|November 24, 2006||2006-11-24|March 12, 2018|2018-03-12||||||||Observational|||Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome|Metabolic Regulation by Tumor Suppressor p53 in Li-Fraumeni Syndrome|Recruiting|||226|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:36:07.048546|2018-06-01 03:36:07.048546
NCT00406432|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2017-09-27|2006-11-30|2006-12-04|Estimate|||||||2017-09-27|2017-09-29|Actual|May 9, 2006|Actual|2006-05-09|September 2017|2017-09-30|June 2, 2006|Actual|2006-06-02|June 2, 2006|Actual|2006-06-02||Interventional|||A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects|A Steady-state Study to Assess the Pharmacokinetic Profile of Paroxetine After 14 Day Repeated Daily Dosing of the Controlled Release Paroxetine Tablet (25 mg) in Healthy Chinese Subjects|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:36:07.130559|2018-06-01 03:36:07.130559
NCT00406419|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30||2013-06-28|2017-05-12|2006-11-30|2006-12-04|Estimate||||2013-06-28|2013-07-04|Estimate|2017-05-12|2017-05-15|Actual|December 2006|Actual|2006-12-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|October 2009|Actual|2009-10-31||Interventional|STAGE||A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)|A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment|Terminated||Phase 3|1015|Actual|Genentech, Inc.||3||"Based on analysis of results and consideration of available treatments, the overall benefit to~   risk profile of ocrelizumab was not favorable in RA."|f||||||||||||||2018-06-01 03:36:07.20499|2018-06-01 03:36:07.20499
NCT00406406|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2007-12-03|2006-11-30|2006-12-04|Estimate|||||||2007-12-03|2007-12-05|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating SKI-606 Administered to Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKI-606 Administered Orally to Healthy Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:36:07.283365|2018-06-01 03:36:07.283365
NCT00405847|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2016-10-26|2006-11-29|2006-11-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2006||2006-07-31|October 2016|2016-10-31|May 2007|Actual|2007-05-31|||||Interventional|||A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients|A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients|Completed||Phase 4|17|Actual|University of Arizona|||||f||||||||||||||2018-06-01 03:36:25.630092|2018-06-01 03:36:25.630092
NCT00406393|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2016-01-06||2016-02-08|2006-11-30|2006-12-04|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|November 2006||2006-11-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2012|Actual|2012-10-31||Interventional|||Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)|A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus With Tacrolimus/Methotrexate as Graft-versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation (BMT CTN #0402)|Completed||Phase 3|304|Actual|Medical College of Wisconsin||2|||f||||t||||||||Yes|Findings will be published in a manuscript.|2018-06-01 03:36:07.357104|2018-06-01 03:36:07.357104
NCT00406380|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2006-12-01|2006-12-01|2006-12-04|Estimate|||||||2006-12-01|2006-12-04|Estimate|September 2006||2006-09-30|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Effect of Avastin in Juxtafoveal Telangiectasias|Does Avastin Change Evolution in Juxtafoveal Telangiectasias?|Unknown status|Recruiting|Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:36:08.184756|2018-06-01 03:36:08.184756
NCT00406367|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2010-08-31||2013-03-13|2006-11-30|2006-12-04|Estimate|2010-10-21|2010-11-16|Estimate||||2013-03-13|2013-03-15|Estimate|October 2006||2006-10-31|March 2013|2013-03-31|July 2009|Actual|2009-07-31|April 2008|Actual|2008-04-30||Interventional|||IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm|Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Blepharospasm|Completed||Phase 3|109|Actual|Merz Pharmaceuticals GmbH||2|||f||||||||||||||2018-06-01 03:36:08.305998|2018-06-01 03:36:08.305998
NCT00406354|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2010-01-14||2010-02-19|2006-11-29|2006-12-04|Estimate|2010-01-14|2010-02-12|Estimate||||2010-02-19|2010-02-26|Estimate|November 2006||2006-11-30|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany|A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder|Completed||Phase 4|181|Actual|Eli Lilly and Company||3|||f||||||||||||||2018-06-01 03:36:08.715207|2018-06-01 03:36:08.715207
NCT00406341|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-11-29|2006-11-29|2006-12-04|Estimate|||||||2006-11-29|2006-12-04|Estimate|April 2004||2004-04-30|November 2006|2006-11-30|March 2005||2005-03-31|||||Interventional|||Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation|Phase 3 Confimatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treament of Postoperative Inflammation|Completed||Phase 3|200||Sirion Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:36:10.443982|2018-06-01 03:36:10.443982
NCT00406315|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2009-12-01||2010-02-02|2006-11-29|2006-12-04|Estimate|2010-01-08|2010-02-02|Estimate||||2010-02-02|2010-02-18|Estimate|November 2006||2006-11-30|February 2010|2010-02-28|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone|A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder|Completed||Phase 4|255|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:36:10.605716|2018-06-01 03:36:10.605716
NCT00406302|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2014-04-28|2006-12-01|2006-12-04|Estimate|||||||2014-04-28|2014-04-29|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)|Multicenter Phase II Study Evaluating Docetaxel, CDDP, and Cetuximab as Induction Regimen Prior to Surgery in Chemo-naive Patients With NSCLC Stage IB, II and IIIA|Completed||Phase 2|41|Actual|Medical University of Vienna|||||f||||f||||||||||2018-06-01 03:36:11.424876|2018-06-01 03:36:11.424876
NCT00406289|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2010-09-03|2006-11-30|2006-12-04|Estimate|||||||2010-09-03|2010-09-06|Estimate|November 2006||2006-11-30|September 2010|2010-09-30|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) in Patients With Head and Neck Tumor|Phase I Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) With Patients With Head and Neck Tumor|Completed||Phase 1|24|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:36:11.568081|2018-06-01 03:36:11.568081
NCT00406276|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2012-03-30||2013-08-19|2006-11-30|2006-12-04|Estimate|2012-04-30|2012-05-28|Estimate||||2013-08-19|2013-08-23|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|December 2010|Actual|2010-12-31||Interventional|||Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer|Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|28|Actual|Emory University||1||data analysis showed insufficient drug efficacy|f||||t||||||||||2018-06-01 03:36:11.663918|2018-06-01 03:36:11.663918
NCT00406263|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2016-07-25|2006-11-30|2006-12-04|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2006||2006-11-30|July 2016|2016-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Comparison of Scheimpflug Photos of the Crystalline Lens in Patients Who Have Undergone Vitrectomy Surgery and Controls|Comparison of Scheimpflug Photos of the Crystalline Lens in Patients Who Have Undergone Vitrectony Surgery and Controls|Completed|||49|Actual|Barnes Retina Institute|||||f||||f||||||||||2018-06-01 03:36:11.995237|2018-06-01 03:36:11.995237
NCT00406250|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2016-02-05|2006-11-30|2006-12-04|Estimate|||||||2016-02-05|2016-02-08|Estimate|November 2006||2006-11-30|February 2016|2016-02-29|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Intravitreal Bevacizumab in Agioid Streaks|Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Angioid Streaks: 24 Months Follow-up|Completed||Phase 1|5|Actual|"University of Campania Luigi Vanvitelli"||1|||f||||t||||||||||2018-06-01 03:36:12.144705|2018-06-01 03:36:12.144705
NCT00406237|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2011-04-01|2006-11-30|2006-12-04|Estimate|||||||2011-04-01|2011-04-04|Estimate|December 2006||2006-12-31|April 2011|2011-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis|Open Label, Single Dose Study Of The Pharmacokinetics Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis|Completed||Phase 1|8|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 03:36:12.590315|2018-06-01 03:36:12.590315
NCT00406224|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2006-12-01|2006-12-01|2006-12-04|Estimate|||||||2006-12-01|2006-12-04|Estimate|December 2002||2002-12-31|November 2006|2006-11-30|December 2003||2003-12-31|||||Interventional|||Effect of Oxygen Breathing on Flicker Induced Blood Flow Changes in the Optic Nerve Head||Completed||N/A|||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:36:12.701596|2018-06-01 03:36:12.701596
NCT00405873|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2013-03-19|2006-11-29|2006-11-30|Estimate|||||||2013-03-19|2013-03-20|Estimate|March 2007||2007-03-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003|A Prospective, Open, Single-arm, Multicenter Phase II Clinical Trial to Evaluate the Tumour Response and Safety in Patients With Advanced Primary Hepatocellular Carcinoma Treated With AMT2003|Terminated||Phase 2|73|Actual|Auron Healthcare GmbH||1||Lack of efficacy|f||||||||||||||2018-06-01 03:36:25.459051|2018-06-01 03:36:25.459051
NCT00406211|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01|||2016-09-14|2006-12-01|2006-12-04|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2004||2004-07-31|September 2016|2016-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine|Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®.|Completed||Phase 3|398|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:36:12.768144|2018-06-01 03:36:12.768144
NCT00406198|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2006-12-01|2006-12-01|2006-12-04|Estimate|||||||2006-12-01|2006-12-04|Estimate|March 1997||1997-03-31|November 2006|2006-11-30|December 1999||1999-12-31|||||Interventional|||Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis|Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis|Completed||Phase 4|400||Hopital Lariboisière|||||f||||||||||||||2018-06-01 03:36:13.012373|2018-06-01 03:36:13.012373
NCT00406185|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2017-10-13|2006-11-30|2006-12-04|Estimate|||||||2017-10-13|2017-10-17|Actual|October 1994||1994-10-31|October 2017|2017-10-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|||Database Registry of the Intermountain Heart Collaborative Study|Database Registry of the Intermountain Heart Collaborative Study|Active, not recruiting|||30000|Anticipated|Intermountain Health Care, Inc.|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 03:36:13.113481|2018-06-01 03:36:13.113481
NCT00406172|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2006-12-04|2006-11-30|2006-12-04|Estimate|||||||2006-12-04|2006-12-05|Estimate||||November 2006|2006-11-30||||||||Interventional|||Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)|Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)|Unknown status|Recruiting|Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:36:13.25216|2018-06-01 03:36:13.25216
NCT00406159|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2009-08-06|2006-11-29|2006-12-04|Estimate|||||||2009-08-06|2009-08-07|Estimate|November 2006||2006-11-30|August 2009|2009-08-31|September 2007|Actual|2007-09-30|||||Interventional|||Effects of Hyperbaric Oxygen Therapy on Children With Autism|Effects of Hyperbaric Oxygen Therapy on Behavioral Measures of Short Term Memory, Learning, and Behavior in Children With Autism|Completed||Phase 1|30|Anticipated|Thoughtful House|||||f||||||||||||||2018-06-01 03:36:13.801061|2018-06-01 03:36:13.801061
NCT00406146|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2006-11-30|2006-11-30|2006-12-04|Estimate|||||||2006-11-30|2006-12-04|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|December 2006||2006-12-31|||||Interventional|||Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children||Unknown status|Active, not recruiting|Phase 3|||University of Ghana Medical School|||||f||||||||||||||2018-06-01 03:36:13.888172|2018-06-01 03:36:13.888172
NCT00406133|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2009-05-11||2017-03-03|2006-12-01|2006-12-04|Estimate|2009-07-20|2009-09-02|Estimate||||2017-03-03|2017-04-14|Actual|December 2006||2006-12-31|March 2017|2017-03-31|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes|A Randomized Clinical Trial to Assess the Efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) in the Management of Type 1 Diabetes|Completed||Phase 3|451|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 03:36:14.126044|2018-06-01 03:36:14.126044
NCT00406120|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2007-05-16|2006-11-29|2006-12-04|Estimate|||||||2007-05-16|2007-05-17|Estimate|January 2007||2007-01-31|May 2007|2007-05-31|December 2017|Anticipated|2017-12-31|||||Observational|||Validation of a Molecular Prognostic Test for Eye Melanoma|Validation of a Molecular Test for Predicting Metastasis in Patients With Uveal Melanoma|Withdrawn|||2000|Anticipated|Washington University School of Medicine||||It has come to our attention that the site was not necessary for our research project.|f||||||||||||||2018-06-01 03:36:16.611062|2018-06-01 03:36:16.611062
NCT00406107|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2013-01-30||2014-09-10|2006-12-01|2006-12-04|Estimate|2014-09-10|2014-09-12|Estimate||||2014-09-10|2014-09-12|Estimate|January 2006||2006-01-31|September 2014|2014-09-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion|Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion|Completed||Phase 4|20|Actual|Palmetto Retina Center, LLC||2|||f||||t||||||||||2018-06-01 03:36:16.774743|2018-06-01 03:36:16.774743
NCT00406094|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2009-01-15|2006-11-30|2006-12-04|Estimate|||||||2009-01-15|2009-01-16|Estimate|November 2006||2006-11-30|January 2009|2009-01-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)|The Evaluation of Singulair for the Treatment of Non-Allergic Rhinitis Eosinophil Syndrome (NARES)|Unknown status|Recruiting|Phase 4|6|Anticipated|Bernstein, Jonathan A., M.D.||2|||f||||||||||||||2018-06-01 03:36:17.234245|2018-06-01 03:36:17.234245
NCT00406081|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2017-01-10|2006-11-30|2006-12-04|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2005||2005-12-31|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Immune Response to Varicella Vaccination in Children With Atopic Dermatitis|Immune Response to Varicella Vaccination in Subjects With Atopic Dermatitis Compared to Nonatopic Controls (VAR 05)|Completed|||69|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||f||||||None Retained|"~     Blood collected for endpoint measurements.~   "|Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 03:36:17.337591|2018-06-01 03:36:17.337591
NCT00406068|ClinicalTrials.gov processed this data on May 31, 2018|2006-12-01||2013-08-28|2016-07-26|2006-12-01|2006-12-04|Estimate||||2013-08-28|2013-09-12|Estimate|2016-07-26|2016-07-28|Estimate|November 2006||2006-11-30|July 2016|2016-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer|Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG|Completed||Phase 2/Phase 3|129|Actual|Bioniche Life Sciences Inc.||1|||f||||t||||||||||2018-06-01 03:36:17.440572|2018-06-01 03:36:17.440572
NCT00406055|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2013-07-24|2006-11-30|2006-12-04|Estimate|||||||2013-07-24|2013-07-26|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||CHOICE: Carotid Stenting For High Surgical-Risk Patients|Carotid Stenting For High Surgical-Risk Patients; Evaluating Outcomes Through The Collection Of Clinical Evidence|Completed|||18855|Actual|Abbott Vascular|||1||f||||||||||||||2018-06-01 03:36:17.543499|2018-06-01 03:36:17.543499
NCT00406042|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2007-03-28|2006-11-29|2006-12-04|Estimate|||||||2007-03-28|2007-03-29|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|June 2006|Actual|2006-06-30|||||Interventional|||The Role of Steroids Following Selective Laser Trabeculoplasty|The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty|Completed||N/A|25||West Virginia University|||||f||||f||||||||||2018-06-01 03:36:17.703147|2018-06-01 03:36:17.703147
NCT00406029|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2016-09-28|2009-04-29|2016-12-15|2006-11-30|2006-12-04|Estimate|2016-12-15|2017-02-08|Estimate|2009-09-30|2009-10-01|Estimate|2016-12-15|2017-02-08|Estimate|November 2006||2006-11-30|December 2016|2016-12-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional||The Safety Population consisted of all participants who received at least one dose of study medication (either preladenant or placebo).|Dyskinesia in Parkinson's Disease (Study P04501)|A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias|Completed||Phase 2|253|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 03:36:18.111914|2018-06-01 03:36:18.111914
NCT00406016|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2011-11-02|2006-11-30|2006-12-04|Estimate|||||||2011-11-02|2011-11-04|Estimate|May 2006||2006-05-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI|A Multi-center, Open-label, Cohort Study to Assess Feasibility, Acute Safety, Tolerability and Pharmacokinetics of 4 Dose Regimens of Continuous Intrathecal ATI355 Infusion and Two Regimen of Repeated Intrathecal Bolus Injections in Acute Spinal Cord Injury Paraplegic and Tetraplegic Patients|Completed||Phase 1|52|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:36:23.136419|2018-06-01 03:36:23.136419
NCT00406003|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2017-09-27|2006-11-30|2006-12-04|Estimate|||||||2017-09-27|2017-09-29|Actual|March 24, 2006|Actual|2006-03-24|September 2017|2017-09-30|April 26, 2006|Actual|2006-04-26|April 26, 2006|Actual|2006-04-26||Interventional|||Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects|A Randomized, Open, Three-period Crossover Study to Compare the Pharmacokinetic Profile of Paroxetine After Single Dosing of Each Enteric-coated Geomatrix Control Release Tablet Strength (12.5, 25, 37.5mg) in Healthy Chinese Subjects|Completed||Phase 1|6|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 03:36:23.216523|2018-06-01 03:36:23.216523
NCT00405990|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|||2015-05-28|2006-11-30|2006-12-04|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||Male Partner Involvement in the Prevention of MTCT of HIV|Optimizing the Impact of Prevention of Mother to Child Transmission of HIV in South Africa: the Forgotten Half of the Equation.|Completed||Phase 4|1000|Anticipated|Imperial College London|||||f||||t||||||||||2018-06-01 03:36:23.288541|2018-06-01 03:36:23.288541
NCT00405977|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2011-09-15|2006-11-29|2006-12-04|Estimate|||||||2011-09-15|2011-09-19|Estimate|May 2006||2006-05-31|September 2011|2011-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|MagRoc||The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block|The Effect of Magnesium Sulphate on the Time Course of Rocuronium Induced Neuromuscular Block - A Randomised Electrophysiology Study|Completed||Phase 4|80|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-06-01 03:36:23.407608|2018-06-01 03:36:23.407608
NCT00405964|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30|2009-03-25||2017-03-15|2006-11-30|2006-12-04|Estimate|2010-10-22|2010-11-19|Estimate||||2017-03-15|2017-04-12|Actual|September 2006||2006-09-30|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)|Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)|Completed||Phase 3|716|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:36:23.70959|2018-06-01 03:36:23.70959
NCT00405951|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-30||2013-08-16|2016-07-19|2006-11-30|2006-12-04|Estimate||||2013-08-16|2013-08-26|Estimate|2016-07-19|2016-07-21|Estimate|October 2006||2006-10-31|July 2016|2016-07-31|September 2009|Actual|2009-09-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer|A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered Every 3 Weeks in Combination With Docetaxel to Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|47|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 03:36:24.113907|2018-06-01 03:36:24.113907
NCT00405938|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2013-01-11||2013-12-05|2006-11-28|2006-11-30|Estimate|2013-02-12|2013-02-15|Estimate||||2013-12-05|2013-12-31|Estimate|November 2006||2006-11-30|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer|A Phase II Trial of Open-Label Bevacizumab Administered With Anastrozole or Fulvestrant as First-Line Therapy in Postmenopausal Hormone Receptor- Positive Metastatic Breast Cancer (With Trastuzumab in HER2-Positive Patients)|Completed||Phase 2|79|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 03:36:24.219522|2018-06-01 03:36:24.219522
NCT00405925|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2010-05-31|2006-11-29|2006-11-30|Estimate|||||||2010-05-31|2010-06-02|Estimate|March 2003||2003-03-31|May 2010|2010-05-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||FREE Study: Efficacy and Toxicity of Trizivir|Free Study: a Randomised, Open Label, Multicentre Strategic Study to Evaluate the Efficacy and Toxicity of an Early Switch From a PI-containing Regimen to Trizivir ® on Guidance of Viral Load in HIV-1 Infected , Antiretroviral naïve Adults|Completed||Phase 3|207|Actual|Rijnstate Hospital||2|||f||||||||||||||2018-06-01 03:36:24.68083|2018-06-01 03:36:24.68083
NCT00405912|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2011-01-24||2011-04-15|2006-11-29|2006-11-30|Estimate|2011-03-16|2011-04-18|Estimate||||2011-04-15|2011-04-19|Estimate|September 2005||2005-09-30|April 2011|2011-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||St. John's Wort for Tobacco Cessation|St. John's Wort for Tobacco Cessation|Completed||Phase 2|118|Actual|Mayo Clinic||3|||f||||||||||||||2018-06-01 03:36:24.784463|2018-06-01 03:36:24.784463
NCT00405899|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2010-05-28|2006-11-28|2006-11-30|Estimate|||||||2010-05-28|2010-05-31|Estimate|October 2006||2006-10-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|||||Observational|||Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections|Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections|Completed|||20|Anticipated|West Penn Allegheny Health System|||2||f||||||||||||||2018-06-01 03:36:25.304132|2018-06-01 03:36:25.304132
NCT00405886|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2011-03-10|2006-11-29|2006-11-30|Estimate|||||||2011-03-10|2011-03-11|Estimate|October 2005||2005-10-31|March 2011|2011-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Neramexane for Tinnitus|A Randomised, Double-Blind, Placebo-Controlled, Clinical Dose-Ranging Trial to Evaluate Efficacy and Safety of a NMDA Antagonist for Oral Administration in Patients With Subjective Tinnitus|Completed||Phase 2|431|Actual|Merz Pharmaceuticals GmbH||4|||f||||f||||||||||2018-06-01 03:36:25.367119|2018-06-01 03:36:25.367119
NCT00405314|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2016-06-22|2006-11-29|2006-11-30|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2002||2002-07-31|June 2016|2016-06-30|March 2006||2006-03-31|||||Interventional|||Prehospital CPAP vs. Usual Care for Acute Respiratory Failure|Prehospital CPAP Versus Usual Care for Acute Respiratory Failure: a Randomized Controlled Trial|Completed||N/A|60||Dalhousie University|||||f||||||||||||||2018-06-01 03:36:38.571747|2018-06-01 03:36:38.571747
NCT00405834|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2008-07-01|2006-11-28|2006-11-30|Estimate|||||||2008-07-01|2008-07-04|Estimate|June 2007||2007-06-30|June 2007|2007-06-30|October 2007|Actual|2007-10-31|||||Observational|||A Pilot Study of the Envision® Surface|A Pilot Study of the Envision® Surface in a Patient Population at High Risk for or Who Have Pressure Ulcers: Evaluation of Pressure Ulcer Incidence, Changes in Existing Pressure Ulcers, Clinical Staff Satisfaction and Patient Comfort|Completed|||30|Actual|Hill-Rom|||||f||||f||||||||||2018-06-01 03:36:25.695705|2018-06-01 03:36:25.695705
NCT00405821|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2012-07-18||2012-08-28|2006-11-29|2006-11-30|Estimate|2012-08-28|2012-09-28|Estimate||||2012-08-28|2012-09-28|Estimate|November 2006||2006-11-30|August 2012|2012-08-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda|A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda|Completed||Phase 2|440|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 03:36:25.825686|2018-06-01 03:36:25.825686
NCT00405808|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2011-01-25|2006-11-28|2006-11-30|Estimate|||||||2011-01-25|2011-01-26|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|PRADO||Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose|A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities|Terminated||Phase 3|2666|Actual|Sanofi||2||EMEA recommendation to suspend Acomplia marketing authorisation|f||||||||||||||2018-06-01 03:36:26.288134|2018-06-01 03:36:26.288134
NCT00405795|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2008-07-01|2006-11-28|2006-11-30|Estimate|||||||2008-07-01|2008-07-04|Estimate|June 2007||2007-06-30|July 2008|2008-07-31|March 2008|Actual|2008-03-31|||||Observational|||Envision® Surface Evaluation|Envision® Surface Evaluation for Patients With Stage II, Stage III, or Stage IV Pressure Ulcers|Completed|||30|Actual|Hill-Rom|||||f||||f||||||||||2018-06-01 03:36:26.420549|2018-06-01 03:36:26.420549
NCT00405782|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2016-06-24|2006-11-28|2006-11-30|Estimate|||||||2016-06-24|2016-06-27|Estimate|August 2006||2006-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|August 2014|Actual|2014-08-31||Interventional|||Exercise Intervention in Women With Metastatic Breast Cancer|Pilot Study of a Moderate-Intensity Exercise Intervention in Women With Metastatic Breast Cancer|Completed||N/A|101|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 03:36:26.499455|2018-06-01 03:36:26.499455
NCT00405769|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2007-10-30|2006-11-29|2006-11-30|Estimate|||||||2007-10-30|2007-10-31|Estimate|January 2007||2007-01-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Lipid Lowering in Patients With Statin Intolerance|Alternative Lipid Lowering in Patients With Statin Intolerance: Use of Red Yeast Rice and Therapeutic Lifestyle Changes in a Randomized, Placebo-Controlled Trial|Completed||N/A|64|Actual|Chestnut Hill Health System||2|||f||||||||||||||2018-06-01 03:36:26.591633|2018-06-01 03:36:26.591633
NCT00405756|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2012-04-16||2016-11-21|2006-11-29|2006-11-30|Estimate|2012-04-16|2012-05-11|Estimate||||2016-11-21|2017-01-11|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|November 2009|Actual|2009-11-30||Interventional|||A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.|A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In Subjects With Newly Diagnosed Multiple Myeloma Who Are 65 Years Of Age Or Older|Completed||Phase 3|459|Actual|Celgene Corporation||3|||f||||t||||||||||2018-06-01 03:36:26.742739|2018-06-01 03:36:26.742739
NCT00405743|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29||2013-09-12|2013-09-12|2006-11-29|2006-11-30|Estimate||||2013-09-12|2013-09-18|Estimate|2013-09-12|2013-09-18|Estimate|May 2006||2006-05-31|September 2013|2013-09-30|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies|A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies|Completed||Phase 1/Phase 2|153|Actual|Clavis Pharma||2|||f||||f||||||||||2018-06-01 03:36:29.445285|2018-06-01 03:36:29.445285
NCT00405730|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2016-11-16|2006-11-29|2006-11-30|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2005||2005-11-30|April 2012|2012-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo|Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo (Nepafenac Vehicle) for the Prevention and Treatment of Ocular Inflammation and Ocular Pain Associated With Cataract Surgery: European Study|Completed||Phase 3|227|Actual|Alcon Research||3|||f||||f||||||||||2018-06-01 03:36:29.52543|2018-06-01 03:36:29.52543
NCT00405717|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2008-11-06|2006-11-29|2006-11-30|Estimate|||||||2008-11-06|2008-11-07|Estimate|February 2006||2006-02-28|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel|Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention|Completed||Phase 4|1300|Anticipated|Shenyang Northern Hospital|||||f||||||||||||||2018-06-01 03:36:29.603957|2018-06-01 03:36:29.603957
NCT00405704|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2014-12-04||2015-04-15|2006-11-29|2006-11-30|Estimate|2015-04-15|2015-04-16|Estimate||||2015-04-15|2015-04-16|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|RIVUR||Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)|Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)|Completed||Phase 3|607|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Results may not apply to children with different demographic or clinical characteristics or in locales where choice of TMP-SMZ may be limited by susceptibility patterns or clinical acceptability. Some subgroup analyses had limited statistical power.|2|||f||||t||||||||||2018-06-01 03:36:29.684054|2018-06-01 03:36:29.684054
NCT00405691|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2011-05-17|2006-11-29|2006-11-30|Estimate|||||||2011-05-17|2011-05-18|Estimate|September 2006||2006-09-30|January 2010|2010-01-31||||||||Interventional|||Safety and Effectiveness Study of the TOPS System, a Total Posterior Arthroplasty Implant Designed to Alleviate Pain Resulting From Moderate to Severe Lumbar Stenosis|A Prospective, Multi-Center Clinical Study to Assess the Saftey and Effectiveness of the Impliant TOPS System|Completed||Phase 3|450|Anticipated|Impliant, Ltd.|||||f||||t||||||||||2018-06-01 03:36:30.214959|2018-06-01 03:36:30.214959
NCT00405678|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2014-07-09|2006-11-29|2006-11-30|Estimate|||||||2014-07-09|2014-07-11|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Interventional|||Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.|The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study|Completed||Phase 1/Phase 2|23|Actual|Duke University||2|||f||||||||||||||2018-06-01 03:36:30.309999|2018-06-01 03:36:30.309999
NCT00405665|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2013-08-30|2006-11-28|2006-11-30|Estimate|||||||2013-08-30|2013-09-02|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis|Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis|Completed||Phase 2|20|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 03:36:30.487218|2018-06-01 03:36:30.487218
NCT00405652|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|2010-12-01||2011-02-08|2006-11-29|2006-11-30|Estimate|2011-02-08|2011-03-03|Estimate||||2011-02-08|2011-03-03|Estimate|January 2007||2007-01-31|February 2011|2011-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients|Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients (MyLiver)|Completed||Phase 3|34|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:36:30.565516|2018-06-01 03:36:30.565516
NCT00405639|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2014-02-04||2014-02-04|2006-11-29|2006-11-30|Estimate|2014-02-04|2014-03-17|Estimate||||2014-02-04|2014-03-17|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|April 2011|Actual|2011-04-30||Interventional|||Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function|To Define in Human Preclinical Systolic Dysfunction (PSD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal, and Humoral Function and on the Integrated Response to Acute Sodium Loading|Completed||Phase 1/Phase 2|37|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:36:30.745562|2018-06-01 03:36:30.745562
NCT00405626|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-11-29|2006-11-29|2006-11-30|Estimate|||||||2006-11-29|2006-11-30|Estimate|April 2007||2007-04-30|February 2006|2006-02-28|September 2007|Anticipated|2007-09-30|||||Interventional|||Double Blind Placebo Controlled Bellis Perenis and Arnica Montana as a Drug for PPH|Phase 2 Study of the Effect of Bellis Perenis and Arnica Montana on Post Partum Hemmorhage|Unknown status|Not yet recruiting|Phase 1|210|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:36:31.067365|2018-06-01 03:36:31.067365
NCT00405613|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-30|Estimate|||||||2006-11-28|2006-11-30|Estimate|May 2003||2003-05-31|November 2006|2006-11-30|December 2005||2005-12-31|||||Interventional|||Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population|Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population|Completed||Phase 2|36||Carolinas Healthcare System|||||f||||||||||||||2018-06-01 03:36:31.173435|2018-06-01 03:36:31.173435
NCT00405600|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2013-02-13|2006-11-28|2006-11-30|Estimate|||||||2013-02-13|2013-02-15|Estimate|November 2006||2006-11-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Spine Fusion Instrumented With BMP-2 vs Uninstrumented With Infuse BMP-2 Alone|A Prospective Randomized Clinical Investigation of Posterolateral Lumbosacral Spinal Fusions With BMP-2 and Titanium Pedicle Screw Instrumentation Versus BMP-2 Alone.|Completed||N/A|50|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-06-01 03:36:31.236273|2018-06-01 03:36:31.236273
NCT00405587|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2016-07-05||2017-08-18|2006-11-28|2006-11-30|Estimate|2017-08-18|2017-08-22|Actual||||2017-08-18|2017-08-22|Actual|November 2006||2006-11-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional||Intent-to-Treat (ITT) Population: All enrolled participants whether or not they fulfilled the eligibility criteria.|Safety Study of PLX4032 in Patients With Solid Tumors|A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX4032 in Patients With Solid Tumors|Completed||Phase 1|109|Actual|Plexxikon||1|||f||||f||||||||||2018-06-01 03:36:31.680395|2018-06-01 03:36:31.680395
NCT00405574|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2008-01-28|2006-11-29|2006-11-30|Estimate|||||||2008-01-28|2008-01-30|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|September 2008|Anticipated|2008-09-30|June 2008|Anticipated|2008-06-30||Interventional|||Study of ATN-224 in Patients With Prostate Cancer|A Randomized, Phase II Study of Two Dose Levels of ATN-224 in Patients With Biochemically Relapsed, Early Stage Prostate Cancer Not on Hormone Therapy|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Attenuon||2|||f||||||||||||||2018-06-01 03:36:35.958317|2018-06-01 03:36:35.958317
NCT00405561|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2013-03-19|2006-11-29|2006-11-30|Estimate|||||||2013-03-19|2013-03-20|Estimate|October 2006||2006-10-31|March 2013|2013-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003|A Prospective, Open, Single-Arm, Multicenter Phase II Clinical Trial to Evaluate the Progression Free Survival and Safety in Patients With Advanced Colorectal Carcinoma Treated With AMT2003|Terminated||Phase 2/Phase 3|67|Actual|Auron Healthcare GmbH||1||Lack of efficacy|f||||||||||||||2018-06-01 03:36:36.059324|2018-06-01 03:36:36.059324
NCT00405548|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2014-04-08||2015-06-03|2006-11-29|2006-11-30|Estimate|2014-04-08|2014-05-09|Estimate||||2015-06-03|2015-07-01|Estimate|March 2008||2008-03-31|June 2015|2015-06-30|August 2012|Actual|2012-08-31|April 2011|Actual|2011-04-30||Interventional|||Human Brain Natriuretic Peptide (BNP) (or Nesiritide) to Help Heart, Kidney and Humoral Function.|To Define in Human Preclinical Diastolic Dysfunction (PDD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal and Humoral Function and on the Integrated Response to Acute Sodium Loading|Completed||Phase 1/Phase 2|41|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:36:36.224785|2018-06-01 03:36:36.224785
NCT00405535|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2016-12-15|2006-11-28|2006-11-30|Estimate|||||||2016-12-15|2016-12-16|Estimate|June 2004||2004-06-30|December 2016|2016-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Adjunctive Glycine for Obsessive Compulsive Disorder|Adjunctive Glycine for Obsessive Compulsive Disorder|Completed||N/A|24|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-06-01 03:36:36.540525|2018-06-01 03:36:36.540525
NCT00405522|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2013-08-19|2006-11-28|2006-11-30|Estimate|||||||2013-08-19|2013-08-20|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children|Co-administration of Propofol and Remifentanil for Lumbar Puncture in Children: Evaluation of Two Dose Combinations|Completed||Phase 3|34|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 03:36:36.618534|2018-06-01 03:36:36.618534
NCT00405509|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2009-05-08||2016-07-20|2006-11-28|2006-11-30|Estimate|2014-09-24|2014-09-30|Estimate||||2016-07-20|2016-08-19|Estimate|October 2006||2006-10-31|July 2016|2016-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years|The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to <14 Years|Completed|||33|Actual|West Penn Allegheny Health System|Respiratory viruses were not detected in approximately 2/3 of the enrolled subjects. Future studies will need to apply more stringent inclusion/exclusion criteria to circumvent this problem.||2||f||||||||||Samples With DNA|"~     Buccal brushing for genotyping~   "|||2018-06-01 03:36:36.698316|2018-06-01 03:36:36.698316
NCT00405496|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2006-11-29|2006-11-29|2006-11-30|Estimate|||||||2006-11-29|2006-11-30|Estimate|March 2000||2000-03-31|November 2006|2006-11-30|April 2001||2001-04-30|||||Interventional|||Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis|Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Inluding Iritis, Cyclitis, Iridocyclitis, and Panuveitis).|Completed||Phase 2|24||Sirion Therapeutics, Inc.|||||f||||||||||||||2018-06-01 03:36:37.013506|2018-06-01 03:36:37.013506
NCT00405483|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2018-02-09|2006-11-28|2006-11-30|Estimate|||||||2018-02-09|2018-02-12|Actual|October 2005||2005-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|||RSA for a Comparison of MIS vs. Standard Exposure in Total Hip Arthroplasty|A Randomized Controlled Trial Utilizing RSA for a Comparison of Minimally Invasive Surgery (MIS) vs. Standard Exposure in Primary Total Hip Arthroplasty With the ProfemurZ Modular Femoral Stem|Active, not recruiting||N/A|100|Anticipated|Dalhousie University||2|||f||||f||||||||||2018-06-01 03:36:37.064984|2018-06-01 03:36:37.064984
NCT00405470|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2010-08-11|2006-11-28|2006-11-30|Estimate|||||||2010-08-11|2010-08-12|Estimate|July 2001||2001-07-31|August 2010|2010-08-31|June 2006|Actual|2006-06-30|June 2005|Actual|2005-06-30||Interventional|||A Prospective Randomized Trial Using Roentgen Stereophotogrammetric Analysis of the Advance Medial Pivot Knee|A Prospective Randomized Trial Using Roentgen Stereophotogrammetric Analysis of the Advance Medial Pivot Knee|Completed||N/A|80|Actual|Dalhousie University||2|||f||||f||||||||||2018-06-01 03:36:37.364537|2018-06-01 03:36:37.364537
NCT00405457|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2010-02-19|2006-11-28|2006-11-30|Estimate|||||||2010-02-19|2010-02-22|Estimate|November 2006||2006-11-30|February 2010|2010-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms|Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms|Completed||Phase 4|50|Anticipated|Innovative Medical||1|||f||||||||||||||2018-06-01 03:36:37.437112|2018-06-01 03:36:37.437112
NCT00405444|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2010-12-10|2006-11-28|2006-11-30|Estimate|||||||2010-12-10|2010-12-13|Estimate|November 2006||2006-11-30|December 2010|2010-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Intranasal Fentanyl Versus Placebo for Catheterization During a Voiding Cystourethrogram in Children|Intranasal Fentanyl Versus Placebo for Catheterization During a Voiding Cystourethrogram in Children|Completed||Phase 3|64|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 03:36:37.513781|2018-06-01 03:36:37.513781
NCT00405431|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2016-11-20|2006-11-28|2006-11-30|Estimate|||||||2016-11-20|2016-11-22|Estimate|March 2004||2004-03-31|November 2016|2016-11-30|November 2007|Actual|2007-11-30|June 2005|Actual|2005-06-30||Interventional|||Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?|Influence of Post-Operative Cyclosporine 0.05% (Restasis) on the Success of Glaucoma Filtering Surgery|Completed||N/A|43|Actual|Wills Eye||2|||f||||f||||||||Yes|manuscript has been published.|2018-06-01 03:36:37.61501|2018-06-01 03:36:37.61501
NCT00405418|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2009-09-14|2006-11-29|2006-11-30|Estimate|||||||2009-09-14|2009-09-15|Estimate|November 2006||2006-11-30|September 2009|2009-09-30||||June 2008|Actual|2008-06-30||Interventional|L2T3||Lantus Versus Levemir Treat-To-Target|Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.|Completed||Phase 4|973|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:36:37.703959|2018-06-01 03:36:37.703959
NCT00405405|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2016-10-19|2006-11-29|2006-11-30|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer|A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer|Completed||Phase 1|13|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:36:37.833992|2018-06-01 03:36:37.833992
NCT00405392|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2016-10-03|2006-11-29|2006-11-30|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2007||2007-03-31|October 2010|2010-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis|An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study|Completed||Phase 4|364|Anticipated|Hoffmann-La Roche|||||f||||||||||||||2018-06-01 03:36:37.91875|2018-06-01 03:36:37.91875
NCT00405379|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2008-04-08|2006-11-28|2006-11-30|Estimate|||||||2008-04-08|2008-04-10|Estimate|July 2002||2002-07-31|April 2008|2008-04-30|February 2007|Actual|2007-02-28|August 2006|Actual|2006-08-31||Interventional|||Trabecular Metal Mesh Tibial Monoblock RSA|"A Prospective Randomized Controlled Trial Using Roentgen Stereophotogrammetric Analysis of Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty Component TMM."|Completed||N/A|67|Actual|Dalhousie University|||||f||||f||||||||||2018-06-01 03:36:38.092342|2018-06-01 03:36:38.092342
NCT00405366|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2017-04-17|2006-11-29|2006-11-30|Estimate|||||||2017-04-17|2017-04-18|Actual|November 2006||2006-11-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|June 2009|Actual|2009-06-30||Interventional|NRR||Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer|A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate for Patients With Stage II or Greater Renal Cell Carcinoma|Completed||Early Phase 1|30|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:36:38.151775|2018-06-01 03:36:38.151775
NCT00405353|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2013-07-11|2006-11-29|2006-11-30|Estimate|||||||2013-07-11|2013-07-12|Estimate|April 2002||2002-04-30|November 2006|2006-11-30|March 2004||2004-03-31|||||Observational|||Testosterone Treatment for Multiple Sclerosis|Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial|Completed|||10||University of California, Los Angeles|||||f||||||||||||||2018-06-01 03:36:38.243985|2018-06-01 03:36:38.243985
NCT00405340|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2015-10-23|2006-11-29|2006-11-30|Estimate|||||||2015-10-23|2015-10-27|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|April 2012|Actual|2012-04-30|July 2010|Actual|2010-07-31||Interventional|||Rituximab in the Treatment of Idiopathic Membranous Nephropathy|Rituximab in the Treatment of Idiopathic Membranous Nephropathy|Completed||Early Phase 1|20|Actual|Mayo Clinic||1|||f||||||||||||||2018-06-01 03:36:38.376863|2018-06-01 03:36:38.376863
NCT00405327|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29||2015-06-29|2017-11-02|2006-11-29|2006-11-30|Estimate||||2015-09-11|2015-09-30|Estimate|2017-11-02|2017-11-06|Actual|June 2006||2006-06-30|November 2017|2017-11-30|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation|A Pilot Study of Tumor Lysate-pulsed Dendritic Cell Vaccine for Immune Augmentation for High-risk Solid Tumor Patients Following Autologous Stem Cell Transplantation|Completed||Phase 2|16|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 03:36:38.48746|2018-06-01 03:36:38.48746
NCT00405301|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2012-02-14|2006-11-29|2006-11-30|Estimate|||||||2012-02-14|2012-02-16|Estimate|December 2006||2006-12-31|February 2012|2012-02-29|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage|Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity|Completed||Phase 4|175|Actual|All India Institute of Medical Sciences, New Delhi||3|||f||||f||||||||||2018-06-01 03:36:38.644562|2018-06-01 03:36:38.644562
NCT00405288|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2013-08-16||2014-01-03|2006-11-28|2006-11-30|Estimate|2014-01-03|2014-02-05|Estimate||||2014-01-03|2014-02-05|Estimate|November 2006||2006-11-30|January 2014|2014-01-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Observational|||The Safety of Proctofoam-HC in the Third Trimester of Pregnancy|The Safety of Proctofoam-HC in the Third Trimester of Pregnancy|Completed|||408|Actual|The Hospital for Sick Children|||2||f||||t||||||||||2018-06-01 03:36:38.763115|2018-06-01 03:36:38.763115
NCT00405275|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|2013-06-05||2013-11-07|2006-11-29|2006-11-30|Estimate|2013-11-07|2013-12-03|Estimate||||2013-11-07|2013-12-03|Estimate|July 2007||2007-07-31|November 2013|2013-11-30|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|RACAT||Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy|CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy|Completed||N/A|353|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:36:39.649589|2018-06-01 03:36:39.649589
NCT00405262|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2013-08-19|2006-11-28|2006-11-30|Estimate|||||||2013-08-19|2013-08-20|Estimate|May 2006||2006-05-31|August 2013|2013-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Comparison of Bupivacaine and Ketorolac for Postoperative Analgesia After Iliac Crest Bone Harvesting|The Effectiveness of Bupivicaine Infusion Versus Intravenous Ketorolac for Postoperative Analgesia After Iliac Crest Bone Harvesting for Lefort I Osteotomy or Alveolar Cleft Repair.|Completed||Phase 3|54|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-06-01 03:36:40.292616|2018-06-01 03:36:40.292616
NCT00405249|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-29|||2009-02-03|2006-11-29|2006-11-30|Estimate|||||||2009-02-03|2009-02-04|Estimate|September 2006||2006-09-30|February 2009|2009-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety Study of Elvucitabine in HIV-1 Subjects|14-Day Randomized Double-Blind Comparative Viral Kinetic Study of Elvucitabine Versus Lamivudine Once Daily to HIv-1 Subjects With M184V|Completed||Phase 2|5|Anticipated|Thomas Jefferson University|||||f||||||||||||||2018-06-01 03:36:40.386758|2018-06-01 03:36:40.386758
NCT00405236|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2006-11-27|2006-11-27|2006-11-29|Estimate|||||||2006-11-27|2006-11-29|Estimate|October 2002||2002-10-31|November 2006|2006-11-30|January 2005||2005-01-31|||||Interventional|||Effect of Tiotropium on Inflammation and Exacerbations in COPD|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Changes in Inflammatory Markers in Induced Sputum Following Treatment With Tiotropium Inhalation Capsules 18mcg Once Daily in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|220||Royal Free and University College Medical School|||||f||||||||||||||2018-06-01 03:36:40.440446|2018-06-01 03:36:40.440446
NCT00405210|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2011-05-20|2006-11-28|2006-11-29|Estimate|||||||2011-05-20|2011-05-23|Estimate|September 2006||2006-09-30|May 2011|2011-05-31|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional|||Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer|Open-label, Multicenter,PhaseI Trial in Order To Determine the Safety and Pharmacokinetics of BAY43-9006 in Combination With Docetaxel as First-line Treatment in Metastatic Hormone Refractory Prostate Cancer Patients|Completed||Phase 1|38|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-06-01 03:36:40.520116|2018-06-01 03:36:40.520116
NCT00405197|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2007-12-10|2006-11-28|2006-11-29|Estimate|||||||2007-12-10|2007-12-12|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||MARIS Study; Mediterranean Approach to Reduce Insulin-Resistance Study|Study on the Effect of Mono-Unsaturated Fatty Acids (MUFA) and the Mediterranean Diet on Hyperinsulinemia and Other Components of the Metabolic Syndrome|Completed||N/A|60|Anticipated|Wageningen University|||||f||||||||||||||2018-06-01 03:36:40.61608|2018-06-01 03:36:40.61608
NCT00405184|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2012-06-05|2006-11-27|2006-11-29|Estimate|||||||2012-06-05|2012-06-07|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)|A Multi-centre, Open-label, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of Ig NextGen 10% With Intragam P in Patients With Primary Immune Deficiency (PID)|Completed||Phase 3|19|Actual|CSL Limited|||||f||||f||||||||||2018-06-01 03:36:40.69827|2018-06-01 03:36:40.69827
NCT00405171|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2010-10-27|2006-11-27|2006-11-29|Estimate|||||||2010-10-27|2010-10-28|Estimate|June 2003||2003-06-30|October 2010|2010-10-31|February 2006||2006-02-28|||||Interventional|||Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia|Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study|Completed||Phase 4|40||University Hospital, Caen|||||f||||||||||||||2018-06-01 03:36:40.800186|2018-06-01 03:36:40.800186
NCT00405158|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-30|2006-11-28|2006-11-29|Estimate|||||||2006-11-30|2006-12-04|Estimate|January 2002||2002-01-31|November 2006|2006-11-30|March 2004||2004-03-31|||||Interventional|||Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding|A RCT in Sweden of Acupuncture and Care Interventions for the Relief of Inflammatory Symptoms of the Breast During Lactation|Completed||N/A|210||Karlstad University|||||f||||||||||||||2018-06-01 03:36:40.962545|2018-06-01 03:36:40.962545
NCT00405145|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|July 2006||2006-07-31|November 2006|2006-11-30|July 2011||2011-07-31|||||Observational|||Mapping of the Epileptic Brain|Mapping of the Eloquent Cortex and of Epileptic Networks Using Functional Magnetic Resonance Imaging and Electroencephalography in Epileptic Patients|Unknown status|Recruiting||400||University Hospital, Grenoble|||||f||||||||||||||2018-06-01 03:36:41.039944|2018-06-01 03:36:41.039944
NCT00405119|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2017-01-18|2006-11-27|2006-11-29|Estimate|||||||2017-01-18|2017-01-19|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.|A Randomized, Double-blind, Four Period Cross-over Comparison of the Effect of Two Doses Lavoltidine, Esomeprazole, and Placebo on 24 Hour Gastric pH and Frequency of Heartburn in Symptomatic GERD Subjects Without Esophageal Erosions|Completed||Phase 2|92|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:36:41.096559|2018-06-01 03:36:41.096559
NCT00405106|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|December 2005||2005-12-31|May 2004|2004-05-31|May 2006||2006-05-31|||||Observational|||The Effect of Final Exam Preparation on Anxiety Level, Self-Perception, Ocular Symptoms, Accommodation and Vergence in Myopia||Completed|||25||Southern California College of Optometry|||||f||||||||||||||2018-06-01 03:36:41.166334|2018-06-01 03:36:41.166334
NCT00405093|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2017-01-17|2006-11-28|2006-11-29|Estimate|||||||2017-01-17|2017-01-19|Estimate|July 2006||2006-07-31|January 2017|2017-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.|Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta. A Retrospective Study.|Completed|||1250|Actual|Weill Medical College of Cornell University|||||f||||f||||||||No||2018-06-01 03:36:41.238688|2018-06-01 03:36:41.238688
NCT00405080|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2017-09-11|2006-11-27|2006-11-29|Estimate|||||||2017-09-11|2017-09-12|Actual|November 11, 2006|Actual|2006-11-11|September 2017|2017-09-30|January 5, 2007|Actual|2007-01-05|January 5, 2007|Actual|2007-01-05||Interventional|||A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).|An Open-Label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of [Rifampin] on the Pharmacokinetics of a Single Oral Dose of [GW679769]|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:36:41.30088|2018-06-01 03:36:41.30088
NCT00405067|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2013-01-18||2014-01-15|2006-11-28|2006-11-29|Estimate|2014-01-15|2014-03-04|Estimate||||2014-01-15|2014-03-04|Estimate|May 2006||2006-05-31|January 2014|2014-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia|A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia|Completed||Phase 2|60|Actual|Aegerion Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 03:36:41.44478|2018-06-01 03:36:41.44478
NCT00405054|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2015-01-23|2006-11-28|2006-11-29|Estimate|||||||2015-01-23|2015-01-26|Estimate|December 2006||2006-12-31|January 2015|2015-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)|A Phase II Study of MK0457 in Patients With T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Terminated||Phase 2|52|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 03:36:42.029438|2018-06-01 03:36:42.029438
NCT00405041|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2008-04-08|2006-11-28|2006-11-29|Estimate|||||||2008-04-08|2008-04-10|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Randomized Controlled Study to Assess the Efficacy of a Dietary Ingredient in Patients With Herniated Lumbar Disc Compression|A Two-Center, Phase II/III, Randomized, Double-Blind, Placebo-Controlled, Study, to Assess the Therapeutic Efficacy of a Dietary Ingredient in Patients With Herniated Lumbar Disc Causing Nerve Root Compression|Completed||Phase 2/Phase 3|79|Actual|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-06-01 03:36:42.112066|2018-06-01 03:36:42.112066
NCT00405015|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2010-08-23|2006-11-28|2006-11-29|Estimate|||||||2010-08-23|2010-08-24|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.|The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy. A Double Blind Placebo- Controlled Cross-over Study in Subjects With the Metabolic Syndrome|Completed||Phase 2|13|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 03:36:42.19868|2018-06-01 03:36:42.19868
NCT00405002|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2011-11-30|2006-11-27|2006-11-29|Estimate|||||||2011-11-30|2011-12-01|Estimate|November 2006||2006-11-30|November 2011|2011-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||A Validation Study of a New System for Measuring the End Expiratory Lung Volume During Mechanical Ventilation|A Validation Study of a New System for Measuring the End Expiratory Lung Volume During Mechanical Ventilation Acute in Intubated Patients|Completed|||30|Actual|Policlinico Hospital|||1||f||||f||||||||||2018-06-01 03:36:42.292865|2018-06-01 03:36:42.292865
NCT00404989|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2017-07-03|2006-11-28|2006-11-29|Estimate|||||||2017-07-03|2017-07-06|Actual|January 1989||1989-01-31|July 2017|2017-07-31|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Observational|APR||Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.|Antiretroviral Pregnancy Registry|Recruiting|||1600|Anticipated|INC Research|||||f||||t||||||||||2018-06-01 03:36:42.357525|2018-06-01 03:36:42.357525
NCT00404976|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|June 2004||2004-06-30|November 2003|2003-11-30|April 2005||2005-04-30|||||Observational|||Inflammatory Markers in Exhaled Breath (Condensate) in Childhood Asthma|Biomarkers in Exhaled Breath (Condensate) Indicate Presence, Severity and Control of Asthma|Completed|||100||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:36:42.431339|2018-06-01 03:36:42.431339
NCT00404963|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2017-01-18|2006-11-27|2006-11-29|Estimate|||||||2017-01-18|2017-01-19|Estimate|October 2006||2006-10-31|January 2017|2017-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects|A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study With Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability of a Tablet Formulation Compared to the Powder for Reconstitution Formulation in Healthy Overweight and Obese Subjects (DIX109177)|Completed||Phase 1|72|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:36:42.486538|2018-06-01 03:36:42.486538
NCT00404950|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2017-02-02|2006-11-28|2006-11-29|Estimate|||||||2017-02-02|2017-02-06|Estimate|July 2005|Actual|2005-07-31|February 2017|2017-02-28|July 2012|Actual|2012-07-31|October 2010|Actual|2010-10-31||Observational|||Effects of Hyperglycemia During Cardiopulmonary Bypass on Renal Function|Effects of Hyperglycemia During Cardiopulmonary Bypass on Renal Function|Completed|||200|Actual|Weill Medical College of Cornell University|||||f||||f||||||Samples Without DNA|"~     At the following times when plasma glucose will be measured, an additional 6 mL of blood will~     be drawn (from indwelling routine arterial line catheter) into EDTA tubes and immediately~     centrifuged: baseline following induction, once during cardiopulmonary bypass, at arrival in~     the intensive care unit, and the morning after surgery- totaling 24 mls of blood. The~     platelet rich plasma will be withdrawn and one half of the volume immediately frozen for~     subsequent HPLC measurement of BH2 and BH4. The remaining plasma will be subjected to~     progressive centrifugation steps in order to concentrate the platelet fraction that will then~     be suspended in buffer and frozen. VASP expression and phosphorylation will be determined by~     Western blot.~   "|No|Will not share|2018-06-01 03:36:42.610981|2018-06-01 03:36:42.610981
NCT00404937|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2012-03-03|2006-11-28|2006-11-29|Estimate|||||||2012-03-03|2012-03-06|Estimate|December 2006||2006-12-31|September 2007|2007-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle|Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle|Withdrawn||Phase 3|0|Actual|Alcon Research|||||f||||||||||||||2018-06-01 03:36:42.681076|2018-06-01 03:36:42.681076
NCT00404924|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2011-04-27||2016-08-24|2006-11-28|2006-11-29|Estimate|2012-02-22|2012-03-26|Estimate||||2016-08-24|2016-09-30|Estimate|November 2006||2006-11-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|October 2009|Actual|2009-10-31||Interventional|||ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures|A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive Care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer After Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)|Completed||Phase 3|1140|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:36:42.760494|2018-06-01 03:36:42.760494
NCT00404911|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2013-06-21|2006-11-28|2006-11-29|Estimate|||||||2013-06-21|2013-06-25|Estimate|October 2006||2006-10-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth|Family Groups to Reduce Youth Behavioral Difficulties|Completed||N/A|416|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 03:36:43.656953|2018-06-01 03:36:43.656953
NCT00404898|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2017-11-20|2006-11-28|2006-11-29|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2007||2007-12-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||NYU/Bellevue WTC Health Impacts Research Registry|NYU/Bellevue Red Cross WTC Health Impacts Research Registry|Recruiting|||7000|Anticipated|New York University School of Medicine|||||f||||||||||||||2018-06-01 03:36:43.814422|2018-06-01 03:36:43.814422
NCT00404885|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2012-06-21|2006-11-27|2006-11-29|Estimate|||||||2012-06-21|2012-06-22|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|LUMINATE||A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis|A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis|Completed||Phase 3|108|Actual|Lux Biosciences, Inc.||4|||f||||t||||||||||2018-06-01 03:36:43.913825|2018-06-01 03:36:43.913825
NCT00404872|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2014-04-10|2006-11-27|2006-11-29|Estimate|||||||2014-04-10|2014-04-14|Estimate|January 1989||1989-01-31|April 2014|2014-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Evaluating the Relationship Between Fatty Acids and Heart Disease|n-3 and Trans Fatty Acids and Major Cardiovascular Outcomes|Completed|||4766||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 03:36:44.073152|2018-06-01 03:36:44.073152
NCT00404859|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-30|2006-11-28|2006-11-29|Estimate|||||||2006-11-30|2006-12-04|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|June 2007||2007-06-30|||||Observational|||FLAME: Airway Inflammation Monitoring in Asthma and Cystic Fibrosis|Monitoring Chronic Airway Inflammation in Children With Asthma and Cystic Fibrosis|Completed|||70||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:36:44.155694|2018-06-01 03:36:44.155694
NCT00404846|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2009-05-01|2006-11-27|2006-11-29|Estimate|||||||2009-05-01|2009-05-05|Estimate|November 2006||2006-11-30|May 2009|2009-05-31|December 2007|Anticipated|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Effects of Hyperbaric Oxygenation Therapy on Adaptive, Aberrant and Stereotyped Behaviors in Children With Autism||Unknown status|Active, not recruiting|N/A|40|Anticipated|The Center for Autism and Related Disorders|||||f||||||||||||||2018-06-01 03:36:44.229673|2018-06-01 03:36:44.229673
NCT00404833|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2013-10-22|2006-11-28|2006-11-29|Estimate|||||||2013-10-22|2013-10-23|Estimate|January 2003||2003-01-31|October 2013|2013-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental|A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)|Completed||Phase 3|16|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:36:44.294615|2018-06-01 03:36:44.294615
NCT00404820|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2011-01-05||2011-06-06|2006-11-28|2006-11-29|Estimate|2011-06-06|2011-07-01|Estimate||||2011-06-06|2011-07-01|Estimate|October 2006||2006-10-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ROSE||Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis|A Multi-center, Randomized, Open-label, Controlled, One-year Trial to Measure the Effect of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteopenia and Osteoporosis|Completed||Phase 3|604|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:36:44.389397|2018-06-01 03:36:44.389397
NCT00404807|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|January 2001||2001-01-31|November 2006|2006-11-30|June 2004||2004-06-30|||||Interventional|||Cardiac Function After CPAP Therapy in Patients With Chronic Heart Failure and Sleep Apnea. A Multicenter Study|Cardiac Function After CPAP Therapy in Patients With Chronic Heart Failure and Sleep Apnea. A Multicenter Study|Terminated||N/A|245||Sociedad Española de Neumología y Cirugía Torácica|||||f||||||||||||||2018-06-01 03:36:44.956499|2018-06-01 03:36:44.956499
NCT00404794|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2013-10-22|2006-11-27|2006-11-29|Estimate|||||||2013-10-22|2013-10-23|Estimate|November 2005||2005-11-30|October 2013|2013-10-31|October 2009|Actual|2009-10-31|||||Interventional|||A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis|A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis|Completed||Phase 3|20|Anticipated|Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:36:45.0123|2018-06-01 03:36:45.0123
NCT00404781|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2009-10-13|2006-11-28|2006-11-29|Estimate|||||||2009-10-13|2009-10-14|Estimate|June 2006||2006-06-30|October 2009|2009-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention|Pilot Study of Personal Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes|Completed||Phase 4|305|Actual|Shenyang Northern Hospital||2|||f||||t||||||||||2018-06-01 03:36:45.069169|2018-06-01 03:36:45.069169
NCT00404768|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|2017-10-02|2012-02-16|2017-12-18|2006-11-27|2006-11-29|Estimate|2017-11-16|2017-12-13|Actual|2012-02-16|2012-02-20|Estimate|2017-12-18|2018-01-16|Actual|October 12, 2007|Actual|2007-10-12|December 2017|2017-12-31|July 7, 2011|Actual|2011-07-07|July 7, 2011|Actual|2011-07-07||Interventional|||The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor|A Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK221149A Administered Intravenously and to Investigate the Pharmacokinetics of GSK221149A Administered Orally to Healthy, Pregnant Females With Uncomplicated Pre-term Labor Between 300/7 and 356/7 Weeks' Gestation|Completed||Phase 2|93|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:36:45.223198|2018-06-01 03:36:45.223198
NCT00404755|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2014-08-20||2018-03-29|2006-11-28|2006-11-29|Estimate|2018-02-15|2018-03-15|Actual||||2018-03-29|2018-04-30|Actual|July 2006||2006-07-31|March 2018|2018-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Dichotic Listening as a Predictor of Medication Response in Depression|Dichotic Listening as a Predictor of Medication Response in Depression|Completed||Phase 4|17|Actual|New York State Psychiatric Institute|This is an open (i.e., unblinded) study having small sample size|3|||f||||f||||||||No||2018-06-01 03:36:46.384435|2018-06-01 03:36:46.384435
NCT00404742|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2012-06-21|2006-11-27|2006-11-29|Estimate|||||||2012-06-21|2012-06-22|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|LUMINATE||A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis|A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis|Completed||Phase 3|232|Actual|Lux Biosciences, Inc.||4|||f||||t||||||||||2018-06-01 03:36:46.576639|2018-06-01 03:36:46.576639
NCT00404729|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|February 2005||2005-02-28|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases|Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases|Completed||Phase 4|60||Fondazione G.B. Bietti, IRCCS|||||f||||||||||||||2018-06-01 03:36:46.682185|2018-06-01 03:36:46.682185
NCT00404716|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|December 2004||2004-12-31|November 2006|2006-11-30|February 2007||2007-02-28|||||Interventional|||Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation|Effects of Triple Versus Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Undergoing Coronary Stent Implantation|Completed||Phase 4|||Shenyang Northern Hospital|||||f||||||||||||||2018-06-01 03:36:47.780093|2018-06-01 03:36:47.780093
NCT00404703|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2016-08-23|2006-11-28|2006-11-29|Estimate|||||||2016-08-23|2016-08-24|Estimate|August 2006||2006-08-31|August 2008|2008-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer|An Open Label Study of the Safety of First-line Treatment With Avastin in Combination With Cisplatin-gemcitabine or Carboplatin-paclitaxel in Patients With Advanced or Recurrent Squamous Non-small Cell Lung Cancer, Who Are Considered to be at High Risk of Pulmonary Haemorrhage|Terminated||Phase 2|37|Actual|Hoffmann-La Roche||1||Primary (safety) endpoint reached|f||||||||||||||2018-06-01 03:36:47.840673|2018-06-01 03:36:47.840673
NCT00404690|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2016-01-27|2006-11-28|2006-11-29|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2006||2006-10-31|January 2016|2016-01-31|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||Bedside Silo Versus Operative Closure for Gastroschisis|Bedside Silo Versus Attempted Operative Closure for Gastroschisis: A Pilot Study|Terminated||N/A|20|Anticipated|Children's Mercy Hospital Kansas City||2||Change in referral pattern changed the population we were studying|f||||f||||||||No||2018-06-01 03:36:47.939929|2018-06-01 03:36:47.939929
NCT00404677|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2008-01-18|2006-11-27|2006-11-29|Estimate|||||||2008-01-18|2008-01-23|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||The Correlation Between Airway Inflammation and Loss of Deep Inhalation Bronchoprotection in Asthmatics|The Correlation Between Airway Inflammation and Loss of Deep Inhalation Bronchoprotection in Asthmatics|Completed||N/A|18|Actual|University of Saskatchewan||2|||f||||||||||||||2018-06-01 03:36:48.013295|2018-06-01 03:36:48.013295
NCT00404664|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|September 2004||2004-09-30|November 2006|2006-11-30|April 2005||2005-04-30|||||Interventional|||Improving Influenza Vaccination Rates Among Health Care Professionals|A Novel Approach To Improve Influenza Vaccination Rates Among Health Care Professionals: A Prospective Randomized Controlled Trial|Completed||N/A|800||The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:36:48.079973|2018-06-01 03:36:48.079973
NCT00404651|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|2014-02-14||2014-04-11|2006-11-28|2006-11-29|Estimate|2014-04-11|2014-05-09|Estimate||||2014-04-11|2014-05-09|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants|Lot to Lot Consistency Study of DTaP-IPV-Hep B-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Mexican Infants|Completed||Phase 3|1189|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 03:36:48.168429|2018-06-01 03:36:48.168429
NCT00404638|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|December 2006||2006-12-31|November 2006|2006-11-30||||||||Interventional|||Treatment of Enuresis Nocturna by Circular Muscle Exercise (Paula Method)|Treatment of Enuresis Nocturna by Circular Muscle Exercise (Paula Method)|Unknown status|Not yet recruiting|N/A|40||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:36:49.077401|2018-06-01 03:36:49.077401
NCT00404625|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2006-11-28|2006-11-28|2006-11-29|Estimate|||||||2006-11-28|2006-11-29|Estimate|October 2006||2006-10-31|November 2006|2006-11-30|November 2006||2006-11-30|||||Observational|||Infections Caused by ESbL-Producing Enterobacteriaceae in Italy|Infections Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases in Italy: Molecular Epidemiology, Clinical Impact, Treatment Outcome and Risk Factors|Unknown status|Recruiting||813||University of Siena|||||f||||||||||||||2018-06-01 03:36:49.139274|2018-06-01 03:36:49.139274
NCT00404612|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2012-10-09|2006-11-27|2006-11-29|Estimate|||||||2012-10-09|2012-10-11|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|LUMINATE||A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis|A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis|Completed||Phase 3|218|Actual|Lux Biosciences, Inc.||4|||f||||t||||||||||2018-06-01 03:36:49.245546|2018-06-01 03:36:49.245546
NCT00404599|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2008-06-09|2006-11-27|2006-11-29|Estimate|||||||2008-06-09|2008-06-10|Estimate|February 2007||2007-02-28|June 2008|2008-06-30|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Interventional|SOS||Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.|A Randomised, Double Blind, Parallel-Group Study of the Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.|Unknown status|Recruiting|Phase 4|60|Anticipated|VU University Medical Center|||||f||||t||||||||||2018-06-01 03:36:49.365029|2018-06-01 03:36:49.365029
NCT00368823|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2006-08-24|2006-08-24|2006-08-29|Estimate|||||||2006-08-24|2006-08-29|Estimate|November 1999||1999-11-30|August 2006|2006-08-31|December 2003||2003-12-31|||||Interventional|||A Trial of Point of Care Information in Ambulatory Pediatrics|A Randomized Clinical Trial to Improve Prescribing Patterns in Ambulatory Pediatrics|Completed||Phase 3|44||University of Washington|||||f||||||||||||||2018-06-01 03:48:57.510606|2018-06-01 03:48:57.510606
NCT00404586|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2017-09-11|2006-11-27|2006-11-29|Estimate|||||||2017-09-11|2017-09-12|Actual|September 11, 2006|Actual|2006-09-11|September 2017|2017-09-30|January 16, 2007|Actual|2007-01-16|January 16, 2007|Actual|2007-01-16||Interventional|||Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber|A Randomised, Placebo-controlled, 4-period, Incomplete Block, Crossover Study of 7 Days Dosing of Intranasal GW784568X (100mcg, 200mcg and 400mcg od), Fluticasone Propionate (200mcg od) and Placebo (Blinded for GW784568X vs Placebo) to Evaluate the Efficacy and Safety Using an Environmental Chamber in Male Subjects With Allergic Rhinitis|Completed||Phase 1|45|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:36:49.517418|2018-06-01 03:36:49.517418
NCT00404573|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2008-01-03|2006-11-27|2006-11-29|Estimate|||||||2008-01-03|2008-01-07|Estimate|November 2006||2006-11-30|January 2008|2008-01-31||||August 2007|Actual|2007-08-31||Interventional|||Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia|Completed||Phase 2|375|Anticipated|Forest Laboratories|||||||||||||||||||2018-06-01 03:36:49.607588|2018-06-01 03:36:49.607588
NCT00404560|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-28|||2018-03-27|2006-11-28|2006-11-29|Estimate|||||||2018-03-27|2018-03-29|Actual|November 27, 2006||2006-11-27|March 15, 2018|2018-03-15||||||||Observational|||Detection and Characterization of Infections and Infection Susceptibility|Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:36:49.688869|2018-06-01 03:36:49.688869
NCT00404547|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|2010-03-08|2009-11-19|2016-12-02|2006-11-27|2006-11-28|Estimate|2010-03-08|2010-03-26|Estimate|2010-03-08|2010-03-26|Estimate|2016-12-02|2017-02-01|Estimate|November 2006||2006-11-30|September 2016|2016-09-30|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)|An Open-Label Randomized, Multicenter Study in Patients With Asthma to Evaluate the Effectiveness of Alvesco® (Ciclesonide) Compared to Asthma Usual Care in a Primary Practice Setting|Completed||Phase 4|1121|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:36:49.860632|2018-06-01 03:36:49.860632
NCT00404534|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2018-02-27|2006-11-27|2006-11-28|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2006||2006-10-31|March 2010|2010-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|HEROES-12||Helicobacter Eradication Relief of Dyspeptic Symptoms|Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up|Completed||Phase 3|407|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-06-01 03:36:50.543725|2018-06-01 03:36:50.543725
NCT00404521|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2014-03-25|2006-11-27|2006-11-28|Estimate|||||||2014-03-25|2014-03-26|Estimate|August 2005||2005-08-31|March 2014|2014-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors|A Phase I Single-institution, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.|Terminated||Phase 1|56|Actual|PharmaMar||1||Low rate recruitment|f||||f||||||||||2018-06-01 03:36:50.652708|2018-06-01 03:36:50.652708
NCT00404508|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-25|||2006-11-27|2006-11-27|2006-11-28|Estimate|||||||2006-11-27|2006-11-28|Estimate|September 2005||2005-09-30|November 2006|2006-11-30|October 2006||2006-10-31|||||Interventional|||A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors|A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors|Completed||Phase 2|15||National Institute of Cancerología|||||f||||||||||||||2018-06-01 03:36:50.739837|2018-06-01 03:36:50.739837
NCT00404495|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|2012-01-13||2012-04-16|2006-11-27|2006-11-28|Estimate|2012-01-13|2012-02-17|Estimate||||2012-04-16|2012-04-18|Estimate|April 2007||2007-04-30|April 2012|2012-04-30|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Combination of Irinotecan and Temozolomide in Children With Brain Tumors.|Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.|Completed||Phase 2|83|Actual|Pfizer|This study had one treatment arm but two distinct cohorts with different diagnostics and treatment durations.|1|||f||||f||||||||||2018-06-01 03:36:50.918532|2018-06-01 03:36:50.918532
NCT00404482|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2009-06-02|2006-11-27|2006-11-28|Estimate|||||||2009-06-02|2009-06-03|Estimate|January 1991||1991-01-31|June 2009|2009-06-30|August 2006||2006-08-31|||||Observational|||Cyclosporine A in the Treatment of Juvenile Idiopathic Arthritis (JIA) Associated Chronic Anterior Uveitis|Efficacy and Adverse Effects of Cyclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis|Completed|||60||St. Franziskus Hospital|||||f||||||||||||||2018-06-01 03:36:51.762786|2018-06-01 03:36:51.762786
NCT00404469|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2008-05-21|2006-11-27|2006-11-28|Estimate|||||||2008-05-21|2008-05-22|Estimate|March 2006||2006-03-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|||||Interventional|||Effects of Peritendinous Corticosteroid Injections, Eccentric Training and Heavy Slow Resistance Training in Patellar Tendinopathy|Effects of Peritendinous Corticosteroid Injections, Eccentric Training and Heavy Slow Resistance Training in Patellar Tendinopathy|Completed||N/A|39|Actual|Bispebjerg Hospital||3|||f||||||||||||||2018-06-01 03:36:51.834586|2018-06-01 03:36:51.834586
NCT00404456|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2008-01-28|2006-11-27|2006-11-28|Estimate|||||||2008-01-28|2008-01-29|Estimate|April 2005||2005-04-30|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients|The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients|Completed||Phase 3|40|Anticipated|Meander Medical Center|||||f||||||||||||||2018-06-01 03:36:51.894599|2018-06-01 03:36:51.894599
NCT00404443|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2008-05-06|2006-11-27|2006-11-28|Estimate|||||||2008-05-06|2008-05-09|Estimate|December 2004||2004-12-31|May 2008|2008-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Acupuncture for the Treatment of Rheumatoid Arthritis|Efficacy of Traditional Chinese Acupuncture in the Treatment of Rheumatoid Arthritis: a Double-Blind Controlled Pilot Study|Completed||Phase 2|36|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-06-01 03:36:51.95112|2018-06-01 03:36:51.95112
NCT00404430|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2016-08-18|2006-11-27|2006-11-28|Estimate|||||||2016-08-18|2016-08-19|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Protocol Chronic Obstructive Pulmonary Disease|Predictive Factors of Endothelial Function in Chronic Obstructive Disease Patients at the End of a Acute Exacerbation.|Active, not recruiting|||121|Actual|University Hospital, Grenoble|||2||f||||t||||||Samples With DNA|"~     Serum samples for analysis of inflammatory and oxidative biological markers~   "|||2018-06-01 03:36:52.012647|2018-06-01 03:36:52.012647
NCT00404417|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2010-03-01|2006-11-27|2006-11-28|Estimate|||||||2010-03-01|2010-03-02|Estimate|March 2007||2007-03-31|February 2010|2010-02-28|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Interventional|||Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain|Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain: A Prospective Randomized Double-blind Placebo-controlled Crossover Study|Unknown status|Active, not recruiting|Phase 4|160|Anticipated|Walter Reed Army Medical Center||4|||f||||t||||||||||2018-06-01 03:36:52.227007|2018-06-01 03:36:52.227007
NCT00404404|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2013-12-17|2006-11-27|2006-11-28|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2006||2006-10-31|April 2007|2007-04-30||||||||Interventional|||ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer|Phase II Trial of Abraxane Administered on a Weekly Schedule in Combination With Bevacizumab in Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:36:52.337463|2018-06-01 03:36:52.337463
NCT00404391|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-26|||2011-01-14|2006-11-26|2006-11-28|Estimate|||||||2011-01-14|2011-01-19|Estimate|October 2003||2003-10-31|January 2011|2011-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery|A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Analgesic Activity of Hydrocodone/Acetaminophen Extended Release and Placebo in Subjects With Pain Following Bunionectomy Surgery|Completed||Phase 2|210|Actual|Abbott||3|||f||||f||||||||||2018-06-01 03:36:52.447242|2018-06-01 03:36:52.447242
NCT00404378|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2017-09-11|2006-11-27|2006-11-28|Estimate|||||||2017-09-11|2017-09-12|Actual|October 20, 2006|Actual|2006-10-20|September 2017|2017-09-30|January 5, 2007|Actual|2007-01-05|January 5, 2007|Actual|2007-01-05||Interventional|||Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]|An Open-label, Two Period, Fixed Sequence Study of Healthy Subjects to Assess the Effect of Repeat Oral Dosing of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of [GW679769]|Completed||Phase 1|15|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:36:52.547761|2018-06-01 03:36:52.547761
NCT00404365|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2013-04-29|2006-11-27|2006-11-28|Estimate|||||||2013-04-29|2013-05-01|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Depression Screening in Patients With Lung Cancer|Maximizing Utilization of Depression Screening in Lung Cancer Patients: A Randomized Trial|Completed||N/A|241|Actual|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-06-01 03:36:52.649803|2018-06-01 03:36:52.649803
NCT00404352|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|2012-05-15||2013-12-18|2006-11-27|2006-11-28|Estimate|2012-08-23|2012-09-24|Estimate||||2013-12-18|2014-01-24|Estimate|November 2006||2006-11-30|December 2013|2013-12-31|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|REFLEX||REbif FLEXible Dosing in Early Multiple Sclerosis (MS)|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)|Completed||Phase 3|517|Actual|Merck KGaA||3|||f||||t||||||||||2018-06-01 03:36:52.89729|2018-06-01 03:36:52.89729
NCT00404339|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2016-04-14|2006-11-27|2006-11-28|Estimate|||||||2016-04-14|2016-04-18|Estimate|September 2005||2005-09-30|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2011|Actual|2011-03-31||Interventional|||Vaccine Therapy in Treating Patients With Head and Neck Cancer|Adjuvant p53 Peptide Loaded DC-Based Therapy for Subjects With Squamous Cell Cancer of the Head and Neck (A Phase I Safety and Immunogenicity Trial)|Completed||Phase 1|17|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 03:36:54.298651|2018-06-01 03:36:54.298651
NCT00404326|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-25|||2006-11-27|2006-11-27|2006-11-28|Estimate|||||||2006-11-27|2006-11-28|Estimate|May 2005||2005-05-31|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer|A Phase II Study of Transcriptional Therapy With the DNA Demethylating Hydralazine and the HDAC Inhibitor Valproate Associated to Concomitant Cisplatin Chemoradiation in FIGO Stage III Cervical Cancer.|Completed||Phase 2|18||National Institute of Cancerología|||||f||||||||||||||2018-06-01 03:36:54.45354|2018-06-01 03:36:54.45354
NCT00404313|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2015-10-19|2006-11-27|2006-11-28|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2008||2008-01-31|October 2015|2015-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of MK0633 in Patients With Chronic Asthma (0633-007)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK0633 in Adult Patients With Chronic Asthma|Terminated||Phase 2|688|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 03:36:54.533232|2018-06-01 03:36:54.533232
NCT00404300|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2010-03-02|2006-11-27|2006-11-28|Estimate|||||||2010-03-02|2010-03-03|Estimate|February 2007||2007-02-28|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||Optivate in People With Von Willebrand Disease Undergoing Surgery|An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate, in Patients With Von Willebrand Disease Who Are Undergoing Surgery|Terminated||Phase 3|25|Anticipated|Bio Products Laboratory||||Due to slow recruitment and a delay in reaching the recruitment target.|f||||||||||||||2018-06-01 03:36:54.602189|2018-06-01 03:36:54.602189
NCT00404287|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2018-01-11|2006-11-27|2006-11-28|Estimate|||||||2018-01-11|2018-01-16|Actual|October 1, 2006|Actual|2006-10-01|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|November 1, 2014|Actual|2014-11-01||Interventional|||Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.|Double Blind Randomized Phase IV Clinical Trial to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in the Haemodynamic Progression of Degenerative Aortic Stenosis. The AORTICA 1 Study.|Suspended||Phase 4|164|Anticipated|AORTICA Group||2||Funding not enough to complete the study|f||||t||||||||No||2018-06-01 03:36:54.654617|2018-06-01 03:36:54.654617
NCT00404274|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2017-08-08|2006-11-27|2006-11-28|Estimate|||||||2017-08-08|2017-08-09|Actual|November 1, 2006|Actual|2006-11-01|August 2017|2017-08-31|March 18, 2007|Actual|2007-03-18|March 18, 2007|Actual|2007-03-18||Interventional|||A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers|An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin When Co-administered With Repeat Doses of Casopitant [GW679769] in Healthy Adult Subjects.|Completed||Phase 1|97|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:36:54.772115|2018-06-01 03:36:54.772115
NCT00395109|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2017-08-25|2006-11-01|2006-11-02|Estimate|||||||2017-08-25|2017-08-28|Actual|November 8, 2006|Actual|2006-11-08|August 2017|2017-08-31|December 31, 2009|Actual|2009-12-31|November 30, 2009|Actual|2009-11-30||Interventional|||PET/CT to Image Hypoxia in Head and Neck Tumours|PET/CT to Image Hypoxia in Head and Neck Tumours|Completed||Early Phase 1|17|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 03:39:57.179623|2018-06-01 03:39:57.179623
NCT00404261|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2012-10-17|2006-11-27|2006-11-28|Estimate|||||||2012-10-17|2012-10-18|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).|An Open Label, Multicentre Study to Evaluate Patient Satisfaction With Fluticasone/Salmeterol HFA MDI With Counter in Adult Subjects (18 Years of Age and Older) With Asthma or COPD.|Completed||Phase 4|132|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:36:55.004357|2018-06-01 03:36:55.004357
NCT00404248|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|2014-11-05||2015-08-05|2006-11-27|2006-11-28|Estimate|2015-08-05|2015-08-11|Estimate||||2015-08-05|2015-08-11|Estimate|January 2007||2007-01-31|August 2015|2015-08-31|February 2012|Actual|2012-02-29|June 2009|Actual|2009-06-30||Interventional||high grade gliomas (GBM, AA or AO) histologically confirmed|Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma|Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma|Completed||Phase 1/Phase 2|35|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|We were not able to complete the phase 2 portion of this study as the company had internal issues and no longer had funds to support the project. We did complete the phase I and determined the (Maxium Tolerated Dose) MTD, 1700mg/day x 5 days|2|||f||||t||||||||||2018-06-01 03:36:55.122058|2018-06-01 03:36:55.122058
NCT00404235|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2016-08-12|2006-11-27|2006-11-28|Estimate|||||||2016-08-12|2016-08-15|Estimate|October 2006||2006-10-31|August 2016|2016-08-31|March 2010|Actual|2010-03-31|December 2008|Actual|2008-12-31||Interventional|||Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase II Trial of Carboplatin (CBDCA) and ABI-007(ABX) in Patients With Unresectable Stage IV Melanoma|Completed||Phase 2|76|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 03:36:55.990445|2018-06-01 03:36:55.990445
NCT00404222|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-26|||2011-07-22|2006-11-26|2006-11-28|Estimate|||||||2011-07-22|2011-07-25|Estimate|November 2005||2005-11-30|July 2011|2011-07-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study Comparing Vicodin® CR and NORCO® to Placebo in Subjects With Acute Pain Following Bunionectomy|A Randomized, Multicenter, Single-blind Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Immediate Release Hydrocodone/Acetaminophen (NORCO®) to Placebo in Subjects With Acute Pain Following Bunionectomy|Completed||Phase 2|90|Actual|Abbott||3|||f||||f||||||||||2018-06-01 03:36:56.253877|2018-06-01 03:36:56.253877
NCT00404209|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-11-29|2006-11-27|2006-11-28|Estimate|||||||2007-11-29|2007-12-03|Estimate|March 2007||2007-03-31|November 2007|2007-11-30|February 2008|Anticipated|2008-02-29|||||Interventional|||Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment|Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment|Unknown status|Recruiting|Phase 3|10|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:36:56.363425|2018-06-01 03:36:56.363425
NCT00404196|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-27|||2007-08-02|2006-11-27|2006-11-28|Estimate|||||||2007-08-02|2007-08-03|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|March 2007|Actual|2007-03-31|||||Interventional|||LEO19123 Cream in the Treatment of Hand Eczema|LEO19123 Cream in the Treatment of Hand Eczema|Completed||Phase 2|75|Anticipated|LEO Pharma|||||f||||||||||||||2018-06-01 03:36:56.459248|2018-06-01 03:36:56.459248
NCT00404183|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-26|||2011-01-14|2006-11-26|2006-11-28|Estimate|||||||2011-01-14|2011-01-19|Estimate|August 2004||2004-08-31|January 2011|2011-01-31||||March 2005|Actual|2005-03-31||Interventional|||A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis|A Randomized, Multi-center, Double-blind Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen and Placebo in Subjects With Osteoarthritis|Completed||Phase 2|120|Actual|Abbott||2|||f||||f||||||||||2018-06-01 03:36:56.760536|2018-06-01 03:36:56.760536
NCT00404170|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2015-05-13|2006-11-24|2006-11-27|Estimate|||||||2015-05-13|2015-05-14|Estimate|November 2006||2006-11-30|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease|Assessing the Determinants of PD Progression - Long-term Dopamine Transporter Imaging in the PRECEPT Cohort|Completed||Phase 2|396|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 03:36:56.836791|2018-06-01 03:36:56.836791
NCT00404157|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2017-04-10|2006-11-22|2006-11-27|Estimate|||||||2017-04-10|2017-04-12|Actual||||April 2017|2017-04-30||||||||Interventional|||A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g|A Phase III, Extension Study to Evaluate the Safety of Rituximab Retreatment in Subjects With ISN/RPS 2003 Class III or IV Lupus Nephritis Previously Enrolled in Study U2970g|Withdrawn||Phase 3|0|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 03:36:56.904757|2018-06-01 03:36:56.904757
NCT00404144|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2015-03-17|2006-11-24|2006-11-27|Estimate|||||||2015-03-17|2015-03-19|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|August 2010|Actual|2010-08-31||Interventional|||PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel|PEPCAD I, The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel Coronary Artery Disease. A Pilot Study|Completed||Phase 2|120|Actual|Heart Centre Rotenburg||1|||f||||||||||||||2018-06-01 03:36:56.9642|2018-06-01 03:36:56.9642
NCT00404131|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2016-11-28|2006-11-22|2006-11-27|Estimate|||||||2016-11-28|2016-11-29|Estimate|March 2001||2001-03-31|November 2016|2016-11-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease|Completed||Phase 3|500|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:36:57.075172|2018-06-01 03:36:57.075172
NCT00404118|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2017-06-02|2006-11-24|2006-11-27|Estimate|||||||2017-06-02|2017-06-06|Actual|September 25, 2007|Actual|2007-09-25|June 2017|2017-06-30|June 30, 2010|Actual|2010-06-30|June 30, 2010|Actual|2010-06-30||Observational|SCORE||Senior Coordinated Referral Study|Senior Coordinated Referral (SCORE) Study|Completed|||543|Actual|VA Office of Research and Development|||||f||||f||||||||||2018-06-01 03:36:57.140662|2018-06-01 03:36:57.140662
NCT00404105|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2006-11-24|2006-11-24|2006-11-27|Estimate|||||||2006-11-24|2006-11-27|Estimate|June 2000||2000-06-30|November 2006|2006-11-30|May 2004||2004-05-31|||||Interventional|||A Comparison of PRK and LASIK for Correction of Myopia|A Prospective, Randomised Trial of Photo-Refractive Keratectomy (PRK) and Laser-in-Situ-Keratomileusis (LASIK) for Correction of Myopia|Completed||Phase 4|40||University of Aarhus|||||f||||||||||||||2018-06-01 03:36:57.219013|2018-06-01 03:36:57.219013
NCT00404092|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|2012-12-12||2013-07-25|2006-11-24|2006-11-27|Estimate|2012-12-12|2013-01-21|Estimate||||2013-07-25|2013-07-31|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis|A Phase II Dose Escalation Study of Caspofungin in Patients With Invasive Aspergillosis|Completed||Phase 2|46|Actual|University of Cologne||4|||f||||t||||||||||2018-06-01 03:36:57.410361|2018-06-01 03:36:57.410361
NCT00404079|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|2011-02-21||2011-04-04|2006-11-24|2006-11-27|Estimate|2011-04-04|2011-04-29|Estimate||||2011-04-04|2011-04-29|Estimate|December 2006||2006-12-31|February 2011|2011-02-28|November 2010|Actual|2010-11-30|August 2009|Actual|2009-08-31||Interventional|||The Glucosamine-study: The Effect of Glucosamine in Treatment of Chronic Low Back Pain|Phase 4 Study of Glucosamine Sulphate in the Treatment for Chronic Low Back Pain Patients With Degenerative Lumbar MRI Findings|Completed||Phase 4|250|Actual|Oslo University Hospital|Free participation and the focus on glucosamine may attract a certain type of patients with specific personality traits. Adjunctive management was permitted, which may influence outcome. Compliance was assessed by capsule counts.|2|||f||||t||||||||||2018-06-01 03:36:58.517094|2018-06-01 03:36:58.517094
NCT00404066|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|2017-02-03||2017-11-28|2006-11-22|2006-11-27|Estimate|2017-11-28|2017-12-22|Actual||||2017-11-28|2017-12-22|Actual|October 2006||2006-10-31|November 2017|2017-11-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer|Phase II Neoadjuvant Chemotherapy Trial in Clinical Stage II/III Her2Neu Positive Breast Cancer With Sequential AC -> Docetaxel With Concurrent Dual EGFR Kinase Blockade by GW572016 (Lapatinib) Followed by 1 Year Adjuvant Trastuzumab|Completed||Phase 2|21|Actual|Stanford University||1|||f||||t|t|f||||||No||2018-06-01 03:36:58.734467|2018-06-01 03:36:58.734467
NCT00404053|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2006-11-28|2006-11-24|2006-11-27|Estimate|||||||2006-11-28|2006-11-29|Estimate|December 2004||2004-12-31|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation|One Year Effects of Different Clopidogrel Maintaining Dosage on Patients With Acute Coronary Syndrome Undergoing Coronary Drug Eluting Stent Implantation|Completed||Phase 4|||Shenyang Northern Hospital|||||f||||||||||||||2018-06-01 03:36:58.935501|2018-06-01 03:36:58.935501
NCT00404040|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2006-11-27|2006-11-24|2006-11-27|Estimate|||||||2006-11-27|2006-11-28|Estimate|October 2000||2000-10-31|November 2006|2006-11-30|July 2002||2002-07-31|||||Interventional|||Movicol in Childhood Constipation (ProMotion Study)|A Single Centre Study to Assess the Safety and Efficacy of Movicol in the Treatment of Faecal Impaction in Children Followed by a Double Blind, Randomised Phase to Compare the Safety and Efficacy of Movicol and Lactulose for Maintenance Therapy|Completed||Phase 2|60||Norgine|||||f||||||||||||||2018-06-01 03:36:59.104815|2018-06-01 03:36:59.104815
NCT00404027|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2017-06-02|2006-11-24|2006-11-27|Estimate|||||||2017-06-02|2017-06-06|Actual|June 4, 2007|Actual|2007-06-04|June 2017|2017-06-30|October 1, 2010|Actual|2010-10-01|October 1, 2010|Actual|2010-10-01||Observational|||Patient and Provider Attitudes in the Healthcare Context|Patient and Provider Attitudes in the Healthcare Context|Completed|||300|Actual|VA Office of Research and Development|||||f||||f||||||||||2018-06-01 03:36:59.164961|2018-06-01 03:36:59.164961
NCT00404014|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24||2012-07-11|2012-10-18|2006-11-24|2006-11-27|Estimate||||2012-10-10|2012-10-12|Estimate|2012-10-18|2012-10-24|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery|A Phase II Study Designed to Evaluate the Safety, Tolerability, and Effect of a Single, Rising Dose of Intravenous AL-208, Followed by a Placebo-Controlled, Double-Blind, Parallel-Group Evaluation of a Single Dose of AL-208, on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery.|Completed||Phase 2|234|Actual|Allon Therapeutics||2|||f||||f||||||||||2018-06-01 03:36:59.233586|2018-06-01 03:36:59.233586
NCT00404001|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2007-09-28|2006-11-22|2006-11-27|Estimate|||||||2007-09-28|2007-10-01|Estimate|November 2006||2006-11-30|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia|A Phase 2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Safety and Efficacy of Orally Administered MD-0727 in Patients With Primary Hypercholesterolemia|Completed||Phase 2|150|Actual|Ironwood Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:36:59.352729|2018-06-01 03:36:59.352729
NCT00403988|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|||2008-11-03|2006-11-23|2006-11-27|Estimate|||||||2008-11-03|2008-11-04|Estimate|June 2004||2004-06-30|August 2008|2008-08-31|December 2007|Actual|2007-12-31|||||Interventional|||Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma|A Clinical Phase II Study of Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma|Terminated||Phase 2|40|Anticipated|American University of Beirut Medical Center||||"The results of a same study design have shown low response with important side effects.~   Accordingly & ethicly, the study has been stopped."|f||||||||||||||2018-06-01 03:36:59.451775|2018-06-01 03:36:59.451775
NCT00403975|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2016-02-19|2006-11-24|2006-11-27|Estimate|||||||2016-02-19|2016-02-22|Estimate|June 2004||2004-06-30|February 2016|2016-02-29|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease|A Multi-Center, Parallel Group, Double-Masked, Randomized, Placebo-Controlled Study of Multiple Ocular Instillations of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease|Completed||Phase 3|640|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:36:59.57874|2018-06-01 03:36:59.57874
NCT00403962|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-09-13|2006-11-23|2006-11-27|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|August 2005|Actual|2005-08-31|||||Interventional|||A Combination Therapy In Patients With Social Anxiety Disorder|A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD)|Completed||Phase 2|204||GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:36:59.643647|2018-06-01 03:36:59.643647
NCT00403949|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|||2015-02-15|2006-11-23|2006-11-27|Estimate|||||||2015-02-15|2015-02-18|Estimate|November 2006||2006-11-30|February 2015|2015-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis|A 6-week, Vehicle-controlled, Randomized, Double-blind, Parallel-group Multicenter Pilot Study of the Efficacy and Safety of Azelaic Acid (AzA) 15% Gel in the Topical Treatment of Mild to Moderate Perioral Dermatitis|Completed||Phase 2|48|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:36:59.746796|2018-06-01 03:36:59.746796
NCT00403936|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2010-02-24|2006-11-24|2006-11-27|Estimate|||||||2010-02-24|2010-02-25|Estimate|April 2005||2005-04-30|February 2010|2010-02-28|May 2005||2005-05-31|||||Interventional|||Effects of OA Decompression on the Autonomic Nervous System|Effects of OA Decompression on Activity of the Autonomic Nervous System|Completed||N/A|100||Nova Southeastern University|||||f||||||||||||||2018-06-01 03:36:59.826582|2018-06-01 03:36:59.826582
NCT00394420|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2010-01-19|2006-10-31|2006-11-01|Estimate|||||||2010-01-19|2010-01-20|Estimate|September 2003||2003-09-30|January 2010|2010-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Emergency Department Telephone Quitline|A Telephone Quitline Intervention for Smoking Cessation Through the Emergency Department|Completed||N/A|40||Mayo Clinic|||||f||||||||||||||2018-06-01 03:40:16.669321|2018-06-01 03:40:16.669321
NCT00403923|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2009-02-13|2006-11-24|2006-11-27|Estimate|||||||2009-02-13|2009-02-16|Estimate|April 2007||2007-04-30|February 2009|2009-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Amount of Lactose Causing Symptoms in People With Lactose Intolerance and Ulcerative Colitis|A Study to Determine the Threshold of Lactose Ingestion That Provokes Symptoms in Lactose Intolerant People Who Also Have Ulcerative Colitis|Completed|||48|Anticipated|University Hospitals, Leicester|||1||f||||t||||||||||2018-06-01 03:36:59.891001|2018-06-01 03:36:59.891001
NCT00403910|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2009-04-16|2006-11-24|2006-11-27|Estimate|||||||2009-04-16|2009-04-17|Estimate|September 2002||2002-09-30|April 2009|2009-04-30|July 2006||2006-07-31|||||Interventional|||Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study|Phase 3 Study Of Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure|Completed||Phase 3|500||Heart Care Foundation|||||f||||||||||||||2018-06-01 03:36:59.965317|2018-06-01 03:36:59.965317
NCT00403897|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2008-04-15|2006-11-24|2006-11-27|Estimate|||||||2008-04-15|2008-04-16|Estimate|August 2001||2001-08-31|April 2008|2008-04-30|January 2003||2003-01-31|||||Interventional|||An Open Single Centre Study To Assess Treatment of Chronic Constipation in Children|An Open Single Centre Study To Assess the Safety and Efficacy of Movicol in the Treatment of Chronic Constipation in Children|Completed||Phase 3|81|Actual|Norgine||1|||f||||f||||||||||2018-06-01 03:37:00.107425|2018-06-01 03:37:00.107425
NCT00403884|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2010-01-11|2006-11-24|2006-11-27|Estimate|||||||2010-01-11|2010-01-13|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|August 2010|Anticipated|2010-08-31|December 2009|Anticipated|2009-12-31||Interventional|||Selective RPE Laser Treatment (SRT) for Various Macular Diseases|Selective RPE Laser Treatment (SRT) for Various Macular Diseases|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Regensburg|||||f||||f||||||||||2018-06-01 03:37:00.258778|2018-06-01 03:37:00.258778
NCT00403871|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|||2007-02-28|2006-11-23|2006-11-27|Estimate|||||||2007-02-28|2007-03-02|Estimate|November 2002||2002-11-30|February 2007|2007-02-28|June 2005||2005-06-30|||||Observational|||Anaesthetic Management of Women With Heart Disease For Labor and Delivery|Anaesthetic Management of Women With Heart Disease For Labor and Delivery|Completed|||700||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||||f||||||||||||||2018-06-01 03:37:00.323819|2018-06-01 03:37:00.323819
NCT00403858|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2007-01-03|2006-11-24|2006-11-27|Estimate|||||||2007-01-03|2007-01-04|Estimate|October 2000||2000-10-31|January 2007|2007-01-31|April 2002||2002-04-30|||||Interventional|||Movicol in Childhood Constipation (ProMotion Study)|A Single Centre Study to Assess the Safety and Efficacy of Movicol in the Treatment of Faecal Impaction in Children Followed by a Double Blind, Randomised Phase to Compare the Safety and Efficacy of Movicol and Lactulose for Maintenance Therapy|Completed||Phase 2|60||Norgine|||||f||||||||||||||2018-06-01 03:37:00.60392|2018-06-01 03:37:00.60392
NCT00403845|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|2011-07-22||2011-07-22|2006-11-24|2006-11-27|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|December 2006||2006-12-31|July 2011|2011-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, 4-period 4-treatment Crossover, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of 3 Doses of Indacaterol (150, 300, and 600 µg) Delivered Via a Single Dose Dry Powder Inhaler in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|50|Actual|Novartis||4|||f||||f||||||||||2018-06-01 03:37:00.700694|2018-06-01 03:37:00.700694
NCT00403832|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2010-07-26|2006-11-24|2006-11-27|Estimate|||||||2010-07-26|2010-07-28|Estimate|August 2005||2005-08-31|August 2009|2009-08-31|February 2007||2007-02-28|||||Interventional|||Acrylate Intraocular Lenses in Cataract Surgery of Uveitis Patients|Comparison of Two Different Acrylate Intraocular Lenses in Cataract Surgery in Patients With Non-infectious Uveitis|Completed||N/A|60||St. Franziskus Hospital|||||f||||||||||||||2018-06-01 03:37:01.083004|2018-06-01 03:37:01.083004
NCT00403819|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2006-11-27|2006-11-24|2006-11-27|Estimate|||||||2006-11-27|2006-11-28|Estimate|April 2002||2002-04-30|November 2006|2006-11-30|April 2003||2003-04-30|||||Interventional|||Study to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children|A Phase III Multi-Centre Placebo-Controlled Crossover Study Followed by an Open Label Post-Study Follow-up to Examine the Efficacy and Safety of Movicol in the Treatment of Chronic Constipation in Children|Completed||Phase 3|60||Norgine|||||f||||||||||||||2018-06-01 03:37:01.143043|2018-06-01 03:37:01.143043
NCT00403806|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2010-08-13|2006-11-24|2006-11-27|Estimate|||||||2010-08-13|2010-08-16|Estimate|February 2005||2005-02-28|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dexamethasone for Paediatric Adeno-tonsillectomy - A Dose-finding Study|Antiemetic and Analgesic Efficacy and Safety of Dexamethasone for Paediatric Adeno-tonsillectomy - A Randomised, Placebo-controlled, Double-blind, Dose-finding Study|Terminated||Phase 4|215|Actual|University Hospital, Geneva||4||drug-related harm|f||||f||||||||||2018-06-01 03:37:01.21999|2018-06-01 03:37:01.21999
NCT00403793|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2015-07-13|2006-11-24|2006-11-27|Estimate|||||||2015-07-13|2015-07-14|Estimate|October 2003||2003-10-31|July 2015|2015-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)|A Phase II -b, Placebo-Controlled Trial Investigating the Efficacy, Safety and Pharmacokinetics of a Subcutaneous Etonogestrel Implant Combined With i.m. Testosterone Undecanoate for Male Contraception|Completed||Phase 2|350|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:37:01.38644|2018-06-01 03:37:01.38644
NCT00403780|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2015-05-06|2006-11-24|2006-11-27|Estimate|||||||2015-05-06|2015-05-08|Estimate|June 2006||2006-06-30|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Interventional|||Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia|Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study|Unknown status|Recruiting|Phase 4|50|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 03:37:01.475848|2018-06-01 03:37:01.475848
NCT00403767|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|2011-12-02|2011-04-22|2014-04-10|2006-11-23|2006-11-27|Estimate|2012-06-13|2012-07-17|Estimate|2011-04-22|2011-04-29|Estimate|2014-04-10|2014-04-29|Estimate|December 2006||2006-12-31|April 2014|2014-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation|A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation|Completed||Phase 3|14269|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||t||||||||||2018-06-01 03:37:02.215264|2018-06-01 03:37:02.215264
NCT00402571|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2009-02-06|2006-11-21|2006-11-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2002||2002-01-31|February 2009|2009-02-28|July 2004||2004-07-31|||||Interventional|||Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics|Assessment of Hepatic Function in Alcoholic Patients Administered Therapeutic Dosing of Acetaminophen- a Multicenter Study|Completed||Phase 4|420||Denver Health and Hospital Authority|||||f||||||||||||||2018-06-01 03:37:30.11363|2018-06-01 03:37:30.11363
NCT00403754|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|2011-07-22||2011-07-22|2006-11-24|2006-11-27|Estimate|2011-07-22|2011-08-17|Estimate||||2011-07-22|2011-08-17|Estimate|November 2006||2006-11-30|July 2011|2011-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Dose Ranging Study for Indacaterol in Japanese Asthma Patients|A Randomized, Double-blind, Placebo-controlled, 4-period 4-treatment Crossover, Multicenter, Single-dose, Dose-ranging Study Followed by a Single Day's Treatment With Open Label Salmeterol Bid (100 µg/Day), to Assess the Efficacy and Safety of 3 Doses of Indacaterol (150, 300, & 600 µg) Delivered Via Single Dose Dry Powder Inhaler (SDDPI) in Japanese Asthma Patients|Completed||Phase 2|41|Actual|Novartis||4|||f||||f||||||||||2018-06-01 03:37:08.462216|2018-06-01 03:37:08.462216
NCT00403741|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2010-02-26|2006-11-24|2006-11-27|Estimate|||||||2010-02-26|2010-03-01|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|July 2009|Actual|2009-07-31|January 2007|Actual|2007-01-31||Interventional|||Consultations in Adapted Physical Activity on Behaviours in Physical Exercise by Type 2 Diabetics|Effects of Individuals Consultations in Adapted Physical Activity on Behaviours in Physical Exercise by Type 2 Diabetics|Completed||N/A|120|Anticipated|University Hospital, Grenoble|||||f||||f||||||||||2018-06-01 03:37:08.840056|2018-06-01 03:37:08.840056
NCT00403728|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2007-04-26|2006-11-24|2006-11-27|Estimate|||||||2007-04-26|2007-04-27|Estimate|September 2004||2004-09-30|April 2007|2007-04-30||||||||Interventional|||Ciclosporin A and Acute Myocardial Infarction|Protection by Ciclosporine A During Reperfused Acute Myocardial Infarction.|Unknown status|Active, not recruiting|Phase 2/Phase 3|60||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:37:08.916791|2018-06-01 03:37:08.916791
NCT00403715|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2016-11-28|2006-11-22|2006-11-27|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2001||2001-02-28|November 2016|2016-11-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease|Completed||Phase 3|500|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:37:08.979291|2018-06-01 03:37:08.979291
NCT00403702|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2009-06-28|2006-11-24|2006-11-27|Estimate|||||||2009-06-28|2009-06-30|Estimate|August 2006||2006-08-31|November 2006|2006-11-30|August 2007|Anticipated|2007-08-31|||||Interventional|||Comparison High-Density Silicone Oils in Retinal Detachment|Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:37:09.096194|2018-06-01 03:37:09.096194
NCT00403689|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2013-08-01|2006-11-24|2006-11-27|Estimate|||||||2013-08-01|2013-08-05|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome|Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome|Completed||N/A|11|Actual|German Institute of Human Nutrition||2|||f||||||||||||||2018-06-01 03:37:09.186011|2018-06-01 03:37:09.186011
NCT00403676|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2012-06-27|2006-11-24|2006-11-27|Estimate|||||||2012-06-27|2012-06-28|Estimate|September 2005||2005-09-30|June 2012|2012-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease|Nursing Consultation in Out-patient Clinics for Patients With Inflammatory Rheumatic Disease|Completed||N/A|68|Actual|Diakonhjemmet Hospital||2|||f||||f||||||||||2018-06-01 03:37:09.287519|2018-06-01 03:37:09.287519
NCT00403663|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|||2009-07-29|2006-11-24|2006-11-27|Estimate|||||||2009-07-29|2009-07-30|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Body Mass Index on the Dose of Intrathecal Hyperbaric Bupivacaine for Elective Cesarean Section|Effect of Body Mass Index on the ED95 of Intrathecal Hyperbaric Bupivacaine for Elective Cesarean Section|Completed||N/A|52|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||||f||||f||||||||||2018-06-01 03:37:09.349173|2018-06-01 03:37:09.349173
NCT00403650|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2013-04-10|2006-11-24|2006-11-27|Estimate|||||||2013-04-10|2013-04-12|Estimate|November 2006||2006-11-30|April 2013|2013-04-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension|Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension|Completed||Phase 4|20|Actual|University of Cincinnati||1|||f||||f||||||||||2018-06-01 03:37:09.405579|2018-06-01 03:37:09.405579
NCT00403637|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2016-11-16|2006-11-24|2006-11-27|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|February 2007||2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Active (Formoterol 12 µg b.i.d) and Placebo Controlled, Multi-center, 5 Period Crossover Study to Assess the Bronchodilatory Efficacy and Safety of Single Doses of Indacaterol 150 µg, 300 µg and 600 µg Delivered Via Single Dose Dry Powder Inhaler (SDDPI) vs. Placebo in Patients With Persistent Asthma|Completed||Phase 2/Phase 3|45|Actual|Novartis|||||f||||||||||||||2018-06-01 03:37:09.478781|2018-06-01 03:37:09.478781
NCT00403624|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|||2010-08-26|2006-11-23|2006-11-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|July 2001||2001-07-31|April 2008|2008-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer|Clinical Study to Evaluate a Protocol of Oxaliplatin -UFT- Radiotherapy for the Neoadjuvant Treatment Rectal Cancer|Completed||Phase 1/Phase 2|38||Sanofi|||||f||||||||||||||2018-06-01 03:37:09.542884|2018-06-01 03:37:09.542884
NCT00403611|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-24|||2015-06-16|2006-11-24|2006-11-27|Estimate|||||||2015-06-16|2015-06-17|Estimate|March 2006||2006-03-31|June 2015|2015-06-30|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil|Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil|Completed||Phase 4|196|Actual|Oswaldo Cruz Foundation||2|||f||||f||||||||||2018-06-01 03:37:09.596515|2018-06-01 03:37:09.596515
NCT00403598|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|||2006-11-23|2006-11-23|2006-11-27|Estimate|||||||2006-11-23|2006-11-27|Estimate||||November 2006|2006-11-30||||||||Observational|||Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders||Unknown status|Not yet recruiting||||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:37:09.671656|2018-06-01 03:37:09.671656
NCT00403585|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-23|2009-04-24||2010-11-24|2006-11-23|2006-11-27|Estimate|2010-10-18|2010-11-24|Estimate||||2010-11-24|2010-12-15|Estimate|July 2006||2006-07-31|November 2010|2010-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814|A Phase IV, Open Label, Single Arm, Multicenter, Extension Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814|Completed||Phase 4|80|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:37:09.736315|2018-06-01 03:37:09.736315
NCT00403572|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2016-10-14|2006-11-22|2006-11-23|Estimate|||||||2016-10-14|2016-10-17|Estimate|November 2006||2006-11-30|October 2016|2016-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||A Study of Cerebral-circulatory Response to Intravenous Antihypertensive Treatment in Women With Serious Preeclampsia|A Study of Cerebral-circulatory Response to Intravenous Antihypertensive Treatment in Women With Serious Preeclampsia|Completed|||8|Actual|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:37:09.992231|2018-06-01 03:37:09.992231
NCT00403559|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2009-03-31|2006-11-22|2006-11-23|Estimate|||||||2009-03-31|2009-04-01|Estimate|January 2007||2007-01-31|October 2007|2007-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A 4 Week Study of Elidel for the Treatment of Seborrheic Dermatitis|A 4 Week Randomized Double-Blind Parallel Group Active Comparator Controlled Study of Elidel for the Treatment of Seborrheic Dermatitis|Completed||Phase 2|110|Anticipated|Dermatology Specialists Research|||||f||||||||||||||2018-06-01 03:37:10.065066|2018-06-01 03:37:10.065066
NCT00403546|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2017-04-17||2017-06-02|2006-11-22|2006-11-23|Estimate|2017-06-02|2017-06-06|Actual||||2017-06-02|2017-06-06|Actual|January 2006|Actual|2006-01-31|June 2017|2017-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|HDZ|All participants who entered the Randomized Trial.|High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms|High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms|Completed||Phase 3|131|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:37:10.162493|2018-06-01 03:37:10.162493
NCT00403533|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2006-11-22|2006-11-22|2006-11-23|Estimate|||||||2006-11-22|2006-11-23|Estimate|February 2006||2006-02-28|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus|Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus|Completed||Phase 2|10||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 03:37:11.234915|2018-06-01 03:37:11.234915
NCT00403520|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2014-07-11|2006-11-21|2006-11-23|Estimate|||||||2014-07-11|2014-07-14|Estimate|November 2006||2006-11-30|July 2014|2014-07-31|August 2010|Actual|2010-08-31|March 2008|Actual|2008-03-31||Interventional|||Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers|Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders|Completed||Phase 4|240|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 03:37:11.310953|2018-06-01 03:37:11.310953
NCT00403507|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2011-05-09|2006-11-22|2006-11-23|Estimate|||||||2011-05-09|2011-05-11|Estimate|October 2006||2006-10-31|November 2006|2006-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Exercise Treatment of Mild-Stage Probable Alzheimer's Disease|Physical Activity as a Treatment of Mild-Stage Probable Alzheimer's Disease|Completed||Phase 2|79|Anticipated|Intermountain Health Care, Inc.||4|||f||||f||||||||||2018-06-01 03:37:11.39659|2018-06-01 03:37:11.39659
NCT00403494|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2014-09-04|2006-11-21|2006-11-23|Estimate|||||||2014-09-04|2014-09-08|Estimate|December 2006||2006-12-31|September 2014|2014-09-30|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||A Phase 2 Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease|A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease|Completed||Phase 2|190|Actual|BioMarin Pharmaceutical||4|||f||||t||||||||||2018-06-01 03:37:11.493441|2018-06-01 03:37:11.493441
NCT00403481|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|2008-11-21||2016-09-28|2006-11-22|2006-11-23|Estimate|2009-08-05|2009-09-15|Estimate||||2016-09-28|2016-11-03|Estimate|November 2006||2006-11-30|September 2016|2016-09-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes|A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension|Completed||Phase 4|192|Actual|Daiichi Sankyo, Inc.||1|||f||||||||||||||2018-06-01 03:37:11.623786|2018-06-01 03:37:11.623786
NCT00403455|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|2014-11-14||2014-12-01|2006-11-22|2006-11-23|Estimate|2014-12-01|2014-12-08|Estimate||||2014-12-01|2014-12-08|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|MTG|The study recruited all veterans that with a CAPS score of >45 and were DSM-IV positive for PTSD. Both males and females with backgrounds in all ethnic groups were aloud to participate in the study.|Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities|Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities|Completed||Phase 3|38|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 03:37:11.978216|2018-06-01 03:37:11.978216
NCT00403442|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2008-07-29|2006-11-22|2006-11-23|Estimate|||||||2008-07-29|2008-07-30|Estimate|September 2006||2006-09-30|July 2008|2008-07-31||||||||Interventional|||Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD|Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD|Terminated||Phase 1|10|Anticipated|Vitreous -Retina- Macula Consultants of New York|||||f||||||||||||||2018-06-01 03:37:12.144963|2018-06-01 03:37:12.144963
NCT00403429|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2016-01-13|2006-11-22|2006-11-23|Estimate|||||||2016-01-13|2016-01-14|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer|Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer.|Completed||Phase 2|36|Actual|National Cancer Institute, Naples||1|||f||||||||||||||2018-06-01 03:37:12.240685|2018-06-01 03:37:12.240685
NCT00403416|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2017-05-16|2006-11-22|2006-11-23|Estimate|||||||2017-05-16|2017-05-18|Actual|October 2006||2006-10-31|May 2017|2017-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients|12-month Open Label, Randomized, Multicenter Study Evaluating Efficacy, Safety and Tolerability of Oral AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), vs. Mycophenolic Acid Plus Tacrolimus in de Novo Renal Transplant Recipients|Completed||Phase 1/Phase 2|215|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:37:12.36317|2018-06-01 03:37:12.36317
NCT00403403|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2010-01-28||2011-04-27|2006-11-21|2006-11-23|Estimate|2011-02-01|2011-02-25|Estimate||||2011-04-27|2011-04-29|Estimate|March 2007||2007-03-31|April 2011|2011-04-30|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)|A Placebo-Controlled, Double-Blind, Multicenter, Randomized, Phase II Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|102|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:37:12.466731|2018-06-01 03:37:12.466731
NCT00401700|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2016-04-22|2006-11-17|2006-11-20|Estimate|||||||2016-04-22|2016-04-25|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|July 2009|Actual|2009-07-31|January 2008|Actual|2008-01-31||Observational|||Influenza Vaccine Postpartum Questionnaire|Acceptability and Feasibility of Influenza Vaccine Administration on the Post-partum Floor Prior to Discharge Home During Flu Season|Completed|||150|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-06-01 03:37:51.795654|2018-06-01 03:37:51.795654
NCT00403390|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2017-01-20||2018-01-24|2006-11-22|2006-11-23|Estimate|2018-01-24|2018-02-23|Actual||||2018-01-24|2018-02-23|Actual|November 2006||2006-11-30|January 2018|2018-01-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Generic vs. Name-Brand Levothyroxine|Generic vs. Name-Brand Levothyroxine: Assessment of Bioequivalence Using TSH as a Marker in Children With Permanent Hypothyroidism|Completed||N/A|34|Actual|Boston Children’s Hospital|Proof of principle study; small sample. Results may not be applicable to all populations.|2|||f||||f||||||||No|Nothing currently planned|2018-06-01 03:37:12.973972|2018-06-01 03:37:12.973972
NCT00403377|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2015-09-29|2006-11-21|2006-11-23|Estimate|||||||2015-09-29|2015-10-01|Estimate|April 2006||2006-04-30|September 2015|2015-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Investigation of a Behavioral Substitute for Sunbathing|Investigation of a Behavioral Substitute for Sunbathing|Completed||Phase 1/Phase 2|307|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-06-01 03:37:13.242962|2018-06-01 03:37:13.242962
NCT00403364|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2006-11-22|2006-11-22|2006-11-23|Estimate|||||||2006-11-22|2006-11-23|Estimate|July 2003||2003-07-31|November 2006|2006-11-30|February 2006||2006-02-28|||||Interventional|||Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-Controlled Trial|Sequential Therapy Versus Triple Therapy for Helicobacter Pylori Eradication: a Placebo-Controlled Trial|Completed||Phase 2/Phase 3|300||St. Orsola Hospital|||||f||||||||||||||2018-06-01 03:37:13.315003|2018-06-01 03:37:13.315003
NCT00403351|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2017-09-20|2006-11-22|2006-11-23|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2006||2006-10-31|September 2017|2017-09-30|November 2020|Anticipated|2020-11-30|June 2008|Actual|2008-06-30||Observational|||Alternative Risk Markers in Coronary Artery Disease (ARMCAD)|Correlation of Multiple Risk Factors With Presence and Severity of Coronary Artery Disease.|Active, not recruiting|||750|Anticipated|Monash University|||2||f||||t||||||Samples Without DNA|"~     Serum specifically for future cardiac biomarkers~   "|||2018-06-01 03:37:13.376606|2018-06-01 03:37:13.376606
NCT00403338|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2009-10-05|2006-11-22|2006-11-23|Estimate|||||||2009-10-05|2009-10-07|Estimate|December 2004||2004-12-31|October 2009|2009-10-31|April 2006|Actual|2006-04-30|||||Observational|||The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R.)|Prospective Evaluation of the Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent, The e-CYPHER(SM)S.T.L.L.R., Registry [Study of Deployment Technique on Clinical Results]|Completed|||1500|Actual|Cordis Corporation|||||f||||f||||||||||2018-06-01 03:37:13.465991|2018-06-01 03:37:13.465991
NCT00403325|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2008-10-31|2006-11-22|2006-11-23|Estimate|||||||2008-10-31|2008-11-03|Estimate|August 2006||2006-08-31|October 2008|2008-10-31||||||||Interventional|||Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy|Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.|Completed||Phase 1|9|Actual|Vitreous -Retina- Macula Consultants of New York|||||f||||||||||||||2018-06-01 03:37:13.528441|2018-06-01 03:37:13.528441
NCT00403312|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2008-06-30|2006-11-22|2006-11-23|Estimate|||||||2008-06-30|2008-07-02|Estimate|January 2003||2003-01-31|June 2008|2008-06-30||||||||Interventional|||Increasing Physical Activity as Part of a Smoking Cessation Program|Increasing Physical Activity to Aid Smoking Cessation|Completed||N/A|400|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:37:13.678552|2018-06-01 03:37:13.678552
NCT00403299|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2011-07-03|2006-11-22|2006-11-23|Estimate|||||||2011-07-03|2011-07-06|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|March 2007|Actual|2007-03-31|||||Interventional|||MDCT of the Coronary Arteries in Heart Transplanted Patients|Multidetector Computer Tomography of the Coronary Arteries in Heart Transplanted Patients|Completed||N/A|50|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:37:13.782129|2018-06-01 03:37:13.782129
NCT00403286|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2009-06-26|2006-11-22|2006-11-23|Estimate|||||||2009-06-26|2009-06-30|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Safety and Efficacy of Fluticasone Propionate Combined With Formoterol Fumarate in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|457|Actual|Dey||8|||||||||||||||||2018-06-01 03:37:13.867224|2018-06-01 03:37:13.867224
NCT00403273|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2012-04-21||2018-04-20|2006-11-21|2006-11-23|Estimate|2016-09-28|2016-11-18|Estimate||||2018-04-20|2018-05-21|Actual|July 2006||2006-07-31|April 2018|2018-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA)|Botulinum Toxin A for Painful Total Knee Arthroplasty (TKA): Randomized, Controlled, Triple-blind Study|Completed||Phase 2|54|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 03:37:14.110426|2018-06-01 03:37:14.110426
NCT00403260|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2009-01-21|2006-11-22|2006-11-23|Estimate|||||||2009-01-21|2009-01-22|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Pyronaridine Artesunate (3:1) Versus Mefloquine Artesunate in P Falciparum Malaria Patients|A Phase III Comparative, Open-Label, Randomised, Multi-Centre, Clinical Study to Assess the Safety and Efficacy of Fixed Dose Formulation Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Mefloquine (250 mg Tablet) Plus Artesunate (100 mg Tablet) in Children and Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 3|1269|Actual|Medicines for Malaria Venture||2|||f||||||||||||||2018-06-01 03:37:14.68671|2018-06-01 03:37:14.68671
NCT00403247|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2007-08-21|2006-11-22|2006-11-23|Estimate|||||||2007-08-21|2007-08-23|Estimate|July 2004||2004-07-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia|Double-Blind Vitamin Intervention to Lower Blood Homocysteine Levels: Amino Acid and Clinical Responses in Individuals With Schizophrenia.|Completed||N/A|50|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-06-01 03:37:14.768435|2018-06-01 03:37:14.768435
NCT00403234|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2010-07-28||2012-08-27|2006-11-22|2006-11-23|Estimate|2010-08-25|2010-09-21|Estimate||||2012-08-27|2012-09-03|Estimate|November 2006||2006-11-30|August 2012|2012-08-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study to Evaluate the Analgesic Efficacy of BTDS on Postoperative Pain During Rehabilitation Following Total Knee Arthroplasty|Terminated||Phase 2|10|Actual|Purdue Pharma LP|This trial was terminated early due to administrative reasons not related to efficacy or safety. The efficacy data are not presented since the objective of this study was changed prior to study unblinding, identifying it as a safety study.|4||due to administrative reasons not related to efficacy or safety.|f||||||||||||||2018-06-01 03:37:14.837526|2018-06-01 03:37:14.837526
NCT00401505|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2016-04-22|2006-11-17|2006-11-20|Estimate|||||||2016-04-22|2016-04-25|Estimate|September 2006||2006-09-30|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Rubella Susceptibility in Multiparous Women|Rubella Susceptibility in Multiparous Women|Completed|||310|Actual|St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 03:37:55.732852|2018-06-01 03:37:55.732852
NCT00403221|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2012-02-09|2006-11-22|2006-11-23|Estimate|||||||2012-02-09|2012-02-10|Estimate|August 2006||2006-08-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer|A Phase I Study of In-Situ, Neoadjuvant, Pre-Radical Prostatectomy RTVP-1 Gene Therapy in Patients With Locally Advanced Adenocarcinoma of the Prostate (SPORE)|Completed||Phase 1|19|Actual|Baylor College of Medicine|||||f||||||||||||||2018-06-01 03:37:15.134781|2018-06-01 03:37:15.134781
NCT00403208|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2006-11-24|2006-11-22|2006-11-23|Estimate|||||||2006-11-24|2006-11-28|Estimate|March 2006||2006-03-31|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Analgesia-Based Sedation During Mechanical Ventilation|Clinical and Economical Impact of an Analgesia-Based, Goal-Directed, Nurse-Driven Sedation Protocol on Patients on Mechanical Ventilation. A Multicenter Study|Unknown status|Recruiting|N/A|280||Pontificia Universidad Catolica de Chile|||||f||||||||||||||2018-06-01 03:37:15.210419|2018-06-01 03:37:15.210419
NCT00403195|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2012-09-07|2006-11-21|2006-11-23|Estimate|||||||2012-09-07|2012-09-10|Estimate|November 2006||2006-11-30|September 2012|2012-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Clinical and Pathophysiological Description of Ocular Ischemic Syndrome|Pathophysiological Analysis of Ocular Ischemic Syndrome and the Response to Vascular Surgery|Completed|||13|Actual|Glostrup University Hospital, Copenhagen|||||f||||t||||||||||2018-06-01 03:37:15.474175|2018-06-01 03:37:15.474175
NCT00403182|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2012-05-31|2006-11-21|2006-11-23|Estimate|||||||2012-05-31|2012-06-01|Estimate|May 2006||2006-05-31|May 2012|2012-05-31||||||||Interventional|||Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer|The CORE Study (Chemotherapy OR Endocrine Treatment First?) A Randomized Study by the Scandinavian Breast Group [CORE]|Withdrawn||Phase 3|0|Actual|Technische Universität München||||study halted prematurely, prior to enrollment of first participant|f||||||||||||||2018-06-01 03:37:15.544123|2018-06-01 03:37:15.544123
NCT00403169|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21||2017-04-18|2017-04-18|2006-11-21|2006-11-23|Estimate||||2017-04-18|2017-04-20|Actual|2017-04-18|2017-04-20|Actual|August 2004||2004-08-31|April 2017|2017-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer|Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)|Completed||Phase 2|26|Anticipated|The Cleveland Clinic||1|||f||||||||||||||2018-06-01 03:37:15.639552|2018-06-01 03:37:15.639552
NCT00403156|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2015-12-30|2006-11-22|2006-11-23|Estimate|||||||2015-12-30|2015-12-31|Estimate|November 2006||2006-11-30|December 2015|2015-12-31||||||||Interventional|||Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|Withdrawn||Phase 1|0|Actual|Vitreous -Retina- Macula Consultants of New York||||Lack of recruitment|f||||||||||||||2018-06-01 03:37:15.720801|2018-06-01 03:37:15.720801
NCT00403143|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2007-05-11|2006-11-22|2006-11-23|Estimate|||||||2007-05-11|2007-05-14|Estimate|October 2006||2006-10-31|May 2007|2007-05-31||||||||Interventional|||Do Blue-Blocking Lenses Block Blue Colour From Our Lives?|Do Blue-Blocking Lenses Block Colour From Our Lives? A Randomised Controlled Study Measuring Colour Vision Using the Gold Standard Colour Vision Test (an Anomaloscope)in Patients With Blue Light Filtering Intraocular Lenses (Tinted Yellow) and Comparing This With Patients Inserted With Clear, Non Blue Light Filtering Intraocular Lenses During Cataract Surgery|Unknown status|Recruiting|N/A|40|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 03:37:15.786235|2018-06-01 03:37:15.786235
NCT00403130|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|2017-02-03||2017-02-03|2006-11-22|2006-11-23|Estimate|2017-02-03|2017-03-24|Actual||||2017-02-03|2017-03-24|Actual|February 2006||2006-02-28|February 2017|2017-02-28|November 2012|Actual|2012-11-30|September 2010|Actual|2010-09-30||Interventional|||Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer|Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer|Completed||Phase 2|31|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 03:37:15.876639|2018-06-01 03:37:15.876639
NCT00403117|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2017-08-07||2018-02-15|2006-11-21|2006-11-23|Estimate|2017-11-20|2017-12-19|Actual||||2018-02-15|2018-03-15|Actual|December 2006||2006-12-31|February 2018|2018-02-28|August 2010|Actual|2010-08-31|May 2008|Actual|2008-05-31||Interventional|||Effects of a Range of Naltrexone Doses in Combination With Smoked Marijuana|Opioid Antagonism Enhances Marijuana's Effects in Heavy Marijuana Smokers|Completed||Phase 2|49|Actual|New York State Psychiatric Institute|A limitation of this study is the small sample size.|10|||f|||||t|f||||||||2018-06-01 03:37:16.122109|2018-06-01 03:37:16.122109
NCT00403104|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2012-06-12|2006-11-22|2006-11-23|Estimate|||||||2012-06-12|2012-06-13|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Multi-centre, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Investigate Efficacy and Safety of ONO-2506PO Compared to Placebo, in the Presence of Riluzole, to Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS), Who Have Had Onset of Muscle Weakness Within 14 Months of Randomization|Completed||Phase 2|420|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 03:37:16.55864|2018-06-01 03:37:16.55864
NCT00403091|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2010-08-10|2006-11-22|2006-11-23|Estimate|||||||2010-08-10|2010-08-11|Estimate|April 2005||2005-04-30|August 2010|2010-08-31|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||Internet Intervention to Improve Rural Diabetes Care|Internet Intervention to Improve Rural Diabetes Care|Completed||N/A|205|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 03:37:17.733857|2018-06-01 03:37:17.733857
NCT00403078|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2014-02-07|2006-11-22|2006-11-23|Estimate|||||||2014-02-07|2014-02-10|Estimate|October 2006||2006-10-31|February 2014|2014-02-28|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Observational|||SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy|Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy (SAPPHIRE Worldwide)|Unknown status|Recruiting||21000|Anticipated|Cordis Corporation|||||f||||t||||||||||2018-06-01 03:37:17.819826|2018-06-01 03:37:17.819826
NCT00403065|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2013-08-23|2006-11-21|2006-11-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2006||2006-10-31|January 2007|2007-01-31|March 2013|Actual|2013-03-31|||||Interventional|||Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery|Quality of Life After Radiotherapy & Steroids. A Phase III Multi-Centre Randomised Controlled Trial to Assess Whether Optimal Supportive Care Alone (Including Dexamathasone) is As Effective as Optimal Supportive Care (Including Dexamethasone ) Plus Whole Brain Radiotherapy in the Treatment of Patients With Inoperable Brain Metastases From Non-Small Cell Lung Cancer|Completed||Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:37:17.92473|2018-06-01 03:37:17.92473
NCT00403052|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2018-02-27|2006-11-21|2006-11-23|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2006||2006-11-30|February 2018|2018-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer|Phase 1 Study of the Combination of 1018 ISS, Irinotecan and Cetuximab in Patients With Metastatic Colorectal Cancer Previously Treated With a Fluoropyrimidine, Oxaliplatin or Irinotecan With or Without Bevacizumab|Terminated||Phase 1|14|Actual|Dynavax Technologies Corporation||3||Administrative reasons|f||||t||||||||Undecided|3/2017 No change in status of this study|2018-06-01 03:37:18.181626|2018-06-01 03:37:18.181626
NCT00403039|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2015-12-31|2006-11-22|2006-11-23|Estimate|||||||2015-12-31|2016-01-01|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema|Phase I Study of Intravitreally Administered Ranibizumab in 20 Subjects With Macular Edema Associated With CRVO.|Completed||Phase 1|41|Actual|Vitreous -Retina- Macula Consultants of New York||1|||f||||||||||||||2018-06-01 03:37:18.298846|2018-06-01 03:37:18.298846
NCT00403026|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2006-11-22|2006-11-22|2006-11-23|Estimate|||||||2006-11-22|2006-11-23|Estimate|August 2006||2006-08-31|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Intravitreal Bevacizumab for Retinal Disorders|Off-Label,Intravitreal Use of Bevacizumab for Retinal Disorders|Unknown status|Recruiting|N/A|150||Narayana Nethralaya|||||f||||||||||||||2018-06-01 03:37:18.376296|2018-06-01 03:37:18.376296
NCT00403013|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2009-07-03|2006-11-22|2006-11-23|Estimate|||||||2009-07-03|2009-07-07|Estimate|April 2007||2007-04-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Plexus Anesthesia in Lateral, Head-Down Position for Elective Surgery of the Shoulder|Axillary Plexus Block for Perioperative Analgesia in Patients Scheduled for Elective Surgery of the Shoulder: Influence of Lateral, Head-Down Position|Completed||N/A|64|Actual|University Hospital Muenster||2|||f||||||||||||||2018-06-01 03:37:18.471361|2018-06-01 03:37:18.471361
NCT00403000|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2013-04-30|2006-11-21|2006-11-23|Estimate|||||||2013-04-30|2013-05-01|Estimate|December 2004||2004-12-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2007|Actual|2007-03-31||Interventional|||Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy|Phase II Study of Dutasteride in Prostate Cancer Recurrent During Androgen Deprivation Therapy|Completed||Phase 2|27|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 03:37:18.557999|2018-06-01 03:37:18.557999
NCT00402987|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2008-11-14||2009-06-08|2006-11-22|2006-11-23|Estimate|2009-02-10|2009-03-12|Estimate||||2009-06-08|2009-06-11|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat|A Double Blind, Randomized, Placebo-Controlled Comparison of the Efficacy, Safety, and Tolerability of Celecoxib 100-150 mg, Including Initial Doses of 50 and 100 mg, and Placebo in the Symptomatic Treatment of Patients With Painful Pharyngitis|Completed||Phase 3|269|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 03:37:18.925243|2018-06-01 03:37:18.925243
NCT00402974|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2008-06-05|2006-11-22|2006-11-23|Estimate|||||||2008-06-05|2008-06-10|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|||||Interventional|||The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children|The VITAKIDS-Study: The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children|Completed||N/A|55|Actual|UMC Utrecht|||||f||||||||||||||2018-06-01 03:37:22.928038|2018-06-01 03:37:22.928038
NCT00402961|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2015-10-09|2006-11-22|2006-11-23|Estimate|||||||2015-10-09|2015-10-12|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Trial of Acupuncture for Reduction of Post-Colectomy Ileus|A Phase II Randomized Controlled Trial of Acupuncture for Reduction of Post-Colectomy Ileus|Completed||Phase 2|90|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 03:37:22.984332|2018-06-01 03:37:22.984332
NCT00402948|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2012-11-30|2006-11-21|2006-11-23|Estimate|||||||2012-11-30|2012-12-03|Estimate|February 2007||2007-02-28|November 2012|2012-11-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, To Evaluate And Compare The Safety, Tolerability And Efficacy Of Two Dosages Of Inhaled TPI ASM8 Administered For 14 Days In Patients With Mild to Moderate Asthma.|Terminated||Phase 2|10|Actual|Pharmaxis||2||Lack of substantial enrollment|f||||f||||||||||2018-06-01 03:37:23.065557|2018-06-01 03:37:23.065557
NCT00402935|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2012-03-16|2006-11-21|2006-11-23|Estimate|||||||2012-03-16|2012-03-20|Estimate|February 2004||2004-02-29|March 2012|2012-03-31|May 2007|Actual|2007-05-31|||||Observational|||Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer|Effects of Cytotoxic Chemotherapy on Ovarian Structure and Function|Withdrawn|||0|Actual|Case Comprehensive Cancer Center||||slow accrual|f||||t||||||Samples With DNA|"~     Blood collection at the same time points for follicle-stimulating hormone, estradiol, and~     inhibin B levels.~   "|||2018-06-01 03:37:23.131729|2018-06-01 03:37:23.131729
NCT00402922|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-22|||2017-01-24|2006-11-22|2006-11-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|August 2006||2006-08-31|January 2017|2017-01-31|May 2012|Actual|2012-05-31|February 2008|Actual|2008-02-29||Observational|||Evaluating the Association Between Pericardial Fat and Coronary Heart Disease - Ancillary to MESA|Pericardial Fat and Subclinical and Clinical Measures of Coronary Heart Disease - Ancillary to MESA|Completed|||6814|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 03:37:23.196783|2018-06-01 03:37:23.196783
NCT00402909|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2017-02-22|2006-11-20|2006-11-22|Estimate|||||||2017-02-22|2017-02-24|Actual|November 2006||2006-11-30|February 2017|2017-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone|A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Compare the Safety and Efficacy of Nateglinide vs. Placebo in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Basal Insulin Glargine in Combination With Metformin and/or Thiazolidinedione (Pioglitazone or Rosiglitazone)|Completed||Phase 4|28|Actual|Novartis|||||||||||||||||||2018-06-01 03:37:23.242163|2018-06-01 03:37:23.242163
NCT00402896|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2015-09-02||2016-02-11|2006-11-21|2006-11-22|Estimate|2016-02-11|2016-03-09|Estimate||||2016-02-11|2016-03-09|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Malignant Pleural Effusion With ZD6474|Treatment of Malignant Pleural Effusion With ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor|Terminated||Phase 2|28|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f||||||||||2018-06-01 03:37:23.305043|2018-06-01 03:37:23.305043
NCT00402883|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2013-08-15||2013-11-27|2006-11-21|2006-11-22|Estimate|2013-11-27|2014-01-13|Estimate||||2013-11-27|2014-01-13|Estimate|November 2006||2006-11-30|November 2013|2013-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer|A Phase II Study of Pemetrexed/Carboplatin/Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer|Terminated||Phase 2|5|Actual|SCRI Development Innovations, LLC||1||Terminated due to bevacizumab and chemoradiotherapy toxicity|f||||f||||||||||2018-06-01 03:37:23.588473|2018-06-01 03:37:23.588473
NCT00402870|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2007-12-03|2006-11-21|2006-11-22|Estimate|||||||2007-12-03|2007-12-04|Estimate|August 2007||2007-08-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Postoperative Analgesic Requirements for the ProSeal Laryngeal Mask Airway Versus the Tracheal Tube in Females Undergoing Gynecological Laparoscopic Surgery|Postoperative Analgesic Requirements for the ProSeal Laryngeal Mask Airway Versus the Tracheal Tube in Females Undergoing Gynecological Laparoscopic Surgery|Completed||N/A|100|Anticipated|Medical University Innsbruck|||||f||||||||||||||2018-06-01 03:37:23.824781|2018-06-01 03:37:23.824781
NCT00402857|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2013-02-11|2006-11-20|2006-11-22|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2006||2006-11-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders|Advanced Parenting Education in Pediatrics: The APEP Project|Completed||Phase 3|345|Actual|Tufts Medical Center||2|||f||||f||||||||||2018-06-01 03:37:23.87805|2018-06-01 03:37:23.87805
NCT00402844|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2007-11-13|2006-11-20|2006-11-22|Estimate|||||||2007-11-13|2007-11-14|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|March 2007|Actual|2007-03-31|||||Interventional|||Safety Study of Pelvic Organ Prolapse Repair Using Transvaginal Mesh|A Multicenter Clinical Safety Assessment of Polypropylene Transvaginal Mesh in Pelvic Reconstructive Surgery|Completed||Phase 2/Phase 3|250||Karolinska Institutet|||||f||||f||||||||||2018-06-01 03:37:23.972262|2018-06-01 03:37:23.972262
NCT00402831|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2017-09-01|2006-11-21|2006-11-22|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2006||2006-10-31|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||ProQuad® Intramuscular vs Subcutaneous|An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months|Completed||Phase 3|405|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:37:24.258233|2018-06-01 03:37:24.258233
NCT00402818|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2014-08-28|2006-11-21|2006-11-22|Estimate|||||||2014-08-28|2014-08-29|Estimate|May 2006||2006-05-31|August 2014|2014-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|RESTORE||RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization|RESTORE (Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-label, Multi-centre, Phase IV Study of Subcutaneously Administered Raptiva® (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva®|Terminated|||294|Actual|Merck KGaA||||"The study was terminated after the EMEA recommended to suspend the marketing authorisation of~   Raptiva in the EU"|f||||||||||||||2018-06-01 03:37:24.346016|2018-06-01 03:37:24.346016
NCT00402805|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2008-04-15|2006-11-21|2006-11-22|Estimate|||||||2008-04-15|2008-04-16|Estimate|October 2006||2006-10-31|November 2006|2006-11-30|July 2007|Actual|2007-07-31|February 2007|Actual|2007-02-28||Interventional|||Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy|Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy|Completed||Phase 4|50|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:37:24.399069|2018-06-01 03:37:24.399069
NCT00402792|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2011-01-24|2006-11-21|2006-11-22|Estimate|||||||2011-01-24|2011-01-25|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy|A Randomized, Multicenter, Double-blind Study Comparing the Analgesic Efficacy and Safety of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) to Placebo in Subjects With Acute Pain Following Bunionectomy|Completed||Phase 3|150|Actual|Abbott||3|||f||||f||||||||||2018-06-01 03:37:24.4584|2018-06-01 03:37:24.4584
NCT00402779|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2018-01-03|2006-11-21|2006-11-22|Estimate|||||||2018-01-03|2018-01-05|Actual|November 2006|Actual|2006-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Erlotinib Prevention of Oral Cancer (EPOC)|Erlotinib Prevention of Oral Cancer (EPOC)|Active, not recruiting||Phase 3|150|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 03:37:24.531154|2018-06-01 03:37:24.531154
NCT00402766|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2015-11-16|2006-11-20|2006-11-22|Estimate|||||||2015-11-16|2015-11-18|Estimate|August 2006||2006-08-31|November 2015|2015-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma|Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma|Completed||Phase 1|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:37:24.665056|2018-06-01 03:37:24.665056
NCT00402753|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2010-01-06|2006-11-21|2006-11-22|Estimate|||||||2010-01-06|2010-01-07|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Ambulatory Physical Exercise Program in Hematopoietic Stem Cell Transplantation Recipients|Physical Exercise to Improve Physical Performance and Health Related Quality of Life in Hematopoietic Stem Cell Transplantation Recipients|Completed||Early Phase 1|128|Anticipated|University of Zurich||2|||f||||t||||||||||2018-06-01 03:37:24.753509|2018-06-01 03:37:24.753509
NCT00402740|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2012-05-07||2012-05-17|2006-11-21|2006-11-22|Estimate|2012-05-17|2012-06-20|Estimate||||2012-05-17|2012-06-20|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|PROTECT||Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA) (PROTECT)|Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)|Completed||N/A|322|Actual|Abbott Vascular|||||f||||t||||||||||2018-06-01 03:37:24.853088|2018-06-01 03:37:24.853088
NCT00402558|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2015-05-06|2006-11-20|2006-11-22|Estimate|||||||2015-05-06|2015-05-08|Estimate|May 2006||2006-05-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Alloreactive NK Cells With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for AML and MDS|Completed||Phase 1|15|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:37:30.176744|2018-06-01 03:37:30.176744
NCT00400959|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2006-11-15|2006-11-15|2006-11-17|Estimate|||||||2006-11-15|2006-11-17|Estimate|June 2004||2004-06-30|November 2006|2006-11-30|October 2006||2006-10-31|||||Interventional|||CD133+ Autologous Cells After Myocardial Infarction|Intracoronary Injection of CD133+ Autologous Hematopoietic Cells After Myocardial Infarction|Completed||Phase 1/Phase 2|15||Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||||||||||||2018-06-01 03:38:03.775845|2018-06-01 03:38:03.775845
NCT00402727|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2009-10-13||2014-11-03|2006-11-21|2006-11-22|Estimate|2009-12-08|2010-01-11|Estimate||||2014-11-03|2014-11-07|Estimate|September 2006||2006-09-30|November 2014|2014-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection|A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections|Completed||Phase 3|813|Actual|Bayer|Ten patients (six from the moxifloxacin group and 4 from the comparator group) did not receive study medication. They were excluded from the safety analyses. No adverse events were reported in these patients.|2|||f||||f||||||||||2018-06-01 03:37:25.190022|2018-06-01 03:37:25.190022
NCT00402714|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2016-06-15||2016-11-23|2006-11-20|2006-11-22|Estimate|2016-11-23|2017-01-18|Estimate||||2016-11-23|2017-01-18|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional||Pent/TBI|A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies|A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies|Completed||Phase 2|14|Actual|Yale University||2|||f||||f||||||||||2018-06-01 03:37:25.856368|2018-06-01 03:37:25.856368
NCT00402701|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2007-10-30|2006-11-21|2006-11-22|Estimate|||||||2007-10-30|2007-11-01|Estimate|November 2004||2004-11-30|October 2007|2007-10-31|April 2006|Actual|2006-04-30|||||Interventional|||Pedestrian Behavior Following Implementation of a Walking School Bus|Pedestrian Behavior Following Implementation of a Walking School Bus|Completed||N/A|735|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:37:26.076367|2018-06-01 03:37:26.076367
NCT00402688|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2009-03-20||2013-09-02|2006-11-21|2006-11-22|Estimate|2009-05-27|2009-07-16|Estimate||||2013-09-02|2013-09-13|Estimate|November 2006||2006-11-30|September 2013|2013-09-30|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis|A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis|Completed||Phase 3|242|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 03:37:26.155344|2018-06-01 03:37:26.155344
NCT00402675|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2010-01-04|2006-11-21|2006-11-22|Estimate|||||||2010-01-04|2010-01-05|Estimate|July 2006||2006-07-31|November 2006|2006-11-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|LIPSIA-NSTEMI||Randomized Trial of Immediate Versus Early and Selective Invasive Percutaneous Coronary Intervention in NSTEMI|Leipzig Immediate Versus Early and Late PercutaneouS Coronary Intervention triAl in NSTEMI - LIPSIA-NSTEMI TRIAL|Completed||Phase 4|600|Anticipated|University of Leipzig||3|||f||||t||||||||||2018-06-01 03:37:26.782936|2018-06-01 03:37:26.782936
NCT00402662|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2013-12-17|2006-11-21|2006-11-22|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma|A Phase II Study of Everolimus in Combination With Imatinib in Metastatic Melanoma|Terminated||Phase 2|3|Actual|Yale University||||unexpected level of toxicity|f||||||||||||||2018-06-01 03:37:26.869187|2018-06-01 03:37:26.869187
NCT00402649|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2008-10-16||2011-06-09|2006-11-21|2006-11-22|Estimate|2008-11-20|2008-11-24|Estimate||||2011-06-09|2011-06-13|Estimate|February 2007||2007-02-28|May 2008|2008-05-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Open-Label Study of H5 Vaccine in Participants of Protocol 04-077|Open-Label Study of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years to 10 Years|Completed||Phase 1/Phase 2|35|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 03:37:26.954852|2018-06-01 03:37:26.954852
NCT00402636|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2007-11-27|2006-11-21|2006-11-22|Estimate|||||||2007-11-27|2007-11-28|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|October 2006|Actual|2006-10-31|||||Interventional|||Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE)|Prospective, Randomized Trial of Rapamycin Plus Estradiol-Eluting Stents Versus Rapamycin-Eluting Stents For The Reduction of Coronary Restenosis (ISAR-PEACE)|Completed||Phase 4|502|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 03:37:27.213689|2018-06-01 03:37:27.213689
NCT00402623|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2017-02-22|2006-11-21|2006-11-22|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2006||2006-01-31|February 2008|2008-02-29|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||The Effect of Quercetin in Sarcoidosis|The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis|Completed||N/A|18|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 03:37:27.277952|2018-06-01 03:37:27.277952
NCT00402610|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-18|||2008-10-23|2006-11-21|2006-11-22|Estimate|||||||2008-10-23|2008-10-24|Estimate|January 1994||1994-01-31|November 2006|2006-11-30|December 1998||1998-12-31|||||Interventional|||A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy|A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy|Completed||Phase 4|332||Sociedad Andaluza de Enfermedades Infecciosas|||||f||||||||||||||2018-06-01 03:37:27.335666|2018-06-01 03:37:27.335666
NCT00402597|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|2012-07-25|2011-04-21|2012-09-28|2006-11-21|2006-11-22|Estimate|2012-07-25|2012-08-29|Estimate|2011-04-21|2011-04-28|Estimate|2012-09-28|2012-10-04|Estimate|November 2006||2006-11-30|September 2012|2012-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes|Completed||Phase 2|3490|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||||||||||||2018-06-01 03:37:27.435231|2018-06-01 03:37:27.435231
NCT00402584|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2007-08-30|2006-11-20|2006-11-22|Estimate|||||||2007-08-30|2007-08-31|Estimate|August 2000||2000-08-31|August 2007|2007-08-31||||||||Interventional|||A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder|Completed||Phase 3|304|Actual|Abbott|||||f||||f||||||||||2018-06-01 03:37:30.062702|2018-06-01 03:37:30.062702
NCT00402545|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2009-10-30|2006-11-21|2006-11-22|Estimate|||||||2009-10-30|2009-11-02|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase I Study of Cetuximab/Docetaxel(Taxotere)/Cisplatin/5-Fluorouracil (C-TPF) in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|29|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 03:37:30.272466|2018-06-01 03:37:30.272466
NCT00402532|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2011-12-07|2006-11-20|2006-11-22|Estimate|||||||2011-12-07|2011-12-08|Estimate|March 2005||2005-03-31|December 2011|2011-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation|Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation|Completed||Phase 3|190|Actual|Hannover Medical School||2|||f||||||||||||||2018-06-01 03:37:30.336225|2018-06-01 03:37:30.336225
NCT00402519|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2016-05-12|2006-11-21|2006-11-22|Estimate|||||||2016-05-12|2016-05-13|Estimate|November 2004||2004-11-30|May 2016|2016-05-31|November 2019|Anticipated|2019-11-30|November 2009|Actual|2009-11-30||Interventional|||APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer|Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast|Active, not recruiting||Phase 3|1300|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||Undecided||2018-06-01 03:37:30.406308|2018-06-01 03:37:30.406308
NCT00402506|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2007-11-15|2006-11-20|2006-11-22|Estimate|||||||2007-11-15|2007-11-16|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG|MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery|Completed||Phase 3|3000|Anticipated|Medicure|||||f||||t||||||||||2018-06-01 03:37:30.48918|2018-06-01 03:37:30.48918
NCT00402493|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2018-04-03|2006-11-21|2006-11-22|Estimate|||||||2018-04-03|2018-04-04|Actual|December 2006||2006-12-31|September 2017|2017-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops|A Prospective,Randomized,Masked,Study to Evaluate the Interaction of Non-Steroidal Anti-Inflammatory Agent With IOP-Lowering Effect of Brimonidine or Latanoprost.|Completed||N/A|51|Actual|Philadelphia Eye Associates||3|||f||||f||||||||||2018-06-01 03:37:30.54902|2018-06-01 03:37:30.54902
NCT00402480|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2013-06-17|2006-11-21|2006-11-22|Estimate|||||||2013-06-17|2013-06-19|Estimate|April 2003||2003-04-30|November 2006|2006-11-30|March 2006||2006-03-31|||||Interventional|||Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity|Effects of Hydroxyurea on the Prevention of Primary Stroke in Children With Sickle Cell Anemia and Elevated Transcranial Doppler (TCD) Flow Velocity|Completed||Phase 2|50||Duke University|||||f||||||||||||||2018-06-01 03:37:30.619004|2018-06-01 03:37:30.619004
NCT00402467|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2014-12-18|2006-11-21|2006-11-22|Estimate|||||||2014-12-18|2014-12-23|Estimate|February 2004||2004-02-29|December 2014|2014-12-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study||Completed||Phase 2|613|Actual|Bayer||6|||f||||t||||||||||2018-06-01 03:37:30.807999|2018-06-01 03:37:30.807999
NCT00402454|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-18|||2007-01-09|2006-11-21|2006-11-22|Estimate|||||||2007-01-09|2007-01-11|Estimate|January 1994||1994-01-31|November 2006|2006-11-30|December 1998||1998-12-31|||||Interventional|||Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis|Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis|Completed||Phase 4|300||Sociedad Andaluza de Enfermedades Infecciosas|||||f||||||||||||||2018-06-01 03:37:30.933099|2018-06-01 03:37:30.933099
NCT00402441|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2009-04-28|2006-11-21|2006-11-22|Estimate|||||||2009-04-28|2009-04-29|Estimate|September 2002||2002-09-30|April 2009|2009-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Risedronate in the Prevention of Osteoporosis in Postmenopausal Women|A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women|Completed||Phase 4|260|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:37:30.993743|2018-06-01 03:37:30.993743
NCT00402428|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20||2009-09-17|2013-08-01|2006-11-20|2006-11-22|Estimate||||2009-09-17|2009-09-22|Estimate|2013-08-01|2013-08-08|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients|Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 1. ACHIEVE-1|Completed||Phase 3|1331|Actual|Human Genome Sciences Inc.||3|||f||||||||||||||2018-06-01 03:37:31.098126|2018-06-01 03:37:31.098126
NCT00402415|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2013-12-17|2006-11-21|2006-11-22|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy|A Phase I Trial of the Combination of Sirolimus and SU11248 (Sutent(R)) in Patients With Advanced Solid Tumors That Are Non-Curable With Standard Therapy|Terminated||Phase 1|18|Actual|Yale University||1|||f||||f||||||||||2018-06-01 03:37:31.445715|2018-06-01 03:37:31.445715
NCT00402402|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-21|||2008-04-15|2006-11-21|2006-11-22|Estimate|||||||2008-04-15|2008-04-16|Estimate|October 2006||2006-10-31|November 2006|2006-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease|Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation|Completed||Phase 4|300|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:37:31.520031|2018-06-01 03:37:31.520031
NCT00402389|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2013-03-27|2006-11-21|2006-11-22|Estimate|||||||2013-03-27|2013-03-29|Estimate|June 2004||2004-06-30|March 2013|2013-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Use of Omega-3 Fatty Acids for Perinatal Depression|Randomized Controlled Trial of Omega-3 Fatty Acids for Perinatal Depression|Completed||Phase 2|50|Actual|University of Arizona||2|||f||||||||||||||2018-06-01 03:37:31.583614|2018-06-01 03:37:31.583614
NCT00400270|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2015-05-27|2006-11-15|2006-11-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|January 2006||2006-01-31|||||Interventional|||Breathing and Relaxation Exercises for Asthma: a Randomised Controlled Trial|A Physical Therapy Treatment for Adults Diagnosed With Asthma in Primary Care: a Randomised Controlled Trial|Completed||N/A|56||University College London Hospitals|||||f||||||||||||||2018-06-01 03:38:15.66278|2018-06-01 03:38:15.66278
NCT00402376|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2011-08-29|2006-11-21|2006-11-22|Estimate|||||||2011-08-29|2011-08-30|Estimate|April 2007||2007-04-30|August 2011|2011-08-31||||||||Interventional|||Evaluation of Myocardial Improvement in Patients Supported by Ventricular Assist Device Under Optimal Pharmacological Therapy|Effects of Combined Ventricular Unloading and Pharmacological Therapy on Left Ventricular Metabolic Dysfunction in Heart Failure|Terminated||Phase 4|20|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:37:31.914829|2018-06-01 03:37:31.914829
NCT00402363|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2010-09-23||2016-12-01|2006-11-20|2006-11-22|Estimate|2010-09-23|2010-10-15|Estimate||||2016-12-01|2017-01-30|Estimate|November 2006||2006-11-30|December 2016|2016-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation|Completed||Phase 3|663|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:37:32.082229|2018-06-01 03:37:32.082229
NCT00402350|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2017-03-13|2006-11-21|2006-11-22|Estimate|||||||2017-03-13|2017-03-15|Actual|April 2006||2006-04-30|February 2008|2008-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Staccato Fentanyl Single and Multidose PK|Safety, Tolerability, and Pharmacokinetics of Staccato® Fentanyl for Inhalation in Normal, Healthy Volunteers|Completed||Phase 1|51|Actual|Alexza Pharmaceuticals, Inc.||6|||f||||f||||||||||2018-06-01 03:37:35.486975|2018-06-01 03:37:35.486975
NCT00402337|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-18|2012-09-28||2013-01-29|2006-11-20|2006-11-22|Estimate|2013-01-29|2013-03-05|Estimate||||2013-01-29|2013-03-05|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation|A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-group, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation|Completed||Phase 2|310|Actual|Ironwood Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-06-01 03:37:35.811826|2018-06-01 03:37:35.811826
NCT00402324|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2009-02-13||2009-05-28|2006-11-17|2006-11-22|Estimate|2009-04-03|2009-05-27|Estimate||||2009-05-28|2009-06-03|Estimate|December 2006||2006-12-31|May 2009|2009-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients|A Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode|Completed||Phase 4|202|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:37:37.107088|2018-06-01 03:37:37.107088
NCT00402311|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2007-01-19|2006-11-20|2006-11-22|Estimate|||||||2007-01-19|2007-01-22|Estimate|April 2002||2002-04-30|November 2006|2006-11-30|August 2005||2005-08-31|||||Interventional|||The Effects and Cost-Effectiveness of an Integrated Multidisciplinary Approach for Psychogeriatric Patients|A Prospective Randomized Trial on the Effects of a Psychogeriatric Diagnostic Day Hospital|Completed||N/A|216||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:37:37.770981|2018-06-01 03:37:37.770981
NCT00402298|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2011-04-01|2006-11-20|2006-11-22|Estimate|||||||2011-04-01|2011-04-04|Estimate|January 2008||2008-01-31|March 2011|2011-03-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Randomized Placebo-controlled Study of MDMA-assisted Psychotherapy in People With PTSD - Israel|MDMA-assisted Psychotherapy in Twelve People With War and Terrorism-related Posttraumatic Stress Disorder (PTSD)|Terminated||Phase 2|12|Anticipated|Multidisciplinary Association for Psychedelic Studies||2||"This study was terminated after enrolling five subjects due to staff turnover and its effects~   on quality of data collection."|f||||f||||||||||2018-06-01 03:37:37.865224|2018-06-01 03:37:37.865224
NCT00402285|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2012-09-13||2015-12-02|2006-11-20|2006-11-22|Estimate|2013-04-09|2013-05-16|Estimate||||2015-12-02|2016-01-01|Estimate|April 2003||2003-04-30|December 2015|2015-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer|The Molecular Effects of Nutrition Supplements (MENS) Prostate Study|Completed||N/A|84|Actual|University of California, San Francisco||3|||f||||||||||||||2018-06-01 03:37:37.956792|2018-06-01 03:37:37.956792
NCT00402272|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2010-10-13|2006-11-17|2006-11-22|Estimate|||||||2010-10-13|2010-10-14|Estimate|November 2006||2006-11-30|October 2010|2010-10-31|June 2010|Actual|2010-06-30|February 2008|Actual|2008-02-29||Interventional|SPIRIT V||SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe|SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions|Completed||Phase 4|2700|Actual|Abbott Vascular||1|||f||||t||||||||||2018-06-01 03:37:38.19158|2018-06-01 03:37:38.19158
NCT00402259|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2009-03-11|2006-11-17|2006-11-22|Estimate|||||||2009-03-11|2009-03-12|Estimate|August 2006||2006-08-31|March 2009|2009-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding|A Randomised, Double-Blind, Double-Dummy, Active-Controlled, Multicenter Study to Assess the Efficacy and Safety of Esomeprazole or Omeprazole for 5 Days in Subjects With Acute Non-Variceal Upper Gastrointestinal Bleeding|Completed||Phase 3|440|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:37:38.374895|2018-06-01 03:37:38.374895
NCT00402246|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2010-09-29||2011-02-23|2006-11-17|2006-11-22|Estimate|2011-01-19|2011-02-16|Estimate||||2011-02-23|2011-02-25|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|CONNECT||CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision|CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision|Completed||N/A|2009|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-06-01 03:37:38.470198|2018-06-01 03:37:38.470198
NCT00402233|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-19|2009-09-22||2014-05-07|2006-11-19|2006-11-22|Estimate|2009-12-10|2010-01-13|Estimate||||2014-05-07|2014-05-16|Estimate|November 2006||2006-11-30|May 2014|2014-05-31||||September 2008|Actual|2008-09-30||Interventional|||A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients|A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID)|Completed||Phase 4|312|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 03:37:39.406295|2018-06-01 03:37:39.406295
NCT00402220|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-18|||2007-10-30|2006-11-20|2006-11-22|Estimate|||||||2007-10-30|2007-10-31|Estimate|January 2007||2007-01-31|October 2007|2007-10-31|January 2010|Anticipated|2010-01-31|||||Interventional|||A Double-Blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression|A Double-Blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression|Unknown status|Recruiting|N/A|120|Anticipated|Bayside Health||2|||f||||||||||||||2018-06-01 03:37:39.936016|2018-06-01 03:37:39.936016
NCT00402207|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2006-11-20|2006-11-20|2006-11-22|Estimate|||||||2006-11-20|2006-11-22|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|October 2006||2006-10-31|||||Interventional|||The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry|The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Exhaled Nitric Oxide, Inflammatory Markers in Exhaled Breath Condensate and Conventional Parameters|Completed||N/A|33||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:37:40.017099|2018-06-01 03:37:40.017099
NCT00402194|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2013-05-06||2013-09-20|2006-11-20|2006-11-22|Estimate|2013-09-20|2013-09-24|Estimate||||2013-09-20|2013-09-24|Estimate|June 2005||2005-06-30|September 2013|2013-09-30|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Treating the Endothelium to Restore Insulin Sensitivity|Treating the Endothelium to Restore Insulin Sensitivity|Completed||N/A|17|Actual|Indiana University|||||f||||t||||||||||2018-06-01 03:37:40.085096|2018-06-01 03:37:40.085096
NCT00402181|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2014-05-13|2006-11-17|2006-11-22|Estimate|||||||2014-05-13|2014-05-14|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma|A Phase 2 Multicenter Study of CNTO 328 (Anti IL-6 Monoclonal Antibody) in Subjects With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|53|Actual|Centocor, Inc.||2|||f||||t||||||||||2018-06-01 03:37:40.296776|2018-06-01 03:37:40.296776
NCT00402168|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2015-11-10|2010-04-29|2016-11-07|2006-11-21|2006-11-22|Estimate|2016-11-07|2017-01-05|Estimate|2010-04-29|2010-05-03|Estimate|2016-11-07|2017-01-05|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2009|Actual|2009-06-30||Interventional||Participants randomized to a treatment arm.|A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids|Belatacept Conversion Trial in Renal Transplantation|Completed||Phase 2|173|Actual|Bristol-Myers Squibb|CNI arm discontinued Year 3, and those not switching treatment discontinued from study. No formal comparisons in calculated GFR were planned post Month 36, and these data up to the final database lock should be interpreted with caution.|2|||f||||t||||||||||2018-06-01 03:37:40.486197|2018-06-01 03:37:40.486197
NCT00402155|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2009-11-11|2006-11-17|2006-11-22|Estimate|||||||2009-11-11|2009-11-13|Estimate|July 2004||2004-07-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|||||Observational|||Visual Discomfort and Reading|Visual Discomfort and Reading|Completed|||100|Anticipated|Southern California College of Optometry|||2||f||||||||||||||2018-06-01 03:37:43.055485|2018-06-01 03:37:43.055485
NCT00402142|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2014-02-25|2006-11-17|2006-11-22|Estimate|||||||2014-02-25|2014-02-26|Estimate|November 2006||2006-11-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dendritic Cell Vaccine in HIV-1 Infection|"Phase II Study of Autologous Myeloid Dendritic Cells as a Cellular Adjuvant for a Therapeutic HIV-1 Vaccine in Early Stage HIV-1+ Patients (DCV-2)."|Completed||Phase 1/Phase 2|60|Actual|Hospital Clinic of Barcelona||5|||f||||t||||||||||2018-06-01 03:37:43.12255|2018-06-01 03:37:43.12255
NCT00402129|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2006-11-20|2006-11-20|2006-11-22|Estimate|||||||2006-11-20|2006-11-22|Estimate|January 2006||2006-01-31|November 2006|2006-11-30|May 2006||2006-05-31|||||Interventional|||Low Fluence 1064nm Laser Hair Reduction for Pseudofolliculitis Barbae in Skin Types IV, V, VI|Clinical Safety and Efficacy of Prototype Devices for Hair Growth Control: Task 2.4|Completed||N/A|22||United States Naval Medical Center, San Diego|||||f||||||||||||||2018-06-01 03:37:43.197734|2018-06-01 03:37:43.197734
NCT00402116|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17||2010-10-25|2010-10-25|2006-11-17|2006-11-22|Estimate||||2010-10-25|2010-10-27|Estimate|2010-10-25|2010-10-27|Estimate|September 2006||2006-09-30|October 2010|2010-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients|Phase 1/2 Study of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|Completed||Phase 1/Phase 2|72|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:37:43.262968|2018-06-01 03:37:43.262968
NCT00402103|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-18|2010-12-13||2011-03-08|2006-11-20|2006-11-22|Estimate|2010-12-13|2011-01-11|Estimate||||2011-03-08|2011-03-10|Estimate|November 2006||2006-11-30|March 2011|2011-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure|A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg / Amlodipine 10 mg in Patients With Essential Hypertension|Completed||Phase 3|556|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:37:43.360065|2018-06-01 03:37:43.360065
NCT00402090|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2006-11-17|2006-11-17|2006-11-22|Estimate|||||||2006-11-17|2006-11-22|Estimate|April 2005||2005-04-30|November 2006|2006-11-30|November 2006||2006-11-30|||||Observational|||DHPLC Determination of TPMT Polymorphisms.|Prevention of Thiopurines Related Toxicity Through the Determination by DHPLC TPMT Polymorphisms in Patients With ALL.|Unknown status|Recruiting||160||National Institute of Cancerología|||||f||||||||||||||2018-06-01 03:37:43.837964|2018-06-01 03:37:43.837964
NCT00402077|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2015-03-05|2006-11-17|2006-11-22|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2006||2006-11-30|February 2015|2015-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects|A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects|Completed||Phase 2|258|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 03:37:43.911823|2018-06-01 03:37:43.911823
NCT00402064|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2009-01-28|2006-11-20|2006-11-22|Estimate|||||||2009-01-28|2009-01-29|Estimate|March 2007||2007-03-31|January 2009|2009-01-31|December 2008||2008-12-31|||||Observational|||The Influence of Bisphosphonates in the Oral Cavity in Children|The Influence of Bisphosphonates in the Oral Cavity in Children|Completed|||60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:37:44.026661|2018-06-01 03:37:44.026661
NCT00402051|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2009-11-30||2010-02-01|2006-11-17|2006-11-22|Estimate|2009-11-30|2010-01-07|Estimate||||2010-02-01|2010-02-17|Estimate|November 2006||2006-11-30|February 2010|2010-02-28|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC|Completed||Phase 2|133|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:37:44.129543|2018-06-01 03:37:44.129543
NCT00402038|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2011-07-18|2006-11-20|2006-11-22|Estimate|||||||2011-07-18|2011-07-19|Estimate|February 2004||2004-02-29|July 2011|2011-07-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study of Methylnaltrexone (MNTX) for the Relief of Constipation|A Double-Blind, Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone(MNTX) for the Relief of Constipation Due to Opioid Therapy in Advance Medical Illness.|Completed||Phase 3|134|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||t||||||||||2018-06-01 03:37:44.774474|2018-06-01 03:37:44.774474
NCT00402025|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2015-11-19||2016-04-11|2006-11-17|2006-11-22|Estimate|2016-04-11|2016-04-15|Estimate||||2016-04-11|2016-04-15|Estimate|November 2006||2006-11-30|April 2016|2016-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||The Intention-to-Treat (ITT) population included all participants who received at least 1 dose of talimogene laherparepvec.|Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer|Targeted Delivery of OncoVEX^GM-CSF by Endoscopic Ultrasound (EUS)-Guided Fine Needle Injection (FNI) in Patients With Irresectable Pancreatic Cancer: A Pilot Multinational Experiment on Safety and Proof of Concept|Completed||Phase 1|17|Actual|BioVex Limited||1|||f||||||||||||||2018-06-01 03:37:44.912471|2018-06-01 03:37:44.912471
NCT00402012|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2015-12-17|2006-11-17|2006-11-22|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||"TAKE TIME Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM"|Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM|Completed||Phase 4|24|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-06-01 03:37:45.838642|2018-06-01 03:37:45.838642
NCT00401999|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-18|||2017-06-30|2006-11-18|2006-11-22|Estimate|||||||2017-06-30|2017-07-02|Actual|November 16, 2006||2006-11-16|January 28, 2011|2011-01-28|January 28, 2011||2011-01-28|||||Observational|||OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine|OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine|Completed|||35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:37:45.935119|2018-06-01 03:37:45.935119
NCT00401986|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2012-05-25|2006-11-17|2006-11-22|Estimate|||||||2012-05-25|2012-05-30|Estimate|December 2006||2006-12-31|May 2012|2012-05-31||||||||Observational|||RISA Extension Study - Long Term Safety|Long Term Safety Evaluation of Bronchial Thermoplasty With the Alair® System in Patients With Severe Asthma|Unknown status|Active, not recruiting||15|Anticipated|Asthmatx, Inc.|||1||f||||t||||||||||2018-06-01 03:37:46.010647|2018-06-01 03:37:46.010647
NCT00401973|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2009-08-27||2009-09-30|2006-11-17|2006-11-22|Estimate|2009-08-27|2009-09-30|Estimate||||2009-09-30|2009-10-06|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine|The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia|Completed||Phase 3|199|Actual|Eli Lilly and Company||3|||f||||||||||||||2018-06-01 03:37:46.157935|2018-06-01 03:37:46.157935
NCT00401960|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2016-12-29||2017-04-06|2006-11-20|2006-11-22|Estimate|2017-04-06|2017-05-03|Actual||||2017-04-06|2017-05-03|Actual|September 2006||2006-09-30|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||see study inclusion criteria|Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.|Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis|Terminated||Phase 4|6|Actual|Weill Medical College of Cornell University|study terminated due to insufficient enrollment; data therefore not analyzed|2||inadequate enrollment|f||||t||||||||No|This was a pilot single arm study, for which IPD are not pertinent|2018-06-01 03:37:47.122486|2018-06-01 03:37:47.122486
NCT00401947|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2015-12-29|2006-11-17|2006-11-22|Estimate|||||||2015-12-29|2015-12-30|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|March 2007|Actual|2007-03-31|||||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ACH-0137171 in Subjects With Chronic Hepatitis C Infection|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects With Chronic Hepatitis C Infection|Terminated||Phase 2|30|Anticipated|Achillion Pharmaceuticals||||Nephrotoxicity|f||||||||||||||2018-06-01 03:37:47.41183|2018-06-01 03:37:47.41183
NCT00401934|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2010-08-26|2006-11-21|2006-11-22|Estimate|||||||2010-08-26|2010-08-27|Estimate|November 2006||2006-11-30|July 2007|2007-07-31||||||||Observational|||Immunity to Human Cholera in Bangladesh|Protective Immunity to Human Cholera in Bangladesh|Unknown status|Recruiting||325||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:37:47.482842|2018-06-01 03:37:47.482842
NCT00401921|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2017-07-12|2006-11-17|2006-11-22|Estimate|||||||2017-07-12|2017-07-14|Actual|October 2006||2006-10-31|July 2017|2017-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy|A Randomized, Placebo-Controlled Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy|Withdrawn||Phase 2|0|Actual|Brigham and Women's Hospital||2||PI moved to a new facility|f||||t||||||||||2018-06-01 03:37:47.536134|2018-06-01 03:37:47.536134
NCT00401908|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2015-09-25|2006-11-20|2006-11-22|Estimate|||||||2015-09-25|2015-09-28|Estimate|November 2006||2006-11-30|September 2015|2015-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding|Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding|Withdrawn|||0|Actual|Maimonides Medical Center|||||f||||||||||||||2018-06-01 03:37:47.607267|2018-06-01 03:37:47.607267
NCT00401895|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2009-01-08|2006-11-20|2006-11-22|Estimate|||||||2009-01-08|2009-01-09|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents|Clinical Efficacy of Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents in Cirrhotic Patients: A Randomized Controlled Study|Terminated||Phase 2|44|Actual|University of Roma La Sapienza||2||"An interim analysis revealed a significantly higher persistence/recurrence of complications of~   portal hypertension in the 8 mm-stent group."|f||||||||||||||2018-06-01 03:37:47.659359|2018-06-01 03:37:47.659359
NCT00401882|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2013-07-18||2017-04-20|2006-11-20|2006-11-22|Estimate|2017-03-23|2017-03-31|Actual||||2017-04-20|2017-05-25|Actual|January 2007||2007-01-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|June 2011|Actual|2011-06-30||Interventional|Shock n Block||Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial|Treatment of Ventricular Tachyarrhythmias Refractory To Shock With Beta Blockers: The SHOCK and BLOCK Trial|Terminated||Phase 2|7|Actual|William Beaumont Hospitals|Early termination secondary to poor enrollment|2||Difficult accrual|f|||||t|||||||||2018-06-01 03:37:47.744174|2018-06-01 03:37:47.744174
NCT00401869|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2010-04-05|2006-11-20|2006-11-22|Estimate|||||||2010-04-05|2010-04-06|Estimate|February 1999||1999-02-28|April 2010|2010-04-30|December 2001|Actual|2001-12-31|||||Interventional|||The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)|The Effect of PROCRIT on Hemoglobin and Hematocrit and the Relationship to Postoperative Function, Vigor and Strength in Patients Undergoing Primary Total Joint Arthroplasty: A Randomized, Parallel Group, Open-Label Trial|Completed||Phase 4|289|Actual|Ortho Biotech Clinical Affairs, L.L.C.|||||f||||||||||||||2018-06-01 03:37:48.022836|2018-06-01 03:37:48.022836
NCT00401856|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2008-12-10|2006-11-20|2006-11-22|Estimate|||||||2008-12-10|2008-12-11|Estimate|December 2007||2007-12-31|December 2008|2008-12-31|July 2010|Anticipated|2010-07-31|December 2009|Anticipated|2009-12-31||Interventional|||CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone|A Randomised, Double-Blinded, Placebo-Controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy With Eplerenone|Unknown status|Recruiting|Phase 4|140|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||||||||||||2018-06-01 03:37:48.079896|2018-06-01 03:37:48.079896
NCT00401843|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2015-07-07|2015-03-27|2018-01-04|2006-11-17|2006-11-22|Estimate|2015-07-07|2015-08-04|Estimate|2015-03-27|2015-04-16|Estimate|2018-01-04|2018-01-08|Actual|November 28, 2006|Actual|2006-11-28|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|August 16, 2011|Actual|2011-08-16||Interventional|||A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade Versus Velcade Alone in Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 2|311|Actual|Janssen Research & Development, LLC||3|||f||||||f||||||||2018-06-01 03:37:48.207715|2018-06-01 03:37:48.207715
NCT00401830|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2009-09-22||2017-07-28|2006-11-20|2006-11-22|Estimate|2009-09-22|2009-10-22|Estimate||||2017-07-28|2017-08-28|Actual|October 2006||2006-10-31|July 2017|2017-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.|A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/Day Lacosamide Tablets in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome|Completed||Phase 2|159|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 03:37:49.405148|2018-06-01 03:37:49.405148
NCT00401817|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|2017-02-23||2017-09-15|2006-11-20|2006-11-22|Estimate|2017-09-15|2017-10-20|Actual||||2017-09-15|2017-10-20|Actual|November 2007|Actual|2007-11-30|September 2017|2017-09-30|November 2013|Actual|2013-11-30|July 2011|Actual|2011-07-31||Interventional|||Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma|Phase II Study of Bevacizumab Plus CHOP-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL)|Completed||Phase 2|11|Actual|Weill Medical College of Cornell University||1|||f||||||||||||||2018-06-01 03:37:49.976449|2018-06-01 03:37:49.976449
NCT00401804|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-20|||2013-01-23|2006-11-20|2006-11-22|Estimate|||||||2013-01-23|2013-01-24|Estimate|February 2006||2006-02-28|July 2010|2010-07-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||Bortezomib-Dexamethasone-Doxorubicin-Study|Bortezomib-Doxorubicin-Dexamethasone as Treatment for Patients With Multiple Myeloma Presenting With Acute Renal Failure|Completed||Phase 2|72|Actual|Austrian Forum Against Cancer|||||f||||||||||||||2018-06-01 03:37:50.146331|2018-06-01 03:37:50.146331
NCT00401791|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2016-01-22|2006-11-17|2006-11-22|Estimate|||||||2016-01-22|2016-01-25|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|December 2008|Actual|2008-12-31||Interventional|||ACTIV- Exercise Intervention in Healthy Young Men|"ACTIVValidation of a Paradigm for the Evaluation of Compounds That Activate Mitochondrial Biogenesis in Skeletal Muscle"|Unknown status|Active, not recruiting|Phase 4|78|Anticipated|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-06-01 03:37:50.215623|2018-06-01 03:37:50.215623
NCT00401778|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2015-01-23||2016-11-03|2006-11-17|2006-11-22|Estimate|2015-06-18|2015-07-14|Estimate||||2016-11-03|2016-12-21|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)|Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|33|Actual|Emory University||3|||f||||t||||||||||2018-06-01 03:37:50.314162|2018-06-01 03:37:50.314162
NCT00401765|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2014-05-23|2006-11-17|2006-11-22|Estimate|||||||2014-05-23|2014-05-26|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined With Docetaxel in Subjects With Metastatic Hormone-Refractory Prostate Cancer|Completed||Phase 1|40|Actual|Centocor, Inc.||4|||f||||f||||||||||2018-06-01 03:37:50.79327|2018-06-01 03:37:50.79327
NCT00401752|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2009-11-12||2010-06-10|2006-11-17|2006-11-22|Estimate|2010-06-10|2010-07-08|Estimate||||2010-06-10|2010-07-08|Estimate|March 2006||2006-03-31|June 2010|2010-06-30|November 2008|Actual|2008-11-30|||||Interventional|||Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer|A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, 8 Week Comparative Efficacy and Safety Study of Esomeprazole 20 mg Every Day (qd) Versus Ranitidine 150 mg Twice a Day (Bid) in Patients With an NSAID-associated Gastric Ulcer When Daily NSAID is Continued|Completed||Phase 3|397|Actual|AstraZeneca|According to the protocol, the sample size was 320 patients which could achieve 80% power of superiority. Since the patient recruitment is very difficult, total 219 patients were randomized in present study, the power decreased to 60%||||f||||||||||||||2018-06-01 03:37:50.903792|2018-06-01 03:37:50.903792
NCT00401739|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2009-09-14|2006-11-16|2006-11-20|Estimate|||||||2009-09-14|2009-09-16|Estimate|December 2006||2006-12-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia|Phase I Study of CSL360 in Patients With Relapsed, Refractory or High-Risk Acute Myeloid Leukemia|Completed||Phase 1|40|Actual|CSL Limited||1|||f||||f||||||||||2018-06-01 03:37:51.149927|2018-06-01 03:37:51.149927
NCT00401726|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2009-03-31||2012-04-19|2006-11-17|2006-11-20|Estimate|2010-05-26|2010-06-29|Estimate||||2012-04-19|2012-04-23|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program|Patient Outcomes With Education, Drug Therapy, and Support (POETS): A Multicenter, Open-label, Randomized Study to Evaluate Depressed Subjects Treated With Venlafaxine Extended-release vs. Venlafaxine Extended-release Plus the Dialogues Time to Talk Program in a Primary Care Setting|Completed||Phase 4|537|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:37:51.248715|2018-06-01 03:37:51.248715
NCT00401713|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2008-09-21|2006-11-17|2006-11-20|Estimate|||||||2008-09-21|2008-09-23|Estimate|February 2004||2004-02-29|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Transplantation of Autologous RPE Versus Translocation of Autologous RPE and Choroid in AMD|Transplantation of Autologous RPE Versus Translocation of Autologous RPE and Choroid in AMD|Completed||N/A|40|Anticipated|The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery|||||f||||||||||||||2018-06-01 03:37:51.722206|2018-06-01 03:37:51.722206
NCT00393887|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|2015-07-29||2015-10-16|2006-10-27|2006-10-30|Estimate|2015-07-29|2015-08-25|Estimate||||2015-10-16|2015-11-20|Estimate|March 2007||2007-03-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Inguinal Hernia Study Using Biodesign IHM|Inguinal Hernia Study: A Double Blinded Randomized Prospective Study|Completed||N/A|100|Actual|Cook Group Incorporated||2|||f||||f||||||||||2018-06-01 03:40:27.408499|2018-06-01 03:40:27.408499
NCT00401687|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-05-19|2006-11-17|2006-11-20|Estimate|||||||2011-05-19|2011-05-20|Estimate|July 2006||2006-07-31|May 2011|2011-05-31|April 2008|Actual|2008-04-30|June 2007|Actual|2007-06-30||Interventional|||DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function|A Multicenter, Phase IV Study to Evaluate the Ability of Definity® Enhanced Versus Unenhanced Echocardiography to Improve the Accuracy and Reproducibility of Left Ventricular Ejection Fraction When Compared to Cardiac Magnetic Resonance Imaging|Completed||Phase 4|131|Actual|Lantheus Medical Imaging|||||f||||f||||||||||2018-06-01 03:37:51.95758|2018-06-01 03:37:51.95758
NCT00401674|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2016-01-13|2006-11-17|2006-11-20|Estimate|||||||2016-01-13|2016-01-14|Estimate|June 2003||2003-06-30|January 2016|2016-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|MITO-5||MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer|Phase II Multicenter Study of the Combination of Weekly Carboplatin and Paclitaxel as First-line Chemotherapy for Elderly Patients With Ovarian Cancer.|Completed||Phase 2|26|Actual|National Cancer Institute, Naples||1|||f||||||||||||||2018-06-01 03:37:52.027357|2018-06-01 03:37:52.027357
NCT00401661|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2009-09-14|2006-11-17|2006-11-20|Estimate|||||||2009-09-14|2009-09-15|Estimate|June 2006||2006-06-30|September 2009|2009-09-30||||December 2007|Actual|2007-12-31||Interventional|SAMBA-Thailand||Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin|Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study.|Completed||Phase 4|110|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:37:52.114763|2018-06-01 03:37:52.114763
NCT00401648|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2009-11-30|2006-11-17|2006-11-20|Estimate|||||||2009-11-30|2009-12-01|Estimate|September 2002||2002-09-30|November 2009|2009-11-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Effect of Brivaracetam in Photosensitive Epileptic Subjects|A Placebo-controlled, Single-blind, Multi-center Study to Explore the Photoparoxysmal Response in Photosensitive Epileptic Subjects After One Single Oral Dose of Brivaracetam in Capsules.|Completed||Phase 2|20||UCB Pharma|||||f||||||||||||||2018-06-01 03:37:52.203708|2018-06-01 03:37:52.203708
NCT00401635|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2007-09-04|2006-11-17|2006-11-20|Estimate|||||||2007-09-04|2007-09-05|Estimate|November 2002||2002-11-30|September 2007|2007-09-30||||||||Interventional|||END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin|Phase II Multicentered Study of First-Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With the Combination of Carboplatin and Liposomal Doxorubicin|Completed||Phase 2|42||National Cancer Institute, Naples|||||f||||||||||||||2018-06-01 03:37:52.268355|2018-06-01 03:37:52.268355
NCT00401622|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2010-05-29||2010-08-20|2006-11-17|2006-11-20|Estimate|2010-08-20|2010-09-16|Estimate||||2010-08-20|2010-09-16|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes||Completed||N/A|320|Actual|LifeScan||2|||f||||f||||||||||2018-06-01 03:37:52.361834|2018-06-01 03:37:52.361834
NCT00401609|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2016-01-13|2006-11-17|2006-11-20|Estimate|||||||2016-01-13|2016-01-14|Estimate|November 2000||2000-11-30|January 2016|2016-01-31|February 2009|Actual|2009-02-28|December 2007|Actual|2007-12-31||Interventional|G-Step||G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients|Evaluation of Activity and Toxicity of Polychemotherapy With 2-drug Combinations Containing Gemcitabine as First Line Treatment of Elderly Patients With Small Cell Lung Cancer|Completed||Phase 1/Phase 2|85||National Cancer Institute, Naples|||||f||||||||||||||2018-06-01 03:37:52.700201|2018-06-01 03:37:52.700201
NCT00401596|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2014-03-18|2006-11-17|2006-11-20|Estimate|||||||2014-03-18|2014-03-19|Estimate|July 2000||2000-07-31|March 2014|2014-03-31|July 2002|Actual|2002-07-31|||||Interventional|||A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)|A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO)|Completed||Phase 3|1899||Genentech, Inc.|||||f||||||||||||||2018-06-01 03:37:52.797983|2018-06-01 03:37:52.797983
NCT00401583|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2017-11-08|2006-11-17|2006-11-20|Estimate|||||||2017-11-08|2017-11-13|Actual|July 28, 2006|Actual|2006-07-28|November 2017|2017-11-30|February 20, 2008|Actual|2008-02-20|February 20, 2008|Actual|2008-02-20||Interventional|||A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes|A Multi-center, Open-Label, Multiple-probe Drug Interaction Study to Determine the Effects of GW786034 on the Metabolism of Cytochrome P450 Probe Drugs in Patients With Solid Tumors|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:37:52.890392|2018-06-01 03:37:52.890392
NCT00401570|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16||2012-04-25|2013-01-28|2006-11-16|2006-11-20|Estimate||||2012-04-25|2012-04-27|Estimate|2013-01-28|2013-01-30|Estimate|March 2005||2005-03-31|January 2013|2013-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer|Phase 2 Open-Label Study of Volociximab (M200) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer Not Previously Treated With Chemotherapy|Completed||Phase 2|40|Actual|AbbVie||2|||f||||||||||||||2018-06-01 03:37:52.964095|2018-06-01 03:37:52.964095
NCT00401557|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-08-03|2006-11-17|2006-11-20|Estimate|||||||2011-08-03|2011-08-04|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|||||Observational|||Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection|Intervenable Host - Leishmania (Viannia) Interactions - Project 3: Immune and Inflammatory Responses in L. (Viannia) Infection - Aim 3: Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection|Completed|||34|Actual|Yale University|||||f||||||||||||||2018-06-01 03:37:53.05276|2018-06-01 03:37:53.05276
NCT00401544|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2011-03-04||2013-12-10|2006-11-16|2006-11-20|Estimate|2013-12-10|2014-01-29|Estimate||||2013-12-10|2014-01-29|Estimate|December 2006||2006-12-31|December 2013|2013-12-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Darbepoetin Alfa With or Without Intravenous (IV) Iron|Once Per Cycle Treatment of Anemia With Darbepoetin Alfa With Iron in Subjects With Non Myeloid Malignancies|Completed||Phase 2|243|Actual|Amgen||4|||f||||||||||||||2018-06-01 03:37:53.148611|2018-06-01 03:37:53.148611
NCT00401531|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2014-02-14||2014-02-14|2006-11-16|2006-11-20|Estimate|2014-02-14|2014-04-01|Estimate||||2014-02-14|2014-04-01|Estimate|October 2006||2006-10-31|February 2014|2014-02-28|August 2008|Actual|2008-08-31|November 2007|Actual|2007-11-30||Interventional|||Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants|Immunogenicity Study of a DTaP IPV Hep B PRP T Combined Vaccine in Comparison to Infanrix Hexa™, Both Concomitantly Administered With Prevnar™ at 2, 4, and 6 Months of Age in Thai Infants|Completed||Phase 3|412|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:37:54.846744|2018-06-01 03:37:54.846744
NCT00401518|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2017-12-13|2006-11-17|2006-11-20|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2006||2006-10-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis|The Investigational Plan for the Evaluation of the ACADIA® Facet Replacement System|Completed||N/A|390|Actual|Globus Medical Inc||2|||f||||t||||||||||2018-06-01 03:37:55.488295|2018-06-01 03:37:55.488295
NCT00401492|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2012-07-12|2006-11-17|2006-11-20|Estimate|||||||2012-07-12|2012-07-13|Estimate|June 2002||2002-06-30|July 2012|2012-07-31|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer|Phase II Study of Chemotherapy With Gemcitabine in Prolonged Infusion or With Schedules With Cisplatin in Non-small Cell Lung Cancer Elderly Patients|Completed||Phase 2|159|Actual|National Cancer Institute, Naples|||||f||||||||||||||2018-06-01 03:37:55.804081|2018-06-01 03:37:55.804081
NCT00401479|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2008-10-15|2006-11-16|2006-11-20|Estimate|||||||2008-10-15|2008-10-16|Estimate|October 2006||2006-10-31|October 2008|2008-10-31||||||||Interventional|||A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers|An Exploratory Phase I Study in Healthy Volunteers of GI Transit Following Administration of the ß3-Adrenergic Receptor Agonist, Solabegron (Study B3I106248)|Completed||Phase 1|36|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:37:55.896495|2018-06-01 03:37:55.896495
NCT00401466|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2011-01-14|2006-11-17|2006-11-20|Estimate|||||||2011-01-14|2011-01-17|Estimate|January 2004||2004-01-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|REFORM||Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy|Remote Follow-up for ICD-Therapy in Patients Meeting MADIT II Criteria (REFORM)|Completed||Phase 4|155|Actual|Biotronik SE & Co. KG||2|||f||||f||||||||||2018-06-01 03:37:55.979534|2018-06-01 03:37:55.979534
NCT00401453|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2010-02-16|2006-11-17|2006-11-20|Estimate|||||||2010-02-16|2010-02-17|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||OatMeal and Insulin Resistance: OMA-IR|Carbohydrate Days as Simple and Efficient Therapy for Patients With Type 2 Diabetes Mellitus and Insulin Resistance: Oatmeal and Insulin Resistance (OMA-IR).|Completed||Phase 3|15|Anticipated|Universitätsmedizin Mannheim|||||f||||||||||||||2018-06-01 03:37:56.07|2018-06-01 03:37:56.07
NCT00401440|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2010-03-11|2006-11-17|2006-11-20|Estimate|||||||2010-03-11|2010-03-12|Estimate|January 2007||2007-01-31|December 2008|2008-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of Two Regimens of Misoprostol for Second Trimester Medical Termination of Pregnancy|Comparison of Twq Different Regimen of Vaginal Misoprostol for Nid Trimester MTP|Completed||Phase 4|185|Actual|Nilratan Sircar Medical College||2|||f||||t||||||||||2018-06-01 03:37:56.152603|2018-06-01 03:37:56.152603
NCT00401427|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2012-07-12|2006-11-17|2006-11-20|Estimate|||||||2012-07-12|2012-07-13|Estimate|November 2002||2002-11-30|July 2012|2012-07-31|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Interventional|||HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer|A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2|Completed||Phase 2|50||National Cancer Institute, Naples|||||f||||||||||||||2018-06-01 03:37:56.242619|2018-06-01 03:37:56.242619
NCT00401414|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2013-03-20||2013-07-30|2006-11-16|2006-11-20|Estimate|2013-07-30|2013-08-30|Estimate||||2013-07-30|2013-08-30|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information|CReating an Optimal Warfarin Nomogram (CROWN) Trial|Completed||N/A|344|Actual|Brigham and Women's Hospital||1|||f||||t||||||||||2018-06-01 03:37:56.346271|2018-06-01 03:37:56.346271
NCT00401401|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2011-10-07||2011-11-21|2006-11-17|2006-11-20|Estimate|2011-11-21|2011-12-23|Estimate||||2011-11-21|2011-12-23|Estimate|December 2006||2006-12-31|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer|An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled|Terminated||Phase 1/Phase 2|30|Actual|Genmab|"All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years.~The planned parallell group of the study was cancelled."|4||"MTD was established and patients completed 16 months safety f-up and response assessments. It~   is considered of limited value to follow patients for 3 years."|f||||t||||||||||2018-06-01 03:37:56.77032|2018-06-01 03:37:56.77032
NCT00401388|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17||2018-02-20|2018-03-06|2006-11-17|2006-11-20|Estimate||||2018-02-20|2018-02-23|Actual|2018-03-06|2018-03-07|Actual|November 2006||2006-11-30|February 2012|2012-02-29|October 2011|Actual|2011-10-31|January 2011|Actual|2011-01-31||Interventional|||A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas|Sarcoma Alliance for Research Through Collaboration (SARC) Multicenter Trial: A Phase II Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas|Completed||Phase 2|72|Actual|AEterna Zentaris||3|||f||||t||||||||||2018-06-01 03:37:57.539565|2018-06-01 03:37:57.539565
NCT00401375|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-07-17|2006-11-17|2006-11-20|Estimate|||||||2011-07-17|2011-07-19|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI).|A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)|Completed||Phase 3|515|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||||||||||||2018-06-01 03:37:57.610398|2018-06-01 03:37:57.610398
NCT00401362|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-07-18|2006-11-17|2006-11-20|Estimate|||||||2011-07-18|2011-07-19|Estimate|February 2003||2003-02-28|July 2011|2011-07-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients|A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness|Completed||Phase 3|154|Actual|Valeant Pharmaceuticals International, Inc.||3|||f||||t||||||||||2018-06-01 03:37:57.669062|2018-06-01 03:37:57.669062
NCT00401349|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-08-03|2006-11-16|2006-11-20|Estimate|||||||2011-08-03|2011-08-04|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|||||Observational|||Expression of Mif Alleles in Individuals With Leishmaniasis|Immune and Inflammatory Responses in L. (Viannia) Infection Aim 2: Expression of Mif Alleles in Individuals With Recurrent Leishmaniasis, Chronic Leishmaniasis and Asymptomatic Infection|Completed|||438|Actual|Yale University|||||f||||t||||||Samples With DNA|"~     DNA samples from bucal swabs are being retained for genetic analyses of MIF alleles and~     possibly other genes associated with disease (leishmaniasis) resistance/susceptibility.~   "|||2018-06-01 03:37:57.729658|2018-06-01 03:37:57.729658
NCT00401336|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2013-03-07|2006-11-17|2006-11-20|Estimate|||||||2013-03-07|2013-03-08|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SURFER||Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging|Quantification of Liver Iron Overload and Steatosis Using a New Magnetic Resonance Imaging Multiecho Gradient-echo Sequence|Completed||N/A|250|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-06-01 03:37:57.779286|2018-06-01 03:37:57.779286
NCT00401323|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2011-01-19|2006-11-17|2006-11-20|Estimate|||||||2011-01-19|2011-01-20|Estimate|January 1998||1998-01-31|January 2011|2011-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma|A Randomized Phase II-III Multicenter Trial of Docetaxel Plus Cisplatin and Docetaxel Plus 5-FU Versus Cisplatin Plus 5-FU in 1st Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.|Completed||Phase 2/Phase 3|568|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:37:57.852312|2018-06-01 03:37:57.852312
NCT00401310|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2015-07-21|2006-11-17|2006-11-20|Estimate|||||||2015-07-21|2015-07-22|Estimate|July 2007||2007-07-31|July 2015|2015-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)|A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke|Terminated||Phase 2|150|Actual|Merck Sharp & Dohme Corp.||2||"Termination date was 20-Oct-2008. Subjects were monitored during the post treatment 90 day~   follow-up period (per protocol) resulting in LPLV 19-Jan-2009."|f||||||||||||||2018-06-01 03:37:57.96703|2018-06-01 03:37:57.96703
NCT00401297|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-08-03|2006-11-16|2006-11-20|Estimate|||||||2011-08-03|2011-08-04|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|||||Observational|||Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes|Intervenable Host- Leishmania (Vianna) Interactions Project 3: Immune and Inflammatory Responses in L. (Viannia) Infection Aim 1: To Determine if Th1/Th2 Polarization Occurs and is Linked to the Outcome of Infection by L. Viannia|Completed|||122|Actual|Yale University|||||f||||t||||||||||2018-06-01 03:37:58.038445|2018-06-01 03:37:58.038445
NCT00401284|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2008-01-02|2006-11-17|2006-11-20|Estimate|||||||2008-01-02|2008-01-07|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Hypnotic Efficacy of EVT 201 in Elderly Patient With Daytime Sleepiness|Completed||Phase 2|135|Anticipated|Evotec Neurosciences GmbH|||||f||||||||||||||2018-06-01 03:37:58.10337|2018-06-01 03:37:58.10337
NCT00401271|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2007-03-06|2006-11-17|2006-11-20|Estimate|||||||2007-03-06|2007-03-07|Estimate|November 2006||2006-11-30|March 2007|2007-03-31|March 2007||2007-03-31|||||Interventional|||Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis|A Phase II Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Four Oral Doses of OPC-67683 in Patients With Uncomplicated, Smear-Positive, Pulmonary Tuberculosis|Completed||Phase 2|54||Otsuka Frankfurt Research Institute GmbH|||||f||||||||||||||2018-06-01 03:37:58.176853|2018-06-01 03:37:58.176853
NCT00401258|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2010-06-25||2018-02-06|2006-11-17|2006-11-20|Estimate|2010-08-06|2010-08-27|Estimate||||2018-02-06|2018-03-09|Actual|November 2006||2006-11-30|February 2018|2018-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome|An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Without Comorbid Major Depressive Disorder|Completed||Phase 4|15|Actual|Mclean Hospital||1|||f||||f||||||||||2018-06-01 03:37:58.241133|2018-06-01 03:37:58.241133
NCT00401245|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|2011-09-06|2009-01-21|2011-10-24|2006-11-17|2006-11-20|Estimate|2011-09-06|2011-10-12|Estimate|2010-05-13|2010-05-14|Estimate|2011-10-24|2011-10-26|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms|The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study|Completed||Phase 3|500|Actual|Pfizer||8|||f||||f||||||||||2018-06-01 03:37:59.612544|2018-06-01 03:37:59.612544
NCT00401232|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2018-03-16|2006-11-17|2006-11-20|Estimate|||||||2018-03-16|2018-03-19|Actual|August 2006|Actual|2006-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development|Blood Collection In Healthy Adult Volunteers To Obtain Serum For Use In Serum Bactericidal Activity Assay Development|Completed||N/A|955|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:38:01.594379|2018-06-01 03:38:01.594379
NCT00401219|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2007-12-04|2006-11-17|2006-11-20|Estimate|||||||2007-12-04|2007-12-06|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation|An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioavailability Study Among 3 New Formulations of Premarin 0.625 mg/Medroxyprogesterone Acetate (Mpa) 2.5 mg Compared With a Reference Formulation of Premarin/Mpa (Prempro) 0.625 mg/2.5 mg in Healthy Postmenopausal Women|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:38:01.763041|2018-06-01 03:38:01.763041
NCT00401206|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-17|||2007-11-02|2006-11-17|2006-11-20|Estimate|||||||2007-11-02|2007-11-05|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Use of Dexmedetomidine for Sedation During Flexible Bronchoscopy in Patients With COPD: A Descriptive Study|Use of Dexmedetomidine for Sedation During Flexible Bronchoscopy in Patients With COPD: A Descriptive Study|Completed||N/A|12|Actual|The Cooper Health System|||||f||||||||||||||2018-06-01 03:38:01.809503|2018-06-01 03:38:01.809503
NCT00401193|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2009-08-31||2015-04-23|2006-11-17|2006-11-20|Estimate|2010-02-01|2010-02-24|Estimate||||2015-04-23|2015-05-13|Estimate|November 2006||2006-11-30|April 2015|2015-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of XP12B in Women With Menorrhagia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia|Completed||Phase 3|304|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-06-01 03:38:01.888975|2018-06-01 03:38:01.888975
NCT00401180|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-07-06|2006-11-16|2006-11-17|Estimate|||||||2011-07-06|2011-07-08|Estimate|June 2002||2002-06-30|September 2007|2007-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer|Phase I Trial of Weekly Docetaxel and Daily Temozolomide in Patients With Metastatic Disease|Completed||Phase 1|25|Actual|The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:38:02.289323|2018-06-01 03:38:02.289323
NCT00401167|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2012-05-24|2006-11-16|2006-11-17|Estimate|||||||2012-05-24|2012-05-25|Estimate|November 2006||2006-11-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Memantine for Agitation and Aggression in Severe Alzheimer's Disease|Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia|Completed||Phase 4|32|Anticipated|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 03:38:02.358059|2018-06-01 03:38:02.358059
NCT00401154|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2014-12-04|2006-11-15|2006-11-17|Estimate|||||||2014-12-04|2014-12-08|Estimate|September 2003||2003-09-30|December 2014|2014-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|PEDALS||Study of a Stationary Cycling Intervention for Children With Spastic Diplegic Cerebral Palsy|Pediatric Endurance and Limb Strengthening (PEDALS)|Completed||N/A|64|Actual|University of Southern California||1|||f||||t||||||||||2018-06-01 03:38:02.43951|2018-06-01 03:38:02.43951
NCT00401141|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2008-08-07|2006-11-16|2006-11-17|Estimate|||||||2008-08-07|2008-08-08|Estimate|April 2004||2004-04-30|August 2008|2008-08-31||||||||Interventional|||Abnormalities of B Lymphocytes During Systemic Lupus|Phenotypic Characteristics and Transcriptomas of B Lymphocytes During Non Active Systemic Lupus Erythematosus|Completed||N/A|30|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:38:02.510586|2018-06-01 03:38:02.510586
NCT00401128|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2017-04-18|2006-11-16|2006-11-17|Estimate|||||||2017-04-18|2017-04-20|Actual|May 2004||2004-05-31|April 2017|2017-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer|Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|9|Actual|The Cleveland Clinic|||||f|||||t|f||||||||2018-06-01 03:38:02.568051|2018-06-01 03:38:02.568051
NCT00401115|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2010-07-22|2006-11-15|2006-11-17|Estimate|||||||2010-07-22|2010-07-26|Estimate|September 2006||2006-09-30|July 2010|2010-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy|A Phase 1, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy|Completed||Phase 1|50|Actual|Santen Inc.||2|||f||||f||||||||||2018-06-01 03:38:02.739866|2018-06-01 03:38:02.739866
NCT00401102|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2012-12-20||2012-12-20|2006-11-15|2006-11-17|Estimate|2012-12-20|2013-01-28|Estimate||||2012-12-20|2013-01-28|Estimate|November 2006||2006-11-30|December 2012|2012-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|IPT-ASI||Interpersonal Psychotherapy for Depressed Adolescents Engaging in Non-suicidal Self-injury|An Open-clinical Trial of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) for Depressed Adolescents Engaged in Non-suicidal Self-injury|Completed||Phase 1|10|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 03:38:02.83009|2018-06-01 03:38:02.83009
NCT00401089|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2012-12-11|2006-11-16|2006-11-17|Estimate|||||||2012-12-11|2012-12-12|Estimate|December 2002||2002-12-31|December 2012|2012-12-31|October 2007|Actual|2007-10-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia|A Placebo-controlled Cross Study of Panax Ginseng in Augmentation of Antipsychotics in 60 Partially Treatment Responsive Patients With Schizophrenia|Completed||Phase 1/Phase 2|60|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-06-01 03:38:02.995153|2018-06-01 03:38:02.995153
NCT00401076|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-07-28|2006-11-16|2006-11-17|Estimate|||||||2011-07-28|2011-08-01|Estimate|July 2008||2008-07-31|July 2011|2011-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency|A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy|Completed||Phase 3|80|Actual|Abbott||1|||f||||f||||||||||2018-06-01 03:38:03.086936|2018-06-01 03:38:03.086936
NCT00401063|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2013-05-28|2006-11-15|2006-11-17|Estimate|||||||2013-05-28|2013-05-30|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Usefulness of Acupuncture in Cancer Pain and Quality of Life|Acupuncture Case Series: Cancer Pain and Quality of Life|Completed||N/A|11|Actual|Southern California University of Health Sciences||1|||f||||f||||||||||2018-06-01 03:38:03.22832|2018-06-01 03:38:03.22832
NCT00401050|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2010-04-16|2006-11-16|2006-11-17|Estimate|||||||2010-04-16|2010-04-20|Estimate|June 2006||2006-06-30|April 2010|2010-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison Study of Two Chiropractic Treatment Protocols for Knee Pain Due to Patellofemoral Pain Syndrome|A Randomized Clinical Trial Comparing Two Chiropractic Protocols for Patellofemoral Pain Syndrome: a Pilot Study|Completed||N/A|31|Actual|Cleveland Chiropractic College|||||f||||f||||||||||2018-06-01 03:38:03.305833|2018-06-01 03:38:03.305833
NCT00401024|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2010-07-24|2006-11-16|2006-11-17|Estimate|||||||2010-07-24|2010-07-27|Estimate|July 2006||2006-07-31|July 2009|2009-07-31||||June 2009|Actual|2009-06-30||Interventional|||Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma|Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration|Completed||N/A|33|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:03.376815|2018-06-01 03:38:03.376815
NCT00401011|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15||2018-02-20|2018-02-20|2006-11-16|2006-11-17|Estimate||||2018-02-20|2018-02-23|Actual|2018-02-20|2018-02-23|Actual|August 2006||2006-08-31|February 2012|2012-02-29|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients|An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib|Completed||Phase 1/Phase 2|84|Actual|AEterna Zentaris||6|||f||||f||||||||||2018-06-01 03:38:03.447147|2018-06-01 03:38:03.447147
NCT00400998|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2018-01-08|2006-11-15|2006-11-17|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2006||2006-03-31|January 2018|2018-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Investigate Two Trial Models; Vienna Challenge Chamber (in and Out of Season) and Park Study (in Season) Using a Drug for Seasonal Allergic Rhinitis|A Randomised, Double Blind, Placebo Controlled, 2-way Crossover, 3 Phase Study, to Investigate the Trial Models, Vienna Challenge Chamber, in and Out of Season, and Park Study in Season and the Clinical Efficacy of Rpt Doses of Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis|Completed||Phase 2|41|Actual|Research Consult GmbH||3|||f||||f||||||||||2018-06-01 03:38:03.54528|2018-06-01 03:38:03.54528
NCT00400985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-06|2006-11-16|2006-11-17|Estimate|||||||2010-04-06|2010-04-07|Estimate|January 2005||2005-01-31|April 2010|2010-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|SENSE-HF||Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure|Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of Heart Failure|Completed||N/A|501|Actual|Medtronic Bakken Research Center|||||f||||f||||||||||2018-06-01 03:38:03.639328|2018-06-01 03:38:03.639328
NCT00400972|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2007-09-27|2006-11-15|2006-11-17|Estimate|||||||2007-09-27|2007-09-28|Estimate|November 2006||2006-11-30|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of GlideScope Videolaryngoscopy to Direct Laryngoscopy for Nasal Intubation|Comparison of GlideScope Videolaryngoscopy to Direct Laryngoscopy for Nasal Intubation|Completed||N/A|70|Anticipated|Lawson Health Research Institute|||||f||||||||||||||2018-06-01 03:38:03.707422|2018-06-01 03:38:03.707422
NCT00400946|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2017-01-17||2017-05-19|2006-11-16|2006-11-17|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|April 2005||2005-04-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|August 2014|Actual|2014-08-31||Interventional||The analysis dataset is comprised of all enrolled patients.|Treatment of Acute Lymphoblastic Leukemia in Children|Treatment of Acute Lymphoblastic Leukemia in Children|Active, not recruiting||Phase 3|800|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 03:38:03.893522|2018-06-01 03:38:03.893522
NCT00400933|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2012-02-09|2006-11-16|2006-11-17|Estimate|||||||2012-02-09|2012-02-13|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of a Six-session Psycho-education Group Program|Evaluation of a Six-session Psycho-education Group Program Delivered to Family Members and Close Friends of Patients Suffering From Eating Disorders and Co-morbid Personality Disorders|Terminated||Phase 1|10|Actual|Norwegian University of Science and Technology||1||shortage of experienced health care personnel after reorganisation of units|f||||f||||||||||2018-06-01 03:38:05.481717|2018-06-01 03:38:05.481717
NCT00400907|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-12-17|2006-11-16|2006-11-17|Estimate|||||||2011-12-17|2011-12-20|Estimate|January 2006||2006-01-31|January 2007|2007-01-31||||||||Observational|||Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9|Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]|Unknown status|Active, not recruiting||667|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:05.552741|2018-06-01 03:38:05.552741
NCT00400894|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2007-02-02|2006-11-16|2006-11-17|Estimate|||||||2007-02-02|2007-02-05|Estimate|September 2005||2005-09-30|February 2007|2007-02-28|September 2006||2006-09-30|||||Observational|||Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma|Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma|Unknown status|Active, not recruiting||750||ProteoSys AG|||||f||||||||||||||2018-06-01 03:38:05.679047|2018-06-01 03:38:05.679047
NCT00400881|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2011-08-18||2017-05-05|2006-11-16|2006-11-17|Estimate|2012-04-18|2012-05-17|Estimate||||2017-05-05|2017-06-09|Actual|January 2007||2007-01-31|May 2017|2017-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)|Comparison Between Two Methods of Spontaneous Breathing Trial (SBT)|Completed||N/A|122|Actual|Texas Tech University Health Sciences Center, El Paso|"General ICU population.~Two subjects in each group were randomized and data collected but were not included in analysis per protocol due to needing re-intubation for upper airway obstruction."|2|||f||||f||||||||No||2018-06-01 03:38:05.751069|2018-06-01 03:38:05.751069
NCT00400868|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2010-02-23|2006-11-15|2006-11-17|Estimate|||||||2010-02-23|2010-02-24|Estimate|July 2006||2006-07-31|February 2010|2010-02-28|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|||Effectiveness of Occupational Therapy in Patients With Rheumatoid Arthritis(RCT)|A Randomized Controlled Study to Evaluate the Short- and Long-term Effectiveness of an Individualized Resource Oriented Occupational Therapy for Patients With Rheumatoid Arthritis|Completed||N/A|54|Actual|University of Zurich||1|||f||||||||||||||2018-06-01 03:38:05.994483|2018-06-01 03:38:05.994483
NCT00400855|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2016-09-13|2006-11-15|2006-11-17|Estimate|||||||2016-09-13|2016-09-15|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate|A Randomised, Double-blind, Placebo-controlled, Incomplete Block, 4-period Crossover, Study to Investigate the Effects of 5-day Repeat Inhaled Doses of Fluticasone Propionate (BID, 50-2000 mcg) on Airway Responsiveness to Adenosine 5-monophosphate (AMP) Challenge When Delivered After the Last Dose in Mild Asthmatic Subjects.|Completed||Phase 2|49|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:38:06.077658|2018-06-01 03:38:06.077658
NCT00400842|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-07-27|2006-11-16|2006-11-17|Estimate|||||||2011-07-27|2011-07-28|Estimate|May 2007||2007-05-31|July 2011|2011-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency|A Double-blind, Placebo-controlled, Parallel-group, Comparative Study to Confirm the Safety and Efficacy of Oral 1.5 g/Day and 3.0 g/Day of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy|Completed||Phase 3|274|Actual|Abbott||3|||f||||f||||||||||2018-06-01 03:38:06.18263|2018-06-01 03:38:06.18263
NCT00400829|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2014-12-23||2014-12-23|2006-11-16|2006-11-17|Estimate|2014-12-23|2015-01-07|Estimate||||2014-12-23|2015-01-07|Estimate|November 2006||2006-11-30|October 2013|2013-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase 2 Study of the Halichondrin B Analog E7389 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a Taxane|Completed||Phase 2|66|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:38:06.394945|2018-06-01 03:38:06.394945
NCT00400816|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2018-01-25|2006-11-16|2006-11-17|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2005||2005-08-31|January 2018|2018-01-31|January 6, 2016|Actual|2016-01-06|January 17, 2008|Actual|2008-01-17||Interventional|||Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma|Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma|Completed||Phase 2|29|Actual|The Cleveland Clinic||1|||f||||t||||||||||2018-06-01 03:38:06.710474|2018-06-01 03:38:06.710474
NCT00400803|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2011-11-10||2017-12-03|2006-11-15|2006-11-17|Estimate|2011-12-20|2012-01-26|Estimate||||2017-12-03|2017-12-28|Actual|March 2007||2007-03-31|December 2017|2017-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer|Phase II Study of Biweekly Carboplatin and Gemcitabine With Bevacizumab as 1st Line Treatment in Patients With Advanced, Inoperable Stage IIIb/IV NSCLC|Completed||Phase 2|38|Actual|Masonic Cancer Center, University of Minnesota|Outcome data is available for 35 (of 38) patients only.|1|||f||||t||||||||||2018-06-01 03:38:06.802755|2018-06-01 03:38:06.802755
NCT00400790|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2010-06-28|2006-11-16|2006-11-17|Estimate|||||||2010-06-28|2010-06-29|Estimate|September 2007||2007-09-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane|A Randomised Controlled Study of Organ Protection Comparing Desflurane and Propofol in Adult Patients Undergoing Coronary Artery Surgery With Cardiopulmonary Bypass|Completed||N/A|182|Actual|University of Melbourne|||||f||||f||||||||||2018-06-01 03:38:07.085376|2018-06-01 03:38:07.085376
NCT00400777|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2008-06-17|2006-11-15|2006-11-17|Estimate|||||||2008-06-17|2008-06-18|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension|An Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy of the Combination of Valsartan and Hydrochlorothiazide and Amlodipine in Hypertensive Patients Not Controlled With Valsartan and Hydrochlorothiazide|Completed||Phase 4|460|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:38:07.151393|2018-06-01 03:38:07.151393
NCT00400764|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2011-09-01||2011-11-15|2006-11-15|2006-11-17|Estimate|2011-09-01|2011-10-07|Estimate||||2011-11-15|2011-11-23|Estimate|June 2006||2006-06-30|November 2011|2011-11-30||||May 2010|Actual|2010-05-31||Interventional|||A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas|A Phase Ib/II, Open-Label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Dulanermin Administered Intravenously in Combination With Rituximab to Subjects With Follicular and Other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas That Have Progressed Following Previous Rituximab Therapy|Terminated||Phase 1/Phase 2|72|Actual|Genentech, Inc.|The Sponsor terminated the study on 5 May 2010, prior to the completion of the 36-month follow-up (FU) period, based on the primary analysis results. All patients were off-study or in survival FU (the treatment period was completed).|5|||f||||||||||||||2018-06-01 03:38:07.347457|2018-06-01 03:38:07.347457
NCT00400751|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2006-11-16|2006-11-16|2006-11-17|Estimate|||||||2006-11-16|2006-11-17|Estimate|September 1999||1999-09-30|September 1999|1999-09-30|May 2003||2003-05-31|||||Interventional|||Family Consultation for Health-Compromised Smokers|Phase 1 Study of Family Consultation for Change-Resistant Smokers|Completed||Phase 1|40||University of Arizona|||||f||||||||||||||2018-06-01 03:38:08.566733|2018-06-01 03:38:08.566733
NCT00400738|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2012-04-03|2006-11-16|2006-11-17|Estimate|||||||2012-04-03|2012-04-05|Estimate|March 2004||2004-03-31|April 2012|2012-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients|Pharmacokinetics of and Rate of HIV-1 RNA Decline in ARV-naive HIV-1 Infected Patients Treated With Low- or Standard-dose Saquinavir HGC (Invirase®) and Lopinavir/Ritonavir (Kaletra®|Completed||Phase 2|48|Actual|The HIV Netherlands Australia Thailand Research Collaboration||4|||f||||f||||||||||2018-06-01 03:38:08.668185|2018-06-01 03:38:08.668185
NCT00400725|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2008-05-28|2006-11-16|2006-11-17|Estimate|||||||2008-05-28|2008-05-29|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|August 2007|Actual|2007-08-31|||||Interventional|||Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis|Comparison of the Maintenance Effect of Clobex® Shampoo 0.05% Used Twice Weekly vs. Vehicle on Scalp Psoriasis in Subjects Who Successfully Responded to a 4-Week Daily Course of Clobex® Shampoo 0.05%|Completed||Phase 3|288|Actual|Galderma||2|||f||||||||||||||2018-06-01 03:38:09.009386|2018-06-01 03:38:09.009386
NCT00400712|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2015-11-06||2016-04-03|2006-11-16|2006-11-17|Estimate|2016-04-03|2016-05-05|Estimate||||2016-04-03|2016-05-05|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional||Hemiparetic stroke (hemorrhagic or ischemic), first ever associated with residual deficits/impairments (i.e. full recovery from previous stoke if applicable)|Client Centred 'Tune-ups': do They Enhance Community Reintegration After Stroke?|Client Centred 'Tune-ups': do They Enhance Community Reintegration and Mobility in Stroke Survivors?|Completed||N/A|103|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 03:38:09.3548|2018-06-01 03:38:09.3548
NCT00400699|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2014-01-30|2006-11-16|2006-11-17|Estimate|||||||2014-01-30|2014-01-31|Estimate|October 2004||2004-10-31|January 2014|2014-01-31||||November 2009|Actual|2009-11-30||Interventional|||Radiation Therapy Outreach Program for Minority or Low-Income Patients With Newly Diagnosed Cancer|UPMC McKeesport/ROCOG Radiation Oncology Minorities Outreach Program|Completed||N/A|3150|Actual|University of Pittsburgh||1|||f||||||||||||||2018-06-01 03:38:09.895634|2018-06-01 03:38:09.895634
NCT00400686|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|2015-06-03||2018-01-24|2006-11-16|2006-11-17|Estimate|2016-10-18|2016-12-09|Estimate||||2018-01-24|2018-02-22|Actual|September 2003||2003-09-30|January 2018|2018-01-31|August 2013|Actual|2013-08-31|January 2009|Actual|2009-01-31||Interventional|||Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma|A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life|Completed||N/A|31|Actual|The Cleveland Clinic||1|||f||||f||||||||||2018-06-01 03:38:10.013168|2018-06-01 03:38:10.013168
NCT00400673|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2011-03-31|2006-11-16|2006-11-17|Estimate|||||||2011-03-31|2011-04-01|Estimate|May 2000||2000-05-31|March 2011|2011-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia|Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia|Completed||Phase 2|581|Actual|Northern Italy Leukemia Group||1|||f||||f||||||||||2018-06-01 03:38:10.202583|2018-06-01 03:38:10.202583
NCT00400660|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2017-09-27|2006-11-15|2006-11-17|Estimate|||||||2017-09-27|2017-09-29|Actual|November 23, 2005|Actual|2005-11-23|September 2017|2017-09-30|July 3, 2006|Actual|2006-07-03|July 3, 2006|Actual|2006-07-03||Interventional|||A First Time In Human Study To Assess The Compound GSK615915|First Time in Human, Single Dose and Repeat Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK615915|Completed||Phase 1|46|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 03:38:10.296994|2018-06-01 03:38:10.296994
NCT00400647|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2017-02-03|2006-11-16|2006-11-17|Estimate|||||||2017-02-03|2017-02-07|Estimate|July 2006||2006-07-31|February 2017|2017-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil|A 12-week Multicenter, Randomized, Open Study to Evaluate the Effects of Enteric-coated Mycophenolate Sodium (EC-MPS) in Terms of Quality of Life in Patients With Gastrointestinal (GI) Symptoms Treated With MMF (Mycophenolate Mofetil) After Kidney Transplant.|Completed||Phase 4|136|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:38:10.409221|2018-06-01 03:38:10.409221
NCT00400634|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2012-05-24||2012-07-06|2006-11-16|2006-11-17|Estimate|2012-07-06|2012-08-14|Estimate||||2012-07-06|2012-08-14|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease|Multicenter, Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects With Idiopathic Parkinson's Disease|Completed||Phase 2|58|Actual|Ceregene||2|||f||||t||||||||||2018-06-01 03:38:10.581071|2018-06-01 03:38:10.581071
NCT00400621|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2006-11-16|2006-11-16|2006-11-17|Estimate|||||||2006-11-16|2006-11-17|Estimate|April 2003||2003-04-30|November 2006|2006-11-30|September 2003||2003-09-30|||||Interventional|||Effects of Therapeutic Doses of Acetaminophen in Moderate Drinkers|Assessment of Hepatic Injury in Subjects Who Consume Moderate Amounts of Alcohol While Being Administered Therapeutic Doses of Acetaminophen:|Completed||Phase 4|150||Denver Health and Hospital Authority|||||f||||||||||||||2018-06-01 03:38:10.983926|2018-06-01 03:38:10.983926
NCT00400608|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2016-10-26|2006-11-15|2006-11-17|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|February 2007|Actual|2007-02-28|||||Interventional|||A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS|A Repeat-dose, Open-label, Randomized, Incomplete Block Design in Pediatric Subjects With Asthma, Ages 4 - 11 Years, to Compare Systemic Exposure and Pharmacodynamics of Fluticasone Propionate and Salmeterol Following Advair HFA 45/21mcg (2 Inhalations), ADVAIR® HFA 45/21mcg (2 Inhalations) With Aerochamber Plus Spacer and Advair Diskus 100/50 Twice Daily|Completed||Phase 4|28|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:38:11.048004|2018-06-01 03:38:11.048004
NCT00400595|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2015-03-16|2006-11-16|2006-11-17|Estimate|||||||2015-03-16|2015-03-18|Estimate|February 2006||2006-02-28|March 2015|2015-03-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Use of Ointments in Prevention of Catheter Related Infections in PD|A Randomized Controlled Double Blind Study Using Mupirocin Versus Polysporin Triple for the Prevention of Catheter-related Infections in Patients Treated With Peritoneal Dialysis|Completed||Phase 4|200|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 03:38:11.156335|2018-06-01 03:38:11.156335
NCT00400582|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2011-07-20|2006-11-15|2006-11-17|Estimate|||||||2011-07-20|2011-07-22|Estimate|November 2006||2006-11-30|July 2011|2011-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Pharmacogenomic Study of Candesartan in Heart Failure|Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms|Completed||Phase 4|300|Anticipated|Montreal Heart Institute|||||f||||f||||||||||2018-06-01 03:38:11.234351|2018-06-01 03:38:11.234351
NCT00400569|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2012-07-25||2012-07-25|2006-11-16|2006-11-17|Estimate|2012-07-25|2012-08-28|Estimate||||2012-07-25|2012-08-28|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma|Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma|Completed||Phase 2|48|Actual|H. Lee Moffitt Cancer Center and Research Institute|The trial was amended to exclude fibrosarcoma after only one patient was accrued while the other cohorts had completed 75% or more of their planned accrual. Only patients with liposarcoma, leiomyosarcoma, or MFH were enrolled after this amendment.|1|||f||||f||||||||||2018-06-01 03:38:11.321753|2018-06-01 03:38:11.321753
NCT00400556|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2006-11-15|2006-11-15|2006-11-17|Estimate|||||||2006-11-15|2006-11-17|Estimate|March 2005||2005-03-31|November 2006|2006-11-30|May 2005||2005-05-31|||||Interventional|||ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells|A Phase I Study of Haematopoietic Stem Cell Mobilization Using G-CSF With ATRA in Patients With Cutaneous Lymphoma and Multiple Myeloma|Completed||Phase 1|6||Peter MacCallum Cancer Centre, Australia|||||f||||||||||||||2018-06-01 03:38:11.574721|2018-06-01 03:38:11.574721
NCT00400543|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2006-11-16|2006-11-16|2006-11-17|Estimate|||||||2006-11-16|2006-11-17|Estimate|January 2004||2004-01-31|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Early Signs of Atherosclerosis in Obstructive Sleep Apnea: Effects of Treatment|Effects of Continuous Positive Airway Pressure (CPAP) on Early Signs of Atherosclerosis in Patients With Obstructive Sleep Apnea: a Randomized Study|Completed||Phase 4|24||University of Sao Paulo|||||f||||||||||||||2018-06-01 03:38:11.635901|2018-06-01 03:38:11.635901
NCT00400530|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2006-11-16|2006-11-16|2006-11-17|Estimate|||||||2006-11-16|2006-11-17|Estimate|December 2005||2005-12-31|November 2006|2006-11-30||||||||Interventional|||Upper GI Handling of Branded vs. Generic Alendronate|A Randomized, Single-Blind Study to Evaluate Upper Gastrointestinal Handling of Branded Versus Generic Alendronate Tablets|Completed||Phase 3|25||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:11.696985|2018-06-01 03:38:11.696985
NCT00400517|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16||2017-04-18|2017-04-18|2006-11-16|2006-11-17|Estimate||||2017-04-18|2017-04-20|Actual|2017-04-18|2017-04-20|Actual|March 2003||2003-03-31|April 2017|2017-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer|Phase II Trial of Neoadjuvant GM-CSF + Thalidomide in High-Risk Patients With Prostate Cancer Undergoing Prostatectomy|Completed||Phase 2|28|Actual|The Cleveland Clinic||1|||f||||||||||||||2018-06-01 03:38:11.760132|2018-06-01 03:38:11.760132
NCT00400504|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2006-11-16|2006-11-16|2006-11-17|Estimate|||||||2006-11-16|2006-11-17|Estimate|November 2006||2006-11-30|November 2006|2006-11-30||||||||Observational|||Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)|Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)|Unknown status|Recruiting||500||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:38:11.852719|2018-06-01 03:38:11.852719
NCT00400491|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2008-05-22|2006-11-16|2006-11-17|Estimate|||||||2008-05-22|2008-05-23|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Vitamin D Supplementation to Patients With Type 2 Diabetes|Vitamin D Supplementation to Patients With Type 2 Diabetes|Completed||Phase 2|40|Actual|University of Tromso||2|||f||||f||||||||||2018-06-01 03:38:11.901038|2018-06-01 03:38:11.901038
NCT00400478|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-16|||2016-05-25|2006-11-16|2006-11-17|Estimate|||||||2016-05-25|2016-05-26|Estimate|January 2006||2006-01-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13|A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13|Completed||Phase 3|683|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||t||||||||||2018-06-01 03:38:11.999912|2018-06-01 03:38:11.999912
NCT00400465|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2015-03-31|2006-11-14|2006-11-16|Estimate|||||||2015-03-31|2015-04-01|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Is the Routine Pressure Dressing After Thyroidectomy Necessary?|Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study|Completed||Phase 4|116|Actual|Khon Kaen University||2|||f||||f||||||||||2018-06-01 03:38:13.412709|2018-06-01 03:38:13.412709
NCT00393874|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|2016-01-07||2016-09-06|2006-10-26|2006-10-30|Estimate|2016-09-06|2016-10-24|Estimate||||2016-09-06|2016-10-24|Estimate|October 2006||2006-10-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|EASI-P||Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)|Efficacy of Adjunct Sleep Interventions for PTSD|Completed||N/A|50|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 03:40:27.691648|2018-06-01 03:40:27.691648
NCT00400452|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2011-07-04|2006-11-15|2006-11-16|Estimate|||||||2011-07-04|2011-07-06|Estimate|May 2007||2007-05-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Manual Wheelchair Skills Training for Long-term-care Residents|Manual Wheelchair Skills Training for Long-term-care Residents: A Pilot Randomized Controlled Trial of Efficacy|Terminated||N/A|8|Actual|Nova Scotia Health Authority||||poor enrollment|f||||f||||||||||2018-06-01 03:38:13.494659|2018-06-01 03:38:13.494659
NCT00400439|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15||2016-07-26|2016-07-27|2006-11-15|2006-11-16|Estimate||||2016-07-26|2016-07-28|Estimate|2016-07-27|2016-07-29|Estimate|January 2007||2007-01-31|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381|A Phase II, Placebo-Controlled, Double-Blind Extension Study of Study NC19453 Assessing Long-term Safety and Efficacy of RO4607381|Completed||Phase 2|77|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:38:13.652503|2018-06-01 03:38:13.652503
NCT00400426|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2013-06-18|2006-11-15|2006-11-16|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer|DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer|Completed||Phase 2|100|Anticipated|University of Aarhus|||||f||||||||||||||2018-06-01 03:38:13.750207|2018-06-01 03:38:13.750207
NCT00400413|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2011-08-29|2006-11-15|2006-11-16|Estimate|||||||2011-08-29|2011-08-30|Estimate|November 2003||2003-11-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Interventional|||Neuroanatomy of Reading in Congenital Deafness.|Phonological Perception and Learning to Read : the Neuroanatomy of Reading in Congenitally Deaf Persons|Completed||N/A|60|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:38:13.849095|2018-06-01 03:38:13.849095
NCT00400400|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2010-12-03||2011-07-14|2006-11-15|2006-11-16|Estimate|2011-07-14|2011-08-15|Estimate||||2011-07-14|2011-08-15|Estimate|October 2006||2006-10-31|July 2011|2011-07-31||||June 2008|Actual|2008-06-30||Interventional|||Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance|A 4-week, Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group Study to Compare the Gastrointestinal Safety and Tolerability of EC-MPS & MMF When Administered in Combination With Calcineurin Inhibitors in Renal Transplant Recipients Experiencing Gastrointestinal Intolerance|Completed||Phase 4|400|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:38:13.994659|2018-06-01 03:38:13.994659
NCT00400387|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2014-09-16|2006-11-15|2006-11-16|Estimate|||||||2014-09-16|2014-09-17|Estimate|November 2006||2006-11-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss|Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss|Completed||Phase 3|449|Actual|University of Jena||2|||f||||||||||||||2018-06-01 03:38:14.644845|2018-06-01 03:38:14.644845
NCT00400374|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2018-03-13|2006-11-15|2006-11-16|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2007||2007-08-31|March 2018|2018-03-31|November 2016|Actual|2016-11-30|December 2012|Actual|2012-12-31||Interventional|||Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2|Phase I Study of Secondary Primary Tumor Prevention With Epidermal Growth Factor Receptor (EGFR), Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva™), and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Early Stage (Stage I/II) Squamous Cell Carcinoma of Head and Neck|Completed||Phase 1|10|Actual|Emory University||1|||f||||t||||||||||2018-06-01 03:38:14.904793|2018-06-01 03:38:14.904793
NCT00400361|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2016-11-01|2006-11-15|2006-11-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.|A Dose-escalation Study of R1507 in Patients With Advanced Solid Tumors.|Completed||Phase 1|98|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:38:15.032404|2018-06-01 03:38:15.032404
NCT00400348|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2008-11-24|2006-11-15|2006-11-16|Estimate|||||||2008-11-24|2008-11-25|Estimate|October 2006||2006-10-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer|A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer|Completed||Phase 2|18|Actual|CASI Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 03:38:15.099542|2018-06-01 03:38:15.099542
NCT00400335|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2012-05-31|2006-11-14|2006-11-16|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2006||2006-10-31|February 2011|2011-02-28||||||||Interventional|||Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride|An Open Label Study to Evaluate the Impact of Novel Fixed-dose Testosterone/Dutasteride Combinations on the Relative Bioavailability of the Individual Dutasteride and Testosterone Components|Completed||Phase 1|60|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:38:15.191573|2018-06-01 03:38:15.191573
NCT00400322|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2009-01-21|2006-11-15|2006-11-16|Estimate|||||||2009-01-21|2009-01-22|Estimate|August 2006||2006-08-31|January 2009|2009-01-31|March 2009|Anticipated|2009-03-31|||||Interventional|||Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection|A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.|Unknown status|Active, not recruiting|N/A|40|Anticipated|Karolinska University Hospital|||||f||||||||||||||2018-06-01 03:38:15.353869|2018-06-01 03:38:15.353869
NCT00400309|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2017-09-08|2006-11-15|2006-11-16|Estimate|||||||2017-09-08|2017-09-11|Actual|June 2006|Actual|2006-06-30|September 2017|2017-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety of REPEVAX® Given One Month After REVAXIS®|A Double Blind, Controlled, Randomised, Clinical Study to Assess the Safety of Repevax® Administered One Month After Revaxis® or Placebo to Healthy Adults|Completed||Phase 3|500|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:38:15.440979|2018-06-01 03:38:15.440979
NCT00400296|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2016-11-01|2006-11-15|2006-11-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2005||2005-05-31|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of R547 in Patients With Advanced Solid Tumors.|A Multiple Ascending Dose (MAD) Study of R547 Administered as an Intravenous Infusion on a Weekly Schedule in Patients With Advanced Solid Tumors|Completed||Phase 1|58|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:38:15.522861|2018-06-01 03:38:15.522861
NCT00400283|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2017-02-22|2006-11-15|2006-11-16|Estimate|||||||2017-02-22|2017-02-24|Actual|January 19, 2001|Actual|2001-01-19|February 2017|2017-02-28|May 3, 2001|Actual|2001-05-03|May 3, 2001|Actual|2001-05-03||Interventional|||A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Multiple Oral Dose, Dose Escalation Trial, Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 55-0414 in Patients With Type 2 Diabetes|Completed||Phase 1|23|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:38:15.595356|2018-06-01 03:38:15.595356
NCT00400257|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2016-05-30|2006-11-15|2006-11-16|Estimate|||||||2016-05-30|2016-06-01|Estimate|May 2007||2007-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|January 2010|Actual|2010-01-31||Observational|||Screening Evaluation of the Evolution of New Heart Failure (SCREEN-HF)|SCREEN-HF (Screening Evaluation of the Evolution of New Heart Failure)|Completed|||3500|Anticipated|The Alfred|||1||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 03:38:15.759226|2018-06-01 03:38:15.759226
NCT00400244|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2009-09-28|2006-11-15|2006-11-16|Estimate|||||||2009-09-28|2009-09-29|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||French-Canadian Version of the Wheelchair Skills Program (WSP)|Translation, Validation and Evaluation of the Efficacy of the French-Canadian Version of the Wheelchair Skills Program (WSP)|Completed||N/A|41|Actual|Nova Scotia Health Authority|||||f||||f||||||||||2018-06-01 03:38:15.857775|2018-06-01 03:38:15.857775
NCT00400231|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2017-03-16|2006-11-15|2006-11-16|Estimate|||||||2017-03-16|2017-03-20|Actual|August 2005||2005-08-31|March 2017|2017-03-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study|The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study|Completed||Phase 2|124|Anticipated|University of Pennsylvania||4|||f||||||||||||||2018-06-01 03:38:15.960099|2018-06-01 03:38:15.960099
NCT00400218|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2017-04-26|2006-11-15|2006-11-16|Estimate|||||||2017-04-26|2017-04-28|Actual|September 1, 2005|Actual|2005-09-01|April 2017|2017-04-30|July 19, 2006|Actual|2006-07-19|July 1, 2006|Actual|2006-07-01||Interventional|||Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)|Evaluate the Safety and Tolerability of Hyzaar(R) (Losartan 50 Mg/ Hydrochlorothiazide 12.5 Mg) In the Treatment of Hypertension|Completed||Phase 3|62|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:16.058236|2018-06-01 03:38:16.058236
NCT00400205|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2010-12-06||2017-10-05|2006-11-15|2006-11-16|Estimate|2010-12-06|2011-01-04|Estimate||||2017-10-05|2017-11-06|Actual|August 2006||2006-08-31|October 2017|2017-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil|Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints|Terminated||Phase 2|14|Actual|Emory University||1||Safety reasons|f||||t||||||||||2018-06-01 03:38:16.185471|2018-06-01 03:38:16.185471
NCT00400192|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2013-04-11|2006-11-15|2006-11-16|Estimate|||||||2013-04-11|2013-04-15|Estimate|November 2006||2006-11-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|August 2010|Actual|2010-08-31||Observational|||Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury|Prospective Study of the Kinetics and Mechanisms of Transfusion-associated Microchimerism in Injured Patients|Completed|||451|Actual|Blood Systems Research Institute|||||f||||f||||||Samples With DNA|"~     Whole blood, plasma, peripheral blood mononuclear cells~   "|||2018-06-01 03:38:16.428002|2018-06-01 03:38:16.428002
NCT00400179|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2012-01-06||2012-03-28|2006-11-15|2006-11-16|Estimate|2012-03-28|2012-04-23|Estimate||||2012-03-28|2012-04-23|Estimate|May 2005||2005-05-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||A Safety and Efficacy Study in Patients With Gastric Cancer|An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease|Completed||Phase 3|1053|Actual|Taiho Oncology, Inc.||2|||f||||f||||||||||2018-06-01 03:38:16.576119|2018-06-01 03:38:16.576119
NCT00400166|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2009-06-10|2006-11-15|2006-11-16|Estimate|||||||2009-06-10|2009-06-12|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Recovery Guide Intervention for Recurrent Psychiatric Hospitalization|Recovery Guide Intervention for Recurrent Psychiatric Hospitalization|Completed||N/A|71|Actual|Yale University||2|||f||||f||||||||||2018-06-01 03:38:18.362441|2018-06-01 03:38:18.362441
NCT00400153|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|2009-04-03||2014-06-09|2006-11-15|2006-11-16|Estimate|2009-04-03|2009-06-01|Estimate||||2014-06-09|2014-06-13|Estimate|November 2006||2006-11-30|June 2014|2014-06-30||||April 2008|Actual|2008-04-30||Interventional||The treated set (TS) included all randomized patients who were documented to have taken at least one actuation of the randomized treatment.|Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)|Safety and Efficacy of Combivent Respimat in Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1480|Actual|Boehringer Ingelheim|The FEV1 and FVC measurements at each observation time point were used to derive the primary and secondary efficacy endpoints and are not reported here. All statistical analyses for secondary endpoints are exploratory and the p-values are nominal.|3|||f||||||||||||||2018-06-01 03:38:18.610426|2018-06-01 03:38:18.610426
NCT00400140|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2010-05-11|2006-11-15|2006-11-16|Estimate|||||||2010-05-11|2010-05-12|Estimate|November 2006||2006-11-30|May 2010|2010-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children|Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children|Completed||N/A|30|Anticipated|Singapore National Eye Centre||1|||f||||||||||||||2018-06-01 03:38:22.08637|2018-06-01 03:38:22.08637
NCT00400127|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2009-06-03|2006-11-15|2006-11-16|Estimate|||||||2009-06-03|2009-06-04|Estimate|September 2005||2005-09-30|June 2009|2009-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||The Effect of Silicone Suspension on Standing Balance for Transfemoral Amputees|The Effect of Silicone Suspension on Standing Balance for Transfemoral Amputees|Terminated||N/A|6|Actual|Nova Scotia Health Authority||1||poor recruitment, pilot outcome measures inappropriate|f||||||||||||||2018-06-01 03:38:22.154296|2018-06-01 03:38:22.154296
NCT00400114|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2017-05-03|2006-11-15|2006-11-16|Estimate|||||||2017-05-03|2017-05-08|Actual|September 25, 2006|Actual|2006-09-25|May 2017|2017-05-31|September 19, 2016|Actual|2016-09-19|September 19, 2016|Actual|2016-09-19||Interventional|||Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer|Adjuvant Sutent Following Chemotherapy, Radiation and Surgery For Esophageal Cancer, A Phase II Trial (ASSET)|Completed||Phase 2|36|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 03:38:22.232947|2018-06-01 03:38:22.232947
NCT00400101|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2006-11-15|2006-11-15|2006-11-16|Estimate|||||||2006-11-15|2006-11-16|Estimate|November 2003||2003-11-30|November 2006|2006-11-30|October 2005||2005-10-31|||||Interventional|||Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides|A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers|Terminated||Phase 1|46||Swiss Tropical & Public Health Institute|||||f||||||||||||||2018-06-01 03:38:22.320798|2018-06-01 03:38:22.320798
NCT00399893|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|2013-01-28||2014-06-25|2006-11-14|2006-11-15|Estimate|2014-06-25|2014-07-24|Estimate||||2014-06-25|2014-07-24|Estimate|December 2006||2006-12-31|June 2014|2014-06-30|September 2010|Actual|2010-09-30|April 2009|Actual|2009-04-30||Interventional|||Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)|Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children and Young Adults With Prader-Willi Syndrome (PWS): Octreotide Intervention Sub-study|Terminated||N/A|5|Actual|Duke University||2||Inadequate recruitment|f||||f||||||||||2018-06-01 03:38:23.56451|2018-06-01 03:38:23.56451
NCT00400088|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2013-02-26|2006-11-15|2006-11-16|Estimate|||||||2013-02-26|2013-02-27|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide|A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study|Terminated||Phase 3|2|Actual|Nova Scotia Health Authority||2||Recruitment difficulties|f||||f||||||||||2018-06-01 03:38:22.384399|2018-06-01 03:38:22.384399
NCT00400075|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2006-11-15|2006-11-15|2006-11-16|Estimate|||||||2006-11-15|2006-11-16|Estimate|July 1996||1996-07-31|November 2006|2006-11-30||||||||Interventional|||CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors|CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients|Unknown status|Active, not recruiting|Phase 4|124||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:38:22.479338|2018-06-01 03:38:22.479338
NCT00400062|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2017-03-22|2006-11-15|2006-11-16|Estimate|||||||2017-03-22|2017-03-27|Actual|July 2007|Actual|2007-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2010|Actual|2010-12-31||Observational|||MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care|MIND-ICU Study: Delirium and Dementia in Veterans Surviving ICU Care|Active, not recruiting|||800|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:38:22.552994|2018-06-01 03:38:22.552994
NCT00400036|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2006-11-14|2006-11-14|2006-11-16|Estimate|||||||2006-11-14|2006-11-16|Estimate|February 2004||2004-02-29|November 2006|2006-11-30|December 2005||2005-12-31|||||Interventional|||Dietary Fish Protein in Subjects With Insulin Resistance|Assessment of Insulin Sensitivity in Insulin-Resistant Subjects Fed Fish Protein|Completed||Phase 2|24||Laval University|||||f||||||||||||||2018-06-01 03:38:22.630013|2018-06-01 03:38:22.630013
NCT00400023|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2011-04-07|2006-11-15|2006-11-16|Estimate|||||||2011-04-07|2011-04-11|Estimate|September 2006||2006-09-30|April 2011|2011-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors|A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of the Dihydropyrimidine Dehydrogenase (Dpd) Inhibitory Action of 5-Chloro-2,4-Dihydroxypyridine (Cdhp) as an S-1 Component|Completed||Phase 1|12|Anticipated|Taiho Oncology, Inc.||2|||f||||||||||||||2018-06-01 03:38:22.69252|2018-06-01 03:38:22.69252
NCT00400010|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2014-04-01|2006-11-14|2006-11-16|Estimate|||||||2014-04-01|2014-04-02|Estimate|October 2004||2004-10-31|April 2014|2014-04-30|November 2006|Actual|2006-11-30|November 2005|Actual|2005-11-30||Interventional|||Alcohol Expert System Intervention for Problematic Alcohol Use|Randomized Controlled Trial of a Expert System for Patients With At-risk Drinking, Alcohol Abuse and Alcohol Dependence in General Hospital|Completed||N/A|347|Actual|University of Luebeck||2|||f||||f||||||||||2018-06-01 03:38:22.755693|2018-06-01 03:38:22.755693
NCT00399997|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-15|||2006-12-20|2006-11-15|2006-11-16|Estimate|||||||2006-12-20|2006-12-22|Estimate|January 2005||2005-01-31|November 2006|2006-11-30|August 2007||2007-08-31|||||Interventional|||Evaluation of Effect of Exercise on Prescription|Effect of Exercise on Prescription on Physical Activity, Physical Fitness, and Health in Patients With Lifestyle Diseases|Unknown status|Active, not recruiting|Phase 2/Phase 3|50||University of Southern Denmark|||||f||||||||||||||2018-06-01 03:38:22.840769|2018-06-01 03:38:22.840769
NCT00399984|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2013-06-11|2006-11-13|2006-11-15|Estimate|||||||2013-06-11|2013-06-13|Estimate|April 2004||2004-04-30|June 2013|2013-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluating a Pediatric Asthma Management Education Program for Physicians|Enhancing Pediatric Asthma Management|Completed||N/A|40|Actual|University of California, San Francisco||2|||f||||||||||||||2018-06-01 03:38:22.97572|2018-06-01 03:38:22.97572
NCT00399971|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2008-11-07|2006-11-14|2006-11-15|Estimate|||||||2008-11-07|2008-11-11|Estimate|November 2002||2002-11-30|November 2008|2008-11-30|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia|Phase I/II Study of An Ex Vivo Immunotherapy for Treatment of Idiopathic Aplastic Anemia|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Shenzhen Zhongxing Yangfan Biotech Co. Ltd.||1|||f||||t||||||||||2018-06-01 03:38:23.091181|2018-06-01 03:38:23.091181
NCT00399945|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2007-05-04|2006-11-14|2006-11-15|Estimate|||||||2007-05-04|2007-05-07|Estimate|May 2006||2006-05-31|May 2007|2007-05-31||||||||Interventional|||Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study|A Phase 1, Single-Dose, Open-Label, Two-Way Crossover, Pharmacoscintigraphy Study of Aerosol Delivery Characteristics (Measured by In Vivo Lung Deposition, Nebulization Time, Serum Tobramycin Concentrations, and Pharmacokinetic Parameters) and Safety of Tobramycin Administered for Inhalation by PARI eFlow® Rapid Electronic Nebulizer (No Compressor) vs. PARI LC PLUS (TM) Jet Nebulizer (With Compressor) in Healthy Subjects and in Subjects With Cystic Fibrosis|Completed||Phase 1|12||Novartis|||||f||||||||||||||2018-06-01 03:38:23.176821|2018-06-01 03:38:23.176821
NCT00399932|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2009-09-17|2006-11-14|2006-11-15|Estimate|||||||2009-09-17|2009-09-18|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|May 2010|Anticipated|2010-05-31|May 2009|Actual|2009-05-31||Observational|||Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome||Unknown status|Recruiting||75|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||Samples Without DNA|"~     liver biopsy serum~   "|||2018-06-01 03:38:23.231902|2018-06-01 03:38:23.231902
NCT00399919|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2011-08-23|2006-11-14|2006-11-15|Estimate|||||||2011-08-23|2011-08-25|Estimate|April 2006||2006-04-30|June 2009|2009-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)|Safety and Efficacy pf Propionyl-L-Carnitine in Combination With Monitored Exercise Training in Peripheral Arterial Disease (Intermittent Claudication).|Completed||Phase 3|69|Actual|Sigma-Tau Research, Inc.||2|||f||||t||||||||||2018-06-01 03:38:23.293098|2018-06-01 03:38:23.293098
NCT00399906|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14||2015-09-23|2015-11-06|2006-11-14|2006-11-15|Estimate||||2015-09-23|2015-10-12|Estimate|2015-11-06|2015-12-07|Estimate|August 2007||2007-08-31|November 2015|2015-11-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Three Different Doses of BMS-582949 Given Orally to Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|99|Actual|Bristol-Myers Squibb||4|||f||||t||||||||||2018-06-01 03:38:23.361722|2018-06-01 03:38:23.361722
NCT00399880|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|2017-06-01||2017-07-28|2006-11-13|2006-11-15|Estimate|2017-07-28|2017-09-25|Actual||||2017-07-28|2017-09-25|Actual|November 2006||2006-11-30|July 2017|2017-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|IMAGE-ACS||Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes|Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes|Completed||N/A|130|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 03:38:23.99059|2018-06-01 03:38:23.99059
NCT00399867|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2006-12-19|2006-11-14|2006-11-15|Estimate|||||||2006-12-19|2006-12-20|Estimate|April 2005||2005-04-30|November 2006|2006-11-30|April 2007||2007-04-30|||||Interventional|||Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.|Determination of the Efficacy and Feasibility of Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma – a Phase II Clinical Trial.|Completed||Phase 2|30||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:38:24.351619|2018-06-01 03:38:24.351619
NCT00399854|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2006-11-14|2006-11-14|2006-11-15|Estimate|||||||2006-11-14|2006-11-15|Estimate|March 2006||2006-03-31|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring|Clinical Study for Evaluation of the Efficacy of Mechanical Massage by Endermologie (Dhermia® – Industra Mecânica Fina Ltda) in Treatment of Cellulite and Body Contouring|Completed||Phase 4|45||Brazilan Center for Studies in Dermatology|||||f||||||||||||||2018-06-01 03:38:24.464918|2018-06-01 03:38:24.464918
NCT00399841|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2013-08-01|2006-11-13|2006-11-15|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||Spinal Cord Stimulation (SCS) for Neuropathic Pain of Back or Lower Extremity|Spinal Cord Stimulation (SCS) for Neuropathic Pain of Back or Lower Extremity: A Comparison of Electrode Placement at T7 and T8|Terminated||Phase 4|13|Actual|Boston Scientific Corporation||2||Investigator Resigned|f||||f||||||||||2018-06-01 03:38:24.516976|2018-06-01 03:38:24.516976
NCT00399828|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2008-03-11|2006-11-14|2006-11-15|Estimate|||||||2008-03-11|2008-03-12|Estimate|August 2006||2006-08-31|March 2008|2008-03-31|November 2006||2006-11-30|||||Interventional|||Evaluation Of The Efficacy and Safety Of Tri-ActiveTM In Treatment Of Cellulite|Clinical Study For Evaluation Of The Efficacy and Safety Of Tri-ActiveTM (Deka M.E.L.A., Itália) In Treatment Of Cellulite|Terminated||Phase 4|20||Brazilan Center for Studies in Dermatology|||||f||||||||||||||2018-06-01 03:38:24.577579|2018-06-01 03:38:24.577579
NCT00399815|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2009-09-17|2006-11-14|2006-11-15|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|May 2010|Anticipated|2010-05-31|May 2009|Actual|2009-05-31||Observational|||Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C||Unknown status|Recruiting||40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||Samples Without DNA|"~     liver biopsy serum~   "|||2018-06-01 03:38:24.629187|2018-06-01 03:38:24.629187
NCT00399802|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|2017-04-05||2018-02-02|2006-11-14|2006-11-15|Estimate|2017-07-12|2018-02-01|Actual||||2018-02-02|2018-03-01|Actual|November 16, 2006|Actual|2006-11-16|February 2018|2018-02-28|December 5, 2007|Actual|2007-12-05|December 5, 2007|Actual|2007-12-05||Interventional|||A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)|A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women With Breast Cancer and Established Bone Metastases (MBD)|Completed||Phase 2|43|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-06-01 03:38:24.689992|2018-06-01 03:38:24.689992
NCT00399789|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13||2018-02-20|2018-02-20|2006-11-13|2006-11-15|Estimate||||2018-02-20|2018-02-21|Estimate|2018-02-20|2018-02-21|Estimate|September 2004||2004-09-30|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer|A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|121|Actual|AEterna Zentaris||3|||f||||f||||||||||2018-06-01 03:38:24.982665|2018-06-01 03:38:24.982665
NCT00399776|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2011-08-03|2006-11-14|2006-11-15|Estimate|||||||2011-08-03|2011-08-04|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy|Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy|Completed|||60|Anticipated|Creighton University|||2||f||||f||||||||||2018-06-01 03:38:25.095218|2018-06-01 03:38:25.095218
NCT00399763|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|2012-08-03||2015-06-12|2006-11-14|2006-11-15|Estimate|2015-06-12|2015-07-08|Estimate||||2015-06-12|2015-07-08|Estimate|September 2005||2005-09-30|June 2015|2015-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder|A Randomized, Placebo-controlled Trial of Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder (SUD)|Completed||N/A|70|Actual|Denver Health and Hospital Authority|"The study was not powered to assess safety.~Participants received individual motivational interviewing/cognitive behavioral therapy for substance treatment. The results may not generalize to samples receiving different behavioral treatment."|2|||f||||f||||||||||2018-06-01 03:38:25.185405|2018-06-01 03:38:25.185405
NCT00399750|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2009-10-14|2006-11-14|2006-11-15|Estimate|||||||2009-10-14|2009-10-15|Estimate|November 2002||2002-11-30|October 2009|2009-10-31|June 2005||2005-06-30|||||Interventional|||TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer|A Randomized Prospective Study Comparing Three Regimens of Oxaliplatin Plus Fluoropyrimidine and Avastin for Evaluation of Safety and Tolerability in First-line Treatment of Patients With Advanced Colorectal Cancer.|Completed||Phase 2|373||Sanofi|||||f||||||||||||||2018-06-01 03:38:25.437144|2018-06-01 03:38:25.437144
NCT00399737|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2006-11-14|2006-11-14|2006-11-15|Estimate|||||||2006-11-14|2006-11-15|Estimate|October 2005||2005-10-31|November 2006|2006-11-30|November 2005||2005-11-30|||||Interventional|||Effects of Peptides Derived From Fermented Milk on Blood Pressure Regulation System in Healthy Volunteers.||Terminated||Phase 1|12||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:38:25.504329|2018-06-01 03:38:25.504329
NCT00399724|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2010-08-30|2006-11-14|2006-11-15|Estimate|||||||2010-08-30|2010-08-31|Estimate|March 2002||2002-03-31|August 2010|2010-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|AT-LANTUS||A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus|A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus.|Completed||Phase 4|7376||Sanofi|||||f||||||||||||||2018-06-01 03:38:25.56559|2018-06-01 03:38:25.56559
NCT00399711|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2017-02-09|2006-11-14|2006-11-15|Estimate|||||||2017-02-09|2017-02-10|Actual|November 2006||2006-11-30|February 2017|2017-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes|Repaglinide and Metformin Combination Tablet (NN4440) in a TID Regimen Compared to a BID Regimen and BID Avandamet in Subjects With Type 2 Diabetes: A Twenty-Six Week, Open-Label, Multicenter, Randomized, Parallel Group Trial to Investigate Efficacy and Safety|Completed||Phase 3|560|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:38:25.664584|2018-06-01 03:38:25.664584
NCT00399698|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2016-06-21|2006-11-13|2006-11-15|Estimate|||||||2016-06-21|2016-06-23|Estimate|May 1999||1999-05-31|June 2016|2016-06-30|June 2005||2005-06-30|||||Interventional|||Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.|Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children|Completed||Phase 3|30||Ohio State University|||||f||||||||||||||2018-06-01 03:38:25.84193|2018-06-01 03:38:25.84193
NCT00399685|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2011-04-13|2006-11-14|2006-11-15|Estimate|||||||2011-04-13|2011-04-14|Estimate|December 2006||2006-12-31|April 2011|2011-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Drug Interaction - Oral Contraceptive|Study to Evaluate the Effect of Efavirenz Coadministration on the Pharmacokinetics of the Active Moieties of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects|Completed||Phase 1|28|Actual|Bristol-Myers Squibb||4|||f||||||||||||||2018-06-01 03:38:25.909834|2018-06-01 03:38:25.909834
NCT00399672|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2016-11-28|2006-11-14|2006-11-15|Estimate|||||||2016-11-28|2016-11-30|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|August 2010|Actual|2010-08-31||Interventional|||Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)|Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study)|Completed||N/A|370|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:38:26.002309|2018-06-01 03:38:26.002309
NCT00399659|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2012-04-30|2006-11-14|2006-11-15|Estimate|||||||2012-04-30|2012-05-01|Estimate|November 2006||2006-11-30|April 2012|2012-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.|A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain|Terminated||Phase 3|360|Actual|Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in~   2007"|||||||||||||||2018-06-01 03:38:26.065996|2018-06-01 03:38:26.065996
NCT00399646|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2009-05-11|2006-11-14|2006-11-15|Estimate|||||||2009-05-11|2009-05-13|Estimate|November 2005||2005-11-30|May 2009|2009-05-31|March 2009|Actual|2009-03-31|November 2007|Actual|2007-11-30||Interventional|GAAME||Evaluation of the Metricath Gemini System, a Device Intended to Make Arterial Measurements and Perform Angioplasty Dilations.|Gemini Angioplasty and Arterial Measurement Evaluation (GAAME) An Evaluation of the Metricath Gemini System, a Percutaneous Interventional Device Intended to Make Arterial Lumen Measurements and Perform Percutaneous Transluminal Angioplasty Dilations.|Completed||Phase 2|145|Actual|Neovasc Inc.|||||f||||t||||||||||2018-06-01 03:38:26.165042|2018-06-01 03:38:26.165042
NCT00399633|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2008-05-13|2006-11-14|2006-11-15|Estimate|||||||2008-05-13|2008-05-14|Estimate|January 2007||2007-01-31|May 2008|2008-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Neuropeptides in the Humane Intra- og Extracerebral Circulation.|Neuropeptides in the Humane Intra- og Extracerebral Circulation - in Relation to Sumatriptan in Healthy Volunteers.|Completed||N/A|16|Actual|Danish Headache Center|||||f||||||||||||||2018-06-01 03:38:26.315425|2018-06-01 03:38:26.315425
NCT00399620|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2009-01-09|2006-11-14|2006-11-15|Estimate|||||||2009-01-09|2009-01-12|Estimate|March 2008||2008-03-31|January 2009|2009-01-31||||||||Interventional|||Chromogranin-A-Derived Peptides and Periodontitis in Diabetic Patients|Chromogranin-A-Derived Peptides in the Gingival Crevicular Fluid and the Saliva of Diabetic Patients With or Without Periodontitis|Unknown status|Recruiting|N/A|90|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 03:38:26.377525|2018-06-01 03:38:26.377525
NCT00399607|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2016-12-07|2006-11-14|2006-11-15|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2006||2006-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Observational|PPS4B||Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention|Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention|Completed|||264|Actual|Emory University|||2||f||||t||||||Samples Without DNA|"~     Biopsies of normal-appearing rectal mucosa will be collected from participants in an~     associated parent study.~   "|||2018-06-01 03:38:26.448228|2018-06-01 03:38:26.448228
NCT00399594|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2015-11-20|2006-11-13|2006-11-15|Estimate|||||||2015-11-20|2015-11-24|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|April 2014|Actual|2014-04-30||Interventional|INCREMENTAL||Effect of Targeting Left Ventricular Lead Position on the Rate of Response to Cardiac Resynchronization Therapy.|Investigating Non-response to Cardiac Resynchronization: Evaluation of Methods to Eliminate Non-response & Target Appropriate Lead Location (INCREMENTAL).|Completed||Phase 2/Phase 3|96|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 03:38:26.536967|2018-06-01 03:38:26.536967
NCT00399581|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|||2013-02-26|2006-11-14|2006-11-15|Estimate|||||||2013-02-26|2013-02-27|Estimate|November 2006||2006-11-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Comparison of Two Methods of High Frequency Oscillatory Ventilation in Individuals With Acute Respiratory Distress Syndrome|Phase II Clinical Trial of Two Approaches to High Frequency Oscillatory Ventilation in Acute Respiratory Distress Syndrome|Completed||Phase 2|100|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:38:26.612117|2018-06-01 03:38:26.612117
NCT00399568|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14|2009-09-25|2009-04-03|2016-09-08|2006-11-14|2006-11-15|Estimate|2010-11-11|2010-12-10|Estimate|2010-11-11|2010-12-10|Estimate|2016-09-08|2016-10-21|Estimate|November 2006||2006-11-30|September 2016|2016-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery|Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel, Multiple-Dose Study of the Analgesic Efficacy and Safety of IV Acetaminophen (APAP) Versus Placebo Over 48 Hours(Hrs) for the Treatment of Postoperative Pain After Gynecologic Surgery|Completed||Phase 3|331|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 03:38:26.774093|2018-06-01 03:38:26.774093
NCT00399555|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2013-11-25|2006-11-14|2006-11-15|Estimate|||||||2013-11-25|2013-11-27|Estimate|November 2006||2006-11-30|November 2013|2013-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Neurodevelopmental Outcomes in Hypoplastic Left Heart Syndrome|Neurodevelopmental Outcomes in Hypoplastic Left Heart Syndrome—Correlation With Cerebral Non-invasive Infrared Spectroscopy (NIRS)|Completed|||28|Actual|Emory University|||1||f||||f||||||||||2018-06-01 03:38:27.324861|2018-06-01 03:38:27.324861
NCT00399542|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|2008-10-07||2013-09-25|2006-11-14|2006-11-15|Estimate|2008-10-29|2008-10-31|Estimate||||2013-09-25|2013-10-29|Estimate|May 2005||2005-05-31|September 2013|2013-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation|Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation|Completed||Phase 3|581|Actual|Sucampo Pharma Americas, LLC|||||f||||||||||||||2018-06-01 03:38:27.448459|2018-06-01 03:38:27.448459
NCT00399529|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13||2012-11-29|2012-12-11|2006-11-14|2006-11-15|Estimate||||2012-12-11|2012-12-13|Estimate|2012-12-11|2012-12-13|Estimate|September 2006||2006-09-30|December 2012|2012-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer|A Feasibility Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for HER-2/Neu-Overexpressing Metastatic Breast Cancer.|Completed||Phase 2|22|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 03:38:28.241928|2018-06-01 03:38:28.241928
NCT00399516|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|2012-02-13||2012-03-07|2006-11-13|2006-11-15|Estimate|2012-03-07|2012-04-04|Estimate||||2012-03-07|2012-04-04|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Effect of Pulse Width With Spinal Cord Stimulation|The Effect of Pulse Width on the Treatment of Chronic Low Back Pain With Spinal Cord Stimulation|Completed||Phase 4|21|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 03:38:28.312747|2018-06-01 03:38:28.312747
NCT00399503|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2016-06-13|2006-11-13|2006-11-15|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2001||2001-09-30|November 2006|2006-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Assessment of Noninvasive Methods to Identify Patients at Risk of Serious Arrhythmias After a Heart Attack|Risk Estimation Following Infarction Noninvasive Evaluation (REFINE)|Completed|||350||University of Calgary|||||f||||||||||||||2018-06-01 03:38:28.421565|2018-06-01 03:38:28.421565
NCT00399490|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-14||2009-04-06|2013-10-08|2006-11-14|2006-11-15|Estimate||||2009-10-07|2009-10-12|Estimate|2013-10-08|2013-11-04|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Open-label Extension Study Of RN624|Open-Label, Multiple-Dose Study Of The Safety And Efficacy Of RN624 In Adults With Pain Due To Osteoarthritis Of The Knee|Completed||Phase 2|281|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:38:28.499173|2018-06-01 03:38:28.499173
NCT00399477|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2011-04-08|2006-11-13|2006-11-14|Estimate|||||||2011-04-08|2011-04-12|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease|Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD)|Completed||Phase 4|200|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 03:38:28.667944|2018-06-01 03:38:28.667944
NCT00399464|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2009-10-01|2006-11-13|2006-11-14|Estimate|||||||2009-10-01|2009-10-02|Estimate|November 2006||2006-11-30|October 2009|2009-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia|Efficacy and Safety of SL77.0499-10 10mg Once Daily in Comparison With Placebo and Tamsulosin Hydrochloride 0.2mg in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH).|Completed||Phase 3|1177|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:38:28.735333|2018-06-01 03:38:28.735333
NCT00399451|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2006-11-20|2006-11-13|2006-11-14|Estimate|||||||2006-11-20|2006-11-22|Estimate|December 2006||2006-12-31|November 2006|2006-11-30|June 2009||2009-06-30|||||Interventional|||Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)|Preliminary Study on Submucous Sclerosis of Pharynges With 1% Polidocanol to Treat Obstructive Sleep Apnea (OSA) & Snoring Subjects (SS)|Unknown status|Not yet recruiting|Phase 1/Phase 2|30||Liaoyang Central Hospital|||||f||||||||||||||2018-06-01 03:38:28.799689|2018-06-01 03:38:28.799689
NCT00399438|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2008-09-25|2006-11-13|2006-11-14|Estimate|||||||2008-09-25|2008-09-26|Estimate|December 2006||2006-12-31|September 2008|2008-09-30|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||A Study of BMS-562086 in Patients With Irritable Bowel Syndrome|A Dose-Ranging Study of the Pharmacodynamic Effects of BMS-562086 on Gastrointestinal Transit in Women With Diarrhea-Predominant Irritable Bowel Syndrome|Completed||Phase 2|39|Anticipated|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 03:38:28.862441|2018-06-01 03:38:28.862441
NCT00399425|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2006-11-13|2006-11-13|2006-11-14|Estimate|||||||2006-11-13|2006-11-14|Estimate|June 2001||2001-06-30|November 2006|2006-11-30|April 2004||2004-04-30|||||Interventional|||Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients|Triple-Blind Clinical Trial With Placebo Control to Evaluate the Efficacy of a Heparin of Low Molecular Weight (Bemiparin) for Treating Slow-Responding Ulcers in Diabetic Foot in Primary Care|Terminated||Phase 2/Phase 3|84||Spanish National Health System|||||f||||||||||||||2018-06-01 03:38:28.926752|2018-06-01 03:38:28.926752
NCT00399412|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2017-02-14|2006-11-10|2006-11-14|Estimate|||||||2017-02-14|2017-02-16|Actual|November 2006||2006-11-30|October 2009|2009-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients|Further Research on Human Feasibility of a Subcutaneous Implantable Defibrillator (S-ICD)- ECG Signal Collections From Various Patient Groups Whilst Attending Outpatient Follow-up|Completed|||86|Actual|Boston Scientific Corporation|||4||f||||f||||||||||2018-06-01 03:38:29.005857|2018-06-01 03:38:29.005857
NCT00399399|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2006-11-13|2006-11-13|2006-11-14|Estimate|||||||2006-11-13|2006-11-14|Estimate|July 1996||1996-07-31|November 2006|2006-11-30||||||||Interventional|||CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors|CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients.|Unknown status|Active, not recruiting|Phase 4|72||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:38:29.097201|2018-06-01 03:38:29.097201
NCT00399386|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2017-02-14|2006-11-10|2006-11-14|Estimate|||||||2017-02-14|2017-02-16|Actual|November 2006||2006-11-30|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Electrocardiogram (ECG) Recordings in Paediatric Population|ECG Recordings From EP Study, Defibrillator Implantation or Ablation Procedure in Paediatric Population|Completed|||62|Actual|Boston Scientific Corporation|||||f||||||||||||||2018-06-01 03:38:29.167979|2018-06-01 03:38:29.167979
NCT00399373|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2017-12-05|2006-11-13|2006-11-14|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2005||2005-11-30|December 2017|2017-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Structuring the Integration of Care Management Services For Medicaid Enrollees Recipients With Chronic Illness, Substance Abuse Problems and Possible Psychiatric Disorders|Structuring the Integration of Services For Medicaid Recipients With Chronic Illness, Substance Abuse Problems and Possible Psychiatric Disorders|Terminated|||258|Actual|Johns Hopkins University|||2||f||||||||||||||2018-06-01 03:38:29.222036|2018-06-01 03:38:29.222036
NCT00398801|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2014-06-16|2006-11-13|2006-11-14|Estimate|||||||2014-06-16|2014-06-17|Estimate|December 2006||2006-12-31|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Observational|GpR||Gastroparesis Registry|Gastroparesis Registry|Completed|||591|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||Samples With DNA|"~     Plasma and serum~   "|||2018-06-01 03:38:37.446835|2018-06-01 03:38:37.446835
NCT00399360|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|2012-05-18||2012-09-13|2006-11-13|2006-11-14|Estimate|2012-09-13|2012-09-14|Estimate||||2012-09-13|2012-09-14|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Lifestyle Modification and Metformin Use in the Treatment of HIV|Strategies for the Treatment of HIV Associated Metabolic Syndrome|Completed||N/A|50|Actual|Massachusetts General Hospital|The study was relatively small and may have been underpowered to assess effect on secondary endpoints and to assess the effects of lifestyle modification. The sample size may have limited our ability to determine differences in dropout rates.|4|||f||||t||||||||||2018-06-01 03:38:29.299053|2018-06-01 03:38:29.299053
NCT00399347|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-12|||2006-11-12|2006-11-12|2006-11-14|Estimate|||||||2006-11-12|2006-11-14|Estimate|January 2005||2005-01-31|November 2006|2006-11-30|December 2005||2005-12-31|||||Observational|||Prevalence of Type 2 Diabetes Mellitus in Ethiopian Community in Israel: an Update|Prevalence of Diabetes Mellitus in Ethiopian Community in Israel: an Update|Unknown status|Active, not recruiting||500||HaEmek Medical Center, Israel|||||f||||||||||||||2018-06-01 03:38:30.776833|2018-06-01 03:38:30.776833
NCT00399334|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2011-05-18|2006-11-10|2006-11-14|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2005||2005-06-30|April 2010|2010-04-30|December 2005|Actual|2005-12-31|||||Observational|||PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders|Study PROFILe3: Clinic Observations Profile of Relapse and Readmission in Emergency/Acute Settings: Epidemiologic Survey in Schizophrenic Patients|Completed|||1607|Actual|Janssen-Cilag, S.A.|||1||f||||||||||||||2018-06-01 03:38:30.826574|2018-06-01 03:38:30.826574
NCT00399321|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2017-07-03|2006-11-13|2006-11-14|Estimate|||||||2017-07-03|2017-07-05|Actual|April 2006||2006-04-30|July 2017|2017-07-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer|A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer|Completed|||9|Actual|University of Michigan Cancer Center|||||f||||t||||||Samples Without DNA|"~     refer to protocol~   "|||2018-06-01 03:38:30.911192|2018-06-01 03:38:30.911192
NCT00399308|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|2013-03-18||2013-08-09|2006-11-13|2006-11-14|Estimate|2013-03-18|2013-05-16|Estimate||||2013-08-09|2013-08-21|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers|An Initial Evaluation Of The Safety And Activity Of Celaderm(TM) Treatment Regimens In Healing Venous Leg Ulcers|Completed||Phase 1/Phase 2|40|Actual|Shire Regenerative Medicine, Inc.|Limitations of the trial include the potential for outcome assessment bias as the study was not blinded.|3|||f||||f||||||||||2018-06-01 03:38:30.983638|2018-06-01 03:38:30.983638
NCT00399295|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2010-04-26|2006-11-10|2006-11-14|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|June 1997|Actual|1997-06-30|||||Interventional|||An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg|An Open-Label Evaluation of the Independent Effect of Coadministration of a High Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCL) 16 mg|Completed||Phase 1|30|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:38:31.378808|2018-06-01 03:38:31.378808
NCT00399282|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2007-04-17|2006-11-13|2006-11-14|Estimate|||||||2007-04-17|2007-04-18|Estimate|October 2006||2006-10-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Omega-3 and Vitamin E Supplementation in Patients With Rheumatoid Arthritis|Comparison of the Effects of Simultaneous Administration of Vitamin E and Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis|Completed||Phase 1|75||Shahid Beheshti University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:38:32.191985|2018-06-01 03:38:32.191985
NCT00399269|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-12|||2009-06-10|2006-11-13|2006-11-14|Estimate|||||||2009-06-10|2009-06-11|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure|Assessment of Efficacy & Safety of Recombinant Human Erythropoietin -Alpha, (rHu-EPO-Alpha) in Patients With Anemia of Chronic Renal Failure.|Completed||Phase 3|100|Actual|Cadila Pharnmaceuticals|||||f||||||||||||||2018-06-01 03:38:32.259412|2018-06-01 03:38:32.259412
NCT00399256|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2007-01-31|2006-11-13|2006-11-14|Estimate|||||||2007-01-31|2007-02-01|Estimate|March 2004||2004-03-31|January 2007|2007-01-31|March 2006||2006-03-31|||||Interventional|||Improved Estimation of GFR by Cystatin C in Preventing Contrast Induced Nephropathy by NAC or Zn|Improved Estimation of Glomerular Filtration Rate by Serum Cystatin C in Preventing Contrast Induced Nephropathy by N-Acetylcysteine or Zinc|Terminated||N/A|60||Robert Bosch Gesellschaft für Medizinische Forschung mbH|||||f||||||||||||||2018-06-01 03:38:32.3195|2018-06-01 03:38:32.3195
NCT00399243|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-12|||2009-01-29|2006-11-13|2006-11-14|Estimate|||||||2009-01-29|2009-02-02|Estimate|November 2006||2006-11-30|January 2009|2009-01-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache|4mg StatDose Imitrex for Acute Treatment of Cluster Headache|Unknown status|Recruiting|Phase 4|20|Anticipated|Diamond Headache Clinic|||||f||||f||||||||||2018-06-01 03:38:32.3873|2018-06-01 03:38:32.3873
NCT00399230|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2007-08-17|2006-11-09|2006-11-14|Estimate|||||||2007-08-17|2007-08-21|Estimate||||August 2007|2007-08-31||||||||Interventional|||A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:38:32.503491|2018-06-01 03:38:32.503491
NCT00399217|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2017-02-14|2006-11-10|2006-11-14|Estimate|||||||2017-02-14|2017-02-16|Actual|November 2006||2006-11-30|May 2010|2010-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Further Acute Research of a Subcutaneous Implantable Defibrillator (S-ICD) System|Acute Intra-operative Testing of Subcutaneous Implantable Defibrillator Emulator and Parasternal Electrode, Acutely Implanted, for Comparison With Transvenous System|Completed|||55|Actual|Boston Scientific Corporation|||||f||||||||||||||2018-06-01 03:38:32.557161|2018-06-01 03:38:32.557161
NCT00399204|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2006-11-13|2006-11-13|2006-11-14|Estimate|||||||2006-11-13|2006-11-14|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients|A Randomised Pilot Study to Compare the Effect of Pioglitazone and Metformin on Cardiovascular Morbidity and Mortality in Patients With Type 2 Diabetes|Unknown status|Recruiting|Phase 4|100||Postgraduate Institute of Medical Education and Research|||||f||||||||||||||2018-06-01 03:38:32.617497|2018-06-01 03:38:32.617497
NCT00399191|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2010-03-17|2006-11-13|2006-11-14|Estimate|||||||2010-03-17|2010-03-18|Estimate|August 2006||2006-08-31|March 2010|2010-03-31||||||||Interventional|||A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia||Completed||Phase 1|15|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 03:38:32.831602|2018-06-01 03:38:32.831602
NCT00398021|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2015-10-01|2006-11-09|2006-11-10|Estimate|||||||2015-10-01|2015-10-05|Estimate|June 2006||2006-06-30|June 2010|2010-06-30|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Observational|||Predictors of Constipation in Healthy Children|Predictors of Constipation in Healthy Children|Completed|||1430|Anticipated|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 03:38:50.27926|2018-06-01 03:38:50.27926
NCT00399178|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2007-08-16|2006-11-13|2006-11-14|Estimate|||||||2007-08-16|2007-08-17|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|June 2007|Actual|2007-06-30|||||Interventional|||A Randomised Open Controlled Parallel Group Study Comparing Norspan and Tramadol|A Randomised Open Controlled Parallel Group Multicenter Study to Evaluate the Efficacy and Safety of Norspan Versus Tiparol Retard in Subjects With Chronic Moderate to Severe OA Pain of the Hip and/or Knee.|Completed||Phase 4|160|Anticipated|Mundipharma AB|||||f||||||||||||||2018-06-01 03:38:32.901267|2018-06-01 03:38:32.901267
NCT00399165|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2008-09-18|2006-11-09|2006-11-14|Estimate|||||||2008-09-18|2008-09-22|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Oral Androgens in Man-4: (Short Title: Oral T-4)|Oral Androgens in Man-4: Gonadotropin Suppression Medicated by Oral Testosterone Enanthate in Oil Plus Dutasteride (Short Title: Oral T-4)|Completed||Phase 1/Phase 2|20|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:38:32.976539|2018-06-01 03:38:32.976539
NCT00399152|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2014-02-14|2006-11-09|2006-11-14|Estimate|||||||2014-02-14|2014-02-19|Estimate|October 2006||2006-10-31|November 2011|2011-11-30|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||Perifosine + Sunitinib Malate for Patients With Advanced Cancers|An Open-Label Phase I Study of the Safety of Perifosine in Combination With Sunitinib Malate for Patients With Advanced Cancers|Completed||Phase 1|15|Actual|AEterna Zentaris||1|||f||||f||||||||||2018-06-01 03:38:33.095126|2018-06-01 03:38:33.095126
NCT00399126|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2014-02-12|2006-11-10|2006-11-14|Estimate|||||||2014-02-12|2014-02-13|Estimate|November 2004||2004-11-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|January 2009|Actual|2009-01-31||Interventional|||Phase I Trial of Paclitaxel With Perifosine|A Phase 1 Trial of the Combination of Perifosine and Paclitaxel Given Either Weekly or Every 3 Weeks|Completed||Phase 1|24|Actual|AEterna Zentaris|||||f||||f||||||||||2018-06-01 03:38:33.169507|2018-06-01 03:38:33.169507
NCT00399113|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2011-07-12|2006-11-13|2006-11-14|Estimate|||||||2011-07-12|2011-07-14|Estimate|May 2007||2007-05-31|July 2011|2011-07-31||||June 2008|Actual|2008-06-30||Interventional|||Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma|An Open-Label Phase I Safety, Pharmacokinetic & Dosimetry Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma|Completed||Phase 1|12|Actual|Pain Therapeutics|||||f||||f||||||||||2018-06-01 03:38:33.247642|2018-06-01 03:38:33.247642
NCT00399100|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2018-03-19|2006-11-13|2006-11-14|Estimate|||||||2018-03-19|2018-03-21|Actual|November 2006|Actual|2006-11-30|November 2006|2006-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Is it Possible to Treat Cyanide Poisoning With HBO?||Completed|||20||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:38:33.322935|2018-06-01 03:38:33.322935
NCT00399087|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2014-02-12|2006-11-10|2006-11-14|Estimate|||||||2014-02-12|2014-02-13|Estimate|November 2004||2004-11-30|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||Phase I Trial of Docetaxel With Perifosine|A Phase 1 Trial of the Combination of Perifosine and Docetaxel With or Without Prednisone|Completed||Phase 1|39|Actual|AEterna Zentaris||3|||f||||f||||||||||2018-06-01 03:38:33.382307|2018-06-01 03:38:33.382307
NCT00399074|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2009-07-01|2006-11-13|2006-11-14|Estimate|||||||2009-07-01|2009-07-02|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia|Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia|Completed||Phase 3|220|Anticipated|Makerere University||2|||f||||||||||||||2018-06-01 03:38:33.450091|2018-06-01 03:38:33.450091
NCT00399061|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2008-09-23|2006-11-09|2006-11-14|Estimate|||||||2008-09-23|2008-09-25|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms|Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms|Completed||Phase 4|55|Actual|Innovative Medical||3|||f||||||||||||||2018-06-01 03:38:33.525679|2018-06-01 03:38:33.525679
NCT00399048|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2010-04-26|2006-11-10|2006-11-14|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|May 2001|Actual|2001-05-31|||||Interventional|||An Effectiveness, Safety and Quality of Life Measures With Hydromorphone HCL, Dilaudid CR (Controlled Release)|A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in Patients With Chronic Osteoarthritis|Completed||Phase 3|140|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:38:33.590118|2018-06-01 03:38:33.590118
NCT00399035|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|2012-03-29|2011-04-06|2016-11-07|2006-11-13|2006-11-14|Estimate|2012-09-28|2012-10-30|Estimate|2011-04-06|2011-04-12|Estimate|2016-11-07|2016-12-28|Estimate|November 2006||2006-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|March 2010|Actual|2010-03-31||Interventional|HORIZON II||Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer|A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer.|Completed||Phase 3|1254|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 03:38:33.733208|2018-06-01 03:38:33.733208
NCT00399022|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2008-01-28|2006-11-13|2006-11-14|Estimate|||||||2008-01-28|2008-01-31|Estimate||||January 2008|2008-01-31||||||||Interventional|||Treatment With Duloxetine for OCD Patients||Withdrawn||N/A|40|Anticipated|Sheba Medical Center||||Funding was not recieved|f||||||||||||||2018-06-01 03:38:35.169128|2018-06-01 03:38:35.169128
NCT00399009|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2008-06-05|2006-11-13|2006-11-14|Estimate|||||||2008-06-05|2008-06-09|Estimate|January 2004||2004-01-31|June 2008|2008-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Comparative Study of Circular Stapling Instruments|Comparative Study of Circular Stapling Instruments Concerning the Risk of Anastomotic Dehiscence After Anterior Resection for Rectal Cancer.|Terminated||N/A|880|Anticipated|Uppsala University Hospital||||"One of the instruments in the study was withdrawn from the market before the calculated number~   of persons were included."|f||||||||||||||2018-06-01 03:38:35.218506|2018-06-01 03:38:35.218506
NCT00398996|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2011-03-23|2006-11-13|2006-11-14|Estimate|||||||2011-03-23|2011-03-24|Estimate|June 2005||2005-06-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|SAPIT||A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients|Study to Compare Three Existing Starting Points of ART Initiation in HIV/TB Co-infected Patients|Completed||Phase 3|642|Actual|Centre for the AIDS Programme of Research in South Africa||3|||f||||t||||||||||2018-06-01 03:38:35.27388|2018-06-01 03:38:35.27388
NCT00398008|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-07-25|2006-11-09|2006-11-10|Estimate|||||||2013-07-25|2013-07-26|Estimate|October 2004||2004-10-31|July 2013|2013-07-31|December 2008|Anticipated|2008-12-31|December 2006|Actual|2006-12-31||Interventional|||HIV Risk Reduction and Drug Abuse Treatment in Iran|HIV Risk Reduction and Drug Abuse Treatment in Iran|Withdrawn||Phase 2|0|Actual|Yale University||2||Study was never able to start in IRAN|f||||||||||||||2018-06-01 03:38:50.367602|2018-06-01 03:38:50.367602
NCT00398983|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2013-01-25||2013-01-25|2006-11-09|2006-11-14|Estimate|2013-01-25|2013-03-04|Estimate||||2013-01-25|2013-03-04|Estimate|August 2006||2006-08-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)|Randomized Study of Decitabine Versus Observation or Continued Standard Chemotherapy as Maintenance Therapy for Adults With Unfavorable Risk AML in First Complete Remission (CR) or Adults With Relapsed AML in Second or Greater CR|Completed||Phase 2/Phase 3|50|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:38:35.438818|2018-06-01 03:38:35.438818
NCT00398970|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2008-02-25|2006-11-13|2006-11-14|Estimate|||||||2008-02-25|2008-02-29|Estimate|June 2005||2005-06-30|February 2008|2008-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Utility of Endobronchial Ultrasound in the Investigation of Suspected Lung Cancer.|Diagnostic Utility of Endobronchial Ultrasound in the Investigation of Suspected Malignant Lung Lesions Where the Lesions Are Not Visible During Bronchoscopy.|Completed||N/A|240|Anticipated|Haukeland University Hospital||2|||f||||||||||||||2018-06-01 03:38:35.665117|2018-06-01 03:38:35.665117
NCT00398957|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2010-04-26|2006-11-10|2006-11-14|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|September 1998|Actual|1998-09-30|||||Interventional|||An Open-Label Evaluation of the Dose Proportionality of OROS� Hydromorphone HCL Tablets 8mg, 16mg, 32mg, 64mg|An Open Label Evaluation of the Dose Proportionality of Dilaudid SR (OROS� Hydromorphone HCL) Tablets 8mg, 16mg, 32mg, and 64mg|Completed||Phase 1|32|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:38:35.750703|2018-06-01 03:38:35.750703
NCT00398944|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2010-07-26|2006-11-13|2006-11-14|Estimate|||||||2010-07-26|2010-07-27|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|ASTI||Impact of a Computerized Guidelines on the Management of Hypertension and Diabetes|Impact of a Computerized Decision Support System, Based on EBM French Guidelines, on the Management of Hypertension and Diabetes: a Randomised Controlled Trial in Primary Care|Completed||N/A|2715|Actual|Société de Formation Thérapeutique du Généraliste|||||f||||f||||||||||2018-06-01 03:38:35.839258|2018-06-01 03:38:35.839258
NCT00398931|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2015-02-16|2006-11-10|2006-11-14|Estimate|||||||2015-02-16|2015-02-18|Estimate|February 1998||1998-02-28|February 2015|2015-02-28|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)|A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial|Completed||Phase 3|1099|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:35.949873|2018-06-01 03:38:35.949873
NCT00398918|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|2010-02-08||2017-06-17|2006-11-13|2006-11-14|Estimate|2010-04-27|2010-05-14|Estimate||||2017-06-17|2017-07-14|Actual|November 2006||2006-11-30|June 2017|2017-06-30|March 2009|Actual|2009-03-31|October 2007|Actual|2007-10-31||Interventional|||Alcohol Self Administration Laboratory|Alcohol Self Administration Laboratory|Completed||N/A|10|Actual|Boston University||2|||f||||f||||||||No||2018-06-01 03:38:36.024532|2018-06-01 03:38:36.024532
NCT00398905|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2009-05-07|2006-11-10|2006-11-14|Estimate|||||||2009-05-07|2009-05-08|Estimate|January 2004||2004-01-31|May 2009|2009-05-31|September 2004|Actual|2004-09-30|||||Interventional|ODIXa-HIP2||Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement|Controlled, Double-Blind, Randomised, Dose-Ranging Study on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXa-HIP2 Study BAY 59-7939|Completed||Phase 2|726|Actual|Bayer||6|||f||||||||||||||2018-06-01 03:38:36.189642|2018-06-01 03:38:36.189642
NCT00398892|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2010-11-05|2006-11-13|2006-11-14|Estimate|||||||2010-11-05|2010-11-08|Estimate|December 2009||2009-12-31|October 2010|2010-10-31|January 2011|Anticipated|2011-01-31|January 2011|Anticipated|2011-01-31||Interventional|||The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes|The Effects of Lipoic Acid on Glycaemic Control in Type 2 Diabetes|Unknown status|Recruiting|Phase 2|18|Anticipated|University of Edinburgh||2|||f||||||||||||||2018-06-01 03:38:36.368594|2018-06-01 03:38:36.368594
NCT00398879|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06||2018-03-12|2018-03-12|2006-11-10|2006-11-14|Estimate||||2018-03-12|2018-03-14|Actual|2018-03-12|2018-03-14|Actual|August 2005||2005-08-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients|A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients|Completed||Phase 2|381|Actual|AEterna Zentaris||2|||f||||f||||||||||2018-06-01 03:38:36.615432|2018-06-01 03:38:36.615432
NCT00398866|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|2017-04-04||2017-07-05|2006-11-10|2006-11-14|Estimate|2017-07-05|2017-07-07|Actual||||2017-07-05|2017-07-07|Actual|August 2006||2006-08-31|July 2017|2017-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of Hyaluronan for the Treatment of Osteoarthritis in the Thumb|A Study of Hyaluronan (Synvisc) for the Treatment of Osteoarthritis in the Thumb: Randomized Control Trial|Completed||Phase 3|200|Actual|Hospital for Special Surgery, New York||3|||f||||t||||||||||2018-06-01 03:38:36.781109|2018-06-01 03:38:36.781109
NCT00398853|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2016-04-07|2006-11-09|2006-11-14|Estimate|||||||2016-04-07|2016-04-08|Estimate|October 2003||2003-10-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes|Chromium and Insulin Action|Completed||Phase 4|100|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 03:38:37.075227|2018-06-01 03:38:37.075227
NCT00398840|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2017-03-02|2006-11-09|2006-11-14|Estimate|||||||2017-03-02|2017-03-06|Actual|November 2006|Actual|2006-11-30|March 2017|2017-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of ARQ 171 in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors|Terminated||Phase 1|14|Actual|ArQule|||||f||||f||||||||||2018-06-01 03:38:37.156782|2018-06-01 03:38:37.156782
NCT00398827|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2015-07-22|2006-11-10|2006-11-14|Estimate|||||||2015-07-22|2015-07-23|Estimate|December 2006||2006-12-31|July 2015|2015-07-31|May 2007|Actual|2007-05-31|||||Interventional|||A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Dexmedetomidine for Sedation During Monitored Anesthesia Care|Completed||Phase 3|326|Actual|Hospira, now a wholly owned subsidiary of Pfizer||3|||f||||||||||||||2018-06-01 03:38:37.272451|2018-06-01 03:38:37.272451
NCT00398814|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2014-02-14|2006-11-09|2006-11-14|Estimate|||||||2014-02-14|2014-02-19|Estimate|October 2006||2006-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers|An Open-Label Phase I Study of the Safety of Perifosine in Combination With Sorafenib for Patients With Advanced Cancers|Completed||Phase 1|30|Actual|AEterna Zentaris||1|||f||||f||||||||||2018-06-01 03:38:37.377437|2018-06-01 03:38:37.377437
NCT00398788|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2010-04-26|2006-11-10|2006-11-14|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|November 2001|Actual|2001-11-30|||||Interventional|||A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back Pain|An Open-Label, Repeated-Dose Trial to Characterize the Efficacy and Safety, and Impact on Quality of Life Measures of Dilaudid CR (Hydromorphone HCI) in Patients With Chronic Low Back Pain|Completed||Phase 2|207|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:38:37.529667|2018-06-01 03:38:37.529667
NCT00398775|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2007-11-19|2006-11-13|2006-11-14|Estimate|||||||2007-11-19|2007-11-20|Estimate|January 2007||2007-01-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Procalcitonin in Fever of Unknown Etiology|Procalcitonin Guided Antimicrobial Discontinuation in Hospitalised Patients With Fever of Unknown Etiology|Terminated||N/A|90|Anticipated|Changi General Hospital||||Very low recruitment|f||||||||||||||2018-06-01 03:38:37.583457|2018-06-01 03:38:37.583457
NCT00398749|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2012-11-05|2006-11-10|2006-11-14|Estimate|||||||2012-11-05|2012-11-06|Estimate|October 2005||2005-10-31|November 2012|2012-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)|Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2|Completed|||1927|Actual|Janssen-Cilag B.V.|||1||f||||||||||||||2018-06-01 03:38:37.65006|2018-06-01 03:38:37.65006
NCT00398736|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2009-07-14|2006-11-13|2006-11-14|Estimate|||||||2009-07-14|2009-07-15|Estimate||||July 2009|2009-07-31||||||||Observational|||A Non-invasive Approach to the Assessment of Volume Status in Mechanically Ventilated Septic Patients.||Completed|||||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 03:38:37.71528|2018-06-01 03:38:37.71528
NCT00398723|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2011-10-11|2006-11-13|2006-11-14|Estimate|||||||2011-10-11|2011-10-13|Estimate|November 2006||2006-11-30|October 2011|2011-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Narrowband UVB Treatment in Patients With Vitiligo|Effects of Narrowband UVB Phototherapy on Melanocyte Proliferation in Patients With Vitiligo|Completed||N/A|20|Actual|Rockefeller University||1|||f||||f||||||||||2018-06-01 03:38:37.764281|2018-06-01 03:38:37.764281
NCT00398710|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09||2018-03-12|2018-03-12|2006-11-09|2006-11-14|Estimate||||2018-03-12|2018-03-15|Actual|2018-03-12|2018-03-15|Actual|October 2006||2006-10-31|November 2011|2011-11-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia|A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia|Completed||Phase 2|37|Actual|AEterna Zentaris||1|||f||||f||||||||||2018-06-01 03:38:37.828495|2018-06-01 03:38:37.828495
NCT00398697|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2014-02-12|2006-11-13|2006-11-14|Estimate|||||||2014-02-12|2014-02-13|Estimate|August 2004||2004-08-31|January 2007|2007-01-31|January 2006||2006-01-31|||||Interventional|||Phase I Perifosine and Gemcitabine Study|Phase 1 Trial of the Combination of Perifosine and Gemcitabine|Completed||Phase 1|19||AEterna Zentaris|||||f||||||||||||||2018-06-01 03:38:37.919632|2018-06-01 03:38:37.919632
NCT00398684|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2008-05-02|2006-11-13|2006-11-14|Estimate|||||||2008-05-02|2008-05-07|Estimate|January 2001||2001-01-31|May 2008|2008-05-31|June 2004|Actual|2004-06-30|||||Interventional|||Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand||Completed||Phase 3|1792||Institut de Recherche pour le Developpement||3|||f||||||||||||||2018-06-01 03:38:37.997335|2018-06-01 03:38:37.997335
NCT00398671|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2015-02-26|2006-11-13|2006-11-14|Estimate|||||||2015-02-26|2015-02-27|Estimate|January 2006||2006-01-31|December 2008|2008-12-31||||June 2006|Actual|2006-06-30||Interventional|||"PreCoCa - Prehospital Cooling With Cool-Caps"||Completed||Phase 2|50|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 03:38:38.08786|2018-06-01 03:38:38.08786
NCT00398658|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2008-10-17|2006-11-13|2006-11-14|Estimate|||||||2008-10-17|2008-10-20|Estimate|March 2002||2002-03-31|November 2006|2006-11-30|December 2004||2004-12-31|||||Interventional|||Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis||Completed||Phase 4|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:38:38.145304|2018-06-01 03:38:38.145304
NCT00398645|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2018-01-18|2006-11-10|2006-11-14|Estimate|||||||2018-01-18|2018-01-23|Actual|November 15, 2006||2006-11-15|January 2018|2018-01-31|August 30, 2007|Actual|2007-08-30|August 1, 2007|Actual|2007-08-01||Interventional|||A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) With Persistent Asthma|Completed||Phase 2|648|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:38:38.220068|2018-06-01 03:38:38.220068
NCT00398632|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|2015-04-19||2017-10-15|2006-11-13|2006-11-14|Estimate|2015-05-30|2015-06-16|Estimate||||2017-10-15|2017-11-17|Actual|November 2006||2006-11-30|October 2017|2017-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Adult patients taking an antidepressant drug and troubled by sexual side effects of the drug|Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction|Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction|Terminated||Phase 4|6|Actual|Stanford University|Open label trial, only six subjects enrolled, only 4 completed the trial|1||Unable to recruit subjects|f||||f||||||||||2018-06-01 03:38:38.397956|2018-06-01 03:38:38.397956
NCT00398619|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2012-01-20|2006-11-10|2006-11-14|Estimate|||||||2012-01-20|2012-01-23|Estimate|November 2006||2006-11-30|January 2012|2012-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes|A Double-blind, Placebo Controlled Pharmacodynamic Study of the Effect of INCB013739 on Systemic and Adipose Tissue 11βHSD1 Activity in Obese, Insulin Resistant Subjects.|Completed||Phase 1|||Incyte Corporation|||||f||||||||||||||2018-06-01 03:38:38.703245|2018-06-01 03:38:38.703245
NCT00398606|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-10|||2013-05-28|2006-11-10|2006-11-14|Estimate|||||||2013-05-28|2013-05-29|Estimate|April 1995||1995-04-30|May 2013|2013-05-31||||February 1998|Actual|1998-02-28||Interventional|||A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)|A Triple-Blind, Randomized, Active-Controlled, Parallel-Group, Multicenter Study to Evaluate and Compare the Efficacy and Tolerability of Alendronate Sodium With Calcium Supplementation in the Treatment of Osteoporosis in Postmenopausal Women|Completed||Phase 3|650||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:38.767838|2018-06-01 03:38:38.767838
NCT00398593|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-13|||2009-02-13|2006-11-13|2006-11-14|Estimate|||||||2009-02-13|2009-02-16|Estimate|December 2007||2007-12-31|February 2009|2009-02-28|April 2009|Anticipated|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Methods of Improvement Adherence With Therapy in Ulcerative Colitis.|Patient Adherence to Prescribed Therapy in Ulcerative Colitis: an Investigation of Barriers & Methods of Improvement.|Unknown status|Active, not recruiting|Phase 3|80|Anticipated|University Hospitals, Leicester|||||f||||||||||||||2018-06-01 03:38:38.821614|2018-06-01 03:38:38.821614
NCT00398580|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2017-05-25|2006-11-08|2006-11-10|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2006||2006-10-31|May 2017|2017-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men|A Phase II, 28-Day, Randomized, Parallel-Group, Open-Label Study Evaluating the Efficacy and Safety of Twice Daily Oral Doses of Testosterone (150-400mg) Co-administered With 0.25mg Dutasteride Compared With 400mg Testosterone Alone and 0.25mg Dutasteride Alone in the Treatment of Hypogonadism|Completed||Phase 2|43|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:38:38.915019|2018-06-01 03:38:38.915019
NCT00398567|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2017-08-10|2011-02-25|2018-04-06|2006-11-09|2006-11-10|Estimate|2018-04-06|2018-04-13|Actual|2011-02-25|2011-03-11|Estimate|2018-04-06|2018-04-13|Actual|April 2007||2007-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2009|Actual|2009-07-31||Interventional||Safety Population|A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer|A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer|Active, not recruiting||Phase 1/Phase 2|45|Actual|Puma Biotechnology, Inc.||3|||f||||f|t|f||||||||2018-06-01 03:38:39.034658|2018-06-01 03:38:39.034658
NCT00398554|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2015-11-17|2006-11-09|2006-11-10|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2005||2005-06-30|November 2015|2015-11-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma|Pilot Study for Therapy Optimising for Hodgkin's Lymphoma in Childhood and Adolescence; Optimising Therapy for Boys With Hodgkin's Lymphoma in Intermediate and Advanced Stages. Safety and Efficacy Study for Drug Combination VECOPA|Completed||Phase 2|16|Actual|Martin-Luther-Universität Halle-Wittenberg||1|||f||||t||||||||||2018-06-01 03:38:39.732167|2018-06-01 03:38:39.732167
NCT00398541|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2017-09-20|2006-11-09|2006-11-10|Estimate|||||||2017-09-20|2017-09-21|Actual|March 1, 2005|Actual|2005-03-01|September 2017|2017-09-30|June 1, 2007|Actual|2007-06-01|April 10, 2007|Actual|2007-04-10||Interventional|||Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)|Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients|Completed||Phase 3|41|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:39.843147|2018-06-01 03:38:39.843147
NCT00398528|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2007-11-30|2006-11-09|2006-11-10|Estimate|||||||2007-11-30|2007-12-05|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis|An fMRI Study of Treatment Optimization Recommendations Comparing Patients Changing Treatment From Glatiramer Acetate 20 mg qd SC (Copaxone®) to IFN-β-1a 30 Mcg qw IM (Avonex®) to Those Changing From to IFN-β-1a 30 Mcg qw IM (Avonex®) to Glatiramer Acetate 20 mg qd SC (Copaxone®) in a Multicenter Study of Patients With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy.|Terminated|||48|Anticipated|Neurognostics||||rate of enrollment|f||||||||||||||2018-06-01 03:38:39.907343|2018-06-01 03:38:39.907343
NCT00398515|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-09-27|2006-11-09|2006-11-10|Estimate|||||||2013-09-27|2013-09-30|Estimate|March 2007||2007-03-31|September 2013|2013-09-30||||February 2012|Actual|2012-02-29||Interventional|||Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma|A Phase I Trial of CC-5013 (Lenalidomide) and CCI-779 in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:38:39.981761|2018-06-01 03:38:39.981761
NCT00398502|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2011-07-22|2006-11-09|2006-11-10|Estimate|||||||2011-07-22|2011-07-25|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Comparisons Of The Bioavailability And Pharmacodynamics Of Various Formulations Of MOA-728 In Subjects On Methadone|A Randomized, Open-label, 3-period Crossover Study to Determine the Relative Bioavailability of Two Oral Formulations of MOA-728 and to Compare the Pharmacodynamics of the Two Oral Formulations of MOA-728 and the Subcutaneous Formulation in Subjects on Stable Methadone Maintenance|Completed||Phase 1|||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:38:40.099234|2018-06-01 03:38:40.099234
NCT00398489|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2010-11-06|2006-11-09|2006-11-10|Estimate|||||||2010-11-06|2010-11-09|Estimate|October 2006||2006-10-31|September 2008|2008-09-30||||||||Interventional|||Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery|Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON]|Unknown status|Active, not recruiting|Phase 2|94|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:40.181509|2018-06-01 03:38:40.181509
NCT00398476|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2017-06-08||2018-01-31|2006-11-09|2006-11-10|Estimate|2017-06-08|2018-01-29|Actual||||2018-01-31|2018-03-01|Actual|December 1, 2006|Actual|2006-12-01|June 2017|2017-06-30|December 4, 2006|Actual|2006-12-04|December 4, 2006|Actual|2006-12-04||Interventional|||Fluticasone Nasal Spray Patient Preference Study|A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subject With Allergic Rhinitis|Completed||Phase 3|127|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:38:40.381255|2018-06-01 03:38:40.381255
NCT00398463|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2011-06-29|2006-11-09|2006-11-10|Estimate|||||||2011-06-29|2011-07-01|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|May 2011|Actual|2011-05-31|July 2008|Actual|2008-07-31||Interventional|3T/2R||Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance|Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel|Completed||Phase 4|263|Actual|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-06-01 03:38:41.379252|2018-06-01 03:38:41.379252
NCT00398450|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2009-02-06|2006-11-09|2006-11-10|Estimate|||||||2009-02-06|2009-02-09|Estimate|February 2006||2006-02-28|January 2007|2007-01-31||||May 2007|Anticipated|2007-05-31||Interventional|||Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma|A Phase I Study of 5-Azacytidine (Vidaza) With Interferon α2b in Metastatic Melanoma Patients|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:41.505808|2018-06-01 03:38:41.505808
NCT00398437|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-08-09|2006-11-09|2006-11-10|Estimate|||||||2013-08-09|2013-08-12|Estimate|September 2006||2006-09-30|March 2007|2007-03-31||||||||Interventional|||Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer|Role of Gadolinium Enhanced Brain Magnetic Resonance in the Follow Up of Metastatic Breast Cancer Patients Overexpressing HER2 Neu. A Randomized Prospective Study|Unknown status|Recruiting|N/A|96|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:41.569788|2018-06-01 03:38:41.569788
NCT00398424|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2009-08-06|2006-11-08|2006-11-10|Estimate|||||||2009-08-06|2009-08-07|Estimate|February 2006||2006-02-28|August 2009|2009-08-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|||Evaluating Patients With Impaired Hepatic Function|A Phase I, Open-Label Study Evaluating The Pharmacokinetics of Components of S-1 Patients With Impaired Hepatic Function|Completed||Phase 1|24|Anticipated|Taiho Oncology, Inc.|||||f||||||||||||||2018-06-01 03:38:41.639057|2018-06-01 03:38:41.639057
NCT00398411|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|2013-08-05||2015-06-01|2006-11-08|2006-11-10|Estimate|2013-10-16|2013-12-11|Estimate||||2015-06-01|2015-06-29|Estimate|October 2006||2006-10-31|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|MoxiProph||Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells|Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells|Completed||Phase 3|66|Actual|University of Cologne||2|||f||||t||||||||||2018-06-01 03:38:41.718167|2018-06-01 03:38:41.718167
NCT00398398|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2013-12-15||2017-07-13|2006-11-09|2006-11-10|Estimate|2015-10-06|2015-11-02|Estimate||||2017-07-13|2017-08-21|Actual|November 2006||2006-11-30|July 2017|2017-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study of XELOX With Cetuximab in Advanced Gastric Cancer|A Prospective Phase II Study of Cetuximab (Erbitux®) in Combination With XELOX [XELoda® (Capecitabine) and OXaliplatin] in Patients With Advanced Gastric Cancer|Completed||Phase 2|44|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 03:38:42.236141|2018-06-01 03:38:42.236141
NCT00398385|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-08-09|2006-11-09|2006-11-10|Estimate|||||||2013-08-09|2013-08-12|Estimate|May 2005||2005-05-31|April 2008|2008-04-30||||April 2010|Anticipated|2010-04-30||Interventional|||Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|170|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:42.390739|2018-06-01 03:38:42.390739
NCT00398372|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2011-05-31|2006-11-09|2006-11-10|Estimate|||||||2011-05-31|2011-06-02|Estimate|November 2000||2000-11-30|July 2010|2010-07-31|September 2009|Actual|2009-09-30|June 2007|Actual|2007-06-30||Interventional|||Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment|Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment|Completed||N/A|500|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 03:38:42.487691|2018-06-01 03:38:42.487691
NCT00398359|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2015-09-30|2006-11-09|2006-11-10|Estimate|||||||2015-09-30|2015-10-02|Estimate|May 2006||2006-05-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Treatment of Childhood Obesity in Primary Care|Treatment of Childhood Obesity in Primary Care|Completed||Phase 3|145|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 03:38:42.593057|2018-06-01 03:38:42.593057
NCT00398333|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-06-19|2006-11-09|2006-11-10|Estimate|||||||2013-06-19|2013-06-20|Estimate|June 2005||2005-06-30|June 2013|2013-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients|Randomized Controlled, Open-label, Pilot Study to Assess the Effectiveness of a Nutritional Supplementation Enriched With Eicosapentaenoic Acid on Chemotherapy Tolerance in Patients With Advanced Colorectal Cancer|Terminated||Phase 4|13|Actual|Hospital Clinic of Barcelona||2||Impossibility to accomplish the sample size in assigned time.|f||||||||||||||2018-06-01 03:38:42.693215|2018-06-01 03:38:42.693215
NCT00398320|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2013-10-15||2017-01-17|2006-11-09|2006-11-10|Estimate|2013-10-15|2013-12-10|Estimate||||2017-01-17|2017-03-01|Actual|November 2006||2006-11-30|January 2017|2017-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors|A Phase II Study of Capecitabine, Oxaliplatin and Bevacizumab for Metastatic or Unresectable Neuroendocrine Tumors|Completed||Phase 2|40|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 03:38:42.78746|2018-06-01 03:38:42.78746
NCT00398307|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2011-04-07|2006-11-08|2006-11-10|Estimate|||||||2011-04-07|2011-04-11|Estimate|February 2006||2006-02-28|April 2011|2011-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Evaluating Patients With Varying Degrees of Renal Function|A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function|Completed||Phase 1|24|Anticipated|Taiho Oncology, Inc.|||||f||||||||||||||2018-06-01 03:38:43.055612|2018-06-01 03:38:43.055612
NCT00398294|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2017-04-07|2006-11-09|2006-11-10|Estimate|||||||2017-04-07|2017-04-11|Actual|May 1, 2005|Actual|2005-05-01|April 2017|2017-04-30|April 4, 2006|Actual|2006-04-04|April 4, 2006|Actual|2006-04-04||Interventional|||To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)|An Open-Label, Single-Arm, Prospective Study to Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet in Patients With Hypercholesterolemia|Completed||Phase 4|30|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:43.125778|2018-06-01 03:38:43.125778
NCT00398281|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2014-01-09|2006-11-09|2006-11-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|September 2012|Actual|2012-09-30|July 2010|Actual|2010-07-31||Interventional|||Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer|Detection of Prostate Cancer With Contrast-Enhanced Ultrasound After Treatment With Dutasteride|Completed||Phase 3|450|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:38:43.204155|2018-06-01 03:38:43.204155
NCT00398268|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-08|2006-11-08|2006-11-10|Estimate|||||||2006-11-08|2006-11-10|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Dislocated Unstable Distal Both-Bone Forearm Fractures in Children|Treatment of Unstable Dislocated Both-Bone Distal Forearm Fractures in Children: A Follow-up Study|Unknown status|Recruiting|N/A|60||Colaris, Joost, M.D.|||||f||||||||||||||2018-06-01 03:38:43.335191|2018-06-01 03:38:43.335191
NCT00398255|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-04-29|2006-11-09|2006-11-10|Estimate|||||||2013-04-29|2013-04-30|Estimate|February 2004||2004-02-29|April 2013|2013-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Healthier Living With Arthritis Online Program|Internet Arthritis Self-Management Study|Completed||N/A|900||Stanford University|||||f||||||||||||||2018-06-01 03:38:43.410894|2018-06-01 03:38:43.410894
NCT00398242|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-08|2006-11-08|2006-11-10|Estimate|||||||2006-11-08|2006-11-10|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Treatment of Stable Both-Bone Midshaft Forearm Fractures in Children|Treatment of Stable Both-Bone Midshaft Forearm Fractures in Children: A Randomized Trial Between Treatment With Above Elbow Cast and a Combination of Above- and Below Elbow Armcast.|Unknown status|Recruiting|N/A|60||Colaris, Joost, M.D.|||||f||||||||||||||2018-06-01 03:38:43.478511|2018-06-01 03:38:43.478511
NCT00398229|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2008-12-31|2006-11-09|2006-11-10|Estimate|||||||2008-12-31|2009-01-01|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|May 2008|Actual|2008-05-31|||||Interventional|||hCG Supplementation in Frozen-Thawed Embryo Transfer Cycle|The Benefit of Human Chorionic Gonadotropin (hCG) Supplementation Throughout the Secretory Phase of Frozen-Thawed Embryo Transfer Cycles|Completed||Phase 2|300|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 03:38:43.548345|2018-06-01 03:38:43.548345
NCT00398216|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2015-02-05||2015-02-05|2006-11-09|2006-11-10|Estimate|2015-02-05|2015-02-25|Estimate||||2015-02-05|2015-02-25|Estimate|May 2006||2006-05-31|February 2015|2015-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery|A Phase IIb, Randomized, Parallel Group, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose, Study of DU-176b Compared to Dalteparin in Patients Undergoing Elective Unilateral Total Hip Replacement|Completed||Phase 2|903|Actual|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 03:38:43.65705|2018-06-01 03:38:43.65705
NCT00398203|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2012-06-11|2006-11-08|2006-11-10|Estimate|||||||2012-06-11|2012-06-12|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Safety and Efficacy of Using NaviAid™ BGE Device (Balloon Guided Endoscopy) For Endoscopic Diagnosis and Treatment|Safety and Efficacy of Using NaviAid™ BGE Device (Balloon Guided Endoscopy) For Endoscopic Diagnosis and Treatment|Completed||N/A|60|Actual|Smart Medical Systems Ltd.|||||f||||f||||||||||2018-06-01 03:38:45.460793|2018-06-01 03:38:45.460793
NCT00398190|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2017-07-24|2006-11-08|2006-11-10|Estimate|||||||2017-07-24|2017-07-26|Actual|October 2006||2006-10-31|July 2017|2017-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Media Literacy to Prevent Adolescent Smoking|Media Literacy to Prevent Adolescent Smoking|Completed||N/A|1211|Actual|University of Pittsburgh||2|||f||||||||||||||2018-06-01 03:38:45.629086|2018-06-01 03:38:45.629086
NCT00398177|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2018-04-03|2006-11-09|2006-11-10|Estimate|||||||2018-04-03|2018-04-05|Actual|January 1999||1999-01-31|April 2018|2018-04-30|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Observational|||Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease|Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease|Recruiting|||9999|Anticipated|Stanford University|||||f||||t||||||Samples Without DNA|"~     tumor tissue~   "|||2018-06-01 03:38:45.924443|2018-06-01 03:38:45.924443
NCT00398151|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2017-09-22|2006-11-09|2006-11-10|Estimate|||||||2017-09-22|2017-09-25|Actual|August 1, 2005|Actual|2005-08-01|September 2017|2017-09-30|January 18, 2006|Actual|2006-01-18|January 18, 2006|Actual|2006-01-18||Interventional|||To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)|An Open-Label Study to Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy|Completed||Phase 3|58|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:46.537575|2018-06-01 03:38:46.537575
NCT00398138|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2015-12-22||2016-02-02|2006-11-09|2006-11-10|Estimate|2016-02-02|2016-03-02|Estimate||||2016-02-02|2016-03-02|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma|Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Thoracic and Myeloid Neoplasms|Completed||Phase 1|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:38:46.661701|2018-06-01 03:38:46.661701
NCT00398125|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2012-07-26|2006-11-08|2006-11-10|Estimate|||||||2012-07-26|2012-07-30|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|April 2007|Actual|2007-04-30|||||Interventional|||Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults|A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults.|Completed||Phase 2|30|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:38:46.851114|2018-06-01 03:38:46.851114
NCT00398112|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2013-11-21||2014-04-28|2006-11-09|2006-11-10|Estimate|2014-01-10|2014-02-10|Estimate||||2014-04-28|2014-05-14|Estimate|August 2007||2007-08-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|November 2008|Actual|2008-11-30||Interventional|||Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of Sunitinib Malate for Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Completed||Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:38:46.946167|2018-06-01 03:38:46.946167
NCT00398099|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2017-02-16|2006-11-09|2006-11-10|Estimate|||||||2017-02-16|2017-02-17|Actual|July 2005||2005-07-31|February 2017|2017-02-28|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)|Clinical Evaluation for the Efficacy, Safety, Tolerability & Medical Resource Utilization of Invanz (Ertapenem Sodium) Therapy|Completed||Phase 3|30||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:47.585787|2018-06-01 03:38:47.585787
NCT00398086|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|2013-06-14||2016-03-24|2006-11-08|2006-11-10|Estimate|2013-06-14|2013-08-21|Estimate||||2016-03-24|2016-04-25|Estimate|November 2006||2006-11-30|March 2016|2016-03-31|December 2010|Actual|2010-12-31|September 2008|Actual|2008-09-30||Interventional|||Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer|A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|67|Actual|Celgene Corporation||3|||f||||f||||||||||2018-06-01 03:38:47.741013|2018-06-01 03:38:47.741013
NCT00398073|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2015-12-22||2017-01-26|2006-11-09|2006-11-10|Estimate|2017-01-26|2017-03-16|Actual||||2017-01-26|2017-03-16|Actual|October 2006||2006-10-31|January 2017|2017-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma|Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse gp100 DNA: A Pilot Study to Compare Intramuscular Jet Injection With Particle Mediated Delivery|Completed||Phase 1|35|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 03:38:49.485978|2018-06-01 03:38:49.485978
NCT00398060|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2008-02-13|2006-11-09|2006-11-10|Estimate|||||||2008-02-13|2008-02-14|Estimate|January 2003||2003-01-31|February 2008|2008-02-29|March 2007|Actual|2007-03-31|December 2004|Actual|2004-12-31||Interventional|||GOAL Life-Style Change Intervention to Prevent Type 2 Diabetes|GOAL Life-Style Change Implementation Intervention to Prevent Type 2 Diabetes in Primary Health Care|Completed||Phase 3|389|Actual|National Institute for Health and Welfare, Finland||1|||f||||f||||||||||2018-06-01 03:38:49.737771|2018-06-01 03:38:49.737771
NCT00398047|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2011-01-21||2017-05-25|2006-11-09|2006-11-10|Estimate|2012-03-23|2012-04-17|Estimate||||2017-05-25|2017-06-20|Actual|September 2006||2006-09-30|March 2012|2012-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes|Combination of Azacitadine and Hematopoietic Growth Factors for Myelodysplastic Syndrome|Terminated||Phase 2|3|Actual|Wake Forest University Health Sciences||1||Slow accrual|f||||f|t|f||||||||2018-06-01 03:38:49.810275|2018-06-01 03:38:49.810275
NCT00398034|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-08|2006-11-08|2006-11-10|Estimate|||||||2006-11-08|2006-11-10|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|October 2008||2008-10-31|||||Interventional|||Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-Treated Chronic Pain Patients: A Pilot Study.|Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-Treated Chronic Pain Patients: A Pilot Study.|Unknown status|Recruiting|Phase 2|62||James J. Peters Veterans Affairs Medical Center|||||f||||||||||||||2018-06-01 03:38:50.118298|2018-06-01 03:38:50.118298
NCT00397995|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-08|2006-11-08|2006-11-10|Estimate|||||||2006-11-08|2006-11-10|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Undislocated Distal Both-Bone Forearm Fractures in Children|Treatment of Undislocated Both-Bone Distal Forearm Fractures in Children: A Randomized Trial Between Treatment With Above- and Under Elbow Cast.|Unknown status|Recruiting|N/A|60||Colaris, Joost, M.D.|||||f||||||||||||||2018-06-01 03:38:50.478499|2018-06-01 03:38:50.478499
NCT00397982|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2016-11-30||2017-05-05|2006-11-09|2006-11-10|Estimate|2017-05-05|2017-06-09|Actual||||2017-05-05|2017-06-09|Actual|January 2008|Actual|2008-01-31|May 2017|2017-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Mel47||Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma|A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma|Completed||Phase 2|17|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||No||2018-06-01 03:38:50.593746|2018-06-01 03:38:50.593746
NCT00397969|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-12-18|2006-11-09|2006-11-10|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2005||2005-02-28|December 2006|2006-12-31|June 2008|Actual|2008-06-30|||||Interventional|||Improving the Frequency of Colonoscopy in Patients With a Previous Colorectal Polyp|Improving Surveillance for Colorectal Polyps|Completed||N/A|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:50.993904|2018-06-01 03:38:50.993904
NCT00397956|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2015-10-29|2006-11-09|2006-11-10|Estimate|||||||2015-10-29|2015-10-30|Estimate|September 2004||2004-09-30|October 2015|2015-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)|An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability & Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults|Completed||Phase 3|30||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:51.058118|2018-06-01 03:38:51.058118
NCT00397943|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09||2012-03-09|2012-03-09|2006-11-09|2006-11-10|Estimate||||2012-03-09|2012-03-14|Estimate|2012-03-09|2012-03-14|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults|Safety, Reactogenicity & Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Administered Intramuscularly According to a Schedule of 0, 1 Month, to Healthy Adults Aged 18 to 50 Years|Completed||Phase 2|110|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-06-01 03:38:51.108141|2018-06-01 03:38:51.108141
NCT00397930|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2014-08-20||2017-01-03|2006-11-09|2006-11-10|Estimate|2015-03-16|2015-03-17|Estimate||||2017-01-03|2017-02-20|Actual|October 2006||2006-10-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|YOCAS||Yoga in Treating Sleep Disturbance in Cancer Survivors|Yoga for Persistent Sleep Disturbance in Cancer Survivors|Completed||Phase 2|410|Actual|University of Rochester|The study did not account for components such as time or attention, as this would have required the use of a placebo yoga intervention for the YOCAS program. The results are not generalizable for all yoga types, nor for all socioeconomic backgrounds.|2|||f||||t||||||||Undecided||2018-06-01 03:38:52.180531|2018-06-01 03:38:52.180531
NCT00397917|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2017-03-30|2006-11-08|2006-11-10|Estimate|||||||2017-03-30|2017-03-31|Actual|November 2006||2006-11-30|March 2017|2017-03-31|July 2013|Actual|2013-07-31|May 2012|Actual|2012-05-31||Interventional|||Oral Cleft Prevention Program|Oral Cleft Prevention Program|Completed||Phase 3|4000|Actual|University of Iowa||2|||f||||t|f|f||||||No|Individual level data will not be shared unless de-identified|2018-06-01 03:38:52.832407|2018-06-01 03:38:52.832407
NCT00397904|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2015-10-22||2015-10-22|2006-11-09|2006-11-10|Estimate|2015-10-22|2015-11-25|Estimate||||2015-10-22|2015-11-25|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin|Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Irinotecan and Cisplatin-Refractory Metastatic Esophageal and Gastric Cancer|Completed||Phase 2|16|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:38:52.928086|2018-06-01 03:38:52.928086
NCT00397891|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|2014-08-20||2014-08-20|2006-11-09|2006-11-10|Estimate|2014-08-20|2014-09-04|Estimate||||2014-08-20|2014-09-04|Estimate|October 2006||2006-10-31|August 2014|2014-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||Safety data set included all randomized participants who received at least 1 dose of study medication.|Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|80|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||t||||||||||2018-06-01 03:38:53.304925|2018-06-01 03:38:53.304925
NCT00397878|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2013-12-17||2014-05-07|2006-11-09|2006-11-10|Estimate|2013-12-17|2014-02-06|Estimate||||2014-05-07|2014-05-23|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||AZD0530 in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer|Phase II Study of AZD0530 (NSC 735464) in Patients With Previously Treated Metastatic Colorectal Cancer|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:38:54.471912|2018-06-01 03:38:54.471912
NCT00397865|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2015-10-01|2006-11-08|2006-11-10|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2006||2006-10-31|July 2010|2010-07-31|August 2007|Actual|2007-08-31|||||Interventional|||A Primary Care Educational Intervention for Families of Overweight Children|A Primary Care Educational Intervention for Families of Overweight Children|Completed||N/A|15|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 03:38:54.724184|2018-06-01 03:38:54.724184
NCT00397852|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-08|2006-11-08|2006-11-10|Estimate|||||||2006-11-08|2006-11-10|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Dislocated Stable Distal Both-Bone Forearm Fractures in Children|Treatment of Stable Dislocated Both-Bone Distal Forearm Fractures in Children: A Randomized Trial Between Treatment With en Without Kirschner-Wires|Unknown status|Recruiting|N/A|110||Colaris, Joost, M.D.|||||f||||||||||||||2018-06-01 03:38:54.794485|2018-06-01 03:38:54.794485
NCT00397839|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|2009-11-17||2009-11-17|2006-11-09|2006-11-10|Estimate|2009-11-17|2009-12-21|Estimate||||2009-11-17|2009-12-21|Estimate|January 2007||2007-01-31|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|STRONG||The Effect Of Oral Ibandronate In Male Osteoporosis|A Parallel, Placebo-controlled, Randomized (2:1) Double-blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-monthly Versus Placebo on LS BMD in Men With Osteoporosis|Completed||Phase 3|135|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:38:54.988535|2018-06-01 03:38:54.988535
NCT00365742|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2006-08-16|2006-08-16|2006-08-17|Estimate|||||||2006-08-16|2006-08-17|Estimate|April 2006||2006-04-30|August 2006|2006-08-31|June 2006||2006-06-30|||||Interventional|||Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements|Simvastatin Vs Therapeutic Lifestyle Changes and Supplements: A Primary Prevention Randomized Trial|Completed||N/A|80||Chestnut Hill Health System|||||f||||||||||||||2018-06-01 03:49:50.866354|2018-06-01 03:49:50.866354
NCT00397826|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2016-01-06|2006-11-09|2006-11-10|Estimate|||||||2016-01-06|2016-01-07|Estimate|January 2005||2005-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|January 2006|Actual|2006-01-31||Interventional|||Evaluation of the Effects of Simvastatin 40mg|Evaluation of the Effects of Simvastatin 40 Mg on Lipid Profiles and Specified Circulatory Parameters in Normotensive Hypercholesterolemia Patients(MK-0733-265)|Completed||Phase 4|20|Actual|Cardinal Tien Hospital||1|||f||||f||||||||No||2018-06-01 03:38:55.442955|2018-06-01 03:38:55.442955
NCT00397813|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2018-03-28|2006-11-09|2006-11-10|Estimate|||||||2018-03-28|2018-03-30|Actual|January 2006||2006-01-31|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|September 18, 2017|Actual|2017-09-18||Interventional|||Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders|Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial|Active, not recruiting||Phase 2|77|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 03:38:55.515736|2018-06-01 03:38:55.515736
NCT00397800|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2012-08-27|2006-11-09|2006-11-10|Estimate|||||||2012-08-27|2012-08-28|Estimate|June 2005||2005-06-30|August 2012|2012-08-31|May 2013|Anticipated|2013-05-31|May 2008|Actual|2008-05-31||Interventional|||Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma|Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Anticipated|Technische Universität München|||||f||||||||||||||2018-06-01 03:38:55.631106|2018-06-01 03:38:55.631106
NCT00397787|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2013-06-03|2006-11-09|2006-11-10|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 2006||2006-11-30|June 2013|2013-06-30||||September 2007|Actual|2007-09-30||Interventional|||Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine|A Phase II Study of Sunitinib Malate (SU11248, NSC #736511, IND #74,019) in Patients With Previously Treated Pancreatic Adenocarcinoma With Measurable Metastatic Disease Following Progression on Front-Line Gemcitabine-Based Therapy|Completed||Phase 2|64|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:38:55.718398|2018-06-01 03:38:55.718398
NCT00397774|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-09|||2015-03-28|2006-11-09|2006-11-10|Estimate|||||||2015-03-28|2015-03-31|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Physical Activity and Functioning in Palliative Cancer Patients - a Clinical Randomised Trial|Phase 3 Physical Activity and Functioning in Palliative Cancer Patients - a Clinical Randomised Trial|Completed||Phase 3|231|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 03:38:55.79741|2018-06-01 03:38:55.79741
NCT00397761|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2009-02-06|2006-11-08|2006-11-09|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2006||2006-07-31|November 2006|2006-11-30||||||||Interventional|||Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer|Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer|Unknown status|Recruiting|Phase 2/Phase 3|33|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:38:55.873615|2018-06-01 03:38:55.873615
NCT00397748|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2018-05-23|2006-11-08|2006-11-09|Estimate|||||||2018-05-23|2018-05-24|Actual|September 15, 2006||2006-09-15|November 27, 2012|2012-11-27|November 27, 2012||2012-11-27|||||Observational|||PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)|PET Scanning of Brain Dopaminergic Signal Transduction Involving Arachidonic Acid in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed|||16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:38:55.964621|2018-06-01 03:38:55.964621
NCT00397735|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2017-01-12|2006-11-08|2006-11-09|Estimate|||||||2017-01-12|2017-01-13|Estimate|October 2006||2006-10-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||N-acetylcysteine in Intra-amniotic Infection/Inflammation|Effect of N-acetylcysteine in Preventing Adverse Neonatal Outcomes in Women With Intra-amniotic Infection/Inflammation|Completed||Phase 1/Phase 2|80|Actual|Ohio State University||2|||f||||f||||||||||2018-06-01 03:38:56.033178|2018-06-01 03:38:56.033178
NCT00397722|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2017-07-10|2006-11-08|2006-11-09|Estimate|||||||2017-07-10|2017-07-11|Actual|November 9, 2006|Actual|2006-11-09|July 2017|2017-07-31|September 5, 2007|Actual|2007-09-05|September 5, 2007|Actual|2007-09-05||Interventional|||Treatment Of Patients With Social Anxiety Disorder|Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)|Completed||Phase 2|299|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:38:56.243969|2018-06-01 03:38:56.243969
NCT00397709|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2008-12-30|2006-11-08|2006-11-09|Estimate|||||||2008-12-30|2008-12-31|Estimate|March 1996||1996-03-31|November 2006|2006-11-30|February 2006||2006-02-28|||||Interventional|||Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection|Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection: A Randomized Clinical Trial.|Terminated||Phase 4|228||Hospital Virgen de la Luz|||||f||||||||||||||2018-06-01 03:38:56.386194|2018-06-01 03:38:56.386194
NCT00397696|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07||2014-03-21|2014-04-16|2006-11-07|2006-11-09|Estimate||||2014-03-21|2014-04-17|Estimate|2014-04-16|2014-05-07|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease|Evaluation of 5-[123I]-A-85380 and SPECT Imaging as a Marker of Nicotinic Receptor Density in the Brain of Parkinson Disease Subjects|Completed||Phase 2|9|Actual|Institute for Neurodegenerative Disorders||1|||f||||t||||||||||2018-06-01 03:38:56.492248|2018-06-01 03:38:56.492248
NCT00397683|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2015-10-30|2006-11-08|2006-11-09|Estimate|||||||2015-10-30|2015-11-02|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)|Proprietary Information - Exploratory (Non-Confirmatory) Trial|Terminated||Phase 2|2|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:38:56.604469|2018-06-01 03:38:56.604469
NCT00397670|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-08|2006-11-08|2006-11-09|Estimate|||||||2006-11-08|2006-11-09|Estimate|January 2004||2004-01-31|November 2006|2006-11-30|May 2006||2006-05-31|||||Interventional|||Open Label Study of the Safety and Contraceptive Efficacy of BufferGel® With Diaphragm|A Multicenter Open-Label Study of the Safety and Contraceptive Efficacy of BufferGel® Spermicide Used With Diaphragm|Completed||Phase 2/Phase 3|200||ReProtect Inc|||||f||||||||||||||2018-06-01 03:38:56.76257|2018-06-01 03:38:56.76257
NCT00397657|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2009-06-16|2006-11-08|2006-11-09|Estimate|||||||2009-06-16|2009-06-17|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|October 2009|Anticipated|2009-10-31|August 2009|Anticipated|2009-08-31||Interventional|||Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis|ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)|Terminated||Phase 4|400|Anticipated|Walter Reed Army Medical Center||2||"Independent steering committee has stopped the trial based on results of a prespecified,~   blinded interim analysis. It was not stopped due to safety concerns."|f||||||||||||||2018-06-01 03:38:56.833518|2018-06-01 03:38:56.833518
NCT00397644|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2007-04-04|2006-11-07|2006-11-09|Estimate|||||||2007-04-04|2007-04-06|Estimate|March 2006||2006-03-31|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||Assisting Low-Income Families at Pediatric Well-Child Care Visits|Enhancing a Medical Home for Vulnerable Children by Addressing Family Psychosocial Problems at Well-Child Care Visits: THE WE CARE Project|Completed||N/A|200||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:38:56.99757|2018-06-01 03:38:56.99757
NCT00397631|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|2009-05-19||2017-04-07|2006-11-08|2006-11-09|Estimate|2009-05-19|2009-07-10|Estimate||||2017-04-07|2017-05-12|Actual|December 19, 2006|Actual|2006-12-19|April 2017|2017-04-30|June 28, 2008|Actual|2008-06-28|June 28, 2008|Actual|2008-06-28||Interventional|||Initial Combination With Pioglitazone Study (0431-064)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|520|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:38:57.088817|2018-06-01 03:38:57.088817
NCT00397605|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2014-09-16|2006-11-08|2006-11-09|Estimate|||||||2014-09-16|2014-09-18|Estimate|November 2006||2006-11-30|September 2014|2014-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Cannabinoids in Bipolar Affective Disorder|Cannabinoids in Bipolar Affective Disorder: A Controlled Pilot Study|Withdrawn||N/A|0|Actual|University of British Columbia||1||study was never started and no patients were ever enrolled|f||||||||||||||2018-06-01 03:38:57.457095|2018-06-01 03:38:57.457095
NCT00397592|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2007-07-02|2006-11-08|2006-11-09|Estimate|||||||2007-07-02|2007-07-03|Estimate|August 2006||2006-08-31|July 2007|2007-07-31|January 2007|Actual|2007-01-31|||||Interventional|||Growth Hormone's Effect on Endothelial Progenitor Cells|The Effect of Exogenous Growth Hormone on the Mobilization of Endothelial Progenitor Cells|Completed||N/A|18|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 03:38:57.53333|2018-06-01 03:38:57.53333
NCT00397579|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2018-05-09|2006-11-08|2006-11-09|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2013||2013-05-31|May 2018|2018-05-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Therapy Targeting the Interleukin-3 Receptor (IL3R) for Patients With Relapsed or Refractory and Elderly or Poor-Risk Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome With DTIL3 (IND# 11314): a Phase I/II Clinical Trial|Completed||Phase 1/Phase 2|10|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 03:38:57.615349|2018-06-01 03:38:57.615349
NCT00397566|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2012-04-26|2006-11-08|2006-11-09|Estimate|||||||2012-04-26|2012-04-27|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|February 2007|Actual|2007-02-28|||||Interventional|||A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects|Randomized, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-707035 in HIV-1 Infected Subjects|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb|||||||||||||||||||2018-06-01 03:38:57.696682|2018-06-01 03:38:57.696682
NCT00397553|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2009-09-17|2006-11-08|2006-11-09|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 2005||2005-01-31|May 2009|2009-05-31||||December 2007|Actual|2007-12-31||Interventional|||Insulin Glulisine, Diabetes Mellitus Type 1|Multicenter, Open, Non-randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine|Completed||Phase 3|104|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:38:57.754984|2018-06-01 03:38:57.754984
NCT00397540|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2009-09-22||2015-05-18|2006-11-07|2006-11-09|Estimate|2010-03-02|2010-03-15|Estimate||||2015-05-18|2015-06-12|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)|Prospective Cohort Study of the Effect of Serum HBV DNA Level on Intrahepatic Recurrence in Locally Treatable, HBV-related HCC Patients|Completed||Phase 4|145|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 03:38:57.833824|2018-06-01 03:38:57.833824
NCT00397527|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2008-05-15|2006-11-08|2006-11-09|Estimate|||||||2008-05-15|2008-05-16|Estimate|July 2006||2006-07-31|May 2008|2008-05-31||||||||Interventional|||Acceptability Dermacyd Wipes - Lactoserum - Hygiene|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up of Dermacyd Wipes|Completed||Phase 3|30||Sanofi|||||f||||||||||||||2018-06-01 03:38:58.073234|2018-06-01 03:38:58.073234
NCT00397514|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2013-03-13||2017-11-16|2006-11-08|2006-11-09|Estimate|2013-06-18|2013-08-30|Estimate||||2017-11-16|2017-12-18|Actual|October 2006||2006-10-31|November 2017|2017-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational||The number of participants analyzed was 25 due to the withdrawal of 9 participants after enrolment as specified.|Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery|Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery|Completed|||34|Actual|University of British Columbia|The study was limited by a small sample.Our study patients underwent BiV pacing just prior to extubation, by which time myocardial dysfunction may have recovered, so they represented a potentially healthier subset in comparison to adults.||1||f||||f||||||||||2018-06-01 03:38:58.131596|2018-06-01 03:38:58.131596
NCT00397501|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2017-04-19|2006-11-08|2006-11-09|Estimate|||||||2017-04-19|2017-04-21|Actual|October 2013||2013-10-31|April 2017|2017-04-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain|A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients|Withdrawn||Phase 1/Phase 2|0|Actual|OHSU Knight Cancer Institute||2||after original approval, IRB closed enrollment; major revisions required to re-open.|f||||t||||||||||2018-06-01 03:38:58.312431|2018-06-01 03:38:58.312431
NCT00395681|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2010-10-21|2006-11-01|2006-11-03|Estimate|||||||2010-10-21|2010-10-22|Estimate|September 2007||2007-09-30|November 2006|2006-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Population PK/PD of Propofol in the Morbidly Obese Patient|Population Pharmacokinetics and Pharmacodynamics of Propofol in the Morbidly Obese Patient|Completed||Phase 4|20|Actual|St. Antonius Hospital||2|||f||||||||||||||2018-06-01 03:39:38.095766|2018-06-01 03:39:38.095766
NCT00397488|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|2015-12-17||2015-12-17|2006-11-08|2006-11-09|Estimate|2015-12-17|2016-01-25|Estimate||||2015-12-17|2016-01-25|Estimate|September 2006||2006-09-30|December 2015|2015-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium|Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|78|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:38:58.434724|2018-06-01 03:38:58.434724
NCT00397475|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2015-05-26|2006-11-07|2006-11-09|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2006||2006-11-30|May 2015|2015-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Evaluation of Colecalciferol Substitution in Dialysis Patients|Evaluation of Colecalciferol Substitution in Dialysis Patients|Completed||N/A|50|Anticipated|University Hospital, Saarland|||||f||||||||||||||2018-06-01 03:38:58.756194|2018-06-01 03:38:58.756194
NCT00397462|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2016-07-22||2016-09-15|2006-11-07|2006-11-09|Estimate|2016-09-15|2016-09-26|Estimate||||2016-09-15|2016-09-26|Estimate|October 2006||2006-10-31|September 2016|2016-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Blood Flow and Bone Density in Healthy Adult Women|Blood Flow and Bone Density in Healthy Adult Women|Completed||N/A|44|Actual|Binghamton University||3|||f||||f||||||||No||2018-06-01 03:38:58.826992|2018-06-01 03:38:58.826992
NCT00397449|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2007-08-09|2006-11-08|2006-11-09|Estimate|||||||2007-08-09|2007-08-10|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|December 2007|Anticipated|2007-12-31|||||Interventional|||GMZ2-Aluminum Hydroxide Phase I, Tübingen|Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|European Malaria Vaccine Initiative||1|||f||||f||||||||||2018-06-01 03:38:59.074988|2018-06-01 03:38:59.074988
NCT00397436|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2016-05-13|2006-11-08|2006-11-09|Estimate|||||||2016-05-13|2016-05-17|Estimate|February 2007||2007-02-28|May 2016|2016-05-31|December 2015|Actual|2015-12-31|November 2011|Actual|2011-11-30||Interventional|||Pilot Study of Protein Profiling of the Human Epidermal Cells After Ultraviolet Irradiation|Pilot Study of Protein Profiling of the Human Epidermal Cells After Ultraviolet Irradiation|Completed||Early Phase 1|60|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-06-01 03:38:59.194606|2018-06-01 03:38:59.194606
NCT00397423|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2007-11-27|2006-11-08|2006-11-09|Estimate|||||||2007-11-27|2007-11-28|Estimate|December 2006||2006-12-31|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response|Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response|Completed||Phase 2|40|Actual|Peking University||2|||f||||||||||||||2018-06-01 03:38:59.297061|2018-06-01 03:38:59.297061
NCT00397410|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2012-05-10|2006-11-08|2006-11-09|Estimate|||||||2012-05-10|2012-05-11|Estimate|May 2005||2005-05-31|May 2012|2012-05-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Prevention of Hip Fractures With Soft and Hard Hip Protectors|Compliance With and Effect of Soft and Hard Hip Protectors in Norwegian Nursing Homes|Completed||N/A|1236|Actual|Norwegian Institute of Public Health|||||f||||||||||||||2018-06-01 03:38:59.360876|2018-06-01 03:38:59.360876
NCT00397397|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-08|2006-11-08|2006-11-09|Estimate|||||||2006-11-08|2006-11-09|Estimate|January 2007||2007-01-31|November 2006|2006-11-30|March 2007||2007-03-31|||||Observational|||Comparative Treatment Study in Patients With Lower Ureteral Stones|Comparative Study in Patients With Lower Ureteral Stones Treated With 10 MG Alfuzosin,10 MG Alfuzosin With Rowatinex, and Rowatinex Alone|Unknown status|Not yet recruiting||60||Hillel Yaffe Medical Center|||||f||||||||||||||2018-06-01 03:38:59.490972|2018-06-01 03:38:59.490972
NCT00397384|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2015-09-28|2006-11-08|2006-11-09|Estimate|||||||2015-09-28|2015-09-30|Estimate|January 2007||2007-01-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer|A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer|Completed||Phase 1|43|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:38:59.556857|2018-06-01 03:38:59.556857
NCT00397358|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2017-05-05|2006-11-08|2006-11-09|Estimate|||||||2017-05-05|2017-05-08|Actual|November 2006|Actual|2006-11-30|May 2017|2017-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients|Open-label Study to Evaluate the Effects of Once Daily Extraneal (7.5% Icodextrin) Peritoneal Dialysis Solution on Triglyceride Levels in Peritoneal Dialysis Patients|Withdrawn||Phase 4|0|Actual|Baxter Healthcare Corporation||||Lack of enrollment|f||||f||||||||||2018-06-01 03:38:59.672746|2018-06-01 03:38:59.672746
NCT00397345|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2010-06-04|2006-11-08|2006-11-09|Estimate|||||||2010-06-04|2010-06-07|Estimate|September 2006||2006-09-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||TroVax Renal Immunotherapy Survival Trial|An International, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate Whether TroVax, Added to First-line Standard of Care Therapy, Prolongs the Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.|Completed||Phase 3|700|Anticipated|Oxford BioMedica||2|||f||||t||||||||||2018-06-01 03:38:59.778645|2018-06-01 03:38:59.778645
NCT00397332|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2015-04-19|2006-11-08|2006-11-09|Estimate|||||||2015-04-19|2015-04-21|Estimate|October 2006||2006-10-31|February 2011|2011-02-28|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Alefacept for Chronic Graft Versus Host Disease|An Investigator Initiated Open-label and Explorative Study of Alefacept Treatment for Chronic Extensive Graft Versus Host Disease|Completed||Phase 1/Phase 2|20|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:39:00.063145|2018-06-01 03:39:00.063145
NCT00397319|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2007-07-02|2006-11-08|2006-11-09|Estimate|||||||2007-07-02|2007-07-03|Estimate|August 2005||2005-08-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Observational|||Growth Hormone's Effect on the Cardiovascular System|The Role of Growth Hormone in Cardiovascular Health|Terminated|||26||Vanderbilt University||||"Inadequate retention of GHD adults to maintain power to study the effect of GH on fibrinolysis.~   A comparison between GHD adults and controls was completed."|f||||||||||||||2018-06-01 03:39:00.149526|2018-06-01 03:39:00.149526
NCT00397306|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2009-04-07|2006-11-07|2006-11-09|Estimate|||||||2009-04-07|2009-04-08|Estimate|November 2006||2006-11-30|April 2009|2009-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of a Bioimpedance Method for Determination of Dry Weight in Dialysis Patients|Study for the Evaluation of a Bioimpedance Method for Determination of Dry Weight in Dialysis Patients|Completed||N/A|16|Actual|University Hospital, Saarland|||||f||||f||||||||||2018-06-01 03:39:00.214395|2018-06-01 03:39:00.214395
NCT00397293|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07||2010-08-12|2010-08-20|2006-11-07|2006-11-09|Estimate||||2010-08-12|2010-08-17|Estimate|2010-08-20|2010-08-24|Estimate|November 2006||2006-11-30|August 2010|2010-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer|An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer After Prior Platinum Containing First Line Chemotherapy|Completed||Phase 1/Phase 2|36|Actual|Ascenta Therapeutics|||||f||||f||||||||||2018-06-01 03:39:00.279767|2018-06-01 03:39:00.279767
NCT00397280|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2018-05-22|2006-11-08|2006-11-09|Estimate|||||||2018-05-22|2018-05-23|Actual|November 7, 2006||2006-11-07|May 4, 2018|2018-05-04||||||||Observational|||Immune Cell Response to Stimuli|Innate Immunity Signal Transduction in Human Leukocytes|Recruiting|||2040|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:39:00.384809|2018-06-01 03:39:00.384809
NCT00397267|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-08|||2006-11-26|2006-11-08|2006-11-09|Estimate|||||||2006-11-26|2006-11-28|Estimate|January 2007||2007-01-31|October 2006|2006-10-31|December 2007||2007-12-31|||||Interventional|||Treatment of Acute Asthma in ER With Combination of Systemic Steroids and Inhaled Steroids||Unknown status|Not yet recruiting|Phase 4|120||Soroka University Medical Center|||||f||||||||||||||2018-06-01 03:39:00.463985|2018-06-01 03:39:00.463985
NCT00397254|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2009-03-06||2010-06-07|2006-11-08|2006-11-09|Estimate|2009-09-17|2009-09-22|Estimate||||2010-06-07|2010-06-08|Estimate|December 2006||2006-12-31|September 2009|2009-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Two Rizatriptan Prescribing Portions for Treatment of Migraine|An Observer-Blind, Randomized, Parallel-Group Study to Compare the Efficacy of Two Rizatriptan Prescribing Portions for the Treatment of Migraine|Completed||Phase 4|197|Actual|Clinvest||2|||f||||f||||||||||2018-06-01 03:39:00.555101|2018-06-01 03:39:00.555101
NCT00397241|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2014-05-09|2006-11-06|2006-11-08|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2006||2006-09-30|May 2014|2014-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||24-hour Intraocular Pressure (IOP) Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-angle Glaucoma|24-hour IOP With DTFC and LTFC Monotherapies and the Adjunctive Therapy of DTFC and Latanoprost in Open-angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy.|Completed||Phase 4|33|Actual|Aristotle University Of Thessaloniki|||||f||||f||||||||||2018-06-01 03:39:00.832681|2018-06-01 03:39:00.832681
NCT00397228|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06||2014-03-21|2016-12-15|2006-11-06|2006-11-08|Estimate||||2014-03-21|2014-04-17|Estimate|2016-12-15|2016-12-16|Estimate|November 2006||2006-11-30|December 2016|2016-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||ALTROPANE® SPECT Imaging in Patients With Parkinson Disease|Optimizing the Performance of ALTROPANE® SPECT Imaging in Patients With Parkinson Disease|Completed||Phase 2|27|Actual|Molecular NeuroImaging||1|||f||||f||||||||||2018-06-01 03:39:00.898039|2018-06-01 03:39:00.898039
NCT00397215|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2012-12-19||2018-01-08|2006-11-07|2006-11-08|Estimate|2013-03-28|2013-05-20|Estimate||||2018-01-08|2018-02-01|Actual|November 1, 2006||2006-11-01|November 2016|2016-11-30|October 27, 2007|Actual|2007-10-27|October 1, 2007|Actual|2007-10-01||Interventional|||Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age|Evaluate Immunogenicity & Safety of a Single or Double-dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-administration Schedule (21 Days Apart) in Adults Over 60 Yrs|Completed||Phase 2|437|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:39:01.052722|2018-06-01 03:39:01.052722
NCT00397202|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2015-04-29|2006-11-07|2006-11-08|Estimate|||||||2015-04-29|2015-04-30|Estimate|November 2006||2006-11-30|April 2015|2015-04-30|June 2011|Actual|2011-06-30|June 2009|Actual|2009-06-30||Interventional|||FLOW-Finding Lasting Options for Women|FLOW-Finding Lasting Options for Women: A Prospective, Randomized, Multicenter Trial Comparing Tampons to a Menstrual Cup|Completed||N/A|110|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 03:39:04.449707|2018-06-01 03:39:04.449707
NCT00397189|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2010-08-26||2018-04-29|2006-11-07|2006-11-08|Estimate|2011-02-28|2011-03-28|Estimate||||2018-04-29|2018-05-01|Actual|October 2006||2006-10-31|April 2018|2018-04-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients|A Double-blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of Circadin® 2 mg in the Treatment of Insomnia Patients With Low Endogenous Melatonin|Completed||Phase 3|930|Actual|Neurim Pharmaceuticals Ltd.||2|||f||||||||||||||2018-06-01 03:39:04.559258|2018-06-01 03:39:04.559258
NCT00397176|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2007-12-19|2006-11-07|2006-11-08|Estimate|||||||2007-12-19|2007-12-28|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women|Ascending, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of DVS SR Administered Orally to Healthy Japanese Female Subjects|Completed||Phase 1|32||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:39:04.964571|2018-06-01 03:39:04.964571
NCT00397163|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2017-05-03|2006-11-07|2006-11-08|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2010||2010-12-31|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Remote Ischemic Preconditioning in Patient Undergoing Cardiac Bypass Surgery|A Clinical Study Investigating Ischemic Preconditioning in Type II Diabetic Patients Undergoing Coronary Artery Bypass Graft Surgery.|Recruiting||Phase 1|200|Anticipated|University College London Hospitals||2|||f||||t||||||||||2018-06-01 03:39:05.062038|2018-06-01 03:39:05.062038
NCT00397150|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2012-12-18||2015-02-20|2006-11-07|2006-11-08|Estimate|2015-02-20|2015-02-24|Estimate||||2015-02-20|2015-02-24|Estimate|November 2006||2006-11-30|February 2015|2015-02-28|April 2011|Actual|2011-04-30|July 2008|Actual|2008-07-31||Interventional|||PROMISE EBF: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV in Sub-Saharan Africa|PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV|Completed||N/A|2579|Actual|Centre For International Health|Trial not entirely blinded.|2|||f||||f||||||||||2018-06-01 03:39:05.153181|2018-06-01 03:39:05.153181
NCT00397137|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2006-11-07|2006-11-07|2006-11-08|Estimate|||||||2006-11-07|2006-11-08|Estimate|September 2000||2000-09-30|November 2006|2006-11-30|December 2003||2003-12-31|||||Interventional|||Stapled Anopexy Versus Closed Haemorrhoidectomy for Haemorrhoids|Prospective Randomized Multi-Centre Trial Comparing the Clinical Efficacy, Safety and Patient Acceptability of Circular Stapled Anopexy With Closed Diathermy Haemorrhoidectomy for Haemorrhoids|Completed||N/A|182||University of Dundee|||||f||||||||||||||2018-06-01 03:39:05.560035|2018-06-01 03:39:05.560035
NCT00397124|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2006-11-07|2006-11-07|2006-11-08|Estimate|||||||2006-11-07|2006-11-08|Estimate|April 2002||2002-04-30|November 2006|2006-11-30||||||||Interventional|||The Role of the Vagus Nerve in Tumor-to-Brain Communication in Lung Cancer Patients|Does the Vagus Nerve Play a Role in Tumor-to-Brain Communication? a Preliminary Study in Patients With Newly Diagnosed Lung Cancer|Unknown status|Recruiting|N/A|40||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:39:05.662526|2018-06-01 03:39:05.662526
NCT00397111|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2018-05-17|2006-11-07|2006-11-08|Estimate|||||||2018-05-17|2018-05-18|Actual|November 6, 2006||2006-11-06|March 12, 2018|2018-03-12||||||||Observational|||Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders|Development of Functional and Structural Magnetic Resonance Imaging Techniques for the Study of Mood and Anxiety Disorders|Recruiting|||340|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:39:05.75943|2018-06-01 03:39:05.75943
NCT00397098|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2009-03-10|2006-11-07|2006-11-08|Estimate|||||||2009-03-10|2009-03-12|Estimate|November 2006||2006-11-30|March 2009|2009-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|VEGA||Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder|A Double-Blind Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A Versus Placebo in the Prevention of Relapse of Anxiety up to 1 Year in Patients With GAD Improved After 12 Weeks of Open Label Treatment With SR58611A.|Terminated||Phase 3|257|Actual|Sanofi||||reprioritization of indications|f||||||||||||||2018-06-01 03:39:05.9179|2018-06-01 03:39:05.9179
NCT00397072|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2014-04-16|2006-11-07|2006-11-08|Estimate|||||||2014-04-16|2014-04-17|Estimate|June 2006||2006-06-30|April 2014|2014-04-30|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|||Epothilone in Recurrent Glioblastoma Patients|Phase II Study: Systemic Treatment With iv ZK219477-Epothilone in Recurrent Glioblastoma Patients|Completed||Phase 2|15|Actual|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||1|||f||||||||||||||2018-06-01 03:39:07.114813|2018-06-01 03:39:07.114813
NCT00397059|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2008-02-05|2006-11-07|2006-11-08|Estimate|||||||2008-02-05|2008-02-06|Estimate|December 2006||2006-12-31|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism|Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism|Completed||Phase 4|16|Anticipated|University of Southern Denmark|||||f||||||||||||||2018-06-01 03:39:07.379222|2018-06-01 03:39:07.379222
NCT00397046|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2017-08-10||2017-08-10|2006-11-07|2006-11-08|Estimate|2017-08-10|2018-02-16|Estimate||||2017-08-10|2018-02-16|Estimate|November 2006|Actual|2006-11-30|August 2017|2017-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors|An Ascending and Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of HKI-272 Administered Orally to Japanese Subjects With Advanced Solid Tumors|Completed||Phase 1|21|Actual|Puma Biotechnology, Inc.||1|||f||||||||||||||2018-06-01 03:39:07.606353|2018-06-01 03:39:07.606353
NCT00397033|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2009-03-16||2013-07-23|2006-11-07|2006-11-08|Estimate|2009-06-05|2009-07-28|Estimate||||2013-07-23|2013-07-29|Estimate|November 2006||2006-11-30|July 2013|2013-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dosages of Paliperidone ER in the Treatment of Patients With Schizoaffective Disorder.|Completed||Phase 3|316|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 03:39:08.662095|2018-06-01 03:39:08.662095
NCT00397020|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2009-06-03|2006-11-07|2006-11-08|Estimate|||||||2009-06-03|2009-06-04|Estimate|December 2006||2006-12-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes|A Single-Blind, Randomized, Naturalistic Pilot Study, Comparison of Divalproex ER and Quetiapine for Adults With Acute Mania or Mixed Episodes|Completed||Phase 4|39|Actual|University of California, San Diego||2|||f||||f||||||||||2018-06-01 03:39:09.532184|2018-06-01 03:39:09.532184
NCT00397007|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2017-09-27|2006-11-07|2006-11-08|Estimate|||||||2017-09-27|2017-10-02|Actual|May 2005||2005-05-31|September 2017|2017-09-30|May 2008|Actual|2008-05-31|||||Interventional|||Psychophysiological Treatment of Chronic Tinnitus|Evaluation of Psychological and Psychophysiological Effects of a Biofeedback-based Cognitive-behavioral Psychotherapy for Chronic Tinnitus-sufferers|Completed||Phase 2|130|Anticipated|Philipps University Marburg Medical Center|||||f||||||||||||||2018-06-01 03:39:09.622169|2018-06-01 03:39:09.622169
NCT00396994|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2013-03-18|2006-11-07|2006-11-08|Estimate|||||||2013-03-18|2013-03-20|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||"VIBES--Low Magnitude Mechanical Stimulation to Improve Bone Mineral Density"|Low Magnitude Mechanical Stimulation (LMMS) to Improve Bone Mineral Density (BMD)|Completed||N/A|174|Actual|Hebrew Rehabilitation Center, Boston||2|||f||||t||||||||||2018-06-01 03:39:09.781343|2018-06-01 03:39:09.781343
NCT00396981|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|2013-02-07||2016-01-19|2006-11-06|2006-11-08|Estimate|2014-01-29|2014-03-18|Estimate||||2016-01-19|2016-02-17|Estimate|March 2007||2007-03-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|January 2011|Actual|2011-01-31||Interventional|MAPS||MAPS Trial: Matrix And Platinum Science|A Prospective, Randomized, Multicenter Trial Investigating Matrix 2® and GDC® Detachable Coils for the Treatment of Intracranial Saccular Aneurysms|Completed||Phase 4|626|Actual|Stryker Neurovascular||2|||f||||t||||||||||2018-06-01 03:39:09.929105|2018-06-01 03:39:09.929105
NCT00396968|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2014-02-10|2006-11-06|2006-11-08|Estimate|||||||2014-02-10|2014-02-11|Estimate||||February 2014|2014-02-28||||||||Interventional|||AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS|AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes|Withdrawn||Phase 1/Phase 2|0|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:39:11.027829|2018-06-01 03:39:11.027829
NCT00396955|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2007-12-19|2006-11-07|2006-11-08|Estimate|||||||2007-12-19|2007-12-28|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee|A Multicenter, Randomized, Double-Blind Comparison of 4 Dose Regimens of Pla-695, Naproxen, and Placebo Administered Daily for 6 Weeks in Subjects With Active Osteoarthritis of the Knee|Terminated||Phase 2|560||Wyeth is now a wholly owned subsidiary of Pfizer||||imbalance of gastrointestinal and the lipase events|||||||||||||||2018-06-01 03:39:11.114303|2018-06-01 03:39:11.114303
NCT00396942|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2017-06-30|2006-11-07|2006-11-08|Estimate|||||||2017-06-30|2017-07-02|Actual|November 2, 2006||2006-11-02|October 3, 2008|2008-10-03|October 3, 2008||2008-10-03|||||Observational|||Motor Skill Learning in People With Parkinson's Disease|Evaluation of the Plasticity of the Primary Motor Cortex and Motor Learning in Parkinson's Disease|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:39:11.380783|2018-06-01 03:39:11.380783
NCT00396760|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2006-11-06|2006-11-06|2006-11-07|Estimate|||||||2006-11-06|2006-11-07|Estimate|January 2005||2005-01-31|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery|The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization|Unknown status|Active, not recruiting|Phase 3|220||German Heart Center|||||f||||||||||||||2018-06-01 03:39:14.214771|2018-06-01 03:39:14.214771
NCT00396929|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2007-05-15|2006-11-07|2006-11-08|Estimate|||||||2007-05-15|2007-05-16|Estimate|August 2005||2005-08-31|May 2007|2007-05-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Efficiency of a New Therapy to Treat Stenosis of Coronary Vessels in Comparison With Two Already Admitted Therapies|Local-Tax Trial: Local Intracoronary Administration of Paclitaxel After Stent Implantation for Prevention of Restenosis in Comparison With Stent Implantation Alone and With Implantation of a Paclitaxel-Eluting Stent|Unknown status|Active, not recruiting|Phase 3|204|Anticipated|University Hospital Tuebingen|||||f||||t||||||||||2018-06-01 03:39:11.478363|2018-06-01 03:39:11.478363
NCT00396916|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2007-04-10|2006-11-07|2006-11-08|Estimate|||||||2007-04-10|2007-04-11|Estimate|December 2004||2004-12-31|April 2007|2007-04-30||||||||Interventional|||Hybrid PET/CT in Cancer Patients|The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin|Completed||N/A|45||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:39:11.563227|2018-06-01 03:39:11.563227
NCT00396903|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2015-04-07|2006-11-07|2006-11-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2003||2003-04-30|April 2015|2015-04-30|November 2005|Actual|2005-11-30|||||Observational|||Evaluation of a Standard Epidural Catheter During Clinical Practice|Evaluation of a Standard Epidural Catheter During Clinical Practice|Completed|||100||Maastricht University Medical Center|||||f||||f||||||||||2018-06-01 03:39:11.615443|2018-06-01 03:39:11.615443
NCT00396890|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2017-06-30|2006-11-07|2006-11-08|Estimate|||||||2017-06-30|2017-07-02|Actual|November 3, 2006||2006-11-03|December 15, 2008|2008-12-15|December 15, 2008||2008-12-15|||||Observational|||Enhancing Brain Activity With Magnetic Stimulation|Enhancing Interhemispheric Disinhibition Between Motor Cortices Using Bilateral Brain Stimulation|Completed|||72||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:39:11.671635|2018-06-01 03:39:11.671635
NCT00396877|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|2011-02-15||2014-10-14|2006-11-07|2006-11-08|Estimate|2011-02-15|2011-03-11|Estimate||||2014-10-14|2014-10-24|Estimate|November 2006||2006-11-30|October 2014|2014-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|CLARINET||Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation|International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt|Completed||Phase 3|906|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:39:11.780959|2018-06-01 03:39:11.780959
NCT00396864|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2017-11-20|2006-11-06|2006-11-08|Estimate|||||||2017-11-20|2017-11-22|Actual|May 2006||2006-05-31|November 2017|2017-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma|Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma|Completed||Phase 1|51|Actual|Celgene||1|||f||||f||||||||Undecided||2018-06-01 03:39:13.343817|2018-06-01 03:39:13.343817
NCT00396851|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2006-11-06|2006-11-06|2006-11-08|Estimate|||||||2006-11-06|2006-11-08|Estimate|January 2007||2007-01-31|November 2006|2006-11-30||||||||Interventional|||Double Blind Randomized Trial to Compare Gurmar (Gymnema Sylvestre) With Metformin in Type 2 Diabetes||Unknown status|Not yet recruiting|N/A|100||Postgraduate Institute of Medical Education and Research|||||f||||||||||||||2018-06-01 03:39:13.430453|2018-06-01 03:39:13.430453
NCT00396838|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2008-10-11|2006-11-07|2006-11-08|Estimate|||||||2008-10-11|2008-10-15|Estimate|November 2006||2006-11-30|March 2008|2008-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Cardiac Autonomic Reactivity and Behavioral Response to Pain in Full-Term Neonates|Cardiac Autonomic Reactivity and Behavioral Response to Pain in Full-Term Neonates|Completed|||300|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:39:13.485146|2018-06-01 03:39:13.485146
NCT00396825|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2012-08-10|2006-11-07|2006-11-08|Estimate|||||||2012-08-10|2012-08-13|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Video-Based Coping Skills Training for Caregivers|Phase II Trial of a Video That Presents Training in Stress Coping Skills for Caregivers of a Relative With Alzheimer's Disease or Other Dementia|Completed||Phase 2|116|Actual|Williams LifeSkills||2|||f||||t||||||||||2018-06-01 03:39:13.527165|2018-06-01 03:39:13.527165
NCT00396812|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|2012-10-11||2013-02-06|2006-11-06|2006-11-08|Estimate|2012-10-11|2012-11-14|Estimate||||2013-02-06|2013-02-12|Estimate|November 2006||2006-11-30|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)|An Open Label, Single Arm, Single Center, Phase I/II Trial of Rituximab (a Monoclonal Antibody to CD20) for the Treatment of Early Rheumatoid Arthritis|Terminated||Phase 1/Phase 2|4|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The trial terminated early due to rituximab’s risk-benefit ratio for individuals with early active Rheumatoid Arthritis. Mechanistic samples were not processed and corresponding endpoints were not assessed. Only descriptive statistics are presented.|1||The perceived risk-benefit ratio for individuals with early active RA|f||||||||||||||2018-06-01 03:39:13.597855|2018-06-01 03:39:13.597855
NCT00396799|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-07|||2007-03-12|2006-11-07|2006-11-08|Estimate|||||||2007-03-12|2007-03-13|Estimate|November 2006||2006-11-30|March 2007|2007-03-31|November 2006||2006-11-30|||||Interventional|||Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women|An Open-Label, Single-Dose, Randomized-to-Sequence, 2-Period, Crossover, Pivotal Bioequivalence Study Between Bazedoxifene Acetate/Conjugated Estrogens (Premarin Current Process) and Bazedoxifene Acetate/Conjugated Estrogens (Premarin New Process) Tablets Administered to Healthy Postmenopausal Women|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:39:13.897413|2018-06-01 03:39:13.897413
NCT00396786|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2014-10-27|2006-11-06|2006-11-07|Estimate|||||||2014-10-27|2014-10-28|Estimate|November 2004||2004-11-30|October 2014|2014-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|ODIXaHIP-OD||Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement|Controlled, Double-Blind, Randomized, Dose-ranging Study of Once-daily Regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement- ODIXaHIP-OD|Completed||Phase 2|877|Actual|Bayer||6|||f||||t||||||||||2018-06-01 03:39:13.951515|2018-06-01 03:39:13.951515
NCT00396773|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2006-11-08|2006-11-06|2006-11-07|Estimate|||||||2006-11-08|2006-11-10|Estimate|February 2007||2007-02-28|November 2006|2006-11-30|January 2008|Anticipated|2008-01-31|||||Observational|||Neonatal Brain Waves After Electrocoagulation|Neonatal Brain Waves After Electrocoagulation|Unknown status|Not yet recruiting||60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:39:14.112529|2018-06-01 03:39:14.112529
NCT00396578|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2006-11-06|2006-11-06|2006-11-07|Estimate|||||||2006-11-06|2006-11-07|Estimate|August 2003||2003-08-31|November 2006|2006-11-30|September 2004||2004-09-30|||||Interventional|||Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation|Aerosolized Antibiotics in Mechanically Ventilated Patients|Completed||Phase 2|80||Stony Brook University|||||f||||||||||||||2018-06-01 03:39:18.430079|2018-06-01 03:39:18.430079
NCT00396747|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2007-10-18|2006-11-06|2006-11-07|Estimate|||||||2007-10-18|2007-10-19|Estimate|June 2003||2003-06-30|October 2007|2007-10-31|September 2005|Actual|2005-09-30|||||Interventional|||A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study|Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone|Completed||Phase 4|45|Actual|Université Catholique de Louvain||3|||f||||t||||||||||2018-06-01 03:39:14.399102|2018-06-01 03:39:14.399102
NCT00396734|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2010-06-09|2006-11-06|2006-11-07|Estimate|||||||2010-06-09|2010-06-10|Estimate|April 2007||2007-04-30|June 2010|2010-06-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||The Effects of Pharmacotherapy on Brain Mechanisms Underlying Cocaine Dependence.|The Effects of Modafinil and Topiramate on Brain Mechanisms Underlying Cue-induced Cocaine Craving and Dependence in Methadone Maintained Cocaine Dependent Patients.|Suspended||N/A|40|Anticipated|Hadassah Medical Organization||||Grant was not renewed|f||||t||||||||||2018-06-01 03:39:14.706923|2018-06-01 03:39:14.706923
NCT00396721|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2011-09-14|2006-11-03|2006-11-07|Estimate|||||||2011-09-14|2011-09-16|Estimate|January 2006||2006-01-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|SIREPNA||Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy|Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus.|Completed||Phase 2|23|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-06-01 03:39:15.032421|2018-06-01 03:39:15.032421
NCT00396708|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2010-02-02|2006-11-06|2006-11-07|Estimate|||||||2010-02-02|2010-02-03|Estimate|August 2006||2006-08-31|February 2010|2010-02-28||||December 2007|Actual|2007-12-31||Interventional|||Wearable Robotic Functional Assistance for Stroke Rehabilitation|Wearable Robotic Functional Assistance for Stroke Rehabilitation|Completed||N/A|20|Anticipated|Myomo|||||f||||||||||||||2018-06-01 03:39:15.116199|2018-06-01 03:39:15.116199
NCT00396695|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2006-11-06|2006-11-06|2006-11-07|Estimate|||||||2006-11-06|2006-11-07|Estimate|October 2006||2006-10-31|November 2006|2006-11-30|December 2007||2007-12-31|||||Observational|||Neuroimmunological Model of Traumatic Memory|Neuroimmunological Model of Traumatic Memory|Unknown status|Recruiting||40||Ziv Hospital|||||f||||||||||||||2018-06-01 03:39:15.406124|2018-06-01 03:39:15.406124
NCT00396682|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2009-02-03|2006-11-06|2006-11-07|Estimate|||||||2009-02-03|2009-02-04|Estimate|February 2007||2007-02-28|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma|Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide|Completed||Phase 3|12|Anticipated|Hannover Medical School|||||f||||||||||||||2018-06-01 03:39:15.563531|2018-06-01 03:39:15.563531
NCT00396669|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2012-03-26|2006-11-06|2006-11-07|Estimate|||||||2012-03-26|2012-03-27|Estimate|July 2007||2007-07-31|March 2012|2012-03-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.|A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers, Using 11 C Raclopride in Positron Emission Tomography (PET)|Unknown status|Recruiting|N/A|24|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-06-01 03:39:15.718941|2018-06-01 03:39:15.718941
NCT00396656|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|2011-01-07||2011-05-05|2006-11-06|2006-11-07|Estimate|2011-05-05|2011-06-06|Estimate||||2011-05-05|2011-06-06|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients|A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients|Completed||Phase 3|30|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:39:15.818941|2018-06-01 03:39:15.818941
NCT00396643|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2007-12-20|2006-11-06|2006-11-07|Estimate|||||||2007-12-20|2007-12-27|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis|Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis: A Randomised, Double Blind, Placebo-Controlled Treatment Trial|Completed||Phase 4|81|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 03:39:16.878968|2018-06-01 03:39:16.878968
NCT00396630|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|2009-02-13||2018-01-09|2006-11-06|2006-11-07|Estimate|2009-02-13|2009-03-13|Estimate||||2018-01-09|2018-02-06|Actual|January 23, 2007|Actual|2007-01-23|November 2017|2017-11-30|February 13, 2008|Actual|2008-02-13|January 23, 2008|Actual|2008-01-23||Interventional|||A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.|A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.|Completed||Phase 3|200|Actual|GlaxoSmithKline||2|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:39:17.184583|2018-06-01 03:39:17.184583
NCT00396617|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2012-06-28|2006-11-06|2006-11-07|Estimate|||||||2012-06-28|2012-07-02|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|March 2014|Anticipated|2014-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy|Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy|Unknown status|Recruiting|Phase 1|14|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 03:39:17.686947|2018-06-01 03:39:17.686947
NCT00396604|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2011-10-24|2006-11-06|2006-11-07|Estimate|||||||2011-10-24|2011-10-25|Estimate|October 2006||2006-10-31|October 2011|2011-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Double-dummy, Active (Formoterol 12 µg b.i.d) and Placebo Controlled, Multi-center, 5 Period Crossover Study to Assess the Bronchodilatory Efficacy and Safety of Single Doses of Indacaterol 150 µg, 300 µg and 600 µg Delivered Via Single Dose Dry Powder Inhaler vs. Placebo in Patients With Moderate to Severe COPD.|Completed||Phase 2/Phase 3|51|Actual|Novartis|||||f||||||||||||||2018-06-01 03:39:17.756956|2018-06-01 03:39:17.756956
NCT00396591|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|2012-08-17|2011-07-21|2013-01-09|2006-11-06|2006-11-07|Estimate|2013-01-09|2013-01-10|Estimate|2011-07-21|2011-07-25|Estimate|2013-01-09|2013-01-10|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites|A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites|Completed||Phase 2|16|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:39:17.856938|2018-06-01 03:39:17.856938
NCT00396565|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|2012-03-27||2014-04-10|2006-11-03|2006-11-07|Estimate|2012-05-30|2012-07-03|Estimate||||2014-04-10|2014-04-29|Estimate|July 2006||2006-07-31|April 2014|2014-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia|A Placebo-Controlled Double Blind Comparative Study of JNS007ER in Patients With Schizophrenia|Completed||Phase 3|394|Actual|Janssen Pharmaceutical K.K.||3|||f||||||||||||||2018-06-01 03:39:18.587484|2018-06-01 03:39:18.587484
NCT00396552|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2013-02-14|2006-11-06|2006-11-07|Estimate|||||||2013-02-14|2013-02-15|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Treating Refractory Obsessive Compulsive Disorder With rTMS|Treating Refractory Obsessive Compulsive Disorder With Repetitive Transcranial Magnetic Stimulation: A Double-blind Sham Controlled Longitudinal Study|Completed||N/A|19|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 03:39:19.199688|2018-06-01 03:39:19.199688
NCT00396539|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2009-02-01|2006-11-06|2006-11-07|Estimate|||||||2009-02-01|2009-02-03|Estimate|January 2007||2007-01-31|November 2006|2006-11-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Observational|||Hydrogen Sulfide Production by Oral Microflora|Detection of Hydrogen Sulfide Production by Oral Microflora Samples|Completed|||60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:39:19.292212|2018-06-01 03:39:19.292212
NCT00396526|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-04|||2006-12-05|2006-11-06|2006-11-07|Estimate|||||||2006-12-05|2006-12-07|Estimate|April 2004||2004-04-30|December 2006|2006-12-31|April 2006||2006-04-30|||||Interventional|||ICMR-Indiaclen Trial on Amoxycillin vs Cotrimoxazole for Non-Severe Pneumonia|Effectiveness of 3 Day Amoxycillin Versus 5 Day co-Trimoxazole in the Treatment of Non-Severe Pneumonia in Children Aged 2- 59 Months of Age: - A Multi-Centric Open Labeled Trial|Completed||Phase 3|2000||King George's Medical University|||||f||||||||||||||2018-06-01 03:39:19.348543|2018-06-01 03:39:19.348543
NCT00396513|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2006-11-03|2006-11-03|2006-11-07|Estimate|||||||2006-11-03|2006-11-07|Estimate|September 2005||2005-09-30|November 2006|2006-11-30||||||||Interventional|||Simvastatin and Metformin Therapy in PCOS Women. Prospective Randomised Trial.|Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial|Unknown status|Recruiting|N/A|||Poznan University of Medical Sciences|||||f||||||||||||||2018-06-01 03:39:19.428516|2018-06-01 03:39:19.428516
NCT00396500|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-04|||2006-11-06|2006-11-06|2006-11-07|Estimate|||||||2006-11-06|2006-11-07|Estimate|April 1994||1994-04-30|November 2006|2006-11-30|December 1996||1996-12-31|||||Interventional|||Deworming and Vitamin A (DEVTA) Prepilot Study|To Assess the Effectiveness of Six-Monthly Deworming With Vitamin A Administration on Growth in 1-5 Year Old Children in the Urban Slums of Lucknow|Completed||Phase 3|4000||King George's Medical University|||||f||||||||||||||2018-06-01 03:39:19.552404|2018-06-01 03:39:19.552404
NCT00396487|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2015-06-10|2006-11-06|2006-11-07|Estimate|||||||2015-06-10|2015-06-11|Estimate|November 2006||2006-11-30|June 2015|2015-06-30|February 2008|Actual|2008-02-29|||||Interventional|||Tailored Treatment in Metastatic Colorectal Cancer|Tailored Treatment of Metastatic Colorectal Cancer Based on Genetic Markers|Terminated||Phase 3|1|Actual|Vejle Hospital||||Only one patient included as per Feb. 4, 2008.|f||||||||||||||2018-06-01 03:39:19.640874|2018-06-01 03:39:19.640874
NCT00396474|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|||2015-04-21|2006-11-06|2006-11-07|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|January 2012|Anticipated|2012-01-31|||||Observational|||Safety Study In Patients Who Were Born Small And Short And Were Treated With Growth Hormone To Achieve Normal Height|Long-Term Metabolic Risk In Small for Gestational Age (SGA) Patients After Growth Hormone Treatment Compared To Matched, Untreated Controls|Withdrawn|||0|Actual|Pfizer|||1|Study design no longer relevant and no patients were recruited.|f||||f||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-06-01 03:39:19.847484|2018-06-01 03:39:19.847484
NCT00396461|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2013-07-18|2006-11-06|2006-11-07|Estimate|||||||2013-07-18|2013-07-19|Estimate|November 2006||2006-11-30|July 2013|2013-07-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|ICULIP||ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients|Phase IV-IV. ICULIP,a Prospective,Multi-centre,Randomised,Comparative,Double-blind Study to Evaluate Two Different Types of Lipid Emulsions Used for Total Parenteral Nutrition in Critical Patients and Their Influence on Nosocomial Infection.|Terminated||Phase 4|212|Anticipated|B. Braun Medical SA||2|||f||||||||||||||2018-06-01 03:39:19.941187|2018-06-01 03:39:19.941187
NCT00396448|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06||2009-08-11|2012-11-05|2006-11-06|2006-11-07|Estimate||||2009-08-11|2009-08-13|Estimate|2012-11-05|2012-11-07|Estimate|February 2007||2007-02-28|November 2012|2012-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.|A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects|Terminated||Phase 3|1253|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:39:20.09417|2018-06-01 03:39:20.09417
NCT00396435|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2010-05-26|2006-11-03|2006-11-07|Estimate|||||||2010-05-26|2010-05-27|Estimate|April 2004||2004-04-30|May 2010|2010-05-31|May 2010|Actual|2010-05-31|April 2009|Actual|2009-04-30||Interventional|||Correction of Anaemia and Progression of Renal Failure on Transplanted Patients|Multicenter, Prospective, Randomised, Open-label Study, Evaluating the Effect of Two Levels of Haemoglobin on Quality of Life and Speed of Progression of Renal Insufficiency on Renal Transplanted Patients With Chronic Graft Dysfunction (CGD)|Completed||Phase 4|128|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-06-01 03:39:20.383088|2018-06-01 03:39:20.383088
NCT00396422|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2011-02-17|2006-11-06|2006-11-07|Estimate|||||||2011-02-17|2011-02-18|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|March 2007|Actual|2007-03-31|||||Interventional|||Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis|A Phase IIa Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multi-Center, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RWJ-445380 Administered to Patients With Plaque Psoriasis|Completed||Phase 2|60|Actual|Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 03:39:20.495959|2018-06-01 03:39:20.495959
NCT00396409|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-06|2010-11-22||2017-02-28|2006-11-06|2006-11-07|Estimate|2011-05-05|2011-06-03|Estimate||||2017-02-28|2017-03-30|Actual|February 2006||2006-02-28|February 2017|2017-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis|A Randomized, 20 Week, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Combination With Depigoid, Versus Depigoid Only, in Adult and Adolescent Patients With Seasonal Allergic Asthma and Comorbid Seasonal Allergic Rhinoconjunctivitis - Open-label Depigoid Monotherapy Extension Periods 2007 and 2008-|Completed||Phase 3|128|Actual|Novartis|Study Start Date: February 2006 (core study)|2|||f||||||||||||||2018-06-01 03:39:20.63016|2018-06-01 03:39:20.63016
NCT00396383|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2009-02-11||2014-02-10|2006-11-02|2006-11-06|Estimate|2010-10-05|2010-10-21|Estimate||||2014-02-10|2014-03-13|Estimate|November 2004||2004-11-30|February 2014|2014-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation|Treatment With AMD3100 in Multiple Myeloma Patients to Mobilize Peripheral Blood Progenitor Cells For Collection and for Transplantation|Terminated||Phase 2|9|Actual|Sanofi|Study had limited enrollment prior to termination.|1||Insufficient cell mobilization for tandem transplants|f||||t||||||||||2018-06-01 03:39:21.83077|2018-06-01 03:39:21.83077
NCT00396370|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2013-09-12|2006-11-03|2006-11-06|Estimate|||||||2013-09-12|2013-09-13|Estimate|December 2008||2008-12-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||BCG Vaccination Delivered Intradermally, Orally and by Combined Routes|Phase I Studies of the Safety and Immunogenicity of Primary and Secondary BCG Vaccination Delivered Intradermally, Orally and by Combined Routes of Administration in Healthy and Previously Immunologically Naïve Volunteers|Completed||Phase 1|69|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 03:39:22.082115|2018-06-01 03:39:22.082115
NCT00396357|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02||2012-12-28|2012-12-28|2006-11-03|2006-11-06|Estimate||||2012-12-28|2013-01-01|Estimate|2012-12-28|2013-01-01|Estimate|October 2006||2006-10-31|December 2012|2012-12-31||||June 2008|Actual|2008-06-30||Interventional|||Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone|A Multicenter, Double-blind, Randomized Parallel-group, Study to Demonstrate the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd as add-on to Metformin 500 mg Bid Compared to Metformin 1000 mg Bid in Patients With Type 2 Diabetes Inadequately Controlled on Metformin 500 mg Bid Monotherapy|Completed||Phase 3|914|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:39:22.163247|2018-06-01 03:39:22.163247
NCT00396344|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2008-05-06|2006-11-03|2006-11-06|Estimate|||||||2008-05-06|2008-05-09|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Cortisol Control of Human Inflammatory Responses to Endotoxin|The Effect of Glucocorticoid Pre-Treatment on the Systemic Cytokine Response to Endotoxin in Human Volunteers|Completed||N/A|36|Anticipated|Dartmouth-Hitchcock Medical Center||3|||f||||||||||||||2018-06-01 03:39:22.248647|2018-06-01 03:39:22.248647
NCT00396331|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2010-11-02||2014-02-10|2006-11-02|2006-11-06|Estimate|2010-11-02|2010-12-02|Estimate||||2014-02-10|2014-03-13|Estimate|October 2005||2005-10-31|February 2014|2014-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts|A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Poor Mobilizing Adult Patients Who Have Previously Failed Stem Cell Collection/Attempts|Completed||Phase 2|100|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:39:22.372034|2018-06-01 03:39:22.372034
NCT00396318|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2010-09-19|2009-06-10|2011-03-29|2006-11-02|2006-11-06|Estimate|2011-03-29|2011-04-27|Estimate|2011-03-29|2011-04-27|Estimate|2011-03-29|2011-04-27|Estimate|December 2006||2006-12-31|March 2011|2011-03-31||||June 2008|Actual|2008-06-30||Interventional|TROPICS 2||A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|Completed||Phase 3|251|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:39:23.605509|2018-06-01 03:39:23.605509
NCT00396305|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2010-08-26|2006-11-03|2006-11-06|Estimate|||||||2010-08-26|2010-08-27|Estimate|November 2006||2006-11-30|May 2010|2010-05-31|January 2008|Actual|2008-01-31|September 2007|Actual|2007-09-30||Interventional|||Th1 Response to Influenza: Aging and Vaccine Efficacy|Th1 Response to Influenza: Aging and Vaccine Efficacy|Terminated||Phase 4|41|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 03:39:23.808094|2018-06-01 03:39:23.808094
NCT00396292|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2013-10-15||2018-01-22|2006-11-03|2006-11-06|Estimate|2013-10-15|2013-12-10|Estimate||||2018-01-22|2018-02-05|Actual|February 2005||2005-02-28|January 2018|2018-01-31|February 2006|Actual|2006-02-28|November 2005|Actual|2005-11-30||Interventional|||Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia|Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in Subjects Who Display Postpartum Anemia|Completed||Phase 3|361|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:39:23.875776|2018-06-01 03:39:23.875776
NCT00396279|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2014-01-23|2010-06-10|2014-07-11|2006-11-02|2006-11-06|Estimate|2014-01-23|2014-03-05|Estimate|2010-06-10|2010-06-14|Estimate|2014-07-11|2014-07-18|Estimate|July 2006||2006-07-31|July 2014|2014-07-31|February 2011|Actual|2011-02-28|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone|An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects With Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone|Completed||Phase 2|37|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:39:24.159364|2018-06-01 03:39:24.159364
NCT00396266|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2010-10-30||2014-02-04|2006-11-02|2006-11-06|Estimate|2010-10-30|2010-11-25|Estimate||||2014-02-04|2014-03-07|Estimate|January 2005||2005-01-31|February 2014|2014-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF|Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF|Completed||Phase 2|22|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:39:25.531484|2018-06-01 03:39:25.531484
NCT00396253|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2010-03-25|2009-06-10|2016-11-25|2006-11-02|2006-11-06|Estimate|2011-07-05|2011-08-02|Estimate|2011-07-05|2011-08-02|Estimate|2016-11-25|2017-01-12|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|TROPICS 4||A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters|A Phase III, Open-Label Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters|Completed||Phase 3|223|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:39:26.091502|2018-06-01 03:39:26.091502
NCT00396240|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2009-03-25|2006-11-03|2006-11-06|Estimate|||||||2009-03-25|2009-03-26|Estimate|February 2002||2002-02-28|March 2009|2009-03-31||||||||Interventional|||ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals|ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals|Withdrawn||Phase 4|1294||AstraZeneca||||study cancelled prior to FSI|f||||||||||||||2018-06-01 03:39:26.398742|2018-06-01 03:39:26.398742
NCT00396058|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2008-03-26|2006-11-03|2006-11-06|Estimate|||||||2008-03-26|2008-03-27|Estimate|November 2006||2006-11-30|March 2008|2008-03-31|March 2008|Actual|2008-03-31|||||Interventional|||The Effect of Methylphenidate on Motor Learning in Stroke Patients|Methylphenidats Betydning for motoriskindlæring Hos Patienter Med Apopleksi|Terminated||Phase 4|13|Anticipated|University of Aarhus||||Recruitment of patients proved much too difficult based on the chosen criteria.|f||||f||||||||||2018-06-01 03:39:30.430678|2018-06-01 03:39:30.430678
NCT00396227|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2016-11-16|2006-11-02|2006-11-06|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2006||2006-10-31|November 2016|2016-11-30||||October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone|A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment With Vildagliptin 100 mg, qd to Thiazolidinedione (TZD) as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in a Community-based Practice Setting.|Completed||Phase 3|2665|Actual|Novartis||2|||||||||||||||||2018-06-01 03:39:26.470286|2018-06-01 03:39:26.470286
NCT00396214|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2008-05-30|2006-11-03|2006-11-06|Estimate|||||||2008-05-30|2008-06-04|Estimate|April 2007||2007-04-30|May 2008|2008-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients|A Randomized, Multicenter, Double-Blind, Parallel Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients|Terminated||Phase 3|83|Actual|Solvay Pharmaceuticals||3||This trial discontinued on 2 May 2008 due to lack of enrolment|f||||f||||||||||2018-06-01 03:39:26.599765|2018-06-01 03:39:26.599765
NCT00396201|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2009-02-10||2014-02-10|2006-11-02|2006-11-06|Estimate|2010-09-17|2010-10-06|Estimate||||2014-02-10|2014-03-13|Estimate|November 2004||2004-11-30|February 2014|2014-02-28|January 2008|Actual|2008-01-31|October 2006|Actual|2006-10-31||Interventional|||AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease|Treatment With AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells in Patients With Hodgkin's Disease|Completed||Phase 2|22|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:39:26.979834|2018-06-01 03:39:26.979834
NCT00396188|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2015-08-13|2006-11-03|2006-11-06|Estimate|||||||2015-08-13|2015-08-17|Estimate|February 2007||2007-02-28|August 2015|2015-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Screening Aid to Identify Corneas That May Have Pathologies or Other Conditions|Corneal Analysis - Pathology Detection Aid|Completed|||769|Actual|Carl Zeiss Meditec, Inc.|||6||f||||t||||||||||2018-06-01 03:39:27.371939|2018-06-01 03:39:27.371939
NCT00396175|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2014-09-25|2006-11-02|2006-11-06|Estimate|||||||2014-09-25|2014-09-26|Estimate|March 1998||1998-03-31|September 2014|2014-09-30||||January 2000|Actual|2000-01-31||Interventional|||Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)|A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia|Completed||Phase 3|355||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 03:39:27.457412|2018-06-01 03:39:27.457412
NCT00396162|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2015-05-28||2016-08-11|2006-11-02|2006-11-06|Estimate|2016-06-23|2016-08-04|Estimate||||2016-08-11|2016-09-20|Estimate|November 2006||2006-11-30|August 2016|2016-08-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis|Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis|Completed||Phase 4|77|Actual|University of Michigan||2|||f||||||||||||||2018-06-01 03:39:27.585297|2018-06-01 03:39:27.585297
NCT00396149|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2013-06-26|2006-11-02|2006-11-06|Estimate|||||||2013-06-26|2013-06-27|Estimate|November 2006||2006-11-30|April 2009|2009-04-30|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1|A Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Higher Multi Dose Regimens to Subjects Sensitised to Birch Pollen|Completed||Phase 1|57|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-06-01 03:39:27.945364|2018-06-01 03:39:27.945364
NCT00396136|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2012-02-22||2012-04-27|2006-11-03|2006-11-06|Estimate|2012-04-27|2012-05-28|Estimate||||2012-04-27|2012-05-28|Estimate|October 2006||2006-10-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||COSMO Post Approval Registry: Corox OTW Steroid LV Lead Monitoring|Corox OTW Steroid LV Lead Monitoring|Completed||Phase 4|221|Actual|Biotronik, Inc.|||||f||||||||||||||2018-06-01 03:39:28.02621|2018-06-01 03:39:28.02621
NCT00396123|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2017-06-01|2006-11-02|2006-11-06|Estimate|||||||2017-06-01|2017-06-05|Actual|November 2006||2006-11-30|June 2017|2017-06-30|July 25, 2008|Actual|2008-07-25|July 25, 2008|Actual|2008-07-25||Observational|||Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study|Effects Of Darbepoetin On Vascular Repair Mechanisms In Kidney Disease The DARBEPC Study|Completed|||12|Actual|University of Michigan|||||f||||f||||||||||2018-06-01 03:39:28.181001|2018-06-01 03:39:28.181001
NCT00396110|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2006-11-03|2006-11-03|2006-11-06|Estimate|||||||2006-11-03|2006-11-06|Estimate|February 2003||2003-02-28|February 2003|2003-02-28||||||||Observational|||Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)|Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)|Completed|||3889||AstraZeneca|||||f||||||||||||||2018-06-01 03:39:28.247737|2018-06-01 03:39:28.247737
NCT00396097|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2013-08-30||2016-03-09|2006-11-02|2006-11-06|Estimate|2013-08-30|2013-11-13|Estimate||||2016-03-09|2016-04-05|Estimate|December 2006||2006-12-31|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature|A Four Year Open Label Multi Center Randomized Two Arm Study Of Genotropin In Idiopathic Short Stature Patients: Comparing An Individualized, Target Driven Treatment Regimen To Standard Dosing Of Genotropin|Completed||Phase 3|316|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:39:28.321664|2018-06-01 03:39:28.321664
NCT00396084|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|2008-11-19||2011-06-09|2006-11-03|2006-11-06|Estimate|2009-05-07|2009-06-25|Estimate||||2011-06-09|2011-06-13|Estimate|February 2004||2004-02-29|March 2010|2010-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis|Randomized, Open Label, Multiple Dose Phase I Study of the Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, and Moxifloxacin in HIV-non-infected Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis|Completed||Phase 1/Phase 2|70|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The small sample size had limited power to detect small differences in EBA between study arms even though we enrolled patients with smear-positive TB and high sputum bacillary burden to improve chances of detecting differences between treatment arms.|6|||f||||||||||||||2018-06-01 03:39:28.986483|2018-06-01 03:39:28.986483
NCT00396071|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2016-11-16|2006-11-02|2006-11-06|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2006||2006-10-31|November 2016|2016-11-30||||November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin|A Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Assess the Effect of Vildagliptin on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin|Completed||Phase 3|22|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:39:30.314788|2018-06-01 03:39:30.314788
NCT00396045|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2006-11-29|2006-11-03|2006-11-06|Estimate|||||||2006-11-29|2006-11-30|Estimate|January 2005||2005-01-31|November 2006|2006-11-30|January 2008||2008-01-31|||||Interventional|||Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma|A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients|Completed||Phase 1/Phase 2|54||University of Turin, Italy|||||f||||||||||||||2018-06-01 03:39:30.5244|2018-06-01 03:39:30.5244
NCT00396032|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2010-03-24|2009-06-10|2010-05-01|2006-11-02|2006-11-06|Estimate|2010-05-01|2010-06-03|Estimate|2010-05-01|2010-06-03|Estimate|2010-05-01|2010-06-03|Estimate|October 2006||2006-10-31|May 2010|2010-05-31||||December 2008|Actual|2008-12-31||Interventional|TROPICS 3||A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters|Completed||Phase 3|150|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:39:30.602553|2018-06-01 03:39:30.602553
NCT00396019|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2017-08-09||2017-10-05|2006-11-02|2006-11-06|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|December 2006|Actual|2006-12-31|October 2017|2017-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of PEG-Intron for Plexiform Neurofibromas|A Phase II Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas|Completed||Phase 2|86|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 03:39:31.046033|2018-06-01 03:39:31.046033
NCT00396006|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|2010-12-15||2017-10-19|2006-11-03|2006-11-06|Estimate|2010-12-15|2011-01-04|Estimate||||2017-10-19|2017-11-24|Actual|October 2006||2006-10-31|March 2011|2011-03-31||||December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)|The Effect of Augmentation Therapy With ARALAST Fraction IV-1 (ARALAST) Alpha1-Proteinase Inhibitor (α1-PI) on the Level of α1-PI and Other Analytes in the Bronchoalveolar (BAL) Epithelial Lining Fluid (ELF)|Completed||Phase 4|21|Actual|Shire|Isoelectric focusing (IEF) analyses that were intended to compare the profile of plasma α1-PI & ELF α1-PI were not carried out due to fact that ELF samples were either missing, insufficient or too dilute for such assays.||||f||||||||||||||2018-06-01 03:39:31.389813|2018-06-01 03:39:31.389813
NCT00395993|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2013-09-16||2018-01-22|2006-11-03|2006-11-06|Estimate|2013-09-16|2013-11-18|Estimate||||2018-01-22|2018-02-20|Estimate|May 2005||2005-05-31|January 2018|2018-01-31|June 2006|Actual|2006-06-30|April 2006|Actual|2006-04-30||Interventional||16 of the 246 subjects randomized to FCM were discontinued prior to dosing and 5 of the 231 subjects randomized to oral iron were discontinued prior to dosing.|Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding|Comparison of the Safety and Efficacy of Intravenous Iron vs Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding|Completed||Phase 3|456|Actual|Luitpold Pharmaceuticals||2|||f||||||||||||||2018-06-01 03:39:31.719725|2018-06-01 03:39:31.719725
NCT00395980|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2008-12-11|2006-11-03|2006-11-06|Estimate|||||||2008-12-11|2008-12-12|Estimate|October 2006||2006-10-31|December 2008|2008-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Muscle Pressure in the Flank Position|Muscle Pressure in the Flank Position|Completed||N/A|20|Actual|University of California, Irvine|||||f||||||||||||||2018-06-01 03:39:32.001114|2018-06-01 03:39:32.001114
NCT00395967|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2009-01-27||2015-04-10|2006-11-02|2006-11-06|Estimate|2010-07-20|2010-08-13|Estimate||||2015-04-10|2015-05-01|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|August 2006|Actual|2006-08-31|July 2005|Actual|2005-07-31||Interventional|||AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone|Effect of AMD3100 (240µg/kg) on the Apheresis Yield of CD34+ Cells When Given To Multiple Myeloma or Non-Hodgkin's Lymphoma Patients Predicted to be Unable to Mobilize ≥2 x 10^6 CD34+ Cells in Three Apheresis Days When Given G-CSF Alone|Terminated||Phase 2|5|Actual|Sanofi|Limited enrollment due to early termination of the study.|1||Enrollment terminated in 2005 to focus on Phase 3 study enrollment.|f||||f||||||||||2018-06-01 03:39:32.073743|2018-06-01 03:39:32.073743
NCT00395954|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2009-02-13|2006-11-02|2006-11-06|Estimate|||||||2009-02-13|2009-02-16|Estimate|November 2006||2006-11-30|February 2009|2009-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Amount of Lactose Causing Symptoms in Lactose Intolerant People|A Study to Determine the Threshold of Lactose Ingestion That Provokes Symptoms in Lactose Intolerant People.|Completed|||48|Anticipated|University Hospitals, Leicester|||||f||||||||||||||2018-06-01 03:39:32.327151|2018-06-01 03:39:32.327151
NCT00395941|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2006-11-03|2006-11-03|2006-11-06|Estimate|||||||2006-11-03|2006-11-06|Estimate|December 2006||2006-12-31|November 2006|2006-11-30||||||||Interventional|||Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis||Unknown status|Not yet recruiting|Phase 2|40||Postgraduate Institute of Medical Education and Research|||||f||||||||||||||2018-06-01 03:39:32.373908|2018-06-01 03:39:32.373908
NCT00395928|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2006-11-03|2006-11-03|2006-11-06|Estimate|||||||2006-11-03|2006-11-06|Estimate|November 2001||2001-11-30|November 2006|2006-11-30|November 2004||2004-11-30|||||Observational|||Chronic and Acute Effects of Smoking on the Left and Right Ventricular Relaxation in Young Healthy Smokers|Chronic and Acute Effect of Smoking on the Left and Right Ventricular Systolic and Diastolic Function in Young Healthy Smokers|Completed|||33||Medical University of Warsaw|||||f||||||||||||||2018-06-01 03:39:32.434698|2018-06-01 03:39:32.434698
NCT00395915|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2009-02-17|2006-11-03|2006-11-06|Estimate|||||||2009-02-17|2009-02-18|Estimate|September 2006||2006-09-30|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|March 2009|Anticipated|2009-03-31||Interventional|CHAT||Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia|Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial.|Unknown status|Active, not recruiting|Phase 4|106|Actual|Universita di Verona|||||f||||t||||||||||2018-06-01 03:39:32.50242|2018-06-01 03:39:32.50242
NCT00395902|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2007-12-20|2006-11-02|2006-11-06|Estimate|||||||2007-12-20|2007-12-28|Estimate|August 2005||2005-08-31|December 2007|2007-12-31||||||||Observational|||Post Transplant Study|A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients|Completed|||50||Amgen|||||f||||||||||||||2018-06-01 03:39:32.569475|2018-06-01 03:39:32.569475
NCT00395889|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-03|||2011-02-18|2006-11-03|2006-11-06|Estimate|||||||2011-02-18|2011-02-21|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Physical Activities in Daily Life After Lung Transplantation|Effects of a 6-month Outpatient Rehabilitation Program Including Structured Exercise Training on Participation in Physical Activities in Daily Life in Lung Transplant Recipients|Completed||Phase 1|40|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-06-01 03:39:32.622738|2018-06-01 03:39:32.622738
NCT00395694|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2012-08-16||2013-04-11|2006-11-02|2006-11-03|Estimate|2012-08-16|2012-09-17|Estimate||||2013-04-11|2013-04-19|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Clinical Evaluation of BW430C in Epilepsy|Clinical Evaluation of BW430C in Epilepsy<Phase III Study>|Completed||Phase 3|102|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:39:37.337934|2018-06-01 03:39:37.337934
NCT00395876|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2010-07-14|2009-05-18|2010-07-14|2006-11-02|2006-11-06|Estimate|2010-07-14|2010-08-10|Estimate|2010-07-14|2010-08-10|Estimate|2010-07-14|2010-08-10|Estimate|November 2006||2006-11-30|July 2010|2010-07-31||||June 2008|Actual|2008-06-30||Interventional|TROPICS 1||A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters|Completed||Phase 3|100|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:39:32.782545|2018-06-01 03:39:32.782545
NCT00395863|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|2009-03-30||2015-03-24|2006-11-03|2006-11-06|Estimate|2009-06-08|2009-07-31|Estimate||||2015-03-24|2015-04-14|Estimate|November 2006||2006-11-30|March 2015|2015-03-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Multihance at 3 Tesla in Brain Tumors|A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T|Completed||Phase 4|46|Actual|Bracco Diagnostics, Inc||2|||f||||f||||||||||2018-06-01 03:39:33.214018|2018-06-01 03:39:33.214018
NCT00395850|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2013-03-14||2013-09-06|2006-11-02|2006-11-03|Estimate|2013-09-06|2013-11-13|Estimate||||2013-09-06|2013-11-13|Estimate|April 2007||2007-04-30|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Disulfiram for Cocaine Abuse|Disulfiram for Cocaine Abuse|Completed||Phase 2|118|Actual|University of Arkansas||4|||f||||t||||||||||2018-06-01 03:39:33.915713|2018-06-01 03:39:33.915713
NCT00395837|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2006-11-01|2006-11-01|2006-11-03|Estimate|||||||2006-11-01|2006-11-03|Estimate|September 2004||2004-09-30|November 2006|2006-11-30|May 2006||2006-05-31|||||Interventional|||Efficacy of Lifestyle Changes in Modifying Practical Markers of Wellness and Aging.|Efficacy of Lifestyle Changes in Modifying Practical Markers of Wellness and Aging|Completed||N/A|56||St. Anthony's Health Care|||||f||||||||||||||2018-06-01 03:39:34.446702|2018-06-01 03:39:34.446702
NCT00395824|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2006-11-02|2006-11-02|2006-11-03|Estimate|||||||2006-11-02|2006-11-03|Estimate|January 2005||2005-01-31|November 2006|2006-11-30|September 2005||2005-09-30|||||Interventional|||Citrate Anticoagulation vs. Heparin-Coated Dialyzers|Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: a Prospective Randomised Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding|Completed||Phase 3|33||Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-06-01 03:39:34.538195|2018-06-01 03:39:34.538195
NCT00395811|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2008-10-28|2006-11-02|2006-11-03|Estimate|||||||2008-10-28|2008-10-29|Estimate|January 2007||2007-01-31|October 2008|2008-10-31|June 2009|Anticipated|2009-06-30|April 2009|Anticipated|2009-04-30||Interventional|||Stem Cell Therapy to Improve Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting (CABG)||Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|China National Center for Cardiovascular Diseases|||||f||||t||||||||||2018-06-01 03:39:34.627952|2018-06-01 03:39:34.627952
NCT00395798|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2011-07-03|2006-11-02|2006-11-03|Estimate|||||||2011-07-03|2011-07-06|Estimate|January 2004||2004-01-31|May 2006|2006-05-31|August 2007||2007-08-31|||||Interventional|||Effect of Cervical Collar in Cervical Radicular Pain.|Effect of Conservative Treatment With Cervical Collar in Patients With Cervical Radiculopathy and Radicular Pain. A Randomized Controlled Study|Completed||Phase 2|120||Oslo University Hospital|||||f||||||||||||||2018-06-01 03:39:34.730279|2018-06-01 03:39:34.730279
NCT00395785|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2007-07-20|2006-11-01|2006-11-03|Estimate|||||||2007-07-20|2007-07-25|Estimate|November 2006||2006-11-30|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Evaluation of the TriActiv ProGuard System During Carotid Artery Stenting|Protection During Carotid Stenting in High Risk Patients With the TriActiv ProGuard System|Terminated||Phase 2/Phase 3|400|Anticipated|Kensey Nash Corporation||||Sponsor elected to not pursue this indication for the study device.|f||||||||||||||2018-06-01 03:39:34.814621|2018-06-01 03:39:34.814621
NCT00395772|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2014-10-27|2006-11-02|2006-11-03|Estimate|||||||2014-10-27|2014-10-28|Estimate|December 2004||2004-12-31|October 2014|2014-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis|Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.|Completed||Phase 2|543|Actual|Bayer||4|||f||||||||||||||2018-06-01 03:39:34.93095|2018-06-01 03:39:34.93095
NCT00395759|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2007-10-21|2006-11-02|2006-11-03|Estimate|||||||2007-10-21|2007-10-23|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||The Visual Effect of an Investigational Artificial Tear in the Tear Layer.|The Visual Effect of an Investigational Artificial Tear in the Tear Layer.|Completed||N/A|30||Southern California College of Optometry|||||f||||||||||||||2018-06-01 03:39:35.167844|2018-06-01 03:39:35.167844
NCT00395746|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2010-02-23|2009-10-26|2017-01-25|2006-11-02|2006-11-03|Estimate|2010-02-23|2010-03-12|Estimate|2009-10-26|2009-10-28|Estimate|2017-01-25|2017-03-08|Actual|October 2006||2006-10-31|January 2017|2017-01-31|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes|Completed||Phase 3|264|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-06-01 03:39:35.285081|2018-06-01 03:39:35.285081
NCT00395733|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2011-07-05||2013-11-25|2006-11-02|2006-11-03|Estimate|2011-07-05|2011-08-03|Estimate||||2013-11-25|2013-12-18|Estimate|October 2006||2006-10-31|November 2013|2013-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients|A Single-blind, Intra-individual, Crossover, Multicenter Study of the Efficacy, Safety and Tolerability of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent in the Enhanced Magnetic Resonance Angiography (MRA) in Chinese Patients|Completed||Phase 3|83|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:39:36.414082|2018-06-01 03:39:36.414082
NCT00395720|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2011-03-25|2006-11-02|2006-11-03|Estimate|||||||2011-03-25|2011-03-28|Estimate|November 2006||2006-11-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV|A Phase I Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Are Infected With HIV|Completed||Phase 1|20|Anticipated|University of Oxford||2|||f||||t||||||||||2018-06-01 03:39:37.03422|2018-06-01 03:39:37.03422
NCT00395707|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2009-02-06|2006-11-01|2006-11-03|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2005||2005-08-31|February 2009|2009-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration|Phase I Study Of Intravitreal Ranibizumab (Lucentis) For The Treatment Of Stage 1 And 2 Retinal Angiomatous Proliferations|Completed||Phase 1/Phase 2|20|Anticipated|The National Retina Institute||2|||f||||||||||||||2018-06-01 03:39:37.137965|2018-06-01 03:39:37.137965
NCT00395655|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2006-11-01|2006-11-01|2006-11-03|Estimate|||||||2006-11-01|2006-11-03|Estimate|June 2005||2005-06-30|November 2006|2006-11-30|August 2006||2006-08-31|||||Interventional|||Hydralazine and Valproate Added to Chemotherapy for Breast Cancer|A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma|Terminated||Phase 2|43||National Institute of Cancerología|||||f||||||||||||||2018-06-01 03:39:38.38992|2018-06-01 03:39:38.38992
NCT00395642|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2009-12-14||2010-01-15|2006-11-01|2006-11-03|Estimate|2009-12-14|2010-01-18|Estimate||||2010-01-15|2010-01-20|Estimate|November 2006||2006-11-30|January 2010|2010-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||TRIAGE-CRT Telemonitoring in Patients With CHF and Indication of CRT-D|TRIAGE-CRT Telemonitoring in Patients With Congestive Heart Failure and Indication of ICD-Cardiac Resynchronization Therapy|Completed||Phase 4|66|Actual|Biotronik, Inc.||1|||f||||f||||||||||2018-06-01 03:39:38.579214|2018-06-01 03:39:38.579214
NCT00395629|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2010-12-06||2011-05-24|2006-11-02|2006-11-03|Estimate|2011-04-19|2011-05-18|Estimate||||2011-05-24|2011-05-30|Estimate|August 2006||2006-08-31|May 2011|2011-05-31|March 2009|Actual|2009-03-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis|A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis.|Completed||Phase 1/Phase 2|49|Actual|Novartis||1|||f||||f||||||||||2018-06-01 03:39:39.320626|2018-06-01 03:39:39.320626
NCT00395616|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2006-11-02|2006-11-02|2006-11-03|Estimate|||||||2006-11-02|2006-11-03|Estimate|November 2006||2006-11-30|November 2006|2006-11-30||||||||Interventional|||Comparison Between Type A Botulinum Toxin Injection and Corticosteroid Injection in the Treatment of Tennis Elbow||Unknown status|Recruiting|N/A|40||E-DA Hospital|||||f||||||||||||||2018-06-01 03:39:40.387843|2018-06-01 03:39:40.387843
NCT00395603|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2017-03-17|2006-11-02|2006-11-03|Estimate|||||||2017-03-17|2017-03-21|Actual|September 2006||2006-09-30|March 2017|2017-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)|Compare Ezetimibe 10mg and Simvastatin 40mg vs Atorvastatin 80mg Daily in Subjects With Cardiovascular Heart Disease and/or Diabetes Mellitus With Uncontrolled Lipids on Statin Therapy|Terminated||Phase 3|550|Anticipated|Merck Sharp & Dohme Corp.||||This study was terminated early due to poor recruitment.|f||||||||||||||2018-06-01 03:39:40.619207|2018-06-01 03:39:40.619207
NCT00395590|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2006-11-02|2006-11-02|2006-11-03|Estimate|||||||2006-11-02|2006-11-03|Estimate|November 2006||2006-11-30|February 2005|2005-02-28|November 2007||2007-11-30|||||Observational|||Polymorphisms in Inflammatory Cytokines Genes in Subjects With Obstructive Sleep Apnea|A Cross Sectional Study of Patients With Obstructive Sleep Apnea for Polymorphisms in Genes of Inflammatory Cytokines.|Unknown status|Not yet recruiting||100||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:39:40.676241|2018-06-01 03:39:40.676241
NCT00395577|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2007-12-05|2006-11-01|2006-11-03|Estimate|||||||2007-12-05|2007-12-07|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702|A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 When Administered Concomitantly With Methotrexate|Completed||Phase 2|120||Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 03:39:40.75778|2018-06-01 03:39:40.75778
NCT00395564|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2016-12-12|2006-11-01|2006-11-03|Estimate|||||||2016-12-12|2016-12-14|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Chart Review of Those Who Have Had Open, Laparoscopic, Ureteroscopic, or Percutaneous Surgery|Retrospective Chart Review of Patients Who Have Had an Open, Laparoscopic, Ureteroscopic or Percutaneous Surgery|Completed|||150|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-06-01 03:39:40.839747|2018-06-01 03:39:40.839747
NCT00395551|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2010-01-07|2006-11-02|2006-11-03|Estimate|||||||2010-01-07|2010-01-08|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.|A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.|Completed||Phase 1|30|Anticipated|Ophthalmic Consultants of Boston||1|||f||||f||||||||||2018-06-01 03:39:40.891216|2018-06-01 03:39:40.891216
NCT00395538|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2018-03-27|2006-11-02|2006-11-03|Estimate|||||||2018-03-27|2018-03-29|Actual|October 30, 2006||2006-10-30|March 12, 2018|2018-03-12|October 4, 2017|Actual|2017-10-04|September 30, 2017|Actual|2017-09-30||Interventional|||Effects of PTH Replacement on Bone in Hypoparathyroidism|Effects of PTH Replacement on Bone in Hypoparathyroidism|Completed||Phase 3|46|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 03:39:41.6081|2018-06-01 03:39:41.6081
NCT00395512|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2013-02-19|2009-07-30|2013-02-19|2006-11-01|2006-11-03|Estimate|2013-02-19|2013-03-27|Estimate|2009-07-30|2009-08-10|Estimate|2013-02-19|2013-03-27|Estimate|November 2006||2006-11-30|February 2013|2013-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes|Completed||Phase 3|655|Actual|Takeda||4|||f||||f||||||||||2018-06-01 03:39:42.631629|2018-06-01 03:39:42.631629
NCT00395499|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2016-06-21|2006-11-02|2006-11-03|Estimate|||||||2016-06-21|2016-06-23|Estimate|May 2001||2001-05-31|June 2016|2016-06-30|April 2003||2003-04-30|||||Observational|||Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva|Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva|Completed|||19||Ohio State University|||||f||||||||||||||2018-06-01 03:39:48.121963|2018-06-01 03:39:48.121963
NCT00395486|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2009-06-09||2011-06-30|2006-11-02|2006-11-03|Estimate|2011-05-17|2011-06-16|Estimate||||2011-06-30|2011-07-11|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||ROMEO (Rosuvastatin in Metabolic syndrOme)|A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C|Completed||Phase 4|258|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:39:48.286756|2018-06-01 03:39:48.286756
NCT00395473|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|||2017-03-07|2006-11-02|2006-11-03|Estimate|||||||2017-03-07|2017-03-08|Actual|March 2005||2005-03-31|March 2017|2017-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)|Ezetimibe Added to Statin Therapy|Completed||Phase 3|141|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:39:49.100318|2018-06-01 03:39:49.100318
NCT00395460|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-02|2011-07-04||2015-05-13|2006-11-02|2006-11-03|Estimate|2011-09-21|2011-11-01|Estimate||||2015-05-13|2015-06-08|Estimate|September 2006||2006-09-30|May 2015|2015-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients|A Single-blind, Multicenter, Randomized, Phase III Study of the Efficacy and Safety of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent for Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions in Chinese Patients|Completed||Phase 3|147|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:39:49.241729|2018-06-01 03:39:49.241729
NCT00395447|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2010-08-24||2015-03-24|2006-11-02|2006-11-03|Estimate|2010-11-01|2010-11-30|Estimate||||2015-03-24|2015-04-14|Estimate|July 2007||2007-07-31|March 2015|2015-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|REPLACE||REPLACE: Implantable Cardiac Pulse Generator Replacement Registry|Prospective Assessment of the Complication Rate After Device Replacement Due to ERI, Advisory or Upgrade|Completed|||1744|Actual|Biotronik, Inc.|||2||f||||t||||||||||2018-06-01 03:39:49.888035|2018-06-01 03:39:49.888035
NCT00395434|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2011-10-28|2006-11-01|2006-11-02|Estimate|||||||2011-10-28|2011-10-31|Estimate|September 2006||2006-09-30|October 2011|2011-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors|OXC4P1-105: A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Combretastatin A4 Phosphate Given in Combination With Bevacizumab to Subjects With Advanced Solid Tumors|Completed||Phase 1|20|Anticipated|Mateon Therapeutics|||||f||||||||||||||2018-06-01 03:39:50.219923|2018-06-01 03:39:50.219923
NCT00395421|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2010-06-09|2006-11-01|2006-11-02|Estimate|||||||2010-06-09|2010-06-10|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin|A Partially-blinded, Randomized, Parallel-group Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between Valopicitabine and Ribavirin When Administered in Combination With Pegylated Interferon Alfa-2a in Treatment-naive Patients With Chronic Hepatitis C|Completed||Phase 2|114|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 03:39:50.33567|2018-06-01 03:39:50.33567
NCT00395408|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2017-02-15|2006-11-01|2006-11-02|Estimate|||||||2017-02-15|2017-02-16|Actual|June 2000||2000-06-30|February 2017|2017-02-28|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Linear Growth Study (0476-097)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel-Group Study Comparing the Effect on Linear Growth of Montelukast With Placebo and Inhaled Beclomethasone in Pediatric Patients (Prepubertal, Tanner Stage I) With Mild Asthma|Completed||Phase 4|360|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:39:50.470717|2018-06-01 03:39:50.470717
NCT00395395|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2007-05-25|2006-10-31|2006-11-02|Estimate|||||||2007-05-25|2007-05-28|Estimate|October 2006||2006-10-31|May 2007|2007-05-31||||||||Interventional|||Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women|A Partially-Blind, Randomized, Single-Dose, Placebo-Controlled Crossover Phase I Study Assessing the Effect of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of SMC021 0.8 mg in Healthy Postmenopausal Women|Completed||Phase 1|56|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:39:50.616332|2018-06-01 03:39:50.616332
NCT00395382|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2010-02-08|2006-11-01|2006-11-02|Estimate|||||||2010-02-08|2010-02-09|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease|Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study|Completed||Phase 4|50|Anticipated|Monash University||2|||f||||t||||||||||2018-06-01 03:39:50.719935|2018-06-01 03:39:50.719935
NCT00395369|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2006-11-02|2006-11-01|2006-11-02|Estimate|||||||2006-11-02|2006-11-03|Estimate|December 2007||2007-12-31|November 2006|2006-11-30||||||||Interventional|||Effect of Intraoperative Aprotinin Administration on Post Cardiac Surgery Optic Nerve and Retinal Thickness.||Unknown status|Not yet recruiting|N/A|30||Soroka University Medical Center|||||f||||||||||||||2018-06-01 03:39:50.914121|2018-06-01 03:39:50.914121
NCT00395356|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2006-11-01|2006-11-01|2006-11-02|Estimate|||||||2006-11-01|2006-11-02|Estimate|September 2005||2005-09-30|November 2006|2006-11-30|June 2007||2007-06-30|||||Interventional|||Efficacy and Feasibility of an Intermittent Weight Loss Program.|Efficacy and Feasibility of an Intermittent Weight Loss Program: A Pilot Study.|Completed||N/A|20||Université de Sherbrooke|||||f||||||||||||||2018-06-01 03:39:51.01986|2018-06-01 03:39:51.01986
NCT00395343|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2009-09-18||2017-04-06|2006-11-01|2006-11-02|Estimate|2009-09-18|2009-10-23|Estimate||||2017-04-06|2017-05-12|Actual|December 11, 2006|Actual|2006-12-11|April 2017|2017-04-30|October 13, 2008|Actual|2008-10-13|October 13, 2008|Actual|2008-10-13||Interventional|||Sitagliptin Added-on to Insulin Study (0431-051)|A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)|Completed||Phase 3|641|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:39:51.186759|2018-06-01 03:39:51.186759
NCT00395330|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2015-08-19|2006-11-01|2006-11-02|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2003||2003-04-30|August 2015|2015-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Airways Dysfunction Following WTC Dust Exposure|Airways Dysfunction Following WTC Dust Exposure|Completed|||500||New York University School of Medicine|||||f||||||||||||||2018-06-01 03:39:51.863453|2018-06-01 03:39:51.863453
NCT00395317|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01||2010-08-12|2012-04-05|2006-11-01|2006-11-02|Estimate||||2011-08-05|2011-08-15|Estimate|2012-04-05|2012-04-09|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)|Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|343|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-06-01 03:39:51.941645|2018-06-01 03:39:51.941645
NCT00395304|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2010-05-17||2018-03-25|2006-11-01|2006-11-02|Estimate|2010-08-23|2010-09-17|Estimate||||2018-03-25|2018-04-25|Actual|March 2007||2007-03-31|March 2018|2018-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|BADGER||Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)|Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)|Completed||Phase 3|182|Actual|Milton S. Hershey Medical Center|The study was not designed or powered to evaluate the long-term safety of long-acting beta-agonists in children. The duration of the trial and its sample size preclude statements regarding long-term risks.|6|||f||||t||||||||||2018-06-01 03:39:52.230456|2018-06-01 03:39:52.230456
NCT00395291|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2011-08-02||2017-01-03|2006-11-01|2006-11-02|Estimate|2011-11-30|2012-01-06|Estimate||||2017-01-03|2017-02-20|Actual|August 2006||2006-08-31|January 2017|2017-01-31|May 2010|Actual|2010-05-31|January 2009|Actual|2009-01-31||Interventional|||Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients|Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients|Completed||N/A|49|Actual|University of Virginia|We completed the appropriate number of subjects to get the statistical data needed. We had several screen fails (subjects that did not meet the inclusion/exclusion criteria.)|2|||f||||t||||||||||2018-06-01 03:39:53.051125|2018-06-01 03:39:53.051125
NCT00395278|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2018-04-04|2006-10-31|2006-11-02|Estimate|||||||2018-04-04|2018-04-05|Actual|October 30, 2006||2006-10-30|March 7, 2018|2018-03-07||||||||Observational|||Development of Serologic Assays for Human Herpes Virus-8|Development of Serologic Assays for Human Herpes Virus-8|Active, not recruiting|||429|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:39:53.592303|2018-06-01 03:39:53.592303
NCT00395265|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2012-01-26|2006-10-31|2006-11-02|Estimate|||||||2012-01-26|2012-01-31|Estimate|June 2006||2006-06-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome|Association of Thrombophilia and Inflammation With Post-Thrombotic Syndrome|Completed|||2211|Actual|University of Vermont|||||f||||f||||||||||2018-06-01 03:39:53.732096|2018-06-01 03:39:53.732096
NCT00395252|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2015-10-01|2006-11-01|2006-11-02|Estimate|||||||2015-10-01|2015-10-02|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|November 2010|Actual|2010-11-30||Interventional|ATIP||Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer|Multicenter Phase II-trial to Investigate Safety and Efficacy of an Adjuvant Therapy With Gemcitabine and Erbitux® in Patients With R0 or R1 Resected Pancreatic Cancer|Completed||Phase 2|76|Actual|Philipps University Marburg Medical Center||1|||f||||t||||||||||2018-06-01 03:39:53.811381|2018-06-01 03:39:53.811381
NCT00395239|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2016-05-24|2006-11-01|2006-11-02|Estimate|||||||2016-05-24|2016-05-26|Estimate|October 2006||2006-10-31|August 2010|2010-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Asthma/Steroid Withdrawal Study|The Temporal Sequence of Inflammatory Mediators During a Controlled Exacerbation of Asthma by Steroid Withdrawal.|Terminated||Phase 4|6|Actual|University of Alberta||1||This project will resume upon the completion of other research committments.|f||||t||||||||||2018-06-01 03:39:53.930376|2018-06-01 03:39:53.930376
NCT00395226|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2011-06-03||2011-06-03|2006-11-01|2006-11-02|Estimate|2011-06-03|2011-06-30|Estimate||||2011-06-03|2011-06-30|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial|"Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial. Prospective, Double Blind, Randomized, Controlled Trial Comparing the Effects of Supplemental Zinc Sulfate and Placebo on the Severity of Rosacea."|Terminated||N/A|65|Actual|Essentia Health||2||Difficulty recruiting subjects|f||||f||||||||||2018-06-01 03:39:54.231367|2018-06-01 03:39:54.231367
NCT00395213|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2015-04-16|2006-10-31|2006-11-02|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|ASK||Antidepressant Safety in Kids Study|Antidepressant Safety in Kids (ASK) Study: An Open-label, Prospective, Cohort Study of Antidepressants in Children and Adolescents With Anxiety Disorders, Depressive Disorders, Eating Disorders, or Obsessive-Compulsive Disorder|Completed|||569|Actual|Duke University|||1||f||||t||||||||||2018-06-01 03:39:54.810507|2018-06-01 03:39:54.810507
NCT00395200|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2011-10-22|2006-11-01|2006-11-02|Estimate|||||||2011-10-22|2011-10-25|Estimate|July 2008||2008-07-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MSCIMS||Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)|Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis|Completed||Phase 1/Phase 2|10|Actual|University of Cambridge||1|||f||||t||||||||||2018-06-01 03:39:54.970131|2018-06-01 03:39:54.970131
NCT00395187|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2007-10-04|2006-11-01|2006-11-02|Estimate|||||||2007-10-04|2007-10-10|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa|A Small Clinical Study: Photodynamic Therapy to Treat Hidradenitis Suppurativa|Completed||N/A|15|Anticipated|University of Kansas Medical Center|||||f||||f||||||||||2018-06-01 03:39:55.090465|2018-06-01 03:39:55.090465
NCT00395174|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2009-12-16|2006-11-01|2006-11-02|Estimate|||||||2009-12-16|2009-12-17|Estimate|October 2006||2006-10-31|December 2009|2009-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults|Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine, to a Licensed Egg-Grown Influenza Vaccine In Ambulatory Elderly Adults|Completed||Phase 3|870|Actual|Protein Sciences Corporation||2|||f||||t||||||||||2018-06-01 03:39:55.157868|2018-06-01 03:39:55.157868
NCT00395161|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2012-11-14||2013-04-16|2006-10-31|2006-11-02|Estimate|2013-04-16|2013-04-18|Estimate||||2013-04-16|2013-04-18|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|CRISIS||The CRISIS Prevention Study|The Critical Illness Stress-induced Immune Suppression Prevention Trial|Terminated||Phase 3|293|Actual|University of Utah|The Data Safety Monitoring Board met on November 30, 2009. Interim analysis of the first 273 patients was presented. Per the Board's recommendations, the study was terminated based on futility.|2||Terminated for futility on 11/30/09 based on the recommendation of the DSMB|f||||t||||||||||2018-06-01 03:39:55.317568|2018-06-01 03:39:55.317568
NCT00395148|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2011-05-09|2006-10-31|2006-11-02|Estimate|||||||2011-05-09|2011-05-10|Estimate|March 2006||2006-03-31|October 2006|2006-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Improving Metabolism With HDL Cholesterol|A Novel Mechanism Mediating Anti-atherosclerotic and Metabolic Actions of HDL Cholesterol|Completed||N/A|13|Actual|Bayside Health|||||f||||f||||||||||2018-06-01 03:39:56.074833|2018-06-01 03:39:56.074833
NCT00395135|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2013-01-04|2012-07-26|2013-01-04|2006-10-31|2006-11-02|Estimate|2013-01-04|2013-02-07|Estimate|2012-08-06|2012-08-14|Estimate|2013-01-04|2013-02-07|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management|BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management; A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients|Completed||Phase 3|3182|Actual|Arena Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:39:56.186813|2018-06-01 03:39:56.186813
NCT00395122|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2006-11-01|2006-11-01|2006-11-02|Estimate|||||||2006-11-01|2006-11-02|Estimate|April 2005||2005-04-30|November 2006|2006-11-30|October 2006||2006-10-31|||||Interventional|||Optical Coherence Tomography Measurements in Eyes With Band Atrophy|Evaluation of the Diagnostic Ability of Optical Coherence Tomography With a Normative Database to Detect Band Atrophy of the Optic Nerve|Completed||N/A|30||University of Sao Paulo|||||f||||||||||||||2018-06-01 03:39:57.138478|2018-06-01 03:39:57.138478
NCT00395096|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2009-02-17|2006-10-31|2006-11-02|Estimate|||||||2009-02-17|2009-02-19|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|||||Observational|||Environmental Exposures, Genetics, and Exhaled Nitric Oxide in Pediatric Asthma|Environmental Exposures, NOS Genes, and Exhaled Nitric Oxide in Pediatric Asthma|Completed|||225|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||f||||||Samples With DNA|"~     Blood and urine~   "|||2018-06-01 03:39:57.267635|2018-06-01 03:39:57.267635
NCT00395083|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2014-08-04||2014-09-04|2006-11-01|2006-11-02|Estimate|2014-08-04|2014-08-21|Estimate||||2014-09-04|2014-09-15|Estimate|July 2006||2006-07-31|September 2014|2014-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|BREATH||Bronchitis and Emphysema Advice and Training to Reduce Hospitalization|CSP #560 - Bronchitis and Emphysema Advice and Training to Reduce Hospitalization (BREATH)|Terminated||Phase 2|426|Actual|VA Office of Research and Development||2||The DMC detected an imbalance in safety outcomes between the two groups.|f||||t||||||||||2018-06-01 03:39:57.336385|2018-06-01 03:39:57.336385
NCT00395070|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2013-09-11|2006-10-31|2006-11-02|Estimate|||||||2013-09-11|2013-09-13|Estimate|October 2006||2006-10-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|March 2012|Actual|2012-03-31||Interventional|||A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma|A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment With 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects With Recurrent Metastatic Melanoma|Completed||Phase 3|390|Actual|Vical||2|||f||||t||||||||||2018-06-01 03:39:58.348059|2018-06-01 03:39:58.348059
NCT00395057|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2011-11-09||2015-08-25|2006-10-31|2006-11-02|Estimate|2011-11-09|2011-12-13|Estimate||||2015-08-25|2015-09-07|Estimate|January 2007||2007-01-31|August 2015|2015-08-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration||Terminated||Phase 2|138|Actual|Allergan|"The study was terminated early due to a company decision (non-safety related). Because the study was terminated early, data for certain outcome measures (ie, Visual Functioning Questionnaire [VFQ] at Month 3) were not analyzed."|4||The study was terminated early due to company decision (non-safety related).|f||||||||||||||2018-06-01 03:39:58.65939|2018-06-01 03:39:58.65939
NCT00395044|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2013-03-15||2016-12-19|2006-11-01|2006-11-02|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|August 2006||2006-08-31|December 2016|2016-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||All subjects who received a randomization number and packet of medication at week 1 were included in primary and secondary outcomes|Gabapentin Treatment of Cannabis Dependence|Gabapentin for Cannabis Withdrawal and Use|Completed||Phase 2|50|Actual|The Scripps Research Institute||2|||f||||f||||||||||2018-06-01 03:39:59.247654|2018-06-01 03:39:59.247654
NCT00395031|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2011-07-28|2006-11-01|2006-11-02|Estimate|||||||2011-07-28|2011-07-29|Estimate|September 2003||2003-09-30|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder|The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder|Completed||Phase 2/Phase 3|57|Actual|Manhattan Psychiatric Center||1|||f||||t||||||||||2018-06-01 03:39:59.731977|2018-06-01 03:39:59.731977
NCT00395018|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2012-03-29||2012-04-30|2006-11-01|2006-11-02|Estimate|2012-04-30|2012-05-31|Estimate||||2012-04-30|2012-05-31|Estimate|April 2007||2007-04-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection|Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection|Completed||Phase 3|109|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:39:59.870959|2018-06-01 03:39:59.870959
NCT00395005|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2007-03-22|2006-11-01|2006-11-02|Estimate|||||||2007-03-22|2007-03-23|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|October 2006||2006-10-31|||||Observational|||Correlation of Urinary Kallikrein With Cytokines, Proteinuria and Renal Function in Chronic Renal Disease Patients|The Correlation of Urine Tissue Kallikrein Protein Level With Cytokines, Degree of Proteinuria and Renal Function Deterioration in Chronic Renal Disease Patients After Angiotensin II Receptor Blocking|Completed|||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:40:00.601941|2018-06-01 03:40:00.601941
NCT00394992|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2014-02-03|2006-11-01|2006-11-02|Estimate|||||||2014-02-03|2014-02-04|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer|Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone|Terminated||Phase 3|79|Actual|Dutch Colorectal Cancer Group||2||Data from the C08 study and Avant study|f||||t||||||||||2018-06-01 03:40:00.671617|2018-06-01 03:40:00.671617
NCT00394966|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2009-10-22|2006-10-31|2006-11-02|Estimate|||||||2009-10-22|2009-10-23|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)|A Phase 2, MultiCenter, Randomized, Placebo-Controlled, Double-Blind, Dose Finding Study to Determine the Safety and Efficacy of SCH 619734 for the Treatment of Chemotherapy Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)|Completed||Phase 2|450|Anticipated|Schering-Plough||5|||f||||f||||||||||2018-06-01 03:40:00.74207|2018-06-01 03:40:00.74207
NCT00394953|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2016-08-12||2016-11-23|2006-11-01|2006-11-02|Estimate|2016-11-23|2017-01-20|Estimate||||2016-11-23|2017-01-20|Estimate|December 2006||2006-12-31|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional||The Safety Population was defined as all participants who received at least one dose of methoxy polyethylene glycol-epoetin beta or darbepoetin alfa and had a safety follow-up, whether withdrawn prematurely or not.|A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients|A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis|Completed||Phase 3|490|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:40:00.836292|2018-06-01 03:40:00.836292
NCT00394940|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2017-12-04|2006-10-31|2006-11-02|Estimate|||||||2017-12-04|2017-12-06|Actual|July 2006||2006-07-31|December 2017|2017-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Identifying Inflammatory Biomarkers of Chronic Obstructive Pulmonary Disease|Serum Inflammatory Biomarkers as Predictors of COPD Morbidity and Mortality|Completed|||2085|Actual|University of Arizona|||||f||||f||||||Samples With DNA|"~     DNA, serum, supernatants~   "|||2018-06-01 03:40:03.238869|2018-06-01 03:40:03.238869
NCT00394927|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|||2012-07-18|2006-11-01|2006-11-02|Estimate|||||||2012-07-18|2012-07-19|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Adverse Event Scale in Patients With Epilepsy (aEscape) - A European Survey for Physicians With Epilepsy Patients|A Multicenter, Non-interventional Surveillance Study to Evaluate the Adverse Effects of Antiepileptic Drug Treatment in Patients With Epilepsy|Completed|||1000|Anticipated|UCB Pharma|||||f||||||||||||||2018-06-01 03:40:03.537568|2018-06-01 03:40:03.537568
NCT00394914|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2013-08-27||2015-06-23|2006-10-31|2006-11-02|Estimate|2013-08-27|2013-10-31|Estimate||||2015-06-23|2015-07-16|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)|A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure|Completed||Phase 2|311|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:40:04.208002|2018-06-01 03:40:04.208002
NCT00394901|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2008-11-07||2010-02-26|2006-10-31|2006-11-02|Estimate|2009-01-26|2009-02-27|Estimate||||2010-02-26|2010-03-02|Estimate|September 2006||2006-09-30|February 2010|2010-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia|A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia|Completed||Phase 3|372|Actual|Pfizer||4|||f||||||||||||||2018-06-01 03:40:06.196619|2018-06-01 03:40:06.196619
NCT00394888|ClinicalTrials.gov processed this data on May 31, 2018|2006-11-01|2011-05-04||2013-09-17|2006-11-01|2006-11-02|Estimate|2011-06-09|2011-07-06|Estimate||||2013-09-17|2013-09-20|Estimate|November 2005||2005-11-30|September 2013|2013-09-30|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||Hemangioma Associated With High Rates of Morbidity|Hemangioma Associated With High Rates of Morbidity:A Prospective Study|Completed||N/A|433|Actual|Medical College of Wisconsin||3|||f||||f||||||||||2018-06-01 03:40:08.858001|2018-06-01 03:40:08.858001
NCT00394875|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2006-10-31|2006-10-31|2006-11-02|Estimate|||||||2006-10-31|2006-11-02|Estimate|March 2002||2002-03-31|October 2006|2006-10-31|January 2005||2005-01-31|||||Interventional|||The Diabetes Specialist Nurse as Delegated Main Care Provider for Patients With Type 2 Diabetes|The Diabetes Specialist Nurse as Delegated Main Care Provider for Patients With Type 2 Diabetes in a Secondary Care Setting: a Randomized Controlled Trial.|Completed||N/A|81||Medical Research Foundation, The Netherlands|||||f||||||||||||||2018-06-01 03:40:09.202634|2018-06-01 03:40:09.202634
NCT00394862|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2012-03-29|2006-10-31|2006-11-01|Estimate|||||||2012-03-29|2012-04-02|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Efficacy of Weekly Versus Daily Folic Acid Supplementation||Completed||N/A|460||Emory University|||||f||||||||||||||2018-06-01 03:40:09.266292|2018-06-01 03:40:09.266292
NCT00394849|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2017-11-03|2006-10-30|2006-11-01|Estimate|||||||2017-11-03|2017-11-07|Actual|July 2000||2000-07-31|November 2017|2017-11-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Effect of Tonsillar Pillar Closure on Postoperative Pain and Bleeding Risk After Tonsillectomy|Effect of Tonsillar Pillar Closure on Postoperative Pain and Bleeding Risk After Tonsillectomy|Completed||N/A|763|Actual|Indiana University||2|||f||||f||||||||No||2018-06-01 03:40:09.323113|2018-06-01 03:40:09.323113
NCT00394836|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2011-07-28||2013-12-12|2006-10-31|2006-11-01|Estimate|2011-11-03|2011-12-08|Estimate||||2013-12-12|2014-01-29|Estimate|May 2007||2007-05-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|April 2009|Actual|2009-04-30||Interventional|||HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab|A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Follicular Lymphoma Who Are Refractory to Rituximab as Monotherapy or in Combination With Chemotherapy|Completed||Phase 2|116|Actual|GlaxoSmithKline|||||f||||t||||||||||2018-06-01 03:40:09.449207|2018-06-01 03:40:09.449207
NCT00394823|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2017-05-16|2006-10-31|2006-11-01|Estimate|||||||2017-05-16|2017-05-18|Actual|November 2005||2005-11-30|May 2017|2017-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients|A Randomized, Open-label, Multicentric Parallel Group Study to Assess the Impact of Supportive Measures on the Drug Adherence of Patients With Essential Hypertension Treated With Valsartan or Valsartan Plus HCTZ for 34 Weeks With or Without Respective Measures|Completed||Phase 3|206|Actual|Novartis|||||f||||||||||||||2018-06-01 03:40:10.447794|2018-06-01 03:40:10.447794
NCT00394810|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2008-11-24|2006-10-30|2006-11-01|Estimate|||||||2008-11-24|2008-11-25|Estimate|November 2006||2006-11-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer|Phase 2 Efficacy and Pharmacodynamic Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion(Panzem® NCD) in Patients With Taxane-Refractory, Metastatic,Hormone-Refractory Prostate Cancer|Completed||Phase 2|21|Actual|CASI Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 03:40:10.527294|2018-06-01 03:40:10.527294
NCT00394797|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2011-05-31|2006-10-31|2006-11-01|Estimate|||||||2011-05-31|2011-06-01|Estimate||||May 2011|2011-05-31||||||||Observational|||Surgical Correction of Moderate Ischemic Mitral Regurgitation||Completed|||||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:40:10.587787|2018-06-01 03:40:10.587787
NCT00394784|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2017-06-09|2006-10-31|2006-11-01|Estimate|||||||2017-06-09|2017-06-12|Actual|December 2006||2006-12-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates|Surveillance Study - Incidence of Antibiotic Resistance in Serial Gram-negative Bloodstream Isolates|Enrolling by invitation|||100|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:40:10.639002|2018-06-01 03:40:10.639002
NCT00394407|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2013-11-20|2006-10-31|2006-11-01|Estimate|||||||2013-11-20|2013-11-21|Estimate|September 2005||2005-09-30|November 2013|2013-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes|Comparative Trial Between Insulin Glargine Plus Supplemental Glulisine (Apidra) Versus Sliding Scale Regular Insulin In Hospitalized Patients With Type 2 Diabetes|Completed||Phase 4|130|Actual|Emory University||2|||f||||t||||||||||2018-06-01 03:40:16.734625|2018-06-01 03:40:16.734625
NCT00394771|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2013-04-25|2011-06-08|2013-07-12|2006-10-30|2006-11-01|Estimate|2013-04-25|2013-06-19|Estimate|2011-06-08|2011-06-22|Estimate|2013-07-12|2013-07-26|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||ITT population|A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale|A Prospective, Multicenter, Double-Blinded, Randomized Study to Evaluate Bleeding Patterns in Women Using One of Three Different Doses of DR-1031 Oral Contraceptive Compared to Seasonale Oral Contraceptive Regimen|Completed||Phase 2|567|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-06-01 03:40:10.729798|2018-06-01 03:40:10.729798
NCT00394758|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2006-10-30|2006-10-30|2006-11-01|Estimate|||||||2006-10-30|2006-11-01|Estimate|January 2000||2000-01-31|October 2006|2006-10-31|December 2005||2005-12-31|||||Interventional|||A Randomized Trial of Surgical Treatments for Vulvar and Vaginal Dysplasia|Comparison of Surgical Procedures in Vulvar and Vaginal Dysplasias|Completed||Phase 3|150||University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-06-01 03:40:11.93499|2018-06-01 03:40:11.93499
NCT00394745|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2017-02-22|2006-10-31|2006-11-01|Estimate|||||||2017-02-22|2017-02-24|Actual|November 2005||2005-11-30|February 2017|2017-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome|A 12 Week Treatment, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome|Completed||Phase 3|45|Actual|Novartis|||||f||||||||||||||2018-06-01 03:40:12.087076|2018-06-01 03:40:12.087076
NCT00394732|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2012-10-11|2006-10-31|2006-11-01|Estimate|||||||2012-10-11|2012-10-12|Estimate|April 2004||2004-04-30|October 2012|2012-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Disc Prosthesis Versus Multidisciplinary Rehabilitation|Effect of Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation Program in Patients With Chronic Low Back Pain and Degenerative Disc. A Prospective Randomized Clinical Multicentre Trial.|Completed||N/A|179|Actual|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:40:12.179101|2018-06-01 03:40:12.179101
NCT00394706|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2012-03-23||2012-04-26|2006-10-30|2006-11-01|Estimate|2012-03-23|2012-04-18|Estimate||||2012-04-26|2012-04-30|Estimate|June 2007||2007-06-30|April 2012|2012-04-30|July 2010|Actual|2010-07-31|November 2009|Actual|2009-11-30||Interventional|||Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve|Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve and Early Versus Delayed Analysis|Terminated||Phase 3|11738|Actual|University of Washington||4||Terminated because preliminary data suggested no difference in the strategies.|f||||t||||||||||2018-06-01 03:40:12.26365|2018-06-01 03:40:12.26365
NCT00394693|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2014-07-15|2006-10-31|2006-11-01|Estimate|||||||2014-07-15|2014-07-16|Estimate|November 2006||2006-11-30|July 2014|2014-07-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma|Phase II Clinical Trial of Intra-lesional Administration of TG1042 (Adenovirus-Interferon-gamma) in Patients With Relapsing Primary Cutaneous B-Cell Lymphomas.|Completed||Phase 2|13|Actual|Transgene|||||f||||||||||||||2018-06-01 03:40:12.925536|2018-06-01 03:40:12.925536
NCT00394680|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2011-05-26|2006-10-31|2006-11-01|Estimate|||||||2011-05-26|2011-05-27|Estimate|November 2006||2006-11-30|May 2011|2011-05-31|May 2007|Actual|2007-05-31|||||Observational|||Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.|Stents, Drug Eluting Stents, and CABG- Financial and Clinical Impact.|Completed|||700|Anticipated|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:40:12.992937|2018-06-01 03:40:12.992937
NCT00394667|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2013-04-19|2006-10-31|2006-11-01|Estimate|||||||2013-04-19|2013-04-22|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|September 2007|Actual|2007-09-30|||||Interventional|||Effect of Tesofensine on Weight Reduction in Patients With Obesity.|Effect of Tesofensine on Weight Reduction in Patients With Obesity. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study.|Completed||Phase 2|200|Anticipated|NeuroSearch A/S|||||f||||||||||||||2018-06-01 03:40:13.05566|2018-06-01 03:40:13.05566
NCT00394654|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2013-10-18||2013-10-18|2006-10-31|2006-11-01|Estimate|2013-10-18|2013-12-11|Estimate||||2013-10-18|2013-12-11|Estimate|November 2006||2006-11-30|October 2013|2013-10-31|January 2008|Actual|2008-01-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma|Completed||Phase 2|30|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 03:40:13.13854|2018-06-01 03:40:13.13854
NCT00394641|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2006-10-31|2006-10-31|2006-11-01|Estimate|||||||2006-10-31|2006-11-01|Estimate||||October 2006|2006-10-31||||||||Interventional|||Impact of Listening to Low Tones on Motor Function in Children With CP|Impact of Listening to Low Tones Via Sterephonic Headphones on Hypertonia and Motor Function in Children With Cerebral Palsy- Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|30||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:40:13.810845|2018-06-01 03:40:13.810845
NCT00394628|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2007-05-29|2006-10-31|2006-11-01|Estimate|||||||2007-05-29|2007-05-30|Estimate|October 2006||2006-10-31|May 2007|2007-05-31||||||||Interventional|||AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme|A Phase 1b/2a, Multicenter, Open-Label Study of AQ4N in Combination With Radiation Therapy and Temozolomide, to Evaluate the Safety, Tolerability, and Efficacy in Subjects With Newly Diagnosed Glioblastoma Multiforme|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Novacea|||||f||||||||||||||2018-06-01 03:40:13.882049|2018-06-01 03:40:13.882049
NCT00394615|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2010-03-25|2006-10-31|2006-11-01|Estimate|||||||2010-03-25|2010-03-29|Estimate|October 2003||2003-10-31|March 2010|2010-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA|Metabolic Imaging: Predicting Histopathologic Response to Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer|Terminated||N/A|15|Anticipated|Stanford University||||Protocol approval expired|f||||||||||||||2018-06-01 03:40:13.977319|2018-06-01 03:40:13.977319
NCT00394602|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2018-05-07|2006-10-30|2006-11-01|Estimate|||||||2018-05-07|2018-05-11|Actual|April 7, 2004|Actual|2004-04-07|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Chemoradiation-Induced Nausea and Emesis: Quality of Life|Chemoradiation-Induced Nausea and Emesis: A Prospective Study to Assess Patient Preferences and Quality of Life|Active, not recruiting|||207|Actual|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-06-01 03:40:14.061165|2018-06-01 03:40:14.061165
NCT00394394|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2006-10-30|2006-10-30|2006-11-01|Estimate|||||||2006-10-30|2006-11-01|Estimate|February 2005||2005-02-28|October 2006|2006-10-31||||||||Interventional|||Antihypertensive Effectiveness of the Associations of Hydrochlorothiazide and Amiloride and Hydrochlorothiazide and Enalapril|Hydrochlorothiazide and Amiloride vs Hydrochlorothiazide and Enalapril: a Randomized Clinical Trial of Antihypertensive Effectiveness.|Completed||Phase 2|||Hospital de Clinicas de Porto Alegre|||||f||||||||||||||2018-06-01 03:40:16.818275|2018-06-01 03:40:16.818275
NCT00394589|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2009-10-28||2017-03-13|2006-10-31|2006-11-01|Estimate|2009-12-17|2010-01-21|Estimate||||2017-03-13|2017-04-11|Actual|March 2006||2006-03-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|Re³||Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)|Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.|Terminated||Phase 3|43|Actual|Merck Sharp & Dohme Corp.||3||Study enrollment was stopped due to insufficient subject accrual.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:40:14.155507|2018-06-01 03:40:14.155507
NCT00394576|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2009-02-13|2006-10-30|2006-11-01|Estimate|||||||2009-02-13|2009-02-16|Estimate|November 2006||2006-11-30|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Assessing Novel Methods of Improving Patient Education of Nutrition|Assessing Novel Methods of Improving Patient Education of Nutrition: eHealth, Health Literacy and Chronic Kidney Disease|Unknown status|Recruiting|N/A|180|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 03:40:14.485196|2018-06-01 03:40:14.485196
NCT00394563|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30||2009-04-04|2009-10-07|2006-10-30|2006-11-01|Estimate||||2009-10-07|2009-10-12|Estimate|2009-10-07|2009-10-12|Estimate|March 2006||2006-03-31|October 2009|2009-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain|A Randomized, Parallel Arm, Placebo-Controlled, Double-Blind, Multiple-Dose Study of the Safety and Efficacy of RN624 in Adults With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee|Completed||Phase 2|450|Actual|Pfizer||6|||f||||t||||||||||2018-06-01 03:40:14.586901|2018-06-01 03:40:14.586901
NCT00394550|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2018-01-20|2006-10-31|2006-11-01|Estimate|||||||2018-01-20|2018-01-23|Actual|January 2002|Actual|2002-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty|Treatment of Children With Obstructive Sleep Apnea and Laryngomalacia: the Role of Laser Supraglottoplasty|Active, not recruiting||N/A|160|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 03:40:14.818332|2018-06-01 03:40:14.818332
NCT00394537|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2007-06-04|2006-10-31|2006-11-01|Estimate|||||||2007-06-04|2007-06-06|Estimate||||May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy||Completed||Phase 4|72|Anticipated|Rabin Medical Center|||||f||||||||||||||2018-06-01 03:40:14.899367|2018-06-01 03:40:14.899367
NCT00394524|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2008-12-08||2013-11-12|2006-10-31|2006-11-01|Estimate|2013-07-26|2013-09-30|Estimate||||2013-11-12|2013-12-05|Estimate|June 2006||2006-06-30|November 2013|2013-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU|Comparative Trial Between a Computer-Guided Intravenous Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU|Completed||N/A|157|Actual|Emory University||2|||f||||t||||||||||2018-06-01 03:40:14.963094|2018-06-01 03:40:14.963094
NCT00394511|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2013-02-08|2006-10-31|2006-11-01|Estimate|||||||2013-02-08|2013-02-11|Estimate|August 1988||1988-08-31|October 2006|2006-10-31||||December 2006|Actual|2006-12-31||Interventional|||Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer|Phase III Randomized Evaluation of Adjuvant Radiotherapy vs No Adjuvant Therapy Following Radical Prostatectomy and Pelvic Lymphadenectomy in Surgical Stage C Adenocarcinoma of the Prostate|Completed||Phase 3|408|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:40:15.217187|2018-06-01 03:40:15.217187
NCT00394498|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2006-10-30|2006-10-30|2006-11-01|Estimate|||||||2006-10-30|2006-11-01|Estimate|September 2005||2005-09-30|October 2006|2006-10-31|October 2006||2006-10-31|||||Interventional|||Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair|Stem Cell Mobilization by G-CSF by Granulocyte Colony Stimulating Factor Post Myocardial Infarction to Promote Myocyte Repair|Unknown status|Recruiting|Phase 2/Phase 3|86||University of Ottawa|||||f||||||||||||||2018-06-01 03:40:15.364218|2018-06-01 03:40:15.364218
NCT00394485|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2009-12-15|2006-10-31|2006-11-01|Estimate|||||||2009-12-15|2009-12-17|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|April 2008||2008-04-30|||||Interventional|||Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients|A Randomized Crossover Trial Comparing the Efficacy and Safety of Tiotropium + Procaterol vs. Tiotropium + Placebo in Moderate COPD Patients|Terminated||Phase 4|50|Anticipated|Otsuka Pharmaceutical, Inc., Philippines||||Difficulty in recruting patients|f||||||||||||||2018-06-01 03:40:15.513977|2018-06-01 03:40:15.513977
NCT00394472|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2011-08-11||2013-02-14|2006-10-31|2006-11-01|Estimate|2013-02-14|2013-03-18|Estimate||||2013-02-14|2013-03-18|Estimate|November 2006||2006-11-30|February 2013|2013-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients|A Randomized, Double-blind, Placebo Controlled, Phase IIA Study to Assess the Effect on Gastroesophageal Reflux Disease (GERD) Symptoms, Pharmacokinetics, Safety and Tolerability of 4 Weeks Treatment With AZD3355 65 mg Bid as add-on Treatment to a Proton Pump Inhibitor (PPI) in Patients With an Incomplete Response to PPI.|Completed||Phase 2|244|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:40:15.604309|2018-06-01 03:40:15.604309
NCT00394459|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2011-05-12|2006-10-31|2006-11-01|Estimate|||||||2011-05-12|2011-05-13|Estimate|April 2005||2005-04-30|May 2011|2011-05-31|May 2009|Actual|2009-05-31|March 2008|Actual|2008-03-31||Interventional|||Safety of Two Epidural Catheters in Thoracic Epidural Anaesthesia (TEA)|Randomised, Prospective, Single-blind, Controlled Multicenter Study on the Safety of Two Epidural Catheters in Patients Undergoing Surgery Under Thoracic Epidural Anaesthesia|Completed||Phase 4|140|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 03:40:15.938609|2018-06-01 03:40:15.938609
NCT00394446|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2008-02-11|2006-10-31|2006-11-01|Estimate|||||||2008-02-11|2008-02-13|Estimate|March 2005||2005-03-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|April 2007|Actual|2007-04-30||Interventional|||Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors|Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.|Completed||Phase 1|48|Actual|Myrexis Inc.|||||f||||f||||||||||2018-06-01 03:40:16.037768|2018-06-01 03:40:16.037768
NCT00394433|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2016-09-26||2017-07-05|2006-10-31|2006-11-01|Estimate|2016-11-21|2017-01-16|Estimate||||2017-07-05|2017-08-01|Actual|September 2006||2006-09-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|November 2008|Actual|2008-11-30||Interventional||The analysis dataset is comprised of all enrolled patients.|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer|A Phase II Trial of Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer|Completed||Phase 2|38|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 03:40:16.15133|2018-06-01 03:40:16.15133
NCT00394381|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2017-02-09|2006-10-31|2006-11-01|Estimate|||||||2017-02-09|2017-02-10|Actual|October 2006||2006-10-31|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome|Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome|Completed||Phase 1/Phase 2|17|Actual|Singapore General Hospital||1|||f||||t||||||||||2018-06-01 03:40:16.878965|2018-06-01 03:40:16.878965
NCT00394368|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2006-10-30|2006-10-30|2006-11-01|Estimate|||||||2006-10-30|2006-11-01|Estimate|November 2004||2004-11-30|October 2006|2006-10-31|September 2005||2005-09-30|||||Interventional|||EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI|DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PARALLEL-GROUP DESIGN CLINICAL TRIAL OF THE EFFICACY AND TOLERABILITY OF CHF 1535 (BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg) pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI (SERETIDE®) IN THE 12-WEEK TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE PERSISTENT ASTHMA|Completed||Phase 3|180||Chiesi Farmaceutici S.p.A.|||||f||||||||||||||2018-06-01 03:40:16.954251|2018-06-01 03:40:16.954251
NCT00394355|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|2010-10-22||2017-03-10|2006-10-31|2006-11-01|Estimate|2011-02-10|2011-03-07|Estimate||||2017-03-10|2017-04-10|Actual|September 2006||2006-09-30|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)|Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Density in Adults With Asthma|Completed||Phase 4|566|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:40:17.066105|2018-06-01 03:40:17.066105
NCT00394329|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2013-02-24||2018-04-24|2006-10-30|2006-11-01|Estimate|2013-04-05|2013-05-17|Estimate||||2018-04-24|2018-05-24|Actual|November 2006||2006-11-30|April 2018|2018-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|TREXA||(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)|Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)|Completed||Phase 3|288|Actual|Milton S. Hershey Medical Center||4|||f||||t||||||||||2018-06-01 03:40:17.584462|2018-06-01 03:40:17.584462
NCT00394316|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2017-06-30|2006-10-31|2006-11-01|Estimate|||||||2017-06-30|2017-07-02|Actual|October 30, 2006||2006-10-30|April 8, 2014|2014-04-08|April 8, 2014|Actual|2014-04-08|April 8, 2014|Actual|2014-04-08||Interventional|||Gene Therapy for Chronic Granulomatous Disease|Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease|Terminated||Early Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:40:18.101764|2018-06-01 03:40:18.101764
NCT00394303|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2009-03-31|2006-10-31|2006-11-01|Estimate|||||||2009-03-31|2009-04-01|Estimate|February 2007||2007-02-28|June 2007|2007-06-30|August 2009|Anticipated|2009-08-31|||||Interventional|||Tight Intra-Operative Glucose Control During Coronary Artery Bypass Surgery|Tight Intra-Operative Glucose Control Using Continuous Insulin Infusion During Coronary Artery Bypass Surgery: Randomized Controlled Trial|Terminated||Phase 4|1400|Anticipated|Rabin Medical Center||2||"Trial suspended on 26 February, following the publication of a trial with negative results (Ann~   Intern Med 146(4), 2007). Pending ethics committee re-approval."|f||||t||||||||||2018-06-01 03:40:18.191847|2018-06-01 03:40:18.191847
NCT00394290|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-31|||2012-10-18|2006-10-31|2006-11-01|Estimate|||||||2012-10-18|2012-10-19|Estimate|November 2006||2006-11-30|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|Morphee||Down Syndrome and Continuous Positive Pressure Therapy|Follow-up of the Therapeutic Coverage by Continuous Positive Pressure of the Obstructive Sleep Apnea Syndrome for Down Syndrome Patients|Unknown status|Recruiting|N/A|30|Anticipated|Institut Jerome Lejeune||1|||f||||f||||||||||2018-06-01 03:40:18.281726|2018-06-01 03:40:18.281726
NCT00394277|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2010-05-27||2010-07-30|2006-10-30|2006-10-31|Estimate|2010-05-27|2010-07-05|Estimate||||2010-07-30|2010-08-03|Estimate|February 2007||2007-02-28|July 2010|2010-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C|Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater Than or Equal to 85 kg|Completed||Phase 4|1175|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 03:40:18.380164|2018-06-01 03:40:18.380164
NCT00394264|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2006-10-27|2006-10-27|2006-10-31|Estimate|||||||2006-10-27|2006-10-31|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|October 2007||2007-10-31|||||Interventional|||How Does Manual Therapy Improve Low Back Pain for Soldiers?|Manual Manipulative Therapy for Back Pain in Active Duty Military Personnel|Unknown status|Recruiting|Phase 2|100||University of North Texas Health Science Center|||||f||||||||||||||2018-06-01 03:40:20.740019|2018-06-01 03:40:20.740019
NCT00394251|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2010-11-02||2013-08-08|2006-10-30|2006-10-31|Estimate|2013-06-14|2013-07-18|Estimate||||2013-08-08|2013-08-15|Estimate|August 2006||2006-08-31|August 2013|2013-08-31|February 2008|Actual|2008-02-29|March 2007|Actual|2007-03-31||Interventional|||Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer|An Open-label, Randomized, Comparative Pilot Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer|Completed||Phase 2|197|Actual|Celgene||2|||f||||t||||||||||2018-06-01 03:40:20.907742|2018-06-01 03:40:20.907742
NCT00394238|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-29|||2006-10-30|2006-10-30|2006-10-31|Estimate|||||||2006-10-30|2006-10-31|Estimate|November 2006||2006-11-30|July 2006|2006-07-31|October 2008||2008-10-31|||||Observational|||Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis||Unknown status|Not yet recruiting||50||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:40:22.119529|2018-06-01 03:40:22.119529
NCT00394225|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2006-10-30|2006-10-30|2006-10-31|Estimate|||||||2006-10-30|2006-10-31|Estimate|July 2005||2005-07-31|October 2006|2006-10-31|May 2006||2006-05-31|||||Interventional|||Helium-Hyperoxia and 6MWT Distance in COPD|The Effects of Helium-Hyperoxia on 6-Minute Walking Distance in Chronic Obstructive Pulmonary Disease – A Randomized, Controlled Trial|Completed||N/A|16||University of Saskatchewan|||||f||||||||||||||2018-06-01 03:40:22.180133|2018-06-01 03:40:22.180133
NCT00393900|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2017-10-17|2006-10-30|2006-10-31|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2006||2006-08-31|October 2017|2017-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion|Middle Ear Pressure Disregulation After Tympanostomy Tube Insertion|Completed|||84|Actual|University of Pittsburgh|||1||f||||f||||||Samples With DNA|"~     Buccal cells obtained for DNA~   "|No||2018-06-01 03:40:27.32866|2018-06-01 03:40:27.32866
NCT00394212|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|2011-08-03||2016-08-12|2006-10-30|2006-10-31|Estimate|2012-10-08|2012-11-07|Estimate||||2016-08-12|2016-09-21|Estimate|November 2006||2006-11-30|October 2012|2012-10-31|May 2009|Actual|2009-05-31|September 2008|Actual|2008-09-30||Interventional|||Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass|Randomized Evaluation of Endoscopic Suturing Transorally for Anastomotic Outlet Reduction (RESTORe) for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass Surgery|Terminated||Phase 3|77|Actual|C. R. Bard|Limitations of this study are that study enrollment was prematurely discontinued; therefore the study was underpowered for the analysis of both the primary and secondary effectiveness endpoints.|2||For business reasons|f||||t||||||||||2018-06-01 03:40:22.339861|2018-06-01 03:40:22.339861
NCT00394199|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27||2010-08-24|2011-06-08|2006-10-30|2006-10-31|Estimate||||2010-08-24|2010-08-27|Estimate|2011-06-08|2011-06-23|Estimate|June 2006||2006-06-30|June 2011|2011-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma|A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent & Adult Patients With Mild to Moderate Asthma|Completed||Phase 3|357|Actual|SkyePharma AG||3|||f||||||||||||||2018-06-01 03:40:22.705822|2018-06-01 03:40:22.705822
NCT00394186|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2009-05-15|2006-10-30|2006-10-31|Estimate|||||||2009-05-15|2009-05-18|Estimate|August 2006||2006-08-31|May 2009|2009-05-31||||||||Interventional|||A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)|A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the Beta-3-Adrenergic Receptor Agonist Solabegron in Subjects With Irritable Bowel Syndrome|Completed||Phase 2|100|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:40:22.846937|2018-06-01 03:40:22.846937
NCT00394173|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2017-02-23|2006-10-30|2006-10-31|Estimate|||||||2017-02-23|2017-02-27|Actual|September 2006||2006-09-30|February 2017|2017-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg b.i.d. Given Orally for 4 Weeks in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)|Completed||Phase 2|180|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:40:23.047447|2018-06-01 03:40:23.047447
NCT00394160|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2017-03-17|2006-10-27|2006-10-31|Estimate|||||||2017-03-17|2017-03-21|Actual|December 2004||2004-12-31|March 2017|2017-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297)|A Randomized, 3-Period, Multiple-Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Plasma Concentration Profile of Montelukast Administered Once Daily as Oral Granules in Children Aged 1 to 3 Months|Completed||Phase 2|12|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:40:23.196251|2018-06-01 03:40:23.196251
NCT00394147|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2012-03-01|2006-10-27|2006-10-31|Estimate|||||||2012-03-01|2012-03-02|Estimate|October 2006||2006-10-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|August 2008|Actual|2008-08-31||Interventional|||Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer|Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN)|Terminated||Phase 2|17|Actual|Fox Chase Cancer Center||||stopped for lack of efficacy|f||||t||||||||||2018-06-01 03:40:23.28135|2018-06-01 03:40:23.28135
NCT00394134|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2018-05-25|2006-10-30|2006-10-31|Estimate|||||||2018-05-25|2018-05-30|Actual|April 2005|Actual|2005-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Targeted Intervention for Melanoma Prevention|A Targeted, Family-Focused Intervention for Melanoma Prevention|Active, not recruiting||N/A|570|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-06-01 03:40:23.350987|2018-06-01 03:40:23.350987
NCT00394121|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27||2010-08-24|2010-08-24|2006-10-30|2006-10-31|Estimate||||2010-08-24|2010-08-27|Estimate|2010-08-24|2010-08-27|Estimate|March 2006||2006-03-31|August 2010|2010-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma|Long-term Open-label Safety Study With SkyePharma FlutiForm HFA pMDI (100/10 µg and 250/10 µg) in Adult and Adolescent Patients With Asthma|Completed||Phase 3|400|Anticipated|SkyePharma AG|||||f||||||||||||||2018-06-01 03:40:23.425065|2018-06-01 03:40:23.425065
NCT00394108|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2007-12-19|2006-10-30|2006-10-31|Estimate|||||||2007-12-19|2007-12-28|Estimate|August 1999||1999-08-31|December 2007|2007-12-31|July 2002|Actual|2002-07-31|||||Interventional|||Changes in Cerebrovascular Reactivity During Cognitive Activation After Cardiopulmonary Bypass: Relation With Intraoperative Embolic Load and Postoperative Neuropsychological Dysfunctions|Changes in Cerebrovascular Reactivity During Cognitive Activation After Cardiopulmonary Bypass: Relation With Intraoperative Embolic Load and Postoperative Neuropsychological Dysfunctions|Completed||N/A|66|Actual|University Ghent|||||f||||f||||||||||2018-06-01 03:40:23.525876|2018-06-01 03:40:23.525876
NCT00394095|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|2011-03-23||2013-04-03|2006-10-27|2006-10-31|Estimate|2013-04-03|2013-04-04|Estimate||||2013-04-03|2013-04-04|Estimate|December 2006||2006-12-31|April 2013|2013-04-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Topiramate vs. Placebo in Preventing Weight Gain in Bipolar Disorder Treated With Olanzapine|A Double-Blind, Randomized, Placebo-Controlled, Pilot Study of Topiramate vs. Placebo in Combination With Olanzapine for the Prevention of Weight Gain in Manic or Mixed Youth With Bipolar Disorder|Completed||Phase 4|31|Actual|University of Cincinnati|One subject experienced hyperthermia and was admitted to hospital. Subject was discontinued from study.|2|||f||||t||||||||||2018-06-01 03:40:23.594444|2018-06-01 03:40:23.594444
NCT00394082|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2013-04-03||2016-03-24|2006-10-30|2006-10-31|Estimate|2013-04-03|2013-05-22|Estimate||||2016-03-24|2016-04-25|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|February 2011|Actual|2011-02-28|September 2009|Actual|2009-09-30||Interventional|||ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer|A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer|Completed||Phase 2|50|Actual|Celgene Corporation|Interpretation of results is limited since the cell receptor subtype status of patients is not known.|1|||f||||f||||||||||2018-06-01 03:40:23.906137|2018-06-01 03:40:23.906137
NCT00394069|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2017-03-17|2006-10-27|2006-10-31|Estimate|||||||2017-03-17|2017-03-21|Actual|July 2003||2003-07-31|March 2017|2017-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||PK Study in 3- to 6- Month-Old Children (0476-268)(COMPLETED)|A Randomized, 3-Period, Multiple-Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Plasma Concentration Profile of Montelukast Administered Once Daily as Oral Granules in Children Aged 3 to 6 Months|Completed||Phase 2|14|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 03:40:24.464154|2018-06-01 03:40:24.464154
NCT00394056|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2016-10-27|2006-10-30|2006-10-31|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss.|Randomised, Double-blind, Placebo Controlled, Cross-over Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 14 Days of Vestipitant or Vestipitant / Paroxetine Combination in an Enriched Population of Subjects With Tinnitus & Hearing Loss|Completed||Phase 2|26|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:40:24.529313|2018-06-01 03:40:24.529313
NCT00394043|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2017-03-14|2006-10-27|2006-10-31|Estimate|||||||2017-03-14|2017-03-16|Actual|October 2006||2006-10-31|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Treatment Efficacy of OMT for Carpal Tunnel Syndrome|Treatment Efficacy of OMT for Carpal Tunnel Syndrome|Completed||Phase 2|138|Actual|University of North Texas Health Science Center||3|||f||||t||||||||||2018-06-01 03:40:24.674163|2018-06-01 03:40:24.674163
NCT00394030|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2017-09-08|2006-10-27|2006-10-31|Estimate|||||||2017-09-08|2017-09-11|Actual|October 16, 2006|Actual|2006-10-16|September 2017|2017-09-30|March 20, 2007|Actual|2007-03-20|March 20, 2007|Actual|2007-03-20||Interventional|||Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers|An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects With Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers|Completed||Phase 1|63|Actual|GlaxoSmithKline||8|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:40:24.744335|2018-06-01 03:40:24.744335
NCT00394017|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2009-10-23|2006-10-30|2006-10-31|Estimate|||||||2009-10-23|2009-10-27|Estimate|November 2006||2006-11-30|October 2009|2009-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Use of Reminders in Implementing an E-learning Program in General Practice|Implementation of an E-learning Program in Diagnostic Evaluation of Dementia by Reminders: A RCT Among General Practitioners in Copenhagen|Completed||N/A|339|Actual|Research Unit Of General Practice, Copenhagen||2|||f||||||||||||||2018-06-01 03:40:24.908861|2018-06-01 03:40:24.908861
NCT00394004|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-28|||2017-06-30|2006-10-28|2006-10-31|Estimate|||||||2017-06-30|2017-07-02|Actual|October 26, 2006||2006-10-26|April 26, 2011|2011-04-26|April 26, 2011||2011-04-26|||||Observational|||Decision-Making of Hispanics and African-Americans With HIV/AIDS Participating in Clinical Trials|Exploring Decision Making of Hispanics and African Americans With HIV/AIDS Participating in Clinical Trials|Completed|||35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:40:24.980934|2018-06-01 03:40:24.980934
NCT00393991|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27||2010-08-24|2011-06-08|2006-10-30|2006-10-31|Estimate||||2010-08-24|2010-08-27|Estimate|2011-06-08|2011-06-23|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel, Stratified, Multi-center, 12-Week Study Comparing the Safety & Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm)100/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI)With the Administration of Placebo or Fluticasone (100 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Mild to Moderate Asthma|Completed||Phase 3|475|Actual|SkyePharma AG||4|||f||||||||||||||2018-06-01 03:40:25.058839|2018-06-01 03:40:25.058839
NCT00393978|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2016-05-16||2017-08-28|2006-10-30|2006-10-31|Estimate|2017-07-27|2017-08-29|Actual||||2017-08-28|2017-09-26|Actual|November 2006||2006-11-30|May 2016|2016-05-31|March 2014|Actual|2014-03-31|December 2011|Actual|2011-12-31||Interventional|||Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania|Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents|Completed||Phase 4|75|Actual|University of Cincinnati||2|||f||||f||||||||No||2018-06-01 03:40:25.213261|2018-06-01 03:40:25.213261
NCT00393965|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2008-02-11|2006-10-30|2006-10-31|Estimate|||||||2008-02-11|2008-02-13|Estimate|December 2005||2005-12-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|August 2007|Actual|2007-08-31||Interventional|||Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases|Phase 1 Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Brain Metastases|Completed||Phase 1|18|Actual|Myrexis Inc.|||||f||||f||||||||||2018-06-01 03:40:25.55514|2018-06-01 03:40:25.55514
NCT00393952|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27||2010-08-24|2011-06-08|2006-10-30|2006-10-31|Estimate||||2010-08-24|2010-08-27|Estimate|2011-06-08|2011-06-23|Estimate|June 2006||2006-06-30|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm(tm) 100/10 µg or 250/10 µg Twice Daily) in a Single Inhaler (SkyePharma HFA pMDI) With the Administration of Placebo or Fluticasone (250 µg Twice Daily) and Formoterol (10 µg Twice Daily) Alone in Adolescent and Adult Patients With Moderate to Severe Asthma|Completed||Phase 3|557|Actual|SkyePharma AG||5|||f||||||||||||||2018-06-01 03:40:25.624986|2018-06-01 03:40:25.624986
NCT00393939|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2011-01-31||2012-07-13|2006-10-30|2006-10-31|Estimate|2011-01-31|2011-02-28|Estimate||||2012-07-13|2012-07-19|Estimate|February 2007||2007-02-28|July 2012|2012-07-31|July 2011|Actual|2011-07-31|February 2010|Actual|2010-02-28||Interventional|SUN 1064||Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer|A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients|Completed||Phase 3|594|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:40:25.839677|2018-06-01 03:40:25.839677
NCT00393926|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|||2014-02-03|2006-10-30|2006-10-31|Estimate|||||||2014-02-03|2014-02-04|Estimate|July 2006||2006-07-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Robot-Assisted Motivating Rehabilitation|Robot-Assisted Motivating Rehabilitation to Increase Upper Limb Function After Stroke|Completed||Phase 1|24|Anticipated|Medical College of Wisconsin|||||f||||||||||||||2018-06-01 03:40:26.986162|2018-06-01 03:40:26.986162
NCT00393913|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-30|2014-02-18||2016-08-03|2006-10-30|2006-10-31|Estimate|2015-01-12|2015-01-19|Estimate||||2016-08-03|2016-08-05|Estimate|October 2006||2006-10-31|August 2016|2016-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational||107 total, with 87 subjects with sleep apnea and 20 without sleep apnea.|Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness|Relating Sleep Disordered Breathing to Daytime Function|Completed|||144|Actual|New York University School of Medicine|||1||f||||t||||||||||2018-06-01 03:40:27.129468|2018-06-01 03:40:27.129468
NCT00393861|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|2015-01-21||2016-02-26|2006-10-27|2006-10-30|Estimate|2015-01-21|2015-01-29|Estimate||||2016-02-26|2016-03-24|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|October 2012|Actual|2012-10-31||Interventional|||Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients|Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors|Completed||Phase 2|29|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 03:40:28.066494|2018-06-01 03:40:28.066494
NCT00393848|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|2014-01-06||2014-05-30|2006-10-27|2006-10-30|Estimate|2014-05-30|2014-06-02|Estimate||||2014-05-30|2014-06-02|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery|Restoration of Muscle Following Hip Surgery|Completed||Phase 2|40|Actual|University of Arkansas||4|||f||||t||||||||||2018-06-01 03:40:28.272986|2018-06-01 03:40:28.272986
NCT00393835|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2008-05-15|2006-10-26|2006-10-30|Estimate|||||||2008-05-15|2008-05-16|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis|A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin Sustained Release (SR) For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis In Japan Adults|Completed||Phase 3|99|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:40:28.602466|2018-06-01 03:40:28.602466
NCT00393822|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2014-07-14|2006-10-26|2006-10-30|Estimate|||||||2014-07-14|2014-07-15|Estimate|August 2005||2005-08-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|December 2007|Actual|2007-12-31||Interventional|||A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer|A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer Receiving 5-FU and Leucovorin as Adjuvant Therapy|Completed||Phase 2/Phase 3|100|Actual|Amgen||2|||f||||f||||||||||2018-06-01 03:40:28.686108|2018-06-01 03:40:28.686108
NCT00393809|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2007-12-25|2006-10-26|2006-10-30|Estimate|||||||2007-12-25|2008-01-07|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer|Phase 1/2a, Dose-Escalation, Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer|Completed||Phase 1/Phase 2|18|Actual|Hebrew University of Jerusalem|||||f||||||||||||||2018-06-01 03:40:28.778984|2018-06-01 03:40:28.778984
NCT00393796|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|2014-06-19||2014-11-07|2006-10-27|2006-10-30|Estimate|2014-11-07|2014-11-13|Estimate||||2014-11-07|2014-11-13|Estimate|May 2006||2006-05-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma|Randomized Blinded Phase II Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma|Terminated||Phase 2|54|Actual|University of Michigan Cancer Center|This multicenter study was limited by premature closure and a small sample size.|2||Low accrual|f||||t||||||||||2018-06-01 03:40:28.980165|2018-06-01 03:40:28.980165
NCT00393783|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2017-06-01|2006-10-27|2006-10-30|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2006|Actual|2006-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity|Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity|Active, not recruiting||Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:40:29.541147|2018-06-01 03:40:29.541147
NCT00393770|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2011-06-09|2006-10-27|2006-10-30|Estimate|||||||2011-06-09|2011-06-10|Estimate|February 2004||2004-02-29|June 2011|2011-06-30|September 2007|Actual|2007-09-30|October 2006|Actual|2006-10-31||Interventional|||Acetylcarnitine and Insulin Sensitivity|A Pilot Study to Evaluate the Short-term Effects of Acetyl-carnitine on Insulin Resistance and the Metabolic Syndrome in Patients at Increased Risk of Type 2 Diabetes: Acetyl-carnitine in Insulin Resistance|Completed||Phase 2|43|Actual|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||||2018-06-01 03:40:29.674483|2018-06-01 03:40:29.674483
NCT00393757|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2010-08-26|2006-10-26|2006-10-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|January 2010||2010-01-31|||||Observational|||Malaria Transmission and Immunity in Highland Kenya|Malaria Transmission and Immunity in Highland Kenya|Unknown status|Recruiting||6400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:40:29.749778|2018-06-01 03:40:29.749778
NCT00393744|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2009-03-16|2006-10-27|2006-10-30|Estimate|||||||2009-03-16|2009-03-17|Estimate|October 2006||2006-10-31|March 2009|2009-03-31||||March 2008|Actual|2008-03-31||Interventional|PRI-angine||Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children|A Phase III, Open, Randomised, Multicentre Study Comparing the Efficacy and Safety of Pristinamycin, at Dosages of 50 mg/kg/d in 2 Doses for Children, and 1g Twice Daily in Adults for 4 Days Versus Amoxicillin at a Dosage of 50 mg/kg/d in 2 Doses in Children and 1 g Twice Daily in Adults for 6 Days, Consumed Orally, in the Treatment of Tonsillitis Induced by Group-A Beta-Haemolytic Streptococcus in Patients Aged Between 6 and 25 Years.|Completed||Phase 3|395|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:40:29.795745|2018-06-01 03:40:29.795745
NCT00393731|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2008-01-11|2006-10-26|2006-10-30|Estimate|||||||2008-01-11|2008-01-16|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Randomized, Control Trial for Preinduction Cervical Ripening|A Randomized, Control Trial for Preinduction Cervical Ripening|Completed||Phase 2|540|Anticipated|The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 03:40:29.851638|2018-06-01 03:40:29.851638
NCT00393718|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|2010-02-23|2009-10-26|2017-01-25|2006-10-27|2006-10-30|Estimate|2010-02-23|2010-03-12|Estimate|2009-10-26|2009-10-28|Estimate|2017-01-25|2017-03-08|Actual|November 2006||2006-11-30|January 2017|2017-01-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional|||Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes|Completed||Phase 3|400|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-06-01 03:40:29.915368|2018-06-01 03:40:29.915368
NCT00393705|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|2010-03-31||2010-07-15|2006-10-26|2006-10-30|Estimate|2010-03-31|2010-04-27|Estimate||||2010-07-15|2010-07-20|Estimate|October 2006||2006-10-31|July 2010|2010-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|S019||Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)|A Comparison of Insulin Lispro MM Intensive Mixture Therapy With Progressive Dose-Titration of Insulin Lispro LM or Biphasic Insulin Aspart 30/70|Completed||Phase 4|302|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:40:30.614187|2018-06-01 03:40:30.614187
NCT00393692|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2017-05-05|2006-10-26|2006-10-30|Estimate|||||||2017-05-05|2017-05-08|Actual|August 2000||2000-08-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|April 2016|Actual|2016-04-30||Observational|||Fundus Autofluorescence Imaging in Age-related Macular Degeneration Using Confocal Scanning Laser Ophthalmoscopy|Prospective Natural History Study of Fundus Autofluorescence Imaging in Age-related Macular Degeneration (FAM-Study) Using Confocal Scanning Laser Ophthalmoscopy|Active, not recruiting|||700|Actual|University Hospital, Bonn|||||f||||f||||||||Undecided||2018-06-01 03:40:31.33715|2018-06-01 03:40:31.33715
NCT00393679|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2014-01-31|2006-10-27|2006-10-30|Estimate|||||||2014-01-31|2014-02-03|Estimate|July 2007||2007-07-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children|Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children|Completed||Phase 3|4112|Actual|Institute of Tropical Medicine, Belgium||4|||f||||t||||||||||2018-06-01 03:40:31.402774|2018-06-01 03:40:31.402774
NCT00393666|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2016-01-25|2006-10-26|2006-10-30|Estimate|||||||2016-01-25|2016-01-26|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Why Are Patients With Absence Seizures Absent? A Brain Imaging Study|Functional Neuroimaging in Childhood Absence Epilepsy|Completed|||180|Actual|Yale University|||||f||||||||||Samples With DNA|"~     Saliva samples~   "|||2018-06-01 03:40:31.489656|2018-06-01 03:40:31.489656
NCT00393653|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2011-05-09|2006-10-26|2006-10-30|Estimate|||||||2011-05-09|2011-05-10|Estimate|October 2006||2006-10-31|May 2011|2011-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Prescription Methods Assessment Project (PMAP)|Prescription Methods Assessment Project (PMAP)|Terminated||N/A|800|Anticipated|American Academy of Family Physicians||||Funding ended early|f||||||||||||||2018-06-01 03:40:31.543502|2018-06-01 03:40:31.543502
NCT00393640|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2009-09-18|2006-10-27|2006-10-30|Estimate|||||||2009-09-18|2009-09-21|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|Pumping||Early and Regular Breast Milk Expression to Help Establish Lactation After Delivery: a Randomized Controlled Trial|Early and Regular Breast Milk Expression to Help Establish Lactation After Delivery: a Randomized Controlled Trial|Completed||N/A|120|Anticipated|National University Hospital, Singapore||4|||f||||t||||||||||2018-06-01 03:40:31.60194|2018-06-01 03:40:31.60194
NCT00393627|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2012-06-12|2006-10-26|2006-10-30|Estimate|||||||2012-06-12|2012-06-14|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Behavioral Sleep Intervention in Adult Family Homes|Efficacy of Behavioral Interventions to Improve Sleep in Adult Family Homes|Completed||Phase 2|47|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:40:31.688897|2018-06-01 03:40:31.688897
NCT00393614|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2009-09-22|2006-10-27|2006-10-30|Estimate|||||||2009-09-22|2009-09-23|Estimate|May 2007||2007-05-31|February 2008|2008-02-29|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA)|Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) - a Placebo Controlled Double-blind Cross-over-study|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:40:31.886424|2018-06-01 03:40:31.886424
NCT00393601|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2010-01-04|2006-10-27|2006-10-30|Estimate|||||||2010-01-04|2010-01-06|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|October 2009|Actual|2009-10-31|||||Observational|||Chart Review of Laparoscopic Radical Cystectomy|Retrospective Chart Review of Laparoscopic Radical Cystectomy|Completed|||200|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-06-01 03:40:31.942603|2018-06-01 03:40:31.942603
NCT00393588|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2017-06-30|2006-10-27|2006-10-30|Estimate|||||||2017-06-30|2017-07-02|Actual|October 26, 2006||2006-10-26|September 29, 2011|2011-09-29|September 29, 2011||2011-09-29|||||Observational|||Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis|The Use of Magnetic Resonance Imaging to Investigate Cortical Damage in Patients With Multiple Sclerosis and Correlation With Cognitive Dysfunction|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:40:32.001259|2018-06-01 03:40:32.001259
NCT00393575|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2017-02-27|2006-10-27|2006-10-30|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2006||2006-01-31|July 2016|2016-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||C2P Mobilization Intervention (Pilot)|Connect To Protect® Partnerships for Youth Prevention Interventions: Phase III|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-06-01 03:40:32.064534|2018-06-01 03:40:32.064534
NCT00393562|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2015-06-25|2006-10-27|2006-10-30|Estimate|||||||2015-06-25|2015-06-26|Estimate|March 2006||2006-03-31|June 2015|2015-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease|Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease|Withdrawn||N/A|0|Actual|VA Office of Research and Development||||Unable to recruit any subjects for this study|f||||f||||||||||2018-06-01 03:40:32.156772|2018-06-01 03:40:32.156772
NCT00393549|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-27|||2007-06-05|2006-10-27|2006-10-30|Estimate|||||||2007-06-05|2007-06-06|Estimate|August 2006||2006-08-31|June 2007|2007-06-30|December 2006|Actual|2006-12-31|||||Interventional|||NeuroPath Comparative Validation Study Plan||Terminated||Phase 3|200|Anticipated|Excel-Tech Ltd.||||Sponsor decision to terminate.|f||||||||||||||2018-06-01 03:40:32.229577|2018-06-01 03:40:32.229577
NCT00393536|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2006-10-26|2006-10-26|2006-10-27|Estimate|||||||2006-10-26|2006-10-27|Estimate|July 1999||1999-07-31|October 2006|2006-10-31|December 2000||2000-12-31|||||Interventional|||Study of Whether Educational Visits to Primary Care Professionals Improves the Quality of Care They Provide.|A Pragmatic Randomized Controlled Trial of Untargeted Educational Outreach Visiting Delivered by Pharmaceutical Advisers in Primary Care.|Completed||N/A|73||Newcastle University|||||f||||||||||||||2018-06-01 03:40:32.284969|2018-06-01 03:40:32.284969
NCT00393523|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2009-05-27||2017-03-15|2006-10-25|2006-10-27|Estimate|2009-09-10|2009-10-12|Estimate||||2017-03-15|2017-04-12|Actual|September 2006||2006-09-30|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)|A Study to Assess the Anamnestic Immune Response 4 to 8 Years After a Primary Vaccination Series With HBVAXPRO|Completed||Phase 3|1478|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:40:32.446988|2018-06-01 03:40:32.446988
NCT00393510|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|2009-11-23||2010-07-06|2006-10-26|2006-10-27|Estimate|2010-06-02|2010-07-01|Estimate||||2010-07-06|2010-07-13|Estimate|November 2000||2000-11-30|July 2010|2010-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers|An Evidence Base Study on the Clinical Effects of Integrated Western Medicine and Traditional Chinese Medicine for Diabetic Foot Ulcer Treatment|Completed||Phase 2|80|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 03:40:33.419763|2018-06-01 03:40:33.419763
NCT00393497|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2014-09-19|2006-10-26|2006-10-27|Estimate|||||||2014-09-19|2014-09-22|Estimate|April 2007||2007-04-30|September 2014|2014-09-30|January 2011|Actual|2011-01-31|October 2009|Actual|2009-10-31||Interventional|||A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment|A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment|Completed||Phase 1|11|Actual|Indiana University|||||f||||t||||||||||2018-06-01 03:40:33.630327|2018-06-01 03:40:33.630327
NCT00393484|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|2010-10-21||2014-11-06|2006-10-26|2006-10-27|Estimate|2010-10-21|2010-11-18|Estimate||||2014-11-06|2014-11-26|Estimate|February 2007||2007-02-28|November 2014|2014-11-30|September 2013|Actual|2013-09-30|January 2009|Actual|2009-01-31||Interventional||All participants who received study drug|A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection|A Phase IV Study of the Antiviral Activity and Safety of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen in Korea|Completed||Phase 4|122|Actual|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 03:40:33.7492|2018-06-01 03:40:33.7492
NCT00393471|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2006-10-26|2006-10-26|2006-10-27|Estimate|||||||2006-10-26|2006-10-27|Estimate|October 2000||2000-10-31|October 2006|2006-10-31|October 2001||2001-10-31|||||Interventional|||Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.|A Double-Blind Study Evaluating the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Comparison to Etanercept Alone or Methotrexate Alone in Rheumatoid Arthritis Patients.|Completed||Phase 3|615||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:40:34.590758|2018-06-01 03:40:34.590758
NCT00393458|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2011-07-22||2011-07-22|2006-10-25|2006-10-27|Estimate|2011-07-22|2011-08-18|Estimate||||2011-07-22|2011-08-18|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control|A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control|Completed||Phase 3|1732|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:40:34.801614|2018-06-01 03:40:34.801614
NCT00393445|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2011-10-02|2006-10-26|2006-10-27|Estimate|||||||2011-10-02|2011-10-04|Estimate|November 2006||2006-11-30|October 2011|2011-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans|Effect of GLP-1 on Glucose Metabolism in Healthy Subjects and Patients With T2DM. Part 1: A Pilot Study to Assess the Efficacy of Exendin(9-39)Amide as a GLP-1 Receptor Antagonist in Healthy Subjects|Completed||Phase 1|6|Actual|Ludwig-Maximilians - University of Munich||1|||f||||f||||||||||2018-06-01 03:40:37.212386|2018-06-01 03:40:37.212386
NCT00393432|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2017-06-30|2006-10-26|2006-10-27|Estimate|||||||2017-06-30|2017-07-02|Actual|October 18, 2006||2006-10-18|July 18, 2008|2008-07-18|July 18, 2008||2008-07-18|||||Observational|||Enhancing Motor Task Training by Action Observation Watching Others Perform the Task|Enhancing Motor Memory Encoding by Action Observation|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:40:37.29774|2018-06-01 03:40:37.29774
NCT00393419|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2006-10-26|2006-10-26|2006-10-27|Estimate|||||||2006-10-26|2006-10-27|Estimate|June 2004||2004-06-30|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||Federal Study of Adherence to Medications in the Elderly (FAME)|Federal Study of Adherence to Medications in the Elderly (FAME)|Completed||N/A|200||Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:40:37.349981|2018-06-01 03:40:37.349981
NCT00393406|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2017-06-30|2006-10-26|2006-10-27|Estimate|||||||2017-06-30|2017-07-02|Actual|October 24, 2006||2006-10-24|October 28, 2008|2008-10-28|October 28, 2008||2008-10-28|||||Observational|||The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach|The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:40:37.417086|2018-06-01 03:40:37.417086
NCT00393393|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2006-10-26|2006-10-26|2006-10-27|Estimate|||||||2006-10-26|2006-10-27|Estimate|January 2006||2006-01-31|October 2006|2006-10-31|January 2006||2006-01-31|||||Interventional|||Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee|A Single-Blind Prospective Parallel Control Group Pilot Study to Assess the Effect of Hylan G-F 20 (Synvisc) Supplementation on Cartilage Preservation in Osteoarthritis of the Knee|Unknown status|Recruiting|Phase 4|80||Cabrini Medical Centre|||||f||||||||||||||2018-06-01 03:40:37.470305|2018-06-01 03:40:37.470305
NCT00393380|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2012-11-06||2013-04-22|2006-10-25|2006-10-27|Estimate|2012-11-06|2012-12-07|Estimate||||2013-04-22|2013-04-29|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|March 2012|Actual|2012-03-31|November 2009|Actual|2009-11-30||Interventional|||Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor|A Phase II Study of Parathyroid Hormone Following Myeloablative Sequential Unrelated Cord Blood Transplantation|Terminated||Phase 2|13|Actual|The EMMES Corporation|The study was closed prematurely due to early mortality and lack of efficacy.|1||Study stopped because of toxicity concerns.|f||||t||||||||||2018-06-01 03:40:37.555028|2018-06-01 03:40:37.555028
NCT00393367|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2010-04-09||2012-08-06|2006-10-25|2006-10-27|Estimate|2011-06-24|2011-07-25|Estimate||||2012-08-06|2012-08-10|Estimate|December 2006||2006-12-31|August 2012|2012-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Budesonide Inhalation Suspension for Acute Asthma in Children|Budesonide Inhalation Suspension for Acute Asthma in Children|Completed||Phase 4|179|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 03:40:37.90629|2018-06-01 03:40:37.90629
NCT00393354|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2015-11-27|2006-10-26|2006-10-27|Estimate|||||||2015-11-27|2015-11-30|Estimate|April 2000||2000-04-30|November 2015|2015-11-30|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)|A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain|Completed||Phase 3|325|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:40:38.439215|2018-06-01 03:40:38.439215
NCT00393341|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2015-08-27|2006-10-25|2006-10-27|Estimate|||||||2015-08-27|2015-08-31|Estimate|October 2006||2006-10-31|August 2015|2015-08-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Observational|EPC||Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer|Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer|Completed|||68|Actual|Indiana University|||2||f||||||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 03:40:38.505057|2018-06-01 03:40:38.505057
NCT00393328|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2011-04-07|2006-10-26|2006-10-27|Estimate|||||||2011-04-07|2011-04-08|Estimate|November 2006||2006-11-30|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Bioequivalence Study of Atazanavir 300 mg Capsule|Bioequivalence Study of Atazanavir Single 300 mg Capsule Relative to Two Atazanavir 150 mg Capsules in Healthy Subjects|Completed||Phase 1|46||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 03:40:38.577157|2018-06-01 03:40:38.577157
NCT00393315|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2010-06-29|2006-10-26|2006-10-27|Estimate|||||||2010-06-29|2010-06-30|Estimate|November 2005||2005-11-30|June 2010|2010-06-30|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses|P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses: A Comparison to the Paclitaxel-Eluting Taxus™ Stent. A Pilot Study|Completed||Phase 2|120|Actual|University Hospital, Saarland|||||f||||||||||||||2018-06-01 03:40:38.654674|2018-06-01 03:40:38.654674
NCT00393302|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2008-07-16|2006-10-26|2006-10-27|Estimate|||||||2008-07-16|2008-07-17|Estimate|September 2003||2003-09-30|July 2008|2008-07-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Observational|||HIV Testing in Pregnant Women: Evaluating an Opt-Out Testing Strategy|HIV Testing in Pregnant Women: An Evaluation of an Opt-Out Strategy in an Ambulatory Care Clinic Setting|Completed|||1074|Actual|St. Michael's Hospital, Toronto|||1||f||||f||||||||||2018-06-01 03:40:38.739098|2018-06-01 03:40:38.739098
NCT00393289|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2016-07-19|2006-10-26|2006-10-27|Estimate|||||||2016-07-19|2016-07-20|Estimate|November 2005||2005-11-30|July 2016|2016-07-31|March 2007|Actual|2007-03-31|April 2006|Actual|2006-04-30||Interventional|||Calcium Absorption and Retention From Marine Products|Calcium Absorption and Retention From Marine Products|Completed||N/A|12|Actual|University of Copenhagen|||||f||||f||||||||Yes||2018-06-01 03:40:38.924277|2018-06-01 03:40:38.924277
NCT00393276|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2014-12-08|2006-10-25|2006-10-27|Estimate|||||||2014-12-08|2014-12-09|Estimate|August 2007||2007-08-31|December 2014|2014-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals|Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by Identifying Determinants of Responsiveness: A Pilot Study|Completed||Phase 1|29|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 03:40:38.989257|2018-06-01 03:40:38.989257
NCT00393263|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2014-05-08|2006-10-26|2006-10-27|Estimate|||||||2014-05-08|2014-05-12|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus|A Double-Blind, Parallel-group Trial of Topical Pimecrolimus Cream 1% (Elidel®) Versus Clobetasol 0.05% Cream for the Treatment of Vulvar Lichen Sclerosus|Completed||Phase 2|38|Actual|Center for Vulvovaginal Disorders||2|||f||||||||||||||2018-06-01 03:40:39.087276|2018-06-01 03:40:39.087276
NCT00393250|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2018-05-11|2006-10-26|2006-10-27|Estimate|||||||2018-05-11|2018-05-14|Actual|October 23, 2006||2006-10-23|March 6, 2018|2018-03-06|June 4, 2012|Actual|2012-06-04|June 4, 2012|Actual|2012-06-04||Interventional|||Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease|Hypnosis as a Pain and Symptom Management Strategy in Patients With Sickle Cell Disease|Completed||Phase 3|31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:40:39.158017|2018-06-01 03:40:39.158017
NCT00393224|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2018-04-04|2006-10-26|2006-10-27|Estimate|||||||2018-04-04|2018-04-05|Actual|July 5, 2005||2005-07-05|August 21, 2017|2017-08-21||||||||Observational|||Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families|Defining Markers of Susceptibility to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families|Completed|||952|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:40:39.234258|2018-06-01 03:40:39.234258
NCT00393211|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2015-11-27|2006-10-26|2006-10-27|Estimate|||||||2015-11-27|2015-11-30|Estimate|April 2000||2000-04-30|November 2015|2015-11-30|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)|A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain|Completed||Phase 3|319|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:40:39.289543|2018-06-01 03:40:39.289543
NCT00393198|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-26|||2014-10-31|2006-10-26|2006-10-27|Estimate|||||||2014-10-31|2014-11-03|Estimate|October 2006||2006-10-31|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia|Multicenter Study to Investigate the Bleeding Profile and the Insertion Easiness in Women Inserted With a Second Consecutive MIRENA for Contraception or Menorrhagia|Completed||Phase 4|204|Actual|Bayer||3|||f||||f||||||||||2018-06-01 03:40:39.419108|2018-06-01 03:40:39.419108
NCT00393185|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2012-10-04|2006-10-24|2006-10-26|Estimate|||||||2012-10-04|2012-10-08|Estimate|January 2006||2006-01-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis|Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis: A Phase I Study|Withdrawn||Phase 1|0|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 03:40:39.535102|2018-06-01 03:40:39.535102
NCT00393172|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2014-12-11|2006-10-25|2006-10-26|Estimate|||||||2014-12-11|2014-12-12|Estimate|May 2006||2006-05-31|December 2014|2014-12-31|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|WISER||Women in Steady Exercise Research [Formerly Women, Oxidative Stress, Exercise and Estrogens (WOSEE)]|Women in Steady Exercise Research (WISER)|Completed||Phase 2/Phase 3|400|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 03:40:39.591875|2018-06-01 03:40:39.591875
NCT00393159|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2006-10-24|2006-10-24|2006-10-26|Estimate|||||||2006-10-24|2006-10-26|Estimate|October 2006||2006-10-31|October 2006|2006-10-31||||||||Interventional|||The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children|The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children|Unknown status|Recruiting|Phase 4|30||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 03:40:39.664418|2018-06-01 03:40:39.664418
NCT00393146|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2015-05-11|2006-10-24|2006-10-26|Estimate|||||||2015-05-11|2015-05-13|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis|A Randomized, Double Blind, Placebo Controlled Study to Investigate the Safety and Tolerability and Clinical Activity of 28 Days of Oral Repeat Dosing With GW856553 at 7.5mg BID in Subjects With Active Rheumatoid Arthritis on Stable Anti-rheumatic Therapy.|Completed||Phase 2|57|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:40:39.749444|2018-06-01 03:40:39.749444
NCT00393120|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24||2010-06-18|2018-03-22|2006-10-24|2006-10-26|Estimate||||2010-06-18|2010-06-22|Estimate|2018-03-22|2018-03-26|Estimate|October 2006||2006-10-31|March 2018|2018-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients|A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.|Completed||Phase 2|45|Actual|Incyte Corporation||3|||f||||f||||||||||2018-06-01 03:40:39.849155|2018-06-01 03:40:39.849155
NCT00393107|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2006-10-25|2006-10-25|2006-10-26|Estimate|||||||2006-10-25|2006-10-26|Estimate|March 2000||2000-03-31|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab|Phase II Study of Rituximab in Combination With Fludarabine and Cyclophosphamide for the Treatment of Relapsed Follicular Lymphoma|Completed||Phase 2|54||Gruppo Italiano Studio Linfomi|||||f||||||||||||||2018-06-01 03:40:39.937307|2018-06-01 03:40:39.937307
NCT00393094|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2012-03-27||2012-07-06|2006-10-25|2006-10-26|Estimate|2012-05-25|2012-07-06|Estimate||||2012-07-06|2012-07-13|Estimate|September 2006||2006-09-30|July 2012|2012-07-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Bevacizumab and Irinotecan to Treat Brain Tumors|A Phase II Trial of Bevacizumab and Irinotecan for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (NCT00271609)(Bevacizumab Alone for Recurrent Gliomas)|Terminated||Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)|Evaluating combination therapy, 19 GBM patients were enrolled. Accrual was terminated after it became clear that we could not reach our efficacy rule of 3 or more of 29 patients responding. The AG arm never fully accrued before the study was closed.|1||Terminated due to the limitations of accrual.|f||||f||||||||||2018-06-01 03:40:40.047606|2018-06-01 03:40:40.047606
NCT00393068|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2012-08-22||2012-10-31|2006-10-25|2006-10-26|Estimate|2012-10-31|2012-11-30|Estimate||||2012-10-31|2012-11-30|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|August 2011|Actual|2011-08-31|September 2009|Actual|2009-09-30||Interventional|||Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer|A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer|Completed||Phase 2|62|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 03:40:40.366257|2018-06-01 03:40:40.366257
NCT00393055|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2011-09-09|2006-10-25|2006-10-26|Estimate|||||||2011-09-09|2011-09-12|Estimate|January 2007||2007-01-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Xylitol Adult Caries Trial (X-ACT)|Xylitol Adult Caries Trial (X-ACT)|Completed||Phase 3|709|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 03:40:40.556796|2018-06-01 03:40:40.556796
NCT00393042|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2015-12-16||2017-03-07|2006-10-25|2006-10-26|Estimate|2017-03-07|2017-04-19|Actual||||2017-03-07|2017-04-19|Actual|January 2006||2006-01-31|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||77 individuals were screened , 13 patients were excluded, 64 patients were randomized. Of the 64 randomized, 21 discontinued at various points during the trial.|Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR|Sleep and Tolerability of Extended Release Dexmethylphenidate vs. Mixed Amphetamine Salts: A Double Blind, Placebo Controlled Study (SAT STUDY)|Completed||Phase 3|77|Actual|Seattle Children's Hospital|"Due to early withdrawal or loss of contact during the study, the sample size for analysis was smaller.~The dosing design of the study may have led to more adverse events than would occur in clinic."|2|||f||||t||||||||||2018-06-01 03:40:40.644994|2018-06-01 03:40:40.644994
NCT00393029|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2011-06-01||2011-08-10|2006-10-25|2006-10-26|Estimate|2011-07-11|2011-08-05|Estimate||||2011-08-10|2011-08-15|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes|Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 T Cell Receptor (TCR)-Gene Engineered Lymphocytes|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 03:40:41.519457|2018-06-01 03:40:41.519457
NCT00393003|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2009-08-28|2006-10-25|2006-10-26|Estimate|||||||2009-08-28|2009-08-31|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index|Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index: Comparison Between Manual Perfusion and Automated Perfusion|Completed||Phase 4|32||Hopital Foch|||||f||||f||||||||||2018-06-01 03:40:41.993744|2018-06-01 03:40:41.993744
NCT00392990|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2017-03-15|2006-10-25|2006-10-26|Estimate|||||||2017-03-15|2017-03-16|Actual|October 2006||2006-10-31|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma|A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma|Active, not recruiting||Phase 2|25|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 03:40:42.065372|2018-06-01 03:40:42.065372
NCT00392977|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2013-12-17|2006-10-25|2006-10-26|Estimate|||||||2013-12-17|2013-12-19|Estimate|August 2006||2006-08-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Brain Manganese Deposition in High Risk Neonates|Brain Manganese Deposition in High Risk Neonates|Completed|||43|Actual|Vanderbilt University|||||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 03:40:42.184546|2018-06-01 03:40:42.184546
NCT00392964|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2007-04-10|2006-10-25|2006-10-26|Estimate|||||||2007-04-10|2007-04-11|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Observational|||Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine|Patterns of Antiacids Use in Patients With IHD Admitted to Department of Internal Medicine|Completed|||1200||Rambam Health Care Campus|||||f||||f||||||||||2018-06-01 03:40:42.25503|2018-06-01 03:40:42.25503
NCT00392951|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2017-06-01||2017-11-02|2006-10-24|2006-10-26|Estimate|2017-11-02|2017-12-06|Actual||||2017-11-02|2017-12-06|Actual|December 2006||2006-12-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2016|Actual|2016-02-29||Interventional|||Sirolimus for Autoimmune Disease of Blood Cells|Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series|Active, not recruiting||Phase 1/Phase 2|30|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-06-01 03:40:42.33032|2018-06-01 03:40:42.33032
NCT00392938|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2017-03-08|2006-10-25|2006-10-26|Estimate|||||||2017-03-08|2017-03-13|Actual|December 2005||2005-12-31|March 2017|2017-03-31||||May 2010|Actual|2010-05-31||Observational|||Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone|Positron Emission Tomography Imaging of Bone in Patients With Metastatic Prostate Cancer - A Pilot Study Evaluating Treatment Response|Completed|||11|Actual|University of Washington|||||f||||||||||||||2018-06-01 03:40:42.569466|2018-06-01 03:40:42.569466
NCT00392769|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2012-08-03||2012-08-03|2006-10-25|2006-10-26|Estimate|2012-08-03|2012-09-06|Estimate||||2012-08-03|2012-09-06|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer|Phase II Study of Cetuximab (Erbitux) in Patients With Progressive or Recurrent Endometrial Cancer|Completed||Phase 2|33|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:40:46.653211|2018-06-01 03:40:46.653211
NCT00392925|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2013-08-12|2011-09-19|2015-03-26|2006-10-24|2006-10-26|Estimate|2014-01-28|2014-02-28|Estimate|2011-09-19|2011-09-26|Estimate|2015-03-26|2015-04-14|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional||177 participants enrolled into the study and started a 4 week lead-in period. 38 participants withdrew from the study during the lead-in period and 139 participants were randomized into one of 3 treatment groups. Baseline demographics presented for all 177 enrolled participants, by treatment group or those not randomized to a treatment group.|A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects|A Phase 2A, Randomized, Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Effect on Body Weight of Recombinant-Methionyl Human Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects|Completed||Phase 2|177|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 03:40:42.712234|2018-06-01 03:40:42.712234
NCT00392912|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2010-08-18|2006-10-25|2006-10-26|Estimate|||||||2010-08-18|2010-08-19|Estimate|April 2007||2007-04-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|November 2009|Actual|2009-11-30||Interventional|||Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone|A Pilot Study of the Effect of Testosterone on Cerebral Glucose Metabolism in Hypogonadal Males With Alzheimer's Disease|Completed||N/A|10|Actual|VA Medical Center, Houston|||||f||||f||||||||||2018-06-01 03:40:43.903055|2018-06-01 03:40:43.903055
NCT00392899|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2016-09-26|2006-10-25|2006-10-26|Estimate|||||||2016-09-26|2016-09-28|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Interventional|||Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery|Randomized Phase III Trial of Adjuvant Chemotherapy With UFT vs. Observation in Curatively Resected Stage II Colon Cancer|Completed||Phase 3|2025|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-06-01 03:40:44.04719|2018-06-01 03:40:44.04719
NCT00392886|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2013-12-17|2006-10-25|2006-10-26|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2004||2004-03-31|October 2010|2010-10-31||||December 2010|Anticipated|2010-12-31||Interventional|||Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors|Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III]|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:40:44.530788|2018-06-01 03:40:44.530788
NCT00392873|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2017-05-03|2006-10-25|2006-10-26|Estimate|||||||2017-05-03|2017-05-08|Actual|September 2006||2006-09-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Increased Calorie Intake to Reverse Energy Deficiency in Exercising Women: Impact on Bone and Menstrual Cyclicity|"REFUEL Active Women's Study II: Increased Caloric Intake to Reverse Energy Deficiency in Exercising Women: Impact on Bone and Menstrual Cyclicity"|Completed||N/A|233|Actual|Penn State University||3|||f||||t||||||||||2018-06-01 03:40:44.694712|2018-06-01 03:40:44.694712
NCT00392860|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2013-06-18||2014-01-04|2006-10-24|2006-10-26|Estimate|2014-01-04|2014-02-21|Estimate||||2014-01-04|2014-02-21|Estimate|August 2008||2008-08-31|January 2014|2014-01-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Development of an Ergonomic Wheelchair Pushrim|Development of an Ergonomic Manual Wheelchair Pushrim- Phase II|Completed||Phase 2|4|Actual|VA Pittsburgh Healthcare System||3|||f||||f||||||||||2018-06-01 03:40:44.780343|2018-06-01 03:40:44.780343
NCT00392847|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2012-07-06|2006-10-25|2006-10-26|Estimate|||||||2012-07-06|2012-07-10|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|CAPEDP||Promoting Parental Skills and Enhancing Attachment in Early Childhood|Promoting Parental Skills and Enhancing Attachment in Early Childhood|Completed||N/A|440|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:40:45.022848|2018-06-01 03:40:45.022848
NCT00392834|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2013-01-24||2018-02-05|2006-10-25|2006-10-26|Estimate|2013-01-24|2013-02-28|Estimate||||2018-02-05|2018-03-06|Actual|September 2006||2006-09-30|February 2018|2018-02-28|July 2013|Actual|2013-07-31|July 2011|Actual|2011-07-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma|Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma|Completed||Phase 2|34|Actual|AIDS Malignancy Consortium||2|||f||||f||||||||||2018-06-01 03:40:45.127912|2018-06-01 03:40:45.127912
NCT00392821|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2014-02-10||2014-02-10|2006-10-25|2006-10-26|Estimate|2014-02-10|2014-03-26|Estimate||||2014-02-10|2014-03-26|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer|Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma|Completed||Phase 1/Phase 2|78|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 03:40:45.500045|2018-06-01 03:40:45.500045
NCT00392808|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2013-08-06||2013-08-06|2006-10-25|2006-10-26|Estimate|2013-08-06|2013-10-11|Estimate||||2013-08-06|2013-10-11|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|CSISP-MENC1||Immunogenicity of the Booster Dose of Two MenC Vaccines|Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life.|Completed||Phase 4|389|Actual|Centro Superior de Investigación en Salud Publica||4|||f||||f||||||||||2018-06-01 03:40:45.799086|2018-06-01 03:40:45.799086
NCT00392795|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2017-03-22|2006-10-25|2006-10-26|Estimate|||||||2017-03-22|2017-03-23|Actual|January 2007||2007-01-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2010|Actual|2010-12-31||Observational|BRAIN-ICU||The BRAIN Intensive Care Unit (ICU) Study: Bringing to Light the Risk Factors|The BRAIN ICU Study: Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors|Active, not recruiting|||826|Actual|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:40:46.166139|2018-06-01 03:40:46.166139
NCT00392782|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2011-06-15||2017-12-03|2006-10-25|2006-10-26|Estimate|2011-06-15|2011-07-15|Estimate||||2017-12-03|2017-12-28|Actual|July 2005||2005-07-31|December 2017|2017-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease|A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies|Terminated||Phase 2|24|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 03:40:46.246082|2018-06-01 03:40:46.246082
NCT00392756|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2017-08-31|2006-10-25|2006-10-26|Estimate|||||||2017-08-31|2017-09-01|Actual|April 1989||1989-04-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)|Role of Gonadotropin Pulsations in the Reversal of Hypogonadotropic Hypogonadism|Recruiting||N/A|800|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 03:40:46.850603|2018-06-01 03:40:46.850603
NCT00392743|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2012-11-01|2006-10-24|2006-10-26|Estimate|||||||2012-11-01|2012-11-05|Estimate|December 2006||2006-12-31|October 2012|2012-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients|An Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders|Completed|||60|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-06-01 03:40:47.055022|2018-06-01 03:40:47.055022
NCT00392730|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2013-12-18|2006-10-25|2006-10-26|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 2006||2006-08-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children|Neurodevelopment and Neuroimaging in Parenterally-fed Infants and Young Children|Completed|||122|Actual|Vanderbilt University|||3||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 03:40:47.164354|2018-06-01 03:40:47.164354
NCT00392717|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2006-10-25|2006-10-25|2006-10-26|Estimate|||||||2006-10-25|2006-10-26|Estimate|February 1998||1998-02-28|October 2006|2006-10-31|March 2002||2002-03-31|||||Interventional|||Regulation of Lipoprotein Metabolism in Obese Men|Effect of Atorvastatin and Fish Oils on Lipoprotein Metabolism in Visceral Obesity|Completed||Phase 3|48||The University of Western Australia|||||f||||||||||||||2018-06-01 03:40:47.273485|2018-06-01 03:40:47.273485
NCT00392704|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2013-01-14||2013-02-18|2006-10-25|2006-10-26|Estimate|2013-01-14|2013-02-15|Estimate||||2013-02-18|2013-02-22|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|August 2008|Actual|2008-08-31||Interventional|||Treatment of Head & Neck Cancer With Chemotherapy and Radiation|A Phase II Trial of Neoadjuvant Chemotherapy Plus Bevacizumab Followed By Concurrent Chemotherapy/Bevacizumab/Erlotinib/Radiation Therapy in the Treatment of Locally Advanced Squamous Carcinoma of the Head and Neck|Completed||Phase 2|60|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 03:40:47.368907|2018-06-01 03:40:47.368907
NCT00392691|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2013-07-09|2006-10-25|2006-10-26|Estimate|||||||2013-07-09|2013-07-10|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment|Ibritumomab Tiuxetan and High-Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation for Elderly Patients With Lymphoma in Relapse or Resistant to Chemotherapy. A Multicenter Phase I Trial|Completed||Phase 1|20|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||||2018-06-01 03:40:47.674336|2018-06-01 03:40:47.674336
NCT00392678|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2013-02-20||2017-11-08|2006-10-25|2006-10-26|Estimate|2013-07-25|2013-07-26|Estimate||||2017-11-08|2017-12-11|Actual|October 2006||2006-10-31|November 2017|2017-11-30|December 2010|Actual|2010-12-31|July 2008|Actual|2008-07-31||Interventional|TINSAL-T2D||Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)|Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate|Completed||Phase 2/Phase 3|277|Actual|Joslin Diabetes Center||4|||f||||t||||||||||2018-06-01 03:40:47.805711|2018-06-01 03:40:47.805711
NCT00392665|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2017-01-24||2017-03-15|2006-10-24|2006-10-26|Estimate|2017-01-24|2017-03-14|Actual||||2017-03-15|2017-04-13|Actual|October 2006||2006-10-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Interventional|||Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck|Randomized Study of Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|36|Actual|Massachusetts General Hospital||2||slow accrual|f||||||||||||||2018-06-01 03:40:48.428116|2018-06-01 03:40:48.428116
NCT00392652|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2016-12-28|2006-10-25|2006-10-26|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2006||2006-11-30|December 2016|2016-12-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Diindolylmethane in Healthy Volunteers|Phase 1 Multiple-Dose Safety, Pharmacokinetic, and Drug Interaction Clinical Study of Nutritional-Grade, Absorption-Enhanced DIM (BR-DIM)|Completed||Phase 1|14|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:40:48.930555|2018-06-01 03:40:48.930555
NCT00392639|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2009-11-30|2006-10-25|2006-10-26|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2006||2006-11-30|July 2007|2007-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Clinical and Economical Interest of Endovascular Cooling in the Management of Cardiac Arrest (ICEREA Study)|Clinical Interest of Endovascular Cooling in the Management of Cardiac Arrest: Impact on Mortality in a Randomized Medico-economical Trial (the ICEREA Study)|Completed||Phase 4|389|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:40:48.994358|2018-06-01 03:40:48.994358
NCT00392613|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2010-01-06|2006-10-25|2006-10-26|Estimate|||||||2010-01-06|2010-01-07|Estimate|January 2005||2005-01-31|July 2007|2007-07-31||||December 2009|Actual|2009-12-31||Interventional|||RAte Control Efficacy in Permanent Atrial Fibrillation|RAte Control Efficacy in Permanent Atrial Fibrillation, a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure.|Completed||N/A|500|Anticipated|University Medical Center Groningen|||||f||||||||||||||2018-06-01 03:40:49.163966|2018-06-01 03:40:49.163966
NCT00392587|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2012-05-31|2006-10-25|2006-10-26|Estimate|||||||2012-05-31|2012-06-04|Estimate|August 2006||2006-08-31|March 2011|2011-03-31||||||||Interventional|||A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)|A Randomised, Double-blind, Placebo-controlled Parallel Study to Assess the Safety, Tolerability,Pharmacodynamics and Steady State Pharmacokinetics of Repeated Doses of GW856553 in Patients With COPD|Completed||Phase 2|30|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:40:49.225862|2018-06-01 03:40:49.225862
NCT00392574|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24||2010-08-27|2015-04-27|2006-10-25|2006-10-26|Estimate||||2010-08-27|2010-08-31|Estimate|2015-04-27|2015-05-15|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea|A Multicenter, Double-Blind, Randomized Study to Compare The Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers|Completed||Phase 3|282|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:40:49.318|2018-06-01 03:40:49.318
NCT00392561|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2017-09-05|2006-10-24|2006-10-26|Estimate|||||||2017-09-05|2017-09-06|Actual|April 2006||2006-04-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BEST||Bangladesh Vitamin E and Selenium Trial|Bangladesh Vitamin E and Selenium Trial|Active, not recruiting||N/A|7000|Actual|University of Chicago||4|||f||||t||||||||||2018-06-01 03:40:49.387354|2018-06-01 03:40:49.387354
NCT00392548|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2006-10-25|2006-10-25|2006-10-26|Estimate|||||||2006-10-25|2006-10-26|Estimate|October 2006||2006-10-31|September 2006|2006-09-30|October 2006||2006-10-31|||||Observational|||URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol|Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence|Unknown status|Not yet recruiting||130||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 03:40:49.457839|2018-06-01 03:40:49.457839
NCT00392535|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2011-05-19|2006-10-25|2006-10-26|Estimate|||||||2011-05-19|2011-05-20|Estimate|October 2002||2002-10-31|July 2009|2009-07-31||||September 2012|Anticipated|2012-09-30||Interventional|||Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer|Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP|Unknown status|Recruiting|Phase 3|2163|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:40:49.516033|2018-06-01 03:40:49.516033
NCT00392522|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2007-10-04|2006-10-25|2006-10-26|Estimate|||||||2007-10-04|2007-10-05|Estimate|November 2006||2006-11-30|October 2007|2007-10-31||||||||Interventional|||50% Nitrous Oxide and 50% Oxygen (MEOPA) Conscious Sedation Versus Placebo in Fiberoptic Bronchoscopy|50% Nitrous Oxide and 50% Oxygen (MEOPA) Conscious Sedation Versus Placebo in Fiberoptic Bronchoscopy : Randomized, Double Blind, Placebo-Controlled Study|Unknown status|Active, not recruiting|Phase 3|64|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:40:49.639825|2018-06-01 03:40:49.639825
NCT00392509|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2009-05-13|2006-10-25|2006-10-26|Estimate|||||||2009-05-13|2009-05-14|Estimate|October 2006||2006-10-31|May 2009|2009-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CLI-001||ALD-301 for Critical Limb Ischemia, Randomized Trial|A Phase I-II Randomized Autologous Bone Marrow Derived Aldehyde Dehydrogenase-Bright (ALDHbr) Cells Against Unfractionated Autologous Mononuclear Bone Marrow in Patients With Rutherford 4 or 5 Peripheral Arterial Occlusive Disease|Completed||Phase 1/Phase 2|20|Anticipated|Aldagen||1|||f||||t||||||||||2018-06-01 03:40:49.688404|2018-06-01 03:40:49.688404
NCT00392496|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2013-10-21||2014-04-28|2006-10-25|2006-10-26|Estimate|2013-10-21|2013-12-12|Estimate||||2014-04-28|2014-05-15|Estimate|February 2007||2007-02-28|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||Two patients who were determined as ineligible were excluded from all analyses|Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma|A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:40:49.76469|2018-06-01 03:40:49.76469
NCT00392483|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2010-06-24|2006-10-25|2006-10-26|Estimate|||||||2010-06-24|2010-06-25|Estimate|November 2006||2006-11-30|November 2006|2006-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Reuptake of an E-Learning Programme in General Practice|The Use and Diffusion of an E-learning Programme in Diagnostic Evaluation of Dementia Among General Practitioners in Denmark|Completed|||3632|Actual|Research Unit Of General Practice, Copenhagen|||||f||||||||||||||2018-06-01 03:40:50.926057|2018-06-01 03:40:50.926057
NCT00392470|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2011-05-24|2006-10-25|2006-10-26|Estimate|||||||2011-05-24|2011-05-25|Estimate|August 2006||2006-08-31|April 2008|2008-04-30||||||||Interventional|||Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer|Neoadjuvant Conformal Radiotherapy and Concomitant CPT-11 and EGFR Inhibition With Cetuximab in Patients With Rectal Cancer Phase I Study|Unknown status|Recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:40:50.987719|2018-06-01 03:40:50.987719
NCT00392457|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2015-02-12|2006-10-25|2006-10-26|Estimate|||||||2015-02-12|2015-02-16|Estimate|July 1995||1995-07-31|April 2010|2010-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Investigating the Regulation of Reproductive Hormones in Adult Men|Feedback Control of FSH Secretion in the Human Male|Completed||N/A|175|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:40:51.069517|2018-06-01 03:40:51.069517
NCT00392444|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2013-10-21||2014-05-05|2006-10-25|2006-10-26|Estimate|2013-10-21|2013-12-13|Estimate||||2014-05-05|2014-05-21|Estimate|February 2007||2007-02-28|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||1 patient was cancelled due to intercurrent illness and another 3 were found to be ineligible after review. Those 4 patients were excluded from all analyses.|Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma|A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma|Completed||Phase 2|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:40:51.166261|2018-06-01 03:40:51.166261
NCT00392431|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2007-03-21|2006-10-25|2006-10-26|Estimate|||||||2007-03-21|2007-03-22|Estimate|January 2003||2003-01-31|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Continuous Versus Episodic Amiodarone Treatment for the Prevention of Permanent Atrial Fibrillation|Continuous Versus Episodic Prophylactic Treatment With Oral Amiodarone for the Prevention of Permanent Atrial Fibrillation: a Randomized Study on Morbidity and Quality of Life|Completed||N/A|220||University Medical Center Groningen|||||f||||||||||||||2018-06-01 03:40:51.406|2018-06-01 03:40:51.406
NCT00392418|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2010-03-11|2006-10-25|2006-10-26|Estimate|||||||2010-03-11|2010-03-15|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|March 2005||2005-03-31|||||Interventional|||Flexible Administration of Sprinkles® in Infants and Young Children in Rural Bangladesh.|The Effectiveness of Flexible Administration of Sprinkles® in a Mixed Population of Anemic and Non-anemic Infants and Young Children in Rural Bangladesh.|Completed||N/A|360||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 03:40:51.549284|2018-06-01 03:40:51.549284
NCT00392405|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2006-10-25|2006-10-25|2006-10-26|Estimate|||||||2006-10-25|2006-10-26|Estimate|November 2006||2006-11-30|October 2006|2006-10-31||||||||Interventional|||Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate|Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate|Unknown status|Not yet recruiting|Phase 2|656||Norton Community Hospital|||||f||||||||||||||2018-06-01 03:40:51.620581|2018-06-01 03:40:51.620581
NCT00392392|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|2013-01-11||2013-09-17|2006-10-25|2006-10-26|Estimate|2013-01-11|2013-02-13|Estimate||||2013-09-17|2013-09-20|Estimate|October 2006||2006-10-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|April 2008|Actual|2008-04-30||Interventional|||Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer|Phase II Study of Preoperative Bevacizumab and Trastuzumab Administered With ABI-007 and Carboplatin in HER2 Overexpressing Breast Cancer|Completed||Phase 2|29|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 03:40:51.717128|2018-06-01 03:40:51.717128
NCT00392379|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2010-06-02||2013-04-16|2006-10-25|2006-10-26|Estimate|2010-08-09|2010-08-30|Estimate||||2013-04-16|2013-04-24|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction|Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction|Completed||Phase 3|270|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:40:52.018318|2018-06-01 03:40:52.018318
NCT00392366|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2009-12-30|2006-10-24|2006-10-26|Estimate|||||||2009-12-30|2010-01-01|Estimate|July 2006||2006-07-31|December 2009|2009-12-31|July 2008|Actual|2008-07-31|||||Interventional|||"Laser Interstitial Thermal Therapy Under Real Time MRI Guidance for Minimal Invasive Treatment of Liver Metastasis"|"The Clinical Evaluation of the Laser Interstitial Thermal Therapy (LITT ), Under Real Time MRI Guidance, for the Minimal Invasive Treatment of Liver Metastasis - a Phase IIa Mono-centric Study, Without Direct Benefice to the Patient"|Completed||N/A|25|Anticipated|BioTex, Inc.|||||f||||||||||||||2018-06-01 03:40:52.276175|2018-06-01 03:40:52.276175
NCT00392353|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2018-03-15|2006-10-25|2006-10-26|Estimate|||||||2018-03-15|2018-03-16|Actual|November 22, 2006|Actual|2006-11-22|March 2018|2018-03-31||||December 31, 2019|Anticipated|2019-12-31||Interventional|||Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia|A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination With Azacitidine in Patients With the Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 1/Phase 2|135|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:40:52.341398|2018-06-01 03:40:52.341398
NCT00392340|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2013-09-16|2006-10-25|2006-10-26|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2008||2008-03-31|June 2009|2009-06-30||||January 2010|Anticipated|2010-01-31||Interventional|||Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma|An Open-Label, Multicentre, Phase II Study of TVD as Treatment for Children With Stage 4 Neuroblastoma Failing to Respond to First-Line Treatment According to HR-NBL-01/ E-SIOP [Topotecan-Vincristine-Doxorubicin in Children With Stage 4 Neuroblastoma Failing to Respond to COJEC (TVD)]|Unknown status|Active, not recruiting|Phase 2|63|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:40:52.483858|2018-06-01 03:40:52.483858
NCT00392327|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2017-08-29|2006-10-25|2006-10-26|Estimate|||||||2017-08-29|2017-08-31|Actual|March 2007||2007-03-31|August 2017|2017-08-31||||June 2018|Anticipated|2018-06-30||Interventional|||Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma|Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients|Recruiting||Phase 3|400|Anticipated|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 03:40:52.617768|2018-06-01 03:40:52.617768
NCT00392314|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-25|||2014-05-08|2006-10-25|2006-10-26|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.|Phase 2 Study.Tailored Therapy for Hodgkin Lymphoma Based on Predefined Risk Factors and Early Interim PET/CT for Response Assessment and Further Therapy Decisions.|Completed||Phase 2|365|Actual|Rambam Health Care Campus||4|||f||||f||||||||||2018-06-01 03:40:53.113152|2018-06-01 03:40:53.113152
NCT00392301|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2018-02-20|2006-10-24|2006-10-25|Estimate|||||||2018-02-20|2018-02-22|Actual|October 2009|Anticipated|2009-10-31|February 2018|2018-02-28|July 1, 2012|Actual|2012-07-01|July 1, 2012|Actual|2012-07-01||Observational|||Split-Thickness Skin Graft Donor Site Wound Healing Study|Split-Thickness Skin Graft Donor Site Wound Healing Study|Withdrawn|||0|Actual|University of Mississippi Medical Center||||Not funded - and PI left for another position in 2012|f||||f||||||||||2018-06-01 03:40:53.197097|2018-06-01 03:40:53.197097
NCT00392288|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2009-07-01||2016-12-02|2006-10-24|2006-10-25|Estimate|2009-11-27|2009-12-30|Estimate||||2016-12-02|2017-02-01|Estimate|September 2006||2006-09-30|September 2016|2016-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.|A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 μg BID or 40 μg BID for 12 Weeks in Patients Aged 4 to <12 Years With Persistent Asthma.|Completed||Phase 3|528|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 03:40:53.284266|2018-06-01 03:40:53.284266
NCT00392275|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2013-04-08|2006-10-24|2006-10-25|Estimate|||||||2013-04-08|2013-04-10|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|May 2006|Actual|2006-05-31|||||Interventional|||Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs|Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs|Completed||Phase 4|48||Indiana University|||||f||||||||||||||2018-06-01 03:40:53.627585|2018-06-01 03:40:53.627585
NCT00392262|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2016-11-16|2006-10-23|2006-10-25|Estimate|||||||2016-11-16|2016-11-18|Estimate|August 2006||2006-08-31|November 2016|2016-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients|An Multicenter Study to Evaluate the Efficacy and Tolerability of a 4-week Therapy With the Combination of Valsartan 160mg + Amlodipine 5mg in Hypertensive Patients Not Adequately Responding to 4-week Treatment With Amlo 5mg or Felodipine 5mg in Monotherapy|Completed||Phase 3|224|Actual|Novartis|||||f||||||||||||||2018-06-01 03:40:53.719554|2018-06-01 03:40:53.719554
NCT00392249|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2008-02-25|2006-10-24|2006-10-25|Estimate|||||||2008-02-25|2008-02-27|Estimate|November 2006||2006-11-30|February 2008|2008-02-29|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||Supervised Treatment of Schizophrenia, a Randomized Controlled Trial.|Supervised Treatment in Outpatients for Schizophrenia (STOPS)Versus Treatment as Usual in Outpatients, a Randomized Controlled Trial.|Unknown status|Active, not recruiting|Phase 1/Phase 2|110|Anticipated|Lady Reading Hospital, Pakistan|||||f||||||||||||||2018-06-01 03:40:53.791288|2018-06-01 03:40:53.791288
NCT00392236|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|2014-03-10||2017-09-22|2006-10-24|2006-10-25|Estimate|2014-03-10|2014-04-29|Estimate||||2017-09-22|2017-10-25|Actual|April 2006||2006-04-30|September 2017|2017-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-way Pagers|2-Way Pagers to Improve Schizophrenia Medication Adherence|Completed||N/A|55|Actual|Northwell Health||2|||f||||t||||||||||2018-06-01 03:40:53.856312|2018-06-01 03:40:53.856312
NCT00392223|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|2009-06-11||2010-01-05|2006-10-23|2006-10-25|Estimate|2009-06-11|2009-08-03|Estimate||||2010-01-05|2010-01-12|Estimate|October 2007||2007-10-31|January 2010|2010-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne|A Phase III, Multicenter, Randomized, Double Blind-Double Dummy Study, To Evaluate Efficacy And Safety Of Treatment With Azithromycin, Microspheres, Oral Powder For Suspension, 2 G, In One Administration A Week, For 8 Weeks, Compared With Treatment With Minocycline Capsules, 100 Mg Die For 8 Weeks, In Outpatients With Moderate To Severe Inflammatory Acne.|Terminated||Phase 3|118|Actual|Pfizer||2||See Detailed Description|f||||||||||||||2018-06-01 03:40:54.17061|2018-06-01 03:40:54.17061
NCT00392210|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|2011-05-03||2017-04-25|2006-10-24|2006-10-25|Estimate|2017-04-25|2017-04-27|Actual||||2017-04-25|2017-04-27|Actual|October 2006||2006-10-31|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery|Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery|Completed||N/A|79|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 03:40:54.989263|2018-06-01 03:40:54.989263
NCT00392197|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2013-12-19||2013-12-19|2006-10-24|2006-10-25|Estimate|2013-12-19|2014-02-12|Estimate||||2013-12-19|2014-02-12|Estimate|November 2006||2006-11-30|December 2013|2013-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||"The glucose metabolism analysis set.~The numbers of excluded subjects from the data of partcipant flow were:~violation of inclusion/exclusion criteria: naïve arm- 4, prior treated arm- 1~no data of blood glucose level after treatment: naïve arm- 3, prior treated arm- 2"|Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-|Post Marketing Clinical Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism-|Completed||Phase 4|111|Actual|Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-06-01 03:40:55.256771|2018-06-01 03:40:55.256771
NCT00392184|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2015-05-29|2006-10-24|2006-10-25|Estimate|||||||2015-05-29|2015-06-01|Estimate|November 2000||2000-11-30|May 2015|2015-05-31|October 2010|Actual|2010-10-31|February 2009|Actual|2009-02-28||Interventional|||Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery|Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery|Completed||Phase 2|274|Actual|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-06-01 03:40:55.566296|2018-06-01 03:40:55.566296
NCT00392171|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2010-04-21||2017-05-15|2006-10-24|2006-10-25|Estimate|2010-04-21|2010-05-17|Estimate||||2017-05-15|2017-06-07|Actual|June 9, 2006|Actual|2006-06-09|May 2017|2017-05-31|September 15, 2009|Actual|2009-09-15|September 15, 2009|Actual|2009-09-15||Interventional|||The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)|The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma|Completed||Phase 2|120|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:40:55.668734|2018-06-01 03:40:55.668734
NCT00392158|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2016-09-23|2006-10-24|2006-10-25|Estimate|||||||2016-09-23|2016-09-26|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|April 2007|Actual|2007-04-30|||||Interventional|||Manual Administration of Propofol-remifentanil Versus Dual Closed-loop Using Bispectral Index as the Control Variable|Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison Between Manual Perfusion and Automated Perfusion|Completed||Phase 4|240||Hopital Foch|||||f||||f||||||||No||2018-06-01 03:40:55.895816|2018-06-01 03:40:55.895816
NCT00392145|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2018-04-16|2006-10-23|2006-10-25|Estimate|||||||2018-04-16|2018-04-17|Actual|November 2006||2006-11-30|April 2018|2018-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis|Emergency Department Rapid Intravenous Rehydration (RIVR) for Pediatric Gastroenteritis: A Randomized Controlled Trial|Completed||Phase 4|226|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 03:40:55.978086|2018-06-01 03:40:55.978086
NCT00392132|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2018-05-29|2006-10-24|2006-10-25|Estimate|||||||2018-05-29|2018-05-30|Actual|October 2005||2005-10-31|May 2018|2018-05-31|October 2006|Anticipated|2006-10-31|October 2006|Anticipated|2006-10-31||Observational|||Impact of Screening Patients With HIV for Kidney Disease|Impact of Screening Patients With HIV for Kidney Disease|Withdrawn|||0|Actual|University of Mississippi Medical Center||||Sufficient study funding was not obtained.|f||||||||||||||2018-06-01 03:40:56.054458|2018-06-01 03:40:56.054458
NCT00392119|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2009-12-30|2006-10-24|2006-10-25|Estimate|||||||2009-12-30|2010-01-01|Estimate|October 2006||2006-10-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|||||Interventional|||"MR Guided Laser Interstitial Thermal Therapy for the Minimal Invasive Treatment of Brain Metastasis and Primary Brain Tumors"|"The Clinical Evaluation of the Stereotactic, MR Guided, Laser Interstitial Thermal Therapy (LITT ) for the Minimal Invasive Treatment of Brain Metastasis and Primary Brain Tumors - a Phase I Study With Direct Patient Benefice"|Completed||Phase 1|18|Anticipated|BioTex, Inc.|||||f||||||||||||||2018-06-01 03:40:56.106131|2018-06-01 03:40:56.106131
NCT00392106|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2008-06-16|2006-10-24|2006-10-25|Estimate|||||||2008-06-16|2008-06-17|Estimate|April 2006||2006-04-30|June 2008|2008-06-30|June 2011|Anticipated|2011-06-30|December 2010|Anticipated|2010-12-31||Interventional|||High Intensity Focused Ultrasound (HIFU) Ablation System Study|Study of Focused Circumferential UltraSound for the Treatment of Atrial Fibrillation|Suspended||Phase 3|240|Anticipated|ProRhythm, Inc.||2||voluntarily by Sponsor to investigate an anticipated SAE|f||||||||||||||2018-06-01 03:40:56.170956|2018-06-01 03:40:56.170956
NCT00392093|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2006-10-23|2006-10-23|2006-10-25|Estimate|||||||2006-10-23|2006-10-25|Estimate|November 1997||1997-11-30|October 2006|2006-10-31|December 2001||2001-12-31|||||Interventional|||Effect of Hormone Replacement Therapy on Lupus Activity|Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial|Completed||Phase 4|108||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||||||||||||2018-06-01 03:40:56.279814|2018-06-01 03:40:56.279814
NCT00392080|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2008-03-18|2006-10-23|2006-10-25|Estimate|||||||2008-03-18|2008-03-24|Estimate|November 2006||2006-11-30|March 2008|2008-03-31|February 2008|Actual|2008-02-29|||||Interventional|||A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers|A Multicenter, Randomized, Placebo And Active-Controlled Study Of The Effect Of CJ-023,423 On The Incidence Gastroduodenal Endoscopic Ulcers In Healthy Subjects|Completed||Phase 1|340|Anticipated|Pfizer||3|||f||||f||||||||||2018-06-01 03:40:56.34752|2018-06-01 03:40:56.34752
NCT00392067|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2008-04-29|2006-10-24|2006-10-25|Estimate|||||||2008-04-29|2008-04-30|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||LEO19123 Cream in the Treatment of Atopic Dermatitis|LEO19123 Cream in the Treatment of Atopic Dermatitis|Completed||Phase 2|75|Anticipated|LEO Pharma|||||f||||||||||||||2018-06-01 03:40:56.424317|2018-06-01 03:40:56.424317
NCT00392054|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2011-07-20|2006-10-23|2006-10-25|Estimate|||||||2011-07-20|2011-07-22|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|RAAFT||First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)|First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment: A Multi-center Randomized Trial|Unknown status|Active, not recruiting|Phase 3|127|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-06-01 03:40:56.482694|2018-06-01 03:40:56.482694
NCT00392041|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2014-02-19|2006-10-24|2006-10-25|Estimate|||||||2014-02-19|2014-02-20|Estimate|August 2006||2006-08-31|February 2014|2014-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Eszopiclone in the Treatment of Insomnia and Fibromyalgia|Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia|Completed||Phase 4|36|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 03:40:56.682926|2018-06-01 03:40:56.682926
NCT00392028|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2007-07-12|2006-10-24|2006-10-25|Estimate|||||||2007-07-12|2007-07-13|Estimate|November 2006||2006-11-30|July 2007|2007-07-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Penetration of Ertapenem Into Bone|Penetration of Ertapenem Into Bone in Patients With Diabetes Mellitus or Peripheral Vascular Diseases Who Underwent Bellow Knee Amputation|Withdrawn||N/A|12|Anticipated|HaEmek Medical Center, Israel||||no recruitment|f||||f||||||||||2018-06-01 03:40:56.77968|2018-06-01 03:40:56.77968
NCT00392015|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24||2015-06-08|2017-10-12|2006-10-24|2006-10-25|Estimate||||2015-06-08|2015-07-07|Estimate|2017-10-12|2017-10-17|Actual|October 12, 2006|Actual|2006-10-12|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2016|Actual|2016-02-29||Interventional|||NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1|A Two Part Clinical Trial Assessing the Safety, Tolerability, Immunogenicity and Protective Efficacy of NMRC-M3V-Ad-PfCA, a Multivalent, Adenovirus-Vectored Plasmodium Falciparum Malaria Vaccine, in Healthy, Malaria-Naïve Adults|Active, not recruiting||Phase 1/Phase 2|70|Anticipated|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-06-01 03:40:56.840998|2018-06-01 03:40:56.840998
NCT00392002|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2008-01-24|2006-10-24|2006-10-25|Estimate|||||||2008-01-24|2008-01-25|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response|A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].|Completed||Phase 4|2000||AstraZeneca|||||f||||||||||||||2018-06-01 03:40:56.921956|2018-06-01 03:40:56.921956
NCT00391989|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2014-01-23||2016-11-16|2006-10-24|2006-10-25|Estimate|2015-01-22|2015-01-26|Estimate||||2016-11-16|2017-01-04|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Adult Ph+ LAL With BMS-354825|A Phase II Multicenter Study on the Treatment of Adult de Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) With the Protein Tyrosine Kinase Inhibitor BMS-354825. EudraCT Number 2005-005107-42.|Completed||Phase 2|53|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||||||||||||2018-06-01 03:40:56.998817|2018-06-01 03:40:56.998817
NCT00391976|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2011-05-18||2011-07-29|2006-10-24|2006-10-25|Estimate|2011-07-29|2011-08-29|Estimate||||2011-07-29|2011-08-29|Estimate|November 2003||2003-11-30|July 2011|2011-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|ELITE||Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis|The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis|Completed||Phase 3|123|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:40:57.234821|2018-06-01 03:40:57.234821
NCT00391963|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2009-01-14|2006-10-24|2006-10-25|Estimate|||||||2009-01-14|2009-01-15|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|April 2007|Actual|2007-04-30|||||Observational|||Comparison of the Bispectral Index and the Entropy of the Electroencephalogram During Total Intravenous Anesthesia|Comparison of the Bispectral Index and the Entropy of the Electroencephalogram During Total Intravenous Anesthesia|Completed|||84||Hopital Foch|||||f||||||||||||||2018-06-01 03:40:57.726587|2018-06-01 03:40:57.726587
NCT00391950|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2009-11-20|2006-10-24|2006-10-25|Estimate|||||||2009-11-20|2009-11-23|Estimate|October 2006||2006-10-31|November 2009|2009-11-30||||May 2007|Actual|2007-05-31||Interventional|||Maintaining Bone Strength in Men With Prostate Cancer|An Open-Label, Randomized, Multicentre Study to Evaluate the Efficacy of Two Zoledronic Acid Schedules on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy|Terminated||Phase 3|300|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:40:57.782065|2018-06-01 03:40:57.782065
NCT00391937|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2013-02-28|2006-10-24|2006-10-25|Estimate|||||||2013-02-28|2013-03-01|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|||Efficacy of a New Resurfacing Hip Prosthesis|Efficacy of a New Resurfacing Hip Prosthesis. A Multicenter, Prospective, Randomized, Controlled Study|Completed||Phase 3|150|Actual|Erasmus Medical Center||2|||f||||||||||||||2018-06-01 03:40:57.854821|2018-06-01 03:40:57.854821
NCT00391924|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2006-10-24|2006-10-24|2006-10-25|Estimate|||||||2006-10-24|2006-10-25|Estimate|May 2000||2000-05-31|October 2006|2006-10-31|January 2003||2003-01-31|||||Interventional|||Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome|Fatigue and General Well-Being in Patients With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome: Effects of Dehydroepiandrosterone Administration|Completed||Phase 2|120||UMC Utrecht|||||f||||||||||||||2018-06-01 03:40:57.931186|2018-06-01 03:40:57.931186
NCT00391911|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2012-03-01|2006-10-24|2006-10-25|Estimate|||||||2012-03-01|2012-03-05|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis|A Randomized Factorial Trial of N-Acetylcysteine and Continuous Veno-Venous Hemo(Dia)Filtration for Rhabdomyolysis|Completed||Phase 2|3|Actual|Royal Alexandra Hospital||4|||f||||f||||||||||2018-06-01 03:40:58.005953|2018-06-01 03:40:58.005953
NCT00391898|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|2011-01-04||2011-02-16|2006-10-24|2006-10-25|Estimate|2011-02-16|2011-03-15|Estimate||||2011-02-16|2011-03-15|Estimate|October 2006||2006-10-31|February 2011|2011-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off|A 3-month, Multi-center, Double-blind, Randomized Study to Evaluate the Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Impairment of Activities of Daily Living and Early Wearing-off With Levodopa|Completed||Phase 4|95|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:40:58.122331|2018-06-01 03:40:58.122331
NCT00391885|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2016-09-26|2006-10-24|2006-10-25|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2006||2006-09-30|September 2016|2016-09-30|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy|Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy of the Electroencephalogram: Comparison Between Manual Perfusion and Automated Perfusion|Completed||Phase 4|60||Hopital Foch|||||f||||f||||||||No||2018-06-01 03:40:58.459052|2018-06-01 03:40:58.459052
NCT00391872|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|2011-01-31||2012-02-10|2006-10-23|2006-10-25|Estimate|2012-02-10|2012-03-13|Estimate||||2012-02-10|2012-03-13|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|PLATO||A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome|A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]|Completed||Phase 3|18624|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:40:58.684265|2018-06-01 03:40:58.684265
NCT00391859|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-24|||2014-03-14|2006-10-24|2006-10-25|Estimate|||||||2014-03-14|2014-03-17|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pharmacist-initiated Intervention Trial in OsteoArthritis (PhIT-OA)|Pharmacist-initiated Intervention Trial in OsteoArthritis (PhIT-OA)|Completed||N/A|135|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 03:41:04.11713|2018-06-01 03:41:04.11713
NCT00391846|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2010-05-10||2012-06-18|2006-10-23|2006-10-25|Estimate|2012-05-15|2012-06-18|Estimate||||2012-06-18|2012-06-25|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone|A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Systolic Dysfunction|Completed||Phase 4|252|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:41:04.22475|2018-06-01 03:41:04.22475
NCT00391833|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-22|||2006-10-22|2006-10-22|2006-10-24|Estimate|||||||2006-10-22|2006-10-24|Estimate|April 2004||2004-04-30|October 2006|2006-10-31|October 2005||2005-10-31|||||Interventional|||Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease||Completed||Phase 1/Phase 2|||Seoul National University Hospital|||||f||||||||||||||2018-06-01 03:41:04.939283|2018-06-01 03:41:04.939283
NCT00391820|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2014-12-01|2006-10-20|2006-10-24|Estimate|||||||2014-12-01|2014-12-03|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of TD-5108 for the Treatment of Chronic Constipation|Completed||Phase 2|360|Anticipated|Theravance Biopharma R & D, Inc.|||||f||||f||||||||||2018-06-01 03:41:04.992611|2018-06-01 03:41:04.992611
NCT00391807|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2010-11-23||2013-04-15|2006-10-20|2006-10-24|Estimate|2010-11-23|2010-12-22|Estimate||||2013-04-15|2013-04-22|Estimate|November 2006||2006-11-30|April 2013|2013-04-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Study of Safety and Efficacy of an Oral Contraceptive|Open-Label Study of the Safety and Efficacy of a Low Dose Oral Contraceptive Containing Norethindrone Acetate and Ethinyl Estradiol|Completed||Phase 3|1683|Actual|Warner Chilcott||1|||f||||f||||||||||2018-06-01 03:41:05.096224|2018-06-01 03:41:05.096224
NCT00391794|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2014-01-09|2006-10-23|2006-10-24|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy of Early Stage Alzheimer's Support Groups|Efficacy of Early Stage Alzheimer's Support Groups|Completed||N/A|154|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:41:05.625642|2018-06-01 03:41:05.625642
NCT00391781|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2007-09-24|2006-10-23|2006-10-24|Estimate|||||||2007-09-24|2007-09-26|Estimate|December 2006||2006-12-31|August 2007|2007-08-31|December 2008||2008-12-31|||||Interventional|||Warm Contrast Media for Pain Reduction During Hystersalpingography|Prospective Randomised Controlled Trian of Warmed vs. Room Temperature Contrast Media for Hystersalpingography|Unknown status|Recruiting|N/A|||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:41:05.709986|2018-06-01 03:41:05.709986
NCT00391768|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2011-03-17||2013-04-25|2006-10-20|2006-10-24|Estimate|2011-05-19|2011-06-20|Estimate||||2013-04-25|2013-05-01|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza|A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) for the Treatment of Children Less Than 24 Months of Age With Confirmed Influenza Infection (CASG 114)|Completed||Phase 1/Phase 2|87|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 03:41:05.823075|2018-06-01 03:41:05.823075
NCT00391755|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-22|||2012-02-08|2006-10-23|2006-10-24|Estimate|||||||2012-02-08|2012-02-10|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches|A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches|Terminated||Phase 4|4|Actual|Charlottesville Neuroscience||2||Failure to recruit necessary number of patients.|f||||t||||||||||2018-06-01 03:41:06.834796|2018-06-01 03:41:06.834796
NCT00391742|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2006-10-23|2006-10-23|2006-10-24|Estimate|||||||2006-10-23|2006-10-24|Estimate|October 2001||2001-10-31|October 2006|2006-10-31|June 2004||2004-06-30|||||Interventional|||Stepped Interventions for Problem Drinkers|A Stepped-Care Approach for General Practice Patients With Alcohol Use Disorders|Completed||N/A|450||University of Luebeck|||||f||||||||||||||2018-06-01 03:41:06.900216|2018-06-01 03:41:06.900216
NCT00391729|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2011-10-14|2006-10-23|2006-10-24|Estimate|||||||2011-10-14|2011-10-18|Estimate|October 2006||2006-10-31|October 2011|2011-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|221|Actual|Abbott||2|||f||||||||||||||2018-06-01 03:41:06.958968|2018-06-01 03:41:06.958968
NCT00391716|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2014-06-09||2014-11-07|2006-10-20|2006-10-24|Estimate|2014-11-07|2014-11-10|Estimate||||2014-11-07|2014-11-10|Estimate|February 2004||2004-02-29|November 2014|2014-11-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional||Sample size estimate was derived from results of a prior trial that found an odds ratio of 2.96 for complete abstinence, estimating a sample size of 150 would show a medium effect size for the difference between gabapentin and placebo in rate of complete abstinence.|Gabapentin Treatment of Alcohol Dependence|Gabapentin Treatment of Alcohol Dependence|Completed||Phase 2|150|Actual|The Scripps Research Institute||3|||f||||f||||||||||2018-06-01 03:41:07.119075|2018-06-01 03:41:07.119075
NCT00391703|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2010-11-10|2006-10-23|2006-10-24|Estimate|||||||2010-11-10|2010-11-11|Estimate|October 2006||2006-10-31|November 2010|2010-11-30|September 2010|Actual|2010-09-30|November 2009|Actual|2009-11-30||Interventional|STIMUCO||Assessment of Quadriceps Muscle Electrostimulation Used in Patients Suffering From Cystic Fibrosis|Assessment of Quadriceps Muscle Electrostimulation Used as an Additional Procedure for Effort Retraining in Patients Suffering From Cystic Fibrosis Associated With Severe Pulmonary Dysfunction|Terminated||N/A|40|Anticipated|University Hospital, Grenoble||2||enrolment difficulties|f||||f||||||||||2018-06-01 03:41:07.51711|2018-06-01 03:41:07.51711
NCT00391690|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2016-11-16|2006-10-23|2006-10-24|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2006||2006-02-28|November 2016|2016-11-30||||December 2010|Actual|2010-12-31||Interventional|||Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer|Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer|Completed||Phase 4|99|Actual|Novartis|||||f||||||||||||||2018-06-01 03:41:07.595098|2018-06-01 03:41:07.595098
NCT00390988|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2009-02-19|2006-10-20|2006-10-23|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Observational|||Capillary and Venous Blood Count Parameters|Comparison of Capillary and Venous Blood Count Parameters|Completed|||250||University of Magdeburg|||||f||||||||||||||2018-06-01 03:41:24.849417|2018-06-01 03:41:24.849417
NCT00391677|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2012-09-27|2006-10-20|2006-10-24|Estimate|||||||2012-09-27|2012-09-28|Estimate|January 2007||2007-01-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia|Effectiveness Trial of Attention Shaping for Schizophrenia|Completed||N/A|120|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-06-01 03:41:07.664505|2018-06-01 03:41:07.664505
NCT00391664|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2008-06-26|2006-10-23|2006-10-24|Estimate|||||||2008-06-26|2008-06-30|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|February 2011||2011-02-28|||||Observational|||Questionnaire Study for Gynecological Cancer Survivors|Gynecologic Cancer Survivorship Survey|Unknown status|Recruiting||1000|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:41:07.750099|2018-06-01 03:41:07.750099
NCT00391651|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2014-06-03|2006-10-23|2006-10-24|Estimate|||||||2014-06-03|2014-06-05|Estimate|January 2002||2002-01-31|June 2014|2014-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Short Course Nitrofurantoin for Acute Cystitis|Short Course Nitrofurantoin For Acute Cystitis|Completed||Phase 2|338|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:41:07.865042|2018-06-01 03:41:07.865042
NCT00391638|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2015-01-14|2006-10-23|2006-10-24|Estimate|||||||2015-01-14|2015-01-15|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|October 2012|Actual|2012-10-31|May 2011|Actual|2011-05-31||Interventional|HB01EMVIPEG||Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients|Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients. ANRS HB 01 EMVIPEG.|Completed||Phase 2/Phase 3|56|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-06-01 03:41:07.952374|2018-06-01 03:41:07.952374
NCT00391625|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2014-03-04||2016-05-13|2006-10-20|2006-10-24|Estimate|2014-05-21|2014-06-23|Estimate||||2016-05-13|2016-06-17|Estimate|February 2005||2005-02-28|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)|An Open-Label Extension of Study TKT025 Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A Enzyme Replacement Therapy|Completed||Phase 1/Phase 2|10|Actual|Shire|Imputation was applied to missing data.|1|||f||||f||||||||||2018-06-01 03:41:08.121145|2018-06-01 03:41:08.121145
NCT00391612|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2011-01-10|2006-10-20|2006-10-24|Estimate|||||||2011-01-10|2011-01-12|Estimate|May 2006||2006-05-31|January 2011|2011-01-31|December 2013|Anticipated|2013-12-31|October 2009|Anticipated|2009-10-31||Interventional|EASE||EASE Trial: Exhale Airway Stents for Emphysema|A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects With Severe Hyperinflation|Unknown status|Active, not recruiting|Phase 3|450|Anticipated|Broncus Technologies||2|||f||||||||||||||2018-06-01 03:41:08.835863|2018-06-01 03:41:08.835863
NCT00391599|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-22|2015-12-18||2016-03-05|2006-10-23|2006-10-24|Estimate|2016-03-05|2016-04-04|Estimate||||2016-03-05|2016-04-04|Estimate|January 2009||2009-01-31|January 2016|2016-01-31||||October 2011|Actual|2011-10-31||Interventional|||Enemas Before Elective Cesarean Section|Are Enemas Given Before Elective Cesarean Section Useful?|Completed||Phase 2|130|Actual|Wolfson Medical Center||2|||f||||||||||||||2018-06-01 03:41:09.16714|2018-06-01 03:41:09.16714
NCT00391586|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|2015-06-15||2015-08-14|2006-10-23|2006-10-24|Estimate|2015-08-14|2015-08-17|Estimate||||2015-08-14|2015-08-17|Estimate|July 2006||2006-07-31|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional||These are patients who received at least one dose of on-study erlotinib|Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung|INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung|Terminated||Phase 2|45|Actual|New Mexico Cancer Care Alliance||1||PI left institution.|f||||t||||||||||2018-06-01 03:41:09.451827|2018-06-01 03:41:09.451827
NCT00391573|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2011-06-14|2006-10-23|2006-10-24|Estimate|||||||2011-06-14|2011-06-16|Estimate|March 2005||2005-03-31|June 2011|2011-06-30|June 2005||2005-06-30|||||Interventional|||Polyglactin Sutures Versus Nylon Sutures for Suturing of Conjunctival Autograft in Pterygium Surgery: a Randomised Controlled Trial|Polyglactin Sutures Versus Nylon Sutures for Suturing of Conjunctival Autograft in Pterygium Surgery: a Randomised Controlled Trial|Completed||N/A|32||Hospital Authority, Hong Kong|||||f||||||||||||||2018-06-01 03:41:09.826462|2018-06-01 03:41:09.826462
NCT00391560|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20||2018-02-15|2018-03-12|2006-10-23|2006-10-24|Estimate||||2018-03-02|2018-03-05|Actual|2018-03-12|2018-03-14|Actual|October 2006||2006-10-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia|Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia|Completed||Phase 2|19|Actual|AEterna Zentaris||2|||f||||f||||||||||2018-06-01 03:41:09.960649|2018-06-01 03:41:09.960649
NCT00391547|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2007-10-18|2006-10-23|2006-10-24|Estimate|||||||2007-10-18|2007-10-22|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|January 2007||2007-01-31|||||Interventional|||Pilot Efficacy Study to Treat Gingivitis|Phase II Pilot Efficacy Study to Treat Gingivitis|Completed||Phase 2|14||Biomedical Development Corporation|||||||||||||||||||2018-06-01 03:41:10.039411|2018-06-01 03:41:10.039411
NCT00391534|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2010-04-14|2006-10-23|2006-10-24|Estimate|||||||2010-04-14|2010-04-15|Estimate|October 2006||2006-10-31|January 2009|2009-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy|Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy|Terminated||Phase 3|100|Anticipated|Desitin Arzneimittel GmbH||2||Low recruitment rate|f||||f||||||||||2018-06-01 03:41:10.293072|2018-06-01 03:41:10.293072
NCT00391521|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2014-01-29|2006-10-23|2006-10-24|Estimate|||||||2014-01-29|2014-01-30|Estimate|August 2006||2006-08-31|January 2014|2014-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||AS703569 Phase I in Patients With Solid Tumours|A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours|Completed||Phase 1|104|Actual|EMD Serono||3|||f||||||||||||||2018-06-01 03:41:10.451435|2018-06-01 03:41:10.451435
NCT00391508|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2006-10-23|2006-10-23|2006-10-24|Estimate|||||||2006-10-23|2006-10-24|Estimate|September 2003||2003-09-30|October 2006|2006-10-31|August 2005||2005-08-31|||||Observational|||Skin Problems in Ostomy Patients: An Epidemiological Study|An Epidemiological Study of Peristomal Skin Problems in Patient With an Ostomy in Roskilde County|Unknown status|Active, not recruiting||200||Zealand University Hospital|||||f||||||||||||||2018-06-01 03:41:10.567313|2018-06-01 03:41:10.567313
NCT00391495|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-22|||2007-06-18|2006-10-22|2006-10-24|Estimate|||||||2007-06-18|2007-06-19|Estimate|September 2007||2007-09-30|August 2006|2006-08-31|December 2007|Anticipated|2007-12-31|||||Observational|ADHD_CYTO||Inflammation in Children With Attention-Deficit/Hyperactivity Disorder|Inflammation in Children With Attention-Deficit/Hyperactivity Disorder|Unknown status|Not yet recruiting||45|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-06-01 03:41:10.764163|2018-06-01 03:41:10.764163
NCT00391482|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2017-01-10|2006-10-20|2006-10-24|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2002||2002-06-30|November 2008|2008-11-30|February 2005||2005-02-28|||||Interventional|||Study to Reduce Intravenous Exposures (STRIVE)|Behavioral Intervention Trial to Reduce Transmission Risks and Improve HCV Treatment Access Among HCV-infected Injection Drug Users|Completed||Phase 2/Phase 3|750||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 03:41:11.242009|2018-06-01 03:41:11.242009
NCT00391469|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2014-11-23||2014-11-23|2006-10-20|2006-10-24|Estimate|2014-11-23|2014-12-02|Estimate||||2014-11-23|2014-12-02|Estimate|December 2007||2007-12-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Induction of Mild Hypothermia Following Out-of-hospital Cardiac Arrest|Study of the Use of Mild Hypothermia in Out-of-hospital Cardiac Arrest Using a Rapid Infusion of 2 Liters of Cold Normal Saline|Completed||Phase 2/Phase 3|1359|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 03:41:11.377476|2018-06-01 03:41:11.377476
NCT00391456|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2016-06-01|2006-10-23|2006-10-24|Estimate|||||||2016-06-01|2016-06-03|Estimate|November 2001||2001-11-30|June 2016|2016-06-30|July 2004||2004-07-31|||||Interventional|||Animal-Assisted Therapy for Hospitalized Heart Failure Patients|Use of Animal-Assisted Therapy to Decrease Cardiopulmonary Pressures, Neurohormone Levels, and State Anxiety in Patients Hospitalized With Heart Failure|Completed||N/A|76||University of California, Los Angeles|||||f||||||||||||||2018-06-01 03:41:11.828424|2018-06-01 03:41:11.828424
NCT00391443|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2012-04-25|2010-02-11|2015-09-09|2006-10-20|2006-10-24|Estimate|2012-04-25|2012-05-25|Estimate|2010-02-11|2010-02-15|Estimate|2015-09-09|2015-09-28|Estimate|February 2007||2007-02-28|August 2015|2015-08-31|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Interventional|BUILD 3||BUILD 3: Bosentan Use in Interstitial Lung Disease|Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.|Completed||Phase 3|616|Actual|Actelion||2|||f||||||||||||||2018-06-01 03:41:11.995661|2018-06-01 03:41:11.995661
NCT00391430|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2017-08-14|2006-10-20|2006-10-24|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2005||2005-05-31|August 2017|2017-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Cognitive Behavioral Therapy Versus Sertraline in the Treatment of Post-Traumatic Stress Disorder|Cognitive Behavioral Therapy vs. Sertraline in the Treatment of Post Traumatic Stress Disorder|Completed||Phase 4|90|Actual|New York University School of Medicine||3|||f||||f|t|f|||t|||||2018-06-01 03:41:13.474119|2018-06-01 03:41:13.474119
NCT00391417|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2006-10-20|2006-10-20|2006-10-24|Estimate|||||||2006-10-20|2006-10-24|Estimate|September 2003||2003-09-30|October 2006|2006-10-31|April 2005||2005-04-30|||||Interventional|||Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms|Phase III, Multicenter, Double-Blind Study of the Safety and Efficacy of Bio-E-Gel (Topical Estradiol Gel) Versus Placebo for Treatment of Vasomotor Symptoms and Vulvovaginal Atrophy in Postmenopausal Females|Completed||Phase 3|431||BioSante Pharmaceuticals|||||||||||||||||||2018-06-01 03:41:13.549952|2018-06-01 03:41:13.549952
NCT00391404|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|||2008-05-22|2006-10-23|2006-10-24|Estimate|||||||2008-05-22|2008-05-23|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|October 2008|Anticipated|2008-10-31|||||Interventional|||Fosamax for Childhood Cancer Survivors|Randomized Controlled Study on the Benefits and Safety of Bisphosphonate Treatment in Childhood Cancer Survivors|Unknown status|Recruiting|Phase 3|100|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 03:41:13.621008|2018-06-01 03:41:13.621008
NCT00391391|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-23|2011-10-12|2010-03-30|2011-11-21|2006-10-23|2006-10-24|Estimate|2011-10-12|2011-11-22|Estimate|2010-03-31|2010-04-02|Estimate|2011-11-21|2011-12-01|Estimate|October 2006||2006-10-31|November 2011|2011-11-30|October 2007|Actual|2007-10-31|March 2007|Actual|2007-03-31||Interventional|||Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children|Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.|Completed||Phase 2|520|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 03:41:13.748748|2018-06-01 03:41:13.748748
NCT00391378|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-21|||2017-06-30|2006-10-21|2006-10-24|Estimate|||||||2017-06-30|2017-07-02|Actual|September 9, 2006||2006-09-09|January 3, 2011|2011-01-03|January 3, 2011||2011-01-03|||||Observational|||Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)|Cerebral Lesions and Outcomes After Cardiac Surgery (CLOCS)|Completed|||363|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:41:14.668401|2018-06-01 03:41:14.668401
NCT00391365|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2016-09-26||2018-02-27|2006-10-20|2006-10-24|Estimate|2016-10-27|2016-12-21|Estimate||||2018-02-27|2018-03-27|Actual|March 1, 2005|Actual|2005-03-01|February 2018|2018-02-28|August 30, 2024|Anticipated|2024-08-30|August 1, 2015|Actual|2015-08-01||Observational|||Treatment Outcomes for Ankle Arthritis|Treatment Outcomes for Ankle Arthritis|Active, not recruiting|||369|Actual|VA Office of Research and Development|This study was not randomized, and no chart review was conducted.||2||f||||f|f|f|||f|None Retained|"~     No biospecimens are used in this project~   "|Undecided||2018-06-01 03:41:14.75592|2018-06-01 03:41:14.75592
NCT00391352|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2014-06-03|2006-10-20|2006-10-23|Estimate|||||||2014-06-03|2014-06-04|Estimate|February 2008||2008-02-29|May 2008|2008-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls|A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-β-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.|Completed|||21|Actual|Waukesha Memorial Hospital|||2||f||||f||||||||||2018-06-01 03:41:15.049293|2018-06-01 03:41:15.049293
NCT00391339|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2006-10-19|2006-10-19|2006-10-23|Estimate|||||||2006-10-19|2006-10-23|Estimate|November 2006||2006-11-30|October 2006|2006-10-31|October 2008||2008-10-31|||||Interventional|||Bryophyllum vs. Nifedipine|Bryophyllum p. Versus Nifedipine for the Treatment of Premature Contractions|Unknown status|Not yet recruiting|Phase 2/Phase 3|140||Weleda AG|||||f||||||||||||||2018-06-01 03:41:15.139205|2018-06-01 03:41:15.139205
NCT00391326|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2008-05-20|2006-10-19|2006-10-23|Estimate|||||||2008-05-20|2008-05-21|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Efficacy and Safety of Prehospital Administration of Bivalirudin in STEMI Patients|Efficacy and Safety of Prehospital Administration of Bivalirudin in STEMI Patients Redirected for Primary PCI Based on Tele-Transmitted 12-Lead ECGs|Completed|||102|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 03:41:15.213016|2018-06-01 03:41:15.213016
NCT00391313|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2015-08-27|2006-10-20|2006-10-23|Estimate|||||||2015-08-27|2015-08-28|Estimate|May 2006||2006-05-31|August 2015|2015-08-31|March 2007|Actual|2007-03-31|||||Interventional|||CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease|CuraChik : Double Blind Placebo-controlled Randomized Trial : Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease.|Terminated||Phase 3|||Assistance Publique Hopitaux De Marseille||||Terminated Chikungunya diseases has regressed and no more patients was suffering|f||||||||||||||2018-06-01 03:41:15.317532|2018-06-01 03:41:15.317532
NCT00391300|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2013-12-17|2006-10-20|2006-10-23|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2006||2006-10-31|October 2008|2008-10-31|April 2007|Anticipated|2007-04-30|April 2007|Anticipated|2007-04-30||Interventional|||Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions|Development of an Electrical Diagnostic for Melanoma and Other Cutaneous Malignancies|Unknown status|Active, not recruiting|Phase 1|100|Anticipated|National Cancer Institute (NCI)|||||f||||f||||||||||2018-06-01 03:41:15.399183|2018-06-01 03:41:15.399183
NCT00391287|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2014-10-02|2006-10-20|2006-10-23|Estimate|||||||2014-10-02|2014-10-03|Estimate|June 2006||2006-06-30|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|PRIMS||Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure|A Prospective, Immunogenicity Surveillance Registry (PRIMS) to Estimate the Incidence of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia Among Subjects With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products|Completed|||15334|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||f||||f||||||||||2018-06-01 03:41:15.537105|2018-06-01 03:41:15.537105
NCT00391274|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2009-12-21||2011-04-08|2006-10-19|2006-10-23|Estimate|2010-03-15|2010-03-30|Estimate||||2011-04-08|2011-04-12|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|December 2008|Actual|2008-12-31||Interventional|||Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy|Completed||Phase 3|211|Actual|Eli Lilly and Company|The primary outcome measure of this trial was designed to include pooled data. In addition, the results for the outcome on Duration of Response could not be presented due to the low number of patients being analyzed in the docetaxel group.|2|||f||||f||||||||||2018-06-01 03:41:16.163807|2018-06-01 03:41:16.163807
NCT00391261|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2010-03-24|2006-10-19|2006-10-23|Estimate|||||||2010-03-24|2010-03-25|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.|A Prospective Open-label Trial of Metformin for Weight Control of Pediatric Patients on Atypical Antipsychotic Medications.|Completed||Phase 4|11|Actual|Cambridge Health Alliance|||||f||||f||||||||||2018-06-01 03:41:16.896554|2018-06-01 03:41:16.896554
NCT00391248|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2013-01-28|2006-10-19|2006-10-23|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)|A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial)|Completed||Phase 2|40|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||t||||||||||2018-06-01 03:41:16.954213|2018-06-01 03:41:16.954213
NCT00391235|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2010-12-02|2006-10-19|2006-10-23|Estimate|||||||2010-12-02|2010-12-06|Estimate|September 2005||2005-09-30|December 2010|2010-12-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Observational|||White Matter in Pediatric Bipolar Disorder: A DTI Study|White Matter Connectivity in Pediatric Bipolar Disorder: A Diffusion Tensor Imaging Study|Completed|||28|Anticipated|Cambridge Health Alliance|||2||f||||f||||||||||2018-06-01 03:41:17.009024|2018-06-01 03:41:17.009024
NCT00391222|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2010-04-19||2014-04-24|2006-10-20|2006-10-23|Estimate|2010-10-07|2010-11-01|Estimate||||2014-04-24|2014-05-09|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder|Completed||Phase 3|585|Actual|Janssen Pharmaceutica N.V., Belgium||3|||f||||f||||||||||2018-06-01 03:41:17.083739|2018-06-01 03:41:17.083739
NCT00391209|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19||2018-03-07|2018-03-07|2006-10-19|2006-10-23|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|October 2006||2006-10-31|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus|A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naive Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|379|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:41:18.737445|2018-06-01 03:41:18.737445
NCT00391196|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19||2009-08-11|2012-11-05|2006-10-19|2006-10-23|Estimate||||2009-08-11|2009-08-13|Estimate|2012-11-05|2012-11-07|Estimate|November 2006||2006-11-30|November 2012|2012-11-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients|A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 3|975|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:41:18.895543|2018-06-01 03:41:18.895543
NCT00391183|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2013-07-10|2006-10-19|2006-10-23|Estimate|||||||2013-07-10|2013-07-11|Estimate|January 2006||2006-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.|Effect of Palliative Biliary Stenting Versus Conservative Treatment on the Quality of Life (QOL) of Patients With Unresectable Carcinoma of the Gallbladder With Hiliar Block: A Randomised Controlled Trial|Completed||Phase 2/Phase 3|60|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||||||||||||2018-06-01 03:41:19.846497|2018-06-01 03:41:19.846497
NCT00391170|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2018-05-08|2006-10-20|2006-10-23|Estimate|||||||2018-05-08|2018-05-09|Actual|October 17, 2006||2006-10-17|April 20, 2018|2018-04-20|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease|Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease|Recruiting||Phase 2|82|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:41:19.933247|2018-06-01 03:41:19.933247
NCT00391157|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2009-09-17|2006-10-20|2006-10-23|Estimate|||||||2009-09-17|2009-09-18|Estimate|August 2005||2005-08-31|September 2009|2009-09-30|January 2008|Actual|2008-01-31|June 2007|Actual|2007-06-30||Interventional|||VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma|VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients.|Completed||Phase 2|40|Actual|PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:41:20.019953|2018-06-01 03:41:20.019953
NCT00391144|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2006-10-20|2006-10-20|2006-10-23|Estimate|||||||2006-10-20|2006-10-23|Estimate|July 2006||2006-07-31|October 2006|2006-10-31|October 2006||2006-10-31|||||Interventional|||Avastin for CNV Secondary to Pattern Dystrophy|Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy|Unknown status|Recruiting|Phase 2/Phase 3|5||University of Trieste|||||f||||||||||||||2018-06-01 03:41:20.121229|2018-06-01 03:41:20.121229
NCT00391131|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2012-06-05|2006-10-20|2006-10-23|Estimate|||||||2012-06-05|2012-06-07|Estimate|April 2007||2007-04-30|June 2012|2012-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Subcutaneous Ig NextGen 16% in PID Patients|A Multi-centre, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Subcutaneous Infusions of Ig NextGen 16% in Patients With Primary Immunodeficiency (PID).|Completed||Phase 3|35|Actual|CSL Limited||1|||f||||||||||||||2018-06-01 03:41:20.220585|2018-06-01 03:41:20.220585
NCT00391118|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19||2011-02-25|2012-07-19|2006-10-19|2006-10-23|Estimate||||2011-02-25|2011-03-11|Estimate|2012-07-19|2012-07-26|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|April 2010|Actual|2010-04-30||Interventional|||"Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (Sugar Pill)"|A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer|Completed||Phase 2|149|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:41:20.406496|2018-06-01 03:41:20.406496
NCT00391105|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2006-10-19|2006-10-19|2006-10-23|Estimate|||||||2006-10-19|2006-10-23|Estimate|April 2004||2004-04-30|October 2006|2006-10-31|November 2005||2005-11-30|||||Interventional|||Remifentanil Versus Morphine for Sedation of Premature Neonates With Respiratory Distress Syndrome|Comparative Study of the Use of Remifentanil Versus Morphine for Sedation and Analgesia of Premature Neonates During Mechanical Ventilation in the Treatment of Respiratory Distress Syndrome (RDS)|Completed||Phase 4|||Federal University of Minas Gerais|||||f||||||||||||||2018-06-01 03:41:20.505473|2018-06-01 03:41:20.505473
NCT00391092|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2015-07-21||2015-08-21|2006-10-20|2006-10-23|Estimate|2015-07-21|2015-08-14|Estimate||||2015-08-21|2015-08-28|Estimate|September 2006||2006-09-30|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Intent-to-treat (ITT) population: All randomized participants, regardless of whether they actually received study treatment or not.|A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.|A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer.|Completed||Phase 3|424|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:41:20.644872|2018-06-01 03:41:20.644872
NCT00391079|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2012-05-30||2013-06-13|2006-10-20|2006-10-23|Estimate|2012-05-30|2012-07-04|Estimate||||2013-06-13|2013-06-24|Estimate|September 2006||2006-09-30|June 2013|2013-06-30|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|||Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS|A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis|Completed||Phase 3|339|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-06-01 03:41:21.69762|2018-06-01 03:41:21.69762
NCT00391066|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19||2015-09-17|2015-09-17|2006-10-19|2006-10-23|Estimate||||2015-09-17|2015-10-02|Estimate|2015-09-17|2015-10-02|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|LUCID||Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)|A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia|Terminated||Phase 2|627|Actual|Biogen||2|||f||||t||||||||||2018-06-01 03:41:22.132343|2018-06-01 03:41:22.132343
NCT00391053|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2010-01-14||2016-04-12|2006-10-20|2006-10-23|Estimate|2010-03-26|2010-04-30|Estimate||||2016-04-12|2016-04-14|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|February 2008|Actual|2008-02-29|July 2007|Actual|2007-07-31||Interventional|||Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly|Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.|Completed||Phase 3|3851|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 03:41:22.556817|2018-06-01 03:41:22.556817
NCT00391040|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2006-10-20|2006-10-20|2006-10-23|Estimate|||||||2006-10-20|2006-10-23|Estimate|November 2003||2003-11-30|October 2006|2006-10-31|May 2006||2006-05-31|||||Interventional|||SGS: a Structured Treatment and Teaching Programme for Elderly Patients With Diabetes Mellitus|SGS: a Structured Treatment and Teaching Programme for Elderly Patients With Diabetes Mellitus - a Prospective Randomized Controlled Multicenter Trial|Completed||N/A|200||German Diabetes Association|||||f||||||||||||||2018-06-01 03:41:23.886221|2018-06-01 03:41:23.886221
NCT00391027|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2009-08-05||2015-06-30|2006-10-19|2006-10-23|Estimate|2009-09-15|2009-10-21|Estimate||||2015-06-30|2015-07-23|Estimate|December 2006||2006-12-31|June 2015|2015-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®|A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents|Completed||Phase 4|261|Actual|Pfizer|Enrollment period concluded earlier than planned due to cancellation of Exubera® program by sponsor; enrollment was undersized to meet requirements of its inferential objectives. Revised analysis approach was descriptive with no inferential analyses.|2|||f||||f||||||||||2018-06-01 03:41:23.978411|2018-06-01 03:41:23.978411
NCT00391014|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2009-05-11|2006-10-20|2006-10-23|Estimate|||||||2009-05-11|2009-05-12|Estimate|January 2006||2006-01-31|May 2009|2009-05-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|AMBINEB||Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis|AMBINEB: Clinical Trial to Evaluate Tolerance and Safety of Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis in Patients With Acute Myeloid Leukemia and Allogeneic Haematopoietic Progenitor Cell Transplant (Alo-HPCT)|Completed||Phase 2|150|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-06-01 03:41:24.695444|2018-06-01 03:41:24.695444
NCT00391001|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2010-02-02|2006-10-20|2006-10-23|Estimate|||||||2010-02-02|2010-02-03|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Taurine in Adolescents With Bipolar Disorder|Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study in Adolescents With Bipolar Disorder|Terminated||Phase 1|4|Actual|Cambridge Health Alliance||2|||f||||f||||||||||2018-06-01 03:41:24.78254|2018-06-01 03:41:24.78254
NCT00390975|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2012-05-03|2006-10-20|2006-10-23|Estimate|||||||2012-05-03|2012-05-04|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis|An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms|Terminated||Phase 4|40|Anticipated|Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in~   2007"|||||||||||||||2018-06-01 03:41:24.899982|2018-06-01 03:41:24.899982
NCT00390962|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2008-09-22|2006-10-20|2006-10-23|Estimate|||||||2008-09-22|2008-09-23|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||"The COSMOS-Study (Copeptin in Osmoregulation and Stress Assessment)"|"Copeptin as a Novel Diagnostic and Prognostic Marker in the Management of Neurological and Neurosurgical Patients With Sodium Imbalance The COSMOS-Study (Copeptin in Osmoregulation and Stress Assessment)"|Completed|||469|Actual|University Hospital, Basel, Switzerland|||||f||||||||||Samples Without DNA|"~     bood sampling~   "|||2018-06-01 03:41:24.955544|2018-06-01 03:41:24.955544
NCT00390949|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2015-05-27|2006-10-20|2006-10-23|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 1998||1998-07-31|October 2006|2006-10-31|February 2003||2003-02-28|||||Interventional|||Scientific Evaluation of Peer Education and STD Treatment to Reduce the Spread of HIV in Zimbabwe|Impact and Process Evaluation of Integrated Community and Clinic-based HIV-1 Control: a Cluster-randomised Trial in Eastern Zimbabwe|Completed||N/A|||Imperial College London|||||f||||||||||||||2018-06-01 03:41:25.019668|2018-06-01 03:41:25.019668
NCT00390936|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2011-01-24|2006-10-20|2006-10-23|Estimate|||||||2011-01-24|2011-01-25|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors|Phase I Multiple Ascending Dose Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Japanese Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|13|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:41:25.08163|2018-06-01 03:41:25.08163
NCT00390923|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2013-08-27|2006-10-19|2006-10-23|Estimate|||||||2013-08-27|2013-08-29|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence|Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence|Terminated||N/A|40|Anticipated|Centre for Addiction and Mental Health||2||Preliminary results did not support the utility of combining selegeline + NRT.|f||||f||||||||||2018-06-01 03:41:25.137154|2018-06-01 03:41:25.137154
NCT00390910|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20||2009-05-20|2016-11-03|2006-10-20|2006-10-23|Estimate||||2009-09-25|2009-09-28|Estimate|2016-11-03|2016-11-04|Estimate|October 2006||2006-10-31|November 2016|2016-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants|Study to Assess the Safety and Immunogenicity of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine When Co-administered With DTPa-HBV-IPV/Hib (Infanrix-Hexa) Vaccine in Preterm Infants as a 3-dose Primary Immunization Course During the First 6 Months of Life.|Completed||Phase 3|286|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:41:25.204808|2018-06-01 03:41:25.204808
NCT00390897|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|||2008-11-26|2006-10-20|2006-10-23|Estimate|||||||2008-11-26|2008-11-27|Estimate|July 2003||2003-07-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|October 2006|Actual|2006-10-31||Interventional|||Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia|Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia|Completed||Phase 4|360||PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:41:25.467133|2018-06-01 03:41:25.467133
NCT00390884|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-20|2009-09-21||2016-04-12|2006-10-20|2006-10-23|Estimate|2009-11-30|2009-12-31|Estimate||||2016-04-12|2016-04-14|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|September 2008|Actual|2008-09-30|June 2007|Actual|2007-06-30||Interventional|||Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.|Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) Among Healthy Children Immunized in Fall 2005 With Fluzone Vaccine or Placebo|Completed||Phase 4|173|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:41:25.62672|2018-06-01 03:41:25.62672
NCT00390871|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2013-04-11|2006-10-19|2006-10-20|Estimate|||||||2013-04-11|2013-04-12|Estimate|April 2005||2005-04-30|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|ANIST||Acute Neurological ICU Sedation Trial (ANIST)|Acute Neurological ICU Sedation Trial (ANIST)|Completed||Phase 2|60|Actual|Johns Hopkins University||2|||f||||||||||||||2018-06-01 03:41:26.113121|2018-06-01 03:41:26.113121
NCT00390858|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2010-12-21||2017-02-12|2006-10-19|2006-10-20|Estimate|2011-07-20|2011-08-15|Estimate||||2017-02-12|2017-03-20|Actual|September 2003||2003-09-30|February 2017|2017-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.|A 4-year Extension to a Phase II a Multicenter Study Evaluating Long-term Safety, Tolerability, Pharmacokinetics and Effects on Liver Iron Concentration of Repeated Doses of 10 mg/kg/Day of Deferasirox in Pediatric Patients With Transfusion Dependent β-thalassemia Major.|Completed||Phase 2|40|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:41:26.228368|2018-06-01 03:41:26.228368
NCT00390845|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18||2009-07-22|2017-08-21|2006-10-18|2006-10-20|Estimate||||2009-07-22|2009-08-10|Estimate|2017-08-21|2017-08-22|Actual|August 30, 2006|Actual|2006-08-30|August 2017|2017-08-31|August 11, 2008|Actual|2008-08-11|August 11, 2008|Actual|2008-08-11||Interventional|||P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain|A Double-blind Placebo-controlled Study of the Efficacy and Safety of the P38 Map Kinase Inhibitor SB681323 in Patients With Neuropathic Pain Following Nerve Trauma|Completed||Phase 2|50|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:41:26.898648|2018-06-01 03:41:26.898648
NCT00390832|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2010-12-16|2006-10-19|2006-10-20|Estimate|||||||2010-12-16|2010-12-17|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|REVIVAL-3||Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3)|Completed||Phase 3|138|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 03:41:26.991316|2018-06-01 03:41:26.991316
NCT00390806|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2013-03-08||2013-12-05|2006-10-19|2006-10-20|Estimate|2013-12-05|2014-01-20|Estimate||||2013-12-05|2014-01-20|Estimate|December 2006||2006-12-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Interventional|||Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer|A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer|Completed||Phase 3|472|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 03:41:27.335811|2018-06-01 03:41:27.335811
NCT00390793|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2018-04-12|2006-10-19|2006-10-20|Estimate|||||||2018-04-12|2018-04-17|Actual|September 2006|Actual|2006-09-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting||Phase 2|115|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-06-01 03:41:29.85478|2018-06-01 03:41:29.85478
NCT00390780|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2012-09-07||2013-09-05|2006-10-19|2006-10-20|Estimate|2013-07-26|2013-08-29|Estimate||||2013-09-05|2013-09-16|Estimate|July 2006||2006-07-31|February 2013|2013-02-28|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients|A Comparative Randomized, Double-blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (Clotrimazole 10mg) Administered Five Times a Day in the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients|Completed||Phase 3|578|Actual|Onxeo||2|||f||||t||||||||||2018-06-01 03:41:29.994046|2018-06-01 03:41:29.994046
NCT00390767|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2015-03-04|2006-10-19|2006-10-20|Estimate|||||||2015-03-04|2015-03-05|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|December 2024|Anticipated|2024-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)|A Phase I Safety, Dose Escalating Study of MultiGeneAngio in Patients With Peripheral Arterial Disease|Active, not recruiting||Phase 1/Phase 2|12|Actual|MultiGene Vascular Systems Ltd.||1|||f||||t||||||||||2018-06-01 03:41:30.678337|2018-06-01 03:41:30.678337
NCT00390754|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2008-07-25|2006-10-19|2006-10-20|Estimate|||||||2008-07-25|2008-07-29|Estimate|October 2006||2006-10-31|July 2008|2008-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Usefulness of Home Pregnancy Testing|Utility of Home Pregnancy Testing in Medicaid Women at Risk for Unintended Pregnancy|Completed||N/A|198|Actual|Michigan State University||2|||f||||t||||||||||2018-06-01 03:41:30.763697|2018-06-01 03:41:30.763697
NCT00390741|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2008-05-27|2006-10-18|2006-10-20|Estimate|||||||2008-05-27|2008-05-29|Estimate|October 1998||1998-10-31|May 2008|2008-05-31|September 2005|Actual|2005-09-30|September 2004|Actual|2004-09-30||Interventional|Hip4||BHS4 - Bone/Muscle Changes Following Hip Fracture in Older White Women|Bone/Muscle Changes Following Hip Fracture in Older White Women|Completed||N/A|170|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 03:41:30.837575|2018-06-01 03:41:30.837575
NCT00390728|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2010-08-30|2006-10-19|2006-10-20|Estimate|||||||2010-08-30|2010-08-31|Estimate|April 2002||2002-04-30|August 2010|2010-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|AT-LANTUS||"Insulin Glargine in Type I Diabetes Mellitus> Main Study AT.LANTUS: A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: HALT(Hypoglycaemia Avoidance With Lantus Trial)"|"A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 1 Diabetes Mellitus/ HALT Sub-study: Multicentre, Open Clinical Trial to Assess the Effect of Insulin Glargine on Symptomatic Hypoglycaemia, Fear of Hypoglycaemia and Quality of Life in Patients With Type 1 Diabetes"|Completed||Phase 4|2346||Sanofi|||||f||||||||||||||2018-06-01 03:41:30.909263|2018-06-01 03:41:30.909263
NCT00390715|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2010-03-11|2006-10-19|2006-10-20|Estimate|||||||2010-03-11|2010-03-15|Estimate|January 1999||1999-01-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|December 2007|Actual|2007-12-31||Observational|||Treatment of Acute Myeloblastic Leukemia in Younger Patients|Prospective Study of the Value of the Cytogenetic and of the Monitoring of the Minimal Residual Disease|Completed|||600|Anticipated|PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:41:30.969919|2018-06-01 03:41:30.969919
NCT00390702|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2012-08-22|2006-10-19|2006-10-20|Estimate|||||||2012-08-22|2012-08-23|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|August 2016|Anticipated|2016-08-31|August 2012|Actual|2012-08-31||Interventional|pfm-01/2005||Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System|International Multicentre Clinical Device Investigation on Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System for VSD Occlusion Developed by Pfm AG, Cologne|Suspended||Phase 2/Phase 3|338|Anticipated|pfm medical ag||1||"further recruitment terminated after CE mark attained; enclosed patients will be followed up to~   5 years"|f||||t||||||||||2018-06-01 03:41:31.074449|2018-06-01 03:41:31.074449
NCT00390689|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2009-03-05||2014-06-23|2006-10-19|2006-10-20|Estimate|2009-07-14|2009-08-25|Estimate||||2014-06-23|2014-07-02|Estimate|October 2006||2006-10-31|April 2014|2014-04-30||||March 2008|Actual|2008-03-31||Interventional|||A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS.|A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Pramipexole at Fixed Doses of 0.25 mg, 0.5 mg, and 0.75 mg in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by a 46-week Open-label Long-term Study|Completed||Phase 3|154|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 03:41:31.159108|2018-06-01 03:41:31.159108
NCT00390676|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2010-12-27|2006-10-19|2006-10-20|Estimate|||||||2010-12-27|2010-12-28|Estimate|November 2006||2006-11-30|December 2010|2010-12-31|November 2009|Actual|2009-11-30|||||Interventional|||A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine|A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006)|Completed||Phase 1|||Adherex Technologies, Inc.|||||f||||||||||||||2018-06-01 03:41:31.963765|2018-06-01 03:41:31.963765
NCT00390663|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2006-10-19|2006-10-19|2006-10-20|Estimate|||||||2006-10-19|2006-10-20|Estimate|October 2006||2006-10-31|October 2006|2006-10-31||||||||Interventional|||A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children|A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children: Antiseptic Cream Alone v's Antiseptic Cream With Nasal Cautery|Unknown status|Recruiting|Phase 4|216||NHS Greater Glasgow Yorkhill Division|||||f||||||||||||||2018-06-01 03:41:32.028736|2018-06-01 03:41:32.028736
NCT00390650|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2011-04-05|2006-10-19|2006-10-20|Estimate|||||||2011-04-05|2011-04-06|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder|An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder|Completed||Phase 3|366|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:41:32.076418|2018-06-01 03:41:32.076418
NCT00390637|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-05-29|2006-10-18|2006-10-20|Estimate|||||||2017-05-29|2017-05-31|Actual|January 2006||2006-01-31|May 2017|2017-05-31|December 2009|Actual|2009-12-31|March 2008|Actual|2008-03-31||Interventional|DIOGENES||Diet, Obesity and Genes (DiOGenes)|Diet, Obesity and Genes|Completed||Phase 4|1020|Anticipated|University of Copenhagen||5|||f||||t||||||||||2018-06-01 03:41:32.13414|2018-06-01 03:41:32.13414
NCT00390624|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2008-05-30|2006-10-19|2006-10-20|Estimate|||||||2008-05-30|2008-06-03|Estimate|July 2003||2003-07-31|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol|Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.|Completed||Phase 2|20|Anticipated|Rocky Mountain Cancer Centers|||||||||t||||||||||2018-06-01 03:41:32.204013|2018-06-01 03:41:32.204013
NCT00390611|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|2014-12-12||2014-12-12|2006-10-19|2006-10-20|Estimate|2014-12-12|2014-12-22|Estimate||||2014-12-12|2014-12-22|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|July 2012|Actual|2012-07-31||Interventional|||Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer|A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer|Completed||Phase 2|85|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 03:41:32.336911|2018-06-01 03:41:32.336911
NCT00390598|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2011-03-23|2006-10-19|2006-10-20|Estimate|||||||2011-03-23|2011-03-24|Estimate|September 2005||2005-09-30|December 2008|2008-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|TARE-05-073M||PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy|A Single Blind, Single Centre, Parallel Group, Randomized Controlled Trial Comparing PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy|Completed||Phase 2/Phase 3|490||Umeå University||2|||f||||||||||||||2018-06-01 03:41:32.748063|2018-06-01 03:41:32.748063
NCT00390585|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2010-03-12|2006-10-19|2006-10-20|Estimate|||||||2010-03-12|2010-03-15|Estimate|July 2006||2006-07-31|February 2008|2008-02-29|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Interventional|||Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)|Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI|Completed||Phase 4|324|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 03:41:32.838398|2018-06-01 03:41:32.838398
NCT00390572|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2014-09-09||2015-04-06|2006-10-19|2006-10-20|Estimate|2014-11-04|2014-11-05|Estimate||||2015-04-06|2015-04-24|Estimate|January 2007||2007-01-31|August 2014|2014-08-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional||Intent to Treat: All participants who were randomized to treatment condition.|Sleep Specialty Consultation: Improving Management of Sleep Disorders|Sleep Specialty Consultation: Improving Management of Sleep Disorders|Completed||N/A|156|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:41:32.941701|2018-06-01 03:41:32.941701
NCT00390559|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2011-11-10||2012-07-06|2006-10-18|2006-10-20|Estimate|2012-07-06|2012-07-18|Estimate||||2012-07-06|2012-07-18|Estimate|October 2005||2005-10-31|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Examining the Effect of the Nicotine Patch in Male and Female Smokers - 3|Effects of Transdermal Nicotine on Tobacco Withdrawal and the Effects of Smoking-related Stimuli in Men and Women|Completed||N/A|80|Actual|Virginia Commonwealth University||4|||f||||f||||||||||2018-06-01 03:41:33.221867|2018-06-01 03:41:33.221867
NCT00390546|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2013-03-11||2017-11-16|2006-10-18|2006-10-20|Estimate|2013-07-05|2013-08-22|Estimate||||2017-11-16|2017-12-13|Actual|October 2006||2006-10-31|November 2017|2017-11-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional||As 1 subject withdrew after being randomized to digoxin due to renal impairment and did not receive the study drug, the baseline analysis including age continuous data were assessed at enrolment with 32 study participants on digoxin and 39 participants on propranolol treatment.|Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia|Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia|Completed||Phase 3|72|Actual|University of British Columbia|Besides issues of recruitment, potential limitations of this study include the selected dosing for propranol, as a higher dosage is sometimes used, and the lack of dose titration before the 2-month visit, both of which could influence drug efficacy.|2|||f||||||||||||||2018-06-01 03:41:33.38622|2018-06-01 03:41:33.38622
NCT00390533|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19||2016-04-25|2016-04-25|2006-10-19|2006-10-20|Estimate||||2016-04-25|2016-05-24|Estimate|2016-04-25|2016-05-24|Estimate|September 2006||2006-09-30|April 2016|2016-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder|An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Efficacy, Safety and Tolerability of Two Fixed Doses (100 and 30 mg Once Daily) of Saredutant in Patients With Generalized Anxiety Disorder|Completed||Phase 3|428|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 03:41:33.640105|2018-06-01 03:41:33.640105
NCT00390520|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2009-07-13|2006-10-19|2006-10-20|Estimate|||||||2009-07-13|2009-07-15|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes|A Single-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Assess the Effect of Vildagliptin on Glucagon Counterregulatory Response During Hypoglycemia in Patients With Type 2 Diabetes.|Completed||Phase 3|28|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:41:33.699173|2018-06-01 03:41:33.699173
NCT00390507|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-19|||2010-09-02|2006-10-19|2006-10-20|Estimate|||||||2010-09-02|2010-09-06|Estimate|October 2006||2006-10-31|September 2010|2010-09-30||||April 2010|Actual|2010-04-30||Interventional|||Modification of Posttetanic Count (PTC) for Monitoring Deep Neuromuscular Block II||Completed||Phase 4|45|Actual|Rigshospitalet, Denmark|||||f||||t||||||||||2018-06-01 03:41:33.7497|2018-06-01 03:41:33.7497
NCT00390494|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2008-06-26|2006-10-17|2006-10-19|Estimate|||||||2008-06-26|2008-06-30|Estimate|December 2005||2005-12-31|June 2008|2008-06-30|December 2010||2010-12-31|||||Observational|||Questionnaire Study to Assess Quality of Life After Treatment of Fibroids|Outcome From Fibroid Therapies: A Comparison With Normal Controls|Unknown status|Active, not recruiting||400|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:41:33.80034|2018-06-01 03:41:33.80034
NCT00390481|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2013-07-29|2006-10-17|2006-10-19|Estimate|||||||2013-07-29|2013-07-30|Estimate|November 2004||2004-11-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Carotid Occlusion and Neurocognition|Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON)|Completed||N/A|294|Anticipated|Columbia University||2|||f||||t||||||||||2018-06-01 03:41:33.857685|2018-06-01 03:41:33.857685
NCT00390468|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2010-11-09||2014-05-13|2006-10-18|2006-10-19|Estimate|2011-05-09|2011-06-07|Estimate||||2014-05-13|2014-05-28|Estimate|October 2006||2006-10-31|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases|A Phase II Study of Tandutinib (MLN518) in Androgen-Independent Prostate Cancer With Bone Metastases|Completed||Phase 2|18|Actual|National Cancer Institute (NCI)|The study was closed to further accrual per design specifications.|1|||f||||f||||||||||2018-06-01 03:41:33.927114|2018-06-01 03:41:33.927114
NCT00390455|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2015-06-01||2018-04-26|2006-10-18|2006-10-19|Estimate|2015-06-01|2015-06-17|Estimate||||2018-04-26|2018-05-24|Actual|September 15, 2006|Actual|2006-09-15|April 2018|2018-04-30||||July 1, 2014|Actual|2014-07-01||Interventional||Four (4) participants who never started treatment were excluded from all analyses|Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive|Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer|Active, not recruiting||Phase 3|295|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 03:41:34.25657|2018-06-01 03:41:34.25657
NCT00390442|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2006-10-17|2006-10-17|2006-10-19|Estimate|||||||2006-10-17|2006-10-19|Estimate||||October 2006|2006-10-31||||||||Interventional|||Out-of-Hospital CPAP for Severe Cardiogenic Pulmonary Edema|Effect of Continuous Positive Airway Pressure as a First Line Therapy in Out-of-Hospital Management of Severe Cardiogenic Pulmonary Edema|Completed||Phase 3|||Hopital Lariboisière|||||f||||||||||||||2018-06-01 03:41:35.451157|2018-06-01 03:41:35.451157
NCT00390429|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2017-01-20||2018-02-12|2006-10-18|2006-10-19|Estimate|2017-10-24|2017-10-26|Actual||||2018-02-12|2018-02-14|Actual|July 2002||2002-07-31|October 2017|2017-10-31|August 2012|Actual|2012-08-31|August 2008|Actual|2008-08-31||Interventional|||Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|Phase I/II Study of Docetaxel and OSI-774 (Erlotinib) in Solid Tumor Patients With an Emphasis on NSCLC Using Molecular Correlates as Potential Markers of Response|Completed||Phase 1/Phase 2|81|Actual|University of California, Davis||3|||f||||t||||||||||2018-06-01 03:41:35.527728|2018-06-01 03:41:35.527728
NCT00390416|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2015-12-15||2016-02-16|2006-10-18|2006-10-19|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma|A Phase II Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma|Completed||Phase 2|48|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:41:36.032912|2018-06-01 03:41:36.032912
NCT00390403|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2012-05-01|2006-10-18|2006-10-19|Estimate|||||||2012-05-01|2012-05-03|Estimate|February 2007||2007-02-28|May 2012|2012-05-31||||June 2009|Actual|2009-06-30||Interventional|||Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I, Open Label Study of AT-101 Plus Radiotherapy and Temozolomide and of AT-101 Plus Adjuvant Temozolomide for Patients With Newly-Diagnosed Glioblastoma Multiforme|Completed||Phase 1|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:41:36.252908|2018-06-01 03:41:36.252908
NCT00390390|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2010-05-24|2006-10-18|2006-10-19|Estimate|||||||2010-05-24|2010-05-25|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn|A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of 14 Day Treatment With Lansoprazole 15 mg Once a Day in Frequent Heartburn|Completed||Phase 3|576||Novartis|||||||||||||||||||2018-06-01 03:41:36.328525|2018-06-01 03:41:36.328525
NCT00390377|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2006-10-18|2006-10-18|2006-10-19|Estimate|||||||2006-10-18|2006-10-19|Estimate|October 2006||2006-10-31|October 2006|2006-10-31||||||||Interventional|||Use of Hair to Diagnose Breast Cancer|A Study to Evaluate a Test for the Diagnosis of Breast Cancer Using X-Ray Diffraction of Hair Fibres.|Unknown status|Recruiting|Phase 2|240||Fermiscan Ltd|||||f||||||||||||||2018-06-01 03:41:36.414607|2018-06-01 03:41:36.414607
NCT00390364|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2014-09-15||2014-10-07|2006-10-18|2006-10-19|Estimate|2014-10-07|2014-10-08|Estimate||||2014-10-07|2014-10-08|Estimate|October 2006||2006-10-31|October 2014|2014-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy|Phase II Study of Single Agent RAD001 in Patients With Colon Cancer and Activating Mutations in the PI3KCA Gene|Terminated||Phase 2|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Out of 28 subjects pre-screened/screened, only one was enrolled and treated, and she progressed after 1 cycle. Study terminated by investigator because of low enrollment.|||Withdrawn due to low accrual|||||||||||||||2018-06-01 03:41:36.466399|2018-06-01 03:41:36.466399
NCT00390351|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2006-10-18|2006-10-18|2006-10-19|Estimate|||||||2006-10-18|2006-10-19|Estimate|February 2006||2006-02-28|October 2006|2006-10-31|July 2008||2008-07-31|||||Observational|||Investigate the Diagnostic Value and Possibilities of OCT in Non-Melanoma Skin Cancer.|Diagnosis of Non-Melanoma Skin Cancer With Optical Coherence Tomography|Unknown status|Recruiting||120||Zealand University Hospital|||||f||||||||||||||2018-06-01 03:41:36.615936|2018-06-01 03:41:36.615936
NCT00390338|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-09-25|2006-10-18|2006-10-19|Estimate|||||||2017-09-25|2017-09-26|Actual|October 2006||2006-10-31|September 2017|2017-09-30|January 2015|Actual|2015-01-31|May 2012|Actual|2012-05-31||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma|Completed||Phase 1|22|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:41:36.672563|2018-06-01 03:41:36.672563
NCT00390325|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-02-14|2006-10-18|2006-10-19|Estimate|||||||2017-02-14|2017-02-15|Actual|October 2006||2006-10-31|February 2017|2017-02-28||||January 2017|Actual|2017-01-31||Interventional|||Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer|Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma|Active, not recruiting||Phase 2|50|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:41:36.728921|2018-06-01 03:41:36.728921
NCT00390312|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2007-12-28|2006-10-17|2006-10-19|Estimate|||||||2007-12-28|2008-01-04|Estimate|September 2001||2001-09-30|December 2007|2007-12-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction|Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Single Dose Comparison of Analgesic Efficacy and Safety of Intranasal Morphine, Immediate Release Oral Morphine, Intravenous Morphine and Placebo in Postsurgical Dental Pain|Completed||Phase 2|225|Actual|Javelin Pharmaceuticals||7|||f||||f||||||||||2018-06-01 03:41:36.798607|2018-06-01 03:41:36.798607
NCT00390299|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2018-05-01|2006-10-18|2006-10-19|Estimate|||||||2018-05-01|2018-05-03|Actual|October 23, 2006|Actual|2006-10-23|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I Trial of a Measles Virus Derivative Producing CEA (MV-CEA) in Patients With Recurrent Glioblastoma Multiforme (GBM)|Suspended||Phase 1|40|Anticipated|Mayo Clinic||2||per study design|f||||f||||||||||2018-06-01 03:41:37.74873|2018-06-01 03:41:37.74873
NCT00390286|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2016-10-24|2006-10-18|2006-10-19|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Observational|||Telemedicine's Utility for Augmenting Clinical Trials and Informed Consent TACTIC|Telemedicine's Utility for Augmenting Clinical Trials and Informed Consent TACTIC|Withdrawn|||0|Actual|University of California, San Diego||||no funding|f||||f||||||||||2018-06-01 03:41:37.832776|2018-06-01 03:41:37.832776
NCT00390273|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2008-10-06|2006-10-18|2006-10-19|Estimate|||||||2008-10-06|2008-10-07|Estimate|December 2006||2006-12-31|October 2008|2008-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Metformin on Lactate Metabolism|Effect of Metformin on Lactate Metabolism in Healthy Subjects|Completed||Phase 1/Phase 2|20|Actual|Centre de Recherche en Nutrition Humaine Rhone-Alpe|||||f||||t||||||||||2018-06-01 03:41:37.88683|2018-06-01 03:41:37.88683
NCT00390260|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-01-31|2006-10-18|2006-10-19|Estimate|||||||2017-01-31|2017-02-02|Estimate|February 2002||2002-02-28|January 2017|2017-01-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)|Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Rofecoxib 50 mg and Hydrocodone 7.5 mg With Acetaminophen 750 mg in Patients With Postoperative Arthroscopic Pain|Completed||Phase 3|420||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:41:37.94705|2018-06-01 03:41:37.94705
NCT00390247|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2016-02-08|2006-10-18|2006-10-19|Estimate|||||||2016-02-08|2016-02-09|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients|Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients: A Randomized Control Trial|Withdrawn||Phase 4|0|Actual|Chinese University of Hong Kong||||Fail of applying funding|f||||||||||||||2018-06-01 03:41:38.009918|2018-06-01 03:41:38.009918
NCT00390234|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2014-11-14||2015-12-03|2006-10-18|2006-10-19|Estimate|2014-11-14|2014-11-21|Estimate||||2015-12-03|2015-12-07|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|August 2013|Actual|2013-08-31|September 2011|Actual|2011-09-30||Interventional|||Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma|A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas|Completed||Phase 2|63|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:41:38.108461|2018-06-01 03:41:38.108461
NCT00390221|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2016-05-31|2014-10-13|2016-05-31|2006-10-18|2006-10-19|Estimate|2016-05-31|2016-07-11|Estimate|2014-10-13|2014-10-22|Estimate|2016-05-31|2016-07-11|Estimate|February 2008||2008-02-29|May 2016|2016-05-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|SELECT||Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis|Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|621|Actual|Biogen||3|||f||||t||||||||||2018-06-01 03:41:39.096213|2018-06-01 03:41:39.096213
NCT00390208|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2010-05-25|2006-10-18|2006-10-19|Estimate|||||||2010-05-25|2010-05-27|Estimate|August 2006||2006-08-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|PDEX||Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration|A Prospective Masked Pilot Study Comparing Group 1 Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Group 2 Monotherapy - Intravitreal Ranibizumab Alone.|Completed||Phase 2|60|Actual|Bay Area Retina Associates||2|||f||||t||||||||||2018-06-01 03:41:40.370103|2018-06-01 03:41:40.370103
NCT00390195|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2009-06-29|2006-10-17|2006-10-19|Estimate|||||||2009-06-29|2009-07-02|Estimate|October 2006||2006-10-31|June 2009|2009-06-30|June 2011|Anticipated|2011-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)|Randomized Phase I/II of Rapamycin Analog, RAD001, in Advanced Hepatocellular Carcinoma - With a Pharmacokinetic Study of RAD001|Unknown status|Recruiting|Phase 1/Phase 2|134|Anticipated|National Health Research Institutes, Taiwan||2|||f||||||||||||||2018-06-01 03:41:40.546965|2018-06-01 03:41:40.546965
NCT00390182|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2013-01-16||2014-04-07|2006-10-18|2006-10-19|Estimate|2014-04-07|2014-04-09|Estimate||||2014-04-07|2014-04-09|Estimate|October 2003||2003-10-31|April 2014|2014-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|GCC0319||Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)|GCC 0319: Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)|Completed||Phase 1/Phase 2|38|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 03:41:40.7574|2018-06-01 03:41:40.7574
NCT00390169|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2012-01-18|2006-10-18|2006-10-19|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|July 2009||2009-07-31|||||Interventional|||Randomized Controlled Trial Comparing MBSR to SET in Breast Cancer Patients|Randomized Controlled Trial Comparing Mindfulness-Based Stress Reduction (MBSR) to Supportive-Expressive Therapy (SET) on Psychological and Biological Outcomes in Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 03:41:40.993952|2018-06-01 03:41:40.993952
NCT00390156|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2013-10-09|2006-10-18|2006-10-19|Estimate|||||||2013-10-09|2013-10-10|Estimate|August 2006||2006-08-31|October 2013|2013-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors|A Phase I Trial of Imatinib, Bevacizumab, & Metronomic Cyclophosphamide as Antiangiogenic Therapy in Refractory Metastatic Solid Tumors|Completed||Phase 1|35|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:41:41.060407|2018-06-01 03:41:41.060407
NCT00390143|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17||2009-09-03|2016-10-21|2006-10-17|2006-10-19|Estimate||||2009-09-03|2009-09-04|Estimate|2016-10-21|2016-10-25|Estimate|February 2007||2007-02-28|October 2016|2016-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612|Assess Long Term Persistence of a Primary Dose of GSK Biologicals' Meningococcal Vaccine 134612 Versus One Dose of Mencevax™ ACWY in Healthy Adolescents/Young Adults (15 to 19 Years at Vaccination)|Completed||Phase 2|46|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:41:41.239207|2018-06-01 03:41:41.239207
NCT00390130|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2013-11-10|2006-10-17|2006-10-19|Estimate|||||||2013-11-10|2013-11-13|Estimate|July 2006||2006-07-31|November 2013|2013-11-30|July 2008|Actual|2008-07-31|June 2007|Actual|2007-06-30||Interventional|||Does the Order in Which Vaccines Are Administered Affect Pain Response?|Does the Order in Which Vaccines Are Administered Affect Pain Response? A Randomized, Double-blind, Clinical Trial of Pentacel vs. Prevnar|Completed||Phase 4|120|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 03:41:41.354376|2018-06-01 03:41:41.354376
NCT00390117|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2016-11-25|2006-10-18|2006-10-19|Estimate|||||||2016-11-25|2016-11-28|Estimate|August 2006||2006-08-31|August 2012|2012-08-31|January 2013|Actual|2013-01-31|March 2012|Actual|2012-03-31||Interventional|||AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma|A Phase I Study of AT7519M Given Twice Weekly in Patients With Advanced Incurable Malignancy|Completed||Phase 1|34|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-06-01 03:41:41.467789|2018-06-01 03:41:41.467789
NCT00390104|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2017-07-06|2006-10-17|2006-10-19|Estimate|||||||2017-07-06|2017-07-11|Actual|January 2002|Actual|2002-01-31|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Molecular Analysis of Patients With Neuromuscular Disease|Molecular Analysis of Nucleic Acids Derived From Patients With Neuromuscular Disease and Their Family Members|Recruiting|||1000|Anticipated|Boston Children’s Hospital|||||f||||t||||||Samples With DNA|"~     DNA from blood or saliva and muscle samples from proband DNA from blood or saliva from family~     members Skin biopsy from proband and family members~   "|Yes|Individual participant data maybe shared with other researchers, but participant samples will be de-identified.|2018-06-01 03:41:41.631652|2018-06-01 03:41:41.631652
NCT00390091|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2015-08-31|2006-10-17|2006-10-19|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2006||2006-09-30|February 2007|2007-02-28||||||||Interventional|||Study of LJP 394 (Abetimus Sodium) in Lupus Patients|A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE)|Withdrawn||Phase 2|0|Actual|La Jolla Pharmaceutical Company|||||||||||||||||||2018-06-01 03:41:41.797172|2018-06-01 03:41:41.797172
NCT00390078|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2009-07-09|2006-10-18|2006-10-19|Estimate|||||||2009-07-09|2009-07-10|Estimate|January 2007||2007-01-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|||Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection|Single-Blind, Randomized, Controlled, Phase I/II Vaccination Study on Safety and Immunogenicity of a Recombinant MVA-HIV Polytope Vaccine (MVA-mBN32) in HIV-1 Infected Patients With CD4 Counts > 250/µl|Completed||Phase 1/Phase 2|30|Anticipated|Bavarian Nordic||2|||f||||||||||||||2018-06-01 03:41:42.065536|2018-06-01 03:41:42.065536
NCT00390065|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2017-03-21|2006-10-17|2006-10-19|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2006||2006-10-31|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Follow-Up at 6 Years of a Cohort of Children Born Very Prematurely|Follow-Up at 6 Years of a Cohort of Children Born Very Prematurely With Respiratory and Neurodevelopmental Impact of Early Treatment With Inhaled Nitric Oxide|Completed||Phase 4|108|Actual|Maternite Regionale Universitaire||3|||f||||t||||||||||2018-06-01 03:41:42.181225|2018-06-01 03:41:42.181225
NCT00390052|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2013-12-13|2006-10-18|2006-10-19|Estimate|||||||2013-12-13|2013-12-16|Estimate|December 2006||2006-12-31|December 2013|2013-12-31||||February 2011|Actual|2011-02-28||Interventional|||3-AP in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone(3-AP,Triapine) in the Treatment of Advanced Solid Tumors|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:41:42.350631|2018-06-01 03:41:42.350631
NCT00390039|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2008-01-11|2006-10-17|2006-10-19|Estimate|||||||2008-01-11|2008-01-14|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery|Randomized, Double-Blind, Active- and Placebo-Controlled Study of Analgesic Efficacy and Safety of Repeated Dosing of MNS075 (Intranasal Morphine), IV Morphine, and Placebo in Acute Post-Operative Pain After Elective Orthopedic Surgery|Completed||Phase 3|256|Actual|Javelin Pharmaceuticals||6|||f||||f||||||||||2018-06-01 03:41:42.550674|2018-06-01 03:41:42.550674
NCT00390026|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2007-05-24|2006-10-17|2006-10-19|Estimate|||||||2007-05-24|2007-05-25|Estimate|November 2006||2006-11-30|May 2007|2007-05-31||||||||Interventional|||The Avastin vs Visudyne for Neovascular AMD Study|A Prospective, Randomized, Double-Masked, Controlled Study on Intravitreal Bevacizumab (Avastin) Versus Verteporfin (Visudyne) Photodynamic Therapy (PDT) for Patients With Neovascular Age-Related Macular Degeneration (AMD)|Withdrawn||Phase 3|100|Anticipated|St. Erik Eye Hospital||||Lucentis, a treatment superior to PDT, has become available i Sweden.|f||||||||||||||2018-06-01 03:41:42.697439|2018-06-01 03:41:42.697439
NCT00390013|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2017-03-30||2017-07-28|2006-10-18|2006-10-19|Estimate|2017-07-28|2017-07-31|Actual||||2017-07-28|2017-07-31|Actual|January 2007|Actual|2007-01-31|July 2017|2017-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||To Evaluate if the Medication Gabapentin Lessens Vulvar Pain|Vulvar Pain: Treatment Trial Using Gabapentin-placebo in a Cross-over Design, Pilot Study.|Terminated||N/A|9|Actual|University of Iowa|Lack of enrollment leading to early termination leading to small numbers of subjects analyzed.|2||poor recruitment|f||||t||||||||No||2018-06-01 03:41:42.767569|2018-06-01 03:41:42.767569
NCT00390000|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2018-02-05|2006-10-18|2006-10-19|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2007|Actual|2007-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors|Phase I Study of PTK/ZK in Combination With Pemetrexed Disodium (ALIMTA)|Active, not recruiting||Phase 1|44|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 03:41:43.361914|2018-06-01 03:41:43.361914
NCT00389805|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2017-01-20||2017-04-07|2006-10-18|2006-10-19|Estimate|2017-04-07|2017-06-23|Actual||||2017-04-07|2017-06-23|Actual|March 2005||2005-03-31|April 2017|2017-04-30|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|||Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|Phase I/II Study of Two Different Schedules of Bortezomib (VELCADE, PS-341) and Pemetrexed (ALIMTA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|27|Actual|University of California, Davis|||||f||||t|t|f||||||||2018-06-01 03:41:46.302061|2018-06-01 03:41:46.302061
NCT00389987|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-02-16|2006-10-18|2006-10-19|Estimate|||||||2017-02-16|2017-02-17|Actual|September 2001||2001-09-30|February 2017|2017-02-28|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)|A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults|Completed||Phase 3|300||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:41:43.480663|2018-06-01 03:41:43.480663
NCT00389974|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2015-02-04||2015-02-04|2006-10-18|2006-10-19|Estimate|2015-02-04|2015-02-16|Estimate||||2015-02-04|2015-02-16|Estimate|January 2007||2007-01-31|March 2014|2014-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||All treated patients|Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery|A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:41:43.57774|2018-06-01 03:41:43.57774
NCT00389948|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2007-04-13|2006-10-18|2006-10-19|Estimate|||||||2007-04-13|2007-04-16|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of 14 Day Treatment With Lansoprazole 15 mg Once a Day in Frequent Heartburn|Completed||Phase 3|576||Novartis|||||||||||||||||||2018-06-01 03:41:43.946897|2018-06-01 03:41:43.946897
NCT00389935|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2011-08-01|2006-10-17|2006-10-19|Estimate|||||||2011-08-01|2011-08-02|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|TAG||Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding|Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding|Completed||Phase 2|14|Actual|Northport Veterans Affairs Medical Center||1|||f||||t||||||||||2018-06-01 03:41:44.057718|2018-06-01 03:41:44.057718
NCT00389922|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2012-04-17|2006-10-18|2006-10-19|Estimate|||||||2012-04-17|2012-04-19|Estimate|December 2005||2005-12-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|April 2009|Actual|2009-04-30||Interventional|||Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors|Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination With Vinorelbine in Advanced Solid Tumors|Completed||Phase 1|22|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 03:41:44.138423|2018-06-01 03:41:44.138423
NCT00389909|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2017-02-23|2006-10-17|2006-10-19|Estimate|||||||2017-02-23|2017-02-27|Actual|November 2006||2006-11-30|February 2017|2017-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants|Evaluation of Dosing Chart Taking Into Account Age and Gender for Calculating the First Dose of Doxapram in Premature Infants|Completed||Phase 4|85|Actual|Maternite Regionale Universitaire||2|||f||||f||||||||No||2018-06-01 03:41:44.336267|2018-06-01 03:41:44.336267
NCT00389896|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-04-06|2006-10-18|2006-10-19|Estimate|||||||2017-04-06|2017-04-10|Actual|July 26, 2001|Actual|2001-07-26|April 2017|2017-04-30|October 4, 2002|Actual|2002-10-04|October 4, 2002|Actual|2002-10-04||Interventional|||A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Balanced, Three-Way Crossover Study to Evaluate the Efficacy of Simvastatin Therapy in Elevating HDL-C Levels in Patients With Type 2 Diabetic Dyslipidemia and Low HDL-C|Completed||Phase 3|150||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:41:44.515931|2018-06-01 03:41:44.515931
NCT00389883|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2012-07-06|2006-10-18|2006-10-19|Estimate|||||||2012-07-06|2012-07-10|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|November 2011|Actual|2011-11-30|January 2010|Actual|2010-01-31||Interventional|||Anaesthesia for Supratentorial Tumor Resection|Anaesthesia for Supratentorial Tumor Resection : a Double-blind Comparison of Target Plasma Concentration of Propofol-remifentanil and Sevoflurane-sufentanil|Completed||Phase 3|69|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:41:44.592561|2018-06-01 03:41:44.592561
NCT00389870|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2013-08-23|2006-10-18|2006-10-19|Estimate|||||||2013-08-23|2013-08-26|Estimate|December 2006||2006-12-31|July 2007|2007-07-31||||March 2010|Anticipated|2010-03-31||Interventional|||Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil|A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)]|Unknown status|Recruiting|Phase 3|1269|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:41:44.705945|2018-06-01 03:41:44.705945
NCT00389857|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2009-02-24||2016-04-12|2006-10-18|2006-10-19|Estimate|2009-03-23|2009-03-24|Estimate||||2016-04-12|2016-04-14|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Trial to Collect Safety Data and Sera for Immunogenicity Testing|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)|Completed||Phase 4|31|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:41:44.886656|2018-06-01 03:41:44.886656
NCT00389844|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2008-05-27|2006-10-18|2006-10-19|Estimate|||||||2008-05-27|2008-05-29|Estimate|July 2000||2000-07-31|May 2008|2008-05-31|September 2005|Actual|2005-09-30|September 2004|Actual|2004-09-30||Interventional|Hip5||BHS5 - Testing the Effectiveness of the Exercise Plus Program|Testing the Effectiveness of the Exercise Plus Program on Efficacy Expectations, Exercise Behavior & Activity of Older Adults Following a Hip Fracture|Completed||N/A|240|Actual|University of Maryland||4|||f||||t||||||||||2018-06-01 03:41:45.324364|2018-06-01 03:41:45.324364
NCT00389831|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2009-07-28||2014-09-24|2006-10-18|2006-10-19|Estimate|2009-07-28|2009-09-04|Estimate||||2014-09-24|2014-10-02|Estimate|August 2006||2006-08-31|February 2011|2011-02-28|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms|A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Trial to Assess the Efficacy, Safety and Tolerability of Ascending Doses of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms in Subjects With Idiopathic Restless Legs Syndrome|Completed||Phase 2|44|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 03:41:45.441748|2018-06-01 03:41:45.441748
NCT00389818|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2012-05-29||2018-02-05|2006-10-18|2006-10-19|Estimate|2012-05-29|2012-06-29|Estimate||||2018-02-05|2018-03-06|Actual|January 2007||2007-01-31|February 2018|2018-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma|A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients With Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|43|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 03:41:45.945819|2018-06-01 03:41:45.945819
NCT00389792|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2009-03-10|2006-10-17|2006-10-19|Estimate|||||||2009-03-10|2009-03-11|Estimate|July 2006||2006-07-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers|A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients With Paroxysmal Atrial Fibrillation and Pacemakers With Atrial Fibrillation Data Logging Capabilities|Completed||Phase 2|72|Actual|ARYx Therapeutics||4|||f||||f||||||||||2018-06-01 03:41:46.826111|2018-06-01 03:41:46.826111
NCT00389779|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17||2014-01-03|2014-02-19|2006-10-18|2006-10-19|Estimate||||2014-01-03|2014-02-04|Estimate|2014-02-19|2014-03-18|Estimate|September 2006||2006-09-30|February 2014|2014-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|Darusentan||DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension|A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group Study to Evaluate the Safety and Efficacy of Darusentan in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo (Protocol DAR-312)|Completed||Phase 3|849|Actual|Gilead Sciences||3|||f||||t||||||||||2018-06-01 03:41:47.012012|2018-06-01 03:41:47.012012
NCT00389766|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2013-07-09|2006-10-18|2006-10-19|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 2008||2008-07-31|June 2007|2007-06-30||||July 2008|Anticipated|2008-07-31||Interventional|||High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma|International Phase II Studies of I-mIBG in Combination With Topotecan and Peripheral Blood Stem Cell Rescue for (A) Primary Resistant High Risk Neuroblastoma and (B) Relapsed Stage 4 Neuroblastoma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||||Withdrawn because protocol has been discontinued. It was never opened.|f||||||||||||||2018-06-01 03:41:47.236133|2018-06-01 03:41:47.236133
NCT00389753|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2010-09-28|2006-10-18|2006-10-19|Estimate|||||||2010-09-28|2010-09-29|Estimate||||September 2010|2010-09-30||||||||Interventional|||Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure|A Prospective, Randomized, Double Blinded Controlled Clinical Trial of the Aruba Aloë Formula F-BC-096 in the Treatment of Split Thickness Donor Sites After Wound Closure|Suspended||N/A|25|Anticipated|University Hospital, Ghent||||study never started|f||||f||||||||||2018-06-01 03:41:47.29297|2018-06-01 03:41:47.29297
NCT00389740|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-06-07|2006-10-18|2006-10-19|Estimate|||||||2017-06-07|2017-06-08|Actual|April 2, 2001|Actual|2001-04-02|June 2017|2017-06-30|January 16, 2003|Actual|2003-01-16|January 16, 2003|Actual|2003-01-16||Interventional|||A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)|A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women With Osteoporosis|Completed||Phase 3|400|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:41:47.352355|2018-06-01 03:41:47.352355
NCT00389727|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2006-10-18|2006-10-18|2006-10-19|Estimate|||||||2006-10-18|2006-10-19|Estimate|September 2004||2004-09-30|September 2004|2004-09-30||||||||Interventional|||Simultaneous Integrated Boost (SIB)- IMRT|A Dose Escalation Study With Intensity Modulated Radiation Therapy (IMRT) in Moderately Advanced (T2N0, T2N1, T3N0) Squamous Cell Carcinomas (SCC) of the Oropharynx, Larynx and Hypopharynx Using a Simultaneous Integrated Boost (SIB) Approach.|Unknown status|Recruiting|Phase 2|||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||||||||||||2018-06-01 03:41:47.424202|2018-06-01 03:41:47.424202
NCT00389714|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2007-12-10|2006-10-18|2006-10-19|Estimate|||||||2007-12-10|2007-12-11|Estimate|February 2007||2007-02-28|December 2007|2007-12-31||||||||Interventional|IABN||Clinical Evaluation of Esthetic Restorations Placed in Primary Molars With Composite Resin Enriched With Insoluble Anti Bacterial Nano Particles|Phase 2 Clinical Study :Evaluation of the Efficacy of Insoluble Antibacterial Nanoparticles Incorporated Into Commercialy Used Composit Resins as an Esthetic Restoration Material in Children|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:41:47.49345|2018-06-01 03:41:47.49345
NCT00389701|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2014-01-09|2006-10-18|2006-10-19|Estimate|||||||2014-01-09|2014-01-10|Estimate|March 2006||2006-03-31|June 2009|2009-06-30||||December 2009|Anticipated|2009-12-31||Interventional|||Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment|Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy|Unknown status|Recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:41:47.560968|2018-06-01 03:41:47.560968
NCT00389688|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2012-07-17|2006-10-18|2006-10-19|Estimate|||||||2012-07-17|2012-07-18|Estimate|August 2006||2006-08-31|July 2012|2012-07-31||||July 2008|Actual|2008-07-31||Interventional|||Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery|Randomized Phase II Study of Pemetrexed and Cisplatin as Either Induction or Adjuvant Chemotherapy in Stage IB-II Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|13|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 03:41:47.621027|2018-06-01 03:41:47.621027
NCT00389675|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17||2014-01-03|2014-01-03|2006-10-18|2006-10-19|Estimate||||2014-01-03|2014-02-04|Estimate|2014-01-03|2014-02-04|Estimate|May 2007||2007-05-31|January 2014|2014-01-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|Darusentan||DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension|A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)|Terminated||Phase 3|661|Actual|Gilead Sciences||2||Study DAR-312 did not meet its primary co-endpoints.|f||||t||||||||||2018-06-01 03:41:47.706315|2018-06-01 03:41:47.706315
NCT00389662|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2007-12-19|2006-10-18|2006-10-19|Estimate|||||||2007-12-19|2007-12-28|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||The Effect of Wearing the 'Nike Free'Shoe on Isokinetic Muscle Strength of Foot and Ankle and on Proprioception.|The Effect of Wearing the 'Nike Free'Shoe on Isokinetic Muscle Strength of Foot and Ankle and on Proprioception.|Completed||N/A|45|Anticipated|University Ghent|||||f||||f||||||||||2018-06-01 03:41:47.93654|2018-06-01 03:41:47.93654
NCT00389649|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2008-04-16|2006-10-18|2006-10-19|Estimate|||||||2008-04-16|2008-04-17|Estimate|November 2001||2001-11-30|April 2008|2008-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Effect of Chronic Changes in Heart Rate on Congestive Heart Failure|Effect of Chronic Changes in Heart Rate on Congestive Heart Failure|Completed||N/A|24||University of Maryland|||||f||||||||||||||2018-06-01 03:41:47.981822|2018-06-01 03:41:47.981822
NCT00389636|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2008-05-05|2006-10-18|2006-10-19|Estimate|||||||2008-05-05|2008-05-07|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers|TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers|Unknown status|Active, not recruiting|N/A|30|Actual|Soluble Systems, LLC||2|||f||||f||||||||||2018-06-01 03:41:48.099902|2018-06-01 03:41:48.099902
NCT00389610|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-10-05|2006-10-18|2006-10-19|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2006||2006-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Vaccine Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery|A Safety and Efficacy Trial of Vaccine Boosting With Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|56|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-06-01 03:41:48.181941|2018-06-01 03:41:48.181941
NCT00389597|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2014-01-03||2017-11-07|2006-10-18|2006-10-19|Estimate|2014-04-01|2014-05-01|Estimate||||2017-11-07|2017-12-11|Actual|April 2006||2006-04-30|November 2017|2017-11-30|November 2015|Actual|2015-11-30|March 2010|Actual|2010-03-31||Interventional|||LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE|LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE|Completed||N/A|599|Actual|LDR Spine USA||2|||f||||t||||||||||2018-06-01 03:41:48.320527|2018-06-01 03:41:48.320527
NCT00389584|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2017-10-31|2006-10-18|2006-10-19|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2002||2002-12-31|October 2017|2017-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors|Phase I/II Study of Irinotecan and Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors|Completed||Phase 1/Phase 2|30|Actual|University of California, Davis|||||f||||t||||||||||2018-06-01 03:41:48.92608|2018-06-01 03:41:48.92608
NCT00389558|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2009-09-18|2006-10-17|2006-10-19|Estimate|||||||2009-09-18|2009-09-21|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Antiseptic Use and Dressing Application|Comparison of Amukin Versus Biseptine Use for Dressing Application of Epicutaneocavous Catheters for Nosocomial Infection Prevention|Completed||Phase 4|453|Actual|Maternite Regionale Universitaire||2|||f||||f||||||||||2018-06-01 03:41:49.003709|2018-06-01 03:41:49.003709
NCT00389545|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2006-10-18|2006-10-18|2006-10-19|Estimate|||||||2006-10-18|2006-10-19|Estimate||||October 2006|2006-10-31||||||||Interventional|||Intracoronary Stem Cells in Large Myocardial Infarction|Intracoronary Stem Cells in Large Myocardial Infarction|Unknown status|Active, not recruiting|Phase 2|||Charles University, Czech Republic|||||f||||||||||||||2018-06-01 03:41:49.073631|2018-06-01 03:41:49.073631
NCT00389532|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|2009-02-24||2016-04-12|2006-10-18|2006-10-19|Estimate|2009-03-27|2009-03-30|Estimate||||2016-04-12|2016-04-14|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|||Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)|Completed||Phase 4|116|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:41:49.130123|2018-06-01 03:41:49.130123
NCT00389519|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2010-01-21||2012-06-06|2006-10-18|2006-10-19|Estimate|2010-04-29|2010-05-19|Estimate||||2012-06-06|2012-06-11|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study Assessing the Efficacy, Safety, and Dose-Response of Ramipril for the Treatment of Hypertension in Children and Adolescents|Terminated||Phase 3|422|Actual|Pfizer||4||"A planned interim analysis was performed after approx. 240 subjects completed the trial. The~   study was stopped, as permitted by protocol, after the analysis."|||||||||||||||2018-06-01 03:41:49.43231|2018-06-01 03:41:49.43231
NCT00389506|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-18|||2012-03-14|2006-10-18|2006-10-19|Estimate|||||||2012-03-14|2012-03-16|Estimate|September 2006||2006-09-30|March 2012|2012-03-31|May 2008|Actual|2008-05-31|||||Interventional|||Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma|A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide|Withdrawn||N/A|0|Actual|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 03:41:50.140139|2018-06-01 03:41:50.140139
NCT00389493|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|2013-10-29||2014-03-20|2006-10-17|2006-10-18|Estimate|2014-03-20|2014-04-25|Estimate||||2014-03-20|2014-04-25|Estimate|October 2006||2006-10-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder|Maximizing Treatment Outcome in OCD|Completed||N/A|100|Actual|New York State Psychiatric Institute||3|||f||||t||||||||||2018-06-01 03:41:50.213664|2018-06-01 03:41:50.213664
NCT00389480|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2009-08-07|2006-10-17|2006-10-18|Estimate|||||||2009-08-07|2009-08-11|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies|A Phase I Study of DB-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) in Adult Patients With Refractory or Metastatic Solid Malignancies|Completed||Phase 1|26|Actual|Arno Therapeutics||1|||f||||t||||||||||2018-06-01 03:41:50.655512|2018-06-01 03:41:50.655512
NCT00389467|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|2013-04-12||2014-02-26|2006-10-16|2006-10-18|Estimate|2014-02-26|2014-03-26|Estimate||||2014-02-26|2014-03-26|Estimate|May 2004||2004-05-31|February 2014|2014-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|MR RESCUE||Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy|Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy|Completed||Phase 2|127|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 03:41:50.731378|2018-06-01 03:41:50.731378
NCT00389454|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2007-10-30|2006-10-17|2006-10-18|Estimate|||||||2007-10-30|2007-10-31|Estimate|January 2004||2004-01-31|August 2006|2006-08-31|June 2007|Actual|2007-06-30|||||Observational|||Acetaminophen Concentration in Cerebrospinal Fluid in Infants|Acetaminophen Concentration in Cerebrospinal Fluid in Infants|Completed|||||Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:41:52.05377|2018-06-01 03:41:52.05377
NCT00389441|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|2013-09-24||2013-09-24|2006-10-17|2006-10-18|Estimate|2013-09-24|2013-11-25|Estimate||||2013-09-24|2013-11-25|Estimate|December 2006||2006-12-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer|A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer|Completed||Phase 2|52|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:41:52.163933|2018-06-01 03:41:52.163933
NCT00389428|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2012-05-16|2006-10-16|2006-10-18|Estimate|||||||2012-05-16|2012-05-17|Estimate|September 2006||2006-09-30|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.|Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies.|Completed||Phase 1|48|Actual|Jazz Pharmaceuticals|||||f||||||||||||||2018-06-01 03:41:52.899825|2018-06-01 03:41:52.899825
NCT00389415|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2008-11-26|2006-10-16|2006-10-18|Estimate|||||||2008-11-26|2008-11-27|Estimate|October 2006||2006-10-31|November 2008|2008-11-30||||||||Interventional|||Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes|A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin (100 mg qd) In Patients With Type 2 Diabetes (Extension Study of Study CLAF237A1303)|Completed||Phase 3|150||Novartis|||||f||||||||||||||2018-06-01 03:41:52.970041|2018-06-01 03:41:52.970041
NCT00389402|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2010-06-10|2006-10-17|2006-10-18|Estimate|||||||2010-06-10|2010-06-11|Estimate|July 2006||2006-07-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|||||Interventional|||BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes|A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofovir Disoproxil Fumarate And Emtricitabine As A First-line Regimen.|Completed||Phase 4|120|Anticipated|International Antiviral Therapy Evaluation Center|||||f||||f||||||||||2018-06-01 03:41:53.037351|2018-06-01 03:41:53.037351
NCT00389389|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2009-04-30|2006-10-17|2006-10-18|Estimate|||||||2009-04-30|2009-05-01|Estimate|September 2006||2006-09-30|April 2009|2009-04-30|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly or Every Two Weeks in Patients With Advanced Solid Malignancies|Completed||Phase 1|75|Anticipated|AstraZeneca|||||f||||f||||||||||2018-06-01 03:41:53.105625|2018-06-01 03:41:53.105625
NCT00389376|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2008-02-15|2006-10-16|2006-10-18|Estimate|||||||2008-02-15|2008-02-20|Estimate|November 2006||2006-11-30|February 2008|2008-02-29|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|SyNCH||Phase I Trial of Silymarin for Chronic Liver Diseases|Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease|Completed||Phase 1|56|Actual|National Center for Complementary and Integrative Health (NCCIH)||7|||t||||t||||||||||2018-06-01 03:41:53.168409|2018-06-01 03:41:53.168409
NCT00389363|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2010-08-16|2006-10-17|2006-10-18|Estimate|||||||2010-08-16|2010-08-17|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects|A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients|Completed||Phase 2/Phase 3|800|Anticipated|ALK-Abelló A/S|||||f||||||||||||||2018-06-01 03:41:53.251525|2018-06-01 03:41:53.251525
NCT00389350|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2006-10-17|2006-10-17|2006-10-18|Estimate|||||||2006-10-17|2006-10-18|Estimate|August 2005||2005-08-31|October 2006|2006-10-31|June 2006||2006-06-30|||||Interventional|||Effect of an Extract of Green Tea on Adults With Type 2 Diabetes|The Effect of an Extract of Green Tea on Glucose Control in Adults With Type 2 Diabetes|Completed||Phase 2/Phase 3|48||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 03:41:53.297158|2018-06-01 03:41:53.297158
NCT00389337|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2006-10-17|2006-10-17|2006-10-18|Estimate|||||||2006-10-17|2006-10-18|Estimate|January 2005||2005-01-31|October 2006|2006-10-31|December 2006||2006-12-31|||||Observational|||Sepsis: Prognosis and Evaluation of Early Diagnosis and Intervention (SPEEDI Study)|Sepsis: Prognosis and Evaluation of Early Diagnosis and Intervention (SPEEDI Study)|Unknown status|Active, not recruiting||300||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 03:41:53.445087|2018-06-01 03:41:53.445087
NCT00389324|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2009-07-30||2015-03-31|2006-10-17|2006-10-18|Estimate|2012-11-09|2012-12-18|Estimate||||2015-03-31|2015-04-20|Estimate|November 2006||2006-11-30|March 2015|2015-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency|An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics and Safety of Subcutaneous Gamunex® 10% (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) in Subjects With Primary Immunodeficiency|Completed||Phase 2|35|Actual|Grifols Therapeutics LLC||1|||f||||f||||||||||2018-06-01 03:41:53.518703|2018-06-01 03:41:53.518703
NCT00389311|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2015-03-30|2006-10-17|2006-10-18|Estimate|||||||2015-03-30|2015-04-01|Estimate|April 2007||2007-04-30|January 2009|2009-01-31|June 2009|Actual|2009-06-30|February 2008|Actual|2008-02-29||Interventional|||A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides|A Pilot Protocol to Determine the Effects of Chemical and Mechanical Stress on Rectal Permeability as a Surrogate for Toxicity Evaluation of Rectally Applied Microbicides|Completed||Early Phase 1|12|Actual|Johns Hopkins University||3|||f||||||||||||||2018-06-01 03:41:53.832123|2018-06-01 03:41:53.832123
NCT00389298|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2009-09-23|2006-10-16|2006-10-18|Estimate|||||||2009-09-23|2009-09-24|Estimate|October 2006||2006-10-31|September 2009|2009-09-30|June 2007|Actual|2007-06-30|||||Interventional|||A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.|A Phase 2, Multicenter, Randomized, Double-blinded, and Placebo-controlled Study of the Antiviral Activity, Safety and Pharmacokinetics of VCH-759 in Subjects With Chronic Hepatitis C-infection.|Completed||Phase 1/Phase 2|36|Anticipated|Vertex Pharmaceuticals Incorporated|||||f||||t||||||||||2018-06-01 03:41:53.924361|2018-06-01 03:41:53.924361
NCT00389285|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2009-05-26|2006-10-16|2006-10-18|Estimate|||||||2009-05-26|2009-05-27|Estimate|October 2006||2006-10-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma|A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly With Sorafenib (Nexavar) in Subjects With Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|52|Actual|ZymoGenetics|||||f||||||||||||||2018-06-01 03:41:54.066212|2018-06-01 03:41:54.066212
NCT00389272|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2007-10-30|2006-10-17|2006-10-18|Estimate|||||||2007-10-30|2007-10-31|Estimate|September 2005||2005-09-30|October 2006|2006-10-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Adding a Second Drug for Febrile Children Treated With Acetaminophen|Adding a Second Drug for Febrile Children Treated With Acetaminophen|Unknown status|Recruiting|N/A|40|Anticipated|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-06-01 03:41:54.222087|2018-06-01 03:41:54.222087
NCT00389259|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2011-04-04|2006-10-17|2006-10-18|Estimate|||||||2011-04-04|2011-04-05|Estimate|October 2007||2007-10-31|March 2010|2010-03-31|December 2009|Anticipated|2009-12-31|||||Interventional|||Scopolamine Treatment for Patients With Organophosphate Poisoning|Scopolamine Treatment for Patients With Organophosphate Poisoning - a Randomized, Double Blind, Placebo-Controlled Study.|Withdrawn||N/A|50|Anticipated|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-06-01 03:41:54.28051|2018-06-01 03:41:54.28051
NCT00389233|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2008-04-15|2006-10-17|2006-10-18|Estimate|||||||2008-04-15|2008-04-16|Estimate|June 2002||2002-06-30|April 2008|2008-04-30|December 2002||2002-12-31|||||Interventional|||A Phase III Trial to Assess the Efficacy, Acceptability and Safety of Moviprep® Versus a 4L PEG+E Standard Solution|A Randomised, Multi-Centre, Single-Blinded, Pivotal Phase III Trial to Assess the Efficacy, Acceptability and Safety of a New 2 Litre Gut Cleansing Solution NRL994 Versus a Standard Colon Preparation With 4L PEG+E.|Completed||Phase 3|360|Actual|Norgine||2|||f||||f||||||||||2018-06-01 03:41:54.488839|2018-06-01 03:41:54.488839
NCT00389220|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2013-09-23|2006-10-13|2006-10-18|Estimate|||||||2013-09-23|2013-09-24|Estimate|November 2006||2006-11-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|May 2008|Actual|2008-05-31||Interventional|LEADERS||Limus Eluted From A Durable Versus ERodable Stent Coating|A Randomized Comparison of a Biolimus-Eluting Stent With a Sirolimus-Eluting Stent for Percutaneous Coronary Intervention|Completed||Phase 3|1707|Actual|Biosensors Europe SA||2|||f||||t||||||||||2018-06-01 03:41:54.60647|2018-06-01 03:41:54.60647
NCT00389207|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2012-01-13||2013-12-09|2006-10-17|2006-10-18|Estimate|2012-02-20|2012-03-26|Estimate||||2013-12-09|2014-01-27|Estimate|October 2006||2006-10-31|December 2013|2013-12-31||||February 2011|Actual|2011-02-28||Interventional|||Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults|Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.|Completed||Phase 3|576|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 03:41:54.815621|2018-06-01 03:41:54.815621
NCT00389194|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2010-06-10|2006-10-17|2006-10-18|Estimate|||||||2010-06-10|2010-06-11|Estimate|April 2006||2006-04-30|June 2010|2010-06-30|October 2008|Actual|2008-10-31|||||Interventional|||PREventing Progression of Adipose Tissue Redistribution|A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults With First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens Versus Pro-actively Replacing of Zidovudine and Lamivudine by Once-Daily Emtricitabine and Tenofovir Disoproxil Fumarate to Prevent Progression of or Reverse Peripheral Lipoatrophy.|Completed||Phase 4|120|Anticipated|International Antiviral Therapy Evaluation Center|||||f||||f||||||||||2018-06-01 03:41:56.701498|2018-06-01 03:41:56.701498
NCT00389181|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2015-06-02|2006-10-16|2006-10-18|Estimate|||||||2015-06-02|2015-06-04|Estimate|October 2006||2006-10-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|June 2013|Actual|2013-06-30||Interventional|ARUBA||A Randomized Trial of Unruptured Brain AVMs|A Randomized Trial of Unruptured Brain Arteriovenous Malformations|Completed||Phase 3|226|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 03:41:56.77404|2018-06-01 03:41:56.77404
NCT00389168|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2012-08-19||2015-05-03|2006-10-17|2006-10-18|Estimate|2015-05-03|2015-05-05|Estimate||||2015-05-03|2015-05-05|Estimate|April 1995||1995-04-30|May 2015|2015-05-31|April 1997|Actual|1997-04-30|April 1997|Actual|1997-04-30||Interventional|SILVHIA||Irbesartan and Atenolol in Hypertensive Heart Disease|Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy|Completed||Phase 2/Phase 3|115|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-06-01 03:41:57.001994|2018-06-01 03:41:57.001994
NCT00389155|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17||2010-09-10|2015-11-06|2006-10-17|2006-10-18|Estimate||||2010-09-10|2010-09-13|Estimate|2015-11-06|2015-12-07|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy|A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy|Completed||Phase 2/Phase 3|34|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:41:57.315677|2018-06-01 03:41:57.315677
NCT00389142|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2017-07-28|2006-10-17|2006-10-18|Estimate|||||||2017-07-28|2017-08-01|Actual|January 15, 2006|Actual|2006-01-15|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Genetic Studies in Interstitial Cystitis (IC)|Genetic Studies in Interstitial Cystitis/Painful Bladder Syndrome/Chronic Pelvic Pain Syndrome (IC/PBS/CPPS)|Recruiting|||500|Anticipated|Boston Children’s Hospital|||||f||||t|f|f||||Samples With DNA|"~     We will collect and store DNA (via saliva) and urine on all participants.~   "|Yes|Data from individual participants will be shared with other researcher, but participant information will be de-identified.|2018-06-01 03:41:57.525041|2018-06-01 03:41:57.525041
NCT00389129|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2007-12-10|2006-10-17|2006-10-18|Estimate|||||||2007-12-10|2007-12-12|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Danish Aspirin Resistance Trial - Pilot Study|Comparative Evaluation of Aspirin Resistance With Point-of-Care Testing - Danish Aspirin Resistance Trial (DANART) - Pilot Study|Completed||N/A|60||University of Aarhus|||||f||||f||||||||||2018-06-01 03:41:57.584722|2018-06-01 03:41:57.584722
NCT00389116|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|||2011-02-24|2006-10-17|2006-10-18|Estimate|||||||2011-02-24|2011-02-25|Estimate|November 2006||2006-11-30|February 2011|2011-02-28|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction|Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction|Completed||Phase 4|242|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-06-01 03:41:57.685585|2018-06-01 03:41:57.685585
NCT00389103|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2014-01-17|2006-10-17|2006-10-18|Estimate|||||||2014-01-17|2014-01-22|Estimate|October 2006||2006-10-31|January 2014|2014-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)|A Phase 1, Placebo-Controlled, Double-Blind Study of the Safety and Immunogenicity of Two Injections of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia Naive Adult Subjects With a History of Atopic Dermatitis (AD)|Withdrawn||Phase 1|0|Actual|Sanofi||1||Senior management decision|f||||t||||||||||2018-06-01 03:41:57.80761|2018-06-01 03:41:57.80761
NCT00389090|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2012-02-07|2006-10-16|2006-10-18|Estimate|||||||2012-02-07|2012-02-09|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|February 2009|Actual|2009-02-28|June 2008|Actual|2008-06-30||Interventional|||A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma|A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma|Terminated||Phase 2|32|Actual|Keryx / AOI Pharmaceuticals, Inc.||1||AOI Pharma terminated the license agreement. IND Transferred to NCI|f||||f||||||||||2018-06-01 03:41:57.892016|2018-06-01 03:41:57.892016
NCT00389077|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16||2018-02-27|2018-03-06|2006-10-16|2006-10-18|Estimate||||2018-02-27|2018-03-01|Actual|2018-03-06|2018-03-07|Actual|January 2005||2005-01-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas|A Phase IIA Trial of Two Schedules of Perifosine|Completed||Phase 2|558|Actual|AEterna Zentaris||2|||f||||t||||||||||2018-06-01 03:41:58.118599|2018-06-01 03:41:58.118599
NCT00389064|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-17|2009-04-15||2012-03-30|2006-10-17|2006-10-18|Estimate|2009-04-15|2009-06-23|Estimate||||2012-03-30|2012-04-04|Estimate|September 2006||2006-09-30|March 2012|2012-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Generalised Anxiety Disorder|Completed||Phase 3|450|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:41:58.223485|2018-06-01 03:41:58.223485
NCT00389051|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2007-08-20|2006-10-16|2006-10-17|Estimate|||||||2007-08-20|2007-08-21|Estimate|October 2006||2006-10-31|May 2007|2007-05-31|September 2007||2007-09-30|||||Interventional|||A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma|A Multicenter, Open Study to Assess the Tolerability, Pharmacokinetics and Antitumor Effect of Bendamustine Hydrochloride (SyB L-0501: 90 or 120 mg/m2/Day) Administered Intravenously for Two Days in Patients With Indolent Lymphoma|Completed||Phase 1|12|Anticipated|SymBio Pharmaceuticals|||||f||||||||||||||2018-06-01 03:41:58.598626|2018-06-01 03:41:58.598626
NCT00389038|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2011-04-21|2006-10-16|2006-10-17|Estimate|||||||2011-04-21|2011-04-25|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|||Pediatric Chronic Headache Trial|Drug and Non-Drug Treatment of Pediatric Chronic Headache|Unknown status|Active, not recruiting|Phase 3|132|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 03:41:58.753594|2018-06-01 03:41:58.753594
NCT00389025|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2016-11-18|2006-10-16|2006-10-17|Estimate|||||||2016-11-18|2016-11-22|Estimate|October 2006||2006-10-31|January 2010|2010-01-31||||April 2007|Actual|2007-04-30||Interventional|||Mast-Cell Stabilizing Effects of Olopatadine|Mast-Cell Stabilizing Effects of Olopatadine|Completed||Phase 4|24|Actual|Alcon Research|||||||||||||||||||2018-06-01 03:41:58.854935|2018-06-01 03:41:58.854935
NCT00389012|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2017-04-04|2006-10-16|2006-10-17|Estimate|||||||2017-04-04|2017-04-06|Actual|May 2004||2004-05-31|April 2010|2010-04-30|October 31, 2010|Actual|2010-10-31|October 31, 2010|Actual|2010-10-31||Interventional|||Strength Training Effectiveness Post-Stroke (STEPS)|Strength Training Effectiveness Post-Stroke (STEPS)|Completed||Phase 2|80||University of Southern California|||||f||||||||||||||2018-06-01 03:41:58.914069|2018-06-01 03:41:58.914069
NCT00388999|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2011-12-02|2006-10-13|2006-10-17|Estimate|||||||2011-12-02|2011-12-05|Estimate|September 2006||2006-09-30|December 2011|2011-12-31|May 2009|Actual|2009-05-31|February 2009|Actual|2009-02-28||Interventional|||Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant|Multi-Center,Open-Label,Randomized,Phase 1B Study Evaluating Safety & Tolerability of Intravenous rhMBL in Pts With Multiple Myeloma Receiving Melphalan-Based High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant|Completed||Phase 1|46|Actual|Enzon Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-06-01 03:41:58.981288|2018-06-01 03:41:58.981288
NCT00388986|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2016-11-01|2006-10-16|2006-10-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2006||2006-10-31|November 2016|2016-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.|An Open-label, Crossover Study to Investigate the Potential Pharmacodynamic and Potential Pharmacokinetic Interaction Between Glyburide and GK Activator(2) in Type 2 Diabetes Patients Inadequately Controlled With Glyburide as Standard Prescribed Therapy.|Completed||Phase 1|18|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:41:59.050795|2018-06-01 03:41:59.050795
NCT00388973|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|2008-12-29||2010-03-22|2006-10-16|2006-10-17|Estimate|2010-03-22|2010-04-01|Estimate||||2010-03-22|2010-04-01|Estimate|September 2006||2006-09-30|March 2010|2010-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) in the Treatment of Elderly Patients With Major Depressive Disorder|Completed||Phase 3|338|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:41:59.137769|2018-06-01 03:41:59.137769
NCT00388960|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13||2012-05-31|2016-11-21|2006-10-13|2006-10-17|Estimate||||2012-05-31|2012-06-05|Estimate|2016-11-21|2016-11-22|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|||Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer|Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)|Completed||Phase 2|99|Actual|Celgene Corporation||3|||f||||t||||||||||2018-06-01 03:41:59.586581|2018-06-01 03:41:59.586581
NCT00388947|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|2012-08-03||2016-07-11|2006-10-16|2006-10-17|Estimate|2012-10-16|2012-11-20|Estimate||||2016-07-11|2016-08-11|Estimate|September 2006||2006-09-30|July 2016|2016-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|POWER1012||Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS Products|The Prolapse Registry: An Observational Collection of Short- and Long-Term Patient Outcomes Following Use of AMS Surgical Devices for the Repair of Female Genital Prolapse|Completed|||1543|Actual|ASTORA Women's Health|||1||f||||f||||||||No||2018-06-01 03:41:59.76197|2018-06-01 03:41:59.76197
NCT00388934|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2013-07-29|2006-10-16|2006-10-17|Estimate|||||||2013-07-29|2013-07-30|Estimate|August 2004||2004-08-31|May 2007|2007-05-31|January 2009|Actual|2009-01-31|January 2006|Actual|2006-01-31||Interventional|SORT-OUTII||Comparison of Cypher Select and Taxus Express Coronary Stents|Randomized Clinical Comparison of Cypher Select and Taxus Express Stent Implantation in Unselected Patients With Coronary Artery Disease.|Completed||Phase 4|2095|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-06-01 03:41:59.910211|2018-06-01 03:41:59.910211
NCT00388921|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-15|||2017-11-25|2006-10-16|2006-10-17|Estimate|||||||2017-11-25|2017-11-28|Actual|October 2005||2005-10-31|November 2005|2005-11-30|December 31, 2007|Actual|2007-12-31|December 31, 2007|Actual|2007-12-31||Interventional|||High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM||Completed||N/A|260||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 03:41:59.987304|2018-06-01 03:41:59.987304
NCT00388908|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2015-07-25|2006-10-16|2006-10-17|Estimate|||||||2015-07-25|2015-07-28|Estimate|November 2006||2006-11-30|July 2015|2015-07-31|July 2012|Actual|2012-07-31|December 2010|Actual|2010-12-31||Interventional|AVOID Fracture||Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures|Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures: The AVOID FRACTURE Study|Completed||N/A|240|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 03:42:00.063452|2018-06-01 03:42:00.063452
NCT00388895|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2008-11-17|2006-10-16|2006-10-17|Estimate|||||||2008-11-17|2008-11-19|Estimate|June 2002||2002-06-30|November 2008|2008-11-30|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Interventional|||Glivec in Ph Positive Lymphoblastic Leukemia|Positive Ph Acute Lymphoblastic Leucemia With Intensive Induction Chemotherapy and Glivec, Before and After the Hematopoetic Progenitor Transplant|Completed||Phase 2|35||PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:42:00.129836|2018-06-01 03:42:00.129836
NCT00388882|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2017-12-27|2006-10-16|2006-10-17|Estimate|||||||2017-12-27|2017-12-28|Actual|October 2006||2006-10-31|December 2017|2017-12-31||||October 2007|Actual|2007-10-31||Interventional|||Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.|A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI|Completed||Phase 4|327|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 03:42:00.258463|2018-06-01 03:42:00.258463
NCT00388869|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-15|||2006-10-16|2006-10-16|2006-10-17|Estimate|||||||2006-10-16|2006-10-17|Estimate|November 2006||2006-11-30|October 2006|2006-10-31||||||||Observational|||Renal Artery Calcium and Hypertension|Calcifications of the Renal Arteries and Renal Artery Stenosis in Patients With and Without Hypertension?|Unknown status|Not yet recruiting||300|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:42:00.488033|2018-06-01 03:42:00.488033
NCT00388856|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2010-02-16|2006-10-16|2006-10-17|Estimate|||||||2010-02-16|2010-02-17|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status|Vitamin C and E Supplementation in Pregnant Women With Low Antioxidant Status|Completed||Phase 2|400|Actual|Showa University|||||f||||t||||||||||2018-06-01 03:42:00.591594|2018-06-01 03:42:00.591594
NCT00388843|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2015-08-21|2006-10-16|2006-10-17|Estimate|||||||2015-08-21|2015-08-24|Estimate|August 2006||2006-08-31|August 2015|2015-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI)|Short Term Carotid Plaque Regression in Patients With Atherosclerotic Disease Taking Statins Assessed by High Field MRI|Withdrawn|||0|Actual|Medical College of Wisconsin|||2|PI has left institution|f||||f||||||||||2018-06-01 03:42:00.697268|2018-06-01 03:42:00.697268
NCT00388830|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2012-11-01|2006-10-13|2006-10-17|Estimate|||||||2012-11-01|2012-11-02|Estimate|May 2006||2006-05-31|November 2012|2012-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Emergency Ultrasound of the Gallbladder|"Emergency Bedside Ultrasonography of the Gallbladder: Does Fasting Matter?"|Completed||N/A|70||Christiana Care Health Services|||||f||||||||||||||2018-06-01 03:42:00.821278|2018-06-01 03:42:00.821278
NCT00388817|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-08|||2006-10-16|2006-10-16|2006-10-17|Estimate|||||||2006-10-16|2006-10-17|Estimate|January 2002||2002-01-31|October 2006|2006-10-31|May 2005||2005-05-31|||||Interventional|||Improving Medication Use in Patients With Hypertension|Improving Medication Use in Patients With Hypertension|Completed||N/A|492||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 03:42:00.892237|2018-06-01 03:42:00.892237
NCT00388804|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-15|2012-06-29||2012-06-29|2006-10-15|2006-10-17|Estimate|2012-06-29|2012-08-08|Estimate||||2012-06-29|2012-08-08|Estimate|February 2005||2005-02-28|June 2012|2012-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer|Randomized Trial of External Beam Radiation With or Without Short-Course Hormonal Therapy in Intermediate Risk Prostate Cancer Patients|Terminated||Phase 3|39|Actual|M.D. Anderson Cancer Center||2||Slow accrual.|f||||t||||||||||2018-06-01 03:42:01.068046|2018-06-01 03:42:01.068046
NCT00388791|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2016-01-26|2006-10-16|2006-10-17|Estimate|||||||2016-01-26|2016-01-28|Estimate|October 2006||2006-10-31|January 2016|2016-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Comparison of Systane Free vs. Saline in the Treatment of Dry Eye|Comparison of Systane Free vs. Saline in the Treatment of Dry Eye|Completed||Phase 4|30||Southern California College of Optometry|||||f||||||||||||||2018-06-01 03:42:01.497798|2018-06-01 03:42:01.497798
NCT00388778|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2008-01-22|2006-10-16|2006-10-17|Estimate|||||||2008-01-22|2008-01-23|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|October 2006||2006-10-31|||||Interventional|||The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne|The Effect of Doxycycline 100mg and Doxycycline 20mg in Treatment of Mild and Moderate Acne|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:42:01.58478|2018-06-01 03:42:01.58478
NCT00388765|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2015-10-01|2006-10-16|2006-10-17|Estimate|||||||2015-10-01|2015-10-05|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Normal Control Cohort Sample Bank|Protocol to Establish a Research Sample Bank of Lung Biopsy and BAL Samples for a Non-Atopic, Non-Asthmatic Subject Cohort|Completed|||10|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 03:42:01.74314|2018-06-01 03:42:01.74314
NCT00388752|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2007-06-05|2006-10-16|2006-10-17|Estimate|||||||2007-06-05|2007-06-06|Estimate|September 2006||2006-09-30|October 2006|2006-10-31||||||||Interventional|||Acupuncture for the Treatment of Phantom Limb and Residual Limb Pain After Amputation|Acupuncture for Post Amputation Limb Pain: A Pilot Study|Unknown status|Recruiting|Phase 1|21|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 03:42:01.810004|2018-06-01 03:42:01.810004
NCT00388739|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2006-10-13|2006-10-13|2006-10-17|Estimate|||||||2006-10-13|2006-10-17|Estimate|November 2006||2006-11-30|October 2006|2006-10-31||||||||Interventional|||Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department|Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department|Unknown status|Not yet recruiting|N/A|251||Baylor College of Medicine|||||f||||||||||||||2018-06-01 03:42:01.898249|2018-06-01 03:42:01.898249
NCT00388726|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|2011-12-22||2014-07-25|2006-10-16|2006-10-17|Estimate|2011-12-22|2012-01-30|Estimate||||2014-07-25|2014-07-31|Estimate|October 2006||2006-10-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer|"The EMBRACE Trial: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389. A Phase III Open-Label, Randomized, Parallel, Two-arm, Multi-center Study of E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent, Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane"|Completed||Phase 3|762|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 03:42:02.034233|2018-06-01 03:42:02.034233
NCT00388713|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-15|||2007-05-15|2006-10-16|2006-10-17|Estimate|||||||2007-05-15|2007-05-16|Estimate|October 2006||2006-10-31|December 2005|2005-12-31|January 2010|Anticipated|2010-01-31|||||Observational|||Radiation Induced Atherosclerosis in Breast Cancer Patients|Radiation Induced Atherosclerosis in Breast Cancer Patients|Unknown status|Recruiting||350|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:42:03.103095|2018-06-01 03:42:03.103095
NCT00388700|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2018-02-13|2006-10-13|2006-10-17|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2006||2006-10-31|February 2018|2018-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer|Open-Label, Phase 2 Study of GM-CT-01 When Added to a Regimen of Leucovorin, 5-FU, and Avastin as First Line Treatment for Locally Advanced, Unresectable or Metastatic Colorectal Cancer in Subjects Unable to Tolerate Intensive Chemotherapy|Withdrawn||Phase 2|0|Actual|Galectin Therapeutics Inc.||1||Financing and re-organization|f||||f||||||||||2018-06-01 03:42:03.156871|2018-06-01 03:42:03.156871
NCT00388687|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2006-10-16|2006-10-16|2006-10-17|Estimate|||||||2006-10-16|2006-10-17|Estimate|July 2006||2006-07-31|October 2006|2006-10-31|July 2007||2007-07-31|||||Observational|||Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer|Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer|Unknown status|Recruiting||25||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:42:03.228205|2018-06-01 03:42:03.228205
NCT00388674|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2017-08-11|2006-10-16|2006-10-17|Estimate|||||||2017-08-11|2017-08-14|Actual|December 18, 2006|Actual|2006-12-18|August 2017|2017-08-31|October 26, 2016|Actual|2016-10-26|October 26, 2016|Actual|2016-10-26||Observational|||Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection|Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated With Nucleoside/Nucleotide Monotherapy for Patients With Chronic HBV Infection: The REALM Study|Completed|||12536|Actual|Bristol-Myers Squibb|||2||f||||t|t|f||||Samples With DNA|"~     buccal~   "|||2018-06-01 03:42:03.310034|2018-06-01 03:42:03.310034
NCT00388661|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2011-07-19|2006-10-16|2006-10-17|Estimate|||||||2011-07-19|2011-07-20|Estimate|April 2007||2007-04-30|July 2011|2011-07-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||Melatonin and Quality of Life in Dialysis Patients|Double Blind Placebo-controlled Study on the Efficacy of Melatonin on Sleep, Resulting in an Improved Quality of Life in Hemodialysis Patients|Completed||Phase 3|68|Actual|Meander Medical Center||2|||f||||f||||||||||2018-06-01 03:42:03.945198|2018-06-01 03:42:03.945198
NCT00388648|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2006-10-16|2006-10-16|2006-10-17|Estimate|||||||2006-10-16|2006-10-17|Estimate|January 2000||2000-01-31|October 2006|2006-10-31|July 2005||2005-07-31|||||Interventional|||Very Low Protein Diet or Dialysis in Uremic Elderly?|Efficacy and Safety of a Very Low Protein Diet in Postponing Dialysis in Elderly: a Prospective Randomized Multicenter Controlled Study|Completed||Phase 4|160||Università degli Studi di Brescia|||||f||||||||||||||2018-06-01 03:42:04.043875|2018-06-01 03:42:04.043875
NCT00388635|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2011-01-08|2006-10-16|2006-10-17|Estimate|||||||2011-01-08|2011-01-11|Estimate|April 2004||2004-04-30|January 2011|2011-01-31|December 2008|Actual|2008-12-31|January 2007|Actual|2007-01-31||Interventional|||Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.|A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.|Completed||Phase 1/Phase 2|60|Actual|PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:42:04.147129|2018-06-01 03:42:04.147129
NCT00388622|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-08|||2006-10-16|2006-10-16|2006-10-17|Estimate|||||||2006-10-16|2006-10-17|Estimate|February 2001||2001-02-28|October 2006|2006-10-31|November 2004||2004-11-30|||||Interventional|||Improving Drug Use for Elderly Heart Failure Patients|Improving Drug Use for Elderly Heart Failure Patients|Completed||N/A|314||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 03:42:04.260741|2018-06-01 03:42:04.260741
NCT00388609|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05||2010-09-10|2010-09-15|2006-10-16|2006-10-17|Estimate||||2010-09-10|2010-09-14|Estimate|2010-09-15|2010-09-17|Estimate|November 2006||2006-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|September 2007|Actual|2007-09-30||Interventional|||Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects|A Randomized, Double-blind, Placebo-Controlled, Parallel Arm, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BMS-646256 in Obese and High Risk Overweight Subjects|Terminated||Phase 2|705|Actual|Bristol-Myers Squibb||7|||f||||f||||||||||2018-06-01 03:42:04.32903|2018-06-01 03:42:04.32903
NCT00388596|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2008-10-09|2006-10-13|2006-10-17|Estimate|||||||2008-10-09|2008-10-13|Estimate|October 2006||2006-10-31|October 2008|2008-10-31||||||||Interventional|||A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.|An Open-Label, Partially Randomized, Interaction Study to Evaluate the Effects of SB-751689 on the Pharmacokinetics of Rosuvastatin and Atorvastatin or the Effects of Ketoconazole on the Pharmacokinetics of SB-751689 in Healthy Postmenopausal Female Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:42:04.408674|2018-06-01 03:42:04.408674
NCT00388583|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|2011-07-14|2010-03-30|2012-04-13|2006-10-16|2006-10-17|Estimate|2011-08-10|2011-09-13|Estimate|2010-03-31|2010-04-02|Estimate|2012-04-13|2012-04-18|Estimate|September 2006||2006-09-30|April 2012|2012-04-30|September 2008|Actual|2008-09-30|June 2007|Actual|2007-06-30||Interventional|||Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects|Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects|Completed||Phase 2|817|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:42:04.488694|2018-06-01 03:42:04.488694
NCT00388570|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2011-11-03|2006-10-16|2006-10-17|Estimate|||||||2011-11-03|2011-11-04|Estimate|October 2006||2006-10-31|November 2011|2011-11-30|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|eNOugh||Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment|A Multicenter, Device Randomized, Open-label Prospective Single-cohort Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment|Completed||N/A|151|Actual|Aerocrine AB|||||f||||f||||||||||2018-06-01 03:42:04.9821|2018-06-01 03:42:04.9821
NCT00388557|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2016-09-16|2006-10-16|2006-10-17|Estimate|||||||2016-09-16|2016-09-19|Estimate|October 2005||2005-10-31|September 2016|2016-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Effect of Ketoconazole on the Pharmacokinetics of Vinflunine|Effect of Ketoconazole on the Pharmacokinetics of Intravenous (IV) Vinflunine in Patients With Advanced Cancer|Completed||Phase 1|35|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:42:05.044024|2018-06-01 03:42:05.044024
NCT00388544|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2012-05-08|2006-10-13|2006-10-17|Estimate|||||||2012-05-08|2012-05-09|Estimate|May 2005||2005-05-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Enhancing Quality of Life for Nursing Home Residents|A Prescription for Enhancing Resident Quality of Life|Completed||Phase 2|128|Actual|Penn State University||4|||f||||t||||||||||2018-06-01 03:42:05.098002|2018-06-01 03:42:05.098002
NCT00388531|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|||2011-09-16|2006-10-16|2006-10-17|Estimate|||||||2011-09-16|2011-09-19|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma|Multicenter, Prospective, Open Label Trial, Uncontrolled to Determine the Efficacy and Safety of Depocyt ® for the Treatment of CNS Relapse in Adult Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma|Completed||Phase 2|10|Anticipated|PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:42:05.244222|2018-06-01 03:42:05.244222
NCT00388518|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16||2016-06-28|2016-11-01|2006-10-16|2006-10-17|Estimate||||2016-06-28|2016-06-30|Estimate|2016-11-01|2016-11-02|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of Aleglitazar in Patients With Type 2 Diabetes|A Randomized, Double-blind Study to Investigate the Effect of Aleglitazar on Glycemic Control in Patients With Type 2 Diabetes Mellitus.|Completed||Phase 2|332|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 03:42:05.341562|2018-06-01 03:42:05.341562
NCT00388505|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-16|2012-06-19||2012-06-19|2006-10-16|2006-10-17|Estimate|2012-06-19|2012-07-24|Estimate||||2012-06-19|2012-07-24|Estimate|February 2006||2006-02-28|June 2012|2012-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|EAGER||Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis|A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects|Completed||Phase 3|517|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:42:05.503779|2018-06-01 03:42:05.503779
NCT00388492|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2007-01-10|2006-10-13|2006-10-16|Estimate|||||||2007-01-10|2007-01-11|Estimate||||October 2006|2006-10-31||||||||Observational|||BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects|"BLADE: A Comparison of Once Daily LPV/r to LPV/r BID in HIV-Infected Virologically Controlled Antiretroviral Experienced Subjects"|Unknown status|Not yet recruiting||45||Bellos, Nicholaos C., M.D.|||||f||||||||||||||2018-06-01 03:42:07.051633|2018-06-01 03:42:07.051633
NCT00388479|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2015-07-16|2006-10-12|2006-10-16|Estimate|||||||2015-07-16|2015-07-20|Estimate|December 2001||2001-12-31|July 2015|2015-07-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus|A Multicenter Phase III, Double-Blind, Placebo-Controlled, Parallel Study of ADL-8-2698 in Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus|Completed||Phase 3|666||Cubist Pharmaceuticals LLC|||||f||||f||||||||||2018-06-01 03:42:07.122612|2018-06-01 03:42:07.122612
NCT00388466|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2006-10-13|2006-10-13|2006-10-16|Estimate|||||||2006-10-13|2006-10-16|Estimate|June 2005||2005-06-30|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||Whole Body Vibration - a New Therapeutic Approach to Improve Muscle Function in CF|Cystic Fibrosis: Improvement of Muscle Force and Function by Whole Body Vibration Exercise|Completed||N/A|10||University of Cologne|||||f||||||||||||||2018-06-01 03:42:07.208769|2018-06-01 03:42:07.208769
NCT00388453|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|2016-03-10||2017-05-24|2006-10-13|2006-10-16|Estimate|2017-05-24|2017-06-27|Actual||||2017-05-24|2017-06-27|Actual|October 2006||2006-10-31|May 2017|2017-05-31|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Interventional|ADHERE|Male and female normal volunteers who had no LPR symptoms or known history of GERD.|Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease|ADHERE Study: Application of Dx-pH Catheter for Extra-esophageal Reflux Evaluation|Completed||N/A|47|Actual|Vanderbilt University Medical Center|Lack of prior validation studies on appropriate positioning of the oropharyngeal pH probe.|3|||f||||f||||||||No||2018-06-01 03:42:07.284365|2018-06-01 03:42:07.284365
NCT00388440|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2016-09-15|2006-10-13|2006-10-16|Estimate|||||||2016-09-15|2016-09-20|Estimate|November 2000||2000-11-30|September 2016|2016-09-30|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.|Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.|Completed||Phase 4|150|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:42:07.56508|2018-06-01 03:42:07.56508
NCT00388427|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2015-05-27|2006-10-13|2006-10-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2007||2007-06-30|January 2014|2014-01-31|February 2013|Actual|2013-02-28|July 2009|Actual|2009-07-31||Interventional|||Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies|Phase I Study of Cetuximab Plus Dasatinib (BMS-354825) in Advanced Solid Malignancies|Completed||Phase 1|31|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:42:07.64672|2018-06-01 03:42:07.64672
NCT00388414|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2017-04-22||2017-11-07|2006-10-13|2006-10-16|Estimate|2017-11-07|2017-12-11|Actual||||2017-11-07|2017-12-11|Actual|September 2006||2006-09-30|November 2017|2017-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Imaging Study of Chronic Low Back Pain in Patients Taking Pain Medication|Functional MRI Neural Correlates of Medication Efficacy in Patients With Chronic Low Back Pain|Completed||N/A|14|Actual|Stanford University||2|||f||||||||||||||2018-06-01 03:42:08.526052|2018-06-01 03:42:08.526052
NCT00388401|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2015-07-16|2006-10-13|2006-10-16|Estimate|||||||2015-07-16|2015-07-20|Estimate|January 2002||2002-01-31|October 2008|2008-10-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus|A Multicenter Phase III, Double-Blind, Placebo-Controlled, Parallel Study of ADL-8-2698 in Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus|Completed||Phase 3|510||Cubist Pharmaceuticals LLC|||||f||||f||||||||||2018-06-01 03:42:08.757649|2018-06-01 03:42:08.757649
NCT00388388|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2015-05-18|2006-10-13|2006-10-16|Estimate|||||||2015-05-18|2015-05-19|Estimate|March 2007||2007-03-31|May 2015|2015-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects|Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects|Terminated||Phase 2|1|Actual|Sir Mortimer B. Davis - Jewish General Hospital||2||Few subjects recruited, sponsor withdrew support.|f||||t||||||||||2018-06-01 03:42:08.88202|2018-06-01 03:42:08.88202
NCT00388375|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2014-10-17|2006-10-12|2006-10-16|Estimate|||||||2014-10-17|2014-10-20|Estimate|October 2006||2006-10-31|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Can Ultrasound be Used to Verify CVC Position and to Exclude Pneumothorax?|Can Ultrasound be Used as an Alternative to Chest Radiography After Central Venous Catheter Insertion to Confirm Proper Catheter Position and to Exclude Pneumothorax?|Terminated||N/A|23|Actual|Christiana Care Health Services||1||Not feasible, did not have the study population.|f||||||||||||||2018-06-01 03:42:08.990105|2018-06-01 03:42:08.990105
NCT00388362|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2016-12-07||2017-03-13|2006-10-13|2006-10-16|Estimate|2017-03-13|2017-04-21|Actual||||2017-03-13|2017-04-21|Actual|November 2005||2005-11-30|March 2017|2017-03-31|August 2012|Actual|2012-08-31|November 2010|Actual|2010-11-30||Interventional||Administration of Sirolimus and Prednisone|Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease|A Phase II Trial of Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease|Completed||Phase 2|36|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 03:42:09.282737|2018-06-01 03:42:09.282737
NCT00388349|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2017-01-09||2017-05-15|2006-10-13|2006-10-16|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|September 2001||2001-09-30|May 2017|2017-05-31|September 2010|Actual|2010-09-30|March 2008|Actual|2008-03-31||Interventional|||Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease|Gemcitabine and High-dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease|Completed||Phase 2|146|Actual|Stanford University||1|||f||||f|t|f||||||No||2018-06-01 03:42:10.080882|2018-06-01 03:42:10.080882
NCT00388336|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2011-05-17|2006-10-13|2006-10-16|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 2004||2004-02-29|April 2010|2010-04-30|March 2005|Actual|2005-03-31|||||Interventional|||PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy|A Pilot Study to Evaluate the Response Rate of PROCRIT� (Epoetin Alfa) at 60,000 Units Every Two Weeks in Anemic Cancer Patients Not Receiving Chemotherapy Or Radiation Therapy|Completed||Phase 2|57|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:42:10.591729|2018-06-01 03:42:10.591729
NCT00388323|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2012-12-10|2006-10-13|2006-10-16|Estimate|||||||2012-12-10|2012-12-11|Estimate|November 2006||2006-11-30|November 2012|2012-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|RIHTA||Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human|Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human : Study of Pro- and Anti-inflammatory Cytokines and ADIPOKINES..|Completed||N/A|47|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 03:42:10.687513|2018-06-01 03:42:10.687513
NCT00388310|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2012-11-07|2006-10-13|2006-10-16|Estimate|||||||2012-11-07|2012-11-09|Estimate|February 2006||2006-02-28|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effective Antibiotic Treatment of MRSA|Effective Duration of Antibiotic Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA)|Completed||N/A|33|Actual|Christiana Care Health Services||4|||f||||||||||||||2018-06-01 03:42:10.892566|2018-06-01 03:42:10.892566
NCT00388297|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2016-09-09|2006-10-12|2006-10-16|Estimate|||||||2016-09-09|2016-09-13|Estimate|October 2006||2006-10-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|TSH||Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy|A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy|Completed||Phase 3|1203|Actual|The George Washington University Biostatistics Center||2|||f||||t||||||||Yes|The data will be shared after the completion of the trial and publication of the main analyses per NIH policy. When made available, requests for the dataset(s) can be sent to mfmudatasets@bsc.gwu.edu.|2018-06-01 03:42:11.054179|2018-06-01 03:42:11.054179
NCT00388284|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2015-12-07|2006-10-13|2006-10-16|Estimate|||||||2015-12-07|2015-12-09|Estimate|August 2006||2006-08-31|February 2008|2008-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Efficacy Study Comparing Thrombin for Arterial Sealing|Comparative Analysis of Thrombin Utilized in Endovascular Procedures of the Femoral Artery - CEASE Study|Completed||Phase 3|270||Vascular Solutions, Inc|||||||||||||||||||2018-06-01 03:42:11.400439|2018-06-01 03:42:11.400439
NCT00388271|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2017-02-08|2006-10-13|2006-10-16|Estimate|||||||2017-02-08|2017-02-10|Actual|October 2006||2006-10-31|February 2017|2017-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Use of Alfuzosin in Stone Treatment With ESWL|To Investigate if Alpha-blocker Therapy (Alfuzosin) Increases Stone Free Rates and Improves Pain Control After ESWL (Extra-corporeal Shock Wave Lithotripsy) for Renal and Ureteric Stones.|Withdrawn||Phase 3|0|Actual|Singapore General Hospital||2||lack of funding|f||||f||||||||||2018-06-01 03:42:11.489629|2018-06-01 03:42:11.489629
NCT00388258|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2017-08-17|2006-10-13|2006-10-16|Estimate|||||||2017-08-17|2017-08-22|Actual|March 1, 2001|Actual|2001-03-01|August 2017|2017-08-31|December 1, 2002|Actual|2002-12-01|December 1, 2002|Actual|2002-12-01||Interventional|||Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus|A Multicenter Phase III, Double-Blind, Placebo-Controlled, Parallel Study of ADL-8-2698 in Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus|Completed||Phase 3|451||Cubist Pharmaceuticals LLC|||||f||||f||||||||||2018-06-01 03:42:11.618401|2018-06-01 03:42:11.618401
NCT00388245|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2006-10-13|2006-10-13|2006-10-16|Estimate|||||||2006-10-13|2006-10-16|Estimate|January 2007||2007-01-31|October 2006|2006-10-31|December 2008||2008-12-31|||||Interventional|||Revascularization in Heart Failure Trial – REHEAT 2|Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery|Unknown status|Not yet recruiting|Phase 4|150||Ministry of Science and Higher Education, Poland|||||f||||||||||||||2018-06-01 03:42:11.718731|2018-06-01 03:42:11.718731
NCT00388232|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2006-10-13|2006-10-13|2006-10-16|Estimate|||||||2006-10-13|2006-10-16|Estimate||||October 2006|2006-10-31||||||||Observational|||Prevalence of COPD: First Epidemiological Data From a Large Region of Turkey|Inonu University, The Department of Pulmonary Medicine|Completed|||1200||Inonu University|||||f||||||||||||||2018-06-01 03:42:11.816868|2018-06-01 03:42:11.816868
NCT00388219|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2007-07-05|2006-10-13|2006-10-16|Estimate|||||||2007-07-05|2007-07-06|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|November 2006||2006-11-30|||||Interventional|||Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations|Single Dose Bioequivalence Trial Comparing a New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch|Terminated||Phase 1|24||Grünenthal GmbH|||||f||||||||||||||2018-06-01 03:42:11.916265|2018-06-01 03:42:11.916265
NCT00388206|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2012-12-14|2006-10-13|2006-10-16|Estimate|||||||2012-12-14|2012-12-18|Estimate|May 2006||2006-05-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|ARIES||A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)|An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology)|Completed|||3998|Actual|Genentech, Inc.|||||f||||||||||Samples With DNA|"~     blood and tumor~   "|||2018-06-01 03:42:12.105052|2018-06-01 03:42:12.105052
NCT00388193|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2014-10-27|2006-10-13|2006-10-16|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2006||2006-08-31|February 2013|2013-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma|Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)|Completed||Phase 2|20|Anticipated|PETHEMA Foundation||1|||f||||||||||||||2018-06-01 03:42:12.175641|2018-06-01 03:42:12.175641
NCT00388180|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2012-03-15|2006-10-13|2006-10-16|Estimate|||||||2012-03-15|2012-03-19|Estimate|December 2004||2004-12-31|February 2011|2011-02-28||||||||Observational|||An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation|A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of 12-week Treatment With GW590735X (20ug) or GW501516X (10mg) Relative to Placebo on Measures of Adiposity and Inflammation in Overweight and Obese Subjects|Completed|||71|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:42:12.321731|2018-06-01 03:42:12.321731
NCT00388167|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-13|||2009-05-11|2006-10-13|2006-10-16|Estimate|||||||2009-05-11|2009-05-13|Estimate|March 2004||2004-03-31|May 2009|2009-05-31|February 2008|Actual|2008-02-29|||||Observational|||Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection|PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection|Completed|||320|Anticipated|PETHEMA Foundation|||1||f||||||||||||||2018-06-01 03:42:12.544623|2018-06-01 03:42:12.544623
NCT00388154|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2014-11-05||2014-11-12|2006-10-12|2006-10-16|Estimate|2014-11-12|2014-11-13|Estimate||||2014-11-12|2014-11-13|Estimate|August 2004||2004-08-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||One participant of the 21 enrolled was not evaluable for response or toxicity after transitioning to comfort care without completing the first treatment cycle.|Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer|A Phase II Study of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer|Completed||Phase 2|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:42:12.826281|2018-06-01 03:42:12.826281
NCT00388141|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2007-11-30|2006-10-12|2006-10-13|Estimate|||||||2007-11-30|2007-12-03|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Nursing and Nurturing Premature Infants|Nursing and Nurturing Premature Infants. An Intervention Study Investigating Systematic Use of Newborn Individualized Developmental Care Assessment Program NIDCAP® Improves Development of Infants and the Mothers' Parental Competence|Completed||Early Phase 1|90|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 03:42:13.36411|2018-06-01 03:42:13.36411
NCT00388128|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2011-06-08|2006-10-12|2006-10-13|Estimate|||||||2011-06-08|2011-06-09|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Caffeine and Intermittent Claudication|Effects of Caffeine in Patients With Intermittent Claudication.|Completed||Phase 3|80|Anticipated|University of Aarhus||1|||f||||t||||||||||2018-06-01 03:42:13.50151|2018-06-01 03:42:13.50151
NCT00388115|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2010-03-25|2006-10-12|2006-10-13|Estimate|||||||2010-03-25|2010-03-29|Estimate|October 2001||2001-10-31|March 2010|2010-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ|A Pilot Study of Radiofrequency Ablation of Early Invasive and In Situ Breast Cancer|Completed||N/A|15|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 03:42:13.703286|2018-06-01 03:42:13.703286
NCT00388089|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2010-06-25|2006-10-12|2006-10-13|Estimate|||||||2010-06-25|2010-06-29|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors|Phase I Study of Weekly Bortezomib (VELCADE, PS-341) and Weekly Topotecan (HYCAMTIN) in Solid Tumor Patients With an Emphasis on Small Cell Lung Cancer (SCLC)|Completed||Phase 1|24|Actual|University of California, Davis|||||f||||t||||||||||2018-06-01 03:42:13.893572|2018-06-01 03:42:13.893572
NCT00388076|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2017-11-13|2006-10-11|2006-10-13|Estimate|||||||2017-11-13|2017-11-17|Actual|April 28, 2006|Actual|2006-04-28|November 2017|2017-11-30|July 21, 2009|Actual|2009-07-21|July 21, 2009|Actual|2009-07-21||Interventional|||Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)|A Phase I, Open-Label, Study of the Safety, Tolerability, and Pharmacokinetics of Pazopanib in Combination With Paclitaxel on a Weekly Schedule for Three Consecutive Weeks of a 28-Day Cycle, Paclitaxel and Carboplatin on an Every 21 Days Schedule and Lapatinib and Paclitaxel on a Weekly Schedule for Three Consecutive Weeks of a 28- Day Cycle|Completed||Phase 1|86|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:42:14.109627|2018-06-01 03:42:14.109627
NCT00388063|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2007-12-17|2006-10-12|2006-10-13|Estimate|||||||2007-12-17|2007-12-21|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma|A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma|Completed||Phase 2|55|Actual|Callisto Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:42:14.307057|2018-06-01 03:42:14.307057
NCT00388050|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2015-04-27|2006-10-12|2006-10-13|Estimate|||||||2015-04-27|2015-04-28|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Diabetes Medication Choice|Wiser Choices for Patients With Type II Diabetes: Diabetes Medication Choice|Completed||N/A|85|Actual|Mayo Clinic||2|||f||||||||||||||2018-06-01 03:42:14.399074|2018-06-01 03:42:14.399074
NCT00388037|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2015-01-09||2015-01-15|2006-10-12|2006-10-13|Estimate|2015-01-09|2015-01-15|Estimate||||2015-01-15|2015-01-27|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||All eligible patients|Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Study of Sunitinib (SU11248; NSC 736511) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Completed||Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:42:14.555554|2018-06-01 03:42:14.555554
NCT00388024|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2017-05-25|2006-10-12|2006-10-13|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2006||2006-02-28|February 2017|2017-02-28|January 2015|Actual|2015-01-31|December 2008|Actual|2008-12-31||Observational|||PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|A Pilot Feasibility Study of PET-CT Imaging in Patients With Cancer of the Head and Neck Treated With Definitive Chemoradiation|Completed|||19|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-06-01 03:42:14.838232|2018-06-01 03:42:14.838232
NCT00388011|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2008-01-11|2006-10-12|2006-10-13|Estimate|||||||2008-01-11|2008-01-14|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery|Randomized, Double-Blind, Placebo and Comparator-Controlled, Dose-Response Trial of the Efficacy and Safety of Intranasal Morphine, Intravenous Morphine and Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery|Completed||Phase 2|187|Actual|Javelin Pharmaceuticals||6|||f||||f||||||||||2018-06-01 03:42:15.008699|2018-06-01 03:42:15.008699
NCT00387998|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2013-08-28|2006-10-12|2006-10-13|Estimate|||||||2013-08-28|2013-08-30|Estimate|October 2004||2004-10-31|January 2008|2008-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Health Education in Improving the Understanding of Medical Information|Randomized Trial of a Primer to Help Patients Understand Risk|Completed||N/A|555|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-06-01 03:42:15.105665|2018-06-01 03:42:15.105665
NCT00387985|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2011-07-22|2006-10-12|2006-10-13|Estimate|||||||2011-07-22|2011-07-25|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bioequivalence Study in Healthy Volunteers|An Open-label, Single-dose, Randomized, 2-period Crossover, Bioequivalence Study Between the Current Formulation and the New Formulation of MOA-728 Administered Subcutaneously in Healthy Subjects|Completed||Phase 1|||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:42:15.180627|2018-06-01 03:42:15.180627
NCT00386204|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2008-06-02|2006-10-10|2006-10-11|Estimate|||||||2008-06-02|2008-06-04|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|September 2006||2006-09-30|||||Interventional|||Side Effects of Q-Switched Ruby Laser for the Treatment of Lentigines in Light and Dark Skin Types|Efficacy and Side Effects of Q-Switched Ruby Laser Treatment of Solar Lentigines in Two Different Fitzpatrick Skin Types II and IV|Completed||Phase 2|90||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:42:51.924484|2018-06-01 03:42:51.924484
NCT00387972|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2015-04-15|2006-10-12|2006-10-13|Estimate|||||||2015-04-15|2015-04-17|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|October 2007|Anticipated|2007-10-31|October 2007|Anticipated|2007-10-31||Interventional|||Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)|A Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus|Withdrawn||Phase 2/Phase 3|0|Actual|GlaxoSmithKline||||Study cancelled before enrollment|f||||||||||||||2018-06-01 03:42:15.251933|2018-06-01 03:42:15.251933
NCT00387959|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2015-12-22||2015-12-22|2006-10-12|2006-10-13|Estimate|2015-12-22|2016-02-01|Estimate||||2015-12-22|2016-02-01|Estimate|July 2006||2006-07-31|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With B Cell Lymphoid Malignancies|Completed||Phase 2|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-06-01 03:42:15.401968|2018-06-01 03:42:15.401968
NCT00387946|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2012-02-15|2006-10-12|2006-10-13|Estimate|||||||2012-02-15|2012-02-17|Estimate|September 2006||2006-09-30|February 2012|2012-02-29|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)|An International, Seven-week, Double-blind, Placebo-controlled, Two Parallel Group Study to Assess the Efficacy of Dianicline 40 mg Bid as an Aid to Smoking Cessation in Cigarette Smokers|Completed||Phase 3|630|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:42:15.600562|2018-06-01 03:42:15.600562
NCT00387933|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2015-10-11|2006-10-12|2006-10-13|Estimate|||||||2015-10-11|2015-10-14|Estimate|July 2005||2005-07-31|November 2012|2012-11-30||||January 2009|Actual|2009-01-31||Interventional|||Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma|Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea|Completed||Phase 1|37|Actual|Duke University||1|||f||||||||||||||2018-06-01 03:42:15.663385|2018-06-01 03:42:15.663385
NCT00387920|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2014-01-27|2006-10-12|2006-10-13|Estimate|||||||2014-01-27|2014-01-28|Estimate|October 2006||2006-10-31|January 2014|2014-01-31||||September 2012|Actual|2012-09-30||Interventional|||Sunitinib in Treating Young Patients With Refractory Solid Tumors|A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:42:15.746773|2018-06-01 03:42:15.746773
NCT00387907|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12||2016-04-06|2016-04-06|2006-10-12|2006-10-13|Estimate||||2016-04-06|2016-05-05|Estimate|2016-04-06|2016-05-05|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer|Open Label, Uncontrolled, Study of XRP9881 (Larotaxel) in Combination With Weekly Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)|Completed||Phase 2|6|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:42:15.861673|2018-06-01 03:42:15.861673
NCT00387894|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2013-04-12||2013-05-25|2006-10-12|2006-10-13|Estimate|2013-04-16|2013-05-17|Estimate||||2013-05-25|2013-06-04|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Phase-2 Study of Tarceva in Patients With Recurrent EGFR Positive and Phosphatase and Tensin Homolog (PTEN) Wild Type Glioblastoma Multiforme and Gliosarcoma|Terminated||Phase 2|6|Actual|University of California, San Francisco|The study was terminated early for 2 reasons: 1. ongoing literature at the time confirming that the selection process was not likely to enrich for a patient population expected to benefit, and 2. Rapid disease progression in the first 6 patients.|1||Insufficient accrual of population likely to benefit; progression in 6 patients|f||||t||||||||||2018-06-01 03:42:15.949389|2018-06-01 03:42:15.949389
NCT00387881|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|2009-02-19||2016-11-02|2006-10-12|2006-10-13|Estimate|2009-05-19|2009-07-10|Estimate||||2016-11-02|2016-12-16|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET)|Completed||Phase 3|679|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:42:16.283131|2018-06-01 03:42:16.283131
NCT00387868|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2014-12-08|2006-10-11|2006-10-13|Estimate|||||||2014-12-08|2014-12-09|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Preoperative Treatment of Patients With High Risk Thymoma|Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence|Completed||Phase 2|21|Actual|Valley Health System||3|||f||||t||||||||||2018-06-01 03:42:17.590377|2018-06-01 03:42:17.590377
NCT00387855|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2016-07-27|2006-10-12|2006-10-13|Estimate|||||||2016-07-27|2016-07-29|Estimate|September 2001||2001-09-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|December 2012|Actual|2012-12-31||Interventional|||An Evaluation of the SOS (Suicide Prevention) Program|An Outcome Evaluation of the SOS Suicide Prevention Program|Completed||N/A|6471|Actual|UConn Health||1|||f||||f||||||||||2018-06-01 03:42:17.99846|2018-06-01 03:42:17.99846
NCT00387842|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2006-10-12|2006-10-12|2006-10-13|Estimate|||||||2006-10-12|2006-10-13|Estimate|March 1997||1997-03-31|October 2006|2006-10-31|March 2008||2008-03-31|||||Interventional|||COlon Cancer Laparoscopic or Open Resection|A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Colon Cancer|Unknown status|Active, not recruiting|Phase 3|1200||Erasmus Medical Center|||||f||||||||||||||2018-06-01 03:42:18.071941|2018-06-01 03:42:18.071941
NCT00387829|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2013-06-07||2017-08-07|2006-10-12|2006-10-13|Estimate|2013-09-17|2013-11-20|Estimate||||2017-08-07|2017-09-07|Actual|October 2006||2006-10-31|August 2017|2017-08-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional||A total of 343 patients were randomized in the study (Intent-to-treat population). Four patients received treatment (1 Duragen Plus; 3 Surgery alone), but were not randomized correctly, and were followed-up for safety only. Hence the total patients in the Safety Population is 347.|DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery|Randomized Controlled Trial of DuraGen Plus® Adhesion Barrier Matrix to Minimize Adhesions Following Lumbar Discectomy|Terminated||N/A|347|Actual|Integra LifeSciences Corporation||2||Sponsor voluntarily terminated study|f||||f||||||||||2018-06-01 03:42:18.197351|2018-06-01 03:42:18.197351
NCT00387803|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2007-01-23|2006-10-11|2006-10-13|Estimate|||||||2007-01-23|2007-01-25|Estimate|February 1998||1998-02-28|January 2007|2007-01-31|August 2001||2001-08-31|||||Interventional|||Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation|VENTAK CHF/CONTAK CD Biventricular Pacing Study|Completed||Phase 2/Phase 3|581||Boston Scientific Corporation|||||||||||||||||||2018-06-01 03:42:18.818774|2018-06-01 03:42:18.818774
NCT00387790|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2013-12-18||2017-12-06|2006-10-12|2006-10-13|Estimate|2013-12-18|2014-02-05|Estimate||||2017-12-06|2018-01-04|Actual|June 2007||2007-06-30|December 2017|2017-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma|A Phase II Study of Motexafin-Gadolinium (NSC 695238, IND #55583) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood|Completed||Phase 2|64|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:42:18.955247|2018-06-01 03:42:18.955247
NCT00387777|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2016-01-08|2006-10-12|2006-10-13|Estimate|||||||2016-01-08|2016-01-11|Estimate|October 2006||2006-10-31|January 2016|2016-01-31|December 2006||2006-12-31|||||Interventional|||Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations|Multiple Dose Bioequivalence Trial Comparing a New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch.|Terminated||Phase 1|24||Grünenthal GmbH|||||f||||||||||||||2018-06-01 03:42:19.331376|2018-06-01 03:42:19.331376
NCT00387764|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2013-08-15||2013-12-12|2006-10-12|2006-10-13|Estimate|2013-10-04|2013-12-03|Estimate||||2013-12-12|2014-01-14|Estimate|September 2006||2006-09-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|December 2009|Actual|2009-12-31||Interventional|||Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer|An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192|Completed||Phase 3|80|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:42:19.504534|2018-06-01 03:42:19.504534
NCT00387751|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2012-12-07||2017-10-19|2006-10-12|2006-10-13|Estimate|2012-12-07|2013-01-17|Estimate||||2017-10-19|2017-11-22|Actual|August 2006|Actual|2006-08-31|October 2017|2017-10-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma|A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma|Completed||Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:42:20.261907|2018-06-01 03:42:20.261907
NCT00387738|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2018-02-27|2006-10-11|2006-10-13|Estimate|||||||2018-02-27|2018-03-01|Actual|April 2006||2006-04-30|February 2018|2018-02-28|March 2008|Actual|2008-03-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults|A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Dose-Regimen Study of the Efficacy and Safety of TOLAMBA™ in Ragweed-Allergic Rhinitis Adults|Terminated||Phase 2|738|Actual|Dynavax Technologies Corporation||3||"Interim data indicated that subjects exhibited no meaningful allergic disease during the first~   ragweed season, making it impossible to measure treatment effect."|f||||t||||||||No|The IND for Tolamba was withdrawn, it was reported to the agency that there was no plan to conduct clinical studies with this compound. [per email from EA 18Dec2015. 3/1/2017 - No update|2018-06-01 03:42:20.558695|2018-06-01 03:42:20.558695
NCT00387725|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|2014-11-14||2014-11-14|2006-10-12|2006-10-13|Estimate|2014-11-14|2014-11-21|Estimate||||2014-11-14|2014-11-21|Estimate|November 2006||2006-11-30|November 2014|2014-11-30|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents|A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years|Completed||Phase 2|127|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 03:42:20.818516|2018-06-01 03:42:20.818516
NCT00387712|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2017-02-21||2017-06-22|2006-10-12|2006-10-13|Estimate|2017-06-22|2017-09-14|Actual||||2017-06-22|2017-09-14|Actual|October 2006||2006-10-31|June 2017|2017-06-30|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Interventional|||Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise|Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise|Completed||N/A|99|Actual|VA Office of Research and Development|Limitations of the study, such as early termination, led to smaller numbers of participants analyzed and technical problems with measurement and participant inability to attend testing or complete testing led to unreliable and missing data.|2|||f||||t||||||||Undecided||2018-06-01 03:42:21.447768|2018-06-01 03:42:21.447768
NCT00387699|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2015-04-27|2006-10-12|2006-10-13|Estimate|||||||2015-04-27|2015-04-28|Estimate|October 2006||2006-10-31|October 2008|2008-10-31|April 2014|Actual|2014-04-30|October 2007|Actual|2007-10-31||Interventional|||Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase II Trial of Bevacizumab in Combination With Cisplatin/Etoposide and Twice Daily Radiation for Patients With Limited-Stage Small Cell Lung Cancer|Completed||Phase 2|79|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:42:22.044855|2018-06-01 03:42:22.044855
NCT00387686|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11||2013-02-21|2013-02-21|2006-10-11|2006-10-13|Estimate||||2013-02-21|2013-02-28|Estimate|2013-02-21|2013-02-28|Estimate|November 2006||2006-11-30|February 2013|2013-02-28|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|||A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures|A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study Of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) In Closed Diaphyseal Tibial Fracture|Terminated||Phase 2/Phase 3|367|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4||"Decision was taken by Wyeth Sr. Management to early terminate the 3100N7-210 study (terminate~   enrollment but complete follow-up)."|f||||f||||||||||2018-06-01 03:42:22.230714|2018-06-01 03:42:22.230714
NCT00387673|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2017-05-09||2017-05-09|2006-10-12|2006-10-13|Estimate|2017-05-09|2017-06-16|Actual||||2017-05-09|2017-06-16|Actual|October 2006||2006-10-31|May 2017|2017-05-31|June 2011|Actual|2011-06-30|October 2009|Actual|2009-10-31||Interventional||Project has officially closed. PI for this project has left VA without forwarding information.|Effect of Prolonged Electrical Stimulation on Neural Plasticity in Spinal Cord Injury|Effect of Prolonged Electrical Stimulation on Neural Plasticity in SCI|Completed||N/A|11|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 03:42:22.483074|2018-06-01 03:42:22.483074
NCT00387660|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2017-01-13||2018-01-05|2006-10-12|2006-10-13|Estimate|2017-03-20|2017-05-01|Actual||||2018-01-05|2018-01-10|Actual|October 2001||2001-10-31|January 2018|2018-01-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer|Phase II Study of Irinotecan and Carboplatin in Metastatic or Relapsed Small-Cell Lung Cancer|Completed||Phase 2|80|Actual|University of California, Davis|Of the 80 patients, 72 were assessable.|2|||f||||f|t|f||||||||2018-06-01 03:42:22.70545|2018-06-01 03:42:22.70545
NCT00387491|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2011-07-22|2006-10-11|2006-10-13|Estimate|||||||2011-07-22|2011-07-25|Estimate|June 2006||2006-06-30|July 2011|2011-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Dose Ranging Study in Healthy Methadone Maintenance Subjects|A Randomized, Double-blind, 4-period Crossover, Dose-ranging Study to Determine the Effects on the Oral-cecal Transit Time of Single Doses of MOA-728 and the Safety and Tolerability of Multiple Doses of MOA-728 in Stable Methadone Maintenance Subjects|Completed||Phase 1|16||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:42:25.862657|2018-06-01 03:42:25.862657
NCT00387647|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2014-05-29||2014-08-19|2006-10-12|2006-10-13|Estimate|2014-05-29|2014-06-30|Estimate||||2014-08-19|2014-08-22|Estimate|August 2006||2006-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|October 2013|Actual|2013-10-31||Interventional||All participants|Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy|A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction Chemotherapy|Completed||Phase 2|24|Actual|H. Lee Moffitt Cancer Center and Research Institute|Only five participants completed study and defined follow-up period and one participant remained on follow-up at time of analysis.|1|||f||||f||||||||||2018-06-01 03:42:23.263436|2018-06-01 03:42:23.263436
NCT00387634|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2012-11-01|2006-10-11|2006-10-13|Estimate|||||||2012-11-01|2012-11-02|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults|A Phase IV, Uncontrolled, Open-label, Single-center Study in Adolescents and Adults: Evaluation of Immunogenicity and Safety of the First Booster Immunization With Novartis' TBE Vaccine for Adults in Participants of Study V48P7 and Long-term Evaluation of Immunogenicity up to 5 Years After First Booster Immunization|Completed||Phase 4|323|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:42:23.73247|2018-06-01 03:42:23.73247
NCT00387621|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2011-10-26||2012-04-18|2006-10-12|2006-10-13|Estimate|2012-04-18|2012-05-17|Estimate||||2012-04-18|2012-05-17|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|PPG1||Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction|To Define in Normal Controls, Human Preclinical Systolic Dysfunction (PSD) and Preclinical Diastolic Dysfunction (PDD) the Actions of Acute Subcutaneous Nesiritide (BNP) on the Cardiorenal and Humoral Function and the Integrated Response to Acute Sodium Loading|Completed||Phase 1/Phase 2|58|Actual|Mayo Clinic|"Different baseline characteristics of the three groups of subjects~Did not define a mechanism for the impaired renal cGMP activation~Future studies needed to determine effects of chronic nesiritide therapy in preclinical HF."|2|||f||||t||||||||||2018-06-01 03:42:23.881447|2018-06-01 03:42:23.881447
NCT00387608|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2012-03-14|2006-10-12|2006-10-13|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|April 2009|Actual|2009-04-30|February 2008|Actual|2008-02-29||Interventional|||ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer|A Phase 0 Pharmacokinetic, Pharmacodynamic Study of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), in Refractory Solid Tumors and Lymphoid Malignancies|Completed||Phase 1|23|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 03:42:24.68618|2018-06-01 03:42:24.68618
NCT00387595|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2008-08-06|2006-10-12|2006-10-13|Estimate|||||||2008-08-06|2008-08-08|Estimate|February 2003||2003-02-28|August 2008|2008-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Family Atherosclerosis Counseling and Testing Project|Family Atherosclerosis Counseling and Testing Project (FACT)|Completed|||||University of British Columbia|||||f||||f||||||||||2018-06-01 03:42:24.815991|2018-06-01 03:42:24.815991
NCT00387582|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2014-05-05|2006-10-11|2006-10-13|Estimate|||||||2014-05-05|2014-05-06|Estimate|July 2006||2006-07-31|May 2014|2014-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema|Lucentis in the Treatment of Macular Edema - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab Versus Focal Laser Treatment in Subjects With Diabetic Macular Edema|Completed||Phase 2|49|Actual|Rocky Mountain Retina Consultants||2|||f||||t||||||||||2018-06-01 03:42:24.896532|2018-06-01 03:42:24.896532
NCT00387569|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2008-05-06|2006-10-12|2006-10-13|Estimate|||||||2008-05-06|2008-05-08|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers|A Randomized, Observer-Blinded, Parallel-Group, Active-Control, Phase 1/2 Trial of the Safety, Immunogenicity, and Tolerability of 20 µg, 60 µg, and 200 µg of Meningococcal Group B rLP2086 Vaccine in Healthy Adolescents Aged 10 to 12 Years|Completed||Phase 1|99|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||t||||||||||2018-06-01 03:42:25.061233|2018-06-01 03:42:25.061233
NCT00387556|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2013-05-09|2006-10-12|2006-10-13|Estimate|||||||2013-05-09|2013-05-13|Estimate|December 2002||2002-12-31|May 2013|2013-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Ondansetron Reduce Vomiting Associated With Ketamine PSA|Does Ondansetron Reduce the Incidence of Vomiting When Used in Conjunction With Ketamine During Procedural Sedation in the Pediatric Emergency Department|Completed||N/A|268|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 03:42:25.164047|2018-06-01 03:42:25.164047
NCT00387543|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2011-04-04|2006-10-12|2006-10-13|Estimate|||||||2011-04-04|2011-04-05|Estimate|January 2000||2000-01-31|April 2011|2011-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Alpha Lipoic Acid for Burning Mouth|Review of Mayo Clinic Experience With Burning Mouth Syndrome - Use of Alpha Lipoic Acid|Completed|||200|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:42:25.386082|2018-06-01 03:42:25.386082
NCT00387530|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2009-02-06|2006-10-12|2006-10-13|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 2006||2006-05-31|March 2008|2008-03-31||||January 2008|Anticipated|2008-01-31||Interventional|||Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer|A Phase II Study of Phenylbutyrate and Valganciclovir in Epstein-Barr Virus Positive Tumors|Unknown status|Active, not recruiting|Phase 2|14|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:42:25.475764|2018-06-01 03:42:25.475764
NCT00387517|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2017-02-03|2006-10-12|2006-10-13|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2006||2006-10-31|February 2017|2017-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension|An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy|Completed||Phase 3|726|Anticipated|Novartis|||||f||||||||||||||2018-06-01 03:42:25.567404|2018-06-01 03:42:25.567404
NCT00387504|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2013-09-10|2006-10-12|2006-10-13|Estimate|||||||2013-09-10|2013-09-12|Estimate|November 2006||2006-11-30|September 2013|2013-09-30||||July 2013|Actual|2013-07-31||Interventional|||Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors|Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors|Completed||Phase 1|21|Anticipated|California Cancer Consortium|||||f||||||||||||||2018-06-01 03:42:25.761481|2018-06-01 03:42:25.761481
NCT00386191|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2010-02-23|2006-10-10|2006-10-11|Estimate|||||||2010-02-23|2010-02-24|Estimate|September 2006||2006-09-30|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment|Evaluation of the Safety and Efficacy of Clopidogrel sulfate50mg and Clopidogrel Sulfate 75mg for the Treatment of Cerebral Infarction|Completed||Phase 4|1110|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:42:52.175163|2018-06-01 03:42:52.175163
NCT00387478|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2010-06-16|2006-10-12|2006-10-13|Estimate|||||||2010-06-16|2010-06-17|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|June 2009|Anticipated|2009-06-30|March 2009|Anticipated|2009-03-31||Interventional|||Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis|A Double Blind Study to Investigate the Clinical Efficacy and Safety of TreeMATAMPL (Allergy Therapeutics, (UK) Ltd.), TreeMATA (Allergy Therapeutics, (UK) Ltd.) and Placebo in Patients With Seasonal Allergic Rhinitis Due to Birch Pollen Allergy, in an Environmental Exposure Chamber (EEC) Model When Exposed to Birch Pollen and Oak Pollen|Suspended||Phase 2|300|Anticipated|Allergy Therapeutics||3||Enrollement target could not be achieved, study will potentially be resumed|f||||||||||||||2018-06-01 03:42:26.020176|2018-06-01 03:42:26.020176
NCT00387465|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2015-04-30|2006-10-12|2006-10-13|Estimate|||||||2015-04-30|2015-05-01|Estimate|August 2006||2006-08-31|March 2014|2014-03-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer|A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|162|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:42:26.317342|2018-06-01 03:42:26.317342
NCT00387452|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2017-04-12|2006-10-11|2006-10-13|Estimate|||||||2017-04-12|2017-04-14|Actual|February 2006|Actual|2006-02-28|April 2017|2017-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes|Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes|Completed||N/A|64|Actual|University of British Columbia||3|||f||||f|f|f||||||No||2018-06-01 03:42:26.50428|2018-06-01 03:42:26.50428
NCT00387439|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2013-09-18|2006-10-12|2006-10-13|Estimate|||||||2013-09-18|2013-09-19|Estimate|October 2006||2006-10-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||ORALIA Trial Medical Treatment vs Anoperineal Physiotherapy for Adult Anal Incontinence.|ORALIA Trial Randomized Controlled Trial of Medical Treatment Alone vs Medical Treatment Associated With Anoperineal Physiotherapy for Adult Anal Incontinence. Assessment of Incontinence Symptoms and Quality of Life.|Terminated||N/A|173|Actual|Hospices Civils de Lyon||2|||f||||||||||||||2018-06-01 03:42:26.650907|2018-06-01 03:42:26.650907
NCT00387426|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2012-07-05||2014-05-12|2006-10-12|2006-10-13|Estimate|2012-07-05|2012-08-14|Estimate||||2014-05-12|2014-05-28|Estimate|September 2006||2006-09-30|October 2013|2013-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Sunitinib in Treating Patients With Idiopathic Myelofibrosis|A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis|Terminated||Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:42:26.785651|2018-06-01 03:42:26.785651
NCT00387413|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2017-08-03|2006-10-11|2006-10-13|Estimate|||||||2017-08-03|2017-08-07|Actual|October 2, 2006|Actual|2006-10-02|August 2017|2017-08-31|May 31, 2007|Actual|2007-05-31|May 31, 2007|Actual|2007-05-31||Interventional|||A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers|A Double-blind, Double-dummy, Placebo-controlled, Incomplete Block, Two Period Crossover Study of the Histamine H3 Antagonist GSK189254 and Duloxetine in the Electrical Hyperalgesia Model of Central Sensitisation in Healthy Volunteers|Completed||Phase 1|40|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:42:27.006003|2018-06-01 03:42:27.006003
NCT00387400|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2016-11-25|2006-10-12|2006-10-13|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 2006||2006-07-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Temozolomide and Everolimus in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme|A Phase I Study of Temozolomide and RAD001C in Patients With Malignant Glioblastoma Multiforme|Completed||Phase 1|32|Actual|Canadian Cancer Trials Group|||||f||||t||||||||||2018-06-01 03:42:28.134236|2018-06-01 03:42:28.134236
NCT00387387|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2017-11-13|2006-10-11|2006-10-13|Estimate|||||||2017-11-13|2017-11-17|Actual|October 20, 2006|Actual|2006-10-20|November 2017|2017-11-30|August 14, 2009|Actual|2009-08-14|August 14, 2009|Actual|2009-08-14||Interventional|||Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)|An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination With FOLFOX 6 or CapeOx in Subjects With Colorectal Cancer|Completed||Phase 1|50|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:42:28.318444|2018-06-01 03:42:28.318444
NCT00387374|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2013-01-15|2006-10-12|2006-10-13|Estimate|||||||2013-01-15|2013-01-17|Estimate|October 2006||2006-10-31|January 2013|2013-01-31||||June 2007|Actual|2007-06-30||Interventional|||Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab|A Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non Small Cell Lung Cancer in Combination With Bevacizumab, Paclitaxel, and Carboplatin in Patients at High Risk for Bevacizumab-Associated Hemoptysis|Completed||Phase 2|72|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:42:28.4597|2018-06-01 03:42:28.4597
NCT00387361|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2011-01-11|2006-10-12|2006-10-13|Estimate|||||||2011-01-11|2011-01-12|Estimate|December 2006||2006-12-31|January 2011|2011-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Osteopathic Manipulative Treatment for Post-Operative Nausea and Vomiting|Osteopathic Manipulative Treatment (OMT) as Possible Prophylaxis Against Post-Operative Nausea and Vomiting (PONV) in Patients Receiving Inhalational Anesthesia|Completed||Phase 1/Phase 2|20|Actual|University of North Texas Health Science Center||2|||f||||f||||||||||2018-06-01 03:42:28.694859|2018-06-01 03:42:28.694859
NCT00387348|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2012-07-12||2012-11-02|2006-10-12|2006-10-13|Estimate|2012-11-02|2012-12-03|Estimate||||2012-11-02|2012-12-03|Estimate|March 2006||2006-03-31|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer|Symptom Management Trial in Cancer Survivors|Terminated||Phase 3|24|Actual|Massachusetts General Hospital|After an interim analaysis, the DSMB decided to terminate the trial early because of the rate of adverse events (HAM-D scores increasing by at least 25%) and deaths were higher in participants receiving placebo.|3||DSMB stopped study because placebo arm had more adverse events|f||||t||||||||||2018-06-01 03:42:28.836294|2018-06-01 03:42:28.836294
NCT00387335|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|2013-12-04||2014-07-21|2006-10-12|2006-10-13|Estimate|2013-12-04|2014-01-22|Estimate||||2014-07-21|2014-07-25|Estimate|August 2006||2006-08-31|December 2012|2012-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:42:29.428142|2018-06-01 03:42:29.428142
NCT00382538|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2008-10-03|2006-09-28|2006-09-29|Estimate|||||||2008-10-03|2008-10-07|Estimate|March 2005||2005-03-31|October 2008|2008-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Mifepristone and Mid-Trimester Termination of Pregnancy|A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy|Completed||N/A|64||Boston University|||||f||||||||||||||2018-06-01 03:44:11.563601|2018-06-01 03:44:11.563601
NCT00387322|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-12|||2010-03-25|2006-10-12|2006-10-13|Estimate|||||||2010-03-25|2010-03-29|Estimate|March 2005||2005-03-31|March 2010|2010-03-31|May 2009|Actual|2009-05-31|October 2007|Actual|2007-10-31||Interventional|||Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|Phase I/II Study of Two Different Schedules of Pemetrexed (ALIMTA) and Erlotinib (TARCEVA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|42|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 03:42:29.977511|2018-06-01 03:42:29.977511
NCT00387309|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2011-07-22|2006-10-11|2006-10-13|Estimate|||||||2011-07-22|2011-07-26|Estimate|December 2006||2006-12-31|July 2011|2011-07-31|November 2007|Actual|2007-11-30|||||Interventional|||Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus.|Completed||Phase 3|495||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:42:30.125857|2018-06-01 03:42:30.125857
NCT00387296|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2009-02-25|2006-10-11|2006-10-13|Estimate|||||||2009-02-25|2009-02-26|Estimate|January 2010||2010-01-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Study of Functional Microarray-Facilitated Lidocaine Liposomal Cream Absorption for Cutaneous Anesthesia in Volunteers|"FAST Lidocaine, Study of Functional Microarray-Facilitated Lidocaine Liposomal Cream Absorption for Cutaneous Anesthesia in Volunteers"|Withdrawn||Phase 2|20|Anticipated|Massachusetts General Hospital||||Funding nonavailability and principal investigator move|f||||t||||||||||2018-06-01 03:42:30.360699|2018-06-01 03:42:30.360699
NCT00387283|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2009-07-06|2006-10-11|2006-10-13|Estimate|||||||2009-07-06|2009-07-08|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|December 2006|Actual|2006-12-31||Interventional|||Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020|Pharmacokinetic Study of AVI-4020 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration|Completed||Phase 1|14||Sarepta Therapeutics|||||f||||||||||||||2018-06-01 03:42:30.425107|2018-06-01 03:42:30.425107
NCT00387270|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2008-01-03|2006-10-10|2006-10-12|Estimate|||||||2008-01-03|2008-01-04|Estimate|October 2006||2006-10-31|September 2007|2007-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease|A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease|Completed||Phase 1/Phase 2|9|Actual|Medivation, Inc.||1|||f||||||||||||||2018-06-01 03:42:30.485998|2018-06-01 03:42:30.485998
NCT00387257|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2015-04-14|2006-10-10|2006-10-12|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effect Of Rilapladib (SB-659032) On Platelet Aggregation|A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers|Completed||Phase 1|58|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:42:30.691182|2018-06-01 03:42:30.691182
NCT00387244|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2013-08-01|2006-10-10|2006-10-12|Estimate|||||||2013-08-01|2013-08-05|Estimate|August 2006||2006-08-31|August 2013|2013-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy of the Spinal Cord Stimulation System as Salvage Therapy|Efficacy of the Precision Spinal Cord Stimulation System as Salvage Therapy for Patients With Chronic Intractable Pain of the Trunk and or Limbs Who Have Failed Treatment With an Intraspinal Infusion Pump or Other Spinal Cord Stimulation Device|Terminated||Phase 4|6|Actual|Boston Scientific Corporation||1||Insufficient Data Collected|f||||f||||||||||2018-06-01 03:42:30.756669|2018-06-01 03:42:30.756669
NCT00387231|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-12|Estimate|||||||2006-10-10|2006-10-12|Estimate|June 1991||1991-06-30|October 2006|2006-10-31|May 2006||2006-05-31|||||Interventional|||Comparison of Anti-Ischemic Drug Therapy and Percutaneous Transluminal Angioplasty After Myocardial Infarction|Swiss Interventional Study on Silent Ischemia (SWISSI 2)|Completed||N/A|||Luzerner Kantonsspital|||||f||||||||||||||2018-06-01 03:42:30.85704|2018-06-01 03:42:30.85704
NCT00387218|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2008-05-21|2006-10-11|2006-10-12|Estimate|||||||2008-05-21|2008-05-23|Estimate|December 2002||2002-12-31|May 2008|2008-05-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Exercise Study For People With Parkinson's Disease|Exercise, Physical Function, and Parkinson's Disease|Unknown status|Recruiting|N/A|170|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:42:30.91836|2018-06-01 03:42:30.91836
NCT00387205|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2018-04-11|2006-10-10|2006-10-12|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2006||2006-06-30|April 2018|2018-04-30|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08||Interventional|||Study To Assess Long Term Safety Of Pazopanib|An Open-Label, Phase Ib Study to Assess the Long Term Safety Profile of Pazopanib in Cancer Patients|Completed||Phase 1|188|Actual|Novartis||1|||f||||f|t|f||||||No||2018-06-01 03:42:31.026736|2018-06-01 03:42:31.026736
NCT00387192|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2010-03-02|2006-10-11|2006-10-12|Estimate|||||||2010-03-02|2010-03-03|Estimate|November 2006||2006-11-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||A Study With OPTIVATE® in People With Von Willebrand Disease|An Open Multi-centre Study in Patients With Von Willebrand Disease to Investigate the Pharmacokinetics, Efficacy and Safety of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate|Terminated||Phase 3|26|Anticipated|Bio Products Laboratory||||Due to slow recruitment and a significant delay in reaching the recruitment target.|f||||f||||||||||2018-06-01 03:42:31.124448|2018-06-01 03:42:31.124448
NCT00387179|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2009-08-24|2006-10-11|2006-10-12|Estimate|||||||2009-08-24|2009-08-25|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|March 2010|Anticipated|2010-03-31|March 2010|Anticipated|2010-03-31||Interventional|||Effectiveness of Combining Light and Non-Light Treatments for Jet Lag and Sleep Disorders|Circadian Integration of Photic and Non-photic Stimuli|Unknown status|Recruiting|N/A|48|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||||||||||||2018-06-01 03:42:31.21666|2018-06-01 03:42:31.21666
NCT00387166|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2012-01-04|2006-10-11|2006-10-12|Estimate|||||||2012-01-04|2012-01-06|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Socioeconomic Status, Psychosocial Factors, and CVD Risk in Mexican-American Women|Cardiovascular Risk Disparities: Socio-Emotional Pathways|Completed|||304|Actual|San Diego State University|||1||f||||t||||||Samples Without DNA|"~     Blood and urine specimens were collected to identify stress hormones and inflammatory~     markers. Whole blood, plasma, and serum are stored for possible future assays based on new~     discoveries.~   "|||2018-06-01 03:42:31.421784|2018-06-01 03:42:31.421784
NCT00386412|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2009-09-17|2006-10-10|2006-10-11|Estimate|||||||2009-09-17|2009-09-18|Estimate|November 2005||2005-11-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant|Phase II, Multicentric, Prospective and Opened Clinical Trial of Advance Valganciclovir Treatment of CMV in Allogenic Hematopoietic Progenitors Transplant|Completed||Phase 2|132|Anticipated|PETHEMA Foundation|||||f||||||||||||||2018-06-01 03:42:43.929145|2018-06-01 03:42:43.929145
NCT00387153|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|2009-06-23||2009-10-27|2006-10-10|2006-10-12|Estimate|2009-09-21|2009-10-22|Estimate||||2009-10-27|2009-11-03|Estimate|August 2005||2005-08-31|October 2009|2009-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer|Phase 1 OL, Dose Escalating, Multiple Dose Study To Determine The Safety, Tolerability, MTD, And Pharmacokinetics Of MPC-2130 Administered As Daily IV Infusions For 5 Days, Repeated Every 21 Days, In Patients With Refractory Cancer|Terminated||Phase 1|8|Actual|Myriad Therapeutics, Inc.||||Last subject enrolled experienced bradycardia; study was terminated by Sponsor.|f||||f||||||||||2018-06-01 03:42:31.57403|2018-06-01 03:42:31.57403
NCT00387140|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2015-10-30|2006-10-09|2006-10-12|Estimate|||||||2015-10-30|2015-11-02|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005)|A Randomized Double-blind, Placebo-and Active Comparator-Controlled 2-Part Study to Evaluate the Efficacy of MK2295 in Patients With Postoperative Dental Pain|Completed||Phase 2|89|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:42:31.792896|2018-06-01 03:42:31.792896
NCT00387127|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|2014-11-06|2012-04-26|2015-05-28|2006-10-10|2006-10-12|Estimate|2014-12-18|2015-01-05|Estimate|2012-04-26|2012-04-30|Estimate|2015-05-28|2015-06-25|Estimate|November 2006||2006-11-30|February 2015|2015-02-28|January 2014|Actual|2014-01-31|June 2009|Actual|2009-06-30||Interventional|||Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer|A Randomized, Double-blind, Placebo Controlled, Multicentre, Phase II Study of Oral Lapatinib in Combination With Concurrent Radiotherapy and Cisplatin Versus Radiotherapy and Cisplatin Alone, in Subjects With Stage III, IVA, B Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|67|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 03:42:31.923472|2018-06-01 03:42:31.923472
NCT00387114|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-12|Estimate|||||||2006-10-10|2006-10-12|Estimate|June 2005||2005-06-30|October 2006|2006-10-31|November 2005||2005-11-30|||||Interventional|||Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study|Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study|Terminated||Phase 3|80||University of Turin, Italy|||||f||||||||||||||2018-06-01 03:42:33.181662|2018-06-01 03:42:33.181662
NCT00387101|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2008-04-30|2006-10-10|2006-10-12|Estimate|||||||2008-04-30|2008-05-02|Estimate|February 2006||2006-02-28|April 2008|2008-04-30|April 2008|Actual|2008-04-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers|Pivotal Study to Evaluate the Efficacy and Safety of Dermal-Living Skin Replacement (Dermal-LSR) in the Treatment of Chronic Diabetic Foot Ulcers|Terminated||Phase 3|288|Anticipated|ApoPharma||||Low recruitment rate|f||||||||||||||2018-06-01 03:42:33.307867|2018-06-01 03:42:33.307867
NCT00387088|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|2009-11-13||2014-05-07|2006-10-11|2006-10-12|Estimate|2009-12-18|2010-01-22|Estimate||||2014-05-07|2014-05-16|Estimate|September 2006||2006-09-30|September 2013|2013-09-30||||January 2009|Actual|2009-01-31||Interventional|||Tiotropium / Respimat One Year Study in COPD.|Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD|Completed||Phase 3|3991|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 03:42:33.536368|2018-06-01 03:42:33.536368
NCT00387075|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2018-03-22|2006-10-10|2006-10-12|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2006||2006-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease|Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease|Active, not recruiting||Phase 2|3000|Anticipated|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 03:42:35.588941|2018-06-01 03:42:35.588941
NCT00387062|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2008-06-23|2006-10-11|2006-10-12|Estimate|||||||2008-06-23|2008-06-24|Estimate|October 2006||2006-10-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment|Computer-Based Training in Patients With Post-Chemotherapy Cognitive Impairment, A Pilot Study|Completed||Phase 1|50|Anticipated|Posit Science Corporation|||||f||||||||||||||2018-06-01 03:42:35.742211|2018-06-01 03:42:35.742211
NCT00387049|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2010-10-21|2006-10-10|2006-10-12|Estimate|||||||2010-10-21|2010-10-22|Estimate|January 2005||2005-01-31|October 2006|2006-10-31|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Interventional|||Anxiety Sensitivity Program for Smoking Cessation|Anxiety Sensitivity Program for Smoking Cessation|Completed||N/A|80|Anticipated|University of Vermont||2|||f||||t||||||||||2018-06-01 03:42:35.938135|2018-06-01 03:42:35.938135
NCT00387036|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|2010-04-08||2015-12-17|2006-10-11|2006-10-12|Estimate|2010-04-30|2010-05-26|Estimate||||2015-12-17|2016-01-21|Estimate|December 2006||2006-12-31|December 2015|2015-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)|A Multicenter, Double-Blind Placebo-Controlled Crossover Study to Investigate the Effects of an Inhaled Corticosteroid on Cardiopulmonary Exercise Parameters in Patients With Chronic Obstructive Pulmonary Disease|Terminated||Phase 2|12|Actual|Merck Sharp & Dohme Corp.||2||Termininated for business reasons|f||||||||||||||2018-06-01 03:42:36.032346|2018-06-01 03:42:36.032346
NCT00387023|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|2013-09-04||2013-09-04|2006-10-11|2006-10-12|Estimate|2013-09-04|2013-11-18|Estimate||||2013-09-04|2013-11-18|Estimate|February 2004||2004-02-29|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma|Pilot Trial of Radioimmunotherapy With Yttrium 90-Labeled (90Y) Zevalin for Low-Grade Follicular Non-Hodgkin's Lymphoma or MALT of the Orbit/Conjunctiva|Completed||N/A|12|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:42:36.355144|2018-06-01 03:42:36.355144
NCT00387010|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|2012-08-17||2012-09-19|2006-10-11|2006-10-12|Estimate|2012-09-19|2012-10-22|Estimate||||2012-09-19|2012-10-22|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain|A 4-week Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Pain|Terminated||Phase 3|218|Actual|Teva Pharmaceutical Industries|This study was terminated early. Additional research is recommended to develop a valid measure of anxiety, specifically related to breakthrough pain.|1||"The sponsor felt enough information was available for the exploratory assessment of the effect~   of treatment with FBT on pain anxiety"|f||||f||||||||||2018-06-01 03:42:36.621173|2018-06-01 03:42:36.621173
NCT00386789|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2017-06-30|2006-10-11|2006-10-12|Estimate|||||||2017-06-30|2017-07-02|Actual|October 5, 2006||2006-10-05|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Observational|||Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age|Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:42:39.179741|2018-06-01 03:42:39.179741
NCT00386997|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2007-08-20|2006-10-10|2006-10-12|Estimate|||||||2007-08-20|2007-08-21|Estimate|November 2006||2006-11-30|August 2007|2007-08-31|September 2007||2007-09-30|||||Interventional|||ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia|ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol|Terminated||Phase 4|20|Anticipated|Gilead Sciences||||Study closed due to recruitment challenges.|f||||||||||||||2018-06-01 03:42:37.555806|2018-06-01 03:42:37.555806
NCT00386984|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2006-10-11|2006-10-11|2006-10-12|Estimate|||||||2006-10-11|2006-10-12|Estimate|October 1999||1999-10-31|October 2006|2006-10-31|February 2003||2003-02-28|||||Interventional|||Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma|Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma|Completed||Phase 3|108||University Hospital Freiburg|||||f||||||||||||||2018-06-01 03:42:37.693204|2018-06-01 03:42:37.693204
NCT00386971|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2017-05-25|2006-10-11|2006-10-12|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2006||2006-10-31|May 2017|2017-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART|Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART|Completed||N/A|13|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 03:42:37.754438|2018-06-01 03:42:37.754438
NCT00386958|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2016-08-22|2006-10-11|2006-10-12|Estimate|||||||2016-08-22|2016-08-23|Estimate|November 2002||2002-11-30|October 2006|2006-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers|A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers|Completed||Phase 2|172||Los Angeles Biomedical Research Institute|||||f||||||||||||||2018-06-01 03:42:37.941545|2018-06-01 03:42:37.941545
NCT00386945|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2011-10-24|2006-10-10|2006-10-12|Estimate|||||||2011-10-24|2011-10-26|Estimate|May 2006||2006-05-31|October 2011|2011-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Tobacco Cessation Via Doctors of Chiropractic||Completed||N/A|201|Actual|Oregon Research Institute||1|||f||||f||||||||||2018-06-01 03:42:38.012849|2018-06-01 03:42:38.012849
NCT00386919|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2017-01-26|2006-10-11|2006-10-12|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Short Course of Radiation for Gliomas in Elderly Patients|A Phase II Study of Hypofractionated Radiation With CyberKnife Stereotactic Radiosurgery Boost for High Grade Gliomas in Elderly Patients With Good Performance Status|Completed||Phase 2|26|Actual|Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 03:42:38.116442|2018-06-01 03:42:38.116442
NCT00386906|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2018-03-13|2006-10-11|2006-10-12|Estimate|||||||2018-03-13|2018-03-15|Actual|May 2000|Actual|2000-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma|Sentinel Lymph Node Localization and Biopsy for Conjunctival and Eyelid Melanoma|Active, not recruiting||Phase 1|38|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-06-01 03:42:38.183439|2018-06-01 03:42:38.183439
NCT00386893|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2015-04-13|2006-10-10|2006-10-12|Estimate|||||||2015-04-13|2015-04-14|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Somatosensory Processing in Depression|Influence of Escitalopram on Somatosensory Processing in Patients With Major Depression|Withdrawn||Phase 4|0|Actual|Ludwig-Maximilians - University of Munich||1|||f||||||||||||||2018-06-01 03:42:38.261325|2018-06-01 03:42:38.261325
NCT00386880|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|2012-08-05||2014-08-04|2006-10-11|2006-10-12|Estimate|2014-08-04|2014-08-22|Estimate||||2014-08-04|2014-08-22|Estimate|August 2006||2006-08-31|August 2014|2014-08-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Observational|||Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs|Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs|Completed|||38|Actual|Thomas Jefferson University|||2||f||||f||||||||||2018-06-01 03:42:38.334101|2018-06-01 03:42:38.334101
NCT00386867|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2007-06-01|2006-10-10|2006-10-12|Estimate|||||||2007-06-01|2007-06-05|Estimate|October 2006||2006-10-31|June 2007|2007-06-30|March 2007||2007-03-31|||||Interventional|||A Randomized Trial of Buccal Compared to Oral Misoprostol Following Mifepristone for Medical Abortion up to 63 Days LMP||Completed||N/A|1200|Anticipated|Gynuity Health Projects|||||||||t||||||||||2018-06-01 03:42:38.528924|2018-06-01 03:42:38.528924
NCT00386854|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-12|Estimate|||||||2006-10-10|2006-10-12|Estimate|April 2003||2003-04-30|October 2006|2006-10-31|August 2003||2003-08-31|||||Interventional|||Metabolic Study of Concentric and Eccentric Muscle Training||Completed||N/A|40||Vorarlberg Institute for Vascular Investigation and Treatment|||||f||||||||||||||2018-06-01 03:42:38.655831|2018-06-01 03:42:38.655831
NCT00386841|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2009-06-29|2006-10-11|2006-10-12|Estimate|||||||2009-06-29|2009-06-30|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression|Associations Between Gene-Polymorphisms, Endo-Phenotypes for Depression and Antidepressive Treatment (AGENDA)|Completed||Phase 4|80|Actual|University of Copenhagen||2|||f||||t||||||||||2018-06-01 03:42:38.742395|2018-06-01 03:42:38.742395
NCT00386828|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2010-11-24|2006-10-11|2006-10-12|Estimate|||||||2010-11-24|2010-11-25|Estimate|October 2006||2006-10-31|November 2010|2010-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial|Phase II Study of Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial|Completed||Phase 2|43|Actual|British Columbia Cancer Agency|||||f||||t||||||||||2018-06-01 03:42:38.879217|2018-06-01 03:42:38.879217
NCT00386815|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2007-04-10|2006-10-10|2006-10-12|Estimate|||||||2007-04-10|2007-04-11|Estimate|October 2006||2006-10-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma|Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|20||Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:42:38.995646|2018-06-01 03:42:38.995646
NCT00386802|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2009-09-17|2006-10-11|2006-10-12|Estimate|||||||2009-09-17|2009-09-18|Estimate|August 2006||2006-08-31|September 2009|2009-09-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Antifungal Use in Oncohematological Neutropenic Patients|ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.|Completed||Phase 4|115|Anticipated|PETHEMA Foundation|||||f||||t||||||||||2018-06-01 03:42:39.069175|2018-06-01 03:42:39.069175
NCT00386763|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2009-03-11|2006-10-11|2006-10-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|August 2006||2006-08-31|March 2009|2009-03-31|March 2007||2007-03-31|||||Interventional|||Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.|A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants and Children.|Completed||Phase 3|890||Novartis|||||f||||||||||||||2018-06-01 03:42:39.511335|2018-06-01 03:42:39.511335
NCT00386750|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2012-04-25|2006-10-11|2006-10-12|Estimate|||||||2012-04-25|2012-04-27|Estimate|June 2005||2005-06-30|April 2012|2012-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function|An Open-label, Single-center Study of the Effects of Co-artemether, Atovaquone-proguanil, and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older.|Terminated||Phase 4|265||Novartis|||||f||||||||||||||2018-06-01 03:42:39.618374|2018-06-01 03:42:39.618374
NCT00386737|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-11|||2006-10-11|2006-10-11|2006-10-12|Estimate|||||||2006-10-11|2006-10-12|Estimate|September 2004||2004-09-30|October 2006|2006-10-31|February 2007||2007-02-28|||||Observational|||Development of a Breath Analyzer for Asthma Screening|Development of a Breath Analyzer for Asthma Screening|Unknown status|Recruiting||2000||Ekips Technologies|||||f||||||||||||||2018-06-01 03:42:39.70791|2018-06-01 03:42:39.70791
NCT00386724|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2013-08-01|2006-10-10|2006-10-12|Estimate|||||||2013-08-01|2013-08-05|Estimate|October 2006||2006-10-31|August 2013|2013-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effectiveness of Precision Spinal Cord Stimulation With Artisan Paddle Electrode|Effectiveness of the Precision Spinal Cord Stimulation System With the Artisan Paddle Electrode in Patients With Back or Lower Extremity Pain|Terminated||Phase 4|8|Actual|Boston Scientific Corporation||1||Insufficient Data Collected|f||||f||||||||||2018-06-01 03:42:39.783996|2018-06-01 03:42:39.783996
NCT00386711|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-12|Estimate|||||||2006-10-10|2006-10-12|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|January 2007||2007-01-31|||||Interventional|||A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care|A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care|Unknown status|Not yet recruiting|Phase 1|2160||Nanjing Medical University|||||f||||||||||||||2018-06-01 03:42:39.867789|2018-06-01 03:42:39.867789
NCT00386698|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2016-10-06|2006-10-09|2006-10-11|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults|Evaluate Reactogenicity & Immunogenicity of Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Administered in Young & Elderly Adults Will be Used as Reference|Completed||Phase 2|200|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:42:39.93763|2018-06-01 03:42:39.93763
NCT00386685|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2011-04-11|2006-10-10|2006-10-11|Estimate|||||||2011-04-11|2011-04-12|Estimate|July 2006||2006-07-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|October 2008|Actual|2008-10-31||Interventional|||XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer|Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin®) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)|Completed||Phase 2|51|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:42:40.036813|2018-06-01 03:42:40.036813
NCT00386672|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2017-01-09|2006-10-10|2006-10-11|Estimate|||||||2017-01-09|2017-01-10|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Calcium Supplementation for a Healthy Weight-Lite (CaSHeW Lite)|Calcium Supplementation for a Healthy Weight- LITE|Completed||N/A|83|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:42:40.13442|2018-06-01 03:42:40.13442
NCT00386659|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-11|Estimate|||||||2006-10-10|2006-10-11|Estimate||||October 2006|2006-10-31||||||||Interventional|||Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.|A Randomized, Pilot Study on the Antiviral Activity and Immunological Effects of Lopinavir/Ritonavir vs. Efavirenz in Treatment-naïve HIV-Infected Patients With CD4 Cell Counts Below 100 Cells/mm3|Terminated||Phase 4|60||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:42:40.230226|2018-06-01 03:42:40.230226
NCT00386646|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2015-06-02|2006-10-10|2006-10-11|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2004||2004-02-29|October 2006|2006-10-31|October 2005||2005-10-31|||||Interventional|||Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye|A Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye: A Randomized Controlled Trial|Completed||Phase 4|100||Chulalongkorn University|||||f||||||||||||||2018-06-01 03:42:40.300858|2018-06-01 03:42:40.300858
NCT00386633|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2015-01-26|2006-10-09|2006-10-11|Estimate|||||||2015-01-26|2015-01-27|Estimate|October 2006||2006-10-31|January 2015|2015-01-31|November 2007|Actual|2007-11-30|||||Interventional|||Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection|Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of Two Different Doses of a Recombinant MVA HIV Polytope Vaccine (MVA-mBN32) in HIV-negative 18-50 Year Old Healthy Volunteers|Completed||Phase 1|36|Anticipated|Bavarian Nordic||2|||f||||f||||||||||2018-06-01 03:42:40.375124|2018-06-01 03:42:40.375124
NCT00386620|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2015-07-06|2006-10-10|2006-10-11|Estimate|||||||2015-07-06|2015-07-07|Estimate|October 2004||2004-10-31|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Observational|||Spousal Relationships and Pain in Metastatic Breast Cancer|Spousal Relationships and Pain in Metastatic Breast Cancer|Completed|||548|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:42:40.437487|2018-06-01 03:42:40.437487
NCT00386607|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|2010-12-20||2014-01-14|2006-10-10|2006-10-11|Estimate|2011-04-07|2011-05-10|Estimate||||2014-01-14|2014-02-10|Estimate|October 2006||2006-10-31|January 2014|2014-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.|A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg /Valsartan 320 mg in Patients With Essential Hypertension Followed by a 26 Week Open-label Extension to Assess the Long-term Safety and Tolerability of the Triple Combination of Aliskiren/Valsartan/Hydrochlorothiazide(HCTZ)|Completed||Phase 3|601|Actual|Novartis|Open label study with no comparator treatment/arm.|2|||f||||||||||||||2018-06-01 03:42:40.650233|2018-06-01 03:42:40.650233
NCT00386581|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2007-06-11|2006-10-10|2006-10-11|Estimate|||||||2007-06-11|2007-06-12|Estimate|July 2004||2004-07-31|June 2007|2007-06-30|February 2005|Actual|2005-02-28|||||Interventional|||Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder|Phase III Multicenter, Randomized, Double-Blind Placebo-Controlled Outpatient Study of Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|105|Actual|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:42:41.305252|2018-06-01 03:42:41.305252
NCT00386555|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2012-08-07|2006-10-10|2006-10-11|Estimate|||||||2012-08-07|2012-08-09|Estimate|May 2007||2007-05-31|May 2007|2007-05-31||||||||Interventional|||A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.|Phase 2 Study of CP-868,596 + Docetaxel, AG-013736 + Docetaxel, or CP-868,596 + AG-013736 + Docetaxel and of Docetaxel Alone in Patients With Stage IIIb or IV Non-Small Cell Lung Cancer.|Withdrawn||Phase 2|0|Actual|Arog Pharmaceuticals, Inc.||||Study was cancelled before patient enrollment|||||||||||||||2018-06-01 03:42:41.415524|2018-06-01 03:42:41.415524
NCT00386542|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2010-06-08|2006-10-10|2006-10-11|Estimate|||||||2010-06-08|2010-06-09|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|May 2010|Actual|2010-05-31|November 2009|Actual|2009-11-30||Interventional|||Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children|Clinical Trial of Safety (Reactogenicity) and Immunogenicity of Needle-free Jet Injection of Reduced-dose, Intradermal Influenza Vaccine (INF) Administered to >= 6 to < 24 Month-old Infants and Toddlers in the Dominican Republic|Completed||Phase 1/Phase 2|450|Actual|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-06-01 03:42:41.486611|2018-06-01 03:42:41.486611
NCT00386529|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2010-12-14|2006-10-09|2006-10-11|Estimate|||||||2010-12-14|2010-12-15|Estimate|September 2006||2006-09-30|December 2010|2010-12-31|August 2008|Actual|2008-08-31|January 2007|Actual|2007-01-31||Interventional|||Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-controlled Hypertensive Patients|A Multi-center, Double-Blind Randomized, Cross-over, Active-control, Comparative Clinical Study to Evaluate the Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-Controlled Hypertensive Patients (Phase IV)|Completed||Phase 4|191|Actual|Boryung Pharmaceutical Co., Ltd|||||f||||t||||||||||2018-06-01 03:42:41.623341|2018-06-01 03:42:41.623341
NCT00386516|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2017-07-31|2006-10-10|2006-10-11|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2006||2006-09-30|August 2014|2014-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer|Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer|Withdrawn||Phase 2|0|Actual|Galectin Therapeutics Inc.||1||Financing and re-organization|f||||f||||||||||2018-06-01 03:42:41.746084|2018-06-01 03:42:41.746084
NCT00386503|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2008-12-08|2006-10-10|2006-10-11|Estimate|||||||2008-12-08|2008-12-09|Estimate|June 2006||2006-06-30|December 2008|2008-12-31||||December 2006|Actual|2006-12-31||Interventional|||Bioavailability of the Fixed Combination of Amodiaquine and Artesunate Under Fed & Fasted Conditions|A Randomized, Open-Label, Cross-Over Study, to Compare the Bioavailability of the Fixed Combination of Amodiaquine and Artesunate (COARSUCAM™) After Single Oral Administration Under Fed and Fasted Conditions in Healthy Subjects|Completed||Phase 1|22||Sanofi|||||f||||||||||||||2018-06-01 03:42:41.837433|2018-06-01 03:42:41.837433
NCT00386490|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2017-09-08|2006-10-10|2006-10-11|Estimate|||||||2017-09-08|2017-09-12|Actual|January 10, 2006|Actual|2006-01-10|September 2017|2017-09-30|February 27, 2006|Actual|2006-02-27|February 27, 2006|Actual|2006-02-27||Interventional|||Safety of Larazotide Acetate in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-Dose Study to Determine the Safety, Tolerance and Pharmacokinetics of 3 Dose Levels of Larazotide Acetate (AT-1001) in Healthy Volunteers|Completed||Phase 1|24|Actual|Innovate Biopharmaceuticals||4|||f||||f|t|f||||||No||2018-06-01 03:42:41.901186|2018-06-01 03:42:41.901186
NCT00386477|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2009-11-11||2010-01-14|2006-10-09|2006-10-11|Estimate|2010-01-14|2010-02-08|Estimate||||2010-01-14|2010-02-08|Estimate|September 2006||2006-09-30|December 2010|2010-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial|Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial|Terminated||N/A|300|Actual|Indiana University|The study was stopped before the planned enrollment of 1000 due to difficulty recruiting. Results are of a planned safety analysis at 300 subjects.|1||Difficulty recruiting|f||||t||||||||||2018-06-01 03:42:42.056167|2018-06-01 03:42:42.056167
NCT00386464|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2007-11-08|2006-10-10|2006-10-11|Estimate|||||||2007-11-08|2007-11-09|Estimate|April 2002||2002-04-30|April 2007|2007-04-30|September 2007|Actual|2007-09-30|||||Interventional|||Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement|Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement|Completed||Phase 2/Phase 3|60|Anticipated|Johns Hopkins University|||||f||||f||||||||||2018-06-01 03:42:42.405103|2018-06-01 03:42:42.405103
NCT00386451|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2009-04-24|2006-10-10|2006-10-11|Estimate|||||||2009-04-24|2009-04-27|Estimate|November 2006||2006-11-30|April 2009|2009-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparing a Closing System Without a Needle With Positive Pressure to a Heparin Lock With Positive Pressure|Prospective Study Which Compares the Use of a Closing System Without a Needle and With Positive Pressure to a Heparin Lock With Positive Pressure for Patients With a Catheter for Chemotherapy|Completed||N/A|60|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:42:42.482879|2018-06-01 03:42:42.482879
NCT00386438|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-11|Estimate|||||||2006-10-10|2006-10-11|Estimate|December 2005||2005-12-31|October 2006|2006-10-31|July 2006||2006-07-31|||||Interventional|||Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification||Completed||Phase 4|||Chulalongkorn University|||||f||||||||||||||2018-06-01 03:42:42.545523|2018-06-01 03:42:42.545523
NCT00386425|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2010-08-26||2010-11-18|2006-10-10|2006-10-11|Estimate|2010-11-18|2010-12-16|Estimate||||2010-11-18|2010-12-16|Estimate|November 2006||2006-11-30|November 2010|2010-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)|A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients With Severe Sepsis and Multiple Organ Dysfunction|Completed||Phase 2|486|Actual|Eli Lilly and Company|Fewer patients than planned had severe PC deficiency so only 2 higher doses were tested & fewer required longer infusions so a large proportion of alternative therapy patients in effect received standard therapy making treatment comparisons difficult|3|||f||||t||||||||||2018-06-01 03:42:42.65561|2018-06-01 03:42:42.65561
NCT00386399|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2015-10-06|2006-10-10|2006-10-11|Estimate|||||||2015-10-06|2015-10-08|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene|Phase II Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene|Withdrawn||Phase 2|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||"All 29 consented subjects tested negative for the BRCA2 mutation. None started study, so PI~   decided to close the study."|f||||||||||||||2018-06-01 03:42:44.011755|2018-06-01 03:42:44.011755
NCT00386386|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2008-03-12|2006-10-06|2006-10-11|Estimate|||||||2008-03-12|2008-03-13|Estimate|May 2007||2007-05-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Recombinant Hyaluronidase in Out-of-Hospital Setting: The EASI Access Trial|Enzymatically Augmented Subcutaneous Infusion (EASI) In Out-Of-Hospital Care|Completed||Phase 3|20|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 03:42:44.070628|2018-06-01 03:42:44.070628
NCT00386373|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2012-07-31|2006-10-10|2006-10-11|Estimate|||||||2012-07-31|2012-08-01|Estimate|August 2003||2003-08-31|July 2012|2012-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients|Use and Tolerability of Imatinib Mesylate (Gleevec®) in Patients With Philadelphia-Positive Chronic Myeloid or Acute Leukemia During the First 100 Days Following Bone Marrow or Stem Cell Transplantation|Completed||N/A|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:42:44.220185|2018-06-01 03:42:44.220185
NCT00386360|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2011-08-12||2011-12-06|2006-10-10|2006-10-11|Estimate|2011-12-06|2012-01-11|Estimate||||2011-12-06|2012-01-11|Estimate|April 2006||2006-04-30|October 2011|2011-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method|A Non-Invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D-Peripheral Quantitative Computed Tomography (3D-pQCT)|Completed||Phase 3|161|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:42:44.308785|2018-06-01 03:42:44.308785
NCT00386347|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2012-05-31|2006-10-06|2006-10-11|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2006||2006-10-31|February 2011|2011-02-28||||||||Interventional|||A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.|A Single Dose, Randomized, 5-Period, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK364735 and Pharmacokinetics Following a Double Blind, Placebo Controlled, Repeat Dose Administration to Healthy Subjects.|Completed||Phase 1|56||GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:42:46.10337|2018-06-01 03:42:46.10337
NCT00386334|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2009-02-13||2016-02-12|2006-10-10|2006-10-11|Estimate|2009-04-06|2009-06-02|Estimate||||2016-02-12|2016-03-14|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia|A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia|Completed||Phase 4|388|Actual|Sunovion|The data gathered was subjective (except for actigraphy endpoints) and relied either on self reporting or patient assessments derived from standardized questionnaires.|2|||f||||f||||||||||2018-06-01 03:42:46.345628|2018-06-01 03:42:46.345628
NCT00386321|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2010-11-17|2006-10-10|2006-10-11|Estimate|||||||2010-11-17|2010-11-18|Estimate|April 2006||2006-04-30|November 2010|2010-11-30|January 2010|Anticipated|2010-01-31|July 2007|Actual|2007-07-31||Interventional|||Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma|Yt90Zevalin Plus CHOP, Z-CHOP|Terminated||Phase 2|10|Actual|Chulalongkorn University||||Participants are no longer being examined or treated.|f||||f||||||||||2018-06-01 03:42:48.840053|2018-06-01 03:42:48.840053
NCT00386308|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2009-12-11||2011-05-03|2006-10-09|2006-10-11|Estimate|2010-02-01|2010-02-22|Estimate||||2011-05-03|2011-05-04|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety Study of XP12B in Women With Menorrhagia|A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia|Completed||Phase 3|196|Actual|Ferring Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:42:48.912165|2018-06-01 03:42:48.912165
NCT00386282|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2014-07-29|2006-10-09|2006-10-11|Estimate|||||||2014-07-29|2014-07-30|Estimate|September 2006||2006-09-30|July 2014|2014-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol|Acceptability and Feasibility of Medical Abortion in Mexico, Puerto Rico, Armenia and Azerbaijan: A Study of Buccal Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days' Gestation|Completed||N/A|1250|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-06-01 03:42:49.293093|2018-06-01 03:42:49.293093
NCT00386269|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2007-11-28|2006-10-10|2006-10-11|Estimate|||||||2007-11-28|2007-11-29|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants|Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants|Completed||Phase 4|44|Anticipated|Institute of Child Health|||||f||||||||||||||2018-06-01 03:42:49.380737|2018-06-01 03:42:49.380737
NCT00386256|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2013-09-11||2014-08-12|2006-10-10|2006-10-11|Estimate|2014-08-12|2014-08-15|Estimate||||2014-08-12|2014-08-15|Estimate|October 2006||2006-10-31|August 2014|2014-08-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Home Telerehabilitation for Deconditioned Older Adults|Home Based Telerehabilitation for Deconditioned Older Adults|Completed||N/A|38|Actual|VA Office of Research and Development|Intervention was developed on a male Veteran population, direct comparisons between groups were formed based on the participant’s preference, exercise adherence was based on participants’ self reports, small convenience sample.|4|||f||||f||||||||||2018-06-01 03:42:49.443013|2018-06-01 03:42:49.443013
NCT00386243|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2013-09-25||2014-04-29|2006-10-10|2006-10-11|Estimate|2014-04-29|2014-05-26|Estimate||||2014-04-29|2014-05-26|Estimate|December 2007||2007-12-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|ESCAPE||Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)|Evaluation of Stepped Care for Chronic Pain in Iraqi/Afghanistan Veterans|Completed||N/A|242|Actual|VA Office of Research and Development|Single VA Center; May not generalize to non-VA samples|2|||f||||t||||||||||2018-06-01 03:42:49.806284|2018-06-01 03:42:49.806284
NCT00386230|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2008-05-01|2006-10-10|2006-10-11|Estimate|||||||2008-05-01|2008-05-02|Estimate|June 1997||1997-06-30|May 2008|2008-05-31|August 2000|Actual|2000-08-31|||||Interventional|||Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1|Short ZDV Course to Prevent Perinatal HIV in Thailand|Completed||Phase 3|1554||Institut de Recherche pour le Developpement||4|||f||||||||||||||2018-06-01 03:42:51.295403|2018-06-01 03:42:51.295403
NCT00386178|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2010-12-20|2006-10-10|2006-10-11|Estimate|||||||2010-12-20|2010-12-21|Estimate|October 2006||2006-10-31|December 2010|2010-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma|Comparison of Gamma-tocopherol Supplementation in Allergic Asthmatics and Normal Volunteers|Completed||Phase 1|16|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 03:42:52.464191|2018-06-01 03:42:52.464191
NCT00386165|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2017-09-08|2006-10-10|2006-10-11|Estimate|||||||2017-09-08|2017-09-11|Actual|November 29, 2005|Actual|2005-11-29|September 2017|2017-09-30|January 26, 2006|Actual|2006-01-26|January 26, 2006|Actual|2006-01-26||Interventional|||Safety Study of Larazotide Acetate to Treat Celiac Disease.|A Phase Ib, Randomized, Double-Blind, Placebo Controlled Study to Determine the Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Effects of Single Doses of Larazotide Acetate (AT-1001) in Celiac Disease Subjects.|Completed||Phase 1|21|Actual|Innovate Biopharmaceuticals||2|||f||||f|t|f||||||No||2018-06-01 03:42:52.790063|2018-06-01 03:42:52.790063
NCT00386152|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2009-04-01||2013-07-12|2006-10-06|2006-10-11|Estimate|2009-04-02|2009-06-01|Estimate||||2013-07-12|2013-07-19|Estimate|November 2006||2006-11-30|July 2013|2013-07-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy|A Randomized, Open-Label, Comparative Study of Epoetin Alfa (PROCRIT) 80,000 Units or 120,000 Units Q3W (Every 3 Weeks) Versus Darbepoetin Alfa (ARANESP) 500 Mcg Q3W in Anemic Cancer Subjects Receiving Chemotherapy|Terminated||Phase 2|235|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Due to the significantly reduced power (stopped prematurely when 235 patients enrolled), all protocol-specified hypothesis tests were not performed. Instead, desriptive statistics were presented for each of the endpoints by treatment group.|3||"No safety signals were noted. The study was stopped because it was no longer consistent with~   the company's scientific and strategic focus."|f||||t||||||||||2018-06-01 03:42:53.22186|2018-06-01 03:42:53.22186
NCT00386139|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2017-02-03|2006-10-10|2006-10-11|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2006||2006-09-30|February 2017|2017-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients|An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension Not Adequately Responsive to Aliskiren 300 mg Monotherapy|Completed||Phase 3|881|Actual|Novartis|||||f||||||||||||||2018-06-01 03:42:55.868878|2018-06-01 03:42:55.868878
NCT00386126|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2006-10-06|2006-10-06|2006-10-11|Estimate|||||||2006-10-06|2006-10-11|Estimate|August 2006||2006-08-31|August 2006|2006-08-31||||||||Interventional|||Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study|Randomized Trial to Assess the Effects of Iron Supplementation in Heart Failure Patients With Anemia: The IRON-HF Study|Unknown status|Recruiting|Phase 2/Phase 3|117||Hospital de Clinicas de Porto Alegre|||||f||||||||||||||2018-06-01 03:42:56.154726|2018-06-01 03:42:56.154726
NCT00386113|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2018-02-22|2006-10-09|2006-10-11|Estimate|||||||2018-02-22|2018-02-26|Actual|October 16, 2006|Actual|2006-10-16|February 2018|2018-02-28|November 14, 2006|Actual|2006-11-14|November 14, 2006|Actual|2006-11-14||Interventional|||Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly|A Phase II, Open, Controlled Study to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals' Adjuvanted Influenza Vaccine in Elderly Adults Previously Vaccinated With Either Fluarix™ or the Adjuvanted Vaccine.|Completed||Phase 2|74|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:42:56.465645|2018-06-01 03:42:56.465645
NCT00386100|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2010-07-08||2016-10-11|2006-10-10|2006-10-11|Estimate|2011-03-03|2011-04-05|Estimate||||2016-10-11|2016-11-23|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin|A Randomized, Parallel Group, Double-blind, Multi-center Study Comparing the Efficacy and Safety of AVANDAMET and Metformin After 80 Weeks of Treatment.|Completed||Phase 4|688|Actual|GlaxoSmithKline|Ten participants who started the study and were randomized did not receive any study medication (6 participants in the metformin arm and 4 participants in the avandamet arm). These participants are not included in any of the analysis populations.|2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:42:57.029375|2018-06-01 03:42:57.029375
NCT00386087|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2008-06-05|2006-10-06|2006-10-11|Estimate|||||||2008-06-05|2008-06-06|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|September 2007|Actual|2007-09-30|||||Interventional|||Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy|A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen|Completed||Phase 2|41|Anticipated|Eli Lilly and Company|||||||||||||||||||2018-06-01 03:43:00.152318|2018-06-01 03:43:00.152318
NCT00386074|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2010-04-20|2006-10-10|2006-10-11|Estimate|||||||2010-04-20|2010-04-21|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|December 2004||2004-12-31|||||Interventional|||Iron-fortified Whole Maize Flour Trial|The Efficacy of Iron Fortified Whole Maize Flour on the Iron Status of School Children in Kenya|Completed||Phase 2|412||Wageningen University|||||f||||||||||||||2018-06-01 03:43:00.207423|2018-06-01 03:43:00.207423
NCT00386061|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2009-04-17|2006-10-10|2006-10-11|Estimate|||||||2009-04-17|2009-04-20|Estimate|October 2001||2001-10-31|April 2009|2009-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe)|Completed||Phase 3|1507|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:43:00.282931|2018-06-01 03:43:00.282931
NCT00386048|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2012-09-17|2006-10-10|2006-10-11|Estimate|||||||2012-09-17|2012-09-18|Estimate|November 2006||2006-11-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Pain Management Protocol for Pediatric Sickle Cell Disease|Home-based Pain Management Protocol for Children With Sickle Cell Disease|Completed|||50|Actual|University of South Carolina|||2||f||||t||||||||||2018-06-01 03:43:00.339773|2018-06-01 03:43:00.339773
NCT00386035|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2014-04-15|2006-10-06|2006-10-11|Estimate|||||||2014-04-15|2014-04-17|Estimate|January 2002||2002-01-31|April 2014|2014-04-30|September 2008|Actual|2008-09-30|January 2006|Actual|2006-01-31||Observational|||Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants|HIV Transmission Risk Behavior Substudy|Completed|||883|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||||||2018-06-01 03:43:00.406631|2018-06-01 03:43:00.406631
NCT00386022|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2014-05-22||2017-04-12|2006-10-06|2006-10-11|Estimate|2017-04-12|2017-04-13|Actual||||2017-04-12|2017-04-13|Actual|January 2002||2002-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2012|Actual|2012-01-31||Interventional||Healthy postmenopausal women who experienced their last menstrual period a minimum of 12 months previously and met all inclusion and exclusion criteria.|The Effects of Aging and Estrogen on the Pituitary|The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration|Active, not recruiting||Phase 2/Phase 3|19|Actual|Massachusetts General Hospital|No significant limitations were present in this study and the subsequent analysis.|2|||f||||t||||||||Yes|Coded data with identifying information can be requested by contacting the PI.|2018-06-01 03:43:00.532095|2018-06-01 03:43:00.532095
NCT00386009|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2009-05-04||2009-07-01|2006-10-09|2006-10-11|Estimate|2009-05-04|2009-06-23|Estimate||||2009-07-01|2009-07-09|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 2|200|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:43:01.862314|2018-06-01 03:43:01.862314
NCT00385996|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2012-10-12||2012-12-13|2006-10-10|2006-10-11|Estimate|2012-10-12|2012-11-14|Estimate||||2012-12-13|2012-12-19|Estimate|October 2006||2006-10-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|November 2008|Actual|2008-11-30||Interventional|||Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer|A Pilot Study of Preoperative Tarceva (Erlotinib) Monotherapy in Patients With Early Stage (I/II) Non-Small Cell Lung Cancer|Completed||Phase 2|22|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 03:43:02.961052|2018-06-01 03:43:02.961052
NCT00385983|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-11|Estimate|||||||2006-10-10|2006-10-11|Estimate||||October 2006|2006-10-31||||||||Interventional|||Total Thyroidectomy With Harmonic Scalpel®|Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|280||Brazilian Society of Head and Neck Surgery|||||f||||||||||||||2018-06-01 03:43:03.26022|2018-06-01 03:43:03.26022
NCT00385970|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-08|||2012-10-25|2006-10-08|2006-10-11|Estimate|||||||2012-10-25|2012-10-26|Estimate|March 2006||2006-03-31|October 2012|2012-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer|A Phase III Trial Comparing UFT+PSK to UFT+LV in Stage IIB, III Colorectal Cancer|Unknown status|Active, not recruiting|Phase 3|380|Anticipated|Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group||2|||f||||t||||||||||2018-06-01 03:43:03.343828|2018-06-01 03:43:03.343828
NCT00385957|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2010-12-14|2006-10-10|2006-10-11|Estimate|||||||2010-12-14|2010-12-15|Estimate||||October 2006|2006-10-31||||||||Interventional|||Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100|Comparison of Antiretroviral Activity and Immunological Effect of Two Triple Treatments With and Without Protease Inhibitors in naïve HIV-1-infected Patients With CD4 < 100/mm3|Completed||Phase 4|70||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:43:03.42037|2018-06-01 03:43:03.42037
NCT00385944|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2010-04-19||2010-08-25|2006-10-06|2006-10-11|Estimate|2010-08-25|2010-09-16|Estimate||||2010-08-25|2010-09-16|Estimate|March 2007||2007-03-31|August 2010|2010-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)|A Randomized Double-Blind Cross-Over Study Comparing the Pharmacodynamic (PD)Response in Subjects With ACS Receiving 14 Days 10-mg Maintenance Dose (MD) Prasugrel vs 14 Days 150-mg MD Clopidogrel After Using a 900-mg Loading Dose (LD) of Clopidogrel to Reduce Ongoing Platelet Activation|Completed||Phase 2|56|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:43:03.536461|2018-06-01 03:43:03.536461
NCT00385931|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2011-11-07|2006-10-09|2006-10-11|Estimate|||||||2011-11-07|2011-11-08|Estimate|January 2002||2002-01-31|October 2006|2006-10-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin|A Multi-centre Study to Evaluate the Effects of Valsartan and the Combination of Valsartan and Simvastatin on Blood Pressure (Ambulatory and Std Cuff) and on Biochemical Markers of Endothelial Function (hsCRP, MCP-1, Serum F2 Isoprostanes, PAI-1, tPA, PICP, PIIINP, MMP9, MMP1, TIMP 1), Safety and Tolerability|Completed||Phase 3|412|Actual|Novartis|||||||||||||||||||2018-06-01 03:43:04.382164|2018-06-01 03:43:04.382164
NCT00385918|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2013-11-12||2014-04-11|2006-10-10|2006-10-11|Estimate|2014-04-11|2014-05-14|Estimate||||2014-04-11|2014-05-14|Estimate|October 2006||2006-10-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||The baseline analysis includes data from individuals who have completed the 3-month robotic and home-base interventions|Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI)|Cardiovascular Parameters for Lokomat Training in Chronic Incomplete SCI|Completed||N/A|18|Actual|VA Office of Research and Development|"Skin irritation caused missed sessions.~Attendance rates were lower than desired given medical and transportation factors.~No clearly defined exclusion criteria for bone density in individuals with SCI using this type intervention."|2|||f||||t||||||||||2018-06-01 03:43:04.489519|2018-06-01 03:43:04.489519
NCT00385905|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2006-10-10|2006-10-10|2006-10-11|Estimate|||||||2006-10-10|2006-10-11|Estimate|February 2006||2006-02-28|October 2006|2006-10-31|January 2007||2007-01-31|||||Interventional|||Excel Drug-Eluting Stent Pilot Clinical Registry|Excel Drug-Eluting Stent Pilot Clinical Registry|Completed||Phase 4|100||JW Medical Systems Ltd|||||f||||||||||||||2018-06-01 03:43:04.986599|2018-06-01 03:43:04.986599
NCT00385892|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2006-10-10|2006-10-10|2006-10-11|Estimate|||||||2006-10-10|2006-10-11|Estimate|August 2005||2005-08-31|October 2006|2006-10-31|October 2005||2005-10-31|||||Interventional|||Safety Study of Textile Binder for Abdominal Compression|Feasibility Study DK150OS. Testing of Compression Textile. A Safety Study Among Healthy Volonteers|Terminated||N/A|11||Coloplast A/S|||||f||||||||||||||2018-06-01 03:43:05.041722|2018-06-01 03:43:05.041722
NCT00385879|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|||2006-10-10|2006-10-10|2006-10-11|Estimate|||||||2006-10-10|2006-10-11|Estimate|May 2006||2006-05-31|October 2006|2006-10-31|January 2008||2008-01-31|||||Interventional|||The Effects of Case Management in a Medicaid Managed Care Plan|The Effects of Case Management in a Medicaid Managed Care Plan|Unknown status|Recruiting|N/A|500||Metropolitan Jewish Health System|||||f||||||||||||||2018-06-01 03:43:05.088047|2018-06-01 03:43:05.088047
NCT00385866|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2016-04-19|2006-10-10|2006-10-11|Estimate|||||||2016-04-19|2016-04-20|Estimate|October 2006||2006-10-31|April 2016|2016-04-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Addressing Disparities in Cancer Care for Latino Medicare Beneficiaries|Addressing Disparities in Cancer Care for Latino Medicare Beneficiaries|Completed||N/A|1272|Actual|Rutgers, The State University of New Jersey||2|||f||||||||||||||2018-06-01 03:43:05.146602|2018-06-01 03:43:05.146602
NCT00385853|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2013-10-18|2006-10-06|2006-10-11|Estimate|||||||2013-10-18|2013-10-21|Estimate|September 2006||2006-09-30|October 2013|2013-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs|A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma|Completed||Phase 1|19|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:43:05.223622|2018-06-01 03:43:05.223622
NCT00385840|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|2013-03-07||2016-10-26|2006-10-10|2006-10-11|Estimate|2013-04-25|2013-04-29|Estimate||||2016-10-26|2016-12-08|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate|A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years and Above.|Completed||Phase 2|678|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:05.304751|2018-06-01 03:43:05.304751
NCT00385827|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2014-05-13|2013-01-31|2014-08-18|2006-10-06|2006-10-11|Estimate|2014-05-13|2014-06-12|Estimate|2013-01-31|2013-02-04|Estimate|2014-08-18|2014-08-20|Estimate|November 2006||2006-11-30|August 2014|2014-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional||Analysis population included all participants who received at least one dose of study drug in Part 1 and all randomized participants in Part 2.|A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)|A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)|Terminated||Phase 2|106|Actual|Centocor, Inc.|Results of few secondary endpoints were not reported as the study was terminated early due to the premature suspension and subsequent halting of study enrollment.|3||"Prematurely stopped after Independent Data Monitoring Committee (IDMC) evaluation for lack of~   efficacy."|f||||t||||||||||2018-06-01 03:43:05.818991|2018-06-01 03:43:05.818991
NCT00385801|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2015-04-30||2017-03-20|2006-10-10|2006-10-11|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|September 2005||2005-09-30|March 2017|2017-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence|A Double-Blind, Placebo-Controlled Study of the Effects of Risperdal Consta on Brain Reward Circuitry, Craving and Cocaine Use in Active Cocaine Dependence|Completed||Phase 2|31|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 03:43:06.856839|2018-06-01 03:43:06.856839
NCT00385788|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2017-08-22||2018-04-06|2006-10-10|2006-10-11|Estimate|2018-04-06|2018-05-09|Actual||||2018-04-06|2018-05-09|Actual|July 2005||2005-07-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease|Allogeneic Stem Cell Transplantation Followed By Adoptive Immunotherapy for Patients With Relapsed and Refractory Hodgkin's Disease|Completed||Phase 2|52|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:43:07.146058|2018-06-01 03:43:07.146058
NCT00385775|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2008-08-20|2006-10-06|2006-10-11|Estimate|||||||2008-08-20|2008-08-21|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|November 2008|Anticipated|2008-11-30|October 2008|Anticipated|2008-10-31||Interventional|||Study of XIAP Antisense for Advanced Cancers|A Phase I Trial of AEG35156 Administered by 2-Hour Intravenous Infusion in Patients With Advanced Cancers|Terminated||Phase 1|30|Anticipated|Aegera Therapeutics||||Dosing cohort (650mg) exceeded current 350mg dosing in other trials.|f||||f||||||||||2018-06-01 03:43:07.422056|2018-06-01 03:43:07.422056
NCT00385762|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2017-02-17||2017-04-19|2006-10-10|2006-10-11|Estimate|2017-04-19|2017-08-02|Actual||||2017-04-19|2017-08-02|Actual|January 2007||2007-01-31|April 2017|2017-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||SSRI Effects on Semen Parameters in Men|Effect of Selective Serotonin Reuptake Inhibitor Antidepressants on Semen Parameters|Completed|||35|Actual|Weill Medical College of Cornell University|||||f|||||t|f||||Samples With DNA|"~     Serum samples Semen samples~   "|Undecided||2018-06-01 03:43:07.479756|2018-06-01 03:43:07.479756
NCT00385749|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2007-10-30|2006-10-10|2006-10-11|Estimate|||||||2007-10-30|2007-11-01|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Right Ventricular Defibrillation Lead Select Site Study|Right Ventricular Defibrillation Lead Select Site Study|Unknown status|Recruiting|N/A|98|Anticipated|Associates in Cardiology, PA|||||f||||||||||||||2018-06-01 03:43:07.614751|2018-06-01 03:43:07.614751
NCT00385736|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-09|2010-04-30||2011-04-07|2006-10-09|2006-10-11|Estimate|2010-04-30|2010-05-27|Estimate||||2011-04-07|2011-04-11|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|March 2010|Actual|2010-03-31|April 2009|Actual|2009-04-30||Interventional|||Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis|A Multicenter, Randomized, Double-blind Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 3|576|Actual|Abbott||3|||f||||f||||||||||2018-06-01 03:43:07.796853|2018-06-01 03:43:07.796853
NCT00385723|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|2012-08-28||2012-11-13|2006-10-10|2006-10-11|Estimate|2012-10-09|2012-11-08|Estimate||||2012-11-13|2012-11-20|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Fish Oil (Omega 3), Immune Function, and Mood|Omega-3 Dietary Supplementation, Immune Function, and Mood|Completed||Phase 2|138|Actual|Ohio State University||3|||f||||t||||||||||2018-06-01 03:43:08.949007|2018-06-01 03:43:08.949007
NCT00385710|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2012-11-02|2006-10-10|2006-10-11|Estimate|||||||2012-11-02|2012-11-05|Estimate|November 2006||2006-11-30|May 2011|2011-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)|Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy|Completed||Phase 2|28|Actual|Nantes University Hospital||2|||f||||||||||||||2018-06-01 03:43:09.324275|2018-06-01 03:43:09.324275
NCT00385697|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-07||2011-11-10|2012-08-21|2006-10-10|2006-10-11|Estimate||||2011-11-10|2011-11-16|Estimate|2012-08-21|2012-08-29|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|June 2010|Actual|2010-06-30||Interventional|||The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus|A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of MGA031, a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus|Completed||Phase 2/Phase 3|554|Actual|MacroGenics||4|||f||||t||||||||||2018-06-01 03:43:09.447775|2018-06-01 03:43:09.447775
NCT00385684|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2014-06-02||2015-11-18|2006-10-06|2006-10-11|Estimate|2015-11-18|2015-11-20|Estimate||||2015-11-18|2015-11-20|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|December 2011|Actual|2011-12-31||Interventional|LDOT|Veterans with severe dementia residing in VA nursing home.|Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)|Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)|Completed||Phase 4|11|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 03:43:09.686218|2018-06-01 03:43:09.686218
NCT00385671|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2010-08-23||2011-07-22|2006-10-06|2006-10-11|Estimate|2010-10-01|2010-10-18|Estimate||||2011-07-22|2011-07-26|Estimate|September 2006||2006-09-30|July 2011|2011-07-31|November 2009|Actual|2009-11-30|August 2009|Actual|2009-08-31||Interventional|||An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain|An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain|Completed||Phase 4|407|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 03:43:10.064929|2018-06-01 03:43:10.064929
NCT00385658|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2017-02-22|2006-10-10|2006-10-11|Estimate|||||||2017-02-22|2017-02-24|Actual|August 2006||2006-08-31|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic Syndrome|A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome|Completed||Phase 4|75|Actual|Novartis|||||f||||||||||||||2018-06-01 03:43:13.745772|2018-06-01 03:43:13.745772
NCT00385645|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2010-03-30|2006-10-10|2006-10-11|Estimate|||||||2010-03-30|2010-03-31|Estimate|May 2006||2006-05-31|March 2010|2010-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis|Comparison of 2 Alternative Antiretroviral Combinations in HIV Post-exposure Prophylaxis: AZT-3TC (Combivir®) + Lopinavir-ritonavir (Kaletra®) Versus AZT-3TC (Combivir®)+ Atazanavir (Reyataz®). Multicentre, Prospective, Randomized, Open Study|Completed||Phase 4|255|Actual|Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:43:13.816242|2018-06-01 03:43:13.816242
NCT00385632|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2014-04-16|2006-10-06|2006-10-11|Estimate|||||||2014-04-16|2014-04-21|Estimate|January 2002||2002-01-31|April 2014|2014-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants|Quality of Life and Healthcare Utilization Substudy|Completed|||1224|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||||||2018-06-01 03:43:13.91564|2018-06-01 03:43:13.91564
NCT00385606|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-10|||2007-08-22|2006-10-10|2006-10-11|Estimate|||||||2007-08-22|2007-08-23|Estimate|January 2003||2003-01-31|August 2007|2007-08-31||||||||Interventional|||GECO: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced Non-Small Cell Lung Cancer|Phase II-III, Factorial Multicenter Randomized Trial Evaluating the Addition of Rofecoxib to Polychemotherapy With Cisplatin and Gemcitabine and the Fixed Dose Rate Infusion of Gemcitabine in Association With Cisplatin in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer|Completed||Phase 2/Phase 3|400||National Cancer Institute, Naples|||||f||||||||||||||2018-06-01 03:43:14.063503|2018-06-01 03:43:14.063503
NCT00385593|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2009-10-14||2010-11-30|2006-10-06|2006-10-09|Estimate|2009-10-14|2009-11-17|Estimate||||2010-11-30|2010-12-16|Estimate|September 2006||2006-09-30|November 2010|2010-11-30|October 2008|Actual|2008-10-31|||||Interventional|||Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults|A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 Micrograms, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week, Randomised, Open-label, Parallel-group, Multicentre Study. Study SPAIN|Terminated||Phase 3|654|Actual|AstraZeneca|The study was prematurely stopped, because it was not possible to recruit the sample size required in the period of time established.||||f||||||||||||||2018-06-01 03:43:14.307595|2018-06-01 03:43:14.307595
NCT00385580|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2010-10-07||2013-04-24|2006-10-06|2006-10-09|Estimate|2011-02-02|2011-03-01|Estimate||||2013-04-24|2013-04-30|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|December 2008|Actual|2008-12-31||Interventional|||Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer|Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer|Completed||Phase 2|94|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:43:15.460525|2018-06-01 03:43:15.460525
NCT00385567|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-01|||2010-08-24|2006-10-05|2006-10-09|Estimate|||||||2010-08-24|2010-08-26|Estimate|January 2007||2007-01-31|August 2010|2010-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Trial of PEHRG214 in HIV-Infected Patients|A Phase 2 Randomized, Controlled Trial of PEHRG214 in HIV-Infected Patients|Terminated||Phase 2|70|Anticipated|Virionyx Corporation Limited||||Difficulty recruiting eligible patients in timely fashion|||||t||||||||||2018-06-01 03:43:18.724413|2018-06-01 03:43:18.724413
NCT00385554|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2012-08-15|2006-10-05|2006-10-09|Estimate|||||||2012-08-15|2012-08-16|Estimate||||August 2012|2012-08-31||||||||Interventional|||Botswana Study of UC-781 Vaginal Microbicide|Phase I Trial of the Safety, Toxicity, and Acceptability of the Microbicide UC-781 When Topically Applied by HIV-uninfected Women and Men in Botswana|Withdrawn||Phase 1|0|Actual|Centers for Disease Control and Prevention||||Study product is no longer being considered for further development.|||||||||||||||2018-06-01 03:43:18.78252|2018-06-01 03:43:18.78252
NCT00385541|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|2010-07-14||2015-03-03|2006-10-05|2006-10-09|Estimate|2010-08-11|2010-08-31|Estimate||||2015-03-03|2015-03-20|Estimate|November 2003||2003-11-30|March 2015|2015-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Comparison of Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia (PCA)|The Comparison of Morphine and Hydromorphone Patient-Controlled Analgesia|Completed||Phase 4|50|Actual|Columbia University|This was a small study under typical clinical conditions.|2|||f||||f||||||||||2018-06-01 03:43:18.967412|2018-06-01 03:43:18.967412
NCT00385528|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2008-10-16|2006-10-06|2006-10-09|Estimate|||||||2008-10-16|2008-10-17|Estimate|November 2002||2002-11-30|October 2006|2006-10-31|April 2006||2006-04-30|||||Interventional|||Effects of a Multi-Faceted Psychiatric Intervention Targeted at the Complex Medically Ill: a Randomized Controlled Trial|Effects of a Multi-Faceted Psychiatric Intervention Targeted at the Complex Medically Ill: a Randomized Controlled Trial|Completed||Phase 4|200||University of Lausanne Hospitals|||||f||||||||||||||2018-06-01 03:43:19.232106|2018-06-01 03:43:19.232106
NCT00385515|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|2009-01-19||2009-04-08|2006-10-05|2006-10-09|Estimate|2009-02-17|2009-03-18|Estimate||||2009-04-08|2009-05-07|Estimate|June 2006||2006-06-30|April 2009|2009-04-30|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy of SNX-1012 in the Treatment of Oral Mucositis|A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer|Completed||Phase 2|81|Actual|Mucosal Therapeutics||2|||f||||f||||||||||2018-06-01 03:43:19.307482|2018-06-01 03:43:19.307482
NCT00385502|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2009-02-05|2006-10-05|2006-10-09|Estimate|||||||2009-02-05|2009-02-09|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|June 2008|Anticipated|2008-06-30|||||Interventional|||A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail|A Phase II Trial of the Safety, Local Tolerability, and Efficacy of EcoNail™ (Econazole 5%/SEPA® 18% Nail Lacquer) in Onychomycosis of the Great Toenail|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|MacroChem Corporation|||||f||||f||||||||||2018-06-01 03:43:19.52546|2018-06-01 03:43:19.52546
NCT00385489|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2009-08-06|2006-10-06|2006-10-09|Estimate|||||||2009-08-06|2009-08-07|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study Evaluating LXR-623 in Healthy Japanese Adults|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Japanese Male Subjects.|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:43:19.590796|2018-06-01 03:43:19.590796
NCT00385476|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2012-07-31|2006-10-06|2006-10-09|Estimate|||||||2012-07-31|2012-08-01|Estimate|August 2005||2005-08-31|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Cancer Patients' Medication Knowledge in the Emergency Center|Cancer Patients' Medication Knowledge in the Emergency Center|Completed|||308|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:43:19.679999|2018-06-01 03:43:19.679999
NCT00385463|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2016-06-15|2006-10-06|2006-10-09|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2006||2006-04-30|June 2016|2016-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray Versus Montelukast in Adolescents/Adults With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus(R) or Placebo|Withdrawn||N/A|0|Actual|Creighton University|||||f||||f||||||||||2018-06-01 03:43:19.738609|2018-06-01 03:43:19.738609
NCT00385450|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2015-04-27|2006-10-06|2006-10-09|Estimate|||||||2015-04-27|2015-04-28|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor|Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor in the Perioperative Period|Terminated||Phase 1|41|Actual|Mayo Clinic||1||Study closed at Mayo prior to completion|f||||t||||||||||2018-06-01 03:43:19.79725|2018-06-01 03:43:19.79725
NCT00385437|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2006-10-05|2006-10-05|2006-10-09|Estimate|||||||2006-10-05|2006-10-09|Estimate|April 2003||2003-04-30|February 2006|2006-02-28|June 2004||2004-06-30|||||Interventional|||Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder|Antidepressant Response to a Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder|Completed||Phase 2|16||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:43:19.859164|2018-06-01 03:43:19.859164
NCT00385411|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2009-10-02|2006-10-06|2006-10-09|Estimate|||||||2009-10-02|2009-10-06|Estimate|March 2006||2006-03-31|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|VAPOP||Study of Valproate in Young Patients Suffering From Epilepsy|Therapeutic Follow-up Observational Study and Population Kinetics Ancillary Study of Valproate Microgranules (Micropakine® SR) in Patients Aged Between 6 Months and 15 Years Suffering From Epilepsy.|Completed||Phase 4|81|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:43:19.914857|2018-06-01 03:43:19.914857
NCT00385398|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2013-08-29|2006-10-06|2006-10-09|Estimate|||||||2013-08-29|2013-09-02|Estimate|July 2008||2008-07-31|August 2013|2013-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC|Phase II Quality of Life Study of Stereotactic RadioSurgery, Temozolomide and Erlotinib Chemotherapy for the Treatment of 1-3 Brain Metastases in Non-small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Rutgers, The State University of New Jersey||||lack of funding and drug supply|f||||t||||||||||2018-06-01 03:43:19.965553|2018-06-01 03:43:19.965553
NCT00385385|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2007-04-27|2006-10-06|2006-10-09|Estimate|||||||2007-04-27|2007-04-30|Estimate|October 2006||2006-10-31|April 2007|2007-04-30|September 2008||2008-09-30|||||Interventional|||RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease|Randomized Evaluation of Short-Term Rifalazil Treatment on Carotid Atherosclerosis and Intima Media Thickness|Unknown status|Recruiting|Phase 2|72|Anticipated|ActivBiotics|||||||||||||||||||2018-06-01 03:43:20.021607|2018-06-01 03:43:20.021607
NCT00385372|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2009-01-27|2006-10-06|2006-10-09|Estimate|||||||2009-01-27|2009-01-29|Estimate|January 2005||2005-01-31|February 2007|2007-02-28|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|||Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria|Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria|Completed||N/A|150||University Hospital Muenster|||||f||||||||||||||2018-06-01 03:43:21.03101|2018-06-01 03:43:21.03101
NCT00385359|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2006-10-06|2006-10-06|2006-10-09|Estimate|||||||2006-10-06|2006-10-09|Estimate|October 2006||2006-10-31|October 2006|2006-10-31||||||||Interventional|||A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control|A Pilot Efficacy Study of Inhaled Albuterol Delivered With Akita Breath Control and Pari Nebulization for the Treatment of Adults With Moderate Asthma|Unknown status|Recruiting|Phase 4|10||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:43:21.089944|2018-06-01 03:43:21.089944
NCT00385346|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2010-06-29|2006-10-05|2006-10-09|Estimate|||||||2010-06-29|2010-06-30|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|February 2009|Actual|2009-02-28|June 2008|Actual|2008-06-30||Interventional|||Expressive Writing in Male Infertility|Expressive Writing as a Therapeutic Intervention in Male Infertility|Completed||N/A|56|Actual|University Hospital, Bonn||1|||f||||||||||||||2018-06-01 03:43:21.155523|2018-06-01 03:43:21.155523
NCT00385333|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2017-06-30|2006-10-06|2006-10-09|Estimate|||||||2017-06-30|2017-07-02|Actual|September 29, 2006||2006-09-29|September 16, 2010|2010-09-16|September 16, 2010|Actual|2010-09-16|June 1, 2008|Actual|2008-06-01||Interventional|||Metabolic Mapping to Measure Retinal Metabolism|A Novel Non-Invasive In Vivo Imaging System to Measure Retinal Metabolism|Completed||Phase 2|28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:43:21.232194|2018-06-01 03:43:21.232194
NCT00385320|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2016-09-15|2006-10-06|2006-10-09|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2001||2001-05-31|September 2016|2016-09-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months|To Assess the Efficacy, Immuno & Safety of 2 Doses of GSK HRV Vaccine at Different Virus Concentrations in Healthy Infants Aged 2 Months & Previously Uninfected With HRV, Concurrently Given With DTPw-HBV, Hib.|Completed||Phase 2|2640|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:21.293644|2018-06-01 03:43:21.293644
NCT00385307|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2009-03-24|2006-10-06|2006-10-09|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)|An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of Two Fixed Doses of SR58611A (175 mg q12/ 350 mg q12) in Outpatients With MDD|Completed||Phase 3|680|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:43:21.367328|2018-06-01 03:43:21.367328
NCT00385294|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2010-10-01|2006-10-05|2006-10-09|Estimate|||||||2010-10-01|2010-10-04|Estimate|September 2006||2006-09-30|October 2010|2010-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Role of B2 Adrenergic Receptors in Labor Pain|Role of B2 Adrenergic Receptors in Labor Pain|Completed|||150|Actual|Columbia University|||||f||||f||||||Samples With DNA|"~     DNA identified by subject number will be retained for analysis.~   "|||2018-06-01 03:43:21.427842|2018-06-01 03:43:21.427842
NCT00385281|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2010-08-26|2006-10-05|2006-10-09|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2006||2006-10-31|March 2010|2010-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Proteomic Profiling for Influenza Vaccination - FluMist|Proteomic Profiling for Influenza Vaccination, 2nd Study: FluMist|Completed||Phase 4|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:43:22.216294|2018-06-01 03:43:22.216294
NCT00385268|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|2013-08-28||2013-11-11|2006-10-06|2006-10-09|Estimate|2013-11-11|2013-12-31|Estimate||||2013-11-11|2013-12-31|Estimate|November 2006||2006-11-30|November 2013|2013-11-30|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|CAMPRAL||Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence|A Phase II, Double-Blind, Placebo-controlled, Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence|Completed||Phase 2|60|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:43:22.277193|2018-06-01 03:43:22.277193
NCT00385255|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2016-10-26|2006-10-06|2006-10-09|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults|A Study to Evaluate Immunogenicity and Safety of Boostrix When Co-administered With Fluarix in Subjects 19 Years of Age and Older|Completed||Phase 3|1726|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:22.54931|2018-06-01 03:43:22.54931
NCT00385242|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2018-05-28|2006-10-06|2006-10-09|Estimate|||||||2018-05-28|2018-05-30|Actual|June 2000||2000-06-30|May 2018|2018-05-31|June 2011|Actual|2011-06-30|June 2006|Actual|2006-06-30||Interventional|||PET and Recovery Following Revascularization (PARR 2)|PET and Recovery Following Revascularization: Outcome and Cost-effectiveness of FDG PET in Left Ventricular Dysfunction (PARR 2)|Completed||Phase 3|430|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-06-01 03:43:22.664852|2018-06-01 03:43:22.664852
NCT00385229|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-06|||2011-11-03|2006-10-06|2006-10-09|Estimate|||||||2011-11-03|2011-11-04|Estimate|September 2002||2002-09-30|November 2011|2011-11-30|July 2004|Actual|2004-07-31|December 2003|Actual|2003-12-31||Interventional|||Post Term Pregnancy - Induction of Labor or Monitoring of Pregnancy|Post Term Pregnancy - Induction of Labor or Monitoring of Pregnancy|Completed||N/A|508|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-06-01 03:43:22.750977|2018-06-01 03:43:22.750977
NCT00385216|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|2010-10-01||2010-12-01|2006-10-05|2006-10-09|Estimate|2010-10-01|2010-10-27|Estimate||||2010-12-01|2010-12-17|Estimate|July 2004||2004-07-31|December 2010|2010-12-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Nicotine as an Adjuvant Analgesic for Third Molar Surgery|Effect of Nicotine on Pain After Third Molar Extraction.|Completed||Phase 4|20|Actual|Columbia University|This was a small study under typical clinical conditions.|2|||f||||f||||||||||2018-06-01 03:43:22.867443|2018-06-01 03:43:22.867443
NCT00385203|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|2012-03-28|2011-04-06|2012-06-11|2006-10-05|2006-10-06|Estimate|2012-06-11|2012-07-16|Estimate|2011-04-06|2011-04-12|Estimate|2012-06-11|2012-07-16|Estimate|September 2006||2006-09-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).|An Open-Label, Phase II Study to Evaluate the Biological Activity of Cediranib (AZD2171) as Measured by [F 18] Fluoro 2 Deoxy D Glucose - Positron Emission Tomography (FDG-PET) Response, in Patients With Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intolerant to Imatinib Mesylate|Completed||Phase 2|35|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:43:23.223771|2018-06-01 03:43:23.223771
NCT00385190|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2009-08-17|2006-10-05|2006-10-06|Estimate|||||||2009-08-17|2009-08-18|Estimate|July 2006||2006-07-31|August 2009|2009-08-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese Men|An Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Study Drug Administred Orally to Healthy Japanese Male Subjects|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:43:23.724082|2018-06-01 03:43:23.724082
NCT00385177|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2009-06-02|2006-10-03|2006-10-06|Estimate|||||||2009-06-02|2009-06-04|Estimate|September 2006||2006-09-30|June 2009|2009-06-30|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors|A Multicenter Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors|Completed||Phase 1|61|Anticipated|Achieve Life Sciences||1|||f||||f||||||||||2018-06-01 03:43:23.776918|2018-06-01 03:43:23.776918
NCT00385164|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2017-07-21|2006-10-04|2006-10-06|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2006||2006-10-31|August 2011|2011-08-31||||||||Observational|||The Utility of FDG-PET for Radiation Treatment in NSCLC|The Utility of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for Radiation Treatment Planning in Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting||50|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 03:43:23.845695|2018-06-01 03:43:23.845695
NCT00385151|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2013-11-15|2006-10-03|2006-10-06|Estimate|||||||2013-11-15|2013-11-18|Estimate|May 2006||2006-05-31|November 2013|2013-11-30|August 2006||2006-08-31|||||Observational|||To Compare the Ischemic Pre-conditioning and Post-conditioning on Reperfusion Injury in Humans.|The Mechanism of Ischemic Post Conditioning in Humans, Minimizing Reperfusion Injury.|Completed|||20||Emory University|||||f||||||||||||||2018-06-01 03:43:23.908654|2018-06-01 03:43:23.908654
NCT00384956|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2014-08-11||2016-10-27|2006-10-05|2006-10-06|Estimate|2014-09-05|2014-09-08|Estimate||||2016-10-27|2016-12-12|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|March 2010|Actual|2010-03-31|August 2008|Actual|2008-08-31||Interventional||25 patients were enrolled and 22 were evaluable (3 patients had acute myeloid leukemia according to the FAB classification on enrollment bone marrow biopsy review and were removed from the study)|A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes|A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes|Completed||Phase 2|25|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 03:43:26.588047|2018-06-01 03:43:26.588047
NCT00385138|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2013-04-22||2014-04-18|2006-10-05|2006-10-06|Estimate|2014-03-24|2014-04-21|Estimate||||2014-04-18|2014-05-05|Estimate|September 2006||2006-09-30|April 2014|2014-04-30|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|Platform|mITT population|Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.|A Clinical Trial Comparing Treatment With Cangrelor (in Combination With Usual Care) to Usual Care, in Subjects Who Require Percutaneous Coronary Intervention (PCI).|Terminated||Phase 3|5364|Actual|The Medicines Company|Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely not meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified.|2||Insufficient evidence of the clinical effectiveness of cangrelor|f||||t||||||||||2018-06-01 03:43:24.033414|2018-06-01 03:43:24.033414
NCT00385125|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2006-10-05|2006-10-05|2006-10-06|Estimate|||||||2006-10-05|2006-10-06|Estimate|August 2004||2004-08-31|October 2006|2006-10-31|August 2010||2010-08-31|||||Interventional|||Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL|Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation.|Unknown status|Recruiting|Phase 2|30||University of Magdeburg|||||f||||||||||||||2018-06-01 03:43:24.916071|2018-06-01 03:43:24.916071
NCT00385112|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2017-01-25|2006-10-03|2006-10-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2006||2006-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Follow Up on Freestyle Valves in Children|Follow Up on Freestyle Valves for Right Ventricular Outflow Tract Reconstruction in Children|Completed|||98|Actual|Emory University|||||f||||f||||||||||2018-06-01 03:43:24.992723|2018-06-01 03:43:24.992723
NCT00385099|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2017-08-07|2006-10-04|2006-10-06|Estimate|||||||2017-08-07|2017-08-08|Actual|December 8, 2006|Actual|2006-12-08|August 2017|2017-08-31|October 15, 2007|Actual|2007-10-15|October 15, 2007|Actual|2007-10-15||Interventional|||Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome|A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)|Completed||Phase 2|10|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:43:25.06078|2018-06-01 03:43:25.06078
NCT00385086|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2015-10-15|2006-10-04|2006-10-06|Estimate|||||||2015-10-15|2015-10-16|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|December 2014|Actual|2014-12-31|October 2012|Actual|2012-10-31||Interventional|||Lumbar Spinal Fibrosis and TNF Alpha Inhibition|Efficacy of TNF-alpha Inhibition in Sciatica With Post-operative Lumbar Spinal Fibrosis|Completed||Phase 3|38|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:43:25.135336|2018-06-01 03:43:25.135336
NCT00385073|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2006-10-05|2006-10-05|2006-10-06|Estimate|||||||2006-10-05|2006-10-06|Estimate|April 2005||2005-04-30|October 2006|2006-10-31|December 2007||2007-12-31|||||Observational|||Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson’s Disease|Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson’s Disease|Unknown status|Recruiting||30||Austin Health|||||f||||||||||||||2018-06-01 03:43:25.226406|2018-06-01 03:43:25.226406
NCT00385047|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2015-06-04|2006-10-04|2006-10-06|Estimate|||||||2015-06-04|2015-06-08|Estimate|September 2006||2006-09-30|June 2015|2015-06-30|September 2007|Actual|2007-09-30|April 2007|Actual|2007-04-30||Interventional|||A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults|Phase I/IIa Study of the Safety, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge of FMP2.1/AS01B and FMP2.1/AS02A Candidate Malaria Vaccines Administered Intramuscularly at Months 0, 1, and 2 in Malaria-naive Adults Living in the United States|Completed||Phase 1/Phase 2|41|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-06-01 03:43:25.295594|2018-06-01 03:43:25.295594
NCT00385034|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2015-11-16|2006-10-04|2006-10-06|Estimate|||||||2015-11-16|2015-11-17|Estimate|March 2005||2005-03-31|November 2015|2015-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Computer-assisted Screening for Intimate Partner Violence in Family Practice|Computer-assisted Screening for Intimate Partner Violence in Family Practice - a Randomized Controlled Trial|Completed||N/A|280||St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 03:43:25.399741|2018-06-01 03:43:25.399741
NCT00385021|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2007-10-31|2006-10-04|2006-10-06|Estimate|||||||2007-10-31|2007-11-02|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer|ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|20|Anticipated|Southwestern Regional Medical Center|||||f||||f||||||||||2018-06-01 03:43:25.475103|2018-06-01 03:43:25.475103
NCT00385008|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2017-04-13||2017-08-02|2006-10-05|2006-10-06|Estimate|2017-08-02|2018-02-12|Actual||||2017-08-02|2018-02-12|Actual|September 13, 2006|Actual|2006-09-13|August 2017|2017-08-31|November 24, 2006|Actual|2006-11-24|November 24, 2006|Actual|2006-11-24||Interventional|||TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine|An Open Label, Single Dose, Parallel Group Study to Evaluate Absorption and Transit Characteristics of TREXIMA and RELPAX in Patients Inside and Outside of an Acute Migraine Attack.|Completed||Phase 3|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:25.597157|2018-06-01 03:43:25.597157
NCT00384995|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2010-11-29|2006-10-05|2006-10-06|Estimate|||||||2010-11-29|2010-12-01|Estimate|December 2006||2006-12-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Bicarbonate v Saline to Prevent Contrast Nephropathy|Phase 4 Study of Bicarbonate Versus Saline Infusion Therapy to Prevent Contrast Induced Nephropathy (CAN-IT PREVENT Protocol)|Terminated||Phase 4|61|Actual|Italian Society of Nephrology||2||Lack of funding|f||||t||||||||||2018-06-01 03:43:26.166871|2018-06-01 03:43:26.166871
NCT00384982|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2010-01-21|2006-10-05|2006-10-06|Estimate|||||||2010-01-21|2010-01-22|Estimate|January 2005||2005-01-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|MYSTAR||Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study|Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: A Multicenter, Randomized Trial Comparing Early and Late Intracoronary or Combined (Intramyocardial and Intracoronary) Administration of Stem Cells|Completed||Phase 2|116|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-06-01 03:43:26.374641|2018-06-01 03:43:26.374641
NCT00384969|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2014-08-15|2006-10-03|2006-10-06|Estimate|||||||2014-08-15|2014-08-18|Estimate|October 2006||2006-10-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Sorafenib and RAD001 Renal Cell Carcinoma|A Phase I Study of Sorafenib and RAD001 in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1|21|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 03:43:26.499015|2018-06-01 03:43:26.499015
NCT00384943|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2006-10-04|2006-10-04|2006-10-06|Estimate|||||||2006-10-04|2006-10-06|Estimate|November 2001||2001-11-30|October 2006|2006-10-31|November 2004||2004-11-30|||||Interventional|||Study of Home-Based Exercise to Alleviate Postpartum Depression|Decreasing Health Care Utilization With Alternative Approaches for the Treatment of Depression: A Randomized Trial of Exercise for Postpartum Depression|Completed||N/A|90||McGill University|||||f||||||||||||||2018-06-01 03:43:27.10948|2018-06-01 03:43:27.10948
NCT00384930|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|2008-10-17||2009-08-26|2006-10-03|2006-10-06|Estimate|2009-07-07|2009-08-19|Estimate||||2009-08-26|2009-09-02|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 2/Phase 3|1058|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 03:43:27.242007|2018-06-01 03:43:27.242007
NCT00384917|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2009-07-08|2006-10-05|2006-10-06|Estimate|||||||2009-07-08|2009-07-10|Estimate|August 2006||2006-08-31|July 2009|2009-07-31|September 2006||2006-09-30|||||Interventional|||Study to Determine the Impact of Multiple Doses of Ketoconazole on Single-Dose Pharmacokinetics of HCV-796|An Open Label, 2-Period, Sequential Study to Determine the Impact of Multiple Doses of Ketoconazole on Single-Dose Pharmacokinetics of HCV-796|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:43:29.599231|2018-06-01 03:43:29.599231
NCT00384904|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03||2010-02-03|2010-02-03|2006-10-05|2006-10-06|Estimate||||2010-02-03|2010-02-05|Estimate|2010-02-03|2010-02-05|Estimate|December 2006||2006-12-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients|Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine With or Without Tenofovir on the Pharmacokinetics of Atazanavir When Given With Ritonavir in HIV-Infected Subjects|Completed||Phase 4|40|Actual|Bristol-Myers Squibb||6|||f||||f||||||||||2018-06-01 03:43:29.654138|2018-06-01 03:43:29.654138
NCT00384891|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2014-10-05|2006-10-05|2006-10-06|Estimate|||||||2014-10-05|2014-10-07|Estimate|February 2002||2002-02-28|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer|A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB)|Terminated||Phase 3|190|Actual|Medical Enterprises Europe B.V.||2||slow accrual|f||||||||||||||2018-06-01 03:43:29.751298|2018-06-01 03:43:29.751298
NCT00384878|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2009-02-06|2006-10-05|2006-10-06|Estimate|||||||2009-02-06|2009-02-09|Estimate|June 2006||2006-06-30|June 2006|2006-06-30||||March 2007|Actual|2007-03-31||Interventional|||Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer|A Phase II Study of Cetuximab Plus P-HDFL (Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) for the First-Line Treatment of Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|35|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 03:43:29.856095|2018-06-01 03:43:29.856095
NCT00384865|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-30|2016-11-16||2017-07-18|2006-10-05|2006-10-06|Estimate|2017-07-18|2017-07-21|Actual||||2017-07-18|2017-07-21|Actual|September 2006||2006-09-30|July 2017|2017-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension|A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension|Terminated||Phase 2|64|Actual|University of Pennsylvania|"The primary end point that should be used in early-stage clinical trials in PAH is uncertain.~We did not include invasive hemodynamic end points.~Early termination led to missing data for those active subjects in the trial at termination (n16)."|4|||f||||t||||||||||2018-06-01 03:43:29.943269|2018-06-01 03:43:29.943269
NCT00384852|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03||2013-02-21|2013-02-21|2006-10-03|2006-10-06|Estimate||||2013-02-21|2013-02-28|Estimate|2013-02-21|2013-02-28|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Study of rhBMP-2/CPM in Closed Fractures of the Humerus|A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy in Closed Fractures of the Humerus|Completed||Phase 2|139|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||||||||||||2018-06-01 03:43:30.432419|2018-06-01 03:43:30.432419
NCT00384839|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2012-06-13|2006-10-05|2006-10-06|Estimate|||||||2012-06-13|2012-06-15|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Vidaza to Restore Hormone Thx Prostate|Phase II Study for the Use of Vidaza™ to Restore Responsiveness of Patients' Prostate Cancers to Hormonal Therapy|Completed||Phase 2|53|Actual|US Oncology Research||1|||f||||f||||||||||2018-06-01 03:43:30.55944|2018-06-01 03:43:30.55944
NCT00384826|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2015-02-12|2006-10-05|2006-10-06|Estimate|||||||2015-02-12|2015-02-16|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma|Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.|Completed||Phase 2|133|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||f||||||||||2018-06-01 03:43:30.661587|2018-06-01 03:43:30.661587
NCT00384813|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|2014-05-20||2014-07-03|2006-10-03|2006-10-06|Estimate|2014-07-03|2014-07-28|Estimate||||2014-07-03|2014-07-28|Estimate|January 2007||2007-01-31|July 2014|2014-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|ASPIRE||Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma|Project ASPIRE: Improving Pediatric Asthma Management for Urban Families|Completed||Phase 2|43|Actual|Emory University||2|||f||||t||||||||||2018-06-01 03:43:30.807815|2018-06-01 03:43:30.807815
NCT00384800|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2009-02-06|2006-10-04|2006-10-06|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 2006||2006-09-30|March 2006|2006-03-31||||||||Interventional|||A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)||Unknown status|Recruiting|Phase 2|41|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 03:43:31.047302|2018-06-01 03:43:31.047302
NCT00384605|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2015-03-12|2006-10-03|2006-10-06|Estimate|||||||2015-03-12|2015-03-13|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Interventional|||An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK0364) in Obese Patients and in Overweight Patients With Obesity-Related Co-Morbidities, Followed by a 1-Year Extension|Terminated||Phase 3|1000|Actual|Merck Sharp & Dohme Corp.||4||The overall profile does not support development for obesity|f||||||||||||||2018-06-01 03:43:32.796784|2018-06-01 03:43:32.796784
NCT00384787|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2014-09-22|2006-10-05|2006-10-06|Estimate|||||||2014-09-22|2014-09-23|Estimate|November 2006||2006-11-30|September 2014|2014-09-30|December 2012|Actual|2012-12-31|November 2008|Actual|2008-11-30||Interventional|||Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults|A Phase Ib Clinical Trial to Compare the Safety, Tolerability, and Immunogenicity of an HIV-1 Adenoviral Vector Boost Administered Intramuscularly, Intradermally, or Subcutaneously After an HIV-1 DNA Plasmid Vaccine Prime Administered Intramuscularly to Healthy Adenovirus Type 5 Seropositive HIV-1-Uninfected Adults|Completed||Phase 1|90|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 03:43:31.111565|2018-06-01 03:43:31.111565
NCT00384774|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2018-01-02|2006-10-05|2006-10-06|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2006||2006-10-31|January 2018|2018-01-31|June 2007|Actual|2007-06-30|||||Interventional|||A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine|A Placebo-Controlled, Group Sequential, Adaptive Treatment Assignment Study of Intravenous COL-144 (LY573144) in the Acute Treatment of Migraine|Completed||Phase 2|160|Anticipated|Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:43:31.258287|2018-06-01 03:43:31.258287
NCT00384761|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2013-11-15|2006-10-05|2006-10-06|Estimate|||||||2013-11-15|2013-11-18|Estimate|March 2006||2006-03-31|November 2013|2013-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Predictive Medicine Research|Predictive Medicine Research: Investigation of Predictors of Health, Sub-clinical and Clinical Organ System Disease|Completed|||223|Actual|Emory University|||||f||||||||||||||2018-06-01 03:43:31.326236|2018-06-01 03:43:31.326236
NCT00384748|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|2014-10-22||2014-11-12|2006-10-03|2006-10-06|Estimate|2014-11-03|2014-11-10|Estimate||||2014-11-12|2014-11-24|Estimate|November 2008||2008-11-30|November 2014|2014-11-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Home-based Telehealth Stroke Care: A Randomized Trial for Veterans|Home-Based Tele-Health Stroke Care: A Randomized Trial for Veterans|Completed||Phase 2|48|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:43:31.391532|2018-06-01 03:43:31.391532
NCT00384735|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2014-11-13|2006-10-04|2006-10-06|Estimate|||||||2014-11-13|2014-11-14|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|June 2010|Actual|2010-06-30||Observational|TOSS||An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial|An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial|Unknown status|Active, not recruiting||500|Actual|Terry Fox Foundation|||4||f||||t||||||||||2018-06-01 03:43:31.576858|2018-06-01 03:43:31.576858
NCT00384722|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2009-06-23|2006-10-03|2006-10-06|Estimate|||||||2009-06-23|2009-06-24|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|July 2006|Actual|2006-07-31||Interventional|||EASYTRAK 3 Downsize Lead|EASYTRAK® 3 Downsize Lead Clinical Investigation|Completed||Phase 2/Phase 3|70|Actual|Boston Scientific Corporation|||||f||||||||||||||2018-06-01 03:43:31.648811|2018-06-01 03:43:31.648811
NCT00384709|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2011-08-17|2006-10-05|2006-10-06|Estimate|||||||2011-08-17|2011-08-18|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|October 2007|Actual|2007-10-31|||||Observational|||Geriatric Education and Its Effect on Certain Aspects of Hospital Care of Nursing Home Patients|Geriatric Education and Its Effect on Certain Aspects of Hospital Care of the Nursing Home Patients|Completed|||||Maimonides Medical Center|||||f||||||||||||||2018-06-01 03:43:31.708033|2018-06-01 03:43:31.708033
NCT00384696|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2017-06-16|2006-10-05|2006-10-06|Estimate|||||||2017-06-16|2017-06-20|Actual|February 2006|Actual|2006-02-28|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Risk Perception Among Quitting Smokers|Health Communications and Risk Processing Among Smokers|Active, not recruiting|||220|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|t|f||||||||2018-06-01 03:43:31.747839|2018-06-01 03:43:31.747839
NCT00384683|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2017-11-02|2006-10-05|2006-10-06|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2006|Actual|2006-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Endothelial Dysfunction As A Predictor Of Perioperative Outcome|Endothelial Dysfunction As A Predictor Of Perioperative Outcome In Major Thoracic Surgery - An Observational Study|Active, not recruiting|||90|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples collected to measure number of circulating blood cells that become endothelial~     cells. During surgery a small sample of lung tissue collected, if available.~   "|||2018-06-01 03:43:32.050636|2018-06-01 03:43:32.050636
NCT00384670|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2012-05-23||2014-01-10|2006-10-05|2006-10-06|Estimate|2014-01-10|2014-02-24|Estimate||||2014-01-10|2014-02-24|Estimate|August 2003||2003-08-31|January 2014|2014-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children|A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children|Completed||Phase 1/Phase 2|7|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||t||||||||||2018-06-01 03:43:32.164368|2018-06-01 03:43:32.164368
NCT00384657|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2017-12-21|2006-10-05|2006-10-06|Estimate|||||||2017-12-21|2017-12-22|Actual|January 2008|Actual|2008-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease|The Effects of Intravenous Iron Therapy for Anemia Correction in Patients With Severe Chronic Heart Failure and Concomitant Moderate Chronic Kidney Disease|Withdrawn||Phase 3|0|Actual|Anemia Working Group Romania||2||Lack of cooperation among centers, Financial reasons|f||||f||||||||||2018-06-01 03:43:32.42081|2018-06-01 03:43:32.42081
NCT00384644|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2008-06-04|2006-10-04|2006-10-06|Estimate|||||||2008-06-04|2008-06-05|Estimate|April 2004||2004-04-30|June 2008|2008-06-30|December 2010|Anticipated|2010-12-31|January 2009|Anticipated|2009-01-31||Observational|||Skeletal Muscle Oxygenation in Critically Ill|Skeletal Muscle Oxygenation in Critically Ill|Unknown status|Recruiting||200|Anticipated|University Medical Centre Ljubljana|||2||f||||t||||||||||2018-06-01 03:43:32.501448|2018-06-01 03:43:32.501448
NCT00384631|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2008-02-14|2006-10-04|2006-10-06|Estimate|||||||2008-02-14|2008-02-15|Estimate|April 2006||2006-04-30|February 2008|2008-02-29|March 2007|Actual|2007-03-31|||||Interventional|IVB NVG||Intravitreal Bevacizumab for Neovascular Glaucoma|Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial|Completed||N/A|26|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 03:43:32.591767|2018-06-01 03:43:32.591767
NCT00384618|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2006-10-04|2006-10-04|2006-10-06|Estimate|||||||2006-10-04|2006-10-06|Estimate|May 2001||2001-05-31|October 2006|2006-10-31|August 2005||2005-08-31|||||Interventional|||Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study|Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease|Terminated||Phase 4|100||VU University Medical Center|||||f||||||||||||||2018-06-01 03:43:32.729425|2018-06-01 03:43:32.729425
NCT00384592|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2009-03-10|2006-10-05|2006-10-06|Estimate|||||||2009-03-10|2009-03-11|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||PPI Sequencing Study|A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI)|Completed||Phase 4|100||AstraZeneca|||||f||||||||||||||2018-06-01 03:43:32.877443|2018-06-01 03:43:32.877443
NCT00384579|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2010-03-01|2006-10-05|2006-10-06|Estimate|||||||2010-03-01|2010-03-02|Estimate|February 2008||2008-02-29|February 2010|2010-02-28|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Pilot Study to Assess the Efficacy of Botulinum Toxin B on Pain and Disability in Subjects With Acute Low Back Pain|Pilot Study to Assess the Efficacy of Botulinum Toxin B (Myobloc®) Treatment of Paravertebral Muscles on Pain and Disability in Subjects Suffering From Acute Low Back Pain|Terminated||Phase 4|0|Actual|Walter Reed Army Medical Center||2||No eligible candidates in 2 years of recruiting|f||||t||||||||||2018-06-01 03:43:32.957594|2018-06-01 03:43:32.957594
NCT00384566|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2015-06-23|2006-10-05|2006-10-06|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2005||2005-06-30|June 2015|2015-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure|The CAMERA Study: CArvedilol MEtoprolol Respiratory Assessment Investigator Trial|Withdrawn||Phase 4|0|Actual|The Alfred||2||"In order to join forces with another study already running which aims to answer the same~   question."|f||||||||||||||2018-06-01 03:43:33.051058|2018-06-01 03:43:33.051058
NCT00384553|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2006-10-05|2006-10-05|2006-10-06|Estimate|||||||2006-10-05|2006-10-06|Estimate|June 2004||2004-06-30|October 2006|2006-10-31|June 2010||2010-06-30|||||Interventional|||Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma|Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma|Unknown status|Recruiting|Phase 1/Phase 2|30||University of Magdeburg|||||f||||||||||||||2018-06-01 03:43:33.119945|2018-06-01 03:43:33.119945
NCT00384540|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2017-08-16|2006-10-05|2006-10-06|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2006|Actual|2006-09-30|August 2017|2017-08-31|December 20, 2016|Actual|2016-12-20|November 22, 2015|Actual|2015-11-22||Interventional|||Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling|Allograft Vasculopathy After Heart Transplantation : Diagnostic Interest of Dobutamine Stress Echocardiography and Brain Natriuretic Peptide Coupling|Completed||N/A|53|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:43:33.187265|2018-06-01 03:43:33.187265
NCT00384527|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2015-05-04|2006-10-05|2006-10-06|Estimate|||||||2015-05-04|2015-05-05|Estimate|December 2006||2006-12-31|October 2008|2008-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease|Multicenter, Double-blind Study of Nitazoxanide Compared to Vancomycin in the Treatment of Clostridium Difficile-associated Disease|Terminated||Phase 3|50|Actual|Romark Laboratories L.C.||2||Study was terminated early due to slow recruitment.|f||||f||||||||||2018-06-01 03:43:33.260978|2018-06-01 03:43:33.260978
NCT00384514|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2006-10-19|2006-10-05|2006-10-06|Estimate|||||||2006-10-19|2006-10-20|Estimate|July 2004||2004-07-31|October 2006|2006-10-31|September 2006||2006-09-30|||||Interventional|||EPC by Intracoronary Injection in Patients With Chronic Stable Angina|A Study for Testing Safety and Efficacy of the Administration of Blood-Borne Autologous Endothelial Progenitor Cells to Alleviate Anginal Symptoms and Myocardial Ischemia in Patients With Severe Anginal Syndrome|Unknown status|Active, not recruiting|Phase 2|24||TheraVitae Ltd.|||||f||||||||||||||2018-06-01 03:43:33.34275|2018-06-01 03:43:33.34275
NCT00384501|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2006-10-05|2006-10-05|2006-10-06|Estimate|||||||2006-10-05|2006-10-06|Estimate|January 2000||2000-01-31|October 2006|2006-10-31|July 2006||2006-07-31|||||Interventional|||Management of Patients With Keratoconus With Intacs|Intacs for the Treatment of Keratoconus|Terminated||N/A|25||University Hospital of Crete|||||f||||||||||||||2018-06-01 03:43:33.39262|2018-06-01 03:43:33.39262
NCT00384488|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2006-10-05|2006-10-05|2006-10-06|Estimate|||||||2006-10-05|2006-10-06|Estimate|May 2004||2004-05-31|October 2006|2006-10-31|May 2006||2006-05-31|||||Interventional|||Automated Diabetes Prevention Program|Effectiveness of Automated Telephone Intervention on Behavioral and Weight Outcomes for Patients With Pre-Diabetes.|Completed||N/A|84||Kaiser Permanente|||||f||||||||||||||2018-06-01 03:43:33.4483|2018-06-01 03:43:33.4483
NCT00384475|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2016-11-29|2006-10-05|2006-10-06|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mcg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older|Completed||Phase 3|500||AstraZeneca|||||f||||||||||||||2018-06-01 03:43:33.499525|2018-06-01 03:43:33.499525
NCT00384462|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2009-02-03|2006-10-05|2006-10-06|Estimate|||||||2009-02-03|2009-02-04|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Observational|||Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants|A Prospective, Non-Interventional Study to Evaluate the Incidence of Hospitalizations and Medically-Attended Lower Respiratory Tract Infection (MALRI) in Premature Infants 32 to 35 Weeks Gestational Age Who Are Not Recommended to Receive Prophylaxis for RSV|Completed|||346|Actual|MedImmune LLC|||2||f||||f||||||||||2018-06-01 03:43:33.576894|2018-06-01 03:43:33.576894
NCT00384449|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2009-04-02|2006-10-05|2006-10-06|Estimate|||||||2009-04-02|2009-04-03|Estimate|October 2006||2006-10-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Lucentis (Ranibizumab) for Eales' Disease|The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease|Completed||Phase 2/Phase 3|5|Anticipated|Oregon Health and Science University|||||f||||||||||||||2018-06-01 03:43:33.839211|2018-06-01 03:43:33.839211
NCT00384436|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2008-01-03|2006-10-05|2006-10-06|Estimate|||||||2008-01-03|2008-01-07|Estimate|October 2006||2006-10-31|January 2008|2008-01-31||||October 2007|Actual|2007-10-31||Interventional|||Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients|Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients|Completed||Phase 4|580|Anticipated|Forest Laboratories|||||||||||||||||||2018-06-01 03:43:33.906821|2018-06-01 03:43:33.906821
NCT00384423|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2008-01-29|2006-10-04|2006-10-06|Estimate|||||||2008-01-29|2008-01-30|Estimate|October 2006||2006-10-31|January 2008|2008-01-31||||October 2007|Actual|2007-10-31||Interventional|||Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept|A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.|Completed||Phase 2|80|Anticipated|Epix Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:43:33.978742|2018-06-01 03:43:33.978742
NCT00384410|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2006-10-04|2006-10-04|2006-10-06|Estimate|||||||2006-10-04|2006-10-06|Estimate|December 2005||2005-12-31|November 2005|2005-11-30||||||||Interventional|||Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients|Use of the Cannabinoid Nabilone for the Promotion of Sleep in Chronic, Non-Malignant Pain Patients: A Placebo-Controlled, Randomized, Crossover Insomnia Pilot Study|Unknown status|Recruiting|Phase 2|16||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:43:34.058514|2018-06-01 03:43:34.058514
NCT00384397|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|2011-05-10|2010-03-31|2016-04-12|2006-10-05|2006-10-06|Estimate|2011-05-10|2011-06-02|Estimate|2010-03-31|2010-04-02|Estimate|2016-04-12|2016-04-14|Estimate|September 2006||2006-09-30|April 2016|2016-04-30|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers|An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age|Completed||Phase 3|1128|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:43:34.170656|2018-06-01 03:43:34.170656
NCT00384384|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2011-01-12|2006-10-05|2006-10-06|Estimate|||||||2011-01-12|2011-01-13|Estimate|August 2006||2006-08-31|January 2011|2011-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients|Glycyrrhetinic Acid-Effect on Serum Potassium and Insulin Resistance in Dialysis Patients|Completed||Phase 2|24||University Hospital Inselspital, Berne|||||||||||||||||||2018-06-01 03:43:34.955535|2018-06-01 03:43:34.955535
NCT00384371|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2009-03-04|2006-10-04|2006-10-06|Estimate|||||||2009-03-04|2009-03-05|Estimate|June 2008||2008-06-30|March 2009|2009-03-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Pilot Study to Assess the Efficacy of Botulinum Toxin A Treatments on Pain and Disability in Sub-Acute Low Back Pain|Pilot Study to Assess the Efficacy of Botulinum Toxin A (BOTOX®) Treatment of Paravertebral Muscles on Pain and Disability in Subjects Suffering From Sub-Acute Low Back Pain.|Terminated||Phase 4|0|Actual|Walter Reed Army Medical Center||2||Funding was unable to be secured for this study|f||||t||||||||||2018-06-01 03:43:35.023723|2018-06-01 03:43:35.023723
NCT00384358|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03||2013-02-21|2013-02-21|2006-10-03|2006-10-06|Estimate||||2013-02-21|2013-02-28|Estimate|2013-02-21|2013-02-28|Estimate|December 2006||2006-12-31|February 2013|2013-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures|A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-Of-Care Controlled, Feasibility And Safety Study Of rhBMP-2/CPM As An Adjuvant Therapy For Fractures Of The Proximal Femur|Completed||Phase 2|108|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 03:43:35.110199|2018-06-01 03:43:35.110199
NCT00384345|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2006-10-04|2006-10-04|2006-10-06|Estimate|||||||2006-10-04|2006-10-06|Estimate|September 2003||2003-09-30|July 2006|2006-07-31|December 2003||2003-12-31|||||Interventional|||Exercise and Bright Light Treatment: Effects on Body Weight and Composition|Moderate Exercise and Bright Light Treatment in Overweight Individuals|Completed||Phase 2|24||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:43:35.212195|2018-06-01 03:43:35.212195
NCT00384332|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2015-07-23||2017-06-29|2006-10-05|2006-10-06|Estimate|2017-06-29|2017-07-31|Actual||||2017-06-29|2017-07-31|Actual|January 2007||2007-01-31|June 2017|2017-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Medication, Weight Gain and GI Hormones|Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones|Completed||Phase 4|20|Actual|Vanderbilt University Medical Center|Treatment was not blinded to participants or treating physicians.|2|||f||||t||||||||||2018-06-01 03:43:35.272953|2018-06-01 03:43:35.272953
NCT00384319|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2008-01-03|2006-10-04|2006-10-06|Estimate|||||||2008-01-03|2008-01-04|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients|Pilot Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients|Completed||Phase 1|10|Actual|Life Recovery Systems|||||f||||f||||||||||2018-06-01 03:43:35.500008|2018-06-01 03:43:35.500008
NCT00384306|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2015-04-15|2006-10-04|2006-10-06|Estimate|||||||2015-04-15|2015-04-16|Estimate|June 2004||2004-06-30|April 2015|2015-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Effects Of Oral Prednisolone On Bone Metabolism In Patients With Chronic Obstructive Pulmonary Disease|Investigation of the Side Effects of Orally Administered Glucocorticoids. An Open Label Study to Investigate the Effects of Orally Administered Prednisolone on Bone Metabolism in Patients With COPD.|Completed||Phase 1|9|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:43:35.553532|2018-06-01 03:43:35.553532
NCT00384293|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|2009-07-23||2015-09-28|2006-10-05|2006-10-06|Estimate|2009-07-23|2009-09-02|Estimate||||2015-09-28|2015-09-30|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|ACHIEVE||Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)|A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK0524A 2g Coadministered With Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Media Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (heFH)|Terminated||Phase 3|937|Actual|Merck Sharp & Dohme Corp.|After a detailed review of pooled carotid IMT data from contemporary studies, the Steering Committee recommended that Merck prematurely stop the study; as designed, the study was significantly underpowered. Efficacy analyses were not performed.|2|||f||||||||||||||2018-06-01 03:43:35.761637|2018-06-01 03:43:35.761637
NCT00384280|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2009-08-10|2006-10-05|2006-10-06|Estimate|||||||2009-08-10|2009-08-12|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796|An Open Label, 2-period, Sequential Study to Determine the Impact of Multiple Doses of Rifampin on Single-dose Pharmacokinetics of HCV-796|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:43:36.116746|2018-06-01 03:43:36.116746
NCT00384267|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2011-11-10|2006-10-04|2006-10-06|Estimate|||||||2011-11-10|2011-11-11|Estimate|October 2006||2006-10-31|September 2008|2008-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Congenital and Neonatal Malaria in Mali|Congenital and Neonatal Malaria in Mali|Completed|||44|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 03:43:36.167501|2018-06-01 03:43:36.167501
NCT00384254|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2011-10-24|2006-10-03|2006-10-06|Estimate|||||||2011-10-24|2011-10-26|Estimate|January 2004||2004-01-31|October 2011|2011-10-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||Tobacco Quitlines:Adjunct to Dental Office Tobacco Intervention|Tobacco Quitlines as an Adjunct to Dental Office Tobacco Intervention|Completed||Phase 2|2177|Actual|Oregon Research Institute||3|||f||||t||||||||||2018-06-01 03:43:36.228539|2018-06-01 03:43:36.228539
NCT00384241|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2013-06-21||2015-05-13|2006-10-04|2006-10-06|Estimate|2015-05-13|2015-06-03|Estimate||||2015-05-13|2015-06-03|Estimate|August 2006||2006-08-31|May 2015|2015-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Evaluating the Relationship Between Inflammation, Genetics, and Stress in the Development of High Blood Pressure|Inflammatory Factors, Genes and Stress Induced Pressure Natriuresis in Youth|Completed|||1099|Actual|Augusta University|No treatment was given.||2||f||||t||||||Samples With DNA|"~     Blood samples of 500 subjects have been collected and stored in previous funded studies.~      Buccal swabs from 599 biological parents have been collected from the current study.~   "|||2018-06-01 03:43:36.300591|2018-06-01 03:43:36.300591
NCT00384228|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-05|||2012-04-11|2006-10-05|2006-10-06|Estimate|||||||2012-04-11|2012-04-12|Estimate|May 2005||2005-05-31|April 2012|2012-04-30||||January 2007|Actual|2007-01-31||Interventional|||A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL|A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant CML, or Relapse/Refractory Ph+ALL|Completed||Phase 1/Phase 2|42|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:43:36.646977|2018-06-01 03:43:36.646977
NCT00384215|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2011-01-10|2006-10-04|2006-10-06|Estimate|||||||2011-01-10|2011-01-11|Estimate|December 2001||2001-12-31|January 2011|2011-01-31|February 2005||2005-02-28|||||Interventional|||Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin|Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin: a Randomized, Open, Parallel Study|Completed||Phase 4|352||Sanofi|||||f||||||||||||||2018-06-01 03:43:36.793554|2018-06-01 03:43:36.793554
NCT00384202|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2014-07-07|2006-10-04|2006-10-05|Estimate|||||||2014-07-07|2014-07-09|Estimate|October 2006||2006-10-31|July 2014|2014-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients|A Multicenter, Open, Single Sequence Crossover Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, FK506E (MR4), Based Immunosuppressive Regimen in Stable Liver Transplant Patients Converted From a Prograf® Based Immunosuppressive Regimen|Completed||Phase 3|112|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 03:43:36.858615|2018-06-01 03:43:36.858615
NCT00384189|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|2016-07-06||2016-12-02|2006-10-04|2006-10-05|Estimate|2016-07-06|2016-08-16|Estimate||||2016-12-02|2017-02-01|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2007|Actual|2007-08-31||Interventional|RAINBOW|Full Analysis Set includes all randomized participants who received at least one dose of study drug, as treated.|A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma|A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children With Asthma|Completed||Phase 3|1080|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 03:43:36.985945|2018-06-01 03:43:36.985945
NCT00384176|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|2012-03-07|2011-04-06|2017-04-13|2006-10-03|2006-10-05|Estimate|2012-10-29|2012-11-28|Estimate|2011-04-06|2011-04-12|Estimate|2017-04-13|2017-04-14|Actual|August 30, 2006|Actual|2006-08-30|April 2017|2017-04-30|August 19, 2015|Actual|2015-08-19|November 15, 2009|Actual|2009-11-15||Interventional|HORIZON III||First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX|A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer|Completed||Phase 2/Phase 3|1814|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:43:38.155794|2018-06-01 03:43:38.155794
NCT00384163|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2013-11-25|2006-10-04|2006-10-05|Estimate|||||||2013-11-25|2013-11-26|Estimate|August 2007||2007-08-31|November 2013|2013-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique|Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique|Terminated|||50||Emory University||||sufficient data collected|f||||||||||||||2018-06-01 03:43:40.145241|2018-06-01 03:43:40.145241
NCT00384150|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04||2015-10-30|2015-10-30|2006-10-04|2006-10-05|Estimate||||2015-10-30|2015-11-26|Estimate|2015-10-30|2015-11-26|Estimate|November 2007||2007-11-30|October 2015|2015-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)|A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination With Rituximab for Subjects With Relapsed, Follicular Non-Hodgkin's Lymphoma Who Previously Responded on Study 114-NH-301|Terminated||Phase 3|16|Actual|Biogen||||"Enrollment challenges due to changes in standards of care resulted in premature termination. No~   safety or efficacy events factored into this action."|f||||f||||||||||2018-06-01 03:43:40.211758|2018-06-01 03:43:40.211758
NCT00384137|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2014-07-07|2006-10-04|2006-10-05|Estimate|||||||2014-07-07|2014-07-09|Estimate|October 2006||2006-10-31|July 2014|2014-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients|A Multicenter, Open, Single Sequence Crossover Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, FK506E (MR4), Based Immunosuppressive Regimen in Stable Kidney Transplant Patients Converted From a Prograf® Based Immunosuppressive Regimen|Completed||Phase 3|128|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-06-01 03:43:40.277563|2018-06-01 03:43:40.277563
NCT00384124|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-04|||2008-03-25|2006-10-04|2006-10-05|Estimate|||||||2008-03-25|2008-03-26|Estimate|November 2006||2006-11-30|March 2008|2008-03-31||||November 2008|Anticipated|2008-11-30||Interventional|||Topical Imiquimod for Bowen's Disease of the Head and Neck|Phase III Trial of 6 Weeks of Imiquimod for the Treatment of Bowens Disease of the Head and Neck. Outcome is Histologic Clearance at 14 Weeks.|Unknown status|Enrolling by invitation|Phase 2/Phase 3|50|Anticipated|Brooke Army Medical Center|||||f||||t||||||||||2018-06-01 03:43:40.360487|2018-06-01 03:43:40.360487
NCT00384111|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2017-10-16|2006-10-03|2006-10-05|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2006||2006-10-31|October 2017|2017-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular NHL|A Phase 3 Open-label Multicenter Randomized Study to Compare the Efficacy and Safety of Zevalin Therapeutic Regimen Following R CVP With R CVP Alone in High Risk Subjects With Previously Untreated CD20 Positive Follicular Non Hodgkin's Lymphoma|Terminated||Phase 3|26|Actual|Spectrum Pharmaceuticals, Inc||2||A pending new protocol will replace this study.|f||||f||||||||||2018-06-01 03:43:40.445656|2018-06-01 03:43:40.445656
NCT00384098|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2014-09-26|2006-10-02|2006-10-04|Estimate|||||||2014-09-26|2014-09-29|Estimate|September 2006||2006-09-30|June 2007|2007-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis|A Randomized, Double-blind, Parallel-group, 4-arm, 12-week Study to Evaluate the Safety and Efficacy of Topically Applied CTA018 vs Vehicle for the Treatment of Adult Subjects With Chronic Plaque Psoriasis|Completed||Phase 2|140||OPKO Health, Inc.|||||f||||f||||||||||2018-06-01 03:43:40.520332|2018-06-01 03:43:40.520332
NCT00384085|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|2011-03-31||2011-05-04|2006-10-03|2006-10-04|Estimate|2011-03-31|2011-04-26|Estimate||||2011-05-04|2011-05-06|Estimate|May 2006||2006-05-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||"Insulin Glargine All to Target Trial"|All to Target Trial Lantus® (Insulin Glargine) With Stepwise Addition of APIDRA® (Insulin Glulisine) or Lantus With One Injection of Apidra vs a Twice-Daily Premixed Insulin Regimen (Novolog® Mix 70/30) in Adult Subjects With Type 2 Diabetes Failing Dual or Triple Therapy With Oral Agents: a 64-week, Multi-center, Randomized, Parallel, Open-label Clinical Study.|Completed||Phase 4|588|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:43:40.615045|2018-06-01 03:43:40.615045
NCT00384072|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2007-12-19|2006-10-03|2006-10-04|Estimate|||||||2007-12-19|2007-12-28|Estimate|May 2006||2006-05-31|May 2007|2007-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women|A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women|Completed||Phase 3|500|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:43:42.292381|2018-06-01 03:43:42.292381
NCT00384059|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|2010-03-26|2009-02-26|2013-01-22|2006-10-02|2006-10-04|Estimate|2012-07-06|2012-08-15|Estimate|2009-09-30|2009-10-01|Estimate|2013-01-22|2013-01-24|Estimate|October 2006||2006-10-31|January 2013|2013-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom|Completed||Phase 3|286|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:43:42.485409|2018-06-01 03:43:42.485409
NCT00384046|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2013-04-15|2006-10-03|2006-10-04|Estimate|||||||2013-04-15|2013-04-17|Estimate|November 2006||2006-11-30|April 2013|2013-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen|24-Week Study to Evaluate the Efficacy/Safety of Transdermal Testosterone in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen Therapy.|Completed||Phase 3|272|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:43:44.300305|2018-06-01 03:43:44.300305
NCT00384033|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|2012-02-09||2012-02-09|2006-10-02|2006-10-04|Estimate|2012-02-09|2012-03-15|Estimate||||2012-02-09|2012-03-15|Estimate|September 2006||2006-09-30|February 2012|2012-02-29|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|638|Actual|Pfizer||4|||||||||||||||||2018-06-01 03:43:44.542925|2018-06-01 03:43:44.542925
NCT00384020|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2010-01-29|2006-10-03|2006-10-04|Estimate|||||||2010-01-29|2010-02-01|Estimate|January 2006||2006-01-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Clinical Pharmacogenomics of Antidepressant Response|Phase 4 Clinical Pharmacogenomics of Antidepressant Response|Completed|||402|Actual|National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 03:43:45.468482|2018-06-01 03:43:45.468482
NCT00384007|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2009-06-04|2006-10-03|2006-10-04|Estimate|||||||2009-06-04|2009-06-05|Estimate|October 2006||2006-10-31|June 2009|2009-06-30||||||||Interventional|||A Randomized Trial Comparing SpineJet® Hydrodiscectomy to Open Lumbar Microdiscectomy for Treatment of Lumbar Radiculopathy Due to Disc Herniation|A Randomized Trial Comparing SpineJet® Hydrodiscectomy to Open Lumbar Microdiscectomy for Treatment of Lumbar Radiculopathy Due to Disc Herniation|Completed||N/A|58|Anticipated|Pinnacle Pain Medicine|||||||||||||||||||2018-06-01 03:43:45.532223|2018-06-01 03:43:45.532223
NCT00383994|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2017-11-28|2006-10-02|2006-10-04|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2006|Actual|2006-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation|Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 1|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:43:45.595362|2018-06-01 03:43:45.595362
NCT00383981|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2006-10-03|2006-10-03|2006-10-04|Estimate|||||||2006-10-03|2006-10-04|Estimate|March 2003||2003-03-31|April 2006|2006-04-30|December 2003||2003-12-31|||||Observational|||Lipid Peroxidation in Workers Exposed to Al,Ga,In,As,and Sb in Optoelectronic Industry||Completed|||170||Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-06-01 03:43:45.696463|2018-06-01 03:43:45.696463
NCT00383968|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2006-10-03|2006-10-03|2006-10-04|Estimate|||||||2006-10-03|2006-10-04|Estimate|October 2006||2006-10-31|October 2006|2006-10-31|December 2006||2006-12-31|||||Observational|||Prevalence of Chronic KIdney Disease in Hypertensive Patients|Prevalence of Chronic KIdney Disease in Hypertensive Patients|Unknown status|Recruiting||248||Aga Khan University|||||f||||||||||||||2018-06-01 03:43:45.737098|2018-06-01 03:43:45.737098
NCT00383955|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2006-10-03|2006-10-03|2006-10-04|Estimate|||||||2006-10-03|2006-10-04|Estimate|October 2006||2006-10-31|October 2006|2006-10-31||||||||Observational|||Comparison of Screening Tools for Coronary Artery Disease|Comparison of Screening Tools for Coronary Artery Disease With Thallium Scintigraphy in Adult Population in Karachi.|Unknown status|Recruiting||450||Aga Khan University|||||f||||||||||||||2018-06-01 03:43:45.878797|2018-06-01 03:43:45.878797
NCT00383942|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|2016-06-01||2017-01-23|2006-10-02|2006-10-04|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|August 31, 2006|Actual|2006-08-31|January 2017|2017-01-31|June 18, 2008|Actual|2008-06-18|June 18, 2008|Actual|2008-06-18||Interventional|RIPE|The baseline analysis population comprises all patients who were randomized|Ripening Interventions: Prostaglandins vs EASI Catheter|The RIPE Study: Ripening Interventions: Prostaglandins vs EASI Catheter|Terminated||Phase 4|80|Actual|Loyola University|This trial was terminated prematurely due to a department policy change regarding inductions of labor.|2||Change in treatment plan for this population terminated the project|f||||t|t|t|f|f|f|||No|There is no plan to share individual participant data|2018-06-01 03:43:45.949337|2018-06-01 03:43:45.949337
NCT00383929|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2008-03-19|2006-10-03|2006-10-04|Estimate|||||||2008-03-19|2008-03-20|Estimate|September 2006||2006-09-30|March 2008|2008-03-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg|A Double Blind, Randomised, 3-Arm Parallel Group, Multicentre, 8-Week, Phase III Study to Assess Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) /HCT 32/12.5mg and 32/25mg vs. CC 32mg Alone in Patients With Inadequate BP Control on Monotherapy With CC 32mg|Completed||Phase 3|1979|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 03:43:46.162279|2018-06-01 03:43:46.162279
NCT00383916|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2007-03-07|2006-10-02|2006-10-04|Estimate|||||||2007-03-07|2007-03-08|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|October 2006||2006-10-31|||||Interventional|||Study Comparing 2 Different Formulations of Pantoprazole in Healthy Adults.|An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between the Altana Formulation of Pantoprazole Delayed-Release Granules and the Wyeth Formulation of Pantoprazole Delayed-Release Granules in Healthy Subjects.|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:43:46.468461|2018-06-01 03:43:46.468461
NCT00383903|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2016-09-14|2006-10-03|2006-10-04|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa|A Phase II, Randomized, Double-blind, Placebo-controlled Study of Safety, Reactogenicity and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine at 10E6.5 CCID50 Viral Concentration in Healthy Infants (Approximately 5-10 Weeks Old) in the Republic of South Africa|Completed||Phase 2|472|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:46.543209|2018-06-01 03:43:46.543209
NCT00383890|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2015-07-23|2006-10-02|2006-10-04|Estimate|||||||2015-07-23|2015-07-24|Estimate|August 2006||2006-08-31|July 2015|2015-07-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine Used for Sedation During Elective Awake Fiberoptic Intubation|Completed||Phase 3|124|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:43:46.643448|2018-06-01 03:43:46.643448
NCT00383877|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2014-11-20|2006-10-03|2006-10-04|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2006||2006-09-30|November 2014|2014-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes|Completed||Phase 3|263|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:43:46.736243|2018-06-01 03:43:46.736243
NCT00383864|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2006-10-05|2006-10-02|2006-10-04|Estimate|||||||2006-10-05|2006-10-06|Estimate|July 2001||2001-07-31|October 2006|2006-10-31|March 2006||2006-03-31|||||Interventional|||Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.|Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation|Completed||Phase 4|55||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:43:46.796801|2018-06-01 03:43:46.796801
NCT00383851|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2007-12-04|2006-10-02|2006-10-04|Estimate|||||||2007-12-04|2007-12-06|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma|A Randomized Phase II Trial of ATN-224 in Combination With Temozolomide or Temozolomide Followed by ATN-224 in Patients With Advanced Melanoma|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Attenuon|||||f||||||||||||||2018-06-01 03:43:46.853431|2018-06-01 03:43:46.853431
NCT00383838|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2006-10-02|2006-10-02|2006-10-04|Estimate|||||||2006-10-02|2006-10-04|Estimate|September 2002||2002-09-30|October 2006|2006-10-31|June 2005||2005-06-30|||||Interventional|||Self-Selected Brief Alcohol Intervention for Adolescents|Self-Selected Brief Alcohol Intervention for Adolescents|Completed||N/A|1200||RAND|||||f||||||||||||||2018-06-01 03:43:46.958022|2018-06-01 03:43:46.958022
NCT00383825|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2006-10-02|2006-10-02|2006-10-04|Estimate|||||||2006-10-02|2006-10-04|Estimate|January 2003||2003-01-31|October 2006|2006-10-31|December 2004||2004-12-31|||||Interventional|||ICG Angiography in Amniotic Membrane Graft and Conjunctival Autograft After Pterygium Excision|Interventional Study of Vascularization Detected by ICG Angiography in Amniotic Membrane Graft and Conjunctival Autograft After Pterygium Excision|Completed||N/A|30||Baskent University|||||f||||||||||||||2018-06-01 03:43:47.016864|2018-06-01 03:43:47.016864
NCT00383812|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2006-10-03|2006-10-03|2006-10-04|Estimate|||||||2006-10-03|2006-10-04|Estimate|May 2006||2006-05-31|October 2006|2006-10-31|May 2008||2008-05-31|||||Interventional|||Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy|Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy|Unknown status|Recruiting|N/A|20||Asan Medical Center|||||f||||||||||||||2018-06-01 03:43:47.200034|2018-06-01 03:43:47.200034
NCT00383799|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2016-04-04|2006-10-03|2006-10-04|Estimate|||||||2016-04-04|2016-04-06|Estimate|September 2005||2005-09-30|March 2016|2016-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia|Comparison of Intravenous Amiodarone Versus Intravenous Procainamide for the Acute Treatment of Regular and Haemodynamically Well Tolerated Wide QRS Tachycardia (Probably of Ventricular Origen). The PROCAMIO Multicenter Study|Terminated||Phase 4|302|Actual|Hospital General Universitario Gregorio Marañon||2||"Steering Committee decision after inclusion of 74 patients after 6 years and very slow~   inclusion rate"|f||||t||||||||||2018-06-01 03:43:47.272054|2018-06-01 03:43:47.272054
NCT00383786|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|2013-09-05||2018-01-17|2006-10-03|2006-10-04|Estimate|2013-12-27|2014-01-31|Estimate||||2018-01-17|2018-02-13|Actual|September 2006||2006-09-30|January 2018|2018-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder|Evaluation of the Efficacy of the NK1 Antagonist GR205171 in Posttraumatic Stress Disorder|Completed||Phase 2|47|Actual|Baylor College of Medicine|Limitations include the small sample size and brief duration of the trial, as 8 weeks might have been insufficient to test the efficacy of GR205171 for chronic PTSD. Sample size was also a limitation.|2|||f||||t||||||||||2018-06-01 03:43:47.384545|2018-06-01 03:43:47.384545
NCT00383773|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-03|||2006-10-03|2006-10-03|2006-10-04|Estimate|||||||2006-10-03|2006-10-04|Estimate|October 2006||2006-10-31|September 2006|2006-09-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion||Unknown status|Not yet recruiting|N/A|10|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:43:47.59771|2018-06-01 03:43:47.59771
NCT00383760|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2014-04-18||2017-09-19|2006-09-29|2006-10-03|Estimate|2016-10-17|2016-12-09|Estimate||||2017-09-19|2017-10-20|Actual|August 2006||2006-08-31|September 2017|2017-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients|A Phase II Study of the Halichondrin B Analog E7389 as Second Line Therapy for Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer|Completed||Phase 2|15|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:43:47.663249|2018-06-01 03:43:47.663249
NCT00356733|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2011-11-30|2006-07-25|2006-07-26|Estimate|||||||2011-11-30|2011-12-02|Estimate|January 2007||2007-01-31|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome|Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome|Completed||Phase 3|62|Actual|UMC Utrecht||3|||f||||||||||||||2018-06-01 03:52:42.860352|2018-06-01 03:52:42.860352
NCT00383747|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2015-04-15||2017-03-20|2006-10-02|2006-10-03|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|April 2004||2004-04-30|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Effects of Nicotine on Cognition in Schizophrenia|A Double Blind Placebo Controlled Trial of the Effects of Transdermal Nicotine on Cognitive Function in Non-Smokers With and Without Schizophrenia|Completed||Phase 4|60|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:43:47.966242|2018-06-01 03:43:47.966242
NCT00383734|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2011-12-21|2006-10-02|2006-10-03|Estimate|||||||2011-12-21|2011-12-22|Estimate|December 2006||2006-12-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE|Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE|Completed||Phase 3|148|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||t||||||||||2018-06-01 03:43:48.263469|2018-06-01 03:43:48.263469
NCT00383721|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2011-07-22||2017-03-13|2006-09-29|2006-10-03|Estimate|2011-09-16|2011-10-26|Estimate||||2017-03-13|2017-04-11|Actual|September 2006||2006-09-30|March 2017|2017-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)|A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD|Completed||Phase 3|1196|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:43:48.380144|2018-06-01 03:43:48.380144
NCT00383708|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2012-06-18|2006-10-02|2006-10-03|Estimate|||||||2012-06-18|2012-06-19|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients|Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone|Completed||Phase 3|125|Actual|Ipsen||1|||f||||f||||||||||2018-06-01 03:43:49.257744|2018-06-01 03:43:49.257744
NCT00383695|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2010-01-12|2006-09-29|2006-10-03|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2005||2005-09-30|January 2010|2010-01-31||||||||Interventional|EXPERT-C||Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer|A Multicentre Randomised Phase II Clinical Trial Comparing Oxaliplatin (Eloxatin), Capecitabine (Xeloda) and Pre-Operative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision for the Treatment of Patients With Magnetic Resonance Imaging (MRI) Defined High Risk Rectal Cancer|Unknown status|Active, not recruiting|Phase 2|164|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||t||||||||||2018-06-01 03:43:49.34433|2018-06-01 03:43:49.34433
NCT00383682|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2006-09-29|2006-09-29|2006-10-03|Estimate|||||||2006-09-29|2006-10-03|Estimate|July 1997||1997-07-31|September 2006|2006-09-30|April 2003||2003-04-30|||||Interventional|||Efficacy of Opioids and Mexiletine for the Treatment of Postamputation Pain|Randomized, Placebo-Controlled, Double-Blind Cross-Over Trial of Opioids Versus Mexiletine in the Treatment of Postamputation Pain|Completed||Phase 2|60||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:43:49.523498|2018-06-01 03:43:49.523498
NCT00383669|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2011-09-02|2006-09-29|2006-10-03|Estimate|||||||2011-09-02|2011-09-05|Estimate|November 2006||2006-11-30|September 2011|2011-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Trial of Vitamins and HAART in HIV Disease Progression|Trial of Vitamins in HIV Progression and Transmission (A Trial of Vitamins and HAART in HIV Disease Progression)|Completed||Phase 3|4012|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-06-01 03:43:49.584635|2018-06-01 03:43:49.584635
NCT00383656|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2017-07-09|2006-09-29|2006-10-03|Estimate|||||||2017-07-09|2017-07-12|Actual|January 1989||1989-01-31|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Pulsatile GnRH in Anovulatory Infertility|Pulsatile GnRH in Anovulatory Infertility|Recruiting||Phase 2|270|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||Yes|Individual patient data will be shared across MGH and NIH protocols to which the participant consents.|2018-06-01 03:43:49.661021|2018-06-01 03:43:49.661021
NCT00383643|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2017-02-15||2017-04-26|2006-10-02|2006-10-03|Estimate|2017-04-26|2017-06-01|Actual||||2017-04-26|2017-06-01|Actual|May 2006||2006-05-31|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.|Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study.|Completed||Phase 2|48|Actual|Stanford University|Insufficient power for most parameters was a planned limitation of the study. Replication with a larger sample is needed.|3|||f||||||||||||||2018-06-01 03:43:49.763083|2018-06-01 03:43:49.763083
NCT00383630|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2013-03-06|2006-09-29|2006-10-03|Estimate|||||||2013-03-06|2013-03-08|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure|The Effect of Intramyocardial Injection of Immunoselected Bone Marrow Cells on Myocardial Function in LVAD Bridge to Transplant Patients|Terminated||Phase 2|1|Actual|Columbia University||3||Study has been terminated due to logistical barriers to cell processing and poor enrollment|f||||t||||||||||2018-06-01 03:43:50.225031|2018-06-01 03:43:50.225031
NCT00383617|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2013-02-12|2006-10-02|2006-10-03|Estimate|||||||2013-02-12|2013-02-13|Estimate|July 2004||2004-07-31|February 2013|2013-02-28||||April 2007|Actual|2007-04-30||Observational|||Referral Recommendations for Axial Spondyloarthritis|Performance of Referral Recommendations in Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis|Completed|||500|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 03:43:50.325063|2018-06-01 03:43:50.325063
NCT00383604|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2013-05-28|2006-10-02|2006-10-03|Estimate|||||||2013-05-28|2013-05-30|Estimate|July 2005||2005-07-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Observational|||Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2|Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2|Completed|||30|Actual|Stanford University|||||f||||t||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:43:50.384073|2018-06-01 03:43:50.384073
NCT00383591|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2017-03-21|2006-10-02|2006-10-03|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2002||2002-03-31|March 2017|2017-03-31|January 2004|Actual|2004-01-31|||||Interventional|||Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years|A Phase III, Clinical Trial Comparing the Persistence of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B at Months 24, 30, 36, in Pre-haemodialysis/Haemodialysis Patients (≥15 Years of Age)|Completed||Phase 3|120||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:43:50.446694|2018-06-01 03:43:50.446694
NCT00383578|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29||2013-01-02|2013-01-02|2006-09-29|2006-10-03|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-02|2013-01-04|Estimate|September 2006||2006-09-30|January 2013|2013-01-31||||May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd or Metformin 1500 mg Daily in Elderly Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|335|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:43:50.515909|2018-06-01 03:43:50.515909
NCT00383565|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2012-07-19||2014-05-02|2006-09-29|2006-10-03|Estimate|2012-07-19|2012-08-22|Estimate||||2014-05-02|2014-05-20|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study of Depsipeptide, a Histone Deacetylase Inhibitor, in Relapsed or Refractory Mantle Cell or Diffuse Large Cell Non-Hodgkin's Lymphoma|Terminated||Phase 2|9|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:43:50.604819|2018-06-01 03:43:50.604819
NCT00383552|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2010-07-15|2009-04-14|2017-03-10|2006-09-29|2006-10-03|Estimate|2011-09-16|2011-10-25|Estimate|2009-10-16|2009-10-20|Estimate|2017-03-10|2017-04-10|Actual|September 2006||2006-09-30|March 2017|2017-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)|A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids|Completed||Phase 3|746|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:43:50.829734|2018-06-01 03:43:50.829734
NCT00383539|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2014-01-10|2006-09-29|2006-10-03|Estimate|||||||2014-01-10|2014-01-14|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults||Completed||Phase 3|2256|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 03:43:51.40415|2018-06-01 03:43:51.40415
NCT00383526|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2014-01-10|2006-09-29|2006-10-03|Estimate|||||||2014-01-10|2014-01-14|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elderly||Completed||Phase 3|3707|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:43:51.485899|2018-06-01 03:43:51.485899
NCT00383513|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29||2012-07-03|2012-07-03|2006-10-02|2006-10-03|Estimate||||2012-07-03|2012-07-12|Estimate|2012-07-03|2012-07-12|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of Epratuzumab in Systemic Lupus Erythematosus|An Open-Label Re-treatment Trial for Patients Previously Randomized Into the SL0003 and SL0004, Randomized, Double-blind, Placebo-controlled, Multi-center Studies of Epratuzumab in Patients With Systemic Lupus Erythematosus|Completed||Phase 2|29|Actual|UCB Pharma||1|||f||||t||||||||||2018-06-01 03:43:51.552685|2018-06-01 03:43:51.552685
NCT00383500|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2012-06-06||2017-02-11|2006-10-02|2006-10-03|Estimate|2017-02-11|2017-03-30|Actual||||2017-02-11|2017-03-30|Actual|May 2005||2005-05-31|February 2017|2017-02-28|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status|To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status|Completed||N/A|75|Actual|Stanford University||3|||f||||t||||||||Undecided|undecided at this time.|2018-06-01 03:43:51.758287|2018-06-01 03:43:51.758287
NCT00383487|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2013-01-25|2006-10-02|2006-10-03|Estimate|||||||2013-01-25|2013-01-28|Estimate|March 2005||2005-03-31|January 2013|2013-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer|A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer|Terminated||Phase 2|20|Actual|Stanford University||||Extreme toxicity|f||||t||||||||||2018-06-01 03:43:52.090289|2018-06-01 03:43:52.090289
NCT00383474|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2015-04-14|2006-09-29|2006-10-03|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2006||2006-08-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase|A Phase I Dose-Escalation Study of R115777 (Tipifarnib) Plus PS-341 (Bortezomib) in Relapsed or Refractory Acute Leukemias|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:43:52.153687|2018-06-01 03:43:52.153687
NCT00383461|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2013-05-28|2006-09-29|2006-10-03|Estimate|||||||2013-05-28|2013-05-29|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Computer-Based Stop Smoking Program in Assisting Doctors in Helping Adults Stop Smoking|Computerized EMR-Assisted Smoking Cessation (CEASCE)|Completed||N/A|4314|Anticipated|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 03:43:52.222234|2018-06-01 03:43:52.222234
NCT00383448|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2015-04-22|2006-09-29|2006-10-03|Estimate|||||||2015-04-22|2015-04-24|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||HSCT for High Risk Inherited Inborn Errors|Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation|Completed||Phase 2|39|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-06-01 03:43:52.272364|2018-06-01 03:43:52.272364
NCT00383435|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2011-07-05||2017-03-13|2006-09-29|2006-10-03|Estimate|2011-08-29|2011-10-03|Estimate||||2017-03-13|2017-04-12|Actual|October 2006||2006-10-31|March 2017|2017-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)|A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD|Completed||Phase 3|1055|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:43:52.388745|2018-06-01 03:43:52.388745
NCT00383422|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29||2009-06-10|2010-01-26|2006-09-29|2006-10-03|Estimate||||2009-10-05|2009-10-07|Estimate|2010-01-26|2010-01-28|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis|The Comparison of the Efficacy and Safety of Arzoxifene Versus Raloxifene in Postmenopausal Women With Osteoporosis|Completed||Phase 3|320|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:43:53.382389|2018-06-01 03:43:53.382389
NCT00383409|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2006-10-02|2006-10-02|2006-10-03|Estimate|||||||2006-10-02|2006-10-03|Estimate|March 2006||2006-03-31|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||Multivitamins do Not Improve Radiation Therapy Related Fatigue|Multivitamins do Not Improve Radiation Therapy Related Fatigue: Results of a Double-Blind Randomized Cross-Over Trial|Completed||Phase 2|40||Faculdade de Medicina do ABC|||||f||||||||||||||2018-06-01 03:43:53.501224|2018-06-01 03:43:53.501224
NCT00383396|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2007-02-12|2006-10-02|2006-10-03|Estimate|||||||2007-02-12|2007-02-13|Estimate||||February 2007|2007-02-28||||||||Interventional|||Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:43:53.561682|2018-06-01 03:43:53.561682
NCT00383383|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2006-10-02|2006-10-02|2006-10-03|Estimate|||||||2006-10-02|2006-10-03|Estimate|December 1999||1999-12-31|October 2006|2006-10-31||||||||Interventional|||Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years|To Compare the Immunogenicity & Safety of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B, in Pre-Haemodialysis/Haemodialysis Patients (≥15 Years of Age)|Completed||Phase 3|141||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:43:53.606852|2018-06-01 03:43:53.606852
NCT00383370|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2011-04-20|2006-10-02|2006-10-03|Estimate|||||||2011-04-20|2011-04-21|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD|A Trial to Assess the Safety and Tolerability of Repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects With Neovascular Age Related Macular Degeneration|Completed||Phase 1|20|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:43:53.673815|2018-06-01 03:43:53.673815
NCT00383357|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2007-09-19|2006-09-29|2006-10-03|Estimate|||||||2007-09-19|2007-09-20|Estimate|August 2004||2004-08-31|September 2007|2007-09-30||||||||Interventional|||Sleepiness and the Risk of Falling|Aging, Hypnotics, Sleep Inertia and the Risk of Falling|Completed||N/A|24|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 03:43:53.741361|2018-06-01 03:43:53.741361
NCT00383344|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2007-04-05|2006-10-02|2006-10-03|Estimate|||||||2007-04-05|2007-04-06|Estimate|September 2006||2006-09-30|October 2006|2006-10-31|May 2007||2007-05-31|||||Interventional|||Use of FDG PET/CT to Evaluate Crohn Disease|Phase II Study on the Role of the Positron Emission Tomography Combined With CT Scan for the Evaluation on Crohn Disease|Unknown status|Recruiting|Phase 2|30||Université de Sherbrooke|||||f||||||||||||||2018-06-01 03:43:53.798309|2018-06-01 03:43:53.798309
NCT00383331|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2009-01-06||2009-05-28|2006-09-29|2006-10-03|Estimate|2009-03-27|2009-05-14|Estimate||||2009-05-28|2009-06-03|Estimate|February 2007||2007-02-28|May 2009|2009-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer|A Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|19|Actual|Eli Lilly and Company|Trial was stopped early due to low enrollment. Some secondary outcomes were not analyzed due to the low numbers.|2||Trial was stopped early due to low enrollment|f||||f||||||||||2018-06-01 03:43:53.870832|2018-06-01 03:43:53.870832
NCT00383318|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2008-01-24|2006-10-02|2006-10-03|Estimate|||||||2008-01-24|2008-01-28|Estimate|September 2006||2006-09-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia|Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia|Completed|||450|Anticipated|Mednax Center for Research, Education, Quality and Safety|||||f||||||||||||||2018-06-01 03:43:54.425943|2018-06-01 03:43:54.425943
NCT00383305|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2006-09-29|2006-09-29|2006-10-03|Estimate|||||||2006-09-29|2006-10-03|Estimate|July 1999||1999-07-31|September 2006|2006-09-30|September 2003||2003-09-30|||||Interventional|||CoolCap Trial, Treatment of Perinatal Hypoxic-Ischemic Encephalopathy|Brain-Cooling for the Treatment of Perinatal Hypoxic-Ischemic Encephalopathy|Completed||N/A|235||Olympic Medical|||||||||||||||||||2018-06-01 03:43:54.586774|2018-06-01 03:43:54.586774
NCT00383292|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29||2012-02-10|2015-08-21|2006-09-29|2006-10-03|Estimate||||2012-02-10|2012-02-14|Estimate|2015-08-21|2015-09-07|Estimate|November 2006||2006-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|September 2011|Actual|2011-09-30||Interventional|||A Study of LY573636 in Treating Patients With Malignant Melanoma|A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle as Second-Line Treatment in Patients With Unresectable or Metastatic Melanoma|Completed||Phase 2|132|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:43:54.697316|2018-06-01 03:43:54.697316
NCT00383279|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2017-01-17|2006-09-29|2006-10-03|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2006||2006-02-28|June 2013|2013-06-30||||February 2007|Actual|2007-02-28||Interventional|||Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer|Improving Employment Among Gynecologic Cancer Survivors|Completed||N/A|70|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 03:43:54.791699|2018-06-01 03:43:54.791699
NCT00383266|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|2015-10-20||2015-12-04|2006-10-02|2006-10-03|Estimate|2015-12-04|2016-01-11|Estimate||||2015-12-04|2016-01-11|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer|A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer|Terminated||Phase 2|9|Actual|Washington University School of Medicine|The study was terminated due to lack of participant accrual.|1||Low accrual|f||||t||||||||||2018-06-01 03:43:54.888361|2018-06-01 03:43:54.888361
NCT00383253|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2009-03-20|2006-10-02|2006-10-03|Estimate|||||||2009-03-20|2009-03-23|Estimate|October 2006||2006-10-31|March 2009|2009-03-31|March 2008|Actual|2008-03-31|||||Interventional|||Methods Study to Characterize Early Indicators of Weight Loss in People|A Randomized, Open-Label, Parallel Group, Fixed Energy Deficit Methodology Trial to Characterize Early Efficacy Biomarkers During Treatment of Obesity in Adult, Obese, Male Subjects.|Completed||N/A|57|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 03:43:55.292637|2018-06-01 03:43:55.292637
NCT00382915|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2013-05-24|2006-09-29|2006-10-02|Estimate|||||||2013-05-24|2013-05-27|Estimate|October 2006||2006-10-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Observational|||Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder|Nicotine Intake in Smokers With Schizophrenia|Completed|||276|Actual|Rutgers, The State University of New Jersey|||3||f||||f||||||Samples With DNA|"~     Whole blood for DNA extraction~   "|||2018-06-01 03:44:04.926093|2018-06-01 03:44:04.926093
NCT00383240|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2010-06-30|2009-10-22|2017-03-13|2006-09-29|2006-10-03|Estimate|2011-02-10|2011-03-07|Estimate|2009-10-22|2009-10-26|Estimate|2017-03-13|2017-04-11|Actual|September 2006||2006-09-30|March 2017|2017-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)|A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects With Persistent Asthma Previously Treated With Medium-Dose Inhaled Glucocorticosteroids|Completed||Phase 3|781|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:43:55.386984|2018-06-01 03:43:55.386984
NCT00383227|ClinicalTrials.gov processed this data on May 31, 2018|2006-10-02|||2016-09-15|2006-10-02|2006-10-03|Estimate|||||||2016-09-15|2016-09-16|Estimate|December 1999||1999-12-31|September 2016|2016-09-30|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years|A Phase III, Clinical Trial Comparing the Immunogenicity and Safety of SmithKline Beecham Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B, in Pre-haemodialysis/Haemodialysis Patients (>=15 Years of Age)|Completed||Phase 3|165|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:56.037294|2018-06-01 03:43:56.037294
NCT00383214|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2012-06-06|2006-09-29|2006-10-03|Estimate|||||||2012-06-06|2012-06-07|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)|A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.|Terminated||Phase 3|54|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 03:43:56.12525|2018-06-01 03:43:56.12525
NCT00383201|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2012-08-15|2006-09-28|2006-10-02|Estimate|||||||2012-08-15|2012-08-16|Estimate|March 2005||2005-03-31|September 2006|2006-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles|Long-Term Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles of Soft Contact Lenses|Completed||N/A|80||Alcon Research|||||f||||||||||||||2018-06-01 03:43:56.373502|2018-06-01 03:43:56.373502
NCT00383188|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28||2009-04-06|2009-10-07|2006-09-28|2006-10-02|Estimate||||2009-10-07|2009-10-12|Estimate|2009-10-07|2009-10-12|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|||||Interventional|||An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis|A 12-Week, Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Safety, Pharmacokinetics, And Efficacy Of PH-797804, Administered Orally Once Daily In Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|305|Actual|Pfizer||5|||f||||f||||||||||2018-06-01 03:43:56.499295|2018-06-01 03:43:56.499295
NCT00383175|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2011-02-17|2006-09-29|2006-10-02|Estimate|||||||2011-02-17|2011-02-21|Estimate|August 2006||2006-08-31|February 2011|2011-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Reading Fluency and Accommodative Lag|Reading Fluency and Accommodative Lag|Completed||N/A|72|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 03:43:56.742972|2018-06-01 03:43:56.742972
NCT00383162|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2008-10-03||2016-12-02|2006-09-29|2006-10-02|Estimate|2010-01-21|2010-02-17|Estimate||||2016-12-02|2017-02-02|Estimate|November 2006||2006-11-30|December 2016|2016-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)|A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)|Completed||Phase 3|173|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:56.831818|2018-06-01 03:43:56.831818
NCT00383149|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|2010-09-24||2016-02-09|2006-09-28|2006-10-02|Estimate|2010-09-24|2010-10-19|Estimate||||2016-02-09|2016-03-10|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer|A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer|Completed||Phase 2|58|Actual|R-Pharm|Study CA163-116 was completed; however, the combination tested in this trial failed to meet the primary objective to demonstrate a 6-month survival rate greater than 50% in participants with metastatic pancreatic cancer.|1|||f||||f||||||||||2018-06-01 03:43:57.707674|2018-06-01 03:43:57.707674
NCT00383136|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2008-01-11|2006-09-29|2006-10-02|Estimate|||||||2008-01-11|2008-01-16|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|FATA||FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab|FATA: Comparison Between Tirofiban and Abciximab in Facilitated Angioplasty With Stent Implantation: Randomized Multicentre Study|Completed||Phase 4|692|Actual|University of Bologna||2|||f||||t||||||||||2018-06-01 03:43:58.832866|2018-06-01 03:43:58.832866
NCT00383123|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2008-10-15||2016-11-03|2006-09-29|2006-10-02|Estimate|2008-12-03|2008-12-04|Estimate||||2016-11-03|2016-12-16|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children|A Phase III, Single-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix® (GSK Biologicals') Compared With Fluzone® (Aventis Pasteur/Sanofi) Administered Intramuscularly in Children (6 Months and Older)|Completed||Phase 3|3327|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:43:58.981696|2018-06-01 03:43:58.981696
NCT00383110|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|2014-08-04||2015-04-06|2006-09-28|2006-10-02|Estimate|2014-09-10|2014-09-17|Estimate||||2015-04-06|2015-04-28|Estimate|November 2004||2004-11-30|June 2014|2014-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational||Participants were adults (age 18 or older) with type 2 diabetes. All participants completed questionnaire, however, discrepancies in number of participants analyzed for specific measures is due to some participants choosing not to answer all questions. All participants are included in baseline measure for age.|Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes|Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes|Completed|||300|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 03:43:59.653754|2018-06-01 03:43:59.653754
NCT00383097|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2012-05-22|2006-09-29|2006-10-02|Estimate|||||||2012-05-22|2012-05-24|Estimate|September 2006||2006-09-30|May 2012|2012-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|ALDI||Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma|Administration of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma or Chronic Active EBV Infection (ALDI)|Terminated||Phase 1|6|Actual|Baylor College of Medicine||||The trial was terminated in 2010 due to lack of enrollment.|f||||t||||||||||2018-06-01 03:44:00.092572|2018-06-01 03:44:00.092572
NCT00383084|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2013-01-29||2017-08-17|2006-09-29|2006-10-02|Estimate|2013-06-28|2013-07-01|Estimate||||2017-08-17|2017-09-15|Actual|September 2006|Actual|2006-09-30|August 2017|2017-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Lifestyle Physical Activity to Reduce Pain and Fatigue in Adults With Fibromyalgia|Lifestyle Physical Activity for Fibromyalgia|Completed||N/A|84|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:44:00.21245|2018-06-01 03:44:00.21245
NCT00383071|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2012-04-26||2016-04-21|2006-09-29|2006-10-02|Estimate|2013-04-04|2013-05-27|Estimate||||2016-04-21|2016-05-26|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|March 2010|Actual|2010-03-31||Interventional||All subjects enrolled into the study|Development of Immune Globulin Treatment for Avian Flu|A Phase II Vaccine Dose Finding Pilot Study for Development of an Anti-Influenza A (H5N1) Intravenous Hyper-Immune Globulin|Terminated||Phase 2|126|Actual|National Institutes of Health Clinical Center (CC)||4||"Not possible to achieve original goal of sufficient volume of high titer plasma to manufacturer~   a high titer IVIG for human trials."|f||||t||||||||||2018-06-01 03:44:00.568638|2018-06-01 03:44:00.568638
NCT00383058|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2009-08-31|2006-09-29|2006-10-02|Estimate|||||||2009-08-31|2009-09-01|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|June 2007|Actual|2007-06-30|||||Interventional|||The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial|The Extract of Green Tea on Obese Women: a Randomized Double Blindness Clinical Trial|Completed||Phase 3|100||Taipei City Hospital|||||f||||t||||||||||2018-06-01 03:44:01.242476|2018-06-01 03:44:01.242476
NCT00383045|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2009-02-23|2006-09-28|2006-10-02|Estimate|||||||2009-02-23|2009-02-24|Estimate|April 2003||2003-04-30|February 2009|2009-02-28|August 2007|Actual|2007-08-31|||||Interventional|||HIV Risk Reduction and Drug Abuse Treatment in Malaysia|HIV Risk Reduction and Drug Abuse Treatment in Malaysia|Completed||Phase 2|180||Yale University|||||f||||||||||||||2018-06-01 03:44:01.312057|2018-06-01 03:44:01.312057
NCT00383032|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2007-12-27|2006-09-29|2006-10-02|Estimate|||||||2007-12-27|2008-01-03|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|June 2006||2006-06-30|||||Interventional|||Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction|Randomized Controlled Trial of Mifepristone Versus Laminaria for Cervical Ripening In Midtrimester Induction|Completed||N/A|72||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 03:44:01.386326|2018-06-01 03:44:01.386326
NCT00383019|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2008-10-01||2009-08-03|2006-09-29|2006-10-02|Estimate|2009-04-02|2009-05-27|Estimate||||2009-08-03|2009-08-06|Estimate|November 2006||2006-11-30|August 2009|2009-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).|A 8-Week, Randomized, Double-Masked, Parallel Group, Phase III Study Comparing The Efficacy And Safety Of Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).|Completed||Phase 3|289|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:44:01.439431|2018-06-01 03:44:01.439431
NCT00383006|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2009-06-02|2006-09-29|2006-10-02|Estimate|||||||2009-06-02|2009-06-03|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|May 2008|Anticipated|2008-05-31|||||Interventional|||Affect Management Group for Adult Survivors of Childhood Trauma||Withdrawn||Phase 1|16|Anticipated|University of Zurich||||Difficulties in finding enough study participants.|f||||f||||||||||2018-06-01 03:44:02.736241|2018-06-01 03:44:02.736241
NCT00382993|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2008-11-14||2016-12-02|2006-09-29|2006-10-02|Estimate|2010-04-01|2010-04-20|Estimate||||2016-12-02|2017-02-02|Estimate|December 2006||2006-12-31|December 2016|2016-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)|A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)|Completed||Phase 3|169|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:02.86929|2018-06-01 03:44:02.86929
NCT00382980|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2010-08-26|2006-09-28|2006-10-02|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2006||2006-10-31|September 2008|2008-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Trial of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Immunization With Inactivated, Vero Cell-Culture Derived Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Young Adults|Completed||Phase 1|308|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 03:44:03.632531|2018-06-01 03:44:03.632531
NCT00382967|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2012-05-14||2012-08-29|2006-09-29|2006-10-02|Estimate|2012-07-26|2012-08-29|Estimate||||2012-08-29|2012-09-03|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms|A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting.|Completed||Phase 4|273|Actual|GE Healthcare||2|||f||||t||||||||||2018-06-01 03:44:03.752494|2018-06-01 03:44:03.752494
NCT00382954|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2010-09-28|2006-09-29|2006-10-02|Estimate|||||||2010-09-28|2010-09-29|Estimate|February 2004||2004-02-29|September 2010|2010-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML|A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute Myelogenous Leukemia|Completed||Phase 1|55|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-06-01 03:44:04.150587|2018-06-01 03:44:04.150587
NCT00382941|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2008-12-05|2006-09-29|2006-10-02|Estimate|||||||2008-12-05|2008-12-08|Estimate||||December 2008|2008-12-31||||||||Interventional|||Study of LED Phototherapy for Musculoligamentous Lesions||Completed||N/A|||Hermano Miguel Foundation|||||f||||||||||||||2018-06-01 03:44:04.270149|2018-06-01 03:44:04.270149
NCT00382928|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|2013-12-12||2015-06-22|2006-09-29|2006-10-02|Estimate|2014-05-29|2014-07-01|Estimate||||2015-06-22|2015-07-15|Estimate|October 2006||2006-10-31|June 2015|2015-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Automatic External Defibrillation Monitoring in Cardiac Arrest|Automatic External Defibrillation Monitoring in Cardiac Arrest|Completed||Phase 1|192|Actual|Atlanta Research and Education Foundation||2|||f||||t||||||||||2018-06-01 03:44:04.359909|2018-06-01 03:44:04.359909
NCT00382902|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2012-08-15|2006-09-28|2006-10-02|Estimate|||||||2012-08-15|2012-08-16|Estimate|August 2004||2004-08-31|September 2006|2006-09-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Silicone Hydrogel Soft Contact Lenses|Clinical Evaluation of the Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution Compared to Two Marketed Multi-Purpose Solutions for Care of Silicone Hydrogel Soft Contact Lenses|Completed||N/A|233||Alcon Research|||||f||||||||||||||2018-06-01 03:44:05.035093|2018-06-01 03:44:05.035093
NCT00382889|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2006-09-29|2006-09-29|2006-10-02|Estimate|||||||2006-09-29|2006-10-02|Estimate|August 2002||2002-08-31|September 2006|2006-09-30|September 2004||2004-09-30|||||Interventional|||As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma|Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.|Completed||Phase 3|480||Chiesi Farmaceutici S.p.A.|||||f||||||||||||||2018-06-01 03:44:05.206197|2018-06-01 03:44:05.206197
NCT00382876|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2006-10-16|2006-09-29|2006-10-02|Estimate|||||||2006-10-16|2006-10-17|Estimate|September 2006||2006-09-30|September 2006|2006-09-30||||||||Observational|||Identifying the Relative Change in Ventilation in Newborns With Placement in Car Bed or Car Seat|Identifying the Relative Change in Ventilation With Changes in Infant Sleeping Position|Unknown status|Recruiting||200||University Medical Centre Ljubljana|||||f||||||||||||||2018-06-01 03:44:05.370186|2018-06-01 03:44:05.370186
NCT00382863|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|2011-05-13||2012-06-07|2006-09-28|2006-10-02|Estimate|2012-06-07|2012-07-13|Estimate||||2012-06-07|2012-07-13|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2011|Actual|2011-05-31||Interventional|PEERLESS-HF||Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial|Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial|Terminated||Phase 2/Phase 3|220|Actual|Paracor Medical, Inc|An interim analysis indicated trial futility based on a primary endpoint. Enrollment was suspended in July, 2009. Study was terminated as of April, 2011 due to insufficient resources.|2||Resources unavailable to continue study follow-up.|f||||t||||||||||2018-06-01 03:44:05.541901|2018-06-01 03:44:05.541901
NCT00382850|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2007-04-04|2006-09-29|2006-10-02|Estimate|||||||2007-04-04|2007-04-06|Estimate|November 2005||2005-11-30|April 2007|2007-04-30|November 2010|Anticipated|2010-11-30|||||Interventional|||Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children|Randomized Controlled Trial of Laparoscopic Compared to Open Nissen Fundoplication in Children Younger Than 2 Years of Age|Unknown status|Recruiting|N/A|68||Johns Hopkins University|||||f||||t||||||||||2018-06-01 03:44:07.00519|2018-06-01 03:44:07.00519
NCT00382837|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2014-05-20|2006-09-29|2006-10-02|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2007||2007-01-31|March 2007|2007-03-31||||||||Interventional|||Study of Epratuzumab in Systemic Lupus Erythematosus|A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems|Withdrawn||Phase 3|0|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 03:44:07.126022|2018-06-01 03:44:07.126022
NCT00382824|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2015-08-04|2006-09-28|2006-10-02|Estimate|||||||2015-08-04|2015-08-06|Estimate|September 2006||2006-09-30|August 2015|2015-08-31|January 2015|Actual|2015-01-31|September 2013|Actual|2013-09-30||Interventional|||Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)|Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study|Completed||Phase 2/Phase 3|62|Actual|Lahey Clinic|||||f||||f||||||||||2018-06-01 03:44:07.351386|2018-06-01 03:44:07.351386
NCT00382811|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28||2016-07-12|2016-07-13|2006-09-28|2006-10-02|Estimate||||2016-07-12|2016-07-14|Estimate|2016-07-13|2016-07-18|Estimate|October 2006||2006-10-31|July 2016|2016-07-31|April 2011|Actual|2011-04-30|April 2009|Actual|2009-04-30||Interventional|OVATURE||OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer|Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy|Completed||Phase 3|142|Actual|MEI Pharma, Inc.||2|||f||||||||||||||2018-06-01 03:44:07.498709|2018-06-01 03:44:07.498709
NCT00382798|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2009-04-23|2006-09-28|2006-10-02|Estimate|||||||2009-04-23|2009-04-27|Estimate|October 2006||2006-10-31|April 2009|2009-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|R7128||Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin|A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, & Food Effect of RO5024048 in Healthy Volunteers & in Patients With Chronic HCV Infection|Completed||Phase 1/Phase 2|75|Anticipated|Pharmasset|||||f||||t||||||||||2018-06-01 03:44:07.723732|2018-06-01 03:44:07.723732
NCT00382785|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|2010-09-29||2010-11-23|2006-09-28|2006-10-02|Estimate|2010-11-23|2010-12-21|Estimate||||2010-11-23|2010-12-21|Estimate|September 2006||2006-09-30|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Psychosocial Outcomes in Online Cancer Support Groups|Psychosocial Outcomes in Online Cancer Support Groups|Completed||N/A|51|Actual|Christiana Care Health Services|One limitation was the lack of a control group of women who did not take part in an online or face-to-face support group. The reasons for this are explained above.|2|||f||||f||||||||||2018-06-01 03:44:07.797878|2018-06-01 03:44:07.797878
NCT00382772|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2016-11-03|2006-09-29|2006-10-02|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).|Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-dose Primary Vaccination.|Completed||Phase 3|1200||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:08.125616|2018-06-01 03:44:08.125616
NCT00382759|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-29|||2009-07-31|2006-09-29|2006-10-02|Estimate|||||||2009-07-31|2009-08-03|Estimate|March 2000||2000-03-31|July 2009|2009-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Nonmyeloablative Stem Cell Transplant in Elderly|Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial|Completed||Phase 2/Phase 3|50|Actual|Azienda Ospedaliera San Giovanni Battista|||||f||||f||||||||||2018-06-01 03:44:08.253865|2018-06-01 03:44:08.253865
NCT00382733|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2013-05-10||2013-07-17|2006-09-28|2006-09-29|Estimate|2013-05-24|2013-07-18|Estimate||||2013-07-17|2013-07-22|Estimate|November 2006||2006-11-30|July 2013|2013-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Oral Topotecan to Treat Recurrent or Persistent Solid Tumors|Oral Topotecan, Utilization for a Metronomic Dosing Schedule to Treat Recurrent or Persistent Solid Tumors|Completed||Phase 1/Phase 2|26|Actual|Accelerated Community Oncology Research Network|||||f||||f||||||||||2018-06-01 03:44:08.508068|2018-06-01 03:44:08.508068
NCT00382720|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2011-04-29||2012-12-19|2006-09-28|2006-09-29|Estimate|2011-07-13|2011-08-10|Estimate||||2012-12-19|2013-01-07|Estimate|September 2006||2006-09-30|December 2012|2012-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Docetaxel and Oxaliplatin in Gastric Cancer|A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease|Completed||Phase 2|275|Actual|Sanofi||3|||f||||||||||||||2018-06-01 03:44:09.522383|2018-06-01 03:44:09.522383
NCT00382707|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2011-08-29|2006-09-28|2006-09-29|Estimate|||||||2011-08-29|2011-08-30|Estimate|May 2006||2006-05-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Interventional|||Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.|Transcranial Magnetic Stimulation and Anti-epileptic Effect: Optimization and Evaluation With Electrophysiology.|Completed||N/A|15|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:44:10.488362|2018-06-01 03:44:10.488362
NCT00382694|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2006-09-28|2006-09-28|2006-09-29|Estimate|||||||2006-09-28|2006-09-29|Estimate|May 2005||2005-05-31|September 2006|2006-09-30|December 2006||2006-12-31|||||Interventional|||Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients|Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients: A Randomised, Placebo Controlled, Double Blind Phase II Trial: NMSG #13/03|Unknown status|Active, not recruiting|Phase 2|80||Nordic Myeloma Study Group|||||f||||||||||||||2018-06-01 03:44:10.550768|2018-06-01 03:44:10.550768
NCT00382681|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2012-02-01|2006-09-28|2006-09-29|Estimate|||||||2012-02-01|2012-02-02|Estimate|July 2004||2004-07-31|February 2012|2012-02-29|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Evaluation of an Investigational Multi-Purpose Disinfecting Solution for Care of Soft Contact Lenses|Clinical Evaluation of the Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution Compared to a Marketed Multi-Purpose Solution for Care of Soft Contact Lenses|Completed||N/A|252|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 03:44:10.616849|2018-06-01 03:44:10.616849
NCT00382668|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2011-04-13|2006-09-28|2006-09-29|Estimate|||||||2011-04-13|2011-04-14|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug|Single-Dose Pharmacokinetics of Dasatinib in Subjects With Hepatic Impairment Compared to Healthy Adult Subjects|Completed|||40|Anticipated|Bristol-Myers Squibb|||3||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 03:44:10.69249|2018-06-01 03:44:10.69249
NCT00382655|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2006-09-27|2006-09-27|2006-09-29|Estimate|||||||2006-09-27|2006-09-29|Estimate|February 2003||2003-02-28|September 2006|2006-09-30|August 2005||2005-08-31|||||Interventional|||Prehospital Screening to Prevent Injury and Illness|Prehospital Screening to Prevent Injury and Illness|Completed||N/A|700||University of Rochester|||||f||||||||||||||2018-06-01 03:44:10.76645|2018-06-01 03:44:10.76645
NCT00382642|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2012-02-03|2006-09-28|2006-09-29|Estimate|||||||2012-02-03|2012-02-07|Estimate|June 2006||2006-06-30|February 2012|2012-02-29|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|||Pharmacological Treatment for Alcoholism|Pharmacological Treatment for Alcoholism|Completed||Phase 3|283|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 03:44:10.825909|2018-06-01 03:44:10.825909
NCT00382629|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2008-02-07|2006-09-27|2006-09-29|Estimate|||||||2008-02-07|2008-02-11|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|June 2007||2007-06-30|||||Interventional|||BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis|BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis|Completed||Phase 2|252||Bayhill Therapeutics|||||||||||||||||||2018-06-01 03:44:10.902085|2018-06-01 03:44:10.902085
NCT00382616|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2006-11-06|2006-09-28|2006-09-29|Estimate|||||||2006-11-06|2006-11-07|Estimate|July 2004||2004-07-31|September 2006|2006-09-30|January 2005||2005-01-31|||||Interventional|||Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD|Studying the Effects of Phosphatidylserine Enriched With Omega-3 Fatty Acids on Symptoms of Attention-Deficit/Hyperactivity Disorder in Children|Completed||Phase 2|90||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 03:44:10.953989|2018-06-01 03:44:10.953989
NCT00382603|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2012-08-15|2006-09-28|2006-09-29|Estimate|||||||2012-08-15|2012-08-16|Estimate|August 2004||2004-08-31|September 2006|2006-09-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Soft Contact Lenses in Symptomatic Patients|Clinical Evaluation of the Safety and Efficacy of an Investigational Multi-Purpose Disinfecting Solution Compared to a Marketed Multi-Purpose Solution for Care of Soft Contact Lenses in Symptomatic Patients|Completed||N/A|362||Alcon Research|||||f||||||||||||||2018-06-01 03:44:11.016111|2018-06-01 03:44:11.016111
NCT00382590|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2009-08-13||2012-08-01|2006-09-28|2006-09-29|Estimate|2011-03-11|2011-04-14|Estimate||||2012-08-01|2012-08-07|Estimate|August 2005||2005-08-31|August 2012|2012-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients|A Randomized Phase II Study of the Combination of 5-Azacytidine With Valproic Acid (VPA) Versus Low-Dose Ara-C in Patients With AML/MDS Not Eligible for Other Studies|Completed||Phase 2|11|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:44:11.083316|2018-06-01 03:44:11.083316
NCT00382577|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2017-02-07|2006-09-28|2006-09-29|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2006||2006-10-31|February 2017|2017-02-28|December 2006|Actual|2006-12-31|||||Interventional|||Efficacy and Safety of Itopride vs Placebo in Heartburn|A Randomized, Double-blind, Two Period, Crossover Study to Evaluate the Effects of a Single Dose of Itopride 200 mg on Esophageal and Gastric pH and Reflux in Patients With Heartburn|Completed||Phase 3|48|Actual|Forest Laboratories|||||f||||f||||||||||2018-06-01 03:44:11.367946|2018-06-01 03:44:11.367946
NCT00382564|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2017-10-05|2006-09-28|2006-09-29|Estimate|||||||2017-10-05|2017-10-06|Actual|September 25, 2006||2006-09-25|May 1, 2012|2012-05-01|May 1, 2012||2012-05-01|||||Observational|||Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease|Magnetic Resonance Angiography (MRA) in the Diagnosis of Atherosclerotic Disease Using High Field (3T) MRI Scanners: A Pilot Technical Development Study|Completed|||216|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:44:11.427195|2018-06-01 03:44:11.427195
NCT00382551|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2009-01-29|2006-09-28|2006-09-29|Estimate|||||||2009-01-29|2009-01-30|Estimate|October 2006||2006-10-31|January 2009|2009-01-31||||||||Interventional|||The Effect of Beer, Red Wine and Fruit Juice on Blood Vessel Function in Persons With Cardiovascular Disease|The Effect of Alcohol and Polyphenolic Compounds on Endothelial Function|Completed||Early Phase 1|49|Actual|Aalborg Universitetshospital|||||f||||||||||||||2018-06-01 03:44:11.502497|2018-06-01 03:44:11.502497
NCT00382525|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2017-09-04|2006-09-28|2006-09-29|Estimate|||||||2017-09-04|2017-09-06|Actual|January 2005||2005-01-31|September 2017|2017-09-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Observational|||PANORAMA Observational Study|Phase IV Long Term Observational Study of Patients Implanted With Medtronic CRDM Implantable Cardiac Devices|Completed|||8586|Actual|Medtronic Bakken Research Center|||1||f||||f||||||||||2018-06-01 03:44:11.622263|2018-06-01 03:44:11.622263
NCT00382512|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2006-09-27|2006-09-27|2006-09-29|Estimate|||||||2006-09-27|2006-09-29|Estimate|May 2003||2003-05-31|September 2006|2006-09-30||||||||Interventional|||A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis|A Randomized, Placebo-Controlled, Single-Blind, Parallel-Group Study to Evaluate the Effects of 12 Weekly Subcutaneous Doses of 1.0 mg/kg Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis|Completed||Phase 1|60||Genentech, Inc.|||||||||||||||||||2018-06-01 03:44:11.727598|2018-06-01 03:44:11.727598
NCT00382499|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2009-09-09|2006-09-28|2006-09-29|Estimate|||||||2009-09-09|2009-09-10|Estimate|November 2006||2006-11-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Intraoperative Lidocaine Infusion for Analgesia (ILIA)|A Prospective Evaluation of the Addition of Intraoperative Intravenous Lidocaine Infusion to General Anesthetic in Total Abdominal Hysterectomy.|Completed||N/A|93|Actual|University of Ottawa||1|||f||||f||||||||||2018-06-01 03:44:11.781351|2018-06-01 03:44:11.781351
NCT00382486|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2007-12-13|2006-09-28|2006-09-29|Estimate|||||||2007-12-13|2007-12-17|Estimate|July 2001||2001-07-31|December 2007|2007-12-31|September 2003|Actual|2003-09-30|||||Observational|||Low Dose Irradiation for Small Bowel Transplant|Low Dose Ex-Vivo X-Irradiation of the Allograft and Simultaneous Bone Marrow Cell Infusion to Enhance Intestinal/Multivisceral Allograft Survival|Completed|||100||University of Pittsburgh|||||f||||||||||||||2018-06-01 03:44:11.862265|2018-06-01 03:44:11.862265
NCT00382473|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2014-04-24|2006-09-28|2006-09-29|Estimate|||||||2014-04-24|2014-04-25|Estimate|September 2006||2006-09-30|April 2014|2014-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Mitochondrial Dysfunction in Type 2 Diabetes Mellitus and Capacity for Fat Oxidation During Exercise|Mitochondrial Dysfunction in Type 2 Diabetes Mellitus and Capacity for Fat Oxidation During Exercise|Terminated||N/A|29|Actual|University of Pittsburgh||1||lack of funding|f||||f||||||||||2018-06-01 03:44:11.912155|2018-06-01 03:44:11.912155
NCT00382460|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27||2010-02-15|2011-04-07|2006-09-27|2006-09-29|Estimate||||2010-02-15|2010-02-17|Estimate|2011-04-07|2011-04-15|Estimate|November 2000||2000-11-30|April 2011|2011-04-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)|Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)|Completed||Phase 4|4000||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 03:44:11.990474|2018-06-01 03:44:11.990474
NCT00382447|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2012-12-12|2006-09-27|2006-09-29|Estimate|||||||2012-12-12|2012-12-13|Estimate|October 2006||2006-10-31|December 2012|2012-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Breath Actuated Nebulizer Study Protocol|Breath Actuated Nebulizer Study Protocol|Withdrawn||N/A|0|Actual|Christiana Care Health Services||1||Unable to put forth the human resources for patient enrollment|f||||t||||||||||2018-06-01 03:44:12.122533|2018-06-01 03:44:12.122533
NCT00382434|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2010-01-13|2006-09-27|2006-09-29|Estimate|||||||2010-01-13|2010-01-14|Estimate|August 2005||2005-08-31|January 2010|2010-01-31|December 2006|Actual|2006-12-31|||||Observational|||Emergency Pharmacist Safety Study|The ED Pharmacist as a Safety Measure in Emergency Medicine|Completed|||10224|Actual|University of Rochester|||1||f||||f||||||||||2018-06-01 03:44:12.191977|2018-06-01 03:44:12.191977
NCT00382421|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2006-10-10|2006-09-28|2006-09-29|Estimate|||||||2006-10-10|2006-10-12|Estimate|February 1992||1992-02-29|October 2006|2006-10-31|April 2006||2006-04-30|||||Interventional|||Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia|Swiss Interventional Study on Silent Ischemia (SWISSI 1)|Completed||N/A|||Luzerner Kantonsspital|||||f||||||||||||||2018-06-01 03:44:12.262793|2018-06-01 03:44:12.262793
NCT00382408|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2011-07-28||2017-03-09|2006-09-27|2006-09-29|Estimate|2012-04-24|2012-05-25|Estimate||||2017-03-09|2017-04-10|Actual|September 2006||2006-09-30|March 2017|2017-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001|Completed||Phase 3|4040|Actual|Teva Pharmaceutical Industries|In the past 6 years, Type-7 ADV has only rarely been recovered from recruits with ARD (Russell 2007). Therefore, it may not be possible to directly measure the protective effect of the vaccine against Type-7 ADV in the proposed study.|2|||f||||t||||||||||2018-06-01 03:44:12.378425|2018-06-01 03:44:12.378425
NCT00382395|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2015-09-17|2006-09-27|2006-09-29|Estimate|||||||2015-09-17|2015-09-18|Estimate|November 2005||2005-11-30|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma|Randomized, Controlled, Multicenter Comparative Trial to Evaluate the SOLX Gold Shunt for the Reduction of Intraocular Pressure (IOP) in Glaucomatous Eyes Following Failed Medical and Conventional Surgical Treatments|Suspended||Phase 3|180|Anticipated|SOLX, Inc.||2|||f||||f||||||||||2018-06-01 03:44:13.051876|2018-06-01 03:44:13.051876
NCT00382382|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2015-03-12|2006-09-28|2006-09-29|Estimate|||||||2015-03-12|2015-03-13|Estimate|July 2008||2008-07-31|March 2015|2015-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Diffusion Tensor Imaging in Autism|Diffusion Tensor Imaging in Autism|Withdrawn||N/A|0|Actual|University of Florida||2||"Study was completed but there were no participants. It was completed as a theoretical study.~   Requests for final progress report can be sent to Dr. Liu."|f||||f||||||||||2018-06-01 03:44:13.16543|2018-06-01 03:44:13.16543
NCT00382369|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2017-02-23|2006-09-28|2006-09-29|Estimate|||||||2017-02-23|2017-02-27|Actual|June 1, 2008|Actual|2008-06-01|February 2017|2017-02-28|December 29, 2008|Actual|2008-12-29|November 17, 2008|Actual|2008-11-17||Observational|||Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis|Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis|Completed|||11|Actual|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     DNA prepared from blood~   "|No||2018-06-01 03:44:13.248097|2018-06-01 03:44:13.248097
NCT00382356|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2012-10-18|2006-09-28|2006-09-29|Estimate|||||||2012-10-18|2012-10-19|Estimate|November 2004||2004-11-30|October 2012|2012-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)|A Pilot Investigation of Dutasteride (Avodart) After Failure of Finasteride (Proscar) In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)|Completed||N/A|20|Actual|North Florida/South Georgia Veterans Health System||1|||f||||t||||||||||2018-06-01 03:44:13.310621|2018-06-01 03:44:13.310621
NCT00381121|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-10-24|2006-09-26|2006-09-27|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2006||2006-09-30|October 2017|2017-10-31|August 2026|Anticipated|2026-08-31|August 2026|Anticipated|2026-08-31||Observational|||"University of Michigan Nephrology Research BioBank"|"Michigan Nephrology Research BioBank for Molecular Analysis of Renal Disease Nephrology Research BioBank"|Recruiting|||420|Anticipated|University of Michigan|||1||f||||f||||||Samples With DNA|"~     Tissue, blood, urine~   "|||2018-06-01 03:44:39.083365|2018-06-01 03:44:39.083365
NCT00382343|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2015-04-27|2006-09-28|2006-09-29|Estimate|||||||2015-04-27|2015-04-28|Estimate|November 1999||1999-11-30|April 2015|2015-04-30|March 2007|Actual|2007-03-31|March 2003|Actual|2003-03-31||Interventional|||A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux|Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux.|Completed||Phase 4|96|Actual|IRCCS Burlo Garofolo||2|||f||||f||||||||||2018-06-01 03:44:13.396689|2018-06-01 03:44:13.396689
NCT00382330|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2013-09-05|2006-09-27|2006-09-29|Estimate|||||||2013-09-05|2013-09-06|Estimate||||April 2013|2013-04-30||||||||Interventional|||Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.|Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.|Withdrawn||N/A|0|Actual|Rutgers, The State University of New Jersey|||||f||||||||||||||2018-06-01 03:44:13.494481|2018-06-01 03:44:13.494481
NCT00382317|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2008-11-25|2006-09-28|2006-09-29|Estimate|||||||2008-11-25|2008-11-26|Estimate|August 2006||2006-08-31|November 2008|2008-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal Angiography|A Clinical Study of Iobitridol in Multislice CT Abdominal Angiography Indications|Completed||Phase 4|||Guerbet|||||f||||f||||||||||2018-06-01 03:44:13.565456|2018-06-01 03:44:13.565456
NCT00382304|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2015-03-17|2006-09-27|2006-09-29|Estimate|||||||2015-03-17|2015-03-19|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|September 2007|Actual|2007-09-30|||||Interventional|||A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea|A Study of the Pharmacokinetics of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea|Completed||Phase 2|24|Anticipated|Sanofi|||||||||||||||||||2018-06-01 03:44:13.624993|2018-06-01 03:44:13.624993
NCT00382291|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|2012-12-14||2013-02-06|2006-09-28|2006-09-29|Estimate|2013-02-06|2013-03-12|Estimate||||2013-02-06|2013-03-12|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder|SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder|Completed||Phase 4|56|Actual|University of Florida|Temporary study suspension led to smaller number of subjects enrolled than initially planned and resulted in smaller number of subjects analyzed, reducing power.|3|||f||||t||||||||||2018-06-01 03:44:13.714732|2018-06-01 03:44:13.714732
NCT00382278|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2008-04-02|2006-09-28|2006-09-29|Estimate|||||||2008-04-02|2008-04-03|Estimate|November 2005||2005-11-30|February 2008|2008-02-29|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Safety Study of Autologous Stem Cell in Liver Cirrhosis|Phase 1/2 Study of Autologous Bone Marrow Derived Mononuclear Cells in Liver Cirrhosis|Terminated||Phase 1/Phase 2|15|Anticipated|Universidade Federal do Rio de Janeiro||||"Other authors showed the same metabolic effect may be obtained when BMMC are delivered~   peripherally, with lower risk and cost than through hepatic artery."|f||||t||||||||||2018-06-01 03:44:13.975034|2018-06-01 03:44:13.975034
NCT00382265|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-28|||2017-03-30|2006-09-28|2006-09-29|Estimate|||||||2017-03-30|2017-04-04|Actual|January 2008||2008-01-31|March 2017|2017-03-31||||October 1, 2016|Actual|2016-10-01||Interventional|STONE||Tamsulosin for Urolithiasis in the Emergency Dept|Study of Tamsulosin for Urolithiasis in the Emergency Department|Completed||Phase 4|500|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 03:44:14.03225|2018-06-01 03:44:14.03225
NCT00382252|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2011-05-12|2006-09-26|2006-09-28|Estimate|||||||2011-05-12|2011-05-13|Estimate|September 2005||2005-09-30|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||PET Scan and CT Scan in Evaluating Response in Patients Undergoing Radiofrequency Ablation for Lung Metastases|Study of Positron Emission Tomography/CT Scan for Response Evaluation After Radiofrequency Ablation in Patients With Lung Metastases|Completed||N/A|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:44:14.104867|2018-06-01 03:44:14.104867
NCT00382239|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2015-02-20|2006-09-26|2006-09-28|Estimate|||||||2015-02-20|2015-02-23|Estimate|September 2006||2006-09-30|January 2015|2015-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes|A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled|Completed||Phase 2|153|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 03:44:14.163174|2018-06-01 03:44:14.163174
NCT00382226|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2016-11-17|2006-09-27|2006-09-28|Estimate|||||||2016-11-17|2016-11-18|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy|IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy|Completed||Phase 4|195|Anticipated|Alcon Research|||||f||||||||||||||2018-06-01 03:44:14.248482|2018-06-01 03:44:14.248482
NCT00382213|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2006-09-27|2006-09-27|2006-09-28|Estimate|||||||2006-09-27|2006-09-28|Estimate|June 2000||2000-06-30|September 2006|2006-09-30|December 2004||2004-12-31|||||Interventional|||A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis|A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis|Completed||Phase 3|210||Daiichi Sankyo, Inc.|||||||||||||||||||2018-06-01 03:44:14.374794|2018-06-01 03:44:14.374794
NCT00382200|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-08-03|2006-09-26|2006-09-28|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2006||2006-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes|Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:44:14.429046|2018-06-01 03:44:14.429046
NCT00382187|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2016-11-30|2006-09-27|2006-09-28|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2006||2006-11-30|February 2012|2012-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults|A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two Surface Antigen Adjuvanted With MF59C.1 Influenza Vaccines Containing 7.5 Micrograms or 15 Micrograms of A/H5N1 Influenza Antigen and of a Non-adjuvanted Influenza Vaccine Containing 15 Micrograms of A/H5N1 Influenza Antigen, in Adults|Completed||Phase 2|40|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:44:14.506302|2018-06-01 03:44:14.506302
NCT00356512|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2017-06-30|2006-07-25|2006-07-26|Estimate|||||||2017-06-30|2017-07-02|Actual|July 19, 2006||2006-07-19|September 2, 2009|2009-09-02||||September 2, 2009|Actual|2009-09-02||Observational|||Physiologic Regulation of FGF-23|Physiologic Regulation of FGF-23|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:46.220118|2018-06-01 03:52:46.220118
NCT00382174|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2009-12-29||2010-01-06|2006-09-26|2006-09-28|Estimate|2010-01-06|2010-02-01|Estimate||||2010-01-06|2010-02-01|Estimate|May 2006||2006-05-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Thymosin Beta 4 in Patients With Pressure Ulcers|A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Pressure Ulcers|Completed||Phase 2|72|Actual|RegeneRx Biopharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 03:44:14.593988|2018-06-01 03:44:14.593988
NCT00382161|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2009-02-12|2006-09-27|2006-09-28|Estimate|||||||2009-02-12|2009-02-13|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|December 2007|Anticipated|2007-12-31|||||Interventional|||Improvement of Erectile Dysfunction by Fluvastatin in Patients With Cardiovascular Risk Factors|Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction|Withdrawn||Phase 3|20|Anticipated|University Hospital, Saarland||||not enough patients meeting inclusion criteria|f||||t||||||||||2018-06-01 03:44:15.055158|2018-06-01 03:44:15.055158
NCT00382148|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2009-11-05||2009-11-12|2006-09-26|2006-09-28|Estimate|2009-11-12|2009-12-15|Estimate||||2009-11-12|2009-12-15|Estimate|November 2006||2006-11-30|November 2009|2009-11-30||||June 2008|Actual|2008-06-30||Interventional|||A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g|A Phase IIb, Open-Label Study of Xolair (Omalizumab) in Peanut-Allergic Subjects Randomized to Study Drug in Study Q2788g (TOPS)|Completed||Phase 2|10|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:44:15.136098|2018-06-01 03:44:15.136098
NCT00382135|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2007-10-23|2006-09-27|2006-09-28|Estimate|||||||2007-10-23|2007-10-25|Estimate|November 2003||2003-11-30|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|||A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg|An Evaluation of Semen Characteristics After 40 Weeks Daily Dosing With 20 mg Tadalafil|Completed||Phase 4|282|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:44:15.459323|2018-06-01 03:44:15.459323
NCT00382122|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2012-05-25|2006-09-27|2006-09-28|Estimate|||||||2012-05-25|2012-05-28|Estimate|September 2006||2006-09-30|September 2007|2007-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Prevalence of Ocular Surface Disease in Glaucoma Patients|Prevalence of Ocular Surface Disease in Glaucoma Patients|Completed|||101|Actual|Alcon Research|||||f||||||||||||||2018-06-01 03:44:16.457914|2018-06-01 03:44:16.457914
NCT00382109|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2015-10-06||2016-12-16|2006-09-26|2006-09-28|Estimate|2016-12-16|2017-02-09|Estimate||||2016-12-16|2017-02-09|Estimate|March 2007||2007-03-31|September 2016|2016-09-30||||May 2011|Actual|2011-05-31||Interventional|||Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission|A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 3|146|Actual|Children's Oncology Group|Outcome Measures 6, 7, 8 and 9 are exploring in nature and did not investigate the actual relapse rates of the 2 treatment regiments.|2|||f||||t||||||||||2018-06-01 03:44:16.550497|2018-06-01 03:44:16.550497
NCT00382096|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26||2013-01-02|2017-05-15|2006-09-26|2006-09-28|Estimate||||2013-01-02|2013-01-04|Estimate|2017-05-15|2017-05-17|Actual|September 2006||2006-09-30|May 2017|2017-05-31|June 3, 2008|Actual|2008-06-03|June 3, 2008|Actual|2008-06-03||Interventional|||Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes|A Randomized, Double-blind, Active-controlled, Multicenter Study to Compare the Effect of 24 Weeks Treatment With a Fixed Combination Therapy of Vildagliptin and Metformin to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|1179|Actual|Novartis||4|||f||||||||||||||2018-06-01 03:44:17.245071|2018-06-01 03:44:17.245071
NCT00382083|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2006-09-27|2006-09-27|2006-09-28|Estimate|||||||2006-09-27|2006-09-28|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|June 2006||2006-06-30|||||Interventional|||Premedication to Reduce Discomfort With Screening Mammography||Completed||Phase 4|||Mountain States Tumor and Medical Research Institute|||||f||||||||||||||2018-06-01 03:44:17.320223|2018-06-01 03:44:17.320223
NCT00382070|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-05-04|2006-09-26|2006-09-28|Estimate|||||||2017-05-04|2017-05-05|Actual|August 2006||2006-08-31|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|January 2016|Actual|2016-01-31||Interventional|||Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer|A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|Active, not recruiting||Phase 3|3966|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 03:44:17.572017|2018-06-01 03:44:17.572017
NCT00382057|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2008-12-04|2006-09-26|2006-09-28|Estimate|||||||2008-12-04|2008-12-05|Estimate|May 2006||2006-05-31|November 2008|2008-11-30|March 2011|Anticipated|2011-03-31|||||Interventional|||Testosterone Effects on Men With the Metabolic Syndrome|Effect of Increasing Testosterone Levels on Insulin Sensitivity in Men With the Metabolic Syndrome|Withdrawn||Phase 2|72|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||||||||||||||||2018-06-01 03:44:19.055409|2018-06-01 03:44:19.055409
NCT00382044|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2008-05-22|2006-09-27|2006-09-28|Estimate|||||||2008-05-22|2008-05-23|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Observational|||Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients|Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience|Completed|||150|Anticipated|Sir Charles Gairdner Hospital|||||f||||f||||||||||2018-06-01 03:44:19.119676|2018-06-01 03:44:19.119676
NCT00382031|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2013-05-28||2013-08-09|2006-09-27|2006-09-28|Estimate|2013-08-09|2013-10-15|Estimate||||2013-08-09|2013-10-15|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|August 2011|Actual|2011-08-31|December 2009|Actual|2009-12-31||Interventional||The full analysis set (FAS) was based on the intent-to-treat principle and thus comprised all randomized patients. The FAS was used for evaluation of all efficacy endpoints and was the primary analysis population.|Zalutumumab in Patients With Non-curable Head and Neck Cancer|An Open-Labeled Randomized Parallel Group Trial of Zalutumumab, a Human Monoclonal Anti-EGFr Antibody, in Combination With Best Supportive Care (BSC) vs BSC, in Pts With Non-Curable SCCHN Who Have Failed Standard Platinum-Based Chemotherapy|Completed||Phase 3|286|Actual|Genmab||2|||f||||t||||||||||2018-06-01 03:44:19.222502|2018-06-01 03:44:19.222502
NCT00381108|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2010-01-04|2006-09-26|2006-09-27|Estimate|||||||2010-01-04|2010-01-06|Estimate|September 2005||2005-09-30|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Study of the Effects of Pomegranate Tablets on Enlarged Prostates|A Randomized, Double Blinded, Controlled Clinical Trial of Pomegranate Tablets vs Placebo: Effects on Symptoms of Benign Prostatic Hyperplasia|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-06-01 03:44:39.151948|2018-06-01 03:44:39.151948
NCT00382018|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2016-12-16||2017-10-03|2006-09-26|2006-09-28|Estimate|2017-02-15|2017-04-04|Actual||||2017-10-03|2017-11-06|Actual|October 2006||2006-10-31|October 2017|2017-10-31|July 11, 2017|Actual|2017-07-11|December 2015|Actual|2015-12-31||Interventional|||S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo|A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment|Completed||Phase 3|624|Actual|Southwest Oncology Group||4|||f||||t||||||||||2018-06-01 03:44:19.9635|2018-06-01 03:44:19.9635
NCT00381992|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-11-03|2006-09-27|2006-09-28|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2005||2005-09-30|December 2014|2014-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Risk Assessment of Long-Haul Truck Drivers|Risk Assessment of Long-Haul Truck Drivers|Completed|||294|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 03:44:21.524771|2018-06-01 03:44:21.524771
NCT00381979|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2015-10-21|2006-09-27|2006-09-28|Estimate|||||||2015-10-21|2015-10-22|Estimate|January 2004||2004-01-31|September 2015|2015-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Supportive Expressive Therapy for Depressed and Anxious Adolescents|Supportive Expressive Therapy for Depressed and Anxious Adolescents|Completed||N/A|20|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||||2018-06-01 03:44:21.581251|2018-06-01 03:44:21.581251
NCT00381966|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2012-11-15|2006-09-27|2006-09-28|Estimate|||||||2012-11-15|2012-11-16|Estimate|June 2006||2006-06-30|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|J0511||Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy|A Pilot Study of Robotic Template Guidance for Needle Placement in Transperineal Prostate Brachytherapy|Completed||N/A|5|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:44:21.641811|2018-06-01 03:44:21.641811
NCT00381953|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2015-03-12|2006-09-27|2006-09-28|Estimate|||||||2015-03-12|2015-03-13|Estimate|February 2003||2003-02-28|March 2015|2015-03-31|July 2006|Actual|2006-07-31|April 2006|Actual|2006-04-30||Interventional|||High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV|A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV|Completed||Phase 3|33|Actual|Foundation for Liver Research||3|||f||||f||||||||||2018-06-01 03:44:21.714671|2018-06-01 03:44:21.714671
NCT00381940|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2014-01-08||2014-06-18|2006-09-26|2006-09-28|Estimate|2014-03-05|2014-04-10|Estimate||||2014-06-18|2014-06-20|Estimate|January 2007||2007-01-31|June 2014|2014-06-30||||June 2008|Actual|2008-06-30||Interventional|||Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy|A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease|Completed||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:44:21.781729|2018-06-01 03:44:21.781729
NCT00381927|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2007-09-19|2006-09-27|2006-09-28|Estimate|||||||2007-09-19|2007-09-20|Estimate|August 2003||2003-08-31|September 2006|2006-09-30|April 2006||2006-04-30|||||Observational|||Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development|Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development|Completed|||80||Baystate Medical Center|||||f||||||||||||||2018-06-01 03:44:22.129031|2018-06-01 03:44:22.129031
NCT00381914|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2012-03-01|2006-09-27|2006-09-28|Estimate|||||||2012-03-01|2012-03-02|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants|Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants|Completed||Phase 2|132|Actual|McGill University||3|||f||||f||||||||||2018-06-01 03:44:22.183578|2018-06-01 03:44:22.183578
NCT00381901|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2011-05-12|2006-09-26|2006-09-28|Estimate|||||||2011-05-12|2011-05-13|Estimate|May 2006||2006-05-31|July 2009|2009-07-31||||May 2011|Actual|2011-05-31||Interventional|||Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery|Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE]|Completed||Phase 3|3400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:44:22.269425|2018-06-01 03:44:22.269425
NCT00381888|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2009-10-29||2017-12-03|2006-09-26|2006-09-28|Estimate|2009-12-29|2010-01-27|Estimate||||2017-12-03|2017-12-28|Actual|January 2007||2007-01-31|December 2017|2017-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer|Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial|Completed||Phase 2|44|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 03:44:22.482375|2018-06-01 03:44:22.482375
NCT00381875|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2012-05-01|2006-09-26|2006-09-28|Estimate|||||||2012-05-01|2012-05-02|Estimate|July 2006||2006-07-31|May 2012|2012-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV|A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance|Completed||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 03:44:22.693065|2018-06-01 03:44:22.693065
NCT00381862|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2011-06-10||2017-05-07|2006-09-26|2006-09-28|Estimate|2011-07-13|2011-08-10|Estimate||||2017-05-07|2017-06-12|Actual|June 2006||2006-06-30|May 2017|2017-05-31|July 2008|Actual|2008-07-31|March 2008|Actual|2008-03-31||Interventional|||Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX|A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX|Completed||Phase 2|54|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 03:44:22.763985|2018-06-01 03:44:22.763985
NCT00381849|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2011-04-12||2016-01-04|2006-09-27|2006-09-28|Estimate|2012-06-12|2012-08-06|Estimate||||2016-01-04|2016-02-04|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|June 2010|Actual|2010-06-30|September 2009|Actual|2009-09-30||Interventional|||Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones|Cystone for Treatment of Nephrolithiasis|Completed||Phase 1/Phase 2|20|Actual|Mayo Clinic|There were no serious adverse events and no adverse events. Power of the study was diminished by failure of patients to return all required 24 hour urine samples. The botanical authenticity of Cystone was not documented.|3|||f||||f||||||||||2018-06-01 03:44:22.997632|2018-06-01 03:44:22.997632
NCT00380926|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2006-09-28|2006-09-25|2006-09-27|Estimate|||||||2006-09-28|2006-09-29|Estimate|April 2004||2004-04-30|September 2006|2006-09-30|November 2004||2004-11-30|||||Interventional|||Fish Oil and Asthma in House Dust Mite Allergy|Anti-Inflammatory Effect of Polyunsaturated Fatty Acids in Allergic Asthma After Allergen Challenge|Completed||Phase 2/Phase 3|23||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 03:44:41.59896|2018-06-01 03:44:41.59896
NCT00381836|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2015-12-03|2006-09-27|2006-09-28|Estimate|||||||2015-12-03|2015-12-04|Estimate|October 2006||2006-10-31|February 2008|2008-02-29|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate Cancer|A Randomized, Multi-center Study to Assess the Effect of Darbepoetin Alfa (Aranesp®) for the Treatment of Anemia in Patients With Advanced Hormone Independent Prostate Cancer and Anaemia|Terminated||Phase 2/Phase 3|140|Anticipated|University of Aarhus||||Terminated by sponsor due to general risk that aranesp caused tumor progression|f||||f||||||||||2018-06-01 03:44:23.404797|2018-06-01 03:44:23.404797
NCT00381823|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2006-09-28|2006-09-27|2006-09-28|Estimate|||||||2006-09-28|2006-09-29|Estimate|July 2001||2001-07-31|September 2006|2006-09-30|August 2004||2004-08-31|||||Interventional|||Healthy Outcomes of Pregnancy Education|Intervention for Risk Factors in Pregnant Women in Washington, D.C. (DC-HOPE)|Unknown status|Active, not recruiting|Phase 2|1750||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:44:23.485238|2018-06-01 03:44:23.485238
NCT00381810|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2009-11-11||2017-07-05|2006-09-26|2006-09-28|Estimate|2009-11-12|2009-12-18|Estimate||||2017-07-05|2017-08-01|Actual|June 22, 2006|Actual|2006-06-22|June 2017|2017-06-30|February 29, 2012|Actual|2012-02-29|July 31, 2008|Actual|2008-07-31||Interventional|VOYAGER||A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus|An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g|Terminated||Phase 3|31|Actual|Genentech, Inc.|Since study U2971g did not demonstrate efficacy, a decision was made not to evaluate efficacy in this study and only safety results were evaluated.|1||"During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended~   that enrollment in this extension trial be terminated."|f||||||||||||||2018-06-01 03:44:23.563786|2018-06-01 03:44:23.563786
NCT00381797|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2012-01-17||2017-10-23|2006-09-26|2006-09-28|Estimate|2013-01-14|2013-01-15|Estimate||||2017-10-23|2017-11-28|Actual|August 2006||2006-08-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma|Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas|Completed||Phase 2|97|Actual|National Cancer Institute (NCI)|Neuroimaging data capturing Volume Enhancing and Perfusion Ratio was so limited to run any statistical model. Similarly, due to limited data, some PK and Biology objectives were not able to be addressed.|1|||f||||t||||||||||2018-06-01 03:44:23.985487|2018-06-01 03:44:23.985487
NCT00381784|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-03-02|2006-09-27|2006-09-28|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2006||2006-07-31|March 2016|2016-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||C2P - Phase III: MPowerment and Community Promise|Connect-To-Protect® Phase III: Local Evaluation of Community Promise Connect-To-Protect® Phase III: Local Evaluation of Mpowerment|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 03:44:24.919728|2018-06-01 03:44:24.919728
NCT00381771|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2010-07-27|2006-09-27|2006-09-28|Estimate|||||||2010-07-27|2010-07-28|Estimate|February 2006||2006-02-28|July 2010|2010-07-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Observational|||Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus|Prevalence of Salivary Hypofunction in Patients With Globus Pharyngeus|Completed|||340|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-06-01 03:44:25.004375|2018-06-01 03:44:25.004375
NCT00381758|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2008-03-07|2006-09-27|2006-09-28|Estimate|||||||2008-03-07|2008-03-10|Estimate|May 2002||2002-05-31|March 2008|2008-03-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||The COMACS Study: A Comparison of Methylphenidates in an Analog Classroom Setting|A Randomized, Double-Blind Comparison of the Time Course of Response to Two Extended-Release Oral Delivery Systems for Methylphenidate in Pediatric Patients With Attention Deficit Hyperactivity Disorder in an Analog Classroom Setting: The CoMACS Study|Completed||Phase 4|184||UCB Pharma|||||f||||||||||||||2018-06-01 03:44:25.074195|2018-06-01 03:44:25.074195
NCT00381732|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2007-11-06|2006-09-27|2006-09-28|Estimate|||||||2007-11-06|2007-11-07|Estimate|October 2003||2003-10-31|November 2007|2007-11-30|June 2006|Actual|2006-06-30|||||Interventional|||A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction|A Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5mg and 5mg) Administered Once Daily to Men With Erectile Dysfunction|Completed||Phase 3|280|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 03:44:25.141123|2018-06-01 03:44:25.141123
NCT00381719|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2008-01-03|2006-09-26|2006-09-28|Estimate|||||||2008-01-03|2008-01-07|Estimate|October 2006||2006-10-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy||Completed||Phase 2|330|Actual|Allergan||4|||f||||||||||||||2018-06-01 03:44:25.211416|2018-06-01 03:44:25.211416
NCT00381706|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2017-01-26||2017-01-26|2006-09-26|2006-09-28|Estimate|2017-01-26|2017-03-15|Actual||||2017-01-26|2017-03-15|Actual|September 2006||2006-09-30|January 2017|2017-01-31||||April 2011|Actual|2011-04-30||Interventional|||Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer|Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer|Completed||Phase 2|245|Actual|Alliance for Clinical Trials in Oncology||3|||f||||f||||||||||2018-06-01 03:44:25.373594|2018-06-01 03:44:25.373594
NCT00381693|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2010-11-09||2011-04-19|2006-09-26|2006-09-28|Estimate|2010-12-22|2011-01-24|Estimate||||2011-04-19|2011-04-21|Estimate|August 2006||2006-08-31|April 2011|2011-04-30|April 2009|Actual|2009-04-30|March 2008|Actual|2008-03-31||Interventional|||Azacitidine in Treating Patients With Myelofibrosis|Phase II Study of Azacitidine in Myelofibrosis|Terminated||Phase 2|10|Actual|Mayo Clinic||||Due to lack of accrual and trial has demonstrated too little clinical benefit|f||||t||||||||||2018-06-01 03:44:28.110537|2018-06-01 03:44:28.110537
NCT00381680|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2016-12-16||2017-04-05|2006-09-26|2006-09-28|Estimate|2017-04-05|2017-05-12|Actual||||2017-04-05|2017-05-12|Actual|March 2007||2007-03-31|December 2016|2016-12-31||||March 2016|Actual|2016-03-31||Interventional|||Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia|Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies|Completed||Phase 3|275|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 03:44:28.463646|2018-06-01 03:44:28.463646
NCT00380185|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2015-05-27|2006-09-22|2006-09-25|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2004||2004-04-30|May 2015|2015-05-31||||July 2008|Actual|2008-07-31||Observational|GenePAD||Understanding the Genetic Basis of Atherosclerosis and Peripheral Arterial Disease|The Genetic Determinants of Peripheral Arterial Disease|Completed|||1789|Actual|Stanford University|||3||f||||t||||||Samples With DNA|"~     Serum, Plasma, White Cells~   "|||2018-06-01 03:44:52.216772|2018-06-01 03:44:52.216772
NCT00381667|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2016-10-26|2006-09-26|2006-09-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study to Assess GW642444 in Asthma Patients|A Randomised, Double-blind, Placebo-controlled, Dose Ascending, Five-way Crossover Study, to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of a Single Administration of Three Inhaled Doses (25, 100 and 400 Âµg) of GW642444M|Completed||Phase 2|14|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:29.601878|2018-06-01 03:44:29.601878
NCT00381654|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2011-09-30|2006-09-27|2006-09-28|Estimate|||||||2011-09-30|2011-10-04|Estimate|October 2006||2006-10-31|September 2011|2011-09-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies|A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies|Terminated||Phase 1|27|Actual|AVEO Pharmaceuticals, Inc.||1||Study did not meet pre-specified objectives.|f||||f||||||||||2018-06-01 03:44:29.69784|2018-06-01 03:44:29.69784
NCT00381641|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2017-08-18||2017-08-18|2006-09-26|2006-09-28|Estimate|2017-08-18|2017-09-15|Actual||||2017-08-18|2017-09-15|Actual|August 2006||2006-08-31|August 2017|2017-08-31||||December 2016|Actual|2016-12-31||Interventional|||Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery|Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers|Active, not recruiting||Phase 2|63|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 03:44:29.785229|2018-06-01 03:44:29.785229
NCT00381628|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2016-12-07||2017-02-10|2006-09-27|2006-09-28|Estimate|2017-02-10|2017-02-15|Actual||||2017-02-10|2017-02-15|Actual|September 2006||2006-09-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations|Use of Nasal Epithelial Cells and Blood Lymphocytes to Identify Markers for Cystic Fibrosis and Cystic Fibrosis Pulmonary Exacerbations|Completed|||59|Actual|University Hospitals Cleveland Medical Center|||4||f||||f|f|f||||||||2018-06-01 03:44:30.525241|2018-06-01 03:44:30.525241
NCT00381615|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2015-02-04||2015-09-11|2006-09-27|2006-09-28|Estimate|2015-09-11|2015-10-09|Estimate||||2015-09-11|2015-10-09|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|August 2008|Actual|2008-08-31|July 2007|Actual|2007-07-31||Interventional||Analysis was performed on all enrolled subjects.|Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study|A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine±OMV, When Administered to Healthy Infants at 2, 4, 6 and/or 12 Months of Age|Completed||Phase 2|147|Actual|Novartis||4|||f||||f||||||||||2018-06-01 03:44:30.886691|2018-06-01 03:44:30.886691
NCT00381602|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26||2011-03-01|2011-03-25|2006-09-27|2006-09-28|Estimate||||2011-03-01|2011-03-16|Estimate|2011-03-25|2011-04-04|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis||Terminated||Phase 2|3|Actual|QLT Inc.||||Lack of enrolment|||||||||||||||2018-06-01 03:44:32.889956|2018-06-01 03:44:32.889956
NCT00381589|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2009-02-11|2006-09-27|2006-09-28|Estimate|||||||2009-02-11|2009-02-12|Estimate|October 2006||2006-10-31|February 2009|2009-02-28||||June 2008|Actual|2008-06-30||Interventional|||Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide|Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide|Completed||N/A|25|Anticipated|Centre for Addiction and Mental Health||1|||f||||f||||||||||2018-06-01 03:44:32.955618|2018-06-01 03:44:32.955618
NCT00381576|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2008-08-11|2006-09-27|2006-09-28|Estimate|||||||2008-08-11|2008-08-12|Estimate|November 2006||2006-11-30|August 2008|2008-08-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Multiple Sclerosis and Heavy Progressive Resistance Training|Multiple Sclerosis and Muscle Function - Effects of Heavy Progressive Resistance Training|Completed||N/A|36|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-06-01 03:44:33.055021|2018-06-01 03:44:33.055021
NCT00381563|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|2011-10-13||2017-05-30|2006-09-27|2006-09-28|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|December 2006||2006-12-31|May 2017|2017-05-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Knee Bracing for People With Patellofemoral Osteoarthritis|Bracing in Patellofemoral Osteoarthritis: A Clinical Trial|Completed||N/A|80|Actual|Boston University|There was no control group without a brace for comparison to the intervention because of concerns about unblinding.|2|||f||||t|f|t|f|f||||No||2018-06-01 03:44:33.13952|2018-06-01 03:44:33.13952
NCT00381550|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2014-04-23||2014-12-16|2006-09-26|2006-09-28|Estimate|2014-04-23|2014-05-21|Estimate||||2014-12-16|2015-01-06|Estimate|August 2006||2006-08-31|June 2014|2014-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia|Phase II Trial of Triapine (NSC #663249, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbone) Plus Fludarabine (NSC #312887, Fludarabine Monophosphate) in Adults With Aggressive Myeloproliferative Disorders (MPDs) Including Chronic Myelomonocytic Leukemia (CMML) and Chronic Myelogenous Leukemia in Accelerated Phase (CML-AP) or Blast Crisis (CML-BC)|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:44:34.172872|2018-06-01 03:44:34.172872
NCT00381537|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2006-12-22|2006-09-27|2006-09-28|Estimate|||||||2006-12-22|2006-12-25|Estimate||||December 2006|2006-12-31||||||||Interventional|||Prediction of Childhood Epilepsy Outcome in Bangladesh||Completed||N/A|92||Institute of Child Health|||||f||||||||||||||2018-06-01 03:44:34.356731|2018-06-01 03:44:34.356731
NCT00381524|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-06-08|2006-09-27|2006-09-28|Estimate|||||||2017-06-08|2017-06-12|Actual|June 2004||2004-06-30|November 2009|2009-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||HIV Prevention in the Primary Care Setting|Special Projects of National Significance|Completed||N/A|234|Actual|University of Alabama at Birmingham|||||f||||||||||||No||2018-06-01 03:44:34.412467|2018-06-01 03:44:34.412467
NCT00381511|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-27|||2006-10-16|2006-09-27|2006-09-28|Estimate|||||||2006-10-16|2006-10-17|Estimate|January 1999||1999-01-31|September 2006|2006-09-30|April 2004||2004-04-30|||||Interventional|||Deferment of Imaging for Pulmonary Embolism|Objective Assessment of Pulmonary Embolism Can be Deferred Without Increased Risk|Completed||Phase 4|300||Azienda Ospedaliera Universitaria Policlinico|||||f||||||||||||||2018-06-01 03:44:34.475345|2018-06-01 03:44:34.475345
NCT00379652|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2015-05-19|2006-09-20|2006-09-22|Estimate|||||||2015-05-19|2015-05-20|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|CHAMPP||Community Partnership to Examine Racial and Ethnic Differences in Health Care for Hypertension and Diabetes|Community, Health Center, and Academic Medicine Partnership Project (CHAMPP)|Completed||N/A|1204|Anticipated|Harvard Medical School||4|||f||||t||||||||||2018-06-01 03:45:17.187408|2018-06-01 03:45:17.187408
NCT00381485|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2010-06-30|2009-04-13|2017-03-22|2006-09-26|2006-09-27|Estimate|2011-02-10|2011-03-07|Estimate|2009-10-16|2009-10-20|Estimate|2017-03-22|2017-04-18|Actual|July 1, 2006|Actual|2006-07-01|March 2017|2017-03-31|January 1, 2008|Actual|2008-01-01|January 1, 2008|Actual|2008-01-01||Interventional|||Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)|A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously Treated With High-Dose Inhaled Glucocorticosteroids|Completed||Phase 3|834|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:44:34.562199|2018-06-01 03:44:34.562199
NCT00381472|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-03-21|2006-09-26|2006-09-27|Estimate|||||||2017-03-21|2017-03-23|Actual|June 2003||2003-06-30|March 2017|2017-03-31|December 2004|Actual|2004-12-31|||||Interventional|||Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole CR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-dopa|Completed||Phase 3|393||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:35.073662|2018-06-01 03:44:35.073662
NCT00381446|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2007-09-26|2006-09-25|2006-09-27|Estimate|||||||2007-09-26|2007-09-27|Estimate|July 2005||2005-07-31|September 2007|2007-09-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Evaluation of Corneal Staining With Various Contact Lens/Solution Combinations|Evaluation of Corneal Staining With Market Contact Lens/Solution Combinations|Unknown status|Recruiting|N/A|200|Anticipated|Andrasko, Gary, OD, LLC|||||f||||||||||||||2018-06-01 03:44:35.300723|2018-06-01 03:44:35.300723
NCT00381433|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2009-07-06|2006-09-25|2006-09-27|Estimate|||||||2009-07-06|2009-07-08|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|October 2006|Actual|2006-10-31||Interventional|||Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid|Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration|Completed||Phase 1|12||Sarepta Therapeutics|||||f||||||||||||||2018-06-01 03:44:35.365751|2018-06-01 03:44:35.365751
NCT00381420|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2008-10-30|2006-09-26|2006-09-27|Estimate|||||||2008-10-30|2008-10-31|Estimate|March 2001||2001-03-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|December 2002|Actual|2002-12-31||Interventional|C-SIRIUS||The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.|A Canadian Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Coated BX Velocity Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions.|Completed||Phase 3|100|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 03:44:35.425476|2018-06-01 03:44:35.425476
NCT00381407|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2013-04-17|2006-09-25|2006-09-27|Estimate|||||||2013-04-17|2013-04-19|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder|Organizational Skills Treatment for ADHD Children|Completed||N/A|157|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-06-01 03:44:35.506794|2018-06-01 03:44:35.506794
NCT00381394|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-09-15|2006-09-26|2006-09-27|Estimate|||||||2017-09-15|2017-09-18|Actual|August 4, 2006|Actual|2006-08-04|September 2017|2017-09-30|September 14, 2007|Actual|2007-09-14|September 14, 2007|Actual|2007-09-14||Interventional|||A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.|A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas.|Completed||Phase 2|61|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:44:35.59432|2018-06-01 03:44:35.59432
NCT00381381|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|2010-08-03||2012-08-23|2006-09-25|2006-09-27|Estimate|2012-06-20|2012-07-27|Estimate||||2012-08-23|2012-08-31|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease|A Multi-center Study for the Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease|Completed||Phase 4|199|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:44:35.68565|2018-06-01 03:44:35.68565
NCT00381368|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2006-12-01|2006-09-25|2006-09-27|Estimate|||||||2006-12-01|2006-12-04|Estimate|October 2006||2006-10-31|November 2006|2006-11-30||||||||Interventional|||Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients|Phase II Open Label Study to Establish the Safety and Efficacy of Intravenous Loading Dose of Ibandronate 6 mg in 3 Consecutive Days in Breast Cancer Patients With Skeletal Metastases|Unknown status|Recruiting|Phase 2|60||University of Turku|||||f||||||||||||||2018-06-01 03:44:36.020307|2018-06-01 03:44:36.020307
NCT00381355|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2014-03-25|2006-09-26|2006-09-27|Estimate|||||||2014-03-25|2014-03-27|Estimate|October 2006||2006-10-31|March 2014|2014-03-31||||April 2007|Actual|2007-04-30||Interventional|||RCT of a Written Action Plan vs. Usual Care in Children With Acute Asthma|Does the Use of a New Written Action Plan Increase Short-term Adherence to Prescribed Medication and Asthma Control in Children Treated for an Asthma Attack in the Emergency Department: A Randomized Controlled Trial.|Completed||Phase 4|218|Actual|McGill University Health Center|||||f||||||||||||||2018-06-01 03:44:36.120871|2018-06-01 03:44:36.120871
NCT00381342|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2015-02-20|2006-09-25|2006-09-27|Estimate|||||||2015-02-20|2015-02-23|Estimate|September 2006||2006-09-30|January 2015|2015-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of Exenatide as Monotherapy|Safety and Efficacy of Exenatide as Monotherapy in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|233|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 03:44:36.220601|2018-06-01 03:44:36.220601
NCT00381329|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2009-01-29|2006-09-26|2006-09-27|Estimate|||||||2009-01-29|2009-01-30|Estimate|September 2007||2007-09-30|January 2009|2009-01-31|May 2010|Anticipated|2010-05-31|||||Interventional|||Pennsylvania Adolescent Smoking Study (PASStudy)|Pennsylvania Adolescent Smoking Study (PASS) - Randomized Controlled Trial Comparing Motivational Interviewing and Structured Brief Advice for the Reduction of Adolescent Cigarette Smoking|Unknown status|Active, not recruiting|Phase 2|330|Anticipated|Pennsylvania Department of Health||2|||f||||t||||||||||2018-06-01 03:44:36.349124|2018-06-01 03:44:36.349124
NCT00381316|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2007-12-03|2006-09-25|2006-09-27|Estimate|||||||2007-12-03|2007-12-05|Estimate|July 2006||2006-07-31|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches|Comparison of Diagnostic Rest/Stress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches|Completed||Phase 4|291|Actual|GE Healthcare||2|||f||||||||||||||2018-06-01 03:44:36.428375|2018-06-01 03:44:36.428375
NCT00381303|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2009-11-24||2014-04-02|2006-09-26|2006-09-27|Estimate|2010-09-30|2010-10-19|Estimate||||2014-04-02|2014-04-21|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.|GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.|Completed||Phase 3|429|Actual|Tibotec, Inc||1|||f||||t||||||||||2018-06-01 03:44:36.561559|2018-06-01 03:44:36.561559
NCT00381290|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2017-11-02|2006-09-25|2006-09-27|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2006||2006-10-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Intensive Diet and Exercise for Improving Knee Osteoarthritis in Obese and Overweight Older Adults|Intensive Diet and Exercise for Arthritis|Completed||N/A|454|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||||2018-06-01 03:44:37.512429|2018-06-01 03:44:37.512429
NCT00381277|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2011-02-18|2006-09-26|2006-09-27|Estimate|||||||2011-02-18|2011-02-21|Estimate|March 2006||2006-03-31|February 2011|2011-02-28|September 2006|Actual|2006-09-30|March 2006|Actual|2006-03-31||Interventional|||The Effects of Sports Drinks on Urinary Lithogenicity|The Effects of Sports Drinks on Urinary Lithogenicity|Completed||N/A|10||VA New York Harbor Healthcare System|||||f||||f||||||||||2018-06-01 03:44:37.601666|2018-06-01 03:44:37.601666
NCT00381264|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2008-02-14|2006-09-25|2006-09-27|Estimate|||||||2008-02-14|2008-02-15|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis|A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis|Completed||Phase 4|23|Anticipated|NEMA Research, Inc.|||||f||||||||||||||2018-06-01 03:44:37.657566|2018-06-01 03:44:37.657566
NCT00381251|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2007-06-08|2006-09-26|2006-09-27|Estimate|||||||2007-06-08|2007-06-11|Estimate|September 2006||2006-09-30|June 2007|2007-06-30|January 2007||2007-01-31|||||Interventional|||Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.|An Open-Label, Single-Dose, Randomized, 3-Period, Crossover, Bioequivalence Study Between Two New Formulations of 0.45 mg/1.5 mg Premarin / Medroxyprogesterone Acetate (MPA) Compared With a Reference Formulation of 0.45mg/1.5mg Premarin / MPA (Prempro™) in Healthy Postmenopausal Women.|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:44:37.754718|2018-06-01 03:44:37.754718
NCT00381238|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2017-02-22|2010-03-29|2017-04-18|2006-09-26|2006-09-27|Estimate|2017-04-18|2017-05-23|Actual|2010-03-29|2010-05-03|Estimate|2017-04-18|2017-05-23|Actual|June 20, 2006||2006-06-20|February 2017|2017-02-28|February 3, 2009|Actual|2009-02-03|February 1, 2009|Actual|2009-02-01||Interventional|||Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease|An Open-label Extension to Study 49653/461, to Assess the Long-term Safety of Rosiglitazone (Extended Release Tablets) in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|33|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:37.916747|2018-06-01 03:44:37.916747
NCT00381225|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2017-09-05|2006-09-26|2006-09-27|Estimate|||||||2017-09-05|2017-09-08|Actual|November 2006||2006-11-30|September 2017|2017-09-30|March 18, 2008|Actual|2008-03-18|March 18, 2008|Actual|2008-03-18||Interventional|||Feasibility of Ultra-sound Guided Radiofrequency Ablation in the Management of Head and Neck Neoplasia.|Feasibility of Ultra-sound Guided Radiofrequency Ablation in the Management of Head and Neck Neoplasia.|Withdrawn||N/A|0|Actual|Johns Hopkins University||1||Administratively withdrawn by the IRB prior to IRB approval|f|||||f|f||||||||2018-06-01 03:44:38.518432|2018-06-01 03:44:38.518432
NCT00381212|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2009-01-28|2006-09-26|2006-09-27|Estimate|||||||2009-01-28|2009-01-29|Estimate|September 2006||2006-09-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|February 2008|Actual|2008-02-29||Interventional|||A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.|A Pilot Study (Phase I/II) Testing the Immunologic Activity and Safety of AGS-004, an Autologous HIV Immunotherapeutic, in HIV-Infected Adults on HAART|Completed||Phase 1/Phase 2|10|Actual|McGill University Health Center||1|||f||||t||||||||||2018-06-01 03:44:38.597143|2018-06-01 03:44:38.597143
NCT00381199|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2007-05-16|2006-09-25|2006-09-27|Estimate|||||||2007-05-16|2007-05-21|Estimate|April 2006||2006-04-30|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia|Nabilone Versus Amitriptyline in Improving Quality of Sleep in Patients With Fibromyalgia|Completed||N/A|32|Actual|McGill University Health Center|||||f||||f||||||||||2018-06-01 03:44:38.677786|2018-06-01 03:44:38.677786
NCT00381186|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2016-11-08|2006-09-25|2006-09-27|Estimate|||||||2016-11-08|2016-11-09|Estimate|February 1999||1999-02-28|September 2006|2006-09-30|June 2006||2006-06-30|||||Interventional|||Impact of 3-year Lifestyle Intervention on Postprandial Glucose Metabolism: the SLIM Study|Impact of 3-year Lifestyle Intervention on Postprandial Glucose Metabolism: the SLIM Study|Completed||N/A|150||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:44:38.738509|2018-06-01 03:44:38.738509
NCT00381173|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2013-05-13|2006-09-26|2006-09-27|Estimate|||||||2013-05-13|2013-05-14|Estimate|November 2006||2006-11-30|July 2011|2011-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing|A Phase 1 Open-Label Study of the Safety and Feasibility of ZYC300 Administration With Cyclophosphamide Pre-Dosing|Completed||Phase 1|22|Actual|Eisai Inc.||1|||f||||f||||||||||2018-06-01 03:44:38.799638|2018-06-01 03:44:38.799638
NCT00381160|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2012-08-08|2006-09-25|2006-09-27|Estimate|||||||2012-08-08|2012-08-10|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|BASH||Reducing Sugar-sweetened Beverage Consumption in Overweight Adolescents|Reducing Sugar-Sweetened Beverage Consumption in Overweight Adolescents|Completed||N/A|224|Actual|Boston Children’s Hospital||2|||f||||||||||||||2018-06-01 03:44:38.882659|2018-06-01 03:44:38.882659
NCT00381147|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2009-01-06|2006-09-26|2006-09-27|Estimate|||||||2009-01-06|2009-01-07|Estimate||||September 2006|2006-09-30||||||||Interventional|||Use of Clarithromycin in Mustard-Induced Bronchiolitis|Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard|Completed||Phase 3|||Baqiyatallah Medical Sciences University|||||f||||||||||||||2018-06-01 03:44:38.958708|2018-06-01 03:44:38.958708
NCT00381134|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2010-03-01|2006-09-26|2006-09-27|Estimate|||||||2010-03-01|2010-03-02|Estimate|July 2003||2003-07-31|March 2010|2010-03-31|December 2006|Actual|2006-12-31|||||Interventional|||Improving Outcomes in Patients With Kidney Disease Due to Diabetes|Improving Outcomes in Diabetic Nephropathy|Completed||Phase 2|92|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:44:39.014467|2018-06-01 03:44:39.014467
NCT00381095|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|2011-08-18||2011-10-21|2006-09-25|2006-09-27|Estimate|2011-08-18|2011-09-27|Estimate||||2011-10-21|2011-10-26|Estimate|December 2006||2006-12-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|COPE||A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer|A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain|Terminated||Phase 4|152|Actual|Pfizer|Efficacy parameters baseline=the last non-missing observation, up to the baseline visit for that efficacy parameter. Baseline mBPI scores=average score in week preceding randomization, minimum 4 datapoints. No formal hypothesis testing conducted.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:44:39.293399|2018-06-01 03:44:39.293399
NCT00381082|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2006-12-08|2006-09-26|2006-09-27|Estimate|||||||2006-12-08|2006-12-12|Estimate|September 2004||2004-09-30|December 2006|2006-12-31|November 2004||2004-11-30|||||Interventional|||A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.|A Randomised, Controlled and Blinded Assessment Study of the Efficacy of MOOV Head Lice Treatment (Ego Pharmaceutical Pty. Ltd.) in the Treatment of Head Lice in Primary School Children.|Completed||Phase 2/Phase 3|152||Uniquest Pty Ltd|||||f||||||||||||||2018-06-01 03:44:39.857475|2018-06-01 03:44:39.857475
NCT00381069|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2010-01-19|2006-09-26|2006-09-27|Estimate|||||||2010-01-19|2010-01-20|Estimate|October 2006||2006-10-31|January 2010|2010-01-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||SDSU MOVE/Me Muevo Project|Obesity Prevention and Control in Community Recreation Centers|Unknown status|Active, not recruiting|N/A|541|Actual|San Diego State University|||||f||||t||||||||||2018-06-01 03:44:39.989967|2018-06-01 03:44:39.989967
NCT00381056|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2006-09-26|2006-09-26|2006-09-27|Estimate|||||||2006-09-26|2006-09-27|Estimate|July 2000||2000-07-31|September 2006|2006-09-30|March 2004||2004-03-31|||||Interventional|||The Labor and Delivery Teamwork Intervention Trial|The Labor and Delivery Teamwork Intervention Trial|Completed||N/A|30000||Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 03:44:40.070789|2018-06-01 03:44:40.070789
NCT00381043|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2012-09-13||2017-04-11|2006-09-26|2006-09-27|Estimate|2013-02-18|2013-03-22|Estimate||||2017-04-11|2017-05-17|Actual|August 2006||2006-08-31|April 2017|2017-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic|Campral (Acamprosate) Treatment of Alcohol Dependence in a Family Medicine Setting: A Randomized, Double-Blind Placebo-Controlled Study|Completed||Phase 4|100|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 03:44:40.165903|2018-06-01 03:44:40.165903
NCT00381030|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2006-09-25|2006-09-25|2006-09-27|Estimate|||||||2006-09-25|2006-09-27|Estimate|October 2002||2002-10-31|September 2006|2006-09-30|March 2005||2005-03-31|||||Interventional|||Effects of Carvedilol on Health Outcomes in Heart Failure|Effects of Inpatient Initiation of Carvedilol and Nurse Management on Health Outcomes in Vulnerable Heart Failure Patients (ECHO Study): a Randomized Trial|Completed||Phase 4|100||Denver Health and Hospital Authority|||||f||||||||||||||2018-06-01 03:44:40.455518|2018-06-01 03:44:40.455518
NCT00381017|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2014-08-11|2006-09-26|2006-09-27|Estimate|||||||2014-08-11|2014-08-13|Estimate|September 2006||2006-09-30|August 2014|2014-08-31||||||||Interventional|||Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)|A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg Interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients With Cirrhotic Hepatitis C Co-infected With Human Immunodeficiency Virus - The ENDURE Study|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||||Non-protocol feasibility|||||||||||||||2018-06-01 03:44:40.535604|2018-06-01 03:44:40.535604
NCT00381004|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|2015-07-20||2015-12-14|2006-09-26|2006-09-27|Estimate|2015-07-20|2015-08-14|Estimate||||2015-12-14|2016-01-14|Estimate|September 2006||2006-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia|Fludarabine, Cyclophosphamide, and Rituximab (FCR) Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:44:40.59346|2018-06-01 03:44:40.59346
NCT00380991|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2008-05-15|2006-09-26|2006-09-27|Estimate|||||||2008-05-15|2008-05-16|Estimate|May 2006||2006-05-31|May 2008|2008-05-31||||||||Interventional|||Topic Compatibility Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene|Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensitivity) of Dermacyd Delicata (New Fragrance)|Completed||Phase 3|50||Sanofi|||||f||||||||||||||2018-06-01 03:44:40.787926|2018-06-01 03:44:40.787926
NCT00380978|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|2011-07-05||2014-03-17|2006-09-25|2006-09-27|Estimate|2011-11-06|2011-12-08|Estimate||||2014-03-17|2014-04-14|Estimate|October 2001||2001-10-31|March 2014|2014-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Neuraxial Versus Systemic Analgesia for Latent Phase Labor Effect on Rate of Operative Delivery|Early Compared With Late Neuraxial Analgesia in Nulliparous Labor Induction|Completed||N/A|1026|Actual|Northwestern University|The study was not powered to detect a small difference between groups in the cesarean delivery rate. It was not blinded. Different obstetric providers have different management styles, and different triggers for performing cesarean delivery.|2|||f||||f||||||||||2018-06-01 03:44:40.875275|2018-06-01 03:44:40.875275
NCT00380965|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2008-02-14|2006-09-25|2006-09-27|Estimate|||||||2008-02-14|2008-02-15|Estimate|October 2006||2006-10-31|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy|A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer|Completed||Phase 4|23|Anticipated|NEMA Research, Inc.|||||f||||||||||||||2018-06-01 03:44:41.290482|2018-06-01 03:44:41.290482
NCT00380952|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2008-05-25|2006-09-26|2006-09-27|Estimate|||||||2008-05-25|2008-05-28|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Interventional|||Intraoperative Use of the BP Device for Detecting Positive Margins During Lumpectomy Procedure|MAST Study Protocol|Completed||N/A|300|Actual|Dune Medical Devices|||||f||||f||||||||||2018-06-01 03:44:41.419539|2018-06-01 03:44:41.419539
NCT00380939|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2006-11-29|2006-09-26|2006-09-27|Estimate|||||||2006-11-29|2006-12-04|Estimate|April 1999||1999-04-30|November 2006|2006-11-30|December 2000||2000-12-31|||||Interventional|||This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.|A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL)|Completed||Phase 4|600||Pfizer|||||||||||||||||||2018-06-01 03:44:41.503082|2018-06-01 03:44:41.503082
NCT00356330|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2007-04-09|2006-07-25|2006-07-26|Estimate|||||||2007-04-09|2007-04-11|Estimate||||April 2007|2007-04-30||||||||Observational|||Safety of Cardiac Pacemakers in 3 Tesla MRI|Study to Evaluate Safety of Cardiac Pacemakers in MR Imaging at 3T Tesla|Unknown status|Recruiting||75||University Hospital, Bonn|||||f||||||||||||||2018-06-01 03:52:48.786732|2018-06-01 03:52:48.786732
NCT00380913|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2008-02-14|2006-09-25|2006-09-27|Estimate|||||||2008-02-14|2008-02-15|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy|A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy|Completed||Phase 4|23|Anticipated|NEMA Research, Inc.|||||f||||||||||||||2018-06-01 03:44:41.653764|2018-06-01 03:44:41.653764
NCT00380900|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2007-12-03|2006-09-26|2006-09-27|Estimate|||||||2007-12-03|2007-12-05|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Test Article or Placebo Administered Orally to Healthy and Osteoarthritis Subjects.|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:44:41.715367|2018-06-01 03:44:41.715367
NCT00380887|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2006-09-26|2006-09-26|2006-09-27|Estimate|||||||2006-09-26|2006-09-27|Estimate|June 2005||2005-06-30|September 2006|2006-09-30||||||||Observational|||Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women|Completed|||54||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:44:41.776584|2018-06-01 03:44:41.776584
NCT00380874|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|2009-03-10||2009-10-01|2006-09-25|2006-09-27|Estimate|2009-03-10|2009-04-17|Estimate||||2009-10-01|2009-10-07|Estimate|January 2007||2007-01-31|October 2009|2009-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial Of The Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy Symptoms In Subjects With Advanced Colorectal Cancer|Terminated||Phase 4|64|Actual|Pfizer|Due to lack of symptom emergence, enrollment was halted, and endpoint modified because primary assumptions upon which it was powered (emergence of symptomatology) were not met, and not all endpoints were able to be reliably analyzed.|2||See detailed description for termination reason|f||||t||||||||||2018-06-01 03:44:41.867111|2018-06-01 03:44:41.867111
NCT00380861|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|2011-01-28||2013-08-06|2006-09-26|2006-09-27|Estimate|2011-03-07|2011-04-05|Estimate||||2013-08-06|2013-08-14|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Does Implant Design Improve Postoperative Flexion?|Does Implant Design Improve Postoperative Flexion?A Prospective, Randomized, Comparative, Multi-center Study Comparing PFC® Sigma™ RP Knee Versus PFC® Sigma™ RP-F Implanted in Simultaneous Bilateral Subjects|Completed||N/A|186|Actual|DePuy Orthopaedics||2|||f||||f||||||||||2018-06-01 03:44:43.078384|2018-06-01 03:44:43.078384
NCT00380848|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2007-04-11|2006-09-25|2006-09-27|Estimate|||||||2007-04-11|2007-04-12|Estimate|March 2006||2006-03-31|May 2006|2006-05-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Impact of Different Dialysis on Sleep Apnea in Patients With Renal Failure|Effect of Hemodiafiltration on Sleep-Disordered Breathing in Patients With End-Stage Renal Disease|Unknown status|Recruiting|N/A|15||McGill University Health Center|||||f||||||||||||||2018-06-01 03:44:43.289438|2018-06-01 03:44:43.289438
NCT00380835|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-26|||2008-09-22|2006-09-26|2006-09-27|Estimate|||||||2008-09-22|2008-09-23|Estimate||||September 2008|2008-09-30|December 2007||2007-12-31|||||Interventional|||Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer|A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer|Withdrawn||Phase 2|66|Anticipated|Celgene||||Study Never Initiated|f||||||||||||||2018-06-01 03:44:43.357533|2018-06-01 03:44:43.357533
NCT00380822|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2006-09-25|2006-09-25|2006-09-27|Estimate|||||||2006-09-25|2006-09-27|Estimate||||September 2006|2006-09-30||||||||Interventional|||Double-Blind Study of Miglitol in Japanese With type2 Diabetes||Completed||Phase 3|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 03:44:43.451247|2018-06-01 03:44:43.451247
NCT00380809|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2013-01-04|2006-09-25|2006-09-26|Estimate|||||||2013-01-04|2013-01-07|Estimate|August 2006||2006-08-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Rotational Atherectomy Prior to Taxus Stent|Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.|Completed||Phase 4|240|Actual|Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH||2|||f||||||||||||||2018-06-01 03:44:43.575032|2018-06-01 03:44:43.575032
NCT00380796|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2013-09-03|2006-09-22|2006-09-26|Estimate|||||||2013-09-03|2013-09-04|Estimate|April 2006||2006-04-30|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).|A Multicenter, Observational Study of the Long-term Safety of Infliximab (REMICADE) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). RESULTS COPD: REMICADE Safety Under Long Term Study in COPD|Completed|||88|Actual|Centocor, Inc.|||1||f||||t||||||||||2018-06-01 03:44:43.64154|2018-06-01 03:44:43.64154
NCT00380783|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2011-05-27|2006-09-22|2006-09-26|Estimate|||||||2011-05-27|2011-05-30|Estimate|October 2006||2006-10-31|May 2011|2011-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis||Terminated||Phase 2|2|Actual|Allergan|||||f||||||||||||||2018-06-01 03:44:43.733609|2018-06-01 03:44:43.733609
NCT00380770|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2010-07-20|2006-09-25|2006-09-26|Estimate|||||||2010-07-20|2010-07-21|Estimate|January 2003||2003-01-31|March 2009|2009-03-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|KAART||HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT|A Prospective Randomized Trial Comparing the Response of HIV Kaposi's Sarcoma (KS) to HAART Versus the Combination of HAART and Chemotherapy (CXT)|Completed||Phase 4|112|Actual|University of KwaZulu||2|||f||||t||||||||||2018-06-01 03:44:43.783898|2018-06-01 03:44:43.783898
NCT00380757|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-23|||2017-01-20|2006-09-23|2006-09-26|Estimate|||||||2017-01-20|2017-01-23|Estimate|October 2006||2006-10-31|May 2012|2012-05-31|November 2006|Actual|2006-11-30|||||Interventional|||Comparison of Bystander Fatigue and CPR Quality When Using Two Different CPR Ratios.|Comparison of Bystander Fatigue and CPR Quality When Using the New 30:2 Versus the Old 15:2 Chest Compression to Ventilation International Guidelines: A Randomised Crossover Trial|Completed||N/A|42|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 03:44:43.859715|2018-06-01 03:44:43.859715
NCT00380172|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2006-09-21|2006-09-21|2006-09-25|Estimate|||||||2006-09-21|2006-09-25|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|October 2007||2007-10-31|||||Interventional|||Long-Term Efficacy in AMD of Rheopheresis in North America|A Multicenter, Open Label, Prospective Study to Determine Safety and Efficacy Over an Additional 12-Month Period With Non-Exudative Age-Related Macular Degeneration (With Follow-on to 12-Months)|Unknown status|Active, not recruiting|N/A|120||OccuLogix|||||||||||||||||||2018-06-01 03:44:52.278191|2018-06-01 03:44:52.278191
NCT00380744|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22||2009-01-30|2009-10-05|2006-09-22|2006-09-26|Estimate||||2009-10-05|2009-10-07|Estimate|2009-10-05|2009-10-07|Estimate|November 2005||2005-11-30|October 2009|2009-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Safety and Pharmacokinetics Study in Patients With Rheumatoid Arthritis|A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis|Completed||Phase 1/Phase 2|104|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 03:44:43.923569|2018-06-01 03:44:43.923569
NCT00380731|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2011-11-29|2006-09-22|2006-09-26|Estimate|||||||2011-11-29|2011-11-30|Estimate|September 2006||2006-09-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Behavior Therapy on Responses to Social Stimuli in People With Social Phobia|fMRI of Emotional Reactivity Cognitive Regulation and CBT for Social Phobia|Completed||N/A|124|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 03:44:44.014626|2018-06-01 03:44:44.014626
NCT00380718|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|2009-09-02||2010-11-01|2006-09-22|2006-09-26|Estimate|2009-09-02|2009-10-06|Estimate||||2010-11-01|2010-11-16|Estimate|November 2006||2006-11-30|November 2010|2010-11-30|November 2009|Actual|2009-11-30|September 2008|Actual|2008-09-30||Interventional|||Chemotherapy for Patients With Non-Small Cell Lung Cancer|Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy|Completed||Phase 4|33|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:44:44.093854|2018-06-01 03:44:44.093854
NCT00380705|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2017-09-19|2006-09-22|2006-09-26|Estimate|||||||2017-09-19|2017-09-20|Actual|March 18, 2005|Actual|2005-03-18|September 2017|2017-09-30|July 29, 2005|Actual|2005-07-29|July 29, 2005|Actual|2005-07-29||Interventional|||Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)|Quality of Life in Asthma and Rhinitis Allergic With Singulair|Completed||Phase 4|91|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:44:45.364192|2018-06-01 03:44:45.364192
NCT00380692|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|2009-05-18||2010-05-05|2006-09-22|2006-09-26|Estimate|2009-05-18|2009-07-08|Estimate||||2010-05-05|2010-05-11|Estimate|October 2006||2006-10-31|May 2010|2010-05-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder|A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder|Completed||Phase 4|97|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:44:45.496035|2018-06-01 03:44:45.496035
NCT00380679|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2006-09-25|2006-09-25|2006-09-26|Estimate|||||||2006-09-25|2006-09-26|Estimate|December 2005||2005-12-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department|Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency Department|Unknown status|Active, not recruiting|Phase 2|||Louisiana State University Health Sciences Center in New Orleans|||||f||||||||||||||2018-06-01 03:44:47.300359|2018-06-01 03:44:47.300359
NCT00380666|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2010-07-09|2006-09-25|2006-09-26|Estimate|||||||2010-07-09|2010-07-12|Estimate|June 2007||2007-06-30|July 2010|2010-07-31|July 2010|Anticipated|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer||Withdrawn||N/A|30|Anticipated|University of Aarhus||||Technical problems.|f||||f||||||||||2018-06-01 03:44:47.440653|2018-06-01 03:44:47.440653
NCT00380653|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-23|||2009-10-18|2006-09-23|2006-09-26|Estimate|||||||2009-10-18|2009-10-20|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes|A Phase I Pharmacologic Study of Oral Sapacitabine in Patients With Advanced Leukemias or Myelodysplastic Syndromes|Completed||Phase 1|||Cyclacel Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 03:44:47.541006|2018-06-01 03:44:47.541006
NCT00380640|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2018-04-17|2006-09-25|2006-09-26|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2006||2006-09-30|April 2018|2018-04-30|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa|The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa: A Randomized, Double Blinded, Placebo Controlled, Cross-over Pilot Study|Completed||Phase 2|10|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 03:44:47.589974|2018-06-01 03:44:47.589974
NCT00380627|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2017-04-06|2006-09-22|2006-09-26|Estimate|||||||2017-04-06|2017-04-10|Actual|September 1, 2005|Actual|2005-09-01|April 2017|2017-04-30|January 31, 2006|Actual|2006-01-31|January 31, 2006|Actual|2006-01-31||Interventional|||Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)|Quality of Life With Arcoxia in Women With Dysmenorrhea|Completed||Phase 4|337||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:44:47.753254|2018-06-01 03:44:47.753254
NCT00380614|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2006-09-25|2006-09-25|2006-09-26|Estimate|||||||2006-09-25|2006-09-26|Estimate|January 2002||2002-01-31|September 2006|2006-09-30|March 2005||2005-03-31|||||Interventional|||A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B||Completed||Phase 4|||Maulana Azad Medical College|||||f||||||||||||||2018-06-01 03:44:47.927474|2018-06-01 03:44:47.927474
NCT00380601|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2009-12-22|2006-09-25|2006-09-26|Estimate|||||||2009-12-22|2009-12-23|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)|An Open-label, PhaseⅢ Study to Evaluate the Efficacy and Safety of MRA in Patients With RA|Completed||Phase 3|20|Anticipated|Chugai Pharmaceutical||1|||f||||||||||||||2018-06-01 03:44:48.018781|2018-06-01 03:44:48.018781
NCT00380588|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|2009-10-15||2009-11-18|2006-09-22|2006-09-26|Estimate|2009-10-15|2009-11-19|Estimate||||2009-11-18|2009-11-20|Estimate|September 2006||2006-09-30|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer|A Randomized Study of Gemcitabine/Cisplatin Versus Single-Agent Gemcitabine in Patients With Biliary Tract Cancer|Completed||Phase 2|84|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:44:48.129697|2018-06-01 03:44:48.129697
NCT00380575|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2014-04-30|2006-09-22|2006-09-26|Estimate|||||||2014-04-30|2014-05-02|Estimate|August 2000||2000-08-31|April 2014|2014-04-30|February 2003|Actual|2003-02-28|||||Interventional|||Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia|A 4-Day, Double-Blind, Placebo-Controlled, Multicenter Study of IV YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia|Completed||Phase 3|84||Cumberland Pharmaceuticals|||||||||||||||||||2018-06-01 03:44:48.797837|2018-06-01 03:44:48.797837
NCT00380562|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2013-09-18|2006-09-25|2006-09-26|Estimate|||||||2013-09-18|2013-09-19|Estimate|July 2006||2006-07-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Baltimore Experience Corps Study|Experience Corps Trial: Improving Health of Older Populations Through Generativity|Completed||N/A|702|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:44:48.918141|2018-06-01 03:44:48.918141
NCT00380549|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-23|||2010-08-19|2006-09-23|2006-09-26|Estimate|||||||2010-08-19|2010-08-23|Estimate|June 2006||2006-06-30|August 2010|2010-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Comparison of an Advanced Metal Hip System to a Resurfacing Hip System|A Prospective Case Series (Pilot Study) Comparing Ion Levels and Clinical Outcomes of the CONSERVE® A-Class Type Hip System With BFH™ Technology to the CONSERVE® Plus Total Hip Resurfacing System|Completed||Phase 4|20|Actual|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-06-01 03:44:49.01033|2018-06-01 03:44:49.01033
NCT00380536|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2013-11-18|2006-09-22|2006-09-26|Estimate|||||||2013-11-18|2013-11-19|Estimate|September 2006||2006-09-30|November 2013|2013-11-30|July 2010|Actual|2010-07-31|April 2009|Actual|2009-04-30||Interventional|||Medical Self-Management for Improving Health Behavior Among Individuals in Community Mental Health Settings|Adapting a Medical Self-Management Program for a Community Mental Health Center|Completed||N/A|111|Anticipated|Emory University||2|||f||||f||||||||||2018-06-01 03:44:49.085675|2018-06-01 03:44:49.085675
NCT00380523|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2015-03-16|2006-09-22|2006-09-26|Estimate|||||||2015-03-16|2015-03-17|Estimate|April 2005||2005-04-30|March 2015|2015-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Analgesic Treatment Mediated by Arcoxia (0663-093)|Analgesic Treatment Mediated by Arcoxia|Completed||Phase 4|237|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:44:49.18741|2018-06-01 03:44:49.18741
NCT00380510|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2006-09-25|2006-09-25|2006-09-26|Estimate|||||||2006-09-25|2006-09-26|Estimate|June 2004||2004-06-30|September 2006|2006-09-30|February 2005||2005-02-28|||||Observational|||The Safe Teen Study|The SAFE TEEN Study: Family Physicians' Reports of Facilitators of and Barriers to Preventive Care for Adolescents.|Completed|||60||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 03:44:49.2468|2018-06-01 03:44:49.2468
NCT00380497|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2013-07-25|2006-09-25|2006-09-26|Estimate|||||||2013-07-25|2013-07-29|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children|Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in children-a Single Blinded Randomized Controlled Trial|Completed||Phase 4|83|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 03:44:49.339166|2018-06-01 03:44:49.339166
NCT00380484|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2008-02-19|2006-09-25|2006-09-26|Estimate|||||||2008-02-19|2008-02-27|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Short- and Long Term Growth in Children With Asthma|Short- and Long Term Growth in Children With Asthma Treated With Budesonide or Montelukast|Completed||Phase 4|52|Actual|Children´s Clinic, Randers||2|||f||||||||||||||2018-06-01 03:44:49.44313|2018-06-01 03:44:49.44313
NCT00380471|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25|||2008-01-22|2006-09-25|2006-09-26|Estimate|||||||2008-01-22|2008-01-23|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|August 2006|Anticipated|2006-08-31|||||Interventional|||Treatment and Complication of Bath PUVA in Vitiligo|Treatment and Complication of Bath PUVA in Vitiligo|Unknown status|Recruiting|Phase 2|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:44:49.520502|2018-06-01 03:44:49.520502
NCT00380458|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2015-08-25|2006-09-22|2006-09-26|Estimate|||||||2015-08-25|2015-08-26|Estimate||||August 2015|2015-08-31||||||||Interventional|||Study to Evaluate Recovery From Postoperative Pain After Sleep Apnea Surgery|Prospective, Randomized, Controlled Clinical Trial to Evaluate Recovery From Post-operative Pain in Adults After Sleep Apnea Surgery Using a Coblation Device Compared to Electrocautery|Withdrawn||Phase 4|0|Actual|ArthroCare Corporation||||No patients enrolled. Study did not start.|f||||f||||||||||2018-06-01 03:44:49.600829|2018-06-01 03:44:49.600829
NCT00380445|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2017-02-20|2006-09-22|2006-09-26|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2006||2006-01-31|February 2017|2017-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes|Effect of Vildagliptin on Adipose Tissue and Skeletal Muscle Metabolism in Obese Patients With Type 2 Diabetes|Completed||Phase 3|21|Actual|Novartis|||||f||||||||||||||2018-06-01 03:44:49.655697|2018-06-01 03:44:49.655697
NCT00380419|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2013-05-29|2006-09-22|2006-09-26|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 2006||2006-10-31|May 2013|2013-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Interpersonal Psychotherapy on Depression During and After Pregnancy|Infant Outcomes and Depression Treatment in Pregnancy|Completed||N/A|120|Actual|University of Michigan||1|||f||||t||||||||||2018-06-01 03:44:49.79307|2018-06-01 03:44:49.79307
NCT00380406|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-23|||2017-04-03|2006-09-25|2006-09-26|Estimate|||||||2017-04-03|2017-04-05|Actual|January 2007||2007-01-31|August 2010|2010-08-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|PROOF||PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial|PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial: A Randomized Controlled Trial of Gonadotropin Releasing Hormone Agonist (GnRHa) for Fertility Preservation in Oncology Patients|Completed||Phase 3|30|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 03:44:49.877699|2018-06-01 03:44:49.877699
NCT00380393|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-25||2009-09-03|2017-04-06|2006-09-25|2006-09-26|Estimate||||2009-09-03|2009-09-04|Estimate|2017-04-06|2017-04-07|Actual|January 3, 2007||2007-01-03|April 2017|2017-04-30|November 11, 2008|Actual|2008-11-11|August 15, 2008|Actual|2008-08-15||Interventional|||Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.|A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS,S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya|Completed||Phase 2|855|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:49.961548|2018-06-01 03:44:49.961548
NCT00380380|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2017-02-20|2006-09-22|2006-09-26|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2006||2006-01-31|February 2017|2017-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.|A Randomized, Single-blind, Placebo Controlled, Cross-over Study to Evaluate the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.|Completed||Phase 3|18||Novartis|||||f||||||||||||||2018-06-01 03:44:50.065543|2018-06-01 03:44:50.065543
NCT00380367|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|2009-01-22||2017-03-23|2006-09-22|2006-09-26|Estimate|2009-03-12|2009-04-14|Estimate||||2017-03-23|2017-04-21|Actual|May 3, 2007|Actual|2007-05-03|March 2017|2017-03-31|February 4, 2008|Actual|2008-02-04|February 4, 2008|Actual|2008-02-04||Interventional|||Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)|Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India|Completed||Phase 3|110|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:44:50.133159|2018-06-01 03:44:50.133159
NCT00380354|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2012-05-31|2006-09-21|2006-09-25|Estimate|||||||2012-05-31|2012-06-04|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|June 2007|Actual|2007-06-30|||||Interventional|||Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma|A Two-centre, Randomised, Double-blind, Placebo-controlled, 2-period Cross-over Study to Evaluate the Effect of Treatment With Repeat Doses of Inhaled GSK256066 on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma|Completed||Phase 2|11|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:44:50.303706|2018-06-01 03:44:50.303706
NCT00380341|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2008-10-16|2006-09-22|2006-09-25|Estimate|||||||2008-10-16|2008-10-17|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|November 2006||2006-11-30|||||Interventional|||Effects of Instrument-Applied Spinal Manipulative Therapy on Postureal Control and Autonomic Balance||Completed||N/A|20||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:44:50.37245|2018-06-01 03:44:50.37245
NCT00380328|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2012-05-10|2006-09-22|2006-09-25|Estimate|||||||2012-05-10|2012-05-14|Estimate|October 2006||2006-10-31|May 2012|2012-05-31|November 2006|Actual|2006-11-30|||||Interventional|||HKI-272 Ketoconazole Drug Interaction Study|An Open-label, Randomized, 2-period Crossover, Drug Interaction Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Ketoconazole and a Single Dose of HKI-272 Administered Orally to Healthy Subjects|Completed||Phase 1|24|Actual|Puma Biotechnology, Inc.|||||f||||||||||||||2018-06-01 03:44:50.414257|2018-06-01 03:44:50.414257
NCT00380315|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2009-06-30|2006-09-21|2006-09-25|Estimate|||||||2009-06-30|2009-07-02|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher|Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study|Completed||Phase 3|396|Actual|Ahn-Gook Pharmaceuticals Co.,Ltd|||||||||||||||||||2018-06-01 03:44:50.475557|2018-06-01 03:44:50.475557
NCT00380302|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2008-12-18|2006-09-22|2006-09-25|Estimate|||||||2008-12-18|2008-12-19|Estimate|September 2006||2006-09-30|December 2008|2008-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.|A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 1/Phase 2|162|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:44:50.531309|2018-06-01 03:44:50.531309
NCT00380289|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2006-09-22|2006-09-22|2006-09-25|Estimate|||||||2006-09-22|2006-09-25|Estimate|September 2006||2006-09-30|September 2006|2006-09-30||||||||Interventional|||Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension|Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension|Unknown status|Recruiting|N/A|66||University of Cambridge|||||f||||||||||||||2018-06-01 03:44:50.604057|2018-06-01 03:44:50.604057
NCT00380276|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2008-08-01|2006-09-22|2006-09-25|Estimate|||||||2008-08-01|2008-08-05|Estimate|September 2006||2006-09-30|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol|Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type|Terminated||Phase 3|1000|Anticipated|Myrexis Inc.||1||Myriad has discontinued the development of Flurizan.|f||||||||||||||2018-06-01 03:44:50.704204|2018-06-01 03:44:50.704204
NCT00380263|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2008-05-29|2006-09-21|2006-09-25|Estimate|||||||2008-05-29|2008-05-30|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow|Basic Scientific Research Investigating PACAP38 Headache Inducing Effects in Migraine Patients|Completed||N/A|12|Actual|Danish Headache Center|||||f||||t||||||||||2018-06-01 03:44:50.88148|2018-06-01 03:44:50.88148
NCT00380250|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2008-10-07||2014-01-13|2006-09-21|2006-09-25|Estimate|2014-01-13|2014-02-11|Estimate||||2014-01-13|2014-02-11|Estimate|May 2005||2005-05-31|January 2014|2014-01-31|July 2006|Actual|2006-07-31|||||Interventional||The Baseline participants data is taken from the intent to treat(ITT) population Whereas the Participant flow data is for all randomized subjects.|Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation|Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation|Completed||Phase 3|590|Actual|Sucampo Pharma Americas, LLC||2|||f||||||||||||||2018-06-01 03:44:50.977747|2018-06-01 03:44:50.977747
NCT00380237|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2008-01-18|2006-09-22|2006-09-25|Estimate|||||||2008-01-18|2008-01-21|Estimate|October 2006||2006-10-31|January 2008|2008-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)|Phase 1 Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study B)|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-06-01 03:44:51.771054|2018-06-01 03:44:51.771054
NCT00380224|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2007-12-18|2006-09-21|2006-09-25|Estimate|||||||2007-12-18|2007-12-27|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.|A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Befeprunox Versus Olanzapine in the Treatment of Outpatients With Schizophrenia.|Completed||Phase 3|120|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:44:51.864443|2018-06-01 03:44:51.864443
NCT00380211|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2016-10-06|2006-09-21|2006-09-25|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults|A Randomized, Double-Blind Trial Evaluating the Safety and Immunogenicity of an Influenza Vaccine With Reduced Preservative (FluLaval™ TR) and a Standard Influenza Vaccine (Fluarix®) in Subjects Between 18-60 and Over 60 Years of Age.|Completed||Phase 3|660|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:52.005309|2018-06-01 03:44:52.005309
NCT00380198|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2017-01-31|2006-09-21|2006-09-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2006||2006-07-31|January 2017|2017-01-31|November 2006||2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.|A Randomized, Double-Blind Comparison of Apadenoson and Adenosine to Treadmill Exercise Stress for Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)|Terminated||Phase 3|1500||Forest Laboratories||||Business decision to end program|f||||||||||||||2018-06-01 03:44:52.103218|2018-06-01 03:44:52.103218
NCT00380159|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21||2014-01-20|2014-02-18|2006-09-21|2006-09-25|Estimate||||2014-01-20|2014-02-13|Estimate|2014-02-18|2014-03-17|Estimate|September 2006||2006-09-30|February 2014|2014-02-28|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A|An Open-Label,48 Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Subjects Who Have Completed 14 Days of Treatment in Protocol ACH443-014A.|Completed||Phase 2|4|Actual|Achillion Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:44:52.339212|2018-06-01 03:44:52.339212
NCT00380146|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2016-10-25|2006-09-22|2006-09-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment in Pregnant Women|An Open-label in Vivo Drug Study to Evaluate the Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment (SP IPT) in Pregnant Women|Completed||N/A|31|Actual|University of Cape Town||1|||f||||t||||||||||2018-06-01 03:44:52.409629|2018-06-01 03:44:52.409629
NCT00380133|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2012-05-31|2006-09-21|2006-09-25|Estimate|||||||2012-05-31|2012-06-04|Estimate|June 2005||2005-06-30|March 2012|2012-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Five-way Crossover Study to Assess the Effects of Single Oral Doses of SB-681323 (7.5 mg and 25 mg) and Prednisolone (10 mg and 30 mg) on Biomarkers in Induced Sputum and Blood in COPD Patients.|Completed||Phase 1|20|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:44:52.486648|2018-06-01 03:44:52.486648
NCT00380120|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2008-03-17|2006-09-22|2006-09-25|Estimate|||||||2008-03-17|2008-03-18|Estimate|January 1999||1999-01-31|March 2008|2008-03-31|June 2006|Actual|2006-06-30|June 2003|Actual|2003-06-30||Interventional|AESOPUS||Ultrasound Findings to Adjust the Duration of Anticoagulation|The AESOPUS Study: Ultrasound Findings to Adjust the Duration of Anticoagulation in Patients With Deep Vein Thrombosis|Completed||Phase 3|538|Actual|University of Padova||2|||f||||t||||||||||2018-06-01 03:44:52.564722|2018-06-01 03:44:52.564722
NCT00380107|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2009-08-05|2006-09-22|2006-09-25|Estimate|||||||2009-08-05|2009-08-06|Estimate|October 2006||2006-10-31|August 2009|2009-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Volume Deficit Prior to Surgery|Estimation of Volume Deficit in Patients Prior to Surgery|Completed|||4|Actual|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:44:52.6366|2018-06-01 03:44:52.6366
NCT00380094|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2009-12-17|2006-09-22|2006-09-25|Estimate|||||||2009-12-17|2009-12-18|Estimate|August 2006||2006-08-31|December 2009|2009-12-31|December 2007|Actual|2007-12-31|||||Observational|||Triage Now: an Observational, Prospective Multimarker Study of Biomarkers in Patients Presenting With Chest Pain|TRIAGE NOW: Triage in Acute General Chest Pain Patients Evaluation|Completed|||1500|Anticipated|Biosite|||||f||||||||||||||2018-06-01 03:44:52.690505|2018-06-01 03:44:52.690505
NCT00380081|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2011-12-15||2012-02-10|2006-09-21|2006-09-25|Estimate|2011-12-15|2012-01-20|Estimate||||2012-02-10|2012-02-14|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia|A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Efficacy and Safety of Sublingual Zolpidem Tartrate Tablet in Adult Patients With Insomnia Characterized by Difficulty Returning to Sleep After Middle-of-the-Night (MOTN) Awakening|Completed||Phase 3|82|Actual|Transcept Pharmaceuticals|Scheduled nocturnal awakening is an established method used to evaluate treatments for naturally occurring middle-of-the-night awakenings. Additional studies are needed to determine the generalizability of the findings to 'real world' conditions.|6|||f||||f||||||||||2018-06-01 03:44:52.780732|2018-06-01 03:44:52.780732
NCT00380068|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2009-07-10||2012-04-02|2006-09-21|2006-09-25|Estimate|2010-10-22|2010-11-19|Estimate||||2012-04-02|2012-04-05|Estimate|August 2006||2006-08-31|April 2012|2012-04-30|May 2009|Actual|2009-05-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension|ARIES-3: A Phase 3, Long-Term, Open-Label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension|Completed||Phase 3|224|Actual|Gilead Sciences||1|||f||||t||||||||||2018-06-01 03:44:53.610798|2018-06-01 03:44:53.610798
NCT00380055|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2011-09-19|2006-09-22|2006-09-25|Estimate|||||||2011-09-19|2011-09-21|Estimate|October 2006||2006-10-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Reducing Cancer Disparities for American Indians in the Rural Intermountain West|Reducing Cancer Disparities for American Indians in the Rural Intermountain West|Completed||N/A|1800|Anticipated|University of Utah||4|||f||||f||||||||||2018-06-01 03:44:54.640685|2018-06-01 03:44:54.640685
NCT00380042|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2009-12-30|2006-09-21|2006-09-25|Estimate|||||||2009-12-30|2009-12-31|Estimate|September 2006||2006-09-30|September 2008|2008-09-30|March 2009|Actual|2009-03-31|October 2007|Actual|2007-10-31||Interventional|PROSPECT||Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder|Feasibility Study of the Safety and Effectiveness of Cortical Stimulation for Subjects With Major Depressive Disorder|Terminated||Phase 1|12|Anticipated|Northstar Neuroscience||2||Study terminated as a result of the dissolution of the Sponsor.|f||||t||||||||||2018-06-01 03:44:54.738001|2018-06-01 03:44:54.738001
NCT00380029|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|2017-03-29||2017-06-20|2006-09-22|2006-09-25|Estimate|2017-05-19|2017-06-19|Actual||||2017-06-20|2017-07-19|Actual|May 2006||2006-05-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|August 2010|Actual|2010-08-31||Interventional|||Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer|A Phase II Study of Erlotinib (Tarceva®) in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy|Completed||Phase 2|27|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:44:54.843658|2018-06-01 03:44:54.843658
NCT00380016|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2017-06-30|2006-09-22|2006-09-25|Estimate|||||||2017-06-30|2017-07-02|Actual|September 20, 2006||2006-09-20|March 3, 2009|2009-03-03|March 3, 2009||2009-03-03|||||Interventional|||Catheter-Based Treatment of Cardiovascular Disease|Catheter-Based Treatment of Cardiovascular Disease in Patients|Completed||N/A|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:44:55.173393|2018-06-01 03:44:55.173393
NCT00380003|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2008-01-29|2006-09-22|2006-09-25|Estimate|||||||2008-01-29|2008-01-30|Estimate|September 2006||2006-09-30|January 2008|2008-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Efficacy Study of EVT 201 to Treat Insomnia|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Crossover Study to Assess the Efficacy of Two Doses of EVT 201 in the Treatment of Primary Insomnia in Adult Patients|Completed||Phase 2|66||Evotec Neurosciences GmbH|||||f||||||||||||||2018-06-01 03:44:55.25221|2018-06-01 03:44:55.25221
NCT00379457|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2013-08-09|2006-09-19|2006-09-21|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2006||2006-06-30|July 2009|2009-07-31||||May 2011|Anticipated|2011-05-31||Interventional|||Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma|A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005]|Unknown status|Recruiting|Phase 3|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:45:19.906491|2018-06-01 03:45:19.906491
NCT00379990|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21||2009-07-22|2012-06-21|2006-09-21|2006-09-25|Estimate||||2009-07-22|2009-08-10|Estimate|2012-06-21|2012-07-02|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Effect on Synovial Thickness and Vascularity of 28 Days Repeat Dosing of GW274150 or 7.5mg Prednisolone in RA Subjects.|Completed||Phase 2|48|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:44:55.335613|2018-06-01 03:44:55.335613
NCT00379977|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2016-10-11|2006-09-22|2006-09-25|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age|Open, Primary Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Administered to Healthy Chinese Infants at 3, 4 and 5 Months of Age.|Completed||Phase 3|30||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:44:55.411422|2018-06-01 03:44:55.411422
NCT00379964|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2017-02-20|2006-09-22|2006-09-25|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2005||2005-06-30|February 2017|2017-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)|A Noncomparative, Multicenter, Open-Label, Study to Evaluate the Safety, Tolerability and Efficacy of MK0991 as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia|Completed||Phase 3|50|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:44:55.481593|2018-06-01 03:44:55.481593
NCT00379951|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2017-02-16|2006-09-22|2006-09-25|Estimate|||||||2017-02-16|2017-02-17|Actual|June 2005||2005-06-30|February 2017|2017-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)|A Prospective, Multicenter, Noncomparative, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections|Completed||Phase 3|107|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 03:44:55.53139|2018-06-01 03:44:55.53139
NCT00379938|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21||2011-07-20|2011-08-11|2006-09-21|2006-09-25|Estimate||||2011-07-20|2011-07-22|Estimate|2011-08-11|2011-08-15|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||B-19 Parvovirus Vaccine Study|A Phase I/II Study of the Safety and Immunogenicity of a Recombinant Human Parvovirus B-19 Vaccine|Terminated||Phase 1/Phase 2|43|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 03:44:55.586834|2018-06-01 03:44:55.586834
NCT00379925|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-22|||2013-07-05|2006-09-22|2006-09-25|Estimate|||||||2013-07-05|2013-07-09|Estimate|July 2006||2006-07-31|July 2013|2013-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effectiveness of a Church-Based Program at Increasing Physical Activity and Healthy Dietary Habits in African Americans|A Partnership to Promote Physical Activity and Healthy Eating in AME Churches|Completed||Phase 3|1600|Actual|University of South Carolina||1|||f||||f||||||||||2018-06-01 03:44:55.660445|2018-06-01 03:44:55.660445
NCT00379912|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2017-02-09||2018-01-18|2006-09-21|2006-09-25|Estimate|2017-05-01|2017-05-31|Actual||||2018-01-18|2018-02-14|Actual|September 2006||2006-09-30|January 2018|2018-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes|Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts)|Terminated||Phase 2|15|Actual|Hoosier Cancer Research Network|Results of interim analysis led to early closure of the study.|2||Insufficient response rate|f||||t||||||||No||2018-06-01 03:44:55.741291|2018-06-01 03:44:55.741291
NCT00379899|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2010-10-01||2014-07-14|2006-09-21|2006-09-25|Estimate|2010-10-01|2010-10-27|Estimate||||2014-07-14|2014-07-23|Estimate|September 2006||2006-09-30|July 2014|2014-07-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis|A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis|Completed||Phase 4|360|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:44:56.284687|2018-06-01 03:44:56.284687
NCT00379886|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2007-11-13|2006-09-21|2006-09-25|Estimate|||||||2007-11-13|2007-11-14|Estimate|January 2003||2003-01-31|November 2007|2007-11-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Comparison of Thiopental and Propofol as Anaesteticum During ECT|Comparison of Thiopental and Propofol as Anaesteticum During ECT|Unknown status|Recruiting|N/A|100|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:44:58.583412|2018-06-01 03:44:58.583412
NCT00379873|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2007-07-31|2006-09-22|2006-09-25|Estimate|||||||2007-07-31|2007-08-01|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Chiropractic Adjustment on Physiological Measurements||Completed||N/A|||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:44:58.669689|2018-06-01 03:44:58.669689
NCT00379860|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2007-03-08|2006-09-21|2006-09-25|Estimate|||||||2007-03-08|2007-03-09|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|January 2007||2007-01-31|||||Interventional|||Study Evaluation LXR-623 in Healthy Adults|A Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of LXR-623 Administered Orally to Healthy Subjects|Terminated||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:44:58.718473|2018-06-01 03:44:58.718473
NCT00379847|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2014-04-30|2006-09-21|2006-09-25|Estimate|||||||2014-04-30|2014-05-02|Estimate|February 2004||2004-02-29|April 2014|2014-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia|A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia|Completed||Phase 3|251|Actual|Cumberland Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:44:58.770978|2018-06-01 03:44:58.770978
NCT00379834|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2013-07-25||2015-01-26|2006-09-21|2006-09-25|Estimate|2015-01-26|2015-02-10|Estimate||||2015-01-26|2015-02-10|Estimate|September 2006||2006-09-30|January 2015|2015-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||12-Month Stability of Diurnal IOP Control on Cosopt|12-Month Stability of Diurnal IOP Control on Cosopt|Completed||Phase 4|10|Actual|West Virginia University||1|||f||||f||||||||||2018-06-01 03:44:58.886721|2018-06-01 03:44:58.886721
NCT00379821|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2011-06-30|2010-07-01|2014-08-07|2006-09-21|2006-09-25|Estimate|2011-06-30|2011-07-27|Estimate|2010-07-01|2010-07-07|Estimate|2014-08-07|2014-08-11|Estimate|February 2007||2007-02-28|July 2014|2014-07-31|September 2012|Actual|2012-09-30|August 2009|Actual|2009-08-31||Interventional|||Chloroquine Alone or in Combination for Malaria in Children in Malawi|A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi|Completed||Phase 3|640|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 03:44:59.198006|2018-06-01 03:44:59.198006
NCT00379808|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|2012-02-14||2012-06-07|2006-09-20|2006-09-22|Estimate|2012-06-07|2012-07-23|Estimate||||2012-06-07|2012-07-23|Estimate|July 2006||2006-07-31|June 2012|2012-06-30|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease|Role of the Arachidonate 5-Lipoxygenase Pathway in Coronary Heart Disease|Completed||N/A|22|Actual|University of Florida|Because there were no order effects, the placebo groups were combined and the montelukast groups were combined. Therefore results from each of these are not reported by arm.|2|||f||||f||||||||||2018-06-01 03:45:00.847916|2018-06-01 03:45:00.847916
NCT00379795|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2011-04-01||2017-04-05|2006-09-21|2006-09-22|Estimate|2011-12-05|2012-01-13|Estimate||||2017-04-05|2017-05-11|Actual|April 2005||2005-04-30|April 2017|2017-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO|An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study|Completed||N/A|853|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:45:01.355642|2018-06-01 03:45:01.355642
NCT00379782|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2011-05-26|2006-09-20|2006-09-22|Estimate|||||||2011-05-26|2011-05-30|Estimate|October 2006||2006-10-31|May 2011|2011-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Kukui Ahi Navigator Cancer Screening and Treatment Demonstration Project||Completed||N/A|628|Anticipated|Queen's Medical Centre|||||f||||||||||||||2018-06-01 03:45:04.332605|2018-06-01 03:45:04.332605
NCT00379769|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2009-08-24||2017-03-21|2006-09-21|2006-09-22|Estimate|2009-10-07|2009-11-13|Estimate||||2017-03-21|2017-03-23|Actual|April 2001||2001-04-30|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|RECORD||RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes|A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia|Completed||Phase 3|4447|Actual|GlaxoSmithKline||4|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:45:05.352453|2018-06-01 03:45:05.352453
NCT00379756|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2017-08-14|2006-09-21|2006-09-22|Estimate|||||||2017-08-14|2017-08-16|Actual|May 22, 2006|Actual|2006-05-22|August 2017|2017-08-31|May 17, 2007|Actual|2007-05-17|May 17, 2007|Actual|2007-05-17||Interventional|||A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia|Completed||Phase 4|395|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:45:16.403373|2018-06-01 03:45:16.403373
NCT00379743|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2018-04-24|2006-09-20|2006-09-22|Estimate|||||||2018-04-24|2018-04-26|Actual|October 2006||2006-10-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Partnership for Healthy Seniors|Cancer Prevention and Treatment Among African American Older Adults: Screening Trial|Completed||N/A|2593|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||||2018-06-01 03:45:16.675675|2018-06-01 03:45:16.675675
NCT00379730|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-07-06|2006-09-20|2006-09-22|Estimate|||||||2017-07-06|2017-07-11|Actual|March 21, 2006||2006-03-21|July 2017|2017-07-31|May 3, 2007|Actual|2007-05-03|||||Interventional|||Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind Study of Treatment With a Known Anti-inflammatory (Prednisolone) to Evaluate Novel Endpoints in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|90||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:45:16.752162|2018-06-01 03:45:16.752162
NCT00379717|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2008-03-12|2006-09-21|2006-09-22|Estimate|||||||2008-03-12|2008-03-13|Estimate|November 2006||2006-11-30|September 2006|2006-09-30|April 2008||2008-04-30|||||Interventional|||Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)|Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): a Phase I/II Trial of Radiation Dose Escalation and Fixed Dose Chemotherapy.|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|AZ-VUB|||||f||||||||||||||2018-06-01 03:45:16.828355|2018-06-01 03:45:16.828355
NCT00379704|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2011-12-07|2006-09-21|2006-09-22|Estimate|||||||2011-12-07|2011-12-08|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects.|TIFACT Study - Tissue Factor Expression by Adipose Tissue in Extremely Obese Subjects. Relationship With Circulating Tissue Factor and Coagulation Activation Markers|Completed|||85|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples Without DNA|"~     samples of plasma and serum and greasy fragments~   "|||2018-06-01 03:45:16.907436|2018-06-01 03:45:16.907436
NCT00379691|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2007-03-19|2006-09-21|2006-09-22|Estimate|||||||2007-03-19|2007-03-21|Estimate|August 2006||2006-08-31|March 2007|2007-03-31|December 2006|Actual|2006-12-31|||||Interventional|||Ideal Dose of Phenylephrine to Treat Low Blood Pressure During Cesarean Section|Phenylephrine Dose-Finding Study to Minimize Hypotension Due to Spinal Anesthesia for Cesarean Section|Completed||N/A|50||Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||||f||||f||||||||||2018-06-01 03:45:16.966087|2018-06-01 03:45:16.966087
NCT00379678|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-03-27|2006-09-20|2006-09-22|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2006||2006-09-30|March 2017|2017-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis|A Pilot Ex-vivo Study to Evaluate the Effect of Pimecrolimus on Antimicrobial Peptide Expression and Vaccinia Virus Growth in Perilesional Skin Cultures of Patients With Atopic Dermatitis|Completed|||28|Actual|National Jewish Health|||1||f||||||||||||||2018-06-01 03:45:17.052145|2018-06-01 03:45:17.052145
NCT00379665|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2012-12-10|2006-09-20|2006-09-22|Estimate|||||||2012-12-10|2012-12-11|Estimate|October 2005||2005-10-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|December 2010|Actual|2010-12-31||Interventional|||Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy|Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy|Completed||Phase 2|25|Actual|Southwestern Regional Medical Center||1|||f||||f||||||||||2018-06-01 03:45:17.108935|2018-06-01 03:45:17.108935
NCT00379639|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|2012-07-05||2012-07-05|2006-09-20|2006-09-22|Estimate|2012-07-05|2012-08-13|Estimate||||2012-07-05|2012-08-13|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors|A Phase I/II Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors.|Completed||Phase 1|36|Actual|Celgene||1|||f||||||||||||||2018-06-01 03:45:17.287602|2018-06-01 03:45:17.287602
NCT00379626|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2017-02-13|2006-09-21|2006-09-22|Estimate|||||||2017-02-13|2017-02-14|Actual|August 2003|Actual|2003-08-31|February 2017|2017-02-28|August 2010|Actual|2010-08-31|August 2008|Actual|2008-08-31||Interventional|||Cognitive and Hormonal Treatment of Sex Offenders|Cognitive Group and Hormonal Treatment of Sex Offenders.|Terminated||Phase 1|5|Actual|Norwegian University of Science and Technology||1||too few patients participated|f||||f||||||||||2018-06-01 03:45:18.455783|2018-06-01 03:45:18.455783
NCT00379613|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2017-08-18|2006-09-21|2006-09-22|Estimate|||||||2017-08-18|2017-08-22|Actual|November 7, 2003|Actual|2003-11-07|August 2017|2017-08-31|July 14, 2004|Actual|2004-07-14|July 14, 2004|Actual|2004-07-14||Interventional|||Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)|A Multi-Center Randomized Safety Assessor-Blinded Placebo-Controlled Parallel and Dose Escalating Dose-Finding Trial in Subjects of ASA 1 - 2 to Assess the Safety, Efficacy and PK of Sugammadex Administered at 5 Min. After Administration of 1.2 mg/kg Esmeron|Completed||Phase 2|45|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-06-01 03:45:18.5271|2018-06-01 03:45:18.5271
NCT00379600|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2016-10-24|2006-09-21|2006-09-22|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2004||2004-11-30|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Anti-inflammatory and Metabolic Effects of Rosiglitazone XR, 8mg Once Daily, in Subjects With Rheumatoid Arthritis|Completed||Phase 2|96|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:45:18.600713|2018-06-01 03:45:18.600713
NCT00379587|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2014-02-03||2014-02-03|2006-09-21|2006-09-22|Estimate|2014-02-03|2014-03-19|Estimate||||2014-02-03|2014-03-19|Estimate|September 2006||2006-09-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Rituximab for Prevention of Chronic GVHD|A Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation|Completed||Phase 1/Phase 2|65|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 03:45:18.714147|2018-06-01 03:45:18.714147
NCT00379574|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|2011-02-04||2013-03-13|2006-09-21|2006-09-22|Estimate|2013-02-12|2013-03-14|Estimate||||2013-03-13|2013-03-15|Estimate|September 2006||2006-09-30|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL|A Phase I/II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients With Advanced Stage Diffuse Large B-cell Lymphomas|Completed||Phase 1/Phase 2|49|Actual|Asan Medical Center||1|||f||||t||||||||||2018-06-01 03:45:18.9152|2018-06-01 03:45:18.9152
NCT00379561|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2009-10-27|2006-09-21|2006-09-22|Estimate|||||||2009-10-27|2009-10-29|Estimate|March 2006||2006-03-31|September 2009|2009-09-30|July 2008|Actual|2008-07-31|May 2007|Actual|2007-05-31||Interventional|||PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer|A Phase 1 Trial of PSA-Activated PSA-PAH1 Therapy for Locally Recurrent Prostate Cancer Without Metastases After Primary Radiation Therapy|Completed||Phase 1|36|Anticipated|Sophiris Bio Corp|||||||||||||||||||2018-06-01 03:45:19.227401|2018-06-01 03:45:19.227401
NCT00379548|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2017-03-17|2006-09-21|2006-09-22|Estimate|||||||2017-03-17|2017-03-20|Actual|November 2005||2005-11-30|March 2017|2017-03-31|September 2014|Actual|2014-09-30|July 2008|Actual|2008-07-31||Interventional|||Changes in Inflammatory State in Asian Americans Changing From Traditional Asian Diets to American Diet - a Pilot Study|A Pilot Study of the Changes in Inflammatory State in Asian Americans Changing From Traditional Asian Diet to Typical American Diets|Completed||N/A|50|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-06-01 03:45:19.296762|2018-06-01 03:45:19.296762
NCT00379535|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2011-10-10|2006-09-21|2006-09-22|Estimate|||||||2011-10-10|2011-10-12|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|December 2008|Actual|2008-12-31||Interventional|||Preventing Lack of Iodine During Pregnancy|Phase III : Preventing Lack of Iodine During Pregnancy. Effect of Supplying Woman With Potassium Iodine to the Neuro-Cognitive Children Development Until Two Years|Terminated||Phase 3|374|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 03:45:19.367873|2018-06-01 03:45:19.367873
NCT00379522|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2014-11-04|2006-09-21|2006-09-22|Estimate|||||||2014-11-04|2014-11-05|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Vasopressin in Traumatic Hemorrhagic Shock Study|A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-study)|Completed||Phase 2/Phase 3|64|Actual|Medical University Innsbruck||2|||f||||t||||||||||2018-06-01 03:45:19.456584|2018-06-01 03:45:19.456584
NCT00379509|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-03-17|2006-09-20|2006-09-22|Estimate|||||||2017-03-17|2017-03-21|Actual|April 2006||2006-04-30|March 2017|2017-03-31|August 2012|Actual|2012-08-31|June 2010|Actual|2010-06-30||Interventional|||Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer|Phase I Radiosensitization Study of GW572016 With Biologic Correlates in Locoregionally Recurrent Breast Cancer|Completed||Phase 1|20|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:45:19.567921|2018-06-01 03:45:19.567921
NCT00379496|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-21|||2006-09-21|2006-09-21|2006-09-22|Estimate|||||||2006-09-21|2006-09-22|Estimate|April 2000||2000-04-30|September 2006|2006-09-30|May 2002||2002-05-31|||||Interventional|||Trial of Acupuncture Added to Usual Treatment for Fibromyalgia|A Randomized Controlled Trial of Acupuncture Added to Usual Treatment for Fibromyalgia|Completed||Early Phase 1|58||University of Sao Paulo|||||f||||||||||||||2018-06-01 03:45:19.660978|2018-06-01 03:45:19.660978
NCT00379483|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-03-18|2006-09-20|2006-09-22|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2002||2002-07-31|March 2015|2015-03-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload|Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload|Completed||Phase 2|66|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:45:19.729532|2018-06-01 03:45:19.729532
NCT00379470|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2012-04-29|2006-09-20|2006-09-21|Estimate|||||||2012-04-29|2012-05-01|Estimate|September 2006||2006-09-30|April 2012|2012-04-30|January 2011|Actual|2011-01-31|November 2009|Actual|2009-11-30||Interventional|||Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)|A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM|Completed||Phase 3|236|Actual|NovoCure Ltd.||2|||f||||t||||||||||2018-06-01 03:45:19.799847|2018-06-01 03:45:19.799847
NCT00379431|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2014-12-04|2006-09-20|2006-09-21|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2006||2006-11-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab|A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 03:45:20.098211|2018-06-01 03:45:20.098211
NCT00379418|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2013-09-11|2006-09-20|2006-09-21|Estimate|||||||2013-09-11|2013-09-12|Estimate|January 2003||2003-01-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|AIR||Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients|Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)|Completed|||220|Actual|Emory University|||||f||||f||||||||||2018-06-01 03:45:20.173865|2018-06-01 03:45:20.173865
NCT00379405|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2008-10-10|2006-09-20|2006-09-21|Estimate|||||||2008-10-10|2008-10-13|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment|Open-Label, Comparative and Randomised Pilot Study to Evaluate the Efficacy and Safety of Saquinavir/Ritonavir in Single Therapy vs Standard HAART Therapy as Maintenance Therapy.|Completed||Phase 4|30|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 03:45:20.244293|2018-06-01 03:45:20.244293
NCT00379392|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2015-04-10|2006-09-19|2006-09-21|Estimate|||||||2015-04-10|2015-04-14|Estimate|January 2003||2003-01-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|July 2008|Actual|2008-07-31||Interventional|||Mental Imagery to Reduce Motor Deficits in Stroke|Mental Imagery to Reduce Motor Deficits in Stroke|Completed||Phase 1|20|Actual|Emory University||2|||f||||t||||||||||2018-06-01 03:45:20.483964|2018-06-01 03:45:20.483964
NCT00379379|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2006-09-20|2006-09-20|2006-09-21|Estimate|||||||2006-09-20|2006-09-21|Estimate|January 2005||2005-01-31|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||Study of Improving Insulin Sensitivity by Electroacupuncture Therapy|Study of Improving Insulin Sensitivity by Combined Both Electroacupuncture and Drug Therapy|Completed||N/A|26||China Medical University Hospital|||||f||||||||||||||2018-06-01 03:45:20.572667|2018-06-01 03:45:20.572667
NCT00379366|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2015-03-17|2006-09-20|2006-09-21|Estimate|||||||2015-03-17|2015-03-18|Estimate|December 2006||2006-12-31|March 2015|2015-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|RASTA||External Ionizing Radiation to Prevent Restenosis on Haemodialysis Vascular Access|Efficacy and Tolerance of Transcutaneous Ionizing Radiations to Prevent Restenosis Caused by Intimal Hyperplasia on Prosthetic Haemodialysis Vascular Access|Terminated||Phase 2/Phase 3|5|Actual|University Hospital, Bordeaux||2||lack of patients|f||||t||||||||||2018-06-01 03:45:20.638203|2018-06-01 03:45:20.638203
NCT00379353|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2012-07-03||2013-01-31|2006-09-19|2006-09-21|Estimate|2012-11-29|2013-01-01|Estimate||||2013-01-31|2013-02-04|Estimate|September 2006||2006-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Effects of Thalidomide on Symptom Clusters|The Effects of Thalidomide on Symptom Clusters|Completed||Phase 2|32|Actual|M.D. Anderson Cancer Center|Limited accrual and attrition led to small sample size.|2|||f||||t||||||||||2018-06-01 03:45:20.741156|2018-06-01 03:45:20.741156
NCT00379340|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2016-12-06||2017-05-17|2006-09-19|2006-09-21|Estimate|2017-05-17|2017-06-14|Actual||||2017-05-17|2017-06-14|Actual|February 2007||2007-02-28|December 2016|2016-12-31||||October 2015|Actual|2015-10-31||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor|Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors|Completed||Phase 3|395|Actual|Children's Oncology Group||5|||f||||t||||||||||2018-06-01 03:45:21.356291|2018-06-01 03:45:21.356291
NCT00379327|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2010-11-17|2006-09-19|2006-09-21|Estimate|||||||2010-11-17|2010-11-18|Estimate|January 2006||2006-01-31|October 2010|2010-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Acupuncture for Promotion of Timely Delivery|Acupuncture for Promotion of Timely Delivery|Completed||Phase 3|103|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 03:45:23.062534|2018-06-01 03:45:23.062534
NCT00379314|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2006-10-31|2006-09-19|2006-09-21|Estimate|||||||2006-10-31|2006-11-01|Estimate|April 2004||2004-04-30|September 2006|2006-09-30|December 2010||2010-12-31|||||Interventional|||Randomized, Multicenter Trial Comparing TVT With TVT-O for Treatment of Female Urinary Incontinence|A Randomized, Prospective, Multicenter Trial Comparing TVT With TVT-O Procedures in Treatment of Female Primary Urinary Stress Incontinence|Unknown status|Active, not recruiting|Phase 3|260||Helsinki University|||||f||||||||||||||2018-06-01 03:45:23.137201|2018-06-01 03:45:23.137201
NCT00379301|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2012-06-13|2006-09-20|2006-09-21|Estimate|||||||2012-06-13|2012-06-14|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|December 2009|Actual|2009-12-31||Interventional|RASTA||Efficacy of Different Ablation Strategies for Controlling Atrial Fibrillation|Efficacy of Different Ablation Strategies in Achieving Long-Term Arrhythmia Control in Patients With Persistent or Permanent Atrial Fibrillation|Completed||N/A|166|Actual|University of Pennsylvania||3|||f||||||||||||||2018-06-01 03:45:23.198248|2018-06-01 03:45:23.198248
NCT00379288|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2010-07-15||2017-03-13|2006-09-19|2006-09-21|Estimate|2010-07-15|2010-08-12|Estimate||||2017-03-13|2017-04-11|Actual|June 2006||2006-06-30|March 2017|2017-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)|A 1-Year Safety Study of Medium and High Doses of Mometasone Furoate/Formoterol Combination Formulation and Medium and High Doses of Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Medium to High Doses of Inhaled Glucocorticosteroids|Completed||Phase 3|404|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:45:23.295218|2018-06-01 03:45:23.295218
NCT00379275|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-06-30|2006-09-20|2006-09-21|Estimate|||||||2017-06-30|2017-07-02|Actual|September 18, 2006||2006-09-18|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Eye and Immunogenetic Features of Sarcoidosis|Ocular and Immuno-Genetic Manifestations of Sarcoidosis|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:45:23.857224|2018-06-01 03:45:23.857224
NCT00379262|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-08-13|2006-09-20|2006-09-21|Estimate|||||||2017-08-13|2017-08-16|Actual|September 2006||2006-09-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Interventional|||Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma|Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma|Active, not recruiting||Phase 3|798|Anticipated|Hong Kong Nasopharyngeal Cancer Study Group Limited||6|||f||||t||||||||||2018-06-01 03:45:23.990162|2018-06-01 03:45:23.990162
NCT00379249|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2009-03-25|2006-09-20|2006-09-21|Estimate|||||||2009-03-25|2009-03-26|Estimate|February 2002||2002-02-28|March 2009|2009-03-31|February 2004|Actual|2004-02-29|||||Interventional|||Rosuvastatin ORBITAL Germany|Effects of a Twelve Months ROSUVASTATIN Treatment Plus Additional Care (Drug Intake Adherence and Lifestyle Enhancing Initiatives ) Compared to ROSUVASTATIN Treatment Alone on Long-Term Disease-Related Costs in Patients With an Indication for Statin Treatment According to the Joint European Guidelines|Completed||Phase 3|8000||AstraZeneca|||||f||||||||||||||2018-06-01 03:45:24.08553|2018-06-01 03:45:24.08553
NCT00379236|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|2009-08-12||2011-12-20|2006-09-20|2006-09-21|Estimate|2009-11-03|2009-12-10|Estimate||||2011-12-20|2011-12-28|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee, With an Open-Label Safety Extension|Completed||N/A|588|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:45:24.163905|2018-06-01 03:45:24.163905
NCT00379223|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2011-03-03|2006-09-20|2006-09-21|Estimate|||||||2011-03-03|2011-03-04|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|OVCR||Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial|Multicenter Trial to Investigate the Safety and Efficacy of Vitrectomy With Radial Optic Neurotomy for the Preservation of Visual Function in Subjects With Central Retinal Vein Occlusion (CRVO)|Terminated||N/A|7|Actual|University Hospital, Bordeaux||2||lack of recruting|f||||t||||||||||2018-06-01 03:45:26.222751|2018-06-01 03:45:26.222751
NCT00379210|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|2010-07-20||2011-12-20|2006-09-20|2006-09-21|Estimate|2011-12-20|2012-01-26|Estimate||||2011-12-20|2012-01-26|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Neural Effects of Mindfulness Training on Attention|Neural Effects of Mindfulness Training on Attention|Completed||N/A|60|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:45:26.323106|2018-06-01 03:45:26.323106
NCT00379197|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2015-04-22||2017-12-03|2006-09-19|2006-09-21|Estimate|2017-04-13|2017-05-19|Actual||||2017-12-03|2017-12-28|Actual|July 2006||2006-07-31|December 2017|2017-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer|Phase II Study of Naltrexone for the Treatment of Hormone-Refractory, Metastatic Breast Cancer|Terminated||Phase 2|13|Actual|Masonic Cancer Center, University of Minnesota||1||slow accrual|f||||t||||||||||2018-06-01 03:45:26.766493|2018-06-01 03:45:26.766493
NCT00379184|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2014-03-28|2006-09-19|2006-09-21|Estimate|||||||2014-03-28|2014-03-31|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Observational|||Sensitization in Osteoarthritic Knees|Quantitative Assessment of Central Sensitization in Osteoarthritis Patients|Completed|||72|Actual|Northern Orthopaedic Division, Denmark|||3||f||||f||||||||||2018-06-01 03:45:26.994081|2018-06-01 03:45:26.994081
NCT00379171|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2008-08-13|2006-09-20|2006-09-21|Estimate|||||||2008-08-13|2008-08-14|Estimate|May 2003||2003-05-31|August 2008|2008-08-31|March 2004||2004-03-31|||||Interventional|||Milk Types and Fish Oil in 9- to 12-Month-Old Infants|The Importance of Complementary Feeding on Growth, Nutritional Status and Markers for Disease. An Intervention Study With Milk Types and LC-PUFA Supplements in 9- to 12-Month-Old Infants|Completed||N/A|100||University of Copenhagen|||||f||||||||||||||2018-06-01 03:45:27.106095|2018-06-01 03:45:27.106095
NCT00379158|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-05-24|2006-09-20|2006-09-21|Estimate|||||||2017-05-24|2017-05-30|Actual|October 2003||2003-10-31|May 2017|2017-05-31|April 2005||2005-04-30|||||Interventional|||Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana|Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements Added to Complementary Foods for Infants in Ghana|Completed||Phase 4|393||University of California, Davis|||||f||||||||||||||2018-06-01 03:45:27.250517|2018-06-01 03:45:27.250517
NCT00379145|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2017-10-13||2017-11-10|2006-09-19|2006-09-21|Estimate|2017-11-10|2017-12-12|Actual||||2017-11-10|2017-12-12|Actual|June 2007||2007-06-30|May 2015|2015-05-31||||January 2012|Actual|2012-01-31||Interventional||Eligible and treated patients|Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus|A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas|Completed||Phase 2|20|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 03:45:27.508373|2018-06-01 03:45:27.508373
NCT00379132|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2009-03-30|2006-09-20|2006-09-21|Estimate|||||||2009-03-30|2009-03-31|Estimate|August 2006||2006-08-31|March 2009|2009-03-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||131-I-TM-601 Study in Adults With Solid Tumors|A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labeled Chlorotoxin in Patients With Recurrent or Refractory Somatic and/or Cerebral Metastatic Solid Tumors|Completed||Phase 1|60|Anticipated|TransMolecular|||||f||||||||||||||2018-06-01 03:45:28.341708|2018-06-01 03:45:28.341708
NCT00379119|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2012-10-09|2006-09-19|2006-09-21|Estimate|||||||2012-10-09|2012-10-11|Estimate|January 2005||2005-01-31|October 2012|2012-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer|Androgen Blockade Therapy and Thymic Function in Individuals Over 50 Years of Age With Adenocarcinoma of the Prostate: A Cross-Sectional Study|Terminated|||20|Actual|University of California, San Francisco||||low accrual|f||||f||||||||||2018-06-01 03:45:28.489656|2018-06-01 03:45:28.489656
NCT00379106|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2010-01-06|2006-09-20|2006-09-21|Estimate|||||||2010-01-06|2010-01-07|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|December 2005|Actual|2005-12-31||Interventional|||Arm Function and Quality of Life Following Mastectomy.|Arm Function and Quality of Life Following Mastectomy.|Completed||N/A|50|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 03:45:28.748651|2018-06-01 03:45:28.748651
NCT00379093|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2009-07-10|2006-09-19|2006-09-21|Estimate|||||||2009-07-10|2009-07-13|Estimate|August 2003||2003-08-31|July 2009|2009-07-31|July 2008|Actual|2008-07-31|April 2007|Actual|2007-04-30||Interventional|HLAYA||Healthy Living as You Age|Preventing Harm From Alcohol Use in Older Adults|Completed||Phase 2|631|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||t||||||||||2018-06-01 03:45:28.874452|2018-06-01 03:45:28.874452
NCT00379080|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2016-07-15||2017-02-22|2006-09-19|2006-09-21|Estimate|2017-02-22|2017-04-07|Actual||||2017-02-22|2017-04-07|Actual|January 2007||2007-01-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional||all pts had to have confirmed histological GBM, prior treatment wih RT and a MMSE of greater or equal to 15.|Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma|A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma|Completed||Phase 1/Phase 2|60|Actual|National Cancer Institute (NCI)|Simon's two-stage design Phase 2, prespecified goal patients alive & progression-free survival 6-months not achieved first stage, 2nd stage not done & trial closed/stopped.|3|||f||||t||||||||||2018-06-01 03:45:29.033687|2018-06-01 03:45:29.033687
NCT00379067|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2014-10-08|2006-09-19|2006-09-21|Estimate|||||||2014-10-08|2014-10-10|Estimate|October 2005||2005-10-31|October 2014|2014-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.|A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia|Completed||Phase 4|882|Actual|Astellas Pharma Inc||2|||f||||||||||||||2018-06-01 03:45:31.653258|2018-06-01 03:45:31.653258
NCT00379054|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2010-11-18|2006-09-19|2006-09-21|Estimate|||||||2010-11-18|2010-11-22|Estimate|September 2005||2005-09-30|November 2010|2010-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Intervention for Support Persons to Help Smokers Quit|Intervention for Support Persons to Help Smokers Quit|Completed||Phase 1/Phase 2|70||Mayo Clinic|||||f||||||||||||||2018-06-01 03:45:33.070153|2018-06-01 03:45:33.070153
NCT00379041|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2018-02-19|2006-09-20|2006-09-21|Estimate|||||||2018-02-19|2018-02-20|Estimate|September 1993||1993-09-30|February 2018|2018-02-28||||October 1998|Actual|1998-10-31||Interventional|||Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma|Protocol H8 for a Prospective Controlled Trial in Clinical Stage I-II Supradiaphragmatic Hodgkin's Disease. Evaluation of Treatment Efficacy and (Long Term) Toxicity in Three Different Prognostic Subgroups [H8 Trial]|Active, not recruiting||Phase 3|1158|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 03:45:33.150561|2018-06-01 03:45:33.150561
NCT00379028|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2011-01-21|2006-09-20|2006-09-21|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2006||2006-09-30|January 2011|2011-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Airway Clearance Study|A Randomized, Double-blind, Two-way Cross-over Study Evaluating Systemic Bioavailability and Airway Clearance of SymbicortTurbuhaler 320/9mcg vs SeretideDiskus 50/500mcg After Single Inhalations in Patients With COPD and Healthy Volunteers|Completed||Phase 4|54|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:45:33.47944|2018-06-01 03:45:33.47944
NCT00379015|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2016-09-27|2006-09-19|2006-09-21|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2006||2006-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer|Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined With Trastuzumab for the Patients With HER-Positive Advanced Breast Cancer|Completed||Phase 2|38|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||f||||||||||2018-06-01 03:45:33.562905|2018-06-01 03:45:33.562905
NCT00379002|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2017-12-21|2006-09-19|2006-09-21|Estimate|||||||2017-12-21|2017-12-26|Actual|July 2006|Actual|2006-07-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||The Women's Urology Center/WISH Database Project|The Women's Urology Center/WISH Database Project|Enrolling by invitation|||10000|Anticipated|William Beaumont Hospitals|||||f||||f||||||||No||2018-06-01 03:45:33.656641|2018-06-01 03:45:33.656641
NCT00378989|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2015-02-09|2006-09-19|2006-09-21|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2004||2004-09-30|February 2015|2015-02-28|October 2006|Actual|2006-10-31|October 2005|Actual|2005-10-31||Interventional|||The Effectiveness of Health Advice and Occupational Health Intervention on Work Ability|The Effectiveness and Cost-effectiveness of Health Advice and Occupational Health Intervention on Work Ability. Two Randomised Trials.|Completed||N/A|418|Actual|Evalua International||2|||f||||f||||||||||2018-06-01 03:45:33.749079|2018-06-01 03:45:33.749079
NCT00378976|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2013-08-21|2006-09-19|2006-09-21|Estimate|||||||2013-08-21|2013-08-22|Estimate|August 2003||2003-08-31|August 2013|2013-08-31|July 2004|Actual|2004-07-31|||||Interventional|||HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.|A Randomized, Double-blind, Placebo-controlled Crossover Trial of Valacyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Men Who Have Sex With Men (MSM).|Completed||Phase 3|20|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:45:33.854604|2018-06-01 03:45:33.854604
NCT00378963|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2007-07-31|2006-09-18|2006-09-21|Estimate|||||||2007-07-31|2007-08-01|Estimate||||May 2007|2007-05-31||||||||Interventional|||Instrument Applied and Manual Manipulation Induced EMG Response in Asymptomatic Subjects||Unknown status|Recruiting|N/A|||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:45:33.991219|2018-06-01 03:45:33.991219
NCT00378950|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-05-01|2006-09-20|2006-09-21|Estimate|||||||2017-05-01|2017-05-04|Actual|March 2007||2007-03-31|May 2016|2016-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Educational Program for Various Health Literacy Levels to Improve the Health of Individuals With Heart Failure|Health Literacy and Self-Management in Heart Failure|Completed||N/A|605|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 03:45:34.128611|2018-06-01 03:45:34.128611
NCT00378937|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2013-08-01|2006-09-20|2006-09-21|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 2004||2004-01-31|July 2007|2007-07-31|February 2006|Actual|2006-02-28|||||Interventional|||Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain|An Open, Randomized, Parallel Group Study in Patients With Cancer Pain, To Compare a Two-Step Analgesic Ladder (Non-Opioid to Oxycodone) With Conventional Management Using A Three-Step Approach|Completed||Phase 4|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:45:34.320698|2018-06-01 03:45:34.320698
NCT00378924|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2017-07-25|2006-09-20|2006-09-21|Estimate|||||||2017-07-25|2017-07-26|Actual|December 2003||2003-12-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Observational|||Cardiology Biobank Registry|Cardiology Biobank Registry|Recruiting|||12000|Anticipated|Emory University|||||f||||f||||||Samples With DNA|"~     60 cc of blood will be obtained from the participant. Blood will be processed and stored in~     -80F freezers as plasma, serum, extracted DNA and whole blood.~   "|||2018-06-01 03:45:34.455796|2018-06-01 03:45:34.455796
NCT00378911|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2014-06-11|2006-09-19|2006-09-21|Estimate|||||||2014-06-11|2014-06-12|Estimate|October 2006||2006-10-31|December 2012|2012-12-31|January 2010|Actual|2010-01-31|June 2007|Actual|2007-06-30||Interventional|||Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus|A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:45:34.562295|2018-06-01 03:45:34.562295
NCT00378898|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|2015-02-26||2017-03-31|2006-09-20|2006-09-21|Estimate|2017-03-31|2017-04-04|Actual||||2017-03-31|2017-04-04|Actual|September 2006||2006-09-30|March 2017|2017-03-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|bravo|Analysis is based on participants that completed the study|Feasibility of Placing Bravo PH Capsule in Proximal Esophagus|DUAL BRAVO PH MONITORING: A Feasibility Trial|Completed||N/A|39|Actual|Vanderbilt University Medical Center|Selection bias may have been a limitation, as patients volunteering may have had worse symptoms and potentially altered esophageal sensitivity as compared to those who opted not to participate.|2|||f||||f|f|t|f|||||No||2018-06-01 03:45:34.752756|2018-06-01 03:45:34.752756
NCT00378885|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2006-09-20|2006-09-20|2006-09-21|Estimate|||||||2006-09-20|2006-09-21|Estimate|January 2003||2003-01-31|September 2006|2006-09-30|August 2003||2003-08-31|||||Interventional|||Effect Study of a Theory-Based Internet Intervention on Safe-Sex Practices|The Effect of a Theory Based Tailored Intervention Online on the Reduction of Risk Behavior for HIV Transmission Among Men Who Have Sex With Men - a Randomized, Single-Blind, Active (Waiting-List) Controlled Trial|Terminated||N/A|642||Public Health Service of Amsterdam|||||f||||||||||||||2018-06-01 03:45:35.330901|2018-06-01 03:45:35.330901
NCT00378872|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2008-05-13|2006-09-20|2006-09-21|Estimate|||||||2008-05-13|2008-05-14|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Tranexamic Acid vs. Quixil - Reducing Blood Loss in Joint Replacement|Prospective Randomised Trial Comparing Intraoperative Topical Quixil and Intravenous Tranexamic Acid, in Reduction of Blood Loss Following Primary Hip & Knee Joint Replacement Surgery.|Completed||N/A|132|Actual|Golden Jubilee National Hospital|||||f||||f||||||||||2018-06-01 03:45:35.494669|2018-06-01 03:45:35.494669
NCT00378859|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2009-01-20|2006-09-20|2006-09-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 2000||2000-11-30|September 2006|2006-09-30|March 2001||2001-03-31|||||Interventional|||The Effect of Milk and Meat on IGFs in Prepubertal Boys|The Effect of Milk and Meat on IGFs in Prepubertal Boys|Completed||N/A|24||University of Copenhagen|||||f||||||||||||||2018-06-01 03:45:35.609842|2018-06-01 03:45:35.609842
NCT00378846|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2012-03-14|2006-09-19|2006-09-21|Estimate|||||||2012-03-14|2012-03-15|Estimate|March 2006||2006-03-31|March 2012|2012-03-31|November 2009|Actual|2009-11-30|||||Interventional|||Three Different Types of Thermometers in Measuring Temperature in Young Patients With Fever and Without Fever|A Study Evaluating the Agreement of Devices for Measuring Temperature in Children|Completed||N/A|32|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:45:35.764817|2018-06-01 03:45:35.764817
NCT00378833|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2017-02-15|2006-09-20|2006-09-21|Estimate|||||||2017-02-15|2017-02-16|Actual|July 2006||2006-07-31|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)|A Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK0524A Versus Niacin Extended-Release|Completed||Phase 3|1300|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:45:36.01525|2018-06-01 03:45:36.01525
NCT00378820|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2009-01-20|2006-09-20|2006-09-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|July 2004||2004-07-31|September 2006|2006-09-30|April 2005||2005-04-30|||||Interventional|||The Effect of Whey and Casein on IGFs in Prepubertal Boys|The Effect of Whey and Casein With and Without Milk Minerals on IGFs in Prepubertal Boys|Unknown status|Active, not recruiting|N/A|60||University of Copenhagen|||||f||||||||||||||2018-06-01 03:45:36.13613|2018-06-01 03:45:36.13613
NCT00378781|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2012-02-22|2006-09-19|2006-09-21|Estimate|||||||2012-02-22|2012-02-24|Estimate||||February 2012|2012-02-29||||||||Interventional|||Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection|Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2||Study withdrawn.|f||||f||||||||||2018-06-01 03:45:36.287389|2018-06-01 03:45:36.287389
NCT00378768|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2011-11-28|2006-09-19|2006-09-21|Estimate|||||||2011-11-28|2011-11-30|Estimate|November 2005||2005-11-30|November 2011|2011-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma|A Phase II Study of Thymoglobulin in Patients With Multiple Myeloma Who Are Candidates for Allogeneic or Autologous Stem Cell Transplant|Completed||Phase 2|12|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 03:45:36.648998|2018-06-01 03:45:36.648998
NCT00378755|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2006-09-21|2006-09-20|2006-09-21|Estimate|||||||2006-09-21|2006-09-22|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|July 2008||2008-07-31|||||Interventional|||Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM|Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) Induction Followed by HDT With ASCT and Maintenance Treatment With Velcade for Newly Diagnosed MM|Unknown status|Recruiting|Phase 2|62||Korean Multiple Myeloma Working Party|||||f||||||||||||||2018-06-01 03:45:36.837142|2018-06-01 03:45:36.837142
NCT00378742|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2018-05-08|2006-09-20|2006-09-21|Estimate|||||||2018-05-08|2018-05-09|Actual|September 11, 2006||2006-09-11|April 27, 2018|2018-04-27||||||||Observational|||Repository for Inherited Eye Diseases|National Ophthalmic Genotyping and Phenotyping Network, Stage 1 - Creation of DNA Repository for Inherited Ophthalmic Diseases|Active, not recruiting|||6618|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:45:37.052808|2018-06-01 03:45:37.052808
NCT00378729|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2011-10-03|2006-09-19|2006-09-21|Estimate|||||||2011-10-03|2011-10-04|Estimate|October 2006||2006-10-31|October 2007|2007-10-31|October 2011|Anticipated|2011-10-31|October 2011|Anticipated|2011-10-31||Interventional|PERCING||Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS)|PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment|Unknown status|Recruiting|Phase 4|252|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 03:45:37.291394|2018-06-01 03:45:37.291394
NCT00378716|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2010-01-08|2006-09-20|2006-09-21|Estimate|||||||2010-01-08|2010-01-11|Estimate|February 1997||1997-02-28|January 2010|2010-01-31|April 2009|Actual|2009-04-30|May 2006|Actual|2006-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Resected Colon Cancer|A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon|Completed||Phase 3|1608|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 03:45:37.500251|2018-06-01 03:45:37.500251
NCT00378703|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2015-04-14||2018-05-28|2006-09-19|2006-09-21|Estimate|2015-04-14|2015-05-05|Estimate||||2018-05-28|2018-05-30|Actual|November 1, 2005|Actual|2005-11-01|April 2018|2018-04-30||||February 7, 2014|Actual|2014-02-07||Interventional||Eligible and treated patients are included in this analysis.|Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer|The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 2|361|Actual|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-06-01 03:45:37.849977|2018-06-01 03:45:37.849977
NCT00378690|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2014-06-02|2006-09-19|2006-09-21|Estimate|||||||2014-06-02|2014-06-04|Estimate|March 2006||2006-03-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|June 2011|Actual|2011-06-30||Interventional|ICELAND||A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD|A Phase IIIb Randomized Study of Intermittent Versus Continuous Androgen Deprivation Therapy Using ELIGARD 22.5 mg 3-month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy|Completed||Phase 3|706|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:45:40.563166|2018-06-01 03:45:40.563166
NCT00378677|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-20|||2007-02-06|2006-09-20|2006-09-21|Estimate|||||||2007-02-06|2007-02-07|Estimate|February 2007||2007-02-28|February 2007|2007-02-28||||||||Interventional|||Dry Powder Inhalation of Cyclosporine A in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome|Pilot Study of Cyclosporine A Dry Powder Inhalation in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome|Unknown status|Recruiting|Early Phase 1|7||University Medical Center Groningen|||||f||||||||||||||2018-06-01 03:45:40.774532|2018-06-01 03:45:40.774532
NCT00378664|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2015-10-13|2006-09-19|2006-09-21|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2006||2006-09-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Lumbar to Sacral Ventral Nerve Re-Routing|Lumbar to Sacral Ventral Nerve Re-Routing|Completed||Phase 2|13|Actual|William Beaumont Hospitals||1|||f||||t||||||||||2018-06-01 03:45:40.928724|2018-06-01 03:45:40.928724
NCT00378651|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2007-12-14|2006-09-19|2006-09-20|Estimate|||||||2007-12-14|2007-12-19|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Use of the Stethoscope to Confirm Breathing Tube Placement|Differentiation Between Esophageal and Tracheal Intubation Utilizing Neck Auscultation|Completed||N/A|23||University of Manitoba|||||f||||||||||||||2018-06-01 03:45:41.218253|2018-06-01 03:45:41.218253
NCT00378638|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2007-10-23|2006-09-18|2006-09-20|Estimate|||||||2007-10-23|2007-10-24|Estimate|June 2006||2006-06-30|October 2007|2007-10-31|October 2008|Anticipated|2008-10-31|||||Interventional|||Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study|Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymp Node Positive Breast Cancer: A Pilot Study|Unknown status|Recruiting|Phase 2|30|Anticipated|Chap, Linnea I., M.D.|||||f||||f||||||||||2018-06-01 03:45:41.328227|2018-06-01 03:45:41.328227
NCT00378625|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2006-09-19|2006-09-19|2006-09-20|Estimate|||||||2006-09-19|2006-09-20|Estimate|April 2000||2000-04-30|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia|Randomised, Double Blind Clinical Trial of the Efficacy, Effect on Gametocytes and Tolerability of Amodiaquine Vs Amodiaquine Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Quibdo, Colombia|Completed||Phase 3|360||Centro Internacional de Entrenamiento e Investigaciones Médicas|||||f||||||||||||||2018-06-01 03:45:41.524036|2018-06-01 03:45:41.524036
NCT00378612|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2014-09-11|2006-09-19|2006-09-20|Estimate|||||||2014-09-11|2014-09-12|Estimate|June 2005||2005-06-30|September 2014|2014-09-30|September 2012|Actual|2012-09-30|April 2007|Actual|2007-04-30||Interventional|||ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial|Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial|Completed||Phase 3|200|Actual|Duke University||1|||f||||t||||||||||2018-06-01 03:45:41.638647|2018-06-01 03:45:41.638647
NCT00378599|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2010-06-17||2017-03-08|2006-09-18|2006-09-20|Estimate|2010-06-17|2010-07-16|Estimate||||2017-03-08|2017-04-06|Actual|May 2006||2006-05-31|March 2017|2017-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)|PROTECT - Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy|Completed||Phase 3|125|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:45:41.820773|2018-06-01 03:45:41.820773
NCT00378586|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2009-06-22|2006-09-19|2006-09-20|Estimate|||||||2009-06-22|2009-06-23|Estimate|January 2010||2010-01-31|June 2009|2009-06-30||||||||Observational|||Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock|Barrier Function and Production of Inflammatory Cytokines in the Rectal Mucosa in Patients With Septic Shock|Unknown status|Not yet recruiting||30|Anticipated|Herlev Hospital|||||f||||||||||||||2018-06-01 03:45:42.154028|2018-06-01 03:45:42.154028
NCT00378573|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2009-09-17||2010-01-21|2006-09-19|2006-09-20|Estimate|2009-12-14|2010-01-18|Estimate||||2010-01-21|2010-01-26|Estimate|January 2007||2007-01-31|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II, Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Terminated||Phase 2|17|Actual|Sanofi|Due to early termination of the study only 17/90 subjects enrolled. Efficacy analysis of Progression Free Survival and Overall Survival were not performed. Efficacy results limited to a descriptive summary of best overall response for each subject.|1||Incidence of GI Perforation|f||||||||||||||2018-06-01 03:45:42.379313|2018-06-01 03:45:42.379313
NCT00378560|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2010-04-21||2017-03-20|2006-09-19|2006-09-20|Estimate|2010-05-27|2010-06-29|Estimate||||2017-03-20|2017-04-17|Actual|June 12, 2006|Actual|2006-06-12|March 2017|2017-03-31|September 16, 2009|Actual|2009-09-16|September 16, 2009|Actual|2009-09-16||Interventional|||V501 Efficacy Study in Women Aged 18 to 26 (V501-027)|V501 Phase II Efficacy Study in Women Aged 18 to 26|Completed||Phase 2|1021|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:45:43.110452|2018-06-01 03:45:43.110452
NCT00378547|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2009-12-31|2006-09-19|2006-09-20|Estimate|||||||2009-12-31|2010-01-01|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Paracetamol, Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Having a Tonsillectomy|Effect of Paracetamol Versus Paracetamol Combined With Pregabalin Versus Paracetamol Combined With Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for Tonsillectomy|Terminated||Phase 4|147|Actual|Glostrup University Hospital, Copenhagen||3||ENT surgery stopped at the recruiting hospital|f||||t||||||||||2018-06-01 03:45:43.954117|2018-06-01 03:45:43.954117
NCT00378534|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|2014-12-22||2015-10-05|2006-09-19|2006-09-20|Estimate|2014-12-22|2015-01-06|Estimate||||2015-10-05|2015-10-28|Estimate|September 2006||2006-09-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants|Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back|Completed||Phase 2|115|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 03:45:44.095381|2018-06-01 03:45:44.095381
NCT00378521|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2007-05-29|2006-09-19|2006-09-20|Estimate|||||||2007-05-29|2007-05-30|Estimate|July 2006||2006-07-31|May 2007|2007-05-31|July 2006|Actual|2006-07-31|||||Interventional|||Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon|Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon|Completed||Phase 2|15|Anticipated|MediQuest Therapeutics|||||||||||||||||||2018-06-01 03:45:44.35036|2018-06-01 03:45:44.35036
NCT00378508|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2012-09-04||2016-07-05|2006-09-18|2006-09-20|Estimate|2012-10-01|2012-10-31|Estimate||||2016-07-05|2016-08-02|Estimate|September 2006||2006-09-30|July 2016|2016-07-31|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|||Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes|Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes|Completed||Phase 2|63|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:45:44.443666|2018-06-01 03:45:44.443666
NCT00378495|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2016-07-11|2006-09-18|2006-09-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2005||2005-04-30|January 2011|2011-01-31|October 2007|Actual|2007-10-31|April 2007|Actual|2007-04-30||Interventional|||Miltefosine for Brazilian Visceral Leishmaniasis||Terminated||Phase 1/Phase 2|80|Anticipated|AB Foundation||||accrual criteria being reviewed|f||||||||||||||2018-06-01 03:45:45.006902|2018-06-01 03:45:45.006902
NCT00378482|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2018-05-30|2006-09-19|2006-09-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 5, 2007|Actual|2007-03-05|May 2018|2018-05-31|January 11, 2019|Anticipated|2019-01-11|January 11, 2019|Anticipated|2019-01-11||Interventional|||A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.|A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols|Active, not recruiting||Phase 2|37|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 03:45:45.099128|2018-06-01 03:45:45.099128
NCT00378469|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2007-07-11|2006-09-19|2006-09-20|Estimate|||||||2007-07-11|2007-07-12|Estimate|September 2006||2006-09-30|May 2007|2007-05-31||||||||Interventional|||Study of the Effects of Muscular Activity on Iron Metabolism|Study of the Effects of Muscular Activity on Iron Metabolism: A Pilot Study on Healthy Volunteers|Unknown status|Recruiting|N/A|14|Anticipated|Rennes University Hospital|||||f||||f||||||||||2018-06-01 03:45:45.23298|2018-06-01 03:45:45.23298
NCT00378456|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2006-09-19|2006-09-19|2006-09-20|Estimate|||||||2006-09-19|2006-09-20|Estimate||||September 2006|2006-09-30||||||||Interventional|||Vitamins and Minerals for Children With Downs Syndrome||Completed||N/A|||Institute of Child Health|||||f||||||||||||||2018-06-01 03:45:45.349199|2018-06-01 03:45:45.349199
NCT00378443|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2006-09-21|2006-09-19|2006-09-20|Estimate|||||||2006-09-21|2006-09-22|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|June 2007||2007-06-30|||||Interventional|||ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT||Unknown status|Active, not recruiting|N/A|||Peking University|||||f||||||||||||||2018-06-01 03:45:45.439607|2018-06-01 03:45:45.439607
NCT00378430|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2013-09-23|2006-09-19|2006-09-20|Estimate|||||||2013-09-23|2013-09-25|Estimate|September 2006||2006-09-30|September 2013|2013-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||" Patients Attitude Towards Physicians and Health Screening Issues Among First Generation Asian-Indian Immigrants to United States."||Terminated|||200|Anticipated|University of California, San Francisco||||poor response to questionnaire|f||||||||||||||2018-06-01 03:45:45.505497|2018-06-01 03:45:45.505497
NCT00378417|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2006-09-19|2006-09-19|2006-09-20|Estimate|||||||2006-09-19|2006-09-20|Estimate|March 1995||1995-03-31|September 2006|2006-09-30|March 1999||1999-03-31|||||Interventional|||Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes|Efficacy Trial in Finnish Children of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Pneumococcal Serotypes in the Vaccines|Completed||Phase 3|3075||National Institute for Health and Welfare, Finland|||||||||||||||||||2018-06-01 03:45:45.553738|2018-06-01 03:45:45.553738
NCT00378404|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2015-06-03|2006-09-19|2006-09-20|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2004||2004-11-30|June 2015|2015-06-30|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC|A Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|10|Actual|University of Kentucky||1||Slow accrual|f||||f||||||||||2018-06-01 03:45:45.66135|2018-06-01 03:45:45.66135
NCT00378391|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2007-06-19|2006-09-19|2006-09-20|Estimate|||||||2007-06-19|2007-06-20|Estimate|November 2005||2005-11-30|June 2007|2007-06-30|February 2007||2007-02-28|||||Observational|||European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry|European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab|Completed|||1800||Jagiellonian University|||||f||||||||||||||2018-06-01 03:45:45.746206|2018-06-01 03:45:45.746206
NCT00378378|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2009-06-24||2017-03-13|2006-09-18|2006-09-20|Estimate|2010-06-24|2010-07-20|Estimate||||2017-03-13|2017-04-11|Actual|July 2006||2006-07-31|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)|Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old|Completed||Phase 3|127|Actual|Merck Sharp & Dohme Corp.|The standard deviation is pooled for Primary and Secondary Outcome Measures.|8|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:45:45.847707|2018-06-01 03:45:45.847707
NCT00378365|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2014-04-15|2006-09-19|2006-09-20|Estimate|||||||2014-04-15|2014-04-16|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Acute Promyelocytic Leukemia 2006 (APL)|A Randomized Trial Assessing the Role of Arsenic Trioxide and/or ATRA During Consolidation Course in Newly Diagnosed Acute Promyelocytic Leukemia (APL)|Unknown status|Recruiting|Phase 3|800|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:45:46.178554|2018-06-01 03:45:46.178554
NCT00378352|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2013-09-30||2017-05-08|2006-09-18|2006-09-20|Estimate|2017-05-08|2017-05-09|Actual||||2017-05-08|2017-05-09|Actual|September 2005||2005-09-30|May 2017|2017-05-31|January 2011|Actual|2011-01-31|July 2009|Actual|2009-07-31||Interventional||One participant was not included|REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction|Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions|Completed||Phase 2|223|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||No||2018-06-01 03:45:46.443989|2018-06-01 03:45:46.443989
NCT00378339|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-19|||2014-03-28|2006-09-19|2006-09-20|Estimate|||||||2014-03-28|2014-03-31|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Gold Against Pains From Osteoarthrosis in the Knee|Clinical Effects From Implants of Gold Around the Arthrotic Knee Joint. A Randomized, Double Blind, Placebo Controlled Investigation.|Withdrawn||Phase 2|0|Actual|Northern Orthopaedic Division, Denmark||||Withdrawn because of lack of approvement from local medical authorities|f||||||||||||||2018-06-01 03:45:47.158174|2018-06-01 03:45:47.158174
NCT00378326|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2015-11-02||2016-01-26|2006-09-19|2006-09-20|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Immunotherapy of the Paraneoplastic Syndromes|Immunotherapy of the Paraneoplastic Syndromes|Completed||N/A|26|Actual|Rockefeller University||1|||f||||t||||||||||2018-06-01 03:45:47.299051|2018-06-01 03:45:47.299051
NCT00378313|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2008-11-24|2006-09-15|2006-09-19|Estimate|||||||2008-11-24|2008-11-26|Estimate|November 2001||2001-11-30|November 2008|2008-11-30|November 2005|Actual|2005-11-30|||||Interventional|||A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer|A Phase 2 Study of Neoadjuvant Chemotherapy With Gemcitabine, Epirubicin and Paclitaxel (Taxol)[GET] in Locally Advanced Breast Cancer|Completed||Phase 2|76||NSABP Foundation Inc|||||f||||||||||||||2018-06-01 03:45:47.524006|2018-06-01 03:45:47.524006
NCT00378300|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2016-03-14|2006-09-18|2006-09-19|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2007||2007-07-31|March 2016|2016-03-31|June 2008|Anticipated|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Effects of Probiotics in Atopic Dermatitis|Probiotics Ameliorate Atopic Dermatitis by Induction of T Regulatory Cells|Withdrawn||N/A|0|Actual|University of California, Los Angeles||||Inadequate funding to support this fellow-in-training initiated study.|f||||f||||||||||2018-06-01 03:45:47.633935|2018-06-01 03:45:47.633935
NCT00378287|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2012-12-07|2006-09-18|2006-09-19|Estimate|||||||2012-12-07|2012-12-10|Estimate|October 2005||2005-10-31|December 2012|2012-12-31|December 2005|Actual|2005-12-31|||||Interventional|||A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole|A Randomized, Controlled, Double-blind, Cross-over Study of the Effect of Oral Rabeprazole 20mg and Intravenous Pantoprazole 40mg on Intragastric pH in Patients|Completed||Phase 1|37|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 03:45:47.730373|2018-06-01 03:45:47.730373
NCT00378274|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2007-11-15|2006-09-18|2006-09-19|Estimate|||||||2007-11-15|2007-11-16|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Observational|||Descriptive Study of Pain, Anxiety and Depression|Pain, Anxiety and Depression in Chronic Pain Patients With and Without Neuropathic Pain Compared With Healthy Volunteers|Completed|||75|Anticipated|Danish Pain Research Center|||||f||||t||||||||||2018-06-01 03:45:47.796137|2018-06-01 03:45:47.796137
NCT00378261|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2011-05-18|2006-09-18|2006-09-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|January 2004||2004-01-31|April 2010|2010-04-30|July 2005|Actual|2005-07-31|||||Interventional|||APART Advanced Profiling of Anti-Rheumatic Therapies|A Multicenter, Randomized, Open Study to Evaluate the Impact of an Electronic Data Capture System on the Care of Patients With Rheumatoid Arthritis|Completed||Phase 4|1079|Actual|Centocor Ortho Biotech Services, L.L.C.|||||f||||||||||||||2018-06-01 03:45:47.846007|2018-06-01 03:45:47.846007
NCT00378248|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2013-11-26|2006-09-18|2006-09-19|Estimate|||||||2013-11-26|2013-11-27|Estimate|May 2004||2004-05-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Ullevål PersonalityProject|Ullevål PersonalityProject. A Randomized Controlled Trial of Intensive Daytreatment Followed by Outpatient Long-term Combined Treatment Compared With Eclectic Individual Therapy for Patients With Personality Disorders|Unknown status|Active, not recruiting|N/A|120|Anticipated|Oslo University Hospital||2|||f||||||||||||||2018-06-01 03:45:47.931375|2018-06-01 03:45:47.931375
NCT00378235|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2014-11-11|2006-09-18|2006-09-19|Estimate|||||||2014-11-11|2014-11-13|Estimate||||November 2014|2014-11-30||||||||Interventional|||Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma|Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma|Withdrawn||Phase 1/Phase 2|0|Actual|INSYS Therapeutics Inc||||"There was a change of sponsor. The new sponsor company did not wish to conduct the study after~   all."|||||||||||||||2018-06-01 03:45:48.070269|2018-06-01 03:45:48.070269
NCT00378222|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2006-09-18|2006-09-18|2006-09-19|Estimate|||||||2006-09-18|2006-09-19|Estimate|January 1996||1996-01-31|September 2006|2006-09-30|November 2005||2005-11-30|||||Interventional|||Autologous Transplantation for Multiple Myeloma|A Prospective, Randomized Study of Single Versus Double Autologous Stem Cell Transplantation for Multiple Myeloma|Completed||Phase 3|324||University of Bologna|||||f||||||||||||||2018-06-01 03:45:48.171505|2018-06-01 03:45:48.171505
NCT00378209|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2013-10-15||2016-10-18|2006-09-18|2006-09-19|Estimate|2014-06-06|2014-06-09|Estimate||||2016-10-18|2016-11-17|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2012|Actual|2012-10-31||Interventional||65 patients were enrolled and 64 were treated. One patient who was never treated was excluded from the analysis.|Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma|Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma|Completed||Phase 2|65|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 03:45:48.247761|2018-06-01 03:45:48.247761
NCT00378196|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2012-11-12|2006-09-18|2006-09-19|Estimate|||||||2012-11-12|2012-11-14|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|December 2008|Actual|2008-12-31|September 2007|Actual|2007-09-30||Interventional|||Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial|Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial|Completed||Phase 1|10|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 03:45:48.564346|2018-06-01 03:45:48.564346
NCT00378183|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2010-04-26|2006-09-18|2006-09-19|Estimate|||||||2010-04-26|2010-04-27|Estimate|February 2001||2001-02-28|April 2010|2010-04-30|May 2002|Actual|2002-05-31|||||Interventional|||A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.|A Randomized Open-Label, Rater Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine|Completed||Phase 4|120|Actual|Janssen, LP|||||f||||||||||||||2018-06-01 03:45:48.654706|2018-06-01 03:45:48.654706
NCT00378170|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2006-12-01|2006-09-18|2006-09-19|Estimate|||||||2006-12-01|2006-12-04|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Laryngoscope Prototype Tested Against the Traditional Macintosh Blade||Unknown status|Recruiting|N/A|210||Herlev Hospital|||||f||||||||||||||2018-06-01 03:45:48.72402|2018-06-01 03:45:48.72402
NCT00378157|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2011-02-21|2006-09-18|2006-09-19|Estimate|||||||2011-02-21|2011-02-23|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Joint Attention Intervention and Young Children With Autism|Effectiveness of Joint Attention Intervention in Young Children With Autism - a Randomized Study|Completed||Phase 1/Phase 2|61|Actual|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:45:48.779533|2018-06-01 03:45:48.779533
NCT00378144|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2012-07-06|2006-09-18|2006-09-19|Estimate|||||||2012-07-06|2012-07-10|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Sinutab on Subjects in the Setting of a Common Cold|A Community Pharmacy Based Investigation in the Self-Medication Area Efficacy and Safety of Sinutab and Pseudoephedrine on Subjects With Nasal Congestion Accompanied by Headache in the Setting of a Common Cold|Completed||Phase 4|469|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 03:45:48.849432|2018-06-01 03:45:48.849432
NCT00378131|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2013-08-30|2006-09-18|2006-09-19|Estimate|||||||2013-08-30|2013-09-02|Estimate|September 2006||2006-09-30|August 2013|2013-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia|A 12-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Phase II Study Comparing the Safety, Tolerability and Beneficial Effects of Daily Doses of RC-1291 and Placebo in Patients With Cancer Anorexia/Cachexia|Completed||Phase 2|51|Actual|Helsinn Therapeutics (U.S.), Inc||3|||f||||t||||||||||2018-06-01 03:45:48.916573|2018-06-01 03:45:48.916573
NCT00378118|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2007-11-05|2006-09-18|2006-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|December 2006||2006-12-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Observational|||Use of OraQuick for Screening HIV in Children Less Than Eighteen Months Old|Evaluation of the Use of OraQuick in Children Less Than Eighteen Months Old|Completed|||1000|Actual|Thrasher Research Fund|||||f||||t||||||||||2018-06-01 03:45:48.994172|2018-06-01 03:45:48.994172
NCT00378105|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|2013-10-15||2017-01-19|2006-09-18|2006-09-19|Estimate|2014-07-31|2014-08-19|Estimate||||2017-01-19|2017-03-03|Actual|September 2006||2006-09-30|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|July 2009|Actual|2009-07-31||Interventional||The numbers excluded 2 patients who went off study prior to start of therapy (phase I part).|Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma|An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|68|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 03:45:49.091995|2018-06-01 03:45:49.091995
NCT00378092|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2014-05-07|2006-09-18|2006-09-19|Estimate|||||||2014-05-07|2014-05-08|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode|A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia|Completed||Phase 4|33|Actual|Janssen Cilag N.V./S.A.||2|||f||||f||||||||||2018-06-01 03:45:49.512171|2018-06-01 03:45:49.512171
NCT00378079|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|2013-08-14||2014-04-01|2006-09-15|2006-09-19|Estimate|2014-04-01|2014-04-03|Estimate||||2014-04-01|2014-04-03|Estimate|September 2003||2003-09-30|April 2014|2014-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|MMP||Methadone Maintenance for Prisoners|Methadone Maintenance for Prisoners|Completed||Phase 3|211|Actual|Friends Research Institute, Inc.|See 2009 manuscript published in the Journal of Substance Abuse Treatment for the a discussion of study limitations. The study was conducted only on males from Baltimore. For results regarding HIV risk behaviors see manuscript by Wilson et. al.|3|||f||||t||||||||||2018-06-01 03:45:49.616395|2018-06-01 03:45:49.616395
NCT00378066|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2013-01-21|2006-09-18|2006-09-19|Estimate|||||||2013-01-21|2013-01-23|Estimate|August 2006||2006-08-31|January 2013|2013-01-31|October 2008|Actual|2008-10-31|August 2006|Actual|2006-08-31||Interventional|||Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer|A Phase II Study of Combination Chemotherapy With Bevacizumab, Capecitabine and Oxaliplatin in Patients With Previously Untreated Metastatic or Recurrent Colorectal Cancer|Completed||Phase 2|49|Actual|Asan Medical Center||1|||f||||t||||||||||2018-06-01 03:45:50.10079|2018-06-01 03:45:50.10079
NCT00378053|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2007-08-14|2006-09-18|2006-09-19|Estimate|||||||2007-08-14|2007-08-16|Estimate|September 2006||2006-09-30|August 2007|2007-08-31|December 2006||2006-12-31|||||Observational|||A Prospective Study of Radiation Exposure to Surgeons|A Prospective Study of Radiation Exposure to Surgeons|Completed|||4||Vanderbilt University|||||f||||||||||||||2018-06-01 03:45:50.237373|2018-06-01 03:45:50.237373
NCT00378040|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2016-05-12|2006-09-15|2006-09-19|Estimate|||||||2016-05-12|2016-05-16|Estimate|June 2004||2004-06-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2006|Actual|2006-12-31||Observational|||Systematic Assessment of Vascular Risk|Toronto Vascular Disease Risk Factor Assessment Program: Systematic Assessment of Vascular Risk|Completed|||800|Actual|University Health Network, Toronto|||||f||||f||||||||Yes|See JAMA Surgery 2016 epublished First Author Dr M Hussain|2018-06-01 03:45:50.381878|2018-06-01 03:45:50.381878
NCT00378027|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2017-01-26|2006-09-18|2006-09-19|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2006|Actual|2006-08-31|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux|Phase IV, Single Arm Study to Obtain Information Regarding the Safety and Efficacy of Fondaparinux Given Outpatient for Treatment of Acute Pulmonary Embolism|Withdrawn|||0|Actual|The Cleveland Clinic|||1|enrollment criteria not met by PI patient population|f||||f|t|f|||t|||No||2018-06-01 03:45:50.443646|2018-06-01 03:45:50.443646
NCT00378014|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|2014-01-16||2015-01-19|2006-09-18|2006-09-19|Estimate|2014-06-02|2014-07-03|Estimate||||2015-01-19|2015-02-06|Estimate|August 2006||2006-08-31|January 2015|2015-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy|Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant Recipients|Completed||Phase 3|276|Actual|Novartis||2|||f||||t||||||||||2018-06-01 03:45:50.593122|2018-06-01 03:45:50.593122
NCT00378001|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2015-02-12|2006-09-15|2006-09-19|Estimate|||||||2015-02-12|2015-02-16|Estimate|March 2005||2005-03-31|February 2015|2015-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF|A Prospective, Multicenter, Investigator Blinded, Randomized, Concurrent Control Study of Efficacy and Tolerability of Two FSH Preparations (Fostimon® Versus Gonal-F®) in Women Undergoing IVF|Completed||Phase 3|152||IBSA Institut Biochimique SA|||||||||||||||||||2018-06-01 03:45:52.374053|2018-06-01 03:45:52.374053
NCT00377988|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2016-07-15|2006-09-18|2006-09-19|Estimate|||||||2016-07-15|2016-07-19|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control|The Risk of Venous Thromboembolism, Myocardial Infarction, and Ischemic Stroke Among Women Using the Transdermal Contraceptive System Compared With Women Using Norgestimate-containing Oral Contraceptives With 35 mcg Ethinyl Estradiol|Completed|||423|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||2||f||||||||||||||2018-06-01 03:45:52.4525|2018-06-01 03:45:52.4525
NCT00377975|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-17|||2016-01-22|2006-09-17|2006-09-19|Estimate|||||||2016-01-22|2016-01-25|Estimate|January 2003||2003-01-31|January 2016|2016-01-31|November 2004||2004-11-30|||||Interventional|||"Pecos B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat"|Synergistic Induction of UCP-1 by Ephedrine/Caffeine and Pioglitazone: A Rationale for Combination Therapy of Obesity|Completed||Phase 2|96||Pennington Biomedical Research Center|||||||||||||||||||2018-06-01 03:45:52.524357|2018-06-01 03:45:52.524357
NCT00377962|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|2011-03-23||2011-05-12|2006-09-15|2006-09-19|Estimate|2011-03-23|2011-04-18|Estimate||||2011-05-12|2011-05-16|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|NOCTET||Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation|Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation: Results at 24 Months|Completed||Phase 4|282|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:45:52.669242|2018-06-01 03:45:52.669242
NCT00377949|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2016-05-02|2006-09-18|2006-09-19|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2005||2005-02-28|May 2016|2016-05-31||||January 2016|Actual|2016-01-31||Observational|||Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients|The Natural History and Outcome of Patients With Scleroderma at High Risk for or With Early Pulmonary Hypertension|Completed|||602|Actual|Georgetown University|||||f||||f||||||Samples Without DNA|"~     Serum stored for future analysis~   "|||2018-06-01 03:45:55.968933|2018-06-01 03:45:55.968933
NCT00377936|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2008-11-13|2006-09-18|2006-09-19|Estimate|||||||2008-11-13|2008-11-14|Estimate|September 2005||2005-09-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas|A Controlled, Randomized, Open Label Phase II Trial to Evaluate Safety and Efficacy of a 1st Line Combination Treatment With Weekly Infusions of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG-1) in Three Dose Levels Compared With Gemcitabine Monotherapy in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas|Completed||Phase 2|212|Actual|MediGene||4|||f||||t||||||||||2018-06-01 03:45:56.068745|2018-06-01 03:45:56.068745
NCT00377923|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2006-09-19|2006-09-18|2006-09-19|Estimate|||||||2006-09-19|2006-09-20|Estimate|August 2005||2005-08-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||Endometrial Effects of Daily Progesterone s.c. 25 and 50 Mg Aqueous Formulation to Female Healthy Volunteers||Completed||Phase 1|24||IBSA Institut Biochimique SA|||||f||||||||||||||2018-06-01 03:45:56.15195|2018-06-01 03:45:56.15195
NCT00377910|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2014-03-28|2006-09-18|2006-09-19|Estimate|||||||2014-03-28|2014-03-31|Estimate|March 2008||2008-03-31|March 2014|2014-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy|Placebo Controlled Trial, Testing the Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles Tendinopathy.|Completed||Phase 4|48|Actual|Northern Orthopaedic Division, Denmark||2|||f||||t||||||||||2018-06-01 03:45:56.319675|2018-06-01 03:45:56.319675
NCT00377897|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2009-02-13|2006-09-18|2006-09-19|Estimate|||||||2009-02-13|2009-02-16|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|September 2008|Anticipated|2008-09-30||Interventional|||Cell Therapy With Bone Marrow Mononuclear Cells in Critical Leg Ischemia (CLI)|Optimisation d'un Produit de thérapie Cellulaire Autologue Par Cellules mononucléées médullaires Dans l'ischémie Critique Des Membres inférieurs liée à l'athérosclérose|Unknown status|Recruiting|Phase 1|20|Anticipated|University of Paris 5 - Rene Descartes|||||f||||||||||||||2018-06-01 03:45:56.407287|2018-06-01 03:45:56.407287
NCT00377884|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2014-04-02|2006-09-18|2006-09-19|Estimate|||||||2014-04-02|2014-04-03|Estimate|January 2004||2004-01-31|April 2014|2014-04-30|June 2009|Anticipated|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Serologic Characterization of Bone-healing|Serologic Based Molecular Characterization of Bone-healing After Cementless Total Hip Arthroplasty|Withdrawn|||0|Actual|Northern Orthopaedic Division, Denmark||||Lack of patients, lack of funding for analysis|f||||||||||||||2018-06-01 03:45:56.530071|2018-06-01 03:45:56.530071
NCT00377871|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2015-05-31|2006-09-18|2006-09-19|Estimate|||||||2015-05-31|2015-06-02|Estimate|May 2007||2007-05-31|February 2008|2008-02-29|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Hemodynamic Performance in Stentless Heart Valves|Hemodynamic Performance in Stentless Heart Valves|Completed||N/A|15|Actual|University of Aarhus||3|||f||||f||||||||||2018-06-01 03:45:56.607145|2018-06-01 03:45:56.607145
NCT00377858|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2009-09-16||2009-12-04|2006-09-14|2006-09-19|Estimate|2009-10-26|2009-12-03|Estimate||||2009-12-04|2009-12-09|Estimate|August 2006||2006-08-31|December 2009|2009-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|IOOX||Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)|Comparison of Two Approaches to Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control on Oral Therapy: Comparison of Premixed Insulin Lispro Mid Mixture With Separate Basal and Bolus Insulin Injections|Completed||Phase 4|484|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:45:56.789197|2018-06-01 03:45:56.789197
NCT00377845|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-18|||2008-03-26|2006-09-18|2006-09-19|Estimate|||||||2008-03-26|2008-03-27|Estimate|September 2006||2006-09-30|March 2008|2008-03-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.|Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.|Completed||Early Phase 1|100|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 03:45:58.395634|2018-06-01 03:45:58.395634
NCT00377832|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2010-12-22||2013-09-05|2006-09-14|2006-09-18|Estimate|2013-09-05|2013-09-16|Estimate||||2013-09-05|2013-09-16|Estimate|July 2007||2007-07-31|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Acetaminophen for Fetal Tachycardia: a Randomized Pilot Trial|Acetaminophen for Fetal Tachycardia: a Randomized Pilot Trial|Terminated||N/A|13|Actual|Weill Medical College of Cornell University|Poor recruitment and lack of funding led to early termination of the trial|2||Poor recruitment and lack of funding|f||||f||||||||||2018-06-01 03:45:58.461866|2018-06-01 03:45:58.461866
NCT00377819|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2010-07-01|2009-11-19|2011-06-30|2006-09-14|2006-09-18|Estimate|2010-07-01|2010-08-03|Estimate|2009-11-19|2009-11-23|Estimate|2011-06-30|2011-07-11|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|July 2008|Actual|2008-07-31|March 2008|Actual|2008-03-31||Interventional|||Study of Transitioning From Alendronate to Denosumab|A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 3|504|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:45:58.772063|2018-06-01 03:45:58.772063
NCT00377806|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2007-12-07|2006-09-15|2006-09-18|Estimate|||||||2007-12-07|2007-12-10|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Topical Diclofenac Gel in Patients With Superficial Inflammation of the Veins|A One Week, Double-Blind, Adaptive, Randomized, Multicenter Study to Compare the Efficacy, Safety and Tolerability of Topical Diclofenac Gel Versus Placebo in Patients With Superficial Thrombophlebitis|Completed||Phase 4|200||Novartis|||||f||||||||||||||2018-06-01 03:45:59.217503|2018-06-01 03:45:59.217503
NCT00377793|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2014-12-23|2006-09-15|2006-09-18|Estimate|||||||2014-12-23|2014-12-24|Estimate|July 2006||2006-07-31|December 2014|2014-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II|A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II|Completed||Phase 4|352|Actual|Bayer||2|||f||||||||||||||2018-06-01 03:45:59.299663|2018-06-01 03:45:59.299663
NCT00377780|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2015-09-22|2006-09-14|2006-09-18|Estimate|||||||2015-09-22|2015-09-23|Estimate|August 2006||2006-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MYOHERTAX||Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer|Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer|Terminated||Phase 2|60|Actual|Catharina Ziekenhuis Eindhoven||1||wothdrawal of sponsor|f||||f||||||||||2018-06-01 03:45:59.449659|2018-06-01 03:45:59.449659
NCT00377767|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2006-09-15|2006-09-15|2006-09-18|Estimate|||||||2006-09-15|2006-09-18|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|September 2009||2009-09-30|||||Interventional|||Improving Primary Care to Prevent Childhood Obesity|Improving Primary Care to Prevent Childhood Obesity|Unknown status|Recruiting|Phase 1/Phase 2|500||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:45:59.595725|2018-06-01 03:45:59.595725
NCT00377754|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2010-08-26|2006-09-14|2006-09-18|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2006||2006-09-30|October 2007|2007-10-31|September 2010||2010-09-30|||||Observational|||Prospective Study of Infant Dengue|A Prospective Study of Dengue Virus Infections During Infancy to Define Correlates of Protective Immunity|Unknown status|Recruiting||20000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:45:59.690675|2018-06-01 03:45:59.690675
NCT00377741|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|2015-11-26||2015-11-26|2006-09-15|2006-09-18|Estimate|2015-11-26|2015-12-31|Estimate||||2015-11-26|2015-12-31|Estimate|December 2004||2004-12-31|November 2015|2015-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.|Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis|Completed||Phase 1|31|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:45:59.761937|2018-06-01 03:45:59.761937
NCT00377728|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2015-04-14|2006-09-15|2006-09-18|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber|A 14 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in an Environmental Exposition Unit (Vienna Challenge Chamber) in Subjects With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|44|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:46:00.095674|2018-06-01 03:46:00.095674
NCT00377715|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2015-11-09|2006-09-15|2006-09-18|Estimate|||||||2015-11-09|2015-11-11|Estimate|September 2005||2005-09-30|November 2015|2015-11-30||||August 2006|Actual|2006-08-31||Interventional|||Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease|Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|183|Actual|Medivation, Inc.||2|||f||||||||||||||2018-06-01 03:46:00.185719|2018-06-01 03:46:00.185719
NCT00377702|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2016-02-17|2006-09-14|2006-09-18|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|July 2006|Actual|2006-07-31|||||Observational|||Lifetime Risk for Cardiovascular Disease Among Non-White Ethnic Groups|Epidemiologic Study of Ethnicity and Lifetime Risks for Cardiovascular Disease|Completed|||500000||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:46:00.251743|2018-06-01 03:46:00.251743
NCT00377689|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2008-10-27|2006-09-15|2006-09-18|Estimate|||||||2008-10-27|2008-10-29|Estimate|September 2006||2006-09-30|October 2008|2008-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke|Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke - a Randomized Controlled Study|Completed||Phase 2|34|Actual|Umeå University|||||f||||||||||||||2018-06-01 03:46:00.310139|2018-06-01 03:46:00.310139
NCT00377676|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2010-11-08||2016-05-09|2006-09-15|2006-09-18|Estimate|2011-10-27|2011-10-28|Estimate||||2016-05-09|2016-06-10|Estimate|July 2004||2004-07-31|May 2016|2016-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety and Tolerability During Treatment of Type 2 Diabetes (T2DM) With Usual Diabetes Therapy (UDT) and Either Cycloset or Placebo|Completed||Phase 3|3095|Actual|VeroScience|Thus HbA1c was only performed on a subset of patients defined as failing (HbA1c >= 7.5) and who were on oral diabetes medications. Forced titration of study drug may have lead to a greater number of discontinuations.|2|||f||||t||||||||||2018-06-01 03:46:00.394168|2018-06-01 03:46:00.394168
NCT00377663|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2014-03-24|2006-09-14|2006-09-18|Estimate|||||||2014-03-24|2014-03-26|Estimate|July 2007||2007-07-31|March 2014|2014-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Internet-Based Program to Improve Asthma Management in Children|Internet-Based Patient-Centered Asthma Management System|Completed||N/A|600|Actual|Seattle Children's Hospital||2|||f||||||||||||||2018-06-01 03:46:00.725455|2018-06-01 03:46:00.725455
NCT00377650|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-01-16|2006-09-14|2006-09-18|Estimate|||||||2007-01-16|2007-01-17|Estimate|September 2005||2005-09-30|January 2007|2007-01-31|December 2007||2007-12-31|||||Interventional|||Polish-Italian-Hungarian RAndomized ThrombEctomy Trial|Polish-Italian-Hungarian RAndomized ThrombEctomy Trial. PIHRATE Trial.|Unknown status|Recruiting|Phase 4|200||Jagiellonian University|||||f||||||||||||||2018-06-01 03:46:00.798976|2018-06-01 03:46:00.798976
NCT00377637|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|2011-08-11||2011-10-31|2006-09-15|2006-09-18|Estimate|2011-10-31|2011-12-06|Estimate||||2011-10-31|2011-12-06|Estimate|July 2005||2005-07-31|October 2011|2011-10-31|March 2010|Actual|2010-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.|A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.|Completed||Phase 3|370|Actual|Hoffmann-La Roche|For many of the Maintenance Phase Outcomes, the total number of events precluded a meaningful time to event statistical analysis, therefore, only events numbers are reported.|4|||f||||||||||||||2018-06-01 03:46:01.079448|2018-06-01 03:46:01.079448
NCT00377624|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2011-01-10|2006-09-14|2006-09-18|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2002||2002-01-31|January 2011|2011-01-31|September 2004||2004-09-30|||||Interventional|||HUPS: Hyalgan Use in Painful Shoulder|Sodium Hyaluronate for Treatment of Chronic Painful Shoulder With Limitation of Motion Due to Glenohumeral Joint Osteoarthritis, Rotator Cuff Tear and/or Primary or Secondary Adhesive Capsulitis|Completed||Phase 3|602||Sanofi|||||f||||||||||||||2018-06-01 03:46:02.834993|2018-06-01 03:46:02.834993
NCT00377442|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2016-11-01|2006-09-15|2006-09-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2006||2006-08-31|November 2016|2016-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.|A Randomized, Open-label Crossover Study to Investigate the Potential Interaction Between GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes|Completed||Phase 1|33|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:46:05.726191|2018-06-01 03:46:05.726191
NCT00377611|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2016-11-02|2006-09-15|2006-09-18|Estimate|||||||2016-11-02|2016-11-04|Estimate|October 2006||2006-10-31|November 2016|2016-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™|An Observational Study to Investigate the Incidence of Influenza and Influenza-related Complications, in Adults Between 50-64 Years and Elderly Adults 65 Years and Over Vaccinated With Fluarix™|Completed||Phase 4|3054|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:46:02.919666|2018-06-01 03:46:02.919666
NCT00377598|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2012-01-31|2006-09-14|2006-09-18|Estimate|||||||2012-01-31|2012-02-02|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia|A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo|Completed||Phase 2/Phase 3|399|Actual|Takeda||5|||f||||f||||||||||2018-06-01 03:46:03.191238|2018-06-01 03:46:03.191238
NCT00377585|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2017-04-20|2006-09-15|2006-09-18|Estimate|||||||2017-04-20|2017-04-24|Actual|September 22, 2006||2006-09-22|April 2017|2017-04-30|January 30, 2007|Actual|2007-01-30|||||Interventional|||Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population|A Phase II/III, Observer-blind, Multi-Country, Multi-Centre, Randomized Study to Demonstrate the Superiority in Terms of Immunogenicity of Adjuvanted Influenza Vaccine Administered in Adults Aged 50 Years and Older Compared to Fluarix™|Completed||Phase 2|3350||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:46:03.347144|2018-06-01 03:46:03.347144
NCT00377572|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2013-01-11||2017-02-14|2006-09-14|2006-09-18|Estimate|2013-06-06|2013-06-07|Estimate||||2017-02-14|2017-03-21|Actual|October 2006||2006-10-31|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ICATA||Inner-City Anti-IgE Therapy for Asthma|Inner-City Anti-IgE Therapy for Asthma (ICAC-08)|Completed||Phase 4|419|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 03:46:03.538162|2018-06-01 03:46:03.538162
NCT00377559|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2015-10-05|2006-09-15|2006-09-18|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2006||2006-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|November 2009|Actual|2009-11-30||Interventional|MYOTAX||Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer|Phase II Multicentre Open Label Trial Evaluating the Efficacy and Safety of the Liposomal Doxorubicin (Myocet®) and Docetaxel (Taxotere®) Combination as First-line Treatment of Patients With Metastatic HER2/Neu Negative Breast Cancer|Completed||Phase 2|70|Actual|Catharina Ziekenhuis Eindhoven||1|||f||||f||||||||||2018-06-01 03:46:04.298723|2018-06-01 03:46:04.298723
NCT00377546|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2008-09-23|2006-09-14|2006-09-18|Estimate|||||||2008-09-23|2008-09-25|Estimate||||September 2008|2008-09-30||||||||Interventional|||Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%||Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:46:04.382784|2018-06-01 03:46:04.382784
NCT00377533|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2010-04-01|2006-09-15|2006-09-18|Estimate|||||||2010-04-01|2010-04-05|Estimate|December 2004||2004-12-31|July 2009|2009-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Wheelchair Handling Skills of Caregivers: Comparison Between Anti-tip Devices and a New Design|Wheelchair Handling Skills of Caregivers: Comparison Between Conventional Rear Anti-tip Devices and a New Design|Completed||N/A|32|Actual|Nova Scotia Health Authority|||||f||||||||||||||2018-06-01 03:46:04.442578|2018-06-01 03:46:04.442578
NCT00377520|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2008-10-21||2009-11-13|2006-09-14|2006-09-18|Estimate|2009-07-13|2009-08-24|Estimate||||2009-11-13|2009-11-20|Estimate|September 2006||2006-09-30|November 2009|2009-11-30|September 2008|Actual|2008-09-30|October 2007|Actual|2007-10-31||Interventional|||A Trial for Patients With Advanced/Recurrent Endometrial Cancer|A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|27|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 03:46:04.529194|2018-06-01 03:46:04.529194
NCT00377507|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2013-07-14|2006-09-14|2006-09-18|Estimate|||||||2013-07-14|2013-07-16|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Catechin Mouth-washing for Removal of Intraoral Bacteria|A Clinical Trial of Tea Catechin Mouth-washing for Removal of Intraoral Bacteria in the Elderly|Terminated||N/A|36|Actual|University of Shizuoka||1||difficult to achieve the sufficient subjects|f||||f||||||||||2018-06-01 03:46:04.981566|2018-06-01 03:46:04.981566
NCT00377494|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2010-08-26|2006-09-14|2006-09-18|Estimate|||||||2010-08-26|2010-08-27|Estimate||||February 2007|2007-02-28|July 2008||2008-07-31|||||Interventional|||CS DNA MVA Trial in Mampong, Ghana|A Phase I Trial of PFCSP DNA/MVA.CSO Prime/Boost Vaccine in Mampong, Ghana|Withdrawn||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 03:46:05.251137|2018-06-01 03:46:05.251137
NCT00377481|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2016-11-01|2006-09-15|2006-09-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.|A Randomised, Cross-Over Study to Investigate the Comfort of Injection of Renal Anaemia Patients Receiving Subcutaneous NeoRecormon® Compared to Darbepoetin Alfa.|Completed||Phase 4|48|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:46:05.313343|2018-06-01 03:46:05.313343
NCT00377468|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2008-06-26|2006-09-14|2006-09-18|Estimate|||||||2008-06-26|2008-06-30|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)|Low Dose Administration of Delta9-Tetrahydrocannabinol for the Prevention of Hyperalgesia and Chronic Pain in Patients With Acute Complex Regional Pain Syndrome (CRPS) of the Upper Limb|Unknown status|Recruiting|Phase 2|100|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:46:05.402706|2018-06-01 03:46:05.402706
NCT00377455|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2011-03-28||2018-04-26|2006-09-14|2006-09-18|Estimate|2011-06-21|2011-07-20|Estimate||||2018-04-26|2018-05-24|Actual|September 2006||2006-09-30|April 2018|2018-04-30|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|||Placebo Controlled Trial of Bosentan in Scleroderma Patients|Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension|Terminated||Phase 2|5|Actual|Georgetown University||2||Study was terminated due to inadequate enrolment|f||||f||||||||||2018-06-01 03:46:05.500602|2018-06-01 03:46:05.500602
NCT00377429|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|2012-03-15||2012-07-16|2006-09-15|2006-09-18|Estimate|2012-06-06|2012-07-11|Estimate||||2012-07-16|2012-07-19|Estimate|September 2006||2006-09-30|July 2012|2012-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy|An Open-Label, Single-Arm, Phase II Safety and Tolerability Study of Catumaxomab (Anti-EpCAM x Anti-CD3) in Women With Advanced Epithelial Ovarian Cancer After a Complete Response to Chemotherapy|Completed||Phase 2|47|Actual|Neovii Biotech||1|||f||||t||||||||||2018-06-01 03:46:05.817167|2018-06-01 03:46:05.817167
NCT00377416|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2018-02-12|2006-09-14|2006-09-18|Estimate|||||||2018-02-12|2018-02-14|Actual|March 2004||2004-03-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency|Preclinical & Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV2-CB-hAAT) Gene Vector to AAT-Deficient Adults|Active, not recruiting||N/A|12|Anticipated|University of Massachusetts, Worcester||1|||f||||||||||||||2018-06-01 03:46:06.210009|2018-06-01 03:46:06.210009
NCT00377403|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2011-03-31||2012-12-24|2006-09-14|2006-09-18|Estimate|2011-06-03|2011-06-29|Estimate||||2012-12-24|2012-12-28|Estimate|October 2006||2006-10-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|May 2009|Actual|2009-05-31||Interventional|||Treatment of Acute Sinusitis|Randomized Clinical Trial to Evaluate Guidelines for Acute Rhinosinusitis (Phase IV Study)|Completed||Phase 4|172|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 03:46:06.285685|2018-06-01 03:46:06.285685
NCT00377390|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2013-02-06|2006-09-14|2006-09-18|Estimate|||||||2013-02-06|2013-02-07|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||ICATA Asthma Mechanistic Study|Inner-City Anti-IgE Therapy for Asthma Mechanistic Study|Completed|||224|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Blood samples, sputum, and nasal secretions~   "|||2018-06-01 03:46:06.490598|2018-06-01 03:46:06.490598
NCT00377377|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2007-05-02|2006-09-15|2006-09-18|Estimate|||||||2007-05-02|2007-05-03|Estimate|November 2005||2005-11-30|July 2006|2006-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Oral Ghrelin Agonist in Healthy Subjects|Pharmacokinetics and Pharmacodynamic Effects of an Oral Ghrelin Agonist in Healthy Subjects|Completed||Phase 1|42||University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:46:06.577093|2018-06-01 03:46:06.577093
NCT00377364|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2011-08-19||2016-04-01|2006-09-15|2006-09-18|Estimate|2013-12-13|2014-01-16|Estimate||||2016-04-01|2016-05-05|Estimate|November 2006||2006-11-30|April 2016|2016-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Acetaminophen (Tylenol) for Mood and Memory Changes Associated With Corticosteroid Therapy|Acetaminophen for Mood and Memory Changes Associated With Prednisone Therapy|Completed||Phase 4|30|Actual|University of Texas Southwestern Medical Center|Limitations include the small sample size and relatively small changes in mood and memory in both groups that limited our ability to detect between-group differences.|2|||f||||f||||||||||2018-06-01 03:46:06.646017|2018-06-01 03:46:06.646017
NCT00377351|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2017-06-30|2006-09-15|2006-09-18|Estimate|||||||2017-06-30|2017-07-02|Actual|September 11, 2006||2006-09-11|August 3, 2010|2010-08-03|August 3, 2010||2010-08-03|||||Observational|||Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort|Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort|Completed|||21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:46:07.038723|2018-06-01 03:46:07.038723
NCT00377338|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2013-07-29|2006-09-15|2006-09-18|Estimate|||||||2013-07-29|2013-07-30|Estimate|May 2006||2006-05-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|ALVEOLE||Safety and Accuracy of Alveoscopy in Interstitial Lung Diseases|Phase II Study of Broncho-Alveoscopy Using Fibered Confocal Fluorescence Microscopy|Completed|||270|Actual|University Hospital, Rouen|||||f||||t||||||Samples Without DNA|"~     distal lung biopsy if of tumoral nature (fixed or frozen sample)~   "|||2018-06-01 03:46:07.088053|2018-06-01 03:46:07.088053
NCT00377325|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|||2014-11-20|2006-09-15|2006-09-18|Estimate|||||||2014-11-20|2014-11-21|Estimate|June 2007||2007-06-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||The Effectiveness of Lower Cyclosporine Doses for Psoriasis|Cyclosporine in the Pharmacotherapy of Psoriasis|Withdrawn||Phase 2|0|Actual|University of Rochester||3||Study terminated by the DSMB due to low recruitment|f||||t||||||||||2018-06-01 03:46:07.166868|2018-06-01 03:46:07.166868
NCT00377312|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2014-04-25||2016-03-18|2006-09-14|2006-09-18|Estimate|2016-03-18|2016-03-22|Estimate||||2016-03-18|2016-03-22|Estimate|September 2006||2006-09-30|March 2016|2016-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional||Eleven subjects received parathyroid hormone (1-34) infusions intravenously for one week.|7 Day Continuous Parathyroid Hormone IV Infusion|Determining the Maximal Safe Dose of a Continuous Infusion of Parathyroid Hormone(1-34): Effects on Bone Formation|Completed||Early Phase 1|11|Actual|University of Pittsburgh|Small number of subjects in each group Study limited to Caucasians Only one timepoint for follow-up was measure Study did not include saline infused controls|2|||f||||t||||||||No||2018-06-01 03:46:07.334049|2018-06-01 03:46:07.334049
NCT00377299|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2011-09-08||2013-07-05|2006-09-14|2006-09-18|Estimate|2013-07-05|2013-08-08|Estimate||||2013-07-05|2013-08-08|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence|A Double-blind, Placebo-controlled Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence|Completed||N/A|60|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 03:46:08.156909|2018-06-01 03:46:08.156909
NCT00377286|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2011-06-12|2006-09-14|2006-09-18|Estimate|||||||2011-06-12|2011-06-14|Estimate|September 2006||2006-09-30|June 2011|2011-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Glucosamine on Joint Structure and Quality of Life (JOG)|Development of Biomarker and Functional Assessment Tools to Evaluate the Effect of Glucosamine on Joint Structure and Quality of Life|Completed||N/A|201|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:46:08.516694|2018-06-01 03:46:08.516694
NCT00377273|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2008-04-08|2006-09-14|2006-09-18|Estimate|||||||2008-04-08|2008-04-10|Estimate|November 2003||2003-11-30|April 2008|2008-04-30|October 2005||2005-10-31|||||Interventional|||An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses||Completed||Phase 4|250||Sanofi|||||f||||||||||||||2018-06-01 03:46:08.58902|2018-06-01 03:46:08.58902
NCT00377091|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2013-05-28|2006-09-13|2006-09-15|Estimate|||||||2013-05-28|2013-05-30|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy|Pilot Pharmacoeconomic Evaluation of Fondaparinux Treatment of Pulmonary Embolism (PE) Compared to Treatment With Unfractionated Heparin|Withdrawn||Phase 4|0|Actual|University of Minnesota - Clinical and Translational Science Institute||||Study pulled due to a grant disagreement between the U of M and SMDC|f||||||||||||||2018-06-01 03:46:12.254326|2018-06-01 03:46:12.254326
NCT00377260|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2010-04-13||2016-10-24|2006-09-14|2006-09-18|Estimate|2010-07-15|2010-08-11|Estimate||||2016-10-24|2016-12-05|Estimate|November 2006||2006-11-30|October 2016|2016-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Acute Otitis Media (AOM) Therapy Trial in Young Children|Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM)|Completed||Phase 4|291|Actual|University of Pittsburgh|Long-term implications of abnormal otoscopic findings (bulging) without symptoms, and persistent middle-ear effusion without findings of acute inflammation as forerunners of subsequent acute otitis media episodes remains uncertain.|2|||f||||t||||||||No||2018-06-01 03:46:08.738946|2018-06-01 03:46:08.738946
NCT00377247|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2016-07-07|2006-09-14|2006-09-18|Estimate|||||||2016-07-07|2016-07-11|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor|Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor (Phase I/II Study)|Terminated||Phase 1|5|Actual|University of Pittsburgh||1||study closed to accrual due to slow accrual|f||||t||||||||||2018-06-01 03:46:09.894268|2018-06-01 03:46:09.894268
NCT00377234|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15|2015-06-25||2016-07-28|2006-09-15|2006-09-18|Estimate|2015-06-25|2015-07-22|Estimate||||2016-07-28|2016-08-01|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||Safety Analysis Set|A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.|Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study.|Completed||Phase 4|356|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:46:09.989465|2018-06-01 03:46:09.989465
NCT00377221|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2006-09-15|2006-09-15|2006-09-18|Estimate|||||||2006-09-15|2006-09-18|Estimate|September 2006||2006-09-30|September 2006|2006-09-30||||||||Observational|||Anorectal Microbicide Project(AMP): Rectal Health, Behaviors and Microbicide Acceptability|Rectal Health, Behaviors and Microbicide Acceptability|Unknown status|Recruiting||896||University of California, Los Angeles|||||f||||||||||||||2018-06-01 03:46:10.350936|2018-06-01 03:46:10.350936
NCT00377208|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2013-02-18|2006-09-14|2006-09-18|Estimate|||||||2013-02-18|2013-02-20|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Individually Tailored Web-Based Program to Improve Blood Pressure Control|Efficacy of Web-Based Feedback to Improve Blood Pressure Control|Completed||N/A|500|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 03:46:10.413973|2018-06-01 03:46:10.413973
NCT00377195|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2018-02-27|2006-09-14|2006-09-18|Estimate|||||||2018-02-27|2018-02-28|Actual|July 8, 2007|Actual|2007-07-08|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 24, 2017|Actual|2017-04-24||Interventional|||Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma|A Prospective Single Arm Trial of Involved Field Radiotherapy Alone for Stage I-II Low Grade Non-gastric Marginal Zone Lymphoma|Active, not recruiting||Phase 2|79|Actual|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||f||||||||||2018-06-01 03:46:10.475759|2018-06-01 03:46:10.475759
NCT00377182|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-15||2016-07-08|2016-11-01|2006-09-15|2006-09-18|Estimate||||2016-07-08|2016-07-12|Estimate|2016-11-01|2016-11-02|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.|A Randomized, Double-blind Study to Evaluate the Safety and Tolerability of the HCV Polymerase Inhibitor Pro-drug in Combination With Pegasys, With or Without Copegus, Versus Pegasys Plus Copegus, in Treatment-naïve Patients With Chronic Hepatitis C, Genotype 1|Completed||Phase 2|107|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 03:46:10.550199|2018-06-01 03:46:10.550199
NCT00377169|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2016-10-31|2006-09-14|2006-09-15|Estimate|||||||2016-10-31|2016-11-01|Estimate||||September 2006|2006-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Collection of Blood Samples From SMART Study Participants for Future Genetic Studies|Genomics: A Substudy of a Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)|Completed|||3261|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:46:10.637647|2018-06-01 03:46:10.637647
NCT00377156|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2017-02-27||2017-07-25|2006-09-13|2006-09-15|Estimate|2017-07-25|2017-08-24|Actual||||2017-07-25|2017-08-24|Actual|July 2006||2006-07-31|July 2017|2017-07-31||||October 2014|Actual|2014-10-31||Interventional|||Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients With One to Three Cerebral Metastases|Active, not recruiting||Phase 3|213|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 03:46:10.972385|2018-06-01 03:46:10.972385
NCT00377143|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2012-02-14|2006-09-13|2006-09-15|Estimate|||||||2012-02-14|2012-02-16|Estimate|July 2006||2006-07-31|September 2011|2011-09-30||||August 2006|Actual|2006-08-31||Interventional|||PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care|PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care|Withdrawn||Phase 4|0|Actual|University of Florida||||similar large study planned by NHLBI|f||||||||||||||2018-06-01 03:46:11.854968|2018-06-01 03:46:11.854968
NCT00377130|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2014-01-30|2006-09-13|2006-09-15|Estimate|||||||2014-01-30|2014-01-31|Estimate|December 2006||2006-12-31|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Stress Management Therapy in Patients Receiving Chemotherapy for Cancer|Stress Management Therapy for Patients Undergoing Chemotherapy|Completed||N/A|442|Actual|University of South Florida||2|||f||||t||||||||||2018-06-01 03:46:11.938329|2018-06-01 03:46:11.938329
NCT00377117|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-07-20|2006-09-14|2006-09-15|Estimate|||||||2007-07-20|2007-07-23|Estimate|May 2006||2006-05-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Observational|||Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II|Diabetes Screening, Risk Management, and Disease Management in a High-Risk Mental Health Population.|Completed|||39|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 03:46:12.097013|2018-06-01 03:46:12.097013
NCT00377104|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2013-07-01|2006-09-13|2006-09-15|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2006||2006-09-30|July 2013|2013-07-31||||November 2012|Actual|2012-11-30||Interventional|||Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I Dose-Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Following Cytoreduction With Chemotherapy|Terminated||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:46:12.158928|2018-06-01 03:46:12.158928
NCT00377078|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2006-09-14|2006-09-14|2006-09-15|Estimate|||||||2006-09-14|2006-09-15|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|October 2007||2007-10-31|||||Interventional|||Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.|Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes to Manage Post-Antibiotic Colonization and Infection With Clostridium Difficile|Unknown status|Recruiting|N/A|30||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:46:12.322707|2018-06-01 03:46:12.322707
NCT00377065|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2016-04-21|2006-09-14|2006-09-15|Estimate|||||||2016-04-21|2016-04-22|Estimate||||April 2016|2016-04-30||||||||Expanded Access|||Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)|Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options|Approved for marketing|||||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 03:46:12.391575|2018-06-01 03:46:12.391575
NCT00377052|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2011-06-21|2006-09-13|2006-09-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|June 2006||2006-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|November 2009|Actual|2009-11-30||Interventional|||Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma|A Phase II Study of Bortezomib and Gemcitabine in Patients With Relapsed Mantle Cell Lymphoma|Completed||Phase 2|29|Actual|Canadian Cancer Trials Group|||||f||||t||||||||||2018-06-01 03:46:12.446028|2018-06-01 03:46:12.446028
NCT00377039|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-09-30|2006-09-14|2006-09-15|Estimate|||||||2007-09-30|2007-10-02|Estimate|August 2006||2006-08-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia|A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study to Investigate the Efficacy, Safety and Tolerability of AD 337 in the Treatment of Fibromyalgia in Female Subjects.|Completed||Phase 2|100|Anticipated|Sosei|||||f||||||||||||||2018-06-01 03:46:12.518625|2018-06-01 03:46:12.518625
NCT00377026|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2009-06-18|2006-09-13|2006-09-15|Estimate|||||||2009-06-18|2009-06-19|Estimate|September 2006||2006-09-30|June 2009|2009-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||FirstWIND: Weight Loss Interventions After Delivery|FirstWIND: Weight Loss Interventions After Delivery|Completed||N/A|50|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-06-01 03:46:12.5739|2018-06-01 03:46:12.5739
NCT00377000|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-10-05|2006-09-14|2006-09-15|Estimate|||||||2007-10-05|2007-10-10|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|March 2006||2006-03-31|||||Interventional|||A Pilot, Multi-Center, Patient Preference Study Comparing Two Clindamycin/Benzoyl Peroxide Gels.||Completed||Phase 4|60||Sanofi|||||f||||||||||||||2018-06-01 03:46:12.635556|2018-06-01 03:46:12.635556
NCT00376987|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-05-25|2006-09-13|2006-09-15|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2003||2003-12-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|October 2006|Actual|2006-10-31||Interventional|||Zinc Supplements in Lowering Cadmium Levels in Smokers|Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?|Completed||Phase 2|61|Actual|Wake Forest University Health Sciences|||||f||||f|t|f||||||||2018-06-01 03:46:12.684195|2018-06-01 03:46:12.684195
NCT00376974|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2006-09-13|2006-09-13|2006-09-15|Estimate|||||||2006-09-13|2006-09-15|Estimate|March 2005||2005-03-31|September 2006|2006-09-30|May 2006||2006-05-31|||||Interventional|||The Effect of Education on Patient Compliance|The Effect of Patient Education on Glaucoma Medication Compliance|Unknown status|Active, not recruiting|Phase 4|40||Michael Debakey Veterans Affairs Medical Center|||||f||||||||||||||2018-06-01 03:46:12.753783|2018-06-01 03:46:12.753783
NCT00376961|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2013-01-02||2017-10-03|2006-09-13|2006-09-15|Estimate|2013-01-02|2013-02-05|Estimate||||2017-10-03|2017-11-06|Actual|August 2006||2006-08-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|December 2012|Actual|2012-12-31||Interventional|||S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade®) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma|Completed||Phase 2|68|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 03:46:12.862202|2018-06-01 03:46:12.862202
NCT00376948|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2014-08-08||2017-10-27|2006-09-13|2006-09-15|Estimate|2014-08-08|2014-08-26|Estimate||||2017-10-27|2017-12-04|Actual|May 2005||2005-05-31|October 2017|2017-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|20|Actual|Barbara Ann Karmanos Cancer Institute|This study was stopped early due to the lack of efficacy.|1|||f||||t||||||||||2018-06-01 03:46:13.558003|2018-06-01 03:46:13.558003
NCT00376935|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2011-10-04|2009-10-20|2015-06-01|2006-09-14|2006-09-15|Estimate|2011-12-22|2012-01-30|Estimate|2009-10-20|2009-10-22|Estimate|2015-06-01|2015-06-30|Estimate|December 2006||2006-12-31|June 2015|2015-06-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults|A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less|Completed||Phase 2|99|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 03:46:13.723157|2018-06-01 03:46:13.723157
NCT00376922|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-05-25|2006-09-13|2006-09-15|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2006||2006-06-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2007|Actual|2007-05-31||Interventional|||Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases|Use of Music to Reduce Anxiety & Perceived Pain for Adult Patients With Hematological Malignancies Undergoing Bone Marrow Biopsy|Completed||N/A|65|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-06-01 03:46:15.933923|2018-06-01 03:46:15.933923
NCT00376909|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2014-11-26|2006-09-13|2006-09-15|Estimate|||||||2014-11-26|2014-12-02|Estimate|November 2001||2001-11-30|September 2006|2006-09-30||||April 2004|Actual|2004-04-30||Interventional|||A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women|New York Prevention Care Manager Project|Completed||Phase 2|2729|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-06-01 03:46:16.049683|2018-06-01 03:46:16.049683
NCT00376896|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-05-15|2006-09-13|2006-09-15|Estimate|||||||2017-05-15|2017-05-16|Actual|November 2006||2006-11-30|May 2017|2017-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers|A Phase IIa Experimental Medicine Study Assessing Alterations in Regional Cerebral Blood Flow by Functional Magnetic Resonance Imaging (fMRI) in Female IBS Patients and Healthy Controls Following Single Doses of GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)|Completed||Phase 1|25|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:46:16.123216|2018-06-01 03:46:16.123216
NCT00376883|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-01-03|2006-09-14|2006-09-15|Estimate|||||||2007-01-03|2007-01-04|Estimate|January 2000||2000-01-31|January 2007|2007-01-31|October 2006||2006-10-31|||||Interventional|||Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month|The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.|Completed||Phase 3|500||Nordic Myeloma Study Group|||||f||||||||||||||2018-06-01 03:46:16.190176|2018-06-01 03:46:16.190176
NCT00376870|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2008-07-30|2006-09-13|2006-09-15|Estimate|||||||2008-07-30|2008-08-01|Estimate|July 2008||2008-07-31|June 2008|2008-06-30|April 2011|Anticipated|2011-04-30|December 2010|Anticipated|2010-12-31||Interventional|||PIoglitazone for PrEvention of Restenosis in Diabetic Patients|Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent|Unknown status|Recruiting|Phase 3|160|Anticipated|University of Rome Tor Vergata||2|||f||||t||||||||||2018-06-01 03:46:16.267484|2018-06-01 03:46:16.267484
NCT00376857|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2006-09-13|2006-09-13|2006-09-15|Estimate|||||||2006-09-13|2006-09-15|Estimate||||September 2006|2006-09-30||||||||Interventional|||Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.|Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green: a Randomised Controlled Clinical Trial|Completed||N/A|60||University of Regensburg|||||f||||||||||||||2018-06-01 03:46:16.357924|2018-06-01 03:46:16.357924
NCT00376844|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2018-02-26|2006-09-13|2006-09-15|Estimate|||||||2018-02-26|2018-02-27|Actual|May 2002||2002-05-31|February 2018|2018-02-28|April 2016|Actual|2016-04-30|May 2009|Actual|2009-05-31||Interventional|PORTEC-2||External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer|PORTEC-2, Postoperative Radiation Therapy for Endometrial Carcinoma - A Multicenter Randomised Phase III Trial Comparing External Beam Radiation and Vaginal Brachytherapy|Completed||Phase 3|427|Actual|Leiden University Medical Center||2|||f||||f||||||||Undecided|Will be decided late 2016|2018-06-01 03:46:16.416015|2018-06-01 03:46:16.416015
NCT00376831|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-08-09|2006-09-14|2006-09-15|Estimate|||||||2007-08-09|2007-08-10|Estimate|January 2007||2007-01-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||The Efficacy of Midazolam & Ketamine Versus Midazolam & Fentanyl for Sedation in Ambulatory Colonoscopies||Completed||Phase 4|91|Actual|Soroka University Medical Center||2|||f||||||||||||||2018-06-01 03:46:16.495944|2018-06-01 03:46:16.495944
NCT00376818|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2012-06-01|2006-09-13|2006-09-15|Estimate|||||||2012-06-01|2012-06-04|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers|Evaluation of a Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers|Completed||N/A|4|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 03:46:16.563415|2018-06-01 03:46:16.563415
NCT00376805|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2010-07-13||2017-12-03|2006-09-13|2006-09-15|Estimate|2010-07-13|2010-08-12|Estimate||||2017-12-03|2017-12-28|Actual|April 2006||2006-04-30|December 2017|2017-12-31|January 2010|Actual|2010-01-31|September 2009|Actual|2009-09-30||Interventional|||Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer|Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer|Terminated||Phase 2|6|Actual|Masonic Cancer Center, University of Minnesota||1||Withdrawn due to toxicity|f||||t||||||||||2018-06-01 03:46:16.657785|2018-06-01 03:46:16.657785
NCT00376792|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2013-08-23|2006-09-13|2006-09-15|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2005||2005-10-31|June 2009|2009-06-30||||December 2012|Anticipated|2012-12-31||Interventional|||Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer|An Open Randomized Phase III Trial of Six Cycles of Docetaxel Versus Surveillance After Radical Prostatectomy in High Grade Prostate Cancer Patients With Margin Positive T2 or T3 Tumours|Unknown status|Recruiting|Phase 3|396|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:46:16.88695|2018-06-01 03:46:16.88695
NCT00376779|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2016-11-02|2006-09-14|2006-09-15|Estimate|||||||2016-11-02|2016-11-04|Estimate|October 2006||2006-10-31|November 2016|2016-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age|A Phase II, Observer-blind, Randomized Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Combined DssiTgdPa-HBV-IPV/Hib Vaccine Containing Diphtheria Toxoid From the Statens Serum Institute (SSI) of Denmark and Tetanus Toxoid From GSK Biologicals' Kft [GD], Compared to the Currently Licensed GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa TM) When Administered to Healthy Infants at 2, 3 and 4 Months of Age.|Completed||Phase 2|450||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:46:17.063381|2018-06-01 03:46:17.063381
NCT00376766|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2015-05-27|2006-09-14|2006-09-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2007||2007-02-28|May 2015|2015-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)|Rapid Oral Treatment of Cluster Epileptic Seizures. Efficacy Assessment of Levetiracetam in Cluster Seizures.|Terminated||Phase 3|112|Anticipated|University Hospital, Grenoble||||recruitment recruitment recruitment recruitment difficulties|f||||f||||||||||2018-06-01 03:46:17.227897|2018-06-01 03:46:17.227897
NCT00376753|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2017-06-30|2006-09-14|2006-09-15|Estimate|||||||2017-06-30|2017-07-02|Actual|September 11, 2006||2006-09-11|May 11, 2011|2011-05-11|May 11, 2011||2011-05-11|||||Observational|||Muscle Contraction in Patients With Focal Hand Dystonia|The Effect of Surround Inhibition During Phasic Compared to Tonic Voluntary Finger Movement in Focal Hand Dystonia|Completed|||84|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:46:17.319295|2018-06-01 03:46:17.319295
NCT00376740|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2011-08-22|2006-09-14|2006-09-15|Estimate|||||||2011-08-22|2011-08-23|Estimate|September 2005||2005-09-30|August 2011|2011-08-31||||November 2010|Actual|2010-11-30||Interventional|||Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole|Phase 3 Study of the Effect of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving the Aromatase Inhibitor, Letrozole, in the Adjuvant Setting|Completed||Phase 3|90|Actual|Soroka University Medical Center||2|||f||||f||||||||||2018-06-01 03:46:17.37193|2018-06-01 03:46:17.37193
NCT00376727|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2010-03-25|2006-09-13|2006-09-15|Estimate|||||||2010-03-25|2010-03-29|Estimate|December 2004||2004-12-31|March 2010|2010-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Cetuximab in Treating Patients With Advanced Solid Tumors|A Phase I Study of the Safety and Tolerability of Four Doses of Cetuximab (C225) in Patients With Advanced Solid Tumors|Completed||Phase 1|27|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 03:46:17.442536|2018-06-01 03:46:17.442536
NCT00376714|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2016-10-26|2006-09-13|2006-09-15|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects.|Completed||Phase 2|45||GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:46:17.52277|2018-06-01 03:46:17.52277
NCT00376701|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2011-09-27|2006-09-14|2006-09-15|Estimate|||||||2011-09-27|2011-09-28|Estimate|September 2006||2006-09-30|September 2011|2011-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Combination Therapy for Age-Related Macular Degeneration.|Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin.|Completed||Phase 2|103|Actual|Lawson Health Research Institute||3|||f||||t||||||||||2018-06-01 03:46:17.616354|2018-06-01 03:46:17.616354
NCT00376688|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2013-12-19||2018-01-19|2006-09-13|2006-09-15|Estimate|2014-04-25|2014-05-26|Estimate||||2018-01-19|2018-02-15|Actual|July 11, 2006|Actual|2006-07-11|November 2017|2017-11-30||||June 12, 2008|Actual|2008-06-12||Interventional||Entire study population|Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer|Phase II Trial of CCI-779 (Temsirolimus) in Patients With Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:46:17.73292|2018-06-01 03:46:17.73292
NCT00376675|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2014-07-30||2016-07-01|2006-09-13|2006-09-15|Estimate|2014-10-09|2014-10-10|Estimate||||2016-07-01|2016-08-01|Estimate|February 2008||2008-02-29|July 2016|2016-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Methylphenidate in Treating Patients With Fatigue Caused by Cancer|Long Acting Methylphenidate (Concerta™) for Cancer-Related Fatigue: A Phase III, Randomized, Double-Blind Placebo Controlled Study|Completed||Phase 3|148|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 03:46:17.997589|2018-06-01 03:46:17.997589
NCT00376662|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2006-09-13|2006-09-13|2006-09-15|Estimate|||||||2006-09-13|2006-09-15|Estimate|August 1992||1992-08-31|September 2006|2006-09-30|October 2000||2000-10-31|||||Interventional|||HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids.|HRT and/or Etidronate in the Prevention and Treatment of Osteoporosis and Fractures in Post-Menopausal Patients With Asthma Receiving Long-Term Oral and/or Inhaled Glucocorticoids:a Randomised Factorial Trial|Completed||Phase 4|750||British Thoracic Society|||||f||||||||||||||2018-06-01 03:46:19.17809|2018-06-01 03:46:19.17809
NCT00376649|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2015-09-20|2006-09-14|2006-09-15|Estimate|||||||2015-09-20|2015-09-22|Estimate|January 2007||2007-01-31|September 2006|2006-09-30|December 2009|Anticipated|2009-12-31|||||Interventional|||Development of Workshop for Lifestyle Changing for Crohn's Disease Patients and Its Affect on the Disease's Indexes|Development of Workshop for Lifestyle Changing for Crohn's Disease Patients and Its Affect on the Disease's Indexes|Withdrawn||N/A|0|Actual|Hadassah Medical Organization||||funding was not granted|f||||||||||||||2018-06-01 03:46:19.257001|2018-06-01 03:46:19.257001
NCT00376636|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-10-29|2006-09-14|2006-09-15|Estimate|||||||2007-10-29|2007-10-30|Estimate|October 2006||2006-10-31|September 2006|2006-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension|A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-Week Study to Investigate the Safety and Efficacy of the Oral Renin Inhibitor SPP635 Once Daily in Patients With Mild to Moderate Hypertension|Completed||Phase 2|35|Actual|Speedel Pharma Ltd.|||||f||||f||||||||||2018-06-01 03:46:19.320378|2018-06-01 03:46:19.320378
NCT00376623|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14||2014-04-30|2014-04-30|2006-09-14|2006-09-15|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|July 2006||2006-07-31|April 2014|2014-04-30||||April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer|An Open, Randomised Clinical Phase II Trial to Investigate the Efficacy, Safety and Pharmacokinetics of a Single Dose of 200 mg of i.v. BI 2536 in Comparison to 50 mg of i.v. BI 2536 Administered on Days 1, 2 and 3 in Patients With Advanced or Metastatic Non Small Cell Lung Cancer|Completed||Phase 2|96|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:46:19.381437|2018-06-01 03:46:19.381437
NCT00376610|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2007-07-03|2006-09-14|2006-09-15|Estimate|||||||2007-07-03|2007-07-04|Estimate||||July 2007|2007-07-31||||||||Interventional|||Prospective Clinical Evaluation of ASR/Re-Cap Resurfacing Arthroplasty|Prospective Clinical Evaluation of ASR/Re-Cap Resurfacing Arthroplasty|Completed||Phase 4|||Frederiksberg University Hospital|||||f||||||||||||||2018-06-01 03:46:19.447964|2018-06-01 03:46:19.447964
NCT00376597|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2017-01-19||2017-08-29|2006-09-13|2006-09-15|Estimate|2017-08-29|2017-10-02|Actual||||2017-08-29|2017-10-02|Actual|June 2006||2006-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|November 2015|Actual|2015-11-30||Interventional||554 patients were treated and analyzed.|Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection|A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer|Active, not recruiting||Phase 3|568|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 03:46:19.53384|2018-06-01 03:46:19.53384
NCT00376584|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2017-02-15|2006-09-14|2006-09-15|Estimate|||||||2017-02-15|2017-02-16|Actual|July 2006||2006-07-31|February 2017|2017-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Study to Evaluate the Efficacy of MK0524 to Improve Tolerability of Extended Release Niacin|Completed||Phase 3|825|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 03:46:19.908768|2018-06-01 03:46:19.908768
NCT00376571|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2016-09-23|2006-09-14|2006-09-15|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 2004||2004-10-31|September 2016|2016-09-30|March 2011|Actual|2011-03-31|June 2005|Actual|2005-06-30||Interventional|BIFI||Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?|Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions? A Strategy of Routine Stenting Both Main Vessel and Side Branch Versus a Strategy of Routine Main Vessel Stenting and Optional Treatment of Side Branch|Completed||Phase 4|413|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-06-01 03:46:19.97482|2018-06-01 03:46:19.97482
NCT00376558|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2012-12-12||2016-05-24|2006-09-14|2006-09-15|Estimate|2016-05-24|2016-07-01|Estimate||||2016-05-24|2016-07-01|Estimate|July 2006||2006-07-31|May 2016|2016-05-31|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31||Interventional|PET-CRA||Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence|Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence|Completed||N/A|50|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 03:46:20.048546|2018-06-01 03:46:20.048546
NCT00376532|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2014-05-05||2014-05-05|2006-09-14|2006-09-15|Estimate|2014-05-05|2014-06-04|Estimate||||2014-05-05|2014-06-04|Estimate|September 2006||2006-09-30|May 2014|2014-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|EMMA|Baseline analysis population was determined by the enrolled subjects for whom the MMP2 and MMP9 assays were completed.|Extracellular Matrix Marker of Arrhythmia Risk (EMMA)|Role of Matrix Metaloproteinase(MMP)9 and MMP 2 in Risk Stratification for Ventricular Tachycardia/Fibrillation in Patients With Implanted Cardioverter Defibrillator (ICD) Devices.|Completed|||63|Actual|Thomas Jefferson University|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 03:46:20.305603|2018-06-01 03:46:20.305603
NCT00376519|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-11-29|2006-09-13|2006-09-15|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2007||2007-05-31|November 2017|2017-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases|Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells|Terminated||Phase 1|3|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||t||||||||||2018-06-01 03:46:20.52899|2018-06-01 03:46:20.52899
NCT00376506|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|2011-11-01||2012-09-25|2006-09-14|2006-09-15|Estimate|2012-09-25|2012-10-26|Estimate||||2012-09-25|2012-10-26|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|January 2011|Actual|2011-01-31|September 2010|Actual|2010-09-30||Interventional|||A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia|A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic Dysphagia|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:46:20.722804|2018-06-01 03:46:20.722804
NCT00376493|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-14|||2008-03-10|2006-09-14|2006-09-15|Estimate|||||||2008-03-10|2008-03-13|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|APA||Prolonged Treatment for Infected Abortion After Hospital Discharge.|Prolonged Treatment for Infected Abortion After Hospital Discharge.|Terminated||Phase 4|56|Actual|Hospital de Clinicas de Porto Alegre||2||The rate of cure in both arms was higher than expected|f||||t||||||||||2018-06-01 03:46:21.051902|2018-06-01 03:46:21.051902
NCT00376480|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2009-11-10|2006-09-13|2006-09-15|Estimate|||||||2009-11-10|2009-11-11|Estimate|March 2005||2005-03-31|July 2009|2009-07-31||||June 2010|Anticipated|2010-06-30||Interventional|||Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases|Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia|Unknown status|Recruiting|Phase 1|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:46:21.158001|2018-06-01 03:46:21.158001
NCT00376467|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2014-02-06|2006-09-13|2006-09-14|Estimate|||||||2014-02-06|2014-02-07|Estimate|December 2001||2001-12-31|February 2014|2014-02-28|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia|STI 571 (GLIVEC) in the Treatment of Philadelphia-chromosome Positive and/or BCR/ABL Rearranged Adult Acute Lymphoblastic Leukemia. GIMEMA LAL 0201.|Completed||Phase 2|105|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||||||||||||2018-06-01 03:46:21.28259|2018-06-01 03:46:21.28259
NCT00376454|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2013-02-11|2006-09-13|2006-09-14|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2002||2002-11-30|February 2013|2013-02-28|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects With Peripheral Neuropathic Pain|Completed||Phase 2|113||GlaxoSmithKline|||||||||||||||||||2018-06-01 03:46:21.402907|2018-06-01 03:46:21.402907
NCT00376441|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2011-08-19|2006-09-13|2006-09-14|Estimate|||||||2011-08-19|2011-08-23|Estimate|August 2006||2006-08-31|August 2011|2011-08-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Evaluate Women After Vaginal Surgery for Urinary Symptoms and Sexual Function|Study of Sexual Function and Urinary Symptoms in Women Having Vaginal Surgeries|Completed|||41|Actual|William Beaumont Hospitals|||||f||||f||||||||||2018-06-01 03:46:21.50236|2018-06-01 03:46:21.50236
NCT00376428|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2015-02-24|2006-09-13|2006-09-14|Estimate|||||||2015-02-24|2015-02-25|Estimate|January 2003||2003-01-31|September 2006|2006-09-30|June 2005||2005-06-30|||||Interventional|||Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients|Application of Functional Electrophysiological Tests to Evaluate Pharmacological Treatments in Patients With Cystic Fibrosis|Terminated||Phase 2|20||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:46:21.561143|2018-06-01 03:46:21.561143
NCT00376415|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2016-09-29|2006-09-12|2006-09-14|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2004||2004-09-30|September 2016|2016-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Safety Study of Lessertia Frutescens in Adults.|A Randomized, Double-blind Placebo-controlled Phase 1 Trial of Lessertia Frutescens in Adults.|Completed||Phase 1|25|Actual|University of Missouri-Columbia||2|||f||||t||||||||Undecided||2018-06-01 03:46:21.628862|2018-06-01 03:46:21.628862
NCT00376402|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-07-17|2006-09-13|2006-09-14|Estimate|||||||2016-07-17|2016-07-19|Estimate|October 2006||2006-10-31|November 2008|2008-11-30|June 2007||2007-06-30|||||Interventional|||Study of a Pandemic Influenza Vaccine in Elderly Participants|Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants|Completed||Phase 2|200||Seqirus|||||f||||||||||||||2018-06-01 03:46:21.702442|2018-06-01 03:46:21.702442
NCT00376376|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2008-11-25|2006-09-13|2006-09-14|Estimate|||||||2008-11-25|2008-11-27|Estimate|September 2006||2006-09-30|November 2008|2008-11-30|November 2006||2006-11-30|||||Interventional|||Urinary Bactericidal Activity of 4 Doses of Levofloxacin Against Fluoroquinolone-Resistant E. Coli|Urinary Bactericidal Activity of 4 Doses of Levofloxacin (250, 500, &750, and 1000 mg) Against Fluoroquinolone-Resistant E. Coli|Completed||N/A|10||Michigan State University|||||f||||||||||||||2018-06-01 03:46:21.769819|2018-06-01 03:46:21.769819
NCT00376363|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2015-05-17||2015-07-25|2006-09-13|2006-09-14|Estimate|2015-05-17|2015-06-04|Estimate||||2015-07-25|2015-08-20|Estimate|November 2005||2005-11-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|ABC|One eye of each patient will be randomized to receive either an Ahmed or a Baerveldt glaucoma drainage implant.|Ahmed Versus Baerveldt Comparison Study|Ahmed Versus Baerveldt Comparison Study|Completed||N/A|276|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 03:46:21.84598|2018-06-01 03:46:21.84598
NCT00376350|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2015-08-21|2006-09-12|2006-09-14|Estimate|||||||2015-08-21|2015-08-24|Estimate|March 2007||2007-03-31|August 2015|2015-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Dose of Spinal Manipulation for Chronic Low Back Pain|Dose-Response/Efficacy of Manipulation for Chronic LBP|Completed||Phase 2/Phase 3|400|Actual|University of Western States||4|||f||||t||||||||||2018-06-01 03:46:22.04835|2018-06-01 03:46:22.04835
NCT00376337|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2013-09-04|2006-09-13|2006-09-14|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2006||2006-06-30|October 2011|2011-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Micafungin Salvage Mono-therapy in Invasive Aspergillosis|A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis|Terminated||Phase 2|17|Actual|Astellas Pharma Inc||2||"Study was stopped due to difficulties in recruitment and changes in standard care for invasive~   aspergillosis"|f||||t||||||||||2018-06-01 03:46:22.129464|2018-06-01 03:46:22.129464
NCT00376324|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2009-07-08|2006-09-12|2006-09-14|Estimate|||||||2009-07-08|2009-07-10|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone|An Open-Label, Multiple-Dose Study of the Pharmacokinetics of Tigecycline in Human Bone|Completed||Phase 1|36|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 03:46:22.247447|2018-06-01 03:46:22.247447
NCT00376311|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2006-09-13|2006-09-13|2006-09-14|Estimate|||||||2006-09-13|2006-09-14|Estimate|September 2002||2002-09-30|June 2002|2002-06-30|May 2004||2004-05-31|||||Interventional|||Effects of Oral Salmon Calcitonin in Human Osteoarthritis|Phase IIa Study of the Effects of a New Oral Formulation of Salmon Calcitonin in Human Osteoarthritis|Terminated||Phase 2|54||Université Catholique de Louvain|||||f||||||||||||||2018-06-01 03:46:22.299401|2018-06-01 03:46:22.299401
NCT00376298|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2015-12-22|2006-09-13|2006-09-14|Estimate|||||||2015-12-22|2015-12-24|Estimate|February 2004||2004-02-29|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Urology Database to Evaluate Clinical Information and Improve Patient Care.|Urology Database for Outcomes Research|Completed|||215|Actual|William Beaumont Hospitals|||||f||||f||||||||||2018-06-01 03:46:22.359096|2018-06-01 03:46:22.359096
NCT00376285|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2015-04-21|2006-09-13|2006-09-14|Estimate|||||||2015-04-21|2015-04-22|Estimate|November 2006||2006-11-30|April 2015|2015-04-30||||||||Interventional|||Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033|A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects|Withdrawn||Phase 1|0|Actual|Pfizer|||||||||||||||||||2018-06-01 03:46:22.410011|2018-06-01 03:46:22.410011
NCT00376272|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2009-04-17|2006-09-12|2006-09-14|Estimate|||||||2009-04-17|2009-04-20|Estimate|November 2004||2004-11-30|April 2009|2009-04-30|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence|Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence|Completed||Phase 3|1442|Actual|Gruppo di Ricerca GISSI||2|||f||||t||||||||||2018-06-01 03:46:22.485723|2018-06-01 03:46:22.485723
NCT00376259|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2010-12-20||2011-06-28|2006-09-13|2006-09-14|Estimate|2011-04-19|2011-05-17|Estimate||||2011-06-28|2011-06-30|Estimate|January 2007||2007-01-31|June 2011|2011-06-30||||August 2008|Actual|2008-08-31||Interventional|||Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone|An Open-label, Multicenter, Randomized Study of Combination Therapy With Oral LDT600 (Telbivudine) Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant|Terminated||Phase 3|43|Actual|Novartis|The study was not completed as planned and was terminated early with agreement from the European Medicines Agency (EMEA).|2||"The study was not completed as planned and was terminated early with agreement from the~   European Medicines Agency (EMEA)"|f||||||||||||||2018-06-01 03:46:22.834475|2018-06-01 03:46:22.834475
NCT00376246|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2008-06-02|2006-09-13|2006-09-14|Estimate|||||||2008-06-02|2008-06-04|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Ezetimibe on Flow-Mediated Brachial Artery Reactivity in Healthy Subjects|Effect of Ezetimibe on Flow-Mediated Brachial Artery Reactivity in Healthy Subjects|Completed||N/A|24|Anticipated|University of California, San Diego|||||f||||||||||||||2018-06-01 03:46:23.233786|2018-06-01 03:46:23.233786
NCT00376233|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2006-10-11|2006-09-13|2006-09-14|Estimate|||||||2006-10-11|2006-10-12|Estimate|February 2004||2004-02-29|September 2006|2006-09-30|June 2005||2005-06-30|||||Observational|||Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia|First Detailed Study on Effects of Long Term Regular Cannabis Use on Arachidonic Acid-Prostaglandine Pathways in Schizophrenia|Completed|||100||University of Jena|||||f||||||||||||||2018-06-01 03:46:23.296245|2018-06-01 03:46:23.296245
NCT00376220|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2016-09-20||2017-02-28|2006-09-13|2006-09-14|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|May 2004||2004-05-31|February 2017|2017-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Mean age was 43 years old. 58.51 % of the study participants where female and 41.49% were men. The participants were 73% white, non-Hispanic, 21% African-American, non -Hispanic, 4% Latino/Hispanic, and 1% Asian.|A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression|A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression|Completed||Phase 2|94|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-06-01 03:46:23.367386|2018-06-01 03:46:23.367386
NCT00376207|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2007-10-16|2006-09-13|2006-09-14|Estimate|||||||2007-10-16|2007-10-17|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Physical Activity After Stroke: How Does it Effect Chronical Inflammation and Insulin Sensitivity||Completed||N/A|200|Anticipated|Bispebjerg Hospital|||||f||||||||||||||2018-06-01 03:46:23.686461|2018-06-01 03:46:23.686461
NCT00376194|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2013-09-17|2006-09-13|2006-09-14|Estimate|||||||2013-09-17|2013-09-18|Estimate|September 2006||2006-09-30|September 2013|2013-09-30|March 2007||2007-03-31|||||Interventional|||Mercury Chelation to Treat Autism|An Investigation of the Efficacy of Mercury Chelation as a Treatment for Autism Spectrum Disorder|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:46:23.752304|2018-06-01 03:46:23.752304
NCT00376181|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2010-06-17|2006-09-12|2006-09-14|Estimate|||||||2010-06-17|2010-06-22|Estimate|June 2006||2006-06-30|June 2010|2010-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus|A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes|Terminated||Phase 3|96|Actual|Takeda||3||Combination formulation concerns|f||||f||||||||||2018-06-01 03:46:23.831815|2018-06-01 03:46:23.831815
NCT00376168|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|2012-05-11||2012-07-25|2006-09-12|2006-09-14|Estimate|2012-07-25|2012-07-26|Estimate||||2012-07-25|2012-07-26|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease|A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease|Completed||Phase 3|32|Actual|Protalix||2|||f||||t||||||||||2018-06-01 03:46:24.026218|2018-06-01 03:46:24.026218
NCT00376155|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-02-09|2006-09-13|2006-09-14|Estimate|||||||2017-02-09|2017-02-10|Actual|May 2006||2006-05-31|February 2017|2017-02-28|February 2007|Actual|2007-02-28|||||Interventional|||Comparison of Two Strategies for the Delivery of IPTc|Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission|Completed||Phase 4|14000|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 03:46:24.469027|2018-06-01 03:46:24.469027
NCT00376142|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2006-09-13|2006-09-13|2006-09-14|Estimate|||||||2006-09-13|2006-09-14|Estimate|April 2005||2005-04-30|September 2006|2006-09-30|November 2005||2005-11-30|||||Interventional|||Translating Clinicians' Beliefs Into Implementation Interventions (TRACII)|Translating Clinicians' Beliefs Into Implementation Interventions (TRACII): a Modelling Experiment to Change Clinicians' Intentions to Implement Evidence-Based Practice.|Completed||N/A|1200||Newcastle University|||||f||||||||||||||2018-06-01 03:46:24.547792|2018-06-01 03:46:24.547792
NCT00376129|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2007-12-07|2006-09-13|2006-09-14|Estimate|||||||2007-12-07|2007-12-10|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis|Open-Label,Singel Center Study to Evaluate the Safety and Efficacy of an Intramuskcular 12 Week-Course of Alefacept in Patients With Atopic Dermatitis|Completed||Phase 2|10|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-06-01 03:46:24.603128|2018-06-01 03:46:24.603128
NCT00376116|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2008-11-14|2006-09-13|2006-09-14|Estimate|||||||2008-11-14|2008-11-17|Estimate|March 2005||2005-03-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|||||Observational|HomeCARE||Home Monitoring in Cardiac Resynchronisation Therapy|Home CARE - Home Monitoring in CArdiac REsynchronisation Therapy|Completed|||513|Actual|Biotronik SE & Co. KG|||||f||||||||||||||2018-06-01 03:46:24.677284|2018-06-01 03:46:24.677284
NCT00376103|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2009-09-17|2006-09-13|2006-09-14|Estimate|||||||2009-09-17|2009-09-18|Estimate|August 2006||2006-08-31|September 2009|2009-09-30||||March 2008|Actual|2008-03-31||Interventional|||Radiation Boost for Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Maximal Resection, Local Radiation Boost With Concomitant Temozolomide, Followed by External Radiation Therapy With Concomitant Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Multiforme|Terminated||Phase 1/Phase 2|3|Actual|Methodist Healthcare||||Loss of funding from sponsor|f||||t||||||||||2018-06-01 03:46:25.742392|2018-06-01 03:46:25.742392
NCT00376090|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-10-13|2006-09-13|2006-09-14|Estimate|||||||2017-10-13|2017-10-16|Actual|July 2005|Actual|2005-07-31|October 2017|2017-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults|A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVA-CMDR (HIV-1 CM235 Env/ CM240 Gag/Pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV-Uninfected Adults|Completed||Phase 1|48|Actual|U.S. Army Medical Research and Materiel Command||8|||f||||f||||||||||2018-06-01 03:46:25.855864|2018-06-01 03:46:25.855864
NCT00376077|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2016-05-05|2006-09-12|2006-09-14|Estimate|||||||2016-05-05|2016-05-09|Estimate|August 2005||2005-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.|A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Rapidly Augmenting Platelet Counts in Childhood ITP.|Completed||Phase 3|32|Actual|The Hospital for Sick Children||2|||f||||t||||||||Yes|Manuscript preparation|2018-06-01 03:46:25.934558|2018-06-01 03:46:25.934558
NCT00376064|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-03-02|2006-09-13|2006-09-14|Estimate|||||||2017-03-02|2017-03-06|Actual|March 2006||2006-03-31|September 2011|2011-09-30||||January 2010|Actual|2010-01-31||Interventional|||Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly|A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy|Completed||Phase 4|20|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:46:26.011782|2018-06-01 03:46:26.011782
NCT00376051|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2017-05-02|2006-09-13|2006-09-14|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2006||2006-09-30|November 2009|2009-11-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia|Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia|Completed||Phase 4|22|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 03:46:26.098943|2018-06-01 03:46:26.098943
NCT00376038|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2012-05-31|2006-09-12|2006-09-14|Estimate|||||||2012-05-31|2012-06-04|Estimate|August 2006||2006-08-31|February 2011|2011-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes|A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.|Completed||Phase 1|13|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:46:26.263331|2018-06-01 03:46:26.263331
NCT00376025|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2008-02-12|2006-09-13|2006-09-14|Estimate|||||||2008-02-12|2008-02-22|Estimate|July 2007||2007-07-31|February 2008|2008-02-29|April 2009|Anticipated|2009-04-30|January 2009|Anticipated|2009-01-31||Interventional|||Antioxidant Supplementation in Patients With Kashin-Beck Disease|Study of the Effects of Antioxidant Supplementation in Patients Suffering From Kashin-Beck Disease|Unknown status|Recruiting|Phase 2|300|Anticipated|Innovative Humanitarian Solutions|||||f||||t||||||||||2018-06-01 03:46:26.339787|2018-06-01 03:46:26.339787
NCT00376012|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|||2008-06-10|2006-09-13|2006-09-14|Estimate|||||||2008-06-10|2008-06-11|Estimate|February 2001||2001-02-28|May 2008|2008-05-31|September 2008|Anticipated|2008-09-30|September 2007|Anticipated|2007-09-30||Interventional|||Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis|Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis|Unknown status|Active, not recruiting|Phase 3|300|Actual|Tuberculosis Research Centre, India||2|||f||||||||||||||2018-06-01 03:46:26.443111|2018-06-01 03:46:26.443111
NCT00375999|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-13|2014-01-14||2014-01-14|2006-09-13|2006-09-14|Estimate|2014-01-14|2014-03-03|Estimate||||2014-01-14|2014-03-03|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Docetaxel and Epirubicin in Advanced Gastric Cancer|A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.|Completed||Phase 2|34|Actual|Yonsei University||1|||f||||||||||||||2018-06-01 03:46:26.539111|2018-06-01 03:46:26.539111
NCT00375986|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2007-11-12|2006-09-12|2006-09-13|Estimate|||||||2007-11-12|2007-11-14|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||A Comparison of Manual vs. Spontaneous Removal of the Placenta at Cesarean Section|A Comparison of Manual vs. Spontaneous Removal of the Placenta at Cesarean Section|Completed||N/A|150|Anticipated|University of Rochester|||||f||||f||||||||||2018-06-01 03:46:26.684992|2018-06-01 03:46:26.684992
NCT00375973|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|2015-03-18||2015-07-31|2006-09-12|2006-09-13|Estimate|2015-06-29|2015-07-27|Estimate||||2015-07-31|2015-08-21|Estimate|September 2006||2006-09-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|June 2012|Actual|2012-06-30||Interventional|CFS||Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome|A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome|Completed||Phase 2/Phase 3|60|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 03:46:26.779017|2018-06-01 03:46:26.779017
NCT00375960|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2007-03-30|2006-09-11|2006-09-13|Estimate|||||||2007-03-30|2007-04-02|Estimate|June 2006||2006-06-30|March 2007|2007-03-31|April 2007||2007-04-30|||||Interventional|||A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Crossover Study of the Safety, Efficacy and Pharmacokinetics of Two Escalating, Oral Doses of V3381 (200 mg BID and 400 mg BID) for 28 Days in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)|Completed||Phase 2|50||Vernalis (R&D) Ltd|||||||||||||||||||2018-06-01 03:46:27.149077|2018-06-01 03:46:27.149077
NCT00375947|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2007-08-22|2006-09-11|2006-09-13|Estimate|||||||2007-08-22|2007-08-23|Estimate|November 2005||2005-11-30|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Study of Effectiveness of Hand Exercises to Treat Symptoms of Hand Osteoarthritis|Efficacy of a Home-Based Hand Range-of-Motion and Strength Training Exercise Program for Improvement of Hand Function in Older Adults With Hand Osteoarthritis: a Randomized Controlled Trial|Completed||N/A|65||The Arthritis Research Institute of America||2|||f||||||||||||||2018-06-01 03:46:27.217402|2018-06-01 03:46:27.217402
NCT00375934|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2010-03-22||2010-09-17|2006-09-11|2006-09-13|Estimate|2010-05-24|2010-06-22|Estimate||||2010-09-17|2010-09-21|Estimate|September 2006||2006-09-30|May 2010|2010-05-31||||January 2007|Actual|2007-01-31||Interventional|||Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery|Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery|Completed||Phase 3|200|Actual|Xanodyne Pharmaceuticals||2|||||||||||||||||2018-06-01 03:46:27.32469|2018-06-01 03:46:27.32469
NCT00375921|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-02-24|2006-09-11|2006-09-13|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Evaluating Taste and Smell Function and Food and Taste Preferences of Head and Neck Cancer Patients During Radiation Therapy/Chemotherapy|Evaluation of Chemosensory Function and Taste Preference of Head and Neck Cancer Patients Prior to, On Completion of and Six Weeks After Oncology Treatment|Completed|||100|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:46:27.865278|2018-06-01 03:46:27.865278
NCT00375908|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2015-08-31|2006-09-11|2006-09-13|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2005||2005-10-31|August 2015|2015-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury|Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury|Completed|||4|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 03:46:27.928843|2018-06-01 03:46:27.928843
NCT00375895|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2012-03-01|2006-09-12|2006-09-13|Estimate|||||||2012-03-01|2012-03-02|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation|Prospective, Open-label, Single Arm Pilot Study Evaluating the Effect on Virological Response of the Switch From Tacrolimus to Cyclosporin Associated With a Peginterferon Alfa-2a / Ribavirin Bitherapy, in Non-responder or With Recurrent VHC+ Disease Liver Transplanted Patients.|Terminated||Phase 3|11|Actual|Rennes University Hospital||1||Insufficient enrollment|f||||f||||||||||2018-06-01 03:46:27.997147|2018-06-01 03:46:27.997147
NCT00375882|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2014-08-14|2006-09-11|2006-09-13|Estimate|||||||2014-08-14|2014-08-15|Estimate|March 2006||2006-03-31|August 2014|2014-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Safety Study to Evaluate the Effect of Lowering Body Temperature During Cochlear Implantation|Mild Hypothermia During Cochlear Implantation|Terminated||Phase 2|19|Actual|University of Miami||1||as specified in the protocol|f||||f||||||||||2018-06-01 03:46:28.120629|2018-06-01 03:46:28.120629
NCT00375869|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2012-03-01|2006-09-12|2006-09-13|Estimate|||||||2012-03-01|2012-03-05|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury|A Prospective Randomized Placebo Controlled Study of the Efficacy and Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury|Completed||Phase 2|10|Actual|Royal Alexandra Hospital||2|||f||||f||||||||||2018-06-01 03:46:28.229802|2018-06-01 03:46:28.229802
NCT00375856|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2016-09-26|2006-09-12|2006-09-13|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2006||2006-10-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Computer-Assisted Total Knee Replacement Kinematics: DePuy Sigma Posterior Cruciate Substituting Knee and the DePuy Sigma RP Rotating Platform Knee|An Investigation of Computer-Assisted Total Knee Replacement Kinematics on Patient Performance: An Examination of the DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee and the DePuy P.F.C.® Sigma RP Rotating Platform Knee Systems|Completed||Phase 4|91|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 03:46:28.307009|2018-06-01 03:46:28.307009
NCT00375843|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2013-02-05|2006-09-12|2006-09-13|Estimate|||||||2013-02-05|2013-02-06|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|June 2007|Actual|2007-06-30||Interventional|||Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication|"Response Variability in Treatment Resistant Depression - an Ancillary Study to Sequenced Treatment Alternatives to Relieve Depression (STAR*D)"|Completed||Phase 4|118|Actual|National Institute of Mental Health (NIMH)||2|||f||||f||||||||||2018-06-01 03:46:28.387078|2018-06-01 03:46:28.387078
NCT00375830|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2018-04-20|2006-09-11|2006-09-13|Estimate|||||||2018-04-20|2018-04-24|Actual|January 2006||2006-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases|Combined 18F NaF/18F FDG PET/MRI for Detection of Skeletal Metastases|Recruiting||Phase 4|170|Anticipated|Stanford University||1|||f||||t||||||||||2018-06-01 03:46:28.468164|2018-06-01 03:46:28.468164
NCT00375817|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2007-10-11|2006-09-12|2006-09-13|Estimate|||||||2007-10-11|2007-10-12|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|January 2008|Anticipated|2008-01-31|||||Interventional|||Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial|A Phase II, Open-Label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)|Unknown status|Active, not recruiting|Phase 2|40|Actual|Bioheart, Inc.|||||f||||t||||||||||2018-06-01 03:46:28.544221|2018-06-01 03:46:28.544221
NCT00375804|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2018-01-05|2006-09-12|2006-09-13|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2003||2003-06-30|January 2018|2018-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Racial Disparity in Endometrial Cancer|Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer|Terminated|||43|Actual|University of Louisville||||Funding and logistical difficuties resulted in the withdrawl of the study.|f||||t||||||||||2018-06-01 03:46:28.604626|2018-06-01 03:46:28.604626
NCT00375791|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11||2018-02-27|2018-02-27|2006-09-11|2006-09-13|Estimate||||2018-02-27|2018-02-28|Actual|2018-02-27|2018-02-28|Actual|December 2005||2005-12-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma|An Open-Label Phase II Study of the Safety and Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|67|Actual|AEterna Zentaris||2|||f||||f||||||||||2018-06-01 03:46:28.660755|2018-06-01 03:46:28.660755
NCT00375778|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2006-09-12|2006-09-12|2006-09-13|Estimate|||||||2006-09-12|2006-09-13|Estimate|April 2005||2005-04-30|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||Parkinson's Disease Evaluated by PET and the Effect of Memantine|Parkinson's Disease Evaluated by Positron Emission Tomography and the Effect of the NMDA Receptor Antagonist Memantine|Completed||N/A|12||University of Aarhus|||||f||||||||||||||2018-06-01 03:46:28.744996|2018-06-01 03:46:28.744996
NCT00375765|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2017-01-17|2006-09-12|2006-09-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|April 2005||2005-04-30|January 2017|2017-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer|A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer|Completed||Phase 4|40||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:46:28.79384|2018-06-01 03:46:28.79384
NCT00375752|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2012-03-30|2011-12-09|2017-06-06|2006-09-11|2006-09-13|Estimate|2012-03-30|2012-04-25|Estimate|2011-12-09|2011-12-22|Estimate|2017-06-06|2017-06-26|Actual|June 1, 2006|Actual|2006-06-01|June 2017|2017-06-30|December 16, 2010|Actual|2010-12-16|December 16, 2010|Actual|2010-12-16||Interventional|FEMZONE||Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer|Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks)|Terminated||Phase 4|168|Actual|Novartis|Study terminated after 178 patients screened and 168 randomized, due to insufficient recruitment rate (no safety issues decided the reason to terminate study). LPLV for study was on 13-DEC-2010. LPLV of the 5-year follow-up period was on 03-FEB-2016.|2|||f||||f||||||||Undecided||2018-06-01 03:46:28.876814|2018-06-01 03:46:28.876814
NCT00375739|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-01-26|2006-09-11|2006-09-13|Estimate|||||||2016-01-26|2016-01-28|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses|A Multi-center, Randomized, Double-blind, Double-dummy, Vehicle-controlled Sequential Cohort Study to Determine the Safety PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses.|Completed||Phase 2|200||Peplin|||||||||||||||||||2018-06-01 03:46:29.329263|2018-06-01 03:46:29.329263
NCT00375726|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2010-12-13|2006-09-12|2006-09-13|Estimate|||||||2010-12-13|2010-12-14|Estimate|October 2006||2006-10-31|December 2010|2010-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3|Completed||Phase 1|58|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 03:46:29.415785|2018-06-01 03:46:29.415785
NCT00375713|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|2009-07-08||2011-08-30|2006-09-12|2006-09-13|Estimate|2009-09-11|2009-10-14|Estimate||||2011-08-30|2011-08-31|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema|A Multi-centre, Double-blind, Double-dummy, Randomized, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Xyzal® 5mg od vs Zyrtec® 10mg od in Subjects Aged 15 Years and Above With Dermatitis and Eczema|Completed||Phase 3|466|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 03:46:29.515874|2018-06-01 03:46:29.515874
NCT00375700|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-02-24|2006-09-11|2006-09-13|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effect of an Oral Supplement on the Total Energy and Protein Intake of Head and Neck Cancer Patients in the Last 2 Weeks of Radiation Therapy|Efficacy of an Oral Nutrition Supplement on the Total Caloric and Protein Intake of Head and Neck Cancer Patients During the Last 2 Weeks of Radiation Therapy|Withdrawn||N/A|0|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:46:29.780948|2018-06-01 03:46:29.780948
NCT00375687|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2006-09-12|2006-09-12|2006-09-13|Estimate|||||||2006-09-12|2006-09-13|Estimate|August 2005||2005-08-31|November 2005|2005-11-30|January 2020||2020-01-31|||||Interventional|||Investigation of Early Hormonotherapy Efficacy of Prostate Cancer|Investigation of Early Hormonotherapy Efficacy of High Risk Patients for Progression of Prostate Cancer After Radical Prostatectomy|Recruiting||N/A|61||Kaunas University of Medicine|||||f||||||||||||||2018-06-01 03:46:29.837249|2018-06-01 03:46:29.837249
NCT00375674|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|2017-02-22||2018-05-25|2006-09-12|2006-09-13|Estimate|2017-07-19|2017-08-18|Actual||||2018-05-25|2018-05-30|Actual|August 1, 2007|Actual|2007-08-01|May 2018|2018-05-31|August 30, 2017|Actual|2017-08-30|April 7, 2016|Actual|2016-04-07||Interventional|S-TRAC||A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer|Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc|Completed||Phase 3|674|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:46:30.020462|2018-06-01 03:46:30.020462
NCT00375661|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2015-09-01|2006-09-12|2006-09-13|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC|Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma|Completed||Phase 4|100|Actual|Kyoto University||1|||f||||||||||||||2018-06-01 03:46:32.324785|2018-06-01 03:46:32.324785
NCT00375648|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2017-05-31|2006-09-11|2006-09-13|Estimate|||||||2017-05-31|2017-06-02|Actual|June 2005||2005-06-30|May 2017|2017-05-31||||July 2007|Actual|2007-07-31||Interventional|TRAPEZE||Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer|Assessment of the Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer|Completed||Phase 3|61|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:46:32.393965|2018-06-01 03:46:32.393965
NCT00375635|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2006-09-12|2006-09-12|2006-09-13|Estimate|||||||2006-09-12|2006-09-13|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|October 2006||2006-10-31|||||Interventional|||Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis|Removal of Protein Bound Uremic Toxins in Chronic Hemodialysis Patients by Modified Plasma Separation and Adsorption Combined With Hemodialysis|Unknown status|Recruiting|N/A|10||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:46:32.459799|2018-06-01 03:46:32.459799
NCT00375622|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2006-09-12|2006-09-12|2006-09-13|Estimate|||||||2006-09-12|2006-09-13|Estimate|February 2005||2005-02-28|September 2006|2006-09-30|June 2006||2006-06-30|||||Interventional|||Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial||Completed||Phase 2|60||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:46:32.52021|2018-06-01 03:46:32.52021
NCT00375609|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2017-07-18||2017-12-21|2006-09-12|2006-09-13|Estimate|2017-07-19|2017-12-15|Actual||||2017-12-21|2018-01-23|Actual|May 2006||2006-05-31|July 2017|2017-07-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional||All randomized patients who took at least 1 dose of study medication after randomization.|Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)|Evaluation of the Factor Xa Inhibitor, PRT054021, Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events After Unilateral Total Knee Replacement (EXPERT)|Completed||Phase 2|215|Actual|Portola Pharmaceuticals||3|||f||||||||||||||2018-06-01 03:46:32.626563|2018-06-01 03:46:32.626563
NCT00375596|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2015-02-19|2006-09-12|2006-09-13|Estimate|||||||2015-02-19|2015-02-20|Estimate||||February 2015|2015-02-28||||||||Interventional|||A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis|Study Withdrawn Prior to Determining Official Title|Withdrawn||Phase 2|0|Actual|Bausch & Lomb Incorporated||||"Study withdrawn without starting or enrolling subjects due to a business decision to not~   proceed with the project."|f||||f||||||||||2018-06-01 03:46:33.037964|2018-06-01 03:46:33.037964
NCT00375583|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2017-06-30|2006-09-12|2006-09-13|Estimate|||||||2017-06-30|2017-07-02|Actual|September 9, 2006||2006-09-09|April 28, 2011|2011-04-28|April 28, 2011|Actual|2011-04-28|April 28, 2011|Actual|2011-04-28||Interventional|||Effect of Albendazole Dose on Clearance of Filarial Worms|Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study|Completed||Phase 2|1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:46:33.087829|2018-06-01 03:46:33.087829
NCT00375570|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2008-08-14|2006-09-12|2006-09-13|Estimate|||||||2008-08-14|2008-08-18|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in Adolescents|An Open Label, Multi-Centre, Phase III, Subject Initiated Safety Study of ME-609 in Treatment of Recurrent Herpes Simplex Labialis in Adolescents|Completed||Phase 3|254|Actual|Medivir||1|||f||||f||||||||||2018-06-01 03:46:33.147167|2018-06-01 03:46:33.147167
NCT00375557|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2015-05-26|2006-09-11|2006-09-13|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2006||2006-10-31|May 2015|2015-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients|An Open Label, Randomized, Flexible Dose, 6-week Clinical Trial of the Safety and Efficacy of Divalproex ER vs Quetiapine in the Treatment of Behavioral Symptoms in the Elderly With Moderate to Severe Alzheimer's Dementia|Withdrawn||Phase 4|0|Actual|University of Cincinnati||2|||f||||f||||||||||2018-06-01 03:46:33.203827|2018-06-01 03:46:33.203827
NCT00375544|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2009-08-12|2006-09-11|2006-09-13|Estimate|||||||2009-08-12|2009-08-14|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|November 2007|Actual|2007-11-30|||||Interventional|||Study to Evaluate the Safety and Efficacy of a Low Level Light Device in Patients With Knee Osteoarthritis|A Phase I Single Center Open Label Study to Evaluate the Safety and Efficacy of a Low Level Light Device in Patients With Knee Osteoarthritis|Completed||Phase 1|10|Anticipated|Light Sciences LLC|||||f||||||||||||||2018-06-01 03:46:33.272584|2018-06-01 03:46:33.272584
NCT00375531|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2018-01-25|2006-09-12|2006-09-13|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2006||2006-10-31|October 2007|2007-10-31|August 2007|Anticipated|2007-08-31|||||Interventional|||Use of Mindfulness Meditation With Iraqi/Afghanistan War Veterans|Use of Mindfulness Meditation With Iraqi/Afghanistan War Veterans With Post Traumatic Stress Disorder|Withdrawn||N/A|0|Actual|Corporal Michael J. Crescenz VA Medical Center||||protocol revisions were deemed unable to be completed by 8/2007|f||||||||||||||2018-06-01 03:46:33.32944|2018-06-01 03:46:33.32944
NCT00375518|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2015-12-16||2015-12-16|2006-09-12|2006-09-13|Estimate|2015-12-16|2016-01-22|Estimate||||2015-12-16|2016-01-22|Estimate|July 2006||2006-07-31|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery|Double-Blind Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery|Completed||N/A|162|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 03:46:33.410869|2018-06-01 03:46:33.410869
NCT00375505|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2015-05-18||2015-08-11|2006-09-11|2006-09-13|Estimate|2015-08-11|2015-09-07|Estimate||||2015-08-11|2015-09-07|Estimate|October 2005||2005-10-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss|Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss|Completed||Phase 3|70|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:46:33.631589|2018-06-01 03:46:33.631589
NCT00375492|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2009-02-25||2015-03-19|2006-09-11|2006-09-13|Estimate|2009-07-30|2009-09-04|Estimate||||2015-03-19|2015-04-07|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Effect on Weight Loss of Exenatide Versus Placebo|Effect on Weight Loss of Exenatide Versus Placebo in Subjects With Type 2 Diabetes Participating in a Lifestyle Modification Program|Completed||Phase 3|196|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:46:34.144538|2018-06-01 03:46:34.144538
NCT00375466|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2012-12-12|2006-09-12|2006-09-13|Estimate|||||||2012-12-12|2012-12-13|Estimate|September 2006||2006-09-30|December 2012|2012-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.|Phase 4 Study of Tranexamic Acid for Elderly Patients Undergoing Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.|Completed||N/A|63|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-06-01 03:46:34.718679|2018-06-01 03:46:34.718679
NCT00375453|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2014-12-30|2006-09-12|2006-09-13|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Dose Escalation Study of SH U04722 in Solid Tumors|Phase I, Open-label, Dose Escalation Study for Evaluation of Safety, Tolerability, Pharmacokinetics, and Tumor-suppressive Efficacy of SH U04722 in Patients With Solid Tumors|Terminated||Phase 1|10|Actual|Bayer||1|||f||||||||||||||2018-06-01 03:46:34.794381|2018-06-01 03:46:34.794381
NCT00375440|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2015-10-02|2006-09-11|2006-09-13|Estimate|||||||2015-10-02|2015-10-05|Estimate|February 2005||2005-02-28|October 2015|2015-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Tranexamic Acid Study|Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty|Withdrawn||N/A|0|Actual|Texas Tech University Health Sciences Center||||Study halted prematurely as investigator left the institution.|f||||||||||||||2018-06-01 03:46:34.858695|2018-06-01 03:46:34.858695
NCT00375427|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|2011-02-28||2012-04-09|2006-09-12|2006-09-13|Estimate|2011-07-11|2011-08-04|Estimate||||2012-04-09|2012-04-11|Estimate|February 2006||2006-02-28|July 2011|2011-07-31||||February 2010|Actual|2010-02-28||Interventional|||Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions|A Prospective, Randomized, Multi-center Comparative 2-arm Trial of Efficacy and Safety of Zoledronic Acid (Every 3-months vs. Every 4 Weeks) Beyond Approximately 1 Year of Treatment With Zoledronic Acid in Patients With Bone Lesions From Breast Cancer|Completed||Phase 3|430|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:46:34.945665|2018-06-01 03:46:34.945665
NCT00375414|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2007-05-04|2006-09-12|2006-09-13|Estimate|||||||2007-05-04|2007-05-07|Estimate|October 2003||2003-10-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Role of Prophylactic Antibiotics in New Introducer PEG-Gastropexy|New Introducer PEG-Gastropexy Does Not Need Prophylactic Antibiotics: Prospective Randomised Double Blind Placebo Controlled Trial|Completed||N/A|97|Actual|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 03:46:35.539978|2018-06-01 03:46:35.539978
NCT00375401|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11||2009-08-11|2012-11-05|2006-09-11|2006-09-13|Estimate||||2009-08-11|2009-08-13|Estimate|2012-11-05|2012-11-07|Estimate|October 2006||2006-10-31|November 2012|2012-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety|A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects|Terminated||Phase 3|2536|Actual|Pfizer||3||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:46:35.627376|2018-06-01 03:46:35.627376
NCT00375388|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2006-09-12|2006-09-12|2006-09-13|Estimate|||||||2006-09-12|2006-09-13|Estimate|January 1998||1998-01-31|September 2006|2006-09-30|October 2002||2002-10-31|||||Interventional|||The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial|Study of Metformin HCL in Patients With Type 2 Diabetes Intensively Treated With Insulin: a Treatment Strategy for Insulin Resistance in Type 2 Diabetes Mellitus: a Randomized Controlled Trial|Completed||Phase 3|400||Bethesda General Hospital, Hoogeveen|||||f||||||||||||||2018-06-01 03:46:35.824942|2018-06-01 03:46:35.824942
NCT00375375|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2007-03-01|2006-09-12|2006-09-13|Estimate|||||||2007-03-01|2007-03-02|Estimate|January 2004||2004-01-31|March 2007|2007-03-31|December 2004||2004-12-31|||||Interventional|||Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life||Completed||Phase 4|80||Postgraduate Institute of Medical Education and Research|||||f||||||||||||||2018-06-01 03:46:35.899239|2018-06-01 03:46:35.899239
NCT00375362|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-12|||2006-09-12|2006-09-12|2006-09-13|Estimate|||||||2006-09-12|2006-09-13|Estimate|July 2006||2006-07-31|July 2006|2006-07-31|September 2006||2006-09-30|||||Interventional|||The Analgesic Effect of Nitroglycerin Patch for Postoperative Pain After Total Knee Replacement|The Analgesic Efficacy of Nitroglycerin Patches for Postoperative Pain in Patients Undergoing Total Knee Arthroplasty|Unknown status|Recruiting|N/A|50||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:46:35.96266|2018-06-01 03:46:35.96266
NCT00375349|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-09-29|2006-09-11|2006-09-12|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2006||2006-09-30|September 2016|2016-09-30|September 2009|Anticipated|2009-09-30|||||Interventional|||Non Alcoholic Fatty Liver Disease Influence of Statin Therapy||Withdrawn||N/A|0|Actual|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:46:36.02881|2018-06-01 03:46:36.02881
NCT00375336|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2008-12-31|2006-09-11|2006-09-12|Estimate|||||||2008-12-31|2009-01-01|Estimate|January 2005||2005-01-31|December 2008|2008-12-31|December 2008|Anticipated|2008-12-31|||||Observational|||Risk Factors Associated With Calcification of the Aortic Valve|Risk Markers of Coronary Artery Disease Associated With Calcific Aortic Valve Disease|Unknown status|Active, not recruiting||300|Anticipated|Charles University, Czech Republic|||3||f||||f||||||Samples Without DNA|"~     serum and plasma specimens retained at -80 deg. C~   "|||2018-06-01 03:46:36.076544|2018-06-01 03:46:36.076544
NCT00375323|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2007-04-19|2006-09-11|2006-09-12|Estimate|||||||2007-04-19|2007-04-20|Estimate||||April 2007|2007-04-30||||||||Interventional|||Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation|Effects of Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation in Patients With Hemophilia A and Antibodies to Factor VIII|Completed||Phase 3|||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:46:36.136145|2018-06-01 03:46:36.136145
NCT00375310|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-02-26|2006-09-11|2006-09-12|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2006||2006-09-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2010|Actual|2010-11-30||Interventional|||Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer|Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma|Completed||Phase 1|27|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 03:46:36.188785|2018-06-01 03:46:36.188785
NCT00375297|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2006-09-08|2006-09-08|2006-09-12|Estimate|||||||2006-09-08|2006-09-12|Estimate|January 2001||2001-01-31|September 2006|2006-09-30|June 2005||2005-06-30|||||Interventional|||Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women|Randomized Double Blind Placebo Controlled Study of Sildenafil for Treatment of Serotonergic Reuptake Inhibitor Associated Sexual Dysfunction in Women With Major Depression Treated to Remission|Completed||Phase 4|100||University of New Mexico|||||||||||||||||||2018-06-01 03:46:36.276703|2018-06-01 03:46:36.276703
NCT00375284|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2013-10-30|2006-09-11|2006-09-12|Estimate|||||||2013-10-30|2013-10-31|Estimate|September 2006||2006-09-30|October 2013|2013-10-31||||July 2007|Actual|2007-07-31||Interventional|||A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS|A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome|Completed||Phase 4|404|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:46:36.339148|2018-06-01 03:46:36.339148
NCT00375271|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2006-09-11|2006-09-11|2006-09-12|Estimate|||||||2006-09-11|2006-09-12|Estimate|August 2006||2006-08-31|September 2006|2006-09-30|June 2007||2007-06-30|||||Interventional|||Perioperative Hemodynamic Optimization in High-Risk Patients Using Less-Invasive Monitoring Methods|Multicenter Randomized Controled Trial of Perioperative Hemodynamic Optimization in High-Risk Patients Using Less-Invasive Monitoringng Methods|Unknown status|Recruiting|N/A|400||Centro de Estudos Mário César de Rezende|||||f||||||||||||||2018-06-01 03:46:36.556547|2018-06-01 03:46:36.556547
NCT00375258|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2011-06-29|2006-09-11|2006-09-12|Estimate|||||||2011-06-29|2011-06-30|Estimate|May 2005||2005-05-31|June 2011|2011-06-30|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage|A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement|Completed||Phase 3|20211|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 03:46:36.657018|2018-06-01 03:46:36.657018
NCT00375245|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2014-01-16|2006-09-11|2006-09-12|Estimate|||||||2014-01-16|2014-01-17|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2009|Actual|2009-05-31||Interventional|||Rapamycin With Grapefruit Juice for Advanced Malignancies|A Phase Ib Study Administering Rapamycin (Sirolimus) With Grapefruit Juice in Patients With Advanced Malignancies|Completed||Phase 1|41|Actual|University of Chicago||1|||f||||t||||||||||2018-06-01 03:46:36.747016|2018-06-01 03:46:36.747016
NCT00375232|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-01-05|2006-09-11|2006-09-12|Estimate|||||||2016-01-05|2016-01-07|Estimate|October 2006||2006-10-31|January 2016|2016-01-31||||||||Interventional|||Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes|Effects of Montelukast on Occult Exercise-Induced Bronchospasm in Athletes|Withdrawn||N/A|0|Actual|Indiana University|||||f||||||||||||||2018-06-01 03:46:36.819179|2018-06-01 03:46:36.819179
NCT00375219|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|2014-05-05|2012-05-03|2014-05-05|2006-09-08|2006-09-12|Estimate|2014-05-05|2014-06-03|Estimate|2012-05-03|2012-05-08|Estimate|2014-05-05|2014-06-03|Estimate|September 2006||2006-09-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|December 2010|Actual|2010-12-31||Interventional||Intent to treat population includes all participants who provide written informed consent and receive at least one dose of study medication.|Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation|A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation|Completed||Phase 2|103|Actual|Teva Pharmaceutical Industries||1|||f||||t||||||||||2018-06-01 03:46:36.929095|2018-06-01 03:46:36.929095
NCT00375206|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2007-01-25|2006-09-11|2006-09-12|Estimate|||||||2007-01-25|2007-01-29|Estimate|September 2006||2006-09-30|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine|A Phase I Study to Assess Safety, Tolerability and Immunogenicity of a Trivalent Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) to Healthy Subjects|Completed||Phase 1|189||PowderMed|||||||||||||||||||2018-06-01 03:46:38.128338|2018-06-01 03:46:38.128338
NCT00375193|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-09||2009-05-19|2016-11-29|2006-09-09|2006-09-12|Estimate||||2009-09-29|2009-10-01|Estimate|2016-11-29|2016-12-01|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|March 2009|Actual|2009-03-31|May 2008|Actual|2008-05-31||Interventional|||Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy|A Phase 2 Trial of Single-Agent Amrubicin in Patients With Extensive Disease Small Cell Lung Cancer That is Refractory or Progressive Within 90 Days of Completion of First Line Platinum-based Chemotherapy|Completed||Phase 2|75|Actual|Celgene Corporation||1|||f||||f||||||||||2018-06-01 03:46:38.205621|2018-06-01 03:46:38.205621
NCT00375180|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-02-24|2006-09-11|2006-09-12|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients|Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients Prior to, on Completion of and Six Weeks After Oncology Treatment|Completed|||100|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:46:38.338396|2018-06-01 03:46:38.338396
NCT00375167|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2008-04-14|2006-09-11|2006-09-12|Estimate|||||||2008-04-14|2008-04-15|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|May 2008||2008-05-31|||||Interventional|||Efficacy of the Recovery Workbook as a Psychoeducational Tool for Facilitating Recovery|Efficacy of the Recovery Workbook as a Psychoeducational Tool for Facilitating Recovery in Persons With Severe and Persistent Mental Illness|Completed||Phase 3|60|Anticipated|Queen's University|||||f||||||||||||||2018-06-01 03:46:38.390052|2018-06-01 03:46:38.390052
NCT00375154|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2011-07-19|2006-09-11|2006-09-12|Estimate|||||||2011-07-19|2011-07-20|Estimate|August 2006||2006-08-31|July 2011|2011-07-31||||||||Interventional|||HERMES STUDY: Study on the Feasibility and Efficiency of Noninvasive Positive-Pressure Ventilation (NPPV) in Prehospital Care|Noninvasive Positive-pressure Ventilation (NPPV) for Acute Respiratory Failure in Out-of-hospital Patients: a Multicenter, Prospective, Randomized Controlled Trial|Withdrawn||N/A|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||||major difficulties in training investigators in other centers|f||||||||||||||2018-06-01 03:46:38.451087|2018-06-01 03:46:38.451087
NCT00375141|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2007-06-04|2006-09-11|2006-09-12|Estimate|||||||2007-06-04|2007-06-06|Estimate||||June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Long-Pulsed Dye Laser and Intense Pulsed Light for Skin Rejuvenation.||Terminated||N/A|||Bispebjerg Hospital||||Inclusion, treatments and follow-up are finished|f||||||||||||||2018-06-01 03:46:38.515719|2018-06-01 03:46:38.515719
NCT00375128|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-10|||2007-10-18|2006-09-10|2006-09-12|Estimate|||||||2007-10-18|2007-10-19|Estimate|September 2006||2006-09-30|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Sporozoite Challenge of Polyprotein Vaccinees|Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Polyprotein Malaria Vaccines 'FP9−PP, MVA−PP' and Control Non−Vaccinated Volunteers|Completed||Phase 1/Phase 2|26||European Malaria Vaccine Initiative|||||f||||f||||||||||2018-06-01 03:46:38.555877|2018-06-01 03:46:38.555877
NCT00375115|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-10|||2007-11-05|2006-09-10|2006-09-12|Estimate|||||||2007-11-05|2007-11-06|Estimate|September 2006||2006-09-30|October 2007|2007-10-31|September 2009|Anticipated|2009-09-30|||||Interventional|||Efficacy of Sambucol in the Treatment of Influenza|Efficacy of Sambucol on the Length of Time to Resolution of Influenza Illness|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:46:38.611214|2018-06-01 03:46:38.611214
NCT00375102|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2014-12-12|2006-09-11|2006-09-12|Estimate|||||||2014-12-12|2014-12-15|Estimate|November 2006||2006-11-30|December 2014|2014-12-31|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Acupuncture and the Relaxation Response for Substance Abuse|Acupuncture and the Relaxation Response for Homeless Veterans With Substance Abuse|Completed||Phase 2/Phase 3|67|Actual|VA Boston Healthcare System||3|||f||||f||||||||||2018-06-01 03:46:38.667432|2018-06-01 03:46:38.667432
NCT00375089|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2014-09-18|2006-09-11|2006-09-12|Estimate|||||||2014-09-18|2014-09-22|Estimate|September 2006||2006-09-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity|Prader-Willi Syndrome and Early-onset Morbid Obesity Natural History Clinical Protocol|Completed|||392|Actual|University of Florida|||2||f||||t||||||Samples With DNA|"~     Blood samples for both DNA and RNA~   "|||2018-06-01 03:46:38.729087|2018-06-01 03:46:38.729087
NCT00375076|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2009-09-17|2006-09-11|2006-09-12|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|May 2008|Actual|2008-05-31|||||Interventional|||Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients|Prevention of Venous Thrombosis in Cancer Patients: A Prospective, Randomized, Double-blind Study Comparing Two Different Dosages of Low-molecular Weight Heparin|Completed||Phase 3|||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:46:38.79923|2018-06-01 03:46:38.79923
NCT00375063|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2006-09-11|2006-09-11|2006-09-12|Estimate|||||||2006-09-11|2006-09-12|Estimate|January 2001||2001-01-31|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)|Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery|Completed||Phase 4|130||Ministry of Science and Higher Education, Poland|||||f||||||||||||||2018-06-01 03:46:38.843107|2018-06-01 03:46:38.843107
NCT00375050|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2018-01-12|2006-09-08|2006-09-12|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2002||2002-05-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Treatment of Refractory Schizophrenia With Riluzole|Neuroprotective Treatment of Refractory Schizophrenia With Riluzole 01T-432|Suspended||N/A|30|Anticipated|Yale University||2|||f||||f||||||||||2018-06-01 03:46:39.002266|2018-06-01 03:46:39.002266
NCT00375037|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2018-03-15|2006-09-11|2006-09-12|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2007||2007-01-31|September 2008|2008-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Multifaceted Intervention to Improve Hand Hygiene|Cluster Randomized Controlled Trial of a Multifaceted Intervention to Improve Hand Hygiene Among Healthcare Workers|Completed||N/A|1500|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 03:46:39.076094|2018-06-01 03:46:39.076094
NCT00375024|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2012-11-02|2006-09-11|2006-09-12|Estimate|||||||2012-11-02|2012-11-06|Estimate|May 2007||2007-05-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Patient Navigator Project|Patient Navigator Project|Completed||N/A|1267|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-06-01 03:46:39.14088|2018-06-01 03:46:39.14088
NCT00375011|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-10|||2012-02-15|2006-09-11|2006-09-12|Estimate|||||||2012-02-15|2012-02-16|Estimate|September 2008||2008-09-30|February 2010|2010-02-28|October 2011|Actual|2011-10-31|||||Observational|||Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics|Use of the BreathID to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients With Cirrhosis in Need of Liver Transplantation|Terminated|||200|Anticipated|Exalenz Bioscience LTD.||||"Company restructured and protocol restructured. Resubmitted with IDE approval under new company~   name-Exalenz"|f||||||||||||||2018-06-01 03:46:39.204217|2018-06-01 03:46:39.204217
NCT00374998|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-10|||2007-02-28|2006-09-10|2006-09-12|Estimate|||||||2007-02-28|2007-03-01|Estimate|April 2006||2006-04-30|February 2007|2007-02-28|January 2007||2007-01-31|||||Interventional|||Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP|A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates FP9 PP and MVA PP in Healthy Adults Using a Prime-Boost Delivery Schedule|Completed||Phase 1|35||European Malaria Vaccine Initiative|||||f||||||||||||||2018-06-01 03:46:39.264999|2018-06-01 03:46:39.264999
NCT00374985|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2014-11-27|2006-09-11|2006-09-12|Estimate|||||||2014-11-27|2014-12-02|Estimate|October 2005||2005-10-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction|Prospective, Open, Multicentre Phase I/II Study to Evaluate the Safety and Efficacy of a Neoadjuvant Radiochemotherapy With Docetaxel and Oxalipaltin in Patients With Adenocarcinoma of the Gastric-oesophageal Junction|Completed||Phase 1/Phase 2|25|Actual|Johannes Gutenberg University Mainz||1|||f||||t||||||||||2018-06-01 03:46:39.3246|2018-06-01 03:46:39.3246
NCT00374972|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2017-05-14|2006-09-11|2006-09-12|Estimate|||||||2017-05-14|2017-05-16|Actual|June 2006|Actual|2006-06-30|April 2017|2017-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Combined Hormonal Versus Progestin Only Contraception During Lactation||Withdrawn|||0|Actual|Shaare Zedek Medical Center|||2|difficulty in recruitment. lack of sponsorship|f||||||||||||||2018-06-01 03:46:39.451796|2018-06-01 03:46:39.451796
NCT00374959|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2006-09-25|2006-09-11|2006-09-12|Estimate|||||||2006-09-25|2006-09-26|Estimate|October 2000||2000-10-31|September 2006|2006-09-30|October 2003||2003-10-31|||||Interventional|||Prevention of Pneumonia Comparing Ceftriaxone With Subglottic Aspiration|The Prevention of Primary Endogenous Ventilator-Associated Pneumonia: A Multicenter Randomized Trial Comparing Continuous Aspiration of Subglottic Content and a 3-Day Course of Ceftriaxone.|Completed||Phase 4|80||Hospital Universitario Principe de Asturias|||||f||||||||||||||2018-06-01 03:46:39.505249|2018-06-01 03:46:39.505249
NCT00374946|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2017-03-22|2006-09-11|2006-09-12|Estimate|||||||2017-03-22|2017-03-24|Actual|December 2000||2000-12-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Observational|||A Clinical Evaluation of Wear Couples in THA|A Randomised Controlled Clinical Study Ofbearing Surfaces in Four Hybrid Prosthesis - Results After 10 Years|Completed|||392|Actual|Frederiksberg University Hospital|||4||f||||f||||||||||2018-06-01 03:46:39.593041|2018-06-01 03:46:39.593041
NCT00374933|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2016-06-07|2006-09-11|2006-09-12|Estimate|||||||2016-06-07|2016-06-08|Estimate|April 2007||2007-04-30|June 2016|2016-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation|Non-Myeloablative Conditioning With Allogeneic Peripheral Blood Progenitor Cell Transplantation Followed by Prophylactic Activated Donor Lymphocyte Infusion (DLI) for the Treatment of High Risk Acute Leukemia/MDS|Completed||Phase 1|18|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||||||||||||2018-06-01 03:46:39.656201|2018-06-01 03:46:39.656201
NCT00374920|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-09|||2008-05-05|2006-09-09|2006-09-12|Estimate|||||||2008-05-05|2008-05-06|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder|A Multicenter, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 1003 for the Treatment of Patients With Bipolar I Disorder Suffering Acute Manic or Mixed Episodes|Completed||Phase 2|60||Memory Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:46:39.741232|2018-06-01 03:46:39.741232
NCT00352586|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2017-06-30|2006-07-13|2006-07-14|Estimate|||||||2017-06-30|2017-07-02|Actual|April 3, 2002||2002-04-03|February 1, 2008|2008-02-01|February 1, 2008||2008-02-01|||||Observational|||Effect of D-cycloserine on Extinction of Fear Conditioning|Psychopharmacology Investigations of Fear Conditioning in Humans|Completed|||160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:42.107662|2018-06-01 03:53:42.107662
NCT00374907|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2010-12-26|2009-07-30|2015-04-20|2006-09-11|2006-09-12|Estimate|2010-12-26|2011-01-21|Estimate|2010-08-13|2010-08-18|Estimate|2015-04-20|2015-05-07|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|December 2009|Actual|2009-12-31|January 2008|Actual|2008-01-31||Interventional|||A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients|Completed||Phase 3|156|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:46:39.859516|2018-06-01 03:46:39.859516
NCT00374894|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2006-09-11|2006-09-11|2006-09-12|Estimate|||||||2006-09-11|2006-09-12|Estimate|March 2004||2004-03-31|April 2004|2004-04-30|August 2004||2004-08-31|||||Observational|||The Combined Effect of 2,3-Dimercaptosuccinic Acid and Multi-Nutrients on Children in Lead Poisoning||Completed|||500||China Medical University, China|||||f||||||||||||||2018-06-01 03:46:40.489942|2018-06-01 03:46:40.489942
NCT00374881|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|||2008-04-14|2006-09-11|2006-09-12|Estimate|||||||2008-04-14|2008-04-15|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|||A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects|A Randomized, Double-Blind, Single-Center, 5 Way Cross-Over Study to Assess the Effect of Adding Oral Phenylephrine and Oral Sorbitol to Low Dose (1.5 mg) Plain Oral Morphine in Human Volunteers: Analgesia and Side Effect Assessment.|Completed||Phase 1/Phase 2|9|Actual|BioLineRx, Ltd.||5|||f||||f||||||||||2018-06-01 03:46:40.548586|2018-06-01 03:46:40.548586
NCT00374868|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-11|2009-04-29||2010-10-20|2006-09-11|2006-09-12|Estimate|2009-04-29|2009-06-17|Estimate||||2010-10-20|2010-11-04|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)|Phase 1/2 Study of Biweekly ALIMTA Plus Cisplatin in Patients With Locally, Advanced, Non-Resectable or Metastatic Urothelial Cancer|Completed||Phase 1/Phase 2|59|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:46:40.647356|2018-06-01 03:46:40.647356
NCT00374855|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2007-05-11|2006-09-08|2006-09-12|Estimate|||||||2007-05-11|2007-05-15|Estimate|September 2006||2006-09-30|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Interventional|||A Study in People With Mild Hypertension|Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension|Completed||Phase 2|153||Eli Lilly and Company|||||||||||||||||||2018-06-01 03:46:41.01625|2018-06-01 03:46:41.01625
NCT00374842|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|2013-03-07||2016-10-06|2006-09-08|2006-09-12|Estimate|2013-03-07|2013-04-22|Estimate||||2016-10-06|2016-11-09|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate|A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidates Compared to Fluarix™ Administered Intramuscularly in Subjects Aged 18-59 Years.|Completed||Phase 2|300|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:46:41.122899|2018-06-01 03:46:41.122899
NCT00374829|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2009-05-06|2006-09-08|2006-09-12|Estimate|||||||2009-05-06|2009-05-08|Estimate|May 2004||2004-05-31|May 2007|2007-05-31|June 2007|Anticipated|2007-06-30|||||Interventional|||Impact of an IT-Based and Healthcare Professional Support Program on Patients With High Blood Pressure|The Impact of a Multidisciplinary, Information Technology Supported Program on Blood Pressure Control in Primary Care (The Loyal Study)|Unknown status|Active, not recruiting|N/A|223|Actual|Université de Montréal|||||f||||f||||||||||2018-06-01 03:46:41.676431|2018-06-01 03:46:41.676431
NCT00374803|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|2012-03-09||2016-03-28|2006-09-08|2006-09-11|Estimate|2012-04-10|2012-05-08|Estimate||||2016-03-28|2016-04-28|Estimate|April 2006||2006-04-30|March 2016|2016-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal|A 12-month, Prospective, Randomized, Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal|Completed||Phase 4|45|Actual|University of Cincinnati||2|||f||||f||||||||No||2018-06-01 03:46:41.743346|2018-06-01 03:46:41.743346
NCT00374790|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2018-05-09|2006-09-08|2006-09-11|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2006||2006-10-31|May 2018|2018-05-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Iron Supplementation of Lead-exposed Infants|Pilot Study to Determine the Efficacy of Iron Supplementation in Preventing the Elevation of Blood Lead Concentrations in Young Children|Completed||Phase 2|50|Anticipated|Cornell University|||||f||||||||||||||2018-06-01 03:46:42.012426|2018-06-01 03:46:42.012426
NCT00374777|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2014-08-19|2006-09-08|2006-09-11|Estimate|||||||2014-08-19|2014-08-20|Estimate|August 2006||2006-08-31|August 2014|2014-08-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients|FK199B (Zolpidem MR Tablet) Phase III Clinical Study -A Double-Blind, Placebo- and Nitrazepam-Controlled, Group-Comparison Study in Patients With Insomnia Associated With Schizophrenia and Manic-Depressive Psychosis|Completed||Phase 3|450|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-06-01 03:46:42.075105|2018-06-01 03:46:42.075105
NCT00374764|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2007-02-15|2006-09-07|2006-09-11|Estimate|||||||2007-02-15|2007-02-16|Estimate|July 2000||2000-07-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||Comparison of Applied Behavioral Analysis (ABA) Versus ABA and Risperidone|Randomized Double Blind Comparison of Applied Behavioral Analysis Versus ABA and Risperidone|Completed||N/A|60||Washington University School of Medicine|||||||||||||||||||2018-06-01 03:46:42.145015|2018-06-01 03:46:42.145015
NCT00374751|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2015-04-27|2006-09-08|2006-09-11|Estimate|||||||2015-04-27|2015-04-29|Estimate|May 2006||2006-05-31|April 2015|2015-04-30||||January 2014|Actual|2014-01-31||Interventional|||Effect of Samarium on the Relief of Pain Due to Vertebral Metastases|Phase I/II Study of the Use of Vertebral Intracavitary Cement and Samarium (VICS) for Painful Vertebral Metastases|Completed||Phase 1/Phase 2|29|Actual|New York Methodist Hospital|||||f||||t||||||||||2018-06-01 03:46:42.200163|2018-06-01 03:46:42.200163
NCT00374738|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-05-10|2006-09-07|2006-09-11|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2006||2006-11-30|May 2016|2016-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function|Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms, Neurosteroids and Brain Function|Completed||N/A|34|Actual|Samueli Institute for Information Biology||2|||f||||f||||||||No|Study terminated/inactive.|2018-06-01 03:46:43.273521|2018-06-01 03:46:43.273521
NCT00374725|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2006-09-08|2006-09-08|2006-09-11|Estimate|||||||2006-09-08|2006-09-11|Estimate|February 2003||2003-02-28|November 2002|2002-11-30|May 2006||2006-05-31|||||Interventional|||Treatment of Ulcerative Colitis With a Combination of Lactobacillus Rhamnosus and Lactobacillus Acidophilus.|Treatment of Ulcerative Colitis With a Combination of Lactobacillus Rhamnosus and Lactobacillus Acidophilus. A Randomised Placebo Controlled Trial|Completed||N/A|130||Odense University Hospital|||||f||||||||||||||2018-06-01 03:46:43.340613|2018-06-01 03:46:43.340613
NCT00374712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-06|2006-09-08|2006-09-11|Estimate|||||||2007-11-06|2007-11-08|Estimate|January 2005||2005-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||Klotho Gene Polymorphism in Dialyzed Patients With Hyperphosphatemia|Study of Klotho Gene Polymorphisms in the Regulation of Serum Phosphate Levels in Hemodialysis Patients|Terminated|||40|Actual|Assistance Publique - Hôpitaux de Paris||||terminated|f||||f||||||Samples With DNA|"~     DNA~   "|||2018-06-01 03:46:43.405641|2018-06-01 03:46:43.405641
NCT00374699|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2009-10-12|2006-09-07|2006-09-11|Estimate|||||||2009-10-12|2009-10-14|Estimate|April 2006||2006-04-30|June 2007|2007-06-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas|A Phase I/II Study of Bortezomib + CHOP in Patients With Advanced Stage Aggressive T Cell or NK/T Cell Lymphomas|Completed||Phase 1/Phase 2|55|Anticipated|Samsung Medical Center|||||f||||||||||||||2018-06-01 03:46:43.466868|2018-06-01 03:46:43.466868
NCT00374686|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2006-09-07|2006-09-07|2006-09-11|Estimate|||||||2006-09-07|2006-09-11|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Study of Prophylactic Vs Preemptive Valganciclovir|Prophylactic Vs Preemptive Oral Valganciclovir for Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients: A Clinical and Pharmacoeconomic Study|Completed||N/A|120||Washington University School of Medicine|||||f||||||||||||||2018-06-01 03:46:43.530362|2018-06-01 03:46:43.530362
NCT00374673|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2015-12-02|2006-09-08|2006-09-11|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders|Efficacy of Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Idiopathic Pain Syndromes : a Double Blind Sham Controlled Study|Completed||Phase 3|60|Actual|Hospital Ambroise Paré Paris||2|||f||||f||||||||||2018-06-01 03:46:43.596672|2018-06-01 03:46:43.596672
NCT00374660|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2015-06-30|2006-09-08|2006-09-11|Estimate|||||||2015-06-30|2015-07-01|Estimate|June 2003||2003-06-30|June 2015|2015-06-30||||August 2007|Actual|2007-08-31||Interventional|||Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors|Phase I-II Clinical and Pharmacokinetic Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1/Phase 2|63|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:46:43.675571|2018-06-01 03:46:43.675571
NCT00374647|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2008-06-05|2006-09-08|2006-09-11|Estimate|||||||2008-06-05|2008-06-06|Estimate|March 2005||2005-03-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts|Open Label Randomized Single Study to Evaluate the Safety & Efficacy of Early CNI Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil; MMF (CellCept) and Sirolimus (Rapamune)|Completed||Phase 4|17|Actual|University of Cincinnati|||||f||||f||||||||||2018-06-01 03:46:43.839323|2018-06-01 03:46:43.839323
NCT00374634|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2011-09-30|2006-09-08|2006-09-11|Estimate|||||||2011-09-30|2011-10-03|Estimate|September 2006||2006-09-30|September 2011|2011-09-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination|Individual Versus Standard rFSH Dose for Controlled Ovarian Stimulation and Intrauterine Insemination. A Prospective Randomised Multi Centre Study|Completed||Phase 4|234|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 03:46:43.909617|2018-06-01 03:46:43.909617
NCT00374621|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2017-04-24|2006-09-07|2006-09-11|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2006||2006-09-30|April 2017|2017-04-30|January 2010|Actual|2010-01-31|December 2007|Actual|2007-12-31||Interventional|||Trial of Cervical Ripening and Labor Induction Using Misoprostol With or Without Intravaginal Isosorbide Mononitrate|Randomized Clinical Trial of Cervical Ripening and Labor Induction Using Stepwise Oral Misoprostol With or Without Intravaginal Isosorbide Mononitrate|Completed||N/A|156|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 03:46:43.991577|2018-06-01 03:46:43.991577
NCT00374608|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2012-05-30|2006-09-08|2006-09-11|Estimate|||||||2012-05-30|2012-06-01|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Exercise in Chronically Paced Children|A Single Center, Prospective, Pilot Study Examining the Evaluation of Exercise Capacity in Chronically RV Paced Children and Young Adults|Completed|||25|Actual|Emory University|||||f||||f||||||||||2018-06-01 03:46:44.071259|2018-06-01 03:46:44.071259
NCT00374595|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2018-03-29|2006-09-08|2006-09-11|Estimate|||||||2018-03-29|2018-04-02|Actual|April 2006||2006-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 29, 2019|Anticipated|2019-03-29||Observational|||Vascular Risk After Kidney Transplantation|Vascular Risk After Kidney Transplantation|Active, not recruiting|||342|Actual|University of Nebraska|||||f||||t|f|f||||||||2018-06-01 03:46:44.147713|2018-06-01 03:46:44.147713
NCT00374582|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2011-03-03|2006-09-08|2006-09-11|Estimate|||||||2011-03-03|2011-03-04|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)|End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)|Completed||N/A|30|Anticipated|University of Cincinnati|||||f||||f||||||||||2018-06-01 03:46:44.222781|2018-06-01 03:46:44.222781
NCT00374569|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2016-01-26|2006-09-08|2006-09-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2005||2005-06-30|January 2016|2016-01-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Dynamic Posturographic Testing and Motor Learning Predictability in Gymnasts|Dynamic Posturographic Testing and Motor Learning Predictability in Gymnasts|Completed||Early Phase 1|300|Actual|Carrick Institute for Graduate Studies||2|||f||||f||||||||No||2018-06-01 03:46:44.308919|2018-06-01 03:46:44.308919
NCT00374556|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|2017-08-25||2017-10-10|2006-09-08|2006-09-11|Estimate|2017-10-10|2017-11-09|Actual||||2017-10-10|2017-11-09|Actual|January 2006||2006-01-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Baseline characteristics were only calculated for the 29 participants above.|Insomnia and Osteoarthritis Study|The Efficacy of Eszopiclone (Lunesta) for Chronic Insomnia Associated With Osteoarthritis.|Completed||N/A|105|Actual|Johns Hopkins University||2|||f||||||||||||||2018-06-01 03:46:44.450608|2018-06-01 03:46:44.450608
NCT00374543|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|2013-05-20||2014-03-20|2006-09-08|2006-09-11|Estimate|2014-03-20|2014-04-16|Estimate||||2014-03-20|2014-04-16|Estimate|February 2006||2006-02-28|March 2014|2014-03-31|November 2008|Actual|2008-11-30|October 2007|Actual|2007-10-31||Interventional|||Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder|Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder|Terminated||Phase 4|3|Actual|Massachusetts General Hospital|This study was terminated due to extreme difficulties in participant recruitment. Therefore, the sample size is extremely low, leaving inconclusive data.|2||Recruitment goal could not be achieved|f||||t||||||||||2018-06-01 03:46:45.159284|2018-06-01 03:46:45.159284
NCT00374530|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2007-07-31|2006-09-08|2006-09-11|Estimate|||||||2007-07-31|2007-08-01|Estimate|August 2006||2006-08-31|July 2007|2007-07-31||||||||Interventional|||Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2|Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2|Completed||N/A|12|Anticipated|Danish Headache Center|||||f||||||||||||||2018-06-01 03:46:45.376039|2018-06-01 03:46:45.376039
NCT00374517|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2017-06-30|2006-09-08|2006-09-11|Estimate|||||||2017-06-30|2017-07-02|Actual|September 5, 2006||2006-09-05|February 2, 2010|2010-02-02|February 2, 2010|Anticipated|2010-02-02|February 2, 2010|Actual|2010-02-02||Interventional|||Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs|A Phase II Clinical Trial of Pimonidazole Hydrochloride as a Hypoxia Marker in Subjects Undergoing Elective Lung Resection for Treatment-Refractory Pulmonary Tuberculosis|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:46:45.446802|2018-06-01 03:46:45.446802
NCT00374504|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2006-09-08|2006-09-08|2006-09-11|Estimate|||||||2006-09-08|2006-09-11|Estimate||||February 2006|2006-02-28||||||||Observational|||Prediction of Postoperative Pain by an Electrical Pain Stimulus||Completed|||46||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:46:45.519085|2018-06-01 03:46:45.519085
NCT00374491|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-01-04|2006-09-07|2006-09-11|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2006||2006-09-30|January 2016|2016-01-31||||||||Observational|||The Long-term Degradation Outcome of Bilok Screws Used for ACL Reconstruction|The Long-term Degradation Outcome of Bilok Biodegradable Interference Fixation Screws Used for Bone-Patellar Tendon-Bone ACL Reconstruction|Withdrawn|||0|Actual|ArthroCare Corporation|||||f||||||||||||||2018-06-01 03:46:45.576312|2018-06-01 03:46:45.576312
NCT00374478|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2007-04-06|2006-09-08|2006-09-11|Estimate|||||||2007-04-06|2007-04-09|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|April 2006|Actual|2006-04-30|||||Interventional|||Effects of Transdermal Scopolamine on Occupational Performance|Effects of Transdermal Scopolamine on Occupational Performance|Completed||Phase 2|33||Boston University|||||f||||f||||||||||2018-06-01 03:46:45.631289|2018-06-01 03:46:45.631289
NCT00374465|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2006-09-08|2006-09-08|2006-09-11|Estimate|||||||2006-09-08|2006-09-11|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|May 2008||2008-05-31|||||Interventional|||Therapy With Verapamil or Carvedilol in Chronic Heart Failure|Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy|Unknown status|Recruiting|Phase 4|100||Medical University of Silesia|||||f||||||||||||||2018-06-01 03:46:45.708842|2018-06-01 03:46:45.708842
NCT00374452|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|2017-10-19||2018-03-02|2006-09-08|2006-09-11|Estimate|2017-10-19|2017-12-18|Actual||||2018-03-02|2018-03-29|Actual|January 2007||2007-01-31|March 2018|2018-03-31|March 2011|Actual|2011-03-31|May 2010|Actual|2010-05-31||Interventional|HTN|Baseline characteristics of primary care providers who started intervention period|VISN Collaborative for Improving Hypertension Management With ATHENA-HTN|VISN Collaborative for Improving Hypertension Management With ATHENA-HTN|Completed||N/A|103|Actual|VA Office of Research and Development|The study has originally planned to include 5 large medical centers. One of the medical centers dropped out before the intervention started. This lowered the number of clinic sites and of participants (clinicians).|2|||f||||f||||||||No||2018-06-01 03:46:45.810878|2018-06-01 03:46:45.810878
NCT00374439|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2017-04-07|2006-09-08|2006-09-11|Estimate|||||||2017-04-07|2017-04-10|Actual|January 2004|Actual|2004-01-31|April 2017|2017-04-30|April 2006|Actual|2006-04-30|January 2006|Actual|2006-01-31||Interventional|||Cognitive Behavioral vs. Interpersonal Therapy (IPT) Prevention of Depression in Adolescents|Promoting Well-being in Teens|Completed||N/A|400|Anticipated|Vanderbilt University||3|||f||||||||||||||2018-06-01 03:46:46.021532|2018-06-01 03:46:46.021532
NCT00374426|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2010-03-01|2006-09-08|2006-09-11|Estimate|||||||2010-03-01|2010-03-02|Estimate|March 1998||1998-03-31|March 2010|2010-03-31|October 2004||2004-10-31|||||Interventional|||Preventing Depression Recurrence in Diabetes|Preventing Depression Recurrence in Diabetes|Completed||Phase 4|262||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:46:46.094381|2018-06-01 03:46:46.094381
NCT00374413|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07||2011-07-19|2013-08-31|2006-09-07|2006-09-11|Estimate||||2011-07-19|2011-07-22|Estimate|2013-08-31|2013-09-13|Estimate|July 2005||2005-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|January 2010|Actual|2010-01-31||Interventional|||"Kineflex|C Artificial Disc System to Treat Cervical Degenerative Disc Disease (DDD)"|"Clinical Study Protocol for the Investigation of the Kineflex|C Spinal System - a Pivotal Study in Continued Access Stage"|Terminated||N/A|343|Actual|SpinalMotion||2||Economic and business factors|f||||f||||||||||2018-06-01 03:46:46.156492|2018-06-01 03:46:46.156492
NCT00374400|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2007-12-20|2006-09-08|2006-09-11|Estimate|||||||2007-12-20|2008-01-03|Estimate|September 2004||2004-09-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Observational|||The Paired Donation Consortium Paired Donation Program|The Paired Donation Consortium Paired Donation Program|Completed|||100|Anticipated|University of Cincinnati|||||f||||||||||||||2018-06-01 03:46:46.253391|2018-06-01 03:46:46.253391
NCT00374387|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2011-03-30|2006-09-08|2006-09-11|Estimate|||||||2011-03-30|2011-03-31|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|August 2009|Actual|2009-08-31||Interventional|||Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire|Psychosocial and Physiological Mechanisms in the Effect of Hormonal Contraception on the Female Sexual Desire|Completed||N/A|150|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:46:46.301182|2018-06-01 03:46:46.301182
NCT00374374|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2006-09-07|2006-09-07|2006-09-11|Estimate|||||||2006-09-07|2006-09-11|Estimate|May 2001||2001-05-31|April 2006|2006-04-30|November 2005||2005-11-30|||||Interventional|||Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn’s Disease.|Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn’s Disease.|Completed||N/A|30||Odense University Hospital|||||f||||||||||||||2018-06-01 03:46:46.3612|2018-06-01 03:46:46.3612
NCT00374361|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-06-06|2006-09-08|2006-09-11|Estimate|||||||2016-06-06|2016-06-08|Estimate|July 2003||2003-07-31|June 2016|2016-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Study of the Relationship Between Blood Vessels and Insulin Response in Adolescents|Relationship of Endothelial Function to Insulin Sensitivity in African American and Caucasian Adolescents|Completed|||66||Ohio State University|||2||f||||f||||||||No|Observational|2018-06-01 03:46:46.425029|2018-06-01 03:46:46.425029
NCT00374348|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2011-09-15|2006-09-08|2006-09-11|Estimate|||||||2011-09-15|2011-09-16|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)|"Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)."|Completed||N/A|10|Actual|Jamaica Hospital Medical Center|||||f||||||||||||||2018-06-01 03:46:46.487716|2018-06-01 03:46:46.487716
NCT00374335|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2011-08-09||2011-09-12|2006-09-08|2006-09-11|Estimate|2011-08-09|2011-09-12|Estimate||||2011-09-12|2011-09-16|Estimate|September 2006||2006-09-30|September 2011|2011-09-30|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas|Multiple Hemangiomas and Large Cutaneous Hemangiomas of Infancy: Incidence of Hepatic Hemangiomatosis|Completed||N/A|261|Actual|Children's Mercy Hospital Kansas City||1|||f||||t||||||||||2018-06-01 03:46:46.568091|2018-06-01 03:46:46.568091
NCT00374322|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2014-07-17|2012-05-10|2014-08-14|2006-09-07|2006-09-11|Estimate|2014-08-14|2014-08-18|Estimate|2012-06-14|2012-06-18|Estimate|2014-08-14|2014-08-18|Estimate|August 2006||2006-08-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|September 2011|Actual|2011-09-30||Interventional|||Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer|A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer|Completed||Phase 3|3166|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 03:46:46.918952|2018-06-01 03:46:46.918952
NCT00374309|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2017-06-30|2006-09-08|2006-09-11|Estimate|||||||2017-06-30|2017-07-02|Actual|September 5, 2006||2006-09-05|May 5, 2009|2009-05-05|May 5, 2009||2009-05-05|||||Interventional|||Experimental Vaccine for Prevention of Ebola Virus Infection|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults|Completed||Phase 1|48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:46:49.018107|2018-06-01 03:46:49.018107
NCT00374296|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07||2015-06-04|2015-06-04|2006-09-07|2006-09-11|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|September 2006||2006-09-30|June 2015|2015-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease|A Phase II Study of MGCD0103 (MG-0103) in Patients With Acute Myelogenous Leukemia/High Risk MDS Who Are Elderly and Have Previously Untreated Disease or Who Are Adult and Have Relapsed/Refractory Disease|Terminated||Phase 2|35|Actual|Mirati Therapeutics Inc.||2||The Clinical Development Program for MGCD0103 is being re-evaluated|f||||f||||||||||2018-06-01 03:46:49.069594|2018-06-01 03:46:49.069594
NCT00374283|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2007-12-20|2006-09-08|2006-09-11|Estimate|||||||2007-12-20|2008-01-03|Estimate|June 2001||2001-06-30|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Observational|||Monitoring of Biopsy-Proven Interstitial Polyomavirus Nephritis in Kidney and Kidney Pancreas Transplant Recipients|Monitoring of Biopsy-Proven Interstitial Polyomavirus Nephritis in Kidney and Kidney Pancreas Transplant Recipients|Completed|||40|Anticipated|University of Cincinnati|||||f||||f||||||||||2018-06-01 03:46:49.237208|2018-06-01 03:46:49.237208
NCT00374270|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2007-12-07|2006-09-08|2006-09-11|Estimate|||||||2007-12-07|2007-12-11|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|SCRIP-HTN||Improving Blood Pressure Management in Patients With Diabetes|Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN|Completed||Phase 4|227|Actual|University of Alberta|||||f||||f||||||||||2018-06-01 03:46:49.292486|2018-06-01 03:46:49.292486
NCT00374257|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2010-03-17|2006-09-08|2006-09-11|Estimate|||||||2010-03-17|2010-03-19|Estimate|August 2006||2006-08-31|March 2010|2010-03-31|August 2010|Anticipated|2010-08-31|September 2008|Actual|2008-09-30||Interventional|||UVB Phototherapy Treatment of Oral Chronic GVHD|Narrow-Band UVB Phototherapy for Treatment of Oral Chronic Graft-versus-Host Disease|Terminated||Phase 2|40|Anticipated|Brigham and Women's Hospital||||Low/slow accrual|f||||t||||||||||2018-06-01 03:46:49.356975|2018-06-01 03:46:49.356975
NCT00374244|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2013-01-10||2016-02-04|2006-09-08|2006-09-11|Estimate|2016-02-04|2016-03-04|Estimate||||2016-02-04|2016-03-04|Estimate|January 2004||2004-01-31|February 2016|2016-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Efficacy of Pimozide Augmentation for Clozapine Partial Response|Efficacy of Pimozide Augmentation for Clozapine Partial Response|Completed||Phase 2|28|Actual|Yale University||2|||f||||f||||||||||2018-06-01 03:46:49.444069|2018-06-01 03:46:49.444069
NCT00374231|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|2013-12-19||2015-11-23|2006-09-08|2006-09-11|Estimate|2015-11-23|2015-12-29|Estimate||||2015-11-23|2015-12-29|Estimate|October 2002||2002-10-31|November 2015|2015-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients|A Single Center, Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients Utilizing a Tacrolimus/Mycophenolate Mofetil Based Maintenance Immunosuppression Protocol|Completed||Phase 4|40|Actual|University of Cincinnati||1|||f||||f||||||||||2018-06-01 03:46:49.907552|2018-06-01 03:46:49.907552
NCT00374218|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2007-08-13|2006-09-08|2006-09-11|Estimate|||||||2007-08-13|2007-08-14|Estimate|September 2006||2006-09-30|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference|Effect of Replacing HFCS With Sucromalt on Glucose Tolerance, Blood Lipids and Inflammatory Markers in Subjects With Raised Waist Circumference|Completed||Phase 2|28|Actual|University of Toronto|||||f||||f||||||||||2018-06-01 03:46:50.122979|2018-06-01 03:46:50.122979
NCT00374205|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2007-11-26|2006-09-08|2006-09-11|Estimate|||||||2007-11-26|2007-11-27|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Randomized Trial on Effectiveness of ACTs in Ghana|A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria|Terminated||Phase 4|245|Actual|Bernhard Nocht Institute for Tropical Medicine||2||Interim analysis showed more LCFs in one of the treatment arms|f||||t||||||||||2018-06-01 03:46:50.186965|2018-06-01 03:46:50.186965
NCT00374192|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2009-08-07|2006-09-08|2006-09-11|Estimate|||||||2009-08-07|2009-08-10|Estimate|February 2006||2006-02-28|August 2009|2009-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women|The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women|Completed||N/A|67|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:46:50.2786|2018-06-01 03:46:50.2786
NCT00374179|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-08|||2009-02-23|2006-09-08|2006-09-11|Estimate|||||||2009-02-23|2009-02-24|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma|A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma|Completed||Phase 1|40|Actual|Adnexus, A Bristol-Myers Squibb R&D Company|||||f||||f||||||||||2018-06-01 03:46:50.363109|2018-06-01 03:46:50.363109
NCT00374166|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07||2016-04-26|2016-04-26|2006-09-07|2006-09-08|Estimate||||2016-04-26|2016-05-25|Estimate|2016-04-26|2016-05-25|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder|An Eight-week, Multicenter, Double-blind, Placebo- and Paroxetine-controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder|Completed||Phase 2|325|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 03:46:50.47213|2018-06-01 03:46:50.47213
NCT00374153|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2010-03-09|2006-09-06|2006-09-08|Estimate|||||||2010-03-09|2010-03-10|Estimate|September 2006||2006-09-30|March 2010|2010-03-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||Southern Methodist Alcohol Research Trial (SMART)|Dismantling Motivational Interviewing and Feedback for College Drinkers|Completed||N/A|363|Actual|The University of Texas Health Science Center, Houston||5|||f||||||||||||||2018-06-01 03:46:50.557424|2018-06-01 03:46:50.557424
NCT00374140|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|2014-01-08||2017-09-18|2006-09-06|2006-09-08|Estimate|2014-01-08|2014-02-27|Estimate||||2017-09-18|2017-10-19|Actual|October 2006||2006-10-31|September 2017|2017-09-30|June 2012|Actual|2012-06-30|December 2008|Actual|2008-12-31||Interventional|||Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer|Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer|Completed||Phase 2|40|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:46:50.646595|2018-06-01 03:46:50.646595
NCT00374127|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2017-08-03||2017-08-03|2006-09-07|2006-09-08|Estimate|2017-08-03|2017-09-01|Actual||||2017-08-03|2017-09-01|Actual|December 2004||2004-12-31|July 2017|2017-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper|Comparison Between Marijuana Smoked in Cigarette Paper (Joints) Versus Cigar Paper (Blunts)|Completed||Phase 2|35|Actual|New York State Psychiatric Institute|It is unknown if the cigar paper would provide physiologically relevant nicotine plasma levels under more extended durations of smoking. The small sample size prohibited an analysis to verify a statistically significant sex difference.|2|||f||||||||||||||2018-06-01 03:46:50.988253|2018-06-01 03:46:50.988253
NCT00374114|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2008-12-12|2006-09-07|2006-09-08|Estimate|||||||2008-12-12|2008-12-15|Estimate|January 2004||2004-01-31|December 2008|2008-12-31|December 2006|Actual|2006-12-31|||||Interventional|||A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia|A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia|Completed||N/A|20|Anticipated|University of Tennessee|||||f||||||||||||||2018-06-01 03:46:51.299523|2018-06-01 03:46:51.299523
NCT00374101|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2007-04-04|2006-09-07|2006-09-08|Estimate|||||||2007-04-04|2007-04-05|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding|Proton Pump Inhibitors in Conjunction to Endoscopic Therapy for Bleeding Peptic Ulcers: a Randomized Clinical Trial of High vs Standard Doses|Completed||Phase 3|450||Casa Sollievo della Sofferenza IRCCS|||||f||||f||||||||||2018-06-01 03:46:51.666489|2018-06-01 03:46:51.666489
NCT00374088|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2011-08-03||2011-12-14|2006-09-07|2006-09-08|Estimate|2011-12-14|2012-01-19|Estimate||||2011-12-14|2012-01-19|Estimate|February 2005||2005-02-28|December 2011|2011-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)|Attenuation of Myocardial Dysfunction by N-Acetylcysteine in Infants Undergoing Arterial Switch Procedure|Completed||Phase 2|21|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 03:46:51.818438|2018-06-01 03:46:51.818438
NCT00374075|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2016-08-22|2006-09-06|2006-09-08|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2003||2003-09-30|August 2016|2016-08-31|February 2006||2006-02-28|||||Interventional|||Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy|In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy|Completed||Phase 1|42||University of Utah|||||f||||||||||||||2018-06-01 03:46:52.205243|2018-06-01 03:46:52.205243
NCT00374062|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2014-07-14|2006-09-07|2006-09-08|Estimate|||||||2014-07-14|2014-07-15|Estimate|December 2007||2007-12-31|July 2014|2014-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of the Subconscious on Mohs Micrographic Surgery|Effect of the Subconscious on Mohs Micrographic Surgery|Completed||N/A|150|Anticipated|Northwestern University||3|||f||||f||||||||||2018-06-01 03:46:52.324684|2018-06-01 03:46:52.324684
NCT00374049|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-07-08|2006-09-07|2006-09-08|Estimate|||||||2016-07-08|2016-07-12|Estimate|June 2006||2006-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|January 2008|Actual|2008-01-31||Interventional|||MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer|A Pilot Dose Finding Study of MUC1 Vaccine in Conjunction With Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM in Patients With Recurrent and/or Advanced Prostate Cancer|Completed||Phase 1|14|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:46:52.396582|2018-06-01 03:46:52.396582
NCT00374036|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2011-10-10|2006-09-07|2006-09-08|Estimate|||||||2011-10-10|2011-10-12|Estimate|June 2005||2005-06-30|October 2011|2011-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Metastatic Gastric Cancer FFCD 03-07|Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach|Completed||Phase 3|416|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 03:46:52.49868|2018-06-01 03:46:52.49868
NCT00374023|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2017-11-25|2006-09-07|2006-09-08|Estimate|||||||2017-11-25|2017-11-28|Actual|July 1, 1993||1993-07-01|May 1993|1993-05-31|November 30, 1995|Actual|1995-11-30|November 30, 1995|Actual|1995-11-30||Interventional|||A Study on Immunological Effect of Vitamin A and Zinc in a Placebo Controlled 4 Cell Trial||Completed||N/A|147||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 03:46:52.603024|2018-06-01 03:46:52.603024
NCT00374010|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2017-05-26|2006-09-07|2006-09-08|Estimate|||||||2017-05-26|2017-05-31|Actual|January 2005||2005-01-31|March 2008|2008-03-31|December 2008|Actual|2008-12-31|June 2007|Actual|2007-06-30||Interventional|||Improving Patient-clinician Communication About End-of-life Care|Improving Patient-clinician Communication Among End-stage Renal Disease African Patients and Their Families|Completed||Phase 2|42|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 03:46:52.685952|2018-06-01 03:46:52.685952
NCT00373997|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2014-04-29|2006-09-06|2006-09-08|Estimate|||||||2014-04-29|2014-05-01|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|December 2009|Actual|2009-12-31|March 2009|Actual|2009-03-31||Interventional|biopsy I||Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux|Role of Esophageal and Laryngeal Biopsies in Suspected Laryngopharyngeal Reflux|Completed||Phase 4|45|Anticipated|Vanderbilt University|||||f||||f||||||||||2018-06-01 03:46:52.744785|2018-06-01 03:46:52.744785
NCT00373984|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2013-10-04|2006-09-07|2006-09-08|Estimate|||||||2013-10-04|2013-10-08|Estimate|January 2005||2005-01-31|October 2013|2013-10-31||||January 2006|Actual|2006-01-31||Observational|||A Study of the Incidence of Post-Thoracotomy Shoulder Pain|A Study of the Incidence of Post-Thoracotomy Shoulder Pain|Completed|||||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:46:52.81544|2018-06-01 03:46:52.81544
NCT00373971|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2006-09-07|2006-09-07|2006-09-08|Estimate|||||||2006-09-07|2006-09-08|Estimate|November 1995||1995-11-30|September 2006|2006-09-30|July 1998||1998-07-31|||||Interventional|||Preventing Loss of Weight, Fat Free Mass and Activities of Daily Living|Nutritional Care – Preventing Loss of Weight, Fat Free Mass and Activities of Daily Living Four Months After Surgery.|Completed||N/A|252||University of Aarhus|||||f||||||||||||||2018-06-01 03:46:52.891432|2018-06-01 03:46:52.891432
NCT00373958|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2010-03-26|2009-02-26|2013-01-17|2006-09-07|2006-09-08|Estimate|2013-01-17|2013-02-21|Estimate|2009-09-30|2009-10-02|Estimate|2013-01-17|2013-02-21|Estimate|September 2006||2006-09-30|January 2013|2013-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States|Completed||Phase 3|666|Actual|Pfizer||2|||f||||||||||||||2018-06-01 03:46:53.082615|2018-06-01 03:46:53.082615
NCT00373945|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2009-05-15|2006-09-07|2006-09-08|Estimate|||||||2009-05-15|2009-05-18|Estimate|August 2006||2006-08-31|May 2009|2009-05-31|August 2007|Actual|2007-08-31|||||Observational|||HLA-B*5701 And Hypersensitivity To Abacavir|A Retrospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B*5701) in Subjects With and Without Hypersensitivity to Abacavir.|Completed|||280|Anticipated|GlaxoSmithKline|||||||||||||||||||2018-06-01 03:46:56.951544|2018-06-01 03:46:56.951544
NCT00373932|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-12-03|2006-09-06|2006-09-08|Estimate|||||||2009-12-03|2009-12-07|Estimate|May 2006||2006-05-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Real-Time Support for Exercise Persistence in COPD|Real-Time Support for Exercise Persistence in COPD|Completed||Phase 1/Phase 2|17|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:46:57.085526|2018-06-01 03:46:57.085526
NCT00373919|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2007-03-02|2006-09-07|2006-09-08|Estimate|||||||2007-03-02|2007-03-05|Estimate||||August 2006|2006-08-31||||||||Interventional|||The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal Esophagectomy||Unknown status|Not yet recruiting|N/A|||Kaplan Medical Center|||||f||||||||||||||2018-06-01 03:46:57.399198|2018-06-01 03:46:57.399198
NCT00373906|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2013-11-26|2006-09-07|2006-09-08|Estimate|||||||2013-11-26|2013-11-27|Estimate||||May 2008|2008-05-31||||||||Interventional|||Velcade in MALT Lymphoma Patients|Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type|Completed||Phase 2|16|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-06-01 03:46:57.571614|2018-06-01 03:46:57.571614
NCT00373893|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2006-09-07|2006-09-07|2006-09-08|Estimate|||||||2006-09-07|2006-09-08|Estimate|December 2005||2005-12-31|October 2005|2005-10-31|February 2006||2006-02-28|||||Interventional|||Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia|Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia|Completed||Phase 1|12||University of California, San Diego|||||f||||||||||||||2018-06-01 03:46:57.634857|2018-06-01 03:46:57.634857
NCT00373880|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2017-08-03||2017-09-05|2006-09-07|2006-09-08|Estimate|2017-09-05|2017-09-11|Actual||||2017-09-05|2017-09-11|Actual|April 2005||2005-04-30|September 2017|2017-09-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Effects of Aripiprazole on Cocaine Craving and Self-Administration|Effects of Aripiprazole on Cocaine Craving and Self-Administration|Completed||Phase 2|26|Actual|New York State Psychiatric Institute|The study did not assess whether the medication would be useful in preventing relapse in abstinent cocaine users or whether aripiprazole would be beneficial to cocaine-dependent individuals being treated for a psychiatric comorbidity.|2|||f||||||||||||||2018-06-01 03:46:57.744453|2018-06-01 03:46:57.744453
NCT00373867|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2013-01-24|2006-09-07|2006-09-08|Estimate|||||||2013-01-24|2013-01-28|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effectiveness of Adding Behavioral Therapy to Physical Therapy to Treat Low Back Pain|Behavioral Interventions for Low Back Pain|Completed||N/A|108|Actual|University of Florida||3|||f||||t||||||||||2018-06-01 03:46:58.187723|2018-06-01 03:46:58.187723
NCT00373854|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-06-06|2006-09-07|2006-09-08|Estimate|||||||2016-06-06|2016-06-08|Estimate|September 2005||2005-09-30|June 2016|2016-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||Study of How Low Blood Sugar Affects the Way Blood Vessels Work|Hypoglycemia and Endothelial Function|Completed|||13|Actual|Ohio State University|||||f||||f||||||||No|Observational study|2018-06-01 03:46:58.332896|2018-06-01 03:46:58.332896
NCT00373841|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2017-07-24|2006-09-07|2006-09-08|Estimate|||||||2017-07-24|2017-07-25|Actual|October 2005||2005-10-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|GAP||Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)|Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis|Recruiting|||500|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Blood samples necessary to analyze disease progression in patient with idiopathic pulmonary~     fibrosis over a long period of time.~   "|||2018-06-01 03:46:58.398795|2018-06-01 03:46:58.398795
NCT00373828|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2013-02-19|2006-09-07|2006-09-08|Estimate|||||||2013-02-19|2013-02-20|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 1: Diagnosis.|Non-cardiac Chest Pain Evaluation and Treatment Study (CARPA) - Part 1: Diagnosis|Completed|||302|Actual|Clinical Locomotion Science|||||f||||||||||||||2018-06-01 03:46:58.47391|2018-06-01 03:46:58.47391
NCT00373815|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2014-05-28|2006-09-06|2006-09-08|Estimate|||||||2014-05-28|2014-05-29|Estimate|September 2006||2006-09-30|May 2014|2014-05-31|October 2009|Actual|2009-10-31|||||Interventional|||Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease|A Phase I Dose Escalation Study With Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Acute GVHD After Allogeneic Hematopoietic Stem Cell Transplantation|Terminated||Phase 1|10|Anticipated|University Hospital Tuebingen||||high incidence of TTP, poor recrual|f||||||||||||||2018-06-01 03:46:58.573632|2018-06-01 03:46:58.573632
NCT00373802|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2009-01-09|2006-09-07|2006-09-08|Estimate|||||||2009-01-09|2009-01-12|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||The Use of Nasal Phenylephrine in Infants With Bronchiolitis|A Randomized, Double-Blinded Placebo Control Trial of Nasal Phenylephrine in Infants With Bronchiolitis|Completed||Phase 2|50||Akron Children's Hospital|||||f||||||||||||||2018-06-01 03:46:58.640958|2018-06-01 03:46:58.640958
NCT00373789|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2011-01-09|2006-09-06|2006-09-08|Estimate|||||||2011-01-09|2011-01-11|Estimate|June 2006||2006-06-30|October 2010|2010-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Refractory Urge Incontinence and Botox Injections|Refractory Urge Incontinence and Botox Injections|Terminated||Phase 3|87|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2||"higher than anticipated rate of increased post-void residual in subjects who received botulinum~   toxin A injection"|f||||t||||||||||2018-06-01 03:46:58.695101|2018-06-01 03:46:58.695101
NCT00373776|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2006-09-07|2006-09-07|2006-09-08|Estimate|||||||2006-09-07|2006-09-08|Estimate|April 2004||2004-04-30|September 2006|2006-09-30|May 2006||2006-05-31|||||Interventional|||Miltefosine for Mucosal Leishmaniasis||Completed||Phase 1/Phase 2|75||AB Foundation|||||f||||||||||||||2018-06-01 03:46:58.792361|2018-06-01 03:46:58.792361
NCT00373763|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2008-08-22|2006-09-06|2006-09-08|Estimate|||||||2008-08-22|2008-08-25|Estimate|January 2007||2007-01-31|August 2008|2008-08-31||||January 2008|Actual|2008-01-31||Interventional|||Fetoscopic Tracheal Balloon Occlusion in Unborns With Severe Congenital Diaphragmatic Hernia - EUROTRIAL I|Randomized Clinical Trial for the Assessment of the Life-Saving Potential of Fetoscopic Tracheal Balloon Occlusion in Fetuses With Severe Congenital Diaphragmatic Hernia - EUROTRIAL I|Withdrawn||N/A|98|Anticipated|University Hospital, Bonn||||"No patients could be recruited and randomized due to other center offering backdoor for~   treatment."|f||||||||||||||2018-06-01 03:46:58.846358|2018-06-01 03:46:58.846358
NCT00373750|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2015-01-09|2006-09-07|2006-09-08|Estimate|||||||2015-01-09|2015-01-12|Estimate|June 2006||2006-06-30|January 2015|2015-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Cradling Our Future Through Family Strengthening Study|In-home Prevention of SA Risks for Native Teen Families|Completed||N/A|322|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 03:46:59.95845|2018-06-01 03:46:59.95845
NCT00373737|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2010-07-23|2006-09-06|2006-09-08|Estimate|||||||2010-07-23|2010-07-27|Estimate|May 1999||1999-05-31|July 2010|2010-07-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Observational|||Microarray Analysis of Gene Expression in Liver Tumors|Microarray Analysis of Gene Expression in Liver Tumors|Completed|||300|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     liver tumor~   "|||2018-06-01 03:47:00.044857|2018-06-01 03:47:00.044857
NCT00373724|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2008-05-07|2006-09-07|2006-09-08|Estimate|||||||2008-05-07|2008-05-09|Estimate|November 2005||2005-11-30|May 2008|2008-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Placebo-Controlled Study Assessing Lateral Branch Radiofrequency Denervation for Sacroiliac (SI) Joint Pain||Completed||N/A|30||Johns Hopkins University|||||f||||t||||||||||2018-06-01 03:47:00.093924|2018-06-01 03:47:00.093924
NCT00373711|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2011-04-07|2006-09-06|2006-09-08|Estimate|||||||2011-04-07|2011-04-11|Estimate|May 2007||2007-05-31|April 2011|2011-04-30||||||||Observational|||Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA|Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection|Withdrawn|||100|Anticipated|Stanford University||||Abandoned|f||||t||||||||||2018-06-01 03:47:00.154235|2018-06-01 03:47:00.154235
NCT00373698|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|2014-07-31||2015-04-06|2006-09-07|2006-09-08|Estimate|2014-11-03|2014-11-07|Estimate||||2015-04-06|2015-04-24|Estimate|March 2008||2008-03-31|June 2014|2014-06-30|April 2012|Actual|2012-04-30|April 2010|Actual|2010-04-30||Interventional|RESPECT-PTSD|To be included, subjects had to meet diagnostic criteria for PTSD, have regular access to a telephone, and speak English. Exclusion criteria were cognitive impairment, history of psychosis or mania, prominent current suicidal ideation, current substance dependence, and current engagement in mental health treatment|Re-Engineering Systems for the Primary Care Treatment for PTSD|Reengineering Systems for the Primary Care Treatment of PTSD|Completed||Phase 3|195|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:47:00.226474|2018-06-01 03:47:00.226474
NCT00373685|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2011-10-26||2012-02-02|2006-09-07|2006-09-08|Estimate|2011-10-26|2011-11-30|Estimate||||2012-02-02|2012-02-06|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|GI-REASONS||GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)|Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In Osteoarthritis Patients|Completed||Phase 4|8067|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:47:00.81899|2018-06-01 03:47:00.81899
NCT00373672|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2010-02-22|2006-09-07|2006-09-08|Estimate|||||||2010-02-22|2010-02-23|Estimate|August 2006||2006-08-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder|Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|60|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 03:47:03.527287|2018-06-01 03:47:03.527287
NCT00373659|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2012-06-12|2006-09-07|2006-09-08|Estimate|||||||2012-06-12|2012-06-13|Estimate|August 2004||2004-08-31|June 2012|2012-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD|Prospective Optical Coherence Tomography (OCT) Imaging of Patients With Neovascular AMD Treated With Intra-Ocular Ranibizumab (Lucentis) (PrONTO) Study|Completed||Phase 2|40|Actual|University of Miami|||||f||||f||||||||||2018-06-01 03:47:03.606974|2018-06-01 03:47:03.606974
NCT00373646|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2009-06-17|2006-09-07|2006-09-08|Estimate|||||||2009-06-17|2009-06-18|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients|Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)|Completed||Phase 2|8|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 03:47:03.694857|2018-06-01 03:47:03.694857
NCT00373633|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2014-08-13|2006-09-07|2006-09-08|Estimate|||||||2014-08-13|2014-08-15|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Extrapleural Intercostal Catheter vs. Thoracic Epidural for Thoracotomy Pain|A Prospective Randomized Trial Comparing Extrapleural Intercostal Local Anesthesia Versus Thoracic Epidural for the Managment of Acute Post Thoracotomy Pain|Terminated||Phase 1|26|Actual|Virginia Commonwealth University||2||terminated due to diminishing frequency of thorocotomies and slow enrollment|f||||||||||||||2018-06-01 03:47:03.782192|2018-06-01 03:47:03.782192
NCT00373620|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2006-09-06|2006-09-06|2006-09-08|Estimate|||||||2006-09-06|2006-09-08|Estimate|January 2006||2006-01-31|December 2005|2005-12-31||||||||Interventional|||A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients|A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy in High-Risk Endometrial Cancer Patients After Operation.|Unknown status|Recruiting|Phase 2|50||Korean Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 03:47:03.855292|2018-06-01 03:47:03.855292
NCT00373607|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2010-09-13|2006-09-07|2006-09-08|Estimate|||||||2010-09-13|2010-09-14|Estimate|July 2003||2003-07-31|September 2010|2010-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru|Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region|Completed||Phase 3|522|Actual|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-06-01 03:47:03.921834|2018-06-01 03:47:03.921834
NCT00373594|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2010-06-18|2006-09-07|2006-09-08|Estimate|||||||2010-06-18|2010-06-22|Estimate|June 2005||2005-06-30|June 2010|2010-06-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Therapy for Chronic Cold Agglutinin Disease|Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicentre Study on the Safety and Efficacy of Rituximab in Combination With Fludarabine.|Completed||Phase 2|30|Anticipated|University of Bergen|||||f||||||||||||||2018-06-01 03:47:03.985088|2018-06-01 03:47:03.985088
NCT00373581|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-10-25|2006-09-07|2006-09-08|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effects of Vigabatrin on Cocaine Self-Administration|Effects of Vigabatrin on Cocaine Self-Administration|Terminated||Phase 2|1|Actual|New York State Psychiatric Institute||2||Funding ran out|f||||f||||||||No||2018-06-01 03:47:04.062673|2018-06-01 03:47:04.062673
NCT00373568|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2010-05-29|2006-09-07|2006-09-08|Estimate|||||||2010-05-29|2010-06-02|Estimate|April 2005||2005-04-30|May 2010|2010-05-31|December 2007||2007-12-31|||||Interventional|||Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis|Miltefosine (42 Days) for Mucosal Leishmaniasisi|Completed||Phase 1/Phase 2|25||AB Foundation|||||f||||||||||||||2018-06-01 03:47:04.146299|2018-06-01 03:47:04.146299
NCT00373555|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2008-09-30|2006-09-07|2006-09-08|Estimate|||||||2008-09-30|2008-10-02|Estimate|September 2006||2006-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|September 2007|Actual|2007-09-30||Interventional|||Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis|Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis|Completed||N/A|50|Anticipated|University of Calgary|||||f||||f||||||||||2018-06-01 03:47:04.215528|2018-06-01 03:47:04.215528
NCT00373542|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-10-27|2006-09-07|2006-09-08|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|(CR-RLS)||12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome|A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep|Completed||Phase 4|39|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:47:04.291769|2018-06-01 03:47:04.291769
NCT00373529|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2011-02-24|2010-02-24|2014-03-17|2006-09-07|2006-09-08|Estimate|2011-02-24|2011-03-24|Estimate|2010-02-24|2010-02-26|Estimate|2014-03-17|2014-04-14|Estimate|October 2006||2006-10-31|March 2014|2014-03-31|May 2010|Actual|2010-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)|A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients With Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit|Completed||Phase 2|116|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 03:47:04.580096|2018-06-01 03:47:04.580096
NCT00373516|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2006-09-06|2006-09-06|2006-09-08|Estimate|||||||2006-09-06|2006-09-08|Estimate|September 2004||2004-09-30|September 2006|2006-09-30|March 2005||2005-03-31|||||Interventional|||Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Study of the Safety and Efficacy of Two Dosing Regimens of QRX-101 (Becocalcidiol) Ointment in the Treatment of Plaque-Type Psoriasis|Completed||Phase 2|150||QuatRx Pharmaceuticals Company|||||||||||||||||||2018-06-01 03:47:05.726654|2018-06-01 03:47:05.726654
NCT00373503|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2013-02-04|2006-09-07|2006-09-08|Estimate|||||||2013-02-04|2013-02-05|Estimate|August 2005||2005-08-31|February 2013|2013-02-28|September 2008|Actual|2008-09-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse|Effect of Lofexidine and Oral THC on Marijuana Withdrawal and Relapse|Completed||Phase 2|8|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 03:47:05.804701|2018-06-01 03:47:05.804701
NCT00373490|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2008-10-20||2015-08-26|2006-09-07|2006-09-08|Estimate|2009-03-30|2009-05-20|Estimate||||2015-08-26|2015-08-27|Estimate|July 2006||2006-07-31|August 2015|2015-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)|MK0683 Phase1 Clinical Study - Solid Tumor -|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:47:05.896905|2018-06-01 03:47:05.896905
NCT00373477|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2006-09-06|2006-09-06|2006-09-08|Estimate|||||||2006-09-06|2006-09-08|Estimate|July 2003||2003-07-31|September 2006|2006-09-30|February 2005||2005-02-28|||||Interventional|||A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid Recipients|A Randomized Trial of the Cost Effectiveness of Generalist Care Managers for the Treatment of Depression in Medicaid Recipients|Completed||N/A|300||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 03:47:06.345294|2018-06-01 03:47:06.345294
NCT00373464|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2011-06-30|2006-09-07|2006-09-08|Estimate|||||||2011-06-30|2011-07-01|Estimate|March 2006||2006-03-31|August 2005|2005-08-31|March 2007|Actual|2007-03-31|||||Interventional|||Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Surgery|Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Gynaecologic Surgery With Expected Need of Post-operative Opioids|Completed||Phase 3|126||Oslo University Hospital|||||f||||||||||||||2018-06-01 03:47:06.415684|2018-06-01 03:47:06.415684
NCT00373451|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2012-05-07|2006-09-07|2006-09-08|Estimate|||||||2012-05-07|2012-05-08|Estimate|July 2006||2006-07-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|ISAR-REACT-4||Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome|Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)|Completed||Phase 4|1721|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 03:47:06.480015|2018-06-01 03:47:06.480015
NCT00373438|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-01-05|2006-09-06|2006-09-08|Estimate|||||||2009-01-05|2009-01-06|Estimate|January 2009||2009-01-31|January 2009|2009-01-31|July 2014|Anticipated|2014-07-31|January 2014|Anticipated|2014-01-31||Interventional|||Fetoscopic Tracheal Balloon Occlusion in Left Diaphragmatic Hernia|Randomized Clinical Trial in Order to Assess the Effect of Fetoscopic Tracheal Balloon Occlusion on the Postnatal Disease Course in Neonates With Left Congenital Diaphragmatic Hernia - FDH-ECMO/BALLOON-TRIAL|Unknown status|Recruiting|Phase 2|98|Anticipated|University Hospital, Bonn||2|||f||||t||||||||||2018-06-01 03:47:06.652302|2018-06-01 03:47:06.652302
NCT00373243|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2017-09-07|2006-09-05|2006-09-07|Estimate|||||||2017-09-07|2017-09-11|Actual|October 19, 2005|Actual|2005-10-19|September 2017|2017-09-30|September 26, 2006|Actual|2006-09-26|September 26, 2006|Actual|2006-09-26||Interventional|||A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment|An Open-label, Non-randomised Study of 20 mg GW406381 Single Dose Pharmacokinetics in Healthy Subjects and in Volunteers With Moderate Hepatic Impairment|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:47:17.74803|2018-06-01 03:47:17.74803
NCT00373425|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2014-04-02||2015-09-01|2006-09-07|2006-09-08|Estimate|2014-05-09|2014-06-03|Estimate||||2015-09-01|2015-09-17|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|April 2013|Actual|2013-04-30||Interventional|RADIANT||A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors|A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors|Completed||Phase 3|1252|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the currency or completeness of the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose and shall not be liable for any damages.|2|||f||||t||||||||||2018-06-01 03:47:06.841138|2018-06-01 03:47:06.841138
NCT00373412|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2008-05-05|2006-09-07|2006-09-08|Estimate|||||||2008-05-05|2008-05-08|Estimate|October 2006||2006-10-31|October 2006|2006-10-31||||February 2008|Actual|2008-02-29||Interventional|||Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge|Randomized, Phase 1 Trial to Evaluate Safety and CMV-Specific Immune Response to a pDNA CMV Trivalent Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge in Healthy, CMV- Seronegative Adults|Completed||Phase 1|16||University of California, San Francisco|||||f||||f||||||||||2018-06-01 03:47:10.278527|2018-06-01 03:47:10.278527
NCT00373399|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2016-10-25|2006-09-07|2006-09-08|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks|Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks|Completed||Phase 2|278|Actual|New York State Psychiatric Institute||2|||f||||||||||||||2018-06-01 03:47:10.442101|2018-06-01 03:47:10.442101
NCT00373386|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2016-06-06||2017-09-18|2006-09-07|2006-09-08|Estimate|2017-09-18|2018-05-30|Actual||||2017-09-18|2018-05-30|Actual|January 2005||2005-01-31|September 2017|2017-09-30|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Growth Hormone and Endothelial Function in Children|Growth Hormone and Endothelial Function in Children|Completed||Phase 4|9|Actual|Ohio State University|Small sample size|1|||f||||f||||||||Yes|Clinical Trials.gov|2018-06-01 03:47:10.542053|2018-06-01 03:47:10.542053
NCT00373373|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-08-18|2006-09-06|2006-09-08|Estimate|||||||2009-08-18|2009-08-19|Estimate|September 2006||2006-09-30|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML|A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML|Completed||Phase 2|200|Anticipated|University Hospital Muenster||2|||f||||t||||||||||2018-06-01 03:47:10.768657|2018-06-01 03:47:10.768657
NCT00373360|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2012-10-19||2013-01-03|2006-09-07|2006-09-08|Estimate|2013-01-03|2013-01-07|Estimate||||2013-01-03|2013-01-07|Estimate|September 2006||2006-09-30|January 2013|2013-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin|Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction|Completed||Phase 4|10|Actual|United Therapeutics||1|||f||||f||||||||||2018-06-01 03:47:10.88996|2018-06-01 03:47:10.88996
NCT00373347|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2016-11-08|2006-09-06|2006-09-08|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2004||2004-11-30|November 2016|2016-11-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma|Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma|Recruiting|||300|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:47:11.475083|2018-06-01 03:47:11.475083
NCT00373334|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2009-08-03|2009-01-22|2009-11-17|2006-09-07|2006-09-08|Estimate|2009-10-09|2009-11-17|Estimate|2009-10-09|2009-11-17|Estimate|2009-11-17|2009-11-18|Estimate|August 2006||2006-08-31|November 2009|2009-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)|A Double-Blind, Randomized, Parallel, Multicenter Study of Axid (Nizatidine) Oral Solution in the Treatment of Gastroesophageal Reflux Disease (GERD) Symptoms in Infants Age 30 Days-1 Year|Completed||Phase 3|138|Actual|Braintree Laboratories||3|||f||||||||||||||2018-06-01 03:47:11.539632|2018-06-01 03:47:11.539632
NCT00373308|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2016-07-14|2006-09-06|2006-09-08|Estimate|||||||2016-07-14|2016-07-15|Estimate|September 2002||2002-09-30|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Observational|||Quality of Life Following Radical Prostatectomy|Quality of Life Following Radical Prostatectomy|Recruiting|||200|Anticipated|Stanford University|||||f||||t||||||||||2018-06-01 03:47:12.419181|2018-06-01 03:47:12.419181
NCT00373295|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2016-10-20||2017-03-30|2006-09-07|2006-09-08|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|May 2006||2006-05-31|March 2017|2017-03-31|January 2010|Actual|2010-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of Baclofen on Marijuana Withdrawal and Relapse|Effect of Baclofen on Marijuana Withdrawal and Relapse|Completed||Phase 2|13|Actual|New York State Psychiatric Institute||6|||f||||f||||||||||2018-06-01 03:47:12.758324|2018-06-01 03:47:12.758324
NCT00373282|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|||2006-10-11|2006-09-07|2006-09-08|Estimate|||||||2006-10-11|2006-10-12|Estimate|June 2001||2001-06-30|August 2006|2006-08-31|June 2003||2003-06-30|||||Interventional|||Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy||Completed||Phase 3|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:47:13.09969|2018-06-01 03:47:13.09969
NCT00373269|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2016-11-04||2017-01-11|2006-09-07|2006-09-08|Estimate|2016-11-04|2017-01-04|Estimate||||2017-01-11|2017-02-27|Actual|October 2001||2001-10-31|January 2017|2017-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study|Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study|Completed|||21|Actual|Temple University|||2||f||||f||||||||No||2018-06-01 03:47:13.193104|2018-06-01 03:47:13.193104
NCT00373256|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-07|2010-06-01||2012-09-05|2006-09-07|2006-09-08|Estimate|2010-09-16|2010-10-08|Estimate||||2012-09-05|2012-09-10|Estimate|November 2006||2006-11-30|September 2012|2012-09-30|August 2011|Actual|2011-08-31|June 2009|Actual|2009-06-30||Interventional|||A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer|A Phase 3 Study Of SU011248 In Combination With Paclitaxel Versus Bevacizumab With Paclitaxel In The First-Line Advanced Disease Setting In Patients Having Breast Cancer|Completed||Phase 3|488|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 03:47:14.2244|2018-06-01 03:47:14.2244
NCT00373230|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-10-22|2006-09-06|2006-09-07|Estimate|||||||2008-10-22|2008-10-23|Estimate|October 2007||2007-10-31|October 2008|2008-10-31|February 2010|Anticipated|2010-02-28|February 2010|Anticipated|2010-02-28||Interventional|||Treating Obesity in Underserved Overweight Populations|Treating Obesity and Its Consequences in Underserved Overweight Populations|Unknown status|Recruiting|N/A|320|Anticipated|Temple University||2|||f||||t||||||||||2018-06-01 03:47:17.840379|2018-06-01 03:47:17.840379
NCT00373217|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2016-08-11|2006-09-06|2006-09-07|Estimate|||||||2016-08-11|2016-08-15|Estimate|February 2008||2008-02-29|August 2016|2016-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Evaluation of the Immunogenicity of Vaccination With Synthetic Peptides in Adjuvant in Patients With Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Terminated||Phase 2|6|Actual|University of Virginia||2||Slow enrollment rate.|f||||||||||||||2018-06-01 03:47:17.926768|2018-06-01 03:47:17.926768
NCT00373204|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2014-07-23|2006-09-06|2006-09-07|Estimate|||||||2014-07-23|2014-07-24|Estimate|May 2006||2006-05-31|July 2014|2014-07-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)|Phase II Trial of Motexafin Gadolinium and Docetaxel for Second Line Treatment of Patients With Advanced Non-small Cell Lung Cancer|Terminated||Phase 2|50|Actual|Pharmacyclics LLC.||1|||f||||||||||||||2018-06-01 03:47:18.040464|2018-06-01 03:47:18.040464
NCT00373191|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2015-10-09|2006-09-06|2006-09-07|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2006||2006-05-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|February 2009|Actual|2009-02-28||Observational|||Effect of Surgery, Radiation Therapy, Chemotherapy, and Hormone Therapy on Biomarkers in Women With Stage I, Stage II, Stage III Breast Cancer, or Ductal Carcinoma In Situ That Can Be Removed By Surgery|Effects of Surgery, Radiation Therapy, Chemotherapy, and Endocrine Therapy on High-Sensitivity C-Reactive Protein in Women With Operable Breast Cancer|Completed|||35|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||Samples With DNA|"~     Serum~   "|||2018-06-01 03:47:18.283523|2018-06-01 03:47:18.283523
NCT00373178|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2012-11-01|2006-09-06|2006-09-07|Estimate|||||||2012-11-01|2012-11-02|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|June 2008|Actual|2008-06-30|January 2007|Actual|2007-01-31||Interventional|||Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes|Metabolic Effects of Treatment in Patients With Recently Diagnosed Type 2 Diabetes|Completed||Phase 4|100|Actual|Aristotle University Of Thessaloniki||1|||f||||||||||||||2018-06-01 03:47:18.498735|2018-06-01 03:47:18.498735
NCT00373165|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2006-09-12|2006-09-06|2006-09-07|Estimate|||||||2006-09-12|2006-09-13|Estimate|August 2000||2000-08-31|September 2006|2006-09-30|October 2003||2003-10-31|||||Interventional|||Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients|Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load|Completed||Phase 4|150||Lower Saxony Center for Nephrology|||||f||||||||||||||2018-06-01 03:47:18.668967|2018-06-01 03:47:18.668967
NCT00373152|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2017-12-03|2006-09-06|2006-09-07|Estimate|||||||2017-12-03|2017-12-05|Actual|March 2005||2005-03-31|December 2017|2017-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer|Breast MRI Assessment of Tumor Viability After Radiofrequency Ablation (RFA)|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||1||No patient accrual|f||||t||||||||||2018-06-01 03:47:18.726943|2018-06-01 03:47:18.726943
NCT00373139|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2013-12-27|2006-09-06|2006-09-07|Estimate|||||||2013-12-27|2013-12-30|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Accuracy of Whole-Blood Testing for Rapid Detection of Pregnancy|Accuracy of Whole-Blood Testing for Rapid Detection of Pregnancy|Completed|||633|Actual|Maimonides Medical Center|||||f||||f||||||||||2018-06-01 03:47:18.793218|2018-06-01 03:47:18.793218
NCT00373126|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2009-05-14|2006-09-05|2006-09-07|Estimate|||||||2009-05-14|2009-05-15|Estimate|April 2005||2005-04-30|May 2009|2009-05-31||||||||Interventional|||The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia|A Double-Blind, Placebo-Controlled Trial of Reward Responsivity During Nicotine Withdrawal in Smokers With Schizophrenia and Normal Controls|Completed||Phase 4|40|Anticipated|North Suffolk Mental Health Association|||||f||||||||||||||2018-06-01 03:47:18.848569|2018-06-01 03:47:18.848569
NCT00373113|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2010-10-20||2012-06-15|2006-09-05|2006-09-07|Estimate|2010-10-20|2010-11-18|Estimate||||2012-06-15|2012-06-25|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|October 2009|Actual|2009-10-31||Interventional|||A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine|Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated|Terminated||Phase 3|482|Actual|Pfizer|Due to patient enrollment termination, PFS/OR/TTP/DR were done by investigator assessment due to lack of central review data and TTR/EORTC QLQ-C30/QLQ BR23 analyses were not done. Those enrolled could receive capecitabine or enter an extension trial.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:47:19.015499|2018-06-01 03:47:19.015499
NCT00373100|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-07-03|2006-09-06|2006-09-07|Estimate|||||||2009-07-03|2009-07-07|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children|The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children Admitted to Mulago Hospital, Uganda.|Completed||Phase 3|328|Anticipated|Makerere University||2|||f||||t||||||||||2018-06-01 03:47:20.762798|2018-06-01 03:47:20.762798
NCT00373087|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2010-04-28|2006-09-06|2006-09-07|Estimate|||||||2010-04-28|2010-04-29|Estimate|October 2006||2006-10-31|July 2007|2007-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|COMT||COMT Polymorphism and Entacapone Efficacy|Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease|Completed||Phase 4|60|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 03:47:20.84427|2018-06-01 03:47:20.84427
NCT00373074|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2009-02-04|2006-09-06|2006-09-07|Estimate|||||||2009-02-04|2009-02-06|Estimate|September 2006||2006-09-30|February 2009|2009-02-28|July 2008|Actual|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||Epidural Blood Patch on the Resolution of Postdural Puncture Headache (PDPH)|A Multi-Center, Randomized Controlled Study Trial to Investigate the Effect of Varying Volumes of Blood Patch on the Resolution of Postdural Puncture Headache (PDPH)|Terminated||Phase 2/Phase 3|0|Anticipated|The University of Texas Health Science Center, Houston||3||Lack of subject population for PI|f||||||||||||||2018-06-01 03:47:20.916825|2018-06-01 03:47:20.916825
NCT00373061|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2018-02-12|2006-09-05|2006-09-07|Estimate|||||||2018-02-12|2018-02-14|Actual|October 20, 2006|Actual|2006-10-20|February 2018|2018-02-28|January 5, 2018|Actual|2018-01-05|December 11, 2017|Actual|2017-12-11||Observational|EXPECT||An Observational Study of the Use and Safety of Xolair® During Pregnancy|The Xolair® Pregnancy Registry: An Observational Study of the Use and Safety of Xolair® (Omalizumab) During Pregnancy|Completed|||309|Actual|Genentech, Inc.|||1||f||||||||||||||2018-06-01 03:47:20.984973|2018-06-01 03:47:20.984973
NCT00373048|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2011-05-23|2006-09-06|2006-09-07|Estimate|||||||2011-05-23|2011-05-24|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|December 2007|Actual|2007-12-31||Interventional|||Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial|Mefloquine Malaria Prophylaxis in HIV-1 Infected Individuals and Its Influence on the Evolution Towards AIDS: a Randomized Placebo-controlled Trial|Completed||N/A|300|Anticipated|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-06-01 03:47:21.053792|2018-06-01 03:47:21.053792
NCT00373035|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2017-01-17|2006-09-06|2006-09-07|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2006||2006-02-28|June 2013|2013-06-30||||July 2006|Actual|2006-07-31||Observational|||Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy|Biomarkers of Prostate Cancer|Completed|||60|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 03:47:21.121735|2018-06-01 03:47:21.121735
NCT00373022|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2010-05-26|2006-09-06|2006-09-07|Estimate|||||||2010-05-26|2010-05-27|Estimate|January 2004||2004-01-31|December 2006|2006-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Moderate Physical Activity in Helping Patients Recover Physically and Emotionally From Stage II Or Stage III Colorectal Cancer|The Effect of Moderate Physical Activity on the Physical and Emotional Recovery of Patients With a History of Colorectal Cancer|Completed||N/A|45|Anticipated|University of Arizona|||||f||||||||||||||2018-06-01 03:47:21.456449|2018-06-01 03:47:21.456449
NCT00373009|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2015-03-12|2006-09-05|2006-09-07|Estimate|||||||2015-03-12|2015-03-17|Estimate|February 2007||2007-02-28|March 2015|2015-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|POLM||Prevention of Low Back Pain in the Military|Prevention of Low Back Pain in the Military. A Randomized Clinical Trial|Completed||N/A|4325|Actual|University of Florida||4|||f||||t||||||||||2018-06-01 03:47:21.529212|2018-06-01 03:47:21.529212
NCT00372996|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2015-06-03|2012-05-08|2015-10-06|2006-09-06|2006-09-07|Estimate|2015-06-29|2015-07-28|Estimate|2012-05-08|2012-05-10|Estimate|2015-10-06|2015-10-28|Estimate|February 2007||2007-02-28|October 2015|2015-10-31|June 2014|Actual|2014-06-30|September 2012|Actual|2012-09-30||Interventional||Safety population: all participants who started treatment, grouped according to main trial therapy treatment actually received.|Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer|A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer|Terminated||Phase 2|219|Actual|Pfizer||2||"This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature~   closure was not prompted by any safety or efficacy concerns."|f||||f||||||||||2018-06-01 03:47:21.679065|2018-06-01 03:47:21.679065
NCT00372983|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2007-12-17|2006-09-06|2006-09-07|Estimate|||||||2007-12-17|2007-12-21|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy|A Randomized, Placebo Controlled, Phase 1b Trial to Evaluate the Safety and Pharmacokinetics of NOV-205 in Chronic Viral Hepatitis C Subjects (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin|Completed||Phase 1|30|Anticipated|Cellectar Biosciences, Inc.|||||f||||f||||||||||2018-06-01 03:47:22.884067|2018-06-01 03:47:22.884067
NCT00372970|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2015-04-16||2015-05-19|2006-09-06|2006-09-07|Estimate|2015-05-19|2015-06-09|Estimate||||2015-05-19|2015-06-09|Estimate|July 2003||2003-07-31|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||All patients with documented gastroparesis|Placebo Controlled Trial of Botulinum Toxin for Gastroparesis|Randomized Placebo-Controlled Double Blind Study of Botulinum Toxin Versus Placebo for the Treatment of Gastroparesis|Completed||N/A|32|Actual|Temple University||2|||f||||f||||||||||2018-06-01 03:47:22.933022|2018-06-01 03:47:22.933022
NCT00372957|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2017-08-18||2017-08-18|2006-09-05|2006-09-07|Estimate|2017-08-18|2018-03-19|Actual||||2017-08-18|2018-03-19|Actual|March 22, 2006|Actual|2006-03-22|August 2017|2017-08-31|June 28, 2006|Actual|2006-06-28|||||Interventional|||Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus|PK/PD Study of GW823093 in Japanese Subjects With T2DM: A Single-blind, Placebo Controlled, Randomized, Multi-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GW823093C Administered Orally for 7 Days in Japanese Subjects With Type 2 Diabetes|Completed||Phase 2|30|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:47:23.318466|2018-06-01 03:47:23.318466
NCT00372944|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05||2013-07-22|2014-08-12|2006-09-05|2006-09-07|Estimate||||2013-07-22|2013-07-24|Estimate|2014-08-12|2014-08-13|Estimate|August 2006||2006-08-31|August 2014|2014-08-31|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy|A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy|Completed||Phase 2|70|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:47:24.091722|2018-06-01 03:47:24.091722
NCT00372931|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2008-04-21|2006-09-06|2006-09-07|Estimate|||||||2008-04-21|2008-04-22|Estimate|May 2006||2006-05-31|April 2008|2008-04-30||||August 2007|Actual|2007-08-31||Interventional|||A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension|A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|120||Alcon Research|||||||||||||||||||2018-06-01 03:47:24.179879|2018-06-01 03:47:24.179879
NCT00372918|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-06-04|2006-09-06|2006-09-07|Estimate|||||||2008-06-04|2008-06-05|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|TNE||Interpretation of Transnasal Esophagoscopy Findings|An Interdisciplinary Interpretation of Transnasal Esophagoscopy Findings|Completed||Phase 4|98|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 03:47:24.233387|2018-06-01 03:47:24.233387
NCT00372905|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2018-04-24|2006-09-06|2006-09-07|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2006||2006-08-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma|A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE®) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 03:47:24.289177|2018-06-01 03:47:24.289177
NCT00372892|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2012-06-06|2006-09-06|2006-09-07|Estimate|||||||2012-06-06|2012-06-07|Estimate|September 2006||2006-09-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)|A Randomized, Double Blind, Placebo Controlled Pilot Trial of Rituximab for Non-splenectomized Adults With Acute Immune Thrombocytopenic Purpura Receiving Standard Treatment (R-ITP)|Completed||Phase 2|60|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 03:47:24.358491|2018-06-01 03:47:24.358491
NCT00372879|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2016-03-01|2006-09-05|2006-09-07|Estimate|||||||2016-03-01|2016-03-03|Estimate|December 2006||2006-12-31|March 2016|2016-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS|Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis.|Completed||Phase 3|32|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 03:47:24.433939|2018-06-01 03:47:24.433939
NCT00372853|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2012-06-05|2006-09-05|2006-09-07|Estimate|||||||2012-06-05|2012-06-06|Estimate|November 2006||2006-11-30|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma|A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1|28|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:47:24.500859|2018-06-01 03:47:24.500859
NCT00372840|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2016-03-01|2006-09-06|2006-09-07|Estimate|||||||2016-03-01|2016-03-03|Estimate|May 2006||2006-05-31|March 2016|2016-03-31||||November 2010|Actual|2010-11-30||Interventional|||Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer|Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment|Unknown status|Active, not recruiting|N/A|332|Anticipated|Fox Chase Cancer Center||2|||f||||||||||||||2018-06-01 03:47:24.565487|2018-06-01 03:47:24.565487
NCT00372827|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2016-11-18|2006-09-06|2006-09-07|Estimate|||||||2016-11-18|2016-11-21|Estimate|February 2004||2004-02-29|May 2008|2008-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension|Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 4|245||Alcon Research|||||f||||||||||||||2018-06-01 03:47:24.641319|2018-06-01 03:47:24.641319
NCT00372814|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2017-06-01|2006-09-05|2006-09-07|Estimate|||||||2017-06-01|2017-06-02|Actual|March 2007||2007-03-31|June 2017|2017-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes|Adherence to IDDM Regimen in Urban Youth|Completed||N/A|146|Actual|Wayne State University||2|||f||||t||||||||No||2018-06-01 03:47:24.699543|2018-06-01 03:47:24.699543
NCT00372801|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-10-15|2006-09-05|2006-09-07|Estimate|||||||2008-10-15|2008-10-16|Estimate|August 2005||2005-08-31|October 2008|2008-10-31||||||||Interventional|||Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of The Knee|A Double-Blind, Randomised, Placebo-Controlled, Cross-Over Pilot Study to Investigate the Efficacy of Ibuprofen in Patients With Osteoarthritis of the Knee Following Administration of a Single Dose|Completed||Phase 1|36||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:47:24.77164|2018-06-01 03:47:24.77164
NCT00372788|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2014-08-12|2006-09-05|2006-09-07|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2006||2006-08-31|August 2014|2014-08-31|December 2008|Actual|2008-12-31|July 2007|Actual|2007-07-31||Interventional|||AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen|A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen|Completed||Phase 2|88|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:47:25.024214|2018-06-01 03:47:25.024214
NCT00372775|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2010-12-08||2011-01-27|2006-09-05|2006-09-07|Estimate|2011-01-27|2011-02-24|Estimate||||2011-01-27|2011-02-24|Estimate|March 2007||2007-03-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases|A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases|Completed||Phase 2|66|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:47:25.152992|2018-06-01 03:47:25.152992
NCT00372762|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2014-03-26|2006-09-06|2006-09-07|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|||Bumetanide Versus Furosemide in Heart Failure|Bumetanide Has a More Favourable Effect on Insulin Resistance Than Furosemide in Patients With Heart Failure - A Pilot Study|Withdrawn||Phase 3|0|Actual|Lawson Health Research Institute||2||Due to changes within the research program this study is not feasible at this time|f||||f||||||||||2018-06-01 03:47:25.684016|2018-06-01 03:47:25.684016
NCT00372749|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2011-03-25|2006-09-05|2006-09-07|Estimate|||||||2011-03-25|2011-03-28|Estimate|October 2006||2006-10-31|February 2007|2007-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Does the Threat of an Aversive Reaction Affect Craving of Alcohol During Cue Exposure in Alcohol Dependent Patients?|Does the Threat of an Aversive Reaction Affect Craving of Alcohol During Cue Exposure in Alcohol Dependent Patients?|Completed||N/A|30|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 03:47:25.779713|2018-06-01 03:47:25.779713
NCT00372736|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2015-10-05|2006-09-06|2006-09-07|Estimate|||||||2015-10-05|2015-10-06|Estimate|June 2006||2006-06-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors|A Phase I Study of AEG35156 Given as a 2 Hour Intravenous Infusion in Combination With Docetaxel in Patients With Solid Tumours|Completed||Phase 1|27|Actual|Canadian Cancer Trials Group|||||f||||f||||||||||2018-06-01 03:47:25.872683|2018-06-01 03:47:25.872683
NCT00372723|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2013-04-25|2006-09-06|2006-09-07|Estimate|||||||2013-04-25|2013-04-26|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)|Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis|Withdrawn||Phase 2|0|Actual|Loyola University||||slow enrollment|f||||||||||||||2018-06-01 03:47:25.962595|2018-06-01 03:47:25.962595
NCT00372710|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-11-20|2006-09-06|2006-09-07|Estimate|||||||2009-11-20|2009-11-23|Estimate|August 2002||2002-08-31|November 2009|2009-11-30||||||||Interventional|||Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions|Efficacy and Tolerability of Intravenous Zoledronic Acid 4mg as an Adjunct to Standard Therapies Including Conversion From Pamidronate in Breast Cancer Patients With Metastatic Bone Lesions. A Prospective, Randomised, Open-label, Clinical Study|Terminated||Phase 3|30||Novartis|||||f||||||||||||||2018-06-01 03:47:26.021964|2018-06-01 03:47:26.021964
NCT00372359|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-03|||2012-09-19|2006-09-03|2006-09-06|Estimate|||||||2012-09-19|2012-09-20|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|||||Observational|||Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions|Adverse Effect of Prolonged Methylphenidate Treatment on Cardiac Functions|Unknown status|Recruiting||50|Anticipated|Barzilai Medical Center|||||f||||t||||||||||2018-06-01 03:47:41.373363|2018-06-01 03:47:41.373363
NCT00372697|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|2011-01-12||2011-04-19|2006-09-06|2006-09-07|Estimate|2011-04-19|2011-05-17|Estimate||||2011-04-19|2011-05-17|Estimate|December 2005||2005-12-31|April 2011|2011-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly|A Randomised, Open-label, Multicenter Study Comparing the Efficacy and Safety of Medical Treatment With Octreotide Acetate 30 mg Administered Every 21 Days for 6 Months With That of Octreotide Acetate 60 mg Administered Every 28 Days for 6 Months in Acromegalic Patients With Uncontrolled Disease|Completed||Phase 3|28|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:47:26.086944|2018-06-01 03:47:26.086944
NCT00372684|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2010-06-18|2006-09-06|2006-09-07|Estimate|||||||2010-06-18|2010-06-22|Estimate|September 2006||2006-09-30|July 2007|2007-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|PALUREA||PALUREA: Severe Imported Malaria in Adults|PALUREA: Severe Falciparum Imported Malaria in Adults: Clinical and Physiopathological Study|Completed|||302|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     physiopathologic~   "|||2018-06-01 03:47:26.29547|2018-06-01 03:47:26.29547
NCT00372671|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2017-08-24|2006-09-06|2006-09-07|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2005|Actual|2005-06-30|August 2017|2017-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation|Evaluation of an Introductory Videotape Intervention to Improve Cardiac Rehabilitation Participation, the CR$P-2 Pilot Study.|Completed||Phase 3|60||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 03:47:26.357563|2018-06-01 03:47:26.357563
NCT00372658|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2006-09-06|2006-09-06|2006-09-07|Estimate|||||||2006-09-06|2006-09-07|Estimate|July 2002||2002-07-31|December 2005|2005-12-31|October 2004||2004-10-31|||||Interventional|||Intracervical Block Versus Placebo to Assess Pain Control During Hysterosalpingogram|Intracervical Block and Pain Perception During the Performance of a Hysterosalpingogram: A Randomized Controlled Trial|Completed||Phase 2|120||Wilford Hall Medical Center|||||f||||||||||||||2018-06-01 03:47:26.426541|2018-06-01 03:47:26.426541
NCT00372645|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2015-03-23|2006-09-06|2006-09-07|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2008|Actual|2008-01-31||Interventional|||Increasing Folate Status of a General Population(FOLSUPP STUDY)|Effects Of A Mixed Diet Intervention Versus Folic Acid Supplementation And Metafolin® Supplementation On Folate Status And Cardiovascular Disease Risk Factors In Healthy Adults|Completed||N/A|180|Actual|Quadram Institute||4|||f||||f||||||||||2018-06-01 03:47:26.510459|2018-06-01 03:47:26.510459
NCT00372632|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2010-09-12|2006-09-05|2006-09-07|Estimate|||||||2010-09-12|2010-09-14|Estimate|December 2005||2005-12-31|September 2010|2010-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda|Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda|Completed||Phase 4|1717|Actual|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-06-01 03:47:26.730973|2018-06-01 03:47:26.730973
NCT00372619|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|2013-12-13||2017-05-03|2006-09-06|2006-09-07|Estimate|2013-12-13|2014-02-03|Estimate||||2017-05-03|2017-06-05|Actual|March 2007||2007-03-31|February 2017|2017-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia|Completed||Phase 1/Phase 2|74|Actual|Children's Oncology Group||7|||f||||t||||||||||2018-06-01 03:47:26.893292|2018-06-01 03:47:26.893292
NCT00372606|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-10-06|2006-09-06|2006-09-07|Estimate|||||||2009-10-06|2009-10-07|Estimate|September 2004||2004-09-30|October 2009|2009-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Evaluation of a Culturally- and Linguistically-Appropriate Online Diet Program for U.S Hispanics|An Evaluation of a Culturally- and Linguistically-Appropriate eHealth Portal to Facilitate Improved Diets, Increased Fitness-Levels, and Weight-Loss Among U.S. Hispanics|Completed||Phase 2|1000|Anticipated|Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 03:47:30.045273|2018-06-01 03:47:30.045273
NCT00372593|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|2015-01-06||2017-03-28|2006-09-06|2006-09-07|Estimate|2015-01-06|2015-01-13|Estimate||||2017-03-28|2017-04-28|Actual|August 2006||2006-08-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults|Completed||Phase 3|1070|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 03:47:30.548899|2018-06-01 03:47:30.548899
NCT00372580|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2006-09-05|2006-09-05|2006-09-07|Estimate|||||||2006-09-05|2006-09-07|Estimate|August 2006||2006-08-31|September 2006|2006-09-30|December 2007||2007-12-31|||||Observational|||Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis|Effect of Atopic Diathesis as Assessed by Serum Th1/Th2 Cytokine Profile on Clinical Manifestation of Psoriasis|Unknown status|Recruiting||110||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:47:33.171538|2018-06-01 03:47:33.171538
NCT00372567|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2010-10-27||2011-03-15|2006-09-05|2006-09-07|Estimate|2010-12-05|2010-12-31|Estimate||||2011-03-15|2011-03-17|Estimate|June 2007||2007-06-30|March 2011|2011-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors|A Phase IIIB, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 Mg Daily Of Imatinib|Terminated||Phase 3|69|Actual|Pfizer|On 18 June 2009, the study was prematurely stopped for operational reasons (poor recruitment, lack of interest, and change of clinical practice) and not related to safety concerns|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:47:33.273313|2018-06-01 03:47:33.273313
NCT00372541|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2010-07-23|2006-09-06|2006-09-07|Estimate|||||||2010-07-23|2010-07-26|Estimate|September 2006||2006-09-30|July 2010|2010-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children|Ceftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in Children Aged Less Than Five Years at Mulago Hospital: A Randomized Controlled Trial|Completed||Phase 3|348|Anticipated|Makerere University|||||f||||||||||||||2018-06-01 03:47:34.093409|2018-06-01 03:47:34.093409
NCT00372346|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2006-09-05|2006-09-05|2006-09-06|Estimate|||||||2006-09-05|2006-09-06|Estimate|June 2006||2006-06-30|August 2006|2006-08-31|December 2007||2007-12-31|||||Interventional|||Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension||Unknown status|Recruiting|N/A|40||Zhejiang University|||||f||||||||||||||2018-06-01 03:47:41.571682|2018-06-01 03:47:41.571682
NCT00372528|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2012-09-21||2012-09-21|2006-09-06|2006-09-07|Estimate|2012-09-21|2012-10-23|Estimate||||2012-09-21|2012-10-23|Estimate|March 2007||2007-03-31|September 2012|2012-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures|An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164|Terminated||Phase 3|21|Actual|Pfizer|This was a compassionate use study and no formal primary outcome measure was specified a priori. Descriptive safety data were collected, subsequently safety outcome was designated as primary outcome as per National Institute of Health (NIH) criteria.|1||"This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug.~   No efficacy or safety concerns factored into this decision."|f||||f||||||||||2018-06-01 03:47:34.180512|2018-06-01 03:47:34.180512
NCT00372515|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2018-01-29|2006-09-06|2006-09-07|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2006||2006-06-30|January 2018|2018-01-31|April 2015|Actual|2015-04-30|December 2012|Actual|2012-12-31||Interventional|||High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations|Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations|Completed||Phase 1|7|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:47:34.446685|2018-06-01 03:47:34.446685
NCT00372502|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-01-12|2006-09-06|2006-09-07|Estimate|||||||2009-01-12|2009-01-14|Estimate|January 2007||2007-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|LactATES||Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation|Lactate Assessment in the Treatment of Early Sepsis: The LactATES Trial|Completed||N/A|300|Actual|National Institute of General Medical Sciences (NIGMS)||2|||f||||t||||||||||2018-06-01 03:47:34.550869|2018-06-01 03:47:34.550869
NCT00372489|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2012-04-26|2012-03-13|2012-06-22|2006-09-05|2006-09-07|Estimate|2012-04-26|2012-05-28|Estimate|2012-03-13|2012-03-15|Estimate|2012-06-22|2012-06-29|Estimate|September 2006||2006-09-30|June 2012|2012-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD|An Open-Label, Multi-Center, Extension Study to Evaluate the Safety and Tolerability of Peginesatide for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease|Terminated||Phase 2|81|Actual|Affymax|Early termination of study due to generation of controlled long-term data in Phase 3 studies. Amended dosing guidelines during the trial to reflect label changes for ESAs; the primary outcome was assessed after the dosing guideline change.|1||Due to more robust long-term data generated in other active-controlled studies|f||||f||||||||||2018-06-01 03:47:34.913427|2018-06-01 03:47:34.913427
NCT00372476|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2017-02-03|2006-09-06|2006-09-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|June 2006||2006-06-30|February 2017|2017-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|INV181||Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer|Open-label Trial of Imatinib in Combination With Vinorelbine for Patients With Advanced Breast Carcinoma: ICON|Completed||Phase 4|33|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:47:37.114993|2018-06-01 03:47:37.114993
NCT00372463|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2011-07-25|2006-09-06|2006-09-07|Estimate|||||||2011-07-25|2011-07-27|Estimate|February 2006||2006-02-28|July 2011|2011-07-31|December 2007|Actual|2007-12-31|||||Interventional|||Internet Diabetes Self-Management|Internet Diabetes Self-Management: A Randomized Trial|Completed||Phase 2|700|Anticipated|Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 03:47:37.269612|2018-06-01 03:47:37.269612
NCT00372450|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-06|||2009-05-09|2006-09-06|2006-09-07|Estimate|||||||2009-05-09|2009-05-12|Estimate|June 2006||2006-06-30|November 2008|2008-11-30||||June 2008|Anticipated|2008-06-30||Interventional|||Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer|A Quality of Life Comparison in Patients With Malignant Dysphagia Treated With Either Self-Expanding Plastic Stents (SEPS) or Self-Expanding Metal Stents (SEMS)|Unknown status|Active, not recruiting|N/A|90|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:47:37.572034|2018-06-01 03:47:37.572034
NCT00372437|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05||2015-06-04|2015-06-04|2006-09-06|2006-09-07|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|September 2006||2006-09-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine|A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine|Completed||Phase 1/Phase 2|47|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 03:47:37.755142|2018-06-01 03:47:37.755142
NCT00372424|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2012-09-28||2012-12-21|2006-09-05|2006-09-07|Estimate|2012-09-28|2012-10-30|Estimate||||2012-12-21|2012-12-28|Estimate|December 2006||2006-12-31|December 2012|2012-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive|An Explorative Study Of The Tolerability Of SU011248 In Combination With Docetaxel And Trastuzumab As First-Line Treatment In Patients With Breast Cancer Over-Expressing HER-2|Completed||Phase 1|26|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:47:37.87003|2018-06-01 03:47:37.87003
NCT00372411|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2013-09-04||2013-12-18|2006-09-05|2006-09-07|Estimate|2013-12-18|2014-01-13|Estimate||||2013-12-18|2014-01-13|Estimate|December 2005||2005-12-31|December 2013|2013-12-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|VA ROBOTICS||Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients|CSP #558 - Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients|Completed||Phase 2|127|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 03:47:38.767419|2018-06-01 03:47:38.767419
NCT00372398|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2010-09-15|2006-09-05|2006-09-06|Estimate|||||||2010-09-15|2010-09-16|Estimate|October 2006||2006-10-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Premature Coronary Atherosclerosis in Scleroderma|Premature Coronary Atherosclerosis in Scleroderma: A Case Control Study|Completed|||28|Actual|Tuen Mun Hospital|||||f||||t||||||||||2018-06-01 03:47:40.207359|2018-06-01 03:47:40.207359
NCT00372385|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|2011-06-22||2014-06-25|2006-09-01|2006-09-06|Estimate|2011-06-22|2011-07-21|Estimate||||2014-06-25|2014-07-23|Estimate|August 2006||2006-08-31|June 2014|2014-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional||The Full Analysis set included all randomized subjects who received at least 1 dose of study drug.|Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C|A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects With Hepatitis C|Completed||Phase 2|334|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-06-01 03:47:40.28355|2018-06-01 03:47:40.28355
NCT00372372|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2007-09-27|2006-09-05|2006-09-06|Estimate|||||||2007-09-27|2007-09-28|Estimate|January 2004||2004-01-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment||Completed||Phase 4|120||Tuen Mun Hospital|||||f||||t||||||||||2018-06-01 03:47:41.291001|2018-06-01 03:47:41.291001
NCT00372333|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-04|||2009-03-19|2006-09-05|2006-09-06|Estimate|||||||2009-03-19|2009-03-20|Estimate|August 2004||2004-08-31|March 2009|2009-03-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||IDEA-033 Open Label Study|A Multiple-Dose, Open-Label Safety, Compliance, and Usage Evaluation Study of Epicutaneously Applied IDEA-033 in Joint / Musculoskeletal Pain or Soft Tissue Inflammation|Completed||Phase 3|491|Actual|IDEA AG|||||f||||||||||||||2018-06-01 03:47:41.710632|2018-06-01 03:47:41.710632
NCT00372320|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-02|||2018-05-30|2006-09-02|2006-09-06|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 1, 2006||2006-09-01|February 8, 2018|2018-02-08|March 19, 2014|Actual|2014-03-19|March 19, 2014|Actual|2014-03-19||Interventional|||Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer|Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of AdhAQP1, an Adenoviral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction|Completed||Phase 1|17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:47:41.835989|2018-06-01 03:47:41.835989
NCT00372307|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-04|||2007-12-19|2006-09-04|2006-09-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|November 2004|Actual|2004-11-30|||||Interventional|||Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris|Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris|Completed||Phase 2|26||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:47:41.913835|2018-06-01 03:47:41.913835
NCT00372294|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-07-28|2006-09-05|2006-09-06|Estimate|||||||2008-07-28|2008-07-30|Estimate|July 2005||2005-07-31|June 2008|2008-06-30|November 2008|Anticipated|2008-11-30|August 2008|Anticipated|2008-08-31||Interventional|||To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis||Unknown status|Active, not recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:47:42.012683|2018-06-01 03:47:42.012683
NCT00372281|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-04|||2009-02-24|2006-09-04|2006-09-06|Estimate|||||||2009-02-24|2009-02-25|Estimate|March 2007||2007-03-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Cliavist in Infectious and Degenerative Diseases of the Spine|Comparison of Cliavist Enhancement in Infectious and Degenerative Diseases of the Spine|Unknown status|Recruiting|Phase 3|40|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-06-01 03:47:42.092392|2018-06-01 03:47:42.092392
NCT00372268|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2012-04-12|2006-09-05|2006-09-06|Estimate|||||||2012-04-12|2012-04-13|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effects of Insufflated Gas on Core Temperature and Post-operative Pain During Laparoscopic Surgery|Evaluation of the Effects of Conditioning of Insufflated Gas on the Core Temperature and the Post-operative Pain During Laparoscopic Surgery|Completed||N/A|248|Actual|University Hospital, Strasbourg, France||4|||f||||f||||||||||2018-06-01 03:47:42.21112|2018-06-01 03:47:42.21112
NCT00372255|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2016-09-22|2006-09-05|2006-09-06|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2005||2005-11-30|September 2016|2016-09-30|March 2006|Actual|2006-03-31|||||Interventional|||Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years|An Open, Phase IV Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years|Completed||Phase 4|240||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:47:42.374368|2018-06-01 03:47:42.374368
NCT00372242|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-04|||2006-09-04|2006-09-04|2006-09-06|Estimate|||||||2006-09-04|2006-09-06|Estimate|December 2000||2000-12-31|April 2003|2003-04-30|September 2002||2002-09-30|||||Interventional|||Feasible Means to Address Moderately Malnourished Children Within BINP Communities||Completed||N/A|1231||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 03:47:42.493816|2018-06-01 03:47:42.493816
NCT00372229|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2016-11-01|2006-09-05|2006-09-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation|A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration|Completed||Phase 3|301|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:47:42.594148|2018-06-01 03:47:42.594148
NCT00372216|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-04|||2010-11-18|2006-09-04|2006-09-06|Estimate|||||||2010-11-18|2010-11-19|Estimate|October 2006||2006-10-31|November 2010|2010-11-30|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction|CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction|Completed||Phase 3|337|Actual|Stiftung Institut fuer Herzinfarktforschung||2|||f||||t||||||||||2018-06-01 03:47:42.778554|2018-06-01 03:47:42.778554
NCT00372203|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-04|||2017-05-03|2006-09-04|2006-09-06|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2006||2006-07-31|May 2017|2017-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Endobronchial Ultrasound vs Mediastinoscopy in NSCLC|Prospective Controlled Trial of Mediastinoscopy Compared With Endobronchial Ultrasound Guided Transbronchial Needle Aspiration for Assessment of the Mediastinum in Lung Cancer.|Completed||Phase 2|200|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 03:47:42.905035|2018-06-01 03:47:42.905035
NCT00372190|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2016-09-07||2017-04-11|2006-09-05|2006-09-06|Estimate|2017-04-11|2017-07-03|Actual||||2017-04-11|2017-07-03|Actual|August 2006||2006-08-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2009|Actual|2009-12-31||Interventional|||Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse.|A Prospective and Comparative Study of the Performance of Tension Free Vaginal Mesh (Prolift) Versus Conventional Vaginal Prolapse Surgery in Recurrent Prolapse|Completed||N/A|194|Actual|Radboud University||2|||f||||f||||||||No||2018-06-01 03:47:43.051831|2018-06-01 03:47:43.051831
NCT00372177|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-05-26|2006-09-05|2006-09-06|Estimate|||||||2008-05-26|2008-05-28|Estimate|July 2007||2007-07-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis|The Use of Anti-CD4 mAb-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis (an Open Proof of Concept Study)|Completed||Phase 1/Phase 2|5|Actual|Biotectid GmbH||1|||f||||t||||||||||2018-06-01 03:47:43.462363|2018-06-01 03:47:43.462363
NCT00372164|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2015-10-20|2006-09-05|2006-09-06|Estimate|||||||2015-10-20|2015-10-21|Estimate|January 1998||1998-01-31|October 2015|2015-10-31|July 2005||2005-07-31|||||Observational|||Retrospective Evaluation of ASIPP Guidelines Implementation|Evaluation of the Effectiveness of Implementation of American Society of Interventional Pain Physician Guidelines for Interventional Techniques: A Retrospective Evaluation|Withdrawn|||0|Actual|Pain Management Center of Paducah|||||f||||||||||||||2018-06-01 03:47:43.566836|2018-06-01 03:47:43.566836
NCT00372151|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-12-15|2006-09-05|2006-09-06|Estimate|||||||2008-12-15|2008-12-16|Estimate|October 2006||2006-10-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||L-Theanine in the Management of Schizophrenia|The Value of Augmenting L-Theanine in the Management of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 3|60|Actual|Sha’ar Menashe Mental Health Center||2|||f||||t||||||||||2018-06-01 03:47:43.610523|2018-06-01 03:47:43.610523
NCT00372138|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2012-03-01|2006-09-05|2006-09-06|Estimate|||||||2012-03-01|2012-03-02|Estimate|September 2006||2006-09-30|March 2012|2012-03-31|July 2008|Actual|2008-07-31|October 2007|Actual|2007-10-31||Interventional|||Prevention of Endoleaks Using Autologous Platelet Gel on Unruptured Abdominal Aortic Aneurysms|Prevention of Endoleaks Using Autologous Platelet Gel During Endovascular Procedures on Unruptured Abdominal Aortic Aneurysms: Pilot Study|Terminated||N/A|20|Actual|Rennes University Hospital||1|||f||||||||||||||2018-06-01 03:47:43.807075|2018-06-01 03:47:43.807075
NCT00372125|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2016-09-11|2006-09-05|2006-09-06|Estimate|||||||2016-09-11|2016-09-13|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome|Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome|Completed||N/A|46|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-06-01 03:47:43.890375|2018-06-01 03:47:43.890375
NCT00372112|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-04|2017-07-06||2018-03-07|2006-09-04|2006-09-06|Estimate|2017-07-06|2018-02-22|Actual||||2018-03-07|2018-04-02|Actual|November 3, 2006|Actual|2006-11-03|March 2018|2018-03-31|May 10, 2007|Actual|2007-05-10|May 1, 2007|Actual|2007-05-01||Interventional|||A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 2-wk Study to Evaluate the Safety, Tolerability,Pharmacodynamics and Pharmacokinetics of GW642444H(100 Administered Once Daily in the Morning Via DISKUS™ Dry-powder Inhaler)Compared With SEREVENT(Salmeterol)(50mcg Administered Twice Daily Via DISKUS Dry-powder Inhaler)and Placebo in Subject w/COPD|Completed||Phase 2|68|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:47:44.203298|2018-06-01 03:47:44.203298
NCT00372099|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2011-12-22|2006-09-05|2006-09-06|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2007||2007-01-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women|Evaluation of the Effects of Salmon Calcitonin Nasal Spray Compared to Placebo on Bone Microarchitecture Measured by High Resolution Peripheral Micro- Computed-tomography Over 2 Years in Postmenopausal Women (a Pilot Study)|Completed||Phase 3|90|Actual|University Hospital, Geneva|||||f||||||||||||||2018-06-01 03:47:48.058038|2018-06-01 03:47:48.058038
NCT00372086|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-03|||2006-09-03|2006-09-03|2006-09-06|Estimate|||||||2006-09-03|2006-09-06|Estimate|August 2003||2003-08-31|September 2006|2006-09-30|September 2005||2005-09-30|||||Interventional|||Rosiglitazone and Insulin in T1DM Adolescents|The Addition of Rosiglitazone to Insulin in Adolescents With Type 1 Diabetes and Poor Glycaemic Control: a Randomized, Placebo Controlled Trial|Completed||Phase 4|32||The University of New South Wales|||||f||||||||||||||2018-06-01 03:47:48.10782|2018-06-01 03:47:48.10782
NCT00372073|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-03|||2011-11-07|2006-09-05|2006-09-06|Estimate|||||||2011-11-07|2011-11-09|Estimate|July 2006||2006-07-31|November 2011|2011-11-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer|A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer|Terminated||Phase 2|160|Anticipated|Cyclacel Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 03:47:48.16591|2018-06-01 03:47:48.16591
NCT00372060|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|2009-01-27||2017-04-06|2006-09-05|2006-09-06|Estimate|2009-02-27|2009-03-31|Estimate||||2017-04-06|2017-05-12|Actual|August 21, 2006|Actual|2006-08-21|April 2017|2017-04-30|February 5, 2008|Actual|2008-02-05|February 5, 2008|Actual|2008-02-05||Interventional|||MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)|MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone add-on Study for Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|134|Actual|Merck Sharp & Dohme Corp.|Period II (Weeks 12-52) was open-label and uncontrolled, with all patients receiving sitagliptin. Results are pooled data from both treatment groups and should be considered in the context of the Type 2 Diabetes Mellitus (T2DM) population studied.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:47:48.2662|2018-06-01 03:47:48.2662
NCT00372047|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-06-02|2006-09-05|2006-09-06|Estimate|||||||2008-06-02|2008-06-04|Estimate||||June 2008|2008-06-30||||||||Observational|||Evaluation of Excessive UV Irradiation on Skin Aging by Multiphoton Laser Imaging and Biophysical Methods||Unknown status|Not yet recruiting||||University of Jena|||||f||||||||||||||2018-06-01 03:47:48.629627|2018-06-01 03:47:48.629627
NCT00372034|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-03|||2009-04-06|2006-09-05|2006-09-06|Estimate|||||||2009-04-06|2009-04-07|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Effect of Punctal Plugs on Tear Volume and Osmolality||Completed||N/A|20||The University of New South Wales|||||f||||||||||||||2018-06-01 03:47:48.678896|2018-06-01 03:47:48.678896
NCT00372021|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2006-10-11|2006-09-05|2006-09-06|Estimate|||||||2006-10-11|2006-10-12|Estimate|January 2003||2003-01-31|November 2002|2002-11-30||||||||Interventional|||Neurotomy of Optic Nerve in Non-Arthritic Anterior Ischemic Optic Neuropathy||Completed||Phase 1/Phase 2|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:47:48.73152|2018-06-01 03:47:48.73152
NCT00372008|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2008-06-18|2006-09-05|2006-09-06|Estimate|||||||2008-06-18|2008-06-20|Estimate|October 2006||2006-10-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males|A Phase II Randomised, Two-Way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone Following Application of Different Testosterone Metered-Dose (MD) Lotion Doses in Hypogonadal Male Subjects|Completed||Phase 2|40|Anticipated|Acrux DDS Pty Ltd|||||||||||||||||||2018-06-01 03:47:48.775017|2018-06-01 03:47:48.775017
NCT00371995|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-05|||2011-06-21|2006-09-05|2006-09-06|Estimate|||||||2011-06-21|2011-06-22|Estimate|October 2007||2007-10-31|September 2008|2008-09-30|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar|The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India|Completed||Phase 2|150|Anticipated|Banaras Hindu University||1|||f||||||||||||||2018-06-01 03:47:48.894979|2018-06-01 03:47:48.894979
NCT00371982|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2006-09-01|2006-09-01|2006-09-04|Estimate|||||||2006-09-01|2006-09-04|Estimate|December 2002||2002-12-31|November 2002|2002-11-30|April 2005||2005-04-30|||||Interventional|||Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women||Terminated||N/A|24||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:47:48.9623|2018-06-01 03:47:48.9623
NCT00371956|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2010-09-15|2006-09-01|2006-09-04|Estimate|||||||2010-09-15|2010-09-16|Estimate|September 2006||2006-09-30|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy|Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study|Completed||Phase 4|114|Actual|Tuen Mun Hospital||2|||f||||t||||||||||2018-06-01 03:47:49.102252|2018-06-01 03:47:49.102252
NCT00371943|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2006-09-14|2006-09-01|2006-09-04|Estimate|||||||2006-09-14|2006-09-15|Estimate|July 2001||2001-07-31|September 2006|2006-09-30|March 2005||2005-03-31|||||Interventional|||EVL Plus Drug to Prevent Variceal Rebleeding|A Controlled Trial of Ligation Plus Drug Vs. Drug Alone in the Prevention of Variceal Rebleeding|Terminated||Phase 4|120||National Science Council, Taiwan|||||f||||||||||||||2018-06-01 03:47:49.169934|2018-06-01 03:47:49.169934
NCT00371930|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2008-06-02|2006-09-01|2006-09-04|Estimate|||||||2008-06-02|2008-06-04|Estimate||||June 2008|2008-06-30||||||||Interventional|||Photodynamic Therapy for Permanent Hair Removal||Unknown status|Not yet recruiting|Phase 1/Phase 2|||University of Jena|||||f||||||||||||||2018-06-01 03:47:49.220723|2018-06-01 03:47:49.220723
NCT00371904|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2008-05-20|2006-09-01|2006-09-04|Estimate|||||||2008-05-20|2008-05-21|Estimate|April 2006||2006-04-30|May 2008|2008-05-31|January 2009|Anticipated|2009-01-31|||||Interventional|RAPTURE||Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients|"A Prospective Open Label Randomised Multicentre Study Evaluating the Efficacy & Safety of Rituximab Given Pre-Transplant to Sensitised Renal Allograft Recipients in Addition to a Standard Desensitisation Regimen Consisting of PE/IVIG & MMF"|Unknown status|Recruiting|Phase 2|192|Anticipated|Hunter and New England Health||2|||f||||||||||||||2018-06-01 03:47:49.274427|2018-06-01 03:47:49.274427
NCT00371891|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2010-11-24|2006-09-01|2006-09-04|Estimate|||||||2010-11-24|2010-11-25|Estimate|September 2006||2006-09-30|November 2010|2010-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)|The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS)|Completed||Phase 4|168|Actual|St. Joseph's Healthcare Hamilton|||||f||||t||||||||||2018-06-01 03:47:49.364534|2018-06-01 03:47:49.364534
NCT00371878|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2008-08-07|2006-09-01|2006-09-04|Estimate|||||||2008-08-07|2008-08-08|Estimate|February 2003||2003-02-28|September 2006|2006-09-30|October 2003||2003-10-31|||||Interventional|||Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection|Open Label Study of Lung and Serum Immunoglobulin Responses to 7-Valent Pneumococcal Conjugate Vaccine in HIV Infected and Non-HIV Infected Malawian Adults|Completed||Phase 4|40||Royal Liverpool University Hospital|||||f||||||||||||||2018-06-01 03:47:49.425316|2018-06-01 03:47:49.425316
NCT00371865|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2015-02-02||2015-03-26|2006-08-31|2006-09-04|Estimate|2015-03-26|2015-04-10|Estimate||||2015-03-26|2015-04-10|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|||Behavioral Treatments for Chronic Pain|Acceptance-Based Treatment for Chronic Pain|Completed||N/A|114|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:47:49.50054|2018-06-01 03:47:49.50054
NCT00371852|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2008-05-15|2006-08-31|2006-09-04|Estimate|||||||2008-05-15|2008-05-16|Estimate|May 2006||2006-05-31|May 2008|2008-05-31||||||||Interventional|||Topic Compatibility Dermacyd Wipes - Lactoserum - Hygiene|Safety Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensibility) of Dermacyd Wipes|Completed||Phase 3|50||Sanofi|||||f||||||||||||||2018-06-01 03:47:49.983835|2018-06-01 03:47:49.983835
NCT00371839|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2014-11-06||2014-11-19|2006-08-31|2006-09-04|Estimate|2014-11-17|2014-11-19|Estimate||||2014-11-19|2014-12-08|Estimate|September 2006||2006-09-30|November 2014|2014-11-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional||Number of participants who completed the study|Clinical Applications for Time-Compressed Speech Tests|Clinical Applications for Time-Compressed Speech Tests|Completed||N/A|78|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 03:47:50.053249|2018-06-01 03:47:50.053249
NCT00371826|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|2013-06-13||2013-06-13|2006-09-01|2006-09-04|Estimate|2013-06-13|2013-08-19|Estimate||||2013-06-13|2013-08-19|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus|A Prospective, Open-label, Controlled Multicenter Trial to Assess the Efficacy and Safety of an Induction Regimen of Cyclosporine Micro Emulsion, Enteric-coated Mycophenolate Sodium (EC-MPS) and Corticosteroids, Followed by Administration of Everolimus and Enteric-coated Mycophenolate Sodium (EC-MPS), With Either the Withdrawal of Cyclosporine Micro Emulsion or Corticosteroids in de Novo Kidney Transplant Recipients|Completed||Phase 4|126|Actual|Novartis||3|||f||||t||||||||||2018-06-01 03:47:50.373626|2018-06-01 03:47:50.373626
NCT00371813|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2015-04-21|2006-08-31|2006-09-04|Estimate|||||||2015-04-21|2015-04-22|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|June 2007|Actual|2007-06-30|||||Interventional|||An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Multinational Study Of Efficacy And Safety Of Varenicline Tartrate For Smoking Cessation|Completed||Phase 3|334|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:47:52.820167|2018-06-01 03:47:52.820167
NCT00371800|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2006-08-31|2006-08-31|2006-09-04|Estimate|||||||2006-08-31|2006-09-04|Estimate|October 2005||2005-10-31|August 2006|2006-08-31|May 2006||2006-05-31|||||Interventional|||The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes|The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes|Completed||Phase 2/Phase 3|72||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 03:47:52.955949|2018-06-01 03:47:52.955949
NCT00371787|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|2010-11-08||2011-01-05|2006-09-01|2006-09-04|Estimate|2010-11-08|2010-12-13|Estimate||||2011-01-05|2011-01-10|Estimate|August 2006||2006-08-31|January 2011|2011-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of the Performance of Non-molded Soft Contact Lenses|Evaluation of the Performance of Non-molded Soft Contact Lenses|Completed||Phase 3|38|Actual|University of Waterloo||2|||f||||f||||||||||2018-06-01 03:47:53.055592|2018-06-01 03:47:53.055592
NCT00371774|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2011-11-15|2006-09-01|2006-09-04|Estimate|||||||2011-11-15|2011-11-17|Estimate|June 2005||2005-06-30|November 2011|2011-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program|Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program|Completed|||426|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-06-01 03:47:53.3212|2018-06-01 03:47:53.3212
NCT00371436|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2014-11-13||2015-03-24|2006-08-31|2006-09-04|Estimate|2015-03-24|2015-04-08|Estimate||||2015-03-24|2015-04-08|Estimate|September 2008||2008-09-30|March 2015|2015-03-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Progressive Intervention Program for Tinnitus Management|Progressive Intervention Program for Tinnitus Management|Completed||N/A|181|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:48:03.5932|2018-06-01 03:48:03.5932
NCT00371761|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2010-07-15||2017-03-08|2006-08-31|2006-09-04|Estimate|2010-11-18|2010-12-15|Estimate||||2017-03-08|2017-04-06|Actual|September 2006||2006-09-30|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)|An Open-Label, Randomized, Comparative Study With PegIntron vs. Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan|Completed||Phase 3|25|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:47:53.428156|2018-06-01 03:47:53.428156
NCT00371748|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2012-02-01|2006-09-01|2006-09-04|Estimate|||||||2012-02-01|2012-02-02|Estimate|February 2005||2005-02-28|February 2012|2012-02-29|April 2011|Actual|2011-04-30|December 2006|Actual|2006-12-31||Interventional|||A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels|TAXUS ATLAS SMALL VESSEL: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions in Small Vessels|Completed||Phase 3|261|Actual|Boston Scientific Corporation||3|||f||||t||||||||||2018-06-01 03:47:53.70317|2018-06-01 03:47:53.70317
NCT00371735|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2016-12-02|2006-09-01|2006-09-04|Estimate|||||||2016-12-02|2016-12-05|Estimate|April 2006||2006-04-30|December 2016|2016-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria|A Multi-centre, Randomised, Double-blind Study to Compare the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Chlorproguanil-dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults in Africa.|Completed||Phase 3|900|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:47:53.809258|2018-06-01 03:47:53.809258
NCT00371722|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-04-19|2006-09-01|2006-09-04|Estimate|||||||2007-04-19|2007-04-20|Estimate|July 2002||2002-07-31|April 2007|2007-04-30|May 2006|Actual|2006-05-31|||||Interventional|||Appendectomy Versus no Appendectomy With Cesarean Section|A Randomized Controlled Trial Evaluating Appendectomy at the Time of Cesarean Section|Completed||N/A|100||Regional Obstetrical Consultants|||||f||||f||||||||||2018-06-01 03:47:53.995752|2018-06-01 03:47:53.995752
NCT00371709|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2012-02-01|2006-09-01|2006-09-04|Estimate|||||||2012-02-01|2012-02-02|Estimate|August 2004||2004-08-31|February 2012|2012-02-29|March 2010|Actual|2010-03-31|November 2005|Actual|2005-11-30||Interventional|||TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions|TAXUS ATLAS: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions|Completed||Phase 3|871|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 03:47:54.081771|2018-06-01 03:47:54.081771
NCT00371696|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2006-09-01|2006-09-01|2006-09-04|Estimate|||||||2006-09-01|2006-09-04|Estimate|December 2001||2001-12-31|January 2003|2003-01-31|December 2003||2003-12-31|||||Interventional|||Feasibility of n-of-1 Trials - a Pilot Study|Pilot Study of the Feasibility of n-of-1 Trials: the Individualisation of Treatments for Osteoarthritis|Completed||Phase 2|10||University of Bristol|||||f||||||||||||||2018-06-01 03:47:54.237576|2018-06-01 03:47:54.237576
NCT00371683|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|2015-10-23||2015-11-25|2006-09-01|2006-09-04|Estimate|2015-11-25|2015-12-30|Estimate||||2015-11-25|2015-12-30|Estimate|November 2006||2006-11-30|November 2015|2015-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Randomized participants were summarized.|Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery|A Phase 3 Randomized, Double-Blind Active-Controlled (Enoxaparin), Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery|Completed||Phase 3|3608|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 03:47:54.564843|2018-06-01 03:47:54.564843
NCT00371670|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2017-03-24|2006-08-31|2006-09-04|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2004||2004-12-31|March 2017|2017-03-31||||July 2006|Actual|2006-07-31||Interventional|||Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee|A Phase II, 12-month, Double-blind, Placebo-controlled, Dose-finding, Multicenter Study to Evaluate the Safety, Tolerability, and Disease Modifying Efficacy of Daily Oral AAE581 (10, 25 and 50 mg Tablets) in Patients With Painful Knee Osteoarthritis, Kellgren-Lawrence Grade 3 by X-ray|Completed||Phase 2|223|Actual|Novartis|||||f||||||||||||||2018-06-01 03:47:56.586484|2018-06-01 03:47:56.586484
NCT00371657|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-01-31|2006-09-01|2006-09-04|Estimate|||||||2008-01-31|2008-02-04|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Maternal Obesity and Small for Gestational Age Infants|Obesity as a Risk Factor for Small for Gestational Age and Intrauterine Growth Restriction Infants|Completed|||420||Oklahoma State University Center for Health Sciences|||||f||||||||||||||2018-06-01 03:47:56.855666|2018-06-01 03:47:56.855666
NCT00371644|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2014-11-17||2015-01-06|2006-08-31|2006-09-04|Estimate|2014-12-08|2014-12-16|Estimate||||2015-01-06|2015-01-15|Estimate|February 2007||2007-02-28|January 2015|2015-01-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional||Numbers differ from enrollment due to participants excluded from data analysis for poor psychotherapeutic fidelity.|Treatment for Veterans With Military Sexual Trauma|Manualized Treatment for Veterans With Military Sexual Trauma|Completed||N/A|129|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:47:57.119409|2018-06-01 03:47:57.119409
NCT00371631|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2014-11-13||2014-11-20|2006-08-31|2006-09-04|Estimate|2014-11-20|2014-11-24|Estimate||||2014-11-20|2014-11-24|Estimate|October 2006||2006-10-31|November 2014|2014-11-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Colonizing Neurogenic Bladders With Benign Flora|Colonizing Neurogenic Bladders With Benign Flora|Completed||Phase 1|13|Actual|VA Office of Research and Development|Lack of placebo control.|1|||f||||f||||||||||2018-06-01 03:47:57.830465|2018-06-01 03:47:57.830465
NCT00371618|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2015-10-20|2006-09-01|2006-09-04|Estimate|||||||2015-10-20|2015-10-21|Estimate|January 1998||1998-01-31|October 2015|2015-10-31|May 2004||2004-05-31|||||Observational|||IPM Procedures With or Without Fluoroscopy: Outcome Comparison|Comparison of Outcomes of Interventional Pain Management Procedures Performed With or Without Fluoroscopy: A Retrospective Analysis|Withdrawn|||0|Actual|Pain Management Center of Paducah|||||f||||||||||||||2018-06-01 03:47:58.838873|2018-06-01 03:47:58.838873
NCT00371423|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2012-02-01|2006-09-01|2006-09-04|Estimate|||||||2012-02-01|2012-02-02|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|September 2010|Actual|2010-09-30|June 2006|Actual|2006-06-30||Interventional|||Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions|A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Direct Stenting Treatment of Patients With de Novo Coronary Artery Lesions|Completed||Phase 3|247|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 03:48:03.83363|2018-06-01 03:48:03.83363
NCT00371605|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-12-14|2006-08-31|2006-09-04|Estimate|||||||2007-12-14|2007-12-17|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Observational|||An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study|An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study|Terminated|||15|Anticipated|University of Pittsburgh||||Enrolled requested number of patients and completed study. In analysis|f||||||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:47:59.096139|2018-06-01 03:47:59.096139
NCT00371592|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2013-09-20|2006-09-01|2006-09-04|Estimate|||||||2013-09-20|2013-09-23|Estimate|September 2006||2006-09-30|September 2013|2013-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)|A Phase II, Randomized, Double-blind, Placebo-controlled Trial of Acyclovir for the Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viral Load and Mucosal Shedding in HIV-1, Herpes Simplex Virus, Type 2 (HSV-2) Co-Infected Women|Completed||Phase 2|50|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 03:47:59.201022|2018-06-01 03:47:59.201022
NCT00371579|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2015-06-02|2006-09-01|2006-09-04|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|October 2007|Anticipated|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Rosuvastatin for Hepatitis C|Treatment With Rosuvastatin in Patients With Hepatitis C|Withdrawn||N/A|0|Actual|UMC Utrecht||||no actual patients recruited within year 1 after ethical committee approval|f||||||||||||||2018-06-01 03:47:59.418799|2018-06-01 03:47:59.418799
NCT00371566|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2008-12-26||2010-04-01|2006-08-31|2006-09-04|Estimate|2010-01-06|2010-01-29|Estimate||||2010-04-01|2010-04-06|Estimate|March 2006||2006-03-31|April 2010|2010-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer|A Randomized, Single Blinded, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|107|Actual|GlaxoSmithKline||2|||||||||||||||||2018-06-01 03:47:59.585408|2018-06-01 03:47:59.585408
NCT00371553|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2009-07-07|2006-09-01|2006-09-04|Estimate|||||||2009-07-07|2009-07-08|Estimate|November 2006||2006-11-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer|Prospective Open-Labeled Non Randomised Phase-II Study of SU011248 (Sunitinib) in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer - A CUOG / GTCSG Cooperative Phase II Study -|Completed||Phase 2|33|Actual|British Columbia Cancer Agency|||||f||||t||||||||||2018-06-01 03:48:01.705278|2018-06-01 03:48:01.705278
NCT00371540|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2016-08-29||2016-11-01|2006-08-31|2006-09-04|Estimate|2016-08-29|2016-10-26|Estimate||||2016-11-01|2016-12-20|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||HIV infected patients who were clinically stable on ART for at least 3 months|Extending HIV Care Beyond the Rural Health Center|Extending HIV Care Beyond the Rural Health Center|Completed||N/A|208|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 03:48:01.834426|2018-06-01 03:48:01.834426
NCT00371527|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2008-10-16|2006-08-31|2006-09-04|Estimate|||||||2008-10-16|2008-10-17|Estimate|October 2002||2002-10-31|August 2006|2006-08-31|January 2004||2004-01-31|||||Interventional|||Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease|Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease|Completed||N/A|200||Kaiser Permanente|||||f||||||||||||||2018-06-01 03:48:02.172455|2018-06-01 03:48:02.172455
NCT00371501|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2010-09-15|2006-09-01|2006-09-04|Estimate|||||||2010-09-15|2010-09-16|Estimate|June 2006||2006-06-30|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus|Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial|Completed||Phase 4|72|Actual|Tuen Mun Hospital||4|||f||||t||||||||||2018-06-01 03:48:02.277545|2018-06-01 03:48:02.277545
NCT00371488|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2017-11-08|2006-08-31|2006-09-04|Estimate|||||||2017-11-08|2017-11-13|Actual|April 6, 2006|Actual|2006-04-06|November 2017|2017-11-30|December 10, 2007|Actual|2007-12-10|December 10, 2007|Actual|2007-12-10||Interventional|||GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer|Phase I Study of Lapatinib in Combination With Trastuzumab|Completed||Phase 1|11|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:48:02.601181|2018-06-01 03:48:02.601181
NCT00371475|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2012-02-01|2006-09-01|2006-09-04|Estimate|||||||2012-02-01|2012-02-02|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|February 2007|Actual|2007-02-28||Interventional|||A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions|TAXUS ATLAS LONG LESION: A Multi-center, Single-arm Study of the TAXUS Liberté™-SR Stent for the Treatment of Patients With Long de Novo Coronary Artery Lesions|Completed||Phase 3|150|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 03:48:02.763907|2018-06-01 03:48:02.763907
NCT00371462|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2016-05-24||2016-08-08|2006-08-31|2006-09-04|Estimate|2016-08-08|2016-10-07|Estimate||||2016-08-08|2016-10-07|Estimate|October 2007||2007-10-31|August 2016|2016-08-31|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Interventional|PDA+|One subject withdrew from the study.|PDA+: A Personal Digital Assistant for Obesity Treatment|PDA+: A Personal Digital Assistant for Obesity Treatment|Terminated||N/A|70|Actual|VA Office of Research and Development||2||"PI no longer has an appointment and has seperated from Hines VAH and project was not~   transferred to another PI?"|f||||||||||||||2018-06-01 03:48:02.879927|2018-06-01 03:48:02.879927
NCT00371449|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|2015-02-18||2015-04-08|2006-09-01|2006-09-04|Estimate|2015-03-19|2015-04-02|Estimate||||2015-04-08|2015-04-29|Estimate|November 2006||2006-11-30|April 2015|2015-04-30|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Observational|||Predicting Success With Hearing Aids|Speech-in-Noise Measures as a Predictor of Hearing Aid Outcomes|Completed|||120|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 03:48:03.296733|2018-06-01 03:48:03.296733
NCT00371410|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2006-08-31|2006-08-31|2006-09-04|Estimate|||||||2006-08-31|2006-09-04|Estimate|April 2005||2005-04-30|August 2006|2006-08-31|October 2007||2007-10-31|||||Interventional|||Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema|The Safety and the Efficacy of Combined Vitrectomy, Intravitreal Triamcinolone Acetonide and Macular Focal Laser Photocoagulation for the Treatment of Intractable Diffuse Diabetic Macular Edema|Completed||Phase 1|||Samsung Medical Center|||||f||||||||||||||2018-06-01 03:48:03.97297|2018-06-01 03:48:03.97297
NCT00371397|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2009-09-16||2016-06-06|2006-08-31|2006-09-04|Estimate|2011-06-07|2011-07-06|Estimate||||2016-06-06|2016-07-06|Estimate|September 2005||2005-09-30|June 2016|2016-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Yoga, Immune Function, and Health|Psychoneuroimmunology and Mind-Body Interventions|Completed||N/A|52|Actual|Ohio State University||3|||f||||t||||||||||2018-06-01 03:48:04.067374|2018-06-01 03:48:04.067374
NCT00371384|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2017-10-11|2006-08-31|2006-09-04|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2006||2006-08-31|October 2017|2017-10-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Effect of Massage on Chronic Low Back Pain|Effect of Massage on Chronic Low Back Pain|Completed||Phase 2/Phase 3|399|Anticipated|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 03:48:04.383586|2018-06-01 03:48:04.383586
NCT00371371|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2012-12-12|2006-09-01|2006-09-04|Estimate|||||||2012-12-12|2012-12-13|Estimate|September 2006||2006-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|JUVENTAS||Intra-arterial Stem Cell Therapy for Patients With Chronic Limb Ischemia (CLI)|Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial|Completed||Phase 1/Phase 2|160|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 03:48:04.466565|2018-06-01 03:48:04.466565
NCT00371345|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|2010-10-06||2011-04-21|2006-09-01|2006-09-04|Estimate|2010-10-07|2010-11-05|Estimate||||2011-04-21|2011-04-26|Estimate|December 2006||2006-12-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer|Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer|Completed||Phase 2|92|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:48:04.598442|2018-06-01 03:48:04.598442
NCT00371332|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2006-09-22|2006-09-01|2006-09-04|Estimate|||||||2006-09-22|2006-09-25|Estimate|January 2004||2004-01-31|September 2006|2006-09-30||||||||Interventional|||Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis||Completed||Phase 3|128||OraPharma|||||||||||||||||||2018-06-01 03:48:05.460555|2018-06-01 03:48:05.460555
NCT00371319|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2014-07-01|2006-09-01|2006-09-04|Estimate|||||||2014-07-01|2014-07-02|Estimate|September 2005||2005-09-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis|To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis|Completed||Phase 4|150|Actual|Tuen Mun Hospital||2|||f||||t||||||||||2018-06-01 03:48:05.535169|2018-06-01 03:48:05.535169
NCT00371306|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2007-04-19|2006-09-01|2006-09-04|Estimate|||||||2007-04-19|2007-04-20|Estimate|September 2002||2002-09-30|April 2007|2007-04-30|September 2008|Anticipated|2008-09-30|||||Interventional|||Comparison of Glucovance to Insulin for Diabetes During Pregnancy|A Comparison of Glucovance (Glyburide and Metformin) to Insulin Therapy for the Treatment of Gestational Diabetes and Adult Onset Diabetes in Pregnancy|Unknown status|Recruiting|N/A|200||Regional Obstetrical Consultants|||||f||||f||||||||||2018-06-01 03:48:05.634701|2018-06-01 03:48:05.634701
NCT00371293|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|2014-12-04||2017-02-18|2006-09-01|2006-09-04|Estimate|2017-02-18|2017-04-05|Actual||||2017-02-18|2017-04-05|Actual|September 2006||2006-09-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Interventional|||The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease|Inflammatory Response to Sleep Apnea in Obese Subjects: The Cardiovascular Effects of Obstructive Sleep Apnea (COSA) Study|Completed||N/A|181|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 03:48:05.869321|2018-06-01 03:48:05.869321
NCT00371280|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|||2010-05-10|2006-09-01|2006-09-04|Estimate|||||||2010-05-10|2010-05-12|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|November 2006|Anticipated|2006-11-30|October 2006|Anticipated|2006-10-31||Interventional|||Prosthetic Motility and Complications in Pegged Versus Unpegged Hydroxyapatite Orbital Implants||Unknown status|Active, not recruiting|Phase 2/Phase 3|50|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-06-01 03:48:06.51367|2018-06-01 03:48:06.51367
NCT00371267|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2014-10-24||2014-10-29|2006-08-31|2006-09-04|Estimate|2014-10-29|2014-11-06|Estimate||||2014-10-29|2014-11-06|Estimate|October 2006||2006-10-31|October 2014|2014-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Telephone-Delivered Cognitive Behavior Therapy for Chronic Pain|Telephone-Delivered Cognitive Behavior Therapy for Chronic Pain|Completed||N/A|101|Actual|VA Office of Research and Development|The fact that the study was conducted in California may have posed some threat to external validity when applying these findings to the nationwide VA system.|2|||f||||t||||||||||2018-06-01 03:48:06.609337|2018-06-01 03:48:06.609337
NCT00371254|ClinicalTrials.gov processed this data on May 31, 2018|2006-09-01|2010-10-07||2011-02-18|2006-09-01|2006-09-04|Estimate|2011-02-18|2011-03-15|Estimate||||2011-02-18|2011-03-15|Estimate|December 2006||2006-12-31|February 2011|2011-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer|Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer|Completed||Phase 2|55|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:48:06.998369|2018-06-01 03:48:06.998369
NCT00371241|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2007-12-03|2006-09-01|2006-09-04|Estimate|||||||2007-12-03|2007-12-06|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Observational|||Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO|Antibody Secreting Cell (ASC) and Immunoactive Protein Profiles in Neonates on Extracorporeal Membrane Oxygenation (ECMO)|Completed|||12|Actual|The University of Texas Health Science Center, Houston|||||f||||t||||||Samples With DNA|"~     Plasma and whole blood~   "|||2018-06-01 03:48:08.827496|2018-06-01 03:48:08.827496
NCT00371228|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-05-16|2006-08-31|2006-09-01|Estimate|||||||2008-05-16|2008-05-19|Estimate|September 2006||2006-09-30|May 2008|2008-05-31||||June 2009|Anticipated|2009-06-30||Interventional|||Timing of Cord Clamping and Neonatal Hemoglobin|Delayed Versus Immediate Cord Clamping and Changes in Neonatal Hemoglobin|Withdrawn||N/A|150|Anticipated|Oklahoma State University Center for Health Sciences||2||PI left university|f||||f||||||||||2018-06-01 03:48:08.885047|2018-06-01 03:48:08.885047
NCT00371215|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2009-03-06|2006-08-30|2006-09-01|Estimate|||||||2009-03-06|2009-03-09|Estimate|August 2006||2006-08-31|March 2009|2009-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of Recombinant Human Thrombin for Bleeding During Autologous Skin Grafting|A Phase 2 Study of Recombinant Human Thrombin (rThrombin) Administered Using a Spray Applicator in Subjects Undergoing Autologous Skin Grafting Following Burn or Traumatic Skin Injury|Completed||Phase 2|72|Actual|ZymoGenetics||1|||f||||t||||||||||2018-06-01 03:48:08.95884|2018-06-01 03:48:08.95884
NCT00371189|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2014-09-18|2006-08-31|2006-09-01|Estimate|||||||2014-09-18|2014-09-22|Estimate|January 2007||2007-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Adenovirus Vaccine for Malaria|A Phase I Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age|Completed||Phase 1|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 03:48:09.108981|2018-06-01 03:48:09.108981
NCT00371176|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|2013-08-30||2013-12-16|2006-08-31|2006-09-01|Estimate|2013-12-16|2014-02-04|Estimate||||2013-12-16|2014-02-04|Estimate|October 2006||2006-10-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Interventional|||A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD|A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD|Completed||N/A|26|Actual|VA Office of Research and Development|The study experienced sustained recruitment difficulties, ultimately recruiting a smaller number of participants (N=26) than originally projected (N=68).|2|||f||||t||||||||||2018-06-01 03:48:09.202332|2018-06-01 03:48:09.202332
NCT00371163|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2015-04-20|2006-08-31|2006-09-01|Estimate|||||||2015-04-20|2015-04-22|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|Spongiotic||Molecular and Cellular Characterization of Spongiotic Dermatitis|Molecular and Cellular Characterization of Spongiotic Dermatitis|Completed|||31|Actual|University of California, Davis|||4||f||||f||||||||||2018-06-01 03:48:10.375857|2018-06-01 03:48:10.375857
NCT00371150|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2012-03-22||2012-03-22|2006-08-31|2006-09-01|Estimate|2012-03-22|2012-04-16|Estimate||||2012-03-22|2012-04-16|Estimate|November 2006||2006-11-30|March 2012|2012-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection|A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive|Completed||Phase 4|131|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:48:10.493256|2018-06-01 03:48:10.493256
NCT00371137|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|2011-09-08||2011-12-21|2006-08-31|2006-09-01|Estimate|2011-10-24|2011-11-30|Estimate||||2011-12-21|2011-12-29|Estimate|August 2006||2006-08-31|December 2011|2011-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia|Completed||Phase 3|548|Actual|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:48:11.435083|2018-06-01 03:48:11.435083
NCT00371124|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2010-08-30|2006-08-30|2006-09-01|Estimate|||||||2010-08-30|2010-08-31|Estimate|March 2006||2006-03-31|May 2010|2010-05-31||||||||Interventional|||Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children|A Randomised, Double-Masked Study to Compare The Safety and Efficacy of Bilateral 0.5%, 0.1% & 0.01% Atropine Treatment In Controlling Progression of Myopia In Children|Unknown status|Active, not recruiting|Phase 2/Phase 3|400|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:48:12.102178|2018-06-01 03:48:12.102178
NCT00371111|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2008-07-28|2006-08-31|2006-09-01|Estimate|||||||2008-07-28|2008-07-30|Estimate|August 2006||2006-08-31|July 2008|2008-07-31|September 2008|Anticipated|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema||Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:48:12.167498|2018-06-01 03:48:12.167498
NCT00371098|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-10-21|2006-08-31|2006-09-01|Estimate|||||||2007-10-21|2007-10-23|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study|Prospective, Randomized, Double-Blind Placebo Controlled Study on Influenza Vaccination in Prevention From Coronary Events in Patients With Coronary Artery Disease Confirmed by Angiography|Completed||Phase 2/Phase 3|658|Actual|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-06-01 03:48:12.332858|2018-06-01 03:48:12.332858
NCT00371085|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2011-09-22|2006-08-31|2006-09-01|Estimate|||||||2011-09-22|2011-09-23|Estimate|October 2004||2004-10-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|COPE||Congestive Heart Failure Outreach Program|Congestive Heart Failure Outreach Program (The COPE Study)|Completed||Phase 4|539|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 03:48:12.41223|2018-06-01 03:48:12.41223
NCT00371072|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2006-10-06|2006-08-31|2006-09-01|Estimate|||||||2006-10-06|2006-10-09|Estimate|March 2004||2004-03-31|July 2003|2003-07-31|November 2005||2005-11-30|||||Interventional|||Trabeculectomy With MMC Versus Ahmed Glaucoma Implant for Treatment of Pediatric Aphakic Glaucoma||Completed||Phase 2/Phase 3|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:12.49153|2018-06-01 03:48:12.49153
NCT00371059|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-05-07|2006-08-30|2006-09-01|Estimate|||||||2008-05-07|2008-05-09|Estimate|September 2007||2007-09-30|May 2008|2008-05-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|MAGD||Memantine for Agitation in Dementia|Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia|Unknown status|Recruiting|Phase 4|164|Anticipated|East Kent Hospitals University NHS Foundation Trust|||||f||||t||||||||||2018-06-01 03:48:12.555975|2018-06-01 03:48:12.555975
NCT00371046|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-03-01|2006-08-31|2006-09-01|Estimate|||||||2007-03-01|2007-03-02|Estimate|October 2003||2003-10-31|March 2007|2007-03-31|December 2006||2006-12-31|||||Interventional|||Does Fetal Fibronectin and Ultrasound Cervical Length Help in the Evaluation of Women With Suspected Preterm Labor?|The Use of Fetal Fibronectin and Transvaginal Ultrasound Cervical Length in Women With Threatened Preterm Labor:A Randomized Trial|Completed||N/A|100||Thomas Jefferson University|||||f||||t||||||||||2018-06-01 03:48:12.644681|2018-06-01 03:48:12.644681
NCT00371033|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2011-03-15|2006-08-31|2006-09-01|Estimate|||||||2011-03-15|2011-03-16|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|April 2008|Anticipated|2008-04-30|January 2008|Actual|2008-01-31||Interventional|CPCRN RCT#2||Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|Unknown status|Active, not recruiting|Phase 3|318|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||||||||||||2018-06-01 03:48:12.717465|2018-06-01 03:48:12.717465
NCT00371020|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-07-11|2006-08-31|2006-09-01|Estimate|||||||2007-07-11|2007-07-12|Estimate|February 2005||2005-02-28|July 2007|2007-07-31|July 2007|Anticipated|2007-07-31|||||Interventional|||The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR||Unknown status|Active, not recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:12.79875|2018-06-01 03:48:12.79875
NCT00371007|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2017-03-31|2006-08-31|2006-09-01|Estimate|||||||2017-03-31|2017-04-04|Actual|June 1, 2004|Actual|2004-06-01|March 2017|2017-03-31|April 25, 2005|Actual|2005-04-25|April 25, 2005|Actual|2005-04-25||Interventional|||MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)|MK0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus|Completed||Phase 2|126||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:48:12.869679|2018-06-01 03:48:12.869679
NCT00370994|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|2012-03-21||2015-10-20|2006-08-30|2006-09-01|Estimate|2015-10-20|2015-11-23|Estimate||||2015-10-20|2015-11-23|Estimate|January 2006||2006-01-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|December 2009|Actual|2009-12-31||Interventional|||Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Neurolysis on Low Back Pain|A Randomized, Prospective, Double-blind Controlled Evaluation of the Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Hypertonic Saline Neurolysis|Completed||N/A|120|Actual|Pain Management Center of Paducah|The results of this study are limited by potentially inadequate double blinding, by the lack of a placebo group.|2|||f||||t||||||||||2018-06-01 03:48:12.966987|2018-06-01 03:48:12.966987
NCT00370981|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30||2013-12-03|2013-12-03|2006-08-30|2006-09-01|Estimate||||2013-12-03|2013-12-27|Estimate|2013-12-03|2013-12-27|Estimate|July 2006||2006-07-31|February 2007|2007-02-28|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Interventional|||Exploratory Study of Pagoclone in Men With Premature Ejaculation.|A Four-arm, Randomized, Double-blind, Parallel, Placebo-controlled Exploratory Study of Pagoclone 0.15mg, 0.30mg, and 0.60mg in Men With Primary Premature Ejaculation.|Completed||Phase 2|100||Endo Pharmaceuticals||4|||f||||f||||||||||2018-06-01 03:48:13.265662|2018-06-01 03:48:13.265662
NCT00370968|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2010-05-12|2006-08-31|2006-09-01|Estimate|||||||2010-05-12|2010-05-13|Estimate|September 2003||2003-09-30|May 2010|2010-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Zinc-ORS in Severe and Complicated Acute Diarrhea|Extended Studies on Safety and Efficacy of Zinc-ORS Compared to ORS Alone in Hospitalized Children With Severe and Complicated Acute Diarrhea|Completed||Phase 2/Phase 3|352||Centre For International Health|||||f||||f||||||||||2018-06-01 03:48:13.36598|2018-06-01 03:48:13.36598
NCT00370955|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2009-12-24|2006-08-31|2006-09-01|Estimate|||||||2009-12-24|2009-12-25|Estimate|March 2007||2007-03-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||The Effect of Hydrodynamic Parameters on Corneal Endothelial Cell Loss After Phacoemulsification|The Effect of Hydrodynamic Parameters on Corneal Endothelial Cell Loss After Phacoemulsification|Completed||N/A|60|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-06-01 03:48:13.448667|2018-06-01 03:48:13.448667
NCT00370942|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2017-03-22|2006-08-30|2006-09-01|Estimate|||||||2017-03-22|2017-03-24|Actual|April 2006||2006-04-30|March 2017|2017-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||GW823093C For The Treatment Of Type 2 Diabetes Mellitus|GW823093 Japan Phase IIa Mono|Terminated||Phase 2|159|Actual|GlaxoSmithKline||3||Safety issue|f||||||||||||||2018-06-01 03:48:13.521007|2018-06-01 03:48:13.521007
NCT00370929|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2016-07-20|2006-08-30|2006-09-01|Estimate|||||||2016-07-20|2016-07-22|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of Meditation as a Treatment for Epilepsy|Treatment of Epilepsy by Meditation and Cultivation of Emotional Balance|Completed||N/A|8|Actual|University of California, Los Angeles||1|||f||||f||||||||No||2018-06-01 03:48:13.591307|2018-06-01 03:48:13.591307
NCT00370916|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2015-04-06|2006-08-30|2006-09-01|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2005||2005-10-31|December 2010|2010-12-31|September 2010|Actual|2010-09-30|March 2006|Actual|2006-03-31||Interventional|||Reducing Transition Drug Risk|Reducing Transition Drug Risks After Patient Transfer|Completed||N/A|612|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 03:48:13.658696|2018-06-01 03:48:13.658696
NCT00370903|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-01-31|2006-08-31|2006-09-01|Estimate|||||||2008-01-31|2008-02-04|Estimate|August 2006||2006-08-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Postpartum Depression and Cesarean Section|Retrospective Study of Relationship of Postpartum Depression to Planned Versus Emergent Cesarean Section|Completed|||200||Oklahoma State University Center for Health Sciences|||||f||||||||||||||2018-06-01 03:48:13.729241|2018-06-01 03:48:13.729241
NCT00370890|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2018-04-20|2006-08-30|2006-09-01|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2006||2006-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy|A Multi-center Prospective Randomized Phase III Trial to Determine the Benefit of Adjuvant Chemotherapy Using Gemcitabine and Cisplatin in Nasopharyngeal Carcinoma Patients With Residual EBV DNA Following Primary Radiotherapy With or Without Concurrent Cisplatin|Active, not recruiting||Phase 3|150|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 03:48:13.792848|2018-06-01 03:48:13.792848
NCT00370877|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2015-03-26|2006-08-30|2006-09-01|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2007||2007-04-30|March 2015|2015-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||rhuFVIIa in Post-partum Hemorrhage|Recombinant Human Activated Factor VII as Salvage Therapy in Women With Severe Postpartum Hemorrhage|Completed||Phase 4|84|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-06-01 03:48:13.891178|2018-06-01 03:48:13.891178
NCT00370864|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2016-07-17|2006-08-31|2006-09-01|Estimate|||||||2016-07-17|2016-07-19|Estimate|September 2006||2006-09-30|November 2008|2008-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Study of a Pandemic Influenza Vaccine in Children|Phase II Study of a Pandemic Influenza Vaccine in Children|Completed||Phase 2|220|Anticipated|Seqirus|||||f||||||||||||||2018-06-01 03:48:14.067873|2018-06-01 03:48:14.067873
NCT00370851|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2009-11-23|2006-08-31|2006-09-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|August 2006||2006-08-31|November 2009|2009-11-30|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial|Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial|Completed||Phase 3|82|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:48:14.141611|2018-06-01 03:48:14.141611
NCT00370838|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|2011-06-22||2011-09-01|2006-08-30|2006-09-01|Estimate|2011-09-01|2011-09-07|Estimate||||2011-09-01|2011-09-07|Estimate|February 2007||2007-02-28|September 2011|2011-09-30|June 2009|Actual|2009-06-30|July 2008|Actual|2008-07-31||Interventional|||Comparison of Keppra and Clonidine in the Treatment of Tics|Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome|Completed||Phase 4|12|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:48:14.231216|2018-06-01 03:48:14.231216
NCT00370825|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2008-09-11|2006-08-31|2006-09-01|Estimate|||||||2008-09-11|2008-09-12|Estimate|September 2006||2006-09-30|September 2008|2008-09-30||||||||Interventional|||Combination Chemotherapy for the Treatment of Indian Kala-Azar|Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study|Completed||Phase 2|200||Banaras Hindu University|||||f||||||||||||||2018-06-01 03:48:14.597196|2018-06-01 03:48:14.597196
NCT00370812|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2008-09-23|2006-08-31|2006-09-01|Estimate|||||||2008-09-23|2008-09-25|Estimate|July 2006||2006-07-31|September 2008|2008-09-30|January 2009|Anticipated|2009-01-31|December 2008|Anticipated|2008-12-31||Interventional|||The Role of Amniotic Membrane Transplantation in Ocular Chemical Burns||Unknown status|Recruiting|Phase 2/Phase 3|90|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:48:14.664929|2018-06-01 03:48:14.664929
NCT00370799|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2013-08-14|2006-08-30|2006-09-01|Estimate|||||||2013-08-14|2013-08-16|Estimate|January 2007||2007-01-31|August 2013|2013-08-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Effectiveness of Caudal Epidural Injections in Treatment of Chronic Low Back and Lower Extremity Pain|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Caudal Epidural Injections in Lumbar Disc Herniations, Spinal Stenosis, Discogenic Pain, and Post-Lumbar Laminectomy Syndrome|Completed||Early Phase 1|240|Actual|Pain Management Center of Paducah||4|||f||||t||||||||||2018-06-01 03:48:14.745034|2018-06-01 03:48:14.745034
NCT00370786|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-07-09|2006-08-30|2006-09-01|Estimate|||||||2008-07-09|2008-07-11|Estimate|November 2005||2005-11-30|July 2008|2008-07-31|February 2008|Actual|2008-02-29|November 2007|Actual|2007-11-30||Interventional|||Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)||Completed||Phase 3|31|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||||||||||||2018-06-01 03:48:14.831788|2018-06-01 03:48:14.831788
NCT00370773|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-09-04|2006-08-30|2006-09-01|Estimate|||||||2008-09-04|2008-09-05|Estimate|January 2006||2006-01-31|August 2008|2008-08-31|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|||Comparison of Intraspinal Nerve Root Stimulation With Dorsal Column Stimulation|Treatment of Chronic Low Back Pain With Spinal Cord Stimulation: Comparison of Subthreshold Intraspinal Nerve Root Stimulation With Subthreshold and Suprathreshold Dorsal Column Stimulation and a Secondary Study of the Effect of Pulse Width|Terminated||Phase 4|4|Actual|Boston Scientific Corporation||||Slow Enrolling|f||||f||||||||||2018-06-01 03:48:14.900337|2018-06-01 03:48:14.900337
NCT00370760|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-06-25|2006-08-30|2006-09-01|Estimate|||||||2008-06-25|2008-06-26|Estimate|September 2006||2006-09-30|June 2008|2008-06-30||||||||Interventional|||Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)||Unknown status|Recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:48:14.973627|2018-06-01 03:48:14.973627
NCT00370747|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2013-03-13|2006-08-30|2006-09-01|Estimate|||||||2013-03-13|2013-03-15|Estimate|September 2006||2006-09-30|March 2013|2013-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome|Efficacy and Safety of Ecabet Ophthalmic Solution for the Treatment of Dry Eye Syndrome|Completed||Phase 2|162||Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:48:15.062644|2018-06-01 03:48:15.062644
NCT00370734|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-02-26|2006-08-31|2006-09-01|Estimate|||||||2007-02-26|2007-02-27|Estimate|May 2005||2005-05-31|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease||Unknown status|Recruiting|Phase 2/Phase 3|50||Shahid Beheshti University of Medical Sciences|||||f||||t||||||||||2018-06-01 03:48:15.130584|2018-06-01 03:48:15.130584
NCT00370721|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-06-25|2006-08-30|2006-09-01|Estimate|||||||2008-06-25|2008-06-26|Estimate|March 2006||2006-03-31|June 2008|2008-06-30||||||||Interventional|||Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)||Unknown status|Recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences||1|||f||||||||||||||2018-06-01 03:48:15.19109|2018-06-01 03:48:15.19109
NCT00370708|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2006-09-06|2006-08-31|2006-09-01|Estimate|||||||2006-09-06|2006-09-07|Estimate|April 2003||2003-04-30|April 2004|2004-04-30|February 2004||2004-02-29|||||Interventional|||Early Oral Intake Following Cesarean Surgery|Early Oral Intake Following Elective Cesarean Surgery in Iranian Women; the Economic Burdens and Patient Satisfaction|Completed||N/A|||Tehran University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:15.258933|2018-06-01 03:48:15.258933
NCT00370695|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2013-08-01|2006-08-30|2006-09-01|Estimate|||||||2013-08-01|2013-08-05|Estimate|February 2006||2006-02-28|August 2013|2013-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Spinal Cord Stimulation for Chronic and Intractable Back Pain|Spinal Cord Stimulation for Chronic and Intractable Back Pain in Patients Who Are Not Surgical Candidates|Terminated||Phase 4|15|Actual|Boston Scientific Corporation||1||Insufficient Data Collected|f||||f||||||||||2018-06-01 03:48:15.31808|2018-06-01 03:48:15.31808
NCT00370682|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|2017-03-08|2015-06-08|2017-05-23|2006-08-30|2006-09-01|Estimate|2017-05-23|2017-05-30|Actual|2015-06-08|2015-07-07|Estimate|2017-05-23|2017-05-30|Actual|April 2007||2007-04-30|May 2017|2017-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand|Phase II, Randomized, Double-blind, Single Center, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults|Completed||Phase 2|120|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f|t|f||||||Yes|GSK|2018-06-01 03:48:15.45528|2018-06-01 03:48:15.45528
NCT00370669|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2007-02-21|2006-08-30|2006-09-01|Estimate|||||||2007-02-21|2007-02-22|Estimate|November 2005||2005-11-30|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema||Unknown status|Recruiting|Phase 3|150||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:16.811168|2018-06-01 03:48:16.811168
NCT00370656|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2009-11-16|2006-08-31|2006-09-01|Estimate|||||||2009-11-16|2009-11-17|Estimate|February 2007||2007-02-28|November 2009|2009-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep|A Double-blind, Randomised, Parallel Groups Investigation Into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering From Diabetic Peripheral Neuropathy|Completed||Phase 2/Phase 3|90|Anticipated|University of Surrey|||||f||||||||||||||2018-06-01 03:48:16.887808|2018-06-01 03:48:16.887808
NCT00370643|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2009-02-18|2006-08-30|2006-09-01|Estimate|||||||2009-02-18|2009-02-19|Estimate|October 2002||2002-10-31|February 2009|2009-02-28|November 2004||2004-11-30|||||Interventional|||Glucose Control in Open Heart Surgery|Intensive Glucose Control Versus Conventional:Tendency Of Better Clinical Outcome In Open Heart Surgery|Completed||Phase 1|98||University of Sao Paulo|||||f||||||||||||||2018-06-01 03:48:16.96487|2018-06-01 03:48:16.96487
NCT00370630|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-31|||2007-02-20|2006-08-31|2006-09-01|Estimate|||||||2007-02-20|2007-02-21|Estimate|August 2006||2006-08-31|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO)||Unknown status|Recruiting|Phase 2|15||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:17.063441|2018-06-01 03:48:17.063441
NCT00370617|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2006-11-13|2006-08-30|2006-08-31|Estimate|||||||2006-11-13|2006-11-14|Estimate|September 2006||2006-09-30|November 2006|2006-11-30|January 2009||2009-01-31|||||Interventional|||Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance|An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance|Unknown status|Recruiting|Phase 4|200||University of Turin, Italy|||||f||||||||||||||2018-06-01 03:48:17.131219|2018-06-01 03:48:17.131219
NCT00370604|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2015-06-19|2006-08-30|2006-08-31|Estimate|||||||2015-06-19|2015-06-23|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Small Versus Large Epidural Needles on Postdural Puncture Headache Study|Randomized Controlled Trial Examining the Effect of Small Versus Large Tuohy-type Epidural Needles on the Incidence and Severity of Postdural Puncture Headache|Completed||N/A|1081|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 03:48:17.212639|2018-06-01 03:48:17.212639
NCT00370591|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2016-09-13|2006-08-30|2006-08-31|Estimate|||||||2016-09-13|2016-09-15|Estimate|December 2002||2002-12-31|September 2016|2016-09-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.|Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50/100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily|Completed||Phase 4|48|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:48:17.301802|2018-06-01 03:48:17.301802
NCT00370578|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2007-08-27|2006-08-30|2006-08-31|Estimate|||||||2007-08-27|2007-08-28|Estimate|September 2006||2006-09-30|August 2006|2006-08-31|June 2008|Anticipated|2008-06-30|||||Interventional|||Aspiration Device in Myocardial Infarction Trial|Aspiration Device Myocardial Infarction Trial|Unknown status|Recruiting|N/A|100|Anticipated|HaEmek Medical Center, Israel|||||f||||t||||||||||2018-06-01 03:48:17.384134|2018-06-01 03:48:17.384134
NCT00370565|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2007-02-09|2006-08-29|2006-08-31|Estimate|||||||2007-02-09|2007-02-13|Estimate|June 1999||1999-06-30|February 2007|2007-02-28|September 2000||2000-09-30|||||Interventional|||Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.|Efficacy And Safety Of Exubera (Inhaled Insulin) Therapy In Subjects With Type 2 Diabetes Mellitus Not Well Controlled With Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial.|Completed||Phase 3|345||Pfizer|||||||||||||||||||2018-06-01 03:48:17.46381|2018-06-01 03:48:17.46381
NCT00370552|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|2011-03-24||2016-02-09|2006-08-30|2006-08-31|Estimate|2011-03-24|2011-04-14|Estimate||||2016-02-09|2016-03-10|Estimate|March 2007||2007-03-31|February 2016|2016-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer|A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 2|136|Actual|R-Pharm||3|||f||||f||||||||||2018-06-01 03:48:17.648596|2018-06-01 03:48:17.648596
NCT00370539|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2006-11-13|2006-08-30|2006-08-31|Estimate|||||||2006-11-13|2006-11-14|Estimate|September 2006||2006-09-30|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD||Unknown status|Recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:18.742946|2018-06-01 03:48:18.742946
NCT00370526|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2008-01-02|2006-08-30|2006-08-31|Estimate|||||||2008-01-02|2008-01-11|Estimate|February 2007||2007-02-28|January 2008|2008-01-31|December 2007|Actual|2007-12-31|April 2007|Actual|2007-04-30||Interventional|||HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study|HEmodynamic Assessment of Optimal Left Heart Lead Placement for Heart Failure Enabled by Magnetic Navigation|Terminated||Phase 4|100|Anticipated|Stereotaxis||||Insufficient enrollment|f||||t||||||||||2018-06-01 03:48:18.809142|2018-06-01 03:48:18.809142
NCT00370513|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2017-11-13|2006-08-29|2006-08-31|Estimate|||||||2017-11-13|2017-11-17|Actual|December 6, 2006|Actual|2006-12-06|November 2017|2017-11-30|April 8, 2009|Actual|2009-04-08|April 8, 2009|Actual|2009-04-08||Interventional|||A Phase I Study of Pazopanib in Adult Patients With Liver Cancer|A Phase I, Open-Label, Dose-Escalation, Multi-Center Study or Pazopanib (GW786034) in Adult Patients With Hepatocellular Cancer|Completed||Phase 1|28|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:48:18.885159|2018-06-01 03:48:18.885159
NCT00370500|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-07-09|2006-08-30|2006-08-31|Estimate|||||||2008-07-09|2008-07-11|Estimate|April 2007||2007-04-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Quetiapine and the Dopaminergic Epigenetic Control|Quetiapine and the Dopaminergic Epigenetic Control - a Pilot Study|Completed||Phase 4|100|Actual|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-06-01 03:48:18.953455|2018-06-01 03:48:18.953455
NCT00370487|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2006-09-05|2006-08-30|2006-08-31|Estimate|||||||2006-09-05|2006-09-06|Estimate|September 2003||2003-09-30|June 2005|2005-06-30|June 2004||2004-06-30|||||Observational|||Comparison of the Safety of First Trimester Abortions Performed by Physicians and Non-Physicians in South Africa and Viet Nam.|Complication Rates of First-Trimester Manual Vacuum Aspiration Abortion Performed by Physicians and Midlevel Providers (MLP) in South Africa and Viet Nam: a Randomised, Controlled, Equivalence Trial.|Completed|||2860||World Health Organization|||||f||||||||||||||2018-06-01 03:48:19.019729|2018-06-01 03:48:19.019729
NCT00370474|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2007-06-14|2006-08-30|2006-08-31|Estimate|||||||2007-06-14|2007-06-18|Estimate|June 2006||2006-06-30|June 2007|2007-06-30|September 2006|Actual|2006-09-30|||||Interventional|||MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance|Multi-Center Assessment of Gain in Navigation Efficiency To Cardiac Resynchronization Therapy|Terminated||Phase 4|27|Actual|Stereotaxis||||Procedure protocol improved - study protocol became obsolete|f||||f||||||||||2018-06-01 03:48:19.070111|2018-06-01 03:48:19.070111
NCT00370461|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2015-11-16|2006-08-29|2006-08-31|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2006||2006-01-31|November 2015|2015-11-30|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Observational|||Basic Life Support Termination of Resuscitation Implementation Study|Basic Life Support Termination of Resuscitation in the Prehospital Environment for Primary Care Paramedics - A Prospective Observational Study of the Implementation of a Clinical Prediction Rule|Completed|||350|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 03:48:19.129774|2018-06-01 03:48:19.129774
NCT00370448|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-11-13|2006-08-30|2006-08-31|Estimate|||||||2008-11-13|2008-11-14|Estimate|September 2007||2007-09-30|November 2008|2008-11-30|October 2008|Anticipated|2008-10-31|||||Interventional|||Evaluation of Interventions to Prevent Suicide of Medical Students Through the School-Based Social Support System|Evaluation of Interventions to Prevent Suicide of Medical Students Through the School-Based Social Support System|Unknown status|Recruiting|N/A|12000|Anticipated|Anhui Medical University||3|||f||||||||||||||2018-06-01 03:48:19.189797|2018-06-01 03:48:19.189797
NCT00370435|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2017-05-25|2006-08-29|2006-08-31|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2005||2005-08-31|May 2017|2017-05-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)|An Open-label, Single Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of 90mg of GW274150 in Adult and Elderly RA Subjects.|Completed||Phase 2|6|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:48:19.261616|2018-06-01 03:48:19.261616
NCT00370422|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2007-03-12|2006-08-30|2006-08-31|Estimate|||||||2007-03-12|2007-03-13|Estimate|November 2005||2005-11-30|October 2005|2005-10-31|September 2006||2006-09-30|||||Interventional|||Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial||Unknown status|Active, not recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:19.322328|2018-06-01 03:48:19.322328
NCT00370409|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-07-31|2006-08-30|2006-08-31|Estimate|||||||2008-07-31|2008-08-01|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Cryotherapy of Sclerotomy Sites for Prevention of Late Postvitrectomy Diabetic Hemorrhage||Completed||N/A|112|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:48:19.394338|2018-06-01 03:48:19.394338
NCT00370396|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2016-11-03|2006-08-30|2006-08-31|Estimate|||||||2016-11-03|2016-11-04|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.|To Assess the Safety, Reactogenicity & Immunogenicity of a 4th Dose of GSK Biologicals' Pneumococcal Vaccine or Prevenar™ in Children (12-18 Months) Previously Vaccinated in the Primary Study 105553 With Either Pneumococcal Vaccine or Prevenar™|Completed||Phase 3|1200|Anticipated|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:48:19.471361|2018-06-01 03:48:19.471361
NCT00370383|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30||2012-07-10|2012-07-31|2006-08-30|2006-08-31|Estimate||||2012-07-19|2012-07-26|Estimate|2012-07-31|2012-08-07|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)|A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy|Completed||Phase 2|100|Actual|Agennix||2|||f||||||||||||||2018-06-01 03:48:19.619402|2018-06-01 03:48:19.619402
NCT00370370|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-06-25|2006-08-30|2006-08-31|Estimate|||||||2008-06-25|2008-06-26|Estimate|November 2005||2005-11-30|June 2008|2008-06-30||||||||Interventional|||Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD||Unknown status|Active, not recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-06-01 03:48:19.723462|2018-06-01 03:48:19.723462
NCT00370357|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-01-10|2006-08-30|2006-08-31|Estimate|||||||2008-01-10|2008-01-16|Estimate|August 2006||2006-08-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Interventional|||SPL7013 Gel - Male Tolerance Study|A Phase 1, Placebo Controlled Study of the Safety of 3% w/w SPL7013 Gel, Administered to the Penis of Healthy Male Volunteers Once Daily for Seven Days|Completed||Phase 1|36||Starpharma Pty Ltd|||||f||||||||||||||2018-06-01 03:48:19.795742|2018-06-01 03:48:19.795742
NCT00370344|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2015-04-23|2006-08-30|2006-08-31|Estimate|||||||2015-04-23|2015-04-24|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|||Small-incision Open Cholecystectomy or Laparoscopic Cholecystectomy for Gallbladder Disease|An Expertise-based Randomized Controlled Trial Comparing Minilaparotomy Cholecystectomy and Laparoscopic Cholecystectomy|Completed||Phase 2/Phase 3|355|Actual|Umeå University||2|||f||||f||||||||||2018-06-01 03:48:19.865095|2018-06-01 03:48:19.865095
NCT00370331|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2009-07-17||2017-03-21|2006-08-29|2006-08-31|Estimate|2010-02-03|2010-02-23|Estimate||||2017-03-21|2017-04-18|Actual|November 2006||2006-11-30|March 2017|2017-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|RAISE||RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag|A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP.|Completed||Phase 3|197|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:48:20.009732|2018-06-01 03:48:20.009732
NCT00370318|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2017-03-21|2006-08-30|2006-08-31|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2006||2006-09-30|March 2017|2017-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines|Multicentre Study to Assess the Effect of Prophylactic Antipyretic Treatment on the Rate of Febrile Reactions Following Concomitant Administration of GSK Biologicals' 10-valent Pneumococcal Conjugate, Infanrix Hexa and Rotarix Vaccines|Completed||Phase 3|400||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:48:21.072278|2018-06-01 03:48:21.072278
NCT00370305|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2018-01-11|2006-08-30|2006-08-31|Estimate|||||||2018-01-11|2018-01-16|Actual|May 2004||2004-05-31|January 2018|2018-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||11ß-HSD1 and Metabolic Syndrome|The Pathogenic Role of 11ß-hydroxysteroid Dehydrogenase in the Metabolic Syndrome - the Effect of Rosiglitazone|Completed||Phase 2|24|Actual|Charite University, Berlin, Germany||1|||f||||||||||||||2018-06-01 03:48:21.193495|2018-06-01 03:48:21.193495
NCT00370292|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2009-09-09||2009-10-15|2006-08-29|2006-08-31|Estimate|2009-09-09|2009-10-12|Estimate||||2009-10-15|2009-10-20|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer. A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial|Completed||Phase 2|19|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:48:21.309732|2018-06-01 03:48:21.309732
NCT00370279|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-06-25|2006-08-30|2006-08-31|Estimate|||||||2008-06-25|2008-06-26|Estimate|September 2005||2005-09-30|June 2008|2008-06-30||||||||Interventional|||Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial||Unknown status|Recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences||4|||f||||||||||||||2018-06-01 03:48:22.086749|2018-06-01 03:48:22.086749
NCT00370266|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-06-16|2006-08-30|2006-08-31|Estimate|||||||2008-06-16|2008-06-17|Estimate|February 2003||2003-02-28|June 2008|2008-06-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion||Completed||Phase 2|30|Anticipated|Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:22.181635|2018-06-01 03:48:22.181635
NCT00370253|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2008-04-09|2006-08-30|2006-08-31|Estimate|||||||2008-04-09|2008-04-11|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Noradrenalin vs Terlipressin in Hepatorenal Syndrome|Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study|Completed||Phase 3|20|Actual|University of Turin, Italy||2|||f||||t||||||||||2018-06-01 03:48:22.242781|2018-06-01 03:48:22.242781
NCT00370240|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2017-11-02|2006-08-30|2006-08-31|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2006||2006-09-30|July 2007|2007-07-31|November 2008|Actual|2008-11-30|July 2007|Actual|2007-07-31||Interventional|||Chlorhydrate of Ropivacaine and Breast Cancer Surgery|Efficacy of Infiltration of Chlorhydrate of Ropivacaine in the Prevention of Chronic Breast Pain After Surgery for Breast Cancer.|Completed||Phase 4|260|Actual|Institut Curie||2|||f||||||||||||||2018-06-01 03:48:22.3153|2018-06-01 03:48:22.3153
NCT00370227|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2016-10-27|2006-08-30|2006-08-31|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|March 2007|Actual|2007-03-31|||||Interventional|||Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine|To Assess Safety, Reactogenicity & Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine, Co-admin With GSK Biologicals' MMRV Vaccine in Children (2nd yr of Life) Primed With the Pneumococcal Conjugate Vaccine in Study 105553.|Completed||Phase 3|390||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:48:22.383924|2018-06-01 03:48:22.383924
NCT00370214|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2013-05-16|2006-08-29|2006-08-31|Estimate|||||||2013-05-16|2013-05-17|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management|REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management|Completed|||3515|Actual|Actelion|||||f||||t||||||||||2018-06-01 03:48:22.573055|2018-06-01 03:48:22.573055
NCT00370201|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-30|||2006-10-06|2006-08-30|2006-08-31|Estimate|||||||2006-10-06|2006-10-09|Estimate|March 2004||2004-03-31|March 2004|2004-03-31|August 2006||2006-08-31|||||Interventional|||Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment||Unknown status|Active, not recruiting|Phase 3|||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:22.696286|2018-06-01 03:48:22.696286
NCT00370188|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2015-07-20|2006-08-29|2006-08-30|Estimate|||||||2015-07-20|2015-07-22|Estimate|September 2006||2006-09-30|July 2015|2015-07-31||||||||Interventional|||Topiramate on Gambling-Related Behaviours|Clinical Assessment of Topiramate on Gambling-Related Behaviours in Problem Gamblers: Effects of Gender and Negative Emotionality|Withdrawn||Phase 2|0|Actual|Centre for Addiction and Mental Health||||Change to investigator's research affiliation and other employment.|f||||||||||||||2018-06-01 03:48:22.755275|2018-06-01 03:48:22.755275
NCT00370162|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2008-05-15|2006-08-29|2006-08-30|Estimate|||||||2008-05-15|2008-05-16|Estimate|June 2006||2006-06-30|May 2008|2008-05-31||||||||Interventional|||Acceptability Dermacyd Delicata - New Fragrance - Lactoserum - Hygiene|Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata New Fragrance|Completed||Phase 3|30||Sanofi|||||f||||||||||||||2018-06-01 03:48:22.825988|2018-06-01 03:48:22.825988
NCT00370149|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|2015-10-19||2016-01-27|2006-08-29|2006-08-30|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Patients <18 years of age who had cardiovascular surgery with a case complexity warranting a central venous catheter received either an antibiotic impregnated catheter or a conventional non-impregnated catheter on a randomized, blinded 1:1 ratio.|Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children|A Randomized, Controlled Trial of Catheter Related Infectious Event Rates Using Antibiotic-impregnated Catheters vs. Conventional Catheters in Pediatric Cardiovascular Surgery Patients|Terminated||Phase 4|326|Actual|Indiana University|A blinded interim analysis by an independent Data Safety Monitoring Board resulted in early termination of the study: of 288 evaluable patients, the rates of CRBSI and line-related complications were similar between the 2 groups.|2||Blinded interim analysis resulted in early termination of the study.|f||||t||||||||No||2018-06-01 03:48:22.881587|2018-06-01 03:48:22.881587
NCT00370136|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2008-06-17|2006-08-29|2006-08-30|Estimate|||||||2008-06-17|2008-06-18|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|April 2008||2008-04-30|March 2008||2008-03-31||Interventional|||Sentinel Node With Ultrasound Contrast in Melanoma|Sentinel Node Diagnostics With Ultrasound Contrast in Melanoma|Completed||N/A|20|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:48:23.129476|2018-06-01 03:48:23.129476
NCT00370123|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2011-06-26|2006-08-29|2006-08-30|Estimate|||||||2011-06-26|2011-06-28|Estimate|September 2006||2006-09-30|June 2011|2011-06-30||||||||Observational|||The Immune Base of Endometriosis|In This Study we Aim to Explore the Immune Nature of Endometriosis as Manifested in the Peripheral Blood, Endometriosis Lesions, Normal Peritoneum and Normal Endometrium of Patients Suffering From Documented Endometriosis.|Withdrawn|||50|Anticipated|Sheba Medical Center||||The study was withrawn do to logistic difficulties|f||||||||||||||2018-06-01 03:48:23.187454|2018-06-01 03:48:23.187454
NCT00370110|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2017-02-07|2006-08-29|2006-08-30|Estimate|||||||2017-02-07|2017-02-09|Estimate|August 2005||2005-08-31|February 2017|2017-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers|A Double-blind, Randomized, Placebo-controlled, Single Center, Parallel Group Study to Evaluate the Effects of Itopride (100 mg and 200 mg t.i.d.) on Gastric Motor and Sensory Functions in Healthy Volunteers|Completed||Phase 1/Phase 2|45|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 03:48:23.232036|2018-06-01 03:48:23.232036
NCT00370097|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2017-09-07|2006-08-28|2006-08-30|Estimate|||||||2017-09-07|2017-09-11|Actual|August 30, 2006|Actual|2006-08-30|September 2017|2017-09-30|April 12, 2007|Actual|2007-04-12|April 12, 2007|Actual|2007-04-12||Interventional|||FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects|PD of Hydrofluoroalkane Propellant of Inhaled Fluticasone Propionate Following Administration in Pediatric Subjects 6-12 Months of Age With Asthma|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:48:23.292839|2018-06-01 03:48:23.292839
NCT00370084|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2017-02-07|2006-08-29|2006-08-30|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 2005||2005-03-31|February 2017|2017-02-28|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia|"Effects of Itopride Hydrochloride on Gastric Emptying, Glycaemia and Meal-related Symptoms in Patients With Type 1 and Type 2 Diabetes Mellitus"|Completed||Phase 1/Phase 2|25|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 03:48:23.37675|2018-06-01 03:48:23.37675
NCT00370071|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2009-10-23||2015-09-29|2006-08-29|2006-08-30|Estimate|2010-01-24|2010-02-10|Estimate||||2015-09-29|2015-10-29|Estimate|November 2006||2006-11-30|September 2015|2015-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis|Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis|Completed||Phase 3|39|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:48:24.462463|2018-06-01 03:48:24.462463
NCT00370058|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2008-07-09|2006-08-29|2006-08-30|Estimate|||||||2008-07-09|2008-07-11|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study on the Influence of Electroconvulsive Therapy (ECT) on Homocysteine Levels|Modulation of Homocysteine-Plasma Levels by ECT - Association With Clinical Response. A Pilot Study in Patients With Major Depression|Completed||Phase 4|10|Actual|University of Erlangen-Nürnberg Medical School|||||f||||||||||||||2018-06-01 03:48:24.791745|2018-06-01 03:48:24.791745
NCT00370045|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2006-08-29|2006-08-29|2006-08-30|Estimate|||||||2006-08-29|2006-08-30|Estimate|March 2006||2006-03-31|August 2006|2006-08-31||||||||Interventional|||Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin|Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin -The CLEAR PLATELETS-2 Study|Unknown status|Recruiting|Phase 4|200||LifeBridge Health|||||f||||||||||||||2018-06-01 03:48:24.852217|2018-06-01 03:48:24.852217
NCT00370032|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|2008-12-19||2015-05-15|2006-08-28|2006-08-30|Estimate|2009-03-02|2009-04-02|Estimate||||2015-05-15|2015-05-18|Estimate|December 2006||2006-12-31|May 2015|2015-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Assess the Effect Of Alosetron On Mucosal Blood Flow|A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects|Completed||Phase 4|49|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:48:24.945858|2018-06-01 03:48:24.945858
NCT00370019|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2017-06-30|2006-08-29|2006-08-30|Estimate|||||||2017-06-30|2017-07-02|Actual|August 25, 2006||2006-08-25|December 12, 2011|2011-12-12|December 12, 2011|Actual|2011-12-12|December 12, 2011|Actual|2011-12-12||Interventional|||Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure|Effect of Transdermal Estradiol Replacement Therapy on Ovulation Rate in Women With Premature Ovarian Failure: A Randomized, Placebo-Controlled Trial|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:48:25.590865|2018-06-01 03:48:25.590865
NCT00370006|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2007-01-10|2006-08-28|2006-08-30|Estimate|||||||2007-01-10|2007-01-11|Estimate|September 2006||2006-09-30|October 2006|2006-10-31|August 2007||2007-08-31|||||Interventional|||Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM|A Phase 1 Clinical Trial to Evaluate the Safety of, and Kinetics and Magnitude of the CMV-Specific Immune Response to, Challenge With a Live Attenuated Strain of CMV (Towne) in Healthy, CMV- Seronegative, Adult Subjects Who Previously Received a CMV Immunotherapeutic Trivalent pDNA Vaccine (VCL CT02) Administered Intradermally or Intramuscularly|Completed||Phase 1|10||University of California, San Francisco|||||||||||||||||||2018-06-01 03:48:25.659799|2018-06-01 03:48:25.659799
NCT00369993|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2016-10-13|2006-08-29|2006-08-30|Estimate|||||||2016-10-13|2016-10-17|Estimate|March 2005||2005-03-31|October 2016|2016-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Spacer Comparison In Adult Asthmatics|A Randomised, Open Label, Five-way Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate and Salmeterol From SERETIDE/ADVAIR 250HFA MDI Alone and With AeroChamber-Max Spacer and VOLUMATIC Both in Their Washed and Unwashed States in Adult Subjects With Mild or Intermittent Asthma|Completed||Phase 2|20|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:48:25.734319|2018-06-01 03:48:25.734319
NCT00369980|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2006-11-06|2006-08-29|2006-08-30|Estimate|||||||2006-11-06|2006-11-07|Estimate|September 1998||1998-09-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient||Completed|||||Gunma University|||||f||||||||||||||2018-06-01 03:48:25.877126|2018-06-01 03:48:25.877126
NCT00369967|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2015-12-10||2016-06-10|2006-08-29|2006-08-30|Estimate|2016-06-10|2016-07-22|Estimate||||2016-06-10|2016-07-22|Estimate|February 2007||2007-02-28|June 2016|2016-06-30|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents|"Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents: A Randomized Controlled Trial"|Terminated||N/A|48|Actual|Virginia Commonwealth University||2||difficulty in subject recruitment|f||||f||||||||No|Not planned.|2018-06-01 03:48:25.972291|2018-06-01 03:48:25.972291
NCT00369954|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2013-06-07|2006-08-29|2006-08-30|Estimate|||||||2013-06-07|2013-06-10|Estimate|April 2006||2006-04-30|October 2007|2007-10-31||||||||Interventional|||Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin|A Phase II Trial of Intravenous Gemcitabine (NSC #613327) and Intraperitoneal Carboplatin (NSC # 241240) in the Treatment of Patients With Platinum-Sensitive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma With Non-Measurable Disease|Withdrawn||Phase 2|0|Actual|Gynecologic Oncology Group||||Trial was never activated|f||||||||||||||2018-06-01 03:48:26.467061|2018-06-01 03:48:26.467061
NCT00369941|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2009-09-18||2017-02-14|2006-08-29|2006-08-30|Estimate|2010-04-20|2010-05-11|Estimate||||2017-02-14|2017-03-21|Actual|August 2006||2006-08-31|February 2017|2017-02-28|February 2012|Actual|2012-02-29|May 2009|Actual|2009-05-31||Interventional|||A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)|A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™|Completed||Phase 3|566|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:48:26.754789|2018-06-01 03:48:26.754789
NCT00369928|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2011-08-04||2011-08-04|2006-08-29|2006-08-30|Estimate|2011-08-04|2011-09-08|Estimate||||2011-08-04|2011-09-08|Estimate|August 2006||2006-08-31|August 2011|2011-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate|A Multicenter, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG-760564 in Adult Patients With RA Receiving Methotrexate|Completed||Phase 2|254|Actual|Procter and Gamble||3|||f||||f||||||||||2018-06-01 03:48:29.215086|2018-06-01 03:48:29.215086
NCT00369915|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|2014-04-11||2016-09-22|2006-08-29|2006-08-30|Estimate|2016-03-29|2016-04-29|Estimate||||2016-09-22|2016-11-10|Estimate|August 2006||2006-08-31|September 2016|2016-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Antidepressant Efficacy of the Anticholinergic Scopolamine|The Antidepressant Efficacy of the Anticholinergic Scopolamine|Terminated||Phase 2|17|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:48:29.775685|2018-06-01 03:48:29.775685
NCT00369902|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2009-07-19|2006-08-29|2006-08-30|Estimate|||||||2009-07-19|2009-07-21|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|May 2007|Actual|2007-05-31|||||Observational|||The Effect of Acupuncture Treatment on the Perception of Pain and Coping With Pain|Pilot Study on the Effect of Acupuncture Treatment on Pain Perception and on the Ability to Cope With Pain|Completed|||41|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:48:30.17925|2018-06-01 03:48:30.17925
NCT00369889|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2014-05-30|2006-08-28|2006-08-30|Estimate|||||||2014-05-30|2014-06-03|Estimate|August 2006||2006-08-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer|A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma|Completed||Phase 2|18|Actual|Indiana University|||||f||||f||||||||||2018-06-01 03:48:30.244997|2018-06-01 03:48:30.244997
NCT00369876|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2007-01-23|2006-08-29|2006-08-30|Estimate|||||||2007-01-23|2007-01-24|Estimate|August 2004||2004-08-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Observational|||Anorexia in Children With Burn Injury and the Reactions of the Immune and Endocrine Systems|The Association Between Anorexia and the Level of Hormones, Cytokines and Neuroendocrine Peptides in Children After Burn Injury|Unknown status|Active, not recruiting||10||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:48:30.316389|2018-06-01 03:48:30.316389
NCT00369863|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-29|||2007-02-27|2006-08-29|2006-08-30|Estimate|||||||2007-02-27|2007-02-28|Estimate|June 2002||2002-06-30|February 2007|2007-02-28|June 2003||2003-06-30|||||Interventional|||A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema||Completed||Phase 2|76||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:48:30.37577|2018-06-01 03:48:30.37577
NCT00369850|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2012-07-26|2006-08-24|2006-08-29|Estimate|||||||2012-07-26|2012-07-27|Estimate|May 2004||2004-05-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|May 2008|Actual|2008-05-31||Interventional|||Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98|Investigating Bone Density and Bone Loss Without Baseline Information|Completed||Phase 3|458|Actual|International Breast Cancer Study Group||4|||f||||t||||||||||2018-06-01 03:48:30.47838|2018-06-01 03:48:30.47838
NCT00369837|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2014-05-21|2006-08-25|2006-08-29|Estimate|||||||2014-05-21|2014-05-22|Estimate|September 2006||2006-09-30|May 2014|2014-05-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|VELOCITY||Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)|Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)|Completed||Phase 3|131|Actual|The Medicines Company||1|||f||||f||||||||||2018-06-01 03:48:30.608535|2018-06-01 03:48:30.608535
NCT00369824|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|2009-09-03||2016-11-03|2006-08-28|2006-08-29|Estimate|2009-09-03|2009-10-08|Estimate||||2016-11-03|2016-12-16|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|February 2008|Actual|2008-02-29|November 2007|Actual|2007-11-30||Interventional|||Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects|A Randomized, Open Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine Co-administered Intramuscularly With Boostrix® and/or Menactra™ in Healthy Female Subjects Aged 11-18 Years|Completed||Phase 3|1330|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:48:30.798952|2018-06-01 03:48:30.798952
NCT00369811|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2007-11-16|2006-08-28|2006-08-29|Estimate|||||||2007-11-16|2007-11-19|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Oxycodone vs Fentanyl for Pain Treatment After Laparoscopic Cholecystectomy|Comparative Study of Oxycodone and Fentanyl Given Intravenously in the Treatment of Early Postoperative Pain After Laparoscopic Cholecystectomy|Completed||Phase 4|80|Anticipated|Danish Pain Research Center|||||f||||t||||||||||2018-06-01 03:48:32.470943|2018-06-01 03:48:32.470943
NCT00369798|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2017-10-05|2006-08-25|2006-08-29|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2, 2006||2006-08-02|October 12, 2016|2016-10-12|October 12, 2016|Actual|2016-10-12|June 16, 2016|Actual|2016-06-16||Interventional|||Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients|Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE 4) in Depressed Patients|Completed||Phase 1|100|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:48:32.536606|2018-06-01 03:48:32.536606
NCT00369785|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2015-07-15||2017-11-27|2006-08-24|2006-08-29|Estimate|2017-01-18|2017-03-09|Actual||||2017-11-27|2017-12-21|Actual|January 2008||2008-01-31|November 2017|2017-11-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional||All randomized patients|Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors|Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain|Completed||Phase 3|198|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||No||2018-06-01 03:48:32.69657|2018-06-01 03:48:32.69657
NCT00369772|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2009-10-15|2006-08-25|2006-08-29|Estimate|||||||2009-10-15|2009-10-16|Estimate|February 2002||2002-02-28|October 2009|2009-10-31|May 2004||2004-05-31|||||Interventional|||STAAR-1 Clinical Study|A Multicenter Study Evaluating Once Every Other Week Subcutaneous Administration of Aranesp (Darbepoetin Alfa) in Subjects With Anemia of Chronic Renal Insufficiency (CRI)|Completed||Phase 4|2000||Amgen|||||f||||||||||||||2018-06-01 03:48:33.501113|2018-06-01 03:48:33.501113
NCT00369759|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2009-03-16|2006-08-25|2006-08-29|Estimate|||||||2009-03-16|2009-03-17|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Observational|||An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants|An Epidemiological Study to Evaluate the Seasonality of Respiratory Syncytial Virus-Associated-Lower Respiratory Tract Infections (LRI) or Apnea in Infants in the Emergency Department|Completed|||2048|Actual|MedImmune LLC|||3||f||||f||||||Samples Without DNA|"~     Nasal wash specimen (RSV)~   "|||2018-06-01 03:48:33.686136|2018-06-01 03:48:33.686136
NCT00369746|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2011-11-23||2014-04-09|2006-08-24|2006-08-29|Estimate|2014-04-09|2014-05-09|Estimate||||2014-04-09|2014-05-09|Estimate|September 2006||2006-09-30|December 2011|2011-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse|Treatment of Depression Concurrent With Alcohol Abuse, an Extension of Alcohol Use Disorder in Patients Treated for Depression|Completed|||674|Actual|New York State Psychiatric Institute|||2||f||||f||||||||||2018-06-01 03:48:33.91444|2018-06-01 03:48:33.91444
NCT00369733|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2010-02-18|2006-08-25|2006-08-29|Estimate|||||||2010-02-18|2010-02-19|Estimate|May 2002||2002-05-31|February 2010|2010-02-28|May 2004|Actual|2004-05-31|March 2004|Actual|2004-03-31||Interventional|||STAAR-3 Clinical Study|Disease/Case Management of Patients Receiving ARANESP™ (Darbepoetin Alfa) to Treat the Anemia of Chronic Renal Insufficiency (CRI)|Completed||Phase 4|443|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:48:34.465289|2018-06-01 03:48:34.465289
NCT00369720|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2007-04-18|2006-08-28|2006-08-29|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|January 2008|Anticipated|2008-01-31|||||Interventional|||Use of Blended Oxygen for Delivery Room Resuscitation of Very Low Birth Weight Infants|Use of Blended Oxygen for Delivery Room Resuscitation of VLBW Infants|Unknown status|Active, not recruiting|N/A|40||University of California, San Diego|||||f||||||||||||||2018-06-01 03:48:34.592947|2018-06-01 03:48:34.592947
NCT00369707|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2017-12-11|2006-08-24|2006-08-29|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2006||2006-08-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL|A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 2|43|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 03:48:34.751414|2018-06-01 03:48:34.751414
NCT00369694|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2008-09-24|2006-08-24|2006-08-29|Estimate|||||||2008-09-24|2008-09-25|Estimate|August 2006||2006-08-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Short Course Terlipressin for Control of Acute Variceal Bleeding|Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed|Completed||Phase 4|130|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 03:48:35.186197|2018-06-01 03:48:35.186197
NCT00369681|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2015-05-20||2015-07-27|2006-08-24|2006-08-29|Estimate|2015-06-10|2015-07-03|Estimate||||2015-07-27|2015-08-17|Estimate|May 2006||2006-05-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma|Phase II Trial of Rituximab -ABVD for Classical Hodgkin's Disease|Completed||Phase 2|50|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 03:48:35.476194|2018-06-01 03:48:35.476194
NCT00369668|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2011-08-10||2012-06-12|2006-08-24|2006-08-29|Estimate|2012-04-13|2012-05-11|Estimate||||2012-06-12|2012-06-15|Estimate|August 2006||2006-08-31|April 2012|2012-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Post Stroke Hand Functions: Bilateral Movements and Electrical Stimulation Treatments|Subacute Stroke Recovery (Upper Extremity Motor Function): Bimanual Coordination Training|Completed||Phase 2|30|Actual|University of Florida||3|||f||||f||||||||||2018-06-01 03:48:36.218874|2018-06-01 03:48:36.218874
NCT00369655|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2013-11-25||2014-04-02|2006-08-24|2006-08-29|Estimate|2014-04-02|2014-05-05|Estimate||||2014-04-02|2014-05-05|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|January 2011|Actual|2011-01-31|March 2008|Actual|2008-03-31||Interventional|||VEGF Trap in Treating Patients With Metastatic Breast Cancer|Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline and/or Taxane|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:48:37.112736|2018-06-01 03:48:37.112736
NCT00369642|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2010-08-05|2006-08-24|2006-08-29|Estimate|||||||2010-08-05|2010-08-09|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|December 2006||2006-12-31|||||Interventional|||A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder|Completed||Phase 3|60||University of South Florida|||||f||||||||||||||2018-06-01 03:48:37.703841|2018-06-01 03:48:37.703841
NCT00369629|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2016-11-23|2006-08-24|2006-08-29|Estimate|||||||2016-11-23|2016-11-25|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|May 2012|Actual|2012-05-31||Interventional|||Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome|Phase I/II Trial of Gemcitabine/Pemetrexed Combination in Patients With Advanced Cutaneous T-Cell Lymphoma|Terminated||Phase 1|14|Actual|Northwestern University||1||"This was planned as a phase I/II study originally, but due to a lack of funding, the phase II~   portion was never conducted."|f||||t||||||||||2018-06-01 03:48:37.844754|2018-06-01 03:48:37.844754
NCT00369616|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2010-11-11|2006-08-28|2006-08-29|Estimate|||||||2010-11-11|2010-11-15|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|October 2005|Actual|2005-10-31|March 2005|Actual|2005-03-31||Interventional|||Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers|Evaluation of Efficacy and Safety of Nicotine-Qbeta (NicQb) Vaccine Versus Placebo in Healthy Smokers|Completed||Phase 2|341|Actual|Cytos Biotechnology AG||2|||f||||||||||||||2018-06-01 03:48:38.261332|2018-06-01 03:48:38.261332
NCT00369603|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2013-04-09|2006-08-28|2006-08-29|Estimate|||||||2013-04-09|2013-04-11|Estimate|October 2006||2006-10-31|June 2008|2008-06-30|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients|Functional Neuroimaging (fMRI) Biomarker of Allosteric Nicotinic Receptor Modulation in Mild Alzheimer's Disease Patients: A Razadyne vs. Aricept Dose Escalation Trial|Terminated||Phase 4|4|Actual|Duke University||2||Reduced access to AchEI medication-naive mild AD patients.|f||||t||||||||||2018-06-01 03:48:38.385244|2018-06-01 03:48:38.385244
NCT00369590|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2015-06-03||2015-08-31|2006-08-24|2006-08-29|Estimate|2015-08-31|2015-10-02|Estimate||||2015-08-31|2015-10-02|Estimate|August 2006||2006-08-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional||16 patients were anaplastic gliomas and 42 were glioblastomas all underwent central pathologic review|VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide|Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas|Completed||Phase 2|58|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:48:38.584813|2018-06-01 03:48:38.584813
NCT00369577|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2017-01-30||2017-05-30|2006-08-25|2006-08-29|Estimate|2017-05-30|2018-01-02|Actual||||2017-05-30|2018-01-02|Actual|August 2006||2006-08-31|June 2013|2013-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Staccato Loxapine in Agitation (Proof of Concept)|A Multi-center, Randomized, Double-blind, Placebo-controlled, Single Dose Efficacy and Safety Study of StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation.|Completed||Phase 2|129|Actual|Alexza Pharmaceuticals, Inc.|Because of the need to provide informed consent, the types of patients enrolled in the study may not have been representative of the most severely agitated patients who present for emergency care.|3|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-06-01 03:48:39.288077|2018-06-01 03:48:39.288077
NCT00369564|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2013-12-09||2014-01-30|2006-08-24|2006-08-29|Estimate|2014-01-30|2014-03-14|Estimate||||2014-01-30|2014-03-14|Estimate|May 2007||2007-05-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer|Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer|Completed||Phase 3|250|Actual|University of South Florida||2|||f||||t||||||||||2018-06-01 03:48:40.123121|2018-06-01 03:48:40.123121
NCT00369551|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2014-03-05|2006-08-24|2006-08-29|Estimate|||||||2014-03-05|2014-03-06|Estimate|June 2006||2006-06-30|January 2013|2013-01-31||||February 2008|Actual|2008-02-29||Interventional|||Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer|A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer|Terminated||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:48:40.774235|2018-06-01 03:48:40.774235
NCT00369538|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2009-02-16|2006-08-28|2006-08-29|Estimate|||||||2009-02-16|2009-02-18|Estimate|August 2006||2006-08-31|February 2009|2009-02-28||||||||Interventional|||Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria|Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria|Suspended||Phase 4|20|Anticipated|University Hospital, Strasbourg, France||2||"principle investigator moved, new investigators will join, insurance expired - project needs to~   be re-examined by an ethic committee"|f||||||||||||||2018-06-01 03:48:40.890582|2018-06-01 03:48:40.890582
NCT00369512|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2013-06-03||2017-05-22|2006-08-25|2006-08-29|Estimate|2013-08-06|2013-08-08|Estimate||||2017-05-22|2017-05-30|Actual|August 2006||2006-08-31|May 2017|2017-05-31|September 2012|Actual|2012-09-30|January 2012|Actual|2012-01-31||Interventional|RAD0503||A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma|A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas|Completed||Phase 2|15|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 03:48:40.998578|2018-06-01 03:48:40.998578
NCT00369499|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2008-02-22|2006-08-28|2006-08-29|Estimate|||||||2008-02-22|2008-02-25|Estimate|March 2007||2007-03-31|February 2008|2008-02-29|June 2009|Anticipated|2009-06-30|||||Interventional|||STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?|STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?|Terminated||N/A|656|Anticipated|St. Jude Medical||||Not enough patients/ ethical concerns|f||||||||||||||2018-06-01 03:48:41.29719|2018-06-01 03:48:41.29719
NCT00369486|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2009-10-14||2016-08-25|2006-08-25|2006-08-29|Estimate|2011-05-12|2011-06-14|Estimate||||2016-08-25|2016-08-26|Estimate|December 2004||2004-12-31|August 2016|2016-08-31|October 2007|Actual|2007-10-31|June 2006|Actual|2006-06-30||Interventional|Peribulbar||A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema|A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema|Completed||Phase 2|113|Actual|Jaeb Center for Health Research||5|||f||||t||||||||||2018-06-01 03:48:41.40034|2018-06-01 03:48:41.40034
NCT00369473|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24||2016-12-09|2016-12-09|2006-08-24|2006-08-29|Estimate||||2016-12-09|2016-12-13|Estimate|2016-12-09|2016-12-13|Estimate|September 2006||2006-09-30|December 2016|2016-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Long-Term Assessment of Safety and Physical Function With AMG 108 in RA|A Long-Term Assessment of Safety and Physical Function With AMG 108 Subcutaneous Monthly Treatment in Subjects With Rheumatoid Arthritis|Completed||Phase 2|690|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:48:42.745033|2018-06-01 03:48:42.745033
NCT00369460|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2015-10-08|2006-08-24|2006-08-29|Estimate|||||||2015-10-08|2015-10-12|Estimate|January 2006||2006-01-31|October 2015|2015-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Changes in Muscle Tissue in Patients With Pancreatic Cancer|Pilot Study of Changes in Fat-Free Mass in Pancreatic Carcinoma Patients|Completed|||9|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 03:48:42.995589|2018-06-01 03:48:42.995589
NCT00369447|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2011-06-30|2006-08-24|2006-08-29|Estimate|||||||2011-06-30|2011-07-01|Estimate|March 2009||2009-03-31|June 2011|2011-06-30|July 2011|Anticipated|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer|A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination With External Radiotherapy in Stage IIB, III and IV NSCLC|Terminated||Phase 1/Phase 2|52|Actual|YM BioSciences||2||The study was closed due to slow accrual.|f||||f||||||||||2018-06-01 03:48:43.102476|2018-06-01 03:48:43.102476
NCT00369434|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2007-05-31|2006-08-25|2006-08-29|Estimate|||||||2007-05-31|2007-06-01|Estimate|June 2006||2006-06-30|May 2007|2007-05-31|February 2007|Actual|2007-02-28|||||Interventional|||Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women|A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of DVS SR for Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|450|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:48:43.245048|2018-06-01 03:48:43.245048
NCT00369421|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2018-05-23|2006-08-25|2006-08-29|Estimate|||||||2018-05-23|2018-05-24|Actual|November 23, 1976||1976-11-23|February 28, 2018|2018-02-28||||||||Observational|||Diagnosis and Treatment of Patients With Inborn Errors of Metabolism|Diagnosis and Treatment of Patients With Inborn Errors of Metabolism or Other Genetic Disorders|Recruiting|||4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:48:43.348397|2018-06-01 03:48:43.348397
NCT00369408|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2011-06-17|2006-08-24|2006-08-29|Estimate|||||||2011-06-17|2011-06-20|Estimate|June 2003||2003-06-30|June 2011|2011-06-30|March 2008|Actual|2008-03-31|August 2007|Actual|2007-08-31||Interventional|||Targeted Naltrexone for Problem Drinkers|Targeted Naltrexone for Problem Drinkers|Completed||Phase 4|163|Actual|UConn Health||2|||f||||t||||||||||2018-06-01 03:48:43.422933|2018-06-01 03:48:43.422933
NCT00369395|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2012-04-25|2006-08-24|2006-08-29|Estimate|||||||2012-04-25|2012-04-27|Estimate|December 2006||2006-12-31|April 2012|2012-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of Volociximab in Metastatic Melanoma|A Phase 2, Open-Label, Two-Stage Study of Volociximab (M200) for the Treatment of Subjects With Metastatic Melanoma|Terminated||Phase 2|19|Actual|Abbott||1||Insufficient clinical activity|f||||f||||||||||2018-06-01 03:48:43.613055|2018-06-01 03:48:43.613055
NCT00369382|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2011-04-26||2011-05-25|2006-08-25|2006-08-29|Estimate|2011-04-26|2011-05-23|Estimate||||2011-05-25|2011-05-30|Estimate|September 2006||2006-09-30|May 2011|2011-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients|A Randomized Open-Label Study To Compare The Safety And Efficacy Of Conversion From A Calcineurin Inhibitor To Sirolimus Vs Continued Use Of A Calcineurin Inhibitor In Heart Transplant Recipients With Mild-Moderate Impaired Renal Function|Completed||Phase 4|121|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 03:48:43.727112|2018-06-01 03:48:43.727112
NCT00369356|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2013-01-20|2006-08-24|2006-08-29|Estimate|||||||2013-01-20|2013-01-23|Estimate|October 2006||2006-10-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|October 2009|Actual|2009-10-31||Interventional|||Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis|Clinical and Angiographic Outcome of Patients Treated With Bare Metal Stent (BMS) Implantation Compared With Drug Eluting Stents or BMS Plus Systemic Prednisone Therapy. A Randomized, Multicentre Study.|Completed||Phase 2/Phase 3|375|Actual|Universita di Verona||3|||f||||t||||||||||2018-06-01 03:48:44.518899|2018-06-01 03:48:44.518899
NCT00369343|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2008-11-26||2012-04-09|2006-08-25|2006-08-29|Estimate|2012-04-09|2012-05-07|Estimate||||2012-04-09|2012-05-07|Estimate|September 2006||2006-09-30|April 2012|2012-04-30|July 2008|Actual|2008-07-31|November 2007|Actual|2007-11-30||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women|A Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder|Completed||Phase 3|381|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:48:44.73758|2018-06-01 03:48:44.73758
NCT00369330|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2012-08-31|2006-08-28|2006-08-29|Estimate|||||||2012-08-31|2012-09-03|Estimate|September 2006||2006-09-30|August 2006|2006-08-31||||||||Interventional|||KONVERT-AF - Relevance of Point in Time for Conversion of Acute Atrial Fibrillation|Prospective, Randomized Parallel-group Study for Evaluation of Impact of Early Versus Delayed Cardioversion of Acute Atrial Fibrillation on Further Clinical Course|Withdrawn||N/A|0|Actual|Atrial Fibrillation Network||||withdrawn because of insufficient financial capacities|f||||||||||||||2018-06-01 03:48:45.423527|2018-06-01 03:48:45.423527
NCT00369317|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2015-01-06||2017-07-10|2006-08-24|2006-08-29|Estimate|2015-01-06|2015-01-13|Estimate||||2017-07-10|2017-08-14|Actual|March 2007||2007-03-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes|The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years|Completed||Phase 3|205|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 03:48:45.51425|2018-06-01 03:48:45.51425
NCT00369304|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2009-08-06|2006-08-25|2006-08-29|Estimate|||||||2009-08-06|2009-08-07|Estimate|July 2006||2006-07-31|August 2009|2009-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate|A Randomized, Open Label, 2-Period Crossover Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate.|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:48:46.222916|2018-06-01 03:48:46.222916
NCT00369291|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2017-11-27|2006-08-24|2006-08-29|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2003||2003-09-30|November 2017|2017-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant|CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution|Terminated||Phase 1|19|Actual|Masonic Cancer Center, University of Minnesota||1||Slow accrual|f||||t||||||||||2018-06-01 03:48:46.378822|2018-06-01 03:48:46.378822
NCT00369278|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2010-12-15||2011-03-25|2006-08-25|2006-08-29|Estimate|2010-12-15|2011-01-12|Estimate||||2011-03-25|2011-03-29|Estimate|June 2006||2006-06-30|March 2011|2011-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating an Intensified Enteric-coated Mycophenolate Sodium (EC-MPS) Dosing Regimen in Comparison to a Standard Dosing Regimen of EC-MPS in Combination With Cyclosporin Microemulsion and Corticosteroids in de Novo Renal Transplant Patients|Completed||Phase 3|128|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:48:46.529794|2018-06-01 03:48:46.529794
NCT00369265|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2012-07-11||2012-08-23|2006-08-24|2006-08-29|Estimate|2012-07-11|2012-08-17|Estimate||||2012-08-23|2012-08-24|Estimate|August 2006||2006-08-31|August 2012|2012-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux|A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis|Terminated||Phase 4|18|Actual|American Institute for Voice and Ear Research|The study was terminated due to inadequate subject recruitment.|2||Pharmaceutical company purchased by another company and funding was terminated.|f||||||||||||||2018-06-01 03:48:47.279056|2018-06-01 03:48:47.279056
NCT00369252|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2007-02-27|2006-08-25|2006-08-29|Estimate|||||||2007-02-27|2007-02-28|Estimate|June 2005||2005-06-30|February 2007|2007-02-28||||||||Interventional|||Phase I Study of Nimotuzumab in Solid Tumours|A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours|Completed||Phase 1|18||YM BioSciences|||||f||||||||||||||2018-06-01 03:48:47.584098|2018-06-01 03:48:47.584098
NCT00369239|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2011-05-16|2006-08-25|2006-08-29|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2006||2006-03-31|April 2010|2010-04-30|November 2007|Actual|2007-11-30|||||Interventional|||Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis|Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?|Completed||Phase 4|303|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 03:48:47.635362|2018-06-01 03:48:47.635362
NCT00369226|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2012-08-08||2013-06-19|2006-08-24|2006-08-29|Estimate|2013-06-19|2013-07-25|Estimate||||2013-06-19|2013-07-25|Estimate|August 2006||2006-08-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|July 2010|Actual|2010-07-31||Interventional|||Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation|Phase I/II Trial of Bortezomib (Velcade) in Addition to Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation|Completed||Phase 1/Phase 2|45|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:48:47.722042|2018-06-01 03:48:47.722042
NCT00369213|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2006-08-24|2006-08-24|2006-08-29|Estimate|||||||2006-08-24|2006-08-29|Estimate|April 1998||1998-04-30|December 2004|2004-12-31|April 2002||2002-04-30|||||Interventional|||Randomised Controlled Trial of Condoms Plus Additional Lubrication|Randomised Controlled Trial of the Effect of Additional Spermicidal Lubrication on Condom Failure|Completed||Phase 4|200||University of Manchester|||||f||||||||||||||2018-06-01 03:48:47.977798|2018-06-01 03:48:47.977798
NCT00369200|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2013-12-10|2006-08-24|2006-08-29|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2006||2006-06-30|December 2013|2013-12-31||||January 2011|Actual|2011-01-31||Interventional|||AFP464 in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors|Terminated||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:48:48.036701|2018-06-01 03:48:48.036701
NCT00369187|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2008-01-07|2006-08-25|2006-08-29|Estimate|||||||2008-01-07|2008-01-10|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|October 2006|Actual|2006-10-31|||||Interventional|||Study of a Large Protein Molecule Administered With Escalating Doses of Recombinant Human Hyaluronidase||Completed||Phase 4|15||Halozyme Therapeutics|||||||||||||||||||2018-06-01 03:48:48.243301|2018-06-01 03:48:48.243301
NCT00369174|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2013-02-12|2006-08-24|2006-08-29|Estimate|||||||2013-02-12|2013-02-13|Estimate|June 2006||2006-06-30|January 2013|2013-01-31||||August 2007|Actual|2007-08-31||Interventional|||Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia|Phase IIA Trial of Rosiglitazone (Avandia) for Oral Leukoplakia|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:48:48.310042|2018-06-01 03:48:48.310042
NCT00369161|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2010-12-17||2017-02-28|2006-08-25|2006-08-29|Estimate|2010-12-17|2011-01-19|Estimate||||2017-02-28|2017-03-03|Actual|June 2006||2006-06-30|February 2017|2017-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients|A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients|Completed||Phase 4|228|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:48:48.455943|2018-06-01 03:48:48.455943
NCT00369148|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2009-08-25|2006-08-28|2006-08-29|Estimate|||||||2009-08-25|2009-08-26|Estimate|July 2004||2004-07-31|August 2009|2009-08-31|March 2006||2006-03-31|||||Interventional|||Combination of Glinides With Premixed Insulin|Evaluation of Usefulness of Combination Therapy of Rapid Acting Insulin Secretagogue (Glinide) With Premixed Insulin in Type 2 Diabetes|Completed||Phase 4|60||Keio University|||||f||||||||||||||2018-06-01 03:48:49.024079|2018-06-01 03:48:49.024079
NCT00369135|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2008-11-20|2006-08-25|2006-08-29|Estimate|||||||2008-11-20|2008-11-21|Estimate|March 2006||2006-03-31|November 2008|2008-11-30|February 2009|Anticipated|2009-02-28|||||Interventional|||Cross-Disciplinary Workplace Intervention Strategy for Chronic Musculoskeletal Disorders|Cross-Disciplinary Workplace Intervention Strategy for Chronic Musculoskeletal Disorders|Unknown status|Recruiting|N/A|120|Anticipated|Institut Universitaire Romand de Sante au Travail|||||f||||t||||||||||2018-06-01 03:48:49.087264|2018-06-01 03:48:49.087264
NCT00369122|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2013-03-05||2018-02-21|2006-08-24|2006-08-29|Estimate|2013-05-15|2013-05-17|Estimate||||2018-02-21|2018-03-20|Actual|August 11, 2006|Actual|2006-08-11|February 2018|2018-02-28|December 15, 2016|Actual|2016-12-15|June 4, 2010|Actual|2010-06-04||Interventional|||Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer|A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)|Ineligible patients are included in the adverse event reporting on ClinicalTrials.gov, but not in endpoint results, nor in any publications, per the protocol.|1|||f||||||||||||||2018-06-01 03:48:49.169546|2018-06-01 03:48:49.169546
NCT00369109|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2013-04-05|2006-08-24|2006-08-29|Estimate|||||||2013-04-05|2013-04-08|Estimate|February 2006||2006-02-28|April 2013|2013-04-30|June 2007|Actual|2007-06-30|November 2006|Actual|2006-11-30||Observational|||Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors|Collection of Skin Biopsy With Hair Follicles as Surrogate to Develop Biomarker Assays From Patients With Advanced Solid Tumor Malignancies Receiving Either Single Agent Weekly Irinotecan or Gemcitabine|Completed|||60|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||f||||||||||2018-06-01 03:48:50.659514|2018-06-01 03:48:50.659514
NCT00369096|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2010-05-13|2006-08-28|2006-08-29|Estimate|||||||2010-05-13|2010-05-14|Estimate|September 2006||2006-09-30|May 2010|2010-05-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|||Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)|Randomized, Controlled and Open Study to Assess the Efficacy (Peritoneal Biocompatibility) of the Addition of Bemiparin to Icodextrin Solution in Patients in Peritoneal Dialysis With Peritoneal Transport Disorders|Completed||Phase 2|76|Anticipated|Fundación Renal Iñigo Alvarez De Toledo|||||f||||t||||||||||2018-06-01 03:48:50.784759|2018-06-01 03:48:50.784759
NCT00369083|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2006-08-28|2006-08-28|2006-08-29|Estimate|||||||2006-08-28|2006-08-29|Estimate|April 2004||2004-04-30|January 2004|2004-01-31|October 2005||2005-10-31|||||Interventional|||Hospitalization at Home of Elderly Patients With Exacerbated COPD|Home Hospitalizationfor Elderly Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: a Randomized Controlled Trial.|Completed||N/A|100||Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-06-01 03:48:50.978719|2018-06-01 03:48:50.978719
NCT00369070|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24||2015-12-14|2018-01-02|2006-08-24|2006-08-29|Estimate||||2015-12-14|2016-01-14|Estimate|2018-01-02|2018-01-04|Actual|January 31, 2007|Actual|2007-01-31|January 2018|2018-01-31|August 3, 2011|Actual|2011-08-03|April 23, 2008|Actual|2008-04-23||Interventional|||A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC|A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer|Terminated||Phase 2|186|Actual|Amgen||3|||f||||t||||||||||2018-06-01 03:48:51.038713|2018-06-01 03:48:51.038713
NCT00369057|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|||2012-03-07|2006-08-25|2006-08-29|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|February 2008|Actual|2008-02-29|||||Observational|||Intra Ocular Pressure During Robotic Prostatectomy|Intra Ocular Pressure During Robotic Prostatectomy|Completed|||15|Actual|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 03:48:51.146402|2018-06-01 03:48:51.146402
NCT00369044|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2009-04-07|2006-08-28|2006-08-29|Estimate|||||||2009-04-07|2009-04-08|Estimate|October 2006||2006-10-31|June 2007|2007-06-30|July 2008|Anticipated|2008-07-31|||||Interventional|||Prednisone for Decompensated Congestive Heart Failure|Chronic Administration of Prednisone in Management of Patients With Decompensated Congestive Heart Failure|Suspended||Phase 2/Phase 3|60|Anticipated|Hebei Medical University|||||f||||||||||||||2018-06-01 03:48:51.209795|2018-06-01 03:48:51.209795
NCT00369031|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2008-04-14|2006-08-24|2006-08-29|Estimate|||||||2008-04-14|2008-04-15|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63|A Phase I, Open Label, Parallel Group Trial To Evaluate Safety And Immunogenicity Of Three Nasal Immunisations Using A Fixed Dose-Level Of HIV gp140 V2 Loop Deleted Protein Adjuvanted With LTK63 Followed By Intramuscular Boosting With HIV gp140 V2 Loop Deleted Protein Adjuvanted With MF59 When Administered To Healthy Adults|Terminated||Phase 1|31|Actual|St George's, University of London||3||Safety issues|f||||f||||||||||2018-06-01 03:48:51.303197|2018-06-01 03:48:51.303197
NCT00369018|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2010-11-26|2006-08-28|2006-08-29|Estimate|||||||2010-11-26|2010-11-30|Estimate|August 2006||2006-08-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.|Methyl Aminolevulinate (MAL) and Hexaminolevulinate (HAL) Photodynamic Therapy (PDT)of Cervical Intraepithelial Lesions (SIL) - a Double-blind Dose-finding Study|Completed||Phase 1/Phase 2|96|Anticipated|Photocure||6|||f||||f||||||||||2018-06-01 03:48:51.384124|2018-06-01 03:48:51.384124
NCT00369005|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2006-08-28|2006-08-28|2006-08-29|Estimate|||||||2006-08-28|2006-08-29|Estimate|December 1992||1992-12-31|August 2006|2006-08-31|June 1999||1999-06-30|||||Interventional|||Liberal Versus Restrictive Transfusion Guidelines for Preterm Infants|Randomized Trial of Liberal Versus Restrictive Guidelines for Red Blood Cell Transfusion in Preterm Infants|Completed||N/A|100||University of Iowa|||||f||||||||||||||2018-06-01 03:48:51.479844|2018-06-01 03:48:51.479844
NCT00368992|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2012-10-30||2015-08-11|2006-08-24|2006-08-29|Estimate|2015-08-11|2015-09-14|Estimate||||2015-08-11|2015-09-14|Estimate|August 2006||2006-08-31|February 2013|2013-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|110|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:48:51.578533|2018-06-01 03:48:51.578533
NCT00368979|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2008-12-05||2014-04-17|2006-08-24|2006-08-29|Estimate|2009-03-03|2009-04-02|Estimate||||2014-04-17|2014-05-15|Estimate|February 2006||2006-02-28|February 2014|2014-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects|Clinical Evaluation of Dutasteride in Benign Prostatic Hyperplasia: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparative Study of GI198745 (Dutasteride) in Subjects With Benign Prostatic Hyperplasia.|Completed||Phase 3|378|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:48:51.954956|2018-06-01 03:48:51.954956
NCT00368966|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2010-03-26|2009-02-26|2012-07-06|2006-08-25|2006-08-29|Estimate|2012-07-06|2012-08-16|Estimate|2009-09-28|2009-09-30|Estimate|2012-07-06|2012-08-16|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain|Completed||Phase 3|619|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:48:52.587337|2018-06-01 03:48:52.587337
NCT00368953|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2010-02-01|2006-08-28|2006-08-29|Estimate|||||||2010-02-01|2010-02-02|Estimate|September 2006||2006-09-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus|A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus|Completed||Phase 4|240|Anticipated|University of Leipzig||2|||f||||||||||||||2018-06-01 03:48:55.409261|2018-06-01 03:48:55.409261
NCT00368940|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-25|2017-02-27||2017-04-28|2006-08-25|2006-08-29|Estimate|2017-04-28|2017-07-24|Actual||||2017-04-28|2017-07-24|Actual|April 2006||2006-04-30|April 2017|2017-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Problem Adaptation Therapy (PATH) vs. Supportive Therapy in Treating Depressed, Cognitively Impaired Older Adults|A Treatment for Depressed, Cognitively Impaired Elders|Completed||N/A|74|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 03:48:55.507429|2018-06-01 03:48:55.507429
NCT00368927|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2013-11-14||2014-05-07|2006-08-24|2006-08-29|Estimate|2013-11-20|2014-01-08|Estimate||||2014-05-07|2014-05-23|Estimate|August 2006||2006-08-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional||Two randomized participants (one in each arm) did not initiate their assigned study intervention, leaving 61 participants evaluable for all analyses.|Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia|Randomized, Phase IIb Trial of Sulindac in Smokers With Bronchial Dysplasia|Completed||Phase 2|61|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:48:55.917396|2018-06-01 03:48:55.917396
NCT00368914|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2010-08-05|2006-08-24|2006-08-29|Estimate|||||||2010-08-05|2010-08-09|Estimate|December 2004||2004-12-31|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors|Pharmacodynamic-Guided Dose Finding Study of Rapamycin (Rapamune®, Sirolimus) in Adult Patients With Solid Tumors|Completed||Phase 1|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:48:56.460515|2018-06-01 03:48:56.460515
NCT00368901|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2010-03-04|2006-08-25|2006-08-29|Estimate|||||||2010-03-04|2010-03-05|Estimate|January 2002||2002-01-31|March 2010|2010-03-31|May 2004|Actual|2004-05-31|March 2004|Actual|2004-03-31||Interventional|||STAAR-2 Clinical Study|A Multicenter Study Using Once Every Other Week Subcutaneous Administration of Aranesp™ (Darbepoetin Alfa) and Iron Guided Algorithms to Treat Subjects With Anemia of Chronic Renal Insufficiency (CRI)|Completed||Phase 4|618|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:48:56.533973|2018-06-01 03:48:56.533973
NCT00368888|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2006-09-11|2006-08-28|2006-08-29|Estimate|||||||2006-09-11|2006-09-12|Estimate|March 2004||2004-03-31|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||Clinical Study of New Urine Collection Bag for Infants.||Completed||N/A|||Bergaliden Barnavårdscentral|||||f||||||||||||||2018-06-01 03:48:56.606469|2018-06-01 03:48:56.606469
NCT00368875|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2015-06-18||2015-10-06|2006-08-24|2006-08-29|Estimate|2015-10-06|2015-11-05|Estimate||||2015-10-06|2015-11-05|Estimate|July 2006||2006-07-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer|Phase I/II Study of a Combination of Suberoylanilide Hydroxamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer|Completed||Phase 1/Phase 2|54|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:48:56.668404|2018-06-01 03:48:56.668404
NCT00368862|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-28|||2006-08-28|2006-08-28|2006-08-29|Estimate|||||||2006-08-28|2006-08-29|Estimate|December 2005||2005-12-31|August 2006|2006-08-31|June 2006||2006-06-30|||||Interventional|||Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism.|Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism|Completed||Phase 4|80||National Institute for Health and Welfare, Finland|||||f||||||||||||||2018-06-01 03:48:56.887612|2018-06-01 03:48:56.887612
NCT00368849|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|2011-05-09||2012-12-18|2006-08-24|2006-08-29|Estimate|2012-10-29|2012-11-27|Estimate||||2012-12-18|2012-12-20|Estimate|November 2005||2005-11-30|December 2012|2012-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Atomoxetine and Huntington's Disease|Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study|Completed||Phase 2|20|Actual|University of Iowa|We cannot rule out carryover effects. Additionally, the sample size may be too low to detect small treatment changes, the treatment duration may have been too brief, and our participants had only early-stage HD which may have limited the drug effect.|2|||f||||t||||||||||2018-06-01 03:48:56.963187|2018-06-01 03:48:56.963187
NCT00368836|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2008-09-29|2006-08-24|2006-08-29|Estimate|||||||2008-09-29|2008-09-30|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Breath Analysis Technique to Diagnose Pulmonary Embolism|Expired CO2/O2 Analysis to Diagnose Pulmonary Embolism|Completed||Phase 2/Phase 3|475|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||1|||f||||t||||||||||2018-06-01 03:48:57.407588|2018-06-01 03:48:57.407588
NCT00368810|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2017-06-30|2006-08-24|2006-08-25|Estimate|||||||2017-06-30|2017-07-02|Actual|February 21, 2006||2006-02-21|November 30, 2006|2006-11-30|November 30, 2006||2006-11-30|||||Observational|||Study of Factors Involved in Resistance to Severe Malaria|Response to Plasmodium Falciparum-Derived TLR Ligands in Severe and Uncomplicated Malaria in Mali|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:48:57.592509|2018-06-01 03:48:57.592509
NCT00368797|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2008-11-14|2006-08-24|2006-08-25|Estimate|||||||2008-11-14|2008-11-18|Estimate|March 2002||2002-03-31|November 2008|2008-11-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|TALISMAN 201||Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.|Completed||Phase 2|125|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:48:57.647478|2018-06-01 03:48:57.647478
NCT00368784|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2018-03-01|2006-08-24|2006-08-25|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2007||2007-01-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||T Cell Repertoire Analysis of Immune Mediated Skin Diseases|T Cell Repertoire Analysis of Immune Mediated Skin Diseases|Recruiting|||50|Anticipated|University of California, Davis|||2||f||||f||||||Samples With DNA|"~     Fifteen tablespoons of blood will be collected prior to the initiation of a treatment and~     again after the patient shows a clinical response to a treatment. The time between blood~     draws will be no less than 3 months. There will be no more than two blood draws per patient.~      Blood samples will be used to determine the patient's HLA haplotype via PCR and DNA~     sequencing. After the patient's haplotype has been established the activated T cell~     repertoire will be analyzed for clonal expansions. Clonal expansions in the T cell repertoire~     will be determined by immunoscope analysis, which is a PCR based technique.~   "|No||2018-06-01 03:48:57.724059|2018-06-01 03:48:57.724059
NCT00368771|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2016-11-23|2006-08-24|2006-08-25|Estimate|||||||2016-11-23|2016-11-28|Estimate|July 2002||2002-07-31|November 2016|2016-11-30|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||A Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome|A Six-Month Study to Compare Outcome Differences and Visceral Response in Subjects Randomized to a Psychological Intervention for Irritable Bowel Syndrome|Completed||N/A|163|Actual|University of California, Los Angeles||3|||f||||||||||||||2018-06-01 03:48:57.800209|2018-06-01 03:48:57.800209
NCT00368758|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2006-08-24|2006-08-24|2006-08-25|Estimate|||||||2006-08-24|2006-08-25|Estimate|August 2006||2006-08-31|August 2006|2006-08-31|September 2007||2007-09-30|||||Interventional|||The Effect of Probioticson Bloating in IBS|The Effect of Probioticson Bloating in IBS|Unknown status|Recruiting|N/A|20||Royal Veterinary and Agricultural University, Denmark|||||f||||||||||||||2018-06-01 03:48:57.878218|2018-06-01 03:48:57.878218
NCT00368745|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|2009-08-10||2009-11-09|2006-08-23|2006-08-25|Estimate|2009-09-28|2009-11-09|Estimate||||2009-11-09|2009-11-11|Estimate|September 2006||2006-09-30|November 2009|2009-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|GAD||Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Pregabalin in Subjects With Generalized Anxiety Disorder (GAD) Switching From Benzodiazepine Therapy.|Completed||Phase 3|108|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:48:58.100219|2018-06-01 03:48:58.100219
NCT00368732|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2016-07-28|2006-08-24|2006-08-25|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2006||2006-07-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Observational|||Genetic and Nutritional Causes of Heart Birth Defects|Gene and Nutrient Etiologies of Human Heart Defects|Completed|||1610|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||Samples With DNA|"~     Buccal cell collection~   "|||2018-06-01 03:48:58.870695|2018-06-01 03:48:58.870695
NCT00368719|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2015-04-06|2006-08-24|2006-08-25|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|July 2016||2016-07-31|||||Interventional|||Evaluation to Assess the Long Term Safety of Tacrolimus Ointment for Atopic Dermatitis|APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long Term Safety Of Tacrolimus Ointment For The Treatment Of Atopic Dermatitis|Withdrawn||Phase 4|0|Actual|University of California, Davis||1||withdrawn due to contractual issues|f||||f||||||||||2018-06-01 03:48:58.933118|2018-06-01 03:48:58.933118
NCT00368706|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2008-04-09|2006-08-24|2006-08-25|Estimate|||||||2008-04-09|2008-04-10|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients|A Randomized, Double-Blind, Paralleled, Active Controlled, Multi-Center Study of the Efficacy and Safety of 5mg Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder|Completed||Phase 3|246|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:48:59.016071|2018-06-01 03:48:59.016071
NCT00368693|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2015-04-06|2006-08-24|2006-08-25|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2005||2005-08-31|April 2015|2015-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety Study of Dermal-Living Skin Replacement to Treat Diabetic Foot Ulcers|Pivotal Study to Evaluate the Efficacy and Safety of Dermal - Living Skin Replacement (Dermal - LSR) in the Treatment of Chronic Diabetic Foot Ulcers|Terminated||Phase 3|20|Actual|University of California, Davis||||Study terminated due to low enrollment.|f||||f||||||||||2018-06-01 03:48:59.078057|2018-06-01 03:48:59.078057
NCT00368680|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2010-12-23|2006-08-24|2006-08-25|Estimate|||||||2010-12-23|2010-12-24|Estimate|January 2007||2007-01-31|April 2007|2007-04-30|September 2009||2009-09-30|April 2008||2008-04-30||Interventional|||Early CPAP in Respiratory Distress Syndrome|Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI)|Unknown status|Recruiting|Phase 4|256|Anticipated|Pontificia Universidad Catolica de Chile|||||f||||||||||||||2018-06-01 03:48:59.142698|2018-06-01 03:48:59.142698
NCT00368667|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2010-01-12|2006-08-24|2006-08-25|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2000||2000-04-30|January 2010|2010-01-31|December 2004||2004-12-31|||||Observational|||Energy Homeostasis in Anorexia Nervosa|Energy Homeostasis in Anorexia Nervosa|Completed|||120||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:48:59.37369|2018-06-01 03:48:59.37369
NCT00368654|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2017-10-31|2006-08-24|2006-08-25|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2007||2007-01-31|October 2017|2017-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy|An Open-Label Study to Evaluate Whether a Short-Term Course of Methotrexate in Psoriasis Patients Treated With Efalizumab is Safe and Increases Efficacy|Completed||Phase 1/Phase 2|12|Actual|University of California, Davis||4|||f||||f||||||||||2018-06-01 03:48:59.451049|2018-06-01 03:48:59.451049
NCT00368641|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|2009-04-30||2017-04-19|2006-08-23|2006-08-25|Estimate|2009-04-30|2009-06-17|Estimate||||2017-04-19|2017-05-22|Actual|August 2006||2006-08-31|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Heart Failure and Peritoneal Ultrafiltration|Treatment-Resistant Heart Failure (HF) and Peritoneal Ultrafiltration (PUF): A Randomized Prospective Trial of Standard Care Versus Standard Care With Peritoneal Ultrafiltration in Patients With Treatment-Resistant Severe Heart Failure|Terminated||Phase 2|12|Actual|Baxter Healthcare Corporation|The number of subjects enrolled & duration of therapy were insufficient to complete the planned efficacy analyses & to draw any conclusion regarding all-cause hospitalization rates in both intervention and standard therapy arms.|2||Enrollment|f||||f||||||||||2018-06-01 03:48:59.578527|2018-06-01 03:48:59.578527
NCT00368628|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2009-03-02|2006-08-24|2006-08-25|Estimate|||||||2009-03-02|2009-03-03|Estimate|November 2004||2004-11-30|March 2009|2009-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Continuous Positive Airway Pressure for the Treatment of Stroke|Continuous Positive Airway Pressure for the Treatment of Acute Ischemic Stroke: A Feasibility Pilot Study|Completed||Phase 2|55|Actual|Yale University|||||f||||||||||||||2018-06-01 03:48:59.952383|2018-06-01 03:48:59.952383
NCT00368615|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2018-03-01|2006-08-24|2006-08-25|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2007||2007-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|Melanoma||Characterization of the Melanoma-Specific Immune Response|Characterization of the Melanoma-Specific Immune Response|Recruiting|||20|Anticipated|University of California, Davis|||2||f||||f||||||Samples With DNA|"~     Peripheral blood will be collected prior to initiation of chemotherapy. There will be no more~     than two blood draws per subject. Most subjects will receive a single blood draw; however,~     some may be asked to return for an additional blood draw if investigators were unable to~     isolate melanoma-specific immune cells after the first blood draw. Two separate blood draws~     will be the maximum.~   "|No||2018-06-01 03:49:00.013844|2018-06-01 03:49:00.013844
NCT00368602|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-24|||2015-04-06|2006-08-24|2006-08-25|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2005||2005-06-30|April 2015|2015-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Beta Blocker for Chronic Wound Healing|Beta Adrenergic Receptor Modulation of Burn Wound Healing|Terminated||Phase 2|40|Actual|University of California, Davis||2||Lack of funding.|f||||f||||||||||2018-06-01 03:49:00.151758|2018-06-01 03:49:00.151758
NCT00368589|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2015-04-15|2006-08-22|2006-08-24|Estimate|||||||2015-04-15|2015-04-16|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging|A 12 Week, Randomised, Double Blind Study Evaluating the Effects of Low Dose (10mg) and High Dose (80mg) Atorvastatin on Macrophage Activity and Carotid Plaque Inflammation as Determined by Ultra Small Super-Paramagnetic Iron Oxide (USPIO) Enhanced Carotid Magnetic Resonance Imaging (MRI)|Completed|||47|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:49:00.229472|2018-06-01 03:49:00.229472
NCT00368576|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2016-12-02|2006-08-22|2006-08-24|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2006||2006-08-31|December 2016|2016-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study To Determine The Effect Of SB-480848 On Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Repeat Dose Study to Assess the Effect of SB-480848 on Overall Asthma Control in Adult Subjects With Persistent Asthma Controlled on Stable, Low-dose, Inhaled Corticosteroids|Completed||Phase 1|67|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:49:00.290137|2018-06-01 03:49:00.290137
NCT00368563|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2009-02-10|2006-08-23|2006-08-24|Estimate|||||||2009-02-10|2009-02-11|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Capacitance and Transepidermal Water Loss Test to Determine the Ability of Sunscreen to Moisturize Skin||Completed||Phase 2/Phase 3|||Loreal USA|||||||||||||||||||2018-06-01 03:49:00.389424|2018-06-01 03:49:00.389424
NCT00368550|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2010-06-04||2011-06-17|2006-08-22|2006-08-24|Estimate|2010-08-11|2010-08-31|Estimate||||2011-06-17|2011-06-21|Estimate|February 2004||2004-02-29|June 2011|2011-06-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Sertraline Pharmacotherapy for Alcoholism Subtypes|Sertraline Pharmacotherapy for Alcoholism Subtypes|Completed||Phase 4|134|Actual|UConn Health||2|||f||||t||||||||||2018-06-01 03:49:00.474135|2018-06-01 03:49:00.474135
NCT00368537|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|2009-09-30||2012-08-08|2006-08-23|2006-08-24|Estimate|2012-08-08|2012-08-09|Estimate||||2012-08-08|2012-08-09|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections|A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections|Completed||Phase 4|550|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:49:00.831015|2018-06-01 03:49:00.831015
NCT00368524|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2006-08-23|2006-08-23|2006-08-24|Estimate|||||||2006-08-23|2006-08-24|Estimate|November 2001||2001-11-30|August 2006|2006-08-31|November 2005||2005-11-30|||||Interventional|||Cost Effective Treatment for Dually Diagnosed Homeless|Cost Effective Treatment for Dually Diagnosed Homeless|Completed||N/A|160||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 03:49:01.427827|2018-06-01 03:49:01.427827
NCT00368511|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2008-05-05|2006-08-23|2006-08-24|Estimate|||||||2008-05-05|2008-05-07|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Fall Prevention Strategies Including Music and Posturography|The Nolwenn Effect in Geriatric Nursing Homes in the Netherlands|Completed||Early Phase 1|50|Actual|Carrick Institute for Graduate Studies||1|||f||||t||||||||||2018-06-01 03:49:01.481076|2018-06-01 03:49:01.481076
NCT00368498|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2006-08-23|2006-08-23|2006-08-24|Estimate|||||||2006-08-23|2006-08-24|Estimate|June 2006||2006-06-30|August 2006|2006-08-31|December 2007||2007-12-31|||||Interventional|||A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely|A Randomized Single Blind Parallel Control Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely|Unknown status|Recruiting|Phase 4|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:49:01.538849|2018-06-01 03:49:01.538849
NCT00368485|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2011-09-19|2006-08-22|2006-08-24|Estimate|||||||2011-09-19|2011-09-21|Estimate|August 2006||2006-08-31|September 2011|2011-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Neural Control of Non-invasive Ventilation in the Preterm|Neural Control of Non-invasive Ventilation in the Preterm|Completed||Phase 1|24|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 03:49:01.595507|2018-06-01 03:49:01.595507
NCT00368472|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2015-06-26||2015-11-05|2006-08-22|2006-08-24|Estimate|2015-11-05|2015-12-10|Estimate||||2015-11-05|2015-12-10|Estimate|October 2006||2006-10-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional||Analysis of baseline characteristics are based on the Full Intent to Treat (ITT) Analysis Set, defined as participants who received at least 1 dose of open-label perampanel and had valid seizure data during the OLE study.|4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures|An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures|Completed||Phase 2|138|Actual|Eisai Inc.||1|||f||||f||||||||||2018-06-01 03:49:01.696627|2018-06-01 03:49:01.696627
NCT00368459|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2015-03-01||2015-03-20|2006-08-22|2006-08-24|Estimate|2015-03-20|2015-04-02|Estimate||||2015-03-20|2015-04-02|Estimate|August 2006||2006-08-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional||Postmenopausal women with Alzheimer's disease of mild to moderate severity|Raloxifene for Women With Alzheimer's Disease|Raloxifene in Women With AD: Randomized Controlled Trial|Completed||Phase 2|42|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 03:49:02.190498|2018-06-01 03:49:02.190498
NCT00368446|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2018-05-08|2006-08-23|2006-08-24|Estimate|||||||2018-05-08|2018-05-09|Actual|August 1, 2006||2006-08-01|April 25, 2018|2018-04-25||||||||Observational|||Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease|Genetic Disorders of Mucociliary Clearance|Completed|||87|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:02.745396|2018-06-01 03:49:02.745396
NCT00368433|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2017-06-30|2006-08-23|2006-08-24|Estimate|||||||2017-06-30|2017-07-02|Actual|August 21, 2006||2006-08-21|May 24, 2011|2011-05-24|May 24, 2011||2011-05-24|||||Observational|||Hypersensitivity in Tourette Syndrome|Hypersensitivity in Tourette Syndrome: An Evaluation of Perceived Intensity Versus Threshold|Completed|||46|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:02.810743|2018-06-01 03:49:02.810743
NCT00368420|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2011-02-11|2006-08-23|2006-08-24|Estimate|||||||2011-02-11|2011-02-15|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|October 2009|Actual|2009-10-31|July 2008|Actual|2008-07-31||Observational|||Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer|Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer|Completed|||122|Actual|AGO Study Group|||||f||||f||||||||||2018-06-01 03:49:02.89818|2018-06-01 03:49:02.89818
NCT00368407|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2006-08-23|2006-08-23|2006-08-24|Estimate|||||||2006-08-23|2006-08-24|Estimate|April 2005||2005-04-30|April 2005|2005-04-30|July 2006||2006-07-31|||||Observational|||Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck|Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck|Completed|||||Fourth Military Medical University|||||f||||||||||||||2018-06-01 03:49:03.105334|2018-06-01 03:49:03.105334
NCT00368394|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2006-08-23|2006-08-23|2006-08-24|Estimate|||||||2006-08-23|2006-08-24|Estimate|January 2004||2004-01-31|August 2006|2006-08-31||||||||Interventional|||Dose-Exposure-Response in Type 1 Diabetes Mellitus|Dose-Exposure-Response Relationship of Insulin Glulisine (HMR1964) in Subjects With Type 1 Diabetes Mellitus Assessed With the Euglycemic Clamp Technique Using the Biostator (TM)|Completed||Phase 1|18||Sanofi|||||f||||||||||||||2018-06-01 03:49:03.178519|2018-06-01 03:49:03.178519
NCT00368381|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2012-02-10|2006-08-23|2006-08-24|Estimate|||||||2012-02-10|2012-02-13|Estimate|September 2006||2006-09-30|February 2012|2012-02-29|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis|A Blinded, Placebo Controlled Trial of Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis|Withdrawn||Phase 4|0|Actual|CAMC Health System||1||Study closed for PI failure to submit renewal paperwork|f||||f||||||||||2018-06-01 03:49:03.273057|2018-06-01 03:49:03.273057
NCT00368368|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2016-11-01|2006-08-22|2006-08-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2006||2006-01-31|November 2016|2016-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.|An Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics/Pharmacodynamics and Safety of GK Activator (2) Following a Single Oral Dose Administration in Patients With Type 2 Diabetes.|Completed||Phase 1|5|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:49:03.389949|2018-06-01 03:49:03.389949
NCT00368355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2017-08-29|2006-08-23|2006-08-24|Estimate|||||||2017-08-29|2017-08-31|Actual|April 2000||2000-04-30|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|MOHEL||T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts|CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning|Recruiting||Phase 2|87|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 03:49:03.503542|2018-06-01 03:49:03.503542
NCT00368342|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2009-02-17|2006-08-23|2006-08-24|Estimate|||||||2009-02-17|2009-02-19|Estimate||||January 2006|2006-01-31||||||||Interventional|||Chronic Bronchiolitis or Resistant Asthma?||Completed||Phase 4|||Baqiyatallah Medical Sciences University|||||f||||||||||||||2018-06-01 03:49:03.667882|2018-06-01 03:49:03.667882
NCT00368329|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2012-07-13|2006-08-23|2006-08-24|Estimate|||||||2012-07-13|2012-07-16|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer|Phase I Study of Dose Escalation Using Image-guided Radiotherapy to Deliver a Stereotactic Radiosurgical Boost After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer|Terminated||Phase 1|4|Actual|Stanford University||||low accrual|f||||t||||||||||2018-06-01 03:49:03.742828|2018-06-01 03:49:03.742828
NCT00368316|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2012-05-09||2012-06-21|2006-08-22|2006-08-24|Estimate|2012-05-09|2012-06-19|Estimate||||2012-06-21|2012-06-22|Estimate|January 2003||2003-01-31|June 2012|2012-06-30|February 2009|Actual|2009-02-28|January 2008|Actual|2008-01-31||Interventional|||Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel|Phase 3 Study (Safety, Immunogenicity and Efficacy) of Improved Shigella Conjugate Vaccines in 1-4 Year Olds in Israel|Completed||Phase 3|2799|Actual|National Institutes of Health Clinical Center (CC)|No efficacy could be assessed after 2nd injection of S. sonnei conjugate due to the small number of positive isolates at that time. There were too few cases of S. flexneri 2a infection for evaluation of vaccine B efficacy.|2|||f||||t||||||||||2018-06-01 03:49:03.897568|2018-06-01 03:49:03.897568
NCT00368303|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2012-05-31|2006-08-22|2006-08-24|Estimate|||||||2012-05-31|2012-06-04|Estimate|December 2006||2006-12-31|March 2011|2011-03-31||||||||Interventional|||A Local Register Study For Major Depression Of Paroxetine Controlled Release|A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression|Completed||Phase 3|362||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:49:04.21874|2018-06-01 03:49:04.21874
NCT00368290|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2013-12-12||2018-02-19|2006-08-22|2006-08-24|Estimate|2013-12-12|2014-01-29|Estimate||||2018-02-19|2018-03-15|Actual|September 2006||2006-09-30|February 2018|2018-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MOD6||Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior|Modafinil Treatment for Cocaine Dependence and HIV-High Risk Behavior|Completed||Phase 2|94|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:49:04.31891|2018-06-01 03:49:04.31891
NCT00368277|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2010-12-14||2011-02-28|2006-08-22|2006-08-24|Estimate|2011-02-28|2011-03-25|Estimate||||2011-02-28|2011-03-25|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly|A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension|Completed||Phase 3|901|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:49:04.569388|2018-06-01 03:49:04.569388
NCT00368264|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2009-10-02|2006-08-23|2006-08-24|Estimate|||||||2009-10-02|2009-10-05|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )|A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V Glomerulonephritis|Terminated||Phase 2/Phase 3|1|Actual|Medical University of Vienna||2||"Failure to recruit patients with membranous lupus nephritis not previously treated with~   azathioprine ."|f||||||||||||||2018-06-01 03:49:05.06895|2018-06-01 03:49:05.06895
NCT00368251|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|2016-03-14|2009-09-09|2017-07-06|2006-08-23|2006-08-24|Estimate|2016-03-14|2016-04-13|Estimate|2009-11-05|2009-11-09|Estimate|2017-07-06|2017-08-01|Actual|November 2006||2006-11-30|July 2017|2017-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||The Baseline Analysis Population contains all randomized subjects who are identical with the Intent-To-Treat (ITT) population.|Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease|Completed||Phase 3|56|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 03:49:05.358571|2018-06-01 03:49:05.358571
NCT00368238|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2006-08-23|2006-08-23|2006-08-24|Estimate|||||||2006-08-23|2006-08-24|Estimate|October 2005||2005-10-31|August 2006|2006-08-31|July 2006||2006-07-31|||||Interventional|||Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects|Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects|Completed||Phase 2|96||Yale University|||||f||||||||||||||2018-06-01 03:49:06.178632|2018-06-01 03:49:06.178632
NCT00368225|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2017-06-30|2006-08-23|2006-08-24|Estimate|||||||2017-06-30|2017-07-02|Actual|June 22, 2006||2006-06-22|January 22, 2009|2009-01-22|January 22, 2009||2009-01-22|||||Observational|||Transplant-Related Accelerated Progression of Hepatitis C|Transplant-Related Accelerated Progression of Hepatitis C (TRAP-C)|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:06.242338|2018-06-01 03:49:06.242338
NCT00368212|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2013-03-15|2006-08-23|2006-08-24|Estimate|||||||2013-03-15|2013-03-19|Estimate|May 2005||2005-05-31|March 2013|2013-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Integrated Treatment Program for Hypochondriasis in Primary Care Settings|Treating Refractory Symptoms in Primary Care (Hypochondriasis: Diagnosis, Description and Medical Care)|Completed||Phase 3|91|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 03:49:06.309056|2018-06-01 03:49:06.309056
NCT00368199|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2018-02-22|2006-08-22|2006-08-24|Estimate|||||||2018-02-22|2018-02-26|Actual|September 1, 2006|Actual|2006-09-01|February 2018|2018-02-28|September 15, 2012|Actual|2012-09-15|September 18, 2008|Actual|2008-09-18||Observational|||Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes|Diagnostic Value Transcranial Duplex Scanning and Single Photon Emission Tomography in Patients Suspected of Having Idiopathic Parkinson Disease or Atypical Parkinson Syndromes|Completed|||196|Actual|Maastricht University Medical Center|||||f||||t||||||None Retained|"~     no biocpsicmens~   "|Yes|Dataset is published with PeerJ|2018-06-01 03:49:06.41358|2018-06-01 03:49:06.41358
NCT00368186|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2006-08-23|2006-08-23|2006-08-24|Estimate|||||||2006-08-23|2006-08-24|Estimate|May 2001||2001-05-31|August 2006|2006-08-31|November 2002||2002-11-30|||||Interventional|||Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.|An Open, Multicenter Clinical Trial to Investigate the Immunogenicity and Safety of the Pneumococcal 7-Valent Conjugate Vaccine (PREVENAR) in Sickle Cell Disease Infants.|Terminated||Phase 4|51||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:49:06.517145|2018-06-01 03:49:06.517145
NCT00368173|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2012-09-11|2006-08-23|2006-08-24|Estimate|||||||2012-09-11|2012-09-13|Estimate||||September 2012|2012-09-30||||||||Interventional|||IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome||Completed||Phase 2/Phase 3|||Insmed Incorporated|||||||||||||||||||2018-06-01 03:49:06.58572|2018-06-01 03:49:06.58572
NCT00368160|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2012-02-21|2006-08-23|2006-08-24|Estimate|||||||2012-02-21|2012-02-22|Estimate|March 2004||2004-03-31|February 2012|2012-02-29|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers|The Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Healthy Volunteers Compared to Placebo|Completed||Phase 1|32|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 03:49:06.729132|2018-06-01 03:49:06.729132
NCT00368147|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2009-02-19|2006-08-23|2006-08-24|Estimate|||||||2009-02-19|2009-02-20|Estimate|April 2002||2002-04-30|February 2009|2009-02-28|February 2007|Actual|2007-02-28|||||Observational|||Access Creation for Hemodialysis: Association With Structural Changes of the Heart|Access Creation for Hemodialysis: Potential Contribution to Left Ventricular Remodelling|Completed|||84|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 03:49:06.849953|2018-06-01 03:49:06.849953
NCT00368134|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2007-06-27|2006-08-23|2006-08-24|Estimate|||||||2007-06-27|2007-06-28|Estimate|August 2006||2006-08-31|June 2007|2007-06-30||||||||Interventional|||To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Compare the Effects of 12 Weeks Treatment With Vildagliptin 50 mg Bid to Voglibose 0.2 mg Tid in Patients With Type 2 Diabetes|Completed||Phase 3|370||Novartis|||||f||||||||||||||2018-06-01 03:49:07.977389|2018-06-01 03:49:07.977389
NCT00368121|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2012-07-12|2006-08-23|2006-08-24|Estimate|||||||2012-07-12|2012-07-13|Estimate|August 2006||2006-08-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|EMMA-1||EMMA-1 (Erbitux for Multiple Myeloma)|Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma)|Terminated||Phase 2|13|Actual|University of Cologne||1||Lack of recruitable patients|f||||f||||||||||2018-06-01 03:49:08.057758|2018-06-01 03:49:08.057758
NCT00368108|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2012-10-23|2012-08-23|2013-05-13|2006-08-22|2006-08-24|Estimate|2013-01-02|2013-02-05|Estimate|2012-08-23|2012-08-30|Estimate|2013-05-13|2013-05-20|Estimate|August 2006||2006-08-31|January 2013|2013-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|Completed||Phase 3|752|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 03:49:08.23957|2018-06-01 03:49:08.23957
NCT00368095|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2008-08-02|2006-08-23|2006-08-24|Estimate|||||||2008-08-02|2008-08-05|Estimate|August 2006||2006-08-31|August 2008|2008-08-31|August 2016|Anticipated|2016-08-31|||||Observational|||Rajavithi Health Promotion Project (Population Base Cohort)|The Rajavithi Prospective Cohort Study on Community's Member Health (HPH-Cohort Study)|Unknown status|Recruiting||2000|Anticipated|Rajavithi Hospital|||||f||||||||||Samples With DNA|"~     Human Genetic Bank will be storaged in Biomolecular center Rajavithi Hospital for determine~     the gene that influence the specific disease in the population~   "|||2018-06-01 03:49:09.07107|2018-06-01 03:49:09.07107
NCT00368082|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2017-10-27|2006-08-22|2006-08-24|Estimate|||||||2017-10-27|2017-10-31|Actual|April 2006||2006-04-30|October 2017|2017-10-31|July 2031|Anticipated|2031-07-31|September 2013|Actual|2013-09-30||Interventional|TGF-beta||Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)|Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma|Active, not recruiting||Phase 1|20|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 03:49:09.1598|2018-06-01 03:49:09.1598
NCT00368069|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|2009-04-01||2015-08-13|2006-08-23|2006-08-24|Estimate|2009-06-05|2009-07-28|Estimate||||2015-08-13|2015-08-26|Estimate|August 2006||2006-08-31|August 2015|2015-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR|A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra® Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.|Completed||Phase 3|158|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 03:49:09.265265|2018-06-01 03:49:09.265265
NCT00368056|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2012-02-21|2006-08-23|2006-08-24|Estimate|||||||2012-02-21|2012-02-22|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability|Effects of a Single Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Patients With Primary Insomnia Compared to Placebo|Completed||Phase 3|32|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 03:49:09.808869|2018-06-01 03:49:09.808869
NCT00368043|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2018-05-23|2006-08-23|2006-08-24|Estimate|||||||2018-05-23|2018-05-24|Actual|August 18, 2006||2006-08-18|March 30, 2015|2015-03-30|March 30, 2015||2015-03-30|||||Observational|||Endocrine and Psychological Evaluation of Adopted Children|Biobehavioral Study of Recently Adopted Children|Terminated|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:09.882369|2018-06-01 03:49:09.882369
NCT00368030|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2012-02-21|2006-08-23|2006-08-24|Estimate|||||||2012-02-21|2012-02-22|Estimate|January 2004||2004-01-31|February 2012|2012-02-29|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder|Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Related to MDD Acronym: DREAMDD|Completed||Phase 3|545|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 03:49:09.99195|2018-06-01 03:49:09.99195
NCT00368017|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2010-11-01|2006-08-23|2006-08-24|Estimate|||||||2010-11-01|2010-11-03|Estimate|April 2006||2006-04-30|November 2010|2010-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease|Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease|Terminated||Phase 2|12|Actual|Vanderbilt University||2||unable to replace Fellow conducting the study who left institution in 2007|f||||f||||||||||2018-06-01 03:49:10.191102|2018-06-01 03:49:10.191102
NCT00368004|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2018-05-23|2006-08-23|2006-08-24|Estimate|||||||2018-05-23|2018-05-24|Actual|July 28, 2006||2006-07-28|April 15, 2013|2013-04-15|April 15, 2013||2013-04-15|||||Observational|||Family Studies of Uveal Coloboma|Family Studies of Uveal Coloboma|Terminated|||100|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:10.272097|2018-06-01 03:49:10.272097
NCT00367991|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|2011-08-09||2017-12-14|2006-08-23|2006-08-24|Estimate|2011-08-09|2011-09-13|Estimate||||2017-12-14|2018-01-12|Actual|November 2006||2006-11-30|December 2017|2017-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction|Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction|Completed||Phase 2|44|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:49:10.332863|2018-06-01 03:49:10.332863
NCT00367978|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2011-11-07|2006-08-23|2006-08-24|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2001||2001-12-31|August 2006|2006-08-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus|A Randomized, Multicenter, Study to Determine the Efficacy and Safety of Amlodipine/Benazepril Hydrochloride Versus Enalapril in the Treatment of Hypertension in an African-American Population With Type 2 Diabetes|Completed||Phase 4|275|Actual|Novartis|||||||||||||||||||2018-06-01 03:49:10.62343|2018-06-01 03:49:10.62343
NCT00367965|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-23|||2012-02-21|2006-08-23|2006-08-24|Estimate|||||||2012-02-21|2012-02-22|Estimate|February 2004||2004-02-29|February 2012|2012-02-29|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis|The Effect of Eszopiclone 3 mg Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis|Completed||Phase 3|153|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 03:49:10.694252|2018-06-01 03:49:10.694252
NCT00367952|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2011-06-22|2006-08-23|2006-08-24|Estimate|||||||2011-06-22|2011-06-23|Estimate|August 2006||2006-08-31|June 2011|2011-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Long Term, Safety Study of Apricitabine in HIV-infected Subjects|An Open Label Long Term Safety Extension Study of Apricitabine in Treatment-experienced HIV-1 Infected Subjects|Completed||Phase 2|42|Actual|Avexa||1|||f||||t||||||||||2018-06-01 03:49:10.843546|2018-06-01 03:49:10.843546
NCT00367757|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2009-07-30|2006-08-22|2006-08-23|Estimate|||||||2009-07-30|2009-07-31|Estimate|August 2006||2006-08-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial|Open, Prospective, Randomized Trial Comparing Trigger vs Substrate vs Hybrid Approaches for AF Ablation|Completed||N/A|107|Actual|St. Jude Medical||3|||f||||f||||||||||2018-06-01 03:49:12.625752|2018-06-01 03:49:12.625752
NCT00367939|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2017-05-16|2006-08-22|2006-08-24|Estimate|||||||2017-05-16|2017-05-18|Actual|December 2005||2005-12-31|May 2017|2017-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine|An Multicenter Study to Evaluate the Efficacy and Safety of a 5 Week Therapy With the Combination of Valsartan 160 mg Plus Amlodipine 10 mg in Hypertensive Patients Not Adequately Responding to a 5 Week Therapy With Ramipril 5 mg and Felodipine 5 mg|Completed||Phase 3|132|Actual|Novartis|||||f||||||||||||||2018-06-01 03:49:10.920056|2018-06-01 03:49:10.920056
NCT00367926|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2006-08-22|2006-08-22|2006-08-23|Estimate|||||||2006-08-22|2006-08-23|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||The Effect of American Ginseng Root and Its Components on Glycemia in Healthy Individuals|Effect of American Ginseng Root and Derived Polysaccharides on Postprandial Glycemia in Healthy Individuals|Completed||Phase 3|12||Risk Factor Modification Centre|||||f||||||||||||||2018-06-01 03:49:11.063866|2018-06-01 03:49:11.063866
NCT00367913|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2006-08-21|2006-08-21|2006-08-23|Estimate|||||||2006-08-21|2006-08-23|Estimate|March 1995||1995-03-31|July 2006|2006-07-31|September 2004||2004-09-30|||||Interventional|||Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease|Treatment of Pulmonary Disease Caused by MAIS, M.Xenopi or M.Malmoense: A Comparison of Two Triple Drug Regimens and an Assessment of the Value of Immunotherapy With M.Vaccae|Completed||Phase 4|400||British Thoracic Society|||||f||||||||||||||2018-06-01 03:49:11.12549|2018-06-01 03:49:11.12549
NCT00367900|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2018-05-08|2006-08-22|2006-08-23|Estimate|||||||2018-05-08|2018-05-09|Actual|February 8, 2006||2006-02-08|April 27, 2018|2018-04-27||||||||Observational|||Parkinson's Genes and Environment Study|The Parkinson's, Genes and Environment (PAGE) Study|Completed|||3100|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:11.189148|2018-06-01 03:49:11.189148
NCT00367887|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21||2013-02-07|2013-02-07|2006-08-21|2006-08-23|Estimate||||2013-02-07|2013-02-11|Estimate|2013-02-07|2013-02-11|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects|A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection|Completed||Phase 2|246|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 03:49:11.289697|2018-06-01 03:49:11.289697
NCT00367874|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2006-08-22|2006-08-22|2006-08-23|Estimate|||||||2006-08-22|2006-08-23|Estimate|February 2003||2003-02-28|August 2006|2006-08-31|November 2003||2003-11-30|||||Interventional|||Treatment of Polydrug-Using Opiate Dependents During Withdrawal|Treatment of Polydrug-Using Opiate Dependents During Withdrawal|Completed||Phase 4|12||Sorlandet Hospital HF|||||f||||||||||||||2018-06-01 03:49:11.420959|2018-06-01 03:49:11.420959
NCT00367861|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2014-02-21|2006-08-22|2006-08-23|Estimate|||||||2014-02-21|2014-02-24|Estimate|May 2002||2002-05-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|April 2012|Actual|2012-04-30||Interventional|||Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance|A Prospective Multicentric Randomized Study of Glivec® in Patients With Advanced Gastrointestinal Stromal Tumors Expressing C-kit Comparing Treatment Interruption After 5 Years vs Treatment Maintenance|Completed||Phase 3|564|Actual|Centre Leon Berard||1|||f||||t||||||||||2018-06-01 03:49:11.483604|2018-06-01 03:49:11.483604
NCT00367848|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2008-05-19|2006-08-22|2006-08-23|Estimate|||||||2008-05-19|2008-05-20|Estimate|November 2006||2006-11-30|May 2008|2008-05-31||||||||Observational|||Efficacy of Ultrasound in Evaluating Occult Fractures|The Efficacy of Ultrasound in Evaluating Fractures in the Ankle and Foot in Children When the X-Ray Does Not Demonstrate Fractures.|Completed|||50|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:49:11.57096|2018-06-01 03:49:11.57096
NCT00367835|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2009-09-10||2010-10-07|2006-08-22|2006-08-23|Estimate|2009-10-20|2009-11-26|Estimate||||2010-10-07|2010-10-13|Estimate|September 2006||2006-09-30|October 2010|2010-10-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms|A Double-Blind, Randomized, Multi-Center, Flexible Dose Study Evaluating the Efficacy and Safety of SPD503 (Guanfacine Hydrochloride) in Children Aged 6-12 With Symptoms of Oppositionality and a Diagnosis of Attention Deficit/Hyperactivity Disorder|Completed||Phase 3|217|Actual|Shire||2|||f||||||||||||||2018-06-01 03:49:11.661368|2018-06-01 03:49:11.661368
NCT00367822|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2012-03-06|2006-08-22|2006-08-23|Estimate|||||||2012-03-06|2012-03-07|Estimate||||January 2010|2010-01-31||||||||Interventional|||Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)|Transdermal Lisuride: a Double-blind, Randomized, Active- and Placebo-controlled Multi-centre Phase III Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)|Completed||Phase 3|300||Axxonis Pharma AG|||||f||||||||||||||2018-06-01 03:49:12.190111|2018-06-01 03:49:12.190111
NCT00367809|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2008-09-12|2006-08-21|2006-08-23|Estimate|||||||2008-09-12|2008-09-16|Estimate|August 2003||2003-08-31|September 2008|2008-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|WIAT||Wellness Interventions After Transplant Study|Impact of Mind-Body Interventions Post Organ Transplant|Completed||Phase 3|140|Actual|National Institute of Nursing Research (NINR)||3|||f||||f||||||||||2018-06-01 03:49:12.255713|2018-06-01 03:49:12.255713
NCT00367796|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2017-06-30|2006-08-22|2006-08-23|Estimate|||||||2017-06-30|2017-07-02|Actual|January 5, 2005||2005-01-05|December 23, 2008|2008-12-23|December 23, 2008||2008-12-23|||||Observational|||Genetic Analysis of Craniosynostosis, Philadelphia Type|Genetic Analysis of Craniosynostosis, Philadelphia Type (OMIM 601222)|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:12.336148|2018-06-01 03:49:12.336148
NCT00367783|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-07-29|2006-08-21|2006-08-23|Estimate|||||||2011-07-29|2011-08-01|Estimate|June 2006||2006-06-30|July 2011|2011-07-31|April 2007|Actual|2007-04-30|||||Interventional|||Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity|A 12-Week, Phase 2A, Randomized, Subject And Investigator Blind, Placebo-Controlled Trial To Evaluate The Effect Of CP-741,952 On Weight Loss In Otherwise Healthy Overweight And Obese Adult Subjects|Terminated||Phase 2|100||Pfizer||||See Detailed Description for termination reason.|||||f||||||||||2018-06-01 03:49:12.382667|2018-06-01 03:49:12.382667
NCT00367770|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|2016-04-11||2016-08-16|2006-08-22|2006-08-23|Estimate|2016-07-05|2016-08-15|Estimate||||2016-08-16|2016-09-22|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology|A Multi-Center, Open-Label Extension Study to Protocol AC-052-405 to Evaluate the Safety and Efficacy of Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology|Completed||Phase 4|37|Actual|Actelion||1|||f||||f||||||||No||2018-06-01 03:49:12.448344|2018-06-01 03:49:12.448344
NCT00367744|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|2016-10-05||2016-12-08|2006-08-21|2006-08-23|Estimate|2016-12-08|2017-02-06|Estimate||||2016-12-08|2017-02-06|Estimate|July 2006||2006-07-31|August 2006|2006-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Rosiglitazone Effect on Mitochondria and Lipoatrophy|Placebo Controlled Study of Rosiglitazone in HIV Lipoatrophy|Completed||Phase 2|71|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Limitations of the study include a relative small sample size as well as loss of follow up of 9 participants at the end of the study.|2|||f||||f||||||||No||2018-06-01 03:49:12.7055|2018-06-01 03:49:12.7055
NCT00367731|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2006-08-22|2006-08-22|2006-08-23|Estimate|||||||2006-08-22|2006-08-23|Estimate|January 2005||2005-01-31|August 2006|2006-08-31|September 2006||2006-09-30|||||Observational|||NOW Thai HAART Study|Neurological Outcomes With in THAI National HAART Program.|Completed|||500||Rajavithi Hospital|||||f||||||||||||||2018-06-01 03:49:13.110943|2018-06-01 03:49:13.110943
NCT00367718|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2006-08-21|2006-08-21|2006-08-23|Estimate|||||||2006-08-21|2006-08-23|Estimate||||August 2006|2006-08-31||||||||Interventional|||Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma|A Phase II Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma|Unknown status|Not yet recruiting|Phase 2|25||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:49:13.170978|2018-06-01 03:49:13.170978
NCT00367705|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2009-08-16|2006-08-22|2006-08-23|Estimate|||||||2009-08-16|2009-08-18|Estimate|August 2009||2009-08-31|August 2006|2006-08-31|December 2010|Anticipated|2010-12-31|September 2010|Anticipated|2010-09-30||Interventional|||VSL#3 Treatment in Children With Crohn's Disease|Double-blind Placebo Controlled Trial of VSL#3 in Children With Crohn's Disease|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-06-01 03:49:13.258665|2018-06-01 03:49:13.258665
NCT00367692|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2009-09-04|2006-08-21|2006-08-23|Estimate|||||||2009-09-04|2009-09-09|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|April 2007||2007-04-30|||||Interventional|||Study Evaluating PSI-697 in Patients With Scleritis|An Exploratory, Double Blind, Placebo-controlled, Randomized, Single-dose, Cross-over, Proof of Mechanism Study of Orally Administered PSI-697 in Patients With Scleritis|Terminated||Phase 1|12|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:49:13.340159|2018-06-01 03:49:13.340159
NCT00367679|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2009-11-19|2009-07-22|2012-06-07|2006-08-22|2006-08-23|Estimate|2010-02-04|2010-03-17|Estimate|2009-07-23|2009-08-10|Estimate|2012-06-07|2012-06-12|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer|A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects With Stage IA, IB, IIA or IIB (to T2) Resectable Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|35|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:49:13.432496|2018-06-01 03:49:13.432496
NCT00367666|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2017-09-15|2006-08-22|2006-08-23|Estimate|||||||2017-09-15|2017-09-18|Actual|March 2002|Actual|2002-03-31|September 2017|2017-09-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Using Diagnostic Tools to Stage Breast Cancer|Evaluation of Multimodality Breast Imaging: Lesion Staging|Active, not recruiting||N/A|400|Anticipated|University of Pennsylvania||1|||f||||||||||||||2018-06-01 03:49:13.836718|2018-06-01 03:49:13.836718
NCT00367653|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2008-09-15|2006-08-22|2006-08-23|Estimate|||||||2008-09-15|2008-09-16|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.|A Phase 3, Randomized, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa|Completed||Phase 3|397|Actual|Pfizer||2|||f||||||||||||||2018-06-01 03:49:13.904282|2018-06-01 03:49:13.904282
NCT00367640|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|2016-01-25||2016-04-18|2006-08-22|2006-08-23|Estimate|2016-04-18|2016-05-23|Estimate||||2016-04-18|2016-05-23|Estimate|November 2004||2004-11-30|April 2016|2016-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional||The intent-to-treat (ITT) population included all patients who received at least one dose of investigational product and had a Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS) and at least one Rhinoconjunctivitis Total Symptom Score (RTSS) in the pollen period while on treatment.|Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis|Randomised,Double-blind,Placebo-controlled,Multinational,Multi-centre,Phase IIb/III Study of the Efficacy and Safety of Three Doses of Sublingual Immunotherapy (SLIT) Administered as Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis|Completed||Phase 2/Phase 3|628|Actual|Stallergenes Greer||4|||f||||f||||||||||2018-06-01 03:49:13.994655|2018-06-01 03:49:13.994655
NCT00367627|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2011-07-11|2006-08-22|2006-08-23|Estimate|||||||2011-07-11|2011-07-12|Estimate|December 2006||2006-12-31|August 2006|2006-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Relative Efficacy of Two Regimens of Ante-helminthic Treatment||Completed||N/A|200|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 03:49:14.310246|2018-06-01 03:49:14.310246
NCT00367614|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2007-12-07|2006-08-21|2006-08-23|Estimate|||||||2007-12-07|2007-12-10|Estimate|January 2007||2007-01-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating Pantoprazole in Adolescents With GERD|A Multicenter, Randomized, Open-Label, Single And Multiple Dose Study Of The Pharmacokinetics And Safety of Two Dose Levels of Pantoprazole Sodium Tablets In Adolescents Aged 12 Through 16 Years With A Clinical Daignosis Of GERD.|Completed||Phase 3|20|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:49:14.371181|2018-06-01 03:49:14.371181
NCT00367601|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|2016-01-13||2016-01-13|2006-08-21|2006-08-23|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|August 2006||2006-08-31|January 2016|2016-01-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer|A Phase II Study of Erlotinib With Bevacizumab in Chemotherapy Naïve Performance Status (PS) 2 Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|25|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||||2018-06-01 03:49:14.439872|2018-06-01 03:49:14.439872
NCT00367588|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2016-10-24|2006-08-22|2006-08-23|Estimate|||||||2016-10-24|2016-10-25|Estimate||||June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||Low Bacterial Diet in Patients With Cytopenia|Low Bacterial Diet in Patients With Cytopenia After Intensive Chemotherapy for Hematological Malignancy: a Study of Efficacy|Completed||N/A|20||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 03:49:14.768028|2018-06-01 03:49:14.768028
NCT00367575|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2010-08-13|2006-08-21|2006-08-23|Estimate|||||||2010-08-13|2010-08-16|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|September 2009||2009-09-30|||||Interventional|||An Internet-based Intervention for Problem Drinking|An Internet-based Intervention for Problem Drinking|Completed||N/A|359|Anticipated|Centre for Addiction and Mental Health|||||f||||||||||||||2018-06-01 03:49:14.82614|2018-06-01 03:49:14.82614
NCT00367562|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2006-10-31|2006-08-22|2006-08-23|Estimate|||||||2006-10-31|2006-11-01|Estimate|January 1996||1996-01-31|January 1996|1996-01-31|December 2005||2005-12-31|||||Interventional|||Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy|Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy|Completed||Phase 4|20||Hospital Britanico|||||f||||||||||||||2018-06-01 03:49:14.896691|2018-06-01 03:49:14.896691
NCT00367549|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2011-07-03|2006-08-22|2006-08-23|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2006||2006-09-30|May 2010|2010-05-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||Nutrition as a Determinant of Labor Outcome|Nutrition as Determinant of Labor Outcome|Completed||N/A|200|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 03:49:14.953648|2018-06-01 03:49:14.953648
NCT00367536|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2015-04-30|2006-08-21|2006-08-23|Estimate|||||||2015-04-30|2015-05-01|Estimate|August 2006||2006-08-31|July 2009|2009-07-31|August 2006||2006-08-31|||||Interventional|||Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution|An Open-label, Single-dose, Randomized-to-sequence, 4-period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women.|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:49:15.100722|2018-06-01 03:49:15.100722
NCT00367523|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2018-05-19|2006-08-22|2006-08-23|Estimate|||||||2018-05-19|2018-05-22|Actual|June 15, 2006||2006-06-15|September 28, 2017|2017-09-28|September 28, 2017||2017-09-28|||||Observational|||Pulmonary Hypertension in Patients With Sickle Cell Disease in Nigeria|Prevalence of Secondary Arterial Hypertension (PAH) in Patients With Sickle Cell Disease in Nigeria and the Role of HIV/AIDS and Endemic Parasitic Infections in the Natural History of Pulmonary Hypertension in Sickle Cell Disease|Completed|||308|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:15.152045|2018-06-01 03:49:15.152045
NCT00367497|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2007-11-19|2006-08-22|2006-08-23|Estimate|||||||2007-11-19|2007-11-20|Estimate|August 2005||2005-08-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma|Phase 2 Study of Rituximab and ESHAP (Etoposide, Methylprednisolone, Cytarabine, and Cisplatin) in Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma|Terminated||Phase 2|5|Actual|Keio University||||The stopping rule was applied because of low response rates.|f||||||||||||||2018-06-01 03:49:15.236706|2018-06-01 03:49:15.236706
NCT00367484|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|2010-04-30||2014-01-26|2006-08-21|2006-08-23|Estimate|2010-08-02|2010-08-27|Estimate||||2014-01-26|2014-02-27|Estimate|May 2004||2004-05-31|January 2014|2014-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis|Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis|Completed||Phase 4|460|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 03:49:15.313506|2018-06-01 03:49:15.313506
NCT00367471|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2018-03-28|2006-08-22|2006-08-23|Estimate|||||||2018-03-28|2018-03-29|Actual|December 7, 2006|Actual|2006-12-07|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 22, 2010|Actual|2010-12-22||Interventional|||Combination Of Lapatinib With Carboplatin, Paclitaxel and Trastuzumab In Metastatic Breast Cancer.|A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, and Herceptin in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 1|31|Actual|Novartis||2|||f||||f|t|f||||||No||2018-06-01 03:49:15.585255|2018-06-01 03:49:15.585255
NCT00367458|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-22|||2009-11-25|2006-08-22|2006-08-23|Estimate|||||||2009-11-25|2009-12-01|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Medications With the Specific Aims of Studying the Effects of Atorvastatin on HIV Viral Load and Immune Activation Markers|A Randomized Placebo Controlled Trial of Atorvastatin in HIV Positive Patients Not on Antiretroviral Medications With the Specific Aims of Studying the Effects of Atorvastatin on HIV Viral Load and Immune Activation Markers|Completed||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:49:15.699529|2018-06-01 03:49:15.699529
NCT00367445|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2008-01-25|2006-08-21|2006-08-22|Estimate|||||||2008-01-25|2008-01-29|Estimate|September 2006||2006-09-30|January 2008|2008-01-31|February 2007|Actual|2007-02-28|||||Interventional|||A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus|A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents|Completed||Phase 4|30||Pfizer|||||||||||||||||||2018-06-01 03:49:15.859672|2018-06-01 03:49:15.859672
NCT00367432|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|2011-12-02||2015-04-01|2006-08-21|2006-08-22|Estimate|2011-12-02|2012-01-16|Estimate||||2015-04-01|2015-04-21|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures|A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in Subjects From 16 to 65 Years With Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized Who Completed in a Previous Study|Completed||Phase 3|398|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:49:15.969247|2018-06-01 03:49:15.969247
NCT00367419|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2008-11-04|2006-08-21|2006-08-22|Estimate|||||||2008-11-04|2008-11-05|Estimate||||March 2006|2006-03-31||||||||Interventional|||Use of Erythromycin in Mustard-Induced Bronchiolitis|Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans|Completed||Phase 4|||Baqiyatallah Medical Sciences University|||||f||||||||||||||2018-06-01 03:49:16.445795|2018-06-01 03:49:16.445795
NCT00367406|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2014-12-04|2006-08-21|2006-08-22|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2006||2006-11-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Comparison Between Gamma 3 Nail and ACE Trochanteric Nail|Comparison Between Gamma 3 Nail and ACE Trochanteric Nail|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 03:49:16.500616|2018-06-01 03:49:16.500616
NCT00367393|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2017-02-22|2006-08-21|2006-08-22|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2006||2006-03-31|February 2017|2017-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis|An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage|Completed||Phase 4|41|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:49:16.569906|2018-06-01 03:49:16.569906
NCT00367380|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-19|2014-03-27||2014-05-02|2006-08-21|2006-08-22|Estimate|2014-05-02|2014-06-03|Estimate||||2014-05-02|2014-06-03|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers|Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers|Completed||Phase 2|18|Actual|Malaria Vaccine and Drug Development Center||3|||f||||t||||||||||2018-06-01 03:49:16.665074|2018-06-01 03:49:16.665074
NCT00367367|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-20|||2006-08-20|2006-08-20|2006-08-22|Estimate|||||||2006-08-20|2006-08-22|Estimate|December 2005||2005-12-31|August 2006|2006-08-31||||||||Interventional|||Endometrial Curettage Before Embryo Transfer|Endometrial Hysteroscopy and Curettage Prior to Embryo Transfer|Unknown status|Recruiting|N/A|90|Anticipated|HaEmek Medical Center, Israel|||||f||||||||||||||2018-06-01 03:49:16.974245|2018-06-01 03:49:16.974245
NCT00367354|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2014-12-08|2006-08-18|2006-08-22|Estimate|||||||2014-12-08|2014-12-09|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|July 2011|Actual|2011-07-31|June 2010|Actual|2010-06-30||Observational|||Respiratory Motion Analysis in Children With MRI|Respiratory Motion Analysis in Children for Improvement of MR (Magnetic Resonance) Imaging of Congenital Heart Disease|Terminated|||6|Actual|Emory University||||Lack of funding|f||||f||||||||||2018-06-01 03:49:17.043442|2018-06-01 03:49:17.043442
NCT00367341|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|2013-11-21||2013-11-21|2006-08-18|2006-08-22|Estimate|2013-11-21|2014-01-09|Estimate||||2013-11-21|2014-01-09|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|August 2011|Actual|2011-08-31||Interventional|||Imaging Predictors of Treatment Response in Depression|Imaging Predictors of Treatment Response in Depression|Completed||N/A|82|Actual|Emory University||2|||f||||t||||||||||2018-06-01 03:49:17.100644|2018-06-01 03:49:17.100644
NCT00367328|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-19|||2015-04-06|2006-08-21|2006-08-22|Estimate|||||||2015-04-06|2015-04-07|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa|To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa|Terminated||Phase 3|10|Actual|University of California, Davis||1||Terminated: recruiting or enrolling participants has halted.|f||||f||||||||||2018-06-01 03:49:17.341959|2018-06-01 03:49:17.341959
NCT00367315|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2012-05-18|2006-08-18|2006-08-22|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2003||2003-09-30|May 2012|2012-05-31||||February 2004|Actual|2004-02-29||Interventional|||Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)|A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator|Completed||Phase 3|1684||Novartis|||||||||||||||||||2018-06-01 03:49:17.406895|2018-06-01 03:49:17.406895
NCT00367302|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2013-04-30|2006-08-21|2006-08-22|Estimate|||||||2013-04-30|2013-05-01|Estimate|August 2006||2006-08-31|April 2013|2013-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release|Buprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-Release|Completed||Phase 1/Phase 2|116|Actual|National Development and Research Institutes, Inc.||2|||f||||f||||||||||2018-06-01 03:49:17.468964|2018-06-01 03:49:17.468964
NCT00367289|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2011-04-27|2006-08-21|2006-08-22|Estimate|||||||2011-04-27|2011-04-28|Estimate|October 2007||2007-10-31|August 2006|2006-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||CT for Diagnosis of Implant Stability in Revision Arthroplasty|CT for Diagnosis of Implant Stability in Revision Arthroplasty|Completed|||100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:49:17.527351|2018-06-01 03:49:17.527351
NCT00367276|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2013-10-10|2006-08-21|2006-08-22|Estimate|||||||2013-10-10|2013-10-11|Estimate|December 2002||2002-12-31|October 2013|2013-10-31|May 2004|Actual|2004-05-31|||||Interventional|||Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.|A Multicentre, Open, Uncontrolled Study to Assess Quality of Life During Six Cycles (24 Weeks) of Treatment With an Oral Contraceptive Containing 30 µg of Ethinylestradiol and 3 mg of Drospirenone (Yasmin).|Completed||Phase 3|221|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:49:17.568775|2018-06-01 03:49:17.568775
NCT00367263|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2007-04-30|2006-08-21|2006-08-22|Estimate|||||||2007-04-30|2007-05-02|Estimate|October 2006||2006-10-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary|A Randomized Cross-Over Design Study Evaluating a Traditional Paper Symptom Diary vs. the VOCEL Mobile Diary in Subjects 12 Years and Older With Mild to Moderate Persistent Asthma Receiving Ciclesonide MDI (Alvesco) 80 ug BID|Completed||N/A|12|Actual|Allergy & Asthma Medical Group & Research Center|||||f||||f||||||||||2018-06-01 03:49:17.620957|2018-06-01 03:49:17.620957
NCT00367250|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2010-09-27|2006-08-21|2006-08-22|Estimate|||||||2010-09-27|2010-09-28|Estimate|July 2006||2006-07-31|September 2010|2010-09-30|June 2011|Anticipated|2011-06-30|June 2011|Anticipated|2011-06-30||Interventional|||Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer|Phase I Study Investigating the Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer With High and Moderate HER2 Expression|Unknown status|Recruiting|Phase 1|32|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-06-01 03:49:17.675158|2018-06-01 03:49:17.675158
NCT00367237|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|2009-03-19||2017-03-13|2006-08-18|2006-08-22|Estimate|2009-05-21|2009-07-07|Estimate||||2017-03-13|2017-04-11|Actual|May 2006||2006-05-31|March 2017|2017-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)|A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis|Completed||Phase 3|115|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:49:17.732725|2018-06-01 03:49:17.732725
NCT00367224|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2009-01-28|2006-08-18|2006-08-22|Estimate|||||||2009-01-28|2009-01-29|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo|Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo|Completed||N/A|17|Actual|Henry Ford Health System|||||f||||f||||||||||2018-06-01 03:49:17.994129|2018-06-01 03:49:17.994129
NCT00367016|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-19|||2011-05-25|2006-08-19|2006-08-22|Estimate|||||||2011-05-25|2011-05-27|Estimate|February 2004||2004-02-29|May 2011|2011-05-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|Xolair||Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)|Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)|Completed||Phase 4|7|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 03:49:23.191647|2018-06-01 03:49:23.191647
NCT00367211|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2008-04-21|2006-08-21|2006-08-22|Estimate|||||||2008-04-21|2008-04-22|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.|A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.|Completed||Phase 3|400||POZEN|||||t||||||||||||||2018-06-01 03:49:18.073838|2018-06-01 03:49:18.073838
NCT00367198|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2011-07-11|2006-08-21|2006-08-22|Estimate|||||||2011-07-11|2011-07-12|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Protein Supplementation in Dialysis Patients|Protein Supplementation in Dialysis Patients|Terminated||Phase 2|6|Actual|Vanderbilt University||4||lack of enrollment|f||||f||||||||||2018-06-01 03:49:18.147065|2018-06-01 03:49:18.147065
NCT00367185|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2006-08-21|2006-08-21|2006-08-22|Estimate|||||||2006-08-21|2006-08-22|Estimate|May 2000||2000-05-31|April 2006|2006-04-30|October 2005||2005-10-31|||||Interventional|||Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma|Comparison of Melphalan-Prednisone(MP),MP-THALIDOMIDE,and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma.|Completed||Phase 3|500||University Hospital, Lille|||||f||||||||||||||2018-06-01 03:49:18.264573|2018-06-01 03:49:18.264573
NCT00367172|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2009-08-03|2006-08-21|2006-08-22|Estimate|||||||2009-08-03|2009-08-06|Estimate|June 2001||2001-06-30|August 2009|2009-08-31|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Interventional|||Directly Observed Antiretroviral Therapy Among Active Drug Users|Directly Observed Antiretroviral Therapy Among Active Drug Users|Completed||N/A|125||Yale University|||||f||||t||||||||||2018-06-01 03:49:18.343908|2018-06-01 03:49:18.343908
NCT00367159|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2009-02-24|2006-08-21|2006-08-22|Estimate|||||||2009-02-24|2009-02-25|Estimate|January 2007||2007-01-31|February 2009|2009-02-28|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|||Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children|Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children|Recruiting||Phase 3|14|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 03:49:18.43146|2018-06-01 03:49:18.43146
NCT00367146|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2011-05-19|2006-08-21|2006-08-22|Estimate|||||||2011-05-19|2011-05-20|Estimate|November 2004||2004-11-30|July 2007|2007-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||MMF After Pediatric Liver Transplantation||Completed||N/A|25|Actual|Hannover Medical School|||||f||||f||||||||||2018-06-01 03:49:18.512735|2018-06-01 03:49:18.512735
NCT00367133|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2009-07-14||2016-08-25|2006-08-18|2006-08-22|Estimate|2010-06-04|2010-07-09|Estimate||||2016-08-25|2016-08-26|Estimate|July 2004||2004-07-31|August 2016|2016-08-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|IVT||Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema|A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema|Completed||Phase 3|840|Actual|Jaeb Center for Health Research||3|||f||||t||||||||||2018-06-01 03:49:18.675023|2018-06-01 03:49:18.675023
NCT00367120|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2010-03-15|2006-08-21|2006-08-22|Estimate|||||||2010-03-15|2010-03-16|Estimate|June 2006||2006-06-30|March 2010|2010-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Zmax Compared to Augmentin in Sinusitis|A Multicenter, Randomized, Open Label Comparative Study Of Azithromycin Extended Release (ZMAX) Versus Amoxicillin/Clavulanate Potassium In Subjects With Acute Bacterial Sinusitis (ABS) In A Physician Practice Environment|Completed||Phase 4|762|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:49:20.733357|2018-06-01 03:49:20.733357
NCT00367107|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2008-02-04|2006-08-21|2006-08-22|Estimate|||||||2008-02-04|2008-02-06|Estimate|August 2008||2008-08-31|February 2008|2008-02-29||||August 2009|Anticipated|2009-08-31||Observational|||Autism in Adult Patients and the Effects on Caregivers|Autism: Long Term Course and Impact|Unknown status|Not yet recruiting||240|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-06-01 03:49:20.801658|2018-06-01 03:49:20.801658
NCT00367094|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2007-07-06|2006-08-21|2006-08-22|Estimate|||||||2007-07-06|2007-07-09|Estimate|July 2006||2006-07-31|March 2007|2007-03-31||||||||Interventional|||Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension|Efficacy and Safety of the Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Benazepril|Completed||Phase 3|296||Novartis|||||f||||||||||||||2018-06-01 03:49:20.928041|2018-06-01 03:49:20.928041
NCT00367081|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2007-07-29|2006-08-20|2006-08-22|Estimate|||||||2007-07-29|2007-07-31|Estimate|May 2003||2003-05-31|July 2007|2007-07-31|August 2004||2004-08-31|||||Interventional|||Treatment of Cerebral Toxoplasmosis in HIV/AIDS|Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial.|Completed||Phase 4|30||Rajavithi Hospital|||||f||||||||||||||2018-06-01 03:49:20.976197|2018-06-01 03:49:20.976197
NCT00367068|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2007-11-15|2006-08-21|2006-08-22|Estimate|||||||2007-11-15|2007-11-19|Estimate|January 2002||2002-01-31|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||Dutch National ITB Study in Children With Cerebral Palsy|Intrathecal Baclofen. Evaluation of a Therapy for Refractory Spasticity in Children With Cerebral Palsy|Completed||Phase 3|18||Maastricht University Medical Center|||||f||||f||||||||||2018-06-01 03:49:21.153033|2018-06-01 03:49:21.153033
NCT00367055|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|2009-10-02||2010-07-20|2006-08-21|2006-08-22|Estimate|2009-10-02|2009-11-05|Estimate||||2010-07-20|2010-07-27|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes|Comparison of the Action of the Rosiglitazone-metformin Fixed-dose Combination and of a Metformin-sulfonylurea Free Combination on the B-cell Function in Type 2 Diabetic Patients Not Controlled With Metformin Alone.|Completed||Phase 4|84|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:49:21.409803|2018-06-01 03:49:21.409803
NCT00367042|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-19|||2015-04-15|2006-08-19|2006-08-22|Estimate|||||||2015-04-15|2015-04-16|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|July 2008|Actual|2008-07-31|July 2006|Actual|2006-07-31||Interventional|||Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks|Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery|Completed||Phase 2/Phase 3|98|Actual|University of California, Davis||1|||f||||t||||||||||2018-06-01 03:49:23.056921|2018-06-01 03:49:23.056921
NCT00367029|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2014-05-06|2006-08-18|2006-08-22|Estimate|||||||2014-05-06|2014-05-07|Estimate|August 2006||2006-08-31|March 2009|2009-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Individualized Motivational Print Materials to Encourage More Physical Activity|Achieving Physical Activity Guidelines Through an Enhanced Print Intervention|Completed||Phase 3|256|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-06-01 03:49:23.128563|2018-06-01 03:49:23.128563
NCT00367003|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2017-11-02|2006-08-18|2006-08-22|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2006||2006-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Deep Brain Stimulation for Treatment Resistant Depression|Deep Brain Stimulation for Treatment Resistant Depression|Recruiting||N/A|20|Anticipated|Emory University||1|||f||||t||||||||||2018-06-01 03:49:23.261835|2018-06-01 03:49:23.261835
NCT00366990|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2016-03-05|2006-08-18|2006-08-22|Estimate|||||||2016-03-05|2016-03-08|Estimate|January 2007||2007-01-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|December 2009|Actual|2009-12-31||Interventional|SAVE||Low Sodium Diet and Behavioral Intervention for Reversing Arterial Stiffening in Overweight Individuals|Clinical Trial to Reverse Early Arterial Stiffening|Completed||N/A|349|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-06-01 03:49:23.354841|2018-06-01 03:49:23.354841
NCT00366977|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2011-04-28|2006-08-18|2006-08-22|Estimate|||||||2011-04-28|2011-05-02|Estimate|June 2000||2000-06-30|April 2011|2011-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Efficacy and Cost of State Quitline Policies|Efficacy and Cost of State Quitline Policies|Completed||Phase 3|4614|Actual|Kaiser Permanente|||||f||||||||||||||2018-06-01 03:49:23.515502|2018-06-01 03:49:23.515502
NCT00366964|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-19|||2015-04-06|2006-08-21|2006-08-22|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2004||2004-10-31|April 2015|2015-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||The Efficacy Of The Wavelight Mydon Laser for Hair Removal And Treatment of Leg Veins|Determine The Efficacy Of The Wavelight Mydon Laser For Hair Removal And Treatment of Leg Veins|Completed||N/A|10|Actual|University of California, Davis||1|||f||||f||||||||||2018-06-01 03:49:23.603718|2018-06-01 03:49:23.603718
NCT00366951|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2007-12-28|2006-08-18|2006-08-22|Estimate|||||||2007-12-28|2008-01-10|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|November 2005|Actual|2005-11-30|||||Interventional|||A Randomized Study on Comparing the Efficacy of Foley Catheter and Extraamniotic Saline Infusion for Labor Induction|A Randomized Clinical Trial Comparing the Efficacy and Safety of Foley Catheter Balloon With Oxytocin and Extraamniotic Saline Infusion (EASI) With Oxytocin for Induction of Labor Requiring Cervical Ripening|Completed||N/A|200||Rush University Medical Center|||||f||||||||||||||2018-06-01 03:49:23.67131|2018-06-01 03:49:23.67131
NCT00366938|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2012-05-18|2006-08-21|2006-08-22|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2003||2003-09-30|May 2012|2012-05-31||||March 2004|Actual|2004-03-31||Interventional|||Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).|A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator|Completed||Phase 3|1464||Novartis|||||||||||||||||||2018-06-01 03:49:23.734759|2018-06-01 03:49:23.734759
NCT00366925|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-21|||2009-04-27|2006-08-21|2006-08-22|Estimate|||||||2009-04-27|2009-04-28|Estimate|April 2006||2006-04-30|April 2009|2009-04-30|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|||CESA 5.10 Investigation to Compare the Efficacy and Safety of the Adacolumn® Apheresis Device in Patients With Active Ulcerative Colitis|Randomized Controlled Multicenter Investigation to Compare the Efficacy and Safety of Adacolumn® Granulocytes, Monocytes/Macrophage Apheresis Device, 5 Versus 10 Treatments, in Patients With Active Ulcerative Colitis|Completed||N/A|174|Anticipated|Otsuka Frankfurt Research Institute GmbH|||||f||||||||||||||2018-06-01 03:49:23.789904|2018-06-01 03:49:23.789904
NCT00366912|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2009-08-10|2006-08-18|2006-08-21|Estimate|||||||2009-08-10|2009-08-11|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Unloading Respiratory Muscles During NIV: Comparison of a Spontaneous and Auto-adjusting Controlled Mode||Terminated||N/A|10||Krankenhaus Kloster Grafschaft||||No longer recruiting: participants are no longer being recruited or enrolled|f||||||||||||||2018-06-01 03:49:23.855559|2018-06-01 03:49:23.855559
NCT00366899|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2010-03-26|2009-02-26|2013-01-17|2006-08-18|2006-08-21|Estimate|2013-01-17|2013-02-22|Estimate|2009-09-28|2009-09-30|Estimate|2013-01-17|2013-02-22|Estimate|October 2006||2006-10-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety,Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in Italy|Completed||Phase 3|605|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:49:24.055259|2018-06-01 03:49:24.055259
NCT00366886|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-06-12|2006-08-17|2006-08-21|Estimate|||||||2007-06-12|2007-06-13|Estimate||||June 2007|2007-06-30|July 2006||2006-07-31|||||Observational|||Patients With NMDA Biomarker Data Following Cardiac Surgery|Retrospective Review of 22 Patients With NMDA Biomarker Data Following Cardiac Surgery|Terminated|||22||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 03:49:26.201526|2018-06-01 03:49:26.201526
NCT00366873|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2009-03-04|2006-08-18|2006-08-21|Estimate|||||||2009-03-04|2009-03-05|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Mineral Absorption in Infants Fed Infant Formula|Evaluation of Mineral Absorption in Infants Fed Infant Formula|Completed||N/A|44|Anticipated|Mead Johnson Nutrition||2|||f||||f||||||||||2018-06-01 03:49:26.248793|2018-06-01 03:49:26.248793
NCT00366860|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2014-12-01|2006-08-17|2006-08-21|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease|Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease|Completed||Phase 1|18|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 03:49:26.410255|2018-06-01 03:49:26.410255
NCT00366847|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2014-05-07|2006-08-17|2006-08-21|Estimate|||||||2014-05-07|2014-05-08|Estimate|June 2001||2001-06-30|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Computer Modeling of Congenital Heart Disease|Computer Modeling of Congenital Heart Disease|Completed|||50|Anticipated|Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 03:49:26.50427|2018-06-01 03:49:26.50427
NCT00366834|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2012-09-06|2006-08-17|2006-08-21|Estimate|||||||2012-09-06|2012-09-10|Estimate|July 2006||2006-07-31|June 2012|2012-06-30|October 2009|Actual|2009-10-31|October 2007|Actual|2007-10-31||Interventional|||Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting|A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron and Dexamethasone for the Prevention of Nausea|Completed||Phase 3|1840|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 03:49:26.597337|2018-06-01 03:49:26.597337
NCT00366821|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2014-11-26|2006-08-17|2006-08-21|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2002||2002-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Retrospective Review of the Outcomes of Newborns With Genetic Abnormalities|Retrospective Review of the Outcomes of Newborns With Genetic Abnormalities|Completed|||1000|Actual|Children's Healthcare of Atlanta|||2||f||||f||||||||||2018-06-01 03:49:27.184867|2018-06-01 03:49:27.184867
NCT00366808|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-10-01|2006-08-17|2006-08-21|Estimate|||||||2007-10-01|2007-10-02|Estimate|February 2006||2006-02-28|July 2006|2006-07-31|August 2007|Actual|2007-08-31|||||Interventional|||Mechanical vs. Alcohol Separation of the Corneal Epithelium During Surface Ablation Refractive Procedures|Mechanical vs. Alcohol Separation of the Corneal Epithelium During Surface Ablation Refractive Procedures|Completed||Phase 4|10|Anticipated|Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:27.415767|2018-06-01 03:49:27.415767
NCT00366795|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18||2016-04-18|2016-04-18|2006-08-18|2006-08-21|Estimate||||2016-04-18|2016-05-18|Estimate|2016-04-18|2016-05-18|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|SPARe-2||Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver|Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo in the Absence of Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.|Terminated||Phase 3|241|Actual|Sanofi||2||Study was terminated due to safety reason.|f||||||||||||||2018-06-01 03:49:27.603035|2018-06-01 03:49:27.603035
NCT00366782|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2012-02-29|2006-08-17|2006-08-21|Estimate|||||||2012-02-29|2012-03-01|Estimate|March 2007||2007-03-31|February 2012|2012-02-29|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults|A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age|Completed||Phase 1|51|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-06-01 03:49:27.950684|2018-06-01 03:49:27.950684
NCT00366769|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2006-08-17|2006-08-17|2006-08-21|Estimate|||||||2006-08-17|2006-08-21|Estimate|September 2005||2005-09-30|March 2006|2006-03-31|February 2006||2006-02-28|||||Interventional|||Evaluation of Outcomes Following LASIK Surgery Using CustomVue|Evaluation of Visual Outcomes, Contrast Sensitivity, Glare, and Induction of High Order Aberrations Following LASIK Surgery Using CustomVue|Completed||N/A|30||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:28.417342|2018-06-01 03:49:28.417342
NCT00366756|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2011-08-04|2006-08-17|2006-08-21|Estimate|||||||2011-08-04|2011-08-05|Estimate|July 2006||2006-07-31|December 2010|2010-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Evaluation of VisionQuest 20/20, a Visual Acuity Testing Software|Evaluation of a Visual Acuity Testing Software for Children, VisionQuest 20/20|Completed|||97|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-06-01 03:49:28.558005|2018-06-01 03:49:28.558005
NCT00366743|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2006-08-17|2006-08-17|2006-08-21|Estimate|||||||2006-08-17|2006-08-21|Estimate|May 2003||2003-05-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Evaluation of Visual Outcomes After Myopic LASIK|Analysis of Visual Outcomes, Contrast Sensitivity, Glare, Induction of High Order Aberrations and Wavefront Technology, Following LASIK Surgery|Completed||N/A|120||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:28.624924|2018-06-01 03:49:28.624924
NCT00366730|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2006-08-18|2006-08-18|2006-08-21|Estimate|||||||2006-08-18|2006-08-21|Estimate|February 2004||2004-02-29|August 2006|2006-08-31|November 2005||2005-11-30|||||Interventional|||Study of Nitazoxanide in the Treatment of Amebiasis in Children|Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children|Completed||Phase 3|50||Romark Laboratories L.C.|||||f||||||||||||||2018-06-01 03:49:28.696461|2018-06-01 03:49:28.696461
NCT00366717|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2006-08-18|2006-08-18|2006-08-21|Estimate|||||||2006-08-18|2006-08-21|Estimate|June 2005||2005-06-30|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy||Completed|||20||Mackay Memorial Hospital|||||f||||||||||||||2018-06-01 03:49:28.779918|2018-06-01 03:49:28.779918
NCT00366704|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17||2013-02-07|2013-02-07|2006-08-18|2006-08-21|Estimate||||2013-02-07|2013-02-11|Estimate|2013-02-07|2013-02-11|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint|A Multicenter, Randomized, Double-blind, Parallel-group Fixed-dose Study of the Effect on Weight of Bifeprunox Versus Risperidone in the Treatment of Outpatients With Schizophrenia.|Terminated||Phase 3|400|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:49:28.872596|2018-06-01 03:49:28.872596
NCT00366691|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-10-01|2006-08-18|2006-08-21|Estimate|||||||2007-10-01|2007-10-02|Estimate|February 2006||2006-02-28|June 2006|2006-06-30|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation|Comparison of Acular LS With Lotemax to Prevent Anterior Segment Inflammation After Phacoemulsification and Intraocular Lens Implantation|Completed||Phase 4|40|Anticipated|Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:29.031609|2018-06-01 03:49:29.031609
NCT00366678|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2010-03-26|2009-02-26|2012-07-06|2006-08-18|2006-08-21|Estimate|2012-07-06|2012-08-15|Estimate|2009-09-30|2009-10-01|Estimate|2012-07-06|2012-08-15|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in France.|Completed||Phase 3|613|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:49:29.23931|2018-06-01 03:49:29.23931
NCT00366665|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2006-08-17|2006-08-17|2006-08-21|Estimate|||||||2006-08-17|2006-08-21|Estimate|March 2005||2005-03-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Comparison of the Performance of the Infiniti Vision and the Series 20000 Legacy Phacoemulsification Systems|Comparison of the Infiniti Vision and the Series 20000 Legacy Systems|Completed||N/A|30||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:31.926333|2018-06-01 03:49:31.926333
NCT00366652|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-05-25|2006-08-17|2006-08-21|Estimate|||||||2007-05-25|2007-05-28|Estimate|September 2006||2006-09-30|May 2007|2007-05-31|September 2006||2006-09-30|||||Interventional|||Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects|A Randomized, Open-Label, Crossover, Drug Interaction Study to Evaluate the Effects of DVS SR And Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects|Completed||Phase 3|20|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:49:31.995467|2018-06-01 03:49:31.995467
NCT00366639|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2009-10-29|2006-08-18|2006-08-21|Estimate|||||||2009-10-29|2009-11-02|Estimate|October 2001||2001-10-31|October 2009|2009-10-31|February 2006|Actual|2006-02-28|||||Observational|||Registry for Acute Decompensated Heart Failure Patients|ADHERE Core III - Acute Decompensated Heart Failure Registry|Completed|||24118|Actual|Scios, Inc.|||1||f||||||||||||||2018-06-01 03:49:32.262572|2018-06-01 03:49:32.262572
NCT00366626|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2012-04-19||2017-05-04|2006-08-17|2006-08-21|Estimate|2012-11-02|2012-12-03|Estimate||||2017-05-04|2017-06-05|Actual|April 2006||2006-04-30|November 2012|2012-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.|Alcohol Research Center Grant. Component #1: Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response|Completed||Phase 4|83|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 03:49:32.376391|2018-06-01 03:49:32.376391
NCT00366613|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-10-02|2006-08-17|2006-08-21|Estimate|||||||2007-10-02|2007-10-03|Estimate|July 2005||2005-07-31|August 2007|2007-08-31||||||||Interventional|||Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation|Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation|Withdrawn||Phase 4|20|Anticipated|Medical University of South Carolina||||We wish to wait until there is more data available using this substance.|f||||||||||||||2018-06-01 03:49:32.691299|2018-06-01 03:49:32.691299
NCT00366600|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2017-09-06|2006-08-18|2006-08-21|Estimate|||||||2017-09-06|2017-09-11|Actual|July 2006||2006-07-31|September 2017|2017-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study Evaluating HKI-272 Administered to Healthy Subjects|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects.|Completed||Phase 1|56|Actual|Puma Biotechnology, Inc.|||||f||||||||||||||2018-06-01 03:49:32.747328|2018-06-01 03:49:32.747328
NCT00366587|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-10-01|2006-08-17|2006-08-21|Estimate|||||||2007-10-01|2007-10-02|Estimate|February 2006||2006-02-28|July 2006|2006-07-31|August 2007|Actual|2007-08-31|||||Interventional|||Comparison of Visual Outcomes and Patient Satisfaction After Cataract Surgery and Implantation of ReSTOR and ReZoom IOLs|Contralateral Eye Comparison of Visual Outcomes and Patient Satisfaction After Routine Phacoemulsification and Implantation of ReSTOR and ReZoom IOLs|Completed||Phase 4|48|Anticipated|Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:32.837561|2018-06-01 03:49:32.837561
NCT00366574|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2006-08-17|2006-08-17|2006-08-21|Estimate|||||||2006-08-17|2006-08-21|Estimate|September 2004||2004-09-30|March 2005|2005-03-31|February 2005||2005-02-28|||||Interventional|||Comparison of a Laser Keratome to a Mechanical Microkeratome|Comparison of INTRALASE® to AMADEUS™ Microkeratome|Completed||N/A|20||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:32.883292|2018-06-01 03:49:32.883292
NCT00366561|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2014-11-26|2006-08-17|2006-08-21|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2002||2002-01-31|November 2014|2014-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Neonates With Neurological Complications|Retrospective Review of Neonates With Neurological Complications Following Cardiac Surgery|Completed|||810|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 03:49:32.992883|2018-06-01 03:49:32.992883
NCT00366548|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2010-03-26|2009-02-26|2012-07-06|2006-08-18|2006-08-21|Estimate|2012-07-06|2012-08-15|Estimate|2009-09-30|2009-10-01|Estimate|2012-07-06|2012-08-15|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants|A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy Infants Given in a 2-, 3-, 4-, and 12-Month Schedule With Routine Pediatric Vaccinations|Completed||Phase 3|500|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 03:49:33.168482|2018-06-01 03:49:33.168482
NCT00366535|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2016-08-31|2006-08-18|2006-08-21|Estimate|||||||2016-08-31|2016-09-01|Estimate|August 2006||2006-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Neurotropin to Treat Fibromyalgia|Neurotropin Treatment of Fibromyalgia|Completed||Phase 2|55|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:49:35.316284|2018-06-01 03:49:35.316284
NCT00366522|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2009-08-06|2006-08-18|2006-08-21|Estimate|||||||2009-08-06|2009-08-07|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study Evaluating LXR-623 in Healthy Subjects|Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:49:35.557469|2018-06-01 03:49:35.557469
NCT00366509|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2018-03-27|2006-08-17|2006-08-21|Estimate|||||||2018-03-27|2018-03-29|Actual|August 8, 2006||2006-08-08|October 16, 2017|2017-10-16||||||||Observational|||Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases|Role of Helicobacter Pylori and Its Toxins in Pulmonary and Oropharyngeal Disease|Completed|||157|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:35.72634|2018-06-01 03:49:35.72634
NCT00366496|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2006-08-17|2006-08-17|2006-08-21|Estimate|||||||2006-08-17|2006-08-21|Estimate|July 2004||2004-07-31|July 2005|2005-07-31|May 2005||2005-05-31|||||Interventional|||Surgical Outcomes After Routine Cataract Extraction & Implantation of a Conventional or Spheric Intraocular Lens|Comparison of Visual Outcomes, Wavefront Analysis, Contrast Sensitivity and Glare Testing Following Cataract Extraction Between Acrysof Single-Piece IOL and Acrysof WF|Completed||N/A|30||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:35.813932|2018-06-01 03:49:35.813932
NCT00366483|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-03-15|2006-08-18|2006-08-21|Estimate|||||||2007-03-15|2007-03-16|Estimate|May 2006||2006-05-31|March 2007|2007-03-31||||||||Interventional|||Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Lecozotan SR Administered Orally to Healthy Young and Elderly Subjects|Completed||Phase 1|40||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:49:35.879055|2018-06-01 03:49:35.879055
NCT00366470|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2012-07-04|2006-08-18|2006-08-21|Estimate|||||||2012-07-04|2012-07-06|Estimate|November 2009||2009-11-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients|A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy|Completed||Phase 3|250|Actual|Christian Medical College, Vellore, India||2|||f||||t||||||||||2018-06-01 03:49:35.957545|2018-06-01 03:49:35.957545
NCT00366457|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2017-02-14||2017-04-07|2006-08-17|2006-08-21|Estimate|2017-02-14|2017-03-31|Actual||||2017-04-07|2017-05-15|Actual|August 2006||2006-08-31|April 2017|2017-04-30|July 2011|Actual|2011-07-31|August 2008|Actual|2008-08-31||Interventional||participants who started treatment|Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer|Phase II Study of Gemcitabine, Bevacizumab and Erlotinib in Locally Advanced and Metastatic Pancreatic Cancer|Completed||Phase 2|32|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:49:36.05798|2018-06-01 03:49:36.05798
NCT00366444|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2010-03-22||2011-04-12|2006-08-18|2006-08-21|Estimate|2011-04-12|2011-04-13|Estimate||||2011-04-12|2011-04-13|Estimate|August 2006||2006-08-31|April 2011|2011-04-30||||October 2006|Actual|2006-10-31||Interventional|||Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery|Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery|Completed||Phase 3|201|Actual|Xanodyne Pharmaceuticals||2|||||||||||||||||2018-06-01 03:49:36.448587|2018-06-01 03:49:36.448587
NCT00366431|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2011-07-22|2006-08-18|2006-08-21|Estimate|||||||2011-07-22|2011-07-25|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Non-Malignant Pain|Completed||Phase 2|420||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:49:36.869411|2018-06-01 03:49:36.869411
NCT00366418|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2017-06-30|2006-08-18|2006-08-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 10, 2006||2006-08-10|February 23, 2011|2011-02-23|June 11, 2009|Actual|2009-06-11|June 11, 2009|Actual|2009-06-11||Interventional|||Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia|A Pilot Study of Fractionated Dose Subcutaneous Rituximab (RTX, Rituxan(Registered Trademark)) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 1|4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:37.006739|2018-06-01 03:49:37.006739
NCT00366405|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2010-10-01|2006-08-17|2006-08-21|Estimate|||||||2010-10-01|2010-10-04|Estimate|February 2006||2006-02-28|October 2010|2010-10-31|September 2007|Actual|2007-09-30|||||Observational|||Comparison of the Torsional Handpiece to Conventional Handpiece During Routine Phacoemulsification|Comparison of the Torsional Handpiece to Conventional Handpiece During Routine Phacoemulsification|Completed|||30|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-06-01 03:49:37.068001|2018-06-01 03:49:37.068001
NCT00366392|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-10-02|2006-08-17|2006-08-21|Estimate|||||||2007-10-02|2007-10-03|Estimate|May 2005||2005-05-31|July 2006|2006-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Project Magnify - A Comparison of Two Strategies to Improve Reading Ability|Project Magnify - A Comparison of Two Strategies (Large Print Versus Optical Aids) for Helping Visually Impaired Students Improve Reading Abilities|Completed||Phase 4|20||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:49:37.117349|2018-06-01 03:49:37.117349
NCT00366379|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2016-11-01|2006-08-18|2006-08-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.|An Open Label Study to Determine the Effect on Fasting Glucose Levels, and Safety, of Increasing Doses of GK Activator (2) in Patients With Type 2 Diabetes Not Optimally Controlled With One Previous Oral Antihyperglycemic Agent.|Completed||Phase 2|127|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-06-01 03:49:37.180698|2018-06-01 03:49:37.180698
NCT00366366|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2016-09-15|2006-08-18|2006-08-21|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2001||2001-09-30|September 2016|2016-09-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines|Phase III, Open, Randomised Immunogenicity and Reactogenicity Study to Assess the Interchangeability Between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd Dose of Primary Vac. Course in Children Who Received HBV Vac. at Birth and One Month of Age and DTPa-IPV/Hib Vac at 3-4 Mth of Age|Completed||Phase 3|150|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:49:37.263087|2018-06-01 03:49:37.263087
NCT00366353|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2015-05-15|2006-08-18|2006-08-21|Estimate|||||||2015-05-15|2015-05-18|Estimate|June 2006||2006-06-30|May 2015|2015-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Sedation Versus No Sedation in a Spontaneous Breathing Trial|A Randomized Trial Comparing Sedation Versus No Sedation For Patients Undergoing a Spontaneous Breathing Trial.|Terminated||N/A|2|Actual|Memorial Medical Center||2||Difficulty obtaining enrollment|f||||f||||||||||2018-06-01 03:49:37.354538|2018-06-01 03:49:37.354538
NCT00366340|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2010-03-26|2009-02-26|2012-06-28|2006-08-18|2006-08-21|Estimate|2012-06-28|2012-08-08|Estimate|2012-06-28|2012-08-08|Estimate|2012-06-28|2012-08-08|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.|A Phase 3, Randomized, Active-Controlled, Double-blind Trial of the Safety, Tolerability, and Immunologic Non-Inferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Germany.|Completed||Phase 3|604|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:49:37.745968|2018-06-01 03:49:37.745968
NCT00366327|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17||2013-02-07|2013-02-07|2006-08-18|2006-08-21|Estimate||||2013-02-07|2013-02-11|Estimate|2013-02-07|2013-02-11|Estimate|January 2007||2007-01-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating Bifeprunox in Patients With Schizophrenia.|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.|Terminated||Phase 3|400|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 03:49:40.84748|2018-06-01 03:49:40.84748
NCT00366314|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-06-12|2006-08-17|2006-08-21|Estimate|||||||2007-06-12|2007-06-13|Estimate|June 2003||2003-06-30|June 2007|2007-06-30||||||||Observational|||Frequency of Accessing Central Lines for Blood Samples|Frequency of Accessing Central Lines for Blood Samples and Medication Administration: A Comparison Between CICU, PICU and NICU|Terminated|||320||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 03:49:41.091855|2018-06-01 03:49:41.091855
NCT00366301|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2010-10-26||2010-10-26|2006-08-18|2006-08-21|Estimate|2010-10-26|2010-11-25|Estimate||||2010-10-26|2010-11-25|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes|The LANCET Trial: A Randomized Clinical Trial of Lantus for C-reactive Protein Reduction in Early Treatment of Type 2 Diabetes|Terminated||Phase 4|500|Actual|Brigham and Women's Hospital||4||Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.|f||||t||||||||||2018-06-01 03:49:41.1615|2018-06-01 03:49:41.1615
NCT00366288|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2009-07-08|2006-08-17|2006-08-21|Estimate|||||||2009-07-08|2009-07-10|Estimate|July 2006||2006-07-31|July 2009|2009-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Study Evaluating PAZ-417 in Healthy Young/Elderly|Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAZ-417 Administered Orally to Healthy Young and Healthy Elderly Subjects|Completed|||56|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||7||f||||||||||Samples With DNA|"~     plasma and urine~   "|||2018-06-01 03:49:41.683814|2018-06-01 03:49:41.683814
NCT00366275|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2009-02-18||2012-10-26|2006-08-18|2006-08-21|Estimate|2010-09-30|2010-10-18|Estimate||||2012-10-26|2012-10-31|Estimate|January 2002||2002-01-31|October 2012|2012-10-31|September 2007|Actual|2007-09-30|January 2007|Actual|2007-01-31||Interventional|||Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma|Phase II of Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Patients With Relapsed or Refractory Follicular Lymphoma|Completed||Phase 2|64|Actual|IRCCS Policlinico S. Matteo||1|||f||||f||||||||||2018-06-01 03:49:41.756296|2018-06-01 03:49:41.756296
NCT00366262|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2008-08-01|2006-08-18|2006-08-21|Estimate|||||||2008-08-01|2008-08-05|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen|A Randomized, Double-Blind, Parallel Group Study To Compare The 7-Day Gastrointestinal Safety of 2 Doses of PLA-695 To That Of Placebo And Naproxen|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:49:41.901693|2018-06-01 03:49:41.901693
NCT00366249|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2009-07-14||2010-04-22|2006-08-17|2006-08-21|Estimate|2009-07-14|2009-08-21|Estimate||||2010-04-22|2010-04-28|Estimate|January 2007||2007-01-31|April 2010|2010-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.|A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes|Completed||Phase 3|1061|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 03:49:42.000751|2018-06-01 03:49:42.000751
NCT00366236|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2006-08-18|2006-08-18|2006-08-21|Estimate|||||||2006-08-18|2006-08-21|Estimate|February 2004||2004-02-29|August 2006|2006-08-31|November 2005||2005-11-30|||||Interventional|||Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents|Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents|Completed||Phase 3|50||Romark Laboratories L.C.|||||f||||||||||||||2018-06-01 03:49:43.183652|2018-06-01 03:49:43.183652
NCT00366223|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2017-06-23|2006-08-18|2006-08-21|Estimate|||||||2017-06-23|2017-06-26|Actual|August 2006|Actual|2006-08-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Changing Patterns of Candida Infections in Urban Medical Centers|Changing Patterns of Candida Infections in Urban Medical Centers: Emphasis on the Emergence of Non-albicans Species and Their Influence on Clinical Outcomes|Completed|||80|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:49:43.256406|2018-06-01 03:49:43.256406
NCT00366210|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2014-12-24|2006-08-18|2006-08-21|Estimate|||||||2014-12-24|2014-12-25|Estimate|October 2005||2005-10-31|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Constraint-Induced Therapy Modified for Rehabilitating Arm Function in Stroke Survivors w/Plegic Hands|Constraint-Induced Therapy Modified for Rehabilitating Arm Function in Stroke Survivors w/Plegic Hands|Completed||Phase 1/Phase 2|21|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-06-01 03:49:43.332221|2018-06-01 03:49:43.332221
NCT00366197|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2014-01-15|2006-08-18|2006-08-21|Estimate|||||||2014-01-15|2014-01-16|Estimate|January 2005||2005-01-31|January 2014|2014-01-31|July 2008|Actual|2008-07-31|||||Observational|||Prediction of Weaning Outcomes by Using Rate of Change of Rapid Shallow Breathing Index|Prediction of Weaning Outcomes by Using Rate of Change of Rapid Shallow Breathing Index|Terminated|||100|Anticipated|Atlantic Health System|||||f||||||||||||||2018-06-01 03:49:43.423259|2018-06-01 03:49:43.423259
NCT00366184|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2017-06-30|2006-08-17|2006-08-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 8, 2006||2006-08-08|May 26, 2010|2010-05-26|May 26, 2010||2010-05-26|||||Observational|||Influence of Theta Burst Stimulation and Carbidopa-Levodopa on Motor Performance in Stroke Patients|Influencing Motor Performance in Patients With Stroke by Combined Theta Burst Stimulation and Carbidopa-Levodopa|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:49:43.481705|2018-06-01 03:49:43.481705
NCT00366171|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-12-18|2006-08-17|2006-08-21|Estimate|||||||2007-12-18|2007-12-27|Estimate|November 2006||2006-11-30|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Open Label Extension Study of Bifeprunox|An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.|Completed||Phase 3|120||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:49:43.565926|2018-06-01 03:49:43.565926
NCT00366158|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-18|||2010-10-08|2006-08-18|2006-08-21|Estimate|||||||2010-10-08|2010-10-11|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional|||EVITA: Evaluation of VIP Feature in Pacemaker Patients|EVITA: Evaluation of VIP Feature in Pacemaker Patients|Completed||N/A|461|Actual|St. Jude Medical||2|||f||||f||||||||||2018-06-01 03:49:43.726632|2018-06-01 03:49:43.726632
NCT00366145|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17||2010-08-24|2011-10-11|2006-08-18|2006-08-21|Estimate||||2011-04-08|2011-04-25|Estimate|2011-10-11|2011-10-13|Estimate|July 2006||2006-07-31|October 2011|2011-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease|A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal(Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid Refractory Acute GVHD|Completed||Phase 3|240|Actual|Osiris Therapeutics||2|||f||||t||||||||||2018-06-01 03:49:43.795672|2018-06-01 03:49:43.795672
NCT00366132|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2006-08-17|2006-08-17|2006-08-18|Estimate|||||||2006-08-17|2006-08-18|Estimate|March 2006||2006-03-31|August 2006|2006-08-31||||||||Interventional|||Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers|DermaGold Indicated for Use of Shockwave Treat of Diabetic Foot Ulcers in Patients With Diabetes Mellitus|Unknown status|Recruiting|Phase 2|200||Tissue Regeneration Technologies|||||||||||||||||||2018-06-01 03:49:43.934642|2018-06-01 03:49:43.934642
NCT00366119|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2007-03-08|2006-08-17|2006-08-18|Estimate|||||||2007-03-08|2007-03-09|Estimate|June 2006||2006-06-30|March 2007|2007-03-31|June 2007||2007-06-30|||||Interventional|||Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension|Phase 4 Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Ramiprin Tab. in Essential Hypertension|Unknown status|Active, not recruiting|Phase 4|86||Pacific Pharmaceuticals|||||f||||||||||||||2018-06-01 03:49:44.15335|2018-06-01 03:49:44.15335
NCT00366106|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2011-09-26||2012-04-04|2006-08-17|2006-08-18|Estimate|2012-04-02|2012-04-05|Estimate||||2012-04-04|2012-04-06|Estimate|July 2006||2006-07-31|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma|A Phase II, Open Label Study Evaluating an Alternative Schedule of Velcade/Dexamethasone Plus Doxil in the Treatment of Multiple Myeloma|Terminated||Phase 2|32|Actual|Accelerated Community Oncology Research Network|The study was closed to enrollment when it became clear that enrollment was too slow to complete the planned enrollment target of 45 patients within the time frame allowed. Response rate was unable to be assessed due to missingness of required data.|||"Study was closed to enrollment when it became clear that enrollment was too slow to complete~   full enrollment target within time frame allowed."|f||||f||||||||||2018-06-01 03:49:44.254796|2018-06-01 03:49:44.254796
NCT00366093|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2012-02-21|2006-08-17|2006-08-18|Estimate|||||||2012-02-21|2012-02-22|Estimate|February 2004||2004-02-29|February 2012|2012-02-29|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause|The Efficacy of Eszopiclone 3 mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause|Completed||Phase 3|410|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 03:49:44.703981|2018-06-01 03:49:44.703981
NCT00366080|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17||2009-07-22|2017-03-09|2006-08-17|2006-08-18|Estimate||||2009-07-22|2009-08-10|Estimate|2017-03-09|2017-03-10|Actual|November 2006||2006-11-30|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy|An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.|Terminated||Phase 2|69|Actual|GlaxoSmithKline||||Study was terminated based on the interim results of a futility test.|f||||f||||||||||2018-06-01 03:49:44.897319|2018-06-01 03:49:44.897319
NCT00366067|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2009-02-18|2006-08-17|2006-08-18|Estimate|||||||2009-02-18|2009-02-19|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|February 2007|Actual|2007-02-28|||||Interventional|||Study of Efficacy of Phenytoin in Therapy of Children With Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Phenytoin Efficacy in Children for Therapy of Bronchial Asthma|Completed||Phase 4|50||Centre of Chinese Medicine, Georgia|||||f||||t||||||||||2018-06-01 03:49:45.079762|2018-06-01 03:49:45.079762
NCT00366041|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2010-01-20|2006-08-17|2006-08-18|Estimate|||||||2010-01-20|2010-01-21|Estimate|February 2006||2006-02-28|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries|Multicentre Clinical Study to Compare the Efficacy and the Tolerance of Cellularised LG002 With the Efficacy and Tolerance of Uncellularised LG002 in the Treatment of Severe Burn Injury|Terminated||Phase 2|20|Anticipated|Laboratoires Genévrier||2||not appropriate to carry on the study|f||||t||||||||||2018-06-01 03:49:45.184606|2018-06-01 03:49:45.184606
NCT00366028|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2014-06-06||2015-04-06|2006-08-16|2006-08-18|Estimate|2014-09-18|2014-09-26|Estimate||||2015-04-06|2015-04-28|Estimate|January 2006||2006-01-31|May 2014|2014-05-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Increasing Evidence-based Clinical Practices in VA|Strengthening Organization to Implement Evidence-based Clinical Practice|Completed||N/A|1624|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:49:45.310314|2018-06-01 03:49:45.310314
NCT00366015|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2017-08-25|2006-08-16|2006-08-18|Estimate|||||||2017-08-25|2017-08-28|Actual|July 29, 2003|Actual|2003-07-29|August 2017|2017-08-31|December 31, 2010|Actual|2010-12-31|December 31, 2010|Actual|2010-12-31||Interventional|||Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room|Same Procedure Cardiac Hybrid Surgery in a Specialty Built OR-- A Pilot Study|Completed||N/A|80|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 03:49:45.592287|2018-06-01 03:49:45.592287
NCT00366002|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2008-01-14|2006-08-17|2006-08-18|Estimate|||||||2008-01-14|2008-01-15|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Interventional|||Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder|A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy|Completed||Phase 4|500|Actual|Novartis||1|||||||||||||||||2018-06-01 03:49:45.684494|2018-06-01 03:49:45.684494
NCT00365989|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2018-03-26|2006-08-17|2006-08-18|Estimate|||||||2018-03-26|2018-03-29|Actual|October 2006||2006-10-31|March 2018|2018-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication|A Clinical Study To Evaluate the Safety and Efficacy of MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Techniques|Completed||N/A|50|Actual|InSightec||1|||f||||||||||||||2018-06-01 03:49:45.826704|2018-06-01 03:49:45.826704
NCT00365976|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2013-03-19||2015-07-02|2006-08-16|2006-08-18|Estimate|2013-05-01|2013-06-07|Estimate||||2015-07-02|2015-07-24|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study of the Insomnia in Patients With Low Back Pain|Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain|Completed||Phase 4|58|Actual|Duke University|"We obtained only self-reported sleep outcomes.~The period of double-blind treatment was relatively short.~We excluded all subjects who might have required opioid therapy to manage their pain which limits study generalizability."|2|||f||||f||||||||||2018-06-01 03:49:46.064127|2018-06-01 03:49:46.064127
NCT00365963|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2016-02-03|2006-08-16|2006-08-18|Estimate|||||||2016-02-03|2016-02-04|Estimate|April 2005||2005-04-30|February 2016|2016-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Web-based Intervention for Lung Cancer Patients and Their Informal Caregivers|Clinician Integration Study|Completed||Phase 3|252|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 03:49:46.486202|2018-06-01 03:49:46.486202
NCT00365950|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2006-08-17|2006-08-17|2006-08-18|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|January 2004|2004-01-31|December 2003||2003-12-31|||||Interventional|||3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE|Clinical Trial of Two Durations of Warfarin Therapy in the Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism|Completed||Phase 4|2400||British Thoracic Society|||||f||||||||||||||2018-06-01 03:49:46.54512|2018-06-01 03:49:46.54512
NCT00365937|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2010-10-14|2006-08-17|2006-08-18|Estimate|||||||2010-10-14|2010-10-15|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|August 2009|Anticipated|2009-08-31|||||Interventional|||Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides|Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides|Terminated||Phase 1/Phase 2|19|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||4||New regulatories of the peptides by the pharmaceutical company (the seller)|f||||f||||||||||2018-06-01 03:49:46.610035|2018-06-01 03:49:46.610035
NCT00365924|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2009-03-20|2006-08-16|2006-08-18|Estimate|||||||2009-03-20|2009-03-23|Estimate|December 2006||2006-12-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|||||Interventional|||A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo|A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo)|Completed||N/A|20|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:49:46.682016|2018-06-01 03:49:46.682016
NCT00365911|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2011-06-01|2006-08-17|2006-08-18|Estimate|||||||2011-06-01|2011-06-02|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Prevalence of Renal Failure and Risk Factors in an Unreferred Healthy Population|Prevalence of Renal Failure and Risk Factors in an Unreferred Healthy Population|Completed||N/A|2000|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:49:46.746145|2018-06-01 03:49:46.746145
NCT00365898|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2006-08-16|2006-08-16|2006-08-18|Estimate|||||||2006-08-16|2006-08-18|Estimate|July 2005||2005-07-31|August 2006|2006-08-31|July 2005||2005-07-31|||||Interventional|||Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain|A Study of the Efficacy and Safety of 8 Mg Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain|Terminated||Phase 3|380||Purdue Pharma LP|||||||||||||||||||2018-06-01 03:49:46.80052|2018-06-01 03:49:46.80052
NCT00365885|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2014-07-09|2006-08-16|2006-08-18|Estimate|||||||2014-07-09|2014-07-11|Estimate|August 2006||2006-08-31|December 2012|2012-12-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Showing Health Information Value in a Community Network|Showing Health Information Value in a Community Network|Completed||N/A|20108|Actual|Duke University||6|||f||||||||||||||2018-06-01 03:49:46.862471|2018-06-01 03:49:46.862471
NCT00365872|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|2013-06-25||2017-02-20|2006-08-17|2006-08-18|Estimate|2013-11-15|2014-01-06|Estimate||||2017-02-20|2017-03-23|Actual|May 2006||2006-05-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||All evaluable participants available for follow-up at time of analysis.|External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma|Combination of External Beam Radiation With Intratumoral Injection of Dendritic Cells as Neo-adjuvant Treatment of High-risk Soft Tissue Sarcoma Patients|Completed||Phase 2|17|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 03:49:46.939596|2018-06-01 03:49:46.939596
NCT00365859|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2009-12-17||2013-11-07|2006-08-17|2006-08-18|Estimate|2009-12-17|2010-01-25|Estimate||||2013-11-07|2013-12-02|Estimate|September 2006||2006-09-30|June 2010|2010-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)|A 52-Week, Open-Label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder|Completed||Phase 3|330|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-06-01 03:49:48.269584|2018-06-01 03:49:48.269584
NCT00365846|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2012-06-22||2012-09-21|2006-08-16|2006-08-18|Estimate|2012-06-22|2012-07-30|Estimate||||2012-09-21|2012-10-03|Estimate|August 2000||2000-08-31|September 2012|2012-09-30|July 2006|Actual|2006-07-31|July 2005|Actual|2005-07-31||Interventional|||"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"|"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"|Completed||Phase 2|29|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 03:49:49.819836|2018-06-01 03:49:49.819836
NCT00365833|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2011-09-28|2006-08-17|2006-08-18|Estimate|||||||2011-09-28|2011-09-30|Estimate|July 2006||2006-07-31|September 2011|2011-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|CEC||CEC/EPC and Cardiovascular Risk in Renal Transplant Recipients|Circulating Endothelial Cell and Endothelial Progenitor Cell Evaluation of Kidney Transplant Patients|Terminated|||8|Actual|University of Florida|||1|difficulty obtaining required data|f||||f||||||||||2018-06-01 03:49:50.137077|2018-06-01 03:49:50.137077
NCT00365820|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2012-04-19|2006-08-17|2006-08-18|Estimate|||||||2012-04-19|2012-04-20|Estimate|July 2006||2006-07-31|April 2012|2012-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain|A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain|Terminated||Phase 2/Phase 3|670||Novartis||||"This study was terminated early as a result of regulatory action suspending tegaserod use in~   2007"|f||||||||||||||2018-06-01 03:49:50.213828|2018-06-01 03:49:50.213828
NCT00365807|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-17|||2012-11-02|2006-08-17|2006-08-18|Estimate|||||||2012-11-02|2012-11-05|Estimate|July 2006||2006-07-31|November 2012|2012-11-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Examination of a Treatment Program for Overweight Children, Adolescents, and Their Families|Effectiveness of a Treatment Program for Pediatric Obesity|Completed||N/A|93|Actual|University of Kansas||2|||f||||f||||||||||2018-06-01 03:49:50.358423|2018-06-01 03:49:50.358423
NCT00365794|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2015-10-12|2006-08-16|2006-08-17|Estimate|||||||2015-10-12|2015-10-14|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Investigator Initiated Study of the Effects of Androgen Therapy on Carbohydrate and Lipid Metabolism In Elderly Men||Completed||Phase 2|20|Actual|University of Southern California||1|||f||||f||||||||||2018-06-01 03:49:50.434638|2018-06-01 03:49:50.434638
NCT00365781|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2007-10-15|2006-08-15|2006-08-17|Estimate|||||||2007-10-15|2007-10-17|Estimate|August 2006||2006-08-31|October 2007|2007-10-31|September 2006||2006-09-30|||||Interventional|||Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715|A Phase 1, Open-Label Examination of the Dermatologic Effects From Subcutaneous Administration of ISIS 113715, and Antisense Oligonucleotide Inhibitor of Protein Tyrosine Phosphatase 1B, in Healthy Volunteers|Completed||Phase 1|10||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 03:49:50.521125|2018-06-01 03:49:50.521125
NCT00365768|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2015-11-06||2016-07-25|2006-08-16|2006-08-17|Estimate|2016-07-25|2016-09-09|Estimate||||2016-07-25|2016-09-09|Estimate|October 2004||2004-10-31|July 2016|2016-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Fifty-six patients were enrolled and 49 were evaluable.|Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors|A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer|Completed||Phase 2|56|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-06-01 03:49:50.582052|2018-06-01 03:49:50.582052
NCT00365755|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2013-08-01|2006-08-16|2006-08-17|Estimate|||||||2013-08-01|2013-08-02|Estimate||||March 2008|2008-03-31|March 2008|Actual|2008-03-31|||||Interventional|||Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma|Comparison of High Dose Rapid Schedule With Conventional Schedule Chemotherapy for Stage 4 Neuroblastoma Over the Age of One Year|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:49:50.789599|2018-06-01 03:49:50.789599
NCT00365729|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2016-01-20|2006-08-16|2006-08-17|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2003||2003-10-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|||Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men|Evaluation of Viral Load Determination and Other Biomarkers of High Risk HPV-Types as a Marker for Progression of Perianal HPV-infections in HIV-positive Men Who Have Sex With Men|Unknown status|Recruiting||1000|Anticipated|Deutsche Luft und Raumfahrt|||||f||||||||||Samples With DNA|"~     Anogenital smears~   "|||2018-06-01 03:49:50.935822|2018-06-01 03:49:50.935822
NCT00365716|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2010-05-19||2015-10-06|2006-08-16|2006-08-17|Estimate|2010-07-06|2010-08-03|Estimate||||2015-10-06|2015-10-07|Estimate|May 2000||2000-05-31|October 2015|2015-10-31|September 2009|Actual|2009-09-30|May 2004|Actual|2004-05-31||Interventional|||Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)|A Placebo-Controlled, Dose-Ranging Study of Quadrivalent HPV Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women|Completed||Phase 2|1158|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-06-01 03:49:51.139219|2018-06-01 03:49:51.139219
NCT00365703|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2007-12-15|2006-08-15|2006-08-17|Estimate|||||||2007-12-15|2007-12-19|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best?|Nasogastric Tube vs. Orogastric Feeding Tube in Preterm Infants: Which is Best?|Completed||N/A|115|Actual|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-06-01 03:49:51.768026|2018-06-01 03:49:51.768026
NCT00365690|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2013-05-06|2006-08-16|2006-08-17|Estimate|||||||2013-05-06|2013-05-07|Estimate|February 2007||2007-02-28|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effectiveness of a Telephone-Delivered Behavioral Treatment to Improve the Quality of Life of Older Adults With HIV|Telephone-Delivered Coping Improvement Intervention for HIV Infected Older Adults|Completed||Phase 2/Phase 3|360|Anticipated|Ohio University||3|||f||||t||||||||||2018-06-01 03:49:51.841469|2018-06-01 03:49:51.841469
NCT00365677|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2011-12-07|2006-08-15|2006-08-17|Estimate|||||||2011-12-07|2011-12-08|Estimate|October 2005||2005-10-31|December 2011|2011-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study to Investigate the Safety and Effectiveness of Aspheric Laser Refractive Surgery Treatments for Myopia|Compare the Safety and Effectiveness of Two Versions of the Bausch & Lomb Zyoptix™ Tissue Saving Aspheric Algorithm to the Current Zyoptix™ Tissue Saving Algorithm When Used for Myopia and Myopic Astigmatism Lasik Treatment|Completed||N/A|127|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:49:51.996185|2018-06-01 03:49:51.996185
NCT00365651|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2007-05-18|2006-08-15|2006-08-17|Estimate|||||||2007-05-18|2007-05-21|Estimate|June 2006||2006-06-30|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Nutrition and Soccer for Pediatric Overweight and Obesity|Multi Intervention Approach to Pediatric Overweight and Obesity: A Randomized Control Group Trial|Completed||Phase 1|22|Actual|Leach Chiropractic Clinic|||||f||||t||||||||||2018-06-01 03:49:52.059283|2018-06-01 03:49:52.059283
NCT00365638|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2006-08-15|2006-08-15|2006-08-17|Estimate|||||||2006-08-15|2006-08-17|Estimate|April 2004||2004-04-30|September 2004|2004-09-30|February 2005||2005-02-28|||||Interventional|||Simvastatin Therapy in Women With Polycystic Ovary Syndrome.|Effects of Simvastatin on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Prospective, Randomized Trial.|Completed||N/A|||Poznan University of Medical Sciences|||||f||||||||||||||2018-06-01 03:49:52.129142|2018-06-01 03:49:52.129142
NCT00365625|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2010-02-01|2006-08-16|2006-08-17|Estimate|||||||2010-02-01|2010-02-02|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|December 2007|Anticipated|2007-12-31|||||Observational|||Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris|Patient Orientated Basic Science Investigation: Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris|Unknown status|Recruiting||30|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 03:49:52.196471|2018-06-01 03:49:52.196471
NCT00365612|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2008-04-09|2006-08-16|2006-08-17|Estimate|||||||2008-04-09|2008-04-10|Estimate|July 2006||2006-07-31|April 2008|2008-04-30|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients|Phase IV, Open-Label, Randomized, Multicenter Study Evaluating Efficacy and Tolerability of Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir DF Compared to Unmodified HAART in HIV-1 Infected Subjects Who Have Achieved Virological Suppression on Their HAART Regimen|Completed||Phase 4|300|Anticipated|Gilead Sciences|||||f||||f||||||||||2018-06-01 03:49:52.273128|2018-06-01 03:49:52.273128
NCT00365599|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2012-02-21||2014-11-10|2006-08-15|2006-08-17|Estimate|2012-02-21|2012-03-26|Estimate||||2014-11-10|2014-11-21|Estimate|February 2006||2006-02-28|November 2014|2014-11-30|August 2012|Actual|2012-08-31|April 2011|Actual|2011-04-30||Interventional|||Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer|Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination With Tamoxifen for Patients With Advanced Breast Cancer Who Have Failed Prior Anti-hormonal Therapy.|Completed||Phase 2|43|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 03:49:52.413462|2018-06-01 03:49:52.413462
NCT00365586|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2008-08-13|2006-08-16|2006-08-17|Estimate|||||||2008-08-13|2008-08-14|Estimate|August 2006||2006-08-31|August 2008|2008-08-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Ketoprofen Topical Patch, 20% in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee|A Phase III Study of the Efficacy, Tolerability and Safety of the Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee, Including a Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase Followed by an Open-Label Treatment Phase|Completed||Phase 3|300|Anticipated|Endo Pharmaceuticals|||||f||||||||||||||2018-06-01 03:49:52.617472|2018-06-01 03:49:52.617472
NCT00365573|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2010-11-04|2006-08-16|2006-08-17|Estimate|||||||2010-11-04|2010-11-05|Estimate|February 2008||2008-02-29|October 2010|2010-10-31||||||||Observational|||Doppler Ultrasonography Evaluation of Tibial Fracture Site Vascularity|Doppler Ultrasonography Evaluation of Tibial Fracture Site Vascularity|Suspended|||30|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:49:52.685689|2018-06-01 03:49:52.685689
NCT00365560|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2013-07-10|2006-08-16|2006-08-17|Estimate|||||||2013-07-10|2013-07-11|Estimate|August 2006||2006-08-31|July 2013|2013-07-31||||November 2007|Actual|2007-11-30||Interventional|||An Efficacy and Safety Evaluation of Tiotropium add-on Therapy in Patients With Severe Persistent Asthma|A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 Mcg (2 Actuations of 2.5 Mcg) and 10 Mcg (2 Actuations of 5 Mcg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler® as Add-on Therapy in Patients With Severe Persistent Asthma|Completed||Phase 2|115||Boehringer Ingelheim|||||||||||||||||||2018-06-01 03:49:52.73581|2018-06-01 03:49:52.73581
NCT00365547|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2012-05-15||2017-12-03|2006-08-16|2006-08-17|Estimate|2012-05-15|2012-06-15|Estimate||||2017-12-03|2017-12-28|Actual|September 2006||2006-09-30|December 2017|2017-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy|Phase II Clinical Study of Weekly Topotecan in Combination With Avastin™ in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Prior Systemic Chemotherapy|Completed||Phase 2|46|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 03:49:52.835448|2018-06-01 03:49:52.835448
NCT00365534|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2010-03-25|2006-08-16|2006-08-17|Estimate|||||||2010-03-25|2010-03-26|Estimate|January 2006||2006-01-31|March 2010|2010-03-31||||||||Interventional|||Use of Magnetic Imaging to Asses the Efficacy of Cap Assisted Colonoscopy in Reducing Looping and Improving Patient Acceptance for the Colonoscopy Procedure|A Double-Blinded Randomized Study Comparison the Mechanism of Looping Formation and Subject's Acceptance During CAC and Regular Colonoscopy by MEI (MIC Study)|Withdrawn||N/A|20|Anticipated|Chinese University of Hong Kong||||The study was incorporated in another study.|f||||||||||||||2018-06-01 03:49:53.058917|2018-06-01 03:49:53.058917
NCT00365521|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2008-05-30|2006-08-16|2006-08-17|Estimate|||||||2008-05-30|2008-06-02|Estimate|April 2009||2009-04-30|May 2008|2008-05-31||||||||Interventional|||Prophylactic Photodynamic Therapy to Organ Transplant Patients||Unknown status|Not yet recruiting|N/A|50|Anticipated|Bispebjerg Hospital|||||f||||||||||||||2018-06-01 03:49:53.10752|2018-06-01 03:49:53.10752
NCT00365508|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2012-11-20||2016-03-01|2006-08-16|2006-08-17|Estimate|2012-12-20|2013-01-30|Estimate||||2016-03-01|2016-03-29|Estimate|February 2006||2006-02-28|March 2016|2016-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking|Comparing the Lozenge to the Patch for Smoking Cessation|Completed||Phase 4|642|Actual|Fox Chase Cancer Center|The study was an effectiveness trial so external vs. internal validity was emphasized. Many participants were lost to follow-up.|2|||f||||f||||||||||2018-06-01 03:49:53.258343|2018-06-01 03:49:53.258343
NCT00365495|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2007-04-03|2006-08-15|2006-08-17|Estimate|||||||2007-04-03|2007-04-04|Estimate|August 2006||2006-08-31|April 2007|2007-04-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Influence of Physical Training on Mitochondrial Function in Type 2 Diabetic Patients||Unknown status|Active, not recruiting|N/A|30||Odense University Hospital|||||f||||||||||||||2018-06-01 03:49:53.504333|2018-06-01 03:49:53.504333
NCT00365482|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2012-05-15|2006-08-15|2006-08-17|Estimate|||||||2012-05-15|2012-05-17|Estimate|August 2006||2006-08-31|May 2012|2012-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Bipolar Disorder in Epilepsy|Bipolar Disorder in Epilepsy|Completed|||102|Actual|Northwell Health|||||f||||f||||||||||2018-06-01 03:49:53.554044|2018-06-01 03:49:53.554044
NCT00365469|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2014-01-07|2006-08-16|2006-08-17|Estimate|||||||2014-01-07|2014-01-09|Estimate|May 2006||2006-05-31|January 2014|2014-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Influence of Probiotics on Atopy, Immunological Responses and Gut Microflora - Follow-up to 5 Years|A Follow-up Study to 5 Years of a Randomized, Double-blinded, Placebo-controlled Study on the Influence of Probiotics on Atopy, Immunological Responses and Gut Microflora|Completed||Phase 2|253|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 03:49:53.605733|2018-06-01 03:49:53.605733
NCT00365456|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2012-05-04||2012-08-16|2006-08-16|2006-08-17|Estimate|2012-06-14|2012-07-20|Estimate||||2012-08-16|2012-08-20|Estimate|July 2006||2006-07-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|PEAK||Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)|An Open Label, International, Multi Centre, Parallel Group, Phase III b, Randomised Trial, Investigating Lumbar Spine Bone Mineral Density (BMD) Changes in Postmenopausal Women With Primary Osteoporosis Initially Treated With 12 Months of Full Length Parathyroid Hormone (PTH 1-84) Followed by 12 Months of Treatment With Risedronate Followed by Either 12 Months Treatment With PTH (1-84) or Risedronate.|Completed||Phase 3|407|Actual|Takeda||2|||f||||t||||||||||2018-06-01 03:49:53.777427|2018-06-01 03:49:53.777427
NCT00365443|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2015-06-18|2006-08-16|2006-08-17|Estimate|||||||2015-06-18|2015-06-19|Estimate|October 2006||2006-10-31|June 2015|2015-06-30||||||||Interventional|||Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)|Proprietary Information - Exploratory (Non-Confirmatory) Trial|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:49:54.416495|2018-06-01 03:49:54.416495
NCT00365430|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2009-01-22|2006-08-16|2006-08-17|Estimate|||||||2009-01-22|2009-01-23|Estimate|September 2006||2006-09-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes|SAFE or SORRY? Development and Testing of an Evidence Based Inpatient Safety Program for the Prevention of Common Complications.|Completed||N/A|3000|Actual|Radboud University|||||f||||t||||||||||2018-06-01 03:49:54.544616|2018-06-01 03:49:54.544616
NCT00365417|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2009-08-21||2015-10-05|2006-08-16|2006-08-17|Estimate|2010-07-16|2010-08-12|Estimate||||2015-10-05|2015-10-26|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|November 2009|Actual|2009-11-30|February 2008|Actual|2008-02-29||Interventional|||Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer|A Phase II Clinical Trial of Bevacizumab Beginning Concurrently With a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy Followed by Postoperative Bevacizumab Alone for Women With Locally Advanced Breast Cancer|Completed||Phase 2|45|Actual|NSABP Foundation Inc|||||f||||f||||||||||2018-06-01 03:49:54.698257|2018-06-01 03:49:54.698257
NCT00365404|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2015-11-25|2006-08-16|2006-08-17|Estimate|||||||2015-11-25|2015-11-26|Estimate|October 2003||2003-10-31|July 2006|2006-07-31|February 2006||2006-02-28|||||Interventional|||Activity, Rheumatoid and Osteoarthritis, and Weight Management|Weight Management, Physical Activity, Less Disability in Rheumatoid and Osteoarthritis|Completed||N/A|465||HealthPartners Institute|||||f||||||||||||||2018-06-01 03:49:55.042586|2018-06-01 03:49:55.042586
NCT00365391|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2013-03-22||2015-06-10|2006-08-16|2006-08-17|Estimate|2013-05-24|2013-07-10|Estimate||||2015-06-10|2015-07-09|Estimate|August 2006||2006-08-31|March 2013|2013-03-31|June 2010|Actual|2010-06-30|August 2008|Actual|2008-08-31||Interventional|||Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer|Phase II Study of Bevacizumab Plus Erlotinib in Patients With Advanced Hepatocellular Cancer (HCC)|Completed||Phase 2|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:49:55.134979|2018-06-01 03:49:55.134979
NCT00365222|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2009-01-21|2006-08-15|2006-08-17|Estimate|||||||2009-01-21|2009-01-22|Estimate|July 2006||2006-07-31|January 2009|2009-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma|Phase II Study of Dose Intensive Temozolomide in Elderly Adults With Newly Diagnosed Glioblastoma|Terminated||Phase 2|1|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||IRB Study Closure|f||||t||||||||||2018-06-01 03:49:59.260907|2018-06-01 03:49:59.260907
NCT00365378|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2010-03-22||2015-10-22|2006-08-16|2006-08-17|Estimate|2010-03-22|2010-04-09|Estimate||||2015-10-22|2015-10-23|Estimate|September 1999||1999-09-30|October 2015|2015-10-31|July 2009|Actual|2009-07-31|March 2004|Actual|2004-03-31||Interventional|||Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)|Study of Pilot Manufacturing Lot of HPV 16 Virus-Like Particle (VLP) Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females|Completed||Phase 2|2409|Actual|Merck Sharp & Dohme Corp.|Of note, the number of subjects reported in the results posting is slightly different than that specified in the publication by Koutsky, et al (2002). The data provided here is based on final data.|2|||f||||f||||||||||2018-06-01 03:49:55.441803|2018-06-01 03:49:55.441803
NCT00365365|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2012-08-16||2012-08-16|2006-08-16|2006-08-17|Estimate|2012-08-16|2012-09-14|Estimate||||2012-08-16|2012-09-14|Estimate|August 2006||2006-08-31|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer|A Phase IIb, Randomized, Multicenter, Noncomparative Pilot Study of the Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab ± Trastuzumab for the Adjuvant Treatment of Patients With Node-Positive & High-Risk Node-Negative Breast Cancer|Completed||Phase 2|214|Actual|Sanofi|The study was originally designed to last for 6-10 years. Based on a protocol amendment, the study was shortened to about 3 years, and the endpoint Overall Survival (OS) was deleted.|3|||f||||t||||||||||2018-06-01 03:49:56.034092|2018-06-01 03:49:56.034092
NCT00365352|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2011-04-21|2009-07-22|2013-07-15|2006-08-15|2006-08-17|Estimate|2011-04-21|2011-05-11|Estimate|2009-07-22|2009-08-10|Estimate|2013-07-15|2013-07-22|Estimate|August 2006||2006-08-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||XP13512 vs. Placebo in Patients With Restless Legs Syndrome.|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.|Completed||Phase 3|325|Actual|XenoPort, Inc.||3|||f||||f||||||||||2018-06-01 03:49:57.050337|2018-06-01 03:49:57.050337
NCT00365339|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2011-04-07|2006-08-16|2006-08-17|Estimate|||||||2011-04-07|2011-04-08|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir|Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Famotidine on the Pharmacokinetics of Atazanavir/Ritonavir/Tenofovir in Healthy Subjects|Completed||Phase 1|40||Bristol-Myers Squibb||5|||f||||||||||||||2018-06-01 03:49:57.89549|2018-06-01 03:49:57.89549
NCT00365326|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2011-03-08|2006-08-15|2006-08-17|Estimate|||||||2011-03-08|2011-03-09|Estimate|January 2006||2006-01-31|August 2006|2006-08-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Safety and Efficacy of Autologous, Intracoronary Stem Cell Injections in Total Coronary Artery Occlusions|Safety and Efficacy of Autologous, Intracoronary Stem Cell Injections in Total Coronary Artery Occlusions|Completed||Phase 1|9|Actual|Case Western Reserve University|||||||||||||||||||2018-06-01 03:49:57.971327|2018-06-01 03:49:57.971327
NCT00365313|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2006-10-26|2006-08-16|2006-08-17|Estimate|||||||2006-10-26|2006-10-27|Estimate|August 2002||2002-08-31|October 2006|2006-10-31|June 2005||2005-06-30|||||Interventional|||Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib|A Phase 3 Double Blinded, Randomized, Placebo Controlled Trial of Proton Pump Inhibitor for the Prevention of Recurrent Ulcer Bleeding in Patients Receiving a COX-2 Inhibitor|Completed||Phase 3|273||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 03:49:58.043269|2018-06-01 03:49:58.043269
NCT00365300|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2009-11-30||2010-04-26|2006-08-16|2006-08-17|Estimate|2009-11-30|2010-01-07|Estimate||||2010-04-26|2010-05-04|Estimate|September 2006||2006-09-30|April 2010|2010-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study of the Efficacy and Safety of Pantoprazole Sodium Enteric-Coated Granules in Infants (1 Through 11 Months) With Symptomatic GERD.|Completed||Phase 3|129|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:49:58.12164|2018-06-01 03:49:58.12164
NCT00365287|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2017-11-27|2006-08-16|2006-08-17|Estimate|||||||2017-11-27|2017-11-29|Actual|June 2000||2000-06-30|November 2017|2017-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer|Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen|Completed||Phase 1/Phase 2|148|Actual|Masonic Cancer Center, University of Minnesota|||||f||||t||||||||||2018-06-01 03:49:58.605807|2018-06-01 03:49:58.605807
NCT00365274|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2013-09-13||2014-05-29|2006-08-16|2006-08-17|Estimate|2013-09-13|2013-11-18|Estimate||||2014-05-29|2014-06-02|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma|A Phase II Study of SGN-30 in Combination With CHOP in Anaplastic Large Cell Lymphoma|Terminated||Phase 2|6|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:49:58.68451|2018-06-01 03:49:58.68451
NCT00365261|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2011-08-24||2016-06-03|2006-08-15|2006-08-17|Estimate|2011-08-24|2011-09-29|Estimate||||2016-06-03|2016-07-11|Estimate|September 2006||2006-09-30|June 2016|2016-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer|Effect of Eszopiclone (Lunesta) on Sleep Disturbance and Pain in Cancer|Completed||Phase 4|45|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-06-01 03:49:58.852048|2018-06-01 03:49:58.852048
NCT00365248|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2012-05-04|2006-08-16|2006-08-17|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2005||2005-10-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|||||Interventional|||TachoSil Paediatric Liver Trial (TC-019-IN)|A Prospective, Multi-centre Phase III-b Study of TachoSil in Paediatric Patients Scheduled for Resection of the Liver With or Without Segmental Liver Transplantation.|Completed||Phase 3|16|Actual|Nycomed|||||f||||t||||||||||2018-06-01 03:49:59.151628|2018-06-01 03:49:59.151628
NCT00365235|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2012-01-11|2006-08-16|2006-08-17|Estimate|||||||2012-01-11|2012-01-12|Estimate|July 2006||2006-07-31|January 2012|2012-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals|Genetic Susceptibility to Common Lipid Disorders in Mexico|Completed|||998|Actual|University of California, Los Angeles|||||f||||||||||Samples With DNA|"~     Whole blood sample is taken from all participants and adipose tissue sample from a subgroup.~   "|||2018-06-01 03:49:59.20805|2018-06-01 03:49:59.20805
NCT00361426|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|||2016-07-17|2006-08-06|2006-08-08|Estimate|||||||2016-07-17|2016-07-19|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||EarlySense Monitoring Device Evaluation on COPD, CHF and Pneumonia Patients|EarlySense Monitoring Device Evaluation on Patients in Med / Surg|Withdrawn|||0|Actual|EarlySense Ltd.||||No need|f||||t||||||||||2018-06-01 03:51:13.146644|2018-06-01 03:51:13.146644
NCT00365209|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2014-04-18||2015-07-30|2006-08-16|2006-08-17|Estimate|2015-07-30|2015-08-27|Estimate||||2015-07-30|2015-08-27|Estimate|October 2006||2006-10-31|March 2014|2014-03-31|January 2011|Actual|2011-01-31|September 2008|Actual|2008-09-30||Interventional||Stage 1: 2g curcumin (N = 22 participants due to 1 participant withdrew consent after start of treatment) Stage 2: 4g curcumin (N = 21 participants)|Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)|Phase IIA Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:49:59.368361|2018-06-01 03:49:59.368361
NCT00365196|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2016-02-17|2006-08-16|2006-08-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 1999||1999-12-31|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|||Hostility Reduction Program to Improve Autonomic Regulation of the Heart|Hostility Reduction and Autonomic Control of the Heart|Completed||N/A|150||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:49:59.860733|2018-06-01 03:49:59.860733
NCT00365183|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2013-10-29|2006-08-15|2006-08-17|Estimate|||||||2013-10-29|2013-10-31|Estimate|June 2006||2006-06-30|October 2013|2013-10-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer|Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer|Terminated||Phase 2|74|Actual|Pharmacyclics LLC.||1|||f||||||||||||||2018-06-01 03:49:59.926449|2018-06-01 03:49:59.926449
NCT00365170|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2016-12-20|2006-08-16|2006-08-17|Estimate|||||||2016-12-20|2016-12-21|Estimate|September 2002||2002-09-30|December 2016|2016-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes|A Randomised, Parallel-group, Open-label, Multinational Trial Comparing the Safety and Efficacy of Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen, in the Treatment of Pregnant Women With Type 1 Diabetes, Focusing on Maternal Hypoglycaemia and Pregnancy Outcomes|Completed||Phase 4|419|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:50:00.036782|2018-06-01 03:50:00.036782
NCT00365157|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|||2018-04-24|2006-08-16|2006-08-17|Estimate|||||||2018-04-24|2018-04-25|Actual|October 23, 2006|Actual|2006-10-23|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction|A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency|Active, not recruiting||Phase 1/Phase 2|132|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:50:00.233544|2018-06-01 03:50:00.233544
NCT00365144|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2013-09-18||2017-12-19|2006-08-16|2006-08-17|Estimate|2013-09-18|2013-11-25|Estimate||||2017-12-19|2018-01-19|Actual|February 2006||2006-02-28|December 2017|2017-12-31|March 2010|Actual|2010-03-31|January 2009|Actual|2009-01-31||Interventional|||Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine|A Phase II Trial of Bevacizumab Plus Erlotinib for Patients With Metastatic Gemcitabine-Refractory Pancreatic Cancer|Completed||Phase 2|36|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 03:50:00.57887|2018-06-01 03:50:00.57887
NCT00365131|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2015-03-04|2006-08-15|2006-08-17|Estimate|||||||2015-03-04|2015-03-05|Estimate|December 1997||1997-12-31|March 2015|2015-03-31|July 2004|Actual|2004-07-31|||||Interventional|||A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.||Completed||Phase 4|40||Sanofi|||||f||||||||||||||2018-06-01 03:50:00.786791|2018-06-01 03:50:00.786791
NCT00365118|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2008-06-02|2006-08-16|2006-08-17|Estimate|||||||2008-06-02|2008-06-03|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Treatment of Naevus Flammeus Using Intense Pulsed Light and Pulsed Dye Laser||Completed||N/A|||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 03:50:00.839447|2018-06-01 03:50:00.839447
NCT00365105|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2014-11-03||2018-04-03|2006-08-16|2006-08-17|Estimate|2014-11-03|2014-11-10|Estimate||||2018-04-03|2018-05-03|Actual|July 11, 2006|Actual|2006-07-11|March 2015|2015-03-31|February 27, 2017|Actual|2017-02-27|January 2012|Actual|2012-01-31||Interventional||Eligible patients|Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer|Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer|Completed||Phase 3|261|Actual|Radiation Therapy Oncology Group|This study stopped accrual early with 261 accrued out of 352 planned, due to a lower than expected rate of skeletal related events in the control arm.|2|||f||||t||||||||||2018-06-01 03:50:00.959066|2018-06-01 03:50:00.959066
NCT00365092|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2006-08-15|2006-08-15|2006-08-17|Estimate|||||||2006-08-15|2006-08-17|Estimate|April 2002||2002-04-30|August 2006|2006-08-31|March 2005||2005-03-31|||||Interventional|||Middle Ear Disease Before Age 3, Treatment With Ear Tubes, and Literacy and Attentional Abilities at Ages 9 to 11|Early Otitis and Literacy and Attention at 9 to 11 Years|Completed||N/A|400||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:50:01.790405|2018-06-01 03:50:01.790405
NCT00365053|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-16|2014-07-09||2018-03-21|2006-08-16|2006-08-17|Estimate|2014-12-17|2014-12-29|Estimate||||2018-03-21|2018-04-18|Actual|June 2006||2006-06-30|March 2018|2018-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery|Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|13|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:50:01.900031|2018-06-01 03:50:01.900031
NCT00365040|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2006-08-15|2006-08-15|2006-08-17|Estimate|||||||2006-08-15|2006-08-17|Estimate|December 2004||2004-12-31|July 2006|2006-07-31|October 2006||2006-10-31|||||Interventional|||Customized PRK With Mitomycin Versus Customized Lasik for Myopic Astigmatism|Customized PRK With Mitomycin Versus Customized Lasik for Myopic Astigmatism|Completed||N/A|40||Federal University of São Paulo|||||f||||||||||||||2018-06-01 03:50:02.355931|2018-06-01 03:50:02.355931
NCT00365027|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2015-09-03|2006-08-15|2006-08-16|Estimate|||||||2015-09-03|2015-09-04|Estimate||||September 2015|2015-09-30||||||||Interventional|||Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.||Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel||||Enrollment difficulties|f||||||||||||||2018-06-01 03:50:02.515171|2018-06-01 03:50:02.515171
NCT00365014|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2013-07-19|2006-08-14|2006-08-16|Estimate|||||||2013-07-19|2013-07-23|Estimate|August 2003||2003-08-31|July 2013|2013-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Progression of Hematopoietic Diseases in Shanghai, China|Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.|Completed|||10757|Actual|University of Colorado, Denver|||1||f||||||||||||||2018-06-01 03:50:02.571769|2018-06-01 03:50:02.571769
NCT00365001|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2010-06-10|2006-08-15|2006-08-16|Estimate|||||||2010-06-10|2010-06-11|Estimate||||June 2010|2010-06-30|April 2008|Actual|2008-04-30|||||Interventional|||A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.|A Randomized, Open-label Study to Assess the Pharmacokinetics of Simvastatin and Methotrexate in Combination With Tocilizumab in Patients With Rheumatoid Arthritis.|Completed||Phase 1|23|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:50:02.646062|2018-06-01 03:50:02.646062
NCT00364988|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2014-10-23|2006-08-14|2006-08-16|Estimate|||||||2014-10-23|2014-10-27|Estimate|January 2005||2005-01-31|October 2014|2014-10-31|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||Pioglitazone and Losartan Provides Additional Renoprotection|Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy|Completed||N/A|60|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||t||||||||||2018-06-01 03:50:02.867157|2018-06-01 03:50:02.867157
NCT00364975|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2015-09-20|2006-08-15|2006-08-16|Estimate|||||||2015-09-20|2015-09-22|Estimate|December 2006||2006-12-31|August 2006|2006-08-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Development of Gourmet Healthy Cooking Workshop for Cancer Patients|Development of Gourmet Healthy Cooking Workshop for Cancer Patients|Withdrawn||N/A|0|Actual|Hadassah Medical Organization||||Was not funded|f||||||||||||||2018-06-01 03:50:02.932908|2018-06-01 03:50:02.932908
NCT00364962|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2006-08-15|2006-08-15|2006-08-16|Estimate|||||||2006-08-15|2006-08-16|Estimate|April 2006||2006-04-30|August 2006|2006-08-31|June 2006||2006-06-30|||||Observational|||Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients||Unknown status|Recruiting||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:50:02.989362|2018-06-01 03:50:02.989362
NCT00364949|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2010-07-19||2013-04-03|2006-08-15|2006-08-16|Estimate|2010-07-19|2010-08-18|Estimate||||2013-04-03|2013-04-10|Estimate|January 2003||2003-01-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands|Genes, Androgens and Intrauterine Environment in PCOS|Completed|||70|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:50:03.0778|2018-06-01 03:50:03.0778
NCT00364936|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-06-10|2006-08-14|2006-08-16|Estimate|||||||2009-06-10|2009-06-11|Estimate|March 2004||2004-03-31|June 2009|2009-06-30|December 2006||2006-12-31|||||Interventional|||Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS)|Proposal to Create a Flagship Neurology and Palliative Care Service for South London|Completed||Phase 1/Phase 2|52|Actual|King's College London|||||f||||t||||||||||2018-06-01 03:50:03.467182|2018-06-01 03:50:03.467182
NCT00364923|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2009-10-23||2013-05-08|2006-08-15|2006-08-16|Estimate|2009-12-22|2010-02-01|Estimate||||2013-05-08|2013-05-10|Estimate|August 2006||2006-08-31|May 2013|2013-05-31|February 2012||2012-02-29|January 2009|Actual|2009-01-31||Interventional|PROPEL||Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|Completed||Phase 2|115|Actual|Spectrum Pharmaceuticals, Inc|Outcome Measure (primary and secondary), Serious Adverse Event and Adverse Event data presented have a cut-off date of August 2009.||||f||||t||||||||||2018-06-01 03:50:03.578577|2018-06-01 03:50:03.578577
NCT00364910|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2017-12-21|2006-08-15|2006-08-16|Estimate|||||||2017-12-21|2017-12-26|Actual|April 2006||2006-04-30|December 2017|2017-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy of Cognitive Behavior Therapy for People With Post-traumatic Stress and Cardiovascular Illness|Post-Traumatic Stress Disorder (PTSD) Treatment in Cardiac Patients|Completed||N/A|60|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||||2018-06-01 03:50:03.964366|2018-06-01 03:50:03.964366
NCT00364897|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2007-04-10|2006-08-15|2006-08-16|Estimate|||||||2007-04-10|2007-04-11|Estimate||||February 2007|2007-02-28||||||||Observational|||Investigation of Clinical Outcome of ACL Reconstruction Utilizing Two Tibial Fixation Techniques, Concentric Tapered Interference Screws and Interference Screw and Sheath|Comparison Between Two Tibial Fixation Techniques in ACL Reconstruction|Withdrawn|||140||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:50:04.05036|2018-06-01 03:50:04.05036
NCT00364884|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2006-08-15|2006-08-15|2006-08-16|Estimate|||||||2006-08-15|2006-08-16|Estimate|August 2006||2006-08-31|August 2006|2006-08-31|August 2007||2007-08-31|||||Interventional|||Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease|Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease|Unknown status|Not yet recruiting|Phase 4|50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:50:04.092489|2018-06-01 03:50:04.092489
NCT00364871|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2008-04-18|2006-08-14|2006-08-16|Estimate|||||||2008-04-18|2008-04-22|Estimate|April 2005||2005-04-30|April 2008|2008-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity|Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled Study of Combination Therapy for Safety and Efficacy in Subjects With Uncomplicated Obesity|Completed||Phase 2|410|Actual|Orexigen Therapeutics, Inc||7|||f||||t||||||||||2018-06-01 03:50:04.14811|2018-06-01 03:50:04.14811
NCT00364858|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2009-05-28||2015-03-17|2006-08-15|2006-08-16|Estimate|2009-07-23|2009-09-02|Estimate||||2015-03-17|2015-04-03|Estimate|December 2001||2001-12-31|March 2015|2015-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease|A Phase IV, Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every Four Weeks Versus Every Two Weeks in the Maintenance Therapy of Patients With Type 1 Gaucher Disease|Completed||Phase 4|95|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:50:04.251178|2018-06-01 03:50:04.251178
NCT00364845|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2010-12-02||2014-04-23|2006-08-15|2006-08-16|Estimate|2014-04-23|2014-05-21|Estimate||||2014-04-23|2014-05-21|Estimate|September 2006||2006-09-30|April 2014|2014-04-30|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients|A Randomised Single-Blind Study to Improve Health-related Quality of Life as Measured by the Short-Form 36 (SF-36) Vitality Score by Correcting Anemia With Aranesp (Darbepoetin Alfa) in the Elderly.|Terminated||Phase 3|51|Actual|Amgen||2||"The reason for the discontinuation of the study is difficulty with recruitment and timely~   enrolment and is not related to safety concerns"|f||||f||||||||||2018-06-01 03:50:04.919029|2018-06-01 03:50:04.919029
NCT00364663|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2006-08-15|2006-08-15|2006-08-16|Estimate|||||||2006-08-15|2006-08-16|Estimate|August 2006||2006-08-31|August 2006|2006-08-31||||||||Observational|||The Utility and Cost-Effectiveness Analysis of 18F-FDG PETin Staging Potential Operable Non-Small Cell Lung Cancer|The Utility and Cost-Effectiveness Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in Staging Potential Operable Non-Small Cell Lung Cancer|Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:50:17.83474|2018-06-01 03:50:17.83474
NCT00364832|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2016-05-03||2016-10-26|2006-08-15|2006-08-16|Estimate|2016-10-26|2016-12-20|Estimate||||2016-10-26|2016-12-20|Estimate|October 2001||2001-10-31|October 2016|2016-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional||The Intent-to-Treat (ITT) population was considered for analysis which included all randomized participants.|A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.|An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Subcutaneous Epoetin Alfa or Beta to Maintenance Treatment With Subcutaneous RO0503821 in Dialysis Patients With Chronic Renal Anemia|Completed||Phase 2|137|Actual|Hoffmann-La Roche||9|||f||||||||||||||2018-06-01 03:50:05.459163|2018-06-01 03:50:05.459163
NCT00364819|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2017-03-18||2017-06-05|2006-08-15|2006-08-16|Estimate|2017-05-01|2017-06-01|Actual||||2017-06-05|2017-07-02|Actual|January 2007||2007-01-31|June 2017|2017-06-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Initial Study of Rituximab to Treat Primary Biliary Cirrhosis|Effects of Rituximab (Rituxan) on B Cell and AMA Response in Patients With Primary Biliary Cirrhosis|Completed||Phase 1/Phase 2|6|Actual|University of California, Davis||1|||f||||t||||||||Yes|IPD may be shared upon request and appropriate approval from Institutional Review Boards and material transfer agreements. No patient identifiers will be shared. Requests for IPD may be made to the Principle Investigator.|2018-06-01 03:50:08.379002|2018-06-01 03:50:08.379002
NCT00364806|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2018-04-15|2006-08-15|2006-08-16|Estimate|||||||2018-04-15|2018-04-17|Actual|August 2006||2006-08-31|April 2018|2018-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Prochlorperazine vs Metoclopramide|Prochlorperazine Verus Metoclopramide for the Treatment of Acute Migraine in the Emergency Department Setting|Completed||Phase 4|76||Montefiore Medical Center|||||f||||||||||||||2018-06-01 03:50:09.365997|2018-06-01 03:50:09.365997
NCT00364793|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|2014-03-06||2014-04-11|2006-08-15|2006-08-16|Estimate|2014-03-06|2014-04-11|Estimate||||2014-04-11|2014-04-29|Estimate|February 2007||2007-02-28|April 2014|2014-04-30|July 2013|Actual|2013-07-31|December 2011|Actual|2011-12-31||Interventional||Treated participants who received at least one dose of study drug (EFV) were analyzed.|Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children|An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age.|Completed||Phase 1/Phase 2|56|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 03:50:09.836643|2018-06-01 03:50:09.836643
NCT00364780|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14||2012-01-24|2012-01-24|2006-08-14|2006-08-16|Estimate||||2012-01-24|2012-01-30|Estimate|2012-01-24|2012-01-30|Estimate|July 2006||2006-07-31|January 2012|2012-01-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||Study of XL647 in Subjects With Non-Small-Cell Lung Cancer|A Phase 2 Study of XL647 in Subjects With Non-Small-Cell Lung Cancer|Completed||Phase 2|55|Actual|Kadmon Corporation, LLC||2|||f||||t||||||||||2018-06-01 03:50:16.003181|2018-06-01 03:50:16.003181
NCT00364767|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2008-05-22|2006-08-15|2006-08-16|Estimate|||||||2008-05-22|2008-05-23|Estimate|October 2004||2004-10-31|May 2008|2008-05-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Moderate Alcohol Consumption, Fat and Carbohydrate Metabolism and Insulin Sensitivity|The Effect of Moderate Alcohol Consumption on Markers of Oxidative Phosphorylation and Lipid Oxidation and on Postprandial Glycemic Control in Healthy, Lean and Overweight, Young Men|Completed||N/A|19|Actual|TNO||2|||f||||t||||||||||2018-06-01 03:50:16.132247|2018-06-01 03:50:16.132247
NCT00364754|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2014-04-18|2006-08-15|2006-08-16|Estimate|||||||2014-04-18|2014-04-21|Estimate|May 2004||2004-05-31|April 2014|2014-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer|A PHARMACOKINETIC INTERACTION PHASE I, MULTI-CENTRE, OPEN-LABEL, CROSS-OVER Study Evaluating the Effect of Tesmilifene on the Plasma Pharmacokinetics of Epirubicin and Cyclophosphamide in Patients With Metastatic/Recurrent Breast Cancer|Completed||Phase 1|28|Actual|YM BioSciences|||||f||||||||||||||2018-06-01 03:50:16.189923|2018-06-01 03:50:16.189923
NCT00364741|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2009-10-15|2006-08-15|2006-08-16|Estimate|||||||2009-10-15|2009-10-16|Estimate|October 2006||2006-10-31|October 2009|2009-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Supplemental Oxygen and Complications After Abdominal Surgery (The PROXI-trial)|PeRioperative OXygen Fraction - Effect on Surgical Site Infection and Pulmonary Complications After Abdominal Surgery (The PROXI-trial)|Completed||Phase 4|1400|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 03:50:16.281479|2018-06-01 03:50:16.281479
NCT00364728|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2010-05-20|2006-08-15|2006-08-16|Estimate|||||||2010-05-20|2010-05-21|Estimate|January 2006||2006-01-31|May 2010|2010-05-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Observational|||Efferocytosis and Genomic Polymorphism in Autoimmune Diseases|Efferocytosis (Clearance of Apoptotic Cells by Phagocytosis) and Autoimmune Diseases in Human|Unknown status|Recruiting||450|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 03:50:16.377912|2018-06-01 03:50:16.377912
NCT00364715|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2006-08-16|2006-08-15|2006-08-16|Estimate|||||||2006-08-16|2006-08-17|Estimate|January 2005||2005-01-31|August 2006|2006-08-31|December 2005||2005-12-31|||||Observational|||Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer|Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer|Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:50:16.503397|2018-06-01 03:50:16.503397
NCT00364702|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2011-08-16|2006-08-15|2006-08-16|Estimate|||||||2011-08-16|2011-08-17|Estimate|August 2006||2006-08-31|July 2006|2006-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder|Virtual Reality a Novel Screening and Treatment Aid in Attention Deficit Disorder|Completed||Phase 2|40|Anticipated|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:50:16.586427|2018-06-01 03:50:16.586427
NCT00364689|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-15|||2010-06-23|2006-08-15|2006-08-16|Estimate|||||||2010-06-23|2010-06-24|Estimate|August 2006||2006-08-31|April 2007|2007-04-30||||||||Interventional|||RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial|RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial|Unknown status|Recruiting|Phase 3|75|Anticipated|University of Miami|||||||||||||||||||2018-06-01 03:50:17.626541|2018-06-01 03:50:17.626541
NCT00364676|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2015-09-18|2006-08-14|2006-08-16|Estimate|||||||2015-09-18|2015-09-22|Estimate|July 2006||2006-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Phase 1 Study of Vinorelbine Liposomes Injection (VLI) for Treatment in Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease|Completed||Phase 1|67|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||||||||||||2018-06-01 03:50:17.701426|2018-06-01 03:50:17.701426
NCT00359060|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2006-10-12|2006-07-31|2006-08-01|Estimate|||||||2006-10-12|2006-10-13|Estimate|January 2005||2005-01-31|July 2006|2006-07-31|September 2006||2006-09-30|||||Interventional|||Physical Activity and Breast Cancer Risk in Postmenopausal Women:the SHAPE Study|Physical Activity and Breast Cancer Risk in Postmenopausal Women: the SHAPE Study|Completed||Phase 3|180||UMC Utrecht|||||f||||||||||||||2018-06-01 03:52:01.264033|2018-06-01 03:52:01.264033
NCT00364650|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2011-07-22|2006-08-14|2006-08-15|Estimate|||||||2011-07-22|2011-07-26|Estimate|July 2006||2006-07-31|July 2011|2011-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation|Probiotic Prophylaxis for Immunosuppressant Associated Diarrhea (IAD) Following Kidney Transplantation: a Single Center Randomized Controlled Trial|Completed||N/A|44|Actual|Swedish Medical Center||2|||f||||t||||||||||2018-06-01 03:50:17.899544|2018-06-01 03:50:17.899544
NCT00364637|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2018-02-26|2006-08-11|2006-08-15|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2005||2005-01-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Volatile Anesthetics in Cardiac Protection|Pharmacological Preconditioning Properties of Volatile Anesthetics|Recruiting||Phase 4|||Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-06-01 03:50:18.028156|2018-06-01 03:50:18.028156
NCT00364624|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-01-15|2006-08-14|2006-08-15|Estimate|||||||2009-01-15|2009-01-16|Estimate|August 2006||2006-08-31|January 2009|2009-01-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Observational|||Adrenal Function in Patients With Newly Diagnosed Lung Cancer|Adrenal Cortical Function in Patients With Newly Diagnosed Lung Cancer|Completed|||133|Actual|Princess Margaret Hospital, Hong Kong|||||f||||f||||||||||2018-06-01 03:50:18.123736|2018-06-01 03:50:18.123736
NCT00364611|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2012-06-18||2012-07-20|2006-08-14|2006-08-15|Estimate|2012-07-20|2012-08-23|Estimate||||2012-07-20|2012-08-23|Estimate|August 2006||2006-08-31|April 2012|2012-04-30|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Interventional|||Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer|A Pilot, Phase II, Multicenter, Open-Label, Prospective Evaluation of Docetaxel and Bevacizumab ± Trastuzumab in the First-Line Treatment of Patients With Metastatic Breast Cancer|Completed||Phase 2|73|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:50:18.214048|2018-06-01 03:50:18.214048
NCT00364598|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-03-27|2006-08-14|2006-08-15|Estimate|||||||2009-03-27|2009-03-30|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|February 2009|Anticipated|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Study of Anginera in Adults With a Left Ventricular Assist Device (LVAD) as Bridge to Transplant|A Phase I Open Label Pilot Study to Obtain Tissue for Histological Analysis After Application of Anginera™ in Adults With A Left Ventricular Assist Device As A Bridge To Transplant|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|Theregen, Inc.|||||f||||f||||||||||2018-06-01 03:50:19.046653|2018-06-01 03:50:19.046653
NCT00364585|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2008-01-16|2006-08-14|2006-08-15|Estimate|||||||2008-01-16|2008-01-17|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|||||Interventional|||A Prospective Evaluation of the GreenLight Model 120 Laser|A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia|Completed||Phase 4|20||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 03:50:19.182277|2018-06-01 03:50:19.182277
NCT00364572|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-01-21|2006-08-14|2006-08-15|Estimate|||||||2009-01-21|2009-01-22|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Epidural Etanercept in the Treatment of Sciatica|Efficacy of Epidural Etanercept in the Treatment of Sciatica|Completed||Phase 1/Phase 2|24|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:50:19.263557|2018-06-01 03:50:19.263557
NCT00364559|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-03-25|2006-08-14|2006-08-15|Estimate|||||||2009-03-25|2009-03-26|Estimate|August 2006||2006-08-31|March 2009|2009-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effect of Rosuvastatin in Intracerebral Hemorrhage|Effect of Rosuvastatin on Outcome by NIHSS After Intracerebral Hemorrhage|Completed||Phase 2|75|Actual|Universidad Autonoma de San Luis Potosí||1|||f||||||||||||||2018-06-01 03:50:19.386361|2018-06-01 03:50:19.386361
NCT00364546|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11||2011-06-02|2011-06-02|2006-08-11|2006-08-15|Estimate||||2011-06-02|2011-06-09|Estimate|2011-06-02|2011-06-09|Estimate|July 2006||2006-07-31|April 2010|2010-04-30|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain|A Randomized, Double-Blind, Active-Control, Parallel-Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee|Completed||Phase 3|877|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:50:19.503942|2018-06-01 03:50:19.503942
NCT00364533|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|2008-12-19||2014-04-03|2006-08-11|2006-08-15|Estimate|2009-05-14|2009-07-08|Estimate||||2014-04-03|2014-04-21|Estimate|October 2006||2006-10-31|April 2014|2014-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension|Terminated||Phase 3|367|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Sponsor terminated study, sample size not reached. The protocol section describes 4 study arms defining the treatment groups in the study design. The participant flow module describes the 5 treatment groups analyzed for the primary endpoint|4||Slow enrollment|f||||f||||||||||2018-06-01 03:50:19.617402|2018-06-01 03:50:19.617402
NCT00364520|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2015-05-19|2006-08-14|2006-08-15|Estimate|||||||2015-05-19|2015-05-21|Estimate|August 2003||2003-08-31|May 2007|2007-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Molecular Epidemiology of Benzene-exposed Workers.|Molecular Epidemiology of Benzene-exposed Workers in Shanghai,China|Completed|||2000|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-06-01 03:50:20.364973|2018-06-01 03:50:20.364973
NCT00364507|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2006-08-14|2006-08-14|2006-08-15|Estimate|||||||2006-08-14|2006-08-15|Estimate|January 2007||2007-01-31|August 2006|2006-08-31|December 2007|Anticipated|2007-12-31|||||Observational|||Serum Levels of Insulin- Like Growth Factor and Fertility|Serum Levels of Insulin-Like Growth Factor in Fertile and Infertile Women Over 40 Years Old|Unknown status|Not yet recruiting||60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:50:20.457682|2018-06-01 03:50:20.457682
NCT00364494|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2009-08-13|2006-08-11|2006-08-15|Estimate|||||||2009-08-13|2009-08-14|Estimate|November 2006||2006-11-30|August 2009|2009-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Hemodilution and Outcome in Cardiac Surgery|Effect of Moderate Hemodilution During Cardiopulmonary Bypass on Postoperative Outcome Following Cardiac Surgery|Terminated||N/A|||Università Vita-Salute San Raffaele||||difficult enrollment after the primary investigator left the centre|f||||t||||||||||2018-06-01 03:50:20.512708|2018-06-01 03:50:20.512708
NCT00356317|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2015-12-17|2006-07-21|2006-07-25|Estimate|||||||2015-12-17|2015-12-18|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia|A Culturally Based Family Therapy for Schizophrenia|Completed||Phase 2|400|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 03:52:48.858993|2018-06-01 03:52:48.858993
NCT00364481|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2012-12-18|2006-08-11|2006-08-15|Estimate|||||||2012-12-18|2012-12-20|Estimate|August 2006||2006-08-31|December 2012|2012-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Tongue Exercises and Reflux Therapy for Upper Airway Resistance Syndrome|Effectiveness of Tongue Exercises and Laryngopharyngeal Reflux Therapy on Upper Airway Resistance Syndrome|Withdrawn||Phase 1|0|Actual|West Side ENT||||Not enough subjects enrolled|f||||||||||||||2018-06-01 03:50:20.586429|2018-06-01 03:50:20.586429
NCT00364468|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2017-02-28|2006-08-14|2006-08-15|Estimate|||||||2017-02-28|2017-03-03|Actual|March 2006||2006-03-31|February 2017|2017-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients|A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma|Completed||Phase 2|107|Actual|Kyowa Hakko Kirin Co., Ltd|||||f||||||||||||||2018-06-01 03:50:20.65757|2018-06-01 03:50:20.65757
NCT00364455|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2010-04-26|2006-08-14|2006-08-15|Estimate|||||||2010-04-26|2010-04-27|Estimate|December 2002||2002-12-31|April 2010|2010-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.|Randomized Trial of Epoetin Alfa in Men With Hormone-refractory Prostate Cancer and Anemia.|Completed||Phase 3|56|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 03:50:20.728483|2018-06-01 03:50:20.728483
NCT00364442|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2017-09-27|2006-08-11|2006-08-15|Estimate|||||||2017-09-27|2017-09-29|Actual|January 28, 2005|Actual|2005-01-28|September 2017|2017-09-30|April 13, 2005|Actual|2005-04-13|April 13, 2005|Actual|2005-04-13||Interventional|||Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics|A Repeat Dose, Randomised, Double Blind, 2-way Crossover Study to Assess the Safety and Systemic Exposure of an Investigational Formulation Compared to Concurrent Administration of Individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS Inhalers in Subjects Aged 18 - 55 Years With Mild Asthma|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:50:20.7884|2018-06-01 03:50:20.7884
NCT00364429|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2016-01-07|2006-08-11|2006-08-15|Estimate|||||||2016-01-07|2016-01-11|Estimate|July 2005||2005-07-31|January 2016|2016-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia|Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study|Terminated||Phase 1|55|Actual|GlaxoSmithKline||||terminated|f||||f||||||||||2018-06-01 03:50:20.900119|2018-06-01 03:50:20.900119
NCT00364416|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2010-04-26|2006-08-14|2006-08-15|Estimate|||||||2010-04-26|2010-04-28|Estimate|October 2002||2002-10-31|April 2010|2010-04-30|April 2006|Actual|2006-04-30|||||Observational|||Longitudinal Registry for Advanced Heart Failure Patients|ADHERE (Acute Decompensated Heart Failure National Registry) Longitudinal Module-Registry of Advanced Heart Failure Patients at High Risk for Rehospitalization|Completed|||1466|Actual|Scios, Inc.|||1||f||||||||||||||2018-06-01 03:50:20.968733|2018-06-01 03:50:20.968733
NCT00364403|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2010-08-27|2006-08-14|2006-08-15|Estimate|||||||2010-08-27|2010-08-30|Estimate|February 2007||2007-02-28|August 2010|2010-08-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||A Low Glycemic Load Diet During Pregnancy in Overweight Women|Glycemic Load and Infant Birth Weight in Pregnant Overweight/Obese Women|Completed||N/A|60|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 03:50:21.026327|2018-06-01 03:50:21.026327
NCT00364390|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-03-27|2006-08-14|2006-08-15|Estimate|||||||2009-03-27|2009-03-30|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|February 2009|Anticipated|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery|A Phase I Open Label Pilot Study to Evaluate the Safety, Efficacy and Tolerability of Anginera for Adults With Left Ventricular Dysfunction AND Reversible Myocardial Ischemia Undergoing CABG Surgery|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|Theregen, Inc.|||||f||||t||||||||||2018-06-01 03:50:21.103793|2018-06-01 03:50:21.103793
NCT00364377|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2011-04-04||2011-11-01|2006-08-14|2006-08-15|Estimate|2011-11-01|2011-12-06|Estimate||||2011-11-01|2011-12-06|Estimate|August 2006||2006-08-31|November 2011|2011-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Incretins in Impaired Fasting Glucose|The Role of Incretins in the Pathogenesis of Fasting and Postprandial Glucose Metabolism in People With Impaired Fasting Glucose|Completed||Phase 4|22|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 03:50:21.167293|2018-06-01 03:50:21.167293
NCT00364364|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2008-12-16|2006-08-14|2006-08-15|Estimate|||||||2008-12-16|2008-12-17|Estimate|May 2007||2007-05-31|December 2008|2008-12-31|June 2008|Anticipated|2008-06-30|||||Interventional|||Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.|Pharmacokinetics, Biodistribution and Targeting of 111 In- Labeled Humanized PAM4IgG in Pre-Surgical Pancreatic Cancer Patients.An Examination of Protein Dose|Terminated||Phase 1|9|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||Loss of funding|f||||||||||||||2018-06-01 03:50:21.428481|2018-06-01 03:50:21.428481
NCT00364351|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2011-04-27||2018-01-24|2006-08-14|2006-08-15|Estimate|2011-04-27|2011-05-24|Estimate||||2018-01-24|2018-01-25|Actual|August 2006||2006-08-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy|A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy|Completed||Phase 3|1574|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:50:21.556768|2018-06-01 03:50:21.556768
NCT00364338|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2015-09-20|2006-08-14|2006-08-15|Estimate|||||||2015-09-20|2015-09-22|Estimate|January 2007||2007-01-31|August 2006|2006-08-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Development of Gourmet Medical Cooking Workshop for Lifestyle Changing and Its Affect on Perimenopausal Women|Development of Gourmet Medical Cooking Workshop for Lifestyle Changing and Its Affect on Perimenopausal Women|Withdrawn||N/A|0|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:50:22.703842|2018-06-01 03:50:22.703842
NCT00364325|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2010-04-26|2006-08-14|2006-08-15|Estimate|||||||2010-04-26|2010-04-28|Estimate|July 2004||2004-07-31|April 2010|2010-04-30|March 2006|Actual|2006-03-31|||||Observational|||Registry for Acute Decompensated Heart Failure Patients Admitted to the ER|Acute Decompensate Heart Failure National Registry ( ADHERE) Emergency Module (EM)|Completed|||18920|Actual|Scios, Inc.|||1||f||||||||||||||2018-06-01 03:50:22.75666|2018-06-01 03:50:22.75666
NCT00364312|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2006-08-11|2006-08-11|2006-08-15|Estimate|||||||2006-08-11|2006-08-15|Estimate|May 2004||2004-05-31|August 2006|2006-08-31|December 2009||2009-12-31|||||Interventional|||Lifestyle Interventions for Long Term Diabetes Control|Improving Control With Activity and Nutrition|Unknown status|Active, not recruiting|N/A|390||University of Virginia|||||f||||||||||||||2018-06-01 03:50:22.812608|2018-06-01 03:50:22.812608
NCT00364299|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2006-10-19|2006-08-11|2006-08-15|Estimate|||||||2006-10-19|2006-10-20|Estimate|October 2002||2002-10-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure|Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure|Completed||N/A|142||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:50:22.867552|2018-06-01 03:50:22.867552
NCT00364286|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2013-06-12||2018-04-24|2006-08-14|2006-08-15|Estimate|2013-06-12|2013-08-21|Estimate||||2018-04-24|2018-05-22|Actual|August 2006||2006-08-31|April 2018|2018-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)|Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)|Completed||Phase 2|17|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:50:22.926159|2018-06-01 03:50:22.926159
NCT00364273|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2017-09-27|2006-08-11|2006-08-15|Estimate|||||||2017-09-27|2017-09-29|Actual|August 24, 2005|Actual|2005-08-24|September 2017|2017-09-30|July 6, 2006|Actual|2006-07-06|July 6, 2006|Actual|2006-07-06||Interventional|||GSK159802 In Healthy Male Subjects And Asthmatics|A Randomised, Double Blind, Placebo Controlled Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Profile of Single Inhaled Dry Powder Doses of GSK159802 in Healthy Male Subjects|Completed||Phase 1|43|Actual|GlaxoSmithKline||14|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:50:23.116642|2018-06-01 03:50:23.116642
NCT00364260|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2011-01-31|2006-08-14|2006-08-15|Estimate|||||||2011-01-31|2011-02-01|Estimate|December 1997||1997-12-31|January 2011|2011-01-31|August 2003|Actual|2003-08-31|||||Interventional|||A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.|A Study to Determine the Impact of Hemoglobin Maintenance and Other Interventional Strategies to Prevent or Delay the Progression of Left Ventricular Mass Growth in Subjects With Early Renal Insufficiency.|Completed||Phase 3|172|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 03:50:23.358985|2018-06-01 03:50:23.358985
NCT00364247|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11||2011-06-02|2011-06-02|2006-08-11|2006-08-15|Estimate||||2011-06-02|2011-06-09|Estimate|2011-06-02|2011-06-09|Estimate||||June 2011|2011-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety.|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy Followed by a Voluntary Open-Label Extension|Completed||Phase 3|602|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:50:23.417212|2018-06-01 03:50:23.417212
NCT00364234|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2015-04-13|2006-08-14|2006-08-15|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD|Low Magnitute Mechanical Stimuli Effects on Bone Structure in ESRD|Completed||N/A|30|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||||2018-06-01 03:50:23.4941|2018-06-01 03:50:23.4941
NCT00364221|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2012-11-20|2006-08-14|2006-08-15|Estimate|||||||2012-11-20|2012-11-22|Estimate|November 2004||2004-11-30|November 2012|2012-11-30|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Interventional|||Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome|The Effect of Rosiglitazone on Adipocyte-derived Cytokines in Nondiabetics With the Metabolic Syndrome|Completed||Phase 4|||University of Colorado, Denver|||||f||||||||||||||2018-06-01 03:50:23.556231|2018-06-01 03:50:23.556231
NCT00364195|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-01-08|2006-08-14|2006-08-15|Estimate|||||||2009-01-08|2009-01-09|Estimate|June 2006||2006-06-30|January 2009|2009-01-31||||||||Interventional|||Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer|A Pharmacokinetic Interaction and Safety and Efficacy Phase II, Open Label Study With a Safety Lead-in Evaluating Docetaxel Plus Tesmilifene (YMB1002) in Patients With Metastatic Breast Cancer Suitable for Treatment With Docetaxel|Completed||Phase 2|33|Anticipated|YM BioSciences|||||||||||||||||||2018-06-01 03:50:23.964788|2018-06-01 03:50:23.964788
NCT00364182|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2011-07-25||2011-08-30|2006-08-14|2006-08-15|Estimate|2011-07-25|2011-08-23|Estimate||||2011-08-30|2011-10-04|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B|A Multicenter, Open-Label Study To Compare On-Demand Treatment With 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX (BeneFIX) Reformulated Drug Product (rFIX-R) In Subjects With Severe Hemophilia B|Completed||Phase 3|50|Actual|Pfizer|Although the protocol-defined endpoint was days lost from work or school after hemarthrosis, data was collected and reported in hours.|2|||f||||f||||||||||2018-06-01 03:50:24.069128|2018-06-01 03:50:24.069128
NCT00364169|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2008-06-27|2006-08-11|2006-08-15|Estimate|||||||2008-06-27|2008-07-01|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Prevention of Constipation: Systematic Nursing Interventions to Reduce Postoperative Constipation After Thoracic Surgery|Systematic Nursing Interventions to Reduce Postoperative Constipation After Thoracic Surgery|Completed||N/A|58|Actual|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:50:24.617639|2018-06-01 03:50:24.617639
NCT00364156|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2010-10-06||2018-02-26|2006-08-14|2006-08-15|Estimate|2010-10-06|2010-11-02|Estimate||||2018-02-26|2018-02-28|Actual|June 2004||2004-06-30|February 2018|2018-02-28|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation|Comparison of Standard Versus Extended Nicotine Patch Therapy for Smoking Cessation|Completed||Phase 3|568|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 03:50:24.684603|2018-06-01 03:50:24.684603
NCT00364143|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2012-01-25|2006-08-11|2006-08-15|Estimate|||||||2012-01-25|2012-01-26|Estimate|September 2006||2006-09-30|January 2012|2012-01-31||||||||Interventional|||Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors|A Phase I Study of IHL-305 (Irinotecan Liposome Injection) in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|40|Anticipated|Yakult Honsha Co., LTD|||||t||||||||||||||2018-06-01 03:50:24.904483|2018-06-01 03:50:24.904483
NCT00364130|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|2014-06-12||2017-03-17|2006-08-14|2006-08-15|Estimate|2014-06-12|2014-07-14|Estimate||||2017-03-17|2017-04-14|Actual|February 2007||2007-02-28|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial|Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial|Completed||N/A|138|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-06-01 03:50:24.985534|2018-06-01 03:50:24.985534
NCT00364117|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2013-05-03|2006-08-11|2006-08-15|Estimate|||||||2013-05-03|2013-05-07|Estimate|August 2006||2006-08-31|May 2013|2013-05-31|August 2008|Actual|2008-08-31|August 2008|Anticipated|2008-08-31||Interventional|||Remote Presence Timely Discharge Management|Remote Presence Timely Discharge Management|Withdrawn||Phase 2/Phase 3|0|Actual|Hackensack University Medical Center||||No patients were enrolled|f||||||||||||||2018-06-01 03:50:25.344727|2018-06-01 03:50:25.344727
NCT00364104|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2009-06-26|2006-08-14|2006-08-15|Estimate|||||||2009-06-26|2009-06-30|Estimate|March 2007||2007-03-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|HEIDC||Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children|Randomized Field Intervention Trial of H. Pylori Eradication to Reduce Iron Deficiency Among Children in El Paso, Texas|Completed||Phase 3|125|Actual|The University of Texas Health Science Center, Houston||4|||f||||t||||||||||2018-06-01 03:50:25.416648|2018-06-01 03:50:25.416648
NCT00364091|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2011-09-26|2006-08-11|2006-08-15|Estimate|||||||2011-09-26|2011-09-27|Estimate|August 2006||2006-08-31|September 2011|2011-09-30||||October 2006|Actual|2006-10-31||Interventional|||Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis|Completed||Phase 3|365|Actual|Vistakon Pharmaceuticals|||||f||||||||||||||2018-06-01 03:50:25.520528|2018-06-01 03:50:25.520528
NCT00364078|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2008-05-19|2006-08-14|2006-08-15|Estimate|||||||2008-05-19|2008-05-21|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Observational|||Transitoriness in Cancer Patients, Psychosocial Issues in Cancer Care|Transitoriness in Cancer Patients: a Cross-Sectional Study of Uncertainty, Locus of Control, Quality of Life and Existentials Views on Finality of Life in Cancer Patients|Completed|||193|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-06-01 03:50:25.58892|2018-06-01 03:50:25.58892
NCT00364065|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2007-04-17|2006-08-14|2006-08-15|Estimate|||||||2007-04-17|2007-04-18|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Study to Evaluate Ferris PainWrap in the Treatment of Chronic Low Back Pain|A Randomized, Controlled, Double-Blind, Pilot Study to Evaluate Ferris PainWrap, a Semipermeable Hydrophilic Polymeric Membrane, in the Treatment of Chronic Low Back Pain|Completed||Phase 4|20||Pain and Rehabilitation Medicine|||||f||||||||||||||2018-06-01 03:50:25.648012|2018-06-01 03:50:25.648012
NCT00364052|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2006-08-16|2006-08-11|2006-08-15|Estimate|||||||2006-08-16|2006-08-17|Estimate|August 2006||2006-08-31|August 2006|2006-08-31|January 2007||2007-01-31|||||Observational|||Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients|Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients: A Single Center Experience With Oral Ganciclovir Versus Valganciclovir|Unknown status|Not yet recruiting||200||Oregon Health and Science University|||||f||||||||||||||2018-06-01 03:50:25.699445|2018-06-01 03:50:25.699445
NCT00364039|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2007-02-27|2006-08-14|2006-08-15|Estimate|||||||2007-02-27|2007-02-28|Estimate|August 2006||2006-08-31|February 2007|2007-02-28||||||||Interventional|||Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650|A Phase 1 Double-Blind, Placebo-Controlled Single Center Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Dose and Multiple Dose Escalations of AV650 in Healthy Subjects|Completed||Phase 1|30||Avigen|||||||||||||||||||2018-06-01 03:50:25.74468|2018-06-01 03:50:25.74468
NCT00364026|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2007-01-17|2006-08-11|2006-08-15|Estimate|||||||2007-01-17|2007-01-18|Estimate|June 2004||2004-06-30|August 2006|2006-08-31|July 2005||2005-07-31|||||Interventional|||A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs|A Phase II Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-201)|Completed||Phase 2|||Gilead Sciences|||||||||||||||||||2018-06-01 03:50:25.788521|2018-06-01 03:50:25.788521
NCT00364013|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2014-02-13|2010-07-20|2017-02-07|2006-08-10|2006-08-15|Estimate|2014-02-13|2014-03-28|Estimate|2010-07-20|2010-07-22|Estimate|2017-02-07|2017-02-09|Estimate|August 2006||2006-08-31|February 2017|2017-02-28|March 2013|Actual|2013-03-31|August 2009|Actual|2009-08-31||Interventional|||PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy|A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer|Completed||Phase 3|1183|Actual|Amgen||2|||f||||t||||||||||2018-06-01 03:50:25.871326|2018-06-01 03:50:25.871326
NCT00364000|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2017-12-21|2006-08-10|2006-08-15|Estimate|||||||2017-12-21|2017-12-22|Actual|January 2012|Actual|2012-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|July 2015|Actual|2015-07-31||Interventional|||Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate|Arterial Stiffness and Arterial Calcifications Evolution in ESRD Haemodialysis Patients Treated by Sevelamer or Calcium Acetate|Withdrawn||N/A|0|Actual|Romanian Society of Nephrology||2||Limitted financial resources|f||||t||||||||||2018-06-01 03:50:27.416899|2018-06-01 03:50:27.416899
NCT00363987|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-13|||2010-09-01|2006-08-13|2006-08-15|Estimate|||||||2010-09-01|2010-09-02|Estimate|May 2006||2006-05-31|August 2010|2010-08-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)|A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy|Completed||Phase 4|179|Actual|Fresenius Kabi||2|||f||||||||||||||2018-06-01 03:50:27.499279|2018-06-01 03:50:27.499279
NCT00363974|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2009-11-30|2006-08-10|2006-08-15|Estimate|||||||2009-11-30|2009-12-01|Estimate|October 2005||2005-10-31|November 2009|2009-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML|An Open-Label Phase I/II Study of XIAP Antisense AEG35156 Administered to Patients With Refractory/Relapsed AML in Combination With Chemotherapy|Completed||Phase 1/Phase 2|54|Anticipated|Aegera Therapeutics|||||f||||f||||||||||2018-06-01 03:50:27.574683|2018-06-01 03:50:27.574683
NCT00363961|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2009-12-09|2006-08-10|2006-08-15|Estimate|||||||2009-12-09|2009-12-10|Estimate|April 2004||2004-04-30|December 2009|2009-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Resistance Training During Maintenance Dialysis|Resistance Training During Maintenance Dialysis|Completed||N/A|51|Actual|Tufts University||2|||f||||t||||||||||2018-06-01 03:50:27.68297|2018-06-01 03:50:27.68297
NCT00363948|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2012-06-12|2006-08-11|2006-08-15|Estimate|||||||2012-06-12|2012-06-13|Estimate|August 2006||2006-08-31|June 2012|2012-06-30||||February 2008|Actual|2008-02-29||Interventional|||Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus|MK-0431/ONO-5435 Phase III Clinical Study - Metformin Add-On Study for Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|188|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 03:50:27.765831|2018-06-01 03:50:27.765831
NCT00348179|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-01-23|2006-07-03|2006-07-04|Estimate|||||||2008-01-23|2008-01-24|Estimate|April 2004||2004-04-30|April 2007|2007-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Vascular Function in Adolescent, Diabetic Children|Vascular Function in Adolescent, Diabetic Children|Completed||N/A|85|Actual|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 03:54:47.291504|2018-06-01 03:54:47.291504
NCT00363935|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2007-04-17|2006-08-10|2006-08-15|Estimate|||||||2007-04-17|2007-04-18|Estimate||||April 2007|2007-04-30||||||||Interventional|||Bariatric Dose-Ranging Study With Dexmedetomidine|A Randomized, Double-Blind, Controlled Study of Dexmedetomidine (Precedex) Infusion for Improving Control of Acute Autonomic Response During Laparoscopic Bariatric Surgery|Completed||Phase 4|||University of Texas Southwestern Medical Center|||||||||||||||||||2018-06-01 03:50:27.88328|2018-06-01 03:50:27.88328
NCT00363922|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2015-09-28|2006-08-10|2006-08-15|Estimate|||||||2015-09-28|2015-09-29|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Rehabilitation After Coronary Bypass Grafting. Comparison of Different Types of Rehabilitation Programs|Rehabilitation After Coronary Bypass Grafting: Home Based Rehabilitation Versus Rehabilitation in Institution and Rehabilitation in Institution Versus Out-patient Rehabilitation at the Hospital|Completed||Phase 2|30|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 03:50:27.93596|2018-06-01 03:50:27.93596
NCT00363909|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2016-12-09|2006-08-10|2006-08-15|Estimate|||||||2016-12-09|2016-12-13|Estimate|November 2006||2006-11-30|December 2016|2016-12-31|December 2010|Actual|2010-12-31|June 2007|Actual|2007-06-30||Interventional|||Citalopram in Treating Postmenopausal Women With Hot Flashes|Phase III Randomized, Double-Blind, Placebo-Controlled Evaluation of Citalopram for the Treatment of Hot Flashes|Completed||Phase 3|254|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-06-01 03:50:28.055615|2018-06-01 03:50:28.055615
NCT00363896|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2012-08-14||2016-11-16|2006-08-14|2006-08-15|Estimate|2012-10-31|2012-11-01|Estimate||||2016-11-16|2017-01-06|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)|Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||Phase 3|843|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:50:28.459862|2018-06-01 03:50:28.459862
NCT00363883|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2015-01-28||2015-01-28|2006-08-10|2006-08-15|Estimate|2015-01-28|2015-02-13|Estimate||||2015-01-28|2015-02-13|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium|Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium|Terminated||Phase 2|14|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.|1||Trial stopped early for futility|f||||||||||||||2018-06-01 03:50:29.457463|2018-06-01 03:50:29.457463
NCT00363870|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2017-03-21|2006-08-10|2006-08-15|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2006||2006-09-30|March 2017|2017-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults|A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults|Completed||Phase 4|7632||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:50:29.769452|2018-06-01 03:50:29.769452
NCT00363857|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2016-10-14|2006-08-11|2006-08-15|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2003||2003-08-31|October 2016|2016-10-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome|A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)|Completed||Phase 3|360|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:50:29.887338|2018-06-01 03:50:29.887338
NCT00363844|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2012-06-12|2006-08-11|2006-08-15|Estimate|||||||2012-06-12|2012-06-14|Estimate|August 2006||2006-08-31|June 2012|2012-06-30||||February 2008|Actual|2008-02-29||Interventional|||Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus|MK-0431/ONO-5435 Phase III Clinical Study - Long-term Treatment Study for Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|209|Actual|Ono Pharmaceutical Co. Ltd||1|||f||||||||||||||2018-06-01 03:50:30.036239|2018-06-01 03:50:30.036239
NCT00363831|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2010-07-27|2006-08-11|2006-08-15|Estimate|||||||2010-07-27|2010-07-28|Estimate|July 2006||2006-07-31|July 2010|2010-07-31||||December 2009|Anticipated|2009-12-31||Interventional|||Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma|A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC)|Unknown status|Recruiting|Phase 2|42|Anticipated|The University of Hong Kong||1|||f||||||||||||||2018-06-01 03:50:30.160159|2018-06-01 03:50:30.160159
NCT00363818|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2008-04-08|2006-08-11|2006-08-15|Estimate|||||||2008-04-08|2008-04-11|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Observational|||The Association of Platelet Function and Endothelial Function of the Brachial Artery|The Association Between Platelet Function and Endothelial Function of the Brachial Artery in Healthy Subjects and in Patients With Coronary Artery Disease|Completed|||151|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:50:30.227677|2018-06-01 03:50:30.227677
NCT00363805|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2013-07-02||2013-09-27|2006-08-10|2006-08-15|Estimate|2013-09-27|2013-11-28|Estimate||||2013-09-27|2013-11-28|Estimate|May 2004||2004-05-31|September 2013|2013-09-30||||March 2009|Actual|2009-03-31||Interventional|||Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease|Chemoprevention of Lung Carcinogenesis Using Green Tea: Phase IIb Randomized, Double-Blinded, Placebo Controlled Trial of Green Tea and Polyphenon E in Former Smokers With Chronic Obstructive Lung Disease (COPD)|Completed||Phase 2|178|Actual|University of Arizona||3|||f||||||||||||||2018-06-01 03:50:30.291275|2018-06-01 03:50:30.291275
NCT00363792|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2006-08-11|2006-08-11|2006-08-15|Estimate|||||||2006-08-11|2006-08-15|Estimate||||August 2006|2006-08-31|May 2007||2007-05-31|||||Interventional|||Effect of GTN and Diamox Measured by BOLD-Response.|The Effect of Glyceryl Trinitrate and Diamox on Blood-Oxygenation-Level-Dependent.Signal (BOLD-Signal) and Cerebral Haemodynamics With the Use of a 3-Tesla MRI-Scan.|Unknown status|Recruiting|N/A|12||Danish Headache Center|||||f||||||||||||||2018-06-01 03:50:30.646697|2018-06-01 03:50:30.646697
NCT00363610|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2008-05-16|2006-08-10|2006-08-15|Estimate|||||||2008-05-16|2008-05-20|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|June 2008|Anticipated|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma|A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of Intravenous Pegaspargase in Combination With Intravenous Gemcitabine HCl in the Treatment of Advanced and/or Metastatic Solid Tumors and Lymphoma|Terminated||Phase 1|19|Actual|Enzon Pharmaceuticals, Inc.||||No recommended Phase II dose was determined.|f||||f||||||||||2018-06-01 03:50:32.832514|2018-06-01 03:50:32.832514
NCT00363779|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2012-03-30||2015-06-26|2006-08-10|2006-08-15|Estimate|2012-05-29|2012-07-06|Estimate||||2015-06-26|2015-07-21|Estimate|June 2006||2006-06-30|June 2015|2015-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia|Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia|Terminated||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|As there were only 5 patients treated, the primary endpoints of this protocol were not met and there is not enough data generated for statistical analysis. This protocol is being terminated due to low accrual and the investigator leaving the NIH.|1||Study terminated due to low accrual and the investigator left the NIH.|f||||f||||||||||2018-06-01 03:50:30.715062|2018-06-01 03:50:30.715062
NCT00363766|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10||2009-10-16|2009-10-16|2006-08-10|2006-08-15|Estimate||||2009-10-16|2009-10-19|Estimate|2009-10-16|2009-10-19|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of LY573636 in Patients With Metastatic Non-Small Cell Lung Cancer|A Phase 2 Study of LY573636 Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|52|Actual|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 03:50:30.913149|2018-06-01 03:50:30.913149
NCT00363753|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2007-03-30|2006-08-10|2006-08-15|Estimate|||||||2007-03-30|2007-04-02|Estimate|August 2006||2006-08-31|March 2007|2007-03-31|March 2007|Anticipated|2007-03-31|||||Interventional|||Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack|Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack|Withdrawn||Phase 1|20||University of California, San Diego|||||f||||||||||||||2018-06-01 03:50:31.084755|2018-06-01 03:50:31.084755
NCT00363740|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2013-04-11|2006-08-11|2006-08-15|Estimate|||||||2013-04-11|2013-04-15|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study of GW685698X In Patients With Seasonal Allergic Rhinitis|Clinical Evaluation of GW685698 for Seasonal Allergic Rhinitis -A Placebo-controlled Study to Determine the Non-inferiority of GW685698 Over Fluticasone Propionate Using a Double-blind Manner-|Completed||Phase 3|38|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:50:31.325794|2018-06-01 03:50:31.325794
NCT00363727|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2017-01-16|2006-08-11|2006-08-15|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2003||2003-12-31|January 2017|2017-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's|A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects.|Completed||Phase 3|209|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:50:31.638696|2018-06-01 03:50:31.638696
NCT00363714|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2008-08-14|2006-08-10|2006-08-15|Estimate|||||||2008-08-14|2008-08-18|Estimate|November 2004||2004-11-30|August 2008|2008-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)||Completed||Phase 1/Phase 2|26|Actual|Allergan||6|||f||||||||||||||2018-06-01 03:50:31.833241|2018-06-01 03:50:31.833241
NCT00363701|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2006-08-14|2006-08-14|2006-08-15|Estimate|||||||2006-08-14|2006-08-15|Estimate|August 2006||2006-08-31|August 2006|2006-08-31|February 2008||2008-02-29|||||Interventional|||Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice|With-Drawal Study of Proton-Pump-Inhibitors in Patients From Primary Care Who Have Previously Been Treated on a Long-Term Basis|Unknown status|Recruiting|Phase 4|150||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 03:50:31.914656|2018-06-01 03:50:31.914656
NCT00363688|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2006-08-10|2006-08-10|2006-08-15|Estimate|||||||2006-08-10|2006-08-15|Estimate|January 1998||1998-01-31|December 1997|1997-12-31|May 2004||2004-05-31|||||Interventional|||Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin|Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin: Is It Safe?|Terminated||Phase 4|||Meir Medical Center|||||f||||||||||||||2018-06-01 03:50:32.021864|2018-06-01 03:50:32.021864
NCT00363675|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2012-02-29||2012-02-29|2006-08-09|2006-08-15|Estimate|2012-02-29|2012-03-28|Estimate||||2012-02-29|2012-03-28|Estimate|August 2006||2006-08-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of Hand Assessments in Children With Severe Hand Burns|Evaluation of Hand Assessments in Children With Severe Hand Burns|Terminated||N/A|3|Actual|Massachusetts General Hospital|This pilot study was discontinued secondary to lack of grant funding for the project.|1||This was a pilot study, but the larger study was not funded.|f||||f||||||||||2018-06-01 03:50:32.191604|2018-06-01 03:50:32.191604
NCT00363662|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2012-06-12|2006-08-09|2006-08-15|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Diagnostic Utility of MRI in Intracerebral Hemorrhage|Diagnostic Utility of MRI in Intracerebral Hemorrhage|Unknown status|Recruiting||160|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 03:50:32.388152|2018-06-01 03:50:32.388152
NCT00363649|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2017-07-12|2006-08-10|2006-08-15|Estimate|||||||2017-07-12|2017-07-17|Actual|September 2006||2006-09-30|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI|A Randomized Phase II Trial of Interferon + GM-CSF Versus K562/GM-CSF Vaccination in CML Patients Achieving a Complete Cytogenetic Response to Frontline Tyrosine Kinase Inhibitor Therapy|Active, not recruiting||Phase 2|36|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-06-01 03:50:32.482813|2018-06-01 03:50:32.482813
NCT00363636|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11||2015-09-17|2015-09-17|2006-08-11|2006-08-15|Estimate||||2015-09-17|2015-10-02|Estimate|2015-09-17|2015-10-02|Estimate|September 2006||2006-09-30|March 2011|2011-03-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)|A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma|Terminated||Phase 3|340|Actual|Biogen||2||"Enrollment challenges due to changes in standards of care resulted in premature termination. No~   safety or efficacy events factored into this action."|f||||t||||||||||2018-06-01 03:50:32.607077|2018-06-01 03:50:32.607077
NCT00363623|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2008-03-20|2006-08-10|2006-08-15|Estimate|||||||2008-03-20|2008-03-21|Estimate|August 2006||2006-08-31|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||Comparison of Contact Lens Maintenance Systems for Silicone Hydrogel Lenses||Completed||N/A|44||University of Melbourne|||||f||||||||||||||2018-06-01 03:50:32.773598|2018-06-01 03:50:32.773598
NCT00363597|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2012-02-28|2006-08-11|2006-08-15|Estimate|||||||2012-02-28|2012-03-01|Estimate|August 2006||2006-08-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Intestinal Permeability in Children/Adolescents With Functional Dyspepsia|Intestinal Permeability and Serum Zonulin Concentration in Children/Adolescents With Functional Dyspepsia|Completed||N/A|42|Actual|Children's Mercy Hospital Kansas City||1|||f||||f||||||||||2018-06-01 03:50:32.96606|2018-06-01 03:50:32.96606
NCT00363584|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2013-08-23|2006-08-10|2006-08-15|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2006||2006-03-31|October 2011|2011-10-31||||August 2013|Actual|2013-08-31||Interventional|||Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer|A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer|Completed||Phase 3|360|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:50:33.249628|2018-06-01 03:50:33.249628
NCT00363571|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-14|||2006-08-14|2006-08-14|2006-08-15|Estimate|||||||2006-08-14|2006-08-15|Estimate|August 2006||2006-08-31|July 2006|2006-07-31|May 2007||2007-05-31|||||Interventional|||The Effect of Glyceryl Trinitate and Diamox on Cerebral Haemodynamics.|The Effect of Glyceryl Trinitrate (GTN) and Diamox on Cerebral Haemodynamics Judged With the Help of 3-Tesla MRI.|Unknown status|Not yet recruiting|N/A|12||Danish Headache Center|||||f||||||||||||||2018-06-01 03:50:33.399797|2018-06-01 03:50:33.399797
NCT00363558|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2006-08-10|2006-08-10|2006-08-15|Estimate|||||||2006-08-10|2006-08-15|Estimate|January 2002||2002-01-31|May 2003|2003-05-31|May 2003||2003-05-31|||||Observational|||Fixation of Skin Grafts in Patients With Burns: Comparison Between Cyanoacrylate Glue and Skin Staples|Fixation of Skin Grafts in Patients With Burns: Comparison Between Cyanoacrylate Glue and Skin Staples|Completed|||44||Rabin Medical Center|||||f||||||||||||||2018-06-01 03:50:33.473229|2018-06-01 03:50:33.473229
NCT00363545|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|2017-01-05||2017-01-05|2006-08-11|2006-08-15|Estimate|2017-01-05|2017-02-23|Actual||||2017-01-05|2017-02-23|Actual|September 2006||2006-09-30|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)|A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV|Completed||Phase 3|1270|Actual|GlaxoSmithKline|None reported.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:50:33.565109|2018-06-01 03:50:33.565109
NCT00363532|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2009-01-27|2006-08-11|2006-08-15|Estimate|||||||2009-01-27|2009-01-28|Estimate|September 2006||2006-09-30|January 2009|2009-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Functional MRI (fMRI) in CGRP Induced Migraine|Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by|Completed||N/A|12|Anticipated|Danish Headache Center|||||f||||||||||||||2018-06-01 03:50:34.199928|2018-06-01 03:50:34.199928
NCT00363519|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2012-06-12|2006-08-11|2006-08-15|Estimate|||||||2012-06-12|2012-06-14|Estimate|August 2006||2006-08-31|June 2012|2012-06-30||||January 2008|Actual|2008-01-31||Interventional|||Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus|MK-0431/ONO-5435 Phase III Clinical Study - Glimepiride add-on Study for Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|195|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||||||||||||2018-06-01 03:50:34.274056|2018-06-01 03:50:34.274056
NCT00363506|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2008-04-22|2006-08-11|2006-08-15|Estimate|||||||2008-04-22|2008-04-24|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|||||Interventional|||American Migraine Prevention Study|Nutritional Based Protocol to Balance Serotonin for the Prevention or Reduced Frequency/Duration/Intensity of Migraines|Unknown status|Recruiting|Phase 4|1000|Anticipated|Dynamic Health Resources|||||f||||||||||||||2018-06-01 03:50:34.363291|2018-06-01 03:50:34.363291
NCT00363480|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2017-02-21||2018-03-06|2006-08-10|2006-08-15|Estimate|2018-03-06|2018-03-09|Actual||||2018-03-06|2018-03-09|Actual|May 17, 2006|Actual|2006-05-17|March 2018|2018-03-31|September 14, 2007|Actual|2007-09-14|September 1, 2007|Actual|2007-09-01||Interventional|||Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data|Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks|Completed||Phase 4|221|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:50:34.439239|2018-06-01 03:50:34.439239
NCT00363467|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2010-08-09||2017-02-20|2006-08-10|2006-08-15|Estimate|2011-08-24|2011-09-30|Estimate||||2017-02-20|2017-03-23|Actual|May 2006||2006-05-31|August 2011|2011-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation|A Pilot Study of Intravenous, Targeted-Dose Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk AML|Terminated||N/A|3|Actual|H. Lee Moffitt Cancer Center and Research Institute|Two patients enrolled and transplanted out of 24 targeted transplant accrual goal. Due to poor enrollment study closed and no further analyses were conducted.|1||Low accrual|f||||t||||||||||2018-06-01 03:50:35.082975|2018-06-01 03:50:35.082975
NCT00363454|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2016-08-06|2006-08-10|2006-08-15|Estimate|||||||2016-08-06|2016-08-09|Estimate|April 2006||2006-04-30|May 2015|2015-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer|Phase I Pharmacokinetic and Pharmacodynamic, Open-Label, Dose Escalation Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer Which Have Activated Akt Demonstrated by Immunohistochemistry|Completed||Phase 1|19|Actual|Prescient Therapeutics, Ltd.||1|||f||||t||||||||||2018-06-01 03:50:35.345316|2018-06-01 03:50:35.345316
NCT00363441|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2012-01-18|2006-08-11|2006-08-15|Estimate|||||||2012-01-18|2012-01-19|Estimate||||January 2011|2011-01-31||||||||Interventional|||A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck|A Randomized Phase II Study of Conventional 3D Radiation (3DCRT) Versus Intensity-Modulated Radiation (IMRT) in Squamous Cell Cancer of the Head and Neck (SCCHN): Pilot Feasibility Study|Withdrawn||Phase 2/Phase 3|0|Actual|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 03:50:35.43233|2018-06-01 03:50:35.43233
NCT00363428|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2017-07-17|2006-08-10|2006-08-15|Estimate|||||||2017-07-17|2017-07-19|Actual|August 2006|Actual|2006-08-31|July 2017|2017-07-31|November 1, 2012|Actual|2012-11-01|November 1, 2012|Actual|2012-11-01||Interventional|||Lung Rehabilitation in Treating Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Surgery for Lung Cancer|A Randomized Trial of Pulmonary Rehabilitation in Patients With Moderate to Severe COPD Who Require Lung Resection for Lung Cancer|Completed||N/A|19|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 03:50:35.500523|2018-06-01 03:50:35.500523
NCT00362869|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2016-12-22|2006-08-11|2006-08-15|Estimate|||||||2016-12-22|2016-12-26|Estimate|February 2008||2008-02-29|April 2010|2010-04-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Enteroaggregative E.Coli (EAEC)|Pathogenicity of Enteroaggregative E. Coli in Adult Volunteers; Dose-Escalation Study|Terminated||Phase 1|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 03:50:47.050698|2018-06-01 03:50:47.050698
NCT00363415|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2009-06-05||2009-10-20|2006-08-10|2006-08-15|Estimate|2009-09-02|2009-10-06|Estimate||||2009-10-20|2009-10-28|Estimate|August 2006||2006-08-31|October 2009|2009-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer|A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer|Completed||Phase 3|908|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:50:35.72285|2018-06-01 03:50:35.72285
NCT00363402|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2009-05-19|2006-08-10|2006-08-15|Estimate|||||||2009-05-19|2009-05-20|Estimate|August 2006||2006-08-31|August 2006|2006-08-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||18FDG- PET/CT Contribution to the Assessment of Lesion Severity in Cystic Fibrosis (CF)|18FDG- PET/CT Contribution to the Assessment of Lesion Severity in Cystic Fibrosis (CF|Completed||N/A|20|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:50:37.42957|2018-06-01 03:50:37.42957
NCT00363389|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2007-08-06|2006-08-10|2006-08-15|Estimate|||||||2007-08-06|2007-08-07|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Hysteroscopy and Misoprostol Project|Self-Administered Vaginal Misoprostol at Home for Cervical Ripening Prior to Outpatient Hysteroscopy: a Randomised Placebo-Controlled Trial.|Completed||Phase 3|86|Actual|Ullevaal University Hospital|||||f||||t||||||||||2018-06-01 03:50:37.488567|2018-06-01 03:50:37.488567
NCT00363376|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2012-04-11|2006-08-09|2006-08-15|Estimate|||||||2012-04-11|2012-04-13|Estimate|January 2008||2008-01-31|April 2012|2012-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain|A Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain|Completed||Phase 3|42|Actual|Lindner Center of HOPE||2|||f||||f||||||||||2018-06-01 03:50:37.542755|2018-06-01 03:50:37.542755
NCT00363363|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2013-08-25|2006-08-10|2006-08-15|Estimate|||||||2013-08-25|2013-08-27|Estimate|August 2006||2006-08-31|August 2013|2013-08-31|May 2009|Actual|2009-05-31|June 2008|Actual|2008-06-30||Interventional|||Physical Activity in Fontan Patients|Identifying Determinants and Optimizing Rehabilitation of Physical Activity for Children After the Fontan Procedure|Completed||Phase 3|64|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 03:50:37.635063|2018-06-01 03:50:37.635063
NCT00363350|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2009-02-23|2006-08-10|2006-08-15|Estimate|||||||2009-02-23|2009-02-24|Estimate|August 2006||2006-08-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Rituximab Treatment in Sjogren's Syndrome|Rituximab for the Treatment of Primary Sjögren's Syndrome: a Double Blinded Randomized Placebo-Controlled Trial|Completed||Phase 1/Phase 2|30|Anticipated|University Medical Center Groningen|||||f||||||||||||||2018-06-01 03:50:37.706804|2018-06-01 03:50:37.706804
NCT00363337|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2011-06-21|2006-08-11|2006-08-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|August 2006||2006-08-31|June 2011|2011-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression||Completed||Phase 4|31|Actual|Lindner Center of HOPE|||||f||||||||||||||2018-06-01 03:50:37.76364|2018-06-01 03:50:37.76364
NCT00363324|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2007-12-27|2006-08-10|2006-08-15|Estimate|||||||2007-12-27|2008-01-09|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Bone Marrow Cells in Myocardial Infarction|Effects of Autologous Bone Marrow Celss on Acute ST-Elevation Myocardial Infarction|Completed||Phase 2/Phase 3|100|Anticipated|University of Oulu|||||f||||||||||||||2018-06-01 03:50:37.823416|2018-06-01 03:50:37.823416
NCT00363311|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|2011-03-31||2016-11-30|2006-08-11|2006-08-15|Estimate|2011-05-12|2011-06-14|Estimate||||2016-11-30|2017-01-18|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men|A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management|Completed||Phase 4|302|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:50:37.908107|2018-06-01 03:50:37.908107
NCT00363298|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2015-04-20||2017-02-07|2006-08-10|2006-08-15|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|August 2006||2006-08-31|February 2017|2017-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||24 Subjects meeting the listed entry criteria.|Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD|Double-blind Trial of Acute and Intermediate-term Dextro-amphetamine Versus Caffeine Augmentation in Treatment Resistant Obsessive Compulsive Disorder (OCD)|Completed||N/A|24|Actual|Stanford University|Modest sample size of 24 subjects, 12 in each drug group. Observation period was only 5 weeks long.|2|||f||||f||||||||No||2018-06-01 03:50:40.150109|2018-06-01 03:50:40.150109
NCT00363285|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2013-08-23|2006-08-10|2006-08-15|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2003||2003-01-31|October 2006|2006-10-31||||||||Interventional|||Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer|Intermittent Hormone Therapy for Newly Diagnosed Metastatic Prostate Cancer|Unknown status|Recruiting|Phase 3|900|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:50:40.382848|2018-06-01 03:50:40.382848
NCT00363272|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2013-01-15|2006-08-10|2006-08-15|Estimate|||||||2013-01-15|2013-01-16|Estimate|June 2006||2006-06-30|January 2013|2013-01-31||||October 2008|Actual|2008-10-31||Interventional|||Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma|A PHASE 1 STUDY OF ISPINESIB (SB-715992) IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:50:40.452224|2018-06-01 03:50:40.452224
NCT00363259|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2006-08-10|2006-08-10|2006-08-15|Estimate|||||||2006-08-10|2006-08-15|Estimate|July 2002||2002-07-31|August 2006|2006-08-31|November 2005||2005-11-30|||||Interventional|||Pegintron Induction Therapy in HCV Non-Responders|Pegintron Induction Therapy in Previous Non-Responders With Chronic HCV: A Dutch Multicenter Randomized Controlled Trial. (PIT-Study)|Completed||Phase 3|110||Foundation for Liver Research|||||f||||||||||||||2018-06-01 03:50:40.527039|2018-06-01 03:50:40.527039
NCT00363246|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2015-06-05||2015-07-27|2006-08-10|2006-08-15|Estimate|2015-07-27|2015-07-29|Estimate||||2015-07-27|2015-07-29|Estimate|June 2007||2007-06-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|November 2009|Actual|2009-11-30||Observational||Only data for 710 participants for some of the Baseline characteristics.|Characterizing Wheelchair-Related Falls in Elderly Veterans|Characterizing Wheelchair-Related Falls in Elderly Veterans|Completed|||766|Actual|VA Office of Research and Development|||1||f||||t||||||||||2018-06-01 03:50:40.689623|2018-06-01 03:50:40.689623
NCT00363233|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2007-01-08|2006-08-11|2006-08-15|Estimate|||||||2007-01-08|2007-01-09|Estimate|March 2006||2006-03-31|January 2007|2007-01-31|December 2006||2006-12-31|||||Interventional|||The Potential Effects and Mechanisms of Flax Lignans on Type 2 Diabetes Mellitus|The Effects of Flax Lignans on Lipid Profile and Glucose Management in Type 2 Diabetes: a Randomized Double-Blind Cross-Over Study|Completed||Phase 2/Phase 3|80||Chinese Academy of Sciences|||||f||||||||||||||2018-06-01 03:50:40.940121|2018-06-01 03:50:40.940121
NCT00363220|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2015-12-16|2006-08-10|2006-08-15|Estimate|||||||2015-12-16|2015-12-17|Estimate|August 2006||2006-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Community - Associated Extended-spectrum Beta-lactamases (ESBL)|Community - Associated Extended-spectrum Beta-lactamases (ESBL)|Completed|||100|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:50:41.016157|2018-06-01 03:50:41.016157
NCT00363207|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2008-05-19|2006-08-10|2006-08-15|Estimate|||||||2008-05-19|2008-05-20|Estimate|May 2007||2007-05-31|April 2007|2007-04-30|May 2008|Actual|2008-05-31|||||Observational|||Behavior of Children Related to Numbness After Dental Local Anesthesia|Behavior of Children in the Following Appointment Related to Numbness Perception After Dental Local Anesthesia|Completed|||100|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 03:50:41.078479|2018-06-01 03:50:41.078479
NCT00363194|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2017-11-13|2006-08-11|2006-08-15|Estimate|||||||2017-11-13|2017-11-17|Actual|September 21, 2006|Actual|2006-09-21|November 2017|2017-11-30|June 19, 2009|Actual|2009-06-19|June 19, 2009|Actual|2009-06-19||Interventional|||A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients|An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Single Doses of Pazopanib in Cancer Patients|Completed||Phase 1|28|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:50:41.138216|2018-06-01 03:50:41.138216
NCT00363181|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2007-03-19|2006-08-09|2006-08-15|Estimate|||||||2007-03-19|2007-03-21|Estimate|April 2006||2006-04-30|March 2007|2007-03-31||||||||Observational|||Side Effects of Antipsychotic Medications|Does Olanzapine Inhibit the Secretory Response to Insulin Resistance?|Unknown status|Recruiting||120||Stanford University|||||f||||||||||||||2018-06-01 03:50:41.20637|2018-06-01 03:50:41.20637
NCT00363168|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2012-04-03||2012-09-18|2006-08-09|2006-08-15|Estimate|2012-09-18|2012-10-19|Estimate||||2012-09-18|2012-10-19|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|May 2009|Actual|2009-05-31|June 2008|Actual|2008-06-30||Interventional|||Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial|Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial|Completed||Phase 1|7|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 03:50:41.282403|2018-06-01 03:50:41.282403
NCT00363155|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2006-08-10|2006-08-10|2006-08-15|Estimate|||||||2006-08-10|2006-08-15|Estimate|March 2003||2003-03-31|August 2006|2006-08-31|July 2006||2006-07-31|||||Interventional|||KRN7000 in Chronic Hepatitis B|Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis B Infection|Completed||Phase 1/Phase 2|28||Foundation for Liver Research|||||f||||||||||||||2018-06-01 03:50:41.508306|2018-06-01 03:50:41.508306
NCT00363142|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|2009-06-11||2010-10-21|2006-08-11|2006-08-15|Estimate|2009-08-21|2009-09-24|Estimate||||2010-10-21|2010-11-05|Estimate|May 2006||2006-05-31|October 2010|2010-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects|See Detailed Description.|Completed||Phase 3|211|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:50:41.607548|2018-06-01 03:50:41.607548
NCT00363129|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2014-07-17||2016-07-01|2006-08-10|2006-08-15|Estimate|2014-07-17|2014-08-08|Estimate||||2016-07-01|2016-07-06|Estimate|December 2006||2006-12-31|July 2016|2016-07-31|August 2014|Actual|2014-08-31|December 2010|Actual|2010-12-31||Interventional|||Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer|The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study|Completed||Phase 3|207|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 03:50:42.364692|2018-06-01 03:50:42.364692
NCT00363116|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2013-10-24|2006-08-10|2006-08-15|Estimate|||||||2013-10-24|2013-10-25|Estimate|April 1999||1999-04-30|October 2013|2013-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients|An Open-Label, Comparative Trial of Two Daclizumab Dosing Strategies Versus No Induction Treatment in Combination With Tacrolimus, Mycophenolate Mofetil, and Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients|Completed||Phase 4|298|Actual|University of Cincinnati||3|||f||||||||||||||2018-06-01 03:50:43.134348|2018-06-01 03:50:43.134348
NCT00363090|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2013-09-19|2006-08-10|2006-08-15|Estimate|||||||2013-09-19|2013-09-20|Estimate|September 2006||2006-09-30|June 2009|2009-06-30||||December 2010|Anticipated|2010-12-31||Interventional|||Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma|Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study|Unknown status|Recruiting|Phase 1/Phase 2|84|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:50:43.242498|2018-06-01 03:50:43.242498
NCT00363077|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|2013-03-21||2016-10-06|2006-08-11|2006-08-15|Estimate|2013-03-21|2013-05-07|Estimate||||2016-10-06|2016-11-09|Estimate|October 2006||2006-10-31|October 2016|2016-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate|A Study to Evaluate the Immunogenicity, Safety and Reactogenicity of Adjuvanted Influenza Vaccine Candidate Compared to Fluarix™ (GlaxoSmithKline Biologicals) Administered Intramuscularly in Elderly Aged 60 Years and Older.|Completed||Phase 2|150|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:50:43.360226|2018-06-01 03:50:43.360226
NCT00363051|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2011-12-02||2013-05-06|2006-08-09|2006-08-15|Estimate|2012-03-01|2012-03-30|Estimate||||2013-05-06|2013-05-10|Estimate|June 2006||2006-06-30|May 2013|2013-05-31|April 2012|Actual|2012-04-30|January 2008|Actual|2008-01-31||Interventional|||Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy|An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy|Completed||Phase 2|160|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:50:43.963817|2018-06-01 03:50:43.963817
NCT00363038|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2010-11-29||2014-05-22|2006-08-10|2006-08-15|Estimate|2012-11-05|2012-12-04|Estimate||||2014-05-22|2014-06-04|Estimate|July 2006||2006-07-31|May 2014|2014-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising|Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising|Completed||N/A|16|Actual|Northwestern University|As only laser-induced bruising on the inner arm was studied, it remains to be seen if this result can be generalized to other postoperative bruises and at other anatomical sites.|1|||f||||f||||||||||2018-06-01 03:50:44.886143|2018-06-01 03:50:44.886143
NCT00363025|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2008-02-20|2006-08-11|2006-08-15|Estimate|||||||2008-02-20|2008-02-21|Estimate|November 1999||1999-11-30|August 2006|2006-08-31|April 2006||2006-04-30|||||Interventional|||A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.|A Randomized Multicenter Study of More Intensive Versus Less Intensive Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia (AML) or Transformed Refractory Anemia With Excess Blasts (RAEB-t).|Terminated||Phase 3|465||Acute Leukemia French Association|||||f||||||||||||||2018-06-01 03:50:45.044155|2018-06-01 03:50:45.044155
NCT00363012|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10||2017-04-03|2017-04-03|2006-08-10|2006-08-15|Estimate||||2017-04-03|2017-04-05|Actual|2017-04-03|2017-04-05|Actual|April 2006||2006-04-30|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2|Development of HER-2/Neu (HER2) ICD Memory Immunity After Vaccination With a Plasmid Encoding HER2 ICD in Patients With Advanced Stage HER2 Overexpressing Breast and Ovarian Cancers|Completed||N/A|56|Actual|University of Washington|||||f||||f||||||||||2018-06-01 03:50:45.134317|2018-06-01 03:50:45.134317
NCT00362999|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2011-07-06|2006-08-10|2006-08-15|Estimate|||||||2011-07-06|2011-07-08|Estimate|August 2006||2006-08-31|July 2011|2011-07-31||||||||Observational|||Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism|Histamine Pharmacodynamics in Patients With Allergic Rhinitis: Validation of Laser Doppler Flowmetry as a Surrogate Endpoint|Unknown status|Recruiting||70|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 03:50:45.210342|2018-06-01 03:50:45.210342
NCT00362986|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2016-12-09|2006-08-10|2006-08-15|Estimate|||||||2016-12-09|2016-12-13|Estimate|October 2006||2006-10-31|December 2016|2016-12-31|October 2009|Actual|2009-10-31|July 2007|Actual|2007-07-31||Interventional|||Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash]|Completed||Phase 3|116|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 03:50:45.328906|2018-06-01 03:50:45.328906
NCT00362973|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2016-12-23|2006-08-10|2006-08-15|Estimate|||||||2016-12-23|2016-12-28|Estimate|May 2006||2006-05-31|May 2013|2013-05-31||||November 2009|Actual|2009-11-30||Observational|||PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer|Early Assessment of Response to Targeted Breast Cancer Therapy|Completed|||42|Actual|University of Washington|||2||f||||||||||||||2018-06-01 03:50:45.693564|2018-06-01 03:50:45.693564
NCT00362960|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2006-10-06|2006-08-11|2006-08-15|Estimate|||||||2006-10-06|2006-10-09|Estimate|May 2003||2003-05-31|August 2006|2006-08-31|September 2004||2004-09-30|||||Interventional|||Olmesartan Medoxomil and Diabetic Nephropathy|Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy|Completed||Phase 3|300||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 03:50:45.766123|2018-06-01 03:50:45.766123
NCT00362947|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2016-11-22|2006-08-11|2006-08-15|Estimate|||||||2016-11-22|2016-11-23|Estimate|August 2006||2006-08-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|||Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis|Randomized Clinical Study of Different Treatment Doses and Duration of Low Molecular Weight Heparin (Parnaparin) in Superficial Vein Thrombosis|Completed||Phase 3|664|Actual|St. Orsola Hospital||3|||f||||t||||||||No||2018-06-01 03:50:45.914553|2018-06-01 03:50:45.914553
NCT00362934|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-11|||2009-07-07|2006-08-11|2006-08-15|Estimate|||||||2009-07-07|2009-07-08|Estimate|October 2006||2006-10-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin|A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With Atorvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 10 mg Atorvastatin Alone|Completed||Phase 3|516|Actual|Solvay Pharmaceuticals||2|||f||||||||||||||2018-06-01 03:50:45.990558|2018-06-01 03:50:45.990558
NCT00362921|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2014-07-09|2006-08-10|2006-08-15|Estimate|||||||2014-07-09|2014-07-10|Estimate|April 2004||2004-04-30|February 2013|2013-02-28|July 2008|Actual|2008-07-31|August 2007|Actual|2007-08-31||Interventional|||Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme|Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|52|Actual|Duke University||1|||f||||f||||||||||2018-06-01 03:50:46.130124|2018-06-01 03:50:46.130124
NCT00362908|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|||2010-10-27|2006-08-10|2006-08-15|Estimate|||||||2010-10-27|2010-10-28|Estimate|September 2006||2006-09-30|October 2010|2010-10-31|June 2010|Actual|2010-06-30|September 2009|Actual|2009-09-30||Interventional|||Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome|Diets for Dyslipidemia in the Metabolic Syndrome|Completed||N/A|71|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:50:46.20941|2018-06-01 03:50:46.20941
NCT00362895|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2012-03-02|2006-08-09|2006-08-15|Estimate|||||||2012-03-02|2012-03-05|Estimate|April 2006||2006-04-30|March 2012|2012-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Bioequivalence Study of Tobradex AF|A Double-Masked, Parallel-Group, Randomized, Single-Dose Bioequivalence Study of Tobradex AF Suspension and TOBRADEX Ophthalmic Suspension|Completed||Phase 3|995|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 03:50:46.298388|2018-06-01 03:50:46.298388
NCT00362882|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-10|2014-04-08||2017-10-31|2006-08-10|2006-08-15|Estimate|2014-10-01|2014-10-02|Estimate||||2017-10-31|2017-12-05|Actual|July 2006||2006-07-31|October 2017|2017-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer|Randomized Phase II Trial of Sequential Versus Concurrent Docetaxel and PS-341 (NSC 681239) in Previously Treated Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|81|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 03:50:46.388219|2018-06-01 03:50:46.388219
NCT00347789|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-06-30|2006-06-30|2006-07-04|Estimate|||||||2006-06-30|2006-07-04|Estimate|May 1997||1997-05-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Observational|||Effectiveness of a Procedure for Previously Failed Glaucoma Surgery|Efficacy of Transconjunctival Mitomycin-C in Needle Revisions of Failing Trabeculectomy|Completed|||100||Glaucoma Research & Education Group|||||f||||||||||||||2018-06-01 03:54:55.813723|2018-06-01 03:54:55.813723
NCT00362856|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-09-11|2006-08-08|2006-08-10|Estimate|||||||2017-09-11|2017-09-12|Actual|September 13, 2006|Actual|2006-09-13|September 2017|2017-09-30|March 6, 2007|Actual|2007-03-06|March 6, 2007|Actual|2007-03-06||Interventional|||Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects|A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.|Completed||Phase 2|80|Actual|Innovate Biopharmaceuticals||7|||f||||f|t|f||||||||2018-06-01 03:50:47.135744|2018-06-01 03:50:47.135744
NCT00362843|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2018-05-26|2006-08-09|2006-08-10|Estimate|||||||2018-05-26|2018-05-30|Actual|August 8, 2006||2006-08-08|May 18, 2018|2018-05-18||||||||Observational|||Protein Synthesis in the Brain of Patients With Fragile X Syndrome|PET Measurement of Regional Rates of Cerebral Protein Synthesis in Subjects With Fragile X Syndrome|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:50:47.221141|2018-06-01 03:50:47.221141
NCT00362830|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2016-09-16|2006-08-09|2006-08-10|Estimate|||||||2016-09-16|2016-09-19|Estimate|August 2006||2006-08-31|September 2016|2016-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study of the Alternative Administration of Ixabepilone and Vinflunine|A Study of the Alternating Administration of Ixabepilone and Vinflunine Every Three Weeks in Patients With Advanced Cancer|Completed||Phase 1|60|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:50:47.28402|2018-06-01 03:50:47.28402
NCT00362817|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2015-02-26||2017-05-01|2006-08-09|2006-08-10|Estimate|2015-05-04|2015-05-06|Estimate||||2017-05-01|2017-06-01|Actual|October 2004|Actual|2004-10-31|May 2017|2017-05-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases|Phase I/II Multicenter Trial of Intra-Arterial Carboplatin and Oral Temozolomide for the Treatment of Recurrent and Symptomatic Residual Brain Metastases.|Completed||Phase 1/Phase 2|17|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:50:47.356044|2018-06-01 03:50:47.356044
NCT00362804|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2012-07-04|2006-08-09|2006-08-10|Estimate|||||||2012-07-04|2012-07-06|Estimate|February 2002||2002-02-28|July 2012|2012-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Tetrabenazine for Partial Responders|Augmentation of Antipsychotic Partial Responders With Tetrabenazine|Completed||N/A|41|Actual|Centre for Addiction and Mental Health|||||f||||f||||||||||2018-06-01 03:50:47.512063|2018-06-01 03:50:47.512063
NCT00362791|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2006-08-09|2006-08-09|2006-08-10|Estimate|||||||2006-08-09|2006-08-10|Estimate|April 2003||2003-04-30|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Project RESPECT: The Efficacy of HIV/STD Prevention Counseling|Multicenter Randomized Controlled Trial Evaluating the Efficacy of HIV/STD Prevention Counseling and Testing in Preventing High Risk Behaviors and New Sexually Transmitted Diseases (Project RESPECT)|Completed||N/A|6000||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 03:50:47.635932|2018-06-01 03:50:47.635932
NCT00362778|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2012-03-19|2006-08-08|2006-08-10|Estimate|||||||2012-03-19|2012-03-20|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|INSUCOR||Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia|Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia|Completed||Phase 4|28|Actual|Hospital Clinic of Barcelona||1|||f||||||||||||||2018-06-01 03:50:47.688501|2018-06-01 03:50:47.688501
NCT00362765|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2008-08-12|2006-08-09|2006-08-10|Estimate|||||||2008-08-12|2008-08-13|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study|Assessment of Insulin Sensitivity in Type 2 Diabetics Treated With Metformin, Fenofibrate and Their Combination.|Terminated||Phase 2/Phase 3|8|Actual|Solvay Pharmaceuticals||4||"The study was prematurely terminated, due to difficulties in the recruitment of T2DM patients~   who are not under statin therapy at inclusion."|f||||f||||||||||2018-06-01 03:50:47.753401|2018-06-01 03:50:47.753401
NCT00362752|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2016-12-06|2006-08-08|2006-08-10|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2006||2006-10-31|December 2016|2016-12-31|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|||A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome|A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome|Completed||Phase 2|9|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-06-01 03:50:47.824154|2018-06-01 03:50:47.824154
NCT00362739|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2016-04-28|2006-08-08|2006-08-10|Estimate|||||||2016-04-28|2016-04-29|Estimate|September 2005||2005-09-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Blood Collection From Individuals With Lung Disease for Genetic Studies|Collection of Blood for Gene Expression/Genomic Studies in Individuals With Chronic Lung Disease|Completed|||3087|Actual|Weill Medical College of Cornell University|||2||f||||t||||||Samples With DNA|"~     In this study, a small amount of blood for extraction of DNA for the study of the genetic~     basis of lung disease will be obtained from each subject. The collected blood (cells and~     serum) will be used for genetic testing in studies relating to the genetic material and/or~     gene expression, and/or studies of proteins or other substances in serum (the liquid portion~     of the blood after it has been allowed to clot). Because these latter protein studies will~     occur at a future date, the serum will be stored for use in these studies.~   "|Undecided||2018-06-01 03:50:47.904246|2018-06-01 03:50:47.904246
NCT00362726|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2011-04-07|2006-08-09|2006-08-10|Estimate|||||||2011-04-07|2011-04-08|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone|Effect of Atazanavir Administered With and Without Ritonavir on the Pharmacokinetics of the Cytochrome P450 2C8 Substrate Rosiglitazone in Healthy Subjects|Completed||Phase 1|14||Bristol-Myers Squibb||5|||f||||||||||||||2018-06-01 03:50:47.959456|2018-06-01 03:50:47.959456
NCT00362713|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2016-09-29|2006-08-09|2006-08-10|Estimate|||||||2016-09-29|2016-09-30|Estimate|March 2007||2007-03-31|December 2009|2009-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection|A Phase 1b Safety and Dose-Assessment Study of Neoadjuvant Ipilimumab Monotherapy in Patients With Urothelial Carcinoma Undergoing Surgical Resection|Completed||Phase 1|12|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:50:48.111161|2018-06-01 03:50:48.111161
NCT00362700|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-01-30|2006-08-08|2006-08-10|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2003||2003-07-31|June 2006|2006-06-30|October 2005||2005-10-31|||||Interventional|||Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201|An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of Retreated Clevudine in Chronic Hepatitis B Patients Who Received Clevudine in L-FMAU-201|Terminated||Phase 2|33||Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 03:50:48.192717|2018-06-01 03:50:48.192717
NCT00362687|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2009-03-30|2006-08-09|2006-08-10|Estimate|||||||2009-03-30|2009-03-31|Estimate|November 2006||2006-11-30|March 2009|2009-03-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance|GMB: Phase IV, Multicenter, Randomized, Open-Label Pilot Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients Who Need to Interrupt HAART and Who Are Infected With HIV Isolates Containing at Least 2 TAMs (or K65R) and M184V|Completed||Phase 4|50|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 03:50:48.27791|2018-06-01 03:50:48.27791
NCT00362674|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-01-30|2006-08-08|2006-08-10|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2005||2005-06-30|December 2010|2010-12-31||||||||Observational|||Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial|An Open-label, Observation Study to Evaluate the Durability of Antiviral Activity in Chronic Hepatitis B Patients Who Showed Complete Response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 Trial|Completed|||||Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 03:50:48.384306|2018-06-01 03:50:48.384306
NCT00362661|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2010-01-11|2006-08-09|2006-08-10|Estimate|||||||2010-01-11|2010-01-12|Estimate|June 2007||2007-06-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Low-dose Cortisol in Chronic Posttraumatic Stress Disorder|Low-dose Cortisol in Chronic Posttraumatic Stress Disorder|Terminated||N/A|20|Anticipated|University of Zurich||||Recruitment: Insufficient number of patients eligible for enrollment|f||||||||||||||2018-06-01 03:50:48.492046|2018-06-01 03:50:48.492046
NCT00362648|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2010-03-11||2017-03-16|2006-08-09|2006-08-10|Estimate|2010-04-26|2010-05-13|Estimate||||2017-03-16|2017-04-13|Actual|March 2007||2007-03-31|March 2017|2017-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Developing World Study for RotaTeq™ (V260-015)(COMPLETED)|Efficacy, Safety, and Immunogenicity of RotaTeq™ Among Infants in Asia and Africa|Completed||Phase 3|7504|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:50:48.610562|2018-06-01 03:50:48.610562
NCT00362635|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2012-07-24|2006-08-08|2006-08-10|Estimate|||||||2012-07-24|2012-07-26|Estimate|August 2006||2006-08-31|July 2012|2012-07-31||||December 2011|Actual|2011-12-31||Interventional|||Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection|A Double-blinded and Randomised Study to Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30 mg qd Versus Lamivudine 100 mg qd for Chronic Hepatitis B Infection|Completed||Phase 3|92|Anticipated|Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 03:50:49.965972|2018-06-01 03:50:49.965972
NCT00362622|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2012-08-14|2006-08-09|2006-08-10|Estimate|||||||2012-08-14|2012-08-16|Estimate|October 2005||2005-10-31|August 2012|2012-08-31|January 2008|Actual|2008-01-31|||||Observational|||Determinants of Compliance With Glaucoma Therapy|Determinants of Compliance With Glaucoma Therapy|Completed|||59|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 03:50:50.032603|2018-06-01 03:50:50.032603
NCT00362609|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2009-11-30|2008-12-17|2010-04-22|2006-08-08|2006-08-10|Estimate|2010-04-22|2010-05-14|Estimate|2010-04-22|2010-05-14|Estimate|2010-04-22|2010-05-14|Estimate|July 2006||2006-07-31|April 2010|2010-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD|A Multicenter, Open-Label, PK, PD and Safety Study of Pantoprazole Delayed-Release Granules Administered as a Suspension in Neonates and Preterm Infants With a Clinical Diagnosis of GERD|Completed||Phase 3|59|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 03:50:50.156065|2018-06-01 03:50:50.156065
NCT00362596|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2006-08-09|2006-08-09|2006-08-10|Estimate|||||||2006-08-09|2006-08-10|Estimate|January 2005||2005-01-31|August 2006|2006-08-31|August 2005||2005-08-31|||||Interventional|||A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand|A Randomized Controlled Crossover Trial of Acylcovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand|Completed||Phase 4|67||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 03:50:50.46952|2018-06-01 03:50:50.46952
NCT00362583|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2012-05-04|2006-08-09|2006-08-10|Estimate|||||||2012-05-04|2012-05-07|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)|A Double-blind, Randomised, Placebo-controlled Trial Confirming the Efficacy of Intranasal Fentanyl Titrated to 50, 100 or 200 µg With an Open Long-term Safety Follow-up in Cancer Patients With Breakthrough Pain|Completed||Phase 3|100|Anticipated|Nycomed|||||f||||||||||||||2018-06-01 03:50:50.541558|2018-06-01 03:50:50.541558
NCT00362570|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-11-28|2006-08-09|2006-08-10|Estimate|||||||2017-11-28|2017-11-30|Actual|May 2005||2005-05-31|November 2017|2017-11-30|March 2011|Actual|2011-03-31|April 2007|Actual|2007-04-30||Interventional|||Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma|Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma|Completed||Phase 2|1|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 03:50:50.599783|2018-06-01 03:50:50.599783
NCT00362557|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2015-08-31|2006-08-09|2006-08-10|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2001||2001-09-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Imaging Techniques in Body MRI|Imaging Techniques in Body MRI|Active, not recruiting|||1000|Anticipated|Johns Hopkins University|||||f||||||||||||||2018-06-01 03:50:50.666911|2018-06-01 03:50:50.666911
NCT00362544|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2015-07-07|2006-08-09|2006-08-10|Estimate|||||||2015-07-07|2015-07-09|Estimate|October 2003||2003-10-31|July 2015|2015-07-31|March 2006||2006-03-31|||||Interventional|||PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia|Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia|Completed||Phase 4|30||Gilead Sciences|||||f||||||||||||||2018-06-01 03:50:50.733802|2018-06-01 03:50:50.733802
NCT00362531|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2006-08-09|2006-08-09|2006-08-10|Estimate|||||||2006-08-09|2006-08-10|Estimate|November 2004||2004-11-30|January 2006|2006-01-31|January 2007||2007-01-31|||||Interventional|||Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome|Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome|Completed||Phase 2/Phase 3|||Peking University|||||f||||||||||||||2018-06-01 03:50:50.811466|2018-06-01 03:50:50.811466
NCT00362518|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2008-09-02|2006-08-09|2006-08-10|Estimate|||||||2008-09-02|2008-09-04|Estimate|July 2004||2004-07-31|September 2008|2008-09-30|March 2008|Actual|2008-03-31|June 2007|Actual|2007-06-30||Interventional|||Vitamins C and Vitamin E and Cardiovascular Risk|Vitamin C and Vitamin E Therapy in Type 2 Diabetes and Cardiovascular Risk|Completed||Phase 3|12|Actual|University of New Mexico||4|||f||||t||||||||||2018-06-01 03:50:50.860315|2018-06-01 03:50:50.860315
NCT00362505|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-01-30|2006-08-08|2006-08-10|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2004||2004-06-30|June 2006|2006-06-30|March 2006||2006-03-31|||||Interventional|||Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials|An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials|Terminated||Phase 3|||Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 03:50:50.936484|2018-06-01 03:50:50.936484
NCT00362492|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2010-10-27|2006-08-09|2006-08-10|Estimate|||||||2010-10-27|2010-10-28|Estimate|June 2004||2004-06-30|October 2010|2010-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement|9-10 Days Versus Prolonged Thromboprophylaxis in Patients Without Evidence of Ultrasound Proximal Thromboembolism After Total Knee Joint Replacement: a Randomized Controlled Trial|Completed||Phase 4|850|Anticipated|University Hospital, Caen|||||f||||||||||||||2018-06-01 03:50:52.00139|2018-06-01 03:50:52.00139
NCT00362479|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2013-08-20|2006-08-09|2006-08-10|Estimate|||||||2013-08-20|2013-08-21|Estimate|August 2006||2006-08-31|August 2013|2013-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive|A Prospective, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of the 28-Day Oral Contraceptive DR-1021|Completed||Phase 3|1347|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 03:50:52.107208|2018-06-01 03:50:52.107208
NCT00362466|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2009-07-24||2009-11-18|2006-08-09|2006-08-10|Estimate|2009-07-24|2009-09-03|Estimate||||2009-11-18|2009-11-20|Estimate|April 2007||2007-04-30|November 2009|2009-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy|An Open-Label Randomized Phase III Study of Dasatinib vs. High-Dose (600 mg) Imatinib Mesylate in the Treatment of Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Are Imatinib Failures or Who Have Had a Suboptimal Response After 3-18 Months of Therapy With 400 mg Imatinib|Terminated||Phase 3|3|Actual|Bristol-Myers Squibb|Study was terminated early due to insufficient enrollment.|2||Insufficient Enrollment|f||||f||||||||||2018-06-01 03:50:52.406343|2018-06-01 03:50:52.406343
NCT00362453|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2009-09-25||2016-04-20|2006-08-09|2006-08-10|Estimate|2010-01-14|2010-02-08|Estimate||||2016-04-20|2016-05-20|Estimate|August 2005||2005-08-31|April 2016|2016-04-30|June 2009|Actual|2009-06-30|March 2008|Actual|2008-03-31||Interventional|||Tai Chi Mind-Body Therapy for Knee Osteoarthritis|Tai Chi Mind-Body Therapy for Knee Osteoarthritis: a Pilot Single-blind Randomized Controlled Trial|Completed||N/A|40|Actual|Tufts Medical Center|small sample size|2|||f||||t||||||||||2018-06-01 03:50:52.843528|2018-06-01 03:50:52.843528
NCT00362440|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2015-12-22||2017-02-02|2006-08-09|2006-08-10|Estimate|2017-02-02|2017-03-23|Actual||||2017-02-02|2017-03-23|Actual|August 2006||2006-08-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome|A Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome: A Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 2|9|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 03:50:53.519298|2018-06-01 03:50:53.519298
NCT00362427|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2014-01-10|2006-08-09|2006-08-10|Estimate|||||||2014-01-10|2014-01-14|Estimate|August 2006||2006-08-31|January 2014|2014-01-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®|A Randomized Trial to Assess the Immunogenicity and Safety of PR5I With an Adjuvant Composition Enhancement to the Hepatitis B Component and When Given Concomitantly With Prevnar®|Completed||Phase 2|460|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 03:50:53.797781|2018-06-01 03:50:53.797781
NCT00362414|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2012-06-12||2016-08-16|2006-08-09|2006-08-10|Estimate|2016-08-16|2016-08-29|Estimate||||2016-08-16|2016-08-29|Estimate|August 2006||2006-08-31|August 2016|2016-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|BETAS||Beta-hCG + Erythropoietin in Acute Stroke|Safety of Beta-hCG + Erythropoietin in Acute Stroke|Completed||Phase 2|15|Actual|University of California, Irvine||1|||f||||f||||||||||2018-06-01 03:50:53.934901|2018-06-01 03:50:53.934901
NCT00362401|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|2009-01-22||2009-08-03|2006-08-09|2006-08-10|Estimate|2009-08-03|2009-09-07|Estimate||||2009-08-03|2009-09-07|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|January 2009|Actual|2009-01-31|||||Observational|||Patients Perception of Mechanical Heart Valve Sounds: Psychoacoustics and Quality of Life|Patients Perception of Mechanical Heart Valve Sounds: Psychoacoustics and Quality of Life|Completed|||90|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 03:50:54.420992|2018-06-01 03:50:54.420992
NCT00362388|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2010-01-26|2006-08-08|2006-08-10|Estimate|||||||2010-01-26|2010-01-27|Estimate|January 2006||2006-01-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Cell Therapy in Chronic Ischemic Heart Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery|Terminated||Phase 3|300|Anticipated|Ministry of Health, Brazil||||low enrollling|f||||t||||||||||2018-06-01 03:50:54.662956|2018-06-01 03:50:54.662956
NCT00362375|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2010-03-08||2010-04-27|2006-08-08|2006-08-10|Estimate|2010-04-27|2010-05-14|Estimate||||2010-04-27|2010-05-14|Estimate|May 2006||2006-05-31|April 2010|2010-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women|Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women by SisterLove, Inc. in Atlanta, GA|Completed||Phase 1/Phase 2|313|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 03:50:54.74833|2018-06-01 03:50:54.74833
NCT00362362|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2017-10-05|2006-08-09|2006-08-10|Estimate|||||||2017-10-05|2017-10-06|Actual|August 7, 2006||2006-08-07|September 9, 2013|2013-09-09|September 9, 2013||2013-09-09|||||Observational|||Collection of Blood Samples for DNA in Motor Neuron Disease|Collection of Blood Samples for DNA Analysis in Motor Neuron Diseases|Completed|||23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:50:55.014327|2018-06-01 03:50:55.014327
NCT00362349|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2016-07-14|2006-08-09|2006-08-10|Estimate|||||||2016-07-14|2016-07-18|Estimate|June 2007||2007-06-30|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients|A Single-arm, Open Label, Multi-centre Study Evaluating the Efficacy and Safety of Ig NexGen 10% in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|Completed||Phase 3|19|Actual|CSL Limited||1|||f||||f||||||||||2018-06-01 03:50:55.091564|2018-06-01 03:50:55.091564
NCT00346827|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2006-06-29|2006-06-29|2006-06-30|Estimate|||||||2006-06-29|2006-06-30|Estimate||||June 2006|2006-06-30||||||||Interventional|||"Apomorphine Nasal Powder in the Treatment of Parkinson's Disease Off Periods."||Unknown status|Not yet recruiting|Phase 2/Phase 3|||Britannia Pharmaceuticals Ltd.|||||f||||||||||||||2018-06-01 03:55:06.411232|2018-06-01 03:55:06.411232
NCT00362336|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2014-02-14||2014-04-01|2006-08-08|2006-08-10|Estimate|2014-04-01|2014-05-02|Estimate||||2014-04-01|2014-05-02|Estimate|August 2006||2006-08-31|April 2014|2014-04-30|August 2009|Actual|2009-08-31|May 2008|Actual|2008-05-31||Interventional|||Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV|Immunogenicity Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine in Comparison to CombAct-HIB® Concomitantly Administered With Engerix B® Paediatric and OPV at 6, 10, and 14 Weeks of Age in South African Infants|Completed||Phase 3|622|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 03:50:55.263895|2018-06-01 03:50:55.263895
NCT00362323|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2010-04-15|2006-08-09|2006-08-10|Estimate|||||||2010-04-15|2010-04-16|Estimate|October 2006||2006-10-31|April 2010|2010-04-30|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Interventional|||Fenofibrate and Metformin Fixed Combination vs Metformin - FAME METFO|A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin.|Completed||Phase 3|482|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:50:56.239726|2018-06-01 03:50:56.239726
NCT00362310|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-09|||2008-04-11|2006-08-09|2006-08-10|Estimate|||||||2008-04-11|2008-04-14|Estimate|June 2003||2003-06-30|April 2008|2008-04-30|July 2007||2007-07-31|||||Interventional|||Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir|A Phase II Trial With the HIV Protease Inhibitor Indinavir for the Treatment of Classical Kaposi's Sarcoma|Completed||Phase 2|28||Istituto Superiore di Sanità|||||f||||||||||||||2018-06-01 03:50:56.388156|2018-06-01 03:50:56.388156
NCT00362297|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2012-03-23||2014-10-02|2006-08-08|2006-08-09|Estimate|2014-10-02|2014-10-08|Estimate||||2014-10-02|2014-10-08|Estimate|September 2006||2006-09-30|October 2014|2014-10-31|September 2011|Actual|2011-09-30|December 2008|Actual|2008-12-31||Interventional|||Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2|A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults|Completed||Phase 4|31|Actual|University of Washington|The trial was performed at a single site, and enrolled mostly white, healthy, sexually active adults with high rates of genital HSV-2 recurrence. The results may not be generalizable to other populations.|2|||f||||f||||||||||2018-06-01 03:50:56.462834|2018-06-01 03:50:56.462834
NCT00362284|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2018-05-03|2006-08-08|2006-08-09|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2005||2005-09-30|May 2018|2018-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Comprehensive Support for Alzheimer's Disease Caregivers|Expanded Counseling and Support for Adult Children Caring for Parents With Alzheimer's Disease or Similar Disorders|Completed||N/A|161|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 03:50:56.695228|2018-06-01 03:50:56.695228
NCT00362271|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2013-11-07|2006-08-08|2006-08-09|Estimate|||||||2013-11-07|2013-11-08|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Aripiprazole and Effexor XR Drug Interaction Study|Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects|Completed||Phase 1|38||Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-06-01 03:50:56.759185|2018-06-01 03:50:56.759185
NCT00362258|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2011-04-01|2006-08-08|2006-08-09|Estimate|||||||2011-04-01|2011-04-04|Estimate|February 2006||2006-02-28|March 2011|2011-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||I PREVENT - Irbesartan In Hypertensive Diabetic Patients|Irbesartan In Hypertensive Diabetic Patients|Completed||Phase 4|797|Actual|Sanofi|||||f||||f||||||||||2018-06-01 03:50:56.905569|2018-06-01 03:50:56.905569
NCT00362245|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2015-11-01|2006-08-08|2006-08-09|Estimate|||||||2015-11-01|2015-11-03|Estimate|September 2006||2006-09-30|November 2015|2015-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Amikacin Penetration Into the Cerebrospinal Fluid|Amikacin Penetration Into the Cerebrospinal Fluid: Pharmacokinetic/Pharmacodynamic Analysis in Adults With Hospital Acquired Gram-negative Meningitis Associated With Intracranial Pressure Monitoring and Draining Devices|Withdrawn||Phase 4|0|Actual|Rambam Health Care Campus||||lack of participants|f||||||||||||||2018-06-01 03:50:56.967856|2018-06-01 03:50:56.967856
NCT00362232|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2012-05-10||2014-10-28|2006-08-08|2006-08-09|Estimate|2012-05-10|2012-06-13|Estimate||||2014-10-28|2014-11-04|Estimate|June 2006||2006-06-30|October 2014|2014-10-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|RECORD 4||Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.|RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-blind, Randomized Study of BAY59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement|Completed||Phase 3|3148|Actual|Bayer||2|||f||||t||||||||||2018-06-01 03:50:57.093207|2018-06-01 03:50:57.093207
NCT00362219|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2011-10-27|2006-08-08|2006-08-09|Estimate|||||||2011-10-27|2011-10-28|Estimate|December 2006||2006-12-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Topical Morphine for Analgesia in Patients With Skin Grafts|Topical Morphine for Analgesia in Patients With Skin Grafts|Completed||Phase 3|40|Actual|Rambam Health Care Campus||4|||f||||||||||||||2018-06-01 03:50:58.427252|2018-06-01 03:50:58.427252
NCT00362206|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2009-07-07|2006-08-08|2006-08-09|Estimate|||||||2009-07-07|2009-07-08|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin|A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Pravastatin Alone|Completed||Phase 3|423|Actual|Solvay Pharmaceuticals||3|||f||||f||||||||||2018-06-01 03:50:58.515578|2018-06-01 03:50:58.515578
NCT00362193|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2010-02-12|2006-08-07|2006-08-09|Estimate|||||||2010-02-12|2010-02-15|Estimate|June 2002||2002-06-30|February 2010|2010-02-28|February 2007|Actual|2007-02-28|||||Interventional|||Glycemic Relapse Prevention: Maintenance Dose Assessment|Longitudinal Diabetes Care: A Randomized Controlled Trial to Prevent Glycemic Relapse|Completed||Phase 4|165||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:50:58.699806|2018-06-01 03:50:58.699806
NCT00361985|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2016-10-31|2006-08-08|2006-08-09|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery|Randomized, Prospective, Double-blind Trial of PPI vs Placebo in Prevention of Gastrojejunal Strictures After Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity|Withdrawn||Phase 4|0|Actual|Weill Medical College of Cornell University||1||Insufficient enrollment|f||||f||||||||||2018-06-01 03:51:03.110538|2018-06-01 03:51:03.110538
NCT00362180|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|2013-02-25|2012-09-19|2016-09-09|2006-08-07|2006-08-09|Estimate|2015-06-19|2015-06-24|Estimate|2012-09-19|2012-09-26|Estimate|2016-09-09|2016-10-21|Estimate|July 2006||2006-07-31|September 2016|2016-09-30|September 2010|Actual|2010-09-30|March 2010|Actual|2010-03-31||Interventional|||Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Apolipoprotein B(ApoB) Reduction by ISIS 301012 on Liver Triglyceride Content in Subjects With Varying Degrees of Hyperlipidemia|Completed||Phase 2|38|Actual|Kastle Therapeutics, LLC|The limitations to this study are 1) post-hoc amendments that caused early termination of cohorts and limited the accomplishment of study objectives and 2) post-hoc amendments which added cohorts into the study that were not previously specified.|9|||f||||t||||||||||2018-06-01 03:50:58.791429|2018-06-01 03:50:58.791429
NCT00362167|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-06-30|2006-08-08|2006-08-09|Estimate|||||||2017-06-30|2017-07-02|Actual|February 15, 2001||2001-02-15|December 13, 2006|2006-12-13|December 13, 2006||2006-12-13|||||Observational|||Pain Evaluation and Treatment|Evaluation and Treatment of Pain (Training Protocol)|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:50:59.835256|2018-06-01 03:50:59.835256
NCT00362141|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2007-03-30|2006-08-08|2006-08-09|Estimate|||||||2007-03-30|2007-04-02|Estimate|October 2006||2006-10-31|March 2007|2007-03-31|April 2008|Anticipated|2008-04-30|||||Interventional|||Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus|Safety and Tolerability of Add-on Levetiracetam in Status Epilepticus|Unknown status|Recruiting|Phase 2|12||Medical Center Haaglanden|||||f||||f||||||||||2018-06-01 03:50:59.882843|2018-06-01 03:50:59.882843
NCT00362128|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2015-07-06||2018-02-15|2006-08-08|2006-08-09|Estimate|2015-08-05|2015-09-04|Estimate||||2018-02-15|2018-03-16|Actual|January 2007||2007-01-31|February 2018|2018-02-28|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Observational|CHA-CHA||Cardiovascular Disease Risk Factors in Chinese American Immigrants|Chinese American Cardiovascular Health Assessment CHA-CHA|Completed|||2072|Actual|Albert Einstein College of Medicine, Inc.|||||f||||f||||||Samples With DNA|"~     Biospecimens are being analyzed to evaluate the relationship between biomarker, behaviors and~     sociodemographic variables. Stored specimens will permit future analysis that may involve~     genetic variables related to biomarker findings.~   "|||2018-06-01 03:50:59.953565|2018-06-01 03:50:59.953565
NCT00362115|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|2011-03-24||2011-03-24|2006-08-07|2006-08-09|Estimate|2011-03-24|2011-04-19|Estimate||||2011-03-24|2011-04-19|Estimate|May 2006||2006-05-31|March 2011|2011-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension|Completed||Phase 2|449|Actual|Takeda||7|||f||||f||||||||||2018-06-01 03:51:00.144239|2018-06-01 03:51:00.144239
NCT00362102|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2016-11-21|2006-08-08|2006-08-09|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2005||2005-10-31|November 2016|2016-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma|A Multi-center, Open Label, Non-randomized, Phase II Study to Assess the Activity and Safety of Cetuximab Plus Irinotecan in Subjects With EGFR-detectable Metastatic Colorectal Carcinoma|Completed||Phase 2|38||Eli Lilly and Company|||||f||||||||||||||2018-06-01 03:51:02.16507|2018-06-01 03:51:02.16507
NCT00362089|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2014-02-03|2006-08-08|2006-08-09|Estimate|||||||2014-02-03|2014-02-04|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Fatty Acids During Pregnancy and Lactation and Body Fat Mass in Newborns|The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development|Completed||N/A|208|Actual|Technische Universität München||2|||f||||t||||||||||2018-06-01 03:51:02.225761|2018-06-01 03:51:02.225761
NCT00362076|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-06-30|2006-08-08|2006-08-09|Estimate|||||||2017-06-30|2017-07-02|Actual|September 3, 1998||1998-09-03|April 19, 2012|2012-04-19|April 19, 2012||2012-04-19|||||Observational|||The Role of Motion in Infants' Ability to Categorize|Categorization Based on Motion-Carried Information in Infancy|Completed|||941|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:02.307041|2018-06-01 03:51:02.307041
NCT00362063|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-04-10|2006-08-08|2006-08-09|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2006||2006-01-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||304-C03/L3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency|Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency|Active, not recruiting||N/A|20|Anticipated|Baylor College of Medicine||2|||f||||||||||||||2018-06-01 03:51:02.371407|2018-06-01 03:51:02.371407
NCT00362050|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2007-08-28|2006-08-08|2006-08-09|Estimate|||||||2007-08-28|2007-08-29|Estimate|June 2006||2006-06-30|August 2007|2007-08-31|January 2007|Actual|2007-01-31|||||Interventional|||RBx11160 Phase II Dose Ranging Study RBx/MMV05-06|A Phase II, Double-Blind, Parallel-Group, Randomized, Dose-Ranging Study Assessing the Antimalarial Activity and Safety of RBx 11160 Administered for 7 Days in Patients With Acute Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 2|255||Medicines for Malaria Venture|||||f||||||||||||||2018-06-01 03:51:02.431288|2018-06-01 03:51:02.431288
NCT00362037|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2011-05-27|2006-08-08|2006-08-09|Estimate|||||||2011-05-27|2011-05-30|Estimate|March 2006||2006-03-31|May 2011|2011-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy|Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy|Completed||Phase 4|281|Actual|Sanofi|||||f||||f||||||||||2018-06-01 03:51:02.614878|2018-06-01 03:51:02.614878
NCT00362024|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2016-05-13|2006-08-08|2006-08-09|Estimate|||||||2016-05-13|2016-05-16|Estimate|November 2006||2006-11-30|May 2016|2016-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)|MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease|Terminated||Phase 2|24|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:51:02.735823|2018-06-01 03:51:02.735823
NCT00362011|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2006-08-08|2006-08-08|2006-08-09|Estimate|||||||2006-08-08|2006-08-09|Estimate|March 2001||2001-03-31|February 2001|2001-02-28||||||||Interventional|||Effect of Chia Seeds (Salvia Hispanica L.) on Glucose Control in Patients With Type 2 Diabetes|Effect of Chia Seeds (Salvia Hispanica L.) on Glucose Control in Patients With Type 2 Diabetes|Completed||Phase 2|||St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 03:51:02.914474|2018-06-01 03:51:02.914474
NCT00361998|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2007-03-01|2006-08-08|2006-08-09|Estimate|||||||2007-03-01|2007-03-02|Estimate|September 2006||2006-09-30|March 2007|2007-03-31|January 2007||2007-01-31|||||Interventional|||Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated Cystitis|Nitrofurantoin Macrocrystals 3 Days Vs. 7 Days in the Treatment of Women With Uncomplicated Cystitis|Withdrawn||Phase 4|400||HaEmek Medical Center, Israel||||recruitment failed|f||||||||||||||2018-06-01 03:51:03.043972|2018-06-01 03:51:03.043972
NCT00361972|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|2016-01-14||2016-06-25|2006-08-08|2006-08-09|Estimate|2016-06-25|2016-08-05|Estimate||||2016-06-25|2016-08-05|Estimate|August 2006||2006-08-31|June 2016|2016-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Elucidation of Acid-Induced Pulmonary Inflammation|Elucidation of Acid-Induced Pulmonary Inflammation|Terminated||Phase 2/Phase 3|17|Actual|University of Utah|Questionnaires were not assessed as many of them were incomplete. Drop out occurred due to incomplete tissues Early termination: the total number of participants could not be enrolled in a timely manner..|2||limited recruitment|f||||f||||||||No||2018-06-01 03:51:03.235818|2018-06-01 03:51:03.235818
NCT00361959|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2017-01-19|2006-08-07|2006-08-09|Estimate|||||||2017-01-19|2017-01-20|Estimate|June 2003|Actual|2003-06-30|January 2017|2017-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease|Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily Via the DISKUS*/ACCUHALER* Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily Via the HandiHaler Inhalation Device on the Rate of Health Care Utilisation Exacerbations in Subjects With Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|1270|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:51:03.615724|2018-06-01 03:51:03.615724
NCT00361946|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-04-21|2006-08-08|2006-08-09|Estimate|||||||2017-04-21|2017-04-24|Actual|August 2006||2006-08-31|April 2017|2017-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).|The Role of Amylin and Incretins on Postprandial Metabolisms in Adolescents With Type 2 Diabetes Mellitus (T2DM).|Completed|||45|Actual|Baylor College of Medicine|||3||f||||t|f|f||||Samples Without DNA|"~     serum~   "|Undecided||2018-06-01 03:51:04.139532|2018-06-01 03:51:04.139532
NCT00361933|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2017-04-14|2006-08-08|2006-08-09|Estimate|||||||2017-04-14|2017-04-18|Actual|December 2008||2008-12-31|April 2017|2017-04-30|May 2009|Anticipated|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease|Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclovir|Withdrawn||Phase 4|0|Actual|University of Washington||1||Research never begun.|f||||t||||||||||2018-06-01 03:51:04.215397|2018-06-01 03:51:04.215397
NCT00361920|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2017-03-27|2006-08-08|2006-08-09|Estimate|||||||2017-03-27|2017-03-29|Actual|August 2006||2006-08-31|March 2017|2017-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Cell Biology of Steroid Resistant Asthma|Investigating Biomarkers of Steroid Resistant Asthma|Completed||N/A|40|Actual|National Jewish Health|||||f||||||||||||||2018-06-01 03:51:04.481289|2018-06-01 03:51:04.481289
NCT00361907|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2016-08-08|2006-08-08|2006-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2005||2005-02-28|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes|Effect of Pulsatile IV Insulin Delivery on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes|Terminated||Phase 2/Phase 3|105|Actual|Florida Atlantic University||2||Administrative - Suspended by IRB|f||||t||||||||||2018-06-01 03:51:04.571321|2018-06-01 03:51:04.571321
NCT00361894|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2014-10-24|2006-08-08|2006-08-09|Estimate|||||||2014-10-24|2014-10-27|Estimate|February 2006||2006-02-28|October 2014|2014-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|RECORD 3||Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.|RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.|Completed||Phase 3|2531|Actual|Bayer||2|||f||||||||||||||2018-06-01 03:51:04.734601|2018-06-01 03:51:04.734601
NCT00361881|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2008-08-14|2006-08-08|2006-08-09|Estimate|||||||2008-08-14|2008-08-18|Estimate|July 2006||2006-07-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis|A Randomized, Double-Blind, Active Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis|Completed||Phase 3|1443|Actual|Medivir||3|||f||||f||||||||||2018-06-01 03:51:05.045584|2018-06-01 03:51:05.045584
NCT00361868|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2008-06-26|2006-08-08|2006-08-09|Estimate|||||||2008-06-26|2008-06-27|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI|A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia|Terminated||Phase 3|88|Anticipated|Solvay Pharmaceuticals||2||The study was discontinued prematurely at the end of March 2007 due to slow enrolment.|f||||t||||||||||2018-06-01 03:51:05.135793|2018-06-01 03:51:05.135793
NCT00361855|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2008-09-09|2006-08-07|2006-08-09|Estimate|||||||2008-09-09|2008-09-10|Estimate|April 2006||2006-04-30|September 2008|2008-09-30||||||||Interventional|||Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle|A Phase 1 Open Label Dose Escalation Study Evaluate The Safety Of a Single Escalating Dose Of NX-CP105 (Human Adult Bone Marrow Derived Somatic Cells [hABM-SC] Administered by Endomyocardial Injection To Cohorts Of Adults 30-60 Days Following Acute Myocardial Infarction|Completed||Phase 1|18|Anticipated|Neuronyx|||||||||||||||||||2018-06-01 03:51:05.475098|2018-06-01 03:51:05.475098
NCT00361842|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07||2012-05-16|2016-07-25|2006-08-07|2006-08-09|Estimate||||2012-05-16|2012-05-18|Estimate|2016-07-25|2016-07-28|Estimate|July 2006||2006-07-31|May 2012|2012-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer|Multicenter, Open-Label, Phase 2 Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Carcinoma|Completed||Phase 2|59|Actual|Jazz Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:51:05.644919|2018-06-01 03:51:05.644919
NCT00361829|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2018-04-24|2006-08-08|2006-08-09|Estimate|||||||2018-04-24|2018-04-25|Actual|February 17, 1988||1988-02-17|April 17, 2018|2018-04-17||||||||Observational|||The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development|Specificity of Mother-Infant Interaction: The Influence of Maternal Age, Employment Status, and Parenthood Status|Active, not recruiting|||2355|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:05.786116|2018-06-01 03:51:05.786116
NCT00361803|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2017-11-13|2006-08-07|2006-08-09|Estimate|||||||2017-11-13|2017-11-17|Actual|September 12, 2006|Actual|2006-09-12|November 2017|2017-11-30|August 9, 2007|Actual|2007-08-09|August 9, 2007|Actual|2007-08-09||Interventional|||Topotecan Pharmacokinetic Characterization Study|A Phase I Study to Characterize the Pharmacokinetics of 4 mg/m2 Weekly Intravenous Topotecan in Patients With Cancer|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:51:05.931782|2018-06-01 03:51:05.931782
NCT00361790|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2013-11-07|2006-08-08|2006-08-09|Estimate|||||||2013-11-07|2013-11-08|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Aripiprazole and Lexapro Drug Interaction Study|Effects on Aripiprazole on the Steady-State Pharmacokinetics of Escitalopram in Healthy Subjects|Completed||Phase 1|25||Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-06-01 03:51:06.007146|2018-06-01 03:51:06.007146
NCT00361777|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-08|||2018-04-04|2006-08-08|2006-08-09|Estimate|||||||2018-04-04|2018-04-05|Actual|September 19, 2002||2002-09-19|May 4, 2017|2017-05-04||||||||Observational|||Diagnostic Performance of Screening Tests for Cushing s Syndrome|The Diagnostic Performance of Screening Tests for the Diagnosis of Cushing's Syndrome|Active, not recruiting|||471|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:06.092543|2018-06-01 03:51:06.092543
NCT00361751|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2010-02-12|2006-08-07|2006-08-09|Estimate|||||||2010-02-12|2010-02-15|Estimate|May 2003||2003-05-31|February 2010|2010-02-28|May 2005|Actual|2005-05-31|||||Interventional|||Substrate Cycling in Energy Metabolism|Phase 2 Trial to Examine the Metabolic Effects of Fenofibrate in Burned Patients|Completed||Phase 2|40||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:51:06.194793|2018-06-01 03:51:06.194793
NCT00361738|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2009-02-06|2006-08-07|2006-08-08|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Response, Multicentre, Multinational Study Evaluating the Efficacy and Safety of AVE2268 Administered Either Twice Daily (Breakfast and Lunch) at a Dose of 300, 600 and 1200 mg or Once Daily (Breakfast) at a Dose of 1200 mg, in Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled|Completed||Phase 2|317|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:51:06.274814|2018-06-01 03:51:06.274814
NCT00361725|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2006-08-09|2006-08-07|2006-08-08|Estimate|||||||2006-08-09|2006-08-15|Estimate|March 2003||2003-03-31|June 2006|2006-06-30|October 2003||2003-10-31|||||Observational|||Comparative Study of the Protein C Pathway in Septic and Non Septic Patients With Organ Failure|Comparative Study of the Protein C Pathway in Septic and Non Septic Patients|Terminated|||90||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:51:06.366634|2018-06-01 03:51:06.366634
NCT00361712|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|2016-11-24||2018-03-12|2006-08-06|2006-08-08|Estimate|2018-03-06|2018-03-12|Actual||||2018-03-12|2018-04-09|Actual|July 2006||2006-07-31|March 2018|2018-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effect of Preemptive Epidural Analgesia in Labor on Cytokine Production|Effect of Preemptive Epidural Analgesia in Labor on Pro and Anti-inflammatory Cytokine Production in a Mother and a Newborn|Completed||Phase 4|41|Actual|Rabin Medical Center||2|||f||||f|f|f|||f|||No||2018-06-01 03:51:06.458617|2018-06-01 03:51:06.458617
NCT00361699|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2016-04-22|2006-08-07|2006-08-08|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2004||2004-03-31|April 2016|2016-04-30||||July 2014|Actual|2014-07-31||Interventional|||hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)|Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon the Serum High Sensitive CRP in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.|Completed||Phase 3|1095|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||||||||||||2018-06-01 03:51:06.756289|2018-06-01 03:51:06.756289
NCT00361686|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|||2015-11-23|2006-08-06|2006-08-08|Estimate|||||||2015-11-23|2015-11-24|Estimate|January 2006||2006-01-31|July 2006|2006-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Comparison of Tramadol vs Remifentanyl Patient Controlled Analgesia for Second Trimester Abortions|Randomized Double Blind Study Comparing Patient Controlled Analgesia With Tramadol vs. Remifentanyl for Women Undergoing 2nd Trimester Abortions|Completed||N/A|40|Anticipated|Rabin Medical Center|||||f||||||||||||||2018-06-01 03:51:07.783836|2018-06-01 03:51:07.783836
NCT00361673|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2013-12-23|2006-08-04|2006-08-08|Estimate|||||||2013-12-23|2013-12-25|Estimate|September 2006||2006-09-30|December 2013|2013-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Evaluating the Effect of Neighborhood Environments on Cardiovascular Risk Factors|Reducing CVD (Cardiovascular Disease) Risk and Health Disparities Through Active Living Communities|Completed|||1140|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-06-01 03:51:07.955915|2018-06-01 03:51:07.955915
NCT00361660|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2015-06-25|2006-08-07|2006-08-08|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|December 2007|Anticipated|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||The Effect of Different Schedules of Functional Task Practice for Improving Hand and Arm Function After Stroke|The Impact of Functional Task Practice Dosing on Motor Control in Hemiplegia From Chronic Stroke|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||"project was only internally funded and would complete for subjects with 2 newer externally~   funded projects"|f||||f||||||||||2018-06-01 03:51:08.055394|2018-06-01 03:51:08.055394
NCT00361647|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2008-06-10|2006-08-07|2006-08-08|Estimate|||||||2008-06-10|2008-06-13|Estimate|January 2006||2006-01-31|June 2008|2008-06-30||||May 2008|Actual|2008-05-31||Interventional|||Screening for Occult Malignancy in Idiopathic Venous Thromboembolism||Completed||N/A|||University of Padova|||||f||||||||||||||2018-06-01 03:51:08.162114|2018-06-01 03:51:08.162114
NCT00361634|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2010-08-13||2013-07-10|2006-08-04|2006-08-08|Estimate|2013-07-10|2013-09-17|Estimate||||2013-07-10|2013-09-17|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis|DCE-MRI of the Wrist to Measure Short-Term Responses in Rheumatoid Arthritis Subjects Treated With Etanercept|Completed||Phase 1|14|Actual|Amgen||1|||t||||||||||||||2018-06-01 03:51:08.346282|2018-06-01 03:51:08.346282
NCT00361621|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2012-11-30|2006-08-07|2006-08-08|Estimate|||||||2012-11-30|2012-12-03|Estimate|July 2006||2006-07-31|October 2009|2009-10-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional|||Ph II CHOP+Velcade in Mediastinal LBCL|Phase II Study of CHOP/Rituxan Plus VELCADE in Mediastinal Large B-cell Lymphoma|Terminated||Phase 2|3|Actual|Dana-Farber Cancer Institute||||Closed due to slow accrual|f||||||||||||||2018-06-01 03:51:09.646019|2018-06-01 03:51:09.646019
NCT00361608|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|||2016-07-17|2006-08-06|2006-08-08|Estimate|||||||2016-07-17|2016-07-19|Estimate|July 2008||2008-07-31|April 2008|2008-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device|Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device|Withdrawn|||0|Actual|EarlySense Ltd.|||||f||||||||||||||2018-06-01 03:51:09.817926|2018-06-01 03:51:09.817926
NCT00361595|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2010-10-13||2017-03-23|2006-08-04|2006-08-08|Estimate|2010-12-14|2011-01-14|Estimate||||2017-03-23|2017-04-21|Actual|August 2006||2006-08-31|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women|Open Label Proof of Concept Study of IV Zoledronic Acid (ZA) 5 mg After Forteo in Postmenopausal Women|Completed||N/A|35|Actual|The Cleveland Clinic||1|||f||||f||||||||No||2018-06-01 03:51:09.955669|2018-06-01 03:51:09.955669
NCT00361582|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04||2011-06-03|2011-06-03|2006-08-04|2006-08-08|Estimate||||2011-06-03|2011-06-15|Estimate|2011-06-03|2011-06-15|Estimate|October 2006||2006-10-31|April 2010|2010-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery|A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in Subjects Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease|Completed||Phase 3|669|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:51:10.384916|2018-06-01 03:51:10.384916
NCT00361569|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2008-12-22||2015-03-30|2006-08-04|2006-08-08|Estimate|2009-03-12|2009-04-14|Estimate||||2015-03-30|2015-04-20|Estimate|August 2006||2006-08-31|March 2015|2015-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Compare the Effects of 12 Weeks of Treatment With DR-2041(Synthetic Conjugated Estrogens, A) Vaginal Cream vs. Placebo Vaginal Cream on Vulvovaginal Atrophy in Healthy Postmenopausal Women|Completed||Phase 3|622|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-06-01 03:51:10.493866|2018-06-01 03:51:10.493866
NCT00361556|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2014-03-11|2006-08-04|2006-08-08|Estimate|||||||2014-03-11|2014-03-13|Estimate|October 2005||2005-10-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Treatment for Nonspecific Low Back Pain in Primary Care: a Trial on Different Health Education Booklets|Treatment for Nonspecific Low Back Pain in Primary Care With Standardized Health Education Booklets: A Randomized Controlled Clinical Trial|Completed||Phase 2|240|Anticipated|Kovacs Foundation||3|||f||||t||||||||||2018-06-01 03:51:11.29381|2018-06-01 03:51:11.29381
NCT00361543|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2015-01-28|2006-08-07|2006-08-08|Estimate|||||||2015-01-28|2015-01-30|Estimate|August 2006||2006-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SERM||Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia|Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?|Completed||Phase 4|54|Actual|The Alfred||2|||f||||||||||||||2018-06-01 03:51:11.436688|2018-06-01 03:51:11.436688
NCT00361530|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2016-04-22|2006-08-07|2006-08-08|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2004||2004-03-31|April 2016|2016-04-30||||July 2014|Actual|2014-07-31||Interventional|||Carotid Intima-media Thickness in Japan Statin Treatment Against Recurrent Stroke(J-STARS Echo)|Effect of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) Reductase Inhibitor Upon Carotid Intima-media Complex Thickness in the Post-ischemic Patients With Hyperlipidemia During the Prospective Study of J-STARS.|Completed||Phase 3|854|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||||||||||||2018-06-01 03:51:11.540783|2018-06-01 03:51:11.540783
NCT00361517|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|||2009-06-23|2006-08-06|2006-08-08|Estimate|||||||2009-06-23|2009-06-25|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|June 2009|Anticipated|2009-06-30|October 2007|Actual|2007-10-31||Interventional|||To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early|Using Serum Galactomannan Levels in a Prospective, Randomised, Non-Blinded Trial to Guide Early Anti-Fungal Therapy in Haematology Patients at Risk of Invasive Aspergillosis.|Terminated||Phase 3|47|Actual|Singapore General Hospital||2||Gm test became routinely available. We could not compare the two arms anymore.|f||||t||||||||||2018-06-01 03:51:11.648557|2018-06-01 03:51:11.648557
NCT00361504|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2009-07-24||2014-04-10|2006-08-04|2006-08-08|Estimate|2009-07-30|2009-09-04|Estimate||||2014-04-10|2014-04-29|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain|A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain|Completed||Phase 3|1123|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 03:51:11.89914|2018-06-01 03:51:11.89914
NCT00361491|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2009-01-15|2006-08-07|2006-08-08|Estimate|||||||2009-01-15|2009-01-16|Estimate|August 2006||2006-08-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|LENA||An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder|An Eight-Week, Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled Study Evaluating the Efficacy, and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Patients With Major Depressive Disorder|Completed||Phase 2|324|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:51:12.559209|2018-06-01 03:51:12.559209
NCT00361478|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2008-08-11|2006-08-07|2006-08-08|Estimate|||||||2008-08-11|2008-08-13|Estimate|July 2005||2005-07-31|July 2006|2006-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effect of the 'Mother and Baby' Program on Well-Being|Effect of the 'Mother and Baby' Program on New Mothers' Psychological and Physical Well-Being.|Completed||Phase 3|160|Actual|University of Melbourne||2|||f||||f||||||||||2018-06-01 03:51:12.63923|2018-06-01 03:51:12.63923
NCT00361465|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2011-03-25|2006-08-07|2006-08-08|Estimate|||||||2011-03-25|2011-03-28|Estimate|August 2006||2006-08-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|||||Observational|||DYSCAR: Characterization of Dystonia|Characterization of Dystonia and Influence of Cognitive-attentional Factors|Completed|||75|Anticipated|University Hospital, Grenoble|||4||f||||f||||||||||2018-06-01 03:51:12.725297|2018-06-01 03:51:12.725297
NCT00361452|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|||2006-08-06|2006-08-06|2006-08-08|Estimate|||||||2006-08-06|2006-08-08|Estimate|December 2000||2000-12-31|November 2000|2000-11-30|May 2001||2001-05-31|||||Interventional|||Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study|Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study|Terminated||Phase 4|30||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:51:12.79592|2018-06-01 03:51:12.79592
NCT00361439|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2012-07-20||2014-01-27|2006-08-04|2006-08-08|Estimate|2012-07-20|2012-08-23|Estimate||||2014-01-27|2014-02-28|Estimate|August 2006||2006-08-31|January 2014|2014-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis|Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis|Terminated||Phase 4|17|Actual|University of Chicago|Early termination due to slow accrual|2||Study stopped early due to slow accrual.|f||||f||||||||||2018-06-01 03:51:12.875861|2018-06-01 03:51:12.875861
NCT00361413|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2015-04-19|2006-08-06|2006-08-08|Estimate|||||||2015-04-19|2015-04-21|Estimate|June 2006||2006-06-30|December 2010|2010-12-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Alefacept for Prevention of Graft Versus Host Disease (GVHD)|An Investigator Initiated Double Blind Randomized Study of Alefacept Treatment Prevention of Graft Versus Host Disease in Myeloablative Stem Cell Transplantation|Terminated||Phase 3|26|Actual|Hadassah Medical Organization||2||company withdrawal of the drug|f||||f||||||||||2018-06-01 03:51:13.204815|2018-06-01 03:51:13.204815
NCT00361400|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2013-08-01|2006-08-04|2006-08-08|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 2005||2005-08-31|August 2013|2013-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study|Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study|Completed|||1387|Actual|University of California, San Francisco|||||f||||||||||Samples Without DNA|"~     urine for pregnancy testing~   "|||2018-06-01 03:51:13.27619|2018-06-01 03:51:13.27619
NCT00361387|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2011-02-23|2006-08-07|2006-08-08|Estimate|||||||2011-02-23|2011-02-24|Estimate|June 2006||2006-06-30|February 2011|2011-02-28|January 2008|Actual|2008-01-31|June 2007|Actual|2007-06-30||Interventional|||Use of Focalin for Fatigue in Sarcoidosis|Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.|Completed||Phase 4|12|Anticipated|University of Cincinnati|||||f||||f||||||||||2018-06-01 03:51:13.333125|2018-06-01 03:51:13.333125
NCT00361374|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2014-04-03||2014-07-17|2006-08-04|2006-08-08|Estimate|2014-07-17|2014-07-18|Estimate||||2014-07-17|2014-07-18|Estimate|July 2006||2006-07-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||We randomized 196 of 389 screened patients. Nineteen subjects dropped out before completing at least one post-baseline visit, leaving 177 evaluable subjects for analysis.|Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression|Omega-3 Fatty Acids for Treatment of Major Depression: Differential Effects of EPA and DHA, and Associated Biochemical and Immune Parameters|Completed||Phase 3|196|Actual|Massachusetts General Hospital|The study was underpowered due to lower than expected recruitment. The high placebo response rate may have impeded signal detection. The n-3 preparations were not pure, but “enriched” for one n-3 or the other, and contained other FAs.|3|||f||||t||||||||||2018-06-01 03:51:13.406865|2018-06-01 03:51:13.406865
NCT00361361|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2008-02-19|2006-08-07|2006-08-08|Estimate|||||||2008-02-19|2008-02-20|Estimate|July 2006||2006-07-31|November 2006|2006-11-30|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||The Efficacy of 308nm Excimer Laser in White Striae|The Efficacy of 308nm Excimer Laser in White Striae|Completed||Phase 1|10|Anticipated|Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:51:13.777766|2018-06-01 03:51:13.777766
NCT00361348|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2014-11-05|2006-08-04|2006-08-08|Estimate|||||||2014-11-05|2014-11-06|Estimate|December 2005||2005-12-31|November 2014|2014-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Palifermin DDI (Drug Drug Interaction)|An Open-label, Randomized, 2-part, Parallel Design Study to Characterize the Effect of Heparin on Palifermin Pharmacokinetics and the Effect of Palifermin on Heparin Pharmacodynamics in Healthy Subjects|Completed||Phase 1|45||Swedish Orphan Biovitrum||3|||f||||f||||||||||2018-06-01 03:51:13.841271|2018-06-01 03:51:13.841271
NCT00361335|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2010-02-24||2014-07-23|2006-08-04|2006-08-08|Estimate|2012-07-23|2012-08-24|Estimate||||2014-07-23|2014-07-29|Estimate|September 2006||2006-09-30|July 2014|2014-07-31|September 2009|Actual|2009-09-30|December 2007|Actual|2007-12-31||Interventional|||A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 3|643|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients.|5|||f||||t||||||||||2018-06-01 03:51:13.99005|2018-06-01 03:51:13.99005
NCT00361322|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|||2006-08-06|2006-08-06|2006-08-08|Estimate|||||||2006-08-06|2006-08-08|Estimate|April 2005||2005-04-30|August 2006|2006-08-31|January 2006||2006-01-31|||||Interventional|||Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris|Topical Clindamycin Salicylic Acid Preparation for the Treatment of Acne Vulgaris|Completed||Phase 1/Phase 2|40||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:51:15.864872|2018-06-01 03:51:15.864872
NCT00361309|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2014-03-16|2006-08-04|2006-08-08|Estimate|||||||2014-03-16|2014-03-18|Estimate|April 2006||2006-04-30|March 2014|2014-03-31|March 2009|Actual|2009-03-31|November 2007|Actual|2007-11-30||Interventional|||SU011248 in Advanced Hepatocellular Carcinoma|A Phase II Study of SU011248 in Advanced Hepatocellular Carcinoma|Completed||Phase 2|34|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 03:51:15.935533|2018-06-01 03:51:15.935533
NCT00361296|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2015-10-30|2006-08-04|2006-08-08|Estimate|||||||2015-10-30|2015-11-02|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes|K562/GM-CSF Vaccination in Patients With Myelodysplastic Syndrome|Unknown status|Active, not recruiting|Early Phase 1|7|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 03:51:16.103275|2018-06-01 03:51:16.103275
NCT00361283|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2012-03-09||2012-04-16|2006-08-04|2006-08-08|Estimate|2012-04-16|2012-05-15|Estimate||||2012-04-16|2012-05-15|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis|Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis|Completed||Phase 4|108|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 03:51:16.203651|2018-06-01 03:51:16.203651
NCT00361270|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2014-11-13||2017-10-18|2006-08-04|2006-08-08|Estimate|2015-08-06|2015-08-26|Estimate||||2017-10-18|2017-11-21|Actual|October 1, 2006|Actual|2006-10-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|February 15, 2010|Actual|2010-02-15||Interventional|CLBP||Treatment of Veterans With Chronic Low Back Pain|Treatment of Veterans With Chronic Low Back Pain|Active, not recruiting||N/A|161|Actual|VA Office of Research and Development|The study is done on a population of Veterans and may not generalize to the larger population. The same provider administered treatment for all four groups.|4|||f||||f|f|f|||f|||No||2018-06-01 03:51:16.371952|2018-06-01 03:51:16.371952
NCT00361257|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2011-01-28||2016-01-07|2006-08-04|2006-08-08|Estimate|2011-06-27|2011-07-26|Estimate||||2016-01-07|2016-02-05|Estimate|March 2007||2007-03-31|January 2016|2016-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults|Phase II, Randomized, Placebo-Controlled, Double-Blind Study of Minocycline in the Treatment of HIV-Associated Cognitive Impairment|Terminated||Phase 2|107|Actual|AIDS Clinical Trials Group|Originally, 100 participants were expected to enroll. As of the early termination notice, 107 participants were randomized, yet not all subjects could complete the 24 week assessment.|2||This study was terminated early due to futility.|f||||t||||||||||2018-06-01 03:51:16.825669|2018-06-01 03:51:16.825669
NCT00361244|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2017-02-16|2006-08-04|2006-08-08|Estimate|||||||2017-02-16|2017-02-17|Actual|July 2006|Actual|2006-07-31|February 2017|2017-02-28|August 2010|Actual|2010-08-31|October 2007|Actual|2007-10-31||Interventional|||SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer|A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer|Terminated||Phase 1/Phase 2|6|Actual|Massachusetts General Hospital||||Slow Accrual|f||||||||||||||2018-06-01 03:51:17.824392|2018-06-01 03:51:17.824392
NCT00361231|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2014-12-03||2016-12-14|2006-08-04|2006-08-08|Estimate|2016-12-14|2017-02-07|Estimate||||2016-12-14|2017-02-07|Estimate|May 2006||2006-05-31|December 2016|2016-12-31|August 2012|Actual|2012-08-31|March 2009|Actual|2009-03-31||Interventional|||Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer|Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer|Completed||Phase 2|35|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-06-01 03:51:17.906382|2018-06-01 03:51:17.906382
NCT00361218|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2013-07-24||2018-04-10|2006-08-04|2006-08-08|Estimate|2013-07-24|2013-09-26|Estimate||||2018-04-10|2018-05-11|Actual|October 2005||2005-10-31|April 2018|2018-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Biological Markers of Response to Treatment in Major Depressive Disorder|Serum Brain-Derived Neurotrophic Factor (BDNF) and QEEG as Biological Markers of Response to (Es)Citalopram Treatment in Major Depressive Disorder|Completed||Phase 3|72|Actual|Massachusetts General Hospital|For the secondary outcome measure, the data were analyzed and reported as part of a larger trial; however, because the analysis could only be done using a proprietary algorithm, the subset for this study could not be independently analyzed.|1|||f||||t||||||||||2018-06-01 03:51:18.196416|2018-06-01 03:51:18.196416
NCT00361205|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-07|||2006-10-16|2006-08-07|2006-08-08|Estimate|||||||2006-10-16|2006-10-17|Estimate|November 2003||2003-11-30|December 2005|2005-12-31|September 2005||2005-09-30|||||Interventional|||Electronic Compliance Monitoring in Parkinson's Disease|Electronic Compliance Monitoring in Parkinson's Disease|Completed||N/A|120||South Glasgow University Hospitals NHS Trust|||||f||||||||||||||2018-06-01 03:51:18.339322|2018-06-01 03:51:18.339322
NCT00361192|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-06|||2006-12-05|2006-08-06|2006-08-08|Estimate|||||||2006-12-05|2006-12-06|Estimate|August 2006||2006-08-31|August 2006|2006-08-31|January 2007||2007-01-31|||||Interventional|||Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis||Unknown status|Recruiting|Early Phase 1|||Shaare Zedek Medical Center|||||||||||||||||||2018-06-01 03:51:18.390249|2018-06-01 03:51:18.390249
NCT00361179|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2006-08-04|2006-08-04|2006-08-07|Estimate|||||||2006-08-04|2006-08-07|Estimate|May 2006||2006-05-31|August 2006|2006-08-31|December 2011||2011-12-31|||||Observational|||Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C|An Extension, Observational Protocol to Evaluate the Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C in the Original Study ML17862|Completed|||320||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:51:18.439966|2018-06-01 03:51:18.439966
NCT00361166|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2007-03-20|2006-08-03|2006-08-07|Estimate|||||||2007-03-20|2007-03-22|Estimate|August 2005||2005-08-31|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone|A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects|Completed||Phase 2|400||ACADIA Pharmaceuticals Inc.|||||||||||||||||||2018-06-01 03:51:18.490392|2018-06-01 03:51:18.490392
NCT00361153|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2008-06-24|2006-08-03|2006-08-07|Estimate|||||||2008-06-24|2008-06-25|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|||Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus|Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|35|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 03:51:18.628295|2018-06-01 03:51:18.628295
NCT00361140|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2013-01-30||2017-01-20|2006-08-03|2006-08-07|Estimate|2013-04-24|2013-06-27|Estimate||||2017-01-20|2017-03-03|Actual|August 2005||2005-08-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)|Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT)|Completed||Phase 4|72|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||t||||||||||2018-06-01 03:51:18.717543|2018-06-01 03:51:18.717543
NCT00361127|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2016-01-27|2006-08-04|2006-08-07|Estimate|||||||2016-01-27|2016-01-28|Estimate|August 2006||2006-08-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure|Influence of ACE Genotype on Lung Diffusion at Rest and After Fluid Overload in Heart Failure Patients Treated With ACE-inhibitors|Completed||N/A|100|Actual|Centro Cardiologico Monzino||1|||f||||||||||||||2018-06-01 03:51:19.053228|2018-06-01 03:51:19.053228
NCT00361114|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2017-01-25|2006-08-03|2006-08-07|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2006||2006-07-31|January 2017|2017-01-31|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.|Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Uncomplicated Malaria and in 2-10 Month Old Asymptomatic Infants.|Terminated||Phase 3|112|Actual|London School of Hygiene and Tropical Medicine||3||SP arms were stopped due to high levels of treatment failure.CD not available.|f||||t||||||||||2018-06-01 03:51:19.123958|2018-06-01 03:51:19.123958
NCT00361101|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2014-02-10|2006-08-03|2006-08-07|Estimate|||||||2014-02-10|2014-02-11|Estimate|October 2005||2005-10-31|February 2014|2014-02-28|April 2010|Actual|2010-04-30|August 2006|Actual|2006-08-31||Interventional|||A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus|Multicenter, Dose-finding Safety and Activity Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus.|Completed||Phase 1|10|Actual|Sanofi|||||f||||f||||||||||2018-06-01 03:51:19.229437|2018-06-01 03:51:19.229437
NCT00361088|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2013-11-21|2006-08-04|2006-08-07|Estimate|||||||2013-11-21|2013-11-25|Estimate|August 2005||2005-08-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma|A Dose Escalation of Zarnestra (R115777) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma|Terminated||Phase 1/Phase 2|42|Actual|H. Lee Moffitt Cancer Center and Research Institute||2||Initial Principal Investigator left Moffitt|f||||t||||||||||2018-06-01 03:51:19.303532|2018-06-01 03:51:19.303532
NCT00361075|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2014-11-04|2006-08-03|2006-08-07|Estimate|||||||2014-11-04|2014-11-05|Estimate|July 1998||1998-07-31|November 2014|2014-11-30|May 2005|Actual|2005-05-31|||||Interventional|||Midlife Cholesterol Study|Mentored Patient Oriented Research Career Development Award|Completed||Phase 4|120||Northwestern University|||||f||||||||||||||2018-06-01 03:51:19.388583|2018-06-01 03:51:19.388583
NCT00361062|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2010-06-03|2006-08-04|2006-08-07|Estimate|||||||2010-06-03|2010-06-04|Estimate|September 2006||2006-09-30|June 2010|2010-06-30||||July 2008|Actual|2008-07-31||Interventional|||Aggressive Behavior Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) During the First Month of Treatment|Aggressive Behavior Induced by SSRIs During the First Month of Treatment|Unknown status|Recruiting|N/A|60|Anticipated|HaEmek Medical Center, Israel|||||f||||||||||||||2018-06-01 03:51:19.447976|2018-06-01 03:51:19.447976
NCT00361049|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2010-11-04|2006-08-03|2006-08-07|Estimate|||||||2010-11-04|2010-11-05|Estimate|September 2004||2004-09-30|November 2010|2010-11-30|November 2010|Actual|2010-11-30|June 2009|Actual|2009-06-30||Interventional|||Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant|Donor Mesenchymal Stem Cell Infusion for Treatment of Graft Versus Host Disease: A Phase I Trial|Completed||Phase 1|49|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 03:51:19.518803|2018-06-01 03:51:19.518803
NCT00361036|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2011-04-14|2006-08-03|2006-08-07|Estimate|||||||2011-04-14|2011-04-18|Estimate|August 2006||2006-08-31|April 2011|2011-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent|Feasibility Evaluation of the Embolic Agent BeadBlock™ in the Treatment of Uterine Fibroids With Uterine Artery Embolization With Comparison of Study Endpoints to Embosphere®|Completed||Phase 1|44|Actual|Worthington-Kirsch, Robert L., M.D.||2|||f||||f||||||||||2018-06-01 03:51:19.61671|2018-06-01 03:51:19.61671
NCT00361023|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2006-08-04|2006-08-04|2006-08-07|Estimate|||||||2006-08-04|2006-08-07|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|July 2006||2006-07-31|||||Interventional|||Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy|Effects of Angiotensin Type 1 Receptor Blockade With Losartan on Insulin Sensitivity and Secretion in Subjects With Type 2 Diabetes and Nephropathy|Completed||N/A|25||Shanghai Jiao Tong University School of Medicine|||||f||||||||||||||2018-06-01 03:51:19.729806|2018-06-01 03:51:19.729806
NCT00361010|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2011-07-27|2006-08-03|2006-08-07|Estimate|||||||2011-07-27|2011-07-28|Estimate|December 2006||2006-12-31|July 2011|2011-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy|A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy|Completed||N/A|20|Anticipated|The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:51:19.790299|2018-06-01 03:51:19.790299
NCT00360997|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2018-05-10|2006-08-04|2006-08-07|Estimate|||||||2018-05-10|2018-05-16|Actual|March 2006||2006-03-31|May 2018|2018-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Investigation of Acceptable Dose of Mobilisation and Tactile Stimulation to Enhance Upper Limb Recovery After Stroke|Mobilisation and Tactile Stimulation to Enhance Upper Limb Recovery After Stroke: Phase I Investigation of Acceptable Dose, Efficacy and Underlying Mechanisms|Completed||N/A|80|Actual|St George's, University of London||2|||f||||f||||||||||2018-06-01 03:51:19.852017|2018-06-01 03:51:19.852017
NCT00360984|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2006-08-04|2006-08-04|2006-08-07|Estimate|||||||2006-08-04|2006-08-07|Estimate|May 2003||2003-05-31|July 2006|2006-07-31|September 2004||2004-09-30|||||Interventional|||Prevention of Severe Hypoglycemia in Type 1 Diabetes|Can Hypoglycaemia Awareness Be Restored in Individuals With Type 1 Diabetes and Severe Hypoglycaemia Employing Optimised Subcutaneous Insulin Regime or Continuous Subcutaneous Insulin Infusion Pump|Completed||Phase 4|21||Newcastle University|||||f||||||||||||||2018-06-01 03:51:19.929851|2018-06-01 03:51:19.929851
NCT00360971|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2014-04-16||2017-11-28|2006-08-03|2006-08-07|Estimate|2014-04-16|2014-05-15|Estimate||||2017-11-28|2017-12-26|Actual|July 2006||2006-07-31|November 2017|2017-11-30|February 2009|Actual|2009-02-28|May 2008|Actual|2008-05-31||Interventional||All eligible patients.|Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer|A Randomized, Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Palifermin (NSC# 740548; IND # 6370) for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Radiation Therapy With Concurrent Chemotherapy (Followed by Surgery for Selected Patients)|Terminated||Phase 3|21|Actual|Radiation Therapy Oncology Group|This study terminated early with 21 subjects accrued out of 298 planned, therefore no statistical testing was performed. The termination was decided due to positive preliminary results from other palifermin studies.|2||Due to positive preliminary results from other palifermin studies.|f||||t||||||||||2018-06-01 03:51:20.030749|2018-06-01 03:51:20.030749
NCT00360958|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2016-01-27|2006-08-03|2006-08-07|Estimate|||||||2016-01-27|2016-01-28|Estimate|August 2006||2006-08-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Treatment of Severe Heart Failure by Ultrafiltration|Ultrafiltration for the Chronic Treatment of Severe Congestive Heart Failure|Completed||Phase 4|60|Actual|Centro Cardiologico Monzino||2|||f||||||||||||||2018-06-01 03:51:20.512053|2018-06-01 03:51:20.512053
NCT00360945|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2013-09-16|2006-08-03|2006-08-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2004||2004-04-30|November 2006|2006-11-30||||||||Interventional|||Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma|Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse|Unknown status|Active, not recruiting|Phase 2|87|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:51:20.573353|2018-06-01 03:51:20.573353
NCT00360932|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2011-10-28|2006-08-04|2006-08-07|Estimate|||||||2011-10-28|2011-10-31|Estimate|October 2005||2005-10-31|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|FACES||"Facial Lipoatrophy Correction Experience With SCULPTRA (FACES Study)"|An Open-Label Registry Study of the Facial Lipoatrophy Correction Experience With SCULPTRA® in Subjects With Human Immunodeficiency Virus (FACES Study)|Completed||Phase 4|290|Actual|Sanofi|||||f||||f||||||||||2018-06-01 03:51:20.719024|2018-06-01 03:51:20.719024
NCT00360919|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2012-08-06|2006-08-03|2006-08-07|Estimate|||||||2012-08-06|2012-08-07|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Assessing the Presence of Casomorphins in Human Plasma After Dairy Ingestion|Assessing the Presence of Casomorphins in Human Plasma After Dairy Ingestion|Completed||Early Phase 1|28|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-06-01 03:51:20.782179|2018-06-01 03:51:20.782179
NCT00360906|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2006-08-04|2006-08-04|2006-08-07|Estimate|||||||2006-08-04|2006-08-07|Estimate|December 2004||2004-12-31|August 2006|2006-08-31|July 2008||2008-07-31|||||Interventional|||Omega-3 Fatty Acid Treatment in Multiple Sclerosis|Omega-3 Fatty Acid Treatment in Multiple Sclerosis|Completed||Phase 2/Phase 3|100||Haukeland University Hospital|||||f||||||||||||||2018-06-01 03:51:20.856026|2018-06-01 03:51:20.856026
NCT00352924|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2018-05-17|2006-07-14|2006-07-17|Estimate|||||||2018-05-17|2018-05-18|Actual|April 30, 1993||1993-04-30|January 23, 2018|2018-01-23||||||||Observational|||Agriculture Health Study|The Main Agricultural Health Study - A Prospective Study of Cancer and Other Diseases Among Men and Women in Agriculture|Active, not recruiting|||89655|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:38.573654|2018-06-01 03:53:38.573654
NCT00360893|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2017-11-16|2006-08-04|2006-08-07|Estimate|||||||2017-11-16|2017-11-20|Actual|April 1994||1994-04-30|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||Epidemiology of Diabetes Interventions and Complications (EDIC)|Epidemiology of Diabetes Interventions and Complications (EDIC)|Active, not recruiting|||1441|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||Yes|NIDDK Repository|2018-06-01 03:51:20.919792|2018-06-01 03:51:20.919792
NCT00360867|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03||2015-07-13|2015-09-24|2006-08-04|2006-08-07|Estimate||||2015-07-13|2015-08-03|Estimate|2015-09-24|2015-10-15|Estimate|December 2005||2005-12-31|September 2015|2015-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||An Open Label Treatment Extension Study of AMG 706|An Open Label Treatment Extension Study of AMG 706|Terminated||Phase 2|94|Actual|Amgen||1||Amgen decision|f||||||||||||||2018-06-01 03:51:20.977463|2018-06-01 03:51:20.977463
NCT00360854|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2013-09-19|2006-08-03|2006-08-07|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 2005||2005-05-31|June 2007|2007-06-30||||||||Interventional|||Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma|Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma|Unknown status|Active, not recruiting|Phase 1|48|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:51:21.118674|2018-06-01 03:51:21.118674
NCT00360841|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2012-12-04|2006-08-04|2006-08-07|Estimate|||||||2012-12-04|2012-12-06|Estimate|June 2006||2006-06-30|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting|Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting: A Prospective Randomized Double-blind Cross-over Study|Completed||Phase 3|103|Actual|National Taiwan University Hospital||3|||f||||f||||||||||2018-06-01 03:51:21.230859|2018-06-01 03:51:21.230859
NCT00360828|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2011-10-03||2017-02-20|2006-08-03|2006-08-07|Estimate|2011-11-07|2011-12-09|Estimate||||2017-02-20|2017-03-23|Actual|February 2006||2006-02-28|November 2011|2011-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas|A Phase II Study of Irinotecan HCI in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas|Terminated||Phase 2|10|Actual|H. Lee Moffitt Cancer Center and Research Institute|Low accrual prevented us from completing the planned analysis. The initial Principal Investigator (PI) left Moffitt and there were only 10 participants.|1||Principal Investigator left Moffitt and study had low accrual.|f||||t||||||||||2018-06-01 03:51:21.315607|2018-06-01 03:51:21.315607
NCT00360815|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2010-03-01|2006-08-04|2006-08-07|Estimate|||||||2010-03-01|2010-03-02|Estimate|August 1983||1983-08-31|March 2010|2010-03-31|April 1993||1993-04-30|||||Interventional|||Diabetes Control and Complications Trial (DCCT)|Diabetes Control and Complications Trial (DCCT)|Completed||N/A|1441||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 03:51:21.548506|2018-06-01 03:51:21.548506
NCT00360802|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2009-05-27|2006-08-04|2006-08-07|Estimate|||||||2009-05-27|2009-05-28|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Effectiveness of Cognitive Behavioral Treatment and Mindfulness Based Stress Reduction (MBSR) for Chronic Low Back Pain|The Effectiveness of Cognitive Behavioral Treatment and Mindfulness Based Stress Reduction for Chronic Low Back Pain Treated in Pain Clinics|Completed||Phase 2|330|Anticipated|Kovacs Foundation||2|||f||||||||||||||2018-06-01 03:51:21.684961|2018-06-01 03:51:21.684961
NCT00360789|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2015-06-05|2006-08-03|2006-08-07|Estimate|||||||2015-06-05|2015-06-08|Estimate|June 2005||2005-06-30|August 2006|2006-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Evaluation of Whether Functional Strength Training Can Enhance Motor Recovery of the Upper Limb After Stroke|The Effects of Standardized Physical Therapy and Functional Strength Training on Upper Limb Function and Neuromuscular Weakness After Stroke: a Pilot Study|Completed||Phase 1/Phase 2|30|Anticipated|St George's, University of London|||||f||||||||||||||2018-06-01 03:51:21.786802|2018-06-01 03:51:21.786802
NCT00360776|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2017-04-04|2006-08-03|2006-08-07|Estimate|||||||2017-04-04|2017-04-05|Actual|June 2, 2006|Actual|2006-06-02|April 2017|2017-04-30||||May 14, 2007|Actual|2007-05-14||Interventional|||Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia|A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:51:21.865475|2018-06-01 03:51:21.865475
NCT00360763|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2006-08-04|2006-08-04|2006-08-07|Estimate|||||||2006-08-04|2006-08-07|Estimate||||August 2006|2006-08-31|December 2006||2006-12-31|||||Interventional|||Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody||Unknown status|Recruiting|Phase 4|600||Huazhong University of Science and Technology|||||f||||||||||||||2018-06-01 03:51:21.945565|2018-06-01 03:51:21.945565
NCT00360750|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2013-09-16|2006-08-03|2006-08-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2005||2005-09-30|June 2009|2009-06-30||||July 2010|Anticipated|2010-07-31||Interventional|||Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye|A Data Collection Study to Compare the Outcome for Children With Advanced Unilateral Retinoblastoma Treated With or Without Post-Enucleation Chemotherapy ± Radiotherapy on RB 2005 11 With Historical Controls Receiving no Additional Therapy|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:51:22.01983|2018-06-01 03:51:22.01983
NCT00360737|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2011-06-08|2006-08-03|2006-08-07|Estimate|||||||2011-06-08|2011-06-09|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|April 2010|Actual|2010-04-30|December 2006|Actual|2006-12-31||Interventional|||Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses|Pharmacokinetics of a Heptavalent Equine-derived Botulinum Antitoxin (NP-018)|Completed||Phase 1|40|Actual|Cangene Corporation||1|||t||||t||||||||||2018-06-01 03:51:22.114823|2018-06-01 03:51:22.114823
NCT00360724|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2013-10-01||2017-07-20|2006-08-03|2006-08-07|Estimate|2015-10-05|2015-11-03|Estimate||||2017-07-20|2017-08-21|Actual|August 2006||2006-08-31|July 2017|2017-07-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||Duloxetine for Chronic Depression: a Double-blind Study|Duloxetine for Chronic Depression: a Double-blind Study|Completed||Phase 4|65|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-06-01 03:51:22.21397|2018-06-01 03:51:22.21397
NCT00360711|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|||2017-06-30|2006-08-04|2006-08-07|Estimate|||||||2017-06-30|2017-07-02|Actual|June 1, 2006||2006-06-01|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Observational|||Genetic Counselors' Experiences of Moral Value Conflicts With Clients|Genetic Counselors' Experiences of Moral Value Conflicts With Clients|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:22.601955|2018-06-01 03:51:22.601955
NCT00360698|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2009-08-20||2011-08-01|2006-08-04|2006-08-07|Estimate|2009-10-27|2009-12-02|Estimate||||2011-08-01|2011-08-08|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|Basal Plus||Insulin Glulisine in Type 2 Diabetic Patients|Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study.|Completed||Phase 4|106|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:51:22.664174|2018-06-01 03:51:22.664174
NCT00360685|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2012-03-30||2013-03-22|2006-08-03|2006-08-07|Estimate|2013-03-22|2013-05-03|Estimate||||2013-03-22|2013-05-03|Estimate|September 2005||2005-09-30|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX|Safety of Tacrolimus And Methotrexate (MTX) Versus Tacrolimus And Mycophenolate Mofetil (MMF) As Graft Versus Host Disease Prophylaxis In Allogeneic Hematopoietic Cell Transplants (HCT)|Completed||N/A|89|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-06-01 03:51:23.125778|2018-06-01 03:51:23.125778
NCT00360672|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-04|2013-05-31||2013-08-05|2006-08-04|2006-08-07|Estimate|2013-05-31|2013-08-01|Estimate||||2013-08-05|2013-08-14|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome|Phase II Study of Lenalidomide in Patients With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome Associated With Chromosome 5 Abnormalities|Completed||Phase 2|27|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:51:23.355782|2018-06-01 03:51:23.355782
NCT00360659|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2008-04-17|2006-08-03|2006-08-04|Estimate|||||||2008-04-17|2008-04-21|Estimate|February 2004||2004-02-29|April 2008|2008-04-30|February 2005||2005-02-28|||||Interventional|||Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP.||Completed||Phase 4|50||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:51:23.489442|2018-06-01 03:51:23.489442
NCT00360646|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2018-04-18|2006-08-02|2006-08-04|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2004||2004-09-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|ILIAD||Drug-Induced Liver Injury (DILN)Network Retrospective|Idiosyncratic Liver Injury Associated With Drugs (ILIAD): A Retrospective Study|Recruiting|||200|Anticipated|Duke University|||2||f||||t||||||Samples With DNA|"~     Samples with DNA~   "|||2018-06-01 03:51:23.543549|2018-06-01 03:51:23.543549
NCT00360633|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2018-04-19|2006-08-02|2006-08-04|Estimate|||||||2018-04-19|2018-04-20|Actual|June 2006||2006-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Psychiatric and Cognitive Manifestations of Parkinson's Disease|Psychiatric and Cognitive Manifestations of Parkinson's Disease: A Prospective Cohort Study|Enrolling by invitation|||500|Anticipated|New York University School of Medicine|||||f||||t|f|f||||||||2018-06-01 03:51:23.639408|2018-06-01 03:51:23.639408
NCT00360607|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2008-12-01|2006-08-03|2006-08-04|Estimate|||||||2008-12-01|2008-12-02|Estimate|July 2004||2004-07-31|December 2008|2008-12-31|April 2005|Actual|2005-04-30|||||Interventional|||A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections|A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections|Completed||Phase 4|307|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:51:23.715736|2018-06-01 03:51:23.715736
NCT00360594|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2017-01-10|2006-08-02|2006-08-04|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Acamprosate Initiated During Alcohol Detoxification|Initiating Acamprosate Within Versus Post-detoxification in the Rehabilitative Treatment of Alcohol Dependence.|Completed||Phase 2|40|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 03:51:23.805779|2018-06-01 03:51:23.805779
NCT00360581|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2008-02-07|2006-08-02|2006-08-04|Estimate|||||||2008-02-07|2008-02-11|Estimate|April 2006||2006-04-30|February 2008|2008-02-29|January 2008|Actual|2008-01-31|||||Interventional|||Preventing Postpartum Relapse to Smoking Using Yoga and Cognitive Behavioral Therapy: A Randomized Pilot Study|Preventing Postpartum Relapse to Smoking Using Yoga and Cognitive Behavioral Therapy: A Randomized Pilot Study|Completed||Phase 1|30|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 03:51:23.914896|2018-06-01 03:51:23.914896
NCT00360568|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2015-01-12|2013-10-25|2015-01-12|2006-08-03|2006-08-04|Estimate|2015-01-12|2015-01-16|Estimate|2013-10-25|2013-11-18|Estimate|2015-01-12|2015-01-16|Estimate|June 2009||2009-06-30|January 2015|2015-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects|Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects|Completed||Phase 3|62|Actual|AbbVie||1|||f||||t||||||||||2018-06-01 03:51:25.062166|2018-06-01 03:51:25.062166
NCT00360555|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2014-03-27||2016-06-06|2006-08-03|2006-08-04|Estimate|2016-06-06|2016-06-27|Estimate||||2016-06-06|2016-06-27|Estimate|July 2006||2006-07-31|June 2016|2016-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||"Demographic data are available for participants who were included in the treated analysis population of 1,581 participants."|Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder|Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America|Completed||Phase 3|1584|Actual|Sprout Pharmaceuticals, Inc||4|||f||||t||||||||||2018-06-01 03:51:26.675821|2018-06-01 03:51:26.675821
NCT00360529|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2012-03-14||2016-06-06|2006-08-03|2006-08-04|Estimate|2016-06-06|2016-06-27|Estimate||||2016-06-06|2016-06-27|Estimate|July 2006||2006-07-31|June 2016|2016-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder|A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America|Completed||Phase 3|880|Actual|Sprout Pharmaceuticals, Inc||3|||f||||t||||||||||2018-06-01 03:51:27.824984|2018-06-01 03:51:27.824984
NCT00360516|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2011-06-28|2006-08-02|2006-08-04|Estimate|||||||2011-06-28|2011-06-29|Estimate|November 2005||2005-11-30|June 2011|2011-06-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Paleolithic Diet and Exercise Study|Paleolithic Diets, Exercise Physiology and Metabolism|Completed||N/A|10|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 03:51:28.783314|2018-06-01 03:51:28.783314
NCT00360503|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2009-02-06|2006-08-02|2006-08-04|Estimate|||||||2009-02-06|2009-02-10|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|||||Observational|||Antimicrobial Resistance in Cystic Fibrosis (CF)|Antimicrobial Resistance in Sputum Obtained From Patients With Cystic Fibrosis (CF)|Completed|||304|Actual|Seattle Children's Hospital|||||f||||f||||||Samples With DNA|"~     Bacterial isolates~   "|||2018-06-01 03:51:28.843202|2018-06-01 03:51:28.843202
NCT00360490|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2009-10-13||2013-11-14|2006-08-02|2006-08-04|Estimate|2009-10-13|2009-11-19|Estimate||||2013-11-14|2013-12-09|Estimate|July 2006||2006-07-31|November 2013|2013-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)|A Multicenter, Randomized, Open Label, Parallel Group, Active Control Study to Evaluate the Efficacy and Safety of LNG IUS (Mirena®) as Compared to Medroxyprogesterone Acetate During 6 Cycles of Treatment in Patients With Idiopathic Menorrhagia|Completed||Phase 3|165|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:51:28.949689|2018-06-01 03:51:28.949689
NCT00360477|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2016-12-12|2006-08-03|2006-08-04|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2004||2004-06-30|December 2016|2016-12-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||FloSeal Tubeless Exit Versus Cope Loop Nephrostomy Versus Fascial Stitch Following Percutaneous Nephrolithotripsy|Prospective Randomized Trial of Floseal Tubeless Exit vs. Cope Loop Nephrostomy vs. Fascial Stitch Following Percutaneous Nephrolithotripsy|Completed||N/A|59|Actual|University of California, Irvine||3|||f||||f||||||||||2018-06-01 03:51:29.672771|2018-06-01 03:51:29.672771
NCT00360464|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2011-04-20|2006-08-03|2006-08-04|Estimate|||||||2011-04-20|2011-04-21|Estimate|October 2006||2006-10-31|April 2011|2011-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases|A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases In Japan Adults|Completed||Phase 3|64|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:51:29.737963|2018-06-01 03:51:29.737963
NCT00360451|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2015-09-09|2006-08-02|2006-08-04|Estimate|||||||2015-09-09|2015-09-10|Estimate|September 2002||2002-09-30|August 2008|2008-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effectiveness of School-Based Cognitive Behavioral Therapy in Preventing Depression in Young Adolescents|Preventing Depression in School Children|Completed||Phase 3|400|Actual|University of Pennsylvania||3|||f||||||||||||||2018-06-01 03:51:29.818949|2018-06-01 03:51:29.818949
NCT00360438|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2012-07-31|2006-08-02|2006-08-04|Estimate|||||||2012-07-31|2012-08-01|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS|Pharmacokinetic Evaluation of Rasburicase Dosed for 5 Consecutive Days as Uricolytic Therapy in Adult Patients With Leukemia and/or Lymphoma at High or Potential Risk of Tumor Lysis Syndrome (TLS)|Completed||Phase 1/Phase 2|18|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:51:29.884082|2018-06-01 03:51:29.884082
NCT00360425|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2011-11-17|2006-08-02|2006-08-04|Estimate|||||||2011-11-17|2011-11-18|Estimate|May 2006||2006-05-31|October 2007|2007-10-31|August 2006|Actual|2006-08-31|||||Interventional|||A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women|A Phase 1 Active- and Placebo-Controlled Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women|Completed||Phase 1|174||AMAG Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 03:51:29.952538|2018-06-01 03:51:29.952538
NCT00360412|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2012-10-23||2014-06-26|2006-08-03|2006-08-04|Estimate|2013-01-02|2013-02-05|Estimate||||2014-06-26|2014-07-11|Estimate|October 2006||2006-10-31|August 2013|2013-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|Terminated||Phase 3|997|Actual|Eisai Inc.|Due to early termination, a limited number of subjects (only 2) completed this open-label extension study. The majority of subjects did not reach the scheduled Week 56 assessment. Many outcomes could only be analyzed to Week 68 as a result.|1||Study stopped due to lack of efficacy.|f||||||||||||||2018-06-01 03:51:30.053327|2018-06-01 03:51:30.053327
NCT00360399|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2016-06-16||2016-07-27|2006-08-02|2006-08-04|Estimate|2016-06-16|2016-07-28|Estimate||||2016-07-27|2016-08-30|Estimate|August 2006||2006-08-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Participants who consented to participate in the trial and who were randomized to a treatment arm.|Identifying Factors That Predict Antidepressant Treatment Response|Predictors of Antidepressant Treatment Response: The Emory CIDAR|Completed||N/A|344|Actual|Emory University||3|||f||||t||||||||||2018-06-01 03:51:30.716441|2018-06-01 03:51:30.716441
NCT00360386|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2010-08-30|2006-08-03|2006-08-04|Estimate|||||||2010-08-30|2010-08-31|Estimate|March 2004||2004-03-31|August 2010|2010-08-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||"ALBION Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"|Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.|Completed||Phase 2|110||Sanofi|||||f||||||||||||||2018-06-01 03:51:31.349226|2018-06-01 03:51:31.349226
NCT00360373|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2014-01-03|2006-08-02|2006-08-04|Estimate|||||||2014-01-03|2014-01-06|Estimate|August 2005||2005-08-31|January 2014|2014-01-31|February 2012|Actual|2012-02-29|March 2009|Actual|2009-03-31||Observational|||Adolescent Gastric By-pass and Diabetic Precursors|Adolescent Gastric By-pass and Diabetic Precursors|Completed|||30|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||||||2018-06-01 03:51:31.394574|2018-06-01 03:51:31.394574
NCT00360360|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2013-08-15||2013-11-11|2006-08-02|2006-08-04|Estimate|2013-08-15|2013-10-21|Estimate||||2013-11-11|2013-12-04|Estimate|July 2006||2006-07-31|November 2013|2013-11-30|March 2009|Actual|2009-03-31|February 2008|Actual|2008-02-29||Interventional|||Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site|A Phase II Study of Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Patients With Carcinoma of Unknown Primary Site|Completed||Phase 2|60|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 03:51:31.481792|2018-06-01 03:51:31.481792
NCT00360347|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2018-02-27|2006-08-03|2006-08-04|Estimate|||||||2018-02-27|2018-03-01|Actual|November 29, 2001|Actual|2001-11-29|February 2018|2018-02-28|April 29, 2003|Actual|2003-04-29|April 29, 2003|Actual|2003-04-29||Interventional|||A Study of Mircera in Anemic Patients With Multiple Myeloma|Open Label, Randomized, Exploratory Study to Investigate the Hemoglobin Dose-response, the Safety and the Pharmacokinetic Profile Following Subcutaneous Administration of Mircera Once Every Three Weeks to Anemic Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|||Hoffmann-La Roche|||||f||||||f||||||||2018-06-01 03:51:31.788167|2018-06-01 03:51:31.788167
NCT00360334|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2009-04-14||2015-03-19|2006-08-02|2006-08-04|Estimate|2009-04-14|2009-06-05|Estimate||||2015-03-19|2015-04-07|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients|An Open Label Study Comparing Exenatide With Basal Insulin in Achieving an HbA1c of ≤ 7.4% With Minimum Weight Gain, in Type 2 Diabetes Patients Who Are Not Achieving Adequate HbA1c Control on Oral Anti Diabetic Therapies Alone|Completed||Phase 3|235|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:51:31.894647|2018-06-01 03:51:31.894647
NCT00360321|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2006-08-03|2006-08-03|2006-08-04|Estimate|||||||2006-08-03|2006-08-04|Estimate||||July 2006|2006-07-31||||||||Observational|||Descriptive Study of a French Sample of “at Risk” and Pathological Gamblers Followed in a French Structure Specialised in Addictive Disorders.|Descriptive Study of a French Sample of “at Risk” and Pathological Gamblers Followed in a French Structure Specialised in Addictive Disorders.|Unknown status|Not yet recruiting||||Nantes University Hospital|||||f||||||||||||||2018-06-01 03:51:32.834962|2018-06-01 03:51:32.834962
NCT00360308|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2012-10-23||2014-06-26|2006-08-03|2006-08-04|Estimate|2012-10-23|2012-11-22|Estimate||||2014-06-26|2014-07-11|Estimate|November 2006||2006-11-30|August 2013|2013-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-centre, Randomised, Double-blind, Placebo and Entacapone Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|Terminated||Phase 3|723|Actual|Eisai Inc.||3||Study stopped due to lack of efficacy.|f||||||||||||||2018-06-01 03:51:32.897563|2018-06-01 03:51:32.897563
NCT00360295|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2008-05-19|2006-08-03|2006-08-04|Estimate|||||||2008-05-19|2008-05-20|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults|A Multicenter, Non-Randomized, Open Label Trial Of Azithromycin SR For The Treatment Of Mild To Moderate Community Acquired Pneumonia In Japanese Adults|Completed||Phase 3|153|Actual|Pfizer|||||f||||||||||||||2018-06-01 03:51:33.475161|2018-06-01 03:51:33.475161
NCT00360282|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2012-11-07||2014-12-04|2006-08-02|2006-08-04|Estimate|2014-12-04|2014-12-08|Estimate||||2014-12-04|2014-12-08|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|March 2010|Actual|2010-03-31|January 2009|Actual|2009-01-31||Interventional||Twenty seven subjects completed screening tests and met study criteria. Twenty five of the 27 subjects enrolled completed both experimental study visits.|Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?|Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs|Completed||N/A|36|Actual|University of Pittsburgh||4|||f||||f||||||||||2018-06-01 03:51:33.60471|2018-06-01 03:51:33.60471
NCT00360269|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2011-11-07||2014-12-08|2006-08-02|2006-08-04|Estimate|2012-03-13|2012-04-09|Estimate||||2014-12-08|2014-12-30|Estimate|November 2005||2005-11-30|December 2014|2014-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Atomoxetine Treatment for ADHD and Marijuana Dependence|Atomoxetine Treatment for ADHD and Marijuana Dependence|Completed||Phase 2|38|Actual|Medical University of South Carolina|Small sample size and poor retention|2|||f||||t||||||||||2018-06-01 03:51:33.807529|2018-06-01 03:51:33.807529
NCT00360256|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2012-04-18|2006-08-02|2006-08-04|Estimate|||||||2012-04-18|2012-04-19|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants|Pharmacogenetic Study of CYP450 2D6 and 2C19 in Patients With Significant Adverse Effects From Antidepressants|Completed|||46|Actual|Augusta University|||2||f||||f||||||||||2018-06-01 03:51:34.143753|2018-06-01 03:51:34.143753
NCT00360243|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|2014-04-25||2016-06-06|2006-08-03|2006-08-04|Estimate|2016-06-06|2016-06-27|Estimate||||2016-06-06|2016-06-27|Estimate|July 2006||2006-07-31|June 2016|2016-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA|6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA|Completed||Phase 3|1385|Actual|Sprout Pharmaceuticals, Inc||4|||f||||t||||||||||2018-06-01 03:51:34.212977|2018-06-01 03:51:34.212977
NCT00360230|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2017-08-04|2009-09-03|2017-08-10|2006-08-03|2006-08-04|Estimate|2017-08-10|2018-02-16|Estimate|2009-09-03|2009-09-04|Estimate|2017-08-10|2018-02-16|Estimate|August 30, 2006|Actual|2006-08-30|August 2017|2017-08-31|May 30, 2008|Actual|2008-05-30|August 25, 2007|Actual|2007-08-25||Interventional|||Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children|A Partially-blind (Observer-blind) Study to Evaluate the Safety and Immunogenicity of 3 Different Vaccination Schedules With 2 GSK Biologicals' Candidate Plasmodium Falciparum Vaccines in Children Aged 5 to 17 Months Living in Ghana|Completed||Phase 2|540|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:51:34.924902|2018-06-01 03:51:34.924902
NCT00360217|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2011-11-17|2006-08-02|2006-08-04|Estimate|||||||2011-11-17|2011-11-18|Estimate|January 2006||2006-01-31|July 2006|2006-07-31|May 2007|Actual|2007-05-31|||||Interventional|||The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes|The Efficacy and Short-Term Safety of Docosahexaenoic Acid (DHA) and Statin Therapy for Subjects With Coronary Artery Disease or Cardiac Risk Equivalents With Moderate Hypertriglyceridemia (IIb)|Completed||N/A|60|Anticipated|Maine Center for Lipids and Cardiovascular Health|||||f||||||||||||||2018-06-01 03:51:36.471978|2018-06-01 03:51:36.471978
NCT00360204|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-03|||2017-07-25|2006-08-03|2006-08-04|Estimate|||||||2017-07-25|2017-07-28|Actual|September 2006||2006-09-30|July 2017|2017-07-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|||Improving Health Outcomes for New Mothers and Babies|Improving Health Outcomes for New Mothers and Babies|Completed||Phase 3|1154|Actual|Milton S. Hershey Medical Center|||||f||||||||||||||2018-06-01 03:51:36.524989|2018-06-01 03:51:36.524989
NCT00360191|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2012-01-10|2006-08-02|2006-08-04|Estimate|||||||2012-01-10|2012-01-12|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence|A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence|Completed||Phase 2|81|Actual|Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:51:36.590298|2018-06-01 03:51:36.590298
NCT00360178|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2016-11-16|2006-08-02|2006-08-04|Estimate|||||||2016-11-16|2016-11-18|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide|An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combination of an Angiotensin Receptor Blocker (Candesartan 32 mg) Plus HCTZ 25 mg|Completed||Phase 3|198|Actual|Novartis|||||f||||||||||||||2018-06-01 03:51:36.663109|2018-06-01 03:51:36.663109
NCT00360152|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2013-07-02|2006-08-02|2006-08-03|Estimate|||||||2013-07-02|2013-07-04|Estimate|August 2006||2006-08-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|January 2009|Actual|2009-01-31||Interventional|||Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes|Minimally Invasive Staging of the Axilla in Breast Cancer: A Pilot Study to Assess the Feasibility of Axillary Ultrasound, Fine Needle Aspiration Biopsy and Molecular Analysis|Completed||Early Phase 1|100|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 03:51:36.732218|2018-06-01 03:51:36.732218
NCT00360139|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2007-08-20|2006-08-02|2006-08-03|Estimate|||||||2007-08-20|2007-08-21|Estimate||||August 2007|2007-08-31|December 2008||2008-12-31|||||Interventional|||Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy|A Phase IV, Prospective, Non-Blinded, Non-Randomized, Single-Center Clinical Trial to Determine the Longevity, Duration, and Volume-Correcting Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy|Withdrawn||Phase 4|15|Anticipated|Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.|||||||||||||||||||2018-06-01 03:51:36.812347|2018-06-01 03:51:36.812347
NCT00360126|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2017-02-13||2017-02-13|2006-08-02|2006-08-03|Estimate|2017-02-13|2017-03-30|Actual||||2017-02-13|2017-03-30|Actual|October 2005||2005-10-31|February 2017|2017-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder|An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode.|Completed||Phase 4|11|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:51:36.880318|2018-06-01 03:51:36.880318
NCT00360100|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2011-05-16|2006-08-02|2006-08-03|Estimate|||||||2011-05-16|2011-05-17|Estimate|August 2006||2006-08-31|May 2011|2011-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media|A Randomized, Multicenter, Comparative Study To Assess Tolerability Of A Single Oral 60 Mg/Kg Dose Of Zmax (Pediatric Concentration) Vs. Zmax (Adult Concentration) In Pediatric Patients With Acute Otitis Media|Completed||Phase 3|120|Actual|Pfizer|||||||||||||||||||2018-06-01 03:51:36.983973|2018-06-01 03:51:36.983973
NCT00360087|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2010-02-11|2006-08-02|2006-08-03|Estimate|||||||2010-02-11|2010-02-12|Estimate|March 2006||2006-03-31|February 2010|2010-02-28|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|ASSET-3||A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study|Long-Term, Open-Label, Multicenter, Extension Study of Bosentan in Patients With Pulmonary Hypertension Associated With Sickle Cell Disease Completing a Double-Blind ASSET Study (AC-052-368 or AC 052-369)|Terminated||Phase 3|236||Actelion||||Slow enrollment|f||||||||||||||2018-06-01 03:51:37.044745|2018-06-01 03:51:37.044745
NCT00360074|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2008-06-06|2006-08-02|2006-08-03|Estimate|||||||2008-06-06|2008-06-09|Estimate|February 2004||2004-02-29|June 2008|2008-06-30|April 2007|Actual|2007-04-30|||||Interventional|||Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation|A Randomised, Controlled, Crossover Study: Treatment With Thyroxin Compared to Thyroxin + Triiodothyronin in Patients With Secondary Hypothyroidism|Completed||Phase 4|25||University Hospital Freiburg|||||f||||||||||||||2018-06-01 03:51:38.08711|2018-06-01 03:51:38.08711
NCT00360061|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2006-08-01|2006-08-01|2006-08-03|Estimate|||||||2006-08-01|2006-08-03|Estimate|September 2001||2001-09-30|June 2001|2001-06-30|June 2005||2005-06-30|||||Interventional|||CBT in Adolescents With Type 1 Diabetes|Randomised Controlled Trial of Cognitive Behaviour Therapy: Efficacy and Acceptability for Adolescents With Type 1 Diabetes.|Completed||N/A|90||University of Bristol|||||f||||||||||||||2018-06-01 03:51:38.157214|2018-06-01 03:51:38.157214
NCT00360048|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2007-12-10|2006-08-02|2006-08-03|Estimate|||||||2007-12-10|2007-12-11|Estimate|August 2006||2006-08-31|December 2007|2007-12-31||||||||Observational|||Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers|Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers|Completed|||10||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:51:38.219296|2018-06-01 03:51:38.219296
NCT00360035|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01||2013-08-16|2013-08-16|2006-08-01|2006-08-03|Estimate||||2013-08-16|2013-08-26|Estimate|2013-08-16|2013-08-26|Estimate|July 2006||2006-07-31|August 2013|2013-08-31|February 2009|Actual|2009-02-28|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia|A Multi-Center, Open-Label, Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Myelofibrosis With Myeloid Metaplasia (MF)|Completed||Phase 2|22|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 03:51:38.283871|2018-06-01 03:51:38.283871
NCT00360022|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2017-04-01|2006-08-02|2006-08-03|Estimate|||||||2017-04-01|2017-04-04|Actual|August 2006|Actual|2006-08-31|April 2017|2017-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)|Improving the Transition of Care From Pediatric GI to Adult GI for Patients With IBD: A Prospective Randomized Trial of a New Model|Terminated||N/A|28|Actual|Vanderbilt University Medical Center||2||problems with subject accrual|f||||f||||||||No||2018-06-01 03:51:38.357741|2018-06-01 03:51:38.357741
NCT00360009|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|2009-08-05||2012-10-25|2006-08-02|2006-08-03|Estimate|2009-12-24|2010-02-02|Estimate||||2012-10-25|2012-10-31|Estimate|January 2004||2004-01-31|October 2012|2012-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease|Cognition and Mood in Parkinson's Disease (PD) in Subthalamic Nucleus (STN) Versus Globus Pallidus Interna (GPi) Deep Brain Stimulation (DBS)|Completed||N/A|62|Actual|University of Florida||3|||f||||t||||||||||2018-06-01 03:51:38.466978|2018-06-01 03:51:38.466978
NCT00359996|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2016-04-11|2006-08-02|2006-08-03|Estimate|||||||2016-04-11|2016-04-12|Estimate|June 2000||2000-06-30|April 2016|2016-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Improving Diabetes Care Collaboratively in the Community|Improving Diabetes Care Collaboratively in the Community|Completed||N/A|6993|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 03:51:39.056654|2018-06-01 03:51:39.056654
NCT00359983|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2012-06-15||2016-11-03|2006-08-02|2006-08-03|Estimate|2012-06-15|2012-07-20|Estimate||||2016-11-03|2016-12-16|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|May 2011|Actual|2011-05-31|November 2007|Actual|2007-11-30||Interventional|||Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB|A Study to Evaluate the Long-term Antibody Persistence at 1, 3 & 5 Years After the Administration of a Fourth Dose of Hib-MenCY-TT Vaccine Compared to ActHIB in Subjects Boosted in a Previous Study.|Completed||Phase 3|270|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:51:39.177168|2018-06-01 03:51:39.177168
NCT00359970|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2015-06-17|2006-08-01|2006-08-03|Estimate|||||||2015-06-17|2015-06-19|Estimate|June 2002||2002-06-30|June 2015|2015-06-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea|Loperamide Plus Azithromycin More Effectively Treats Travelers' Diarrhea In Mexico Than Azithromycin Alone|Completed||Phase 4|176|Actual|The University of Texas Health Science Center, Houston||3|||f||||f||||||||||2018-06-01 03:51:39.640117|2018-06-01 03:51:39.640117
NCT00359957|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2010-03-01|2006-08-01|2006-08-03|Estimate|||||||2010-03-01|2010-03-02|Estimate|July 2006||2006-07-31|March 2010|2010-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|ADVANCE||Efficacy of Increasing Physical Activity to Reduce Children's Visceral Fat|Activity, Diet, and Visceral Adiposity: New Care Emerging (ADVANCE) Project|Completed||Phase 1/Phase 2|29|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 03:51:39.718225|2018-06-01 03:51:39.718225
NCT00359944|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|2011-04-11||2013-05-28|2006-08-01|2006-08-03|Estimate|2013-05-28|2013-07-02|Estimate||||2013-05-28|2013-07-02|Estimate|February 2006||2006-02-28|May 2013|2013-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||132 subjects were from the full analysis set, which was defined as all randomized subjects who took at least one dose of study drug and had greater than/equal to one post-baseline ADAS-Cog assessment|Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|171|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 03:51:39.805701|2018-06-01 03:51:39.805701
NCT00359931|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2017-10-05|2006-08-02|2006-08-03|Estimate|||||||2017-10-05|2017-10-06|Actual|July 28, 2006||2006-07-28|March 7, 2016|2016-03-07|March 7, 2016||2016-03-07|||||Observational|||Brain Imaging of Tinnitus|Neural Modeling and Brain Imaging of Tinnitus|Completed|||58|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:40.321659|2018-06-01 03:51:40.321659
NCT00359918|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2009-08-06|2006-08-01|2006-08-03|Estimate|||||||2009-08-06|2009-08-07|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|LIPSIA STEMI||Randomized Multicenter Trial of Prehospital Initiated Facilitated Percutaneous Coronary Intervention (PCI) Versus Primary PCI in ST-segment-Elevation MI (STEMI)|Randomized, Controlled Multicenter Trial of Prehospital Initiated Facilitated PCI Versus Primary PCI in Patients With STEMI LIPSIA-STEMI Trial|Completed||Phase 4|162|Actual|University of Leipzig|||||f||||t||||||||||2018-06-01 03:51:40.390556|2018-06-01 03:51:40.390556
NCT00359905|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2009-02-18|2006-08-02|2006-08-03|Estimate|||||||2009-02-18|2009-02-19|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|January 2008|Actual|2008-01-31|May 2007|Actual|2007-05-31||Interventional|||Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH|Evaluation of the Efficacy and Safety of Silodosin vs. Tamsulosin and Placebo in the Treatment of the Signs and Symptoms of BPH. Multicentre, Randomised, Double-Blind, Controlled Trial With an Optional Long-Term, Open-Label Extension Phase.|Completed||Phase 3|1228|Actual|Recordati Industria Chimica e Farmaceutica S.p.A.||3|||f||||f||||||||||2018-06-01 03:51:40.454556|2018-06-01 03:51:40.454556
NCT00359892|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2012-08-03|2006-08-02|2006-08-03|Estimate|||||||2012-08-03|2012-08-06|Estimate|July 2006||2006-07-31|August 2012|2012-08-31|November 2008|Actual|2008-11-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma|A Multi-Center, Open-Label Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Relapsed or Refractory Hodgkin's Lymphoma|Completed||Phase 2|13|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 03:51:40.543993|2018-06-01 03:51:40.543993
NCT00359879|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2015-02-20|2006-08-01|2006-08-03|Estimate|||||||2015-02-20|2015-02-23|Estimate|September 2006||2006-09-30|January 2015|2015-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes|Safety and Efficacy of Exenatide Taken Before Lunch and Before Dinner Compared With Before Breakfast and Before Dinner in Patients With Type 2 Diabetes Using Oral Antidiabetic Therapy|Completed||Phase 3|377|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 03:51:40.61114|2018-06-01 03:51:40.61114
NCT00359866|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-02|||2016-06-13|2006-08-02|2006-08-03|Estimate|||||||2016-06-13|2016-06-15|Estimate|February 2006||2006-02-28|June 2016|2016-06-30|January 2016|Actual|2016-01-31|July 2010|Actual|2010-07-31||Interventional|||Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients|Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients|Completed||Phase 1|28|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 03:51:40.706914|2018-06-01 03:51:40.706914
NCT00359853|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2006-08-01|2006-08-01|2006-08-03|Estimate|||||||2006-08-01|2006-08-03|Estimate|September 2000||2000-09-30|June 2004|2004-06-30|March 2005||2005-03-31|||||Interventional|||Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis|Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis|Completed||Phase 4|70||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:51:40.772648|2018-06-01 03:51:40.772648
NCT00359840|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2012-08-30|2006-08-01|2006-08-03|Estimate|||||||2012-08-30|2012-08-31|Estimate|July 2006||2006-07-31|August 2012|2012-08-31||||September 2007|Actual|2007-09-30||Interventional|||A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor|A Randomized, Dose - Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor|Completed||Phase 2|120|Anticipated|Kyowa Hakko Kirin Co., Ltd|||||f||||||||||||||2018-06-01 03:51:40.836784|2018-06-01 03:51:40.836784
NCT00359814|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2009-02-13|2006-08-01|2006-08-02|Estimate|||||||2009-02-13|2009-02-16|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction After Heart Transplantation|Conversion Study to Optimize Immunosuppressive Regimen by Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction for Patients After Heart Transplantation in Lon-Term|Completed||N/A|23|Actual|Hannover Medical School||1|||f||||f||||||||||2018-06-01 03:51:40.914597|2018-06-01 03:51:40.914597
NCT00359801|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2009-12-22||2010-01-29|2006-07-31|2006-08-02|Estimate|2009-12-22|2010-01-27|Estimate||||2010-01-29|2010-02-02|Estimate|July 2006||2006-07-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|VOLUME||Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety|An International, Multicenter, Large Simple Trial To Evaluate The Long-Term Pulmonary And Cardiovascular Safety Of Exubera In Patients With Diabetes Mellitus|Completed||Phase 4|1976|Actual|Pfizer|Pursuant to Pfizer’s announcement that it would exit marketing of Exubera®, study enrollment was halted on 26-October-2007.|2|||f||||t||||||||||2018-06-01 03:51:41.083699|2018-06-01 03:51:41.083699
NCT00359788|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|2009-04-17||2014-05-07|2006-08-01|2006-08-02|Estimate|2009-10-05|2009-11-10|Estimate||||2014-05-07|2014-05-16|Estimate|July 2006||2006-07-31|September 2013|2013-09-30||||April 2008|Actual|2008-04-30||Interventional|||A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.|A Randomized, Double-blind, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium 18 mcg Daily to Combivent MDI 2 Actuations Qid in COPD Patients Previously Prescribed Combivent MDI|Completed||Phase 4|349|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:51:42.665847|2018-06-01 03:51:42.665847
NCT00359775|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2012-02-16|2006-07-31|2006-08-02|Estimate|||||||2012-02-16|2012-02-20|Estimate|July 2006||2006-07-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Coping Skills Training (CST) for Children With Chronic Health Conditions|Coping Skills Training (CST) for Children With Chronic Health Conditions: An Extension From Children With Diabetes to Children With Rheumatologic Conditions, Epilepsy, Spina Bifida, and Asthma|Completed||Phase 2|38|Actual|Children's Hospital and Health System Foundation, Wisconsin|||||f||||||||||||||2018-06-01 03:51:44.977809|2018-06-01 03:51:44.977809
NCT00359762|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2012-03-29||2015-08-17|2006-07-31|2006-08-02|Estimate|2013-02-11|2013-03-14|Estimate||||2015-08-17|2015-09-15|Estimate|September 2006||2006-09-30|August 2015|2015-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Exenatide Versus Glimepiride in Patients With Type 2 Diabetes|Long Term Treatment With Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Pretreated With Metformin (EUREXA: European Exenatide Study)|Completed||Phase 3|1029|Actual|AstraZeneca|Only patients who reached primary endpoint 12 months or more before the projected end of the study could enter period III.|2|||f||||f||||||||||2018-06-01 03:51:45.104472|2018-06-01 03:51:45.104472
NCT00359736|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2013-09-10||2017-09-29|2006-07-31|2006-08-02|Estimate|2014-09-29|2014-10-06|Estimate||||2017-09-29|2017-11-01|Actual|July 2006||2006-07-31|September 2017|2017-09-30|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Interventional|||Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis|Vasodilator Therapy and Exercise Tolerance in IPF Patients|Completed||Phase 2|29|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 03:51:46.857649|2018-06-01 03:51:46.857649
NCT00359723|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2009-09-03|2006-07-31|2006-08-02|Estimate|||||||2009-09-03|2009-09-04|Estimate|July 2004||2004-07-31|September 2009|2009-09-30||||||||Interventional|||Methylphenidate and Parkinson's Disease|Subacute Trial of Methylphenidate in Parkinson's Disease|Completed||Phase 2|24||Oregon Health and Science University|||||f||||||||||||||2018-06-01 03:51:47.076111|2018-06-01 03:51:47.076111
NCT00359710|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2017-06-30|2006-08-01|2006-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|April 19, 2006||2006-04-19|February 23, 2011|2011-02-23|February 23, 2011||2011-02-23|||||Observational|||Patients' Perspectives on Identity, Ancestry and Genetics|Identity, Ancestry and Genetics: Patients' Perspectives|Completed|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:47.127246|2018-06-01 03:51:47.127246
NCT00359697|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2014-11-05|2006-08-01|2006-08-02|Estimate|||||||2014-11-05|2014-11-06|Estimate||||November 2014|2014-11-30||||||||Interventional|||Comparison of Two Different Medications Used to Treat Elevated Intracranial Pressure|Prospective, Randomized Clinical Trialto Compare Mannitol and Hypertonic Saline for Treatment of Increased Intracranial Pressure|Unknown status|Not yet recruiting|Phase 1|50|Anticipated|Thomas Jefferson University|||||f||||||||||||||2018-06-01 03:51:47.170207|2018-06-01 03:51:47.170207
NCT00359684|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2018-03-27|2006-08-01|2006-08-02|Estimate|||||||2018-03-27|2018-03-29|Actual|July 6, 1978||1978-07-06|November 24, 2017|2017-11-24|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Use of Cysteamine in the Treatment of Cystinosis|Natural History Study of the Use of Cysteamine in the Treatment of Cystinosis|Recruiting||Phase 4|300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:47.483663|2018-06-01 03:51:47.483663
NCT00359671|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2016-11-28|2006-08-01|2006-08-02|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2006||2006-12-31|November 2016|2016-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)|Phase I Study Evaluating MK6592 in Combination With Docetaxel in Adult Patients With Relapsed or Refractory Advanced Solid Tumors|Terminated||Phase 1|38|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:51:47.618767|2018-06-01 03:51:47.618767
NCT00359658|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2009-02-12|2006-08-01|2006-08-02|Estimate|||||||2009-02-12|2009-02-13|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation|Conversion Study to Optimize Immunosuppressive Regimen by Withdrawal of Steroids, Cyclosporine A Dose Reduction and a Switch to Mycophenolatmofetile for Patients After Heart Transplantation in the Long-Term.|Completed||N/A|40|Actual|Hannover Medical School||1|||f||||f||||||||||2018-06-01 03:51:47.774778|2018-06-01 03:51:47.774778
NCT00359645|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2017-05-15|2006-08-01|2006-08-02|Estimate|||||||2017-05-15|2017-05-16|Actual|June 21, 2006|Actual|2006-06-21|May 2017|2017-05-31|December 18, 2015|Actual|2015-12-18|December 18, 2015|Actual|2015-12-18||Interventional|||Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population|DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality.|Completed||Phase 3|1993|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||||||||||||2018-06-01 03:51:47.944705|2018-06-01 03:51:47.944705
NCT00359632|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2014-12-16||2015-06-03|2006-07-28|2006-08-02|Estimate|2015-06-03|2015-06-26|Estimate||||2015-06-03|2015-06-26|Estimate|November 2008||2008-11-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater|Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater|Terminated||Phase 3|34|Actual|Pfizer|This pilot study was exploratory and not designed to be powered for safety or efficacy. Controls were not followed post-baseline whereas linezolid patients returned for multiple study visits. The study was terminated early due to slow enrollment.|2||"Study was stopped due to poor enrollment on 28 Feb 2012. Reason for termination was not due to~   safety concerns."|f||||f||||||||||2018-06-01 03:51:48.103569|2018-06-01 03:51:48.103569
NCT00359619|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2012-12-19|2011-02-04|2016-10-11|2006-08-01|2006-08-02|Estimate|2015-01-08|2015-02-10|Estimate|2011-02-04|2011-02-09|Estimate|2016-10-11|2016-11-23|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|August 2009|Actual|2009-08-31|February 2007|Actual|2007-02-28||Interventional|||Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine|A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study|Completed||Phase 2|383|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:51:48.589647|2018-06-01 03:51:48.589647
NCT00359606|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2015-05-05|2006-08-01|2006-08-02|Estimate|||||||2015-05-05|2015-05-06|Estimate|April 1999||1999-04-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer|Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine|Completed||Phase 1|58|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 03:51:51.883578|2018-06-01 03:51:51.883578
NCT00359593|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2008-03-19|2006-07-31|2006-08-02|Estimate|||||||2008-03-19|2008-03-20|Estimate|September 2006||2006-09-30|July 2006|2006-07-31|April 2008|Anticipated|2008-04-30|||||Interventional|||Stroke Canada Optimization of Rehabilitation by Evidence Implementation Trial SCORE-IT)|Stroke Canada Optimization of Rehabilitation by Evidence Implementation Trial (SCORE IT)|Unknown status|Recruiting|Phase 2/Phase 3|2000|Anticipated|Toronto Rehabilitation Institute|||||f||||||||||||||2018-06-01 03:51:52.019286|2018-06-01 03:51:52.019286
NCT00359580|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2018-04-24|2006-08-01|2006-08-02|Estimate|||||||2018-04-24|2018-04-25|Actual|September 18, 1997||1997-09-18|April 10, 2018|2018-04-10||||||||Observational|||Genetic Studies in the Amish and Mennonites|Genetic Studies in the Amish and Mennonites|Completed|||157|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:52.08799|2018-06-01 03:51:52.08799
NCT00359567|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2011-07-06|2006-08-01|2006-08-02|Estimate|||||||2011-07-06|2011-07-07|Estimate|July 2006||2006-07-31|July 2011|2011-07-31|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic Chemotherapy|Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy|Completed||Phase 3|1140|Anticipated|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 03:51:52.147657|2018-06-01 03:51:52.147657
NCT00359554|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2007-02-06|2006-07-31|2006-08-02|Estimate|||||||2007-02-06|2007-02-07|Estimate|September 2006||2006-09-30|February 2007|2007-02-28|October 2007||2007-10-31|||||Interventional|||Influenza Vaccination of Nursing Home Workers.|VAXICOL: Effectiveness of Influenza Vaccination of Nursing Home Workers on Mortality of Nursing Home Residents. A Cluster Randomized Trial.|Terminated||N/A|4000||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:51:52.22508|2018-06-01 03:51:52.22508
NCT00359541|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2017-06-30|2006-08-01|2006-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|January 19, 2006||2006-01-19|June 25, 2010|2010-06-25|June 25, 2010||2010-06-25|||||Observational|||Voriconazole Blood Levels and Toxicity|Voriconazole Plasma Concentration and Toxicity|Completed|||98|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:52.286559|2018-06-01 03:51:52.286559
NCT00359515|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2017-06-30|2006-08-01|2006-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|February 17, 2001||2001-02-17|February 3, 2009|2009-02-03|February 3, 2009||2009-02-03|||||Observational|||Genetic Analysis of Oculocerebrorenal Syndrome of Lowe|Mutation Detection for Lowe Syndrome|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:52.336178|2018-06-01 03:51:52.336178
NCT00359489|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2007-09-13|2006-07-31|2006-08-02|Estimate|||||||2007-09-13|2007-09-17|Estimate|April 2007||2007-04-30|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Observational|||Methods Study to Evaluate Use of Cardiac Ultrasound to Assess Heart Valve Abnormality in People.|A Randomized, Open-Label, Methodology Trial To Investigate The Utility Of Echocardiography In Assessment Of Cardiac Valvular Regurgitation In Adult Subjects|Completed|||30||Pfizer|||||f||||||||||||||2018-06-01 03:51:52.379816|2018-06-01 03:51:52.379816
NCT00359476|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01||2010-02-27|2010-02-27|2006-08-01|2006-08-02|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|March 2007||2007-03-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||A Study of Vinflunine in Patients With Gastric Cancer|A Multicenter, Single-Arm, Phase II Study of Single-Agent Vinflunine in the Second-line Treatment of Patients With Gastric Cancer|Terminated||Phase 2/Phase 3|55|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:51:52.42486|2018-06-01 03:51:52.42486
NCT00359463|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-11-08|2006-07-28|2006-08-02|Estimate|||||||2017-11-08|2017-11-13|Actual|April 18, 2006|Actual|2006-04-18|November 2017|2017-11-30|March 7, 2007|Actual|2007-03-07|March 7, 2007|Actual|2007-03-07||Interventional|||Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment|An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers With Mild, Moderate or Severe Hepatic Impairment|Completed||Phase 1|33|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 03:51:52.501293|2018-06-01 03:51:52.501293
NCT00359450|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01||2010-02-27|2010-02-27|2006-08-01|2006-08-02|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|July 2006||2006-07-31|September 2007|2007-09-30||||March 2007|Actual|2007-03-31||Interventional|||Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)|A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients|Terminated||Phase 2|186||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 03:51:52.575449|2018-06-01 03:51:52.575449
NCT00359437|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01||2016-04-25|2016-04-25|2006-08-01|2006-08-02|Estimate||||2016-04-25|2016-05-24|Estimate|2016-04-25|2016-05-24|Estimate|July 2006||2006-07-31|April 2016|2016-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|SPARe-1||Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver|Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo With Concomitant Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.|Terminated||Phase 3|501|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:51:52.651476|2018-06-01 03:51:52.651476
NCT00359424|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2013-07-04||2013-11-19|2006-07-31|2006-08-02|Estimate|2013-11-19|2013-12-13|Estimate||||2013-11-19|2013-12-13|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|July 2012|Actual|2012-07-31||Interventional|IMSIII|A sample of 900 was calculated to provide an effect size of 10 percentage points assuming that 40% of the patients had a good outcome in the IV t-PA group, as noted in patients in the NINDS rt-PA Stroke Study who had age and baseline stroke severity similar to the eligibility criteria for the IMS3 trial. The trial was halted at 656 subjects.|Interventional Management of Stroke (IMS) III Trial|Interventional Management of Stroke Trial (IMS III): A Phase III Clinical Trial Examining Whether a Combined Intravenous (IV) and Intra-Arterial (IA) Approach to Recanalization is Superior to Standard IV Rt-PA (Activase®) Alone|Terminated||Phase 3|656|Actual|University of Cincinnati|The IMS III trial was stopped early because of futility, according to the prespecified rules. A limitation of our trial is that it did not compare the efficacy of the new stent retrievers with that of intravenous t-PA alone.|2||NINDS/NIH-DSMB recommended halting trial due to futility, no safety concerns.|f||||t||||||||||2018-06-01 03:51:53.950256|2018-06-01 03:51:53.950256
NCT00359411|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2017-06-30|2006-08-01|2006-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|May 22, 1996||1996-05-22|February 1, 2010|2010-02-01|February 1, 2010||2010-02-01|||||Observational|||Genetic Studies of X-linked Lymphoproliferative Disease|Genetic Studies of the X-Linked Lymphoproliferative Disease|Completed|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:57.248874|2018-06-01 03:51:57.248874
NCT00359047|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-11-17|2006-07-28|2006-08-01|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2003||2003-06-30|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|October 2007|Actual|2007-10-31||Interventional|||Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme|Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme|Active, not recruiting||N/A|2830|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-06-01 03:52:01.326299|2018-06-01 03:52:01.326299
NCT00359398|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2016-04-13|2006-08-01|2006-08-02|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Sequestration of Platelets Prior to Bypass Reduces Bleeding After Cardiac Surgery|Post-operative Administration of Platelet Rich Plasma Sequestered Prior to Cardiopulmonary Bypass Reduces the Coagulopathy Associated With Complex Cardiac Surgery|Terminated||Phase 2|30|Actual|Royal Brompton & Harefield NHS Foundation Trust||2||Funding expired, low recruitment|f||||t||||||||||2018-06-01 03:51:57.303979|2018-06-01 03:51:57.303979
NCT00359385|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2011-11-15|2006-08-01|2006-08-02|Estimate|||||||2011-11-15|2011-11-16|Estimate|July 2006||2006-07-31|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|AlenPostPara||The Effects of Alendronate After Cure of Primary Hyperparathyroidism|The Effects of Alendronate After Cure of Primary Hyperparathyroidism|Withdrawn||Phase 4|0|Actual|Columbia University||2||incomplete enrollment|f||||f||||||||||2018-06-01 03:51:57.371579|2018-06-01 03:51:57.371579
NCT00359372|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2017-06-30|2006-08-01|2006-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|July 28, 2006||2006-07-28|May 29, 2007|2007-05-29|May 29, 2007||2007-05-29|||||Observational|||Predicting Response to Cardiac Resynchronization Therapy in Heart Failure|Predicting Response to Cardiac Resynchronization Therapy in Heart Failure|Completed|||180||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:57.520833|2018-06-01 03:51:57.520833
NCT00359359|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2014-11-03|2006-08-01|2006-08-02|Estimate|||||||2014-11-03|2014-11-04|Estimate|July 2006||2006-07-31|November 2014|2014-11-30|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer|Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC)|Completed||Phase 1/Phase 2|26|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:51:57.580573|2018-06-01 03:51:57.580573
NCT00359346|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2017-06-30|2006-08-01|2006-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|July 14, 2006||2006-07-14|April 16, 2009|2009-04-16|April 16, 2009||2009-04-16|||||Observational|||Plasma Exchange for Autoimmune Autonomic Failure|Plasma Exchange for Autoimmune Autonomic Failure|Completed|||3||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:57.68898|2018-06-01 03:51:57.68898
NCT00359333|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2013-10-28|2006-08-01|2006-08-02|Estimate|||||||2013-10-28|2013-10-30|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|STS||Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST|Multiple Centers, Prospective, Phase II Trial of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Locally Advanced/Metastatic Soft Tissue Sarcoma or Imatinib Mesylate Refractory Advanced/Metastatic Malignant Gastrointestinal Stromal Tumor|Completed||Phase 2|58|Actual|National Health Research Institutes, Taiwan||1|||f||||t||||||||||2018-06-01 03:51:57.739401|2018-06-01 03:51:57.739401
NCT00359320|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2015-03-17|2006-08-01|2006-08-02|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2006||2006-07-31|March 2015|2015-03-31|December 2015||2015-12-31|July 2015||2015-07-31||Interventional|||A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy|A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy|Unknown status|Recruiting|N/A|||Thomas Jefferson University|||||f||||||||||||||2018-06-01 03:51:57.81195|2018-06-01 03:51:57.81195
NCT00359307|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2018-05-23|2006-08-01|2006-08-02|Estimate|||||||2018-05-23|2018-05-24|Actual|June 8, 2000||2000-06-08|March 21, 2013|2013-03-21|March 21, 2013||2013-03-21|||||Observational|||Genetic Factors in Atherosclerosis|Chemokine System Polymorphisms and Risk of Atherosclerosis (CAD)|Completed|||1888|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:57.882549|2018-06-01 03:51:57.882549
NCT00359294|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2009-04-20|2006-08-01|2006-08-02|Estimate|||||||2009-04-20|2009-04-21|Estimate|May 2006||2006-05-31|October 2008|2008-10-31|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma|A Phase I Multicenter, Open-Label, Dose-Escalating Clinical and Pharmacokinetic Study of PM00104 Administered Intravenously Over 1 Hour Daily for 5 Days, Every 3 Weeks, to Subjects With Advanced Malignant Solid Tumors or Lymphoma.|Terminated||Phase 1|35|Anticipated|PharmaMar||1||"Considered not necessary to continue with this trial; recommended dose was reached in other~   phase I trials"|f||||t||||||||||2018-06-01 03:51:57.932651|2018-06-01 03:51:57.932651
NCT00359281|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2013-01-18||2018-02-21|2006-08-01|2006-08-02|Estimate|2014-01-15|2014-03-04|Estimate||||2018-02-21|2018-02-23|Actual|March 2006||2006-03-31|February 2018|2018-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents|A Phase II, Fixed-sequenced, Open- Label, Research Study to Assess Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Therapies in Healthy Volunteers|Completed||Phase 2|125|Actual|Aegerion Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:51:58.056661|2018-06-01 03:51:58.056661
NCT00359268|ClinicalTrials.gov processed this data on May 31, 2018|2006-08-01|||2018-03-27|2006-08-01|2006-08-02|Estimate|||||||2018-03-27|2018-03-29|Actual|April 27, 2001||2001-04-27|July 11, 2017|2017-07-11||||||||Observational|||Identification of Viruses Associated With Diseases of Unknown Cause|Identification of Novel Viruses|Enrolling by invitation|||56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:51:58.980296|2018-06-01 03:51:58.980296
NCT00359255|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-05-08|2006-07-28|2006-08-01|Estimate|||||||2017-05-08|2017-05-10|Actual|July 2006||2006-07-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of Additional Arm Therapy on Arm Function After Stroke|The Effect of a Supplementary Exercise Program for Upper Extremity Function in Stroke Rehabilitation|Completed||N/A|120|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 03:51:59.045026|2018-06-01 03:51:59.045026
NCT00359242|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-07-25|2006-07-28|2006-08-01|Estimate|||||||2017-07-25|2017-07-28|Actual|June 2006||2006-06-30|July 2017|2017-07-31|December 2009|Actual|2009-12-31|November 2008|Actual|2008-11-30||Interventional|||The SLeeping and Intake Methods Taught to Infants and Mothers Early in Life (SLIMTIME) Project|Primary Prevention of Obesity Through Infancy Interventions|Completed||Phase 1|160|Actual|Milton S. Hershey Medical Center||4|||f||||||||||||||2018-06-01 03:51:59.119392|2018-06-01 03:51:59.119392
NCT00359229|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2009-09-14|2006-07-31|2006-08-01|Estimate|||||||2009-09-14|2009-09-15|Estimate|July 2006||2006-07-31|September 2009|2009-09-30||||September 2007|Actual|2007-09-30||Interventional|STEP||Stilnox Treatment in Elderly Patients With Insomnia|A Multicentre Prospective, Open Label ,3 Weeks Phase IV Study to Evaluate the Efficacy and Safety in Elder Patients With Insomnia in China|Completed||Phase 4|115|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:51:59.191805|2018-06-01 03:51:59.191805
NCT00357838|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2006-10-17|2006-07-27|2006-07-28|Estimate|||||||2006-10-17|2006-10-18|Estimate|July 2006||2006-07-31|July 2006|2006-07-31||||||||Observational|||Pulse Waves and Tongue Diagnosis Differences Between Follicular and Luteal Phase in Normal Healthy Women||Unknown status|Recruiting||||China Medical University Hospital|||||f||||||||||||||2018-06-01 03:52:28.878581|2018-06-01 03:52:28.878581
NCT00359216|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2009-01-23||2017-03-15|2006-07-31|2006-08-01|Estimate|2009-06-11|2009-08-03|Estimate||||2017-03-15|2017-04-12|Actual|May 2006||2006-05-31|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)|A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Single-Site Study of Mometasone Furoate Nasal Spray (MFNS) In Subjects With Sleep-disordered Breathing Associated With Perennial Allergic Rhinitis (PAR) Using Home-Monitored Cardio-Respiratory Methodology.|Completed||Phase 4|30|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:51:59.24853|2018-06-01 03:51:59.24853
NCT00359203|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2013-05-22||2015-09-28|2006-07-31|2006-08-01|Estimate|2013-10-24|2013-11-18|Estimate||||2015-09-28|2015-09-30|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Interventional|||ISSUE3: International Study on Syncope of Uncertain Etiology 3|ISSUE3: International Study on Syncope of Uncertain Etiology 3 Pacemaker Therapy for Patients With Asystolic Neurally-mediated Syncope|Completed||Phase 4|511|Actual|Medtronic Bakken Research Center||2|||f||||||||||||||2018-06-01 03:51:59.514059|2018-06-01 03:51:59.514059
NCT00359190|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-11-08|2006-07-28|2006-08-01|Estimate|||||||2017-11-08|2017-11-13|Actual|June 29, 2004|Actual|2004-06-29|November 2017|2017-11-30|January 9, 2008|Actual|2008-01-09|January 9, 2008|Actual|2008-01-09||Interventional|||Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer|A Phase I, Open Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Versus Twice Daily Dosing Regimens in Patients With Treatment- Naive Breast Cancer|Completed||Phase 1|28|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:51:59.802668|2018-06-01 03:51:59.802668
NCT00359177|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-09-21|2006-07-28|2006-08-01|Estimate|||||||2017-09-21|2017-09-25|Actual|December 1, 2005|Actual|2005-12-01|September 2017|2017-09-30|October 12, 2006|Actual|2006-10-12|October 12, 2006|Actual|2006-10-12||Interventional|||Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Hepatic Impairment|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:51:59.943701|2018-06-01 03:51:59.943701
NCT00359164|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2008-08-12|2006-07-31|2006-08-01|Estimate|||||||2008-08-12|2008-08-14|Estimate|July 2006||2006-07-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.|A Randomized, Controlled, Double-Masked, Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab (Avastin), in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD)|Completed||Phase 2|36|Anticipated|University of British Columbia||3|||f||||||||||||||2018-06-01 03:52:00.056715|2018-06-01 03:52:00.056715
NCT00359151|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2008-05-22|2006-07-28|2006-08-01|Estimate|||||||2008-05-22|2008-05-30|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Celebrex Total Knee Arthroplasty Study|Multicenter, Double Blind, Randomized, Placebo Controlled Trial Of The Efficacy And Safety Of Usual Care Plus Celecoxib Compared To Placebo For Peri-Operative And Rehabilitation Pain Control And Return To Function In Osteoarthritis Patients Undergoing Total Knee Arthroplasty|Terminated||Phase 4|22|Actual|Pfizer||2||This study was terminated early due to slow enrollment.|f||||f||||||||||2018-06-01 03:52:00.133192|2018-06-01 03:52:00.133192
NCT00359138|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2010-05-27||2015-05-29|2006-07-31|2006-08-01|Estimate|2010-10-07|2010-11-01|Estimate||||2015-05-29|2015-06-26|Estimate|February 2006||2006-02-28|May 2015|2015-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)|A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation|Completed||Phase 4|36|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 03:52:00.213176|2018-06-01 03:52:00.213176
NCT00359125|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2014-01-21|2006-07-28|2006-08-01|Estimate|||||||2014-01-21|2014-01-22|Estimate|July 2006||2006-07-31|January 2014|2014-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||RU-486 in the Treatment of Bipolar Depression|Efficacy of Mifepristone (RU-486) in the Treatment of Bipolar Depression.|Withdrawn||Phase 2|0|Actual|University of British Columbia||2|||f||||||||||||||2018-06-01 03:52:00.464115|2018-06-01 03:52:00.464115
NCT00359112|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-05-15|2006-07-31|2006-08-01|Estimate|||||||2009-05-15|2009-05-18|Estimate|February 2004||2004-02-29|May 2009|2009-05-31||||||||Interventional|||AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes|A Randomised, Multi-Centre, Phase IV, Double-Blind, Parallel Group Study Comparing the Effects of 52 Weeks Administration of AVANDAMET and Metformin Plus Sulphonylurea on Change in HbA1c From Baseline in Overweight Type 2 Diabetics Poorly Controlled on Metformin.|Completed||Phase 3|544||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:52:00.559089|2018-06-01 03:52:00.559089
NCT00359099|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2013-11-25|2006-07-31|2006-08-01|Estimate|||||||2013-11-25|2013-11-27|Estimate|January 1980||1980-01-31|November 2013|2013-11-30|July 2006||2006-07-31|||||Observational|||Hepatitis C in Adults Who Underwent Congenital Heart Surgery Before Screening|Proposal for Retrospective Review of the Prevalence of Hepatitis C Infection in Adult Patients Who Underwent Congenital Heart Surgery Before Screening|Terminated|||1000||Emory University|||||f||||||||||||||2018-06-01 03:52:00.919741|2018-06-01 03:52:00.919741
NCT00359086|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31||2015-06-04|2015-06-04|2006-07-31|2006-08-01|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma|A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma|Completed||Phase 2|74|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 03:52:00.973193|2018-06-01 03:52:00.973193
NCT00359073|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2010-08-17||2018-03-12|2006-07-28|2006-08-01|Estimate|2018-03-12|2018-03-13|Actual||||2018-03-12|2018-03-13|Actual|October 2006|Actual|2006-10-31|March 2018|2018-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma|Effect of Montelukast on Experimentally-Induced RV16 Infection in Volunteers With Mild Asthma|Completed||N/A|25|Actual|University of Wisconsin, Madison|Was a pilot study; small sample size limited statistical power; subgroup analysis not applicable|2|||f||||f||||||||No||2018-06-01 03:52:01.056588|2018-06-01 03:52:01.056588
NCT00359034|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2014-02-04|2006-07-31|2006-08-01|Estimate|||||||2014-02-04|2014-02-06|Estimate|May 2006||2006-05-31|January 2013|2013-01-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Fetal Aortic Pulsewave Velocity: A Novel Doppler Ultrasound Method of Measuring the Biophysical Properties of the Fetal Aorta|Fetal Aortic Pulsewave Velocity: A Novel Doppler Ultrasound Method of Measuring the Biophysical Properties of the Fetal Aorta|Withdrawn|||0|Actual|University of British Columbia||||Could not resolve technical difficulties|f||||f||||||||||2018-06-01 03:52:01.455584|2018-06-01 03:52:01.455584
NCT00359021|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2013-01-29||2014-05-06|2006-07-28|2006-08-01|Estimate|2013-01-29|2013-03-07|Estimate||||2014-05-06|2014-05-16|Estimate|June 2006||2006-06-30|May 2014|2014-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).|An Open-label Trial With TMC125 as Part of an ART Including TMC114/Rtv and an Investigator-selected OBR in HIV-1 Infected Subjects Who Participated in a DUET Phase III Trial (TMC125-C206 or TMC125-C216).|Completed||Phase 3|503|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||f||||||||||2018-06-01 03:52:01.549142|2018-06-01 03:52:01.549142
NCT00359008|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-30|||2008-01-10|2006-07-30|2006-08-01|Estimate|||||||2008-01-10|2008-01-15|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Observational|||PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)|PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)|Completed|||336|Actual|Notal Vision Ltd|||2||f||||t||||||||||2018-06-01 03:52:02.40194|2018-06-01 03:52:02.40194
NCT00358995|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2014-02-17|2006-07-28|2006-08-01|Estimate|||||||2014-02-17|2014-02-19|Estimate|July 2002||2002-07-31|February 2014|2014-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Cognitive Behavioral Therapy of Primary Obsessions in Obsessive Compulsive Disorder|A New Cognitive Behavioral Therapy to Target Distorted Appraisals Characteristic of Primary Obsessions in Obsessive Compulsive Disorder|Completed||N/A|84|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:52:02.460543|2018-06-01 03:52:02.460543
NCT00358982|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31||2015-06-05|2015-06-05|2006-07-31|2006-08-01|Estimate||||2015-06-05|2015-07-03|Estimate|2015-06-05|2015-07-03|Estimate|August 2006||2006-08-31|June 2015|2015-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma|Terminated||Phase 2|51|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 03:52:02.52817|2018-06-01 03:52:02.52817
NCT00358969|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2006-07-31|2006-07-31|2006-08-01|Estimate|||||||2006-07-31|2006-08-01|Estimate|July 2006||2006-07-31|July 2006|2006-07-31||||||||Interventional|||Guanfacine to Treat Borderline Personality Disorder|Guanfacine in the Treatment of Borderline Personality Disorder|Unknown status|Recruiting|N/A|||Bronx VA Medical Center|||||f||||||||||||||2018-06-01 03:52:02.595795|2018-06-01 03:52:02.595795
NCT00358956|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2011-04-27|2011-03-28|2016-12-07|2006-07-28|2006-08-01|Estimate|2012-07-30|2012-08-31|Estimate|2011-03-28|2011-04-06|Estimate|2016-12-07|2017-01-30|Estimate|August 2006||2006-08-31|December 2016|2016-12-31|May 2014|Actual|2014-05-31|January 2008|Actual|2008-01-31||Interventional|||A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer|A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer|Completed||Phase 2|19|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:52:02.66098|2018-06-01 03:52:02.66098
NCT00358943|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2017-08-17|2006-07-31|2006-08-01|Estimate|||||||2017-08-17|2017-08-22|Actual|April 1991|Actual|1991-04-30|August 2017|2017-08-31|January 31, 2030|Anticipated|2030-01-31|January 31, 2030|Anticipated|2030-01-31||Observational|||International Collaborative Gaucher Group (ICGG) Gaucher Registry|International Collaborative Gaucher Group (ICGG) Gaucher Registry|Recruiting|||12000|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 03:52:03.050049|2018-06-01 03:52:03.050049
NCT00358930|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-04-27|2006-07-28|2006-08-01|Estimate|||||||2009-04-27|2009-04-28|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Study of ARQ 501 in Patients With Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|60||ArQule|||||f||||||||||||||2018-06-01 03:52:03.181423|2018-06-01 03:52:03.181423
NCT00358917|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2009-11-12||2011-04-07|2006-07-28|2006-08-01|Estimate|2010-01-07|2010-02-01|Estimate||||2011-04-07|2011-04-11|Estimate|August 2006||2006-08-31|April 2011|2011-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects|A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir (LPV/r) Tablets 800/200 Milligram (mg) Once-Daily (QD) Versus 400/100 mg Twice-Daily (BID) When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-Experienced, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects|Completed||Phase 3|599|Actual|Abbott||2|||f||||t||||||||||2018-06-01 03:52:03.330808|2018-06-01 03:52:03.330808
NCT00358904|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2011-04-26|2006-07-31|2006-08-01|Estimate|||||||2011-04-26|2011-04-27|Estimate|May 2006||2006-05-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Assessment of Weber Humeral Derotational Osteotomy Using CT Scan|Assessment of Weber Humeral Derotational Osteotomy Using CT Scan|Completed|||20|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:52:03.979814|2018-06-01 03:52:03.979814
NCT00358891|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-30|||2006-08-01|2006-07-30|2006-08-01|Estimate|||||||2006-08-01|2006-08-02|Estimate|August 2006||2006-08-31|July 2006|2006-07-31|July 2009||2009-07-31|||||Observational|||Follow-Up of VLBW Infants With Chronic Lung Disease: Respiratory Health and Neurodevelopment|Follow-Up of Very Low Birth Weight Preterm Infants With Chronic Lung Disease at Preschool Ages: Respiratory Health and Neurodevelopment|Unknown status|Not yet recruiting||98||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:52:04.032172|2018-06-01 03:52:04.032172
NCT00358878|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31||2016-04-26|2016-04-26|2006-07-31|2006-08-01|Estimate||||2016-04-26|2016-05-26|Estimate|2016-04-26|2016-05-26|Estimate|July 2006||2006-07-31|April 2016|2016-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|CATS||Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)|Satavaptan Cirrhotic Ascites Treatment Study: a Double-blind, Randomised, Parallel-group Comparison of Treatment With Satavaptan at 5 to 10 mg Daily Versus Placebo on Top of Conventional Treatment in Patients With Ascites Due to Cirrhosis of the Liver|Completed||Phase 3|463|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:52:04.095147|2018-06-01 03:52:04.095147
NCT00358865|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2008-04-30|2006-07-31|2006-08-01|Estimate|||||||2008-04-30|2008-05-07|Estimate|December 2005||2005-12-31|April 2008|2008-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Checking the Usability of a Virtual Reality System in Children With Brain Injury|Checking the Usability of Video Projected Virtual Reality Sytem in Children With Acquired Brain Injury|Completed|||30|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:52:04.204818|2018-06-01 03:52:04.204818
NCT00358852|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2014-03-18|2006-07-28|2006-08-01|Estimate|||||||2014-03-18|2014-03-19|Estimate|August 2006||2006-08-31|March 2014|2014-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|PRE-COG||Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia|Scale Validation of Prediction of Relapse and Rehospitalization Short Term in Patients With Schizophrenia|Completed|||2339|Actual|Janssen-Cilag, S.A.|||1||f||||f||||||||||2018-06-01 03:52:04.254444|2018-06-01 03:52:04.254444
NCT00358839|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2006-11-09|2006-07-31|2006-08-01|Estimate|||||||2006-11-09|2006-11-10|Estimate|July 2006||2006-07-31|November 2006|2006-11-30|October 2006||2006-10-31|||||Interventional|||Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.|Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.|Completed||N/A|20||Danish Headache Center|||||f||||||||||||||2018-06-01 03:52:04.325945|2018-06-01 03:52:04.325945
NCT00358826|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2012-06-15||2012-07-19|2006-07-28|2006-08-01|Estimate|2012-07-19|2012-07-23|Estimate||||2012-07-19|2012-07-23|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Study Effect of VIA-2291 on Vascular Inflammation|Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event|Completed||Phase 2|191|Actual|Tallikut Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-06-01 03:52:04.408537|2018-06-01 03:52:04.408537
NCT00358813|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-08-03|2006-07-28|2006-08-01|Estimate|||||||2017-08-03|2017-08-04|Actual|September 8, 2006|Actual|2006-09-08|August 2017|2017-08-31|August 22, 2008|Actual|2008-08-22|August 22, 2008|Actual|2008-08-22||Interventional|||Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment|Completed||Phase 1|18|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:52:05.138096|2018-06-01 03:52:05.138096
NCT00358800|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2006-07-28|2006-07-28|2006-08-01|Estimate|||||||2006-07-28|2006-08-01|Estimate|February 2005||2005-02-28|July 2006|2006-07-31|December 2005||2005-12-31|||||Interventional|||REMStar Auto With C-Flex – In-Laboratory Performance v. Conventionally Titrated CPAP Therapy: Performances and Preferences|A Randomized Cross Over Study to Compare REMStar Auto With C-Flex to Standard CPAP Therapy in Patients With OSAHS, and to Assess Its Safety, Tolerability and Efficacy and Preference Over CPAP.|Completed||N/A|15||University of British Columbia|||||f||||||||||||||2018-06-01 03:52:05.359463|2018-06-01 03:52:05.359463
NCT00358787|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2018-01-08|2006-07-28|2006-08-01|Estimate|||||||2018-01-08|2018-01-10|Actual|July 2008||2008-07-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Management of Displaced Supracondylar Fractures of the Humerus Using Lateral vs. Crossed K-wires|Management of Displaced Supracondylar Fractures of the Humerus Using Lateral Versus Cross K Wires: A Prospective Randomized Clinical Trial|Completed||N/A|55|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 03:52:05.422222|2018-06-01 03:52:05.422222
NCT00358774|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2015-10-13|2006-07-31|2006-08-01|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2001||2001-03-31|October 2015|2015-10-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Efficacy of Homeopathic Nasal Formulation for Management of Experimental Rhinoviral Colds|A Double-blind, Placebo-controlled Trial to Test the Efficacy of Homeopathic Nasal Formulation for the Management of Experimental Rhinoviral Colds in an Outpatient Setting|Completed||Phase 1/Phase 2|40||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 03:52:05.49929|2018-06-01 03:52:05.49929
NCT00358761|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-29|||2018-05-18|2006-07-29|2006-08-01|Estimate|||||||2018-05-18|2018-05-21|Actual|July 20, 2006||2006-07-20|December 11, 2012|2012-12-11|December 11, 2012||2012-12-11|||||Observational|||Investigation of Southern Tick-Associated Rash Illness (STARI)|Investigation of Southern Tick-Associated Rash Illness (STARI)|Terminated|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:05.55427|2018-06-01 03:52:05.55427
NCT00358748|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2011-04-11|2006-07-28|2006-08-01|Estimate|||||||2011-04-11|2011-04-12|Estimate|July 2005||2005-07-31|April 2011|2011-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants|Early Use of Hydrocortisone in Hypotensive Very Low Birth Weight Infants|Completed||Phase 3|40|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:52:05.602918|2018-06-01 03:52:05.602918
NCT00358735|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-30|2014-09-14||2014-10-21|2006-07-31|2006-08-01|Estimate|2014-10-19|2014-10-21|Estimate||||2014-10-21|2014-10-30|Estimate|June 2006||2006-06-30|October 2014|2014-10-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|SAFE||Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)|Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty (THA): Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)|Completed||N/A|411|Actual|Medical Compression Systems||2|||f||||t||||||||||2018-06-01 03:52:05.690254|2018-06-01 03:52:05.690254
NCT00358722|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31||2009-07-21|2009-07-21|2006-07-31|2006-08-01|Estimate||||2009-07-21|2009-08-10|Estimate|2009-07-21|2009-08-10|Estimate|July 2006||2006-07-31|July 2009|2009-07-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|ALCON||An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate|A Long-term, Open-label Continuation Study to Assess the Safety of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia|Terminated||Phase 2|44|Actual|Ineos Healthcare Limited||1||Limited number of subjects|f||||t||||||||||2018-06-01 03:52:06.259957|2018-06-01 03:52:06.259957
NCT00358709|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2008-06-18|2006-07-28|2006-08-01|Estimate|||||||2008-06-18|2008-06-19|Estimate|June 2002||2002-06-30|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Two State-of-the-Art Interventions|Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Cognitive-Behavioral Therapy and Skills Training Symptom Management on Measures of Symptoms and on Other Indices of Well-Being|Completed||Phase 3|129|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 03:52:06.357567|2018-06-01 03:52:06.357567
NCT00358696|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-10-19|2006-07-28|2006-08-01|Estimate|||||||2009-10-19|2009-10-20|Estimate|July 2006||2006-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients|TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus.|Completed||Phase 4|30|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:52:06.472232|2018-06-01 03:52:06.472232
NCT00358683|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2012-05-25|2006-07-28|2006-08-01|Estimate|||||||2012-05-25|2012-05-28|Estimate|November 2007||2007-11-30|May 2012|2012-05-31||||||||Interventional|||A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease|Open Label Long Term Clinical Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87055 Study.|Withdrawn||Phase 3|0|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 03:52:06.572698|2018-06-01 03:52:06.572698
NCT00358670|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2010-04-08||2017-03-13|2006-07-31|2006-08-01|Estimate|2010-10-22|2010-11-19|Estimate||||2017-03-13|2017-04-11|Actual|May 2006||2006-05-31|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)|A Long-Term Efficacy and Safety Study of Infliximab in the Treatment of Moderate to Severe Plaque-Type Psoriasis|Terminated||Phase 3|441|Actual|Merck Sharp & Dohme Corp.||2||"Infusion reactions during re-induction cycles after a period of no treatment. Please see~   Purpose section."|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:52:06.651853|2018-06-01 03:52:06.651853
NCT00358657|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2018-05-21|2006-07-28|2006-08-01|Estimate|||||||2018-05-21|2018-05-22|Actual|May 24, 2006|Actual|2006-05-24|May 2018|2018-05-31||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders|HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide|Recruiting||Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 03:52:07.021041|2018-06-01 03:52:07.021041
NCT00358644|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2009-04-13||2013-05-13|2006-07-31|2006-08-01|Estimate|2009-08-03|2009-09-07|Estimate||||2013-05-13|2013-05-20|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|||Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)|A Phase II Study of Decitabine For the Front-line Treatment of Older Patients With Acute Myeloid Leukemia|Completed||Phase 2|55|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:52:07.165335|2018-06-01 03:52:07.165335
NCT00358631|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2009-04-10|2006-07-31|2006-08-01|Estimate|||||||2009-04-10|2009-04-13|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder|An Eight-Week, Multicenter, Double-Blind, Placebo- and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Major Depressive Disorder|Completed||Phase 2|319|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:52:07.47637|2018-06-01 03:52:07.47637
NCT00358618|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-08-17|2006-07-28|2006-08-01|Estimate|||||||2009-08-17|2009-08-18|Estimate|September 2008||2008-09-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats|The Effects of Three Effect-site-targeted Propofol Concentrations on Dispersion of Myocardial Repolarization in Children|Completed||N/A|60|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 03:52:07.529155|2018-06-01 03:52:07.529155
NCT00358605|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2016-05-18|2006-07-28|2006-08-01|Estimate|||||||2016-05-18|2016-05-20|Estimate|August 2005||2005-08-31|May 2016|2016-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Use of Oral Appliances as an Adjunct to Continuous Positive Airway Pressure (CPAP) in the Treatment of Obstructive Sleep Apnoea|A Randomized Study to Compare Oral Appliances to Standard CPAP Therapy in Patients With OSAHS, and to Assess Its Safety, Tolerability and Efficacy and Preference Over CPAP for Its Short-term Use.|Completed||N/A|22|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 03:52:07.584063|2018-06-01 03:52:07.584063
NCT00358592|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2013-05-20|2006-07-31|2006-08-01|Estimate|||||||2013-05-20|2013-05-21|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|||||Interventional|||Comparison of Tissue Retractors During Cesarean Delivery in Obese Women|Randomized Controlled Trial of the Efficacy of the Mobius ™ Retractor in Performing Cesarean Sections in Patients With BMI ≥35kg/m2|Unknown status|Recruiting|N/A|60|Anticipated|Thomas Jefferson University|||||f||||||||||||||2018-06-01 03:52:07.750668|2018-06-01 03:52:07.750668
NCT00358579|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-30|2010-08-03||2017-02-09|2006-07-30|2006-08-01|Estimate|2011-07-12|2011-08-09|Estimate||||2017-02-09|2017-03-17|Actual|March 2006||2006-03-31|February 2017|2017-02-28|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|PIVOT||Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest|A Randomised, Double-blinded Multi-centre Trial Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest at the Emergency Department. (Preadmission Intravenous Vasopressin, Adrenaline Outcome Trial: PIVOT vII)|Completed||Phase 3|727|Actual|Singapore General Hospital|As the study was conducted over a relatively long period, results may be affected by secular trends.Variations in post-resuscitation care can affect survival to discharge status and variations between institutions are difficult to account for.|2|||f||||t||||||||||2018-06-01 03:52:07.847545|2018-06-01 03:52:07.847545
NCT00358566|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2008-05-16|2006-07-31|2006-08-01|Estimate|||||||2008-05-16|2008-05-19|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Interventional|||GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer|"Primovax - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer."|Terminated||Phase 3|360|Actual|Pharmexa A/S||2||"Preliminary data showed no survival benefit in the GV1001 group compared to the gemcitabine~   group."|t||||t||||||||||2018-06-01 03:52:08.21541|2018-06-01 03:52:08.21541
NCT00358553|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|||2007-03-12|2006-07-31|2006-08-01|Estimate|||||||2007-03-12|2007-03-13|Estimate||||March 2007|2007-03-31||||||||Interventional|||A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin||Completed||Phase 1|||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 03:52:08.380392|2018-06-01 03:52:08.380392
NCT00358540|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2017-11-08|2006-07-28|2006-08-01|Estimate|||||||2017-11-08|2017-11-13|Actual|June 1, 2006|Actual|2006-06-01|November 2017|2017-11-30|October 22, 2010|Actual|2010-10-22|October 22, 2010|Actual|2010-10-22||Interventional|||Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide|An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen|Completed||Phase 1|18|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:52:08.42402|2018-06-01 03:52:08.42402
NCT00358527|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-31|2010-02-18||2015-07-21|2006-07-31|2006-08-01|Estimate|2010-02-18|2010-03-11|Estimate||||2015-07-21|2015-07-28|Estimate|May 2006||2006-05-31|July 2015|2015-07-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)|A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis|Completed||Phase 4|401|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:52:08.495511|2018-06-01 03:52:08.495511
NCT00358514|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2010-03-26|2006-07-28|2006-08-01|Estimate|||||||2010-03-26|2010-03-30|Estimate|September 2008||2008-09-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Continuous Pressure Monitoring In Lower Leg Fractures|Continuous Compartment Pressure Monitoring (Ccpm) Following Tibial Fracture: A Prospective Randomized Trial|Terminated||N/A|250|Anticipated|University of British Columbia||||"Large sample size and change in Orthopaedic practice to use of CCPM in conjunction with~   Clinical Monitoring rendered project less timely."|f||||f||||||||||2018-06-01 03:52:08.676593|2018-06-01 03:52:08.676593
NCT00358501|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2016-03-26|2011-06-07|2016-12-02|2006-07-28|2006-08-01|Estimate|2016-12-02|2017-01-30|Estimate|2011-06-07|2011-06-21|Estimate|2016-12-02|2017-01-30|Estimate|July 2006||2006-07-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|September 2008|Actual|2008-09-30||Interventional|||Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients|Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy|Completed||Phase 3|134|Actual|Jazz Pharmaceuticals|Primary endpoint was changed after all patients were treated and current results reflect the final protocol. Adverse event severity was only reported for treatment group as control group was not assessed for severity.|2|||f||||t||||||||||2018-06-01 03:52:09.756162|2018-06-01 03:52:09.756162
NCT00358488|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2016-10-26|2006-07-27|2006-07-31|Estimate|||||||2016-10-26|2016-10-28|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients|A Multi-enter, Randomized, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (10, 15, and 20 mcg) of GSK159797|Completed||Phase 2|54|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:52:10.814551|2018-06-01 03:52:10.814551
NCT00358475|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2013-04-11|2006-07-27|2006-07-31|Estimate|||||||2013-04-11|2013-04-15|Estimate|June 2005||2005-06-30|May 2012|2012-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Of Perennial Allergic Rhinitis|Study of Perennial Allergic Rhinitis -Long Term Treatment Study-|Completed||Phase 3|65|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:52:10.958455|2018-06-01 03:52:10.958455
NCT00358462|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|2013-02-01||2013-02-01|2006-07-27|2006-07-31|Estimate|2013-02-01|2013-03-08|Estimate||||2013-02-01|2013-03-08|Estimate|January 2007||2007-01-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)|Mycoplasma Genitalium Antibiotic Susceptibility and Treatment: A Randomized Double-blind Trial of the Efficacy of Azithromycin and Doxycycline for Clinical and Microbiological Cure of M. Genitalium in Men With Nongonococcal Urethritis|Completed||Phase 3|606|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:52:11.02534|2018-06-01 03:52:11.02534
NCT00358449|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|2015-11-05|2009-11-30|2017-04-17|2006-07-27|2006-07-31|Estimate|2016-02-11|2016-03-10|Estimate|2009-11-30|2009-12-02|Estimate|2017-04-17|2017-05-18|Actual|September 11, 2006|Actual|2006-09-11|April 2017|2017-04-30|November 25, 2008|Actual|2008-11-25|November 25, 2008|Actual|2008-11-25||Interventional|||Intravenous Mepolizumab In Children With Eosinophilic Esophagitis|A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219)|Completed||Phase 2|84|Actual|GlaxoSmithKline||3|||f||||f|t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:52:11.556811|2018-06-01 03:52:11.556811
NCT00358436|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|2012-08-14||2016-11-16|2006-07-28|2006-07-31|Estimate|2012-10-31|2012-11-01|Estimate||||2016-11-16|2017-01-04|Estimate|August 2006||2006-08-31|November 2016|2016-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)||Completed||Phase 3|804|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:52:13.985249|2018-06-01 03:52:13.985249
NCT00358423|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2008-05-08|2006-07-27|2006-07-31|Estimate|||||||2008-05-08|2008-05-12|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema|Pilot Study of the Effect of Pegaptanib Sodium in Patients With Chronic, Post-Operative Cystoid Macular Edema|Terminated||Phase 1/Phase 2|1|Actual|Johns Hopkins University||2||Difficulty enrolling eligible subjects|f||||f||||||||||2018-06-01 03:52:14.860939|2018-06-01 03:52:14.860939
NCT00358410|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2017-02-06|2006-07-28|2006-07-31|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2006||2006-01-31|February 2017|2017-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia|An Exploratory Study to Investigate the Effects of the NK1 Antagonist GW679769, 60 mg Once Daily for 4 Days, on Gastric Accommodation, Gastric Emptying and Gastric Distension-induced Perception and Discomfort in Adult Male and Female Patients With Functional Dyspepsia, in a Single Center, Placebo-controlled, Double-blind, Randomised, Two-period Crossover Study|Completed||Phase 2|13|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:52:14.94866|2018-06-01 03:52:14.94866
NCT00358397|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2016-10-12|2006-07-27|2006-07-31|Estimate|||||||2016-10-12|2016-10-14|Estimate|July 2006||2006-07-31|October 2016|2016-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy|Phase I Safety Study of Clostridium Novyi-NT Spores in Patients With Treatment-Refractory Solid Tumor Malignancies|Terminated||Phase 1|2|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||Design Problem|f||||t||||||||||2018-06-01 03:52:15.019764|2018-06-01 03:52:15.019764
NCT00358384|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2017-11-08|2006-07-27|2006-07-31|Estimate|||||||2017-11-08|2017-11-13|Actual|September 26, 2005|Actual|2005-09-26|November 2017|2017-11-30|February 24, 2006|Actual|2006-02-24|February 24, 2006|Actual|2006-02-24||Interventional|||Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034|A Study to Investigate the Irritation Potential on Healthy Intact Skin and Effect on Psoriatic Skin of Topical Applications of GW786034|Completed||Phase 1|10|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 03:52:15.129233|2018-06-01 03:52:15.129233
NCT00358371|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2017-09-27|2006-07-27|2006-07-31|Estimate|||||||2017-09-27|2017-09-29|Actual|January 6, 2005|Actual|2005-01-06|September 2017|2017-09-30|February 8, 2005|Actual|2005-02-08|February 8, 2005|Actual|2005-02-08||Interventional|||Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)|A Mono-center, Open, Randomized, Three-way, Twelve-sequence, Cross-over Study to Determine the Extent of Absorption (Absolute Bioavailability), Rate of Absorption and to Further Characterize Distribution and Elimination Characteristics of a Commercial 250 mg and a 500 mg Capsule of Flucloxacillin Each Given as a Single Oral Dose vs. One 250 or 500 mg Intravenous Dose to 24 Healthy Male and/or Female Subjects in the Fasting State|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:52:15.201276|2018-06-01 03:52:15.201276
NCT00358358|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2017-01-19|2006-07-27|2006-07-31|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2006||2006-03-31|January 2017|2017-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Chronic Obstructive Pulmonary Disease Endpoints Study|A Randomized, Double-blind Placebo-controlled Study of Treatments With Salmeterol, Fluticasone Propionate and Their Combination to Evaluate Novel Endpoints in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|163|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:52:15.440691|2018-06-01 03:52:15.440691
NCT00358345|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2008-01-10|2006-07-27|2006-07-31|Estimate|||||||2008-01-10|2008-01-15|Estimate|October 2003||2003-10-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Observational|||PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization|PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization|Completed|||347|Actual|Notal Vision Ltd|||2||f||||t||||||||||2018-06-01 03:52:15.548981|2018-06-01 03:52:15.548981
NCT00358332|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|2008-12-09||2011-10-18|2006-07-27|2006-07-31|Estimate|2009-02-04|2009-03-04|Estimate||||2011-10-18|2011-10-24|Estimate|November 2006||2006-11-30|October 2011|2011-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Phase I Pediatric FMP2.1/AS02A Trial in Mali|Randomized, Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali|Completed||Phase 1|100|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||||||||||||2018-06-01 03:52:15.6865|2018-06-01 03:52:15.6865
NCT00358319|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2013-11-21|2006-07-27|2006-07-31|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2005||2005-03-31|February 2011|2011-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma|Phase I/II Trial of Valproic Acid and Karenitecin for Metastatic Malignant Melanoma|Terminated||Phase 1/Phase 2|42|Actual|H. Lee Moffitt Cancer Center and Research Institute||2||PI left Moffitt|f||||t||||||||||2018-06-01 03:52:16.547148|2018-06-01 03:52:16.547148
NCT00358306|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2010-02-16|2006-07-28|2006-07-31|Estimate|||||||2010-02-16|2010-02-17|Estimate|April 2008||2008-04-30|February 2010|2010-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)|The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)|Completed|||36|Actual|University of Alabama at Birmingham|||1||f||||t||||||||||2018-06-01 03:52:16.63687|2018-06-01 03:52:16.63687
NCT00358293|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2009-01-20|2006-07-27|2006-07-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|December 2006||2006-12-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity|A Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS Patients|Completed||Phase 1/Phase 2|20||Teva GTC|||||f||||||||||||||2018-06-01 03:52:16.701951|2018-06-01 03:52:16.701951
NCT00358280|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-03-25|2006-07-28|2006-07-31|Estimate|||||||2009-03-25|2009-03-26|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|September 2006|Actual|2006-09-30|||||Interventional|||Ropivacaine Versus Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery|A Randomised, Double-Blind, Multi-Centre, Parallel Group Study Comparing Efficacy and Safety of 5 mg/ml Ropivacaine and 5 mg/ml Bupivacaine for Spinal Anaesthesia in Patients Undergoing Unilateral Lower Limb Surgery|Completed||Phase 3|220||AstraZeneca|||||f||||||||||||||2018-06-01 03:52:16.766793|2018-06-01 03:52:16.766793
NCT00358267|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2016-02-24|2006-07-27|2006-07-31|Estimate|||||||2016-02-24|2016-02-26|Estimate|July 2006||2006-07-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Randomized Trial Comparing Partial Resection of Inferior Turbinate(PRIT) and Radiofrequency Ablation(RFA) for Inferior Turbinate Reduction|A Randomized Trial Comparing Two Surgical Techniques for Inferior Turbinate Reduction|Withdrawn||N/A|0|Actual|Weill Medical College of Cornell University||2|||f||||||||||||||2018-06-01 03:52:16.831042|2018-06-01 03:52:16.831042
NCT00358254|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2010-07-21|2006-07-27|2006-07-31|Estimate|||||||2010-07-21|2010-07-22|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|December 2007|Actual|2007-12-31|||||Observational|||Noninvasive Skin Spectroscopy for Diabetes Screening|Noninvasive Skin Spectroscopy for Diabetes Screening|Completed|||1000|Anticipated|InLight Solutions|||||f||||||||||||||2018-06-01 03:52:16.907458|2018-06-01 03:52:16.907458
NCT00358241|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2006-07-27|2006-07-27|2006-07-31|Estimate|||||||2006-07-27|2006-07-31|Estimate||||July 2006|2006-07-31||||||||Interventional|||Effects of Nerve Block on Knee Function After Knee Replacement|Effects of Continuous Lumbar Plexus Nerve Block on Functional Restoration and Outcome After Unilateral Total Knee Arthroplasty|Unknown status|Recruiting|N/A|||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:52:16.96321|2018-06-01 03:52:16.96321
NCT00358228|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2010-12-09|2006-07-28|2006-07-31|Estimate|||||||2010-12-09|2010-12-10|Estimate|September 2002||2002-09-30|December 2010|2010-12-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)|Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US, EFC4964) - A Randomized, Double-blind, 3-arm, Placebo-controlled, Parallel-group, Fixed-dose, 52-week, Multi-center Study.|Completed||Phase 3|787|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:52:17.022172|2018-06-01 03:52:17.022172
NCT00358215|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|2013-10-23||2014-07-14|2006-07-27|2006-07-31|Estimate|2013-10-23|2013-12-13|Estimate||||2014-07-14|2014-07-23|Estimate|June 2006||2006-06-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia|Completed||Phase 3|2278|Actual|Amgen||2|||f||||t||||||||||2018-06-01 03:52:17.234477|2018-06-01 03:52:17.234477
NCT00358202|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2007-10-29|2006-07-27|2006-07-31|Estimate|||||||2007-10-29|2007-10-31|Estimate|March 2002||2002-03-31|October 2007|2007-10-31|April 2006|Actual|2006-04-30|||||Interventional|||Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia|Phase 4 Study of Once-Daily Intramuscular Cefepime Versus Ceftriaxone for In-Home Treatment of Nursing Home-Acquired Pneumonia|Completed||Phase 4|69|Actual|CPL Associates||2|||f||||||||||||||2018-06-01 03:52:21.122722|2018-06-01 03:52:21.122722
NCT00358189|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-02-03|2006-07-28|2006-07-31|Estimate|||||||2009-02-03|2009-02-05|Estimate|October 2006||2006-10-31|July 2006|2006-07-31|May 2008|Actual|2008-05-31|||||Observational|||Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease|Deep Brain Stimulation and Motor Function in Parkinson's Patients|Completed|||20|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 03:52:21.187062|2018-06-01 03:52:21.187062
NCT00358176|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-12-11|2006-07-28|2006-07-31|Estimate|||||||2009-12-11|2009-12-15|Estimate|July 2004||2004-07-31|December 2009|2009-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women|A Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Noninferiority Study Comparing 75mg Risedronate Dosed on 2 Consecutive Days Monthly With 5mg Daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed Over 24 Months.|Completed||Phase 3|1231|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:52:21.238141|2018-06-01 03:52:21.238141
NCT00358163|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2009-10-30|2006-07-28|2006-07-31|Estimate|||||||2009-10-30|2009-11-02|Estimate|April 2006||2006-04-30|October 2009|2009-10-31|April 2010|Anticipated|2010-04-30|April 2008|Anticipated|2008-04-30||Interventional|||Trial of PTK787/ZK 222584 Plus Paclitaxel|Phase I Study of the Oral Vascular Endothelial Growth Factor Inhibitor PTK787/ZK 222584 in Combination With Paclitaxel in Patients With Advanced Solid Tumors.|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 03:52:21.305254|2018-06-01 03:52:21.305254
NCT00358150|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|2014-08-22|2011-12-16|2016-12-22|2006-07-27|2006-07-31|Estimate|2014-08-22|2014-09-03|Estimate|2011-12-16|2011-12-22|Estimate|2016-12-22|2017-02-15|Actual|June 2006||2006-06-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|August 2009|Actual|2009-08-31||Interventional||Full analysis set consists of all participants who signed informed consent and received at least one dose of eliglustat.|A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients|A Phase 2, Open-Label, Multi-Center Study Evaluating the Efficacy, Safety and Pharmacokinetics of Genz-112638 in Gaucher Type 1 Patients|Completed||Phase 2|26|Actual|Sanofi|Due to the very small number of participants at Year 9, the point estimates of mean and standard deviation are not reliable.|1|||f||||||||||||||2018-06-01 03:52:21.450972|2018-06-01 03:52:21.450972
NCT00358137|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2016-02-17|2006-07-28|2006-07-31|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1997||1997-07-31|December 2007|2007-12-31|January 2003|Actual|2003-01-31|||||Interventional|||Effect of Aerobic Exercise on Blood Pressure Changes|Psychophysiologic Stress, Exercise, & Autonomic Control|Completed||N/A|149|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:52:22.749538|2018-06-01 03:52:22.749538
NCT00358124|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-28|||2011-01-10|2006-07-28|2006-07-31|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2001||2001-01-31|January 2011|2011-01-31|June 2002||2002-06-30|||||Interventional|||Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy||Completed||Phase 4|220||Sanofi|||||f||||||||||||||2018-06-01 03:52:22.798543|2018-06-01 03:52:22.798543
NCT00358111|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2014-05-12|2006-07-27|2006-07-28|Estimate|||||||2014-05-12|2014-05-13|Estimate|July 2006||2006-07-31|May 2014|2014-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of LUMA Cervical Imaging System as Adjunct to Colposcopy|A Single Arm Multi-Center Post Approval Study of LUMA as Adjunct to Colposcopy|Terminated||Phase 4|10|Actual|SpectraScience||||PMA withdrawn|f||||t||||||||||2018-06-01 03:52:22.855095|2018-06-01 03:52:22.855095
NCT00358098|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2014-09-26|2006-07-27|2006-07-28|Estimate|||||||2014-09-26|2014-09-30|Estimate|August 2006||2006-08-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer|For Women With Estrogen Positive Metastatic Breast Cancer Discordance of Pre-treatment FDG-PET and FES-PET in Addition to Presence of Ki-67 and Human Epidermal Growth Factor 2 (HER-2) Overexpression Will Predict for Hormone Refractory Disease When Compared to Standard Response Criteria|Terminated|||51|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 03:52:22.903357|2018-06-01 03:52:22.903357
NCT00358085|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2006-07-26|2006-07-26|2006-07-28|Estimate|||||||2006-07-26|2006-07-28|Estimate|September 2006||2006-09-30|July 2006|2006-07-31|January 2008||2008-01-31|||||Interventional|||NExT ERA: National Expertise Based Trial of Elective Repair of Abdominal Aortic Aneurysms: A Pilot Study|Expertise Based Randomized Controlled Trial of Open Versus Endovascular Repair of Abdominal Aortic Aneurysms: A Pilot Study|Unknown status|Not yet recruiting|Phase 3|30||McMaster University|||||f||||||||||||||2018-06-01 03:52:22.950715|2018-06-01 03:52:22.950715
NCT00358072|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2010-12-28|2006-07-26|2006-07-28|Estimate|||||||2010-12-28|2010-12-29|Estimate|May 2000||2000-05-31|December 2010|2010-12-31|September 2008|Actual|2008-09-30|December 2006|Actual|2006-12-31||Interventional|||Treatment of Adult ALL With an MRD-directed Programme.|Treatment of Adult Acute Lymphoblastic Leukemia Using a Post-remission Programme Whose Intensity Varies Depending on the Risk Class Defined on the Basis of Minimal Residual Disease.|Completed||Phase 2|280|Actual|Northern Italy Leukemia Group||1|||f||||f||||||||||2018-06-01 03:52:23.026505|2018-06-01 03:52:23.026505
NCT00358059|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2006-07-26|2006-07-26|2006-07-28|Estimate|||||||2006-07-26|2006-07-28|Estimate|October 2000||2000-10-31|October 2005|2005-10-31|January 2006||2006-01-31|||||Interventional|||Behavior Therapy for Families of Diabetic Adolescents|Behavior Therapy for Families of Diabetic Adolescents|Completed||Phase 3|120||Nemours Children's Clinic|||||f||||||||||||||2018-06-01 03:52:23.326674|2018-06-01 03:52:23.326674
NCT00358046|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2007-02-05|2006-07-26|2006-07-28|Estimate|||||||2007-02-05|2007-02-07|Estimate|June 2006||2006-06-30|February 2007|2007-02-28||||||||Interventional|||Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia|A Phase 2, Randomized, Dose-Ranging, Single-Blind, Efficacy and Tolerability Study of ILY101 in Patients With Chronic Kidney Disease With Hyperphosphatemia on Hemodialysis|Unknown status|Active, not recruiting|Phase 2|120||Ilypsa|||||f||||||||||||||2018-06-01 03:52:23.396406|2018-06-01 03:52:23.396406
NCT00358033|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2014-04-14|2006-07-26|2006-07-28|Estimate|||||||2014-04-14|2014-04-16|Estimate|July 2003||2003-07-31|April 2014|2014-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic|Effectiveness of Different Strategies in Maintaining Target Goals of Cardiovascular Risk Factors in Patients Discharged From Cardiovascular Risk Reduction Clinic|Completed||Phase 3|200|Actual|Providence VA Medical Center||3|||f||||t||||||||||2018-06-01 03:52:23.478606|2018-06-01 03:52:23.478606
NCT00358020|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2006-11-30|2006-07-27|2006-07-28|Estimate|||||||2006-11-30|2006-12-04|Estimate|November 2004||2004-11-30|November 2006|2006-11-30|December 2008||2008-12-31|||||Interventional|||Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients|A Phase II, Multi-Center, Open Label Study Of Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients|Completed||Phase 2|30||University of Turin, Italy|||||f||||||||||||||2018-06-01 03:52:23.552347|2018-06-01 03:52:23.552347
NCT00358007|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|2014-06-12||2016-10-19|2006-07-27|2006-07-28|Estimate|2014-08-20|2014-08-21|Estimate||||2016-10-19|2016-11-29|Estimate|March 2007||2007-03-31|October 2016|2016-10-31|September 2010|Actual|2010-09-30|February 2008|Actual|2008-02-29||Interventional|||Use of Cone Beam Kilovoltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer|Evaluation of Cone Beam Kilovoltage Imaging During Radiation Therapy for Tumors of the Head and Neck|Terminated||Phase 2|30|Actual|Thomas Jefferson University||1||Administratively Terminated by PI|f||||t||||||||||2018-06-01 03:52:23.631811|2018-06-01 03:52:23.631811
NCT00357994|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|2015-01-12|2012-10-16|2015-01-12|2006-07-27|2006-07-28|Estimate|2015-01-12|2015-01-16|Estimate|2012-10-16|2012-10-18|Estimate|2015-01-12|2015-01-16|Estimate|January 2009||2009-01-31|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects|A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations|Completed||Phase 3|36|Actual|AbbVie||2|||f||||t||||||||||2018-06-01 03:52:23.960583|2018-06-01 03:52:23.960583
NCT00357981|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-08-27|2006-07-26|2006-07-28|Estimate|||||||2013-08-27|2013-08-29|Estimate||||August 2013|2013-08-31||||||||Interventional|||Continuous Use of the Contraceptive Patch and the Personal Economic Impact.|Patient Experiences Using Evra for Management of Menstrual Related Symptoms.|Withdrawn||N/A|0|Actual|University of California, San Francisco||1||Both sponsor and UCSF decided this study was not clinical relevant at this time|f||||||||||||||2018-06-01 03:52:24.794844|2018-06-01 03:52:24.794844
NCT00357968|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2010-04-19||2010-08-25|2006-07-26|2006-07-28|Estimate|2010-07-09|2010-08-09|Estimate||||2010-08-25|2010-08-31|Estimate|August 2006||2006-08-31|August 2010|2010-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|PRINCIPLE||Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting|Protocol H7T-MC-TABL(a) PRasugrel IN Comparison to Clopidogrel for Inhibition of PLatelet Activation and AggrEgation (PRINCIPLE) - TIMI 44|Completed||Phase 2|201|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:52:24.901471|2018-06-01 03:52:24.901471
NCT00357955|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2014-01-14||2014-04-14|2006-07-26|2006-07-28|Estimate|2014-04-14|2014-05-13|Estimate||||2014-04-14|2014-05-13|Estimate|August 2004||2004-08-31|April 2014|2014-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Age, mean in years; Gender, % male; Baseline level of glycemic control|Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients|Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients|Completed||N/A|118|Actual|Providence VA Medical Center||2|||f||||t||||||||||2018-06-01 03:52:25.934724|2018-06-01 03:52:25.934724
NCT00357942|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2014-02-20|2006-07-27|2006-07-28|Estimate|||||||2014-02-20|2014-02-21|Estimate|September 2006||2006-09-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Topical Morphine for Stomatitis-related Pain Induced by Chemotherapy|Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children|Completed||Phase 4|72|Actual|Danish University of Pharmaceutical Sciences||3|||f||||t||||||||||2018-06-01 03:52:26.150064|2018-06-01 03:52:26.150064
NCT00357929|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-27|||2017-10-18|2006-07-27|2006-07-28|Estimate|||||||2017-10-18|2017-10-20|Actual|August 2006||2006-08-31|October 2017|2017-10-31|June 14, 2007|Actual|2007-06-14|June 14, 2007|Actual|2007-06-14||Interventional|||Weaning From Mechanical Ventilation Using Permissive Hypercarbia|Weaning From Mechanical Ventilation Using Permissive Hypercarbia|Terminated||N/A|3|Actual|Milton S. Hershey Medical Center||||insufficient recruitment|f||||||||||||||2018-06-01 03:52:26.219269|2018-06-01 03:52:26.219269
NCT00357916|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2016-04-04|2006-07-26|2006-07-28|Estimate|||||||2016-04-04|2016-04-05|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of PEP005 Topical Gel (0.01% Concentration) in Healthy Volunteers Using a Repeat Insult Patch Test Design|Completed||Phase 1|200||Peplin|||||||||||||||||||2018-06-01 03:52:26.348535|2018-06-01 03:52:26.348535
NCT00357903|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2010-11-04||2017-02-07|2006-07-27|2006-07-28|Estimate|2010-11-04|2010-12-06|Estimate||||2017-02-07|2017-02-09|Estimate|April 1997||1997-04-30|February 2017|2017-02-28|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials|Open-Label Extension Treatment With Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) for Participating Patients in Tumor Necrosis Factor Receptor Fusion Protein (TNFR:Fc) Clinical Trials|Completed||Phase 3|639|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:52:26.506207|2018-06-01 03:52:26.506207
NCT00357890|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2016-06-10|2006-07-26|2006-07-28|Estimate|||||||2016-06-10|2016-06-14|Estimate|December 2005||2005-12-31|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)|A Pilot Study of the Effect of Continuous Subcutaneous Insulin Infusion in Adolescents With Newly-diagnosed Type 1 Diabetes on Insulin Resistance, Beta-cell Function and the Honeymoon Period.|Completed||N/A|12|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-06-01 03:52:28.032046|2018-06-01 03:52:28.032046
NCT00357877|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2016-10-18||2017-05-15|2006-07-26|2006-07-28|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|July 2006||2006-07-31|May 2017|2017-05-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||Prevention of Adult Caries Study (PACS)|Prevention of Adult Caries Study|Completed||Phase 3|983|Actual|Tufts University||2|||f||||t||||||||No||2018-06-01 03:52:28.297178|2018-06-01 03:52:28.297178
NCT00357864|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2007-08-29|2006-07-26|2006-07-28|Estimate|||||||2007-08-29|2007-08-30|Estimate|July 2006||2006-07-31|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Observational|||Carbachol´s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow|Basic Research on Carbachol´s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow in a Humane Experimental Headache Model|Completed|||15|Actual|Danish Headache Center|||||f||||t||||||||||2018-06-01 03:52:28.765259|2018-06-01 03:52:28.765259
NCT00357851|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2010-10-13|2006-07-26|2006-07-28|Estimate|||||||2010-10-13|2010-10-14|Estimate|March 2005||2005-03-31|October 2010|2010-10-31||||||||Interventional|||Can Aprotinin Reduce Pancreatitis After Scoliosis Surgery||Completed||Phase 1|120|Anticipated|Nemours Children's Clinic|||||||||||||||||||2018-06-01 03:52:28.823802|2018-06-01 03:52:28.823802
NCT00357825|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-05-14|2006-07-26|2006-07-28|Estimate|||||||2013-05-14|2013-05-15|Estimate|August 2006||2006-08-31|May 2013|2013-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia|An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of [S,S]-Reboxetine Administered Once Daily in Patients With Fibromyalgia|Completed||Phase 2|246||Pfizer|||||||||||||||||||2018-06-01 03:52:28.929351|2018-06-01 03:52:28.929351
NCT00357812|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-01-14|2006-07-26|2006-07-28|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2006||2006-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|||||Observational|||The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)|A Study to Compare the Efficacy of Two Potential Diagnostic Assays: a Fluorescein Conjugated Monoclonal Antibody in Vivo Assay and Nested Real Time PCR Assay to Rapidly and Accurately Diagnose Herpes Simplex Keratitis.|Completed|||50|Anticipated|University of Ulster|||||f||||||||||||||2018-06-01 03:52:29.143497|2018-06-01 03:52:29.143497
NCT00357799|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-08-22|2006-07-26|2006-07-28|Estimate|||||||2011-08-22|2011-08-24|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||VeinViewer for Peripheral IV Placement in Children With Difficult Intravenous (IV) Access|VeinViewer for Peripheral IV Placement in Children With Difficult IV Access|Completed||Phase 2/Phase 3|170|Anticipated|Children's Hospital and Health System Foundation, Wisconsin||2|||f||||f||||||||||2018-06-01 03:52:29.349998|2018-06-01 03:52:29.349998
NCT00357786|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-08-16|2006-07-26|2006-07-27|Estimate|||||||2011-08-16|2011-08-17|Estimate|October 2003||2003-10-31|December 2008|2008-12-31||||December 2008|Actual|2008-12-31||Interventional|||An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease|An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal® (Registered Trademark) in Patients With Fabry Disease|Completed||Phase 1|3||National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 03:52:29.587818|2018-06-01 03:52:29.587818
NCT00357773|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-26|2006-07-26|2006-07-27|Estimate|||||||2006-07-26|2006-07-27|Estimate|May 2004||2004-05-31|July 2006|2006-07-31|June 2005||2005-06-30|||||Interventional|||Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis|Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis|Completed||Phase 3|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:30.62285|2018-06-01 03:52:30.62285
NCT00357760|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2017-02-08||2017-05-30|2006-07-26|2006-07-27|Estimate|2017-02-08|2017-04-04|Actual||||2017-05-30|2017-06-23|Actual|December 2007||2007-12-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Eligible and treated patients are included in this analysis.|Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|94|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 03:52:30.738372|2018-06-01 03:52:30.738372
NCT00357747|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-09-16|2006-07-26|2006-07-27|Estimate|||||||2011-09-16|2011-09-19|Estimate|April 2005||2005-04-30|September 2011|2011-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||AEG35156 and Docetaxel in Treating Patients With Solid Tumors|A Phase I Study of AEG35156 in Combination With Docetaxel in Patients With Solid Tumors|Completed||Phase 1|10|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-06-01 03:52:31.492916|2018-06-01 03:52:31.492916
NCT00357734|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2016-05-17||2016-08-29|2006-07-26|2006-07-27|Estimate|2016-05-17|2016-06-23|Estimate||||2016-08-29|2016-08-30|Estimate|January 2005||2005-01-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Iressa Follow-up Trial|Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials.|Completed||Phase 3|14|Actual|AstraZeneca|The study was stopped after enrolling 14 of 100 patients. The outcome was biased by the limited number of patients. Therefore, data allow only a limited statement on efficacy and long term safety.|1|||f||||f||||||||||2018-06-01 03:52:31.573062|2018-06-01 03:52:31.573062
NCT00357721|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2011-04-05|2006-07-26|2006-07-27|Estimate|||||||2011-04-05|2011-04-06|Estimate|June 2006||2006-06-30|April 2011|2011-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Atazanavir Twice Daily|Randomized, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics of Atazanavir Administered Twice-Daily in Health Subjects|Completed||Phase 1|18||Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 03:52:31.83906|2018-06-01 03:52:31.83906
NCT00357708|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-01-04|2006-07-26|2006-07-27|Estimate|||||||2013-01-04|2013-01-07|Estimate|June 2006||2006-06-30|January 2013|2013-01-31||||October 2009|Actual|2009-10-31||Interventional|||Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases|A Phase I Trial of SAHA (NSC 701852) and Decitabine (IND 50733, NSC 127716) in Patients With Relapsed, Refractory or Poor Prognosis Leukemia|Completed||Phase 1|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:52:31.931423|2018-06-01 03:52:31.931423
NCT00357695|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-06-30|2006-07-26|2006-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|November 18, 2003||2003-11-18|October 28, 2008|2008-10-28|October 28, 2008||2008-10-28|||||Observational|||Role of the Brain in Processing Visually Presented Objects|Role of the Parieto-Frontal Network in Automatic Processing of Visually Presented Objects|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:32.025934|2018-06-01 03:52:32.025934
NCT00357682|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2016-05-17|2006-07-26|2006-07-27|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2005||2005-03-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|AspECT||A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia|A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia|Unknown status|Active, not recruiting|Phase 3|2513|Actual|University of Oxford||4|||f||||t||||||||||2018-06-01 03:52:32.079307|2018-06-01 03:52:32.079307
NCT00357669|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2015-05-15|2006-07-25|2006-07-27|Estimate|||||||2015-05-15|2015-05-18|Estimate|November 2006||2006-11-30|May 2015|2015-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht-Lundborg Disease|Completed||Phase 3|50|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 03:52:32.154507|2018-06-01 03:52:32.154507
NCT00356746|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2015-06-23|2006-07-24|2006-07-26|Estimate|||||||2015-06-23|2015-06-24|Estimate|March 2006||2006-03-31|June 2008|2008-06-30|March 2009|Actual|2009-03-31|December 2007|Actual|2007-12-31||Observational|IRAS||Inflammatory Response During Anesthesia and Surgery|A Prospective, Randomized Trial to Study the Effects of Different Anesthetic Agents on the Perioperative Immune Response|Completed|||120|Actual|UMC Utrecht|||2||f||||f||||||Samples Without DNA|"~     Full blood smaples~   "|||2018-06-01 03:52:41.880774|2018-06-01 03:52:41.880774
NCT00357656|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2017-01-11||2017-10-19|2006-07-26|2006-07-27|Estimate|2017-04-12|2017-05-19|Actual||||2017-10-19|2017-10-23|Actual|June 1, 2006||2006-06-01|January 2017|2017-01-31|December 1, 2015|Actual|2015-12-01|October 1, 2015|Actual|2015-10-01||Interventional|||Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery|Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusion (CI) Versus Intermittent Bolus Infusion (BI) in Subjects With Severe or Moderately Severe Hemophilia A Undergoing Major Orthopedic Surgery|Completed||Phase 4|85|Actual|Shire||2|||f||||t||||||||||2018-06-01 03:52:32.27874|2018-06-01 03:52:32.27874
NCT00357643|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2006-07-26|2006-07-26|2006-07-27|Estimate|||||||2006-07-26|2006-07-27|Estimate|October 1992||1992-10-31|June 2005|2005-06-30|February 1996||1996-02-29|||||Interventional|||Effect of Calcium and Vitamin D on Bone Loss From the Hip|Effect of Calcium and Vitamin D on Bone Loss From the Hip|Completed||Phase 3|450||Tufts University|||||f||||||||||||||2018-06-01 03:52:32.835372|2018-06-01 03:52:32.835372
NCT00357630|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2009-04-11|2006-07-26|2006-07-27|Estimate|||||||2009-04-11|2009-04-14|Estimate|June 2006||2006-06-30|October 2008|2008-10-31||||February 2007|Actual|2007-02-28||Interventional|||Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary|Phase II Protocol: Gemcitabine for Metastatic Cancer With Unknown Primary Site - Analysis of Symptom Benefit|Completed||Phase 2|52|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:52:32.90467|2018-06-01 03:52:32.90467
NCT00357617|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2010-12-23|2006-07-26|2006-07-27|Estimate|||||||2010-12-23|2010-12-24|Estimate|June 2006||2006-06-30|January 2008|2008-01-31||||||||Interventional|||Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery|Evaluation of the Effect of Celecoxib on Angiogenesis Markers in Patients With Operable Head and Neck Squamous Cell Carcinoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:52:32.998928|2018-06-01 03:52:32.998928
NCT00357604|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-04-07|2006-07-26|2006-07-27|Estimate|||||||2011-04-07|2011-04-08|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females|The Effect of the Co-administration of Atazanavir (ATV) and Ritonavir (RTV) on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects|Completed||Phase 1|22||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 03:52:33.070918|2018-06-01 03:52:33.070918
NCT00357591|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2009-12-24|2006-07-26|2006-07-27|Estimate|||||||2009-12-24|2009-12-25|Estimate|September 2004||2004-09-30|August 2009|2009-08-31|January 2008|Actual|2008-01-31|January 2008|Anticipated|2008-01-31||Interventional|||Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation|MOMENTUM: Multicenter Trial of the Orqis Medical CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy|Terminated||N/A|200|Anticipated|Orqis Medical Corporation||1||Projected neutral significance for primary composite efficacy endpoint.|f||||t||||||||||2018-06-01 03:52:33.130943|2018-06-01 03:52:33.130943
NCT00357578|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-06-30|2006-07-26|2006-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|April 14, 2000||2000-04-14|September 19, 2007|2007-09-19|September 19, 2007||2007-09-19|||||Observational|||Genetic Study of Age-Related Macular Degeneration|A Case Control Study of Age-Related Macular Degeneration (AMD) Examining Gene Expression Patterns in Circulating Monocytes From Peripheral Blood Samples|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:33.276879|2018-06-01 03:52:33.276879
NCT00357565|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2018-01-03|2006-07-26|2006-07-27|Estimate|||||||2018-01-03|2018-01-05|Actual|November 2005|Actual|2005-11-30|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia|Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome|Recruiting||Phase 2|20|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 03:52:33.339585|2018-06-01 03:52:33.339585
NCT00357552|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2012-05-23||2018-02-21|2006-07-25|2006-07-27|Estimate|2012-08-23|2012-09-25|Estimate||||2018-02-21|2018-03-20|Actual|January 2008||2008-01-31|February 2018|2018-02-28|May 2012|Actual|2012-05-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy|A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens|Completed||N/A|123|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-06-01 03:52:33.468213|2018-06-01 03:52:33.468213
NCT00357539|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-26|2006-07-26|2006-07-27|Estimate|||||||2006-07-26|2006-07-27|Estimate|February 2002||2002-02-28|July 2006|2006-07-31|March 2002||2002-03-31|||||Interventional|||Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers|Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers|Completed||Phase 1|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:33.85266|2018-06-01 03:52:33.85266
NCT00357526|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2007-04-19|2006-07-26|2006-07-27|Estimate|||||||2007-04-19|2007-04-23|Estimate|April 2003||2003-04-30|March 2006|2006-03-31|August 2004||2004-08-31|||||Interventional|||Oral Contraceptive Pills Compared to Vaginal Rings|YOUNG WOMEN’S EXPERIENCES: ORAL CONTRACEPTIVE PILLS VS The VAGINAL RING|Completed||N/A|130||University of California, San Francisco|||||f||||||||||||||2018-06-01 03:52:33.911762|2018-06-01 03:52:33.911762
NCT00357513|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-06-30|2006-07-26|2006-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|June 3, 2002||2002-06-03|December 15, 2008|2008-12-15|December 15, 2008||2008-12-15|||||Observational|||Genetic Studies to Identify Stroke Subtypes and Outcome|Stroke Genomics - A Correlative Study of Stroke Subtypes, Neuroimaging, Therapy and Outcome Measures|Completed|||840||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:33.968839|2018-06-01 03:52:33.968839
NCT00357500|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2012-12-13||2014-09-19|2006-07-26|2006-07-27|Estimate|2014-08-28|2014-09-09|Estimate||||2014-09-19|2014-10-01|Estimate|January 2005||2005-01-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional||The analysis population represents patients who started treatment.|Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer|Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer|Completed||Phase 2|101|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:52:34.055015|2018-06-01 03:52:34.055015
NCT00357487|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-08-29|2006-07-26|2006-07-27|Estimate|||||||2011-08-29|2011-08-30|Estimate|June 2006||2006-06-30|August 2011|2011-08-31|December 2007||2007-12-31|||||Interventional|||Evaluation of Two New Medical Instruments Dedicated to the Sentinel Lymph Node Technique in Case of Breast Cancer|Sentinel Lymph Node Identification in Case of Breast Cancer. Clinical Evaluation of a New Intra-operative Probe and a Mini Gamma Camera|Completed||N/A|25||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:52:34.460594|2018-06-01 03:52:34.460594
NCT00357474|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-12-02|2006-07-26|2006-07-27|Estimate|||||||2013-12-02|2013-12-04|Estimate|October 2005||2005-10-31|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs|A Multicenter, Randomized, Controlled Trial of the Effective Therapy for Multiple, Small Hepatocellular Carcinomas: Comparing Transarterial Chemoembolization With Percutaneous Ethanol Injection Therapy.|Completed||Phase 3|22|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 03:52:34.515722|2018-06-01 03:52:34.515722
NCT00357461|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-05-14|2006-07-26|2006-07-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 2006||2006-05-31|May 2013|2013-05-31||||||||Interventional|||Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma|A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb|||||||||||||||||||2018-06-01 03:52:34.577715|2018-06-01 03:52:34.577715
NCT00357448|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2018-05-01|2006-07-26|2006-07-27|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2005||2005-04-30|May 2018|2018-05-31||||November 2009|Actual|2009-11-30||Interventional|||Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer|Phase I Dose Escalation Study of Intraperitoneal (I.P.) ONTAK® Administered to Patients With Advanced Stage Ovarian Cancer|Active, not recruiting||Phase 1|11|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 03:52:34.637355|2018-06-01 03:52:34.637355
NCT00357435|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2018-05-23|2006-07-26|2006-07-27|Estimate|||||||2018-05-23|2018-05-24|Actual|October 6, 2003||2003-10-06|July 21, 2016|2016-07-21|July 21, 2016||2016-07-21|||||Observational|||Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases|Clinical and Molecular Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases|Completed|||86|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:34.706287|2018-06-01 03:52:34.706287
NCT00357422|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-12-02|2006-07-26|2006-07-27|Estimate|||||||2013-12-02|2013-12-04|Estimate|October 2005||2005-10-31|December 2013|2013-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparison Study of Operation and PEIT for Small, Solitary Hepatocellular Carcinoma (HCC)|Prospective Randomized Trial of the Effective Therapy for Small, Solitary HCC Comparing Operation and Percutaneous Ethanol Injection Therapy|Completed||Phase 3|36|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 03:52:34.759604|2018-06-01 03:52:34.759604
NCT00357409|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-06-30|2006-07-26|2006-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|February 11, 2002||2002-02-11|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||GABA Levels in the Brains of Blind People|GABA Levels in the Occipital Cortex of Blind Human Subjects|Completed|||39||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:34.81811|2018-06-01 03:52:34.81811
NCT00357396|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2015-10-22||2015-10-22|2006-07-26|2006-07-27|Estimate|2015-10-22|2015-11-25|Estimate||||2015-10-22|2015-11-25|Estimate|June 2005||2005-06-30|October 2015|2015-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors|A Phase II Trial of a Chemotherapy Based Regimen of Intravenous Busulfan (Busulfex), Melphalan and Thiotepa as Myeloablative Regimen Followed by a T- Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant From and HLA-Compatible Donor in the Treatment of High Risk Ewing's Sarcoma Family Tumors|Completed||Phase 2|10|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:52:34.963228|2018-06-01 03:52:34.963228
NCT00357383|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-26|2006-07-26|2006-07-27|Estimate|||||||2006-07-26|2006-07-27|Estimate|October 2002||2002-10-31|July 2006|2006-07-31|October 2002||2002-10-31|||||Interventional|||Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers|Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers|Completed||Phase 1|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:35.241241|2018-06-01 03:52:35.241241
NCT00357370|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2016-09-30||2017-03-31|2006-07-26|2006-07-27|Estimate|2017-03-31|2017-05-11|Actual||||2017-03-31|2017-05-11|Actual|October 2006||2006-10-31|March 2017|2017-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||All randomized patients who received at least 1 dose of study medication|A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes|A Pilot Study of the Efficacy and Safety of BMS-512148 on Glycemic Control in Subjects With Type 2 Diabetes Treated Aggressively But Not Controlled on Combination Antihyperglycemic Therapy With Metformin and/or Thiazolidinedione (TZD) and Insulin.|Completed||Phase 2/Phase 3|163|Actual|AstraZeneca|Cohort 1 data provided information on insulin dose adjustment (n=4).|4|||f||||f||||||||||2018-06-01 03:52:35.319241|2018-06-01 03:52:35.319241
NCT00357357|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2008-08-20|2006-07-26|2006-07-27|Estimate|||||||2008-08-20|2008-08-21|Estimate|July 2006||2006-07-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients|Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease|Completed||Phase 2|40|Anticipated|Hunter-Fleming Ltd||4|||f||||t||||||||||2018-06-01 03:52:35.805323|2018-06-01 03:52:35.805323
NCT00357344|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-06-30|2006-07-26|2006-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|May 24, 2006||2006-05-24|October 3, 2008|2008-10-03|October 3, 2008||2008-10-03|||||Observational|||Study of Effects From Gastric Bypass Weight Loss on Brain Tissue|Weight Changes and the Brain (Study of the Effects of a Large and Intentional Weight Loss Induced by Roux-en-Y Gastric Bypass on Brain Tissue Composition of Obese Patients Using Magnetic Resonance Imaging and Voxel-Based Morphometry)|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:35.889088|2018-06-01 03:52:35.889088
NCT00357331|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2017-02-21||2017-05-11|2006-07-26|2006-07-27|Estimate|2017-05-11|2017-06-12|Actual||||2017-05-11|2017-06-12|Actual|August 2006|Actual|2006-08-31|May 2017|2017-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Effects of Potassium Citrate on Bone Metabolism|A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia|Completed||Phase 4|83|Actual|Weill Medical College of Cornell University|Possible dual effect of calcium citrate, which mitigated the net effect of the alkalinizing treatment. The dose of K-citrate may not be sufficient to produce a change in BMD. Duration of treatment may have been too short to see changes in BMD.|2|||f||||t|t|f|||f|||No||2018-06-01 03:52:35.958057|2018-06-01 03:52:35.958057
NCT00357318|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2014-02-21|2006-07-26|2006-07-27|Estimate|||||||2014-02-21|2014-02-24|Estimate|June 2006||2006-06-30|June 2013|2013-06-30||||July 2012|Actual|2012-07-31||Interventional|||Bevacizumab and Sunitinib in Treating Patients With Solid Tumors|A Phase I Study of Bevacizumab in Combination With SU11248|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:52:36.227956|2018-06-01 03:52:36.227956
NCT00357305|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-05-01|2006-07-26|2006-07-27|Estimate|||||||2013-05-01|2013-05-03|Estimate|May 2006||2006-05-31|May 2013|2013-05-31||||November 2011|Actual|2011-11-30||Interventional|||Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders|Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or SAHA) in Combination With Cytosine Arabinoside (Ara-C) and Etoposide for Patients With Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:52:36.303501|2018-06-01 03:52:36.303501
NCT00357292|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-26|2006-07-26|2006-07-27|Estimate|||||||2006-07-26|2006-07-27|Estimate|March 2002||2002-03-31|July 2006|2006-07-31|April 2002||2002-04-30|||||Interventional|||Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers|Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers|Completed||Phase 1|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:36.395278|2018-06-01 03:52:36.395278
NCT00357279|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25||2011-03-24|2015-10-09|2006-07-26|2006-07-27|Estimate||||2011-03-30|2011-04-07|Estimate|2015-10-09|2015-11-04|Estimate|July 2006||2006-07-31|October 2015|2015-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease|A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease|Completed||Phase 3|352|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:52:36.442183|2018-06-01 03:52:36.442183
NCT00357266|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-06-30|2006-07-26|2006-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|February 1, 2002||2002-02-01|October 24, 2007|2007-10-24|October 24, 2007||2007-10-24|||||Observational|||Differences in Genes and Proteins in Active and Controlled Uveitis|Analysis of Differential Gene Expression Profiles in Patients With Defined Ocular Inflammatory Diseases Using CDNA Microarrays and Proteomics|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:36.501758|2018-06-01 03:52:36.501758
NCT00357253|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2013-01-08|2006-07-26|2006-07-27|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma|A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas and High Grade Gliomas|Completed||Phase 1|24|Actual|Pediatric Brain Tumor Consortium|||||f||||t||||||||||2018-06-01 03:52:36.555731|2018-06-01 03:52:36.555731
NCT00357240|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2011-04-07|2006-07-26|2006-07-27|Estimate|||||||2011-04-07|2011-04-08|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Drug Interaction Study With Proton Pump Inhibitor|Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Omeprazole 20 mg on the Pharmacokinetics of Atazanavir Administered With Ritonavir in Healthy Subjects|Completed||Phase 1|56||Bristol-Myers Squibb||8|||f||||||||||||||2018-06-01 03:52:36.637049|2018-06-01 03:52:36.637049
NCT00357227|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2007-04-18|2006-07-25|2006-07-27|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2004||2004-01-31|April 2007|2007-04-30||||||||Observational|||Atrial Fibrillation and the Risk for Neurological Complications|Atrial Fibrillation and the Risk for Neurological Complications|Unknown status|Recruiting||1000||University Hospital Muenster|||||f||||||||||||||2018-06-01 03:52:36.713068|2018-06-01 03:52:36.713068
NCT00357214|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-08-08|2006-07-26|2006-07-27|Estimate|||||||2011-08-08|2011-08-09|Estimate|September 2006||2006-09-30|August 2011|2011-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults|Effect of Potassium Bicarbonate on Bone and Muscle|Completed||Phase 2|171|Actual|Tufts University||4|||f||||f||||||||||2018-06-01 03:52:36.76156|2018-06-01 03:52:36.76156
NCT00357201|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-26|2006-07-26|2006-07-27|Estimate|||||||2006-07-26|2006-07-27|Estimate|November 2004||2004-11-30|July 2006|2006-07-31|May 2005||2005-05-31|||||Interventional|||Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome|Evaluation of the Efficacy of T1675, a Per Os Omega 3 and Omega 6 Polyunsaturated Essential Fatty Acid Dietary Formulation Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome|Completed||Phase 2|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:36.827335|2018-06-01 03:52:36.827335
NCT00357188|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-04-07|2006-07-26|2006-07-27|Estimate|||||||2011-04-07|2011-04-08|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects|Open-Label, Multiple Dose Study to Determine the Relative Bioavailability of Atazanavir (ATV) 400 mg Administered With Ritonavir (RTV) and Efavirenz (EFV) Compared to Atazanavir 300 mg Administered With Ritonavir Alone in Healthy Subjects|Completed||Phase 1|22||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 03:52:36.868545|2018-06-01 03:52:36.868545
NCT00357162|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2013-02-13||2014-05-02|2006-07-26|2006-07-27|Estimate|2013-02-13|2013-03-20|Estimate||||2014-05-02|2014-05-20|Estimate|May 2006||2006-05-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Belinostat in Treating Patients With Myelodysplastic Syndromes|Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:52:36.93771|2018-06-01 03:52:36.93771
NCT00357149|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2009-12-04|2006-07-26|2006-07-27|Estimate|||||||2009-12-04|2009-12-07|Estimate|January 2003||2003-01-31|December 2009|2009-12-31||||February 2008|Actual|2008-02-29||Interventional|||Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)|Randomized Phase II Trial of Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.|Completed||Phase 2|101|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:52:37.273599|2018-06-01 03:52:37.273599
NCT00357136|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2014-02-24|2006-07-26|2006-07-27|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2006||2006-07-31|February 2014|2014-02-28|July 2007|Actual|2007-07-31|December 2006|Actual|2006-12-31||Observational|||Online Survey on Computer Password Usage.||Completed|||50|Anticipated|Towson University|||||f||||||||||||||2018-06-01 03:52:37.340453|2018-06-01 03:52:37.340453
NCT00357123|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2011-02-18|2006-07-26|2006-07-27|Estimate|||||||2011-02-18|2011-02-21|Estimate|August 2006||2006-08-31|September 2010|2010-09-30|September 2011|Anticipated|2011-09-30|July 2011|Anticipated|2011-07-31||Interventional|||Effect of Rosuvastatin in Abdominal Sepsis|Use of Rosuvastatin in Integral Management of Abdominal Sepsis|Unknown status|Recruiting|Phase 2|60|Anticipated|Universidad Autonoma de San Luis Potosí|||||f||||t||||||||||2018-06-01 03:52:37.387786|2018-06-01 03:52:37.387786
NCT00357110|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|2009-12-18||2010-12-03|2006-07-26|2006-07-27|Estimate|2009-12-18|2010-01-22|Estimate||||2010-12-03|2010-12-21|Estimate|April 2006||2006-04-30|December 2010|2010-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|@FAME||Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer|A Randomised Phase II Study Comparing Anastrozole and Fulvestrant to Anastrozole for Adjuvant Treatment of Postmenopausal Patients With Early Breast Cancer and Disseminated Tumour Cells in Bone Marrow|Completed||Phase 2|13|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:52:37.474187|2018-06-01 03:52:37.474187
NCT00357097|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2008-12-12||2012-05-31|2006-07-26|2006-07-27|Estimate|2009-08-11|2009-09-16|Estimate||||2012-05-31|2012-06-07|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome|A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany|Completed||Phase 3|240|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:52:37.772435|2018-06-01 03:52:37.772435
NCT00357084|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2010-09-10|2006-07-26|2006-07-27|Estimate|||||||2010-09-10|2010-09-14|Estimate|May 2006||2006-05-31|September 2010|2010-09-30||||August 2007|Actual|2007-08-31||Interventional|||Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant|A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation|Completed||Phase 2|53|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 03:52:38.277931|2018-06-01 03:52:38.277931
NCT00357071|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2018-03-27|2006-07-26|2006-07-27|Estimate|||||||2018-03-27|2018-03-29|Actual|April 7, 2003||2003-04-07|January 29, 2018|2018-01-29||||||||Observational|||Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases|Evaluation of Immune Responses to Different Antigens in Non Infectious Ocular Inflammatory Diseases|Enrolling by invitation|||220|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:38.369607|2018-06-01 03:52:38.369607
NCT00357058|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-06-30|2006-07-26|2006-07-27|Estimate|||||||2017-06-30|2017-07-02|Actual|December 12, 2001||2001-12-12|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Observational|||Role of Brain Region Changes in Tactile (Touch) Ability Following Nerve Block|Substrates Mediating Deafferentiation-Induced Enhancement of Tactile Spatial Acuity|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:52:38.418317|2018-06-01 03:52:38.418317
NCT00357045|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-25|2006-07-25|2006-07-27|Estimate|||||||2006-07-25|2006-07-27|Estimate||||December 2003|2003-12-31||||||||Interventional|||Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine|Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine; THE HEPDEP II STUDY|Completed||Phase 4|||Portland VA Medical Center|||||f||||||||||||||2018-06-01 03:52:38.461608|2018-06-01 03:52:38.461608
NCT00357032|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2014-10-08||2018-03-19|2006-07-26|2006-07-27|Estimate|2014-10-08|2014-10-13|Estimate||||2018-03-19|2018-04-17|Actual|May 2006||2006-05-31|March 2018|2018-03-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||PXD101 in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of PXD101 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or Patients Over 60 With Newly-Diagnosed Acute Myelogenous Leukemia|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:52:38.52824|2018-06-01 03:52:38.52824
NCT00357019|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2006-07-26|2006-07-26|2006-07-27|Estimate|||||||2006-07-26|2006-07-27|Estimate|April 2001||2001-04-30|July 2006|2006-07-31|October 2002||2002-10-31|||||Interventional|||Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis|Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis|Completed||Phase 4|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:38.780381|2018-06-01 03:52:38.780381
NCT00357006|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2015-03-01||2015-05-07|2006-07-26|2006-07-27|Estimate|2015-03-30|2015-04-01|Estimate||||2015-05-07|2015-05-12|Estimate|July 2006||2006-07-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|October 2011|Actual|2011-10-31||Interventional|||A Definitive Estrogen Patch Study (ADEPT)|Multisite Double-Blind Randomized Controlled Study of Estradiol Plus Antipsychotic Versus Placebo Plus Antipsychotic in the Treatment of Psychotic Symptoms in Women With Schizophrenia|Completed||Phase 2|180|Actual|The Alfred||3|||f||||t||||||||||2018-06-01 03:52:38.837513|2018-06-01 03:52:38.837513
NCT00356993|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2017-04-05|2006-07-25|2006-07-27|Estimate|||||||2017-04-05|2017-04-06|Actual|October 2005||2005-10-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)|The STOP (Stop Smoking Therapy for Ontario Patients) Study: The Effectiveness of Nicotine Replacement Therapy in Ontario Smokers.|Recruiting||N/A|10000|Anticipated|Centre for Addiction and Mental Health||1|||f||||f||||||||No||2018-06-01 03:52:39.076388|2018-06-01 03:52:39.076388
NCT00356980|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2012-03-14|2006-07-26|2006-07-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors|A Phase I Trial of TNF-Bound Colloidal Gold (CYT-6091) by Intravenous Administration in Subjects With Advanced Solid Organ Malignancies|Completed||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 03:52:39.143954|2018-06-01 03:52:39.143954
NCT00356967|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2008-12-18|2006-07-26|2006-07-27|Estimate|||||||2008-12-18|2008-12-19|Estimate|June 2006||2006-06-30|December 2008|2008-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|EURODIAN||Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation|An International 7-Week, Double-Blind, Placebo-Controlled, 2-Parallel Group Study to Assess the Efficacy of Dianicline 40 mg BID as an Aid to Smoking Cessation in Cigarette Smokers|Completed||Phase 3|602|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:52:39.195375|2018-06-01 03:52:39.195375
NCT00356954|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2006-11-24|2006-07-26|2006-07-27|Estimate|||||||2006-11-24|2006-11-27|Estimate|February 2005||2005-02-28|November 2006|2006-11-30|April 2006||2006-04-30|||||Interventional|||NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization|N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization: NASPI Study-A Randomized Controlled Trial|Completed||Phase 4|250||Seoul National University Hospital|||||f||||||||||||||2018-06-01 03:52:39.253495|2018-06-01 03:52:39.253495
NCT00356941|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-11-27|2006-07-26|2006-07-27|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2006||2006-04-30|November 2017|2017-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC|Phase I Study of Oxaliplatin in Combination With Docetaxel and Radiotherapy in Patients With Unresectable or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|4|Actual|Masonic Cancer Center, University of Minnesota||1||Withdrawn due to lack of accrual|f||||t||||||||||2018-06-01 03:52:39.317464|2018-06-01 03:52:39.317464
NCT00356928|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|||2017-07-12|2006-07-26|2006-07-27|Estimate|||||||2017-07-12|2017-07-13|Actual|May 2006||2006-05-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||Cyclophosphamide Plus Transplantation of Partially HLA-mismatched, CD8+ T Cell-depleted Peripheral Blood Cells for Patients With Myelodysplastic Syndrome , Refractory Acute Myeloid Leukemia, Refractory Lymphoma or Myeloproliferative Disorders|Cyclophosphamide Plus Transplantation of Partially HLA-Mismatched (Haploidentical), CD8+ T Cell-Depleted Peripheral Blood Cells (PBCs) for Patients With Myelodysplastic (MDS) or Myeloproliferative Disorders (MPD)|Active, not recruiting||N/A|9|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||t||||||||||2018-06-01 03:52:39.380662|2018-06-01 03:52:39.380662
NCT00356915|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2010-10-01||2016-12-16|2006-07-25|2006-07-27|Estimate|2011-11-29|2012-01-04|Estimate||||2016-12-16|2017-02-09|Estimate|July 2006||2006-07-31|December 2016|2016-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.|A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail.|Completed||Phase 3|1381|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:52:39.463233|2018-06-01 03:52:39.463233
NCT00356902|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2007-09-14|2006-07-26|2006-07-27|Estimate|||||||2007-09-14|2007-09-18|Estimate|July 2005||2005-07-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of Different Oxygen Delivery Strategies During Resuscitation of Babies|Effect of Titrating Oxygen Concentration During Resuscitation of the Newborn on Achieving Normoxemia|Completed||N/A|215|Anticipated|University of Calgary|||||f||||||||||||||2018-06-01 03:52:40.361501|2018-06-01 03:52:40.361501
NCT00356889|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-26|2013-02-22||2014-05-12|2006-07-26|2006-07-27|Estimate|2013-04-01|2013-05-20|Estimate||||2014-05-12|2014-05-28|Estimate|May 2006||2006-05-31|April 2013|2013-04-30|June 2010|Actual|2010-06-30|October 2008|Actual|2008-10-31||Interventional|||Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors|A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:52:40.445925|2018-06-01 03:52:40.445925
NCT00356863|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2010-06-08||2017-10-17|2006-07-25|2006-07-26|Estimate|2012-02-26|2012-03-26|Estimate||||2017-10-17|2017-11-20|Actual|February 2004||2004-02-29|October 2017|2017-10-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|MECRIS||Effect of an Educational Intervention on Cardiac Patients' Participation Rate in Cardiac Rehabilitation Programs|The Influence of Increasing Awareness of Cardiac Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery to Cardiac Rehabilitation (CR) on Actual Participation Rates and; Patients' Related Barriers to CR Programs Participation|Completed||N/A|1024|Actual|Sheba Medical Center|"Lack of randomization~No biochemical tests were performed by the study and information regarding biochemical parameters was drawn from the medical records during baseline and from medical documents during follow up."|2|||f||||f||||||||||2018-06-01 03:52:40.819411|2018-06-01 03:52:40.819411
NCT00356850|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-25|2006-07-25|2006-07-26|Estimate|||||||2006-07-25|2006-07-26|Estimate|May 2002||2002-05-31|July 2006|2006-07-31|June 2002||2002-06-30|||||Interventional|||Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers|Ocular Pharmacokinetics After a Single Drop Instillation, in Each Eye of One of Three Different Concentrations of T1225 (0.5% - 1% - 1.5% Dihydrate) in 91 Healthy Volunteers|Completed||Phase 1|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:41.208546|2018-06-01 03:52:41.208546
NCT00356837|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2010-12-10|2006-07-24|2006-07-26|Estimate|||||||2010-12-10|2010-12-13|Estimate|August 2006||2006-08-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Diagnosing Extremity Fractures and/or Dislocations Using Ultrasound Presenting to the Emergency Department|Diagnosing Extremity Fractures and/or Dislocations Using Ultrasound in Adult Patients Presenting to the Emergency Department|Terminated||N/A|323|Anticipated|United States Army Institute of Surgical Research||1||IRB terminated study due to non compliance with continuing review date.|f||||f||||||||||2018-06-01 03:52:41.252292|2018-06-01 03:52:41.252292
NCT00356824|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2010-07-30|2006-07-25|2006-07-26|Estimate|||||||2010-07-30|2010-08-02|Estimate|November 2005||2005-11-30|July 2010|2010-07-31|May 2010|Actual|2010-05-31|April 2007|Actual|2007-04-30||Observational|||Relationship Between HIV and Malaria in Ugandan Children|"Prospective Longitudinal Study of Interactions Between HIV and Malaria in Ugandan Children: A UCSF/Makerere University Children With HIV and Malaria Project"|Completed|||300|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 03:52:41.308491|2018-06-01 03:52:41.308491
NCT00356811|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2014-05-08||2014-06-19|2006-07-25|2006-07-26|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|May 2006||2006-05-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|March 2008|Actual|2008-03-31||Interventional|||Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer|An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients|Completed||Phase 2|57|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:52:41.39053|2018-06-01 03:52:41.39053
NCT00356798|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2007-11-08|2006-07-25|2006-07-26|Estimate|||||||2007-11-08|2007-11-09|Estimate|December 2005||2005-12-31|November 2007|2007-11-30|April 2006||2006-04-30|||||Interventional|||Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects|The Phase-I Clinical Trial Protocol for the Pandemic Inactivated Influenza Vaccine|Completed||Phase 1|120||Sinovac Biotech Co., Ltd|||||f||||||||||||||2018-06-01 03:52:41.655396|2018-06-01 03:52:41.655396
NCT00356785|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-25|2006-07-25|2006-07-26|Estimate|||||||2006-07-25|2006-07-26|Estimate|January 2001||2001-01-31|April 2006|2006-04-30|December 2001||2001-12-31|||||Interventional|||Changes in Body Composition and Metabolic Risk Parameters by Life Style Intervention.|Body Compositional and Endocrine-Metabolic Changes by Long-Term Lifestyle Intervention With Health Education, Diet (Almased®), Physical Activity or a Combination of Diet and Physical Activity in Overweight and Obese Persons.|Completed||N/A|90||University Hospital Freiburg|||||f||||||||||||||2018-06-01 03:52:41.704561|2018-06-01 03:52:41.704561
NCT00356772|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-25|2006-07-25|2006-07-26|Estimate|||||||2006-07-25|2006-07-26|Estimate|February 2003||2003-02-28|July 2006|2006-07-31|March 2003||2003-03-31|||||Interventional|||Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers|Comparison of Azithromycin Level in Tears and in Conjunctiva After Repeated Instillations of T1225 1.5% Eye Drops or After a Single Per Os Administration of Zithromax® (Azithromycin 1g), in 36 Healthy Volunteers|Completed||Phase 1|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:41.754658|2018-06-01 03:52:41.754658
NCT00356759|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2010-02-26|2006-07-25|2006-07-26|Estimate|||||||2010-02-26|2010-03-01|Estimate|December 2006||2006-12-31|December 2008|2008-12-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients|A Randomized Double-blind Study of 4-weekly Versus 12-weekly Monitoring of Stable Patients on Long-term Anticoagulation With Warfarin|Completed||Phase 2|250|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 03:52:41.808536|2018-06-01 03:52:41.808536
NCT00356720|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-25|2006-07-25|2006-07-26|Estimate|||||||2006-07-25|2006-07-26|Estimate|January 2004||2004-01-31|July 2006|2006-07-31|May 2004||2004-05-31|||||Interventional|||Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma|Clinical Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% (Instilled Twice Daily for 2 or 3 Days) Versus Oral Azithromycin in Treatment of Trachoma|Completed||Phase 3|||Laboratoires Thea|||||f||||||||||||||2018-06-01 03:52:42.93476|2018-06-01 03:52:42.93476
NCT00356707|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2012-03-27|2006-07-25|2006-07-26|Estimate|||||||2012-03-27|2012-03-28|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Evaluating the Link Between Neighborhood Environments and Obesity Among African American Women|Effect of Urban Form on Exercise and BMI in Black Women|Completed|||23000|Actual|Boston University|||1||f||||f||||||||||2018-06-01 03:52:42.987246|2018-06-01 03:52:42.987246
NCT00356681|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24||2015-04-16|2015-09-24|2006-07-24|2006-07-26|Estimate||||2015-04-16|2015-05-06|Estimate|2015-09-24|2015-10-15|Estimate|December 2006||2006-12-31|September 2015|2015-09-30|August 2012|Actual|2012-08-31|February 2009|Actual|2009-02-28||Interventional|||A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer|A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer|Terminated||Phase 2|282|Actual|Amgen||3||Sponsor decision to close study|f||||t||||||||||2018-06-01 03:52:43.058486|2018-06-01 03:52:43.058486
NCT00356668|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2015-07-13|2006-07-24|2006-07-26|Estimate|||||||2015-07-13|2015-07-14|Estimate|July 2006||2006-07-31|July 2015|2015-07-31|September 2007|Actual|2007-09-30|||||Interventional|||Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure|Observational, Cross-over Study of the Positive Distending Pressure Generated by Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure|Completed||Phase 3|16|Actual|Children's Hospitals and Clinics of Minnesota|||||f||||||||||||||2018-06-01 03:52:43.149595|2018-06-01 03:52:43.149595
NCT00356655|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2008-05-12|2006-07-25|2006-07-26|Estimate|||||||2008-05-12|2008-05-14|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|January 2009|Anticipated|2009-01-31|||||Interventional|||The ACHIEVA Study of Enhanced Pharmacist Care on Antidepressant Use and Response|A COHORT AND INTERVENTION STUDY EVALUATING ANTIDEPRESSANT EPIDEMIOLOGY AND ADHERENCE: The ACHIEVA Study|Terminated||N/A|106|Anticipated|University of Alberta||||Low recruitment|f||||||||||||||2018-06-01 03:52:43.222123|2018-06-01 03:52:43.222123
NCT00356642|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2017-09-27|2006-07-25|2006-07-26|Estimate|||||||2017-09-27|2017-09-29|Actual|June 10, 2005|Actual|2005-06-10|September 2017|2017-09-30|December 21, 2005|Actual|2005-12-21|December 21, 2005|Actual|2005-12-21||Interventional|||Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis|A Randomised, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Ten Day Repeat Topical Applications of GW842470X Cream on the Skin of Patients With Atopic Dermatitis|Completed||Phase 1|45|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 03:52:43.296084|2018-06-01 03:52:43.296084
NCT00356629|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2008-11-13|2006-07-25|2006-07-26|Estimate|||||||2008-11-13|2008-11-14|Estimate|July 2006||2006-07-31|November 2008|2008-11-30|July 2008|Anticipated|2008-07-31|||||Observational|||Development of a Noninvasive Method of Evaluation of Pulmonary Inflammation in the Condensates of Exhaled Air|Development of a Noninvasive Method of Evaluation of the Pulmonary Inflammation in the Condensates of Exhaled Air|Terminated|||100|Anticipated|University Hospital, Tours||||Technical problem|f||||f||||||||||2018-06-01 03:52:43.460459|2018-06-01 03:52:43.460459
NCT00356616|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2008-01-25|2006-07-25|2006-07-26|Estimate|||||||2008-01-25|2008-01-29|Estimate|September 2005||2005-09-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients|Open-Label, Single-Centre, Randomised Pilot Study to Evaluate Immunovirological and Clinical Evolution of a Combination With Nucleoside Analogues/Nucleotides (Trizivir +Tenofovir) in Multiresistant Patients With Virological Failure|Terminated||Phase 4|24|Actual|Germans Trias i Pujol Hospital||2||terminated|f||||f||||||||||2018-06-01 03:52:43.537924|2018-06-01 03:52:43.537924
NCT00356603|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2017-06-22||2017-11-17|2006-07-25|2006-07-26|Estimate|2017-11-17|2017-11-20|Actual||||2017-11-17|2017-11-20|Actual|June 20, 2006|Actual|2006-06-20|June 2017|2017-06-30|August 7, 2006|Actual|2006-08-07|August 7, 2006|Actual|2006-08-07||Interventional|||Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan|Imigran STATdose - Japan Clinical Experience Study for Self-injection|Completed||Phase 3|75|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:52:43.637683|2018-06-01 03:52:43.637683
NCT00356590|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2010-11-05||2013-05-10|2006-07-24|2006-07-26|Estimate|2010-11-05|2010-12-08|Estimate||||2013-05-10|2013-05-14|Estimate|December 1998||1998-12-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012|Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012|Completed||Phase 3|468|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:52:44.044818|2018-06-01 03:52:44.044818
NCT00356564|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2016-10-11|2006-07-25|2006-07-26|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2006||2006-07-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib|Multicentre Study to Assess Persistence of Antibodies Against Hepatitis B and Immune Response to a Hepatitis B Challenge Dose in Healthy Children 7 to 9 Years Old Previously Vaccinated With 4 Doses of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine|Completed||Phase 4|350||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:52:44.842949|2018-06-01 03:52:44.842949
NCT00356551|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2016-07-29|2006-07-25|2006-07-26|Estimate|||||||2016-07-29|2016-08-01|Estimate|May 2002||2002-05-31|July 2016|2016-07-31|September 2005||2005-09-30|||||Interventional|||Family Spirit Study|Family Strengthening in Native Communities Project|Completed||N/A|320||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:52:44.986917|2018-06-01 03:52:44.986917
NCT00356525|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2009-06-08||2010-08-09|2006-07-24|2006-07-26|Estimate|2009-06-08|2009-07-29|Estimate||||2010-08-09|2010-08-17|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|April 2009|Actual|2009-04-30|June 2008|Actual|2008-06-30||Interventional|||Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor|Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs. Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy|Terminated||Phase 2|41|Actual|Eli Lilly and Company|The trial terminated early due to slow enrollment. Secondary outcomes were not analyzed due to insufficient data. Original results reported were interim analyses. Results have now been updated with final data.|4||Stopped early due to low enrollment|f||||f||||||||||2018-06-01 03:52:45.120624|2018-06-01 03:52:45.120624
NCT00356486|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2009-09-02|2006-07-25|2006-07-26|Estimate|||||||2009-09-02|2009-09-03|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV|Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a (40 KD) (270 μg/Week) and Ribavirin (1600 mg/Day) With Epoetin β Support (450 IU/kg/Week)|Completed||Phase 4|74|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 03:52:46.352228|2018-06-01 03:52:46.352228
NCT00356473|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2012-06-21|2006-07-25|2006-07-26|Estimate|||||||2012-06-21|2012-06-22|Estimate|March 2003||2003-03-31|June 2006|2006-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Effects of Atorvastatin on Disease Activity and HDL Cholesterol Function in Patients With Rheumatoid Arthritis|Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis|Completed||Phase 4|20|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 03:52:46.440136|2018-06-01 03:52:46.440136
NCT00356460|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2014-03-17|2006-07-24|2006-07-26|Estimate|||||||2014-03-17|2014-03-19|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma|A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti Transforming Growth Factor-beta (TGFβ) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma|Completed||Phase 1|29|Actual|Sanofi||8|||f||||t||||||||||2018-06-01 03:52:46.511446|2018-06-01 03:52:46.511446
NCT00356447|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2014-09-30|2006-07-25|2006-07-26|Estimate|||||||2014-09-30|2014-10-01|Estimate|May 2006||2006-05-31|September 2014|2014-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.|A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq® (Drospirenone 2mg and Estradiol 1mg) in Postmenopausal Chinese Women With Vasomotor Symptoms Over Four 28-day Treatment Cycles.|Completed||Phase 3|249|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:52:46.599158|2018-06-01 03:52:46.599158
NCT00356434|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2017-04-18||2017-07-20|2006-07-24|2006-07-26|Estimate|2017-07-20|2017-08-18|Actual||||2017-07-20|2017-08-18|Actual|November 2008||2008-11-30|July 2017|2017-07-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population|Study of Patient Compliance and Comfort Using Sequential Compression Devices and Foot Pumps for DVT Prevention|Terminated||N/A|11|Actual|Johns Hopkins University||2||PI assigned to a different hospital;difficulty recruiting patients|f||||f||||||||||2018-06-01 03:52:46.688426|2018-06-01 03:52:46.688426
NCT00356421|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2009-06-24||2009-08-25|2006-07-24|2006-07-26|Estimate|2009-06-24|2009-08-11|Estimate||||2009-08-25|2009-09-02|Estimate|November 2006||2006-11-30|January 2009|2009-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®|A 52-Week Multicenter, Open-Label, Randomized, Parallel, Two - Arm Study Comparing Exubera® (Inhaled Human Insulin) Vs. Humalog® (Insulin Lispro), Both In Combination With Insulin Glargine In Subjects With Type 1 Diabetes Mellitus|Terminated||Phase 4|58|Actual|Pfizer|As a result of Pfizer’s decision to stop marketing Exubera ®, this study was terminated. Due to the early termination of the study and the low number of subjects who completed, no descriptive statistics for efficacy endpoints are provided.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 03:52:46.985191|2018-06-01 03:52:46.985191
NCT00356408|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|2011-02-23||2014-08-26|2006-07-25|2006-07-26|Estimate|2011-04-21|2011-05-25|Estimate||||2014-08-26|2014-09-05|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|COSPAR II||Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease|An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).|Completed||Phase 3|106|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:52:47.542975|2018-06-01 03:52:47.542975
NCT00356395|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2006-07-25|2006-07-25|2006-07-26|Estimate|||||||2006-07-25|2006-07-26|Estimate|August 2003||2003-08-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Safety and Effects of Ramipril Combined With Candesartan|Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients|Completed||Phase 4|40||Gachon University Gil Medical Center|||||f||||||||||||||2018-06-01 03:52:48.376708|2018-06-01 03:52:48.376708
NCT00356382|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2008-05-12|2006-07-25|2006-07-26|Estimate|||||||2008-05-12|2008-05-14|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Decreasing Rates of Illness in Kids (DRINK)|Decreasing Rates of Illnesses in Kids (DRINK)|Completed||Phase 3|638||Georgetown University|||||f||||t||||||||||2018-06-01 03:52:48.422466|2018-06-01 03:52:48.422466
NCT00356369|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25||2012-07-26|2016-10-24|2006-07-25|2006-07-26|Estimate||||2012-07-26|2012-08-03|Estimate|2016-10-24|2016-10-25|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|February 2008|Actual|2008-02-29|September 2007|Actual|2007-09-30||Interventional|||Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine|Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age)|Completed||Phase 2|500|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:52:48.470064|2018-06-01 03:52:48.470064
NCT00356356|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2013-05-10|2006-07-24|2006-07-26|Estimate|||||||2013-05-10|2013-05-14|Estimate|April 2002||2002-04-30|May 2013|2013-05-31|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||16.0040 Ankylosing Spondylitis Study|Open-label, Long-term Extension Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis Who Participated in Protocol 16.0037|Completed||Phase 3|257|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:52:48.643092|2018-06-01 03:52:48.643092
NCT00356343|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-25|||2011-01-09|2006-07-25|2006-07-26|Estimate|||||||2011-01-09|2011-01-11|Estimate|July 2004||2004-07-31|January 2011|2011-01-31||||September 2009|Anticipated|2009-09-30||Interventional|||Strength Training Using Neuromuscular Electrical Stimulation For Children With Cerebral Palsy|Strength Training Using NMES for Children With Cerebral Palsy|Unknown status|Active, not recruiting|Phase 1|45|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||3|||f||||t||||||||||2018-06-01 03:52:48.715615|2018-06-01 03:52:48.715615
NCT00356304|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|2014-02-24||2014-04-10|2006-07-21|2006-07-25|Estimate|2014-04-10|2014-05-08|Estimate||||2014-04-10|2014-05-08|Estimate|April 2006||2006-04-30|April 2014|2014-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression|Antidepressant Adherence Among Hispanics: A Motivational Interviewing Approach|Completed||Phase 1|50|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 03:52:48.939781|2018-06-01 03:52:48.939781
NCT00356291|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2013-07-23|2006-07-21|2006-07-25|Estimate|||||||2013-07-23|2013-07-25|Estimate|April 2007||2007-04-30|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Improving HIV Prevention Skills in People With Serious Mental Illnesses|HIV Prevention for the Mentally Ill: Motivation-Skills|Completed||Phase 2|53|Actual|Boston Medical Center||2|||f||||||||||||||2018-06-01 03:52:49.126216|2018-06-01 03:52:49.126216
NCT00356278|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2014-11-07||2016-01-06|2006-07-24|2006-07-25|Estimate|2014-11-17|2014-11-19|Estimate||||2016-01-06|2016-01-08|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD|A Cognitive Enhancer May Facilitate Behavioral Exposure Therapy for Veterans With PTSD|Completed||Phase 2/Phase 3|156|Actual|Emory University|The study had a high dropout rate. 31 participants dropped out before the first treatment session. Although disheartening, the dropout rate is similar to rates in other studies with veterans and active duty personnel.|3|||f||||f||||||||||2018-06-01 03:52:49.214645|2018-06-01 03:52:49.214645
NCT00356265|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2017-11-08||2017-12-28|2006-07-24|2006-07-25|Estimate|2017-12-28|2018-01-23|Actual||||2017-12-28|2018-01-23|Actual|July 2006|Actual|2006-07-31|December 2017|2017-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide|Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide|Terminated||N/A|18|Actual|University of Michigan||3||"Futility: Impossible to recruit enough hypertensive participants to match Chronic Kidney~   Disease (CKD) participants on needed parameters."|f||||||||||||||2018-06-01 03:52:49.660327|2018-06-01 03:52:49.660327
NCT00356252|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2008-07-23|2006-07-24|2006-07-25|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 2002||2002-04-30|July 2008|2008-07-31|December 2003||2003-12-31|||||Interventional|||Biological Functions of Carotenoids in Humans|Functional Bioavailability of Carotenoids in Humans|Completed||N/A|40||Tufts University|||||f||||||||||||||2018-06-01 03:52:50.049333|2018-06-01 03:52:50.049333
NCT00356239|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2007-04-09|2006-07-24|2006-07-25|Estimate|||||||2007-04-09|2007-04-11|Estimate|July 2006||2006-07-31|April 2007|2007-04-30||||||||Observational|||Implantable Cardioverter Defibrillators And Magnetic Resonance Imaging of the Heart at 1.5 Tesla|Evaluation of Safety and Feasibility Magnetic Resonance Imaging of the Heart at 1.5 Tesla In Patients With Implantable Cardioverter Defibrillators|Unknown status|Recruiting||25||University Hospital, Bonn|||||f||||t||||||||||2018-06-01 03:52:50.100112|2018-06-01 03:52:50.100112
NCT00356226|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2006-11-30|2006-07-24|2006-07-25|Estimate|||||||2006-11-30|2006-12-04|Estimate|October 2000||2000-10-31|October 2000|2000-10-31||||||||Interventional|||The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients|The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients With Ascites and Activation of Sympathetic Nervous System: a Randomized Double-Blind Placebo Controlled Study.|Completed||N/A|64||CHU de Charleroi|||||f||||||||||||||2018-06-01 03:52:50.155217|2018-06-01 03:52:50.155217
NCT00356213|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2017-09-13|2006-07-24|2006-07-25|Estimate|||||||2017-09-13|2017-09-14|Actual|October 30, 2006|Actual|2006-10-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Comparison of Laparoscopic Sleeve Gastrectomy and Roux-Y-gastric Bypass in the Treatment of Morbid Obesity|Laparoscopic Sleeve Gastrectomy or Laparoscopic Proximal Roux-Y-gastric Bypass in the Treatment of Morbid Obesity|Completed||N/A|217|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 03:52:50.212598|2018-06-01 03:52:50.212598
NCT00356200|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2010-11-15||2010-12-20|2006-07-24|2006-07-25|Estimate|2010-12-20|2010-12-22|Estimate||||2010-12-20|2010-12-22|Estimate|July 2006||2006-07-31|December 2010|2010-12-31|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Interventional|||Fluphenazine Decanoate for Psoriasis|Ascending-Dose, Double-Blind, Placebo-Controlled, Bilateral Study of Intralesional Fluphenazine Decanoate in Psoriasis|Terminated||Phase 2|10|Actual|Tufts Medical Center||2||Enrollment criteria met|f||||f||||||||||2018-06-01 03:52:50.290862|2018-06-01 03:52:50.290862
NCT00356187|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2018-01-09||2018-02-20|2006-07-24|2006-07-25|Estimate|2018-01-09|2018-02-07|Actual||||2018-02-20|2018-03-15|Actual|February 15, 2006|Actual|2006-02-15|February 2018|2018-02-28|January 31, 2009|Actual|2009-01-31|January 31, 2009|Actual|2009-01-31||Interventional||Insufficient enrollment to derive any results. Study closed in 2009 and is past the HIPAA data retention date. PI has left institution and does not have any access to any data.|Beta Blockade in Critical Injury|Beta-blockade Reduces Catabolism in Severely Injured Trauma Patients|Terminated||Phase 2|15|Actual|Denver Health and Hospital Authority||2||Slow enrollment, end of funding|f|||||t|f||||||||2018-06-01 03:52:50.55996|2018-06-01 03:52:50.55996
NCT00356174|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2016-09-26|2006-07-21|2006-07-25|Estimate|||||||2016-09-26|2016-09-28|Estimate|July 2006||2006-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Observational|||An Observational Study of Childhood Food Allergy|A Prospective Cohort Study of Immune Mechanisms, Genetic Factors, and Clinical and Environmental Characteristics Associated With the Occurrence and Clinical Outcome of Food Allergy (CoFAR2)|Completed|||515|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||t||||||Samples With DNA|"~     Buccal swab (DNA)~   "|||2018-06-01 03:52:50.697198|2018-06-01 03:52:50.697198
NCT00356161|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2006-07-24|2006-07-24|2006-07-25|Estimate|||||||2006-07-24|2006-07-25|Estimate|April 2002||2002-04-30|July 2006|2006-07-31|April 2008||2008-04-30|||||Interventional|||HAI Via Interventionally Implanted Port Catheter Systems|Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms.|Unknown status|Recruiting|Phase 2|100||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 03:52:50.772122|2018-06-01 03:52:50.772122
NCT00356148|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2012-04-20||2012-12-19|2006-07-24|2006-07-25|Estimate|2012-12-19|2013-01-30|Estimate||||2012-12-19|2013-01-30|Estimate|October 2003||2003-10-31|December 2012|2012-12-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.|Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25.|Completed||Phase 4|372|Actual|Marmara University||2|||f||||t||||||||||2018-06-01 03:52:50.860325|2018-06-01 03:52:50.860325
NCT00355966|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2010-03-24|2006-07-24|2006-07-25|Estimate|||||||2010-03-24|2010-03-25|Estimate|August 2006||2006-08-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of Misoprostol and PGE2 Gel for Induction of Labour in Women With Premature Rupture of Membranes at Term|Comparison of Misorostol & PGE2 Gel for Immediate Induction of Labour for Premature Ropture of Membranes at Term|Completed||Phase 4|212|Actual|Nilratan Sircar Medical College||2|||f||||t||||||||||2018-06-01 03:52:55.187814|2018-06-01 03:52:55.187814
NCT00356135|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|2009-12-10||2010-10-20|2006-07-21|2006-07-25|Estimate|2010-02-22|2010-03-09|Estimate||||2010-10-20|2010-11-03|Estimate|July 2006||2006-07-31|October 2010|2010-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|SWAP||Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event|A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndrome Who Are Receiving Clopidogrel|Completed||Phase 2|139|Actual|Eli Lilly and Company||3|||f||||||||||||||2018-06-01 03:52:51.057268|2018-06-01 03:52:51.057268
NCT00356122|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2011-08-09||2011-10-07|2006-07-24|2006-07-25|Estimate|2011-08-09|2011-09-16|Estimate||||2011-10-07|2011-10-17|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase II Multicenter Study of Docetaxel and Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Chemotherapy-Naïve Subjects With Unresectable Locally Advanced and/or Recurrent (Stage IIIB) or Metastatic (Stage IV) Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|53|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:52:52.014306|2018-06-01 03:52:52.014306
NCT00356109|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21||2018-03-07|2018-03-07|2006-07-21|2006-07-25|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|August 2006||2006-08-31|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes|A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|494|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 03:52:52.355175|2018-06-01 03:52:52.355175
NCT00356096|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2012-05-18|2006-07-24|2006-07-25|Estimate|||||||2012-05-18|2012-05-21|Estimate|July 2006||2006-07-31|May 2012|2012-05-31||||June 2007|Actual|2007-06-30||Interventional|||Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances|A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances|Completed||Phase 4|404|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:52:52.500044|2018-06-01 03:52:52.500044
NCT00356083|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2016-07-28|2006-07-24|2006-07-25|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Opioid Rotation From Morphine to Methadone in Treatment of Non-malignant Pain|Opioid Switching From Oral Slow Release Morphine to Oral Methadone May Improve Pain Control in Chronic Non-malignant Pain: a Nine-month Follow-up Study.|Completed||Phase 3|12|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-06-01 03:52:52.608459|2018-06-01 03:52:52.608459
NCT00356070|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2017-04-26|2006-07-24|2006-07-25|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2006|Actual|2006-01-31|April 2017|2017-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison|Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison|Completed||N/A|40||Norwegian University of Science and Technology|||||f||||||||||||||2018-06-01 03:52:52.66842|2018-06-01 03:52:52.66842
NCT00356057|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|2008-12-02||2018-01-29|2006-07-24|2006-07-25|Estimate|2011-06-10|2011-07-08|Estimate||||2018-01-29|2018-02-27|Actual|December 2004||2004-12-31|January 2018|2018-01-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|AVAIL||Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace|AVAIL CLS/CRT: AV-node Ablation With CLS and CRT Pacing Therapies for the Treatment of AF|Terminated||N/A|153|Actual|Biotronik, Inc.|Early termination due lack of enrollment.|3||Slow enrollment.|f||||f||||||||||2018-06-01 03:52:52.762093|2018-06-01 03:52:52.762093
NCT00356044|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2007-07-10|2006-07-24|2006-07-25|Estimate|||||||2007-07-10|2007-07-11|Estimate|May 2004||2004-05-31|July 2007|2007-07-31|December 2005|Actual|2005-12-31|||||Interventional|||Arterial Access for Coronary Intervention in Myocardial Infarction|Femoral Versus Radial Access for Coronary Intervention in the Acute Phase of ST-Elevation Myocardial Infarction|Completed||Phase 4|439|Actual|Hospital Juan Canalejo|||||f||||f||||||||||2018-06-01 03:52:53.31512|2018-06-01 03:52:53.31512
NCT00356031|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|2017-02-16||2017-04-14|2006-07-21|2006-07-25|Estimate|2017-04-14|2017-05-19|Actual||||2017-04-14|2017-05-19|Actual|July 2006||2006-07-31|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bevacizumab and Radiation Therapy for Sarcomas|A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas|Completed||Phase 2|20|Actual|Massachusetts General Hospital|Small number of patients. Results require validation in a larger cohort of patients.|1|||f||||t||||||||||2018-06-01 03:52:53.40131|2018-06-01 03:52:53.40131
NCT00356018|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2012-05-31|2006-07-21|2006-07-25|Estimate|||||||2012-05-31|2012-06-01|Estimate|July 2006||2006-07-31|May 2012|2012-05-31|February 2007|Actual|2007-02-28|||||Observational|||Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:|Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy: A Randomized, Parallel, Prospectively-Controlled Outpatient Comparison|Completed|||5|Actual|Orlando Health, Inc.|||||f||||f||||||||||2018-06-01 03:52:53.691361|2018-06-01 03:52:53.691361
NCT00356005|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2012-10-31|2006-07-24|2006-07-25|Estimate|||||||2012-10-31|2012-11-01|Estimate|August 2006||2006-08-31|October 2012|2012-10-31||||August 2007|Actual|2007-08-31||Interventional|||Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh|Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open Label Randomized Controlled Trial|Completed||Phase 2|228|Actual|Medical University of Vienna||2|||f||||||||||||||2018-06-01 03:52:53.740974|2018-06-01 03:52:53.740974
NCT00355992|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2009-05-11|2006-07-24|2006-07-25|Estimate|||||||2009-05-11|2009-05-12|Estimate|September 2006||2006-09-30|May 2009|2009-05-31|December 2007|Anticipated|2007-12-31|||||Observational|IMAgine||The Ischemia Modified Albumin In Diagnosing Ischemic New Events|The Ischemia Modified Albumin In Diagnosing Ischemic New Events (IMAGINE Study).|Terminated|||1250|Anticipated|Inverness Medical Innovations|||||f||||||||||||||2018-06-01 03:52:53.819136|2018-06-01 03:52:53.819136
NCT00355979|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2006-10-17|2006-07-24|2006-07-25|Estimate|||||||2006-10-17|2006-10-18|Estimate|March 2006||2006-03-31|July 2006|2006-07-31|March 2008||2008-03-31|||||Interventional|||Comparative Study of Intragastric Balloon and Pharmacotherapy for Non-Morbid Obesity|Randomized Trial of Intragastric Balloon and Pharmacotherapy for Non-Morbid Obesity|Unknown status|Recruiting|Phase 3|100||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 03:52:54.985909|2018-06-01 03:52:54.985909
NCT00355940|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2013-04-26|2006-07-24|2006-07-25|Estimate|||||||2013-04-26|2013-04-29|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Comparing Fluoroscopy and Technological Methods for Guidance During Endovascular Procedures|Comparing Fluoroscopy and Technological Methods for Guidance During Endovascular Procedures Traditional Fluoroscopy Navigation Based on Preoperative CT and Intraoperative DynaCT|Completed||Phase 1|17|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 03:52:55.350796|2018-06-01 03:52:55.350796
NCT00355927|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-23|||2007-11-01|2006-07-23|2006-07-25|Estimate|||||||2007-11-01|2007-11-02|Estimate|September 2006||2006-09-30|August 2006|2006-08-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.|Changes of the Neuronal Activity in the Subthalamic Nucleus Under Propofol Sedation During Stereotactic Electrode Implantation.|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:52:55.434031|2018-06-01 03:52:55.434031
NCT00355914|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2012-12-06||2013-09-27|2006-07-24|2006-07-25|Estimate|2013-09-27|2013-11-26|Estimate||||2013-09-27|2013-11-26|Estimate|August 2003||2003-08-31|September 2013|2013-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effectiveness of Lumbar Facet Joint Nerve Blocks|A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Lumbar Facet Joint Nerve Blocks|Completed||N/A|120|Actual|Pain Management Center of Paducah||2|||f||||t||||||||||2018-06-01 03:52:55.516768|2018-06-01 03:52:55.516768
NCT00355901|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2008-08-02|2006-07-24|2006-07-25|Estimate|||||||2008-08-02|2008-08-05|Estimate|September 2006||2006-09-30|August 2008|2008-08-31|November 2012||2012-11-30|||||Observational|||An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis|An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis|Terminated|||300|Anticipated|Facet Biotech|||||||||t||||||||||2018-06-01 03:52:55.862169|2018-06-01 03:52:55.862169
NCT00355888|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2014-11-27|2006-07-24|2006-07-25|Estimate|||||||2014-11-27|2014-12-02|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors|A Phase I, Open Label Study of MBP-426 Given by Intravenous Infusion in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|39|Actual|Mebiopharm Co., Ltd||1|||f||||f||||||||||2018-06-01 03:52:55.979692|2018-06-01 03:52:55.979692
NCT00355875|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-22|||2006-11-06|2006-07-22|2006-07-25|Estimate|||||||2006-11-06|2006-11-07|Estimate|July 2005||2005-07-31|November 2006|2006-11-30|October 2006||2006-10-31|||||Interventional|||The Effect of Oxygen Exposure During Newborn Resuscitation on Lung Injury|Oxygen Exposure During Newborn Resuscitation and Pulmonary Oxidative Stress|Completed||N/A|30||University of Calgary|||||f||||||||||||||2018-06-01 03:52:56.063609|2018-06-01 03:52:56.063609
NCT00355862|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2014-07-29|2006-07-24|2006-07-25|Estimate|||||||2014-07-29|2014-07-30|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|May 2014|Actual|2014-05-31|April 2009|Actual|2009-04-30||Interventional|||Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma|A Prospective Randomised, Open-labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma|Completed||Phase 3|525|Actual|University of Regensburg||2|||f||||t||||||||||2018-06-01 03:52:56.132932|2018-06-01 03:52:56.132932
NCT00355849|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21||2018-03-07|2018-03-07|2006-07-21|2006-07-25|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|August 2006||2006-08-31|March 2018|2018-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients With Type 2 Diabetes Treated With Once-Daily Insulin Glargine|Completed||Phase 3|555|Actual|Eli Lilly and Company||3|||f||||||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 03:52:56.258799|2018-06-01 03:52:56.258799
NCT00355836|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2015-11-04|2006-07-24|2006-07-25|Estimate|||||||2015-11-04|2015-11-05|Estimate|November 2004||2004-11-30|November 2015|2015-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Recovery of Hand Function Through Mental Practice.|Can Motor Imagery Enhance Recovery of Hand Function After Stroke? Evaluation of Motor Imagery Training.|Completed||N/A|135|Anticipated|University of Aberdeen|||||f||||||||||||||2018-06-01 03:52:56.419845|2018-06-01 03:52:56.419845
NCT00355823|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2008-05-20|2006-07-24|2006-07-25|Estimate|||||||2008-05-20|2008-05-21|Estimate|August 2006||2006-08-31|November 2006|2006-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Bioelectric Field Imaging Near Human Skin Wounds|Phase I Study of the Electric Field Near Human Skin Wounds|Completed|||40|Actual|National Institute of General Medical Sciences (NIGMS)|||||f||||f||||||||||2018-06-01 03:52:56.472138|2018-06-01 03:52:56.472138
NCT00355810|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2016-07-18|2006-07-24|2006-07-25|Estimate|||||||2016-07-18|2016-07-19|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|December 2006|Actual|2006-12-31|April 2006|Actual|2006-04-30||Interventional|||Probiotics for Irritable Bowel Syndrome|Lactobacillus Plantarum MF 1298 vs Placebo for Irritable Bowel Syndrome.|Completed||N/A|19|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 03:52:56.525284|2018-06-01 03:52:56.525284
NCT00355797|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|2011-06-06||2012-12-18|2006-07-24|2006-07-25|Estimate|2011-06-06|2011-06-27|Estimate||||2012-12-18|2012-12-20|Estimate|May 2006||2006-05-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|February 2008|Actual|2008-02-29||Interventional|CLEAR||Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response|CLEAR: Cylos Pacemaker Responds With Physiologic Rate Changes During Daily Activities|Completed||Phase 4|1491|Actual|Biotronik, Inc.||3|||f||||f||||||||||2018-06-01 03:52:56.644301|2018-06-01 03:52:56.644301
NCT00355784|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2013-03-13||2015-12-02|2006-07-24|2006-07-25|Estimate|2013-07-17|2013-07-22|Estimate||||2015-12-02|2016-01-01|Estimate|September 2005||2005-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2011|Actual|2011-12-31||Interventional|||Growth Hormone as a Determinant of Weight Regulation|Growth Hormone as a Determinant of Weight Regulation.|Completed||N/A|24|Actual|University of Michigan|The short duration of our intervention was a limitation. The metabolic measurements that were performed in the postabsorptive state was a limitation.|3|||f||||||||||||||2018-06-01 03:52:57.331956|2018-06-01 03:52:57.331956
NCT00355771|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2008-01-12|2006-07-24|2006-07-25|Estimate|||||||2008-01-12|2008-01-15|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis|Placebo Controlled Pilot Study on the Efficacy of Levocetirizine 5 mg in Reducing Symptoms, Airway Resistance, and Sleep Impairment in Patients With Persistent Allergic Rhinitis|Completed||Phase 4|100|Actual|Institut für Atemwegsforschung GmbH||2|||f||||f||||||||||2018-06-01 03:52:57.73458|2018-06-01 03:52:57.73458
NCT00355758|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2010-08-31|2006-07-24|2006-07-25|Estimate|||||||2010-08-31|2010-09-01|Estimate|April 2005||2005-04-30|August 2010|2010-08-31|June 2009|Actual|2009-06-30|||||Observational|||UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling|Prostate Cancer Detection by Serum Proteomic Profiling|Terminated|||200|Anticipated|University of California, Irvine||||Lack of personnel|f||||f||||||Samples Without DNA|"~     Whole blood is collected from subjects. The whole blood is spun down by centrifugation and~     only serum is retained and stored.~   "|||2018-06-01 03:52:57.806041|2018-06-01 03:52:57.806041
NCT00355745|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-22|||2011-06-08|2006-07-24|2006-07-25|Estimate|||||||2011-06-08|2011-06-09|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Using CBUS™ System for Ultrasound Breast Imaging Designed for Breast Tumor Diagnosis||Terminated||N/A|50|Anticipated|Helix Medical Systems|||||f||||||||||||||2018-06-01 03:52:57.859818|2018-06-01 03:52:57.859818
NCT00355732|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-23|||2006-10-25|2006-07-23|2006-07-25|Estimate|||||||2006-10-25|2006-10-26|Estimate||||July 2006|2006-07-31||||||||Interventional|||Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients|Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients; Randomized Prospective Study|Completed||Phase 4|||Dr. Josip Benčević General Hospital|||||f||||||||||||||2018-06-01 03:52:57.91326|2018-06-01 03:52:57.91326
NCT00355719|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|||2009-06-16|2006-07-24|2006-07-25|Estimate|||||||2009-06-16|2009-06-17|Estimate|January 2007||2007-01-31|June 2009|2009-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients|Clinical Pilot Trial to Evaluate the Influence of Nevirapine in Exposure to Atazanavir in Steady State Equilibrium in HIV-Infected Adult Patients.|Completed||Phase 4|14|Actual|Germans Trias i Pujol Hospital|||||f||||f||||||||||2018-06-01 03:52:57.979964|2018-06-01 03:52:57.979964
NCT00355706|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-24|2012-12-06||2013-09-27|2006-07-24|2006-07-25|Estimate|2013-09-27|2013-11-26|Estimate||||2013-09-27|2013-11-26|Estimate|August 2003||2003-08-31|September 2013|2013-09-30|July 2011|Actual|2011-07-31|July 2006|Actual|2006-07-31||Interventional|||Effectiveness of Thoracic Facet Joint Nerve Blocks|Effectiveness of Thoracic Facet Joint Nerve Blocks: A Randomized, Prospective, Double-Blind Controlled Evaluation|Completed||N/A|100|Actual|Pain Management Center of Paducah||2|||f||||t||||||||||2018-06-01 03:52:58.076046|2018-06-01 03:52:58.076046
NCT00355693|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2006-08-23|2006-07-21|2006-07-24|Estimate|||||||2006-08-23|2006-08-24|Estimate|October 2006||2006-10-31|April 2006|2006-04-30|February 2007||2007-02-28|||||Interventional|||Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients|Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol A) in Oral Surgery Patients B) in General Dentistry Patients C) in Colonoscopy Patients|Unknown status|Not yet recruiting|Phase 4|60||University of Glasgow|||||f||||||||||||||2018-06-01 03:52:58.435794|2018-06-01 03:52:58.435794
NCT00355680|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2009-02-10|2006-07-21|2006-07-24|Estimate|||||||2009-02-10|2009-02-11|Estimate|December 2005||2005-12-31|February 2009|2009-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy|Comparative Study of Indigenous Green Laser With Already Available Green Laser in Proliferative Diabetic Retinopathy|Completed||Phase 3|24|Actual|Aurolab||2|||f||||f||||||||||2018-06-01 03:52:58.518918|2018-06-01 03:52:58.518918
NCT00355667|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2016-08-17|2006-07-21|2006-07-24|Estimate|||||||2016-08-17|2016-08-18|Estimate|June 2006||2006-06-30|August 2016|2016-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|J-MELODIC||Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure|Japanese Multicenter Evaluation of Long- Versus Short-acting Diuretics in Congestive Heart Failure|Completed||Phase 4|320|Actual|Hyogo College of Medicine||2|||f||||t||||||||Undecided||2018-06-01 03:52:58.599708|2018-06-01 03:52:58.599708
NCT00355654|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2015-01-06|2006-07-20|2006-07-24|Estimate|||||||2015-01-06|2015-01-07|Estimate|September 2006||2006-09-30|January 2015|2015-01-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®|Safety and Immunogenicity of Booster Vaccination With PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination With Infanrix® Hexa When Both Vaccines Are Co-Administered With Prevenar® to Toddlers 11-18 Months of Age|Completed||Phase 3|847|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:52:58.712994|2018-06-01 03:52:58.712994
NCT00355641|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2016-10-27|2006-07-20|2006-07-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2005||2005-10-31|October 2016|2016-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome|A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)|Completed||Phase 3|450|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:52:58.914732|2018-06-01 03:52:58.914732
NCT00355628|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2012-08-30|2006-07-21|2006-07-24|Estimate|||||||2012-08-30|2012-08-31|Estimate|July 2006||2006-07-31|August 2012|2012-08-31||||July 2007|Actual|2007-07-31||Interventional|||Clinical Study of KW-2246 in Patients With Cancer Pain|Phase II Clinical Study of KW-2246 in Patients With Cancer Pain - Maintenance Switch Study in Oral Morphine or Oral Oxycodone-treated Patients|Completed||Phase 2|40|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 03:52:59.137272|2018-06-01 03:52:59.137272
NCT00355615|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|2009-05-29||2011-08-29|2006-07-21|2006-07-24|Estimate|2009-05-29|2009-07-20|Estimate||||2011-08-29|2011-08-31|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin|A Phase IIIb, Efficacy, and Safety Study of Rosuvastatin in Children 10-17 Years of Age With Heterozygous Familial Hypercholesterolemia: a 12-week, Double-blind, Randomized, Multicenter, Placebo-controlled Study With a 40-week, Open-label, Follow-up|Completed||Phase 3|173|Actual|AstraZeneca||5|||f||||||||||||||2018-06-01 03:52:59.328895|2018-06-01 03:52:59.328895
NCT00355602|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2009-02-10|2006-07-21|2006-07-24|Estimate|||||||2009-02-10|2009-02-11|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Antibiotics for the Treatment of Ulcerative Colitis|Use of Antibiotics to Eradicate Bacterial Pathogens Colonising the Colonic Mucosa in Ulcerative Colitis Patients|Completed||N/A|40|Anticipated|University of Dundee|||||f||||||||||||||2018-06-01 03:52:59.921275|2018-06-01 03:52:59.921275
NCT00355589|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2012-10-08|2006-07-20|2006-07-24|Estimate|||||||2012-10-08|2012-10-10|Estimate|July 2006||2006-07-31|October 2012|2012-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension|A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Efficacy and Safety of a Combination of Ramipril Plus Hydrochlorothiazide Versus the Component Monotherapies in Subjects With Essential Hypertension|Completed||Phase 3|||Pfizer|||||||||||||||||||2018-06-01 03:53:00.056439|2018-06-01 03:53:00.056439
NCT00355576|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2011-01-31|2006-07-21|2006-07-24|Estimate|||||||2011-01-31|2011-02-01|Estimate|July 2006||2006-07-31|January 2011|2011-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis|Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis|Completed||Phase 2|86|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 03:53:00.204226|2018-06-01 03:53:00.204226
NCT00355563|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2009-01-08|2006-07-21|2006-07-24|Estimate|||||||2009-01-08|2009-01-09|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|EPIC||Study of the PAS-Port® Proximal Anastomosis System in Coronary Bypass Surgery|Use of the PAS-Port Proximal Anastomosis System for Creation of Aorto-Venous Proximal Anastomoses in Coronary Bypass Surgery|Completed||Phase 3|220|Anticipated|Cardica, Inc|||||f||||t||||||||||2018-06-01 03:53:00.316579|2018-06-01 03:53:00.316579
NCT00355550|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2009-12-10|2006-07-20|2006-07-24|Estimate|||||||2009-12-10|2009-12-11|Estimate|July 2006||2006-07-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Ketasyn In Age-Associated Memory Impairment|A Double-Blind, Placebo-Controlled Study of Ketasyn (AC-1202) Administered For Ninety Days In Subjects With Age-Associated Memory Impairment|Completed||Phase 2|150||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 03:53:00.378051|2018-06-01 03:53:00.378051
NCT00355537|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2010-03-29|2006-07-21|2006-07-24|Estimate|||||||2010-03-29|2010-03-30|Estimate|February 2006||2006-02-28|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Testosterone Replacement in Diabetes With Vascular Disease (Version 2)|A Randomised, Double Blind, Placebo-controlled Parallel Study to Test the Effect of Testosterone Treatment on Peripheral Vascular Disease in Hypogonadal Men With Type 2 Diabetes Mellitus|Completed||Phase 4|19|Actual|Barnsley Hospital||2|||f||||f||||||||||2018-06-01 03:53:00.452677|2018-06-01 03:53:00.452677
NCT00355524|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2013-07-05|2006-07-21|2006-07-24|Estimate|||||||2013-07-05|2013-07-08|Estimate|June 2006||2006-06-30|July 2013|2013-07-31|March 2011|Actual|2011-03-31|August 2007|Actual|2007-08-31||Interventional|||A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents|A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/Rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents|Completed||Phase 2|80|Actual|Tibotec Pharmaceuticals, Ireland||7|||f||||t||||||||||2018-06-01 03:53:00.538267|2018-06-01 03:53:00.538267
NCT00355511|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2015-04-25|2006-07-21|2006-07-24|Estimate|||||||2015-04-25|2015-04-28|Estimate|July 2007||2007-07-31|April 2015|2015-04-30|February 2009|Anticipated|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Heart Failure Evaluation Acute Referral Team Trial (HEARTT)|Heart Failure Evaluation Acute Referral Team Trial (HEARTT)|Withdrawn||N/A|0|Actual|University of Alberta||||unable to recruit patients|f||||f||||||||||2018-06-01 03:53:00.666544|2018-06-01 03:53:00.666544
NCT00355498|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2015-12-02|2006-07-20|2006-07-24|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2005||2005-09-30|December 2015|2015-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Amyloid Plaque and Tangle Imaging in Aging and Dementia|Amyloid Plaque and Tangle Imaging in Aging and Dementia|Completed|||194|Actual|University of California, Los Angeles|||4||f||||t||||||||||2018-06-01 03:53:00.736337|2018-06-01 03:53:00.736337
NCT00355485|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-21|||2015-07-08|2006-07-21|2006-07-24|Estimate|||||||2015-07-08|2015-07-10|Estimate|September 2006||2006-09-30|July 2015|2015-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Microdermabrasion for Acne|Microdermabrasion for Acne Vulgaris|Completed||Phase 2|24|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 03:53:00.79861|2018-06-01 03:53:00.79861
NCT00355472|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|2012-08-07||2012-10-17|2006-07-20|2006-07-24|Estimate|2012-08-07|2012-09-07|Estimate||||2012-10-17|2012-10-18|Estimate|February 2007||2007-02-28|October 2012|2012-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL|Phase I Dose Escalation Study of KW-0761 in Patients With Relapsed Adult T-Cell Lymphoma (ATL) and Peripheral T-Cell Lymphoma (PTCL)|Completed||Phase 1|16|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 03:53:00.882118|2018-06-01 03:53:00.882118
NCT00355459|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2011-03-21|2006-07-20|2006-07-24|Estimate|||||||2011-03-21|2011-03-23|Estimate|August 2005||2005-08-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease|A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease|Terminated||N/A|0|Actual|University of Texas Southwestern Medical Center||||The PI has elected to terminate study at this time|f||||||||||||||2018-06-01 03:53:01.346978|2018-06-01 03:53:01.346978
NCT00355446|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2007-10-16|2006-07-20|2006-07-24|Estimate|||||||2007-10-16|2007-10-17|Estimate|July 2001||2001-07-31|October 2007|2007-10-31|October 2004||2004-10-31|||||Interventional|||Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.|Bioavailabilty of Bimatoprost Ophthalmic Solution in Human Aqueous.|Completed||Phase 4|48||Indiana University|||||f||||||||||||||2018-06-01 03:53:01.455565|2018-06-01 03:53:01.455565
NCT00355433|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2006-07-20|2006-07-20|2006-07-24|Estimate|||||||2006-07-20|2006-07-24|Estimate|July 2006||2006-07-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||Comparison of Body and Room Temperature Saline in Urodynamics|Comparison of Urodynamic Volume Measurements Using Room and Body Temperature Saline|Unknown status|Recruiting|Phase 4|24||Tripler Army Medical Center|||||f||||||||||||||2018-06-01 03:53:01.53042|2018-06-01 03:53:01.53042
NCT00355420|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2014-03-03|2006-07-20|2006-07-21|Estimate|||||||2014-03-03|2014-03-04|Estimate|October 2006||2006-10-31|March 2013|2013-03-31||||||||Observational|||Evaluation of the Change in Length of the Leg in Children After Treatment of Femur Fractures.|Evaluation of the Change in Length of the Femur and Tibia in Children After Treatment of Femur Fractures With External Fixators, Plaster of Paris or Internal Fixation|Withdrawn|||0|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:53:01.586032|2018-06-01 03:53:01.586032
NCT00355407|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2009-03-12|2006-07-19|2006-07-21|Estimate|||||||2009-03-12|2009-03-13|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation|A Pilot Study of Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation|Completed||N/A|31||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 03:53:01.751337|2018-06-01 03:53:01.751337
NCT00355394|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2013-01-08||2015-10-30|2006-07-19|2006-07-21|Estimate|2013-07-29|2013-08-30|Estimate||||2015-10-30|2015-11-30|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Treatment of Acute Migraine Headache in Children|Treatment of Acute Migraine Headache in Children|Completed||Phase 2|31|Actual|Children's Hospital of Philadelphia|Study was performed in tertiary care setting and may not be generalizable to all settings. Small number of subjects (n=31). None admitted or received additional rescue medication, suggesting most severely affected may not have been enrolled.|2|||f||||f||||||||||2018-06-01 03:53:01.840162|2018-06-01 03:53:01.840162
NCT00355381|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2009-01-27|2006-07-19|2006-07-21|Estimate|||||||2009-01-27|2009-01-28|Estimate|September 2004||2004-09-30|January 2009|2009-01-31|September 2009|Anticipated|2009-09-30|April 2008|Actual|2008-04-30||Interventional|||Evaluating Patient Information Prescriptions|Evaluating Patient Information Prescriptions in Different Service Environments|Unknown status|Active, not recruiting|Phase 2|299|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 03:53:02.217441|2018-06-01 03:53:02.217441
NCT00355368|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|2011-08-08||2011-11-10|2006-07-20|2006-07-21|Estimate|2011-11-10|2011-12-15|Estimate||||2011-11-10|2011-12-15|Estimate|August 2006||2006-08-31|November 2011|2011-11-30|July 2010|Actual|2010-07-31|August 2006|Actual|2006-08-31||Interventional|||Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care|Phase 4 Study of Succinylcholine Versus Rocuronium as Neuromuscular Blocking Agent for Emergency Intubation in Intensive Care|Completed||Phase 4|420|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 03:53:02.291765|2018-06-01 03:53:02.291765
NCT00355355|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19||2014-12-19|2015-01-22|2006-07-19|2006-07-21|Estimate||||2014-12-19|2015-01-09|Estimate|2015-01-22|2015-01-30|Estimate|July 2006||2006-07-31|January 2015|2015-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)|A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC)|Completed||Phase 3|208|Actual|Light Sciences Oncology||2|||f||||t||||||||||2018-06-01 03:53:02.576318|2018-06-01 03:53:02.576318
NCT00355342|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2017-08-22||2017-08-23|2006-07-19|2006-07-21|Estimate|2017-08-23|2018-03-20|Actual||||2017-08-23|2018-03-20|Actual|April 28, 2004|Actual|2004-04-28|August 2017|2017-08-31|September 6, 2007|Actual|2007-09-06|September 6, 2007|Actual|2007-09-06||Interventional|||Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.|A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Twice Daily Via DISKUS® Inhaler Versus Salmeterol 50mcg Twice Daily Via DISKUS® Inhaler on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|186|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:02.738832|2018-06-01 03:53:02.738832
NCT00355329|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2006-10-19|2006-07-20|2006-07-21|Estimate|||||||2006-10-19|2006-10-20|Estimate||||July 1999|1999-07-31||||||||Interventional|||Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation|Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation|Completed||Phase 3|30||The University of Hong Kong|||||f||||||||||||||2018-06-01 03:53:03.449488|2018-06-01 03:53:03.449488
NCT00355316|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-06-19|2006-07-19|2006-07-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|November 2005||2005-11-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients|Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients|Completed||N/A|224|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 03:53:03.520466|2018-06-01 03:53:03.520466
NCT00355303|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2015-07-21|2006-07-20|2006-07-21|Estimate|||||||2015-07-21|2015-07-22|Estimate|August 2006||2006-08-31|July 2015|2015-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Misoprostol and Prostaglandin E2 (PGE2) Gel for Induction of Labour in Premature Rupture of Membranes at Term|Comparison of Misoprostol and PGE2 Gel for Induction of Labour in in Premature Rupture of Membranes at Term- A Randomized Comparative Trial|Completed||Phase 4|932|Actual|Nilratan Sircar Medical College||1|||f||||t||||||||||2018-06-01 03:53:03.617018|2018-06-01 03:53:03.617018
NCT00355290|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2008-05-05|2006-07-20|2006-07-21|Estimate|||||||2008-05-05|2008-05-08|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Changes in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial|Changes in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial|Completed||N/A|114|Anticipated|Hospital de Clinicas de Porto Alegre|||||f||||||||||||||2018-06-01 03:53:03.69546|2018-06-01 03:53:03.69546
NCT00355277|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2013-04-02|2006-07-20|2006-07-21|Estimate|||||||2013-04-02|2013-04-04|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|December 2007||2007-12-31|||||Interventional|||Local Anaesthetic Effects of Transcutaneous Amitriptyline|Local Anaesthetic Effects of Transcutaneous Amitriptyline in Human Volunteers : a Controlled, Double-blinded, Randomised Study Versus Placebo and Transcutaneous Local Anaesthetic (EMLA(R))|Completed||Phase 1|16||University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:53:03.75641|2018-06-01 03:53:03.75641
NCT00355264|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2014-08-11|2006-07-19|2006-07-21|Estimate|||||||2014-08-11|2014-08-13|Estimate|August 2006||2006-08-31|August 2014|2014-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency|Phase 2, Multicenter, Open Label Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to Primary BH4 Deficiency|Completed||Phase 2|12|Actual|BioMarin Pharmaceutical||1|||f||||||||||||||2018-06-01 03:53:03.823995|2018-06-01 03:53:03.823995
NCT00355251|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2014-03-19|2006-07-19|2006-07-21|Estimate|||||||2014-03-19|2014-03-20|Estimate|July 2006||2006-07-31|February 2014|2014-02-28|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|||Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption|Study of the Influence of Atorvastatin in Plasma Viral Replication Given Prior to Antiretroviral Treatment Interruption in Patients With HIV-1 Infection and Viral Suppression.|Terminated||Phase 4|5|Actual|Germans Trias i Pujol Hospital||2||"On the basis of published results of SMART study, it has been observed that the results are~   worse in patients who have interrupted their treatments."|f||||f||||||||||2018-06-01 03:53:03.896486|2018-06-01 03:53:03.896486
NCT00355238|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20||2012-04-18|2015-09-23|2006-07-20|2006-07-21|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|December 2006||2006-12-31|September 2015|2015-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer|A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy|Completed||Phase 2|135|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-06-01 03:53:03.980495|2018-06-01 03:53:03.980495
NCT00355225|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2006-10-06|2006-07-20|2006-07-21|Estimate|||||||2006-10-06|2006-10-09|Estimate||||July 2006|2006-07-31||||||||Interventional|||Community-Effectiveness of the Distribution of Insecticide-Treated Bed Nets Through Social Marketing Antenatal Care Services in Malaria Control in Rural Burkina Faso||Completed||N/A|||Heidelberg University|||||f||||||||||||||2018-06-01 03:53:04.080806|2018-06-01 03:53:04.080806
NCT00355212|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2006-07-21|2006-07-19|2006-07-21|Estimate|||||||2006-07-21|2006-07-25|Estimate|January 2001||2001-01-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Comparison Between Radiofrequency Versus Ethanol Injection for the Treatment of Hepatocellular Carcinoma|Comparative Study Between Radiofrequency and Ethanol Injection for the Ablation of Small Hepatocellular Carcinoma Associated With Liver Cirrhosis|Terminated||Phase 3|240||Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-06-01 03:53:04.144836|2018-06-01 03:53:04.144836
NCT00355199|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|2017-03-16||2017-08-08|2006-07-20|2006-07-21|Estimate|2017-08-08|2017-08-10|Actual||||2017-08-08|2017-08-10|Actual|May 2005||2005-05-31|August 2017|2017-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.|Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas|Completed||Phase 3|246|Actual|Gruppo Italiano Terapie Innovative nei Linfomi||2|||f||||f||||||||||2018-06-01 03:53:04.207862|2018-06-01 03:53:04.207862
NCT00355186|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2012-11-08|2006-07-20|2006-07-21|Estimate|||||||2012-11-08|2012-11-12|Estimate|August 2006||2006-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI)|SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI)|Completed||Phase 2|200|Actual|University of Zurich||3|||f||||||||||||||2018-06-01 03:53:04.615001|2018-06-01 03:53:04.615001
NCT00355173|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2011-05-11|2006-07-20|2006-07-21|Estimate|||||||2011-05-11|2011-05-12|Estimate|May 2006||2006-05-31|February 2010|2010-02-28|November 2010|Actual|2010-11-30|||||Interventional|||Pilot Study to Assess the Efficacy and Safety of the Lubo Cervical Collar|Pilot Study to Assess the Efficacy and Safety of the Lubo Cervical Collar|Completed||Phase 1|50|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:53:04.700565|2018-06-01 03:53:04.700565
NCT00355160|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-05-13|2006-07-19|2006-07-21|Estimate|||||||2013-05-13|2013-05-15|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting|Non-Rhinologic Etiologies of Headaches and Facial Pain in Tertiary Care Setting|Completed|||20|Actual|Penn State University|||||f||||f||||||||||2018-06-01 03:53:04.750758|2018-06-01 03:53:04.750758
NCT00355147|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2014-07-15||2015-04-06|2006-07-18|2006-07-21|Estimate|2015-01-23|2015-02-10|Estimate||||2015-04-06|2015-04-24|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|June 2011|Actual|2011-06-30||Interventional|TOOLS|Compared groups on strata, age, sex, race/ethnicity, education level, living status, has Caregiver Number of participants were determined by protocol and followed intention to treat. For 3 and 6 month outcomes, we included respondent's last score assuming no change among those with missing data.|Adapting Tools to Implement Stroke Risk Management to Veterans|Adapting Tools to Implement Stroke Risk Management to Veterans|Completed||N/A|174|Actual|VA Office of Research and Development|Both our intervention and control groups experienced attrition during the study period but the rate between groups did not differ significantly.|2|||f||||f||||||||||2018-06-01 03:53:04.830287|2018-06-01 03:53:04.830287
NCT00355134|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2012-05-23||2012-08-02|2006-07-19|2006-07-21|Estimate|2012-05-23|2012-06-26|Estimate||||2012-08-02|2012-08-07|Estimate|June 2006||2006-06-30|August 2012|2012-08-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|FREEDOMS II||Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis|24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|Completed||Phase 3|1083|Actual|Novartis||3|||f||||t||||||||||2018-06-01 03:53:05.487319|2018-06-01 03:53:05.487319
NCT00355121|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|2011-07-25|2010-09-02|2011-08-22|2006-07-20|2006-07-21|Estimate|2011-07-25|2011-08-23|Estimate|2010-09-02|2010-09-08|Estimate|2011-08-22|2011-08-24|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®|Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.|Completed||Phase 2|882|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 03:53:07.393647|2018-06-01 03:53:07.393647
NCT00355108|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2010-12-22|2006-07-20|2006-07-21|Estimate|||||||2010-12-22|2010-12-23|Estimate|September 2006||2006-09-30|December 2010|2010-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome|ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome. Beneficial or Iatrogenic Effects.|Completed||Phase 3|170|Actual|Hospices Civils de Lyon|||||f||||t||||||||||2018-06-01 03:53:07.945632|2018-06-01 03:53:07.945632
NCT00355095|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2012-09-12|2006-07-20|2006-07-21|Estimate|||||||2012-09-12|2012-09-13|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis|Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT)|Completed||Phase 2|40|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||f||||||||||2018-06-01 03:53:08.012628|2018-06-01 03:53:08.012628
NCT00354224|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2018-04-06|2006-07-19|2006-07-20|Estimate|||||||2018-04-06|2018-04-10|Actual|January 2005||2005-01-31|April 2018|2018-04-30||||August 2008|Actual|2008-08-31||Interventional|||Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer|A Phase II Study of XELOX in Locally Advanced or Metastatic Gastric Cancer|Completed||Phase 2|46|Anticipated|Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:53:20.031247|2018-06-01 03:53:20.031247
NCT00355082|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2009-09-08||2016-11-15|2006-07-19|2006-07-21|Estimate|2009-10-15|2009-11-25|Estimate||||2016-11-15|2017-01-02|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy|A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures|Completed||Phase 3|226|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:08.112693|2018-06-01 03:53:08.112693
NCT00355069|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2014-05-27|2006-07-19|2006-07-21|Estimate|||||||2014-05-27|2014-05-28|Estimate|August 2001||2001-08-31|May 2014|2014-05-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Better Pediatric Asthma Outcomes Through Chronic Care|Better Pediatric Asthma Outcomes Through Chronic Care|Completed||N/A|548|Actual|UConn Health||4|||f||||t||||||||||2018-06-01 03:53:09.737864|2018-06-01 03:53:09.737864
NCT00355056|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2016-02-11|2006-07-19|2006-07-21|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2006||2006-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Premium Migraine Trial|Prospective, Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects With Migraine and PFO Using the AMPLATZER PFO Occluder to Medical Management.|Completed||Phase 2|230|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 03:53:09.928817|2018-06-01 03:53:09.928817
NCT00355043|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-20|||2011-07-11|2006-07-20|2006-07-21|Estimate|||||||2011-07-11|2011-07-12|Estimate|February 2006||2006-02-28|July 2006|2006-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy of Zinc in the Treatment of Bronchiolitis and Prevention of Wheezing Respiratory Illness in Children Less Than Two Years Old||Completed||Phase 3|330|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 03:53:10.080158|2018-06-01 03:53:10.080158
NCT00355030|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2016-08-10||2016-08-24|2006-07-18|2006-07-20|Estimate|2016-08-24|2016-10-18|Estimate||||2016-08-24|2016-10-18|Estimate|June 2006||2006-06-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Phoenix|The full analysis set (FAS) includes all data from all randomized patients receiving at least one dose of the study drug according to the treatment to which the patients were assigned and with at least one follow-up visit.|Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature|Efficacy and Safety of Somatropin in Combination With Leuprorelin Compared to Somatropin Alone in Pubertal Children With Idiopathic Short Stature|Completed||Phase 3|91|Actual|Eli Lilly and Company|No statistical analyses was performed after the early treatment termination. All data represented is descriptive statistics only and no confirmatory conclusions can be drawn from this study.|2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 03:53:10.192084|2018-06-01 03:53:10.192084
NCT00355017|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2006-10-17|2006-07-19|2006-07-20|Estimate|||||||2006-10-17|2006-10-18|Estimate|September 2003||2003-09-30|July 2006|2006-07-31|September 2005||2005-09-30|||||Interventional|||BNP Guided Care in Addition to Multidisciplinary Care|NT-BNP Guided Care in Addition to Multidisciplinary Care in Patients With Chronic Heart Failure A Three-Arm, Prospective, Randomised Study|Terminated||N/A|||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:53:10.835199|2018-06-01 03:53:10.835199
NCT00355004|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-12-18|2006-07-19|2006-07-20|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2005||2005-03-31|January 2007|2007-01-31|February 2009|Actual|2009-02-28|||||Interventional|||Computerized and Mailed Reminders in Increasing the Rate of Colorectal Cancer Screening in Adults With an Average Risk for Colorectal Cancer|Improving Systems for Colorectal Cancer Screening|Completed||N/A|21860|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:53:10.884179|2018-06-01 03:53:10.884179
NCT00354991|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2017-05-05|2006-07-19|2006-07-20|Estimate|||||||2017-05-05|2017-05-09|Actual|June 1, 2006|Actual|2006-06-01|May 2017|2017-05-31|April 1, 2007|Actual|2007-04-01|April 1, 2007|Actual|2007-04-01||Interventional|||Hyzaar Asia HEAALTH (0954A-950)|An Open Label Study to Assess the Efficacy of Losartan/HCTZ Combination Therapy in Patients With Essential Hypertension Who Were Inadequately Controlled on Current Antihypertensive Monotherapy|Completed||Phase 3|437|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 03:53:10.942571|2018-06-01 03:53:10.942571
NCT00354978|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2011-06-14||2011-09-14|2006-07-18|2006-07-20|Estimate|2011-09-14|2011-10-21|Estimate||||2011-09-14|2011-10-21|Estimate|January 2005||2005-01-31|September 2011|2011-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients|Phase II Study of Irinotecan, Leucovorin, 5-Fluorouracil (FOLFIRI) Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer|Completed||Phase 2|49|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:53:11.098988|2018-06-01 03:53:11.098988
NCT00354965|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2017-07-31|2006-07-18|2006-07-20|Estimate|||||||2017-07-31|2017-08-01|Actual|January 19, 2006|Actual|2006-01-19|July 2017|2017-07-31|April 2, 2007|Actual|2007-04-02|April 2, 2007|Actual|2007-04-02||Interventional|||Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients|A Study to Determine PK Profiles of AUGMENTIN XR in Adolescents Weight at Least 40 kg Receiving Augmentin XR BID for 10 Days|Completed||Phase 1|52|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:11.310515|2018-06-01 03:53:11.310515
NCT00354952|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2006-07-19|2006-07-19|2006-07-20|Estimate|||||||2006-07-19|2006-07-20|Estimate|July 2002||2002-07-31|November 2003|2003-11-30|October 2003||2003-10-31|||||Interventional|||Selection of Antibiotic Resistance by Azithromycin and Clarithromycin in the Oral Flora|Impact of Azithromycin and Clarithromycin Therapy on Pharyngeal Carriage of Macrolide-Resistant Streptococci Among Healthy Volunteers: A Randomised, Double-Blind, Placebo-Controlled Trial|Completed||N/A|203||Universiteit Antwerpen|||||f||||||||||||||2018-06-01 03:53:11.421911|2018-06-01 03:53:11.421911
NCT00354939|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2010-08-30|2006-07-19|2006-07-20|Estimate|||||||2010-08-30|2010-08-31|Estimate|October 2003||2003-10-31|August 2010|2010-08-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|SAFIR||Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement|10-week, Open, National, Multicenter Clinical Trial to Evaluate the Safety of Insulin Glargine in Type 2 Diabetes Mellitus Patients, on Intensified Conventional Therapy (ICT)|Completed||Phase 4|480||Sanofi|||||f||||||||||||||2018-06-01 03:53:11.484305|2018-06-01 03:53:11.484305
NCT00354926|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2016-01-05|2006-07-18|2006-07-20|Estimate|||||||2016-01-05|2016-01-07|Estimate|July 2006||2006-07-31|January 2013|2013-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma|Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY 2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 1|67|Actual|Applied Molecular Evolution||1|||f||||f||||||||||2018-06-01 03:53:11.545282|2018-06-01 03:53:11.545282
NCT00354913|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2012-12-07||2013-01-14|2006-07-19|2006-07-20|Estimate|2012-12-07|2013-01-14|Estimate||||2013-01-14|2013-01-18|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|October 2010|Actual|2010-10-31|March 2009|Actual|2009-03-31||Interventional|||Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma|A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma|Completed||Phase 2|21|Actual|Duke University||1|||f||||t||||||||||2018-06-01 03:53:11.665038|2018-06-01 03:53:11.665038
NCT00354900|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2009-08-03|2006-07-18|2006-07-20|Estimate|||||||2009-08-03|2009-08-04|Estimate|July 2006||2006-07-31|August 2009|2009-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Phase I Study of Aprotinin in Advanced Breast Cancer|Phase I Study of Aprotinin in Advanced Breast Cancer|Terminated||Phase 1|18||Dartmouth-Hitchcock Medical Center||||"The FDA changed the labeling for this agent, and we felt we could not offer it to patients on a~   non-surgical study."|f||||t||||||||||2018-06-01 03:53:11.910632|2018-06-01 03:53:11.910632
NCT00354887|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2011-06-14||2012-10-22|2006-07-18|2006-07-20|Estimate|2011-06-14|2011-07-14|Estimate||||2012-10-22|2012-10-29|Estimate|November 2004||2004-11-30|October 2012|2012-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater|A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater|Completed||Phase 2|31|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:53:12.017018|2018-06-01 03:53:12.017018
NCT00354874|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2016-09-13|2006-07-18|2006-07-20|Estimate|||||||2016-09-13|2016-09-15|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Investigation Of A New Medication (GW642444) In Asthmatic Patients|A Multi-centre, Randomised, Double-blind, Placebo Controlled, Dose Ascending, Four Way Crossover Study to Examine Efficacy (FEV1), Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Doses of GW642444|Completed||Phase 2|28|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:12.2179|2018-06-01 03:53:12.2179
NCT00354861|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2008-04-22|2006-07-19|2006-07-20|Estimate|||||||2008-04-22|2008-04-25|Estimate|May 2005||2005-05-31|April 2008|2008-04-30|February 2006|Actual|2006-02-28|November 2005|Actual|2005-11-30||Interventional|||A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321|A Phase I, Single-Blind Study to Determine the Safety, Tolerability and Pharmacodynamic Profiles of a Hepatitis B Antigen Combined With IMP321 Versus the Hepatitis B Antigen Alone and a Reference Vaccine in Healthy Young Male Volunteers|Completed||Phase 1|48|Actual|Immutep S.A.||3|||f||||f||||||||||2018-06-01 03:53:12.325074|2018-06-01 03:53:12.325074
NCT00354835|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2016-07-08||2017-06-27|2006-07-19|2006-07-20|Estimate|2017-06-27|2017-07-25|Actual||||2017-06-27|2017-07-25|Actual|December 2006||2006-12-31|December 2016|2016-12-31||||December 2014|Actual|2014-12-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma|Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)|Completed||Phase 3|481|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 03:53:12.496724|2018-06-01 03:53:12.496724
NCT00354822|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2009-09-17|2006-07-19|2006-07-20|Estimate|||||||2009-09-17|2009-09-18|Estimate|August 2005||2005-08-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|Z0105||Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.|Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas.|Terminated||Phase 2|25|Actual|A.O. Ospedale Papa Giovanni XXIII||||Inability to recruit in time a sufficient number of patients|f||||f||||||||||2018-06-01 03:53:13.766417|2018-06-01 03:53:13.766417
NCT00354809|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2015-04-14|2006-07-18|2006-07-20|Estimate|||||||2015-04-14|2015-04-16|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Morning Administration of GW679769 (10mg and 30 mg) on Polysomnograph Sleep Recordings, Subjective Sleep Assessment, Daytime Cognition and Psychomotor Function in Subjects With Primary Insomnia|Completed||Phase 2|68|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:53:13.844284|2018-06-01 03:53:13.844284
NCT00354796|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2011-07-03|2006-07-19|2006-07-20|Estimate|||||||2011-07-03|2011-07-06|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|October 2015|Anticipated|2015-10-31|||||Observational|||The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin|The Effect of Reduced Dose of Enoxaparin on the Laboratory and Clinical Outcomes of Treatment With Enoxaparin|Unknown status|Recruiting||500|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 03:53:13.925598|2018-06-01 03:53:13.925598
NCT00354783|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2006-07-18|2006-07-18|2006-07-20|Estimate|||||||2006-07-18|2006-07-20|Estimate|January 2007||2007-01-31|July 2006|2006-07-31|December 2007||2007-12-31|||||Observational|||Continuity of Leg Movements in VLBW Premature Infants: From Spontaneous Kicking and Supported Stepping to Independent Walking||Unknown status|Not yet recruiting||15||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:53:13.986358|2018-06-01 03:53:13.986358
NCT00354770|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2012-03-01||2016-10-24|2006-07-18|2006-07-20|Estimate|2013-12-12|2014-01-15|Estimate||||2016-10-24|2016-12-16|Estimate|July 2006||2006-07-31|October 2016|2016-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||N-Acetyl Cysteine in Trichotillomania|A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania|Completed||Phase 2|50|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 03:53:14.036122|2018-06-01 03:53:14.036122
NCT00354757|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2012-11-30|2006-07-18|2006-07-20|Estimate|||||||2012-11-30|2012-12-03|Estimate|June 2005||2005-06-30|November 2012|2012-11-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing|The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease|Completed||Phase 4|200|Actual|National Taiwan University Hospital||2|||f||||||||||||||2018-06-01 03:53:14.24198|2018-06-01 03:53:14.24198
NCT00354744|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2013-09-03||2016-09-14|2006-07-19|2006-07-20|Estimate|2013-11-20|2014-01-10|Estimate||||2016-09-14|2016-10-24|Estimate|July 2006||2006-07-31|September 2016|2016-09-30||||January 2010|Actual|2010-01-31||Interventional|||High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma|Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma|Active, not recruiting||Phase 3|109|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 03:53:14.437598|2018-06-01 03:53:14.437598
NCT00354731|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2012-11-12|2006-07-18|2006-07-20|Estimate|||||||2012-11-12|2012-11-14|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Pentoxifylline on Primary Nephrotic Syndrome|Clinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic Syndrome|Completed||Phase 3|62|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 03:53:15.063723|2018-06-01 03:53:15.063723
NCT00354705|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2017-09-29|2006-07-18|2006-07-20|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2006|Actual|2006-01-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients|Prognostic Molecular and Environmental Factors in High-Risk Stage II and Stage III Colon Cancer Patients|Active, not recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     20 ml of blood for genomic analysis collected at baseline, at completion of adjuvant~     chemotherapy ( <28 days after its completion) if applicable, at each subsequent surveillance~     visit (every 3 months after discontinuation of adjuvant chemotherapy, continuing for 2~     years), and at time of disease recurrence, if applicable.~      20 ml of blood for proteomic analysis studies collected at baseline, at completion of~     adjuvant chemotherapy, if applicable ( <28 days after its completion), and at time of disease~     recurrence, if applicable.~      Tissue (0.2gm of tissue) from primary resection obtained at time of study enrollment. A~     tissue sample (0.2gm of tissue) also obtained, if possible, from patients that require~     surgical intervention at M.D. Anderson Cancer Center, for recurrent disease.~   "|||2018-06-01 03:53:15.143489|2018-06-01 03:53:15.143489
NCT00354692|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2012-08-10|2006-07-18|2006-07-20|Estimate|||||||2012-08-10|2012-08-14|Estimate|June 2006||2006-06-30|August 2012|2012-08-31||||November 2006|Actual|2006-11-30||Interventional|||Effect of Two Iron Preparations on Protein in the Urine|A Randomized Cross-over Pilot Study of the Effect of Sodium Ferric Gluconate Complex vs. Iron Sucrose on Proteinuria in Non-dialysis Chronic Kidney Disease Patients|Completed||Phase 4|12|Actual|Watson Pharmaceuticals||1|||f||||||||||||||2018-06-01 03:53:15.211168|2018-06-01 03:53:15.211168
NCT00354679|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2016-01-14||2016-04-12|2006-07-19|2006-07-20|Estimate|2016-01-14|2016-02-12|Estimate||||2016-04-12|2016-05-16|Estimate|April 2006||2006-04-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer|Phase II Trial of Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma|Completed||Phase 2|34|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 03:53:15.285444|2018-06-01 03:53:15.285444
NCT00354666|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2016-08-31|2006-07-18|2006-07-20|Estimate|||||||2016-08-31|2016-09-01|Estimate|September 2004||2004-09-30|August 2016|2016-08-31|December 2004|Actual|2004-12-31|||||Interventional|||Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma|A Randomised, Double-blind, Placebo-controlled, Dose Ascending Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Inhaled GSK159797 Delivered by Dry Powder Inhaler in Mild to Moderate Asthmatic Subjects|Completed||Phase 2|20||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:15.50447|2018-06-01 03:53:15.50447
NCT00354653|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2007-07-24|2006-07-19|2006-07-20|Estimate|||||||2007-07-24|2007-07-25|Estimate|February 2002||2002-02-28|July 2007|2007-07-31||||||||Interventional|||A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone|AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-Core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN.|Unknown status|Active, not recruiting|Phase 4|100||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:53:15.573261|2018-06-01 03:53:15.573261
NCT00354640|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2013-03-18||2013-05-15|2006-07-19|2006-07-20|Estimate|2013-05-15|2013-06-24|Estimate||||2013-05-15|2013-06-24|Estimate|June 2006||2006-06-30|May 2013|2013-05-31|November 2011|Actual|2011-11-30|October 2008|Actual|2008-10-31||Interventional|||Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer|A Trial Assessing the Effect of Simvastatin on the Pharmacokinetics of Anastrozole|Completed||Phase 2|11|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Small sample size, difficulty in recruiting due to women either already taking a statin or on a different aromatase inhibitor.|1|||f||||f||||||||||2018-06-01 03:53:15.642679|2018-06-01 03:53:15.642679
NCT00354627|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2015-06-11|2006-07-18|2006-07-20|Estimate|||||||2015-06-11|2015-06-12|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs|Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options|Completed||Phase 3|5178|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||f||||||||||2018-06-01 03:53:15.848106|2018-06-01 03:53:15.848106
NCT00354614|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2017-04-11||2017-04-11|2006-07-18|2006-07-20|Estimate|2017-04-11|2017-06-28|Actual||||2017-04-11|2017-06-28|Actual|June 2006||2006-06-30|April 2017|2017-04-30|July 2007|Actual|2007-07-31|March 2007|Actual|2007-03-31||Observational|||Validation of the ApneaLink Sleep Screener for Obstructive Sleep Apnea (OSA)|Validation of the ApneaLink Sleep Screener in a Suspected Sleep Disordered Breathing Population|Completed|||81|Actual|ResMed|||||f||||f||t|f||f|||No|There is no plan to share IPD.|2018-06-01 03:53:16.345877|2018-06-01 03:53:16.345877
NCT00354601|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2009-03-09||2017-07-31|2006-07-19|2006-07-20|Estimate|2009-05-15|2009-05-18|Estimate||||2017-07-31|2017-08-30|Actual|January 2006||2006-01-31|March 2017|2017-03-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer|A Phase II Study of Weekly Docetaxel and Capecitabine for Persistent or Recurrent Platinum Resistant Epithelial Carcinoma of the Ovary, Fallopian Tube or Peritoneum|Terminated||Phase 2|2|Actual|Wake Forest University Health Sciences|Early closure due to discontinuation of funding|1||funding withdrawn|f|||||t|f||||||||2018-06-01 03:53:16.494281|2018-06-01 03:53:16.494281
NCT00354588|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2010-11-03|2006-07-19|2006-07-20|Estimate|||||||2010-11-03|2010-11-04|Estimate|January 2006||2006-01-31|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Arterial Stiffness, Wave Reflections and Renal Failure|Observational Study on the Prognostic Significance (Renal and Cardiovascular) of Arterial Stiffness and Arterial Wave Reflections in Patients With Mild to Moderate Renal Impairment|Completed|||115|Actual|Klinikum Wels-Grieskirchen|||||f||||||||||||||2018-06-01 03:53:16.677735|2018-06-01 03:53:16.677735
NCT00354575|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2008-08-14|2006-07-18|2006-07-20|Estimate|||||||2008-08-14|2008-08-18|Estimate|September 2006||2006-09-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Effect of Chinese Herb on Chronic Constipation for Residents in Long-Term Care Units|A Randomized, Placebo-Controlled, Double-Blind, Parallel Study on the Efficacy and Safety of Traditional Chinese Medicines for Chronic Constipation Residents in Long-Term Care Units|Completed||Phase 2|168|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 03:53:16.731315|2018-06-01 03:53:16.731315
NCT00354562|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2011-01-05|2006-07-18|2006-07-20|Estimate|||||||2011-01-05|2011-01-07|Estimate|February 2007||2007-02-28|September 2010|2010-09-30||||February 2008|Actual|2008-02-29||Interventional|||A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer|A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination With Docetaxel Versus Docetaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|75|Actual|Abbott||2|||f||||f||||||||||2018-06-01 03:53:16.813289|2018-06-01 03:53:16.813289
NCT00354549|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-04-09|2006-07-19|2006-07-20|Estimate|||||||2013-04-09|2013-04-10|Estimate|January 2006||2006-01-31|April 2013|2013-04-30|September 2010|Actual|2010-09-30|April 2009|Actual|2009-04-30||Interventional|||Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC|Bevacizumab and Erlotinib First-Line Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (Stage IIIB/IV) Followed by Platinum-Based Chemotherapy at Disease Progression. A Multicenter Phase II Trial|Completed||Phase 2|104|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 03:53:16.946818|2018-06-01 03:53:16.946818
NCT00354536|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2016-10-24|2006-07-18|2006-07-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2006||2006-02-28|October 2016|2016-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus|A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injections of GSK 716155 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|60|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:17.031939|2018-06-01 03:53:17.031939
NCT00354523|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2014-12-16|2006-07-18|2006-07-20|Estimate|||||||2014-12-16|2014-12-17|Estimate|December 2004||2004-12-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|November 2006|Actual|2006-11-30||Interventional|||Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma|A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma|Terminated||Phase 1/Phase 2|21|Actual|M.D. Anderson Cancer Center||1||Study closed following Phase I portion, insufficient activity to continue to Phase II.|f||||f||||||||||2018-06-01 03:53:17.143053|2018-06-01 03:53:17.143053
NCT00354510|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2012-05-31|2006-07-19|2006-07-20|Estimate|||||||2012-05-31|2012-06-04|Estimate|March 2006||2006-03-31|March 2011|2011-03-31||||||||Interventional|||Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis|Randomised, Double-blind, Placebo-controlled Study of Topical GW842470X Formulation in Adults With Moderate Atopic Dermatitis|Completed||Phase 2|190||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:53:17.217283|2018-06-01 03:53:17.217283
NCT00354497|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-09-19|2006-07-19|2006-07-20|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2002||2002-03-31|August 2008|2008-08-31||||||||Interventional|||Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men|Prostate Cancer Screening and Dietary HA Exposure in African-Americans: Phase II|Unknown status|Recruiting|Phase 2|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:53:17.297925|2018-06-01 03:53:17.297925
NCT00354484|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2013-10-08||2018-01-22|2006-07-17|2006-07-20|Estimate|2013-10-08|2013-12-05|Estimate||||2018-01-22|2018-02-20|Actual|May 2006||2006-05-31|January 2018|2018-01-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients|Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients|Completed||Phase 3|291|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:53:17.385103|2018-06-01 03:53:17.385103
NCT00354471|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2009-02-04|2006-07-19|2006-07-20|Estimate|||||||2009-02-04|2009-02-05|Estimate||||July 2006|2006-07-31||||||||Observational|||Uterine Artery Embolization for Symptomatic Fibroids|Short and Long Term Outcomes of Uterine Artery Embolization.|Completed|||||University of Manitoba|||||f||||||||||||||2018-06-01 03:53:17.623764|2018-06-01 03:53:17.623764
NCT00354458|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2009-10-08|2006-07-18|2006-07-20|Estimate|||||||2009-10-08|2009-10-09|Estimate|October 2006||2006-10-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy|Completed||Phase 3|1102|Actual|NovaCardia, Inc.||2|||f||||t||||||||||2018-06-01 03:53:17.672039|2018-06-01 03:53:17.672039
NCT00354445|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2007-01-12|2006-07-18|2006-07-20|Estimate|||||||2007-01-12|2007-01-15|Estimate|June 2006||2006-06-30|January 2007|2007-01-31||||||||Interventional|||A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD|A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement|Unknown status|Recruiting|Phase 4|1000||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 03:53:17.740473|2018-06-01 03:53:17.740473
NCT00354432|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2015-07-15||2017-11-27|2006-07-19|2006-07-20|Estimate|2017-04-12|2017-05-18|Actual||||2017-11-27|2017-12-21|Actual|February 2007||2007-02-28|November 2017|2017-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Soy Protein/Effexor Hormone Therapy for Prostate Cancer|Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer|Terminated||Phase 3|120|Actual|Wake Forest University Health Sciences|The study was stopped early by the DSMB due to a lack of effect.|4||Stopped by the DSMB for lack of effect per interim stopping rule.|f||||t|t|f||||||No||2018-06-01 03:53:17.803918|2018-06-01 03:53:17.803918
NCT00354419|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2011-01-03|2006-07-19|2006-07-20|Estimate|||||||2011-01-03|2011-01-05|Estimate|February 2006||2006-02-28|January 2011|2011-01-31||||December 2010|Actual|2010-12-31||Interventional|||Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant|A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood|Terminated||Phase 1|30|Anticipated|Fred Hutchinson Cancer Research Center||1||Low accrual|f||||f||||||||||2018-06-01 03:53:18.342816|2018-06-01 03:53:18.342816
NCT00354406|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2011-11-13|2006-07-19|2006-07-20|Estimate|||||||2011-11-13|2011-11-16|Estimate|April 2006||2006-04-30|November 2011|2011-11-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty|A Randomized Trial Comparing the Efficacy on Myocardial Infarct Size Reduction of Early vs. Late Abciximab Administration During Primary Percutaneous Coronary Angioplasty|Completed||Phase 4|110|Actual|University of Pisa||2|||f||||f||||||||||2018-06-01 03:53:18.502907|2018-06-01 03:53:18.502907
NCT00354393|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2009-02-06|2006-07-19|2006-07-20|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2002||2002-08-31|October 2007|2007-10-31||||||||Interventional|||Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma|Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:53:18.598176|2018-06-01 03:53:18.598176
NCT00354380|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2006-10-23|2006-07-19|2006-07-20|Estimate|||||||2006-10-23|2006-10-24|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|November 2006||2006-11-30|||||Interventional|||Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study||Completed||Phase 2|||Heidelberg University|||||f||||||||||||||2018-06-01 03:53:18.68574|2018-06-01 03:53:18.68574
NCT00354367|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2012-05-25|2006-07-18|2006-07-20|Estimate|||||||2012-05-25|2012-05-28|Estimate|January 2007||2007-01-31|May 2012|2012-05-31||||||||Interventional|||Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas|A Phase IIIB Multicenter, Open Label, Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor (TNF) in Crohn's Disease Patients With Draining Fistulas.|Withdrawn||Phase 3|0|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 03:53:18.75136|2018-06-01 03:53:18.75136
NCT00354354|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2011-04-18|2006-07-18|2006-07-20|Estimate|||||||2011-04-18|2011-04-19|Estimate|March 2006||2006-03-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Bronchodilators and Oxygen Kinetics With Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients|Bronchodilator Effect on O2 Deficit and V'O2 Kinetics During Moderate Intensity Exercise in Normoxemic COPD.|Completed||Phase 4|12|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 03:53:18.813254|2018-06-01 03:53:18.813254
NCT00354341|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2016-03-01||2016-03-01|2006-07-19|2006-07-20|Estimate|2016-03-01|2016-03-31|Estimate||||2016-03-01|2016-03-31|Estimate|September 2002||2002-09-30|March 2016|2016-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional||Intent-to-treat (ITT) population included all randomized participants who received at least one dose of study medication.|(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy|An Open, Randomized, Multi-centre Trial to Investigate the Effect of Anemia Correction on Cardiac Structure and Function in Patients With Early Diabetic Nephropathy|Completed||Phase 3|170|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:53:18.941816|2018-06-01 03:53:18.941816
NCT00354328|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2017-10-26|2006-07-18|2006-07-20|Estimate|||||||2017-10-26|2017-10-27|Actual|May 27, 2005||2005-05-27|October 22, 2017|2017-10-22|October 22, 2013||2013-10-22|||||Observational|||Heart Function and Exercise Capacity in Patients With Hypertrophic Cardiomyopathy|Relationship of Diastolic Function and Functional Capacity in Hypertrophic Cardiomyopathy: A Post-Hoc Analysis of Protocols 01-H-0066 and 96-H-0144|Completed|||110|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:19.533411|2018-06-01 03:53:19.533411
NCT00354315|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2009-02-13|2006-07-18|2006-07-20|Estimate|||||||2009-02-13|2009-02-16|Estimate|September 2006||2006-09-30|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||DÉCISION+, a Continuous Professional Development Program to Improve Optimal Drug Prescription : a Feasibility Study|DÉCISION+, a Continuous Professional Development Program to Improve Optimal Drug Prescription : a Feasibility Study|Completed||N/A|642|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-06-01 03:53:19.587496|2018-06-01 03:53:19.587496
NCT00354302|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2016-11-25|2006-07-19|2006-07-20|Estimate|||||||2016-11-25|2016-11-28|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27|The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer|Completed||Phase 3|497|Actual|Canadian Cancer Trials Group|||||f||||t||||||||||2018-06-01 03:53:19.665511|2018-06-01 03:53:19.665511
NCT00354276|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2014-01-09|2006-07-19|2006-07-20|Estimate|||||||2014-01-09|2014-01-10|Estimate|May 2006||2006-05-31|May 2009|2009-05-31||||December 2008|Anticipated|2008-12-31||Interventional|||VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia|Unknown status|Active, not recruiting|Phase 2|85|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:53:19.75102|2018-06-01 03:53:19.75102
NCT00354263|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2008-04-23|2006-07-19|2006-07-20|Estimate|||||||2008-04-23|2008-04-24|Estimate|April 2005||2005-04-30|April 2008|2008-04-30|February 2006|Actual|2006-02-28|September 2005|Actual|2005-09-30||Interventional|||Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen|IMP321 Phase I Study of Four Increasing Doses (3, 10, 30 and 100 µg) of a New Immunostimulatory Factor (IMP321) Given Alone or as an Adjuvant to a Reference Flu Antigen in Healthy Young Male Volunteers|Completed||Phase 1|60|Actual|Immutep S.A.||2|||f||||f||||||||||2018-06-01 03:53:19.819131|2018-06-01 03:53:19.819131
NCT00354250|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-06-04|2006-07-19|2006-07-20|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 2006||2006-05-31|June 2013|2013-06-30||||February 2007|Actual|2007-02-28||Interventional|||Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Advanced Renal Cell Cancer|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:53:19.886653|2018-06-01 03:53:19.886653
NCT00354237|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2014-11-17|2006-07-19|2006-07-20|Estimate|||||||2014-11-17|2014-11-18|Estimate|July 2005||2005-07-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||DARE: Diabetes in cArdiac REhabilitation|Effect of Strict Glycemic Control on Improvement of Exercise Capacities (VO2 Peak, Peak Workload After Cardiac Rehabilitation, in Patients With Type 2 Diabetes Mellitus With Coronary Artery Disease.|Completed||N/A|60|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-06-01 03:53:19.949954|2018-06-01 03:53:19.949954
NCT00354211|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2013-02-08|2006-07-19|2006-07-20|Estimate|||||||2013-02-08|2013-02-11|Estimate|July 2006||2006-07-31|February 2013|2013-02-28|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Observational|||Using Minimally Invasive Cardiac Output Data vs. Standard Care for Patients Emergently Admitted to the Intensive Care Unit Who Are Hemodynamically Unstable|TREASURE: Treatment With Minimally-Invasive Cardiac Output for Assessment of User Derived Results Evaluating Economic Benefit|Completed|||392|Actual|Edwards Lifesciences|||2||f||||t||||||||||2018-06-01 03:53:20.149132|2018-06-01 03:53:20.149132
NCT00354198|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2012-11-12|2006-07-19|2006-07-20|Estimate|||||||2012-11-12|2012-11-14|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis|Clinical Efficacy of Combined Pentoxifylline and Conventional Immunosuppressive Regimens on Patients With Rapidly Progressive Glomerulonephritis|Terminated||Phase 3|7|Actual|National Taiwan University Hospital||2||short of participants|f||||f||||||||||2018-06-01 03:53:20.211323|2018-06-01 03:53:20.211323
NCT00354185|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-05-15|2006-07-19|2006-07-20|Estimate|||||||2013-05-15|2013-05-16|Estimate|May 2006||2006-05-31|May 2013|2013-05-31||||February 2008|Actual|2008-02-29||Interventional|||PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma|A Phase I Study of PXD101 in Combination With 17-AAG in Advanced Malignancies|Terminated||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:53:20.285676|2018-06-01 03:53:20.285676
NCT00354172|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2009-11-30|2009-07-31|2017-12-03|2006-07-19|2006-07-20|Estimate|2009-11-30|2009-12-31|Estimate|2009-11-30|2009-12-31|Estimate|2017-12-03|2017-12-28|Actual|February 2006||2006-02-28|December 2017|2017-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.|Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells|Terminated||Phase 2|16|Actual|Masonic Cancer Center, University of Minnesota||1||Competing study was started.|f||||t||||||||||2018-06-01 03:53:20.379476|2018-06-01 03:53:20.379476
NCT00354159|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2012-01-12||2012-08-07|2006-07-19|2006-07-20|Estimate|2012-08-07|2012-08-09|Estimate||||2012-08-07|2012-08-09|Estimate|April 2006||2006-04-30|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|REDUCEhf||Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)|Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic HF (REDUCEhf)|Completed||N/A|442|Actual|Medtronic Cardiac Rhythm and Heart Failure|The study was terminated early after 400 of an estimated 1300 subjects required were randomized. The study was terminated due to a pressure lead integrity issue based on analysis of pressure leads from other clinical trials.|2|||f||||t||||||||||2018-06-01 03:53:20.716389|2018-06-01 03:53:20.716389
NCT00354146|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2011-01-31|2006-07-18|2006-07-20|Estimate|||||||2011-01-31|2011-02-01|Estimate|April 2001||2001-04-30|January 2011|2011-01-31|July 2003|Actual|2003-07-31|||||Interventional|||A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.|A Phase 2 Study Evaluating the Efficacy of the Farnesyl Transferase Inhibitor (FTI) R115777 in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML)|Completed||Phase 2|252|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:53:23.090668|2018-06-01 03:53:23.090668
NCT00354133|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2012-01-27|2006-07-19|2006-07-20|Estimate|||||||2012-01-27|2012-01-31|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|June 2012|Anticipated|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease|The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)|Unknown status|Active, not recruiting|Phase 4|251|Actual|German Parkinson Study Group (GPS)||2|||f||||t||||||||||2018-06-01 03:53:23.157109|2018-06-01 03:53:23.157109
NCT00354120|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2014-03-20|2006-07-19|2006-07-20|Estimate|||||||2014-03-20|2014-03-21|Estimate|March 2005||2005-03-31|March 2014|2014-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|GLOBAL||Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant|Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors|Completed||Phase 2/Phase 3|121|Actual|Gruppo Italiano Trapianto di Midollo Osseo||2|||f||||f||||||||||2018-06-01 03:53:23.248455|2018-06-01 03:53:23.248455
NCT00354107|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|2013-10-24||2018-02-14|2006-07-19|2006-07-20|Estimate|2013-11-12|2014-01-01|Estimate||||2018-02-14|2018-03-14|Actual|January 2007||2007-01-31|February 2018|2018-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma|A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC# 731636, IND#) in Children With CD30+ Recurrent Anaplastic Large Cell Lymphoma|Terminated||Phase 1/Phase 2|5|Actual|National Cancer Institute (NCI)|Number of participants analyzed = 4. One patient was not evaluable for response. The Secondary Outcome measures will never be reported as data were not collected to assess these study aims.|1|||f||||t||||||||||2018-06-01 03:53:23.449067|2018-06-01 03:53:23.449067
NCT00354094|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2007-11-07|2006-07-18|2006-07-20|Estimate|||||||2007-11-07|2007-11-08|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.|A Phase 2B Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Postherpetic Neuralgia (PHN).|Terminated||Phase 2|600||Pfizer||||The study was stopped due to business/operational issues.|f||||||||||||||2018-06-01 03:53:23.735281|2018-06-01 03:53:23.735281
NCT00354081|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-07-11|2006-07-19|2006-07-20|Estimate|||||||2013-07-11|2013-07-12|Estimate|April 1999||1999-04-30|May 2010|2010-05-31|February 2008|Actual|2008-02-29|June 2007|Actual|2007-06-30||Interventional|WENBIT||WENBIT - Western Norway B Vitamin Intervention Trial|A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography|Completed||Phase 3|3096|Actual|Haukeland University Hospital||4|||f||||t||||||||||2018-06-01 03:53:23.864284|2018-06-01 03:53:23.864284
NCT00354068|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-19|||2013-03-26|2006-07-19|2006-07-20|Estimate|||||||2013-03-26|2013-03-28|Estimate|July 2004||2004-07-31|March 2013|2013-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma|A Phase I Study of Imatinib Mesylate in Combination With Temozolomide in Patients With Malignant Glioma|Completed||Phase 1|65|Actual|Duke University|||||f||||||||||||||2018-06-01 03:53:24.012833|2018-06-01 03:53:24.012833
NCT00354042|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2009-05-15|2006-07-18|2006-07-20|Estimate|||||||2009-05-15|2009-05-18|Estimate|August 2004||2004-08-31|May 2009|2009-05-31||||||||Interventional|||Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects|A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 4 Period Crossover Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of GW597901X in Asthmatic Subjects|Completed||Phase 1|24||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:53:24.087081|2018-06-01 03:53:24.087081
NCT00354029|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2011-05-24||2011-07-19|2006-07-18|2006-07-19|Estimate|2011-07-19|2011-07-20|Estimate||||2011-07-19|2011-07-20|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|May 2009|Actual|2009-05-31|June 2008|Actual|2008-06-30||Interventional|||Effect of Perioperative i.v. Low-dose S(+) Ketamine|Effect of Perioperative i.v. Low-dose S(+) Ketamine in Patients Undergoing Hemorrhoidectomy|Completed||Phase 4|83|Actual|Asker & Baerum Hospital||2|||f||||||||||||||2018-06-01 03:53:24.155922|2018-06-01 03:53:24.155922
NCT00354016|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2007-03-12|2006-07-18|2006-07-19|Estimate|||||||2007-03-12|2007-03-13|Estimate|July 2006||2006-07-31|March 2007|2007-03-31||||||||Interventional|||Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects|A Phase III, Multicenter, Uncontrolled, Open-Label Study to Demonstrate Safety and Immunogenicity of a Commercially Available Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 When Administered to Non-Elderly Adult and Elderly Subjects|Completed||Phase 3|125||Novartis|||||f||||||||||||||2018-06-01 03:53:24.41933|2018-06-01 03:53:24.41933
NCT00354003|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2009-04-17|2006-07-17|2006-07-19|Estimate|||||||2009-04-17|2009-04-21|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|August 2008|Actual|2008-08-31|||||Observational|||The Study of the Impact of Disclosing Imaging Study Information to Trial Participants|Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials|Completed|||800|Anticipated|Institute for Neurodegenerative Disorders|||||f||||t||||||||||2018-06-01 03:53:24.56356|2018-06-01 03:53:24.56356
NCT00353990|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2007-04-24|2006-07-18|2006-07-19|Estimate|||||||2007-04-24|2007-04-25|Estimate|August 2006||2006-08-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Bioavailability of Insulin Administered in Duodenum|Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart Administered in the Duodenum in Healthy Volunteers – an Open Single Blinded and Uncontrolled Explorative Trial|Completed||Phase 1/Phase 2|12||University of Aarhus|||||f||||f||||||||||2018-06-01 03:53:24.62952|2018-06-01 03:53:24.62952
NCT00353977|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2013-04-30||2014-06-05|2006-07-18|2006-07-19|Estimate|2014-06-05|2014-07-08|Estimate||||2014-06-05|2014-07-08|Estimate|May 2004||2004-05-31|June 2014|2014-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors|A Pilot Trial of an Accelerated Immunization Schedule With ALVAC-pp65 (vCP260) for Inducing CMV-Specific Immunity in Stem Cell Allotransplant Donors and Healthy Volunteers|Completed||Phase 2|38|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 03:53:24.702922|2018-06-01 03:53:24.702922
NCT00353964|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2006-07-27|2006-07-18|2006-07-19|Estimate|||||||2006-07-27|2006-07-28|Estimate||||July 2006|2006-07-31||||||||Interventional|||Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery|A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery|Unknown status|Recruiting|Phase 2|||Evolutec Group|||||||||||||||||||2018-06-01 03:53:24.85637|2018-06-01 03:53:24.85637
NCT00353951|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2008-05-19|2006-07-18|2006-07-19|Estimate|||||||2008-05-19|2008-05-20|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care|Genomics to Combat Resistance Against Antibiotics in Community-Acquired LRTI in Europe: GRACE. Workpackage 8. An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care|Completed|||3402|Actual|Cardiff University|||||f||||||||||||||2018-06-01 03:53:24.991595|2018-06-01 03:53:24.991595
NCT00353938|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17||2011-07-31|2017-03-27|2006-07-17|2006-07-19|Estimate||||2011-08-05|2011-08-15|Estimate|2017-03-27|2017-03-28|Actual|October 2006||2006-10-31|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder|Phase II Pilot Randomized Double-Blind Placebo-Controlled Study of 3,4-methylenedioxymethamphetamine (MDMA)Assisted Psychotherapy in Posttraumatic Stress Disorder (PTSD)- Switzerland|Completed||Phase 2|14|Actual|Multidisciplinary Association for Psychedelic Studies||2|||f||||f||||||||||2018-06-01 03:53:25.054782|2018-06-01 03:53:25.054782
NCT00353925|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2017-06-30|2006-07-18|2006-07-19|Estimate|||||||2017-06-30|2017-07-02|Actual|October 5, 1999||1999-10-05|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Genetic Analysis of African-Americans With High Blood Pressure|Genetic Analysis of African-American Hypertensives|Completed|||1000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:25.135703|2018-06-01 03:53:25.135703
NCT00353912|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2016-11-16|2006-07-17|2006-07-19|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension|A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension|Completed||Phase 3|571|Actual|Novartis|||||f||||||||||||||2018-06-01 03:53:25.185601|2018-06-01 03:53:25.185601
NCT00353899|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2018-05-22|2006-07-18|2006-07-19|Estimate|||||||2018-05-22|2018-05-23|Actual|July 14, 2006||2006-07-14|April 26, 2017|2017-04-26|April 26, 2017||2017-04-26|||||Observational|||Cardiovascular Magnetic Resonance Imaging of Pediatric Normal Volunteers|Cardiovascular Magnetic Resonance Imaging of Pediatric Healthy Volunteers|Completed|||41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:25.265949|2018-06-01 03:53:25.265949
NCT00353886|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2007-07-19|2006-07-17|2006-07-19|Estimate|||||||2007-07-19|2007-07-23|Estimate|September 2002||2002-09-30|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Observational|||Study of Antiepileptic Drug Effects on Child Development|Retrospective Study of In Utero Antiepileptic Drug Effects in Neurodevelopment|Completed|||81|Actual|Augusta University|||||f||||||||||||||2018-06-01 03:53:25.325198|2018-06-01 03:53:25.325198
NCT00353691|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2011-01-10|2006-07-17|2006-07-19|Estimate|||||||2011-01-10|2011-01-11|Estimate|October 2002||2002-10-31|January 2011|2011-01-31|November 2004||2004-11-30|||||Interventional|||Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus|Glimepiride Versus Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus: A Single Blind Comparison Study|Completed||Phase 3|100||Sanofi|||||f||||||||||||||2018-06-01 03:53:27.472134|2018-06-01 03:53:27.472134
NCT00353873|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2017-03-13||2018-03-15|2006-07-18|2006-07-19|Estimate|2017-03-13|2017-04-24|Actual||||2018-03-15|2018-05-28|Estimate|November 18, 2005|Actual|2005-11-18|March 2018|2018-03-31|October 26, 2006|Actual|2006-10-26|October 26, 2006|Actual|2006-10-26||Interventional|||Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids|A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100µg Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200µg Twice Daily, Both Delivered Via a Dry Powder Inhaler (DiskusTM) for 12 Weeks in Asthma in Children Aged 4-11 Years Not Controlled by Inhaled Corticosteroids Alone at Medium Dose|Completed||Phase 4|506|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:25.445236|2018-06-01 03:53:25.445236
NCT00353860|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2018-05-12|2006-07-18|2006-07-19|Estimate|||||||2018-05-12|2018-05-15|Actual|January 23, 2002||2002-01-23|November 21, 2016|2016-11-21|November 29, 2007|Actual|2007-11-29|November 29, 2007|Actual|2007-11-29||Interventional|||Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Role of Preparative Regimen and T Cell Dose in Graft Rejection and GVHD|Completed||Phase 2|70|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:25.882163|2018-06-01 03:53:25.882163
NCT00353847|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2006-11-15|2006-07-18|2006-07-19|Estimate|||||||2006-11-15|2006-11-16|Estimate|July 2006||2006-07-31|June 2006|2006-06-30||||||||Interventional|||Acupuncture for Treatment of Chronic LBP, RCT, Single Blinded|A Randomized, Single Blind, Controlled Clinical Trial to Evaluate the Pain Relief Efficacy, Functional Improvement and Safety of Acupuncture in Patients With Chronic Low Back Pain|Unknown status|Active, not recruiting|Phase 3|50||Korea Institute of Oriental Medicine|||||f||||||||||||||2018-06-01 03:53:25.951776|2018-06-01 03:53:25.951776
NCT00353834|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2017-12-07||2017-12-07|2006-07-18|2006-07-19|Estimate|2017-12-07|2018-01-09|Actual||||2017-12-07|2018-01-09|Actual|August 2006||2006-08-31|December 2017|2017-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes|The Effect of Exenatide Compared to Lantus Insulin on Vascular Function Before and After a Meal Tolerance Test in Patients With Type 2 Diabetes|Completed||Phase 4|72|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-06-01 03:53:26.026529|2018-06-01 03:53:26.026529
NCT00353821|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2018-05-24|2006-07-18|2006-07-19|Estimate|||||||2018-05-24|2018-05-25|Actual|June 5, 2003||2003-06-05|March 2, 2018|2018-03-02|March 2, 2018||2018-03-02|||||Observational|||Investigating Cytokine Genes of Stem Cell Donors|Cytokine Gene Polymorphisms in Allotransplant Donors|Completed|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:26.232987|2018-06-01 03:53:26.232987
NCT00353808|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2011-04-06|2006-07-17|2006-07-19|Estimate|||||||2011-04-06|2011-04-07|Estimate|July 2006||2006-07-31|April 2011|2011-04-30|October 2007|Actual|2007-10-31|||||Interventional|||A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.|An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN).|Terminated||Phase 2|112|Actual|Pfizer||1||"This study has been terminated early as the esreboxetine development program is being~   discontinued. There are no safety or efficacy concerns."|f||||||||||||||2018-06-01 03:53:26.29452|2018-06-01 03:53:26.29452
NCT00353795|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2009-08-04||2010-05-25|2006-07-18|2006-07-19|Estimate|2010-05-25|2010-06-22|Estimate||||2010-05-25|2010-06-22|Estimate|July 2005||2005-07-31|September 2009|2009-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)|Coronary Atherosclerosis Evaluation by Arterial Wall MRI|Completed||N/A|179|Actual|Johns Hopkins University|Cross sectional study||||f||||||||||||||2018-06-01 03:53:26.509293|2018-06-01 03:53:26.509293
NCT00353782|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2018-05-16|2006-07-18|2006-07-19|Estimate|||||||2018-05-16|2018-05-17|Actual|September 15, 2003||2003-09-15|February 27, 2018|2018-02-27||||||||Observational|||Causes and Natural History of Dyslipidemias|Disease Pathogenesis and Natural History of Lipid Disorders|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:26.668965|2018-06-01 03:53:26.668965
NCT00353769|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2017-02-09|2006-07-17|2006-07-19|Estimate|||||||2017-02-09|2017-02-10|Actual|November 2002||2002-11-30|February 2017|2017-02-28|February 2005||2005-02-28|||||Interventional|||Comparison Study on Hair Apposition Technique Performed Between Nurses and Doctors in Emergency Department.|A Single-blinded Comparative Study on Hair Apposition Technique Performed Between Nurses and Doctors in Emergency Department.(HAT2 Study)|Completed||Phase 3|360||Singapore General Hospital|||||f||||||||||||||2018-06-01 03:53:26.737093|2018-06-01 03:53:26.737093
NCT00353756|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2006-10-10|2006-07-17|2006-07-19|Estimate|||||||2006-10-10|2006-10-11|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|September 2007||2007-09-30|||||Interventional|||Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease|A Placebo-Controlled, Phase 1, Single and Multiple IV Dose Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of C326 in Adults With Crohn’s Disease|Unknown status|Recruiting|Phase 1|52||Avidia|||||f||||||||||||||2018-06-01 03:53:26.805565|2018-06-01 03:53:26.805565
NCT00353743|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2008-12-18|2006-07-17|2006-07-19|Estimate|||||||2008-12-18|2008-12-19|Estimate|May 2006||2006-05-31|March 2007|2007-03-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|APA||The Use of Antibiotics After Hospital Discharge in Septic Abortion|A Randomized Clinical Trial on the Use or Not of Antibiotics After Hospital Discharge in Septic Abortion.|Terminated||N/A|56|Actual|Hospital de Clinicas de Porto Alegre||2||Rate of cure was higher than expected, IRB suspended for no additional benefit|f||||t||||||||||2018-06-01 03:53:26.959328|2018-06-01 03:53:26.959328
NCT00353730|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2018-03-27|2006-07-18|2006-07-19|Estimate|||||||2018-03-27|2018-03-29|Actual|August 9, 2002||2002-08-09|October 6, 2017|2017-10-06||||||||Observational|||Identification of Genes Expressed in Atherosclerotic Plaque|Identification of Genes Expressed in Atherosclerotic Plaques|Completed|||69|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:27.049062|2018-06-01 03:53:27.049062
NCT00353717|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2009-01-12|2006-07-18|2006-07-19|Estimate|||||||2009-01-12|2009-01-13|Estimate|November 2006||2006-11-30|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|||||Interventional|||Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma|Phase II of Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-06-01 03:53:27.127858|2018-06-01 03:53:27.127858
NCT00353704|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|2011-05-24||2011-07-19|2006-07-18|2006-07-19|Estimate|2011-07-19|2011-07-20|Estimate||||2011-07-19|2011-07-20|Estimate|November 2005||2005-11-30|July 2011|2011-07-31|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|||Analgetic and Anxiolytic Effect of Preoperative Pregabalin|Analgetic and Anxiolytic Effect of Preoperative Pregabalin in Patients Undergoing Surgery of the Vertebral Columna|Completed||Phase 4|50|Actual|Asker & Baerum Hospital||2|||f||||||||||||||2018-06-01 03:53:27.221256|2018-06-01 03:53:27.221256
NCT00353678|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2013-03-19|2006-07-18|2006-07-19|Estimate|||||||2013-03-19|2013-03-21|Estimate|June 2006||2006-06-30|March 2013|2013-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)|Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin|Completed||Phase 2|1141|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 03:53:27.544005|2018-06-01 03:53:27.544005
NCT00353665|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2009-03-30|2006-07-18|2006-07-19|Estimate|||||||2009-03-30|2009-04-01|Estimate|July 2005||2005-07-31|March 2009|2009-03-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)|Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis|Completed||Phase 2/Phase 3|63|Actual|University of Lisbon||2|||f||||t||||||||||2018-06-01 03:53:27.860248|2018-06-01 03:53:27.860248
NCT00353652|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|2014-12-02||2014-12-16|2006-07-18|2006-07-19|Estimate|2014-12-16|2014-12-29|Estimate||||2014-12-16|2014-12-29|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Evaluating the Link Between Thiazide Medications, the Nervous System, and Diabetes in Individuals With High Blood Pressure|Neural Mechanisms of Thiazide-induced Insulin Resistance|Completed||Phase 4|176|Actual|University of Texas Southwestern Medical Center||4|||f||||t||||||||||2018-06-01 03:53:27.949538|2018-06-01 03:53:27.949538
NCT00353639|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-18|||2018-05-22|2006-07-18|2006-07-19|Estimate|||||||2018-05-22|2018-05-23|Actual|January 30, 2006||2006-01-30|June 5, 2017|2017-06-05||||||||Observational|||Telomere Repair Gene Mutation in Inflammatory Bowel Disease|Telomere Repair Gene Mutations in Inflammatory Bowel Disease|Completed|||95|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:28.283053|2018-06-01 03:53:28.283053
NCT00353626|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-16|||2008-03-19|2006-07-16|2006-07-18|Estimate|||||||2008-03-19|2008-03-24|Estimate|June 2006||2006-06-30|March 2008|2008-03-31|September 2007|Actual|2007-09-30|July 2007|Actual|2007-07-31||Observational|||Gait Evaluation of Experienced Below Knee Amputees|Gait Evaluation of Experienced Post Traumatic Below Knee Amputees|Completed|||9|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:53:28.346956|2018-06-01 03:53:28.346956
NCT00353613|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2013-06-17|2006-07-17|2006-07-18|Estimate|||||||2013-06-17|2013-06-18|Estimate|March 2007||2007-03-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prevention of Surgical Site Infections|Prevention of Surgical Site Infections|Completed||N/A|900|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-06-01 03:53:28.399332|2018-06-01 03:53:28.399332
NCT00353600|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2017-06-30|2006-07-17|2006-07-18|Estimate|||||||2017-06-30|2017-07-02|Actual|August 19, 1994||1994-08-19|August 16, 2011|2011-08-16|August 16, 2011||2011-08-16|||||Observational|||Delaying the Progression of Diabetic Nephropathy in Pima Indians|Delaying the Progression of Diabetic Nephropathy in Pima Indians|Completed|||25|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:28.487285|2018-06-01 03:53:28.487285
NCT00353587|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2015-04-29|2006-07-14|2006-07-18|Estimate|||||||2015-04-29|2015-05-01|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin|Phase 2/3, Randomized, Double-blind, Placebo- and Active Comparator-controlled, Parallel, Multicenter Study to Determine Safety and Efficacy of Metaglidasen in Treatment of Type 2 Diabetes Suboptimally Controlled on Insulin|Completed||Phase 2/Phase 3|396|Actual|CymaBay Therapeutics, Inc.||5|||f||||f||||||||||2018-06-01 03:53:28.546846|2018-06-01 03:53:28.546846
NCT00353574|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17||2014-01-03|2014-02-19|2006-07-17|2006-07-18|Estimate||||2014-01-03|2014-02-04|Estimate|2014-02-19|2014-03-18|Estimate|September 2006||2006-09-30|February 2014|2014-02-28|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Interventional|Darusentan||DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension|DORADO-EX - A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311-E)|Terminated||Phase 3|282|Actual|Gilead Sciences||3||Study DAR-312 did not meet primary co-endpoints|f||||t||||||||||2018-06-01 03:53:28.695964|2018-06-01 03:53:28.695964
NCT00353561|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2008-05-21|2006-07-17|2006-07-18|Estimate|||||||2008-05-21|2008-05-22|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Diabetes Mellitus and Vulvovaginal Candidiasis|Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management|Completed||Phase 3|100|Actual|Indian Council of Medical Research||2|||f||||||||||||||2018-06-01 03:53:28.927724|2018-06-01 03:53:28.927724
NCT00353548|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2012-07-20|2006-07-14|2006-07-18|Estimate|||||||2012-07-20|2012-07-23|Estimate|April 2005||2005-04-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Determining the Response to Sipping Beverages Without Swallowing in People With Eating Disorders|Study of Response to the Taste of Beverages That Are Not Swallowed (Sipping and Spitting in Eating Disorders)|Completed|||80|Actual|New York State Psychiatric Institute|||5||f||||f||||||||||2018-06-01 03:53:28.999703|2018-06-01 03:53:28.999703
NCT00353535|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2006-07-17|2006-07-17|2006-07-18|Estimate|||||||2006-07-17|2006-07-18|Estimate|January 2000||2000-01-31|September 2005|2005-09-30|December 2002||2002-12-31|||||Interventional|||Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal Graft|Phase 1 Study of TLI Pretransplant to Prevent Recurrence of FSGS in the Graft|Completed||Phase 1|10||University of Sao Paulo|||||f||||||||||||||2018-06-01 03:53:29.075005|2018-06-01 03:53:29.075005
NCT00353522|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17||2016-06-28|2016-11-01|2006-07-17|2006-07-18|Estimate||||2016-06-28|2016-06-30|Estimate|2016-11-01|2016-11-02|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.|A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 Over a 24-week Period in Patients With CHD or a CHD Risk Equivalent|Completed||Phase 2|135|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:53:29.135013|2018-06-01 03:53:29.135013
NCT00353509|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-16|||2013-10-08|2006-07-16|2006-07-18|Estimate|||||||2013-10-08|2013-10-09|Estimate||||October 2013|2013-10-31||||||||Interventional|||Safety and Effectiveness Study of the Solysafe Septal Occluder|Prospective Mono-center Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device in Patients With Atrial Septum Defect (ASD)|Completed||N/A|||Carag AG|||||f||||||||||||||2018-06-01 03:53:29.297338|2018-06-01 03:53:29.297338
NCT00353327|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2008-03-28|2006-07-17|2006-07-18|Estimate|||||||2008-03-28|2008-03-31|Estimate|October 2006||2006-10-31|March 2008|2008-03-31||||||||Interventional|||Study of the Effectiveness of Passive Immunotherapy in HIV-Infected Patients Who Are in Virologic Failure|Passive Immunotherapy in HIV-Infected Patients Who Fail to Respond to Multiple Highly Active Antiretroviral Treatment. Randomized Study in Two Phases.|Suspended||Phase 2/Phase 3|30|Anticipated|Hospital Clinic of Barcelona||||low recruitment|f||||||||||||||2018-06-01 03:53:33.969712|2018-06-01 03:53:33.969712
NCT00353496|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|2015-01-15||2015-02-18|2006-07-17|2006-07-18|Estimate|2015-02-17|2015-02-18|Estimate||||2015-02-18|2015-03-06|Estimate|June 2006||2006-06-30|February 2015|2015-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CLARINET|Analysis based on intent-to-treat (ITT) population comprised of 204 subjects.|Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours|Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour|Completed||Phase 3|264|Actual|Ipsen||2|||f||||||||||||||2018-06-01 03:53:29.417955|2018-06-01 03:53:29.417955
NCT00353483|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2018-04-12|2006-07-17|2006-07-18|Estimate|||||||2018-04-12|2018-04-17|Actual|September 14, 2005|Actual|2005-09-14|April 2018|2018-04-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Observational|||Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells|Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells|Recruiting|||200|Anticipated|Washington University School of Medicine|||1||f||||f|f|f||||Samples With DNA|"~     Breast cancer tissue, peripheral blood, and bone marrow~   "|No||2018-06-01 03:53:30.279606|2018-06-01 03:53:30.279606
NCT00353470|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2018-04-30|2006-07-14|2006-07-18|Estimate|||||||2018-04-30|2018-05-03|Actual|September 2006||2006-09-30|April 2018|2018-04-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Comparison of Psychotherapy Programs to Treat Panic Disorder|Dynamic Treatment vs. CBT for Panic Disorder|Completed||Phase 3|201|Actual|Weill Medical College of Cornell University||3|||f||||t||||||||||2018-06-01 03:53:30.402979|2018-06-01 03:53:30.402979
NCT00353457|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2016-09-23|2006-07-14|2006-07-18|Estimate|||||||2016-09-23|2016-09-26|Estimate|February 2006||2006-02-28|September 2016|2016-09-30||||July 2011|Actual|2011-07-31||Interventional|||Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma|Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma|Completed||Phase 2|6|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 03:53:30.490679|2018-06-01 03:53:30.490679
NCT00353444|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2008-11-05|2006-07-17|2006-07-18|Estimate|||||||2008-11-05|2008-11-06|Estimate|December 2006||2006-12-31|November 2008|2008-11-30|March 2007||2007-03-31|||||Observational|||Transcranial Doppler Measurement and Prognosis in Moderate Head Injury|Transcranial Doppler Measurement and Prognosis in Moderate Head Injury|Suspended|||70||Universidad Autonoma de San Luis Potosí||||Technical Conflicts|f||||||||||||||2018-06-01 03:53:30.552126|2018-06-01 03:53:30.552126
NCT00353431|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|2011-10-31||2012-05-10|2006-07-17|2006-07-18|Estimate|2012-05-06|2012-05-08|Estimate||||2012-05-10|2012-05-18|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia|Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia|Completed||N/A|130|Actual|University Hospital, Basel, Switzerland|Small sample size|2|||f||||f||||||||||2018-06-01 03:53:30.603861|2018-06-01 03:53:30.603861
NCT00353418|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|2010-05-14||2010-07-30|2006-07-17|2006-07-18|Estimate|2010-05-14|2010-06-15|Estimate||||2010-07-30|2010-08-03|Estimate|June 2006||2006-06-30|July 2010|2010-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection|A Randomized, Multicenter, Double Blinded Study Comparing the Safety and Efficacy of Pegasys® 180 ug Plus Copegus® 1000 or 1200 mg to the Currently Approved Combination of Pegasys® 180 ug Plus Copegus® 800 mg in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection and HIV-1|Completed||Phase 4|415|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:53:31.072594|2018-06-01 03:53:31.072594
NCT00353405|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2012-01-18|2006-07-14|2006-07-18|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||HIV and STD Prevention for High-Risk, Inner-City, African American Youth|A Multilevel HIV Prevention Strategy for High-Risk Youth|Completed||Phase 3|1650|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 03:53:31.80091|2018-06-01 03:53:31.80091
NCT00353392|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2013-12-18|2006-07-17|2006-07-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2006||2006-03-31|November 2006|2006-11-30|August 2006||2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Q-Switched Nd:YAG in Macular Amyloidosis||Completed||Phase 1|20||Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:53:31.893675|2018-06-01 03:53:31.893675
NCT00353379|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2017-02-09|2006-07-14|2006-07-18|Estimate|||||||2017-02-09|2017-02-10|Actual|September 1995|Actual|1995-09-30|February 2017|2017-02-28|May 1997|Actual|1997-05-31|May 1997|Actual|1997-05-31||Interventional|||Pharmacology of Cognition in Schizotypal Personality Disorder|Pharmacology of Cognition in Schizotypal Personality Disorder: Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder|Terminated||Phase 4|29|Actual|Icahn School of Medicine at Mount Sinai||2||low enrollment|f||||t||||||||||2018-06-01 03:53:31.963605|2018-06-01 03:53:31.963605
NCT00353366|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|2011-07-07||2012-11-21|2006-07-17|2006-07-18|Estimate|2011-07-07|2011-08-03|Estimate||||2012-11-21|2012-11-27|Estimate|November 2006||2006-11-30|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination|Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First Vaccination|Completed|||1432|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-06-01 03:53:32.069017|2018-06-01 03:53:32.069017
NCT00353353|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2007-07-06|2006-07-17|2006-07-18|Estimate|||||||2007-07-06|2007-07-09|Estimate|July 2006||2006-07-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||The Bread Trial: Effects of Bread Fortified With Folic Acid and Vitamin B12|The Bread Trial: a Demonstration Trial to Show Effects of Fortification of Food With Both Folic Acid and Vitamin B12|Completed||N/A|150|Anticipated|Wageningen University|||||f||||f||||||||||2018-06-01 03:53:33.333259|2018-06-01 03:53:33.333259
NCT00353340|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2010-02-24|2006-07-17|2006-07-18|Estimate|||||||2010-02-24|2010-02-25|Estimate|January 2005||2005-01-31|February 2010|2010-02-28|May 2009|Actual|2009-05-31|January 2008|Actual|2008-01-31||Interventional|||Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine|Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine in Patients Undergoing Cardiac Catheterization|Completed||N/A|250|Anticipated|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 03:53:33.667192|2018-06-01 03:53:33.667192
NCT00353301|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|2013-12-23||2014-03-17|2006-07-14|2006-07-18|Estimate|2013-12-23|2014-02-17|Estimate||||2014-03-17|2014-04-14|Estimate|July 2006||2006-07-31|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional||It was calculated that 25 participants will provide 80% power to detect an improvement in progression-free survival from 12 to 24 weeks in a pretreated population of renal cell carcinoma patients.|Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma|A Phase II Single Arm Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Tarceva™ (Erlotinib Hydrochloride) and Rapamune™ (Sirolimus) in the Treatment of Metastatic Renal Cell Carcinoma.|Completed||Phase 2|25|Actual|University of Colorado, Denver|One limitation of this study was the lack of von Hippel–Lindau (VHL) mutational status assessment.|1|||f||||t||||||||||2018-06-01 03:53:34.153827|2018-06-01 03:53:34.153827
NCT00353288|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2016-10-06|2006-07-17|2006-07-18|Estimate|||||||2016-10-06|2016-10-07|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™|Comparative Study Evaluating the Immunogenicity and Safety of MeMuRu-OKA Vaccine and Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Measles-mumps-rubella Vaccine|Completed||Phase 2|446|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:34.434501|2018-06-01 03:53:34.434501
NCT00353275|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|2014-02-19||2014-05-02|2006-07-17|2006-07-18|Estimate|2014-04-01|2014-05-05|Estimate||||2014-05-02|2014-05-15|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Hyperglycemia in Surgical Infections|Studies on Hyperglycemia in Surgical Infections|Terminated||N/A|5|Actual|The University of Texas Health Science Center, Houston||2||Difficulty in enrolling eligible patients|f||||t||||||||||2018-06-01 03:53:34.700759|2018-06-01 03:53:34.700759
NCT00353262|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|2015-12-04||2016-02-04|2006-07-17|2006-07-18|Estimate|2015-12-04|2016-01-08|Estimate||||2016-02-04|2016-03-04|Estimate|July 2005||2005-07-31|February 2016|2016-02-29|April 2008|Actual|2008-04-30|September 2006|Actual|2006-09-30||Interventional|||A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.|An Open-label Study to Assess the Pharmacokinetic Interaction Between Xeloda and Oxaliplatin in Patients With Metastatic Colorectal Cancer.|Completed||Phase 1|36|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:53:35.111076|2018-06-01 03:53:35.111076
NCT00353249|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2014-05-06|2006-07-17|2006-07-18|Estimate|||||||2014-05-06|2014-05-08|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Homeless Women|Cognitive Behavioral Therapy for Homeless Women With Post-Traumatic Stress Disorder (PTSD)|Completed||Phase 1|31|Actual|RAND||2|||f||||||||||||||2018-06-01 03:53:35.896094|2018-06-01 03:53:35.896094
NCT00353236|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2006-07-17|2006-07-17|2006-07-18|Estimate|||||||2006-07-17|2006-07-18|Estimate||||July 2006|2006-07-31||||||||Observational|||The Contribution of Internal Maternal Resources to Creation of Motherhood. Comparison Among Mothers to Twins and Singleton||Unknown status|Recruiting||||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:53:35.999118|2018-06-01 03:53:35.999118
NCT00353223|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2013-05-30|2006-07-14|2006-07-18|Estimate|||||||2013-05-30|2013-06-03|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Interpersonal Psychotherapy for Depression in People With Heart Failure|Interpersonal Psychotherapy for Depression in Patients With Heart Failure|Completed||Phase 1/Phase 2|66|Actual|University of Iowa||2|||f||||f||||||||||2018-06-01 03:53:36.064219|2018-06-01 03:53:36.064219
NCT00353210|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-16|||2017-11-26|2006-07-17|2006-07-18|Estimate|||||||2017-11-26|2017-11-28|Actual|April 2004||2004-04-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos|The Derivation of Human Embryonic Stem Cell Lines From PGD Embryos|Recruiting|||30|Anticipated|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     Retain serum samples of embryo donors.~   "|||2018-06-01 03:53:36.157765|2018-06-01 03:53:36.157765
NCT00353197|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-16|||2017-11-26|2006-07-16|2006-07-18|Estimate|||||||2017-11-26|2017-11-28|Actual|July 2002|Actual|2002-07-31|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Derivation of New Human Embryonic Stem Cell Lines Lines for Clinical Use|The Derivation of New Human Embryonic Stem Cell Lines for Clinical Use|Recruiting|||40|Anticipated|Hadassah Medical Organization|||||f||||t||||||Samples With DNA|"~     Blood serum samples of donor couple.~   "|||2018-06-01 03:53:36.236108|2018-06-01 03:53:36.236108
NCT00353184|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2010-02-23|2006-07-17|2006-07-18|Estimate|||||||2010-02-23|2010-02-24|Estimate|September 2001||2001-09-30|February 2010|2010-02-28|February 2005|Actual|2005-02-28|October 2004|Actual|2004-10-31||Interventional|||Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years|Randomized Controlled Trial of Oral Montelukast Added to Standard Therapy for Acute Asthma Exacerbations in Children Age 6 to 14 Years|Terminated||N/A|27|Actual|Washington University School of Medicine||||Results of the interim analysis suggested no significant diff between study groups.|f||||||||||||||2018-06-01 03:53:36.311952|2018-06-01 03:53:36.311952
NCT00353171|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-17|||2018-04-04|2006-07-17|2006-07-18|Estimate|||||||2018-04-04|2018-04-05|Actual|March 1, 2003||2003-03-01|June 7, 2017|2017-06-07||||||||Observational|||Organochlorine Exposure in Relation to Timing of Natural Menopause|Organochlorine Exposure in Relation to Timing of Natural Menopause|Completed|||514|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:36.427564|2018-06-01 03:53:36.427564
NCT00353158|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2018-03-01|2006-07-14|2006-07-17|Estimate|||||||2018-03-01|2018-03-02|Actual|July 11, 2006||2006-07-11|November 20, 2017|2017-11-20|September 20, 2011|Actual|2011-09-20|September 20, 2011|Actual|2011-09-20||Interventional|||A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity|A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity|Completed||Phase 1|62|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:53:36.498215|2018-06-01 03:53:36.498215
NCT00353145|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2012-08-01|2006-07-13|2006-07-17|Estimate|||||||2012-08-01|2012-08-02|Estimate|February 2004||2004-02-29|August 2012|2012-08-31|January 2010|Actual|2010-01-31|March 2007|Actual|2007-03-31||Interventional|||Gemox as First and Second Line Therapy in Unknown Primary Cancer|A Phase II Study to Evaluate the Efficacy and Toxicity of Oxaliplatin in Combination With Gemcitabine as First and Second Line Therapy in Unknown Primary Cancer|Completed||Phase 2|29|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:53:36.606761|2018-06-01 03:53:36.606761
NCT00352937|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2014-05-14|2006-07-14|2006-07-17|Estimate|||||||2014-05-14|2014-05-15|Estimate|March 2006||2006-03-31|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Comparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear Stress Test|Comparison of Cardiac Computed Tomography for the Detection of Coronary Artery Disease With Nuclear Stress Test|Completed|||98|Actual|Providence VA Medical Center|||||f||||t||||||||||2018-06-01 03:53:38.504992|2018-06-01 03:53:38.504992
NCT00353119|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|2010-11-23||2011-09-01|2006-07-14|2006-07-17|Estimate|2010-11-23|2010-12-21|Estimate||||2011-09-01|2011-09-09|Estimate|April 2006||2006-04-30|September 2011|2011-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis|Phase 3 Study With a Placebo-Controlled, Double-blind, on the Safety and Efficacy of Etanercept in Palmo-Plantar Pustulosis|Completed||Phase 3|15|Actual|Innovaderm Research Inc.||2|||f||||f||||||||||2018-06-01 03:53:36.731236|2018-06-01 03:53:36.731236
NCT00353106|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2012-07-27|2006-07-13|2006-07-17|Estimate|||||||2012-07-27|2012-07-30|Estimate|February 2006||2006-02-28|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Experience of Having Chronic Graft-Versus-Host Disease|The Experience of Having Chronic Graft-Versus-Host Disease|Completed|||187|Actual|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-06-01 03:53:37.077567|2018-06-01 03:53:37.077567
NCT00353093|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2006-10-19|2006-07-14|2006-07-17|Estimate|||||||2006-10-19|2006-10-20|Estimate|January 2003||2003-01-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||The ERASMUS Study: Limited vs Extended US for DVT Diagnosis|Limited Versus Extended Ultrasonography for the Diagnosis of Clinically Symptomatic Deep Vein Thrombosis of the Lower Extremities. A Randomized Study|Completed||N/A|2000||University of Padova|||||f||||||||||||||2018-06-01 03:53:37.207264|2018-06-01 03:53:37.207264
NCT00353080|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2009-12-11|2006-07-13|2006-07-17|Estimate|||||||2009-12-11|2009-12-15|Estimate|December 2002||2002-12-31|December 2009|2009-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women|A Two-year, Multicenter, Double-blind, Randomized, Placebo-controlled and Parallel Group Study of Oral Risedronate 5 mg Daily in the Prevention of Osteoporosis in Osteopenic Postmenopausal Women (More Than 5 Years Postmenopausal)|Completed||Phase 3|171|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:53:37.26346|2018-06-01 03:53:37.26346
NCT00353067|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2006-11-28|2006-07-14|2006-07-17|Estimate|||||||2006-11-28|2006-11-29|Estimate|May 2006||2006-05-31|November 2006|2006-11-30||||||||Interventional|||Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Veliflapon (DG-031) in Reducing the Risk of Acute Cardiovascular Events in African American Patients With Coronary Artery Disease(The LTCAD Study).|Suspended||Phase 3|3450||deCODE genetics|||||f||||||||||||||2018-06-01 03:53:37.335728|2018-06-01 03:53:37.335728
NCT00353054|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2006-07-14|2006-07-14|2006-07-17|Estimate|||||||2006-07-14|2006-07-17|Estimate|January 2003||2003-01-31|November 2002|2002-11-30|July 2005||2005-07-31|||||Interventional|||Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.|A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Calcium/Vitamin D Supplementation (Caltrate 600+ D) on Body Weight and Fat Loss in Overweight and Obese Individuals on a Weight-Reducing Program.|Completed||Phase 4|80||Laval University|||||f||||||||||||||2018-06-01 03:53:37.408338|2018-06-01 03:53:37.408338
NCT00353041|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2006-07-13|2006-07-13|2006-07-17|Estimate|||||||2006-07-13|2006-07-17|Estimate|July 2006||2006-07-31|July 2006|2006-07-31|December 2006||2006-12-31|||||Interventional|||A Study of the Effect of Time on Topical Anesthetic Efficacy.|A Study of the Effect of Time on Topical Anesthetic Efficacy.|Unknown status|Recruiting|N/A|90||University of Toronto|||||f||||||||||||||2018-06-01 03:53:37.58007|2018-06-01 03:53:37.58007
NCT00353028|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2010-03-03|2006-07-14|2006-07-17|Estimate|||||||2010-03-03|2010-03-04|Estimate|October 2006||2006-10-31|March 2010|2010-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents|SME3110 (Fluvoxamine Maleate) in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placeb-controlled Study|Completed||Phase 4|90|Actual|Solvay Pharmaceuticals||2|||f||||t||||||||||2018-06-01 03:53:37.690998|2018-06-01 03:53:37.690998
NCT00353015|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2012-08-01|2006-07-13|2006-07-17|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 2003||2003-03-31|August 2012|2012-08-31|July 2009|Actual|2009-07-31|December 2007|Actual|2007-12-31||Interventional|||Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract|A Phase II Study of Irinotecan and Cisplatin for Metastatic or Unresectable High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract|Completed||Phase 2|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:53:37.801458|2018-06-01 03:53:37.801458
NCT00353002|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2017-08-25|2006-07-14|2006-07-17|Estimate|||||||2017-08-25|2017-08-28|Actual|July 2006|Actual|2006-07-31|August 2017|2017-08-31|December 2006||2006-12-31|||||Interventional|||A Comparison of Amethocaine Cream vs. Liposomal Lidocaine Cream for Venipuncture in Children.|A Comparison of Amethocaine Creams Versus Liposomal Lidocaine Cream as Pain Reliever Prior to Venipuncture in Children at the Paediatric Emergency Department.|Withdrawn||N/A|0|Actual|Lawson Health Research Institute|||||f||||t||||||||||2018-06-01 03:53:37.888202|2018-06-01 03:53:37.888202
NCT00352989|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2007-09-26|2006-07-14|2006-07-17|Estimate|||||||2007-09-26|2007-09-27|Estimate|July 2006||2006-07-31|September 2007|2007-09-30||||||||Interventional|||Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children|Efficacy of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children|Completed||Phase 3|300|Anticipated|Ipsen|||||f||||||||||||||2018-06-01 03:53:37.978111|2018-06-01 03:53:37.978111
NCT00352976|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2017-12-03|2006-07-14|2006-07-17|Estimate|||||||2017-12-03|2017-12-05|Actual|May 18, 2006|Actual|2006-05-18|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||TBI Dose De-escalation for Fanconi Anemia|Total Body Irradiation Dose De-escalation Study in Patients With Fanconi Anemia Undergoing Alternate Donor Hematopoietic Cell Transplantation|Recruiting||Phase 2/Phase 3|120|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|f|f||||||||2018-06-01 03:53:38.100452|2018-06-01 03:53:38.100452
NCT00352963|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2016-09-14|2006-07-14|2006-07-17|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).|Study to Assess Immunogenicity and Reactogenicity of Three Doses of GSK Bio's Combined Hib-MenC Vaccine Co-admind With GSK Bio's DTPa-HBV-IPV Vaccine and of Two Doses of Baxters Meningococcal C Conjugate Vaccine Co-admind With GSK Bio's DTPa-HBV-IPV/Hib Vaccine|Completed||Phase 3|480|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:38.262297|2018-06-01 03:53:38.262297
NCT00352950|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2007-12-20|2006-07-14|2006-07-17|Estimate|||||||2007-12-20|2007-12-28|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|February 2008||2008-02-29|||||Interventional|||Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer|An Open-Label Clinical Trial Evaluating the Safety and Pharmacodynamics of Sirolimus and Panitumumab in Subjects With Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 1|40||Amgen|||||||||||||||||||2018-06-01 03:53:38.40726|2018-06-01 03:53:38.40726
NCT00352911|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2009-04-15||2010-03-04|2006-07-13|2006-07-17|Estimate|2009-12-22|2010-01-27|Estimate||||2010-03-04|2010-03-09|Estimate|July 2006||2006-07-31|March 2010|2010-03-31|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects|A Randomized, Placebo-controlled, Dose Escalating, Phase II Trial of the Anti -HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects|Completed||Phase 2|19|Actual|VGX Pharmaceuticals, LLC||2|||||||||||||||||2018-06-01 03:53:38.662174|2018-06-01 03:53:38.662174
NCT00352898|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2016-10-06|2006-07-14|2006-07-17|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™|Comparative Study Evaluating the Immunogenicity & Safety of MeMuRu-OKA Vaccine & Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™) in Children Primed With Both Measles-mumps-rubella & Varicella Vaccines|Completed||Phase 2|400|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:53:38.97809|2018-06-01 03:53:38.97809
NCT00352885|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2014-03-08||2014-10-02|2006-07-13|2006-07-17|Estimate|2014-05-26|2014-06-27|Estimate||||2014-10-02|2014-10-09|Estimate|January 2006||2006-01-31|October 2014|2014-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment|IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention|Completed||Phase 4|20|Actual|Emory University||2|||f||||t||||||||||2018-06-01 03:53:39.127655|2018-06-01 03:53:39.127655
NCT00352872|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2018-02-28|2006-07-13|2006-07-17|Estimate|||||||2018-02-28|2018-03-02|Actual|February 2005||2005-02-28|February 2018|2018-02-28|January 13, 2009|Actual|2009-01-13|January 13, 2009|Actual|2009-01-13||Observational|||Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer|A Pilot Study of Cytochrome P450 Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer|Terminated|||23|Actual|Indiana University||||This study has been difficult to recruit.|f||||||||||Samples With DNA|"~     Whole blood Plasma~   "|||2018-06-01 03:53:39.335794|2018-06-01 03:53:39.335794
NCT00352859|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2014-12-26|2006-07-14|2006-07-17|Estimate|||||||2014-12-26|2014-12-30|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib|A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma|Terminated||Phase 4|2|Actual|Bayer||2|||||||||||||||||2018-06-01 03:53:39.395|2018-06-01 03:53:39.395
NCT00352846|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2013-04-30||2013-06-20|2006-07-13|2006-07-17|Estimate|2013-04-30|2013-06-20|Estimate||||2013-06-20|2013-07-02|Estimate|January 2006||2006-01-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss|Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss in Non-Hodgkin's Lymphoma Patients Receiving Chemotherapy|Completed||Phase 3|135|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 03:53:39.478213|2018-06-01 03:53:39.478213
NCT00352833|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2007-10-25|2006-07-14|2006-07-17|Estimate|||||||2007-10-25|2007-10-26|Estimate|July 2006||2006-07-31|June 2007|2007-06-30|September 2007|Actual|2007-09-30|||||Interventional|||Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma|Multicenter, Open-Label and Randomized Phase II Study to Evaluate Safety and Efficacy of the Trifunctional Bispecific Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) in Patients After Curative Resection of a Confirmed Gastric Adenocarcinoma Compared With Surgery Alone|Completed||Phase 2|40|Anticipated|Neovii Biotech|||||f||||||||||||||2018-06-01 03:53:39.652095|2018-06-01 03:53:39.652095
NCT00352820|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2012-07-31|2006-07-13|2006-07-17|Estimate|||||||2012-07-31|2012-08-01|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Experience of Brain Tumor Caregivers|The Experience of Informal Caregivers of Patients With Brain Tumors|Completed|||40|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:53:39.713382|2018-06-01 03:53:39.713382
NCT00352807|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2007-10-16|2006-07-14|2006-07-17|Estimate|||||||2007-10-16|2007-10-17|Estimate|February 2005||2005-02-28|October 2007|2007-10-31|December 2005||2005-12-31|||||Interventional|||Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients|Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients.|Completed||N/A|22||Indiana University|||||||||||||||||||2018-06-01 03:53:39.774099|2018-06-01 03:53:39.774099
NCT00352794|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2018-01-10|2006-07-14|2006-07-17|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2006|Actual|2006-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Lenalidomide for Patients With Myelofibrosis (MF)|Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)|Active, not recruiting||Phase 2|41|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:53:39.829591|2018-06-01 03:53:39.829591
NCT00352781|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2012-02-15||2017-12-04|2006-07-13|2006-07-17|Estimate|2012-03-23|2012-04-17|Estimate||||2017-12-04|2017-12-28|Actual|July 2006||2006-07-31|December 2017|2017-12-31|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|STOP||Stop Smoking Therapy for Ontario Patients|The STOP (Stop Smoking Therapy for Ontario Patients) Study: The Effectiveness of Nicotine Replacement Therapy in Ontario Smokers PHASE II|Completed||N/A|1767|Actual|Centre for Addiction and Mental Health|Many participants could not be reached 6 and 12 months after treatment to complete the follow-up questionnaires. Data pertaining to smoker and provider satisfaction and healthcare utilization were not collected.|1|||f||||f||||||||||2018-06-01 03:53:39.984722|2018-06-01 03:53:39.984722
NCT00352768|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2010-03-03|2006-07-14|2006-07-17|Estimate|||||||2010-03-03|2010-03-04|Estimate|August 2006||2006-08-31|March 2010|2010-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents|SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study|Terminated||Phase 4|20|Actual|Solvay Pharmaceuticals||2||This study was prematurely terminated (26 June 2009) due to slow recruitment|f||||t||||||||||2018-06-01 03:53:40.208403|2018-06-01 03:53:40.208403
NCT00352599|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2016-11-18|2006-07-13|2006-07-14|Estimate|||||||2016-11-18|2016-11-22|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|NF1||Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)|Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)|Completed||Phase 1|44|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 03:53:42.044147|2018-06-01 03:53:42.044147
NCT00352755|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|2016-10-19||2016-10-19|2006-07-14|2006-07-17|Estimate|2016-10-19|2016-12-13|Estimate||||2016-10-19|2016-12-13|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis|A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis|Terminated||Phase 2|18|Actual|Washington University School of Medicine||1||"after interim analysis it was determined that the risks were too great in comparision to the~   results"|f||||||||||||||2018-06-01 03:53:40.318869|2018-06-01 03:53:40.318869
NCT00352742|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2008-10-27|2006-07-13|2006-07-17|Estimate|||||||2008-10-27|2008-10-28|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|December 2008|Anticipated|2008-12-31|September 2008|Anticipated|2008-09-30||Interventional|||A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma|A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib|Terminated||Phase 1/Phase 2|46|Anticipated|Attenuon||1|||f||||||||||||||2018-06-01 03:53:40.635997|2018-06-01 03:53:40.635997
NCT00352729|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2015-07-20|2006-07-13|2006-07-17|Estimate|||||||2015-07-20|2015-07-21|Estimate|November 2006||2006-11-30|July 2015|2015-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|ACell||Evaluation of ACell Hydrated Wound Dressing for Autogenous Skin Donor Sites|Evaluation of ACell Hydrated Wound Dressing for Autogenous Skin Donor Sites|Withdrawn||N/A|0|Actual|United States Army Institute of Surgical Research||1||PI decided to use another product|f||||f||||||||||2018-06-01 03:53:40.729548|2018-06-01 03:53:40.729548
NCT00352716|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2007-09-26|2006-07-14|2006-07-17|Estimate|||||||2007-09-26|2007-09-27|Estimate|June 2006||2006-06-30|September 2007|2007-09-30||||||||Interventional|||Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children|Efficacy of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children|Completed||Phase 3|300||Ipsen|||||f||||||||||||||2018-06-01 03:53:40.806418|2018-06-01 03:53:40.806418
NCT00352703|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2014-10-31|2006-07-14|2006-07-17|Estimate|||||||2014-10-31|2014-11-03|Estimate|April 2006||2006-04-30|October 2014|2014-10-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation|An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation|Completed||Phase 4|145|Actual|Swedish Orphan Biovitrum||1|||f||||f||||||||||2018-06-01 03:53:40.887479|2018-06-01 03:53:40.887479
NCT00352690|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|2015-04-13||2016-10-27|2006-07-14|2006-07-17|Estimate|2015-05-07|2015-05-27|Estimate||||2016-10-27|2016-12-12|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer|A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer|Terminated||Phase 2|10|Actual|Washington University School of Medicine|(3) grade 5 serious adverse events occurred and led to the study closing early for the safety of participants.|2||Safety of patients|f||||t||||||||||2018-06-01 03:53:40.992998|2018-06-01 03:53:40.992998
NCT00352677|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2009-05-29|2006-07-14|2006-07-17|Estimate|||||||2009-05-29|2009-06-01|Estimate|July 2006||2006-07-31|May 2009|2009-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INNO-406 in Adult Patients With Imatinib-Resistant or Intolerant Philadelphia Chromosome-Positive (Ph+) Leukemias|Completed||Phase 1|100|Anticipated|CytRx|||||f||||f||||||||||2018-06-01 03:53:41.418977|2018-06-01 03:53:41.418977
NCT00352664|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|2009-05-21||2016-04-05|2006-07-12|2006-07-14|Estimate|2009-11-23|2009-12-29|Estimate||||2016-04-05|2016-05-09|Estimate|November 2003||2003-11-30|December 2009|2009-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The Effect of Donepezil on Sedation and Other Symptoms|Donepezil for Cancer Patients With Sedation Related to Opioid Treatment: A Double-blind Placebo Controlled Randomized Study|Terminated||Phase 3|27|Actual|M.D. Anderson Cancer Center|Insufficient drug supply and low patient accrual closed study early.|2||Low patient accrual|f||||f||||||||||2018-06-01 03:53:41.493631|2018-06-01 03:53:41.493631
NCT00352651|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2011-04-12|2006-07-12|2006-07-14|Estimate|||||||2011-04-12|2011-04-14|Estimate|June 2006||2006-06-30|March 2011|2011-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo|Placebo-Controlled Study of Pregabalin for the Pain of Acute Herpes Zoster|Terminated||Phase 2|34|Anticipated|University of California, San Francisco||||"This study should be terminated as the study has been closed for years and the investigator has~   since retired. No records are available.~    Thank you, Marlene"|f||||||||||||||2018-06-01 03:53:41.678616|2018-06-01 03:53:41.678616
NCT00352638|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2014-05-15|2006-07-13|2006-07-14|Estimate|||||||2014-05-15|2014-05-16|Estimate|August 2005||2005-08-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|February 2012|Actual|2012-02-29||Interventional|||Educational Intervention With or Without Telephone Counseling in Increasing Colorectal Cancer Screening Compliance in Brothers and Sisters of Patients With Colorectal Cancer|Colorectal Cancer Screening Intervention for Family Members of Colorectal Cancer Patients|Completed||Phase 3|660|Anticipated|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 03:53:41.743635|2018-06-01 03:53:41.743635
NCT00352625|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-08-13|2006-07-12|2006-07-14|Estimate|||||||2008-08-13|2008-08-14|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee|Completed||Phase 3|330||Endo Pharmaceuticals|||||f||||||||||||||2018-06-01 03:53:41.819131|2018-06-01 03:53:41.819131
NCT00352612|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2012-04-10||2013-04-01|2006-07-13|2006-07-14|Estimate|2013-04-01|2013-05-13|Estimate||||2013-04-01|2013-05-13|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections|Comparison of Cephalexin Versus Clindamycin in the Empiric, Outpatient Treatment of Suspected Staphylococcal Cutaneous Infections in the Era of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA)|Completed||Phase 4|200|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:53:41.880295|2018-06-01 03:53:41.880295
NCT00352573|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2018-04-04|2006-07-13|2006-07-14|Estimate|||||||2018-04-04|2018-04-05|Actual|September 1, 2002||2002-09-01|May 12, 2017|2017-05-12||||||||Observational|||Ethical Dilemmas in Clinical Practice: A Survey of European Physicians|Values at the Bedside: A Survey of European Physicians Regarding Ethical Dilemmas in Clinical Practice|Completed|||1357|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:42.166969|2018-06-01 03:53:42.166969
NCT00352560|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12||2010-02-15|2010-02-15|2006-07-13|2006-07-14|Estimate||||2010-02-15|2010-02-17|Estimate|2010-02-15|2010-02-17|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)|Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)|Completed||Phase 3|44|Anticipated|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 03:53:42.216765|2018-06-01 03:53:42.216765
NCT00352547|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2017-10-05|2006-07-13|2006-07-14|Estimate|||||||2017-10-05|2017-10-06|Actual|May 21, 2004||2004-05-21|December 2, 2013|2013-12-02|December 2, 2013||2013-12-02|||||Observational|||Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation|Influence of MDR-1 CYP3A4 and CYP3A5 Genotypes/Haplotypes on Sirolimus Pharmacokinetics and Pharmacodynamics in Patients With Renal Transplantation|Completed|||93|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:42.284277|2018-06-01 03:53:42.284277
NCT00352534|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2016-10-26||2017-04-05|2006-07-13|2006-07-14|Estimate|2017-04-05|2017-05-15|Actual||||2017-04-05|2017-05-15|Actual|October 2006||2006-10-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Interventional||Stage I or II: Patients who have either Very Low Risk Disease, Low Risk Stage I or II no LOH, and Standard Risk, Stage I or II with LOH prior to final Risk Group Assignment. Stage III: Patients who have either Standard Risk, Stage III and High Risk Patients prior to final Risk Group Assignment.|Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor|Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor|Completed||Phase 3|808|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 03:53:42.363218|2018-06-01 03:53:42.363218
NCT00352521|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2014-07-18|2006-07-13|2006-07-14|Estimate|||||||2014-07-18|2014-07-22|Estimate|April 2006||2006-04-30|February 2013|2013-02-28|July 2009|Actual|2009-07-31|December 2006|Actual|2006-12-31||Interventional|||Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma|Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas|Completed||Phase 2|20|Actual|Duke University||1|||f||||t||||||||||2018-06-01 03:53:43.424464|2018-06-01 03:53:43.424464
NCT00352508|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-19|||2006-07-13|2006-07-13|2006-07-14|Estimate|||||||2006-07-13|2006-07-14|Estimate|September 2004||2004-09-30|March 2006|2006-03-31|December 2004||2004-12-31|||||Interventional|||The Dietary Intervention in e-Shopping Trial|The Dietary Intervention in e-Shopping Trial|Completed||N/A|500||The George Institute|||||f||||||||||||||2018-06-01 03:53:43.495695|2018-06-01 03:53:43.495695
NCT00352495|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2014-02-11|2006-07-13|2006-07-14|Estimate|||||||2014-02-11|2014-02-13|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma|A Phase I Study of Vinblastine in Combination With Carboplatin for Children With Newly Diagnosed and Recurrent Low-Grade Gliomas|Completed||Phase 1|26|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 03:53:43.554572|2018-06-01 03:53:43.554572
NCT00352482|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2016-07-28|2006-07-13|2006-07-14|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2004||2004-11-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension|Sildenafil Treatment in Patients With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - a Pilot Cross-over Study|Completed||Phase 2|20|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:53:43.661799|2018-06-01 03:53:43.661799
NCT00352469|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2008-12-05|2006-07-13|2006-07-14|Estimate|||||||2008-12-05|2008-12-08|Estimate|February 2006||2006-02-28|December 2008|2008-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety|12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety|Completed||Phase 4|20|Anticipated|Creighton University||1|||f||||t||||||||||2018-06-01 03:53:43.721438|2018-06-01 03:53:43.721438
NCT00352456|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2017-06-30|2006-07-13|2006-07-14|Estimate|||||||2017-06-30|2017-07-02|Actual|August 27, 2004||2004-08-27|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Psychological Mechanisms of Behavioral Dysregulation|Psychobiological Mechanisms of Behavioral Dysregulation|Completed|||160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:43.801865|2018-06-01 03:53:43.801865
NCT00352443|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2015-03-05|2006-07-13|2006-07-14|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2006||2006-09-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|August 2007|Actual|2007-08-31||Interventional|||S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989) and Everolimus (RAD001) in Patients With Advanced Solid Tumors|Completed||Phase 1|66|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 03:53:43.847755|2018-06-01 03:53:43.847755
NCT00352430|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2018-05-19|2006-07-13|2006-07-14|Estimate|||||||2018-05-19|2018-05-22|Actual|July 9, 2006||2006-07-09|December 7, 2015|2015-12-07|March 10, 2010|Actual|2010-03-10|March 10, 2010|Actual|2010-03-10||Interventional|||Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension|Cardiopulmonary Function Assessment and NO Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension|Completed||Phase 1|31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:43.954188|2018-06-01 03:53:43.954188
NCT00352417|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|2012-06-15||2012-07-19|2006-07-12|2006-07-14|Estimate|2012-06-15|2012-07-20|Estimate||||2012-07-19|2012-07-27|Estimate|July 2006||2006-07-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy|A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-Lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients With Carotid Stenosis Undergoing Elective Carotid Endarterectomy|Completed||Phase 2|50|Actual|Tallikut Pharmaceuticals, Inc.|The small number, less than optimal quality, and diversity of types of plaque samples posed a significant limitation to the interpretation of the plaque data in this study.|2|||f||||t||||||||||2018-06-01 03:53:44.026324|2018-06-01 03:53:44.026324
NCT00342758|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 1, 2001||2001-10-01|October 15, 2007|2007-10-15|October 15, 2007||2007-10-15|||||Observational|||Early Life Factors and Respiratory Health in Mexico City Children|Early Life Factors and Respiratory Health in Mexico City Children|Completed|||6800||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:16.022086|2018-06-01 03:56:16.022086
NCT00352404|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2006-07-13|2006-07-13|2006-07-14|Estimate|||||||2006-07-13|2006-07-14|Estimate|August 2003||2003-08-31|August 2003|2003-08-31|November 2004||2004-11-30|||||Interventional|||Chromoscopic Guided Endomicroscpy to Diagnose Colitis Associated Dysplasia|Diagnosis of Intraepithelial Neoplasia in Patients With Long Standing Ulcerative Colitis With Chromoscopic Guided Endomicroscopy|Completed||Phase 3|114||Johannes Gutenberg University Mainz|||||f||||||||||||||2018-06-01 03:53:44.381788|2018-06-01 03:53:44.381788
NCT00352391|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2016-02-02|2006-07-12|2006-07-14|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2004||2004-08-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients|Vanguard Study Characterizing Occurrence of Recurrent or Second Primary Tumors in Patients With Prior History of Definitively Treated Stage I/II Head and Neck or Non-Small Cell Lung Cancer Who Are Current or Former Smokers|Completed|||54|Actual|M.D. Anderson Cancer Center|||1||f||||t||||||Samples With DNA|"~     Samples of lung tissue, saliva, blood, and scrapings from inside of cheek. Fluid and mucous~     collected during bronchoscopies.~   "|||2018-06-01 03:53:44.43529|2018-06-01 03:53:44.43529
NCT00352378|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2011-06-23|2006-07-13|2006-07-14|Estimate|||||||2011-06-23|2011-06-27|Estimate|June 2002||2002-06-30|September 2007|2007-09-30|January 2006|Actual|2006-01-31|October 2005|Actual|2005-10-31||Interventional|||Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer|A Phase III Randomized Study of Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer|Completed||Phase 3|209|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-06-01 03:53:45.464318|2018-06-01 03:53:45.464318
NCT00352365|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2013-05-15||2014-07-25|2006-07-13|2006-07-14|Estimate|2013-07-02|2013-07-04|Estimate||||2014-07-25|2014-07-31|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional||Eligible patients who began protocol therapy|Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy|Completed||Phase 2|41|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:53:45.580385|2018-06-01 03:53:45.580385
NCT00352352|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2006-07-13|2006-07-13|2006-07-14|Estimate|||||||2006-07-13|2006-07-14|Estimate||||July 1999|1999-07-31||||||||Interventional|||Use of Acupuncture In Children With Autistic Spectrum Disorder|Randomized Control Trial of Using Acupuncture In Children With Autistic Spectrum Disorder|Completed||Phase 3|30||The University of Hong Kong|||||f||||||||||||||2018-06-01 03:53:46.266429|2018-06-01 03:53:46.266429
NCT00352339|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2009-08-03|2006-07-13|2006-07-14|Estimate|||||||2009-08-03|2009-08-06|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||The New Strategy for Pharmacological Treatment in People With Schizophrenia|Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia|Unknown status|Recruiting|Phase 4|90|Anticipated|Inje University||3|||f||||t||||||||||2018-06-01 03:53:46.337257|2018-06-01 03:53:46.337257
NCT00352326|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2017-05-18|2006-07-12|2006-07-14|Estimate|||||||2017-05-18|2017-05-19|Actual|January 2006||2006-01-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Optimizing Assisted Communication Devices for Children With Motor Impairments Using a Model of Information Rate and Channel Capacity|Optimizing Assisted Communication Devices for Children With Motor Impairments Using a Model of Information Rate and Channel Capacity|Completed||N/A|29|Actual|University of Southern California||1|||f|||||f|f||||||||2018-06-01 03:53:46.438124|2018-06-01 03:53:46.438124
NCT00352313|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2012-05-01|2006-07-13|2006-07-14|Estimate|||||||2012-05-01|2012-05-02|Estimate|May 2006||2006-05-31|May 2012|2012-05-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma|A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent Intracranial Malignant Glioma|Completed||Phase 1/Phase 2|82|Anticipated|National Institutes of Health Clinical Center (CC)||2|||||||||||||||||2018-06-01 03:53:46.507909|2018-06-01 03:53:46.507909
NCT00352300|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2014-12-29|2006-07-13|2006-07-14|Estimate|||||||2014-12-29|2014-12-31|Estimate|June 2006||2006-06-30|December 2014|2014-12-31||||July 2010|Actual|2010-07-31||Interventional|||Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer|A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined With Paclitaxel and Pegfilgrastim (Neulasta): A Feasibility Study in Patients With Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer|Completed||Phase 1|43|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 03:53:46.594963|2018-06-01 03:53:46.594963
NCT00352287|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2006-07-12|2006-07-12|2006-07-14|Estimate|||||||2006-07-12|2006-07-14|Estimate|March 2003||2003-03-31|July 2006|2006-07-31|April 2005||2005-04-30|||||Interventional|||Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults|Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT|Completed||Phase 4|60||Stanford University|||||||||||||||||||2018-06-01 03:53:46.691285|2018-06-01 03:53:46.691285
NCT00352261|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2009-03-25|2006-07-12|2006-07-14|Estimate|||||||2009-03-25|2009-03-26|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|April 2007|Actual|2007-04-30|||||Interventional|||An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients|An Open-Label, 2-Way Crossover Study of Steady-State Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients|Completed||Phase 4|80||AstraZeneca|||||f||||||||||||||2018-06-01 03:53:46.749504|2018-06-01 03:53:46.749504
NCT00352248|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2006-07-13|2006-07-13|2006-07-14|Estimate|||||||2006-07-13|2006-07-14|Estimate||||July 1999|1999-07-31||||||||Interventional|||Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder|Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder|Completed||Phase 3|50||The University of Hong Kong|||||f||||||||||||||2018-06-01 03:53:46.834406|2018-06-01 03:53:46.834406
NCT00352235|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2006-07-13|2006-07-13|2006-07-14|Estimate|||||||2006-07-13|2006-07-14|Estimate|August 2003||2003-08-31|July 2006|2006-07-31|May 2005||2005-05-31|||||Interventional|||Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection|Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection|Completed||Phase 1/Phase 2|36||Foundation for Liver Research|||||f||||||||||||||2018-06-01 03:53:46.908676|2018-06-01 03:53:46.908676
NCT00352222|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2008-09-25|2006-07-12|2006-07-14|Estimate|||||||2008-09-25|2008-09-29|Estimate|January 2004||2004-01-31|September 2008|2008-09-30|February 2007|Actual|2007-02-28|July 2005|Actual|2005-07-31||Interventional|MELODIE||Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries|A Prospective, Multicenter, Single Arm Study to Obtain Additional Data on the Safety and Efficacy of the Express Vascular LD Implantation in the Treatment of Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries|Completed||Phase 3|150||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 03:53:47.056641|2018-06-01 03:53:47.056641
NCT00352209|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2017-06-30|2006-07-13|2006-07-14|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2, 2006||2006-05-02|May 16, 2007|2007-05-16|May 16, 2007||2007-05-16|||||Observational|||Cardiomyopathy Following Stem Cell Transplantation|Retrospective Review of Cardiomyopathy Patient Cases Post Allogeneic Hematopoietic Stem Cell Transplantation|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:47.138794|2018-06-01 03:53:47.138794
NCT00352196|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2015-01-13|2006-07-12|2006-07-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2001||2001-11-30|January 2015|2015-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study|A Biological Basis of Therapy for Negative Symptom Spectrum Disorders: Risperdal Effect on Frontal Metabolism in Asperger's Disorder|Completed||Phase 4|23|Actual|Augusta University||2|||f||||f||||||||||2018-06-01 03:53:47.210139|2018-06-01 03:53:47.210139
NCT00352183|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2009-07-07|2006-07-13|2006-07-14|Estimate|||||||2009-07-07|2009-07-08|Estimate|January 2006||2006-01-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy|A Multicenter, Double-Blind, Randomized Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Simvastatin Alone.|Completed||Phase 3|450|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:53:47.316798|2018-06-01 03:53:47.316798
NCT00352170|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2008-08-08|2006-07-12|2006-07-14|Estimate|||||||2008-08-08|2008-08-11|Estimate|May 2000||2000-05-31|August 2008|2008-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Calcium and Vitamin D Malnutrition in Elderly Women|Calcium and Vitamin D Malnutrition in Elderly Women|Completed||Phase 3|1180|Actual|Creighton University||3|||f||||t||||||||||2018-06-01 03:53:47.476511|2018-06-01 03:53:47.476511
NCT00352157|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2009-07-20|2006-07-13|2006-07-14|Estimate|||||||2009-07-20|2009-07-21|Estimate|July 2006||2006-07-31|July 2009|2009-07-31|March 2007|Actual|2007-03-31|||||Interventional|||Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women|Effect of Revival Soy on Weight Loss and Appearance of Skin, Hair, and Nails in High BMI Premenopausal Women|Completed||Phase 4|40||Physicians Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 03:53:47.557574|2018-06-01 03:53:47.557574
NCT00352144|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2012-02-21|2006-07-12|2006-07-14|Estimate|||||||2012-02-21|2012-02-22|Estimate|October 2003||2003-10-31|February 2012|2012-02-29|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia|A Six-Month, Chronic Efficacy and Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia: A Randomized Double-Blind, Placebo-Controlled Study|Completed||Phase 3|830|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 03:53:47.648224|2018-06-01 03:53:47.648224
NCT00352131|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2010-03-16|2006-07-13|2006-07-14|Estimate|||||||2010-03-16|2010-03-17|Estimate|February 2005||2005-02-28|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors|A Phase I Study to Assess the Safety and Pharmacokinetics of huC242-DM4 Administered as a Single Intravenous Infusion Once Every Three Weeks to Subjects With Solid Tumors|Completed||Phase 1|50|Anticipated|ImmunoGen, Inc.|||||f||||||||||||||2018-06-01 03:53:47.795958|2018-06-01 03:53:47.795958
NCT00352118|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2009-06-02||2017-12-03|2006-07-13|2006-07-14|Estimate|2009-06-02|2009-07-21|Estimate||||2017-12-03|2017-12-28|Actual|March 2006||2006-03-31|December 2017|2017-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer|Phase II Pilot Study of TPF (Docetaxel, Cisplatin, and 5-FU) Induction Chemotherapy Followed by Concurrent Cisplatin and Reduced Dose Radiation in Locally Advanced Head and Neck Cancer|Terminated||Phase 2|4|Actual|Masonic Cancer Center, University of Minnesota|All 4 patients received high dose radiation (66-70 Gy). The radiation oncologist on this study deemed low dose radiation treatment was not appropriate for these patients. Therefore, the study participants are not evaluable.|1||Low dose radiation treatment was not appropriate for these patients.|f||||f||||||||||2018-06-01 03:53:47.882189|2018-06-01 03:53:47.882189
NCT00352105|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2011-11-17||2012-11-01|2006-07-13|2006-07-14|Estimate|2012-01-31|2012-03-01|Estimate||||2012-11-01|2012-11-05|Estimate|April 2006||2006-04-30|November 2012|2012-11-30|May 2010|Actual|2010-05-31|September 2008|Actual|2008-09-30||Interventional|||Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer|A Phase I/II Trial of Concurrent Chemotherapy and ZD1839 (IRESSA) With Hyperfractionated Radiation Therapy, Followed by Maintenance ZD1839 (IRESSA) for Patients With Locally Advanced Squamous Cell Head and Neck Cancer|Completed||Phase 1/Phase 2|60|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:53:48.137969|2018-06-01 03:53:48.137969
NCT00352092|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2014-11-12|2006-07-13|2006-07-14|Estimate|||||||2014-11-12|2014-11-13|Estimate|June 2002||2002-06-30|November 2014|2014-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pilot Study for HLA Identical Living Donor Renal Transplant Recipients|A Pilot Study of Corticosteroid-Free, Calcineurin-Sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipient|Completed||Phase 4|20|Actual|University of Cincinnati|||||f||||f||||||||||2018-06-01 03:53:48.568571|2018-06-01 03:53:48.568571
NCT00352079|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2012-12-17|2006-07-13|2006-07-14|Estimate|||||||2012-12-17|2012-12-19|Estimate|April 2006||2006-04-30|December 2012|2012-12-31|January 2012|Actual|2012-01-31|||||Interventional|||BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer|A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder|Terminated||Phase 3|41|Actual|Canadian Cancer Trials Group||2||terminated due to poor accrual|f||||t||||||||||2018-06-01 03:53:48.647377|2018-06-01 03:53:48.647377
NCT00352066|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2011-06-21|2006-07-12|2006-07-14|Estimate|||||||2011-06-21|2011-06-23|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together|A Phase I, Open Label, Controlled, Intra-subject Comparison Study to Investigate the Effect of Co-administration Upon the Pharmacokinetics of Tipranavir (Ritonavir Boosted) and Apricitabine.|Completed||Phase 1|18|Actual|Avexa|||||f||||f||||||||||2018-06-01 03:53:48.758426|2018-06-01 03:53:48.758426
NCT00351871|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2009-02-03|2006-07-12|2006-07-13|Estimate|||||||2009-02-03|2009-02-04|Estimate|April 2002||2002-04-30|February 2009|2009-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy|Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy|Completed||Phase 4|400|Actual|Louisiana State University Health Sciences Center in New Orleans|||||f||||||||||||||2018-06-01 03:53:54.163666|2018-06-01 03:53:54.163666
NCT00352053|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2010-03-05||2015-06-15|2006-07-13|2006-07-14|Estimate|2010-07-23|2010-08-19|Estimate||||2015-06-15|2015-07-14|Estimate|June 2006||2006-06-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|September 2008|Actual|2008-09-30||Interventional||Safety Analysis Set: participants were randomized and received at least 1 dose of study medication.|Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents|Completed||Phase 3|87|Actual|Gilead Sciences|Participants left the study for a number of reasons (eg, turned 18 years old, switched to a different HIV treatment regimen), which led to small numbers of participants analyzed at later time points, and the study was concluded earlier than planned.|2|||f||||t||||||||||2018-06-01 03:53:48.895029|2018-06-01 03:53:48.895029
NCT00352027|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|2016-04-27||2018-01-30|2006-07-13|2006-07-14|Estimate|2016-09-19|2016-10-07|Estimate||||2018-01-30|2018-01-31|Actual|July 20, 2006|Actual|2006-07-20|October 2017|2017-10-31|November 2022|Anticipated|2022-11-30|May 2015|Actual|2015-05-31||Interventional|||Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma|Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma|Active, not recruiting||Phase 2|81|Actual|St. Jude Children's Research Hospital||1|||f||||t|t|f||||||||2018-06-01 03:53:50.490372|2018-06-01 03:53:50.490372
NCT00352014|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2018-04-10|2006-07-13|2006-07-14|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2006||2006-01-31|April 2018|2018-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Evaluation and Comparison of Several Point-of-care Platelet Function Tests in Predicting Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI.|Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)|Completed|||1000|Anticipated|R&D Cardiologie|||||f||||||||||||||2018-06-01 03:53:52.801665|2018-06-01 03:53:52.801665
NCT00352001|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2013-02-13|2006-07-13|2006-07-14|Estimate|||||||2013-02-13|2013-02-15|Estimate|May 2006||2006-05-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes|A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS)|Completed||Phase 1/Phase 2|36|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:53:52.859457|2018-06-01 03:53:52.859457
NCT00351988|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2017-08-25|2006-07-12|2006-07-14|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2006|Actual|2006-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Effects of Cancer Symptoms on Caregivers|Effects of Cancer Symptoms on Minority Caregivers|Recruiting|||250|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-06-01 03:53:52.938997|2018-06-01 03:53:52.938997
NCT00351975|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2014-12-22|2006-07-13|2006-07-14|Estimate|||||||2014-12-22|2014-12-23|Estimate|June 2006||2006-06-30|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases|A Phase I Study of PXD101 in Combination With Azacitidine (5-Aza) for Advanced Hematologic Malignancies|Completed||Phase 1|56|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:53:53.128444|2018-06-01 03:53:53.128444
NCT00351962|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2017-09-20|2006-07-12|2006-07-13|Estimate|||||||2017-09-20|2017-09-21|Actual|September 2006|Actual|2006-09-30|July 2013|2013-07-31|July 2, 2014|Actual|2014-07-02|July 2014|Actual|2014-07-31||Interventional|||Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours|Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours|Completed||N/A|58|Actual|AHS Cancer Control Alberta||2|||f||||||||||||||2018-06-01 03:53:53.228712|2018-06-01 03:53:53.228712
NCT00351949|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2010-01-06|2006-07-12|2006-07-13|Estimate|||||||2010-01-06|2010-01-07|Estimate|September 2005||2005-09-30|January 2010|2010-01-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)|IMP321 Phase 1 Study in Advanced or Metastatic Renal Cell Carcinoma Patients (P003)|Completed||Phase 1|24|Actual|Immutep S.A.|||||f||||||||||||||2018-06-01 03:53:53.291026|2018-06-01 03:53:53.291026
NCT00351936|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|2012-12-20||2013-01-30|2006-07-12|2006-07-13|Estimate|2012-12-20|2013-01-28|Estimate||||2013-01-30|2013-02-04|Estimate|December 2005||2005-12-31|January 2013|2013-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Placebo-Controlled, Cross-Over Trial of Aripiprazole|A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia|Completed||Phase 4|16|Actual|North Suffolk Mental Health Association|The small sample size and the short duration of active treatment and washout period may have prevented detection of other metabolic benefits, including possible reductions in fasting insulin and insulin resistance (measured by HOMA-IR).|2|||f||||f||||||||||2018-06-01 03:53:53.373502|2018-06-01 03:53:53.373502
NCT00351923|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2008-10-09|2006-07-12|2006-07-13|Estimate|||||||2008-10-09|2008-10-13|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes|Open, Multicenter, Randomised, Controlled Phase IIIb Study Evaluating the Immunogenicity and Safety of Subcutaneous Versus Alternative Administration Route of Combined MeMuRu-OKA Vaccine to Healthy Children Aged 11 to 21 Months.|Completed||Phase 3|330||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:53:53.69384|2018-06-01 03:53:53.69384
NCT00351910|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2011-01-25|2006-07-12|2006-07-13|Estimate|||||||2011-01-25|2011-01-26|Estimate|May 2006||2006-05-31|January 2011|2011-01-31|April 2007|Actual|2007-04-30|||||Interventional|ONYX||Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment|Completed||Phase 3|494|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:53:53.801284|2018-06-01 03:53:53.801284
NCT00351897|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2008-02-19|2006-07-12|2006-07-13|Estimate|||||||2008-02-19|2008-02-20|Estimate|April 2006||2006-04-30|July 2007|2007-07-31|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||The Efficacy of Pulsed Dye Laser in Dermatophytosis|The Efficacy of Pulsed Dye Laser in Dermatophytosis|Completed||Phase 1|10|Actual|Shahid Beheshti University of Medical Sciences|||||f||||||||||||||2018-06-01 03:53:54.003402|2018-06-01 03:53:54.003402
NCT00351884|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2016-11-16|2006-07-11|2006-07-13|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2006||2006-05-31|November 2016|2016-11-30||||November 2007|Actual|2007-11-30||Interventional|||Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes|A Multicenter, Double-blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 MG QD to Placebo as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy|Completed||Phase 3|370|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:53:54.0676|2018-06-01 03:53:54.0676
NCT00351858|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2015-04-30|2006-07-12|2006-07-13|Estimate|||||||2015-04-30|2015-05-01|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|February 2009|Actual|2009-02-28|||||Interventional|IV REXBC 02||Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer|Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer|Terminated||Phase 2|40|Anticipated|Neovii Biotech||||company focus on other projects|f||||||||||||||2018-06-01 03:53:54.31566|2018-06-01 03:53:54.31566
NCT00351845|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2009-04-21|2006-07-11|2006-07-13|Estimate|||||||2009-04-21|2009-04-22|Estimate|April 2004||2004-04-30|April 2009|2009-04-30|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Clinical Study to Test the Effects of a Low-Carbohydrate Diet on Body Weight|A Clinical Study to Evaluate the Effect of a Modified Carbohydrate Diet on Body Weight in Overweight or Obese Men and Women|Completed||N/A|86|Actual|Provident Clinical Research|||||f||||f||||||||||2018-06-01 03:53:54.47316|2018-06-01 03:53:54.47316
NCT00351832|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2007-05-07|2006-07-11|2006-07-13|Estimate|||||||2007-05-07|2007-05-09|Estimate|June 2006||2006-06-30|May 2007|2007-05-31||||||||Interventional|||A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin (50mg qd, 50mg Bid, 100mg qd) to Placebo in Patients With Type 2 Diabetes|Completed||Phase 3|236||Novartis|||||f||||||||||||||2018-06-01 03:53:54.522828|2018-06-01 03:53:54.522828
NCT00351819|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|2017-03-24||2017-05-26|2006-07-12|2006-07-13|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|April 2006||2006-04-30|May 2017|2017-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TAP||Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception|Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome|Completed||Phase 2|84|Actual|Boston University||2|||f||||f|t|f||||||No||2018-06-01 03:53:54.625179|2018-06-01 03:53:54.625179
NCT00351806|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2013-08-05|2006-07-12|2006-07-13|Estimate|||||||2013-08-05|2013-08-07|Estimate|July 2005||2005-07-31|August 2013|2013-08-31|November 2006||2006-11-30|||||Interventional|||AISTCM-Outcome Measurement of Acute Ischemic Stroke With Traditional Chinese Medicine|AISTCM-The Pathological Pattern Differentiation and Outcome Measurement of Acute Ischemic Stroke Treated With Traditional Chinese Medicine|Completed||Phase 4|500||Guangzhou University of Traditional Chinese Medicine||2|||f||||||||||||||2018-06-01 03:53:55.847835|2018-06-01 03:53:55.847835
NCT00351793|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2017-01-30|2006-07-12|2006-07-13|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2003||2003-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Clinical Trial Follow-up Study of the Genesis II Posterior Stabilized Total Knee Replacement|A Clinical Trial Follow-up Study of the Genesis II Posterior Stabilized Total Knee Replacement|Active, not recruiting|||186|Actual|Nova Scotia Health Authority|||2||f||||f||||||||||2018-06-01 03:53:55.961715|2018-06-01 03:53:55.961715
NCT00351780|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2011-07-15|2006-07-12|2006-07-13|Estimate|||||||2011-07-15|2011-07-18|Estimate|June 2004||2004-06-30|July 2011|2011-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Fractional Flow Reserve-guided Provisional Side Branch Intervention|Physiologic Evaluation of the Provisional Side Branch Intervention Strategy for Bifurcation Lesions Using Fractional Flow Reserve|Completed||Phase 4|100|Anticipated|Seoul National University Hospital|||||f||||||||||||||2018-06-01 03:53:56.032404|2018-06-01 03:53:56.032404
NCT00351767|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11||2013-01-16|2013-01-16|2006-07-11|2006-07-13|Estimate||||2013-01-16|2013-01-25|Estimate|2013-01-16|2013-01-25|Estimate|January 2006||2006-01-31|January 2013|2013-01-31||||January 2008|Actual|2008-01-31||Interventional|||A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Diabetic Foot Ulcers|Completed||Phase 2|170|Actual|Genentech, Inc.||4|||f||||||||||||||2018-06-01 03:53:56.090455|2018-06-01 03:53:56.090455
NCT00351754|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-01-03|2006-07-11|2006-07-13|Estimate|||||||2008-01-03|2008-01-07|Estimate|July 2006||2006-07-31|January 2008|2008-01-31|November 2006|Actual|2006-11-30|||||Interventional|||Detection of Pulmonary Embolism With CECT|Detection of Pulmonary Embolism Comparing Isovue-370 and Visipaque 320 Using 64-Slice Multi-Detector Computed Tomographic Angiography|Completed||Phase 4|120||Bracco Diagnostics, Inc|||||f||||f||||||||||2018-06-01 03:53:56.24556|2018-06-01 03:53:56.24556
NCT00351741|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|2010-07-16||2015-09-08|2006-07-11|2006-07-13|Estimate|2010-11-30|2010-12-28|Estimate||||2015-09-08|2015-09-21|Estimate|July 2006||2006-07-31|September 2015|2015-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study-|BEST (Burn Center Evaluation of Standard Therapies) Ventilator Mode Study: A Prospective Randomized Controlled Trial|Terminated||N/A|62|Actual|United States Army Institute of Surgical Research|After 3 yrs of enrollment, interim analysis revealed a significant number of subjects in the Conventional arm required rescue, which served as the trigger to close the study to further enrollment.|2|||f||||f||||||||||2018-06-01 03:53:56.335086|2018-06-01 03:53:56.335086
NCT00351728|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2016-07-05|2006-07-12|2006-07-13|Estimate|||||||2016-07-05|2016-07-07|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone||Completed|||174|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 03:53:56.716961|2018-06-01 03:53:56.716961
NCT00351715|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2013-01-24|2006-07-12|2006-07-13|Estimate|||||||2013-01-24|2013-01-28|Estimate|July 2008||2008-07-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients|Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients: a Phase II Multicenter, Open Label, Feasibility Study|Terminated||Phase 2|60|Anticipated|AHS Cancer Control Alberta||||Study stopped due to low accrual|f||||||||||||||2018-06-01 03:53:56.821737|2018-06-01 03:53:56.821737
NCT00351702|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2016-06-06|2006-07-12|2006-07-13|Estimate|||||||2016-06-06|2016-06-07|Estimate|February 2001||2001-02-28|June 2016|2016-06-30|June 2011|Actual|2011-06-30|September 2008|Actual|2008-09-30||Interventional|||Preventive Therapy for Tuberculosis in HIV Infected Persons|Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons|Completed||Phase 3|650|Actual|Tuberculosis Research Centre, India||1|||f||||f||||||||||2018-06-01 03:53:56.966431|2018-06-01 03:53:56.966431
NCT00351689|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2012-10-02|2006-07-12|2006-07-13|Estimate|||||||2012-10-02|2012-10-03|Estimate|January 2004||2004-01-31|October 2012|2012-10-31|July 2004||2004-07-31|||||Interventional|||Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation|Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation|Completed||Phase 1|50||L'Oreal|||||f||||t||||||||||2018-06-01 03:53:57.152483|2018-06-01 03:53:57.152483
NCT00351676|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2007-12-07|2006-07-12|2006-07-13|Estimate|||||||2007-12-07|2007-12-11|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|July 2007|Actual|2007-07-31|||||Interventional|||Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment|Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE)|Completed||Phase 4|452|Actual|University of Alberta|||||f||||f||||||||||2018-06-01 03:53:57.269685|2018-06-01 03:53:57.269685
NCT00351663|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2016-04-19|2006-07-12|2006-07-13|Estimate|||||||2016-04-19|2016-04-20|Estimate|February 2007||2007-02-28|April 2016|2016-04-30|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Interventional|||The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients|Prospective Randomised Study of the Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients|Completed||Phase 4|39|Actual|Shaare Zedek Medical Center||3|||f||||f||||||||||2018-06-01 03:53:57.366001|2018-06-01 03:53:57.366001
NCT00351650|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2017-06-30|2006-07-12|2006-07-13|Estimate|||||||2017-06-30|2017-07-02|Actual|July 9, 2006||2006-07-09|February 6, 2008|2008-02-06|February 6, 2008||2008-02-06|||||Observational|||Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan|Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:53:57.456406|2018-06-01 03:53:57.456406
NCT00351637|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2012-01-18|2006-07-12|2006-07-13|Estimate|||||||2012-01-18|2012-01-19|Estimate|December 2006||2006-12-31|January 2012|2012-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients|Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients: a Phase II Multicenter, Open Label, Feasibility Study|Terminated||Phase 2|60|Anticipated|AHS Cancer Control Alberta||||Study suspended due to low accrual|f||||||||||||||2018-06-01 03:53:57.545157|2018-06-01 03:53:57.545157
NCT00351624|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2014-05-16|2006-07-11|2006-07-13|Estimate|||||||2014-05-16|2014-05-20|Estimate|May 2006||2006-05-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Effects of Docosahexaenoic Acid (DHA) on Cognitive Function in Children 4 Years of Age|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in Preschool Children|Completed||Phase 3|216|Actual|DSM Nutritional Products, Inc.||2|||f||||||||||||||2018-06-01 03:53:57.664352|2018-06-01 03:53:57.664352
NCT00351611|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2018-05-16|2006-07-11|2006-07-13|Estimate|||||||2018-05-16|2018-05-17|Actual|July 26, 2006|Actual|2006-07-26|May 2018|2018-05-31|November 11, 2019|Anticipated|2019-11-11|November 11, 2019|Anticipated|2019-11-11||Interventional|||Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo|Prospective Randomized 12-week Controlled Study Of Visual Field Change In Subjects With Partial Seizures Receiving Pregabalin Or Placebo|Recruiting||Phase 4|284|Anticipated|Pfizer||2|||f||||f|t|f||||||||2018-06-01 03:53:57.84532|2018-06-01 03:53:57.84532
NCT00351598|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2014-07-31|2006-07-11|2006-07-13|Estimate|||||||2014-07-31|2014-08-04|Estimate|September 1999||1999-09-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|February 2009|Actual|2009-02-28||Observational|||Lung Tumour Volume Database|Tumour Volume as an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer - A Protocol for a Prospective Database.|Completed|||531|Actual|Trans-Tasman Radiation Oncology Group (TROG)|||1||f||||f||||||||||2018-06-01 03:53:58.194781|2018-06-01 03:53:58.194781
NCT00351585|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2012-05-04|2006-07-11|2006-07-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|July 2004||2004-07-31|May 2012|2012-05-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes|A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Effects of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|39|Actual|Novartis|||||f||||||||||||||2018-06-01 03:53:58.275913|2018-06-01 03:53:58.275913
NCT00351572|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2011-04-15|2006-07-11|2006-07-13|Estimate|||||||2011-04-15|2011-04-18|Estimate|July 2006||2006-07-31|April 2011|2011-04-30||||||||Observational|||Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients|Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients|Completed|||30|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 03:53:58.322548|2018-06-01 03:53:58.322548
NCT00351559|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2009-11-18|2006-07-11|2006-07-13|Estimate|||||||2009-11-18|2009-11-20|Estimate|January 2005||2005-01-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|||||Interventional|||IMAGE: A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection|Invasive Monitoring Attenuation Through Gene Expression (IMAGE) Trial|Completed||N/A|629|Actual|XDx|||||f||||||||||||||2018-06-01 03:53:58.378158|2018-06-01 03:53:58.378158
NCT00351546|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2012-05-04|2006-07-11|2006-07-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|December 2005|Actual|2005-12-31|November 2005|Actual|2005-11-30||Interventional|||A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes|A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes|Completed||Phase 3|12|Actual|Novartis|||||f||||||||||||||2018-06-01 03:53:58.464854|2018-06-01 03:53:58.464854
NCT00351533|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|2011-02-16||2011-08-26|2006-07-11|2006-07-13|Estimate|2011-08-26|2011-10-03|Estimate||||2011-08-26|2011-10-03|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)|A Randomized, Double-blind Study of the Effect of Fish Oil (Eicosapentaenoic Acid and Docosahexanoic Acid) on Lung and Systemic Inflammation in Patients With Acute Lung Injury (ALI)|Completed||Phase 2|90|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:53:58.537902|2018-06-01 03:53:58.537902
NCT00351520|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2011-09-19|2006-07-12|2006-07-13|Estimate|||||||2011-09-19|2011-09-20|Estimate|May 2006||2006-05-31|September 2011|2011-09-30|June 2007|Actual|2007-06-30|||||Interventional|||Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica|Phase 3, Clinical Trials of Drug Against Cutaneous Leishmaniasis|Completed||Phase 3|148|Actual|Tehran University of Medical Sciences|||||f||||||||||||||2018-06-01 03:54:00.751736|2018-06-01 03:54:00.751736
NCT00351507|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2012-05-04|2006-07-11|2006-07-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2005||2005-05-31|May 2012|2012-05-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes|A Double-blind, Crossover, Placebo-Controlled, Multiple-dose Study to Evaluate the Effects of Vildagliptin on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes|Completed||Phase 3|10|Actual|Novartis|||||f||||||||||||||2018-06-01 03:54:00.816559|2018-06-01 03:54:00.816559
NCT00351494|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2007-11-21|2006-07-12|2006-07-13|Estimate|||||||2007-11-21|2007-11-22|Estimate|July 2006||2006-07-31|November 2007|2007-11-30|June 2009|Anticipated|2009-06-30|||||Observational|||Myoma Microvascularization Analysis Using Sonovue Before and After Uterine Artery Embolization|Myoma Microvascularization Analysis Using Sonovue Before and After Uterine Artery Embolization|Unknown status|Recruiting||40|Anticipated|University Hospital, Tours|||||f||||f||||||||||2018-06-01 03:54:00.879212|2018-06-01 03:54:00.879212
NCT00351481|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2008-05-28|2006-07-12|2006-07-13|Estimate|||||||2008-05-28|2008-05-29|Estimate|July 2006||2006-07-31|April 2007|2007-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Failure of Implantation After Recurrent Embryo Transfers|Recurrent Embryo Implantation Failure in Women Undergoing IVF/ ICSI; an Investigation of the Intra-Uterine Environment During the Window of Implantation|Completed|||80|Anticipated|UMC Utrecht|||||f||||||||||||||2018-06-01 03:54:00.953935|2018-06-01 03:54:00.953935
NCT00351468|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2016-07-06||2017-03-05|2006-07-10|2006-07-12|Estimate|2017-03-05|2017-04-17|Actual||||2017-03-05|2017-04-17|Actual|June 2006||2006-06-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|EXTEND||EXTEND (Eltrombopag Extended Dosing Study)|EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.|Completed||Phase 3|302|Actual|Novartis||1|||f||||f||||||||||2018-06-01 03:54:01.178355|2018-06-01 03:54:01.178355
NCT00351455|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2010-12-02|2006-07-11|2006-07-12|Estimate|||||||2010-12-02|2010-12-06|Estimate|May 2006||2006-05-31|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Watchful Waiting of Incisional Hernias|Watchful Waiting of Incisional Hernias: A Prospective Trial|Completed||N/A|50|Anticipated|Baylor College of Medicine|||||f||||f||||||||||2018-06-01 03:54:02.316874|2018-06-01 03:54:02.316874
NCT00351442|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2014-04-08|2006-07-11|2006-07-12|Estimate|||||||2014-04-08|2014-04-09|Estimate|February 2007||2007-02-28|April 2014|2014-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Examining Factors That May Influence Resistance to HIV-1 Infection|Prospective Study of the Determinants of Host Resistance to HIV-1 Infection|Completed|||522|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||||||||||||2018-06-01 03:54:02.388161|2018-06-01 03:54:02.388161
NCT00351429|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2009-02-10|2006-07-11|2006-07-12|Estimate|||||||2009-02-10|2009-02-11|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Study of PGA Suture in Ophthalmology|Evaluating the Safety and Efficacy of Polyglycolic Acid Suture in Ophthalmic Surgical Procedures|Completed||Phase 4|50|Actual|Aurolab||1|||f||||f||||||||||2018-06-01 03:54:02.464185|2018-06-01 03:54:02.464185
NCT00351416|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2017-03-16||2017-06-28|2006-07-10|2006-07-12|Estimate|2017-03-16|2017-04-27|Actual||||2017-06-28|2017-07-27|Actual|January 21, 2004|Actual|2004-01-21|June 2017|2017-06-30||||June 29, 2009|Actual|2009-06-29||Interventional|||Letrozole Treatment in Normal and GnRH Deficient Women|Letrozole Treatment in Normal and GnRH Deficient Women|Active, not recruiting||Phase 1/Phase 2|15|Actual|Massachusetts General Hospital||2|||f||||t|t|f||||||No|Once published, de-identified individual level data will be shared upon request to the PI.|2018-06-01 03:54:02.572276|2018-06-01 03:54:02.572276
NCT00351403|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2010-02-05|2006-07-11|2006-07-12|Estimate|||||||2010-02-05|2010-02-08|Estimate|July 2006||2006-07-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection|Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA|Completed||Phase 4|390|Anticipated|FGK Clinical Research GmbH||2|||f||||f||||||||||2018-06-01 03:54:02.922451|2018-06-01 03:54:02.922451
NCT00351390|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2018-03-20|2006-07-10|2006-07-12|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2005||2005-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2009|Actual|2009-06-30||Interventional|PROTECT||Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.|The Use of Pro-Brain Natriuretic Peptide Targeted Therapy to Tailor Medical Management of Patients With Congestive Heart Failure Followed in an Outpatient Setting: the ProBNP Outpatient Tailored CHF Therapy (PROTECT) Study|Active, not recruiting||N/A|300|Anticipated|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 03:54:03.091333|2018-06-01 03:54:03.091333
NCT00351377|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2010-12-14||2011-04-19|2006-07-10|2006-07-12|Estimate|2010-12-14|2011-01-12|Estimate||||2011-04-19|2011-04-21|Estimate|June 2006||2006-06-30|April 2011|2011-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate|Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate (MPA)|Completed||Phase 3|111|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:54:03.186516|2018-06-01 03:54:03.186516
NCT00351364|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2014-12-01|2006-07-10|2006-07-12|Estimate|||||||2014-12-01|2014-12-03|Estimate|July 2006||2006-07-31|December 2014|2014-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Does Montelukast Have an Affect on the Function of the Artery in Patients With Heart Disease|The Effect of Leukotriene Receptor Blockade on Endothelial Function in Acute Coronary Syndrome Patients|Terminated||Phase 4|40|Actual|University of Calgary||2||Diffic;ulty recruiting|f||||t||||||||||2018-06-01 03:54:03.441729|2018-06-01 03:54:03.441729
NCT00351351|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|2012-12-04||2017-03-01|2006-07-11|2006-07-12|Estimate|2013-01-17|2013-02-20|Estimate||||2017-03-01|2017-03-30|Actual|July 2006||2006-07-31|February 2013|2013-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy|Randomized Control Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy|Completed||N/A|70|Actual|Indiana Kidney Stone Institute|Multiple surgeons were involved,thus subtle differences in PCNL technique existed between sites. Some surgeons may have defined the stone removal time differently.|2|||f||||f||||||||||2018-06-01 03:54:03.53029|2018-06-01 03:54:03.53029
NCT00351338|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2007-04-10|2006-07-11|2006-07-12|Estimate|||||||2007-04-10|2007-04-11|Estimate|July 2006||2006-07-31|July 2006|2006-07-31||||||||Observational|||Nutritional Deficiencies in the Bariatric Patients|Preoperative Nutritional Deficiencies in the Bariatric Surgery Patients|Unknown status|Recruiting||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:54:03.939674|2018-06-01 03:54:03.939674
NCT00351325|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2009-09-03|2006-07-11|2006-07-12|Estimate|||||||2009-09-03|2009-09-04|Estimate|September 2007||2007-09-30|September 2009|2009-09-30|March 2009|Anticipated|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies|A Phase I, Multiple Ascending Dose Study of BMS-663513, an Agonistic Anti-CD137 Monoclonal Antibody, Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies|Terminated||Phase 1|45|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:54:03.998834|2018-06-01 03:54:03.998834
NCT00351312|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2006-07-11|2006-07-11|2006-07-12|Estimate|||||||2006-07-11|2006-07-12|Estimate|June 2006||2006-06-30|July 2006|2006-07-31|June 2006||2006-06-30|||||Interventional|||Creation of a Pressure Reducing Areas in Socks|Evaluation of Foot Pressure in Volunteers Wearing Socks Weaved With Pressure Reducing Soles|Unknown status|Active, not recruiting|N/A|4||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:54:04.064066|2018-06-01 03:54:04.064066
NCT00351299|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2017-03-29||2017-05-09|2006-07-10|2006-07-12|Estimate|2017-03-29|2017-05-09|Actual||||2017-05-09|2017-06-09|Actual|January 2006||2006-01-31|May 2017|2017-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium|Study of Dexmedetomidine as an Effective Sedative to Treat Acute ICU Delirium|Completed||Phase 2|53|Actual|Brigham and Women's Hospital||2|||f||||t||||||||Undecided||2018-06-01 03:54:04.14262|2018-06-01 03:54:04.14262
NCT00351286|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2006-10-17|2006-07-10|2006-07-12|Estimate|||||||2006-10-17|2006-10-18|Estimate|March 2006||2006-03-31|July 2006|2006-07-31||||||||Interventional|||Efficacy Study of Oral L-Citrulline in Patients Taking Simvastatin With Peripheral Arterial Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral L-Citrulline Compared to Placebo in Patients Taking Background Simvastatin 40 mg qD and With Peripheral Arterial Disease Including Intermittent Claudication|Unknown status|Active, not recruiting|Phase 2|160||Angiogenix|||||f||||||||||||||2018-06-01 03:54:04.472786|2018-06-01 03:54:04.472786
NCT00351273|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2009-08-05||2016-08-10|2006-07-10|2006-07-12|Estimate|2016-06-27|2016-08-10|Estimate||||2016-08-10|2016-09-20|Estimate|May 2006||2006-05-31|June 2016|2016-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria|Phase 3 Trial to Assess the Efficacy of Long-term (6 Months) Combination Antibiotics as a Treatment for Chlamydia-induced Reactive Arthritis|Completed||Phase 3|42|Actual|University of South Florida||3|||f||||f||||||||Yes||2018-06-01 03:54:04.585365|2018-06-01 03:54:04.585365
NCT00351260|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2008-04-15|2006-07-11|2006-07-12|Estimate|||||||2008-04-15|2008-04-16|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|BBC ONE||BBC ONE - British Bifurcation Coronary Study|British Bifurcation Coronary Study - Old, New and Evolving Strategies.|Completed||Phase 3|500|Actual|Royal Sussex County Hospital|||||f||||t||||||||||2018-06-01 03:54:04.901585|2018-06-01 03:54:04.901585
NCT00351247|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2006-07-11|2006-07-11|2006-07-12|Estimate|||||||2006-07-11|2006-07-12|Estimate|July 2006||2006-07-31|July 2006|2006-07-31|May 2007||2007-05-31|||||Interventional|||Postconditioning in Primary PCI and Direct Stenting|Clinical and MRI Evaluation of 2 Vs 4 Cycles of Postconditioning During Primary PCI With Direct Stenting|Unknown status|Not yet recruiting|N/A|45||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:54:04.968196|2018-06-01 03:54:04.968196
NCT00351234|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2012-02-24|2006-07-11|2006-07-12|Estimate|||||||2012-02-24|2012-02-28|Estimate|October 2004||2004-10-31|February 2012|2012-02-29|April 2007|Actual|2007-04-30|||||Observational|||Carnitine Levels and Carnitine Supplementation in Type I Diabetes|Correlation Between Carnitine Deficiency and Hypoglycemic Events in Type I Diabetes; Effects of Carnitine Supplementation on Hypoglycemic Events in Type I Diabetes|Completed|||200|Actual|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 03:54:05.055903|2018-06-01 03:54:05.055903
NCT00351221|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2007-03-29|2006-07-11|2006-07-12|Estimate|||||||2007-03-29|2007-03-30|Estimate||||February 2007|2007-02-28||||||||Interventional|||Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome|A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome|Terminated||Phase 2|24||Insmed Incorporated||||Terminated due to a patent legal settlement|||||||||||||||2018-06-01 03:54:05.142675|2018-06-01 03:54:05.142675
NCT00351208|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2006-07-11|2006-07-11|2006-07-12|Estimate|||||||2006-07-11|2006-07-12|Estimate|May 2006||2006-05-31|June 2006|2006-06-30|August 2006||2006-08-31|||||Interventional|||Spinal Cord Stimulation Efficacy Measures|The Efficacy of Spinal Cord Stimulation at Varying Stimulation Frequencies and Pulse-Widths|Unknown status|Recruiting|Phase 1|20||New York Neurosurgery & Neuroscience Associates, PLLC|||||f||||||||||||||2018-06-01 03:54:05.229844|2018-06-01 03:54:05.229844
NCT00351195|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2008-08-25|2006-07-11|2006-07-12|Estimate|||||||2008-08-25|2008-08-26|Estimate|February 2006||2006-02-28|August 2008|2008-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)|A Phase II Study of Etoposide, Oxaliplatin and Capecitabine in Patients With Advanced HCC|Terminated||Phase 2|39|Anticipated|Rigshospitalet, Denmark||||Did not meet the criteria for continuation to second stage|f||||||||||||||2018-06-01 03:54:05.318865|2018-06-01 03:54:05.318865
NCT00351182|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2006-07-11|2006-07-11|2006-07-12|Estimate|||||||2006-07-11|2006-07-12|Estimate|September 2005||2005-09-30|June 2006|2006-06-30||||||||Interventional|||Controlled Trial: 5-Day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus|Phase 3 Study of Controlled Trial: 5-Day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus|Unknown status|Recruiting|Phase 3|||Chosun University Hospital|||||f||||||||||||||2018-06-01 03:54:05.387023|2018-06-01 03:54:05.387023
NCT00351169|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2008-12-18|2006-07-11|2006-07-12|Estimate|||||||2008-12-18|2008-12-22|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|AMBER||Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised, Parallel Group, Placebo- Controlled and Active Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono- Therapy in the Treatment of Adult Patients With Major Depressive Disorder|Completed||Phase 3|450|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:54:05.462271|2018-06-01 03:54:05.462271
NCT00351156|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10||2010-08-17|2010-08-17|2006-07-10|2006-07-12|Estimate||||2010-08-17|2010-08-19|Estimate|2010-08-17|2010-08-19|Estimate|July 2006||2006-07-31|August 2010|2010-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease|A Multicenter Study to Evaluate and Characterize the Ex Vivo Effect of Pharmacological Chaperone Therapy in Blood Cell Lines Derived From Patients With Gaucher Disease|Completed|||50||Amicus Therapeutics|||||f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 03:54:05.572481|2018-06-01 03:54:05.572481
NCT00351143|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2017-09-08|2006-07-11|2006-07-12|Estimate|||||||2017-09-08|2017-09-11|Actual|July 26, 2005|Actual|2005-07-26|September 2017|2017-09-30|June 13, 2007|Actual|2007-06-13|June 13, 2007|Actual|2007-06-13||Interventional|||A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control|A Randomized, Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50/250 mcg b.i.d. Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only|Completed||Phase 4|274|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 03:54:05.643319|2018-06-01 03:54:05.643319
NCT00350974|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2017-06-01|2006-07-10|2006-07-11|Estimate|||||||2017-06-01|2017-06-05|Actual|July 2006||2006-07-31|June 2017|2017-06-30|March 8, 2007|Actual|2007-03-08|March 8, 2007|Actual|2007-03-08||Observational|||ADMA Levels in End-Stage Renal Disease|Determination of Asymmetrical Dimethylarginine (ADMA) Accumulation in End Stage Renal Disease|Completed|||61|Actual|University of Michigan|||3||f||||f||||||||||2018-06-01 03:54:07.035605|2018-06-01 03:54:07.035605
NCT00351130|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2017-02-22|2006-07-10|2006-07-12|Estimate|||||||2017-02-22|2017-02-24|Actual|June 2006||2006-06-30|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy|An 8 Week Extension to a Randomized, Double-blind, Parallel Group, Active-controlled, Multi-center, 14 Week Study to Evaluate the Effectiveness of a Valsartan Versus and Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy|Completed||Phase 4|79|Actual|Novartis|||||f||||||||||||||2018-06-01 03:54:05.740768|2018-06-01 03:54:05.740768
NCT00351117|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2009-07-10|2006-07-11|2006-07-12|Estimate|||||||2009-07-10|2009-07-14|Estimate|March 2007||2007-03-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||St. John's Wort in the Treatment of Raynaud's Phenomenon|A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon|Completed||Phase 3|20|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 03:54:05.898217|2018-06-01 03:54:05.898217
NCT00351104|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-08-13|2006-07-11|2006-07-12|Estimate|||||||2008-08-13|2008-08-14|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Ankle Sprain or Strain|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment of Pain Associated With Grade 1 or Grade 2 Ankle Sprain or Strain|Completed||Phase 3|200|Actual|Endo Pharmaceuticals|||||f||||||||||||||2018-06-01 03:54:05.992217|2018-06-01 03:54:05.992217
NCT00351091|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2012-02-15|2006-07-11|2006-07-12|Estimate|||||||2012-02-15|2012-02-17|Estimate|November 2002||2002-11-30|February 2012|2012-02-29|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Risedronate in Postmenopausal Women With Low Bone Density|a Six Month, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group Study to Estimate the Pharmacodynamic Response of Two Risedronate Regimens Compared With 5mg Daily : 150mg Monthly Dose for Six Months and 15mg Daily for Thirty Days Followed by 150mg Monthly Dose for 5 Months in Postmenopausal Women With Low Bone Density.|Completed||Phase 2|150|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:54:06.066872|2018-06-01 03:54:06.066872
NCT00351078|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2017-12-11|2006-07-11|2006-07-12|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2006||2006-12-31|April 2017|2017-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||PTC124 for the Treatment of Cystic Fibrosis|A Phase 2b Extension Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis|Completed||Phase 2|19|Actual|PTC Therapeutics||1|||f||||f||||||||No||2018-06-01 03:54:06.123654|2018-06-01 03:54:06.123654
NCT00351065|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2006-07-11|2006-07-11|2006-07-12|Estimate|||||||2006-07-11|2006-07-12|Estimate|September 2004||2004-09-30|July 2006|2006-07-31|March 2005||2005-03-31|||||Interventional|||Phase II Trial of SK3530 in Erectile Dysfunction|an 8week, Multi-Center, Randomized, Double Blind, Placebo-Controlled,Parallel Group, Fixed Dose, Dose-Finding Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction.|Terminated||Phase 2|120||SK Chemicals Co.,Ltd.|||||f||||||||||||||2018-06-01 03:54:06.202065|2018-06-01 03:54:06.202065
NCT00351052|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2008-01-15|2006-07-10|2006-07-12|Estimate|||||||2008-01-15|2008-01-17|Estimate|December 2001||2001-12-31|January 2008|2008-01-31|September 2004|Actual|2004-09-30|||||Interventional|||Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis|A 24-Week, Randomized, Multicenter, Parallel-Group, Double-Blind, Vehicle-Controlled Study on Pimecrolimus Cream 1% Assessing the Steroid-Sparing Effect in the Long Term Management of Pediatric Patients With Severe Atopic Dermatitis|Completed||Phase 3|184|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:54:06.264711|2018-06-01 03:54:06.264711
NCT00351039|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|2009-10-09||2017-02-20|2006-07-11|2006-07-12|Estimate|2010-08-09|2010-08-30|Estimate||||2017-02-20|2017-03-23|Actual|July 2006||2006-07-31|August 2010|2010-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer|Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in the First-Line Treatment of Elderly Patients With Advanced (Stage IIIB(With Malignant Pleural Effusion) or IV) Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1/Phase 2|8|Actual|H. Lee Moffitt Cancer Center and Research Institute|This study was closed early due to poor accrual. The recommended Phase II dose was determined after the brief Phase I run-in, but the Phase II component of this study was never initiated.|1||slow accrual|f||||t||||||||||2018-06-01 03:54:06.351948|2018-06-01 03:54:06.351948
NCT00351026|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2016-09-06|2006-07-11|2006-07-12|Estimate|||||||2016-09-06|2016-09-07|Estimate|June 2008||2008-06-30|September 2016|2016-09-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Methadone Maintenance & HIV Risk in Ukraine|Methadone Maintenance & HIV Risk in Ukraine|Completed||Phase 3|50|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:54:06.596164|2018-06-01 03:54:06.596164
NCT00351013|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2009-02-03|2006-07-11|2006-07-12|Estimate|||||||2009-02-03|2009-02-04|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||The Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities|A Pilot Study of the Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities|Completed||Phase 4|731|Actual|Malamed||1|||f||||t||||||||||2018-06-01 03:54:06.669078|2018-06-01 03:54:06.669078
NCT00351000|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|2012-12-20||2016-11-16|2006-07-11|2006-07-12|Estimate|2012-12-20|2013-01-28|Estimate||||2016-11-16|2017-01-13|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|March 2007|Actual|2007-03-31|||||Interventional|||Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus|An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia|Completed||Phase 4|24|Actual|North Suffolk Mental Health Association|The sample size in this study may not have been adequate to demonstrate the effectiveness of ziprasidone as an adjuvant therapy. The receptor-binding profile of ziprasidone may not significantly counteract the mechanisms of metabolic disturbances.||||f||||||||||||||2018-06-01 03:54:06.746217|2018-06-01 03:54:06.746217
NCT00350987|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-11|||2008-09-22|2006-07-11|2006-07-12|Estimate|||||||2008-09-22|2008-09-23|Estimate|October 2006||2006-10-31|September 2008|2008-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||"Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The ProHOSP Study"|"Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The ProHOSP Study"|Completed||N/A|1002|Actual|University Hospital, Basel, Switzerland||2|||f||||||||||||||2018-06-01 03:54:06.947417|2018-06-01 03:54:06.947417
NCT00342498|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 12, 1994||1994-01-12|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Observational|||Estrogen Receptor Gene Mutations|Estrogen Receptor Gene Mutations|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.264414|2018-06-01 03:56:18.264414
NCT00350961|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2008-08-25|2006-07-10|2006-07-11|Estimate|||||||2008-08-25|2008-08-26|Estimate|June 2004||2004-06-30|August 2008|2008-08-31|February 2008|Actual|2008-02-29|||||Interventional|||Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma|Phase I-II Study of bi-Weekly Fixed Dose Rate Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma|Completed||Phase 1/Phase 2|39|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 03:54:07.096521|2018-06-01 03:54:07.096521
NCT00350948|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2013-11-26|2006-07-10|2006-07-11|Estimate|||||||2013-11-26|2013-11-27|Estimate|May 2006||2006-05-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ASSIST-5||Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer|Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5)|Terminated||Phase 3|244|Actual|Telik||2||Business reasons|f||||t||||||||||2018-06-01 03:54:07.204741|2018-06-01 03:54:07.204741
NCT00350935|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2010-06-25|2006-07-10|2006-07-11|Estimate|||||||2010-06-25|2010-06-28|Estimate|September 2006||2006-09-30|June 2010|2010-06-30|April 2009|Actual|2009-04-30|||||Observational|||Attention and Visual Perception in Schizophrenia: A Functional Magnetic Resonance Imaging (fMRI) Study|Attention and Grouping of Visual Information: What is Disturbed in Patients With Schizophrenia?|Completed|||52|Anticipated|University Hospital, Strasbourg, France|||2||f||||||||||||||2018-06-01 03:54:07.374286|2018-06-01 03:54:07.374286
NCT00350922|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-08|||2006-07-08|2006-07-08|2006-07-11|Estimate|||||||2006-07-08|2006-07-11|Estimate|September 2003||2003-09-30|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||A Clinical Trial of a Self-Management Education Program for People With Chronic Stable Angina|A Psychoeducation Trial for People With Chronic Stable Angina|Unknown status|Active, not recruiting|Phase 1|130||University of Toronto|||||f||||||||||||||2018-06-01 03:54:07.437983|2018-06-01 03:54:07.437983
NCT00350909|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2008-10-16|2006-07-10|2006-07-11|Estimate|||||||2008-10-16|2008-10-20|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Brief Intervention for Drug Abusing Adolescents|Brief Intervention for Drug Abusing Students|Completed||Phase 2|160|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 03:54:07.507286|2018-06-01 03:54:07.507286
NCT00350896|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2006-07-10|2006-07-10|2006-07-11|Estimate|||||||2006-07-10|2006-07-11|Estimate|December 2003||2003-12-31|January 2006|2006-01-31|December 2005||2005-12-31|||||Interventional|||Safety Study of Thumb Orthoses in Osteoarthritis in the Base of the Thumb (BTOA)|Comparative Study of the Efficacy of Thumb Orthoses in the Base of the Thumb (BTOA)|Completed||N/A|120||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:54:07.605098|2018-06-01 03:54:07.605098
NCT00350883|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2012-05-02|2006-07-07|2006-07-11|Estimate|||||||2012-05-02|2012-05-03|Estimate|July 2006||2006-07-31|May 2012|2012-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Cognitive Therapy for Negative Symptoms and Functioning|Cognitive Therapy for Negative Symptoms and Functioning|Completed||Phase 2|61|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 03:54:07.673086|2018-06-01 03:54:07.673086
NCT00350870|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|2014-11-12||2014-11-26|2006-07-07|2006-07-11|Estimate|2014-11-26|2014-12-03|Estimate||||2014-11-26|2014-12-03|Estimate|April 2005||2005-04-30|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||CBT With Disulfiram and Contingency Management|Maximizing the Efficacy of Cognitive Behavioral Therapy With Medication and Contingency Management|Completed||Phase 1|181|Actual|Yale University||4|||f||||t||||||||||2018-06-01 03:54:07.760063|2018-06-01 03:54:07.760063
NCT00350857|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2014-02-19|2006-07-10|2006-07-11|Estimate|||||||2014-02-19|2014-02-20|Estimate|July 2006||2006-07-31|November 2009|2009-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Young Adult and Pediatric Bipolar Study|A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder.|Completed||Phase 4|161|Actual|Validus Pharmaceuticals||1|||f||||||||||||||2018-06-01 03:54:08.113047|2018-06-01 03:54:08.113047
NCT00350844|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2013-02-18||2013-03-28|2006-07-10|2006-07-11|Estimate|2013-03-28|2013-05-08|Estimate||||2013-03-28|2013-05-08|Estimate|July 2006||2006-07-31|March 2013|2013-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension|A Pilot Study of Hydroxyurea for the Treatment of Pulmonary Hypertension in Children and Young Adults With Sickle Cell Disease|Terminated||Phase 1/Phase 2|6|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|Early termination leading to no data analysis completed.|1||Low subject accrual|f||||f||||||||||2018-06-01 03:54:08.192574|2018-06-01 03:54:08.192574
NCT00350831|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2008-08-14|2006-07-07|2006-07-11|Estimate|||||||2008-08-14|2008-08-18|Estimate|July 2006||2006-07-31|August 2008|2008-08-31||||||||Interventional|||Study of XL820 Given Orally Daily to Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the KIT Inhibitor XL820 Administered Orally Daily to Subjects With Solid Tumors|Completed||Phase 1|30|Anticipated|Exelixis|||||||||||||||||||2018-06-01 03:54:08.449559|2018-06-01 03:54:08.449559
NCT00350818|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2012-07-27|2006-07-07|2006-07-11|Estimate|||||||2012-07-27|2012-07-30|Estimate|October 2005||2005-10-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)|Azacitidine Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for AML and MDS|Completed||Phase 1|90|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:54:08.502726|2018-06-01 03:54:08.502726
NCT00350805|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2017-10-04|2006-07-10|2006-07-11|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2005|Actual|2005-09-30|September 2017|2017-09-30|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Observational|||Measuring Time Windows in Patients With Schizophrenia and Healthy Controls|Relating the 'Experienced Present' With the Mechanisms of Neuronal Function: A Comparative Study in Patients With Schizophrenia and Healthy Controls Using Psychophysical and Neurophysiological Methods|Completed|||126|Actual|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-06-01 03:54:08.586566|2018-06-01 03:54:08.586566
NCT00350792|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2009-11-05||2010-10-11|2006-07-10|2006-07-11|Estimate|2009-11-05|2009-12-09|Estimate||||2010-10-11|2010-10-13|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients|A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients|Completed||Phase 2|62|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:54:08.697351|2018-06-01 03:54:08.697351
NCT00350597|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2006-07-10|2006-07-10|2006-07-11|Estimate|||||||2006-07-10|2006-07-11|Estimate|September 2004||2004-09-30|July 2006|2006-07-31|July 2010||2010-07-31|||||Interventional|||GM-CSF as Adjuvant Therapy of Melanoma|Immunologic and Antibody Responses in Patients Receiving GM-CSF, (Leukine, Sargramostim) as Adjuvant Therapy of Stage II (T4), III and IV Melanoma.|Completed||Phase 2|50||Northern California Melanoma Center|||||f||||||||||||||2018-06-01 03:54:13.931617|2018-06-01 03:54:13.931617
NCT00350779|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|2009-05-13||2017-04-06|2006-07-07|2006-07-11|Estimate|2009-05-13|2009-07-03|Estimate||||2017-04-06|2017-05-12|Actual|June 12, 2006|Actual|2006-06-12|April 2017|2017-04-30|June 11, 2008|Actual|2008-06-11|September 25, 2007|Actual|2007-09-25||Interventional|||Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Metformin and a PPARg Agonist|Completed||Phase 3|262|Actual|Merck Sharp & Dohme Corp.|Non-serious adverse event results represent those events included in the primary safety analysis for this study (events occurred prior to initiation of glycemic rescue therapy). Site 0520039 was non-compliant with GDP, data was removed from analyses.|2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:54:09.104184|2018-06-01 03:54:09.104184
NCT00350766|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2017-03-29|2006-07-10|2006-07-11|Estimate|||||||2017-03-29|2017-03-30|Actual|July 1, 2006|Actual|2006-07-01|March 2017|2017-03-31|July 14, 2014|Actual|2014-07-14|January 21, 2014|Actual|2014-01-21||Interventional|EMRTCC||Cell Therapy in Myocardial Infarction|Multicenter Prospective Randomized Double Blind Trial of Bone Marrow Mononuclear Cells Transplantation Through Intracoronary Injection in Patients With Acute Myocardial Infarction.|Terminated||Phase 2/Phase 3|166|Actual|Ministry of Health, Brazil||2||Slow recruitment rate and consequent financial exhaustion.|f||||t||||||||Undecided||2018-06-01 03:54:09.65406|2018-06-01 03:54:09.65406
NCT00350753|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2009-07-14|2006-07-10|2006-07-11|Estimate|||||||2009-07-14|2009-07-15|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Avastin and Tarceva for Upper Gastrointestinal Cancers|A Phase II Study of Erlotinib and Bevacizumab in Patients With Advanced Upper Gastrointestinal Carcinomas, Refractory or Intolerable to Standard Systemic Therapy|Completed||Phase 2|126|Anticipated|Rigshospitalet, Denmark||1|||f||||||||||||||2018-06-01 03:54:09.753243|2018-06-01 03:54:09.753243
NCT00350727|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2010-12-26||2013-04-11|2006-07-10|2006-07-11|Estimate|2011-05-19|2011-06-20|Estimate||||2013-04-11|2013-04-19|Estimate|December 2006||2006-12-31|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|VEG102857||Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma|Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma|Completed||Phase 2|75|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:54:09.931053|2018-06-01 03:54:09.931053
NCT00350714|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2011-06-19|2006-07-10|2006-07-11|Estimate|||||||2011-06-19|2011-06-21|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||BreathID Multi-center HCV Liver Breath Test Study|Validation of a Breath Test for Assessment of Liver Fibrosis in Patients With Chronic Hepatitis C Viral Infection|Terminated||Phase 2|75|Actual|Exalenz Bioscience LTD.||1||Due to FDA comments, protocol changed; new trial will be proposed shortly|f||||f||||||||||2018-06-01 03:54:12.434174|2018-06-01 03:54:12.434174
NCT00350701|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2012-12-17|2006-07-10|2006-07-11|Estimate|||||||2012-12-17|2012-12-18|Estimate|July 2006||2006-07-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Effect of Androgel on Type 2 Diabetic Males With Hypogonadism|Effect of Androgel on Inflammatory Mediators and Oxidative Stress in Type 2 Diabetic Males With Hypogonadism|Unknown status|Active, not recruiting|Phase 4|36|Anticipated|Kaleida Health||3|||f||||f||||||||||2018-06-01 03:54:12.521304|2018-06-01 03:54:12.521304
NCT00350688|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2012-07-11|2006-07-07|2006-07-11|Estimate|||||||2012-07-11|2012-07-13|Estimate|November 2005||2005-11-30|July 2007|2007-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy|Phase II Trial To Evaluate The Potential For Helical Tomotherapy IMRT To Improve Bladder Cancer Chemoradiation|Terminated||Phase 2|9|Actual|Ottawa Hospital Research Institute||||More advanced treatments superceded study design|f||||f||||||||||2018-06-01 03:54:12.599347|2018-06-01 03:54:12.599347
NCT00350675|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-09|||2006-07-09|2006-07-09|2006-07-11|Estimate|||||||2006-07-09|2006-07-11|Estimate|July 2006||2006-07-31|July 2006|2006-07-31||||||||Observational|||Medical Utilization in Israel During Second Intifada|Medical Utilization, Psychotropic Prescriptions, and Somatic Complaints in Israel During the Second Intifada: An Ecological Study of the Impact of Stress.|Unknown status|Not yet recruiting||||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:54:12.661272|2018-06-01 03:54:12.661272
NCT00350662|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2012-11-16|2006-07-10|2006-07-11|Estimate|||||||2012-11-16|2012-11-19|Estimate|January 2002||2002-01-31|November 2012|2012-11-30||||||||Interventional|||Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients|Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients|Completed||Phase 3|95|Actual|Lipomed||3|||f||||f||||||||||2018-06-01 03:54:12.705396|2018-06-01 03:54:12.705396
NCT00350649|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2011-09-26|2006-07-07|2006-07-11|Estimate|||||||2011-09-26|2011-09-27|Estimate|December 2004||2004-12-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management|Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management|Completed||Phase 2|205|Actual|Yale University||4|||f||||t||||||||||2018-06-01 03:54:12.874123|2018-06-01 03:54:12.874123
NCT00350636|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|2010-04-13||2010-04-13|2006-07-10|2006-07-11|Estimate|2010-04-13|2010-05-10|Estimate||||2010-04-13|2010-05-10|Estimate|June 2006||2006-06-30|April 2010|2010-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo|Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension|Completed||Phase 3|789|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:54:12.987482|2018-06-01 03:54:12.987482
NCT00350623|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|2010-10-20||2015-08-11|2006-07-10|2006-07-11|Estimate|2010-10-20|2010-11-04|Estimate||||2015-08-11|2015-08-25|Estimate|October 2006||2006-10-31|August 2015|2015-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)|A Phase IIa Dose-Refinement Study of the Safety and Immunogenicity of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy Adults|Terminated||Phase 2|210|Actual|Merck Sharp & Dohme Corp.|An interim analysis of a related study, V520-023 (NCT00095576), showed that the vaccine used in V520-027 (NCT00350623) was not efficacious; therefore, vaccinations in V520-027 were stopped and only a high level summary of safety data was performed.|3|||f||||||||||||||2018-06-01 03:54:13.471075|2018-06-01 03:54:13.471075
NCT00350610|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2013-01-28|2006-07-07|2006-07-11|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2007||2007-11-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CBT4CBT||Computer-Based Training in Cognitive Behavior Therapy|Computer-Based Training in Cognitive Behavior Therapy|Completed||Phase 1|100|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:54:13.859067|2018-06-01 03:54:13.859067
NCT00350584|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-10|||2011-07-28|2006-07-10|2006-07-11|Estimate|||||||2011-07-28|2011-07-29|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of Telehealth Interventions for Post-Trauma Stress|Evaluation of Two Telehealth Interventions Targeting Post-Trauma Stress in Combat Veterans: Comparing Mindfulness and Psychoeducation|Completed||N/A|33|Actual|VA Boston Healthcare System||2|||f||||f||||||||||2018-06-01 03:54:13.995087|2018-06-01 03:54:13.995087
NCT00350571|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2014-09-16|2006-07-10|2006-07-11|Estimate|||||||2014-09-16|2014-09-17|Estimate|November 2004||2004-11-30|September 2014|2014-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Brief Interventions for Drop-out Re-engagement|Adaptive Brief Interventions for Drop-out Re-engagement|Completed||Phase 1|299|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:54:14.059861|2018-06-01 03:54:14.059861
NCT00350545|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2016-12-12||2017-10-19|2006-07-05|2006-07-10|Estimate|2017-10-19|2017-11-20|Actual||||2017-10-19|2017-11-20|Actual|August 2006||2006-08-31|October 2017|2017-10-31|October 2014|Actual|2014-10-31|May 2012|Actual|2012-05-31||Interventional|||A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease|A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease|Completed||N/A|37|Actual|Stanford University||1|||f||||t||||||||Yes|IPD will be available in the publication which is forthcoming.|2018-06-01 03:54:14.23166|2018-06-01 03:54:14.23166
NCT00350532|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2009-03-23||2017-11-03|2006-07-05|2006-07-10|Estimate|2009-08-18|2009-09-23|Estimate||||2017-11-03|2017-11-07|Actual|September 2004||2004-09-30|May 2017|2017-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain|Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain|Completed||Phase 2|43|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-06-01 03:54:14.544269|2018-06-01 03:54:14.544269
NCT00350519|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|2009-02-20||2013-07-02|2006-07-07|2006-07-10|Estimate|2009-03-23|2009-05-06|Estimate||||2013-07-02|2013-07-22|Estimate|August 2006||2006-08-31|July 2013|2013-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery|An Open Label, Multicenter, Randomized, Controlled Study to Evaluate Efficacy and Safety of PROCRIT in Subjects Undergoing Elective Major Abdominal and/or Pelvic Surgery|Terminated||Phase 4|37|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No formal analysis was conducted due to early termination.|2||The study was stopped due to slow enrollment|f||||f||||||||||2018-06-01 03:54:14.761111|2018-06-01 03:54:14.761111
NCT00350506|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2007-08-15|2006-07-06|2006-07-10|Estimate|||||||2007-08-15|2007-08-16|Estimate|October 2005||2005-10-31|August 2007|2007-08-31||||||||Interventional|||A Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT|An Open-Label, Non-Randomized, Multi-Center Trial Evaluating the Clinical Applicability, Correlation, and Modeling of Cardiac CT Using 64 Detector Row VCT|Completed||N/A|144||GE Healthcare|||||f||||||||||||||2018-06-01 03:54:15.241942|2018-06-01 03:54:15.241942
NCT00350493|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-09-25|2006-07-06|2006-07-10|Estimate|||||||2008-09-25|2008-09-26|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||Three Year Follow up of a Randomised Controlled Trial (RCT) of an Intervention for Tobacco Dependence Among Those With a Psychotic Illness|Three Year Follow up of a Randomised Controlled Trial of an Intervention for Tobacco Dependence Among Those With a Psychotic Illness|Completed|||298||The University of New South Wales|||||f||||||||||||||2018-06-01 03:54:15.29574|2018-06-01 03:54:15.29574
NCT00350480|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2015-03-10|2006-07-06|2006-07-10|Estimate|||||||2015-03-10|2015-03-11|Estimate|April 2003||2003-04-30|March 2015|2015-03-31|June 2005||2005-06-30|||||Interventional|||Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial|Treatment of Non-Gestational Acute Uterine BleedingComparing Oral Medroxyprogesterone Acetate and Monophasic Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol|Completed||N/A|240||Kaiser Permanente|||||f||||||||||||||2018-06-01 03:54:15.354024|2018-06-01 03:54:15.354024
NCT00350467|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2011-05-18|2006-07-07|2006-07-10|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2006||2006-06-30|May 2010|2010-05-31|September 2007|Actual|2007-09-30|||||Interventional|||A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia|A Randomized, 6-week Double-blind, Parallel Study to Evaluate the Efficacy and the Safety of Flexible Doses of Extended Release OROS Paliperidone Compared With Olanzapine in the Treatment of Patients With Schizophrenia|Completed||Phase 3|288|Actual|Xian-Janssen Pharmaceutical Ltd.|||||f||||||||||||||2018-06-01 03:54:15.422811|2018-06-01 03:54:15.422811
NCT00350454|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2008-01-10|2006-07-07|2006-07-10|Estimate|||||||2008-01-10|2008-01-11|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3)|Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)|Completed||Phase 4|605|Actual|Deutsches Herzzentrum Muenchen||3|||f||||t||||||||||2018-06-01 03:54:15.509228|2018-06-01 03:54:15.509228
NCT00350441|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2006-10-10|2006-07-07|2006-07-10|Estimate|||||||2006-10-10|2006-10-11|Estimate|June 2006||2006-06-30|July 2006|2006-07-31||||||||Interventional|||Does Sildenafil Protect Against Pulmonary Related Complications Following Cardiopulmonary Bypass?|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study of the Pre-Operative Effect of Sildenafil Citrate on Pulmonary Related Complications Following Cardiopulmonary Bypass in Children Undergoing Cardiac Surgical Repair.|Unknown status|Recruiting|Phase 4|12||NHS Greater Glasgow Yorkhill Division|||||f||||||||||||||2018-06-01 03:54:15.583644|2018-06-01 03:54:15.583644
NCT00350428|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2006-10-23|2006-07-07|2006-07-10|Estimate|||||||2006-10-23|2006-10-24|Estimate|October 2001||2001-10-31|October 2004|2004-10-31|October 2007||2007-10-31|||||Interventional|||Laser Iridotomy Versus Phacoemulsification in Acute Angle Closure|Angle Closure: Laser Iridotomy Versus Phacoemulsification Study (ACLIPS)- A Study of Acute Primary Angle Closure Glaucoma Comparing Two Treatment Modalities: Laser Peripheral vs Phacoemulsification With Posterior Intraocular Lens Implant|Completed||N/A|70||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:15.649942|2018-06-01 03:54:15.649942
NCT00350415|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2013-04-15|2006-07-06|2006-07-10|Estimate|||||||2013-04-15|2013-04-17|Estimate|June 2006||2006-06-30|April 2013|2013-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Double Blind Study for the Treatment of Acute Ulcerative Colitis|A Double-blind, Randomized, 6-week, Parallel-group Design Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day for the Treatment of Moderately Active Ulcerative Colitis.|Completed||Phase 3|772|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:54:15.729643|2018-06-01 03:54:15.729643
NCT00342264|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-12|2006-06-19|2006-06-21|Estimate|||||||2018-05-12|2018-05-15|Actual|January 12, 1999||1999-01-12|October 18, 2017|2017-10-18||||||||Observational|||A Nested Case-Control Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners|Diesel Exhaust Among Miners Study|Completed|||824|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:19.925526|2018-06-01 03:56:19.925526
NCT00350402|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2012-02-06||2012-04-04|2006-07-05|2006-07-10|Estimate|2012-03-07|2012-04-04|Estimate||||2012-04-04|2012-04-06|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Masked Faces in Parkinson Disease: Mechanism and Treatment|Masked Faces in Parkinson Disease: A Randomized Double-blind Sham-treatment Controlled Clinical Trial of High Intensity Respiratory Muscle Strength Training (MST) for Treatment of Reduced Facial Expression in Parkinson Disease|Completed||Phase 2|44|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 03:54:16.07269|2018-06-01 03:54:16.07269
NCT00350389|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2015-06-01|2006-07-06|2006-07-10|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2005||2005-06-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|VISIBLE||VISIBLE Study (Visual Intervention Strategy Incorporating Bifocal & Long-distance Eyewear)|Randomised Controlled Falls Prevention Trial of Plain Distance Glasses in Elderly Multifocal Wearers.|Completed||N/A|606|Actual|The University of New South Wales||2|||f||||t||||||||||2018-06-01 03:54:16.337789|2018-06-01 03:54:16.337789
NCT00350376|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2006-07-05|2006-07-05|2006-07-10|Estimate|||||||2006-07-05|2006-07-10|Estimate|June 2006||2006-06-30|July 2006|2006-07-31||||||||Observational|||Impact of Asthma Treatments on Daily Activities|Study on Asthma Treatments on Daily Activities as Reported by Patients (STAR)|Unknown status|Recruiting||1500||Ovation Research Group|||||f||||||||||||||2018-06-01 03:54:16.433795|2018-06-01 03:54:16.433795
NCT00350363|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2014-05-15||2015-01-26|2006-07-05|2006-07-10|Estimate|2015-01-26|2015-01-29|Estimate||||2015-01-26|2015-01-29|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||patients undergoing eye surgery|One Hour Preoperative Gatifloxacin|One Hour Preoperative Gatifloxacin|Completed||Phase 4|60|Actual|Stanford University||1|||f||||||||||||||2018-06-01 03:54:16.515648|2018-06-01 03:54:16.515648
NCT00350350|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2012-04-20|2006-07-06|2006-07-10|Estimate|||||||2012-04-20|2012-04-23|Estimate|October 2003||2003-10-31|July 2006|2006-07-31|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Observational|||OGT Spray in the Management of Xerostomia in the Elderly|Multicenter, Controlled Parallel Groups Trial to Evaluate the Efficacy, Safety and Acceptability of OGT Oromucosal Spray Versus a Saliva Substitute in the Treatment of Xerostomia in Geriatrics|Completed|||74|Actual|Laboratoires CARILENE|||1||f||||t||||||||||2018-06-01 03:54:16.666372|2018-06-01 03:54:16.666372
NCT00350337|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-07-16|2006-07-06|2006-07-10|Estimate|||||||2008-07-16|2008-07-17|Estimate|January 2006||2006-01-31|July 2008|2008-07-31||||July 2008|Actual|2008-07-31||Interventional|||A Phase II Trial of a WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults|Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule, to Healthy Adults|Completed||Phase 2|88||Walter Reed Army Institute of Research (WRAIR)|||||f||||||||||||||2018-06-01 03:54:16.739525|2018-06-01 03:54:16.739525
NCT00350311|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-09-25|2006-07-06|2006-07-10|Estimate|||||||2008-09-25|2008-09-26|Estimate|February 2007||2007-02-28|September 2008|2008-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study|Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study|Completed||Phase 2|43|Actual|The University of New South Wales|||||f||||||||||||||2018-06-01 03:54:16.84692|2018-06-01 03:54:16.84692
NCT00350298|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07||2010-10-25|2010-10-26|2006-07-07|2006-07-10|Estimate||||2010-10-26|2010-11-01|Estimate|2010-10-26|2010-11-01|Estimate|July 2006||2006-07-31|October 2010|2010-10-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease|A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease|Completed||Phase 2|200|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 03:54:16.920026|2018-06-01 03:54:16.920026
NCT00350285|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2008-10-21|2006-07-05|2006-07-10|Estimate|||||||2008-10-21|2008-10-23|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|TMCU3||The Teen Marijuana Check-Up|Reaching and Motivating Change in Teen Marijuana Smokers|Completed||Phase 2|310|Actual|University of Washington||3|||f||||f||||||||||2018-06-01 03:54:17.040181|2018-06-01 03:54:17.040181
NCT00350272|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|2016-02-22|2014-01-20|2016-05-16|2006-07-07|2006-07-10|Estimate|2016-02-22|2016-03-22|Estimate|2014-01-20|2014-02-13|Estimate|2016-05-16|2016-06-17|Estimate|May 2006||2006-05-31|May 2016|2016-05-31|April 2009|Actual|2009-04-30|August 2007|Actual|2007-08-31||Interventional||The baseline analysis population was the safety population, defined as all randomized subjects who received at least one dose of study drug.|Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects|A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects. There is a 36 Week, Open Label, Extension Phase for Eligible Subjects.|Completed||Phase 2|76|Actual|Achillion Pharmaceuticals||2|||f||||t||||||||Yes|Individual Participant Data is available to only this study's Principal Investigator upon request.|2018-06-01 03:54:17.15134|2018-06-01 03:54:17.15134
NCT00350259|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2008-04-29|2006-07-07|2006-07-10|Estimate|||||||2008-04-29|2008-04-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 03:54:17.865015|2018-06-01 03:54:17.865015
NCT00350246|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2010-01-27|2006-07-07|2006-07-10|Estimate|||||||2010-01-27|2010-01-28|Estimate|July 2004||2004-07-31|January 2010|2010-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Long-term Effects of Laser Refractive Surgery|Long-term Effects of Laser Refractive Surgery|Completed||Phase 4|62|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:54:17.893651|2018-06-01 03:54:17.893651
NCT00350233|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2012-09-13|2006-07-06|2006-07-10|Estimate|||||||2012-09-13|2012-09-17|Estimate|May 2006||2006-05-31|September 2012|2012-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors|MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors|Completed||Phase 1|10|Actual|InSightec||1|||f||||||||||||||2018-06-01 03:54:18.019713|2018-06-01 03:54:18.019713
NCT00350220|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2010-01-19||2015-05-29|2006-07-05|2006-07-10|Estimate|2010-02-11|2010-02-25|Estimate||||2015-05-29|2015-06-26|Estimate|July 2006||2006-07-31|May 2015|2015-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Transfusion Strategies in Pediatric Cardiothoracic Surgery|A Prospective, Randomized, Controlled Clinical Trial Comparing Two Transfusion Strategies in Pediatric Patients Undergoing Cavopulmonary Connection.|Completed||Phase 2|60|Actual|University of Rochester|There were no limitations to this study. There was 100% compliance with study procedures. There were no adverse events.|2|||f||||||||||||||2018-06-01 03:54:18.110896|2018-06-01 03:54:18.110896
NCT00350207|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|2009-08-24||2013-11-27|2006-07-07|2006-07-10|Estimate|2009-10-08|2009-11-17|Estimate||||2013-11-27|2013-12-24|Estimate|July 2006||2006-07-31|September 2013|2013-09-30||||September 2008|Actual|2008-09-30||Interventional||Treated set includes all patients who were dispensed randomised study medication and were documented to have taken at least one dose of investigational treatment.|Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg|A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype|Completed||Phase 2|388|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:54:18.405468|2018-06-01 03:54:18.405468
NCT00350194|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2012-02-29|2006-07-06|2006-07-10|Estimate|||||||2012-02-29|2012-03-02|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|June 2012|Anticipated|2012-06-30|October 2011|Actual|2011-10-31||Interventional|||The Effects of Omega-3 Fatty Acids on Metabolic Syndrome|Pilot Study: The Effects of Omega-3 Fatty Acids on Metabolic Syndrome and Vascular Structure in Metabolic Syndrome as Assessed by Carotid IMT|Unknown status|Active, not recruiting|Early Phase 1|100|Anticipated|University of Washington||1|||f||||t||||||||||2018-06-01 03:54:19.815015|2018-06-01 03:54:19.815015
NCT00350181|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2010-10-07|2006-07-05|2006-07-10|Estimate|||||||2010-10-07|2010-10-08|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|April 2010|Actual|2010-04-30|August 2007|Actual|2007-08-31||Interventional|||Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant|Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplantation|Completed||Phase 2|38|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 03:54:19.90198|2018-06-01 03:54:19.90198
NCT00350168|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2016-11-16|2006-07-07|2006-07-10|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension|An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension|Completed||Phase 3|647|Actual|Novartis|||||f||||||||||||||2018-06-01 03:54:19.959813|2018-06-01 03:54:19.959813
NCT00350155|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2007-12-12|2006-07-05|2006-07-10|Estimate|||||||2007-12-12|2007-12-13|Estimate|May 2006||2006-05-31|December 2007|2007-12-31||||||||Interventional|||Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel|A 16-Day, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Trial Comparing Lumiracoxib 100mg o.d. With Naproxen 500 mg b.i.d. Plus Omeprazole 20mg o.d. and Placebo in Healthy Volunteers to Investigate on the Safety and Tolerability of Lumiracoxib in the Small Bowel.|Completed||Phase 4|150||Novartis|||||f||||||||||||||2018-06-01 03:54:20.015929|2018-06-01 03:54:20.015929
NCT00350142|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2013-12-06||2016-12-26|2006-07-05|2006-07-10|Estimate|2014-08-06|2014-08-22|Estimate||||2016-12-26|2017-02-14|Actual|April 2006||2006-04-30|December 2016|2016-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer|Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer|Completed||Phase 2|20|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 03:54:20.07818|2018-06-01 03:54:20.07818
NCT00350129|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2008-09-25|2006-07-07|2006-07-10|Estimate|||||||2008-09-25|2008-09-26|Estimate|December 2002||2002-12-31|September 2008|2008-09-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Observational|||Effect of Glucose on Ocular Blood Flow|Influence of Plasma Glucose Levels on Retinal Vascular Diameter and Choroidal Blood Flow in Vasospastic Subjects|Completed|||24|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-06-01 03:54:20.227775|2018-06-01 03:54:20.227775
NCT00350116|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2006-07-06|2006-07-06|2006-07-10|Estimate|||||||2006-07-06|2006-07-10|Estimate|January 2001||2001-01-31|July 2006|2006-07-31|December 2004||2004-12-31|||||Interventional|||Topical Vitamin B12 in Chronic Plaque Psoriasis|Topical Vitamin B12 in Chronic Plaque Psoriasis|Completed||Phase 3|48||Ruhr University of Bochum|||||f||||||||||||||2018-06-01 03:54:20.282468|2018-06-01 03:54:20.282468
NCT00350103|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2014-09-19|2006-07-06|2006-07-10|Estimate|||||||2014-09-19|2014-09-22|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy|A Multicenter, Randomized, Double-blind, Placebo Controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy Using Two Different Titration Schemes|Completed||Phase 3|537|Anticipated|UCB Pharma|||||f||||||||||||||2018-06-01 03:54:20.333841|2018-06-01 03:54:20.333841
NCT00350090|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2011-05-17|2006-07-07|2006-07-10|Estimate|||||||2011-05-17|2011-05-19|Estimate|September 2002||2002-09-30|March 2010|2010-03-31|March 2004|Actual|2004-03-31|||||Interventional|||A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.|A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin Alfa) at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy|Terminated||Phase 3|98|Actual|Ortho Biotech Products, L.P.||||This study was stopped early due to slow enrollment.|f||||f||||||||||2018-06-01 03:54:20.389578|2018-06-01 03:54:20.389578
NCT00350077|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2011-12-19|2006-07-06|2006-07-10|Estimate|||||||2011-12-19|2011-12-20|Estimate|July 2006||2006-07-31|December 2011|2011-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|Vitamin C||The Effect of High Dose Vitamin C in Burn Patients|The Effect of High Dose Versus Low Dose Intravenous Vitamin C (Ascorbic Acid)on Burn Injury Resuscitation|Withdrawn||N/A|0|Actual|United States Army Institute of Surgical Research||||Inadequate resources to submit for approval|f||||f||||||||||2018-06-01 03:54:20.541386|2018-06-01 03:54:20.541386
NCT00350064|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-08-07|2006-07-06|2006-07-10|Estimate|||||||2008-08-07|2008-08-08|Estimate|April 2004||2004-04-30|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|June 2006|Anticipated|2006-06-30||Interventional|||Impact of Exercise Training Intensity on Abdominal Visceral Fat and Risk Factors Associated With the Metabolic Syndrome|Impact of Exercise Training Intensity on Abdominal Visceral Fat and Risk Factors Associated With the Metabolic Syndrome|Unknown status|Active, not recruiting|N/A|165|Anticipated|University of Virginia|||||f||||f||||||||||2018-06-01 03:54:20.631152|2018-06-01 03:54:20.631152
NCT00350051|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2014-12-02|2006-07-07|2006-07-10|Estimate|||||||2014-12-02|2014-12-04|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer|Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer|Completed||Phase 2|53|Actual|Bayer||1|||f||||f||||||||||2018-06-01 03:54:20.727915|2018-06-01 03:54:20.727915
NCT00350038|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2008-01-18|2006-07-07|2006-07-10|Estimate|||||||2008-01-18|2008-01-23|Estimate|February 2005||2005-02-28|January 2008|2008-01-31|August 2007||2007-08-31|||||Interventional|||Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions|Investigations of the Effects of Aprovel, Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry.|Completed||Phase 4|60||Sanofi|||||f||||||||||||||2018-06-01 03:54:20.852927|2018-06-01 03:54:20.852927
NCT00350025|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|2016-12-21||2017-02-14|2006-07-07|2006-07-10|Estimate|2017-02-14|2017-03-31|Actual||||2017-02-14|2017-03-31|Actual|August 2006||2006-08-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|July 2010|Actual|2010-07-31||Interventional|||Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer|Randomized Phase II Trial of Cetuximab With and Without Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer|Completed||Phase 2|41|Actual|Fox Chase Cancer Center||2|||f||||t||||||||||2018-06-01 03:54:20.961223|2018-06-01 03:54:20.961223
NCT00350012|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2016-02-22|2006-07-06|2006-07-10|Estimate|||||||2016-02-22|2016-02-24|Estimate|May 2004||2004-05-31|February 2016|2016-02-29|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|||Spatial Neglect and Bias in Near and Far Space|Spatial Neglect and Bias in Near and Far Space|Unknown status|Recruiting||950|Anticipated|Kessler Foundation|||2||f||||t||||||||||2018-06-01 03:54:21.529924|2018-06-01 03:54:21.529924
NCT00349999|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2013-09-05|2006-07-06|2006-07-10|Estimate|||||||2013-09-05|2013-09-09|Estimate|June 2008||2008-06-30|October 2009|2009-10-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Observational|||Protective Immunity to Human Cholera in Bangladesh|Protective Immunity to Human Cholera in Bangladesh-EGD Substudy|Completed|||125|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Duodenal biopsy samples and blood.~   "|||2018-06-01 03:54:21.598628|2018-06-01 03:54:21.598628
NCT00349986|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2009-12-04|2006-07-07|2006-07-10|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 2006||2006-09-30|December 2009|2009-12-31||||June 2007|Actual|2007-06-30||Interventional|||LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus|The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients|Terminated||Phase 4|4|Actual|Sanofi||||prematurely terminated due to loss of interest|f||||||||||||||2018-06-01 03:54:21.656361|2018-06-01 03:54:21.656361
NCT00349973|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-01-11|2006-07-05|2006-07-10|Estimate|||||||2013-01-11|2013-01-14|Estimate|May 2001||2001-05-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2008|Actual|2008-09-30||Interventional|||Clinical Trial of Dipyridamole in Schizophrenia|Clinical Trial of Dipyridamole in Schizophrenia|Completed||N/A|29|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 03:54:21.717902|2018-06-01 03:54:21.717902
NCT00349960|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2006-07-06|2006-07-06|2006-07-10|Estimate|||||||2006-07-06|2006-07-10|Estimate|March 2004||2004-03-31|February 2006|2006-02-28|December 2005||2005-12-31|||||Interventional|||Epoetin Dosing Regimens in Haemodialysis|Once-Weekly Versus Once-Fortnightly Subcutaneous Epoetin Beta Administration in the Maintenance Phase of Anaemia Treatment in Haemodialyzed Patients|Completed||N/A|200||Romanian Society of Nephrology|||||f||||||||||||||2018-06-01 03:54:21.795574|2018-06-01 03:54:21.795574
NCT00349947|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2013-06-05|2006-07-06|2006-07-10|Estimate|||||||2013-06-05|2013-06-07|Estimate|November 2006||2006-11-30|June 2013|2013-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|AAA:STOP||Exercise Therapy to Treat Adults With Abdominal Aortic Aneurysms|Abdominal Aortic Aneurysms: Simple Treatment or Prevention (AAA: STOP)|Completed||Phase 1|2400|Anticipated|Stanford University||2|||f||||t||||||||||2018-06-01 03:54:21.864717|2018-06-01 03:54:21.864717
NCT00349934|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2010-01-06|2006-07-07|2006-07-10|Estimate|||||||2010-01-06|2010-01-07|Estimate|July 2006||2006-07-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|November 2009|Actual|2009-11-30||Interventional|||IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma|IMP321 Phase I Study in Metastatic Breast Carcinoma Patients Receiving First-line Paclitaxel|Completed||Phase 1|33|Actual|Immutep S.A.||1|||f||||f||||||||||2018-06-01 03:54:21.939912|2018-06-01 03:54:21.939912
NCT00349921|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2009-05-12||2017-11-03|2006-07-05|2006-07-10|Estimate|2014-01-08|2014-02-26|Estimate||||2017-11-03|2017-11-07|Actual|August 2004||2004-08-31|May 2017|2017-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Clonidine Versus Adenosine to Treat Neuropathic Pain|Clonidine Versus Adenosine to Treat Neuropathic Pain|Completed||Phase 2|24|Actual|Wake Forest University Health Sciences||4|||f||||t||||||||||2018-06-01 03:54:22.033702|2018-06-01 03:54:22.033702
NCT00349908|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|2011-02-02||2014-05-28|2006-07-06|2006-07-10|Estimate|2013-08-05|2013-10-11|Estimate||||2014-05-28|2014-06-30|Estimate|September 2006||2006-09-30|May 2014|2014-05-31|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|||A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries|A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries|Completed||Phase 1|20|Actual|Codman & Shurtleff||2|||f||||f||||||||||2018-06-01 03:54:22.324241|2018-06-01 03:54:22.324241
NCT00349895|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2014-04-07|2006-07-06|2006-07-10|Estimate|||||||2014-04-07|2014-04-08|Estimate|August 2006||2006-08-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2008|Actual|2008-01-31||Interventional|||Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth|Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth. A Clinical, Multi-center, Prospective, Non-Randomized Study|Completed||Phase 4|100|Actual|OrbusNeich|||||f||||t||||||||||2018-06-01 03:54:22.677036|2018-06-01 03:54:22.677036
NCT00349882|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2006-07-05|2006-07-05|2006-07-10|Estimate|||||||2006-07-05|2006-07-10|Estimate|June 2005||2005-06-30|July 2006|2006-07-31||||||||Interventional|||Effects of Contact Lens Care Regimens on the Corneal Epithelium|Effects of Contact Lens Care Regimens on the Corneal Epithelium|Completed||Phase 4|30||University of Waterloo|||||f||||||||||||||2018-06-01 03:54:22.775666|2018-06-01 03:54:22.775666
NCT00349869|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2017-09-22|2006-07-06|2006-07-10|Estimate|||||||2017-09-22|2017-09-26|Actual|August 2006||2006-08-31|September 2017|2017-09-30|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Yoga for Rheumatoid Arthritis|Yoga for Persons With Rheumatoid Arthritis|Completed||N/A|75|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 03:54:22.823336|2018-06-01 03:54:22.823336
NCT00349856|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2009-02-17|2006-07-05|2006-07-10|Estimate|||||||2009-02-17|2009-02-18|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Dispensing Overnight Study in Lenses|Dispensing Overnight Study in Lenses|Completed||Phase 3|40|Actual|University of Waterloo||1|||f||||f||||||||||2018-06-01 03:54:22.901594|2018-06-01 03:54:22.901594
NCT00349843|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2015-12-15|2006-07-05|2006-07-10|Estimate|||||||2015-12-15|2015-12-16|Estimate|June 2005||2005-06-30|December 2015|2015-12-31||||||||Interventional|||Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort|Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort With Daily Wear FDA Group IV Hydrogel Lenses|Completed||Phase 4|30||University of Waterloo|||||f||||||||||||||2018-06-01 03:54:23.003727|2018-06-01 03:54:23.003727
NCT00349830|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2016-07-11|2006-07-05|2006-07-10|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2002||2002-01-31|July 2016|2016-07-31||||January 2022|Anticipated|2022-01-31||Observational|||Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy|Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy|Recruiting|||2000|Anticipated|Stanford University|||||f||||||||||Samples Without DNA|"~     blood~   "|||2018-06-01 03:54:23.077319|2018-06-01 03:54:23.077319
NCT00349817|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2006-07-06|2006-07-06|2006-07-10|Estimate|||||||2006-07-06|2006-07-10|Estimate|October 2005||2005-10-31|July 2006|2006-07-31|January 2007||2007-01-31|||||Interventional|||Genetics Education: Preparing Physicians for the Future||Unknown status|Recruiting|N/A|64||University of Toronto|||||f||||||||||||||2018-06-01 03:54:23.170023|2018-06-01 03:54:23.170023
NCT00349804|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2012-03-09|2006-07-05|2006-07-10|Estimate|||||||2012-03-09|2012-03-12|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Intermittent Cold and Dry Air Underneath Football Shoulder Pads|Intermittent Cold and Dry Air Underneath Football Shoulder Pads as a Method to Assist in Temperature Homeostasis: Evaluation of Efficacy|Completed||Phase 3|15|Actual|University of Florida||1|||f||||||||||||||2018-06-01 03:54:23.225727|2018-06-01 03:54:23.225727
NCT00349791|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2013-04-15|2006-07-07|2006-07-10|Estimate|||||||2013-04-15|2013-04-17|Estimate|June 2002||2002-06-30|April 2013|2013-04-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido|A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 24 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.|Completed||Phase 3|549|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:54:24.237599|2018-06-01 03:54:24.237599
NCT00349778|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2017-04-26||2017-11-08|2006-07-05|2006-07-10|Estimate|2017-11-08|2017-12-12|Actual||||2017-11-08|2017-12-12|Actual|August 2006||2006-08-31|November 2017|2017-11-30|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional||all patients who proceeded to transplant on trial|High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma|High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma|Completed||Phase 2|102|Actual|Stanford University||1|||f||||t|t|f|||f|||No||2018-06-01 03:54:24.314355|2018-06-01 03:54:24.314355
NCT00349765|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-09-12|2006-07-06|2006-07-10|Estimate|||||||2007-09-12|2007-09-14|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|February 2006||2006-02-28|||||Interventional|||Effects of Various Higher Fat and Lower Fat Snacks on Cardiovascular Risk Factors in Men and Women.|Cardiovascular Health Effects of Isocaloric Substitution of Polyunsaturated Fat Rich Snacks for Saturated and Trans Fat or Refined Carbohydrate Snacks in Moderately Hypercholesterolemic Individuals.|Completed||Phase 2|42||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 03:54:24.472826|2018-06-01 03:54:24.472826
NCT00349752|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2010-07-01||2014-08-26|2006-07-06|2006-07-10|Estimate|2010-10-29|2010-12-01|Estimate||||2014-08-26|2014-09-05|Estimate|November 2006||2006-11-30|October 2010|2010-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|COSPAR1||Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease|A Phase IIIb Multicenter, Double-blind, Placebo-controlled,Randomized Trial to Examine the Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease.|Terminated||Phase 3|174|Actual|UCB Pharma|Recruitment was stopped early due to slow enrolment of this population. With no safety concerns, the study continued normally for the 174 subjects already recruited. Results should be treated with caution due to the early termination of this study.|2||"Recruitment was stopped early due to slow enrolment of this population. With no safety~   concerns, the study continued normally for subjects already recruited"|f||||f||||||||||2018-06-01 03:54:24.566129|2018-06-01 03:54:24.566129
NCT00349739|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2010-01-14|2006-07-06|2006-07-10|Estimate|||||||2010-01-14|2010-01-15|Estimate|January 2003||2003-01-31|January 2010|2010-01-31|August 2008|Anticipated|2008-08-31|||||Expanded Access|||Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate|Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension|No longer available|||||University of Iowa|||||||||||||||||||2018-06-01 03:54:25.236263|2018-06-01 03:54:25.236263
NCT00349726|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2017-06-19|2006-07-06|2006-07-10|Estimate|||||||2017-06-19|2017-06-20|Actual|June 2006||2006-06-30|June 2017|2017-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|INS-1||Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants|Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants|Completed||Phase 2|74|Actual|NICHD Neonatal Research Network||4|||f||||t|t|f||||||||2018-06-01 03:54:25.30546|2018-06-01 03:54:25.30546
NCT00349713|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|2016-12-20||2017-04-25|2006-07-06|2006-07-10|Estimate|2017-04-25|2017-07-24|Actual||||2017-04-25|2017-07-24|Actual|November 2004||2004-11-30|April 2017|2017-04-30|December 2006|Actual|2006-12-31|December 2005|Actual|2005-12-31||Interventional|||FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali|Double Blind Randomized, Controlled Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the WRAIR AMA1 Malaria Antigen (FMP2.1) Adjuvanted in GSK's AS02A Versus Rabies Vaccine in Malaria-experienced Adults in Bandiagara, Mali|Completed||Phase 1|60|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||Yes|"Plan to share data with~National Institute of Allergy and Infectious Diseases (NIAID)~Walter Reed Army Institute of Research (WRAIR)~GlaxoSmithKline~University of Maryland"|2018-06-01 03:54:25.456197|2018-06-01 03:54:25.456197
NCT00349700|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2016-05-05|2006-07-07|2006-07-10|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 2003||2003-01-31|July 2006|2006-07-31|May 2005||2005-05-31|||||Interventional|||Wound Dressings Adapted to Wound Exudate and Bacterial Load in Therapy Resistant Large Sized Leg Ulcers|An Open Prospective Controlled Trial: Efficiency of Wound Dressings Adapted to Wound Exudate and Bacterial Load in Therapy Resistant Large Sized Leg Ulcers|Completed||N/A|139||Ruhr University of Bochum|||||f||||||||||||||2018-06-01 03:54:26.499921|2018-06-01 03:54:26.499921
NCT00349687|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2011-11-22|2006-07-06|2006-07-10|Estimate|||||||2011-11-22|2011-11-23|Estimate|May 2004||2004-05-31|November 2011|2011-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Practicing Self-Control Lowers the Risk of Smoking Lapse|Practicing Self-Control Lowers the Risk of Smoking Lapse|Completed||Phase 1/Phase 2|120|Actual|University at Albany|||||f||||f||||||||||2018-06-01 03:54:26.562371|2018-06-01 03:54:26.562371
NCT00349674|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2007-10-09|2006-07-06|2006-07-07|Estimate|||||||2007-10-09|2007-10-10|Estimate|January 1999||1999-01-31|October 2007|2007-10-31||||||||Interventional|||WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides|Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial|Unknown status|Active, not recruiting|Phase 3|126||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:54:26.620625|2018-06-01 03:54:26.620625
NCT00349310|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-10-31|2006-07-05|2006-07-06|Estimate|||||||2013-10-31|2013-11-01|Estimate|April 2006||2006-04-30|October 2013|2013-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Profile of Depressive Symptoms in Parkinsons Disease|Profile of Depressive Symptoms in Parkinson's Disease (PRODEST-PD)|Completed|||1018||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:54:31.894011|2018-06-01 03:54:31.894011
NCT00349661|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-08-22|2006-07-06|2006-07-07|Estimate|||||||2008-08-22|2008-08-25|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel|Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel Associated To Aspirin: Double-Blind Randomized Trial Against Placebo|Completed||Phase 3|120|Anticipated|University Hospital, Brest|||||f||||||||||||||2018-06-01 03:54:26.691299|2018-06-01 03:54:26.691299
NCT00349648|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2006-07-06|2006-07-06|2006-07-07|Estimate|||||||2006-07-06|2006-07-07|Estimate|March 2001||2001-03-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||Conservative or Operative Treatment for the Shoulder Impingement Syndrome?|Conservative or Operative Treatment for the Shoulder Impingement Syndrome? A Randomized Controlled Trial of 140 Patients Followed Up for Two Years.|Unknown status|Active, not recruiting|N/A|140||Central Hospital of Kanta-Hame|||||f||||||||||||||2018-06-01 03:54:26.766193|2018-06-01 03:54:26.766193
NCT00349635|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2007-08-31|2006-07-06|2006-07-07|Estimate|||||||2007-08-31|2007-09-03|Estimate|October 2004||2004-10-31|August 2007|2007-08-31||||||||Interventional|||A Controlled-Study on the Effect of a Combination of Fenofibrate and Metformin on Weight Loss and Weight Loss-Maintenance, in Obese Patients.|A Double-Blind, 3-Arm Study on Weight Loss With a Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Per Day Compared to Metformin 1,700 mg and to Placebo, at 6 Months, in Obese Patients, Followed by: A Double-Blind, 2-Arm Investigation of Weight-Loss Maintenance With the Same Combination of Micronised Fenofibrate 267 mg and Metformin 1,700 mg Compared to Placebo, at 6 Months, in the Responders.|Completed||Phase 2|148||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 03:54:26.831246|2018-06-01 03:54:26.831246
NCT00349622|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2013-10-23||2014-04-01|2006-07-05|2006-07-07|Estimate|2014-02-14|2014-04-01|Estimate||||2014-04-01|2014-04-21|Estimate|July 2006||2006-07-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Clinical Trial Ceftriaxone in Subjects With ALS|Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 3|513|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 03:54:26.941148|2018-06-01 03:54:26.941148
NCT00349596|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2014-10-13|2006-07-06|2006-07-07|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2006||2006-07-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)|Phase I Study of Low Dose 5-Aza-2'-Deoxycytidine Administered Daily for 5 Days Every Other Week for Patients With Relapsed or Refractory Acute Lymphocytic Leukemia|Completed||Phase 1|40|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:54:27.860963|2018-06-01 03:54:27.860963
NCT00349583|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2007-05-30|2006-07-05|2006-07-07|Estimate|||||||2007-05-30|2007-06-01|Estimate||||May 2007|2007-05-31||||||||Interventional|||Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation|Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:27.929151|2018-06-01 03:54:27.929151
NCT00349570|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2008-10-20|2006-07-05|2006-07-07|Estimate|||||||2008-10-20|2008-10-21|Estimate|August 2006||2006-08-31|October 2008|2008-10-31|March 2008|Actual|2008-03-31|||||Interventional|||Xtract™ Aspiration Catheter Registry Study|Xtract™ Aspiration Catheter Registry Study|Completed||N/A|||Lumen Biomedical|||||f||||f||||||||||2018-06-01 03:54:27.996521|2018-06-01 03:54:27.996521
NCT00349557|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2014-07-15|2006-07-06|2006-07-07|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2006||2006-04-30|July 2014|2014-07-31||||||||Interventional|||Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer|Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer|Completed||Phase 2|18|Anticipated|Benaroya Research Institute|||||||||||||||||||2018-06-01 03:54:28.068393|2018-06-01 03:54:28.068393
NCT00349544|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-05-07|2006-07-06|2006-07-07|Estimate|||||||2008-05-07|2008-05-09|Estimate|October 2005||2005-10-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|||||Observational|||Validation of the Spanish Version of the Neck Disability Index|Validation of the Transcultural Adaptation of the Neck Disability Index in the Spanish Population|Completed|||221|Actual|Kovacs Foundation|||||f||||t||||||||||2018-06-01 03:54:28.151092|2018-06-01 03:54:28.151092
NCT00349531|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2012-05-18|2006-07-06|2006-07-07|Estimate|||||||2012-05-18|2012-05-21|Estimate|July 2006||2006-07-31|May 2012|2012-05-31||||May 2007|Actual|2007-05-31||Interventional|||A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS|A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome|Completed||Phase 4|369|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:54:28.231804|2018-06-01 03:54:28.231804
NCT00349518|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2016-02-16|2006-07-06|2006-07-07|Estimate|||||||2016-02-16|2016-02-17|Estimate|December 2006||2006-12-31|April 2011|2011-04-30||||January 2007|Actual|2007-01-31||Interventional|||Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL|A Phase II Study of Dasatinib (BMS-354825) in Subjects With Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib|Withdrawn||Phase 2/Phase 3|0|Actual|Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 03:54:28.375725|2018-06-01 03:54:28.375725
NCT00349505|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2006-10-05|2006-07-06|2006-07-07|Estimate|||||||2006-10-05|2006-10-06|Estimate|September 2004||2004-09-30|September 2006|2006-09-30||||||||Interventional|||Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma|Phase II Study of Intra-Peritoneal Hyper-Thermic Chemotherapy as Consolidation Therapy for Advanced Epithelial Ovarian Carcinoma|Unknown status|Recruiting|Phase 2|67||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 03:54:28.456027|2018-06-01 03:54:28.456027
NCT00349492|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-12-03|2006-07-05|2006-07-07|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|October 2013|Actual|2013-10-31|December 2011|Actual|2011-12-31||Interventional|||A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer|Randomized, Phase III Trial Comparing Etoposide/Cisplatin (EP) With Irinotecan/Cisplatin (IP) in Patients With Previously Untreated, Extensive Disease (ED) Small Cell Lung Cancer (SCLC)|Completed||Phase 3|372|Anticipated|Clinical Research Center for Solid Tumor, Korea||1|||f||||||||||||||2018-06-01 03:54:28.51273|2018-06-01 03:54:28.51273
NCT00349479|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-02-22|2006-07-05|2006-07-07|Estimate|||||||2013-02-22|2013-02-25|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|INSTINCT||Increasing Stroke Treatment Through Interventional Change Tactics Study|Clinical Trial to Increase t-PA Use in Stroke Treatment|Completed||N/A|24|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 03:54:28.591213|2018-06-01 03:54:28.591213
NCT00349297|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2010-05-11|2006-07-05|2006-07-06|Estimate|||||||2010-05-11|2010-05-12|Estimate|November 2003||2003-11-30|May 2010|2010-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||The Microbiological Spectrum in Acute Dacryocystitis||Completed|||||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:31.982319|2018-06-01 03:54:31.982319
NCT00349466|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|2011-06-20||2015-02-12|2006-07-06|2006-07-07|Estimate|2011-07-19|2011-08-12|Estimate||||2015-02-12|2015-03-04|Estimate|January 2007||2007-01-31|August 2011|2011-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca|A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Keratoconjunctivitis Sicca|Completed||Phase 2|80|Actual|Can-Fite BioPharma||2|||f||||f||||||||||2018-06-01 03:54:28.685045|2018-06-01 03:54:28.685045
NCT00349453|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2011-12-09|2006-07-06|2006-07-07|Estimate|||||||2011-12-09|2011-12-12|Estimate|March 2005||2005-03-31|December 2011|2011-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients|Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients|Completed||Phase 2|24|Actual|Lipomed||2|||f||||f||||||||||2018-06-01 03:54:28.980064|2018-06-01 03:54:28.980064
NCT00349440|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2008-09-23|2006-07-05|2006-07-07|Estimate|||||||2008-09-23|2008-09-26|Estimate|September 2006||2006-09-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy|Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy|Completed||Phase 4|93|Actual|Innovative Medical||2|||f||||||||||||||2018-06-01 03:54:29.071874|2018-06-01 03:54:29.071874
NCT00349427|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2012-05-31|2006-07-06|2006-07-07|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2005||2005-10-31|February 2011|2011-02-28||||||||Interventional|||A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients|A Randomized, Double-Blind, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin|Completed||Phase 3|256|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 03:54:29.135581|2018-06-01 03:54:29.135581
NCT00349414|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-05-13|2006-07-06|2006-07-07|Estimate|||||||2008-05-13|2008-05-15|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma|A Comparison of the Safety and Efficacy of Conventional Versus Micropulse Transscleral Diode Laser Cyclophotocoagulation in Refractory Glaucoma|Unknown status|Recruiting|Phase 1/Phase 2|70|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 03:54:29.21426|2018-06-01 03:54:29.21426
NCT00349401|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2017-11-01|2006-07-05|2006-07-07|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2006||2006-12-31|May 2009|2009-05-31||||||||Interventional|||Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation|Intrathecal Ketorolac in Patients With Intrathecal Morphine Dose Escalation|Withdrawn||Phase 2|0|Actual|Wake Forest University Health Sciences||||Study was not initiated. No subjects were screened or enrolled.|||||||||||||||2018-06-01 03:54:29.280289|2018-06-01 03:54:29.280289
NCT00349388|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2014-07-24||2014-08-13|2006-07-05|2006-07-07|Estimate|2014-08-13|2014-08-15|Estimate||||2014-08-13|2014-08-15|Estimate|July 2006||2006-07-31|August 2014|2014-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||No patients enrolled into intervention arm due to lack of enrollment.Only 1 subject was enrolled in Control arm. Therefore no data can be compared for study outcome|Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients|A Randomized Trial Comparing Once Daily Dosing vs. Multiple Doses a Day of Mesalamine in Pediatric Patients With Quiescent Ulcerative Colitis|Terminated||N/A|1|Actual|Atlantic Health System|No subjects were analysed due to lack of enrollment. No subject was enrolled into the once a day dosing arm to answer our primary or secondary outcomes.|2||none enrolled in second arm, therfore no analysis|f||||f||||||||||2018-06-01 03:54:29.341878|2018-06-01 03:54:29.341878
NCT00349375|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2009-07-07|2006-07-06|2006-07-07|Estimate|||||||2009-07-07|2009-07-08|Estimate|November 2005||2005-11-30|July 2009|2009-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy|A Multicenter, Double-Blind, Randomized, Active Comparator, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 20 mg Simvastatin Alone|Completed||Phase 3|1040|Actual|Solvay Pharmaceuticals||3|||f||||||||||||||2018-06-01 03:54:29.53001|2018-06-01 03:54:29.53001
NCT00349362|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2010-03-29|2006-07-06|2006-07-07|Estimate|||||||2010-03-29|2010-03-30|Estimate|July 2006||2006-07-31|March 2010|2010-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Testosterone for Men With Insulin Treated Type 2 Diabetes|A Randomised Double Blind Placebo Controlled, Parallel Pilot Study to Test the Effect of Testosterone Replacement on Glycaemic Control and Arterial Wall Properties of Hypogonadal Men With Type 2 Diabetes Treated With Insulin|Completed||Phase 4|40|Anticipated|Barnsley Hospital||2|||f||||||||||||||2018-06-01 03:54:29.726633|2018-06-01 03:54:29.726633
NCT00349349|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|2011-10-20||2014-05-29|2006-07-06|2006-07-07|Estimate|2011-10-20|2011-11-29|Estimate||||2014-05-29|2014-06-04|Estimate|June 2006||2006-06-30|June 2013|2013-06-30|June 2012|Actual|2012-06-30|May 2008|Actual|2008-05-31||Interventional|||HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab|A Single-arm, International, Multi-center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab|Completed||Phase 2|223|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:54:29.846807|2018-06-01 03:54:29.846807
NCT00349336|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|2009-06-02||2012-09-12|2006-07-06|2006-07-07|Estimate|2010-02-10|2010-02-26|Estimate||||2012-09-12|2012-09-18|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.|A Randomized, Open Label Trial to Assess the Steady State Pharmacokinetics of Avastin Given With Either XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer|Completed||Phase 3|64|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:54:31.2198|2018-06-01 03:54:31.2198
NCT00349323|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-06|||2008-05-07|2006-07-06|2006-07-07|Estimate|||||||2008-05-07|2008-05-08|Estimate|August 2006||2006-08-31|February 2008|2008-02-29|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Observational|||Community Directed Treatment of Soil-Transmitted Helminths Among Young Children in Zambia|Community-Directed Treatment in the Control of Soil-Transmitted Helminths Among Children Aged 12-59 Months in Mazabuka District of Zambia|Completed|||100|Anticipated|DBL -Institute for Health Research and Development|||||f||||f||||||||||2018-06-01 03:54:31.828637|2018-06-01 03:54:31.828637
NCT00349284|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2007-08-31|2006-07-05|2006-07-06|Estimate|||||||2007-08-31|2007-09-03|Estimate|January 2005||2005-01-31|August 2007|2007-08-31||||||||Interventional|||A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome|A Randomised, Double-Blind Study Comparing the Efficacy and Safety of 145 mg Fenofibrate, 10 mg Ezetimibe and Their Combination in Patients With Type IIb Dyslipidemia and Features of the Metabolic Syndrome|Completed||Phase 3|181||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 03:54:32.031484|2018-06-01 03:54:32.031484
NCT00349271|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2017-03-09|2006-07-05|2006-07-06|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2006||2006-01-31|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Cell Therapy in Chagas Cardiomyopathy|Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Chagas Cardiomyopathy|Terminated||Phase 3|182|Actual|Ministry of Health, Brazil||2||Change the sample size due to smaller variance than expected|f||||||||||||||2018-06-01 03:54:32.159182|2018-06-01 03:54:32.159182
NCT00349258|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2006-07-05|2006-07-05|2006-07-06|Estimate|||||||2006-07-05|2006-07-06|Estimate|August 2004||2004-08-31|February 2006|2006-02-28|May 2006||2006-05-31|||||Interventional|||The Use of GnRH Agonist Trigger in the Prevention of OHSS|A Prospective Randomized Study Comparing the Use of hCG or GnRH Agonist to Trigger Final Oocyte Maturation in High Responders Undergoing in-Vitro Fertilization Treatment|Completed||Phase 4|66||UConn Health|||||f||||||||||||||2018-06-01 03:54:32.232067|2018-06-01 03:54:32.232067
NCT00349245|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2016-03-22|2006-07-05|2006-07-06|Estimate|||||||2016-03-22|2016-03-23|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Dexmedetomidine vs. Remifentanil for Sedation During AFI|A Randomized, Double-Blind Comparison Of Dexmedetomidine And Remifentanil For Sedation During Awake Fiberoptic Intubations|Completed||Phase 4|30|Actual|The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 03:54:32.293295|2018-06-01 03:54:32.293295
NCT00349232|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2006-07-06|2006-07-04|2006-07-06|Estimate|||||||2006-07-06|2006-07-10|Estimate|July 2006||2006-07-31|July 2006|2006-07-31|July 2007||2007-07-31|||||Interventional|||Lifestyle Intervention in Obese Children Attending Special Primary Education.|Prevalence of Overweight and Obesity in Children Attending Special Primary Education and the Effect of a Lifestyle Intervention.|Unknown status|Not yet recruiting|Phase 1/Phase 2|100||University College of Antwerp|||||f||||||||||||||2018-06-01 03:54:32.370172|2018-06-01 03:54:32.370172
NCT00349219|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2016-01-14|2006-07-04|2006-07-06|Estimate|||||||2016-01-14|2016-01-15|Estimate|December 2006||2006-12-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|TORCH||TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer|An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer|Completed||Phase 3|760|Actual|National Cancer Institute, Naples||2|||f||||t||||||||||2018-06-01 03:54:32.446657|2018-06-01 03:54:32.446657
NCT00349206|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2014-04-09|2006-07-05|2006-07-06|Estimate|||||||2014-04-09|2014-04-10|Estimate|April 2006||2006-04-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma|Phase 1 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma|Completed||Phase 1|69|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:54:32.622387|2018-06-01 03:54:32.622387
NCT00349193|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2011-04-07|2006-07-05|2006-07-06|Estimate|||||||2011-04-07|2011-04-08|Estimate|March 2005||2005-03-31|April 2011|2011-04-30|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|||A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod|A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects|Completed||Phase 2|306|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 03:54:32.707585|2018-06-01 03:54:32.707585
NCT00349180|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2009-03-26|2006-07-04|2006-07-06|Estimate|||||||2009-03-26|2009-03-27|Estimate|June 2006||2006-06-30|March 2009|2009-03-31||||||||Interventional|||Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)|Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement|Completed||Phase 3|156||Sanofi|||||f||||||||||||||2018-06-01 03:54:32.771542|2018-06-01 03:54:32.771542
NCT00349167|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2012-11-29|2006-07-05|2006-07-06|Estimate|||||||2012-11-29|2012-11-30|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||PR-104 in Treating Patients With Advanced Solid Tumors|A Phase I, Multi-Center, Open Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR-104 Given Every 3 Weeks in Patients With Solid Tumors|Completed||Phase 1|27|Actual|Proacta, Incorporated||1|||f||||f||||||||||2018-06-01 03:54:32.89917|2018-06-01 03:54:32.89917
NCT00349141|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2015-10-07|2006-07-05|2006-07-06|Estimate|||||||2015-10-07|2015-10-09|Estimate|June 2006||2006-06-30|October 2007|2007-10-31||||||||Interventional|||Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)|A Phase I/II Dose Escalation Study of a Vero Cell-Derived, Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 45 Years|Completed||Phase 1/Phase 2|270||Ology Bioservices|||||f||||||||||||||2018-06-01 03:54:32.970217|2018-06-01 03:54:32.970217
NCT00349128|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2007-08-31|2006-07-05|2006-07-06|Estimate|||||||2007-08-31|2007-09-03|Estimate|January 2004||2004-01-31|August 2007|2007-08-31||||||||Interventional|||Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes|A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia.|Completed||Phase 2/Phase 3|382||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 03:54:33.04136|2018-06-01 03:54:33.04136
NCT00349115|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2008-05-05|2006-07-04|2006-07-06|Estimate|||||||2008-05-05|2008-05-06|Estimate|June 2006||2006-06-30|July 2006|2006-07-31|June 2008|Anticipated|2008-06-30|||||Interventional|||TCD Followed by autoSCT for Newly Diagnosed MM Patients|Induction Therapy With TCD Regimen (Thalidomide, Cyclophosphamide, Dexamethasone) Followed by Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients|Unknown status|Recruiting|Phase 2|43|Anticipated|Korean Multiple Myeloma Working Party|||||f||||||||||||||2018-06-01 03:54:33.213607|2018-06-01 03:54:33.213607
NCT00349102|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2017-01-31|2006-07-05|2006-07-06|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2006|Actual|2006-07-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2012|Actual|2012-01-31||Interventional|||Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer|Evaluation of the Interest of Breath Holding for the Prevention of Radiation Pneumonitis Following Conformal Radiation Therapy|Completed||Phase 3|242|Actual|Centre Leon Berard||2|||f||||t||||||||||2018-06-01 03:54:33.294518|2018-06-01 03:54:33.294518
NCT00349089|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2011-05-02|2006-07-04|2006-07-06|Estimate|||||||2011-05-02|2011-05-03|Estimate|October 2006||2006-10-31|May 2011|2011-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy|Adjuvant Chemotherapy With Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin in NSCLC IB, IIA, IIB, T3N1: a Randomized Phase II Study|Unknown status|Active, not recruiting|Phase 2|134|Anticipated|Thoraxklinik am Universitätsklinikum Heidelberg||2|||f||||t||||||||||2018-06-01 03:54:33.392248|2018-06-01 03:54:33.392248
NCT00349076|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2016-07-29|2006-07-05|2006-07-06|Estimate|||||||2016-07-29|2016-08-01|Estimate|July 2006||2006-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer|Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rectal Cancer|Completed||Phase 3|1256|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||||||||||||2018-06-01 03:54:33.540012|2018-06-01 03:54:33.540012
NCT00349063|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2006-07-17|2006-07-04|2006-07-06|Estimate|||||||2006-07-17|2006-07-19|Estimate|July 2005||2005-07-31|July 2006|2006-07-31||||||||Interventional|||Contact Lens Wettability|The Impact of Short Term Wearing Time on In Vivo and Ex Vivo Wettability|Completed||Phase 4|55||University of Waterloo|||||f||||||||||||||2018-06-01 03:54:33.742804|2018-06-01 03:54:33.742804
NCT00349050|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2012-04-26|2006-07-05|2006-07-06|Estimate|||||||2012-04-26|2012-04-30|Estimate|July 2006||2006-07-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception|Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception|Withdrawn||Phase 2/Phase 3|0|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 03:54:33.809846|2018-06-01 03:54:33.809846
NCT00349037|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2007-01-25|2006-07-05|2006-07-06|Estimate|||||||2007-01-25|2007-01-29|Estimate|September 2006||2006-09-30|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Study of the Ability of a Flu Vaccine to Prevent Flu Infection|A Prospective, Randomised, Double Blind, Placebo-Controlled Study to Assess the Efficacy of a Trivalent (A/New Caledonia/20/99, A/Panama/2007/99, B/Jiangsu/10/20) DNA Influenza Vaccine Administered by Particle Mediated Epidermal Delivery (PMED) Against a Controlled Influenza Virus Challenge.|Completed||Phase 1|105||PowderMed|||||f||||||||||||||2018-06-01 03:54:33.892844|2018-06-01 03:54:33.892844
NCT00349024|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-09-19|2006-07-05|2006-07-06|Estimate|||||||2013-09-19|2013-09-20|Estimate|July 2005||2005-07-31|June 2009|2009-06-30||||December 2009|Anticipated|2009-12-31||Interventional|||Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer|Efficacy of Gelclair™ in Reducing the Pain of Oral Mucositis in Children and Young People With Cancer (SC 2005 07)|Unknown status|Active, not recruiting|N/A|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:54:33.97231|2018-06-01 03:54:33.97231
NCT00349011|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2006-07-05|2006-07-05|2006-07-06|Estimate|||||||2006-07-05|2006-07-06|Estimate|August 2002||2002-08-31|July 2006|2006-07-31|March 2004||2004-03-31|||||Interventional|||Genetic Counseling for Menopausal Therapy Decision-Making for Women at Increased Risk for Breast Cancer|Menopausal Therapy in Women at Increased Risk for Breast Cancer: Does a Personalized Risk Assessment and Counseling Intervention Aid in Decision-Making?|Completed||N/A|60||Yale University|||||f||||||||||||||2018-06-01 03:54:34.083649|2018-06-01 03:54:34.083649
NCT00348998|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-11-05|2006-07-05|2006-07-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|April 2006||2006-04-30|November 2008|2008-11-30||||||||Interventional|||Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer|Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|18|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:54:34.140328|2018-06-01 03:54:34.140328
NCT00348985|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-05-01|2006-07-05|2006-07-06|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2006||2006-03-31|May 2013|2013-05-31||||January 2010|Actual|2010-01-31||Interventional|||PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas|A Phase 1 Study of PXD101 in Combination With Bortezomib (PS-341) in Patients With Advanced Solid Tumors and Lymphoma|Completed||Phase 1|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:54:34.203832|2018-06-01 03:54:34.203832
NCT00348972|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2006-07-04|2006-07-04|2006-07-06|Estimate|||||||2006-07-04|2006-07-06|Estimate|February 2002||2002-02-28|July 2006|2006-07-31||||||||Interventional|||Lantus in Prediabetes|Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)|Completed||Phase 1|20||Sanofi|||||||||||||||||||2018-06-01 03:54:34.286631|2018-06-01 03:54:34.286631
NCT00348959|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2012-06-12|2006-07-05|2006-07-06|Estimate|||||||2012-06-12|2012-06-13|Estimate|August 2006||2006-08-31|June 2012|2012-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation|An Evaluation of the Effect of 'Open Window', an Art Intervention, on Psychological Well-being and Experience of Stem Cell Transplantation for the Treatment of Haematological Malignancies|Completed||N/A|198|Actual|St. James's Hospital, Ireland|||||f||||f||||||||||2018-06-01 03:54:34.341812|2018-06-01 03:54:34.341812
NCT00348946|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2016-10-18|2006-07-05|2006-07-06|Estimate|||||||2016-10-18|2016-10-19|Estimate|July 2006||2006-07-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Androgen Effect on Klinefelter Syndrome Motor Outcome|Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome|Active, not recruiting||Phase 2|150|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 03:54:34.398027|2018-06-01 03:54:34.398027
NCT00348933|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|2011-06-16||2012-09-21|2006-07-03|2006-07-06|Estimate|2012-09-21|2012-09-24|Estimate||||2012-09-21|2012-09-24|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Dietary Supplements for the Treatment of Angelman Syndrome|Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome|Completed||N/A|90|Actual|University of California, San Diego||1|||f||||t||||||||||2018-06-01 03:54:34.488028|2018-06-01 03:54:34.488028
NCT00348920|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2013-07-22|2006-07-05|2006-07-06|Estimate|||||||2013-07-22|2013-07-24|Estimate|February 2007||2007-02-28|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Effects of High Spinal Anesthesia on Heart Function, Stress Response and Pain Control in Aortic Valve Surgery|The Effects of High Spinal Anesthesia on Hemodynamics, Stress Response, Renal Function and Post-operative Pain Control in Patients Undergoing Aortic Valve Replacement for Aortic Stenosis|Completed||N/A|14|Actual|University of Manitoba||2|||f||||t||||||||||2018-06-01 03:54:34.740238|2018-06-01 03:54:34.740238
NCT00348907|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2007-10-31|2006-07-05|2006-07-06|Estimate|||||||2007-10-31|2007-11-01|Estimate|July 2006||2006-07-31|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Interventional|||EVENT: Hydrotherapy and Deep Venous Thrombosis|Evaluation of the Efficacy of the Thermal Cure in the Prevention of the Post-Thrombotic Syndrome After a Deep Venous Thrombosis of Lower Limbs.|Terminated||Phase 3|3|Actual|Association Francaise pour la Recherche Thermale||2||decision to stop the study because of enrollment difficulties.|f||||f||||||||||2018-06-01 03:54:34.820145|2018-06-01 03:54:34.820145
NCT00348894|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2011-05-31|2006-07-04|2006-07-06|Estimate|||||||2011-05-31|2011-06-01|Estimate|July 2006||2006-07-31|May 2011|2011-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.|A Phase 2b Long-Term, Randomized, Open-Label, Safety And Tolerability Trial Comparing [S,S]-Reboxetine (PNU-165442g) With Routine Care In Patients With Chronic Painful Diabetic Peripheral Neuropathy (DPN).|Terminated||Phase 2|136|Actual|Pfizer||2||"- Study was terminated due to insufficient clinical efficacy observed in previous studies~   conducted in postherpetic neuralgia."|f||||f||||||||||2018-06-01 03:54:34.919041|2018-06-01 03:54:34.919041
NCT00348881|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2013-06-10||2013-08-15|2006-07-05|2006-07-06|Estimate|2013-08-15|2013-10-22|Estimate||||2013-08-15|2013-10-22|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|June 2008|Actual|2008-06-30|October 2007|Actual|2007-10-31||Interventional|||Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants|Large Scale Safety and Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix HepB/Hib™, Both Given Concomitantly With OPV at 6, 10, and 14 Weeks of Age in Healthy Filipino Infants|Completed||Phase 3|2133|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:54:35.096505|2018-06-01 03:54:35.096505
NCT00348868|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2008-03-14|2006-07-05|2006-07-06|Estimate|||||||2008-03-14|2008-03-18|Estimate|July 2006||2006-07-31|April 2007|2007-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Buprenorphine HIV Care Integration Project|Miami Buprenorphine HIV Care Integration Project|Completed||N/A|10|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 03:54:36.457354|2018-06-01 03:54:36.457354
NCT00348855|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2011-11-12|2006-07-05|2006-07-06|Estimate|||||||2011-11-12|2011-11-15|Estimate|November 2006||2006-11-30|November 2011|2011-11-30|March 2010|Actual|2010-03-31|September 2009|Actual|2009-09-30||Interventional|ESCAPE||Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice|Effects of a Series of Intensified Prevention Consultations on the Changes in Goals and Risk Factors in Hypertensive Patients at High Cardiovascular Risk|Completed||Phase 4|1836|Actual|Collège National des Généralistes Enseignants||2|||f||||t||||||||||2018-06-01 03:54:36.5293|2018-06-01 03:54:36.5293
NCT00348842|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2011-04-07|2006-07-05|2006-07-06|Estimate|||||||2011-04-07|2011-04-08|Estimate|March 2006||2006-03-31|February 2006|2006-02-28|June 2006|Anticipated|2006-06-30|||||Interventional|||Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer Modalities|Phase II: Safety and Primary Efficacy of Clinical Application of Newcastle Disease Virus for the Treatment of Patients Resistant to All Conventional Modalities|Withdrawn||Phase 2|||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:54:36.618622|2018-06-01 03:54:36.618622
NCT00348829|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2016-10-25|2006-07-05|2006-07-06|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2006||2006-06-30|May 2009|2009-05-31|September 2012|Actual|2012-09-30|December 2008|Actual|2008-12-31||Interventional|||Mitral Valve Reconstruction in Chronic Heart Failure (CHF): Identification of Predictors for a Successful Therapy|Mitral Valve Reconstruction in Patients With Chronic Heart Failure and Secondary Mitral Insufficiency: Identification of Predictors for a Successful Therapy|Terminated||Phase 2|5|Actual|University of Leipzig||2||not enough patients to e recruited, problems with the conductance catheter|f||||f||||||||||2018-06-01 03:54:36.671847|2018-06-01 03:54:36.671847
NCT00348816|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2017-04-05||2017-11-03|2006-07-05|2006-07-06|Estimate|2017-04-05|2017-05-15|Actual||||2017-11-03|2017-12-08|Actual|May 2006||2006-05-31|April 2017|2017-04-30|July 8, 2016|Actual|2016-07-08|July 8, 2016|Actual|2016-07-08||Interventional||21 patients were consented, 1 patient was screen failure due to lung mass found during staging.|Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer|A Phase II Study to Assess the Feasibility and Activity of Concomitant Radiation and Docetaxel Chemotherapy Followed by Docetaxel Chemotherapy in Prostate Cancer Patients With a Persistent or Rising PSA After Radical Prostatectomy|Terminated||Phase 2|21|Actual|The University of Texas Health Science Center at San Antonio||1||Loss of funding|f||||||||||||||2018-06-01 03:54:36.763422|2018-06-01 03:54:36.763422
NCT00348803|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2006-07-05|2006-07-05|2006-07-06|Estimate|||||||2006-07-05|2006-07-06|Estimate||||June 2006|2006-06-30||||||||Observational|||Gene Mutations in Secondary Pulmonary Hypertension||Unknown status|Recruiting||||Medical University of Vienna|||||f||||||||||||||2018-06-01 03:54:37.177738|2018-06-01 03:54:37.177738
NCT00348790|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2014-10-21||2014-10-21|2006-07-05|2006-07-06|Estimate|2014-10-21|2014-10-27|Estimate||||2014-10-21|2014-10-27|Estimate|May 2006||2006-05-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|November 2010|Actual|2010-11-30||Interventional|||Vatalanib in Treating Patients With Recurrent or Progressive Meningioma|A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas|Completed||Phase 2|25|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 03:54:37.257356|2018-06-01 03:54:37.257356
NCT00348777|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-04|||2011-06-21|2006-07-05|2006-07-06|Estimate|||||||2011-06-21|2011-06-22|Estimate|June 2006||2006-06-30|June 2011|2011-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||THERMARTHROSE: Gonarthrosis and Water Cure|Evaluation of the Effects of a Water Cure on Gonarthrosis: Randomized Clinical Study Including Water Cure Versus Continuation of the Usual Treatment|Completed||Phase 3|462|Actual|Association Francaise pour la Recherche Thermale||2|||f||||f||||||||||2018-06-01 03:54:37.547267|2018-06-01 03:54:37.547267
NCT00348764|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2006-07-05|2006-07-05|2006-07-06|Estimate|||||||2006-07-05|2006-07-06|Estimate|March 2004||2004-03-31|July 2006|2006-07-31|December 2006||2006-12-31|||||Interventional|||ESGVS: Sclerotherapy With Lauromacrogol|Treatment of Greater Saphenous Vein (GSV) Insufficiency Using Echo-Guided Sclerotherapy With Lauromacrogol 400 Foam –Comparative Study of 3% Versus 1% Concentration.|Completed||Phase 3|150||University Hospital, Grenoble|||||f||||||||||||||2018-06-01 03:54:37.620589|2018-06-01 03:54:37.620589
NCT00348751|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-05-07|2006-07-05|2006-07-06|Estimate|||||||2008-05-07|2008-05-08|Estimate|June 2004||2004-06-30|June 2006|2006-06-30|November 2005||2005-11-30|||||Interventional|||CholGate - The Effect of Alerting Versus on Demand Computer Based Decision Support on Treatment of Dyslipidaemia by General Practitioners|The Effect of Alerting Versus on Demand Computer Based Decision Support on Treatment of Dyslipidaemia by General Practitioners - The CholGate Randomized Trial|Completed||N/A|||Erasmus Medical Center|||||f||||||||||||||2018-06-01 03:54:37.680947|2018-06-01 03:54:37.680947
NCT00348192|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2009-05-28|2006-06-30|2006-07-04|Estimate|||||||2009-05-28|2009-06-02|Estimate|May 2006||2006-05-31|May 2009|2009-05-31||||||||Interventional|||SB-742457 And Donepezil In Alzheimer's Disease|A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|200||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:54:47.181951|2018-06-01 03:54:47.181951
NCT00348738|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2007-10-31|2006-07-05|2006-07-06|Estimate|||||||2007-10-31|2007-11-02|Estimate|July 2000||2000-07-31|October 2007|2007-10-31|July 2009|Anticipated|2009-07-31|||||Interventional|||Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome|The Influence of the Pre-Therapeutic Increase in the Hemoglobin Level in the Blood Through Erythropoietin to the Therapy Results of the Primary Radiation Therapy for Carcinoma of the Cervix|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 03:54:37.737857|2018-06-01 03:54:37.737857
NCT00348725|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2007-08-31|2006-07-05|2006-07-06|Estimate|||||||2007-08-31|2007-09-03|Estimate|April 2005||2005-04-30|August 2007|2007-08-31||||||||Interventional|||Acceptability of a Fixed Combination of Fenofibrate and Metformin|An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia|Completed||Phase 3|69||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 03:54:37.832527|2018-06-01 03:54:37.832527
NCT00348712|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2017-02-28|2006-07-05|2006-07-06|Estimate|||||||2017-02-28|2017-03-01|Actual|October 30, 2006|Actual|2006-10-30|February 2017|2017-02-28|March 5, 2008|Actual|2008-03-05|March 5, 2008|Actual|2008-03-05||Interventional|||Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes|Efficacy and Safety of Inhaled Pre-prandial Human Insulin Plus Metformin Versus Rosiglitazone Plus Metformin in Type 2 Diabetes|Terminated||Phase 3|301|Actual|Novo Nordisk A/S||2||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:54:37.939071|2018-06-01 03:54:37.939071
NCT00348699|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|||2014-02-21|2006-07-05|2006-07-06|Estimate|||||||2014-02-21|2014-02-24|Estimate|July 2006||2006-07-31|December 2011|2011-12-31||||January 2013|Actual|2013-01-31||Interventional|||AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery|A Phase I Study and Pharmacological Trial of Once Weekly Aminoflavone Prodrug (AFP464) Administered 3 Out of Every 4 Weeks in Solid Tumor Patients|Completed||Phase 1|68|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:54:38.240921|2018-06-01 03:54:38.240921
NCT00348686|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|2009-06-08||2012-03-05|2006-07-03|2006-07-06|Estimate|2012-03-05|2012-04-02|Estimate||||2012-03-05|2012-04-02|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)|A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy|Completed||Phase 4|315|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 03:54:38.339114|2018-06-01 03:54:38.339114
NCT00348673|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-05|2013-08-14||2013-08-14|2006-07-05|2006-07-06|Estimate|2013-08-14|2013-10-18|Estimate||||2013-08-14|2013-10-18|Estimate|February 2006||2006-02-28|August 2013|2013-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061|A Randomised, Double Blind, Placebo-controlled, Multicenter Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061|Completed||Phase 2|49|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:54:38.614804|2018-06-01 03:54:38.614804
NCT00348660|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2016-04-22|2006-06-30|2006-07-04|Estimate|||||||2016-04-22|2016-04-25|Estimate|August 2005||2005-08-31|April 2016|2016-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic|The Seroprevalence of Hepatitis C and Course of Infection Among Pregnant Women Attending a Toronto Inner City Antenatal Care Clinic|Completed|||653|Actual|St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 03:54:39.531845|2018-06-01 03:54:39.531845
NCT00348647|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|December 2004||2004-12-31|December 2004|2004-12-31|March 2006||2006-03-31|||||Interventional|||Prevention of Injuries by an Exercise Program – a RCT|Can Lower Extremity Overuse Injuries Be Prevented by an Exercise Program Aiming at Muscular Strength, Flexibility and Coordination – a RCT|Unknown status|Active, not recruiting|N/A|900||Amager Hospital|||||f||||||||||||||2018-06-01 03:54:39.583311|2018-06-01 03:54:39.583311
NCT00348634|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2016-03-02|2006-07-03|2006-07-04|Estimate|||||||2016-03-02|2016-03-04|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients|The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation|Terminated||Phase 4|60|Anticipated|Novartis||||Terminated early due to regulatory action suspending tegaserod use in 2007|||||||||||||||2018-06-01 03:54:39.631813|2018-06-01 03:54:39.631813
NCT00348621|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2017-10-04|2006-07-03|2006-07-04|Estimate|||||||2017-10-04|2017-10-06|Actual|June 1999||1999-06-30|October 2017|2017-10-31|June 2002|Actual|2002-06-30|December 2001|Actual|2001-12-31||Interventional|||A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents|Clinical Trial of Interventions for Visual Loss in Nursing Home Residents|Completed||Phase 4|2544|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-06-01 03:54:39.699048|2018-06-01 03:54:39.699048
NCT00348608|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-06-28|2006-06-30|2006-07-04|Estimate|||||||2007-06-28|2007-07-02|Estimate|June 2006||2006-06-30|June 2007|2007-06-30||||||||Interventional|||Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast–Enhanced CT Angiography of Arteries of the Heart||Completed||Phase 3|540||GE Healthcare|||||||||||||||||||2018-06-01 03:54:39.760626|2018-06-01 03:54:39.760626
NCT00348595|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2016-06-30|2006-06-30|2006-07-04|Estimate|||||||2016-06-30|2016-07-01|Estimate|May 2006||2006-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer|Phase I/II Double Blinded Randomized Study to Determine the Tolerability and Efficacy of 2 Different Doses of Revlimid (CC-5013, Lenalidomide) in Biochemically Relapsed Prostate Cancer Patients (M0) After Local Treatment|Completed||Phase 1/Phase 2|60|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||Undecided||2018-06-01 03:54:39.898735|2018-06-01 03:54:39.898735
NCT00348582|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-06-21|2006-06-30|2006-07-04|Estimate|||||||2007-06-21|2007-06-25|Estimate||||June 2007|2007-06-30||||||||Interventional|||Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery|Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:39.984024|2018-06-01 03:54:39.984024
NCT00348569|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-08-15|2006-06-30|2006-07-04|Estimate|||||||2007-08-15|2007-08-16|Estimate|May 2006||2006-05-31|August 2007|2007-08-31||||||||Interventional|||A Study of Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain|A Prospective, Multicenter Study of GE LightSpeed Volume Computed Tomography (CT) for Evaluation of Coronary Artery Blockages in Typical or Atypical Chest Pain Patients Suspected of Coronary Artery Disease|Completed||N/A|304||GE Healthcare|||||f||||||||||||||2018-06-01 03:54:40.063826|2018-06-01 03:54:40.063826
NCT00348556|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2012-09-14||2017-10-03|2006-07-03|2006-07-04|Estimate|2012-09-14|2012-10-17|Estimate||||2017-10-03|2017-11-06|Actual|December 2005||2005-12-31|October 2017|2017-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure|Efficacy of Intra-renal Infusion of BNP in Enhancing Renal Function in Human CHF With Cardiorenal Syndrome: A Pilot Study|Terminated||Phase 1/Phase 2|4|Actual|Mayo Clinic|The study was terminated early because the company providing catheter was bought out, and funding and supplies were terminated.|1||Company providing catheter bought out, funding and supplies terminated|f||||t||||||||||2018-06-01 03:54:40.133134|2018-06-01 03:54:40.133134
NCT00348543|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2011-08-03|2006-07-03|2006-07-04|Estimate|||||||2011-08-03|2011-08-05|Estimate|December 1999||1999-12-31|October 1999|1999-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Prophylactic Laser Treatment of Drusen Maculopathy|Prophylactic Laser Treatment of Drusen Maculopathy in Age-related Macular Degeneration.|Completed||N/A|150||University Hospital, Linkoeping|||||f||||||||||||||2018-06-01 03:54:40.301429|2018-06-01 03:54:40.301429
NCT00348530|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-10-17|2006-07-03|2006-07-04|Estimate|||||||2006-10-17|2006-10-18|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|December 2007||2007-12-31|||||Interventional|||Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy|Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy|Unknown status|Recruiting|Phase 4|120||Medical University of Silesia|||||f||||||||||||||2018-06-01 03:54:40.364547|2018-06-01 03:54:40.364547
NCT00348517|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2012-03-02|2006-06-30|2006-07-04|Estimate|||||||2012-03-02|2012-03-05|Estimate|July 2006||2006-07-31|March 2012|2012-03-31|November 2006||2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety/Efficacy of Systane Free vs Refresh Liquigel|An Evaluation of the Safety and Efficacy of Systane Free FID 105783|Completed||N/A|100|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 03:54:40.440868|2018-06-01 03:54:40.440868
NCT00348504|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-11-16|2006-06-30|2006-07-04|Estimate|||||||2007-11-16|2007-11-20|Estimate|March 2003||2003-03-31|November 2007|2007-11-30|June 2005|Actual|2005-06-30|||||Interventional|||Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.|Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.|Completed||Phase 3|1300||Abbott|||||f||||||||||||||2018-06-01 03:54:40.50607|2018-06-01 03:54:40.50607
NCT00348491|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2017-02-21|2006-07-03|2006-07-04|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2006||2006-02-28|February 2017|2017-02-28||||May 2006|Actual|2006-05-31||Interventional|||Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib|A Randomized, Double-blind, Double-dummy, Parallel Group, Single-center Study Evaluating the Analgesic Effect of Single Doses of Lumiracoxib 400 mg, Celecoxib 400 mg and Placebo in the Treatment of Post-dental Surgery Pain|Completed||Phase 4|364||Novartis|||||||||||||||||||2018-06-01 03:54:40.586582|2018-06-01 03:54:40.586582
NCT00348478|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2011-10-27|2006-07-03|2006-07-04|Estimate|||||||2011-10-27|2011-10-28|Estimate|December 2005||2005-12-31|November 2005|2005-11-30|January 2008||2008-01-31|||||Interventional|||Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger|Determination of the Impact of Water and Health Education on Trachoma and Ocular C. Trachomatis in Niger|Completed||Phase 4|720||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:54:40.656754|2018-06-01 03:54:40.656754
NCT00348465|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2018-04-04|2006-07-03|2006-07-04|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2006|Actual|2006-05-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Observational|||Prostate Volume Changes Following Prostate Brachytherapy With Iodine-125 Seeds|An Observational Study to Evaluate the Changes in Prostate Volume Over Time With The Use of Transrectal Ultrasound and Computed Tomography Following Permanent Prostate Brachytherapy With Iodine-125 Seeds.|Completed|||29|Actual|New York Methodist Hospital|||||f||||t||||||||||2018-06-01 03:54:40.72085|2018-06-01 03:54:40.72085
NCT00348452|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2012-06-20|2006-07-03|2006-07-04|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2002||2002-09-30|June 2012|2012-06-30|August 2003||2003-08-31|||||Interventional|||A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100 mg, 200 mg and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA)|Double-blind, Randomized, Dose-ranging, Parallel-group Comparison of the Efficacy and Safety of Extended Release Tramadol Hydrochloride (Tramadol HCl ER) 100 mg, 200 mg, 300 mg, Celecoxib 200 mg and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip.|Completed||Phase 3|1000||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:54:40.776121|2018-06-01 03:54:40.776121
NCT00348439|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2011-12-07|2006-06-30|2006-07-04|Estimate|||||||2011-12-07|2011-12-08|Estimate|April 2006||2006-04-30|December 2011|2011-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment|A Multicenter, Randomized, Double Masked, Placebo Controlled, Sequential Dose Response Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)|Terminated||Phase 2|29|Actual|Bausch & Lomb Incorporated||2||Lack of Efficacy|f||||t||||||||||2018-06-01 03:54:40.827357|2018-06-01 03:54:40.827357
NCT00348426|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-02|||2006-11-07|2006-07-02|2006-07-04|Estimate|||||||2006-11-07|2006-11-08|Estimate|June 2006||2006-06-30|November 2006|2006-11-30|September 2006||2006-09-30|||||Observational|||Botulism Outbreak in Thailand (Episode II)|Clinical Manifestations of Botulism Outbreak in Northern Thailand: A Case Series of Botulism Treated With Botulinum Anti-Toxin.|Completed|||200||Rajavithi Hospital|||||f||||||||||||||2018-06-01 03:54:40.905234|2018-06-01 03:54:40.905234
NCT00348413|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2010-05-11|2006-07-03|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|June 2003||2003-06-30|May 2010|2010-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Thyroid Treatment Trial|Comparison of Efficacy and Safety of Intravenous Pulsed Methylprednisolone and Oral Methotrexate Versus Intravenous Pulsed Methylprednisolone and Oral Placebo in the Treatment of Active Moderate and Severe Thyroid Eye Disease - a Prospective, Randomized, Double-blind, Parallel, Controlled Multidisciplinary Clinical Trial and Imaging Study.|Completed||N/A|80|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:41.001092|2018-06-01 03:54:41.001092
NCT00348400|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-05-30|2006-06-30|2006-07-04|Estimate|||||||2007-05-30|2007-06-01|Estimate||||May 2007|2007-05-31||||||||Interventional|||Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost|Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:41.119449|2018-06-01 03:54:41.119449
NCT00348387|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2014-01-20|2006-07-03|2006-07-04|Estimate|||||||2014-01-20|2014-01-22|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV||Completed||Phase 3|600|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:54:41.186013|2018-06-01 03:54:41.186013
NCT00348374|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2009-08-03||2010-03-02|2006-06-30|2006-07-04|Estimate|2010-03-02|2010-03-16|Estimate||||2010-03-02|2010-03-16|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes|A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Trial Assessing The Efficacy Of Exubera Vs. Lispro Introduced Into A Lantus Based Regimen In Suboptimally Controlled Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|191|Actual|Pfizer|Due to cancellation of the EXUBERA program the sample size was too small to adequately address the inferential objectives of this study. Descriptive statistics for the PSIT Questionnaire and the markers of cardiovascular risk were not provided.|2|||f||||f||||||||||2018-06-01 03:54:41.430141|2018-06-01 03:54:41.430141
NCT00348361|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-10-09|2006-06-30|2006-07-04|Estimate|||||||2008-10-09|2008-10-13|Estimate|April 2005||2005-04-30|October 2008|2008-10-31||||||||Interventional|||Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)|A Study to Validate Key Therapeutic Targets and Biomarkers During Allergen Exposure in Subjects With Allergic Rhinitis|Completed||Phase 1|48||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:54:43.404462|2018-06-01 03:54:43.404462
NCT00348348|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2009-06-30||2015-03-04|2006-06-30|2006-07-04|Estimate|2009-06-30|2009-08-13|Estimate||||2015-03-04|2015-03-24|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis|Completed||Phase 3|1161|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:54:43.497947|2018-06-01 03:54:43.497947
NCT00348335|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2011-07-28|2006-06-30|2006-07-04|Estimate|||||||2011-07-28|2011-07-29|Estimate|June 2006||2006-06-30|July 2011|2011-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy of Topical Cyclosporin for Ocular Rosacea|Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea|Completed||Phase 4|35|Actual|Ophthalmic Consultants of Long Island||2|||f||||t||||||||||2018-06-01 03:54:43.838126|2018-06-01 03:54:43.838126
NCT00348322|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-09-23|2006-06-30|2006-07-04|Estimate|||||||2008-09-23|2008-09-25|Estimate|July 2006||2006-07-31|September 2008|2008-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety/Efficacy of Systane Free vs Refresh Tears|An Evaluation of the Safety and Efficacy of Systane Free FID 105783 - II|Completed||N/A|100||Alcon Research|||||f||||||||||||||2018-06-01 03:54:43.907403|2018-06-01 03:54:43.907403
NCT00348309|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2017-04-21|2010-03-29|2017-10-23|2006-06-30|2006-07-04|Estimate|2017-10-23|2017-11-28|Actual|2010-04-22|2010-05-03|Estimate|2017-10-23|2017-11-28|Actual|July 6, 2006||2006-07-06|September 2017|2017-09-30|January 28, 2009|Actual|2009-01-28|January 1, 2009|Actual|2009-01-01||Interventional|REFLECT-2||Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease|A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.|Completed||N/A|1496|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:54:44.091249|2018-06-01 03:54:44.091249
NCT00348296|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2010-07-28|2006-07-03|2006-07-04|Estimate|||||||2010-07-28|2010-07-30|Estimate|July 2006||2006-07-31|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis|A Randomized, Double-blind, Placebo-controlled Multi-center Study of GB-0998 for Treatment of Systemic Sclerosis|Completed||Phase 3|60|Anticipated|Benesis Corporation|||||f||||||||||||||2018-06-01 03:54:46.128332|2018-06-01 03:54:46.128332
NCT00348283|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2009-09-15||2011-04-07|2006-06-30|2006-07-04|Estimate|2010-01-06|2010-02-11|Estimate||||2011-04-07|2011-04-11|Estimate|August 2006||2006-08-31|April 2011|2011-04-30||||September 2008|Actual|2008-09-30||Interventional|||Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon|Completed||Phase 3|135|Actual|Abbott||2|||f||||f||||||||||2018-06-01 03:54:46.268528|2018-06-01 03:54:46.268528
NCT00348270|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2010-05-11|2006-07-03|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|July 2005||2005-07-31|May 2010|2010-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses|Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 Three-piece Silicone Posterior Chamber Intraocular Lens and Alcon Laboratories MA60 Acrysof Three-piece Acrylic Posterior Chamber Intraocular Lens|Completed||Phase 4|80|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:46.716979|2018-06-01 03:54:46.716979
NCT00348257|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-02|||2007-02-27|2006-07-02|2006-07-04|Estimate|||||||2007-02-27|2007-02-28|Estimate|July 2006||2006-07-31|February 2007|2007-02-28|September 2006||2006-09-30|||||Interventional|||Safety and Efficacy of Using LEORTEC-300 System For Hair Removal Treatment|Safety and Efficacy of Using LEORTEC-300 System For Hair Removal Treatment|Completed||Phase 1/Phase 2|30||Leortec Medical Systems Ltd|||||f||||t||||||||||2018-06-01 03:54:46.765837|2018-06-01 03:54:46.765837
NCT00348244|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-01-15|2006-06-30|2006-07-04|Estimate|||||||2007-01-15|2007-01-17|Estimate||||January 2007|2007-01-31||||||||Interventional|||Ketorolac vs. Steroid in the Prevention of CME|A Masked Comparison of Acular LS Plus Steroid Versus Steroid Alone for the Prevention of Macular Leakage in Cataract Patients|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:46.877465|2018-06-01 03:54:46.877465
NCT00348231|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-08-31|2006-07-03|2006-07-04|Estimate|||||||2006-08-31|2006-09-01|Estimate|November 2004||2004-11-30|June 2006|2006-06-30|August 2006||2006-08-31|||||Interventional|||Jikei Optimal Insulin Therapy in Type 2 Diabetes||Unknown status|Recruiting|N/A|60||Jikei University School of Medicine|||||f||||||||||||||2018-06-01 03:54:46.940374|2018-06-01 03:54:46.940374
NCT00348218|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2010-05-10|2006-07-03|2006-07-04|Estimate|||||||2010-05-10|2010-05-12|Estimate|June 2006||2006-06-30|May 2010|2010-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Pilot Study of Neurovision to Improve Vision and Slow Myopia Progression in Children With Myopia|Pilot Study To Evaluate The Efficacy Of Neurovision'S NVC™- Vision Correction Technology For The Improvement In Visual Acuity In Myopic Children And Slowing Down Of Myopia Progression|Completed||Phase 1|30|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:47.006142|2018-06-01 03:54:47.006142
NCT00348205|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30||2010-04-09|2012-12-20|2006-07-03|2006-07-04|Estimate||||2010-04-09|2010-04-22|Estimate|2012-12-20|2012-12-28|Estimate|June 2005||2005-06-30|December 2012|2012-12-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia||Completed||N/A|97|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 03:54:47.107301|2018-06-01 03:54:47.107301
NCT00348166|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2011-10-03|2006-07-03|2006-07-04|Estimate|||||||2011-10-03|2011-10-05|Estimate|December 2005||2005-12-31|October 2011|2011-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children?|Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten|Withdrawn||Phase 1|180|Anticipated|KK Women's and Children's Hospital||||Stringent eligibility criterion caused difficulties in recruiting patients.|f||||||||||||||2018-06-01 03:54:47.364462|2018-06-01 03:54:47.364462
NCT00348153|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2012-11-30|2006-07-03|2006-07-04|Estimate|||||||2012-11-30|2012-12-03|Estimate|August 2006||2006-08-31|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)|Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients With Different Forms of Refractory Uveitis Acronym: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)|Unknown status|Active, not recruiting|Phase 2/Phase 3|40|Anticipated|Heidelberg University||2|||f||||||||||||||2018-06-01 03:54:47.428557|2018-06-01 03:54:47.428557
NCT00348140|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2017-04-21|2010-03-29|2017-08-03|2006-06-30|2006-07-04|Estimate|2017-08-03|2017-09-05|Actual|2010-04-22|2010-05-03|Estimate|2017-08-03|2017-09-05|Actual|July 12, 2006|Actual|2006-07-12|August 2017|2017-08-31|March 20, 2009|Actual|2009-03-20|March 20, 2009|Actual|2009-03-20||Interventional|REFLECT-3||Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease|A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 3|1468|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:54:47.725617|2018-06-01 03:54:47.725617
NCT00348127|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2010-06-23|2006-07-03|2006-07-04|Estimate|||||||2010-06-23|2010-06-24|Estimate|March 2003||2003-03-31|January 2010|2010-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Singapore Pilot Study to Assess Neurovision in Treatment of Low Myopia|A Singapore Pilot Study To Evaluate The Efficacy Of A Computerized System For The Vision Improvement Of People With Low Myopia|Completed||Phase 1|||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:52.210704|2018-06-01 03:54:52.210704
NCT00348114|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|May 2002||2002-05-31|January 2002|2002-01-31|May 2006||2006-05-31|||||Interventional|||Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency|Transplantation of Ex-Vivo Expanded Human Limbal Epithelial Stem Cells (LSC) on Amniotic Membrane (AM) for Limbal Stem Cell Deficiency (LSCD).|Suspended||Phase 2|8||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:52.278144|2018-06-01 03:54:52.278144
NCT00348101|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2007-05-29|2006-07-03|2006-07-04|Estimate|||||||2007-05-29|2007-05-30|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation|The Influence of Continuous Perioperative Beta-Blocker Therapy in Combination With Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation and Myocardial Ischaemia in High-Risk Vascular Surgery Patients|Completed||Phase 3|75|Actual|Klinikum Ludwigshafen|||||f||||f||||||||||2018-06-01 03:54:52.329776|2018-06-01 03:54:52.329776
NCT00348088|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2012-12-12|2006-06-30|2006-07-04|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2006||2006-05-31|December 2012|2012-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Melanoma Biomarker Study|CXCL1 Biomarker Study in Metastatic Melanoma|Completed|||20|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 03:54:52.390928|2018-06-01 03:54:52.390928
NCT00348075|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2010-05-11|2006-07-03|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|January 2004||2004-01-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Singapore Study to Assess How Neurovision Improve the Vision of Adults With Low to Moderate Myopia|A Singapore Study To Evaluate The Efficacy OF Neurovision'S NVC™- Vision Correction Technology For The Visual Improvement In Subjects With Low Or Moderate Adult Myopia|Completed||N/A|||Singapore National Eye Centre||1|||f||||||||||||||2018-06-01 03:54:52.448812|2018-06-01 03:54:52.448812
NCT00348062|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-05-30|2006-06-30|2006-07-04|Estimate|||||||2007-05-30|2007-06-01|Estimate||||May 2007|2007-05-31||||||||Interventional|||A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension|A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:52.522171|2018-06-01 03:54:52.522171
NCT00348049|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-10-23|2006-07-03|2006-07-04|Estimate|||||||2006-10-23|2006-10-24|Estimate|November 2002||2002-11-30|October 2002|2002-10-31|August 2005||2005-08-31|||||Interventional|||Efficacy of LASIK Versus PRK in Asians With Mild and Moderate Myopia|A Prospective, Randomized Trial Evaluating the Operational Efficacy of LASIK vs. PRK for the Correction of Low and Moderate Myopia in the Singapore Armed Forces|Completed||N/A|||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:52.579849|2018-06-01 03:54:52.579849
NCT00348036|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2013-04-29|2006-06-30|2006-07-04|Estimate|||||||2013-04-29|2013-04-30|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Group Intervention for Interpersonal Trauma|Trauma Interventions for Low-income Women in Primary Care|Completed||N/A|27|Actual|Georgetown University||2|||f||||f||||||||||2018-06-01 03:54:52.647385|2018-06-01 03:54:52.647385
NCT00348023|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-02-07|2006-06-30|2006-07-04|Estimate|||||||2007-02-07|2007-02-09|Estimate||||February 2007|2007-02-28||||||||Interventional|||Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension|Comparison of Bimatoprost 0.03% Monotherapy vs. Dual Therapy With Travoprost 0.004% and Timolol 0.5% in Patients With Glaucoma and Ocular Hypertension|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:52.776435|2018-06-01 03:54:52.776435
NCT00348010|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-02|||2012-06-20|2006-07-02|2006-07-04|Estimate|||||||2012-06-20|2012-06-21|Estimate|November 2000||2000-11-30|June 2012|2012-06-30|July 2001||2001-07-31|||||Interventional|||A Study Comparing the Effectiveness and Safety of Extended Release Tramadol Versus Placebo for the Treatment of Osteoarthritis (OA) of the Knee|Double-blind, Randomized, Dose-titration, Parallel-group Comparison of the Efficacy and Safety of Extended Release Tramadol Hydrochloride (Tramadol HCl ER) and Placebo in the Treatment of Osteoarthritis of the Knee.|Completed||Phase 3|245||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:54:52.890562|2018-06-01 03:54:52.890562
NCT00347997|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2011-12-07|2006-07-03|2006-07-04|Estimate|||||||2011-12-07|2011-12-08|Estimate||||December 2011|2011-12-31||||||||Interventional|||A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix for Lasik||Withdrawn||N/A|0|Actual|Bausch & Lomb Incorporated||1||Decision made by B&L to cancel the study, no subjects enrolled.|f||||f||||||||||2018-06-01 03:54:52.957988|2018-06-01 03:54:52.957988
NCT00347984|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2012-04-07|2006-07-03|2006-07-04|Estimate|||||||2012-04-07|2012-04-10|Estimate|December 2005||2005-12-31|August 2008|2008-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Product Preference With Systane Compared to Artificial Tears on Frequency of Drop Use|The Effect of Systane® Compared to Marketed Artificial Tears on Frequency of Drop Use|Completed||N/A|50||Alcon Research|||||f||||||||||||||2018-06-01 03:54:53.038663|2018-06-01 03:54:53.038663
NCT00347971|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-09-04|2006-06-30|2006-07-04|Estimate|||||||2008-09-04|2008-09-05|Estimate|June 2006||2006-06-30|September 2008|2008-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma|Phase 1, Open-Label, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered in Combination With Rituxan (Rituximab) in Subjects With B-Cell Non Hodgkin's Lymphoma|Completed||Phase 1|23|Actual|ZymoGenetics|||||f||||||||||||||2018-06-01 03:54:53.118546|2018-06-01 03:54:53.118546
NCT00347958|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|2010-05-14||2013-11-11|2006-07-03|2006-07-04|Estimate|2010-06-22|2010-07-22|Estimate||||2013-11-11|2013-12-04|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Interventional|||Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine|Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose|Completed||Phase 4|545|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:54:53.252793|2018-06-01 03:54:53.252793
NCT00347945|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|October 2000||2000-10-31|January 2002|2002-01-31|November 2001||2001-11-30|||||Interventional|||Randomized Trial of Treatments for Convergence Insufficiency|A Randomized Clinical Trial of Pencil Push-Ups Versus Office Based Vision Therapy For the Treatment of Convergence Insufficiency|Completed||Phase 3|90||Pennsylvania College of Optometry|||||f||||||||||||||2018-06-01 03:54:53.604096|2018-06-01 03:54:53.604096
NCT00347932|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2009-06-29||2015-03-04|2006-06-30|2006-07-04|Estimate|2009-08-12|2009-08-13|Estimate||||2015-03-04|2015-03-24|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.|A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.|Completed||Phase 3|957|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:54:53.693243|2018-06-01 03:54:53.693243
NCT00347919|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2009-11-19||2016-01-28|2006-07-03|2006-07-04|Estimate|2011-01-22|2011-02-21|Estimate||||2016-01-28|2016-02-25|Estimate|July 2006||2006-07-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|August 2008|Actual|2008-08-31||Interventional|||Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer|A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors|Completed||Phase 2|189|Actual|GlaxoSmithKline|In 2008 at primary completion, study was terminated. In 2011, protocol amendment 4 (Am4), allowed continuation of treatment until PD for the 1 par. This par. completed the study per Am 4. Par. last visit occurred, the study is considered completed.|3|||f||||f||||||||||2018-06-01 03:54:54.046403|2018-06-01 03:54:54.046403
NCT00347906|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2010-01-11|2006-07-03|2006-07-04|Estimate|||||||2010-01-11|2010-01-12|Estimate|November 2003||2003-11-30|November 2003|2003-11-30|September 2005||2005-09-30|||||Interventional|||Photodynamic Therapy (PDT) Versus Transpupillary Thermotherapy (TTT) in Occult Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (AMD)|Photodynamic Therapy Versus Transpupillary Thermotherapy in Occult CNV in Age-related Macular Degeneration|Terminated||N/A|||University Hospital, Linkoeping||||Difficulties in recruiting patients|f||||f||||||||||2018-06-01 03:54:55.241398|2018-06-01 03:54:55.241398
NCT00347893|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-06-30|2006-06-30|2006-07-04|Estimate|||||||2006-06-30|2006-07-04|Estimate|May 2006||2006-05-31|June 2006|2006-06-30||||||||Observational|||The Efficacy of Selective Laser Trabeculoplasty|Clinical Results of Selective Laser Trabeculoplasty in Treatment of Open Angle Glaucoma|Unknown status|Recruiting||||Glaucoma Research & Education Group|||||f||||||||||||||2018-06-01 03:54:55.310043|2018-06-01 03:54:55.310043
NCT00347880|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2012-03-01|2006-07-03|2006-07-04|Estimate|||||||2012-03-01|2012-03-02|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|July 2007|Actual|2007-07-31|||||Observational|||Atrial and Brain Natriuretic Peptides in Bronchiolitis|Atrial and Brain Natriuretic Peptides in Bronchiolitis|Completed|||100|Actual|University of Florida|||||f||||t||||||||||2018-06-01 03:54:55.384533|2018-06-01 03:54:55.384533
NCT00347867|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|July 2006||2006-07-31|June 2006|2006-06-30||||||||Interventional|||Viagra for the Treatment of IUGR|Improvement of Utero-Placental Perfusion and Fetal Growth in IUGR and PET by Administration of Sildenafil Citrate in Pregnancy|Unknown status|Not yet recruiting|Phase 4|20||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:54:55.462424|2018-06-01 03:54:55.462424
NCT00347854|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2016-11-18|2006-07-03|2006-07-04|Estimate|||||||2016-11-18|2016-11-22|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Fluorophotometry Evaluation of Lubricant Eye Drops|Fluorophotometry Evaluation of Lubricant Eye Drops FID 105783|Completed||N/A|40|Actual|Alcon Research||4|||f||||f||||||||||2018-06-01 03:54:55.529796|2018-06-01 03:54:55.529796
NCT00347841|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-05-30|2006-06-30|2006-07-04|Estimate|||||||2007-05-30|2007-06-01|Estimate||||May 2007|2007-05-31||||||||Interventional|||Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost|Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:55.599066|2018-06-01 03:54:55.599066
NCT00347828|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|June 2006||2006-06-30|June 2006|2006-06-30|June 2006||2006-06-30|||||Interventional|||Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose|Prospective Study Comparing the Effectiveness of Zymar and Vigamox for Preoperative Antibiotic Sterilization of the Ocular Surface After Loading Dose|Unknown status|Active, not recruiting|Phase 4|40||Ophthalmic Consultants of Boston|||||f||||||||||||||2018-06-01 03:54:55.65487|2018-06-01 03:54:55.65487
NCT00347815|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|June 2006||2006-06-30|June 2006|2006-06-30|August 2006||2006-08-31|||||Interventional|||Pharmacokinetics and Pharmacodynamics of Buprenorphine in Healthy Volunteers|Pharmacokinetics and Pharmacodynamics of Buprenorphine After Intravenous Administration in Healthy Volunteers|Unknown status|Recruiting|Phase 1|24||Danish University of Pharmaceutical Sciences|||||f||||||||||||||2018-06-01 03:54:55.715625|2018-06-01 03:54:55.715625
NCT00347802|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-05-30|2006-06-30|2006-07-04|Estimate|||||||2007-05-30|2007-06-01|Estimate||||May 2007|2007-05-31||||||||Interventional|||Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%|Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:55.76917|2018-06-01 03:54:55.76917
NCT00347776|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|2017-04-13||2017-06-27|2006-07-03|2006-07-04|Estimate|2017-06-27|2017-08-07|Actual||||2017-06-27|2017-08-07|Actual|August 2001||2001-08-31|June 2017|2017-06-30|December 2006|Actual|2006-12-31|December 2003|Actual|2003-12-31||Interventional|STAR||Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia|Trial of Antibiotics to Reduce Recurrent Trichiasis (STAR)|Completed||Phase 4|1452|Actual|Johns Hopkins University|1.Azithromycin administered was observed.Compliance was 100%.In tetracycline group,only 1st application of ointment was observed.Data on compliance for next 6 weeks were not collected.|3|||f||||t||||||||||2018-06-01 03:54:55.98303|2018-06-01 03:54:55.98303
NCT00347763|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2013-04-12|2006-07-03|2006-07-04|Estimate|||||||2013-04-12|2013-04-15|Estimate|June 2000||2000-06-30|May 2004|2004-05-31|October 2002|Actual|2002-10-31|September 2002|Actual|2002-09-30||Interventional|||Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania|Strategies for the Control of Blinding Trachoma: Effect of Fly Spray|Completed||Phase 4|350||Johns Hopkins University||2|||f||||||||||||||2018-06-01 03:54:56.302737|2018-06-01 03:54:56.302737
NCT00347750|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2015-11-01|2006-07-03|2006-07-04|Estimate|||||||2015-11-01|2015-11-03|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations|Pharmacokinetics and Pharmacodynamics of Lopinavir an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations|Withdrawn|||0|Actual|Rambam Health Care Campus||||lack of participants|f||||||||||||||2018-06-01 03:54:56.369025|2018-06-01 03:54:56.369025
NCT00347737|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2013-01-14|2006-06-30|2006-07-04|Estimate|||||||2013-01-14|2013-01-16|Estimate|June 2006||2006-06-30|January 2013|2013-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL|The Effects of Therapy With Teriparatide (Recombinant Parathyroid Hormone (1-34) on Vascular Compliance and Osteoprotegerin/RANKL|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 03:54:56.427269|2018-06-01 03:54:56.427269
NCT00347724|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-02|||2012-06-20|2006-07-02|2006-07-04|Estimate|||||||2012-06-20|2012-06-21|Estimate|November 2000||2000-11-30|June 2012|2012-06-30|November 2001||2001-11-30|||||Interventional|||A Study Comparing the Effectiveness and Safety of Extended-release Tramadol Versus Placebo in the Treatment of Chronic Low Back Pain|Double-blind, Randomized, Placebo-controlled, Parallel Group Comparison of the Efficacy and Safety of Extended Release Tramadol (Tramadol ER) 300 mg and 200 mg to Placebo in the Treatment of Chronic Low Back Pain|Completed||Phase 3|600||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:54:56.496739|2018-06-01 03:54:56.496739
NCT00347711|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate||||June 2006|2006-06-30||||||||Interventional|||Bevacizumab and Retinal Vascular Occlusions||Unknown status|Recruiting|Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:54:56.559575|2018-06-01 03:54:56.559575
NCT00347698|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-06-30|2006-06-30|2006-07-04|Estimate|||||||2006-06-30|2006-07-04|Estimate|March 2006||2006-03-31|June 2006|2006-06-30|August 2007||2007-08-31|||||Interventional|||Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy|Intravitreal Bevacizumab Vs Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A One-Year Prospective, Contralateral Eye Study|Unknown status|Recruiting|Phase 2/Phase 3|30||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:54:56.613189|2018-06-01 03:54:56.613189
NCT00347685|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-01|||2012-06-20|2006-07-01|2006-07-04|Estimate|||||||2012-06-20|2012-06-21|Estimate|October 2000||2000-10-31|June 2012|2012-06-30|February 2003||2003-02-28|||||Interventional|||A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.|Open-label Assessment of the Safety and Effectiveness of Extended Release Tramadol (Tramadol ER) in the Treatment of Chronic Non-malignant Pain.|Completed||Phase 3|650||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:54:56.699062|2018-06-01 03:54:56.699062
NCT00347672|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2008-01-18|2006-07-03|2006-07-04|Estimate|||||||2008-01-18|2008-01-21|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults|Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic|Completed||Phase 1|42|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||f||||||||||2018-06-01 03:54:56.77619|2018-06-01 03:54:56.77619
NCT00347659|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-02-27|2006-06-30|2006-07-04|Estimate|||||||2008-02-27|2008-03-06|Estimate|June 2006||2006-06-30|February 2008|2008-02-29|September 2007|Actual|2007-09-30|December 2006|Actual|2006-12-31||Interventional|||US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study|Phase 1 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema|Completed||Phase 1|6|Actual|Aeris Therapeutics||1|||f||||t||||||||||2018-06-01 03:54:56.880479|2018-06-01 03:54:56.880479
NCT00347646|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2011-12-07|2006-06-30|2006-07-04|Estimate|||||||2011-12-07|2011-12-09|Estimate|September 2006||2006-09-30|December 2011|2011-12-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)|An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)|Terminated||Phase 1/Phase 2|4|Actual|Bausch & Lomb Incorporated||1||Lack of Efficacy|f||||t||||||||||2018-06-01 03:54:56.950313|2018-06-01 03:54:56.950313
NCT00347620|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2010-03-12|2006-06-30|2006-07-04|Estimate|||||||2010-03-12|2010-03-15|Estimate|August 2000||2000-08-31|March 2010|2010-03-31|December 2003||2003-12-31|||||Interventional|||Improving Vision and Quality of Life in the Nursing Home|Improving Vision and Quality of Life in the Nursing Home|Completed||N/A|400||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 03:54:57.011531|2018-06-01 03:54:57.011531
NCT00347607|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2011-10-27|2006-07-03|2006-07-04|Estimate|||||||2011-10-27|2011-10-28|Estimate|April 2002||2002-04-30|March 2002|2002-03-31|November 2005||2005-11-30|||||Interventional|||Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania|Cost-effectiveness of Three Alternative Azithromycin Treatment Strategies for Trachoma Control in Tanzania|Completed||Phase 4|2700||Johns Hopkins University|||||f||||||||||||||2018-06-01 03:54:57.102439|2018-06-01 03:54:57.102439
NCT00347594|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2014-01-15|2006-06-30|2006-07-04|Estimate|||||||2014-01-15|2014-01-17|Estimate|August 2005||2005-08-31|January 2014|2014-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)|A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)|Completed||N/A|76|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 03:54:57.169164|2018-06-01 03:54:57.169164
NCT00347581|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2006-07-03|2006-07-03|2006-07-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|May 2003||2003-05-31|January 2005|2005-01-31|August 2004||2004-08-31|||||Interventional|||A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children|A Randomized Clinical Trial of the Effectiveness of Base-in Prism Reading Glasses Vs. Placebo Reading Glasses for Symptomatic Convergence Insufficiency in Children|Completed||Phase 3|72||Pennsylvania College of Optometry|||||f||||||||||||||2018-06-01 03:54:57.232205|2018-06-01 03:54:57.232205
NCT00347568|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2012-06-04|2006-06-29|2006-07-04|Estimate|||||||2012-06-04|2012-06-05|Estimate|July 2006||2006-07-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|September 2007|Actual|2007-09-30||Interventional|||BC-DAISY: A Breast Cancer Decision Aid System|BC-DAISY: A Breast Cancer Decision Aid System|Completed||N/A|195|Actual|Rhode Island Hospital|||||f||||||||||||||2018-06-01 03:54:57.314512|2018-06-01 03:54:57.314512
NCT00347555|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2013-04-11|2006-06-29|2006-07-04|Estimate|||||||2013-04-11|2013-04-12|Estimate|May 2006||2006-05-31|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly|Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly|Completed||Phase 1|80|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 03:54:57.373408|2018-06-01 03:54:57.373408
NCT00347542|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2013-05-31|2006-06-30|2006-07-04|Estimate|||||||2013-05-31|2013-06-03|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||A Trial to Study the Effect of Vitamin D Supplementation on Glucose and Insulin Metabolism in Centrally Obese Men|A Double Blind Randomized Control Trial to Study the Effect of Vitamin D Supplementation on Peripheral Insulin Sensitivity in Centrally Obese Men|Completed||N/A|100||Sitaram Bhartia Institute of Science and Research|||||f||||||||||||||2018-06-01 03:54:57.449872|2018-06-01 03:54:57.449872
NCT00347529|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2007-01-25|2006-06-30|2006-07-04|Estimate|||||||2007-01-25|2007-01-29|Estimate|August 2006||2006-08-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu|A Randomised Double Blind Dose-Ranging Study to Assess the Safety, Tolerability and Immunogenicity of a Monovalent H5 DNA Influenza Vaccine (A Vietnam/1194/2004) Administered by Particle Mediated Epidermal Delivery (PMED) to Healthy Adults|Completed||Phase 1|75||PowderMed|||||f||||||||||||||2018-06-01 03:54:57.516292|2018-06-01 03:54:57.516292
NCT00347516|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2010-05-11|2006-06-30|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|December 2005||2005-12-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Comparative Study of Three IOL Power Calculation Formulae for Asian Eyes Shorter Than 22mm or Longer Than 25mm|Comparative Study of Three Intraocular Lens Power Calculation Formulae for Asian Eyes With Axial Lengths Less Than 22mm and Greater Than 25mm|Completed||N/A|210|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:57.566149|2018-06-01 03:54:57.566149
NCT00347503|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2007-07-12|2006-06-29|2006-07-04|Estimate|||||||2007-07-12|2007-07-13|Estimate||||July 2007|2007-07-31||||||||Interventional|||Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients|Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients|Completed||Phase 4|||Innovative Medical|||||f||||||||||||||2018-06-01 03:54:57.728641|2018-06-01 03:54:57.728641
NCT00347490|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-01-22|2006-06-30|2006-07-04|Estimate|||||||2008-01-22|2008-01-24|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||HENOX: Enoxaparine in Hemodialysis|Efficacy and Safety in Hemodialysis With Enoxaparine|Completed||Phase 4|100|Anticipated|Sanofi|||||f||||||||||||||2018-06-01 03:54:57.775465|2018-06-01 03:54:57.775465
NCT00347477|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2009-04-30|2006-06-30|2006-07-04|Estimate|||||||2009-04-30|2009-05-01|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|March 2009||2009-03-31|April 2007|Actual|2007-04-30||Interventional|||Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest|Fluid Shift in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest, and How do They Manage Life Afterwards?|Completed||Phase 3|23|Anticipated|Haukeland University Hospital|||||f||||||||||||||2018-06-01 03:54:57.828833|2018-06-01 03:54:57.828833
NCT00347464|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2015-12-01|2006-06-29|2006-07-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2006||2006-06-30|December 2015|2015-12-31|August 2008|Anticipated|2008-08-31|||||Observational|||Adaptive Behavior Assessment of Men With 49, XXXXY, Klinefelter Syndrome|Adaptive Behavior Assessment of Men With 49, XXXXY, Klinefelter Syndrome|Withdrawn|||0|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 03:54:57.899368|2018-06-01 03:54:57.899368
NCT00347451|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2010-05-11|2006-06-30|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|October 2005||2005-10-31|May 2010|2010-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.|Optical Coherence Tomography Imaging of the Posterior Segment in High Myopia.|Completed|||150|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:54:57.950101|2018-06-01 03:54:57.950101
NCT00347438|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|2015-10-05||2015-11-05|2006-06-29|2006-07-04|Estimate|2015-11-05|2015-12-14|Estimate||||2015-11-05|2015-12-14|Estimate|September 2006||2006-09-30|November 2015|2015-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer|A Phase II Study to Evaluate the Efficacy, Safety, and Genomic Markers of Response of Capecitabine as NeoAdjuvant Therapy in Women With Newly Diagnosed Locally Advanced Breast Cancer|Terminated||Phase 2|18|Actual|University of Chicago||1||a result of slow accrual|f||||t||||||||||2018-06-01 03:54:58.044964|2018-06-01 03:54:58.044964
NCT00347425|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-05-20|2006-06-30|2006-07-04|Estimate|||||||2008-05-20|2008-05-21|Estimate|December 2006||2006-12-31|May 2008|2008-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Switch Study of Existing Atypical Antipsychotics to Bifeprunox|A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|286|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 03:54:58.244172|2018-06-01 03:54:58.244172
NCT00347412|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2011-11-07|2006-06-29|2006-07-04|Estimate|||||||2011-11-07|2011-11-09|Estimate|November 2006||2006-11-30|March 2010|2010-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer|Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 3|880|Anticipated|Cellectar Biosciences, Inc.||2|||f||||t||||||||||2018-06-01 03:54:58.488205|2018-06-01 03:54:58.488205
NCT00347399|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-06-30|2006-06-30|2006-07-04|Estimate|||||||2006-06-30|2006-07-04|Estimate|March 2006||2006-03-31|June 2006|2006-06-30|June 2007||2007-06-30|||||Interventional|||Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration|Effects of Intravitreal Injection of Bevacizumab in Combination With Verteporfin Photodynamic Therapy|Unknown status|Recruiting|Phase 2|25||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:54:58.667757|2018-06-01 03:54:58.667757
NCT00347386|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2010-12-06|2006-06-30|2006-07-04|Estimate|||||||2010-12-06|2010-12-07|Estimate|July 2005||2005-07-31|December 2010|2010-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Therapeutic Zinc in Infant Bacterial Illness|Zinc as an Immunomodulator in the Treatment of Possible Serious Bacterial Infections in Infants 7 Days and up to 4 Months of Age|Completed||Phase 2/Phase 3|700|Actual|Centre For International Health||2|||f||||t||||||||||2018-06-01 03:54:58.742608|2018-06-01 03:54:58.742608
NCT00347373|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-06-30|2006-06-30|2006-07-04|Estimate|||||||2006-06-30|2006-07-04|Estimate|August 2004||2004-08-31|June 2006|2006-06-30|September 2005||2005-09-30|||||Interventional|||Effect of Conjugated Linoleic Acid Supplement on Body Composition|Conjugated Linoleic Acid and Body Fat Mass in Obese Humans|Completed||N/A|60||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 03:54:58.834976|2018-06-01 03:54:58.834976
NCT00347360|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|2009-04-22||2016-11-03|2006-06-29|2006-07-04|Estimate|2009-09-28|2009-11-09|Estimate||||2016-11-03|2016-12-26|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment With 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication|Completed||Phase 3|654|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:54:58.97571|2018-06-01 03:54:58.97571
NCT00347347|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2010-05-11|2006-06-30|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|February 2006||2006-02-28|May 2010|2010-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Comparative Study of Cycloplegic Refraction and Subjective Refraction With Fogging in School Age Children||Completed|||150|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:01.558348|2018-06-01 03:55:01.558348
NCT00347334|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2016-01-27|2006-06-29|2006-07-04|Estimate|||||||2016-01-27|2016-01-28|Estimate|March 2006||2006-03-31|January 2014|2014-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Is Home Positioning Time Associated With Torticollis Rate of Recovery?|Is Home Positioning Time Associated With Torticollis Rate of Recovery?|Completed|||150|Anticipated|The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:55:01.67024|2018-06-01 03:55:01.67024
NCT00347321|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2009-12-02|2006-06-29|2006-07-04|Estimate|||||||2009-12-02|2009-12-03|Estimate|July 2006||2006-07-31|March 2007|2007-03-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|ETOC||Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC)|Evaluation of Early Percutaneous Tracheostomy in Patients Undergoing Cardiovascular Surgery and Requiring Prolonged Mechanical Ventilation|Completed||Phase 3|212|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:55:01.747146|2018-06-01 03:55:01.747146
NCT00347308|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|2009-08-10||2012-04-29|2006-06-29|2006-07-04|Estimate|2009-08-10|2009-09-16|Estimate||||2012-04-29|2012-05-03|Estimate|July 2007||2007-07-31|April 2012|2012-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Photographic Assessment of Eyebrow Position and Range of Motion|Photographic Assessment of Eyebrow Position and Range of Motion|Completed|||40|Actual|The New York Eye & Ear Infirmary|||||f||||f||||||||||2018-06-01 03:55:01.826231|2018-06-01 03:55:01.826231
NCT00347295|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2017-12-27|2006-06-30|2006-07-04|Estimate|||||||2017-12-27|2017-12-28|Actual|June 2006||2006-06-30|December 2017|2017-12-31|January 2007||2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.|A Randomised, Double-blinded, Double-dummy, Multi-center, Paralleled Study to Investigate the Safety and Efficacy of Brotizolam (Lendormin) Compared With Estazolam in Insomnia Outpatients.|Completed||Phase 3|253||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:55:01.957792|2018-06-01 03:55:01.957792
NCT00347282|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2010-05-11|2006-06-30|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Post Enucleation Socket Syndrome Study|Post-enucleation Socket Syndrome Study (PESSS): Part 1 - Three Dimensional Volumetric Assessment of Anophthalmic Sockets With the New Multi-detector Computed Tomographic Technology|Completed|||10|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:02.127041|2018-06-01 03:55:02.127041
NCT00347269|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2017-04-08||2017-04-08|2006-06-30|2006-07-04|Estimate|2017-04-08|2017-05-19|Actual||||2017-04-08|2017-05-19|Actual|June 2006||2006-06-30|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Primary Care Intervention Strategy for Anxiety Disorders|Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes|Completed||Phase 4|1004|Actual|University of Washington||2|||f||||t||||||||Yes|Limited access datasets are available through the National Database for Clinical Trials Related to Mental Illness (NDCT), part of the NIMH Data Archive: https://data-archive.nimh.nih.gov/ndct/.|2018-06-01 03:55:02.219217|2018-06-01 03:55:02.219217
NCT00347256|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-12-09|2006-06-29|2006-07-04|Estimate|||||||2008-12-09|2008-12-10|Estimate||||December 2008|2008-12-31||||||||Interventional|||Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer|Preoperative Radiotherapy and Concomitant Chemotherapy Followed by Surgery for Advanced Paranasal Sinus Carcinoma|Withdrawn||N/A|60|Anticipated|University of Tennessee|||||f||||||||||||||2018-06-01 03:55:02.533144|2018-06-01 03:55:02.533144
NCT00347243|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-10-25|2006-06-30|2006-07-04|Estimate|||||||2006-10-25|2006-10-26|Estimate|September 2005||2005-09-30|March 2006|2006-03-31|June 2006||2006-06-30|||||Interventional|||Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical Intraocular Lenses|Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical|Completed||Phase 4|||Federal University of São Paulo|||||f||||||||||||||2018-06-01 03:55:02.597255|2018-06-01 03:55:02.597255
NCT00347230|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-07-03|2006-06-30|2006-07-04|Estimate|||||||2006-07-03|2006-07-07|Estimate|October 2005||2005-10-31|September 2005|2005-09-30||||||||Interventional|||Intacs for Keratoconus|Intacs for Keratoconus|Unknown status|Recruiting|N/A|20||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:02.66731|2018-06-01 03:55:02.66731
NCT00347217|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2011-08-29|2006-06-30|2006-07-04|Estimate|||||||2011-08-29|2011-08-30|Estimate|February 2006||2006-02-28|August 2011|2011-08-31|January 2009|Actual|2009-01-31|||||Observational|||Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event|An Observational Study Into the Usage and Efficacy of Crestor 5mg as a Start Dosage in Achieving the LDL-C Target Level in Both Statin-naive and Treated Primary and Secondary Prevention Patients With a High Risk of a Cardiovascular Event.|Completed|||3840|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:55:02.752396|2018-06-01 03:55:02.752396
NCT00347204|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2006-06-29|2006-06-29|2006-07-04|Estimate|||||||2006-06-29|2006-07-04|Estimate|January 2006||2006-01-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Interventional|||Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK|Double Masked Evaluation of Acular LS Versus Nevanac for Postoperative Pain Control in Eyes Undergoing PRK|Completed||Phase 4|40||Center For Excellence In Eye Care|||||f||||||||||||||2018-06-01 03:55:03.289864|2018-06-01 03:55:03.289864
NCT00347191|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2011-06-22|2006-06-30|2006-07-04|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|June 2006|Actual|2006-06-30|||||Observational|||Relationship Between Central Corneal Thickness and Intraocular Pressure Measures Instruments.|Phase 4 Study Evaluating the Relationship Between Intraocular Pressure and Central Corneal Thickness Using Various Instruments in Ocular Hypertension, Normal-tension Glaucoma, Primary Open Angle Glaucoma, Keratoconus and Normal Eyes.|Completed|||1000||Aston University|||||f||||f||||||||||2018-06-01 03:55:03.422298|2018-06-01 03:55:03.422298
NCT00347178|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-06-30|2006-06-30|2006-07-04|Estimate|||||||2006-06-30|2006-07-04|Estimate|January 2005||2005-01-31|June 2006|2006-06-30|January 2013||2013-01-31|||||Interventional|||Asymptomatic Narrow Angles - Laser Iridotomy Study; Multicentric RCT|Prophylactic Laser Iridotomy for Eyes With Narrow Drainage Angles; A Randomised Controlled Trial|Unknown status|Recruiting|N/A|544||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:03.492958|2018-06-01 03:55:03.492958
NCT00347165|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2006-06-30|2006-06-30|2006-07-04|Estimate|||||||2006-06-30|2006-07-04|Estimate|September 2005||2005-09-30|June 2006|2006-06-30|September 2006||2006-09-30|||||Interventional|||Intravitreal Bevacizumab for Age-Related Macular Degeneration|Intravitreal Bevacizumab Therapy for Neovascular Age-Related Macular Degeneration: A Pilot Study|Unknown status|Recruiting|Phase 2|50||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:55:03.571305|2018-06-01 03:55:03.571305
NCT00347152|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-09-10|2006-06-30|2006-07-04|Estimate|||||||2008-09-10|2008-09-12|Estimate|November 2006||2006-11-30|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability|Overnight Versus Progressive Conversion of Multiple Daily Dose Enteric-Coated Divalproex to Once-Daily Divalproex Extended Release: Which Strategy is Better Tolerated by Patients With Intellectual Disabilities?|Completed||N/A|18|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 03:55:03.640521|2018-06-01 03:55:03.640521
NCT00347139|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2017-09-12|2006-06-29|2006-07-04|Estimate|||||||2017-09-12|2017-09-14|Actual|May 23, 2006|Actual|2006-05-23|September 2017|2017-09-30|January 10, 2007|Actual|2007-01-10|January 10, 2007|Actual|2007-01-10||Interventional|||Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients|Multi-centre, Randomised, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study, to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (25, 100 and 400 mcg Once Daily) of GW642444|Completed||Phase 2|55|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:03.732207|2018-06-01 03:55:03.732207
NCT00347126|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2010-05-11|2006-06-30|2006-07-04|Estimate|||||||2010-05-11|2010-05-12|Estimate|April 2006||2006-04-30|May 2010|2010-05-31|April 2008|Actual|2008-04-30|||||Observational|||Results of Mass Switch From Latanoprost to Travoprost|Efficacy and Safety of a Systematic Switch From Latanoprost to Travoprost in Patients With Glaucoma|Completed|||372|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:03.855782|2018-06-01 03:55:03.855782
NCT00347113|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2014-09-22|2006-06-30|2006-07-04|Estimate|||||||2014-09-22|2014-09-23|Estimate|July 2006||2006-07-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania|The Effect of Schistosome and Soil-transmitted Helminth Infections on Malaria,Infection, Morbidity and Antibody Response Among School and Pre-school Children in Mwanza, Tanzania|Completed||N/A|620|Anticipated|DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 03:55:03.914975|2018-06-01 03:55:03.914975
NCT00347100|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2009-09-14|2006-06-30|2006-07-04|Estimate|||||||2009-09-14|2009-09-15|Estimate|June 2006||2006-06-30|September 2009|2009-09-30||||May 2008|Actual|2008-05-31||Interventional|TARGET||Insulin Glargine in Type 2 Diabetic Patients|Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy|Completed||Phase 4|387|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:55:03.98938|2018-06-01 03:55:03.98938
NCT00347087|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2007-10-30|2006-06-30|2006-07-04|Estimate|||||||2007-10-30|2007-10-31|Estimate|July 2004||2004-07-31|October 2007|2007-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure|Effect of the Angiotensin II Receptor Antagonist Irbesartan on Insulin Sensitivity and Metabolic Profile in Patients With Chronic Heart Failure|Completed||Phase 4|36|Actual|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 03:55:04.06914|2018-06-01 03:55:04.06914
NCT00347074|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-07-03|2006-06-30|2006-07-04|Estimate|||||||2006-07-03|2006-07-07|Estimate|September 2003||2003-09-30|September 2003|2003-09-30|March 2005||2005-03-31|||||Observational|||A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients||Completed|||120||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:04.138459|2018-06-01 03:55:04.138459
NCT00347061|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2009-10-01|2006-06-30|2006-07-04|Estimate|||||||2009-10-01|2009-10-02|Estimate|May 2006||2006-05-31|October 2009|2009-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH|A Long-term Safety and Efficacy of SL77.0499-10 10mg Once-daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH).A Multicenter, 52-week, Open Label, Uncontrolled Study.|Completed||Phase 3|148|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:55:04.198249|2018-06-01 03:55:04.198249
NCT00347048|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2014-08-25|2006-06-30|2006-07-04|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients|Tacrolimus (FK506) P-III Placebo-Controlled Double-Blind Study in Moderate to Severe Refractory Ulcerative Colitis Patients|Completed||Phase 3|62|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 03:55:04.246789|2018-06-01 03:55:04.246789
NCT00347035|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2006-10-25|2006-06-30|2006-07-04|Estimate|||||||2006-10-25|2006-10-26|Estimate||||June 2006|2006-06-30||||||||Interventional|||INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE|INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE|Terminated||Phase 4|||Federal University of São Paulo|||||f||||||||||||||2018-06-01 03:55:04.332332|2018-06-01 03:55:04.332332
NCT00347022|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2011-12-23||2013-04-08|2006-06-30|2006-07-04|Estimate|2013-04-08|2013-04-09|Estimate||||2013-04-08|2013-04-09|Estimate|May 2006||2006-05-31|April 2013|2013-04-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications||Completed||Phase 4|145|Actual|Guerbet||2|||f||||||||||||||2018-06-01 03:55:04.38148|2018-06-01 03:55:04.38148
NCT00346814|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2009-06-28|2006-06-29|2006-06-30|Estimate|||||||2009-06-28|2009-06-30|Estimate|July 2006||2006-07-31|June 2006|2006-06-30|November 2006|Anticipated|2006-11-30|||||Interventional|||Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome|Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome|Unknown status|Recruiting|Phase 2/Phase 3|||Asociación para Evitar la Ceguera en México|||||f||||||||||||||2018-06-01 03:55:06.463789|2018-06-01 03:55:06.463789
NCT00347009|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|2010-09-20|2010-08-12|2012-05-31|2006-06-30|2006-07-04|Estimate|2010-09-20|2010-10-15|Estimate|2010-08-12|2010-08-18|Estimate|2012-05-31|2012-06-04|Estimate|May 2005||2005-05-31|March 2011|2011-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis|An Open Label Study of Adefovir Dipivoxil for the Treatment of Patients With Chronic Hepatitis B Related Advanced Fibrosis or Cirrhosis.|Completed||Phase 4|155|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:55:04.636535|2018-06-01 03:55:04.636535
NCT00346996|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2012-08-31|2006-06-30|2006-07-04|Estimate|||||||2012-08-31|2012-09-03|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||Insulin Analogues and Severe Hypoglycaemia|The Effect of Insulin Analogues and Human Insulin on the Incidence of Severe Hypoglycaemia in Hypoglycaemia Prone Type 1 Diabetic Patients|Completed||Phase 4|179|Actual|Steno Diabetes Center||2|||f||||f||||||||||2018-06-01 03:55:05.11952|2018-06-01 03:55:05.11952
NCT00346983|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-05-08|2006-06-29|2006-07-04|Estimate|||||||2008-05-08|2008-05-12|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics|Pilot Study of the Effect of Pegaptanib Sodium to Prevent Worsening of Cystoid Macular Edema Following Cataract Surgery in Diabetics|Terminated||Phase 1/Phase 2|4|Actual|Johns Hopkins University||2||Difficulty enrolling eligible subjects|f||||f||||||||||2018-06-01 03:55:05.209758|2018-06-01 03:55:05.209758
NCT00346970|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2008-05-05|2006-06-30|2006-07-04|Estimate|||||||2008-05-05|2008-05-06|Estimate|July 2006||2006-07-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|||||Interventional|||The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)|Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.|Completed||Phase 4|32|Actual|Hannover Medical School||2|||f||||||||||||||2018-06-01 03:55:05.290157|2018-06-01 03:55:05.290157
NCT00346957|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2012-03-03|2006-06-30|2006-07-04|Estimate|||||||2012-03-03|2012-03-06|Estimate|April 1999||1999-04-30|March 2012|2012-03-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration||Completed||Phase 2|128|Actual|Alcon Research||4|||f||||||||||||||2018-06-01 03:55:05.36042|2018-06-01 03:55:05.36042
NCT00346944|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2012-08-27|2006-06-29|2006-07-04|Estimate|||||||2012-08-27|2012-08-28|Estimate|September 2002||2002-09-30|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam|Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam - A Study of Patients Examined at the Dental Biomaterials Adverse Reaction Unit in 1993 to 1999|Completed||Phase 4|50|Actual|University of Bergen||2|||f||||t||||||||||2018-06-01 03:55:05.49064|2018-06-01 03:55:05.49064
NCT00346931|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2010-07-22|2006-06-29|2006-07-04|Estimate|||||||2010-07-22|2010-07-23|Estimate|December 2004||2004-12-31|June 2006|2006-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Phacotrabeculotomy Versus CCI+Phaco in Patients With Borderline Control of Intraocular Pressure|Phacotrabeculotomy vs. CCI+Phaco in Patients With Borderline Control of Intraocular Pressure|Terminated||N/A|9|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 03:55:05.574109|2018-06-01 03:55:05.574109
NCT00346918|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2014-02-26|2006-06-28|2006-06-30|Estimate|||||||2014-02-26|2014-02-27|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study.|Completed||Phase 3|100|Actual|University of Zurich||2|||f||||t||||||||||2018-06-01 03:55:05.644639|2018-06-01 03:55:05.644639
NCT00346905|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|2017-03-14||2017-06-22|2006-06-29|2006-06-30|Estimate|2017-06-22|2017-07-21|Actual||||2017-06-22|2017-07-21|Actual|October 2003||2003-10-31|June 2017|2017-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Endoscopic Implantation of Enteryx for the Treatment of GERD|Endoscopic Implantation of Enteryx for the Treatment of Gastroesophageal Reflux Disease (GERD): Post Market Study|Completed||N/A|16|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-06-01 03:55:05.755442|2018-06-01 03:55:05.755442
NCT00346892|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2016-09-08|2006-06-29|2006-06-30|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2001||2001-11-30|September 2016|2016-09-30||||March 2003|Actual|2003-03-31||Interventional|||To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV|Reactogenicity & Immunogenicity Study of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Co-administered With Either OPV or IPV in Healthy Infants (Approximately 5-10 Weeks Old) in South Africa|Completed||Phase 2|450||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:05.997156|2018-06-01 03:55:05.997156
NCT00346879|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2016-02-22|2006-06-28|2006-06-30|Estimate|||||||2016-02-22|2016-02-23|Estimate|August 2006||2006-08-31|February 2016|2016-02-29|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Study to Determine Effective Dosing of Fondaparinux in Obese Persons|Thromboprophylaxis in the Morbidly Obese With Weight Based Dosing of Fondaparinux: A Pharmacodynamic Study|Withdrawn||Phase 1|0|Actual|Indiana University||||Funding withdrawn; study closed due to lack of accrual.|f||||t||||||||||2018-06-01 03:55:06.08832|2018-06-01 03:55:06.08832
NCT00346866|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2008-08-04|2006-06-28|2006-06-30|Estimate|||||||2008-08-04|2008-08-05|Estimate|May 2000||2000-05-31|August 2008|2008-08-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Anecortave Acetate Versus Placebo in AMD Patients Following PDT|Anecortave Acetate Versus Placebo in AMD Patients Following PDT|Completed||Phase 2|136||Alcon Research|||||||||||||||||||2018-06-01 03:55:06.170168|2018-06-01 03:55:06.170168
NCT00346853|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2008-07-09|2006-06-28|2006-06-30|Estimate|||||||2008-07-09|2008-07-10|Estimate|November 2005||2005-11-30|July 2008|2008-07-31|September 2006|Actual|2006-09-30|May 2006|Actual|2006-05-31||Interventional|||Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy|Clinical Interventions Against Stargardt Macular Dystrophy: Phase 1 Pilot Study of 4-MP as an Inhibitor of Dark Adaptation|Completed||Phase 1|10|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 03:55:06.239864|2018-06-01 03:55:06.239864
NCT00346840|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2012-06-15|2006-06-29|2006-06-30|Estimate|||||||2012-06-15|2012-06-18|Estimate|June 2003||2003-06-30|June 2012|2012-06-30|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|||Safety and Efficacy Study of Misoprostol Vaginal Insert for Induction of Labour|Controlled-Release Misoprostol Vaginal Insert in Parous Women for Labor Induction: Randomized Trial|Completed||Phase 2|124|Actual|Ferring Pharmaceuticals||4|||f||||f||||||||||2018-06-01 03:55:06.323135|2018-06-01 03:55:06.323135
NCT00346801|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2012-10-19|2006-06-28|2006-06-30|Estimate|||||||2012-10-19|2012-10-22|Estimate|September 2003||2003-09-30|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|||CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|20|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:55:06.536346|2018-06-01 03:55:06.536346
NCT00346788|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2011-06-27|2006-06-29|2006-06-30|Estimate|||||||2011-06-27|2011-06-28|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Subvastus Approach in Total Knee Arthroplasty|The Subvastus Approach in Total Knee Arthroplasty|Completed||Phase 4|126|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-06-01 03:55:06.617369|2018-06-01 03:55:06.617369
NCT00346775|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2017-06-08||2017-12-13|2006-06-28|2006-06-30|Estimate|2017-11-13|2017-12-06|Actual||||2017-12-13|2018-01-16|Actual|May 1, 2006|Actual|2006-05-01|December 2017|2017-12-31|June 29, 2006|Actual|2006-06-29|June 29, 2006|Actual|2006-06-29||Interventional|||Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)|A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects With Seasonal Allergic Rhinitis During a Three-week Cross-over Study|Completed||Phase 3|97|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:06.721192|2018-06-01 03:55:06.721192
NCT00346762|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2014-05-16|2006-06-29|2006-06-30|Estimate|||||||2014-05-16|2014-05-19|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Evaluating Host and Viral Factors Among HIV Infected Former Commercial Blood Donors in Fuyang, Anhui Province, China|Host and Viral Factors in HIV-1-Infected Typical Progressors and Long-Term Survivors Among Former Blood Donors in Anhui Province, China|Completed|||186|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Whole blood and urine~   "|||2018-06-01 03:55:07.075557|2018-06-01 03:55:07.075557
NCT00346749|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2016-10-27|2006-06-28|2006-06-30|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2006||2006-12-31|October 2016|2016-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.|A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared With Salmeterol DISKUS 50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Terminated||Phase 4|180||GlaxoSmithKline||1||"The study was terminated due to difficulties with finding sites and subjects willing to~   participate."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:07.154715|2018-06-01 03:55:07.154715
NCT00346736|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-09-01|2006-06-29|2006-06-30|Estimate|||||||2008-09-01|2008-09-03|Estimate|May 2005||2005-05-31|September 2008|2008-09-30|March 2007|Actual|2007-03-31|June 2006|Actual|2006-06-30||Interventional|||Use of Acupuncture In Children With Autistic Spectrum Disorder|Use of Acupuncture In Autistic Spectrum Disorder|Completed||Phase 3|80|Anticipated|The University of Hong Kong|||||f||||||||||||||2018-06-01 03:55:07.284834|2018-06-01 03:55:07.284834
NCT00346723|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2009-01-29|2006-06-29|2006-06-30|Estimate|||||||2009-01-29|2009-01-30|Estimate|July 2006||2006-07-31|January 2009|2009-01-31||||||||Interventional|||Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.|Immunogenicity and Reactogenicity of Trivalent Influenza Subunit Vaccine Influvac® for the Season 2006/2007. An Open, Baseline-Controlled Study in Two Groups of Healthy Subjects: Adults and Elderly.|Completed||Phase 3|120||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 03:55:07.368438|2018-06-01 03:55:07.368438
NCT00346710|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2017-09-22|2006-06-28|2006-06-30|Estimate|||||||2017-09-22|2017-09-26|Actual|June 1, 2006|Actual|2006-06-01|September 2017|2017-09-30|June 2, 2006|Actual|2006-06-02|June 2, 2006|Actual|2006-06-02||Observational|||Patient Experiences in Rheumatology|Communication Skills in Rheumatology Fellows|Withdrawn|||0|Actual|Johns Hopkins University||||"Information was entered by mistake by a Research Assistant. Study never went beyond the initial~   discussion phase."|f||||f|f|f||||||||2018-06-01 03:55:07.585161|2018-06-01 03:55:07.585161
NCT00346697|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|2014-07-15||2014-11-04|2006-06-29|2006-06-30|Estimate|2014-11-04|2014-11-05|Estimate||||2014-11-04|2014-11-05|Estimate|October 2006||2006-10-31|November 2014|2014-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients|A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy|Completed||Phase 4|48|Actual|Brown, Todd, M.D., Ph.D.||2|||f||||f||||||||||2018-06-01 03:55:07.674191|2018-06-01 03:55:07.674191
NCT00346684|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-08-11|2006-06-29|2006-06-30|Estimate|||||||2008-08-11|2008-08-12|Estimate|July 2006||2006-07-31|August 2008|2008-08-31||||November 2007|Actual|2007-11-30||Interventional|||Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)|Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.|Completed||Phase 2|||University of Cologne|||||f||||||||||||||2018-06-01 03:55:08.255868|2018-06-01 03:55:08.255868
NCT00346671|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2012-09-20|2006-06-29|2006-06-30|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|October 2009|Actual|2009-10-31||Interventional|||Effects of Reiki on Stress|Effects of Reiki on Physiological Consequences of Acute Stress|Completed||Phase 1|257|Actual|The Cleveland Clinic||3|||f||||t||||||||||2018-06-01 03:55:08.386416|2018-06-01 03:55:08.386416
NCT00346658|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2008-12-12|2006-06-28|2006-06-30|Estimate|||||||2008-12-12|2008-12-15|Estimate|July 2002||2002-07-31|December 2008|2008-12-31|September 2006||2006-09-30|||||Interventional|||Magnesium Supplementation to Prevent Bone Loss|Magnesium Supplementation to Prevent Bone Loss|Completed||Phase 1|74||University of Tennessee|||||f||||||||||||||2018-06-01 03:55:08.489155|2018-06-01 03:55:08.489155
NCT00346645|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2013-02-05|2006-06-29|2006-06-30|Estimate|||||||2013-02-05|2013-02-06|Estimate|June 2006||2006-06-30|January 2012|2012-01-31|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Interventional|||A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer|A Phase II Study of Velcade® (Bortezomib) in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Chemotherapy|Terminated||Phase 2|46|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||||stopped after planned interim analysis for lack of efficacy|f||||||||||||||2018-06-01 03:55:08.573201|2018-06-01 03:55:08.573201
NCT00346632|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2016-07-29||2016-08-16|2006-06-28|2006-06-30|Estimate|2016-08-02|2016-08-12|Estimate||||2016-08-16|2016-09-28|Estimate|June 2006||2006-06-30|August 2016|2016-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia|Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)|Terminated||Phase 1|37|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1||Terminated due to suboptimal dosing schedule|f||||t||||||||Undecided||2018-06-01 03:55:08.792669|2018-06-01 03:55:08.792669
NCT00346619|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2010-01-19|2006-06-28|2006-06-30|Estimate|||||||2010-01-19|2010-01-20|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults|Investigating the Time of Nelfinavir Treatment Necessary for an Increase in Thymic Naive T Cells in Adults.|Completed||Phase 1|25|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:55:12.931225|2018-06-01 03:55:12.931225
NCT00346606|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2006-06-29|2006-06-29|2006-06-30|Estimate|||||||2006-06-29|2006-06-30|Estimate|January 2006||2006-01-31|May 2006|2006-05-31||||||||Interventional|||The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria|A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Desloratadine 5mg (Denosin®) With Levocetirizine 5mg (Xyzal®) in the Treatment of Chronic Idiopathic Urticaria Patients|Unknown status|Recruiting|Phase 4|60||Lotus Pharmaceutical|||||f||||||||||||||2018-06-01 03:55:12.986458|2018-06-01 03:55:12.986458
NCT00346593|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2007-02-08|2006-06-29|2006-06-30|Estimate|||||||2007-02-08|2007-02-12|Estimate|May 2004||2004-05-31|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||Investigation of the Clinical Performance of Silicone Hydrogel Contact Lenses During Continuous Wear||Completed||N/A|||University of Melbourne|||||f||||||||||||||2018-06-01 03:55:13.080723|2018-06-01 03:55:13.080723
NCT00346580|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2011-04-01|2006-06-28|2006-06-30|Estimate|||||||2011-04-01|2011-04-05|Estimate|June 2003||2003-06-30|April 2011|2011-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||The Effects of HIV Protease Inhibitors in Severe Sepsis|The Effects of HIV Protease Inhibitors in Severe Sepsis|Completed||Phase 1|60||Mayo Clinic|||||f||||||||||||||2018-06-01 03:55:13.129406|2018-06-01 03:55:13.129406
NCT00346567|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2016-02-22|2006-06-29|2006-06-30|Estimate|||||||2016-02-22|2016-02-23|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|April 2011|Actual|2011-04-30|October 2010|Actual|2010-10-31||Interventional|||Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)|Clinical Trial: Backup With Combivir (AZT/3TC) or Single Dose (sd) Truvada (FTC/TDF) in Order to Avoid NNRTI Resistance After sd Nevirapine for the Prevention of Mother-to-child Transmission (MTCT)|Completed||N/A|566|Actual|Rigshospitalet, Denmark||2|||f||||||||||||||2018-06-01 03:55:13.199954|2018-06-01 03:55:13.199954
NCT00346554|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2014-02-01|2006-06-28|2006-06-30|Estimate|||||||2014-02-01|2014-02-04|Estimate|April 2006||2006-04-30|February 2014|2014-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||To Study the Prevalence of Insomnia in Geriatric COPD Patients Who Are Enrolled in a Pulmonary Rehabilitation Program.|To Study the Prevalence of Insomnia in Geriatric COPD Patients Who Are Enrolled in a Pulmonary Rehabilitation Program.|Completed|||50|Actual|Hackensack University Medical Center|||||f||||t||||||||||2018-06-01 03:55:13.275021|2018-06-01 03:55:13.275021
NCT00346541|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2006-06-29|2006-06-29|2006-06-30|Estimate|||||||2006-06-29|2006-06-30|Estimate|July 2005||2005-07-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Observational|||Role of Polymorphisms in the IL-1 Gene Cluster|Investigating the Genetic Basis of Glaucoma: Role of Polymorphisms in the IL-1 Gene Cluster|Completed|||400||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:14.236134|2018-06-01 03:55:14.236134
NCT00346528|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2012-03-01|2006-06-28|2006-06-30|Estimate|||||||2012-03-01|2012-03-05|Estimate|July 2006||2006-07-31|March 2012|2012-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Safety of NGOIS Compared to BSS Plus in Pediatric Patients|Safety of NGOIS Compared to BSS Plus in Pediatric Patients|Completed||Phase 3|18|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 03:55:14.288507|2018-06-01 03:55:14.288507
NCT00346515|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-10-20|2006-06-29|2006-06-30|Estimate|||||||2008-10-20|2008-10-21|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|||||Interventional|||EPIC US Feasibility Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting|Evaluating the Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting: The EPIC US Feasibility Study|Completed||N/A|30||Lumen Biomedical|||||f||||t||||||||||2018-06-01 03:55:14.346598|2018-06-01 03:55:14.346598
NCT00346502|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2013-12-10|2006-06-29|2006-06-30|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of 20% Betulinic Acid Ointment for Treatment of Dysplastic Nevi (Moderate to Severe Dysplasia)|Phase I/II Evaluation of Topical Application of 20% Betulinic Acid Ointment in the Treatment of Dysplastic Nevi With Moderate to Severe Dysplasia|Suspended||Phase 1/Phase 2|200|Anticipated|University of Illinois at Chicago||1||The study has been temporarily suspended due to funding issues|f||||||||||||||2018-06-01 03:55:14.404545|2018-06-01 03:55:14.404545
NCT00346489|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2007-12-21|2006-06-28|2006-06-30|Estimate|||||||2007-12-21|2007-12-27|Estimate|September 2004||2004-09-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C|Intermediate Term Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin c in Trabeculectomy Surgery.|Completed||Phase 4|70||Indiana University|||||f||||||||||||||2018-06-01 03:55:14.520113|2018-06-01 03:55:14.520113
NCT00346476|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2011-01-14||2011-02-09|2006-06-28|2006-06-30|Estimate|2011-01-20|2011-02-09|Estimate||||2011-02-09|2011-02-11|Estimate|April 2006||2006-04-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa|A Study of the Effects of Antiretroviral Therapy on Rates and Transmission of Tuberculosis|Completed|||1250|Actual|CIPRA SA|||1||f||||f||||||Samples With DNA|"~     Sputum, Saliva~   "|||2018-06-01 03:55:14.599581|2018-06-01 03:55:14.599581
NCT00346463|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2008-04-25|2006-06-29|2006-06-30|Estimate|||||||2008-04-25|2008-04-28|Estimate|July 2006||2006-07-31|June 2006|2006-06-30|July 2013|Anticipated|2013-07-31|||||Interventional|||Antenatal Allopurinol in Intrauterine Growth Restriction|Does Antenatal Allopurinol Administration Improve Maternal and Neonatal Outcome in Intrauterine Growth Restriction?|Unknown status|Not yet recruiting|N/A|50|Anticipated|UMC Utrecht|||||f||||||||||||||2018-06-01 03:55:14.890773|2018-06-01 03:55:14.890773
NCT00346450|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-29|||2010-01-11|2006-06-29|2006-06-30|Estimate|||||||2010-01-11|2010-01-13|Estimate|October 2001||2001-10-31|January 2010|2010-01-31|December 2003|Actual|2003-12-31|||||Interventional|||Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation|Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface|Completed||Phase 3|80|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:14.972943|2018-06-01 03:55:14.972943
NCT00346437|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2012-02-08|2006-06-28|2006-06-30|Estimate|||||||2012-02-08|2012-02-09|Estimate|October 2001||2001-10-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|January 2005|Actual|2005-01-31||Interventional|||Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients With Stable Angina|Completed||Phase 2/Phase 3|416|Actual|Cardium Therapeutics||3|||f||||t||||||||||2018-06-01 03:55:15.054342|2018-06-01 03:55:15.054342
NCT00346424|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2008-08-12|2006-06-29|2006-06-30|Estimate|||||||2008-08-12|2008-08-14|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters|Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Occluded Central Venous Access Devices|Completed||Phase 3|300|Actual|ARCA Biopharma, Inc.|||||f||||t||||||||||2018-06-01 03:55:15.135409|2018-06-01 03:55:15.135409
NCT00346411|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2017-10-03|2006-06-28|2006-06-29|Estimate|||||||2017-10-03|2017-10-05|Actual|September 1, 2005|Actual|2005-09-01|October 2017|2017-10-31|December 12, 2011|Actual|2011-12-12|December 12, 2011|Actual|2011-12-12||Observational|HORA||Health Outcomes in Rheumatoid Arthritis|Health Outcomes in Rheumatoid Arthritis|Completed|||164|Actual|Johns Hopkins University|||||f||||||||||||||2018-06-01 03:55:15.211404|2018-06-01 03:55:15.211404
NCT00346398|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2013-08-29||2017-03-29|2006-06-27|2006-06-29|Estimate|2013-12-13|2013-12-16|Estimate||||2017-03-29|2017-05-01|Actual|May 2006||2006-05-31|March 2017|2017-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|GPAC||Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study|A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease (ITN025AD)|Completed||Phase 2|51|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|One participant in the placebo group could not be included in intent-to-treat analyses because a sibling was also in the study|2|||f||||t||||||||Yes|Data access is provided to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.|2018-06-01 03:55:15.435482|2018-06-01 03:55:15.435482
NCT00346385|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2015-03-24|2006-06-28|2006-06-29|Estimate|||||||2015-03-24|2015-03-26|Estimate|March 2002||2002-03-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901|Completed||Phase 1|97|Actual|ImmunoGen, Inc.|||||f||||||||||||||2018-06-01 03:55:15.964799|2018-06-01 03:55:15.964799
NCT00346372|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2018-01-02|2006-06-27|2006-06-29|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2004||2004-03-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|December 2019|Anticipated|2019-12-31||Observational|||Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy||Recruiting|||800|Anticipated|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 03:55:16.051752|2018-06-01 03:55:16.051752
NCT00346359|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2010-05-12|2006-06-28|2006-06-29|Estimate|||||||2010-05-12|2010-05-14|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|November 2007|Actual|2007-11-30|||||Interventional|||Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer|Conditioning For Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies|Completed||Phase 2|40|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 03:55:16.121817|2018-06-01 03:55:16.121817
NCT00346346|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2018-05-23|2006-06-28|2006-06-29|Estimate|||||||2018-05-23|2018-05-24|Actual|April 17, 2006||2006-04-17|January 23, 2013|2013-01-23|January 23, 2013||2013-01-23|||||Observational|||Analysis of the Immune Response to the Malaria Parasite in Mali, West Africa|Longitudinal Analysis of the B-Cell Immune Response to Plasmodium Falciparum in Mali|Completed|||237|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:16.206039|2018-06-01 03:55:16.206039
NCT00346333|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2012-06-18||2013-12-12|2006-06-27|2006-06-29|Estimate|2013-12-12|2014-01-31|Estimate||||2013-12-12|2014-01-31|Estimate|July 2003||2003-07-31|December 2013|2013-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A|Randomized Clinical Trial for Retinitis Pigmentosa|Completed||Phase 3|240|Actual|National Eye Institute (NEI)||2|||f||||t||||||||||2018-06-01 03:55:16.286288|2018-06-01 03:55:16.286288
NCT00346320|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2016-11-25|2006-06-28|2006-06-29|Estimate|||||||2016-11-25|2016-11-28|Estimate|April 2006||2006-04-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|February 2012|Actual|2012-02-29||Interventional|||Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) For Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|80|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-06-01 03:55:16.71844|2018-06-01 03:55:16.71844
NCT00346294|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2009-02-19|2006-06-28|2006-06-29|Estimate|||||||2009-02-19|2009-02-20|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|July 2006|Actual|2006-07-31|March 2006|Actual|2006-03-31||Interventional|||An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-Injector in Subjects With Rheumatoid Arthritis|An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-Injector in Subjects With Rheumatoid Arthritis|Completed||Phase 4|115|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:55:16.845776|2018-06-01 03:55:16.845776
NCT00346281|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2006-06-28|2006-06-28|2006-06-29|Estimate|||||||2006-06-28|2006-06-29|Estimate|June 2006||2006-06-30|June 2006|2006-06-30|June 2008||2008-06-30|||||Interventional|||32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer|A Phase IIa, Safety Study of the Active Implantable(Radiological) Medical Device 32P BioSilicon, Administered Intratumourally to Patients With Advanced, Unresectable Pancreatic Cancer, in Addition to Standard IV Gemcitabine Chemotherapy|Unknown status|Recruiting|Phase 2|15||pSiMedica Limited|||||f||||||||||||||2018-06-01 03:55:16.91522|2018-06-01 03:55:16.91522
NCT00346268|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2011-09-21||2011-09-21|2006-06-28|2006-06-29|Estimate|2011-09-21|2011-10-28|Estimate||||2011-09-21|2011-10-28|Estimate|December 2006||2006-12-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|PROSTATECTOMY||Morphine-Sparing Efficacy Of Parecoxib In Pain Treatment After Radical Prostatectomy|Randomized, Double-Blind Study Of The Morphine-Sparing Efficacy And Safety Of Parecoxib Sodium 40 Mg IV Followed By 20 Mg IV Every 12 Hours In The Treatment Of Pain Following Radical Prostatectomy|Terminated||Phase 4|105|Actual|Pfizer|This study was terminated prematurely due to slow recruitment.|2||See termination reason in detailed description.|f||||t||||||||||2018-06-01 03:55:17.021022|2018-06-01 03:55:17.021022
NCT00346255|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2013-04-22|2006-06-28|2006-06-29|Estimate|||||||2013-04-22|2013-04-23|Estimate|April 2005||2005-04-30|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|IMGN901||BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma|Completed||Phase 1|37|Actual|ImmunoGen, Inc.|||||f||||f||||||||||2018-06-01 03:55:17.663806|2018-06-01 03:55:17.663806
NCT00346242|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2012-04-29|2006-06-27|2006-06-29|Estimate|||||||2012-04-29|2012-05-01|Estimate|March 2004||2004-03-31|April 2012|2012-04-30||||March 2006|Actual|2006-03-31||Interventional|||Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events|Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events|Completed||Phase 4|60||Novartis|||||f||||||||||||||2018-06-01 03:55:17.741765|2018-06-01 03:55:17.741765
NCT00346229|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2016-03-18|2006-06-28|2006-06-29|Estimate|||||||2016-03-18|2016-03-22|Estimate|April 2006||2006-04-30|October 2013|2013-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer|A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin (ThermoDox™) and Hyperthermia in Patients With Local-Regionally Recurrent Breast Cancer|Terminated||Phase 1|29|Actual|Duke University||1||Funding|f||||||||||||||2018-06-01 03:55:17.803923|2018-06-01 03:55:17.803923
NCT00346216|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2017-03-21||2017-05-25|2006-06-28|2006-06-29|Estimate|2017-03-21|2017-05-01|Actual||||2017-05-25|2017-06-19|Actual|October 4, 2006|Actual|2006-10-04|May 2017|2017-05-31|April 12, 2016|Actual|2016-04-12|April 12, 2016|Actual|2016-04-12||Interventional|PRECISION||Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen|A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen|Completed||Phase 4|24081|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 03:55:18.269768|2018-06-01 03:55:18.269768
NCT00346190|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2007-04-11|2006-06-27|2006-06-29|Estimate|||||||2007-04-11|2007-04-12|Estimate|January 2003||2003-01-31|January 2006|2006-01-31|April 2007|Anticipated|2007-04-30|||||Interventional|||The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.|A Six Month Double-Blind, Placebo-Controlled Trial Followed by Six Month Open-Label Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.|Unknown status|Recruiting|Phase 3|10||McGill University Health Center|||||f||||||||||||||2018-06-01 03:55:26.428222|2018-06-01 03:55:26.428222
NCT00346177|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2010-09-10|2006-06-27|2006-06-29|Estimate|||||||2010-09-10|2010-09-14|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2012|Anticipated|2012-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Stem Cell Study for Patients With Heart Failure|Injection of Autologous CD34+ Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia and LVEF < 40%|Withdrawn||Phase 2|30|Anticipated|Losordo, Douglas, M.D.||2||Funding not obtained. No subjects enrolled.|f||||t||||||||||2018-06-01 03:55:26.496397|2018-06-01 03:55:26.496397
NCT00346164|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2016-04-25||2017-09-07|2006-06-28|2006-06-29|Estimate|2017-09-07|2017-10-06|Actual||||2017-09-07|2017-10-06|Actual|February 2007||2007-02-28|December 2016|2016-12-31||||September 2014|Actual|2014-09-30||Interventional|||Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma|Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age|Completed||Phase 3|588|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 03:55:26.657504|2018-06-01 03:55:26.657504
NCT00346151|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2011-06-08||2017-03-23|2006-06-27|2006-06-29|Estimate|2011-09-29|2011-11-07|Estimate||||2017-03-23|2017-04-21|Actual|December 2006||2006-12-31|March 2017|2017-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|BESTT||Belatacept to Prevent Organ Rejection in Kidney Transplant Patients|The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)|Terminated||Phase 2|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The trial was stopped early due to meeting an acute rejection threshold of three acute rejections based on local pathology reads in the first five participants enrolled.|1||Stopping rule-acute rejection threshold-was met based on local biopsy results|f||||t||||||||Yes|Data access is provided to the public in Participant level data and additional relevant materials are available to the public in : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.|2018-06-01 03:55:27.944691|2018-06-01 03:55:27.944691
NCT00346138|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2010-01-14|2006-06-27|2006-06-29|Estimate|||||||2010-01-14|2010-01-15|Estimate|June 2005||2005-06-30|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema|Deep Lamellar Endothelial Keratoplasty as Surgical Treatment for Corneal Endothelial Decompensation|Completed||N/A|29|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:55:28.512615|2018-06-01 03:55:28.512615
NCT00346125|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2017-12-03|2006-06-28|2006-06-29|Estimate|||||||2017-12-03|2017-12-05|Actual|April 2006||2006-04-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma|An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma|Active, not recruiting||N/A|70|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||f||||||||||2018-06-01 03:55:28.573438|2018-06-01 03:55:28.573438
NCT00346112|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2010-11-05|2006-06-28|2006-06-29|Estimate|||||||2010-11-05|2010-11-09|Estimate|June 2006||2006-06-30|November 2010|2010-11-30|December 2009||2009-12-31|||||Interventional|||Rehabilitation, Quality of Life, and Exercise Tolerance in Patients With an ICD|Rehabilitation, Quality of Life, and Exercise Tolerance in Internal Cardioverter-Defibrillator-patients, RELAX-ICD Trial|Terminated||N/A|||University Hospital Inselspital, Berne||||insufficient recruitment|f||||||||||||||2018-06-01 03:55:28.657765|2018-06-01 03:55:28.657765
NCT00345917|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2012-04-10|2006-06-28|2006-06-29|Estimate|||||||2012-04-10|2012-04-11|Estimate|February 2002||2002-02-28|April 2012|2012-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study in Retinal Transplantation for Retinitis Pigmentosa.|Safety Study in Retinal Transplantation for Retinitis Pigmentosa.|Completed||Phase 2|10|Actual|Radtke, Norman D., M.D.|||||f||||||||||||||2018-06-01 03:55:30.683112|2018-06-01 03:55:30.683112
NCT00346099|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2007-12-21|2006-06-28|2006-06-29|Estimate|||||||2007-12-21|2008-01-07|Estimate|June 2006||2006-06-30|December 2007|2007-12-31|May 2007|Anticipated|2007-05-31|||||Interventional|||Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum|A Phase II Study to Determine the Efficacy and Safety of Panitumumab in Combination With Chemoradiotherapy for Unresectable or Locally Recurrent Adenocarcinoma of the Rectum With or Without Metastatic Disease|Withdrawn||Phase 2|0|Actual|NSABP Foundation Inc||||"Protocol closed based on new (and as yet unpublished) information from a phase II clinical~   trial."|f||||f||||||||||2018-06-01 03:55:28.712218|2018-06-01 03:55:28.712218
NCT00346086|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2017-08-10|2006-06-27|2006-06-29|Estimate|||||||2017-08-10|2017-08-14|Actual|May 18, 2001|Actual|2001-05-18|August 2017|2017-08-31|August 21, 2001|Actual|2001-08-21|August 21, 2001|Actual|2001-08-21||Interventional|||DNA Vaccine for Ragweed Allergic Adults|A Phase II Observer-blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, Tolerability, and Immunogenicity of Subcutaneously Administered Dynavax Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate (AIC) in Ragweed-Allergic Adults (Sponsor's Protocol NRH01)|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||||"The study was halted prior to enrollment pending submission of a IRB amendment which was never~   completed"|||||||||||||||2018-06-01 03:55:28.769551|2018-06-01 03:55:28.769551
NCT00346073|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2016-10-26|2006-06-28|2006-06-29|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2006||2006-07-31|October 2016|2016-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years|A Study to Evaluate Immunogenicity and Safety of Boostrix Compared to Adacel When Administered as a Booster Vaccination in Adults Aged 19 to 64 Years of Age|Completed||Phase 3|2337|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:28.843192|2018-06-01 03:55:28.843192
NCT00346060|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2014-03-12|2006-06-28|2006-06-29|Estimate|||||||2014-03-12|2014-03-13|Estimate|February 2002||2002-02-28|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.|Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.|Completed||Phase 2|10|Actual|Radtke, Norman D., M.D.|||||f||||||||||||||2018-06-01 03:55:29.129454|2018-06-01 03:55:29.129454
NCT00346047|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2008-04-11|2006-06-28|2006-06-29|Estimate|||||||2008-04-11|2008-04-15|Estimate|May 2006||2006-05-31|April 2008|2008-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain|A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Determine the Efficacy and Safety of BTDS Compared to Placebo in Subjects With Moderate to Severe Low Back Pain|Completed||Phase 3|238|Actual|Mundipharma Pte Ltd.||2|||f||||||||||||||2018-06-01 03:55:29.218709|2018-06-01 03:55:29.218709
NCT00346034|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2009-02-12||2009-03-30|2006-06-28|2006-06-29|Estimate|2009-02-12|2009-03-13|Estimate||||2009-03-30|2009-04-02|Estimate|December 2006||2006-12-31|March 2009|2009-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia|A 12 Week, Open-Label, Safety Trial Of Pregabalin In Patients With Fibromyalgia|Completed||Phase 3|357|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 03:55:29.344939|2018-06-01 03:55:29.344939
NCT00346021|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2012-06-19|2006-06-27|2006-06-29|Estimate|||||||2012-06-19|2012-06-20|Estimate|February 2005||2005-02-28|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Sun Protection for Florida's Children|Sun Protection for Florida's Children|Completed||N/A|2984|Actual|University of South Florida||2|||f||||f||||||||||2018-06-01 03:55:29.643063|2018-06-01 03:55:29.643063
NCT00346008|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2013-05-29|2006-06-27|2006-06-29|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 2005||2005-10-31|December 2008|2008-12-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Observational|||Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members|Genetic Epidemiologic Studies of Melanoma in Iceland|Completed|||2500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:55:29.712951|2018-06-01 03:55:29.712951
NCT00345982|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2010-09-24|2006-06-28|2006-06-29|Estimate|||||||2010-09-24|2010-09-27|Estimate|September 2006||2006-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Augmenting Clozapine With Sertindole - SERCLOZ|Augmenting Clozapine With Sertindole - a Double Blinded Randomized Placebo Study|Completed||N/A|50|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 03:55:29.778684|2018-06-01 03:55:29.778684
NCT00345969|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2016-01-15||2018-01-22|2006-06-27|2006-06-29|Estimate|2018-01-22|2018-02-21|Estimate||||2018-01-22|2018-02-21|Estimate|November 2004||2004-11-30|January 2018|2018-01-31|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional||Men who completed the intervention and provided baseline and follow-up data for primary outcome measures.|Exercise and Testosterone Therapy in Elderly Men With Physical Frailty|Exercise and Testosterone Therapy in Elderly Men With Physical Frailty|Completed||Phase 3|25|Actual|Washington University School of Medicine|Small number of subjects enrolled, single site trial, included both hip fracture patients and a few patients with elective hip joint replacement.|2|||f||||f||||||||No||2018-06-01 03:55:29.895768|2018-06-01 03:55:29.895768
NCT00345956|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2016-10-27|2006-06-28|2006-06-29|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|March 2007|Actual|2007-03-31|||||Interventional|||To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)|A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam|Completed||Phase 3|375|Anticipated|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:30.432386|2018-06-01 03:55:30.432386
NCT00345943|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2018-02-13|2006-06-28|2006-06-29|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2004||2004-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||An fMRI Study of Self-regulation in Adolescents With Bulimia Nervosa|An fMRI Study of Self-regulation in Adolescents With Bulimia Nervosa|Active, not recruiting|||71|Actual|New York State Psychiatric Institute|||2||f||||t||||||||Yes||2018-06-01 03:55:30.510915|2018-06-01 03:55:30.510915
NCT00345930|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2018-04-18|2006-06-28|2006-06-29|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2004||2004-09-30|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||DILIN's Prospective Study|A Multi-Center, Longitudinal Study of Drug-and CAM-Induced Liver Injury|Recruiting|||1600|Anticipated|Duke University|||2||f||||t||||||Samples With DNA|"~     Samples with DNA~   "|||2018-06-01 03:55:30.588523|2018-06-01 03:55:30.588523
NCT00345904|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2016-09-27|2006-06-28|2006-06-29|Estimate|||||||2016-09-27|2016-09-28|Estimate|July 2006||2006-07-31|September 2016|2016-09-30|August 2006|Actual|2006-08-31|||||Interventional|||Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above|A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2006/2007 in People Aged 18 Years or Above|Completed||Phase 3|120||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:30.759362|2018-06-01 03:55:30.759362
NCT00345891|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2014-07-23|2006-06-27|2006-06-29|Estimate|||||||2014-07-23|2014-07-25|Estimate|June 2004||2004-06-30|May 2010|2010-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Quit Smoking Program for Lung Cancer Patients' Families (The Family Ties Project)|Quite Smoking Program for Lung Cancer Patients' Families|Completed||N/A|496|Actual|Duke University|||||f||||f||||||||||2018-06-01 03:55:30.826871|2018-06-01 03:55:30.826871
NCT00345878|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|2009-11-12||2016-11-03|2006-06-28|2006-06-29|Estimate|2009-11-12|2009-12-15|Estimate||||2016-11-03|2016-12-16|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years|Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up|Completed||Phase 3|271|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:31.025952|2018-06-01 03:55:31.025952
NCT00345865|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2018-02-12|2006-06-28|2006-06-29|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2005||2005-08-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|Autologous Peripheral Blood Stem Cell Transplant for Patients With Lymphoma|Active, not recruiting||Phase 2|421|Actual|Masonic Cancer Center, University of Minnesota||3|||f||||t||||||||||2018-06-01 03:55:31.36231|2018-06-01 03:55:31.36231
NCT00345852|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2007-06-28|2006-06-27|2006-06-29|Estimate|||||||2007-06-28|2007-06-29|Estimate|March 2002||2002-03-31|June 2006|2006-06-30|May 2007||2007-05-31|||||Interventional|||Fetoscopic Selective Laser Photocoagulation in Twin-Twin Transfusion Syndrome|A Prospective, Randomized Multicenter Trial of Amnioreduction Vs Selective Fetoscopic Laser Photocoagulation for the Treatment of Severe Twin-Twin Transfusion Syndrome|Unknown status|Active, not recruiting|N/A|150||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 03:55:31.465186|2018-06-01 03:55:31.465186
NCT00345839|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2013-06-06||2018-04-18|2006-06-28|2006-06-29|Estimate|2013-12-05|2014-01-22|Estimate||||2018-04-18|2018-05-15|Actual|August 22, 2006|Actual|2006-08-22|April 2018|2018-04-30|May 30, 2012|Actual|2012-05-30|January 28, 2012|Actual|2012-01-28||Interventional|EVOLVE||E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events|EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events|Completed||Phase 3|3883|Actual|Amgen||2|||f||||t||||||||||2018-06-01 03:55:31.755267|2018-06-01 03:55:31.755267
NCT00345826|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2013-01-07|2006-06-28|2006-06-29|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 2005||2005-11-30|January 2013|2013-01-31||||July 2010|Actual|2010-07-31||Interventional|||Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia|Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Subjects Who Experienced Clinical Benefit on Protocol CA 180-002|Completed||Phase 1|19|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:55:35.699694|2018-06-01 03:55:35.699694
NCT00345813|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2017-11-27|2006-06-28|2006-06-29|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2003||2003-10-31|November 2017|2017-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer|Randomized Phase IIb Preprostatectomy Study of Dietary Supplementation With Soy and Biomarkers of Prostate Cancer Risk and Progression|Completed||N/A|62|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-06-01 03:55:35.767545|2018-06-01 03:55:35.767545
NCT00345800|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-28|||2015-06-18|2006-06-28|2006-06-29|Estimate|||||||2015-06-18|2015-06-19|Estimate|April 2006||2006-04-30|June 2015|2015-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes|Single Center, Therapeutic Exploratory Clinical Trial to Evaluate the Safety of Sodium Oxybate (Xyrem) 500 mg/mL Oral Solution on Potential Endocrine Changes at Currently Labeled Therapeutic Dose Regimens (4.5 - 9 g/Day Divided Into Two Equal Doses) During 12 Weeks of Treatment of Cataplexy in Adult Patients With Narcolepsy.|Completed||Phase 4|25|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:55:35.911952|2018-06-01 03:55:35.911952
NCT00345787|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2008-04-11|2006-06-28|2006-06-29|Estimate|||||||2008-04-11|2008-04-15|Estimate|May 2006||2006-05-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain|A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Determine the Efficacy and Safety of BTDS Compared to Placebo in Subjects With Moderate to Severe Osteoarthritic Pain of the Hip or Knee|Completed||Phase 3|262|Actual|Mundipharma Pte Ltd.||2|||f||||||||||||||2018-06-01 03:55:35.993589|2018-06-01 03:55:35.993589
NCT00345774|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2008-05-27|2006-06-27|2006-06-28|Estimate|||||||2008-05-27|2008-05-29|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|June 2007|Actual|2007-06-30|||||Interventional|||Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Short-Term Efficacy and Safety of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease|Completed||Phase 2|72|Anticipated|Epix Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:55:36.176048|2018-06-01 03:55:36.176048
NCT00345761|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2010-08-13|2006-06-27|2006-06-28|Estimate|||||||2010-08-13|2010-08-16|Estimate|February 2006||2006-02-28|August 2010|2010-08-31|July 2010|Actual|2010-07-31|October 2008|Actual|2008-10-31||Interventional|||Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer|Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|64|Actual|Chugai Pharmaceutical||3|||f||||f||||||||||2018-06-01 03:55:36.260683|2018-06-01 03:55:36.260683
NCT00345592|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2014-04-04||2017-02-27|2006-06-27|2006-06-28|Estimate|2014-05-13|2014-06-11|Estimate||||2017-02-27|2017-03-28|Actual|October 2006||2006-10-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|TRADE HF||TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients|TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients|Completed||Phase 4|420|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 03:55:38.504722|2018-06-01 03:55:38.504722
NCT00345748|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23||2011-04-11|2011-04-11|2006-06-27|2006-06-28|Estimate||||2011-04-11|2011-04-25|Estimate|2011-04-11|2011-04-25|Estimate|June 2006||2006-06-30|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate|A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate|Completed||Phase 2|194|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 03:55:36.349598|2018-06-01 03:55:36.349598
NCT00345735|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2012-05-04|2006-06-26|2006-06-28|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2006||2006-05-31|May 2012|2012-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)|Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients. A Randomised, Double-blind, Placebo-controlled, Cross-over Confirmatory Trial Testing Fentanyl and Placebo in Eight Breakthrough Pain Episodes|Completed||Phase 2|150|Anticipated|Nycomed|||||f||||||||||||||2018-06-01 03:55:36.53101|2018-06-01 03:55:36.53101
NCT00345722|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2007-05-07|2006-06-26|2006-06-28|Estimate|||||||2007-05-07|2007-05-08|Estimate|June 2006||2006-06-30|May 2007|2007-05-31|February 2007|Actual|2007-02-28|||||Interventional|||The Effect of Strawberries in a Cholesterol-Lowering Dietary Portfolio|The Long-Term Effect of Viscous Fibers, Soy Protein, and Plant Sterol Foods in Combination on Serum Cholesterol and Other Risk Factors for Cardiovascular Disease|Completed||Phase 2|50||University of Toronto|||||f||||||||||||||2018-06-01 03:55:36.595515|2018-06-01 03:55:36.595515
NCT00345709|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2015-10-05|2006-06-27|2006-06-28|Estimate|||||||2015-10-05|2015-10-07|Estimate|September 2003||2003-09-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Elizabeth Registry for Low Grade Ovarian Cancer|The Elizabeth Registry for Low Grade Ovarian Cancer|Completed|||60|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-06-01 03:55:36.682882|2018-06-01 03:55:36.682882
NCT00345696|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2011-08-23|2006-06-27|2006-06-28|Estimate|||||||2011-08-23|2011-08-24|Estimate|June 2006||2006-06-30|August 2011|2011-08-31|January 2011|Actual|2011-01-31|October 2008|Actual|2008-10-31||Interventional|||1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.|Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients.|Completed||Phase 2|32|Actual|Unidad Integral de Investigación en Oncología S.L.|||||f||||f||||||||||2018-06-01 03:55:36.761083|2018-06-01 03:55:36.761083
NCT00345683|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2012-06-15|2009-06-08|2016-10-18|2006-06-26|2006-06-28|Estimate|2012-06-15|2012-07-20|Estimate|2009-09-28|2009-09-30|Estimate|2016-10-18|2016-11-29|Estimate|July 2007||2007-07-31|October 2016|2016-10-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.|Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.|Completed||Phase 3|4021|Actual|GlaxoSmithKline|Only information about specific categories of AEs (SAEs, NOCIs, rash and AEs resulting in ER visits) were collected in this study.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:36.872728|2018-06-01 03:55:36.872728
NCT00345670|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2008-09-02|2006-06-27|2006-06-28|Estimate|||||||2008-09-02|2008-09-03|Estimate|June 2006||2006-06-30|September 2008|2008-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy RSV and PIV3 Seropositive 1-9 Year-Old Children|Completed||Phase 1|120||MedImmune LLC||3|||f||||t||||||||||2018-06-01 03:55:37.342265|2018-06-01 03:55:37.342265
NCT00345657|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2006-06-27|2006-06-27|2006-06-28|Estimate|||||||2006-06-27|2006-06-28|Estimate|July 2003||2003-07-31|June 2006|2006-06-30|May 2004||2004-05-31|||||Interventional|||Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care|Extended-Release Niacin/Lovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting (EXTEND Study)|Completed||Phase 4|100||In His Image|||||f||||||||||||||2018-06-01 03:55:37.422627|2018-06-01 03:55:37.422627
NCT00345644|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2009-12-04|2006-06-27|2006-06-28|Estimate|||||||2009-12-04|2009-12-07|Estimate|March 2006||2006-03-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|OSMAUSE||Risedronate in Osteopenic Postmenopausal Women|A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 24 Month, Monocenter Study Comparing Weekly Oral Risedronate 35 mg and Placebo|Completed||Phase 3|156|Anticipated|Sanofi||2|||f||||f||||||||||2018-06-01 03:55:37.477719|2018-06-01 03:55:37.477719
NCT00345631|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2012-02-27||2012-05-25|2006-06-26|2006-06-28|Estimate|2012-02-27|2012-03-19|Estimate||||2012-05-25|2012-06-01|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device|ECLIPSE Trial - Ensure's Vascular Closure Device Speeds Hemostasis Trial|Completed||Phase 3|488|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 03:55:37.57197|2018-06-01 03:55:37.57197
NCT00345618|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27||2016-02-19|2016-02-19|2006-06-27|2006-06-28|Estimate||||2016-02-19|2016-03-21|Estimate|2016-02-19|2016-03-21|Estimate|June 2006||2006-06-30|February 2016|2016-02-29|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CASSIOPEA||Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach|An International, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Study of 3-month or 6-month Treatment With SSR126517E (3.0 mg s.c. Once-weekly) Versus Oral INR-adjusted Warfarin in the Treatment of Patients With Symptomatic Pulmonary Embolism With or Without Symptomatic Deep Venous Thrombosis|Completed||Phase 3|3202|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:55:38.085698|2018-06-01 03:55:38.085698
NCT00345605|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2014-05-15||2018-01-26|2006-06-26|2006-06-28|Estimate|2014-11-03|2014-11-05|Estimate||||2018-01-26|2018-01-31|Actual|February 2008||2008-02-29|October 2015|2015-10-31|November 2012|Actual|2012-11-30|May 2011|Actual|2011-05-31||Interventional|||Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder|A Randomized, Double-Blind, Crossover Study of Sodium Phenylbutyrate and Low-Dose Arginine Compared to High-Dose Arginine Alone on Liver Function, Ureagenesis and Subsequent Nitric Oxide Production in Patients With Argininosuccinic Aciduria|Completed||Phase 2|12|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 03:55:38.257289|2018-06-01 03:55:38.257289
NCT00345579|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2012-06-15|2009-04-27|2016-11-03|2006-06-26|2006-06-28|Estimate|2009-04-20|2009-06-11|Estimate|2009-09-25|2009-09-28|Estimate|2016-11-03|2016-12-16|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age|A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.|Completed||Phase 3|4432|Actual|GlaxoSmithKline|Solicited symptoms and unslocited AEs were not collected during this study. Only information about specific categories of AEs (SAEs, NOCIs, rash and AEs resulting in ER visits) were collected in this study.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:38.846652|2018-06-01 03:55:38.846652
NCT00345566|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2006-06-27|2006-06-27|2006-06-28|Estimate|||||||2006-06-27|2006-06-28|Estimate|August 2006||2006-08-31|June 2006|2006-06-30|December 2007||2007-12-31|||||Interventional|||Effect of Protein Composition on Gastric Emptying|Effect of the Protein Composition on the Gastric Emptying Rate in Children With Cerebral Paresis|Unknown status|Not yet recruiting|N/A|25||Ullevaal University Hospital|||||f||||||||||||||2018-06-01 03:55:39.311353|2018-06-01 03:55:39.311353
NCT00345553|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2018-02-15|2006-06-27|2006-06-28|Estimate|||||||2018-02-15|2018-02-19|Actual|May 2006||2006-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|BASIC||Biliary Atresia Study in Infants and Children|Biliary Atresia Study in Infants and Children (BASIC)|Recruiting|||1265|Anticipated|Arbor Research Collaborative for Health|||2||f||||t||||||Samples With DNA|"~     Samples of blood and urine will be collected for research purposes.~   "|Yes|The data will be transferred to NIDDK at the end of the study.|2018-06-01 03:55:39.362985|2018-06-01 03:55:39.362985
NCT00345540|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2013-07-09||2015-02-25|2006-06-26|2006-06-28|Estimate|2015-02-25|2015-03-10|Estimate||||2015-02-25|2015-03-10|Estimate|July 2006||2006-07-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer|Phase 2 Trial of NOV-002 With Carboplatin in Women With Recurrent and Platinum Resistant Tumors of Mullerian Origin|Completed||Phase 2|15|Actual|Cellectar Biosciences, Inc.|The criterion for continuing to Stage II of the study (≥ 2 responses) was not met.|1|||f||||f||||||||||2018-06-01 03:55:39.468704|2018-06-01 03:55:39.468704
NCT00345527|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2013-02-11|2006-06-27|2006-06-28|Estimate|||||||2013-02-11|2013-02-13|Estimate||||February 2013|2013-02-28||||November 2006|Actual|2006-11-30||Interventional|||A Randomized Control Trial Examining Two Treatments for Problem Gambling|A Randomized Control Trial Examining Two Treatments for Problem Gambling|Withdrawn||N/A|0|Actual|Centre for Addiction and Mental Health||||Study moved to British Columbia|f||||f||||||||||2018-06-01 03:55:40.768852|2018-06-01 03:55:40.768852
NCT00345514|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2012-11-08|2006-06-27|2006-06-28|Estimate|||||||2012-11-08|2012-11-09|Estimate|September 2002||2002-09-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Provider and Organization in Asthma Guidelines|The Provider and Organization in Asthma Guidelines|Completed||N/A|36|Actual|UConn Health||3|||f||||f||||||||||2018-06-01 03:55:40.833377|2018-06-01 03:55:40.833377
NCT00345501|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2007-08-22|2006-06-27|2006-06-28|Estimate|||||||2007-08-22|2007-08-24|Estimate|November 2005||2005-11-30|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention|Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients With Preexisting Renal Dysfunction Undergoing a Coronary Procedure|Completed||Phase 2/Phase 3|208|Actual|Onassis Cardiac Surgery Centre||2|||f||||t||||||||||2018-06-01 03:55:40.901099|2018-06-01 03:55:40.901099
NCT00345488|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2006-06-27|2006-06-27|2006-06-28|Estimate|||||||2006-06-27|2006-06-28|Estimate|September 2002||2002-09-30|May 2006|2006-05-31|June 2005||2005-06-30|||||Observational|||Fast Track Admittance of Hip Fracture Patients|Fast Track ER Admittance of Hip Fracture Patients|Unknown status|Active, not recruiting||300||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 03:55:40.965506|2018-06-01 03:55:40.965506
NCT00345475|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2016-09-01|2006-06-26|2006-06-28|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2004||2004-12-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)|A Prospective Study Of Pregnancies Exposed to UCB Antiepileptic Drugs to Determine if There is a Potential Increase in the Risk of Major Birth Defects|Completed|||516|Actual|UCB Pharma|||1||f||||t||||||||||2018-06-01 03:55:41.008005|2018-06-01 03:55:41.008005
NCT00345462|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2010-02-05|2006-06-27|2006-06-28|Estimate|||||||2010-02-05|2010-02-08|Estimate|June 2006||2006-06-30|February 2010|2010-02-28||||||||Interventional|||Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.|Immunogenicity and Reactogenicity of Trivalent Virosomal Influenza Vaccine Invivac® for the Season 2006/2007. An Open, Baseline-controlled Study in Two Groups of Healthy Subjects: Adults and Elderly.|Withdrawn||Phase 3|120||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 03:55:41.065283|2018-06-01 03:55:41.065283
NCT00345449|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2009-07-08|2006-06-27|2006-06-28|Estimate|||||||2009-07-08|2009-07-09|Estimate|September 2006||2006-09-30|July 2009|2009-07-31|September 2008|Actual|2008-09-30|||||Interventional|||Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation|Evaluation of a Decision Aid for Adult Cystic Fibrosis Patients Considering Bilateral Lung Transplantation|Completed||N/A|200|Anticipated|Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 03:55:41.119626|2018-06-01 03:55:41.119626
NCT00345436|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2017-06-30|2006-06-27|2006-06-28|Estimate|||||||2017-06-30|2017-07-02|Actual|February 8, 2006||2006-02-08|May 11, 2011|2011-05-11|May 11, 2011||2011-05-11|||||Observational|||Exercise in Insulin-Resistant Minority Adolescents|An Exercise Intervention in Insulin-Resistant Minority Adolescents|Completed|||40|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:41.890056|2018-06-01 03:55:41.890056
NCT00345410|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2008-12-18|2006-06-27|2006-06-28|Estimate|||||||2008-12-18|2008-12-19|Estimate|June 2006||2006-06-30|December 2008|2008-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Three Doses of AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia|Completed||Phase 2|345|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:55:41.945564|2018-06-01 03:55:41.945564
NCT00345215|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2011-06-27|2006-06-24|2006-06-27|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|May 2007|Actual|2007-05-31|December 2006|Actual|2006-12-31||Interventional|||The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Healthy Humans.|The Effect of High and Low Sodium Intake on Aquaporin-2 in Healthy Humans, During Basal Conditions and After Hypertonic Saline Infusion.|Completed||N/A|26|Actual|Regional Hospital Holstebro|||||f||||f||||||||||2018-06-01 03:55:44.121575|2018-06-01 03:55:44.121575
NCT00345397|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2015-02-26||2018-04-10|2006-06-27|2006-06-28|Estimate|2015-05-06|2015-05-22|Estimate||||2018-04-10|2018-05-11|Actual|May 1, 2006|Actual|2006-05-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|March 31, 2014|Actual|2014-03-31||Interventional|||A Colonic Tube to Improve Bowel Function in Spinal Cord Injury|Percutaneous Colostomy for Bowel Management in Spinal Cord Injury|Active, not recruiting||N/A|7|Actual|VA Office of Research and Development|"Difficulty in recruitment from a limited population reduced our intended enrollment and prolonged our study.~This also reduced our statistical significance and limited our conclusions."|1|||f||||f|f|t|f|f|f|||No||2018-06-01 03:55:42.016666|2018-06-01 03:55:42.016666
NCT00345384|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2011-08-10||2016-01-12|2006-06-27|2006-06-28|Estimate|2015-07-27|2015-08-20|Estimate||||2016-01-12|2016-02-08|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||13 were withdrawn from study prior to initiation of drug due to exclusion criteria that required an overnight stay in Recovery or ICU.|Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients|Post-Operative Infusion of Low-Dose Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients: A Randomized, Double-Blind, Controlled Pilot Study|Completed||Phase 1/Phase 2|38|Actual|Baylor Research Institute|Pilot study with small numbers of participants.|2|||f||||f||||||||||2018-06-01 03:55:42.186298|2018-06-01 03:55:42.186298
NCT00345371|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2017-01-03||2017-02-23|2006-06-27|2006-06-28|Estimate|2017-01-03|2017-02-23|Actual||||2017-02-23|2017-03-27|Actual|April 2006||2006-04-30|February 2017|2017-02-28|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Topiramate for the Treatment of Methamphetamine Dependence - 1|Phase 2, Double-Blind, Placebo-Controlled Trial of Topiramate for the Treatment of Methamphetamine Dependence|Completed||Phase 2|140|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||||||||||||2018-06-01 03:55:42.420938|2018-06-01 03:55:42.420938
NCT00345358|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27||2012-03-09|2012-09-06|2006-06-27|2006-06-28|Estimate||||2012-03-09|2012-03-14|Estimate|2012-09-06|2012-09-11|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine|Evaluate Immunogenicity, Safety & Reactogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-dose Primary Immunization in Children Before 6 mo of Age|Completed||Phase 3|600|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 03:55:42.8142|2018-06-01 03:55:42.8142
NCT00345345|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2018-03-27|2006-06-27|2006-06-28|Estimate|||||||2018-03-27|2018-03-29|Actual|June 21, 2006||2006-06-21|November 22, 2017|2017-11-22|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia|Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath)|Active, not recruiting||Phase 2|29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:42.930617|2018-06-01 03:55:42.930617
NCT00345332|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|2016-04-04||2017-06-07|2006-06-27|2006-06-28|Estimate|2017-06-07|2017-07-11|Actual||||2017-06-07|2017-07-11|Actual|October 2005||2005-10-31|June 2017|2017-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of Botox for Severe Refractory Urge Urinary Incontinence|Completed||N/A|31|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 03:55:43.016839|2018-06-01 03:55:43.016839
NCT00345319|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2011-12-12|2006-06-27|2006-06-28|Estimate|||||||2011-12-12|2011-12-14|Estimate|March 2006||2006-03-31|December 2011|2011-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Purified Rabies Vaccine for Human Use (Chick-embryo Cell)|Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years.|Completed||Phase 3|630|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:55:43.243939|2018-06-01 03:55:43.243939
NCT00345306|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2008-05-06|2006-06-27|2006-06-28|Estimate|||||||2008-05-06|2008-05-07|Estimate|March 2007||2007-03-31|June 2006|2006-06-30||||||||Interventional|||Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan|Artificial Endometrial Preparation for Frozen Thawed Embryo Transfer Applying Either Endometrin or Utrogestan - a Clinical Comparative Study|Suspended||Phase 4|120|Anticipated|Hadassah Medical Organization||||no patient was recruited till 1/2008|f||||f||||||||||2018-06-01 03:55:43.305949|2018-06-01 03:55:43.305949
NCT00345293|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2015-06-24||2016-04-01|2006-06-26|2006-06-28|Estimate|2016-04-01|2016-04-18|Estimate||||2016-04-01|2016-04-18|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|December 2013|Actual|2013-12-31||Interventional|||Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer|A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate Cancer Patients.|Completed||Phase 1/Phase 2|13|Actual|Rockefeller University||1|||f||||t||||||||||2018-06-01 03:55:43.379647|2018-06-01 03:55:43.379647
NCT00345280|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-27|||2008-06-16|2006-06-27|2006-06-28|Estimate|||||||2008-06-16|2008-06-17|Estimate|August 2006||2006-08-31|June 2008|2008-06-30|September 2008|Anticipated|2008-09-30|||||Observational|||Ocular Surface Changes in Patients With Cystic Fibrosis|Chosen Parameters of the Immune Response in the Origin of Ocular Changes in Patients With Cystic Fibrosis|Unknown status|Recruiting||26|Anticipated|University of Bialystok|||||f||||f||||||||||2018-06-01 03:55:43.603937|2018-06-01 03:55:43.603937
NCT00345267|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2006-06-26|2006-06-26|2006-06-28|Estimate|||||||2006-06-26|2006-06-28|Estimate|August 2004||2004-08-31|June 2006|2006-06-30|March 2005||2005-03-31|||||Interventional|||Effect of an Integrated Care Pathway on Asthma Care in Hospital|Cluster Randomised Controlled Trial of the Effect of the Introduction of an Acute Wheeze/Asthma Integrated Care Pathway on Patient Outcome|Completed||N/A|180||University of Edinburgh|||||f||||||||||||||2018-06-01 03:55:43.744978|2018-06-01 03:55:43.744978
NCT00345254|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2016-11-11||2017-04-05|2006-06-26|2006-06-27|Estimate|2016-11-11|2017-01-10|Estimate||||2017-04-05|2017-05-11|Actual|September 2003||2003-09-30|April 2017|2017-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Severing Nuchal Cord at the Time of Delivery.|Study That Clarifies Whether Cord Around the Neck Should be Severed at Delivery.|Completed||N/A|60|Actual|Wolfson Medical Center||2|||f||||f||||||||No||2018-06-01 03:55:43.820086|2018-06-01 03:55:43.820086
NCT00345241|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2008-06-19|2006-06-23|2006-06-27|Estimate|||||||2008-06-19|2008-06-23|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points|Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points|Completed||N/A|12|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:55:44.007189|2018-06-01 03:55:44.007189
NCT00345228|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2006-06-26|2006-06-26|2006-06-27|Estimate|||||||2006-06-26|2006-06-27|Estimate|June 2004||2004-06-30|May 2004|2004-05-31|December 2006||2006-12-31|||||Observational|||Myopic Macular Haemorrhages|Myopic Macular Haemorrhages|Completed|||30||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:44.068068|2018-06-01 03:55:44.068068
NCT00345202|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2008-05-14|2006-06-26|2006-06-27|Estimate|||||||2008-05-14|2008-05-15|Estimate|September 2004||2004-09-30|May 2008|2008-05-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects|Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects.|Completed||Phase 4|20||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:55:44.193013|2018-06-01 03:55:44.193013
NCT00345189|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2009-07-10|2006-06-23|2006-06-27|Estimate|||||||2009-07-10|2009-07-14|Estimate|February 2006||2006-02-28|July 2009|2009-07-31|April 2009|Actual|2009-04-30|July 2008|Actual|2008-07-31||Interventional|||Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, PK, and PD Study of CNF2024 Administered Orally Twice Weekly for 3 Weeks of a 4 Week Course or Twice Weekly for 4 Weeks of a 4 Week Course to Patients With Advanced Solid Tumors|Completed||Phase 1|70|Actual|Biogen||2|||f||||t||||||||||2018-06-01 03:55:44.250871|2018-06-01 03:55:44.250871
NCT00345176|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2013-11-01||2015-04-13|2006-06-23|2006-06-27|Estimate|2013-11-01|2013-12-24|Estimate||||2015-04-13|2015-05-05|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|AREDS2||Age-Related Eye Disease Study 2 (AREDS2)|Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration|Completed||Phase 3|4203|Actual|National Eye Institute (NEI)||4|||f||||t||||||||||2018-06-01 03:55:44.377179|2018-06-01 03:55:44.377179
NCT00345163|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2017-05-15|2006-06-26|2006-06-27|Estimate|||||||2017-05-15|2017-05-16|Actual|July 2006|Actual|2006-07-31|May 2017|2017-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|BRAIN||A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)|A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse|Completed||Phase 2|167|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 03:55:44.965392|2018-06-01 03:55:44.965392
NCT00345150|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2006-06-24|2006-06-24|2006-06-27|Estimate|||||||2006-06-24|2006-06-27|Estimate||||June 2006|2006-06-30||||||||Interventional|||Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls|Phase 1 Study of the Effects of Systemic Nitric Oxide Inhibition With Ng-Monomethyl-L-Arginine on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls|Completed||Phase 1|30||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:55:45.028306|2018-06-01 03:55:45.028306
NCT00345137|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2006-06-24|2006-06-24|2006-06-27|Estimate|||||||2006-06-24|2006-06-27|Estimate||||June 2006|2006-06-30||||||||Interventional|||Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis|Phase 1 Study of Systemic Effects of Ng-Monomethyl-L-Arginine on Renal Hemodynamics in Patients With Polycystic Kidney Disease and Chronic Glomerulonephritis|Completed||Phase 1|75||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:55:45.073284|2018-06-01 03:55:45.073284
NCT00345124|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2011-06-27|2006-06-24|2006-06-27|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential Hypertension|The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Essential Hypertension, During Basal Conditions and After Hypertonic Saline Infusion.|Completed||N/A|50|Actual|Regional Hospital Holstebro|||||f||||f||||||||||2018-06-01 03:55:45.128486|2018-06-01 03:55:45.128486
NCT00345111|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2014-09-26|2006-06-23|2006-06-27|Estimate|||||||2014-09-26|2014-09-29|Estimate|July 2005||2005-07-31|September 2014|2014-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||ACRYSOF® Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance RESTOR IOL SN60WF IOL (Control Group)|ACRYSOF® Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance With RESTOR IOL Compared With SN60WF IOL (Control Group)|Withdrawn||Phase 4|0|Actual|University of Texas Southwestern Medical Center||||Verified with former investigator that recruitment activity did not take place|f||||||||||||||2018-06-01 03:55:45.27705|2018-06-01 03:55:45.27705
NCT00345098|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2009-03-10|2006-06-26|2006-06-27|Estimate|||||||2009-03-10|2009-03-12|Estimate|May 2006||2006-05-31|March 2009|2009-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|CALYPSO||A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder|A Double-Blind, Multi-Center, Multinational, Randomized Withdrawal Study Evaluating the Efficacy and Safety of SR58611A (350mg q12) Versus Placebo in the Prevention of Depression Relapse up to 1 Year in Patients With Major Depressive Disorder Improved After 12 Weeks of Open Treatment With SR58611A (350mg q12)|Completed||Phase 3|704|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:55:45.338818|2018-06-01 03:55:45.338818
NCT00345085|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2014-07-24|2006-06-23|2006-06-27|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 2005||2005-03-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|||||Observational|||Comparison of Higher Order Aberrations and Contrast Sensitivity Between Acrysof SN60AT, SN60WF and Restore Intraocular Lenses|Comparison of Higher Order Aberrations and Contrast Sensitivity Between Acrysof SN60AT, SN60WF and Restore Intraocular Lenses|Completed|||40|Actual|University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 03:55:45.41768|2018-06-01 03:55:45.41768
NCT00345072|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2006-06-26|2006-06-26|2006-06-27|Estimate|||||||2006-06-26|2006-06-27|Estimate|July 2003||2003-07-31|June 2006|2006-06-30||||||||Interventional|||A Menopause Interactive Decision Aid System|A Menopause Interactive Decision Aid System|Unknown status|Active, not recruiting|N/A|296||Rhode Island Hospital|||||f||||||||||||||2018-06-01 03:55:45.472966|2018-06-01 03:55:45.472966
NCT00345059|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2016-01-13|2006-06-26|2006-06-27|Estimate|||||||2016-01-13|2016-01-14|Estimate|May 2005||2005-05-31|January 2016|2016-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|DISTAL-2||The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer|Single Agent Chemotherapy With Weekly Docetaxel vs Combination Chemotherapy in Second-line Treatment of Advanced Non Small Cell Lung Cancer|Terminated||Phase 3|84|Actual|National Cancer Institute, Naples||3||slow accrual|f||||f||||||||||2018-06-01 03:55:45.537731|2018-06-01 03:55:45.537731
NCT00345046|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2013-12-24||2015-06-02|2006-06-26|2006-06-27|Estimate|2014-03-17|2014-04-21|Estimate||||2015-06-02|2015-06-03|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Comparison of Three Different Formulations of Prednisolone Acetate 1%|A Comparison of Three Different Formulations of Topical Prednisolone Acetate 1% for Control of Post Glaucoma and/or Cataract Surgery Inflammation.|Completed||Phase 4|60|Actual|Indiana University||3|||f||||f||||||||||2018-06-01 03:55:45.664829|2018-06-01 03:55:45.664829
NCT00345033|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|2012-04-26||2014-06-10|2006-06-23|2006-06-27|Estimate|2012-08-14|2012-09-13|Estimate||||2014-06-10|2014-06-23|Estimate|March 2005||2005-03-31|June 2014|2014-06-30|October 2010|Actual|2010-10-31|October 2009|Actual|2009-10-31||Interventional|||Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia|Aripiprazole for Clozapine Associated Medical Morbidity|Completed||Phase 4|38|Actual|Massachusetts General Hospital|The limitations of this study include the relatively small sample size, short intervention period (8 weeks) and the lack of generalizability of our findings to patients with schizophrenia treated by antipsychotic agents other than clozapine.|2|||f||||t||||||||||2018-06-01 03:55:45.902544|2018-06-01 03:55:45.902544
NCT00345020|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2008-06-19|2006-06-23|2006-06-27|Estimate|||||||2008-06-19|2008-06-23|Estimate|May 2006||2006-05-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|Completed|||0|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:55:46.204138|2018-06-01 03:55:46.204138
NCT00345007|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2006-06-26|2006-06-26|2006-06-27|Estimate|||||||2006-06-26|2006-06-27|Estimate|June 2005||2005-06-30|May 2005|2005-05-31|October 2006||2006-10-31|||||Observational|||Macular Function After Scleral Buckle|Assessment of Recovery of Macula Function After Successful Scleral Buckling Surgery for Rhegmatogenous Retinal Detachment|Completed|||27||Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:46.259274|2018-06-01 03:55:46.259274
NCT00344994|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2011-05-12|2006-06-23|2006-06-27|Estimate|||||||2011-05-12|2011-05-13|Estimate|May 2006||2006-05-31|May 2011|2011-05-31|April 2010|Actual|2010-04-30|September 2007|Actual|2007-09-30||Interventional|||SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole|An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose|Completed||Phase 4|20|Anticipated|Augusta University|||||f||||||||||||||2018-06-01 03:55:46.314614|2018-06-01 03:55:46.314614
NCT00344981|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2010-05-21|2006-06-23|2006-06-27|Estimate|||||||2010-05-21|2010-05-24|Estimate|June 2003||2003-06-30|May 2010|2010-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|HADIT||Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression|A Study to Probe The Safety And Durability of Tenofovir And a Cell Cycle Agent to Maintain Viral Suppression|Completed||N/A|9|Actual|University of Maryland|||||f||||t||||||||||2018-06-01 03:55:46.380279|2018-06-01 03:55:46.380279
NCT00344968|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2013-09-27||2014-04-08|2006-06-26|2006-06-27|Estimate|2014-04-08|2014-05-07|Estimate||||2014-04-08|2014-05-07|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|FAME|Three subjects were randomized but did not receive treatment. These subjects were not included in the safety analysis, which accounts for the discrepancy in the overall number of participants.|Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema|A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/Day and ASI-001B 0.2 μg/Day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Edema|Completed||Phase 3|956|Actual|Alimera Sciences||3|||f||||||||||||||2018-06-01 03:55:46.52975|2018-06-01 03:55:46.52975
NCT00344955|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2008-05-14|2006-06-26|2006-06-27|Estimate|||||||2008-05-14|2008-05-15|Estimate|January 2003||2003-01-31|May 2008|2008-05-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects|Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects|Completed||Phase 4|20||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:55:48.442311|2018-06-01 03:55:48.442311
NCT00344942|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2009-12-04|2006-06-26|2006-06-27|Estimate|||||||2009-12-04|2009-12-07|Estimate|April 2006||2006-04-30|December 2009|2009-12-31||||April 2007|Actual|2007-04-30||Interventional|RhiCNANI||Efficacy and Safety Study of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults|A Randomised, Double-blind, French Multi-centre Study, to Evaluate the Efficacy and Tolerance, in Comparison With Placebo, of Nasacort in Chronic Non Allergic and Non Infectious Rhinitis in Adults|Terminated||Phase 3|77|Actual|Sanofi||2||patient's recruitment too difficult|f||||f||||||||||2018-06-01 03:55:48.499101|2018-06-01 03:55:48.499101
NCT00344929|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2007-04-26|2006-06-26|2006-06-27|Estimate|||||||2007-04-26|2007-04-27|Estimate|November 2005||2005-11-30|April 2007|2007-04-30||||||||Observational|||Severe Post Partum Haemorrhage (PPH): A Randomized Trial on Transversal Intervention in 6 French Perinatal Networks|Severe Post Partum Haemorrhage (PPH): A Randomized Trial on Transversal Intervention in 6 French Perinatal Networks|Unknown status|Recruiting||6500|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 03:55:48.577595|2018-06-01 03:55:48.577595
NCT00344916|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2006-07-10|2006-06-24|2006-06-27|Estimate|||||||2006-07-10|2006-07-11|Estimate||||June 2006|2006-06-30||||||||Interventional|||Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis|NO-Synthesis in Patients With Liver Cirrhosis: Effect of L-NMMA on Renal Hemodynamics, Sodium Excretion and Plasma Levels of Vasoactive Hormones|Completed||Phase 1|30||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:55:48.635959|2018-06-01 03:55:48.635959
NCT00344903|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2010-07-07|2006-06-23|2006-06-27|Estimate|||||||2010-07-07|2010-07-08|Estimate|September 2007||2007-09-30|February 2009|2009-02-28|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Observational|||Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort|Longitudinal Cohort Study of Dallas County Residents to Identify Novel Determinants of Atherosclerotic Heart Disease: The DHS 2|Completed|||3400|Actual|University of Texas Southwestern Medical Center|||||f||||t||||||Samples With DNA|"~     Plasma Serum DNA~   "|||2018-06-01 03:55:48.711757|2018-06-01 03:55:48.711757
NCT00344890|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2015-04-03|2006-06-23|2006-06-27|Estimate|||||||2015-04-03|2015-04-07|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety Study of Preservon-Treated Bone Implants for Cervical Fusion in the Treatment of Cervical Radiculopathy or Myelopathy|A Safety and Efficacy Comparison of Preservon Treated Allograft Bone Dowels Versus Traditional Freeze-Dried Allograft Bone Dowels for Fusion of Degenerated Cervical Intervertebral Discs in the Treatment of Cervical Radiculopathy or Myelopathy|Completed||N/A|106|Actual|LifeNet Health||2|||f||||t||||||||||2018-06-01 03:55:48.772704|2018-06-01 03:55:48.772704
NCT00344877|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2017-06-30|2006-06-23|2006-06-27|Estimate|||||||2017-06-30|2017-07-02|Actual|June 19, 2006||2006-06-19|May 5, 2009|2009-05-05|May 5, 2009||2009-05-05|||||Observational|||Electrical Brain Stimulation to Reduce Epileptic Seizures|Anticonvulsive Effects of Transcranial DC Stimulation in Pharmacoresistant Focal Epilepsy|Completed|||56||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:48.837927|2018-06-01 03:55:48.837927
NCT00342251|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 20, 2003||2003-06-20|April 4, 2012|2012-04-04|April 4, 2012||2012-04-04|||||Observational|||Investigating Age-Related Macular Degeneration|Age-Related Macular Degeneration: A Genetic Epidemiology Study in the Amish|Completed|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.004085|2018-06-01 03:56:20.004085
NCT00344864|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2011-03-22|2006-06-23|2006-06-27|Estimate|||||||2011-03-22|2011-03-23|Estimate|January 2006||2006-01-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||A Prospective Clinical Research Project Evaluating The Effects of Soft Contact Lenses on Higher Order Visual Aberrations|A Prospective Clinical Research Project Evaluating The Effects of Soft Contact Lenses on Higher Order Visual Aberrations|Terminated|||30|Anticipated|University of Texas Southwestern Medical Center||||Terminated due to lack of patient recruitment|f||||f||||||||||2018-06-01 03:55:48.889781|2018-06-01 03:55:48.889781
NCT00344851|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2007-07-10|2006-06-23|2006-06-27|Estimate|||||||2007-07-10|2007-07-11|Estimate|June 2006||2006-06-30|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Exenatide and Metformin Therapy in Overweight Women With PCOS|Comparison of the Effects of Monotherapy With Exenatide or Metformin to Combined Exenatide and Metformin Therapy on Menstrual Cyclicity in Overweight Women With Polycystic Ovary Syndrome|Completed||Phase 2|60|Actual|Metabolic Center of Louisiana Research Foundation|||||f||||f||||||||||2018-06-01 03:55:48.945833|2018-06-01 03:55:48.945833
NCT00344838|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2018-01-28|2006-06-23|2006-06-27|Estimate|||||||2018-01-28|2018-01-30|Actual|September 2003||2003-09-30|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|December 2015|Actual|2015-12-31||Observational|||Customized Laser Ablation: Comparing Results of LADAR Vision and VISX Platforms|Customized Laser Ablation: Comparing Results of LADAR Vision and VISX Platforms|Completed|||458|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:55:49.015947|2018-06-01 03:55:49.015947
NCT00344825|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2013-12-02|2006-06-26|2006-06-27|Estimate|||||||2013-12-02|2013-12-04|Estimate|January 2004||2004-01-31|December 2013|2013-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)|Observational Study for Evaluation of Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia.|Completed|||300|Actual|Sanofi|||1||f||||f||||||||||2018-06-01 03:55:49.069215|2018-06-01 03:55:49.069215
NCT00344812|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2006-06-26|2006-06-26|2006-06-27|Estimate|||||||2006-06-26|2006-06-27|Estimate|January 1996||1996-01-31|March 2006|2006-03-31|June 1998||1998-06-30|||||Interventional|||Opioid Maintenance Medications Comparison Study||Completed||Phase 2|220||Johns Hopkins University|||||||||||||||||||2018-06-01 03:55:49.149069|2018-06-01 03:55:49.149069
NCT00344799|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2017-09-12|2006-06-26|2006-06-27|Estimate|||||||2017-09-12|2017-09-13|Actual|January 8, 2005|Actual|2005-01-08|September 2017|2017-09-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||Cytogenetic Study of Ocular Melanoma|Molecular and Cytogenetic Studies of Ocular Melanoma|Recruiting|||200|Anticipated|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 03:55:49.245055|2018-06-01 03:55:49.245055
NCT00344786|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2009-06-04|2006-06-23|2006-06-27|Estimate|||||||2009-06-04|2009-06-05|Estimate|February 2006||2006-02-28|June 2009|2009-06-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL|A Phase 1, Dose-Escalation Study of CNF2024 Administered Orally to Patients With B Cell Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 1|15|Actual|Biogen||1||Sponsor's decision|f||||f||||||||||2018-06-01 03:55:49.303484|2018-06-01 03:55:49.303484
NCT00344773|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|2008-12-19||2010-06-24|2006-06-26|2006-06-27|Estimate|2010-05-11|2010-06-04|Estimate||||2010-06-24|2010-06-29|Estimate|March 2006||2006-03-31|June 2010|2010-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation|An Open-label, Multi-centre Study to Evaluate Efficacy and Safety of Gefitinib as the First-line Treatment for Locally Advanced (IIIB), Metastatic (IV) or Recurrent Pulmonary Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation.|Completed||Phase 2|46|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 03:55:49.388793|2018-06-01 03:55:49.388793
NCT00344760|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2013-02-07|2006-06-23|2006-06-27|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 2005||2005-01-31|February 2013|2013-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy|Viral Decay Kinetics During Induction Therapy With or Without the Use of Enfuvirtide in HAART-naÃ-ve Patients With Advanced HIV|Completed||Phase 4|2|Anticipated|University of Maryland||2|||f||||t||||||||||2018-06-01 03:55:49.632552|2018-06-01 03:55:49.632552
NCT00344747|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-25|||2010-09-19|2006-06-25|2006-06-27|Estimate|||||||2010-09-19|2010-09-21|Estimate|September 2006||2006-09-30|September 2010|2010-09-30|August 2009|Actual|2009-08-31|||||Interventional|||Multidisciplinary Ambulatory Intervention Program in Family of Children and Adolescents With Obesity|Multidisciplinary Ambulatory Intervention Program (Dietary Behavioral Physical Activity) in Family of Children and Adolescents With Obesity|Completed||N/A|40|Anticipated|Soroka University Medical Center|||||f||||||||||||||2018-06-01 03:55:49.711992|2018-06-01 03:55:49.711992
NCT00344734|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-24|||2006-06-24|2006-06-24|2006-06-27|Estimate|||||||2006-06-24|2006-06-27|Estimate||||June 2006|2006-06-30||||||||Interventional|||Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure|Effects of Acute L-NMMA Treatment on Renal Hemodynamics, Sodium and Water Excretion and Plasma Levels of Vasoactive Hormones in Patients With Congestive Heart Failure and Healthy Controls|Completed||Phase 1|30||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 03:55:49.781961|2018-06-01 03:55:49.781961
NCT00344721|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2018-05-07|2006-06-23|2006-06-27|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2004||2004-09-30|May 2018|2018-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome|A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome|Completed||N/A|42|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-06-01 03:55:49.843102|2018-06-01 03:55:49.843102
NCT00344708|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2008-06-19|2006-06-23|2006-06-27|Estimate|||||||2008-06-19|2008-06-23|Estimate|September 2000||2000-09-30|June 2008|2008-06-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Transplantation of Tissue Cultured Human Amniotic Epithelial Cells Onto Damaged Ocular Surfaces|Transplantation of Tissue Cultured Human Amniotic Epithelial Cells Onto Damaged Ocular Surfaces|Unknown status|Recruiting|N/A|20|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:55:49.912442|2018-06-01 03:55:49.912442
NCT00344695|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2006-06-23|2006-06-23|2006-06-27|Estimate|||||||2006-06-23|2006-06-27|Estimate||||June 2006|2006-06-30|April 2003||2003-04-30|||||Interventional|||Bupropion Treatment for Youth Smoking Cessation||Completed||Phase 3|||University of Arizona|||||||||||||||||||2018-06-01 03:55:49.980636|2018-06-01 03:55:49.980636
NCT00344331|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2018-04-21|2006-06-23|2006-06-26|Estimate|||||||2018-04-21|2018-04-24|Actual|June 19, 2006||2006-06-19|April 20, 2018|2018-04-20||||||||Observational|||Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C|Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:53.931275|2018-06-01 03:55:53.931275
NCT00344682|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2013-01-16||2014-01-09|2006-06-22|2006-06-27|Estimate|2013-09-23|2013-11-25|Estimate||||2014-01-09|2014-02-07|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Memantine Augmentation of Antidepressants|A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders|Completed||Phase 4|31|Actual|University of Massachusetts, Worcester|Early termination due to slow enrollment, leading to small numbers of subjects enrolled.|2|||f||||f||||||||||2018-06-01 03:55:50.040176|2018-06-01 03:55:50.040176
NCT00344669|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2006-10-16|2006-06-25|2006-06-27|Estimate|||||||2006-10-16|2006-10-17|Estimate|August 2000||2000-08-31|June 2006|2006-06-30|November 2003||2003-11-30|||||Interventional|||Effect of Mass Deworming on Child Growth|"Increased Weight Gain in Preschool Children Due to Mass Albendazole Treatment Given During Child Health Days in Uganda"|Completed||N/A|10000||Makerere University|||||f||||||||||||||2018-06-01 03:55:50.320831|2018-06-01 03:55:50.320831
NCT00344656|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2012-04-18|2006-06-23|2006-06-27|Estimate|||||||2012-04-18|2012-04-19|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Observational|||Appetite-Related Brain Activity in Women With Anorexia Nervosa|The Study of Appetite-Related Brain Activity With Functional Magnetic Resonance Imaging in Women With Anorexia Nervosa|Completed|||15|Actual|New York State Psychiatric Institute|||1||f||||t||||||||||2018-06-01 03:55:50.37815|2018-06-01 03:55:50.37815
NCT00344643|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2008-06-19|2006-06-23|2006-06-27|Estimate|||||||2008-06-19|2008-06-23|Estimate|October 2004||2004-10-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Comparison of 12 Month Daily Wear of Two Novel O2 Permeable Silicone Hydrogel CLs (HOP/SiH) and A Control, Standard O2 Lens|A Comparison of 12 Month Daily Wear of Two Novel Hyper-Oxygen Permeable Silicone Hydrogel Contact Lenses (HOP/SiH) and A Control, Standard Oxygen Permeable Lens; and, 30-Night Versus 6-Night Immediate Extended Wear of Two HOP/SiH Lenses.|Completed||N/A|187|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:55:50.618945|2018-06-01 03:55:50.618945
NCT00344630|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2008-10-07|2006-06-23|2006-06-27|Estimate|||||||2008-10-07|2008-10-08|Estimate|May 2006||2006-05-31|October 2008|2008-10-31|June 2006||2006-06-30|||||Interventional|||TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?|TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What's Your Real Life Experience?|Completed||N/A|2500||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 03:55:50.67722|2018-06-01 03:55:50.67722
NCT00344617|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2007-09-25|2006-06-23|2006-06-27|Estimate|||||||2007-09-25|2007-09-26|Estimate|June 2006||2006-06-30|September 2007|2007-09-30|May 2008|Anticipated|2008-05-31|||||Interventional|||Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy|Off-Label Use of AVASTIN (BEVACIZUMAB)Intravitreal Injection For the Treatment of Serosanguinous Maculopathy|Unknown status|Active, not recruiting|Phase 3|50|Anticipated|Singapore National Eye Centre|||||f||||||||||||||2018-06-01 03:55:50.727301|2018-06-01 03:55:50.727301
NCT00344604|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2008-06-19|2006-06-23|2006-06-27|Estimate|||||||2008-06-19|2008-06-23|Estimate|March 2004||2004-03-31|June 2008|2008-06-30|June 2006|Actual|2006-06-30|||||Observational|||The Role of Psychosocial and Other Quality of Life Parameters in Evaluating Functional Changes Prior to and Following Laser in-Situ Keratomileusis (LASIK)Changes Laser in-Situ Keratomileusis (LASIK)|The Role of Psychosocial and Other Quality of Life Parameters in Evaluating Functional Changes Prior to and Following Laser in-Situ Keratomileusis (LASIK)|Terminated|||0|Actual|University of Texas Southwestern Medical Center||||PI decided to terminate the study at this time|f||||f||||||||||2018-06-01 03:55:50.783787|2018-06-01 03:55:50.783787
NCT00344591|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2015-07-22|2006-06-23|2006-06-27|Estimate|||||||2015-07-22|2015-07-24|Estimate|January 2005||2005-01-31|July 2015|2015-07-31||||June 2009|Actual|2009-06-30||Interventional|||Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison|Ecosystems Therapy for Men Reintegrating Into Their Family|Completed||Phase 2|162|Actual|University of California, San Francisco||2|||f||||||||||||||2018-06-01 03:55:50.85934|2018-06-01 03:55:50.85934
NCT00344578|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2011-03-22|2006-06-23|2006-06-27|Estimate|||||||2011-03-22|2011-03-23|Estimate|March 2006||2006-03-31|June 2006|2006-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Clinical Outcomes After AcrySof® ReStor IOL Surgery in Faculty Practice at UTSW Medical Center at Dallas: A Retrospective Review|Clinical Outcomes After AcrySof® ReStor IOL Surgery in Faculty Practice at UTSW Medical Center at Dallas: A Retrospective Review|Completed|||120|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 03:55:50.919851|2018-06-01 03:55:50.919851
NCT00344565|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-26|||2012-11-30|2006-06-26|2006-06-27|Estimate|||||||2012-11-30|2012-12-03|Estimate|November 2005||2005-11-30|November 2012|2012-11-30|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||A Placebo-Controlled Double-Blind Combined Treatment of Modafinil and CBT for Cocaine Dependence|Combined Treatment of Modafinil and Cognitive Behavioral Therapy for Cocaine Dependence|Completed||Phase 2|15|Actual|Research Foundation for Mental Hygiene, Inc.||2|||f||||t||||||||||2018-06-01 03:55:50.977655|2018-06-01 03:55:50.977655
NCT00344552|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2009-11-12|2006-06-23|2006-06-27|Estimate|||||||2009-11-12|2009-11-13|Estimate|June 2006||2006-06-30|November 2009|2009-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer|Phase II Study to Evaluate Efficacy and Safety of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer. This Study is an Extension Study for Japanese Registration Only.|Completed||Phase 2|53|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:55:51.071192|2018-06-01 03:55:51.071192
NCT00344539|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2013-05-30|2006-06-22|2006-06-26|Estimate|||||||2013-05-30|2013-06-03|Estimate|May 2005||2005-05-31|March 2013|2013-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||AMA1-C1/Alhydrogel + CpG 7909 for Malaria|Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria|Completed||Phase 1|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 03:55:51.21456|2018-06-01 03:55:51.21456
NCT00344526|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2007-06-27|2006-06-23|2006-06-26|Estimate|||||||2007-06-27|2007-06-28|Estimate|January 2000||2000-01-31|June 2007|2007-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis|Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial .|Completed||Phase 3|100||University Hospital, Limoges|||||f||||||||||||||2018-06-01 03:55:51.291269|2018-06-01 03:55:51.291269
NCT00344136|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2016-07-28|2006-06-23|2006-06-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2000||2000-09-30|October 2006|2006-10-31|March 2004|Actual|2004-03-31|||||Observational|||Identifying Genes That May Increase the Risk for Heart Disease in African Americans|Health Disparities and CVD: Admixture Mapping in the Jackson Heart Study|Completed|||5302||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 03:55:56.167072|2018-06-01 03:55:56.167072
NCT00344513|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2016-09-13|2006-06-23|2006-06-26|Estimate|||||||2016-09-13|2016-09-15|Estimate|December 2002||2002-12-31|September 2016|2016-09-30|June 2005|Actual|2005-06-30|||||Interventional|||Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)|Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients|Completed||Phase 4|50000||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:51.369655|2018-06-01 03:55:51.369655
NCT00344500|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2015-04-03||2016-03-08|2006-06-22|2006-06-26|Estimate|2015-05-12|2015-05-18|Estimate||||2016-03-08|2016-04-06|Estimate|October 2005||2005-10-31|March 2016|2016-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|MAMAO|Participants (14) randomized to Usual Care group who later elected to change over to Lifestyle Balance were excluded from statistical analysis.|Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications|Management of Antipsychotic Medication Associated Obesity|Completed||N/A|122|Actual|VA Office of Research and Development|Limitations to our study were its single-site recruitment yielding subjects mostly male and all veterans, limiting of statistical power by control subjects allowed to join treatment group resulting in exclusion from data, and a high dropout rate.|2|||f||||t||||||||||2018-06-01 03:55:51.490271|2018-06-01 03:55:51.490271
NCT00344487|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2012-08-03||2018-02-23|2006-06-22|2006-06-26|Estimate|2014-12-17|2014-12-19|Estimate||||2018-02-23|2018-03-21|Actual|December 2005||2005-12-31|December 2014|2014-12-31|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study|The Effect of Kaletra on CD4 Immune Reconstitution in HIV-infected Patients With Long-term Virologic Suppression on a Non-Kaletra Containing ART Regimen, But With a Blunted Immune Response|Terminated||N/A|3|Actual|University of Maryland|We screened and enrolled a total of three participants. Two of the three participants completed the study. Unable to meet the stated goals of the study, it was decided that it should be closed.|1||Inability to enroll subjects.|f||||t||||||||||2018-06-01 03:55:52.366406|2018-06-01 03:55:52.366406
NCT00344474|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2011-06-24|2006-06-22|2006-06-26|Estimate|||||||2011-06-24|2011-06-27|Estimate|November 2003||2003-11-30|February 2006|2006-02-28|July 2008|Actual|2008-07-31|May 2006|Actual|2006-05-31||Interventional|Preventure||Personality-targeted Interventions for Adolescent Alcohol Misuse|A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness|Completed||Phase 2/Phase 3|710|Actual|King's College London||4|||f||||||||||||||2018-06-01 03:55:52.492359|2018-06-01 03:55:52.492359
NCT00344461|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2015-10-02||2017-10-12|2006-06-22|2006-06-26|Estimate|2017-10-12|2017-11-14|Actual||||2017-10-12|2017-11-14|Actual|March 2004||2004-03-31|October 2017|2017-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine|Cell Cycle Independent Antiretroviral Therapy: Combination of Nevirapine, FTC, and Tenofovir|Completed||Phase 4|54|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 03:55:52.575425|2018-06-01 03:55:52.575425
NCT00344448|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|2011-02-14||2015-11-17|2006-06-23|2006-06-26|Estimate|2015-11-17|2015-12-21|Estimate||||2015-11-17|2015-12-21|Estimate|June 2006||2006-06-30|November 2015|2015-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pilot Study of Raptiva to Treat Sjogren's Syndrome|A Randomized, Placebo Controlled, Proof of Concept, Study of Raptiva, a Humanized Anti-CD-11a Monoclonal Antibody, in Patients With Sjogren's Syndrome|Terminated||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)|Early termination due to serious adverse event described in psoriasis which led to the withdrawal of the drug from market.|2||Increased risk of PML associated with raptiva in other studies|f||||t||||||||||2018-06-01 03:55:52.912998|2018-06-01 03:55:52.912998
NCT00344435|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2018-04-04|2006-06-23|2006-06-26|Estimate|||||||2018-04-04|2018-04-05|Actual|May 24, 2005||2005-05-24|April 5, 2016|2016-04-05|April 5, 2016||2016-04-05|||||Observational|||Genetic Susceptibility to Factor VIII Inhibitors|Factor VIII Inhibitor Formation: Identifying Predisposing Genetic Factors|Completed|||1187|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:53.209354|2018-06-01 03:55:53.209354
NCT00344422|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2011-06-08|2006-06-23|2006-06-26|Estimate|||||||2011-06-08|2011-06-10|Estimate|October 2000||2000-10-31|April 2010|2010-04-30|June 2004|Actual|2004-06-30|||||Interventional|||Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|A Multi-Center Randomized Study of Vincristine, Doxil and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Multiple Myeloma|Completed||Phase 3|198|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:55:53.268838|2018-06-01 03:55:53.268838
NCT00344409|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2012-08-30|2006-06-22|2006-06-26|Estimate|||||||2012-08-30|2012-08-31|Estimate|March 2006||2006-03-31|August 2012|2012-08-31||||May 2007|Actual|2007-05-31||Interventional|||A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients|A Double-blind, Placebo Controlled, Randomized Study of KRN321 for the Treatment of Anemia in Cancer Patients|Completed||Phase 3|200||Kyowa Hakko Kirin Co., Ltd|||||f||||||||||||||2018-06-01 03:55:53.327812|2018-06-01 03:55:53.327812
NCT00344383|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2011-03-03|2006-06-23|2006-06-26|Estimate|||||||2011-03-03|2011-03-04|Estimate|November 2003||2003-11-30|March 2011|2011-03-31|July 2004|Actual|2004-07-31|||||Interventional|||An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen|An Open-Label Study Evaluating the Bleeding Profile of Ortho Tri-Cyclen Lo (Norgestimate/Ethinyl Estradiol) Administered as an Extended Regimen|Completed||Phase 2|61|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||||||||||||||||2018-06-01 03:55:53.391532|2018-06-01 03:55:53.391532
NCT00344370|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|2009-09-01||2010-01-25|2006-06-23|2006-06-26|Estimate|2009-12-11|2010-01-18|Estimate||||2010-01-25|2010-02-02|Estimate|August 2006||2006-08-31|January 2010|2010-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia|Double-Blind, Follow-On Study of Pitavastatin (4 mg) Versus Atorvastatin (20 mg and 40 mg), With a Single-Blind Extension of Treatment, in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia|Completed||Phase 3|214|Actual|Kowa Research Europe||2|||f||||f||||||||||2018-06-01 03:55:53.511038|2018-06-01 03:55:53.511038
NCT00344344|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2017-06-30|2006-06-23|2006-06-26|Estimate|||||||2017-06-30|2017-07-02|Actual|October 19, 2000||2000-10-19|September 11, 2006|2006-09-11|September 11, 2006||2006-09-11|||||Observational|||A Pilot Study to Evaluate the Efficacy of Refined Methods to Mitigate Indoor Allergens in North Carolina and Boston, Massachusetts Homes|A Pilot Study to Evaluate the Efficacy of Refined Methods to Mitigate Indoor Allergens in North Carolina and Boston, Massachusetts Homes|Completed|||88||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:53.865895|2018-06-01 03:55:53.865895
NCT00344318|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2016-11-03|2006-06-23|2006-06-26|Estimate|||||||2016-11-03|2016-11-07|Estimate|August 2006||2006-08-31|November 2016|2016-11-30|October 2007|Actual|2007-10-31|April 2007|Actual|2007-04-30||Interventional|||Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine|To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age|Completed||Phase 3|806|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:54.036628|2018-06-01 03:55:54.036628
NCT00344305|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2010-07-29||2017-07-21|2006-06-22|2006-06-26|Estimate|2010-10-11|2010-11-01|Estimate||||2017-07-21|2017-07-24|Actual|May 1, 2006|Actual|2006-05-01|July 2017|2017-07-31|December 1, 2006|Actual|2006-12-01|July 1, 2006|Actual|2006-07-01||Interventional|||A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children|A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to Less Than 60 Months of Age|Completed||Phase 2|200|Actual|MedImmune LLC||2|||f||||f|t|f||||||||2018-06-01 03:55:54.181103|2018-06-01 03:55:54.181103
NCT00344292|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2017-11-06|2006-06-23|2006-06-26|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2006||2006-03-31|March 2017|2017-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Understanding the Genetic and Hereditary Basis of Atherosclerosis|SNPs and Extent of Atherosclerosis (SEA) Study|Completed|||2763|Actual|Wake Forest University Health Sciences|||||f||||t||||||Samples With DNA|"~     DNA~   "|||2018-06-01 03:55:54.869056|2018-06-01 03:55:54.869056
NCT00344279|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2017-06-30|2006-06-23|2006-06-26|Estimate|||||||2017-06-30|2017-07-02|Actual|August 8, 2005||2005-08-08|January 31, 2012|2012-01-31|January 31, 2012||2012-01-31|||||Observational|||Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis|Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection|Completed|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:54.923751|2018-06-01 03:55:54.923751
NCT00344266|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2018-04-03|2006-06-23|2006-06-26|Estimate|||||||2018-04-03|2018-04-04|Actual|June 19, 2006||2006-06-19|March 27, 2018|2018-03-27||||||||Observational|||Gene Expression and Inflammation in Overweight Subjects|Gene Expression and Release of Inflammatory Mediators in Overweight Subjects Before and After Weight Loss|Completed|||144|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:55.024031|2018-06-01 03:55:55.024031
NCT00344253|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2012-11-30|2006-06-22|2006-06-26|Estimate|||||||2012-11-30|2012-12-03|Estimate|March 2006||2006-03-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|||Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis|A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)|Completed||Phase 3|19|Actual|Heidelberg University||2|||f||||t||||||||||2018-06-01 03:55:55.087717|2018-06-01 03:55:55.087717
NCT00344240|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2010-02-02|2006-06-23|2006-06-26|Estimate|||||||2010-02-02|2010-02-03|Estimate|August 2005||2005-08-31|April 2007|2007-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Exercise and Activity Guidance in Older Adults With Diabetes|Aerobic Performance,Mobility Limitations and Exercise in Older Adults With Diabetes|Completed||N/A|240|Anticipated|University of Michigan|||||f||||||||||||||2018-06-01 03:55:55.19763|2018-06-01 03:55:55.19763
NCT00344227|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2006-06-23|2006-06-23|2006-06-26|Estimate|||||||2006-06-23|2006-06-26|Estimate|August 2004||2004-08-31|June 2006|2006-06-30|April 2007||2007-04-30|||||Interventional|||Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)|Prospective Optical Coherence Tomography (OCT) Imaging of Patients With Neovascular Age-Related Macular Degeneration (AMD) Treated With Intra-Ocular Lucentis™ (Ranibizumab): PrONTO Study|Completed||Phase 2|40||University of Miami|||||||||||||||||||2018-06-01 03:55:55.273253|2018-06-01 03:55:55.273253
NCT00344214|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2012-09-27|2006-06-23|2006-06-26|Estimate|||||||2012-09-27|2012-09-28|Estimate|October 2006||2006-10-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||STD Risk Reduction for Heterosexual Methamphetamine Users|Reducing HIV/STD Risk, Methamphetamine Use, and Depression Among Heterosexuals|Completed||N/A|432|Actual|University of California, San Diego||2|||f||||||||||||||2018-06-01 03:55:55.338287|2018-06-01 03:55:55.338287
NCT00344201|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2010-05-11|2006-06-23|2006-06-26|Estimate|||||||2010-05-11|2010-05-12|Estimate|November 2004||2004-11-30|May 2010|2010-05-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery|Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of Ocular Surface Reconstruction|Completed||Phase 1|32|Actual|Singapore National Eye Centre|||||f||||t||||||||||2018-06-01 03:55:55.528925|2018-06-01 03:55:55.528925
NCT00344188|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2018-03-27|2006-06-23|2006-06-26|Estimate|||||||2018-03-27|2018-03-29|Actual|August 22, 2001||2001-08-22|October 11, 2017|2017-10-11||||||||Observational|||Diagnosis and Treatment of Leishmanial Infections|Diagnosis and Treatment of Leishmanial Infections|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:55.615312|2018-06-01 03:55:55.615312
NCT00344175|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2009-09-01||2010-01-25|2006-06-23|2006-06-26|Estimate|2009-12-11|2010-01-18|Estimate||||2010-01-25|2010-02-02|Estimate|June 2006||2006-06-30|January 2010|2010-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors|Double-blind follow-on Study of Pitavastatin (4mg) Versus Simvastatin (40mg and 80mg) With a Single-blind Extension of Treatment in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease|Completed||Phase 3|178|Actual|Kowa Research Europe||2|||f||||f||||||||||2018-06-01 03:55:55.701766|2018-06-01 03:55:55.701766
NCT00344162|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2017-06-30|2006-06-23|2006-06-26|Estimate|||||||2017-06-30|2017-07-02|Actual|January 31, 2005||2005-01-31|September 22, 2006|2006-09-22|September 22, 2006||2006-09-22|||||Observational|||Family Study on Preeclampsia|A Familial Genetic Study on Preeclampsia: A Pilot Study|Completed|||1000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:55.98791|2018-06-01 03:55:55.98791
NCT00344149|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2014-03-25|2006-06-23|2006-06-26|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2006||2006-06-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Rituximab as Second Line Treatment for ITP|"Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. The RITP Study"|Completed||Phase 3|112|Actual|Ostfold Hospital Trust||2|||f||||t||||||||||2018-06-01 03:55:56.038351|2018-06-01 03:55:56.038351
NCT00343759|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2015-12-09|2006-06-21|2006-06-23|Estimate|||||||2015-12-09|2015-12-11|Estimate|June 2006||2006-06-30|December 2015|2015-12-31|December 2009|Anticipated|2009-12-31|May 2009|Anticipated|2009-05-31||Interventional|||Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy||Withdrawn||Phase 2|0|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 03:56:00.576796|2018-06-01 03:56:00.576796
NCT00344123|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2016-02-02|2006-06-22|2006-06-26|Estimate|||||||2016-02-02|2016-02-04|Estimate|February 2007||2007-02-28|February 2016|2016-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects|Pharmacokinetic Evaluation of Single-dose Rosuvastatin 10 mg When Co-administered With Steady-state Tipranavir 500 mg/Ritonavir 200 mg TPV/r) B.I.D. in Healthy Adult Volunteers|Completed||Phase 1|29|Actual|Johns Hopkins University||1|||f||||t||||||||No|This is a prospective, open-label pharmacokinetic study|2018-06-01 03:55:56.219982|2018-06-01 03:55:56.219982
NCT00344110|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2016-11-16|2006-06-22|2006-06-26|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Placebo and Active-controlled, Multicenter, Parallel-group Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg to Evaluate Efficacy, Safety and Pharmacokinetics in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 3|768|Actual|Novartis|||||f||||||||||||||2018-06-01 03:55:56.298522|2018-06-01 03:55:56.298522
NCT00344097|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2013-03-21|2006-06-23|2006-06-26|Estimate|||||||2013-03-21|2013-03-22|Estimate|March 2006||2006-03-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effects of Soy Protein on Post-thoracotomy Pain|The Effects of Soy Protein Supplementation on Post-thoracotomy Pain|Withdrawn||Phase 2|0|Actual|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 03:55:56.363593|2018-06-01 03:55:56.363593
NCT00344084|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2018-05-23|2006-06-23|2006-06-26|Estimate|||||||2018-05-23|2018-05-24|Actual|March 16, 2006||2006-03-16|September 17, 2012|2012-09-17|September 17, 2012||2012-09-17|||||Observational|||Surveillance for Leishmaniasis Skin Lesions in Mali|Active Surveillance for Cutaneous Leishmaniasis in Mali|Completed|||1593|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:56.425431|2018-06-01 03:55:56.425431
NCT00344071|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2017-06-30|2006-06-23|2006-06-26|Estimate|||||||2017-06-30|2017-07-02|Actual|September 8, 2004||2004-09-08|September 23, 2009|2009-09-23||||April 27, 2007|Actual|2007-04-27||Observational|||Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia|Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia|Completed|||250||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:55:56.484828|2018-06-01 03:55:56.484828
NCT00344058|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2006-06-23|2006-06-23|2006-06-26|Estimate|||||||2006-06-23|2006-06-26|Estimate|January 2001||2001-01-31|August 2005|2005-08-31|August 2004||2004-08-31|||||Interventional|||Abbreviated MgSO4 Therapy in Post-Partum Preeclampsia|Abbreviated Post-Partum Magnesium Sulfate Seizure Prophylaxis in Preeclampsia: A Comparison of 12 and 24 Hour Regimens|Completed||N/A|200||Case Western Reserve University|||||f||||||||||||||2018-06-01 03:55:56.53698|2018-06-01 03:55:56.53698
NCT00344045|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23||2015-09-23|2015-10-12|2006-06-23|2006-06-26|Estimate||||2015-10-12|2015-11-04|Estimate|2015-10-12|2015-11-04|Estimate|April 2006||2006-04-30|October 2015|2015-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty|A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy And Safety of IV Paracetamol Versus Placebo in Subjects With Postoperative Pain After Total Hip Arthroplasty|Completed||Phase 4|86|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 03:55:56.610303|2018-06-01 03:55:56.610303
NCT00344032|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|2009-11-12||2016-11-03|2006-06-23|2006-06-26|Estimate|2009-11-12|2009-12-15|Estimate||||2016-11-03|2016-12-16|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women|Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV-16/18 VLP/AS04 Vaccine Administered Intramuscularly at 0, 1, 6 Months in Healthy Indian Female Subjects Aged 18-35 Yrs|Completed||Phase 3|354|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:56.710896|2018-06-01 03:55:56.710896
NCT00344019|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2017-04-13||2017-12-01|2006-06-22|2006-06-26|Estimate|2017-06-05|2017-07-02|Actual||||2017-12-01|2018-01-02|Actual|May 2006|Actual|2006-05-31|December 2017|2017-12-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional||Study terminated by previous investigator due to slow enrollment. Database no longer available. Data report based on IRB termination report; only gender, race data avail. 97 screened, 23 reported as completed study. Screening data as avail reported herein.|Effects of Atorvastatin on Myonecrosis|Effects of Single-Dose Atorvastatin on Peri-Procedural Myonecrosis During Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes - The NO-MI Study|Terminated||Phase 4|97|Actual|Beth Israel Deaconess Medical Center||3||slow recruitment|f||||f|t|f|||f|||No|no plans to share data|2018-06-01 03:55:57.053578|2018-06-01 03:55:57.053578
NCT00344006|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2016-12-02|2006-06-22|2006-06-26|Estimate|||||||2016-12-02|2016-12-05|Estimate|June 2006||2006-06-30|December 2016|2016-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria|A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adolescents in Africa.|Completed||Phase 3|1395|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:57.388739|2018-06-01 03:55:57.388739
NCT00343993|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-23|||2007-04-03|2006-06-23|2006-06-26|Estimate|||||||2007-04-03|2007-04-04|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Noninvasive Positive Pressure Ventilation for ALI/ARDS:a Multicentre Randomized Controlled Trial||Unknown status|Recruiting|Phase 1|200||Beijing Chao Yang Hospital|||||f||||t||||||||||2018-06-01 03:55:57.544068|2018-06-01 03:55:57.544068
NCT00343980|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2017-02-28|2006-06-22|2006-06-23|Estimate|||||||2017-02-28|2017-03-01|Actual|October 10, 2006|Actual|2006-10-10|February 2017|2017-02-28|March 10, 2008|Actual|2008-03-10|March 10, 2008|Actual|2008-03-10||Interventional|||Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes|Safety and Efficacy of Inhaled Pre-prandial Human Insulin Plus Glimepiride Versus Rosiglitazone Plus Glimepiride in Type 2 Diabetes|Terminated||Phase 3|363|Actual|Novo Nordisk A/S||2||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:55:57.644651|2018-06-01 03:55:57.644651
NCT00343954|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2006-06-21|2006-06-21|2006-06-23|Estimate|||||||2006-06-21|2006-06-23|Estimate||||June 2006|2006-06-30||||||||Interventional|||PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease|Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease|Unknown status|Not yet recruiting|Phase 1|12||Angiogenix|||||||||||||||||||2018-06-01 03:55:57.788392|2018-06-01 03:55:57.788392
NCT00343941|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2008-10-09|2006-06-22|2006-06-23|Estimate|||||||2008-10-09|2008-10-13|Estimate|November 2004||2004-11-30|October 2008|2008-10-31||||||||Interventional|||Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults|A Phase II Multicentre, Randomized, Double Blind, Parallel Group, Placebo Controlled Pilot Study of Tucaresol at Two Dosing Levels (25,50 mg) in HIV-1 Infected Adult Subjects With Plasma HIV-1 RNA < 50 Copies/ml on Stable Highly Active Antiretroviral Therapy Regimen for at Least 3 Months|Completed||Phase 2|45||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:55:57.872305|2018-06-01 03:55:57.872305
NCT00343928|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2017-03-21|2006-06-22|2006-06-23|Estimate|||||||2017-03-21|2017-03-23|Actual|June 2006||2006-06-30|March 2017|2017-03-31||||June 2008|Actual|2008-06-30||Interventional|||Amino Acids, Serotonin, and Body Weight Regulation|Amino Acids, Serotonin, and Body Weight Regulation|Completed||Phase 2|21|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-06-01 03:55:57.956772|2018-06-01 03:55:57.956772
NCT00343915|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2008-12-23||2016-09-29|2006-06-22|2006-06-23|Estimate|2009-03-18|2009-03-31|Estimate||||2016-09-29|2016-11-21|Estimate|April 2004||2004-04-30|September 2016|2016-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs|Long-term Study of Immune Response Persistence of GSK Biologicals' 2-dose Thiomersal-free Engerix™-B and 3-dose Preservative-free Engerix™-B Vaccines in Subjects Aged 11-15 Yrs|Completed||Phase 3|267|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:55:58.057129|2018-06-01 03:55:58.057129
NCT00343902|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2006-06-21|2006-06-21|2006-06-23|Estimate|||||||2006-06-21|2006-06-23|Estimate|January 2000||2000-01-31|June 2006|2006-06-30|May 2004||2004-05-31|||||Interventional|||Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial|Randomized Clinical Trial of a Crataegus Oxycantha Extract in Chronic Heart Failure|Completed||Phase 3|120||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 03:55:58.763238|2018-06-01 03:55:58.763238
NCT00343889|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|2013-09-09||2013-11-11|2006-06-21|2006-06-23|Estimate|2013-11-11|2013-12-10|Estimate||||2013-11-11|2013-12-10|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|April 2008|Actual|2008-04-30|November 2007|Actual|2007-11-30||Interventional|||Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine|Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix-HepB/Hib™, Both Given Concomitantly With the Oral Polio Vaccine at 6, 10, and 14 Weeks of Age in Healthy Infants in the Philippines|Completed||Phase 3|379|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:55:58.855153|2018-06-01 03:55:58.855153
NCT00343876|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2008-08-20|2006-06-21|2006-06-23|Estimate|||||||2008-08-20|2008-08-21|Estimate|July 2005||2005-07-31|August 2008|2008-08-31|November 2006|Actual|2006-11-30|||||Interventional|||Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial|A Single Center, Double-Blind, Randomized Trial to Evaluate the Effects of Aspirin 325 mg + Clopidogrel 75 mg v. Aspirin 325 mg + Placebo on Plasma Concentration of C-Reactive Protein: The CATER Trial Protocol|Completed||Phase 4|100|Anticipated|Intermountain Health Care, Inc.|||||||||||||||||||2018-06-01 03:55:59.269035|2018-06-01 03:55:59.269035
NCT00343863|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2017-04-14||2017-06-10|2006-06-22|2006-06-23|Estimate|2017-06-10|2017-07-11|Actual||||2017-06-10|2017-07-11|Actual|January 2006||2006-01-31|June 2017|2017-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer|Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients|Completed||N/A|41|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:55:59.3916|2018-06-01 03:55:59.3916
NCT00343850|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2013-01-09|2006-06-21|2006-06-23|Estimate|||||||2013-01-09|2013-01-10|Estimate|September 2006||2006-09-30|January 2013|2013-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis|Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis: A Randomized Pilot Trial|Completed||Phase 3|30|Actual|University of Chicago|||||f||||||||||||||2018-06-01 03:55:59.906816|2018-06-01 03:55:59.906816
NCT00343824|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2014-12-04|2006-06-21|2006-06-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Bacterial Control in Partial Thickness Burns Using Silver-containing Wound Dressings|Bacterial Control in Partial Thickness Burns Using Silver-containing Wound Dressings|Unknown status|Active, not recruiting|N/A|100|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 03:55:59.998639|2018-06-01 03:55:59.998639
NCT00343811|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2014-05-08|2006-06-21|2006-06-23|Estimate|||||||2014-05-08|2014-05-09|Estimate|June 2006||2006-06-30|May 2014|2014-05-31|September 2006|Actual|2006-09-30|||||Interventional|||Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment|A 6-week, Double-Blind, Placebo-Controlled, Parallel Group Randomized Withdrawal Study to Evaluate the Continued Efficacy of Modafinil Treatment in Dosages up to 425mg/Day in Patients With Attention-Deficit/Hyperactivity Disorder Who Are Responders to Modafinil Treatment, Followed by a 12-Month Open-Label Extension Period|Completed||Phase 3|120||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 03:56:00.08893|2018-06-01 03:56:00.08893
NCT00343798|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2015-02-10|2006-06-22|2006-06-23|Estimate|||||||2015-02-10|2015-02-11|Estimate|April 2006||2006-04-30|February 2015|2015-02-28||||July 2013|Actual|2013-07-31||Interventional|||A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies|A Pilot Study to Evaluate the Co-infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies|Completed||Phase 1|23|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 03:56:00.198944|2018-06-01 03:56:00.198944
NCT00343785|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2017-01-26||2017-03-16|2006-06-22|2006-06-23|Estimate|2017-01-26|2017-03-16|Actual||||2017-03-16|2017-04-13|Actual|February 2006||2006-02-28|March 2017|2017-03-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant|Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation From HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Trial|Completed||Phase 2|21|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 03:56:00.34519|2018-06-01 03:56:00.34519
NCT00343733|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2014-05-08|2006-06-21|2006-06-23|Estimate|||||||2014-05-08|2014-05-09|Estimate|August 2006||2006-08-31|May 2014|2014-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain|A 12-Week Open-Label Study With 3 Within-Patient Double-Blind Placebo-Controlled Periods to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain|Completed||Phase 3|120||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 03:56:00.637581|2018-06-01 03:56:00.637581
NCT00343720|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2008-03-11|2006-06-22|2006-06-23|Estimate|||||||2008-03-11|2008-03-13|Estimate||||March 2008|2008-03-31||||October 2007|Actual|2007-10-31||Interventional|||Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy|A Randomized, Open-Label, Multicenter Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy|Completed||Phase 2|||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 03:56:00.706679|2018-06-01 03:56:00.706679
NCT00343707|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2016-09-13|2006-06-21|2006-06-23|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients|A Double-blind, Triple Dummy, Placebo-controlled, Randomised, Parallel Group Positron Emission Tomography Study to Investigate the Effects of a 8 Week Administration of GW597599 and Paroxetine Either Alone or in Combination on Regional Cerebral Blood Flow During a Public Speaking Test in Subjects Affected by Social Phobia.|Completed||Phase 2|72|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:56:00.75572|2018-06-01 03:56:00.75572
NCT00343681|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2014-01-16|2006-06-21|2006-06-23|Estimate|||||||2014-01-16|2014-01-17|Estimate|July 2006||2006-07-31|January 2014|2014-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine|Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)|Completed||Phase 2|120|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 03:56:00.840854|2018-06-01 03:56:00.840854
NCT00343668|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2010-05-25|2006-06-22|2006-06-23|Estimate|||||||2010-05-25|2010-05-26|Estimate|September 2005||2005-09-30|June 2006|2006-06-30|July 2008|Anticipated|2008-07-31|March 2007|Actual|2007-03-31||Interventional|||S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer|A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy|Unknown status|Recruiting|Phase 2|44|Anticipated|Korean Cancer Study Group|||||f||||f||||||||||2018-06-01 03:56:00.905538|2018-06-01 03:56:00.905538
NCT00343655|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2008-06-13|2006-06-20|2006-06-23|Estimate|||||||2008-06-13|2008-06-17|Estimate|January 2007||2007-01-31|June 2008|2008-06-30|August 2007|Actual|2007-08-31|||||Interventional|||Evaluation of Atorvastatin Treatment on Carotid Plaque.|A Randomized Clinical Trial Of Atorvastatin 10 Mg And 80 Mg In The Reversal Of Or Stabilization Of Carotid Atheroma Lipid Pool|Terminated||Phase 3|160||Pfizer||||"The study was terminated on June 22, 2007 for inability to enroll patients within an~   appropriate timeframe. There were no efficacy/safety concerns."|f||||||||||||||2018-06-01 03:56:00.99286|2018-06-01 03:56:00.99286
NCT00343642|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2014-01-24|2006-06-21|2006-06-23|Estimate|||||||2014-01-24|2014-01-28|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Dietary Treatment of Crohn's Disease|Dietary Treatment of Crohn's Disease|Completed||Phase 1/Phase 2|73|Actual|Rush University Medical Center||3|||f||||t||||||||||2018-06-01 03:56:01.04352|2018-06-01 03:56:01.04352
NCT00343629|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2015-04-27|2006-06-22|2006-06-23|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2006||2006-04-30|December 2006|2006-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers|Bioequivalency Study of Sulindac in Capsule vs. Tablet Formulations|Completed||N/A|28|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:56:01.237308|2018-06-01 03:56:01.237308
NCT00343616|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2012-07-26|2006-06-22|2006-06-23|Estimate|||||||2012-07-26|2012-07-27|Estimate|April 2005||2005-04-30|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98|Investigating Cognitive Function for Patients Participating in the BIG Trial 1-98 in Select Centers|Completed||Phase 3|135|Actual|International Breast Cancer Study Group||4|||f||||t||||||||||2018-06-01 03:56:01.299369|2018-06-01 03:56:01.299369
NCT00343603|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2016-10-24|2006-06-22|2006-06-23|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2004||2004-10-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Tracking Optical Coherence Tomography|Tracking Optical Coherence Tomography|Completed|||100|Actual|University of Pittsburgh|||||f||||f||||||||Undecided||2018-06-01 03:56:01.397711|2018-06-01 03:56:01.397711
NCT00343590|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2008-10-16|2006-06-21|2006-06-23|Estimate|||||||2008-10-16|2008-10-17|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study|Whole Body Vibration Therapy in a Participant With Multiple Sclerosis Related Balance Deficits - A Case Study|Completed||N/A|||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:56:01.45107|2018-06-01 03:56:01.45107
NCT00343577|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2013-11-17|2006-06-21|2006-06-23|Estimate|||||||2013-11-17|2013-11-19|Estimate|January 2001||2001-01-31|June 2006|2006-06-30|December 2006||2006-12-31|||||Observational|||Antiproteinuric Agents and Fabry Disease|Observational Study of Antiproteinuric Agents in Patients With Fabry Disease Treated With Enzyme Replacement Therapy|Completed|||12||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 03:56:01.506785|2018-06-01 03:56:01.506785
NCT00343564|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|2016-08-08||2016-08-08|2006-06-21|2006-06-23|Estimate|2016-08-08|2016-10-04|Estimate||||2016-08-08|2016-10-04|Estimate|April 2006||2006-04-30|August 2016|2016-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma|A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma|Completed||Phase 1/Phase 2|68|Actual|Cytokinetics||2|||f||||||||||||||2018-06-01 03:56:01.62347|2018-06-01 03:56:01.62347
NCT00343018|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 21, 2004||2004-01-21|October 5, 2006|2006-10-05|October 5, 2006||2006-10-05|||||Observational|||Interviewing Children About Past Events: Evaluating the NICHD Interview Protocol|Evaluating the NICHD Interview Protocol in an Analog Study|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:14.52848|2018-06-01 03:56:14.52848
NCT00343551|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2017-02-21|2006-06-22|2006-06-23|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2006||2006-05-31|February 2017|2017-02-28||||January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.|A Nine-week, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg Compared to Irbesartan 300 mg and Ramipril 10 mg in the Setting of a Missed Dose in Patients With Essential Hypertension|Completed||Phase 3|654||Novartis|||||f||||||||||||||2018-06-01 03:56:04.628137|2018-06-01 03:56:04.628137
NCT00343525|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2008-04-28|2006-06-21|2006-06-23|Estimate|||||||2008-04-28|2008-05-07|Estimate|May 2006||2006-05-31|April 2008|2008-04-30||||January 2007|Actual|2007-01-31||Interventional|||Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C|A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients With Chronic Hepatitis C|Completed||Phase 1|24|Actual|Peregrine Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:56:04.716333|2018-06-01 03:56:04.716333
NCT00343512|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2010-10-11||2012-04-21|2006-06-22|2006-06-23|Estimate|2010-10-11|2010-11-09|Estimate||||2012-04-21|2012-04-27|Estimate|February 2004||2004-02-29|April 2012|2012-04-30|March 2011|Actual|2011-03-31|March 2008|Actual|2008-03-31||Interventional|||Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer|Pilot Study of Neoadjuvant Dose Dense Docetaxel With Correlative Molecular Studies in Stage II/III Breast Cancer|Terminated||Phase 2|34|Actual|Vanderbilt-Ingram Cancer Center|"All adverse events have been included in the other adverse event section. They are not differentiated by causality (eg. related to disease, con-meds)."|1||closed due to competing neoadjuvant studies for a small patient population|f||||t||||||||||2018-06-01 03:56:04.801973|2018-06-01 03:56:04.801973
NCT00343499|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2008-08-20|2006-06-22|2006-06-23|Estimate|||||||2008-08-20|2008-08-21|Estimate|November 2004||2004-11-30|August 2008|2008-08-31|July 2007|Actual|2007-07-31|||||Interventional|||The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)|A Single Center, Randomized Trial to Evaluate the Effects of Diovan to Maintain Sinus Rhythm in Patients With Persistent Atrial Fibrillation|Terminated||Phase 4|200|Anticipated|Intermountain Health Care, Inc.||||Inability to recruit|f||||||||||||||2018-06-01 03:56:05.156951|2018-06-01 03:56:05.156951
NCT00343486|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2009-05-15|2006-06-21|2006-06-23|Estimate|||||||2009-05-15|2009-05-18|Estimate|May 2006||2006-05-31|May 2009|2009-05-31||||||||Interventional|||Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms|An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as Well as the Pharmacokinetic Profile of Oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women With Overactive Bladder|Completed||Phase 2|240||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:56:05.239718|2018-06-01 03:56:05.239718
NCT00343473|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-02-07|2006-06-22|2006-06-23|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2005||2005-10-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Novel Diagnostics With Optical Coherence Tomography: Imaging the Anterior Eye|Novel Diagnostics With Optical Coherence Tomography: Imaging of the Anterior Eye|Recruiting|||201|Anticipated|New York University School of Medicine|||||f||||t|f|f||||||Undecided||2018-06-01 03:56:05.388856|2018-06-01 03:56:05.388856
NCT00343460|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2016-09-09||2017-02-10|2006-06-22|2006-06-23|Estimate|2016-10-31|2016-12-28|Estimate||||2017-02-10|2017-02-23|Actual|June 2006||2006-06-30|February 2017|2017-02-28|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional||Modified Intent-to-Treat Population|APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer|A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens|Completed||Phase 3|1428|Actual|Heron Therapeutics||3|||f||||f||||||||No||2018-06-01 03:56:05.535403|2018-06-01 03:56:05.535403
NCT00343447|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2012-05-01|2006-06-22|2006-06-23|Estimate|||||||2012-05-01|2012-05-03|Estimate|August 2006||2006-08-31|May 2012|2012-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia|Phase II Randomized Trial of Early Versus Late Vaccination in Patients With High Risk CLL|Withdrawn||Phase 2|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-06-01 03:56:07.260741|2018-06-01 03:56:07.260741
NCT00343434|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2017-01-17|2006-06-22|2006-06-23|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2005||2005-01-31|June 2013|2013-06-30||||July 2007|Actual|2007-07-31||Interventional|||Soy-Based Meal Replacement in Helping Women With Stage I, Stage II, or Stage III Breast Cancer in Complete Remission Lose Weight|Use of a Soy-Based Meal Replacement Weight Loss Intervention for Survivors of ER/PR Negative Breast Cancer|Completed||N/A|25|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 03:56:07.316388|2018-06-01 03:56:07.316388
NCT00343421|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2016-06-01|2006-06-21|2006-06-23|Estimate|||||||2016-06-01|2016-06-03|Estimate|July 2006||2006-07-31|June 2016|2016-06-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers|Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix®-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age|Completed||Phase 3|588|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:56:07.373255|2018-06-01 03:56:07.373255
NCT00343408|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2010-11-07|2006-06-22|2006-06-23|Estimate|||||||2010-11-07|2010-11-09|Estimate|August 2005||2005-08-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||AZD2171 and Standard Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer or Colorectal Cancer|A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer|Completed||Phase 1|30|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 03:56:07.442713|2018-06-01 03:56:07.442713
NCT00343395|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2011-03-15|2006-06-21|2006-06-23|Estimate|||||||2011-03-15|2011-03-17|Estimate|June 2006||2006-06-30|March 2011|2011-03-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Combined Rosiglitazone/Metformin (Avandamet®) vs. Placebo on Serological Outcomes in Non-Diabetic Patients With Stable Coronary Syndromes|Terminated||Phase 4|200|Anticipated|Intermountain Health Care, Inc.||2||FDA concerns regarding Avandamet|f||||f||||||||||2018-06-01 03:56:07.500422|2018-06-01 03:56:07.500422
NCT00343382|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|2014-07-16||2016-07-12|2006-06-22|2006-06-23|Estimate|2014-09-24|2014-09-30|Estimate||||2016-07-12|2016-08-12|Estimate|December 2006||2006-12-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|July 2009|Actual|2009-07-31||Interventional|||Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer|Pilocarpine for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study|Completed||Phase 3|201|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-06-01 03:56:07.761083|2018-06-01 03:56:07.761083
NCT00343369|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-22|||2013-08-23|2006-06-22|2006-06-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2003||2003-01-31|June 2006|2006-06-30||||||||Interventional|||Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia|Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia|Unknown status|Recruiting|N/A|550|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:56:08.668313|2018-06-01 03:56:08.668313
NCT00343356|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-06-21|2006-06-21|2006-06-22|Estimate|||||||2006-06-21|2006-06-22|Estimate|June 1996||1996-06-30|May 1996|1996-05-31|July 2003||2003-07-31|||||Interventional|||Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder|Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management|Completed||Phase 2|138||LanZhou University|||||f||||||||||||||2018-06-01 03:56:08.772857|2018-06-01 03:56:08.772857
NCT00343343|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-02-06|2006-06-21|2006-06-22|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2006||2006-06-30|February 2017|2017-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Comparison of NovoFine® Needles (4 mm vs. 6 mm)|A Comparative, Randomised Study With NovoFine® 4 mm Needle Versus NovoFine® 6 mm Needle in Regard to Anatomical Deposition of Sterile Air in Children and Thin Adults With Diabetes and Backflow of Test Medium (Only Adults) After Injection in Thigh and Abdomen|Completed||Phase 2|62|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:56:08.827305|2018-06-01 03:56:08.827305
NCT00343317|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2006-06-21|2006-06-21|2006-06-22|Estimate|||||||2006-06-21|2006-06-22|Estimate|February 2003||2003-02-28|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women|Prophylactic Intrapartum Antibiotics and Immunological Markers for Postpartum Morbidity in HIV Positive Women|Completed||N/A|1372||University of KwaZulu|||||f||||||||||||||2018-06-01 03:56:08.880275|2018-06-01 03:56:08.880275
NCT00343304|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2006-06-20|2006-06-20|2006-06-22|Estimate|||||||2006-06-20|2006-06-22|Estimate|April 2005||2005-04-30|April 2005|2005-04-30|May 2006||2006-05-31|||||Interventional|||Pilot Study - Comparison of Upper Body Ergometer Vs. Robot in Upper Extremity Motor Recovery Post-Stroke||Completed||N/A|30||Burke Rehabilitation Hospital|||||f||||||||||||||2018-06-01 03:56:09.106645|2018-06-01 03:56:09.106645
NCT00343291|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|2011-05-13||2011-05-13|2006-06-20|2006-06-22|Estimate|2011-05-13|2011-06-07|Estimate||||2011-05-13|2011-06-07|Estimate|December 2006||2006-12-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC|Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 2|121|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:56:09.216895|2018-06-01 03:56:09.216895
NCT00343278|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2015-04-13|2006-06-21|2006-06-22|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets|Post-Marketing Clinical Study of Valaciclovir Hydrochloride Tablets -Single Oral Dose Study in Hemodialysis Patients-|Completed||Phase 4|18||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:56:10.103198|2018-06-01 03:56:10.103198
NCT00343265|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2013-08-14|2006-06-20|2006-06-22|Estimate|||||||2013-08-14|2013-08-15|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Vaginal Progesterone Versus Placebo in Multiple Pregnancy|Pilot Randomized Trial of Vaginal Progesterone to Prevent Preterm Birth in Multiple Pregnancy|Completed||N/A|84|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 03:56:10.165212|2018-06-01 03:56:10.165212
NCT00343252|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|2010-06-08||2011-05-20|2006-06-20|2006-06-22|Estimate|2010-06-08|2010-07-12|Estimate||||2011-05-20|2011-05-26|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis|The Effect of Teriparatide Compared With Risedronate on Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures|Completed||Phase 3|712|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 03:56:10.332559|2018-06-01 03:56:10.332559
NCT00343239|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2014-11-03|2006-06-21|2006-06-22|Estimate|||||||2014-11-03|2014-11-04|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|NEOTAX||Docetaxel in Locally Advanced Gastric Adenocarcinoma|Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study|Completed||Phase 2|59|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:56:11.900786|2018-06-01 03:56:11.900786
NCT00343226|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2010-08-24|2006-06-20|2006-06-22|Estimate|||||||2010-08-24|2010-08-25|Estimate|May 2002||2002-05-31|August 2010|2010-08-31||||April 2005|Actual|2005-04-30||Interventional|||"An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in de Novo Liver Transplantation."|"An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in de Novo Liver Transplantation."|Completed||Phase 4|48|Actual|Novartis|||||f||||||||||||||2018-06-01 03:56:11.968072|2018-06-01 03:56:11.968072
NCT00343213|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2011-08-29|2006-06-21|2006-06-22|Estimate|||||||2011-08-29|2011-08-30|Estimate|June 2006||2006-06-30|August 2011|2011-08-31||||||||Interventional|||Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix.|Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix. Immunohistochemical Study on Biopsies (Retrospective and Prospective Analysis) and on Liquid Based (SurePath) Cervical Cytology (Prospective Analysis). Correlation With HPV Typing and Clinical Outcome.|Unknown status|Recruiting|N/A|300|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:56:12.01695|2018-06-01 03:56:12.01695
NCT00343200|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2008-09-09|2006-06-20|2006-06-22|Estimate|||||||2008-09-09|2008-09-10|Estimate|July 2006||2006-07-31|September 2008|2008-09-30|September 2007|Actual|2007-09-30|||||Interventional|||A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.|A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study To Assess The Efficacy And Safety Of Viagra (Sildenafil Citrate) In Men With Erectile Dysfunction (ED) Who Do Not Self Identify.|Completed||Phase 4|371|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 03:56:12.083814|2018-06-01 03:56:12.083814
NCT00341549|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|April 24, 2002||2002-04-24|December 28, 2017|2017-12-28||||||||Observational|||Family Myopia Study|Family Myopia Study|Completed|||7477|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.721869|2018-06-01 03:56:23.721869
NCT00343187|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2011-05-27|2006-06-20|2006-06-22|Estimate|||||||2011-05-27|2011-05-30|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash|A Phase II, Randomized, Double-Blind, Parallel Design Study to Evaluate ACZONE™ (Dapsone) Gel, 5% As a Treatment For Rash Related to the Human Epidermal Growth Factor Receptor 1 (HER1)/Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor Tarceva® (Erlotinib)|Terminated||Phase 2|2|Actual|Allergan||||Lack of enrollment|f||||||||||||||2018-06-01 03:56:12.195241|2018-06-01 03:56:12.195241
NCT00343174|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2006-06-20|2006-06-20|2006-06-22|Estimate|||||||2006-06-20|2006-06-22|Estimate||||January 2002|2002-01-31||||||||Interventional|||Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms|Multicenter Parallel Randomized Double-Blind Placebo Controlled Study of Efficacy and Safety of Intravenous Ancrod ( Arvin ) Given Within 6 Hours After the Onset of Acute Ischemic Stroke: European Stroke Treatment With Ancrod Trial ESTAT|Completed||Phase 3|||Heidelberg University|||||f||||||||||||||2018-06-01 03:56:12.252435|2018-06-01 03:56:12.252435
NCT00343161|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2011-01-21|2006-06-21|2006-06-22|Estimate|||||||2011-01-21|2011-01-24|Estimate|August 2006||2006-08-31|January 2011|2011-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|SYMPATHY||Symptom Adapted Therapy in GERD Patients|A Randomized, Open, Parallel-group, Multi-national, Multi-centre, Phase IV Study to Evaluate the Efficacy of Three Different Patient Management Strategies With and Without Esomeprazole 20 mg During a 3 Months Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related|Completed||Phase 4|441||AstraZeneca|||||f||||||||||||||2018-06-01 03:56:12.400448|2018-06-01 03:56:12.400448
NCT00343148|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2009-07-06|2006-06-20|2006-06-22|Estimate|||||||2009-07-06|2009-07-08|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2006|Actual|2006-06-30||Interventional|||Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid|Pharmacokinetic Study of AVI-4126 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration|Completed||Phase 1|6||Sarepta Therapeutics|||||f||||||||||||||2018-06-01 03:56:12.60884|2018-06-01 03:56:12.60884
NCT00343135|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2012-11-21|2006-06-20|2006-06-22|Estimate|||||||2012-11-21|2012-11-22|Estimate|December 2004||2004-12-31|November 2012|2012-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||AUGMENTIN 1gm In Skin And Soft Tissue Infection|An Open, Non-comparative Study to Evaluate the Efficacy and Safety of AUGMENTIN 1gm (875mg Amoxicillin/125mg Clavulanic Acid) po q 12 Hours in the Treatment of Uncomplicated Skin and Soft Tissue Infections in Pakistan|Completed||Phase 4|195|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 03:56:12.894314|2018-06-01 03:56:12.894314
NCT00343122|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2007-09-14|2006-06-20|2006-06-22|Estimate|||||||2007-09-14|2007-09-17|Estimate|June 2006||2006-06-30|September 2007|2007-09-30||||||||Observational|||Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline|Evaluation of Two Methods for the Echocardiographic Assessment of Intrapulmonary Vasodilatation in Patients With Liver Cirrhosis: Agitated Saline Versus Polygelatine|Unknown status|Recruiting||100|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-06-01 03:56:12.975472|2018-06-01 03:56:12.975472
NCT00343109|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20||2017-04-03|2018-05-01|2006-06-20|2006-06-22|Estimate||||2017-04-03|2017-04-05|Actual|2018-05-01|2018-05-03|Actual|March 2004||2004-03-31|May 2018|2018-05-31||||June 2015|Actual|2015-06-30||Interventional|||Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer|Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Patients With Locally Advanced or Stage IV HER2 Positive Breast Cancer|Active, not recruiting||Phase 2|38|Anticipated|University of Washington||1|||f||||f||||||||||2018-06-01 03:56:13.076055|2018-06-01 03:56:13.076055
NCT00343096|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-21|||2012-07-09|2006-06-21|2006-06-22|Estimate|||||||2012-07-09|2012-07-10|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children.|Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial|Terminated||Phase 3|800|Actual|University of Malawi College of Medicine||||"The buccal arm of the study was 30% less effective in stopping seizures within 10 minutes~   compared with the IV dose. This met a stopping rule for the study"|f||||||||||||||2018-06-01 03:56:13.405199|2018-06-01 03:56:13.405199
NCT00343083|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|2013-04-12||2016-02-18|2006-06-20|2006-06-22|Estimate|2014-04-07|2014-04-09|Estimate||||2016-02-18|2016-03-16|Estimate|December 2004||2004-12-31|February 2016|2016-02-29|May 2012|Actual|2012-05-31|June 2011|Actual|2011-06-30||Interventional|||Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)|A Phase II Study of Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck|Completed||Phase 2|43|Actual|University of Maryland||1|||f||||t||||||||||2018-06-01 03:56:13.512098|2018-06-01 03:56:13.512098
NCT00343070|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2010-08-30|2006-06-20|2006-06-22|Estimate|||||||2010-08-30|2010-08-31|Estimate|March 2007||2007-03-31|August 2010|2010-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Functional Neuroimaging in Depression|Functional Neuroimaging in Depression: Longitudinal Study of PET Metabolism in Correlation With Changes in Attentional Bias, Autobiographical Memory, Future Fluency and Facial Recognition in Depressed Patients Treated With Escitalopram.|Completed||Phase 2|40|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:56:13.710557|2018-06-01 03:56:13.710557
NCT00343057|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2009-09-03|2006-06-21|2006-06-22|Estimate|||||||2009-09-03|2009-09-04|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|June 2004|Actual|2004-06-30|||||Observational|||DISCO - Influence of a Simple Information Booklet on the Evolution of Acute Low Back Pain (LBP)|Influence of a Simple Information Booklet on the Evolution of Acute Low Back Pain (LBP): a Quasi-experimental Study in a Primary Care Setting.|Completed|||2830|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:56:13.859506|2018-06-01 03:56:13.859506
NCT00343044|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|2013-07-29||2015-04-29|2006-06-20|2006-06-22|Estimate|2015-04-29|2015-05-15|Estimate||||2015-04-29|2015-05-15|Estimate|June 2006||2006-06-30|April 2015|2015-04-30|August 2011|Actual|2011-08-31|January 2010|Actual|2010-01-31||Interventional|||Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers|Phase II Study of Weekly Topotecan With Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers|Completed||Phase 2|40|Actual|Benaroya Research Institute||1|||f||||f||||||||||2018-06-01 03:56:13.984475|2018-06-01 03:56:13.984475
NCT00343031|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|May 14, 2001||2001-05-14|December 4, 2017|2017-12-04||||||||Observational|||Effect of the Antiandrogen DDE on Anthropometric Measures at Birth|Effect of the Antiandrogen DDE on Anthropometric Measures at Birth|Completed|||2118|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:14.415702|2018-06-01 03:56:14.415702
NCT00343005|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 23, 2004||2004-04-23|January 22, 2008|2008-01-22|January 22, 2008||2008-01-22|||||Interventional|||Experimental Vaccine for Malaria in Adults in Mali|Double-Blind, Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria, in Semi-Immune Adults in Doneguebougou, Mali|Completed||Phase 1|54||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:14.635804|2018-06-01 03:56:14.635804
NCT00342992|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|August 31, 1985||1985-08-31|March 19, 2018|2018-03-19||||||||Observational|||Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study|Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study (ATBC Study) Population|Completed|||29133|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:14.712636|2018-06-01 03:56:14.712636
NCT00342966|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 14, 1999||1999-06-14|July 23, 2010|2010-07-23|July 23, 2010||2010-07-23|||||Observational|||Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation|Characterization of the Pharmacokinetics of Oral Selenium Compounds in Humans Before and Following Supplementation|Completed|||34|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:14.787899|2018-06-01 03:56:14.787899
NCT00342953|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-24|2006-06-19|2006-06-21|Estimate|||||||2018-04-24|2018-04-25|Actual|January 10, 2003||2003-01-10|April 11, 2018|2018-04-11||||||||Observational|||Study of Health Effects of Cosmetic Breast Augmentation|Extended Mortality Follow-Up of Women With Augmentation Mammoplasty|Completed|||17424|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:14.868169|2018-06-01 03:56:14.868169
NCT00342940|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2017-04-19|2006-06-20|2006-06-21|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2006||2006-10-31|April 2017|2017-04-30||||||||Interventional|||Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older|A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects|Withdrawn||Phase 2|0|Actual|Novartis||||Lack of Vaccine Supplies|f||||||||||||||2018-06-01 03:56:14.9604|2018-06-01 03:56:14.9604
NCT00342927|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-03|2006-06-19|2006-06-21|Estimate|||||||2018-04-03|2018-04-04|Actual|March 6, 2001||2001-03-06|March 22, 2018|2018-03-22||||||||Observational|||Family Investigation of Nephropathy and Diabetes (F.I.N.D.)|Family Investigation of Nephropathy and Diabetes (F.I.N.D.)|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.032344|2018-06-01 03:56:15.032344
NCT00342888|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-12|2006-06-19|2006-06-21|Estimate|||||||2018-05-12|2018-05-15|Actual|October 30, 2001||2001-10-30|May 17, 2017|2017-05-17||||||||Observational|||Case-Control Study of Pesticides and Childhood Leukemia|A Case-Control Study of Pesticides and Childhood Leukemia|Completed|||629|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.095542|2018-06-01 03:56:15.095542
NCT00342875|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-08|2006-06-19|2006-06-21|Estimate|||||||2018-05-08|2018-05-09|Actual|February 27, 2002||2002-02-27|April 20, 2018|2018-04-20||||||||Observational|||The New England Bladder Cancer Study|The New England Bladder Cancer Study|Completed|||2681|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.187341|2018-06-01 03:56:15.187341
NCT00342862|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2013-12-10|2006-06-19|2006-06-21|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2003||2003-12-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||AMEVIVE® Pregnancy Registry|Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Pregnancy Exposure Registry|Terminated|||3|Actual|Astellas Pharma Inc|||1|"The Sponsor has made a decision, driven by business needs, to cease promotion, manufacturing,~   distribution and sales of Amevive"|f||||t||||||||||2018-06-01 03:56:15.248364|2018-06-01 03:56:15.248364
NCT00342849|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 15, 1994||1994-07-15|June 10, 2015|2015-06-10|June 10, 2015|Actual|2015-06-10|August 29, 2007|Actual|2007-08-29||Interventional|||Treatment of Lead-Exposed Children Trial|Treatment of Lead-Exposed Children (TLC) Trial|Completed||Phase 3|780|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:56:15.332543|2018-06-01 03:56:15.332543
NCT00342836|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2007-03-22|2006-06-19|2006-06-21|Estimate|||||||2007-03-22|2007-03-23|Estimate|April 2005||2005-04-30|February 2006|2006-02-28||||||||Interventional|||Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer|Immunohistochemical Analysis of Human Transbronchial Biopsy Specimens Collected in a Phase I Chemoprevention Trial of Myo-Inositol in Heavy Smokers Conducted Outside the Intramural NCI Program|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.426692|2018-06-01 03:56:15.426692
NCT00342823|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 20, 2003||2003-10-20|June 30, 2010|2010-06-30|June 30, 2010||2010-06-30|||||Observational|||Immunogenetics of Visceral Leishmaniasis|Immunogenetics of Visceral Leishmaniasis|Completed|||7000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.472138|2018-06-01 03:56:15.472138
NCT00342810|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|June 25, 2003||2003-06-25|April 25, 2018|2018-04-25|April 25, 2018||2018-04-25|||||Observational|||Analyses of Existing Framingham Data|Continued Analyses of Epidemiologic Risk Factors Using Existing Framingham Eye and Heart Study Data|Completed|||6061|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.555398|2018-06-01 03:56:15.555398
NCT00342797|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|November 17, 1993||1993-11-17|August 25, 2017|2017-08-25||||||||Observational|||Retinoblastoma Biomarker Study|Retinoblastoma Biomarker Study|Active, not recruiting|||1995|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.645434|2018-06-01 03:56:15.645434
NCT00342784|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 8, 2004||2004-11-08|March 6, 2018|2018-03-06||||||||Observational|||Identification of Prostate Cancer Genes|Genetic Analysis of Cases, Controls, and Families With Prostate Cancer|Completed|||5118|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.8889|2018-06-01 03:56:15.8889
NCT00342771|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 8, 2004||2004-11-08|September 19, 2017|2017-09-19||||||||Observational|||An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males|A Case-Control Study of Prostate Cancer in the Greater Baltimore Area: An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males|Active, not recruiting|||2033|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:15.949415|2018-06-01 03:56:15.949415
NCT00342732|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|April 9, 1999||1999-04-09|October 19, 2017|2017-10-19||||||||Observational|||The Food Intake Phenotype: Assessing Eating Behavior and Food Preferences as Risk Factors for Obesity|The Food Intake Phenotype: Assessing Eating Behavior and Food Preferences as Risk Factors for Obesity|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:16.078558|2018-06-01 03:56:16.078558
NCT00342706|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 10, 2005||2005-01-10|April 29, 2011|2011-04-29|April 29, 2011|Actual|2011-04-29|April 29, 2011|Actual|2011-04-29||Interventional|||Building Healthy Teen Relationships and Reproductive Practices to Increase Intervals Between Pregnancies|Building Healthy Teen Relationships and Reproductive Practices to Increase Interpregnancy Intervals|Completed||Phase 2|750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:16.144637|2018-06-01 03:56:16.144637
NCT00342693|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|February 21, 2006||2006-02-21|September 3, 2013|2013-09-03|September 3, 2013||2013-09-03|||||Observational|||Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine|Thyroid Abnormalities Associated With Protracted Childhood I-131 Exposure From Atmospheric Emissions From the Mayak Nuclear Plant in Russia|Terminated|||360|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:16.244846|2018-06-01 03:56:16.244846
NCT00342667|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|December 8, 1997||1997-12-08|August 17, 2017|2017-08-17||||||||Observational|||Clinical, Biochemical, Histological and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients With Preterm Labor and Premature Rupture of Membranes|Clinical, Biochemical, Histological and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients With Preterm Labor and Premature Rupture of Membranes|Completed|||4673|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:16.339119|2018-06-01 03:56:16.339119
NCT00342654|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|May 20, 1999||1999-05-20|January 31, 2018|2018-01-31||||||||Observational|||Nutrition Intervention Trials in Linxian Follow-up Study|Nutritional Intervention Trials in Linxian China- Continued Follow-up|Active, not recruiting|||32902|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:16.395238|2018-06-01 03:56:16.395238
NCT00342641|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 8, 2005||2005-06-08|December 13, 2011|2011-12-13|December 13, 2011||2011-12-13|||||Observational|||Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers|Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans|Completed|||815000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:16.552005|2018-06-01 03:56:16.552005
NCT00342628|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2012-03-30||2012-05-22|2006-06-19|2006-06-21|Estimate|2012-05-22|2012-06-27|Estimate||||2012-05-22|2012-06-27|Estimate|July 2006||2006-07-31|May 2012|2012-05-31|January 2011|Actual|2011-01-31|April 2008|Actual|2008-04-30||Interventional|||Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants|Evaluation of the Safety, Immunogenicity and Compatibility With DTP of an Investigational Vi-rEPA Conjugate Vaccine for Typhoid Fever When Administered to Infants in Vietnam Concurrently With DTP|Completed||Phase 2|301|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||t||||||||||2018-06-01 03:56:16.639271|2018-06-01 03:56:16.639271
NCT00342602|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2009-03-16|2006-06-19|2006-06-21|Estimate|||||||2009-03-16|2009-03-17|Estimate|August 2005||2005-08-31|June 2006|2006-06-30||||||||Observational|||Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome|Influence of Host Genetic Factors in Development of PML in an AIDS Cohort|Completed|||450||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:17.270872|2018-06-01 03:56:17.270872
NCT00342589|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-27|2006-06-19|2006-06-21|Estimate|||||||2018-04-27|2018-04-30|Actual|April 10, 1999||1999-04-10|September 20, 2017|2017-09-20||||||||Observational|||New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia|Studies of Human Pneumocystis Infection|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:17.398159|2018-06-01 03:56:17.398159
NCT00342576|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-11|2006-06-19|2006-06-21|Estimate|||||||2018-05-11|2018-05-14|Actual|April 23, 1994||1994-04-23|September 1, 2017|2017-09-01||||||||Observational|||Host Response to Infection and Treatment in Lymphatic Filarial Disease in India|Host Response to Infection and Treatment in Lymphatic Filarial Disease Strongyloidiasis in India|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:17.475543|2018-06-01 03:56:17.475543
NCT00342563|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2016-10-24||2018-01-12|2006-06-19|2006-06-21|Estimate|2017-04-06|2017-05-17|Actual||||2018-01-12|2018-01-17|Actual|May 2004||2004-05-31|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||One hundred and thirty six (136) individuals were randomized in this study with equal number of participants assigned to treatment (n=68) and placebo (n=68) groups. Randomization was stratified by gender and smoking status.|Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients|Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients|Completed||Phase 2|136|Actual|Yale University||4|||f||||t||||||||||2018-06-01 03:56:17.561658|2018-06-01 03:56:17.561658
NCT00342550|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|March 17, 1998||1998-03-17|October 17, 2017|2017-10-17||||||||Observational|||Cervical Volume by Three-Dimensional Ultrasound as a Predictor of Preterm Delivery|Cervical Volume by Three-Dimensional Ultrasound as a Predictor of Preterm Delivery|Completed|||648|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:17.963859|2018-06-01 03:56:17.963859
NCT00342537|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|December 31, 2003||2003-12-31|August 18, 2017|2017-08-18||||||||Observational|||Genetics of Familial Testicular Cancer|Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Studies of Familial Testicular Germ Cell Tumors|Completed|||1842|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.031458|2018-06-01 03:56:18.031458
NCT00342524|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 6, 2005||2005-07-06|February 8, 2007|2007-02-08|February 8, 2007||2007-02-08|||||Observational|||Collection of Convalescent SARS Plasma by Apheresis|Collection of Convalescent SARS Plasma by Apheresis|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.145911|2018-06-01 03:56:18.145911
NCT00342511|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 9, 2006||2006-01-09|December 13, 2011|2011-12-13|December 13, 2011||2011-12-13|||||Observational|||Pilots of Self-Collection for HPV DNA Detection|Pilots of Self-Collection Devices for HPV DNA Detection|Completed|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.201789|2018-06-01 03:56:18.201789
NCT00342485|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 12, 1993||1993-04-12|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients|In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients|Completed|||5000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.315368|2018-06-01 03:56:18.315368
NCT00342472|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|July 14, 1998||1998-07-14|August 21, 2017|2017-08-21||||||||Observational|||Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China|Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China|Completed|||81|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.366532|2018-06-01 03:56:18.366532
NCT00342446|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-11|2006-06-19|2006-06-21|Estimate|||||||2018-05-11|2018-05-14|Actual|June 5, 1996||1996-06-05|November 3, 2017|2017-11-03||||||||Observational|||A Follow-up Study of Women Evaluated and Treated for Infertility|Follow-Up Study of Women Evaluated and Treated for Infertility|Completed|||12193|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.454994|2018-06-01 03:56:18.454994
NCT00342433|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|May 5, 1999||1999-05-05|December 14, 2017|2017-12-14||||||||Observational|||Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study|Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study|Completed|||553|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.505861|2018-06-01 03:56:18.505861
NCT00342407|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-08|2006-06-19|2006-06-21|Estimate|||||||2018-05-08|2018-05-09|Actual|November 6, 2001||2001-11-06|April 27, 2018|2018-04-27||||||||Observational|||The Incidence of Breast and Other Cancers Among Female Flight Attendants|The Incidence of Breast and Other Cancers Among Female Flight Attendants|Completed|||6138|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.715837|2018-06-01 03:56:18.715837
NCT00342394|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 14, 2001||2001-11-14|May 1, 2013|2013-05-01|May 1, 2013||2013-05-01|||||Observational|||Fungicide Exposure Assessment Among Apple and Peach Farmers in the Argicultural Health Study|Fungicide Exposure Assessment Among Apple and Peach Farmers in the Agricultural Health Study|Completed|||75|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:18.784998|2018-06-01 03:56:18.784998
NCT00342381|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2007-12-12|2006-06-20|2006-06-21|Estimate|||||||2007-12-12|2007-12-17|Estimate|June 2006||2006-06-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation|Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation|Completed||Phase 2|120|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-06-01 03:56:18.842725|2018-06-01 03:56:18.842725
NCT00342368|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2007-10-31|2006-06-19|2006-06-21|Estimate|||||||2007-10-31|2007-11-01|Estimate|June 2005||2005-06-30|October 2007|2007-10-31|March 2009|Anticipated|2009-03-31|||||Interventional|HelmetCPAP||Helmet CPAP vs Venturi O2 to Treat Early ALI/ARDS|A Comparison of CPAP Delivered by Helmet and O2 Therapy With a Venturi Mask as First Line Intervention in Early ALI/ARDS|Unknown status|Recruiting|N/A|190|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 03:56:18.957684|2018-06-01 03:56:18.957684
NCT00342355|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2009-09-14||2013-04-29|2006-06-19|2006-06-21|Estimate|2013-03-04|2013-04-16|Estimate||||2013-04-29|2013-05-21|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|August 2008|Actual|2008-08-31|March 2008|Actual|2008-03-31||Interventional|||Antiretroviral Therapy for Advanced HIV Disease in South Africa|Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL|Completed||Phase 4|1771|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||t||||||||||2018-06-01 03:56:19.078576|2018-06-01 03:56:19.078576
NCT00342342|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|December 4, 2002||2002-12-04|July 5, 2017|2017-07-05||||||||Observational|||Family Studies of Eye Traits|Family Studies of Ocular Traits|Completed|||7370|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:19.488823|2018-06-01 03:56:19.488823
NCT00342329|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 16, 2001||2001-04-16|March 7, 2007|2007-03-07|March 7, 2007||2007-03-07|||||Observational|||Lupus Nephritis: Role of Environmental and Occupational Exposures|Lupus Nephritis: Role of Environmental and Occupational Exposures|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:19.556162|2018-06-01 03:56:19.556162
NCT00342316|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2016-09-22|2006-06-20|2006-06-21|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia|Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation With Reduced Conditioning (RICT) Versus Best Standard of Care in Acute Myeloid Leukemia (AML)in First Complete Remission (CR)|Active, not recruiting||Phase 3|360|Actual|Vastra Gotaland Region||2|||f||||t||||||||||2018-06-01 03:56:19.611679|2018-06-01 03:56:19.611679
NCT00342303|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 8, 1993||1993-06-08|July 13, 2010|2010-07-13|July 13, 2010||2010-07-13|||||Observational|||Activity of Essential Fatty Acid Elongation/Desaturation Pathway During Early Life in Human Infants, In Vivo|Essential Fatty Acid Metabolism in the Newborn: Equivalence of Precusors and Mediators in the Synthesis of Long Chain Polyunsaturated Fatty Acids of the n-6 and n-3 Series|Completed|||110|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:19.712819|2018-06-01 03:56:19.712819
NCT00342290|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|March 22, 1998||1998-03-22|June 29, 2012|2012-06-29|June 29, 2012||2012-06-29|||||Observational|||Early Pregnancy Evaluation by Three-Dimensional Ultrasound|Early Pregnancy Evaluation by Three-Dimensional Ultrasound|Terminated|||69|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:19.779064|2018-06-01 03:56:19.779064
NCT00342277|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-16|2006-06-19|2006-06-21|Estimate|||||||2018-05-16|2018-05-17|Actual|December 21, 1999||1999-12-21|April 19, 2018|2018-04-19||||||||Observational|||Microarray Expression Profiling to Identify Stereotypic mRNA Profiles for Preterm Delivery in Order to Unravel the Biological Mechanisms|Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition|Completed|||6838|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:19.840067|2018-06-01 03:56:19.840067
NCT00342225|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 19, 2002||2002-12-19|December 21, 2006|2006-12-21|December 21, 2006||2006-12-21|||||Observational|||Mother-Child Relationships During Pregnancy Among Bofi Foragers|Mother-Child Relationships During Pregnancy Among the Bofi Foragers in the Northern Congo|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.069779|2018-06-01 03:56:20.069779
NCT00342212|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2011-05-24|2006-06-19|2006-06-21|Estimate|||||||2011-05-24|2011-05-25|Estimate|March 2006||2006-03-31|May 2011|2011-05-31|April 2008|Actual|2008-04-30|||||Observational|||Actigraph Accelerometer Validation Study|Actigraph Accelerometer Validation Study|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.122945|2018-06-01 03:56:20.122945
NCT00342199|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|July 3, 2001||2001-07-03|February 26, 2014|2014-02-26|February 26, 2014||2014-02-26|||||Observational|||Surveillance of Streptococcal Infections in Children in India|Epidemiological Surveillance in India of Group A Streptococcal Infections Including Pharyngitis and Impetigo Supported by Indo-US Vaccine Action Program|Completed|||663|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.235938|2018-06-01 03:56:20.235938
NCT00342186|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 27, 2002||2002-09-27|February 22, 2018|2018-02-22||||||||Observational|||Genes Involved in Resistance or Susceptibility to Hepatitis B Virus|Human Genes Involved in Susceptibility or Resistance to Hepatitis B Virus|Completed|||2303|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.301924|2018-06-01 03:56:20.301924
NCT00342173|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|May 20, 1999||1999-05-20|January 31, 2018|2018-01-31||||||||Observational|||Costa Rican Natural History Study of HPV and Cervical Neoplasia|Costa Rican Natural History Study of HPV and Cervical Neoplasia|Completed|||11545|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.402449|2018-06-01 03:56:20.402449
NCT00342160|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|February 15, 2006||2006-02-15|November 13, 2012|2012-11-13|November 13, 2012||2012-11-13|||||Observational|||Viral and Immunologic Factors Contributing to the Lack of HIV Transmission Among Couples in Rakai, Uganda|Virologic and Immunologic Factors Contributing to the Lack of HIV-1 Transmission in HIV-Discordant Couples in Rakai, Uganda|Completed|||88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.483999|2018-06-01 03:56:20.483999
NCT00342147|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-16|2006-06-19|2006-06-21|Estimate|||||||2018-05-16|2018-05-17|Actual|November 7, 1995||1995-11-07|July 25, 2017|2017-07-25||||||||Observational|||Family Study of Head and Neck Cancers in Taiwan|Family Study of Head and Neck Cancers in Taiwan|Active, not recruiting|||3795|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.547586|2018-06-01 03:56:20.547586
NCT00342134|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 1, 2002||2002-05-01|May 4, 2011|2011-05-04|May 4, 2011|Actual|2011-05-04|May 4, 2011|Actual|2011-05-04||Interventional|||Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis|Immunological Mechanisms of Immune Ablation and Autologous Hematopoietic Stem Cell Transplantation in Secondary Progressive Multiple Sclerosis|Completed||Phase 2|34|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.624061|2018-06-01 03:56:20.624061
NCT00342121|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|May 3, 2002||2002-05-03|September 19, 2017|2017-09-19||||||||Observational|||Influence of Corn Farming on the Immune System|Influence of Corn Farming on the Immune System|Completed|||40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:20.69717|2018-06-01 03:56:20.69717
NCT00342108|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2010-11-02|2006-06-20|2006-06-21|Estimate|||||||2010-11-02|2010-11-03|Estimate|September 2007||2007-09-30|November 2010|2010-11-30|October 2010|Actual|2010-10-31|July 2009|Actual|2009-07-31||Interventional|||Cortical Visual Impairment and Visual Attentiveness|Cortical Visual Impairment and Visual Attentiveness: The Effect of Visual and Cross-Modal Environments on Children Diagnosed With Cerebral Palsy and Cortical Visual Impairment|Completed||N/A|60|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 03:56:20.945358|2018-06-01 03:56:20.945358
NCT00342095|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 17, 1996||1996-12-17|March 7, 2007|2007-03-07|March 7, 2007||2007-03-07|||||Observational|||Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study|Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus Study (CLU) and Disease Progression and Activity in the Carolina Lupus Study|Completed|||640||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.030731|2018-06-01 03:56:21.030731
NCT00342082|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 25, 2004||2004-06-25|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Observational|||Effects of Anti-HIV Therapy on Red Blood Cells of HIV-infected Mothers and Their Infants|A Pilot Study to Investigate Micronucleated Erythrocyte Frequencies in Infants Exposed to Nucleoside Antiretrovial Drugs in Utero and for 6 Weeks Postnatally|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.099379|2018-06-01 03:56:21.099379
NCT00342069|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 17, 2004||2004-12-17|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Prevalence of Ambivalence Regarding Prenatal Testing|Facilitating Informed for Prenatal Testing: The Role of Ambivalence|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.148624|2018-06-01 03:56:21.148624
NCT00342056|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2011-05-24|2006-06-19|2006-06-21|Estimate|||||||2011-05-24|2011-05-25|Estimate|January 2005||2005-01-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|||||Observational|||Role of Gene Variation in Effectiveness of Gleevec Treatment|Analysis of ABCG2 Genotype in Gleevec Treated Cancer Patients to Assess the Association of a Single Nucleotide Polymorphism (C421A) in ABCG2 and Response to Treatment|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.201505|2018-06-01 03:56:21.201505
NCT00342043|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 2, 2005||2005-08-02|April 16, 2009|2009-04-16|April 16, 2009||2009-04-16|||||Observational|||Examination of Protective Factors Against Severe Malaria|Multidisciplinary Studies of Malaria Protection by Hemoglobinopathies and G6PD Deficiency in Mali|Completed|||4850||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.251801|2018-06-01 03:56:21.251801
NCT00342030|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|November 1, 2002||2002-11-01|April 12, 2012|2012-04-12|April 12, 2012||2012-04-12|||||Observational|||Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans|Dietary and Genetic Factors in Asthma & Chronic Bronchitis in a Cohort of Chinese Singaporeans|Completed|||63257|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.315428|2018-06-01 03:56:21.315428
NCT00342017|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 20, 2002||2002-05-20|August 4, 2009|2009-08-04||||September 2, 2008|Actual|2008-09-02||Observational|||The Effect of Parasitic Worm Infections on the Immune Response to Tuberculosis Bacteria|Immunological Consequences of Helminth and Mycobacterial Coinfection|Completed|||5200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.366063|2018-06-01 03:56:21.366063
NCT00342004|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|May 12, 1997||1997-05-12|April 20, 2018|2018-04-20||||||||Observational|||A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women|A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women|Active, not recruiting|||75366|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.483457|2018-06-01 03:56:21.483457
NCT00341991|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 1, 2001||2001-11-01|February 6, 2018|2018-02-06||||||||Observational|||Molecular Epidemiology of Cutaneous Malignant Melanoma|Molecular Epidemiology of Cutaneous Malignant Melanoma|Completed|||15401|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.559328|2018-06-01 03:56:21.559328
NCT00341965|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|January 27, 1999||1999-01-27|November 4, 2013|2013-11-04|November 4, 2013||2013-11-04|||||Observational|||Pesticide Exposure and Health Status in North Carolina African American Male Farmers and Farm Workers|Pesticide Exposure and Health Status in NC African American Male Farmers and Farm Workers|Completed|||275|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.622941|2018-06-01 03:56:21.622941
NCT00341952|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|April 15, 1998||1998-04-15|January 23, 2018|2018-01-23||||||||Observational|||Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma|Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma|Completed|||2378|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.674548|2018-06-01 03:56:21.674548
NCT00341939|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 7, 2004||2004-09-07|October 10, 2017|2017-10-10||||||||Observational|||Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data|Retrospective Analysis of Drug Disposition and Response-related Genotypes in Cancer Patients and Correlation With Pharmacokinetics and Pharmacodynamics Data|Completed|||484|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.733157|2018-06-01 03:56:21.733157
NCT00341913|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 16, 2000||2000-03-16|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Observational|||Network on Antimicrobial Resistance in Staphylococcus Aureus|Network on Antimicrobial Resistance in Staphylococcus Aureus|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.791017|2018-06-01 03:56:21.791017
NCT00341900|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-08|2006-06-19|2006-06-21|Estimate|||||||2018-05-08|2018-05-09|Actual|November 9, 2001||2001-11-09|April 27, 2018|2018-04-27||||||||Observational|||Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews|Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews|Completed|||134|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.839468|2018-06-01 03:56:21.839468
NCT00341887|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|January 14, 2004||2004-01-14|November 7, 2012|2012-11-07|November 7, 2012||2012-11-07|||||Observational|||Epidemiological Study of HIV in the South African National Defense Force|PHIDISA I: A Prospective, Observational Cohort Study of HIV Infection (Both Treated and Untreated) and Risk-Related Co-Infections in the South African National Defence Force (SANDF)|Terminated|||8676|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:21.899314|2018-06-01 03:56:21.899314
NCT00341874|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|September 8, 1992||1992-09-08|April 9, 2018|2018-04-09||||||||Observational|||Non-Syndrome Hereditary Hearing Impairment - Gene Mapping: India/Pakistan Protocol|Non-Syndromic Hereditary Hearing Impairment - Gene Mapping: India/Pakistan Protocol|Recruiting|||24000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.042995|2018-06-01 03:56:22.042995
NCT00341861|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-24|2006-06-19|2006-06-21|Estimate|||||||2018-04-24|2018-04-25|Actual|September 1, 1998||1998-09-01|November 3, 2017|2017-11-03||||||||Observational|||Interdisciplinary Case-Control Study of Bladder Cancer in Spain|Interdisciplinary Case-Control Study of Bladder Cancer in Spain|Completed|||2925|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.101258|2018-06-01 03:56:22.101258
NCT00341848|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|December 6, 2001||2001-12-06|June 27, 2017|2017-06-27||||||||Observational|||Postpartum Uterine Regression|Postpartum Uterine Regression|Completed|||374|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.155489|2018-06-01 03:56:22.155489
NCT00341835|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|August 26, 2003||2003-08-26|July 5, 2017|2017-07-05||||||||Observational|||Genetic Epidemiology of Lung Cancer|Genetic Epidemiology of Lung Cancer|Recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.222595|2018-06-01 03:56:22.222595
NCT00341822|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 29, 2006||2006-03-29|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Observational|||Invasive Prenatal Testing Decisions in Pregnancy After Infertility|Prenatal Testing Decisions in Pregnancy After Infertility|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.304865|2018-06-01 03:56:22.304865
NCT00341809|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 30, 2004||2004-07-30|September 4, 2012|2012-09-04|September 4, 2012||2012-09-04|||||Observational|||Genetic Analysis of Psoriasis and Psoriatic Arthritis|Role of HLA and KIR in the Natural History of Psoriasis|Completed|||2653|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.359282|2018-06-01 03:56:22.359282
NCT00341796|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-03-03|2006-06-19|2006-06-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|August 2006|2006-08-31|August 2006||2006-08-31|||||Observational|||Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India|A Prospective Cohort Study of the Seroprevalence of, and Interventions to Decrease the Risk of Mother-to-Child Transmission of, Human Immunodeficiency Virus Type 1 (HIV) in Tamil Nadu, India|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.409976|2018-06-01 03:56:22.409976
NCT00341783|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2009-01-06|2006-06-19|2006-06-21|Estimate|||||||2009-01-06|2009-01-07|Estimate|July 2002||2002-07-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Observational|||Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali|Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Doneguebougou, Mali|Terminated|||515||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.458575|2018-06-01 03:56:22.458575
NCT00341770|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 12, 1991||1991-04-12|November 23, 2010|2010-11-23|November 23, 2010||2010-11-23|||||Observational|||Assessment of Sympathetic Nervous System Activity by Microneurography Recording Technique|Assessment of Sympathetic Nervous System Activity by Microneurography Recording Technique|Completed|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.512082|2018-06-01 03:56:22.512082
NCT00341757|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|September 12, 2000||2000-09-12|July 7, 2011|2011-07-07|July 7, 2011||2011-07-07|||||Observational|||Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)|Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)|Completed|||5190|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.557046|2018-06-01 03:56:22.557046
NCT00341744|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2018-01-24|2006-06-20|2006-06-21|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2001||2001-07-31|January 2018|2018-01-31|December 2028|Anticipated|2028-12-31|December 2028|Anticipated|2028-12-31||Observational|||Providing Access to the Visual Environment|Providing Access to the Visual Environment|Recruiting|||795|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||||2018-06-01 03:56:22.607116|2018-06-01 03:56:22.607116
NCT00341731|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2009-11-25|2006-06-19|2006-06-21|Estimate|||||||2009-11-25|2009-12-01|Estimate|December 2000||2000-12-31|October 2008|2008-10-31||||||||Observational|||Environmental Factors in the Development of Polycystic Ovary Syndrome|Environmental Factors in the Development of Polycystic Ovary Syndrome|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.670679|2018-06-01 03:56:22.670679
NCT00341718|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 29, 2006||2006-03-29|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Observational|||Experiences of Genetics Patients With Visible Abnormalities Who Facilitate Teaching in Genetics Clinics|The Experiences of Genetics Patients With Visible Differences Who Facilitate Teaching in Genetics Clinics|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.713263|2018-06-01 03:56:22.713263
NCT00341705|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-19|2006-06-19|2006-06-21|Estimate|||||||2018-05-19|2018-05-22|Actual|April 27, 2001||2001-04-27|April 2, 2013|2013-04-02|April 2, 2013||2013-04-02|||||Observational|||The Second Multicenter Hemophilia Cohort Study|The Second Multicenter Hemophilia Cohort Study|Completed|||2565|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.761376|2018-06-01 03:56:22.761376
NCT00341692|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|April 7, 2003||2003-04-07|March 27, 2018|2018-03-27||||||||Observational|||Studying Normal Breast Tissue and Cancer Risk|Pilot Study to Collect Normal Breast Tissue From Organ and Tissue Donors|Completed|||13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:22.859911|2018-06-01 03:56:22.859911
NCT00341679|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 13, 2005||2005-07-13|December 4, 2017|2017-12-04||||||||Observational|||Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases|Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases|Completed|||719|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.04812|2018-06-01 03:56:23.04812
NCT00341666|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 3, 2006||2006-04-03|July 15, 2011|2011-07-15|July 15, 2011||2011-07-15|||||Observational|||Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites|Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites|Completed|||360|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.108153|2018-06-01 03:56:23.108153
NCT00341653|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|December 1, 1998||1998-12-01|September 18, 2017|2017-09-18||||||||Observational|||A Cohort Study of Smoking Prevention and Health Promotion for Middle School Students in Wuhan, China|A Cohort Study of Smoking Prevention and Health Promotion for Middle School Students in Wuhan, China|Completed|||5051|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.163556|2018-06-01 03:56:23.163556
NCT00341640|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 6, 2005||2005-01-06|December 1, 2006|2006-12-01|December 1, 2006||2006-12-01|||||Interventional|||Metabolism of Nicotine and Cotinine in Pregnant African-American Women|Pharmacokinetics of Nicotine and Cotinine in Pregnant African-American Women and Implications for Pharmacological Interventions|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.213698|2018-06-01 03:56:23.213698
NCT00341627|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|February 1, 1999||1999-02-01|August 21, 2017|2017-08-21||||||||Observational|||Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families|Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families|Completed|||56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.263272|2018-06-01 03:56:23.263272
NCT00341614|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2007-08-14|2006-06-19|2006-06-21|Estimate|||||||2007-08-14|2007-08-16|Estimate|June 2006||2006-06-30|August 2007|2007-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Exercise Training in Older Diabetic Women|The Effects of an Exercise and Diet Intervention on Cardiovascular Risk Factors in Postmenopausal Type 2 Diabetics|Completed||Phase 1|35|Anticipated|University of San Francisco|||||f||||f||||||||||2018-06-01 03:56:23.322606|2018-06-01 03:56:23.322606
NCT00341601|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|January 3, 2005||2005-01-03|January 29, 2018|2018-01-29|January 29, 2018||2018-01-29|||||Observational|||Multi-Drug Resistant Tuberculosis in Korea|A Natural History Study of Multidrug-Resistant Tuberculosis Strains and Host Susceptibility Genes in Korean Patients With Pulmonary Tuberculosis|Completed|||777|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.390746|2018-06-01 03:56:23.390746
NCT00341588|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|January 18, 2002||2002-01-18|May 9, 2018|2018-05-09||||||||Observational|||A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen|A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen|Completed|||2772|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.453831|2018-06-01 03:56:23.453831
NCT00341575|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|September 28, 2005||2005-09-28|August 2, 2010|2010-08-02|August 2, 2010||2010-08-02|||||Observational|||Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer|Psychosocial Aspects of Genetic Testing for HNPCC|Completed|||80|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.573131|2018-06-01 03:56:23.573131
NCT00341562|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-03-03|2006-06-19|2006-06-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2005||2005-09-30|July 2006|2006-07-31|July 2006||2006-07-31|||||Observational|||Genomics of In-Stent Restenosis|Genomics of In-Stent Restenosis: Endarterectomy Study|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.65047|2018-06-01 03:56:23.65047
NCT00341536|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|June 17, 2004||2004-06-17|November 20, 2013|2013-11-20|November 20, 2013||2013-11-20|||||Observational|||Feasibility Study for Prospective Diet and Lifestyle Cohorts in Delhi, Kerala, and Kolkota, India|A Feasibility Study for Prospective Cohort in India|Completed|||4044|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.790992|2018-06-01 03:56:23.790992
NCT00341523|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|July 1, 1994||1994-07-01|March 8, 2018|2018-03-08||||||||Observational|||Early Detection of Esophageal Cancer|Early Detection of Esophageal Cancer|Recruiting|||8000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.854618|2018-06-01 03:56:23.854618
NCT00341510|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 17, 2005||2005-10-17|November 28, 2006|2006-11-28|November 28, 2006||2006-11-28|||||Observational|||Health Behaviors in School-age Children: A World Health Organization Cross-National Study|U.S. Health Behavior in School Children Survey|Completed|||14350||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:23.931902|2018-06-01 03:56:23.931902
NCT00341497|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|August 28, 1996||1996-08-28|June 2, 2017|2017-06-02||||||||Observational|||Biomarkers for Oral Cancer|Biomarkers for Oral Cancer|Completed|||80|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.040416|2018-06-01 03:56:24.040416
NCT00341484|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|June 1, 1998||1998-06-01|March 27, 2018|2018-03-27||||||||Observational|||Genetic Susceptibility to Oncogenic Viruses|Genetic Susceptibility to Oncogenic Viruses|Completed|||2580|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.135385|2018-06-01 03:56:24.135385
NCT00341471|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 18, 2006||2006-01-18|May 18, 2011|2011-05-18|October 8, 2008|Actual|2008-10-08|October 8, 2008|Actual|2008-10-08||Interventional|||Building Futures for Youth - Phase III|Adolescent Pregnancy Prevention: Building Futures for Youth|Completed||Phase 3|2500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.214984|2018-06-01 03:56:24.214984
NCT00341458|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|September 1, 1999||1999-09-01|April 5, 2018|2018-04-05||||||||Observational|||Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics|Breast, Ovarian and Endometrial Cancer Case-Control Study in Poland|Completed|||6086|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.273632|2018-06-01 03:56:24.273632
NCT00341445|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|August 12, 2004||2004-08-12|September 11, 2013|2013-09-11|February 12, 2007|Actual|2007-02-12|February 12, 2007|Actual|2007-02-12||Interventional|||Cockroach Allergen Reduction by Extermination Alone in Low-Income, Urban Homes: A Randomized Control Trial|Cockroach Allergen Reduction by Extermination Alone in Low-Income, Urban Homes-A Randomized Control Trial|Completed||Phase 1|64|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.344998|2018-06-01 03:56:24.344998
NCT00341432|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 16, 2005||2005-08-16|April 20, 2011|2011-04-20|April 20, 2011|Actual|2011-04-20|||||Interventional|||Effectiveness of Nicotine Replacement Therapy in Reducing the Risk of Nicotine Exposure in Pregnant Minority Smokers|Nicotine Replacement Therapy Methods for Pregnant Women|Completed||Phase 2|300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.412314|2018-06-01 03:56:24.412314
NCT00341419|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|February 16, 2005||2005-02-16|May 14, 2013|2013-05-14|May 14, 2013||2013-05-14|||||Observational|||Genetic Analysis of Patients With Pseudoxanthoma Elasticum|Genetic Analysis of Patients With Pseudoxanthoma Elasticum (PXE)|Completed|||188|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.478261|2018-06-01 03:56:24.478261
NCT00341406|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|September 4, 2003||2003-09-04|September 21, 2017|2017-09-21||||||||Observational|||Fat Cell Size in Insulin Resistance|Adipose Cell Size In Human Insulin Resistance|Recruiting|||9999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.528199|2018-06-01 03:56:24.528199
NCT00341393|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|February 16, 2006||2006-02-16|November 15, 2007|2007-11-15|November 15, 2007||2007-11-15|||||Observational|||Validation of System for Monitoring the Effectiveness of Antiretroviral Therapy in HIV-Infected Patients in Africa|Validation of Algorithm for Monitoring the Virological Efficacy of Antiretroviral Therapy in Africa|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.579612|2018-06-01 03:56:24.579612
NCT00341380|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 24, 2002||2002-09-24|January 22, 2018|2018-01-22||||||||Observational|||Prevention of Tumor Spread Due to Lung Cancer Surgery|Venous or Arterial Ligation and Intraoperative Dissemination (VALID) of Cancer Cells: A Randomized Clinical Trial For Patients With Resectable Non-Small Cell Lung Cancer|Completed|||41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.62323|2018-06-01 03:56:24.62323
NCT00341367|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 10, 2002||2002-12-10|March 11, 2010|2010-03-11|March 11, 2010||2010-03-11|||||Observational|||Blood Sample Donations to Study the Role of Genes in Pain|Genetic Risk of Chronic Pain After Acute Sciatica|Completed|||320|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.675058|2018-06-01 03:56:24.675058
NCT00341354|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 27, 2006||2006-01-27|September 6, 2007|2007-09-06|September 6, 2007||2007-09-06|||||Interventional|||Coated Endotracheal Tube and Mucus Shaver to Prevent Hospital-Acquired Infections|Evaluation of Silver-Sulfadiazine Tracheal Tubes / Mucus Shaver in Intubated Patients Expected to Have a Prolonged Mechanical Ventilation|Completed||Phase 2|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.719277|2018-06-01 03:56:24.719277
NCT00341341|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 7, 2004||2004-12-07|July 16, 2010|2010-07-16|July 16, 2010||2010-07-16|||||Observational|||Impact of Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk and Receptivity to Quit Smoking|Impact of a Patient's Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk Information and Receptivity to Quit Smoking|Completed|||757|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.769604|2018-06-01 03:56:24.769604
NCT00341120|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2, 2003||2003-01-02|August 29, 2012|2012-08-29|August 29, 2012||2012-08-29|||||Observational|||Genetic Causes of Male Infertility|Methylenetetrahydrofolate Reductase C677T Mutation, Other Variant Genotypes, and Male Infertility|Completed|||400|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.858108|2018-06-01 03:56:25.858108
NCT00341328|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2013-04-25|2006-06-20|2006-06-21|Estimate|||||||2013-04-25|2013-04-26|Estimate|March 2007||2007-03-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.|Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters|Completed||Phase 3|300|Actual|Ministry of Science and Technology, India||2|||f||||t||||||||||2018-06-01 03:56:24.816767|2018-06-01 03:56:24.816767
NCT00341315|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-24|2006-06-19|2006-06-21|Estimate|||||||2018-04-24|2018-04-25|Actual|May 17, 2004||2004-05-17|April 11, 2018|2018-04-11||||||||Observational|||Breast Cancer, Breast Disease, and Pesticides|A Study of Breast Cancer, Breast Disease, Mammographic Density and Pesticides Among a Population From Triana, Alabama|Completed|||228|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:24.88956|2018-06-01 03:56:24.88956
NCT00341302|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 25, 2002||2002-07-25|July 13, 2017|2017-07-13||||||||Observational|||A Prospective, Observational Study of HIV-Infected Pregnant Women and Their Infants at Clinical Sites in Latin American and Caribbean Countries|A Prospective, Observational Study of HIV-Infected Pregnant Women and HIV-Exposed, Uninfected Children at Clinical Sites in Latin American Countries|Completed|||3554|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.080318|2018-06-01 03:56:25.080318
NCT00341289|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 17, 2003||2003-03-17|September 2, 2009|2009-09-02||||January 10, 2007|Actual|2007-01-10||Observational|||Environmental and Behavioral Risk Factors for Childhood Drowning|Environmental and Behavioral Risk Factors for Childhood Drowning|Completed|||1430||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.155371|2018-06-01 03:56:25.155371
NCT00341276|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|July 6, 1995||1995-07-06|April 11, 2018|2018-04-11||||||||Observational|||Esophageal Cancer Genetics Studies|Esophageal Cancer Genetics Studies|Recruiting|||8000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.209528|2018-06-01 03:56:25.209528
NCT00341263|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 21, 2003||2003-11-21|January 23, 2018|2018-01-23||||||||Observational|||Maternal and Umbilical Cord Hormone Concentrations in Twin and Singleton Pregnancies|Study of Maternal and Umbilical Cord Hormone Concentrations in Monochorionic and Dichorionic Pregnancies|Completed|||111|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.271587|2018-06-01 03:56:25.271587
NCT00341250|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 19, 2006||2006-01-19|April 29, 2009|2009-04-29|December 8, 2006||2006-12-08|||||Interventional|||Malaria Vaccine in Children in Mali|Randomized, Controlled, Phase 1/2 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria in Children in Doneguebougou and Bancoumana, Mali|Completed||Phase 1/Phase 2|900||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.330208|2018-06-01 03:56:25.330208
NCT00341237|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-26|2006-06-19|2006-06-21|Estimate|||||||2018-05-26|2018-05-30|Actual|November 24, 2003||2003-11-24|May 22, 2018|2018-05-22||||||||Observational|||Environmental Polymorphisms Registry|Environmental Polymorphism Registry (EPR)|Recruiting|||20000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.389759|2018-06-01 03:56:25.389759
NCT00341224|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 23, 2003||2003-07-23|December 9, 2009|2009-12-09|December 9, 2009|Actual|2009-12-09|December 9, 2009|Actual|2009-12-09||Interventional|||Steppin' Up: Positive Youth Development Program|Steppin' Up: Positive Youth Development Program|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.454231|2018-06-01 03:56:25.454231
NCT00341211|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 11, 1996||1996-04-11|December 1, 2010|2010-12-01|December 1, 2010||2010-12-01|||||Observational|||Specimens From Normal Controls|Specimens From Normal Controls|Completed|||27|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.507602|2018-06-01 03:56:25.507602
NCT00341198|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 2, 2002||2002-04-02|December 12, 2006|2006-12-12|December 12, 2006||2006-12-12|||||Observational|||Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study|Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study|Completed|||700||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.548868|2018-06-01 03:56:25.548868
NCT00341185|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|March 5, 1998||1998-03-05|November 18, 2016|2016-11-18|November 18, 2016||2016-11-18|||||Observational|||Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing|Studies of Thyroid Abnormalities in Northeastern Kazakhstan Associated With Nuclear Weapons Testing|Completed|||2997|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.594128|2018-06-01 03:56:25.594128
NCT00341172|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-12|2006-06-19|2006-06-21|Estimate|||||||2018-05-12|2018-05-15|Actual|November 1, 2004||2004-11-01|November 6, 2017|2017-11-06||||||||Observational|||The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis|Discovery of Genetic Variants Contributing to the Incidence or Course of CMV Disease in AIDS Patients|Completed|||2232|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.651505|2018-06-01 03:56:25.651505
NCT00341159|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-19|2006-06-19|2006-06-21|Estimate|||||||2018-05-19|2018-05-22|Actual|January 18, 2005||2005-01-18|February 24, 2015|2015-02-24|February 24, 2015||2015-02-24|||||Observational|||Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study|Genetic Analysis of Cancer Susceptibility Alleles in the CARE Case-Control Study|Completed|||9257|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.706689|2018-06-01 03:56:25.706689
NCT00341146|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|November 20, 2001||2001-11-20|May 4, 2018|2018-05-04||||||||Observational|||Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)|Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NPC Susceptibility Gene(s)|Completed|||6490|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.754623|2018-06-01 03:56:25.754623
NCT00341133|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 13, 1999||1999-12-13|August 4, 2009|2009-08-04||||November 27, 2006|Actual|2006-11-27||Observational|||Genetic Analysis of Left-Right Axis Formations|Genetic Analysis of Left-Right Axis Malformations|Completed|||900||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.805409|2018-06-01 03:56:25.805409
NCT00341107|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-03-03|2006-06-19|2006-06-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1999||1999-02-28|January 2006|2006-01-31||||||||Observational|||Physicians Survey on Genetic Testing|Physicians Survey on Genetic Testing|Completed|||1350||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:25.903418|2018-06-01 03:56:25.903418
NCT00341094|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|May 1, 1995||1995-05-01|December 14, 2017|2017-12-14||||||||Observational|||Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Ukraine Following the Chernobyl Accident|Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Diseases in Ukraine Following the Chernobyl Accident|Active, not recruiting|||23143|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:26.892868|2018-06-01 03:56:26.892868
NCT00341081|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2011-05-24|2006-06-19|2006-06-21|Estimate|||||||2011-05-24|2011-05-25|Estimate|October 2002||2002-10-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|||||Observational|||Validation of Self-Reported Needle Sharing Among Injection Drug Users|Validation of Self-Reported Needle Sharing Among Injection Drug Users|Completed|||442||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:26.951045|2018-06-01 03:56:26.951045
NCT00341068|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|January 1, 2000||2000-01-01|November 21, 2017|2017-11-21||||||||Observational|||Genetic Analysis of Neural Tube and Orofacial Cleft Defects in the Irish Population|Genetic Analysis of Neural Tube and Orofacial Cleft Defects in the Irish Population|Active, not recruiting|||7451|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.006233|2018-06-01 03:56:27.006233
NCT00341055|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2011-06-08|2006-06-19|2006-06-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|June 2003||2003-06-30|March 2010|2010-03-31|May 2004|Actual|2004-05-31|||||Interventional|||A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.|A Pilot Study to Evaluate the Hematologic Response Rate of PROCRIT� (Epoetin Alfa) at 80,000 Units Once Weekly in Anemic Cancer Patients Receiving Chemotherapy|Completed||Phase 3|69|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:56:27.05977|2018-06-01 03:56:27.05977
NCT00341042|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|January 4, 2005||2005-01-04|May 1, 2013|2013-05-01|May 1, 2013||2013-05-01|||||Observational|||Collection of Tissue Specimens in Mali, West Africa, for HIV and Tuberculosis Research|Establishment of Normal Parameters for Blood and Sputum With Samples Obtained From Volunteers in Bamako|Terminated|||253|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.114847|2018-06-01 03:56:27.114847
NCT00341029|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 7, 2005||2005-12-07|June 26, 2009|2009-06-26|September 30, 2007|Actual|2007-09-30|September 30, 2007|Actual|2007-09-30||Observational|||Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate|Measurement of Cytogenetic Endpoints in Lymphocytes of Children Diagnosed With Attention Deficit/Hyperactivity Disorder (ADHD) and Treated With Methylphenidate or Adderall|Completed|||84||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.164137|2018-06-01 03:56:27.164137
NCT00341016|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|August 26, 1996||1996-08-26|February 23, 2018|2018-02-23||||||||Observational|||Scientific Protocol for the Study of Leukemia and Other Hematologic Diseases Among Clean-up Workers in Ukraine Following the Chernobyl Accident|Scientific Protocol for the Study of Leukemia and Other Hematologic Diseases Among Clean-up Workers in Ukraine Following the Chernobyl Accident|Active, not recruiting|||1779|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.215474|2018-06-01 03:56:27.215474
NCT00341003|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 22, 2005||2005-07-22|January 14, 2011|2011-01-14|January 14, 2011||2011-01-14|||||Observational|||Severe Malaria and Anti-malarial Drug Resistance in Cambodia|Multidisciplinary Studies of Severe Malaria and Antimalarial Drug Resistance in Cambodia|Completed|||2090|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.269304|2018-06-01 03:56:27.269304
NCT00340990|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|October 6, 2003||2003-10-06|November 27, 2015|2015-11-27|November 27, 2015||2015-11-27|||||Observational|||Immune Responses to Mycobacterium Tuberculosis|Pilot Study of CD4+ T Cell Immune Responses to Mycobacterium Tuberculosis|Completed|||111|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.31879|2018-06-01 03:56:27.31879
NCT00340977|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-02|2006-06-19|2006-06-21|Estimate|||||||2018-05-02|2018-05-03|Actual|September 6, 1995||1995-09-06|December 26, 2017|2017-12-26||||||||Observational|||Svangerskap, Arv, og Miljo (Pregnancy, Heredity and Environment)|Svangerskap, Arv, Og Miljo (Pregnancy, Heredity and Environment)|Completed|||4091|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.462364|2018-06-01 03:56:27.462364
NCT00340964|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|June 13, 2005||2005-06-13|January 6, 2014|2014-01-06|January 6, 2014||2014-01-06|||||Observational|||Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences|Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences|Completed|||44|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.528697|2018-06-01 03:56:27.528697
NCT00340951|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 23, 2005||2005-06-23|April 13, 2007|2007-04-13|April 13, 2007||2007-04-13|||||Observational|||Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?|Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.586747|2018-06-01 03:56:27.586747
NCT00340938|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|November 8, 2004||2004-11-08|January 9, 2018|2018-01-09|August 20, 2009|Actual|2009-08-20|August 20, 2009|Actual|2009-08-20||Interventional|||Family Management of Childhood Diabetes Study|Family Management of Childhood Diabetes Study|Completed||Phase 1|1298|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.645833|2018-06-01 03:56:27.645833
NCT00340912|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 7, 1988||1988-12-07|October 1, 2009|2009-10-01||||December 7, 1988|Actual|1988-12-07||Observational|||Use of Biopsy Punch for Skin Biopsies for Fibroblasts Culturing|Use of Biopsy Punch for Skin Biopsies for Fibroblasts Culturing|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.719861|2018-06-01 03:56:27.719861
NCT00340899|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|December 4, 1997||1997-12-04|October 6, 2017|2017-10-06||||||||Observational|||Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study|Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Restriction: A Longitudinal Study|Completed|||19134|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.771146|2018-06-01 03:56:27.771146
NCT00340860|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|May 14, 2002||2002-05-14|January 2, 2018|2018-01-02||||||||Observational|||The Norwegian Mother and Child Study - Environmental Specimen Collection|The Norwegian Mother and Child Study - Environmental Specimen Collection|Completed|||81093|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:27.960227|2018-06-01 03:56:27.960227
NCT00340847|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 9, 2001||2001-08-09|May 19, 2010|2010-05-19|May 19, 2010||2010-05-19|||||Observational|||Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer|Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer|Completed|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:28.012188|2018-06-01 03:56:28.012188
NCT00340834|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2011-01-04||2017-08-18|2006-06-20|2006-06-21|Estimate|2011-04-20|2011-05-16|Estimate||||2017-08-18|2017-09-21|Actual|May 2006||2006-05-31|August 2017|2017-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|TRANSFORMS||Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase|Completed||Phase 3|1292|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:56:28.185767|2018-06-01 03:56:28.185767
NCT00340821|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 17, 1993||1993-05-17|March 1, 2011|2011-03-01|March 1, 2011||2011-03-01|||||Observational|||A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis|A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica|Completed|||1800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.540967|2018-06-01 03:56:30.540967
NCT00340808|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|March 19, 2004||2004-03-19|September 19, 2017|2017-09-19||||||||Observational|||Molecular Staging of Endometrial Cancer|Integration of an Epidemiologic Questionnaire Into Gynecologic Oncology Group Trials: First Project, Protocol 210|Completed|||5492|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.598657|2018-06-01 03:56:30.598657
NCT00340795|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 4, 2005||2005-08-04|March 7, 2007|2007-03-07|March 7, 2007||2007-03-07|||||Observational|||Media-Smart Youth Program Evaluation Study|Media-Smart Youth Program Evaluation Study|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.664003|2018-06-01 03:56:30.664003
NCT00340782|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 13, 2006||2006-04-13|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Influence of Social and Environmental Factors on Women's Reproductive Function in a Maya Community of Guatemala|The Influence of Social and Environmental Factors on Fecundability in a Maya Community of Guatemala|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.717069|2018-06-01 03:56:30.717069
NCT00340769|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 18, 2001||2001-04-18|December 20, 2006|2006-12-20|December 20, 2006||2006-12-20|||||Observational|||Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic|Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.767676|2018-06-01 03:56:30.767676
NCT00340756|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 6, 2003||2003-08-06|February 25, 2011|2011-02-25|February 25, 2011||2011-02-25|||||Observational|||Evaluating Serum Sex Steroid Hormones|Reproducibility of Serum Sex Steroid Measurement: A Proof of Performance Study|Completed|||60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.820001|2018-06-01 03:56:30.820001
NCT00340743|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|April 21, 2004||2004-04-21|September 26, 2017|2017-09-26||||||||Observational|||Diet and Genetic Damage|Inhibition of Fried Meat-Induced DNA Damage: A Dietary Intervention Study|Completed|||16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.862431|2018-06-01 03:56:30.862431
NCT00340730|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 4, 2001||2001-12-04|November 2, 2006|2006-11-02|November 2, 2006||2006-11-02|||||Observational|||Community Based Youth Injury Prevention Program|Community Based Youth Injury Prevention Program|Completed|||392||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.917021|2018-06-01 03:56:30.917021
NCT00340717|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-03-03|2006-06-19|2006-06-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|September 2006|2006-09-30||||||||Observational|||Markers for Early Detection of Prostate Cancer|Multi-Institutional Pilot Study to Evaluate Molecular Markers in Urine and Serum in the Early Detection of Prostate Cancer|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:30.95994|2018-06-01 03:56:30.95994
NCT00340704|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2015-08-10||2016-01-20|2006-06-19|2006-06-21|Estimate|2016-01-20|2016-02-17|Estimate||||2016-01-20|2016-02-17|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||Treated Set: Includes all patients who are dispensed study medication and are documented to have taken at least one dose of treatment. In this study, some of the subjects are in multiple phases: PK and Group D-Denovo. Thus, the baseline characteristics are based on the unique subject entered into the study.|PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder|An Uncontrolled, Open-label, Titration, Long-term Safety (up to 12 Months) and Efficacy Study of Tamsulosin Hydrochloride in Children With Neuropathic Bladder, With a Randomized Pharmacokinetic Sub-study Investigating Low, Medium and High Dose Ranges.|Completed||Phase 2|143|Actual|Boehringer Ingelheim|In Group D-527.51 Rollover study, due to the early termination caution should be used in interpreting these results due to the impact of the early termination, as well as the impact of the study design on interpretation of results by dose.|3|||f||||f||||||||||2018-06-01 03:56:31.05431|2018-06-01 03:56:31.05431
NCT00340691|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 6, 2004||2004-12-06|November 25, 2008|2008-11-25||||October 4, 2007|Actual|2007-10-04||Interventional|||Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis|Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline|Completed||Phase 2|1500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:32.519941|2018-06-01 03:56:32.519941
NCT00340678|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2013-03-26||2014-07-16|2006-06-19|2006-06-21|Estimate|2013-10-22|2013-11-19|Estimate||||2014-07-16|2014-07-24|Estimate|August 1995||1995-08-31|October 2013|2013-10-31|March 2014|Actual|2014-03-31|May 2012|Actual|2012-05-31||Interventional||Of 170 subjects enrolled, one lost follow up. So all analysis was performed based on 169 subjects.|Renoprotection in Early Diabetic Nephropathy in Pima Indians|Renoprotection in Early Diabetic Nephropathy in Pima Indians|Completed||Phase 3|170|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||t||||||||||2018-06-01 03:56:32.601152|2018-06-01 03:56:32.601152
NCT00340665|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-10|2006-06-19|2006-06-21|Estimate|||||||2018-05-10|2018-05-11|Actual|May 5, 2003||2003-05-05|August 22, 2012|2012-08-22|August 22, 2012||2012-08-22|||||Observational|||Study of Infant Diets on Estrogen Activity and Development|Study of Estrogen Activity & Development (SEAD) SEAD2: Physical Exam and Ballard Markers; Sead 3: Biochemistry|Completed|||239|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.056305|2018-06-01 03:56:33.056305
NCT00340652|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|August 26, 2003||2003-08-26|August 22, 2012|2012-08-22|August 22, 2012||2012-08-22|||||Observational|||Effects of Infant Diets on Estrogen Activity and Development|Study of Estrogen Activity & Development (SEAD) - SEAD 1 Sonography|Completed|||157|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.118717|2018-06-01 03:56:33.118717
NCT00340639|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 28, 2003||2003-01-28|November 2, 2006|2006-11-02|November 2, 2006||2006-11-02|||||Observational|||Management of Type 1 Diabetes Among Adolescents|Developmental Influences on Management of Type I Diabetes|Completed|||240||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.177832|2018-06-01 03:56:33.177832
NCT00340626|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-24|2006-06-19|2006-06-21|Estimate|||||||2018-04-24|2018-04-25|Actual|June 25, 1997||1997-06-25|April 11, 2018|2018-04-11||||||||Observational|||Genetic Analysis of Hereditary Non-Syndromic Oral Clefts|Genetic Analysis of Hereditary Non-Syndromic Oral Clefts|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.233904|2018-06-01 03:56:33.233904
NCT00340613|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2016-07-12|2006-06-19|2006-06-21|Estimate|||||||2016-07-12|2016-07-14|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes|A School Intervention: Lunch Time Insulin Injections in Children With Poorly Controlled Type 1 Diabetes|Completed||Phase 4|36|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 03:56:33.297996|2018-06-01 03:56:33.297996
NCT00340600|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|March 18, 1998||1998-03-18|October 18, 2017|2017-10-18||||||||Observational|||Continuation of Follow-up of DES-Exposed Cohorts|Continuation of Follow-up of DES-Exposed Cohorts|Active, not recruiting|||10805|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.364195|2018-06-01 03:56:33.364195
NCT00340587|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2, 1997||1997-05-02|February 24, 2016|2016-02-24|February 24, 2016||2016-02-24|||||Observational|||Human Sperm Binding to Transgenic Mouse Eggs|Human Sperm Binding to Transgenic Mouse Eggs|Completed|||13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.424079|2018-06-01 03:56:33.424079
NCT00340574|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 8, 2005||2005-03-08|July 2, 2008|2008-07-02|July 2, 2008||2008-07-02|||||Interventional|||Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)|Phase I Study of the Safety and Immunogenicity of AMA-1-C1/Alhydrogel + CPG 7909, An Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria|Completed||Phase 1|0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.478547|2018-06-01 03:56:33.478547
NCT00340561|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-03-03|2006-06-19|2006-06-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2005||2005-01-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Observational|||Effect of Experience on Driving Performance in New Teenage Drivers|Effects of Experience on the Driving Performance of Novice Teen Drivers|Completed|||48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.534296|2018-06-01 03:56:33.534296
NCT00340548|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|April 9, 2002||2002-04-09|November 6, 2017|2017-11-06||||||||Observational|||Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)|Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)|Completed|||333|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.596196|2018-06-01 03:56:33.596196
NCT00340535|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|June 23, 2004||2004-06-23|March 9, 2018|2018-03-09||||||||Observational|||Effect of Genetic Differences on Levels of Water Disinfection Byproducts in Blood After Showering|Levels of Selected Potentially Carcinogenic Drinking Water Disinfection Byproducts in Whole Blood After Showering|Completed|||100|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.67462|2018-06-01 03:56:33.67462
NCT00340522|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|September 7, 2004||2004-09-07|August 11, 2014|2014-08-11|August 11, 2014||2014-08-11|||||Observational|||Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development|Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development|Completed|||20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.728826|2018-06-01 03:56:33.728826
NCT00340509|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|October 26, 2001||2001-10-26|July 23, 2013|2013-07-23|July 23, 2013||2013-07-23|||||Observational|||A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study|A Genome-Wide Scan For Quantitative Trait Loci of Serum Bilirubin - A Framingham Study|Completed|||1888|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.7795|2018-06-01 03:56:33.7795
NCT00340496|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-03-03|2006-06-19|2006-06-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1996||1996-08-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Observational|||Analysis of NF2 Mutations in Radiation-Related Neural Tumors|Analysis of NF2 Mutations in Radiation-Related Neural Tumors|Completed|||112||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.829383|2018-06-01 03:56:33.829383
NCT00340483|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 25, 2004||2004-05-25|December 14, 2006|2006-12-14|December 14, 2006||2006-12-14|||||Interventional|||Smoking Cessation Aid for Young Smokers|X-Pack: A Smoking Cessation Aid for Young Smokers|Completed||Phase 1|291||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:33.996168|2018-06-01 03:56:33.996168
NCT00340470|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 24, 2003||2003-07-24|February 6, 2007|2007-02-06|February 6, 2007||2007-02-06|||||Interventional|||Michigan Driver Education Study|Michigan Young Drivers Intervention Study|Completed||Phase 3|0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.052495|2018-06-01 03:56:34.052495
NCT00340457|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 15, 2001||2001-11-15|January 31, 2018|2018-01-31||||||||Observational|||Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States|Case-Control Study of Renal Cell Cancer Among Caucasians and African Americans in the United States|Completed|||2424|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.104791|2018-06-01 03:56:34.104791
NCT00340444|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|November 6, 2003||2003-11-06|September 19, 2007|2007-09-19|September 19, 2007||2007-09-19|||||Observational|||Genetic Studies of Inflammatory Bowel Disease|Genetic Study of Inflammatory Bowel Disease|Completed|||10000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.166055|2018-06-01 03:56:34.166055
NCT00340431|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 9, 2004||2004-06-09|February 6, 2008|2008-02-06|February 6, 2008||2008-02-06|||||Interventional|||Experimental Vaccine for Plasmodium Falciparum Malaria|Phase 1 Study of the Safety and Immunogenicity of MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, Asexual Blood-Stage Vaccines for Plasmodium Falciparum Malaria|Completed||Phase 1|0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.225573|2018-06-01 03:56:34.225573
NCT00340418|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 23, 2005||2005-06-23|April 13, 2007|2007-04-13|April 13, 2007||2007-04-13|||||Observational|||Mechanisms of Lung Allograft Rejection|Mechanisms of Lung Allograft Rejection|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.278479|2018-06-01 03:56:34.278479
NCT00340405|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|April 23, 1992||1992-04-23|December 14, 2017|2017-12-14||||||||Observational|||Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China|Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China|Active, not recruiting|||9759|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.329475|2018-06-01 03:56:34.329475
NCT00340392|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 7, 2006||2006-04-07|March 23, 2011|2011-03-23|March 23, 2011||2011-03-23|||||Observational|||Isolation and Characterization of Mammary Stem Cells|Isolation and Characterization of Mammary Stem Cells|Completed|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.389601|2018-06-01 03:56:34.389601
NCT00340379|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|2011-06-28||2014-08-15|2006-06-20|2006-06-21|Estimate|2013-06-03|2013-06-04|Estimate||||2014-08-15|2014-08-19|Estimate|April 2003||2003-04-30|February 2012|2012-02-29|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression|A Comparison of Two Different Treatments for Major Depression With Psychotic Features: Ziprasidone vs. Combined Sertraline and Haloperidol|Completed||Phase 2/Phase 3|72|Actual|Duke University||2|||f||||f||||||||||2018-06-01 03:56:34.498215|2018-06-01 03:56:34.498215
NCT00340366|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 16, 2003||2003-12-16|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Influence of Genetics on Vitamin Metabolism in Pregnant Women|Investigation Into the Influence of Genetic Variation on Folate, Cobalamin and Related Metabolites|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.771704|2018-06-01 03:56:34.771704
NCT00340353|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 7, 2005||2005-04-07|April 12, 2012|2012-04-12|April 12, 2012||2012-04-12|||||Observational|||Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research|Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development|Completed|||99999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.823703|2018-06-01 03:56:34.823703
NCT00340340|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|June 28, 2001||2001-06-28|May 7, 2018|2018-05-07||||||||Observational|||Genetic Epidemiology of Lung Cancer and Smoking|Genetic Epidemiology of Lung Cancer and Smoking Current Title: Environmental And Genetic Lung Cancer Etiology (EAGLE)|Completed|||4429|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:34.880311|2018-06-01 03:56:34.880311
NCT00340327|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2007-12-03|2006-06-20|2006-06-21|Estimate|||||||2007-12-03|2007-12-05|Estimate|June 2006||2006-06-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Evaluating IMA-638 in Healthy Japanese|An Ascending Single Dose Study of the Safety and Pharmacokinetics of IMA-638 Administered to Healthy Japanese Subjects|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:56:34.968881|2018-06-01 03:56:34.968881
NCT00340314|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2010-07-27|2006-06-19|2006-06-21|Estimate|||||||2010-07-27|2010-07-28|Estimate|January 2005||2005-01-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|APAF2||A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF)|A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial|Completed||Phase 4|198||IRCCS San Raffaele|||||f||||||||||||||2018-06-01 03:56:35.029761|2018-06-01 03:56:35.029761
NCT00340301|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|June 3, 2003||2003-06-03|February 7, 2018|2018-02-07||||||||Observational|||Exposure to Neurotoxins as Risk Factors for ALS|Exposure to Neurotoxins as Risk Factors for ALS: Measurement of Genes, Proteins, Neurotoxicants, and Other Factors Potentially Associated With ALS|Completed|||397|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.110702|2018-06-01 03:56:35.110702
NCT00340288|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|June 27, 2001||2001-06-27|December 12, 2017|2017-12-12||||||||Observational|||Fibroid Growth Study|Fibroid Growth Study|Completed|||123|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.174389|2018-06-01 03:56:35.174389
NCT00340275|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 14, 1999||1999-04-14|November 18, 2010|2010-11-18|November 18, 2010||2010-11-18|||||Observational|||Longitudinal Study of Vaginal Flora|Longitudinal Study of Vaginal Flora|Completed|||5500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.237059|2018-06-01 03:56:35.237059
NCT00340262|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|April 7, 2000||2000-04-07|March 6, 2018|2018-03-06||||||||Observational|||Bone Mineral Density and Subsequent Cancer Risk|Bone Mineral Density and Subsequent Cancer Risk|Completed|||15595|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.285941|2018-06-01 03:56:35.285941
NCT00340249|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2012-06-13|2006-06-19|2006-06-21|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 1995||1995-07-31|June 2012|2012-06-30||||||||Observational|||Use of the Perinatal Database and Biologic Tissue Bank at The Perinatology Research Branch (PRB)|Use of a Perinatal Database and Biologic Tissue Bank at the Perinatology Research Branch (PRB)|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.3448|2018-06-01 03:56:35.3448
NCT00340223|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2012-05-09|2006-06-19|2006-06-21|Estimate|||||||2012-05-09|2012-05-10|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|September 2007|Actual|2007-09-30|||||Observational|||HLA-B35 Alleles and AIDS|Comparison of HIV-1 Epitopes That May be Recognized by HLA-B*3501 (PY) and -B*3503 (Px) Early After Seroconversion and After Development of AIDS|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.395663|2018-06-01 03:56:35.395663
NCT00340210|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-11|2006-06-19|2006-06-21|Estimate|||||||2018-05-11|2018-05-14|Actual|January 14, 1999||1999-01-14|August 18, 2017|2017-08-18||||||||Observational|||Extended Follow-up of Columbia, MO Serum Bank Participants|Extended Follow-up of Columbia, MO Serum Bank Participants|Completed|||6720|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.458047|2018-06-01 03:56:35.458047
NCT00340184|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2010-10-17|2006-06-20|2006-06-21|Estimate|||||||2010-10-17|2010-10-19|Estimate|August 2004||2004-08-31|January 2006|2006-01-31||||||||Interventional|||A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients|A Phase II Trial of Radiation Therapy With Concurrent Paclitaxel/Carboplatin Chemotherapy in High-risk Cervical Cancer Patients After Radical Hysterectomy|Completed||Phase 2|55||Korean Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 03:56:35.520477|2018-06-01 03:56:35.520477
NCT00340171|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|December 4, 1997||1997-12-04|September 19, 2017|2017-09-19||||||||Observational|||Fetal Growth Evaluation by Three-Dimensional Ultrasound|Fetal Growth Evaluation by Three-Dimensional Ultrasound|Completed|||1919|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.580969|2018-06-01 03:56:35.580969
NCT00340158|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2010-04-22|2006-06-19|2006-06-21|Estimate|||||||2010-04-22|2010-04-23|Estimate|June 2003||2003-06-30|April 2009|2009-04-30||||||||Observational|||Establishing an Inflammatory Breast Cancer Registry|The Establishment of an Inflammatory Breast Cancer Registry and Biospecimen Repository|Completed|||164|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.632506|2018-06-01 03:56:35.632506
NCT00340132|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-03-09|2006-06-19|2006-06-21|Estimate|||||||2018-03-09|2018-03-12|Actual|August 18, 1982||1982-08-18|August 30, 2017|2017-08-30||||||||Observational|||"Cross-Sectional and Longitudinal Studies of Pre-Diabetes in the Pima Indians"|"Cross-Sectional and Longitudinal Studies of Pre-Diabetes"|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.681702|2018-06-01 03:56:35.681702
NCT00340119|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 21, 2005||2005-03-21|March 1, 2012|2012-03-01|March 1, 2012||2012-03-01|||||Observational|||Genetic Susceptibility to Cardiovascular Disease in Patients on Kidney Dialysis|Prospective Study of Inflammatory Markers and Genes as Predictors of Atherosclerotic Cardiovascular Disease in Dialysis Patients|Completed|||871|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.738693|2018-06-01 03:56:35.738693
NCT00340106|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 25, 2005||2005-07-25|May 18, 2011|2011-05-18|May 18, 2010|Actual|2010-05-18|March 5, 2010|Actual|2010-03-05||Interventional|||Prevention of Environmental Tobacco Smoke Exposure in Children 0-12 Months Old|Prevention of Environmental Tobacco Smoke (ETS) Exposure to Children, Ages 0-12 Months|Completed||Phase 2|375|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.787814|2018-06-01 03:56:35.787814
NCT00340093|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 23, 2002||2002-08-23|March 6, 2007|2007-03-06|March 6, 2007||2007-03-06|||||Interventional|||Diabetes Management Personal Trainer|The Diabetes Management Study|Completed||Phase 1|0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:35.845276|2018-06-01 03:56:35.845276
NCT00340080|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2010-01-21|2006-06-19|2006-06-21|Estimate|||||||2010-01-21|2010-01-25|Estimate|April 2006||2006-04-30|January 2010|2010-01-31||||||||Interventional|||Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity|A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity|Completed||Phase 4|1806||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:56:35.925592|2018-06-01 03:56:35.925592
NCT00340054|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2012-03-07|2006-06-19|2006-06-21|Estimate|||||||2012-03-07|2012-03-08|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|March 2007|Actual|2007-03-31|||||Observational|||Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields|Assessment of Occupational EMF Exposure - Validation of Interview Procedures Used in Brain Tumor Study|Completed|||108|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.484091|2018-06-01 03:56:36.484091
NCT00340028|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|January 18, 2005||2005-01-18|February 7, 2018|2018-02-07||||||||Observational|||Hormonal Changes in Early Pregnancy|Hormonal Changes in Early Pregnancy: Pilot Study to Evaluate Stored Urine Specimens|Completed|||40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.565233|2018-06-01 03:56:36.565233
NCT00340015|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|October 24, 1995||1995-10-24|February 16, 2018|2018-02-16||||||||Observational|||A Prospective Study of Diet and Cancer in Members of the American Association of Retired Persons|NCI-AARP Diet and Health Study|Completed|||566401|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.636683|2018-06-01 03:56:36.636683
NCT00340002|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|November 26, 1997||1997-11-26|October 25, 2017|2017-10-25||||||||Observational|||Fetal Anatomy by Three-Dimensional Ultrasound|Fetal Anatomy by Three-Dimensional Ultrasound|Completed|||3650|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.708384|2018-06-01 03:56:36.708384
NCT00339989|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|September 12, 2003||2003-09-12|April 5, 2018|2018-04-05||||||||Observational|||Cervical Cancer Early Endpoints and Determinants|A Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED)|Active, not recruiting|||3013|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.77972|2018-06-01 03:56:36.77972
NCT00339976|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 6, 2002||2002-08-06|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis|Ascertainment of Death in ALS Patients|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.851028|2018-06-01 03:56:36.851028
NCT00339963|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 9, 2001||2001-11-09|November 1, 2017|2017-11-01||||||||Observational|||Genome Expression in Lymphoma, Leukemia and Multiple Myeloma|Expression of the Genome in Lymphoid Malignancies|Completed|||1340|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.911176|2018-06-01 03:56:36.911176
NCT00339950|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|February 14, 2000||2000-02-14|August 25, 2017|2017-08-25||||||||Observational|||Colorectal Neoplasia Screening With Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Centers: The CONCeRN Trial|Diet, Other Risk Factors, Genetics and the Risk of Colorectal Neoplasia in a Screening Trial of Asymptomatic Women: A Sub-Study of the CONCeRN Trial|Completed|||937|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:36.977095|2018-06-01 03:56:36.977095
NCT00339937|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|July 30, 1998||1998-07-30|February 7, 2018|2018-02-07||||||||Observational|||Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily|Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily|Completed|||4622|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.046436|2018-06-01 03:56:37.046436
NCT00339924|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 11, 2005||2005-07-11|January 26, 2018|2018-01-26||||||||Observational|||Physicians' Understanding of Human Genetic Variation|Physicians' Understanding of Human Genetic Variation|Completed|||1258|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.112342|2018-06-01 03:56:37.112342
NCT00339911|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-22|2006-06-19|2006-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|October 19, 1999||1999-10-19|April 3, 2018|2018-04-03||||||||Observational|||Collection and Distribution of Blood Samples From Healthy Donors for In Vitro Research at the NCI Frederick Cancer Research and Development Center|Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick|Enrolling by invitation|||838|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.161876|2018-06-01 03:56:37.161876
NCT00339898|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|March 12, 2004||2004-03-12|January 13, 2015|2015-01-13|January 13, 2015||2015-01-13|||||Observational|||Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma|Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma|Completed|||414|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.212922|2018-06-01 03:56:37.212922
NCT00339885|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|March 24, 1995||1995-03-24|August 29, 2017|2017-08-29||||||||Observational|||Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus|Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus|Recruiting|||60000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.262575|2018-06-01 03:56:37.262575
NCT00339872|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-20|||2007-12-03|2006-06-20|2006-06-21|Estimate|||||||2007-12-03|2007-12-05|Estimate|February 2006||2006-02-28|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Study Evaluating IMA-638 in Asthma|Randomized, Double-Blind, Placebo-Controlled, Sequential-Group, Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IMA-638 Administered Subcutaneously and Intravenously to Subjects With Asthma|Completed||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:56:37.323973|2018-06-01 03:56:37.323973
NCT00339859|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-01-25|2006-06-19|2006-06-21|Estimate|||||||2018-01-25|2018-01-26|Actual|June 2, 1995||1995-06-02|January 22, 2018|2018-01-22||||||||Observational|||DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer|DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer|Recruiting|||6000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.375386|2018-06-01 03:56:37.375386
NCT00339846|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 5, 2005||2005-01-05|September 17, 2008|2008-09-17|September 17, 2008||2008-09-17|||||Observational|||Genetic Analysis of Craniofrontonasal Syndrome|Genetic Analysis of Craniofrontonasal Syndrome|Completed|||152||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.429157|2018-06-01 03:56:37.429157
NCT00339833|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2010-12-29||2013-01-29|2006-06-19|2006-06-21|Estimate|2013-01-29|2013-03-06|Estimate||||2013-01-29|2013-03-06|Estimate|March 2003||2003-03-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers|The Effect of Salsalate Treatment on Insulin Sensitivity and Insulin Secretion in Obese Non-Diabetic Individuals|Completed||Phase 4|54|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 03:56:37.479008|2018-06-01 03:56:37.479008
NCT00339807|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 17, 2002||2002-01-17|August 11, 2011|2011-08-11|August 11, 2011||2011-08-11|||||Observational|||Natural History of HTLV-I Infection: Prospective Follow-up of a Cohort of Blood Donors in Jamaica|Natural History of HTVL-I: A Cross-Sectional Study of a Cohort of Blood Donors in Jamaica|Completed|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.834821|2018-06-01 03:56:37.834821
NCT00339794|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 7, 2004||2004-12-07|July 16, 2010|2010-07-16|July 16, 2010||2010-07-16|||||Observational|||Clinical Integration of Genetic Risk Assessment in Family Medicine|Clinical Integration of Genetic Risk Assessment in Family Medicine|Completed|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.880434|2018-06-01 03:56:37.880434
NCT00339781|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2009-09-22|2006-06-19|2006-06-21|Estimate|||||||2009-09-22|2009-09-23|Estimate|February 2005||2005-02-28|September 2009|2009-09-30||||September 2007|Actual|2007-09-30||Observational|||Predictive and Protective Factors in the Cause of Diabetes - A Study in Twins|Predictive and Protective Factors in the Cause of Diabetes: A Study in Twins|Completed|||240||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:37.929983|2018-06-01 03:56:37.929983
NCT00339768|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|July 1, 1995||1995-07-01|January 31, 2018|2018-01-31|June 10, 1996|Actual|1996-06-10|June 10, 1996|Actual|1996-06-10||Interventional|||A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province|Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province, China|Completed||Phase 3|3411|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 03:56:37.976532|2018-06-01 03:56:37.976532
NCT00339742|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|March 25, 2003||2003-03-25|March 8, 2018|2018-03-08||||||||Observational|||Stomach and Esophageal Cancers in Northern Iran|Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Phase I: Case-Control Study|Active, not recruiting|||1163|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:38.053253|2018-06-01 03:56:38.053253
NCT00339729|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 7, 1997||1997-05-07|May 24, 2007|2007-05-24|May 24, 2007||2007-05-24|||||Observational|||Johnston County ADHD Study: Environmental, Reporductive, and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD)|Johnston County ADHD Study: Environmental, Reproductive and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD)|Completed|||8000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:38.10856|2018-06-01 03:56:38.10856
NCT00339716|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|March 21, 1994||1994-03-21|April 4, 2018|2018-04-04||||||||Observational|||Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident|Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident|Recruiting|||21000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:38.155841|2018-06-01 03:56:38.155841
NCT00339703|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-06-19|2006-06-19|2006-06-21|Estimate|||||||2006-06-19|2006-06-21|Estimate|November 2004||2004-11-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Observational|||Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.|Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.|Unknown status|Active, not recruiting||50||Wilford Hall Medical Center|||||f||||||||||||||2018-06-01 03:56:38.212594|2018-06-01 03:56:38.212594
NCT00339690|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-24|2006-06-19|2006-06-21|Estimate|||||||2018-05-24|2018-05-25|Actual|June 6, 2005||2005-06-06|November 27, 2015|2015-11-27|February 11, 2009|Actual|2009-02-11|February 11, 2009|Actual|2009-02-11||Interventional|||Dust Mite Allergen Reduction Study|Dust Mite Allergen Reduction Study|Completed||Phase 2|60|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 03:56:38.254749|2018-06-01 03:56:38.254749
NCT00339677|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 6, 2003||2003-11-06|March 1, 2018|2018-03-01||||||||Observational|||Recontacting Participants in the Observing Protein and Energy Nutrition (OPEN) Study: Re-OPEN|Recontacting Participants in the Observing Protein and Energy Nutrition Study: ReOPEN|Completed|||384|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:38.331446|2018-06-01 03:56:38.331446
NCT00339664|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-08|2006-06-19|2006-06-21|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2, 2003||2003-07-02|May 4, 2018|2018-05-04||||||||Observational|||Analyses of Human Samples Collected in Clinical Trials|Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute|Enrolling by invitation|||2569|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:38.392402|2018-06-01 03:56:38.392402
NCT00339651|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-24|2006-06-19|2006-06-21|Estimate|||||||2018-04-24|2018-04-25|Actual|November 25, 2002||2002-11-25|April 3, 2018|2018-04-03||||||||Observational|||Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer|Preliminary Study of Endometrial Hyperplasia: Groundwork for a Study to Define an Optimal Classification of Endometrial Carcinoma Precursors|Active, not recruiting|||745|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:38.459455|2018-06-01 03:56:38.459455
NCT00339638|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 21, 2004||2004-12-21|May 26, 2011|2011-05-26|May 26, 2011||2011-05-26|||||Observational|||Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1|Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study|Completed|||228|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:38.511447|2018-06-01 03:56:38.511447
NCT00339625|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-12|2006-06-19|2006-06-21|Estimate|||||||2018-05-12|2018-05-15|Actual|June 19, 1991||1991-06-19|March 27, 2018|2018-03-27|April 14, 2011|Actual|2011-04-14|||||Interventional|||Polyp Prevention Trial|Polyp Prevention Trial|Completed||Phase 3|2079|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 03:56:39.503989|2018-06-01 03:56:39.503989
NCT00339612|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|July 30, 2002||2002-07-30|July 24, 2017|2017-07-24||||||||Observational|||NISDI Pediatric Latin American Countries Epidemiologic Study (PLACES): A Prospective Observational Study of HIV-Infected Children at Clinical Sites in Latin American Countries|NISDI Pediatric Latin American Countries Epidemiologic Study (PLACES): A Prospective Observational Study of HIV-Infected Children at Clinical Sites in Latin American Countries|Completed|||2129|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:39.590974|2018-06-01 03:56:39.590974
NCT00339599|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-28|2006-06-19|2006-06-21|Estimate|||||||2018-04-28|2018-05-01|Actual|September 20, 2005||2005-09-20|August 3, 2015|2015-08-03|August 3, 2015||2015-08-03|||||Observational|||Genetic Predictors of Cardiovascular Disease|Study of Chemokine Markers and Genes as Predictors of Cardiovascular Disease|Completed|||2306|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:39.670249|2018-06-01 03:56:39.670249
NCT00339586|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-06-19|2006-06-19|2006-06-21|Estimate|||||||2006-06-19|2006-06-21|Estimate|January 2006||2006-01-31|January 2006|2006-01-31||||||||Interventional|||First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene|Prospective Evaluation of Small Molecule EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene|Unknown status|Recruiting|Phase 2|40||AZ-VUB|||||f||||||||||||||2018-06-01 03:56:39.728291|2018-06-01 03:56:39.728291
NCT00339573|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-20|2006-06-19|2006-06-21|Estimate|||||||2018-04-20|2018-04-23|Actual|June 30, 1998||1998-06-30|November 24, 2017|2017-11-24||||||||Observational|||National Survey of Lead and Allergen Hazards in Housing|National Survey of Lead Hazards and Allergens in Housing|Completed|||831|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:39.800222|2018-06-01 03:56:39.800222
NCT00339560|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|May 16, 1997||1997-05-16|February 6, 2018|2018-02-06||||||||Observational|||A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China|A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China|Completed|||2624|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:39.858666|2018-06-01 03:56:39.858666
NCT00339547|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-28|2006-06-19|2006-06-21|Estimate|||||||2018-04-28|2018-05-01|Actual|November 1, 1995||1995-11-01|June 28, 2017|2017-06-28||||||||Observational|||Risk Factors for Uterine Fibroids: A Case Control Study|Risk Factors for Uterine Fibroids: A Case Control Study and Follow-up Amendment to Study Disease Progression|Completed|||1529|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:39.915325|2018-06-01 03:56:39.915325
NCT00339534|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|June 26, 2002||2002-06-26|November 3, 2017|2017-11-03||||||||Observational|||Survey of Prostate Cancer in Accra, Ghana|Survey of Prostate Cancer in Accra, Ghana|Completed|||1758|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.060811|2018-06-01 03:56:40.060811
NCT00339521|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|October 15, 1998||1998-10-15|December 4, 2017|2017-12-04||||||||Observational|||Genetic Susceptibility to Childhood Respiratory IIlness in Mexico City|Genetic Susceptibility to Childhood Respiratory Illness in Mexico City|Completed|||2362|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.139503|2018-06-01 03:56:40.139503
NCT00339508|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|March 19, 2002||2002-03-19|May 9, 2017|2017-05-09|May 9, 2017||2017-05-09|||||Observational|||Exploratory Data Analysis for Disease Pedigrees and Cancer Genetics|Exploratory Data Analysis for Disease Pedigrees and Cancer Genetics|Completed|||13385|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.217881|2018-06-01 03:56:40.217881
NCT00339495|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|July 21, 1997||1997-07-21|March 16, 2018|2018-03-16||||||||Observational|||Early Marker and Etiologic Studies in the PLCO Trial|Etiologic and Early Marker Studies in the PLCO Trial|Active, not recruiting|||154900|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.28018|2018-06-01 03:56:40.28018
NCT00339482|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 3, 1976||1976-09-03|November 16, 2017|2017-11-16||||||||Observational|||Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community|Prospective Studies of Diabetes Mellitus and Its Complications in the Gila River Indian Community|Completed|||12647|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.342387|2018-06-01 03:56:40.342387
NCT00339469|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-19|2006-06-19|2006-06-21|Estimate|||||||2018-05-19|2018-05-22|Actual|August 3, 2005||2005-08-03|February 13, 2018|2018-02-13|February 13, 2018|Actual|2018-02-13|May 19, 2008|Actual|2008-05-19||Interventional|||Effect of High-Legume Diet on Colorectal Cancer Risk|The Effects of a High Legume Low Glycemic Index Diet on Insulin Resistance and Inflammation in Patients at High Risk for Colorectal Adenoma Recurrence|Completed||Early Phase 1|65|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 03:56:40.405283|2018-06-01 03:56:40.405283
NCT00339456|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-18|2006-06-19|2006-06-21|Estimate|||||||2018-05-18|2018-05-21|Actual|August 21, 2002||2002-08-21|May 20, 2014|2014-05-20|February 1, 2008|Actual|2008-02-01|February 1, 2008|Actual|2008-02-01||Interventional|||Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda|A Randomized, Controlled Trial of Short Cycle Intermittent Versus Continuous HAART for the Treatment of Chronic HIV Infection in Uganda|Completed||Phase 3|155|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.481295|2018-06-01 03:56:40.481295
NCT00339443|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|November 6, 2001||2001-11-06|May 19, 2010|2010-05-19|May 19, 2010||2010-05-19|||||Observational|||Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different Methods|Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different Methods|Completed|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.547756|2018-06-01 03:56:40.547756
NCT00339430|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 15, 2002||2002-07-15|August 18, 2010|2010-08-18|August 18, 2010||2010-08-18|||||Observational|||HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)|HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)|Completed|||3500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.598519|2018-06-01 03:56:40.598519
NCT00339417|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|February 22, 2006||2006-02-22|August 17, 2011|2011-08-17|August 17, 2011|Actual|2011-08-17|August 1, 2008|Actual|2008-08-01||Interventional|||Effect of Albendazole Dose on Clearance of Filarial Worms|Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study|Completed||Phase 2|1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.644006|2018-06-01 03:56:40.644006
NCT00339404|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|March 4, 1999||1999-03-04|March 7, 2011|2011-03-07|March 7, 2011||2011-03-07|||||Observational|||Genetic Analysis of Familial Melanoma|Genetic Analysis of Familial Melanoma|Completed|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.699376|2018-06-01 03:56:40.699376
NCT00339391|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-17|2006-06-19|2006-06-21|Estimate|||||||2018-05-17|2018-05-18|Actual|August 19, 2001||2001-08-19|November 30, 2016|2016-11-30|November 30, 2016||2016-11-30|||||Observational|||Socioenvironmental Determinants of Psychological Functioning, Mental Health and AIDS in Mali|Socio-Environmental Determinants of Psychological Functioning, Mental Health and AIDS in Mali|Completed|||1002|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.748264|2018-06-01 03:56:40.748264
NCT00339378|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 28, 2000||2000-06-28|June 11, 2007|2007-06-11|June 11, 2007||2007-06-11|||||Observational|||Incidence and Mortality of Childhood Cancer Among Children of Farmer Pesticide Applications|Incidence and Mortality of Childhood Cancer Among Children of Farmer Pesticide Applicators|Completed|||21985||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.797869|2018-06-01 03:56:40.797869
NCT00339365|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2012-05-16|2006-06-19|2006-06-21|Estimate|||||||2012-05-16|2012-05-17|Estimate|April 2007||2007-04-30|May 2012|2012-05-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||Promoting Infant Mental Health in Foster Care|Promoting Infant Mental Health in Foster Care|Completed||Phase 2/Phase 3|236|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 03:56:40.844565|2018-06-01 03:56:40.844565
NCT00339352|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|February 24, 1999||1999-02-24|September 19, 2017|2017-09-19||||||||Observational|||A Family Study of Adults With Glioma|A Family Study of Adults With Glioma|Completed|||1871|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.912069|2018-06-01 03:56:40.912069
NCT00339339|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-26|2006-06-19|2006-06-21|Estimate|||||||2018-04-26|2018-04-27|Actual|July 26, 2004||2004-07-26|January 22, 2013|2013-01-22|January 22, 2013||2013-01-22|||||Observational|||Levels of Bisphenol A in Urine and Saliva Following Placement of Composite Restorations|Bisphenol A and Metabolites in Urine and Saliva Associated With Placement of Composite Restorations|Completed|||172|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:40.965611|2018-06-01 03:56:40.965611
NCT00339326|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 1, 2002||2002-09-01|January 23, 2018|2018-01-23||||||||Observational|||Risk Factors for Non-HIV-Related Kaposi s Sarcoma|Cofactors for Classical Kaposi's Sarcoma and for Kaposi's Sarcoma-Associated Herpesvirus Infection: A Case-Control Study in Sicily|Completed|||1383|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.098075|2018-06-01 03:56:41.098075
NCT00339313|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 12, 2000||2000-01-12|June 24, 2011|2011-06-24|June 24, 2011||2011-06-24|||||Observational|||Food Intake and Appetite in the Children of Mothers With Diabetes|Food Intake and Appetite in the Children of Mothers With Diabetes|Completed|||240|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.159934|2018-06-01 03:56:41.159934
NCT00339300|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-04|2006-06-19|2006-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|August 19, 1994||1994-08-19|February 26, 2018|2018-02-26|February 26, 2018||2018-02-26|||||Observational|||A Case-Referent Study of Brain Tumors in Adults|A Case-Referent Study of Brain Tumors in Adults|Completed|||1581|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.217034|2018-06-01 03:56:41.217034
NCT00339287|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-03-20|2006-06-19|2006-06-21|Estimate|||||||2018-03-20|2018-03-21|Actual|February 12, 2001||2001-02-12|March 6, 2018|2018-03-06||||||||Observational|||Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens|Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.279242|2018-06-01 03:56:41.279242
NCT00339274|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 14, 1999||1999-10-14|March 16, 2012|2012-03-16|March 16, 2012||2012-03-16|||||Observational|||International Cooperation for Post-Cherynobyl NIS Thyroid Tissue and Data Banks|The Chernobyl Tissue Bank|Completed|||4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.409183|2018-06-01 03:56:41.409183
NCT00339261|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 16, 2003||2003-12-16|October 26, 2006|2006-10-26|October 26, 2006||2006-10-26|||||Observational|||Disease Progression and Activity in Patients With Systemic Lupus Erythematosus|Disease Progression and Activity in the Carolinas Lupus Study - MUSC Medical University of South Carolina Follow up|Completed|||716||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.462395|2018-06-01 03:56:41.462395
NCT00339248|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2009-03-12|2006-06-19|2006-06-21|Estimate|||||||2009-03-12|2009-03-13|Estimate|December 2004||2004-12-31|October 2007|2007-10-31||||||||Observational|||Markers for Breast Cancer|Risk of Breast Cancer and Hyperplastic Conditions in the Breast Cancer Serum Bank in Relation to Inherited Genetic Variants|Completed|||2632||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.514121|2018-06-01 03:56:41.514121
NCT00339235|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-05-23|2006-06-19|2006-06-21|Estimate|||||||2018-05-23|2018-05-24|Actual|January 6, 1998||1998-01-06|October 25, 2017|2017-10-25||||||||Observational|||Establishment of a Perinatal Database and a Bank of Biological Materials|Establishment of a Clinical Perinatal Database and Bank of Biological Materials|Completed|||30570|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.57121|2018-06-01 03:56:41.57121
NCT00339222|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-03-13|2006-06-19|2006-06-21|Estimate|||||||2018-03-13|2018-03-14|Actual|November 5, 2001||2001-11-05|May 18, 2017|2017-05-18||||||||Observational|||Family Study of Melanoma in Italy|Family Study of Melanoma in Italy|Recruiting|||1600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.651476|2018-06-01 03:56:41.651476
NCT00339209|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2006-06-19|2006-06-21|Estimate|||||||2017-06-30|2017-07-02|Actual|June 23, 2005||2005-06-23|April 13, 2007|2007-04-13|April 13, 2007||2007-04-13|||||Observational|||Prospective Lung Transplant Database for Genetic Research|Prospective Lung Transplant Database for Genetic Research|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:56:41.726271|2018-06-01 03:56:41.726271
NCT00339196|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2011-05-06|2006-06-19|2006-06-20|Estimate|||||||2011-05-06|2011-05-09|Estimate|July 2006||2006-07-31|March 2007|2007-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS|Multi Centers, Open-trial Phase II Study Evaluating 5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®) in Patients With Acute Myelogenous Leukemia and High Risk Myelodysplasia.|Completed||Phase 2|25|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:56:41.780869|2018-06-01 03:56:41.780869
NCT00339183|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2014-04-03|2010-07-20|2017-02-07|2006-06-16|2006-06-20|Estimate|2014-04-03|2014-05-06|Estimate|2010-07-20|2010-07-22|Estimate|2017-02-07|2017-02-09|Estimate|June 2006||2006-06-30|February 2017|2017-02-28|November 2010|Actual|2010-11-30|April 2009|Actual|2009-04-30||Interventional|||Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone|A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer|Completed||Phase 3|1186|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:56:41.919147|2018-06-01 03:56:41.919147
NCT00339170|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2016-04-08|2006-06-16|2006-06-20|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2000||2000-04-30|April 2016|2016-04-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Cognitive Training and Enhanced Supported Employment in Schizophrenia|Cognitive Training and Enhanced Supported Employment|Completed||N/A|98|Actual|Yale University||2|||f||||||||||||||2018-06-01 03:56:43.295219|2018-06-01 03:56:43.295219
NCT00339157|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2010-07-19|2006-06-16|2006-06-20|Estimate|||||||2010-07-19|2010-07-20|Estimate|June 2006||2006-06-30|July 2010|2010-07-31|July 2008|Actual|2008-07-31|||||Interventional|||Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS|ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS)|Completed||Phase 2/Phase 3|24||Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-06-01 03:56:43.389159|2018-06-01 03:56:43.389159
NCT00339144|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2010-10-07||2010-11-19|2006-06-19|2006-06-20|Estimate|2010-11-19|2010-12-15|Estimate||||2010-11-19|2010-12-15|Estimate|January 2007||2007-01-31|November 2010|2010-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study of Dasatinib (BMS-354825) in Patients With Solid Tumors|A Phase I Study of BMS-354825 in Patients With Solid Tumors|Completed||Phase 1|16|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 03:56:43.535045|2018-06-01 03:56:43.535045
NCT00339131|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-17|||2011-10-07|2006-06-17|2006-06-20|Estimate|||||||2011-10-07|2011-10-12|Estimate|June 2006||2006-06-30|October 2011|2011-10-31|January 2007|Actual|2007-01-31|||||Interventional|||ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid|Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid|Completed||Phase 1|24|Anticipated|Molecular Insight Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 03:56:44.532434|2018-06-01 03:56:44.532434
NCT00339118|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-06-19|2006-06-19|2006-06-20|Estimate|||||||2006-06-19|2006-06-20|Estimate||||June 2006|2006-06-30||||||||Interventional|||EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children||Unknown status|Not yet recruiting|Phase 4|||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:56:44.587287|2018-06-01 03:56:44.587287
NCT00339105|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2007-01-14|2006-06-19|2006-06-20|Estimate|||||||2007-01-14|2007-01-17|Estimate|June 2006||2006-06-30|January 2007|2007-01-31|January 2007||2007-01-31|||||Observational|||The Usefulness of HyperQ Recordings for the Early Diagnosis of Acute Coronary Syndrome in Patients Presenting With Chest Pain|The Usefulness of HyperQ Recordings for the Early Diagnosis of Acute Coronary Syndrome in Patients Presenting With Chest Pain|Unknown status|Recruiting||50||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:56:44.637744|2018-06-01 03:56:44.637744
NCT00339092|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2013-04-17|2006-06-16|2006-06-20|Estimate|||||||2013-04-17|2013-04-19|Estimate|January 2003||2003-01-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Modified Directly Observed Therapy for Improving Antiretroviral Therapy Adherence in People With HIV|Project Title: A RCT of HIV Adherence Case Management and Modified Directly Observed Therapy|Completed||N/A|150|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:56:44.69312|2018-06-01 03:56:44.69312
NCT00339079|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2017-01-12||2017-03-24|2006-06-16|2006-06-20|Estimate|2017-01-12|2017-03-03|Actual||||2017-03-24|2017-04-25|Actual|June 2006||2006-06-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Treatment of Hypochondriasis With CBT and/or SSRI|Treatment of Hypochondriasis With CBT and/or SSRI|Completed||Phase 1/Phase 2|195|Actual|Brigham and Women's Hospital|1) Limited generalizability since we studied volunteers not medical patients. 2) Sampling bias possible as many subjects sought CBT and were unwilling to take chance of being randomized to medication. 3) Relatively high rates of attrition.|4|||f||||t||||||||||2018-06-01 03:56:44.840108|2018-06-01 03:56:44.840108
NCT00339066|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2013-08-07|2006-06-16|2006-06-20|Estimate|||||||2013-08-07|2013-08-09|Estimate|August 2001||2001-08-31|February 2008|2008-02-29|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression|Treatment Outcomes of Vascular Depression|Completed||N/A|131|Actual|Duke University|||||f||||||||||||||2018-06-01 03:56:45.126685|2018-06-01 03:56:45.126685
NCT00339053|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-10-20|2006-06-19|2006-06-20|Estimate|||||||2006-10-20|2006-10-23|Estimate|September 2004||2004-09-30|October 2006|2006-10-31|January 2008||2008-01-31|||||Interventional|||Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair|The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta|Unknown status|Recruiting|Phase 4|142||St. Antonius Hospital|||||f||||||||||||||2018-06-01 03:56:45.192913|2018-06-01 03:56:45.192913
NCT00339040|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2011-09-07|2010-08-03|2014-12-30|2006-06-19|2006-06-20|Estimate|2011-12-12|2012-01-16|Estimate|2010-08-03|2010-08-05|Estimate|2014-12-30|2015-01-13|Estimate|October 2006||2006-10-31|December 2014|2014-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children|Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age|Completed||Phase 2|130|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:56:45.275676|2018-06-01 03:56:45.275676
NCT00339027|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2006-09-07|2006-06-16|2006-06-20|Estimate|||||||2006-09-07|2006-09-08|Estimate|May 2004||2004-05-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||HealthSpark: Health Access for Children in Federally-Subsidized Child Care||Completed|||960||University of Miami|||||f||||||||||||||2018-06-01 03:56:45.942041|2018-06-01 03:56:45.942041
NCT00339014|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-18|||2008-04-18|2006-06-18|2006-06-20|Estimate|||||||2008-04-18|2008-04-22|Estimate|May 2006||2006-05-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity|A Dose Parallel, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Multiple Regimens of the Combination of Zonisamide CR Plus Bupropion SR in the Treatment of Subjects With Uncomplicated Obesity|Completed||Phase 2|611|Actual|Orexigen Therapeutics, Inc||7|||f||||t||||||||||2018-06-01 03:56:46.004713|2018-06-01 03:56:46.004713
NCT00339001|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-06-19|2006-06-19|2006-06-20|Estimate|||||||2006-06-19|2006-06-20|Estimate|April 2006||2006-04-30|June 2006|2006-06-30|December 2006||2006-12-31|||||Observational|||Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity|The Possible Influence of Erythropoietin and Early Iron Supplements on the Prevalence and Severity of Retinopathy of Prematurity and Other Short Term Outcome of Prematurity|Unknown status|Recruiting||400||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:56:46.098263|2018-06-01 03:56:46.098263
NCT00338988|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2010-11-03||2012-07-27|2006-06-16|2006-06-20|Estimate|2010-11-03|2010-12-08|Estimate||||2012-07-27|2012-08-01|Estimate|August 2003||2003-08-31|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma|A Phase II Study of Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma, Including Carcinoma of the Gallbladder and Biliary Tract|Completed||Phase 2|44|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:56:46.166659|2018-06-01 03:56:46.166659
NCT00338975|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2015-06-01|2006-06-16|2006-06-20|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2005||2005-06-30|June 2015|2015-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia|Cognitive Behavioral Skills Training for Schizophrenia|Completed||N/A|179|Actual|Veterans Medical Research Foundation||2|||f||||t||||||||||2018-06-01 03:56:46.342969|2018-06-01 03:56:46.342969
NCT00338962|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|2015-11-04||2016-01-06|2006-06-19|2006-06-20|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|October 2001||2001-10-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Naltrexone & SSRI in Alcoholics With Depression/PTSD|Naltrexone & SSRI in Alcoholics With Depression/PTSD|Completed||Phase 3|88|Actual|Yale University||4|||f||||t||||||||||2018-06-01 03:56:46.432626|2018-06-01 03:56:46.432626
NCT00338949|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2013-08-06|2006-06-16|2006-06-20|Estimate|||||||2013-08-06|2013-08-09|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes|The Metabolic Syndrome in Patients With Schizophrenia|Completed||Phase 4|77|Actual|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-06-01 03:56:46.844063|2018-06-01 03:56:46.844063
NCT00338936|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-11-07|2006-06-16|2006-06-20|Estimate|||||||2011-11-07|2011-11-08|Estimate|May 2006||2006-05-31|November 2011|2011-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)|A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) -|Completed||Phase 3|362|Actual|Novartis|||||f||||||||||||||2018-06-01 03:56:46.925384|2018-06-01 03:56:46.925384
NCT00338923|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2007-08-16|2006-06-19|2006-06-20|Estimate|||||||2007-08-16|2007-08-17|Estimate|June 2006||2006-06-30|August 2007|2007-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.|Wound Healing Effects of HO/03/03 In Patients With Diabetic Neuropathic Plantar and Venous Ulcers, Pilot Study.|Completed||Phase 1|22|Actual|HealOr||1|||f||||||||||||||2018-06-01 03:56:46.972716|2018-06-01 03:56:46.972716
NCT00338546|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2009-05-19|2006-06-16|2006-06-20|Estimate|||||||2009-05-19|2009-05-21|Estimate||||May 2009|2009-05-31||||||||Interventional|||Study to Improve Scientific Understanding of the Cardiovascular Actions of Cocaine|Cocaine and Sympathetic Nerve Activity in Humans|Unknown status|Recruiting|Phase 1|440|Anticipated|University of Texas Southwestern Medical Center|||||||||||||||||||2018-06-01 03:56:51.654286|2018-06-01 03:56:51.654286
NCT00338910|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2007-12-10|2006-06-19|2006-06-20|Estimate|||||||2007-12-10|2007-12-11|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy Volunteers|Pharmacokinetic Interaction Study Between Budesonide and Metronidazole in Healthy Volunteers|Completed||Phase 4|12|Actual|University Hospital Tuebingen|||||f||||t||||||||||2018-06-01 03:56:47.030278|2018-06-01 03:56:47.030278
NCT00338897|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-12-09|2006-06-19|2006-06-20|Estimate|||||||2008-12-09|2008-12-10|Estimate|May 2006||2006-05-31|December 2008|2008-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|DRIVE||Dose Ranging Study in Elective Total Hip Replacement Surgery|A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery|Completed||Phase 2/Phase 3|1090|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:56:47.136379|2018-06-01 03:56:47.136379
NCT00338884|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2010-04-20||2012-08-22|2006-06-19|2006-06-20|Estimate|2011-05-10|2011-06-14|Estimate||||2012-08-22|2012-08-31|Estimate|September 2006||2006-09-30|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer|A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer|Completed||Phase 2|120|Actual|Pfizer||1|||f||||||||||||||2018-06-01 03:56:47.273275|2018-06-01 03:56:47.273275
NCT00338871|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2016-04-07|2006-06-19|2006-06-20|Estimate|||||||2016-04-07|2016-04-08|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Home Based Exercise Program for Brain Injury Children||Completed||N/A|40|Actual|Alyn Pediatric & Adolecent Rehabilitation Center||2|||f||||||||||||||2018-06-01 03:56:48.74469|2018-06-01 03:56:48.74469
NCT00338858|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2011-02-14|2006-06-19|2006-06-20|Estimate|||||||2011-02-14|2011-02-15|Estimate|June 2006||2006-06-30|June 2006|2006-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||The Connection Between Gait Variability Parameters and Balance Performance in Children With Physical Disability|The Connection Between Gait Variability Parameters and Balance Performance in Children With Physical Disability|Completed||N/A|60|Actual|Alyn Pediatric & Adolecent Rehabilitation Center||3|||f||||t||||||||||2018-06-01 03:56:48.810749|2018-06-01 03:56:48.810749
NCT00338845|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2013-04-09|2006-06-16|2006-06-20|Estimate|||||||2013-04-09|2013-04-11|Estimate|December 2003||2003-12-31|April 2013|2013-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Share Safer Sex Counseling Program for Changing Sexual Risk Behaviors in Mexican Female Sex Workers|Safer Sex Intervention for At-risk Women in Mexico|Completed||Phase 2|1800|Actual|University of California, San Diego||2|||f||||||||||||||2018-06-01 03:56:48.876635|2018-06-01 03:56:48.876635
NCT00338832|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2013-08-06|2006-06-16|2006-06-20|Estimate|||||||2013-08-06|2013-08-09|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia|Adapting a Physical Activity Intervention for Schizophrenia|Completed||Phase 3|86|Actual|Veterans Medical Research Foundation||2|||f||||t||||||||||2018-06-01 03:56:48.944035|2018-06-01 03:56:48.944035
NCT00338819|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-18|||2006-06-18|2006-06-18|2006-06-20|Estimate|||||||2006-06-18|2006-06-20|Estimate||||June 2006|2006-06-30||||||||Observational|||ActiveCare+SFT Hemodynamic Profile Compare to SCD Express in Ventilated Patients|ActiveCare+SFT Hemodynamic Profile Compare to SCD Express in Ventilated Patients|Unknown status|Not yet recruiting||||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 03:56:49.00604|2018-06-01 03:56:49.00604
NCT00338806|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2016-06-14||2017-07-17|2006-06-19|2006-06-20|Estimate|2017-07-17|2017-08-15|Actual||||2017-07-17|2017-08-15|Actual|November 2006||2006-11-30|July 2017|2017-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder|Prevention for Symptomatic Offspring of Bipolar Parents|Completed||N/A|7|Actual|New York State Psychiatric Institute|Limitations include a very small sample size due to recruitment difficulty. In addition, participation with follow-up evaluations was poor.|2|||f||||t||||||||No||2018-06-01 03:56:49.075068|2018-06-01 03:56:49.075068
NCT00338793|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2008-08-25|2006-06-19|2006-06-20|Estimate|||||||2008-08-25|2008-08-26|Estimate|July 2006||2006-07-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|||||Interventional|||Corticosteroids in the Treatment of Tuberculous Pleurisy|A Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Corticosteroids for Treatment of Patients With Tuberculous Pleurisy|Completed||N/A|1500|Anticipated|Guangxi Medical University|||||f||||t||||||||||2018-06-01 03:56:49.643453|2018-06-01 03:56:49.643453
NCT00338780|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-10-27|2006-06-19|2006-06-20|Estimate|||||||2006-10-27|2006-10-30|Estimate|November 2000||2000-11-30|October 2006|2006-10-31|January 2005||2005-01-31|||||Interventional|||Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)|A Randomised, Double-Blinded, Placebo-Controlled Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)|Completed||Phase 4|||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 03:56:49.694924|2018-06-01 03:56:49.694924
NCT00338767|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2013-11-13|2006-06-16|2006-06-20|Estimate|||||||2013-11-13|2013-11-15|Estimate|January 2001||2001-01-31|November 2013|2013-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy|Depression Treatment to Improve Antiretroviral Adherence|Completed||Phase 2|150|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:56:49.756386|2018-06-01 03:56:49.756386
NCT00338754|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-18|||2007-09-10|2006-06-18|2006-06-20|Estimate|||||||2007-09-10|2007-09-11|Estimate|November 2005||2005-11-30|September 2007|2007-09-30||||||||Interventional|||Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 2/3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Adalimumab in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2/Phase 3|160||Abbott|||||f||||||||||||||2018-06-01 03:56:49.821839|2018-06-01 03:56:49.821839
NCT00338741|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2010-04-30||2013-08-02|2006-06-16|2006-06-20|Estimate|2010-04-30|2010-06-02|Estimate||||2013-08-02|2013-08-05|Estimate|December 2002||2002-12-31|August 2011|2011-08-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Observational|||Rebif® Pregnancy Registry|Rebif® Pregnancy Registry|Completed|||36|Actual|EMD Serono|Despite a consistent and exhaustive expenditure of resources over 5 years only 36 subjects were enrolled into the Registry, a number which precludes meaningful statistical analysis of the potential risks of Rebif® during pregnancy.||2||f||||||||||||||2018-06-01 03:56:50.014857|2018-06-01 03:56:50.014857
NCT00338533|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-01-06|2006-06-15|2006-06-20|Estimate|||||||2013-01-06|2013-01-08|Estimate|April 1997||1997-04-30|January 2013|2013-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Endoscopic Goniotomy for Infantile Glaucoma|Endoscopic Goniotomy for Infantile Glaucoma|Completed||N/A|7|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 03:56:51.720905|2018-06-01 03:56:51.720905
NCT00338728|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2017-12-01|2006-06-19|2006-06-20|Estimate|||||||2017-12-01|2017-12-05|Actual|October 2003|Actual|2003-10-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Breast Cancer Patients|Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer|Active, not recruiting||Phase 2|45|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:56:50.296756|2018-06-01 03:56:50.296756
NCT00338715|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2011-02-07|2006-06-19|2006-06-20|Estimate|||||||2011-02-07|2011-02-08|Estimate|July 2006||2006-07-31|February 2011|2011-02-28|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Effectiveness of Pulmonary Vein Isolation in Prevention of Atrial Fibrillation Following Heart Bypass Surgery|A Randomized Controlled Trial of Prophylactic Pulmonary Vein Isolation as Adjunct to Coronary Artery Bypass Grafting|Completed||Phase 3|193|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-06-01 03:56:50.369058|2018-06-01 03:56:50.369058
NCT00338702|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2015-05-19|2006-06-16|2006-06-20|Estimate|||||||2015-05-19|2015-05-21|Estimate|March 2008||2008-03-31|May 2015|2015-05-31|October 2009|Anticipated|2009-10-31|October 2009||2009-10-31||Interventional|||A Randomized, Controlled Trial of Autologous Platelet Gel Treatment in Diabetic Foot Ulcers||Withdrawn||Phase 4|0|Actual|St. Michael's Hospital, Toronto||||Industry support and funding not forthcoming|f||||f||||||||||2018-06-01 03:56:50.438606|2018-06-01 03:56:50.438606
NCT00338689|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2015-09-14|2006-06-19|2006-06-20|Estimate|||||||2015-09-14|2015-09-15|Estimate|October 2002||2002-10-31|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|August 2006|Actual|2006-08-31||Interventional|CHOP||European Childhood Obesity Project: Early Programming by Infant Nutrition?|Childhood Obesity - Programming by Infant Nutrition|Unknown status|Active, not recruiting|N/A|1678|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-06-01 03:56:50.500711|2018-06-01 03:56:50.500711
NCT00338676|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-02-27|2006-06-19|2006-06-20|Estimate|||||||2017-02-27|2017-03-01|Actual|November 2006||2006-11-30|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Aortic Stenosis in Elderly : Determinant of Progression|Aortic Stenosis in Elderly : Determinant of Progression. COFRASA (French Cohort)|Unknown status|Active, not recruiting||273|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     blood samples~   "|No||2018-06-01 03:56:50.581489|2018-06-01 03:56:50.581489
NCT00338663|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2007-08-22|2006-06-16|2006-06-20|Estimate|||||||2007-08-22|2007-08-23|Estimate|May 2006||2006-05-31|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||A Study on Knee Immobilization and Pain Levels After an Anterior Cruciate Ligament (ACL) Reconstruction Surgery|The Effect of Knee Immobilization on Postoperative Pain Following an Anterior Cruciate Ligament (ACL) Reconstruction: A Randomized Clinical Trial|Completed||N/A|88||LifeMark Health Research Group|||||f||||t||||||||||2018-06-01 03:56:50.635198|2018-06-01 03:56:50.635198
NCT00338650|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2007-11-28|2006-06-19|2006-06-20|Estimate|||||||2007-11-28|2007-11-29|Estimate|June 2006||2006-06-30|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)|A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab|Completed||Phase 3|1000||Abbott|||||||||||||||||||2018-06-01 03:56:50.77907|2018-06-01 03:56:50.77907
NCT00338637|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2006-06-19|2006-06-19|2006-06-20|Estimate|||||||2006-06-19|2006-06-20|Estimate|April 2006||2006-04-30|June 2006|2006-06-30|October 2006||2006-10-31|||||Interventional|||Measuring the Balance Improvement on Multiple Sclerosis Patients After a Short Training Period With an APOS (All Phase Of Step Cycle) Kit||Unknown status|Recruiting|Phase 2|30||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:56:50.978283|2018-06-01 03:56:50.978283
NCT00338624|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-05-20|2006-06-16|2006-06-20|Estimate|||||||2011-05-20|2011-05-24|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|June 2005|Actual|2005-06-30|||||Interventional|||An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.|A Double-Blind, Randomized, Parallel Group Trial of Ditropan XL (Oxybutynin Chloride) Extended Release Tablets or Placebo in Combination With FLOMAX (Tamsulosin Hydrochloride) for the Treatment of Lower Urinary Tract Symptoms.|Completed||Phase 3|420|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||||||||||||||||2018-06-01 03:56:51.041067|2018-06-01 03:56:51.041067
NCT00338611|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2010-03-24|2006-06-15|2006-06-20|Estimate|||||||2010-03-24|2010-03-25|Estimate|July 2005||2005-07-31|October 2008|2008-10-31|September 2009|Anticipated|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Convergence Insufficiency Treatment Trial (CITT)|Convergence Insufficiency Treatment Trial (CITT)|Unknown status|Active, not recruiting|Phase 3|221|Actual|National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 03:56:51.091833|2018-06-01 03:56:51.091833
NCT00338598|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|2017-02-28||2018-01-12|2006-06-15|2006-06-20|Estimate|2017-04-11|2017-04-12|Actual||||2018-01-12|2018-01-17|Actual|June 2003||2003-06-30|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism|Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism|Completed||Phase 2|20|Actual|Yale University||2|||f||||t||||||||||2018-06-01 03:56:51.170717|2018-06-01 03:56:51.170717
NCT00338585|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2008-01-08|2006-06-15|2006-06-20|Estimate|||||||2008-01-08|2008-01-15|Estimate|April 2006||2006-04-30|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery|Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)|Terminated||Phase 3|300||ARCA Biopharma, Inc.||||Based upon preliminary safety and efficacy results from a similar study.|f||||t||||||||||2018-06-01 03:56:51.450805|2018-06-01 03:56:51.450805
NCT00338572|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2012-06-07|2006-06-16|2006-06-20|Estimate|||||||2012-06-07|2012-06-08|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effect of Exercise and Diet on Inflammation in Hypertensive Individuals|Sympathetic Nervous System Regulation of Cell Adhesion|Completed||N/A|185|Actual|University of California, San Diego||3|||f||||t||||||||||2018-06-01 03:56:51.524306|2018-06-01 03:56:51.524306
NCT00338559|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2014-12-02|2006-06-15|2006-06-20|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2006||2006-05-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Does LMA Instead of ET Tube Affect Incidence of Postoperative Vomiting in Children Undergoing Strabismus Correction?|Does Using Laryngeal Mask Airway (LMA) Instead of an Endotracheal Tube (ET Tube) Affect the Incidence of Postoperative Vomiting in Children Undergoing Strabismus Correction? - An Observational Study|Completed|||71|Actual|The University of Texas Health Science Center, Houston|||2||f||||f||||||||||2018-06-01 03:56:51.594856|2018-06-01 03:56:51.594856
NCT00338520|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2012-10-19|2006-06-15|2006-06-20|Estimate|||||||2012-10-19|2012-10-22|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Hyperphenylalaninemia in Cerebral Malaria|Hyperphenylalaninemia in Cerebral Malaria|Completed|||285|Actual|University of Utah|||4||f||||f||||||Samples With DNA|"~     urine, CSF, blood~   "|||2018-06-01 03:56:51.778066|2018-06-01 03:56:51.778066
NCT00338507|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2007-12-05|2006-06-16|2006-06-20|Estimate|||||||2007-12-05|2007-12-06|Estimate|March 2006||2006-03-31|December 2007|2007-12-31||||||||Interventional|||Phase 2 Study - Erdosteine in Patients With CB/COPD|A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Dose_Ranging Study of Erdosteine for the Treatment of Stable Chronic Bronchitis Associated With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|400||Adams Respiratory Therapeutics|||||||||||||||||||2018-06-01 03:56:51.832768|2018-06-01 03:56:51.832768
NCT00338494|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-01-28|2006-06-15|2006-06-20|Estimate|||||||2015-01-28|2015-01-29|Estimate|October 2005||2005-10-31|January 2015|2015-01-31|April 2011|Actual|2011-04-30|March 2010|Actual|2010-03-31||Interventional|||Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma|Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermed.Grade B-Cell/T-Cell Lymphoma|Completed||Phase 1|16|Actual|Yale University||1|||f||||f||||||||||2018-06-01 03:56:51.883236|2018-06-01 03:56:51.883236
NCT00338481|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-07-26|2006-06-16|2006-06-20|Estimate|||||||2011-07-26|2011-07-27|Estimate|April 2006||2006-04-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||"Red Morphine Drops for Symptomatic Treatment of Dyspnoea in Lung Cancer"|"Red Morphine Drops for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study"|Completed||Phase 4|20|Actual|Sankt Lukas Hospice||2|||f||||t||||||||||2018-06-01 03:56:51.942897|2018-06-01 03:56:51.942897
NCT00338468|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-05-17|2006-06-16|2006-06-20|Estimate|||||||2011-05-17|2011-05-19|Estimate|November 2003||2003-11-30|March 2010|2010-03-31|September 2005|Actual|2005-09-30|||||Interventional|||A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)|An Open-Label Pilot Study to Assess Disability in Anemic Elderly Patients With Chronic Kidney Disease Receiving PROCRIT (Epoetin Alfa)|Terminated||Phase 4|13|Actual|Ortho Biotech Products, L.P.||||The study was stopped early due to slow enrollment.|f||||f||||||||||2018-06-01 03:56:52.008903|2018-06-01 03:56:52.008903
NCT00338455|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2008-10-22||2014-11-20|2006-06-16|2006-06-20|Estimate|2008-12-04|2008-12-05|Estimate||||2014-11-20|2014-12-08|Estimate|September 2006||2006-09-30|November 2014|2014-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC|Investigation of the Use of Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC|Terminated||Phase 2|16|Actual|Scios, Inc.|Early termination of the study due to enrollment difficulties (change in standard of care for patient population as well as changing organ allocation rules by United Network for Organ Sharing); efficacy not analyzed due to limited sample size (n=16).|2||"DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated~   due to slow enrollment"|f||||t||||||||||2018-06-01 03:56:52.070202|2018-06-01 03:56:52.070202
NCT00338442|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-04-01|2006-06-15|2006-06-20|Estimate|||||||2013-04-01|2013-04-04|Estimate|February 2006||2006-02-28|April 2013|2013-04-30|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Expanded Access|||Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection|Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection|Approved for marketing|||||Cangene Corporation|||||||||f||||||||||2018-06-01 03:56:52.487252|2018-06-01 03:56:52.487252
NCT00338429|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2016-09-01|2006-06-15|2006-06-20|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|Sleep||Better Days, Better Nights: Treatment for Sleep Difficulties (Telephone Coached)|Better Days, Better Nights: Treatment for Sleep Difficulties (A Sleep Intervention Module of the Family Help Program)|Completed||Phase 2|61|Actual|IWK Health Centre||2|||f||||f||||||||No|Aggregate summary data would be made available but not individual data.|2018-06-01 03:56:52.546405|2018-06-01 03:56:52.546405
NCT00338416|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-06-08|2006-06-16|2006-06-20|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2003||2003-03-31|April 2010|2010-04-30|January 2005|Actual|2005-01-31|||||Interventional|||An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks|An Open-Labeled Pilot Study to Evaluate the Effects of High Dose PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a Every Three Week Regimen|Completed||Phase 2|115|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:56:52.617532|2018-06-01 03:56:52.617532
NCT00338403|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-09-04|2006-06-16|2006-06-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2006||2006-06-30|September 2013|2013-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effects of Continuous Airway Pressure on the Ability to Heat and Humidify Air|Effects of Continuous Airway Pressure on the Ability to Heat and Humidify Air|Completed||N/A|10||University of Chicago|||||f||||||||||||||2018-06-01 03:56:52.670378|2018-06-01 03:56:52.670378
NCT00338390|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-03-19|2006-06-16|2006-06-20|Estimate|||||||2015-03-19|2015-03-24|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC|Study of Changes in CD4 Lymphocyte Count in Patients With a HAART Regimen Including DDI + Tenofovir and With Viral Suppression Following the Replacement of Tenofovir With Abacavir Once Daily or Following the Double Replacement of DDI + Tenofovir With Abacavir + Lamivudine in a Single Tablet|Completed||Phase 3|75|Actual|Hospital de Granollers||3|||f||||f||||||||||2018-06-01 03:56:52.732904|2018-06-01 03:56:52.732904
NCT00338377|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2017-08-15|2006-06-15|2006-06-20|Estimate|||||||2017-08-15|2017-08-18|Actual|February 2006|Actual|2006-02-28|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma|Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma|Recruiting||Phase 2|189|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-06-01 03:56:52.828583|2018-06-01 03:56:52.828583
NCT00338364|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-09-11|2006-06-15|2006-06-20|Estimate|||||||2013-09-11|2013-09-12|Estimate|January 2006||2006-01-31|September 2013|2013-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|ERPain||Painful Procedures in the Emergency Department: A Distraction Intervention|Painful Procedures in the Emergency Department:Does a Formal Program in Distracting Techniques for Parents and Children Reduce Pain and Anxiety in Children?|Completed||Phase 2|189|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 03:56:52.932043|2018-06-01 03:56:52.932043
NCT00338351|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2016-09-27|2006-06-16|2006-06-20|Estimate|||||||2016-09-27|2016-09-28|Estimate|April 2006||2006-04-30|September 2016|2016-09-30|October 2006|Actual|2006-10-31|||||Interventional|||Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.|To Assess Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (Infanrix™ Hexa) at 2, 4 and 6 Months of Age.|Completed||Phase 2|240||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:56:53.085216|2018-06-01 03:56:53.085216
NCT00338338|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2017-10-05|2006-06-16|2006-06-20|Estimate|||||||2017-10-05|2017-10-09|Actual|November 7, 2005|Actual|2005-11-07|October 2017|2017-10-31|September 14, 2007|Actual|2007-09-14|September 14, 2007|Actual|2007-09-14||Interventional|||The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients|A Randomized, Double-blind, Parallel Group, Single-Centre Study to Evaluate the Efficacy and Safety of Lacidipine and Amlodipine Once-daily Treatment in Hypertensive Adult Patients|Completed||Phase 4|70||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:56:53.174089|2018-06-01 03:56:53.174089
NCT00338325|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-06-15|2006-06-15|2006-06-20|Estimate|||||||2015-06-15|2015-06-16|Estimate|June 2005||2005-06-30|June 2015|2015-06-30|April 2006|Actual|2006-04-30|June 2005|Actual|2005-06-30||Interventional|||Reading Preoperatively to Reduce Anxiety in Day Surgery|A Randomized Trial Of Reading Preoperatively To Day Surgery Children To Reduce Anxiety and Pain|Completed||Phase 2|200|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 03:56:53.253733|2018-06-01 03:56:53.253733
NCT00338312|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-04-15|2006-06-15|2006-06-20|Estimate|||||||2013-04-15|2013-04-17|Estimate|June 2002||2002-06-30|April 2013|2013-04-30|July 2006|Actual|2006-07-31|December 2004|Actual|2004-12-31||Interventional|||Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido|A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.|Completed||Phase 3|610|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:56:53.318124|2018-06-01 03:56:53.318124
NCT00338299|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-05-19|2006-06-16|2006-06-20|Estimate|||||||2011-05-19|2011-05-23|Estimate|August 2003||2003-08-31|April 2010|2010-04-30|April 2004|Actual|2004-04-30|||||Interventional|||Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia|An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of PROCRIT� (Epoetin Alfa) in the Treatment of Patients With Cancer and Chemotherapy Induced Anemia (60,000 Units Weekly for Four Weeks Followed by 60,000 Units Every Two Weeks)|Completed||Phase 2|51|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:56:53.388414|2018-06-01 03:56:53.388414
NCT00338286|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2015-12-22||2018-02-15|2006-06-16|2006-06-20|Estimate|2016-02-23|2016-03-24|Estimate||||2018-02-15|2018-03-19|Actual|March 2, 2006|Actual|2006-03-02|February 2018|2018-02-28|January 31, 2017|Actual|2017-01-31|July 7, 2014|Actual|2014-07-07||Interventional||The intent to treat (ITT) population included all participants who were randomized in either Standard of Care (SOC) or Epoetin alfa group.|A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy|A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy|Completed||Phase 3|2098|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-06-01 03:56:53.518125|2018-06-01 03:56:53.518125
NCT00338273|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-11-07|2006-06-15|2006-06-20|Estimate|||||||2013-11-07|2013-11-08|Estimate|December 2006||2006-12-31|February 2012|2012-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode|Withdrawn||Phase 3|0|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 03:56:55.175574|2018-06-01 03:56:55.175574
NCT00338260|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-07-29|2006-06-15|2006-06-20|Estimate|||||||2015-07-29|2015-07-30|Estimate|June 1995||1995-06-30|July 2015|2015-07-31|November 2001|Actual|2001-11-30|September 2001|Actual|2001-09-30||Interventional|||Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)|A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy|Completed||Phase 3|496|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:56:55.261173|2018-06-01 03:56:55.261173
NCT00338247|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2016-04-04|2006-06-16|2006-06-20|Estimate|||||||2016-04-04|2016-04-06|Estimate|July 2006||2006-07-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Expanded Access|||EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer|An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer|Approved for marketing|||||Novartis|||||||||||||||||||2018-06-01 03:56:55.42652|2018-06-01 03:56:55.42652
NCT00338234|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2008-05-05|2006-06-16|2006-06-20|Estimate|||||||2008-05-05|2008-05-06|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|FAIRe||Observational Study of Iron Metabolism in Anemia in ICU and Post-Operative Patients|Observational Study of Iron Metabolism in Anemia in ICU and Post-Operative Patients, Role of Hepcidin|Completed|||153|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-06-01 03:56:57.146175|2018-06-01 03:56:57.146175
NCT00338221|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2008-10-27|2006-06-15|2006-06-20|Estimate|||||||2008-10-27|2008-10-28|Estimate|August 2004||2004-08-31|October 2008|2008-10-31|April 2005||2005-04-30|||||Interventional|||Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition|Prospective Double Blinded Randomized Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition|Withdrawn||Phase 3|108||University of Virginia|||||f||||f||||||||||2018-06-01 03:56:57.204548|2018-06-01 03:56:57.204548
NCT00338208|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-08-19|2006-06-15|2006-06-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|October 2003||2003-10-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|PAVE||Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot|Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot|Completed||N/A|2|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 03:56:57.260135|2018-06-01 03:56:57.260135
NCT00338195|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-03-06|2006-06-15|2006-06-20|Estimate|||||||2013-03-06|2013-03-07|Estimate|May 2001||2001-05-31|March 2013|2013-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Assessment and Treatment of Caffeine Dependence||Completed||Phase 1|94|Actual|Johns Hopkins University||1|||f||||||||||||||2018-06-01 03:56:57.317951|2018-06-01 03:56:57.317951
NCT00338182|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2017-04-21|2006-06-16|2006-06-20|Estimate|||||||2017-04-21|2017-04-24|Actual|May 23, 2006|Actual|2006-05-23|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|June 6, 2008|Actual|2008-06-06||Interventional|||AZD1152 in Patients With Advanced Solid Malignancies|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2-hour or 48-hour Intravenous Infusions in Patients With Advanced Solid Malignancies|Completed||Phase 1|43|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 03:56:57.380581|2018-06-01 03:56:57.380581
NCT00338156|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2015-07-27|2006-06-16|2006-06-20|Estimate|||||||2015-07-27|2015-07-28|Estimate|August 2003||2003-08-31|July 2010|2010-07-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Observational|||Observational Study of the Remodelling Process Following Myocardial Infarct|Assessment of the Relationship Between Collagen Turnover, Left Ventricular Remodelling and Myocardial Scarring Assessed by Cardiac Magnetic Resonance and Neurohumoral Activation in Patients With Previous Myocardial Infarction|Completed|||119|Actual|Helse Stavanger HF|||||f||||f||||||Samples Without DNA|"~     Serum Plasma~   "|||2018-06-01 03:56:57.43782|2018-06-01 03:56:57.43782
NCT00338143|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2014-02-28|2006-06-15|2006-06-20|Estimate|||||||2014-02-28|2014-03-04|Estimate|October 2003||2003-10-31|February 2014|2014-02-28|May 2004|Actual|2004-05-31|||||Interventional|||A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies|A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned From Systemic Therapies|Completed||Phase 3|1200||Genentech, Inc.|||||||||||||||||||2018-06-01 03:56:57.490869|2018-06-01 03:56:57.490869
NCT00338130|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2014-08-12|2006-06-16|2006-06-20|Estimate|||||||2014-08-12|2014-08-13|Estimate|July 2006||2006-07-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|September 2007|Actual|2007-09-30||Interventional|||Randomised Study to Compare the Efficacy of AZD6244 vs TMZ|A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma|Completed||Phase 2|239|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:56:57.629659|2018-06-01 03:56:57.629659
NCT00338117|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2010-04-26|2006-06-16|2006-06-20|Estimate|||||||2010-04-26|2010-04-28|Estimate|August 1995||1995-08-31|April 2010|2010-04-30|May 1997|Actual|1997-05-31|||||Interventional|||Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease|A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia|Completed||Phase 3|554|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:56:57.787856|2018-06-01 03:56:57.787856
NCT00338104|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|2008-12-01||2009-04-03|2006-06-15|2006-06-20|Estimate|2009-04-03|2009-04-06|Estimate||||2009-04-03|2009-04-06|Estimate|July 2004||2004-07-31|March 2009|2009-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin|Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin|Completed||Phase 4|75|Actual|Northwestern University|not all patients were analyzed in each group because insulin not given appropriately to those patients|3|||f||||f||||||||||2018-06-01 03:56:57.86361|2018-06-01 03:56:57.86361
NCT00338091|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2006-06-16|2006-06-16|2006-06-20|Estimate|||||||2006-06-16|2006-06-20|Estimate|January 2002||2002-01-31|January 2002|2002-01-31|May 2006||2006-05-31|||||Interventional|||Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency||Terminated||N/A|||Southern Medical University, China|||||f||||||||||||||2018-06-01 03:56:58.122921|2018-06-01 03:56:58.122921
NCT00338078|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2008-07-01|2006-06-16|2006-06-20|Estimate|||||||2008-07-01|2008-07-02|Estimate|March 1999||1999-03-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|||||Interventional|||Nocturnal Oxygen Treatment in Heart Failure and Cheyne-Stokes Respiration|Nocturnal Oxygen Treatment in Heart Failure and Cheyne-Stokes Respiration. A Randomized Double-Blind Placebo Controlled Cross-Over Study|Completed||N/A|62|Actual|Umeå University|||||f||||||||||||||2018-06-01 03:56:58.184208|2018-06-01 03:56:58.184208
NCT00338065|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2018-03-27|2006-06-15|2006-06-20|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2006||2006-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||External Influences Upon Ocular Homeostasis|External Influences Upon Ocular Homeostasis|Recruiting||N/A|200|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||Undecided||2018-06-01 03:56:58.252078|2018-06-01 03:56:58.252078
NCT00338052|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2008-05-07|2006-06-16|2006-06-20|Estimate|||||||2008-05-07|2008-05-08|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study of Bleeding With Extended Administration of an Oral Contraceptive|Open-Label Study of Cycle Control With Extended Administration of Norethindrone Acetate 1 mg / Ethinyl Estradiol 20 Mcg Oral Tablets|Completed||Phase 2|207|Actual|Warner Chilcott|||||f||||f||||||||||2018-06-01 03:56:58.337923|2018-06-01 03:56:58.337923
NCT00338039|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|2012-06-26||2013-02-18|2006-06-16|2006-06-20|Estimate|2013-02-18|2013-03-22|Estimate||||2013-02-18|2013-03-22|Estimate|September 2005||2005-09-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients|Induction Cetuximab (IM-C225), Gemcitabine and Oxaliplatin, Followed by Radiotherapy With Concurrent Capecitabine, and Cetuximab, Followed by Maintenance Cetuximab and Gemcitabine for Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 2|69|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:56:58.437494|2018-06-01 03:56:58.437494
NCT00338026|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2008-07-10|2006-06-16|2006-06-20|Estimate|||||||2008-07-10|2008-07-15|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Phase I Study of ECO-4601 in Patients With Advanced Cancer|A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose|Completed||Phase 1|26|Actual|Thallion Pharmaceuticals||1|||f||||t||||||||||2018-06-01 03:56:58.616902|2018-06-01 03:56:58.616902
NCT00338013|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-01-06|2006-06-15|2006-06-20|Estimate|||||||2013-01-06|2013-01-08|Estimate|February 2001||2001-02-28|January 2013|2013-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Patient Sleep Position Questionnaire|Patient Sleep Position Questionnaire|Completed|||140|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 03:56:58.680321|2018-06-01 03:56:58.680321
NCT00338000|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-01-31|2006-06-16|2006-06-20|Estimate|||||||2011-01-31|2011-02-01|Estimate|June 2001||2001-06-30|January 2011|2011-01-31|May 2005|Actual|2005-05-31|||||Interventional|||EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure|An Open-Label Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure|Completed||Phase 4|292|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 03:56:58.724281|2018-06-01 03:56:58.724281
NCT00337987|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|2015-01-28||2015-02-09|2006-06-15|2006-06-20|Estimate|2015-01-28|2015-02-10|Estimate||||2015-02-09|2015-02-27|Estimate|November 2005||2005-11-30|February 2015|2015-02-28|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma|A Pilot Phase II Study to Determine the Safety of the Combination of ONTAK (DAB389IL-2), an Interleukin-2 Fusion Toxin, in Combination With CHOP in Peripheral T-Cell Lymphoma|Completed||Phase 2|49|Actual|Yale University|||||f||||||||||||||2018-06-01 03:56:58.777437|2018-06-01 03:56:58.777437
NCT00337974|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-10-29|2006-06-15|2006-06-20|Estimate|||||||2015-10-29|2015-11-02|Estimate|March 2005||2005-03-31|October 2015|2015-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Computer-Based Training for Cognitive Enhancement: In Home Study|Computer-Based Training for Cognitive Enhancement: In Home Study|Completed||N/A|182|Actual|Posit Science Corporation||3|||f||||f||||||||||2018-06-01 03:56:58.912725|2018-06-01 03:56:58.912725
NCT00337961|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2013-01-06|2006-06-16|2006-06-20|Estimate|||||||2013-01-06|2013-01-08|Estimate|July 2000||2000-07-31|January 2013|2013-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Optic Nerve Sheath Fenestration|Optic Nerve Sheath Fenestration|Completed||N/A|20|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 03:56:59.070622|2018-06-01 03:56:59.070622
NCT00337948|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2011-06-08|2006-06-16|2006-06-20|Estimate|||||||2011-06-08|2011-06-10|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|February 2005|Actual|2005-02-28|||||Interventional|||An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks|An Open-Labeled Pilot Study to Evaluate the Effects of High Dose PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a Weekly or Every Four Week Regimen|Completed||Phase 2|129|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:56:59.140525|2018-06-01 03:56:59.140525
NCT00337935|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|2010-07-16||2013-05-07|2006-06-16|2006-06-20|Estimate|2013-05-07|2013-05-13|Estimate||||2013-05-07|2013-05-13|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.|An Open-Label, Randomized, Multi-center, Controlled Study of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease in the Long Term Care Setting|Completed||Phase 2|157|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Upper 95% confidence limit for the Standard of Care Group was not estimable because an insufficient number of participates reached the event at the final time point for assessment.|2|||f||||f||||||||||2018-06-01 03:56:59.222405|2018-06-01 03:56:59.222405
NCT00337922|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-16|||2008-10-15|2006-06-16|2006-06-20|Estimate|||||||2008-10-15|2008-10-16|Estimate|July 2006||2006-07-31|October 2008|2008-10-31||||||||Interventional|||Pharmacokinetic Study Of EPZICOM Tablet|Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) - Pharmacokinetic Study in HIV-Infected Patients -|Completed||Phase 4|8||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:56:59.712392|2018-06-01 03:56:59.712392
NCT00337909|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-10-29|2006-06-15|2006-06-20|Estimate|||||||2015-10-29|2015-11-02|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Computer-Based Training for Cognitive Enhancement: Classroom Study|Computer-Based Training for Cognitive Enhancement: Classroom Study|Completed||N/A|94|Actual|Posit Science Corporation||3|||f||||f||||||||||2018-06-01 03:56:59.775421|2018-06-01 03:56:59.775421
NCT00337896|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-08-15|2006-06-15|2006-06-20|Estimate|||||||2013-08-15|2013-08-16|Estimate|March 2006||2006-03-31|April 2011|2011-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||T and B Cell Response to Avian Flu Vaccine|T and B Cell Immune Responses to Influenza A/H5N1 Vaccine|Completed|||30|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples Without DNA|"~     blood~   "|||2018-06-01 03:56:59.846925|2018-06-01 03:56:59.846925
NCT00337883|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2014-02-28|2006-06-15|2006-06-20|Estimate|||||||2014-02-28|2014-03-04|Estimate|July 2003||2003-07-31|February 2014|2014-02-28|October 2005|Actual|2005-10-31|||||Interventional|||A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)|A Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)|Completed||Phase 2|110||Genentech, Inc.|||||||||||||||||||2018-06-01 03:56:59.903416|2018-06-01 03:56:59.903416
NCT00337870|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2013-09-11|2006-06-15|2006-06-20|Estimate|||||||2013-09-11|2013-09-12|Estimate|March 2006||2006-03-31|September 2013|2013-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|ERPain||Painful Procedures in the Emergency Department: A Distraction Intervention (3-5 Year Olds)|Painful Procedures in the Emergency Department: Does a Formal Program in Distracting Techniques for Parents and Children Reduce Pain and Anxiety in Children (3-5 Year Olds)?|Completed||Phase 2|131|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 03:56:59.956924|2018-06-01 03:56:59.956924
NCT00337831|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2011-06-29|2006-06-15|2006-06-16|Estimate|||||||2011-06-29|2011-06-30|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|May 2007|Actual|2007-05-31|February 2007|Actual|2007-02-28||Interventional|||Clinical Study on Optimised Removal of Protein-bound Uremic Toxins With Convective Dialysis Treatment.|Clinical Study on Optimised Removal of Protein-bound Uremic Toxins With Convective Dialysis Treatment.|Completed||N/A|17|Actual|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:57:00.039935|2018-06-01 03:57:00.039935
NCT00337818|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|2009-11-12||2017-05-25|2006-06-15|2006-06-16|Estimate|2010-02-12|2010-03-02|Estimate||||2017-05-25|2017-05-30|Actual|June 2006||2006-06-30|May 2017|2017-05-31|January 2009|Actual|2009-01-31|June 2006|Actual|2006-06-30||Interventional|||Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women|A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study|Completed||Phase 3|770|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 03:57:00.124146|2018-06-01 03:57:00.124146
NCT00337805|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2009-09-17|2006-06-14|2006-06-16|Estimate|||||||2009-09-17|2009-09-18|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery|A Randomized Trial of Synthetic vs Normal Saline for the Flow-based Algorithmic Hemodynamic Resuscitation of Patients Post-cardiac Surgery|Completed||Phase 2/Phase 3|240|Actual|McGill University Health Center||2|||f||||f||||||||||2018-06-01 03:57:00.533514|2018-06-01 03:57:00.533514
NCT00337792|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2016-03-16|2006-06-15|2006-06-16|Estimate|||||||2016-03-16|2016-03-18|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparing the Effectiveness of Oral Versus Intravenous Pain Medicine for Suction Curettage (D&C)|A Randomized Clinical Trial Comparing Oral Conscious Sedation With Intravenous Conscious Sedation for First Trimester Surgical Abortion|Terminated||N/A|132|Actual|Planned Parenthood League of Massachusetts||||DSMB review at 50% recruitment, further recruitment unlikely to change result|f||||t||||||||||2018-06-01 03:57:00.590225|2018-06-01 03:57:00.590225
NCT00337779|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2010-01-18||2011-10-06|2006-06-14|2006-06-16|Estimate|2010-04-23|2010-05-14|Estimate||||2011-10-06|2011-10-10|Estimate|August 2006||2006-08-31|October 2011|2011-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).|A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)|Completed||Phase 3|1155|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 03:57:00.66506|2018-06-01 03:57:00.66506
NCT00337766|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-10-20|2006-06-15|2006-06-16|Estimate|||||||2015-10-20|2015-10-21|Estimate|June 2006||2006-06-30|May 2013|2013-05-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Desmopressin in Cardiac Surgery|Efficacy of Desmopressin (1-deamin0-8-D-arginine-vasopressin) in Reducing Active Microvascular Bleeding After Cardiac Surgery|Completed||Phase 4|||Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-06-01 03:57:01.329039|2018-06-01 03:57:01.329039
NCT00337753|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2010-01-04|2006-06-14|2006-06-16|Estimate|||||||2010-01-04|2010-01-05|Estimate|June 2006||2006-06-30|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Cognitive Behavioral Therapy for Pathological Gambling|Cognitive Behavioral Therapy for Pathological Gambling|Completed||Phase 2|76|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 03:57:01.425253|2018-06-01 03:57:01.425253
NCT00337740|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2012-04-20|2006-06-15|2006-06-16|Estimate|||||||2012-04-20|2012-04-23|Estimate||||September 2006|2006-09-30||||||||Interventional|||Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding|Randomized Study Comparing Ligation With Propranolol for Primary Prophylaxis of Variceal Bleeding in Candidates for Liver Transplantation|Terminated||Phase 3|120|Anticipated|University of Padova||||"From the interim analysis resulted that more than 1000 patients were required to demonstrate a~   significant difference between the 2 treatments."|f||||||||||||||2018-06-01 03:57:01.496115|2018-06-01 03:57:01.496115
NCT00337727|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2009-09-30||2017-05-02|2006-06-14|2006-06-16|Estimate|2009-09-30|2009-11-06|Estimate||||2017-05-02|2017-06-02|Actual|January 1, 2007|Actual|2007-01-01|May 2017|2017-05-31|November 19, 2008|Actual|2008-11-19|October 28, 2008|Actual|2008-10-28||Interventional|||Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)|A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC)|Completed||Phase 3|848|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:57:01.595978|2018-06-01 03:57:01.595978
NCT00337714|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2011-05-13|2006-06-14|2006-06-16|Estimate|||||||2011-05-13|2011-05-16|Estimate|July 2006||2006-07-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|||||Interventional|NanoAgCVC||Comparison of Central Venous Catheters With Silver Nanoparticles Versus Conventional Catheters|A Parallel, Randomized Multicenter Comparison of Triple Lumen Central Venous Catheters Impregnated With Silver Nanoparticles (AgTive®) Versus Conventional Catheters in Intensive Care Unit Patients|Completed||Phase 4|472|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-06-01 03:57:02.038596|2018-06-01 03:57:02.038596
NCT00337701|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2015-11-02|2006-06-15|2006-06-16|Estimate|||||||2015-11-02|2015-11-03|Estimate|June 2006||2006-06-30|November 2015|2015-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection|Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection|Completed||Phase 4|326|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 03:57:02.122441|2018-06-01 03:57:02.122441
NCT00337688|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2011-09-13|2006-06-14|2006-06-16|Estimate|||||||2011-09-13|2011-09-14|Estimate|July 2006||2006-07-31|September 2011|2011-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Power Wheelchair Joystick Use in Spastic Cerebral Palsy|Joystick Use for Virtual Electric Power Wheelchair Driving in Individuals With Spastic Cerebral Palsy|Completed|||50|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 03:57:02.255752|2018-06-01 03:57:02.255752
NCT00337675|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2010-02-19||2017-03-09|2006-06-14|2006-06-16|Estimate|2010-02-19|2010-03-15|Estimate||||2017-03-09|2017-04-06|Actual|October 2006||2006-10-31|March 2017|2017-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared With Placebo in the Treatment of Episodic Asthma in Children Aged 6 Months to 5 Years|Completed||Phase 3|1771|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 03:57:02.33551|2018-06-01 03:57:02.33551
NCT00337662|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2008-12-03||2010-02-08|2006-06-14|2006-06-16|Estimate|2009-06-19|2009-08-04|Estimate||||2010-02-08|2010-02-17|Estimate|May 2006||2006-05-31|February 2010|2010-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia|Predicting Response to Risperidone Treatment Through Identification of Early-onset of Antipsychotic Drug Action in Schizophrenia.|Completed||Phase 4|628|Actual|Eli Lilly and Company||3|||f||||||||||||||2018-06-01 03:57:02.856576|2018-06-01 03:57:02.856576
NCT00337649|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2016-11-01|2006-06-15|2006-06-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2004||2004-05-31|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer.|An Open -Label Study to Evaluate the Effect of Combination Therapy With Epothilone D and Herceptin on Tumor Response in Patients With HER-2 Overexpressing Locally Advanced or Metastatic Breast Cancer.|Completed||Phase 2|27|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:57:04.097435|2018-06-01 03:57:04.097435
NCT00337636|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2015-01-13|2006-06-13|2006-06-16|Estimate|||||||2015-01-13|2015-01-15|Estimate|May 2006||2006-05-31|January 2015|2015-01-31|September 2009|Actual|2009-09-30|February 2009|Actual|2009-02-28||Interventional|||Study of HuCNS-SC Cells in Patients With Infantile or Late Infantile Neuronal Ceroid Lipofuscinosis (NCL)|A Phase I Study of the Safety and Preliminary Effectiveness of Human CNS Stem Cells (HuCNS-SC) in Patients With Neuronal Ceroid Lipofuscinosis Caused by Palmitoyl Protein Thioesterase 1 (PPT1) or Tripeptidyl Peptidase 1 (TPP-I) Deficiency|Completed||Phase 1|6|Actual|StemCells, Inc.||1|||f||||t||||||||||2018-06-01 03:57:04.177833|2018-06-01 03:57:04.177833
NCT00337623|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2006-06-22|2006-06-15|2006-06-16|Estimate|||||||2006-06-22|2006-06-23|Estimate|June 2000||2000-06-30|June 2006|2006-06-30|July 2006||2006-07-31|||||Interventional|||Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.|Corticosteroids and Cataracts : Prospective Study of the Impact of Systemic Corticosteroid Therapy on Lens Transparency Evaluated by Scheimpflug Photography and Quantification of Lens Autofluorescence.|Completed||N/A|22||University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:57:04.245026|2018-06-01 03:57:04.245026
NCT00337610|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2009-09-24||2016-05-11|2006-06-14|2006-06-16|Estimate|2010-04-29|2010-05-27|Estimate||||2016-05-11|2016-05-12|Estimate|June 2006||2006-06-30|May 2016|2016-05-31|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus|A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy|Completed||Phase 3|190|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 03:57:04.314461|2018-06-01 03:57:04.314461
NCT00337597|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2008-07-18|2006-06-15|2006-06-16|Estimate|||||||2008-07-18|2008-07-21|Estimate|May 2006||2006-05-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Continuous Regional Analgesia After Total Knee Arthroplasty|Continuous Regional Analgesia After Total Knee Arthroplasty. Normal Saline or Dextrose 5% in Water as Fluid Medium for Pre-Placement Expansion in Order to Facilitate the Catheter Passing|Completed||Phase 3|50|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 03:57:04.641055|2018-06-01 03:57:04.641055
NCT00337584|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2017-03-09|2006-06-14|2006-06-16|Estimate|||||||2017-03-09|2017-03-13|Actual|December 2005||2005-12-31|March 2017|2017-03-31|June 2007|Actual|2007-06-30|||||Interventional|||A Pre-Operative Screening Questionnaire (AMS-Q) for Ambulatory Orthopedic Surgery Patients||Completed||N/A|||Hospital for Special Surgery, New York|||||f||||||||||||||2018-06-01 03:57:04.716765|2018-06-01 03:57:04.716765
NCT00337571|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2009-06-03||2013-11-07|2006-06-15|2006-06-16|Estimate|2009-06-03|2009-07-23|Estimate||||2013-11-07|2013-12-02|Estimate|June 2006||2006-06-30|November 2009|2009-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)|A Multicenter Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Three Fixed Doses of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)|Completed||Phase 3|218|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||t||||||||||2018-06-01 03:57:04.819941|2018-06-01 03:57:04.819941
NCT00337558|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2014-09-17|2006-06-15|2006-06-16|Estimate|||||||2014-09-17|2014-09-18|Estimate|May 2006||2006-05-31|September 2014|2014-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|SOLAR||A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)|Solifenacin Succinate in a Flexible Dose Regimen With Simplified Bladder Training Versus Solifenacin Succinate in a Flexible Dose Regimen Alone in a Prospective, Randomized, Parallel Group, Overactive Bladder Symptom Study|Completed||Phase 4|643|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 03:57:05.571127|2018-06-01 03:57:05.571127
NCT00337545|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2007-10-05|2006-06-15|2006-06-16|Estimate|||||||2007-10-05|2007-10-10|Estimate|May 2006||2006-05-31|October 2007|2007-10-31|April 2007||2007-04-30|||||Interventional|||Phase II Trial of RAD001 in Refractory Colorectal Cancer|Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer|Completed||Phase 2|22|Actual|Swedish Medical Center|||||f||||||||||||||2018-06-01 03:57:05.711788|2018-06-01 03:57:05.711788
NCT00337532|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14||2010-02-02|2010-02-02|2006-06-15|2006-06-16|Estimate||||2010-02-02|2010-02-04|Estimate|2010-02-02|2010-02-04|Estimate|May 2005||2005-05-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer|A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer|Completed||Phase 2/Phase 3|50||Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 03:57:05.764029|2018-06-01 03:57:05.764029
NCT00337519|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2009-01-28|2006-06-15|2006-06-16|Estimate|||||||2009-01-28|2009-01-29|Estimate|January 2003||2003-01-31|January 2009|2009-01-31|April 2009|Anticipated|2009-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia|Chemo-Immunotherapy With Allogeneic Blood Stem Cell Transplantation in Patients With Chronic Lymphocytic Leukemia (Study #02)|Unknown status|Active, not recruiting|Phase 2|82|Anticipated|Charite University, Berlin, Germany||1|||f||||||||||||||2018-06-01 03:57:05.824193|2018-06-01 03:57:05.824193
NCT00337506|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2006-06-15|2006-06-15|2006-06-16|Estimate|||||||2006-06-15|2006-06-16|Estimate|August 2003||2003-08-31|August 2004|2004-08-31||||||||Interventional|||Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|A Multicenter Open-Label Phase II Study of Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|Terminated||Phase 2|50||Nantes University Hospital|||||f||||||||||||||2018-06-01 03:57:05.893059|2018-06-01 03:57:05.893059
NCT00337493|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2012-09-14|2006-06-15|2006-06-16|Estimate|||||||2012-09-14|2012-09-17|Estimate|December 2005||2005-12-31|September 2012|2012-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.|A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation|Completed||Phase 4|155|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:57:05.954038|2018-06-01 03:57:05.954038
NCT00337480|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2013-04-12|2006-06-14|2006-06-16|Estimate|||||||2013-04-12|2013-04-15|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|September 2009|Actual|2009-09-30|July 2008|Actual|2008-07-31||Interventional|||Study of the Efficiency of Education About Cardiovascular Risk Factors in Patients After an Acute Coronary Syndrome|A Network to Control Risk Factors After Acute Coronary Syndrome|Completed||N/A|504|Actual|Resicard||2|||f||||t||||||||||2018-06-01 03:57:06.038873|2018-06-01 03:57:06.038873
NCT00337467|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2010-05-21||2010-06-18|2006-06-15|2006-06-16|Estimate|2010-06-18|2010-07-19|Estimate||||2010-06-18|2010-07-19|Estimate|June 2006||2006-06-30|June 2010|2010-06-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|OREY||Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression|Phase IIIb Multicenter, Single Arm, Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY (Only REYataz) Study|Completed||Phase 3|61|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:57:06.126796|2018-06-01 03:57:06.126796
NCT00337259|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2016-02-13|2006-06-14|2006-06-15|Estimate|||||||2016-02-13|2016-02-17|Estimate|June 2006||2006-06-30|February 2016|2016-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Gemcitabine for Marginal Zone Lymphoma|Phase II Study of Gemcitabine in Patients With Advanced Stage Marginal Zone B-cell Lymphoma|Terminated||Phase 2|43|Actual|Asan Medical Center||1||poor accrual and response less than expected on interim analysis|f||||t||||||||No||2018-06-01 03:57:10.304204|2018-06-01 03:57:10.304204
NCT00337454|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14||2010-02-04|2011-04-07|2006-06-15|2006-06-16|Estimate||||2010-02-04|2010-02-08|Estimate|2011-04-07|2011-04-14|Estimate|July 2005||2005-07-31|April 2011|2011-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan|A Phase I/II Study of BMS-354825 in Subjects With Imatinib Resistant or Intolerant Philadelphia Chromosome Positive Chronic Myelogenous Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Treatment|Completed||Phase 1/Phase 2|48||Bristol-Myers Squibb||6|||f||||||||||||||2018-06-01 03:57:06.740815|2018-06-01 03:57:06.740815
NCT00337441|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2006-06-14|2006-06-14|2006-06-16|Estimate|||||||2006-06-14|2006-06-16|Estimate|January 2003||2003-01-31|June 2006|2006-06-30|July 2005||2005-07-31|||||Interventional|||Treatment of Chronic Anemia With Epoetin Alfa in Elderly|Chronic Anemia And Fatigue In Elderly Patients: A Randomized Double-Blind Placebo-Controlled Cross-Over Study With Epoetin Alfa.|Unknown status|Active, not recruiting|Phase 2|62||Research and Education Foundation of Michael Reese Hospital|||||f||||||||||||||2018-06-01 03:57:06.86067|2018-06-01 03:57:06.86067
NCT00337428|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|2010-01-14||2016-09-27|2006-06-15|2006-06-16|Estimate|2010-01-14|2010-02-11|Estimate||||2016-09-27|2016-11-16|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)|An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With REPEVAX™ in Healthy Adolescents 11-17 Years of Age|Completed||Phase 3|843|Actual|Merck Sharp & Dohme Corp.|Safety results have been previously reported in the literature.|4|||f||||||||||||||2018-06-01 03:57:07.008144|2018-06-01 03:57:07.008144
NCT00337415|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2015-05-15|2006-06-14|2006-06-16|Estimate|||||||2015-05-15|2015-05-18|Estimate|May 2006||2006-05-31|May 2015|2015-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||MK0354 Clinical Efficacy and Tolerability Study (0354-004)|Proprietary Information - Exploratory (Non-Confirmatory) Trial|Terminated||Phase 2|65|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 03:57:07.803326|2018-06-01 03:57:07.803326
NCT00337402|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-15|||2006-11-20|2006-06-15|2006-06-16|Estimate|||||||2006-11-20|2006-11-22|Estimate|January 2002||2002-01-31|June 2006|2006-06-30|June 2005||2005-06-30|||||Observational|||Effects of Gastrostomy on Amyotrophic Lateral Sclerosis|Effects of Gastrostomy on Quality of Life and Survival in Patients With Amyotrophic Lateral Sclerosis|Completed|||380||University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:57:07.847826|2018-06-01 03:57:07.847826
NCT00337389|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2007-11-15|2006-06-14|2006-06-16|Estimate|||||||2007-11-15|2007-11-19|Estimate|May 2006||2006-05-31|November 2007|2007-11-30||||||||Interventional|||Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.|A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma|Unknown status|Active, not recruiting|Phase 3|1200|Anticipated|Mast Therapeutics, Inc.||2|||f||||||||||||||2018-06-01 03:57:07.917688|2018-06-01 03:57:07.917688
NCT00337376|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2014-01-13|2006-06-13|2006-06-15|Estimate|||||||2014-01-13|2014-01-14|Estimate|February 2006||2006-02-28|January 2014|2014-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers|A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Solid Cancers|Terminated||Phase 1|23|Actual|Yale University||1|||f||||f||||||||||2018-06-01 03:57:08.038983|2018-06-01 03:57:08.038983
NCT00337350|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2012-12-19||2015-04-15|2006-06-13|2006-06-15|Estimate|2013-01-30|2013-03-06|Estimate||||2015-04-15|2015-05-08|Estimate|September 2003||2003-09-30|April 2015|2015-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment|A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis|Completed||Phase 4|20|Actual|Massachusetts General Hospital|Our findings in this study were limited by the small sample size. It is possible that with a larger sample, significant improvements might be observed not only in glucose metabolism but also in lipid metabolism.|2|||f||||||||||||||2018-06-01 03:57:08.120624|2018-06-01 03:57:08.120624
NCT00337337|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2006-10-17|2006-06-14|2006-06-15|Estimate|||||||2006-10-17|2006-10-18|Estimate|April 2005||2005-04-30|June 2006|2006-06-30|February 2007||2007-02-28|||||Interventional|||Multiple Grain in Type 2 Diabetes|Effect of Reconstitute Multiple Grain on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes|Unknown status|Recruiting|Phase 4|30||National Cheng-Kung University Hospital|||||f||||||||||||||2018-06-01 03:57:08.39705|2018-06-01 03:57:08.39705
NCT00337324|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2006-06-14|2006-06-14|2006-06-15|Estimate|||||||2006-06-14|2006-06-15|Estimate|March 2002||2002-03-31|March 2002|2002-03-31|May 2004||2004-05-31|||||Interventional|||Electromagnetic Stimulation (FREMS) in Patients With Painful Diabetic Neuropathy|Clinical Assessment of Transcutaneous Neurostimulation and Biofeedback (FREMS)in Patients With Diabetic Neuropathy|Completed||Phase 2/Phase 3|38||IRCCS San Raffaele|||||f||||||||||||||2018-06-01 03:57:08.454923|2018-06-01 03:57:08.454923
NCT00337298|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2009-06-22|2006-06-14|2006-06-15|Estimate|||||||2009-06-22|2009-06-23|Estimate|July 2006||2006-07-31|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes|Lack of Effect of Antihypertensive Treatment With Amlodipine and Lisinopril on Retinal Autoregulation in Patients With Type 1 Diabetes and Mild Diabetic Retinopathy. A Prospective Randomized Clinical Trial.|Completed||N/A|25|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 03:57:08.514151|2018-06-01 03:57:08.514151
NCT00337285|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2009-05-28||2012-08-16|2006-06-14|2006-06-15|Estimate|2009-05-28|2009-07-17|Estimate||||2012-08-16|2012-08-20|Estimate|July 2006||2006-07-31|August 2012|2012-08-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|349|Actual|New River Pharmaceuticals||1|||f||||f||||||||||2018-06-01 03:57:08.587834|2018-06-01 03:57:08.587834
NCT00337272|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2009-06-02||2011-08-18|2006-06-13|2006-06-15|Estimate|2009-06-02|2009-07-21|Estimate||||2011-08-18|2011-08-22|Estimate|August 2006||2006-08-31|August 2011|2011-08-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||Treating Chronic Insomnia in Breast Cancer Patients|Phase IV: Treatment of Chronic Insomnia in Patients With Breast Cancer Following Completion of Chemotherapy|Terminated||Phase 4|16|Actual|Accelerated Community Oncology Research Network|Early study termination due to slow enrollment; Small sample size analyzed; Some IVRS and Patient Care Monitor (PCM) data were lost and could not be retrieved; Some subject non-compliance with study requirements|2||Lack of enrollment.|f||||f||||||||||2018-06-01 03:57:09.872044|2018-06-01 03:57:09.872044
NCT00337246|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2013-08-01|2006-06-13|2006-06-15|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|March 2011|Actual|2011-03-31|||||Interventional|||Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia|A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia|Completed||Phase 2|56|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:10.468044|2018-06-01 03:57:10.468044
NCT00337233|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2017-05-25|2006-06-13|2006-06-15|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2004||2004-01-31|September 2015|2015-09-30|November 2016|Actual|2016-11-30|November 2006|Actual|2006-11-30||Interventional|||Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer|Restorative Yoga for Symptom Management and Stress Reduction in Women With Ovarian Cancer|Completed||N/A|106|Actual|Wake Forest University Health Sciences|||||f||||t|f|f||||||||2018-06-01 03:57:10.580869|2018-06-01 03:57:10.580869
NCT00337220|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2013-08-13|2006-06-14|2006-06-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Urine Testing to Detect Kidney Transplant Rejection|Noninvasive Diagnosis of Renal Allograft Rejection by Urinary Cell mRNA Profiling|Completed|||492|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     Blood and urine collection~   "|||2018-06-01 03:57:10.690451|2018-06-01 03:57:10.690451
NCT00337207|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2012-10-21||2018-04-03|2006-06-13|2006-06-15|Estimate|2012-10-21|2012-11-19|Estimate||||2018-04-03|2018-05-01|Actual|March 2006||2006-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2008|Actual|2008-11-30||Interventional|||Bevacizumab in Treating Patients With Recurrent or Progressive Glioma|A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas|Active, not recruiting||Phase 2|55|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 03:57:10.77564|2018-06-01 03:57:10.77564
NCT00337194|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2015-02-10||2015-02-10|2006-06-13|2006-06-15|Estimate|2015-02-10|2015-02-23|Estimate||||2015-02-10|2015-02-23|Estimate|April 2006||2006-04-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2008|Actual|2008-09-30||Interventional|||SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Randomized Double-Blinded Placebo Controlled Phase II Study of the Anti-CD30 Antibody, SGN-30 (NSC #731636), in Combination With Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD) for Patients With Relapsed/Refractory Hodgkin Lymphoma|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:57:11.048299|2018-06-01 03:57:11.048299
NCT00337181|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2017-05-02|2006-06-14|2006-06-15|Estimate|||||||2017-05-02|2017-05-05|Actual|May 2006||2006-05-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|December 2006|Actual|2006-12-31||Observational|||Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial|Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Become HIV-1 Infected During Participation in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX® B/E.|Active, not recruiting|||130|Anticipated|U.S. Army Medical Research and Materiel Command|||||f||||f||||||||No||2018-06-01 03:57:11.689475|2018-06-01 03:57:11.689475
NCT00337168|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2012-06-05||2015-03-05|2006-06-13|2006-06-15|Estimate|2012-06-05|2012-07-10|Estimate||||2015-03-05|2015-03-25|Estimate|October 2006||2006-10-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|December 2008|Actual|2008-12-31||Interventional|||S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase II Trial of Cytarabine and Clofarabine in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2|36|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 03:57:11.876234|2018-06-01 03:57:11.876234
NCT00337155|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2014-12-23|2006-06-14|2006-06-15|Estimate|||||||2014-12-23|2014-12-24|Estimate|May 2006||2006-05-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||BAY88-8223, Dose Finding Study in Patients With HRPC|A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases|Completed||Phase 2|122|Actual|Bayer||3|||f||||f||||||||||2018-06-01 03:57:12.328236|2018-06-01 03:57:12.328236
NCT00337142|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2009-06-28|2006-06-13|2006-06-15|Estimate|||||||2009-06-28|2009-06-30|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Follow up Glucose Levels Among Infants of Diabetic Mothers||Completed|||250|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-06-01 03:57:12.406574|2018-06-01 03:57:12.406574
NCT00337129|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2012-07-20||2015-08-11|2006-06-13|2006-06-15|Estimate|2012-07-20|2012-08-29|Estimate||||2015-08-11|2015-08-25|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|August 2008|Actual|2008-08-31||Interventional|||S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|42|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:57:12.502144|2018-06-01 03:57:12.502144
NCT00337116|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2010-01-27|2006-06-14|2006-06-15|Estimate|||||||2010-01-27|2010-01-28|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2008|Anticipated|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients|Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients|Withdrawn||Phase 4|80|Anticipated|Soroka University Medical Center||||LOGISTIC DIFFICULTIES|f||||f||||||||||2018-06-01 03:57:12.922345|2018-06-01 03:57:12.922345
NCT00337103|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2013-07-31||2018-01-16|2006-06-13|2006-06-15|Estimate|2013-07-31|2013-09-30|Estimate||||2018-01-16|2018-02-13|Actual|June 15, 2006|Actual|2006-06-15|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|March 12, 2012|Actual|2012-03-12||Interventional|||E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes|A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes|Completed||Phase 3|1102|Actual|Eisai Inc.||2|||f|||||t|||||||||2018-06-01 03:57:13.090368|2018-06-01 03:57:13.090368
NCT00337090|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2013-07-01|2006-06-14|2006-06-15|Estimate|||||||2013-07-01|2013-07-02|Estimate||||July 2013|2013-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)|A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder|Completed||Phase 2|1108|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 03:57:13.994986|2018-06-01 03:57:13.994986
NCT00334503|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2008-10-08|2006-06-05|2006-06-07|Estimate|||||||2008-10-08|2008-10-10|Estimate||||October 2008|2008-10-31||||||||Interventional|||Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide||Completed||Phase 3|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 03:57:51.946253|2018-06-01 03:57:51.946253
NCT00337077|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2014-02-14||2014-05-21|2006-06-13|2006-06-15|Estimate|2014-05-21|2014-06-23|Estimate||||2014-05-21|2014-06-23|Estimate|November 2006||2006-11-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|June 2009|Actual|2009-06-30||Interventional||Eligible and treated patients are included in this analysis.|Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of E7389 (Halichondrin B Analog), in Patients With Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|121|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 03:57:14.173728|2018-06-01 03:57:14.173728
NCT00337064|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2006-06-13|2006-06-13|2006-06-15|Estimate|||||||2006-06-13|2006-06-15|Estimate|June 2006||2006-06-30|May 2006|2006-05-31||||||||Interventional|||Partial Breast Radiation to the Lumpectomy Cavity With IMRT in Elderly Women|Phase I/II Trial to Evaluate Partial Breast Radiation to the Region of the Lumpectomy Cavity Using Intensity Modulated Radiation in Elderly Women With Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|75||University of Vermont|||||f||||||||||||||2018-06-01 03:57:14.78155|2018-06-01 03:57:14.78155
NCT00337051|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2010-06-22|2006-06-14|2006-06-15|Estimate|||||||2010-06-22|2010-06-23|Estimate|June 2006||2006-06-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|SévoRein||Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN)|Sevoflurane-induced Prevention of Ischemia-reperfusion Lesions in Renal Allograft Transplants Recipients|Completed||Phase 3|120|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 03:57:14.850764|2018-06-01 03:57:14.850764
NCT00337038|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2012-06-21|2006-06-14|2006-06-15|Estimate|||||||2012-06-21|2012-06-22|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Endothelial Function as a Marker for Blood Pressure Control Among Hypertensive Diabetic Patients||Completed||Early Phase 1|50|Actual|Soroka University Medical Center|||||f||||||||||||||2018-06-01 03:57:14.925464|2018-06-01 03:57:14.925464
NCT00337012|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2008-11-28|2006-06-13|2006-06-15|Estimate|||||||2008-11-28|2008-12-01|Estimate|July 2007||2007-07-31|November 2008|2008-11-30||||||||Observational|||The Effect of Duloxetine on Interoceptive Awareness|The Effect of Duloxetine on Interoceptive Awareness, Thermal Heat Pain Perception, and Bodily Symptoms in Major Depressive: a Pilot Study With fMRI.|Unknown status|Recruiting||36|Anticipated|University Hospital, Bonn|||||f||||||||||||||2018-06-01 03:57:14.977164|2018-06-01 03:57:14.977164
NCT00336986|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2016-11-10|2006-06-14|2006-06-15|Estimate|||||||2016-11-10|2016-11-11|Estimate|September 2004||2004-09-30|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy Study of IL-21 to Treat Metastatic Melanoma|An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma|Completed||Phase 2|54|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:57:15.027783|2018-06-01 03:57:15.027783
NCT00336973|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2009-04-15||2015-07-01|2006-06-13|2006-06-15|Estimate|2009-04-15|2009-06-05|Estimate||||2015-07-01|2015-07-23|Estimate|May 2006||2006-05-31|April 2009|2009-04-30||||February 2008|Actual|2008-02-29||Interventional|||A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent|A Phase IV Open-Label Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Raptiva (Efalizumab) in Adult Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent|Completed||Phase 4|73|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 03:57:15.098945|2018-06-01 03:57:15.098945
NCT00336960|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2013-03-02|2006-06-13|2006-06-15|Estimate|||||||2013-03-02|2013-03-05|Estimate|July 2002||2002-07-31|March 2013|2013-03-31|March 2008|Actual|2008-03-31|November 2004|Actual|2004-11-30||Interventional|||Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery|Phase II Pilot Study of Pre-Operative Celecoxib (Celebrex) in Combination With Prolonged Venous Infusion 5FU and Radiation Therapy for Patients With Stage II/III Resectable Rectal Cancer|Completed||Phase 2|24|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-06-01 03:57:15.230542|2018-06-01 03:57:15.230542
NCT00336947|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2013-05-14|2006-06-13|2006-06-15|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 2006||2006-04-30|December 2008|2008-12-31||||March 2012|Anticipated|2012-03-31||Interventional|||S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer|Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:15.316159|2018-06-01 03:57:15.316159
NCT00336934|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13||2011-03-15|2011-08-08|2006-06-13|2006-06-15|Estimate||||2011-05-16|2011-05-19|Estimate|2011-08-08|2011-08-15|Estimate|November 2005||2005-11-30|August 2011|2011-08-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled Study of The Effects of Pomegranate Extract On Rising Prostate-Specific Antigen Levels In Men Following Primary Therapy|Completed||N/A|183|Actual|Roll International Corporation||2|||f||||t||||||||||2018-06-01 03:57:15.418921|2018-06-01 03:57:15.418921
NCT00336921|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-14|||2009-09-14|2006-06-14|2006-06-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|February 2006||2006-02-28|September 2009|2009-09-30||||April 2007|Actual|2007-04-30||Interventional|||Alfuzosin for Treating Acute Urinary Retention|A Double-blind, Randomized,Placebo Controlled Study of Alfuzosin 10mg od in the Return to Successful Voiding in Patients With a First Episode of Acute Urinary Retention Due to Benign Prostatic Hyperplasia|Completed||Phase 2|156|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:57:15.564381|2018-06-01 03:57:15.564381
NCT00336908|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2007-11-26|2006-06-13|2006-06-14|Estimate|||||||2007-11-26|2007-11-27|Estimate|November 2005||2005-11-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery|Inflammatory Responses of Intravenous Fish Oil, Soybean Oil and Medium Chain Triglyceride Fat Emulsions in Young Children Before and After Open Heart Surgery|Completed||Phase 2/Phase 3|32|Anticipated|University of Alberta|||||f||||||||||||||2018-06-01 03:57:15.625538|2018-06-01 03:57:15.625538
NCT00336895|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|2016-05-19||2016-11-03|2006-06-12|2006-06-14|Estimate|2016-11-03|2016-11-07|Estimate||||2016-11-03|2016-11-07|Estimate|November 2006||2006-11-30|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional||30 potential participants were screened but only 29 enrolled.|Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients|Conversion of CellCept to Myfortic: A Prospective Study on the Tolerability and Safety of Myfortic in Liver Transplant Recipients|Completed||N/A|29|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:57:15.694924|2018-06-01 03:57:15.694924
NCT00333606|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-03|||2006-06-03|2006-06-03|2006-06-06|Estimate|||||||2006-06-03|2006-06-06|Estimate|January 2005||2005-01-31|June 2006|2006-06-30||||||||Interventional|||Acupuncture and Auditory Evoked Potentials|Effects of Acupuncture on the Auditory Evoked Potentials: a Randomized Volunteer Crossover Study|Unknown status|Recruiting|Phase 1/Phase 2|10||University Medicine Greifswald|||||f||||||||||||||2018-06-01 03:58:09.868318|2018-06-01 03:58:09.868318
NCT00336882|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2012-03-01|2006-06-13|2006-06-14|Estimate|||||||2012-03-01|2012-03-02|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|PROMIS||Anaesthesia With Propofol Versus Midazolam : Effect on Oxidative Stress in the Brain of Head Trauma Patients|Anaesthesia With Propofol Versus Midazolam : Effect on Oxidative Stress in the Brain of Head Trauma Patients|Terminated||Phase 3|30|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-06-01 03:57:15.867828|2018-06-01 03:57:15.867828
NCT00336869|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2013-11-15|2006-06-12|2006-06-14|Estimate|||||||2013-11-15|2013-11-18|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|Meta-Health||Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership|Partnership Programs to Reduce Cardiovascular Disparities- Morehouse- Emory Partnership|Completed|||680|Actual|Emory University|||||f||||||||||Samples Without DNA|"~     Blood samples metabolic testing~   "|||2018-06-01 03:57:15.941049|2018-06-01 03:57:15.941049
NCT00336856|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|2016-01-12||2016-06-01|2006-06-12|2006-06-14|Estimate|2016-06-01|2016-07-12|Estimate||||2016-06-01|2016-07-12|Estimate|June 2006||2006-06-30|June 2016|2016-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional||Patients who received at least one dose of Irinotecan administered at a dose of 150a or 180 mg/m2 IV every two weeks, were thus evaluable and included in outcome analyses.|Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy|A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer|Completed||Phase 2|35|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 03:57:16.000459|2018-06-01 03:57:16.000459
NCT00336843|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2016-02-13|2006-06-13|2006-06-14|Estimate|||||||2016-02-13|2016-02-17|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|May 2010|Actual|2010-05-31|February 2009|Actual|2009-02-28||Interventional|||Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma|Combining 90Y-ibritumomab Tiuxetan With High-dose Chemotherapy of BuCyE and Autologous Stem Cell Transplantation in Patients With B-cell Non-Hodgkin's Lymphoma - an Open-labeled Phase II Study|Completed||Phase 2|19|Actual|Asan Medical Center||1|||f||||t||||||||No||2018-06-01 03:57:16.341957|2018-06-01 03:57:16.341957
NCT00336830|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2014-03-26|2006-06-13|2006-06-14|Estimate|||||||2014-03-26|2014-03-27|Estimate|May 2003||2003-05-31|March 2014|2014-03-31|December 2009|Actual|2009-12-31|June 2007|Actual|2007-06-30||Interventional|||Improving Cardiac Rehabilitation Participation in Women and Men|Improving Cardiac Rehabilitation Participation in Women and Men|Completed||Phase 3|1035|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 03:57:16.410959|2018-06-01 03:57:16.410959
NCT00336817|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|2016-05-23||2017-03-08|2006-06-12|2006-06-14|Estimate|2017-03-08|2017-03-09|Actual||||2017-03-08|2017-03-09|Actual|November 2006||2006-11-30|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients|A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients|Completed||N/A|30|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 03:57:16.505925|2018-06-01 03:57:16.505925
NCT00336791|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2012-02-13|2006-06-12|2006-06-14|Estimate|||||||2012-02-13|2012-02-14|Estimate|September 2003||2003-09-30|February 2012|2012-02-29|September 2010|Actual|2010-09-30|August 2007|Actual|2007-08-31||Interventional|||Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer|Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression Profile-Based Test to Select Patients for Preoperative Taxane/Anthracycline Chemotherapy for Stage I-III Breast Cancer|Completed||Phase 3|273|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 03:57:16.980167|2018-06-01 03:57:16.980167
NCT00336778|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2010-05-21|2006-06-12|2006-06-14|Estimate|||||||2010-05-21|2010-05-24|Estimate|January 2004||2004-01-31|May 2010|2010-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression|A Phase I Pilot Study Of An Antiretroviral Bridging Regimen In Highly Experienced Patients Unable To Achieve Viral Suppression.|Completed||Phase 1|6|Actual|University of Maryland|||||f||||t||||||||||2018-06-01 03:57:17.089139|2018-06-01 03:57:17.089139
NCT00336765|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2011-10-17|2006-06-12|2006-06-14|Estimate|||||||2011-10-17|2011-10-18|Estimate|July 2006||2006-07-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Study of XL647 Administered Orally Daily to Patients With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors|Completed||Phase 1|31|Actual|Kadmon Corporation, LLC|||||f||||t||||||||||2018-06-01 03:57:17.156032|2018-06-01 03:57:17.156032
NCT00336752|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2016-09-06|2006-06-13|2006-06-14|Estimate|||||||2016-09-06|2016-09-07|Estimate|June 2003||2003-06-30|September 2016|2016-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Operative Versus Non Operative Treatment for Unstable Ankle Fractures|A Prospective Randomized Multi-Centre Study to Compare Operative Versus Non Operative Functional Treatment in Patients With Unstable Isolated Fibula Fractures|Completed||N/A|80|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-06-01 03:57:17.222772|2018-06-01 03:57:17.222772
NCT00336739|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2007-07-20|2006-06-12|2006-06-14|Estimate|||||||2007-07-20|2007-07-23|Estimate|April 2006||2006-04-30|June 2007|2007-06-30|March 2007|Actual|2007-03-31|||||Interventional|||The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects||Completed||N/A|17|Actual|Tufts University|||||f||||f||||||||||2018-06-01 03:57:17.294214|2018-06-01 03:57:17.294214
NCT00336726|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2011-03-23|2006-06-13|2006-06-14|Estimate|||||||2011-03-23|2011-03-24|Estimate||||December 2004|2004-12-31||||||||Observational|||Neuroendocrine Dysfunction in Traumatic Brain Injury: Correlation With Cognitive Dysfunction and Repair||Terminated|||||Denver Research Institute|||||f||||||||||||||2018-06-01 03:57:17.368795|2018-06-01 03:57:17.368795
NCT00336713|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13||2016-04-13|2016-04-13|2006-06-13|2006-06-14|Estimate||||2016-04-13|2016-05-13|Estimate|2016-04-13|2016-05-13|Estimate|May 2006||2006-05-31|April 2016|2016-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)|A Multicenter, 24-52-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder|Completed||Phase 3|430|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:57:17.413042|2018-06-01 03:57:17.413042
NCT00336700|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|2015-12-23||2016-07-27|2006-06-12|2006-06-14|Estimate|2016-07-27|2016-09-19|Estimate||||2016-07-27|2016-09-19|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer|A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer|Terminated||Phase 2|25|Actual|University of Pittsburgh||1||Study published November 2010 and no further work will be done|f||||t||||||||||2018-06-01 03:57:17.488951|2018-06-01 03:57:17.488951
NCT00336687|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2010-03-26|2006-06-13|2006-06-14|Estimate|||||||2010-03-26|2010-03-29|Estimate|July 2005||2005-07-31|March 2010|2010-03-31|November 2006|Actual|2006-11-30|||||Observational|||Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation.|Study of Incidence, of Mechanisms and Prognosis of the Thrombopenia From Patients of Reanimation.|Completed|||322|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:57:17.701173|2018-06-01 03:57:17.701173
NCT00336674|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2018-05-27|2006-06-12|2006-06-14|Estimate|||||||2018-05-27|2018-05-30|Actual|December 2006||2006-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|INITII||Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes|A Randomised, Double-blind, Placebo-controlled Trial of Intranasal Insulin (440 IU) in Children and Young Adults at Risk of Type 1 Diabetes: Intranasal Insulin Trial II|Active, not recruiting||Phase 2|110|Actual|Melbourne Health||2|||f||||t||||||||No||2018-06-01 03:57:17.777828|2018-06-01 03:57:17.777828
NCT00336661|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2007-05-17|2006-06-12|2006-06-14|Estimate|||||||2007-05-17|2007-05-21|Estimate|January 2006||2006-01-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|||PerioWave Re-Treatment Protocol Compared to Scaling and Root Planing (SRP) and a Single Treatment With PerioWave|A Multicenter, Randomized, Blinded Study of Two Treatments of Photoactivated Disinfection With SRP Against One Treatment of Photoactivated Disinfection With SRP Against SRP Alone in the Treatment of Chronic Periodontitis|Completed||Phase 3|105|Actual|Ondine Research Laboratories|||||f||||||||||||||2018-06-01 03:57:17.847625|2018-06-01 03:57:17.847625
NCT00336648|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2012-07-26|2006-06-13|2006-06-14|Estimate|||||||2012-07-26|2012-07-30|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Preop Chemoradiation Resectable Pancreas|A Phase II Pilot Study of Preoperative Gemcitabine and Bevacizumab-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreas|Completed||Phase 2|11|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 03:57:17.995032|2018-06-01 03:57:17.995032
NCT00336635|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2007-04-17|2006-06-13|2006-06-14|Estimate|||||||2007-04-17|2007-04-19|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Safety and Immunogenicity of CJ-50300|Randomized, Double Blind, Placebo Control Study to Evaluate the Safety and Immunogenicity of CJ-50300 in Healthy Volunteers : Phase I|Completed||Phase 1|24||Seoul National University Hospital|||||f||||t||||||||||2018-06-01 03:57:18.087941|2018-06-01 03:57:18.087941
NCT00336622|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2011-02-18|2006-06-12|2006-06-14|Estimate|||||||2011-02-18|2011-02-21|Estimate|June 2004||2004-06-30|February 2011|2011-02-28|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Efficacy of Wrist/Hand Splints and Tendon/Nerve Gliding Exercises for Carpal Tunnel Syndrome: A RCT|The Efficacy of a Wrist and Hand Splint in Conjunction With Tendon and Nerve Gliding Exercise for the Treatment of Carpal Tunnel Syndrome: A Randomized Clinical Trial|Completed||N/A|56|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 03:57:18.143748|2018-06-01 03:57:18.143748
NCT00336609|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2007-04-19|2006-06-12|2006-06-14|Estimate|||||||2007-04-19|2007-04-20|Estimate|November 2005||2005-11-30|April 2007|2007-04-30|May 2007||2007-05-31|||||Observational|||TRIAD Burden of Illness Mucositis Study|Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-Small Cell Lung Cancers or Non-Hodgkin's Lymphoma|Unknown status|Recruiting||1600||TRIAD Burden of Illness|||||f||||||||||||||2018-06-01 03:57:18.203825|2018-06-01 03:57:18.203825
NCT00336596|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|||2007-04-25|2006-06-13|2006-06-14|Estimate|||||||2007-04-25|2007-04-27|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|June 2009|Anticipated|2009-06-30|||||Interventional|||Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion|Transcranial Ultrasound Enhanced Thrombolysis (TRUST)|Unknown status|Recruiting|Phase 3|400||University of Zurich|||||f||||t||||||||||2018-06-01 03:57:18.301717|2018-06-01 03:57:18.301717
NCT00336583|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-13|2009-05-05||2010-05-25|2006-06-13|2006-06-14|Estimate|2010-05-25|2010-06-22|Estimate||||2010-05-25|2010-06-22|Estimate|June 2006||2006-06-30|September 2009|2009-09-30|January 2008|Actual|2008-01-31|December 2006|Actual|2006-12-31||Interventional|||Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)|Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOX) for Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma|Completed||Phase 2|27|Actual|Asan Medical Center||1|||f||||t||||||||||2018-06-01 03:57:18.389862|2018-06-01 03:57:18.389862
NCT00336570|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2013-11-15|2006-06-12|2006-06-14|Estimate|||||||2013-11-15|2013-11-18|Estimate|February 2006||2006-02-28|November 2013|2013-11-30|October 2010|Actual|2010-10-31|||||Observational|||Predictive Medicine Research. (PRE MED)|Predictive Medicine Research (PRE MED) :Investigation of Predictors of Health, Sub-clinical and Clinical Organ System Diseases in Healthy Adult Population.|Completed|||288|Actual|Emory University|||||f||||f||||||Samples With DNA|"~     Whole Blood and Urine were collected. Samples of Serum, Plasma and Urine are stored.~   "|||2018-06-01 03:57:18.593375|2018-06-01 03:57:18.593375
NCT00336557|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2013-10-29|2006-06-12|2006-06-13|Estimate|||||||2013-10-29|2013-10-30|Estimate|July 2006||2006-07-31|October 2013|2013-10-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Observational|||Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy|A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns Versus Usual Care in High-Dose Interferon Treated Patients|Completed|||1230|Actual|Teva Pharmaceutical Industries|||2||f||||f||||||Samples Without DNA|"~     blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.~   "|||2018-06-01 03:57:18.672483|2018-06-01 03:57:18.672483
NCT00336544|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2009-09-03||2010-01-29|2006-06-09|2006-06-13|Estimate|2010-01-29|2010-02-26|Estimate||||2010-01-29|2010-02-26|Estimate|June 2006||2006-06-30|January 2010|2010-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia|A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults|Completed||Phase 3|522|Actual|Advanced Life Sciences, Inc.||2|||f||||f||||||||||2018-06-01 03:57:18.844431|2018-06-01 03:57:18.844431
NCT00336531|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-11|||2008-11-17|2006-06-11|2006-06-13|Estimate|||||||2008-11-17|2008-11-19|Estimate|April 2006||2006-04-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation|Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors|Completed||Phase 4|100|Anticipated|Samsung Medical Center|||||f||||||||||||||2018-06-01 03:57:19.207945|2018-06-01 03:57:19.207945
NCT00332267|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2008-09-02|2006-05-31|2006-06-01|Estimate|||||||2008-09-02|2008-09-04|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia|Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia|Completed||N/A|36|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 03:58:25.709008|2018-06-01 03:58:25.709008
NCT00336518|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2006-06-12|2006-06-12|2006-06-13|Estimate|||||||2006-06-12|2006-06-13|Estimate|June 2006||2006-06-30|August 2005|2005-08-31|July 2009||2009-07-31|||||Interventional|||Continuing Treatment With Pegasys and Copegus|Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24|Unknown status|Recruiting|Phase 3|100||Májbetegekért Alapítvány|||||f||||||||||||||2018-06-01 03:57:19.278835|2018-06-01 03:57:19.278835
NCT00336505|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2009-09-03||2010-01-29|2006-06-09|2006-06-13|Estimate|2010-01-29|2010-02-26|Estimate||||2010-01-29|2010-02-26|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)|A Double-Blinded, Randomized, Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300 mg QD to Clarithromycin (BIAXIN® Filmtab®) 250 mg BID for the Treatment of Community-Acquired Pneumonia in Adults|Completed||Phase 3|584|Actual|Advanced Life Sciences, Inc.||2|||f||||f||||||||||2018-06-01 03:57:19.365153|2018-06-01 03:57:19.365153
NCT00336492|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2011-07-14|2009-12-16|2013-07-24|2006-06-09|2006-06-13|Estimate|2011-07-14|2011-08-10|Estimate|2009-12-16|2009-12-18|Estimate|2013-07-24|2013-07-30|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|April 2010|Actual|2010-04-30|May 2009|Actual|2009-05-31||Interventional|||A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis|A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE�) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 3|60|Actual|Centocor, Inc.||2|||f||||||||||||||2018-06-01 03:57:19.657058|2018-06-01 03:57:19.657058
NCT00336479|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2011-06-22||2014-06-25|2006-06-09|2006-06-13|Estimate|2011-06-22|2011-07-21|Estimate||||2014-06-25|2014-07-23|Estimate|June 2006||2006-06-30|June 2014|2014-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||The Full Analysis set included all randomized subjects who received at least 1 dose of study drug.|Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C|A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment|Completed||Phase 2|263|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-06-01 03:57:19.987865|2018-06-01 03:57:19.987865
NCT00336466|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2007-11-26|2006-06-12|2006-06-13|Estimate|||||||2007-11-26|2007-11-27|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|May 2005||2005-05-31|||||Interventional|||The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)|The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial.|Completed||Phase 2|32||University of Calgary|||||f||||||||||||||2018-06-01 03:57:20.892465|2018-06-01 03:57:20.892465
NCT00336453|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2009-12-16|2006-06-12|2006-06-13|Estimate|||||||2009-12-16|2009-12-17|Estimate|October 2006||2006-10-31|December 2009|2009-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics|Evaluation of the Safety, Reactogenicity and Immunogenicity of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly to Healthy Children Aged 6 To 59 Months|Completed||Phase 1/Phase 2|156|Actual|Protein Sciences Corporation||5|||f||||t||||||||||2018-06-01 03:57:20.940524|2018-06-01 03:57:20.940524
NCT00336427|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2006-06-09|2006-06-09|2006-06-13|Estimate|||||||2006-06-09|2006-06-13|Estimate|September 2005||2005-09-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Observational|||MRSA Colonization in Peripartum Women and Their Offspring|A Prospective Study of MRSA Colonization in Peripartum Women and Their Offspring|Completed|||600||Orlando Regional Medical Center|||||f||||||||||||||2018-06-01 03:57:21.015715|2018-06-01 03:57:21.015715
NCT00336414|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2018-03-19|2006-06-12|2006-06-13|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2006||2006-06-30|June 2007|2007-06-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis|Five-Year Single-Blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis: Oral Cyclophosphamide Versus High Dose Intravenous Cyclophosphamide Versus Intermediate Dose Intravenous Cyclophosphamide|Withdrawn||Phase 3|0|Actual|Istituto Giannina Gaslini||||the study is withdrawn due to low and unexpected enrollment rate|f||||||||||||||2018-06-01 03:57:21.052676|2018-06-01 03:57:21.052676
NCT00336401|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2010-07-29|2006-06-12|2006-06-13|Estimate|||||||2010-07-29|2010-07-30|Estimate|October 2006||2006-10-31|September 2006|2006-09-30|February 2008|Actual|2008-02-29|||||Interventional|||Peri-Operative And Long-Term Cardioprotective Properties Of Sevoflurane In High Risk Patients Undergoing Non-Cardiac Surgery|Peri-Operative And Long-Term Cardioprotective Properties Of Sevoflurane In High Risk Patients Undergoing Non-Cardiac Surgery|Completed||Phase 4|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:57:21.107899|2018-06-01 03:57:21.107899
NCT00336388|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-10|||2010-03-08|2006-06-10|2006-06-13|Estimate|||||||2010-03-08|2010-03-09|Estimate|July 2006||2006-07-31|March 2010|2010-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Use of Rapid Diagnostic Tests for Malaria Case Management in Kenya|Introduction of Malaria Rapid Diagnostic Tests, Artemisinin-based Combination Therapy, and Malaria Case Management Guidelines at Health Facilities in Kenya: A Cluster Randomized Trial to Evaluate Adherence and Acceptance by Health Care Workers, Impact on Antimalarial Prescription Practices, and Patient Perceptions|Completed||N/A|3600||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 03:57:21.155626|2018-06-01 03:57:21.155626
NCT00336375|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2007-10-31|2006-06-12|2006-06-13|Estimate|||||||2007-10-31|2007-11-01|Estimate|June 2006||2006-06-30|October 2007|2007-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping|Treatment of Uncomplicated Childhood Malaria by an Artemisinin Derivative in Combination With Lumefantrine. Efficacy, Safety and Genotyping.|Completed||Phase 4|50|Actual|Karolinska University Hospital||2|||f||||||||||||||2018-06-01 03:57:21.207977|2018-06-01 03:57:21.207977
NCT00336362|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2012-12-18|2006-06-12|2006-06-13|Estimate|||||||2012-12-18|2012-12-20|Estimate|July 2006||2006-07-31|December 2012|2012-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major|A Pilot Study to Assess the Safety and Efficacy of G-CSF Mobilization With and Without Hydroxyurea Pretreatment in Adults With Beta Thalassemia Major|Completed||N/A|26|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 03:57:22.217573|2018-06-01 03:57:22.217573
NCT00336349|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2011-07-25|2006-06-12|2006-06-13|Estimate|||||||2011-07-25|2011-07-26|Estimate|June 2006||2006-06-30|July 2011|2011-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Neuropathic Foot Pain|A Study of Intra-dermal Injection of Botulinum Toxin Type A for the Diabetic Neuropathic Foot Pain|Completed||N/A|30|Actual|Taipei Medical University Hospital|||||f||||f||||||||||2018-06-01 03:57:22.304045|2018-06-01 03:57:22.304045
NCT00336336|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2015-08-13|2006-06-12|2006-06-13|Estimate|||||||2015-08-13|2015-08-14|Estimate|August 2002||2002-08-31|September 2010|2010-09-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF|A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure|Completed||Phase 3|6975|Actual|Gruppo di Ricerca GISSI||4|||f||||t||||||||||2018-06-01 03:57:22.450436|2018-06-01 03:57:22.450436
NCT00336323|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2011-03-16||2016-08-25|2006-06-09|2006-06-13|Estimate|2011-06-14|2011-07-12|Estimate||||2016-08-25|2016-08-26|Estimate|June 2006||2006-06-30|August 2016|2016-08-31|February 2008|Actual|2008-02-29|November 2006|Actual|2006-11-30||Interventional|Bevacizumab||A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)|A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)|Completed||Phase 2|121|Actual|Jaeb Center for Health Research||5|||f||||t||||||||||2018-06-01 03:57:23.176229|2018-06-01 03:57:23.176229
NCT00336310|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2006-06-12|2006-06-12|2006-06-13|Estimate|||||||2006-06-12|2006-06-13|Estimate|July 2006||2006-07-31|June 2006|2006-06-30||||||||Interventional|||A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients|A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients|Unknown status|Not yet recruiting|Phase 4|50||National Cheng-Kung University Hospital|||||f||||||||||||||2018-06-01 03:57:25.696488|2018-06-01 03:57:25.696488
NCT00336297|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2006-11-28|2006-06-09|2006-06-13|Estimate|||||||2006-11-28|2006-11-29|Estimate|May 2004||2004-05-31|February 2005|2005-02-28|February 2005||2005-02-28|||||Interventional|||Testing Methods of Screening for Woman Abuse in Health Care Settings.|Testing Screening Formats for Indicator-Based and Universal Screening Measurements in the Identification of Woman Abuse.|Completed||N/A|2000||McMaster University|||||f||||||||||||||2018-06-01 03:57:25.771224|2018-06-01 03:57:25.771224
NCT00336284|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2010-01-12||2010-07-28|2006-06-09|2006-06-13|Estimate|2010-03-16|2010-03-30|Estimate||||2010-07-28|2010-08-03|Estimate|November 2005||2005-11-30|July 2010|2010-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TRUST||TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up|TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up|Completed||Phase 4|1450|Actual|Biotronik, Inc.||2|||f||||f||||||||||2018-06-01 03:57:25.884968|2018-06-01 03:57:25.884968
NCT00336271|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2007-03-14|2006-06-09|2006-06-13|Estimate|||||||2007-03-14|2007-03-15|Estimate|April 2006||2006-04-30|March 2007|2007-03-31|March 2007||2007-03-31|||||Observational|||The Effects of Coffee|The Effects of Coffee|Completed|||50||American University|||||f||||||||||||||2018-06-01 03:57:26.391078|2018-06-01 03:57:26.391078
NCT00336258|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2010-12-13|2006-06-12|2006-06-13|Estimate|||||||2010-12-13|2010-12-14|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||US-Doppler and Procoagulant Microparticles for the Diagnosis of Asymptomatic DVT in Advanced Cancer Patients With Poor Performance Status|US-Doppler and Procoagulant Microparticles for the Diagnosis of Asymptomatic DVT in Advanced Cancer Patients With Poor Performance Status|Completed|||100|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:57:26.457432|2018-06-01 03:57:26.457432
NCT00336245|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-11|||2015-03-05|2006-06-11|2006-06-13|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2002||2002-06-30|August 2009|2009-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Randomized Trial of IUD Versus Hormonal Contraception in HIV-infected Women in Zambia|A Randomized Trial of IUD Versus Hormonal Contraception in HIV-infected Women in Zambia|Completed||Phase 3|600||University of Alabama at Birmingham||2|||f||||||||||||||2018-06-01 03:57:26.510007|2018-06-01 03:57:26.510007
NCT00336232|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|2016-03-07||2017-10-23|2006-06-12|2006-06-13|Estimate|2016-04-22|2016-05-30|Estimate||||2017-10-23|2017-11-27|Actual|May 2006||2006-05-31|October 2017|2017-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Determinants of Vitamin K Metabolism|Dietary and Non-dietary Components of Vitamin K Metabolism|Completed||N/A|59|Actual|Tufts University||1|||f||||f||||||||Yes||2018-06-01 03:57:26.58185|2018-06-01 03:57:26.58185
NCT00336219|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2012-05-04|2006-06-12|2006-06-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|August 2006||2006-08-31|October 2008|2008-10-31|April 2007|Actual|2007-04-30|November 2006|Actual|2006-11-30||Interventional|||Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)|COMPETITION: Investigation of Clinical Endpoints for Treatment-induced Gastroesophageal Reflux Disease (GERD) Symptom Changes|Completed||Phase 3|628|Actual|Takeda||1|||f||||||||||||||2018-06-01 03:57:26.784548|2018-06-01 03:57:26.784548
NCT00336206|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2006-07-21|2006-06-12|2006-06-13|Estimate|||||||2006-07-21|2006-07-25|Estimate|July 2006||2006-07-31|June 2006|2006-06-30|October 2009||2009-10-31|||||Interventional|||Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia|Subcutaneous Injection, Low Dose Alemtuzumab for Consolidation and Maintenance of Patients in Clinical Response After Having Achieved Partial or Complete Remission After 1st or 2nd Line Anti-Tumor Therapy for B-Cell CLL|Unknown status|Not yet recruiting|N/A|60||Tawam Hospital|||||f||||||||||||||2018-06-01 03:57:26.919708|2018-06-01 03:57:26.919708
NCT00336193|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-10|||2011-02-10|2006-06-10|2006-06-13|Estimate|||||||2011-02-10|2011-02-11|Estimate|August 2005||2005-08-31|February 2011|2011-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Competency Training, Staff Performance, & Family Outcomes|University of Colorado Health Sciences Center: Competency Training, Staff Performance, & Family Outcomes|Completed||Phase 2|1075|Anticipated|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-06-01 03:57:26.972552|2018-06-01 03:57:26.972552
NCT00336180|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2013-03-19|2006-06-09|2006-06-13|Estimate|||||||2013-03-19|2013-03-21|Estimate|September 2003||2003-09-30|March 2013|2013-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Adolescent Drug and HIV Prevention in South Africa|Adolescent Drug and HIV Prevention in South Africa|Completed||Phase 2/Phase 3|7695|Actual|Penn State University||1|||f||||t||||||||||2018-06-01 03:57:27.183616|2018-06-01 03:57:27.183616
NCT00336167|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2007-04-06|2006-06-09|2006-06-13|Estimate|||||||2007-04-06|2007-04-09|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|July 2007|Anticipated|2007-07-31|||||Interventional|||Bezafibrate Trial in CPT2 Deficiency|Clinical Trial on the Effect of Bezafibrate in the Muscular Form of Carnitine Palmitoyltransferase 2 Deficiency|Unknown status|Recruiting|Phase 3|12||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:57:27.262138|2018-06-01 03:57:27.262138
NCT00336154|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2006-06-12|2006-06-12|2006-06-13|Estimate|||||||2006-06-12|2006-06-13|Estimate||||June 2006|2006-06-30||||||||Interventional|||Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa|Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa|Unknown status|Not yet recruiting|Phase 4|20||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 03:57:27.348158|2018-06-01 03:57:27.348158
NCT00336141|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2014-05-19|2006-06-12|2006-06-13|Estimate|||||||2014-05-19|2014-05-21|Estimate|June 2006||2006-06-30|May 2014|2014-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer|Phase I/II Clinical Trial With Vorinostat and Infusional 5-FU/LV in Patients With Metastatic Colorectal Cancer Who Failed 5-FU-Based Chemotherapy|Completed||Phase 1|10|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 03:57:27.410934|2018-06-01 03:57:27.410934
NCT00336128|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-12|||2008-05-06|2006-06-12|2006-06-13|Estimate|||||||2008-05-06|2008-05-07|Estimate|October 2003||2003-10-31|May 2008|2008-05-31|July 2009|Anticipated|2009-07-31|May 2006|Actual|2006-05-31||Interventional|||Population Based Intervention to Prevent Obesity in Kindergartens (TigerKids)||Unknown status|Active, not recruiting|N/A|30000|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 03:57:27.47221|2018-06-01 03:57:27.47221
NCT00336115|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2007-10-22|2006-06-09|2006-06-12|Estimate|||||||2007-10-22|2007-10-23|Estimate|July 2006||2006-07-31|October 2007|2007-10-31|May 2008|Anticipated|2008-05-31|||||Interventional|||The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients|Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults|Unknown status|Enrolling by invitation|Phase 4|10|Anticipated|Queen Elizabeth II Health Sciences Centre|||||f||||f||||||||||2018-06-01 03:57:27.534727|2018-06-01 03:57:27.534727
NCT00336102|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2015-07-07|2006-06-08|2006-06-12|Estimate|||||||2015-07-07|2015-07-09|Estimate|April 2006||2006-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers|Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed With Breast Cancer and the Magnitude of Change in Thyroid Function Post-Chemotherapy|Completed|||541|Actual|University of South Florida|||2||f||||t||||||Samples Without DNA|"~     Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free~     T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12~     months and again 24 months after enrollment. All thyroid function marker assays will be~     performed by LabCorp.~   "|||2018-06-01 03:57:27.598141|2018-06-01 03:57:27.598141
NCT00336089|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2013-09-16|2006-06-08|2006-06-12|Estimate|||||||2013-09-16|2013-09-17|Estimate|January 2006||2006-01-31|July 2009|2009-07-31||||December 2008|Anticipated|2008-12-31||Interventional|||Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors|The Effects of Cross Training on Fatigue and Pain Levels in Breast Cancer Survivors|Unknown status|Recruiting|N/A|54|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:27.787027|2018-06-01 03:57:27.787027
NCT00336076|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2016-11-03|2006-06-09|2006-06-12|Estimate|||||||2016-11-03|2016-11-07|Estimate|July 2004||2004-07-31|November 2016|2016-11-30|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Observational|||Molecular Mechanisms and Diagnosis of Mastocytosis|Investigation of Cellular and Molecular Pathologic Mechanisms in Mast Cell Disorders.|Completed|||136|Actual|University of Michigan|||1||f||||f||||||Samples With DNA|"~     Plasma and nucleic acid.~   "|No||2018-06-01 03:57:27.854782|2018-06-01 03:57:27.854782
NCT00336063|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2018-04-20|2006-06-08|2006-06-12|Estimate|||||||2018-04-20|2018-04-23|Actual|March 3, 2006|Actual|2006-03-03|April 2018|2018-04-30||||April 19, 2013|Actual|2013-04-19||Interventional|||Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma|A Phase I Trial of 5Azacitidine and Suberoylanilide Hydroxamic Acid in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma and Nasal NK-T Cell Lymphoma|Active, not recruiting||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:57:27.924277|2018-06-01 03:57:27.924277
NCT00336050|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2016-07-28|2006-06-09|2006-06-12|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2000||2000-11-30|February 2009|2009-02-28|September 2010|Actual|2010-09-30|||||Observational|FACES||Effect of Air Pollution on Long-Term Asthma Severity and Lung Function in Children|Fresno Asthmatic Children's Environment Study|Unknown status|Active, not recruiting||315|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||f||||||Samples With DNA|"~     Password-protected database and storage facility that is part of the UCB SPH biorepository~   "|||2018-06-01 03:57:28.020025|2018-06-01 03:57:28.020025
NCT00336024|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2017-11-06|2006-06-08|2006-06-12|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2007||2007-08-31|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma|A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children &lt;36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate|Completed||Phase 3|96|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 03:57:28.119911|2018-06-01 03:57:28.119911
NCT00336011|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2006-06-09|2006-06-09|2006-06-12|Estimate|||||||2006-06-09|2006-06-12|Estimate|December 2002||2002-12-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Safety of Cardiac Pacemakers in 1.5T Tesla MRI|Studie Zur Sicherheit Von Medtronic Schrittmachern Bei Magnetresonanz-Bildgebungsverfahren an 1,5 Tesla-Systemen Study to Evaluate Safety Medtronic Pacemakers in MR Imaging at 1.5T Tesla)|Completed|||75||University Hospital, Bonn|||||f||||||||||||||2018-06-01 03:57:28.401933|2018-06-01 03:57:28.401933
NCT00335998|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2013-01-10|2006-06-08|2006-06-12|Estimate|||||||2013-01-10|2013-01-11|Estimate|March 2006||2006-03-31|January 2013|2013-01-31||||October 2008|Actual|2008-10-31||Interventional|||Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies|Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies.|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:57:28.449552|2018-06-01 03:57:28.449552
NCT00335985|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2014-11-03|2006-06-09|2006-06-12|Estimate|||||||2014-11-03|2014-11-05|Estimate|June 2006||2006-06-30|February 2012|2012-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)|A Randomized, Double-blind, Controlled Clinical Study of GB-0998 for the Steroid-resistant Polymyositis and Dermatomyositis|Completed||Phase 3|26|Actual|Japan Blood Products Organization||2|||f||||f||||||||||2018-06-01 03:57:28.520719|2018-06-01 03:57:28.520719
NCT00332254|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2013-05-29|2006-05-30|2006-06-01|Estimate|||||||2013-05-29|2013-05-30|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study to Prevent Cartilage Damage Following Acute Knee Injury.|IL-1ra for Prevention of Chondropathy Following Knee Injury|Completed||Phase 1/Phase 2|10|Actual|Duke University||2|||f||||t||||||||||2018-06-01 03:58:25.791847|2018-06-01 03:58:25.791847
NCT00335972|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2017-01-31||2017-08-09|2006-06-09|2006-06-12|Estimate|2017-08-09|2017-08-11|Actual||||2017-08-09|2017-08-11|Actual|June 2006||2006-06-30|August 2017|2017-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of Dexmedetomidine and Remifentanil on Carotid Patients|Phase 4: The Effects of Dexmedetomidine and Remifentanil on Postoperative Hemodynamics and Pain/Opioids in Patients Undergoing Carotid Endarterectomy|Terminated||Phase 4|142|Actual|The Cleveland Clinic||2||Closed due to lack of enrollment|f||||t||||||||No||2018-06-01 03:57:28.586247|2018-06-01 03:57:28.586247
NCT00335959|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2012-07-12||2012-07-12|2006-06-08|2006-06-12|Estimate|2012-07-12|2012-08-17|Estimate||||2012-07-12|2012-08-17|Estimate|May 2006||2006-05-31|July 2012|2012-07-31||||April 2009|Actual|2009-04-30||Interventional|||S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery|Neoadjuvant Chemoradiation Therapy With Oxaliplatin and Capecitabine for Patients With Surgically Resectable Gastric Cancer: A Pilot Phase II Trial With Molecular Correlates|Terminated||Phase 2|7|Actual|Southwest Oncology Group||1||Closed due to slow accrual|f||||t||||||||||2018-06-01 03:57:29.008125|2018-06-01 03:57:29.008125
NCT00335946|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2008-10-16|2006-06-08|2006-06-12|Estimate|||||||2008-10-16|2008-10-17|Estimate|June 2006||2006-06-30|July 2007|2007-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Pilot Investigational Study: Treatment of Anxiety With Non-Needle Electro-Acupuncture||Completed||Phase 1|40||Logan College of Chiropractic|||||f||||f||||||||||2018-06-01 03:57:29.407432|2018-06-01 03:57:29.407432
NCT00335933|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2007-08-01|2006-06-08|2006-06-12|Estimate|||||||2007-08-01|2007-08-02|Estimate|May 2006||2006-05-31|June 2006|2006-06-30|July 2007|Actual|2007-07-31|||||Interventional|||Safety and Efficacy of Gabapentin in Postherpetic Neuralgia|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia|Completed||Phase 3|378|Anticipated|Depomed|||||||||||||||||||2018-06-01 03:57:29.4666|2018-06-01 03:57:29.4666
NCT00335920|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2008-02-04|2006-06-09|2006-06-12|Estimate|||||||2008-02-04|2008-02-05|Estimate|October 2003||2003-10-31|February 2008|2008-02-29|July 2007|Actual|2007-07-31|July 2006|Actual|2006-07-31||Interventional|||Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss|A Prospective, Randomized, Double Blind, Placebo Controlled, Multicenter Study on the Safety and Efficacy of Continuous Infusion of Corticosteroid Delivered Via Catheter in Patients With Idiopathic Sudden Sensorineural Hearing Loss|Completed||Phase 3|23|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 03:57:29.525946|2018-06-01 03:57:29.525946
NCT00335907|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2010-08-23|2006-06-09|2006-06-12|Estimate|||||||2010-08-23|2010-08-25|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|January 2011|Anticipated|2011-01-31|June 2010|Anticipated|2010-06-30||Interventional|||Protocol-driven Hemodynamic Support for Patients With Septic Shock|Protocol-driven Hemodynamic Support for Patients With Septic Shock|Unknown status|Recruiting|N/A|70|Anticipated|National Institute of General Medical Sciences (NIGMS)|||||f||||||||||||||2018-06-01 03:57:29.591339|2018-06-01 03:57:29.591339
NCT00335894|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2010-03-09|2006-06-09|2006-06-12|Estimate|||||||2010-03-09|2010-03-10|Estimate|May 2005||2005-05-31|December 2008|2008-12-31|March 2009||2009-03-31|May 2008|Actual|2008-05-31||Interventional|||Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).|A Prospective, Randomized, Investigator-blind, Controlled, Clinical Study of Phase III on the Efficacy and Tolerability of hMG-IBSA (IBSA) vs Menopur (Ferring) Administered s.c. in Women Undergoing COH in an ART Programme (IVF)|Completed||Phase 3|144|Anticipated|IBSA Institut Biochimique SA|||||f||||||||||||||2018-06-01 03:57:29.679523|2018-06-01 03:57:29.679523
NCT00335881|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2016-10-06|2006-06-09|2006-06-12|Estimate|||||||2016-10-06|2016-10-07|Estimate|June 2006||2006-06-30|October 2016|2016-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib|Multicentre Study to Assess Persistence of Antibodies Against Hepatitis B & Immune Response to a Hepatitis B Challenge Dose in Healthy Children 4 to 6 Years Old Previously Vaccinated With 4 Doses of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine|Completed||Phase 4|300||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:57:29.753768|2018-06-01 03:57:29.753768
NCT00335868|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2013-12-17|2006-06-08|2006-06-12|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2007||2007-03-31|July 2009|2009-07-31||||December 2009|Anticipated|2009-12-31||Interventional|||PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy|A Pilot Phase II Study of PHA-739358 in Patients With Chronic Myeloid Leukemia Relapsing on Gleevec or c-ABL Therapy|Unknown status|Active, not recruiting|Phase 2|16|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:57:29.886674|2018-06-01 03:57:29.886674
NCT00335855|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2010-08-26|2006-06-08|2006-06-12|Estimate|||||||2010-08-26|2010-08-27|Estimate||||April 2009|2009-04-30|October 2006||2006-10-31|||||Interventional|||Pharma-Pen (Formerly Innoject) Auto-injectory TIV|Demonstration of Safety, Effectiveness, and Ease-of-Use of an Advanced Self-Delivery System (Pharma-Pen™) for IM and SC Administration of Vaccines by Untrained Users - Phase I|Withdrawn||Phase 1|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:57:29.948718|2018-06-01 03:57:29.948718
NCT00335829|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2017-04-19||2017-07-24|2006-06-08|2006-06-12|Estimate|2017-07-24|2017-08-28|Actual||||2017-07-24|2017-08-28|Actual|May 2006||2006-05-31|July 2017|2017-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Phase II Trial of Bevacizumab Combined With Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma|Completed||Phase 2|26|Actual|Yale University||1|||f||||t||||||||||2018-06-01 03:57:30.032177|2018-06-01 03:57:30.032177
NCT00335816|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2018-04-05|2006-06-08|2006-06-12|Estimate|||||||2018-04-05|2018-04-09|Actual|August 2008|Actual|2008-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer|Timing of Rectal Cancer Response to Chemoradiation|Active, not recruiting||Phase 2|248|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||t||||||||||2018-06-01 03:57:30.365645|2018-06-01 03:57:30.365645
NCT00335803|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2009-01-22|2006-06-09|2006-06-12|Estimate|||||||2009-01-22|2009-01-23|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|||||Observational|||A Research Study To Compare Two Kinds Of Daily Headache|A Comparison Of Subjects With New Daily Persistent Headache (NDPH) And Subjects With Transformed Migraine (TM)|Completed|||||Thomas Jefferson University|||||f||||||||||||||2018-06-01 03:57:30.463295|2018-06-01 03:57:30.463295
NCT00335790|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2007-04-09|2006-06-09|2006-06-12|Estimate|||||||2007-04-09|2007-04-10|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||A Controlled Trial of the Clinical Effects of Hyperbaric Therapy in Autistic Children|A Prospective, Randomized, Double-Blind, Controlled Study on the Clinical Effects of Hyperbaric Therapy in Autistic Children|Completed||N/A|60||International Hyperbarics Association|||||f||||||||||||||2018-06-01 03:57:30.501139|2018-06-01 03:57:30.501139
NCT00335777|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2010-10-26||2014-03-21|2006-06-09|2006-06-12|Estimate|2011-09-12|2011-10-14|Estimate||||2014-03-21|2014-04-16|Estimate|August 2006||2006-08-31|March 2014|2014-03-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine|An Open-Label Pilot Trial To Collect And Evaluate Data On The Use Of Migranal® In The Treatment Of Two Acute Migraine Attacks Associated With Cutaneous Allodynia|Completed||Phase 4|64|Actual|Thomas Jefferson University||2|||f||||||||||||||2018-06-01 03:57:30.553462|2018-06-01 03:57:30.553462
NCT00335764|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2016-12-28|2006-06-08|2006-06-12|Estimate|||||||2016-12-28|2016-12-29|Estimate|April 2006||2006-04-30|December 2016|2016-12-31|September 2012|Actual|2012-09-30|February 2010|Actual|2010-02-28||Interventional|||Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma|Completed||Phase 1/Phase 2|31|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||No||2018-06-01 03:57:30.681596|2018-06-01 03:57:30.681596
NCT00335751|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2016-01-29|2006-06-08|2006-06-12|Estimate|||||||2016-01-29|2016-02-02|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|October 2011|Actual|2011-10-31|July 2008|Actual|2008-07-31||Interventional|||PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma|Glucose Metabolic Response by PET/CT to Sarcoma Treatments|Completed||N/A|120|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||No||2018-06-01 03:57:30.880157|2018-06-01 03:57:30.880157
NCT00335738|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2015-12-02||2018-03-19|2006-06-08|2006-06-12|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|December 2005||2005-12-31|March 2018|2018-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma|A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy|Completed||Phase 3|331|Actual|Children's Oncology Group|The COG SDC reviewed the NLM notification related to ct.gov AE/SAE reporting. The information in ‘Additional Description’ is accurate with respect to data supplied to ct.gov.COG plans to submit data AE/SAE data consistent with the text in this field.|2|||f||||t||||||||||2018-06-01 03:57:30.973078|2018-06-01 03:57:30.973078
NCT00335725|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|2015-02-12||2015-03-23|2006-06-09|2006-06-12|Estimate|2015-03-23|2015-03-27|Estimate||||2015-03-23|2015-03-27|Estimate|March 2003||2003-03-31|March 2015|2015-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.|Multicentric Prospective, Randomised, Controlled Clinical Study on Clinical Efficacy and Tolerability of Urinary FSH (Fostimon® , IBSA) Versus r-FSH (Gonal-F®, Serono) in ICSI.|Completed||Phase 3|151|Actual|IBSA Institut Biochimique SA||2|||f||||||||||||||2018-06-01 03:57:31.552364|2018-06-01 03:57:31.552364
NCT00335712|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2012-06-12|2006-06-09|2006-06-12|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2006||2006-06-30|June 2012|2012-06-30||||||||Interventional|||Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus|Phase II Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|81|Actual|Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 03:57:31.796181|2018-06-01 03:57:31.796181
NCT00335699|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2007-12-12|2006-06-09|2006-06-12|Estimate|||||||2007-12-12|2007-12-17|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome|A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C|Completed||Phase 4|370||AstraZeneca|||||f||||||||||||||2018-06-01 03:57:31.862732|2018-06-01 03:57:31.862732
NCT00335686|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2008-02-19|2006-06-09|2006-06-12|Estimate|||||||2008-02-19|2008-02-29|Estimate|October 2003||2003-10-31|June 2007|2007-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients|Randomised, Prospective Multicentre Clinical Study on the Effect of the Combination of Lopinavir/Rtv + Nevirapine as Maintenance Bitherapy (Without Nucleoside Analogues) in Comparison With a Triple Therapy Including Lopinavir/Rtv + Nucleoside Analogues in HIV-Infected Patients|Completed||Phase 4|67|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 03:57:31.943977|2018-06-01 03:57:31.943977
NCT00335673|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2011-03-31|2006-06-09|2006-06-12|Estimate|||||||2011-03-31|2011-04-01|Estimate|February 2006||2006-02-28|March 2011|2011-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients|Irbesartan in Mild to Moderate Hypertensive Patients|Completed||Phase 4|1630|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:57:32.060461|2018-06-01 03:57:32.060461
NCT00335660|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2008-02-15|2006-06-09|2006-06-12|Estimate|||||||2008-02-15|2008-02-25|Estimate|June 2006||2006-06-30|February 2008|2008-02-29|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity|Terminated||Phase 2|62|Anticipated|Avera Pharmaceuticals||||Animal Safety Data|f||||||||||||||2018-06-01 03:57:32.11859|2018-06-01 03:57:32.11859
NCT00335647|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2013-11-05|2006-06-08|2006-06-12|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 2006||2006-01-31|April 2008|2008-04-30||||April 2008|Actual|2008-04-30||Interventional|||Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma|A Phase I/IIa, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerance, and Preliminary Activity of Intravenous High-Dose Fluphenazine HCI in Patients With Advanced Multiple Myeloma|Completed||Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:57:32.220438|2018-06-01 03:57:32.220438
NCT00335634|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2015-12-09|2006-06-08|2006-06-12|Estimate|||||||2015-12-09|2015-12-10|Estimate|June 2006||2006-06-30|December 2015|2015-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Sexual Dysfunction and Adaptation in Couples Affected by Prostate Cancer Surgery|Sexual Dysfunction and Adaptation in Couples Affected by Prostate Cancer Surgery: Steps Towards a Bio-Psychosocial Model of Treatment|Completed|||50|Actual|University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:57:32.293188|2018-06-01 03:57:32.293188
NCT00335621|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2010-07-27|2006-06-08|2006-06-12|Estimate|||||||2010-07-27|2010-07-28|Estimate|June 2006||2006-06-30|May 2006|2006-05-31|December 2007||2007-12-31|||||Interventional|||Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable Chronic Obstructive Pulmonary Disease (COPD)|Replacement of Nebulised Ipratropium With Inhaled Tiotropium in Stable COPD|Withdrawn||Phase 4|45|Anticipated|NHS Greater Glasgow and Clyde||||Study terminated prior to recruitment - recruitment proved impossible|f||||||||||||||2018-06-01 03:57:32.373648|2018-06-01 03:57:32.373648
NCT00335595|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2013-02-19|2006-06-09|2006-06-12|Estimate|||||||2013-02-19|2013-02-20|Estimate|July 2006||2006-07-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients|Randomized, Multicenter, Phase III Study, to Evaluate the Efficacy and Safety of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy After Initial Chemotherapy Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients|Completed||Phase 3|480|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-06-01 03:57:32.429787|2018-06-01 03:57:32.429787
NCT00335582|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2009-10-08|2006-06-08|2006-06-12|Estimate|||||||2009-10-08|2009-10-09|Estimate|June 2006||2006-06-30|May 2009|2009-05-31|December 2009|Anticipated|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine)|The EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Study: A Randomized, Double-blinded Trial of Clonidine for Reducing Cardiac Morbidity and Mortality Following Non-cardiac Surgery.|Unknown status|Active, not recruiting|Phase 4|165|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:57:32.502655|2018-06-01 03:57:32.502655
NCT00335569|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-09|||2011-05-31|2006-06-09|2006-06-12|Estimate|||||||2011-05-31|2011-06-01|Estimate|August 2005||2005-08-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|||||Interventional|||Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation|A Prospective, Randomized, Controlled Clinical Study on the Assessment of Tolerance and Clinical Equivalence of hCG- IBSA (IBSA) Versus Ovitrelle (Serono), Both Administered Sub-cutaneously in Women Undergoing in Vitro Fertilization (IVF).|Completed||Phase 3|144|Anticipated|IBSA Institut Biochimique SA|||||f||||f||||||||||2018-06-01 03:57:32.555567|2018-06-01 03:57:32.555567
NCT00335556|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2016-11-28||2017-06-22|2006-06-08|2006-06-12|Estimate|2017-05-12|2017-06-14|Actual||||2017-06-22|2017-07-21|Actual|June 2006||2006-06-30|April 2016|2016-04-30||||December 2015|Actual|2015-12-31||Interventional|||Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors|Treatment of High Risk Renal Tumors: A Groupwide Phase II Study|Completed||Phase 2|291|Actual|Children's Oncology Group||6|||f||||t||||||||||2018-06-01 03:57:32.685032|2018-06-01 03:57:32.685032
NCT00335543|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2013-08-09|2006-06-08|2006-06-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|June 2003||2003-06-30|August 2009|2009-08-31|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery|Preoperative Chemoradiation in Locally Resectable Adenocarcinoma of Pancreatic Head Without Metastasis|Completed||Phase 2|254|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:34.194334|2018-06-01 03:57:34.194334
NCT00335517|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2012-02-16||2014-12-03|2006-06-08|2006-06-12|Estimate|2012-12-05|2013-01-09|Estimate||||2014-12-03|2014-12-19|Estimate|June 2006||2006-06-30|December 2012|2012-12-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|DepoDur||Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients|Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients|Completed||N/A|98|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 03:57:35.249824|2018-06-01 03:57:35.249824
NCT00335504|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2012-11-26||2016-12-28|2006-06-08|2006-06-12|Estimate|2013-01-03|2013-02-08|Estimate||||2016-12-28|2017-02-15|Actual|March 2006||2006-03-31|December 2016|2016-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia|Randomized, Phase II Trial of Atorvastatin, RAFTILOSE Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia|Completed||Phase 2|85|Actual|National Cancer Institute (NCI)|Variation in endpoint measurement across sites, relatively small sample size, and rectal biomarker assessments only may have contributed to challenges in full data interpretation.|4|||f||||||||||||||2018-06-01 03:57:35.400435|2018-06-01 03:57:35.400435
NCT00335491|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2011-09-28|2006-06-08|2006-06-12|Estimate|||||||2011-09-28|2011-09-30|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors|A RENEW Intervention for Elderly Cancer Survivors|Completed||N/A|49|Actual|University of Utah|||||f||||t||||||||||2018-06-01 03:57:35.882926|2018-06-01 03:57:35.882926
NCT00335478|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2011-06-07||2017-05-07|2006-06-08|2006-06-12|Estimate|2011-07-12|2011-08-09|Estimate||||2017-05-07|2017-05-09|Actual|December 2006||2006-12-31|May 2017|2017-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Daptomycin in Treating Neutropenia and Fever in Patients With Cancer|Phase II Open Label Pilot Trial of Empiric Daptomycin Treatment for Oncology Patients With Neutropenic Fever|Completed||Phase 2|54|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 03:57:36.023394|2018-06-01 03:57:36.023394
NCT00335465|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2009-12-04|2006-06-08|2006-06-09|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 2005||2005-09-30|December 2009|2009-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Lantus Effect on Myocardial Glucose Metabolism in T2|Pilot Study for the Evaluation of the Effects of Insulin Treatment on Myocardial Function, Perfusion, and Glucose Metabolism in Patients With Primary Left Ventricular Dysfunction and Type 2 Diabetes.|Completed||Phase 4|15|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:57:36.175862|2018-06-01 03:57:36.175862
NCT00335452|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2010-09-15||2010-11-09|2006-06-08|2006-06-09|Estimate|2010-09-15|2010-10-07|Estimate||||2010-11-09|2010-11-18|Estimate|June 2006||2006-06-30|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|CURRENT/OASIS7||Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS|Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.|Completed||Phase 3|25086|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 03:57:36.373544|2018-06-01 03:57:36.373544
NCT00335439|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2016-01-12|2006-06-08|2006-06-09|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2006||2006-06-30|January 2016|2016-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effect of Prophylactic Ketorolac on CME After Cataract Surgery|Effect of Prophylactic NSAID Drops on Cystoid Macular Edema After Cataract Surgery Using Optical Coherence Tomography|Completed||N/A|98|Actual|Queen's University|||||f||||||||||||||2018-06-01 03:57:39.571192|2018-06-01 03:57:39.571192
NCT00335426|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2009-08-28|2006-06-07|2006-06-09|Estimate|||||||2009-08-28|2009-09-01|Estimate|June 2006||2006-06-30|August 2009|2009-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Influence of Spinal Manipulative Therapy Upon Stroop Task Performance||Completed||N/A|||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 03:57:39.6261|2018-06-01 03:57:39.6261
NCT00325104|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2017-06-30|2006-05-11|2006-05-12|Estimate|||||||2017-06-30|2017-07-02|Actual|May 9, 2006||2006-05-09|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Interventional|||Cinacalcet to Treat Familial Primary Hyperparathyroidism|Cinacalcet Actions in Familial Primary Hyperparathyroidism|Completed||Phase 3|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:00:28.498572|2018-06-01 04:00:28.498572
NCT00335413|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2008-06-04|2006-06-07|2006-06-09|Estimate|||||||2008-06-04|2008-06-05|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|April 2007|Actual|2007-04-30|||||Interventional|||Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy|Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy|Completed||Phase 4|17|Actual|Steno Diabetes Center|||||f||||||||||||||2018-06-01 03:57:39.673818|2018-06-01 03:57:39.673818
NCT00335400|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2016-01-12|2006-06-08|2006-06-09|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Anesthetic and Dilating Gel for Cataract Surgery|Comparison of an Anesthetic and Dilating Gel Cocktail Versus the Standard Pre-operative Pharmacologic Regimen for Cataract Surgery on Corneal Anesthesia and Pupil Dilation.|Completed||N/A|20|Anticipated|Queen's University|||||f||||||||||||||2018-06-01 03:57:39.726173|2018-06-01 03:57:39.726173
NCT00335374|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2009-02-05|2006-06-08|2006-06-09|Estimate|||||||2009-02-05|2009-02-06|Estimate|August 2007||2007-08-31|February 2009|2009-02-28|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients|An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients|Completed||Phase 3|202|Actual|Solvay Pharmaceuticals||1|||f||||t||||||||||2018-06-01 03:57:39.797035|2018-06-01 03:57:39.797035
NCT00335361|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2007-04-05|2006-06-07|2006-06-09|Estimate|||||||2007-04-05|2007-04-06|Estimate|September 2006||2006-09-30|April 2007|2007-04-30|September 2009|Anticipated|2009-09-30|||||Interventional|||Implantable Device for Male Reproductive Sterilization|The Intra Vas Device (IVD) As A Means of Male Reproductive Sterilization A Single Armed Feasibility Study|Unknown status|Active, not recruiting|Phase 1|90||Shepherd Medical Company|||||f||||||||||||||2018-06-01 03:57:40.033448|2018-06-01 03:57:40.033448
NCT00335348|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-01-07|2006-06-07|2006-06-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|June 2006||2006-06-30|August 2011|2011-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse|Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse An Australian Myeloma Forum Multi-Centre Phase II Trial|Completed||Phase 2|101|Actual|Peter MacCallum Cancer Centre, Australia||1|||f||||||||||||||2018-06-01 03:57:40.09177|2018-06-01 03:57:40.09177
NCT00335335|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2007-06-28|2006-06-07|2006-06-09|Estimate|||||||2007-06-28|2007-07-02|Estimate|May 2006||2006-05-31|June 2007|2007-06-30||||||||Interventional|||Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast–Enhanced CT Angiography of Arteries of the Heart||Completed||Phase 3|540||GE Healthcare|||||||||||||||||||2018-06-01 03:57:40.162434|2018-06-01 03:57:40.162434
NCT00335322|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2012-04-17||2012-04-17|2006-06-08|2006-06-09|Estimate|2012-04-17|2012-05-15|Estimate||||2012-04-17|2012-05-15|Estimate|February 2007||2007-02-28|April 2012|2012-04-30|November 2011|Actual|2011-11-30|March 2011|Actual|2011-03-31||Interventional|||ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens|A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection.|Completed||Phase 4|329|Actual|Kirby Institute|Inadequate sample size for true comparison of non-inferiority|3|||f||||t||||||||||2018-06-01 03:57:40.220829|2018-06-01 03:57:40.220829
NCT00335309|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2013-10-06|2006-06-08|2006-06-09|Estimate|||||||2013-10-06|2013-10-08|Estimate|October 2005||2005-10-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Maxillary Sinus Irrigation in the Management of Chronic Rhinosinusitis|Effectiveness of Maxillary Sinus Saline Irrigation in Conjunction With Systemic Antibiotic Therapy Versus Systemic Antibiotic Therapy Alone in the Management of Chronic Rhinosinusitis, a Prospective Randomized Controlled Trial|Completed||N/A|50|Actual|Carmel Medical Center||2|||f||||t||||||||||2018-06-01 03:57:40.686044|2018-06-01 03:57:40.686044
NCT00335296|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2007-12-18|2006-06-08|2006-06-09|Estimate|||||||2007-12-18|2007-12-24|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|||PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)|The Paradigm IIca/III Trial: PFx Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness|Suspended||N/A|100|Anticipated|Cierra|||||f||||||||||||||2018-06-01 03:57:40.76128|2018-06-01 03:57:40.76128
NCT00335283|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|2011-03-28||2012-07-17|2006-06-07|2006-06-09|Estimate|2012-07-17|2012-08-21|Estimate||||2012-07-17|2012-08-21|Estimate|August 2006||2006-08-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PND||Efficacy of Lansoprazole in Chronic Post Nasal Drip|Randomized Placebo-Controlled Trial of BID Lansoprazole in Isolated Chronic Post Nasal Drip|Completed||Phase 3|75|Actual|Vanderbilt University|Sample size of 75 participants is small. Lack of an objective measure of postnasal drainage limited the study outcome to be symptom based.|2|||f||||f||||||||||2018-06-01 03:57:40.841599|2018-06-01 03:57:40.841599
NCT00335270|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-05-13|2006-06-07|2006-06-09|Estimate|||||||2013-05-13|2013-05-14|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|December 2007||2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination|A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination|Completed||Phase 4|100||Duke University|||||f||||||||||||||2018-06-01 03:57:41.144819|2018-06-01 03:57:41.144819
NCT00335257|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2014-11-06||2014-11-14|2006-06-08|2006-06-09|Estimate|2014-11-14|2014-11-18|Estimate||||2014-11-14|2014-11-18|Estimate|August 2005||2005-08-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC)|International Active Surveillance Study of Women Taking Oral Contraceptives (INAS OC)|Completed|||85109|Actual|Center for Epidemiology and Health Research, Germany|In non-experimental studies the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.||2||f||||t||||||||||2018-06-01 03:57:41.394558|2018-06-01 03:57:41.394558
NCT00335244|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07||2013-05-21|2015-01-26|2006-06-07|2006-06-09|Estimate||||2013-05-21|2013-05-29|Estimate|2015-01-26|2015-02-02|Estimate|May 2006||2006-05-31|January 2015|2015-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery|A Phase III Single-Blind, Randomized, Placebo Controlled, Clinical Trial to Determine the Safety and Efficacy of Intravenous L-Citrulline Versus Placebo in Children Undergoing Cardiopulmonary Bypass|Completed||Phase 3|77|Actual|Asklepion Pharmaceuticals, LLC||2|||f||||t||||||||||2018-06-01 03:57:41.843243|2018-06-01 03:57:41.843243
NCT00335231|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2018-04-30|2006-06-08|2006-06-09|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2006||2006-06-30|April 2018|2018-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery|The Effect of Preoperative Topical Gatifloxacin on Anterior Chamber Sample Cultures After Cataract Surgery.|Withdrawn||N/A|0|Actual|Queen's University||2||Protocol changes underway. Trial never started|f||||||||||||||2018-06-01 03:57:41.913152|2018-06-01 03:57:41.913152
NCT00335218|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2014-12-29|2006-06-08|2006-06-09|Estimate|||||||2014-12-29|2014-12-30|Estimate|July 2002||2002-07-31|December 2014|2014-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Fat Distribution in Healthy Early Postmenopausal Women|A Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled, Two-arm, Phase IV Study to Investigate the Influence of a Continuous Combined Estrogen-progestin Regimen Containing 2 mg Estradiol Valerate and 2 mg Dienogest (Climodien® / Lafamme®) on the Fat Distribution in Otherwise Healthy Early Postmenopausal Women|Completed||Phase 4|67|Actual|Bayer||2|||f||||f||||||||||2018-06-01 03:57:41.974379|2018-06-01 03:57:41.974379
NCT00335205|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2006-06-08|2006-06-08|2006-06-09|Estimate|||||||2006-06-08|2006-06-09|Estimate|April 2003||2003-04-30|June 2006|2006-06-30||||||||Interventional|||A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.|A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression.|Unknown status|Recruiting|Phase 4|60||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:57:42.12483|2018-06-01 03:57:42.12483
NCT00335192|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2008-09-05|2006-06-08|2006-06-09|Estimate|||||||2008-09-05|2008-09-08|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir|Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients Treated With Abacavir and/or Lamivudine Given With or Without TDF.|Completed||Phase 4|32|Actual|Germans Trias i Pujol Hospital||3|||f||||f||||||||||2018-06-01 03:57:42.196266|2018-06-01 03:57:42.196266
NCT00335179|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2010-07-22|2006-06-08|2006-06-09|Estimate|||||||2010-07-22|2010-07-23|Estimate|January 2003||2003-01-31|July 2010|2010-07-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream|Double-Blind, Vehicle-Controlled Study to Evaluate Cellular and Molecular Events During Four Weeks of Treatment for Actinic Keratosis With Aldara (Imiquimod) Cream, 5%|Completed||Phase 2|17|Actual|Graceway Pharmaceuticals, LLC||2|||f||||f||||||||||2018-06-01 03:57:42.273119|2018-06-01 03:57:42.273119
NCT00335166|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|||2008-04-01|2006-06-08|2006-06-09|Estimate|||||||2008-04-01|2008-04-03|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease|A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.|Completed||Phase 3|330|Anticipated|Solvay Pharmaceuticals||3|||f||||t||||||||||2018-06-01 03:57:42.360023|2018-06-01 03:57:42.360023
NCT00335153|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-08|2015-01-12|2013-06-14|2015-01-12|2006-06-08|2006-06-09|Estimate|2015-01-12|2015-01-16|Estimate|2013-06-14|2013-06-24|Estimate|2015-01-12|2015-01-16|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease|An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications|Completed||Phase 3|354|Actual|AbbVie||1|||f||||t||||||||||2018-06-01 03:57:42.602171|2018-06-01 03:57:42.602171
NCT00335140|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|2017-04-17||2017-05-23|2006-06-07|2006-06-08|Estimate|2017-05-23|2017-06-28|Actual||||2017-05-23|2017-06-28|Actual|December 2006||2006-12-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Eligible patients who began protocol therapy|Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma|Terminated||Phase 2|26|Actual|Eastern Cooperative Oncology Group||1||slow accrual|f||||f|t|f||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 03:57:43.805623|2018-06-01 03:57:43.805623
NCT00335114|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2006-06-08|2006-06-07|2006-06-08|Estimate|||||||2006-06-08|2006-06-09|Estimate|November 2005||2005-11-30|June 2006|2006-06-30|April 2006||2006-04-30|||||Interventional|||Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers|Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers|Completed||N/A|40||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 03:57:44.241455|2018-06-01 03:57:44.241455
NCT00335101|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2007-05-14|2006-06-06|2006-06-08|Estimate|||||||2007-05-14|2007-05-15|Estimate|June 2006||2006-06-30|May 2007|2007-05-31||||||||Interventional|||Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography||Terminated||Phase 4|384||GE Healthcare|||||f||||||||||||||2018-06-01 03:57:44.295517|2018-06-01 03:57:44.295517
NCT00335088|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2007-05-31|2006-06-07|2006-06-08|Estimate|||||||2007-05-31|2007-06-01|Estimate|June 2006||2006-06-30|March 2007|2007-03-31|May 2007|Anticipated|2007-05-31|||||Interventional|||Local Moxifloxacin and Povidone Iodine Versus Povidone Iodine Alone as a Prophylaxis Before Eye Operations||Unknown status|Recruiting|Phase 3|500|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 03:57:44.349684|2018-06-01 03:57:44.349684
NCT00335075|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2017-05-12|2006-06-06|2006-06-08|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2, 2005|Actual|2005-03-02|May 2017|2017-05-31|February 23, 2006|Actual|2006-02-23|February 23, 2006|Actual|2006-02-23||Interventional|||Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)|A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma|Completed||Phase 3|151|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 03:57:44.430524|2018-06-01 03:57:44.430524
NCT00335062|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2014-07-24|2006-06-06|2006-06-08|Estimate|||||||2014-07-24|2014-07-25|Estimate|August 2005||2005-08-31|July 2014|2014-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease|TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease|Completed|||19|Actual|Boston Children’s Hospital|||||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells.~   "|||2018-06-01 03:57:44.489584|2018-06-01 03:57:44.489584
NCT00335049|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2010-10-07|2006-06-07|2006-06-08|Estimate|||||||2010-10-07|2010-10-08|Estimate|December 2006||2006-12-31|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Study of Theories About Myopia Progression (STAMP)|Study of Theories About Myopia Progression (STAMP)|Completed||N/A|85|Actual|Ohio State University||2|||f||||t||||||||||2018-06-01 03:57:44.544287|2018-06-01 03:57:44.544287
NCT00325091|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2018-05-23|2006-05-11|2006-05-12|Estimate|||||||2018-05-23|2018-05-24|Actual|May 9, 2006||2006-05-09|January 6, 2014|2014-01-06|January 6, 2014||2014-01-06|||||Observational|||Long-Term Motor Learning in Focal Hand Dystonia|Long-Term Motor Learning in Focal Hand Dystonia|Completed|||19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:00:28.567957|2018-06-01 04:00:28.567957
NCT00335036|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2017-07-05|2006-06-06|2006-06-08|Estimate|||||||2017-07-05|2017-07-07|Actual|June 2006||2006-06-30|July 2017|2017-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pediatric Lead Extractability and Survival Evaluation (PLEASE)|Pediatric Lead Extractability and Survival Evaluation (PLEASE)Study: A Prospective Assessment of Implantable Cardioverter Defibrillator (ICD) Lead Extractability and Survival in Children and Congenital Heart Disease Patients|Terminated||N/A|55|Actual|Children's Research Institute||2||Lead was recalled and manufacturing halted|f||||t||||||||||2018-06-01 03:57:44.612507|2018-06-01 03:57:44.612507
NCT00335023|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2011-07-19|2006-06-07|2006-06-08|Estimate|||||||2011-07-19|2011-07-20|Estimate|May 2004||2004-05-31|July 2011|2011-07-31||||March 2011|Actual|2011-03-31||Interventional|WOMB||Well Being of Obstetric Patients on Minimal Blood Transfusions|Well Being of Obstetric Patients on Minimal Blood Transfusions|Completed||Phase 4|500|Actual|Sanquin Research & Blood Bank Divisions||2|||f||||f||||||||||2018-06-01 03:57:44.79763|2018-06-01 03:57:44.79763
NCT00335010|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2006-06-07|2006-06-07|2006-06-08|Estimate|||||||2006-06-07|2006-06-08|Estimate|May 2005||2005-05-31|June 2006|2006-06-30|December 2005||2005-12-31|||||Interventional|||Intravenous NTG to Preserve Gastric Microcirculation During Gastric Tube Reconstruction|A Prospective Double Blinded Study on the Effect of Intravenously Administrated Nitroglycerine on Gastric Tissue Microvascular Bloodflow and Microvascular Hemoglobin Saturation During Gastric Tube Reconstruction|Completed||N/A|32||Erasmus Medical Center|||||f||||||||||||||2018-06-01 03:57:44.868021|2018-06-01 03:57:44.868021
NCT00334997|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-12-18|2006-06-07|2006-06-08|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Endoscopic Surgery or Radiation Therapy in Treating Patients With Stage 0, Stage I, or Stage II Laryngeal Cancer of the Glottis|Early Stage Glottic Cancer: Endoscopic Excision or Radiotherapy [EaStER]|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:44.936214|2018-06-01 03:57:44.936214
NCT00334984|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-07-09|2006-06-07|2006-06-08|Estimate|||||||2013-07-09|2013-07-11|Estimate|January 2007||2007-01-31|July 2013|2013-07-31||||||||Interventional|||Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma|Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study|Withdrawn||N/A|0|Actual|Children's Oncology Group||||Withdrawn due to inability to reach an acceptable agreement with industry sponsor|||||||||||||||2018-06-01 03:57:44.998585|2018-06-01 03:57:44.998585
NCT00334971|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-11-05|2006-06-07|2006-06-08|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2004||2004-09-30|November 2013|2013-11-30|January 2018|Anticipated|2018-01-31|January 2012|Actual|2012-01-31||Interventional|||Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women|Aromatase Activity and Ovarian Growth Factors in Preovulatory Follicles|Unknown status|Active, not recruiting|N/A|116|Anticipated|Massachusetts General Hospital||4|||f||||t||||||||||2018-06-01 03:57:45.056245|2018-06-01 03:57:45.056245
NCT00334958|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|2012-04-16||2013-01-02|2006-06-07|2006-06-08|Estimate|2013-01-02|2013-02-05|Estimate||||2013-01-02|2013-02-05|Estimate|February 2006||2006-02-28|January 2013|2013-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|Completed||Phase 3|356|Actual|Eisai Inc.||2|||f||||f||||||||||2018-06-01 03:57:45.166731|2018-06-01 03:57:45.166731
NCT00334945|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2011-11-11|2006-06-07|2006-06-08|Estimate|||||||2011-11-11|2011-11-16|Estimate|April 2006||2006-04-30|November 2011|2011-11-30|August 2011|Actual|2011-08-31|June 2010|Actual|2010-06-30||Observational|||Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent|Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23 (a Known Phosphaturic Agent)|Completed|||35|Actual|University of Alabama at Birmingham|||2||f||||f||||||||||2018-06-01 03:57:45.660671|2018-06-01 03:57:45.660671
NCT00334932|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2014-01-09|2006-06-07|2006-06-08|Estimate|||||||2014-01-09|2014-01-10|Estimate|February 2006||2006-02-28|August 2008|2008-08-31||||January 2010|Anticipated|2010-01-31||Interventional|||Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma|Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|32|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:45.716864|2018-06-01 03:57:45.716864
NCT00334919|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2010-06-23|2006-06-06|2006-06-08|Estimate|||||||2010-06-23|2010-06-24|Estimate|May 2006||2006-05-31|May 2009|2009-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||RCT of the Naturopathic Anti-Inflammatory Diet|Randomized Clinical Trial of the Naturopathic Anti-Inflammatory Diet|Completed||Phase 2|30|Actual|National University of Natural Medicine|||||f||||t||||||||||2018-06-01 03:57:45.786422|2018-06-01 03:57:45.786422
NCT00334906|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2008-01-03|2006-06-06|2006-06-08|Estimate|||||||2008-01-03|2008-01-07|Estimate|July 2005||2005-07-31|January 2008|2008-01-31||||November 2007|Actual|2007-11-30||Interventional|||Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)|An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type|Completed||Phase 4|75||Forest Laboratories|||||||||||||||||||2018-06-01 03:57:45.856098|2018-06-01 03:57:45.856098
NCT00334893|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|2013-10-16||2017-10-24|2006-06-07|2006-06-08|Estimate|2013-10-16|2013-12-10|Estimate||||2017-10-24|2017-11-29|Actual|April 2006||2006-04-30|October 2017|2017-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer|A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer|Completed||Phase 2|74|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:57:45.932002|2018-06-01 03:57:45.932002
NCT00334880|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2009-07-01|2006-06-07|2006-06-08|Estimate|||||||2009-07-01|2009-07-02|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|November 2006|Actual|2006-11-30|||||Interventional|||Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|420|Actual|New River Pharmaceuticals|||||f||||f||||||||||2018-06-01 03:57:46.260468|2018-06-01 03:57:46.260468
NCT00334867|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-06-27|2006-06-07|2006-06-08|Estimate|||||||2013-06-27|2013-06-28|Estimate|December 2005||2005-12-31|June 2013|2013-06-30||||January 2006|Actual|2006-01-31||Interventional|||Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma|A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma|Withdrawn||Phase 3|0|Actual|Children's Oncology Group||2||withdrawn|f||||||||||||||2018-06-01 03:57:46.378865|2018-06-01 03:57:46.378865
NCT00334854|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-08-09|2006-06-07|2006-06-08|Estimate|||||||2013-08-09|2013-08-12|Estimate|March 2006||2006-03-31|July 2009|2009-07-31||||May 2010|Anticipated|2010-05-31||Interventional|||Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma|Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas|Unknown status|Recruiting|Phase 3|250|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:46.462511|2018-06-01 03:57:46.462511
NCT00334841|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2007-11-05|2006-06-07|2006-06-08|Estimate|||||||2007-11-05|2007-11-06|Estimate|July 2006||2006-07-31|May 2006|2006-05-31||||||||Observational|||Leptin and Cytokines in Diabetic Pregnancy - Physiologic or Pathogenic Role|Leptin and Cytokines in Diabetic Pregnancy - Physiologic or Pathogenic Role|Unknown status|Recruiting||30|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:57:46.591506|2018-06-01 03:57:46.591506
NCT00334828|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06||2013-05-21|2017-07-21|2006-06-06|2006-06-08|Estimate||||2013-05-21|2013-05-29|Estimate|2017-07-21|2017-07-25|Actual|June 2006||2006-06-30|July 2017|2017-07-31||||January 2011|Actual|2011-01-31||Interventional|||ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis|ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis|Completed||Phase 3|2000|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 03:57:46.661683|2018-06-01 03:57:46.661683
NCT00334815|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|2015-09-22||2018-03-22|2006-06-07|2006-06-08|Estimate|2016-01-29|2016-02-29|Estimate||||2018-03-22|2018-04-20|Actual|June 15, 2006|Actual|2006-06-15|March 2018|2018-03-31||||July 1, 2014|Actual|2014-07-01||Interventional||All eligible patients who received protocol treatment.|Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer|Active, not recruiting||Phase 2|29|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 03:57:47.24334|2018-06-01 03:57:47.24334
NCT00334802|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|2009-05-29||2010-03-10|2006-06-06|2006-06-08|Estimate|2009-05-29|2009-07-20|Estimate||||2010-03-10|2010-03-16|Estimate|June 2006||2006-06-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|February 2008|Actual|2008-02-29||Interventional|||Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer|Combination Study of LY188011 and Paclitaxel in Patients With Metastatic/Recurrent Breast Cancer After Neo-adjuvant/Adjuvant Chemotherapy With Anthracycline|Completed||Phase 2|62|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 03:57:48.176469|2018-06-01 03:57:48.176469
NCT00334789|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2018-04-02|2006-06-07|2006-06-08|Estimate|||||||2018-04-02|2018-04-03|Actual|June 12, 2006|Actual|2006-06-12|October 2017|2017-10-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery|A Phase 1 Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies|Completed||Phase 1|51|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:57:48.875941|2018-06-01 03:57:48.875941
NCT00334776|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2014-05-19|2006-06-07|2006-06-08|Estimate|||||||2014-05-19|2014-05-21|Estimate|October 2003||2003-10-31|May 2014|2014-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma|Completed||Phase 2|6|Actual|University of Southern California|||||f||||||||||||||2018-06-01 03:57:48.957547|2018-06-01 03:57:48.957547
NCT00334763|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2012-07-09|2006-06-07|2006-06-08|Estimate|||||||2012-07-09|2012-07-10|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|November 2007|Actual|2007-11-30|May 2007|Actual|2007-05-31||Interventional|||Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Radiation Followed by Paclitaxel, Carboplatin, and Bevacizumab (PCA) in Patients With Stage IIIB and IV Squamous Non-Small Cell Lung Cancer|Terminated||Phase 2|32|Anticipated|Northwestern University||||Principal Investigator felt risk to patients was too high.|||||||||||||||2018-06-01 03:57:49.040075|2018-06-01 03:57:49.040075
NCT00334750|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2010-09-08|2006-06-05|2006-06-08|Estimate|||||||2010-09-08|2010-09-09|Estimate|November 2007||2007-11-30|September 2010|2010-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada|Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada|Completed|||410|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 03:57:49.125145|2018-06-01 03:57:49.125145
NCT00334737|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-11-06|2006-06-07|2006-06-08|Estimate|||||||2013-11-06|2013-11-08|Estimate|June 2006||2006-06-30|September 2013|2013-09-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Darbepoetin Administration to Preterm Infants|A Randomized, Masked, Placebo Controlled Study to Assess the Safety and Efficacy of Darbepoetin Alfa Administered to Preterm Infants|Unknown status|Active, not recruiting|Phase 2|102|Actual|University of New Mexico||3|||f||||t||||||||||2018-06-01 03:57:49.213033|2018-06-01 03:57:49.213033
NCT00334724|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2015-12-28|2006-06-07|2006-06-08|Estimate|||||||2015-12-28|2015-12-29|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study|Home Blood Pressure-guided Antihypertensive Intervention for Elderly (HBP-GUIDE) Study|Withdrawn||Phase 4|0|Actual|Kyoto University, Graduate School of Medicine||2||Patients were not appropriately enrolled|f||||t||||||||||2018-06-01 03:57:49.297017|2018-06-01 03:57:49.297017
NCT00334711|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2006-11-28|2006-06-07|2006-06-08|Estimate|||||||2006-11-28|2006-11-29|Estimate|January 2004||2004-01-31|June 2006|2006-06-30|January 2006||2006-01-31|||||Interventional|||Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations|A Prospective Study of Sulfonylureas in Patients With Diabetes Due to Kir6.2 Mutations|Completed||N/A|50||Royal Devon and Exeter NHS Foundation Trust|||||f||||||||||||||2018-06-01 03:57:49.359476|2018-06-01 03:57:49.359476
NCT00334698|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2010-02-02|2006-06-07|2006-06-08|Estimate|||||||2010-02-02|2010-02-03|Estimate|July 2006||2006-07-31|May 2007|2007-05-31|September 2006|Actual|2006-09-30|||||Interventional|||Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms in Patients With Allergic Rhinitis|A Randomized, Double Blind, Placebo-controlled, Four Way Cross-over Study to Assess the Effect of a Combination of Cetirizine With Pseudoephedrine Versus Cetirizine Alone on Symptoms Scores and Rhinomanometry in Patients With Allergic Rhinitis Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC)|Completed||N/A|51|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||||||||||||2018-06-01 03:57:49.415491|2018-06-01 03:57:49.415491
NCT00330525|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2010-01-19|2006-05-25|2006-05-29|Estimate|||||||2010-01-19|2010-01-20|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity|Pharmacodynamic Effects of Sibutramine on Gastric Function in Obesity|Completed||Phase 2|72|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 03:58:48.238926|2018-06-01 03:58:48.238926
NCT00334685|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2008-07-15|2006-06-07|2006-06-08|Estimate|||||||2008-07-15|2008-07-17|Estimate|July 2006||2006-07-31|July 2008|2008-07-31||||||||Interventional|||[S,S]-Reboxetine Add-On Trial|[S,S]-Reboxetine Add-On Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN) Concomitantly Treated With Pregabalin.|Terminated||Phase 2|354||Pfizer||||The DMC terminated the study on the basis of futility (insufficient clinical response).|f||||t||||||||||2018-06-01 03:57:49.469559|2018-06-01 03:57:49.469559
NCT00334672|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2013-09-16|2006-06-07|2006-06-08|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2006||2006-03-31|June 2009|2009-06-30||||November 2010|Anticipated|2010-11-30||Interventional|||Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis|Hemophagocytic Lymphohistiocytosis|Unknown status|Active, not recruiting|Phase 3|288|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 03:57:50.530017|2018-06-01 03:57:50.530017
NCT00334659|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2011-06-21|2006-06-06|2006-06-08|Estimate|||||||2011-06-21|2011-06-23|Estimate|June 2006||2006-06-30|June 2011|2011-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects|A Double-blind, Placebo-controlled, Positive Controlled, Randomized, Crossover Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects|Completed||Phase 1|37|Actual|Avexa|||||f||||f||||||||||2018-06-01 03:57:50.608159|2018-06-01 03:57:50.608159
NCT00334646|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2017-11-13|2006-06-06|2006-06-08|Estimate|||||||2017-11-13|2017-11-17|Actual|August 10, 2005|Actual|2005-08-10|November 2017|2017-11-30|October 14, 2009|Actual|2009-10-14|October 14, 2009|Actual|2009-10-14||Interventional|||Cyclophosphamide Drug Interaction Study In Cancer Patients|An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 and Intravenous Cyclophosphamide in Cancer Patients|Terminated||Phase 1|25|Actual|GlaxoSmithKline||2||compound terminated|f||||||||||||||2018-06-01 03:57:50.66318|2018-06-01 03:57:50.66318
NCT00334633|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|2011-03-03||2017-10-26|2006-06-07|2006-06-08|Estimate|2011-05-24|2011-06-23|Estimate||||2017-10-26|2017-12-02|Actual|November 2004||2004-11-30|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Treatment of Bacterial Vaginosis (BV) With Tinidazole|Tinidazole for the Treatment of Bacterial Vaginosis|Completed||Phase 4|593|Actual|University of Alabama at Birmingham||3|||f||||||||||||||2018-06-01 03:57:50.751104|2018-06-01 03:57:50.751104
NCT00334620|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2006-06-07|2006-06-07|2006-06-08|Estimate|||||||2006-06-07|2006-06-08|Estimate|July 1998||1998-07-31|November 2005|2005-11-30|May 2005||2005-05-31|||||Interventional|||Effectiveness of Radon Spa Therapy in Multimodal Rehabilitative Treatment of Rheumatoid Arthritis||Completed||Phase 4|140||Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster|||||f||||||||||||||2018-06-01 03:57:50.98897|2018-06-01 03:57:50.98897
NCT00334607|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2016-11-02|2006-06-07|2006-06-08|Estimate|||||||2016-11-02|2016-11-04|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Interventional|||Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA|Assess the Immunogenicity of 3 Doses of Pediarix®, Prevnar® & ActHIB® Given to Healthy Infants When Administered With GSK Biologicals' 2 Dose Oral Live Attenuated Human Rotavirus Vaccine Given During the Same Vaccination Visit or Separately|Completed||Phase 3|484|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:57:51.145355|2018-06-01 03:57:51.145355
NCT00334594|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2017-12-12|2006-06-07|2006-06-08|Estimate|||||||2017-12-12|2017-12-13|Actual|November 14, 2005|Actual|2005-11-14|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|March 26, 2014|Actual|2014-03-26||Interventional|||Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma|Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma (MPM) With or Without Hemithoracic Radiotherapy. A Randomized Multicenter Phase II Trial|Active, not recruiting||Phase 2|153|Actual|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||||2018-06-01 03:57:51.302622|2018-06-01 03:57:51.302622
NCT00334581|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2009-09-14|2006-06-07|2006-06-08|Estimate|||||||2009-09-14|2009-09-15|Estimate|May 2006||2006-05-31|September 2009|2009-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria|A Study of Irbesartan 150mg Verses 300mg in Chinese Hypertensive Patients With Diabetes and Microalbuminuria|Completed||Phase 4|192|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:57:51.42317|2018-06-01 03:57:51.42317
NCT00334568|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2013-01-10|2006-06-06|2006-06-08|Estimate|||||||2013-01-10|2013-01-14|Estimate|December 2004||2004-12-31|January 2013|2013-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease|A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilisation and Cognition in Subjects With Mild to Moderate Alzheimers Disease (AD)|Terminated||Phase 2|12|Actual|GlaxoSmithKline||2||Slow recruitment|f||||||||||||||2018-06-01 03:57:51.498014|2018-06-01 03:57:51.498014
NCT00334555|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2009-08-11|2006-06-07|2006-06-08|Estimate|||||||2009-08-11|2009-08-12|Estimate|May 2003||2003-05-31|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Control of Trichomoniasis|Control of Trichomoniasis - A Paradigm for STD Control|Completed||N/A|599|Actual|University of Alabama at Birmingham||3|||f||||||||||||||2018-06-01 03:57:51.566139|2018-06-01 03:57:51.566139
NCT00334542|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|2013-03-18||2013-07-03|2006-06-07|2006-06-08|Estimate|2013-05-15|2013-06-25|Estimate||||2013-07-03|2013-07-18|Estimate|March 2006||2006-03-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|June 2009|Actual|2009-06-30||Interventional|||Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer|A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer|Completed||Phase 2|50|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 03:57:51.660198|2018-06-01 03:57:51.660198
NCT00334529|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2017-06-30|2006-06-07|2006-06-08|Estimate|||||||2017-06-30|2017-07-02|Actual|June 5, 2006||2006-06-05|September 23, 2009|2009-09-23|April 10, 2007|Actual|2007-04-10|April 10, 2007|Actual|2007-04-10||Interventional|||Alternative Oseltamivir Dosing Strategies|Evaluation of Alternative Oseltamivir (Tamiflu[R]) Dosing Strategies for Use During Influenza Prophylaxis|Completed||Phase 2|48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:57:51.82454|2018-06-01 03:57:51.82454
NCT00334516|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-07|||2018-04-03|2006-06-07|2006-06-08|Estimate|||||||2018-04-03|2018-04-04|Actual|June 6, 2006||2006-06-06|August 3, 2015|2015-08-03|August 3, 2015||2015-08-03|||||Observational|||Brain Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis|Cortical Function in Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis|Completed|||77|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:57:51.883154|2018-06-01 03:57:51.883154
NCT00334490|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2015-07-30|2006-06-06|2006-06-07|Estimate|||||||2015-07-30|2015-07-31|Estimate|March 2005||2005-03-31|July 2015|2015-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?|A Phase II, Double Blind Randomized Controlled Trial to Determine the Safety and Efficacy of 12.5mg of Oral Sildenafil (Viagra) Compared to Placebo to Decrease Pulmonary Hypertension in Cardiac Patients After Cardiopulmonary Bypass|Completed||Phase 2|40|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-06-01 03:57:52.014625|2018-06-01 03:57:52.014625
NCT00334477|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2006-06-06|2006-06-06|2006-06-07|Estimate|||||||2006-06-06|2006-06-07|Estimate||||April 2006|2006-04-30||||||||Interventional|||Efficacy and Safety of Tadalafil in Hemodialysis Patients|Efficacy and Safety of Tadalafil 20mg for the Treatment of Erectile Dysfunction in Chronic Renal Patients in Hemodialysis.|Unknown status|Not yet recruiting|Phase 2|60||University of Pernambuco|||||f||||||||||||||2018-06-01 03:57:52.118402|2018-06-01 03:57:52.118402
NCT00334464|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2008-08-20|2006-06-05|2006-06-07|Estimate|||||||2008-08-20|2008-08-21|Estimate|February 2006||2006-02-28|August 2008|2008-08-31|November 2007|Actual|2007-11-30|||||Interventional|||"A Pharmacogenetic Study of Warfarin Dosing, The COUMA-GEN Study"|A Controlled Clinical Pharmacogenetic Study of a CYP2C9 Plus VKORC1 Polymorphism-Based Individualized Dosing Algorithm for Warfarin to Increase Efficiency of Achieving Therapeutic Dosing|Completed||N/A|200|Anticipated|Intermountain Health Care, Inc.|||||f||||||||||||||2018-06-01 03:57:52.302648|2018-06-01 03:57:52.302648
NCT00334451|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2014-02-20|2006-06-05|2006-06-07|Estimate|||||||2014-02-20|2014-02-24|Estimate|May 2006||2006-05-31|February 2014|2014-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||RAPID-RF: Remote Active Monitoring in Patients With Heart Failure|Remote Active Monitoring in Patients With Heart Failure|Completed|||891|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 03:57:52.373634|2018-06-01 03:57:52.373634
NCT00334438|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2016-12-22|2006-06-06|2006-06-07|Estimate|||||||2016-12-22|2016-12-23|Estimate|July 2006||2006-07-31|December 2016|2016-12-31|October 2011|Actual|2011-10-31|October 2008|Actual|2008-10-31||Interventional|||Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma|A Phase I Study Evaluating Combined Zevalin (Ibritumomab Tiuxetan) and Valcade (Bortezomib) in Relapsed/Refractory Low-Grade or Follicular B-Cell and Mantle Cell Lymphoma|Completed||Phase 1|12|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 03:57:52.429286|2018-06-01 03:57:52.429286
NCT00334425|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2006-06-09|2006-06-06|2006-06-07|Estimate|||||||2006-06-09|2006-06-13|Estimate|April 2006||2006-04-30|June 2006|2006-06-30||||||||Interventional|||The Effect of LH-Priming During Early Follicular Phase in IVF Treatment.|The Effect of LH-Priming During Early Follicular Phase on Ovarian Response and Pregnancy Outcome in GnRHa Down-Regulated Women, Stimulated With Exogenous Gonadotrophins in IVF Treatment|Unknown status|Recruiting|Phase 4|150||Central Jutland Regional Hospital|||||f||||||||||||||2018-06-01 03:57:52.601934|2018-06-01 03:57:52.601934
NCT00334412|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2015-07-07|2006-06-05|2006-06-07|Estimate|||||||2015-07-07|2015-07-09|Estimate|March 2004||2004-03-31|July 2015|2015-07-31|May 2006||2006-05-31|||||Interventional|||COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis|AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study.|Completed||Phase 4|30||Gilead Sciences|||||f||||||||||||||2018-06-01 03:57:52.675233|2018-06-01 03:57:52.675233
NCT00334399|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2008-10-08|2006-06-05|2006-06-07|Estimate|||||||2008-10-08|2008-10-10|Estimate||||October 2008|2008-10-31||||||||Interventional|||Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide||Completed||Phase 3|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 03:57:52.73533|2018-06-01 03:57:52.73533
NCT00334386|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2015-03-05|2006-06-06|2006-06-07|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2005||2005-04-30|March 2015|2015-03-31|February 2006||2006-02-28|||||Interventional|||Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.|Multicentre, Multinational, Parallel, Randomised, Double Blind Clinical Trial, to Evaluate the Non-inferiority of PR Torasemide Versus IR Torasemide in Patients With Mild or Moderate Arterial Hypertension.|Completed||Phase 4|388||Ferrer Internacional S.A.|||||f||||||||||||||2018-06-01 03:57:52.807878|2018-06-01 03:57:52.807878
NCT00334373|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2015-05-26|2006-06-06|2006-06-07|Estimate|||||||2015-05-26|2015-05-28|Estimate|June 2006||2006-06-30|May 2015|2015-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Post Conditioning in PCI for Acute ST Elevation Myocardial Infarction|Post Conditioning in PCI for Acute ST Elevation Myocardial Infarction|Completed||Phase 4|102|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 03:57:52.919359|2018-06-01 03:57:52.919359
NCT00334360|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2016-06-27|2006-06-06|2006-06-07|Estimate|||||||2016-06-27|2016-06-29|Estimate|September 2004||2004-09-30|June 2016|2016-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Dexmed/Buspirone Synergism on Shivering|Do Dexmedetomidine and Buspirone Synergistically Reduce the Threshold, Gain, and Maximum Intensity of Shivering?|Completed||Phase 4|8|Actual|The Cleveland Clinic||4|||f||||f||||||||||2018-06-01 03:57:52.997726|2018-06-01 03:57:52.997726
NCT00334347|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2007-12-03|2006-06-05|2006-06-07|Estimate|||||||2007-12-03|2007-12-06|Estimate|June 2006||2006-06-30|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR|A Comparison Study of the Efficacy and Tolerability Between Depakote ER and Depakote in the Acute Treatment of Mania and Mixed Mania|Completed||Phase 4|5|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 03:57:53.077304|2018-06-01 03:57:53.077304
NCT00334334|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2016-11-03|2006-06-06|2006-06-07|Estimate|||||||2016-11-03|2016-11-04|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.|To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With DTPa-combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.|Completed||Phase 3|1572|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:57:53.160977|2018-06-01 03:57:53.160977
NCT00334321|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2015-10-01|2006-06-06|2006-06-07|Estimate|||||||2015-10-01|2015-10-05|Estimate|April 2006||2006-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|April 2011|Actual|2011-04-30||Interventional|||Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients|Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Endometrial Cancer Patients|Completed||Phase 1|65|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 03:57:53.324694|2018-06-01 03:57:53.324694
NCT00334308|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2009-01-16|2006-06-06|2006-06-07|Estimate|||||||2009-01-16|2009-01-21|Estimate||||January 2009|2009-01-31||||||||Interventional|||Barley Protein and CVD|Barley Protein and Coronary Heart Disease Risk Reduction|Completed||Phase 2|40|Anticipated|University of Toronto|||||f||||||||||||||2018-06-01 03:57:53.387963|2018-06-01 03:57:53.387963
NCT00334295|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|2012-01-11||2012-06-11|2006-06-05|2006-06-07|Estimate|2012-06-11|2012-07-31|Estimate||||2012-06-11|2012-07-31|Estimate|December 2002||2002-12-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.|An Open, Non-randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 mg Monthly Dose of i.m. Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.|Completed||Phase 2|35|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:57:53.458215|2018-06-01 03:57:53.458215
NCT00334282|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|2009-11-19||2016-01-11|2006-06-05|2006-06-07|Estimate|2010-07-06|2010-08-02|Estimate||||2016-01-11|2016-02-05|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|May 2008|Actual|2008-05-31||Interventional|||Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma|A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma|Completed||Phase 3|435|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 03:57:53.834638|2018-06-01 03:57:53.834638
NCT00334269|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2009-09-27|2006-06-06|2006-06-07|Estimate|||||||2009-09-27|2009-09-29|Estimate|May 2004||2004-05-31|September 2009|2009-09-30|December 2005||2005-12-31|||||Interventional|||Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Action Toward Obesity Prevention (SHARE-AP Action)|Study of Health Assessment and Risk Evaluation (SHARE) in Aboriginal Peoples (AP) Action Toward Obesity Prevention (SHARE-AP Action)|Completed||N/A|174||Population Health Research Institute|||||f||||||||||||||2018-06-01 03:57:55.081582|2018-06-01 03:57:55.081582
NCT00334256|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2011-12-02|2006-06-06|2006-06-07|Estimate|||||||2011-12-02|2011-12-05|Estimate|October 2006||2006-10-31|December 2011|2011-12-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|TEmAA||Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)|Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia|Completed||Phase 2|72|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 03:57:55.229158|2018-06-01 03:57:55.229158
NCT00334243|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2011-10-05|2006-06-06|2006-06-07|Estimate|||||||2011-10-05|2011-10-06|Estimate|June 2006||2006-06-30|October 2011|2011-10-31|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||Protocols for Improved in Vitro Fertilization (IVF) Outcomes|Protocol Evaluation for Improved In Vitro Fertilization Outcomes|Terminated||Phase 4|2|Actual|University of California, San Francisco||||"stopped due to limited enrollment. 2 subjects were enrolled. There was NO enrollment after~   November 2007."|f||||t||||||||||2018-06-01 03:57:55.318956|2018-06-01 03:57:55.318956
NCT00334230|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-06|||2017-06-30|2006-06-06|2006-06-07|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2, 2006||2006-06-02|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Gait Training and Brain Changes in Stroke Patients|Mechanisms of Training Induced Improvements in Gait Function After Stroke|Completed|||58||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:57:55.371596|2018-06-01 03:57:55.371596
NCT00334217|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2009-06-17|2006-06-02|2006-06-06|Estimate|||||||2009-06-17|2009-06-18|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|August 2007|Actual|2007-08-31||Interventional|||Cognitive Remediation in Early Substance Abuse Treatment|Cognitive Remediation in the Initial Phase of Substance Abuse Treatment: Feasibility and Efficacy|Terminated||N/A|40|Anticipated|VA Office of Research and Development||2||"The intervention could not be successfully carried out in the SADP setting because of issues~   independent of the cognitive training intervention."|f||||||||||||||2018-06-01 03:57:55.413675|2018-06-01 03:57:55.413675
NCT00334204|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2013-04-11||2013-06-26|2006-06-02|2006-06-06|Estimate|2013-06-26|2013-08-01|Estimate||||2013-06-26|2013-08-01|Estimate|August 2004||2004-08-31|June 2013|2013-06-30|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?|Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?|Terminated||Phase 4|58|Actual|University of Mississippi Medical Center|Early termination leading to lesser-than-planned numbers of subjects analyzed|1||run out of independent funding|f||||f||||||||||2018-06-01 03:57:55.472502|2018-06-01 03:57:55.472502
NCT00334191|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2009-07-06|2006-06-05|2006-06-06|Estimate|||||||2009-07-06|2009-07-07|Estimate|June 2006||2006-06-30|July 2009|2009-07-31|June 2006||2006-06-30|||||Interventional|||Sodium Bicarbonate in Cardiac Surgery|A Randomised, Double Blind, Placebo Controlled Pilot Study of the Effect of Sodium Bicarbonate on Postoperative Renal Function and Oxidative Stress in Patients Undergoing Elective Cardiopulmonary Bypass.|Completed||Phase 2|100||Austin Health|||||f||||||||||||||2018-06-01 03:57:55.587668|2018-06-01 03:57:55.587668
NCT00334178|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2007-09-06|2006-06-05|2006-06-06|Estimate|||||||2007-09-06|2007-09-10|Estimate|November 2004||2004-11-30|September 2007|2007-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine|A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine|Completed||Phase 3|74|Actual|Lotus Pharmaceutical|||||f||||f||||||||||2018-06-01 03:57:55.726045|2018-06-01 03:57:55.726045
NCT00334165|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-03|||2011-02-25|2006-06-05|2006-06-06|Estimate|||||||2011-02-25|2011-02-28|Estimate|June 2005||2005-06-30|February 2011|2011-02-28|June 2008||2008-06-30|March 2007|Actual|2007-03-31||Interventional|||Auricular Acupuncture for Analgesia During Total Hip Arthroplasty|Auricular Acupuncture (AA) vs. Sham Acupuncture for Complementary Analgesia During Elective Total Hip Arthroplasty: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|360|Anticipated|University Medicine Greifswald|||||f||||||||||||||2018-06-01 03:57:55.786312|2018-06-01 03:57:55.786312
NCT00334152|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2017-03-21|2006-06-02|2006-06-06|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2006||2006-03-31|March 2017|2017-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women|A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis|Completed||Phase 3|515|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:57:55.85069|2018-06-01 03:57:55.85069
NCT00334139|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2017-02-03|2006-06-05|2006-06-06|Estimate|||||||2017-02-03|2017-02-07|Estimate|May 2006|Actual|2006-05-31|February 2017|2017-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer|A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis|Completed||Phase 4|411|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:57:56.040682|2018-06-01 03:57:56.040682
NCT00334126|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2011-05-17|2006-06-02|2006-06-06|Estimate|||||||2011-05-17|2011-05-18|Estimate|April 2006||2006-04-30|March 2010|2010-03-31|September 2007|Actual|2007-09-30|||||Interventional|||Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Paliperidone ER Compared to Quetiapine in Subjects With an Acute Exacerbation of Schizophrenia|Completed||Phase 3|399|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 03:57:56.131032|2018-06-01 03:57:56.131032
NCT00334113|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2014-11-21||2014-12-16|2006-06-02|2006-06-06|Estimate|2014-11-21|2014-11-27|Estimate||||2014-12-16|2015-01-06|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Telerehabilitation Intervention to Promote Exercise for Diabetes|Telerehabilitation Intervention to Promote Exercise for Diabetes|Completed||N/A|89|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:57:56.204859|2018-06-01 03:57:56.204859
NCT00334100|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2014-10-07|2006-06-02|2006-06-06|Estimate|||||||2014-10-07|2014-10-09|Estimate|April 2006||2006-04-30|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|September 2011|Actual|2011-09-30||Interventional|||Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness|Treadmill Training in Chronic MS: Efficacy and Cost-Effectiveness|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1||Difficulty with recruiting|f||||t||||||||||2018-06-01 03:57:56.401222|2018-06-01 03:57:56.401222
NCT00334087|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2007-04-15|2006-06-05|2006-06-06|Estimate|||||||2007-04-15|2007-04-17|Estimate|June 2007||2007-06-30|April 2007|2007-04-30|September 2007||2007-09-30|||||Observational|||The Relation Between Pregnancy,Birth Outcome, Feeding , Oral Hygiene Habits and Early Childhood Caries Development.|Assessment of Pregnancy History, Birth Outcome, Feeding and Oral Practices With Development of Early Childhood Caries in Offspring of Women Who Have Not Participated in Previous Birth Preparation Class|Unknown status|Not yet recruiting||200|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:57:56.457634|2018-06-01 03:57:56.457634
NCT00334074|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2013-04-01||2013-07-15|2006-06-05|2006-06-06|Estimate|2013-07-15|2013-07-17|Estimate||||2013-07-15|2013-07-17|Estimate|August 2005||2005-08-31|July 2013|2013-07-31|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Interventional|||Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in Selected Elderly Patients at High Risk of Anthracycline Toxicity|Completed||Phase 2|30|Actual|Baylor Research Institute||1|||f||||f||||||||||2018-06-01 03:57:56.524407|2018-06-01 03:57:56.524407
NCT00334061|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2008-11-20||2009-01-09|2006-06-02|2006-06-06|Estimate|2009-01-09|2009-01-12|Estimate||||2009-01-09|2009-01-12|Estimate|June 2006||2006-06-30|December 2008|2008-12-31|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||Study to Assess the Safety and Effectiveness of the Penumbra System|Evaluation of the Penumbra™ Stroke System in the Revascularization of Patients With Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease|Completed||Phase 2|125|Actual|Penumbra Inc.|||||||||t||||||||||2018-06-01 03:57:56.722609|2018-06-01 03:57:56.722609
NCT00334048|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2015-02-18|2006-06-02|2006-06-06|Estimate|||||||2015-02-18|2015-02-19|Estimate|June 2006||2006-06-30|February 2015|2015-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo|Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants|Completed||Phase 4|9|Actual|St. Luke's-Roosevelt Hospital Center|||||f||||f||||||||||2018-06-01 03:57:56.872509|2018-06-01 03:57:56.872509
NCT00334035|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2011-02-17|2006-06-02|2006-06-06|Estimate|||||||2011-02-17|2011-02-18|Estimate|August 2003||2003-08-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Antipsychotic Therapy and First Episode|Duration of Maintenance Anti-psychotic Therapy After First -Episode Schizophrenia: a Double-blind Randomized Placebo-control Relapse Prevention Study|Completed||Phase 4|169|Actual|The University of Hong Kong|||||f||||||||||||||2018-06-01 03:57:56.938857|2018-06-01 03:57:56.938857
NCT00334022|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2012-06-04|2006-06-02|2006-06-06|Estimate|||||||2012-06-04|2012-06-05|Estimate|February 2006||2006-02-28|June 2012|2012-06-30|January 2010|Actual|2010-01-31|July 2007|Actual|2007-07-31||Interventional|||Fuzeon Viral Decay Pilot Study|A Pilot Randomized Controlled Trial of Adding Enfuvirtide to Standard Combination Antiretroviral Therapy in HIV-infected Individuals With Full Virologic Suppression to Further Suppress Proviral HIV DNA|Completed||N/A|18|Actual|Canadian Immunodeficiency Research Collaborative||2|||f||||||||||||||2018-06-01 03:57:56.994146|2018-06-01 03:57:56.994146
NCT00334009|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2008-03-03|2006-06-05|2006-06-06|Estimate|||||||2008-03-03|2008-03-06|Estimate|June 2006||2006-06-30|March 2008|2008-03-31|November 2006||2006-11-30|||||Observational|||Catecholamine-O-Methyl-Transferase(COMT)-Polymorphism in Cardiac Surgery|Impact of Catecholamine-O-Methyl-Transferase Enzyme Activity on Clinical and Biological Parameters in Patients After Cardiac Surgery.|Completed|||250||Austin Health|||||f||||||||||||||2018-06-01 03:57:57.057076|2018-06-01 03:57:57.057076
NCT00333996|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2011-05-27|2006-06-05|2006-06-06|Estimate|||||||2011-05-27|2011-05-30|Estimate|May 2006||2006-05-31|May 2011|2011-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis||Terminated||Phase 2/Phase 3|5|Actual|Allergan|||||f||||||||||||||2018-06-01 03:57:57.108384|2018-06-01 03:57:57.108384
NCT00333983|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2013-08-30||2014-02-03|2006-06-02|2006-06-06|Estimate|2014-02-03|2014-03-20|Estimate||||2014-02-03|2014-03-20|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|February 2011|Actual|2011-02-28|April 2010|Actual|2010-04-30||Interventional|||Evaluation of Robotic Arm Rehabilitation in Stroke Patients|Evaluation of Robotic Arm Rehabilitation in Stroke Patients|Completed||N/A|62|Actual|VA Office of Research and Development|This study was terminated early with the current number of subjects analyzed. A midstudy futility analysis showed a need for 99 participants per group to determine signifcance between the robotic training over the intensive conventional exercise.|2|||f||||t||||||||||2018-06-01 03:57:57.173178|2018-06-01 03:57:57.173178
NCT00333970|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2014-10-02||2014-10-06|2006-06-02|2006-06-06|Estimate|2014-10-06|2014-10-09|Estimate||||2014-10-06|2014-10-09|Estimate|August 2004||2004-08-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|October 2013|Actual|2013-10-31||Interventional||individuals randomized to Arm 1 or Arm 2|Predictors of Response to Cognitive Remediation in Schizophrenia|Predictors of Response to Cognitive Remediation in Schizophrenia|Completed||N/A|103|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:57:57.444127|2018-06-01 03:57:57.444127
NCT00333957|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2018-05-03|2006-06-05|2006-06-06|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2006||2006-07-31|October 2007|2007-10-31|August 2008|Actual|2008-08-31|||||Observational|||Capsule Endoscopy in Cystic Fibrosis|Capsule Endoscopy in Cystic Fibrosis-Screening for Small Bowel Disease in Cystic Fibrosis Patient.|Completed|||200|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:57:57.622314|2018-06-01 03:57:57.622314
NCT00333944|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2006-06-05|2006-06-05|2006-06-06|Estimate|||||||2006-06-05|2006-06-06|Estimate|May 2000||2000-05-31|May 2000|2000-05-31|June 2003||2003-06-30|||||Interventional|||Study to Know the Efficacy of Higher Doses of Pralidoxime in Patients of Organophpsphorus Poisoning.|Effectiveness of High Dose Pralidoxime in the Treatment of Organophosphorus Pesticide Poisoning – a Randomised Controlled Trial|Completed||N/A|200||Giriraj Hospital|||||f||||||||||||||2018-06-01 03:57:57.666502|2018-06-01 03:57:57.666502
NCT00333931|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2006-06-02|2006-06-02|2006-06-06|Estimate|||||||2006-06-02|2006-06-06|Estimate|June 2006||2006-06-30|June 2006|2006-06-30||||||||Interventional|||Pilot Trial of Neural Correlates of Response to Treatment of PTSD-Associated Impulsive Aggression|Pilot Trial of Neural Correlates of Response to Treatment of PTSD-Associated Impulsive Aggression|Unknown status|Recruiting|N/A|12||VA Medical Center, Houston|||||f||||||||||||||2018-06-01 03:57:57.809377|2018-06-01 03:57:57.809377
NCT00333918|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-04|||2013-02-13|2006-06-05|2006-06-06|Estimate|||||||2013-02-13|2013-02-15|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery|Efficacy and Safety Study of Topical Bromfenac Ophthalmic Solution vs. Placebo for Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery|Completed||Phase 3|522|Actual|Bausch & Lomb Incorporated||2|||f||||||||||||||2018-06-01 03:57:57.878371|2018-06-01 03:57:57.878371
NCT00333905|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2009-02-03|2006-06-02|2006-06-06|Estimate|||||||2009-02-03|2009-02-05|Estimate|March 2006||2006-03-31|June 2006|2006-06-30|February 2008|Actual|2008-02-29|||||Interventional|||The Effect of Ischemic Training on Exercise Endurance|The Effect of Ischemic Training on Exercise Endurance|Completed||N/A|50|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 03:57:57.953692|2018-06-01 03:57:57.953692
NCT00333892|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2012-06-04|2006-06-02|2006-06-06|Estimate|||||||2012-06-04|2012-06-05|Estimate|August 2003||2003-08-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|||||Observational|||Leukapheresis to Obtain Lymphocytes for Studies on Antiretroviral Naive HIV-infected Patients|Leukapheresis Procedures to Obtain Lymphocytes for Research Studies on Antiretroviral Naive HIV-infected Patients|Completed|||220|Actual|Canadian Immunodeficiency Research Collaborative|||||f||||||||||Samples With DNA|"~     Obtain lymphocytes for research studies on anti-retroviral naive HIV-infected patients.~   "|||2018-06-01 03:57:58.042962|2018-06-01 03:57:58.042962
NCT00333879|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2013-09-16||2013-11-20|2006-06-02|2006-06-06|Estimate|2013-09-16|2013-11-19|Estimate||||2013-11-20|2013-12-16|Estimate|March 2009||2009-03-31|November 2013|2013-11-30|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Virtual Reality Mobility Training System for Veterans With Vision Loss|Virtual Reality Mobility Training System for Veterans With Vision Loss|Completed||N/A|4|Actual|VA Office of Research and Development|Early termination leading to small numbers of subjects analyzed. Technical problems with Virtual Sound System. None of the first 4 Subjects could distinguish between sounds in front versus sounds beside them.|1|||f||||f||||||||||2018-06-01 03:57:58.112963|2018-06-01 03:57:58.112963
NCT00333866|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2008-11-20||2013-04-25|2006-06-02|2006-06-06|Estimate|2009-03-26|2009-05-13|Estimate||||2013-04-25|2013-05-27|Estimate|July 2006||2006-07-31|March 2009|2009-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional||Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study medication, regardless of medication compliance.|Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.|A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.|Completed||Phase 3|747|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 03:57:58.34388|2018-06-01 03:57:58.34388
NCT00333853|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2008-05-12|2006-06-02|2006-06-06|Estimate|||||||2008-05-12|2008-05-13|Estimate|August 2003||2003-08-31|May 2008|2008-05-31|June 2005||2005-06-30|||||Interventional|||Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)|Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm) to Improve Glycemic Control Through Behavioral and Therapeutic Changes|Completed||N/A|250||LifeScan|||||f||||f||||||||||2018-06-01 03:58:00.379275|2018-06-01 03:58:00.379275
NCT00333840|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2013-03-15||2013-08-07|2006-06-02|2006-06-06|Estimate|2013-08-07|2013-10-14|Estimate||||2013-08-07|2013-10-14|Estimate|June 2000||2000-06-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia|A Phase III Study of STI571 Versus Interferon-α (IFN-α) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Completed||Phase 3|1106|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:58:00.57186|2018-06-01 03:58:00.57186
NCT00333827|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2017-03-09|2006-06-05|2006-06-06|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2006||2006-01-31|March 2017|2017-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Cell Therapy In Dilated Cardiomyopathy|Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Dilated Cardiomyopathy|Completed||Phase 3|115|Actual|Ministry of Health, Brazil||2|||f||||||||||||||2018-06-01 03:58:05.097298|2018-06-01 03:58:05.097298
NCT00333814|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2010-10-12|2009-11-30|2011-03-11|2006-06-05|2006-06-06|Estimate|2011-03-11|2011-04-14|Estimate|2009-11-30|2009-12-02|Estimate|2011-03-11|2011-04-14|Estimate|May 2006||2006-05-31|March 2011|2011-03-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis||Completed||Phase 2/Phase 3|229|Actual|Allergan||3|||f||||||||||||||2018-06-01 03:58:05.186076|2018-06-01 03:58:05.186076
NCT00333801|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2014-11-25||2015-03-06|2006-06-05|2006-06-06|Estimate|2015-03-06|2015-03-19|Estimate||||2015-03-06|2015-03-19|Estimate|April 2006||2006-04-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|April 2010|Actual|2010-04-30||Interventional||Veterans with PTSD were randomly assigned to a treatment goup.|The Impact of Vocational Rehabilitation on Mentally III Veterans|The Impact of Vocational Rehabilitation on Mentally III Veterans|Completed||N/A|100|Actual|VA Office of Research and Development|The elements of the study that limit generalizability include the single-site design, the small number of IPS interventionists, low number of women in the sample, and the exclusion of nonveterans.|2|||f||||f||||||||||2018-06-01 03:58:05.540927|2018-06-01 03:58:05.540927
NCT00333788|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2011-04-13||2011-08-30|2006-06-02|2006-06-06|Estimate|2011-06-14|2011-07-12|Estimate||||2011-08-30|2011-08-31|Estimate|October 2006||2006-10-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|Welcome2||Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease|Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study.|Completed||Phase 3|233|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 03:58:06.022168|2018-06-01 03:58:06.022168
NCT00333775|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|2015-07-22||2015-12-21|2006-06-05|2006-06-06|Estimate|2015-12-21|2016-01-27|Estimate||||2015-12-21|2016-01-27|Estimate|March 2006||2006-03-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2007|Actual|2007-10-31||Interventional||Intent-to-treat population: All randomized participants, regardless of whether they received study drug or not.|A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer|A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer.|Completed||Phase 3|736|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 03:58:06.696483|2018-06-01 03:58:06.696483
NCT00333762|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2013-09-24||2015-10-30|2006-06-02|2006-06-06|Estimate|2015-10-30|2015-12-03|Estimate||||2015-10-30|2015-12-03|Estimate|June 2006||2006-06-30|October 2015|2015-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||"Use of Smart Wheelchairs to Provide Independent Mobility to Visual and Mobility Impairments"|"Use of Smart Wheelchairs to Provide Independent Mobility to Visual and Mobility Impairments"|Completed||N/A|4|Actual|VA Office of Research and Development|Only four subjects actually tested the chair. It was decided to stop after these four subject tests because the chairs were clearly not viable for this population of persons who were totally blind, and thus there was no need for further testing.|1|||f||||f||||||||||2018-06-01 03:58:08.478167|2018-06-01 03:58:08.478167
NCT00333749|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2009-09-03|2006-06-05|2006-06-06|Estimate|||||||2009-09-03|2009-09-04|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effectiveness of Pasteurized Goat Milk in the Treatment of Childhood Oral Ulcer Diseases|Phase 1 1 Study Assesing the Benefit of Pasteurized Goat Milk in Reducing Disease Severity of Young Children With Oral Ulcer Diseases|Completed||Phase 1|65|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-06-01 03:58:08.603383|2018-06-01 03:58:08.603383
NCT00333736|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2012-06-04|2006-06-02|2006-06-06|Estimate|||||||2012-06-04|2012-06-05|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Interventional|||Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration|Prospective Study to Assess Patient Satisfaction, Quality of Life and Adverse Events of Patients Using the Biojector Versus Standard Needles for Enfuvirtide Administration|Completed||Phase 2|337|Actual|Canadian Immunodeficiency Research Collaborative|||||f||||t||||||||||2018-06-01 03:58:08.673373|2018-06-01 03:58:08.673373
NCT00333723|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2017-10-05|2006-06-02|2006-06-06|Estimate|||||||2017-10-05|2017-10-09|Actual|July 28, 2000|Actual|2000-07-28|October 2017|2017-10-31|January 6, 2003|Actual|2003-01-06|January 6, 2003|Actual|2003-01-06||Interventional|||AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone|A 24-Week Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of AVANDIA (8mg Once Daily) in Combination With Glyburide in African American and Hispanic Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Glyburide Monotherapy|Completed||Phase 4|245|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:58:08.74852|2018-06-01 03:58:08.74852
NCT00333710|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2014-11-19||2014-12-09|2006-06-02|2006-06-06|Estimate|2014-12-09|2014-12-15|Estimate||||2014-12-09|2014-12-15|Estimate|September 2006||2006-09-30|December 2014|2014-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD|Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD|Completed||N/A|53|Actual|VA Office of Research and Development|Small sample size, all male, reliance on self-report measures.|3|||f||||f||||||||||2018-06-01 03:58:08.822584|2018-06-01 03:58:08.822584
NCT00333697|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2011-03-17|2006-06-02|2006-06-06|Estimate|||||||2011-03-17|2011-03-21|Estimate|November 2005||2005-11-30|March 2011|2011-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Single Comprehensive Ultrasound to Rule Out DVT in High-risk Patients|Ultrasound-sparing Strategy for Suspected DVT: A Prospective Clinical Cohort Study|Completed||N/A|199|Actual|Intermountain Health Care, Inc.|||||f||||f||||||||||2018-06-01 03:58:09.152777|2018-06-01 03:58:09.152777
NCT00333684|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2012-06-04|2006-06-02|2006-06-06|Estimate|||||||2012-06-04|2012-06-05|Estimate|December 2004||2004-12-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|November 2006|Actual|2006-11-30||Interventional|||Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid|A Prospective Study Evaluating the Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid Soft Tissue Endoprosthesis|Completed||Phase 2|36|Actual|Canadian Immunodeficiency Research Collaborative||2|||f||||||||||||||2018-06-01 03:58:09.222614|2018-06-01 03:58:09.222614
NCT00333671|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2012-09-18|2006-06-02|2006-06-06|Estimate|||||||2012-09-18|2012-09-19|Estimate|December 2004||2004-12-31|September 2012|2012-09-30|April 2007|Actual|2007-04-30|February 2006|Actual|2006-02-28||Interventional|||Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema)|Diabetic Macular Oedema: the Retinal Thickness as a Function of Changes in Plasma Osmolality Evaluated by OCT.|Completed||N/A|15|Actual|Glostrup University Hospital, Copenhagen|||||f||||f||||||||||2018-06-01 03:58:09.286429|2018-06-01 03:58:09.286429
NCT00333658|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2009-06-24|2006-06-02|2006-06-06|Estimate|||||||2009-06-24|2009-06-25|Estimate|December 2003||2003-12-31|June 2009|2009-06-30|September 2008|Actual|2008-09-30|October 2007|Actual|2007-10-31||Interventional|||A Behavioral Intervention to Improve Work Outcomes|A Behavioral Intervention to Improve Outcomes in VA Work Programs|Completed||N/A|57|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:58:09.345468|2018-06-01 03:58:09.345468
NCT00333645|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-04|||2007-04-12|2006-06-04|2006-06-06|Estimate|||||||2007-04-12|2007-04-13|Estimate|October 2003||2003-10-31|December 2006|2006-12-31|March 2007||2007-03-31|||||Interventional|||Prophylaxis With Caspofungin in High-Risk Liver Transplantation|Prophylaxis With Caspofungin for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients|Unknown status|Recruiting|Phase 2|70||Grupo de Estudio de Infecciones en Transplantados|||||f||||||||||||||2018-06-01 03:58:09.412868|2018-06-01 03:58:09.412868
NCT00333632|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2014-07-11|2006-06-02|2006-06-06|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 2006||2006-06-30|June 2011|2011-06-30|June 2011|Actual|2011-06-30|||||Interventional|||Effect of Dexmedetomidine Upon Sleep Postoperatively|Restorative Sleep: Effect of Dexmedetomidine|Withdrawn||Phase 4|0|Actual|Duke University|||||f||||||||||||||2018-06-01 03:58:09.498585|2018-06-01 03:58:09.498585
NCT00333619|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2014-10-23||2015-04-06|2006-06-02|2006-06-06|Estimate|2015-03-23|2015-04-06|Estimate||||2015-04-06|2015-04-24|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation|Non-Pharmacological Interventions on Sleep in Post-Acute Rehabilitation|Completed||N/A|219|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:58:09.63978|2018-06-01 03:58:09.63978
NCT00333593|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-05|||2006-12-26|2006-06-05|2006-06-06|Estimate|||||||2006-12-26|2006-12-27|Estimate|June 2006||2006-06-30|December 2006|2006-12-31|November 2006||2006-11-30|||||Interventional|||Super High-Flux - High Volume Dialysis in Sepsis-Induced Acute Renal Failure|Randomized, Cross Over Study Comparing Standard Hemodialysis to Hemodialysis With a Novel Polyamide Membrane (P2SH) in Patients With Sepsis and Acute Renal Failure|Completed||Phase 1/Phase 2|10||Austin Health|||||f||||||||||||||2018-06-01 03:58:09.9685|2018-06-01 03:58:09.9685
NCT00333580|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2015-04-07|2006-06-02|2006-06-06|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Veteran-Centered Outcomes Using Qualitative and Quantitative Methods|Veteran-Centered Outcomes Using Qualitative and Quantitative Methods|Completed|||15|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 03:58:10.049713|2018-06-01 03:58:10.049713
NCT00333567|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2007-12-12|2006-06-01|2006-06-05|Estimate|||||||2007-12-12|2007-12-13|Estimate|August 2006||2006-08-31|December 2007|2007-12-31||||||||Interventional|||Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy of a Single Dose of Lumiracoxib 400 mg Given Pre-Emptively Versus Post-Operatively, in Reducing Pain Associated With Ambulatory Arthroscopic Knee Surgery|Completed||Phase 4|110||Novartis|||||f||||||||||||||2018-06-01 03:58:10.114365|2018-06-01 03:58:10.114365
NCT00333554|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2016-05-13|2006-06-02|2006-06-05|Estimate|||||||2016-05-13|2016-05-16|Estimate|June 2006||2006-06-30|May 2016|2016-05-31|April 2013|Actual|2013-04-30|February 2008|Actual|2008-02-29||Interventional|||Nutritional Intervention to Prevent Diabetes||Completed||N/A|99|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 03:58:10.172202|2018-06-01 03:58:10.172202
NCT00333541|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2015-03-03|2006-06-02|2006-06-05|Estimate|||||||2015-03-03|2015-03-05|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Internet Access and Use in Adolescent Women Initiating Contraception|Internet Access and Use in Women at High Risk for Unintended Pregnancy: A Randomized Clinical Trial|Completed||N/A|100|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 03:58:10.261359|2018-06-01 03:58:10.261359
NCT00333528|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2018-01-16|2006-06-02|2006-06-05|Estimate|||||||2018-01-16|2018-01-18|Actual|December 1, 2007||2007-12-01|January 2018|2018-01-31|August 1, 2008|Actual|2008-08-01|April 1, 2008|Actual|2008-04-01||Interventional|||A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly|A Phase 1, Randomized, Observer-Blinded, Single Dose, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Plasma-Derived Human Butyrylcholinesterase (HuBChE) Administered Intramuscularly (IM)|Completed||Phase 1|8|Actual|Shire||2|||f||||t||||||||||2018-06-01 03:58:10.331532|2018-06-01 03:58:10.331532
NCT00333515|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2018-01-04|2006-06-02|2006-06-05|Estimate|||||||2018-01-04|2018-01-08|Actual|January 1, 2007||2007-01-01|January 2018|2018-01-31|August 1, 2008|Actual|2008-08-01|April 1, 2008|Actual|2008-04-01||Interventional|||Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously|A Phase 1, Randomized, Observer-blinded, Single Dose, Placebo Controlled Dosage-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Plasma-Derived Human Butyrylcholinesterase (HuBChE) Administered Intravenously (IV)|Completed||Phase 1|28|Actual|Shire||2|||f||||t||||||||||2018-06-01 03:58:10.395998|2018-06-01 03:58:10.395998
NCT00333502|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2017-04-18|2006-06-01|2006-06-05|Estimate|||||||2017-04-18|2017-04-20|Actual|May 2006||2006-05-31|April 2017|2017-04-30|April 2012|Actual|2012-04-30|November 2011|Actual|2011-11-30||Interventional|||Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors|A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors|Completed||Phase 1/Phase 2|62|Actual|NewLink Genetics Corporation||1|||f||||||||||||||2018-06-01 03:58:10.455008|2018-06-01 03:58:10.455008
NCT00333489|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2011-11-07|2006-06-02|2006-06-05|Estimate|||||||2011-11-07|2011-11-08|Estimate|March 2004||2004-03-31|June 2006|2006-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension|A National, Multicentric and Comparative Study to Evaluate Efficacy and Tolerability of the Association of Valsartan and Amlodipine Versus Amlodipine Alone in the Treatment of Essential Arterial Hypertension - Stages I and II (Mild to Moderate).|Completed||Phase 4|551|Actual|Novartis|||||f||||||||||||||2018-06-01 03:58:10.525118|2018-06-01 03:58:10.525118
NCT00333476|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2007-11-27|2006-06-01|2006-06-05|Estimate|||||||2007-11-27|2007-11-28|Estimate|May 2006||2006-05-31|November 2007|2007-11-30||||||||Interventional|||"A Study of MSI-1256F (Squalamine Lactate) To Treat Wet Age-Related Macular Degeneration"|A Phase 2, Randomized, Open Label, Safety, and Pharmacodynamic Study of Squalamine Lactate for Injection for the Treatment of Minimally Classic or Active Occult Choroidal Neovascularization Associated With Age-Related Macular Degeneration|Terminated||Phase 2|140||Genaera Corporation|||||||||||||||||||2018-06-01 03:58:10.769658|2018-06-01 03:58:10.769658
NCT00333463|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2016-11-17|2006-06-01|2006-06-05|Estimate|||||||2016-11-17|2016-11-18|Estimate|June 2006||2006-06-30|March 2010|2010-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Compliance With Once Daily Glaucoma Medication|Compliance With Once Daily Glaucoma Medication|Completed|||700|Anticipated|Alcon Research|||2||f||||||||||||||2018-06-01 03:58:10.850061|2018-06-01 03:58:10.850061
NCT00333450|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2016-10-06|2006-06-02|2006-06-05|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.|Multicentre Immune Memory Study in Healthy Children Following a 3 Dose Primary Vaccination With Prevenar or GSK Biologicals' Pneumococcal Conjugate Vaccine Via the Administration of a Single Booster Dose of Pneumovax 23|Completed||Phase 3|120||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:58:10.924721|2018-06-01 03:58:10.924721
NCT00333437|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|2013-05-06||2013-09-23|2006-06-02|2006-06-05|Estimate|2013-05-06|2013-05-17|Estimate||||2013-09-23|2013-11-13|Estimate|May 2006||2006-05-31|September 2013|2013-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement|Pulmonary Involvement in Scleroderma: Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients|Completed||N/A|7|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 03:58:11.067441|2018-06-01 03:58:11.067441
NCT00333255|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2009-07-07|2006-06-01|2006-06-02|Estimate|||||||2009-07-07|2009-07-08|Estimate|September 2005||2005-09-30|July 2009|2009-07-31||||March 2006|Actual|2006-03-31||Interventional|||Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery|Preoperative and Postoperative Nevanac 0.1% Compared to Acular LS for the Treatment of Ocular Inflammation Associated With Cataract Surgery|Completed||Phase 3|267|Actual|Alcon Research|||||||||||||||||||2018-06-01 03:58:13.135841|2018-06-01 03:58:13.135841
NCT00333424|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2012-06-11|2006-06-01|2006-06-05|Estimate|||||||2012-06-11|2012-06-13|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Thai Prophylactic HIV Vaccine Phase I Study|A Randomised, Placebo-Controlled, Double-Blind, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS-HIV-AE DNA Prime and rFPV-HIV-AE Boost HIV Vaccination Strategy|Terminated||Phase 1/Phase 2|8|Actual|Kirby Institute||1||"Vaccines safe but not immunogenic in 8 participants; trial closed to further recruitment by the~   protocol steering committee & DSMB."|f||||t||||||||||2018-06-01 03:58:11.339452|2018-06-01 03:58:11.339452
NCT00333411|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02||2014-04-30|2014-06-13|2006-06-02|2006-06-05|Estimate||||2014-06-13|2014-06-19|Estimate|2014-06-13|2014-06-19|Estimate|June 2006||2006-06-30|June 2014|2014-06-30||||June 2008|Actual|2008-06-30||Interventional|||Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis|A 12 Week Double-blind, Randomised, Placebo-controlled, Modified Dose-escalation Trial to Investigate Safety, Efficacy, and Pharmacokinetics of BIRT 2584XX Tablets at Doses of 100, 300 and 500 mg Administered Once Daily in Patients With Moderate to Severe Psoriasis With a 12 Week Treatment Extension|Completed||Phase 2|360|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 03:58:11.433392|2018-06-01 03:58:11.433392
NCT00333398|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2010-08-26|2006-06-01|2006-06-05|Estimate|||||||2010-08-26|2010-08-27|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults|A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults Greater Than or Equal to 18 to Less Than 65 Years of Age|Completed||Phase 3|1359|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 03:58:11.5736|2018-06-01 03:58:11.5736
NCT00333385|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2006-06-02|2006-06-02|2006-06-05|Estimate|||||||2006-06-02|2006-06-05|Estimate|October 2001||2001-10-31|March 2001|2001-03-31|April 2004||2004-04-30|||||Interventional|||Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis||Terminated||Phase 4|120||Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|||||f||||||||||||||2018-06-01 03:58:11.664539|2018-06-01 03:58:11.664539
NCT00333372|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2009-01-12|2006-06-02|2006-06-05|Estimate|||||||2009-01-12|2009-01-14|Estimate|April 2006||2006-04-30|January 2009|2009-01-31||||||||Interventional|||To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia|To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms|Completed||Phase 2|440||Zeria Pharmaceutical|||||f||||||||||||||2018-06-01 03:58:11.744873|2018-06-01 03:58:11.744873
NCT00333359|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|2011-04-28|2010-10-13|2013-07-15|2006-06-01|2006-06-05|Estimate|2011-05-26|2011-06-23|Estimate|2011-02-07|2011-02-10|Estimate|2013-07-15|2013-07-22|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.|An Open-Label, 52-Week Extension Study Assessing XP13512 Safety and Efficacy in Patients With Restless Legs Syndrome.|Completed||Phase 3|581|Actual|XenoPort, Inc.||1|||f||||f||||||||||2018-06-01 03:58:11.839492|2018-06-01 03:58:11.839492
NCT00333346|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2010-08-30|2006-06-02|2006-06-05|Estimate|||||||2010-08-30|2010-08-31|Estimate|September 2006||2006-09-30|August 2010|2010-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Tramadol iv. : Influence of Dose and Dose Intervals on Therapeutic Accuracy and Side Effects When Used for Postoperative Pain Relief in Ambulatory Surgery|Tramadol iv. : Influence of Dose and Dose Intervals on Therapeutic Accuracy and Side Effects When Used for Postoperative Pain Relief in Ambulatory Surgery|Completed||Phase 2|200|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 03:58:12.562492|2018-06-01 03:58:12.562492
NCT00333333|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2008-06-12|2006-06-02|2006-06-05|Estimate|||||||2008-06-12|2008-06-13|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Observational|||Mechanism of Thrombocytopenia in Infants|Mechanism of Thrombocytopenia in Small for Gestational Age Infants Versus Infants With Maternal Preeclampsia Exposure|Completed|||30|Anticipated|Christiana Care Health Services|||2||f||||f||||||Samples Without DNA|"~     Cord blood~   "|||2018-06-01 03:58:12.621698|2018-06-01 03:58:12.621698
NCT00333320|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2012-10-22|2006-06-02|2006-06-05|Estimate|||||||2012-10-22|2012-10-23|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|July 2010|Actual|2010-07-31||Interventional|||Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction|Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction|Completed||Phase 1/Phase 2|46|Actual|French Cardiology Society||2|||f||||t||||||||||2018-06-01 03:58:12.678473|2018-06-01 03:58:12.678473
NCT00333307|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2010-03-12|2006-06-01|2006-06-05|Estimate|||||||2010-03-12|2010-03-16|Estimate|October 2006||2006-10-31|March 2010|2010-03-31||||||||Interventional|||Evaluation of the Safety of Relaxin in Preeclampsia|A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia|Suspended||Phase 1|18|Anticipated|Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies|||||||||||||||||||2018-06-01 03:58:12.737952|2018-06-01 03:58:12.737952
NCT00333294|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-02|||2007-12-16|2006-06-02|2006-06-05|Estimate|||||||2007-12-16|2007-12-19|Estimate|September 2004||2004-09-30|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|||Phase II Iressa + Irradiation Followed by Chemo in NSCLC|A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSA™) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non Small Cell Lung Cancer|Completed||Phase 2|50||AstraZeneca|||||f||||||||||||||2018-06-01 03:58:12.925313|2018-06-01 03:58:12.925313
NCT00333281|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2007-10-23|2006-05-31|2006-06-02|Estimate|||||||2007-10-23|2007-10-25|Estimate|June 2005||2005-06-30|October 2007|2007-10-31|August 2006|Actual|2006-08-31|||||Interventional|||A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months|A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Effects of 5 mg Tadalafil (IC351, LY450190) and 50 mg Sildenafil Administered Once Daily for 6 Months on Visual Function in Healthy Subjects or Subjects With Mild Erectile Dysfunction|Completed||Phase 4|198||Eli Lilly and Company|||||||||||||||||||2018-06-01 03:58:12.987973|2018-06-01 03:58:12.987973
NCT00333268|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2012-03-01|2006-06-01|2006-06-02|Estimate|||||||2012-03-01|2012-03-05|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus|Clinical Evaluation of the Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for Use During Cataract Extraction and IOL Implantation|Completed||Phase 3|369|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 03:58:13.076743|2018-06-01 03:58:13.076743
NCT00333242|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2017-01-10|2006-06-01|2006-06-02|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2002||2002-09-30|August 2008|2008-08-31||||August 2006|Actual|2006-08-31||Interventional|||Hyperalgesia in Methadone Patients: Can it be Treated?||Unknown status|Active, not recruiting|Phase 1|40|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 03:58:13.187947|2018-06-01 03:58:13.187947
NCT00333229|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|2014-11-17||2014-11-17|2006-06-01|2006-06-02|Estimate|2014-11-17|2014-11-25|Estimate||||2014-11-17|2014-11-25|Estimate|March 2006||2006-03-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss|Influence of Zoledronic Acid on Bone Mineral Density and Bone Ultrasonometry in Premenopausal Women With Hormone Receptor Negative Breast Cancer and Adjuvant Chemotherapeutic Treatment|Terminated||Phase 4|11|Actual|Novartis||2||"Due to rare patient population, planned number of patients could not be recruited in a~   reasonable timeframe. Recruitment was stopped prematurely."|f||||||||||||||2018-06-01 03:58:13.266609|2018-06-01 03:58:13.266609
NCT00333216|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31||2012-11-27|2012-11-27|2006-05-31|2006-06-02|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|May 2005||2005-05-31|December 2011|2011-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Anecortave Acetate Risk-Reduction Trial (AART)|Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD)|Terminated||Phase 3|24|Actual|Alcon Research||3||Lack of efficacy|f||||f||||||||||2018-06-01 03:58:13.63761|2018-06-01 03:58:13.63761
NCT00333203|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2012-03-01|2006-06-01|2006-06-02|Estimate|||||||2012-03-01|2012-03-05|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Next Generation Ophthalmic Irrigating Solution Posterior Segment Study|Clinical Evaluation of the Safety of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for Use During Surgery for Removal of Epimacular Membrane and Vitrectomy|Completed||Phase 3|369|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 03:58:13.708292|2018-06-01 03:58:13.708292
NCT00333190|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2012-03-15|2006-06-01|2006-06-02|Estimate|||||||2012-03-15|2012-03-16|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|March 2009|Actual|2009-03-31|March 2007|Actual|2007-03-31||Interventional|||CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation|CD8+ T Cell Depletion as Graft Versus Host Disease Prophylaxis After HLA-Matched Unrelated Donor Non-myeloablative Peripheral Blood Stem Cell Transplantation|Completed||N/A|30|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 03:58:13.778922|2018-06-01 03:58:13.778922
NCT00333177|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2013-03-27|2006-06-01|2006-06-02|Estimate|||||||2013-03-27|2013-03-29|Estimate|March 2006||2006-03-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia|Developmental Processes in Schizophrenic Disorders: Cognitive Remediation, Medication Adherence, and Work Outcome in Recent-Onset Schizophrenia|Completed||Phase 4|153|Actual|University of California, Los Angeles||4|||f||||t||||||||||2018-06-01 03:58:13.849599|2018-06-01 03:58:13.849599
NCT00333164|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2017-12-18|2006-06-01|2006-06-02|Estimate|||||||2017-12-18|2017-12-19|Actual|May 2006||2006-05-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis|Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis (CATHARSIS)|Completed||Phase 3|200|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||||||||||||2018-06-01 03:58:13.946163|2018-06-01 03:58:13.946163
NCT00333151|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2017-01-24|2006-06-01|2006-06-02|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|LEAD-4||Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes|Completed||Phase 3|576|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:58:14.042444|2018-06-01 03:58:14.042444
NCT00333138|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|2012-04-05||2017-08-17|2006-06-01|2006-06-02|Estimate|2012-09-27|2012-10-30|Estimate||||2017-08-17|2017-09-15|Actual|May 2003||2003-05-31|August 2017|2017-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis|Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase|Completed||Phase 2|281|Actual|Novartis||3|||f||||||||||||||2018-06-01 03:58:14.262199|2018-06-01 03:58:14.262199
NCT00333125|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2016-11-17|2006-05-31|2006-06-02|Estimate|||||||2016-11-17|2016-11-18|Estimate|April 2006||2006-04-30|May 2012|2012-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|319|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 03:58:15.244244|2018-06-01 03:58:15.244244
NCT00333112|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2014-09-17|2006-06-01|2006-06-02|Estimate|||||||2014-09-17|2014-09-18|Estimate|May 2006||2006-05-31|September 2014|2014-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|VICTOR||A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Safety and Efficacy, Phase 4 Study of VESIcare® (Solifenacin Succinate) or Placebo in Combination With Tamsulosin HCl for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men VICTOR: VESIcare® In Combination With Tamsulosin in OAB Residual Symptoms|Completed||Phase 4|398|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 03:58:15.468125|2018-06-01 03:58:15.468125
NCT00333099|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2012-09-13|2006-06-01|2006-06-02|Estimate|||||||2012-09-13|2012-09-14|Estimate|May 2006||2006-05-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||INEC Study: Immuno-modulating Enteral Nutrition in Cancer|Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer|Completed||Phase 4|250|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-06-01 03:58:15.642538|2018-06-01 03:58:15.642538
NCT00333086|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2012-04-18|2006-06-01|2006-06-02|Estimate|||||||2012-04-18|2012-04-19|Estimate|January 2000||2000-01-31|April 2012|2012-04-30||||June 2006|Actual|2006-06-30||Interventional|||A Study of Letrozole in the Treatment of Endometrial Cancer|A PHASE II STUDY OF LETROZOLE IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER|Completed||Phase 2|36|Actual|Novartis|||||f||||||||||||||2018-06-01 03:58:15.72183|2018-06-01 03:58:15.72183
NCT00333073|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2014-02-14|2006-06-01|2006-06-02|Estimate|||||||2014-02-14|2014-02-17|Estimate|March 2006||2006-03-31|July 2013|2013-07-31|May 2010|Actual|2010-05-31|October 2008|Actual|2008-10-31||Interventional|||Effectiveness and Safety of Bulkamid® as Bulking Agent for the Treatment of Female Urinary Incontinence|Effectiveness and Safety of Bulkamid® as Bulking Agent for the Treatment of Female Urinary Incontinence|Completed||N/A|125|Actual|Contura||1|||f||||||||||||||2018-06-01 03:58:15.781935|2018-06-01 03:58:15.781935
NCT00332865|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2013-06-18|2006-06-01|2006-06-02|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 2006||2006-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Swallow Exercise as Prophylaxis of Dysphagia After Radiotherapy|Swallow Exercise as Prophylaxis of Dysphagia After Radiotherapy|Completed||Phase 1/Phase 2|60|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 03:58:17.413138|2018-06-01 03:58:17.413138
NCT00333060|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2008-03-31|2006-05-31|2006-06-02|Estimate|||||||2008-03-31|2008-04-02|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|January 2008|Anticipated|2008-01-31|||||Interventional|||Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal|Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients|Terminated||Phase 2|164|Anticipated|Othera Pharmaceuticals|||||f||||||||||||||2018-06-01 03:58:15.942682|2018-06-01 03:58:15.942682
NCT00333047|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2009-11-18|2006-05-31|2006-06-02|Estimate|||||||2009-11-18|2009-11-19|Estimate|July 2002||2002-07-31|November 2009|2009-11-30||||||||Interventional|||Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy|A Study of Letrozole in the Treatment of Metastatic Breast Cancer in Combination With Chemotherapy|Completed||Phase 2/Phase 3|24||Novartis|||||f||||||||||||||2018-06-01 03:58:16.025626|2018-06-01 03:58:16.025626
NCT00333034|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2007-12-04|2006-06-01|2006-06-02|Estimate|||||||2007-12-04|2007-12-06|Estimate|June 2006||2006-06-30|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis|A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|120|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 03:58:16.099822|2018-06-01 03:58:16.099822
NCT00333021|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2009-07-09|2006-06-01|2006-06-02|Estimate|||||||2009-07-09|2009-07-10|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|February 2007|Actual|2007-02-28|||||Interventional|||Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism (VTE) After Abdominal Surgery|Completed||Phase 3|127|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:58:16.21711|2018-06-01 03:58:16.21711
NCT00333008|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2006-09-25|2006-05-31|2006-06-02|Estimate|||||||2006-09-25|2006-09-26|Estimate|May 2006||2006-05-31|September 2006|2006-09-30||||||||Interventional|||A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.|Phase II Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell NHL > 60 Years or With Compromised Cardiac Status|Unknown status|Recruiting|Phase 2|27||The Alvin and Lois Lapidus Cancer Institute|||||f||||||||||||||2018-06-01 03:58:16.329419|2018-06-01 03:58:16.329419
NCT00332995|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2009-08-31|2006-06-01|2006-06-02|Estimate|||||||2009-08-31|2009-09-01|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|August 2005||2005-08-31|||||Interventional|||Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium|Double-blind, Randomized, Placebo Controlled Trial to Study Safety, Local and Systemic Availability of TMC120 From a Vaginal Ring.|Completed||Phase 1|13||International Partnership for Microbicides, Inc.|||||f||||||||||||||2018-06-01 03:58:16.428604|2018-06-01 03:58:16.428604
NCT00332982|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2006-11-20|2006-06-01|2006-06-02|Estimate|||||||2006-11-20|2006-11-22|Estimate|November 2005||2005-11-30|June 2005|2005-06-30|September 2007||2007-09-30|||||Interventional|||Ontario ICU Clinical Best Practices Demonstration Project|Ontario ICU Clinical Best Practices Demonstration Project|Completed||N/A|||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 03:58:16.509665|2018-06-01 03:58:16.509665
NCT00332969|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2017-03-30|2006-06-01|2006-06-02|Estimate|||||||2017-03-30|2017-03-31|Actual|September 2005||2005-09-30|November 2011|2011-11-30||||October 2010|Actual|2010-10-31||Interventional|||Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma|Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size|Completed||Phase 2|25|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:58:16.576359|2018-06-01 03:58:16.576359
NCT00332956|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01||2011-06-29|2011-11-28|2006-06-01|2006-06-02|Estimate||||2011-06-29|2011-07-01|Estimate|2011-11-28|2011-12-02|Estimate|May 2006||2006-05-31|November 2011|2011-11-30|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Interventional|||Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers|A Phase 2 (a), Dose-Blinded, Block-Randomized, Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers|Completed||Phase 2|400|Actual|DynPort Vaccine Company LLC, A CSC Company||4|||f||||t||||||||||2018-06-01 03:58:16.6525|2018-06-01 03:58:16.6525
NCT00332943|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2007-09-19|2006-06-01|2006-06-02|Estimate|||||||2007-09-19|2007-09-20|Estimate|December 2005||2005-12-31|September 2007|2007-09-30|May 2006|Actual|2006-05-31|||||Interventional|||MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil|MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil|Completed||Phase 4|20|Anticipated|Herlev Hospital|||||f||||||||||||||2018-06-01 03:58:16.740722|2018-06-01 03:58:16.740722
NCT00332930|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2007-02-26|2006-06-01|2006-06-02|Estimate|||||||2007-02-26|2007-02-27|Estimate|September 2002||2002-09-30|June 2006|2006-06-30|September 2003||2003-09-30|||||Interventional|||ITV Extension Study|An Extension Study to Protocol VIR-NCHR-01 to Assess the Antiretrovirological Properties of a Therapeutic HIV Vaccine Candidate Based on Recombinant Fowlpox Virus (rFPV) (ITV Extension Study)|Completed||Phase 1/Phase 2|35||Kirby Institute|||||f||||||||||||||2018-06-01 03:58:16.79812|2018-06-01 03:58:16.79812
NCT00332917|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2009-01-23|2006-06-01|2006-06-02|Estimate|||||||2009-01-23|2009-01-26|Estimate|February 2007||2007-02-28|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients|An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients|Completed||Phase 3|224|Actual|Solvay Pharmaceuticals||1|||f||||t||||||||||2018-06-01 03:58:16.885486|2018-06-01 03:58:16.885486
NCT00332904|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2010-06-03|2006-05-31|2006-06-02|Estimate|||||||2010-06-03|2010-06-04|Estimate|August 2006||2006-08-31|June 2010|2010-06-30|December 2010|Anticipated|2010-12-31|July 2008|Actual|2008-07-31||Interventional|PEKASYS||Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis|Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems|Unknown status|Active, not recruiting|Phase 4|22|Actual|Hvidovre University Hospital||3|||f||||t||||||||||2018-06-01 03:58:17.0876|2018-06-01 03:58:17.0876
NCT00332891|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2009-03-06|2006-06-01|2006-06-02|Estimate|||||||2009-03-06|2009-03-09|Estimate|March 2006||2006-03-31|March 2009|2009-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|ELECTRA||An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder|An 8-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy and Safety of 2 Fixed Doses of SR58611A (175 mg q12 and 350 mg q12) in Outpatients With GAD|Completed||Phase 3|508|Actual|Sanofi|||||f||||||||||||||2018-06-01 03:58:17.149202|2018-06-01 03:58:17.149202
NCT00332878|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2015-01-22|2006-06-01|2006-06-02|Estimate|||||||2015-01-22|2015-01-26|Estimate|March 2003||2003-03-31|January 2015|2015-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Stepping Stones Program for Preventing HIV Infection in Residents of Rural South African Communities|RCT of Stepping Stones Behavioural Intervention for HIV|Completed||Phase 3|2801|Actual|Medical Research Council, South Africa||2|||f||||t||||||||||2018-06-01 03:58:17.210682|2018-06-01 03:58:17.210682
NCT00332852|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2017-02-21|2006-06-01|2006-06-02|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2006||2006-03-31|February 2017|2017-02-28||||July 2010|Actual|2010-07-31||Interventional|||Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer|An Open Phase III Trial With Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer|Completed||Phase 3|655|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:58:17.486942|2018-06-01 03:58:17.486942
NCT00332839|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|2014-03-14||2014-08-15|2006-05-31|2006-06-02|Estimate|2014-08-15|2014-08-28|Estimate||||2014-08-15|2014-08-28|Estimate|November 2005||2005-11-30|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-coated Mycophenolate Sodium and Everolimus in Comparison to Standard Therapy With Enteric-coated Mycophenolate Sodium and Ciclosporin Microemulsion in Stable Renal Transplant Patients|Terminated||Phase 4|93|Actual|Novartis|Adverse Events data were not collected during the Follow-up period.|2||"The trial was terminated early due to slow enrollment. It was determined that the planned~   sample size of 300 could not be achieved."|f||||||||||||||2018-06-01 03:58:17.663061|2018-06-01 03:58:17.663061
NCT00332826|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2012-05-03|2006-06-01|2006-06-02|Estimate|||||||2012-05-03|2012-05-04|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma|A Phase 3, 12-month Treatment, Multicenter, Randomized, Open-Label, Parallel Group Clinical Trial Comparing Prandial Subcutaneous Insulin With Prandial Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma|Terminated||Phase 3|3|Actual|Mannkind Corporation||||Non-safety related business decision to combine special population protocols|||||||||||||||2018-06-01 03:58:18.065482|2018-06-01 03:58:18.065482
NCT00332813|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2013-03-26|2006-06-01|2006-06-02|Estimate|||||||2013-03-26|2013-03-28|Estimate|February 2006||2006-02-28|January 2006|2006-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Reducing HIV Risk Among Pregnant Women in Drug Treatment|Reducing HIV Risk Among Pregnant Women in Drug Treatment|Completed||Phase 1/Phase 2|98|Anticipated|Rhode Island Hospital|||||f||||||||||||||2018-06-01 03:58:18.190239|2018-06-01 03:58:18.190239
NCT00332800|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2006-05-31|2006-05-31|2006-06-02|Estimate|||||||2006-05-31|2006-06-02|Estimate|October 2003||2003-10-31|June 2005|2005-06-30|December 2005||2005-12-31|||||Interventional|||Study Impact of Nutritional Supplementary Treatment of Undernourished Stroke Patient on Functional Outcome Measures|What Impact Does Intensive Vs. Standard Nutritional Supplementary Treatment of Undernourished Stroke Patient Have on Functional Outcome Measures on an Acute Rehabilitation Unit – a Pilot Study|Completed||N/A|100||Burke Rehabilitation Hospital|||||f||||||||||||||2018-06-01 03:58:19.176257|2018-06-01 03:58:19.176257
NCT00332787|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2014-01-07|2006-06-01|2006-06-02|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2000||2000-06-30|January 2014|2014-01-31|October 2005||2005-10-31|||||Interventional|||Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents|Childhood Depression: Remission and Relapse|Completed||N/A|200||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 03:58:19.227797|2018-06-01 03:58:19.227797
NCT00332774|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2012-03-01|2006-06-01|2006-06-02|Estimate|||||||2012-03-01|2012-03-05|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Nevanac 3-Month Safety Study With QID Dosing|A 3-Month Clinical Safety Comparison of Nevanac 0.1% to Acular LS 0.4% and Vehicle Following Cataract Surgery|Completed||Phase 3|149|Actual|Alcon Research||3|||f||||||||||||||2018-06-01 03:58:20.082345|2018-06-01 03:58:20.082345
NCT00332761|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|||2008-08-19|2006-06-01|2006-06-02|Estimate|||||||2008-08-19|2008-08-20|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|September 2007|Actual|2007-09-30|||||Interventional|CUSP||Caduet in an Untreated Subject Population|An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untreated Subject Population)|Completed||Phase 4|220||Pfizer|||||f||||||||||||||2018-06-01 03:58:20.174771|2018-06-01 03:58:20.174771
NCT00332748|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31||2010-02-27|2010-02-27|2006-06-01|2006-06-02|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|December 2006||2006-12-31|September 2007|2007-09-30||||December 2007|Actual|2007-12-31||Interventional|||A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer|Effect of Esomeprazole on the Pharmacokinetics of BMS-275183 in Patients With Advanced Malignancies|Terminated||Phase 1|36||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 03:58:20.275961|2018-06-01 03:58:20.275961
NCT00332735|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2007-04-18|2006-05-31|2006-06-02|Estimate|||||||2007-04-18|2007-04-19|Estimate|May 2006||2006-05-31|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Spinal Anesthesia With Articaine and Bupivacaine for Outpatient Lower Limb Surgery|Spinal Anesthesia With 5% Articaine and 0.5% Bupivacaine for Outpatient Lower Limb Surgery. A Double-Blind Randomised Clinical Trial|Completed||Phase 3|80||Reinier de Graaf Groep|||||f||||||||||||||2018-06-01 03:58:20.331933|2018-06-01 03:58:20.331933
NCT00332722|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|2012-12-06||2013-09-27|2006-05-31|2006-06-02|Estimate|2013-09-27|2013-10-01|Estimate||||2013-09-27|2013-10-01|Estimate|September 2003||2003-09-30|September 2013|2013-09-30|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Effectiveness of Cervical Facet Joint Nerve Blocks|Effectiveness of Cervical Facet Joint Nerve Blocks: A Randomized, Prospective, Double-Blind Controlled Evaluation|Completed||N/A|120|Actual|Pain Management Center of Paducah|The study limitations include the lack of a placebo group.|2|||f||||t||||||||||2018-06-01 03:58:20.406302|2018-06-01 03:58:20.406302
NCT00332709|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|2011-08-11||2011-10-10|2006-06-01|2006-06-02|Estimate|2011-10-10|2011-11-16|Estimate||||2011-10-10|2011-11-16|Estimate|January 2006||2006-01-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer|An Open Phase III Trial With Letrozole Alone or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer|Completed||Phase 3|83|Actual|Novartis||2|||f||||||||||||||2018-06-01 03:58:20.766983|2018-06-01 03:58:20.766983
NCT00332696|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|2011-01-17||2011-09-20|2006-06-01|2006-06-02|Estimate|2011-05-13|2011-06-15|Estimate||||2011-09-20|2011-09-23|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis|Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis|Completed||Phase 2|64|Actual|Novartis|Study was terminated prematurely due to low enrollment|2|||f||||f||||||||||2018-06-01 03:58:21.273308|2018-06-01 03:58:21.273308
NCT00332683|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2017-08-25|2006-05-31|2006-06-02|Estimate|||||||2017-08-25|2017-08-28|Actual|June 6, 2006|Actual|2006-06-06|August 2017|2017-08-31|July 31, 2013|Actual|2013-07-31|July 31, 2013|Actual|2013-07-31||Interventional|||Reducing Dysphagia Associated With Anterior Cervical Spine Surgery by Maintaining Low Endotracheal Tube Cuff Pressure|Endotracheal Tube Cuff Pressure Protocol to Reduce Dysphagia Following Anterior Cervical Spine Surgery: A Prospective Randomized Pilot Study|Completed||N/A|40|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 03:58:21.849429|2018-06-01 03:58:21.849429
NCT00332670|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2008-08-12|2006-05-31|2006-06-02|Estimate|||||||2008-08-12|2008-08-15|Estimate|January 2003||2003-01-31|August 2008|2008-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Light Therapy for Elderly Depression|High Cortisol Levels as a Risk Factor for Depression in the Elderly and the Effect of Bright Light Treatment on Mood, Sleep-Wake Pattern and Self-Sufficiency|Terminated||Phase 2/Phase 3|89|Actual|GGZ Buitenamstel||2||End of research time, time-resources|f||||f||||||||||2018-06-01 03:58:21.935773|2018-06-01 03:58:21.935773
NCT00332657|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31||2012-11-27|2012-11-27|2006-05-31|2006-06-02|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Anecortave Acetate Risk Reduction Trial (AART)||Terminated||Phase 3|36|Actual|Alcon Research||3||Management Decision|f||||||||||||||2018-06-01 03:58:22.018448|2018-06-01 03:58:22.018448
NCT00332644|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-01|2011-10-21||2011-10-21|2006-06-01|2006-06-02|Estimate|2011-10-21|2011-11-30|Estimate||||2011-10-21|2011-11-30|Estimate|September 2004||2004-09-30|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms|Pharmacotherapies: Efficacy, Mechanisms and Algorithms|Completed||Phase 4|1504|Actual|University of Wisconsin, Madison||6|||f||||f||||||||||2018-06-01 03:58:22.119742|2018-06-01 03:58:22.119742
NCT00332631|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2009-07-06|2006-05-31|2006-06-01|Estimate|||||||2009-07-06|2009-07-07|Estimate|August 2004||2004-08-31|July 2009|2009-07-31|March 2006||2006-03-31|||||Interventional|||High-Dose N-Acetylcysteine in Cardiac Surgery|High-Dose N-Acetylcysteine in Cardiac Surgery Patients at High-Risk of Postoperative Renal Dysfunction.|Completed||Phase 2|60||Austin Health|||||f||||||||||||||2018-06-01 03:58:22.654704|2018-06-01 03:58:22.654704
NCT00332618|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2006-06-06|2006-05-31|2006-06-01|Estimate|||||||2006-06-06|2006-06-07|Estimate|September 2003||2003-09-30|March 2003|2003-03-31|April 2004||2004-04-30|||||Observational|||Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia|Multicenter Controlled Parallel-Groups Trial to Evaluate the Efficacy, Safety and Acceptability of TGO Buccal Spray Versus a Saliva Substitute in the Treatment of Psychotropic Medicines-Induced Xerostomia|Completed|||74||Laboratoires CARILENE|||||f||||||||||||||2018-06-01 03:58:22.727266|2018-06-01 03:58:22.727266
NCT00332605|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2012-03-01||2017-10-24|2006-05-30|2006-06-01|Estimate|2013-06-18|2013-07-24|Estimate||||2017-10-24|2017-11-30|Actual|June 2006||2006-06-30|October 2017|2017-10-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence|A Double-Blind Study of N-Acetyl Cysteine Plus Naltrexone in the Treatment of Methamphetamine Dependence|Completed||Phase 2|45|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 03:58:22.795748|2018-06-01 03:58:22.795748
NCT00332592|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2011-07-20|2006-05-31|2006-06-01|Estimate|||||||2011-07-20|2011-07-22|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Observational|||Intragastric and Peritoneal Microdialysis in Infants With Necrotizing Enterocolitis (NEC)|Intragastric and Intraperitoneal Microdialysis in Infants With NEC|Completed|||14|Actual|Odense University Hospital|||||f||||f||||||||||2018-06-01 03:58:23.045203|2018-06-01 03:58:23.045203
NCT00332579|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2012-03-01||2012-04-09|2006-05-30|2006-06-01|Estimate|2012-04-09|2012-05-04|Estimate||||2012-04-09|2012-05-04|Estimate|May 2006||2006-05-31|April 2012|2012-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Double-Blind Naltrexone in Kleptomania|A Double-Blind, Placebo-Controlled Study of Naltrexone in Kleptomania|Completed||Phase 2|25|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 03:58:23.107397|2018-06-01 03:58:23.107397
NCT00332566|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2016-09-27|2006-05-31|2006-06-01|Estimate|||||||2016-09-27|2016-09-28|Estimate|June 2006||2006-06-30|September 2016|2016-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib|Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals' DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals' DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines.|Completed||Phase 3|148|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:58:23.301243|2018-06-01 03:58:23.301243
NCT00332553|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2007-05-11|2006-05-30|2006-06-01|Estimate|||||||2007-05-11|2007-05-15|Estimate|February 2002||2002-02-28|May 2007|2007-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen|Study of Vasomotor Symptoms in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen|Completed||Phase 2|150||Eli Lilly and Company|||||||||||||||||||2018-06-01 03:58:23.389784|2018-06-01 03:58:23.389784
NCT00332540|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-05-27|2006-05-30|2006-06-01|Estimate|||||||2011-05-27|2011-05-30|Estimate|August 2001||2001-08-31|May 2011|2011-05-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|520|Actual|Allergan|||||f||||||||||||||2018-06-01 03:58:23.437721|2018-06-01 03:58:23.437721
NCT00332514|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2016-02-19|2006-05-31|2006-06-01|Estimate|||||||2016-02-19|2016-02-23|Estimate|March 2004||2004-03-31|March 2006|2006-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care|Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care|Completed||Phase 2|200||Boston Medical Center||1|||f||||f||||||||||2018-06-01 03:58:23.489287|2018-06-01 03:58:23.489287
NCT00332488|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|2014-07-22|2009-06-09|2014-10-09|2006-05-31|2006-06-01|Estimate|2014-10-09|2014-10-16|Estimate|2009-10-01|2009-10-05|Estimate|2014-10-09|2014-10-16|Estimate|December 2004||2004-12-31|October 2014|2014-10-31||||March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes|A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and a Secretagogue) in Subjects With Type 2 Diabetes Mellitus Sub-optimally Controlled on Combination Metformin and a Secretagogue.|Completed||Phase 3|547|Actual|Mannkind Corporation|Wks 12–24 was a non-randomized treatment period of the trial; outcomes were not analyzed for Wks 12–24. Safety results include entire trial; patients counted in multiple treatments for safety.|3|||f||||||||||||||2018-06-01 03:58:23.662459|2018-06-01 03:58:23.662459
NCT00332462|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2010-12-13||2011-03-01|2006-05-30|2006-06-01|Estimate|2010-12-13|2011-01-11|Estimate||||2011-03-01|2011-03-07|Estimate|May 2006||2006-05-31|March 2011|2011-03-31|January 2009|Actual|2009-01-31|April 2008|Actual|2008-04-30||Interventional|||A Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine in de Novo Liver Transplant Recipients|A Multicenter, Open-label, Exploratory Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine During the First 7 Days Post Transplant Followed by Treatment With Cyclosporine Micro Emulsion in de Novo Liver Transplant Recipients|Completed||Phase 4|34|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:58:24.298433|2018-06-01 03:58:24.298433
NCT00332449|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2008-04-14|2006-05-31|2006-06-01|Estimate|||||||2008-04-14|2008-04-15|Estimate|June 2007||2007-06-30|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|June 2008|Anticipated|2008-06-30||Observational|||Early Breast Feeding and Glucose Levels in High Risk Newborns|Does Early Breast Feeding Prevents Neonatal Hypoglycemia in High Risk Newborns|Unknown status|Recruiting||100|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:58:24.687173|2018-06-01 03:58:24.687173
NCT00332436|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-05-27|2006-05-30|2006-06-01|Estimate|||||||2011-05-27|2011-05-30|Estimate|December 1999||1999-12-31|May 2011|2011-05-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|586|Actual|Allergan|||||f||||||||||||||2018-06-01 03:58:24.74443|2018-06-01 03:58:24.74443
NCT00332410|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2015-12-16|2006-05-31|2006-06-01|Estimate|||||||2015-12-16|2015-12-17|Estimate|May 2006||2006-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Intravenous Voriconazole in Patients With Renal Compromise|Intravenous Voriconazole in Patients With Renal Compromise|Completed|||150|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:58:24.795176|2018-06-01 03:58:24.795176
NCT00332397|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2008-06-16|2006-05-31|2006-06-01|Estimate|||||||2008-06-16|2008-06-17|Estimate|March 2006||2006-03-31|June 2008|2008-06-30|July 2007|Actual|2007-07-31|||||Interventional|ISAR-TEST-2||The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent Restenosis|Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis|Completed||Phase 4|1007|Actual|Deutsches Herzzentrum Muenchen||3|||f||||t||||||||||2018-06-01 03:58:24.848818|2018-06-01 03:58:24.848818
NCT00332384|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-05-27|2006-05-30|2006-06-01|Estimate|||||||2011-05-27|2011-05-30|Estimate|January 2000||2000-01-31|May 2011|2011-05-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|573|Actual|Allergan|||||f||||||||||||||2018-06-01 03:58:24.921828|2018-06-01 03:58:24.921828
NCT00332371|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2012-07-05|2006-05-31|2006-06-01|Estimate|||||||2012-07-05|2012-07-09|Estimate|December 2006||2006-12-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||COMPACT - COMbining Plasma-filtration and Adsorption Clinical Trial|COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU|Terminated||N/A|184|Actual|Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva||2||The study was prematurely interrupted for futility.|f||||t||||||||||2018-06-01 03:58:24.975353|2018-06-01 03:58:24.975353
NCT00332345|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-05-27|2006-05-30|2006-06-01|Estimate|||||||2011-05-27|2011-05-30|Estimate|July 1999||1999-07-31|May 2011|2011-05-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 2|73|Actual|Allergan|||||f||||||||||||||2018-06-01 03:58:25.080126|2018-06-01 03:58:25.080126
NCT00332332|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2010-11-05||2014-07-18|2006-05-30|2006-06-01|Estimate|2011-06-03|2011-06-14|Estimate||||2014-07-18|2014-07-25|Estimate|March 2006||2006-03-31|July 2014|2014-07-31|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis|Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis|Completed||Phase 4|246|Actual|Amgen||1|||f||||||||||||||2018-06-01 03:58:25.13311|2018-06-01 03:58:25.13311
NCT00332319|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2015-04-15|2006-05-30|2006-06-01|Estimate|||||||2015-04-15|2015-04-17|Estimate|January 2006||2006-01-31|March 2011|2011-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients|See Detailed Description|Terminated||Phase 2|1|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 03:58:25.400086|2018-06-01 03:58:25.400086
NCT00332306|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2009-10-07|2006-05-30|2006-06-01|Estimate|||||||2009-10-07|2009-10-08|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|December 2011|Anticipated|2011-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment|Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis|Unknown status|Active, not recruiting|Phase 3|180|Anticipated|Tuberculosis Research Centre, India||2|||f||||t||||||||||2018-06-01 03:58:25.475818|2018-06-01 03:58:25.475818
NCT00332293|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2016-11-16|2006-05-31|2006-06-01|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||AL-15469A for the Treatment of Bacterial Conjunctivitis|An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India|Completed||Phase 3|695|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 03:58:25.549646|2018-06-01 03:58:25.549646
NCT00332280|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2013-03-19|2006-05-31|2006-06-01|Estimate|||||||2013-03-19|2013-03-20|Estimate|May 2006||2006-05-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo|A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo|Terminated||Phase 2/Phase 3|67|Actual|Auron Healthcare GmbH||1||Lack of efficacy. Stopped at first interim evaluation point|f||||||||||||||2018-06-01 03:58:25.621912|2018-06-01 03:58:25.621912
NCT00332241|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|2009-06-03||2013-11-07|2006-05-31|2006-06-01|Estimate|2009-06-03|2009-07-23|Estimate||||2013-11-07|2013-12-02|Estimate|June 2006||2006-06-30|December 2009|2009-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)|A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)|Completed||Phase 3|98|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-06-01 03:58:25.90391|2018-06-01 03:58:25.90391
NCT00332228|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2012-10-25|2006-05-30|2006-06-01|Estimate|||||||2012-10-25|2012-10-26|Estimate|June 2002||2002-06-30|October 2012|2012-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence|Study Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence|Completed||Phase 2|125|Actual|New York State Psychiatric Institute||4|||f||||t||||||||||2018-06-01 03:58:26.400354|2018-06-01 03:58:26.400354
NCT00332215|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2008-11-26|2006-05-30|2006-06-01|Estimate|||||||2008-11-26|2008-12-01|Estimate|February 2006||2006-02-28|November 2008|2008-11-30||||||||Interventional|||A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.|Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study.|Terminated||Phase 1|70|Anticipated|University of Minnesota - Clinical and Translational Science Institute||||"Dr. Milla has left University of Minnesota. The study is no longer being conducted at this~   site."|||||||||||||||2018-06-01 03:58:26.4821|2018-06-01 03:58:26.4821
NCT00332202|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30||2013-04-30|2013-10-30|2006-05-30|2006-06-01|Estimate||||2013-04-30|2013-05-08|Estimate|2013-10-30|2013-11-25|Estimate|June 2006||2006-06-30|October 2013|2013-10-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin|A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin|Completed||Phase 3|709|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 03:58:26.579949|2018-06-01 03:58:26.579949
NCT00332189|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2012-09-13||2012-10-17|2006-05-31|2006-06-01|Estimate|2012-10-17|2012-11-16|Estimate||||2012-10-17|2012-11-16|Estimate|July 2006||2006-07-31|October 2012|2012-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006|A Phase 3b, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006|Completed||Phase 3|111|Actual|BioMarin Pharmaceutical|||||f||||||||||||||2018-06-01 03:58:26.934478|2018-06-01 03:58:26.934478
NCT00332176|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2008-04-03|2006-05-30|2006-06-01|Estimate|||||||2008-04-03|2008-04-08|Estimate|June 2006||2006-06-30|April 2008|2008-04-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C|A Phase II Randomized, Active-Controlled Study to Assess the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin Over 12 Weeks in Treatment-Naïve Patients With Chronic Hepatitis C|Unknown status|Recruiting|Phase 2|50|Anticipated|BioWest Therapeutics Inc||3|||f||||||||||||||2018-06-01 03:58:27.134667|2018-06-01 03:58:27.134667
NCT00332163|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|2016-01-12|2010-07-20|2016-01-26|2006-05-31|2006-06-01|Estimate|2016-01-26|2016-02-23|Estimate|2014-03-28|2014-04-25|Estimate|2016-01-26|2016-02-23|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|STEPP||Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy|A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab|Completed||Phase 2|95|Actual|Amgen||2|||f||||f||||||||||2018-06-01 03:58:27.234605|2018-06-01 03:58:27.234605
NCT00332150|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2013-01-23|2006-05-31|2006-06-01|Estimate|||||||2013-01-23|2013-01-24|Estimate|March 2006||2006-03-31|January 2013|2013-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Mothers' Approach to Clinical Research Amongst Their Preterm or Healthy Newborns|Mothers' Approach to Clinical Research Amongst Their Preterm or Healthy Newborns|Completed|||200|Actual|Sheba Medical Center|||||f||||||||||||||2018-06-01 03:58:27.997769|2018-06-01 03:58:27.997769
NCT00332137|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-03-21|2006-05-31|2006-06-01|Estimate|||||||2011-03-21|2011-03-23|Estimate|September 2005||2005-09-30|March 2011|2011-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects|Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects|Completed||Phase 2|36||Mayo Clinic|||||f||||||||||||||2018-06-01 03:58:28.065777|2018-06-01 03:58:28.065777
NCT00332124|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2017-08-29|2006-05-31|2006-06-01|Estimate|||||||2017-08-29|2017-08-31|Actual|June 2006|Actual|2006-06-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Effectiveness of Taking Choline Supplements During Pregnancy for Improving Infant Brain Development|Double-blind Trial of Phosphatidylcholine During Pregnancy and Infant Serum Choline Levels|Completed||Phase 1|351|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 03:58:28.121148|2018-06-01 03:58:28.121148
NCT00332111|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2013-01-15|2006-05-30|2006-06-01|Estimate|||||||2013-01-15|2013-01-17|Estimate|April 2006||2006-04-30|January 2013|2013-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Infectious Outcomes Following Pancreas Transplantation|Infectious Outcomes Following Pancreas Transplantation|Completed|||300|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 03:58:28.191756|2018-06-01 03:58:28.191756
NCT00332098|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2014-05-16|2006-05-30|2006-06-01|Estimate|||||||2014-05-16|2014-05-20|Estimate|August 2006||2006-08-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effectiveness of Family-Focused Treatment Plus Pharmacotherapy for Bipolar Disorder in Adolescents|Family-Focused Treatment for Bipolar Adolescents|Completed||Phase 3|145|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 03:58:28.249707|2018-06-01 03:58:28.249707
NCT00332085|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2007-10-29|2006-05-30|2006-06-01|Estimate|||||||2007-10-29|2007-10-31|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|March 2007|Actual|2007-03-31|||||Interventional|||Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes|Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes: Impact on Blood Sugar Control and Insulin Resistance|Terminated||Phase 1|40|Anticipated|Bastyr University||||Issues w/recruitment|f||||||||||||||2018-06-01 03:58:28.326219|2018-06-01 03:58:28.326219
NCT00332072|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-05-27|2006-05-30|2006-06-01|Estimate|||||||2011-05-27|2011-05-30|Estimate|August 2001||2001-08-31|May 2011|2011-05-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension||Completed||Phase 3|541|Actual|Allergan|||||f||||||||||||||2018-06-01 03:58:28.385435|2018-06-01 03:58:28.385435
NCT00332059|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-05-27|2006-05-30|2006-06-01|Estimate|||||||2011-05-27|2011-05-30|Estimate|May 2003||2003-05-31|May 2011|2011-05-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|445|Actual|Allergan|||||f||||||||||||||2018-06-01 03:58:28.437362|2018-06-01 03:58:28.437362
NCT00332046|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2008-10-15|2006-05-30|2006-06-01|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2006||2006-01-31|October 2008|2008-10-31||||||||Interventional|||fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder|A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD).|Completed||Phase 1|57||GlaxoSmithKline|||||||||||||||||||2018-06-01 03:58:28.497686|2018-06-01 03:58:28.497686
NCT00332033|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-31|||2017-06-30|2006-05-31|2006-06-01|Estimate|||||||2017-06-30|2017-07-02|Actual|May 25, 2006||2006-05-25|February 16, 2007|2007-02-16|February 16, 2007||2007-02-16|||||Interventional|||Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)|Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)|Completed||Phase 2|32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:58:28.555378|2018-06-01 03:58:28.555378
NCT00332020|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2015-01-26|2006-05-30|2006-05-31|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2006||2006-02-28|January 2015|2015-01-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|RECORD 2||Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement|RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Hip Replacement.|Completed||Phase 3|2457|Actual|Bayer||2|||f||||||||||||||2018-06-01 03:58:28.639118|2018-06-01 03:58:28.639118
NCT00332007|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2009-08-28|2006-05-30|2006-05-31|Estimate|||||||2009-08-28|2009-08-31|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Tonabersat in the Prophylaxis of Migraine With Aura|A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura|Completed||Phase 2|39|Actual|Minster Research Ltd||2|||f||||f||||||||||2018-06-01 03:58:28.926616|2018-06-01 03:58:28.926616
NCT00331994|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2009-07-17|2006-05-30|2006-05-31|Estimate|||||||2009-07-17|2009-07-20|Estimate|April 2006||2006-04-30|July 2009|2009-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth|Efficacy Evaluation of Enterogermina, 2 Billion Bacillus Clausii Spores, on Eradication of Small Intestinal Bacterial Overgrowth: a Randomised, Parallel-group, Open Study.|Completed||Phase 4|250|Actual|Sanofi||2|||f||||||||||||||2018-06-01 03:58:28.990643|2018-06-01 03:58:28.990643
NCT00331981|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2008-04-08|2006-05-30|2006-05-31|Estimate|||||||2008-04-08|2008-04-10|Estimate|February 2004||2004-02-29|April 2008|2008-04-30||||||||Interventional|||Amisulpride in Schizophrenic Patients|Study of the Efficacy and Safety After Long-Term Treatment With Amisulpride in Schizophrenic Patients|Completed||Phase 4|138||Sanofi|||||f||||f||||||||||2018-06-01 03:58:29.062325|2018-06-01 03:58:29.062325
NCT00331955|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2013-07-01|2006-05-30|2006-05-31|Estimate|||||||2013-07-01|2013-07-02|Estimate|March 2006||2006-03-31|July 2013|2013-07-31||||June 2012|Actual|2012-06-30||Interventional|||Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors|Phase I Trial of Vorinostat (NSC-701852, Suberoylanilide Hydroxamic Acid) and Doxorubicin (NSC-123127, Adriamycin)|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:58:29.110671|2018-06-01 03:58:29.110671
NCT00331942|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-27|||2007-03-01|2006-05-30|2006-05-31|Estimate|||||||2007-03-01|2007-03-02|Estimate|July 2006||2006-07-31|April 2006|2006-04-30|May 2008||2008-05-31|||||Observational|||Breast Cancer Associated Antibodies|Study of Breast Cancer Associated Antibodies|Unknown status|Recruiting||100||Lab Discoveries Ltd.|||||f||||||||||||||2018-06-01 03:58:29.186994|2018-06-01 03:58:29.186994
NCT00331929|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-28|||2008-06-18|2006-05-30|2006-05-31|Estimate|||||||2008-06-18|2008-06-20|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Respiratory Health Study of Children in Kiryat Tivon|Respiratory Health Study of Children in Kiryat Tivon|Completed||N/A|638|Actual|Carmel Medical Center||1|||f||||t||||||||||2018-06-01 03:58:29.239486|2018-06-01 03:58:29.239486
NCT00331916|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2009-09-25|2006-05-30|2006-05-31|Estimate|||||||2009-09-25|2009-09-29|Estimate|November 2005||2005-11-30|September 2009|2009-09-30||||May 2007|Actual|2007-05-31||Interventional|||AL-15469A for the Treatment of Bacterial Conjunctivitis|AL-15469A for the Treatment of Bacterial Conjunctivitis|Completed||Phase 3|600|Anticipated|Alcon Research|||||||||||||||||||2018-06-01 03:58:29.369026|2018-06-01 03:58:29.369026
NCT00331890|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2012-06-19|2006-05-30|2006-05-31|Estimate|||||||2012-06-19|2012-06-20|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|ICTUS||ICTUS Study: International Citicoline Trial on Acute Stroke|Citicoline in the Treatment of Acute Ischemic Stroke. An International Randomized Multicenter Placebo-controlled Study|Terminated||Phase 3|2298|Actual|Ferrer Internacional S.A.||2||With 2078 patients, a statistical stopping boundary has now been crossed|f||||t||||||||||2018-06-01 03:58:29.438117|2018-06-01 03:58:29.438117
NCT00331877|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2006-05-30|2006-05-30|2006-05-31|Estimate|||||||2006-05-30|2006-05-31|Estimate|May 2005||2005-05-31|May 2006|2006-05-31|January 2006||2006-01-31|||||Interventional|||A Communication Strategy for Families of Patients Dying in the ICU|A Proactive Communication Strategy for Family Members of Patients Dying in the ICU: A Multicenter Randomized Controlled Trial|Terminated||N/A|136||Famirea Study Group|||||f||||||||||||||2018-06-01 03:58:29.616988|2018-06-01 03:58:29.616988
NCT00331695|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-05-06|2006-05-30|2006-05-31|Estimate|||||||2011-05-06|2011-05-09|Estimate|June 2006||2006-06-30|March 2007|2007-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery|Evaluation of the Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery|Completed||Phase 4|560|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 03:58:34.196514|2018-06-01 03:58:34.196514
NCT00331864|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2010-12-09||2011-02-15|2006-05-29|2006-05-31|Estimate|2010-12-09|2011-01-04|Estimate||||2011-02-15|2011-02-18|Estimate|April 2006||2006-04-30|February 2011|2011-02-28|April 2008||2008-04-30|April 2008|Actual|2008-04-30||Interventional|||SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovasculariza-tion Secondary to Age-related Macular Degeneration|Completed||Phase 3|531|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:58:29.719652|2018-06-01 03:58:29.719652
NCT00331851|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2017-01-25|2006-05-30|2006-05-31|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|LEAD-5||Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.|Completed||Phase 3|584|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 03:58:30.38723|2018-06-01 03:58:30.38723
NCT00331838|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2013-01-14|2006-05-30|2006-05-31|Estimate|||||||2013-01-14|2013-01-15|Estimate|May 2006||2006-05-31|January 2013|2013-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|TREK||Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery|A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, Dose Response Study of Subcutaneous AVE5026 With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery|Completed||Phase 2|705|Actual|Sanofi||8|||f||||t||||||||||2018-06-01 03:58:30.642525|2018-06-01 03:58:30.642525
NCT00331825|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2006-05-30|2006-05-30|2006-05-31|Estimate|||||||2006-05-30|2006-05-31|Estimate|July 2000||2000-07-31|February 2000|2000-02-29|July 2003||2003-07-31|||||Interventional|||Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism|A Randomized Controlled Trial Study of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism|Completed||Phase 4|70||Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan|||||f||||||||||||||2018-06-01 03:58:30.752338|2018-06-01 03:58:30.752338
NCT00331812|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2011-01-18|2006-05-30|2006-05-31|Estimate|||||||2011-01-18|2011-01-19|Estimate|February 2006||2006-02-28|January 2011|2011-01-31|February 2008|Anticipated|2008-02-29|||||Observational|||Mitochondrial Functions and Oxidative Stress in ALS Patients|Study of Mitochondrial Functions and Oxidative Stress in ALS Patients.|Unknown status|Recruiting||40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:58:30.805818|2018-06-01 03:58:30.805818
NCT00331799|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2013-04-15||2013-07-01|2006-05-30|2006-05-31|Estimate|2013-07-01|2013-08-02|Estimate||||2013-07-01|2013-08-02|Estimate|April 2007||2007-04-30|June 2013|2013-06-30|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Pilot Study of Duloxetine in Psychological Resilience|A Pilot Study of Duloxetine in Psychological Resilience and Its Correlation With Blockade of Serotonin and Norepinephrine Transporter|Completed||Phase 2|18|Actual|Duke University||1|||f||||t||||||||||2018-06-01 03:58:30.864803|2018-06-01 03:58:30.864803
NCT00331786|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2009-02-06|2006-05-30|2006-05-31|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2006||2006-07-31|May 2007|2007-05-31||||||||Interventional|||Nitric Oxide-Releasing Acetylsalicyclic Acid in Preventing Colorectal Cancer in Patients at High Risk of Colorectal Cancer|Phase I Multiple-Dose Safety, Pharmacokinetic and Pharmacodynamic Clinical Study of Nitric Oxide Releasing Aspirin (NCX 4016)|Completed||Phase 1|240|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 03:58:30.994791|2018-06-01 03:58:30.994791
NCT00331773|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2016-11-29||2018-03-14|2006-05-30|2006-05-31|Estimate|2017-02-28|2017-04-13|Actual||||2018-03-14|2018-04-12|Actual|April 2006||2006-04-30|March 2018|2018-03-31||||July 2015|Actual|2015-07-31||Interventional||Eligible patients who did not withdraw consent.|Radiation Therapy in Treating Patients With Stage II Prostate Cancer|A Phase III Randomized Study of Hypofractionated 3D-CRT/MRT Versus Conventionally Fractionated 3D-CRT/MRT in Patients With Favorable-Risk Prostate Cancer|Active, not recruiting||Phase 3|1115|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 03:58:31.125566|2018-06-01 03:58:31.125566
NCT00331760|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2013-04-12||2016-12-30|2006-05-30|2006-05-31|Estimate|2013-04-12|2013-06-03|Estimate||||2016-12-30|2017-02-17|Actual|March 2006||2006-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|February 2009|Actual|2009-02-28||Interventional||All registered patients.|Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery|A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma|Completed||Phase 2|106|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 03:58:33.232265|2018-06-01 03:58:33.232265
NCT00331747|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2006-07-05|2006-05-30|2006-05-31|Estimate|||||||2006-07-05|2006-07-07|Estimate|May 2006||2006-05-31|July 2006|2006-07-31||||||||Interventional|||Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate|Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate|Unknown status|Recruiting|N/A|20||Sheba Medical Center|||||f||||||||||||||2018-06-01 03:58:33.896923|2018-06-01 03:58:33.896923
NCT00331721|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2008-05-21|2006-05-30|2006-05-31|Estimate|||||||2008-05-21|2008-05-22|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|May 2009|Anticipated|2009-05-31|May 2009|Anticipated|2009-05-31||Interventional|||Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST|A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke|Terminated||Phase 2|24|Actual|PAION Deutschland GmbH||2||Scientific data called into question the viability of the substance class|f||||t||||||||||2018-06-01 03:58:33.960562|2018-06-01 03:58:33.960562
NCT00331708|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2016-10-25|2006-05-30|2006-05-31|Estimate|||||||2016-10-25|2016-10-26|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria|An Open-label in Vivo Drug Study to Evaluate Artesunate Plus Sulfadoxine-pyrimethamine (ASSP) Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes in Pregnant Women With Uncomplicated Falciparum Malaria|Terminated||N/A|3|Actual|University of Cape Town||1||Lack of suitable participants|f||||t||||||||||2018-06-01 03:58:34.135655|2018-06-01 03:58:34.135655
NCT00318253|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2009-07-08|2006-04-24|2006-04-26|Estimate|||||||2009-07-08|2009-07-09|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||The Effects of Cranberry Juice on Bacterial Adhesion|The Effects of Cranberry Juice on Urine and Bacterial Adhesion to Cells|Completed||N/A|12|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 04:02:39.379568|2018-06-01 04:02:39.379568
NCT00331682|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2013-11-21||2014-05-12|2006-05-30|2006-05-31|Estimate|2013-11-21|2014-01-10|Estimate||||2014-05-12|2014-05-28|Estimate|March 2006||2006-03-31|November 2013|2013-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer|An Open-Label, Non-Randomized Phase II Study of Alvocidib (Flavopiridol) in Combination With Docetaxel in Refractory, Metastatic Pancreatic Cancer (NCI #6366)|Completed||Phase 2|10|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:58:34.309125|2018-06-01 03:58:34.309125
NCT00331669|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2009-03-03|2006-05-30|2006-05-31|Estimate|||||||2009-03-03|2009-03-04|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|December 2010|Anticipated|2010-12-31|||||Interventional|||Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia|Multicenter, Randomized Trial on the Effects of Pallidal Deep Brain Stimulation for Tardive Dystonia|Unknown status|Recruiting|Phase 2|24|Anticipated|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-06-01 03:58:34.573078|2018-06-01 03:58:34.573078
NCT00331656|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2008-05-06|2006-05-30|2006-05-31|Estimate|||||||2008-05-06|2008-05-07|Estimate|June 2008||2008-06-30|May 2006|2006-05-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure.|Non-Invasive Positive Pressure Mask Ventilation vs Extrathoracic Biphasic Cuirass Ventilation in Patients With Acute Respiratory Failure: A Randomized Prospective Study.|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:58:34.661386|2018-06-01 03:58:34.661386
NCT00331643|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2014-11-13|2006-05-30|2006-05-31|Estimate|||||||2014-11-13|2014-11-14|Estimate|April 2006||2006-04-30|January 2014|2014-01-31|June 2009|Actual|2009-06-30|October 2007|Actual|2007-10-31||Interventional|||Ixabepilone in Treating Young Patients With Refractory Solid Tumors|Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors|Completed||Phase 2|120|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:58:34.746695|2018-06-01 03:58:34.746695
NCT00331630|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2018-02-02|2006-05-30|2006-05-31|Estimate|||||||2018-02-02|2018-02-06|Actual|May 2006||2006-05-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2014|Actual|2014-08-31||Interventional|||Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer|Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)|Active, not recruiting||Early Phase 1|30|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 03:58:34.831173|2018-06-01 03:58:34.831173
NCT00331604|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2017-02-28|2006-05-29|2006-05-31|Estimate|||||||2017-02-28|2017-03-01|Actual|August 31, 2006|Actual|2006-08-31|February 2017|2017-02-28|May 5, 2008|Actual|2008-05-05|May 5, 2008|Actual|2008-05-05||Interventional|||Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes|Inhaled Pre-prandial Human Insulin With the AERx® iDMS Versus s.c. Insulin Aspart in Type 2 Diabetes: A 104 Week, Open-label, Multicenter, Randomised, Trial Followed by a 12 Week Re-randomised Extension to Investigate Safety and Efficacy|Terminated||Phase 3|618|Actual|Novo Nordisk A/S||3||See termination reason in detailed description|f||||f||||||||||2018-06-01 03:58:34.936513|2018-06-01 03:58:34.936513
NCT00331578|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2009-01-19|2006-05-30|2006-05-31|Estimate|||||||2009-01-19|2009-01-21|Estimate|June 2006||2006-06-30|January 2009|2009-01-31|December 2006|Actual|2006-12-31|||||Interventional|CREATE||Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent|Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent|Completed||Phase 4|2077|Actual|JW Medical Systems Ltd|||||f||||t||||||||||2018-06-01 03:58:35.09684|2018-06-01 03:58:35.09684
NCT00331565|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-29|||2014-12-02|2006-05-29|2006-05-31|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin|Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin|Completed||Phase 4|36|Actual|University of Oslo School of Pharmacy||1|||f||||||||||||||2018-06-01 03:58:35.142133|2018-06-01 03:58:35.142133
NCT00331552|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2017-04-14||2017-06-27|2006-05-30|2006-05-31|Estimate|2017-06-27|2017-07-26|Actual||||2017-06-27|2017-07-26|Actual|February 2006||2006-02-28|June 2017|2017-06-30|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer|Phase I - II Study of Doxil® In Combination With Daily Oral Cyclophosphamide and Herceptin for Patients With HER-2/Neu Positive Disease In Patients With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|30|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 03:58:35.229541|2018-06-01 03:58:35.229541
NCT00331539|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2006-10-06|2006-05-30|2006-05-31|Estimate|||||||2006-10-06|2006-10-09|Estimate|May 2006||2006-05-31|July 2005|2005-07-31|June 2008||2008-06-30|||||Interventional|||Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant|Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant|Unknown status|Recruiting|Phase 4|20||Bnai Zion Medical Center|||||f||||||||||||||2018-06-01 03:58:35.668809|2018-06-01 03:58:35.668809
NCT00331526|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2013-03-22|2006-05-30|2006-05-31|Estimate|||||||2013-03-22|2013-03-25|Estimate|February 1999||1999-02-28|March 2013|2013-03-31|April 2012|Actual|2012-04-30|December 2008|Actual|2008-12-31||Interventional|||Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme|Phase II Trial of Intralesional Adoptive Cellular Therapy of Glioblastoma With Interleukin-2-Stimulated Lymphocytes|Completed||Phase 2|83|Actual|Hoag Memorial Hospital Presbyterian|||||f||||||||||||||2018-06-01 03:58:35.73718|2018-06-01 03:58:35.73718
NCT00331513|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2013-09-27|2006-05-30|2006-05-31|Estimate|||||||2013-09-27|2013-09-30|Estimate|March 2006||2006-03-31|September 2013|2013-09-30||||January 2010|Actual|2010-01-31||Interventional|||Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes|A Phase 1 Study of Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) in Combination With Idarubicin in Relapsed or Refractory Leukemia|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:58:35.803659|2018-06-01 03:58:35.803659
NCT00331500|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2017-08-10|2006-05-30|2006-05-31|Estimate|||||||2017-08-10|2017-08-14|Actual|April 18, 2006|Actual|2006-04-18|June 2008|2008-06-30|July 27, 2006|Actual|2006-07-27|July 27, 2006|Actual|2006-07-27||Interventional|||Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis|A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis|Completed||Phase 3|287|Actual|Alcon Research||2|||||||||||||||||2018-06-01 03:58:35.889752|2018-06-01 03:58:35.889752
NCT00331487|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2012-02-27|2006-05-30|2006-05-31|Estimate|||||||2012-02-27|2012-02-28|Estimate|September 2000||2000-09-30|February 2012|2012-02-29|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia|Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia|Completed||Phase 3|719|Actual|Takeda||2|||f||||f||||||||||2018-06-01 03:58:35.9719|2018-06-01 03:58:35.9719
NCT00331474|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2009-02-13|2006-05-30|2006-05-31|Estimate|||||||2009-02-13|2009-02-16|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|August 2009|Anticipated|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants|The Effect of BCG Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants|Unknown status|Active, not recruiting|Phase 1/Phase 2|180|Anticipated|University of Stellenbosch|||||f||||||||||||||2018-06-01 03:58:36.155686|2018-06-01 03:58:36.155686
NCT00331448|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2006-08-10|2006-05-30|2006-05-31|Estimate|||||||2006-08-10|2006-08-15|Estimate|June 2000||2000-06-30|May 2006|2006-05-31|July 2007||2007-07-31|||||Observational|||Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults|Fat Redistribution and Metabolic Change in HIV Infection (FRAM)|Unknown status|Active, not recruiting||1483||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 03:58:36.22688|2018-06-01 03:58:36.22688
NCT00331435|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2011-03-30|2006-05-30|2006-05-31|Estimate|||||||2011-03-30|2011-03-31|Estimate|June 2006||2006-06-30|March 2011|2011-03-31|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|||PDT Study for Exudative AMD With PCV|Clinical Research of Photodynamic Therapy for Exudative Age-related Macular Degeneration Accompanied With Polypoidal Choroidal Vasculopathy|Completed||Phase 4|113|Actual|Ophthalmic PDT Study Group||2|||f||||t||||||||||2018-06-01 03:58:36.301389|2018-06-01 03:58:36.301389
NCT00331422|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2009-11-23||2017-12-03|2006-05-30|2006-05-31|Estimate|2010-01-19|2010-02-08|Estimate||||2017-12-03|2017-12-28|Actual|October 2005||2005-10-31|December 2017|2017-12-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase II Study of Carboplatin and Paclitaxel as Neoadjuvant Chemotherapy Followed by Interval Cytoreduction in Women With Advanced Staged Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma for High-Risk Surgical Candidates or Patients Unlikely to be Optimally Surgically Cytoreduced|Terminated||Phase 2|7|Actual|Masonic Cancer Center, University of Minnesota|1 of the 2 evaluable patients was switched from Paclitaxel to Taxotere during the course of her treatment due to toxicity (adverse effects), but since it remains a platinum-based chemotherapy she is included in the evaluable group.|1||Study was terminated due to lack of available funding.|f||||t||||||||||2018-06-01 03:58:36.42953|2018-06-01 03:58:36.42953
NCT00331409|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2011-06-13||2017-09-25|2006-05-30|2006-05-31|Estimate|2011-09-06|2011-10-05|Estimate||||2017-09-25|2017-10-26|Actual|January 2006||2006-01-31|September 2017|2017-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma|Completed||Phase 2|23|Actual|OHSU Knight Cancer Institute|Our phase II study closed after the first stage of accrual due to an insufficient number of participants who remained progression-free at 3 months, per the study design.|1|||f||||t||||||||||2018-06-01 03:58:36.711691|2018-06-01 03:58:36.711691
NCT00331370|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|||2006-05-30|2006-05-30|2006-05-31|Estimate|||||||2006-05-30|2006-05-31|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|June 2009||2009-06-30|||||Interventional|||Hypertension Related Damage to the Microcirculation in South Asian: Emergence, Predictive Power and Reversibility|Hypertension Related Damage to the Microcirculation in South Asian: Emergence,Predictive Power and Reversibility|Unknown status|Not yet recruiting|N/A|2880||Aga Khan University|||||f||||||||||||||2018-06-01 03:58:36.966007|2018-06-01 03:58:36.966007
NCT00331357|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-29|||2006-05-29|2006-05-29|2006-05-31|Estimate|||||||2006-05-29|2006-05-31|Estimate|June 2006||2006-06-30|May 2006|2006-05-31|December 2008||2008-12-31|||||Observational|||Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire|Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire|Unknown status|Not yet recruiting||100||University Hospital, Angers|||||f||||||||||||||2018-06-01 03:58:37.037771|2018-06-01 03:58:37.037771
NCT00331344|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-30|2017-06-02||2017-10-02|2006-05-30|2006-05-31|Estimate|2017-10-02|2017-10-31|Actual||||2017-10-02|2017-10-31|Actual|April 2006||2006-04-30|October 2017|2017-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy|Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy|Completed||Phase 1/Phase 2|100|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 03:58:37.133051|2018-06-01 03:58:37.133051
NCT00331331|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-27|||2018-04-04|2006-05-27|2006-05-29|Estimate|||||||2018-04-04|2018-04-05|Actual|May 19, 2006||2006-05-19|September 8, 2017|2017-09-08||||||||Observational|||The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease|The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease|Enrolling by invitation|||138|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:58:37.425645|2018-06-01 03:58:37.425645
NCT00331318|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-27|||2017-06-30|2006-05-27|2006-05-29|Estimate|||||||2017-06-30|2017-07-02|Actual|May 24, 2006||2006-05-24|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Improving Hand Movement Training Through Electrical Stimulation of the Brain|Encoding a Motor Memory Through Metaplasticity|Completed|||31||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:58:37.473824|2018-06-01 03:58:37.473824
NCT00331305|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2013-08-28|2006-05-26|2006-05-29|Estimate|||||||2013-08-28|2013-08-29|Estimate|August 1999||1999-08-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Exercise Training Versus Drug Therapy for Treating Depression in Older Adults|Exercise Training and Depression in Older Adults II|Completed||Phase 3|457|Actual|Duke University|||||f||||t||||||||||2018-06-01 03:58:37.599837|2018-06-01 03:58:37.599837
NCT00331292|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2008-10-15|2006-05-26|2006-05-29|Estimate|||||||2008-10-15|2008-10-16|Estimate|August 2006||2006-08-31|October 2008|2008-10-31||||||||Observational|||A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients|A Study to Identify a Transcriptomic Profile Indicative of Cycle AMP Pathway Activation in the Lung|Terminated|||30||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:58:37.675219|2018-06-01 03:58:37.675219
NCT00331279|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2012-12-06|2006-05-25|2006-05-29|Estimate|||||||2012-12-06|2012-12-10|Estimate|August 2005||2005-08-31|January 2011|2011-01-31|February 2006|Actual|2006-02-28|September 2005|Actual|2005-09-30||Interventional|||The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study|The Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study|Completed||Phase 1|1|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 03:58:37.721391|2018-06-01 03:58:37.721391
NCT00330512|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2009-06-28|2006-05-25|2006-05-26|Estimate|||||||2009-06-28|2009-06-30|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Maternal Hypotension During Cesarean Section and Short Term Neonatal Outcome.|Maternal Hypotension During Elective Cesarean Section and Short Term Neonatal Outcome.|Terminated|||500|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 03:58:48.299908|2018-06-01 03:58:48.299908
NCT00331253|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2007-04-25|2006-05-26|2006-05-29|Estimate|||||||2007-04-25|2007-04-27|Estimate|April 2007||2007-04-30|April 2007|2007-04-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).|A 54-WEEK, PHASE 2, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INDOCYANINE GREEN-MEDIATED PHOTOTHROMBOSIS (i-MP) FOR THE TREATMENT OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.|Unknown status|Recruiting|Phase 2|280||Opto Eletronica S.A.|||||f||||t||||||||||2018-06-01 03:58:37.795416|2018-06-01 03:58:37.795416
NCT00331240|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2014-05-09|2006-05-26|2006-05-29|Estimate|||||||2014-05-09|2014-05-12|Estimate|March 2006||2006-03-31|May 2014|2014-05-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination|24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination|Completed||Phase 3|32||Aristotle University Of Thessaloniki|||||f||||f||||||||||2018-06-01 03:58:37.860414|2018-06-01 03:58:37.860414
NCT00331227|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2007-03-14|2006-05-26|2006-05-29|Estimate|||||||2007-03-14|2007-03-15|Estimate|May 2006||2006-05-31|March 2007|2007-03-31|December 2006||2006-12-31|||||Interventional|||Flavonoid Supplementation and Endothelial Function|Effect of Supplemental Flavonoids on Endothelial Function, Lipids, and Markers of Inflammation|Completed||Phase 4|25||Carolinas Healthcare System|||||f||||||||||||||2018-06-01 03:58:37.914429|2018-06-01 03:58:37.914429
NCT00331214|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2013-04-15|2006-05-26|2006-05-29|Estimate|||||||2013-04-15|2013-04-17|Estimate|June 2002||2002-06-30|April 2013|2013-04-30|July 2006|Actual|2006-07-31|December 2003|Actual|2003-12-31||Interventional|||Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido|Study to Evaluate the Efficacy and Safety of Transdermal Testosterone in Women With Hypoactive Sexual Desire Disorder on Concurrent Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy|Completed||Phase 3|533|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:58:37.970931|2018-06-01 03:58:37.970931
NCT00331201|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2006-11-27|2006-05-25|2006-05-29|Estimate|||||||2006-11-27|2006-11-28|Estimate|July 2005||2005-07-31|November 2006|2006-11-30|April 2006||2006-04-30|||||Interventional|||SAFEstart Feeding Intolerance Study Phase II|SAFEstart Treatment for NICU Patients With Feeding Intolerance; a Phase II Randomized, Controlled Trial|Completed||Phase 2|20||Intermountain Health Care, Inc.|||||f||||||||||||||2018-06-01 03:58:38.069589|2018-06-01 03:58:38.069589
NCT00331188|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2008-07-07|2006-05-26|2006-05-29|Estimate|||||||2008-07-07|2008-07-08|Estimate|May 2006||2006-05-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding|The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension|Completed||Phase 3|70|Actual|Debiovision|||||f||||f||||||||||2018-06-01 03:58:38.145433|2018-06-01 03:58:38.145433
NCT00331175|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2006-12-14|2006-05-26|2006-05-29|Estimate|||||||2006-12-14|2006-12-15|Estimate|July 2006||2006-07-31|December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults|A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects|Completed||Phase 1|31||Pfizer|||||||||||||||||||2018-06-01 03:58:38.26543|2018-06-01 03:58:38.26543
NCT00331162|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2018-03-29|2006-05-26|2006-05-29|Estimate|||||||2018-03-29|2018-04-02|Actual|February 2005|Actual|2005-02-28|March 2018|2018-03-31|November 28, 2011|Actual|2011-11-28|November 28, 2011|Actual|2011-11-28||Interventional|||Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation|Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation|Completed||Phase 4|236|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-06-01 03:58:38.326742|2018-06-01 03:58:38.326742
NCT00331149|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2017-08-21|2006-05-26|2006-05-29|Estimate|||||||2017-08-21|2017-08-22|Actual|June 20, 2006|Actual|2006-06-20|August 2017|2017-08-31|August 29, 2007|Actual|2007-08-29|August 29, 2007|Actual|2007-08-29||Interventional|||A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's|A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment With Ropinirole Immediate Release Tablets (REQUIP IR) or Ropinirole Prolonged Release Tablets (SK&F-101468) in Advanced Stage Parkinson's Disease Subjects Who Are Not Adequately Controlled on L-dopa.|Completed||Phase 3|343|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:58:38.433364|2018-06-01 03:58:38.433364
NCT00331136|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2008-05-19|2006-05-26|2006-05-29|Estimate|||||||2008-05-19|2008-05-20|Estimate|June 2006||2006-06-30|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria|An Open-Label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) In Children With Acute Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 2|45|Actual|Medicines for Malaria Venture||3|||f||||||||||||||2018-06-01 03:58:38.631361|2018-06-01 03:58:38.631361
NCT00331123|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2013-04-15|2006-05-26|2006-05-29|Estimate|||||||2013-04-15|2013-04-17|Estimate|May 2002||2002-05-31|April 2013|2013-04-30|July 2006|Actual|2006-07-31|December 2003|Actual|2003-12-31||Interventional|||Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido|Study to Evaluate Efficacy and Safety of Transdermal Testosterone and Safety for an Open-label Period in Women With Hypoactive Sexual Desire Disorder on Estrogen Replacement Therapy and Undergone Hysterectomy/Bilateral Oophorectomy.|Completed||Phase 3|562|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 03:58:38.725175|2018-06-01 03:58:38.725175
NCT00331110|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2007-12-20|2006-05-26|2006-05-29|Estimate|||||||2007-12-20|2008-01-03|Estimate|May 2006||2006-05-31|April 2007|2007-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study of How An Ankle Strap Changes Effects of Insole Treatment for Knee Osteoarthritis|Immediate and Short-Term Analgesic and Biomechanical Effects of a Laterally Wedged Insole With Ankle Strapping for Medial Compartment Knee Osteoarthritis|Completed||Phase 2/Phase 3|14||University of Iowa|||||f||||||||||||||2018-06-01 03:58:38.819903|2018-06-01 03:58:38.819903
NCT00331097|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2017-03-27|2006-05-26|2006-05-29|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2003||2003-07-31|March 2017|2017-03-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment|Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF|Completed||Phase 3|300|Actual|National Cancer Institute, Naples||2|||f||||f||||||||||2018-06-01 03:58:38.882775|2018-06-01 03:58:38.882775
NCT00331084|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2009-08-06|2006-05-26|2006-05-29|Estimate|||||||2009-08-06|2009-08-07|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery|Efficacy of Antibiotic Steroid Combination Compared With Individual Administration in Prevention of Postoperative Inflammation in Patients Having Cataract Surgery|Completed||N/A|132|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 03:58:38.959992|2018-06-01 03:58:38.959992
NCT00331071|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2016-07-15|2006-05-26|2006-05-29|Estimate|||||||2016-07-15|2016-07-19|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks|Postmarketing Study of ORTHO EVRA in Relation to Venous Thromboembolism, Ischemic Stroke, and Myocardial Infarction|Completed|||334|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||2||f||||||||||||||2018-06-01 03:58:39.029147|2018-06-01 03:58:39.029147
NCT00331058|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2017-06-27|2006-05-26|2006-05-29|Estimate|||||||2017-06-27|2017-06-28|Actual|February 18, 2006|Actual|2006-02-18|June 2017|2017-06-30|July 7, 2011|Actual|2011-07-07|July 7, 2011|Actual|2011-07-07||Interventional|||Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects|A Study To Validate Key Therapeutic Targets and Characterise Their Response to Corticosteroids in Multiple Asthma Phenotypes|Terminated||Phase 1|58|Actual|GlaxoSmithKline||2||"The study was truncated due to the long period of enrollment and the collection of a sufficient~   amount of data that allowed the scientific objectives to be met"|f||||f||||||||||2018-06-01 03:58:39.097187|2018-06-01 03:58:39.097187
NCT00331045|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2015-09-01|2006-05-26|2006-05-29|Estimate|||||||2015-09-01|2015-09-02|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid|Clinical Evaluation of Alvimopan (SB767905) on Constipation and Related Symptoms Associated With Opioid -A Placebo-controlled Double-blind Study in Cancer Patients-|Terminated||Phase 2|21|Actual|Cubist Pharmaceuticals LLC||4||"Subject registration did not proceed as expected; difficult to complete within scheduled time~   frame; prematurely terminated w/ 21 subjects randomized."|f||||||||||||||2018-06-01 03:58:39.174097|2018-06-01 03:58:39.174097
NCT00331032|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2013-08-22|2006-05-25|2006-05-29|Estimate|||||||2013-08-22|2013-08-23|Estimate|December 2006||2006-12-31|August 2013|2013-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||VivaGel™ in Healthy Young Women|An Expanded Phase I Randomized Placebo Controlled Trial of the Safety and Tolerability of 3 Percent w/w SPL7013 Gel (VivaGel™) in Healthy Young Women When Administered Twice Daily for 14 Days|Completed||Phase 1|56|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 03:58:39.241323|2018-06-01 03:58:39.241323
NCT00331019|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2015-12-14|2006-05-26|2006-05-29|Estimate|||||||2015-12-14|2015-12-15|Estimate|July 2006||2006-07-31|December 2015|2015-12-31||||July 2006|Actual|2006-07-31||Observational|||Rapid Detection of Group B Strep- 35-37 Week Study|Rapid Detection of Group B Streptococcus Using a Bedside Microfluidics Device: 35-37 Week Study|Withdrawn|||0|Actual|University of Michigan||||HandyLab device determined to not work for the science|f||||f||||||||||2018-06-01 03:58:39.312588|2018-06-01 03:58:39.312588
NCT00331006|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2013-01-07||2013-06-07|2006-05-26|2006-05-29|Estimate|2013-06-07|2013-06-11|Estimate||||2013-06-07|2013-06-11|Estimate|June 2006||2006-06-30|June 2013|2013-06-30|January 2012|Actual|2012-01-31|November 2010|Actual|2010-11-30||Interventional|RICH|All subjects who began the screening phase|Rituximab to Treat Severe Hemophilia A|Rituximab for the Treatment of Inhibitors in Congenital Hemophilia A (A TMH CTN Study)|Completed||Phase 2|23|Actual|New England Research Institutes|The study was terminated before reaching its target sample size of 50 subjects due to low enrollment rates. Therefore, confidence intervals for proportions are wide.|1|||f||||t||||||||||2018-06-01 03:58:39.386274|2018-06-01 03:58:39.386274
NCT00330993|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2007-01-24|2006-05-26|2006-05-29|Estimate|||||||2007-01-24|2007-01-25|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|August 2006||2006-08-31|||||Interventional|||Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation|Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation|Completed||Phase 2|120||University of Pittsburgh|||||||||||||||||||2018-06-01 03:58:39.693004|2018-06-01 03:58:39.693004
NCT00330980|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2014-03-19|2006-05-26|2006-05-29|Estimate|||||||2014-03-19|2014-03-20|Estimate|April 2000||2000-04-30|July 2008|2008-07-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels|Statins and Noncardiovascular Endpoints|Completed||Phase 4|1000|Anticipated|University of California, San Diego||3|||f||||||||||||||2018-06-01 03:58:39.839811|2018-06-01 03:58:39.839811
NCT00330967|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2015-01-22||2015-03-17|2006-05-26|2006-05-29|Estimate|2015-03-04|2015-03-17|Estimate||||2015-03-17|2015-04-03|Estimate|April 2006||2006-04-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|January 2012|Actual|2012-01-31||Observational|||Mechanisms of Insulin Resistance in Humans|Mechanisms of Insulin Resistance in Humans|Completed|||25|Actual|VA Office of Research and Development|The study's original Principal Investigator left the VA prior to the completion of data acquisition and no further subjects were enrolled. The data entered were analyzed based solely on study files in the system.||2||f||||f||||||Samples Without DNA|"~     Blood samples, muscle biopsies~   "|||2018-06-01 03:58:39.967158|2018-06-01 03:58:39.967158
NCT00330954|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2010-03-03|2006-05-26|2006-05-29|Estimate|||||||2010-03-03|2010-03-05|Estimate|June 2006||2006-06-30|March 2010|2010-03-31|April 2008|Actual|2008-04-30|||||Observational|||Gene Expression Profiling in Type 1 Diabetes|Gene Expression Profiling in Type 1 Diabetes|Completed|||64|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||Samples With DNA|"~     Whole Blood saved frozen for 1 year~   "|||2018-06-01 03:58:40.376705|2018-06-01 03:58:40.376705
NCT00330941|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2016-06-27|2006-05-25|2006-05-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|January 2003||2003-01-31|June 2016|2016-06-30|December 2004||2004-12-31|||||Interventional|||Intravenous Lidocaine and Acute Rehabilitation|Intravenous Lidocaine Infusion Improves Outcome After Laparoscopic Colectomy|Completed||Phase 4|45||The Cleveland Clinic|||||f||||||||||||||2018-06-01 03:58:40.461262|2018-06-01 03:58:40.461262
NCT00330928|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2009-01-28||2016-08-29|2006-05-26|2006-05-29|Estimate|2009-04-06|2009-05-28|Estimate||||2016-08-29|2016-10-10|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|SPECTACL||SPECTACL: SPECTroscopic Assessment of Coronary Lipid|Coronary Artery Plaque Characterization by NIR Spectroscopy in Patients Undergoing Elective Percutaneous Coronary Intervention|Completed||Phase 2/Phase 3|106|Actual|InfraReDx|Technical limits of the prototype device factored into the data set reduction(28 patients).Data made available to evaluate handling of the device(30 patients) could not be prospectively evaluated for the primary endpoint of Spectral Similarity.|1|||f||||t||||||||||2018-06-01 03:58:40.555271|2018-06-01 03:58:40.555271
NCT00330915|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2009-06-03||2009-06-03|2006-05-26|2006-05-29|Estimate|2009-06-03|2009-07-21|Estimate||||2009-06-03|2009-07-21|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.|A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer|Completed||Phase 2|37|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 03:58:40.791668|2018-06-01 03:58:40.791668
NCT00330902|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2007-10-30|2006-05-25|2006-05-29|Estimate|||||||2007-10-30|2007-10-31|Estimate|January 2004||2004-01-31|October 2007|2007-10-31|November 2004|Actual|2004-11-30|||||Interventional|||Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan|Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan|Completed||Phase 3|104|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-06-01 03:58:41.081383|2018-06-01 03:58:41.081383
NCT00330889|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2012-10-18|2006-05-26|2006-05-29|Estimate|||||||2012-10-18|2012-10-22|Estimate|February 2004||2004-02-29|October 2012|2012-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Effects Of Prednisolone On Rheumatoid Arthritis Patients|A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients|Completed|||32|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:58:41.15318|2018-06-01 03:58:41.15318
NCT00330876|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2009-08-26||2010-03-09|2006-05-26|2006-05-29|Estimate|2009-12-11|2010-01-18|Estimate||||2010-03-09|2010-03-16|Estimate|June 2006||2006-06-30|March 2010|2010-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Open-Label, Long-Term (> 1 Year) Extension Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Completed||Phase 3|545|Actual|Kowa Research Europe||2|||f||||f||||||||||2018-06-01 03:58:41.242802|2018-06-01 03:58:41.242802
NCT00330863|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2014-07-14|2006-05-26|2006-05-29|Estimate|||||||2014-07-14|2014-07-15|Estimate|May 2006||2006-05-31|July 2014|2014-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|PROACTIVE||Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy|Preventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)|Completed||Phase 4|357|Actual|Northwell Health||2|||f||||t||||||||||2018-06-01 03:58:41.647014|2018-06-01 03:58:41.647014
NCT00330850|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2007-03-30|2006-05-26|2006-05-29|Estimate|||||||2007-03-30|2007-04-02|Estimate|May 2006||2006-05-31|March 2007|2007-03-31|December 2006||2006-12-31|||||Interventional|||An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack||Completed||Phase 3|650||ProEthic Pharmaceuticals|||||||||||||||||||2018-06-01 03:58:41.77215|2018-06-01 03:58:41.77215
NCT00330837|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2008-02-07|2006-05-26|2006-05-29|Estimate|||||||2008-02-07|2008-02-15|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|February 2007|Actual|2007-02-28|||||Observational|||Ultrasound Scanning of Vascular Access Sites|Ultrasound Scanning of Vascular Access Sites|Completed|||100|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 03:58:41.838718|2018-06-01 03:58:41.838718
NCT00330824|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2009-08-06|2006-05-26|2006-05-29|Estimate|||||||2009-08-06|2009-08-07|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Post Operative Inflammation in LASIK Surgery|Efficacy of Antibiotic Steroid Combination Compared With Individual Administration in Prevention of Post Operative Inflammation in Patients Having LASIK Surgery|Completed||N/A|64|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-06-01 03:58:41.883478|2018-06-01 03:58:41.883478
NCT00330811|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2016-11-30|2006-05-25|2006-05-29|Estimate|||||||2016-11-30|2016-12-02|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Observational|||B-type Natriuretic Peptide in the Non-Cardiac Pediatric Patient|B-type Natriuretic Peptide in the Non-Cardiac Pediatric Patient|Completed|||87|Actual|Emory University|||||f||||f||||||||||2018-06-01 03:58:41.950881|2018-06-01 03:58:41.950881
NCT00330798|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2016-11-17|2006-05-25|2006-05-29|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief|A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief of Patients Status Post-Photorefractive Keratectomy: A Double-Masked Randomized Prospective Study|Completed||Phase 4|40|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 03:58:41.997991|2018-06-01 03:58:41.997991
NCT00330785|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2010-01-06|2006-05-26|2006-05-29|Estimate|||||||2010-01-06|2010-01-08|Estimate|October 2004||2004-10-31|April 2007|2007-04-30|September 2005||2005-09-30|||||Interventional|JEWEL I||Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia|An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)|Completed||Phase 3|1250||Pfizer|||||f||||||||||||||2018-06-01 03:58:42.085568|2018-06-01 03:58:42.085568
NCT00330772|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2017-08-02|2006-05-26|2006-05-29|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2006||2006-07-31|August 2017|2017-08-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|PAPA CABG||Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting: The PAPA CABG Study|Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery|Completed||Phase 3|150|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 03:58:43.27164|2018-06-01 03:58:43.27164
NCT00330759|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|2010-12-09|2010-06-29|2014-07-14|2006-05-25|2006-05-29|Estimate|2014-03-04|2014-04-09|Estimate|2010-06-29|2010-07-01|Estimate|2014-07-14|2014-07-23|Estimate|June 2006||2006-06-30|July 2014|2014-07-31|October 2011|Actual|2011-10-31|April 2009|Actual|2009-04-30||Interventional|||Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.|Completed||Phase 3|1779|Actual|Amgen||2|||f||||t||||||||||2018-06-01 03:58:43.429989|2018-06-01 03:58:43.429989
NCT00330746|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2012-05-17|2006-05-26|2006-05-29|Estimate|||||||2012-05-17|2012-05-18|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|CALC-1||CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer|Randomized Phase II Study of Cetuximab in Combination With Gemcitabine or Gemcitabine Followed by Cetuximab in Advanced Non Small-cell Lung Cancer Patients Who Are Not Candidates for Platinum Based Therapy.|Completed||Phase 2|100|Actual|National Cancer Institute, Naples||2|||f||||f||||||||||2018-06-01 03:58:45.43834|2018-06-01 03:58:45.43834
NCT00330551|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2013-11-02|2006-05-26|2006-05-29|Estimate|||||||2013-11-02|2013-11-05|Estimate|March 2006||2006-03-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia|Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia|Completed||Phase 4|135|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-06-01 03:58:48.077828|2018-06-01 03:58:48.077828
NCT00330733|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2013-12-18||2014-04-15|2006-05-26|2006-05-29|Estimate|2014-04-15|2014-04-22|Estimate||||2014-04-15|2014-04-22|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional||Seventy-eight individuals entered the placebo run-in phase. Of these, 71 were randomised and 70 returned to receive study medication|Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk|Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk|Completed||Phase 2/Phase 3|71|Actual|VA Office of Research and Development|Since we did not measure endogenous glucose production and lipolysis, the effects on hepatic glucose and lipid metabolism deserve further study. Sufficient numbers of women were not included, with which to confidently extend these results to women|2|||f||||t||||||||||2018-06-01 03:58:45.560017|2018-06-01 03:58:45.560017
NCT00330720|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2006-05-26|2006-05-26|2006-05-29|Estimate|||||||2006-05-26|2006-05-29|Estimate|November 2002||2002-11-30|September 2004|2004-09-30|June 2004||2004-06-30|||||Interventional|||Impact of An Emergency Response System on Anxiety and Health-Care Use|A Randomized Clinical Trial To Asses The Impact of An Emergency Response System on Anxiety and Health-Care Use Among Older Emergency Patients After A Fall|Completed||N/A|80||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 03:58:45.779817|2018-06-01 03:58:45.779817
NCT00330707|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2011-03-02|2006-05-26|2006-05-29|Estimate|||||||2011-03-02|2011-03-04|Estimate|October 1995||1995-10-31|March 2011|2011-03-31|June 2005||2005-06-30|||||Interventional|||Combined Use of BCG and Interferon Alpha in Bladder Cancer|A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer|Completed||Phase 2/Phase 3|140||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 03:58:45.843134|2018-06-01 03:58:45.843134
NCT00330694|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2008-09-01|2006-05-24|2006-05-29|Estimate|||||||2008-09-01|2008-09-03|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Efficiency of Physiotherapeutic Care in Parkinson's Disease|Efficiency of Physiotherapeutic Care in Parkinson's Disease|Completed||Phase 3|708|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 03:58:45.899188|2018-06-01 03:58:45.899188
NCT00330681|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2016-10-28||2017-04-10|2006-05-26|2006-05-29|Estimate|2017-04-10|2017-05-17|Actual||||2017-04-10|2017-05-17|Actual|May 2006||2006-05-31|April 2017|2017-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)|A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner.|Completed||Phase 3|206|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 03:58:46.125172|2018-06-01 03:58:46.125172
NCT00330668|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2011-02-28||2011-05-31|2006-05-26|2006-05-29|Estimate|2011-05-31|2011-06-27|Estimate||||2011-05-31|2011-06-27|Estimate|November 2005||2005-11-30|May 2011|2011-05-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency|Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study|Terminated||Phase 3|114|Actual|Ipsen|The study was terminated by the sponsor on identification of an unacceptable frequency of hypoglycemia which was reported at doses of ≥200 mcg/kg once daily. Only safety results are presented as efficacy data were not analyzed according to protocol.|||Unacceptable frequency of hypoglycemia observed at and above 200 ug/kg/day|f||||t||||||||||2018-06-01 03:58:46.77454|2018-06-01 03:58:46.77454
NCT00330655|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2007-08-10|2006-05-25|2006-05-29|Estimate|||||||2007-08-10|2007-08-14|Estimate|May 2006||2006-05-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder|An Open-Label, Prospective Trial of Memantine in the Treatment of Moderate to Severe Binge Eating Disorder Associated With Obesity|Completed||Phase 4|15|Actual|Mclean Hospital|||||f||||f||||||||||2018-06-01 03:58:46.967997|2018-06-01 03:58:46.967997
NCT00330642|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2015-12-14|2006-05-26|2006-05-29|Estimate|||||||2015-12-14|2015-12-15|Estimate|July 2006||2006-07-31|December 2015|2015-12-31||||July 2006|Actual|2006-07-31||Observational|||Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study|Rapid Detection of Group B Streptococcus Using a Bedside Microfluidics Device: Labor and Delivery Study|Withdrawn|||0|Actual|University of Michigan||||HandyLab device did not work for the science|f||||f||||||||||2018-06-01 03:58:47.020004|2018-06-01 03:58:47.020004
NCT00330629|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2016-07-01|2006-05-26|2006-05-29|Estimate|||||||2016-07-01|2016-07-04|Estimate|January 2002||2002-01-31|July 2016|2016-07-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|PREFER||Preference and Vegetarian Diet in Weight Loss Treatment|Preference and Vegetarian Diet in Weight Loss Treatment|Completed||N/A|200|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 03:58:47.183016|2018-06-01 03:58:47.183016
NCT00330616|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2008-11-26||2015-04-13|2006-05-26|2006-05-29|Estimate|2009-03-19|2009-03-20|Estimate||||2015-04-13|2015-05-04|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan|Clinical Evaluation of Bupropion SR (323U66)in Patients With Depression - Investigation in Elderly Patients With Depression|Completed||Phase 2|35|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:58:47.288187|2018-06-01 03:58:47.288187
NCT00330603|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2011-03-04|2006-05-26|2006-05-29|Estimate|||||||2011-03-04|2011-03-08|Estimate|April 2006||2006-04-30|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Observational|||Serial Exhaled Breath pH Monitoring|Serial Exhaled Breath pH Monitoring|Unknown status|Recruiting||99|Anticipated|University of Virginia|||||f||||||||||||||2018-06-01 03:58:47.715399|2018-06-01 03:58:47.715399
NCT00330590|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2008-02-07|2006-05-26|2006-05-29|Estimate|||||||2008-02-07|2008-02-15|Estimate||||February 2008|2008-02-29|December 2006|Actual|2006-12-31|||||Observational|||Central Venous Access Catheter Placement Using the Sonic Flashlight|Central Venous Access Catheter Placement by Interventional Radiologists Using the Sonic Flashlight for Real Time Ultrasound Guidance|Completed|||150|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 03:58:47.783254|2018-06-01 03:58:47.783254
NCT00330577|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|||2014-05-09|2006-05-26|2006-05-29|Estimate|||||||2014-05-09|2014-05-12|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|July 2007|Actual|2007-07-31|April 2007|Actual|2007-04-30||Interventional|||24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients|24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients|Completed||Phase 4|30||Aristotle University Of Thessaloniki|||||f||||||||||||||2018-06-01 03:58:47.837799|2018-06-01 03:58:47.837799
NCT00330564|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-26|2011-06-01||2012-02-23|2006-05-26|2006-05-29|Estimate|2011-06-01|2011-06-30|Estimate||||2012-02-23|2012-02-27|Estimate|May 2006||2006-05-31|February 2012|2012-02-29|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow|A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome|Terminated||Phase 2|15|Actual|M.D. Anderson Cancer Center|Limitations include the conclusion of the study before maximum enrollment and the use of archival tissue that was not related to the participants in the clinical trial.|1||Slow accrual.|f||||f||||||||||2018-06-01 03:58:47.897313|2018-06-01 03:58:47.897313
NCT00330499|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2017-07-10|2006-05-25|2006-05-26|Estimate|||||||2017-07-10|2017-07-12|Actual|October 2002||2002-10-31|July 2017|2017-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.|A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder|Completed||Phase 3|67|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||f||||||||||2018-06-01 03:58:48.350076|2018-06-01 03:58:48.350076
NCT00330486|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2008-09-18|2006-05-25|2006-05-26|Estimate|||||||2008-09-18|2008-09-19|Estimate|April 2006||2006-04-30|September 2008|2008-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Open Label Trial of Acamprosate in Bipolar Alcoholics|The Use of Acamprosate in Alcohol-Dependent Individuals With Bipolar Disorder|Completed||Phase 1/Phase 2|9|Actual|Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:58:48.454846|2018-06-01 03:58:48.454846
NCT00330473|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24||2018-03-07|2018-03-07|2006-05-24|2006-05-26|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|June 2006||2006-06-30|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare Insulin Use and Its Effect on Glycemic Control in Patients With Type 2 Diabetes Mellitus: Two Populations With Different Insulin Treatment Options|Completed||Phase 3|1019|Actual|Eli Lilly and Company||2|||f||||||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 03:58:48.520058|2018-06-01 03:58:48.520058
NCT00330460|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|2010-06-18|2009-11-23|2011-01-20|2006-05-24|2006-05-26|Estimate|2010-06-18|2010-07-19|Estimate|2009-11-23|2009-11-25|Estimate|2011-01-20|2011-01-24|Estimate|May 2006||2006-05-31|January 2011|2011-01-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.|A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Denisty|Completed||Phase 3|1189|Actual|Amgen||2|||f||||||||||||||2018-06-01 03:58:48.840372|2018-06-01 03:58:48.840372
NCT00330447|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2018-05-18|2006-05-25|2006-05-26|Estimate|||||||2018-05-18|2018-05-22|Actual|August 2005||2005-08-31|May 2018|2018-05-31|December 2032|Anticipated|2032-12-31|April 2025|Anticipated|2025-04-30|18 Years|Observational [Patient Registry]|||Effects of Oncological Treatment During Pregnancy on Mother and Child|Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring|Recruiting|||5000|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||Samples With DNA|"~     Maternal blood serum and sediment of blood; from 2010 on we collect umbilical cord blood.~      Since new approval of protocol version 4.2 (08-02-2018) we collect samples of placental~     tissue, umbilical cord tissue and membranes.~   "|||2018-06-01 03:58:49.379274|2018-06-01 03:58:49.379274
NCT00330434|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2008-04-07|2006-05-25|2006-05-26|Estimate|||||||2008-04-07|2008-04-09|Estimate|December 2005||2005-12-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism|Human CYP2B6: Induction by Ethanol and Polymorphisms|Completed||N/A|80|Anticipated|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||f||||||||||2018-06-01 03:58:49.565501|2018-06-01 03:58:49.565501
NCT00330421|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|2013-11-05||2014-04-01|2006-05-25|2006-05-26|Estimate|2014-02-17|2014-03-17|Estimate||||2014-04-01|2014-04-30|Estimate|June 2006||2006-06-30|November 2013|2013-11-30|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)|A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma|Completed||Phase 2|15|Actual|National Cancer Institute (NCI)|No Grade 4 toxicities were noted (15 patients). IFP measurements were obtained in only 6 of 15 patients at baseline. Only 2 of these 6 patients had SD at 28 and 56 days and therefore, second IFP measurements were only obtained in those 2 patients.|2|||f||||||||||||||2018-06-01 03:58:49.637048|2018-06-01 03:58:49.637048
NCT00330408|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2006-05-25|2006-05-25|2006-05-26|Estimate|||||||2006-05-25|2006-05-26|Estimate|September 2005||2005-09-30|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Impact of Training of GPs on Adherence of Hypertensive Individuals to Antihypertensive Medication|Impact of Training of GPs on Adherence of Hypertensive Individuals to Antihypertensive Medication|Unknown status|Active, not recruiting|N/A|178||Aga Khan University|||||f||||||||||||||2018-06-01 03:58:49.812699|2018-06-01 03:58:49.812699
NCT00330395|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2017-02-20|2006-05-24|2006-05-26|Estimate|||||||2017-02-20|2017-02-23|Actual|May 2006||2006-05-31|February 2017|2017-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)|A Multicenter, Sequential-Panel, Open-Label, Noncomparative Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Caspofungin Acetate in Neonates and Infants Less Than 3 Months of Age.|Completed||Phase 2|16|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:58:49.872618|2018-06-01 03:58:49.872618
NCT00330382|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|2014-10-03||2014-12-16|2006-05-25|2006-05-26|Estimate|2014-12-16|2014-12-19|Estimate||||2014-12-16|2014-12-19|Estimate|January 1999||1999-01-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|July 2010|Actual|2010-07-31||Interventional|||Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia|Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial|Completed||Phase 2|325|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 03:58:49.962982|2018-06-01 03:58:49.962982
NCT00330369|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24||2014-01-03|2014-02-19|2006-05-24|2006-05-26|Estimate||||2014-01-03|2014-02-04|Estimate|2014-02-19|2014-03-18|Estimate|June 2006||2006-06-30|February 2014|2014-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension|DORADO - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-311)|Completed||Phase 3|352|Actual|Gilead Sciences||4|||f||||t||||||||||2018-06-01 03:58:50.428818|2018-06-01 03:58:50.428818
NCT00330356|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2006-05-25|2006-05-25|2006-05-26|Estimate|||||||2006-05-25|2006-05-26|Estimate|September 2005||2005-09-30|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Effects of Low Salt Diet Versus High Salt Diet on Blood Pressure|Effects of Low Salt Diet Versus High Salt Diet on Blood Pressure|Unknown status|Active, not recruiting|N/A|200||Aga Khan University|||||f||||||||||||||2018-06-01 03:58:50.710505|2018-06-01 03:58:50.710505
NCT00330343|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|2012-04-10||2017-07-18|2006-05-25|2006-05-26|Estimate|2017-07-18|2017-07-19|Actual||||2017-07-18|2017-07-19|Actual|May 2004||2004-05-31|July 2017|2017-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents|The Optimal Dose of Prophylactic Naloxone in Ameliorating Opioid Induced Side Effects in Children and Adolescents Receiving Intravenous Patient Controlled Analgesia (IVPCA) Morphine for Moderate to Severe Pain: A Pharmacodynamic, Pharmacokinetic, and Pharmacogenetic Study|Completed||Phase 2|75|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-06-01 03:58:50.772519|2018-06-01 03:58:50.772519
NCT00330330|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2008-02-04|2006-05-24|2006-05-26|Estimate|||||||2008-02-04|2008-02-06|Estimate|February 2003||2003-02-28|February 2008|2008-02-29|August 2006||2006-08-31|||||Interventional|||Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment|A Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 in Patients With Type 2 Diabetes Mellitus Who Have Not Received Prior Therapy|Completed||Phase 2|96||Ionis Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 03:58:50.905365|2018-06-01 03:58:50.905365
NCT00330317|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2017-02-03|2006-05-24|2006-05-26|Estimate|||||||2017-02-03|2017-02-07|Estimate|February 2006||2006-02-28|February 2017|2017-02-28|November 16, 2010|Actual|2010-11-16|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer|Neoadjuvant Hormone Therapy for Postmenopausal Women With HR+ Primary Breast Cancer: A Multi-center Study to Determine the Optimum Length of Treatment With Letrozole on Tumour Regression to Permit Breast Conserving Surgery.|Completed||Phase 3|300|Actual|Novartis||1|||f||||f||||||||||2018-06-01 03:58:50.966422|2018-06-01 03:58:50.966422
NCT00330304|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2010-09-07|2006-05-24|2006-05-26|Estimate|||||||2010-09-07|2010-09-08|Estimate|January 2003||2003-01-31|September 2010|2010-09-30|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Interventional|||Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children|Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With Concomitant Cotrimoxazole (CTX) in HIV-infected Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of Tuberculosis|Unknown status|Active, not recruiting|Phase 3|450|Actual|University of Cape Town||2|||f||||||||||||||2018-06-01 03:58:51.054|2018-06-01 03:58:51.054
NCT00330291|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2012-09-06|2006-05-24|2006-05-26|Estimate|||||||2012-09-06|2012-09-07|Estimate|August 2005||2005-08-31|September 2012|2012-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Xyrem for Treatment Refractory Insomnia Due to PTSD|Xyrem for Treatment Refractory Insomnia Due to PTSD|Withdrawn||Phase 2|0|Actual|State University of New York - Upstate Medical University||||terminated due to inability to recruit subjects|||||||||||||||2018-06-01 03:58:51.12127|2018-06-01 03:58:51.12127
NCT00330278|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2007-09-26|2006-05-25|2006-05-26|Estimate|||||||2007-09-26|2007-09-27|Estimate|January 2003||2003-01-31|January 2006|2006-01-31|January 2006|Actual|2006-01-31|||||Interventional|||Timing of Prophylactic Antibiotics for Cesarean Sections|A Randomized, Double-Blind, Placebo Controlled Trial of Cefazolin Given Either 30 Minutes Prior to Cesarean Section or at Cord Clamping|Completed||N/A|350||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:58:51.231066|2018-06-01 03:58:51.231066
NCT00330265|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2008-08-25|2006-05-24|2006-05-26|Estimate|||||||2008-08-25|2008-08-26|Estimate|January 2006||2006-01-31|August 2008|2008-08-31|September 2009|Anticipated|2009-09-30|March 2009|Anticipated|2009-03-31||Interventional|KC-002PT||Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers|A Prospective, Randomized, Controlled, Unmasked, Multiple Treatment, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of an Interactive Wound Dressing Containing Cultured Keratinocytes Versus Conventional Wound Therapy for the Treatment of Diabetic Foot Ulcers|Unknown status|Recruiting|Phase 2|300|Anticipated|KeraCure||2|||f||||t||||||||||2018-06-01 03:58:51.298043|2018-06-01 03:58:51.298043
NCT00330252|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2016-05-11|2006-05-25|2006-05-26|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2006||2006-05-31|May 2016|2016-05-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL|Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL|Completed||Phase 1|29|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 03:58:51.41292|2018-06-01 03:58:51.41292
NCT00330239|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2007-10-02|2006-05-25|2006-05-26|Estimate|||||||2007-10-02|2007-10-03|Estimate|January 2003||2003-01-31|October 2007|2007-10-31|May 2005||2005-05-31|||||Interventional|||Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence|Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence|Completed||Phase 4|25||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:58:51.483929|2018-06-01 03:58:51.483929
NCT00330226|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2010-07-21|2006-05-25|2006-05-26|Estimate|||||||2010-07-21|2010-07-23|Estimate|January 2006||2006-01-31|July 2010|2010-07-31|December 2012|Anticipated|2012-12-31|||||Observational|||Efficacy and Safety of Psychopharmacotherapy in Patients With Schizophrenia or Bipolar Disorders|Naturalistic Prospective Follow-Up of Patients With Schizophrenia or Bipolar Disorders Receiving Atypical Antipsychotics and/or Mood Stabilizers|Unknown status|Recruiting||500|Anticipated|Seoul National University Hospital|||1||f||||t||||||Samples Without DNA|"~     regular lab tests for evaluating the changes in medical condition~   "|||2018-06-01 03:58:51.54793|2018-06-01 03:58:51.54793
NCT00330213|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2006-05-24|2006-05-24|2006-05-26|Estimate|||||||2006-05-24|2006-05-26|Estimate|October 2004||2004-10-31|September 2004|2004-09-30|April 2005||2005-04-30|||||Interventional|||Effects of Red Wine and Cognac on Coronary Circulation|Effects of Red Wine and Cognac on Coronary Circulation|Completed||N/A|25||University of Turku|||||f||||||||||||||2018-06-01 03:58:51.611102|2018-06-01 03:58:51.611102
NCT00330200|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2008-04-25|2006-05-24|2006-05-26|Estimate|||||||2008-04-25|2008-05-01|Estimate|November 2006||2006-11-30|April 2008|2008-04-30|May 2008|Anticipated|2008-05-31|||||Interventional|||Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics|A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of ISIS 113715 Monotherapy on Insulin Sensitivity, Glucose and Lipid Metabolism and Energy Expenditure in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|2|Actual|Ionis Pharmaceuticals, Inc.||||Due to poor enrollment|f||||f||||||||||2018-06-01 03:58:51.668742|2018-06-01 03:58:51.668742
NCT00330187|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|||2006-05-25|2006-05-25|2006-05-26|Estimate|||||||2006-05-25|2006-05-26|Estimate|March 2004||2004-03-31|April 2006|2006-04-30|September 2008||2008-09-30|||||Interventional|||Combined Pharmaco/Behavior Therapy in Adolescent Smokers|Combined Pharmaco/Behavior Therapy in Adolescent Smokers|Unknown status|Recruiting|N/A|216||Medical University of South Carolina|||||f||||||||||||||2018-06-01 03:58:51.724272|2018-06-01 03:58:51.724272
NCT00330174|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|2013-05-29||2015-04-10|2006-05-25|2006-05-26|Estimate|2015-04-10|2015-04-13|Estimate||||2015-04-10|2015-04-13|Estimate|April 2006||2006-04-30|April 2015|2015-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Acamprosate in Alcoholics With Comorbid Anxiety or Depression|The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression|Completed||Phase 4|90|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-06-01 03:58:51.800241|2018-06-01 03:58:51.800241
NCT00330161|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-25|2014-04-25||2014-04-25|2006-05-25|2006-05-26|Estimate|2014-04-25|2014-05-26|Estimate||||2014-04-25|2014-05-26|Estimate|March 2006||2006-03-31|December 2012|2012-12-31|May 2011|Actual|2011-05-31|September 2009|Actual|2009-09-30||Interventional||Of the 29 patients enrolled, only 27 were analyzed. Two patients were deemed ineligible after treatment started and they were excluded from all analysis except adverse event collection.|Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer|Phase II Evaluation of Suberoylanilide Hydroxamic Acid (NSC 701852) in Patients With Advanced Prostate Cancer That Has Progressed on One Prior Chemotherapy|Completed||Phase 2|29|Actual|National Cancer Institute (NCI)|The primary objective was to determine the number of patients wtih progression-free survival at 6 months. Unfortunately all eligible patients were off therapy before the 6 month time point.|1|||f||||||||||||||2018-06-01 03:58:52.055797|2018-06-01 03:58:52.055797
NCT00330148|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2006-05-24|2006-05-24|2006-05-26|Estimate|||||||2006-05-24|2006-05-26|Estimate|March 2001||2001-03-31|May 2006|2006-05-31|June 2004||2004-06-30|||||Interventional|||Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis|Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase|Terminated||Phase 3|435||Epicentre|||||f||||||||||||||2018-06-01 03:58:52.262739|2018-06-01 03:58:52.262739
NCT00330135|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2008-01-07|2006-05-23|2006-05-25|Estimate|||||||2008-01-07|2008-01-09|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis|Multicentre, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Investigate the Efficacy of Sodium Hyaluronate in Patients With Symptomatic Hip Osteoarthritis|Terminated||Phase 3|85|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 03:58:52.324581|2018-06-01 03:58:52.324581
NCT00330122|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2006-05-24|2006-05-24|2006-05-25|Estimate|||||||2006-05-24|2006-05-25|Estimate|March 2006||2006-03-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Restoration of the Radial Length in Compound Wrist Fractures Using Anterior Locking Plates|Restoration of the Radial Length in Compound Wrist Fractures Using Anterior Locking Plates|Unknown status|Recruiting|N/A|120||University Hospital, Angers|||||f||||||||||||||2018-06-01 03:58:52.395666|2018-06-01 03:58:52.395666
NCT00330109|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2017-01-13|2006-05-23|2006-05-25|Estimate|||||||2017-01-13|2017-01-16|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology|Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology|Active, not recruiting||N/A|113|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 03:58:52.478185|2018-06-01 03:58:52.478185
NCT00330096|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2015-10-28|2006-05-24|2006-05-25|Estimate|||||||2015-10-28|2015-10-29|Estimate|March 2006||2006-03-31|October 2013|2013-10-31|April 2009|Actual|2009-04-30|||||Interventional|||Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women||Completed||Phase 3|110|Anticipated|Nestlé||2|||f||||||||||||||2018-06-01 03:58:52.534477|2018-06-01 03:58:52.534477
NCT00330083|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2007-09-20|2006-05-23|2006-05-25|Estimate|||||||2007-09-20|2007-09-21|Estimate|May 2006||2006-05-31|September 2007|2007-09-30||||||||Interventional|||Safety of ALK Ragweed Tablet|A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY|Completed||Phase 1|72|Anticipated|ALK-Abelló A/S|||||f||||||||||||||2018-06-01 03:58:52.594741|2018-06-01 03:58:52.594741
NCT00330070|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2007-02-14|2006-05-23|2006-05-25|Estimate|||||||2007-02-14|2007-02-16|Estimate|May 2006||2006-05-31|February 2007|2007-02-28|January 2007||2007-01-31|||||Interventional|||Control of Asthma Patients Symptomatic on Inhaled Corticosteroids|An 8 Week, Randomized, Double-Blind, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of Oral IPL512,602 to Placebo in Subjects With Moderate to Severe Persistent Asthma Inadequately Controlled on Inhaled Corticosteroids|Completed||Phase 2|200||Inflazyme Pharmaceuticals Ltd|||||f||||||||||||||2018-06-01 03:58:52.644542|2018-06-01 03:58:52.644542
NCT00330044|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2016-12-01|2006-05-24|2006-05-25|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2006||2006-04-30|December 2016|2016-12-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer|A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.|Completed||Phase 1|18|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:58:52.712678|2018-06-01 03:58:52.712678
NCT00330018|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2015-04-19|2006-05-24|2006-05-25|Estimate|||||||2015-04-19|2015-04-21|Estimate|February 2006||2006-02-28|August 2009|2009-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)|An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation|Completed||Phase 3|40|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 03:58:52.767308|2018-06-01 03:58:52.767308
NCT00330005|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2006-05-24|2006-05-24|2006-05-25|Estimate|||||||2006-05-24|2006-05-25|Estimate|July 2002||2002-07-31|May 2006|2006-05-31|January 2005||2005-01-31|||||Interventional|||A Pilot Study of Psychodynamic Psychotherapy for Bipolar Disorder|A Pilot Study of Psychodynamic Psychotherapy for Bipolar Disorder|Completed||N/A|24||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 03:58:52.93999|2018-06-01 03:58:52.93999
NCT00329992|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2010-01-19|2006-05-23|2006-05-25|Estimate|||||||2010-01-19|2010-01-20|Estimate|April 2004||2004-04-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial|Brief Eclectic Psychotherapy for PTSD - a Randomized Controlled Trial|Completed||Phase 3|30|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 03:58:52.996553|2018-06-01 03:58:52.996553
NCT00329979|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2010-06-09|2006-05-23|2006-05-25|Estimate|||||||2010-06-09|2010-06-10|Estimate|May 2006||2006-05-31|June 2010|2010-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Femoral vs Radial Approach and MRI Evaluation of Strokes|Silent Cerebral Infarction After Heart Catheterization: A Randomized Comparison of Radial and Femoral Arterial Access.|Completed|||152|Anticipated|University Hospital, Caen|||2||f||||||||||||||2018-06-01 03:58:53.075567|2018-06-01 03:58:53.075567
NCT00329329|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2012-03-21|2006-05-22|2006-05-24|Estimate|||||||2012-03-21|2012-03-23|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies|Phase 1 Study of the Oral Platinum Agent Satraplatin in Combination With Capecitabine for the Treatment of Patients With Advanced Solid Malignancies|Terminated||Phase 1|24|Actual|Agennix||||Sponsor decided to discontinue study drug development|f||||||||||||||2018-06-01 03:59:09.10255|2018-06-01 03:59:09.10255
NCT00329966|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2006-09-13|2006-05-23|2006-05-25|Estimate|||||||2006-09-13|2006-09-14|Estimate|June 2006||2006-06-30|September 2006|2006-09-30||||||||Interventional|||Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects|Completed||Phase 2|100||Novartis|||||f||||||||||||||2018-06-01 03:58:53.133683|2018-06-01 03:58:53.133683
NCT00329940|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2017-02-22|2006-05-23|2006-05-25|Estimate|||||||2017-02-22|2017-02-24|Actual|November 2005||2005-11-30|February 2017|2017-02-28||||January 2008|Actual|2008-01-31||Interventional|||Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer|Assessment of Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Having Discontinued Anastrozole Adjuvant Treatment Due to Musculoskeletal Disorders|Completed||Phase 3|200|Actual|Novartis||1|||f||||||||||||||2018-06-01 03:58:53.191352|2018-06-01 03:58:53.191352
NCT00329927|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2006-09-13|2006-05-23|2006-05-25|Estimate|||||||2006-09-13|2006-09-14|Estimate|June 2006||2006-06-30|September 2006|2006-09-30||||||||Interventional|||Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2006-2007, When Administered to Elderly Subjects.|Completed||Phase 2|60||Novartis|||||f||||||||||||||2018-06-01 03:58:53.253739|2018-06-01 03:58:53.253739
NCT00329914|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2011-07-22|2006-05-24|2006-05-25|Estimate|||||||2011-07-22|2011-07-25|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|September 2010|Actual|2010-09-30|February 2009|Actual|2009-02-28||Interventional|||Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies?|Effectiveness of Vaginally Administered Progesterone to Prevent Preterm Delivery in Twin Pregnancies - A Multicentre Randomized Trial|Completed||Phase 2|677|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 03:58:53.312168|2018-06-01 03:58:53.312168
NCT00329901|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2013-08-27||2014-06-16|2006-05-23|2006-05-25|Estimate|2014-06-16|2014-06-18|Estimate||||2014-06-16|2014-06-18|Estimate|April 2006||2006-04-30|June 2014|2014-06-30|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Interventional||Baseline Characteristics are summarized for all enrolled population|Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years|A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis (Tdap) Vaccine and Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Acellular Pertussis (Tdap) Vaccine, or One Dose of Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years|Completed||Phase 3|1072|Actual|Novartis||3|||f||||f||||||||||2018-06-01 03:58:53.475301|2018-06-01 03:58:53.475301
NCT00329888|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2006-05-24|2006-05-24|2006-05-25|Estimate|||||||2006-05-24|2006-05-25|Estimate|March 2006||2006-03-31|April 2006|2006-04-30|May 2006||2006-05-31|||||Observational|||Comparison of Papillary Balloon Dilatation Vs.Sphincterotomy for Lithotripsy in Difficult Sphincterotomy or Distal CBD Tapering|Comparison of Endoscopic Papillary Balloon Dilatation and Sphincterotomy for CBD Stones With Difficult Sphincterotomy or Distal CBD Tapering|Unknown status|Active, not recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 03:58:54.358635|2018-06-01 03:58:54.358635
NCT00329862|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2011-11-14|2006-05-23|2006-05-25|Estimate|||||||2011-11-14|2011-11-15|Estimate|May 2006||2006-05-31|November 2011|2011-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Laparoscopic Adjustable Gastric Banding With Truncal Vagotomy|Pilot Study Assessing Advantage of Adding Truncal Vagotomy to LAGB|Terminated||N/A|25|Anticipated|Central Carolina Surgery, PA||||study size reached|f||||||||||||||2018-06-01 03:58:54.422687|2018-06-01 03:58:54.422687
NCT00329849|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2013-08-30||2013-08-30|2006-05-23|2006-05-25|Estimate|2013-08-30|2013-11-05|Estimate||||2013-08-30|2013-11-05|Estimate|May 2006||2006-05-31|August 2013|2013-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional||Analysis was done on all enrolled subjects.|Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age|A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With That of a Licensed Meningococcal ACWY Polysaccharide Vaccine (Menomune®) Administered to Healthy Children 2 to 10 Years of Age|Completed||Phase 3|1500|Actual|Novartis||2|||f||||f||||||||||2018-06-01 03:58:54.527171|2018-06-01 03:58:54.527171
NCT00329836|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|2011-07-21||2011-07-21|2006-05-24|2006-05-25|Estimate|2011-07-21|2011-08-16|Estimate||||2011-07-21|2011-08-16|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||A Research Study to Examine Cutaneous Allodynia and Cluster Headache||Completed|||41|Actual|Thomas Jefferson University|||1||f||||f||||||||||2018-06-01 03:58:55.075052|2018-06-01 03:58:55.075052
NCT00329823|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2006-05-23|2006-05-23|2006-05-25|Estimate|||||||2006-05-23|2006-05-25|Estimate|September 2005||2005-09-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Etanercept in Hidradenitis Suppurativa|A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa|Completed||Phase 2|10||University of Athens|||||f||||||||||||||2018-06-01 03:58:55.208238|2018-06-01 03:58:55.208238
NCT00329810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-07|2006-05-24|2006-05-25|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Effect on Cognitive Function of a Treatment With Aripiprazole|A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients|Completed||Phase 4|500|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-06-01 03:58:55.271682|2018-06-01 03:58:55.271682
NCT00329797|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2017-07-25||2017-10-23|2006-05-23|2006-05-25|Estimate|2017-10-23|2017-11-29|Actual||||2017-10-23|2017-11-29|Actual|March 2006||2006-03-31|October 2017|2017-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Eligible patients|Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy|A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer|Completed||Phase 3|109|Actual|Radiation Therapy Oncology Group|This study stopped accrual early due to unmet targeted accrual goals with 109 subjects accrued out of 1272 planned, less than 10% than what was planned.|2|||f||||t||||||||||2018-06-01 03:58:55.380668|2018-06-01 03:58:55.380668
NCT00329784|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2016-11-01||2017-01-25|2006-05-23|2006-05-25|Estimate|2016-11-01|2016-12-28|Estimate||||2017-01-25|2017-03-08|Actual|December 2006||2006-12-31|January 2017|2017-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|LEAP|Intent-to-treat|Promoting Tolerance to Peanut in High-Risk Children|Induction of Tolerance Through Early Introduction of Peanut in High-Risk Children (ITN032AD)|Completed||Phase 2|640|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.|2018-06-01 03:58:55.88457|2018-06-01 03:58:55.88457
NCT00329771|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|2014-03-04||2014-03-14|2006-05-24|2006-05-25|Estimate|2014-03-14|2014-04-21|Estimate||||2014-03-14|2014-04-21|Estimate|March 2006||2006-03-31|March 2014|2014-03-31|March 2008|Actual|2008-03-31|December 2006|Actual|2006-12-31||Observational|||Research Study to Determine Sensitivity to Gentle Touch and Pressure During an Active Migraine Attack.|Brush Allodynia in Patients With Episodic Migraine During an Acute Attack.|Completed|||28|Actual|Thomas Jefferson University|||1||f||||f||||||||||2018-06-01 03:58:57.608453|2018-06-01 03:58:57.608453
NCT00329758|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2010-06-23|2006-05-23|2006-05-25|Estimate|||||||2010-06-23|2010-06-24|Estimate|July 2006||2006-07-31|March 2009|2009-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Rosuvastatin on Amnesia and Orientation Through Galveston Outcome Amnesia Test in Moderate Head Injury|Phase II Study of Rosuvastatin´s Effect on Amnesia and Orientation Through Galveston Outcome Amnesia Test in Humans With Moderate Head Injury|Completed||Phase 2|20|Actual|Universidad Autonoma de San Luis Potosí||2|||f||||t||||||||||2018-06-01 03:58:57.812294|2018-06-01 03:58:57.812294
NCT00329745|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|2009-07-02||2016-10-27|2006-05-24|2006-05-25|Estimate|2009-09-11|2009-10-14|Estimate||||2016-10-27|2016-12-09|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)|A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants.|Completed||Phase 3|8687|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:58:57.905996|2018-06-01 03:58:57.905996
NCT00329732|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|2011-05-24||2015-04-16|2006-05-24|2006-05-25|Estimate|2011-05-24|2011-06-27|Estimate||||2015-04-16|2015-05-06|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks|Double-Blind, Placebo Controlled Trial Of Greater Occipital Nerve Block For The Treatment Of Migraine Status|Terminated||N/A|2|Actual|Thomas Jefferson University||2||Study terminated due to inadequate recruitment|f||||||||||||||2018-06-01 03:58:58.166099|2018-06-01 03:58:58.166099
NCT00329719|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2014-06-02||2018-03-21|2006-05-23|2006-05-25|Estimate|2015-05-29|2015-06-02|Estimate||||2018-03-21|2018-04-25|Actual|March 24, 2006|Actual|2006-03-24|March 2018|2018-03-31||||February 1, 2013|Actual|2013-02-01||Interventional|||Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma|A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma|Completed||Phase 1/Phase 2|115|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 03:58:58.452116|2018-06-01 03:58:58.452116
NCT00329706|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2017-05-01|2006-05-24|2006-05-25|Estimate|||||||2017-05-01|2017-05-02|Actual|June 2006||2006-06-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)|Early and Long-Term Value of Imaging Brain Metabolism|Completed||N/A|710|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 03:58:59.998223|2018-06-01 03:58:59.998223
NCT00329693|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2011-05-18|2006-05-24|2006-05-25|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|May 2008|Actual|2008-05-31|August 2007|Actual|2007-08-31||Interventional|||Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide|A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.|Completed||Phase 2|182|Actual|Ferring Pharmaceuticals||4|||f||||t||||||||||2018-06-01 03:59:00.081724|2018-06-01 03:59:00.081724
NCT00329680|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2009-12-30|2006-05-23|2006-05-25|Estimate|||||||2009-12-30|2009-12-31|Estimate|June 2007||2007-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis|Investigating Nutritional Therapy With EPA, GLA and Antioxidants Role in Sepsis Treatment-INTERSEPT STUDY|Completed||Phase 4|115|Actual|Fernandes Tavora Hospital||2|||f||||t||||||||||2018-06-01 03:59:00.149342|2018-06-01 03:59:00.149342
NCT00329667|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2010-09-09|2006-05-23|2006-05-25|Estimate|||||||2010-09-09|2010-09-10|Estimate|January 2003||2003-01-31|September 2010|2010-09-30|September 2008|Actual|2008-09-30|March 2006|Actual|2006-03-31||Interventional|EPIC||Observational Study of Prosthetic Tissue Aortic and Mitral Heart Valve|An Observational, Prospective Evaluation of the SJM Epic Valve|Completed||N/A|761|Actual|St. Jude Medical|||||f||||||||||||||2018-06-01 03:59:00.229874|2018-06-01 03:59:00.229874
NCT00329654|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2015-07-30|2006-05-23|2006-05-25|Estimate|||||||2015-07-30|2015-07-31|Estimate|March 2006||2006-03-31|July 2015|2015-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||James EMBAR® Light Therapy in the Treatment of Burn Wounds of Intermediate Depth|A Prospective, Randomized, Single Blinded, Controlled Clinical Investigation of James Embar® Light Therapy in the Treatment of Burn Wounds With Little Healing Potential|Completed||N/A|40|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 03:59:00.360185|2018-06-01 03:59:00.360185
NCT00329641|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2012-06-05||2014-07-25|2006-05-23|2006-05-25|Estimate|2012-06-05|2012-07-11|Estimate||||2014-07-25|2014-07-31|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye|Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:59:00.440647|2018-06-01 03:59:00.440647
NCT00329316|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2008-06-26|2006-05-23|2006-05-24|Estimate|||||||2008-06-26|2008-06-27|Estimate||||June 2007|2007-06-30||||||||Interventional|||Prevention of Recurrent Preterm Delivery by a Natural Progesterone Agent||Withdrawn||N/A|||The Baruch Padeh Medical Center, Poriya||||"Study withdrawn for financial problems. We didnwt get a grant we needed for purchesing the~   medication for the study."|f||||||||||||||2018-06-01 03:59:09.155696|2018-06-01 03:59:09.155696
NCT00329628|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2014-10-27|2006-05-24|2006-05-25|Estimate|||||||2014-10-27|2014-10-28|Estimate|February 2006||2006-02-28|October 2014|2014-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin|RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement|Completed||Phase 3|4541|Actual|Bayer||2|||f||||||||||||||2018-06-01 03:59:00.700088|2018-06-01 03:59:00.700088
NCT00329615|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2009-08-20|2006-05-23|2006-05-25|Estimate|||||||2009-08-20|2009-08-21|Estimate|January 2000||2000-01-31|August 2009|2009-08-31|September 2005|Actual|2005-09-30|||||Interventional|||Insulin Treatment in Cancer Cachexia|Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism and Physical Functioning. A Randomized Prospective Study.|Completed||Phase 4|135||Göteborg University|||||f||||||||||||||2018-06-01 03:59:01.154344|2018-06-01 03:59:01.154344
NCT00329602|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2009-09-10||2017-03-21|2006-05-23|2006-05-25|Estimate|2010-04-29|2010-05-27|Estimate||||2017-03-21|2017-03-23|Actual|March 2006||2006-03-31|March 2017|2017-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Long-term Study Of Ropinirole In Restless Legs Syndrome|A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome.|Completed||Phase 4|404|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:59:01.262101|2018-06-01 03:59:01.262101
NCT00329589|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-24|||2017-05-05|2006-05-24|2006-05-25|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2005||2005-09-30|May 2017|2017-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients|A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients|Completed||Phase 1|54|Actual|Thomas Jefferson University||3|||f||||t||||||||||2018-06-01 03:59:02.013507|2018-06-01 03:59:02.013507
NCT00329576|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2016-09-27|2006-05-23|2006-05-24|Estimate|||||||2016-09-27|2016-09-28|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|August 2006|Actual|2006-08-31|||||Interventional|||Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine|Evaluate the Anti-HBs Antibody Persistence, in Subjects Who Received GSK Biologicals' Preservative-free or Thiomersal-free Engerix™-B or Engerix™-B Containing Thiomersal, Approximately 5 to 6 Yrs Earlier|Completed||Phase 4|632||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:59:02.07799|2018-06-01 03:59:02.07799
NCT00329563|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2017-04-13|2006-05-22|2006-05-24|Estimate|||||||2017-04-13|2017-04-17|Actual|November 2004||2004-11-30|April 2017|2017-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Pilot Community Clinical Study of Hypothermia in Cardiac Arrest|Pilot Community Clinical Study of Hypothermia in Cardiac Arrest|Completed||Phase 1/Phase 2|125|Actual|University of Washington||2|||f||||||||||||||2018-06-01 03:59:02.143702|2018-06-01 03:59:02.143702
NCT00329550|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|2009-04-07||2015-02-27|2006-05-22|2006-05-24|Estimate|2009-09-25|2009-11-10|Estimate||||2015-02-27|2015-03-18|Estimate|May 2006||2006-05-31|February 2015|2015-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease|A 26-week, Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed Clinical Efficacy in a Remission Induction Study (Study C87037 [NCT00291668]), at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals|Completed||Phase 2|40|Actual|UCB Pharma|Due to the small number of subjects in this study, the percentages of subjects with adverse events may be misleading.|3|||f||||f||||||||||2018-06-01 03:59:02.288083|2018-06-01 03:59:02.288083
NCT00329537|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2013-12-02|2006-05-23|2006-05-24|Estimate|||||||2013-12-02|2013-12-04|Estimate|June 2006||2006-06-30|December 2013|2013-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study of Sargramostim in Moderately to Severely Active Crohn's Disease|Open-Label Phase 1 Study to Assess the Tolerability, Pharmacokinetics and Safety of 2 and 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 4 Weeks, and Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Efficacy and Safety of 6 µg/kg Sargramostim (SH L 04023) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease (Sargramostim Phase 1/2 Study)|Terminated||Phase 2|11|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:59:04.307756|2018-06-01 03:59:04.307756
NCT00329524|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|2009-06-17||2015-04-07|2006-05-22|2006-05-24|Estimate|2009-06-17|2009-08-07|Estimate||||2015-04-07|2015-05-04|Estimate|June 2006||2006-06-30|April 2015|2015-04-30|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus|Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus|Completed||N/A|5|Actual|University of Arkansas|Study was ended early and analysis was limited to only 5 subjects. A follow up study using a revised protocol is underway.|1|||f||||f||||||||||2018-06-01 03:59:04.374878|2018-06-01 03:59:04.374878
NCT00329511|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2018-01-26|2006-05-22|2006-05-24|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2004||2004-09-30|January 2018|2018-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy|A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy|Withdrawn||N/A|0|Actual|University of California, Irvine||2||Feasibility of study. PI termination|f||||f||||||||||2018-06-01 03:59:04.516651|2018-06-01 03:59:04.516651
NCT00329498|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2006-10-25|2006-05-23|2006-05-24|Estimate|||||||2006-10-25|2006-10-26|Estimate|May 1998||1998-05-31|October 2006|2006-10-31|August 2005||2005-08-31|||||Interventional|||L-Ascorbic Acid Depletion to Treat Acute Myeloid Leukemia and Myelodysplastic Syndromes|Manipulation of L-Ascorbic Acid Level For The Treatment of Selected Cases Of Acute Myeloid Leukemia and Myelodysplastic Syndromes|Suspended||Phase 2|25||Samsung Medical Center|||||f||||||||||||||2018-06-01 03:59:04.582633|2018-06-01 03:59:04.582633
NCT00329485|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2007-08-01|2006-05-23|2006-05-24|Estimate|||||||2007-08-01|2007-08-02|Estimate|June 2006||2006-06-30|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients|The Effect of Ribose on B-Type Natriuretic Peptide Levels in Congestive Heart Failure Patients|Terminated||N/A|120||Valen Labs||||Poor recruitment and through put|f||||f||||||||||2018-06-01 03:59:04.635087|2018-06-01 03:59:04.635087
NCT00329472|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2010-08-26|2006-05-23|2006-05-24|Estimate|||||||2010-08-26|2010-08-27|Estimate|April 2006||2006-04-30|July 2010|2010-07-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Efficacy Study of Induction Chemotherapy Before Surgery in Operable Non-small Cell Lung Cancer|Randomized Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Plus Adjuvant Chemotherapy Versus Surgery Plus Adjuvant Chemotherapy in Stage IB, IIA, IIB and T3N1 Non-small Cell Lung Cancer (ICON)|Withdrawn||Phase 3|0|Actual|Samsung Medical Center||2||poor enrollment|f||||||||||||||2018-06-01 03:59:04.803289|2018-06-01 03:59:04.803289
NCT00329459|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2016-10-20|2006-05-22|2006-05-24|Estimate|||||||2016-10-20|2016-10-24|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea|A Randomized, Double-blind, Single Migraine Attack, Placebo -Controlled, Patallel-group Multicenter Study to Evaluate the Efficacy and Tolerability or Trexima (Sumatriptan Succinate/Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea|Completed||Phase 3|320|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:59:04.877604|2018-06-01 03:59:04.877604
NCT00329446|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2009-03-24|2006-05-22|2006-05-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|September 2007|Actual|2007-09-30|||||Interventional|GOLD||Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder|Completed||Phase 3|800|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:59:05.028202|2018-06-01 03:59:05.028202
NCT00329433|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|2011-03-11||2011-06-14|2006-05-22|2006-05-24|Estimate|2011-05-11|2011-06-13|Estimate||||2011-06-14|2011-06-16|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery|The Use of Desirudin Versus Heparin for Thrombosis Prophylaxis in Cardiothoracic Surgery Patients|Completed||Phase 2/Phase 3|120|Actual|Washington University School of Medicine|The study size was small and a surrogate end point was the primary outcome. The study was not powered to show statistical differences in clinical outcomes. Many patients received both desirudin and heparin during the study.|2|||f||||t||||||||||2018-06-01 03:59:05.246963|2018-06-01 03:59:05.246963
NCT00329420|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|2009-05-01||2015-02-27|2006-05-22|2006-05-24|Estimate|2009-09-25|2009-11-10|Estimate||||2015-02-27|2015-03-18|Estimate|May 2006||2006-05-31|February 2015|2015-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)|A Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed no Clinical Efficacy in a Remission Induction Study (Study C87037) But Showed Clinical Efficacy After Additional Remission Induction Therapy Was Applied, at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals|Completed||Phase 2|46|Actual|UCB Pharma|Due to the small number of subjects in this study, the percentages of subjects with adverse events may be misleading.|3|||f||||f||||||||||2018-06-01 03:59:05.595481|2018-06-01 03:59:05.595481
NCT00329407|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|2010-07-07||2010-08-30|2006-05-22|2006-05-24|Estimate|2010-07-07|2010-08-04|Estimate||||2010-08-30|2010-09-08|Estimate|September 2003||2003-09-30|August 2010|2010-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects||Completed||Phase 4|10|Actual|Boston University|Limitation of this trial include the small number of subjects included and lack of blinding, and inculsion of a placebo control group. An other limitation was the testing the active medication topiramate at om=nly one dose level (i.e. 400 mg daily).|1|||f||||||||||||||2018-06-01 03:59:08.517647|2018-06-01 03:59:08.517647
NCT00329394|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2008-10-07|2006-05-23|2006-05-24|Estimate|||||||2008-10-07|2008-10-08|Estimate|April 2006||2006-04-30|October 2008|2008-10-31|September 2008|Anticipated|2008-09-30|September 2008|Anticipated|2008-09-30||Interventional|||Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient|Study of the Efficacity of the Systemic Ketamine for the Improvement of Post-Operative Analgesia After ORL Carcinological Surgery at the Alcohol-Dependent Patient.|Suspended||Phase 3|56|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 03:59:08.640617|2018-06-01 03:59:08.640617
NCT00329381|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2008-06-03|2006-05-23|2006-05-24|Estimate|||||||2008-06-03|2008-06-04|Estimate|May 2006||2006-05-31|January 2007|2007-01-31|October 2007|Actual|2007-10-31|May 2007|Actual|2007-05-31||Interventional|||Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy|A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab)on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids|Completed||Phase 4|14|Actual|University of Mississippi Medical Center||2|||f||||t||||||||||2018-06-01 03:59:08.69541|2018-06-01 03:59:08.69541
NCT00329368|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2012-03-08|2006-05-22|2006-05-24|Estimate|||||||2012-03-08|2012-03-09|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer|A Phase I Study of EC90 With GPI-0100 Adjuvant Followed by EC17 With Cytokines (Interleukin-2 [IL-2] and Interferon-alpha [IFN-alpha]) in Patients With Refractory or Metastatic Cancer|Completed||Phase 1|13|Actual|Endocyte|||||f||||f||||||||||2018-06-01 03:59:08.749084|2018-06-01 03:59:08.749084
NCT00329355|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2017-01-20|2006-05-23|2006-05-24|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)|A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea|Completed||Phase 3|351|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:59:08.810223|2018-06-01 03:59:08.810223
NCT00329342|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2007-11-26|2006-05-23|2006-05-24|Estimate|||||||2007-11-26|2007-11-27|Estimate|April 2006||2006-04-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Return to Work Interventions for Patients With Low Back Pain|Return to Work Interventions for Patients With Low Back Pain During Inpatient Rehabilitation: a Quasi-Experimental Study|Completed||N/A|80|Actual|Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster||2|||f||||f||||||||||2018-06-01 03:59:09.04122|2018-06-01 03:59:09.04122
NCT00329303|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2013-09-06|2006-05-22|2006-05-24|Estimate|||||||2013-09-06|2013-09-09|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis|Efficacy and Safety of Re-treatment With Cimzia® at 2 Dose Regimens for 12 Weeks in Subject Suffering From Moderate to Severe Chronic Plaque Psoriasis Having Relapsed After Response to First Treatment|Completed||Phase 2|75||UCB Pharma|||||f||||||||||||||2018-06-01 03:59:09.213113|2018-06-01 03:59:09.213113
NCT00329290|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2013-02-06|2006-05-22|2006-05-24|Estimate|||||||2013-02-06|2013-02-08|Estimate|February 2002||2002-02-28|February 2013|2013-02-28|April 2007|Actual|2007-04-30|||||Observational|||Evaluation of Maternal and Fetal Outcomes in Pregnancies in Women With Prosthetic Heart Valves||Completed|||100|Anticipated|University of California, Irvine|||||f||||||||||||||2018-06-01 03:59:09.305482|2018-06-01 03:59:09.305482
NCT00329277|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2008-05-22|2006-05-23|2006-05-24|Estimate|||||||2008-05-22|2008-05-28|Estimate|April 2006||2006-04-30|November 2006|2006-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Detection of Topographic Residual Acuity in Patients With Age Related Macular Degeneration||Completed||N/A|30|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:59:09.419019|2018-06-01 03:59:09.419019
NCT00329264|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2009-03-24|2006-05-22|2006-05-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|August 2007|Actual|2007-08-31|||||Interventional|TITANIUM||Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder|Completed||Phase 3|876|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 03:59:09.474668|2018-06-01 03:59:09.474668
NCT00329251|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2006-05-22|2006-05-22|2006-05-24|Estimate|||||||2006-05-22|2006-05-24|Estimate|April 2003||2003-04-30|May 2006|2006-05-31|March 2006||2006-03-31|||||Interventional|||Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV|Study of the Influence of Immunological Repeated Stimuli With Commercial Vaccines Over the Viral Load (VL), Resistance Development and Specific Immunological Response Against HIV in Early Stage HIV Patients With Undetectable VL After HAART|Completed||Phase 4|26||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 03:59:09.591497|2018-06-01 03:59:09.591497
NCT00329238|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|2011-08-10||2014-05-08|2006-05-23|2006-05-24|Estimate|2011-08-10|2011-09-14|Estimate||||2014-05-08|2014-05-19|Estimate|May 2006||2006-05-31|December 2013|2013-12-31||||October 2010|Actual|2010-10-31||Interventional|RE-MEDY|The FAS consisted of all randomised patients who were documented to have taken at least 1 dose of study drug.|Secondary Prevention of Venous Thrombo Embolism (VTE).|A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.|Completed||Phase 3|2867|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 03:59:09.725449|2018-06-01 03:59:09.725449
NCT00329225|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2016-09-13|2006-05-22|2006-05-24|Estimate|||||||2016-09-13|2016-09-15|Estimate|September 2002||2002-09-30|September 2016|2016-09-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin|Completed||Phase 4|630|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:59:13.231056|2018-06-01 03:59:13.231056
NCT00329212|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2006-11-14|2006-05-23|2006-05-24|Estimate|||||||2006-11-14|2006-11-15|Estimate||||November 2006|2006-11-30||||||||Observational|||The Pharmacokinetics Study of Concentrated Herbal Formula and Traditional Herbal Decoctions in Humans|Bioequivalence of Bioactive Markers Between Concentrated Herbal Formula and Traditional Herbal Decoctions in Humans|Completed|||||Committee on Chinese Medicine and Pharmacy|||||f||||||||||||||2018-06-01 03:59:13.468426|2018-06-01 03:59:13.468426
NCT00329199|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2007-08-16|2006-05-22|2006-05-24|Estimate|||||||2007-08-16|2007-08-20|Estimate|December 2006||2006-12-31|August 2007|2007-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Pennsylvania Adolescent Intervention Research Study (PAIRStudy)|TRIAD Project: Pennsylvania Adolescent Intervention Research Study (PAIRStudy; Project 3a)|Terminated||Phase 2|240|Anticipated|Pennsylvania Department of Health||||Trial was rewritten and will no longer focus on the link between smoking and depression.|f||||||||||||||2018-06-01 03:59:13.516297|2018-06-01 03:59:13.516297
NCT00329186|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2013-02-06|2006-05-23|2006-05-24|Estimate|||||||2013-02-06|2013-02-08|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects|A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers|Completed||Phase 3|14|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:59:13.694805|2018-06-01 03:59:13.694805
NCT00329173|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2009-03-13|2006-05-22|2006-05-24|Estimate|||||||2009-03-13|2009-03-16|Estimate|November 2003||2003-11-30|March 2009|2009-03-31|August 2004|Actual|2004-08-31|||||Interventional|||PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.|A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) With Atorvastatin (20 mg) in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD|Completed||Phase 3|1000||AstraZeneca|||||f||||||||||||||2018-06-01 03:59:13.752152|2018-06-01 03:59:13.752152
NCT00329160|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|2011-03-17||2011-08-29|2006-05-22|2006-05-24|Estimate|2011-06-16|2011-07-15|Estimate||||2011-08-29|2011-08-31|Estimate|October 2005||2005-10-31|August 2011|2011-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease|A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease as Measured by Intravascular Ultrasonography|Completed||Phase 4|214|Actual|AstraZeneca|Because there was no placebo arm the net effect of rosuvastatin was not clarified. This study examined only single measurable plaques, which might not represent pan-coronary nature of plaque.||||f||||||||||||||2018-06-01 03:59:13.824519|2018-06-01 03:59:13.824519
NCT00329147|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-23|||2007-12-06|2006-05-23|2006-05-24|Estimate|||||||2007-12-06|2007-12-07|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects|A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects|Completed||Phase 3|20|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 03:59:14.169863|2018-06-01 03:59:14.169863
NCT00329134|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2009-04-16|2006-05-22|2006-05-24|Estimate|||||||2009-04-16|2009-04-17|Estimate|July 2006||2006-07-31|April 2009|2009-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria|Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria|Completed||Phase 2|56|Anticipated|University Ghent|||||f||||f||||||||||2018-06-01 03:59:14.229703|2018-06-01 03:59:14.229703
NCT00329121|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2015-01-16|2006-05-22|2006-05-24|Estimate|||||||2015-01-16|2015-01-19|Estimate|May 2006||2006-05-31|January 2015|2015-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ|Multi-centre, Open-label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)|Completed||Phase 2|24||Peplin|||||f||||||||||||||2018-06-01 03:59:14.280958|2018-06-01 03:59:14.280958
NCT00329108|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2008-12-22||2009-04-01|2006-05-22|2006-05-24|Estimate|2009-03-12|2009-03-13|Estimate||||2009-04-01|2009-05-01|Estimate|November 2006||2006-11-30|April 2009|2009-04-30|January 2008|Actual|2008-01-31|July 2007|Actual|2007-07-31||Interventional|ZOOM||Ziprasidone And Olanzapine's Outcomes In Mania|A Multicenter, Randomized, Double-Blind, Parallel Group Study, Comparing The Efficacy And Tolerability Of Ziprasidone (Zeldox, Geodon) vs. Olanzapine (Zyprexa) In The Treatment And Maintenance Of Response In Patients With Acute Mania|Terminated||Phase 4|29|Actual|Pfizer|The study was terminated due to poor recruitment. No efficacy data were summarized due to very low sample size. Only safety data were summarized.|2||Please see Brief Summary for Termination Reason.|f||||f||||||||||2018-06-01 03:59:14.357357|2018-06-01 03:59:14.357357
NCT00329095|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2006-05-22|2006-05-22|2006-05-24|Estimate|||||||2006-05-22|2006-05-24|Estimate|December 2005||2005-12-31|May 2006|2006-05-31|April 2006||2006-04-30|||||Interventional|||An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance|An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures|Completed||Phase 4|60||Robin, Alan L., M.D.|||||f||||||||||||||2018-06-01 03:59:14.584623|2018-06-01 03:59:14.584623
NCT00329082|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19||2009-06-10|2009-10-05|2006-05-19|2006-05-24|Estimate||||2009-10-05|2009-10-07|Estimate|2009-10-05|2009-10-07|Estimate|May 2006||2006-05-31|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers|LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers|Completed||Phase 2|25|Actual|Eli Lilly and Company||5|||f||||t||||||||||2018-06-01 03:59:14.910756|2018-06-01 03:59:14.910756
NCT00329069|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2006-05-22|2006-05-22|2006-05-24|Estimate|||||||2006-05-22|2006-05-24|Estimate|May 2002||2002-05-31|May 2006|2006-05-31|March 2006||2006-03-31|||||Interventional|||The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia|Vascular Endothelial Receptor Activity in Patients With Coronary Artery Disease on Medication With Statins|Completed||N/A|50||University of Ulm|||||f||||||||||||||2018-06-01 03:59:14.998558|2018-06-01 03:59:14.998558
NCT00329056|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2010-07-19|2006-05-22|2006-05-24|Estimate|||||||2010-07-19|2010-07-21|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|November 2007|Actual|2007-11-30|||||Interventional|||A Trial of MitoQ for the Treatment of People With Parkinson's Disease|A Double-Blind, Prospective, Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients With Parkinson's Disease|Completed||Phase 2|128|Actual|Antipodean Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-06-01 03:59:15.063678|2018-06-01 03:59:15.063678
NCT00329043|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2018-04-23|2006-05-19|2006-05-24|Estimate|||||||2018-04-23|2018-04-25|Actual|May 2006|Actual|2006-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy|A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy|Active, not recruiting||Phase 2|64|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 03:59:15.147407|2018-06-01 03:59:15.147407
NCT00329030|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|2016-01-28||2017-08-24|2006-05-22|2006-05-24|Estimate|2016-05-04|2016-06-10|Estimate||||2017-08-24|2017-09-25|Actual|December 2005||2005-12-31|August 2017|2017-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401)|Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401)|Completed||Phase 3|224|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-06-01 03:59:15.26025|2018-06-01 03:59:15.26025
NCT00329017|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2017-02-13|2006-05-19|2006-05-24|Estimate|||||||2017-02-13|2017-02-14|Actual|May 2005||2005-05-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer|Correlation of SNP Patterns With Fine Needle Aspiration Cytomorphology in High Risk Postmenopausal Women|Active, not recruiting|||500|Anticipated|University of Kansas Medical Center|||1||f||||f||||||Samples With DNA|"~     Fine needle aspirate~   "|No|Global results will be published.|2018-06-01 03:59:15.982754|2018-06-01 03:59:15.982754
NCT00329004|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2011-01-24|2006-05-19|2006-05-24|Estimate|||||||2011-01-24|2011-01-25|Estimate|August 2006||2006-08-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors|A Phase I Dose Escalation Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|89|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 03:59:16.053356|2018-06-01 03:59:16.053356
NCT00328991|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2006-05-22|2006-05-22|2006-05-24|Estimate|||||||2006-05-22|2006-05-24|Estimate|October 2004||2004-10-31|January 2006|2006-01-31|December 2005||2005-12-31|||||Interventional|||Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts|Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris|Completed||N/A|90||Minneapolis Veterans Affairs Medical Center|||||f||||||||||||||2018-06-01 03:59:16.124128|2018-06-01 03:59:16.124128
NCT00328978|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2009-03-24|2006-05-22|2006-05-24|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 2003||2003-10-31|March 2009|2009-03-31|September 2005|Actual|2005-09-30|||||Interventional|||Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects|A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day in Schizophrenic or Schizoaffective Subjects.|Completed||Phase 3|330||AstraZeneca|||||f||||||||||||||2018-06-01 03:59:16.186824|2018-06-01 03:59:16.186824
NCT00328965|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2010-08-12|2006-05-22|2006-05-24|Estimate|||||||2010-08-12|2010-08-16|Estimate|November 2004||2004-11-30|August 2010|2010-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea|An Open Label, Multi-centre, Single Arm Phase IV Study to Evaluate the Antihypertensive Effect of Lacidipine in Mild to Moderate Essential Hypertension Patients With Type 2 Diabetes in Korea|Completed||Phase 4|||GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 03:59:16.253731|2018-06-01 03:59:16.253731
NCT00328952|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2009-09-15|2006-05-22|2006-05-24|Estimate|||||||2009-09-15|2009-09-16|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Patients With Schizophrenia|Naturalistic Multicenter Study of Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Schizophrenia|Completed|||40|Actual|Seoul National University Hospital|||||f||||t||||||Samples Without DNA|"~     routine lab tests for changes in medical condition~   "|||2018-06-01 03:59:16.311993|2018-06-01 03:59:16.311993
NCT00328939|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2012-05-31|2006-05-22|2006-05-24|Estimate|||||||2012-05-31|2012-06-04|Estimate|May 2004||2004-05-31|February 2011|2011-02-28||||||||Interventional|||ARIXTRA Local Study For Registration In China.|Randomized, Single Blind, Parallel Study to Compare the Safety and Efficacy of ARIXTRA to Enoxaparine in Patients Undergoing Elective Major Hip or Knee Replacement or a Revision of Components.|Completed||Phase 3|240||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:59:16.368209|2018-06-01 03:59:16.368209
NCT00328926|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-20|2013-05-22||2013-08-04|2006-05-22|2006-05-24|Estimate|2013-05-22|2013-07-12|Estimate||||2013-08-04|2013-08-07|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])|A Phase IV, Multicenter, Randomized, Double-blinded, Clinical Trial to Confirm the Efficacy of the 75 IU Dose of Luveris® vs. Placebo When Administered With Follitropin Alfa for Induction of Follicular Development and Pregnancy in Hypogonadotropic Hypogonadal Women With Profound LH Deficiency, as Defined by a Baseline LH Level <1.2 IU/L|Terminated||Phase 4|11|Actual|EMD Serono||3||"Please see Purpose statement"|f||||||||||||||2018-06-01 03:59:16.440745|2018-06-01 03:59:16.440745
NCT00328913|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2007-01-08|2006-05-22|2006-05-24|Estimate|||||||2007-01-08|2007-01-09|Estimate|March 2006||2006-03-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||The Effect of 5-Hydroxytryptophan (5-HTP) on Satiety|Effectiveness of 5-Hydroxytryptophan on Satiety in a Randomised, Placebo Controlled, Time Blinded Study, in Overweight Women|Completed||Phase 2|24||TNO|||||f||||||||||||||2018-06-01 03:59:16.876271|2018-06-01 03:59:16.876271
NCT00328900|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2012-05-31|2006-05-22|2006-05-24|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2006||2006-01-31|April 2007|2007-04-30||||||||Interventional|||"Measurement of Stress During Anesthesia With Pain Detector on Patients Receiving Atropine"||Unknown status|Recruiting|N/A|24|Anticipated|Rikshospitalet University Hospital|||||f||||f||||||||||2018-06-01 03:59:16.932085|2018-06-01 03:59:16.932085
NCT00328887|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-22|||2016-05-02|2006-05-22|2006-05-24|Estimate|||||||2016-05-02|2016-05-03|Estimate|November 2004||2004-11-30|May 2016|2016-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma|Phase I, Initial Safety/Toxicity Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdCUCD40L) to Patients With Stage III or IV Esophageal Carcinoma|Withdrawn||Phase 1|0|Actual|Weill Medical College of Cornell University||1||No funding was obtained for this study. No subject were receruited.|f||||t||||||||No||2018-06-01 03:59:17.005472|2018-06-01 03:59:17.005472
NCT00328874|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-21|||2008-03-25|2006-05-22|2006-05-24|Estimate|||||||2008-03-25|2008-03-27|Estimate|May 2006||2006-05-31|March 2008|2008-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy|Mono-Center, Prospective, Double-Blind, Placebo-Controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy|Completed||Phase 2|20|Actual|German Parkinson Study Group (GPS)|||||f||||f||||||||||2018-06-01 03:59:17.075385|2018-06-01 03:59:17.075385
NCT00328861|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-20|2012-10-04||2012-10-04|2006-05-20|2006-05-22|Estimate|2012-10-04|2012-11-05|Estimate||||2012-10-04|2012-11-05|Estimate|May 2006||2006-05-31|October 2012|2012-10-31|April 2009|Actual|2009-04-30|July 2007|Actual|2007-07-31||Interventional|||Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer|Phase II Study in Metastatic Melanoma or Kidney Cancer Using Autologous Natural Killer Cells Plus Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy|Completed||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 03:59:17.153626|2018-06-01 03:59:17.153626
NCT00328848|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2014-07-16|2006-05-18|2006-05-22|Estimate|||||||2014-07-16|2014-07-17|Estimate|October 2005||2005-10-31|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||After Discharge Management of Low Income Frail Elderly|After Discharge Management of Low Income Frail Elderly (AD-LIFE)|Completed||N/A|530|Actual|Summa Health System||1|||f||||t||||||||||2018-06-01 03:59:17.606204|2018-06-01 03:59:17.606204
NCT00328835|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2006-10-16|2006-05-18|2006-05-22|Estimate|||||||2006-10-16|2006-10-17|Estimate|March 2006||2006-03-31|May 2006|2006-05-31|April 2006||2006-04-30|||||Interventional|||Optic Nerve Compliance Study|Optic Nerve Compliance Study|Completed||N/A|100||Capital Vision Research Trust|||||f||||||||||||||2018-06-01 03:59:17.676296|2018-06-01 03:59:17.676296
NCT00328822|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2008-03-17|2006-05-19|2006-05-22|Estimate|||||||2008-03-17|2008-03-18|Estimate|December 2006||2006-12-31|October 2006|2006-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial|Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial|Completed||N/A|16|Anticipated|Khon Kaen University||2|||f||||||||||||||2018-06-01 03:59:17.732187|2018-06-01 03:59:17.732187
NCT00328809|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2013-06-03|2006-05-19|2006-05-22|Estimate|||||||2013-06-03|2013-06-04|Estimate||||June 2013|2013-06-30||||||||Interventional|||Spironolactone Safety in Dialysis Patients|Subjects With Severe Heart Failure and End-Stage Renal Disease on Hemodialysis: A Pilot Study to Assess Safety and Tolerability of Spironolactone|Withdrawn||Phase 4|0|Actual|State University of New York - Upstate Medical University||1||personnel shortage|f||||||||||||||2018-06-01 03:59:17.805408|2018-06-01 03:59:17.805408
NCT00328796|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2008-10-03|2006-05-19|2006-05-22|Estimate|||||||2008-10-03|2008-10-06|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|February 2008|Actual|2008-02-29|July 2007|Actual|2007-07-31||Interventional|||Acupuncture for Pain Relief During Perineal Repair After Childbirth|Acupuncture or Local Anaesthetics for Pain Relief During Perineal Repair After Vaginal Delivery: A Randomised Controlled Trial|Completed||N/A|207|Actual|Sonderborg Hospital|||||f||||||||||||||2018-06-01 03:59:17.863727|2018-06-01 03:59:17.863727
NCT00302289|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2006-03-13|2006-03-13|2006-03-14|Estimate|||||||2006-03-13|2006-03-14|Estimate|January 2000||2000-01-31|December 2000|2000-12-31|December 2000||2000-12-31|||||Interventional|||B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients|B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients|Completed||Phase 1|12||University of Copenhagen|||||f||||||||||||||2018-06-01 04:07:16.215519|2018-06-01 04:07:16.215519
NCT00328783|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|2014-01-27||2017-12-11|2006-05-19|2006-05-22|Estimate|2014-03-28|2014-04-30|Estimate||||2017-12-11|2018-01-11|Actual|October 2002||2002-10-31|December 2017|2017-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer|A Pilot Study Investigating Active Breathing Coordinator (ABC) to Reduce Radiation Dose to Normal Structures in Breast Cancer Patients|Completed||N/A|112|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:59:17.932498|2018-06-01 03:59:17.932498
NCT00328770|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|2012-06-12||2013-06-18|2006-05-19|2006-05-22|Estimate|2012-08-27|2012-10-01|Estimate||||2013-06-18|2013-06-24|Estimate|December 1996||1996-12-31|June 2013|2013-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma|De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects|Completed||Phase 2/Phase 3|70|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 03:59:18.134924|2018-06-01 03:59:18.134924
NCT00328757|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2011-06-27|2006-05-19|2006-05-22|Estimate|||||||2011-06-27|2011-06-28|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|April 2007|Anticipated|2007-04-30|||||Interventional|||Safety of Regular Diet as the First Meal in Patients Who Underwent Surgical Treatment for Gynecologic Cancer|Regular Versus Liquid Diet as the First Meal in Patients Undergoing Major Abdominal Gynecologic Cancer Operation: A Randomized Controlled Trial|Withdrawn||Phase 3|240|Anticipated|Chiang Mai University||||"Before starting the recruitment process, new data from literature were available. The~   investigators considered that this study was no longer needed."|f||||||||||||||2018-06-01 03:59:18.336677|2018-06-01 03:59:18.336677
NCT00328744|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2012-04-19|2006-05-19|2006-05-22|Estimate|||||||2012-04-19|2012-04-20|Estimate|July 2006||2006-07-31|October 2008|2008-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Reducing Snack Variety in Weight Loss Treatment|Reducing Snack Food Variety During Obesity Treatment|Completed||N/A|202|Actual|The Miriam Hospital||2|||f||||||||||||||2018-06-01 03:59:18.395306|2018-06-01 03:59:18.395306
NCT00328731|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2006-05-19|2006-05-19|2006-05-22|Estimate|||||||2006-05-19|2006-05-22|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|January 2006||2006-01-31|||||Interventional|||Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques).|The Effectiveness of Milk Allergy Elimination Through NAET Treatments|Completed||Phase 1/Phase 2|26||Nambudripad's Allergy Research Foundation|||||f||||||||||||||2018-06-01 03:59:18.455025|2018-06-01 03:59:18.455025
NCT00328718|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2017-01-19|2006-05-19|2006-05-22|Estimate|||||||2017-01-19|2017-01-20|Estimate|October 2005|Actual|2005-10-31|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets|Randomised, Double-blind, Double-dummy, Parallel-group, Comparative Study of Salmeterol/FP 50/100mcg bd Inhalation Powder Via Diskus With Oral Montelukast (5mg QD) Chewable Tablets in Children 6-14 Years|Completed||Phase 3|526||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:59:18.521207|2018-06-01 03:59:18.521207
NCT00328705|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2008-02-11|2006-05-19|2006-05-22|Estimate|||||||2008-02-11|2008-02-13|Estimate|May 2006||2006-05-31|February 2008|2008-02-29|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management|D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management|Completed||N/A|65|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-06-01 03:59:18.604011|2018-06-01 03:59:18.604011
NCT00328692|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2009-10-08|2006-05-19|2006-05-22|Estimate|||||||2009-10-08|2009-10-09|Estimate|August 2006||2006-08-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy|Completed||Phase 3|932|Actual|NovaCardia, Inc.||2|||f||||t||||||||||2018-06-01 03:59:18.659837|2018-06-01 03:59:18.659837
NCT00328679|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2008-10-06|2006-05-18|2006-05-22|Estimate|||||||2008-10-06|2008-10-08|Estimate|June 2006||2006-06-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Evaluation of Food Hypersensitivity in Children/Adolescents With Functional Dyspepsia|Food-Specific IgE, IgG, IgG4, Skin Prick Testing and Atopy Patch Testing in Children/Adolescents With Functional Dyspepsia: A Pilot Study|Completed||Phase 1|41|Actual|Children's Mercy Hospital Kansas City||1|||f||||f||||||||||2018-06-01 03:59:18.723872|2018-06-01 03:59:18.723872
NCT00328666|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2015-11-24|2006-05-18|2006-05-22|Estimate|||||||2015-11-24|2015-11-25|Estimate|February 2005||2005-02-28|November 2015|2015-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||The Penn Lifestyle Modification and Blood Pressure Study|Cardiovascular Effects of Iyengar Yoga vs. Enhanced Usual Care in Patients With High-normal to Stage I Hypertension|Completed||N/A|60||University of Pennsylvania|||||f||||||||||||||2018-06-01 03:59:18.777509|2018-06-01 03:59:18.777509
NCT00328653|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2008-08-20|2006-05-19|2006-05-22|Estimate|||||||2008-08-20|2008-08-21|Estimate|May 2006||2006-05-31|August 2008|2008-08-31||||||||Interventional|||Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)|Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC|Completed||Phase 2/Phase 3|114|Anticipated|Santen SAS|||||f||||||||||||||2018-06-01 03:59:18.854934|2018-06-01 03:59:18.854934
NCT00328640|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2007-04-25|2006-05-18|2006-05-22|Estimate|||||||2007-04-25|2007-04-27|Estimate|December 2005||2005-12-31|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Quality Improvement in Stroke Prevention (QUISP)|Secondary Prevention After Ischemic Stroke: A Trial of an Evidence-Based System-Wide Intervention|Completed||Phase 4|1500||University of California, San Francisco|||||f||||t||||||||||2018-06-01 03:59:19.058051|2018-06-01 03:59:19.058051
NCT00328627|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|2013-02-19|2009-07-30|2013-02-19|2006-05-19|2006-05-22|Estimate|2013-02-19|2013-04-04|Estimate|2009-07-30|2009-08-10|Estimate|2013-02-19|2013-04-04|Estimate|May 2006||2006-05-31|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS®), in Subjects With Type 2 Diabetes|Completed||Phase 3|1554|Actual|Takeda||12|||f||||f||||||||||2018-06-01 03:59:19.440658|2018-06-01 03:59:19.440658
NCT00328432|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2008-09-15|2006-05-19|2006-05-22|Estimate|||||||2008-09-15|2008-09-17|Estimate|June 2003||2003-06-30|September 2008|2008-09-30|December 2005||2005-12-31|||||Interventional|||A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy|Phase IB Study of Biomarker Modulation by Celecoxib vs. Placebo in Women With Newly-Diagnosed Breast Cancer|Completed||Phase 1|100||University of Kansas Medical Center|||||f||||||||||||||2018-06-01 03:59:31.783371|2018-06-01 03:59:31.783371
NCT00328614|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|2013-06-24||2016-10-19|2006-05-19|2006-05-22|Estimate|2013-09-05|2013-11-08|Estimate||||2016-10-19|2016-11-29|Estimate|March 2003||2003-03-31|October 2016|2016-10-31|June 2011|Actual|2011-06-30|February 2009|Actual|2009-02-28||Interventional|||Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer|A Phase I Pilot Study of Samarium-153 Combined With Neoadjuvant Hormonal Therapy and Radiation Therapy in Men With Locally Advanced Prostate Cancer|Completed||Phase 1|32|Actual|Thomas Jefferson University||6|||f||||t||||||||||2018-06-01 03:59:30.01744|2018-06-01 03:59:30.01744
NCT00328601|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2008-07-29|2006-05-19|2006-05-22|Estimate|||||||2008-07-29|2008-07-30|Estimate|February 2005||2005-02-28|July 2008|2008-07-31|June 2005||2005-06-30|||||Interventional|||Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)|Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-Blind,Placebo-Controlled Multicentre Trial With 4 Parallel Groups|Completed||Phase 3|170||MEDA Pharma GmbH & Co. KG|||||f||||||||||||||2018-06-01 03:59:30.543303|2018-06-01 03:59:30.543303
NCT00328588|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2007-12-26|2006-05-19|2006-05-22|Estimate|||||||2007-12-26|2008-01-02|Estimate|December 2006||2006-12-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy||Completed||Phase 2|37|Actual|Astellas Pharma Inc||1|||f||||||||||||||2018-06-01 03:59:30.617405|2018-06-01 03:59:30.617405
NCT00328575|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2016-10-19|2006-05-19|2006-05-22|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2005||2005-10-31|October 2016|2016-10-31|June 2011|Actual|2011-06-30|July 2009|Actual|2009-07-31||Interventional|||Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases|Phase I Dose Escalation Trial in Patients With Brain Metastases Using IMRT|Completed||Phase 1|10|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:59:30.688458|2018-06-01 03:59:30.688458
NCT00328562|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|2014-06-09||2016-10-19|2006-05-19|2006-05-22|Estimate|2014-08-07|2014-08-11|Estimate||||2016-10-19|2016-11-29|Estimate|December 2003||2003-12-31|October 2016|2016-10-31|September 2010|Actual|2010-09-30|April 2008|Actual|2008-04-30||Interventional|||ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer|A Phase I Study of ZD1839 (Iressa) and Hypofractionated Thoracic Radiotherapy With Stereotactic Body Frame Immobilization for Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|13|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-06-01 03:59:30.764451|2018-06-01 03:59:30.764451
NCT00328549|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2011-05-17|2006-05-19|2006-05-22|Estimate|||||||2011-05-17|2011-05-19|Estimate|October 2001||2001-10-31|April 2010|2010-04-30|December 2002|Actual|2002-12-31|||||Interventional|||A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)|A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN|Completed||Phase 2|105|Actual|Ortho Biotech Products, L.P.|||||f||||||||||||||2018-06-01 03:59:30.964056|2018-06-01 03:59:30.964056
NCT00328536|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2009-05-07|2006-05-19|2006-05-22|Estimate|||||||2009-05-07|2009-05-08|Estimate|April 2007||2007-04-30|May 2009|2009-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus|Effects of Treatment With Omacor for 6 Weeks on Preprandial and Postprandial Endothelial Function Following a High Fat Meal in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|34|Anticipated|Ruhr University of Bochum|||||f||||f||||||||||2018-06-01 03:59:31.014036|2018-06-01 03:59:31.014036
NCT00328523|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2017-03-07|2006-05-19|2006-05-22|Estimate|||||||2017-03-07|2017-03-10|Actual|June 2004||2004-06-30|March 2017|2017-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)|Ezetimibe Together With Any Statin Cholesterol Enhancement|Completed||Phase 3|1496|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 03:59:31.061867|2018-06-01 03:59:31.061867
NCT00328510|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|2013-04-30||2016-10-19|2006-05-19|2006-05-22|Estimate|2013-07-16|2013-08-19|Estimate||||2016-10-19|2016-11-29|Estimate|February 2005||2005-02-28|October 2016|2016-10-31|September 2009|Actual|2009-09-30|January 2008|Actual|2008-01-31||Interventional|||Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy|A Randomized Trial Comparing Two Forms of Immobilization of the Head for Fractioned Stereotactic Radiotherapy|Completed||Phase 3|83|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 03:59:31.11079|2018-06-01 03:59:31.11079
NCT00328497|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2010-03-09|2006-05-19|2006-05-22|Estimate|||||||2010-03-09|2010-03-10|Estimate|May 2006||2006-05-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors|A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors|Completed||Phase 2|31|Actual|CASI Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 03:59:31.460609|2018-06-01 03:59:31.460609
NCT00328484|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2016-07-28|2006-05-19|2006-05-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2002||2002-01-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease|Exercise and Disability in COPD Patients|Completed||Phase 3|318|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 03:59:31.521188|2018-06-01 03:59:31.521188
NCT00328471|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2012-01-06|2006-05-18|2006-05-22|Estimate|||||||2012-01-06|2012-01-09|Estimate|June 2002||2002-06-30|January 2012|2012-01-31|June 2009|Actual|2009-06-30|January 2008|Actual|2008-01-31||Interventional|||A Post Discharge Intervention to Improve Stroke Outcomes|A Post Discharge Intervention to Improve Stroke Outcomes|Completed||N/A|380|Actual|Summa Health System|||||f||||t||||||||||2018-06-01 03:59:31.602742|2018-06-01 03:59:31.602742
NCT00328458|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2011-03-11|2006-05-19|2006-05-22|Estimate|||||||2011-03-11|2011-03-14|Estimate|February 2004||2004-02-29|March 2011|2011-03-31|July 2009|Actual|2009-07-31|May 2008|Actual|2008-05-31||Interventional|||EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients|A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer|Completed||Phase 1|39|Actual|Thomas Jefferson University|||||t||||t||||||||||2018-06-01 03:59:31.656459|2018-06-01 03:59:31.656459
NCT00328445|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2017-01-11|2006-05-19|2006-05-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|September 2014|2014-09-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Randomized Trial of the Positive Action Program in Hawaii Schools|The Positive Action Program: Outcomes and Mediators|Completed||N/A|2500|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 03:59:31.716153|2018-06-01 03:59:31.716153
NCT00327847|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2008-09-23|2006-05-18|2006-05-19|Estimate|||||||2008-09-23|2008-09-25|Estimate|December 2004||2004-12-31|September 2008|2008-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Optimizing Vitamin D Nutrition in Healthy Adults|Optimizing Vitamin D Nutrition in Healthy Adults|Completed||N/A|150|Anticipated|Winthrop University Hospital|||||f||||||||||||||2018-06-01 03:59:36.960186|2018-06-01 03:59:36.960186
NCT00328419|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-19|||2011-12-28|2006-05-19|2006-05-22|Estimate|||||||2011-12-28|2011-12-30|Estimate|May 2006||2006-05-31|December 2011|2011-12-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Consequences of Parenteral Nutrition Photoprotection on Oxidant Related Diseases Among Extremely Low Birth Weight Infants|Consequences of Parenteral Nutrition Photoprotection on the Oxidant Related Diseases Among Extremely Low Birth Weight Infants : A Randomized Controlled Study|Completed||N/A|591|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 03:59:31.915017|2018-06-01 03:59:31.915017
NCT00328393|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2012-07-06|2006-05-17|2006-05-19|Estimate|||||||2012-07-06|2012-07-10|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|March 2007|Actual|2007-03-31||Interventional|||Effect of Pioglitazone on Ambulatory Blood Pressure|Effect of Pioglitazone on Ambulatory Blood Pressure|Completed||Phase 3|2|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||||||||||||2018-06-01 03:59:31.982254|2018-06-01 03:59:31.982254
NCT00328380|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2009-12-21|2006-05-17|2006-05-19|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|September 2008|Actual|2008-09-30|December 2006|Actual|2006-12-31||Interventional|||Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety of Rifaximin for the Prevention of Travelers' Diarrhea in Subjects Traveling Outside the United States|Completed||Phase 3|660|Anticipated|Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 03:59:32.046099|2018-06-01 03:59:32.046099
NCT00328367|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2008-10-28|2006-05-17|2006-05-19|Estimate|||||||2008-10-28|2008-10-29|Estimate|December 2005||2005-12-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|December 2006|Actual|2006-12-31||Interventional|||Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia|A Double-Blind Randomized Placebo Controlled Study of Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia|Completed||Phase 4|61|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 03:59:32.102112|2018-06-01 03:59:32.102112
NCT00328354|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2018-04-04|2006-05-18|2006-05-19|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2006|Actual|2006-12-31|April 2018|2018-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Mammography SPECT With Rotating Slant Hole Collimator||Withdrawn|||0|Actual|Johns Hopkins University||||Ran out of time/ funding|f||||||||||||||2018-06-01 03:59:32.193973|2018-06-01 03:59:32.193973
NCT00328341|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2013-09-18|2006-05-17|2006-05-19|Estimate|||||||2013-09-18|2013-09-19|Estimate|April 2006||2006-04-30|September 2013|2013-09-30|December 2011|Actual|2011-12-31|April 2009|Actual|2009-04-30||Observational|||The Use of Tissue Oxygen Monitoring in Critically Injured Patients|The Use of Tissue Oxygen Monitoring in Critically Injured Patients|Terminated|||67|Actual|University of California, San Francisco||||Slow to enroll.|f||||f||||||||||2018-06-01 03:59:32.247533|2018-06-01 03:59:32.247533
NCT00328315|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2018-04-04|2006-05-18|2006-05-19|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2006|Actual|2006-10-31|April 2018|2018-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Cardiac SPECT With Rotating Slant Hole Collimator|Myocardial Perfusion SPECT Using a Rotating Multi-segment Slant-hole Collimator|Completed|||5|Actual|Johns Hopkins University|||||f||||||||||||||2018-06-01 03:59:32.304777|2018-06-01 03:59:32.304777
NCT00328302|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2006-05-18|2006-05-18|2006-05-19|Estimate|||||||2006-05-18|2006-05-19|Estimate|September 2000||2000-09-30|June 2000|2000-06-30|April 2006||2006-04-30|||||Interventional|||Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy|Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB|Unknown status|Active, not recruiting|Phase 4|13||Karolinska University Hospital|||||f||||||||||||||2018-06-01 03:59:32.363388|2018-06-01 03:59:32.363388
NCT00328289|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2011-01-12|2006-05-18|2006-05-19|Estimate|||||||2011-01-12|2011-01-13|Estimate|May 2006||2006-05-31|January 2011|2011-01-31|March 2007|Actual|2007-03-31|||||Interventional|||Effect of Intradialytic Electrical Muscle Stimulation and Passive Leg Mobilisation on Blood Pressure and Dialysis Efficacy|Effect of Intradialytic Electrical Muscle Stimulation and Passive Leg Mobilisation on Blood Pressure and Dialysis Efficacy|Completed||N/A|12||University Hospital Inselspital, Berne|||||f||||||||||||||2018-06-01 03:59:32.422525|2018-06-01 03:59:32.422525
NCT00328276|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2006-05-18|2006-05-18|2006-05-19|Estimate|||||||2006-05-18|2006-05-19|Estimate|December 2004||2004-12-31|May 2006|2006-05-31|December 2005||2005-12-31|||||Interventional|||Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia|NMDA Enhancers in the Treatment of Schizophrenia|Completed||Phase 2|20||China Medical University Hospital|||||f||||||||||||||2018-06-01 03:59:32.494347|2018-06-01 03:59:32.494347
NCT00328263|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|2012-08-28||2014-07-15|2006-05-17|2006-05-19|Estimate|2014-07-15|2014-08-07|Estimate||||2014-07-15|2014-08-07|Estimate|March 2006||2006-03-31|July 2014|2014-07-31|October 2007|Actual|2007-10-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients|A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy and Safety of BIO-K*+ CL-1285* in the Prevention of Antibiotic-associated Diarrhea in Adult Patients Exposed to Nosocomial Infection.|Completed||Phase 3|472|Actual|Bio-K Plus International Inc.||2|||f||||t||||||||||2018-06-01 03:59:32.557196|2018-06-01 03:59:32.557196
NCT00328250|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2012-01-11|2006-05-17|2006-05-19|Estimate|||||||2012-01-11|2012-01-12|Estimate|October 2006||2006-10-31|January 2012|2012-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effectiveness of Internet Cognitive Behavioral Therapy Intervention for Treating Insomnia|Internet Insomnia Intervention: Development and Feasibility|Completed||Phase 1/Phase 2|44|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 03:59:32.737816|2018-06-01 03:59:32.737816
NCT00328237|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2006-06-23|2006-05-17|2006-05-19|Estimate|||||||2006-06-23|2006-06-26|Estimate|November 2005||2005-11-30|November 2005|2005-11-30||||||||Interventional|||Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation|Treatment of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed by Single-Unit or Double-Unit Cord Blood Transplantation: A Phase II Study|Unknown status|Recruiting|Phase 2|20||Colorado Blood Cancer Institute|||||f||||||||||||||2018-06-01 03:59:32.800088|2018-06-01 03:59:32.800088
NCT00328224|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2007-10-31|2006-05-18|2006-05-19|Estimate|||||||2007-10-31|2007-11-01|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|October 2007|Actual|2007-10-31|||||Observational|||Oral Status and Prevalence of Dental Trauma in Children Treated With Ritalin Due to Attention-Deficit Hyperactivity Disorder (ADHD)|Oral Status and Prevalence of Dental Trauma in Children Treated With Ritalin Due to Attention-Deficit Hyperactivity Disorder (ADHD)|Completed|||50|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 03:59:32.867501|2018-06-01 03:59:32.867501
NCT00328211|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2016-12-06|2006-05-18|2006-05-19|Estimate|||||||2016-12-06|2016-12-08|Estimate|September 2005||2005-09-30|December 2016|2016-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Intralumenal Effects on Cholesterol Absorption/Synthesis|Intralumenal Effects on Cholesterol Absorption/Synthesis|Completed||N/A|35|Actual|Children's Hospital Medical Center, Cincinnati||4|||f||||t||||||||Undecided||2018-06-01 03:59:32.913301|2018-06-01 03:59:32.913301
NCT00328198|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|2012-06-25||2014-02-10|2006-05-18|2006-05-19|Estimate|2012-06-25|2012-08-10|Estimate||||2014-02-10|2014-03-13|Estimate|May 2006||2006-05-31|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH®, MabCampath®) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|86|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:59:33.008204|2018-06-01 03:59:33.008204
NCT00328185|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2012-03-14|2006-05-18|2006-05-19|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|December 2006|Actual|2006-12-31|||||Observational|||Allograft Fibrosis Following Pediatric Cardiac Transplantation|Allograft Fibrosis: Its Regulation and Significance Following Pediatric Cardiac Transplantation|Terminated|||100|Actual|Children's Healthcare of Atlanta||||unable to gather sufficient data|f||||||||||||||2018-06-01 03:59:33.733613|2018-06-01 03:59:33.733613
NCT00328172|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|2011-05-13||2014-02-15|2006-05-18|2006-05-19|Estimate|2011-05-13|2011-06-07|Estimate||||2014-02-15|2014-03-14|Estimate|May 2006||2006-05-31|February 2014|2014-02-28||||August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients|A Randomized, Double-blind, Placebo-controlled, Five Parallel Group Study Investigating the Efficacy and Safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg Administered Orally Once Daily) Over 12 Weeks in Drug Naive and Treated Patients With Type 2 Diabetes With Insufficient Glycemic Control (Study Includes an Open-label Metformin Treatment Arm)|Completed||Phase 2|302|Actual|Boehringer Ingelheim||5|||||||||||||||||2018-06-01 03:59:33.810775|2018-06-01 03:59:33.810775
NCT00328159|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2011-02-16|2006-05-18|2006-05-19|Estimate|||||||2011-02-16|2011-02-17|Estimate|June 2006||2006-06-30|March 2007|2007-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids|Dietary Therapy of Mitochondrial Fatty Acids Oxidation. A Clinical Study of Treatment With Odd Carbons Medium-chain Fatty Acids|Completed||N/A|20|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 03:59:34.471721|2018-06-01 03:59:34.471721
NCT00328146|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2017-02-27|2006-05-18|2006-05-19|Estimate|||||||2017-02-27|2017-03-01|Actual|February 2001||2001-02-28|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Re-operative Surgery in Children:A Technique for Sternal Re-Entry|Re-operative Surgery in Children: A Technique for Sternal Re-Entry|Completed|||802|Actual|Children's Healthcare of Atlanta|||1||f||||f||||||||||2018-06-01 03:59:34.528011|2018-06-01 03:59:34.528011
NCT00328133|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2012-05-09|2006-05-17|2006-05-19|Estimate|||||||2012-05-09|2012-05-10|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Observational|||The Use of rFVIIa in Trauma Patients: A Multi-Center Case Registry|The Use of rFVIIa in Trauma Patients: A WTA/AAST Multi-Center Case Registry|Completed|||380|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 03:59:34.579977|2018-06-01 03:59:34.579977
NCT00328120|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2010-11-16|2006-05-18|2006-05-19|Estimate|||||||2010-11-16|2010-11-17|Estimate|April 2004||2004-04-30|November 2010|2010-11-30|June 2010|Actual|2010-06-30|April 2006|Actual|2006-04-30||Interventional|||Faslodex 500mg Multiple Dose Tolerability Study in BC Patients|An Open, Multicentre Phase I Clinical Study to Assess the Tolerability of Fulvestrant 500 mg in Postmenopausal Women With Hormone Receptor Positive Advanced or Recurrent Breast Cancer|Completed||Phase 1|20|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 03:59:34.635318|2018-06-01 03:59:34.635318
NCT00328107|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2010-01-08|2006-05-17|2006-05-19|Estimate|||||||2010-01-08|2010-01-12|Estimate|November 2004||2004-11-30|January 2010|2010-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults|Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years.|Completed||Phase 2/Phase 3|459|Actual|Protein Sciences Corporation||3|||f||||f||||||||||2018-06-01 03:59:34.704331|2018-06-01 03:59:34.704331
NCT00328094|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|2013-02-28||2013-04-10|2006-05-18|2006-05-19|Estimate|2013-02-28|2013-04-09|Estimate||||2013-04-10|2013-04-17|Estimate|March 2006||2006-03-31|April 2013|2013-04-30|May 2009|Actual|2009-05-31|April 2008|Actual|2008-04-30||Interventional||assessed for eligibility 252. 10 were found ineligible. 242 were randomized.6 patients did not receive interventions they were supposed to. Total number of patients analyzed were 236.|Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery|Impact of Tight Control of Perioperative Blood Glucose in Patients Undergoing Vascular Surgery on Their Perioperative Cardiovascular and Overall Morbidity and Mortality|Terminated||N/A|242|Actual|Beth Israel Deaconess Medical Center|A trial to adequately address mortality would require 5000 to 6000 patients. The alpha levels for significance were not adjusted for the interim analyses because of the unplanned issues with subject recruitement as surgery became percutaneous.|2||The recruitment rate slowed considerably|f||||t||||||||||2018-06-01 03:59:34.787194|2018-06-01 03:59:34.787194
NCT00328081|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2007-09-13|2006-05-18|2006-05-19|Estimate|||||||2007-09-13|2007-09-14|Estimate|May 2006||2006-05-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Observational|||State of Obesity Care in Canada Evaluation Registry|State of Obesity Care in Canada Evaluation Registry An Observational Study of Clinical Care of Patients With Obesity|Terminated|||1906|Actual|McMaster University||||Principal Investigator left the institution|f||||||||||||||2018-06-01 03:59:35.002107|2018-06-01 03:59:35.002107
NCT00328068|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2013-02-12|2006-05-18|2006-05-19|Estimate|||||||2013-02-12|2013-02-13|Estimate|July 2006||2006-07-31|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)|Prospective, International, Multi-centre Study on ASAS Classification Criteria for SpA|Unknown status|Recruiting||992|Anticipated|Charite University, Berlin, Germany|||1||f||||t||||||Samples With DNA|"~     DNA and RNA will be collected in selected centres for analysis of candidate gene variants in~     ankylosing spondylitis/ spondyloarthritis. Serum and plasma sample will be collected for~     biomarker analysis with special focus on markers of bone metabolism~   "|||2018-06-01 03:59:35.057494|2018-06-01 03:59:35.057494
NCT00328055|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2011-04-21|2006-05-18|2006-05-19|Estimate|||||||2011-04-21|2011-04-25|Estimate|August 2004||2004-08-31|April 2011|2011-04-30|July 2005||2005-07-31|||||Interventional|||Comparison of an Easy to Read Advance Directive Versus a Standard Advance Directive|Effects of an Easy to Read Advance Directive on Acceptability, Knowledge, and Self-efficacy Compared to a Standard Advance Directive|Completed||N/A|200||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 03:59:35.335401|2018-06-01 03:59:35.335401
NCT00328042|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|2014-08-26||2015-04-06|2006-05-17|2006-05-19|Estimate|2014-09-22|2014-09-25|Estimate||||2015-04-06|2015-04-24|Estimate|May 2007||2007-05-31|July 2014|2014-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Hepatitis C Self-Management|A Self-Management Intervention for Veterans With Hepatitis C|Completed||N/A|134|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 03:59:35.407901|2018-06-01 03:59:35.407901
NCT00328029|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2009-02-24|2006-05-18|2006-05-19|Estimate|||||||2009-02-24|2009-02-25|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|June 2012|Anticipated|2012-06-30|January 2012|Anticipated|2012-01-31||Interventional|||Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population|Assessment of Respiratory Functions After a Conditioning Regimen With Busulfan for Allograft or Autograft in a Unicenter Pediatric and Prospective Population|Unknown status|Recruiting|Phase 2|35|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 03:59:35.677598|2018-06-01 03:59:35.677598
NCT00328016|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|2013-04-30||2017-06-05|2006-05-18|2006-05-19|Estimate|2017-06-05|2017-07-02|Actual||||2017-06-05|2017-07-02|Actual|April 2006||2006-04-30|December 2016|2016-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||Of the 44 subjects randomly assigned to treatment and control group, 12 subjects were excluded from data analysis due to either non-compliance with the intervention or abnormal breathing pattern during baseline session.|Breathe: Slow Paced Breathing to Lower Blood Pressure|Respiratory Adaptations to Behavioral Interventions in Elevated Blood Pressure|Completed||N/A|44|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||No|There is no plan to share individual level data.|2018-06-01 03:59:35.768485|2018-06-01 03:59:35.768485
NCT00327990|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2017-05-24|2006-05-18|2006-05-19|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2005||2005-04-30|May 2017|2017-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate|A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg)|Completed||Phase 4|300|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 03:59:35.990141|2018-06-01 03:59:35.990141
NCT00327977|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2014-11-25|2006-05-18|2006-05-19|Estimate|||||||2014-11-25|2014-12-02|Estimate|January 2001||2001-01-31|November 2014|2014-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Hypoxemia in Infants After Palliative Surgery|A Retrospective Study of Hypoxemia in Infants After Palliative Neonatal Surgery for Congenital Heart Disease|Completed|||375|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 03:59:36.183222|2018-06-01 03:59:36.183222
NCT00327964|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2008-10-01|2006-05-18|2006-05-19|Estimate|||||||2008-10-01|2008-10-02|Estimate|October 2005||2005-10-31|October 2008|2008-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda|Utility of Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda|Completed|||600|Actual|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Dried blood spots on filter paper~   "|||2018-06-01 03:59:36.239668|2018-06-01 03:59:36.239668
NCT00327951|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2012-03-14|2006-05-18|2006-05-19|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2001||2001-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|March 2006|Actual|2006-03-31||Observational|||Infant Weight Gain With Trisomy 21 and CAVC|The Impact of Weight Gain in the Pre-operative Infant With Trisomy 21 (Down Syndrome) and Complete Atrioventricular Canal (CAVC)|Terminated|||46|Actual|Children's Healthcare of Atlanta||||sufficient data collected for significant conclusion|f||||f||||||||||2018-06-01 03:59:36.334366|2018-06-01 03:59:36.334366
NCT00327938|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2007-04-19|2006-05-18|2006-05-19|Estimate|||||||2007-04-19|2007-04-20|Estimate|May 2006||2006-05-31|April 2007|2007-04-30||||||||Interventional|||Genetic Variation – The Need for Opioids During Surgery|Genetically Variation – May the Need of Opioids During Surgery be Known Beforehand by Giving Noxious Stimulation and Measure the Skin Conductance Response Before Surgery?|Completed||N/A|50||Rikshospitalet University Hospital|||||f||||f||||||||||2018-06-01 03:59:36.395293|2018-06-01 03:59:36.395293
NCT00327925|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2007-03-01|2006-05-18|2006-05-19|Estimate|||||||2007-03-01|2007-03-02|Estimate|July 2006||2006-07-31|May 2006|2006-05-31|June 2008||2008-06-30|||||Observational|||Blood Test for Ovarian Cancer Associated Antibodies (CAAb)|Study to Assess the Effectiveness of the CAAb Test With Ovarian Cancer Patients|Unknown status|Recruiting||60||Lab Discoveries Ltd.|||||f||||||||||||||2018-06-01 03:59:36.456614|2018-06-01 03:59:36.456614
NCT00327912|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2017-02-01|2006-05-18|2006-05-19|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2006||2006-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ASGARD||Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity|Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial|Active, not recruiting||Phase 4|60|Anticipated|Göteborg University||2|||f||||||||||||||2018-06-01 03:59:36.536259|2018-06-01 03:59:36.536259
NCT00327899|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2011-11-18|2006-05-18|2006-05-19|Estimate|||||||2011-11-18|2011-11-21|Estimate|March 2006||2006-03-31|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Observational|||Home Inotropic Therapy in Children|Home Inotropic Therapy in Children|Terminated|||13|Actual|Children's Healthcare of Atlanta||||Per PI instruction.|f||||f||||||||||2018-06-01 03:59:36.607664|2018-06-01 03:59:36.607664
NCT00327886|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2007-06-12|2006-05-18|2006-05-19|Estimate|||||||2007-06-12|2007-06-13|Estimate|February 2006||2006-02-28|June 2007|2007-06-30|February 2006||2006-02-28|||||Observational|||Managing Cyanosis Following Bidirectional Glenn Operation|A Retrospective Review of Postoperative Management of Cyanosis Following Bidirectional Glenn Operation|Terminated|||150||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 03:59:36.665551|2018-06-01 03:59:36.665551
NCT00327873|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2009-12-10|2006-05-18|2006-05-19|Estimate|||||||2009-12-10|2009-12-14|Estimate|May 2005||2005-05-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Palliative Oxygen for the Relief of Breathlessness|A Multi-center Randomized Double-blind Controlled Trial of Oxygen Versus Medical Air for the Relief of Breathlessness in Patients With Intractable Dyspnea and PaO2>55mmHg|Completed||N/A|240|Anticipated|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 03:59:36.727719|2018-06-01 03:59:36.727719
NCT00327860|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2017-08-18|2006-05-18|2006-05-19|Estimate|||||||2017-08-18|2017-08-22|Actual|October 2003||2003-10-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|CKiD||Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)|Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)|Recruiting|||1196|Anticipated|Johns Hopkins Bloomberg School of Public Health|||3||f||||t||||||Samples With DNA|"~     Blood and urine specimens will be collected at the baseline visit and at each annual~     follow-up visit. Nail clippings and hair samples will be collected at baseline.Specimens will~     be stored at the NIDDK Biosample Repository, which is Fisher BioServices Corporation in~     Rockville, MD.~      The genetics repository will receive blood samples and process them to create immortalized~     cell lines, and DNA samples. Whole blood for the genetic repository will be collected at~     baseline. The genetics repository is at Rutgers, the State University of New Jersey in New~     Brunswick, NJ.~   "|||2018-06-01 03:59:36.838283|2018-06-01 03:59:36.838283
NCT00327834|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2011-06-21|2006-05-17|2006-05-19|Estimate|||||||2011-06-21|2011-06-22|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Atomoxetine in the Treatment of Binge Eating Disorder|Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients|Completed||Phase 4|||Lindner Center of HOPE|||||f||||||||||||||2018-06-01 03:59:37.012784|2018-06-01 03:59:37.012784
NCT00327821|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2006-07-20|2006-05-18|2006-05-19|Estimate|||||||2006-07-20|2006-07-21|Estimate|July 2002||2002-07-31|May 2003|2003-05-31|March 2003||2003-03-31|||||Interventional|||The Effectiveness of Commercial Weight Loss Programmes|A Randomised Control Trial of Commercial Weight Loss Programme in a Community Based Sample of Obese Adults.|Completed||N/A|300||University of Surrey|||||f||||||||||||||2018-06-01 03:59:37.062539|2018-06-01 03:59:37.062539
NCT00327808|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2012-11-30|2006-05-17|2006-05-19|Estimate|||||||2012-11-30|2012-12-03|Estimate|May 2006||2006-05-31|November 2012|2012-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma|Multi-Center, Randomized, Double-Blind, Repeated Doses Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI-1020 Versus Inhaled Budesonide in Smokers With Mild Reversible Asthma|Completed||Phase 2|27|Actual|Pharmaxis||2|||f||||f||||||||||2018-06-01 03:59:37.109599|2018-06-01 03:59:37.109599
NCT00327795|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2012-03-14|2006-05-18|2006-05-19|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|November 2007|Actual|2007-11-30|||||Observational|||Surgical Outcomes in Pediatric Patients With Coarctation and VSD|Staged Approach to Coarctation and VSD Can Offer Optimal Outcomes|Terminated|||32||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 03:59:37.172433|2018-06-01 03:59:37.172433
NCT00327782|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2007-05-02|2006-05-18|2006-05-19|Estimate|||||||2007-05-02|2007-05-04|Estimate|January 1995||1995-01-31|May 2007|2007-05-31|April 2006||2006-04-30|||||Observational|||Palliative Care of Children With End-Stage Heart Failure|Palliative Care of Children With End-Stage Heart Failure|Terminated|||||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 03:59:37.211991|2018-06-01 03:59:37.211991
NCT00327769|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2011-01-24|2006-05-18|2006-05-19|Estimate|||||||2011-01-24|2011-01-25|Estimate|November 2005||2005-11-30|January 2011|2011-01-31|September 2007|Actual|2007-09-30|||||Interventional|||Faslodex Advanced Breast Cancer Local Chinese Study|A Double Blind, Double Dummy, Randomised, Multicentre Study to Compare the Efficacy and Safety of Fulvestrant 250mg With Arimidex 1mg as a Secondary-line Therapy in the Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer|Completed||Phase 3|234|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 03:59:37.257663|2018-06-01 03:59:37.257663
NCT00327756|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-18|||2011-11-22|2006-05-18|2006-05-19|Estimate|||||||2011-11-22|2011-11-23|Estimate|May 2006||2006-05-31|May 2009|2009-05-31||||May 2009|Actual|2009-05-31||Interventional|||Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder|An Investigation Examining the Evidence for Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:59:37.33186|2018-06-01 03:59:37.33186
NCT00327743|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04||2016-04-18|2016-04-18|2006-05-16|2006-05-18|Estimate||||2016-04-18|2016-05-18|Estimate|2016-04-18|2016-05-18|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer|A Dose-escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and Taxane Therapy|Completed||Phase 1/Phase 2|34|Actual|Sanofi||1|||f||||||||||||||2018-06-01 03:59:37.499765|2018-06-01 03:59:37.499765
NCT00327730|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2014-04-17|2006-05-17|2006-05-18|Estimate|||||||2014-04-17|2014-04-21|Estimate|April 2006||2006-04-30|April 2014|2014-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain - A Double Blind, Randomised, Placebo Controlled Clinical Trial|Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain|Completed||Phase 3|240|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 03:59:37.563553|2018-06-01 03:59:37.563553
NCT00327717|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|2010-10-28||2014-08-14|2006-05-17|2006-05-18|Estimate|2014-08-14|2014-08-15|Estimate||||2014-08-14|2014-08-15|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures|A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures|Completed||Phase 3|240|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 03:59:37.651973|2018-06-01 03:59:37.651973
NCT00327704|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2011-04-05|2006-05-17|2006-05-18|Estimate|||||||2011-04-05|2011-04-06|Estimate|July 2006||2006-07-31|April 2011|2011-04-30|January 2011|Actual|2011-01-31|June 2010|Actual|2010-06-30||Interventional|||Early Albumin Resuscitation During Septic Shock|Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline|Completed||Phase 4|794|Actual|Laboratoire français de Fractionnement et de Biotechnologies||2|||f||||||||||||||2018-06-01 03:59:37.968238|2018-06-01 03:59:37.968238
NCT00327691|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2007-05-01|2006-05-16|2006-05-18|Estimate|||||||2007-05-01|2007-05-03|Estimate|April 1998||1998-04-30|May 2007|2007-05-31|August 2004||2004-08-31|||||Interventional|TNT||A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels|The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD|Completed||Phase 4|8600||Pfizer|||||||||||||||||||2018-06-01 03:59:38.082483|2018-06-01 03:59:38.082483
NCT00327678|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2016-06-23|2006-05-16|2006-05-18|Estimate|||||||2016-06-23|2016-06-27|Estimate|May 2006||2006-05-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults|Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph|Completed||Phase 3|1080|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 03:59:40.222471|2018-06-01 03:59:40.222471
NCT00327665|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2017-05-05|2006-05-17|2006-05-18|Estimate|||||||2017-05-05|2017-05-08|Actual|May 1, 2006|Actual|2006-05-01|May 2017|2017-05-31|January 8, 2007|Actual|2007-01-08|January 1, 2007|Actual|2007-01-01||Interventional|||Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population|A Phase I/II, Randomized, Observer Blinded Study to Evaluate and Compare the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline Biologicals' Investigational Pneumococcal Vaccine Formulations Versus a Licensed Non-GlaxoSmithKline Biologicals' Vaccine and GlaxoSmithKline Biologicals' Aluminum-based 10-valent Pneumococcal Conjugate Vaccine, in Healthy Elderly Subjects|Completed||Phase 1|335|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:59:40.290506|2018-06-01 03:59:40.290506
NCT00327652|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2008-04-22|2006-05-17|2006-05-18|Estimate|||||||2008-04-22|2008-04-24|Estimate|October 2006||2006-10-31|April 2008|2008-04-30||||February 2008|Actual|2008-02-29||Interventional|||Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases|Phase 1 Dose-Escalation Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases|Completed||Phase 1|9|Actual|Anza Therapeutics, Inc.|||||f||||t||||||||||2018-06-01 03:59:40.398159|2018-06-01 03:59:40.398159
NCT00327639|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2006-05-17|2006-05-17|2006-05-18|Estimate|||||||2006-05-17|2006-05-18|Estimate|July 2005||2005-07-31|July 2005|2005-07-31||||||||Observational|||Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto|Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto|Unknown status|Recruiting||50||University Health Network, Toronto|||||f||||||||||||||2018-06-01 03:59:40.457172|2018-06-01 03:59:40.457172
NCT00327626|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2007-05-18|2006-05-16|2006-05-18|Estimate|||||||2007-05-18|2007-05-21|Estimate|May 2006||2006-05-31|May 2007|2007-05-31|March 2008||2008-03-31|||||Interventional|||Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 Administered Daily in Patients With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea|Withdrawn||Phase 2|96||Ionis Pharmaceuticals, Inc.||||study was never started due to regional geopolitical conflict|f||||||||||||||2018-06-01 03:59:40.50713|2018-06-01 03:59:40.50713
NCT00327613|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2008-09-25|2006-05-17|2006-05-18|Estimate|||||||2008-09-25|2008-09-26|Estimate|June 2005||2005-06-30|September 2008|2008-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma|Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG)|Completed|||60|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 03:59:40.578485|2018-06-01 03:59:40.578485
NCT00327600|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2010-09-14|2006-05-17|2006-05-18|Estimate|||||||2010-09-14|2010-09-15|Estimate|July 2005||2005-07-31|September 2010|2010-09-30|December 2007|Actual|2007-12-31|January 2007|Actual|2007-01-31||Interventional|||Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma|A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma|Completed||Phase 1/Phase 2|68|Actual|AmpliMed Corporation||1|||f||||t||||||||||2018-06-01 03:59:40.728042|2018-06-01 03:59:40.728042
NCT00327587|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2011-11-07|2006-05-16|2006-05-18|Estimate|||||||2011-11-07|2011-11-08|Estimate|May 2006||2006-05-31|November 2011|2011-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension|An 8-week, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension.|Completed||Phase 3|2279|Actual|Novartis|||||f||||||||||||||2018-06-01 03:59:40.804705|2018-06-01 03:59:40.804705
NCT00327574|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2006-05-25|2006-05-17|2006-05-18|Estimate|||||||2006-05-25|2006-05-26|Estimate|June 2004||2004-06-30|May 2006|2006-05-31|September 2007||2007-09-30|||||Interventional|||Population Based Strategies for Effective Control of High Blood Pressure in Pakistan||Unknown status|Active, not recruiting|N/A|||Aga Khan University|||||f||||||||||||||2018-06-01 03:59:40.86418|2018-06-01 03:59:40.86418
NCT00327561|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-05-16|2006-05-16|2006-05-18|Estimate|||||||2006-05-16|2006-05-18|Estimate|September 2003||2003-09-30|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Effect of Intensive Periodontal Therapy on Vascular Function|Effects of Non-Surgical Periodontal Therapy on Endothelial Function A Randomized Controlled Clinical Trial|Completed||Phase 3|120||Eastman Dental Insitute and Hospital|||||f||||||||||||||2018-06-01 03:59:40.927222|2018-06-01 03:59:40.927222
NCT00327548|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-10-04|2006-05-16|2006-05-18|Estimate|||||||2006-10-04|2006-10-05|Estimate||||July 2002|2002-07-31||||||||Interventional|||Use of Guided Imagery for Functional Abdominal Pain in Children:|Treatment of Functional Abdominal Pain in Children:Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities|Completed||Phase 3|||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 03:59:40.991329|2018-06-01 03:59:40.991329
NCT00327535|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2016-08-09|2006-05-16|2006-05-18|Estimate|||||||2016-08-09|2016-08-11|Estimate|May 2006||2006-05-31|August 2016|2016-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.|A Multicenter, Randomized, Open Label Dose Finding Study of Mircera in Anemic Patients With Stage IIIB or IV Non-small Cell Lung Cancer Receiving First Line Myelosuppressive Chemotherapy|Completed||Phase 2|153|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 03:59:41.051117|2018-06-01 03:59:41.051117
NCT00327522|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2008-10-09|2006-05-17|2006-05-18|Estimate|||||||2008-10-09|2008-10-13|Estimate|June 2006||2006-06-30|October 2008|2008-10-31||||||||Interventional|||Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.|An Open, Phase I/II Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 11PCV Vaccine Given as a 2-Dose Vaccination in Adults Aged 18-40 Years Old.|Completed||Phase 2|10||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:59:41.210935|2018-06-01 03:59:41.210935
NCT00327509|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2009-08-19|2006-05-17|2006-05-18|Estimate|||||||2009-08-19|2009-08-20|Estimate|January 2004||2004-01-31|August 2009|2009-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||mRNA Expression in Lymphocytes of Glaucoma Patients|Messenger Ribonucleic Acid Expression in Lymphocytes of Glaucoma Patients|Completed|||60|Actual|University Hospital, Basel, Switzerland|||6||f||||f||||||Samples With DNA|"~     white cells~   "|||2018-06-01 03:59:41.284919|2018-06-01 03:59:41.284919
NCT00327496|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-05-16|2006-05-16|2006-05-18|Estimate|||||||2006-05-16|2006-05-18|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|June 2006||2006-06-30|||||Interventional|||Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells||Unknown status|Active, not recruiting|N/A|10||Mackay Memorial Hospital|||||f||||||||||||||2018-06-01 03:59:41.339151|2018-06-01 03:59:41.339151
NCT00327483|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-05-16|2006-05-16|2006-05-18|Estimate|||||||2006-05-16|2006-05-18|Estimate|July 2005||2005-07-31|May 2006|2006-05-31|April 2006||2006-04-30|||||Interventional|||Web Based Renal Transplant Patient Medication Education|Web Based Renal Transplant Patient Medication Education|Unknown status|Recruiting|Phase 4|250||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 03:59:41.376952|2018-06-01 03:59:41.376952
NCT00327119|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2009-09-11|2006-05-16|2006-05-18|Estimate|||||||2009-09-11|2009-09-14|Estimate|April 2006||2006-04-30|September 2009|2009-09-30||||||||Interventional|||Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer|A Phase 2 Multicenter Single Arm Clinical Trial of ABX EGF (Panitumumab) Monotherapy in Japanese Subjects With Metastatic Colorectal Cancer Who Developed Progressive Disease or Relapsed While on or After Prior Fluoropyrimidine, Irinotecan and Oxaliplatin Chemotherapy|Completed||Phase 2|50||Amgen|||||f||||||||||||||2018-06-01 03:59:46.578627|2018-06-01 03:59:46.578627
NCT00327470|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|2010-04-13||2012-04-02|2006-05-17|2006-05-18|Estimate|2010-11-22|2010-12-17|Estimate||||2012-04-02|2012-04-04|Estimate|July 2006||2006-07-31|January 2011|2011-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|PERSPECTIVES||An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD|A 102-Week, Open Label, Multicenter Trial To Investigate The Efficacy Of Macugen For The Preservation Of Visual Function In Subjects With Neovascular Age-Related Macular Degeneration (AMD) And To Assess The Benefit Of Treating Early Choroidal Neovascularization (CNV).|Terminated||Phase 4|288|Actual|Pfizer||1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 03:59:41.582412|2018-06-01 03:59:41.582412
NCT00327457|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2011-02-18|2006-05-16|2006-05-18|Estimate|||||||2011-02-18|2011-02-21|Estimate|June 2002||2002-06-30|February 2011|2011-02-28|March 2005||2005-03-31|||||Interventional|||Coordinated Endoscopic Colorectal Cancer Screening|Coordinated Endoscopic Colorectal Cancer Screening|Completed||N/A|599|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 03:59:42.547609|2018-06-01 03:59:42.547609
NCT00327444|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2012-08-17|2011-07-21|2012-11-30|2006-05-16|2006-05-18|Estimate|2012-11-30|2013-01-01|Estimate|2011-07-21|2011-07-25|Estimate|2012-11-30|2013-01-01|Estimate|July 2006||2006-07-31|July 2011|2011-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites|Completed||Phase 2/Phase 3|58|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 03:59:42.641485|2018-06-01 03:59:42.641485
NCT00327431|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2008-05-21|2006-05-17|2006-05-18|Estimate|||||||2008-05-21|2008-05-22|Estimate|November 2006||2006-11-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|||||Observational|||Relationship of Genes and Life Events to Blood Pressure||Completed|||120|Anticipated|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 03:59:43.268503|2018-06-01 03:59:43.268503
NCT00327418|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2007-05-08|2006-05-16|2006-05-18|Estimate|||||||2007-05-08|2007-05-10|Estimate|January 1997||1997-01-31|May 2007|2007-05-31|February 2004||2004-02-29|||||Interventional|CARDS||CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events|A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)|Completed||Phase 4|2800||Pfizer|||||||||||||||||||2018-06-01 03:59:43.346881|2018-06-01 03:59:43.346881
NCT00327405|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2006-05-17|2006-05-17|2006-05-18|Estimate|||||||2006-05-17|2006-05-18|Estimate||||January 2006|2006-01-31||||||||Observational|||Results of Ocular Compression and Suture Release in Trabeculectomy and Combined Surgery|A Retrospective Study of Surgical Outcomes.|Completed|||||University of Cincinnati|||||f||||||||||||||2018-06-01 03:59:43.575417|2018-06-01 03:59:43.575417
NCT00327392|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2012-03-01||2012-05-17|2006-05-16|2006-05-18|Estimate|2012-05-17|2012-06-20|Estimate||||2012-05-17|2012-06-20|Estimate|May 2006||2006-05-31|May 2012|2012-05-31|December 2007|Actual|2007-12-31|||||Interventional|||A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.|A Phase 3 Open-Label, Single Arm Study to Assess the Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal-to-Moderate Sedation in Patients Undergoing Minor Surgical Procedures|Completed||Phase 2/Phase 3|123|Actual|Eisai Inc.|||||||||||||||||||2018-06-01 03:59:43.648812|2018-06-01 03:59:43.648812
NCT00327379|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2014-11-27|2006-05-16|2006-05-18|Estimate|||||||2014-11-27|2014-12-01|Estimate|February 2006||2006-02-28|November 2014|2014-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fusion Surgery|Completed||Phase 3|54|Actual|Bayer||2|||f||||||||||||||2018-06-01 03:59:43.875295|2018-06-01 03:59:43.875295
NCT00327366|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2009-10-18|2006-05-17|2006-05-18|Estimate|||||||2009-10-18|2009-10-19|Estimate|September 2003||2003-09-30|October 2009|2009-10-31|April 2006|Actual|2006-04-30|||||Interventional|||Effect of Bright Light on Sex Hormones and Ovulation in Humans||Completed||N/A|27|Actual|Russian Academy of Medical Sciences|||||f||||f||||||||||2018-06-01 03:59:44.037107|2018-06-01 03:59:44.037107
NCT00327353|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2009-05-21|2006-05-16|2006-05-18|Estimate|||||||2009-05-21|2009-05-22|Estimate|January 2004||2004-01-31|May 2009|2009-05-31||||||||Interventional|||Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol|Single-Centre Randomised Open Crossover Study to Examine the Influence of Different Internal Resistances of Discus and Turbohaler Respectively on the Effects of Salmeterol and Formoterol in Asthmatic Subjects|Completed||Phase 4|77||GlaxoSmithKline|||||f||||||||||||||2018-06-01 03:59:44.094177|2018-06-01 03:59:44.094177
NCT00327340|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2012-07-26||2012-10-02|2006-05-16|2006-05-18|Estimate|2012-07-26|2012-08-29|Estimate||||2012-10-02|2012-10-05|Estimate|July 2006||2006-07-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC|Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|70|Actual|Achieve Life Sciences||2|||f||||f||||||||||2018-06-01 03:59:44.181699|2018-06-01 03:59:44.181699
NCT00327327|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2010-09-14|2006-05-17|2006-05-18|Estimate|||||||2010-09-14|2010-09-15|Estimate|February 2004||2004-02-29|September 2010|2010-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma|A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma|Completed||Phase 1|105|Actual|AmpliMed Corporation|||||f||||t||||||||||2018-06-01 03:59:44.708112|2018-06-01 03:59:44.708112
NCT00327314|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-12-27|2006-05-16|2006-05-18|Estimate|||||||2006-12-27|2006-12-28|Estimate|December 2002||2002-12-31|December 2006|2006-12-31|October 2006||2006-10-31|||||Interventional|||Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma||Unknown status|Recruiting|Phase 2|100||Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-06-01 03:59:44.787421|2018-06-01 03:59:44.787421
NCT00327301|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2015-03-09|2006-05-17|2006-05-18|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2006||2006-10-31|March 2015|2015-03-31||||May 2008|Actual|2008-05-31||Observational|||Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease|Systematic Characterization of the Cellular Proteome From Human Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease|Withdrawn|||0|Actual|University Hospital, Basel, Switzerland||||was replaced by an other study|f||||f||||||None Retained|"~     plasma~   "|||2018-06-01 03:59:44.858097|2018-06-01 03:59:44.858097
NCT00325988|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2018-05-23|2006-05-13|2006-05-15|Estimate|||||||2018-05-23|2018-05-24|Actual|December 17, 2004||2004-12-17|February 3, 2014|2014-02-03|February 3, 2014||2014-02-03|||||Observational|||Biomarkers in Multiple Sclerosis|NINDS Biomarkers in Multiple Sclerosis Study (BioMS)|Completed|||858|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:00:12.156419|2018-06-01 04:00:12.156419
NCT00327288|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2015-06-22|2006-05-17|2006-05-18|Estimate|||||||2015-06-22|2015-06-24|Estimate|October 2005||2005-10-31|June 2015|2015-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients|A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Taxotere® (Docetaxel) in Previously Treated Inoperable Stage III and Stage IV Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic Previously Treated Breast Cancer or Hormone Refractory Prostate Cancer|Completed||Phase 1|34|Actual|AmpliMed Corporation||1|||f||||f||||||||||2018-06-01 03:59:44.913319|2018-06-01 03:59:44.913319
NCT00327275|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-05-16|2006-05-16|2006-05-18|Estimate|||||||2006-05-16|2006-05-18|Estimate|March 2004||2004-03-31|May 2006|2006-05-31|January 2005||2005-01-31|||||Interventional|||The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis|The Strength Training and Remicade Study|Completed||N/A|35||University of Arizona|||||f||||||||||||||2018-06-01 03:59:44.984374|2018-06-01 03:59:44.984374
NCT00327262|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-06-16|2006-05-16|2006-05-18|Estimate|||||||2006-06-16|2006-06-20|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|December 2008||2008-12-31|||||Interventional|||Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase|Multicenter, Phase III Study Comparing Imatinib (STI571, Glivec®) Standard Dose (400 Mg/Day) With Imatinib High Dose Induction (800 Mg/Day) Followed by Standard Dose Maintenance (400 Mg/Day) in Pretreated CML Patients in Chronic Phase|Unknown status|Recruiting|Phase 3|240||Central European Leukemia Study Group|||||f||||||||||||||2018-06-01 03:59:45.043324|2018-06-01 03:59:45.043324
NCT00327249|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2009-08-07|2006-05-17|2006-05-18|Estimate|||||||2009-08-07|2009-08-11|Estimate|October 2005||2005-10-31|August 2009|2009-08-31|January 2008|Actual|2008-01-31|July 2006|Actual|2006-07-31||Interventional|||Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients|A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) for Patients With Previously Treated Multiple Myeloma|Completed||Phase 1/Phase 2|||AmpliMed Corporation|||||f||||f||||||||||2018-06-01 03:59:45.133296|2018-06-01 03:59:45.133296
NCT00327236|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2018-01-02|2006-05-17|2006-05-18|Estimate|||||||2018-01-02|2018-01-04|Actual|January 1995||1995-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes|Killer T Cell Activity in the Paraneoplastic Neurologic Syndromes|Recruiting|||100|Anticipated|Rockefeller University|||||f||||f||||||Samples With DNA|"~     serum, cells)~   "|||2018-06-01 03:59:45.19822|2018-06-01 03:59:45.19822
NCT00327223|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2008-03-12|2006-05-17|2006-05-18|Estimate|||||||2008-03-12|2008-03-14|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy|A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy|Completed||Phase 1|18|Actual|AmpliMed Corporation||1|||f||||f||||||||||2018-06-01 03:59:45.276265|2018-06-01 03:59:45.276265
NCT00327210|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2017-11-06|2006-05-16|2006-05-18|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2005||2005-05-31|November 2017|2017-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Feasibility and Efficacy of Delivering Blood Glucose Awareness Training Over the Internet|Blood Glucose Awareness Training Delivered Over the Internet (BGATHome.Com): Feasibility and Efficacy|Completed||N/A|35|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 03:59:45.341282|2018-06-01 03:59:45.341282
NCT00327197|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2017-08-02|2006-05-17|2006-05-18|Estimate|||||||2017-08-02|2017-08-04|Actual|August 2, 2005|Actual|2005-08-02|August 2017|2017-08-31|June 6, 2011|Actual|2011-06-06|June 6, 2011|Actual|2011-06-06||Interventional|||Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma|A Study to Assess Disease Pathology and Key Therapeutic Targets in Severe Asthma|Terminated||Phase 1|47|Actual|GlaxoSmithKline||4||"The study was truncated due to the long period of enrollment and the collection of a sufficient~   amount of data that allowed the scientific objectives to be met"|f||||||||||||||2018-06-01 03:59:45.413737|2018-06-01 03:59:45.413737
NCT00327184|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2016-10-06|2006-05-17|2006-05-18|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine|Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC Given With Infanrix™ Penta Versus NeisVac-C™ Given With Infanrix™ Hexa at 3, 5 Months of Age and Persistence Prior to a Hib-MenC Booster at 11 Months and Immunogenicity of the Booster|Completed||Phase 3|709|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 03:59:45.49247|2018-06-01 03:59:45.49247
NCT00327171|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2012-08-17|2011-08-08|2016-05-04|2006-05-16|2006-05-18|Estimate|2012-09-17|2012-10-18|Estimate|2011-08-08|2011-08-15|Estimate|2016-05-04|2016-06-07|Estimate|May 2006||2006-05-31|May 2016|2016-05-31|March 2010|Actual|2010-03-31|April 2008|Actual|2008-04-30||Interventional|||Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer|A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer|Completed||Phase 2|218|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 03:59:45.635043|2018-06-01 03:59:45.635043
NCT00327158|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2010-01-27|2006-05-16|2006-05-18|Estimate|||||||2010-01-27|2010-01-28|Estimate|May 2006||2006-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||A Prospective Study to Determine the Effectiveness of Reaming in Reducing Fat Emboli to the Lungs|Using Transesophageal Echocardiography To Assess Fat Emboli As A Result Of Reaming In A Prospective Randomized Control Trial To Determine The Effectiveness Of Reaming In Diminishing Fat Emboli To The Lungs|Completed||N/A|24|Anticipated|University of Kentucky|||||f||||f||||||||||2018-06-01 03:59:46.330936|2018-06-01 03:59:46.330936
NCT00327145|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2016-11-16|2006-05-16|2006-05-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|March 2006||2006-03-31|November 2016|2016-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy|A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy|Completed||Phase 3|894|Actual|Novartis|||||f||||||||||||||2018-06-01 03:59:46.377975|2018-06-01 03:59:46.377975
NCT00327132|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2016-03-23|2006-05-17|2006-05-18|Estimate|||||||2016-03-23|2016-03-25|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome|Multicentre,Prospective Study of First-line Antibiotic Therapy for Early-stage Low-grade and High-grade Gastric Mucosa-associated Lymphoid Tissue-type Lymphoma and Potential Predicting Factor for Treatment Outcome|Completed||N/A|47|Actual|National Health Research Institutes, Taiwan||1|||f||||||||||||||2018-06-01 03:59:46.493311|2018-06-01 03:59:46.493311
NCT00327106|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2009-06-09|2006-05-17|2006-05-18|Estimate|||||||2009-06-09|2009-06-11|Estimate|April 2005||2005-04-30|June 2009|2009-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|THIF||Tranexamic Acid in HIp Fracture Surgery (THIF Study)|Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.|Completed||Phase 3|110|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t||||||||||2018-06-01 03:59:46.628707|2018-06-01 03:59:46.628707
NCT00327093|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2009-02-06|2006-05-17|2006-05-18|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases|Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases|Terminated||Phase 4|31|Actual|Hospices Civils de Lyon||2||The scientific commitee decided to stop the inclusions and exploit the results.|f||||||||||||||2018-06-01 03:59:46.693731|2018-06-01 03:59:46.693731
NCT00327080|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2018-05-16|2006-05-17|2006-05-18|Estimate|||||||2018-05-16|2018-05-17|Actual|May 12, 2006||2006-05-12|November 13, 2012|2012-11-13|March 18, 2009|Actual|2009-03-18|March 18, 2009|Actual|2009-03-18||Interventional|||Sildenafil to Treat HIV-Associated Pulmonary Hypertension|Evaluation of Endothelial and Hemodynamic Function in HIV Associated Pulmonary Hypertension and a Phase I/II Safety and Efficacy Trial of Sildenafil in HIV Associated Pulmonary Hypertension|Terminated||Phase 1|20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:59:46.753876|2018-06-01 03:59:46.753876
NCT00327067|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-17|||2017-06-30|2006-05-17|2006-05-18|Estimate|||||||2017-06-30|2017-07-02|Actual|May 12, 2006||2006-05-12|March 1, 2012|2012-03-01|March 1, 2012||2012-03-01|||||Observational|||Iron Replacement in Blood Donors|Iron Replacement in Blood Donors|Completed|||1820|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:59:46.817941|2018-06-01 03:59:46.817941
NCT00327054|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2015-06-30|2006-05-16|2006-05-17|Estimate|||||||2015-06-30|2015-07-01|Estimate|February 2006||2006-02-28|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia|Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|80|Actual|Aga Khan University||2|||f||||f||||||||||2018-06-01 03:59:46.881686|2018-06-01 03:59:46.881686
NCT00327041|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-05-15|2006-05-15|2006-05-17|Estimate|||||||2006-05-15|2006-05-17|Estimate|January 2006||2006-01-31|May 2006|2006-05-31|September 2006||2006-09-30|||||Observational|||Monitoring Response to Antiplatelet Therapy|Pilot Study Investigating the Use of a Variety of Assays to Detect Individual Response to Antiplatelet Therapy|Unknown status|Recruiting||40||NHS Greater Glasgow and Clyde|||||f||||||||||||||2018-06-01 03:59:46.948697|2018-06-01 03:59:46.948697
NCT00327028|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2009-02-18|2006-05-15|2006-05-17|Estimate|||||||2009-02-18|2009-02-19|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|December 2005||2005-12-31|||||Interventional|||Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Phenytoin Efficacy in Bronchial Asthma Therapy|Completed||Phase 4|61||Centre of Chinese Medicine, Georgia|||||f||||||||||||||2018-06-01 03:59:46.997758|2018-06-01 03:59:46.997758
NCT00327015|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|2009-08-17||2015-04-08|2006-05-15|2006-05-17|Estimate|2009-08-17|2009-09-25|Estimate||||2015-04-08|2015-04-29|Estimate|May 2006||2006-05-31|March 2015|2015-03-31|December 2008|Actual|2008-12-31|November 2007|Actual|2007-11-30||Interventional|||A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 3|1306|Actual|AstraZeneca||4|||f||||t||||||||||2018-06-01 03:59:47.101731|2018-06-01 03:59:47.101731
NCT00327002|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2015-12-09|2006-05-15|2006-05-17|Estimate|||||||2015-12-09|2015-12-11|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|November 2006|Actual|2006-11-30|September 2006|Actual|2006-09-30||Interventional|||A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism|A Mechanistic Study of the Effects of LY518674 on HDL C Metabolism|Completed||Phase 2|40|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 03:59:48.058502|2018-06-01 03:59:48.058502
NCT00326989|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2017-03-20|2006-05-16|2006-05-17|Estimate|||||||2017-03-20|2017-03-21|Actual|May 2006||2006-05-31|March 2017|2017-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium|Extracorporal Shock Wave Therapy for Induction of Therapeutic Neovascularization and Homing of Bone Marrow Progenitor Cells in Patients With Chronic Ischemic Heart Disease|Completed||Phase 1/Phase 2|103|Actual|Johann Wolfgang Goethe University Hospital||5|||f||||f||||||||||2018-06-01 03:59:48.112276|2018-06-01 03:59:48.112276
NCT00326976|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2007-12-03|2006-05-16|2006-05-17|Estimate|||||||2007-12-03|2007-12-04|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury|"A Multicenter, Double Blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 (a Fibrin Derived Peptide Bbeta15-42) on Ischemia Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI): The F.I.R.E. Study"|Completed||Phase 2|234|Actual|Fibrex Medical Research & Development GmbH||2|||f||||t||||||||||2018-06-01 03:59:48.172674|2018-06-01 03:59:48.172674
NCT00326963|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2016-03-23||2016-07-07|2006-05-16|2006-05-17|Estimate|2016-07-07|2016-08-16|Estimate||||2016-07-07|2016-08-16|Estimate|March 2006||2006-03-31|July 2016|2016-07-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional||Baseline analysis was performed on all randomized participants including two participants who does not received study drug.|BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.|A Multicenter, Open-label Study Evaluating the Safety and Efficacy of a New Protease Inhibitor (Darunavir) With Fuzeon® (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-class Treatment-experienced Patients|Completed||Phase 4|142|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 03:59:48.39674|2018-06-01 03:59:48.39674
NCT00326950|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2011-11-16||2012-03-06|2006-05-16|2006-05-17|Estimate|2011-11-16|2011-12-20|Estimate||||2012-03-06|2012-03-08|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Phase I Clinical Study of E7389|Phase I Clinical Study of E7389 in Patients With Solid Tumors|Completed||Phase 1|15|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 03:59:48.990348|2018-06-01 03:59:48.990348
NCT00326924|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|2017-03-13||2018-01-17|2006-05-15|2006-05-17|Estimate|2018-01-17|2018-01-19|Actual||||2018-01-17|2018-01-19|Actual|May 2006||2006-05-31|January 2018|2018-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Age of Red Blood Cells in Premature Infants Study (ARIPI)|Age of Red Blood Cells in Premature Infants Study (ARIPI)|Completed||N/A|377|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-06-01 03:59:49.257947|2018-06-01 03:59:49.257947
NCT00326911|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|2009-11-03||2011-05-19|2006-05-15|2006-05-17|Estimate|2009-11-03|2009-12-04|Estimate||||2011-05-19|2011-05-25|Estimate|May 2006||2006-05-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer|A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas|Terminated||Phase 2|61|Actual|ImClone LLC|Accrual on the trial was stopped earlier than planned due to insufficient efficacy in both arms.|2||"The planned enrollment was 130 patients and the study was halted prematurely due to lack of~   efficacy in both arms. Enrolled patients continued treatment."|f||||t||||||||||2018-06-01 03:59:49.607649|2018-06-01 03:59:49.607649
NCT00326898|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2016-10-18||2016-12-15|2006-05-16|2006-05-17|Estimate|2016-10-18|2016-12-12|Estimate||||2016-12-15|2017-02-08|Estimate|April 2006||2006-04-30|December 2016|2016-12-31|August 2015|Actual|2015-08-31|December 2010|Actual|2010-12-31||Interventional|ASSURE|All randomized patients|Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery|ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma|Completed||Phase 3|1943|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 03:59:50.475769|2018-06-01 03:59:50.475769
NCT00326885|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|2011-06-15||2016-08-18|2006-05-15|2006-05-17|Estimate|2012-11-14|2012-12-11|Estimate||||2016-08-18|2016-09-26|Estimate|June 2006||2006-06-30|August 2016|2016-08-31|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional|||Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites|A Single-Arm, Open-Label, Phase II Study to Assess the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites|Completed||Phase 2|32|Actual|Neovii Biotech||1|||f||||||||||||||2018-06-01 03:59:53.63424|2018-06-01 03:59:53.63424
NCT00326872|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2013-07-10||2017-07-21|2006-05-16|2006-05-17|Estimate|2013-07-10|2013-09-26|Estimate||||2017-07-21|2017-08-18|Actual|May 2006||2006-05-31|July 2017|2017-07-31|May 31, 2016|Actual|2016-05-31|August 21, 2011|Actual|2011-08-21||Interventional|||AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine|A Phase II Study of AZD2171 in Adult Patients With Neurofibromatosis Type 1 and Extensive Plexiform and Paraspinal Neurofibromas|Terminated||Phase 2|26|Actual|National Cancer Institute (NCI)||1||Closed due to slow accrual prior to interim analysis.|f||||||||||||||2018-06-01 03:59:54.103695|2018-06-01 03:59:54.103695
NCT00326859|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2006-10-12|2006-05-16|2006-05-17|Estimate|||||||2006-10-12|2006-10-13|Estimate|August 2005||2005-08-31|October 2006|2006-10-31|September 2006||2006-09-30|||||Interventional|||Comparison of Monitored Anesthesia Care Using Remifentanil or Fentanyl for Major Dressing Changes in Burns||Terminated||Phase 4|40||Montreal Burn Centre|||||f||||||||||||||2018-06-01 03:59:54.512155|2018-06-01 03:59:54.512155
NCT00326833|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2008-08-07|2006-05-16|2006-05-17|Estimate|||||||2008-08-07|2008-08-08|Estimate|January 2006||2006-01-31|August 2008|2008-08-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||How Many Patients Are in Need of Vitamin B12 Injections?|How Many Patients Are in Need of Vitamin B12 Injections?|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|University of Aarhus|||||f||||||||||||||2018-06-01 03:59:54.630243|2018-06-01 03:59:54.630243
NCT00326820|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2013-03-12|2006-05-16|2006-05-17|Estimate|||||||2013-03-12|2013-03-13|Estimate|January 2006||2006-01-31|March 2013|2013-03-31|October 2015|Anticipated|2015-10-31|December 2012|Actual|2012-12-31||Interventional|||Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer|Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases|Unknown status|Active, not recruiting|Phase 3|1404|Actual|Wales Cancer Trials Unit||2|||f||||t||||||||||2018-06-01 03:59:54.74564|2018-06-01 03:59:54.74564
NCT00326807|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-05-15|2006-05-15|2006-05-17|Estimate|||||||2006-05-15|2006-05-17|Estimate|June 2001||2001-06-30|May 2006|2006-05-31|June 2004||2004-06-30|||||Interventional|||Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling|A Randomized, Double-Blind, Placebo-Controlled Trial of Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling|Completed||N/A|50||Centre for Addiction and Mental Health|||||f||||||||||||||2018-06-01 03:59:54.99404|2018-06-01 03:59:54.99404
NCT00326794|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-05-15|2006-05-15|2006-05-17|Estimate|||||||2006-05-15|2006-05-17|Estimate|October 2002||2002-10-31|June 2005|2005-06-30|September 2005||2005-09-30|||||Interventional|||Efficacy of Shoulder Mobilisation Versus Conventional Immobilisation for Nonsurgically Proximal Humerus Fracture|Effectiveness at 3 Months of Immediate Shoulder Mobilisation Versus Conventional Immobilisation for Impacted Nonsurgically Treated Proximal Humerus Fracture: a Randomised Controlled Trial.|Terminated||Phase 3|76||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 03:59:55.068629|2018-06-01 03:59:55.068629
NCT00326781|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|2009-05-15||2010-08-16|2006-05-15|2006-05-17|Estimate|2010-03-05|2010-03-19|Estimate||||2010-08-16|2010-08-24|Estimate|December 1999||1999-12-31|March 2010|2010-03-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy (NRT)|Bio-Behavioral Predictors of the Efficacy of Nicotine Replacement Therapy - Transdisciplinary Tobacco Use Research Center (TTURC), Project 2|Completed||Phase 4|674|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 03:59:55.1936|2018-06-01 03:59:55.1936
NCT00326768|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2017-12-27|2006-05-16|2006-05-17|Estimate|||||||2017-12-27|2017-12-28|Actual|May 2006||2006-05-31|December 2017|2017-12-31|August 2007||2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension|An Open-Label, Long-term (52-week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation|Completed||Phase 3|184|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 03:59:55.43585|2018-06-01 03:59:55.43585
NCT00326742|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2007-05-09|2006-05-16|2006-05-17|Estimate|||||||2007-05-09|2007-05-10|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Observational|||Validation in Humans of Genes Involved in Alcohol Drinking, Stress-Induced Alcohol Drinking and Relapse|Validation in Humans of Genes Involved in Alcohol Drinking, Stress-Induced Alcohol Drinking and Relapse|Completed|||281|Actual|Central Institute of Mental Health, Mannheim|||||f||||||||||||||2018-06-01 03:59:55.517087|2018-06-01 03:59:55.517087
NCT00326729|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-06-15|2006-05-15|2006-05-17|Estimate|||||||2006-06-15|2006-06-16|Estimate|May 2006||2006-05-31|May 2006|2006-05-31||||||||Observational|||Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation||Unknown status|Recruiting||40||Montreal Burn Centre|||||f||||||||||||||2018-06-01 03:59:55.580763|2018-06-01 03:59:55.580763
NCT00326716|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|2011-01-05||2011-11-04|2006-05-16|2006-05-17|Estimate|2011-03-07|2011-04-07|Estimate||||2011-11-04|2011-11-16|Estimate|June 2006||2006-06-30|November 2011|2011-11-30|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women|A Study of the Pharmacokinetics of Atazanavir (ATV)/Ritonavir(RTV) Administered as Part of Highly Active Antiretroviral Therapy (HAART) in HIV-1 Infected Pregnant Women|Completed||Phase 1|69|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 03:59:55.719803|2018-06-01 03:59:55.719803
NCT00326703|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-10-16|2006-05-15|2006-05-17|Estimate|||||||2006-10-16|2006-10-17|Estimate|October 2002||2002-10-31|May 2006|2006-05-31|April 2003||2003-04-30|||||Interventional|||Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort|Investigation to Determine the Effects of Aircraft Cabin Altitudes on Passenger Comfort and Discomfort|Completed||N/A|500||The Boeing Company|||||f||||||||||||||2018-06-01 03:59:57.321368|2018-06-01 03:59:57.321368
NCT00326690|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-06-08|2006-05-15|2006-05-17|Estimate|||||||2006-06-08|2006-06-09|Estimate|November 2005||2005-11-30|May 2006|2006-05-31|July 2007||2007-07-31|||||Interventional|||Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity|A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart|Unknown status|Recruiting|Phase 4|100||BioVentrix|||||f||||||||||||||2018-06-01 03:59:57.388204|2018-06-01 03:59:57.388204
NCT00326677|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2011-02-17|2006-05-15|2006-05-17|Estimate|||||||2011-02-17|2011-02-18|Estimate|May 2006||2006-05-31|February 2011|2011-02-28|December 2013|Anticipated|2013-12-31|June 2012|Anticipated|2012-06-30||Interventional|||Primary Prevention of Major Depression in Later Life|Primary Prevention of Major Depression in Later Life|Unknown status|Active, not recruiting|N/A|306|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-06-01 03:59:57.493545|2018-06-01 03:59:57.493545
NCT00326664|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2016-03-04|2006-05-16|2006-05-17|Estimate|||||||2016-03-04|2016-03-07|Estimate|March 2006||2006-03-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors|A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors|Completed||Phase 1|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 03:59:57.558933|2018-06-01 03:59:57.558933
NCT00326651|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2007-01-31|2006-05-15|2006-05-17|Estimate|||||||2007-01-31|2007-02-01|Estimate|May 2006||2006-05-31|January 2007|2007-01-31|May 2007||2007-05-31|||||Observational|||Home Usage of Conception Kit Instructions|Home Usage of Conception Kit Instructions|Unknown status|Active, not recruiting||60||Conceivex|||||f||||||||||||||2018-06-01 03:59:57.707065|2018-06-01 03:59:57.707065
NCT00326638|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2016-09-15|2006-05-15|2006-05-17|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|January 2015|Actual|2015-01-31||Interventional|||3D-Conformal Radiation vs Helical Tomotherapy in Prostate Cancer|Randomized Phase III Trial of 3D Conformal Radiotherapy Versus Helical Tomotherapy IMRT in High-Risk Prostate Cancer|Active, not recruiting||Phase 3|72|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 03:59:57.764614|2018-06-01 03:59:57.764614
NCT00326625|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2018-02-17|2006-05-16|2006-05-17|Estimate|||||||2018-02-17|2018-02-20|Estimate|July 31, 2006|Actual|2006-07-31|February 2018|2018-02-28|July 31, 2008|Actual|2008-07-31|June 30, 2008|Actual|2008-06-30||Interventional|||Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)|A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|366|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 03:59:57.838148|2018-06-01 03:59:57.838148
NCT00326612|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|2011-03-10||2011-09-19|2006-05-15|2006-05-17|Estimate|2011-09-19|2011-10-26|Estimate||||2011-09-19|2011-10-26|Estimate|June 2006||2006-06-30|September 2011|2011-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures|Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy|Completed||Phase 2|358|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 03:59:57.922776|2018-06-01 03:59:57.922776
NCT00326599|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2016-12-07||2017-02-16|2006-05-16|2006-05-17|Estimate|2016-12-07|2017-01-31|Estimate||||2017-02-16|2017-03-21|Actual|June 2007||2007-06-30|February 2017|2017-02-28|February 2010|Actual|2010-02-28|April 2009|Actual|2009-04-30||Interventional||All participants who received treatment.|Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|101|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 03:59:58.325054|2018-06-01 03:59:58.325054
NCT00326586|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2011-01-24|2006-05-15|2006-05-17|Estimate|||||||2011-01-24|2011-01-25|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer|A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer|Completed||Phase 1|54|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 03:59:59.500867|2018-06-01 03:59:59.500867
NCT00326573|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-05-15|2006-05-15|2006-05-17|Estimate|||||||2006-05-15|2006-05-17|Estimate|October 2001||2001-10-31|October 2004|2004-10-31|June 2005||2005-06-30|||||Interventional|||Trial of Motivational Interviewing in Adolescents With Diabetes|A Multicentre, Randomised Controlled Trial of Motivational Interviewing in Adolescents With Diabetes|Terminated||Phase 1/Phase 2|80||Cardiff University|||||f||||||||||||||2018-06-01 03:59:59.567871|2018-06-01 03:59:59.567871
NCT00326560|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-06-15|2006-05-15|2006-05-17|Estimate|||||||2006-06-15|2006-06-16|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|September 2007||2007-09-30|||||Interventional|||Comparison of Glue With Sutures for Pterygium Surgery|Comparison of Cut and Paste With Sutured Autograft Pterygium Excision|Unknown status|Recruiting|Phase 3|40||Wellington Hospital|||||f||||||||||||||2018-06-01 03:59:59.615081|2018-06-01 03:59:59.615081
NCT00326534|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2009-03-06|2006-05-15|2006-05-17|Estimate|||||||2009-03-06|2009-03-09|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Observational|||Rickettsial Genesis to Sarcoidosis in Denmark|Rickettsial Genesis to Sarcoidosis in Denmark|Completed|||36|Actual|Statens Serum Institut|||2||f||||f||||||Samples With DNA|"~     Buffy coats, serum, bronchoalveolar lavage fluid and transbronchial biopsies~   "|||2018-06-01 03:59:59.677107|2018-06-01 03:59:59.677107
NCT00326521|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2008-06-05|2006-05-15|2006-05-17|Estimate|||||||2008-06-05|2008-06-06|Estimate|October 2006||2006-10-31|June 2008|2008-06-30|May 2009|Anticipated|2009-05-31|||||Observational|||Evaluation of Fever Occurring in Labor in Patients Receiving Epidural Anesthesia|Evaluation of Intrapartum Fever in Patients Receiving Epidural Anesthesia|Unknown status|Recruiting||50|Anticipated|MemorialCare|||||f||||f||||||Samples With DNA|"~     Maternal serum, amniotic fluid, and umbilical cord blood~   "|||2018-06-01 03:59:59.74121|2018-06-01 03:59:59.74121
NCT00326508|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2017-06-30|2006-05-16|2006-05-17|Estimate|||||||2017-06-30|2017-07-02|Actual|May 11, 2006||2006-05-11|December 20, 2006|2006-12-20|December 20, 2006||2006-12-20|||||Interventional|||Combination Daclizumab/Denileukin Diftitox to Treat Uveitis|Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis|Completed||Phase 2|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 03:59:59.894385|2018-06-01 03:59:59.894385
NCT00326495|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|2015-07-10||2017-06-23|2006-05-16|2006-05-17|Estimate|2015-07-10|2015-08-07|Estimate||||2017-06-23|2017-07-24|Actual|May 10, 2006|Actual|2006-05-10|June 2017|2017-06-30|November 7, 2014|Actual|2014-11-07|November 5, 2014|Actual|2014-11-05||Interventional|||BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer|A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC)|Completed||Phase 2|51|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 03:59:59.990567|2018-06-01 03:59:59.990567
NCT00326482|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-16|||2018-05-18|2006-05-16|2006-05-17|Estimate|||||||2018-05-18|2018-05-21|Actual|May 15, 2006||2006-05-15|May 17, 2018|2018-05-17||||||||Observational|||Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy|A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients With Chronically Elevated Transaminases on Antiretroviral Therapy|Recruiting|||180|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:00:00.81279|2018-06-01 04:00:00.81279
NCT00326469|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2010-11-30|2006-05-15|2006-05-16|Estimate|||||||2010-11-30|2010-12-01|Estimate|May 2006||2006-05-31|November 2010|2010-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours|Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy|Completed||Phase 2|30|Actual|Ipsen||1|||f||||||||||||||2018-06-01 04:00:00.978814|2018-06-01 04:00:00.978814
NCT00326456|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2017-07-14|2006-05-15|2006-05-16|Estimate|||||||2017-07-14|2017-07-17|Actual|January 2003||2003-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2013|Actual|2013-12-31||Interventional|||MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer|Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer|Active, not recruiting||Phase 3|820|Actual|National Cancer Institute, Naples||2|||f||||t||||||||||2018-06-01 04:00:01.28519|2018-06-01 04:00:01.28519
NCT00326443|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2014-05-08|2006-05-12|2006-05-16|Estimate|||||||2014-05-08|2014-05-09|Estimate|February 2006||2006-02-28|February 2010|2010-02-28|August 2008|Actual|2008-08-31|September 2007|Actual|2007-09-30||Interventional|||CVD 909 Vi Prime Boost Study|Phase I Randomized, Double-Blind, Heterologous Prime-Boost Study of the Safety and Immunogenicity of Vi Polysaccharide Typhoid Vaccine After Priming by Live Attenuated Oral Vi+ Salmonella Typhi Strain CVD 909|Completed||Phase 1|21|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:00:01.691691|2018-06-01 04:00:01.691691
NCT00326430|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-05-15|2006-05-15|2006-05-16|Estimate|||||||2006-05-15|2006-05-16|Estimate|October 2001||2001-10-31|May 2006|2006-05-31|June 2004||2004-06-30|||||Interventional|||Residential Cognitive and Interpersonal Therapy for Social Phobia|Residential Cognitive Therapy Versus Residential Interpersonal Therapy for Social Phobia: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|80||Modum Bad|||||f||||||||||||||2018-06-01 04:00:02.069783|2018-06-01 04:00:02.069783
NCT00326417|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2016-08-10||2017-09-27|2006-05-12|2006-05-16|Estimate|2016-08-10|2016-10-04|Estimate||||2017-09-27|2017-10-27|Actual|January 2006||2006-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)|Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)|Completed||Phase 1/Phase 2|97|Actual|Medical College of Wisconsin||4|||f||||t||||||||Yes|Findings will be published in a manuscript.|2018-06-01 04:00:02.346518|2018-06-01 04:00:02.346518
NCT00326404|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2008-07-17|2006-05-12|2006-05-16|Estimate|||||||2008-07-17|2008-07-18|Estimate|May 2006||2006-05-31|July 2008|2008-07-31|May 2009|Anticipated|2009-05-31|May 2008|Anticipated|2008-05-31||Interventional|||Continuous Versus Cyclic Use of Oral Contraceptive Pills in Adolescents|Continuous Versus Cyclic Use of an Oral Contraceptive Pills in Adolescents|Unknown status|Recruiting|Phase 3|130|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 04:00:03.795461|2018-06-01 04:00:03.795461
NCT00326391|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2011-05-20|2006-05-12|2006-05-16|Estimate|||||||2011-05-20|2011-05-24|Estimate|April 2006||2006-04-30|April 2010|2010-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder|A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate the Efficacy and Safety of CONCERTA (Methylphenidate HCl) Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg Per Day.|Completed||Phase 3|229|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||||||||||||||||2018-06-01 04:00:03.953476|2018-06-01 04:00:03.953476
NCT00326378|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2015-06-03|2006-05-15|2006-05-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|October 2005||2005-10-31|November 2012|2012-11-30|May 2015|Actual|2015-05-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy Study of Additional Chemotherapy After Concurrent Chemoradiation in Non-small Cell Lung Cancer|A Multinational, Multicenter, Phase III Open Randomized Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-small Cell Lung Cancer (CCheIN)|Completed||Phase 3|434|Actual|Samsung Medical Center||2|||f||||||||||||||2018-06-01 04:00:04.075149|2018-06-01 04:00:04.075149
NCT00326365|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2007-10-30|2006-05-15|2006-05-16|Estimate|||||||2007-10-30|2007-10-31|Estimate|June 2006||2006-06-30|May 2006|2006-05-31||||||||Interventional|||Effect of Homeopathic Remedy Kalium Bichromicum on Viscosity and Amount of Sputum Mechanically Ventilated ICU Patients.|A Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Investigate the Efficacy and Safety of the Homeopathic Remedy Kalium Bichromicum (Potassium Dichromate) to Decrease Viscosity and Amount of Sputum as Well as Time to Extubation, in Intubated Mechanically Ventilated ICU Patients.|Unknown status|Not yet recruiting|Phase 3|56|Anticipated|Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 04:00:04.240223|2018-06-01 04:00:04.240223
NCT00326352|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2006-05-15|2006-05-15|2006-05-16|Estimate|||||||2006-05-15|2006-05-16|Estimate|July 2003||2003-07-31|May 2006|2006-05-31|June 2005||2005-06-30|||||Interventional|||Comparison of Sedation/Analgesia: Midazolam/Morphine Vs Propofol/Remifentanil|Comparison of Sedation/Analgesia: Midazolam/Morphine Vs Propofol/Remifentanil|Terminated||N/A|40||University of Edinburgh|||||f||||||||||||||2018-06-01 04:00:04.397432|2018-06-01 04:00:04.397432
NCT00326339|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2009-04-16|2006-05-12|2006-05-16|Estimate|||||||2009-04-16|2009-04-20|Estimate|August 2006||2006-08-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate|Completed||Phase 2|189|Actual|Rigel Pharmaceuticals||4|||f||||t||||||||||2018-06-01 04:00:04.508992|2018-06-01 04:00:04.508992
NCT00326326|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2009-05-06|2006-05-12|2006-05-16|Estimate|||||||2009-05-06|2009-05-07|Estimate|July 2006||2006-07-31|May 2009|2009-05-31|June 2007|Actual|2007-06-30|||||Interventional|||Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus|Completed||Phase 2|84||Pfizer|||||||||||||||||||2018-06-01 04:00:04.865614|2018-06-01 04:00:04.865614
NCT00326313|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-14|||2006-05-15|2006-05-15|2006-05-16|Estimate|||||||2006-05-15|2006-05-16|Estimate|June 2006||2006-06-30|May 2006|2006-05-31||||||||Observational|||Clinical Outcome of Neonates With GBS Positive Culture-12 Year Retrospective Study|Clinical Outcome of Neonate With GBS Positive Culture-12 Year Retrospective Study|Unknown status|Not yet recruiting||74||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:00:05.037431|2018-06-01 04:00:05.037431
NCT00326300|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2011-05-20|2006-05-12|2006-05-16|Estimate|||||||2011-05-20|2011-05-24|Estimate|April 2006||2006-04-30|April 2010|2010-04-30|August 2007|Actual|2007-08-31|||||Interventional|||A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder|An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder|Completed||Phase 3|560|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||||||||||||||||2018-06-01 04:00:05.128968|2018-06-01 04:00:05.128968
NCT00326287|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12||2011-06-03|2012-07-25|2006-05-12|2006-05-16|Estimate||||2011-06-03|2011-06-16|Estimate|2012-07-25|2012-08-02|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia|A Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Placebo in the Treatment of Subjects Hospitalized With Community-Acquired Pneumonia|Completed||Phase 3|638|Actual|Basilea Pharmaceutica||2|||||||t||||||||||2018-06-01 04:00:05.263658|2018-06-01 04:00:05.263658
NCT00326274|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2009-02-10|2006-05-15|2006-05-16|Estimate|||||||2009-02-10|2009-02-11|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|November 2006||2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Clinical Safety Trial of Long-Term Intermittent Use of Helioblock® SX Cream||Completed||Phase 3|||Loreal USA|||||||||||||||||||2018-06-01 04:00:05.383943|2018-06-01 04:00:05.383943
NCT00326261|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2008-12-17|2006-05-12|2006-05-16|Estimate|||||||2008-12-17|2008-12-18|Estimate||||April 2006|2006-04-30||||||||Observational|||Randomized Controlled Trial of Ultrasound Guided Needle Placement Versus Nerve Stimulation for Coracoid Infraclavicular Brachial Plexus Block|Randomized Controlled Trial of Ultrasound Guided Needle Placement Versus Nerve Stimulation for Coracoid Infraclavicular Brachial Plexus Block|Completed|||||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:00:05.557112|2018-06-01 04:00:05.557112
NCT00326248|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2016-10-24|2006-05-12|2006-05-16|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women|A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50mg Oral Dosing With the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis|Completed||Phase 3|482|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:00:05.883989|2018-06-01 04:00:05.883989
NCT00326235|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2017-01-11|2006-05-12|2006-05-16|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2002||2002-01-31|March 2005|2005-03-31|July 2004||2004-07-31|||||Interventional|||Effects of Buspirone in Opiate Withdrawal|Effects of Buspirone in Withdrawal From Opiates|Completed||Phase 4|||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:00:06.117712|2018-06-01 04:00:06.117712
NCT00326222|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2016-07-18|2006-05-15|2006-05-16|Estimate|||||||2016-07-18|2016-07-19|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Patient Education in NorthTrondelag Hospital Trust|Patient Education in NorthTrondelag Hospital Trust - Interventions, Effects and Patient Experience|Completed||N/A|146|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:00:07.507076|2018-06-01 04:00:07.507076
NCT00326209|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2017-12-11|2006-05-12|2006-05-16|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2005||2005-12-31|December 2017|2017-12-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Long-Term Safety and Tolerability of Mesalamine Pellets in Patients With Ulcerative Colitis in Remission|A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation|Completed||Phase 3|394|Actual|Valeant Pharmaceuticals International, Inc.|||||f||||||||||||||2018-06-01 04:00:07.673389|2018-06-01 04:00:07.673389
NCT00326196|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2013-07-01||2014-04-07|2006-05-12|2006-05-16|Estimate|2013-12-18|2014-02-06|Estimate||||2014-04-07|2014-04-25|Estimate|July 2006||2006-07-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|VA CARDS||Coronary Artery Revascularization in Diabetes|CSP #557 - Coronary Artery Revascularization in Diabetes (VA CARDS)|Terminated||Phase 4|198|Actual|VA Office of Research and Development|Low participant recruitment led to the study being terminated early.|2||Lack of participant enrollment|f||||t||||||||||2018-06-01 04:00:07.855757|2018-06-01 04:00:07.855757
NCT00326183|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2008-10-21||2017-01-31|2006-05-15|2006-05-16|Estimate|2008-11-18|2008-11-20|Estimate||||2017-01-31|2017-03-13|Actual|March 2007||2007-03-31|January 2017|2017-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)|An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age|Completed||Phase 4|1800|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:00:08.523373|2018-06-01 04:00:08.523373
NCT00326170|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2011-06-06||2012-06-12|2006-05-12|2006-05-16|Estimate|2011-06-06|2011-07-11|Estimate||||2012-06-12|2012-06-15|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Phase II 5-Azacytidine Plus VPA Plus ATRA|Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia|Completed||Phase 2|34|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:00:08.909215|2018-06-01 04:00:08.909215
NCT00326157|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2010-02-11|2006-05-10|2006-05-16|Estimate|||||||2010-02-11|2010-02-12|Estimate|June 2006||2006-06-30|February 2010|2010-02-28|November 2009|Actual|2009-11-30|January 2009|Actual|2009-01-31||Interventional|||PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation|Phase II Pilot Study on Safety of Administration of 3mg/kg/Day Three Times a Week Until Day 22 (21 Days After Transplantation Day) and 7 mg/kg Weekly From Day 29 to the End of Treatment (Day 50-8th Week) of AmBisome® in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem-cell Transplantation|Completed||Phase 2|34|Actual|Gilead Sciences||1|||f||||f||||||||||2018-06-01 04:00:09.161404|2018-06-01 04:00:09.161404
NCT00326144|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2009-03-24|2006-05-15|2006-05-16|Estimate|||||||2009-03-24|2009-03-25|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|May 2007|Actual|2007-05-31|||||Interventional|OPAL||Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Mono-Therapy in the Treatment of Adult Patients With Major Depressive Disorder|Completed||Phase 3|310|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:00:09.297494|2018-06-01 04:00:09.297494
NCT00326131|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2010-02-27|2006-05-15|2006-05-16|Estimate|||||||2010-02-27|2010-03-02|Estimate|April 2006||2006-04-30|August 2007|2007-08-31||||March 2007|Actual|2007-03-31||Interventional|||A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer|Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer|Terminated||Phase 1|6||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:00:09.565764|2018-06-01 04:00:09.565764
NCT00326118|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2009-09-18||2016-09-28|2006-05-12|2006-05-16|Estimate|2009-09-18|2009-10-23|Estimate||||2016-09-28|2016-11-03|Estimate|June 2006||2006-06-30|September 2016|2016-09-30|October 2012|Actual|2012-10-31|November 2007|Actual|2007-11-30||Interventional|||Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.|Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix™, Versus MenC-CRM197 Vaccine With Hiberix™ & Priorix™ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination.|Completed||Phase 3|433|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:00:09.880031|2018-06-01 04:00:09.880031
NCT00326105|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2009-03-24|2006-05-15|2006-05-16|Estimate|||||||2009-03-24|2009-03-25|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|July 2007|Actual|2007-07-31|||||Interventional|PEARL||Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment (PEARL STUDY)|Completed||Phase 3|450|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:00:10.724417|2018-06-01 04:00:10.724417
NCT00326092|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2016-11-17|2006-05-12|2006-05-16|Estimate|||||||2016-11-17|2016-11-18|Estimate|May 2006||2006-05-31|September 2007|2007-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|88||Alcon Research|||||f||||||||||||||2018-06-01 04:00:10.894053|2018-06-01 04:00:10.894053
NCT00326079|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2013-03-28|2006-05-12|2006-05-16|Estimate|||||||2013-03-28|2013-03-29|Estimate|August 2004||2004-08-31|March 2013|2013-03-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2|A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents|Unknown status|Active, not recruiting|Phase 4|61|Actual|Glaukos Corporation||2|||f||||t||||||||||2018-06-01 04:00:10.982911|2018-06-01 04:00:10.982911
NCT00326066|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2018-03-07|2006-05-12|2006-05-16|Estimate|||||||2018-03-07|2018-03-09|Actual|February 2005||2005-02-28|March 2018|2018-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients.|A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Newly Diagnosed Open Angle Glaucoma and Subjects Diagnosed With Ocular Hypertension|Completed||N/A|47|Actual|Glaukos Corporation||2|||f||||t||||||||||2018-06-01 04:00:11.064883|2018-06-01 04:00:11.064883
NCT00326053|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2011-01-21|2006-05-12|2006-05-16|Estimate|||||||2011-01-21|2011-01-24|Estimate|May 2006||2006-05-31|January 2011|2011-01-31|May 2007|Actual|2007-05-31|||||Interventional|PARADE||Prevention of Asthma Relapse After Discharge From Emergency|A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse|Completed||Phase 3|600|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:00:11.155604|2018-06-01 04:00:11.155604
NCT00326040|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2008-07-23|2006-05-12|2006-05-16|Estimate|||||||2008-07-23|2008-07-25|Estimate|April 2003||2003-04-30|July 2008|2008-07-31|August 2007|Actual|2007-08-31|||||Interventional|||A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects|A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects.|Completed||Phase 4|45|Actual|Glaukos Corporation||1|||f||||t||||||||||2018-06-01 04:00:11.351605|2018-06-01 04:00:11.351605
NCT00326027|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-15|||2012-05-04|2006-05-15|2006-05-16|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2006||2006-10-31|May 2012|2012-05-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Non-erosive Reflux or Gastroesophageal Reflux Disease (BY1023/DE-004)|Profi-Study: Symptom Reduction in Hospitalized Patients Suffering From Symptomatic Non-erosive or Erosive Gastroesophageal Reflux Disease Treated With Pantoprazole 20 or 40 mg o.d. for 7 Days|Completed||Phase 3|29|Actual|Nycomed||2|||f||||f||||||||||2018-06-01 04:00:11.456349|2018-06-01 04:00:11.456349
NCT00326014|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2015-06-03|2006-05-12|2006-05-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2003||2003-04-30|June 2015|2015-06-30|December 2009|Actual|2009-12-31|March 2008|Actual|2008-03-31||Interventional|||A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.|A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.|Completed||Phase 4|58|Actual|Glaukos Corporation||1|||f||||t||||||||||2018-06-01 04:00:11.631803|2018-06-01 04:00:11.631803
NCT00326001|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2009-05-13||2010-02-03|2006-05-12|2006-05-16|Estimate|2010-01-08|2010-02-04|Estimate||||2010-02-03|2010-02-18|Estimate|June 2004||2004-06-30|August 2009|2009-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8)|AURUM 8 - Ablation of the Cavotricuspid Isthmus in Patients With Atrial Flutter Using an 8 mm Gold Alloy Tip Electrode|Completed||Phase 4|463|Actual|Biotronik SE & Co. KG||2|||f||||||||||||||2018-06-01 04:00:11.769263|2018-06-01 04:00:11.769263
NCT00325962|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2009-07-17|2006-05-11|2006-05-15|Estimate|||||||2009-07-17|2009-07-21|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|December 2008|Actual|2008-12-31|December 2006|Actual|2006-12-31||Interventional|||A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension|Completed||Phase 2|84||BioMarin Pharmaceutical|||||f||||||||||||||2018-06-01 04:00:12.313066|2018-06-01 04:00:12.313066
NCT00325949|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2011-07-22|2006-05-12|2006-05-15|Estimate|||||||2011-07-22|2011-07-25|Estimate|May 2006||2006-05-31|July 2011|2011-07-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||A Study of Pain Relief in Low Back Pain|A Phase 3, Open-Label Period Followed By a Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) Compared to Placebo in Subjects With Chronic Low Back Pain|Completed||Phase 3|770|Actual|Abbott||3|||f||||f||||||||||2018-06-01 04:00:12.447801|2018-06-01 04:00:12.447801
NCT00325936|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2008-08-26|2006-05-12|2006-05-15|Estimate|||||||2008-08-26|2008-08-27|Estimate|July 2005||2005-07-31|August 2008|2008-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||The Effects of Cilnidipine on Metabolic Syndrome Improvement|A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS]|Completed||Phase 4|186|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-06-01 04:00:12.646453|2018-06-01 04:00:12.646453
NCT00325923|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2010-03-24|2006-05-11|2006-05-15|Estimate|||||||2010-03-24|2010-03-25|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|June 2006||2006-06-30|||||Interventional|||Impact of a Decision Aid Regarding Natural Health Products for Menopausal Symptoms|A Patient Decision Aid Regarding Natural Health Products for Menopausal Symptoms:a Randomized Controlled Trial|Completed||N/A|70||CHU de Quebec-Universite Laval|||||f||||f||||||||||2018-06-01 04:00:12.736392|2018-06-01 04:00:12.736392
NCT00325910|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2008-05-12|2006-05-12|2006-05-15|Estimate|||||||2008-05-12|2008-05-14|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study|Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study|Terminated||Phase 3|100||University of Alberta||||Insufficient study participants|f||||||||||||||2018-06-01 04:00:12.800303|2018-06-01 04:00:12.800303
NCT00325897|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2011-08-18||2016-08-25|2006-05-12|2006-05-15|Estimate|2012-05-01|2012-06-07|Estimate||||2016-08-25|2016-10-19|Estimate|March 2006||2006-03-31|August 2016|2016-08-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease|Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations|Completed||N/A|1142|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-06-01 04:00:12.903583|2018-06-01 04:00:12.903583
NCT00325884|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2011-08-25|2006-05-12|2006-05-15|Estimate|||||||2011-08-25|2011-08-29|Estimate|August 2001||2001-08-31|August 2011|2011-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Long-term Outcomes of Patients After Coronary Bifurcation Stenting|Long-term Outcomes of Patients After Coronary Bifurcation Stenting|Completed|||160|Actual|VA Boston Healthcare System|||||f||||f||||||||||2018-06-01 04:00:13.477702|2018-06-01 04:00:13.477702
NCT00325871|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2017-03-21|2006-05-12|2006-05-15|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2006||2006-04-30|March 2017|2017-03-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Observational|||Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer|The Effect of Concurrent Chemoradiation on Circulating Endothelial Progenitor Cells in Colorectal Cancer|Completed|||30|Actual|Mackay Memorial Hospital|||||f||||||||||||No||2018-06-01 04:00:13.558251|2018-06-01 04:00:13.558251
NCT00325858|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2012-08-24|2006-05-11|2006-05-15|Estimate|||||||2012-08-24|2012-08-27|Estimate|January 2002||2002-01-31|September 2006|2006-09-30|December 2003||2003-12-31|||||Interventional|||A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip|Double-Blind, Randomized,Dose-Ranging, Parallel-Group Comparison Of The Efficacy And Safety Of Extended-Release Tramadol Hydrochloride(Tramadol HCl ER)100 Mg, 200 Mg, 300 Mg, And 400 Mg With Placebo In The Treatment Of Osteoarthritis Of Knee And/Or Hip|Completed||Phase 3|1000||Valeant Pharmaceuticals International, Inc.|||||f||||f||||||||||2018-06-01 04:00:13.635547|2018-06-01 04:00:13.635547
NCT00325845|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2006-09-12|2006-05-12|2006-05-15|Estimate|||||||2006-09-12|2006-09-13|Estimate|May 2006||2006-05-31|September 2006|2006-09-30|May 2008||2008-05-31|||||Interventional|||Synvisc Injections for Lumbar Facet Joint Pain|Efficacy and Safety of Intra-Articular Synvisc Injections as Treatment of Painful Lumbar Facet Joint Arthrosis|Unknown status|Recruiting|Phase 3|15||Sheltering Arms Physical Rehabilitation Hospitals|||||||||||||||||||2018-06-01 04:00:13.723482|2018-06-01 04:00:13.723482
NCT00325832|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2010-08-20|2006-05-12|2006-05-15|Estimate|||||||2010-08-20|2010-08-23|Estimate|January 2006||2006-01-31|May 2008|2008-05-31||||||||Interventional|CAMBO||Conventional Versus Automated Measurement of Blood Pressure in the Office (The CAMBO Study)||Completed||Phase 4|750|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 04:00:13.80395|2018-06-01 04:00:13.80395
NCT00325819|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|2013-07-17||2017-10-11|2006-05-11|2006-05-15|Estimate|2014-02-25|2014-04-07|Estimate||||2017-10-11|2017-10-13|Actual|May 2006||2006-05-31|October 2017|2017-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||Participants who did not receive acetaminophen or placebo due to postal problems (3), who were not given a first dose of acetaminophen or placebo (13) or who were lost to follow-up due to study diary not being returned (6) were not included in analysis.|Acetaminophen Before Vaccines for Infants Study (AVIS)|A Randomized Placebo-controlled Trial of Acetaminophen for Prevention of Post-vaccination Fever in Infants|Completed||Phase 3|374|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 04:00:13.894642|2018-06-01 04:00:13.894642
NCT00325806|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2013-03-07|2006-05-12|2006-05-15|Estimate|||||||2013-03-07|2013-03-08|Estimate|May 2000||2000-05-31|March 2013|2013-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Ramipril - Hypertension|Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.|Completed||Phase 4|1008|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:00:14.354675|2018-06-01 04:00:14.354675
NCT00325793|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2006-05-12|2006-05-12|2006-05-15|Estimate|||||||2006-05-12|2006-05-15|Estimate|January 2004||2004-01-31|May 2006|2006-05-31||||||||Interventional|||IV Double and Triple Concentrated Nicardipine for Stroke and ICH|An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage|Unknown status|Recruiting|Phase 4|50||OSF Healthcare System|||||f||||||||||||||2018-06-01 04:00:14.422303|2018-06-01 04:00:14.422303
NCT00325780|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2009-08-26||2010-01-25|2006-05-11|2006-05-15|Estimate|2009-12-11|2010-01-18|Estimate||||2010-01-25|2010-02-02|Estimate|July 2006||2006-07-31|January 2010|2010-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Open-Label, Long-Term (1 Year) Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Completed||Phase 3|1355|Actual|Kowa Research Europe||1|||f||||f||||||||||2018-06-01 04:00:14.555214|2018-06-01 04:00:14.555214
NCT00325767|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2006-05-12|2006-05-12|2006-05-15|Estimate|||||||2006-05-12|2006-05-15|Estimate|May 2004||2004-05-31|April 2006|2006-04-30|September 2005||2005-09-30|||||Interventional|||Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol|Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol|Completed||Phase 4|10||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:00:15.035342|2018-06-01 04:00:15.035342
NCT00325754|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|2016-05-20||2016-10-17|2006-05-11|2006-05-15|Estimate|2016-07-08|2016-08-18|Estimate||||2016-10-17|2016-11-28|Estimate|March 2005||2005-03-31|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Benefits of Lightweight Ambulatory Oxygen Systems for Individuals With Chronic Obstructive Pulmonary Disease|Benefits of Ambulatory Oxygen in Hypoxemic COPD Patients|Terminated||N/A|22|Actual|University of Minnesota - Clinical and Translational Science Institute|The Data Safety and Monitoring Board requested termination of this study due to low recruitment. 22 participants were randomized out of a goal of 100.|2||low recruitment|f||||t||||||||No||2018-06-01 04:00:15.136166|2018-06-01 04:00:15.136166
NCT00325741|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2009-08-06|2006-05-12|2006-05-15|Estimate|||||||2009-08-06|2009-08-07|Estimate|June 2004||2004-06-30|August 2009|2009-08-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus|Allogeneic Hematopoietic Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus Using a Non-Myeloablative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin|Unknown status|Recruiting|Phase 1|15|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t||||||||||2018-06-01 04:00:15.612748|2018-06-01 04:00:15.612748
NCT00325728|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2017-08-10|2006-05-11|2006-05-15|Estimate|||||||2017-08-10|2017-08-14|Actual|March 21, 2006|Actual|2006-03-21|August 2017|2017-08-31|August 20, 2007|Actual|2007-08-20|August 1, 2007|Actual|2007-08-01||Interventional|||Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects|Completed||Phase 2|74|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:00:15.680317|2018-06-01 04:00:15.680317
NCT00325715|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2011-06-01|2006-05-11|2006-05-15|Estimate|||||||2011-06-01|2011-06-02|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers||Completed||Phase 1|150|Actual|Allergan||2|||f||||||||||||||2018-06-01 04:00:15.998511|2018-06-01 04:00:15.998511
NCT00325702|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2011-10-17|2006-05-11|2006-05-15|Estimate|||||||2011-10-17|2011-10-18|Estimate|October 2006||2006-10-31|October 2011|2011-10-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|Get REAL||Addressing Young Men's Substance Use and HIV Risk|Addressing Young Men's Substance Use and HIV Risk|Completed||N/A|761|Actual|Public Health Management Corporation|||||f||||f||||||||||2018-06-01 04:00:16.079771|2018-06-01 04:00:16.079771
NCT00325689|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2013-11-07|2006-05-12|2006-05-15|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 2006||2006-07-31|April 2011|2011-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.|A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy.|Completed||Phase 4|323|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 04:00:16.168782|2018-06-01 04:00:16.168782
NCT00325676|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2012-05-04|2006-05-12|2006-05-15|Estimate|||||||2012-05-04|2012-05-07|Estimate|June 2006||2006-06-30|June 2007|2007-06-30||||||||Interventional|||Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)|CONFIRM - Confirmation of Superiority of Complete Remission Concept Versus Classical Healing Concept for Treatment of Patients With Erosive GERD|Completed||Phase 4|639|Actual|Takeda|||||f||||||||||||||2018-06-01 04:00:16.365685|2018-06-01 04:00:16.365685
NCT00325663|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2006-05-12|2006-05-12|2006-05-15|Estimate|||||||2006-05-12|2006-05-15|Estimate|April 2004||2004-04-30|April 2004|2004-04-30|April 2005||2005-04-30|||||Interventional|||Acupuncture in Osteoarthritis of the Knee|Specific and Non-Specific Effects of Acupuncture: A Double-Blinded, Randomized, Controlled Trial in Patients With Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|125||Heidelberg University|||||f||||||||||||||2018-06-01 04:00:16.541014|2018-06-01 04:00:16.541014
NCT00325650|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12||2016-04-19|2016-04-19|2006-05-12|2006-05-15|Estimate||||2016-04-19|2016-05-18|Estimate|2016-04-19|2016-05-18|Estimate|May 2006||2006-05-31|April 2016|2016-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|RAPSODI||Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of Long-term Administration of Rimonabant in the Prevention of Type 2 Diabetes in Patients With Prediabetic Status (i.e., Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Both)|Terminated||Phase 3|2420|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 04:00:16.602476|2018-06-01 04:00:16.602476
NCT00325637|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2008-12-11|2006-05-11|2006-05-15|Estimate|||||||2008-12-11|2008-12-12|Estimate|January 2005||2005-01-31|December 2008|2008-12-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients With Hypertension|A Multi-Center, Double Blind, Randomized and Non-Inferiority Clinical Study of Cilnidipine to Compare the Effects on Cerebral Blood Flow With Losartan in Patients With Ischemic Stroke Hypertension|Completed||Phase 3|250|Actual|Boryung Pharmaceutical Co., Ltd||1|||f||||t||||||||||2018-06-01 04:00:16.684147|2018-06-01 04:00:16.684147
NCT00325624|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2012-05-21|2006-05-12|2006-05-15|Estimate|||||||2012-05-21|2012-05-23|Estimate|November 2006||2006-11-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|DREAM-Tel||Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel)|Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel)|Completed||Phase 1|40|Actual|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:00:16.768916|2018-06-01 04:00:16.768916
NCT00325598|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|2016-09-19||2017-04-27|2006-05-12|2006-05-15|Estimate|2016-09-19|2016-11-07|Estimate||||2017-04-27|2017-05-30|Actual|February 14, 2006|Actual|2006-02-14|April 2017|2017-04-30|April 16, 2017|Actual|2017-04-16|April 16, 2013|Actual|2013-04-16||Interventional|||Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer|Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer: A Phase I/II Feasibility Study|Completed||Phase 1/Phase 2|100|Actual|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-06-01 04:00:16.946211|2018-06-01 04:00:16.946211
NCT00325585|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2013-04-05|2006-05-11|2006-05-15|Estimate|||||||2013-04-05|2013-04-09|Estimate|April 2005||2005-04-30|April 2013|2013-04-30|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||HIV Prevention Intervention for Couples|Couples HIV Intervention Randomized Controlled Trial|Completed||Phase 2|780|Anticipated|National Development and Research Institutes, Inc.|||||f||||||||||||||2018-06-01 04:00:17.539783|2018-06-01 04:00:17.539783
NCT00325572|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2013-01-13|2006-05-12|2006-05-15|Estimate|||||||2013-01-13|2013-01-15|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism|Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism|Completed||Phase 1|3|Actual|Penn State University||2|||f||||t||||||||||2018-06-01 04:00:17.605037|2018-06-01 04:00:17.605037
NCT00325559|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2011-01-12|2006-05-12|2006-05-15|Estimate|||||||2011-01-12|2011-01-13|Estimate|June 2006||2006-06-30|January 2011|2011-01-31||||March 2007|Actual|2007-03-31||Interventional|||The Effect of Hyperglycaemia on Local Energy Stores in the Working Muscle in Patients With Type 1 Diabetes Mellitus|The Effect of Hyperglycaemia on Local Energy Stores in the Working Muscle in Patients With Type 1 Diabetes Mellitus|Completed||N/A|10|Anticipated|University Hospital Inselspital, Berne|||||f||||||||||||||2018-06-01 04:00:17.67077|2018-06-01 04:00:17.67077
NCT00325546|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2009-04-06|2006-05-12|2006-05-15|Estimate|||||||2009-04-06|2009-04-07|Estimate|April 2006||2006-04-30|April 2009|2009-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20mg), Multi-National, Multicentre Study of Weight-Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities|Completed||Phase 3|643|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:00:17.726213|2018-06-01 04:00:17.726213
NCT00325533|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2014-06-11|2006-05-12|2006-05-15|Estimate|||||||2014-06-11|2014-06-12|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Effectiveness of a Barbershop-Based Program to Improve High Blood Pressure Control and Awareness in Black Men|Group Randomized Trial of a Barber-Based Intervention to Improve Hypertension Control in Black Men|Completed||N/A|2319|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-06-01 04:00:17.803775|2018-06-01 04:00:17.803775
NCT00325520|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-12|||2014-08-14|2006-05-12|2006-05-15|Estimate|||||||2014-08-14|2014-08-15|Estimate|May 2006||2006-05-31|July 2013|2013-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||A Neurocognitive Model of Anorexia Nervosa|A Neurocognitive Model of Anorexia Nervosa|Completed|||152|Actual|New York State Psychiatric Institute|||2||f||||t||||||||||2018-06-01 04:00:17.868349|2018-06-01 04:00:17.868349
NCT00325507|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2008-07-31|2006-05-10|2006-05-12|Estimate|||||||2008-07-31|2008-08-01|Estimate|November 2005||2005-11-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma|Safety, Immunology, and Biological Activity Evaluation of TroVax® in Treatment of Patients With Locally Advanced or Metastatic Renal Carcinoma|Completed||Phase 2|25|Anticipated|Oxford BioMedica|||||||||||||||||||2018-06-01 04:00:17.920798|2018-06-01 04:00:17.920798
NCT00325494|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2014-07-16|2006-05-11|2006-05-12|Estimate|||||||2014-07-16|2014-07-17|Estimate|May 2006||2006-05-31|July 2014|2014-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer|A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects With Advanced Mesothelin-expressing Tumors|Completed||Phase 1|24|Actual|Morphotek||6|||f||||||||||||||2018-06-01 04:00:17.989719|2018-06-01 04:00:17.989719
NCT00325481|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2007-07-17|2006-05-11|2006-05-12|Estimate|||||||2007-07-17|2007-07-18|Estimate|June 2006||2006-06-30|July 2007|2007-07-31|December 2006||2006-12-31|||||Interventional|||Study To Evaluate the Safety of Bivalent Vaccine|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|Completed||Phase 3|300||MedImmune LLC|||||||||||||||||||2018-06-01 04:00:18.07067|2018-06-01 04:00:18.07067
NCT00325468|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2013-01-03||2017-07-03|2006-05-10|2006-05-12|Estimate|2013-07-23|2013-07-30|Estimate||||2017-07-03|2017-08-01|Actual|May 1, 2006|Actual|2006-05-01|July 2017|2017-07-31|August 2, 2012|Actual|2012-08-02|March 28, 2011|Actual|2011-03-28||Interventional|||An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density|An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 3|200|Actual|Amgen||1|||f||||f||||||||||2018-06-01 04:00:18.153592|2018-06-01 04:00:18.153592
NCT00325455|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2015-02-27|2006-05-11|2006-05-12|Estimate|||||||2015-02-27|2015-03-02|Estimate|June 2006||2006-06-30|February 2015|2015-02-28|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||MK0859 Dose-Ranging Study (0859-003)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of MK-0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|Terminated||Phase 2|500|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:00:20.751585|2018-06-01 04:00:20.751585
NCT00325442|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|2013-01-18||2017-07-31|2006-05-11|2006-05-12|Estimate|2013-05-06|2013-06-10|Estimate||||2017-07-31|2017-08-02|Actual|October 2006||2006-10-31|July 2017|2017-07-31|December 2010|Actual|2010-12-31|September 2008|Actual|2008-09-30||Interventional|||FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)|A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 3|354|Actual|United Therapeutics||2|||f||||||||||||||2018-06-01 04:00:20.883235|2018-06-01 04:00:20.883235
NCT00325429|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2009-01-06|2006-05-10|2006-05-12|Estimate|||||||2009-01-06|2009-01-07|Estimate|April 2006||2006-04-30|January 2009|2009-01-31||||||||Interventional|||Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes|A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes|Completed||Phase 3|150||Novartis|||||f||||||||||||||2018-06-01 04:00:22.104217|2018-06-01 04:00:22.104217
NCT00325416|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|2014-03-17||2018-02-14|2006-05-11|2006-05-12|Estimate|2014-04-22|2014-05-23|Estimate||||2018-02-14|2018-03-14|Actual|November 19, 2001|Actual|2001-11-19|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|July 15, 2013|Actual|2013-07-15||Interventional||Participants: 177 included in Baseline; 129 included in Phase I Maximum Tolerated Dose Outcome; 51 Phase II participants with responsive disease prior to transplant were re-evaluated for the Overall Response Rate; 79 treated in Phase II and evaluable at time of analysis are included in the Event Free Survival and Overall Survival Outcome Measures.|Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.|A Study of Intensive-Dose Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.|Completed||Phase 1/Phase 2|177|Actual|H. Lee Moffitt Cancer Center and Research Institute|Data on presence of chromosomal abnormalities at time of diagnosis were not available for majority of patients. The cancer center will continue to collect information about the participant's disease and its treatment for the rest of their life.|2|||f||||t||||||||||2018-06-01 04:00:22.200431|2018-06-01 04:00:22.200431
NCT00325403|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|2013-01-03||2013-02-12|2006-05-11|2006-05-12|Estimate|2013-02-12|2013-03-18|Estimate||||2013-02-12|2013-03-18|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)|A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 3|349|Actual|United Therapeutics||2|||f||||t||||||||||2018-06-01 04:00:22.832125|2018-06-01 04:00:22.832125
NCT00325390|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2009-03-24|2006-05-11|2006-05-12|Estimate|||||||2009-03-24|2009-03-25|Estimate|July 2004||2004-07-31|March 2009|2009-03-31||||||||Interventional|||Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation|Double-Blind Parallel Comparison Study of SR25990C Versus Standard Therapy in Japan(Ticlopidine) in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Who Are Planned for Percutaneous Coronary Intervention|Completed||Phase 3|800||Sanofi|||||f||||||||||||||2018-06-01 04:00:23.767601|2018-06-01 04:00:23.767601
NCT00325377|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2007-07-08|2006-05-11|2006-05-12|Estimate|||||||2007-07-08|2007-07-10|Estimate|April 2006||2006-04-30|July 2007|2007-07-31|January 2008|Anticipated|2008-01-31|||||Interventional|||The Effects of the MME Procedure on Chronic Low Back Pain|A Randomized Sham-Controlled Clinical Study to Evaluate the Effects of the Magnetic Molecular Energizer (MME)on Chronic Low Back Pain|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Advanced Magnetic Research Institute International|||||f||||f||||||||||2018-06-01 04:00:23.825646|2018-06-01 04:00:23.825646
NCT00325364|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10||2018-03-07|2018-03-07|2006-05-10|2006-05-12|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|April 2006||2006-04-30|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes|A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Insulin-Naive Patients With Type 2 Diabetes Mellitus.|Completed||Phase 3|415|Actual|Eli Lilly and Company||2|||f||||||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 04:00:23.918257|2018-06-01 04:00:23.918257
NCT00325351|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2014-10-31|2006-05-11|2006-05-12|Estimate|||||||2014-10-31|2014-11-03|Estimate|August 2006||2006-08-31|October 2014|2014-10-31|March 2009|Actual|2009-03-31|July 2008|Actual|2008-07-31||Interventional|||ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer|Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer|Completed||Phase 2|45|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:00:24.108121|2018-06-01 04:00:24.108121
NCT00325338|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2010-06-16|2006-05-11|2006-05-12|Estimate|||||||2010-06-16|2010-06-17|Estimate|May 2006||2006-05-31|June 2010|2010-06-30|July 2006||2006-07-31|||||Interventional|||Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis|Follow-up Study to Evaluate the Sustained Clinical Efficacy of Ragweed MATA MPL (Allergy Therapeutics®) in Patients With Ragweed-induced Seasonal Allergic Rhinitis Upon Re-exposure to Ragweed Pollen in an Environmental Exposure Chamber (EEC) Model, Approximately One Year After Pre-seasonal Treatment in 2005|Completed||Phase 2|100||Allergy Therapeutics|||||f||||||||||||||2018-06-01 04:00:24.237195|2018-06-01 04:00:24.237195
NCT00325325|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2006-10-25|2006-05-11|2006-05-12|Estimate|||||||2006-10-25|2006-10-26|Estimate|January 2006||2006-01-31|May 2006|2006-05-31|June 2007||2007-06-30|||||Interventional|||Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus|A Pilot Study to Investigate Pharmacokinetic Characteristics of Everolimus in Patients Treated With Tacrolimus-Based Immunosuppression in De Novo Kidney Transplantation|Unknown status|Recruiting|Phase 2|40||Hospital Universitario Ramon y Cajal|||||f||||||||||||||2018-06-01 04:00:24.302943|2018-06-01 04:00:24.302943
NCT00325312|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2006-05-12|2006-05-11|2006-05-12|Estimate|||||||2006-05-12|2006-05-15|Estimate|January 2001||2001-01-31|May 2006|2006-05-31|March 2003||2003-03-31|||||Interventional|||Subcutaneous Carbon Dioxide Insufflations for Acute Non Specific Neck Pain|Evaluation of the Efficacy of Subcutaneous Carbon Dioxide Insufflations for Treating Acute Non Specific Neck Pain in General Practice|Completed||Phase 2|114||Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster|||||f||||||||||||||2018-06-01 04:00:24.368469|2018-06-01 04:00:24.368469
NCT00325299|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2006-05-11|2006-05-11|2006-05-12|Estimate|||||||2006-05-11|2006-05-12|Estimate||||May 2006|2006-05-31|September 2005||2005-09-30|||||Interventional|||Magnesium After Alcohol Withdrawal Treatment|Magnesium After Alcohol Withdrawal Treatment|Completed||Phase 4|178||Finnish Foundation for Alcohol Studies|||||f||||||||||||||2018-06-01 04:00:24.428452|2018-06-01 04:00:24.428452
NCT00325286|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2007-12-13|2006-05-10|2006-05-12|Estimate|||||||2007-12-13|2007-12-14|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder|Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|Creighton University||1|||f||||f||||||||||2018-06-01 04:00:24.487506|2018-06-01 04:00:24.487506
NCT00325273|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2015-03-16|2006-05-11|2006-05-12|Estimate|||||||2015-03-16|2015-03-17|Estimate|April 2005||2005-04-30|June 2011|2011-06-30|April 2010|Actual|2010-04-30|April 2008|Actual|2008-04-30||Interventional|||Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonatal Period|Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonate|Completed||Phase 3|180|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-06-01 04:00:24.593307|2018-06-01 04:00:24.593307
NCT00325260|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2006-10-31|2006-05-11|2006-05-12|Estimate|||||||2006-10-31|2006-11-01|Estimate|March 2006||2006-03-31|October 2006|2006-10-31||||||||Interventional|||Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China|A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China.|Completed||Phase 3|900||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:00:24.670501|2018-06-01 04:00:24.670501
NCT00325247|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2011-07-11|2006-05-11|2006-05-12|Estimate|||||||2011-07-11|2011-07-12|Estimate|February 2005||2005-02-28|May 2006|2006-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Efficacy of Zinc Therapy in Acute Diarrhoea in Young Children|Efficacy of Short Course Zinc Therapy (5 vs 10 d) With 20 mg Elemental Zinc Daily in the Treatment of Acute Diarrhoea: A Double-blind Individually Randomized Controlled Community Trial.|Completed||Phase 3|2050|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:00:24.731924|2018-06-01 04:00:24.731924
NCT00325234|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2011-04-26||2011-04-26|2006-05-10|2006-05-12|Estimate|2011-04-26|2011-05-20|Estimate||||2011-04-26|2011-05-20|Estimate|June 2006||2006-06-30|April 2011|2011-04-30|August 2010|Actual|2010-08-31|April 2010|Actual|2010-04-30||Interventional|||Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer|A Randomized Phase II Study of Two Chemotherapy Regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxanes Pretreated Advanced Breast Cancer Patients|Completed||Phase 2|135|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:00:24.958505|2018-06-01 04:00:24.958505
NCT00325221|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2013-01-30|2006-05-11|2006-05-12|Estimate|||||||2013-01-30|2013-01-31|Estimate|August 2006||2006-08-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|January 2012|Actual|2012-01-31||Interventional|||Psychosomatic Effects of Implantable Cardioverter Defibrillator With Home Monitoring Function (QUANTUM)|QUANTUM - Quality-of-Life, Anxiety and Depression in ICD Patients Using Home Monitoring|Completed||N/A|148|Actual|Biotronik SE & Co. KG||2|||f||||f||||||||||2018-06-01 04:00:25.702178|2018-06-01 04:00:25.702178
NCT00325208|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2006-12-22|2006-05-11|2006-05-12|Estimate|||||||2006-12-22|2006-12-25|Estimate||||December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Feeding Bottle Design, Milk Intake and Infant Growth||Unknown status|Recruiting|N/A|152||Institute of Child Health|||||f||||||||||||||2018-06-01 04:00:25.836261|2018-06-01 04:00:25.836261
NCT00325195|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2010-10-13||2011-02-24|2006-05-10|2006-05-12|Estimate|2011-02-01|2011-02-25|Estimate||||2011-02-24|2011-02-28|Estimate|May 2006||2006-05-31|February 2011|2011-02-28|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout|Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout|Completed||Phase 3|225|Actual|Savient Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:00:25.923504|2018-06-01 04:00:25.923504
NCT00325182|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2017-03-13|2006-05-11|2006-05-12|Estimate|||||||2017-03-13|2017-03-15|Actual|January 2006|Actual|2006-01-31|April 2007|2007-04-30|October 2009|Actual|2009-10-31|January 2007|Actual|2007-01-31||Interventional|||The Effects of Levetiracetam on Alcohol Dependent Subjects|The Effects of Levetiracetam on Alcohol Dependent Subjects|Completed||Phase 4|40|Actual|Boston University||2|||f||||||||||||No||2018-06-01 04:00:26.780219|2018-06-01 04:00:26.780219
NCT00325169|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2016-10-19|2006-05-10|2006-05-12|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2005||2005-12-31|October 2016|2016-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||SERETIDE Plus Tiotropium Versus Individual Components|A Randomised, Double-blind, Double Dummy, 3 Way Crossover Study Evaluating the Effects of a Combination of Seretide 50/500mcg Twice Daily Plus Tiotropium Bromide 18mcg Once Daily Compared With the Individual Agents (Tiotropium Bromide 18mcg Alone and Seretide50/500mcg Alone) in the Treatment of Subjects With COPD|Completed||Phase 2|41|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:00:26.863219|2018-06-01 04:00:26.863219
NCT00325156|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2016-12-14||2016-12-14|2006-05-11|2006-05-12|Estimate|2016-12-14|2017-02-07|Estimate||||2016-12-14|2017-02-07|Estimate|November 2004||2004-11-30|November 2016|2016-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants|An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants.|Completed||Phase 4|2590|Actual|GlaxoSmithKline|None reported.|1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:00:26.960456|2018-06-01 04:00:26.960456
NCT00325143|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2016-12-13||2017-02-16|2006-05-11|2006-05-12|Estimate|2016-12-13|2017-02-07|Estimate||||2017-02-16|2017-03-21|Actual|December 2003||2003-12-31|February 2017|2017-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine|Assess Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Admnd at 3 & 4 Mths & DTPa-HBV-IPV/Hib Vaccine Admnd at 5 Mths, Followed by DTPa-IPV/Hib Vaccine at 18 Mths in Infants Who Received hepatitisB Vaccine at Birth & at One Month of Age|Completed||Phase 3|702|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:00:27.403286|2018-06-01 04:00:27.403286
NCT00325130|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|2009-05-19||2015-02-23|2006-05-11|2006-05-12|Estimate|2009-05-19|2009-07-13|Estimate||||2015-02-23|2015-03-12|Estimate|April 2006||2006-04-30|February 2015|2015-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)|An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V501 Given Concomitantly With Menactra™ and ADACEL™ in Healthy Adolescents 11-17 Years of Age|Completed||Phase 3|1042|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:00:27.739811|2018-06-01 04:00:27.739811
NCT00325117|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2007-05-10|2006-05-10|2006-05-12|Estimate|||||||2007-05-10|2007-05-14|Estimate|April 2006||2006-04-30|May 2007|2007-05-31||||||||Interventional|||To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin to Placebo as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy|Completed||Phase 3|200||Novartis|||||f||||||||||||||2018-06-01 04:00:28.439108|2018-06-01 04:00:28.439108
NCT00325078|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|2014-03-18||2015-11-19|2006-05-11|2006-05-12|Estimate|2015-11-19|2015-12-29|Estimate||||2015-11-19|2015-12-29|Estimate|May 2006||2006-05-31|November 2015|2015-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease|Tumor Necrosis Factor Alpha Inhibitor (Lnfliximab, Adalimumab) Treatment for Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences|Terminated||Phase 1/Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)|Due to limited subject participation and lack of sustained clinical benefits (1 year), there is insufficient complete data to generate meaningful statistics for the outcome measures. Instead, this data are reported as a case series.|2||Insufficient patient participation|f||||t||||||||||2018-06-01 04:00:28.641353|2018-06-01 04:00:28.641353
NCT00325065|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-11|||2017-06-30|2006-05-11|2006-05-12|Estimate|||||||2017-06-30|2017-07-02|Actual|May 5, 2006||2006-05-05|April 16, 2010|2010-04-16|April 16, 2010||2010-04-16|||||Observational|||Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders|Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders|Completed|||71|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:00:29.087264|2018-06-01 04:00:29.087264
NCT00325039|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2012-03-26||2013-12-12|2006-05-10|2006-05-11|Estimate|2012-08-27|2012-09-27|Estimate||||2013-12-12|2014-01-14|Estimate|April 2006||2006-04-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2010|Actual|2010-06-30||Interventional|TOMUS||TOMUS-Trial Of Mid-Urethral Slings|TOMUS-Trial Of Mid-Urethral Slings|Completed||Phase 4|597|Actual|New England Research Institutes||2|||f||||t||||||||||2018-06-01 04:00:29.168501|2018-06-01 04:00:29.168501
NCT00325026|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2012-03-01|2006-05-10|2006-05-11|Estimate|||||||2012-03-01|2012-03-02|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation|Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation|Completed||Phase 2|130|Actual|University of Florida|||||||||||||||||||2018-06-01 04:00:29.530182|2018-06-01 04:00:29.530182
NCT00325013|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2015-03-10|2006-05-10|2006-05-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Evaluation of DHA for the Treatment of PSC|Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC)|Completed||Phase 1|10|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-06-01 04:00:29.610868|2018-06-01 04:00:29.610868
NCT00325000|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2006-12-19|2006-05-09|2006-05-11|Estimate|||||||2006-12-19|2006-12-20|Estimate|November 2000||2000-11-30|October 2000|2000-10-31|August 2004||2004-08-31|||||Interventional|||Interpersonal Psychotherapy for Severely Depressed Inpatients|An Intensive Treatment Program of Interpersonal Psychotherapy Plus Pharmacotherapy for Severely Depressed Inpatients|Terminated||N/A|||German Research Foundation|||||f||||||||||||||2018-06-01 04:00:29.68152|2018-06-01 04:00:29.68152
NCT00324987|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2017-05-10||2017-08-15|2006-05-10|2006-05-11|Estimate|2017-08-15|2017-09-14|Actual||||2017-08-15|2017-09-14|Actual|April 2008||2008-04-30|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|S0502||Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor|A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors|Terminated||Phase 3|12|Actual|National Cancer Institute (NCI)|Trial was terminated due to poor accrual. No conclusions should be drawn from the reported data due to the small sample size.|2||The trial failed to accrue|f||||t||||||||||2018-06-01 04:00:29.773051|2018-06-01 04:00:29.773051
NCT00324974|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2010-07-20|2006-05-09|2006-05-11|Estimate|||||||2010-07-20|2010-07-22|Estimate|June 2006||2006-06-30|July 2010|2010-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux|A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux|Completed||Phase 3|162|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:00:30.611629|2018-06-01 04:00:30.611629
NCT00324961|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2009-08-27||2009-10-26|2006-05-09|2006-05-11|Estimate|2009-08-27|2009-10-02|Estimate||||2009-10-26|2009-10-28|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B|A 2-year Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B|Completed||Phase 4|533|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:00:30.745852|2018-06-01 04:00:30.745852
NCT00324948|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2009-03-09|2006-05-09|2006-05-11|Estimate|||||||2009-03-09|2009-03-10|Estimate|September 2004||2004-09-30|March 2009|2009-03-31|November 2006|Actual|2006-11-30|August 2006|Actual|2006-08-31||Interventional|||Topical Alprostadil for Female Sexual Arousal Disorder|A Double-Blind, Randomized, 6-Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women With Female Sexual Arousal Disorder (FSAD)|Completed||Phase 2|300||VIVUS, Inc.|||||||||||||||||||2018-06-01 04:00:31.127472|2018-06-01 04:00:31.127472
NCT00324922|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2009-07-27|2006-05-09|2006-05-11|Estimate|||||||2009-07-27|2009-07-29|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus (MRSA) Osteomyelitis (VOTSMO)|A Prospective, Randomized Trial Comparing Vancomycin With Trimethoprim/Sulfamethoxazole for the Treatment of MRSA Osteomyelitis|Unknown status|Active, not recruiting|N/A|300|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 04:00:31.244046|2018-06-01 04:00:31.244046
NCT00324909|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2007-04-09|2006-05-09|2006-05-11|Estimate|||||||2007-04-09|2007-04-10|Estimate||||April 2007|2007-04-30||||||||Interventional|||Effects of Hyperbaric Oxygen Therapy in Autistic Children: A Pilot Study|Effects of Hyperbaric Oxygen Therapy on Clinical Symptoms and Markers of Inflammation and Oxidative Stress in Autistic Children: A Pilot Study|Completed||N/A|18||International Hyperbarics Association|||||f||||||||||||||2018-06-01 04:00:31.364257|2018-06-01 04:00:31.364257
NCT00324896|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2013-01-23|2009-11-06|2013-04-24|2006-05-09|2006-05-11|Estimate|2013-04-24|2013-05-31|Estimate|2012-01-26|2012-01-30|Estimate|2013-04-24|2013-05-31|Estimate|May 2006||2006-05-31|April 2013|2013-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone|Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone|Completed||Phase 3|30|Actual|Rutgers, The State University of New Jersey|This was only a 6-week trial with small group of participants.|2|||f||||f||||||||||2018-06-01 04:00:31.453437|2018-06-01 04:00:31.453437
NCT00324883|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2013-07-08|2006-05-09|2006-05-11|Estimate|||||||2013-07-08|2013-07-09|Estimate|March 2006||2006-03-31|July 2013|2013-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Urine Chloride/Creatinine Ratio for Estimation of Urine Sodium|Urine Chloride/Creatinine Ratio for Estimation of Urine Sodium|Completed|||81|Actual|Weill Medical College of Cornell University|||||f||||f||||||Samples Without DNA|"~     urine~   "|||2018-06-01 04:00:31.777101|2018-06-01 04:00:31.777101
NCT00324870|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2015-08-10||2015-12-10|2006-05-10|2006-05-11|Estimate|2015-08-10|2015-09-09|Estimate||||2015-12-10|2016-01-13|Estimate|February 2006||2006-02-28|October 2013|2013-10-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer|Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With the VEGF Inhibitor Bevacizumab in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:00:31.873988|2018-06-01 04:00:31.873988
NCT00324857|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2014-12-18||2015-12-15|2006-05-09|2006-05-11|Estimate|2015-12-15|2016-01-22|Estimate||||2015-12-15|2016-01-22|Estimate|September 2006||2006-09-30|December 2015|2015-12-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Educational Intervention for Knee Pain|Knee Replacement Disparity: A Randomized, Controlled Intervention|Completed||N/A|663|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 04:00:32.134803|2018-06-01 04:00:32.134803
NCT00324831|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2013-12-17|2006-05-10|2006-05-11|Estimate|||||||2013-12-17|2013-12-18|Estimate||||March 2007|2007-03-31||||||||Interventional|||GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|Phase III, Double-Blind, Randomized, Placebo-Controlled Trial of FavID® (Id/KLH) and GM-CSF Following CHOP/Rituximab as First-Line Therapy in Subjects With High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma|Suspended||Phase 3|480|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:00:32.533341|2018-06-01 04:00:32.533341
NCT00324818|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2017-02-27|2006-05-09|2006-05-11|Estimate|||||||2017-02-27|2017-03-01|Actual|July 2002||2002-07-31|February 2017|2017-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Treatment of Bacterial Vaginosis|Therapy and Prevention for Sexually Associated Bacterial Vaginosis|Completed||Phase 4|600||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 04:00:32.670657|2018-06-01 04:00:32.670657
NCT00324805|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2018-01-12||2018-02-12|2006-05-10|2006-05-11|Estimate|2018-02-12|2018-02-14|Actual||||2018-02-12|2018-02-14|Actual|June 1, 2007|Actual|2007-06-01|February 2018|2018-02-28|October 16, 2023|Anticipated|2023-10-16|October 20, 2015|Actual|2015-10-20||Interventional||All randomized patients|Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer|A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|1501|Actual|National Cancer Institute (NCI)||2|||f||||t|t|f||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 04:00:33.103183|2018-06-01 04:00:33.103183
NCT00324792|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2008-06-11|2006-05-10|2006-05-11|Estimate|||||||2008-06-11|2008-06-13|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|October 2007|Actual|2007-10-31|||||Interventional|||I3LTE4: Intensive Insulin Therapy and Production of LTE4 in Patients With Diabetes|Effect of an Intensive Insulin Therapy on the Production of LTE4 in Patients With Diabetes|Completed||N/A|45|Anticipated|University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:00:36.882022|2018-06-01 04:00:36.882022
NCT00324779|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2015-09-24|2006-05-10|2006-05-11|Estimate|||||||2015-09-24|2015-09-25|Estimate|March 2004||2004-03-31|September 2015|2015-09-30||||April 2011|Actual|2011-04-30||Interventional|||Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia|Multicenter Therapy Study for Children With Mature B-NHL or B-ALL With a Rituximab - Window Before Chemotherapy|Completed||Phase 2|79|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:00:36.999194|2018-06-01 04:00:36.999194
NCT00324766|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2012-06-25|2006-05-10|2006-05-11|Estimate|||||||2012-06-25|2012-06-26|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.|Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.|Completed||Phase 4|61|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 04:00:37.162852|2018-06-01 04:00:37.162852
NCT00324753|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2015-04-24|2006-05-09|2006-05-11|Estimate|||||||2015-04-24|2015-04-27|Estimate|April 2007||2007-04-30|April 2015|2015-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Quality Improvement of Patient-Provider Communication For Colorectal Cancer Screening|Improving Patient-Provider Communication For Colorectal Cancer Screening|Completed||N/A|450|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:00:37.246226|2018-06-01 04:00:37.246226
NCT00324740|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2015-07-20||2015-10-22|2006-05-10|2006-05-11|Estimate|2015-10-22|2015-11-24|Estimate||||2015-10-22|2015-11-24|Estimate|March 2006||2006-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|February 2011|Actual|2011-02-28||Interventional|||Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer|A Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination With Isotretinoin (13-cis Retinoic Acid, 13-CRA) in the Treatment of Patients With Advanced Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:00:37.352551|2018-06-01 04:00:37.352551
NCT00324727|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2013-10-22|2006-05-10|2006-05-11|Estimate|||||||2013-10-22|2013-10-23|Estimate|February 2006||2006-02-28|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma|A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver|Completed||Phase 3|93|Actual|Delcath Systems Inc.||2|||f||||||||||||||2018-06-01 04:00:37.611219|2018-06-01 04:00:37.611219
NCT00324714|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2012-11-28|2006-05-10|2006-05-11|Estimate|||||||2012-11-28|2012-11-29|Estimate|February 2003||2003-02-28|November 2012|2012-11-30||||||||Interventional|||Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS|A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women|Withdrawn||Phase 3|0|Actual|International Breast Cancer Study Group|||||f||||||||||||||2018-06-01 04:00:37.759937|2018-06-01 04:00:37.759937
NCT00322933|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2006-10-25|2006-05-05|2006-05-08|Estimate|||||||2006-10-25|2006-10-26|Estimate|April 2001||2001-04-30|April 2005|2005-04-30|March 2005||2005-03-31|||||Observational|||Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure|Multicentre Randomised Trial of Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure|Terminated|||1628||Ziekenhuis Netwerk Antwerpen (ZNA)|||||f||||||||||||||2018-06-01 04:01:07.950029|2018-06-01 04:01:07.950029
NCT00324701|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2014-11-06||2015-04-06|2006-05-09|2006-05-11|Estimate|2014-11-24|2014-11-26|Estimate||||2015-04-06|2015-04-24|Estimate|September 2006||2006-09-30|September 2014|2014-09-30|October 2012|Actual|2012-10-31|July 2011|Actual|2011-07-31||Interventional||Older adult Veterans (age 60 or older) presenting for services at VA primary care clinics and meeting DSM-IV criteria for major depressive disorder.|Telepsychology-Service Delivery for Depressed Elderly Veterans|Telepsychology-Service Delivery for Depressed Elderly Veterans|Completed||N/A|241|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:00:37.911577|2018-06-01 04:00:37.911577
NCT00324688|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2014-03-11|2006-05-10|2006-05-11|Estimate|||||||2014-03-11|2014-03-12|Estimate|March 2003||2003-03-31|March 2014|2014-03-31|June 2006||2006-06-30|||||Interventional|3OD||Safety Study of Once a Day ART and Opiate Substitute.|Open-label Multicenter Study to Assess the Efficacy, the Tolerability and the Adherence of a Once Daily (QD) Taken Antiretroviral Therapy (ART) Containing the NtRTI Tenofovir DF 300 mg in Combination With the Best Suitable Once a Day Regimen Being 1 NRTI Plus 1 PI or 1 NRTI Plus 1 NNRTI in HIV-1-infected IVDU- Patients With Opiate Substitution Being Either Antiretroviral-naive or With Suppressed Viral Load and Without a History of Virological Failure|Completed||Phase 4|60||Gilead Sciences|||||f||||f||||||||||2018-06-01 04:00:38.242746|2018-06-01 04:00:38.242746
NCT00324675|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2011-09-15||2011-10-27|2006-05-09|2006-05-11|Estimate|2011-09-15|2011-10-21|Estimate||||2011-10-27|2011-11-02|Estimate|August 2006||2006-08-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy|Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy|Completed||N/A|28|Actual|Technische Universität Dresden||2|||f||||t||||||||||2018-06-01 04:00:38.331445|2018-06-01 04:00:38.331445
NCT00324662|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2008-09-29|2006-05-10|2006-05-11|Estimate|||||||2008-09-29|2008-09-30|Estimate|August 2003||2003-08-31|September 2008|2008-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study to Verify Proper Detection of Supraventricular Tachyarrhythmia With Single-Lead Dual-Chamber Implantable Cardioverter-Defibrillators (ADRIA)|ADRIA - Belos A+ vs DR Clinical Investigation of Arrhythmia Discrimination|Completed||Phase 4|260|Anticipated|Biotronik SE & Co. KG|||||f||||||||||||||2018-06-01 04:00:38.564912|2018-06-01 04:00:38.564912
NCT00324649|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2009-03-30||2015-08-13|2006-05-09|2006-05-11|Estimate|2009-03-30|2009-05-20|Estimate||||2015-08-13|2015-08-17|Estimate|May 2006||2006-05-31|August 2015|2015-08-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|RECOMB||Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada|Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study).|Completed||Phase 4|80|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 04:00:38.693721|2018-06-01 04:00:38.693721
NCT00324623|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2012-11-19|2006-05-10|2006-05-11|Estimate|||||||2012-11-19|2012-11-20|Estimate|September 2005||2005-09-30|November 2012|2012-11-30||||November 2011|Actual|2011-11-30||Interventional|||Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma|Phase I Study of In Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma|Completed||Phase 1|8|Actual|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||||2018-06-01 04:00:39.356473|2018-06-01 04:00:39.356473
NCT00324610|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2006-05-16|2006-05-09|2006-05-11|Estimate|||||||2006-05-16|2006-05-18|Estimate|March 2006||2006-03-31|May 2006|2006-05-31||||||||Interventional|||Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen|Phase I/II Study of Tolerance and Pharmacokinetics With Capecitabine Given 5 Days Out of 7 in Metastatic Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|46||Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|||||f||||||||||||||2018-06-01 04:00:39.435235|2018-06-01 04:00:39.435235
NCT00324597|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2013-09-16|2006-05-10|2006-05-11|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 2005||2005-10-31|April 2007|2007-04-30||||||||Interventional|||AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase Ib, Open-Label, Sequential, Dose-Finding, Study of AMG 706 in Combination With Gemcitabine to Treat Subjects With Solid Tumors|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:00:39.501513|2018-06-01 04:00:39.501513
NCT00324584|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2006-07-04|2006-05-10|2006-05-11|Estimate|||||||2006-07-04|2006-07-07|Estimate|April 2003||2003-04-30|July 2006|2006-07-31|September 2004||2004-09-30|||||Interventional|||Web-Based Follow-Up Using Cellular Phone in Type 1 Diabetic Patients Under Insulin Pump Therapy : The PumpNet Study|Surveillance Des données De l’Autosurveillance glycémique Via Internet Et Le réseau téléphonique GSM Chez Le diabétique De Type 1 Sous Traitement Insulinique Par Pompe Externe : Etude Prospective randomisée PumpNet.|Completed||Phase 3|40||University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:00:39.578901|2018-06-01 04:00:39.578901
NCT00324571|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2015-03-17|2006-05-09|2006-05-11|Estimate|||||||2015-03-17|2015-03-18|Estimate|March 2001||2001-03-31|March 2015|2015-03-31|February 2006||2006-02-28|||||Interventional|||Dialysis Clinical Outcomes Revisited (DCOR) Trial|A Randomized, Open Label, Parallel Design Study of Renagel® Phosphate Binder Versus Calcium-Based Phosphate Binders in Hemodialysis Patients|Completed||Phase 4|2000||Sanofi|||||||||||||||||||2018-06-01 04:00:39.642352|2018-06-01 04:00:39.642352
NCT00324558|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2012-06-07|2006-05-09|2006-05-11|Estimate|||||||2012-06-07|2012-06-08|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|September 2010|Actual|2010-09-30|February 2010|Actual|2010-02-28||Interventional|||Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)|Multicenter, Randomized, Open and Sequential Study to Evaluate the Efficacy and Safety of Bemiparin Administration on the Response to Treatment in Patients Diagnosed With Limited Small Cell Lung Cancer|Terminated||Phase 2|39|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2||Sponsor stopped due to difficulties to recruit 130 patients required by protocol|f||||f||||||||||2018-06-01 04:00:39.942005|2018-06-01 04:00:39.942005
NCT00324545|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2006-05-09|2006-05-09|2006-05-11|Estimate|||||||2006-05-09|2006-05-11|Estimate|January 2000||2000-01-31|May 2006|2006-05-31|December 2002||2002-12-31|||||Interventional|||Cardiovascular Outcomes Of Diet Counseling|Long-Term Adherence and Cardiovascular Outcomes of a Randomized Controlled Trial of Medium-Intensity Minimally-Directive Counseling for Different Diets|Completed||Phase 2|120||The Camelot Foundation|||||f||||||||||||||2018-06-01 04:00:40.042101|2018-06-01 04:00:40.042101
NCT00324532|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2015-01-26|2006-05-09|2006-05-11|Estimate|||||||2015-01-26|2015-01-27|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|May 2007|Actual|2007-05-31|||||Interventional|||to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD|An Open Label, Non Comparative, Prospective Pilot Study, to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD|Completed||Phase 3|60|Anticipated|BioBalance Corporation|||||f||||||||||||||2018-06-01 04:00:40.119657|2018-06-01 04:00:40.119657
NCT00324519|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2012-03-01|2006-05-10|2006-05-11|Estimate|||||||2012-03-01|2012-03-05|Estimate|February 2005||2005-02-28|March 2012|2012-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester|Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester|Completed||Phase 4|30|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 04:00:40.184607|2018-06-01 04:00:40.184607
NCT00324506|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2013-06-17|2006-05-09|2006-05-11|Estimate|||||||2013-06-17|2013-06-19|Estimate|May 2006||2006-05-31|June 2013|2013-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis|A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis|Completed||Phase 2|43|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 04:00:40.271091|2018-06-01 04:00:40.271091
NCT00324493|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2006-11-29|2006-05-09|2006-05-11|Estimate|||||||2006-11-29|2006-11-30|Estimate|June 2004||2004-06-30|June 2005|2005-06-30|June 2009||2009-06-30|||||Observational|||Musculoskeletal Function in Hemophilia|Musculoskeletal Function in Hemophilia in Developing Countries|Unknown status|Active, not recruiting||250||Christian Medical College, Vellore, India|||||f||||||||||||||2018-06-01 04:00:40.353478|2018-06-01 04:00:40.353478
NCT00324480|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2014-02-21|2006-05-10|2006-05-11|Estimate|||||||2014-02-21|2014-02-24|Estimate|March 2006||2006-03-31|October 2011|2011-10-31||||April 2009|Actual|2009-04-30||Interventional|||Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Flavopiridol in Advanced Solid Tumors|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:00:40.412496|2018-06-01 04:00:40.412496
NCT00324467|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2017-11-24|2006-05-09|2006-05-11|Estimate|||||||2017-11-24|2017-11-28|Actual|August 2006||2006-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LYTPET||Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment|Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results|Active, not recruiting||Phase 2|150|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-06-01 04:00:40.508163|2018-06-01 04:00:40.508163
NCT00324454|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2013-06-17|2006-05-09|2006-05-11|Estimate|||||||2013-06-17|2013-06-19|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease|A Pilot Trial of Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease|Completed||Phase 2|20|Actual|Duke University|||||f||||f||||||||||2018-06-01 04:00:40.681228|2018-06-01 04:00:40.681228
NCT00324441|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2006-05-09|2006-05-09|2006-05-11|Estimate|||||||2006-05-09|2006-05-11|Estimate|January 2004||2004-01-31|August 2003|2003-08-31|July 2005||2005-07-31|||||Interventional|||Mild Water-Filtered Near Infrared Whole-Body-Hyperthermia as an Adjunct in the Treatment of Fibromyalgia|A Randomized Controlled Trial on the Effectiveness of Mild Water-Filtered Near Infrared Hyperthermia as an Adjunct to a Standard Multimodal Rehabilitation in the Treatment of Fibromyalgia|Completed||Phase 2|132||Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster|||||f||||||||||||||2018-06-01 04:00:40.761084|2018-06-01 04:00:40.761084
NCT00324428|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2017-03-17|2006-05-10|2006-05-11|Estimate|||||||2017-03-17|2017-03-21|Actual|May 2006|Actual|2006-05-31|March 2017|2017-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||TMS for the Treatment of Pancreatic Cancer Pain|The Effect of a 10-day Course of Transcranial Magnetic Stimulation on Abdominal Pain in Patients With Locally Advanced and Advanced Pancreatic Cancer, a Randomized Phase II Study.|Completed||N/A|3|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-06-01 04:00:40.827716|2018-06-01 04:00:40.827716
NCT00324415|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2015-07-22||2018-02-05|2006-05-10|2006-05-11|Estimate|2015-08-17|2015-09-17|Estimate||||2018-02-05|2018-03-06|Actual|September 2006||2006-09-30|January 2018|2018-01-31|May 2016|Actual|2016-05-31|April 2014|Actual|2014-04-30||Interventional|||Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer|Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma|Completed||Phase 2|45|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 04:00:40.927578|2018-06-01 04:00:40.927578
NCT00324402|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2008-07-08|2006-05-10|2006-05-11|Estimate|||||||2008-07-08|2008-07-09|Estimate|August 2006||2006-08-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|||||Observational|||Plasma Brain Natriuretic Peptide Levels in Pregnancy|Plasma Brain Natriuretic Peptide Levels in Pregnancy|Completed|||50|Anticipated|Oklahoma State University Center for Health Sciences|||1||f||||f||||||||||2018-06-01 04:00:41.312945|2018-06-01 04:00:41.312945
NCT00324389|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2010-08-26|2006-05-09|2006-05-11|Estimate|||||||2010-08-26|2010-08-27|Estimate|May 2006||2006-05-31|April 2009|2009-04-30|June 2006||2006-06-30|||||Interventional|||Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes|A Pilot Study to Characterize Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes Using High Density Oligonucleotide Microarray Expression Analysis in Caucasian and African American Patients With Chronic Hepatitis C|Completed||Phase 2|2||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:00:41.420458|2018-06-01 04:00:41.420458
NCT00324376|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2015-03-04|2006-05-09|2006-05-11|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2003||2003-03-31|March 2015|2015-03-31|May 2004|Actual|2004-05-31|||||Interventional|||Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing|A Randomized, Cross-Over Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing|Completed||Phase 2|24||Sanofi|||||||||||||||||||2018-06-01 04:00:41.48958|2018-06-01 04:00:41.48958
NCT00324363|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2015-02-20|2006-05-10|2006-05-11|Estimate|||||||2015-02-20|2015-02-23|Estimate|January 2006||2006-01-31|January 2015|2015-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin|Completed||Phase 3|466|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:00:41.61187|2018-06-01 04:00:41.61187
NCT00324350|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|2012-03-15||2012-09-05|2006-05-10|2006-05-11|Estimate|2012-09-05|2012-10-05|Estimate||||2012-09-05|2012-10-05|Estimate|October 2003||2003-10-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|ACCORD-BONE||Intensive Glycemic Control and Skeletal Health Study|Intensive Glycemic Control and Skeletal Health Study - Ancillary Study to the Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD-BONE)|Completed||Phase 3|7287|Actual|University of California, San Francisco|The initial identification of a possible fracture event relied on self-report at annual visits with the possibility of under- or over-reporting of fractures.|2|||f||||t||||||||||2018-06-01 04:00:41.777995|2018-06-01 04:00:41.777995
NCT00324324|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2017-05-07|2006-05-10|2006-05-11|Estimate|||||||2017-05-07|2017-05-09|Actual|May 2006||2006-05-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|April 2007|Actual|2007-04-30||Interventional|||Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant|Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation|Terminated||Phase 3|240|Anticipated|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 04:00:42.260482|2018-06-01 04:00:42.260482
NCT00324311|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2011-05-08|2006-05-10|2006-05-11|Estimate|||||||2011-05-08|2011-05-10|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|||Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care|Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)|Completed||Phase 3|182|Actual|MediWound Ltd||2|||f||||t||||||||||2018-06-01 04:00:42.548065|2018-06-01 04:00:42.548065
NCT00324298|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2013-08-09|2006-05-10|2006-05-11|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2003||2003-07-31|January 2007|2007-01-31|March 2011|Actual|2011-03-31|||||Interventional|||Bleomycin, Etoposide, and Cisplatin in Treating Patients With Metastatic Germ Cell Cancer of the Testicles|A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3|Completed||Phase 3|210|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:00:42.850302|2018-06-01 04:00:42.850302
NCT00324285|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-10|||2017-11-25|2006-05-10|2006-05-11|Estimate|||||||2017-11-25|2017-11-28|Actual|July 2001||2001-07-31|May 2006|2006-05-31|June 30, 2005|Actual|2005-06-30|June 30, 2005|Actual|2005-06-30||Interventional|||Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children.|Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children With Watery Diarrhoea Due to Vibrio Cholerae|Completed||Phase 3|180||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:00:43.080568|2018-06-01 04:00:43.080568
NCT00324272|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2011-04-12||2011-07-18|2006-05-08|2006-05-10|Estimate|2011-07-18|2011-08-11|Estimate||||2011-07-18|2011-08-11|Estimate|January 2003||2003-01-31|May 2006|2006-05-31|June 2010|Actual|2010-06-30|December 2006|Actual|2006-12-31||Interventional|||Post-Operative Drainage Following Lymph Node Dissection|Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial.|Completed||Phase 4|74|Actual|Oxford University Hospitals NHS Trust||4|||f||||f||||||||||2018-06-01 04:00:43.216208|2018-06-01 04:00:43.216208
NCT00324259|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2014-10-08||2015-01-29|2006-05-08|2006-05-10|Estimate|2015-01-29|2015-02-16|Estimate||||2015-01-29|2015-02-16|Estimate|August 2004||2004-08-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|March 2011|Actual|2011-03-31||Interventional|||Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer|A Phase II Randomized Study of Physiological (6 mg Daily) and High Dose (30 mg Daily) Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer|Completed||Phase 2|66|Actual|Washington University School of Medicine|The slight imbalance in numbers assigned to the 2 groups was a because of yearly data and safety monitoring, which led to early closure of the 30mg group for toxicity concerns after 32 patients had been enrolled.|2|||f||||f||||||||||2018-06-01 04:00:44.154436|2018-06-01 04:00:44.154436
NCT00324246|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2008-06-19|2006-05-09|2006-05-10|Estimate|||||||2008-06-19|2008-06-20|Estimate|September 2006||2006-09-30|January 2007|2007-01-31|December 2007|Actual|2007-12-31|||||Observational|||Feasibility Study of the NEW NORMA-SENSE|Feasibility Study of the NEW NORMA-SENSE Indicator Strip and Vaginal Secretion Buffer Capacity Measurement - IN-VITRO Study.|Completed|||160|Actual|Carmel Medical Center|||||f||||t||||||None Retained|"~     Vaginal secretions.~   "|||2018-06-01 04:00:45.665363|2018-06-01 04:00:45.665363
NCT00324233|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2012-01-09||2012-11-29|2006-05-09|2006-05-10|Estimate|2012-11-29|2013-01-01|Estimate||||2012-11-29|2013-01-01|Estimate|April 2006||2006-04-30|November 2012|2012-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Evaluation of Residual Urine After Intermittent Catheterisation|Evaluation of Residual Urine After Intermittent Catheterisation - Comparison of 2 Hydrophilic Coated, Intermittent Catheters|Completed||N/A|36|Actual|Coloplast A/S||2|||f||||||||||||||2018-06-01 04:00:45.758688|2018-06-01 04:00:45.758688
NCT00324220|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08||2015-06-04|2015-06-04|2006-05-08|2006-05-10|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia|A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome or Acute Myelogenous Leukemia|Completed||Phase 1/Phase 2|66|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 04:00:46.123628|2018-06-01 04:00:46.123628
NCT00324207|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2010-03-03|2006-05-08|2006-05-10|Estimate|||||||2010-03-03|2010-03-05|Estimate|February 2006||2006-02-28|March 2010|2010-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Molecular Quantification of Insulin mRNA|Prediction of Type 1 Diabetes: Molecular Quantification of Insulin mRNA in the While Cell Fraction of Whole Blood|Completed|||400|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 04:00:46.245912|2018-06-01 04:00:46.245912
NCT00324194|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2015-01-06|2006-05-08|2006-05-10|Estimate|||||||2015-01-06|2015-01-08|Estimate|February 2005||2005-02-28|January 2015|2015-01-31|August 2008|Actual|2008-08-31|March 2008|Actual|2008-03-31||Interventional|||A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes|A Phase I Study of MGCD0103 Given as a Twice Weekly Oral Dose in Patients With Leukemia or Myelodysplastic Syndromes|Completed||Phase 1|25|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 04:00:46.328678|2018-06-01 04:00:46.328678
NCT00324181|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2009-08-03|2006-05-09|2006-05-10|Estimate|||||||2009-08-03|2009-08-04|Estimate|June 2006||2006-06-30|August 2009|2009-08-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Observational|||Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient|Psychopathology of Normal-tension Glaucoma in Hong Kong Chinese Out-patient|Unknown status|Active, not recruiting||100|Anticipated|Chinese University of Hong Kong|||||f||||t||||||||||2018-06-01 04:00:46.404063|2018-06-01 04:00:46.404063
NCT00324168|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2012-11-29||2013-12-12|2006-05-05|2006-05-10|Estimate|2013-04-10|2013-06-14|Estimate||||2013-12-12|2014-01-15|Estimate|September 2006||2006-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|February 2011|Actual|2011-02-28||Interventional|SCUT||Steroids for Corneal Ulcers Trial|Steroids for Corneal Ulcers Trial|Completed||Phase 4|500|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:00:46.484279|2018-06-01 04:00:46.484279
NCT00322920|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2008-02-13|2006-05-05|2006-05-08|Estimate|||||||2008-02-13|2008-02-15|Estimate|July 2005||2005-07-31|February 2008|2008-02-29||||||||Interventional|||Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer|A Phase I Study of Weekly Topotecan With Cisplatin for the Management of Advanced Stage or Recurrent Carcinoma of the Cervix|Terminated||Phase 1|30|Anticipated|University of Alabama at Birmingham||||Low accrual|f||||||||||||||2018-06-01 04:01:08.010466|2018-06-01 04:01:08.010466
NCT00324155|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2014-01-22|2011-01-29|2014-10-24|2006-05-09|2006-05-10|Estimate|2014-01-22|2014-03-10|Estimate|2011-06-17|2011-06-20|Estimate|2014-10-24|2014-11-03|Estimate|August 2006||2006-08-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|January 2011|Actual|2011-01-31||Interventional||Number of Randomized Participants|Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma|A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo|Completed||Phase 3|681|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 04:00:47.28027|2018-06-01 04:00:47.28027
NCT00324142|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2012-07-31|2006-05-09|2006-05-10|Estimate|||||||2012-07-31|2012-08-02|Estimate||||July 2012|2012-07-31||||||||Interventional|||A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis|A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis|Withdrawn||Phase 2|0|Actual|Kaiser Permanente||||Study Terminated Prematurely|f||||||||||||||2018-06-01 04:00:48.673515|2018-06-01 04:00:48.673515
NCT00324129|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2015-01-06|2006-05-08|2006-05-10|Estimate|||||||2015-01-06|2015-01-08|Estimate|February 2005||2005-02-28|January 2015|2015-01-31|December 2008|Actual|2008-12-31|July 2006|Actual|2006-07-31||Interventional|||A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes|A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose In Patients With Leukemia Or Myelodysplastic Syndromes|Completed||Phase 1|29|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 04:00:48.738436|2018-06-01 04:00:48.738436
NCT00324116|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2009-08-25||2010-03-15|2006-05-09|2006-05-10|Estimate|2009-10-01|2009-10-02|Estimate||||2010-03-15|2010-03-23|Estimate|July 2006||2006-07-31|March 2010|2010-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions|A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions|Completed||Phase 4|81|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:00:48.839991|2018-06-01 04:00:48.839991
NCT00324103|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2006-05-08|2006-05-08|2006-05-10|Estimate|||||||2006-05-08|2006-05-10|Estimate|June 2001||2001-06-30|October 2005|2005-10-31|June 2004||2004-06-30|||||Interventional|||Structured Treatment Interruptions in Chronic HIV Infection|Antiretroviral Treatment With Structured Treatment Interruptions (STI) Versus Continuous Antiretroviral Treatment in HIV+ Patients With Persistent Suppression of Viral Replication|Completed||Phase 3|600||Istituto Superiore di Sanità|||||f||||||||||||||2018-06-01 04:00:49.131966|2018-06-01 04:00:49.131966
NCT00324090|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2009-01-20|2006-05-09|2006-05-10|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2002||2002-03-31|February 2002|2002-02-28|July 2002||2002-07-31|||||Interventional|||Glycemic Index, Body Weight and Health|Glycemic Index, Body Weight and Health|Completed||N/A|43||University of Copenhagen|||||f||||||||||||||2018-06-01 04:00:49.188975|2018-06-01 04:00:49.188975
NCT00324077|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2016-02-16|2006-05-09|2006-05-10|Estimate|||||||2016-02-16|2016-02-17|Estimate|August 2006||2006-08-31|April 2011|2011-04-30||||February 2007|Actual|2007-02-28||Interventional|||Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase|A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||||Insufficient Enrollment|f||||||||||||||2018-06-01 04:00:49.243706|2018-06-01 04:00:49.243706
NCT00324064|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2010-03-03|2006-05-08|2006-05-10|Estimate|||||||2010-03-03|2010-03-05|Estimate|July 2007||2007-07-31|March 2010|2010-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing|Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing|Completed||N/A|90|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 04:00:49.302815|2018-06-01 04:00:49.302815
NCT00324051|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2016-11-21|2006-05-08|2006-05-10|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|PREFERENCE||Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet|PREFERENCE: 12-Week Open Label Trial On Olanzapine Orodispersible Tablet Vs. Oral Olanzapine Preference Study|Completed||Phase 4|284|Actual|Eli Lilly and Company|||||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 04:00:49.362797|2018-06-01 04:00:49.362797
NCT00324038|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|2009-07-17||2011-06-13|2006-05-09|2006-05-10|Estimate|2010-03-17|2010-03-30|Estimate||||2011-06-13|2011-06-14|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|December 2007|Actual|2007-12-31|||||Interventional|||Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly|An Open, Randomised, Multicentre Study to Compare Buprenorphine Transdermal Delivery System (BTDS) With Standard Treatment in Elderly Subjects With OA of the Hip and/or Knee|Completed||Phase 4|219|Actual|Napp Pharmaceuticals Limited||2|||f||||||||||||||2018-06-01 04:00:49.441091|2018-06-01 04:00:49.441091
NCT00324025|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2008-12-11|2006-05-08|2006-05-10|Estimate|||||||2008-12-11|2008-12-12|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS|Terminated||Phase 2|3|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:00:49.679976|2018-06-01 04:00:49.679976
NCT00324012|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2012-02-20|2006-05-08|2006-05-10|Estimate|||||||2012-02-20|2012-02-22|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma|Phase II Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma|Completed||Phase 2|19|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-06-01 04:00:49.812157|2018-06-01 04:00:49.812157
NCT00323999|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2006-05-09|2006-05-09|2006-05-10|Estimate|||||||2006-05-09|2006-05-10|Estimate|December 2004||2004-12-31|May 2006|2006-05-31|December 2007||2007-12-31|||||Interventional|||Hysteroscopic Monopolar and Bipolar Resection|A Randomised Trial to Compare the Differences Between Monopolar Surgery (Loop Resection) With Glycine 1,5% and Bipolar Surgery With Saline (Olympus,Versapoint) on Hysteroscopic Surgery.|Unknown status|Recruiting|N/A|||Ullevaal University Hospital|||||f||||||||||||||2018-06-01 04:00:49.904936|2018-06-01 04:00:49.904936
NCT00323986|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2006-05-08|2006-05-08|2006-05-10|Estimate|||||||2006-05-08|2006-05-10|Estimate|October 2004||2004-10-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Azithromycin Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and Tracheostomy|Azithromycin Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and Tracheostomy. Effects on Recurrent Respiratory Infections, Inflammatory Parameters and Bacterial Persistence|Terminated||Phase 2|30||University of Milan|||||f||||||||||||||2018-06-01 04:00:49.97851|2018-06-01 04:00:49.97851
NCT00323973|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2010-11-23|2006-05-08|2006-05-10|Estimate|||||||2010-11-23|2010-11-24|Estimate|July 2003||2003-07-31|November 2010|2010-11-30|July 2006|Actual|2006-07-31|July 2005|Actual|2005-07-31||Interventional|||Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity|A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy.|Completed||Phase 3|500|Actual|Fundación Cardiovascular de Colombia||2|||f||||t||||||||||2018-06-01 04:00:50.072381|2018-06-01 04:00:50.072381
NCT00323960|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2011-02-16|2006-05-09|2006-05-10|Estimate|||||||2011-02-16|2011-02-17|Estimate|May 2006||2006-05-31|February 2011|2011-02-28|May 2011|Anticipated|2011-05-31|December 2006|Actual|2006-12-31||Interventional|PRINTOJDMTR||Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis|Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate|Unknown status|Recruiting|Phase 3|120|Anticipated|Istituto Giannina Gaslini||3|||f||||f||||||||||2018-06-01 04:00:50.170594|2018-06-01 04:00:50.170594
NCT00323947|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2013-07-31|2006-05-08|2006-05-10|Estimate|||||||2013-07-31|2013-08-01|Estimate|May 2003||2003-05-31|July 2013|2013-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy|Double Blind, Placebo Controlled, Crossover Study of Extended Release Methylphenidate for Treatment of ADHD in Children With Epilepsy|Completed||Phase 4|33|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 04:00:50.298597|2018-06-01 04:00:50.298597
NCT00323934|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2015-01-06|2006-05-08|2006-05-10|Estimate|||||||2015-01-06|2015-01-08|Estimate|April 2004||2004-04-30|January 2015|2015-01-31|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|A Phase I Study of MGCD0103 Given as a Three-Times Weekly Oral Dose in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Completed||Phase 1|42|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-06-01 04:00:50.407227|2018-06-01 04:00:50.407227
NCT00323921|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2012-08-02|2006-05-09|2006-05-10|Estimate|||||||2012-08-02|2012-08-03|Estimate|August 2005||2005-08-31|August 2012|2012-08-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Determination of Safety and Efficacy of a Laser With Cooling for Treatment of Skin||Completed||N/A|36|Actual|Candela Corporation|||||f||||f||||||||||2018-06-01 04:00:50.49184|2018-06-01 04:00:50.49184
NCT00323908|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2012-02-06|2006-05-08|2006-05-10|Estimate|||||||2012-02-06|2012-02-07|Estimate|June 2005||2005-06-30|February 2012|2012-02-29|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer|QM-MSP, Ki-67, and Cytomorphology of RPFNA Specimens From High Risk Women|Completed|||281|Actual|University of Kansas Medical Center|||1||f||||f||||||||||2018-06-01 04:00:50.552865|2018-06-01 04:00:50.552865
NCT00323895|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2010-07-28|2006-05-09|2006-05-10|Estimate|||||||2010-07-28|2010-07-29|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CRISTAL||The Intra-Drug Eluting Stent (DES) Restenosis Study|A Prospective, Randomized, Multi-Center Comparison of the CYPHER Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients With Intra-Des Restenosis|Completed||Phase 4|320|Anticipated|Cordis Corporation||3|||f||||t||||||||||2018-06-01 04:00:50.626256|2018-06-01 04:00:50.626256
NCT00323882|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2014-07-23|2011-01-29|2014-08-14|2006-05-08|2006-05-10|Estimate|2014-08-14|2014-08-28|Estimate|2011-11-04|2011-11-10|Estimate|2014-08-14|2014-08-28|Estimate|January 2006||2006-01-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|September 2009|Actual|2009-09-30||Interventional||All participants who received at least one dose of study therapy.|Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase I/II, Open-label, Dose-escalation Study of MDX-010 Administered Every 3 Weeks for 4 Doses in Patients With Metastatic Hormone-Refractory Prostate Cancer|Completed||Phase 1/Phase 2|75|Actual|Bristol-Myers Squibb|Due to the small number of participants who underwent more than 4 doses of treatment (induction period) and the exploratory nature of this study, not all of the secondary objectives were completed.|1|||f||||f||||||||||2018-06-01 04:00:50.815987|2018-06-01 04:00:50.815987
NCT00323869|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2016-04-20||2016-07-30|2006-05-08|2006-05-10|Estimate|2016-06-14|2016-07-27|Estimate||||2016-07-30|2016-09-07|Estimate|June 2006||2006-06-30|July 2016|2016-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer|Phase II Trial of Bevacizumab in Combination With Gemcitabine and Carboplatin in Patients With Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell Carcinoma)|Completed||Phase 2|48|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 04:00:52.800804|2018-06-01 04:00:52.800804
NCT00323856|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2018-03-08|2006-05-08|2006-05-10|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2003|Actual|2003-01-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A|Phase IV A Study of Immunologic Safety for Alphanate in Previously Treated Patients Diagnosed With Severe Hemophilia A|Recruiting||Phase 4|60|Anticipated|Grifols Biologicals Inc.||1|||f||||f||||||||||2018-06-01 04:00:53.09054|2018-06-01 04:00:53.09054
NCT00323843|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2007-01-29|2006-05-08|2006-05-10|Estimate|||||||2007-01-29|2007-01-30|Estimate|June 2006||2006-06-30|January 2007|2007-01-31|February 2007||2007-02-28|||||Interventional|||Retrograde Intrarenal Stone Surgery - A Method of Treating the ESWL Resistant Kidney Stone|RIRS - A Method of Treating the ESWL Resistant Kidney Stone|Unknown status|Active, not recruiting|Phase 2|10||Fredericia Hosptial|||||f||||||||||||||2018-06-01 04:00:53.158976|2018-06-01 04:00:53.158976
NCT00323830|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2011-11-08|2006-05-08|2006-05-10|Estimate|||||||2011-11-08|2011-11-09|Estimate|October 2004||2004-10-31|November 2011|2011-11-30|April 2011|Actual|2011-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma|Phase III Randomized Controlled Trial of Adjuvant Capecitabine/Cisplatin Chemotherapy and Chemoradiation Therapy for Gastric Adenocarcinoma|Completed||Phase 3|458|Actual|Samsung Medical Center||2|||f||||||||||||||2018-06-01 04:00:53.218657|2018-06-01 04:00:53.218657
NCT00323817|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2015-05-26|2006-05-08|2006-05-10|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2006||2006-04-30|May 2015|2015-05-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia||Completed||Phase 2|282|Anticipated|Zeria Pharmaceutical|||||f||||||||||||||2018-06-01 04:00:53.299614|2018-06-01 04:00:53.299614
NCT00323804|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2014-09-03|2006-05-09|2006-05-10|Estimate|||||||2014-09-03|2014-09-04|Estimate|May 2006||2006-05-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.|Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients.|Completed||Phase 2/Phase 3|372|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 04:00:54.380385|2018-06-01 04:00:54.380385
NCT00323791|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2009-12-10|2006-05-08|2006-05-10|Estimate|||||||2009-12-10|2009-12-11|Estimate|April 2006||2006-04-30|December 2009|2009-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Trial of Gemzar (Gemcitabine) and Gleevec (Imatinib Mesylate) in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|100|Anticipated|Rutgers, The State University of New Jersey||||slow accrual|f||||t||||||||||2018-06-01 04:00:54.645342|2018-06-01 04:00:54.645342
NCT00323778|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2008-02-04|2006-05-08|2006-05-10|Estimate|||||||2008-02-04|2008-02-06|Estimate|May 2006||2006-05-31|February 2008|2008-02-29||||September 2007|Actual|2007-09-30||Interventional|||Prospective Assessment of the Efficacy of Hyaluronate Knee Injections in Patients With Osteoarthritis|Prospective Assessment of the Efficacy of Intra-Articular Hyaluronate to Affect Extracellular Matrix Changes in Patients With Osteoarthritis|Terminated||Phase 3|40|Anticipated|Hospital for Special Surgery, New York|||||||||||||||||||2018-06-01 04:00:54.716236|2018-06-01 04:00:54.716236
NCT00323765|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-09|||2017-06-30|2006-05-09|2006-05-10|Estimate|||||||2017-06-30|2017-07-02|Actual|May 5, 2006||2006-05-05|May 20, 2008|2008-05-20|May 20, 2008||2008-05-20|||||Observational|||Plasticity in Cervical Dystonia|Plasticity in Cervical Dystonia|Completed|||44||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:00:54.767303|2018-06-01 04:00:54.767303
NCT00323752|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2008-09-24|2006-05-08|2006-05-09|Estimate|||||||2008-09-24|2008-09-25|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.|Recombinant Human Erythropoietin Compared to Autologous Pre-Donation Prior to Scoliosis Surgery in Children.|Completed||Phase 3|20|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:00:54.818909|2018-06-01 04:00:54.818909
NCT00323739|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2012-12-19||2013-07-18|2006-05-05|2006-05-09|Estimate|2013-01-29|2013-03-06|Estimate||||2013-07-18|2013-07-26|Estimate|May 2006||2006-05-31|July 2013|2013-07-31|March 2011|Actual|2011-03-31|November 2008|Actual|2008-11-30||Interventional|||Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma|Phase II Trial of Bevacizumab(Avastin) and RAD001(Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma|Completed||Phase 2|80|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:00:54.990325|2018-06-01 04:00:54.990325
NCT00323726|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2015-06-16|2006-05-05|2006-05-09|Estimate|||||||2015-06-16|2015-06-18|Estimate|December 2005||2005-12-31|June 2015|2015-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study|Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study|Withdrawn|||0|Actual|New Mexico Cancer Care Alliance||||The study was limited to IRB Exempt chart review; not an applicable trial.|f||||||||||||||2018-06-01 04:00:55.425664|2018-06-01 04:00:55.425664
NCT00323713|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2011-06-23|2006-05-05|2006-05-09|Estimate|||||||2011-06-23|2011-06-27|Estimate|February 2005||2005-02-28|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|July 2011|Anticipated|2011-07-31||Interventional|||Very Low Protein Diet and Renal Death in Chronic Kidney Disease (CKD)-ERIKA Study|Effects of Very Low Protein Diet Supplemented With Ketoanalogs on Renal Death in Phase 4/5 Chronic Kidney Disease (CKD) - ERIKA Study|Unknown status|Active, not recruiting|N/A|360|Anticipated|Azienda Sanitaria ASL Avellino 2||2|||f||||t||||||||||2018-06-01 04:00:55.49074|2018-06-01 04:00:55.49074
NCT00323700|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2009-04-17|2006-05-08|2006-05-09|Estimate|||||||2009-04-17|2009-04-21|Estimate|December 2008||2008-12-31|April 2009|2009-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD)|A Naturalistic Prospective Study of Treatment Effectiveness for ADHD|Withdrawn|||200|Anticipated|University of British Columbia||||Merged with the study NCT00307268|f||||f||||||||||2018-06-01 04:00:55.595334|2018-06-01 04:00:55.595334
NCT00323687|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2008-06-06|2006-05-05|2006-05-09|Estimate|||||||2008-06-06|2008-06-09|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|January 2007|Actual|2007-01-31|October 2006|Actual|2006-10-31||Interventional|||SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada|"Switch to a Completely ONce Daily Regimen Containing Emtricitabine/Tenofovir - Fixed Dose Combination Plus Third QD Partner: SONETT"|Completed||Phase 4|50|Anticipated|Gilead Sciences|||||f||||f||||||||||2018-06-01 04:00:55.650164|2018-06-01 04:00:55.650164
NCT00323674|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-07|||2014-12-04|2006-05-07|2006-05-09|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2006||2006-03-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Minimally Invasive Open Preperitoneal Surgery With Polysoft Mesh Versus a Classic Open Surgery With Light Weight Mesh|Prospective Randomized Study to Evaluate the Recovery of a Hernia Inguinalis by a Minimally Invasive Open Preperitoneal Surgery With Polysoft Mesh Versus a Classic Open Surgery According to Modified Lichtenstein Procedure With Light Weight Mesh|Unknown status|Active, not recruiting|N/A|50|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 04:00:55.710959|2018-06-01 04:00:55.710959
NCT00323661|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2012-02-10|2006-05-08|2006-05-09|Estimate|||||||2012-02-10|2012-02-13|Estimate|May 2006||2006-05-31|February 2012|2012-02-29|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|COGNITION||Closed Loop Stimulation, Cognitive Performance, and Quality of Life in Pacemaker Patients|COGNITION - Cognitive Performance & Closed Loop Stimulation|Completed||Phase 4|405|Actual|Biotronik SE & Co. KG||2|||f||||||||||||||2018-06-01 04:00:55.790117|2018-06-01 04:00:55.790117
NCT00323648|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-07|||2014-12-04|2006-05-07|2006-05-09|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2006||2006-05-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|May 2010|Actual|2010-05-31||Interventional|||Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis|Does it Make Sense to Give Postoperative Antibiotics to Patients With an Uncomplicated Acute Cholecystitis|Completed||Phase 2|50|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:00:56.030061|2018-06-01 04:00:56.030061
NCT00322738|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2010-08-26|2006-05-04|2006-05-08|Estimate|||||||2010-08-26|2010-08-27|Estimate|June 2006||2006-06-30|February 2008|2008-02-29|January 2007||2007-01-31|||||Observational|||Time to Infection With Malaria Parasites|Time to Infection With Malaria Parasites in Adults|Unknown status|Recruiting||552||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:01:11.991274|2018-06-01 04:01:11.991274
NCT00323635|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2013-08-09||2018-03-01|2006-05-05|2006-05-09|Estimate|2014-12-02|2014-12-04|Estimate||||2018-03-01|2018-03-29|Actual|April 2006||2006-04-30|March 2018|2018-03-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.|A Parallel, Double-blind Comparison of Tolterodine vs. Placebo Treatments for Nocturia in Postmenopausal Women.|Terminated||Phase 4|19|Actual|Brigham and Women's Hospital||2||New department chairman instructed PI to discontinue study.|f||||t||||||||||2018-06-01 04:00:56.128754|2018-06-01 04:00:56.128754
NCT00323622|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-03-29||2016-10-27|2006-05-08|2006-05-09|Estimate|2014-02-27|2014-03-27|Estimate||||2016-10-27|2016-12-09|Estimate|April 2005||2005-04-30|October 2016|2016-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine|An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose.|Completed||Phase 2|1737|Actual|GlaxoSmithKline||8|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:00:56.53857|2018-06-01 04:00:56.53857
NCT00323609|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2012-06-29||2017-12-06|2006-05-08|2006-05-09|Estimate|2012-06-29|2012-08-08|Estimate||||2017-12-06|2018-01-02|Actual|August 2006||2006-08-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||KAVIAR Study - Kyphoplasty And Vertebroplasty In the Augmentation and Restoration of Vertebral Body Compression Fractures|A Multicenter, Randomized, Prospective Clinical Trial to Compare the Short- and Long-term Safety and Effectiveness of Balloon Kyphoplasty to Vertebroplasty in the Treatment of Painful, Acute Osteoporosis-related Vertebral Body Compression Fractures (VCFs).|Terminated||N/A|404|Actual|Medtronic Spinal and Biologics|The original study design required n=1,234 randomized patients; however, the study was stopped early with only n=404 enrolled patients, due to low enrollment, difficulty in willingness to randomize patients and a high proportion of early terminations|2||"Due to high number of patients terminating study early, low patient enrollment and difficulty~   in patient/investigator willingness for randomization"|f||||||||||||||2018-06-01 04:00:57.570178|2018-06-01 04:00:57.570178
NCT00323596|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2009-10-23|2006-05-08|2006-05-09|Estimate|||||||2009-10-23|2009-10-27|Estimate|September 2004||2004-09-30|October 2009|2009-10-31|December 2008|Actual|2008-12-31|||||Observational|||Trial of a Home Based Strength and Balance Retraining Program in Reducing Falls Risk Factors|Action Seniors!: A 12-month Randomized Controlled Trial of a Home Based Strength and Balance Retraining Program in Reducing Falls Risk Factors|Completed|||71|Anticipated|University of British Columbia|||||f||||f||||||None Retained|"~     None retained~   "|||2018-06-01 04:00:59.427433|2018-06-01 04:00:59.427433
NCT00323583|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2007-05-07|2006-05-05|2006-05-09|Estimate|||||||2007-05-07|2007-05-08|Estimate|May 2006||2006-05-31|May 2007|2007-05-31||||||||Interventional|||Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer|Phase II Study of Paclitaxel, Oxaliplatin, Leucovorin and 5-Fluorouracil (POLF) in Gemcitabine-Refractory Advanced Pancreatic Cancer|Unknown status|Recruiting|Phase 2|80|Anticipated|Seattle Cancer Treatment and Wellness Center|||||f||||||||||||||2018-06-01 04:00:59.478846|2018-06-01 04:00:59.478846
NCT00323570|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2012-06-26|2006-05-08|2006-05-09|Estimate|||||||2012-06-26|2012-06-27|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma|A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ NiaStase®) in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients|Withdrawn||Phase 3|0|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:00:59.555449|2018-06-01 04:00:59.555449
NCT00323557|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2012-04-06||2012-12-03|2006-05-05|2006-05-09|Estimate|2012-04-06|2012-05-02|Estimate||||2012-12-03|2012-12-05|Estimate|June 2004||2004-06-30|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients|Immuno-Augmentation With GM-CSF in Patients Receiving Pneumococcal Vaccine While Undergoing Treatment for Advanced Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|39|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 04:00:59.747431|2018-06-01 04:00:59.747431
NCT00323544|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2008-06-30|2006-05-05|2006-05-09|Estimate|||||||2008-06-30|2008-07-04|Estimate|October 2004||2004-10-31|June 2008|2008-06-30|October 2007|Actual|2007-10-31|June 2007|Actual|2007-06-30||Interventional|||SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection|A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Twice Daily co-Formulated Zidovudine and Lamivudine (Combivir®) or Zidovudine and Lamivudine, in Virologically Suppressed, HIV Infected Patients Taking Efavirenz|Completed||Phase 3|220||Gilead Sciences|||||f||||f||||||||||2018-06-01 04:00:59.987236|2018-06-01 04:00:59.987236
NCT00323531|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2008-05-06|2006-05-08|2006-05-09|Estimate|||||||2008-05-06|2008-05-09|Estimate|March 2006||2006-03-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Thoracoscopy Versus Fibrinolysis in Children With Empyema|Thoracoscopy Versus Fibrinolysis in Children With Empyema|Completed||Phase 2/Phase 3|36|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 04:01:00.079232|2018-06-01 04:01:00.079232
NCT00323518|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08||2015-02-02|2016-03-14|2006-05-08|2006-05-09|Estimate||||2016-02-16|2016-03-15|Estimate|2016-03-14|2016-04-13|Estimate|May 2006||2006-05-31|March 2016|2016-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis|A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant|Completed||Phase 2|390|Actual|Celldex Therapeutics||4|||f||||t||||||||||2018-06-01 04:01:00.187573|2018-06-01 04:01:00.187573
NCT00323505|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2006-05-08|2006-05-08|2006-05-09|Estimate|||||||2006-05-08|2006-05-09|Estimate|March 2001||2001-03-31|May 2006|2006-05-31|December 2004||2004-12-31|||||Interventional|||A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma||Completed||Phase 2|||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:01:00.471311|2018-06-01 04:01:00.471311
NCT00323310|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2010-08-16||2010-10-13|2006-05-05|2006-05-09|Estimate|2010-09-20|2010-10-06|Estimate||||2010-10-13|2010-10-22|Estimate|April 2006||2006-04-30|October 2010|2010-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of MultiHance in Pediatric Patients|A Phase III Multi-Center Open Label Study to Evaluate Safety and Efficacy of MultiHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients|Terminated||Phase 3|92|Actual|Bracco Diagnostics, Inc||1||Adequate statistical power at 92 dosed pts to meet study objectives.|f||||f||||||||||2018-06-01 04:01:03.06927|2018-06-01 04:01:03.06927
NCT00323492|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2009-03-20||2010-01-13|2006-05-05|2006-05-09|Estimate|2009-11-20|2009-12-23|Estimate||||2010-01-13|2010-01-20|Estimate|September 2005||2005-09-30|January 2010|2010-01-31|March 2008|Actual|2008-03-31|July 2007|Actual|2007-07-31||Interventional|TOTEM||TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada|Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients.|Completed||Phase 4|92|Actual|Gilead Sciences|Comparison of adverse events between Truvada and maintain baseline regimen groups is inappropriate since numbers at risk (and exposure to study drug) are not balanced, as described in the adverse event treatment group descriptions.|4|||f||||f||||||||||2018-06-01 04:01:00.54986|2018-06-01 04:01:00.54986
NCT00323479|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2010-01-26||2012-03-13|2006-05-08|2006-05-09|Estimate|2012-03-13|2012-04-06|Estimate||||2012-03-13|2012-04-06|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Arthralgia During Anastrozole Therapy for Breast Cancer|A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer|Completed||Phase 4|114|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:01:01.062497|2018-06-01 04:01:01.062497
NCT00323466|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2014-12-04|2006-05-05|2006-05-09|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||A Study of the Effect on Oro-dental Complications of Intensity Modulated Radiotherapy (IMRT) Versus Conventional Radiotherapy in Patients With Cancer of the Head or Neck|A Study of the Effect on Oro-dental Complications of Intensity Modulated Radiotherapy (IMRT) Versus Conventional Radiotherapy in Patients With Cancer of the Head or Neck|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:01:01.279447|2018-06-01 04:01:01.279447
NCT00323453|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2012-12-18|2006-05-05|2006-05-09|Estimate|||||||2012-12-18|2012-12-19|Estimate|March 2006||2006-03-31|May 2009|2009-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Wound Infection Alexis Wound Retractor|Rate of Surgical Wound Infection After Open Appendectomy Using the Alexis Wound Retractor|Completed||Phase 4|119|Actual|Santa Barbara Cottage Hospital||2|||f||||t||||||||||2018-06-01 04:01:01.365614|2018-06-01 04:01:01.365614
NCT00323440|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-07|||2017-10-10|2006-05-07|2006-05-09|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2008|Anticipated|2008-08-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2010|Anticipated|2010-08-31||Observational|||Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission|Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission|Withdrawn|||0|Actual|Sheba Medical Center|||4|Collaboration could not be established|f||||t||||||||||2018-06-01 04:01:01.434823|2018-06-01 04:01:01.434823
NCT00323427|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2013-09-26||2014-01-17|2006-05-05|2006-05-09|Estimate|2014-01-17|2014-03-06|Estimate||||2014-01-17|2014-03-06|Estimate|May 2007||2007-05-31|January 2014|2014-01-31|September 2010|Actual|2010-09-30|February 2009|Actual|2009-02-28||Interventional|||"Clinical Trial of the Living Well With Hearing Loss Workshop"|"Clinical Trial of the Living Well With Hearing Loss Workshop"|Completed||Phase 2|135|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:01:01.59146|2018-06-01 04:01:01.59146
NCT00323414|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2017-08-24||2018-02-22|2006-05-05|2006-05-09|Estimate|2018-02-22|2018-02-23|Actual||||2018-02-22|2018-02-23|Actual|April 2006||2006-04-30|October 2017|2017-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver|Randomized Controlled Trial of Omega-3 Fatty Acids in the Treatment of Non-Alcoholic Steatohepatitis in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|37|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 04:01:01.87219|2018-06-01 04:01:01.87219
NCT00323401|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2011-11-04|2006-05-08|2006-05-09|Estimate|||||||2011-11-04|2011-11-07|Estimate|May 2006||2006-05-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2009|Actual|2009-12-31||Interventional|||The Influence of Antenatal Classes on Pregnancy, Birth and Parenthood|The Influence of Antenatal Classes on Pregnancy, Birth and Parenthood|Unknown status|Active, not recruiting|Phase 4|1000|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-06-01 04:01:02.245114|2018-06-01 04:01:02.245114
NCT00323388|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2010-01-06|2006-05-05|2006-05-09|Estimate|||||||2010-01-06|2010-01-07|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Identification of Risk Allels for Prostate Cancer|Identification of Risk Allels for Prostate Cancer|Completed|||||University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:02.349249|2018-06-01 04:01:02.349249
NCT00323375|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2006-05-05|2006-05-05|2006-05-09|Estimate|||||||2006-05-05|2006-05-09|Estimate|August 1999||1999-08-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Phase 1 Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine|Randomized Controlled Trial of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine|Completed||Phase 1|122||Tulane University Health Sciences Center|||||||||||||||||||2018-06-01 04:01:02.418818|2018-06-01 04:01:02.418818
NCT00323362|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2013-11-18||2014-04-25|2006-05-08|2006-05-09|Estimate|2014-04-25|2014-05-22|Estimate||||2014-04-25|2014-05-22|Estimate|April 2006||2006-04-30|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer|Phase II Study of Imatinib Mesylate and Gemcitabine for Recurrent/Metastatic Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|17|Actual|Rutgers, The State University of New Jersey||1||Toxicity|f||||f||||||||||2018-06-01 04:01:02.559736|2018-06-01 04:01:02.559736
NCT00323349|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-06|||2007-06-27|2006-05-06|2006-05-09|Estimate|||||||2007-06-27|2007-06-28|Estimate|April 2003||2003-04-30|June 2007|2007-06-30|December 2004||2004-12-31|||||Interventional|||A Study of Attitudes About the Risk of Developing Type 2 Diabetes|Cues to Action in Diabetes Risk Education (CADRE): Randomized Study Assessing the Impact of Knowledge of Impaired Glucose Tolerance on Perceived Risk and Behavior Change Motivation|Completed||N/A|276||Eastern Virginia Medical School|||||f||||||||||||||2018-06-01 04:01:02.815944|2018-06-01 04:01:02.815944
NCT00323336|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2010-01-22|2006-05-05|2006-05-09|Estimate|||||||2010-01-22|2010-01-25|Estimate|May 2006||2006-05-31|January 2010|2010-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Markers of Bone Turnover in Saliva and How This Compares to Urine and Blood|Salivary Markers of Bone Turnover Compared to Urine and Blood|Completed|||100|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:01:02.885336|2018-06-01 04:01:02.885336
NCT00323323|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2017-01-19|2006-05-08|2006-05-09|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2004||2004-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|August 2012|Actual|2012-08-31||Interventional|||CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas|A Phase I Study of CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas|Completed||Phase 1|24|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:01:02.940694|2018-06-01 04:01:02.940694
NCT00323297|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2013-08-23||2014-10-27|2006-05-05|2006-05-09|Estimate|2013-09-18|2013-11-19|Estimate||||2014-10-27|2014-11-04|Estimate|September 2006||2006-09-30|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension|A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah)|Completed||Phase 4|105|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:01:03.398379|2018-06-01 04:01:03.398379
NCT00323284|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-06|2012-09-04||2017-12-14|2006-05-06|2006-05-09|Estimate|2012-09-04|2012-10-04|Estimate||||2017-12-14|2018-01-12|Actual|June 2005||2005-06-30|March 2016|2016-03-31|March 2010|Actual|2010-03-31|July 2009|Actual|2009-07-31||Interventional|||A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma|A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects.|Completed||Phase 3|240|Actual|Glaukos Corporation|Open label given no way to mask treatment group to surgeon and visibility of iStent device upon gonioscopy.|2|||f||||f||||||||||2018-06-01 04:01:04.00496|2018-06-01 04:01:04.00496
NCT00323271|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2015-07-21||2015-08-25|2006-05-05|2006-05-09|Estimate|2015-08-25|2015-09-25|Estimate||||2015-08-25|2015-09-25|Estimate|July 2006||2006-07-31|August 2015|2015-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Cognitive-behavior Therapy for MS-Related Chronic Pain|Cognitive-behavior Therapy for MS-Related Chronic Pain|Completed||N/A|26|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:01:04.277435|2018-06-01 04:01:04.277435
NCT00323258|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2012-03-19||2013-01-11|2006-05-05|2006-05-09|Estimate|2012-04-16|2012-04-19|Estimate||||2013-01-11|2013-01-18|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|PILOT-EBM||Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease|PILOT-EBM: Patient Focused Intervention to Improve Long-term Adherence to Evidence Based Medications|Completed||N/A|143|Actual|Duke University||2|||f||||f||||||||||2018-06-01 04:01:04.52162|2018-06-01 04:01:04.52162
NCT00323245|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2011-04-12|2006-05-08|2006-05-09|Estimate|||||||2011-04-12|2011-04-14|Estimate|March 2006||2006-03-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Regaining Bladder Control in Postmenopausal Women With Osteoporosis|Regaining Urinary Continence in Postmenopausal Women With Osteoporosis: A Randomized Controlled Trial.|Completed||N/A|48|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:01:04.858426|2018-06-01 04:01:04.858426
NCT00323232|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2011-04-26|2006-05-08|2006-05-09|Estimate|||||||2011-04-26|2011-04-27|Estimate|December 2010||2010-12-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Comparison of Treatment Outcomes in Hip Fractures Surgically Fixed With Either a Two or Four Hole Device.|Two-Hole Versus Four-Hole Dynamic Hip Screw (DHS) for the Treatment of Intertrochanteric Fractures: A Prospective Randomized Trial|Completed||Phase 4|400|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:01:04.923281|2018-06-01 04:01:04.923281
NCT00323219|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2012-02-06|2006-05-08|2006-05-09|Estimate|||||||2012-02-06|2012-02-08|Estimate|January 2004||2004-01-31|February 2012|2012-02-29|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department|Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tissue Infections in the Emergency Department|Unknown status|Recruiting|Phase 3|390|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:01:04.987828|2018-06-01 04:01:04.987828
NCT00323206|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2017-02-20|2006-05-05|2006-05-09|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2004||2004-06-30|January 2009|2009-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma|Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma|Completed||N/A|24|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|f|f||||||||2018-06-01 04:01:05.051606|2018-06-01 04:01:05.051606
NCT00323193|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2014-10-01||2014-10-06|2006-05-08|2006-05-09|Estimate|2014-10-06|2014-10-09|Estimate||||2014-10-06|2014-10-09|Estimate|July 2006||2006-07-31|October 2014|2014-10-31|August 2011|Actual|2011-08-31|January 2010|Actual|2010-01-31||Interventional|||Using MOVE! With Seriously Mentally Ill Veterans|Using MOVE! With Seriously Mentally Ill Veterans|Completed||N/A|109|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:01:05.134739|2018-06-01 04:01:05.134739
NCT00323180|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2010-01-06|2006-05-05|2006-05-09|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2005||2005-08-31|November 2009|2009-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Investigation of Protein Biomarkers of Prostate Cancer|Investigation of Protein Biomarkers of Prostate Cancer|Completed|||||University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:05.417492|2018-06-01 04:01:05.417492
NCT00323167|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2018-01-24|2006-05-08|2006-05-09|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2006||2006-05-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|October 2012|Actual|2012-10-31||Observational|||Rare Genetic Disorders of the Breathing Airways|Rare Genetic Disorders of the Airways: Cross-sectional Comparison of Clinical Features, and Development of Novel Screening and Genetic Tests|Active, not recruiting|||360|Anticipated|University of North Carolina, Chapel Hill|||||f||||t||||||Samples With DNA|"~     Respiratory cultures, nasal samples, and blood samples~   "|||2018-06-01 04:01:05.547762|2018-06-01 04:01:05.547762
NCT00323154|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2008-09-24|2006-05-08|2006-05-09|Estimate|||||||2008-09-24|2008-09-25|Estimate|March 2004||2004-03-31|September 2008|2008-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Nalbuphine for the Treatment of Opioid Induced Pruritus in Children|Nalbuphine for the Treatment of Opioid Induced Pruritus in Children|Completed||Phase 3|134|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:01:05.658631|2018-06-01 04:01:05.658631
NCT00323141|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-07|||2014-12-04|2006-05-07|2006-05-09|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2006||2006-03-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Intraperitoneal Mesh With 3cm Overlap Versus a Rives-Stoppa Repair With a 6cm Overlap in Hernia Umbilicalis|Prospective Randomized Trial to Study the Effectiveness of an Intraperitoneal Mesh With an Overlap of 3cm Versus a Rives-Stoppa Repair With an Overlap of 6cm With Patients With a Hernia Umbilicalis|Unknown status|Active, not recruiting|N/A|50|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 04:01:05.751208|2018-06-01 04:01:05.751208
NCT00323128|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2011-06-01|2006-05-08|2006-05-09|Estimate|||||||2011-06-01|2011-06-02|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|April 2008|Actual|2008-04-30||Interventional|||Validation of Serum Creatinine Dosage and Renal Clearance|Validation of Serum Creatinine Dosage and Renal Clearance|Completed||Phase 1|30|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:01:05.848218|2018-06-01 04:01:05.848218
NCT00322205|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2017-01-10|2006-05-04|2006-05-05|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 1999||1999-06-30|May 2006|2006-05-31|March 2002||2002-03-31|||||Interventional|||Bio-behavioral Lung Cancer Prevention Program|Bio-behavioral Lung Cancer Prevention Program|Completed||Phase 4|555||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:01:23.042668|2018-06-01 04:01:23.042668
NCT00323115|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2012-08-24||2015-10-08|2006-05-05|2006-05-09|Estimate|2012-08-24|2012-09-26|Estimate||||2015-10-08|2015-11-02|Estimate|May 2006||2006-05-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|April 2008|Actual|2008-04-30||Interventional|||Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme|A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|11|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||||2018-06-01 04:01:05.939669|2018-06-01 04:01:05.939669
NCT00323102|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2008-01-18|2006-05-05|2006-05-09|Estimate|||||||2008-01-18|2008-01-23|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|March 2007|Actual|2007-03-31|||||Interventional|ENHANCE||A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain|Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain|Completed||Phase 4|114||Bracco Diagnostics, Inc|||||f||||f||||||||||2018-06-01 04:01:06.201787|2018-06-01 04:01:06.201787
NCT00323089|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|||2018-01-23|2006-05-08|2006-05-09|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2003||2003-04-30|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Removal of Lung Nodules After Being Marked With a Microcoil|Thoracoscopic Resection of Subcentimetre Lung Nodules After Localization Using Percutaneous Inserted Platinum Microcoil Under CT Guidance: a Pilot Study|Completed||N/A|151|Actual|University of British Columbia||1|||f||||f|f|f||||||No||2018-06-01 04:01:06.277105|2018-06-01 04:01:06.277105
NCT00323076|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2014-10-01|2006-05-05|2006-05-09|Estimate|||||||2014-10-01|2014-10-02|Estimate|September 2004||2004-09-30|January 2014|2014-01-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours|A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-[18]F-fluoroarabinofuranosyl)-2-nitroimidazole ([18]F-FAZA) in Patients With Known Squamous Cell Carcinoma of the Head & Neck, Small Cell and Non-Small Cell Carcinoma of the Lung, Lymphoma, Glioblastoma Multiforme, Neuroendocrine Tumours or Renal Cell Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|160|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||||2018-06-01 04:01:06.360453|2018-06-01 04:01:06.360453
NCT00323063|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-08|2017-03-31||2017-10-23|2006-05-08|2006-05-09|Estimate|2017-10-23|2017-11-29|Actual||||2017-10-23|2017-11-29|Actual|May 1, 2006|Actual|2006-05-01|October 2017|2017-10-31|June 20, 2016|Actual|2016-06-20|April 15, 2011|Actual|2011-04-15||Interventional||Study was prematurely closed due to slow accrual.|Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer|Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer|Terminated||Phase 2|49|Actual|Rutgers, The State University of New Jersey|This study was underpowered to draw any conclusion regarding a difference in TTP between the two groups at the time is was prematurely closed.|2||Slow accrual|f||||f||||||||||2018-06-01 04:01:06.49637|2018-06-01 04:01:06.49637
NCT00323050|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-09-15|2006-05-08|2006-05-09|Estimate|||||||2016-09-15|2016-09-16|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects|Evaluate Immunogenicity,Safety & Reactogenicity of a Booster Dose of Hib-MenC Conjugate Vaccine When Given to Healthy Subjects Aged 13-14 Months Who Were Primed With 3 Doses of Hib-MenC vs a Booster Dose of Infanrix Hexa Given to Subjects Primed With 3 Doses of Infanrix Hexa and Meningitec|Completed||Phase 3|468|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:01:07.006933|2018-06-01 04:01:07.006933
NCT00323037|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2009-01-16||2018-01-25|2006-05-08|2006-05-09|Estimate|2009-03-12|2009-03-13|Estimate||||2018-01-25|2018-02-22|Actual|March 2006||2006-03-31|January 2018|2018-01-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|COMPARE||A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure|A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure|Completed||Phase 3|318|Actual|CTI-1, LLC||2|||f||||f||||||||||2018-06-01 04:01:07.151674|2018-06-01 04:01:07.151674
NCT00323024|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2007-08-29|2006-05-05|2006-05-09|Estimate|||||||2007-08-29|2007-08-30|Estimate|September 2006||2006-09-30|July 2006|2006-07-31|May 2007||2007-05-31|||||Interventional|||Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension|An Open-Label, Dose-Determination Safety, Tolerability, and Activity Study of Inhaled NX1011 in Patients With Pulmonary Arterial Hypertension|Withdrawn||Phase 2|72||NITROX, LLC|||||||||||||||||||2018-06-01 04:01:07.447397|2018-06-01 04:01:07.447397
NCT00323011|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2014-05-20|2006-05-05|2006-05-09|Estimate|||||||2014-05-20|2014-05-21|Estimate|May 2006||2006-05-31|May 2014|2014-05-31|November 2007|Actual|2007-11-30|||||Interventional|||FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer|A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer|Terminated||Phase 2|5|Actual|University of Southern California||3||drug not available|f||||||||||||||2018-06-01 04:01:07.510058|2018-06-01 04:01:07.510058
NCT00322985|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2016-03-14|2006-05-05|2006-05-09|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma|A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma|Completed||Phase 2|40|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:01:07.651212|2018-06-01 04:01:07.651212
NCT00322972|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2015-09-05|2006-05-05|2006-05-09|Estimate|||||||2015-09-05|2015-09-09|Estimate|June 2006||2006-06-30|September 2015|2015-09-30|May 2014|Actual|2014-05-31|November 2009|Actual|2009-11-30||Interventional|TANA||Trachoma Amelioration in Northern Amhara (TANA)|Eliminating Trachoma With Repeat Mass Drug Treatment|Completed||Phase 4|33000|Actual|University of California, San Francisco||6|||f||||t||||||||||2018-06-01 04:01:07.73556|2018-06-01 04:01:07.73556
NCT00322959|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2008-09-19|2006-05-05|2006-05-08|Estimate|||||||2008-09-19|2008-09-22|Estimate|August 2004||2004-08-31|September 2008|2008-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Tai-Chi-Chuan on Differentiation and Maturation of Dendritic Cells|Effect of Tai-Chi-Chuan on Differentiation and Maturation of Human Dendritic Cells|Completed|||20|Actual|Mackay Memorial Hospital|||||f||||t||||||||||2018-06-01 04:01:07.826375|2018-06-01 04:01:07.826375
NCT00322946|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2009-08-05|2006-05-04|2006-05-08|Estimate|||||||2009-08-05|2009-08-07|Estimate|January 2007||2007-01-31|November 2008|2008-11-30||||August 2009|Actual|2009-08-31||Interventional|||Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4|Completed||Phase 1|84|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 04:01:07.881411|2018-06-01 04:01:07.881411
NCT00322907|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2006-05-05|2006-05-05|2006-05-08|Estimate|||||||2006-05-05|2006-05-08|Estimate|April 2000||2000-04-30|October 1999|1999-10-31|January 2003||2003-01-31|||||Interventional|||Cotrifazid Safety and Efficacy Against Malaria|A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea|Terminated||Phase 2|330||Policlinique Médicale Universitaire|||||f||||||||||||||2018-06-01 04:01:08.105812|2018-06-01 04:01:08.105812
NCT00322894|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2017-09-15|2006-05-05|2006-05-08|Estimate|||||||2017-09-15|2017-09-19|Actual|February 2006||2006-02-28|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|20 Years|Observational [Patient Registry]|||Expanded Breast Cancer Registry and Tissue Repository|Expanded Breast Cancer Registry and Tissue Repository|Active, not recruiting|||500|Anticipated|New Mexico Cancer Care Alliance|||||f||||t||||||Samples With DNA|"~     Sample of tumor, buccal cells and blood collected at the time of study enrollment.~   "|No||2018-06-01 04:01:08.176149|2018-06-01 04:01:08.176149
NCT00322881|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2015-01-06||2017-03-22|2006-05-05|2006-05-08|Estimate|2015-06-12|2015-06-17|Estimate||||2017-03-22|2017-03-24|Actual|April 2006||2006-04-30|March 2017|2017-03-31|April 2010|Actual|2010-04-30|April 2008|Actual|2008-04-30||Interventional|||Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer|A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer|Terminated||Phase 2|12|Actual|Dana-Farber Cancer Institute|This study terminated early due to 3 deaths on study and consequently results are limited.|1||Early closure based on audit by study investigators after 3 patients died on study.|f||||t||||||||||2018-06-01 04:01:08.250377|2018-06-01 04:01:08.250377
NCT00322868|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2016-12-03||2018-02-21|2006-05-04|2006-05-08|Estimate|2018-02-21|2018-02-23|Actual||||2018-02-21|2018-02-23|Actual|April 2006||2006-04-30|February 2018|2018-02-28|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional||21 subjects were screened and enrolled with 1 subject withdrawal due to disease progression.|Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease|A Pilot Study Assessing the Safety and Efficacy of Pioglitazone as an Anti-inflammatory Agent for the Treatment of CF Lung Disease in Patients With Cystic Fibrosis|Completed||N/A|21|Actual|University Hospitals Cleveland Medical Center||1|||f||||f||||||||No|Individualized personal data (IPD) will not be shared|2018-06-01 04:01:08.451169|2018-06-01 04:01:08.451169
NCT00322855|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2015-06-16||2015-07-10|2006-05-05|2006-05-08|Estimate|2015-06-16|2015-07-09|Estimate||||2015-07-10|2015-07-31|Estimate|August 2005||2005-08-31|July 2015|2015-07-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Observational|||Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma|Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma|Terminated|||1|Actual|New Mexico Cancer Care Alliance|||1|Low accrual|f||||t||||||||||2018-06-01 04:01:09.737416|2018-06-01 04:01:09.737416
NCT00322842|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2010-10-30||2014-02-10|2006-05-04|2006-05-08|Estimate|2010-10-30|2010-11-25|Estimate||||2014-02-10|2014-03-13|Estimate|September 2004||2004-09-30|February 2014|2014-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients|Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF|Completed||Phase 2|35|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:01:09.902021|2018-06-01 04:01:09.902021
NCT00322829|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2008-09-18|2006-05-04|2006-05-08|Estimate|||||||2008-09-18|2008-09-19|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|February 2009|Anticipated|2009-02-28|||||Observational|||Development and Optimization of a GBS Diagnostic Test|Development and Optimization of a GBS Micro Total Analysis System (µTAS) Prototype for the Direct Detection of Group B Streptococci in Vaginal/Anal Specimens From Intrapartum Maternity Patients|Suspended|||320|Anticipated|Laval University||||Temporarily suspended in between validating test systems.|f||||t||||||Samples With DNA|"~     Vaginal/anal swab samples taken from pregnant women admitted for delivery to the Centre~     Hospitalier Universitaire de Québec (CHUQ).~   "|||2018-06-01 04:01:10.351406|2018-06-01 04:01:10.351406
NCT00322816|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2010-08-26|2006-05-04|2006-05-08|Estimate|||||||2010-08-26|2010-08-27|Estimate|June 2006||2006-06-30|February 2008|2008-02-29|January 2007||2007-01-31|||||Observational|||Malaria Prevalence in Children|Malaria Prevalence, Incidence and Mortality in Children|Unknown status|Recruiting||2000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:01:10.408579|2018-06-01 04:01:10.408579
NCT00322803|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2006-09-27|2006-05-05|2006-05-08|Estimate|||||||2006-09-27|2006-09-29|Estimate|May 2006||2006-05-31|September 2006|2006-09-30|October 2006||2006-10-31|||||Interventional|||ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment|International, Multicenter, Randomized, Double-Blind, Placebo Controlled, Two-Period, Cross-Over Study to Demonstrate Safety, Tolerability and Anxiolytic Effects of 600 mg ELB139 Given Orally t.i.d. to Patients With Concurrent Panic Disorder, Challenged by Inhalation of 35% CO2 After a Single Dose and One Week of Treatment|Terminated||Phase 2|24||elbion AG|||||f||||||||||||||2018-06-01 04:01:11.257721|2018-06-01 04:01:11.257721
NCT00322790|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2015-04-02|2006-05-05|2006-05-08|Estimate|||||||2015-04-02|2015-04-03|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|January 2010|Anticipated|2010-01-31||Observational|||Differences in Trends Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study|INST 0549C Differences in 30-year Trends in Incidence and Survival for Malignant Germ Cell Tumors in Males and Females: A SEER Population-based Study|Withdrawn|||0|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||||||2018-06-01 04:01:11.347923|2018-06-01 04:01:11.347923
NCT00322777|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2015-06-17||2016-02-04|2006-05-04|2006-05-08|Estimate|2016-02-04|2016-03-03|Estimate||||2016-02-04|2016-03-03|Estimate|January 2005||2005-01-31|February 2016|2016-02-29|December 2008|Actual|2008-12-31|December 2006|Actual|2006-12-31||Interventional|||Spirituality Teaching Program for Depressed Adults|A Spirituality Teaching Program for Depression in Adults: A Randomized Controlled Trial|Completed||N/A|84|Actual|Canadian Institute of Natural and Integrative Medicine||2|||f||||f||||||||No||2018-06-01 04:01:11.422178|2018-06-01 04:01:11.422178
NCT00322764|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2007-11-08|2006-05-04|2006-05-08|Estimate|||||||2007-11-08|2007-11-09|Estimate|March 2006||2006-03-31|November 2007|2007-11-30||||||||Interventional|||Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression|Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression|Completed||Phase 2|80|Anticipated|Repligen Corporation|||||||||||||||||||2018-06-01 04:01:11.763781|2018-06-01 04:01:11.763781
NCT00322751|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2010-01-06|2006-05-05|2006-05-08|Estimate|||||||2010-01-06|2010-01-07|Estimate|April 2006||2006-04-30|November 2009|2009-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer|Phase I Study of Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer (NSCLC) (Stage I to IIIA)|Completed||Phase 1|10|Anticipated|University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:11.834212|2018-06-01 04:01:11.834212
NCT00322725|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2016-02-24|2006-05-05|2006-05-08|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2006||2006-02-28|February 2016|2016-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Bevacizumab (Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review|Bevacizumab(Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review|Completed|||25|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:12.082248|2018-06-01 04:01:12.082248
NCT00322712|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2015-02-11||2015-03-02|2006-05-05|2006-05-08|Estimate|2015-03-02|2015-03-04|Estimate||||2015-03-02|2015-03-04|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Observational|||INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer|INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer|Completed|||12|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:12.154197|2018-06-01 04:01:12.154197
NCT00322699|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2012-10-25|2006-05-04|2006-05-08|Estimate|||||||2012-10-25|2012-10-26|Estimate|February 2005||2005-02-28|August 2011|2011-08-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer|Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer|Completed||Phase 1/Phase 2|22|Actual|North Florida/South Georgia Veterans Health System||1|||f||||t||||||||||2018-06-01 04:01:12.303726|2018-06-01 04:01:12.303726
NCT00322686|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2012-03-16|2006-05-04|2006-05-08|Estimate|||||||2012-03-16|2012-03-20|Estimate|May 2006||2006-05-31|March 2012|2012-03-31||||December 2006|Actual|2006-12-31||Interventional|||Study of Oglemilast for the Treatment of Asthma|Efficacy and Safety of Oglemilast in the Prevention of Allergen-induced Bronchospasm|Completed||Phase 2|6|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 04:01:12.37864|2018-06-01 04:01:12.37864
NCT00322673|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2010-02-18|2006-05-04|2006-05-08|Estimate|||||||2010-02-18|2010-02-22|Estimate|May 2006||2006-05-31|February 2010|2010-02-28|May 2007|Actual|2007-05-31|November 2006|Actual|2006-11-30||Interventional|||Study of XL999 in Patients With Acute Myeloid Leukemia (AML)|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia|Terminated||Phase 2|14|Actual|Symphony Evolution, Inc.||||Study was terminated due to cardiac toxicities|f||||t||||||||||2018-06-01 04:01:12.450747|2018-06-01 04:01:12.450747
NCT00322660|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2007-06-27|2006-05-05|2006-05-08|Estimate|||||||2007-06-27|2007-06-28|Estimate|June 2006||2006-06-30|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Adrenaline Injections to Children Born at Elective CS|Can the Risk of RD and Hypoglycemia in Children Born at Elective CS be Reduced by Injection of Adrenaline|Completed||N/A|270|Actual|Hvidovre University Hospital|||||f||||t||||||||||2018-06-01 04:01:12.523285|2018-06-01 04:01:12.523285
NCT00322647|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2010-01-06|2006-05-05|2006-05-08|Estimate|||||||2010-01-06|2010-01-07|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|June 2007|Actual|2007-06-30|||||Observational|||Cancer Center Trials: Reasons for Low Accrual Rates at One Academic Institution Vs. The Community Setting|Cancer Center Trials: Reasons for Low Accrual Rates at One Academic Institution Vs. The Community Setting|Completed|||20|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:12.589763|2018-06-01 04:01:12.589763
NCT00322634|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2012-09-17|2006-05-05|2006-05-08|Estimate|||||||2012-09-17|2012-09-19|Estimate|February 2006||2006-02-28|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors|Investigator Initiated Trial: Prospective Study of Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors|Completed|||25|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||||||2018-06-01 04:01:12.650849|2018-06-01 04:01:12.650849
NCT00322621|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2008-10-30||2011-02-03|2006-05-05|2006-05-08|Estimate|2009-11-13|2009-12-18|Estimate||||2011-02-03|2011-02-07|Estimate|April 2006||2006-04-30|February 2011|2011-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)|Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients With Diabetic Peripheral Neuropathic Pain|Completed||Phase 4|216|Actual|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:01:12.781924|2018-06-01 04:01:12.781924
NCT00322608|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2011-01-06|2006-05-04|2006-05-08|Estimate|||||||2011-01-06|2011-01-10|Estimate|April 2006||2006-04-30|January 2011|2011-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or Lymphoma|Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients With Advanced Solid Tumor Malignancies or Lymphoma|Completed||Phase 1|35|Anticipated|Nereus Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 04:01:13.751938|2018-06-01 04:01:13.751938
NCT00322595|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2008-12-18|2006-05-05|2006-05-08|Estimate|||||||2008-12-18|2008-12-22|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|SILVER||Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder|An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER)|Completed||Phase 3|800|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:01:13.841375|2018-06-01 04:01:13.841375
NCT00322582|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2012-01-24|2006-05-05|2006-05-08|Estimate|||||||2012-01-24|2012-01-25|Estimate|May 2007||2007-05-31|January 2007|2007-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||The Genetic Basis for Familial Cardiomyopathy in Patients With Idiopathic Cardiomyopathy|Open Labeled of the Study the Genetic Basis for Familial Cardiomyopathy in Patients With Idiopathic|Terminated|||41|Actual|Carmel Medical Center||||no financial resources were available to complete the study|f||||||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 04:01:13.999769|2018-06-01 04:01:13.999769
NCT00322569|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2013-03-05|2006-05-04|2006-05-08|Estimate|||||||2013-03-05|2013-03-06|Estimate|July 2006||2006-07-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|October 2007|Actual|2007-10-31||Interventional|||A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)|A Randomized, Multi-Center Study of the Pimecrolimus-Eluting (Corio™) and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System (SymBio™) in Patients With De Novo Lesions of the Native Coronary Arteries|Completed||Phase 3|246|Actual|Cordis Corporation||3|||f||||t||||||||||2018-06-01 04:01:14.054324|2018-06-01 04:01:14.054324
NCT00322556|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2012-09-27||2012-09-27|2006-05-05|2006-05-08|Estimate|2012-09-27|2012-10-26|Estimate||||2012-09-27|2012-10-26|Estimate|November 2005||2005-11-30|September 2012|2012-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)|A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)|Completed||Phase 3|55|Actual|CSL Behring||1|||f||||||||||||||2018-06-01 04:01:14.154076|2018-06-01 04:01:14.154076
NCT00322543|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2008-10-16|2006-05-04|2006-05-08|Estimate|||||||2008-10-16|2008-10-17|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|May 2008|Actual|2008-05-31|November 2006|Actual|2006-11-30||Interventional|||Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)|Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID) A Multi-Center Study of the Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System (Corio™) in Patients With De Novo Lesions of the Native Coronary Arteries|Terminated||Phase 3|3|Actual|Conor Medsystems||1|||f||||f||||||||||2018-06-01 04:01:14.661043|2018-06-01 04:01:14.661043
NCT00322530|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2012-08-23|2006-05-04|2006-05-08|Estimate|||||||2012-08-23|2012-08-24|Estimate|April 2006||2006-04-30|August 2012|2012-08-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|rescue||Comparison of Dialysis Strategies in Critically Ill Patients With Acute Renal Failure|Comparison of Dialysis Strategies in Critically Ill Patients With Acute Renal Failure on the Intensive Care Unit|Completed||N/A|230|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 04:01:14.735302|2018-06-01 04:01:14.735302
NCT00322517|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17||2009-05-09|2011-05-10|2006-05-05|2006-05-08|Estimate||||2009-09-24|2009-09-28|Estimate|2011-05-10|2011-05-17|Estimate|April 2006||2006-04-30|May 2011|2011-05-31|July 2009|Actual|2009-07-31|June 2008|Actual|2008-06-30||Interventional|||Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer|A Phase 2 Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer|Completed||Phase 2|90|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:01:14.827146|2018-06-01 04:01:14.827146
NCT00322504|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2010-01-06|2006-05-05|2006-05-08|Estimate|||||||2010-01-06|2010-01-07|Estimate|January 2006||2006-01-31|November 2006|2006-11-30|September 2006||2006-09-30|||||Interventional|||Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study||Completed||N/A|10||University of New Mexico|||||f||||||||||||||2018-06-01 04:01:14.920919|2018-06-01 04:01:14.920919
NCT00322491|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2010-10-30||2014-02-10|2006-05-04|2006-05-08|Estimate|2010-10-30|2010-11-24|Estimate||||2014-02-10|2014-03-13|Estimate|March 2004||2004-03-31|February 2014|2014-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients|Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF|Completed||Phase 2|49|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:01:14.991034|2018-06-01 04:01:14.991034
NCT00322478|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|||2015-10-30|2006-05-05|2006-05-08|Estimate|||||||2015-10-30|2015-11-03|Estimate|April 2006||2006-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes|Non-Significant Risk Investigational Device Study of the Wireless GlucoMON™ Glucose Meter Accessory and Real-time Blood Glucose Alerts as an Enabling Technology for People Who Team Manage Diabetes|Completed||Phase 2/Phase 3|432|Actual|Diabetech||1|||f||||t||||||||||2018-06-01 04:01:15.538265|2018-06-01 04:01:15.538265
NCT00322465|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2010-06-17|2010-06-17|2014-11-13|2006-05-04|2006-05-08|Estimate|2011-07-21|2011-08-17|Estimate|2011-07-21|2011-08-17|Estimate|2014-11-13|2014-11-25|Estimate|November 2006||2006-11-30|May 2011|2011-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)|Phase II Randomized, Placebo-Controlled Double-Blind 4-Arm Trial for the Treatment of Non-Gonococcal Urethritis (NGU): Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)|Completed||Phase 2|305|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:01:15.647898|2018-06-01 04:01:15.647898
NCT00322452|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2009-04-29||2013-10-14|2006-05-05|2006-05-08|Estimate|2010-04-21|2010-05-17|Estimate||||2013-10-14|2013-11-07|Estimate|March 2006||2006-03-31|October 2013|2013-10-31|June 2010|Actual|2010-06-30|April 2008|Actual|2008-04-30||Interventional|IPASS||First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia|Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia|Completed||Phase 3|1329|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:01:16.432823|2018-06-01 04:01:16.432823
NCT00322439|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-05|2014-02-11||2016-02-19|2006-05-05|2006-05-08|Estimate|2014-02-11|2014-03-26|Estimate||||2016-02-19|2016-03-21|Estimate|May 2006||2006-05-31|February 2016|2016-02-29|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31|5 Years|Observational [Patient Registry]||Full Analysis Set, which consisted of all participants who received at least one dose of etanercept during the study.|Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis|Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis|Completed|||2511|Actual|Amgen|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma.~   "|||2018-06-01 04:01:17.440167|2018-06-01 04:01:17.440167
NCT00322426|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2006-06-22|2006-05-04|2006-05-05|Estimate|||||||2006-06-22|2006-06-23|Estimate|July 2006||2006-07-31|May 2006|2006-05-31|January 2007||2007-01-31|||||Interventional|||Sensory Cues for Freezing in Parkinson's Disease|Effect of Randomized Patient-Triggered Sensory Cues for Freezing of Gait in Parkinson's Disease|Unknown status|Not yet recruiting|N/A|20||Austin Health|||||f||||||||||||||2018-06-01 04:01:18.155528|2018-06-01 04:01:18.155528
NCT00322413|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2006-07-20|2006-05-04|2006-05-05|Estimate|||||||2006-07-20|2006-07-21|Estimate|January 1997||1997-01-31|May 2006|2006-05-31|April 1997||1997-04-30|||||Interventional|||Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial|Efficacy and Safety of Epoetin Omega in Patients Undergoing Regular Dialysis. Part II: Comparative Trial Versus Epoetin Alfa|Completed||Phase 3|80||General Hospital Sveti Duh|||||f||||||||||||||2018-06-01 04:01:18.218828|2018-06-01 04:01:18.218828
NCT00322400|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2013-07-30|2006-05-04|2006-05-05|Estimate|||||||2013-07-30|2013-07-31|Estimate|March 2006||2006-03-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|April 2009|Actual|2009-04-30||Interventional|||Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer|An Open-label, Dose-finding Study to Evaluate the Safety of AMG 706 in Combination With Paclitaxel or Docetaxel as Treatment for Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 1|46|Actual|Amgen||9|||f||||f||||||||||2018-06-01 04:01:18.370828|2018-06-01 04:01:18.370828
NCT00322387|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2010-06-15||2014-02-10|2006-05-04|2006-05-05|Estimate|2010-06-15|2010-07-14|Estimate||||2014-02-10|2014-03-13|Estimate|April 2004||2004-04-30|February 2014|2014-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients|Treatment With Plerixafor in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given With A Mobilizing Regimen of Chemotherapy and G-CSF|Completed||Phase 2|40|Actual|Sanofi|The number and complexity of the cohorts make generalizations regarding the data problematic. Each cohort was small, and mobilizing and high-dose conditioning regimens varied across sites. AEs may include residual effects of chemotherapy.|4|||f||||t||||||||||2018-06-01 04:01:18.476732|2018-06-01 04:01:18.476732
NCT00322374|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2010-07-06||2016-02-09|2006-05-04|2006-05-05|Estimate|2010-07-06|2010-08-10|Estimate||||2016-02-09|2016-03-10|Estimate|August 2006||2006-08-31|February 2016|2016-02-29|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Phase I Combination w/ Epirubicin|A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer|Completed||Phase 1|42|Actual|R-Pharm||3|||f||||f||||||||||2018-06-01 04:01:19.494451|2018-06-01 04:01:19.494451
NCT00322361|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2017-03-15|2006-05-04|2006-05-05|Estimate|||||||2017-03-15|2017-03-16|Actual|May 2006||2006-05-31|March 2017|2017-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)|A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process|Completed||Phase 2|566|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:01:20.317797|2018-06-01 04:01:20.317797
NCT00322348|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2010-11-11||2010-12-22|2006-05-03|2006-05-05|Estimate|2010-12-22|2011-01-24|Estimate||||2010-12-22|2011-01-24|Estimate|April 2006||2006-04-30|December 2010|2010-12-31|November 2009|Actual|2009-11-30|||||Interventional|||Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women|An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer|Completed||Phase 2|98|Actual|AstraZeneca|The criteria for non-inferiority were not met for the primary efficacy endpoint (PFS at Week 24). However, since recruitment was terminated prematurely, the study was no longer adequately powered to detect non-inferiority.|2|||f||||||||||||||2018-06-01 04:01:20.408459|2018-06-01 04:01:20.408459
NCT00322335|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|2010-09-17||2016-09-23|2006-05-04|2006-05-05|Estimate|2010-12-15|2011-01-14|Estimate||||2016-09-23|2016-10-20|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|September 2010|Actual|2010-09-30|July 2006|Actual|2006-07-31||Interventional|||Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC|Phase III, Open, Multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC Compared to a Booster Dose of Infanrix™ Hexa When Given to 14 Month-old Subjects Primed in Study DTPa-HBV-IPV-097 & Boosted in Study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097|Completed||Phase 3|230|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:01:20.747404|2018-06-01 04:01:20.747404
NCT00322322|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2011-05-03|2006-05-03|2006-05-05|Estimate|||||||2011-05-03|2011-05-04|Estimate|June 2006||2006-06-30|March 2007|2007-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Early Administration of L-carnitine in Hemodialysis Patients|Early Administration of L-carnitine in Hemodialysis Patients: Double Blind Randomized Trial Versus Placebo|Completed||Phase 3|110|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:01:21.393473|2018-06-01 04:01:21.393473
NCT00322309|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2013-07-23||2017-04-18|2006-05-03|2006-05-05|Estimate|2017-04-18|2017-04-20|Actual||||2017-04-18|2017-04-20|Actual|September 2005||2005-09-30|April 2017|2017-04-30|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects|The Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects|Completed||Phase 2|24|Actual|Boston University||2|||f||||t|t|f||||||No||2018-06-01 04:01:21.475211|2018-06-01 04:01:21.475211
NCT00322296|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2013-04-15|2006-05-04|2006-05-05|Estimate|||||||2013-04-15|2013-04-16|Estimate|April 2001||2001-04-30|May 2006|2006-05-31|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis|A Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis: a Topical Chemoprevention Strategy for Cutaneous T-cell Lymphoma.|Terminated||Phase 2|8|Actual|Fox Chase Cancer Center||||The response rate (5/8) had reached a statistical significant endpoint.|||||||||||||||2018-06-01 04:01:21.761806|2018-06-01 04:01:21.761806
NCT00322283|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2012-04-07|2006-05-04|2006-05-05|Estimate|||||||2012-04-07|2012-04-10|Estimate|May 2006||2006-05-31|April 2012|2012-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study of Oglemilast for the Prevention of Asthma.|Efficacy and Safety of Oglemilast in the Prevention of Exercise-Induced Bronchospasm|Completed||Phase 2|24|Actual|Forest Laboratories||2|||f||||||||||||||2018-06-01 04:01:21.835611|2018-06-01 04:01:21.835611
NCT00322270|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2008-08-12|2006-05-03|2006-05-05|Estimate|||||||2008-08-12|2008-08-15|Estimate|January 2006||2006-01-31|August 2008|2008-08-31||||||||Interventional|||Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters|Phase 3, Multicenter, Multinational, Open-Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects With Occluded Central Venous Access Devices (SONOMA-3)|Completed||Phase 3|||ARCA Biopharma, Inc.|||||f||||f||||||||||2018-06-01 04:01:21.896784|2018-06-01 04:01:21.896784
NCT00322257|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2017-02-28|2006-05-04|2006-05-05|Estimate|||||||2017-02-28|2017-03-01|Actual|May 1, 2006|Actual|2006-05-01|February 2017|2017-02-28|April 2, 2008|Actual|2008-04-02|April 2, 2008|Actual|2008-04-02||Interventional|||Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes|Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy|Terminated||Phase 3|596|Actual|Novo Nordisk A/S||2||See termination reason in detailed description|f||||f||||||||||2018-06-01 04:01:21.986354|2018-06-01 04:01:21.986354
NCT00322244|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2011-01-31|2006-05-03|2006-05-05|Estimate|||||||2011-01-31|2011-02-01|Estimate|January 2003||2003-01-31|January 2011|2011-01-31|October 2003||2003-10-31|||||Interventional|||Massage Therapy for Osteoarthritis of the Knee|Massage Therapy for Osteoarthritis of the Knee|Completed||N/A|66||Rutgers, The State University of New Jersey|||||f||||||||||||||2018-06-01 04:01:22.367741|2018-06-01 04:01:22.367741
NCT00322231|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2010-05-12||2015-01-14|2006-05-04|2006-05-05|Estimate|2010-11-17|2010-12-15|Estimate||||2015-01-14|2015-01-26|Estimate|May 2006||2006-05-31|January 2015|2015-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)|A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live in Subjects With a History of Herpes Zoster|Completed||Phase 3|101|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:01:22.436278|2018-06-01 04:01:22.436278
NCT00322218|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2008-10-22|2006-05-04|2006-05-05|Estimate|||||||2008-10-22|2008-10-23|Estimate|May 2006||2006-05-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R|A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|CTI BioPharma||2|||f||||||||||||||2018-06-01 04:01:22.71797|2018-06-01 04:01:22.71797
NCT00322192|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2015-06-08|2006-05-04|2006-05-05|Estimate|||||||2015-06-08|2015-06-10|Estimate|January 2004||2004-01-31|May 2006|2006-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Evaluation of Whether Functional Strength Training Can Enhance Recovery of Mobility After Stroke|The Effects of Functional Strength Training on Weakness and Function of the Lower Limb After Stroke|Completed||Phase 2|300|Anticipated|St George's, University of London|||||f||||||||||||||2018-06-01 04:01:23.105667|2018-06-01 04:01:23.105667
NCT00322179|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2015-03-04|2006-05-04|2006-05-05|Estimate|||||||2015-03-04|2015-03-06|Estimate|November 2005||2005-11-30|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2007|Actual|2007-11-30||Observational|||Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C|Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C|Completed|||22|Actual|Palo Alto Veterans Institute for Research|||2||f||||||||||||||2018-06-01 04:01:23.189602|2018-06-01 04:01:23.189602
NCT00322166|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2009-10-20|2006-05-04|2006-05-05|Estimate|||||||2009-10-20|2009-10-21|Estimate|July 2006||2006-07-31|October 2009|2009-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||The FREEDOM Study: a Randomised Controlled Trial of Sunlight and Calcium in Older People|A Randomised Controlled Trial of Sunlight and Calcium Supplementation to Reduce Vitamin D Deficiency and Falls in Older People in Residential Care|Completed||N/A|600|Anticipated|University of Sydney||3|||f||||f||||||||||2018-06-01 04:01:23.251779|2018-06-01 04:01:23.251779
NCT00322153|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2010-07-20||2010-08-25|2006-05-04|2006-05-05|Estimate|2010-08-25|2010-09-16|Estimate||||2010-08-25|2010-09-16|Estimate|June 2005||2005-06-30|August 2010|2010-08-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type|Completed||Phase 3|677|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 04:01:23.353251|2018-06-01 04:01:23.353251
NCT00322140|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2017-06-30|2006-05-04|2006-05-05|Estimate|||||||2017-06-30|2017-07-02|Actual|May 1, 2006||2006-05-01|August 25, 2011|2011-08-25|January 14, 2008|Actual|2008-01-14|January 14, 2008|Actual|2008-01-14||Interventional|||CDDO to Treat Solid Tumors and Lymphomas|Phase I Study of CDDO in Solid Tumors and Lymphomas|Completed||Phase 1|7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:01:23.914466|2018-06-01 04:01:23.914466
NCT00322127|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-04|||2018-03-27|2006-05-04|2006-05-05|Estimate|||||||2018-03-27|2018-03-29|Actual|May 3, 2006||2006-05-03|January 8, 2018|2018-01-08|January 23, 2015|Actual|2015-01-23|January 23, 2015|Actual|2015-01-23||Interventional|||An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers|A Pilot Study of the Safety and Activity of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers|Completed||Phase 1|44|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:01:23.973554|2018-06-01 04:01:23.973554
NCT00322114|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2013-09-19|2006-05-03|2006-05-04|Estimate|||||||2013-09-19|2013-09-20|Estimate|February 2006||2006-02-28|July 2009|2009-07-31||||February 2009|Anticipated|2009-02-28||Interventional|||Lycopene in Preventing Prostate Cancer in Healthy Participants|Mechanism of Prostate Cancer Prevention by Lycopene|Unknown status|Recruiting|N/A|150|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 04:01:24.063092|2018-06-01 04:01:24.063092
NCT00322101|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2013-04-04||2014-10-23|2006-05-02|2006-05-04|Estimate|2013-08-21|2013-10-28|Estimate||||2014-10-23|2014-10-31|Estimate|January 2006||2006-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|April 2012|Actual|2012-04-30||Interventional|||Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia|A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia|Completed||Phase 3|25|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 04:01:24.288477|2018-06-01 04:01:24.288477
NCT00322075|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2007-09-11|2006-05-03|2006-05-04|Estimate|||||||2007-09-11|2007-09-12|Estimate|April 2006||2006-04-30|September 2007|2007-09-30|November 2006||2006-11-30|||||Interventional|||LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous|Comparison of Glycaemic Fluctuations During 3 Days Subcutaneous Continuous Monitoring in Patients With Basal Substitution Human Insulin NPH vs Insuline Glargine|Completed||Phase 4|35||Sanofi|||||f||||||||||||||2018-06-01 04:01:24.633311|2018-06-01 04:01:24.633311
NCT00322062|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2008-04-15|2006-05-02|2006-05-04|Estimate|||||||2008-04-15|2008-04-16|Estimate|April 2002||2002-04-30|April 2008|2008-04-30|March 2003||2003-03-31|||||Interventional|||MOVIPREP® Versus NaP Pivotal Phase III Study|A Prospective Randomised Single-Blinded Multicentric and Pivotal Phase III Study Comparing the Efficacy, Safety and Acceptability of a New 2 Litres Gut Lavage Solution NRL994 Versus a Sodium Phosphate Solution for Colonoscopy Preparation|Completed||Phase 3|340|Actual|Norgine||2|||f||||f||||||||||2018-06-01 04:01:24.701984|2018-06-01 04:01:24.701984
NCT00322049|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2017-02-28|2017-02-16|2017-12-20|2006-05-03|2006-05-04|Estimate|2017-06-21|2017-07-19|Actual|2017-02-16|2017-02-17|Actual|2017-12-20|2018-01-19|Actual|February 2004||2004-02-29|December 2017|2017-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants|A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants|Completed||Phase 1/Phase 2|51|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||t||||||||Undecided||2018-06-01 04:01:24.817347|2018-06-01 04:01:24.817347
NCT00322036|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2008-08-01|2006-05-02|2006-05-04|Estimate|||||||2008-08-01|2008-08-05|Estimate|May 2006||2006-05-31|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's|Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type|Terminated||Phase 3|800|Actual|Myrexis Inc.||2||Myriad has discontinued the development of Flurizan.|f||||t||||||||||2018-06-01 04:01:25.579834|2018-06-01 04:01:25.579834
NCT00322023|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2008-10-27|2006-05-02|2006-05-04|Estimate|||||||2008-10-27|2008-10-29|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Safety and Effectiveness of D-Serine in Schizophrenia|PK/PD Study of Escalating Dose D-Serine as Adjunctive Treatment in Schizophrenia|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|National Institute of Mental Health (NIMH)||1|||f||||t||||||||||2018-06-01 04:01:25.767269|2018-06-01 04:01:25.767269
NCT00322010|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2014-03-17|2006-05-02|2006-05-04|Estimate|||||||2014-03-17|2014-03-18|Estimate|June 2005||2005-06-30|March 2014|2014-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Early Directed Physical Therapy in the Management of Mechanically Ventilated Patients in a Medical Intensive Care Unit|A Randomized Trial of Early Physical and Occupational Therapy in Mechanically Ventilated, Critically Ill Patients|Completed||Phase 2|104|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 04:01:25.897477|2018-06-01 04:01:25.897477
NCT00321997|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2006-05-02|2006-05-02|2006-05-04|Estimate|||||||2006-05-02|2006-05-04|Estimate|May 2001||2001-05-31|May 2006|2006-05-31|October 2007||2007-10-31|||||Interventional|||A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.|A PHASE II/III RANDOMIZED, DOUBLE-MASKED, CONTROLLED, DOSE-RANGING, MULTI-CENTER COMPARATIVE TRIAL, IN PARALLEL GROUPS, TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTIONS OF EYE001 (ANTI-VEGF PEGYLATED APTAMER) GIVEN EVERY 6 WEEKS FOR 54 WEEKS, IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION (AMD)|Completed||Phase 2/Phase 3|540||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 04:01:25.954393|2018-06-01 04:01:25.954393
NCT00321984|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2009-02-26||2011-04-25|2006-05-02|2006-05-04|Estimate|2009-02-26|2009-03-23|Estimate||||2011-04-25|2011-04-28|Estimate|June 2006||2006-06-30|April 2011|2011-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease|A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|947|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:01:26.027169|2018-06-01 04:01:26.027169
NCT00321971|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2014-02-12||2018-03-06|2006-05-02|2006-05-04|Estimate|2018-02-04|2018-03-07|Actual||||2018-03-06|2018-04-03|Actual|February 2007||2007-02-28|March 2018|2018-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Of the 73 subjects enrolled in the study, 54 (71%) completed the study. Using an intention-to- treat approach, we performed a repeated-measures linear mixed effects analysis with the total sample (N=73) .|Prevention of Depression in Spouses of People With Cognitive Impairment|Prevention of Psychiatric Morbidity in AD Caregivers|Completed||N/A|73|Actual|University of Pittsburgh|The relatively small size and racial composition of the sample was a limitation. The generalizability of our findings are reduced by our focus on family caregivers who reside with the individual with cognitive impairment.|2|||f||||t|f|f||||||No||2018-06-01 04:01:26.786961|2018-06-01 04:01:26.786961
NCT00321958|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2017-03-28|2006-05-03|2006-05-04|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2006||2006-04-30|March 2017|2017-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer|Cryotherapy Ablation of Barrett's Esophagus and Early Esophageal Cancer|Terminated||Phase 2|23|Actual|University of Maryland||||The sponsor determined that adequate data had been acquired.|f||||t||||||||||2018-06-01 04:01:27.056725|2018-06-01 04:01:27.056725
NCT00321945|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2013-09-26|2006-05-03|2006-05-04|Estimate|||||||2013-09-26|2013-09-27|Estimate|December 2005||2005-12-31|September 2013|2013-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers|A Retrospective Analysis of the Use of ACE-inhibitors and Angiotensin Receptor Blockers on Post-Operative Atrial Fibrillation|Completed|||546|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:01:27.191358|2018-06-01 04:01:27.191358
NCT00321932|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2012-05-04||2017-01-26|2006-05-02|2006-05-04|Estimate|2012-09-26|2012-10-26|Estimate||||2017-01-26|2017-03-09|Actual|July 2005||2005-07-31|January 2017|2017-01-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant|A Randomized Phase II of Zoledronic Acid (Zometa) in the Prevention of Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|61|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 04:01:27.262925|2018-06-01 04:01:27.262925
NCT00321919|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2016-02-24||2016-05-27|2006-05-03|2006-05-04|Estimate|2016-04-18|2016-05-25|Estimate||||2016-05-27|2016-06-29|Estimate|July 2000||2000-07-31|May 2016|2016-05-31|December 2004|Actual|2004-12-31|October 2004|Actual|2004-10-31||Interventional||Baseline characteristics were described for the intent-to-treat (ITT) population, which included all participants randomized according to their randomized treatment group, regardless of the treatment actually received.|A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia|A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy.|Completed||Phase 3|605|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:01:27.668415|2018-06-01 04:01:27.668415
NCT00321906|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2013-12-17||2016-09-19|2006-05-02|2006-05-04|Estimate|2013-12-17|2014-02-04|Estimate||||2016-09-19|2016-09-21|Estimate|April 2002||2002-04-30|September 2016|2016-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of Sirolimus and Azathioprine in Lung Transplantation|Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen Versus Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation|Completed||Phase 4|181|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:01:29.45454|2018-06-01 04:01:29.45454
NCT00321893|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2014-10-08||2015-12-21|2006-05-02|2006-05-04|Estimate|2015-04-24|2015-04-27|Estimate||||2015-12-21|2016-01-25|Estimate|January 2006||2006-01-31|October 2014|2014-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Three (3) participants in Arm I: Budesonide, and one (1) in Arm II: Placebo later refused follow up CT and were excluded from overall analysis.|Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer|Randomized Phase II Trial of Budesonide Turbuhaler® 800 Micrograms/Twice Daily Versus Placebo in High-Risk Population With Undetermined Lung Nodules Detected at Screening Low Dose CT Scan|Completed||Phase 2|225|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 04:01:29.82357|2018-06-01 04:01:29.82357
NCT00321880|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2017-05-25|2006-05-02|2006-05-04|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2006||2006-02-28|July 2012|2012-07-31|October 2008|Actual|2008-10-31|February 2007|Actual|2007-02-28||Interventional|||Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia|Healing Touch as a Supportive Intervention for Adult Acute Leukemia Patients: A Pilot Study|Completed||N/A|40|Actual|Wake Forest University Health Sciences|||||f||||f|f|f||||||||2018-06-01 04:01:30.474857|2018-06-01 04:01:30.474857
NCT00321867|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2014-05-27|2006-05-03|2006-05-04|Estimate|||||||2014-05-27|2014-05-28|Estimate|January 2004||2004-01-31|May 2014|2014-05-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||Graft-Augmented Rectocele Repair-A Randomized Surgical Trial|Porcine-Derived Small Intestine Submucosa Graft-Augmented Rectocele Repair-A Randomized Trial|Completed||N/A|160|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-06-01 04:01:30.548908|2018-06-01 04:01:30.548908
NCT00321854|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2009-12-18||2014-05-07|2006-05-03|2006-05-04|Estimate|2009-12-18|2010-01-26|Estimate||||2014-05-07|2014-05-16|Estimate|May 2006||2006-05-31|March 2014|2014-03-31||||April 2009|Actual|2009-04-30||Interventional|||Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)|A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease.|Completed||Phase 4|535|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 04:01:30.736426|2018-06-01 04:01:30.736426
NCT00321828|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2012-10-31||2013-01-16|2006-05-02|2006-05-04|Estimate|2013-01-08|2013-01-14|Estimate||||2013-01-16|2013-01-24|Estimate|March 2006||2006-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2009|Actual|2009-11-30||Interventional|||Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery|A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients With Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor|Completed||Phase 2|90|Actual|NSABP Foundation Inc||1|||f||||t||||||||||2018-06-01 04:01:32.203619|2018-06-01 04:01:32.203619
NCT00321815|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03||2010-08-09|2010-12-16|2006-05-03|2006-05-04|Estimate||||2010-08-09|2010-08-11|Estimate|2010-12-16|2010-12-23|Estimate|August 2006||2006-08-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer|A Randomized Phase 2 Trial Of Erlotinib With Or Without PF-3512676 For The Treatment Of Patients With Advanced EGFR-Positive Non-Small Cell Lung Cancer After Failure Of At Least One Prior Chemotherapy Regimen|Completed||Phase 2|43|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:01:33.384065|2018-06-01 04:01:33.384065
NCT00321802|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2014-12-30|2006-05-03|2006-05-04|Estimate|||||||2014-12-30|2015-01-01|Estimate|April 2006||2006-04-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PAFRIOSIES||Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins|Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins|Completed||Phase 2|40|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 04:01:33.502472|2018-06-01 04:01:33.502472
NCT00321789|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2014-09-02||2015-04-06|2006-05-03|2006-05-04|Estimate|2014-09-25|2014-09-26|Estimate||||2015-04-06|2015-04-24|Estimate|September 2007||2007-09-30|August 2014|2014-08-31|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|CouPLES||A Patient-Spouse Intervention for Self-Managing High Cholesterol|A Patient-Spouse Intervention for Self-Managing High Cholesterol|Completed||N/A|255|Actual|VA Office of Research and Development|The dietary measure underestimates dietary intake but should not invalidate differences between groups or across time. Sample size for dietary analyses was reduced due to missing data, but non-responders did not differ on measured characteristics.|2|||f||||f||||||||||2018-06-01 04:01:33.60858|2018-06-01 04:01:33.60858
NCT00321763|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|2013-03-21||2016-09-23|2006-05-03|2006-05-04|Estimate|2013-05-16|2013-06-24|Estimate||||2016-09-23|2016-10-20|Estimate|April 2006||2006-04-30|September 2016|2016-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate|Demonstrate the Lot-to-lot Consistency of 3 Consecutive Production Lots of an Adjuvanted Influenza Vaccine Candidate and Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate Versus Fluarix™ Administered Intramuscularly in Elderly|Completed||Phase 2|3124|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:01:35.055968|2018-06-01 04:01:35.055968
NCT00321750|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2006-10-17|2006-05-02|2006-05-04|Estimate|||||||2006-10-17|2006-10-18|Estimate|December 2004||2004-12-31|May 2006|2006-05-31|April 2005||2005-04-30|||||Interventional|||Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream|Phase 2 Study of the Treatment of Oral Erosive Lichen Planus With 1% Pimecrolimus Cream: a Double Blind Randomized Prospective Trial With Measurement of Pimecrolimus Levels in the Blood|Terminated||Phase 2|14||Centre Hospitalier Universitaire de Nice|||||f||||||||||||||2018-06-01 04:01:36.506867|2018-06-01 04:01:36.506867
NCT00321737|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2009-02-20||2012-02-01|2006-05-02|2006-05-04|Estimate|2009-07-20|2009-08-28|Estimate||||2012-02-01|2012-02-03|Estimate|May 2006||2006-05-31|February 2012|2012-02-29|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis|A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.|Completed||Phase 3|445|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:01:36.602469|2018-06-01 04:01:36.602469
NCT00321724|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2013-01-14|2006-05-02|2006-05-04|Estimate|||||||2013-01-14|2013-01-15|Estimate|May 2006||2006-05-31|January 2013|2013-01-31||||May 2007|Actual|2007-05-31||Interventional|||AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase II Trial of AZD2171 in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Patients|Completed||Phase 2|35|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:01:37.397016|2018-06-01 04:01:37.397016
NCT00321711|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2010-11-18||2013-07-31|2006-05-02|2006-05-04|Estimate|2011-03-03|2011-04-05|Estimate||||2013-07-31|2013-08-08|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|October 2010|Actual|2010-10-31|April 2009|Actual|2009-04-30||Interventional|||Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents|A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim (AMG 531) Treatment of Subjects With Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents|Completed||Phase 2|69|Actual|Amgen||5|||f||||||||||||||2018-06-01 04:01:37.522981|2018-06-01 04:01:37.522981
NCT00321698|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2014-12-30||2017-05-14|2006-05-02|2006-05-04|Estimate|2016-12-28|2016-12-30|Estimate||||2017-05-14|2017-05-16|Actual|January 2006||2006-01-31|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|October 2009|Actual|2009-10-31||Interventional|||Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer|Phase I/II Study of Preoperative Radiation and Docetaxel Activity in High Risk Localized Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|25|Actual|OHSU Knight Cancer Institute|Patient accrual was not completed due to the sponsor withdrawing funding.|2|||f||||t||||||||||2018-06-01 04:01:39.429446|2018-06-01 04:01:39.429446
NCT00321685|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2015-04-21||2018-04-20|2006-05-02|2006-05-04|Estimate|2015-04-21|2015-05-12|Estimate||||2018-04-20|2018-04-24|Actual|July 25, 2006|Actual|2006-07-25|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|August 12, 2013|Actual|2013-08-12||Interventional||Eligible and treated patients|Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer|Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer|Active, not recruiting||Phase 2|57|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:01:39.89553|2018-06-01 04:01:39.89553
NCT00321490|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2009-03-24|2006-05-01|2006-05-03|Estimate|||||||2009-03-24|2009-03-25|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|May 2007|Actual|2007-05-31|||||Interventional|DIAMOND||Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled and Active-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD|Completed||Phase 3|600||AstraZeneca|||||f||||||||||||||2018-06-01 04:01:44.55958|2018-06-01 04:01:44.55958
NCT00321672|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2010-06-16||2011-05-13|2006-05-02|2006-05-04|Estimate|2011-05-13|2011-06-14|Estimate||||2011-05-13|2011-06-14|Estimate|June 2006||2006-06-30|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy|A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy|Completed||Phase 3|494|Actual|NeurogesX|Differences between the 60- and 30-minute Control groups prevented pooling according to prespecified criteria resulting in treatment comparisons between 60- and 30-minute NGX-4010 groups and their respective Control groups with relatively low power.|4|||f||||f||||||||||2018-06-01 04:01:40.531531|2018-06-01 04:01:40.531531
NCT00321659|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2017-03-10|2006-05-03|2006-05-04|Estimate|||||||2017-03-10|2017-03-14|Actual|October 10, 2002|Actual|2002-10-10|March 2017|2017-03-31|September 21, 2005|Actual|2005-09-21|September 21, 2005|Actual|2005-09-21||Interventional|||Optimizing Fibromyalgia Self-management|Short and Long-term Effects of Exercise and Education as Self-management in Women With Fibromyalgia|Completed||N/A|207|Actual|Beth Israel Deaconess Medical Center||4|||f||||f|f|f||||||No|No plan was prepared, as no data was to be shared.|2018-06-01 04:01:41.186313|2018-06-01 04:01:41.186313
NCT00321646|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2013-11-06||2016-04-13|2006-05-02|2006-05-04|Estimate|2013-11-06|2013-12-25|Estimate||||2016-04-13|2016-05-16|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|November 2008|Actual|2008-11-30||Interventional||42 enrolled, 1 participant withdrew before receiving treatment.|Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy|A Phase II Study of Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy|Completed||Phase 2|42|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:01:41.257239|2018-06-01 04:01:41.257239
NCT00321633|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2013-08-23|2006-05-02|2006-05-04|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2005||2005-09-30|July 2009|2009-07-31||||September 2009|Actual|2009-09-30||Interventional|||Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer|A Randomized Phase II Pilot Trial of Carboplatin Compared to Docetaxel for Patients With Metastatic Genetic Breast Cancer [BRCA Trial]|Completed||Phase 2|148|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:01:41.687962|2018-06-01 04:01:41.687962
NCT00321620|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2010-12-10|2010-06-29|2016-02-19|2006-05-02|2006-05-04|Estimate|2014-02-04|2014-03-21|Estimate|2010-06-29|2010-07-01|Estimate|2016-02-19|2016-03-21|Estimate|April 2006||2006-04-30|February 2016|2016-02-29|February 2012|Actual|2012-02-29|October 2009|Actual|2009-10-31||Interventional|||Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Completed||Phase 3|1904|Actual|Amgen||2|||f||||t||||||||||2018-06-01 04:01:41.865309|2018-06-01 04:01:41.865309
NCT00321594|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2017-03-27||2017-10-03|2006-05-02|2006-05-04|Estimate|2017-08-28|2017-09-26|Actual||||2017-10-03|2017-11-06|Actual|May 2006||2006-05-31|October 2017|2017-10-31|October 2012|Actual|2012-10-31|August 2010|Actual|2010-08-31||Interventional||42 Patients from Phase II (including last 6 patients from Phase I)|Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|A Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation|Completed||Phase 1/Phase 2|54|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:01:43.574387|2018-06-01 04:01:43.574387
NCT00321581|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2018-05-12|2006-05-03|2006-05-04|Estimate|||||||2018-05-12|2018-05-15|Actual|May 1, 2006||2006-05-01|June 29, 2012|2012-06-29|October 6, 2011|Actual|2011-10-06|||||Interventional|||AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia|Phase I Trial of CEDIRANIB (AZD2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors|Completed||Phase 1|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:01:44.063567|2018-06-01 04:01:44.063567
NCT00321568|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2017-06-30|2006-05-03|2006-05-04|Estimate|||||||2017-06-30|2017-07-02|Actual|May 1, 2006||2006-05-01|April 19, 2011|2011-04-19|April 19, 2011||2011-04-19|||||Observational|||Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis|An Exploratory Study on Detection of Cortical and White Matter Damage in Patients With Multiple Sclerosis Using Magnetic Resonance Imaging at 7 Tesla|Completed|||60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:01:44.122209|2018-06-01 04:01:44.122209
NCT00321555|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-03|||2018-05-22|2006-05-03|2006-05-04|Estimate|||||||2018-05-22|2018-05-23|Actual|May 2, 2006||2006-05-02|May 4, 2018|2018-05-04|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||LMB-2 to Treat Hairy Cell Leukemia|A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia|Active, not recruiting||Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 04:01:44.173271|2018-06-01 04:01:44.173271
NCT00321542|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2015-07-28|2006-05-02|2006-05-03|Estimate|||||||2015-07-28|2015-07-29|Estimate|September 2006||2006-09-30|February 2015|2015-02-28|September 2017|Anticipated|2017-09-30|September 2015|Anticipated|2015-09-30||Observational|||Coronary CT Angiography in Asymptomatic Diabetes Mellitus|Assessment of the Additive Value of Multislice Computed Tomographic Angiography of the Coronary Arteries in the Prediction of Acute Cardiac Events in Asymptomatic Individuals With Type II Diabetes Mellitus|Unknown status|Active, not recruiting||793|Actual|Carmel Medical Center|||||f||||t||||||||||2018-06-01 04:01:44.253954|2018-06-01 04:01:44.253954
NCT00321529|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2007-05-23|2006-05-01|2006-05-03|Estimate|||||||2007-05-23|2007-05-24|Estimate||||May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Observational|||Comparison of the ProAdjuster Analysis to the Penning Method of Determining Intersegmental Motion of the Cervical Spine||Completed|||||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 04:01:44.313701|2018-06-01 04:01:44.313701
NCT00321516|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2013-11-07|2006-05-01|2006-05-03|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder|Effects of Aripiprazole on the Steady-State Pharmacokinetics of Lamotrigine in Subjects With Bipolar I Disorder|Completed||Phase 1|20||Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-06-01 04:01:44.365242|2018-06-01 04:01:44.365242
NCT00321503|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2013-12-06|2006-05-02|2006-05-03|Estimate|||||||2013-12-06|2013-12-09|Estimate|May 2006||2006-05-31|December 2013|2013-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)|Diagnosis and Response to Treatment of Laryngopharyngeal Reflux Using an Oropharyngeal Aerosolized pH Probe|Completed|||45|Actual|Emory University|||||f||||||||||||||2018-06-01 04:01:44.499396|2018-06-01 04:01:44.499396
NCT00312585|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2016-04-05|2006-04-06|2006-04-10|Estimate|||||||2016-04-05|2016-04-07|Estimate|February 2005||2005-02-28|May 2011|2011-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Acupuncture for the Prevention of Postdates Pregnancy|A Randomized Controlled Trial of Acupuncture to Prevent Postdates Pregnancy|Completed||Phase 2|89|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-06-01 04:04:24.002663|2018-06-01 04:04:24.002663
NCT00321477|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2017-01-19|2006-05-01|2006-05-03|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2005||2005-12-31|January 2017|2017-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder|NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms|Completed||Phase 2|160|Anticipated|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:01:44.665251|2018-06-01 04:01:44.665251
NCT00321464|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2010-12-10|2010-06-29|2017-01-25|2006-05-02|2006-05-03|Estimate|2014-01-23|2014-03-10|Estimate|2010-06-29|2010-07-01|Estimate|2017-01-25|2017-03-08|Actual|April 2006||2006-04-30|January 2017|2017-01-31|April 2012|Actual|2012-04-30|March 2009|Actual|2009-03-31||Interventional|||A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.|A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer|Completed||Phase 3|2049|Actual|Amgen||2|||f||||t||||||||||2018-06-01 04:01:44.849844|2018-06-01 04:01:44.849844
NCT00321451|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2016-01-28|2006-05-02|2006-05-03|Estimate|||||||2016-01-28|2016-01-29|Estimate|May 2006||2006-05-31|January 2016|2016-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia|Behavioral Insomnia Therapy With Fibromyalgia|Completed||Phase 2/Phase 3|111|Actual|Duke University||3|||f||||t||||||||||2018-06-01 04:01:46.710543|2018-06-01 04:01:46.710543
NCT00321438|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2009-05-15|2006-05-02|2006-05-03|Estimate|||||||2009-05-15|2009-05-18|Estimate|July 2005||2005-07-31|May 2009|2009-05-31||||||||Observational|||Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus|Prospective, Observational Study of Subjects With CXCR4-Tropic or Non-Phenotypeable HIV to Assess Changes in Tropism Over Time|Terminated|||150||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:01:46.79269|2018-06-01 04:01:46.79269
NCT00321425|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2008-05-20|2006-05-02|2006-05-03|Estimate|||||||2008-05-20|2008-05-22|Estimate|May 2006||2006-05-31|October 2007|2007-10-31||||||||Interventional|||Ultrasound Guidance Vs. Electrical Nerve Stimulation for Infraclavicular Brachial Plexus Block||Completed||N/A|80|Anticipated|Rikshospitalet University Hospital|||||f||||||||||||||2018-06-01 04:01:46.930653|2018-06-01 04:01:46.930653
NCT00321412|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01||2014-05-27|2014-05-27|2006-05-01|2006-05-03|Estimate||||2014-05-27|2014-05-30|Estimate|2014-05-27|2014-05-30|Estimate|March 2006||2006-03-31|May 2014|2014-05-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas|A Double-blind, Randomized, Placebo-controlled Multicenter Study to Assess the Safety and Efficacy of AST-120 in Mild to Moderately Active Crohn's Patients With Fistulas|Completed||Phase 3|191|Actual|Ocera Therapeutics||2|||f||||f||||||||||2018-06-01 04:01:47.015805|2018-06-01 04:01:47.015805
NCT00321399|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-07-15|2006-05-01|2006-05-03|Estimate|||||||2014-07-15|2014-07-16|Estimate|June 2006||2006-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|March 2010|Actual|2010-03-31||Observational|SPARC||Study of Perfusion and Anatomy's Role in Coronary Artery (CAD)|SPARC, Including Its Pilot CT Angiographic Study, is a Prospective, Open-label, Multicenter, Sequentially Sampled, Observational Registry to Define the Clinical Value of Stress Perfusion (Stress SPECT, Stress PET), Noninvasive Angiography (CTA) and Combined Perfusion-anatomy (PET/CT) Studies in Patients With Known or Suspected CAD With Respect to Post-test Resource Utilization and Prediction of Cardiac Death and Non-fatal Myocardial Infarction|Completed|||3019|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 04:01:47.253173|2018-06-01 04:01:47.253173
NCT00321386|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2011-06-27|2006-05-01|2006-05-03|Estimate|||||||2011-06-27|2011-06-28|Estimate|December 2003||2003-12-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|December 2008|Actual|2008-12-31||Observational|||Analysis of Clinical Profiles of Chinese Patients With Normal Tension Glaucoma|Parameters for Disease Progression in Chinese Patients With Normal Tension Glaucoma|Unknown status|Recruiting||500|Anticipated|Chinese University of Hong Kong|||||f||||t||||||Samples With DNA|"~     Blood taking for glaucoma genetics analysis shall be performed.~   "|||2018-06-01 04:01:47.36215|2018-06-01 04:01:47.36215
NCT00321373|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2013-03-14||2016-09-23|2006-05-02|2006-05-03|Estimate|2013-03-14|2013-05-01|Estimate||||2016-09-23|2016-10-20|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study to Evaluate an Influenza Vaccine Candidate|A Study to Demonstrate the Non-Inferiority of Influenza Vaccine Candidate, Compared With Fluarix™ Administered Intramuscularly in Elderly Aged 60 Years Old and Above|Completed||Phase 2|1220|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:01:47.468082|2018-06-01 04:01:47.468082
NCT00321360|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2012-02-04|2006-05-01|2006-05-03|Estimate|||||||2012-02-04|2012-02-07|Estimate|May 2006||2006-05-31|February 2012|2012-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Healthy Volunteers|Reaction Time Monitored Patient Maintained Propofol Sedation: a Volunteer Safety Study|Completed||Phase 4|20|Anticipated|University of Glasgow|||||f||||t||||||||||2018-06-01 04:01:48.050223|2018-06-01 04:01:48.050223
NCT00321347|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2012-06-21|2006-05-01|2006-05-03|Estimate|||||||2012-06-21|2012-06-22|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|May 2009|Anticipated|2009-05-31|||||Interventional|||Intravenous (IV) Lidocaine for Opioid-refractory Pain|A Randomized, Placebo Controlled Phase II Study of Parenteral Lidocaine's Ability To Acutely Relieve Opioid Refractory Pain|Withdrawn||Phase 2|0|Actual|San Diego Hospice & Palliative Care||||No patients enrolled and clinician no longer at institution.|f||||t||||||||||2018-06-01 04:01:48.105544|2018-06-01 04:01:48.105544
NCT00321334|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-08-04|2006-05-01|2006-05-03|Estimate|||||||2014-08-04|2014-08-06|Estimate|March 2006||2006-03-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLC|Survival Study of Neo-adjuvant Versus Adjuvant Chemotherapy With Docetaxel Combined Carboplatin in Resectable Stage IB to IIIA Non-small Lung Cancer|Completed||Phase 3|410|Actual|Chinese Society of Lung Cancer||1|||f||||t||||||||||2018-06-01 04:01:48.163376|2018-06-01 04:01:48.163376
NCT00321321|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|2008-09-29||2015-06-23|2006-05-02|2006-05-03|Estimate|2008-10-01|2008-10-02|Estimate||||2015-06-23|2015-07-16|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes|Phase 2 Study of The Beta Cell Responsiveness to GIP With and Without Sulfonylurea in Patients With Type 2 Diabetes|Completed||Phase 2|12|Actual|University Hospital, Gentofte, Copenhagen|||||f||||t||||||||||2018-06-01 04:01:48.224399|2018-06-01 04:01:48.224399
NCT00320957|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2008-05-23|2006-05-01|2006-05-03|Estimate|||||||2008-05-23|2008-05-26|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|December 2006||2006-12-31|||||Interventional|||Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital|Study of the Safety and Effectiveness of the Ologen (OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery|Completed||Phase 3|61|Actual|Pro Top & Mediking Company Limited|||||f||||||||||||||2018-06-01 04:01:52.135385|2018-06-01 04:01:52.135385
NCT00321308|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02||2009-09-24|2009-09-24|2006-05-02|2006-05-03|Estimate||||2009-09-24|2009-09-28|Estimate|2009-09-24|2009-09-28|Estimate|September 2006||2006-09-30|September 2009|2009-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer|A Randomized Phase II Trial Of Pemetrexed With Or Without PF-3512676 For The Treatment Of Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer After Failure Of One Prior Chemotherapy Regimen For Advanced Disease|Terminated||Phase 2|36|Actual|Pfizer||2||See Termination Reason in Detailed Description.|f||||f||||||||||2018-06-01 04:01:48.335184|2018-06-01 04:01:48.335184
NCT00321295|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2011-04-02|2006-05-01|2006-05-03|Estimate|||||||2011-04-02|2011-04-05|Estimate|August 2004||2004-08-31|April 2011|2011-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery|Prospective Evaluation Of Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery|Completed||Phase 3|40||William Beaumont Hospitals|||||f||||||||||||||2018-06-01 04:01:48.546919|2018-06-01 04:01:48.546919
NCT00321282|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2013-09-26|2006-05-01|2006-05-03|Estimate|||||||2013-09-26|2013-09-27|Estimate|February 2006||2006-02-28|September 2013|2013-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Retrospective Analysis of the Predictive Potential of Pre-operative|A Retrospective Analysis of the Predictive Potential of Pre-operative Data on Post-operative Atrial Fibrillation|Terminated||Phase 2|600|Anticipated|Emory University||||The study never started.|f||||f||||||||||2018-06-01 04:01:48.610882|2018-06-01 04:01:48.610882
NCT00321269|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2014-11-12||2015-11-23|2006-05-01|2006-05-03|Estimate|2015-09-21|2015-10-21|Estimate||||2015-11-23|2015-12-24|Estimate|October 2007||2007-10-31|November 2015|2015-11-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Depression and Congestive Heart Failure in Outpatients.|Depression and CHF in Outpatients|Completed||N/A|134|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:01:48.678655|2018-06-01 04:01:48.678655
NCT00321256|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2012-03-01|2006-05-02|2006-05-03|Estimate|||||||2012-03-01|2012-03-02|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|July 2007|Actual|2007-07-31|||||Interventional|||Human Islet Transplantation in Brittle Type 1 Diabetes Mellitus. The GRAGIL 2 Study.|Transplantation d'Ilots Pancreatiques Allogeniques Adultes Pour le Traitement du Diabete Insulino-dependant: Etude GRAGIL 2.|Completed||Phase 1/Phase 2|22||University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:01:48.876374|2018-06-01 04:01:48.876374
NCT00321243|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2008-06-03|2006-05-02|2006-05-03|Estimate|||||||2008-06-03|2008-06-04|Estimate|May 2006||2006-05-31|June 2008|2008-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Evaluation of Emergency Triage Using a Computerized Simulator|Evaluation of a Four-Level Triage Scale (the Geneva Emergency Triage Scale) Using a Computer Triage Simulator|Completed||N/A|150||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:01:48.942223|2018-06-01 04:01:48.942223
NCT00321230|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2008-04-15|2006-05-02|2006-05-03|Estimate|||||||2008-04-15|2008-04-16|Estimate|January 2001||2001-01-31|April 2008|2008-04-30|May 2001||2001-05-31|||||Interventional|||Clinical Evaluation of a New Reduced Volume Bowel Preparation|"A Pilot Monocentric, Open Phase II Study to Investigate the Efficacy and Safety of a New Oral Gut Cleansing Solution (Low Dose Bowel Prep) in 30 Patients Submitted to Colonoscopy"|Completed||Phase 2|30||Norgine|||||f||||f||||||||||2018-06-01 04:01:48.998491|2018-06-01 04:01:48.998491
NCT00321217|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2012-08-15|2006-05-02|2006-05-03|Estimate|||||||2012-08-15|2012-08-16|Estimate|May 2004||2004-05-31|November 2011|2011-11-30|April 2014|Anticipated|2014-04-30|November 2013|Anticipated|2013-11-30||Observational|||Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis|Pharmacogenomics of Anti-TNF Treatment in Patients With Rheumatoid Arthritis|Unknown status|Recruiting||700|Anticipated|Radboud University|||||f||||f||||||||||2018-06-01 04:01:49.053935|2018-06-01 04:01:49.053935
NCT00321204|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-04-21|2006-05-01|2006-05-03|Estimate|||||||2014-04-21|2014-04-23|Estimate|December 2005||2005-12-31|April 2014|2014-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias|A Retrospective Study of the Role of Thiazolidinediones to Reduce the Incidence of Atrial Arrhythmias in Patients After Cardiac Surgery|Terminated|||600||Emory University||||Terminated: We are no longer recruiting.|f||||f||||||||||2018-06-01 04:01:49.104136|2018-06-01 04:01:49.104136
NCT00321191|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2015-06-23|2006-05-02|2006-05-03|Estimate|||||||2015-06-23|2015-06-24|Estimate|May 2006||2006-05-31|August 2008|2008-08-31|September 2006|Actual|2006-09-30|||||Interventional|||Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients|Measurement of the Second Gas Effect on Sevoflurane in Anaesthetised Patients|Completed||Phase 4|14|Actual|Austin Health||2|||f||||||||||||||2018-06-01 04:01:49.155263|2018-06-01 04:01:49.155263
NCT00321178|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2010-06-29|2006-05-02|2006-05-03|Estimate|||||||2010-06-29|2010-06-30|Estimate|May 2006||2006-05-31|April 2010|2010-04-30|February 2009|Actual|2009-02-28|January 2008|Actual|2008-01-31||Interventional|BURULICO||BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA|Randomised Trial for Early Lesions Caused by M. Ulcerans - Comparison Between 8 Weeks Streptomycin and Rifampicin (SR), or 4 Weeks SR Followed by 4 Weeks R Plus Clarithromycin|Completed||Phase 2/Phase 3|151|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-06-01 04:01:49.206074|2018-06-01 04:01:49.206074
NCT00321165|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2009-02-10|2006-05-02|2006-05-03|Estimate|||||||2009-02-10|2009-02-11|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The AOT (Acridine Orange and Taurolidine) Trial|The AOT (Acridine Orange and Taurolidine) Trial: a Survey on Diagnosis and Prevention of Catheter-Related Infections in Patients on Home Parenteral Nutrition|Completed||Phase 3|60|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:01:49.269363|2018-06-01 04:01:49.269363
NCT00321152|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2010-06-07|2006-05-01|2006-05-03|Estimate|||||||2010-06-07|2010-06-08|Estimate|November 2006||2006-11-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|August 2008|Actual|2008-08-31||Interventional|||A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)|A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF Among SSRI-Resistant Outpatients With Major Depressive Disorder (MDD)|Completed||Phase 4|150|Anticipated|Massachusetts General Hospital||3|||f||||f||||||||||2018-06-01 04:01:49.324354|2018-06-01 04:01:49.324354
NCT00321139|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-12-12|2006-05-01|2006-05-03|Estimate|||||||2014-12-12|2014-12-15|Estimate|April 2006||2006-04-30|September 2014|2014-09-30||||January 2007|Actual|2007-01-31||Observational|||Assessment of Translesional Markers and Metabolomics|An Assessment of Translesional Markers and Metabolomics|Completed|||50|Anticipated|Emory University|||||f||||||||||||||2018-06-01 04:01:50.281771|2018-06-01 04:01:50.281771
NCT00320931|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2008-04-16|2006-04-28|2006-05-03|Estimate|||||||2008-04-16|2008-04-17|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Assessment of Coronary Artery Disease by Hybrid PET/CT|Assessment of Coronary Flow Reserve and CT Angiography By Hybrid PET/CT: Relation to Clinically Indicated SPECT Studies|Completed||Phase 4|30|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 04:01:52.211506|2018-06-01 04:01:52.211506
NCT00321126|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2006-05-02|2006-05-02|2006-05-03|Estimate|||||||2006-05-02|2006-05-03|Estimate|January 1999||1999-01-31|May 2006|2006-05-31|April 2002||2002-04-30|||||Interventional|||Zinc Supplementation in Shigella Patients|Effect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following recoveryEffect of Zinc Supplementation on the Immune and Inflammatory Responses of Children to Shigella Flexneri Infection, and Correlation With Clinical Severity of Illness and Growth Following Recovery|Completed||Phase 3|56||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:01:50.359845|2018-06-01 04:01:50.359845
NCT00321113|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2017-02-22|2006-05-01|2006-05-03|Estimate|||||||2017-02-22|2017-02-24|Actual|September 2004||2004-09-30|February 2017|2017-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|TIGRE||Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys|An Open, Multicentre, Randomised, Parallel Group Study to Compare in Marginal Old-for-old Renal Transplant Patients the Safety and Efficacy of Two Treatments: Sequential Mycophenolate Mofetil/Delayed Tacrolimus Plus Steroids vs Tacrolimus Plus Mycophenolate Mofetil in Patients Requiring Induction With Anti-IL2 Antibody|Completed||Phase 3|142|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 04:01:50.422617|2018-06-01 04:01:50.422617
NCT00321100|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-05-05|2006-05-01|2006-05-03|Estimate|||||||2014-05-05|2014-05-07|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|April 2009|Actual|2009-04-30||Interventional|||Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab|Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer|Terminated||Phase 2|23|Actual|Fox Chase Cancer Center||2||Enrollment closed 10/15/2008 based on data about KRAS.|f||||t||||||||||2018-06-01 04:01:50.526594|2018-06-01 04:01:50.526594
NCT00321087|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-01-19|2006-05-01|2006-05-03|Estimate|||||||2014-01-19|2014-01-22|Estimate|August 2006||2006-08-31|January 2014|2014-01-31|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||A Study of T2000 in Essential Tremor|Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study|Terminated||Phase 2|10|Actual|Taro Pharmaceuticals USA||3||Slow enrollment|f||||t||||||||||2018-06-01 04:01:50.605227|2018-06-01 04:01:50.605227
NCT00321074|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-08-25|2006-05-01|2006-05-03|Estimate|||||||2014-08-25|2014-08-26|Estimate|May 2005||2005-05-31|August 2014|2014-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|PANTERA||Tacrolimus and Daclizumab Versus Tacrolimus and Steroids in Liver Recipients Receiving Sub-optimal Grafts|AN OPEN, MULTICENTRE, RANDOMISED PARALLEL GROUP CLINICAL STUDY TO COMPARE SAFETY AND EFFICACY OF TACROLIMUS (FK506) WITH MONOCLONAL ANTI-IL2R ANTIBODIES (DACLIZUMAB) VS TACROLIMUS (FK506) WITH STEROIDS AND EVALUATE PHARMACOKINETICS IN LIVER ALLOGRAFT RECIPIENTS RECEIVING SUBOPTIMAL LIVERS|Completed||Phase 3|101|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 04:01:50.681665|2018-06-01 04:01:50.681665
NCT00321061|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-02|||2017-06-30|2006-05-02|2006-05-03|Estimate|||||||2017-06-30|2017-07-02|Actual|April 25, 2006||2006-04-25|December 2, 2009|2009-12-02|December 2, 2009|Actual|2009-12-02|December 2, 2009|Actual|2009-12-02||Interventional|||Phase I Study of Vaccination Schedule of Experimental HIV Vaccines|VRC 011: A Phase I Clinical Trial of Intramuscular, Subcutaneous and Intradermal Administration of an HIV-1 Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, and an HIV-1 Multiclade Adenoviral Vector Vaccine,VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers|Completed||Phase 1|60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:01:50.767547|2018-06-01 04:01:50.767547
NCT00321048|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2014-11-25|2006-05-01|2006-05-03|Estimate|||||||2014-11-25|2014-11-26|Estimate|June 2006||2006-06-30|March 2014|2014-03-31|October 2017|Anticipated|2017-10-31|January 2010|Actual|2010-01-31||Interventional|||Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator|Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator|Unknown status|Active, not recruiting|Phase 3|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 04:01:51.618091|2018-06-01 04:01:51.618091
NCT00321035|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2008-05-21|2006-05-01|2006-05-03|Estimate|||||||2008-05-21|2008-05-22|Estimate|December 2005||2005-12-31|May 2008|2008-05-31||||January 2008|Actual|2008-01-31||Interventional|||Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital|Study of the Safety and Effectiveness of the OculusGen Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery|Completed||Phase 3|60|Anticipated|Pro Top & Mediking Company Limited|||||f||||||||||||||2018-06-01 04:01:51.690714|2018-06-01 04:01:51.690714
NCT00321022|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2012-03-16|2006-05-01|2006-05-03|Estimate|||||||2012-03-16|2012-03-19|Estimate|August 2003||2003-08-31|May 2006|2006-05-31|September 2005||2005-09-30|||||Interventional|||Transient Ischemic Attack (TIA) Accelerated Diagnostic Protocol|Costs and Outcomes of an Emergency Department-based Accelerated Diagnostic Protocol vs Hospitalization for Patients With Transient Ischemic Attack: a Randomized Controlled Trial.|Completed||N/A|154||William Beaumont Hospitals|||||f||||||||||||||2018-06-01 04:01:51.755785|2018-06-01 04:01:51.755785
NCT00321009|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2006-05-01|2006-05-01|2006-05-03|Estimate|||||||2006-05-01|2006-05-03|Estimate|March 2000||2000-03-31|May 2006|2006-05-31|April 2004||2004-04-30|||||Interventional|||LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin|A Prospective Randomized Trial Comparing Enoxaparin to Warfarin for the Prevention of LV Thrombus Formation After Anterior Wall Myocardial Infarction: A 60 Patient Pilot Study|Completed||N/A|60||William Beaumont Hospitals|||||||||||||||||||2018-06-01 04:01:51.813806|2018-06-01 04:01:51.813806
NCT00320996|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2010-01-06|2006-05-01|2006-05-03|Estimate|||||||2010-01-06|2010-01-07|Estimate|March 2002||2002-03-31|October 2008|2008-10-31|February 2005|Actual|2005-02-28|July 2004|Actual|2004-07-31||Observational|||SGO Society of Gynecologic Oncologists Data Outcomes Project|SGO Society of Gynecologic Oncologists Data Outcomes Project|Completed|||100|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:51.885602|2018-06-01 04:01:51.885602
NCT00320983|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2010-01-06|2006-05-01|2006-05-03|Estimate|||||||2010-01-06|2010-01-07|Estimate|March 2002||2002-03-31|October 2008|2008-10-31|December 2005|Actual|2005-12-31|June 2004|Actual|2004-06-30||Interventional|||Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer|A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer|Completed||Phase 1|11|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:51.934691|2018-06-01 04:01:51.934691
NCT00320970|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2007-08-01|2006-04-28|2006-05-03|Estimate|||||||2007-08-01|2007-08-02|Estimate|August 2002||2002-08-31|March 2006|2006-03-31|September 2004||2004-09-30|||||Interventional|||Angiotensin II Antagonism of TGF-Beta 1|Angiotensin II Antagonism of TGF-Beta 1: A Candesartan Dose - TGF-Beta 1 Response Relationship Study|Completed||N/A|36||Providence Health & Services|||||f||||||||||||||2018-06-01 04:01:51.995187|2018-06-01 04:01:51.995187
NCT00320918|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2010-01-06|2006-04-28|2006-05-03|Estimate|||||||2010-01-06|2010-01-07|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|October 2006|Actual|2006-10-31|August 2006|Actual|2006-08-31||Observational|||Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib|Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib|Completed|||10|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:01:52.32127|2018-06-01 04:01:52.32127
NCT00320905|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2010-07-19|2006-05-01|2006-05-03|Estimate|||||||2010-07-19|2010-07-20|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Observational|||Smart Heart Study: Cognitive Benefits of Cardiac Rehabilitation|Smart Heart Study: Cognitive Benefits of Cardiac Rehabilitation|Completed|||70|Actual|Summa Health System|||||f||||f||||||||||2018-06-01 04:01:52.392393|2018-06-01 04:01:52.392393
NCT00320892|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2012-07-03|2006-05-01|2006-05-03|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|December 2009|Actual|2009-12-31||Interventional|||"Death Rattle - A Double Blind, Randomly Controlled, Crossover Trial"|"Death Rattle - A Double Blind, Randomly Controlled, Crossover Trial"|Terminated||N/A|2|Actual|Soroka University Medical Center||||Difficulties in recruiting appropriate participants to the study|f||||||||||||||2018-06-01 04:01:52.465776|2018-06-01 04:01:52.465776
NCT00320879|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2006-05-17|2006-05-01|2006-05-03|Estimate|||||||2006-05-17|2006-05-18|Estimate|September 2003||2003-09-30|July 2003|2003-07-31|November 2004||2004-11-30|||||Interventional|||Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria|Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria|Completed||Phase 4|52||Steno Diabetes Center|||||f||||||||||||||2018-06-01 04:01:52.58581|2018-06-01 04:01:52.58581
NCT00320866|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2008-04-29|2006-05-01|2006-05-03|Estimate|||||||2008-04-29|2008-04-30|Estimate|February 2002||2002-02-28|May 2006|2006-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Evaluation of Symptoms, Complications and Side Effects of Adding Medications Continuously To Subcutaneous Infusion (Hypodermoclysis) In Home Care Hospice Patients||Completed||N/A|27||Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:01:52.668562|2018-06-01 04:01:52.668562
NCT00320853|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2006-05-01|2006-05-01|2006-05-03|Estimate|||||||2006-05-01|2006-05-03|Estimate|April 2006||2006-04-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||A Study to Evaluate the Effect of Vitamin D Supplementation on Insulin Sensitivity and Secretion|A Pilot Study to Evaluate the Effect of Vitamin D Supplementation on Insulin Secretion and Peripheral Insulin Sensitivity|Completed||N/A|30||Sitaram Bhartia Institute of Science and Research|||||f||||||||||||||2018-06-01 04:01:52.731182|2018-06-01 04:01:52.731182
NCT00320840|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-30|||2006-04-30|2006-04-30|2006-05-03|Estimate|||||||2006-04-30|2006-05-03|Estimate|May 2006||2006-05-31|April 2006|2006-04-30|May 2012||2012-05-31|||||Observational|||Internal and Familial Resources and Motherhood. Follow Up of Mothers With Twins and Preterm Infants Versus Mothers With Single Full Term Infants|The Contribution of Internal and Familial Resources to the Development of Motherhood. Long Term Follow Up of Mothers With Twins and Preterm Infants Versus Mothers With Single Full Term Infants|Unknown status|Not yet recruiting||150||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:01:52.798941|2018-06-01 04:01:52.798941
NCT00320827|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2007-09-10|2006-04-28|2006-05-03|Estimate|||||||2007-09-10|2007-09-11|Estimate||||September 2007|2007-09-30||||||||Interventional|||Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)|Phase 1 Study of CS-1008, a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)|Completed||Phase 1|40|Anticipated|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:01:52.853893|2018-06-01 04:01:52.853893
NCT00320814|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2011-06-08|2006-04-28|2006-05-03|Estimate|||||||2011-06-08|2011-06-10|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Interventional|||Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema|An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intravitreal Administration of VEGF Trap in Patients With Diabetic Macular Edema|Completed||Phase 1|5|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:01:52.905511|2018-06-01 04:01:52.905511
NCT00320801|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2010-07-28||2012-08-27|2006-04-28|2006-05-03|Estimate|2010-08-23|2010-09-20|Estimate||||2012-08-27|2012-09-03|Estimate|January 2004||2004-01-31|August 2012|2012-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.|A Randomized, Double-Blind, Multicenter Study Evaluating The Safety and Efficacy of BTDS in Subjects With Moderate to Severe Osteoarthritis Pain. Includes a 52-Week Extension Phase.|Terminated||Phase 3|188|Actual|Purdue Pharma LP|Study terminated due to administrative reasons. The primary objective was changed to a safety study prior to unblinding.|2||This study was terminated early due to administrative reasons.|f||||t||||||||||2018-06-01 04:01:53.004241|2018-06-01 04:01:53.004241
NCT00320788|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2011-12-16|2010-11-30|2012-01-27|2006-04-28|2006-05-03|Estimate|2012-01-27|2012-03-01|Estimate|2010-11-30|2010-12-02|Estimate|2012-01-27|2012-03-01|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)|A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration|Completed||Phase 2|159|Actual|Regeneron Pharmaceuticals|This is a phase 2 study with small numbers of patients per group limiting the conclusions that can be drawn from the resulting data.|5|||f||||f||||||||||2018-06-01 04:01:53.682834|2018-06-01 04:01:53.682834
NCT00320775|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2015-03-16|2006-04-28|2006-05-03|Estimate|||||||2015-03-16|2015-03-18|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD|An Exploratory Study of the Safety, Tolerability and Biological Effect of Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration|Completed||Phase 1|51|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:01:55.160232|2018-06-01 04:01:55.160232
NCT00320762|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2008-05-21|2006-05-01|2006-05-03|Estimate|||||||2008-05-21|2008-05-22|Estimate|January 2006||2006-01-31|May 2008|2008-05-31||||December 2007|Actual|2007-12-31||Interventional|||Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital|Study of the Safety and Effectiveness of the Ologen (OculusGen) Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery|Completed||Phase 3|60|Anticipated|Pro Top & Mediking Company Limited|||||f||||||||||||||2018-06-01 04:01:55.246657|2018-06-01 04:01:55.246657
NCT00319410|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-11-27|2006-04-27|2006-04-27|Estimate|||||||2006-11-27|2006-11-28|Estimate|July 2005||2005-07-31|April 2006|2006-04-30|December 2005||2005-12-31|||||Interventional|||Comparison of Two Hysteroscopy Approaches|A New Approach to Office Hysteroscopy Compared With Traditional Hysteroscopy|Completed||Phase 3|130||Wolfson Medical Center|||||f||||||||||||||2018-06-01 04:02:21.419567|2018-06-01 04:02:21.419567
NCT00320749|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2015-09-15||2016-05-25|2006-04-28|2006-05-03|Estimate|2015-09-15|2015-10-19|Estimate||||2016-05-25|2016-06-27|Estimate|December 2005||2005-12-31|May 2016|2016-05-31|January 2011|Actual|2011-01-31|October 2008|Actual|2008-10-31||Interventional|||Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer|A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer|Completed||Phase 1|21|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:01:55.31911|2018-06-01 04:01:55.31911
NCT00320736|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2009-05-15|2006-04-28|2006-05-03|Estimate|||||||2009-05-15|2009-05-19|Estimate|January 2004||2004-01-31|May 2009|2009-05-31|May 2006||2006-05-31|||||Interventional|||Galantamine for Cognition in People With Schizophrenia|Effect of Nicotine Agonist Galantamine Added to High Potency Medications for Cognitive Function in Patients With Schizophrenia and Schizoaffective Disorder|Completed||Phase 4|20||North Suffolk Mental Health Association|||||f||||||||||||||2018-06-01 04:01:55.531453|2018-06-01 04:01:55.531453
NCT00320723|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2009-05-15|2006-04-28|2006-05-03|Estimate|||||||2009-05-15|2009-05-19|Estimate|July 2001||2001-07-31|May 2009|2009-05-31|December 2005||2005-12-31|||||Interventional|||Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia|Nicotine Replacement Therapy Added to Cognitive Behavioral Therapy for Smoking Cessation in Patients With Major Mental Illness|Completed||Phase 4|100||North Suffolk Mental Health Association|||||f||||||||||||||2018-06-01 04:01:55.594549|2018-06-01 04:01:55.594549
NCT00320710|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2014-07-08||2014-08-18|2006-04-28|2006-05-03|Estimate|2014-07-08|2014-08-04|Estimate||||2014-08-18|2014-08-22|Estimate|February 2006||2006-02-28|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer|A Prospective, Randomized, Double-blind, Stratified, Multi-center, 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer|Completed||Phase 3|416|Actual|Novartis||3|||f||||t||||||||||2018-06-01 04:01:55.713694|2018-06-01 04:01:55.713694
NCT00320697|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2016-09-23|2006-04-28|2006-05-03|Estimate|||||||2016-09-23|2016-09-27|Estimate|April 2006||2006-04-30|September 2016|2016-09-30|August 2009|Actual|2009-08-31|October 2008|Actual|2008-10-31||Interventional|||Smoking Relapse Prevention in Schizophrenia|A Trial of the Effects of Bupropion, Nicotine Replacement Therapy and CBT on Smoking Cessation and Smoking Relapse in Patients With Schizophrenia|Completed||Phase 4|25|Actual|North Suffolk Mental Health Association||3|||f||||||||||||||2018-06-01 04:01:56.909848|2018-06-01 04:01:56.909848
NCT00320684|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2012-06-28|2006-05-01|2006-05-03|Estimate|||||||2012-06-28|2012-07-02|Estimate|July 2003||2003-07-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Serotonin Transporter Concentrations in Women With a History of Anorexia Nervosa|A Positron Emission Tomography Study of the Serotonin Transporter in Weight-Restored Women With Anorexia Nervosa|Completed|||20|Actual|New York State Psychiatric Institute|||2||f||||f||||||||||2018-06-01 04:01:57.037|2018-06-01 04:01:57.037
NCT00320671|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2016-03-22||2016-09-07|2006-05-01|2006-05-03|Estimate|2016-07-19|2016-08-31|Estimate||||2016-09-07|2016-09-08|Estimate|December 2005||2005-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis|Preventing Morbidity in First Episode Schizophrenia, Part II|Completed||Phase 4|198|Actual|Northwell Health|Metabolic data only capture initial effects and may been impacted by Healthy Lifestyles program neg symptoms are only assessed in the initial context of pos symptoms and may not generalize to neg symptoms in the absence of pos symptoms.|2|||f||||t||||||||Yes||2018-06-01 04:01:57.108263|2018-06-01 04:01:57.108263
NCT00320658|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2008-01-18|2006-05-01|2006-05-03|Estimate|||||||2008-01-18|2008-01-21|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant|Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 04:01:57.597098|2018-06-01 04:01:57.597098
NCT00320632|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2015-08-17|2006-04-28|2006-05-03|Estimate|||||||2015-08-17|2015-08-19|Estimate|August 1990||1990-08-31|August 2015|2015-08-31|July 1993||1993-07-31|||||Interventional|||Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression|Psychopharmacology of Biogenic Amines in Depression|Completed||Phase 4|43||Harvard Medical School|||||f||||||||||||||2018-06-01 04:01:57.687002|2018-06-01 04:01:57.687002
NCT00320619|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2016-07-28|2006-04-28|2006-05-03|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2000||2000-09-30|March 2009|2009-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery|Aminocaproic Acid and Bleeding in Spinal Surgery|Completed||N/A|182|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||||||||||||2018-06-01 04:01:57.756525|2018-06-01 04:01:57.756525
NCT00320606|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2011-06-08||2017-04-06|2006-05-02|2006-05-03|Estimate|2011-06-08|2011-07-06|Estimate||||2017-04-06|2017-05-12|Actual|May 2006||2006-05-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|August 2010|Actual|2010-08-31||Interventional|WISP-R||Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients|Immunosuppression Withdrawal for Pediatric Living-donor Liver Transplant Recipients (ITN029ST)|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||Yes|Participant level data and additional study materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from Division of Allergy, Immunology, and Transplantation (DAIT)-funded grants and contracts and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal.|2018-06-01 04:01:57.85844|2018-06-01 04:01:57.85844
NCT00320593|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2011-05-17||2016-07-15|2006-04-28|2006-05-03|Estimate|2011-05-17|2011-06-21|Estimate||||2016-07-15|2016-07-19|Estimate|April 2005||2005-04-30|July 2016|2016-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|COMET2||Correction of Myopia Evaluation Trial 2|Correction of Myopia Evaluation Trial 2 (COMET2): A Randomized Trial of the Effect of Progressive Addition Lenses Versus Single Vision Lenses on Low Myopia Associated With Large Accommodative Lags and Near Esophoria in Children|Completed||Phase 3|118|Actual|Jaeb Center for Health Research|Limitations include: differential loss to follow up , differential compliance between the groups, power of near addition was not customized in PAL group, and we have no data on whether PAL group was looking through the near addition.|2|||f||||t||||||||||2018-06-01 04:01:58.141045|2018-06-01 04:01:58.141045
NCT00319397|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2009-12-10|2006-04-26|2006-04-27|Estimate|||||||2009-12-10|2009-12-14|Estimate|April 2004||2004-04-30|January 2009|2009-01-31|March 2007||2007-03-31|||||Observational|||Effects of Age and Exercise on Blood Pressure Regulation|Arterial Stiffness With Age: Part 1 and 2|Unknown status|Recruiting||80|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:02:21.47545|2018-06-01 04:02:21.47545
NCT00320580|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2011-06-30|2006-04-28|2006-05-03|Estimate|||||||2011-06-30|2011-07-01|Estimate||||June 2011|2011-06-30|March 2003|Actual|2003-03-31|||||Interventional|||An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen|A Randomized, Open-Label, Multicenter Study Comparing the Bleeding Profile of Ortho Evra (Norelgestromin/Ethinyl Estradiol) Continuous Regimen vs. Ortho Evra Cyclic Regimen|Completed||Phase 2|239|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||1|||||||||||||||||2018-06-01 04:01:58.957585|2018-06-01 04:01:58.957585
NCT00320567|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2011-06-30|2006-04-28|2006-05-03|Estimate|||||||2011-06-30|2011-07-01|Estimate||||June 2011|2011-06-30|April 2004|Actual|2004-04-30|||||Interventional|||The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa|The Effect of Ortho Tri-Cyclen on Bone Mineral Density in Pediatric Subjects With Anorexia Nervosa: A Double-Blind, Placebo-Controlled Study|Completed||Phase 2|123|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||1|||||||||||||||||2018-06-01 04:01:59.014111|2018-06-01 04:01:59.014111
NCT00320554|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2007-05-23|2006-05-01|2006-05-03|Estimate|||||||2007-05-23|2007-05-24|Estimate||||May 2007|2007-05-31|September 2006|Actual|2006-09-30|||||Observational|||Motion Characteristics of the Foot and Ankle as Measured by Durometer Readings||Completed|||||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 04:01:59.07816|2018-06-01 04:01:59.07816
NCT00320541|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2010-04-26||2013-07-15|2006-04-28|2006-05-03|Estimate|2010-07-01|2010-07-27|Estimate||||2013-07-15|2013-07-22|Estimate|May 2006||2006-05-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|April 2009|Actual|2009-04-30||Interventional|||A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer|A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|187|Actual|Eli Lilly and Company|Of 191 randomized patients, 4 patients were disqualified from inclusion in any efficacy or safety analyses due to significant Good Clinical Practice (GCP) violations; data is reported for the remaining 187 randomized patients.|2|||f||||t||||||||||2018-06-01 04:01:59.23675|2018-06-01 04:01:59.23675
NCT00320528|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2009-09-30||2009-12-02|2006-05-02|2006-05-03|Estimate|2009-12-02|2010-01-06|Estimate||||2009-12-02|2010-01-06|Estimate|April 2006||2006-04-30|December 2009|2009-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder With or Without Comorbid Conditions|Completed||Phase 3|269|Actual|Eli Lilly and Company|The original intent was to also calculate change and 95% confidence intervals at end of Period III; however, due to low number of patients completing Period III, variations from baseline (LOCF), are not suitable for further analysis or description.|3|||f||||f||||||||||2018-06-01 04:02:00.45001|2018-06-01 04:02:00.45001
NCT00320515|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2009-07-09||2009-08-19|2006-04-28|2006-05-03|Estimate|2009-08-19|2009-09-28|Estimate||||2009-08-19|2009-09-28|Estimate|March 2004||2004-03-31|August 2009|2009-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer|Phase 1/2 Study of Pemetrexed Plus Cisplatin in Unresectable, Advanced Gastric Carcinoma.|Completed||Phase 1/Phase 2|89|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:02:01.375247|2018-06-01 04:02:01.375247
NCT00320502|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-30|||2008-08-21|2006-05-01|2006-05-03|Estimate|||||||2008-08-21|2008-08-25|Estimate|May 2006||2006-05-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|March 2008|Actual|2008-03-31||Interventional|||A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effects of BXT-51072 on CK-MB in High-Risk Type 2 Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention|Completed||Phase 2|60|Anticipated|Synvista Therapeutics, Inc|||||f||||f||||||||||2018-06-01 04:02:01.650432|2018-06-01 04:02:01.650432
NCT00320489|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2010-09-29||2012-01-19|2006-05-02|2006-05-03|Estimate|2010-09-29|2010-10-22|Estimate||||2012-01-19|2012-01-23|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia|A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia|Completed||Phase 3|524|Actual|Eli Lilly and Company|Results for Outcome Measures 17 and 18 were corrected as a result of an identified programming error.|2|||f||||f||||||||||2018-06-01 04:02:01.856314|2018-06-01 04:02:01.856314
NCT00320476|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2008-05-05|2006-05-01|2006-05-03|Estimate|||||||2008-05-05|2008-05-06|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates|Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed By Melphalan, Prednisone, Thalidomide (MPT) Maintenance As a First Line Treatment For The Patients With Multiple Myeloma Who Are Non-Transplant Candidates|Completed||Phase 2|35|Actual|Korean Multiple Myeloma Working Party|||||f||||t||||||||||2018-06-01 04:02:03.098315|2018-06-01 04:02:03.098315
NCT00320463|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2016-10-11|2006-04-28|2006-05-03|Estimate|||||||2016-10-11|2016-10-12|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|January 2007|Actual|2007-01-31|||||Interventional|||Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants|Compare Immunogenicity & Reactogenicity of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine (New vs Current) Given in Healthy Infants. The DTPa-HBV-IPV Vaccine (New Formulation) Will Also be Assessed in a 3rd Group of Subjects|Completed||Phase 3|415||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:03.16035|2018-06-01 04:02:03.16035
NCT00320450|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2013-10-31|2006-04-28|2006-05-03|Estimate|||||||2013-10-31|2013-11-04|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||SB-681323 In Subjects With Rheumatoid Arthritis|A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA)|Completed||Phase 2|78|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:02:03.270274|2018-06-01 04:02:03.270274
NCT00320437|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-30|||2006-11-29|2006-04-30|2006-05-03|Estimate|||||||2006-11-29|2006-11-30|Estimate|May 2007||2007-05-31|November 2006|2006-11-30|December 2008|Anticipated|2008-12-31|||||Observational|||Intergenerational Transmission of Terror|The Intergenerational Transmission of Trauma From Terror: A Developmental Perspective|Unknown status|Not yet recruiting||300|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:02:03.378264|2018-06-01 04:02:03.378264
NCT00320424|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2017-05-12||2017-10-18|2006-05-01|2006-05-03|Estimate|2017-05-12|2017-10-11|Actual||||2017-10-18|2017-11-20|Actual|February 16, 2006|Actual|2006-02-16|October 2017|2017-10-31|October 26, 2006|Actual|2006-10-26|October 26, 2006|Actual|2006-10-26||Interventional|||Hip Fracture Study of GSK576428 (Fondaparinux Sodium)|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery|Completed||Phase 3|48|Actual|GlaxoSmithKline|||||f||||f|f|f||||||||2018-06-01 04:02:03.463773|2018-06-01 04:02:03.463773
NCT00320411|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2009-11-10||2013-04-11|2006-05-01|2006-05-03|Estimate|2009-11-10|2009-12-14|Estimate||||2013-04-11|2013-04-19|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer|Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer|Completed||Phase 2|62|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:02:03.953454|2018-06-01 04:02:03.953454
NCT00320398|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2017-05-12||2017-12-20|2006-05-01|2006-05-03|Estimate|2017-12-20|2017-12-21|Actual||||2017-12-20|2017-12-21|Actual|January 30, 2006|Actual|2006-01-30|December 2017|2017-12-31|July 18, 2006|Actual|2006-07-18|July 18, 2006|Actual|2006-07-18||Interventional|||Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)|Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery|Completed||Phase 3|114|Actual|GlaxoSmithKline|||||f||||f|f|f||||||||2018-06-01 04:02:04.497353|2018-06-01 04:02:04.497353
NCT00320385|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2011-10-20||2016-01-28|2006-05-01|2006-05-03|Estimate|2011-10-21|2011-11-30|Estimate||||2016-01-28|2016-02-26|Estimate|November 2005||2005-11-30|April 2015|2015-04-30|October 2010|Actual|2010-10-31|June 2007|Actual|2007-06-30||Interventional|||Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer|A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens|Completed||Phase 3|296|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:02:04.873441|2018-06-01 04:02:04.873441
NCT00320372|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2015-12-18||2015-12-22|2006-05-01|2006-05-03|Estimate|2015-12-22|2015-12-23|Estimate||||2015-12-22|2015-12-23|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Observational||A total of 878 subjects were screened. Thirty-seven were not eligible and 46 were eligible but not treated for various reasons. This left a total of 795 patients in the Safety Population (SP). The total number of patients in each group may be lower than SP if there was missing D-21 assessment data, as D-21 baseline data was not identical to D-23.|Treatment-Resistant Depression Registry|A Long-term, Prospective, Observational, Multi-center Patient Outcome Registry to Collect Data in Patients With Treatment-resistant Depression (TRD) Who Are Currently in a Major Depressive Episode.|Completed|||795|Actual|Cyberonics, Inc.|||2||f||||f||||||||||2018-06-01 04:02:05.706831|2018-06-01 04:02:05.706831
NCT00320359|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2017-02-27|2006-05-01|2006-05-03|Estimate|||||||2017-02-27|2017-03-01|Actual|August 2002||2002-08-31|February 2017|2017-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer|An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer|Completed||Phase 3|700|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:02:06.691471|2018-06-01 04:02:06.691471
NCT00320346|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2016-07-17|2006-05-01|2006-05-03|Estimate|||||||2016-07-17|2016-07-19|Estimate|July 2006||2006-07-31|November 2008|2008-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Phase II Study of Pandemic Influenza Vaccine|A Double-Blind, Randomised, Multi-Centre Study to Evaluate the Safety, Tolerability, Immunogenicity and Lot to Lot Consistency of Two Formulations of CSL Limited's Inactivated Prototype Pandemic Influenza Vaccine in a Healthy Adult Population (≤18 Years to ≥64 Years of Age).|Completed||Phase 2|400||Seqirus|||||f||||||||||||||2018-06-01 04:02:06.948568|2018-06-01 04:02:06.948568
NCT00320333|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2006-05-17|2006-05-01|2006-05-03|Estimate|||||||2006-05-17|2006-05-18|Estimate|December 2004||2004-12-31|May 2006|2006-05-31|December 2007||2007-12-31|||||Observational|||COPD Rehabilitation in Primary and Secondary Health Care|Comparison of Pulmonary Rehabilitation of Patients With Chronic Obstructive Pulmonary Disease in Primary and Secondary Health Care|Unknown status|Recruiting||120||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 04:02:07.022105|2018-06-01 04:02:07.022105
NCT00320320|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2008-11-24|2006-05-01|2006-05-03|Estimate|||||||2008-11-24|2008-11-25|Estimate|April 2005||2005-04-30|November 2008|2008-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer|A Pilot Phase II Trial of Irinotecan Discontinuation and Reintroduction in Patients With Previously Untreated Advanced Colorectal Cancer|Terminated||Phase 2|72||Gachon University Gil Medical Center||||Poor accrual|f||||f||||||||||2018-06-01 04:02:07.101847|2018-06-01 04:02:07.101847
NCT00320307|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2008-10-15|2006-05-01|2006-05-03|Estimate|||||||2008-10-15|2008-10-16|Estimate|September 2005||2005-09-30|October 2008|2008-10-31||||||||Interventional|||Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects|An Open-Label, Two-Period, Crossover, Pharmacokinetic Study of Abacavir and Its Intracellular Anabolite Carbovir Triphosphate Following Once-Daily and Twice-Daily Administration of Abacavir in HIV-Infected Subjects.|Completed||Phase 1|30|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:02:07.183525|2018-06-01 04:02:07.183525
NCT00320294|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2007-03-09|2006-05-02|2006-05-03|Estimate|||||||2007-03-09|2007-03-12|Estimate|February 2005||2005-02-28|March 2007|2007-03-31|March 2007||2007-03-31|||||Interventional|||ILF With/Without Cisplatin for Advanced Gastric Cancer|A Randomized Trial of Irinotecan, Leucovorin, 5-FU (ILF) Versus ILF Plus Cisplatin (PILF) Combination Chemotherapy in Patients With Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|86||Gachon University Gil Medical Center|||||f||||||||||||||2018-06-01 04:02:07.265538|2018-06-01 04:02:07.265538
NCT00320281|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2013-03-01||2013-06-22|2006-04-28|2006-05-03|Estimate|2013-06-22|2013-07-29|Estimate||||2013-06-22|2013-07-29|Estimate|April 2006||2006-04-30|June 2013|2013-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.|Botulinum Toxin A for the Treatment of Cervical/Shoulder Pain Following Acute Spinal Cord Injury.|Completed||Phase 4|19|Actual|Craig Hospital||2|||f||||t||||||||||2018-06-01 04:02:07.350634|2018-06-01 04:02:07.350634
NCT00320268|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|||2009-03-24|2006-05-01|2006-05-03|Estimate|||||||2009-03-24|2009-03-25|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|May 2007|Actual|2007-05-31|||||Interventional|MOONSTONE||Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-Release (SEROQUEL®) as Monotherapy in the Treatment of Patients With MDD|Completed||Phase 3|600||AstraZeneca|||||f||||||||||||||2018-06-01 04:02:07.642729|2018-06-01 04:02:07.642729
NCT00320255|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2016-03-14||2016-08-11|2006-05-02|2006-05-03|Estimate|2016-08-11|2016-08-16|Estimate||||2016-08-11|2016-08-16|Estimate|June 2006||2006-06-30|August 2016|2016-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||All participants who were randomized to receive treatment|A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer|A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study|Completed||Phase 2|130|Actual|Bristol-Myers Squibb||6|||f||||t||||||||||2018-06-01 04:02:07.830111|2018-06-01 04:02:07.830111
NCT00320242|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2015-12-23||2017-06-16|2006-04-28|2006-05-03|Estimate|2017-06-16|2017-07-14|Actual||||2017-06-16|2017-07-14|Actual|April 2006||2006-04-30|June 2017|2017-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional||32 subjects initially signed the consent form, but 6 dropped out prior to any exposure to the laserlight visual cue. Therefore, data in this study are included for the 26 subjects who entered the study and were eventually exposed to the laserlight visual cue.|Laser Light Cues for Gait Freezing in Parkinson's Disease|An Open Label Study to Assess the Efficacy of Visual Cues in the Form of the Laser Cane or the U-Step Walker With Laser Accessory in Parkinson's Disease Patients Who Experience Freezing of Gait.|Completed||N/A|32|Actual|Beth Israel Deaconess Medical Center||2|||f||||f|f|t|f|f||||No|Some individual participant data was included in the publication. There is no plan to share additional individual participant data.|2018-06-01 04:02:09.261634|2018-06-01 04:02:09.261634
NCT00320229|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-05-15|2006-05-01|2006-05-03|Estimate|||||||2006-05-15|2006-05-16|Estimate|December 2004||2004-12-31|January 2006|2006-01-31|July 2005||2005-07-31|||||Interventional|||Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen||Terminated||Phase 4|84||Azienda Sanitaria Ospedaliera|||||f||||||||||||||2018-06-01 04:02:09.601605|2018-06-01 04:02:09.601605
NCT00320216|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2009-10-23||2015-03-31|2006-04-28|2006-05-03|Estimate|2012-11-20|2012-12-19|Estimate||||2015-03-31|2015-04-20|Estimate|November 2003||2003-11-30|March 2015|2015-03-31|March 2005|Actual|2005-03-31|June 2004|Actual|2004-06-30||Interventional|||A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis|A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis|Completed||Phase 2|320|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|5|||f||||f||||||||||2018-06-01 04:02:09.696254|2018-06-01 04:02:09.696254
NCT00320203|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01||2012-11-27|2012-11-27|2006-05-01|2006-05-03|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|March 2006||2006-03-31|February 2008|2008-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Anecortave Acetate in Patients With Open-angle Glaucoma|A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma|Completed||Phase 2|86|Actual|Alcon Research||4|||f||||||||||||||2018-06-01 04:02:10.331616|2018-06-01 04:02:10.331616
NCT00320190|ClinicalTrials.gov processed this data on May 31, 2018|2006-05-01|2011-06-06||2013-10-01|2006-05-02|2006-05-03|Estimate|2011-06-06|2011-07-07|Estimate||||2013-10-01|2013-10-30|Estimate|August 2006||2006-08-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib|An Open-label, Randomized Study of Dasatinib vs High-dose (800-mg) Imatinib in the Treatment of Subjects With Chronic Phase Chronic Myeloid Leukemia Who Have Had a Suboptimal Response After at Least 3 Months of Therapy With 400 mg Imatinib|Terminated||Phase 2|52|Actual|Bristol-Myers Squibb|Enrollment terminated prematurely on September 5, 2008, due to slow accrual. Only 32 of 156 planned participants were randomized from August 2, 2006. Per BMS standards, findings were reported in a synopsis format, with only safety results included.|2||Terminated due to slow participant accrual|f||||f||||||||||2018-06-01 04:02:10.41538|2018-06-01 04:02:10.41538
NCT00320177|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-29|||2018-05-18|2006-05-02|2006-05-03|Estimate|||||||2018-05-18|2018-05-21|Actual|November 26, 2003||2003-11-26|October 28, 2014|2014-10-28|October 28, 2014||2014-10-28|||||Observational|||Eating Behavior in Children|Eating Behavior in Children|Completed|||263|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:02:11.996437|2018-06-01 04:02:11.996437
NCT00320164|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2017-05-23|2006-04-27|2006-05-03|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2006||2006-01-31|May 2017|2017-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals|Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals|Completed|||8|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||Undecided||2018-06-01 04:02:12.048475|2018-06-01 04:02:12.048475
NCT00320151|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2017-05-23|2006-04-27|2006-05-03|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2006||2006-04-30|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases|Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases|Completed|||3087|Actual|Weill Medical College of Cornell University|||||f||||f||||||||Undecided||2018-06-01 04:02:12.100471|2018-06-01 04:02:12.100471
NCT00320138|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2012-01-11|2006-04-27|2006-05-03|Estimate|||||||2012-01-11|2012-01-12|Estimate|March 2006||2006-03-31|January 2012|2012-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Acupuncture for the Treatment of Posttraumatic Stress Among Military Personnel|Acupuncture for the Treatment of Trauma Survivors|Completed||Phase 1|55|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||||2018-06-01 04:02:12.15303|2018-06-01 04:02:12.15303
NCT00320125|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2015-05-01|2006-04-28|2006-05-03|Estimate|||||||2015-05-01|2015-05-05|Estimate|March 2002||2002-03-31|October 2008|2008-10-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Effects of Dairy Foods on Adolescent Pregnant Mothers and Their Newborns|Effects of Dairy Foods on Adolescent Pregnant Mothers and Their Newborns|Completed||Phase 3|72|Actual|University of Utah||3|||f||||||||||||||2018-06-01 04:02:12.223445|2018-06-01 04:02:12.223445
NCT00320112|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2014-09-19||2015-04-06|2006-04-27|2006-05-03|Estimate|2014-11-06|2014-11-10|Estimate||||2015-04-06|2015-04-24|Estimate|February 2007||2007-02-28|August 2014|2014-08-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional||125 participants were randomized to Reciprocal Peer Support (RPS), and 119 to Nurse case management (NCM).|Improving Insulin Therapy With Enhanced Care Management|Improving Insulin Therapy With Enhanced Care Management and Peer Support|Completed||Phase 3|244|Actual|VA Office of Research and Development|"study only included male patients.~intervention only lasted six months.~the nature of the intervention prevented blinding to treatment group.~A final limitation is the relatively low rate of uptake of the intervention."|2|||f||||f||||||||||2018-06-01 04:02:12.314961|2018-06-01 04:02:12.314961
NCT00320099|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2010-04-05|2006-04-27|2006-05-03|Estimate|||||||2010-04-05|2010-04-06|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|COIITSS||Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock|Phase 3 Study of Corticotherapy (Hydrocortisone Alone Versus Hydrocortisone Plus Fludrocortisone) Versus Corticotherapy Plus Intensive Insulin Therapy for Septic Shock|Completed||Phase 3|508|Actual|University of Versailles||4|||f||||t||||||||||2018-06-01 04:02:12.796497|2018-06-01 04:02:12.796497
NCT00320086|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2009-01-13|2006-04-28|2006-05-03|Estimate|||||||2009-01-13|2009-01-14|Estimate|August 2005||2005-08-31|September 2008|2008-09-30|November 2008|Anticipated|2008-11-30|||||Observational|||Microalbuminuria in Children With and Without Diabetes|Microalbuminuria in Children With and Without Diabetes|Unknown status|Recruiting||220|Anticipated|University of New Mexico|||||f||||||||||||||2018-06-01 04:02:12.90694|2018-06-01 04:02:12.90694
NCT00320073|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2012-05-14|2006-04-27|2006-05-03|Estimate|||||||2012-05-14|2012-05-16|Estimate|August 2006||2006-08-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|October 2008|Actual|2008-10-31||Interventional|||Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors|A Two Arm Phase I Dose Escalation Trial of Vinflunine With Erlotinib or Pemetrexed in Refractory Solid Tumors|Completed||Phase 1|41|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:02:13.00727|2018-06-01 04:02:13.00727
NCT00320060|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-04-27|2006-04-27|2006-04-27|Estimate|||||||2006-04-27|2006-04-27|Estimate|October 2001||2001-10-31|April 2006|2006-04-30|January 2003||2003-01-31|||||Interventional|||Effect of Pyridorin in Patients With Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes|Completed||Phase 2|128||BioStratum|||||||||||||||||||2018-06-01 04:02:13.106776|2018-06-01 04:02:13.106776
NCT00320047|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2013-08-08|2006-04-28|2006-04-27|Estimate|||||||2013-08-08|2013-08-12|Estimate|April 2005||2005-04-30|September 2008|2008-09-30|June 2007|Actual|2007-06-30|June 2006|Actual|2006-06-30||Interventional|||Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder|Effects of Baclofen on Binge Eating in Bulimia Nervosa and Binge Eating Disorder|Completed||N/A|10|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 04:02:13.161344|2018-06-01 04:02:13.161344
NCT00320034|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2011-02-28|2006-04-27|2006-04-27|Estimate|||||||2011-02-28|2011-03-02|Estimate|April 2006||2006-04-30|July 2009|2009-07-31|November 2009|Actual|2009-11-30|June 2008|Actual|2008-06-30||Interventional|||Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma|Double-blind, Crossover, Placebo-controlled Evaluation of the Effect of Levalbuterol (R-albuterol) on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma|Completed||Phase 2|15|Anticipated|McMaster University|||||f||||||||||||||2018-06-01 04:02:13.230939|2018-06-01 04:02:13.230939
NCT00320021|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-04-27|2006-04-27|2006-04-27|Estimate|||||||2006-04-27|2006-04-27|Estimate|July 2002||2002-07-31|April 2006|2006-04-30|September 2003||2003-09-30|||||Interventional|||Effect of Pyridorin in Patients With Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled, Escalating Dose, Pilot Study to Evaluate the Safety, Tolerability and Biologic Activity of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes|Completed||Phase 2|80||BioStratum|||||||||||||||||||2018-06-01 04:02:13.294273|2018-06-01 04:02:13.294273
NCT00320008|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2016-04-11|2006-04-27|2006-04-27|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 1992||1992-01-31|April 2016|2016-04-30|December 2025|Anticipated|2025-12-31|December 2001|Actual|2001-12-31||Interventional|Steno-2||Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria|Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria|Active, not recruiting||N/A|160|Actual|Steno Diabetes Center||2|||f||||t||||||||No||2018-06-01 04:02:13.349137|2018-06-01 04:02:13.349137
NCT00319995|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2017-05-10|2006-04-28|2006-04-27|Estimate|||||||2017-05-10|2017-05-11|Actual|March 1, 2006|Actual|2006-03-01|May 2017|2017-05-31|June 28, 2006|Actual|2006-06-28|June 1, 2006|Actual|2006-06-01||Interventional|||Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)|Efficacy and Safety of Combination Loratadine/Montelukast QD vs Pseudoephedrine and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|1095|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:02:13.440574|2018-06-01 04:02:13.440574
NCT00319982|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2015-01-26||2015-03-24|2006-04-27|2006-04-27|Estimate|2015-03-24|2015-04-07|Estimate||||2015-03-24|2015-04-07|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional||Participants enrolled through Brigham and Women’s Hospital (Boston, MA), Boston Children’s Hospital, and Royal Prince Alfred Hospital (Sydney, Australia) were randomized 1:1 to diltiazem or placebo. Participants were 5-39 years old, carried the sarcomere mutation presumed to cause HCM in the family, and had normal LV wall thickness by echo.|Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem|Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem|Completed||Phase 2/Phase 3|39|Actual|Brigham and Women's Hospital|Small number of participants and short follow-up duration. Currently available tools to monitor treatment response/ phenotypic progression are may lack adequate resolution. The penetrance of sarcomere mutations is variable and may not be complete.|2|||f||||t||||||||||2018-06-01 04:02:13.507247|2018-06-01 04:02:13.507247
NCT00319969|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27||2009-09-28|2009-09-28|2006-04-27|2006-04-27|Estimate||||2009-09-28|2009-09-30|Estimate|2009-09-28|2009-09-30|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|||Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.|A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy|Completed||Phase 2|76|Actual|Celgene||2|||t||||f||||||||||2018-06-01 04:02:13.831618|2018-06-01 04:02:13.831618
NCT00319956|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2012-06-07|2006-04-27|2006-04-27|Estimate|||||||2012-06-07|2012-06-08|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Trial II of Lung Protection With Azithromycin in the Preterm Infant|Trial II of Lung Protection With Azithromycin in the Preterm Infant|Completed||Phase 2|220|Actual|University of Kentucky||2|||f||||t||||||||||2018-06-01 04:02:14.03699|2018-06-01 04:02:14.03699
NCT00319943|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-04-27|2006-04-27|2006-04-27|Estimate|||||||2006-04-27|2006-04-27|Estimate|September 2004||2004-09-30|April 2006|2006-04-30|July 2006||2006-07-31|||||Interventional|||Computer-Based Therapy for Mild Cognitive Impairment|Computer-Based Therapy for Mild Cognitive Impairment|Completed||Phase 1|48||Posit Science Corporation|||||f||||||||||||||2018-06-01 04:02:14.118244|2018-06-01 04:02:14.118244
NCT00302276|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2009-01-20|2006-03-13|2006-03-14|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2004||2004-01-31|November 2004|2004-11-30|July 2004||2004-07-31|||||Interventional|||Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)|Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)|Completed||Phase 2/Phase 3|80||University of Copenhagen|||||f||||||||||||||2018-06-01 04:07:16.327871|2018-06-01 04:07:16.327871
NCT00319930|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2010-03-04|2006-04-27|2006-04-27|Estimate|||||||2010-03-04|2010-03-08|Estimate|May 2005||2005-05-31|March 2010|2010-03-31|May 2007|Actual|2007-05-31|||||Interventional|||Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Pharmacodynamic Study of Intravenously Administered CNF1010 (17-(Allylamino)-17-demethoxy-geldanamycin [17-AAG]) in Patients With ZAP-70 Positive B-Cell Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 1|10|Actual|Biogen||||Discontinuation of program|||||||||||||||2018-06-01 04:02:14.201931|2018-06-01 04:02:14.201931
NCT00319917|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2014-08-19|2006-04-27|2006-04-27|Estimate|||||||2014-08-19|2014-08-21|Estimate|April 2006||2006-04-30|August 2014|2014-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients|FK506 Phase 4 Study: A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients|Completed||Phase 4|123|Actual|Astellas Pharma Inc||2|||f||||||||||||||2018-06-01 04:02:14.27668|2018-06-01 04:02:14.27668
NCT00319904|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2017-10-17|2006-04-27|2006-04-27|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2001||2001-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||The Partners Genetics Collaborative Study of Schizophrenia|The Partners Genetics Collaborative Study of Schizophrenia|Completed|||451|Actual|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     DNA is extracted and stored for future anaysis of genes that may be associated with~     schizophrenia~   "|||2018-06-01 04:02:14.37243|2018-06-01 04:02:14.37243
NCT00319891|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2013-05-13|2006-04-27|2006-04-27|Estimate|||||||2013-05-13|2013-05-15|Estimate|September 2004||2004-09-30|May 2013|2013-05-31|October 2006||2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Computer-Based Training for Mild Alzheimer's Disease|Computer-Based Training for Mild Cognitive Impairment and Mild Alzheimer's Disease|Completed||Phase 1|6||Posit Science Corporation|||||f||||||||||||||2018-06-01 04:02:14.436267|2018-06-01 04:02:14.436267
NCT00319878|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2008-10-06|2006-04-28|2006-04-27|Estimate|||||||2008-10-06|2008-10-07|Estimate|May 2006||2006-05-31|October 2008|2008-10-31|December 2009|Anticipated|2009-12-31|July 2009|Anticipated|2009-07-31||Interventional|||Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia|A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia|Unknown status|Recruiting|Phase 1/Phase 2|52|Anticipated|Office of Rare Diseases (ORD)||1|||f||||||||||||||2018-06-01 04:02:14.522123|2018-06-01 04:02:14.522123
NCT00319865|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2006-04-28|2006-04-28|2006-04-27|Estimate|||||||2006-04-28|2006-04-27|Estimate|November 2005||2005-11-30|April 2006|2006-04-30|September 2008||2008-09-30|||||Interventional|||PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma|PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 2|47||Korean Multiple Myeloma Working Party|||||f||||||||||||||2018-06-01 04:02:14.625338|2018-06-01 04:02:14.625338
NCT00319852|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2012-04-13|2006-04-28|2006-04-27|Estimate|||||||2012-04-13|2012-04-16|Estimate|April 2006||2006-04-30|April 2012|2012-04-30|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV||Completed||Phase 3|442|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:02:14.705844|2018-06-01 04:02:14.705844
NCT00319839|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2013-06-26||2018-01-11|2006-04-27|2006-04-27|Estimate|2018-01-11|2018-01-12|Actual||||2018-01-11|2018-01-12|Actual|March 2006||2006-03-31|January 2018|2018-01-31|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|||Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab|A Phase II Study of Albumin Bound-Paclitaxel (AbraxaneTM) for Treatment of Recurrent or Metastatic Head and Neck Cancer With the Addition of Cetuximab (Erbitux) (IMC-225) on Disease Progression|Terminated||Phase 2|10|Actual|University of California, Irvine||1||slow accrual|f||||t||||||||||2018-06-01 04:02:14.79874|2018-06-01 04:02:14.79874
NCT00319826|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2016-04-26|2006-04-27|2006-04-27|Estimate|||||||2016-04-26|2016-04-28|Estimate|March 2004||2004-03-31|April 2016|2016-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Virulence Determinants in S Aureus Bacteremia|Virulence Determinants in Staphylococcus Aureus Bacteremia|Completed|||1354|Actual|Duke University|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 04:02:15.00528|2018-06-01 04:02:15.00528
NCT00319813|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2008-04-15|2006-04-28|2006-04-27|Estimate|||||||2008-04-15|2008-04-16|Estimate||||April 2008|2008-04-30|September 2007||2007-09-30|||||Observational|||General Practice Quality Assurance Project. Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Treatment|General Practice Quality Assurance Project. COPD Diagnosis and Treatment|Completed|||8000||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:02:15.083622|2018-06-01 04:02:15.083622
NCT00319800|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2008-03-10|2006-04-28|2006-04-27|Estimate|||||||2008-03-10|2008-03-12|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|March 2007||2007-03-31|||||Interventional|||Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC|A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response|Unknown status|Active, not recruiting|Phase 2|50||Gachon University Gil Medical Center|||||f||||||||||||||2018-06-01 04:02:15.13283|2018-06-01 04:02:15.13283
NCT00319787|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2011-01-24|2006-04-27|2006-04-27|Estimate|||||||2011-01-24|2011-01-25|Estimate|December 2003||2003-12-31|January 2011|2011-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer|A Randomized Placebo Controlled Study to Assess the Rate of PSA Decrease, Anatomical & Metabolic Changes in the Prostate Determined by MRI/3D-MRS & Histological Changes by Biopsy in Subjects With Locally Advanced Prostate Carcinoma Treated With Either Casodex® (Bicalutamide) Alone or the Combination of Casodex® & ZD1839 (Iressa™)|Completed||Phase 2|102||AstraZeneca|||||f||||||||||||||2018-06-01 04:02:15.184175|2018-06-01 04:02:15.184175
NCT00319774|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-04-27|2006-04-27|2006-04-27|Estimate|||||||2006-04-27|2006-04-27|Estimate|December 2002||2002-12-31|September 2003|2003-09-30|July 2003||2003-07-31|||||Interventional|||Hemocontrol and Blood Pressure Control in Dialysis Patients|Assessment of Hemocontrol Biofeedback System Efficiency on Long Term Blood Pressure Control, Nursing Interventions, and Quality of Life in Hemodialysis Patients: a Randomized Controlled Trial|Completed||Phase 3|60||Université de Montréal|||||f||||||||||||||2018-06-01 04:02:15.23795|2018-06-01 04:02:15.23795
NCT00319761|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2009-01-29|2006-04-27|2006-04-27|Estimate|||||||2009-01-29|2009-01-30|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy|The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy|Completed||Phase 4|10||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:02:15.303306|2018-06-01 04:02:15.303306
NCT00319384|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2012-10-03|2006-04-26|2006-04-27|Estimate|||||||2012-10-03|2012-10-04|Estimate|April 2006||2006-04-30|October 2012|2012-10-31|May 2007|Anticipated|2007-05-31|||||Interventional|||Outpatient Ultrafiltration Therapy in Heart Failure Patients Trial|Outpatient Ultrafiltration Therapy in Heart Failure Feasibility Trial|Withdrawn||N/A|0|Actual|Minneapolis Medical Research Foundation||||Lack of enrollment|f||||f||||||||||2018-06-01 04:02:21.538496|2018-06-01 04:02:21.538496
NCT00319748|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2009-08-17|2009-04-06|2017-12-03|2006-04-27|2006-04-27|Estimate|2009-08-17|2009-09-25|Estimate|2009-12-15|2009-12-17|Estimate|2017-12-03|2017-12-28|Actual|April 2006||2006-04-30|December 2017|2017-12-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers|Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers|Completed||Phase 2|15|Actual|Masonic Cancer Center, University of Minnesota|Other Adverse Events that occurred were noted as targeted toxicities and not captured as adverse events.|2|||f||||t||||||||||2018-06-01 04:02:15.374821|2018-06-01 04:02:15.374821
NCT00319735|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2016-01-11||2016-03-28|2006-04-27|2006-04-27|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|April 2006||2006-04-30|March 2016|2016-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas|A Pilot Study With Cetuximab and Radiation Therapy for Patients With Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group Study (GI05-92)|Completed||Phase 2|41|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-06-01 04:02:15.722377|2018-06-01 04:02:15.722377
NCT00319722|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2010-05-03|2006-04-27|2006-04-27|Estimate|||||||2010-05-03|2010-05-04|Estimate|February 2006||2006-02-28|May 2010|2010-05-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Observational|||EEG Studies of Sensory Processing in Autistic Children|Electrophysiologic Indicators of Gating and Timing Abnormalities in Autism|Unknown status|Recruiting||130|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:02:16.141824|2018-06-01 04:02:16.141824
NCT00319709|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2009-03-10|2006-04-28|2006-04-27|Estimate|||||||2009-03-10|2009-03-12|Estimate|April 2006||2006-04-30|March 2009|2009-03-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|ZEPHIR||An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression|An Eight-Week, Double-Blind Placebo Controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Elderly Patients With Major Depressive Disorder (MDD)|Completed||Phase 3|288|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:02:16.218119|2018-06-01 04:02:16.218119
NCT00319696|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2012-06-29||2012-09-27|2006-04-27|2006-04-27|Estimate|2012-06-29|2012-08-08|Estimate||||2012-09-27|2012-10-03|Estimate|July 2004||2004-07-31|September 2012|2012-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|RAPIDS 2 OL||Bosentan in Digital Ulcers|Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers|Completed||Phase 3|116|Actual|Actelion||1|||f||||f||||||||||2018-06-01 04:02:16.343929|2018-06-01 04:02:16.343929
NCT00319683|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2008-12-12|2006-04-27|2006-04-27|Estimate|||||||2008-12-12|2008-12-15|Estimate||||December 2008|2008-12-31||||||||Interventional|||A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma|A Phase 1/2 Study in Subjects With Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma, Evaluating the Safety, and Anti-Tumor Activity of ADH300004 (Eniluracil) With Escalating Doses of 5 Fluorouracil Administered Orally Once Weekly for 3 Weeks Out of Every 4 (Adherex Protocol Number AHX-03-103)|Terminated||Phase 1/Phase 2|||Adherex Technologies, Inc.||||Lack of funds|t||||||||||||||2018-06-01 04:02:17.029145|2018-06-01 04:02:17.029145
NCT00319670|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2013-02-06|2006-04-27|2006-04-27|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2006||2006-03-31|February 2013|2013-02-28||||May 2006|Actual|2006-05-31||Interventional|||A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children|A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children|Completed||Phase 4|25||Braintree Laboratories|||||||||||||||||||2018-06-01 04:02:17.089041|2018-06-01 04:02:17.089041
NCT00319657|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2018-05-08|2006-04-28|2006-04-27|Estimate|||||||2018-05-08|2018-05-14|Actual|July 2004||2004-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs|Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-Cell Transfusion in HLA-Matched Living Donor Kidney Transplantation|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|Stanford University||1|||f||||t|t|f||||||No|Individual Patient Data will not be shared|2018-06-01 04:02:17.14559|2018-06-01 04:02:17.14559
NCT00319644|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2011-03-24||2012-10-16|2006-04-27|2006-04-27|Estimate|2012-10-16|2012-11-16|Estimate||||2012-10-16|2012-11-16|Estimate|May 2006||2006-05-31|October 2012|2012-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia|Impact of Using Mini-Bronchoalveolar Lavage as a Diagnostic Test for Ventilator-Associated Pneumonia|Completed||N/A|37|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:02:17.215929|2018-06-01 04:02:17.215929
NCT00319631|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2017-01-27|2006-04-27|2006-04-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2006|Actual|2006-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)|Role of Vascular Endothelial Growth Factor (VEGF) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)|Withdrawn|||0|Actual|Weill Medical College of Cornell University||||Under the discretion of the PI the study has been withdrawn.|f||||t||||||||Undecided||2018-06-01 04:02:17.427161|2018-06-01 04:02:17.427161
NCT00319618|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2007-12-14|2006-04-27|2006-04-27|Estimate|||||||2007-12-14|2007-12-18|Estimate|June 2003||2003-06-30|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer|A Randomised Phase II Study: Treatment With Daily p.o. Iressa™ (ZD1839) or Placebo in Combination With Weekly IV Infusion of Docetaxel in Patients With Metastatic Breast Cancer|Completed||Phase 2|66||AstraZeneca|||||f||||||||||||||2018-06-01 04:02:17.569862|2018-06-01 04:02:17.569862
NCT00319605|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2012-05-24|2006-04-28|2006-04-27|Estimate|||||||2012-05-24|2012-05-25|Estimate|April 2006||2006-04-30|May 2012|2012-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam|Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)|Completed|||600|Anticipated|UCB Pharma|||||f||||||||||||||2018-06-01 04:02:17.628675|2018-06-01 04:02:17.628675
NCT00319592|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2012-07-11||2012-08-16|2006-04-28|2006-04-27|Estimate|2012-07-11|2012-08-16|Estimate||||2012-08-16|2012-08-20|Estimate|May 2005||2005-05-31|August 2012|2012-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX|Randomized, Double-blind, Phase II Study of the Safety, Tolerability and Immunogenicity Following Administration of Live Attenuated JE Vaccine (ChimeriVax™ JE) Compared With Mouse Brain-derived Inactivated JE Vaccine (JE VAX®).|Completed||Phase 2|60|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:02:17.785877|2018-06-01 04:02:17.785877
NCT00319579|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2018-02-22|2006-04-27|2006-04-27|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2005||2005-01-31|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||A Prospective Study of Living Kidney Donation|The Long Term Medical and Psychological Implications of Becoming a Living Kidney Donor: A Prospective Pilot Study|Active, not recruiting|||600|Anticipated|Lawson Health Research Institute|||1||f||||f||||||Samples Without DNA|"~     Serum and urine samples~   "|||2018-06-01 04:02:18.368646|2018-06-01 04:02:18.368646
NCT00319566|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-04-27|2006-04-27|2006-04-27|Estimate|||||||2006-04-27|2006-04-27|Estimate|July 1992||1992-07-31|January 2002|2002-01-31|July 2001||2001-07-31|||||Interventional|||Heart and Estrogen-Progestin Replacement Study (HERS)|Heart and Estrogen-Progestin Replacement Study (HERS)|Completed||Phase 3|2430||University of California, San Francisco|||||||||||||||||||2018-06-01 04:02:18.455657|2018-06-01 04:02:18.455657
NCT00319553|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2010-09-28||2012-09-28|2006-04-28|2006-04-27|Estimate|2010-09-28|2010-10-21|Estimate||||2012-09-28|2012-10-05|Estimate|May 2006||2006-05-31|September 2012|2012-09-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®|Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX®|Completed||Phase 4|647|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:02:18.548715|2018-06-01 04:02:18.548715
NCT00319540|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2006-04-28|2006-04-28|2006-04-27|Estimate|||||||2006-04-28|2006-04-27|Estimate|March 2001||2001-03-31|January 2001|2001-01-31|March 2002||2002-03-31|||||Interventional|||RCT of Psychoeducational Program of Depression|A Randomized Controlled Trial of a Psychoeducational Group Program for Unipolar Depression in Adults in Norway|Completed||Phase 2|155||Norwegian Institute of Public Health|||||f||||||||||||||2018-06-01 04:02:18.878267|2018-06-01 04:02:18.878267
NCT00319527|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2009-07-06|2006-04-27|2006-04-27|Estimate|||||||2009-07-06|2009-07-07|Estimate|May 2004||2004-05-31|July 2009|2009-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Long-Term Study of Living Kidney Donors|Long-Term Medical and Psychological Implications of Becoming a Living Kidney Donor: A Historical Matched Cohort Study|Completed|||311|Actual|Lawson Health Research Institute|||1||f||||f||||||Samples Without DNA|"~     Serum and urine samples~   "|||2018-06-01 04:02:18.930811|2018-06-01 04:02:18.930811
NCT00319514|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|||2008-03-10|2006-04-28|2006-04-27|Estimate|||||||2008-03-10|2008-03-12|Estimate|April 2004||2004-04-30|March 2008|2008-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC|Randomized Phase II Trial of Two Different Schedules of Docetaxel Plus Cisplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|78||Gachon University Gil Medical Center|||||f||||||||||||||2018-06-01 04:02:18.996162|2018-06-01 04:02:18.996162
NCT00319501|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|2016-07-06|2013-01-10|2016-08-17|2006-04-27|2006-04-27|Estimate|2016-07-06|2016-08-16|Estimate|2013-01-10|2013-01-18|Estimate|2016-08-17|2016-09-23|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Participants who were randomized to receive treatment|Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.|A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures|Completed||Phase 3|234|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:02:19.109806|2018-06-01 04:02:19.109806
NCT00319488|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2016-07-28|2006-04-27|2006-04-27|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2004||2004-02-29|April 2012|2012-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|AIMS||Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)|Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)|Completed||N/A|238|Actual|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||t||||||||||2018-06-01 04:02:20.500569|2018-06-01 04:02:20.500569
NCT00319475|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-10-08|2006-04-27|2006-04-27|Estimate|||||||2006-10-08|2006-10-11|Estimate|February 2006||2006-02-28|October 2006|2006-10-31|July 2006||2006-07-31|||||Interventional|||Evaluation of Mechanical Stapler for Aortic Anastomoses|Evaluation of Mechanical Stapler for Aortic Anastomoses|Unknown status|Active, not recruiting|N/A|10||SVSE 2000 Ltd.|||||f||||||||||||||2018-06-01 04:02:20.604395|2018-06-01 04:02:20.604395
NCT00319462|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2007-04-18|2006-04-27|2006-04-27|Estimate|||||||2007-04-18|2007-04-19|Estimate|November 2006||2006-11-30|April 2006|2006-04-30|April 2007|Anticipated|2007-04-30|||||Interventional|||Localization of Point A in Cervical Cancer|Localization of Anatomic Point A in Cervical Cancer Patients|Unknown status|Recruiting|N/A|20||Mackay Memorial Hospital|||||f||||t||||||||||2018-06-01 04:02:20.677645|2018-06-01 04:02:20.677645
NCT00319449|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-28|2011-04-14||2015-10-09|2006-04-28|2006-04-27|Estimate|2011-04-14|2011-05-10|Estimate||||2015-10-09|2015-10-12|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)|A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population.|Completed||Phase 4|22|Actual|Merck Sharp & Dohme Corp.|Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.|2|||f||||||||||||||2018-06-01 04:02:20.765291|2018-06-01 04:02:20.765291
NCT00319436|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|2010-11-05||2016-10-27|2006-04-26|2006-04-27|Estimate|2014-01-20|2014-02-14|Estimate||||2016-10-27|2016-12-12|Estimate|August 2004||2004-08-31|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Stage I Randomized Trial of Mentalization-Based Therapy for Substance Using Mothers of Infants and Toddlers|Fostering Mothers' Emotionally Responsive Parenting|Completed||N/A|47|Actual|Yale University|Sample most representative of addicted mothers in mid-30’s, Caucasian, high school educated, unemployed, moderate involvement with child welfare. Caution in generalizing to higher risk mothers (adolescent mothers, ethnic minority,less educated).|2|||f||||t||||||||||2018-06-01 04:02:21.093643|2018-06-01 04:02:21.093643
NCT00319423|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2010-02-04|2006-04-27|2006-04-27|Estimate|||||||2010-02-04|2010-02-05|Estimate|April 2005||2005-04-30|April 2006|2006-04-30||||February 2009|Actual|2009-02-28||Interventional|||Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis. a RCT.|Evaluation of Function and Effect of Exercise Therapy in Patients With Osteoarthritis of the Hip. A Randomized Controlled Trial.|Completed||N/A|110|Anticipated|Ullevaal University Hospital||2|||f||||||||||||||2018-06-01 04:02:21.340961|2018-06-01 04:02:21.340961
NCT00319371|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2008-09-25|2006-04-27|2006-04-27|Estimate|||||||2008-09-25|2008-09-26|Estimate|November 2005||2005-11-30|September 2008|2008-09-30|June 2006|Actual|2006-06-30|||||Observational|||Registration of Skin-Temperatures and Sleep-Wake Behaviour|Registration of Skin-Temperatures and Sleep-Wake Behaviour in the Daily Life of Women With Vasospasm in Comparison to Controls|Completed|||40|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-06-01 04:02:21.616215|2018-06-01 04:02:21.616215
NCT00319358|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2009-01-28|2006-04-26|2006-04-27|Estimate|||||||2009-01-28|2009-01-29|Estimate|October 2003||2003-10-31|January 2009|2009-01-31|October 2006|Actual|2006-10-31|||||Interventional|||Role of Antioxidants Supplementation in Chronic Pancreatitis|Effect of Antioxidant Supplementation on Pain, Antioxidant Profile and Oxidative Stress in Patients With Chronic Pancreatitis|Completed||Phase 3|127|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-06-01 04:02:21.67116|2018-06-01 04:02:21.67116
NCT00319345|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2010-06-22|2006-04-27|2006-04-27|Estimate|||||||2010-06-22|2010-06-23|Estimate|November 2003||2003-11-30|April 2006|2006-04-30|November 2005||2005-11-30|||||Interventional|||Sodium-Lactate and Traumatic Brain Injury|Sodium-Lactate Versus Mannitol in the Treatment of Intracranial Hypertensive Episodes in Severe Traumatic Brain Injured Patients|Terminated||Phase 2/Phase 3|34||Institut d'Anesthesiologie des Alpes Maritimes|||||f||||||||||||||2018-06-01 04:02:21.733391|2018-06-01 04:02:21.733391
NCT00319332|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2015-04-15|2006-04-26|2006-04-27|Estimate|||||||2015-04-15|2015-04-17|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen|A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients With Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||||This study has been cancelled prior to enrollment|f||||||||||||||2018-06-01 04:02:21.784827|2018-06-01 04:02:21.784827
NCT00319319|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2007-04-18|2006-04-26|2006-04-27|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2003||2003-01-31|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Nicotinic Receptor Augmentation of SSRI Antidepressants|A Double-Blind,Randomized,Placebo-Controlled Trial of Mecamylamine Hydrochloride for the Treatment of SSRI-Refractory Major Depressive Disorder.|Completed||Phase 2|60||Yale University|||||f||||f||||||||||2018-06-01 04:02:21.849453|2018-06-01 04:02:21.849453
NCT00319306|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2009-03-16|2006-04-27|2006-04-27|Estimate|||||||2009-03-16|2009-03-17|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|December 2006|Actual|2006-12-31|||||Interventional|RELEASE||Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy|Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy|Completed||Phase 3|550||AstraZeneca|||||f||||||||||||||2018-06-01 04:02:21.908826|2018-06-01 04:02:21.908826
NCT00319293|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2006-10-10|2006-04-26|2006-04-27|Estimate|||||||2006-10-10|2006-10-11|Estimate||||October 2006|2006-10-31||||||||Interventional|||Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome||Unknown status|Not yet recruiting|N/A|20||Aarhus University Hospital Skejby|||||f||||||||||||||2018-06-01 04:02:23.135733|2018-06-01 04:02:23.135733
NCT00319280|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2014-03-28|2006-04-27|2006-04-27|Estimate|||||||2014-03-28|2014-03-31|Estimate|December 2004||2004-12-31|March 2014|2014-03-31|December 2008|Actual|2008-12-31|June 2006|Actual|2006-06-30||Interventional|||Proximal Tibial Open Wedge Osteotomy. A Clinical Prospective, Randomized RSA-trial.|Proximal Tibial Open Wedge Osteotomy. Stability and Healing Evaluated in a Clinical Prospective, Randomized Trial Using RSA.|Completed||Phase 4|45|Actual|Northern Orthopaedic Division, Denmark||3|||f||||f||||||||||2018-06-01 04:02:23.186531|2018-06-01 04:02:23.186531
NCT00319267|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2016-05-23|2006-04-26|2006-04-27|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2005||2005-05-31|May 2016|2016-05-31|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|FUTURE-1||Bosentan in Children With Pulmonary Arterial Hypertension|An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension|Completed||Phase 3|36|Actual|Actelion||1|||f||||||||||||||2018-06-01 04:02:23.250186|2018-06-01 04:02:23.250186
NCT00319254|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2012-10-04|2010-01-27|2012-12-21|2006-04-26|2006-04-27|Estimate|2012-12-21|2013-01-31|Estimate|2010-01-27|2010-02-01|Estimate|2012-12-21|2013-01-31|Estimate|May 2006||2006-05-31|December 2012|2012-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer|Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer|Completed||Phase 2|75|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:02:23.356306|2018-06-01 04:02:23.356306
NCT00319241|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2008-06-16|2006-04-26|2006-04-27|Estimate|||||||2008-06-16|2008-06-18|Estimate|January 1998||1998-01-31|June 2008|2008-06-30|November 2003|Actual|2003-11-30|October 2003|Actual|2003-10-31||Interventional|||Relational Parenting Group for Opioid-Addicted Mothers|Relational Parenting Group for Opioid-Addicted Mothers|Completed||Phase 2|120||Yale University|||||f||||||||||||||2018-06-01 04:02:23.737808|2018-06-01 04:02:23.737808
NCT00319228|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2018-03-08|2006-04-26|2006-04-27|Estimate|||||||2018-03-08|2018-03-12|Actual|January 2006|Actual|2006-01-31|March 2018|2018-03-31|March 2029|Anticipated|2029-03-31|December 2028|Anticipated|2028-12-31||Interventional|||Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.|A Phase II/III Pivotal Trial Evaluating the Safety, Pharmacokinetic Properties and Efficacy of a Plasma-Derived Anti-thrombin III Concentrate With Administration in Surgery, Pregnancy and Thromboembolic or Thrombotic Events.|Active, not recruiting||Phase 2/Phase 3|30|Anticipated|Grifols Biologicals Inc.||1|||f||||t||||||||||2018-06-01 04:02:23.813943|2018-06-01 04:02:23.813943
NCT00319215|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2007-04-24|2006-04-26|2006-04-27|Estimate|||||||2007-04-24|2007-04-25|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Interventional|||Effects of Ramelteon on Driving Ability|A Study to Investigate the Residual Effects of Ramelteon (8 mg), Zopiclone (7.5 mg) and Placebo on Actual Driving, Memory, Psychomotor Performance and Mood|Completed||Phase 1|30||Utrecht Institute for Pharmaceutical Sciences|||||f||||||||||||||2018-06-01 04:02:23.898463|2018-06-01 04:02:23.898463
NCT00319202|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2012-11-02|2006-04-26|2006-04-27|Estimate|||||||2012-11-02|2012-11-06|Estimate|June 2006||2006-06-30|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2010|Actual|2010-02-28||Interventional|ARAMIA||Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects|"A Randomized, Double Blind, Cross-Over, Placebo-Controlled Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism, of Non Diabetic, Non Hypertensive Subjects With Dysglycemia and Abdominal Obesity.ARAMIA"|Terminated||Phase 4|56|Actual|Fundación Cardiovascular de Colombia||2||Difficulties in completing the required sample size|f||||t||||||||||2018-06-01 04:02:23.974046|2018-06-01 04:02:23.974046
NCT00319189|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2006-05-09|2006-04-27|2006-04-27|Estimate|||||||2006-05-09|2006-05-10|Estimate|November 2002||2002-11-30|April 2006|2006-04-30|November 2003||2003-11-30|||||Interventional|||Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients|Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance|Completed||Phase 4|15||University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:02:24.087769|2018-06-01 04:02:24.087769
NCT00319163|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2009-08-05|2006-04-27|2006-04-27|Estimate|||||||2009-08-05|2009-08-07|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women|An Open-label, Single-dose, Randomized, 2-period, Crossover, Bioequivalence Study to Compare Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women|Completed||Phase 1|26||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:02:24.217704|2018-06-01 04:02:24.217704
NCT00319150|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2009-02-11|2006-04-26|2006-04-27|Estimate|||||||2009-02-11|2009-02-12|Estimate|October 2006||2006-10-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial|Resistance to ErythroPoietin Effectiveness Algorithm Trial|Terminated||Phase 3|6|Actual|Queen's University||2||New evidence and trouble recruiting|f||||t||||||||||2018-06-01 04:02:24.280354|2018-06-01 04:02:24.280354
NCT00319137|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2012-05-31|2006-04-26|2006-04-27|Estimate|||||||2012-05-31|2012-06-04|Estimate|December 2005||2005-12-31|February 2011|2011-02-28||||||||Interventional|||An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine|A Randomized, Single-Blind, Single-Attack, Placebo-Controlled, Adaptive Design Study to Assess the Safety and Efficacy of Doses of 5-180 mg of the iNOS Inhibitor GW274150 in the Treatment of Acute Migraine During the Mild Headache Phase|Completed||Phase 2|126||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:02:24.355654|2018-06-01 04:02:24.355654
NCT00319124|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2016-03-01|2006-04-27|2006-04-27|Estimate|||||||2016-03-01|2016-03-02|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|October 2010|Actual|2010-10-31|August 2008|Actual|2008-08-31||Observational|||Exercise Therapy and Patient Education for Individuals With Hip Osteoarthritis of the Hip. A Case-Control Study|Evaluation of Function and Effect of Exercise in Patients With Osteoarthritis of the Hip.A Case-control Study.|Completed|||52|Actual|Oslo University Hospital|||2||f||||f||||||||||2018-06-01 04:02:24.413781|2018-06-01 04:02:24.413781
NCT00319111|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|2012-05-24||2012-11-29|2006-04-26|2006-04-27|Estimate|2012-11-29|2012-12-31|Estimate||||2012-11-29|2012-12-31|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|BENEFIT OL||Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT, NCT00313222)|Completed||Phase 3|151|Actual|Actelion||1|||f||||||||||||||2018-06-01 04:02:24.514297|2018-06-01 04:02:24.514297
NCT00319098|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|2017-01-31||2017-04-21|2006-04-26|2006-04-27|Estimate|2017-04-21|2017-08-03|Actual||||2017-04-21|2017-08-03|Actual|May 1, 2006|Actual|2006-05-01|April 2017|2017-04-30|July 31, 2007|Actual|2007-07-31|January 1, 2007|Actual|2007-01-01||Interventional|||Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above|A Phase III, Observer-blind, Randomised Study to Evaluate the Safety and Immunogenicity of One and Two Administrations of Pandemic Monovalent (H5N1) Influenza Vaccine (Adjuvanted Split Virus Formulation) in Adults Aged 18 Years and Older|Completed||Phase 3|5075|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:25.166723|2018-06-01 04:02:25.166723
NCT00319085|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2015-04-09|2006-04-27|2006-04-27|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Preheating of Femur Component in Hybrid Total Hip Arthroplasty|Comparison Between Preheated and Non-preheated Femur Component in Hybrid Total Hip Arthroplasty (THA) A Prospective Randomized Study of the 80 THA Using Radiostereometry.|Completed||Phase 2|80|Actual|Northern Orthopaedic Division, Denmark|||||f||||t||||||||||2018-06-01 04:02:26.39878|2018-06-01 04:02:26.39878
NCT00319072|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2006-04-26|2006-04-26|2006-04-27|Estimate|||||||2006-04-26|2006-04-27|Estimate|March 2004||2004-03-31|April 2006|2006-04-30|December 2005||2005-12-31|||||Interventional|||Hormone Replacement Therapy (HRT) Website Tool|Testing an Interactive Website for Hormone Replacement|Completed||Phase 2|280||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:02:26.540828|2018-06-01 04:02:26.540828
NCT00319059|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2016-04-21|2006-04-27|2006-04-27|Estimate|||||||2016-04-21|2016-04-22|Estimate|March 2006||2006-03-31|April 2016|2016-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance|The Influence of the 34C>T Variant in the AMPD1 Gene on Individual Susceptibility for Ischemia-reperfusion.|Completed||N/A|14||Radboud University|||||f||||||||||||||2018-06-01 04:02:26.618802|2018-06-01 04:02:26.618802
NCT00319046|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|2012-04-24||2012-05-24|2006-04-27|2006-04-27|Estimate|2012-04-24|2012-05-23|Estimate||||2012-05-24|2012-06-01|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Oral Miglustat in Adult Patients With Stable Type 1 Gaucher Disease|Open-label, Non Comparative, Multi-center Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Oral Miglustat as a Maintenance Therapy After a Switch From Enzyme Replacement Therapy in Adult Patients With Stable Type 1 Gaucher Disease|Completed||Phase 3|42|Actual|Actelion||1|||f||||||||||||||2018-06-01 04:02:26.688374|2018-06-01 04:02:26.688374
NCT00319033|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2015-04-28|2006-04-26|2006-04-27|Estimate|||||||2015-04-28|2015-04-30|Estimate|July 2004||2004-07-31|April 2015|2015-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|BUILD 2 OL||Open-label Study With Bosentan in Interstitial Lung Disease|Long-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330.|Completed||Phase 2/Phase 3|132||Actelion|||||f||||||||||||||2018-06-01 04:02:26.993359|2018-06-01 04:02:26.993359
NCT00319020|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|2017-02-09|2012-03-09|2017-05-16|2006-04-26|2006-04-27|Estimate|2017-02-09|2017-03-29|Actual|2012-03-09|2012-03-13|Estimate|2017-05-16|2017-06-14|Actual|August 23, 2005|Actual|2005-08-23|May 2017|2017-05-31|October 28, 2011|Actual|2011-10-28|October 28, 2011|Actual|2011-10-28||Interventional|FUTURE 2||Bosentan in Children With Pulmonary Arterial Hypertension Extension Study|An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1|Completed||Phase 3|33|Actual|Actelion||1|||f|||||t|f||||||||2018-06-01 04:02:27.142401|2018-06-01 04:02:27.142401
NCT00319007|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-27|||2007-08-09|2006-04-27|2006-04-27|Estimate|||||||2007-08-09|2007-08-10|Estimate|April 2006||2006-04-30|August 2007|2007-08-31|December 2006||2006-12-31|||||Interventional|||Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis|Adenoma-Carcinoma Sequence in the Ileal Pouch Anal Anastomosis in Patients With Familial Adenomatous Polyposis: Studies on Luminal and Mucosal Risk Factors and Chemoprevention|Unknown status|Recruiting|Phase 2|30|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:02:27.989611|2018-06-01 04:02:27.989611
NCT00318994|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2017-08-31|2006-04-26|2006-04-27|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2002||2002-02-28|August 2017|2017-08-31|May 2007|Actual|2007-05-31|September 2005|Actual|2005-09-30||Interventional|||Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis|Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis|Completed||Phase 4|6||Pfizer|||||f||||||||||||||2018-06-01 04:02:28.252337|2018-06-01 04:02:28.252337
NCT00318981|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2006-09-08|2006-04-26|2006-04-27|Estimate|||||||2006-09-08|2006-09-11|Estimate|December 2004||2004-12-31|September 2006|2006-09-30|December 2006||2006-12-31|||||Interventional|||Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD|Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD|Unknown status|Active, not recruiting|Phase 4|40||University of Maryland|||||||||||||||||||2018-06-01 04:02:28.448898|2018-06-01 04:02:28.448898
NCT00318968|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2009-01-23|2006-04-26|2006-04-27|Estimate|||||||2009-01-23|2009-01-26|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|November 2007|Actual|2007-11-30|||||Interventional|||Nexium RESPONSE Trial|Development of an Algorithm for Identification of Responders to Short Term Treatment With Esomeprazole (Nexium) in Primary Care|Completed||Phase 4|1000|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:02:28.679912|2018-06-01 04:02:28.679912
NCT00318955|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2017-03-16|2006-04-25|2006-04-27|Estimate|||||||2017-03-16|2017-03-20|Actual|November 2005||2005-11-30|June 2015|2015-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Post-Marketing Clinical Study to Assess Efficacy and Safety of Dexmedetomidine in Post-Operative Patients|A Post-Marketing, Open-Label, Randomized, Comparative Study Comparing the Usefulness of Dexmedetomidine at the Time of Extubation and Post Extubation Period to Other Sedative Management in Post-Operative Patients|Completed||Phase 4|85|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 04:02:28.908333|2018-06-01 04:02:28.908333
NCT00318942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2014-06-29|2006-04-25|2006-04-27|Estimate|||||||2014-06-29|2014-07-01|Estimate|February 2003||2003-02-28|June 2014|2014-06-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety of Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients|CRISTAL: Colloids Compared to Crystalloids in Fluid Resuscitation of Critically Ill Patients: A Multinational Randomised Controlled Trial|Completed||Phase 3|2857|Actual|University of Versailles||2|||f||||t||||||||||2018-06-01 04:02:29.043095|2018-06-01 04:02:29.043095
NCT00318929|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|2009-03-31||2018-01-08|2006-04-25|2006-04-27|Estimate|2010-06-14|2010-07-09|Estimate||||2018-01-08|2018-02-02|Estimate|April 2006||2006-04-30|January 2018|2018-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Tolerability and Efficacy of Depakote-extended Release in the Elderly|Tolerability and Efficacy of Depakote-ER in the Elderly|Completed||N/A|14|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 04:02:29.281111|2018-06-01 04:02:29.281111
NCT00318903|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2010-12-30|2006-04-25|2006-04-27|Estimate|||||||2010-12-30|2011-01-04|Estimate|January 2002||2002-01-31|December 2010|2010-12-31|April 2006|Actual|2006-04-30|||||Interventional|||Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer|A Phase II Study of Irinotecan and Taxotere With Concurrent Radiotherapy as a Preoperative Treatment in Resectable Esophageal Cancer|Completed||Phase 2|25|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 04:02:29.503672|2018-06-01 04:02:29.503672
NCT00318890|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2011-02-11|2006-04-25|2006-04-27|Estimate|||||||2011-02-11|2011-02-14|Estimate|October 2002||2002-10-31|February 2011|2011-02-28|December 2007|Actual|2007-12-31|April 2007|Actual|2007-04-30||Interventional|||Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Trial of Induction Cisplatin and Docetaxel Followed by Concomitant Docetaxel/Radiotherapy With Subcutaneous Amifostine for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1/Phase 2|48|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 04:02:29.612952|2018-06-01 04:02:29.612952
NCT00318877|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2012-12-12|2006-04-25|2006-04-27|Estimate|||||||2012-12-12|2012-12-17|Estimate|May 2006||2006-05-31|December 2012|2012-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Sports to Prevent Obesity|Sports to Prevent Obesity Randomized Trial|Completed||N/A|79|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 04:02:29.717128|2018-06-01 04:02:29.717128
NCT00318864|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2006-04-25|2006-04-25|2006-04-27|Estimate|||||||2006-04-25|2006-04-27|Estimate|June 2002||2002-06-30|April 2006|2006-04-30|July 2005||2005-07-31|||||Interventional|||Biological CVD Risk Factors in Older Depressed Patients|Stress, the HPA and Health in Aging|Completed||N/A|70||Stanford University|||||f||||||||||||||2018-06-01 04:02:29.798876|2018-06-01 04:02:29.798876
NCT00318851|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2010-08-25|2006-04-25|2006-04-27|Estimate|||||||2010-08-25|2010-08-26|Estimate|September 2003||2003-09-30|March 2006|2006-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Carotid Artery Stenting With Protection Registry|Treatment of Carotid Stenosis With Carotid Stenting and Neurologic Protection With Pre-Procedure and Follow-Up With MRI DIffusion Imaging and Neuropsychological Testing|Completed||Phase 3|62|Actual|Providence Health & Services||1|||f||||f||||||||||2018-06-01 04:02:29.870164|2018-06-01 04:02:29.870164
NCT00318838|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2017-01-31|2006-04-26|2006-04-27|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effect of Azimilide Dihydrochloride on Renal Function|A Double-blind, Randomized, Parallel-group, Placebo-controlled, Multiple-dose Study to Assess the Effect of 125 mg/Day Orally Administered Azimilide Dihydrochloride on Renal Function and Hemodynamics in Healthy Volunteers|Completed||Phase 1|21|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 04:02:29.964019|2018-06-01 04:02:29.964019
NCT00318825|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2010-11-30|2006-04-25|2006-04-27|Estimate|||||||2010-11-30|2010-12-01|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Nitrous Oxide for Analgesia During Colonoscopy|Use of Nitrous Oxide for Analgesia During Colonoscopy - A Randomised Trial|Completed||Phase 4|200|Anticipated|Rikshospitalet University Hospital|||||f||||||||||||||2018-06-01 04:02:30.028337|2018-06-01 04:02:30.028337
NCT00318812|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|2013-06-26||2016-04-05|2006-04-25|2006-04-27|Estimate|2014-04-02|2014-05-02|Estimate||||2016-04-05|2016-05-10|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure|Heme Iron Polypeptide for the Treatment of Iron Deficiency Anemia in Pre-Dialysis Patients: A Pilot Randomized Controlled Study|Completed||Phase 2/Phase 3|55|Actual|Ottawa Hospital Research Institute|Recruitment for the trial was a challenge; over 1100 patients screened - 55 consented - 40 randomized|2|||f||||f||||||||||2018-06-01 04:02:30.098649|2018-06-01 04:02:30.098649
NCT00318240|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2017-08-25|2006-04-24|2006-04-26|Estimate|||||||2017-08-25|2017-08-28|Actual|April 2006|Actual|2006-04-30|August 2017|2017-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound (HIFU)|Feasibility Study for Locally Recurrent Prostate Cancer Treatment Following Radiation Failure With High Intensity Focused Ultrasound (HIFU)|Completed||N/A|40|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-06-01 04:02:39.471272|2018-06-01 04:02:39.471272
NCT00318799|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2013-11-20|2006-04-26|2006-04-27|Estimate|||||||2013-11-20|2013-11-25|Estimate|April 2006||2006-04-30|November 2013|2013-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters|A Single-centre, Open-label, Crossover, Controlled, Randomized Study to Investigate the Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters in 30 Healthy Female Volunteers Over 3 Treatment Cycles|Completed||Phase 2|29|Actual|Bayer||2|||f||||||||||||||2018-06-01 04:02:30.324117|2018-06-01 04:02:30.324117
NCT00318786|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2017-01-05|2006-04-26|2006-04-27|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes|Trial to Investigate the Efficacy and the Safety of Thrice-Daily NN2000-Mix70 (NovoRapid 70 Mix) Compared to Twice-Daily NN-X14Mix30 (NovoRapid 30 Mix) in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|289|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:02:30.391677|2018-06-01 04:02:30.391677
NCT00318773|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2009-02-26|2006-04-25|2006-04-27|Estimate|||||||2009-02-26|2009-02-27|Estimate|February 2002||2002-02-28|April 2006|2006-04-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS)|Short-Term Versus Long-Term Treatment for Severe PMS|Completed||Phase 4|174|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 04:02:30.447187|2018-06-01 04:02:30.447187
NCT00318760|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2018-04-04|2006-04-25|2006-04-27|Estimate|||||||2018-04-04|2018-04-05|Actual|June 14, 2005||2005-06-14|July 8, 2014|2014-07-08|August 7, 2013|Actual|2013-08-07|||||Interventional|||Effect of Clonidine on Responses to Imagery Scripts|Effect of Clonidine on Responses to Imagery Scripts|Completed||Phase 1|92|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 04:02:30.505525|2018-06-01 04:02:30.505525
NCT00318747|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2013-02-01|2006-04-25|2006-04-27|Estimate|||||||2013-02-01|2013-02-05|Estimate|April 2006||2006-04-30|February 2013|2013-02-28|November 2006|Actual|2006-11-30|||||Interventional|||Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug|Asthma Immunotherapy With a Ragweed Allergen Immunostimulatory Sequence Conjugate|Terminated||Phase 2|140||National Institute of Allergy and Infectious Diseases (NIAID)||||Poor enrollment|||||||||||||||2018-06-01 04:02:30.574624|2018-06-01 04:02:30.574624
NCT00318734|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2016-04-15|2006-04-25|2006-04-27|Estimate|||||||2016-04-15|2016-04-19|Estimate|May 2006||2006-05-31|December 2011|2011-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Examining the Link Between Trace Elements and Cardiovascular Disease Risk Factors in Young Adults|Trace Elements and CVD Risk Factors Among Young Adults|Completed|||4362|Actual|University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 04:02:30.641443|2018-06-01 04:02:30.641443
NCT00318721|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2009-11-03|2006-04-25|2006-04-27|Estimate|||||||2009-11-03|2009-11-04|Estimate|June 2006||2006-06-30|June 2009|2009-06-30|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Interventional|KALANET||Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar|Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar|Completed||N/A|20000|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 04:02:30.703073|2018-06-01 04:02:30.703073
NCT00318708|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|2012-04-27||2018-03-22|2006-04-25|2006-04-27|Estimate|2012-12-28|2013-02-04|Estimate||||2018-03-22|2018-03-23|Actual|June 2006||2006-06-30|March 2018|2018-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|MIA||Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)|Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)|Completed||Phase 3|92|Actual|Milton S. Hershey Medical Center|Participants underwent endobronchial biopsy for characterization of lower airway status for M pneumoniae or C pneumoniae. The target sample size was 72 positives and 72 negatives. Only 80 and 12 were recruited, respectively.|2|||f||||t||||||||||2018-06-01 04:02:30.82766|2018-06-01 04:02:30.82766
NCT00318695|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|||2009-01-21|2006-04-26|2006-04-27|Estimate|||||||2009-01-21|2009-01-22|Estimate|May 2004||2004-05-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|July 2008|Actual|2008-07-31||Interventional|||Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses|Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses- A Randomized Double-Blind Placebo Controlled Trial|Completed||Phase 2|253|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-06-01 04:02:31.103069|2018-06-01 04:02:31.103069
NCT00318682|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2009-02-11|2006-04-25|2006-04-27|Estimate|||||||2009-02-11|2009-02-12|Estimate|May 2006||2006-05-31|September 2006|2006-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|FIBROSTIC||Evaluation and Medico-Economic Study of FIBROSCAN in Patients With Viral Hepatitis|Evaluation and Medico Economic Study of FIBROSCAN in Patients With Viral Hepatitis|Terminated|||2000|Actual|Assistance Publique - Hôpitaux de Paris||||enough patients have been enrolled for the statistic analysis|f||||f||||||Samples Without DNA|"~     biological samples to evaluate the hepato-fibrosis~   "|||2018-06-01 04:02:31.161464|2018-06-01 04:02:31.161464
NCT00318669|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2013-04-11|2006-04-25|2006-04-27|Estimate|||||||2013-04-11|2013-04-15|Estimate|December 2005||2005-12-31|July 2012|2012-07-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Social Anxiety Disorder Study Of Paroxetine|Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study>|Completed||Phase 3|390|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:02:31.211927|2018-06-01 04:02:31.211927
NCT00318656|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|2008-10-17||2009-04-10|2006-04-25|2006-04-27|Estimate|2009-02-18|2009-03-18|Estimate||||2009-04-10|2009-05-07|Estimate|November 2005||2005-11-30|April 2009|2009-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes|Comparison of the Effects of Rosiglitazone and Glimepiride, Both Given in Combination With Metformin, on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone. A 3-Month Multicentre, Randomized, Parallel-Group, Open-Label Study.|Completed||Phase 4|23|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:02:31.316758|2018-06-01 04:02:31.316758
NCT00318643|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2008-04-03|2006-04-25|2006-04-27|Estimate|||||||2008-04-03|2008-04-09|Estimate|March 2006||2006-03-31|April 2008|2008-04-30||||||||Interventional|||A Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Superficial Bladder Cancer|A Phase I-IIa, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|27|Actual|Halozyme Therapeutics|||||f||||f||||||||||2018-06-01 04:02:32.589334|2018-06-01 04:02:32.589334
NCT00318630|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2017-09-21|2006-04-25|2006-04-27|Estimate|||||||2017-09-21|2017-09-25|Actual|July 22, 2005|Actual|2005-07-22|September 2017|2017-09-30|June 30, 2006|Actual|2006-06-30|June 30, 2006|Actual|2006-06-30||Interventional|||The Effect Of AVANDIA On The Late Asthmatic Response|A Randomised Double-blind Two-period Crossover Study to Investigate the Effect of Treatment With Repeat Doses of a PPAR Gamma Agonist on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma Compared With Repeat Doses of Placebo|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:32.662899|2018-06-01 04:02:32.662899
NCT00318617|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2012-03-15|2006-04-25|2006-04-27|Estimate|||||||2012-03-15|2012-03-19|Estimate|December 2005||2005-12-31|February 2011|2011-02-28||||||||Observational|||Effect Of GW501516X On How The Heart Obtains And Uses Energy|A Two Part Study to Separately Evaluate the Effect of 4-week Treatment With GW501516X Relative to Placebo on Cardiac Energetics in a Randomized, Single-blind, Repeat Dose, Parallel Group Design in Healthy Male Subjects|Terminated|||30||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:02:32.760919|2018-06-01 04:02:32.760919
NCT00318604|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2006-05-11|2006-04-25|2006-04-27|Estimate|||||||2006-05-11|2006-05-12|Estimate||||April 2006|2006-04-30||||||||Observational|||Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker||Unknown status|Not yet recruiting||||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:02:32.814915|2018-06-01 04:02:32.814915
NCT00318591|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-26|2011-02-23||2015-08-06|2006-04-26|2006-04-27|Estimate|2011-04-26|2011-05-25|Estimate||||2015-08-06|2015-08-24|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections|A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters.|Completed||Phase 4|219|Actual|Coloplast A/S||2|||f||||t||||||||||2018-06-01 04:02:32.917719|2018-06-01 04:02:32.917719
NCT00318578|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2007-08-13|2006-04-25|2006-04-27|Estimate|||||||2007-08-13|2007-08-15|Estimate|March 2005||2005-03-31|August 2007|2007-08-31|January 2007||2007-01-31|||||Observational|||Prognosis Factors Associated With Convulsive Status Epilepticus in Adults|Prognosis Factors Associated With Convulsive Status Epilepticus in Adults: A Multicenter Cohort Study|Completed|||100|Anticipated|Versailles Hospital|||||f||||||||||||||2018-06-01 04:02:33.372412|2018-06-01 04:02:33.372412
NCT00318565|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|2009-07-08||2012-03-01|2006-04-25|2006-04-27|Estimate|2010-02-17|2010-03-02|Estimate||||2012-03-01|2012-03-05|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|February 2008|Actual|2008-02-29|September 2007|Actual|2007-09-30||Interventional|||Catheter Evaluation for Endocardial Ablation in Patients With Typical Atrial Flutter|Navistar Thermocool Evaluation of the Catheter With the Stockert 70 Radiofrequency Generator for Endocardial Ablation in Patients With Typical Atrial Flutter|Completed||Phase 4|291|Actual|Biosense Webster, Inc.||1|||f||||f||||||||||2018-06-01 04:02:33.506162|2018-06-01 04:02:33.506162
NCT00318552|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2017-08-31|2006-04-26|2006-04-27|Estimate|||||||2017-08-31|2017-09-01|Actual|January 2002||2002-01-31|August 2017|2017-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.|Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients. An Open, Randomized Multi-center Study.|Completed||Phase 4|160||Pfizer|||||f||||||||||||||2018-06-01 04:02:33.725183|2018-06-01 04:02:33.725183
NCT00318539|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2011-01-20|2006-04-25|2006-04-27|Estimate|||||||2011-01-20|2011-01-21|Estimate|December 2003||2003-12-31|January 2011|2011-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study|Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder, a Double-blind, Placebo-controlled Study|Completed||Phase 2|90||AstraZeneca|||||f||||||||||||||2018-06-01 04:02:33.794509|2018-06-01 04:02:33.794509
NCT00318513|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2006-05-09|2006-04-24|2006-04-26|Estimate|||||||2006-05-09|2006-05-10|Estimate||||April 2006|2006-04-30||||||||Interventional|||Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema|Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema|Unknown status|Not yet recruiting|Phase 1|35||Premiere Oncology of Arizona|||||||||||||||||||2018-06-01 04:02:33.852251|2018-06-01 04:02:33.852251
NCT00318500|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2007-12-07|2006-04-25|2006-04-26|Estimate|||||||2007-12-07|2007-12-10|Estimate|May 2006||2006-05-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 75 mg and 150 mg Doses of ERB-041 on the Reduction of Symptoms Associated With Endometriosis During Treatment and Post Treatment in Reproductive-Aged Women|Completed||Phase 2|150||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:02:33.937582|2018-06-01 04:02:33.937582
NCT00318487|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2014-12-04|2006-04-25|2006-04-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Bilateral Sinus Floor Augmentation in Conjunction With Immediate Implant Loading - Study on 3i Dental Implants|Bilateral Sinus Floor Augmentation in Conjunction With Immediate Implant Loading - A Clinical and Histomorphometric Follow-Up Study on 3i Dental Implants|Unknown status|Active, not recruiting|N/A|15|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:02:34.168965|2018-06-01 04:02:34.168965
NCT00318474|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2014-06-03||2016-02-04|2006-04-24|2006-04-26|Estimate|2014-09-24|2014-10-01|Estimate||||2016-02-04|2016-03-07|Estimate|January 2002||2002-01-31|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2008|Actual|2008-03-31||Interventional|||Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy|A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy|Terminated||Phase 3|184|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2||DSMB recommended stopping the trial because of lack of effect.|f||||t||||||||||2018-06-01 04:02:34.249789|2018-06-01 04:02:34.249789
NCT00318461|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|2010-02-23|2009-11-09|2017-01-24|2006-04-25|2006-04-26|Estimate|2010-02-23|2010-03-12|Estimate|2009-11-09|2009-11-11|Estimate|2017-01-24|2017-03-07|Actual|May 2006||2006-05-31|January 2017|2017-01-31|November 2008|Actual|2008-11-30|May 2007|Actual|2007-05-31||Interventional|LEAD-2||To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together|Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes|Completed||Phase 3|1091|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-06-01 04:02:34.70904|2018-06-01 04:02:34.70904
NCT00318448|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2009-04-06|2006-04-25|2006-04-26|Estimate|||||||2009-04-06|2009-04-07|Estimate|April 2006||2006-04-30|April 2009|2009-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|Zolkids||Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia|Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 3|201|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:02:37.007252|2018-06-01 04:02:37.007252
NCT00318435|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2008-08-17|2006-04-25|2006-04-26|Estimate|||||||2008-08-17|2008-08-19|Estimate|May 2006||2006-05-31|April 2006|2006-04-30|August 2006|Actual|2006-08-31|||||Interventional|||Fluency Stent-Graft Versus Luminex Stent for Angioplasty of Recurrent Stenosis of the Cephalic Arch in Autogenous Arteriovenous (AV) Access for Hemodialysis||Completed||Phase 4|50||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 04:02:37.062573|2018-06-01 04:02:37.062573
NCT00318422|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2017-01-24|2006-04-25|2006-04-26|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2006||2006-05-31|January 2017|2017-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|LEAD-1||Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.|Completed||Phase 3|1041|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:02:37.11862|2018-06-01 04:02:37.11862
NCT00318409|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2013-04-24||2014-10-09|2006-04-24|2006-04-26|Estimate|2014-10-09|2014-10-17|Estimate||||2014-10-09|2014-10-17|Estimate|September 2006||2006-09-30|October 2014|2014-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM|Pilot Study of Acceptability of Bupropion Treatment for Methamphetamine Dependence Among Men Who Have Sex With Men.|Completed||Phase 2|30|Actual|San Francisco Department of Public Health||2|||f||||t||||||||||2018-06-01 04:02:37.425867|2018-06-01 04:02:37.425867
NCT00318396|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2017-04-11|2006-04-24|2006-04-26|Estimate|||||||2017-04-11|2017-04-12|Actual|June 2004||2004-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Compaction Femur Preparation for Cementless Total Hip Arthroplasty (THA) Unilateral|Compaction Femur Total Hip Arthroplasty (THA) Uni-lateral|Active, not recruiting||N/A|26|Actual|Northern Orthopaedic Division, Denmark||2|||f||||t||||||||||2018-06-01 04:02:37.736947|2018-06-01 04:02:37.736947
NCT00318383|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2017-01-11|2006-04-24|2006-04-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2006||2006-05-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Efficacy of NicVAX in Smokers Who Want to Quit Smoking|A Phase 2, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking|Completed||Phase 2|313|Actual|National Institute on Drug Abuse (NIDA)||6|||f||||t||||||||||2018-06-01 04:02:37.806005|2018-06-01 04:02:37.806005
NCT00318370|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2012-01-27||2015-09-04|2006-04-24|2006-04-26|Estimate|2012-02-09|2012-02-15|Estimate||||2015-09-04|2015-09-09|Estimate|May 2006||2006-05-31|September 2015|2015-09-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy|A Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse|Completed||Phase 2|58|Actual|Morphotek||2|||f||||f||||||||||2018-06-01 04:02:37.913752|2018-06-01 04:02:37.913752
NCT00318357|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2008-05-30|2006-04-25|2006-04-26|Estimate|||||||2008-05-30|2008-06-04|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||CARE-HF LTFU: CArdiac REsynchronization in Heart Failure Long-Term Follow-up|CARE-HF LTFU: CArdiac REsynchronization in Heart Failure Long-Term Follow-up|Unknown status|Active, not recruiting||550|Anticipated|Medtronic Bakken Research Center|||1||f||||t||||||None Retained|"~     No biospecimens are retained~   "|||2018-06-01 04:02:38.349945|2018-06-01 04:02:38.349945
NCT00318344|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2010-02-01|2006-04-24|2006-04-26|Estimate|||||||2010-02-01|2010-02-02|Estimate|April 2006||2006-04-30|February 2010|2010-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Evaluation of Atuna Racemosa Toxicity|Evaluation of Atuna Racemosa Toxicity|Completed||Phase 1|20|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 04:02:38.560101|2018-06-01 04:02:38.560101
NCT00318331|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2008-03-10|2006-04-24|2006-04-26|Estimate|||||||2008-03-10|2008-03-13|Estimate|May 2006||2006-05-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Enteral Glutamine in Critical Illness|Randomized Clinical Trial Comparing Enteral Glutamine Supplementation to Standard of Care Enteral Feeding in Critical Illness|Terminated||Phase 2/Phase 3|20|Actual|Christiana Care Health Services||2||Unable to meet enrollment numbers|f||||t||||||||||2018-06-01 04:02:38.615279|2018-06-01 04:02:38.615279
NCT00318318|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2009-07-08|2006-04-24|2006-04-26|Estimate|||||||2009-07-08|2009-07-09|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|||Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed by Human Genome Array|Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed by Human Genome Array|Completed||Phase 1|20|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 04:02:38.706476|2018-06-01 04:02:38.706476
NCT00318305|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2009-12-01|2006-04-24|2006-04-26|Estimate|||||||2009-12-01|2009-12-02|Estimate|March 2005||2005-03-31|December 2009|2009-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Patient Preference With Visicol Tablet Preparation for Colonoscopy|Patient Preference and Acceptance With Sodium Phosphate Tablet Preparation for Colonoscopy: A Prospective Study|Completed|||53|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 04:02:38.770612|2018-06-01 04:02:38.770612
NCT00318292|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2009-02-18||2010-10-22|2006-04-24|2006-04-26|Estimate|2009-03-17|2009-03-18|Estimate||||2010-10-22|2010-11-18|Estimate|April 2006||2006-04-30|October 2010|2010-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Preemptive Local Anesthesia in Vaginal Surgery|Preemptive Local Anesthesia in Vaginal Surgery, A Prospective, Randomised Trial|Completed||Phase 4|90|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 04:02:38.834979|2018-06-01 04:02:38.834979
NCT00318279|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2017-08-24|2006-04-24|2006-04-26|Estimate|||||||2017-08-24|2017-08-25|Actual|May 2006||2006-05-31|April 2006|2006-04-30|September 2007||2007-09-30|||||Interventional|||Evaluation of Surgical Simulator for Practicing a Vascular Anastomosis|Benefits of a Surgical Skills Lab Vascular Anastomosis Simulator: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:02:39.120351|2018-06-01 04:02:39.120351
NCT00318266|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2017-08-24|2006-04-24|2006-04-26|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2006||2006-01-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.|NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers|Completed|||73|Actual|Lawson Health Research Institute|||1||f||||f||||||||||2018-06-01 04:02:39.264492|2018-06-01 04:02:39.264492
NCT00318227|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2017-08-25|2006-04-24|2006-04-26|Estimate|||||||2017-08-25|2017-08-28|Actual|June 21, 2004|Actual|2004-06-21|August 2017|2017-08-31|February 23, 2010|Actual|2010-02-23|April 21, 2009|Actual|2009-04-21||Interventional|||Randomized Trial of a Liberal Versus a Restrictive Transfusion Strategy in Elderly Cardiac Surgery Patients|Evaluation of a Liberal Versus Restrictive Blood Transfusion Strategy in Elderly Patients Following Coronary Bypass or Aortic Valve Surgery|Completed||N/A|73|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:02:39.535167|2018-06-01 04:02:39.535167
NCT00318214|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24||2008-12-04|2012-05-24|2006-04-25|2006-04-26|Estimate||||2009-11-05|2009-11-09|Estimate|2012-05-24|2012-06-01|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers||Terminated||Phase 2|16|Actual|Pfizer||2||"The study had poor enrollment with only 16 patients randomized across 19 study centers over an~   18-month period."|f||||f||||||||||2018-06-01 04:02:39.626914|2018-06-01 04:02:39.626914
NCT00318201|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2012-04-05|2006-04-25|2006-04-26|Estimate|||||||2012-04-05|2012-04-06|Estimate|April 2006||2006-04-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers|The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers|Completed||Phase 4|7|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 04:02:39.727813|2018-06-01 04:02:39.727813
NCT00318188|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2018-04-05|2006-04-25|2006-04-26|Estimate|||||||2018-04-05|2018-04-09|Actual|September 2005|Actual|2005-09-30|April 2018|2018-04-30|January 2014|Actual|2014-01-31|December 2011|Actual|2011-12-31||Interventional|SCLEREDUC||Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis|Effects of a Personalized Standardized Rehabilitation Program on the Quality of Life of Patients With Systemic Sclerosis Patients : a Randomized Controlled Trial|Completed||N/A|220|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-06-01 04:02:39.805956|2018-06-01 04:02:39.805956
NCT00318175|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2007-09-07|2006-04-24|2006-04-26|Estimate|||||||2007-09-07|2007-09-10|Estimate|June 2006||2006-06-30|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis|Study to Assess the Effect of Bosentan on the Treatment of Skin Fibrosis in Patients With Systemic Sclerosis (BTSF)|Completed||Phase 2|10|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||||||||||||2018-06-01 04:02:39.878632|2018-06-01 04:02:39.878632
NCT00318162|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2006-05-02|2006-04-25|2006-04-26|Estimate|||||||2006-05-02|2006-05-03|Estimate||||April 2006|2006-04-30||||||||Interventional|||Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)|Randomized Double-Blind Trial of Low-Dose Naltrexone for Children With PDD|Unknown status|Not yet recruiting|Phase 1/Phase 2|50|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:02:39.936862|2018-06-01 04:02:39.936862
NCT00318149|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2016-09-23|2006-04-25|2006-04-26|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 2005||2005-10-31|September 2016|2016-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population|Demonstrate the Non-inferiority in Term of Cellular Mediated Immune Response of GSK Biologicals' Influenza Candidate Vaccines Containing Various Adjuvants Administered in Elderly Population (Aged 65 Years &Amp; Older) vs Fluarix™ (Known as Alpha-Rix™ in Belgium) Administered in Adults (18-40 Years)|Completed||Phase 2|425|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:40.015605|2018-06-01 04:02:40.015605
NCT00318136|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2010-03-19||2010-05-05|2006-04-24|2006-04-26|Estimate|2010-03-19|2010-04-06|Estimate||||2010-05-05|2010-05-11|Estimate|September 2005||2005-09-30|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)|A Pilot Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer|Completed||Phase 2|47|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 04:02:40.112727|2018-06-01 04:02:40.112727
NCT00318123|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2008-01-25|2006-04-25|2006-04-26|Estimate|||||||2008-01-25|2008-01-29|Estimate|April 2004||2004-04-30|January 2008|2008-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients|Multicentre, Open Label, Prospective, Randomised Clinical Trial to Evaluate the Effectiveness of Abacavir 600 mg+ Lamivudine 300 mg as QD+ Efavirenz 600 mg QD Versus Kaletra 400/100 mg BID as Initial Antiretroviral Treatment|Completed||Phase 3|126|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 04:02:40.332071|2018-06-01 04:02:40.332071
NCT00318110|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2016-07-25|2006-04-24|2006-04-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|April 2006||2006-04-30|July 2016|2016-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma|Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma|Terminated||Phase 2|4|Actual|Center for International Blood and Marrow Transplant Research||1||Unable to meet subject enrollment goal.|f||||t||||||||No|Only 2 subjects enrolled prior to study closure due to slow accrual.|2018-06-01 04:02:40.4724|2018-06-01 04:02:40.4724
NCT00318097|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2018-02-02|2006-04-25|2006-04-26|Estimate|||||||2018-02-02|2018-02-06|Actual|August 1, 2004|Actual|2004-08-01|February 2018|2018-02-28|August 1, 2007|Actual|2007-08-01|August 1, 2007|Actual|2007-08-01||Observational|||Histamine Responsiveness in McCune-Albright Syndrome|Histamine Responsiveness in Patients With McCune-Albright Syndrome|Completed|||22|Actual|Children's Mercy Hospital Kansas City|||2||f||||||||||||||2018-06-01 04:02:40.56314|2018-06-01 04:02:40.56314
NCT00318084|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2007-08-15|2006-04-25|2006-04-26|Estimate|||||||2007-08-15|2007-08-17|Estimate|January 2003||2003-01-31|August 2007|2007-08-31||||||||Interventional|||PPI Test in GP Patients|The Proton Pump Inhibitor Test in Reflux Disease: a Study Using Nexium in General Practice Patients|Completed||Phase 4|100||AstraZeneca|||||f||||||||||||||2018-06-01 04:02:40.653389|2018-06-01 04:02:40.653389
NCT00318071|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2014-11-06|2006-04-25|2006-04-26|Estimate|||||||2014-11-06|2014-11-07|Estimate|January 2004||2004-01-31|November 2014|2014-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|Multi-MERCI||Multi MERCI (Mechanical Embolus Removal in Cerebral Ischemia [MERCI™])|A Multinational Controlled Registry to Evaluate the Concentric Merci Retriever System (Mechanical Embolus Removal in Cerebral Ischemia [MERCI™])|Completed||N/A|164|Actual|Stryker Neurovascular||1|||f||||t||||||||||2018-06-01 04:02:40.727116|2018-06-01 04:02:40.727116
NCT00315679|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-04-18|2006-04-18|2006-04-19|Estimate|||||||2006-04-18|2006-04-19|Estimate|June 1996||1996-06-30|March 2006|2006-03-31|November 1998||1998-11-30|||||Interventional|||A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis||Completed||N/A|30||Manchester University NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:03:24.082937|2018-06-01 04:03:24.082937
NCT00318058|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-25|||2017-05-04|2006-04-25|2006-04-26|Estimate|||||||2017-05-04|2017-05-08|Actual|October 3, 2005|Actual|2005-10-03|May 2017|2017-05-31|November 4, 2005|Actual|2005-11-04|November 1, 2005|Actual|2005-11-01||Interventional|||Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population|A Phase I/II, Open, Controlled Study in Order to Evaluate the Reactogenicity and the Immunogenicity of GlaxoSmithKline Biologicals Influenza Candidate Adjuvanted Vaccine in an Elderly Population Aged Over 65 Years Previously Vaccinated in 2004 With the Same Candidate Vaccine|Completed||Phase 1|84|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:40.791241|2018-06-01 04:02:40.791241
NCT00318045|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2006-04-21|2006-04-21|2006-04-25|Estimate|||||||2006-04-21|2006-04-25|Estimate|October 2005||2005-10-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Effects of Optical Blur on Performance and Comfort of Computer Users|Effects of Optical Blur on Performance and Comfort of Computer Users|Unknown status|Active, not recruiting|Phase 3|35||Vision Council of America|||||f||||||||||||||2018-06-01 04:02:40.861697|2018-06-01 04:02:40.861697
NCT00318032|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2014-07-01|2006-04-24|2006-04-25|Estimate|||||||2014-07-01|2014-07-02|Estimate|August 2004||2004-08-31|July 2014|2014-07-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|ADDITION||A Study to Investigate the Benefits of the Early Detection and Intensive Treatment of Type 2 Diabetes|A Randomised Trial of the Cost Effectiveness of Screening and Intensive Multi-factorial Intervention for Type 2 Diabetes|Unknown status|Active, not recruiting|N/A|8579|Actual|University Hospitals, Leicester||1|||f||||||||||||||2018-06-01 04:02:40.907669|2018-06-01 04:02:40.907669
NCT00318019|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2011-11-16|2006-04-21|2006-04-25|Estimate|||||||2011-11-16|2011-11-17|Estimate|June 2006||2006-06-30|November 2011|2011-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of OPC Factor on Energy Levels|The Effect of OPC Factor on Energy Levels in Healthy Individuals Aged 45-65: A Randomized Controlled Trial|Completed||Phase 2|27|Actual|University of Pennsylvania||2|||f||||||||||||||2018-06-01 04:02:40.963702|2018-06-01 04:02:40.963702
NCT00318006|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2015-01-28|2006-04-21|2006-04-25|Estimate|||||||2015-01-28|2015-01-30|Estimate|December 2005||2005-12-31|January 2015|2015-01-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms|A Randomized Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms|Completed||Phase 4|127|Actual|University of Michigan||2|||f||||||||||||||2018-06-01 04:02:41.149566|2018-06-01 04:02:41.149566
NCT00317993|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2014-12-02|2006-04-24|2006-04-25|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2004||2004-04-30|December 2014|2014-12-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||LDL Receptor Under Ezetimibe and Simvastatin|Effects of Ezetimibe and Simvastatin on LDL Receptor Protein Expression and on LDL Receptor and HMG-CoA Reductase mRNA Expression in Mononuclear Cells: a Randomized Controlled Study in Healthy Men|Completed||Phase 4|60||University of Cologne|||||f||||||||||||||2018-06-01 04:02:41.231124|2018-06-01 04:02:41.231124
NCT00317980|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2009-01-20|2006-04-21|2006-04-25|Estimate|||||||2009-01-20|2009-01-22|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|Lowdosesb||Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis|Phase IV Randomized Controlled Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Pentavalent Antimony Compared to the Standard Dose in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)Braziliensis|Completed||Phase 4|280|Actual|University of Brasilia||2|||f||||f||||||||||2018-06-01 04:02:41.289748|2018-06-01 04:02:41.289748
NCT00317967|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2013-12-05|2006-04-24|2006-04-25|Estimate|||||||2013-12-05|2013-12-09|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart|Statin Induced Regression of Cardiomyopathy Trial - SirCat|Completed||Phase 3|22|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 04:02:41.364578|2018-06-01 04:02:41.364578
NCT00317954|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2006-04-21|2006-04-21|2006-04-25|Estimate|||||||2006-04-21|2006-04-25|Estimate|September 2003||2003-09-30|August 2005|2005-08-31|July 2005||2005-07-31|||||Interventional|||Spironolactone in Diabetic Nephropathy|Spironolactone in Diabetic Nephropathy|Completed||Phase 4|48||Steno Diabetes Center|||||f||||||||||||||2018-06-01 04:02:41.430007|2018-06-01 04:02:41.430007
NCT00317941|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2013-05-24||2013-08-15|2006-04-24|2006-04-25|Estimate|2013-08-15|2013-10-21|Estimate||||2013-08-15|2013-10-21|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif|The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®).|Completed||Phase 4|220|Actual|Bayer||3|||f||||f||||||||||2018-06-01 04:02:41.523382|2018-06-01 04:02:41.523382
NCT00317928|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2006-10-10|2006-04-24|2006-04-25|Estimate|||||||2006-10-10|2006-10-11|Estimate|August 2001||2001-08-31|August 2001|2001-08-31|September 2004||2004-09-30|||||Interventional|||Efficacy of Metformin in PCOS: Metabolic and Hormonal Factors||Unknown status|Active, not recruiting|N/A|50||Aarhus University Hospital Skejby|||||f||||||||||||||2018-06-01 04:02:42.378678|2018-06-01 04:02:42.378678
NCT00317915|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2006-04-24|2006-04-24|2006-04-25|Estimate|||||||2006-04-24|2006-04-25|Estimate||||April 2006|2006-04-30||||||||Interventional|||Irbesartan in Type 2 Diabetes|The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)|Completed||Phase 3|||Steno Diabetes Center|||||f||||||||||||||2018-06-01 04:02:42.434|2018-06-01 04:02:42.434
NCT00317902|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2011-05-17|2006-04-21|2006-04-25|Estimate|||||||2011-05-17|2011-05-19|Estimate|October 2002||2002-10-31|April 2010|2010-04-30|May 2004|Actual|2004-05-31|||||Interventional|||An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)|An Open-Label Study to Evaluate The Effect of Every Other Week PROCRIT (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients|Completed||Phase 4|292|Actual|Ortho Biotech Products, L.P.|||||f||||||||||||||2018-06-01 04:02:42.491479|2018-06-01 04:02:42.491479
NCT00317889|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2017-10-04|2006-04-24|2006-04-25|Estimate|||||||2017-10-04|2017-10-05|Actual|May 2001||2001-05-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Compaction Total Hip Arthroplasty (THA) Bilateral|Compaction THA Bilateral|Completed||N/A|20|Actual|Northern Orthopaedic Division, Denmark||2|||f||||||||||||||2018-06-01 04:02:42.550428|2018-06-01 04:02:42.550428
NCT00300443|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2011-05-27|2006-03-07|2006-03-09|Estimate|||||||2011-05-27|2011-05-30|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 2/Phase 3|561|Actual|Allergan|||||f||||||||||||||2018-06-01 04:07:42.498207|2018-06-01 04:07:42.498207
NCT00317876|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2012-04-18|2006-04-24|2006-04-25|Estimate|||||||2012-04-18|2012-04-20|Estimate|June 1998||1998-06-30|April 2012|2012-04-30||||July 2003|Actual|2003-07-31||Interventional|||Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia|Dose-Finding Study for Cyclophosphamide as Conditioning Regimens for Bone Marrow Transplantation From Related Donors in Patients With Fanconi Anemia|Completed||Phase 1|25|Actual|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:02:42.639595|2018-06-01 04:02:42.639595
NCT00317863|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2017-09-14|2006-04-24|2006-04-25|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2004|Actual|2004-01-31|September 2017|2017-09-30|January 1, 2008|Actual|2008-01-01|January 1, 2008|Actual|2008-01-01||Observational|||Zink and Bone Strength|Zink and Bone Strength|Completed|||40|Actual|Northern Orthopaedic Division, Denmark|||||f||||t||||||||||2018-06-01 04:02:42.71005|2018-06-01 04:02:42.71005
NCT00317850|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2012-02-29|2006-04-21|2006-04-25|Estimate|||||||2012-02-29|2012-03-02|Estimate|April 2004||2004-04-30|February 2012|2012-02-29|February 2006||2006-02-28|||||Interventional|||Gabapentin for the Treatment of Tinnitus|Gabapentin for the Relief of Idiopathic Subjective Tinnitus|Terminated||Phase 2/Phase 3|160||Washington University School of Medicine|||||f||||||||||||||2018-06-01 04:02:42.765565|2018-06-01 04:02:42.765565
NCT00317837|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2014-03-28|2006-04-23|2006-04-25|Estimate|||||||2014-03-28|2014-03-31|Estimate|October 2004||2004-10-31|March 2014|2014-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Bipolar Versus Unipolar Hemiarthroplasty for Patients With a Hip Fracture|Bipolar vs. Unipolar Hemiarthroplasty for Patients Aged 70 Years or Above, With a Dislocated Medial Femoral Neck Fracture|Withdrawn||N/A|0|Actual|Northern Orthopaedic Division, Denmark||2||Recruitment was too slow, primary investigator has left the organisation|f||||||||||||||2018-06-01 04:02:42.815651|2018-06-01 04:02:42.815651
NCT00317811|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2013-11-05|2006-04-24|2006-04-25|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 2005||2005-11-30|June 2011|2011-06-30||||February 2009|Actual|2009-02-28||Interventional|||Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma|A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|Completed||Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:02:42.879053|2018-06-01 04:02:42.879053
NCT00317798|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2011-08-29|2006-04-24|2006-04-25|Estimate|||||||2011-08-29|2011-08-30|Estimate|April 2006||2006-04-30|August 2011|2011-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma|A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)|Completed||Phase 1|18|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:02:43.060739|2018-06-01 04:02:43.060739
NCT00317785|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2010-05-05|2006-04-24|2006-04-25|Estimate|||||||2010-05-05|2010-05-07|Estimate|May 2005||2005-05-31|May 2010|2010-05-31||||November 2007|Actual|2007-11-30||Interventional|||Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases|A Phase II Trial of Total Body Irradiation Plus Metabolism-Based Cyclophosphamide Dosing as Preparative Therapy for Allogeneic Hematopoietic Cell Transplant for Patients With Hematological Malignancy|Completed||Phase 2|50|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:02:43.133106|2018-06-01 04:02:43.133106
NCT00317772|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2017-10-25|2006-04-21|2006-04-25|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2, 2004|Actual|2004-09-02|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I/II Study of Weekly Topotecan and Gefitinib (Iressa) in Patients With Platinum-Resistant Ovarian, Peritoneal, of Fallopian Tube Cancer|Active, not recruiting||Phase 1/Phase 2|19|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 04:02:43.215833|2018-06-01 04:02:43.215833
NCT00317759|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2015-09-30|2006-04-24|2006-04-25|Estimate|||||||2015-09-30|2015-10-01|Estimate|May 2003||2003-05-31|May 2010|2010-05-31|October 2008|Actual|2008-10-31|||||Interventional|||Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Fludarabine Lymphodepletion for Patients With Metastatic Melanoma|Completed||Phase 1|12|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:02:43.285071|2018-06-01 04:02:43.285071
NCT00317746|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2017-05-19|2006-04-21|2006-04-25|Estimate|||||||2017-05-19|2017-05-22|Actual|November 2006||2006-11-30|May 2017|2017-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|PICCO||Trial of Citalopram for the Prevention of Depression|A Randomized, Placebo Controlled Trial of Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Co-infected Individuals Initiating Pegylated Interferon/Ribavirin Therapy|Completed||Phase 3|76|Actual|McGill University Health Center||2|||f||||t||||||||||2018-06-01 04:02:43.340044|2018-06-01 04:02:43.340044
NCT00317733|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2009-03-19|2006-04-21|2006-04-25|Estimate|||||||2009-03-19|2009-03-20|Estimate||||March 2009|2009-03-31|January 2004||2004-01-31|||||Interventional|||Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee|A Double-Blind, Placebo-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 (Ketoprofen in Transfersome) in Comparison to Oral Celecoxib for the Treatment of Pain Associated With Osteoarthritis of the Knee|Completed||Phase 2|360||IDEA AG|||||f||||||||||||||2018-06-01 04:02:43.409661|2018-06-01 04:02:43.409661
NCT00317720|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|2013-04-30||2014-06-12|2006-04-21|2006-04-25|Estimate|2014-06-10|2014-06-12|Estimate||||2014-06-12|2014-06-26|Estimate|April 2006||2006-04-30|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Participants were pooled from 2 separate clinical trials (MDACC ClinicalTrials.gov ID NCT00317720) and (BIDMC/DFCI ClinicalTrials.gov ID NCT00458237)|Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer|Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy|Completed||Phase 1/Phase 2|40|Actual|M.D. Anderson Cancer Center|Trial Results were combined for the 2 trials at MDACC & BIDMC/DFCI with US Food & Drug Administration approval for completion with adequate power. As results were pooled for analytic purposes, BIDMC/DFCI protocol was amended to match MDACC protocol.|1|||f||||f||||||||||2018-06-01 04:02:43.480763|2018-06-01 04:02:43.480763
NCT00317707|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2012-01-17|2006-04-21|2006-04-25|Estimate|||||||2012-01-17|2012-01-18|Estimate|February 2004||2004-02-29|January 2012|2012-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk|Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk|Completed||Phase 3|12513|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||t||||||||||2018-06-01 04:02:43.648855|2018-06-01 04:02:43.648855
NCT00317694|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21||2009-07-21|2009-07-21|2006-04-21|2006-04-25|Estimate||||2009-07-21|2009-08-10|Estimate|2009-07-21|2009-08-10|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients|A Multicentre Phase II Study With Magnesium Iron Hydroxycarbonate: an Open-label, Dose-ranging Phase Followed by a Placebo-controlled, Double-blind, Parallel-group Comparison in Haemodialysis Subjects With Hyperphosphataemia|Completed||Phase 2|111|Actual|Ineos Healthcare Limited||2|||f||||t||||||||||2018-06-01 04:02:43.707553|2018-06-01 04:02:43.707553
NCT00317681|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2007-09-07|2006-04-21|2006-04-25|Estimate|||||||2007-09-07|2007-09-10|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|February 2007|Actual|2007-02-28|||||Interventional|||Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)|The Efficacy of Topical Tacrolimus in the Treatment of Cutaneous Lupus Erythematosus - a Multi-Center-Trial|Completed||Phase 2|30|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||||||||||||2018-06-01 04:02:43.78524|2018-06-01 04:02:43.78524
NCT00317668|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2007-04-29|2006-04-23|2006-04-25|Estimate|||||||2007-04-29|2007-05-01|Estimate|November 2006||2006-11-30|April 2006|2006-04-30||||||||Observational|||Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients||Unknown status|Recruiting||250|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:02:43.838633|2018-06-01 04:02:43.838633
NCT00317655|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2007-05-16|2006-04-23|2006-04-25|Estimate|||||||2007-05-16|2007-05-17|Estimate|April 2006||2006-04-30|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain|Glucosamine Sulphate, Ginger, Ginger-Avocado-Soya and Ginger-Ibuprofen for Chronic Back Pain - a Randomized, Double Blind, Placebo-Controlled Clinical Investigation With Parallel Groups for 3 Months to Enlighten Joint Health|Completed||Phase 4|175|Actual|Ferrosan AS|||||f||||||||||||||2018-06-01 04:02:43.925944|2018-06-01 04:02:43.925944
NCT00317642|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|2011-08-11||2014-03-17|2006-04-24|2006-04-25|Estimate|2011-08-11|2011-09-15|Estimate||||2014-03-17|2014-04-14|Estimate|August 2006||2006-08-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)|A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens|Completed||Phase 3|326|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:02:45.211737|2018-06-01 04:02:45.211737
NCT00317629|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2010-11-23|2006-04-21|2006-04-25|Estimate|||||||2010-11-23|2010-11-24|Estimate|May 2006||2006-05-31|November 2010|2010-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis|Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis|Terminated||Phase 3|178|Actual|Fundación Cardiovascular de Colombia||2||An interim analysis showed that nitric oxide patches are not enough effective|f||||t||||||||||2018-06-01 04:02:48.867846|2018-06-01 04:02:48.867846
NCT00317616|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-24|||2018-03-15|2006-04-24|2006-04-25|Estimate|||||||2018-03-15|2018-03-16|Actual|April 2006||2006-04-30|March 2018|2018-03-31|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Observational|Pre-fALS||The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study|The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study|Recruiting|||500|Anticipated|University of Miami|||||f||||f||||||Samples With DNA|"~     Serum, Plasma, CSF, DNA, Urine, Cell lines~   "|||2018-06-01 04:02:49.048532|2018-06-01 04:02:49.048532
NCT00317603|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2017-03-01|2006-04-21|2006-04-25|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2005||2005-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients|A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Breast Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Metastatic Breast Cancer Patients|Active, not recruiting||Phase 1|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 04:02:49.433089|2018-06-01 04:02:49.433089
NCT00317590|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2007-10-30|2006-04-23|2006-04-25|Estimate|||||||2007-10-30|2007-10-31|Estimate|April 2006||2006-04-30|October 2007|2007-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Effectiveness and Cost-Effectiveness of a Rapid Diagnostic Test for Malaria|Evaluation de l'utilité et du coût-efficacité du Test Rapide Paracheck® Pour la Prise en Charge Des Cas de Paludisme Dans Les régions Des Hauts Bassins et Des Cascades, au Burkina Faso|Completed||Phase 4|4000|Anticipated|Centro per le Malattie Tropicali|||||f||||||||||||||2018-06-01 04:02:49.545538|2018-06-01 04:02:49.545538
NCT00317577|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-23|||2006-04-23|2006-04-23|2006-04-25|Estimate|||||||2006-04-23|2006-04-25|Estimate|December 1998||1998-12-31|April 2006|2006-04-30|May 2004||2004-05-31|||||Interventional|||Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma|A Multicenter, Double-Masked, 2-Arm Parallel Group Study Comparing the Effect of Brimonidine 0.2% Versus Timolol 0.5% on Visual Field Stability in Patients With Low-Pressure Glaucoma|Completed||Phase 2|160||Chicago Center for Vision Research|||||f||||||||||||||2018-06-01 04:02:49.632125|2018-06-01 04:02:49.632125
NCT00317564|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2013-12-05|2006-04-21|2006-04-25|Estimate|||||||2013-12-05|2013-12-09|Estimate|April 2006||2006-04-30|December 2013|2013-12-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|||Betaseron Pregnancy Registry|Betaseron Pregnancy Registry|Completed|||113|Actual|INC Research|||||f||||t||||||||||2018-06-01 04:02:49.748495|2018-06-01 04:02:49.748495
NCT00317551|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2006-10-16|2006-04-21|2006-04-25|Estimate|||||||2006-10-16|2006-10-17|Estimate|April 2005||2005-04-30|December 2005|2005-12-31||||||||Interventional|||Cambridge Anti-Myopia Trial: Accommodation Training and Aberration Control in Myopia Development|Accommodation Training and Aberration Control in Myopia Development|Completed||Phase 2|200||Anglia Ruskin University|||||f||||||||||||||2018-06-01 04:02:49.807532|2018-06-01 04:02:49.807532
NCT00317538|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2011-05-18|2006-04-21|2006-04-25|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2003||2003-06-30|April 2010|2010-04-30|November 2004|Actual|2004-11-30|||||Interventional|||Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept|Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Switch to Infliximab After Incomplete Response to Etanercept|Completed||Phase 3|28|Actual|Centocor Ortho Biotech Services, L.L.C.|||||||||||||||||||2018-06-01 04:02:49.872569|2018-06-01 04:02:49.872569
NCT00317525|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2006-09-07|2006-04-21|2006-04-25|Estimate|||||||2006-09-07|2006-09-11|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|June 2006||2006-06-30|||||Interventional|||Effects of Different Add Powers on the Comfort and Productivity of Computer Users With Fixed or Free Head Movement|Effects of Different Add Powers on the Comfort and Productivity of Computer Users With Fixed or Free Head Movement|Completed||Phase 3|36||American Optometric Association|||||f||||||||||||||2018-06-01 04:02:49.929186|2018-06-01 04:02:49.929186
NCT00317512|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2008-05-15|2006-04-21|2006-04-25|Estimate|||||||2008-05-15|2008-05-16|Estimate|December 2003||2003-12-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|April 2005|Actual|2005-04-30||Interventional|||Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization|A Multi-Center,Randomized,Double-Blind,Placebo-Controlled,Dose Finding Pilot Study, to Evaluate Safety/Feasibility of HBOC-201 in Elective Percutaneous Coronary Revascularization of Subjects With Acute Coronary Syndromes|Completed||Phase 2|45|Actual|Biopure Corporation||3|||f||||t||||||||||2018-06-01 04:02:50.298151|2018-06-01 04:02:50.298151
NCT00317499|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2010-12-22|2006-04-21|2006-04-25|Estimate|||||||2010-12-22|2010-12-23|Estimate|April 2000||2000-04-30|December 2010|2010-12-31|July 2002|Actual|2002-07-31|June 2002|Actual|2002-06-30||Interventional|||Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis|Double-Blind, Randomized, Placebo-Controlled Study of Etanercept (ENBREL) in the Treatment of Psoriatic Arthritis (PsA) and Psoriasis|Completed||Phase 3|205|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:02:51.385729|2018-06-01 04:02:51.385729
NCT00317486|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21||2010-02-11|2010-02-11|2006-04-21|2006-04-25|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|September 2003||2003-09-30|February 2010|2010-02-28|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology|Completed||Phase 4|54|Actual|Actelion|||||f||||||||||||||2018-06-01 04:02:51.455111|2018-06-01 04:02:51.455111
NCT00317473|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|2017-01-24||2017-05-04|2006-04-20|2006-04-24|Estimate|2017-05-04|2017-10-02|Actual||||2017-05-04|2017-10-02|Actual|June 2003||2003-06-30|May 2017|2017-05-31|July 2005|Actual|2005-07-31|July 2004|Actual|2004-07-31||Interventional||one subject from FMP1/AS02A Cohort A withdrew after randomization and prior to baseline measurement|Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children|Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine.|Completed||Phase 1|135|Actual|U.S. Army Medical Research and Materiel Command||4|||f||||t||||||||Yes|Kenya Medical Research Institute; WRAIR; The Path Malaria Vaccine Initiative; United States Agency for International Development; GlaxoSmith Kline|2018-06-01 04:02:51.962988|2018-06-01 04:02:51.962988
NCT00317460|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2014-07-08|2006-04-21|2006-04-24|Estimate|||||||2014-07-08|2014-07-09|Estimate|September 2005||2005-09-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2009|Actual|2009-10-31||Interventional|||Buprenorphine and Integrated HIV Care|On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings|Completed||Phase 4|52|Actual|Yale University||2|||f||||f||||||||||2018-06-01 04:02:54.26685|2018-06-01 04:02:54.26685
NCT00317447|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2006-04-20|2006-04-20|2006-04-24|Estimate|||||||2006-04-20|2006-04-24|Estimate|February 2002||2002-02-28|April 2006|2006-04-30|April 2004||2004-04-30|||||Interventional|||The Efficacy of Oral Steroids in the Treatment of Acute Sciatica|Oral Steroids in the Treatment of Acute Sciatica A Randomized Controlled Study|Completed||Phase 3|160||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:02:54.359877|2018-06-01 04:02:54.359877
NCT00317434|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2009-12-10|2006-04-20|2006-04-24|Estimate|||||||2009-12-10|2009-12-15|Estimate|November 2005||2005-11-30|December 2009|2009-12-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer|A Phase I Trial of Lapatinib in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer|Terminated||Phase 1|12|Actual|University of Alabama at Birmingham||||"Due to unacceptable non-dose limiting toxicities, excessive treatment delays and limited~   clinical responses."|||||||||||||||2018-06-01 04:02:54.449726|2018-06-01 04:02:54.449726
NCT00317421|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2006-04-20|2006-04-20|2006-04-24|Estimate|||||||2006-04-20|2006-04-24|Estimate|March 2004||2004-03-31|February 2004|2004-02-29|November 2005||2005-11-30|||||Interventional|||Effect of Regular Sildenafil on Blood Pressure and Arterial Function in Hypertension|Effects of Regular Treatment With Sildenafil on Blood Pressure and Endothelial Function in Untreated Hypertensives|Completed||Phase 2|20||University of Edinburgh|||||f||||||||||||||2018-06-01 04:02:54.573467|2018-06-01 04:02:54.573467
NCT00317408|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2015-09-24|2006-04-21|2006-04-24|Estimate|||||||2015-09-24|2015-09-25|Estimate|April 2004||2004-04-30|September 2015|2015-09-30||||February 2014|Actual|2014-02-28||Interventional|||Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma|Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence|Unknown status|Active, not recruiting|N/A|96|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:02:54.636528|2018-06-01 04:02:54.636528
NCT00317395|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21||2010-08-24|2014-11-17|2006-04-21|2006-04-24|Estimate||||2010-08-24|2010-08-27|Estimate|2014-11-17|2014-12-03|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|SEPIA-ACS1||Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome|A Randomized, Double-blind, Triple-dummy, Dose-ranging Study, Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban, in Patients With Non-ST Elevation Acute Coronary Syndrome and Planned Early Invasive Strategy|Completed||Phase 2|3241|Actual|Sanofi||6|||f||||t||||||||||2018-06-01 04:02:55.090124|2018-06-01 04:02:55.090124
NCT00317382|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2015-02-18|2006-04-20|2006-04-24|Estimate|||||||2015-02-18|2015-02-19|Estimate|December 2004||2004-12-31|February 2015|2015-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Does Static Ultrasound-Preview Reduce the Incidence of Difficult Lumbar Puncture?|Does Static Ultrasound-Preview Reduce the Incidence of Traumatic and/or Difficult Lumbar Puncture? A Randomized Control Trial|Terminated||N/A|60|Actual|St. Luke's-Roosevelt Hospital Center||2||We could not get physicians in the ED to enroll patients.|f||||t||||||||||2018-06-01 04:02:55.375538|2018-06-01 04:02:55.375538
NCT00317369|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2008-04-28|2006-04-21|2006-04-24|Estimate|||||||2008-04-28|2008-05-06|Estimate|May 2006||2006-05-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease|A Dose-Finding Study of OPC-6535 in Patients With Active Crohn's Disease|Terminated||Phase 2|60|Anticipated|Otsuka Pharmaceutical Co., Ltd.||||Efficacy was not cleared at US study|f||||f||||||||||2018-06-01 04:02:55.444168|2018-06-01 04:02:55.444168
NCT00317356|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-21|||2008-04-28|2006-04-21|2006-04-24|Estimate|||||||2008-04-28|2008-05-06|Estimate|May 2006||2006-05-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Dose-Finding Study of OPC-6535 in Patients With Active Ulcerative Colitis|A Dose-Finding Study of OPC-6535 in Patients With Active Ulcerative Colitis|Terminated||Phase 2|160|Anticipated|Otsuka Pharmaceutical Co., Ltd.||||Efficacy was not cleared at US study|f||||f||||||||||2018-06-01 04:02:55.550465|2018-06-01 04:02:55.550465
NCT00317343|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2012-05-04|2006-04-19|2006-04-24|Estimate|||||||2012-05-04|2012-05-07|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|February 2008|Anticipated|2008-02-29|||||Observational|||RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)|RIAPRE - A Non-interventional Registry on the Anticoagulation Treatment in High Risk Elective Percutaneous Coronary Interventions|Withdrawn|||0|Actual|Nycomed|||||f||||t||||||||||2018-06-01 04:02:55.650092|2018-06-01 04:02:55.650092
NCT00317330|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2010-08-26|2006-04-20|2006-04-24|Estimate|||||||2010-08-26|2010-08-27|Estimate|December 2004||2004-12-31|August 2006|2006-08-31|June 2005||2005-06-30|||||Interventional|||A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis|A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis|Completed||Phase 3|6400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:02:55.705205|2018-06-01 04:02:55.705205
NCT00317317|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2009-08-27|2006-04-20|2006-04-24|Estimate|||||||2009-08-27|2009-08-28|Estimate|October 2005||2005-10-31|August 2009|2009-08-31|November 2009|Anticipated|2009-11-30|November 2009|Anticipated|2009-11-30||Interventional|||The Effect of Acupuncture on Infertility With In-Vitro Fertilization (IVF) Patients|Acupuncture for Infertility Patients: The Effect on IVF|Unknown status|Active, not recruiting|Phase 1|60|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 04:02:55.761529|2018-06-01 04:02:55.761529
NCT00317304|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2012-10-03|2006-04-20|2006-04-24|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2005||2005-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Mindfulness Based Stress Reduction for Hot Flashes|Mindfulness Based Stress Reduction for Hot Flashes|Completed||Phase 1|110|Actual|University of Massachusetts, Worcester||1|||f||||t||||||||||2018-06-01 04:02:55.829755|2018-06-01 04:02:55.829755
NCT00317291|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2009-09-16|2006-04-20|2006-04-24|Estimate|||||||2009-09-16|2009-09-18|Estimate|November 2005||2005-11-30|September 2009|2009-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Acupuncture/Moxibustion for Peripheral Neuropathy in HIV|Acu/Moxa for Peripheral Neuropathy in Persons With HIV|Completed||Phase 2|50|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 04:02:55.940275|2018-06-01 04:02:55.940275
NCT00317278|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2009-12-04|2006-04-21|2006-04-24|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Effects of Massage on the Immune System of Preterm Infants|Effects of Massage on Immune System of Preterm Infants|Completed||Phase 1/Phase 2|120|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 04:02:55.999415|2018-06-01 04:02:55.999415
NCT00317265|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2006-10-12|2006-04-20|2006-04-24|Estimate|||||||2006-10-12|2006-10-13|Estimate|January 1999||1999-01-31|March 2006|2006-03-31|January 2005||2005-01-31|||||Interventional|||Coronary Bypass Surgery Trial: Complete Arterial Revascularization and Conventional Coronary Artery Surgery|Complete Arterial Revascularization and Conventional Coronary Artery Surgery Study (CARACCASS)-European Multicenter Study|Terminated||N/A|2000||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:02:56.067968|2018-06-01 04:02:56.067968
NCT00317252|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2012-10-19|2006-04-20|2006-04-24|Estimate|||||||2012-10-19|2012-10-22|Estimate|July 2006||2006-07-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization|"Angiotensin Converting Enzyme Inhibitors and Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization The CAPTAIN Trial"|Completed||Phase 2|220|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 04:02:56.137756|2018-06-01 04:02:56.137756
NCT00317239|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|2013-09-16||2018-01-22|2006-04-20|2006-04-24|Estimate|2013-09-16|2013-11-25|Estimate||||2018-01-22|2018-02-20|Estimate|May 2005||2005-05-31|January 2018|2018-01-31|August 2007|Actual|2007-08-31|February 2007|Actual|2007-02-28||Interventional|||VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease|Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease|Completed||Phase 3|255|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:02:56.220091|2018-06-01 04:02:56.220091
NCT00317226|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|2013-09-16||2018-01-22|2006-04-20|2006-04-24|Estimate|2015-06-08|2015-06-10|Estimate||||2018-01-22|2018-02-20|Actual|June 2005||2005-06-30|January 2018|2018-01-31|September 2007|Actual|2007-09-30|March 2007|Actual|2007-03-31||Interventional|||Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease|Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT45 in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease|Completed||Phase 3|145|Actual|Luitpold Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:02:56.663152|2018-06-01 04:02:56.663152
NCT00317213|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2008-04-09|2006-04-20|2006-04-24|Estimate|||||||2008-04-09|2008-04-14|Estimate|February 2002||2002-02-28|April 2008|2008-04-30|July 2002||2002-07-31|||||Interventional|||Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture|Phase IIB Study of the Efficacy and Safety of LIBERTAL, A Phosphatidic-Acid-Enriched Phospholipid, on Smoking Cessation|Completed||Phase 2|500||Kaplan Medical Center|||||f||||||||||||||2018-06-01 04:02:56.836031|2018-06-01 04:02:56.836031
NCT00317200|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2011-04-28|2006-04-20|2006-04-24|Estimate|||||||2011-04-28|2011-05-02|Estimate|April 2006||2006-04-30|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer|Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study|Completed||Phase 2|34|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||||2018-06-01 04:02:56.892843|2018-06-01 04:02:56.892843
NCT00317187|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2011-09-29|2006-04-20|2006-04-24|Estimate|||||||2011-09-29|2011-10-03|Estimate|June 2004||2004-06-30|September 2011|2011-09-30||||||||Interventional|||Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.|Partially Blinded Study to Assess Reactogenicity & Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ in Healthy Infants After a Hepatitis B Birth Dose|Completed||Phase 3|500||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:02:56.974982|2018-06-01 04:02:56.974982
NCT00317174|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2016-09-08|2006-04-20|2006-04-24|Estimate|||||||2016-09-08|2016-09-09|Estimate|July 2003||2003-07-31|September 2016|2016-09-30|April 2004|Actual|2004-04-30|||||Interventional|||A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.|Assess Immune Persistence & Memory by Giving Plain PRP,PSA & PSC (10 Mths Age), & Immunogenicity & Safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 Booster (15-18 Mths Age) in Previously Primed Subjects|Completed||Phase 2|450||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:57.087316|2018-06-01 04:02:57.087316
NCT00317161|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2016-09-19|2006-04-20|2006-04-24|Estimate|||||||2016-09-19|2016-09-20|Estimate|August 2004||2004-08-31|September 2016|2016-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.|Study to Show Lot-to-lot Consistency of Hib-MenAC Mixed With Tritanrix™-HBV, Its Non-inferiority to Tritanrix™-HBV/Hiberix™ With or Without Meningitec™, and MenA Response in 2, 4, 6 Month Infants With Hepatitis B Birth Dose|Completed||Phase 3|1000|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:57.16413|2018-06-01 04:02:57.16413
NCT00317148|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2017-04-06|2006-04-20|2006-04-24|Estimate|||||||2017-04-06|2017-04-07|Actual|August 2005|Actual|2005-08-31|April 2017|2017-04-30|December 2007|Actual|2007-12-31|September 2006|Actual|2006-09-30||Interventional|||Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women|Phase II-III Placebo-Controlled, Study to Evaluate the Effects of DHEA on Vasomotor Symptoms (Hot Flashes) in Postmenopausal Women|Completed||Phase 2/Phase 3|50|Actual|CHU de Quebec-Universite Laval||2|||f||||f|f|f||||||No||2018-06-01 04:02:57.249459|2018-06-01 04:02:57.249459
NCT00317135|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2011-09-29|2006-04-20|2006-04-24|Estimate|||||||2011-09-29|2011-10-03|Estimate|December 2003||2003-12-31|September 2011|2011-09-30||||||||Interventional|||Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.|Assess Reactogenicity & Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Compared to Tritanrix™-HepB/Hiberix™ (Control) in Healthy Infants (2,4,6 Mths Age), After a Hepatitis B Birth Dose|Completed||Phase 3|500||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:02:57.329138|2018-06-01 04:02:57.329138
NCT00317122|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2016-09-20|2006-04-20|2006-04-24|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2004||2004-10-31|September 2016|2016-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth|Demonstrate Non-inferiority of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ With Respect to Anti-HBs Immune Response, When Given to Healthy Infants at 6,10 & 14 Weeks Age, After a Birth Dose of Hepatitis B Vaccine|Completed||Phase 3|192|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:57.390981|2018-06-01 04:02:57.390981
NCT00317109|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|2017-01-10||2017-01-10|2006-04-20|2006-04-24|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|April 2006||2006-04-30|October 2016|2016-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects|Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007|Completed||Phase 3|168|Actual|GlaxoSmithKline|None reported.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:02:57.502309|2018-06-01 04:02:57.502309
NCT00317096|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2018-03-07|2006-04-21|2006-04-24|Estimate|||||||2018-03-07|2018-03-08|Actual|November 1998||1998-11-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2001|Actual|2001-06-30||Interventional|||FCM Versus R-FCM Followed by R-Maintenance or Observation Only|Treatment of Relapsed CBCC, CC and LPIC Lymphoma With FCM Chemotherapy Alone or in Combination With the Monoclonal Anti CD 20 Antibody Rituximab Followed by Anti-CD 20 Maintenance or Observation Only|Active, not recruiting||Phase 3|319|Actual|Ludwig-Maximilians - University of Munich||4|||f||||f||||||||||2018-06-01 04:02:57.971242|2018-06-01 04:02:57.971242
NCT00317083|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2006-04-21|2006-04-21|2006-04-24|Estimate|||||||2006-04-21|2006-04-24|Estimate|November 2001||2001-11-30|January 2004|2004-01-31|February 2003||2003-02-28|||||Interventional|||Cough Reflex and Obstructive Sleep Apnea Syndrome|Effect of Obstructive Sleep Apnea Syndrome Associated With Obesity on Cough Reflex Threshold to Citric Acid|Completed||N/A|40||Bichat Hospital|||||f||||||||||||||2018-06-01 04:02:58.05683|2018-06-01 04:02:58.05683
NCT00317070|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2009-05-08|2006-04-20|2006-04-24|Estimate|||||||2009-05-08|2009-05-11|Estimate|April 2006||2006-04-30|May 2008|2008-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)|A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC)|Terminated||Phase 2|10|Actual|Nova Scotia Health Authority||2||Poor recruitment, poor patient compliance, lack of funding|f||||||||||||||2018-06-01 04:02:58.122618|2018-06-01 04:02:58.122618
NCT00317057|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2007-01-04|2006-04-20|2006-04-24|Estimate|||||||2007-01-04|2007-01-05|Estimate|April 2006||2006-04-30|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease|Outpatient Management of Patients With Exacerbation of Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|1500||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 04:02:58.184953|2018-06-01 04:02:58.184953
NCT00317044|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|2009-04-23||2014-05-09|2006-04-20|2006-04-24|Estimate|2014-05-09|2014-06-09|Estimate||||2014-05-09|2014-06-09|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|RELAX||Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma|A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma|Completed||Phase 2|961|Actual|AstraZeneca|Numbers of patients analyzed in each of the Outcome Measures varies due to the amount of qualifying data captured for the patients.|3|||f||||||||||||||2018-06-01 04:02:58.268526|2018-06-01 04:02:58.268526
NCT00317031|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2008-06-26|2006-04-19|2006-04-21|Estimate|||||||2008-06-26|2008-06-27|Estimate|November 2002||2002-11-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Individually Adapted Therapy of Alcoholism|Individually Adapted Therapy of Alcoholism: Clinical Studies|Completed||Phase 4|435|Actual|Central Institute of Mental Health, Mannheim||3|||f||||||||||||||2018-06-01 04:02:59.012865|2018-06-01 04:02:59.012865
NCT00317018|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2014-04-25|2006-04-19|2006-04-21|Estimate|||||||2014-04-25|2014-04-28|Estimate|May 2008||2008-05-31|April 2014|2014-04-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Implementing Telemedicine-Based Collaborative Care for MDD in Contract CBOCs|Implementing Telemedicine-Based Collaborative Care for MDD in Contract CBOCs|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||This study was withdrawn prior to enrollment.|f||||f||||||||||2018-06-01 04:02:59.089013|2018-06-01 04:02:59.089013
NCT00317005|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-04-20|2006-04-20|2006-04-21|Estimate|||||||2006-04-20|2006-04-21|Estimate|April 2003||2003-04-30|May 2005|2005-05-31|March 2005||2005-03-31|||||Interventional|||Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events|Randomized Clinical Trial of Folate Therapy/Placebo for Reduction of Homocysteine Serum Levels in Uremic Patients and Influence on Cardiovascular Mortality|Completed||Phase 4|186||Universidade Estadual de Londrina|||||f||||||||||||||2018-06-01 04:02:59.158987|2018-06-01 04:02:59.158987
NCT00316992|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2010-05-31|2006-04-19|2006-04-21|Estimate|||||||2010-05-31|2010-06-02|Estimate|April 2006||2006-04-30|May 2010|2010-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease|A Study of the Safety of Ramelteon in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 4|25|Actual|Takeda||1|||f||||f||||||||||2018-06-01 04:02:59.232408|2018-06-01 04:02:59.232408
NCT00316979|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2010-06-06|2006-04-20|2006-04-21|Estimate|||||||2010-06-06|2010-06-08|Estimate|April 2006||2006-04-30|June 2010|2010-06-30||||||||Interventional|||Efficacy of rTMS in the Treatment of Patients With Migraine|Therapeutic Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Migraine Using Somatosensory Evoked High-Frequency Oscillations as a Parameter: A 3-year Study.|Unknown status|Recruiting|N/A|80|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f||||||||||2018-06-01 04:02:59.341113|2018-06-01 04:02:59.341113
NCT00316966|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2010-08-09|2006-04-20|2006-04-21|Estimate|||||||2010-08-09|2010-08-10|Estimate|June 2003||2003-06-30|May 2005|2005-05-31||||||||Interventional|||A Clinical Trial to Determine Outcomes and Cost Effectiveness of Nutritional Intervention in Elderly Patients||Completed||N/A|180||Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:02:59.41931|2018-06-01 04:02:59.41931
NCT00316953|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2013-02-04|2006-04-19|2006-04-21|Estimate|||||||2013-02-04|2013-02-05|Estimate|March 2006||2006-03-31|January 2013|2013-01-31||||September 2009|Actual|2009-09-30||Interventional|||Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate|A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (BMS Trial CA180038)|Completed||Phase 1|48|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:02:59.473473|2018-06-01 04:02:59.473473
NCT00316940|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2013-09-19|2006-04-19|2006-04-21|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 2005||2005-12-31|December 2007|2007-12-31|February 2011|Actual|2011-02-28|June 2008|Actual|2008-06-30||Interventional|||Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|36|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:02:59.551037|2018-06-01 04:02:59.551037
NCT00316927|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2013-06-25|2006-04-19|2006-04-21|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 2002||2002-12-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer|A Randomized Phase III Trial of Dexamethasone and Aspirin (DA) Versus Dexamethasone, Diethylstilbestrol and Aspirin (DAS) in Locally Advanced or Metastatic Cancer of the Prostate - Immediate Versus Deferred Diethylstilbestrol|Completed||Phase 3|260|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:02:59.618505|2018-06-01 04:02:59.618505
NCT00316914|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2012-11-26||2016-07-11|2006-04-19|2006-04-21|Estimate|2013-02-19|2013-03-25|Estimate||||2016-07-11|2016-08-11|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|November 2012|Actual|2012-11-30|January 2008|Actual|2008-01-31||Interventional|||Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery|A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity|Completed||Phase 3|104|Actual|Alliance for Clinical Trials in Oncology|Data cutoff was done after 127 days because of premature study closure and because of the protocol modification mandating that the Ca/Mg therapy be discontinued.|2|||f||||t||||||||||2018-06-01 04:02:59.732436|2018-06-01 04:02:59.732436
NCT00316901|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2012-03-14|2006-04-19|2006-04-21|Estimate|||||||2012-03-14|2012-03-15|Estimate|April 2006||2006-04-30|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial|PET/CT Evaluation of Subjects Treated on Surgery Branch Adoptive Cell Therapy Protocols|Completed||Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 04:03:00.352729|2018-06-01 04:03:00.352729
NCT00316888|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2016-07-18||2017-05-18|2006-04-19|2006-04-21|Estimate|2016-07-18|2016-08-29|Estimate||||2017-05-18|2017-05-22|Actual|January 2007||2007-01-31|October 2016|2016-10-31|May 2022|Anticipated|2022-05-31|November 2015|Actual|2015-11-30||Interventional||all eligible and treated patients|Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer|Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma|Active, not recruiting||Phase 2|63|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 04:03:00.4348|2018-06-01 04:03:00.4348
NCT00316875|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2013-11-06|2006-04-19|2006-04-21|Estimate|||||||2013-11-06|2013-11-08|Estimate|May 2006||2006-05-31|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer|A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer|Completed||Phase 1|23|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 04:03:01.222986|2018-06-01 04:03:01.222986
NCT00316862|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2017-01-26||2018-04-09|2006-04-19|2006-04-21|Estimate|2017-01-26|2017-03-15|Actual||||2018-04-09|2018-05-08|Actual|February 2006|Actual|2006-02-28|April 2018|2018-04-30|October 15, 2014|Actual|2014-10-15|December 2012|Actual|2012-12-31||Interventional|||Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery|A Phase II Trial of Preoperative Irinotecan, Cisplatin and Radiation in Esophageal Cancer|Completed||Phase 2|82|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:03:01.350006|2018-06-01 04:03:01.350006
NCT00316849|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2013-04-09|2006-04-19|2006-04-21|Estimate|||||||2013-04-09|2013-04-10|Estimate|May 2006||2006-05-31|April 2013|2013-04-30||||November 2010|Actual|2010-11-30||Interventional|||Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I Study of CCI-779, and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme|Completed||Phase 1|56|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:03:01.787096|2018-06-01 04:03:01.787096
NCT00316836|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2017-08-07|2006-04-19|2006-04-21|Estimate|||||||2017-08-07|2017-08-08|Actual|April 2006||2006-04-30|August 2017|2017-08-31||||October 2010|Actual|2010-10-31||Observational|||Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole|The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27|Active, not recruiting|||550|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 04:03:01.946412|2018-06-01 04:03:01.946412
NCT00316823|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2014-02-21|2006-04-19|2006-04-21|Estimate|||||||2014-02-21|2014-02-24|Estimate|July 2005||2005-07-31|December 2008|2008-12-31||||December 2009||2009-12-31||Interventional|||Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules|Gene Expression Analysis in Thyroid Nodule FNA Samples|Completed||N/A|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:03:02.461905|2018-06-01 04:03:02.461905
NCT00316810|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2012-06-18|2006-04-19|2006-04-21|Estimate|||||||2012-06-18|2012-06-19|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Simultaneous Pancreas-kidney Transplantation With Campath Protocol|An Open-label, Randomized, Prospective Study to Investigate the Safety and Efficacy of Campath-1H as an Induction Agent in Combination With Tacrolimus Monotherapy Compared to Short-course ATG-induction in Combination With Tacrolimus, Mycophenolate Mofetil and Short-term Steroids Application in de Novo SPK Transplanted Diabetic Patients|Completed||Phase 3|30|Actual|Medical University Innsbruck||2|||f||||||||||||||2018-06-01 04:03:02.516665|2018-06-01 04:03:02.516665
NCT00316797|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2014-04-09|2006-04-19|2006-04-21|Estimate|||||||2014-04-09|2014-04-10|Estimate|April 2006||2006-04-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects|Phase 1 Assessment of the Biodistribution and Safety of 123-I INER in Healthy Subjects|Completed||Phase 1|35|Actual|Institute for Neurodegenerative Disorders||1|||f||||t||||||||||2018-06-01 04:03:02.592867|2018-06-01 04:03:02.592867
NCT00316784|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2009-03-19|2006-04-19|2006-04-21|Estimate|||||||2009-03-19|2009-03-20|Estimate|July 2005||2005-07-31|March 2009|2009-03-31|May 2006||2006-05-31|||||Interventional|||IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA|A Double-Blind, Placebo-Controlled Evaluation of Dose Related Safety and Efficacy of Epicutaneously Applied IDEA-033 for 3 Months Treatment of OA of the Knee Followed by a Double-Blind, Dose-Controlled Evaluation of Safety and Efficacy of Epicutaneously Applied IDEA-033 for 12 Weeks Treatment of OA of the Knee|Completed||Phase 3|704||IDEA AG|||||f||||||||||||||2018-06-01 04:03:02.658626|2018-06-01 04:03:02.658626
NCT00316771|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20||2016-07-07|2016-11-01|2006-04-20|2006-04-21|Estimate||||2016-07-07|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|November 2005||2005-11-30|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy|A Randomized, Double-blind, Placebo-controlled, Study to Determine the Efficacy and Safety of 5 Dose Regimens of RO4402257 in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy.|Completed||Phase 2|374|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 04:03:02.716341|2018-06-01 04:03:02.716341
NCT00316758|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2016-11-01|2006-04-20|2006-04-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.|A Multi-center, Open Label, Extension Study to Evaluate the Long-term Safety and Tolerability of GK Activator (2) in Type 2 Diabetic Patients From Studies BM18248 or BM18249|Completed||Phase 2|259|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 04:03:03.918046|2018-06-01 04:03:03.918046
NCT00316745|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2007-10-31|2006-04-19|2006-04-21|Estimate|||||||2007-10-31|2007-11-01|Estimate|April 2006||2006-04-30|October 2007|2007-10-31|March 2009|Anticipated|2009-03-31|||||Interventional|||IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer|Irinotecan Combined With S-1( IRIS ) Followed by mFOLFOX6 Regimen Versus mFOLFOX6 Followed by IRIS Regimen in Advanced Colorectal Cancer|Suspended||Phase 3|200|Anticipated|Hokkaido Gastrointestinal Cancer Study Group||2||"Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line~   setting."|f||||t||||||||||2018-06-01 04:03:04.170187|2018-06-01 04:03:04.170187
NCT00316732|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2017-10-13|2006-04-20|2006-04-21|Estimate|||||||2017-10-13|2017-10-16|Actual|October 25, 2004|Actual|2004-10-25|October 2017|2017-10-31|December 19, 2006|Actual|2006-12-19|December 19, 2006|Actual|2006-12-19||Observational|||Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS|Observational Sutdy to Assess the Effectiveness of Avodart in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice|Completed|||173|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:03:04.274608|2018-06-01 04:03:04.274608
NCT00316719|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2009-06-15||2009-10-01|2006-04-19|2006-04-21|Estimate|2009-06-16|2009-08-03|Estimate||||2009-10-01|2009-10-06|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients|Phase III Study of Adefovir Dipivoxil Tablets in Patients With Compensated Chronic Hepatitis B -Comparative Study Against Lamivudine-|Completed||Phase 3|105|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:03:04.411604|2018-06-01 04:03:04.411604
NCT00316706|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2009-11-12||2012-09-13|2006-04-19|2006-04-21|Estimate|2010-02-12|2010-03-01|Estimate||||2012-09-13|2012-09-18|Estimate|October 2005||2005-10-31|September 2012|2012-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine|A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013|Completed||Phase 3|1245|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:03:04.8223|2018-06-01 04:03:04.8223
NCT00316693|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2009-11-12||2017-05-03|2006-04-19|2006-04-21|Estimate|2009-11-12|2009-12-16|Estimate||||2017-05-03|2017-05-15|Actual|April 26, 2006||2006-04-26|March 2017|2017-03-31|February 10, 2009|Actual|2009-02-10|February 10, 2009|Actual|2009-02-10||Interventional|||Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine|A Phase II Study to Assess the Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Japanese Female Subjects Aged 20 - 25 Years.|Completed||Phase 2|1046|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:03:05.405344|2018-06-01 04:03:05.405344
NCT00315666|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2009-02-19|2006-04-18|2006-04-19|Estimate|||||||2009-02-19|2009-02-20|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Prophylactic Effect of Memantine in Chronic Tension-Type Headache|Prophylactic Effect of Memantine in Chronic Tension-Type Headache|Completed||Phase 3|40||Danish Headache Center|||||f||||t||||||||||2018-06-01 04:03:24.147218|2018-06-01 04:03:24.147218
NCT00316680|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2016-10-06|2006-04-20|2006-04-21|Estimate|||||||2016-10-06|2016-10-07|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.|Study to Assess Immunogenicity and Safety of GlaxoSmithKline Biologicals' Kft's DTPw-HBV/Hib vs DTPwCSL-HBV/Hib Kft and vs Concomitant Administration of CSL's Triple Antigen and GlaxoSmithKline Biologicals' Hiberix, to Infants at 2, 4, 6 Months of Age, After a Birth Dose of Hepatitis B|Terminated||Phase 3|288||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:03:07.20308|2018-06-01 04:03:07.20308
NCT00316667|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2012-10-02|2006-04-19|2006-04-21|Estimate|||||||2012-10-02|2012-10-03|Estimate|June 2006||2006-06-30|October 2012|2012-10-31|June 2008|Actual|2008-06-30|||||Observational|||Health2006 - an Observational Study of Cardiovascular Disease, Diabetes, Asthma and Allergy|Health2006 - an Observational Population-based Study of Cardiovascular Disease, Type 2 Diabetes, Asthma and Allergy|Completed|||3471|Actual|Glostrup University Hospital, Copenhagen|||||f||||||||||Samples With DNA|"~     Extracted DNA, urine, serum~   "|||2018-06-01 04:03:07.292198|2018-06-01 04:03:07.292198
NCT00316654|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2017-07-21|2006-04-19|2006-04-21|Estimate|||||||2017-07-21|2017-07-25|Actual|February 2005||2005-02-28|July 2017|2017-07-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Persistence of Antibody Response to N. Meningitidis Group C in Children|A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule|Completed||Phase 4|489|Actual|Novartis|||||f||||||||||||||2018-06-01 04:03:07.35691|2018-06-01 04:03:07.35691
NCT00316641|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2006-11-06|2006-04-20|2006-04-21|Estimate|||||||2006-11-06|2006-11-07|Estimate||||March 2006|2006-03-31||||||||Interventional|||The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles||Unknown status|Recruiting|Phase 3|||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:03:07.439457|2018-06-01 04:03:07.439457
NCT00316628|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2006-09-13|2006-04-19|2006-04-21|Estimate|||||||2006-09-13|2006-09-14|Estimate|June 2005||2005-06-30|September 2006|2006-09-30||||||||Interventional|||Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects.|Completed||Phase 2|50||Novartis|||||f||||||||||||||2018-06-01 04:03:07.506991|2018-06-01 04:03:07.506991
NCT00316615|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2006-09-13|2006-04-19|2006-04-21|Estimate|||||||2006-09-13|2006-09-14|Estimate|June 2005||2005-06-30|September 2006|2006-09-30||||||||Interventional|||Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.|A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, When Administered to Non-Elderly Adult and Elderly Subjects|Completed||Phase 2|100||Novartis|||||f||||||||||||||2018-06-01 04:03:07.567327|2018-06-01 04:03:07.567327
NCT00316602|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-20|||2015-10-08|2006-04-20|2006-04-21|Estimate|||||||2015-10-08|2015-10-12|Estimate|July 2006||2006-07-31|October 2015|2015-10-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis|A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis|Completed||Phase 2|632|Actual|Bavarian Nordic||2|||f||||t||||||||||2018-06-01 04:03:07.63586|2018-06-01 04:03:07.63586
NCT00316589|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2015-09-28|2006-04-19|2006-04-21|Estimate|||||||2015-09-28|2015-09-29|Estimate|June 2006||2006-06-30|September 2015|2015-09-30|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients|A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl.|Completed||Phase 2|581|Actual|Bavarian Nordic||3|||f||||t||||||||||2018-06-01 04:03:07.76093|2018-06-01 04:03:07.76093
NCT00316576|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2008-01-16|2006-04-19|2006-04-21|Estimate|||||||2008-01-16|2008-01-17|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|November 2006|Actual|2006-11-30|||||Observational|||Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)|Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients|Terminated|||160|Anticipated|University Hospital, Caen||||The study was stopped on november 2006 after inclusion was fulfilled|f||||||||||||||2018-06-01 04:03:07.873704|2018-06-01 04:03:07.873704
NCT00316563|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2010-02-08|2006-04-19|2006-04-21|Estimate|||||||2010-02-08|2010-02-09|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|November 2009|Actual|2009-11-30|||||Interventional|||Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study|A Double-blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study|Completed||Phase 2|80|Anticipated|AHS Cancer Control Alberta||2|||f||||t||||||||||2018-06-01 04:03:07.935521|2018-06-01 04:03:07.935521
NCT00316550|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2008-02-15|2006-04-19|2006-04-21|Estimate|||||||2008-02-15|2008-02-25|Estimate|April 2006||2006-04-30|February 2008|2008-02-29|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study to Assess the Effects of AV608 on Central Processing of Visceral Stimuli in Subjects With Irritable Bowel Syndrome|Terminated||Phase 1|24|Anticipated|Avera Pharmaceuticals||||Animal Safety Data|f||||f||||||||||2018-06-01 04:03:08.008424|2018-06-01 04:03:08.008424
NCT00316537|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2007-08-07|2006-04-17|2006-04-21|Estimate|||||||2007-08-07|2007-08-09|Estimate|October 2006||2006-10-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers|A Multicenter, Randomized Study of the Safety and Preliminary Efficacy of Low-Dose Nicotine Gel (ATG002) in Patients With Plantar Diabetic Foot Ulcers|Terminated||Phase 1/Phase 2|48|Anticipated|CoMentis||||Sponsor Decision|f||||||||||||||2018-06-01 04:03:08.076577|2018-06-01 04:03:08.076577
NCT00315653|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2008-03-12|2006-04-18|2006-04-19|Estimate|||||||2008-03-12|2008-03-14|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|November 2007|Actual|2007-11-30|||||Observational|||Survivin Urine mRNA Assay Risk of Bladder Cancer Study|Evaluation of the Survivin Urine mRNA Assay to Estimate Risk of Bladder Cancer Found on Cystoscopy|Completed|||600||Fujirebio Diagnostics, Inc.|||||f||||||||||||||2018-06-01 04:03:24.204618|2018-06-01 04:03:24.204618
NCT00316524|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2015-06-02|2006-04-19|2006-04-21|Estimate|||||||2015-06-02|2015-06-03|Estimate|May 2006||2006-05-31|June 2015|2015-06-30|August 2007|Actual|2007-08-31|||||Interventional|||A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects|A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects|Completed||Phase 2|745|Actual|Bavarian Nordic||4|||f||||||||||||||2018-06-01 04:03:08.163379|2018-06-01 04:03:08.163379
NCT00316511|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2008-10-24|2006-04-19|2006-04-21|Estimate|||||||2008-10-24|2008-10-27|Estimate|March 2006||2006-03-31|October 2008|2008-10-31||||June 2008|Actual|2008-06-30||Interventional|||Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma|A Phase 1 Multi-Center, Dose Escalation and Pharmacokinetic Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma|Completed||Phase 1|21|Actual|Agenus Inc.|||||||||||||||||||2018-06-01 04:03:08.238291|2018-06-01 04:03:08.238291
NCT00316498|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2017-06-30|2006-04-19|2006-04-20|Estimate|||||||2017-06-30|2017-07-02|Actual|October 17, 2002||2002-10-17|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease|A Phase I/II Randomized, Controlled Study of OGT 918 in Adult and Juvenile Patients With Niemann Pick C Disease|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:08.298194|2018-06-01 04:03:08.298194
NCT00316485|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2017-10-05|2006-04-19|2006-04-20|Estimate|||||||2017-10-05|2017-10-06|Actual|April 14, 2006||2006-04-14|January 28, 2013|2013-01-28|January 28, 2013||2013-01-28|||||Observational|||Diagnosis, Evaluation and Treatment of Patients in Need of Third Molar Removal|Diagnosis, Evaluation and Treatment of Patients in Need of Third Molar Removal|Completed|||718|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:08.358877|2018-06-01 04:03:08.358877
NCT00316472|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2009-01-14|2006-04-18|2006-04-20|Estimate|||||||2009-01-14|2009-01-16|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|December 2007|Actual|2007-12-31|April 2007|Actual|2007-04-30||Interventional|||The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients|The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients|Completed||Phase 1|40||Washington University School of Medicine|||||f||||||||||||||2018-06-01 04:03:08.410762|2018-06-01 04:03:08.410762
NCT00316459|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2007-04-11|2006-04-19|2006-04-20|Estimate|||||||2007-04-11|2007-04-13|Estimate|May 2006||2006-05-31|April 2007|2007-04-30||||||||Interventional|||Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects|A Randomized, Double-Blind, Placebo and Moxifloxacin (Open-Label) Controlled, 4-Period, Crossover Study of the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|64||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:03:08.539767|2018-06-01 04:03:08.539767
NCT00316446|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2012-09-18|2006-04-18|2006-04-20|Estimate|||||||2012-09-18|2012-09-20|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Study to Determine Incidence of Hypoventilation in Patients Who Have Undergone Gastric Bypass|A Prospective Double Blind Pilot Study to Determine the Incidence of Postoperative Hypoventilation in Patients With Clinically Significant Obesity Who Have Undergone Gastric Bypass Procedures Under General Anesthesia|Completed|||20|Actual|University of South Florida|||||f||||f||||||||||2018-06-01 04:03:08.589685|2018-06-01 04:03:08.589685
NCT00316433|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2007-04-04|2006-04-18|2006-04-20|Estimate|||||||2007-04-04|2007-04-05|Estimate|February 2005||2005-02-28|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer|Phase II Study of Oxaliplatin and CPT-11 as First Line Treatment for Extensive Stage Small Cell Lung Cancer|Terminated||Phase 2|24||Swedish Medical Center|||||||||||||||||||2018-06-01 04:03:08.637567|2018-06-01 04:03:08.637567
NCT00316420|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2010-03-04|2006-04-18|2006-04-20|Estimate|||||||2010-03-04|2010-03-08|Estimate|December 2003||2003-12-31|March 2010|2010-03-31|August 2009|Actual|2009-08-31|February 2009|Actual|2009-02-28||Interventional|||Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer|Phase I Trial of Gemcitabine and Capecitabine (Xeloda) in Patients With Advanced Pancreatic Carcinoma|Completed||Phase 1|20|Actual|Swedish Medical Center|||||f||||f||||||||||2018-06-01 04:03:08.685129|2018-06-01 04:03:08.685129
NCT00316407|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2011-02-16|2006-04-18|2006-04-20|Estimate|||||||2011-02-16|2011-02-18|Estimate|August 2005||2005-08-31|March 2010|2010-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients|Phase I/II Lapatinib Plus Carboplatin and Paclitaxel in Stage III or IV Relapsed Ovarian or Stage IV Breast Cancer Patients|Completed||Phase 1/Phase 2|30|Actual|Swedish Medical Center|||||f||||f||||||||||2018-06-01 04:03:08.745939|2018-06-01 04:03:08.745939
NCT00316394|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-10-10|2006-04-18|2006-04-20|Estimate|||||||2006-10-10|2006-10-11|Estimate|November 2002||2002-11-30|April 2006|2006-04-30|March 2003||2003-03-31|||||Interventional|||Improving Preventive Service Delivery at Adult Complete Health Check-Ups|Improving Preventive Service Delivery at Adult Complete Health Check-Ups: the Preventive Health Evidence-Based Recommendation Form (PERFORM) Cluster Randomized Controlled Trial|Completed||N/A|||St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 04:03:08.871326|2018-06-01 04:03:08.871326
NCT00316381|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2008-05-20|2006-04-18|2006-04-20|Estimate|||||||2008-05-20|2008-05-22|Estimate|November 2004||2004-11-30|May 2008|2008-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Stem Cell Therapy to Improve Myocardial Function in Patients With Acute Myocardial Infarction|Myocardial REGeneration by Intracoronary Infusion of Selected Population of stEm Cells in Acute Myocardial iNfarcTion. Randomized Multicenter Trial|Completed||N/A|200|Anticipated|Silesian School of Medicine|||||f||||t||||||||||2018-06-01 04:03:08.917252|2018-06-01 04:03:08.917252
NCT00316368|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2009-12-22|2006-04-18|2006-04-20|Estimate|||||||2009-12-22|2009-12-23|Estimate|October 2006||2006-10-31|December 2009|2009-12-31|October 2008|Actual|2008-10-31|||||Interventional|||A Study to Determine the Effect of Bi-Ventricular Pacing on Cardiac Hemodynamics After Coronary Artery Bypass Graft|A Study to Determine the Effect of Bi-Ventricular Pacing on Cardiac Hemodynamics After Coronary Artery Bypass Graft|Completed||Phase 1|60|Anticipated|St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 04:03:08.983563|2018-06-01 04:03:08.983563
NCT00316355|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2016-03-29||2018-01-24|2006-04-18|2006-04-20|Estimate|2016-05-05|2016-06-06|Estimate||||2018-01-24|2018-02-21|Estimate|June 2006||2006-06-30|January 2018|2018-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Participants randomized to treatment conditions|Stepped Care for Treating Obsessive-Compulsive Disorder|Stepped Care for Obsessive-Compulsive Disorder|Completed||N/A|34|Actual|Hartford Hospital||2|||f||||t||||||||No||2018-06-01 04:03:09.050953|2018-06-01 04:03:09.050953
NCT00316342|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2007-11-28|2006-04-18|2006-04-20|Estimate|||||||2007-11-28|2007-11-29|Estimate|January 1997||1997-01-31|November 2007|2007-11-30|November 2004|Actual|2004-11-30|||||Interventional|||Workplace Based Rehabilitation for Low Back Disorders|Workplace Based Rehabilitation for Low Back Disorders|Completed||Phase 3|433||Rush University Medical Center|||||f||||||||||||||2018-06-01 04:03:09.257423|2018-06-01 04:03:09.257423
NCT00316329|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2008-04-21|2006-04-18|2006-04-20|Estimate|||||||2008-04-21|2008-04-22|Estimate|March 2006||2006-03-31|April 2008|2008-04-30||||||||Interventional|||ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria|Multinational, Randomized, Comparative Study of the Efficacy and Safety of Three Therapeutic Regimens: Coarsucam™ (Artesunate + Amodiaquine Fixed-Dose Combination) Administered in 1 or 2 Intakes Per Day Versus Coartem® (Artemether + Lumefantrine) in the Treatment of Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 3|1032||Sanofi|||||f||||||||||||||2018-06-01 04:03:09.322441|2018-06-01 04:03:09.322441
NCT00316316|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2012-03-15|2006-04-18|2006-04-20|Estimate|||||||2012-03-15|2012-03-16|Estimate|March 2006||2006-03-31|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder|Cognitive Behavioral Therapy Plus Motivational Interviewing for Obsessive Compulsive Disorder|Completed||Phase 1|30|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 04:03:09.392087|2018-06-01 04:03:09.392087
NCT00316303|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2013-04-04||2013-04-04|2006-04-18|2006-04-20|Estimate|2013-04-04|2013-05-22|Estimate||||2013-04-04|2013-05-22|Estimate|February 2006||2006-02-28|April 2013|2013-04-30|August 2012|Actual|2012-08-31|April 2009|Actual|2009-04-30||Interventional|||Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder|The STIRR Intervention for Dually Diagnosed Clients|Completed||Phase 2|236|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||||||||||||2018-06-01 04:03:09.485373|2018-06-01 04:03:09.485373
NCT00316290|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2013-02-22|2006-04-18|2006-04-20|Estimate|||||||2013-02-22|2013-02-25|Estimate|April 2006||2006-04-30|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Integrated Parent Training for Treating Depression in Mothers of Children With Attention Deficit Hyperactivity Disorder|Integrated Treatment for Depressed Mothers of ADHD Children|Completed||N/A|98|Anticipated|University of Maryland||2|||f||||||||||||||2018-06-01 04:03:09.817911|2018-06-01 04:03:09.817911
NCT00316277|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2012-05-08||2013-02-01|2006-04-18|2006-04-20|Estimate|2012-06-20|2012-07-27|Estimate||||2013-02-01|2013-02-06|Estimate|May 2006||2006-05-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|July 2009|Actual|2009-07-31||Interventional|||Prescription Opioid Addiction Treatment Study (POATS)|A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence|Completed||Phase 3|653|Actual|Mclean Hospital|A treatment providing infrequent or no medical management was not included. It is not known if less intensive medical management would affect outcomes. Length of the trial may have also affected results. Pain severity was only moderate on average.|2|||f||||t||||||||||2018-06-01 04:03:09.913985|2018-06-01 04:03:09.913985
NCT00316264|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2012-10-03||2012-11-13|2006-04-18|2006-04-20|Estimate|2012-11-13|2012-12-11|Estimate||||2012-11-13|2012-12-11|Estimate|April 2006||2006-04-30|November 2012|2012-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season|A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season|Completed||Phase 2|260|Actual|MedImmune LLC||3|||f||||t||||||||||2018-06-01 04:03:10.339672|2018-06-01 04:03:10.339672
NCT00316251|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-11-20|2006-04-19|2006-04-20|Estimate|||||||2006-11-20|2006-11-22|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|September 2006||2006-09-30|||||Interventional|||Application of Specific Frequencies to Stimulate the Spinocerebellar Tract in Subjects With Unilateral Dysafferentation||Completed||N/A|2||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 04:03:11.100485|2018-06-01 04:03:11.100485
NCT00316238|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2007-06-06|2006-04-18|2006-04-20|Estimate|||||||2007-06-06|2007-06-08|Estimate|April 2006||2006-04-30|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia|A Double-Blind Dose-Response Study Comparing Rapid Acting Intramuscular Olanzapine and Intramuscular Placebo in Agitated Patients With Schizophrenia|Completed||Phase 2|160|Anticipated|Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:03:11.149846|2018-06-01 04:03:11.149846
NCT00316225|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2010-03-10||2010-06-10|2006-04-18|2006-04-20|Estimate|2010-06-10|2010-07-09|Estimate||||2010-06-10|2010-07-09|Estimate|December 2006||2006-12-31|June 2010|2010-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen|A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid|Completed||Phase 2|31|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:03:11.283994|2018-06-01 04:03:11.283994
NCT00316212|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2016-11-17|2006-04-18|2006-04-20|Estimate|||||||2016-11-17|2016-11-18|Estimate|April 2006||2006-04-30|November 2016|2016-11-30||||August 2006|Actual|2006-08-31||Interventional|||Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass|Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel Group Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Graft Surgery Involving Cardiopulmonary Bypass|Terminated||Phase 2|160||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:03:11.62351|2018-06-01 04:03:11.62351
NCT00316199|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2009-04-22||2009-06-12|2006-04-18|2006-04-20|Estimate|2009-04-22|2009-06-11|Estimate||||2009-06-12|2009-06-17|Estimate|April 2006||2006-04-30|June 2009|2009-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer|Phase II Study of Gemcitabine-Paclitaxel 3-Weekly Schedule as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure|Completed||Phase 2|60|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:03:11.737941|2018-06-01 04:03:11.737941
NCT00316186|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2009-04-29||2015-04-20|2006-04-19|2006-04-20|Estimate|2009-08-20|2009-09-29|Estimate||||2015-04-20|2015-05-07|Estimate|June 2005||2005-06-30|April 2015|2015-04-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin|An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer|Completed||Phase 2|33|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:03:12.038739|2018-06-01 04:03:12.038739
NCT00316173|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|2009-10-20||2012-11-21|2006-04-19|2006-04-20|Estimate|2009-10-20|2009-11-26|Estimate||||2012-11-21|2012-11-27|Estimate|March 2005||2005-03-31|November 2012|2012-11-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer|An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 Every 21 Days) HYCAMTIN in Combination With Carboplatin (Day 1 Every 21 Days) as Second-Line Therapy in Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer|Completed||Phase 2|77|Actual|GlaxoSmithKline|As only 17 of 55 participants had CR/PR, the treatment was not effective. The follow up of participants for survival was thus stopped early (original plan: every 3 months for 2 years; then every 6 months for 3-5 years; then annually/until death).|1|||f||||t||||||||||2018-06-01 04:03:12.323281|2018-06-01 04:03:12.323281
NCT00316160|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2017-05-24|2006-04-18|2006-04-20|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2004||2004-09-30|May 2017|2017-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Sexual Functioning Study With Antidepressants|A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/Day) and Extended-release Venlafaxine (EFFEXOR XR, 75-225 mg/Day) in Subjects With Major Depressive Disorder|Completed||Phase 4|347||GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:03:13.054303|2018-06-01 04:03:13.054303
NCT00316147|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2016-09-27|2006-04-18|2006-04-20|Estimate|||||||2016-09-27|2016-09-28|Estimate|December 2005||2005-12-31|September 2016|2016-09-30|August 2006|Actual|2006-08-31|||||Interventional|||Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules|Phase IIIb, Open, Randomized, Multicenter Study to Assess the Immunogenicity & Safety of GSK Biologicals' Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants When Given at 6-10-14 Weeks of Age or at 2-4-6 Months of Age|Completed||Phase 3|224||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:03:13.162575|2018-06-01 04:03:13.162575
NCT00316134|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2011-11-07|2006-04-18|2006-04-20|Estimate|||||||2011-11-07|2011-11-08|Estimate|March 2006||2006-03-31|November 2011|2011-11-30|February 2008|Actual|2008-02-29|||||Observational|||Multiple Biomarkers in Undiagnosed Pleural Effusion|Evaluation of Multiple Biomarkers in Serum and Pleural Fluid to Estimate the Probability of Cancer in Patients Presenting With an Undiagnosed Pleural Effusion|Terminated|||200|Actual|Fujirebio Diagnostics, Inc.|||1|The study was terminated on completion of the Pilot Study phase.|f||||f||||||Samples Without DNA|"~     Serum and pleural fluids~   "|||2018-06-01 04:03:13.250208|2018-06-01 04:03:13.250208
NCT00316121|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2011-01-19||2011-02-08|2006-04-18|2006-04-20|Estimate|2011-02-08|2011-03-03|Estimate||||2011-02-08|2011-03-03|Estimate|April 2006||2006-04-30|February 2011|2011-02-28||||January 2010|Actual|2010-01-31||Interventional|||Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease|A Prospective, Multicenter, Randomized Study Comparing the Use of HEALOS® to Autograft in a Transforaminal Lumbar Interbody Fusion (TLIF) Approach|Completed||Phase 3|138|Actual|Advanced Technologies and Regenerative Medicine, LLC (ATRM)|Stringent criteria for endpoint.Minimum sample size not reached; no hypothesis testing.High portion of current/prior smokers in both groups may impact fusion success.Product usage was appropriate and not low.This study is not on label for HEALOS.|2|||f||||||||||||||2018-06-01 04:03:13.321428|2018-06-01 04:03:13.321428
NCT00316108|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2014-08-26|2006-04-18|2006-04-20|Estimate|||||||2014-08-26|2014-08-28|Estimate|February 2002||2002-02-28|August 2014|2014-08-31|November 2007|Actual|2007-11-30|May 2005|Actual|2005-05-31||Interventional|BEACH||Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)|Boston Scientific EPI: A Carotid Stenting Trial for High-Risk Surgical Patients|Completed||N/A|747|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-06-01 04:03:13.711047|2018-06-01 04:03:13.711047
NCT00316095|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-19|||2013-10-31|2006-04-19|2006-04-20|Estimate|||||||2013-10-31|2013-11-01|Estimate|April 2006||2006-04-30|October 2013|2013-10-31|August 2007||2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia|Reduced Factorial Design, Randomized, Double Blind Trial Comparing Combinations of Telmisartan 20 or 80 mg and Simvastatin 20 or 40 mg With Single Component Therapies in the Treatment of Hypertension and Dyslipidemia|Completed||Phase 3|1695||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:03:13.905285|2018-06-01 04:03:13.905285
NCT00316082|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2009-08-17||2015-04-08|2006-04-19|2006-04-20|Estimate|2009-08-17|2009-09-25|Estimate||||2015-04-08|2015-04-29|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 3|365|Actual|AstraZeneca||5|||f||||||||||||||2018-06-01 04:03:14.159029|2018-06-01 04:03:14.159029
NCT00001675|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|2006-04-19|2006-04-20|Estimate|||||||2018-05-23|2018-05-24|Actual|January 23, 1998||1998-01-23|December 23, 2015|2015-12-23|December 23, 2015||2015-12-23|||||Observational|||The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics|Functional Neuroanatomy of Positive and Negative Affect in Alcoholics and Non-Alcoholics|Completed|||1194|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:15.006836|2018-06-01 04:03:15.006836
NCT00001673|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|2006-04-19|2006-04-20|Estimate|||||||2017-10-05|2017-10-06|Actual|October 2, 1997||1997-10-02|December 15, 2015|2015-12-15|December 15, 2015||2015-12-15|||||Observational|||Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Screening Evaluation for NIAAA Protocols|Completed|||2220|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:15.070275|2018-06-01 04:03:15.070275
NCT00316069|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2018-05-23|2006-04-18|2006-04-19|Estimate|||||||2018-05-23|2018-05-24|Actual|April 12, 2006||2006-04-12|August 2, 2017|2017-08-02|August 2, 2017||2017-08-02|||||Observational|||Stem Cell Collection|Peripheral Blood Collection of Adult Stem Cells|Terminated|||429|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:15.126511|2018-06-01 04:03:15.126511
NCT00316056|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2017-06-30|2006-04-18|2006-04-19|Estimate|||||||2017-06-30|2017-07-02|Actual|April 14, 2006||2006-04-14|August 25, 2009|2009-08-25||||October 17, 2007|Actual|2007-10-17||Observational|||Use of Virtual Reality to Communicate Concepts of Genomics to the General Public|Using Virtual Reality to Test Communication Strategies for Genomic Concepts|Completed|||346||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:15.18277|2018-06-01 04:03:15.18277
NCT00316043|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2007-07-30|2006-04-14|2006-04-19|Estimate|||||||2007-07-30|2007-07-31|Estimate|May 2006||2006-05-31|July 2007|2007-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Prevention of Renal Failure in Children With Urinary Tract Infections|Prevention of Renal Failure in Children With Urinary Tract Infections in General Practice: Current Clinical Management, Possibilities for Improvement and Potential Cost-Efficiency|Completed||N/A|124|Actual|Radboud University|||||f||||f||||||||||2018-06-01 04:03:15.228843|2018-06-01 04:03:15.228843
NCT00316030|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2016-06-07|2006-04-17|2006-04-19|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2004||2004-01-31|March 2008|2008-03-31||||||||Interventional|||Study of Bexarotene in Patients With Acute Myeloid Leukemia|A Phase I Study of Bexarotene in Patients With Acute Myeloid Leukemia|Completed||Phase 1|54||Abramson Cancer Center of the University of Pennsylvania|||||f||||||||||||||2018-06-01 04:03:15.289363|2018-06-01 04:03:15.289363
NCT00315107|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2006-05-25|2006-04-13|2006-04-17|Estimate|||||||2006-05-25|2006-05-26|Estimate|May 2006||2006-05-31|May 2006|2006-05-31|August 2007||2007-08-31|||||Interventional|||Estrogen Treatment in Acromegalic Women||Unknown status|Recruiting|Phase 2|30||Université de Montréal|||||f||||||||||||||2018-06-01 04:03:43.402095|2018-06-01 04:03:43.402095
NCT00316017|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|2010-09-02||2011-02-25|2006-04-17|2006-04-19|Estimate|2010-10-15|2010-11-11|Estimate||||2011-02-25|2011-03-01|Estimate|May 2006||2006-05-31|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Hypertonic Resuscitation Following Traumatic Injury|Phase 3 Study of Hypertonic Resuscitation Following Traumatic Injury With Hypovolemic Shock|Terminated||Phase 3|895|Actual|University of Washington|The trial was stopped early for futility in the presence of a potential safety concern regarding increased mortality among patients receiving hypertonic solutions and no blood transfusions. This was no longer evident 6 hr after hospital admission.|3||"Futility & potential safety concern (increased early mortality in the HS/HSD arms for those~   with no PRBC in 1st 24 hr, post-randomization subgp)"|f||||t||||||||||2018-06-01 04:03:15.377185|2018-06-01 04:03:15.377185
NCT00316004|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|2011-02-11||2011-05-16|2006-04-17|2006-04-19|Estimate|2011-04-08|2011-05-09|Estimate||||2011-05-16|2011-05-19|Estimate|May 2006||2006-05-31|May 2011|2011-05-31|January 2010|Actual|2010-01-31|May 2009|Actual|2009-05-31||Interventional|||Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)|Phase 3 Study of Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)|Terminated||Phase 3|1331|Actual|University of Washington|The trial was stopped early for futility at a planned data and safety monitoring board review. The futility boundary was crossed for each of the 2 group comparisons (hypertonic saline/dextran vs normal saline and hypertonic saline vs normal saline).|3||Futility|f||||t||||||||||2018-06-01 04:03:16.13211|2018-06-01 04:03:16.13211
NCT00315991|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2013-01-14|2006-04-18|2006-04-19|Estimate|||||||2013-01-14|2013-01-16|Estimate|April 2006||2006-04-30|January 2013|2013-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Blood Glucose Awareness Training for Parents|Parent-Child Co-Regulation of Pediatric Diabetes, Phase 2|Completed||N/A|77|Actual|University of Virginia||2|||f||||||||||||||2018-06-01 04:03:17.686837|2018-06-01 04:03:17.686837
NCT00315978|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2007-07-09|2006-04-17|2006-04-19|Estimate|||||||2007-07-09|2007-07-10|Estimate|June 2003||2003-06-30|April 2006|2006-04-30|February 2004||2004-02-29|||||Interventional|||The Impact of Patient Involvement in Decision-Making About Heart Disease Prevention|Decision Aid to Improve Coronary Heart Disease Risk Modification: a Pilot Randomized Trial|Completed||N/A|120||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 04:03:17.769162|2018-06-01 04:03:17.769162
NCT00315965|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2007-06-13|2006-04-17|2006-04-19|Estimate|||||||2007-06-13|2007-06-14|Estimate|July 2006||2006-07-31|May 2007|2007-05-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects|Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects|Unknown status|Recruiting|Phase 1|107|Anticipated|University Hospital Tuebingen|||||f||||t||||||||||2018-06-01 04:03:17.841943|2018-06-01 04:03:17.841943
NCT00315952|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2008-02-15|2006-04-17|2006-04-19|Estimate|||||||2008-02-15|2008-02-18|Estimate|April 2006||2006-04-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|||||Interventional|||Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes|Open-Label Randomized Two-Way Crossover Pilot Study to Estimate the Effects of Inhaled vs. IV Infusion of Human Insulin With Regards to Glucose Disposal in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 4|12|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:03:17.918312|2018-06-01 04:03:17.918312
NCT00315939|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2014-08-08||2014-09-09|2006-04-18|2006-04-19|Estimate|2014-08-28|2014-09-09|Estimate||||2014-09-09|2014-09-18|Estimate|January 2006||2006-01-31|August 2014|2014-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|BPK002||Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes|Improving Metabolic Control and Reducing Hypoglycemic Risk in Type 1 Diabetes Mellitus With Biological and Behavioral Feedback|Completed||N/A|120|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 04:03:17.984312|2018-06-01 04:03:17.984312
NCT00315926|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2010-06-29|2006-04-18|2006-04-19|Estimate|||||||2010-06-29|2010-06-30|Estimate|January 2007||2007-01-31|November 2006|2006-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Melatonin and Cardiac Outcome After Major Surgery|Melatonin and Cardiac Morbidity After Elective Abdominal Aortic Aneurism Repair|Completed||Phase 2/Phase 3|52|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-06-01 04:03:18.284683|2018-06-01 04:03:18.284683
NCT00315913|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2017-11-06|2006-04-17|2006-04-19|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2004||2004-01-31|November 2017|2017-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Abnormal Labor|Placebo-Controlled Randomized Trial of Oxytocin Alone Versus Oxytocin and Propranolol for the Treatment of Dysfunctional Labor|Terminated||Phase 2|2|Actual|University of California, Irvine||2||Low study enrollment|f||||f||||||||||2018-06-01 04:03:18.358191|2018-06-01 04:03:18.358191
NCT00315900|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2017-04-25|2006-04-17|2006-04-19|Estimate|||||||2017-04-25|2017-04-27|Actual|May 1, 2006|Actual|2006-05-01|April 2017|2017-04-30|February 28, 2008|Actual|2008-02-28|December 1, 2007|Actual|2007-12-01||Interventional|||Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia|Depakote ER vs. Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia|Terminated||Phase 3|20|Actual|Tuscaloosa Research & Education Advancement Corporation||2||Investigator closed study and left VAMC.|f||||f|t|f|||f|||No||2018-06-01 04:03:18.439978|2018-06-01 04:03:18.439978
NCT00315887|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-05-01|2006-04-18|2006-04-19|Estimate|||||||2006-05-01|2006-05-03|Estimate|April 1999||1999-04-30|April 2006|2006-04-30|October 1999||1999-10-31|||||Interventional|||The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Back Pain.|A Double-Blind Comparative Study of Buprenorphine Transdermal System (BTDS) and Hydrocodone/Acetaminophen Tablets in Patients With Chronic Back Pain|Completed||Phase 3|250||Purdue Pharma LP|||||||||||||||||||2018-06-01 04:03:18.525098|2018-06-01 04:03:18.525098
NCT00315874|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2013-05-13|2006-04-18|2006-04-19|Estimate|||||||2013-05-13|2013-05-14|Estimate|April 1997||1997-04-30|May 2013|2013-05-31|January 1998||1998-01-31|||||Interventional|||The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.|Safety and Efficacy of Buprenorphine TDS (Transdermal Delivery System) 5, 10 and 20 Applied Every 7 Days for Sixty Days vs. 5 mg Oxycodone/325 mg Acetaminophen Tablets q6h Prn vs. Placebo in Patients With Chronic Low Back Pain|Completed||Phase 3|225||Purdue Pharma LP|||||||||||||||||||2018-06-01 04:03:18.674557|2018-06-01 04:03:18.674557
NCT00315861|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2009-01-22|2006-04-17|2006-04-19|Estimate|||||||2009-01-22|2009-01-23|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|May 2008|Actual|2008-05-31||Interventional|||Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies|A Phase I Study of Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies|Completed||Phase 1|15|Anticipated|SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:03:18.771832|2018-06-01 04:03:18.771832
NCT00315848|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-04-29|2006-04-18|2006-04-19|Estimate|||||||2006-04-29|2006-05-03|Estimate|November 1996||1996-11-30|April 2006|2006-04-30|December 1999||1999-12-31|||||Interventional|||The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.|A Multi-Center, Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Buprenorphine Transdermal Delivery System Vs. Oxycodone/Acetaminophen Tablets Vs. Placebo in Patients With Chronic Pain Due to Osteoarthritis|Completed||Phase 3|225||Purdue Pharma LP|||||||||||||||||||2018-06-01 04:03:18.85921|2018-06-01 04:03:18.85921
NCT00315835|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2006-04-17|2006-04-17|2006-04-19|Estimate|||||||2006-04-17|2006-04-19|Estimate|October 1996||1996-10-31|April 2006|2006-04-30|November 1997||1997-11-30|||||Interventional|||Safety of the Buprenorphine Transdermal Delivery System in Subjects With Mod-to-Sev Pain Following Orthopedic Surgery.|A Single Dose, Randomized, Double-Blind, Parallel Group Study of the Safety and Pharmacokinetics of Buprenorphine TDS (12.5, 25, 50 Mcg/Hour) Vs. Placebo in Patients With Moderate to Severe Pain Following Orthopedic Surgery|Completed||Phase 2|100||Purdue Pharma LP|||||||||||||||||||2018-06-01 04:03:18.938453|2018-06-01 04:03:18.938453
NCT00315822|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|2016-11-29||2017-02-22|2006-04-18|2006-04-19|Estimate|2017-02-22|2017-04-06|Actual||||2017-02-22|2017-04-06|Actual|May 2006||2006-05-31|February 2017|2017-02-28|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Supplemental Postoperative Oxygen and Wound Infection in Morbidly Obese Patients|Supplemental Postoperative Oxygen & Wound Infection in Morbidly Obese Patients|Terminated||N/A|400|Actual|The Cleveland Clinic||2||Study was terminated due to futility|f||||f||||||||||2018-06-01 04:03:19.009783|2018-06-01 04:03:19.009783
NCT00315809|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2011-06-22|2006-04-17|2006-04-19|Estimate|||||||2011-06-22|2011-06-23|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|||||Observational|||Molecular Epidemiology of Leprosy - Philippines|Molecular Epidemiology of Leprosy - Philippines|Completed|||310|Actual|Colorado State University|||||f||||f||||||||||2018-06-01 04:03:19.177855|2018-06-01 04:03:19.177855
NCT00315796|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2015-03-31|2006-04-17|2006-04-19|Estimate|||||||2015-03-31|2015-04-01|Estimate|August 2004||2004-08-31|January 2005|2005-01-31|June 2005||2005-06-30|||||Interventional|||Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy|Nature Sights and Sounds to Reduce Pain in Cancer Patients Undergoing Bone Marrow Aspiration and Biopsy|Completed||Phase 3|120||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:03:19.230683|2018-06-01 04:03:19.230683
NCT00315783|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2006-04-17|2006-04-17|2006-04-19|Estimate|||||||2006-04-17|2006-04-19|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|June 2006||2006-06-30|||||Observational|||Comparison of Data Obtained by Echocardiography and Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy|Comparison of Data Obtained by Echocardiography and Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy|Unknown status|Recruiting||30||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:03:19.370631|2018-06-01 04:03:19.370631
NCT00315770|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-04-20|2006-04-18|2006-04-19|Estimate|||||||2006-04-20|2006-04-21|Estimate|January 2004||2004-01-31|April 2006|2006-04-30|April 2005||2005-04-30|||||Interventional|||Health of Young European Families and Fish Consumption|Health of Young European Families and Fish Consumption|Unknown status|Active, not recruiting|Phase 1|320||Landspitali University Hospital|||||f||||||||||||||2018-06-01 04:03:19.429818|2018-06-01 04:03:19.429818
NCT00315757|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17||2011-03-30|2013-08-01|2006-04-17|2006-04-19|Estimate||||2011-04-11|2011-04-25|Estimate|2013-08-01|2013-08-08|Estimate|May 2006||2006-05-31|August 2013|2013-08-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 2, Multi-Center, Open-Label, Randomized Study of Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|105|Actual|Human Genome Sciences Inc.||3|||f||||f||||||||||2018-06-01 04:03:19.515855|2018-06-01 04:03:19.515855
NCT00315744|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2017-10-18|2006-04-17|2006-04-19|Estimate|||||||2017-10-18|2017-10-19|Actual|November 4, 2004|Actual|2004-11-04|October 2017|2017-10-31|April 12, 2007|Actual|2007-04-12|April 12, 2007|Actual|2007-04-12||Interventional|||Viapaed Study In Children And Adolescents With Asthma|Steroid-sparing Management of the Salmeterol/Fluticasone 50/100µg b.i.d. Combination Compared to Fluticasone 200µg b.i.d. in Children and Adolescents With Moderate Asthma|Completed||Phase 4|285|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:03:19.663457|2018-06-01 04:03:19.663457
NCT00315731|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|2012-03-29||2017-06-09|2006-04-17|2006-04-19|Estimate|2012-03-29|2012-04-23|Estimate||||2017-06-09|2017-07-11|Actual|March 31, 2003|Actual|2003-03-31|June 2017|2017-06-30|June 30, 2013|Actual|2013-06-30|December 4, 2006|Actual|2006-12-04||Interventional|||A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma|A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:03:19.962954|2018-06-01 04:03:19.962954
NCT00315718|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2006-04-18|2006-04-18|2006-04-19|Estimate|||||||2006-04-18|2006-04-19|Estimate|June 2002||2002-06-30|April 2006|2006-04-30|June 2005||2005-06-30|||||Interventional|||Long-Term Effects of Sucontral(TM) on Mild and Moderate Cases of Diabetes Mellitus (Type 2)|Controlled Clinical Trial on Long Term Effects of Hintonia Latiflora Extract in Mild to Moderate Type 2 Diabetes|Completed||Phase 3|10||Harras Pharma Curarina GmbH|||||f||||||||||||||2018-06-01 04:03:20.470593|2018-06-01 04:03:20.470593
NCT00315705|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|2011-04-27||2014-03-17|2006-04-18|2006-04-19|Estimate|2011-06-10|2011-06-30|Estimate||||2014-03-17|2014-04-14|Estimate|March 2006||2006-03-31|March 2014|2014-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.|A Phase 1/2 Dose-Escalation Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Pediatric Patients With Refractory or Relapsed Acute Leukemias.|Completed||Phase 1/Phase 2|50|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 04:03:20.638219|2018-06-01 04:03:20.638219
NCT00315692|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-18|||2011-11-07|2006-04-18|2006-04-19|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2005||2005-12-31|November 2011|2011-11-30|February 2007|Actual|2007-02-28|||||Observational|||Risk of Ovarian Cancer in Patients With a Pelvic Mass|Evaluation of a Multiple Biomarker Assay to Estimate the Risk of Ovarian Cancer in Patients Presenting With a Pelvic Mass.|Completed|||566|Actual|Fujirebio Diagnostics, Inc.|||2||f||||f||||||Samples Without DNA|"~     Serum, plasma and urine~   "|||2018-06-01 04:03:24.000007|2018-06-01 04:03:24.000007
NCT00315640|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17||2012-11-27|2012-11-27|2006-04-17|2006-04-19|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation|A Study of the Safety and Efficacy of Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation|Completed||Phase 2|70|Actual|Alcon Research||4|||f||||||||||||||2018-06-01 04:03:24.263197|2018-06-01 04:03:24.263197
NCT00315627|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|2016-12-19||2017-04-18|2006-04-14|2006-04-18|Estimate|2017-04-18|2017-05-25|Actual||||2017-04-18|2017-05-25|Actual|July 2005||2005-07-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation|Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation|Completed||Phase 2|3|Actual|University of Miami||1|||f||||f||||||||No||2018-06-01 04:03:24.367591|2018-06-01 04:03:24.367591
NCT00315614|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|2013-12-20||2017-03-29|2006-04-14|2006-04-18|Estimate|2013-12-20|2014-02-10|Estimate||||2017-03-29|2017-04-04|Actual|December 2000||2000-12-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus|Islet Cell Transplantation Alone and CD34+ Enriched Donor Bone Marrow Cell Infusion in Patients With Type 1 Diabetes Mellitus; Steroid Free Regimen|Terminated||Phase 2|3|Actual|University of Miami||1||"We did not achieve a tolerogenic profile. Subjects withdrew from protocol and enrolled in other~   islet transplant trials."|f||||t||||||||No|Single arm few subjects.|2018-06-01 04:03:24.712185|2018-06-01 04:03:24.712185
NCT00315601|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2009-02-12|2006-04-17|2006-04-18|Estimate|||||||2009-02-12|2009-02-13|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Intrapulmonary Pharmacokinetics of Antibiotics|Comparison of the Intrapulmonary and Plasma Concentrations of Telithromycin and Azithromycin in Healthy Adult Subjects|Terminated||Phase 4|35|Actual|University of Illinois at Chicago||||Sanofi-Aventis wanted the study terminated.|f||||f||||||||||2018-06-01 04:03:25.012287|2018-06-01 04:03:25.012287
NCT00315588|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|2016-12-19||2017-02-28|2006-04-14|2006-04-18|Estimate|2017-02-28|2017-04-12|Actual||||2017-02-28|2017-04-12|Actual|December 2000||2000-12-31|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation|Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation|Completed||Phase 2|7|Actual|University of Miami||1|||f||||t||||||||No||2018-06-01 04:03:25.10737|2018-06-01 04:03:25.10737
NCT00315575|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2009-01-22|2006-04-14|2006-04-18|Estimate|||||||2009-01-22|2009-01-26|Estimate|August 2005||2005-08-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Memory Imaging of Normal Aging|BOLD and Perfusion fMRI of Alzheimer's Disease Risk|Completed|||90|Anticipated|National Institute on Aging (NIA)|||2||f||||f||||||||||2018-06-01 04:03:25.353902|2018-06-01 04:03:25.353902
NCT00315562|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2015-02-03|2006-04-14|2006-04-18|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2006||2006-04-30|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Study of Early Versus Delayed Carotid Endarterectomy (CEA) for Small to Medium-sized Ischemic Stroke Caused by High-grade Carotid Stenosis|Pilot Study of Early Versus Delayed Carotid Endarterectomy (CEA) for Small to Medium-sized Ischemic Stroke Caused by High-grade Carotid Stenosis|Withdrawn||Phase 1|0|Actual|University of California, San Diego||2|||f||||||||||||||2018-06-01 04:03:25.429215|2018-06-01 04:03:25.429215
NCT00315549|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2009-04-02|2006-04-17|2006-04-18|Estimate|||||||2009-04-02|2009-04-03|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults|Multinational, Randomized, Double Blind, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 800 mg od Versus 10 Days Penicillin V 500 mg Tid in Adolescent and Adult Subjects Equal to or Over 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis|Terminated||Phase 3|233|Actual|Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2018-06-01 04:03:25.487465|2018-06-01 04:03:25.487465
NCT00315536|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2012-01-03|2006-04-14|2006-04-18|Estimate|||||||2012-01-03|2012-01-05|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children|Echocardiographic Study of the Haemodynamic Effects of Remifentanil With and Without Glycopyrrolate in Healthy Children|Completed||Phase 2|63|Actual|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:03:25.560513|2018-06-01 04:03:25.560513
NCT00315523|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2013-12-13|2006-04-14|2006-04-18|Estimate|||||||2013-12-13|2013-12-16|Estimate|July 2006||2006-07-31|May 2012|2012-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen|Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEC.|Completed||Phase 3|403||UCB Pharma|||||f||||||||||||||2018-06-01 04:03:25.888193|2018-06-01 04:03:25.888193
NCT00315510|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2008-09-22|2006-04-17|2006-04-18|Estimate|||||||2008-09-22|2008-09-23|Estimate|April 2006||2006-04-30|September 2008|2008-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Rosuvastatin and Ischemia Reperfusion|Does Rosuvastatin Reduce Ischemia/Reperfusion Injury in Humans In-Vivo? A Randomized Double Blind Placebo Controlled Trial|Completed||Phase 2|20||Radboud University|||||f||||||||||||||2018-06-01 04:03:25.978679|2018-06-01 04:03:25.978679
NCT00315497|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2018-04-23|2006-04-14|2006-04-18|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2006|Actual|2006-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis|Longitudinal Protocol for Giant Cell Arteritis|Recruiting|||500|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood (serum and plasma), urine, and DNA~   "|No||2018-06-01 04:03:26.042364|2018-06-01 04:03:26.042364
NCT00315484|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2011-05-17|2006-04-14|2006-04-18|Estimate|||||||2011-05-17|2011-05-19|Estimate|February 2003||2003-02-28|April 2010|2010-04-30|October 2004|Actual|2004-10-31|||||Interventional|||Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia|A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) To Evaluate Hematologic Response Rate In Anemic Cancer Patients Receiving Chemotherapy|Completed||Phase 4|358|Actual|Ortho Biotech Products, L.P.|||||f||||||||||||||2018-06-01 04:03:26.131755|2018-06-01 04:03:26.131755
NCT00315471|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2018-04-23|2006-04-14|2006-04-18|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2006|Actual|2006-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis|VCRC Longitudinal Protocol for Takayasu's Arteritis|Recruiting|||250|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood (serum and plasma), urine, and DNA~   "|No||2018-06-01 04:03:26.192542|2018-06-01 04:03:26.192542
NCT00315458|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|2010-07-28||2012-08-27|2006-04-17|2006-04-18|Estimate|2010-08-30|2010-09-23|Estimate||||2012-08-27|2012-09-03|Estimate|December 2003||2003-12-31|August 2012|2012-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.|Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Determine Efficacy and Safety of Buprenorphine Transdermal System in Subjects With Moderate To Severe Osteoarthritis Pain Requiring Daily Treatment With Opioids|Terminated||Phase 3|107|Actual|Purdue Pharma LP|This study was terminated early for administrative reasons. The efficacy data are not presented since the primary objective of this study was changed identifying it as a safety study.|2||Administrative reasons.|f||||||||||||||2018-06-01 04:03:26.316749|2018-06-01 04:03:26.316749
NCT00315445|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|2011-05-17||2012-08-27|2006-04-17|2006-04-18|Estimate|2011-08-03|2011-08-10|Estimate||||2012-08-27|2012-09-03|Estimate|December 1997||1997-12-31|August 2012|2012-08-31|May 1998|Actual|1998-05-31|May 1998|Actual|1998-05-31||Interventional|BP96-0604||The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.|A Comparative Study of Buprenorphine TDS, Oxycodone/ Acetaminophen Tablets Qid and Placebo in Patients With Chronic Back Pain|Completed||Phase 3|134|Actual|Purdue Pharma LP|There was a large percentage of discontinuations across treatment groups.|3|||f||||||||||||||2018-06-01 04:03:26.809266|2018-06-01 04:03:26.809266
NCT00315432|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2011-05-17|2006-04-14|2006-04-18|Estimate|||||||2011-05-17|2011-05-19|Estimate|September 2000||2000-09-30|April 2010|2010-04-30|November 2003|Actual|2003-11-30|||||Interventional|||NATURAL HISTORY-Hepatitis C Virus/ Human Immunodeficiency Virus Coinfection|)A Study to Evaluate the Erythropoietic Response in HCV/HIV Co-Infected Patients Receiving Combination Ribavirin/Interferon Therapy|Completed||Phase 2|91|Actual|Ortho Biotech Products, L.P.|||||f||||||||||||||2018-06-01 04:03:27.586529|2018-06-01 04:03:27.586529
NCT00315419|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2010-04-19|2006-04-14|2006-04-18|Estimate|||||||2010-04-19|2010-04-21|Estimate|April 2006||2006-04-30|July 2009|2009-07-31|July 2009|Anticipated|2009-07-31|July 2009|Anticipated|2009-07-31||Observational|||Identifying Characteristics of Bone Marrow Failure Syndromes|Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias|Unknown status|Active, not recruiting||450|Anticipated|Office of Rare Diseases (ORD)|||||f||||||||||Samples With DNA|"~     Residual samples from peripheral blood and bone marrow aspiration/biopsies~   "|||2018-06-01 04:03:27.769385|2018-06-01 04:03:27.769385
NCT00315406|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2018-04-23|2006-04-14|2006-04-18|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2006|Actual|2006-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Determining Disease Activity Biomarkers in Individuals With Polyarteritis Nodosa|Longitudinal Protocol of Polyarteritis Nodosa|Recruiting|||150|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood (serum and plasma), urine, and DNA~   "|No||2018-06-01 04:03:28.064275|2018-06-01 04:03:28.064275
NCT00315393|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2018-04-23|2006-04-14|2006-04-18|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2006||2006-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis|Determining Disease Activity Biomarkers in Individuals With Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis|Recruiting|||1200|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood (serum and plasma), urine, and DNA~   "|||2018-06-01 04:03:28.393469|2018-06-01 04:03:28.393469
NCT00315380|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2018-04-23|2006-04-14|2006-04-18|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2006||2006-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)|Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss)|Recruiting|||500|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood (serum and plasma), urine, and DNA~   "|No||2018-06-01 04:03:28.751058|2018-06-01 04:03:28.751058
NCT00315367|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2007-10-15|2006-04-14|2006-04-18|Estimate|||||||2007-10-15|2007-10-16|Estimate|September 2004||2004-09-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties|A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function|Completed||Phase 4|26|Anticipated|Neurognostics|||||f||||||||||||||2018-06-01 04:03:29.071298|2018-06-01 04:03:29.071298
NCT00315354|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2016-11-22|2006-04-14|2006-04-18|Estimate|||||||2016-11-22|2016-11-23|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|April 2013|Actual|2013-04-30|June 2010|Actual|2010-06-30||Interventional|||Popular Diets Study|Popular Diets, Metabolism, and CVD Risk|Completed||N/A|24|Actual|Boston Children’s Hospital||3|||f||||||||||||||2018-06-01 04:03:29.375008|2018-06-01 04:03:29.375008
NCT00315341|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-16|2013-05-17||2016-11-09|2006-04-16|2006-04-18|Estimate|2016-11-09|2017-01-06|Estimate||||2016-11-09|2017-01-06|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Starting Treatment With Agonist Replacement Therapies (START)|Starting Treatment With Agonist Replacement Therapies (START)|Completed||Phase 4|1269|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-06-01 04:03:29.701342|2018-06-01 04:03:29.701342
NCT00315328|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|2009-09-09||2016-05-19|2006-04-14|2006-04-18|Estimate|2011-05-03|2011-06-06|Estimate||||2016-05-19|2016-06-24|Estimate|August 2005||2005-08-31|May 2016|2016-05-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|ATS9||Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds|A Randomized Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds|Completed||Phase 3|233|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 04:03:30.022679|2018-06-01 04:03:30.022679
NCT00315315|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2012-05-16|2006-04-14|2006-04-18|Estimate|||||||2012-05-16|2012-05-17|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|NLD2||Study of Surgical Procedures for Treatment of Persistent Nasolacrimal Duct Obstruction in Children < 4 Years Old|A Prospective Study of Surgical Procedures for the Treatment of Persistent Nasolacrimal Duct Obstruction in Children Less Than Four Years Old|Completed|||194|Actual|Jaeb Center for Health Research|||||f||||t||||||||||2018-06-01 04:03:31.838436|2018-06-01 04:03:31.838436
NCT00315302|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|2009-08-03||2016-07-15|2006-04-14|2006-04-18|Estimate|2011-07-18|2011-08-11|Estimate||||2016-07-15|2016-07-19|Estimate|February 2005||2005-02-28|July 2016|2016-07-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|ATS8||Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old|A Randomized Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye As Prescribed Treatments for Amblyopia in Children 3 to <7 Years Old|Completed||Phase 3|240|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 04:03:32.132881|2018-06-01 04:03:32.132881
NCT00315289|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2010-02-26|2006-04-14|2006-04-18|Estimate|||||||2010-02-26|2010-03-02|Estimate|February 2005||2005-02-28|January 2010|2010-01-31|September 2006|Actual|2006-09-30|||||Observational|NLD1||Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old|A Prospective Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old|Completed|||973|Actual|Jaeb Center for Health Research|||||f||||t||||||||||2018-06-01 04:03:37.651378|2018-06-01 04:03:37.651378
NCT00315276|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2012-08-22|2006-04-17|2006-04-18|Estimate|||||||2012-08-22|2012-08-24|Estimate|May 2006||2006-05-31|November 2007|2007-11-30|January 2007|Actual|2007-01-31|||||Interventional|||Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD|A 9-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With Attention Deficit/Hyperactivity Disorder|Completed||Phase 2|370||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:03:38.048816|2018-06-01 04:03:38.048816
NCT00315263|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2011-08-25|2006-04-14|2006-04-18|Estimate|||||||2011-08-25|2011-08-26|Estimate|April 2006||2006-04-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|October 2008|Actual|2008-10-31||Observational|||Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology|Genomics, SNPs, and Clinical Neonatology|Completed|||63|Actual|Children's Mercy Hospital Kansas City|||||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 04:03:38.330987|2018-06-01 04:03:38.330987
NCT00315250|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14||2014-03-21|2014-04-21|2006-04-14|2006-04-18|Estimate||||2014-03-21|2014-04-17|Estimate|2014-04-21|2014-05-09|Estimate|January 2006||2006-01-31|April 2014|2014-04-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease|Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease|Completed||Phase 2|225|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 04:03:38.582939|2018-06-01 04:03:38.582939
NCT00315237|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2010-01-06|2006-04-17|2006-04-18|Estimate|||||||2010-01-06|2010-01-07|Estimate|July 2005||2005-07-31|January 2010|2010-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract|Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract|Completed||Phase 3|364|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 04:03:38.864444|2018-06-01 04:03:38.864444
NCT00315224|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2006-04-14|2006-04-14|2006-04-18|Estimate|||||||2006-04-14|2006-04-18|Estimate|February 2005||2005-02-28|March 2005|2005-03-31|October 2005||2005-10-31|||||Interventional|||Sports in Hypertension of the Elderly|The Impact of Pulse Pressure on Cardiovascular Effects of Exercise Training in Hypertension of the Elderly|Completed||N/A|54||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:03:39.249131|2018-06-01 04:03:39.249131
NCT00315211|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-17|||2007-10-31|2006-04-17|2006-04-18|Estimate|||||||2007-10-31|2007-11-02|Estimate|November 2004||2004-11-30|October 2007|2007-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer|Phase 2 Study of Weekly Topotecan With Docetaxel for Recurrent Small Cell Lung Cancer|Terminated||Phase 2|40|Anticipated|Aultman Hospital||1||Slow Accrual|f||||||||||||||2018-06-01 04:03:39.486846|2018-06-01 04:03:39.486846
NCT00315198|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2010-03-23|2006-04-17|2006-04-18|Estimate|||||||2010-03-23|2010-03-24|Estimate|February 2005||2005-02-28|May 2009|2009-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|ATS6||Trial Comparing Near Versus Distance Activities While Patching for Amblyopia in Children 3 to <7 Years Old|A Randomized Trial Comparing Near Versus Distance Activities While Patching for Amblyopia in Children 3 to <7 Years Old|Completed||Phase 3|425|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 04:03:39.776394|2018-06-01 04:03:39.776394
NCT00315185|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2010-09-22|2006-04-17|2006-04-18|Estimate|||||||2010-09-22|2010-09-23|Estimate|December 2004||2004-12-31|September 2010|2010-09-30|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer|Phase II Study as First Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|53|Actual|Fox Chase Cancer Center|||||f||||t||||||||||2018-06-01 04:03:40.146943|2018-06-01 04:03:40.146943
NCT00315172|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-15|||2017-06-30|2006-04-15|2006-04-17|Estimate|||||||2017-06-30|2017-07-02|Actual|April 13, 2006||2006-04-13|November 7, 2008|2008-11-07|November 7, 2008||2008-11-07|||||Interventional|||Non-Exercise Activity Thermogenesis (NEAT) in Children|Non-Exercise Activity Thermogenesis (NEAT) in Children|Completed||Phase 1|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:40.428101|2018-06-01 04:03:40.428101
NCT00315159|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2015-01-09|2006-04-13|2006-04-17|Estimate|||||||2015-01-09|2015-01-12|Estimate|August 2003||2003-08-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients.|Conservative Management With Isolated Sentinel Lymph Node Biopsy in Vulvar Cancer Patients With Sentinel Lymph Nodes Determined to be Negative for Metastatic Disease.|Completed||N/A|74|Actual|Women and Infants Hospital of Rhode Island||1|||f||||t||||||||||2018-06-01 04:03:40.689955|2018-06-01 04:03:40.689955
NCT00315146|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|2013-03-07||2017-01-23|2006-04-13|2006-04-17|Estimate|2014-12-18|2014-12-19|Estimate||||2017-01-23|2017-03-07|Actual|April 2006||2006-04-30|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional||These numbers match the number of people who STARTED in each group in the flow module.|Optimizing Body Composition for Function in Older Adults|Optimizing Body Composition for Function in Older Adults (OPTIMA) - A Pepper Pilot Study|Completed||Phase 4|88|Actual|Wake Forest University Health Sciences||4|||f||||t||||||||||2018-06-01 04:03:40.839664|2018-06-01 04:03:40.839664
NCT00315133|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2017-01-13|2006-04-13|2006-04-17|Estimate|||||||2017-01-13|2017-01-18|Estimate|December 2003||2003-12-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus|Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes Mellitus- a Phase I/II Study|Completed||Phase 1/Phase 2|25|Actual|University of Sao Paulo||1|||f||||t||||||||Undecided|IPD may be shared if the responsible investigators feel it may increase understanding, reliability and reproducibility of the present study.|2018-06-01 04:03:41.327852|2018-06-01 04:03:41.327852
NCT00315120|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|2013-10-17||2016-05-24|2006-04-13|2006-04-17|Estimate|2016-05-24|2016-07-06|Estimate||||2016-05-24|2016-07-06|Estimate|August 2006||2006-08-31|May 2016|2016-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Osteopathic Health Outcomes in Chronic Low Back Pain (OSTEOPATHIC) Trial|A Randomized Controlled Trial of Osteopathic Manipulative Treatment and Ultrasound Physical Therapy for Chronic Low Back Pain|Completed||Phase 3|455|Actual|University of North Texas Health Science Center|Co-morbid conditions, work disability and low back pain co-treatments were self reported by participants, but were not verified through medical or employment records. Missing data were imputed for 13% of participants at the final encounter.|4|||f||||t||||||||No||2018-06-01 04:03:42.056987|2018-06-01 04:03:42.056987
NCT00315094|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2012-02-27|2006-04-13|2006-04-17|Estimate|||||||2012-02-27|2012-02-28|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|November 2011|Actual|2011-11-30|July 2010|Actual|2010-07-31||Interventional|||Technological Home Care: Improving HPN Care With Videophone And Internet Education|Prevention of Home Parenteral Nutrition (HPN) Infection, Depression and Improving Caregiving Problem Solving|Completed||N/A|172|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 04:03:43.457852|2018-06-01 04:03:43.457852
NCT00315081|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2006-04-13|2006-04-13|2006-04-17|Estimate|||||||2006-04-13|2006-04-17|Estimate|May 2006||2006-05-31|November 2005|2005-11-30|May 2008||2008-05-31|||||Interventional|||Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine|Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia|Unknown status|Not yet recruiting|Phase 3|20||University Hospital, Bonn|||||f||||||||||||||2018-06-01 04:03:43.656539|2018-06-01 04:03:43.656539
NCT00315068|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2007-04-19|2006-04-14|2006-04-17|Estimate|||||||2007-04-19|2007-04-20|Estimate|April 2004||2004-04-30|April 2007|2007-04-30|August 2007|Anticipated|2007-08-31|||||Observational|||Usefulness of Markers to Predict Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation|The Value of Amino-Terminal Brain Natriuretic Peptide and C-Reactive Protein Serum Levels for Predicting Recurrence of Atrial Fibrillation and/or Atrial Flutter After Radiofrequency Catheter Ablation|Unknown status|Active, not recruiting||180||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:03:43.807053|2018-06-01 04:03:43.807053
NCT00315055|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|2013-09-09||2014-09-04|2006-04-13|2006-04-17|Estimate|2014-01-02|2014-02-04|Estimate||||2014-09-04|2014-09-12|Estimate|July 2006||2006-07-31|September 2014|2014-09-30|February 2008|Actual|2008-02-29|July 2007|Actual|2007-07-31||Interventional|||Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule|Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2, 3, and 4 Months Primary Schedule in Healthy Turkish Infants|Completed||Phase 3|310|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:03:43.887169|2018-06-01 04:03:43.887169
NCT00315042|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2009-04-02|2006-04-14|2006-04-17|Estimate|||||||2009-04-02|2009-04-03|Estimate|March 2006||2006-03-31|April 2009|2009-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||TELI TON - Telithromycin in Tonsillitis|Multinational, Randomized, Double-Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 10 Days Penicillin V 13.3 mg/kg Tid in Children 6 Months to Less Than 13 Years With Streptococcus Pyogenes Tonsillitis/Pharyngitis|Terminated||Phase 3|314|Actual|Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2018-06-01 04:03:44.311008|2018-06-01 04:03:44.311008
NCT00315029|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2008-10-24|2006-04-14|2006-04-17|Estimate|||||||2008-10-24|2008-10-27|Estimate|November 2006||2006-11-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Patient-Centered Implementation Trial for Single Embryo Transfer|Patient-Centered Implementation of Elective Single Embryo Transfer (eSET) in in Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection (ICSI)|Completed||N/A|230|Actual|Radboud University||2|||f||||||||||||||2018-06-01 04:03:44.374674|2018-06-01 04:03:44.374674
NCT00315016|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2012-05-25|2006-04-14|2006-04-17|Estimate|||||||2012-05-25|2012-05-28|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Eplerenone, ACE Inhibition and Albuminuria|Eplerenone, ACE Inhibition and Albuminuria|Completed||Phase 2|30|Actual|Radboud University||3|||f||||f||||||||||2018-06-01 04:03:44.444987|2018-06-01 04:03:44.444987
NCT00315003|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2009-04-02|2006-04-14|2006-04-17|Estimate|||||||2009-04-02|2009-04-03|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||TELI COM - Telithromycin in Children With Otitis Media|Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/kg od for 4 Days, in Children With Acute Otitis Media|Terminated||Phase 3|1500||Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2018-06-01 04:03:44.524504|2018-06-01 04:03:44.524504
NCT00314990|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2006-04-14|2006-04-14|2006-04-17|Estimate|||||||2006-04-14|2006-04-17|Estimate|January 1996||1996-01-31|April 2006|2006-04-30|January 2003||2003-01-31|||||Interventional|||VITRO-Trial. B Vitamins and the Secondary Prevention of Venous Thrombosis|Homocysteine Lowering by B Vitamins and the Secondary Prevention of Deep-Vein Thrombosis and Pulmonary Embolism. A Randomized, Placebo-Controlled, Double Blind Trial.|Completed||N/A|620||Radboud University|||||f||||||||||||||2018-06-01 04:03:44.595181|2018-06-01 04:03:44.595181
NCT00314977|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2010-03-17|2006-04-14|2006-04-17|Estimate|||||||2010-03-17|2010-03-18|Estimate|February 2006||2006-02-28|March 2010|2010-03-31||||April 2009|Actual|2009-04-30||Interventional|INTENS||Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.|Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable and/or Locally Advanced Breast Cancer. The INTENS Study|Completed||Phase 3|200|Anticipated|Radboud University||2|||f||||f||||||||||2018-06-01 04:03:44.659131|2018-06-01 04:03:44.659131
NCT00314964|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2011-03-14|2006-04-13|2006-04-17|Estimate|||||||2011-03-14|2011-03-16|Estimate|August 2006||2006-08-31|March 2011|2011-03-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Evaluating PD-0299685 for Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 2|527|Actual|Pfizer|||||||||||||||||||2018-06-01 04:03:44.773209|2018-06-01 04:03:44.773209
NCT00314951|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|2011-07-01|2010-08-27|2017-03-23|2006-04-13|2006-04-17|Estimate|2011-09-16|2011-10-26|Estimate|2010-08-27|2010-08-31|Estimate|2017-03-23|2017-04-21|Actual|May 2, 2006|Actual|2006-05-02|March 2017|2017-03-31|August 21, 2008|Actual|2008-08-21|July 23, 2008|Actual|2008-07-23||Interventional|||Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)|A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea|Completed||Phase 3|629|Actual|Optimer Pharmaceuticals LLC||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:03:45.097464|2018-06-01 04:03:45.097464
NCT00314938|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2011-05-12|2006-04-13|2006-04-17|Estimate|||||||2011-05-12|2011-05-16|Estimate|April 2006||2006-04-30|May 2011|2011-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency|A Double Blind, Single Dose Study To Explore The Safety, Pharmacokinetics And Pharmacodynamics Of PHA-794428 In Pediatric Patients With Growth Hormone Deficiency|Terminated||Phase 2|32||Pfizer||||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:03:45.856315|2018-06-01 04:03:45.856315
NCT00314925|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2010-02-23|2006-04-13|2006-04-17|Estimate|||||||2010-02-23|2010-02-25|Estimate|April 2006||2006-04-30|February 2010|2010-02-28|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features|Phase I Dose-Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Patients With Advanced Solid Tumors With Neuroendocrine Features|Unknown status|Active, not recruiting|Phase 1|60|Anticipated|Neotropix||1|||f||||||||||||||2018-06-01 04:03:45.937949|2018-06-01 04:03:45.937949
NCT00314912|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2007-07-13|2006-04-13|2006-04-17|Estimate|||||||2007-07-13|2007-07-16|Estimate|May 2006||2006-05-31|July 2007|2007-07-31||||||||Interventional|||Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease|An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease|Unknown status|Active, not recruiting|Phase 3|650||Bellus Health Inc|||||||||||||||||||2018-06-01 04:03:46.031073|2018-06-01 04:03:46.031073
NCT00314899|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2010-08-26|2006-04-13|2006-04-17|Estimate|||||||2010-08-26|2010-08-27|Estimate|May 2007||2007-05-31|October 2007|2007-10-31|September 2011||2011-09-30|||||Observational|||Fetal Immunity to Falciparum Malaria|Fetal Immunity to Plasmodium Falciparum Malaria|Unknown status|Recruiting||1020||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:03:46.08697|2018-06-01 04:03:46.08697
NCT00314886|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2011-01-18|2006-04-14|2006-04-17|Estimate|||||||2011-01-18|2011-01-19|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|July 2005|Anticipated|2005-07-31|||||Interventional|||Effect of Butyrogenic Fibers in IBS Patients|Effect of an Enriched Butyrogenic Fibres Diet on Rectal Sensitivity in Healthy Control and IBS Patients.|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 04:03:46.141592|2018-06-01 04:03:46.141592
NCT00314873|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2014-05-30|2006-04-13|2006-04-17|Estimate|||||||2014-05-30|2014-06-03|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma|Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma|Completed||Phase 1|11|Actual|Indiana University|||||f||||||||||||||2018-06-01 04:03:46.214652|2018-06-01 04:03:46.214652
NCT00314860|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2016-10-17|2006-04-13|2006-04-17|Estimate|||||||2016-10-17|2016-10-18|Estimate|February 2006||2006-02-28|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole|A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)|Completed||Phase 3|568|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:03:46.294673|2018-06-01 04:03:46.294673
NCT00314847|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2010-07-30|2006-04-14|2006-04-17|Estimate|||||||2010-07-30|2010-08-02|Estimate|June 2005||2005-06-30|July 2010|2010-07-31|October 2009|Actual|2009-10-31|||||Interventional|||Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock|National Multicenter Randomized Trial, Comparing Two Treatments of Myocardial Infarction Complicated With Cardiogenic Shock: Standard Treatment vs Standard Treatment Plus ECLS (Extracorporeal Life Support)|Terminated||Phase 4|19|Actual|University Hospital, Caen||2||The study was stopped prematurely due to insufficient recruitment|f||||t||||||||||2018-06-01 04:03:46.488458|2018-06-01 04:03:46.488458
NCT00314834|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-14|||2006-04-14|2006-04-14|2006-04-17|Estimate|||||||2006-04-14|2006-04-17|Estimate|January 2001||2001-01-31|March 2005|2005-03-31|December 2004||2004-12-31|||||Interventional|||Effect of Intradialytic Parenteral Nutrition on Morbidity and Mortality of Malnourished Hemodialysis Patients|Effect of Intradialytic Parenteral Nutrition on Morbidity and Mortality of Malnourished Hemodialysis Patients|Terminated||Phase 4|204||EZUS-LYON 1|||||f||||||||||||||2018-06-01 04:03:46.584643|2018-06-01 04:03:46.584643
NCT00314821|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2017-04-17|2006-04-13|2006-04-17|Estimate|||||||2017-04-17|2017-04-18|Actual|September 2005|Actual|2005-09-30|April 2017|2017-04-30|March 17, 2008|Actual|2008-03-17|June 1, 2007|Actual|2007-06-01||Interventional|||Ropinirole in the Treatment of Bipolar Depression|A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder|Completed||Phase 4|40|Anticipated|Cambridge Health Alliance|||||||||||||||||||2018-06-01 04:03:46.638382|2018-06-01 04:03:46.638382
NCT00314808|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|2013-05-02||2014-07-10|2006-04-14|2006-04-17|Estimate|2013-07-03|2013-08-06|Estimate||||2014-07-10|2014-07-16|Estimate|April 2006||2006-04-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas|A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas|Completed||Phase 1|33|Actual|Duke University||1|||f||||f||||||||||2018-06-01 04:03:46.708815|2018-06-01 04:03:46.708815
NCT00314795|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13||2016-11-29|2016-11-29|2006-04-13|2006-04-17|Estimate||||2016-11-29|2016-11-30|Estimate|2016-11-29|2016-11-30|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease|An Open-Label Study to Investigate the Efficacy and Safety of Peginesatide in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease|Completed||Phase 2|22|Actual|Takeda||1|||f||||f||||||||||2018-06-01 04:03:46.892808|2018-06-01 04:03:46.892808
NCT00314782|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2013-03-11|2006-04-13|2006-04-17|Estimate|||||||2013-03-11|2013-03-12|Estimate|March 2006||2006-03-31|March 2010|2010-03-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC|A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer|Completed||Phase 1|44|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 04:03:46.971335|2018-06-01 04:03:46.971335
NCT00314769|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2018-05-23|2006-04-13|2006-04-14|Estimate|||||||2018-05-23|2018-05-24|Actual|April 7, 2006||2006-04-07|December 16, 2013|2013-12-16|December 16, 2013||2013-12-16|||||Observational|||Long-Term Improvement in Motor Learning by Transcranial Direct Current Stimulation|Long-Term Improvement in Training Effects by Transcranial DC Stimulation|Completed|||196|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:47.046412|2018-06-01 04:03:47.046412
NCT00314756|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2017-11-01|2006-04-12|2006-04-14|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2005||2005-03-31|March 2005|2005-03-31|November 2005||2005-11-30|||||Interventional|||Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage|Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage|Completed||Phase 4|15||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 04:03:47.218704|2018-06-01 04:03:47.218704
NCT00314743|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2013-05-22|2006-04-12|2006-04-14|Estimate|||||||2013-05-22|2013-05-24|Estimate|October 2005||2005-10-31|May 2013|2013-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation|A Study Evaluating the Efficacy and Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combination With Ondansetron and Dexamethasone in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation|Completed||Early Phase 1|48|Actual|Washington University School of Medicine||2|||f||||||||||||||2018-06-01 04:03:47.278046|2018-06-01 04:03:47.278046
NCT00314730|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2007-04-18|2006-04-13|2006-04-14|Estimate|||||||2007-04-18|2007-04-19|Estimate|May 2006||2006-05-31|April 2007|2007-04-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Outcomes in the Palm of Your Hand: Improving the Quality and Continuity of Patient Care|Outcomes in the Palm of Your Hand: Improving the Quality and Continuity of Patient Care|Unknown status|Active, not recruiting|N/A|400||University of Toronto|||||f||||||||||||||2018-06-01 04:03:47.363277|2018-06-01 04:03:47.363277
NCT00314717|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-13|||2011-06-20|2006-04-13|2006-04-14|Estimate|||||||2011-06-20|2011-06-21|Estimate|April 2006||2006-04-30|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Women With Gestational Hyperglycemia|The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Women With Gestational Hyperglycemia|Completed||Phase 2|47|Actual|University of Toronto|||||f||||f||||||||||2018-06-01 04:03:47.422301|2018-06-01 04:03:47.422301
NCT00314704|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2010-01-29|2006-04-12|2006-04-14|Estimate|||||||2010-01-29|2010-02-01|Estimate|December 2003||2003-12-31|April 2006|2006-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Dopamine and Norepinephrine in Shock Patients|Comparison of Dopamine and Norepinephrine as the First Vasopressor Agent in the Management of Shock|Completed||Phase 3|1679|Actual|Sepsis Occurrence in Acutely Ill Patients|||||f||||||||||||||2018-06-01 04:03:47.490587|2018-06-01 04:03:47.490587
NCT00314691|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2011-07-27|2006-04-12|2006-04-14|Estimate|||||||2011-07-27|2011-07-28|Estimate|April 2006||2006-04-30|July 2007|2007-07-31|September 2006||2006-09-30|||||Interventional|||Development of New Prenatal Diagnostic Tests From Maternal Blood|Development of New Prenatal Diagnostic Tests From Maternal Blood|Terminated||N/A|10|Actual|University Hospital, Strasbourg, France||||Leaving of the person responsible for the data collection|f||||||||||||||2018-06-01 04:03:47.579964|2018-06-01 04:03:47.579964
NCT00314678|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2016-12-06|2006-04-12|2006-04-14|Estimate|||||||2016-12-06|2016-12-08|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer|Cisplatin Induction Followed by Paclitaxel Consolidation for the Treatment of Stage III and IV Epithelial Ovarian Cancer and Primary Peritoneal Cancer With In Vitro Correlates of Response|Completed||Phase 2|40|Anticipated|University of California, Irvine|||||f||||||||||||||2018-06-01 04:03:47.634438|2018-06-01 04:03:47.634438
NCT00314665|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2007-12-03|2006-04-12|2006-04-14|Estimate|||||||2007-12-03|2007-12-06|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|August 2006|Actual|2006-08-31|||||Interventional|||Use of Thalidomide in Chronic Uveitis|Use of Thalidomide in Chronic Uveitis|Terminated||Phase 4|15||University of Cincinnati|||||f||||||||||||||2018-06-01 04:03:47.765218|2018-06-01 04:03:47.765218
NCT00314652|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2006-04-29|2006-04-12|2006-04-14|Estimate|||||||2006-04-29|2006-05-03|Estimate|June 1999||1999-06-30|April 2006|2006-04-30|October 1999||1999-10-31|||||Interventional|||Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.|A Double-Blind Placebo-Controlled Study of Buprenorphine Transdermal System (BTDS) in Patients With Osteoarthritis of the Hip or Knee|Completed||Phase 3|260||Purdue Pharma LP|||||||||||||||||||2018-06-01 04:03:47.824209|2018-06-01 04:03:47.824209
NCT00314639|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2009-02-11|2006-04-12|2006-04-14|Estimate|||||||2009-02-11|2009-02-12|Estimate|September 2005||2005-09-30|April 2007|2007-04-30||||June 2008|Actual|2008-06-30||Interventional|||Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia|The Impact of Modafinil as an Adjunctive to a Second Generation Antipsychotic on Cognitive Functioning in Schizophrenia and Schizophrenia Spectrum Psychosis.|Completed||Phase 1/Phase 2|30|Anticipated|Laval University|||||f||||||||||||||2018-06-01 04:03:47.947573|2018-06-01 04:03:47.947573
NCT00314626|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2008-01-25|2006-04-12|2006-04-14|Estimate|||||||2008-01-25|2008-01-29|Estimate|November 2004||2004-11-30|November 2007|2007-11-30|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily|Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC Once Daily|Completed||Phase 3|99|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 04:03:48.036618|2018-06-01 04:03:48.036618
NCT00314613|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2017-11-29|2006-04-12|2006-04-14|Estimate|||||||2017-11-29|2017-12-02|Actual|April 2006||2006-04-30|May 2010|2010-05-31||||December 2006|Actual|2006-12-31||Interventional|||Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal|Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal|Terminated||Phase 4|30|Anticipated|Duke University|||||f||||||||||||||2018-06-01 04:03:48.173529|2018-06-01 04:03:48.173529
NCT00314600|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2007-02-23|2006-04-12|2006-04-14|Estimate|||||||2007-02-23|2007-02-26|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Treatment of Non-Dislocated Midshaft Both-Bone Fractures|Above Elbow Cast in Non-Dislocated Both-Bone Midshaft Forearm Fractures in Children: Necessity or Needless Cruelty? A Randomized Trial|Unknown status|Recruiting|N/A|60||Colaris, Joost, M.D.|||||f||||||||||||||2018-06-01 04:03:48.237291|2018-06-01 04:03:48.237291
NCT00314587|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2007-02-23|2006-04-12|2006-04-14|Estimate|||||||2007-02-23|2007-02-26|Estimate|January 2006||2006-01-31|November 2006|2006-11-30||||||||Interventional|||Treatment of Unstable Both-Bone Midshaft Forearm Fractures in Children|Treatment of Unstable Both-Bone Midshaft Forearm Fractures in Children: A Randomized Trial Between 1 and 2 Elastic Stable Intramedullary Nails|Unknown status|Recruiting|N/A|60||Colaris, Joost, M.D.|||||f||||||||||||||2018-06-01 04:03:48.317293|2018-06-01 04:03:48.317293
NCT00314574|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|2011-03-31||2012-02-08|2006-04-12|2006-04-14|Estimate|2011-09-01|2011-10-13|Estimate||||2012-02-08|2012-02-09|Estimate|December 2005||2005-12-31|February 2012|2012-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)|A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects With Moderate to Severe Persistent Asthma Who Are Inadequately Controlled With High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists|Completed||Phase 3|850|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 04:03:48.437606|2018-06-01 04:03:48.437606
NCT00314197|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2007-09-24|2006-04-11|2006-04-13|Estimate|||||||2007-09-24|2007-09-26|Estimate|April 2006||2006-04-30|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|||Improving Health Behaviors Through Telephone Linked Care|Study That Examines Integration of the Telephone Linked Care Behavioral Change (Automated Counseling) System Into Primary Care|Completed||N/A|400|Actual|American Academy of Family Physicians|||||f||||f||||||||||2018-06-01 04:03:54.227636|2018-06-01 04:03:54.227636
NCT00314561|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2011-06-30|2006-04-12|2006-04-14|Estimate|||||||2011-06-30|2011-07-01|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|December 2006||2006-12-31|||||Interventional|||The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome|The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome: A Prospective, Randomized, Open-label, Crossover Trial|Completed||Phase 4|40||Korea University Anam Hospital|||||f||||||||||||||2018-06-01 04:03:48.861831|2018-06-01 04:03:48.861831
NCT00314548|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2010-05-18|2006-04-12|2006-04-14|Estimate|||||||2010-05-18|2010-05-19|Estimate|May 2006||2006-05-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Inhaled Prostacyclin for Adult Respiratory Distress Syndrome (ARDS) and Pulmonary Hypertension|Trial of Inhaled Alprostadil to Improve Hypoxia and Pulmonary Hypertension|Completed||N/A|67|Actual|Aga Khan University||2|||f||||t||||||||||2018-06-01 04:03:48.913869|2018-06-01 04:03:48.913869
NCT00314535|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2016-02-24|2006-04-13|2006-04-14|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2005||2005-07-31|March 2012|2012-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe|Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe|Completed|||40|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:03:48.978706|2018-06-01 04:03:48.978706
NCT00314522|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2016-02-23|2006-04-13|2006-04-14|Estimate|||||||2016-02-23|2016-02-25|Estimate|September 2005||2005-09-30|December 2011|2011-12-31|March 2006||2006-03-31|||||Observational|||Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe|Optimization of Spectroscopic Imaging Parameters and Procedures for Prostate at 3 Tesla Using an External Probe|Completed|||5|Actual|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:03:49.021941|2018-06-01 04:03:49.021941
NCT00314509|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2016-12-02|2006-04-12|2006-04-14|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2005||2005-07-31|December 2016|2016-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)|ADVICE: A Dose Range Finding Study of Formoterol Administered Once Daily in the Evening in Combination With Ciclesonide Using the Ultrahaler™ Versus Monotherapy of Each Drug in Asthmatic Patients|Completed||Phase 2|240||AstraZeneca|||||f||||||||||||||2018-06-01 04:03:49.073155|2018-06-01 04:03:49.073155
NCT00314496|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2016-02-24|2006-04-13|2006-04-14|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Development of Magnetic Resonance (MR) Simulation for Treatment Planning|Development of MR Simulation for Treatment Planning|Completed|||10|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:03:49.290146|2018-06-01 04:03:49.290146
NCT00314483|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2007-07-03|2006-04-12|2006-04-14|Estimate|||||||2007-07-03|2007-07-06|Estimate|June 2007||2007-06-30|July 2007|2007-07-31|June 2008|Anticipated|2008-06-30|||||Interventional|||Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of Graft Versus Host Disease|Evaluation of Potential Mesenchymal Stem Cells for the Treatment of Graft Versus Host Disease Following an Allogeneic Stem Cell Transplant|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|Christian Medical College, Vellore, India|||||f||||t||||||||||2018-06-01 04:03:49.342755|2018-06-01 04:03:49.342755
NCT00314470|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2016-02-24|2006-04-13|2006-04-14|Estimate|||||||2016-02-24|2016-02-26|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute|Image and Dosimetry Related Research of Department of Medical Physics, Cross Cancer Institute|Completed|||40|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:03:49.414158|2018-06-01 04:03:49.414158
NCT00314457|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2009-07-10|2006-04-12|2006-04-14|Estimate|||||||2009-07-10|2009-07-13|Estimate|August 2005||2005-08-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|February 2007|Actual|2007-02-28||Interventional|||Efficacy Study of Continuous Intraarticular Infusion in Patients Undergoing Arthroscopic Knee and Shoulder Operations|A Randomized, Double-blind Trial Comparing the Analgesic Efficacy and Side Effects of Continuous Intraarticular Infusion of Bupivacaine Versus Normal Saline in Patients Undergoing Knee and Shoulder Operations|Terminated||Phase 4|16|Actual|Children's Hospital of Philadelphia||||Bupivacaine has recently been shown to inhibit osteoclast formation in vitro.|f||||f||||||||||2018-06-01 04:03:49.46146|2018-06-01 04:03:49.46146
NCT00314444|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2017-06-30|2006-04-12|2006-04-13|Estimate|||||||2017-06-30|2017-07-02|Actual|April 7, 2006||2006-04-07|April 14, 2009|2009-04-14|April 14, 2009||2009-04-14|||||Observational|||Treatment for Psychogenic Disorders|Treatment for Psychogenic Movement Disorders|Completed|||15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:49.523092|2018-06-01 04:03:49.523092
NCT00314431|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2017-11-01|2006-04-11|2006-04-13|Estimate|||||||2017-11-01|2017-11-06|Actual|May 1996||1996-05-31|April 2006|2006-04-30|August 2000||2000-08-31|||||Interventional|||Post-hospitalization Nursing Effectiveness (PHONE) Study|Randomized Comparison of Two Models of Post-NICU Care for Preterm Infants With Neonatal Chronic Lung Disease|Completed||Phase 3|150||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 04:03:49.573508|2018-06-01 04:03:49.573508
NCT00314418|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2006-04-11|2006-04-11|2006-04-13|Estimate|||||||2006-04-11|2006-04-13|Estimate|September 2005||2005-09-30|April 2006|2006-04-30|March 2006||2006-03-31|||||Interventional|||Patient Position and Impact on Colonoscopy Time|Patient Position and Impact on Colonoscopic Cecal Intubation Time|Completed||N/A|120||VA Connecticut Healthcare System|||||f||||||||||||||2018-06-01 04:03:49.647681|2018-06-01 04:03:49.647681
NCT00314405|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2008-08-07|2006-04-11|2006-04-13|Estimate|||||||2008-08-07|2008-08-08|Estimate|April 2006||2006-04-30|February 2008|2008-02-29||||April 2007|Actual|2007-04-30||Interventional|||Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope|Identification of Sentinel Lymph Node (SLN) in Breast Cancer Care: Clinical and Economical Evaluation of a Double Method Using Isotope and Methylene Blue Dye Injection.|Completed||N/A|100|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:03:49.708113|2018-06-01 04:03:49.708113
NCT00314392|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2008-02-04|2006-04-11|2006-04-13|Estimate|||||||2008-02-04|2008-02-06|Estimate|September 2006||2006-09-30|February 2008|2008-02-29|December 2007|Actual|2007-12-31|||||Interventional|||Gender, Pain, and Placebo Analgesia|Effect of Participant Gender, Experimenter Gender, and Drug-Related Information on Placebo Analgesia|Completed||N/A|74|Anticipated|University Hospital of North Norway|||||f||||||||||||||2018-06-01 04:03:49.762102|2018-06-01 04:03:49.762102
NCT00314379|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2009-01-20|2006-04-12|2006-04-13|Estimate|||||||2009-01-20|2009-01-22|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Endothelial Function in a Sample Group of Patients From the ICARE Study|Vitamin E Treatment and Endothelial Function in Type 2 Diabetic Patients With Hp 2-2 Phenotype From the I CARE Study (EFI)|Completed||Phase 2/Phase 3|50|Anticipated|Technion, Israel Institute of Technology|||||f||||||||||||||2018-06-01 04:03:49.81215|2018-06-01 04:03:49.81215
NCT00314366|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2015-06-05||2016-10-17|2006-04-11|2006-04-13|Estimate|2015-10-20|2015-11-23|Estimate||||2016-10-17|2016-11-28|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|April 2021|Anticipated|2021-04-30|August 2009|Actual|2009-08-31||Interventional|||Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells for Therapeutic Angiogenesis (FOCUS Br)|Phase IB Randomized Controlled Double-Blind Trial of Intramyocardial Injection of Autologous Aldehyde Dehydrogenase-Bright Stem Cells Under Electromechanical Guidance for Therapeutic Angiogenesis|Active, not recruiting||Phase 1|21|Actual|Texas Heart Institute|The study is a preliminary study based on a small sample size which limits the statistical rigor of the analysis.|2|||f||||t||||||||No|Relevant results are summarized and published. No need for individual results to be shared.|2018-06-01 04:03:49.893843|2018-06-01 04:03:49.893843
NCT00314353|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2008-11-07||2018-04-05|2006-04-11|2006-04-13|Estimate|2008-12-01|2008-12-02|Estimate||||2018-04-05|2018-05-08|Actual|March 2006||2006-03-31|April 2018|2018-04-30|June 2010|Actual|2010-06-30|May 2008|Actual|2008-05-31||Interventional|||Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon|Randomized Phase II Clinical Trial of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Line Treatment for Metastatic Colorectal Cancer|Terminated||Phase 2|7|Actual|NSABP Foundation Inc|The study was closed early due to low enrollment and new information regarding the benefit of the study regimen.|2||"The study was closed early due to low enrollment and new information regarding the benefit of~   the study regimen."|f||||f||||||||||2018-06-01 04:03:51.416239|2018-06-01 04:03:51.416239
NCT00314340|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2012-11-20||2017-05-25|2006-04-11|2006-04-13|Estimate|2013-07-11|2013-07-12|Estimate||||2017-05-25|2017-05-30|Actual|November 2005||2005-11-30|May 2017|2017-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine|A CTSC Clinical Research Center Study: A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine|Completed||Phase 4|12|Actual|University of California, Davis||3|||f||||f||||||||||2018-06-01 04:03:51.670963|2018-06-01 04:03:51.670963
NCT00314327|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2015-04-13||2018-04-18|2006-04-11|2006-04-13|Estimate|2015-04-13|2015-04-29|Estimate||||2018-04-18|2018-05-16|Actual|April 2006||2006-04-30|April 2018|2018-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ORP||Optimizing Response in Psychosis Study|Optimizing Response in Psychosis Study|Terminated||Phase 4|1|Actual|Northwell Health||1||Recruitment for the study was limited.|f||||t||||||||||2018-06-01 04:03:51.844364|2018-06-01 04:03:51.844364
NCT00314314|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2009-07-09|2006-04-11|2006-04-13|Estimate|||||||2009-07-09|2009-07-13|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder|A Randomized, Double-Blind Controlled Trial Evaluating the Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder|Completed||Phase 3|60|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 04:03:52.073609|2018-06-01 04:03:52.073609
NCT00314301|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2006-04-14|2006-04-12|2006-04-13|Estimate|||||||2006-04-14|2006-04-17|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|September 2007||2007-09-30|||||Interventional|||Motion Analysis of Sit-to-Stand Movements in Children With Spastic Diplegia|Motion Analysis of Sit-to-Stand Movements in Children With Spastic Diplegia Before and After Loaded Sit-to-Stand Training|Unknown status|Not yet recruiting|N/A|20||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:03:52.152049|2018-06-01 04:03:52.152049
NCT00314288|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2017-01-19|2006-04-12|2006-04-13|Estimate|||||||2017-01-19|2017-01-23|Estimate|July 2002||2002-07-31|January 2017|2017-01-31|July 2003||2003-07-31|||||Interventional|||Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia|A Multicenter, Multinational, Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Investigate the Anti-dyskinetic Efficacy and Safety of Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia|Completed||Phase 2|360||EMD Serono|||||||||||||||||||2018-06-01 04:03:52.235442|2018-06-01 04:03:52.235442
NCT00314275|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2012-04-19|2006-04-11|2006-04-13|Estimate|||||||2012-04-19|2012-04-20|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|May 2006|Actual|2006-05-31||Interventional|ENDEAVOR PK||The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System|Evaluation of Pharmacokinetics (PK) and Safety of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|Completed||N/A|43|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-06-01 04:03:52.366419|2018-06-01 04:03:52.366419
NCT00314262|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2014-09-08||2014-10-21|2006-04-11|2006-04-13|Estimate|2014-10-21|2014-10-24|Estimate||||2014-10-21|2014-10-24|Estimate|October 2006||2006-10-31|October 2014|2014-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor|Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers|Completed||Phase 1/Phase 2|17|Actual|Emory University|One limitation is the small number of patients who were evaluable for response.|1|||f||||t||||||||||2018-06-01 04:03:52.463237|2018-06-01 04:03:52.463237
NCT00314249|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2009-06-30||2010-01-14|2006-04-11|2006-04-13|Estimate|2009-09-25|2009-11-02|Estimate||||2010-01-14|2010-01-20|Estimate|April 2006||2006-04-30|January 2010|2010-01-31||||June 2008|Actual|2008-06-30||Interventional|||Study of Milnacipran for the Treatment of Fibromyalgia|A Phase III Pivotal, Multicenter, Double-blind, Randomized, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of Fibromyalgia.|Completed||Phase 3|1025|Actual|Forest Laboratories||2|||f||||||||||||||2018-06-01 04:03:52.808259|2018-06-01 04:03:52.808259
NCT00314236|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2015-11-05||2015-12-17|2006-04-12|2006-04-13|Estimate|2015-12-17|2015-12-18|Estimate||||2015-12-17|2015-12-18|Estimate|December 2005||2005-12-31|December 2015|2015-12-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|||Trial Comparing BST-CarGel and Microfracture in Repair of Articular Cartilage Lesions in the Knee|A Randomized, Comparative Multicenter Clinical Trial Evaluating BST-CarGel™ and Microfracture in Repair of Focal Articular Cartilage Lesions on the Femoral Condyle|Completed||N/A|80|Actual|Piramal Healthcare Canada Ltd||2|||f||||f||||||||||2018-06-01 04:03:53.370098|2018-06-01 04:03:53.370098
NCT00314223|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-12|||2006-04-12|2006-04-12|2006-04-13|Estimate|||||||2006-04-12|2006-04-13|Estimate|February 2006||2006-02-28|April 2006|2006-04-30|December 2006||2006-12-31|||||Observational|||Identification of Gene Polymorphism in Patients With Sick Sinus Syndrome in Chinese Population in Taiwan||Unknown status|Recruiting||300||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:03:53.926486|2018-06-01 04:03:53.926486
NCT00314210|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2009-03-24|2006-04-12|2006-04-13|Estimate|||||||2009-03-24|2009-03-25|Estimate|March 2006||2006-03-31|March 2009|2009-03-31|August 2007|Actual|2007-08-31|||||Interventional|PLATINUM||Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.|A Multi-Centre,Double-Blind,Randomised-Withdrawal,Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine SR as Monotherapy in the Maintenance Treatment of Patients With GAD Following an Open-Label Stabilisation Period|Completed||Phase 3|575||AstraZeneca|||||f||||||||||||||2018-06-01 04:03:54.022206|2018-06-01 04:03:54.022206
NCT00314184|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2008-12-19|2006-04-11|2006-04-13|Estimate|||||||2008-12-19|2008-12-22|Estimate|March 2005||2005-03-31|December 2008|2008-12-31|July 2007|Actual|2007-07-31|||||Interventional|SPaRCLe||Quetiapine Fumarate Bipolar Maintenance Monotherapy|Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 Weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients|Completed||Phase 3|1255|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:03:54.436664|2018-06-01 04:03:54.436664
NCT00314171|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2016-11-17|2006-04-12|2006-04-13|Estimate|||||||2016-11-17|2016-11-18|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|437|Actual|Alcon Research||2|||f||||f||||||||||2018-06-01 04:03:54.742807|2018-06-01 04:03:54.742807
NCT00314158|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2016-11-17|2006-04-12|2006-04-13|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2005||2005-11-30|March 2012|2012-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|523|Actual|Alcon Research||3|||f||||||||||||||2018-06-01 04:03:54.829064|2018-06-01 04:03:54.829064
NCT00314145|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2012-11-06||2012-12-04|2006-04-12|2006-04-13|Estimate|2012-11-06|2012-12-05|Estimate||||2012-12-04|2012-12-06|Estimate|November 2005||2005-11-30|December 2012|2012-12-31|November 2006|Actual|2006-11-30|June 2006|Actual|2006-06-30||Interventional|||A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX|A Multicentre, Randomized, Double-blind, Phase III Study of The Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (ChimeriVax™-JE and JE-VAX®)|Completed||Phase 3|820|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:03:54.929546|2018-06-01 04:03:54.929546
NCT00314132|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2012-11-06||2012-12-04|2006-04-11|2006-04-13|Estimate|2012-11-06|2012-12-05|Estimate||||2012-12-04|2012-12-06|Estimate|October 2005||2005-10-31|December 2012|2012-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.|Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)|Completed||Phase 3|2004|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:03:55.35309|2018-06-01 04:03:55.35309
NCT00314119|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2018-03-27|2006-04-11|2006-04-12|Estimate|||||||2018-03-27|2018-03-29|Actual|April 10, 2006||2006-04-10|June 28, 2017|2017-06-28||||||||Observational|||Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1|Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1|Completed|||17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:03:55.767866|2018-06-01 04:03:55.767866
NCT00314106|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2012-09-18||2012-09-18|2006-04-11|2006-04-12|Estimate|2012-09-18|2012-10-18|Estimate||||2012-09-18|2012-10-18|Estimate|April 2006||2006-04-30|September 2012|2012-09-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma|Phase II Study Using a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution With CD34+ Stem Cells in Metastatic Melanoma|Completed||Phase 2|26|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 04:03:55.859498|2018-06-01 04:03:55.859498
NCT00314093|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2013-08-19|2006-04-11|2006-04-12|Estimate|||||||2013-08-19|2013-08-20|Estimate|April 2006||2006-04-30|August 2013|2013-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||RFT-5-dgA in Patients With Metastatic Melanoma|Phase II Evaluation of RFT5-dgA in Patients With Metastatic Melanoma|Completed||Phase 2|41|Anticipated|University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:03:56.30036|2018-06-01 04:03:56.30036
NCT00314080|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2008-10-23|2006-04-11|2006-04-12|Estimate|||||||2008-10-23|2008-10-24|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|April 2006||2006-04-30|||||Observational|||Treatment of Survivors After Botulism Outbreak|An Outbreak of Botulism in Thailand: Clinical Manifestations and Management of Severe Respiratory Failure|Completed|||18||Rajavithi Hospital|||||f||||||||||||||2018-06-01 04:03:56.355581|2018-06-01 04:03:56.355581
NCT00314067|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-10-17|2006-04-10|2006-04-12|Estimate|||||||2013-10-17|2013-10-18|Estimate|July 2006||2006-07-31|June 2008|2008-06-30|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Evaluation of Case Management to Improve the Outpatient Care of Alcohol-related Disorders|Comprehensive Quality Management in Out-patient Care for Alcohol-related Disorders (AQAH). Transfer and Dissemination Into Routine Practice|Completed||N/A|112|Actual|University Hospital Freiburg||3|||f||||||||||||||2018-06-01 04:03:56.412348|2018-06-01 04:03:56.412348
NCT00314054|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2008-04-10|2006-04-11|2006-04-12|Estimate|||||||2008-04-10|2008-04-14|Estimate|May 2006||2006-05-31|April 2008|2008-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults|An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of HCV-796 in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults|Completed||Phase 1|27|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-06-01 04:03:56.518552|2018-06-01 04:03:56.518552
NCT00314041|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-02-20|2006-04-11|2006-04-12|Estimate|||||||2013-02-20|2013-02-21|Estimate|June 1997||1997-06-30|February 2013|2013-02-28|April 1998|Actual|1998-04-30|April 1998|Actual|1998-04-30||Interventional|||Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants|A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age.|Completed||Phase 2|240||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:03:56.665175|2018-06-01 04:03:56.665175
NCT00314028|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-12-13|2006-04-10|2006-04-12|Estimate|||||||2013-12-13|2013-12-16|Estimate|April 2003||2003-04-30|December 2013|2013-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effectiveness of HIV Risk Reduction Program Among African American Men|Promoting HIV Risk Reduction Among African American Men|Completed||Phase 3|270|Actual|University of Kentucky||2|||f||||||||||||||2018-06-01 04:03:56.727767|2018-06-01 04:03:56.727767
NCT00314015|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2014-12-04|2006-04-11|2006-04-12|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of the Success Rate of Immediately Loaded Implants|Evaluation of the Success Rate of Immediately Loaded Implants|Unknown status|Recruiting|N/A|200|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:03:56.786947|2018-06-01 04:03:56.786947
NCT00312936|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2016-05-12|2006-04-07|2006-04-11|Estimate|||||||2016-05-12|2016-05-16|Estimate|July 2006||2006-07-31|May 2016|2016-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Mindfulness Based Approach to HIV Treatment Side Effects|A Mindfulness Based Approach to HIV Treatment Side Effects|Completed||Phase 1/Phase 2|76|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:04:17.55392|2018-06-01 04:04:17.55392
NCT00314002|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2009-08-06|2006-04-11|2006-04-12|Estimate|||||||2009-08-06|2009-08-07|Estimate|October 2005||2005-10-31|August 2009|2009-08-31|April 2007||2007-04-30|||||Interventional|||Catheter Thrombectomy in Patients With Massive Pulmonary Embolism|Compassionate Use of Catheter Thrombectomy (Aspirex 11F) in Patients With Massive Pulmonary Embolism|Terminated||Phase 1/Phase 2|50|Anticipated|Straub Medical AG||||"After treatment of 7 patients, it was decided that the handling characteristics of the test~   device should be upgraded before continuing the trial as planned."|f||||||||||||||2018-06-01 04:03:56.878011|2018-06-01 04:03:56.878011
NCT00313989|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2014-12-04|2006-04-11|2006-04-12|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Evaluation of Osseo-integration After Placement of Dental Implants With Patients Receiving Radiotherapy for Buccopharyngeal Oncology|Evaluation of Osseo-integration After Placement of Dental Implants With Patients Receiving Radiotherapy for Buccopharyngeal Oncology|Unknown status|Recruiting|N/A|200|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:03:56.959093|2018-06-01 04:03:56.959093
NCT00313976|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2015-03-09|2006-04-11|2006-04-12|Estimate|||||||2015-03-09|2015-03-10|Estimate||||December 2008|2008-12-31||||||||Interventional|||Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)|A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis|Withdrawn||Phase 3|0|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:03:57.038306|2018-06-01 04:03:57.038306
NCT00313963|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-08-09|2006-04-10|2006-04-12|Estimate|||||||2013-08-09|2013-08-13|Estimate|April 2006||2006-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|August 2008|Actual|2008-08-31||Interventional|||MAST - Magnesium for Sickle Cell Acute Crisis in Children|MAST - Magnesium for Sickle Cell Acute Crisis in Children|Completed||Phase 3|120|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 04:03:57.118384|2018-06-01 04:03:57.118384
NCT00313950|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2014-01-17|2006-04-11|2006-04-12|Estimate|||||||2014-01-17|2014-01-22|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine|Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children|Completed||Phase 4|470|Actual|Sanofi||3|||f||||f||||||||||2018-06-01 04:03:57.194198|2018-06-01 04:03:57.194198
NCT00313937|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2009-12-04|2006-04-11|2006-04-12|Estimate|||||||2009-12-04|2009-12-07|Estimate|November 2001||2001-11-30|December 2009|2009-12-31||||June 2004|Actual|2004-06-30||Interventional|||SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1|Single Centre, Open, Controlled, Randomised (1:1), Parallel Group: Insulin Glargine vs. NPH: FPG (Fasting Plasma Glucose) in Patients With DM Type 1 Who Skip the Morning Meal During Treatment With MDI (Multiple Daily Injection) Basal/Bolus Insulin|Completed||Phase 4|91|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:03:57.277008|2018-06-01 04:03:57.277008
NCT00313924|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2007-02-19|2006-04-11|2006-04-12|Estimate|||||||2007-02-19|2007-02-21|Estimate|February 2006||2006-02-28|February 2007|2007-02-28|March 2006||2006-03-31|||||Interventional|||Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome|The Applicability of the OAB Assessment Tool for Evaluation of Treatment Efficacy of Overactive Bladder.|Unknown status|Recruiting|Phase 4|100||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:03:57.349451|2018-06-01 04:03:57.349451
NCT00313911|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2012-09-18||2014-04-02|2006-04-11|2006-04-12|Estimate|2012-10-18|2012-11-19|Estimate||||2014-04-02|2014-04-21|Estimate|July 2006||2006-07-31|April 2014|2014-04-30|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.|Large Scale Safety Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine, in Comparison to Tritanrix-Hep B/Hib™ and OPV Administered at 2, 4, and 6 Months of Age in Latin American Infants|Completed||Phase 3|2133|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:03:57.449592|2018-06-01 04:03:57.449592
NCT00313898|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2007-05-16|2006-04-11|2006-04-12|Estimate|||||||2007-05-16|2007-05-17|Estimate|September 2005||2005-09-30|April 2006|2006-04-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males|The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction|Unknown status|Recruiting|Phase 4|100|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-06-01 04:03:58.055072|2018-06-01 04:03:58.055072
NCT00313885|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2010-11-29|2006-04-07|2006-04-12|Estimate|||||||2010-11-29|2010-11-30|Estimate|April 2004||2004-04-30|November 2010|2010-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia|Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-center, Randomized, Double-blind, Placebo-controlled Study.|Completed||Phase 2|205|Actual|Sanofi||3|||f||||||||||||||2018-06-01 04:03:58.125414|2018-06-01 04:03:58.125414
NCT00313872|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2012-01-10|2006-04-11|2006-04-12|Estimate|||||||2012-01-10|2012-01-12|Estimate|May 2003||2003-05-31|January 2012|2012-01-31|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer|Phase III Randomized Trial of Taxotere/Cisplatin Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer|Completed||Phase 3|200|Actual|Samsung Medical Center||2|||f||||||||||||||2018-06-01 04:03:58.210595|2018-06-01 04:03:58.210595
NCT00313859|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2012-01-31|2006-04-11|2006-04-12|Estimate|||||||2012-01-31|2012-02-02|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|August 2007|Actual|2007-08-31|||||Interventional|||Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC|Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic Colorectal Cancer|Completed||Phase 2|50|Actual|Samsung Medical Center|||||f||||||||||||||2018-06-01 04:03:58.299783|2018-06-01 04:03:58.299783
NCT00313846|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2010-07-28||2012-08-27|2006-04-11|2006-04-12|Estimate|2010-09-27|2010-09-28|Estimate||||2012-08-27|2012-09-03|Estimate|April 2003||2003-04-30|August 2012|2012-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of the Buprenorphine Transdermal Delivery System in Subjects With Moderate to Severe Osteoarthritic Pain of Hip or Knee|Completed||Phase 3|529|Actual|Purdue Pharma LP||2|||f||||||||||||||2018-06-01 04:03:58.390511|2018-06-01 04:03:58.390511
NCT00313833|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2006-04-29|2006-04-10|2006-04-12|Estimate|||||||2006-04-29|2006-05-03|Estimate|December 2000||2000-12-31|April 2006|2006-04-30|November 2001||2001-11-30|||||Interventional|||Safety and Effectiveness of Buprenorphine Transdermal System in Elderly Subjects With Chronic Pain: Pilot Study.|A Randomized, Double Blind, Pilot Evaluation of the Effectiveness of BTDS Versus Placebo on Health Outcomes Associated With Analgesic Management of Elderly Residents in Supervised Living Environments|Completed||Phase 3|100||Purdue Pharma LP|||||||||||||||||||2018-06-01 04:03:58.718234|2018-06-01 04:03:58.718234
NCT00313820|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2009-09-08||2009-10-09|2006-04-11|2006-04-12|Estimate|2009-09-08|2009-10-09|Estimate||||2009-10-09|2009-10-15|Estimate|August 2006||2006-08-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain|A 13-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150-600 Mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Central Post-Stroke Pain (CPSP)|Completed||Phase 4|220|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:03:58.832195|2018-06-01 04:03:58.832195
NCT00313807|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2015-03-10|2006-04-11|2006-04-12|Estimate|||||||2015-03-10|2015-03-11|Estimate|November 2005||2005-11-30|March 2015|2015-03-31|September 2008||2008-09-30|||||Interventional|||Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage|CoNTRST - Contrast Nephropathy and Travasol for Renal Safety Trial: Intravenous Amino Acid Infusion for the Prevention of Contrast-mediated Acute Renal Failure Following Coronary Catheterization|Withdrawn||Phase 2|0|Actual|Queen's University||2||Abandoned due to lack of recruitment Oct 2006|f||||t||||||||||2018-06-01 04:03:59.621608|2018-06-01 04:03:59.621608
NCT00313794|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10||2009-03-20|2012-06-05|2006-04-10|2006-04-12|Estimate||||2009-09-24|2009-09-28|Estimate|2012-06-05|2012-06-07|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment|Phase 2, Single Arm Study Of Ticilimumab In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum|Completed||Phase 2|49|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 04:03:59.705417|2018-06-01 04:03:59.705417
NCT00313781|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2013-01-18|2012-05-08|2013-03-05|2006-04-10|2006-04-12|Estimate|2013-03-05|2013-04-11|Estimate|2012-05-08|2012-05-10|Estimate|2013-03-05|2013-04-11|Estimate|May 2006||2006-05-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)|A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of CP-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer|Completed||Phase 2|204|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:03:59.874606|2018-06-01 04:03:59.874606
NCT00313768|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10||2009-09-24|2009-09-24|2006-04-10|2006-04-12|Estimate||||2009-09-24|2009-09-28|Estimate|2009-09-24|2009-09-28|Estimate|December 2005||2005-12-31|September 2009|2009-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC|A Randomized Phase 2 Trial Of Paclitaxel, Carboplatin And Bevacizumab With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer|Terminated||Phase 2|23|Actual|Pfizer||2||See Termination Reason in Detailed Description.|f||||f||||||||||2018-06-01 04:04:02.059084|2018-06-01 04:04:02.059084
NCT00313755|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2007-11-15|2006-04-10|2006-04-12|Estimate|||||||2007-11-15|2007-11-16|Estimate|April 2006||2006-04-30|November 2006|2006-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Magnification Narrow Band Imaging Colonoscopy for Hereditary Non-Polyposis Colorectal Cancer Surveillance|Back-to Back Trial of Narrow Band Imaging (NBI) With Magnification Versus Standard Colonoscopy for Colonic Neoplasia Surveillance in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients|Completed||N/A|60||London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:04:02.210149|2018-06-01 04:04:02.210149
NCT00313742|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2014-11-25|2006-04-11|2006-04-12|Estimate|||||||2014-11-25|2014-11-26|Estimate|April 2006||2006-04-30|November 2014|2014-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins|An Assessment of the Impact of Performing Physical Exercise on the Maximum Plasma Glucose Decline in Subjects With Type 1 Diabetes Managed on a Basal Bolus Insulin Regimen: A Comparison of 3 Basal Insulin Treatments - Insulin Detemir, Insulin Glargine and NPH Insulin|Completed||Phase 4|51|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:04:02.296215|2018-06-01 04:04:02.296215
NCT00313729|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2017-09-15|2006-04-11|2006-04-12|Estimate|||||||2017-09-15|2017-09-18|Actual|May 1999||1999-05-31|September 2017|2017-09-30|June 12, 2017|Actual|2017-06-12|September 25, 2014|Actual|2014-09-25||Interventional|||Temozolomide in Treating Patients With Low-Grade Glioma|A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma|Completed||Phase 2|120|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:04:02.384282|2018-06-01 04:04:02.384282
NCT00313716|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2014-07-28||2014-09-02|2006-04-10|2006-04-12|Estimate|2014-09-02|2014-09-10|Estimate||||2014-09-02|2014-09-10|Estimate|April 2006||2006-04-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury|Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury|Completed||Phase 2/Phase 3|200|Actual|Baylor College of Medicine||6|||f||||t||||||||||2018-06-01 04:04:02.529124|2018-06-01 04:04:02.529124
NCT00313703|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2010-10-06||2018-04-16|2006-04-10|2006-04-12|Estimate|2011-04-15|2011-05-09|Estimate||||2018-04-16|2018-05-15|Actual|March 2004|Actual|2004-03-31|April 2018|2018-04-30|November 2005|Actual|2005-11-30|August 2005|Actual|2005-08-31||Observational|||Prospective ED Headache Cohort Study|Predicting Poor Pain and Functional Outcomes After Discharge From the Emergency Department With a Primary Headache|Completed|||477|Actual|Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:04:04.376742|2018-06-01 04:04:04.376742
NCT00313690|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2014-05-20|2006-04-10|2006-04-12|Estimate|||||||2014-05-20|2014-05-21|Estimate|April 2006||2006-04-30|May 2014|2014-05-31||||||||Interventional|||Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer|Phase I/II Study of Neoadjuvant Bortezomib in Combination With Docetaxel and Cisplatin Followed by Surgery in Early Stage Non-Small Cell Lung Cancer.|Withdrawn||Phase 1/Phase 2|0|Actual|University of Southern California||||Recruitment difficulties|f||||||||||||||2018-06-01 04:04:04.578062|2018-06-01 04:04:04.578062
NCT00313677|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2018-05-10|2006-04-10|2006-04-12|Estimate|||||||2018-05-10|2018-05-16|Actual|April 2006||2006-04-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Clinical Trial Readiness for the Dystroglycanopathies|Clinical Trial Readiness for the Dystroglycanopathies|Recruiting|||120|Anticipated|University of Iowa|||||f||||f||||||Samples With DNA|"~     fibroblasts, whole blood~   "|No||2018-06-01 04:04:04.631744|2018-06-01 04:04:04.631744
NCT00313625|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2010-09-20|2006-04-11|2006-04-12|Estimate|||||||2010-09-20|2010-09-21|Estimate|September 2005||2005-09-30|September 2010|2010-09-30||||July 2007|Actual|2007-07-31||Interventional|||Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma|A Phase II Study of Intravenous Melphalan and Busulfan Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma|Completed||Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:04:04.718857|2018-06-01 04:04:04.718857
NCT00313612|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2015-04-13||2015-10-27|2006-04-11|2006-04-12|Estimate|2015-10-27|2015-11-27|Estimate||||2015-10-27|2015-11-27|Estimate|January 2006||2006-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Interventional|||Oxaliplatin and Topotecan in Advance Ovarian Cancer|A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer|Terminated||Phase 2|39|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:04:04.790112|2018-06-01 04:04:04.790112
NCT00313599|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2014-07-01|2006-04-11|2006-04-12|Estimate|||||||2014-07-01|2014-07-02|Estimate|February 2006||2006-02-28|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors|Completed||Phase 1|28|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:04:05.006819|2018-06-01 04:04:05.006819
NCT00313586|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2014-11-18||2016-12-08|2006-04-11|2006-04-12|Estimate|2014-11-18|2014-11-25|Estimate||||2016-12-08|2017-02-02|Estimate|August 2006||2006-08-31|December 2016|2016-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||All treated patients were included in the analysis.|Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia|A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia|Completed||Phase 2|197|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 04:04:05.123551|2018-06-01 04:04:05.123551
NCT00313573|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2013-09-19|2006-04-11|2006-04-12|Estimate|||||||2013-09-19|2013-09-20|Estimate|February 2006||2006-02-28|May 2009|2009-05-31||||January 2010|Anticipated|2010-01-31||Interventional|||Telemedicine or Standard Care in Treating Patients With Depression and/or Pain Caused By Cancer|TeleCare Management of Pain and Depression in Cancer|Unknown status|Active, not recruiting|Phase 3|480|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:04:07.146553|2018-06-01 04:04:07.146553
NCT00313560|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2016-04-05|2006-04-11|2006-04-12|Estimate|||||||2016-04-05|2016-04-06|Estimate|January 2006||2006-01-31|January 2016|2016-01-31||||December 2008|Actual|2008-12-31||Interventional|||Erlotinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer That Can Be Removed By Surgery|Phase II Study of Erlotinib (Tarceva) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer|Completed||Phase 2|52|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-06-01 04:04:07.229755|2018-06-01 04:04:07.229755
NCT00313547|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2008-05-02|2006-04-11|2006-04-12|Estimate|||||||2008-05-02|2008-05-06|Estimate|April 2006||2006-04-30|August 2007|2007-08-31|March 2008|Actual|2008-03-31|April 2007|Actual|2007-04-30||Interventional|||High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients|Impact of High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine on Autonomic Regulation and on Sympathetic Activation in Response to Cold Exposure in Hypertensive Patients With Impaired Glucose Tolerance, Diabetes or Coronary Artery Disease|Terminated||Phase 4|40|Anticipated|Montreal Heart Institute||||Very difficult to recruit patients/slow recruitment(2 patients in nearly 2 years).|f||||||||||||||2018-06-01 04:04:07.40196|2018-06-01 04:04:07.40196
NCT00313534|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2012-10-09|2006-04-11|2006-04-12|Estimate|||||||2012-10-09|2012-10-11|Estimate|June 2005||2005-06-30|October 2012|2012-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer|A Phase I Study of NDGA in Patients With Non-Metastatic Biochemically Relapsed Prostate Cancer|Terminated||Phase 1|15|Actual|University of California, San Francisco||||Ran out of drug|f||||t||||||||||2018-06-01 04:04:07.481311|2018-06-01 04:04:07.481311
NCT00313521|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2013-09-19|2006-04-11|2006-04-12|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 1995||1995-06-30|December 2006|2006-12-31||||November 1997|Anticipated|1997-11-30||Interventional|||Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors|Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:04:07.571793|2018-06-01 04:04:07.571793
NCT00313508|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2014-02-20|2006-04-11|2006-04-12|Estimate|||||||2014-02-20|2014-02-21|Estimate|February 2006||2006-02-28|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Dendritic Cell Vaccination During Lymphoid Reconstruction|A Dose Ranging Trial of MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured Using Cytokines With Autologous Lymphocyte Infusion With or Without Escalating Doses of Fludarabine for Patients With Chemotherapy-naive Metastatic Melanoma|Completed||Phase 1|18|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 04:04:07.640278|2018-06-01 04:04:07.640278
NCT00313495|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2011-03-04|2006-04-10|2006-04-12|Estimate|||||||2011-03-04|2011-03-07|Estimate|February 2006||2006-02-28|March 2011|2011-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Cooperative Huntington's Observational Research Trial|Cooperative Huntington's Observational Research Trial|Recruiting|||5000|Anticipated|HP Therapeutics Foundation|||||f||||f||||||Samples With DNA|"~     Blood, DNA and Urine~   "|||2018-06-01 04:04:07.765391|2018-06-01 04:04:07.765391
NCT00313482|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2012-05-09|2006-04-10|2006-04-12|Estimate|||||||2012-05-09|2012-05-11|Estimate|April 2006||2006-04-30|May 2012|2012-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC|A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer|Terminated||Phase 2|35|Actual|Veeda Oncology||||Low accrual|f||||f||||||||||2018-06-01 04:04:07.954139|2018-06-01 04:04:07.954139
NCT00313469|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2011-08-24|2006-04-10|2006-04-12|Estimate|||||||2011-08-24|2011-08-25|Estimate|September 2005||2005-09-30|August 2011|2011-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Sources of the Variability of the Response to Fluindione in Elderly Patients (PREPA)|Sources of the Variability of the Response to Fluindione in Elderly Patients (PREPA) [Etude Des Sources de variabilité de la réponse à la Fluindione Chez Les Personnes âgées de 80 Ans et Plus (PREPA) ]|Completed|||152|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     Blood samples for the measure of drug concentrations Blood samples with DNA measurements~   "|||2018-06-01 04:04:08.037194|2018-06-01 04:04:08.037194
NCT00313456|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2012-05-09|2006-04-11|2006-04-12|Estimate|||||||2012-05-09|2012-05-10|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel|A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel|Terminated||Phase 1|25|Actual|Agennix||||Sponsor decided to discontinue study drug development|f||||||||||||||2018-06-01 04:04:08.113323|2018-06-01 04:04:08.113323
NCT00313443|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2009-06-18||2011-07-06|2006-04-10|2006-04-12|Estimate|2009-08-04|2009-08-06|Estimate||||2011-07-06|2011-07-14|Estimate|April 2006||2006-04-30|June 2009|2009-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|ATACA||Concentrations of Amiodarone in Fat Tissue During Chronic Treatment|Study of Concentrations of Amiodarone in Fat Tissue Obtained by Needle Aspiration in Patients on Chronic Treatment|Completed||Phase 4|30|Actual|Hopital Lariboisière|Small number of patients included. High variability of amiodarone concentrations in fat tissue between the 2 simultaneous samples for some patients. Incidence of amiodarone-related adverse effects probably overestimated.|1|||f||||f||||||||||2018-06-01 04:04:08.184539|2018-06-01 04:04:08.184539
NCT00313430|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2015-08-19|2006-04-11|2006-04-12|Estimate|||||||2015-08-19|2015-08-21|Estimate|May 2004||2004-05-31|August 2015|2015-08-31||||March 2008|Actual|2008-03-31||Observational|||Urinary Concentration and Diluting Ability in Patients With Chronic Renal Disease and/ or Hypertension|Urinary Concentration and Diluting Ability in Patients With Chronic Renal Disease or Hypertension|Completed|||50|Actual|Regional Hospital Holstebro|||2||f||||||||||||||2018-06-01 04:04:08.415942|2018-06-01 04:04:08.415942
NCT00313417|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2013-04-03|2006-04-11|2006-04-12|Estimate|||||||2013-04-03|2013-04-05|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Creatine as a New Therapeutic Strategy in Depression|A Double-blind, Parallel, Randomized, add-on Clinical Trial of Creatine Versus Placebo Added to Antidepressant Treatment of Patients With Major Depressive Episode.|Terminated||Phase 4|18|Actual|Herzog Hospital||2|||f||||t||||||||||2018-06-01 04:04:08.472213|2018-06-01 04:04:08.472213
NCT00313404|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-11-18|2006-04-10|2006-04-12|Estimate|||||||2013-11-18|2013-11-19|Estimate|February 2006||2006-02-28|November 2013|2013-11-30|April 2011|Actual|2011-04-30|January 2007|Actual|2007-01-31||Interventional|||Infectivity of Norovirus in Groundwater-Human Challenge Study|Assessment of Calicivirus Survival in Surface Water and Subsurface Water|Completed||N/A|13|Actual|Emory University||1|||f||||f||||||||||2018-06-01 04:04:08.53494|2018-06-01 04:04:08.53494
NCT00313391|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2014-09-23|2006-04-10|2006-04-12|Estimate|||||||2014-09-23|2014-09-25|Estimate|December 2005||2005-12-31|September 2014|2014-09-30||||December 2007|Actual|2007-12-31||Interventional|||Risperdal Consta and Health Care Utilization in Patients With Schizophrenia|The Effects of Risperdal Consta on Health Care Utilization Costs in Chronically Ill Schizophrenic Patients|Completed||Phase 4|||Emory University|||||f||||||||||||||2018-06-01 04:04:08.657905|2018-06-01 04:04:08.657905
NCT00313378|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2013-04-02|2006-04-11|2006-04-12|Estimate|||||||2013-04-02|2013-04-04|Estimate|April 2004||2004-04-30|April 2013|2013-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy|Effects of Perioperative Systemic Ketamine on Development of Long-term Neuropathic Pain After Thoracotomy.|Completed||Phase 3|78|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-06-01 04:04:08.717908|2018-06-01 04:04:08.717908
NCT00313365|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-09-23|2006-04-11|2006-04-12|Estimate|||||||2013-09-23|2013-09-24|Estimate|April 2006||2006-04-30|September 2013|2013-09-30|July 2013|Anticipated|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Surgical Lavage vs Serial Needle Aspiration for Infected Joints|Arthrotomy With Irrigation and Debridement Versus Serial Arthrocentesis as Treatment for Septic Arthritis in Adults|Withdrawn||Phase 3|0|Actual|Emory University||||Study was never started because Dr. Hammerberg left before it could be started.|f||||||||||||||2018-06-01 04:04:08.808876|2018-06-01 04:04:08.808876
NCT00313352|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-11-08|2006-04-10|2006-04-12|Estimate|||||||2013-11-08|2013-11-13|Estimate|January 1997||1997-01-31|November 2013|2013-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Effects of Beta-adrenergic in Adults w/Transposition of Great Arteries on Systemic Ventricular Function|Effects of Beta-adrenergic Blocking Agents in Adult Patients With Transposition of the Great Arteries on Systemic Ventricular Function|Completed|||110|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:04:08.8759|2018-06-01 04:04:08.8759
NCT00313339|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-11-15|2006-04-10|2006-04-12|Estimate|||||||2013-11-15|2013-11-18|Estimate|March 2006||2006-03-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2009|Actual|2009-03-31||Interventional|AMR-1||Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction|AMORCYTE MYOCARDIAL REPAIR STUDY- A Phase I Trial of Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction. (AMRS)|Completed||Phase 1|31|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:04:08.932524|2018-06-01 04:04:08.932524
NCT00313326|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2008-10-07|2006-04-11|2006-04-12|Estimate|||||||2008-10-07|2008-10-08|Estimate|February 2005||2005-02-28|October 2008|2008-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Comparative Study of Duration of Respiratory Weaning Between Adaptive Support Ventilation and Succession of Controlled Ventilation Then Spontaneous Ventilation for Patients After Surgery|Comparative Study of Duration of Respiratory Weaning Between Adaptive Support Ventilation and Succession of Controlled Ventilation Then Spontaneous Ventilation for Patients After Surgery|Terminated||Phase 3|66|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 04:04:09.009771|2018-06-01 04:04:09.009771
NCT00313313|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2009-08-17||2015-04-14|2006-04-11|2006-04-12|Estimate|2009-08-17|2009-09-25|Estimate||||2015-04-14|2015-05-04|Estimate|April 2006||2006-04-30|March 2015|2015-03-31|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas|A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone|Completed||Phase 3|768|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:04:09.125793|2018-06-01 04:04:09.125793
NCT00313300|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2015-09-11||2015-11-25|2006-04-11|2006-04-12|Estimate|2015-09-11|2015-10-15|Estimate||||2015-11-25|2015-12-30|Estimate|May 2006||2006-05-31|November 2015|2015-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||All randomized participants were summarized.|Safety Study of Apixaban in Recent Acute Coronary Syndrome|A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.|Completed||Phase 2|1741|Actual|Bristol-Myers Squibb||4|||f||||t||||||||||2018-06-01 04:04:09.864642|2018-06-01 04:04:09.864642
NCT00313287|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2017-01-30|2006-04-11|2006-04-12|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2003||2003-06-30|April 2006|2006-04-30|November 2004||2004-11-30|||||Interventional|||Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV|A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 mg QD in Patients Chronically Infected With Hepatitis B Virus|Terminated||Phase 3|180||Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 04:04:12.633016|2018-06-01 04:04:12.633016
NCT00313274|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2017-01-30|2006-04-11|2006-04-12|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2003||2003-07-31|April 2006|2006-04-30|December 2004||2004-12-31|||||Interventional|||Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV|A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine (L-FMAU) 30 mg QD in Patients With HBeAg Negative Chronic Hepatitis B|Terminated||Phase 3|80||Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 04:04:12.727033|2018-06-01 04:04:12.727033
NCT00313261|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|||2012-10-16|2006-04-11|2006-04-12|Estimate|||||||2012-10-16|2012-10-17|Estimate|June 2003||2003-06-30|October 2012|2012-10-31|February 2005||2005-02-28|||||Interventional|||Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group|An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group|Terminated||Phase 2|||Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 04:04:12.888792|2018-06-01 04:04:12.888792
NCT00313248|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11||2015-09-24|2015-11-11|2006-04-11|2006-04-12|Estimate||||2015-09-24|2015-10-15|Estimate|2015-11-11|2015-12-10|Estimate|April 2006||2006-04-30|November 2015|2015-11-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer|Phase 2 Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients With Metastatic Breast Cancer|Completed||Phase 2|65|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:04:12.95835|2018-06-01 04:04:12.95835
NCT00313235|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2013-06-12|2006-04-10|2006-04-12|Estimate|||||||2013-06-12|2013-06-13|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Combined Modality Treatment for Patients With Stage IV Melanoma|Combined Modality Treatment for Patients With Stage IV Melanoma: Cyclophosphamide and a Dendritic Cell Vaccine Loaded With Killed Allogeneic Melanoma Cells|Completed||Phase 1/Phase 2|41|Actual|Baylor Research Institute||1|||f||||t||||||||||2018-06-01 04:04:13.062817|2018-06-01 04:04:13.062817
NCT00313222|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10||2010-02-11|2010-02-11|2006-04-10|2006-04-12|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|October 2005||2005-10-31|February 2010|2010-02-28|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Completed||Phase 3|157|Actual|Actelion|||||f||||||||||||||2018-06-01 04:04:13.125325|2018-06-01 04:04:13.125325
NCT00313209|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-11|2011-03-17||2016-11-01|2006-04-11|2006-04-12|Estimate|2011-04-20|2011-05-19|Estimate||||2016-11-01|2016-12-14|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|February 2008|Actual|2008-02-29|July 2007|Actual|2007-07-31||Interventional|EOS||Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)|Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study|Completed||Phase 3|933|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:04:13.238732|2018-06-01 04:04:13.238732
NCT00313196|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10||2010-02-11|2012-01-11|2006-04-10|2006-04-12|Estimate||||2010-02-11|2010-02-15|Estimate|2012-01-11|2012-01-16|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|ASSET-2||Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)|Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Hypertension Associated With Sickle Cell Disease|Terminated||Phase 3|12|Actual|Actelion||2||Slow enrollment|f||||||||||||||2018-06-01 04:04:13.9863|2018-06-01 04:04:13.9863
NCT00313183|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2015-03-05|2006-04-10|2006-04-12|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2006||2006-04-30|January 2015|2015-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus|A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of SYMLIN in Adolescent Subjects With Type 1 Diabetes Mellitus|Completed||Phase 2|12|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 04:04:14.153942|2018-06-01 04:04:14.153942
NCT00313170|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2009-06-10||2018-03-01|2006-04-11|2006-04-12|Estimate|2011-07-29|2011-08-29|Estimate||||2018-03-01|2018-03-29|Actual|May 30, 2006|Actual|2006-05-30|February 2018|2018-02-28|January 2, 2019|Anticipated|2019-01-02|June 13, 2008|Actual|2008-06-13||Interventional|FINDER II||A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg|Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy|Active, not recruiting||Phase 2|143|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:04:14.257778|2018-06-01 04:04:14.257778
NCT00313157|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2014-05-11|2006-04-10|2006-04-12|Estimate|||||||2014-05-11|2014-05-13|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|RATAF||RATe Control in Atrial Fibrillation|Rate Control in Atrial Fibrillation|Completed||Phase 3|80|Actual|Asker & Baerum Hospital||4|||f||||f||||||||||2018-06-01 04:04:14.732162|2018-06-01 04:04:14.732162
NCT00313144|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2011-03-04||2018-01-16|2006-04-10|2006-04-12|Estimate|2011-08-23|2011-08-26|Estimate||||2018-01-16|2018-02-12|Actual|June 9, 2006|Actual|2006-06-09|January 2018|2018-01-31|May 1, 2009|Actual|2009-05-01|December 1, 2008|Actual|2008-12-01||Interventional|||Aralast alpha1-proteinase Inhibitor Surveillance Study|ARALAST alpha1-proteinase Inhibitor (α1-PI) Surveillance Study|Terminated||Phase 4|127|Actual|Shire|Study was terminated early due to Aralast being phased out of the market.|||Study terminated early due to Aralast being phased out of the market.|f||||f||||||||||2018-06-01 04:04:14.852093|2018-06-01 04:04:14.852093
NCT00313131|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2006-04-07|2006-04-07|2006-04-11|Estimate|||||||2006-04-07|2006-04-11|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|May 2005||2005-05-31|||||Interventional|||Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments|A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge|Completed||Phase 3|1524||Université de Sherbrooke|||||f||||||||||||||2018-06-01 04:04:15.729307|2018-06-01 04:04:15.729307
NCT00313118|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2017-03-27|2006-04-10|2006-04-11|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2006||2006-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|September 2010|Actual|2010-09-30||Observational|||Mean Values of Oxidative Stress Parameters in Healthy Subjects|Determination of the Mean Values of Oxidative Stress Parameters in the Plasma of Healthy Subjects|Withdrawn|||0|Actual|University Hospital, Basel, Switzerland||||Problems with recruiting|f||||f||||||None Retained|"~     plasma~   "|No||2018-06-01 04:04:15.801089|2018-06-01 04:04:15.801089
NCT00313105|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2009-09-14|2006-04-10|2006-04-11|Estimate|||||||2009-09-14|2009-09-15|Estimate|April 2006||2006-04-30|September 2009|2009-09-30|August 2010|Anticipated|2010-08-31|April 2010|Anticipated|2010-04-30||Interventional|||Smoking Cessation With Smokeless Tobacco, Nicotine Tablets and Nicotine Patches|Smoking Cessation by Nurses With Smokeless Tobacco Buccal Tablets, Nicotine Buccal Tablets, Nicotine Patches With Repeated Therapy Every 6 Months for 2 Years|Unknown status|Active, not recruiting|Phase 2/Phase 3|600|Anticipated|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-06-01 04:04:15.856647|2018-06-01 04:04:15.856647
NCT00313092|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2015-10-01|2006-04-10|2006-04-11|Estimate|||||||2015-10-01|2015-10-02|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||Obstructive Sleep Apnea Syndrome in Glaucoma|Does Plasma Matrix-metalloproteinase Activity Predict Glaucomas in Patients With OSAS (Obstructive Sleep Apnea Syndrome) and Does the Level of Plasma Matrix-metalloproteinase Activity Decrease After One Month of nCPAP-treatment|Terminated|||60|Actual|University Hospital, Basel, Switzerland||||recruiting problems|f||||f||||||None Retained|"~     plasma~   "|||2018-06-01 04:04:15.928622|2018-06-01 04:04:15.928622
NCT00313079|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2012-06-29|2006-04-07|2006-04-11|Estimate|||||||2012-06-29|2012-07-03|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|July 2009|Actual|2009-07-31|February 2009|Actual|2009-02-28||Interventional|||Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia|A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Adult Patients With Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia|Completed||Phase 1|9|Actual|Stanford University|||||f||||t||||||||||2018-06-01 04:04:16.048475|2018-06-01 04:04:16.048475
NCT00313066|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-09|||2006-04-09|2006-04-09|2006-04-11|Estimate|||||||2006-04-09|2006-04-11|Estimate|November 2005||2005-11-30|April 2006|2006-04-30|November 2006||2006-11-30|||||Observational|||Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion|Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Among Tuberculous Pleurisy and Malignant Pleural Effusion Patients|Unknown status|Recruiting||80||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 04:04:16.115841|2018-06-01 04:04:16.115841
NCT00313053|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2016-06-01|2006-04-07|2006-04-11|Estimate|||||||2016-06-01|2016-06-03|Estimate|September 2004||2004-09-30|November 2012|2012-11-30|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|||Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia|A Phase I Study of mAb 216 With Chemotherapy for the Treatment of Pediatric Patients With Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia|Terminated||Phase 1|4|Actual|Stanford University||1|||f||||||||||||||2018-06-01 04:04:16.197614|2018-06-01 04:04:16.197614
NCT00313040|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2011-06-08|2006-04-07|2006-04-11|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2004||2004-03-31|June 2011|2011-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Study to Promote Physical Activity Among Overweight Persons|Promoting Increased Physical Activity as the Main Outcome of Treatment for Overweight Persons: A Pilot Randomized Controlled Trial|Completed||Phase 1/Phase 2|30||Stanford University|||||f||||||||||||||2018-06-01 04:04:16.267335|2018-06-01 04:04:16.267335
NCT00313027|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2012-07-05|2006-04-10|2006-04-11|Estimate|||||||2012-07-05|2012-07-09|Estimate|November 2002||2002-11-30|July 2012|2012-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation|Cervical Nodal Metastasis in Squamous Cell Carcinoma of the Head and Neck - Novel MRI, FDG-PET, and Histopathologic Correlation|Completed||N/A|30|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:04:16.335088|2018-06-01 04:04:16.335088
NCT00313014|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|2010-07-28||2012-08-27|2006-04-10|2006-04-11|Estimate|2010-09-13|2010-09-29|Estimate||||2012-08-27|2012-09-03|Estimate|February 2004||2004-02-29|August 2012|2012-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain|A Multicenter, Randomized, Double-blind, Active Comparator Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-release Versus BTDS 5 in Subjects With Moderate to Severe Low Back Pain|Terminated||Phase 3|660|Actual|Purdue Pharma LP|BUP3015 was terminated early due to administrative reasons unrelated to efficacy or safety.|3||Terminated early due to administrative reasons unrelated to efficacy or safety.|f||||f||||||||||2018-06-01 04:04:16.428964|2018-06-01 04:04:16.428964
NCT00313001|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-08|||2017-01-05|2006-04-08|2006-04-11|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.|Effects of NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea|Completed||Phase 3|373|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:04:17.204526|2018-06-01 04:04:17.204526
NCT00312988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-04-10|2006-04-10|2006-04-11|Estimate|||||||2006-04-10|2006-04-11|Estimate|January 2000||2000-01-31|September 2005|2005-09-30|December 2009||2009-12-31|||||Interventional|||Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy|Topotecan-Monotherapy Vs. Topotecan + Etoposide Vs. Topotecan + Gemcitabine in Therapy in Patients With Recurrent Ovarian Cancer|Completed||Phase 3|450||North Eastern Germany Society of Gynaecologic Oncology|||||f||||||||||||||2018-06-01 04:04:17.273173|2018-06-01 04:04:17.273173
NCT00312975|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07||2009-04-20|2012-06-05|2006-04-07|2006-04-11|Estimate||||2009-09-24|2009-09-28|Estimate|2012-06-05|2012-06-07|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|February 2010|Actual|2010-02-28|April 2008|Actual|2008-04-30||Interventional|||Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)|Phase 2 Randomized, Non-Comparative Study Of CP-675,206 Or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy In Patients With Stage IIIB (With Effusion) Or Stage IV Non-Small Cell Lung Cancer That Has Responded Or Remained Stable|Completed||Phase 2|90|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:04:17.338341|2018-06-01 04:04:17.338341
NCT00312962|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2014-03-07|2006-04-07|2006-04-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|April 2004||2004-04-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|CRIS||Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia|Neuroscience-Guided Remediation of Cognitive Deficits in Schizophrenia|Completed||Phase 1/Phase 2|80|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:04:17.427844|2018-06-01 04:04:17.427844
NCT00312949|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2015-04-15|2006-04-07|2006-04-11|Estimate|||||||2015-04-15|2015-04-16|Estimate|April 2006||2006-04-30|April 2015|2015-04-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Effectiveness of an Interactive Educational Website for Improving the Quality of Mental Health Care for People With Schizophrenia|Consumer Internet Education About Mental Health Quality|Completed||N/A|56|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 04:04:17.492449|2018-06-01 04:04:17.492449
NCT00312923|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|2013-05-23||2013-07-19|2006-04-07|2006-04-11|Estimate|2013-07-12|2013-07-15|Estimate||||2013-07-19|2013-07-26|Estimate|September 2005||2005-09-30|July 2013|2013-07-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional||54 eligible participants were randomized to the study arms. 39 participants completed the study. An intent-to-treat analysis was performed.|Preliminary Study of Safety and Efficacy of Policosanol|Preliminary Study of Safety and Efficacy of Policosanol|Completed||Phase 2|54|Actual|Rush University Medical Center|It is possible that other constituents underlie policosanol’s lipid-lowering activity. One study found that triacontanol inhibited HMG-CoA reductase in rat liver cells. Triacontanol was not detected in either lot of policosanol used in this study.|2|||f||||t||||||||||2018-06-01 04:04:17.750197|2018-06-01 04:04:17.750197
NCT00312910|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-09|||2008-05-21|2006-04-09|2006-04-11|Estimate|||||||2008-05-21|2008-05-22|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Probiotics for the Prevention of Major Complications of Cirrhosis|Probiotics for the Prevention of Major Complications of Cirrhosis|Completed||N/A|50|Anticipated|Meir Medical Center|||||f||||||||||||||2018-06-01 04:04:17.985188|2018-06-01 04:04:17.985188
NCT00312897|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|2017-04-17||2018-03-20|2006-04-07|2006-04-11|Estimate|2018-01-18|2018-02-15|Actual||||2018-03-20|2018-04-19|Actual|December 2005||2005-12-31|March 2018|2018-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||3 participants in Omega-3 Fatty Acids arm were discontinued prior to receiving treatment and were not included in the data results|Omega-3 Fatty Acids in Adolescent Depression|Omega-3 Fatty Acids in Adolescent Depression|Completed||Phase 2|57|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||||2018-06-01 04:04:18.067509|2018-06-01 04:04:18.067509
NCT00312884|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|2015-10-27||2016-04-26|2006-04-07|2006-04-11|Estimate|2016-04-26|2016-05-30|Estimate||||2016-04-26|2016-05-30|Estimate|May 2006||2006-05-31|November 2007|2007-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Home-HF: Evaluation of Patients With Heart Failure Using Home Telemonitoring|Home-HF: a Randomised Controlled Evaluation of Home Telemonitoring of Patients With Heart Failure Recently Discharged From Hospital.|Completed||Phase 3|182|Actual|Imperial College London||2|||f||||||||||||||2018-06-01 04:04:18.270532|2018-06-01 04:04:18.270532
NCT00312871|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2011-05-16|2006-04-07|2006-04-11|Estimate|||||||2011-05-16|2011-05-17|Estimate|February 2001||2001-02-28|April 2010|2010-04-30|June 2003|Actual|2003-06-30|||||Interventional|||Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency|Effect of Early Correction of Anemia on the Progression of Chronic Renal Insufficiency (ECAP)|Terminated||Phase 4|217|Actual|Janssen Cilag S.A.S.||||"Study was stopped due to restrictions in labeling for the subcutaneous route of administration~   of EPREX."|f||||f||||||||||2018-06-01 04:04:18.50791|2018-06-01 04:04:18.50791
NCT00312858|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|2009-03-24||2017-03-16|2006-04-07|2006-04-11|Estimate|2009-06-12|2009-08-03|Estimate||||2017-03-16|2017-04-13|Actual|April 2006||2006-04-30|March 2017|2017-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067)|An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age|Completed||Phase 4|653|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:04:18.690586|2018-06-01 04:04:18.690586
NCT00312845|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|2011-06-29||2012-06-19|2006-04-07|2006-04-11|Estimate|2011-06-29|2011-07-26|Estimate||||2012-06-19|2012-06-25|Estimate|March 2006||2006-03-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-cell Non-Hodgkin's Lymphoma|Completed||Phase 3|676|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||||||||||||2018-06-01 04:04:19.648297|2018-06-01 04:04:19.648297
NCT00312832|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2006-10-23|2006-04-10|2006-04-11|Estimate|||||||2006-10-23|2006-10-24|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|February 2005||2005-02-28|||||Interventional|||Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy|A Randomized Open Label Study Comparing the Impact of Reducing the Dose of Stavudine Versus Switching to Tenofovir on Plasma Lipids, Body Composition and Mitochondrial Function in HIV-Infected Patients Receiving Antiretroviral Therapy|Completed||N/A|60||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 04:04:20.808294|2018-06-01 04:04:20.808294
NCT00312819|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2010-08-30|2006-04-10|2006-04-11|Estimate|||||||2010-08-30|2010-08-31|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer|Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine|Completed||Phase 2/Phase 3|60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:04:20.859724|2018-06-01 04:04:20.859724
NCT00312806|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2012-05-04|2006-04-10|2006-04-11|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2006||2006-05-31|December 2008|2008-12-31|July 2007|Actual|2007-07-31|March 2007|Actual|2007-03-31||Interventional|||Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)|Real Life: Treatment Response in Patients With Symptoms Due to Gastroesophageal Reflux Disease Either With or Without Esophagitis Treated With Pantoprazole Sodium 40 mg o.d. Over 8 Weeks|Completed||Phase 3|2000|Anticipated|Takeda|||||f||||||||||||||2018-06-01 04:04:20.936845|2018-06-01 04:04:20.936845
NCT00312793|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-10|||2009-06-21|2006-04-10|2006-04-11|Estimate|||||||2009-06-21|2009-06-23|Estimate||||June 2009|2009-06-30||||||||Interventional|||The Efficacy and Safety of Electronic Stimulation in Patients Who Underwent Reconstruction of the Anterior Cruciate Ligament|Phase 2 Study to Evaluate the Efficacy and Safety of Electronic Stimulation of the Quadriceps Muscle in the Thigh by the MyoSpare Device, in Patients Who Underwent Reconstruction of the Anterior Cruciate Ligament (ACL)|Terminated||Phase 1/Phase 2|60|Anticipated|Hadassah Medical Organization||||the study stopped becaust the sponsor did not wish to proceede with the study|f||||||||||||||2018-06-01 04:04:22.272704|2018-06-01 04:04:22.272704
NCT00312780|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2010-02-22|2006-04-07|2006-04-11|Estimate|||||||2010-02-22|2010-02-23|Estimate|March 2006||2006-03-31|February 2010|2010-02-28|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy|A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects With Albuminuria Due to Diabetic Nephropathy|Completed||Phase 2|125|Actual|Symphony Evolution, Inc.||2|||f||||t||||||||||2018-06-01 04:04:22.339641|2018-06-01 04:04:22.339641
NCT00312767|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2014-02-04|2006-04-07|2006-04-11|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2006||2006-04-30|February 2014|2014-02-28||||||||Interventional|||A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.|A Multicenter, Open-Label, Cross-Over Trial to Evaluate the Pharmacokinetics of Fabrazyme During Simultaneous Fabrazyme Infusion and Chronic Hemodialysis in Patients With Fabry Disease.|Withdrawn||Phase 4|0|Actual|Sanofi|||||||||||||||||||2018-06-01 04:04:22.577158|2018-06-01 04:04:22.577158
NCT00312754|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2016-09-16|2006-04-10|2006-04-11|Estimate|||||||2016-09-16|2016-09-19|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome|A Phase IV, One-arm, Open-label, Multicenter Study Evaluating Effect of Treatment Change to Atazanavir/Ritonavir on Brachial Endothelial Function of HIV Infected Patient Receiving Function in HIV Infected Patient Receiving Potent Antiretroviral Combination Therapy|Terminated||Phase 4|70||Bristol-Myers Squibb||||insufficient enrollment|f||||||||||||||2018-06-01 04:04:22.649274|2018-06-01 04:04:22.649274
NCT00312741|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2009-02-26|2006-04-07|2006-04-11|Estimate|||||||2009-02-26|2009-02-27|Estimate|April 2006||2006-04-30|February 2009|2009-02-28|May 2008|Anticipated|2008-05-31|||||Observational|||Usefulness of Microbiological Tests in Community-Acquired Pneumonia|Prospective Study on Benefits Derived From Microbiological Tests in Community-Acquired Pneumonia|Unknown status|Recruiting||250|Anticipated|Hospital Arnau de Vilanova|||||f||||f||||||||||2018-06-01 04:04:22.726078|2018-06-01 04:04:22.726078
NCT00312728|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|2011-03-18||2011-08-03|2006-04-07|2006-04-11|Estimate|2011-05-25|2011-06-22|Estimate||||2011-08-03|2011-08-08|Estimate|March 2006||2006-03-31|August 2011|2011-08-31||||June 2009|Actual|2009-06-30||Interventional|||A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)|A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 2|115|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 04:04:22.810054|2018-06-01 04:04:22.810054
NCT00312715|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-08|||2017-10-05|2006-04-08|2006-04-10|Estimate|||||||2017-10-05|2017-10-06|Actual|April 3, 2006||2006-04-03|July 8, 2014|2014-07-08|July 8, 2014||2014-07-08|||||Observational|||Thyroid and Fat Tissue Metabolism|Thyroid Hormone-Induced Lipolysis: An In Vivo Microdialysis Study|Completed|||41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:04:23.103497|2018-06-01 04:04:23.103497
NCT00312702|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2012-08-09|2006-04-06|2006-04-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|April 2006||2006-04-30|August 2012|2012-08-31|April 2007|Actual|2007-04-30|October 2006|Actual|2006-10-31||Interventional|||Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America|A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS02A Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States|Completed||Phase 1/Phase 2|36|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-06-01 04:04:23.175389|2018-06-01 04:04:23.175389
NCT00312689|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2007-04-11|2006-04-07|2006-04-10|Estimate|||||||2007-04-11|2007-04-12|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|April 2007|Anticipated|2007-04-30|||||Observational|||Microbiological Examination of Children Operated for Congenital Lacrimal Stenosis|Microbiological Examination of Children Operated for Congenital Lacrimal Stenosis|Unknown status|Active, not recruiting||120||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:04:23.317239|2018-06-01 04:04:23.317239
NCT00312676|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2006-04-06|2006-04-06|2006-04-10|Estimate|||||||2006-04-06|2006-04-10|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|October 2006||2006-10-31|||||Interventional|||Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote|Conversion From Multiple-Daily Dose Enteric-Coated Depakote to Once-Daily Depakote ER in Elderly Outpatients With Epilepsy or Behavioral Disturbances:|Unknown status|Recruiting|Phase 4|20||Veterans Affairs Medical Center, Miami|||||f||||||||||||||2018-06-01 04:04:23.36492|2018-06-01 04:04:23.36492
NCT00312663|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2012-08-09|2006-04-06|2006-04-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|April 2006||2006-04-30|August 2012|2012-08-31|April 2007|Actual|2007-04-30|October 2006|Actual|2006-10-31||Interventional|||Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America|A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS01B Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States|Completed||Phase 1/Phase 2|36|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-06-01 04:04:23.520742|2018-06-01 04:04:23.520742
NCT00312650|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2015-01-09|2006-04-07|2006-04-10|Estimate|||||||2015-01-09|2015-01-12|Estimate|April 2006||2006-04-30|January 2015|2015-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Doxil and Gemcitabine in Recurrent Ovarian Cancer|A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer|Terminated||Phase 2|24||Women and Infants Hospital of Rhode Island|||||f||||||||||||||2018-06-01 04:04:23.625728|2018-06-01 04:04:23.625728
NCT00312637|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2012-04-27|2006-04-06|2006-04-10|Estimate|||||||2012-04-27|2012-05-01|Estimate|March 2005||2005-03-31|April 2012|2012-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease|High-Resolution Axillary MRI With Magnetic Resonance Spectroscopy as a Non-Invasive Test for Determining Pathologic Lymph Node Status in Patients With Invasive Breast Cancer|Withdrawn||N/A|0|Actual|UNC Lineberger Comprehensive Cancer Center||||Lack of funding.|f||||t||||||||||2018-06-01 04:04:23.697789|2018-06-01 04:04:23.697789
NCT00312624|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2011-06-09|2006-04-07|2006-04-10|Estimate|||||||2011-06-09|2011-06-10|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|December 2008|Actual|2008-12-31|||||Observational|||Morphological Predictors of Sudden Cardiac Death in Patients With Known Cardiomyopathies|Morphological Predictors of Sudden Cardiac Death in Patients With Known Cardiomyopathies|Completed|||50|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:04:23.7636|2018-06-01 04:04:23.7636
NCT00312611|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-03-28|2006-04-06|2006-04-10|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2004||2004-08-31|March 2017|2017-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Screened Health Assessment & Pacer Evaluation|Screened Health Assessment & Pacer Evaluation|Completed||N/A|200||University of Pennsylvania|||||||||||||||||No||2018-06-01 04:04:23.832219|2018-06-01 04:04:23.832219
NCT00312598|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2014-01-10|2006-04-06|2006-04-10|Estimate|||||||2014-01-10|2014-01-13|Estimate|August 2005||2005-08-31|January 2014|2014-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine|Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole|Completed|||30|Actual|University of North Carolina, Chapel Hill|||1||f||||t||||||Samples Without DNA|"~     serum collected at baseline and end of study to be assayed in the future for related~     metabolic tests which are not specified at this time.~   "|||2018-06-01 04:04:23.908444|2018-06-01 04:04:23.908444
NCT00312572|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|2010-07-29||2012-08-27|2006-04-07|2006-04-10|Estimate|2010-09-01|2010-09-23|Estimate||||2012-08-27|2012-09-03|Estimate|June 2003||2003-06-30|August 2012|2012-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain|A Randomized, Double-Blind Study Evaluating the Dose Conversion From Vicodin® to Buprenorphine Transdermal System (BTDS) in Subjects With Osteoarthritis (OA) Pain|Completed||Phase 3|204|Actual|Purdue Pharma LP||2|||f||||||||||||||2018-06-01 04:04:24.130988|2018-06-01 04:04:24.130988
NCT00312559|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2007-08-17|2006-04-06|2006-04-10|Estimate|||||||2007-08-17|2007-08-20|Estimate|February 2006||2006-02-28|August 2007|2007-08-31|March 2007|Actual|2007-03-31|||||Interventional|||The Therapeutics Effects of Yoga in Individuals With Parkinson's Disease|The Therapeutic Effects of Yoga in Individuals With Parkinson's Disease|Completed||N/A|18||University of Kansas Medical Center|||||f||||||||||||||2018-06-01 04:04:24.447112|2018-06-01 04:04:24.447112
NCT00312546|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2012-05-11|2006-04-06|2006-04-10|Estimate|||||||2012-05-11|2012-05-14|Estimate|June 2006||2006-06-30|May 2012|2012-05-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Study of Valproic Acid to Treat HIV Infected Adults|Inhibiting Histone Deacetylase: Toward Eradication of HIV|Terminated||Phase 1|14|Actual|University of North Carolina, Chapel Hill||4|||f||||||||||||||2018-06-01 04:04:24.507582|2018-06-01 04:04:24.507582
NCT00312533|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2008-08-22|2006-04-06|2006-04-10|Estimate|||||||2008-08-22|2008-08-25|Estimate|April 2006||2006-04-30|August 2008|2008-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Outcome Following Hylan F- 20 (Synvisc) + Corticosteroid Injections for the Treatment of Osteoarthritis of the Knee|Outcome Following Hylan F- 20 (Synvisc) + Corticosteroid Injections for the Treatment of Osteoarthritis of the Knee|Completed|||60|Anticipated|Steadman Hawkins Research Foundation|||||f||||||||||||||2018-06-01 04:04:24.59793|2018-06-01 04:04:24.59793
NCT00312520|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2018-04-17|2006-04-06|2006-04-10|Estimate|||||||2018-04-17|2018-04-19|Actual|July 2002|Actual|2002-07-31|April 2018|2018-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy|The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial|Completed||Phase 3|20||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:04:24.66765|2018-06-01 04:04:24.66765
NCT00312507|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2006-10-16|2006-04-06|2006-04-10|Estimate|||||||2006-10-16|2006-10-17|Estimate|April 2006||2006-04-30|October 2006|2006-10-31||||||||Interventional|||Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration|Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration|Unknown status|Recruiting|Phase 3|20||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:04:24.738503|2018-06-01 04:04:24.738503
NCT00312494|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|2009-12-17||2010-02-02|2006-04-06|2006-04-10|Estimate|2009-12-17|2010-01-22|Estimate||||2010-02-02|2010-02-18|Estimate|April 2006||2006-04-30|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects|A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex|Completed||Phase 3|680|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 04:04:24.853507|2018-06-01 04:04:24.853507
NCT00312481|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2007-12-12|2006-04-06|2006-04-10|Estimate|||||||2007-12-12|2007-12-17|Estimate|July 2005||2005-07-31|December 2007|2007-12-31|May 2006|Actual|2006-05-31|||||Interventional|||MOVIPREP® Versus PICOLAX® Pilot Study|A Randomised, Single-Centre, Parallel-Group, Pilot Study to Assess the Efficacy, Safety and Patient Acceptability of a New 2-Litre Bowel Preparation Agent (MOVIPREP®) Compared With a Standard Bowel Preparation Agent (PICOLAX®)|Completed||Phase 2|65|Actual|Norgine||2|||f||||f||||||||||2018-06-01 04:04:25.70156|2018-06-01 04:04:25.70156
NCT00312468|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2006-10-18|2006-04-06|2006-04-10|Estimate|||||||2006-10-18|2006-10-19|Estimate|October 2006||2006-10-31|October 2006|2006-10-31||||||||Observational|||Examining the Link Between Heart Disease and HIV Infection in Women|Mechanisms of Atherosclerosis and CVD in HIV+ Women|Unknown status|Active, not recruiting||1000||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:04:25.790182|2018-06-01 04:04:25.790182
NCT00312455|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2017-01-11|2006-04-06|2006-04-10|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2004||2004-07-31|August 2008|2008-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Effects of Fatty Acid Supplementation on Substance Dependent Individuals|Cholesterol and Fatty Acids in Cocaine Addiction Relapse|Completed||Phase 2|||National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:04:25.843822|2018-06-01 04:04:25.843822
NCT00312442|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2010-05-31|2006-04-07|2006-04-10|Estimate|||||||2010-05-31|2010-06-02|Estimate|May 2006||2006-05-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|July 2008|Actual|2008-07-31||Interventional|||Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy|Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy|Terminated||Phase 2/Phase 3|16|Actual|STEBA France||1||"STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11~   make it safer and better candidate for therapeutic applications."|f||||t||||||||||2018-06-01 04:04:25.905293|2018-06-01 04:04:25.905293
NCT00312429|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2012-04-02|2006-04-06|2006-04-10|Estimate|||||||2012-04-02|2012-04-03|Estimate|January 2002||2002-01-31|April 2012|2012-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer|Cord Blood Transplantation in Adult Recipients|Completed||Phase 1/Phase 2|34|Actual|Duke University|||||f||||f||||||||||2018-06-01 04:04:25.970196|2018-06-01 04:04:25.970196
NCT00312416|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2007-02-09|2006-04-07|2006-04-10|Estimate|||||||2007-02-09|2007-02-12|Estimate|February 2004||2004-02-29|February 2007|2007-02-28|December 2004||2004-12-31|||||Interventional|||Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise|Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise|Completed||Phase 4|18||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:04:26.029944|2018-06-01 04:04:26.029944
NCT00312403|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2010-01-14|2006-04-06|2006-04-10|Estimate|||||||2010-01-14|2010-01-15|Estimate|November 2005||2005-11-30|January 2010|2010-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?|Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?|Completed||N/A|400|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 04:04:26.10621|2018-06-01 04:04:26.10621
NCT00312390|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2014-12-05|2006-04-06|2006-04-10|Estimate|||||||2014-12-05|2014-12-08|Estimate|July 2003||2003-07-31|November 2014|2014-11-30||||||||Interventional|||Amblyopia and Neurovascular Coupling in the Retina of Humans|Amblyopia and Neurovascular Coupling in the Retina of Humans|Withdrawn||N/A|0|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-06-01 04:04:26.17229|2018-06-01 04:04:26.17229
NCT00312377|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|2011-04-27||2016-08-24|2006-04-06|2006-04-10|Estimate|2011-04-27|2011-05-24|Estimate||||2016-08-24|2016-09-30|Estimate|May 2006||2006-05-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|August 2008|Actual|2008-08-31||Interventional|ZODIAC||ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer|A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination With ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC|Completed||Phase 3|1690|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:04:26.326102|2018-06-01 04:04:26.326102
NCT00312364|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06||2008-12-04|2012-05-24|2006-04-06|2006-04-10|Estimate||||2009-11-05|2009-11-09|Estimate|2012-05-24|2012-06-01|Estimate|December 2005||2005-12-31|May 2012|2012-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers||Completed||Phase 2|322|Actual|Pfizer|||||||||||||||||||2018-06-01 04:04:27.715018|2018-06-01 04:04:27.715018
NCT00312351|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2007-01-12|2006-04-07|2006-04-10|Estimate|||||||2007-01-12|2007-01-15|Estimate|April 2006||2006-04-30|January 2007|2007-01-31|November 2006||2006-11-30|||||Interventional|||A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)|An Exploratory Randomized, Double-Masked, Multi-Center Comparative Trial, in Parallel Groups, to Explore the Safety and Efficacy of Three Different Doses of Intravitreous Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 102 Weeks, in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (AMD)|Terminated||Phase 4|262||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 04:04:27.845958|2018-06-01 04:04:27.845958
NCT00312338|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|2009-07-15||2012-10-31|2006-04-04|2006-04-10|Estimate|2010-01-13|2010-02-02|Estimate||||2012-10-31|2012-11-02|Estimate|June 2006||2006-06-30|February 2010|2010-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora|Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora|Completed||Phase 4|137|Actual|Alcon Research|Limited source documents.|2|||f||||||||||||||2018-06-01 04:04:27.906|2018-06-01 04:04:27.906
NCT00312325|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2006-04-07|2006-04-07|2006-04-10|Estimate|||||||2006-04-07|2006-04-10|Estimate|July 2005||2005-07-31|March 2006|2006-03-31|August 2005||2005-08-31|||||Interventional|||Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans|Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans|Completed||Phase 4|24||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:04:28.121871|2018-06-01 04:04:28.121871
NCT00312312|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2007-06-11|2006-04-05|2006-04-10|Estimate|||||||2007-06-11|2007-06-12|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Allergy Towards Grass and Bronchial Inflammation - Related to Immunotherapy and Exhaled Nitrogen Oxide|Does Specific Immunotherapy Possess Immunomodulative Effects at the Bronchial Mucosa Level Among Adults With Atopic Diseases?|Unknown status|Recruiting|N/A|40|Anticipated|Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:04:28.188769|2018-06-01 04:04:28.188769
NCT00312299|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-07|||2012-07-11|2006-04-07|2006-04-10|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|July 2011|Actual|2011-07-31||Interventional|||Posterior Capsule Opacification Study|Posterior Capsule Opacification After Implantation of Square Edge PMMA, Round Edge PMMA and Acrysof Intraocular Lenses: Randomized Controlled Study|Completed||Phase 4|100|Actual|Aurolab||4|||f||||f||||||||||2018-06-01 04:04:28.374013|2018-06-01 04:04:28.374013
NCT00312286|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06||2016-09-12|2016-09-12|2006-04-06|2006-04-10|Estimate||||2016-09-12|2016-09-23|Estimate|2016-09-12|2016-09-23|Estimate|April 2006||2006-04-30|September 2016|2016-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.|A Randomized, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection|Terminated||Phase 2|538|Actual|Takeda||11||Lack of efficacy|f||||f||||||||||2018-06-01 04:04:28.463613|2018-06-01 04:04:28.463613
NCT00312273|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2006-07-26|2006-04-05|2006-04-07|Estimate|||||||2006-07-26|2006-07-27|Estimate|January 2001||2001-01-31|September 2003|2003-09-30|July 2004||2004-07-31|||||Interventional|||Aminophylline in Bradyasystolic Cardiac Arrest|Aminophylline in Bradyasystolic Cardiac Arrest: A Randomized Placebo-Controlled Trial|Completed||Phase 2|966||Vancouver General Hospital|||||f||||||||||||||2018-06-01 04:04:28.66435|2018-06-01 04:04:28.66435
NCT00312260|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2016-04-25|2006-04-06|2006-04-07|Estimate|||||||2016-04-25|2016-04-27|Estimate|April 2006||2006-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|May 2010|Actual|2010-05-31||Interventional|||Comparing Gabapentin and Amitriptyline for the Treatment of Neuropathic Pain in Children and Adolescents|Randomized Controlled Trial Comparing Gabapentin and Amitriptyline for the Treatment of Neuropathic Pain in Children and Adolescents|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 04:04:28.736704|2018-06-01 04:04:28.736704
NCT00312247|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2015-05-18|2006-04-05|2006-04-07|Estimate|||||||2015-05-18|2015-05-19|Estimate|April 2006||2006-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|||Biomechanical Analysis of Gait in Individuals With Duchenne Muscular Dystrophy|Biomechanical Analysis of Gait in Individuals With Duchenne Muscular Dystrophy|Completed|||85|Actual|Shriners Hospitals for Children|||2||f||||f||||||||||2018-06-01 04:04:28.808228|2018-06-01 04:04:28.808228
NCT00312234|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2013-12-17|2006-04-06|2006-04-07|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2005||2005-08-31|December 2013|2013-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Qigong vs. Aerobic Exercise in the Treatment of Childhood Chronic Musculoskeletal Pain|Feasibility and Impact of Qigong as Compared to Aerobic Exercise in the Treatment of Childhood Chronic Musculoskeletal Pain: A Pilot Randomized Controlled Trial.|Completed||Phase 2|30||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:04:28.888358|2018-06-01 04:04:28.888358
NCT00312221|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|2010-07-15||2012-09-05|2006-04-06|2006-04-07|Estimate|2010-09-14|2010-09-15|Estimate||||2012-09-05|2012-09-10|Estimate|April 2004||2004-04-30|September 2012|2012-09-30|August 2005|Actual|2005-08-31|July 2005|Actual|2005-07-31||Interventional|||Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain|Randomized, Double-blind, Multicenter Study to Determine the Efficacy and Safety of BTDS 20 or Oxycodone Immediate-Release (OxyIR) Versus BTDS 5 in Subjects With Moderate to Severe Osteoarthritis (OA) Pain|Terminated||Phase 3|418|Actual|Purdue Pharma LP|This study was terminated early for administrative reasons not related to safety or efficacy. Low enrollment at termination led to reduced power.|3||terminated early for administrative reasons unrelated to safety or efficacy|f||||f||||||||||2018-06-01 04:04:28.970232|2018-06-01 04:04:28.970232
NCT00306059|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2014-12-04|2006-03-21|2006-03-22|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Early Goal Directed Therapy for Acute Kidney Injury|Early Goal Directed Therapy for Acute Kidney Injury|Unknown status|Recruiting|Phase 2|340|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:06:18.598395|2018-06-01 04:06:18.598395
NCT00312208|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|2009-10-29||2013-12-04|2006-04-05|2006-04-07|Estimate|2010-02-15|2010-02-17|Estimate||||2013-12-04|2013-12-30|Estimate|November 2001||2001-11-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2008|Actual|2008-10-31||Interventional|||Docetaxel in Breast Cancer|A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes|Completed||Phase 3|3299|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:04:29.725377|2018-06-01 04:04:29.725377
NCT00312195|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|2010-07-29||2012-09-05|2006-04-06|2006-04-07|Estimate|2010-09-28|2010-10-15|Estimate||||2012-09-05|2012-09-10|Estimate|March 2001||2001-03-31|September 2012|2012-09-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain|An Open-label Run-in, Followed by a Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Show the Effectiveness of Buprenorphine Transdermal System in Management of Patients With Chronic Nonmalignant Pain Syndromes|Completed||Phase 3|267|Actual|Purdue Pharma LP||2|||f||||||||||||||2018-06-01 04:04:31.061623|2018-06-01 04:04:31.061623
NCT00312182|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2009-04-09|2006-04-05|2006-04-07|Estimate|||||||2009-04-09|2009-04-10|Estimate|March 2006||2006-03-31|April 2009|2009-04-30|June 2006|Actual|2006-06-30|||||Interventional|||Thorough QT Study of Nelfinavir|Evaluation Of The Effect Of Nelfinavir On QT Intervals At Steady-State After Twice-Daily Administration Of Nelfinavir Tablets To Healthy Volunteers|Completed||Phase 4|68|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:04:31.425011|2018-06-01 04:04:31.425011
NCT00312169|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2008-05-20|2006-04-05|2006-04-07|Estimate|||||||2008-05-20|2008-05-22|Estimate|April 2006||2006-04-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)|Evolution of L74V or K65R Mutations in VIremic Subjects on TDF or ABC (EVITA)|Completed|||20|Anticipated|Orlando Immunology Center|||||f||||||||||||||2018-06-01 04:04:31.486416|2018-06-01 04:04:31.486416
NCT00312156|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2017-01-26|2006-04-05|2006-04-07|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2002||2002-08-31|January 2017|2017-01-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes|Completed||Phase 3|347|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:04:31.557812|2018-06-01 04:04:31.557812
NCT00312143|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2011-02-01|2006-04-05|2006-04-07|Estimate|||||||2011-02-01|2011-02-02|Estimate|February 2004||2004-02-29|February 2011|2011-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients|A Prospective, Open Label, Multicenter Study to Assess the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients|Completed||Phase 4|35|Actual|Novartis|||||f||||||||||||||2018-06-01 04:04:31.653831|2018-06-01 04:04:31.653831
NCT00312130|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-06|||2016-11-16|2006-04-06|2006-04-07|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2005||2005-04-30|November 2016|2016-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes|A Single-blind, Single-treatment Study to Evaluate the Effects of Vildagliptin on Response to an Intravenous Glucose Load in Pre-diabetic Subjects With Impaired Fasting Glucose|Completed||Phase 3|20||Novartis|||||f||||||||||||||2018-06-01 04:04:31.697402|2018-06-01 04:04:31.697402
NCT00312117|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2015-03-10|2006-04-05|2006-04-07|Estimate|||||||2015-03-10|2015-03-11|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|February 2006|Actual|2006-02-28|||||Interventional|||Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate|A Randomized Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate|Completed||Phase 3|300||Kaiser Permanente|||||f||||t||||||||||2018-06-01 04:04:31.844484|2018-06-01 04:04:31.844484
NCT00312104|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2017-01-26|2006-04-05|2006-04-07|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2002||2002-04-30|January 2017|2017-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes.|Completed||Phase 3|325|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:04:31.922948|2018-06-01 04:04:31.922948
NCT00312091|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05||2009-09-01|2012-09-10|2006-04-05|2006-04-07|Estimate||||2009-08-24|2009-08-26|Estimate|2012-09-10|2012-09-12|Estimate|December 2006||2006-12-31|September 2012|2012-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children|A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months and Older to Less Than 13 Years of Age in Thailand|Completed||Phase 1/Phase 2|44|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:04:32.045751|2018-06-01 04:04:32.045751
NCT00312078|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2007-10-31|2006-04-05|2006-04-07|Estimate|||||||2007-10-31|2007-11-01|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Effect of Yogurt on Minimal Hepatic Encephalopathy|Effect of Yogurt Supplementation on Psychometric Test Performance in Cirrhotic Patients With Minimal Hepatic Encephalopathy. A Prospective Pilot Trial.|Completed||N/A|30|Anticipated|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 04:04:32.13264|2018-06-01 04:04:32.13264
NCT00312065|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2015-04-06|2006-04-06|2006-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2003||2003-10-31|April 2015|2015-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study of the Need for Temperature Probe Covers for Newborn Babies on Radiant Warmers|Servocontrolled Radiant Warmers and the Role of Thermistor Probe Reflective Shields in Neonates|Completed||Phase 1|11|Actual|Maimonides Medical Center||1|||f||||f||||||||||2018-06-01 04:04:32.21603|2018-06-01 04:04:32.21603
NCT00312052|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05||2013-05-21|2016-12-01|2006-04-05|2006-04-07|Estimate||||2013-05-21|2013-05-29|Estimate|2016-12-01|2016-12-05|Estimate|September 2007||2007-09-30|November 2016|2016-11-30|August 2009|Actual|2009-08-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease|Completed||Phase 2|720|Actual|Eisai Inc.||4|||f||||||||||||||2018-06-01 04:04:32.362464|2018-06-01 04:04:32.362464
NCT00311857|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2006-09-07|2006-04-05|2006-04-06|Estimate|||||||2006-09-07|2006-09-08|Estimate|February 2006||2006-02-28|September 2006|2006-09-30||||||||Interventional|||Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)|Treatment of Primary Glioblastoma Multiforme With Cetuximab, Radiotherapy and Temozolomide (GERT) – Phase I/II Trial|Unknown status|Recruiting|Phase 1/Phase 2|46||Heidelberg University|||||f||||||||||||||2018-06-01 04:04:33.926837|2018-06-01 04:04:33.926837
NCT00312039|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2014-01-20|2006-04-06|2006-04-07|Estimate|||||||2014-01-20|2014-01-22|Estimate|March 2006||2006-03-31|January 2014|2014-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|Resistance||Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation|A 14 Day Randomized, Double Blind, Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation|Completed||Phase 1/Phase 2|20|Anticipated|Achillion Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:04:32.432753|2018-06-01 04:04:32.432753
NCT00312026|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2017-02-13|2006-04-05|2006-04-07|Estimate|||||||2017-02-13|2017-02-15|Actual|March 30, 2006||2006-03-30|February 2017|2017-02-28|November 28, 2006|Actual|2006-11-28|November 28, 2006|Actual|2006-11-28||Interventional|||A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet|A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 1.0 mg/kg Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet|Completed||Phase 4|75||Genentech, Inc.|||||f||||||||||||||2018-06-01 04:04:32.513507|2018-06-01 04:04:32.513507
NCT00312013|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2017-03-21|2006-04-05|2006-04-07|Estimate|||||||2017-03-21|2017-03-23|Actual|May 2006||2006-05-31|March 2017|2017-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer|A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate|Completed||Phase 3|503|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:04:32.579397|2018-06-01 04:04:32.579397
NCT00312000|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2008-09-05|2006-04-05|2006-04-07|Estimate|||||||2008-09-05|2008-09-08|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|December 2006|Actual|2006-12-31|February 2006|Actual|2006-02-28||Interventional|||Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma|A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma|Completed||Phase 3|820|Actual|Dutch Colorectal Cancer Group||2|||f||||t||||||||||2018-06-01 04:04:32.792399|2018-06-01 04:04:32.792399
NCT00311987|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2013-04-01|2006-04-05|2006-04-07|Estimate|||||||2013-04-01|2013-04-02|Estimate|April 2006||2006-04-30|April 2006|2006-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Study of 3,5-Diiodothyropropionic Acid (DITPA) in Hypercholesterolemic Patients|A Randomized, Double-Blind Placebo-Controlled Study of 3,5-diiodothyropropionic Acid (DITPA) in Combination With Standard Therapy to Attain NCEP ATP III Goal for LDL Cholesterol in Hypercholesterolemic Patients|Terminated||Phase 1/Phase 2|60|Anticipated|Johns Hopkins University||||Curtailment of funding by sponsor|||||f||||||||||2018-06-01 04:04:32.856333|2018-06-01 04:04:32.856333
NCT00311974|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2010-02-17|2006-04-05|2006-04-07|Estimate|||||||2010-02-17|2010-02-18|Estimate|April 2006||2006-04-30|February 2010|2010-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals|The Effect of Dihydralazine on Renal Tubular Function and Vasoactive Hormones in Healthy Individuals|Completed||Phase 4|16||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:04:32.920934|2018-06-01 04:04:32.920934
NCT00311961|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2009-08-25|2006-04-05|2006-04-07|Estimate|||||||2009-08-25|2009-08-26|Estimate|June 2001||2001-06-30|August 2009|2009-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Intravenous Versus Oral Administration of Prednisolone in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease|Completed||Phase 4|256||Isala|||||f||||||||||||||2018-06-01 04:04:32.982571|2018-06-01 04:04:32.982571
NCT00311948|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2012-09-27|2006-04-04|2006-04-06|Estimate|||||||2012-09-27|2012-09-28|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|QWIThelper||Telephone and Web-based Teen Tobacco Cessation in HMOs|Telephone and Web-based Teen Tobacco Cessation in HMOs|Completed||Phase 3|600|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 04:04:33.289259|2018-06-01 04:04:33.289259
NCT00311935|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2009-02-02|2006-04-05|2006-04-06|Estimate|||||||2009-02-02|2009-02-03|Estimate|April 2006||2006-04-30|February 2009|2009-02-28|May 2010|Anticipated|2010-05-31|||||Interventional|||Laparoscopic vs Open Hernia Mesh Repair for Inguinal Hernia|Randomized Controlled Trial of Laparoscopic vs. Open Mesh Inguinal Hernia Repair in Men Under the Age of 60|Unknown status|Recruiting|N/A|350|Anticipated|Waitemata District Health Board|||||f||||f||||||||||2018-06-01 04:04:33.409273|2018-06-01 04:04:33.409273
NCT00311922|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2008-02-15|2006-04-04|2006-04-06|Estimate|||||||2008-02-15|2008-02-18|Estimate|March 2006||2006-03-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Improving Care for Patients With Diabetes and Poor Numeracy Skills|Improving Care for Patients With Diabetes and Poor Numeracy Skills|Completed||N/A|106|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:04:33.482362|2018-06-01 04:04:33.482362
NCT00311909|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2006-04-05|2006-04-05|2006-04-06|Estimate|||||||2006-04-05|2006-04-06|Estimate|June 2005||2005-06-30|April 2006|2006-04-30||||||||Interventional|||Thalamic Deep Brain Stimulation for Tourette Syndrome|Thalamic Deep Brain Stimulation for Tourette Syndrome: A Prospective Clinical Trial|Completed||Phase 2|5||University Hospitals Cleveland Medical Center|||||||||||||||||||2018-06-01 04:04:33.551688|2018-06-01 04:04:33.551688
NCT00311896|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2012-06-07|2006-04-05|2006-04-06|Estimate|||||||2012-06-07|2012-06-08|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|February 2009|Actual|2009-02-28||Interventional|||Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)|Multicentric, Randomized, Placebo Controlled and Double-blind Study to Evaluate the Efficacy and Safety of Antithrombotic Prophylaxis With Bemiparin (3,500 UI/Day) in Cancer Patients With a Central Venous Catheter (CVC)(BECAT)|Terminated||Phase 3|402|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2||Sponsor stopped due to difficulties to recruit 402 patients required by protocol|f||||f||||||||||2018-06-01 04:04:33.615022|2018-06-01 04:04:33.615022
NCT00311883|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2008-01-25|2006-04-04|2006-04-06|Estimate|||||||2008-01-25|2008-01-30|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Hydroxychloroquine in Cystic Fibrosis|Phase 1 Study of Hydroxychloroquine in Cystic Fibrosis|Completed||Phase 1|20|Actual|Vanderbilt University|||||f||||t||||||||||2018-06-01 04:04:33.78208|2018-06-01 04:04:33.78208
NCT00311870|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2006-04-04|2006-04-04|2006-04-06|Estimate|||||||2006-04-04|2006-04-06|Estimate|March 1993||1993-03-31|April 1999|1999-04-30|April 1999||1999-04-30|||||Interventional|||Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy||Completed||Phase 4|52||Steno Diabetes Center|||||f||||||||||||||2018-06-01 04:04:33.862944|2018-06-01 04:04:33.862944
NCT00298051|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2017-05-24|2006-02-28|2006-03-01|Estimate|||||||2017-05-24|2017-05-30|Actual|October 2003||2003-10-31|May 2017|2017-05-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Umbilical Cord Clamping and Infant Iron Status|Umbilical Cord Clamping and Infant Iron Status|Completed||N/A|476|Actual|University of California, Davis||2|||f||||||||||||||2018-06-01 04:08:23.781527|2018-06-01 04:08:23.781527
NCT00311844|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2017-05-10|2006-04-04|2006-04-06|Estimate|||||||2017-05-10|2017-05-11|Actual|March 1, 2005|Actual|2005-03-01|May 2017|2017-05-31|May 28, 2005|Actual|2005-05-28|May 28, 2005|Actual|2005-05-28||Interventional|||A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)|A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms|Completed||Phase 4|41|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:04:34.000692|2018-06-01 04:04:34.000692
NCT00311831|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2018-04-16|2006-04-04|2006-04-06|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2006||2006-03-31|April 2018|2018-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||The Implementation of a Gastroenteritis Education Program|The Implementation of a Gastroenteritis Education Program|Completed||Phase 3|105|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 04:04:34.065503|2018-06-01 04:04:34.065503
NCT00311818|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2009-09-14|2006-04-05|2006-04-06|Estimate|||||||2009-09-14|2009-09-15|Estimate|June 2003||2003-06-30|September 2009|2009-09-30||||May 2005|Actual|2005-05-31||Interventional|||Insulin Glargine in Type 2 Diabetes Mellitus|44-week, Parallel, Open, Randomized, Multinational, Multi-center Clinical Trial to Compare Efficacy and Safety of the Combination Therapy of an Oral Anti-diabetic Drug Treatment With Either HOE901 Insulin Once Daily or Lispro Insulin Analogue at Mealtime in Type 2 Diabetes Mellitus Patients Poorly Controlled With Oral Anti-diabetic Drug Treatment.|Completed||Phase 4|||Sanofi|||||f||||||||||||||2018-06-01 04:04:34.146335|2018-06-01 04:04:34.146335
NCT00311805|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2015-03-30|2006-04-04|2006-04-06|Estimate|||||||2015-03-30|2015-03-31|Estimate|April 2006||2006-04-30|March 2015|2015-03-31||||December 2012|Actual|2012-12-31||Interventional|||Autologous CD34+ Stem Cell Injection for Severe Intermittent Claudication (Leg Pain)|Injection of Autologous CD34-Positive Stem Cells for Neovascularization and Symptom Relief in Patients With Severe Intermittent Claudication|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|Losordo, Douglas, M.D.||3|||f||||t||||||||||2018-06-01 04:04:34.207871|2018-06-01 04:04:34.207871
NCT00311792|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2007-08-29|2006-04-05|2006-04-06|Estimate|||||||2007-08-29|2007-08-30|Estimate|August 2006||2006-08-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Transfer of Skills From VR-Trainer to Operation Room|Transfer of Skills From LapSimGyn VR-Simulator to a Laparoscopic Salpingectomy|Completed||Phase 2/Phase 3|24|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 04:04:34.283707|2018-06-01 04:04:34.283707
NCT00311779|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2006-07-11|2006-04-04|2006-04-06|Estimate|||||||2006-07-11|2006-07-12|Estimate|March 2006||2006-03-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||A Dose Ranging Study of Different Strengths of Spinosad Topical Creme in Subjects With Pediculosis Capitis|Phase 2 Study of Efficacy and Safety of Different Strengths of Spinosad Topical Creme Rinse (0%, 0.5% or 1.0%) in Subjects 2 Years of Age or Older With Pediculosis Capitis - A Dose Ranging Study|Completed||Phase 2|120||ParaPRO LLC|||||||||||||||||||2018-06-01 04:04:34.369673|2018-06-01 04:04:34.369673
NCT00311766|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|2013-05-22||2014-04-25|2006-04-04|2006-04-06|Estimate|2013-06-07|2013-06-10|Estimate||||2014-04-25|2014-05-12|Estimate|February 2006||2006-02-28|April 2014|2014-04-30|November 2012|Actual|2012-11-30|July 2010|Actual|2010-07-31||Interventional|||A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa|A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa|Terminated||Phase 2|30|Actual|RegeneRx Biopharmaceuticals, Inc.|Early termination of the study leading to randomizing 30 of the 36 participants planned. This was due to the small pool of participants and therefore resulting in low availability of eligible participants.|2||Lack of patient availability and expiration of study drug|f||||f||||||||||2018-06-01 04:04:34.43234|2018-06-01 04:04:34.43234
NCT00311753|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2017-02-22|2006-04-04|2006-04-06|Estimate|||||||2017-02-22|2017-02-24|Actual|February 2006||2006-02-28|February 2017|2017-02-28||||December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients|An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients|Completed||Phase 3|342|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:04:34.678161|2018-06-01 04:04:34.678161
NCT00311740|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2017-02-21|2006-04-04|2006-04-06|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2006||2006-03-31|February 2017|2017-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)|A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients With Essential Hypertension (Factorial Study)|Completed||Phase 3|582|Actual|Novartis|||||f||||||||||||||2018-06-01 04:04:34.739105|2018-06-01 04:04:34.739105
NCT00311727|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2013-08-15|2006-04-05|2006-04-06|Estimate|||||||2013-08-15|2013-08-16|Estimate|October 2005||2005-10-31|May 2007|2007-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine|Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine|Completed||N/A|339|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 04:04:34.791293|2018-06-01 04:04:34.791293
NCT00311714|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2018-05-29|2006-04-05|2006-04-06|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2007||2007-04-30|May 2018|2018-05-31|December 2007||2007-12-31|||||Interventional|||Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958|CS-8958 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects|Completed||Phase 1|40||Vaxart|||||||||||||||||||2018-06-01 04:04:34.843736|2018-06-01 04:04:34.843736
NCT00311701|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2011-05-12|2006-04-05|2006-04-06|Estimate|||||||2011-05-12|2011-05-13|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|December 2006||2006-12-31|||||Observational|||Chart Review of Antivirals for Influenza in Infants|A Retrospective Chart Review to Assess the Safety of Oseltamivir (Tamiflu®) Compared to Alternate Antiviral Therapy (Amantadine or Rimantadine) Administered to Children Less Than 12 Months of Age With Diagnosed or Suspected Influenza (CASG 113)|Completed|||200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:04:34.888754|2018-06-01 04:04:34.888754
NCT00311688|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2016-11-08|2006-04-04|2006-04-06|Estimate|||||||2016-11-08|2016-11-09|Estimate|December 2003||2003-12-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31|5 Years|Observational [Patient Registry]|||Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies|An Omnibus Proleukin (IL-2) Trial in HIV Infected Patients Including Interrupted Versus Continuous Antiretrovirals (OPTICA)|Completed|||||National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||||||2018-06-01 04:04:34.956229|2018-06-01 04:04:34.956229
NCT00311675|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2010-08-26|2006-04-05|2006-04-06|Estimate|||||||2010-08-26|2010-08-27|Estimate|April 2006||2006-04-30|July 2008|2008-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||St. Jude Open Label H5 Trial|A Single Center, Open-Label, Phase I/II Study of Two 90-µg Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Adult Subjects|Completed||Phase 1/Phase 2|35|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 04:04:35.02671|2018-06-01 04:04:35.02671
NCT00311662|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2009-08-28|2006-04-04|2006-04-06|Estimate|||||||2009-08-28|2009-08-31|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache|Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache|Completed||Phase 2|124|Actual|Minster Research Ltd||2|||f||||f||||||||||2018-06-01 04:04:35.216701|2018-06-01 04:04:35.216701
NCT00311649|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2011-08-11|2006-04-05|2006-04-06|Estimate|||||||2011-08-11|2011-08-12|Estimate|November 2005||2005-11-30|March 2007|2007-03-31|September 2006||2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities|Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities|Completed||Phase 1/Phase 2|83|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:04:35.321239|2018-06-01 04:04:35.321239
NCT00311636|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2013-06-25|2006-04-05|2006-04-06|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2003||2003-09-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery|Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression With Triptorelin Vs. Control in Young Breast Cancer Patients. A Randomized Phase III Multicenter Study [PROMISE]|Completed||Phase 3|280|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:04:35.396328|2018-06-01 04:04:35.396328
NCT00311623|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2011-02-18|2006-04-05|2006-04-06|Estimate|||||||2011-02-18|2011-02-21|Estimate|August 2006||2006-08-31|February 2009|2009-02-28||||January 2008|Anticipated|2008-01-31||Interventional|||Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer|A Pharmacodynamic Study of Pre-Prostatectomy Rapamycin in Men With Advanced Localized Prostate Cancer|Unknown status|Active, not recruiting|N/A|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:04:35.519727|2018-06-01 04:04:35.519727
NCT00311610|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2016-06-28|2006-04-05|2006-04-06|Estimate|||||||2016-06-28|2016-06-29|Estimate|January 2006||2006-01-31|June 2016|2016-06-30|June 2010|Actual|2010-06-30|January 2007|Actual|2007-01-31||Interventional|||Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer|Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin|Completed||Phase 2|30|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:04:35.590606|2018-06-01 04:04:35.590606
NCT00311597|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2017-03-13|2006-04-05|2006-04-06|Estimate|||||||2017-03-13|2017-03-14|Actual|June 2002|Actual|2002-06-30|March 2017|2017-03-31|March 2009|Actual|2009-03-31|September 2007|Actual|2007-09-30||Interventional|||Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors|A Phase I/II Dose-Escalation/Efficacy Study of Palliative Extracranial Radiosurgery Using the Elektra Stereotactic Body Frame System|Completed||Phase 1/Phase 2|48|Anticipated|Wake Forest University Health Sciences||1|||f||||f||||||||||2018-06-01 04:04:35.756016|2018-06-01 04:04:35.756016
NCT00311584|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|2013-12-02||2014-09-16|2006-04-05|2006-04-06|Estimate|2013-12-02|2014-01-16|Estimate||||2014-09-16|2014-09-30|Estimate|April 2006||2006-04-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|March 2009|Actual|2009-03-31||Interventional||Patients were evaluable for inclusion in the analysis of response if eligible, had an event (relapse, PD, death or secondary malignancy) any time after enrollment, or completed at least 2 courses of Irinotecan/Temozolomide therapy. Patients off therapy before completion of 2 courses by choice or toxicity were not evaluable for response analysis.|Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma|A Phase II Study of Irinotecan + Temozolomide in Children With Recurrent Neuroblastoma|Completed||Phase 2|59|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 04:04:35.867231|2018-06-01 04:04:35.867231
NCT00311571|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2006-09-01|2006-04-04|2006-04-06|Estimate|||||||2006-09-01|2006-09-04|Estimate|August 2001||2001-08-31|April 2006|2006-04-30|June 2003||2003-06-30|||||Interventional|||Toulouse Male Long Term Bed Rest 2001-2002|Simulation of a Mission Aboard the International Space Station by a Long Duration Anti-Orthostatic Bed Confinement at – 6° (90 Days) on Healthy Subjects:1/Perfecting of Preventive Methods (Muscular Exercise and Biphosphonates) and Evaluation of the Effects on the Locomotion and Cardiovascular Systems and on the Lipid and Energy Metabolisms. 2/Pharmacokinetic Assessment: Effects of Position on the Absorption Mechanisms: Pharmacokinetics of Paracetamol Used as Model to Study Oral Absorption in Simulated Weightlessness|Completed||Phase 1|28||Centre National d'Etudes Spatiales|||||f||||||||||||||2018-06-01 04:04:36.422868|2018-06-01 04:04:36.422868
NCT00311558|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2018-01-24|2006-04-05|2006-04-06|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2005||2005-10-31|January 2018|2018-01-31|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma|Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b for Solid Tumors, Lymphoma or Myeloma|Terminated||Phase 1|18|Actual|The Cleveland Clinic||1|||f||||t||||||||||2018-06-01 04:04:36.499411|2018-06-01 04:04:36.499411
NCT00311545|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2013-02-19|2006-04-05|2006-04-06|Estimate|||||||2013-02-19|2013-02-20|Estimate||||February 2013|2013-02-28||||||||Interventional|||S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Advanced or Metastatic Renal Cell Cancer|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||1||withdrawal of support for drug supply|f||||t||||||||||2018-06-01 04:04:36.570047|2018-06-01 04:04:36.570047
NCT00311532|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2007-07-16|2006-04-05|2006-04-06|Estimate|||||||2007-07-16|2007-07-18|Estimate|March 2006||2006-03-31|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Observational|||Observational Study of Pergolide Mesylate and Cardiac Valvulopathy|Observational Study to Determine the Incidence of New-Onset Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinson's Disease|Completed|||200|Anticipated|Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:04:36.634903|2018-06-01 04:04:36.634903
NCT00311519|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2006-04-05|2006-04-05|2006-04-06|Estimate|||||||2006-04-05|2006-04-06|Estimate|November 2005||2005-11-30|April 2006|2006-04-30|January 2006||2006-01-31|||||Interventional|||A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects|A Phase IIIB Double Blind, Randomized, Placebo-Controlled, Dose-Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects|Completed||Phase 4|50||Halozyme Therapeutics|||||||||||||||||||2018-06-01 04:04:36.730495|2018-06-01 04:04:36.730495
NCT00311506|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-25|||2017-05-12|2006-04-04|2006-04-06|Estimate|||||||2017-05-12|2017-05-16|Actual|October 1999|Actual|1999-10-31|May 2017|2017-05-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Observational|||A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease|A Study to Determine the Variability of a 6-Minute Walk Test in Cystic Fibrosis Subjects With Advanced Lung Disease|Completed|||25||Genentech, Inc.|||||f||||||||||||||2018-06-01 04:04:36.790329|2018-06-01 04:04:36.790329
NCT00311493|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2007-03-12|2006-04-03|2006-04-06|Estimate|||||||2007-03-12|2007-03-13|Estimate|February 2006||2006-02-28|March 2007|2007-03-31||||||||Interventional|||Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults|A Phase IV, Randomized, Open-Label, Multi-Center Study in Adults: Evaluation of Long-Term Immunogenicity in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer) in Study V48P2E1, 5 Years After First Booster Immunization and Evaluation of Booster Kinetics in Subjects Boosted With a New TBE Vaccine for Adults (Free of Protein-Derived Stabilizer), 5 Years After First Booster Immunization|Completed||Phase 4|179||Novartis|||||f||||||||||||||2018-06-01 04:04:36.836898|2018-06-01 04:04:36.836898
NCT00311480|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2007-03-12|2006-04-04|2006-04-06|Estimate|||||||2007-03-12|2007-03-13|Estimate|March 2006||2006-03-31|March 2007|2007-03-31||||||||Interventional|||Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects|A Phase II, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 7.5 mg or 15 mg of H5N1 Influenza Antigen, in Non-Elderly Adult and Elderly Subjects|Completed||Phase 2|520||Novartis|||||f||||||||||||||2018-06-01 04:04:36.890515|2018-06-01 04:04:36.890515
NCT00311467|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-05|||2012-05-15|2006-04-05|2006-04-06|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2004||2004-03-31|May 2012|2012-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma|Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma: a Prospective, Randomized, Multi-center phaseIII-Trial|Terminated||Phase 3|172|Actual|Central European Cooperative Oncology Group||2||no patient recruitment|f||||f||||||||||2018-06-01 04:04:36.955011|2018-06-01 04:04:36.955011
NCT00311454|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2006-04-04|2006-04-04|2006-04-06|Estimate|||||||2006-04-04|2006-04-06|Estimate|April 2006||2006-04-30|April 2006|2006-04-30||||||||Interventional|||Quaternium-15, Use Test|An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15|Unknown status|Not yet recruiting|Phase 4|10||Mekos Laboratories AS|||||||||||||||||||2018-06-01 04:04:37.03111|2018-06-01 04:04:37.03111
NCT00311441|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2008-03-14|2006-04-03|2006-04-06|Estimate|||||||2008-03-14|2008-03-17|Estimate|March 2005||2005-03-31|March 2008|2008-03-31||||||||Interventional|||Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children|A Phase IV, Randomized, Controlled, Single-Blind, Multi-Center Study in Children to Evaluate the Safety, Tolerability and Immunogenicity of Two TBE Vaccines Administered According to Two Different Schedules.|Completed||Phase 4|300||Novartis|||||f||||||||||||||2018-06-01 04:04:37.078012|2018-06-01 04:04:37.078012
NCT00311428|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-09-13|2006-04-03|2006-04-06|Estimate|||||||2006-09-13|2006-09-14|Estimate|October 2005||2005-10-31|September 2006|2006-09-30||||||||Interventional|||Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months|A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months.|Completed||Phase 4|270||Novartis|||||f||||||||||||||2018-06-01 04:04:37.133865|2018-06-01 04:04:37.133865
NCT00311415|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2012-02-06|2006-04-05|2006-04-06|Estimate|||||||2012-02-06|2012-02-08|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children|A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Infants as One Dose Given at 2 or 6 Months of Age With a Booster at 12-16 Months of Age, in Comparison to Two Doses in the First Year of Life, Given Two Months Apart, With a Booster at 12-16 Months of Age; and in Comparison to One Dose Given at 12-16 Months of Age|Completed||Phase 3|257|Actual|Novartis||4|||f||||f||||||||||2018-06-01 04:04:37.200139|2018-06-01 04:04:37.200139
NCT00311402|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|2010-02-16||2014-01-21|2006-04-04|2006-04-06|Estimate|2010-02-16|2010-03-11|Estimate||||2014-01-21|2014-02-14|Estimate|April 2006||2006-04-30|January 2014|2014-01-31||||March 2009|Actual|2009-03-31||Interventional|||JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme|JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily|Completed||Phase 3|1295|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 04:04:37.452784|2018-06-01 04:04:37.452784
NCT00311389|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2012-02-11|2006-04-04|2006-04-06|Estimate|||||||2012-02-11|2012-02-14|Estimate|January 2003||2003-01-31|February 2012|2012-02-29|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension|A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|408|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 04:04:38.756116|2018-06-01 04:04:38.756116
NCT00311376|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|2011-09-09|2011-05-03|2015-11-05|2006-04-04|2006-04-06|Estimate|2011-09-09|2011-10-17|Estimate|2011-05-03|2011-05-05|Estimate|2015-11-05|2015-12-04|Estimate|August 2006||2006-08-31|November 2015|2015-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder||Completed||Phase 3|416|Actual|Allergan||4|||f||||||||||||||2018-06-01 04:04:38.849221|2018-06-01 04:04:38.849221
NCT00311363|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2011-04-28|2009-07-22|2013-07-15|2006-04-03|2006-04-05|Estimate|2011-04-28|2011-05-25|Estimate|2009-07-22|2009-08-10|Estimate|2013-07-15|2013-07-22|Estimate|April 2006||2006-04-30|May 2011|2011-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional||"Single-blind (SB) Safety Population: subjects who received at least 1 dose of SB study drug~1 subject withdrew from the SB period prior to receiving drug due to protocol non-compliance, and thus was excluded from the SB-Safety Population"|Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.|A Long-Term Study of XP13512 Versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients With Restless Legs Syndrome.|Completed||Phase 3|327|Actual|XenoPort, Inc.||2|||f||||f||||||||||2018-06-01 04:04:39.551972|2018-06-01 04:04:39.551972
NCT00311350|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2011-07-22|2006-04-03|2006-04-05|Estimate|||||||2011-07-22|2011-07-25|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|August 2006||2006-08-31|||||Interventional|||Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects|Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of MOA-728 Administered Orally to Healthy Subjects|Completed||Phase 1|48||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 04:04:40.442936|2018-06-01 04:04:40.442936
NCT00311337|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-04-04|2006-04-04|2006-04-05|Estimate|||||||2006-04-04|2006-04-05|Estimate|October 2005||2005-10-31|March 2006|2006-03-31|October 2010||2010-10-31|||||Interventional|||VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)|Evaluation of Safety and Efficacy of VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following High-Dose Melphalan Treatment and Autologous PBSCT (Minimal Residual Disease, Partial Remission or Stable Disease)|Unknown status|Recruiting|Phase 2|61||University of Wuerzburg|||||f||||||||||||||2018-06-01 04:04:40.53141|2018-06-01 04:04:40.53141
NCT00311324|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2015-12-03|2006-03-31|2006-04-05|Estimate|||||||2015-12-03|2015-12-04|Estimate|February 2001||2001-02-28|December 2015|2015-12-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||A Church Based Intervention to Improve Diabetes Care|A Church Based Intervention to Improve Diabetes Care|Completed||N/A|201|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 04:04:41.619649|2018-06-01 04:04:41.619649
NCT00311311|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2011-12-12||2013-07-19|2006-04-03|2006-04-05|Estimate|2012-05-15|2012-05-24|Estimate||||2013-07-19|2013-09-23|Estimate|April 2006||2006-04-30|July 2013|2013-07-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients|A Prospective, Randomized, Open-Label, Pilot Study To Compare The Effect On Carotid Atherosclerosis Of A Tacrolimus-Based Regimen With Conversion From A Tacrolimus- To A Sirolimus-Based Regimen At 3-4 Months Post-Transplant In De Novo Renal Transplant Recipients|Terminated||Phase 3|72|Actual|Pfizer||2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:04:41.797095|2018-06-01 04:04:41.797095
NCT00311298|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2009-08-03|2006-04-03|2006-04-05|Estimate|||||||2009-08-03|2009-08-04|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Nutrition, Diabetes and Pulmonary TB/HIV|The Role of Nutritional Support and Diabetes During Treatment of Pulmonary TB: Two Randomized Nutritional Supplementation Trials in Tanzania|Completed||Phase 3|1250|Actual|University of Copenhagen||4|||f||||||||||||||2018-06-01 04:04:43.106503|2018-06-01 04:04:43.106503
NCT00311285|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2007-06-28|2006-04-03|2006-04-05|Estimate|||||||2007-06-28|2007-07-02|Estimate||||March 2006|2006-03-31|March 2007||2007-03-31|||||Interventional|||Physical and Mental Load in the Surgeon Performing Laparoscopic Tasks|Physical and Mental Load During Laparoscopic Tasks. A Prospective Randomized Trial of the Ergonomics in a Black Box Model|Unknown status|Not yet recruiting|N/A|12|Anticipated|University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:04:43.233723|2018-06-01 04:04:43.233723
NCT00311272|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2009-02-17|2006-04-03|2006-04-05|Estimate|||||||2009-02-17|2009-02-18|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|September 2007|Actual|2007-09-30|||||Interventional|||Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer|Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate (MelCancerVac) for Treatment of Patients With Advanced Colorectal Cancer|Completed||Phase 2|40|Anticipated|University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:04:43.3391|2018-06-01 04:04:43.3391
NCT00311259|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-04-03|2006-04-03|2006-04-05|Estimate|||||||2006-04-03|2006-04-05|Estimate|May 2006||2006-05-31|February 2006|2006-02-28|November 2006||2006-11-30|||||Observational|||Melatonin Treatment and Inflammation, Oxidative Stress and Autonomic Function in Connection With Surgery||Unknown status|Not yet recruiting||40||University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:04:43.47893|2018-06-01 04:04:43.47893
NCT00311246|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2011-06-28|2006-04-04|2006-04-05|Estimate|||||||2011-06-28|2011-06-30|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||Trial of Adalimumab in Progressive Sarcoidosis|A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis|Terminated||Phase 2|11|Actual|University of Chicago||||Difficulty in recruiting subjects|f||||t||||||||||2018-06-01 04:04:43.556993|2018-06-01 04:04:43.556993
NCT00311233|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2008-05-22|2006-04-03|2006-04-05|Estimate|||||||2008-05-22|2008-05-23|Estimate|February 2006||2006-02-28|May 2008|2008-05-31|April 2008|Actual|2008-04-30|||||Observational|||Recurrent Abdominal Pain in Childhood -Characteristics and Course|Recurrent Abdominal Pain in Childhood, Characteristics and Course|Completed|||152|Actual|Sykehuset Innlandet HF|||||f||||||||||Samples Without DNA|"~     All patients have blood tests for hemoglobin, total leucocyte and differential count,~     sedimention rate, C-reactive protein, total IgE and IgE screen for food allergies, and~     antiendomysial and antigliadin antibodies (IgG and IgA) and anti-tissue transglutaminase~     antibodies for celiac disease. Furthermore, urine analyses for protein, blood and and~     leucocytes, three stool specimen for occult blood and one stool specimen for quantification~     of calprotectin.~   "|||2018-06-01 04:04:43.645165|2018-06-01 04:04:43.645165
NCT00311220|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-04-03|2006-04-03|2006-04-05|Estimate|||||||2006-04-03|2006-04-05|Estimate|January 2004||2004-01-31|April 2006|2006-04-30|November 2006||2006-11-30|||||Interventional|||Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers|Phase IV Study of the Quantiferon-RD1 Test|Unknown status|Recruiting|Phase 4|300||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 04:04:43.726092|2018-06-01 04:04:43.726092
NCT00311207|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2006-04-03|2006-04-03|2006-04-05|Estimate|||||||2006-04-03|2006-04-05|Estimate|December 2005||2005-12-31|April 2006|2006-04-30|November 2006||2006-11-30|||||Observational|||Development of Tuberculosis Diagnostic Kit|Development of Tuberculosis Diagnostic Kit|Unknown status|Recruiting||200||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 04:04:43.809404|2018-06-01 04:04:43.809404
NCT00311194|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-04-03|2006-04-03|2006-04-05|Estimate|||||||2006-04-03|2006-04-05|Estimate|February 1998||1998-02-28|May 2002|2002-05-31|July 2002||2002-07-31|||||Interventional|||Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure|A Randomised, Controlled Trial of an Interactive CD-Program on 6 Months Readmission Rate in Patients With Heart Failure|Completed||N/A|206||Swedish Heart Lung Foundation|||||f||||||||||||||2018-06-01 04:04:43.887474|2018-06-01 04:04:43.887474
NCT00311181|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2011-07-24||2012-07-27|2006-04-03|2006-04-05|Estimate|2012-07-27|2012-08-30|Estimate||||2012-07-27|2012-08-30|Estimate|August 2006||2006-08-31|July 2012|2012-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||POWER (Pulse Width Optimized Waveform Evaluation Trial)|Phase 4 Study That Compares the DFT (Defibrillation Threshold) Efficacy of 3 Different Membrane Time Constant Based Biphasic Defibrillation Waveforms|Completed||Phase 4|217|Actual|St. Jude Medical||1|||f||||f||||||||||2018-06-01 04:04:43.968467|2018-06-01 04:04:43.968467
NCT00311168|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2011-03-28|2006-04-04|2006-04-05|Estimate|||||||2011-03-28|2011-03-29|Estimate|February 2006||2006-02-28|March 2011|2011-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)|Reduce Ventricular Pacing Using Ventricular Intrinsic Preference: VIP™ Study|Completed||Phase 4|100|Anticipated|St. Jude Medical|||||f||||f||||||||||2018-06-01 04:04:44.150505|2018-06-01 04:04:44.150505
NCT00311155|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2010-10-12|2010-10-12|2010-11-23|2006-04-03|2006-04-05|Estimate|2010-10-12|2010-11-10|Estimate|2010-10-12|2010-11-10|Estimate|2010-11-23|2010-12-10|Estimate|March 2006||2006-03-31|November 2010|2010-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|OLMETREAT||Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension|Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension|Completed||Phase 4|694|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-06-01 04:04:44.244498|2018-06-01 04:04:44.244498
NCT00311142|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2008-04-15|2006-04-04|2006-04-05|Estimate|||||||2008-04-15|2008-04-16|Estimate|March 2003||2003-03-31|April 2008|2008-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Actigraphic Sleep Patterns in Newborns Delivered Via Vacuum Extraction vs. Partum Spontaneous and Cesarean Section|Actigraphic Sleep Patterns in Newborns Delivered Via Vacuum Extraction vs. Partum Spontaneous and Cesarean Section.|Completed|||24|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:04:44.753809|2018-06-01 04:04:44.753809
NCT00311129|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2013-12-02|2006-03-31|2006-04-05|Estimate|||||||2013-12-02|2013-12-04|Estimate|December 2005||2005-12-31|December 2013|2013-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL|A Multicenter Study to Assess the Antitumor Effect and Safety of Fludarabine Phosphate Tablet (SH T 586) in Combination With Rituximab Administered in 6 Treatment Cycles (1 Treatment Cycle: Rituximab 375 mg/m2 iv on Day 1 Along With 5-Consecutive Day Oral Dosing of SH T 586 40 mg/m2/Day From Day 1 to Day 5, Followed by an Observation Period of 23 Days) in Patients With Indolent Lymphoma|Completed||Phase 2|41|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:04:44.831556|2018-06-01 04:04:44.831556
NCT00311116|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2013-12-17|2006-04-03|2006-04-05|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 2002||2002-07-31|December 2013|2013-12-31|February 2005||2005-02-28|||||Interventional|||Vitamin E to Prevent Mucositis in Children With Cancer|Serial Controlled N-of-1 Trials of Topical Vitamin E as Prophylaxis for Chemotherapy-induced Oral Mucositis in Pediatric Patients|Completed||Phase 2/Phase 3|16||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:04:44.927259|2018-06-01 04:04:44.927259
NCT00311103|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2014-09-12|2006-04-03|2006-04-05|Estimate|||||||2014-09-12|2014-09-15|Estimate|October 2005||2005-10-31|September 2014|2014-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|DIME||Disability of Musculoskeletal Origin in Community-dwelling Elderly|Disability of Musculoskeletal Origin in Community-dwelling Elderly: Efficacy of a Specific Clinical Intervention.|Completed||N/A|214|Actual|Spanish Foundation of Rheumatology||2|||f||||t||||||||||2018-06-01 04:04:44.996975|2018-06-01 04:04:44.996975
NCT00311090|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04||2016-02-19|2016-02-19|2006-04-04|2006-04-05|Estimate||||2016-02-19|2016-03-21|Estimate|2016-02-19|2016-03-21|Estimate|April 2006||2006-04-30|February 2016|2016-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|EQUINOX||Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs|International, Multicenter, Randomized, Parallel Group, Double-blind Study, in Patients With Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds During a 6-month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity|Completed||Phase 3|757|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:04:45.178033|2018-06-01 04:04:45.178033
NCT00311077|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2009-12-04|2006-04-03|2006-04-05|Estimate|||||||2009-12-04|2009-12-07|Estimate|April 2004||2004-04-30|December 2009|2009-12-31||||October 2004|Actual|2004-10-31||Interventional|||Insulin Glulisine in Healthy Lean and Obese Subjects|Pharmacodynamic and Pharmacokinetic Properties of Insulin Glulisine (Apidra) in Comparison to Insulin Lispro (Humalog) in Healthy Lean and Obese Subjects|Completed||Phase 1|||Sanofi|||||f||||||||||||||2018-06-01 04:04:45.326774|2018-06-01 04:04:45.326774
NCT00311064|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2007-08-20|2006-04-04|2006-04-05|Estimate|||||||2007-08-20|2007-08-21|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|January 2008|Anticipated|2008-01-31|||||Interventional|||Inflammatory Response and Pregnancy Outcome in Women With Type 2 Diabetes or Overweight|Inflammatory Response and Pregnancy Outcome in Women With Type 2 Diabetes or Only Overweight. The Influence of Physical Activity|Withdrawn||Phase 1|280|Anticipated|Rigshospitalet, Denmark||||because of lack of funding and recruitment problems the study has been closed.|f||||||||||||||2018-06-01 04:04:45.387502|2018-06-01 04:04:45.387502
NCT00311051|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-01|||2012-04-13|2006-04-01|2006-04-05|Estimate|||||||2012-04-13|2012-04-16|Estimate|April 2005||2005-04-30|April 2012|2012-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite|A Randomized Double-blind and Placebo-controlled Study to the Influence of Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Patients With Mild to Moderate Atopic Asthma (House Dust Mite)|Withdrawn||Phase 2/Phase 3|0|Actual|Research Center Borstel|||||f||||||||||||||2018-06-01 04:04:45.46475|2018-06-01 04:04:45.46475
NCT00311038|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2012-06-12|2006-04-03|2006-04-05|Estimate|||||||2012-06-12|2012-06-13|Estimate|April 2006||2006-04-30|June 2012|2012-06-30||||||||Interventional|||Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT|Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice Computed Tomography (CT) Due to Suspected Coronary Artery Disease|Completed||Phase 2|90|Anticipated|Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:04:45.544851|2018-06-01 04:04:45.544851
NCT00311025|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-04-03|2006-04-03|2006-04-05|Estimate|||||||2006-04-03|2006-04-05|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Stroke: Reduction of Physical Performance Post Stroke. Inactivity or Secondary Complications?|Stroke: Reduction of Physical Performance Post Stroke. Inactivity or Secondary Complications? How to Cope Daily Life Activities for as Long as Possible.|Completed||Phase 1/Phase 2|60||Oslo University College|||||f||||||||||||||2018-06-01 04:04:45.620261|2018-06-01 04:04:45.620261
NCT00311012|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2011-11-07|2006-04-04|2006-04-05|Estimate|||||||2011-11-07|2011-11-08|Estimate|August 2004||2004-08-31|June 2006|2006-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||SPP100 Dose Finding Study in Japan|Dose-finding Study of SPP100 in Essential Hypertension|Completed||Phase 2|445|Actual|Novartis|||||f||||||||||||||2018-06-01 04:04:45.695252|2018-06-01 04:04:45.695252
NCT00310999|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2007-04-12|2006-04-03|2006-04-05|Estimate|||||||2007-04-12|2007-04-13|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|June 2006|Actual|2006-06-30|||||Interventional|||C-Spine Movement - Shikani Optical Scope vs Macintosh Laryngoscope for Patients With Cervical Spine Injury|Comparison of Shikani Optical Scope to Macintosh Laryngoscope for Intubation of Patients With Potential Cervical Spine Injury|Completed||N/A|24||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:04:45.784668|2018-06-01 04:04:45.784668
NCT00310986|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2010-05-27|2006-04-04|2006-04-05|Estimate|||||||2010-05-27|2010-05-28|Estimate|April 2006||2006-04-30|August 2009|2009-08-31|May 2011|Anticipated|2011-05-31|December 2009|Anticipated|2009-12-31||Interventional|||Breathing Meditation With Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder|Breathing Meditation With Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder Children: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|22|Anticipated|Khon Kaen University|||||f||||||||||||||2018-06-01 04:04:45.864684|2018-06-01 04:04:45.864684
NCT00310973|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2015-04-20|2006-04-03|2006-04-05|Estimate|||||||2015-04-20|2015-04-22|Estimate|February 2003||2003-02-28|April 2015|2015-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||HIV Prevention Within High-Risk Bulgarian and Hungarian Social Networks|HIV Prevention Within High-Risk Social Networks|Completed||Phase 2/Phase 3|320|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 04:04:45.95264|2018-06-01 04:04:45.95264
NCT00310960|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2011-08-31|2006-04-03|2006-04-05|Estimate|||||||2011-08-31|2011-09-02|Estimate|June 2004||2004-06-30|August 2011|2011-08-31|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Observational|||An Observational Study of Infantile, Acquired Non-accommodative, and Acquired Partially-accommodative Esotropia|An Observational Study of Infantile, Acquired Non-accommodative, and Acquired Partially-accommodative Esotropia|Completed|||293|Actual|Jaeb Center for Health Research|||||f||||t||||||||||2018-06-01 04:04:46.045273|2018-06-01 04:04:46.045273
NCT00310947|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-04-04|2006-04-04|2006-04-05|Estimate|||||||2006-04-04|2006-04-05|Estimate|March 2005||2005-03-31|March 2003|2003-03-31|January 2006||2006-01-31|||||Observational|||Impact of Patient-Prosthesis-Mismatch on Coronary Flow Reserve|Impact of Patient-Prosthesis-Mismatch and Aortic Valve Design on Coronary Flow Reserve Following Aortic Valve Replacement|Completed|||48||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:04:46.109295|2018-06-01 04:04:46.109295
NCT00310934|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-10-23|2006-04-03|2006-04-05|Estimate|||||||2006-10-23|2006-10-24|Estimate|August 2005||2005-08-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||A Stepwise Strategy Utilizing Buprenorphine and Methadone|Graded Strategy for Pharmacological Treatment of Heroin Dependence|Completed||Phase 4|96||Karolinska University Hospital|||||f||||||||||||||2018-06-01 04:04:46.166273|2018-06-01 04:04:46.166273
NCT00310921|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2007-04-10|2006-04-03|2006-04-05|Estimate|||||||2007-04-10|2007-04-11|Estimate|May 2001||2001-05-31|November 2005|2005-11-30|May 2006||2006-05-31|||||Interventional|||A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination|A Randomized Study of Cervical Priming With Misoprostol Prior to Elective First Trimester Pregnancy Termination: Effects on Pain, Ease of Procedure and Complications|Completed||Phase 2|200||Kaiser Permanente|||||||||||||||||||2018-06-01 04:04:46.245105|2018-06-01 04:04:46.245105
NCT00310908|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2009-02-15|2006-04-04|2006-04-05|Estimate|||||||2009-02-15|2009-02-17|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic|Efficacy of Tramadol Hcl in the Treatment of Renal Colic|Completed||Phase 4|100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 04:04:46.308011|2018-06-01 04:04:46.308011
NCT00310895|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2015-12-22|2006-04-04|2006-04-05|Estimate|||||||2015-12-22|2015-12-24|Estimate|March 2006||2006-03-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies|Completed||Phase 1|85|Anticipated|Geron Corporation||1|||f||||f||||||||||2018-06-01 04:04:46.370438|2018-06-01 04:04:46.370438
NCT00310882|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-04|||2011-04-07|2006-04-04|2006-04-05|Estimate|||||||2011-04-07|2011-04-08|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|May 2008|Anticipated|2008-05-31|||||Observational|||Involvement of Endogenous Digitalis-like Compounds in Breast Cancer|Involvement of Endogenous Digitalis-like Compounds in Breast Cancer|Withdrawn|||250|Anticipated|Hadassah Medical Organization||||the PI is no longer work at Hadassah|f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-06-01 04:04:46.437844|2018-06-01 04:04:46.437844
NCT00310869|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2017-06-27|2006-04-03|2006-04-05|Estimate|||||||2017-06-27|2017-06-28|Actual|January 2005|Actual|2005-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Adolescents Born Preterm; Nurtured Beginnings|Adolescents Born Preterm: Nurtured Beginnings|Active, not recruiting||N/A|70|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||||2018-06-01 04:04:46.485736|2018-06-01 04:04:46.485736
NCT00310856|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2013-08-29||2013-08-29|2006-04-03|2006-04-05|Estimate|2013-08-29|2013-11-01|Estimate||||2013-08-29|2013-11-01|Estimate|June 2005||2005-06-30|August 2013|2013-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional||Analysis was done for all enrolled subjects.|Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)|A Phase 2, Partially Randomized, Open Label, Multicenter Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Young Children|Completed||Phase 2|175|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:04:46.576918|2018-06-01 04:04:46.576918
NCT00310843|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2013-07-31|2006-04-02|2006-04-05|Estimate|||||||2013-07-31|2013-08-01|Estimate|February 2006||2006-02-28|July 2013|2013-07-31||||September 2008|Actual|2008-09-30||Observational|||Case-Control Viramune (Nevirapine) Toxicogenomics Study|A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy|Completed|||889|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-06-01 04:04:47.118375|2018-06-01 04:04:47.118375
NCT00310830|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03||2010-02-11|2010-02-11|2006-04-03|2006-04-05|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|March 2006||2006-03-31|February 2010|2010-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)|Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Symptomatic Pulmonary Arterial Hypertension Associated With Sickle Cell Disease|Terminated||Phase 3|14|Actual|Actelion||2||Slow enrollment|f||||||||||||||2018-06-01 04:04:47.37539|2018-06-01 04:04:47.37539
NCT00310817|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2013-08-29||2015-10-06|2006-04-03|2006-04-05|Estimate|2015-10-06|2015-11-06|Estimate||||2015-10-06|2015-11-06|Estimate|March 2005||2005-03-31|October 2015|2015-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.|A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.|Completed||Phase 2|623|Actual|Novartis||4|||||||||||||||||2018-06-01 04:04:47.528366|2018-06-01 04:04:47.528366
NCT00310804|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2012-12-11||2013-01-18|2006-04-03|2006-04-05|Estimate|2012-12-11|2013-01-18|Estimate||||2013-01-18|2013-02-01|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|April 2006|Actual|2006-04-30|October 2005|Actual|2005-10-31||Interventional|||Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)|A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Or of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs, in Healthy Adult Subjects Aged >=18 to <=60|Completed||Phase 3|1200|Actual|Novartis|Because of potential issues related to Good Clinical Practice (GCP), data from one of the sites were not used in the analyses.|4|||f||||f||||||||||2018-06-01 04:04:48.716814|2018-06-01 04:04:48.716814
NCT00310791|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2011-06-22||2018-03-15|2006-04-03|2006-04-05|Estimate|2012-12-27|2013-02-01|Estimate||||2018-03-15|2018-04-11|Actual|April 2004||2004-04-30|March 2018|2018-03-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa|Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa|Completed||Phase 2/Phase 3|80|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 04:04:49.330604|2018-06-01 04:04:49.330604
NCT00310778|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2008-09-19|2006-04-03|2006-04-04|Estimate|||||||2008-09-19|2008-09-22|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker|Effects of Sodium Intake on Pharmacokinetic/Pharmacodynamic Relationship of a Single Dose of a Renin Angiotensin System-Blocker, or a Beta-Blocker in Normotensive Sodium-Depleted or Replated Volunteers in a Cross-Over Study|Completed||Phase 1|64|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:04:49.562952|2018-06-01 04:04:49.562952
NCT00310765|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2012-09-04|2006-03-31|2006-04-04|Estimate|||||||2012-09-04|2012-09-05|Estimate|March 2006||2006-03-31|September 2012|2012-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Pregabalin for Abdominal Pain From Adhesions|Pregabalin for the Treatment of Abdominal Pain From Adhesions: Placebo Controlled Trial|Terminated||Phase 4|18|Actual|Henry Ford Health System||2||Study was terminated by the sponsor due to low accrual.|f||||f||||||||||2018-06-01 04:04:49.70018|2018-06-01 04:04:49.70018
NCT00310752|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2008-07-31|2006-04-03|2006-04-04|Estimate|||||||2008-07-31|2008-08-01|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Evaluation of DermStream(tm) - an Irrigation Product for Chronic Wound Management||Completed||Phase 1/Phase 2|11|Actual|EnzySurge|||||f||||||||||||||2018-06-01 04:04:49.791155|2018-06-01 04:04:49.791155
NCT00310739|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-11-06|2006-04-03|2006-04-04|Estimate|||||||2006-11-06|2006-11-07|Estimate||||April 2005|2005-04-30||||||||Observational|||Urinary Marker for Oxidative Stress in Human Cisplatin- Induced Renal Injury||Unknown status|Recruiting||||Hamamatsu University|||||f||||||||||||||2018-06-01 04:04:49.8583|2018-06-01 04:04:49.8583
NCT00310726|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2011-07-26|2006-04-03|2006-04-04|Estimate|||||||2011-07-26|2011-07-27|Estimate|May 2001||2001-05-31|July 2011|2011-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Zambia Exclusive Breastfeeding Study|Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission|Completed||N/A|1435|Actual|Boston Medical Center||2|||f||||t||||||||||2018-06-01 04:04:49.92296|2018-06-01 04:04:49.92296
NCT00310713|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2014-09-18|2006-04-03|2006-04-04|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2006||2006-04-30|September 2014|2014-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine|A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age|Completed||Phase 4|33|Actual|Novartis||5|||f||||||||||||||2018-06-01 04:04:50.019863|2018-06-01 04:04:50.019863
NCT00310700|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2014-09-18|2006-04-03|2006-04-04|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2005||2005-05-31|September 2014|2014-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Kinetics of B Cell Response in Infants Menjugate Vaccination|A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age|Completed||Phase 4|75||Novartis|||||f||||||||||||||2018-06-01 04:04:50.120914|2018-06-01 04:04:50.120914
NCT00310687|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2014-09-18|2006-04-03|2006-04-04|Estimate|||||||2014-09-18|2014-09-19|Estimate|October 2004||2004-10-31|September 2014|2014-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Persistence of Immune Response After Vaccination With MCC|A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign|Completed||Phase 4|1244||Novartis|||||f||||||||||||||2018-06-01 04:04:50.220155|2018-06-01 04:04:50.220155
NCT00310674|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2007-03-12|2006-04-03|2006-04-04|Estimate|||||||2007-03-12|2007-03-13|Estimate|September 2004||2004-09-30|March 2007|2007-03-31||||||||Interventional|||Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age|A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine|Completed||Phase 3|150||Novartis|||||f||||||||||||||2018-06-01 04:04:50.2836|2018-06-01 04:04:50.2836
NCT00310661|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2015-07-22|2006-04-03|2006-04-04|Estimate|||||||2015-07-22|2015-07-23|Estimate|December 2004||2004-12-31|July 2015|2015-07-31|March 2008||2008-03-31|September 2006|Actual|2006-09-30||Interventional|||Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia|A Dual-centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine the Effects of Various Adjunctive Doses of Sarizotan in the Treatment of Patients With Neuroleptic-induced Tardive Dyskinesia|Terminated||N/A|60|Actual|Centre for Addiction and Mental Health||2||Funding|f||||f||||||||||2018-06-01 04:04:50.344797|2018-06-01 04:04:50.344797
NCT00310323|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2009-03-17|2006-03-30|2006-04-03|Estimate|||||||2009-03-17|2009-03-19|Estimate|January 2003||2003-01-31|March 2009|2009-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea|Effect of Chronic Intermittent Nocturnal Hypoxia on Hepatic Drug Biotransformation in Children With Obstructive Sleep Apnea|Completed||N/A|69|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-06-01 04:04:58.956159|2018-06-01 04:04:58.956159
NCT00310648|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-09-13|2006-04-03|2006-04-04|Estimate|||||||2006-09-13|2006-09-14|Estimate|January 2006||2006-01-31|September 2006|2006-09-30||||||||Interventional|||Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)|Part 1:Phase I Open-Label, Single-Center to Evaluate the Safety of a Commercially Available Adjuvanted Influenza Vaccine When Administered to Elderly Subjects Part 2: A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Immunogenicity and Safety of a Commercially Available Influenza Vaccine and a Conventional Commercially Available Influenza Vaccine When Administered to Elderly Subjects|Completed||Phase 3|600||Novartis|||||f||||||||||||||2018-06-01 04:04:50.436934|2018-06-01 04:04:50.436934
NCT00310635|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2006-10-25|2006-04-03|2006-04-04|Estimate|||||||2006-10-25|2006-10-26|Estimate|June 2005||2005-06-30|October 2006|2006-10-31||||||||Interventional|||Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age|A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age|Completed||Phase 4|241||Novartis|||||f||||||||||||||2018-06-01 04:04:50.494503|2018-06-01 04:04:50.494503
NCT00310622|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-02|||2007-02-28|2006-04-03|2006-04-04|Estimate|||||||2007-02-28|2007-03-01|Estimate|March 2006||2006-03-31|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Assessment of HyperQ Signal for Detecting Ischemia During Dobutamine Stress ECG|An Assessment of the HyperQ Signal for Detecting Ischemia During Dobutamine Stress Echocardiography (DSE)|Unknown status|Recruiting|Phase 3|150||BSP Biological Signal Processing Ltd.|||||f||||||||||||||2018-06-01 04:04:50.562185|2018-06-01 04:04:50.562185
NCT00310609|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2014-12-29|2006-03-31|2006-04-04|Estimate|||||||2014-12-29|2014-12-30|Estimate|December 2003||2003-12-31|December 2014|2014-12-31|October 2004|Actual|2004-10-31|||||Interventional|||Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches|Multicenter, Open-label Study of the Safety (Open-label) and Efficacy (Open-label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients With Known or Suspected Disease of the Aortic Arch and Cerebral Branches Who Are Undergoing MRA of These Vessels With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as the Standard of Reference.|Completed||Phase 3|123|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:04:50.638465|2018-06-01 04:04:50.638465
NCT00310596|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2014-12-29|2006-04-03|2006-04-04|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|March 2004|Actual|2004-03-31|||||Interventional|||Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects|Cardiovascular Safety Study of 0.1 and 0.3 mmol/kg Magnevist® Injection at Two Injection Rates (Bolus and 10 mL/15 Sec.) in Normal Subjects Following a Randomized, Cross-over Design Using Placebo and a Concurrent Positive Control|Completed||Phase 1|71|Actual|Bayer||6|||f||||||||||||||2018-06-01 04:04:50.703737|2018-06-01 04:04:50.703737
NCT00310583|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2007-04-04|2006-04-03|2006-04-04|Estimate|||||||2007-04-04|2007-04-05|Estimate|July 2006||2006-07-31|April 2006|2006-04-30|April 2008|Anticipated|2008-04-30|||||Interventional|||Effects of Pregabalin on Mechanical Hyperalgesia|Effects of Pregabalin on Mechanical Hyperalgesia - EPOM|Unknown status|Recruiting|Phase 4|120||Professional Associations Clinic Bergmannsheil|||||f||||||||||||||2018-06-01 04:04:50.787913|2018-06-01 04:04:50.787913
NCT00310570|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-02|||2006-04-02|2006-04-02|2006-04-04|Estimate|||||||2006-04-02|2006-04-04|Estimate|May 2006||2006-05-31|April 2006|2006-04-30|September 2007||2007-09-30|||||Interventional|||Comparison of Splinting Interventions for Treating Mallet Finger Injuries|Comparison of Splinting Interventions for Minimising Extensor Lag in Mallet Finger Injuries|Unknown status|Not yet recruiting|N/A|100||Bayside Health|||||f||||||||||||||2018-06-01 04:04:50.93095|2018-06-01 04:04:50.93095
NCT00310557|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2014-12-28|2006-03-31|2006-04-04|Estimate|||||||2014-12-28|2014-12-30|Estimate|December 2003||2003-12-31|December 2014|2014-12-31|December 2004|Actual|2004-12-31|||||Interventional|||Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries|Multicenter, Open-label Study of the Safety (Open-label) and Efficacy (Open-label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients With Known or Suspected Renal Artery Disease Undergoing MRA of the Renal Arteries With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as the Standard of Reference|Completed||Phase 3|116|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:04:50.999878|2018-06-01 04:04:50.999878
NCT00310544|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2014-12-11|2006-04-03|2006-04-04|Estimate|||||||2014-12-11|2014-12-15|Estimate|March 2006||2006-03-31|December 2014|2014-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction|Multicenter, Single-blind, Randomized, Intraindividual Study of the Safety and Efficacy of Magnevist Gadopentetate Dimeglumine (Magnevist® Injection) at 0.1 and 0.2 mmol/kg for the Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction|Completed||Phase 2|73|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:04:51.063877|2018-06-01 04:04:51.063877
NCT00310531|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2014-12-29|2006-03-31|2006-04-04|Estimate|||||||2014-12-29|2014-12-30|Estimate|February 2004||2004-02-29|December 2014|2014-12-31|June 2007|Actual|2007-06-30|||||Interventional|||3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women|A Multicenter, Double-Blind, Double-Dummy, Randomized, Active- Controlled, 3-Year Study to Evaluate the Antiresorptive Efficacy, Safety and Tolerability of a Ultra-Low Dose Estradiol Transdermal Delivery System Releasing 0.014 mg / Day Versus Oral Raloxifene Hydrochloride 60 mg / Day - as a Therapy for the Prevention of Osteoporosis in Postmenopausal Female Osteopenic Patients.|Completed||Phase 3|500|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:04:51.144717|2018-06-01 04:04:51.144717
NCT00310518|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2009-04-28|2006-03-31|2006-04-04|Estimate|||||||2009-04-28|2009-04-29|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma|A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma|Completed||Phase 2|30||ArQule|||||f||||||||||||||2018-06-01 04:04:51.333497|2018-06-01 04:04:51.333497
NCT00310505|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2008-09-11|2006-04-03|2006-04-04|Estimate|||||||2008-09-11|2008-09-12|Estimate|January 2003||2003-01-31|September 2008|2008-09-30||||||||Interventional|||Amphotericin B Treatment in Visceral Leishmaniasis|Randomised Double Blind Dose Ranging Study of Amphotericin B in Visceral Leishmaniasis|Completed||N/A|1500||Banaras Hindu University|||||f||||||||||||||2018-06-01 04:04:51.390433|2018-06-01 04:04:51.390433
NCT00307944|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2007-12-10|2006-03-27|2006-03-28|Estimate|||||||2007-12-10|2007-12-12|Estimate|August 2004||2004-08-31|December 2007|2007-12-31|August 2006||2006-08-31|||||Interventional|||Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea|Randomized, Placebo-Controlled Trial of Pantoprazole for Sleepiness Associated With Acid Reflux and Obstructive Sleep Disordered Breathing|Completed||Phase 4|68||University of Cincinnati|||||f||||||||||||||2018-06-01 04:05:39.962283|2018-06-01 04:05:39.962283
NCT00310492|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-02|||2015-12-28|2006-04-02|2006-04-04|Estimate|||||||2015-12-28|2015-12-29|Estimate|April 2006||2006-04-30|December 2015|2015-12-31|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis|Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Demonstrate the Efficacy of a 12-month Subcutaneous Specific Immunotherapy With ALK-depot SQ Milbenmischung in Patients With Atopic Dermatitis and Proven IgE-mediated Sensitization to House Dust Mites|Completed||Phase 3|154|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-06-01 04:04:51.450584|2018-06-01 04:04:51.450584
NCT00310479|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|||2016-02-24|2006-04-03|2006-04-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 2006||2006-06-30|March 2012|2012-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer|Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer|Completed||N/A|16|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:04:51.518912|2018-06-01 04:04:51.518912
NCT00310466|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-02|2009-03-12||2013-04-29|2006-04-02|2006-04-04|Estimate|2009-06-19|2009-08-06|Estimate||||2013-04-29|2013-05-14|Estimate|June 2005||2005-06-30|April 2013|2013-04-30|January 2007|Actual|2007-01-31|August 2006|Actual|2006-08-31||Interventional|||Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever|A Multicentre, Randomised, Double-blind, Placebo-controlled Parallel Group Clinical Trial to Investigate the Efficacy and Safety of Specific Sublingual Immunotherapy With SLITone Birch in Patients With Seasonal Birch Pollen Induced Rhinoconjunctivitis|Completed||Phase 3|226|Actual|ALK-Abelló A/S|Clinical improvement following SLIT is thought to be due to immunological mechanisms that develop over time. Even though clear immunological changes were observed in this trial it appears that the treatment was too short to reach full clinical effect|2|||f||||f||||||||||2018-06-01 04:04:51.610293|2018-06-01 04:04:51.610293
NCT00310453|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-02|||2006-05-03|2006-04-02|2006-04-04|Estimate|||||||2006-05-03|2006-05-04|Estimate|March 2006||2006-03-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Tolerability of ALK Grass Tablet in Children|A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of ALK Grass Tablet in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)|Completed||Phase 1|32||ALK-Abelló A/S|||||f||||||||||||||2018-06-01 04:04:52.205492|2018-06-01 04:04:52.205492
NCT00310440|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-03|2015-12-10||2018-05-16|2006-04-03|2006-04-04|Estimate|2016-01-13|2016-02-10|Estimate||||2018-05-16|2018-05-18|Actual|January 2006||2006-01-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2014|Actual|2014-05-31||Interventional|||An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation|An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation|Active, not recruiting||N/A|319|Actual|CeraPedics, Inc||2|||f||||t||||||||||2018-06-01 04:04:52.296183|2018-06-01 04:04:52.296183
NCT00310427|ClinicalTrials.gov processed this data on May 31, 2018|2006-04-01|2010-03-05||2010-04-13|2006-04-01|2006-04-03|Estimate|2010-03-25|2010-04-09|Estimate||||2010-04-13|2010-04-20|Estimate|March 2006||2006-03-31|April 2010|2010-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of LY686017 on Alcohol Craving|NK1 Receptor Antagonism for Treatment of Anxiety and Craving in Anxious Alcohol Dependent Subjects During Early Abstinence|Completed||Phase 2|66|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 04:04:53.103946|2018-06-01 04:04:53.103946
NCT00310414|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2017-06-30|2006-03-31|2006-04-03|Estimate|||||||2017-06-30|2017-07-02|Actual|March 30, 2006||2006-03-30|March 13, 2012|2012-03-13|March 13, 2012||2012-03-13|||||Observational|||fMRI Studies of Task Specificity in Focal Hand Dystonia|fMRI Studies of Task Specificity in Focal Hand Dystonia|Completed|||51|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:04:53.421402|2018-06-01 04:04:53.421402
NCT00310401|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|2013-06-24||2018-02-14|2006-03-31|2006-04-03|Estimate|2013-06-24|2013-09-02|Estimate||||2018-02-14|2018-03-16|Actual|April 2007||2007-04-30|February 2018|2018-02-28|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||The Effect of Nebulized Albuterol on Donor Oxygenation|The Effect of Nebulized Albuterol on Donor Oxygenation|Completed||Phase 2|506|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-06-01 04:04:53.479504|2018-06-01 04:04:53.479504
NCT00310388|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2017-08-14|2006-03-30|2006-04-03|Estimate|||||||2017-08-14|2017-08-17|Actual|July 5, 2006|Actual|2006-07-05|August 2017|2017-08-31|April 19, 2018|Anticipated|2018-04-19|April 19, 2017|Actual|2017-04-19||Interventional|||Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097|A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)|Active, not recruiting||Phase 3|376|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:04:53.788257|2018-06-01 04:04:53.788257
NCT00310375|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|2016-07-27||2018-03-12|2006-03-30|2006-04-03|Estimate|2016-10-04|2016-11-25|Estimate||||2018-03-12|2018-04-09|Actual|May 1, 2006|Actual|2006-05-01|February 2018|2018-02-28|March 15, 2017|Actual|2017-03-15|November 30, 2016|Actual|2016-11-30||Interventional|||Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial|A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)|Completed||Phase 3|181|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:04:54.688246|2018-06-01 04:04:54.688246
NCT00310362|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|2014-09-16||2015-04-06|2006-03-30|2006-04-03|Estimate|2014-09-22|2014-09-25|Estimate||||2015-04-06|2015-04-24|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|GIVER||Use of Telehealth In-home Messaging to Improve GI (Gastrointestinal) Endoscopy Completion Rates|Use of Telehealth In-Home Messaging to Improve GI Endoscopy Completion Rates|Completed||N/A|3610|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:04:58.491359|2018-06-01 04:04:58.491359
NCT00310349|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2007-12-12|2006-03-31|2006-04-03|Estimate|||||||2007-12-12|2007-12-13|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|January 2009|Anticipated|2009-01-31|||||Interventional|||PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease|PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease|Unknown status|Not yet recruiting|Phase 3|210|Anticipated|University of Melbourne|||||f||||||||||||||2018-06-01 04:04:58.736975|2018-06-01 04:04:58.736975
NCT00310336|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2010-10-27|2006-03-31|2006-04-03|Estimate|||||||2010-10-27|2010-10-28|Estimate|August 2006||2006-08-31|October 2010|2010-10-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine|Chronic Hepatitis C: Treatment of (Peg)Interferon Alpha - Ribavirin Non-Responders With Pegylated Interferon alpha2b, Ribavirin, AdoMet and Betaine|Completed||Phase 2/Phase 3|30|Anticipated|University Hospital, Basel, Switzerland|||||f||||||||||||||2018-06-01 04:04:58.83141|2018-06-01 04:04:58.83141
NCT00297674|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-02-27|2006-02-27|2006-02-28|Estimate|||||||2006-02-27|2006-02-28|Estimate|June 2004||2004-06-30|July 2004|2004-07-31|December 2005||2005-12-31|||||Interventional|||Intravenous Clarithromycin in Septic Syndrome|Clarithromycin as Immunomodulatory Therapy for the Management of Septic Syndrome by Ventilator-Associated Pneumonia|Completed||Phase 4|200||University of Athens|||||f||||||||||||||2018-06-01 04:08:27.969642|2018-06-01 04:08:27.969642
NCT00310310|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|2014-12-23||2017-03-22|2006-03-30|2006-04-03|Estimate|2017-01-31|2017-03-22|Actual||||2017-03-22|2017-04-20|Actual|April 2006||2006-04-30|March 2017|2017-03-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional||The target population for this study is all Veterans with OSA. It was expected that most participants would be middle-aged and older men and women, from a variety of ethnic backgrounds and with a full range of medical co-morbidities.|Effect of Self-Management on Improving Sleep Apnea Outcomes|Effect of Self-Management on Improving Sleep Apnea Outcomes|Completed||Phase 2/Phase 3|240|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-06-01 04:04:59.063445|2018-06-01 04:04:59.063445
NCT00310297|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2011-01-10|2006-03-31|2006-04-03|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2004||2004-11-30|July 2008|2008-07-31||||December 2004|Actual|2004-12-31||Interventional|||Insulin Glulisine in Type 2 Diabetes Mellitus|A Randomized, Open Label, Two-arm, Cross-over Design Study to Compare the Pharmacodynamics and Pharmacokinetics of Insulin Glulisine and Insulin Lispro in Obese Patients With Type 2 Diabetes.|Completed||Phase 1|||Sanofi|||||f||||||||||||||2018-06-01 04:04:59.500021|2018-06-01 04:04:59.500021
NCT00310284|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-03-31|2006-03-31|2006-04-03|Estimate|||||||2006-03-31|2006-04-03|Estimate|January 2006||2006-01-31|March 2006|2006-03-31||||||||Interventional|||A Treatment Study Comparing Two Non-Drug, Self-Help Treatment of Chronic Insomnia.|Computerized Self-Help Treatment for Primary Insomnia|Unknown status|Recruiting|N/A|200||PICS, Inc.|||||f||||||||||||||2018-06-01 04:04:59.567228|2018-06-01 04:04:59.567228
NCT00310271|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2008-11-20|2006-03-31|2006-04-03|Estimate|||||||2008-11-20|2008-11-21|Estimate|April 2006||2006-04-30|November 2008|2008-11-30|December 2006||2006-12-31|||||Interventional|||A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects|A Phase I Study Assessing Safety and Tolerability of a DNA Vaccine With a DNA Encoded Immunostimulator , Administered by Particle Mediated Epidermal Delivery Using the PowderMed ND10 Delivery System in HSV-2 Seronegative Healthy Volunteers|Completed||Phase 1|42||PowderMed|||||||||||||||||||2018-06-01 04:04:59.657814|2018-06-01 04:04:59.657814
NCT00310258|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2017-01-10|2006-03-30|2006-04-03|Estimate|||||||2017-01-10|2017-01-11|Estimate|April 2005||2005-04-30|March 2006|2006-03-31|February 2006||2006-02-28|||||Interventional|||Drug Use Prevention Among Girls Through a Mother-Daughter Intervention|Drug Abuse Prevention: A Mother-Daughter Intervention|Completed||Phase 3|2000||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:04:59.717953|2018-06-01 04:04:59.717953
NCT00310245|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-07-21|2006-03-31|2006-04-03|Estimate|||||||2006-07-21|2006-07-24|Estimate|November 2000||2000-11-30|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||BASTA Study on STI in HIV Infected Patients|Strategic Long Term, Immunologically Driven Treatment Interruptions in Patients on Effective HAART: a Controlled, Randomized Study|Completed||Phase 3|130||A.O. Ospedale Papa Giovanni XXIII|||||f||||||||||||||2018-06-01 04:04:59.791595|2018-06-01 04:04:59.791595
NCT00310232|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2007-06-29|2006-03-31|2006-04-03|Estimate|||||||2007-06-29|2007-07-03|Estimate|February 2001||2001-02-28|March 2006|2006-03-31|April 2004|Actual|2004-04-30|||||Interventional|||Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)|Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20)|Terminated||Phase 3|70|Actual|Ontario Clinical Oncology Group (OCOG)||||Recommendation of DSMB for safety issue, increased mortality with study drug.|f||||t||||||||||2018-06-01 04:04:59.918899|2018-06-01 04:04:59.918899
NCT00310219|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2014-01-23|2006-03-29|2006-04-03|Estimate|||||||2014-01-23|2014-01-24|Estimate|February 2006||2006-02-28|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2010|Actual|2010-11-30||Interventional|||Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer|Comparative Study of Gross Tumor Volume Definition With or Without PET Fusion for Patients With Non-Small Cell Lung Carcinoma|Completed||N/A|52|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 04:05:00.076683|2018-06-01 04:05:00.076683
NCT00310206|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2013-05-30|2006-03-30|2006-04-03|Estimate|||||||2013-05-30|2013-06-03|Estimate|July 2005||2005-07-31|October 2009|2009-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults|A Randomized, Open-Label, Phase I Clinical Trial Comparing the Safety, Reactogenicity, and Immunogenicity of Immunization With Inactivated Influenza A/H5N1 Vaccine Administered by the Intradermal or the Intramuscular Route Among Healthy Adults|Completed||Phase 1|100|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:05:00.204097|2018-06-01 04:05:00.204097
NCT00310180|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2018-05-28|2006-03-29|2006-04-03|Estimate|||||||2018-05-28|2018-05-30|Actual|April 7, 2006|Actual|2006-04-07|January 2018|2018-01-31||||March 2, 2018|Actual|2018-03-02||Interventional|TAILORx||Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)|Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial|Active, not recruiting||Phase 3|10357|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-06-01 04:05:00.54712|2018-06-01 04:05:00.54712
NCT00310167|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-11-16|2006-03-29|2006-04-03|Estimate|||||||2017-11-16|2017-11-17|Actual|October 2005||2005-10-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|July 2013|Actual|2013-07-31||Interventional|FoRT||Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma|A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma|Completed||Phase 3|614|Actual|University College, London||2|||f||||t||||||||||2018-06-01 04:05:03.932275|2018-06-01 04:05:03.932275
NCT00310154|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-05-25|2006-03-29|2006-04-03|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2003||2003-11-30|November 2011|2011-11-30|August 2010|Actual|2010-08-31|July 2007|Actual|2007-07-31||Interventional|||Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study|Completed||Phase 1|45|Anticipated|Wake Forest University Health Sciences|||||f||||f|t|f||||||||2018-06-01 04:05:04.035344|2018-06-01 04:05:04.035344
NCT00310141|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-08-18|2006-03-29|2006-04-03|Estimate|||||||2017-08-18|2017-08-22|Actual|April 8, 2002|Actual|2002-04-08|August 2017|2017-08-31|August 30, 2016|Actual|2016-08-30|August 17, 2006|Actual|2006-08-17||Interventional|||Computer-Assisted Counseling in Helping African American Smokers Stop Smoking|Treatment of Nicotine Dependence Among African Americans|Completed||N/A|462|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 04:05:04.155756|2018-06-01 04:05:04.155756
NCT00309959|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2014-12-29|2006-03-29|2006-04-03|Estimate|||||||2014-12-29|2014-12-31|Estimate|November 2006||2006-11-30|December 2014|2014-12-31||||February 2011|Actual|2011-02-28||Interventional|||ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix|Completed||Phase 2|37|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 04:05:06.728536|2018-06-01 04:05:06.728536
NCT00310128|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2016-02-01|2006-03-29|2006-04-03|Estimate|||||||2016-02-01|2016-02-03|Estimate|February 2006||2006-02-28|February 2016|2016-02-29||||||||Interventional|||Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma|Phase II Study of Induction Therapy Comprising Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Followed by Consolidation Therapy Comprising Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma|Withdrawn||Phase 2|0|Actual|AIDS Malignancy Consortium||||Drug supply unavailable|f||||||||||||||2018-06-01 04:05:04.260813|2018-06-01 04:05:04.260813
NCT00310115|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2016-09-21|2006-03-29|2006-04-03|Estimate|||||||2016-09-21|2016-09-23|Estimate|April 2002||2002-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy|Smoking Relapse Prevention Among Postpartum Women|Completed|||469|Actual|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-06-01 04:05:04.362354|2018-06-01 04:05:04.362354
NCT00310089|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2013-06-18|2006-03-29|2006-04-03|Estimate|||||||2013-06-18|2013-06-20|Estimate|January 2006||2006-01-31|January 2007|2007-01-31|July 2007|Actual|2007-07-31|||||Interventional|||AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer|A Pilot Study to Evaluate The Effects of Neoadjuvant AZD2171, a VEGF Receptor Tyrosine Kinase Inhibitor With Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy in Previously Untreated Locally Advanced Breast Cancer|Completed||N/A|33|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:05:04.488549|2018-06-01 04:05:04.488549
NCT00310076|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|2012-07-24||2017-12-18|2006-03-29|2006-04-03|Estimate|2012-07-24|2012-08-28|Estimate||||2017-12-18|2018-01-18|Actual|October 2002||2002-10-31|February 2017|2017-02-28|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|||Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer|Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer|Completed||Phase 2|29|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-06-01 04:05:04.582112|2018-06-01 04:05:04.582112
NCT00310063|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-02-21|2006-03-29|2006-04-03|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2005||2005-04-30|February 2017|2017-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy|Acupressure for the Prevention of Chemotherapy-Associated Nausea and Vomiting in Children|Completed||N/A|28|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 04:05:04.838065|2018-06-01 04:05:04.838065
NCT00310050|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-02-21|2006-03-29|2006-04-03|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2005||2005-10-31|February 2017|2017-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase I Dose-Escalating Study of Induction Gemcitabine/Pemetrexed Followed by Pemetrexed and Concurrent Upper Abdominal Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer|Terminated||Phase 1|4|Actual|Wake Forest University Health Sciences||||slow accrual|f||||f||||||||||2018-06-01 04:05:04.918784|2018-06-01 04:05:04.918784
NCT00310037|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2016-06-17|2006-03-29|2006-04-03|Estimate|||||||2016-06-17|2016-06-20|Estimate|June 2006||2006-06-30|June 2016|2016-06-30||||December 2013|Actual|2013-12-31||Interventional|||Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma|A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma|Active, not recruiting||Phase 2|151|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 04:05:05.004872|2018-06-01 04:05:05.004872
NCT00310024|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2013-02-06|2006-03-29|2006-04-03|Estimate|||||||2013-02-06|2013-02-07|Estimate|November 2005||2005-11-30|February 2013|2013-02-28||||February 2008|Actual|2008-02-29||Interventional|||Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Study of SAHA in Combination With Bortezomib in Relapsed and Refractory Multiple Myeloma|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:05:05.156689|2018-06-01 04:05:05.156689
NCT00310011|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-01-17|2006-03-29|2006-04-03|Estimate|||||||2017-01-17|2017-01-19|Estimate|June 1998||1998-06-30|June 2013|2013-06-30|August 2009|Actual|2009-08-31|October 2005|Actual|2005-10-31||Interventional|||Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium|A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|71|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 04:05:05.234172|2018-06-01 04:05:05.234172
NCT00309998|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2014-09-16|2006-03-29|2006-04-03|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2005||2005-09-30|September 2014|2014-09-30||||May 2007|Actual|2007-05-31||Interventional|||Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer|Completed||Phase 2|50|Anticipated|University of Rochester|||||||||||||||||||2018-06-01 04:05:05.299614|2018-06-01 04:05:05.299614
NCT00309985|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|2015-12-17||2017-02-05|2006-03-29|2006-04-03|Estimate|2016-02-01|2016-03-03|Estimate||||2017-02-05|2017-03-15|Actual|July 2006||2006-07-31|February 2017|2017-02-28|December 2022|Anticipated|2022-12-31|December 2013|Actual|2013-12-31||Interventional|CHAARTED|All randomized patients|Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer|CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer|Active, not recruiting||Phase 3|790|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 04:05:05.568247|2018-06-01 04:05:05.568247
NCT00309972|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2014-12-01|2006-03-29|2006-04-03|Estimate|||||||2014-12-01|2014-12-03|Estimate|December 2005||2005-12-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|SOCCAR||Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Randomized Phase III Trial of Sequential Chemotherapy Followed By Radical Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Chemotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer and Good Performance Status|Completed||Phase 3|130|Actual|University College, London||2|||f||||t||||||||||2018-06-01 04:05:06.641337|2018-06-01 04:05:06.641337
NCT00309231|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-03-13|2006-03-29|2006-03-31|Estimate|||||||2017-03-13|2017-03-15|Actual||||June 2010|2010-06-30|January 2008||2008-01-31|||||Observational|||Clinical Islet Transplantation Using the Edmonton Protocol|Clinical Islet Transplantation Using the Edmonton Protocol|Withdrawn|||0|Actual|Lawson Health Research Institute||||no funding|f||||f||||||||||2018-06-01 04:05:17.346239|2018-06-01 04:05:17.346239
NCT00309946|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|2013-07-01||2014-07-25|2006-03-29|2006-04-03|Estimate|2013-07-01|2013-09-10|Estimate||||2014-07-25|2014-07-31|Estimate|December 2005||2005-12-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery|Phase II Study of AZD2171 (NSC#732208) in Patients With Malignant Mesothelioma|Completed||Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:05:06.92185|2018-06-01 04:05:06.92185
NCT00309933|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2010-03-09|2006-03-29|2006-04-03|Estimate|||||||2010-03-09|2010-03-10|Estimate|October 2005||2005-10-31|March 2010|2010-03-31||||||||Observational|||Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance|Quality of Life in Younger Breast Cancer Survivors|Unknown status|Active, not recruiting||2697|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:05:07.29463|2018-06-01 04:05:07.29463
NCT00309920|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2009-02-06|2006-03-29|2006-04-03|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2004||2004-01-31|April 2006|2006-04-30||||||||Interventional|||Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer|Adjuvant Therapy of Breast Cancer: Impact of Erythropoiesis Stimulating Factors on Event Free Survival High Risk Breast Cancer Treatment|Unknown status|Recruiting|N/A|1234|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:05:07.557261|2018-06-01 04:05:07.557261
NCT00309907|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|2014-01-06||2017-09-01|2006-03-29|2006-04-03|Estimate|2014-01-06|2014-02-14|Estimate||||2017-09-01|2017-09-29|Actual|April 2006||2006-04-30|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant|Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation|Completed||Phase 2|39|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 04:05:07.732345|2018-06-01 04:05:07.732345
NCT00309894|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2012-10-09|2006-03-29|2006-04-03|Estimate|||||||2012-10-09|2012-10-11|Estimate|April 2004||2004-04-30|October 2012|2012-10-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy|Phase II Trial to Assess the Activity of Ketoconazole Plus GM-CSF in Patients With Prostate Cancer Progressive After Androgen Deprivation|Completed||Phase 2|49|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 04:05:08.206607|2018-06-01 04:05:08.206607
NCT00309881|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2016-09-30|2006-03-29|2006-04-03|Estimate|||||||2016-09-30|2016-10-03|Estimate|April 2003||2003-04-30|September 2016|2016-09-30|March 2011|Actual|2011-03-31|March 2006|Actual|2006-03-31||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)|CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)|Completed||Phase 2|75|Anticipated|German CLL Study Group|||||f||||f||||||||Undecided||2018-06-01 04:05:08.287416|2018-06-01 04:05:08.287416
NCT00309868|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2014-03-24|2006-03-30|2006-04-03|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2002||2002-12-31|March 2014|2014-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study of Nesiritide in Diastolic Heart Failure.|A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure.|Completed||Phase 1/Phase 2|20|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:05:08.404759|2018-06-01 04:05:08.404759
NCT00309855|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2012-07-27|2006-03-31|2006-04-03|Estimate|||||||2012-07-27|2012-07-31|Estimate|December 2005||2005-12-31|July 2012|2012-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men|Mechanisms of Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men: Modulation of GHRH, GHRP and Somatostatin Action by Estrogenic Versus Androgenic Steroids|Completed||Phase 1|80|Actual|Mayo Clinic||4|||f||||||||||||||2018-06-01 04:05:08.470104|2018-06-01 04:05:08.470104
NCT00309842|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-11-29|2006-03-29|2006-04-03|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2005||2005-07-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases|Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen|Recruiting||Phase 2|150|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 04:05:08.546354|2018-06-01 04:05:08.546354
NCT00309816|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-03-30|2006-03-30|2006-04-03|Estimate|||||||2006-03-30|2006-04-03|Estimate|December 2001||2001-12-31|March 2006|2006-03-31|February 2006||2006-02-28|||||Interventional|||Study of Sildenafil in Patient With Heart Failure.|Measurement of the Effect of Sildenafil Citrate (Viagra) on the Hemodynamics of Exercise Tolerance in Advanced Congestive Heart Failure.|Completed||Phase 3|40||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:05:08.748452|2018-06-01 04:05:08.748452
NCT00309803|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2008-10-20|2006-03-30|2006-04-03|Estimate|||||||2008-10-20|2008-10-21|Estimate|March 2006||2006-03-31|October 2008|2008-10-31||||||||Interventional|||EPIC European Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting|Evaluating the Use of the FiberNet® Embolic Protection Device in Carotid Artery Stenting: The EPIC European Study|Completed||N/A|50|Anticipated|Lumen Biomedical|||||f||||f||||||||||2018-06-01 04:05:08.824932|2018-06-01 04:05:08.824932
NCT00309790|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2009-08-07|2006-03-30|2006-04-03|Estimate|||||||2009-08-07|2009-08-11|Estimate|May 2003||2003-05-31|August 2009|2009-08-31|March 2006|Actual|2006-03-31|||||Interventional|||Study of Sildenafil in Advanced Heart Failure.|Phase 3 Study of the Effects of Chronic Sildenafil Citrate Therapy on Exercise Tolerance and Hemodynamics in Patients With Advanced Heart Failure.|Completed||Phase 3|40|Anticipated|Massachusetts General Hospital|||||||||||||||||||2018-06-01 04:05:08.891122|2018-06-01 04:05:08.891122
NCT00309777|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2009-08-26||2010-01-07|2006-03-31|2006-04-03|Estimate|2009-11-13|2009-12-16|Estimate||||2010-01-07|2010-01-12|Estimate|September 2005||2005-09-30|January 2010|2010-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin|Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Completed||Phase 3|857|Actual|Kowa Research Europe||4|||f||||f||||||||||2018-06-01 04:05:08.970914|2018-06-01 04:05:08.970914
NCT00309764|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-03-31|2006-03-31|2006-04-03|Estimate|||||||2006-03-31|2006-04-03|Estimate|November 2001||2001-11-30|March 2006|2006-03-31|August 2002||2002-08-31|||||Interventional|||CHF Management Using Telemedicine|Improving CHF Outcomes Through Interactive Voice Recognition (IVR) Data Acquisition and Targeted Nurse Follow-Up|Completed||N/A|106||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:05:09.480797|2018-06-01 04:05:09.480797
NCT00309751|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|2009-08-26||2010-02-17|2006-03-31|2006-04-03|Estimate|2009-12-11|2010-01-18|Estimate||||2010-02-17|2010-02-23|Estimate|December 2005||2005-12-31|February 2010|2010-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia|Study of Pitavastatin Vs. Atorvastatin (Following Up-Titration) in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia|Completed||Phase 3|418|Actual|Kowa Research Europe||2|||f||||f||||||||||2018-06-01 04:05:09.564539|2018-06-01 04:05:09.564539
NCT00309738|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|2009-08-26||2010-03-09|2006-03-31|2006-04-03|Estimate|2009-12-11|2010-01-18|Estimate||||2010-03-09|2010-03-16|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin|Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease|Completed||Phase 3|355|Actual|Kowa Research Europe||2|||f||||f||||||||||2018-06-01 04:05:09.856647|2018-06-01 04:05:09.856647
NCT00309725|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2011-05-17|2006-03-31|2006-04-03|Estimate|||||||2011-05-17|2011-05-18|Estimate||||January 2011|2011-01-31|October 1999|Actual|1999-10-31|||||Interventional|||A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.|Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study.|Completed||Phase 3|139|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:05:10.127747|2018-06-01 04:05:10.127747
NCT00309712|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2008-08-20|2006-03-30|2006-04-03|Estimate|||||||2008-08-20|2008-08-21|Estimate|August 2002||2002-08-31|August 2008|2008-08-31|September 2006||2006-09-30|||||Interventional|||Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study|Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease|Completed||N/A|300||Intermountain Health Care, Inc.|||||f||||||||||||||2018-06-01 04:05:10.177405|2018-06-01 04:05:10.177405
NCT00309699|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2014-06-19|2006-03-31|2006-04-03|Estimate|||||||2014-06-19|2014-06-20|Estimate|April 2006||2006-04-30|June 2014|2014-06-30|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder|Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared With Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes in Bipolar Disorder|Completed||Phase 3|493|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-06-01 04:05:10.249022|2018-06-01 04:05:10.249022
NCT00309686|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2011-05-17|2006-03-31|2006-04-03|Estimate|||||||2011-05-17|2011-05-18|Estimate|April 2006||2006-04-30|March 2010|2010-03-31|August 2007|Actual|2007-08-31|||||Interventional|||A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stabilizers in the Treatment of Acute Manic and Mixed Episodes Associated With Bipolar I Disorder|Completed||Phase 3|300|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:05:10.4796|2018-06-01 04:05:10.4796
NCT00309673|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-03-31|2006-03-31|2006-04-03|Estimate|||||||2006-03-31|2006-04-03|Estimate||||March 2006|2006-03-31||||||||Interventional|||Local Anesthesia and Tuberculin Skin Test in Infants and Children|Local Anesthesia Effect on Tuberculin Skin Test Results in Infants and Children|Unknown status|Not yet recruiting|N/A|60||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:05:10.559927|2018-06-01 04:05:10.559927
NCT00309660|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-09-20|2006-03-31|2006-04-03|Estimate|||||||2006-09-20|2006-09-21|Estimate|November 2005||2005-11-30|September 2006|2006-09-30|June 2007||2007-06-30|||||Interventional|||Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis||Unknown status|Recruiting|Phase 1/Phase 2|20||Herlev Hospital|||||f||||||||||||||2018-06-01 04:05:10.635908|2018-06-01 04:05:10.635908
NCT00309647|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2017-05-05|2006-03-31|2006-04-03|Estimate|||||||2017-05-05|2017-05-08|Actual|March 29, 2006|Actual|2006-03-29|May 2017|2017-05-31|November 16, 2006|Actual|2006-11-16|November 1, 2006|Actual|2006-11-01||Interventional|||Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age|A Partially-blind Multi-centric Study in Adults Aged Between 18-60 Years Designed to Evaluate the Reactogenicity and Immunogenicity of 1 and 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses and Adjuvanted or Not|Completed||Phase 1|400|Actual|GlaxoSmithKline||8|||f||||||||||||||2018-06-01 04:05:10.705747|2018-06-01 04:05:10.705747
NCT00309634|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2017-05-09|2006-03-31|2006-04-03|Estimate|||||||2017-05-09|2017-05-10|Actual|March 27, 2006|Actual|2006-03-27|May 2017|2017-05-31|October 28, 2006|Actual|2006-10-28|October 28, 2006|Actual|2006-10-28||Interventional|||Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years|Observer-blind Monocentric Study in Adults Aged Between 18-60 Years to Evaluate Reactogenicity and Immunogenicity of 1 and 2 Administrations of Pandemic Monovalent Influenza Vaccines Administered at Different Antigen Doses and Adjuvanted or Not|Completed||Phase 1|400|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:05:10.788153|2018-06-01 04:05:10.788153
NCT00309621|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2010-07-16|2006-03-30|2006-04-03|Estimate|||||||2010-07-16|2010-07-19|Estimate|April 2006||2006-04-30|July 2010|2010-07-31|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis|Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis|Completed||Phase 3|250||Basilea Pharmaceutica|||||f||||||||||||||2018-06-01 04:05:10.895272|2018-06-01 04:05:10.895272
NCT00309608|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|2011-05-13||2014-06-24|2006-03-31|2006-04-03|Estimate|2011-05-13|2011-06-15|Estimate||||2014-06-24|2014-07-08|Estimate|April 2006||2006-04-30|December 2013|2013-12-31||||August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes|A Randomised, Double-blind, Placebo-controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS (1 mg, 5 mg and 10 mg Administered Orally Once Daily) Over 12 Weeks as add-on Therapy in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Metformin Therapy, Including an Open-label Glimepiride Treatment Arm.|Completed||Phase 2|333|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-06-01 04:05:11.103815|2018-06-01 04:05:11.103815
NCT00309595|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2009-06-10|2006-03-31|2006-04-03|Estimate|||||||2009-06-10|2009-06-12|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|SIT-UP||The Study to Compare SMART Nitinol Stent and Balloon Angioplasty|A Multi-Center Prospective, Randomized, Two-Arm Clinical Investigation of the Cordis SMARTTM Nitinol Self Expandable Stent Versus Balloon Angioplasty Only for the Treatment of Superficial Femoral Artery Occlusions.|Completed||Phase 4|50|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:05:11.75373|2018-06-01 04:05:11.75373
NCT00309582|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-03-30|2006-03-30|2006-04-03|Estimate|||||||2006-03-30|2006-04-03|Estimate||||November 2005|2005-11-30||||||||Observational|||Nevirapine Levels and Fluconazole|Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole|Completed|||||Bamrasnaradura Infectious Diseases Institute|||||f||||||||||||||2018-06-01 04:05:11.836524|2018-06-01 04:05:11.836524
NCT00309569|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-03-31|2006-03-31|2006-04-03|Estimate|||||||2006-03-31|2006-04-03|Estimate|October 1991||1991-10-31|October 1999|1999-10-31||||||||Interventional|||Randomized Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment in Receptor-Negative Patients|A Randomized Phase III Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment Hormone Receptor-Negative Breast Cancer Patients|Completed||Phase 3|480||Austrian Breast & Colorectal Cancer Study Group|||||f||||||||||||||2018-06-01 04:05:11.880793|2018-06-01 04:05:11.880793
NCT00309556|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2011-12-29|2006-03-31|2006-04-03|Estimate|||||||2011-12-29|2011-12-30|Estimate|February 2005||2005-02-28|December 2011|2011-12-31|November 2011|Actual|2011-11-30|November 2009|Actual|2009-11-30||Interventional|||Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer|A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastuzumab to Epirubicin and Docetaxel + G-CSF ± Trastuzumab as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer|Completed||Phase 3|536|Actual|Austrian Breast & Colorectal Cancer Study Group||2|||f||||f||||||||||2018-06-01 04:05:11.961358|2018-06-01 04:05:11.961358
NCT00309543|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-03-31|2006-03-31|2006-04-03|Estimate|||||||2006-03-31|2006-04-03|Estimate|November 1993||1993-11-30|March 2006|2006-03-31||||||||Interventional|||Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B|A Prospectively Randomized Study on Adjuvant Chemotherapy in Patients With Operated Colon Carcinoma Dukes B (Stage II; T3-4, N0, M0).|Completed||Phase 3|636||Austrian Breast & Colorectal Cancer Study Group|||||f||||||||||||||2018-06-01 04:05:12.082372|2018-06-01 04:05:12.082372
NCT00309530|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-03-31|2006-03-31|2006-04-03|Estimate|||||||2006-03-31|2006-04-03|Estimate|October 1990||1990-10-31|April 1999|1999-04-30||||||||Interventional|||Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C|A Prospectively Randomized Phase III Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Patients With Operated Colon Carcinoma Dukes C (Stage III; T1-4, N1-30, M0).|Completed||Phase 3|598||Austrian Breast & Colorectal Cancer Study Group|||||f||||||||||||||2018-06-01 04:05:12.169741|2018-06-01 04:05:12.169741
NCT00309517|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-03-31|2006-03-31|2006-04-03|Estimate|||||||2006-03-31|2006-04-03|Estimate|July 1997||1997-07-31|October 2000|2000-10-31||||||||Interventional|||Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C|A Prospectively Randomized Study on Neoadjuvant Radio-Chemotherapy in Patients With Operated Rectal Carcinoma Dukes B and C (pT2, pN1-3; pT3-4, pN0-3; M0.|Terminated||Phase 3|700||Austrian Breast & Colorectal Cancer Study Group|||||f||||||||||||||2018-06-01 04:05:12.248517|2018-06-01 04:05:12.248517
NCT00309504|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2016-02-24|2006-03-31|2006-04-03|Estimate|||||||2016-02-24|2016-02-26|Estimate|March 2006||2006-03-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy|Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy|Completed|||40|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:05:12.30967|2018-06-01 04:05:12.30967
NCT00309491|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2016-04-08|2006-03-31|2006-04-03|Estimate|||||||2016-04-08|2016-04-11|Estimate|December 1990||1990-12-31|April 2016|2016-04-30||||||||Interventional|||Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients|A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients|Completed||Phase 3|2020|Actual|Austrian Breast & Colorectal Cancer Study Group||2|||f||||f||||||||Undecided||2018-06-01 04:05:12.361456|2018-06-01 04:05:12.361456
NCT00309478|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-31|||2006-05-18|2006-03-31|2006-04-03|Estimate|||||||2006-05-18|2006-05-19|Estimate|December 1990||1990-12-31|June 1999|1999-06-30||||||||Interventional|||Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients|A Randomized Phase III Study Comparing Cyclophosphamide + Methotrexate + Fluorouracil Vs. Goserelin + Tamoxifen in Premenopausal, Hormone Receptor-Positive, Lymph Node-Positive or -Negative Patients|Completed||Phase 3|1099||Austrian Breast & Colorectal Cancer Study Group|||||f||||||||||||||2018-06-01 04:05:12.444075|2018-06-01 04:05:12.444075
NCT00309465|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|2012-10-01||2012-11-01|2006-03-30|2006-03-31|Estimate|2012-11-01|2012-12-03|Estimate||||2012-11-01|2012-12-03|Estimate|October 2005||2005-10-31|November 2012|2012-11-30|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Perioperative Insulin Glargine Dosing Study|A Study of the Relationship Between the Proportional Insulin Glargine Evening Dose and the Perioperative Serum Glucose Values in Patients With Diabetes Undergoing Surgery|Completed||Phase 4|402|Actual|William Beaumont Hospitals|Limitations include use of point-of-care glucometers, which are less precise than central laboratory testing; estimated 75% power in the insulin glargine only group; and varying fasting lengths, usual glycemic control and surgery starting times.|3|||f||||f||||||||||2018-06-01 04:05:12.522766|2018-06-01 04:05:12.522766
NCT00309452|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|2016-05-25||2016-12-12|2006-03-29|2006-03-31|Estimate|2016-09-12|2016-10-31|Estimate||||2016-12-12|2017-02-08|Estimate|March 2006||2006-03-31|December 2016|2016-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|STEP||Specialized Treatment Early in Psychosis (STEP)|Randomized Trial of Usual Care Versus Specialized, Phase-specific Care in the Public Sector for First Episode Psychosis.|Completed||N/A|120|Actual|Yale University||2|||f||||t||||||||||2018-06-01 04:05:12.965803|2018-06-01 04:05:12.965803
NCT00309439|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2012-06-12|2006-03-29|2006-03-31|Estimate|||||||2012-06-12|2012-06-13|Estimate||||June 2012|2012-06-30||||||||Interventional|||ALA and Prostate Cancer|Studies of Serum PSA to Help Resolve the Current Implication of Alpha-linolenic Acid (ALA) and Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|||University of Toronto|||||f||||||||||||||2018-06-01 04:05:13.475137|2018-06-01 04:05:13.475137
NCT00309426|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-05-18|2006-03-27|2006-03-31|Estimate|||||||2006-05-18|2006-05-22|Estimate|March 2001||2001-03-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Observational|||Effect of Fetuin A in Hemodialysis Patients|The Effect of Serum Fetuin A Concentration on the 5-Year Prognosis in Hemodialysis Patients|Unknown status|Active, not recruiting||300||University of Shizuoka|||||f||||||||||||||2018-06-01 04:05:13.535702|2018-06-01 04:05:13.535702
NCT00309413|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2008-07-23|2006-03-30|2006-03-31|Estimate|||||||2008-07-23|2008-07-25|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|March 2008|Actual|2008-03-31||Interventional|||A Clinical Trial on the Antipsychotic Properties of Cannabidiol|A Placebo-Controlled Randomized Cross-Over Clinical Trial on the Antipsychotic Properties of the Endocannabinoid Modulator Cannabidiol|Completed||Phase 2|29|Actual|University of Cologne||2|||f||||f||||||||||2018-06-01 04:05:13.604914|2018-06-01 04:05:13.604914
NCT00309400|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2014-08-19|2006-03-30|2006-03-31|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2006||2006-01-31|August 2014|2014-08-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Observational|||The Early History of Universal Screening for Metabolic Disorders|The Early History of Universal Screening for Metabolic Disorders|Completed|||10|Actual|University of Miami|||||f||||f||||||||||2018-06-01 04:05:13.685744|2018-06-01 04:05:13.685744
NCT00309387|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|2012-03-28||2013-04-30|2006-03-29|2006-03-31|Estimate|2012-03-28|2012-04-24|Estimate||||2013-04-30|2013-05-06|Estimate|May 1995||1995-05-31|April 2013|2013-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|CTNS||Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)|Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)|Completed||Phase 3|1020|Actual|National Eye Institute (NEI)||2|||f||||t||||||||||2018-06-01 04:05:13.770534|2018-06-01 04:05:13.770534
NCT00309374|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2007-01-04|2006-03-30|2006-03-31|Estimate|||||||2007-01-04|2007-01-05|Estimate|March 2006||2006-03-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Anti-Inflammatory Effect of Statins in the Human Endotoxin Model|Anti-Inflammatory Effect of Statins in the Human Endotoxin Model|Completed||Phase 1|6||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:05:14.35043|2018-06-01 04:05:14.35043
NCT00309361|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-11-16|2006-03-30|2006-03-31|Estimate|||||||2006-11-16|2006-11-17|Estimate|February 2006||2006-02-28|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures|A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Dental Patients Undergoing Mandibular Procedures|Completed||Phase 3|240||Novalar Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:05:14.502866|2018-06-01 04:05:14.502866
NCT00309348|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2017-09-26|2006-03-30|2006-03-31|Estimate|||||||2017-09-26|2017-09-27|Actual|February 27, 2006|Actual|2006-02-27|September 2017|2017-09-30|April 30, 2008|Actual|2008-04-30|April 30, 2008|Actual|2008-04-30||Interventional|||Ultrasound Instrument to Prevent Dialysis Graft Failure|New Doppler Instrument for Preventing Impending Access-Graft Failure Randomized Trial|Completed||N/A|111|Actual|DVX, LLC||2|||f||||f|f|f||||||||2018-06-01 04:05:14.618918|2018-06-01 04:05:14.618918
NCT00309335|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-11-16|2006-03-30|2006-03-31|Estimate|||||||2006-11-16|2006-11-17|Estimate|February 2006||2006-02-28|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures|A Phase 3, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Efficacy, Pharmacodynamics and Safety in Dental Patients Undergoing Maxillary Procedures|Completed||Phase 3|240||Novalar Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:05:14.835373|2018-06-01 04:05:14.835373
NCT00309322|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-11-16|2006-03-30|2006-03-31|Estimate|||||||2006-11-16|2006-11-17|Estimate|March 2006||2006-03-31|November 2006|2006-11-30|August 2006||2006-08-31|||||Interventional|||Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures|A Phase 2, Multicenter, Randomized, Blinded, Controlled Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Mandibular and Maxillary Procedures|Completed||Phase 2|150||Novalar Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:05:14.915268|2018-06-01 04:05:14.915268
NCT00309309|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2007-07-02|2006-03-30|2006-03-31|Estimate|||||||2007-07-02|2007-07-03|Estimate|April 2005||2005-04-30|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Metabolic and Renal Effects of Rosiglitazone in Kidney Transplant|A Prospective, Longitudinal Study to Assess the Metabolic and Renal Effects of Rosiglitazone in Albuminuric Kidney Transplant Recipients|Completed||Phase 2|10|Actual|Mario Negri Institute for Pharmacological Research|||||f||||f||||||||||2018-06-01 04:05:15.076679|2018-06-01 04:05:15.076679
NCT00309296|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2011-02-11|2006-03-30|2006-03-31|Estimate|||||||2011-02-11|2011-02-14|Estimate|November 2005||2005-11-30|February 2011|2011-02-28|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Longitudinal Care: Smoking Reduction to Aid Cessation|Longitudinal Care: Smoking Reduction to Aid Cessation; Part of Hatsukami's Tobacco Exposure Reduction|Completed||N/A|443|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-06-01 04:05:15.239743|2018-06-01 04:05:15.239743
NCT00309283|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2013-04-23|2006-03-30|2006-03-31|Estimate|||||||2013-04-23|2013-04-24|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ALADIN||Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study|Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study|Completed||Phase 3|78|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-06-01 04:05:15.547389|2018-06-01 04:05:15.547389
NCT00309270|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-05-18|2006-03-30|2006-03-31|Estimate|||||||2006-05-18|2006-05-22|Estimate|February 2003||2003-02-28|March 2006|2006-03-31|April 2010||2010-04-30|||||Interventional|||Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation|A Prospective, Randomized Study to Compare the Effect of Campath-1,Low Dose Sirolimus Versus Campath-1H, Low Dose CsA Both in Addition to Low Dose Mycophenolate Mofetil on Phenotypic and Functional Profiles of PBMCs in Kidney Transplant Recipients in a Steroid-Free Regimen|Completed||Phase 2|21||Mario Negri Institute for Pharmacological Research|||||f||||||||||||||2018-06-01 04:05:15.699306|2018-06-01 04:05:15.699306
NCT00309257|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2009-10-05|2006-03-30|2006-03-31|Estimate|||||||2009-10-05|2009-10-06|Estimate|January 2004||2004-01-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|June 2008|Actual|2008-06-30||Interventional|||Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome|Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome|Completed||Phase 2|9|Actual|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||||2018-06-01 04:05:15.915936|2018-06-01 04:05:15.915936
NCT00309244|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2014-07-22|2009-06-09|2014-10-09|2006-03-29|2006-03-31|Estimate|2014-10-09|2014-10-16|Estimate|2009-10-01|2009-10-05|Estimate|2014-10-09|2014-10-16|Estimate|February 2006||2006-02-28|October 2014|2014-10-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional||Safety population (23 Subjects randomized but never dosed are not included).|Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up|A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere /Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up|Completed||Phase 3|677|Actual|Mannkind Corporation||2|||f||||||||||||||2018-06-01 04:05:16.191687|2018-06-01 04:05:16.191687
NCT00309218|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2015-04-22|2006-03-30|2006-03-31|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 1999||1999-03-31|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Steroid Withdrawal in Pediatric Renal Transplant Recipients Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)|Multicenter, Open-label, Randomized Study on Steroid-free Immunosuppression, in Comparison With Daily Steroid Therapy, in Children With Stable Renal Transplant Function Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)|Completed||Phase 3|42|Actual|Klinik für Kinder- und Jugendmedizin||2|||f||||t||||||||||2018-06-01 04:05:17.429924|2018-06-01 04:05:17.429924
NCT00309205|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2009-08-31|2006-03-30|2006-03-31|Estimate|||||||2009-08-31|2009-09-01|Estimate|December 2005||2005-12-31|August 2009|2009-08-31||||||||Interventional|||A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium|A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.|Completed||Phase 1/Phase 2|36||International Partnership for Microbicides, Inc.|||||f||||||||||||||2018-06-01 04:05:17.604562|2018-06-01 04:05:17.604562
NCT00309192|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2006-09-13|2006-03-30|2006-03-31|Estimate|||||||2006-09-13|2006-09-14|Estimate|April 2006||2006-04-30|September 2006|2006-09-30|April 2008||2008-04-30|||||Interventional|||Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema|Efficacy and Safety of Intravitreal Triamcinolone as Treatment of the Diffuse Diabetic Macular Edema|Unknown status|Recruiting|Phase 3|292||Instituto Universitario de Oftalmobiología Aplicada|||||f||||||||||||||2018-06-01 04:05:17.706501|2018-06-01 04:05:17.706501
NCT00309179|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29||2016-04-11|2017-09-06|2006-03-29|2006-03-31|Estimate||||2016-04-11|2016-05-06|Estimate|2017-09-06|2017-09-14|Actual|September 24, 2007|Actual|2007-09-24|September 2017|2017-09-30|February 13, 2017|Actual|2017-02-13|December 14, 2009|Actual|2009-12-14||Interventional|||A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors|A Single Arm Phase II Study of the Efficacy, Safety, and Biomarkers of Activity of E7820 Plus Cetuximab in Advanced Solid Tumors Preceded by a Run-In Study to Determine Safety of the Combination|Completed||Phase 2|41|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 04:05:17.985426|2018-06-01 04:05:17.985426
NCT00309166|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2016-09-08|2006-03-28|2006-03-31|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2006||2006-04-30|September 2016|2016-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.|An Observer-blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years|Completed||Phase 2|270|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:05:18.172784|2018-06-01 04:05:18.172784
NCT00309140|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29||2010-05-27|2010-05-27|2006-03-29|2006-03-31|Estimate||||2010-05-27|2010-06-02|Estimate|2010-05-27|2010-06-02|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||An Open Label Study of Oral Enzastaurin in Patients With Cancer|An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies|Completed||Phase 2|23|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:05:18.357096|2018-06-01 04:05:18.357096
NCT00309127|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2015-08-21|2006-03-30|2006-03-31|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2003||2003-05-31|August 2015|2015-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy|A Multicentre, Randomised Study to Examine the Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy|Completed||N/A|205|Actual|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:05:18.492697|2018-06-01 04:05:18.492697
NCT00309114|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2017-02-21|2006-03-30|2006-03-31|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2004||2004-02-29|February 2017|2017-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)|Prevention of UTI in Persons With Spinal Cord Injury|Completed||N/A|65|Actual|Baylor College of Medicine||2|||f||||t||||||||No||2018-06-01 04:05:18.567881|2018-06-01 04:05:18.567881
NCT00309101|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2009-06-02|2006-03-29|2006-03-31|Estimate|||||||2009-06-02|2009-06-03|Estimate|February 2006||2006-02-28|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Open Study for Steroid Resistant, Non-Thymectomized MG Patients|FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients|Completed||Phase 3|11|Actual|Astellas Pharma Inc||1|||f||||||||||||||2018-06-01 04:05:18.719286|2018-06-01 04:05:18.719286
NCT00309088|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2014-08-22|2006-03-29|2006-03-31|Estimate|||||||2014-08-22|2014-08-25|Estimate|April 2006||2006-04-30|August 2014|2014-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients|FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients|Completed||Phase 3|80|Actual|Astellas Pharma Inc||2|||f||||||||||||||2018-06-01 04:05:18.815003|2018-06-01 04:05:18.815003
NCT00309075|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2014-12-29|2006-03-30|2006-03-31|Estimate|||||||2014-12-29|2014-12-30|Estimate|December 2003||2003-12-31|December 2014|2014-12-31|November 2004|Actual|2004-11-30|||||Interventional|||Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries|Multicenter, Open-label Study of the Safety (Open-label) and Efficacy (Open-label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients With Known or Suspected Disease of the Calf and/or Pedal Arteries Undergoing MRA of the Calf and Pedal Arteries With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as the Standard of Reference.|Completed||Phase 3|126|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:05:18.964815|2018-06-01 04:05:18.964815
NCT00309062|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2013-03-08|2006-03-30|2006-03-31|Estimate|||||||2013-03-08|2013-03-11|Estimate|December 2003||2003-12-31|March 2013|2013-03-31|June 2009|Actual|2009-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1|Completed||Phase 3|||Allergopharma GmbH & Co. KG|||||f||||f||||||||||2018-06-01 04:05:19.074642|2018-06-01 04:05:19.074642
NCT00309049|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-01-27|2006-03-30|2006-03-31|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2006||2006-04-30|January 2017|2017-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Ixabepilone Administered as an Enteric Coated Formulation.|An Exploratory Study of Ixabepilone Administered as an Enteric Coated Formulation in Patients With Advanced Cancer.|Completed||Phase 1/Phase 2|30||R-Pharm||3|||f||||||||||||||2018-06-01 04:05:19.196582|2018-06-01 04:05:19.196582
NCT00309036|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-30|||2013-03-08|2006-03-30|2006-03-31|Estimate|||||||2013-03-08|2013-03-11|Estimate|January 2004||2004-01-31|March 2013|2013-03-31|May 2008|Actual|2008-05-31|September 2006|Actual|2006-09-30||Interventional|||Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Cocktail of Recombinant Derivatives of Major Allergens of Timothy Grass (Phleum Pratense).|Completed||Phase 3|||Allergopharma GmbH & Co. KG|||||f||||||||||||||2018-06-01 04:05:19.459139|2018-06-01 04:05:19.459139
NCT00309023|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29||2010-09-10|2015-09-23|2006-03-29|2006-03-31|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|December 2005||2005-12-31|September 2015|2015-09-30|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|||Study of BMS-663513 in Patients With Advanced Cancer|A Phase I/II, Ascending Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients With Metastatic or Locally Advanced Solid Malignancies|Terminated||Phase 1/Phase 2|115|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:05:19.524575|2018-06-01 04:05:19.524575
NCT00309010|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2017-06-30|2006-03-29|2006-03-30|Estimate|||||||2017-06-30|2017-07-02|Actual|March 28, 2006||2006-03-28|February 24, 2009|2009-02-24|February 24, 2009||2009-02-24|||||Observational|||Neurophysiology of Task-Specificity of Focal Hand Dystonia|Neurophysiology of Task-Specificity of Focal Hand Dystonia|Completed|||115||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:05:19.588551|2018-06-01 04:05:19.588551
NCT00308997|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|2012-11-14||2012-12-13|2006-03-28|2006-03-30|Estimate|2012-12-13|2013-01-24|Estimate||||2012-12-13|2013-01-24|Estimate|February 2006||2006-02-28|December 2012|2012-12-31|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||"Transcranial Magnetic Stimulation for Voices"|"Transcranial Magnetic Stimulation Guided by Neuroimaging for Patients With Persistent Voices"|Completed||Phase 2|85|Actual|Yale University||2|||f||||t||||||||||2018-06-01 04:05:20.666057|2018-06-01 04:05:20.666057
NCT00308984|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2012-03-06|2006-03-28|2006-03-30|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Observational|||CARE--Childhood Awareness and Recall Evaluation|Multi-Center Study on the Incidence of Intra-operative Awareness and Recall in the Pediatric Population Undergoing General Anesthesia: CARE--Childhood Awareness and Recall Evaluation|Completed|||1784|Actual|Medtronic - MITG|||||f||||f||||||||||2018-06-01 04:05:20.929968|2018-06-01 04:05:20.929968
NCT00308971|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2009-07-08|2006-03-28|2006-03-30|Estimate|||||||2009-07-08|2009-07-09|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)|Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)|Completed||Phase 2|62|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:05:20.997435|2018-06-01 04:05:20.997435
NCT00308958|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2013-05-28|2006-03-28|2006-03-30|Estimate|||||||2013-05-28|2013-05-30|Estimate|February 2006||2006-02-28|May 2013|2013-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Comparison of Airway Clearance Efficacy of Two High Frequency Chest Wall Oscillation (HFCWO) Devices in Cystic Fibrosis|Comparison of Airway Clearance Efficacy of Sine Wave and Triangular Wave High Frequency Chest Wall Oscillation (HFCWO) Devices in Patients With Cystic Fibrosis|Completed||N/A|15||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:05:21.182582|2018-06-01 04:05:21.182582
NCT00308945|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2008-01-14|2006-03-29|2006-03-30|Estimate|||||||2008-01-14|2008-01-17|Estimate|November 2003||2003-11-30|January 2008|2008-01-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Influence of Prostaglandins on Ocular Blood Flow in Glaucoma Patients|Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients|Completed||Phase 4|20|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 04:05:21.281296|2018-06-01 04:05:21.281296
NCT00308932|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2011-09-16|2006-03-28|2006-03-30|Estimate|||||||2011-09-16|2011-09-20|Estimate|February 2003||2003-02-28|August 2004|2004-08-31|April 2004||2004-04-30|||||Interventional|||Effect of Age and Device on Delivery of Fluticasone|Relative Amount of Fluticasone Delivered by HFA-MDI Through Chamber/Mask to Young Children With Asthma|Completed||Phase 4|60||University of Florida|||||||||||||||||||2018-06-01 04:05:21.399293|2018-06-01 04:05:21.399293
NCT00308919|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2010-06-18|2006-03-28|2006-03-30|Estimate|||||||2010-06-18|2010-06-22|Estimate|April 2004||2004-04-30|May 2010|2010-05-31|November 2005|Actual|2005-11-30|||||Interventional|||Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy|Phase II Study of Photodynamic Therapy With WST-09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure : Effect of the Light Dose and the Number of Fibres|Completed||Phase 2|28|Actual|STEBA France||1|||f||||||||||||||2018-06-01 04:05:22.364445|2018-06-01 04:05:22.364445
NCT00308906|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2016-01-30|2006-03-29|2006-03-30|Estimate|||||||2016-01-30|2016-02-02|Estimate|June 2006||2006-06-30|January 2016|2016-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children|Assessment of Gene and Urinary Protein Expression in Aminoglycoside-treated and Untreated Infants, Children and Adolescents|Completed|||166|Actual|Virginia Commonwealth University|||3||f||||f||||||Samples With DNA|"~     Waste blood samples will be collected in order to evaluate potential genetic mechanisms of~     aminoglyoside induced renal injury. Waste urine samples will be collected in order to~     evaluate candidate protein biomarkers of aminoglycoside induced renal injury.~   "|||2018-06-01 04:05:22.439244|2018-06-01 04:05:22.439244
NCT00308893|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2013-12-17|2006-03-28|2006-03-30|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 2006||2006-07-31|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||BDNF Gene Polymorphism and Antidepressants Treatment|Brain Derived Neurotrophic Factor (BDNF) Gene Polymorphism and Response to Antidepressants Treatment in Major Depression|Completed||Phase 4|188|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-06-01 04:05:22.515451|2018-06-01 04:05:22.515451
NCT00308880|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2006-03-29|2006-03-29|2006-03-30|Estimate|||||||2006-03-29|2006-03-30|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|March 2007||2007-03-31|||||Interventional|||Tranexamic Acid and Head and Neck Surgery Patients|If Tranexamic Acid Could Reduce the Duration of Drainage Tube Placement ? —A Prospective Randomized Study in Head and Neck Surgery Patients|Unknown status|Recruiting|Phase 3|80||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 04:05:22.585676|2018-06-01 04:05:22.585676
NCT00308867|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2008-04-10|2006-03-29|2006-03-30|Estimate|||||||2008-04-10|2008-04-11|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK|Photodynamic Therapy With PD P 506 A or Its Placebo Compared With Cryosurgery for the Treatment of Mild to Moderate Actinic Keratosis|Completed||Phase 3|349|Actual|photonamic GmbH & Co. KG|||||f||||f||||||||||2018-06-01 04:05:22.674668|2018-06-01 04:05:22.674668
NCT00308854|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2008-04-10|2006-03-29|2006-03-30|Estimate|||||||2008-04-10|2008-04-11|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AK|PD P 506 A or Its Placebo in Combination With Red Light for Photodynamic Therapy of Mild to Moderate Actinic Keratosis|Completed||Phase 3|107|Actual|photonamic GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 04:05:22.800258|2018-06-01 04:05:22.800258
NCT00308841|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2008-10-17|2006-03-29|2006-03-30|Estimate|||||||2008-10-17|2008-10-20|Estimate||||September 2005|2005-09-30||||||||Interventional|||"Anesthetic Efficacy of Intrauterine Lidocaine for Removal of a Lost Intrauterine Device"||Completed||Phase 1|||Suleyman Demirel University|||||f||||||||||||||2018-06-01 04:05:23.01564|2018-06-01 04:05:23.01564
NCT00308828|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2008-06-05|2006-03-29|2006-03-30|Estimate|||||||2008-06-05|2008-06-06|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||The Prevalence of Osteoporosis in Hemodialysis Patients|Prevalence of Osteoporosis in Hemodialysis Patients and Relevance With Renal Bone Disease|Completed|||166|Actual|Papageorgiou General Hospital|||||f||||||||||||||2018-06-01 04:05:23.090763|2018-06-01 04:05:23.090763
NCT00308815|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2006-03-28|2006-03-28|2006-03-30|Estimate|||||||2006-03-28|2006-03-30|Estimate|January 2005||2005-01-31|October 2004|2004-10-31||||||||Interventional|||Comparison of Manual Cardiopulmonary Resuscitation (CPR) Versus Automatic CPR Machine During Ambulance Transport.|Comparison of Manual Cardiopulmonary Resuscitation (CPR) Versus Automatic CPR Machine on the CPR Performance for Out-of-Hospital Cardiac Arrest During Ambulance Transport.|Unknown status|Recruiting|N/A|100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:05:23.14709|2018-06-01 04:05:23.14709
NCT00308802|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2013-08-29|2006-03-28|2006-03-30|Estimate|||||||2013-08-29|2013-09-02|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients|Noninvasive Monitoring to Predict Outcome in De Novo Kidney Transplant Recipients|Completed|||280|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     Blood samples may be retained~   "|||2018-06-01 04:05:23.223373|2018-06-01 04:05:23.223373
NCT00308789|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2009-05-04|2006-03-28|2006-03-30|Estimate|||||||2009-05-04|2009-05-05|Estimate|April 2006||2006-04-30|May 2009|2009-05-31|December 2009|Anticipated|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||A Trial of Infant Flow Biphasic Nasal Continuous Airway Pressure (NCPAP) Versus Infant Flow NCPAP for the Facilitation of Extubation in Infants </= 1250 Grams|Infant Flow Biphasic NCPAP Versus Infant Flow NCPAP for the Facilitation of Successful Extubation in Infants </= 1250 Grams: A Randomized Controlled Trial|Terminated||Phase 2|136|Actual|Mount Sinai Hospital, Canada||2||Poor enrollment|f||||f||||||||||2018-06-01 04:05:23.316605|2018-06-01 04:05:23.316605
NCT00308776|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2012-05-25|2006-03-28|2006-03-30|Estimate|||||||2012-05-25|2012-05-28|Estimate|October 2003||2003-10-31|May 2012|2012-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa|Effect of Cholecystokinin on Binge Eating in Bulimia Nervosa|Terminated||N/A|6|Actual|New York State Psychiatric Institute||2||Unable to recruit subjects|f||||f||||||||||2018-06-01 04:05:23.405171|2018-06-01 04:05:23.405171
NCT00308763|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2014-05-20|2006-03-28|2006-03-30|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2004||2004-01-31|May 2014|2014-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals|Clinical Trial of Two Medications on Smoking Cessation|Completed||N/A|594|Actual|University of Tennessee||3|||f||||t||||||||||2018-06-01 04:05:23.482545|2018-06-01 04:05:23.482545
NCT00308750|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28||2010-05-27|2010-05-27|2006-03-28|2006-03-30|Estimate||||2010-05-27|2010-06-02|Estimate|2010-05-27|2010-06-02|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||First Line Chemotherapy Treatment of Advanced NSCLC|A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|217|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 04:05:23.565178|2018-06-01 04:05:23.565178
NCT00308737|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|2014-07-22|2009-06-09|2014-10-09|2006-03-28|2006-03-30|Estimate|2014-10-09|2014-10-16|Estimate|2009-10-01|2009-10-05|Estimate|2014-10-09|2014-10-16|Estimate|June 2005||2005-06-30|October 2014|2014-10-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional||Safety population, excluding subjects who were not dosed with study medication (17 diabetics randomized but not dosed, 1 non-diabetic elected not to participate)|Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes|Pulmonary Outcomes Within a 2-Year Period in Subjects With Diabetes Mellitus Treated With Technosphere /Insulin or Usual Antidiabetic Treatment and in Subjects Without Abnormalities in Glucose Control.|Completed||Phase 3|2053|Actual|Mannkind Corporation||3|||f||||||||||||||2018-06-01 04:05:23.746152|2018-06-01 04:05:23.746152
NCT00308724|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2015-07-21|2006-03-28|2006-03-30|Estimate|||||||2015-07-21|2015-07-23|Estimate|March 2004||2004-03-31|January 2015|2015-01-31|April 2015|Actual|2015-04-30|January 2008|Actual|2008-01-31||Interventional|||Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care|Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care|Completed||Phase 3|148|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 04:05:25.317017|2018-06-01 04:05:25.317017
NCT00308711|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2009-07-29||2012-06-15|2006-03-28|2006-03-30|Estimate|2010-01-29|2010-02-19|Estimate||||2012-06-15|2012-06-25|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor|A Multi-center, Randomized, Double-blind Phase III Study of the Efficacy and Safety of the Misoprostol Vaginal Insert Compared to Cervidil for Women Requiring Cervical Ripening and Induction of Labor (The MVP Study).|Completed||Phase 3|1308|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-06-01 04:05:25.43142|2018-06-01 04:05:25.43142
NCT00308698|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2006-03-29|2006-03-29|2006-03-30|Estimate|||||||2006-03-29|2006-03-30|Estimate||||July 2004|2004-07-31||||||||Observational|||Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning Hemodialysis (HD)|Recombinant Human Erythropoietin Dose, Serum Adiponectin, and All-Cause Mortality in Patients Beginning Hemodialysis|Completed|||||Hamamatsu University|||||f||||||||||||||2018-06-01 04:05:26.4274|2018-06-01 04:05:26.4274
NCT00308685|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28||2013-08-27|2015-10-29|2006-03-28|2006-03-30|Estimate||||2013-08-27|2013-09-12|Estimate|2015-10-29|2015-11-26|Estimate|July 2007||2007-07-31|October 2015|2015-10-31||||July 2008|Actual|2008-07-31||Interventional|||Chronic-dose Safety and Efficacy Study of a Bronchodilator Inhaler in Pediatric Asthmatics||Completed||Phase 3|100|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 04:05:26.484197|2018-06-01 04:05:26.484197
NCT00308490|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2007-03-12|2006-03-28|2006-03-29|Estimate|||||||2007-03-12|2007-03-13|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|January 2007||2007-01-31|||||Interventional|||Changes in Iron Markers Following Iron Loading in Hemodialysis Patients|Phase IV Study of Iron Indices' Kinetics in Hemodialysis Patients|Completed||Phase 4|160||Papageorgiou General Hospital|||||f||||||||||||||2018-06-01 04:05:30.528803|2018-06-01 04:05:30.528803
NCT00308672|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2006-03-29|2006-03-29|2006-03-30|Estimate|||||||2006-03-29|2006-03-30|Estimate|August 2005||2005-08-31|March 2006|2006-03-31|July 2006||2006-07-31|||||Observational|||The Prevalence of Metabolic Syndrome and Its Associated Factors in an Urban City|The Study for the Prevalence of Metabolic Syndrome and Its Associated Factors in an Urban City- Comparison of Agreement for Prevalence of Metabolic Syndrome Among the WHO, NCEP ATP III and Taiwan Definitions|Unknown status|Recruiting||3000||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:05:26.569529|2018-06-01 04:05:26.569529
NCT00308659|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2006-03-28|2006-03-28|2006-03-30|Estimate|||||||2006-03-28|2006-03-30|Estimate|March 2006||2006-03-31|March 2006|2006-03-31||||||||Interventional|||Study to Evaluate Two Diagnostic Strategies for the Treatment of Severe Community Acquired Pneumonia (SCAP)|Diagnostic Strategy Evaluation Study of Two Diagnostic Strategies for the Treatment of SCAP : Noninvasive Strategy and Semiinvasive Strategy Including FOB Distal Samplings|Unknown status|Recruiting|N/A|||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:05:26.635907|2018-06-01 04:05:26.635907
NCT00308646|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-29|||2006-03-29|2006-03-29|2006-03-30|Estimate|||||||2006-03-29|2006-03-30|Estimate|October 2004||2004-10-31|March 2006|2006-03-31|July 2005||2005-07-31|||||Observational|||Instrument Development of Screening Prediabetes Patients|Instrument Development of Screening Prediabetes Patients|Terminated|||3000||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:05:26.697749|2018-06-01 04:05:26.697749
NCT00308633|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2017-06-30|2006-03-28|2006-03-29|Estimate|||||||2017-06-30|2017-07-02|Actual|March 23, 2006||2006-03-23|October 30, 2009|2009-10-30||||December 28, 2007|Actual|2007-12-28||Observational|||Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants|Mechanism and Vascular Effects of Endothelial Progenitor Cell Mobilization in Patients With Coronary Artery Disease Undergoing Cardiac Rehabilitation|Completed|||55||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:05:26.746478|2018-06-01 04:05:26.746478
NCT00308620|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2011-09-26||2012-07-09|2006-03-27|2006-03-29|Estimate|2012-07-09|2012-08-17|Estimate||||2012-07-09|2012-08-17|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine|A Randomized, Pilot Study of the Anti-Viral and Anti-Inflammatory Effects of Chloroquine in Early HIV Infection|Terminated||Phase 2/Phase 3|13|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Insufficient financial support; lack of efficacy for primary endpoint|f||||f||||||||||2018-06-01 04:05:26.814674|2018-06-01 04:05:26.814674
NCT00308607|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2009-04-02|2006-03-28|2006-03-29|Estimate|||||||2009-04-02|2009-04-03|Estimate|August 2005||2005-08-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma|Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma|Completed||Phase 2|27|Actual|University of Turku|||||f||||f||||||||||2018-06-01 04:05:27.10253|2018-06-01 04:05:27.10253
NCT00308594|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2011-04-27|2006-03-28|2006-03-29|Estimate|||||||2011-04-27|2011-04-28|Estimate|November 2006||2006-11-30|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Oral Dexamethasone for the Treatment of Cervical Radiculopathy|Oral Dexamethasone for the Treatment of Cervical Radiculopathy: A Double Blinded, Randomized, Placebo Controlled Trial|Terminated||Phase 2|100||University of Manitoba||||Study terminated due to withdrawl of participating co-investigators.|f||||f||||||||||2018-06-01 04:05:27.173929|2018-06-01 04:05:27.173929
NCT00308581|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|2009-07-07||2011-08-30|2006-03-28|2006-03-29|Estimate|2009-10-09|2009-11-17|Estimate||||2011-08-30|2011-08-31|Estimate|April 2006||2006-04-30|April 2011|2011-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab|Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab|Completed||Phase 3|539|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 04:05:27.364277|2018-06-01 04:05:27.364277
NCT00308568|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2017-05-02|2006-03-27|2006-03-29|Estimate|||||||2017-05-02|2017-05-04|Actual|February 2006||2006-02-28|May 2017|2017-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||RCT of Mailed Brochure to Boost Adherence to Screening Colonoscopy|Randomized Controlled Trial of a Mailed Brochure to Increase Adherence to Referrals for Screening Colonoscopy|Completed||N/A|628||University of Colorado, Denver|||||f||||f|f|f||||||No|only through publication in journals, this is not an applicable clinical trial|2018-06-01 04:05:29.274362|2018-06-01 04:05:29.274362
NCT00308555|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2013-05-23||2016-10-26|2006-03-27|2006-03-29|Estimate|2013-05-28|2013-07-22|Estimate||||2016-10-26|2016-12-09|Estimate|May 2006||2006-05-31|October 2016|2016-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Opioid and Cannabinoid Pharmacokinetic Interactions|Opioid and Cannabinoid Pharmacokinetic Interactions: A Pilot Study|Completed||Phase 1|24|Actual|University of California, San Francisco|Small number of participants, powered to detect a 25% change in AUC(12).Further research is needed to determine how cannabis delivery systems other than vapor affect metabolism of opioids and other drugs.|1|||f||||||||||||||2018-06-01 04:05:29.378459|2018-06-01 04:05:29.378459
NCT00308542|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2012-02-09|2006-03-27|2006-03-29|Estimate|||||||2012-02-09|2012-02-13|Estimate||||February 2012|2012-02-29||||||||Interventional|||A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema||Completed||Phase 1/Phase 2|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 04:05:29.722395|2018-06-01 04:05:29.722395
NCT00308529|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2010-06-18|2006-03-27|2006-03-29|Estimate|||||||2010-06-18|2010-06-22|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|April 2007|Actual|2007-04-30||Interventional|||Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer|Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer|Completed||Phase 2|55||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:05:29.791418|2018-06-01 04:05:29.791418
NCT00308516|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|2013-03-26||2013-05-14|2006-03-28|2006-03-29|Estimate|2013-03-26|2013-05-14|Estimate||||2013-05-14|2013-05-21|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|February 2012|Actual|2012-02-29|April 2009|Actual|2009-04-30||Interventional|||5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer|A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer|Completed||Phase 2|66|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 04:05:29.883393|2018-06-01 04:05:29.883393
NCT00308503|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2010-11-29|2006-03-28|2006-03-29|Estimate|||||||2010-11-29|2010-11-30|Estimate|February 2006||2006-02-28|November 2010|2010-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|EPOCH||Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia|Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: A 6 Week, Multicenter, Randomized, Double -Blind, Placebo-controlled Study|Completed||Phase 3|608|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:05:30.421022|2018-06-01 04:05:30.421022
NCT00308464|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2011-05-17|2006-03-27|2006-03-29|Estimate|||||||2011-05-17|2011-05-18|Estimate|July 2006||2006-07-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency|A Double Blind Parallel Group Randomised Multiple Dose Study To Evaluate The Pharmacodynamic Response And Safety Of PHA-794428 In Adult Growth Hormone Deficient Patients|Terminated||Phase 2|136||Pfizer||||See termination reason in detailed description.|f||||||||||||||2018-06-01 04:05:30.761544|2018-06-01 04:05:30.761544
NCT00308451|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-03-27|2006-03-27|2006-03-29|Estimate|||||||2006-03-27|2006-03-29|Estimate|November 2003||2003-11-30|March 2006|2006-03-31|April 2004||2004-04-30|||||Interventional|||A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM|”A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Study to Evaluate the Improvement in Glycemic Control After Daily Administration of Chromium Picolinate and Biotin in Patients With Type 2 Diabetes Mellitus”|Completed||N/A|40||Nutrition 21, Inc.|||||f||||||||||||||2018-06-01 04:05:30.885811|2018-06-01 04:05:30.885811
NCT00308438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-12-15|2006-03-27|2006-03-29|Estimate|||||||2017-12-15|2017-12-19|Actual|March 1, 2004||2004-03-01|December 2017|2017-12-31|June 1, 2006|Actual|2006-06-01|November 1, 2005|Actual|2005-11-01||Interventional|||Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008|An Open Label Extension Study of the Safety and Efficacy of ALX-0600 in Subjects With Crohn's Disease Who Completed the Pilot Study Protocol CL0600-008|Completed||Phase 2|67|Actual|Shire||1|||t||||f||||||||||2018-06-01 04:05:30.978202|2018-06-01 04:05:30.978202
NCT00308425|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2011-01-28|2006-03-27|2006-03-29|Estimate|||||||2011-01-28|2011-01-31|Estimate|October 2002||2002-10-31|January 2011|2011-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS|Effect of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Valsartan as Part of Intensified Multi-factorial Intervention Compared to EC-MPS Plus Standard Practice of Care on Development of Transplant Nephropathy in Cadaver Donor Kidney Recipients Given Basiliximab, Cyclosporine Microemulsion (CsA-ME) and Short-term Steroids: a 12-month, Prospective, Randomized, Open-label Multicentre Study (MYTHOS)|Completed||Phase 3|119|Actual|Novartis|||||f||||||||||||||2018-06-01 04:05:31.091085|2018-06-01 04:05:31.091085
NCT00308412|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2010-07-15|2006-03-28|2006-03-29|Estimate|||||||2010-07-15|2010-07-16|Estimate|June 2006||2006-06-30|July 2010|2010-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants|Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age|Completed||Phase 1|45|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 04:05:31.15206|2018-06-01 04:05:31.15206
NCT00308399|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2011-03-22|2006-03-27|2006-03-29|Estimate|||||||2011-03-22|2011-03-23|Estimate|November 2005||2005-11-30|March 2011|2011-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study to Evaluate the Effect of a Medicine on Gastric Functions in Healthy Volunteers.|A Double Blind, Randomized, Placebo-controlled, Single Center, Parallel Group Study to Evaluate the Effects of Itopride (100 mg and 200 mg t.i.d.) on Gastric Motor and Sensory Functions in Healthy Volunteers.|Completed||Phase 2/Phase 3|45|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 04:05:31.257235|2018-06-01 04:05:31.257235
NCT00308386|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2011-02-28|2006-03-27|2006-03-29|Estimate|||||||2011-02-28|2011-03-01|Estimate|August 2006||2006-08-31|February 2011|2011-02-28|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||DYNAMIC Study: (Diabetes Nurse Case Management And Motivational Interviewing for Change)|Impact of Nurse Case Management on Diabetes Co-morbidities|Unknown status|Active, not recruiting|Phase 3|820|Anticipated|Milton S. Hershey Medical Center|||||f||||t||||||||||2018-06-01 04:05:31.333052|2018-06-01 04:05:31.333052
NCT00308373|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2010-01-19|2006-03-27|2006-03-29|Estimate|||||||2010-01-19|2010-01-20|Estimate|July 2004||2004-07-31|January 2010|2010-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus|Effects of Elevated Free Fatty Acids on Endogenous Glucose Production in People With and Without Type 2 Diabetes Mellitus|Completed||N/A|73|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:05:31.437453|2018-06-01 04:05:31.437453
NCT00308360|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2006-03-28|2006-03-28|2006-03-29|Estimate|||||||2006-03-28|2006-03-29|Estimate|September 1999||1999-09-30|March 2006|2006-03-31|April 2004||2004-04-30|||||Interventional|||Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility|Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility|Completed||Phase 4|46||Nathan Kline Institute for Psychiatric Research|||||f||||||||||||||2018-06-01 04:05:31.53802|2018-06-01 04:05:31.53802
NCT00308347|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2015-02-18|2006-03-27|2006-03-29|Estimate|||||||2015-02-18|2015-02-20|Estimate|May 1996||1996-05-31|February 2015|2015-02-28|April 2001|Actual|2001-04-30|February 2001|Actual|2001-02-28||Interventional|||A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy|Completed||Phase 3|1513|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:05:31.628184|2018-06-01 04:05:31.628184
NCT00308334|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2009-06-10|2006-03-27|2006-03-29|Estimate|||||||2009-06-10|2009-06-11|Estimate|October 2003||2003-10-31|June 2009|2009-06-30|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Domperidone on the Nutrient Composition of Preterm Mother's Breast Milk|A Double Blind Placebo Controlled Trial Examining the Effect of Domperidone on the Composition of Breast Milk|Completed||Phase 2/Phase 3|46|Actual|IWK Health Centre||2|||f||||||||||||||2018-06-01 04:05:31.697906|2018-06-01 04:05:31.697906
NCT00308321|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2007-11-28|2006-03-28|2006-03-29|Estimate|||||||2007-11-28|2007-11-29|Estimate|September 2003||2003-09-30|November 2007|2007-11-30|October 2008|Anticipated|2008-10-31|||||Interventional|||Long Term Tapering or Standard Steroids for Nephrotic Syndrome|Long Term Tapering or Standard Steroids for Nephrotic Syndrome|Unknown status|Recruiting|Phase 4|50|Anticipated|Institute of Child Health|||||f||||||||||||||2018-06-01 04:05:31.774471|2018-06-01 04:05:31.774471
NCT00308126|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2007-12-07|2006-03-28|2006-03-29|Estimate|||||||2007-12-07|2007-12-11|Estimate|June 2005||2005-06-30|March 2006|2006-03-31|September 2006||2006-09-30|||||Interventional|||Study to Evaluate the Effect of Hydroxyethyl Starch (HES) in Complications of Patients After Abdominal Surgery|Phase IV, Open-Label, Randomized, Albumin-Controlled, Parallel Group, Multicenter Study to Evaluate the Effect of Medium Molecule HES (130/0.4) in Complications for Patients After Abdominal Surgery|Completed||Phase 4|624||Fresenius Kabi|||||f||||f||||||||||2018-06-01 04:05:36.817486|2018-06-01 04:05:36.817486
NCT00308308|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2014-07-22|2009-06-09|2014-10-09|2006-03-27|2006-03-29|Estimate|2014-10-09|2014-10-16|Estimate|2009-10-01|2009-10-05|Estimate|2014-10-09|2014-10-16|Estimate|February 2006||2006-02-28|October 2014|2014-10-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional||ITT Population (589 were randomized - 24 Subjects randomized but never dosed)|Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes|A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up|Completed||Phase 3|589|Actual|Mannkind Corporation||2|||f||||||||||||||2018-06-01 04:05:32.037842|2018-06-01 04:05:32.037842
NCT00308295|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2007-10-15|2006-03-27|2006-03-29|Estimate|||||||2007-10-15|2007-10-16|Estimate|April 2006||2006-04-30|October 2007|2007-10-31|May 2006||2006-05-31|||||Interventional|||A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients|A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients|Completed||N/A|27||Indiana University|||||f||||||||||||||2018-06-01 04:05:33.368605|2018-06-01 04:05:33.368605
NCT00308282|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2008-09-17|2006-03-28|2006-03-29|Estimate|||||||2008-09-17|2008-09-19|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Patients With Rheumatoid Arthritis|Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate|Completed||Phase 2|126|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 04:05:33.606422|2018-06-01 04:05:33.606422
NCT00308269|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2014-12-18|2006-03-27|2006-03-29|Estimate|||||||2014-12-18|2014-12-19|Estimate|March 2006||2006-03-31|December 2014|2014-12-31|July 2008|Actual|2008-07-31|August 2007|Actual|2007-08-31||Interventional|||Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)|Protocol EC-FV-01: A Phase 1 Study of EC145 Administered in Weeks 1 and 3 of a 4-Week Cycle|Completed||Phase 1|32|Actual|Endocyte||5|||f||||f||||||||||2018-06-01 04:05:33.966273|2018-06-01 04:05:33.966273
NCT00308256|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2011-12-28|2006-03-28|2006-03-29|Estimate|||||||2011-12-28|2011-12-30|Estimate|March 2006||2006-03-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Nurse-counselling in the Improvement of the type1 Diabetes Control in Adolescents|Effects of Nurse-counselling in the Improvement of the type1 Diabetes Control in Adolescents: a Randomized Controlled Trial|Completed||N/A|77|Actual|Hospices Civils de Lyon||2|||f||||||||||||||2018-06-01 04:05:34.104083|2018-06-01 04:05:34.104083
NCT00308243|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2011-07-17|2006-03-27|2006-03-29|Estimate|||||||2011-07-17|2011-07-19|Estimate|March 2006||2006-03-31|July 2011|2011-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.|Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study. Stage 1)|Completed||Phase 1|15|Anticipated|Emphycorp|||||||||||||||||||2018-06-01 04:05:34.171907|2018-06-01 04:05:34.171907
NCT00308230|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2013-09-10||2014-07-16|2006-03-27|2006-03-29|Estimate|2014-07-16|2014-07-17|Estimate||||2014-07-16|2014-07-17|Estimate|December 2001||2001-12-31|July 2014|2014-07-31|September 2004|Actual|2004-09-30|March 2004|Actual|2004-03-31||Interventional|||Pilot Study of B-Type Natrieutic Peptide (BNP) Levels in Patients With Congenital Heart Disease(BNP)|A Pilot Study of B-Type Natriuretic Peptide (BNP) Levels in Patients With Congenital Heart Disease and Systemic Right Ventricles or Volume Overloaded Pulmonic Right Ventricles|Completed||N/A|34|Actual|Emory University||3|||f||||f||||||||||2018-06-01 04:05:34.248117|2018-06-01 04:05:34.248117
NCT00308217|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2013-12-11|2006-03-27|2006-03-29|Estimate|||||||2013-12-11|2013-12-12|Estimate|June 2005||2005-06-30|December 2013|2013-12-31|June 2005||2005-06-30|||||Observational|||Single Ventricle Outcome|The Examination of Outcome in Children With Single Ventricle Physiology|Completed|||30||Emory University|||||f||||||||||||||2018-06-01 04:05:34.518258|2018-06-01 04:05:34.518258
NCT00308204|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2007-05-22|2006-03-28|2006-03-29|Estimate|||||||2007-05-22|2007-05-24|Estimate|March 2006||2006-03-31|May 2007|2007-05-31||||||||Interventional|||Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva|Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva|Terminated||Phase 2|10|Anticipated|The Cleveland Clinic||||inadequate number of enrolled study subjects|||||||||||||||2018-06-01 04:05:34.584255|2018-06-01 04:05:34.584255
NCT00308191|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2008-03-05|2006-03-27|2006-03-29|Estimate|||||||2008-03-05|2008-03-07|Estimate|April 2006||2006-04-30|March 2008|2008-03-31|December 2006|Actual|2006-12-31|May 2006|Actual|2006-05-31||Interventional|||A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD|A 6-Week Double-Blind, Parallel-Group, Active-Controlled Trial to Compare the Efficacy and Safety of Concomitant Treatment of Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|128||Dey|||||||||||||||||||2018-06-01 04:05:34.65112|2018-06-01 04:05:34.65112
NCT00308178|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2013-02-15|2006-03-28|2006-03-29|Estimate|||||||2013-02-15|2013-02-18|Estimate|March 2006||2006-03-31|February 2013|2013-02-28|June 2008|Actual|2008-06-30|September 2006|Actual|2006-09-30||Interventional|||Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer|Dose Dense AB1-007 (Abraxane) in Adjuvant Chemotherapy for Breast Cancer: A Feasibility Study|Completed||N/A|66|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:05:34.747822|2018-06-01 04:05:34.747822
NCT00308165|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2015-01-13|2006-03-27|2006-03-29|Estimate|||||||2015-01-13|2015-01-15|Estimate|March 2004||2004-03-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|September 2011|Actual|2011-09-30||Interventional|||Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors|A Phase I Study of Topotecan by Intracerebral Clysis for the Treatment of Recurrent Primary Malignant Brain Tumors|Unknown status|Active, not recruiting|Phase 1/Phase 2|18|Actual|Columbia University||1|||f||||t||||||||||2018-06-01 04:05:34.810111|2018-06-01 04:05:34.810111
NCT00308152|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2016-07-25|2006-03-28|2006-03-29|Estimate|||||||2016-07-25|2016-07-27|Estimate|February 2006||2006-02-28|July 2016|2016-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Intravenous Saline Pre-hydration in Patients Undergoing Outpatient Colonoscopy|Randomised, Controlled Trial of Intravenous Saline Pre-hydration in Patients Undergoing Outpatient Colonoscopy|Completed||Phase 2|1000|Anticipated|The Canberra Hospital||2|||f||||f||||||||No||2018-06-01 04:05:34.890127|2018-06-01 04:05:34.890127
NCT00308139|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2012-02-14|2011-06-17|2015-07-29|2006-03-27|2006-03-29|Estimate|2012-07-12|2012-08-17|Estimate|2011-06-17|2011-06-27|Estimate|2015-07-29|2015-08-26|Estimate|April 2006||2006-04-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)|A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications|Completed||Phase 3|303|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:05:35.010648|2018-06-01 04:05:35.010648
NCT00308113|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2013-08-07||2013-10-16|2006-03-27|2006-03-29|Estimate|2013-08-07|2013-10-11|Estimate||||2013-10-16|2013-11-08|Estimate|April 2007||2007-04-30|October 2013|2013-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||CoQ10 and Prednisone in Non-Ambulatory DMD|PITT0503: Clinical Trial of Coenzyme Q10 and Prednisone in Duchenne Muscular Dystrophy|Terminated||Phase 3|3|Actual|Cooperative International Neuromuscular Research Group|In December 2007 the CINRG Data Safety and Monitoring Board (DSMB) met and recommended to close the study as the AAN had released practice parameters recommending that all patients with DMD should be offered treatment with corticosteroids.|4||New enrollment has been suspended, currently following previously enrolled participants|f||||t||||||||||2018-06-01 04:05:36.892823|2018-06-01 04:05:36.892823
NCT00308100|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|||2009-01-14|2006-03-28|2006-03-29|Estimate|||||||2009-01-14|2009-01-15|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation|A Multicenter, Randomized, Open-Label, Parallel-Group, Albumin-Controlled Phase IV Study to Evaluate the Efficacy and Safety of Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Patients Undergoing Liver Transplantation|Terminated||Phase 4|53|Actual|Fresenius Kabi||2||Study is prematurely ended due to poor patient recruitment rate.|f||||t||||||||||2018-06-01 04:05:37.148509|2018-06-01 04:05:37.148509
NCT00308087|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|2010-06-11||2013-12-02|2006-03-28|2006-03-29|Estimate|2010-08-03|2010-08-30|Estimate||||2013-12-02|2013-12-27|Estimate|May 2006||2006-05-31|December 2013|2013-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PREMIER||Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma|Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-cell Lymphoma|Terminated||Phase 2|75|Actual|Sanofi|One hundred ninety-six patients were planned and 75 enrolled prior to termination. The study was terminated early due to low enrollment, and the extent of changes needed to the protocol to keep pace with therapeutic changes for indolent lymphoma.|2||Terminated by sponsor due to low enrollment; see details below|f||||t||||||||||2018-06-01 04:05:37.261491|2018-06-01 04:05:37.261491
NCT00308074|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-28|2015-03-11||2016-12-30|2006-03-28|2006-03-29|Estimate|2016-11-03|2017-01-02|Estimate||||2016-12-30|2017-02-15|Actual|February 2006||2006-02-28|December 2016|2016-12-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders|A Prospective Open-Label Trial of Aripiprazole Monotherapy in the Autism Spectrum Disorders (ASD)|Completed||Phase 2|14|Actual|Cambridge Health Alliance||1|||f||||f||||||||||2018-06-01 04:05:37.991104|2018-06-01 04:05:37.991104
NCT00308061|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2017-01-04||2017-05-03|2006-03-24|2006-03-28|Estimate|2017-05-03|2017-07-31|Actual||||2017-05-03|2017-07-31|Actual|July 2003||2003-07-31|May 2017|2017-05-31|July 2005|Actual|2005-07-31|September 2004|Actual|2004-09-30||Interventional|||Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali|Double Blind Randomized Controlled Phase I Trial to Evaluate the Safety and Immunogenicity of WRAIR's MSP1 Candidate Malaria Vaccine (FMP1) Adjuvant in GSK Bio's AS02A vs. Rabies Vaccine in Semi-immune Adults in Bandiagara, Mali.|Completed||Phase 1|40|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f|t|||||||No||2018-06-01 04:05:38.221475|2018-06-01 04:05:38.221475
NCT00308048|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2011-07-03|2006-03-27|2006-03-28|Estimate|||||||2011-07-03|2011-07-06|Estimate|March 2004||2004-03-31|March 2006|2006-03-31|September 2006||2006-09-30|||||Interventional|||14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response|14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response|Completed||Phase 3|435||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:05:38.557638|2018-06-01 04:05:38.557638
NCT00308035|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2008-06-12|2006-03-24|2006-03-28|Estimate|||||||2008-06-12|2008-06-13|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|June 2006|Actual|2006-06-30|||||Observational|||Foot Posture in People With Paralysis on One Side After Stroke|Foot Posture in People With Hemiplegia After Stroke|Completed|||17|Actual|University of Kansas Medical Center|||||f||||f||||||||||2018-06-01 04:05:38.617935|2018-06-01 04:05:38.617935
NCT00308022|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2006-09-08|2006-03-24|2006-03-28|Estimate|||||||2006-09-08|2006-09-11|Estimate|January 2006||2006-01-31|March 2006|2006-03-31|December 2009||2009-12-31|||||Interventional|||Comparison Study of High Frequency Percussive Ventilation With Conventional Ventilation|A Prospective Randomized Controlled Trial Comparing High Frequency Percussive Ventilation With Conventional Mechanical Ventilation Utilizing Protective Lung Strategies in Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome|Unknown status|Recruiting|Phase 2/Phase 3|180||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:05:38.659053|2018-06-01 04:05:38.659053
NCT00308009|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2015-04-27|2006-03-27|2006-03-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|February 2002||2002-02-28|November 2007|2007-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Comparison of the Result of TVT Performed at the Time of Prolapse Surgery or 3 Months After|Multicenter Prospective Randomized Trial Comparing to Strategies When Incontinence Surgery is Needed in Addition to Prolapse Surgery|Completed||N/A|194|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 04:05:38.715486|2018-06-01 04:05:38.715486
NCT00307996|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-03-27|2006-03-27|2006-03-28|Estimate|||||||2006-03-27|2006-03-28|Estimate|March 2004||2004-03-31|March 2006|2006-03-31|December 2004||2004-12-31|||||Interventional|||The Effect of CoQ10 Administration on Hemodialysis Patients|The Effect of CoQ10 Administration on the Oxidative and Antioxidative Markers in Hemodialysis Patients|Completed||Phase 4|40||University of Shizuoka|||||f||||||||||||||2018-06-01 04:05:38.780083|2018-06-01 04:05:38.780083
NCT00307983|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-03-27|2006-03-27|2006-03-28|Estimate|||||||2006-03-27|2006-03-28|Estimate|April 2004||2004-04-30|March 2006|2006-03-31|February 2006||2006-02-28|||||Observational|||Effect of Malnutrition on the Prognosis in Hemodialysis Patients|Effect of Malnutrition on the Prognosis in Hemodialysis Patients|Unknown status|Recruiting||600||University of Shizuoka|||||f||||||||||||||2018-06-01 04:05:39.770934|2018-06-01 04:05:39.770934
NCT00307970|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2011-09-16|2006-03-24|2006-03-28|Estimate|||||||2011-09-16|2011-09-20|Estimate|April 2003||2003-04-30|June 2004|2004-06-30|September 2003||2003-09-30|||||Interventional|||Impact of Anti-static Chamber/Mask|The Impact of an Anti-static Valved-holding Chamber on Bioavailability of Inhaled Fluticasone Propionate in Young Children With Asthma|Completed||Phase 4|12||University of Florida|||||||||||||||||||2018-06-01 04:05:39.833222|2018-06-01 04:05:39.833222
NCT00307957|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2007-12-10|2006-03-27|2006-03-28|Estimate|||||||2007-12-10|2007-12-12|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Study to Determine the Effectiveness of Pillar Palatal Implants to Treat Obstructive Sleep Apnea|Pillar Palatal Implant System Multi-Institutional, Randomized Placebo-Controlled Study for Obstructive Sleep Apnea|Completed||Phase 4|100|Anticipated|University of Cincinnati|||||f||||||||||||||2018-06-01 04:05:39.893802|2018-06-01 04:05:39.893802
NCT00307931|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2009-09-08||2011-08-30|2006-03-24|2006-03-28|Estimate|2009-09-15|2009-10-19|Estimate||||2011-08-30|2011-08-31|Estimate|April 2007||2007-04-30|December 2009|2009-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab|Certolizumab Pegol in the Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Have Been Previously Treated Successfully With Infliximab But Who Have Subsequently Lost Response or Developed Intolerance to Infliximab|Terminated||Phase 3|16|Actual|UCB Pharma|This study was terminated early due to slow recruitment, namely only 17 subjects were recruited although the sample size had planned for approximately 50 subjects. As a consequence, the majority of secondary outcome measures were not summarized.|1||Study was terminated early because of slow recruitment|f||||f||||||||||2018-06-01 04:05:40.057109|2018-06-01 04:05:40.057109
NCT00307918|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2007-09-30|2006-03-27|2006-03-28|Estimate|||||||2007-09-30|2007-10-02|Estimate|May 2006||2006-05-31|September 2007|2007-09-30||||||||Interventional|||Acupuncture for Elevated Intraocular Pressure|Acupuncture Treatment for Elevated Intraocular Pressure: A Pilot Study|Terminated||Phase 3|10|Anticipated|Shaare Zedek Medical Center||||lack of patients|f||||||||||||||2018-06-01 04:05:40.417605|2018-06-01 04:05:40.417605
NCT00307905|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2010-10-28|2006-03-27|2006-03-28|Estimate|||||||2010-10-28|2010-10-29|Estimate|January 2011||2011-01-31|October 2010|2010-10-31||||June 2012|Anticipated|2012-06-30||Interventional|||TRAUMEEL for Pain After Fracture of Neck of Femur|A Randomised, Double - Blind, Placebo Controlled Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Controlling Post-operative Pain After Fracture of Neck of Femur|Withdrawn||Phase 3|224|Anticipated|Shaare Zedek Medical Center||2||Anticipation of inadequate recruitment according to current format.|f||||||||||||||2018-06-01 04:05:40.484862|2018-06-01 04:05:40.484862
NCT00307892|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2010-10-28|2006-03-27|2006-03-28|Estimate|||||||2010-10-28|2010-10-29|Estimate|January 2011||2011-01-31|October 2010|2010-10-31||||January 2012|Anticipated|2012-01-31||Interventional|||Traumeel S for Reduction of Post Operative Pain Following Arthroscopy|A Randomised, Double- Blind, Placebo Controlled, Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Reducing Pain After Arthroscopy|Suspended||Phase 3|98|Anticipated|Shaare Zedek Medical Center||2||Inability to recruit patients|f||||||||||||||2018-06-01 04:05:40.571443|2018-06-01 04:05:40.571443
NCT00307879|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-03-27|2006-03-27|2006-03-28|Estimate|||||||2006-03-27|2006-03-28|Estimate|March 2004||2004-03-31|March 2004|2004-03-31|February 2005||2005-02-28|||||Interventional|||Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion|Phase 2 MAGIC Cell (Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion) Trial|Terminated||Phase 2|20||Seoul National University Hospital|||||f||||||||||||||2018-06-01 04:05:40.661533|2018-06-01 04:05:40.661533
NCT00307866|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2009-05-15|2006-03-27|2006-03-28|Estimate|||||||2009-05-15|2009-05-18|Estimate|April 2001||2001-04-30|May 2009|2009-05-31|May 2003|Actual|2003-05-31|||||Interventional|||Identification of Hepatic Lesions|A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.|Completed||Phase 3|218|Actual|Bayer||1|||f||||||||||||||2018-06-01 04:05:40.741313|2018-06-01 04:05:40.741313
NCT00307853|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2009-10-18|2006-03-27|2006-03-28|Estimate|||||||2009-10-18|2009-10-20|Estimate|August 2008||2008-08-31|October 2009|2009-10-31||||August 2009|Anticipated|2009-08-31||Interventional|||TRAUMEEL for Pain After Total Knee/Hip Arthroplasty|A Randomised, Double - Blind, Placebo Controlled Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Controlling Pain After Total Knee and Total Hip Arthroplasty.|Terminated||Phase 3|224|Anticipated|Shaare Zedek Medical Center||2||lack of patients|f||||||||||||||2018-06-01 04:05:40.849958|2018-06-01 04:05:40.849958
NCT00307840|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-03-27|2006-03-27|2006-03-28|Estimate|||||||2006-03-27|2006-03-28|Estimate|February 2005||2005-02-28|August 2005|2005-08-31|July 2005||2005-07-31|||||Interventional|||Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism|Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism|Completed||Phase 4|||Papageorgiou General Hospital|||||f||||||||||||||2018-06-01 04:05:40.930229|2018-06-01 04:05:40.930229
NCT00307827|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2012-04-26|2006-03-24|2006-03-28|Estimate|||||||2012-04-26|2012-04-27|Estimate|April 2006||2006-04-30|April 2012|2012-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)|A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis|Terminated||Phase 2|38|Actual|Abbott||3||Study Canceled|f||||t||||||||||2018-06-01 04:05:41.046239|2018-06-01 04:05:41.046239
NCT00307814|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2011-05-17|2006-03-24|2006-03-28|Estimate|||||||2011-05-17|2011-05-19|Estimate|January 2002||2002-01-31|April 2010|2010-04-30|January 2004|Actual|2004-01-31|||||Interventional|||A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)|A Randomized, Open-Label Clinical Evaluation of PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease|Completed||Phase 2|519|Actual|Ortho Biotech Products, L.P.|||||f||||||||||||||2018-06-01 04:05:41.159414|2018-06-01 04:05:41.159414
NCT00307801|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|2011-03-02||2014-12-08|2006-03-27|2006-03-28|Estimate|2011-07-05|2011-07-29|Estimate||||2014-12-08|2014-12-30|Estimate|February 2006||2006-02-28|December 2014|2014-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.|Completed||Phase 3|231|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:05:41.304304|2018-06-01 04:05:41.304304
NCT00307788|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2012-05-24|2006-03-24|2006-03-28|Estimate|||||||2012-05-24|2012-05-25|Estimate|May 2004||2004-05-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|LBP||Acupuncture Analgesia in Relation to Psychiatric Comorbidity|The Association Amongst Acupuncture Analgesia, Expectancy, and Psychiatric Comorbidity in Patients With Low Back Pain|Completed||Phase 3|60|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 04:05:42.536203|2018-06-01 04:05:42.536203
NCT00307775|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2012-04-28|2006-03-27|2006-03-28|Estimate|||||||2012-04-28|2012-05-01|Estimate|March 2006||2006-03-31|February 2007|2007-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Vaginal Estrogen for the Treatment of Faecal Incontinence in Women|A Pilot Study to Examine the Efficacy of Vaginally Administered Oestradiol in the Treatment of Faecal Incontinence in Post Menopausal Women|Terminated||N/A|43||London North West Healthcare NHS Trust||||Lack of recruitment|f||||||||||||||2018-06-01 04:05:42.603404|2018-06-01 04:05:42.603404
NCT00307762|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2015-03-30|2006-03-27|2006-03-28|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2003||2003-05-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Interventional|||Gait Trainer vs Traditional Physiotherapy in Acute Stroke|Body-weight Supported Therapy Using Gait Trainer Versus Traditional Gait-oriented Physiotherapy in Acute Phase of Stroke. The Effectiveness of Gait Training and Brain Networks Using NBS (Navigating Brain Stimulation)|Completed||Phase 3|57|Actual|Kuopio University Hospital||3|||f||||f||||||||||2018-06-01 04:05:42.660346|2018-06-01 04:05:42.660346
NCT00307749|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2007-12-26|2006-03-27|2006-03-28|Estimate|||||||2007-12-26|2007-12-28|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy|A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy|Completed||Phase 2|420|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||||||||||||2018-06-01 04:05:42.72482|2018-06-01 04:05:42.72482
NCT00307736|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2017-01-27||2017-03-30|2006-03-24|2006-03-28|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|May 2006||2006-05-31|March 2017|2017-03-31|July 2011|Actual|2011-07-31|April 2010|Actual|2010-04-30||Interventional|||Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer|A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer|Completed||Phase 1/Phase 2|32|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:05:42.83635|2018-06-01 04:05:42.83635
NCT00307723|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2009-08-07|2006-03-24|2006-03-28|Estimate|||||||2009-08-07|2009-08-10|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|July 2009|Actual|2009-07-31|August 2007|Actual|2007-08-31||Interventional|||Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer|A Tolerability and Efficacy Study of the Angiogenesis Inhibitor Bevacizumab in Combination With 5-Fluorouracil, Oxaliplatin, and External Beam Radiation Therapy Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer|Terminated||Phase 1/Phase 2|52|Actual|Massachusetts General Hospital||2||poor accrual|f||||t||||||||||2018-06-01 04:05:43.346719|2018-06-01 04:05:43.346719
NCT00307710|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2012-07-27|2006-03-24|2006-03-28|Estimate|||||||2012-07-27|2012-07-31|Estimate|August 2004||2004-08-31|July 2012|2012-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma|Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma: A Phase II, Double-Blind Pilot Study - Version 4|Completed||Phase 2|28|Actual|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-06-01 04:05:43.435683|2018-06-01 04:05:43.435683
NCT00307697|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2013-11-26|2006-03-27|2006-03-28|Estimate|||||||2013-11-26|2013-11-28|Estimate|June 2006||2006-06-30|March 2006|2006-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Letter Intervention in Primary Care Patients to Improve Depression and Anxiety Disorders|A Randomised Controlled Trial of a Letter Intervention in Primary Care Patients to Improve Depression and Anxiety Disorders|Completed||Phase 1|200|Anticipated|Bayside Health|||||f||||f||||||||||2018-06-01 04:05:43.519632|2018-06-01 04:05:43.519632
NCT00307684|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2009-07-16||2014-04-02|2006-03-24|2006-03-28|Estimate|2010-02-04|2010-02-23|Estimate||||2014-04-02|2014-04-21|Estimate|January 2006||2006-01-31|April 2014|2014-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|An Open International Multicentre Long-Term Follow Up Study to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder|Completed||Phase 3|155|Actual|Janssen-Cilag International NV|Planned sample size for DB phase was 80 subjects. Of 99 subjects at the end of OL phase only 45 subjects consented. No cutoffs for key efficacy assessments in DB entry criteria.|3|||f||||f||||||||||2018-06-01 04:05:43.626983|2018-06-01 04:05:43.626983
NCT00307671|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2011-09-09|2006-03-27|2006-03-28|Estimate|||||||2011-09-09|2011-09-12|Estimate|July 2005||2005-07-31|March 2007|2007-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|CORTAGE||Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years|Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants|Completed||Phase 4|108|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:05:44.211539|2018-06-01 04:05:44.211539
NCT00307658|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-05-18|2006-03-27|2006-03-28|Estimate|||||||2006-05-18|2006-05-22|Estimate|March 2001||2001-03-31|April 2003|2003-04-30|July 2006||2006-07-31|||||Interventional|||Intravenous Immunoglobulin After Relapse in Vasculitis|Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener’s Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial|Terminated||Phase 3|40||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:05:44.296322|2018-06-01 04:05:44.296322
NCT00307645|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-04-07|2006-03-27|2006-03-28|Estimate|||||||2006-04-07|2006-04-10|Estimate|May 2003||2003-05-31|March 2003|2003-03-31|August 2009||2009-08-31|||||Interventional|||IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis|Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis|Terminated||Phase 3|160||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:05:44.370543|2018-06-01 04:05:44.370543
NCT00307632|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2014-05-14|2006-03-27|2006-03-28|Estimate|||||||2014-05-14|2014-05-15|Estimate|February 2003||2003-02-28|May 2014|2014-05-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol|An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol|Completed||Phase 4|580|Actual|Janssen-Cilag Farmaceutica Ltda.||1|||f||||||||||||||2018-06-01 04:05:44.442169|2018-06-01 04:05:44.442169
NCT00307619|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2011-01-27|2006-03-27|2006-03-28|Estimate|||||||2011-01-27|2011-01-31|Estimate|November 2003||2003-11-30|January 2011|2011-01-31|April 2005|Actual|2005-04-30|||||Interventional|||An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.|Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder|Completed||Phase 3|73|Actual|Janssen-Cilag Farmaceutica Ltda.|||||f||||||||||||||2018-06-01 04:05:44.539858|2018-06-01 04:05:44.539858
NCT00307606|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2007-09-05|2006-03-27|2006-03-28|Estimate|||||||2007-09-05|2007-09-06|Estimate|December 2005||2005-12-31|December 2005|2005-12-31|December 2007||2007-12-31|||||Interventional|||Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma|Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma|Unknown status|Recruiting|Phase 4|40|Anticipated|Herlev Hospital|||||f||||t||||||||||2018-06-01 04:05:44.602517|2018-06-01 04:05:44.602517
NCT00307593|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2007-11-16|2006-03-24|2006-03-28|Estimate|||||||2007-11-16|2007-11-19|Estimate|May 2004||2004-05-31|March 2007|2007-03-31|June 2007|Actual|2007-06-30|||||Interventional|||RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides|Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides With Positive ANCA After Relapse or Resistant Immunosuppressant Therapies|Completed||N/A|20|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:05:44.702237|2018-06-01 04:05:44.702237
NCT00307580|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-25|||2014-04-08|2006-03-25|2006-03-28|Estimate|||||||2014-04-08|2014-04-09|Estimate|April 2002||2002-04-30|April 2014|2014-04-30|May 2003|Actual|2003-05-31|||||Interventional|||Cathflo Activase Pediatric Study|Cathflo Activase (Alteplase) Pediatric Study (CAPS)|Completed||Phase 4|300||Genentech, Inc.|||||f||||||||||||||2018-06-01 04:05:44.773573|2018-06-01 04:05:44.773573
NCT00307567|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2016-09-22|2006-03-23|2006-03-28|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2005||2005-11-30|September 2016|2016-09-30|March 2006|Actual|2006-03-31|||||Interventional|||Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488|A Phase II, Multicentre Booster Study to Evaluate Booster Vaccination With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or to Evaluate the Immune Memory Following the Administration of a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children, Previously Vaccinated in Infancy in the Primary Study 11PN-PD-DIT-002 (103488)|Completed||Phase 2|689||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:05:44.838291|2018-06-01 04:05:44.838291
NCT00307554|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2016-09-23|2006-03-23|2006-03-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2005||2005-11-30|September 2016|2016-09-30|June 2006|Actual|2006-06-30|||||Interventional|||A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study|Assess Lot-to-lot Consistency of 3 Lots (Double Blind Design) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Vaccine and Evaluate Non-inferiority to Prevenar™ (Single Blind Design) When Administered as 3-dose Primary Immunization Course Before 6 Months of Age|Completed||Phase 3|1600||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:05:45.096704|2018-06-01 04:05:45.096704
NCT00307541|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2016-09-22|2006-03-23|2006-03-28|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2005||2005-10-31|September 2016|2016-09-30|April 2006|Actual|2006-04-30|||||Interventional|||Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine|Phase IIIa Randomized, Controlled Study to Assess the Immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered as a 3-dose Primary Immunization Course Before 6 Months of Age|Completed||Phase 3|120||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:05:45.24014|2018-06-01 04:05:45.24014
NCT00307528|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2017-05-24|2006-03-23|2006-03-28|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2004||2004-01-31|May 2017|2017-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population|A Study to Evaluate the Safety, Reactogenicity & Immunogenicity of the GSK Biologicals Candidate Pneumococcal Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations, in Healthy Elderly Subjects|Completed||Phase 2|146|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 04:05:45.400752|2018-06-01 04:05:45.400752
NCT00307515|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2009-01-08|2006-03-27|2006-03-28|Estimate|||||||2009-01-08|2009-01-09|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Evaluation of Fibrin Sealant 2 in Retroperitoneal or Intra-Abdominal Surgery|A Prospective, Randomized, Controlled Evaluation of Fibrin Sealant 2 (FS2) as an Adjunct to Hemostasis for Soft Tissue Bleeding During Retroperitoneal or Intra-Abdominal Surgery|Completed||Phase 3|135|Actual|Ethicon, Inc.||2|||f||||f||||||||||2018-06-01 04:05:45.496361|2018-06-01 04:05:45.496361
NCT00307502|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2010-02-22|2006-03-27|2006-03-28|Estimate|||||||2010-02-22|2010-02-23|Estimate|January 2005||2005-01-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV|Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects|Completed||Phase 1|675|Anticipated|Germans Trias i Pujol Hospital||11|||f||||f||||||||||2018-06-01 04:05:45.59718|2018-06-01 04:05:45.59718
NCT00307489|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2009-01-30||2011-10-04|2006-03-24|2006-03-28|Estimate|2009-05-26|2009-07-07|Estimate||||2011-10-04|2011-11-01|Estimate|March 2006||2006-03-31|October 2011|2011-10-31|October 2010|Actual|2010-10-31|January 2008|Actual|2008-01-31||Interventional|||Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil|A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine Plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated With Adefovir Dipivoxil for Chronic Hepatitis B and Having Persistent Viral Replication|Completed||Phase 2|106|Actual|Gilead Sciences|The randomized and treated (RAT) analysis set includes all subjects who were ongoing at the time of analysis (i.e., those on blinded therapy and those who switched to open-label FTC/TDFdue to persistent viremia).|2|||f||||f||||||||||2018-06-01 04:05:45.770178|2018-06-01 04:05:45.770178
NCT00307476|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2007-12-19|2006-03-24|2006-03-28|Estimate|||||||2007-12-19|2007-12-24|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Comparison of Rectal Trumpet and Standard Care|A Clinical Comparison of the Rectal Trumpet and Standard Care in Acutely Ill Patients With Fecal Incontinence|Terminated||N/A|100|Anticipated|Christiana Care Health Services||||Unable to recruit target enrollment numbers|f||||||||||||||2018-06-01 04:05:46.5143|2018-06-01 04:05:46.5143
NCT00307463|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2013-09-06|2006-03-27|2006-03-28|Estimate|||||||2013-09-06|2013-09-09|Estimate|September 2005||2005-09-30|September 2013|2013-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation|Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation: a Randomised, Prospective and Controlled Study|Completed||Phase 4|258|Actual|Ege University||2|||f||||t||||||||||2018-06-01 04:05:46.584485|2018-06-01 04:05:46.584485
NCT00306774|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2011-09-21|2006-03-22|2006-03-24|Estimate|||||||2011-09-21|2011-09-23|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Vitamin D to Slow Progression of Knee Osteoarthritis|Trial of Vitamin D to Reduce the Progression of Knee Osteoarthritis: A Double-Blind, Placebo-Controlled Once Daily Dosing Regimen|Completed||Phase 2|146|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-06-01 04:06:03.727303|2018-06-01 04:06:03.727303
NCT00307450|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2009-07-31|2006-03-27|2006-03-28|Estimate|||||||2009-07-31|2009-08-03|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|LeLeDys||Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease|Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study|Completed||Phase 4|34|Anticipated|Technische Universität Dresden|||||f||||t||||||||||2018-06-01 04:05:46.672848|2018-06-01 04:05:46.672848
NCT00307437|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2009-10-23||2013-01-16|2006-03-24|2006-03-28|Estimate|2012-10-05|2012-11-02|Estimate||||2013-01-16|2013-01-24|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|October 2011|Actual|2011-10-31|December 2006|Actual|2006-12-31||Interventional|||A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.|Completed||Phase 3|1230|Actual|Centocor Research & Development, Inc.|The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.|3|||f||||t||||||||||2018-06-01 04:05:46.823591|2018-06-01 04:05:46.823591
NCT00307424|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-03-27|2006-03-27|2006-03-28|Estimate|||||||2006-03-27|2006-03-28|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|June 2005||2005-06-30|||||Interventional|||Comparison Between Auto CPAP and Fixed CPAP in Chinese Patients With OSA|Comparison of Auto-Continuous Positive Airway Pressure Device(Auto-CPAP) With Conventional Fixed CPAP in Chinese Patients With Obstructive Sleep Apnea (OSA)|Completed||N/A|||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:05:49.449464|2018-06-01 04:05:49.449464
NCT00307411|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-27|||2006-04-03|2006-03-27|2006-03-28|Estimate|||||||2006-04-03|2006-04-04|Estimate|August 2006||2006-08-31|March 2006|2006-03-31|July 2007||2007-07-31|||||Interventional|||Effect of Growth Hormone in Metabolic Syndrome|Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome|Unknown status|Not yet recruiting|Phase 4|32||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:05:49.503346|2018-06-01 04:05:49.503346
NCT00307398|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24||2012-11-27|2012-11-27|2006-03-24|2006-03-28|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|March 2004||2004-03-31|May 2009|2009-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Anecortave Acetate Risk-Reduction Trial (AART)||Terminated||Phase 3|2596|Actual|Alcon Research||2||Management decision|f||||||||||||||2018-06-01 04:05:49.566203|2018-06-01 04:05:49.566203
NCT00307385|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-25|||2017-06-30|2006-03-25|2006-03-27|Estimate|||||||2017-06-30|2017-07-02|Actual|March 23, 2006||2006-03-23|March 27, 2008|2008-03-27|March 27, 2008||2008-03-27|||||Observational|||Transcranial Direct Current Stimulation to Improve Hand Movement in Stroke Patients|Modulation of Motor Learning After Stroke Using Principles of Metaplasticity|Completed|||82||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:05:49.630258|2018-06-01 04:05:49.630258
NCT00307346|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2017-06-30|2006-03-24|2006-03-27|Estimate|||||||2017-06-30|2017-07-02|Actual|March 23, 2006||2006-03-23|January 25, 2011|2011-01-25|January 25, 2011||2011-01-25|||||Observational|||Physiology of Weakness in Movement Disorders|Physiology of Weakness With Movement Disorders|Completed|||6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:05:49.681633|2018-06-01 04:05:49.681633
NCT00307333|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2012-04-03||2013-05-16|2006-03-24|2006-03-27|Estimate|2013-04-01|2013-05-17|Estimate||||2013-05-16|2013-05-27|Estimate|August 2005||2005-08-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|February 2011|Actual|2011-02-28||Interventional|HeRO||Impact of Heart Rate Characteristics Monitoring in Neonates|Impact of Heart Rate Characteristics Monitoring in Neonates|Completed||N/A|3003|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 04:05:49.737413|2018-06-01 04:05:49.737413
NCT00307320|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2009-12-29|2006-03-24|2006-03-27|Estimate|||||||2009-12-29|2009-12-30|Estimate|March 2006||2006-03-31|August 2008|2008-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study Examining Stress During Pregnancy|Coping With Stress During Pregnancy|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Virginia||2|||f||||||||||||||2018-06-01 04:05:51.153506|2018-06-01 04:05:51.153506
NCT00307307|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2006-05-18|2006-03-24|2006-03-27|Estimate|||||||2006-05-18|2006-05-22|Estimate|January 2000||2000-01-31|March 2006|2006-03-31|September 2005||2005-09-30|||||Interventional|||Carotid Atherosclerosis Regression at Magnetic Resonance Assessment.|Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology|Completed||Phase 4|69||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:05:51.225542|2018-06-01 04:05:51.225542
NCT00307294|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2016-01-14||2017-10-20|2006-03-24|2006-03-27|Estimate|2016-01-14|2016-02-12|Estimate||||2017-10-20|2017-11-24|Actual|March 2006||2006-03-31|January 2016|2016-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)|Phase II Trial of Thalidomide and Doxil® (Doxorubicin HCL Liposome Injection) in Patients With Androgen Independent Prostate Cancer (AIPC) With a Rising PSA While on Chemotherapy|Completed||Phase 2|40|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:05:51.305855|2018-06-01 04:05:51.305855
NCT00307281|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2017-06-22|2006-03-24|2006-03-27|Estimate|||||||2017-06-22|2017-06-26|Actual|August 2000||2000-08-31|June 2017|2017-06-30|July 2030|Anticipated|2030-07-31|July 2030|Anticipated|2030-07-31|2 Years|Observational [Patient Registry]|||Emphysema Research Registry|Emphysema Research Registry; Screening Study and Genetic Testing|Recruiting|||3000|Anticipated|University of Pittsburgh|||1||f||||f||||||||Undecided||2018-06-01 04:05:51.787551|2018-06-01 04:05:51.787551
NCT00307268|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2013-01-21|2006-03-23|2006-03-27|Estimate|||||||2013-01-21|2013-01-23|Estimate|March 2008||2008-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|January 2010|Actual|2010-01-31||Observational|||Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD|Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adolescents With ADHD: An Observational, Long-Term Follow-up Study of Routine Clinical Care|Completed|||195|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:05:51.966734|2018-06-01 04:05:51.966734
NCT00307255|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2012-04-02|2006-03-24|2006-03-27|Estimate|||||||2012-04-02|2012-04-04|Estimate|August 2006||2006-08-31|April 2012|2012-04-30|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors|Phase I Trial of Abraxane in Combination With Gemcitabine in Patients With Solid Tumors|Completed||Phase 1|18|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 04:05:52.031503|2018-06-01 04:05:52.031503
NCT00306761|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2014-09-15|2006-03-23|2006-03-24|Estimate|||||||2014-09-15|2014-09-16|Estimate|April 2006||2006-04-30|September 2014|2014-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effects of Dynamic Wheelchair Seating on Spasticity and Functional Mobility in Children|Effects of Dynamic Wheelchair Seating on Spasticity and Functional Mobility in Children|Completed||N/A|20|Anticipated|Montana State University|||||f||||f||||||||||2018-06-01 04:06:03.800509|2018-06-01 04:06:03.800509
NCT00307242|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2014-12-08|2006-03-24|2006-03-27|Estimate|||||||2014-12-08|2014-12-09|Estimate|May 2005||2005-05-31|December 2014|2014-12-31||||||||Interventional|||Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B|A Single Center Open-Label, Randomized Study Comparing the Safety of Immediately Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir for 12 Weeks Before Instituting Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B|Completed||Phase 4|40|Anticipated|Thomas Jefferson University|||||f||||t||||||||||2018-06-01 04:05:52.114587|2018-06-01 04:05:52.114587
NCT00307229|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2012-05-31|2006-03-24|2006-03-27|Estimate|||||||2012-05-31|2012-06-04|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|July 2009|Actual|2009-07-31||Interventional|||Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)|A Phase I Trial Investigating the Safety and Immunogenicity of an Adenovirus Encoding Rat HER-2 Administered Intradermally to Patients With Metastatic or Locally Recurrent Breast Cancer|Completed||Phase 1|8|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||||||||||||2018-06-01 04:05:52.201557|2018-06-01 04:05:52.201557
NCT00307216|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2013-03-28|2006-03-23|2006-03-27|Estimate|||||||2013-03-28|2013-03-29|Estimate|April 2006||2006-04-30|March 2013|2013-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis|Randomized Controlled Trial of the Graduated Recovery Intervention Program for First-Episode Psychosis|Completed||N/A|46|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 04:05:52.277328|2018-06-01 04:05:52.277328
NCT00307203|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2017-01-10|2006-03-23|2006-03-27|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 1998||1998-08-31|September 2008|2008-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke|Nicotine and Smoking Cessation in Schizophrenia|Completed||Phase 4|51|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:05:52.372834|2018-06-01 04:05:52.372834
NCT00307190|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2012-05-25|2006-03-23|2006-03-27|Estimate|||||||2012-05-25|2012-05-28|Estimate|October 2004||2004-10-31|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Hormone Release and Stomach Disturbances in People With Binge Eating Disorder|Postprandial Cholecystokinin Release and Gastric Emptying in Binge Eating Disorder|Completed|||24|Actual|New York State Psychiatric Institute|||2||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-06-01 04:05:52.47413|2018-06-01 04:05:52.47413
NCT00307177|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2014-12-04|2006-03-24|2006-03-27|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2004||2004-08-31|November 2006|2006-11-30|April 2005||2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma|Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma: A Phase II, Double-Blind Pilot Study|Completed||Phase 2|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:05:52.545395|2018-06-01 04:05:52.545395
NCT00307164|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2011-08-23|2009-09-10|2013-11-25|2006-03-23|2006-03-27|Estimate|2011-08-23|2011-10-04|Estimate|2009-09-10|2009-09-14|Estimate|2013-11-25|2013-12-19|Estimate|September 2006||2006-09-30|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy|A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy|Completed||Phase 2/Phase 3|167|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:05:52.665496|2018-06-01 04:05:52.665496
NCT00307151|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2011-07-05||2017-03-15|2006-03-24|2006-03-27|Estimate|2011-07-05|2011-08-03|Estimate||||2017-03-15|2017-04-13|Actual|December 2005||2005-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2010|Actual|2010-12-31||Interventional|P1060||Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV|Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-to-Child HIV Transmission|Completed||Phase 2|452|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Accrual to Cohort I was terminated early by the Data Safety Monitoring Committee after enrollment of 164 of the planned 288 subjects.|4|||f||||t||||||||||2018-06-01 04:05:53.779183|2018-06-01 04:05:53.779183
NCT00307138|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2006-05-19|2006-03-24|2006-03-27|Estimate|||||||2006-05-19|2006-05-22|Estimate|September 2004||2004-09-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Hetastarch and Bleeding Complications After Off-Pump Coronary Bypass Surgery|Hetastarch (Hextend) and Bleeding Complications After Off-Pump Coronary Bypass Surgery|Completed||Phase 3|330||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:05:55.545218|2018-06-01 04:05:55.545218
NCT00307125|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2015-02-27||2015-03-11|2006-03-23|2006-03-27|Estimate|2015-03-11|2015-03-23|Estimate||||2015-03-11|2015-03-23|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Intent-to-treat|Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies|B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection|Completed||Phase 2|757|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Slow accrual. In order to ensure the study was completed within the time frame allotted, randomization to the control arm (Pilot Phase-Placebo plus immunosuppression) was suspended. Enrollment continued to lag. The study was stopped early.|2|||f||||t||||||||||2018-06-01 04:05:55.638989|2018-06-01 04:05:55.638989
NCT00307112|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2010-08-26|2006-03-23|2006-03-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2006||2006-08-31|September 2007|2007-09-30|August 2008||2008-08-31|||||Observational|||Rheumatic Heart Disease Prevalence in Leon, Nicaragua|Study of the Prevalence of Rheumatic Heart Disease in Leon, Nicaragua|Unknown status|Recruiting||3600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:05:56.183914|2018-06-01 04:05:56.183914
NCT00307099|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2013-06-06|2006-03-23|2006-03-27|Estimate|||||||2013-06-06|2013-06-07|Estimate|October 2006||2006-10-31|February 2007|2007-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU|Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU): Impact on Antimicrobial Resistance, Superinfections, Length of ICU Stay and Hospitalization, and Mortality|Terminated||Phase 3|460|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:05:56.244871|2018-06-01 04:05:56.244871
NCT00307086|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2013-03-05||2017-01-20|2006-03-23|2006-03-27|Estimate|2013-08-09|2013-10-24|Estimate||||2017-01-20|2017-03-06|Actual|June 2005||2005-06-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants|An Evaluation of Bortezomib (VelcadeR ) Followed by High-Dose Melphalan and Bortezomib (VelcadeR) as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants in Patients With Primary Refractory Multiple Myeloma and Plasma Cell Leukemia|Completed||Phase 2|30|Actual|H. Lee Moffitt Cancer Center and Research Institute|per protocol subjects are followed for 2 years post transplant; however, subjects are followed on our long-term follow-up protocol(MCC12567/IRB6101) to assess overall and disease free survival. additional data available at time manuscript was written|1|||f||||t||||||||||2018-06-01 04:05:56.332574|2018-06-01 04:05:56.332574
NCT00307073|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2006-10-11|2006-03-24|2006-03-27|Estimate|||||||2006-10-11|2006-10-12|Estimate|May 2005||2005-05-31|October 2006|2006-10-31|November 2005||2005-11-30|||||Interventional|||Adapta Pacing System Clinical Study|Adapta Clinical Study to Evaluate the Overall System Safety and Clinical Performance of the Adapta Pacing System|Completed||N/A|120||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:05:56.54177|2018-06-01 04:05:56.54177
NCT00307060|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2017-04-10|2006-03-23|2006-03-27|Estimate|||||||2017-04-10|2017-04-12|Actual|December 1, 2004|Actual|2004-12-01|April 2017|2017-04-30|June 2, 2005|Actual|2005-06-02|June 1, 2005|Actual|2005-06-01||Interventional|||MK0954A-264 Filter Study (0954A-264)(COMPLETED)|A Randomized, Double-Blind, Parallel-Filter Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan-HCTZ Combination as Compared to Losartan Monotherapy in Patients With Essential Hypertension|Completed||Phase 3|274|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:05:56.60039|2018-06-01 04:05:56.60039
NCT00307047|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2010-08-30||2012-10-08|2006-03-23|2006-03-27|Estimate|2010-10-05|2010-10-21|Estimate||||2012-10-08|2012-11-07|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|August 2009|Actual|2009-08-31||Interventional|||SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System|SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions|Completed||Phase 3|3687|Actual|Abbott Vascular||2|||f||||t||||||||||2018-06-01 04:05:56.735669|2018-06-01 04:05:56.735669
NCT00307034|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|2016-12-13||2017-02-16|2006-03-24|2006-03-27|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|January 2006||2006-01-31|February 2017|2017-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule|An Open, Randomized, Phase IIIa Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly According to a 2-4-11 Months Vaccination Schedule|Completed||Phase 3|351|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:05:59.453227|2018-06-01 04:05:59.453227
NCT00307021|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2017-04-24|2006-03-23|2006-03-27|Estimate|||||||2017-04-24|2017-04-25|Actual|April 7, 2006||2006-04-07|April 2017|2017-04-30|August 22, 2007|Actual|2007-08-22|September 15, 2006|Actual|2006-09-15||Interventional|||Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children|Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years|Completed||Phase 2|180|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:00.421013|2018-06-01 04:06:00.421013
NCT00307008|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-24|||2013-04-11|2006-03-24|2006-03-27|Estimate|||||||2013-04-11|2013-04-15|Estimate|October 2003||2003-10-31|September 2011|2011-09-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.|An Open, Phase II Study to Evaluate the Response Rate to the Licensed Single-Dose Polysaccharide Pneumococcal Vaccine Pneumovax 23™ (MSD Aventis Pasteur) in Elderly Population.|Completed||Phase 2|1198|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:06:00.51353|2018-06-01 04:06:00.51353
NCT00306995|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2017-09-11|2006-03-24|2006-03-27|Estimate|||||||2017-09-11|2017-09-12|Actual|May 11, 2005|Actual|2005-05-11|September 2017|2017-09-30|July 4, 2006|Actual|2006-07-04|July 4, 2006|Actual|2006-07-04||Interventional|||Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population|A Phase III, Open, Randomized, Multicenter, Comparative Vaccination Study to Evaluate the Immunogenicity and Reactogenicity of Various Formulations of a Monovalent Candidate Pandemic Influenza A Vaccine in Individuals Over 60 Years of Age|Completed||Phase 2|385|Actual|GlaxoSmithKline||7|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:00.598893|2018-06-01 04:06:00.598893
NCT00306982|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2016-10-11|2006-03-24|2006-03-27|Estimate|||||||2016-10-11|2016-10-12|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™|An Observational Study to Investigate the Incidence of Influenza, Downstream Complications of Influenza and Hospitalizations, in Elderly Subjects Vaccinated With GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly.|Completed|||1524|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:00.72485|2018-06-01 04:06:00.72485
NCT00306969|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2006-03-23|2006-03-23|2006-03-27|Estimate|||||||2006-03-23|2006-03-27|Estimate|December 2001||2001-12-31|September 2004|2004-09-30|April 2004||2004-04-30|||||Interventional|||Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma|Phase I/II Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma|Completed||Phase 1/Phase 2|18||Boston University|||||f||||||||||||||2018-06-01 04:06:00.810192|2018-06-01 04:06:00.810192
NCT00306956|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2008-09-18|2006-03-24|2006-03-27|Estimate|||||||2008-09-18|2008-09-19|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|May 2008|Actual|2008-05-31|August 2007|Actual|2007-08-31||Interventional|||Influence of Pacifiers on Breastfeeding Duration|Influence of Pacifiers on Breastfeeding Duration: a Multicentre, Randomised Controlled Trial|Completed||Phase 3|1021|Actual|Fundacion para la Salud Materno Infantil||2|||f||||t||||||||||2018-06-01 04:06:00.871334|2018-06-01 04:06:00.871334
NCT00304941|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2017-06-30|2006-03-17|2006-03-20|Estimate|||||||2017-06-30|2017-07-02|Actual|March 14, 2006||2006-03-14|September 17, 2010|2010-09-17|September 17, 2010||2010-09-17|||||Observational|||Insulin Resistance and Breast Cancer|Breast Cancer and Insulin Resistance: Implications for Preventive Counseling in Familial and Sporadic Cases|Completed|||25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:06:33.931438|2018-06-01 04:06:33.931438
NCT00306943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-09-20|2006-03-24|2006-03-27|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2005||2005-07-31|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Annual Study for Fluarix Registration|Phase III Vaccination Study for Evaluation of Immunogenicity and Reactogenicity of Influsplit SSW 2004/2005 in People Age 18 or Beyond|Completed||Phase 3|120|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:00.943982|2018-06-01 04:06:00.943982
NCT00306930|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2014-07-28|2006-03-24|2006-03-27|Estimate|||||||2014-07-28|2014-07-29|Estimate|July 2000||2000-07-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical Study Evaluating an Acetabular Cup System After Total Hip Replacement|Multi-center, Prospective, Clinical Evaluation of Pinnacle Acetabular Implants in Total Hip Arthroplasty|Completed||N/A|1593|Actual|DePuy Orthopaedics||1|||f||||f||||||||||2018-06-01 04:06:01.017802|2018-06-01 04:06:01.017802
NCT00306917|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2010-01-29||2011-12-01|2006-03-23|2006-03-27|Estimate|2010-02-23|2010-03-10|Estimate||||2011-12-01|2011-12-05|Estimate|November 2002||2002-11-30|December 2011|2011-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement|A Prospective, Randomized Study of Summit™ Porocoat® Versus Summit™ DuoFix™ HA in Cementless Total Hip Arthroplasty|Terminated||Phase 4|245|Actual|DePuy Orthopaedics|The protocol called for 400 subjects to be followed for 5 years, but due to slow enrollment the study closed early. 245 subjects were enrolled & study endpoint was modified to 2 years. Enrollment closed on June 30, 2006; study closed on Jan 29, 2009.|2||Terminated due to limited enrollment and follow up.|f||||f||||||||||2018-06-01 04:06:01.091663|2018-06-01 04:06:01.091663
NCT00306904|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2008-07-24|2006-03-23|2006-03-27|Estimate|||||||2008-07-24|2008-07-25|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema|A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Diabetic Macular Edema|Completed||Phase 2|48|Actual|OPKO Health, Inc.||3|||f||||t||||||||||2018-06-01 04:06:01.440062|2018-06-01 04:06:01.440062
NCT00306891|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2012-04-03|2011-04-06|2012-10-03|2006-03-23|2006-03-27|Estimate|2012-10-03|2012-11-01|Estimate|2011-04-06|2011-04-12|Estimate|2012-10-03|2012-11-01|Estimate|June 2006||2006-06-30|October 2012|2012-10-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|||Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)|Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin™), Followed by an Assessment of the Safety & Tolerability of Fixed and Individualised Daily Dosing|Completed||Phase 2|60|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 04:06:01.577149|2018-06-01 04:06:01.577149
NCT00306878|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2011-04-11|2006-03-23|2006-03-27|Estimate|||||||2011-04-11|2011-04-13|Estimate|August 1995||1995-08-31|April 2011|2011-04-30|May 1997|Actual|1997-05-31|May 1997|Actual|1997-05-31||Interventional|||Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris|Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris|Completed||Phase 1|45||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:06:02.438618|2018-06-01 04:06:02.438618
NCT00306865|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2017-06-30|2006-03-23|2006-03-24|Estimate|||||||2017-06-30|2017-07-02|Actual|March 17, 2006||2006-03-17|October 14, 2010|2010-10-14|October 14, 2010||2010-10-14|||||Observational|||Brain Changes in Patients With Focal Hand Dystonia|Evaluation of Density and Pattern of Distribution of GABA A Receptors in the Brain of Patients With Focal Hand Dystonia Studied With PET Using [11C] Flumazenil|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:06:02.505038|2018-06-01 04:06:02.505038
NCT00306852|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2015-07-24||2015-10-22|2006-03-23|2006-03-24|Estimate|2015-10-22|2015-11-25|Estimate||||2015-10-22|2015-11-25|Estimate|October 1999||1999-10-31|October 2015|2015-10-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Tube Versus Trabeculectomy (TVT) Study|Tube Versus Trabeculectomy (TVT) Study|Completed||N/A|212|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 04:06:02.588519|2018-06-01 04:06:02.588519
NCT00306839|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2009-02-12|2006-03-22|2006-03-24|Estimate|||||||2009-02-12|2009-02-13|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|May 2008|Actual|2008-05-31|||||Interventional|||Efficacy Study of Tissucol/Tisseel Fibrin Sealant to Treat Inguinal Hernia|Prospective, Controlled, Randomized Study to Evaluate Pain and Further Disabling Complications in Patients Undergoing Lichtenstein Technique for Primary Inguinal Hernia Repair by Fixing the Mesh With Fibrin Sealant Versus Sutures|Completed||Phase 4|325|Actual|University of Milan||2|||f||||t||||||||||2018-06-01 04:06:03.019151|2018-06-01 04:06:03.019151
NCT00306826|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2010-02-01|2006-03-23|2006-03-24|Estimate|||||||2010-02-01|2010-02-02|Estimate||||June 2008|2008-06-30|May 2009||2009-05-31|||||Interventional|||Pioglitazone in Impaired Glucose Tolerance|Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance|Withdrawn||Phase 4|120||University of Leipzig||||financial support withdrawn|f||||||||||||||2018-06-01 04:06:03.11141|2018-06-01 04:06:03.11141
NCT00306813|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2009-08-03|2006-03-23|2006-03-24|Estimate|||||||2009-08-03|2009-08-04|Estimate|September 2004||2004-09-30|March 2006|2006-03-31|December 2008||2008-12-31|||||Interventional|||Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma|A Multicenter Phase I/II Trial Evaluating the Safety and Efficacy of Lenalidomide (Revlimid, CC-5013) in Combination With Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|53|Anticipated|University of Wuerzburg|||||f||||||||||||||2018-06-01 04:06:03.187386|2018-06-01 04:06:03.187386
NCT00306800|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2010-09-01|2006-03-22|2006-03-24|Estimate|||||||2010-09-01|2010-09-03|Estimate|September 2007||2007-09-30|September 2010|2010-09-30|October 2007|Actual|2007-10-31|||||Interventional|||Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp|A Multicenter, Double Blind, Vehicle-Controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 Mg/g Cream and Aktilite CL128 LED Light in Patients With Multiple Actinic Keratosis on the Face and/or Scalp|Completed||Phase 3|80|Anticipated|Galderma|||||f||||||||||||||2018-06-01 04:06:03.256775|2018-06-01 04:06:03.256775
NCT00306787|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|2009-08-20||2011-06-28|2006-03-22|2006-03-24|Estimate|2011-05-16|2011-06-17|Estimate||||2011-06-28|2011-06-30|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes|A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes|Completed||Phase 3|1179|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:06:03.367006|2018-06-01 04:06:03.367006
NCT00306748|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2009-03-22|2006-03-23|2006-03-24|Estimate|||||||2009-03-22|2009-03-24|Estimate|March 2006||2006-03-31|March 2009|2009-03-31|August 2006||2006-08-31|||||Interventional|||Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation|A Randomized, Multicenter, Double-Blind, Parallel-Design, Phase 2 Trial of Oral MD-1100 Acetate Administered for 14 Days Once Daily at 100 ug, 300 ug, 1000 ug, or Placebo to Patients With Chronic Constipation|Completed||Phase 2|40||Ironwood Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:06:03.884044|2018-06-01 04:06:03.884044
NCT00306735|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2016-12-01|2006-03-22|2006-03-24|Estimate|||||||2016-12-01|2016-12-05|Estimate|March 2006||2006-03-31|November 2015|2015-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.|A Double-blind Phase 2 Study to Assess the Safety and Efficacy of Aloxi (Palonosetron HCl) for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving High-dose Melphalan as Conditioning Chemotherapy for Stem Cell Transplantation|Completed||Phase 2|75|Anticipated|Eisai Inc.||1|||f||||f||||||||||2018-06-01 04:06:03.950264|2018-06-01 04:06:03.950264
NCT00306722|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2008-11-06|2006-03-22|2006-03-24|Estimate|||||||2008-11-06|2008-11-07|Estimate|April 2006||2006-04-30|November 2008|2008-11-30|May 2007|Actual|2007-05-31|||||Interventional|||An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy|A Phase 3, Randomized, Double-Blind, Dose-Controlled Study To Assess The Efficacy And Safety Of AQUAVAN® (Fospropofol Disodium) Injection For Minimal-To-Moderate Sedation In Patients Undergoing Flexible Bronchoscopy|Completed||Phase 3|250||Eisai Inc.|||||||||||||||||||2018-06-01 04:06:04.017898|2018-06-01 04:06:04.017898
NCT00306709|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2010-09-17|2006-03-22|2006-03-24|Estimate|||||||2010-09-17|2010-09-21|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|June 2010|Actual|2010-06-30|June 2007|Actual|2007-06-30||Interventional|||Take HEED (Healthy Eating and Exercise Decisions)|Take HEED (Healthy Eating and Exercise Decisions)|Completed||N/A|223|Actual|Kaiser Permanente||1|||f||||f||||||||||2018-06-01 04:06:04.244364|2018-06-01 04:06:04.244364
NCT00306696|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2016-09-13|2006-03-22|2006-03-24|Estimate|||||||2016-09-13|2016-09-15|Estimate|October 2002||2002-10-31|September 2016|2016-09-30|January 2004|Actual|2004-01-31|||||Interventional|||Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.|A Randomised Study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated With Avandia|Completed||Phase 4|388|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:04.324719|2018-06-01 04:06:04.324719
NCT00306683|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2011-02-17|2006-03-23|2006-03-24|Estimate|||||||2011-02-17|2011-02-18|Estimate|April 2006||2006-04-30|April 2007|2007-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions|Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions|Completed||Phase 3|40|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:06:04.477871|2018-06-01 04:06:04.477871
NCT00306670|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|2016-12-20||2016-12-20|2006-03-23|2006-03-24|Estimate|2016-12-20|2017-02-10|Actual||||2016-12-20|2017-02-10|Actual|April 2006||2006-04-30|December 2016|2016-12-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional||Patients diagnosed with acquired FVIII inhibitors were to be randomized to Rituximab versus oral cyclophosphamide to evaluate efficacy of inhibitor eradication and safety|Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A|A Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia A|Terminated||Phase 2/Phase 3|2|Actual|Georgetown University|Sponsor terminated study prior to patient receiving first dose of study drug.|2||Sponsor no longer funding study.|f||||f||||||||||2018-06-01 04:06:04.555883|2018-06-01 04:06:04.555883
NCT00306657|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2011-06-23|2006-03-23|2006-03-24|Estimate|||||||2011-06-23|2011-06-27|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|December 2012|Anticipated|2012-12-31|||||Interventional|||Normal Tension and Chronic Open Angle Glaucoma and Cerebrospinal Fluid Composition|Normal Tension and Chronic Open Angle Glaucoma, Cerebrospinal Fluid Composition in Subarachnoid Space of Affected Optic Nerves|Unknown status|Recruiting|N/A|30|Anticipated|Kantonsspital Aarau|||||f||||||||||||||2018-06-01 04:06:04.794439|2018-06-01 04:06:04.794439
NCT00306644|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2016-08-31|2006-03-22|2006-03-24|Estimate|||||||2016-08-31|2016-09-01|Estimate|May 2002||2002-05-31|August 2016|2016-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes|Effect of Rosiglitazone and Placebo on Carotid Intima Media Thickness in Patients With Insulin Resistance Syndrome and/or Type 2 Diabetes|Completed||Phase 4|556|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:04.930389|2018-06-01 04:06:04.930389
NCT00306631|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2009-06-02|2006-03-22|2006-03-24|Estimate|||||||2009-06-02|2009-06-03|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|||A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1|A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer|Completed||Phase 2|65|Actual|CASI Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-06-01 04:06:05.047193|2018-06-01 04:06:05.047193
NCT00306618|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2008-12-09|2006-03-22|2006-03-24|Estimate|||||||2008-12-09|2008-12-10|Estimate|January 2006||2006-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|November 2007|Actual|2007-11-30||Interventional|||Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma|A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|27|Actual|CASI Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 04:06:05.123748|2018-06-01 04:06:05.123748
NCT00306605|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2017-06-19|2006-03-23|2006-03-24|Estimate|||||||2017-06-19|2017-06-21|Actual|March 2006||2006-03-31|June 2017|2017-06-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Observational|||Emotional Experiences in Fathers of NICU Infants|Emotional Experiences in Fathers of NICU Babies: A Comparison of Fathers in Medical and Surgical NICUs.|Completed|||35|Actual|Christiana Care Health Services|||||f||||f||||||||||2018-06-01 04:06:05.189369|2018-06-01 04:06:05.189369
NCT00306410|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2007-02-28|2006-03-22|2006-03-23|Estimate|||||||2007-02-28|2007-03-01|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|July 2007||2007-07-31|||||Interventional|||The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients|The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients|Unknown status|Recruiting|Phase 2|85||Radboud University|||||f||||||||||||||2018-06-01 04:06:07.789238|2018-06-01 04:06:07.789238
NCT00306592|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2009-06-30||2017-02-14|2006-03-22|2006-03-24|Estimate|2009-12-20|2010-01-26|Estimate||||2017-02-14|2017-03-21|Actual|March 2006||2006-03-31|February 2017|2017-02-28|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional||Participants from 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) are combined.|Natalizumab Re-Initiation of Dosing|An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation|Completed||Phase 3|404|Actual|Biogen||1|||f||||f||||||||||2018-06-01 04:06:05.299038|2018-06-01 04:06:05.299038
NCT00306579|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2017-08-07|2006-03-23|2006-03-24|Estimate|||||||2017-08-07|2017-08-08|Actual|August 2003||2003-08-31|August 2017|2017-08-31|May 2005||2005-05-31|||||Observational|||Myocardial Damage In Patients With Cerebral Infarction|Myocardial Damage In Patients With Cerebral Infarction. Prevalence and Characteristics as Measured by Troponins, Electrocardiographic Changes and Myocardial Perfusion Imaging.|Completed|||250||Danish Heart Foundation|||||f||||||||||||||2018-06-01 04:06:05.676797|2018-06-01 04:06:05.676797
NCT00306566|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2007-09-19|2006-03-23|2006-03-24|Estimate|||||||2007-09-19|2007-09-20|Estimate||||September 2007|2007-09-30||||||||Interventional|||Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients|A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage II Malignant Melanoma|Completed||Phase 1/Phase 2|||Cytos Biotechnology AG|||||f||||||||||||||2018-06-01 04:06:05.739007|2018-06-01 04:06:05.739007
NCT00306553|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2006-09-18|2006-03-23|2006-03-24|Estimate|||||||2006-09-18|2006-09-19|Estimate||||September 2006|2006-09-30||||||||Interventional|||Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients||Completed||Phase 2|||Cytos Biotechnology AG|||||f||||||||||||||2018-06-01 04:06:05.78457|2018-06-01 04:06:05.78457
NCT00306540|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2010-12-08|2006-03-22|2006-03-24|Estimate|||||||2010-12-08|2010-12-09|Estimate|December 2004||2004-12-31|December 2010|2010-12-31|August 2008|Actual|2008-08-31|September 2007|Actual|2007-09-30||Interventional|||Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder|A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder|Completed||Phase 3|90|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:06:05.833068|2018-06-01 04:06:05.833068
NCT00306527|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|2012-12-06||2016-02-08|2006-03-22|2006-03-24|Estimate|2012-12-06|2013-01-11|Estimate||||2016-02-08|2016-03-09|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|April 2006|Actual|2006-04-30|December 2005|Actual|2005-12-31||Interventional|||Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly|A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity (in a Subset) Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before in the V58P4 Study.|Completed||Phase 3|2235|Actual|Novartis||8|||f||||||||||||||2018-06-01 04:06:05.931443|2018-06-01 04:06:05.931443
NCT00306514|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-23|||2007-09-19|2006-03-23|2006-03-24|Estimate|||||||2007-09-19|2007-09-20|Estimate||||September 2007|2007-09-30||||||||Interventional|||Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients|A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma|Completed||Phase 1/Phase 2|||Cytos Biotechnology AG|||||f||||||||||||||2018-06-01 04:06:07.096394|2018-06-01 04:06:07.096394
NCT00306501|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2017-06-30|2006-03-22|2006-03-23|Estimate|||||||2017-06-30|2017-07-02|Actual|March 17, 2006||2006-03-17|October 29, 2010|2010-10-29|December 16, 2009|Actual|2009-12-16|December 16, 2009|Actual|2009-12-16||Interventional|||Volitional Swallowing in Stroke Patients With Chronic Dysphagia|Induction of Volitional Swallowing in Chronic Dysphagia Post Stroke: A Novel Mechanism-Based Intervention|Completed||Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-06-01 04:06:07.148376|2018-06-01 04:06:07.148376
NCT00306488|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|2011-04-21||2011-08-16|2006-03-22|2006-03-23|Estimate|2011-06-30|2011-07-29|Estimate||||2011-08-16|2011-08-17|Estimate|March 2006||2006-03-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration|A Phase II Study of OT-551 Antioxidant Eye Drop in Participants With Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration|Completed||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 04:06:07.227056|2018-06-01 04:06:07.227056
NCT00306475|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2010-01-06|2006-03-22|2006-03-23|Estimate|||||||2010-01-06|2010-01-07|Estimate|March 2006||2006-03-31|January 2010|2010-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?|Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?|Completed||Phase 4|60|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:06:07.473465|2018-06-01 04:06:07.473465
NCT00306462|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2009-11-06|2006-03-21|2006-03-23|Estimate|||||||2009-11-06|2009-11-09|Estimate|March 2006||2006-03-31|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor|Randomized Double-Blinded Trial of Magnesium Sulfate Tocolysis Versus Nifedipine Tocolysis in Women With Preterm Labor Between 24 to 32 6/7 Weeks' Gestation|Terminated||N/A|33|Actual|University of Cincinnati||2||No enrollment in past year, lack of interest|f||||f||||||||||2018-06-01 04:06:07.538774|2018-06-01 04:06:07.538774
NCT00306449|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2006-03-21|2006-03-21|2006-03-23|Estimate|||||||2006-03-21|2006-03-23|Estimate|September 2002||2002-09-30|March 2006|2006-03-31|September 2005||2005-09-30|||||Interventional|||Prevention of Weight Gain in Young Adults|Prevention of Weight Gain in Young Adults|Completed||N/A|110||Université de Sherbrooke|||||f||||||||||||||2018-06-01 04:06:07.613495|2018-06-01 04:06:07.613495
NCT00306436|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2007-06-12|2006-03-21|2006-03-23|Estimate|||||||2007-06-12|2007-06-13|Estimate|May 2006||2006-05-31|June 2007|2007-06-30|May 2008|Anticipated|2008-05-31|||||Interventional|||Comprehensive Management of Diabetic Patients With Renal Impairment : Impact on Blood Pressure and Glycemic Control|Evaluation of the Impact of a Comprehensive Clinical Management on the Quality of Blood Pressure and Glycemic Control in Diabetic Uremic Patients|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Bordeaux|||||f||||t||||||||||2018-06-01 04:06:07.674353|2018-06-01 04:06:07.674353
NCT00306423|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2017-03-30|2006-03-21|2006-03-23|Estimate|||||||2017-03-30|2017-04-04|Actual|June 2003|Actual|2003-06-30|March 2017|2017-03-31|August 2014|Actual|2014-08-31|August 2011|Actual|2011-08-31||Interventional|||Rehabilitation Post Lumbar Microdiscectomy||Completed||Phase 1|100|Anticipated|University of Southern California|||||f||||||||||||||2018-06-01 04:06:07.734007|2018-06-01 04:06:07.734007
NCT00306397|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2010-06-29|2006-03-22|2006-03-23|Estimate|||||||2010-06-29|2010-06-30|Estimate|January 2005||2005-01-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients|Open, Single Centre, Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for De Novo Renal Transplant Recipients Followed by Randomisation to Calcineurin Inhibitor Containing or Calcineurin Inhibitor Free Immunosuppression|Completed||Phase 4|100|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 04:06:08.889197|2018-06-01 04:06:08.889197
NCT00306384|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2013-02-17||2013-02-17|2006-03-21|2006-03-23|Estimate|2013-02-17|2013-03-22|Estimate||||2013-02-17|2013-03-22|Estimate|March 2006||2006-03-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Long-term Safety of Alogliptin in Patients With Type 2 Diabetes Mellitus|A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects With Type 2 Diabetes|Completed||Phase 3|3323|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:06:09.08115|2018-06-01 04:06:09.08115
NCT00306371|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2006-03-22|2006-03-22|2006-03-23|Estimate|||||||2006-03-22|2006-03-23|Estimate|July 2004||2004-07-31|July 2004|2004-07-31|February 2006||2006-02-28|||||Observational|||Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser|Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser|Completed|||15||Skincare Physicians of Chestnut Hill|||||f||||||||||||||2018-06-01 04:06:11.456691|2018-06-01 04:06:11.456691
NCT00306358|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2006-03-22|2006-03-22|2006-03-23|Estimate|||||||2006-03-22|2006-03-23|Estimate|May 2005||2005-05-31|March 2006|2006-03-31|October 2005||2005-10-31|||||Interventional|||Plasma Holotranscobalamin as Compared to Plasma Cobalamins for Assessment of Vitamin B12 Absorption|Plasma Holotranscobalamin as Compared to Plasma Cobalamins for Assessment of Vitamin B12 Absorption. Optimisation of a Non-Radioactive Vitamin B12 Absorption Test (CobaSorb)|Completed||N/A|78||University of Aarhus|||||f||||||||||||||2018-06-01 04:06:11.51642|2018-06-01 04:06:11.51642
NCT00306345|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2007-07-11|2006-03-22|2006-03-23|Estimate|||||||2007-07-11|2007-07-12|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|December 2008||2008-12-31|||||Observational|||Outreach: A Programme for Timely Treatment of Critically Ill Patients in a University Hospital|Outreach: A Programme for Early Recognition, Quick Response and Timely Treatment of Critically Ill Patients in a University Hospital|Unknown status|Recruiting||1500|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:06:11.584252|2018-06-01 04:06:11.584252
NCT00306332|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2009-08-17|2006-03-22|2006-03-23|Estimate|||||||2009-08-17|2009-08-18|Estimate|March 2006||2006-03-31|August 2009|2009-08-31||||||||Interventional|||T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation|T-cel and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation by Using Immunomagnetic Negative and Positive Selection Procedures|Terminated||Phase 3|250|Anticipated|Radboud University||||Interim analysis has shown that the objectives of this study can not be reached|f||||||||||||||2018-06-01 04:06:11.670642|2018-06-01 04:06:11.670642
NCT00306319|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2008-05-20|2006-03-22|2006-03-23|Estimate|||||||2008-05-20|2008-05-21|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia|Pharmacokinetic Interaction Study of Rifampicin, Isoniazid and Moxifloxacin in Tuberculosis Patients in Bandung, Indonesia|Completed||Phase 2|23||Radboud University|||||f||||||||||||||2018-06-01 04:06:11.737434|2018-06-01 04:06:11.737434
NCT00306306|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2008-08-04|2006-03-21|2006-03-23|Estimate|||||||2008-08-04|2008-08-05|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||COOL RCN: Cooling to Prevent Radiocontrast Nephropathy|COOL RCN: Cooling to Prevent Radiocontrast Nephropathy in Patients Undergoing Diagnostic or Interventional Catheterization|Terminated||Phase 2/Phase 3|400|Anticipated|Radiant Medical|||||||||||||||||||2018-06-01 04:06:11.797169|2018-06-01 04:06:11.797169
NCT00306293|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2017-04-14||2017-08-28|2006-03-21|2006-03-23|Estimate|2017-08-28|2018-03-23|Actual||||2017-08-28|2018-03-23|Actual|February 20, 2006|Actual|2006-02-20|August 2017|2017-08-31|November 27, 2006|Actual|2006-11-27|November 27, 2006|Actual|2006-11-27||Interventional|||VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2|The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection|Completed||Phase 4|70|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:11.887765|2018-06-01 04:06:11.887765
NCT00306280|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2006-09-19|2006-03-21|2006-03-23|Estimate|||||||2006-09-19|2006-09-20|Estimate|March 2006||2006-03-31|September 2006|2006-09-30|March 2007||2007-03-31|||||Interventional|||Feasibility Study of Phototherapy System to Treat H Pylori|Phase 1 Study of Phototherapy System to Treat H Pylori|Unknown status|Recruiting|N/A|60||LumeRx|||||||||||||||||||2018-06-01 04:06:12.372109|2018-06-01 04:06:12.372109
NCT00306267|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2011-05-17|2006-03-21|2006-03-23|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2006||2006-03-31|March 2010|2010-03-31|May 2007|Actual|2007-05-31|||||Interventional|||A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy|A Pilot Study to Evaluate the Safety and Efficacy of PROCRIT (Epoetin Alfa) 80,000 Units Once Every Four Weeks (Q4W) vs. 40,000 Units Once Every Two Weeks (Q2W) in Cancer Subjects With Non-Chemotherapy Anemia (NCA)|Terminated||Phase 2|61|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"Study stopped as it would not address important survival concerns raised in other recently~   conducted clinical studies."|||||f||||||||||2018-06-01 04:06:12.444244|2018-06-01 04:06:12.444244
NCT00306254|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2007-10-05|2006-03-21|2006-03-23|Estimate|||||||2007-10-05|2007-10-10|Estimate|March 2006||2006-03-31|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|||Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery|A Phase 2B, Randomized, Multicenter, Dose-Ranging Study Assessing the Safety and Efficacy of PD 0348292 in the Prevention of Venous Thromboembolic Events (VTE) in Subjects Undergoing an Elective, Unilateral Total Knee Replacement|Completed||Phase 2|1225||Pfizer|||||f||||||||||||||2018-06-01 04:06:12.518869|2018-06-01 04:06:12.518869
NCT00306241|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2016-11-02|2006-03-22|2006-03-23|Estimate|||||||2016-11-02|2016-11-04|Estimate|March 2006||2006-03-31|November 2016|2016-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years|A Phase III, Double-blind, Randomized, Controlled Study to Evaluate Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly (0, 1, 6 Month Schedule) in Healthy Females Aged 18 - 35 Years|Completed||Phase 3|300|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:06:12.719396|2018-06-01 04:06:12.719396
NCT00306228|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2009-09-25|2006-03-21|2006-03-23|Estimate|||||||2009-09-25|2009-09-28|Estimate|October 2004||2004-10-31|September 2009|2009-09-30|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|GRACIA3||Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty|A Randomised Trial to Evaluate the Role of Paclitaxel Eluting Stent and Tirofiban to Improve the Results of Facilitated PCI in the Treatment of Acute ST- Segment Elevation Myocardial Infarction|Completed||Phase 4|436|Actual|GRACIA Group||4|||f||||t||||||||||2018-06-01 04:06:13.002999|2018-06-01 04:06:13.002999
NCT00306215|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2012-02-08|2006-03-21|2006-03-23|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease|A Multinational, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease|Completed||Phase 2|436|Actual|ChemoCentryx||4|||f||||t||||||||||2018-06-01 04:06:13.120236|2018-06-01 04:06:13.120236
NCT00306202|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2012-06-11||2017-09-20|2006-03-21|2006-03-23|Estimate|2012-06-18|2012-07-23|Estimate||||2017-09-20|2017-09-26|Actual|February 22, 2006|Actual|2006-02-22|September 2017|2017-09-30|October 4, 2022|Anticipated|2022-10-04|May 25, 2011|Actual|2011-05-25||Interventional|||Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia|Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005|Active, not recruiting||Phase 1|63|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 04:06:13.540432|2018-06-01 04:06:13.540432
NCT00306189|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2009-12-22|2009-11-23|2013-06-13|2006-03-21|2006-03-23|Estimate|2009-12-22|2010-01-27|Estimate|2009-11-23|2009-11-25|Estimate|2013-06-13|2013-06-20|Estimate|January 2006||2006-01-31|June 2013|2013-06-30|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects|Dose Response Study of AMG 162 (Denosumab) in Subjects With Osteoporosis - A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects -|Completed||Phase 2|212|Actual|Amgen||4|||f||||||||||||||2018-06-01 04:06:16.822623|2018-06-01 04:06:16.822623
NCT00306176|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|||2007-04-03|2006-03-22|2006-03-23|Estimate|||||||2007-04-03|2007-04-04|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|October 2006||2006-10-31|||||Interventional|||Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus|Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|100||Aristotle University Of Thessaloniki|||||f||||||||||||||2018-06-01 04:06:17.26109|2018-06-01 04:06:17.26109
NCT00306163|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-22|2010-04-06|2009-11-19|2016-12-02|2006-03-22|2006-03-23|Estimate|2010-04-06|2010-04-26|Estimate|2010-04-06|2010-04-26|Estimate|2016-12-02|2017-02-01|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)|Nebulizer Trial: Evaluation of the Influence of Particle Size of Aerosolized AMP on Bronchial Responsiveness in Patients With Asthma and the Effects of Treatment With Ciclesonide Versus Fluticasone.|Completed||Phase 3|37|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:06:17.648372|2018-06-01 04:06:17.648372
NCT00306150|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2014-12-16|2006-03-21|2006-03-23|Estimate|||||||2014-12-16|2014-12-17|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy|A Multi-center, Randomized, Double Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy.|Terminated||Phase 3|57|Actual|Bayer||2|||f||||||||||||||2018-06-01 04:06:17.904565|2018-06-01 04:06:17.904565
NCT00306137|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2014-12-08|2006-03-21|2006-03-23|Estimate|||||||2014-12-08|2014-12-09|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung Cancer or Esophageal Cancer|Terminated||Phase 3|104|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:06:18.122848|2018-06-01 04:06:18.122848
NCT00306124|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2007-10-24|2006-03-21|2006-03-22|Estimate|||||||2007-10-24|2007-10-25|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment|Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI)|Unknown status|Recruiting|Phase 4|120|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:06:18.236313|2018-06-01 04:06:18.236313
NCT00306111|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2014-05-28|2006-03-20|2006-03-22|Estimate|||||||2014-05-28|2014-05-29|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2008|Actual|2008-12-31||Interventional|||Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma|Pegfilgrastim Versus Filgrastim - Intraindividual Comparison of Quantity and Quality of Mobilized Peripheral Blood Stem Cells in Patients With Non Hodgkin-lymphoma|Completed||Phase 2|14|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-06-01 04:06:18.30692|2018-06-01 04:06:18.30692
NCT00306098|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2017-10-06|2006-03-17|2006-03-22|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2000||2000-12-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression|Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression|Active, not recruiting||Phase 2|40|Anticipated|University of Miami||1|||f||||t||||||||||2018-06-01 04:06:18.383902|2018-06-01 04:06:18.383902
NCT00306085|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-03-21|2006-03-21|2006-03-22|Estimate|||||||2006-03-21|2006-03-22|Estimate|April 2005||2005-04-30|March 2006|2006-03-31|April 2006||2006-04-30|||||Interventional|||Autologous Bone Marrow Cell Treatment in Peripheral Atherosclerosis|Autologous Bone Marrow Cell Treatment in Patients With Peripheral Atherosclerosis|Unknown status|Recruiting|Phase 1|20||University of Naples|||||f||||||||||||||2018-06-01 04:06:18.462161|2018-06-01 04:06:18.462161
NCT00306072|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2010-01-26|2006-03-20|2006-03-22|Estimate|||||||2010-01-26|2010-01-27|Estimate|June 2005||2005-06-30|March 2006|2006-03-31|September 2005||2005-09-30|||||Interventional|||Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes|Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes|Completed||Phase 1/Phase 2|82||Ross Products|||||f||||||||||||||2018-06-01 04:06:18.533203|2018-06-01 04:06:18.533203
NCT00306046|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2006-03-20|2006-03-20|2006-03-22|Estimate|||||||2006-03-20|2006-03-22|Estimate|February 2002||2002-02-28|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||18F-Fluoride Positron Emission Tomography (PET) in Paget's Disease of Bone|Use of 18F-Fluoride Positron Emission Tomography in the Assessment and Evaluation of Therapy in Monostotic Paget's Disease of Bone|Completed||N/A|20||Université Catholique de Louvain|||||f||||||||||||||2018-06-01 04:06:18.671493|2018-06-01 04:06:18.671493
NCT00306033|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2006-03-31|2006-03-21|2006-03-22|Estimate|||||||2006-03-31|2006-04-03|Estimate|March 2004||2004-03-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis|IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial|Completed||Phase 3|50||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:06:18.729769|2018-06-01 04:06:18.729769
NCT00306020|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2012-07-03|2006-03-21|2006-03-22|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2006||2006-01-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Analgesia and Wound Healing Assessment Following Topical Morphine Applied to Patients With Cutaneous Cancer Related Pain|Analgesia and Wound Healing Assessment Following Topical Morphine Applied to Patients With Cutaneous Cancer Related Pain|Withdrawn||N/A|0|Actual|Soroka University Medical Center||||"The study was withdrawn due to difficulties in recruiting appropriate patients in community~   clinic setting"|f||||||||||||||2018-06-01 04:06:18.798867|2018-06-01 04:06:18.798867
NCT00306007|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2013-06-23|2006-03-21|2006-03-22|Estimate|||||||2013-06-23|2013-06-25|Estimate|November 2005||2005-11-30|June 2013|2013-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|LMUP||Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women|Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women|Completed|||320|Actual|University of California, San Francisco|||4||f||||f||||||||||2018-06-01 04:06:19.036026|2018-06-01 04:06:19.036026
NCT00305981|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2007-04-17|2006-03-21|2006-03-22|Estimate|||||||2007-04-17|2007-04-19|Estimate|October 2005||2005-10-31|October 2005|2005-10-31||||||||Observational|||The ICU Care Knowledge Study|The ICU Care Knowledge Study: A Prospective Study of Family Members' Knowledge of ICU Care and Prognosis|Completed|||154||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:06:19.092864|2018-06-01 04:06:19.092864
NCT00305968|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2011-12-20|2006-03-21|2006-03-22|Estimate|||||||2011-12-20|2011-12-21|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Evaluation of Patient Education in Irritable Bowel Syndrome|Evaluation of Patient Education in Patients With Irritable Bowel Syndrome - a Randomized Multi Center Study|Completed||Phase 3|200|Actual|Sorlandet Hospital HF|||||f||||||||||||||2018-06-01 04:06:19.138652|2018-06-01 04:06:19.138652
NCT00305955|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2010-03-23|2006-03-20|2006-03-22|Estimate|||||||2010-03-23|2010-03-24|Estimate|August 2004||2004-08-31|October 2009|2009-10-31|October 2006|Actual|2006-10-31|July 2006|Actual|2006-07-31||Observational|ATS7||Bilateral Refractive Amblyopia Treatment Study|Bilateral Refractive Amblyopia Treatment Study|Completed|||113|Actual|Jaeb Center for Health Research|||||f||||f||||||||||2018-06-01 04:06:19.201662|2018-06-01 04:06:19.201662
NCT00305942|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|2012-12-18||2013-01-24|2006-03-20|2006-03-22|Estimate|2012-12-18|2013-01-24|Estimate||||2013-01-24|2013-01-31|Estimate|March 2006||2006-03-31|January 2013|2013-01-31|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|||Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer|A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|61|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:06:19.29263|2018-06-01 04:06:19.29263
NCT00305929|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2010-05-31|2006-03-20|2006-03-22|Estimate|||||||2010-05-31|2010-06-02|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure|Phase II Study of Photodynamic Therapy With WST09 in Patients With Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure - Repeat Procedure|Completed||Phase 2|8|Anticipated|STEBA France||1|||f||||f||||||||||2018-06-01 04:06:19.64344|2018-06-01 04:06:19.64344
NCT00305916|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2008-02-22|2006-03-21|2006-03-22|Estimate|||||||2008-02-22|2008-02-26|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|CMD-scanner||Multislice Spiral Computed Tomography and Cardiomyopathy|"Accuracy of Multislice Spiral Computed Tomography in Diagnosis of Coronary Artery Disease Associated to Idiopathic Cardiomyopathy in Sinus Rhythm (MSCT-IC Study)."|Completed||N/A|60|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-06-01 04:06:19.718971|2018-06-01 04:06:19.718971
NCT00305903|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2007-12-17|2006-03-20|2006-03-22|Estimate|||||||2007-12-17|2007-12-21|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease|A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20)|Completed||Phase 4|150|Anticipated|Novartis|||||||||||||||||||2018-06-01 04:06:19.796653|2018-06-01 04:06:19.796653
NCT00305890|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2014-07-11|2006-03-20|2006-03-22|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2004||2004-01-31|August 2013|2013-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Weight Management and Coping Skills Training For Patients With Knee Osteoarthritis|Duke University Pain Prevention: Weight Management and Coping Skills Training For Patients With Osteoarthritis of the Knee|Completed||N/A|412|Actual|Duke University||4|||f||||t||||||||||2018-06-01 04:06:19.857506|2018-06-01 04:06:19.857506
NCT00305877|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2013-09-24||2014-05-06|2006-03-21|2006-03-22|Estimate|2013-09-24|2013-11-25|Estimate||||2014-05-06|2014-05-21|Estimate|February 2006||2006-02-28|December 2012|2012-12-31|February 2012|Actual|2012-02-29|July 2008|Actual|2008-07-31||Interventional||All treated patients are included in this analysis.|Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery|An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination With Gemcitabine and in Combination With Chemoradiation (Capecitabine and Radiation) in Patients With Completely-Resected Pancreatic Carcinoma|Completed||Phase 2|137|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:06:19.952993|2018-06-01 04:06:19.952993
NCT00305864|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2013-03-05||2018-02-02|2006-03-21|2006-03-22|Estimate|2013-05-16|2013-05-17|Estimate||||2018-02-02|2018-03-05|Actual|February 9, 2006|Actual|2006-02-09|February 2018|2018-02-28|March 15, 2011|Actual|2011-03-15|February 16, 2011|Actual|2011-02-16||Interventional|||Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME|Completed||Phase 1/Phase 2|118|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 04:06:20.49949|2018-06-01 04:06:20.49949
NCT00305851|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2016-02-19|2006-03-21|2006-03-22|Estimate|||||||2016-02-19|2016-02-23|Estimate|April 2006||2006-04-30|February 2016|2016-02-29||||April 2012|Actual|2012-04-30||Interventional|||Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant|Music Video and Adolescent/Young Adult Resilience During Transplant|Completed||Phase 3|118|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 04:06:22.149829|2018-06-01 04:06:22.149829
NCT00305838|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2013-08-09|2006-03-21|2006-03-22|Estimate|||||||2013-08-09|2013-08-12|Estimate|March 2004||2004-03-31|June 2009|2009-06-30||||December 2008|Anticipated|2008-12-31||Interventional|||CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen|Use of Changes in CA 125 Doubling Time to Detect Activity of Cytostatic Agents in Women Relapsing With Ovarian Carcinoma. Study 1-Tamoxifen|Unknown status|Recruiting|Phase 2|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:06:22.284619|2018-06-01 04:06:22.284619
NCT00305825|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2017-08-30|2006-03-21|2006-03-22|Estimate|||||||2017-08-30|2017-08-31|Actual|August 2004||2004-08-31|August 2017|2017-08-31|May 24, 2016|Actual|2016-05-24|May 30, 2006|Actual|2006-05-30||Interventional|||Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery|A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer|Completed||Phase 2|43|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:06:22.410597|2018-06-01 04:06:22.410597
NCT00305812|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2010-11-07|2006-03-21|2006-03-22|Estimate|||||||2010-11-07|2010-11-09|Estimate|December 2005||2005-12-31|March 2010|2010-03-31|June 2008|Actual|2008-06-30|||||Interventional|||Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma|A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma|Completed||Phase 2|92|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 04:06:22.487696|2018-06-01 04:06:22.487696
NCT00305799|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2014-11-20|2006-03-21|2006-03-22|Estimate|||||||2014-11-20|2014-11-24|Estimate|November 2005||2005-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|December 2012|Actual|2012-12-31||Observational|||Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors|Auditory and Vestibular Function Evaluation in Patients With Solid Tumors Treated With Oxaliplatin-Containing Chemotherapy|Completed|||59|Actual|Case Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 04:06:22.562052|2018-06-01 04:06:22.562052
NCT00305786|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2016-12-14|2006-03-21|2006-03-22|Estimate|||||||2016-12-14|2016-12-15|Estimate|August 2005||2005-08-31|December 2016|2016-12-31|May 2010|Actual|2010-05-31|December 2007|Actual|2007-12-31||Interventional|||Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease|Completed||Phase 2|30|Actual|University of Miami|||||f||||t||||||||||2018-06-01 04:06:22.619417|2018-06-01 04:06:22.619417
NCT00305773|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2013-03-28||2014-04-30|2006-03-21|2006-03-22|Estimate|2013-03-28|2013-05-16|Estimate||||2014-04-30|2014-05-19|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|January 2010|Actual|2010-01-31|May 2009|Actual|2009-05-31||Interventional|||Vorinostat in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML)|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:06:22.826235|2018-06-01 04:06:22.826235
NCT00305760|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2015-06-18||2015-06-18|2006-03-21|2006-03-22|Estimate|2015-06-18|2015-07-15|Estimate||||2015-06-18|2015-07-15|Estimate|December 2005||2005-12-31|June 2015|2015-06-30||||February 2009|Actual|2009-02-28||Interventional|||Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer|A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Erbitux (Cetuximab) for the Treatment of Advanced Pancreatic Adenocarcinoma|Completed||Phase 2|60|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 04:06:23.36519|2018-06-01 04:06:23.36519
NCT00305747|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2014-01-14|2006-03-21|2006-03-22|Estimate|||||||2014-01-14|2014-01-15|Estimate|August 2005||2005-08-31|January 2014|2014-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy|Phase I Study of Bioresponse-dim in Non-Metastatic, Hormone-Refractory Prostate Cancer Patients With Rising Serum PSA|Completed||Phase 1|12|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 04:06:23.559297|2018-06-01 04:06:23.559297
NCT00305734|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2013-01-24|2006-03-21|2006-03-22|Estimate|||||||2013-01-24|2013-01-25|Estimate|August 2006||2006-08-31|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer|Phase II Trial of PS-341 (Bortezomib, NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:06:23.624759|2018-06-01 04:06:23.624759
NCT00305708|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2012-11-08|2006-03-21|2006-03-22|Estimate|||||||2012-11-08|2012-11-12|Estimate|August 2000||2000-08-31|November 2012|2012-11-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission|Bone Marrow Stem Cell Transplantation for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myeloid Leukemia in 1Remission|Completed||Phase 1/Phase 2|40|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:06:23.698752|2018-06-01 04:06:23.698752
NCT00305695|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2017-08-23|2006-03-21|2006-03-22|Estimate|||||||2017-08-23|2017-08-24|Actual|November 28, 2005|Actual|2005-11-28|August 2017|2017-08-31||||December 22, 2011|Actual|2011-12-22||Interventional|||Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries|A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery That Results in Removal of Both Ovaries|Active, not recruiting||Phase 2|115|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 04:06:23.770759|2018-06-01 04:06:23.770759
NCT00305682|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2017-12-03|2006-03-21|2006-03-22|Estimate|||||||2017-12-03|2017-12-05|Actual|June 2005||2005-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant|Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen|Active, not recruiting||Phase 2|293|Actual|Masonic Cancer Center, University of Minnesota||6|||f||||t||||||||||2018-06-01 04:06:23.88431|2018-06-01 04:06:23.88431
NCT00305669|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2014-06-24|2006-03-21|2006-03-22|Estimate|||||||2014-06-24|2014-06-25|Estimate|July 2006||2006-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|January 2011|Actual|2011-01-31||Interventional|||GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer|A Pilot Study of Two Dose Schedules of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) as Neo-Adjuvant Therapy in Patients With Localized Prostate Cancer|Completed||Phase 1|24|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:06:25.030694|2018-06-01 04:06:25.030694
NCT00305656|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21||2013-07-26|2013-08-14|2006-03-21|2006-03-22|Estimate||||2013-08-14|2013-08-22|Estimate|2013-08-14|2013-08-22|Estimate|January 2006||2006-01-31|July 2013|2013-07-31||||April 2012|Actual|2012-04-30||Interventional|||AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase II Study of AZD2171 in Recurrent Glioblastoma|Completed||Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:06:25.100821|2018-06-01 04:06:25.100821
NCT00305643|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|2012-01-25||2015-11-19|2006-03-21|2006-03-22|Estimate|2015-11-19|2015-12-24|Estimate||||2015-11-19|2015-12-24|Estimate|February 2006||2006-02-28|November 2015|2015-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer|A Multicenter Phase III Placebo-Controlled Trial of Celecoxib for Prevention of Capecitabine-Induced Palmar/Plantar (Hand/Foot) Syndrome in Patients With Metastatic Breast and Colorectal Cancer|Terminated||Phase 3|11|Actual|M.D. Anderson Cancer Center|Due to low accrual in this trial, no outcome measures were evaluable.|2||Terminated due to low accrual. No data analyzed.|f||||t||||||||||2018-06-01 04:06:25.203707|2018-06-01 04:06:25.203707
NCT00305630|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2006-03-20|2006-03-20|2006-03-22|Estimate|||||||2006-03-20|2006-03-22|Estimate|July 2002||2002-07-31|March 2006|2006-03-31|November 2005||2005-11-30|||||Interventional|||Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)|Neovascular Age Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy|Completed||Phase 2/Phase 3|100||Johns Hopkins University|||||||||||||||||||2018-06-01 04:06:25.488682|2018-06-01 04:06:25.488682
NCT00305617|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2011-05-13|2006-03-21|2006-03-22|Estimate|||||||2011-05-13|2011-05-17|Estimate|January 2004||2004-01-31|July 2009|2009-07-31||||December 2007|Actual|2007-12-31||Interventional|||Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer|Evaluation of CSF Levels of Tarceva (OSI-774) in Patients With Stage III Non-Small Cell Lung Cancer and No CNS Involvement Undergoing Treatment With Tarceva|Completed||N/A|10|Anticipated|The Cleveland Clinic|||||f||||||||||||||2018-06-01 04:06:25.630979|2018-06-01 04:06:25.630979
NCT00305604|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|2009-02-24||2017-04-05|2006-03-20|2006-03-22|Estimate|2009-03-19|2009-05-01|Estimate||||2017-04-05|2017-05-11|Actual|March 8, 2006|Actual|2006-03-08|April 2017|2017-04-30|March 12, 2008|Actual|2008-03-12|March 12, 2008|Actual|2008-03-12||Interventional|||Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Sitagliptin in Elderly Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|206|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:06:25.714162|2018-06-01 04:06:25.714162
NCT00305591|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2015-05-28|2006-03-21|2006-03-22|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.|Functional Magnetic Resonance Imaging and Spectroscopy of the Brain in Patients With Chronic Hepatic Encephalopathy|Completed||N/A|50|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:06:26.173377|2018-06-01 04:06:26.173377
NCT00305578|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2015-06-30||2016-06-16|2006-03-20|2006-03-22|Estimate|2015-10-02|2015-11-02|Estimate||||2016-06-16|2016-07-18|Estimate|August 2005||2005-08-31|June 2016|2016-06-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression|Memantine Augmentation of Lamotrigine Incomplete Response in Bipolar Depression: A Randomized Placebo Controlled Clinical Trial|Completed||Phase 4|29|Actual|Indiana University|Small number of subjects|2|||f||||t||||||||No||2018-06-01 04:06:26.260755|2018-06-01 04:06:26.260755
NCT00305565|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|2011-01-06||2013-12-06|2006-03-20|2006-03-22|Estimate|2013-01-21|2013-02-25|Estimate||||2013-12-06|2014-01-07|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses|Randomized Comparison of Outcomes in Patients With Treatment-Resistant Depression Who Receive VNS Therapy Administered at Different Amounts of Electrical Charge|Completed||Phase 4|331|Actual|Cyberonics, Inc.||3|||f||||t||||||||||2018-06-01 04:06:26.622196|2018-06-01 04:06:26.622196
NCT00305552|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2011-04-29|2006-03-21|2006-03-22|Estimate|||||||2011-04-29|2011-05-02|Estimate|February 2005||2005-02-28|January 2007|2007-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||SARCOTHAL. Thalidomide in Skin Sarcoidosis|Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis|Completed||Phase 3|40|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:06:27.789315|2018-06-01 04:06:27.789315
NCT00305539|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2012-07-06|2006-03-21|2006-03-22|Estimate|||||||2012-07-06|2012-07-10|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis|HECTHOR: A Pilot Multicenter Double-blind Randomised Study of 3 Months Treatment With Humira Added to Steroids in Giant Cell Arteritis|Completed||Phase 3|69|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 04:06:27.865611|2018-06-01 04:06:27.865611
NCT00305526|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2007-08-08|2006-03-21|2006-03-22|Estimate|||||||2007-08-08|2007-08-09|Estimate|April 2006||2006-04-30|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||REBEAT Resynchronisation and Beta-Blocker European Trial|Resynchronisation and Beta-Blocker European Trial|Terminated||Phase 4|354|Anticipated|Guidant Corporation||||lack of enrolment|f||||||||||||||2018-06-01 04:06:27.946565|2018-06-01 04:06:27.946565
NCT00305513|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2010-06-02|2006-03-21|2006-03-22|Estimate|||||||2010-06-02|2010-06-03|Estimate||||March 2006|2006-03-31||||||||Interventional|||Effectiveness of Rehabilitation on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect|Effectiveness of Rehabilitation (Phasic Alerting and Visual Spatial Scanning Training) on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect: Using Functional Imaging PET and Standardized Neurobehavioral and Functional Tests|Unknown status|Not yet recruiting|Phase 2|6|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:06:28.054063|2018-06-01 04:06:28.054063
NCT00305500|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2006-07-25|2006-03-21|2006-03-22|Estimate|||||||2006-07-25|2006-07-26|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|December 2006||2006-12-31|||||Interventional|||Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD)|Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults|Completed||Phase 3|100||Abarbanel Mental Health Center|||||f||||||||||||||2018-06-01 04:06:28.123028|2018-06-01 04:06:28.123028
NCT00305487|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2016-11-29|2006-03-21|2006-03-22|Estimate|||||||2016-11-29|2016-11-30|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, Once Daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age|Completed||Phase 3|660||AstraZeneca|||||f||||||||||||||2018-06-01 04:06:28.197611|2018-06-01 04:06:28.197611
NCT00305474|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2009-06-23|2006-03-21|2006-03-22|Estimate|||||||2009-06-23|2009-06-24|Estimate|December 2003||2003-12-31|June 2009|2009-06-30||||January 2010|Anticipated|2010-01-31||Interventional|||Identification and Treatment of the Liability to Develop Schizophrenia|Identification and Treatment of the Liability to Develop Schizophrenia|Unknown status|Recruiting|Phase 4|100|Anticipated|Central South University|||||f||||||||||||||2018-06-01 04:06:28.332006|2018-06-01 04:06:28.332006
NCT00305461|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-21|||2016-12-02|2006-03-21|2006-03-22|Estimate|||||||2016-12-02|2016-12-05|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|February 2008|Actual|2008-02-29|March 2007|Actual|2007-03-31||Interventional|||Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)|A Pilot Study on the Impact of Two Different Doses of Ciclesonide (160 mcg/Day and 320 mcg/Day) Administered in the Evening on Quality of Life in Patients With Moderate Persistent Asthma.|Completed||Phase 3|101|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:06:28.404562|2018-06-01 04:06:28.404562
NCT00305448|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|2009-03-17||2012-02-14|2006-03-20|2006-03-22|Estimate|2011-07-29|2011-08-29|Estimate||||2012-02-14|2012-02-15|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|March 2008|Actual|2008-03-31||Interventional|FINDER I||A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg|Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy|Completed||Phase 2|143|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:06:28.505549|2018-06-01 04:06:28.505549
NCT00305435|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2014-09-11|2006-03-20|2006-03-22|Estimate|||||||2014-09-11|2014-09-12|Estimate|February 2006||2006-02-28|September 2014|2014-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety Study of AMG 531 in Japanese Subjects With ITP|An Open Label Phase 2 Study Evaluating the Safety of Starting Dose of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura|Completed||Phase 2|12|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-06-01 04:06:28.987583|2018-06-01 04:06:28.987583
NCT00305422|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2009-06-09|2006-03-20|2006-03-22|Estimate|||||||2009-06-09|2009-06-11|Estimate|November 2001||2001-11-30|June 2009|2009-06-30|January 2003|Actual|2003-01-31|||||Interventional|||Effect of Quetiapine on Negative Symptoms and Cognition|Efficacy of Quetiapine Compared to Risperidone on Negative Symptoms and Cognition With Regard to Underlying Neurobiological Mechanisms and Brain Activation.|Completed||Phase 3|45|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:06:29.061064|2018-06-01 04:06:29.061064
NCT00305409|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2009-02-10|2006-03-20|2006-03-21|Estimate|||||||2009-02-10|2009-02-11|Estimate|June 2006||2006-06-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Synbiotic Treatment in Crohn's Disease Patients|Synbiotic Treatment in Crohn's Disease Patients|Completed||N/A|50|Anticipated|University of Dundee|||||f||||||||||||||2018-06-01 04:06:29.122643|2018-06-01 04:06:29.122643
NCT00305396|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2006-03-20|2006-03-20|2006-03-21|Estimate|||||||2006-03-20|2006-03-21|Estimate|April 2004||2004-04-30|March 2006|2006-03-31|March 2005||2005-03-31|||||Interventional|||Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation|Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplant Recipients.|Completed||Phase 4|80||Vanderbilt University|||||f||||||||||||||2018-06-01 04:06:29.189747|2018-06-01 04:06:29.189747
NCT00305383|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2012-06-21|2006-03-17|2006-03-21|Estimate|||||||2012-06-21|2012-06-22|Estimate|November 2005||2005-11-30|June 2012|2012-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C|Analysis of Hepatitis C Viral Kinetics and Viramidine Pharmacokinetics Utilizing Two Treatment Regimens in Therapy-Naive Patients With Chronic Hepatitis C|Terminated||Phase 2|100||Valeant Pharmaceuticals International, Inc.||||Dose levels were determined to be subtherapeutic|f||||||||||||||2018-06-01 04:06:29.257206|2018-06-01 04:06:29.257206
NCT00305370|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-19|||2008-08-06|2006-03-19|2006-03-21|Estimate|||||||2008-08-06|2008-08-07|Estimate|August 2005||2005-08-31|March 2006|2006-03-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD|Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial|Completed||Phase 4|20|Anticipated|Federal University of Rio Grande do Sul|||||f||||||||||||||2018-06-01 04:06:29.346042|2018-06-01 04:06:29.346042
NCT00305357|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2011-04-12|2006-03-17|2006-03-21|Estimate|||||||2011-04-12|2011-04-14|Estimate|November 2001||2001-11-30|March 2011|2011-03-31|December 2006|Actual|2006-12-31|November 2005|Actual|2005-11-30||Observational|||Evolution of Pain From Herpes Zoster|Evolution of Pain and Neural Dysfunction From Acute Herpes Zoster to Post-Herpetic Neuralgia|Completed|||100|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:06:29.424442|2018-06-01 04:06:29.424442
NCT00305344|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|2012-03-02||2012-07-03|2006-03-17|2006-03-21|Estimate|2012-07-03|2012-07-10|Estimate||||2012-07-03|2012-07-10|Estimate|April 2005||2005-04-30|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Umbilical Cord Blood Infusion to Treat Type 1 Diabetes|Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children With Type 1 Diabetes - A Pilot Study|Completed||Phase 1/Phase 2|23|Actual|University of Florida|Small sample size. No randomized control group|1|||f||||t||||||||||2018-06-01 04:06:29.497371|2018-06-01 04:06:29.497371
NCT00305331|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2012-07-26|2006-03-20|2006-03-21|Estimate|||||||2012-07-26|2012-07-30|Estimate|March 2006||2006-03-31|July 2012|2012-07-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease|Phase II Clinical Trial of Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease|Terminated||Phase 2|25|Anticipated|University Health Network, Toronto||||lack of recruitment|f||||||||||||||2018-06-01 04:06:29.666635|2018-06-01 04:06:29.666635
NCT00305305|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2017-01-09|2006-03-17|2006-03-21|Estimate|||||||2017-01-09|2017-01-11|Estimate|August 2003||2003-08-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Brain Development Research Program|Disorders of Cerebral Development: A Phenotypic and Genetic Analysis|Recruiting|||2000|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:06:29.731506|2018-06-01 04:06:29.731506
NCT00305292|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2011-03-23|2006-03-17|2006-03-21|Estimate|||||||2011-03-23|2011-03-25|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|August 2006||2006-08-31|||||Interventional|||Modafinil-Alcohol Interactions in Healthy Volunteers|"Modafinil-Alcohol Interactions Assessed Using Tests of Thermal Stimulation, Cognition, Mood, and Motor Function in Healthy Volunteers"|Terminated||N/A|32||University of California, San Francisco||||"This study should be terminated as the study closed prior to 2007 and the investigator has~   since retired. No records are available."|f||||||||||||||2018-06-01 04:06:29.846169|2018-06-01 04:06:29.846169
NCT00305279|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2013-10-09|2006-03-17|2006-03-21|Estimate|||||||2013-10-09|2013-10-10|Estimate|February 2006||2006-02-28|October 2013|2013-10-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||The Effects of Dietary Phosphate Intake on Calciotropic Hormones and FGF23.|The Effects of Dietary Phosphate Intake on Calciotropic Hormones and FGF23|Withdrawn||N/A|0|Actual|University of California, San Francisco||3|||f||||||||||||||2018-06-01 04:06:29.959198|2018-06-01 04:06:29.959198
NCT00305266|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2007-11-30|2006-03-20|2006-03-21|Estimate|||||||2007-11-30|2007-12-03|Estimate|August 2005||2005-08-31|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Observational|||Study of CIDP Patients During IVIG Treatment|"Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy"|Completed|||11|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 04:06:30.035305|2018-06-01 04:06:30.035305
NCT00305253|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|2009-07-07||2013-05-09|2006-03-17|2006-03-21|Estimate|2011-06-18|2011-07-15|Estimate||||2013-05-09|2013-05-14|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt|Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt|Completed||Phase 1/Phase 2|990|Actual|University of California, San Francisco|Non-randomized, non-blinded pre-intervention/intervention design|2|||f||||t||||||||||2018-06-01 04:06:30.111815|2018-06-01 04:06:30.111815
NCT00305240|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2008-02-11|2006-03-20|2006-03-21|Estimate|||||||2008-02-11|2008-02-13|Estimate|October 2003||2003-10-31|February 2008|2008-02-29|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients|Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients (MASTER I)|Completed||N/A|656||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:06:30.340898|2018-06-01 04:06:30.340898
NCT00305227|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|2014-06-03||2016-01-13|2006-03-20|2006-03-21|Estimate|2014-06-03|2014-07-04|Estimate||||2016-01-13|2016-02-08|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection|Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infections|Completed||Phase 2|100|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:06:30.436423|2018-06-01 04:06:30.436423
NCT00305214|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2008-02-11|2006-03-20|2006-03-21|Estimate|||||||2008-02-11|2008-02-13|Estimate|October 2003||2003-10-31|February 2008|2008-02-29|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients|Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients (MASTER II)|Completed||N/A|405||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:06:30.654258|2018-06-01 04:06:30.654258
NCT00305201|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2016-05-22|2006-03-20|2006-03-21|Estimate|||||||2016-05-22|2016-05-24|Estimate|April 2006||2006-04-30|May 2016|2016-05-31|May 2007|Anticipated|2007-05-31|||||Interventional|||Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease|Cardiovascular Risk Markers Before and After Therapy With Statins in Patients With History of Kawasaki Disease|Withdrawn||Phase 2|0|Actual|Pontificia Universidad Catolica de Chile||||Withdrawn due to lack of study participants|f||||f||||||||||2018-06-01 04:06:30.872209|2018-06-01 04:06:30.872209
NCT00305188|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20||2016-04-06|2016-04-06|2006-03-20|2006-03-21|Estimate||||2016-04-06|2016-05-04|Estimate|2016-04-06|2016-05-04|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.|A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV|Completed||Phase 3|879|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:06:30.938635|2018-06-01 04:06:30.938635
NCT00305175|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2017-09-05|2006-03-17|2006-03-21|Estimate|||||||2017-09-05|2017-09-06|Actual|March 3, 2006|Actual|2006-03-03|September 2017|2017-09-30|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Observational|||Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease|Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease|Active, not recruiting|||260|Actual|St. Jude Children's Research Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 04:06:31.046138|2018-06-01 04:06:31.046138
NCT00305162|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|2013-04-22||2014-04-22|2006-03-20|2006-03-21|Estimate|2014-03-25|2014-04-23|Estimate||||2014-04-22|2014-05-08|Estimate|April 2006||2006-04-30|April 2014|2014-04-30|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|PCI|Intent-to-treat (ITT) population|A Clinical Trial to Demonstrate the Efficacy of Cangrelor|A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).|Terminated||Phase 3|8882|Actual|The Medicines Company|Discontinued per prespecified stopping rules after the 70% interim analyses was conducted indicating the trial was not likely to meet the goal of demonstrating superiority to clopidogrel administered as usual care. No safety issues were identified.|2||Insufficient evidence of the clinical effectiveness of cangrelor|f||||t||||||||||2018-06-01 04:06:31.141811|2018-06-01 04:06:31.141811
NCT00305149|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2006-03-20|2006-03-20|2006-03-21|Estimate|||||||2006-03-20|2006-03-21|Estimate|July 1999||1999-07-31|March 2006|2006-03-31|December 2005||2005-12-31|||||Interventional|||Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma|Use of Risk Factors for Initiation Therapy With Beacopp or Escalated Beacopp and Interim Evaluation and Modification of Therapy Based on Scintigraphy Results.|Completed||N/A|130||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:06:32.052807|2018-06-01 04:06:32.052807
NCT00305136|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-19|||2017-10-10|2006-03-19|2006-03-21|Estimate|||||||2017-10-10|2017-10-11|Actual|December 2005|Actual|2005-12-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Observational|||Advancement of Psychophysics of Pain Modulation From Lab to Clinic: Constructing Susceptibility Profile for Appearance of Postoperative Neuropathic Pain|Advancement of Psychophysics of Pain Modulation From Lab to Clinic: Constructing Susceptibility Profile for Appearance of Postoperative Neuropathic Pain|Completed|||200|Actual|Rambam Health Care Campus|||||f||||f||||||||||2018-06-01 04:06:32.109346|2018-06-01 04:06:32.109346
NCT00304174|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2016-05-23|2006-03-15|2006-03-17|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2005||2005-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|June 2014|Actual|2014-06-30||Observational|||Motivating Factors That Play a Role in Bulimia Nervosa|Translational Research on Eating Disorders: Behavioral Assessment of Motivation to Eat|Completed|||90|Actual|New York State Psychiatric Institute|||2||f||||f||||||||||2018-06-01 04:06:41.628816|2018-06-01 04:06:41.628816
NCT00305123|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2013-02-14|2006-03-17|2006-03-21|Estimate|||||||2013-02-14|2013-02-15|Estimate|April 2006||2006-04-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Molecular Epidemiology of Streptococcus Pyogenes Among Children in Bamako, Mali|The Molecular Epidemiology of Streptococcus Pyogenes Among Children in Bamako, Mali (Bamako BGAS2000)|Completed|||1757|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     GAS isolates.~   "|||2018-06-01 04:06:32.167771|2018-06-01 04:06:32.167771
NCT00305110|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2009-02-17|2006-03-17|2006-03-21|Estimate|||||||2009-02-17|2009-02-19|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain|Safety and Speed of Onset of a Fixed Dose of Intravenous Hydromorphone in the Treatment of Adult Patients Presenting to the Emergency Department With Acute Severe Pain|Completed||Phase 4|300|Anticipated|Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:06:32.224038|2018-06-01 04:06:32.224038
NCT00305097|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2018-03-02|2006-03-20|2006-03-21|Estimate|||||||2018-03-02|2018-03-06|Actual|May 2006|Actual|2006-05-31|March 2018|2018-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance|Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance|Completed||N/A|45|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||f|f|f||||||||2018-06-01 04:06:32.292878|2018-06-01 04:06:32.292878
NCT00305084|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2013-01-28|2006-03-20|2006-03-21|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|April 2008|Actual|2008-04-30|May 2007|Actual|2007-05-31||Interventional|||Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors|A Phase IB Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Solid Tumors|Completed||Phase 1|15|Actual|MolMed S.p.A.||1|||f||||f||||||||||2018-06-01 04:06:32.372196|2018-06-01 04:06:32.372196
NCT00305071|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-19|||2006-03-19|2006-03-19|2006-03-21|Estimate|||||||2006-03-19|2006-03-21|Estimate|April 2006||2006-04-30|March 2006|2006-03-31||||||||Interventional|||Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets in Acute Bacterial Cystitis.|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Adjuvant Treatment With Compound Cranberry Extract Tablets (UmayC) in Acute Bacterial Cystitis.|Unknown status|Not yet recruiting|Phase 2|60||Min-Sheng General Hospital|||||f||||||||||||||2018-06-01 04:06:32.441208|2018-06-01 04:06:32.441208
NCT00305058|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2006-03-17|2006-03-17|2006-03-21|Estimate|||||||2006-03-17|2006-03-21|Estimate|July 2005||2005-07-31|June 2005|2005-06-30||||||||Interventional|||Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain|A Randomized Clinical Trial Comparing Intravenous Morphine and Intravenous Hydromorphone in the Treatment of Adult ED Patients With Moderate to Severe Pain|Unknown status|Recruiting|Phase 4|178||Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:06:32.500592|2018-06-01 04:06:32.500592
NCT00305045|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-19|||2012-01-23|2006-03-19|2006-03-21|Estimate|||||||2012-01-23|2012-01-24|Estimate|March 2005||2005-03-31|January 2012|2012-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation|Treating Refractory Major Depressive Disorder With Repetitive Transcranial Magnetic Stimulation: A Double-blind, Sham-controlled, Longitudinal Study.|Completed||N/A|73|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 04:06:32.571299|2018-06-01 04:06:32.571299
NCT00305032|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2016-02-26|2006-03-20|2006-03-21|Estimate|||||||2016-02-26|2016-02-29|Estimate|March 2006||2006-03-31|February 2016|2016-02-29|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Effect of Endoscopic Gastric Balloon Insertion on Obstructive Sleep Apnea in Patients With Morbid Obesity|Effect of Endoscopic Gastric Balloon Insertion on Obstructive Sleep Apnea in Patients With Morbid Obesity|Completed||N/A|60|Actual|Chinese University of Hong Kong||1|||f||||t||||||||||2018-06-01 04:06:32.649259|2018-06-01 04:06:32.649259
NCT00305019|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2006-04-11|2006-03-19|2006-03-21|Estimate|||||||2006-04-11|2006-04-12|Estimate|July 2002||2002-07-31|April 2006|2006-04-30|March 2004||2004-03-31|||||Interventional|||Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus|A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus|Terminated||Phase 2|120||Bukwang Pharmaceutical|||||f||||||||||||||2018-06-01 04:06:32.714206|2018-06-01 04:06:32.714206
NCT00305006|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2011-01-12|2006-03-20|2006-03-21|Estimate|||||||2011-01-12|2011-01-13|Estimate|July 2007||2007-07-31|January 2011|2011-01-31|February 2011|Anticipated|2011-02-28|December 2009|Anticipated|2009-12-31||Interventional|CIMT||Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy|Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy|Unknown status|Recruiting|Phase 1|40|Anticipated|Columbia University||1|||f||||f||||||||||2018-06-01 04:06:32.772098|2018-06-01 04:06:32.772098
NCT00304993|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2006-03-17|2006-03-17|2006-03-21|Estimate|||||||2006-03-17|2006-03-21|Estimate|January 2001||2001-01-31|March 2006|2006-03-31|February 2005||2005-02-28|||||Interventional|||Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia|Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia|Completed||Phase 4|30||Foundation Research, Florida|||||f||||||||||||||2018-06-01 04:06:32.865205|2018-06-01 04:06:32.865205
NCT00304980|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-20|||2010-09-12|2006-03-20|2006-03-21|Estimate|||||||2010-09-12|2010-09-14|Estimate|March 2003||2003-03-31|September 2010|2010-09-30|April 2005||2005-04-30|||||Interventional|||Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status|Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia|Terminated||N/A|3000||Institute of Tropical Medicine, Belgium|||||f||||||||||||||2018-06-01 04:06:32.917961|2018-06-01 04:06:32.917961
NCT00304967|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-18|||2017-06-30|2006-03-18|2006-03-20|Estimate|||||||2017-06-30|2017-07-02|Actual|March 15, 2006||2006-03-15|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Observational|||Dynamic Light Scattering to Study Crystalline Proteins in Young Normal Lenses|A Study of Crystalline Proteins in Young Normal Lenses Using the NASA-NEI Dynamic Light Scattering (DLS) Device|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:06:33.079077|2018-06-01 04:06:33.079077
NCT00304954|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|2011-01-31||2016-11-28|2006-03-17|2006-03-20|Estimate|2011-03-11|2011-04-12|Estimate||||2016-11-28|2016-11-29|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|AMDB1||Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration|Treatment of Choroidal Subretinal Neovascularization With Agents Directed Against the Immune Response|Completed||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||t||||||||||2018-06-01 04:06:33.152493|2018-06-01 04:06:33.152493
NCT00304915|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2014-09-10||2016-11-10|2006-03-16|2006-03-20|Estimate|2014-09-10|2014-09-17|Estimate||||2016-11-10|2016-12-29|Estimate|February 2007||2007-02-28|November 2016|2016-11-30|November 2016|Actual|2016-11-30|July 2009|Actual|2009-07-31||Interventional|HI-TIDES||HIV Translating Initiatives for Depression Into Effective Solutions|HIV Translating Initiatives for Depression Into Effective Solutions|Completed||N/A|249|Actual|VA Office of Research and Development||2|||f||||t||||||||Yes|Investigators can request IPD by contacting the PI.|2018-06-01 04:06:34.007804|2018-06-01 04:06:34.007804
NCT00304902|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2010-09-09|2006-03-16|2006-03-20|Estimate|||||||2010-09-09|2010-09-10|Estimate|February 2006||2006-02-28|September 2010|2010-09-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Observational|||Chart Review of Outcome of Treatment for S. Aureus Bacteremia|Retrospective Chart Review of the Outcome of Treatment for Staphylococcus Aureus Bacteremia|Completed|||120|Actual|VA Medical Center, Houston|||||f||||f||||||||||2018-06-01 04:06:34.268467|2018-06-01 04:06:34.268467
NCT00304889|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2015-06-01|2006-03-16|2006-03-20|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2006||2006-01-31|February 2013|2013-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis|Vancomycin Vs. Nitazoxanide to Treat Clostridium Difficile Colitis That Has Failed Therapy With Metronidazole|Completed|||52|Actual|VA Medical Center, Houston|||||f||||||||||||||2018-06-01 04:06:34.324298|2018-06-01 04:06:34.324298
NCT00304876|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2010-09-09|2006-03-16|2006-03-20|Estimate|||||||2010-09-09|2010-09-10|Estimate|October 2005||2005-10-31|September 2010|2010-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea|Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea|Completed|||5|Actual|VA Medical Center, Houston|||||f||||f||||||||||2018-06-01 04:06:34.388727|2018-06-01 04:06:34.388727
NCT00304863|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2017-05-09|2006-03-16|2006-03-20|Estimate|||||||2017-05-09|2017-05-10|Actual|August 1, 2008|Anticipated|2008-08-01|May 2017|2017-05-31|July 31, 2010|Anticipated|2010-07-31|July 31, 2010|Anticipated|2010-07-31||Interventional|||Addition of Lactobacillus to Metronidazole in Treatment of CDAD|Addition of a Probiotic (Lactobacillus GG) to Metronidazole for the Treatment of Clostridium Difficile Associated Disease|Withdrawn||Phase 4|0|Actual|VA Medical Center, Houston||2||The assistant who was going to do this study moved to a different med center|f||||||||||||||2018-06-01 04:06:34.447854|2018-06-01 04:06:34.447854
NCT00304850|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2009-12-24|2006-03-17|2006-03-20|Estimate|||||||2009-12-24|2009-12-29|Estimate|March 2006||2006-03-31|December 2009|2009-12-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|PoLyDOL||Polyamine-free Diet to Prevent Post Surgery Hyperalgesia|Efficacy of a Polyamine-free Diet Associated or Not With Ketamine on Early and Late Hyperalgesia After Breast Cancer Surgery|Completed||Phase 2|160|Anticipated|University Hospital, Bordeaux||4|||f||||t||||||||||2018-06-01 04:06:34.536449|2018-06-01 04:06:34.536449
NCT00304837|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2010-10-18|2006-03-16|2006-03-20|Estimate|||||||2010-10-18|2010-10-19|Estimate||||April 2008|2008-04-30|April 2008|Actual|2008-04-30|||||Interventional|||VEGF Gene Transfer for Critical Limb Ischemia||Completed||Phase 1|||Losordo, Douglas, M.D.|||||||||||||||||||2018-06-01 04:06:34.620752|2018-06-01 04:06:34.620752
NCT00304824|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2008-09-25|2006-03-17|2006-03-20|Estimate|||||||2008-09-25|2008-09-26|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|November 2005|Actual|2005-11-30|||||Observational|||Assessment of the Ability to Distinguish Odors in Glaucoma Patients|Olfactory Function in Glaucoma Patients|Completed|||30|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 04:06:34.679206|2018-06-01 04:06:34.679206
NCT00304811|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2009-09-25|2006-03-16|2006-03-20|Estimate|||||||2009-09-25|2009-09-28|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection|Vancomycin Versus Vancomycin Plus Gentamycin For Treating Bacteremic Infection Due to Methicillin-Resistant Staphylococcus Aureus (MRSA)|Completed||Phase 4|160|Anticipated|VA Medical Center, Houston|||||f||||||||||||||2018-06-01 04:06:34.731166|2018-06-01 04:06:34.731166
NCT00304798|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2015-02-03|2006-03-16|2006-03-20|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2006||2006-03-31|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Study of Admission Versus Discharge After Transient Ischemic Attack (TIA)|Pilot Study of Admission Versus Discharge After Transient Ischemic Attack (TIA)|Withdrawn||Phase 1|0|Actual|University of California, San Diego||2|||f||||||||||||||2018-06-01 04:06:34.807783|2018-06-01 04:06:34.807783
NCT00304785|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2007-10-23|2006-03-17|2006-03-20|Estimate|||||||2007-10-23|2007-10-24|Estimate|May 2005||2005-05-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Latanoprost Versus Fotil||Completed||Phase 4|36|Anticipated|Pharmaceutical Research Network|||||f||||||||||||||2018-06-01 04:06:34.880984|2018-06-01 04:06:34.880984
NCT00304772|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2017-03-14|2006-03-17|2006-03-20|Estimate|||||||2017-03-14|2017-03-15|Actual|August 2006||2006-08-31|March 2017|2017-03-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Fluconazole Versus Micafungin for Candida Bloodstream Infection in Non-Neutropenic Patients|A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients|Withdrawn||Phase 4|0|Actual|Kyoto University||2||Subjects were not recruited as intended.|f||||f||||||||||2018-06-01 04:06:34.940796|2018-06-01 04:06:34.940796
NCT00304759|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2017-07-28|2006-03-17|2006-03-20|Estimate|||||||2017-07-28|2017-07-31|Actual|May 2006||2006-05-31|December 2016|2016-12-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||PROFIT - Prostate Fractionated Irradiation Trial|A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer|Completed||Phase 3|1204|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 04:06:35.024288|2018-06-01 04:06:35.024288
NCT00304746|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2010-09-24||2010-11-17|2006-03-16|2006-03-20|Estimate|2010-10-20|2010-11-17|Estimate||||2010-11-17|2010-11-24|Estimate|April 2006||2006-04-30|November 2010|2010-11-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment|A Parallel-Group, Placebo-Controlled Trial of AndroGel in Men With Major Depressive Disorder Who Display an Incomplete Response to Standard Antidepressant Treatment|Completed||Phase 4|100|Actual|Mclean Hospital|The small number of participants limited statistical power. Also, the study recruited “treatment-resistant” men, who are often poorly responsive. For a detailed discussion, see the published report of the study.|2|||f||||f||||||||||2018-06-01 04:06:35.14767|2018-06-01 04:06:35.14767
NCT00304733|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2006-03-16|2006-03-16|2006-03-20|Estimate|||||||2006-03-16|2006-03-20|Estimate|August 2001||2001-08-31|August 2001|2001-08-31|April 2005||2005-04-30|||||Interventional|||Wound Healing: Total Contact Cast Vs. Custom-Made Temporary Footwear for Patients With Diabetic Foot Ulceration|Wound Healing: Total Contact Cast Vs. Custom-Made Temporary Footwear for Patients With Diabetic Foot Ulceration|Unknown status|Active, not recruiting|N/A|43||Rehabilitation Centre Amsterdam|||||f||||||||||||||2018-06-01 04:06:35.387593|2018-06-01 04:06:35.387593
NCT00304720|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2008-02-06|2006-03-17|2006-03-20|Estimate|||||||2008-02-06|2008-02-08|Estimate|March 2004||2004-03-31|March 2004|2004-03-31||||||||Interventional|||Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor|Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched Family Donor Hematopoietic Cell Transplants|Unknown status|Recruiting|Phase 2|40|Anticipated|Colorado Blood Cancer Institute|||||f||||||||||||||2018-06-01 04:06:35.438105|2018-06-01 04:06:35.438105
NCT00304707|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|2017-04-05||2017-05-04|2006-03-17|2006-03-20|Estimate|2017-05-04|2017-05-15|Actual||||2017-05-04|2017-05-15|Actual|April 2005||2005-04-30|May 2017|2017-05-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|||Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence|Bupropion Treatment for Smokers in Recovery|Completed||Phase 3|143|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||||||||||||2018-06-01 04:06:35.50452|2018-06-01 04:06:35.50452
NCT00304694|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2006-03-16|2006-03-16|2006-03-20|Estimate|||||||2006-03-16|2006-03-20|Estimate|March 2006||2006-03-31|March 2006|2006-03-31||||||||Observational|||Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients|Whole-Body 18F-FDG PET in Evaluating Induction Chemotherapeutic Response for Locally Advanced Nasopharyngeal Cancer Patients and Correlating With Histopathology: a Prospective Study|Unknown status|Recruiting||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:06:35.73412|2018-06-01 04:06:35.73412
NCT00304681|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2011-05-16|2006-03-17|2006-03-20|Estimate|||||||2011-05-16|2011-05-17|Estimate||||April 2010|2010-04-30|February 2004|Actual|2004-02-29|||||Interventional|||An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children|The Effectiveness of CONCERTA® vs. Usual Clinical Care With Immediate Release Methylphenidate (IR MPH) in Children (6-12 Years) With Attention Deficit Hyperactivity Disorder (ADHD): A Randomized, Open-Label Trial|Completed||Phase 3|147|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:06:35.782755|2018-06-01 04:06:35.782755
NCT00304668|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2015-12-08|2006-03-17|2006-03-20|Estimate|||||||2015-12-08|2015-12-10|Estimate||||May 2006|2006-05-31||||||||Interventional|||A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in South Africa|A Phase I/II Single-Centre Double-Blinded Randomized Study of the Safety and Tolerability of TMC120 Vaginal Microbicide Gel (TMC120 Gel-002) vs. HEC-Based Universal Placebo Gel in Healthy HIV-Negative Women.|Withdrawn||Phase 1/Phase 2|0|Actual|International Partnership for Microbicides, Inc.|||||f||||||||||||||2018-06-01 04:06:35.929295|2018-06-01 04:06:35.929295
NCT00304655|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2009-12-15|2006-03-17|2006-03-20|Estimate|||||||2009-12-15|2009-12-17|Estimate|July 2004||2004-07-31|December 2009|2009-12-31|October 2007|Actual|2007-10-31|May 2006|Actual|2006-05-31||Interventional|||Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)|Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder.|Completed||Phase 4|300||Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-06-01 04:06:36.005358|2018-06-01 04:06:36.005358
NCT00304642|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2006-06-01|2006-03-17|2006-03-20|Estimate|||||||2006-06-01|2006-06-02|Estimate|November 2005||2005-11-30|June 2006|2006-06-30||||||||Interventional|||A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel|A Study to Assess the Pharmacokinetics of Dapivirine (TMC120) Vaginal Microbicide Gel in Healthy HIV-Negative Women.|Completed||Phase 1|18||International Partnership for Microbicides, Inc.|||||||||||||||||||2018-06-01 04:06:36.073996|2018-06-01 04:06:36.073996
NCT00304629|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2011-01-31|2006-03-17|2006-03-20|Estimate|||||||2011-01-31|2011-02-01|Estimate|March 2000||2000-03-31|January 2011|2011-01-31|March 2002|Actual|2002-03-31|||||Interventional|||Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease|Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)|Completed||Phase 3|241|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:06:36.137447|2018-06-01 04:06:36.137447
NCT00304616|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2009-12-15|2006-03-17|2006-03-20|Estimate|||||||2009-12-15|2009-12-17|Estimate|October 2004||2004-10-31|December 2009|2009-12-31|October 2007|Actual|2007-10-31|June 2006|Actual|2006-06-30||Interventional|||SWitching to Abilify Trial (SWAT)|A Multi-center, Randomized, Open, Treatment-switching Study From Orally Administered Antipsychotic Monotherapy in the Treatment of Chronic Schizophrenic and Schizoaffective Patients|Completed||Phase 4|500||Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-06-01 04:06:36.205127|2018-06-01 04:06:36.205127
NCT00304603|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2012-11-27|2006-03-17|2006-03-20|Estimate|||||||2012-11-27|2012-11-28|Estimate|April 2004||2004-04-30|November 2012|2012-11-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Observational|||Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus|A Study to Evaluate the Mode of Action of Topiramate in the Treatment of Obese Subjects With and Without Type 2 Diabetes Mellitus Using DNA Samples From Subjects Who Were Randomized Within Select Previous Topiramate Studies|Completed|||1145|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 04:06:36.271986|2018-06-01 04:06:36.271986
NCT00304590|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2010-02-18|2006-03-16|2006-03-20|Estimate|||||||2010-02-18|2010-02-22|Estimate|February 2006||2006-02-28|February 2010|2010-02-28|May 2007|Actual|2007-05-31|December 2006|Actual|2006-12-31||Interventional|||Study of XL999 in Patients With Multiple Myeloma|A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 2|4|Actual|Symphony Evolution, Inc.||||Study was terminated due to cardiac toxicities in the subjects|f||||t||||||||||2018-06-01 04:06:36.349575|2018-06-01 04:06:36.349575
NCT00304577|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2006-03-17|2006-03-17|2006-03-20|Estimate|||||||2006-03-17|2006-03-20|Estimate|January 1998||1998-01-31|September 2005|2005-09-30|December 2001||2001-12-31|||||Observational|||Bilateral Recession or Unilateral Recession-Resection as Surgery for Infantile Esotropia|A Randomized Comparison of Bilateral Recession With Unilateral Recession-Resection as Surgery for Infantile Esotropia|Completed|||||Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:06:36.435656|2018-06-01 04:06:36.435656
NCT00304564|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2016-01-26|2006-03-16|2006-03-20|Estimate|||||||2016-01-26|2016-01-27|Estimate|February 2006||2006-02-28|January 2016|2016-01-31|March 2007|Actual|2007-03-31|April 2006|Actual|2006-04-30||Interventional|||Study of the Effect of the Music of Nolwenn Leroy in Fall Prevention Strategies in Texas Nursing Homes|Fall Prevention and The Nolwenn Effect in Texas Geriatric Nursing Home Settings|Completed||N/A|100|Actual|Carrick Institute for Graduate Studies||1|||f||||f||||||||No||2018-06-01 04:06:36.512232|2018-06-01 04:06:36.512232
NCT00304551|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-05|||2010-06-01|2006-03-16|2006-03-20|Estimate|||||||2010-06-01|2010-06-03|Estimate|June 2006||2006-06-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)|A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC|Completed||Phase 3|180|Anticipated|Chugai Pharmaceutical||3|||f||||f||||||||||2018-06-01 04:06:36.599799|2018-06-01 04:06:36.599799
NCT00304538|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2006-08-21|2006-03-16|2006-03-20|Estimate|||||||2006-08-21|2006-08-23|Estimate|March 2006||2006-03-31|August 2006|2006-08-31|July 2006||2006-07-31|||||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Very Low Dose-Glucagon in Subjects With Type 1 Diabetes Mellitus|A Phase 1b, Single-Blind Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Three Separate Dose Levels of Very Low Dose-Glucagon Administered Subcutaneously Overnight for 6, 9 or 12 Hours in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|10||DiObex|||||||||||||||||||2018-06-01 04:06:36.710487|2018-06-01 04:06:36.710487
NCT00304525|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2016-11-15|2006-03-17|2006-03-20|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|CHIR-265-MEL01||A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma|A Phase I/II, Open-label, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265)Administered Orally to Patients With Locally Advanced or Metastatic Melanoma.|Completed||Phase 2|104|Actual|Novartis||5|||f||||f||||||||||2018-06-01 04:06:36.800848|2018-06-01 04:06:36.800848
NCT00304512|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17||2010-08-17|2018-01-09|2006-03-17|2006-03-20|Estimate||||2010-08-17|2010-08-19|Estimate|2018-01-09|2018-01-16|Actual|May 2006||2006-05-31|January 2018|2018-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease|A Phase 2, Open-Label, Multiple Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Female Patients With Fabry Disease|Completed||Phase 2|9|Actual|Amicus Therapeutics||3|||f||||t||||||||||2018-06-01 04:06:36.913974|2018-06-01 04:06:36.913974
NCT00304499|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2011-05-18|2006-03-17|2006-03-20|Estimate|||||||2011-05-18|2011-05-19|Estimate|December 1995||1995-12-31|April 2010|2010-04-30|December 1996||1996-12-31|||||Interventional|||Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence|Efficacy and Safety of OROS® Oxybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence|Completed||Phase 3|176||Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:06:37.012326|2018-06-01 04:06:37.012326
NCT00304473|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-17|||2009-03-24|2006-03-17|2006-03-20|Estimate|||||||2009-03-24|2009-03-25|Estimate|August 2004||2004-08-31|March 2009|2009-03-31|April 2006|Actual|2006-04-30|||||Interventional|||Fast Titration in the Treatment of Schizophrenia, Taiwan|Fast Titration of Quetiapine Versus Conventional Titration in the Treatment of Schizophrenia/Schizoaffective Disorder: a Randomised, Parallel Group Open Trial|Completed||Phase 3|40||AstraZeneca|||||f||||||||||||||2018-06-01 04:06:37.073401|2018-06-01 04:06:37.073401
NCT00304460|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2018-05-23|2006-03-16|2006-03-17|Estimate|||||||2018-05-23|2018-05-24|Actual|March 13, 2006||2006-03-13|February 27, 2014|2014-02-27|February 27, 2014|Actual|2014-02-27|February 27, 2014|Actual|2014-02-27||Interventional|||Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer|Studies on the Mechanism of Action of High-Dose IL-2 in Metastatic Melanoma and Renal Cell Cancer|Completed||Phase 1|138|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:06:37.138437|2018-06-01 04:06:37.138437
NCT00304447|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2009-07-28|2006-03-15|2006-03-17|Estimate|||||||2009-07-28|2009-07-29|Estimate|April 2002||2002-04-30|July 2009|2009-07-31|January 2004||2004-01-31|||||Interventional|||Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia|A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML)|Completed||Phase 4|30||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:06:37.208759|2018-06-01 04:06:37.208759
NCT00304434|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2009-09-21|2006-03-16|2006-03-17|Estimate|||||||2009-09-21|2009-09-23|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.|Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01)|Completed||Phase 4|48|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:06:37.266197|2018-06-01 04:06:37.266197
NCT00304421|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2007-09-14|2006-03-16|2006-03-17|Estimate|||||||2007-09-14|2007-09-17|Estimate|January 2004||2004-01-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD|Comparison of the Nighttime Effects of Rabeprazole 20 mg to Pantoprazole 40 mg on Standard Meal Stimulated Gastric Acid Secretion and Intragastric pH in H. Pylori Negative Volunteer Subjects With GERD|Completed||Phase 4|23|Anticipated|VA Greater Los Angeles Healthcare System|||||f||||||||||||||2018-06-01 04:06:37.358243|2018-06-01 04:06:37.358243
NCT00304408|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2010-09-09|2006-03-16|2006-03-17|Estimate|||||||2010-09-09|2010-09-10|Estimate|January 2005||2005-01-31|September 2010|2010-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody|Association Between Clinical Response of Clostridium Difficile Colitis to Treatment and Emergence of Anti-C.Difficile Toxin Antibody|Completed|||10|Actual|VA Medical Center, Houston|||||f||||f||||||||||2018-06-01 04:06:37.424829|2018-06-01 04:06:37.424829
NCT00304395|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2010-09-09|2006-03-16|2006-03-17|Estimate|||||||2010-09-09|2010-09-10|Estimate|January 2004||2004-01-31|September 2010|2010-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Pulmonary Infections Masquerading as Community-Acquired Pneumonia|Pulmonary Infections Masquerading as Community-Acquired Pneumonia|Completed|||40|Actual|VA Medical Center, Houston|||||f||||f||||||||||2018-06-01 04:06:37.482718|2018-06-01 04:06:37.482718
NCT00304382|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2017-09-01|2006-03-16|2006-03-17|Estimate|||||||2017-09-01|2017-09-05|Actual|January 1, 2003|Actual|2003-01-01|September 2017|2017-09-30|June 1, 2012|Actual|2012-06-01|September 1, 2006|Actual|2006-09-01||Interventional|||Humoral Determinants of Immunity to Pneumococcal Infection|Humoral Determinants of Immunity to Pneumococcal Infection|Completed||Phase 4|114|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 04:06:37.535719|2018-06-01 04:06:37.535719
NCT00304369|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2013-02-14|2006-03-16|2006-03-17|Estimate|||||||2013-02-14|2013-02-18|Estimate|June 2005||2005-06-30|February 2013|2013-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Response of Clostridium Difficile Infection to Metronidazole Therapy|The Response of Clostridium Difficile Infection to Metronidazole Therapy|Completed|||290|Anticipated|VA Medical Center, Houston|||||f||||f||||||||||2018-06-01 04:06:37.614307|2018-06-01 04:06:37.614307
NCT00304356|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2013-02-19||2017-05-08|2006-03-16|2006-03-17|Estimate|2017-05-08|2017-12-15|Actual||||2017-05-08|2017-12-15|Actual|January 2004||2004-01-31|May 2017|2017-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection|Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Colitis in Patients Who Have Failed Conventional Therapy|Completed||Phase 3|22|Actual|VA Medical Center, Houston||1|||f||||f||||||||||2018-06-01 04:06:37.673964|2018-06-01 04:06:37.673964
NCT00304330|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2017-06-23|2006-03-15|2006-03-17|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2006||2006-09-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients|Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients; a Comparative Study With a Non-transplant Population|Completed|||1000|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 04:06:37.856436|2018-06-01 04:06:37.856436
NCT00304317|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2017-01-23|2006-03-16|2006-03-17|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2006||2006-03-31|January 2017|2017-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Celecoxib (Celebrex) in the Management of Acute Renal Colic|Celecoxib in the Management of Acute Renal Colic|Withdrawn||Phase 4|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||PI is no longer at the University of Minnesota|f||||f||||||||||2018-06-01 04:06:37.901732|2018-06-01 04:06:37.901732
NCT00304304|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2016-02-14|2006-03-16|2006-03-17|Estimate|||||||2016-02-14|2016-02-17|Estimate|February 2006||2006-02-28|February 2016|2016-02-29|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|||HealthSpark 2: Improving Asthma Care for Preschool Children|Community - Based Asthma Intervention in Subsidized Preschools|Completed||N/A|2000|Actual|University of Miami||2|||f||||f||||||||No||2018-06-01 04:06:37.965406|2018-06-01 04:06:37.965406
NCT00304291|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2006-11-27|2006-03-15|2006-03-17|Estimate|||||||2006-11-27|2006-11-28|Estimate|August 2001||2001-08-31|March 2006|2006-03-31|May 2004||2004-05-31|||||Interventional|||A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)|A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)|Completed||Phase 4|5||State University of New York at Buffalo|||||f||||||||||||||2018-06-01 04:06:38.039093|2018-06-01 04:06:38.039093
NCT00304278|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2016-11-02||2017-06-27|2006-03-16|2006-03-17|Estimate|2017-06-27|2017-07-27|Actual||||2017-06-27|2017-07-27|Actual|March 2006||2006-03-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)|Phase II Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)|Completed||Phase 2|21|Actual|Southern Illinois University||1|||f||||t||||||||||2018-06-01 04:06:38.118928|2018-06-01 04:06:38.118928
NCT00304265|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2011-02-10||2016-04-12|2006-03-16|2006-03-17|Estimate|2011-03-08|2011-04-07|Estimate||||2016-04-12|2016-04-14|Estimate|March 2006||2006-03-31|April 2016|2016-04-30|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Interventional|||Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine|Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination|Completed||Phase 4|215|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:06:38.335185|2018-06-01 04:06:38.335185
NCT00304252|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2013-08-04|2006-03-15|2006-03-17|Estimate|||||||2013-08-04|2013-08-06|Estimate|November 2001||2001-11-30|August 2013|2013-08-31|September 2003|Actual|2003-09-30|||||Interventional|||Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease|A Phase II, Multicenter, Randomised, Double-blind, Placebo Controlled, Dose Finding Study of Subcutaneously Administered Interferon Beta-1a for Maintenance of Remission in Patients With Crohn's Disease|Terminated||Phase 2|192||EMD Serono||||Lack of Efficacy|f||||||||||||||2018-06-01 04:06:38.587948|2018-06-01 04:06:38.587948
NCT00304239|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2010-09-01|2006-03-16|2006-03-17|Estimate|||||||2010-09-01|2010-09-03|Estimate|March 2006||2006-03-31|September 2010|2010-09-30|January 2007|Actual|2007-01-31|||||Interventional|||Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp|A Multicenter, Double Blind, Vehicle-controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream and Aktilite CL128 LED Light in Patients With Multiple Actinic Keratosis on the Face and/or Scalp|Completed||Phase 3|80||Galderma|||||||||f||||||||||2018-06-01 04:06:38.658205|2018-06-01 04:06:38.658205
NCT00304226|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2016-11-15|2006-03-16|2006-03-17|Estimate|||||||2016-11-15|2016-11-16|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy|A 14 Week Study to Evaluate Effectiveness of a Valsartan Versus an Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy|Completed||Phase 4|1288|Actual|Novartis|||||f||||||||||||||2018-06-01 04:06:39.54311|2018-06-01 04:06:39.54311
NCT00304213|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2015-02-12|2006-03-16|2006-03-17|Estimate|||||||2015-02-12|2015-02-13|Estimate|March 2006||2006-03-31|February 2015|2015-02-28|April 2009|Anticipated|2009-04-30|||||Interventional|||Does Testosterone Improve Function in Hypogonadal Older Men|Does Testosterone Improve Function in Hypogonadal Older Men|Withdrawn||Phase 4|0|Actual|North Florida Foundation for Research and Education||||Study never started, PI relocation|f||||||||||||||2018-06-01 04:06:39.761852|2018-06-01 04:06:39.761852
NCT00304200|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-12|||2009-02-03|2006-03-16|2006-03-17|Estimate|||||||2009-02-03|2009-02-05|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|October 2007|Actual|2007-10-31||Interventional|||Temodar and Sutent as Therapy for Melanoma|Temodar and Sutent as Therapy for Patients With Malignant Melanoma, a Phase I/II Study|Terminated||Phase 1/Phase 2|7|Actual|Northern California Melanoma Center||1||Funding was inadequate to continue; Companies requested closure.|f||||t||||||||||2018-06-01 04:06:40.538813|2018-06-01 04:06:40.538813
NCT00304187|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2013-04-24||2017-10-17|2006-03-15|2006-03-17|Estimate|2013-06-21|2013-07-30|Estimate||||2017-10-17|2017-10-19|Actual|September 2004||2004-09-30|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa|Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa|Completed||Phase 2|29|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 04:06:40.94432|2018-06-01 04:06:40.94432
NCT00304161|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2012-06-12||2016-12-01|2006-03-15|2006-03-17|Estimate|2015-03-10|2015-03-13|Estimate||||2016-12-01|2017-01-30|Estimate|July 2004||2004-07-31|December 2016|2016-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease|Depression Diagnosis and Treatment in Parkinson Disease|Completed||Phase 4|55|Actual|University of Pennsylvania|First, the sample size was relatively small. Second, the diagnostic criteria for depression which are typically used in clinical trials were not used as an inclusion criterion. Third, antidepressant use at baseline was common in our population.|2|||f||||f||||||||||2018-06-01 04:06:41.776322|2018-06-01 04:06:41.776322
NCT00304148|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2018-02-09|2006-03-16|2006-03-17|Estimate|||||||2018-02-09|2018-02-12|Actual|July 2003||2003-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|CRIC||SDCC - Prospective Cohort Study of Chronic Renal Insufficiency|Prospective Cohort Study of Chronic Renal Insufficiency|Active, not recruiting|||5112|Anticipated|University of Pennsylvania|||2||f||||t||||||Samples With DNA|"~     DNA, urine, serum, blood~   "|||2018-06-01 04:06:43.58443|2018-06-01 04:06:43.58443
NCT00304135|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2016-05-27|2006-03-15|2006-03-17|Estimate|||||||2016-05-27|2016-05-30|Estimate|October 2005||2005-10-31|December 2006|2006-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery|Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract|Completed||Phase 2/Phase 3|34|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||||2018-06-01 04:06:43.754779|2018-06-01 04:06:43.754779
NCT00304096|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2013-01-15||2013-02-26|2006-03-15|2006-03-17|Estimate|2013-02-26|2013-04-09|Estimate||||2013-02-26|2013-04-09|Estimate|December 2005||2005-12-31|February 2013|2013-02-28|April 2008|Actual|2008-04-30|June 2007|Actual|2007-06-30||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer|Evaluation of the Safety and Immunogenicity of Vaccination With Multiple Synthetic Peptides in Participants With Advanced Breast Cancer|Completed||Phase 1|12|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 04:06:44.009071|2018-06-01 04:06:44.009071
NCT00304083|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2018-04-16||2018-04-16|2006-03-15|2006-03-17|Estimate|2018-04-16|2018-05-25|Actual||||2018-04-16|2018-05-25|Actual|December 2005||2005-12-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors|Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors|Completed||Phase 2|74|Actual|Sarcoma Alliance for Research through Collaboration||2|||f||||f||||||||||2018-06-01 04:06:44.579203|2018-06-01 04:06:44.579203
NCT00304070|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2016-10-21||2017-05-11|2006-03-15|2006-03-17|Estimate|2017-05-11|2017-06-12|Actual||||2017-05-11|2017-06-12|Actual|September 2006||2006-09-30|November 2016|2016-11-30||||December 2015|Actual|2015-12-31||Interventional|||Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor|Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study|Completed||Phase 3|78|Actual|Children's Oncology Group||3|||f||||||||||||||2018-06-01 04:06:45.281779|2018-06-01 04:06:45.281779
NCT00304031|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2014-03-28||2016-12-30|2006-03-15|2006-03-17|Estimate|2014-03-28|2014-04-30|Estimate||||2016-12-30|2017-02-17|Actual|January 2006||2006-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|February 2011|Actual|2011-02-28||Interventional||Eligible patients who were randomized.|Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma|Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma|Completed||Phase 3|1173|Actual|Radiation Therapy Oncology Group|This was a two-stage study in which participants were registered, received concomitant RT and TMZ, and then were randomized to standard or dose-dense adjuvant TMZ. Some patients were not randomized, resulting in the third arm (No adjuvant TMZ).|3|||f||||t||||||||||2018-06-01 04:06:46.434667|2018-06-01 04:06:46.434667
NCT00304018|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2013-08-13|2006-03-15|2006-03-17|Estimate|||||||2013-08-13|2013-08-14|Estimate|October 2002||2002-10-31|August 2013|2013-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer|Pilot Study of Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies|Completed||Phase 1|5|Actual|University of California, San Francisco||1|||f||||||||||||||2018-06-01 04:06:48.92186|2018-06-01 04:06:48.92186
NCT00304005|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2013-07-17|2006-03-15|2006-03-17|Estimate|||||||2013-07-17|2013-07-18|Estimate|July 2005||2005-07-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|October 2005|Actual|2005-10-31||Interventional|||VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders|A Phase I/II Study of Cloretazine in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia or Richter's Syndrome|Completed||Phase 1/Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:06:49.003906|2018-06-01 04:06:49.003906
NCT00303992|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2018-01-12|2006-03-15|2006-03-17|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2004||2004-05-31|January 2018|2018-01-31|January 2013|Actual|2013-01-31|November 16, 2006|Actual|2006-11-16||Interventional|||Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer|Weekly Trastuzumab (Herceptin) and Irinotecan in Patients With HER-2 Positive Advanced Breast Cancer: A Phase II Trial|Completed||Phase 2|9|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:06:49.065151|2018-06-01 04:06:49.065151
NCT00303979|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2012-11-21||2012-11-21|2006-03-15|2006-03-17|Estimate|2012-11-21|2012-12-27|Estimate||||2012-11-21|2012-12-27|Estimate|May 2005||2005-05-31|November 2012|2012-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|IMPROVE-HF||IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting|Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting|Completed|||34810|Actual|Medtronic Cardiac Rhythm and Heart Failure|||3||f||||f||||||||||2018-06-01 04:06:49.159723|2018-06-01 04:06:49.159723
NCT00303966|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2013-11-08||2014-04-17|2006-03-15|2006-03-17|Estimate|2014-03-05|2014-04-10|Estimate||||2014-04-17|2014-05-07|Estimate|November 2005||2005-11-30|January 2014|2014-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|A Phase II Study of BAY 43-9006 in Relapsed Chronic Lymphocytic Leukemia|Terminated||Phase 2|5|Actual|National Cancer Institute (NCI)|Early termination leading to small number of subjects|1||Slow accrual|f||||||||||||||2018-06-01 04:06:49.894097|2018-06-01 04:06:49.894097
NCT00303953|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2012-02-28||2014-04-23|2006-03-15|2006-03-17|Estimate|2012-08-20|2012-09-19|Estimate||||2014-04-23|2014-05-12|Estimate|January 2006||2006-01-31|April 2013|2013-04-30|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|||PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma|Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:06:50.165138|2018-06-01 04:06:50.165138
NCT00303940|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2012-03-14|2006-03-15|2006-03-17|Estimate|||||||2012-03-14|2012-03-15|Estimate|December 2005||2005-12-31|March 2012|2012-03-31|February 2010|Actual|2010-02-28|||||Interventional|||Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors|A Phase I Trial and Pharmacokinetic Study of Talabostat (PT-100, Val-Boro-Pro) in Combination With Temozolomide or Carboplatin in Pediatric Patients With Relapsed or Refractory Solid Tumors Including Brain Tumors|Completed||Phase 1|26|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 04:06:50.629381|2018-06-01 04:06:50.629381
NCT00303927|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2010-03-18|2006-03-15|2006-03-17|Estimate|||||||2010-03-18|2010-03-19|Estimate|December 2005||2005-12-31|March 2010|2010-03-31||||September 2007|Actual|2007-09-30||Interventional|||Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene|Thymidylate Synthase (TS) Genotype-Directed Phase II Trial of Oral Capecitabine for 2-Line Treatment of Advanced Pancreatic Cancer|Completed||Phase 2|65|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:06:50.712746|2018-06-01 04:06:50.712746
NCT00303914|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2012-07-19|2006-03-15|2006-03-17|Estimate|||||||2012-07-19|2012-07-20|Estimate|April 2006||2006-04-30|August 2009|2009-08-31||||||||Observational|||Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer|A Survey of Disease and Treatment-Related Symptoms in Patients With Invasive Cancer: Prevalence, Severity and Treatment|Unknown status|Active, not recruiting||2310|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:06:50.788237|2018-06-01 04:06:50.788237
NCT00303901|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2015-02-09||2015-02-09|2006-03-15|2006-03-17|Estimate|2015-02-09|2015-02-23|Estimate||||2015-02-09|2015-02-23|Estimate|November 2005||2005-11-30|February 2015|2015-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery|Percutaneous Thoracic Cryotherapy (PTC) for Inoperable Primary Lung Cancer and Metastatic Management|Completed||N/A|40|Actual|Barbara Ann Karmanos Cancer Institute|There were no study limitations.|1|||f||||t||||||||||2018-06-01 04:06:50.897123|2018-06-01 04:06:50.897123
NCT00303888|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2018-01-12|2006-03-15|2006-03-17|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2006|Actual|2006-05-31|January 2018|2018-01-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|A Randomized Placebo-Controlled Phase Ib/IIa Safety, Tolerability and Efficacy Study of Oral Phenoxodiol in Combination With Docetaxel Versus Docetaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Terminated||Phase 1|31|Actual|Yale University||2|||f||||t|t|f||||||No||2018-06-01 04:06:51.069031|2018-06-01 04:06:51.069031
NCT00303875|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2017-02-21|2006-03-15|2006-03-17|Estimate|||||||2017-02-21|2017-02-23|Actual|December 2003||2003-12-31|February 2013|2013-02-28|May 2009|Actual|2009-05-31|June 2008|Actual|2008-06-30||Interventional|||Exercise and Dietary Counseling in Improving Physical Activity, Nutrition, and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight|RENEW: Reach Out to Enhance Wellness in Older Survivors|Completed||Phase 2|641|Actual|Duke University||2|||f||||t||||||||||2018-06-01 04:06:51.264716|2018-06-01 04:06:51.264716
NCT00303862|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2013-07-08||2014-05-05|2006-03-15|2006-03-17|Estimate|2013-09-17|2013-11-20|Estimate||||2014-05-05|2014-05-21|Estimate|March 2006||2006-03-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer|A Phase 2 Study of AZD2171 in Patients With Advanced Renal Cell Carcinoma|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:06:51.386371|2018-06-01 04:06:51.386371
NCT00303849|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2018-05-02|2006-03-15|2006-03-17|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2005||2005-09-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors|Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma|Recruiting||Phase 1/Phase 2|43|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 04:06:51.621579|2018-06-01 04:06:51.621579
NCT00303836|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2013-06-05|2006-03-15|2006-03-17|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2005||2005-11-30|June 2013|2013-06-30||||January 2007|Actual|2007-01-31||Interventional|||Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma|A Phase II Study Using a Peptide Vaccine With or Without Aldesleukin Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma|Terminated||Phase 2|58|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:06:51.754806|2018-06-01 04:06:51.754806
NCT00303823|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2012-07-13||2015-04-14|2006-03-15|2006-03-17|Estimate|2012-07-13|2012-08-17|Estimate||||2015-04-14|2015-05-05|Estimate|September 2005||2005-09-30|April 2013|2013-04-30|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia|A Phase II Trial of Polyphenon E for Cervical Cancer Prevention|Completed||Phase 2|98|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 04:06:51.873277|2018-06-01 04:06:51.873277
NCT00303810|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2014-01-27|2006-03-15|2006-03-17|Estimate|||||||2014-01-27|2014-01-28|Estimate|January 2001||2001-01-31|July 2009|2009-07-31||||December 2013|Actual|2013-12-31||Interventional|||Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma|Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma|Completed||N/A|567|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||||||||||||2018-06-01 04:06:52.23591|2018-06-01 04:06:52.23591
NCT00303797|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2013-03-18|2006-03-15|2006-03-17|Estimate|||||||2013-03-18|2013-03-19|Estimate|December 2005||2005-12-31|March 2013|2013-03-31||||May 2010|Actual|2010-05-31||Interventional|||Sorafenib and Bortezomib in Treating Patients With Advanced Cancer|A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination With the Proteasome Inhibitor PS-341 in Patients With Advanced Malignancies|Completed||Phase 1|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:06:52.305467|2018-06-01 04:06:52.305467
NCT00303784|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2016-10-26|2006-03-15|2006-03-17|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|PATCH||Prostate Adenocarcinoma TransCutaneous Hormones|A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer|Recruiting||Phase 3|2200|Anticipated|Imperial College London||2|||f||||||||||||||2018-06-01 04:06:52.38855|2018-06-01 04:06:52.38855
NCT00303771|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2016-05-27|2006-03-15|2006-03-17|Estimate|||||||2016-05-27|2016-05-30|Estimate|June 2003||2003-06-30|May 2016|2016-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer|Completed||Phase 3|282|Actual|Federation Francophone de Cancerologie Digestive||4|||f||||t||||||||||2018-06-01 04:06:52.562398|2018-06-01 04:06:52.562398
NCT00303758|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2014-03-03|2006-03-15|2006-03-17|Estimate|||||||2014-03-03|2014-03-04|Estimate|October 2005||2005-10-31|December 2006|2006-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression|Completed||Phase 3|202|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||||||||||||2018-06-01 04:06:52.735897|2018-06-01 04:06:52.735897
NCT00303745|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2008-07-23|2006-03-15|2006-03-17|Estimate|||||||2008-07-23|2008-07-24|Estimate|June 2006||2006-06-30|December 2006|2006-12-31||||||||Interventional|||Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Randomized Study of Second-Line Therapy Comprising Irinotecan With or Without Capecitabine in Patients Aged At Least 75 Years With Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|78|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:06:52.880623|2018-06-01 04:06:52.880623
NCT00303732|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2016-03-01|2006-03-15|2006-03-17|Estimate|||||||2016-03-01|2016-03-03|Estimate|December 2004||2004-12-31|March 2016|2016-03-31|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Interventional|PTK/RAD||Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors|PTK787/ZK222584 and RAD001 for Patients With Advanced Solid Tumors|Completed||Phase 1|37|Actual|Duke University||1|||f||||t||||||||||2018-06-01 04:06:52.961702|2018-06-01 04:06:52.961702
NCT00303719|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2017-12-03|2006-03-15|2006-03-17|Estimate|||||||2017-12-03|2017-12-05|Actual|March 26, 2002|Actual|2002-03-26|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|June 15, 2018|Anticipated|2018-06-15||Interventional|||Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy|Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy|Active, not recruiting||Phase 2|344|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 04:06:53.049791|2018-06-01 04:06:53.049791
NCT00303706|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2007-09-27|2006-03-15|2006-03-17|Estimate|||||||2007-09-27|2007-09-28|Estimate|April 2005||2005-04-30|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Study of Endoscopic Versus Open Harvest of the Radial Artery in Coronary Artery Bypass Surgery|A Prospective Randomized Trial of Endoscopic Versus Conventional Harvesting of the Radial Artery in Coronary Artery Bypass|Completed||Phase 2/Phase 3|119|Actual|Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:06:53.145586|2018-06-01 04:06:53.145586
NCT00303667|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2015-06-11||2017-12-03|2006-03-15|2006-03-17|Estimate|2015-06-11|2015-07-03|Estimate||||2017-12-03|2017-12-28|Actual|January 2005||2005-01-31|December 2017|2017-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant|Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation|Completed||Phase 1/Phase 2|50|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 04:06:53.353902|2018-06-01 04:06:53.353902
NCT00303654|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2013-03-25|2006-03-15|2006-03-17|Estimate|||||||2013-03-25|2013-03-26|Estimate|August 2005||2005-08-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection|Quality Assessment of the Roei Loop Resectoscope for Transurethral Resection of Bladder Neoplasm and BPH|Completed||N/A|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:06:53.781622|2018-06-01 04:06:53.781622
NCT00303641|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2017-08-25|2006-03-15|2006-03-17|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2004|Actual|2004-11-30|August 2017|2017-08-31|February 2006|Actual|2006-02-28|November 2005|Actual|2005-11-30||Interventional|||Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients|A Prospective Randomized Study of the Safety and Effectiveness of the Medtronic Resting Heart System|Completed||Phase 1|60||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:06:53.841008|2018-06-01 04:06:53.841008
NCT00303628|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2016-01-28||2016-07-13|2006-03-15|2006-03-17|Estimate|2016-01-28|2016-02-26|Estimate||||2016-07-13|2016-08-24|Estimate|February 2006||2006-02-28|July 2016|2016-07-31|April 2019|Anticipated|2019-04-30|April 2015|Actual|2015-04-30||Interventional||All randomized patients (intent-to-treat population)|Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer|Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients With Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation|Terminated||Phase 3|355|Actual|Eastern Cooperative Oncology Group||2||The study was terminated before reaching its accrual goal due to slow accrual.|f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 04:06:54.092751|2018-06-01 04:06:54.092751
NCT00303615|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2008-10-17|2006-03-16|2006-03-17|Estimate|||||||2008-10-17|2008-10-20|Estimate|June 2005||2005-06-30|October 2008|2008-10-31|July 2007|Actual|2007-07-31|June 2007|Anticipated|2007-06-30||Interventional|||Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer|Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer, Phase II Study|Terminated||Phase 2|5|Actual|Legacy Health System||||Low accrural|f||||||||||||||2018-06-01 04:06:55.884676|2018-06-01 04:06:55.884676
NCT00303602|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2008-12-19||2009-06-05|2006-03-15|2006-03-17|Estimate|2009-04-09|2009-06-02|Estimate||||2009-06-05|2009-06-10|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)|BMI Evaluation: Placebo and Active Comparator Trial of Olanzapine Zydis Pills Used Sublingually (PLATYPUS)|Completed||Phase 4|149|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 04:06:55.965018|2018-06-01 04:06:55.965018
NCT00303420|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2008-12-17|2006-03-15|2006-03-16|Estimate|||||||2008-12-17|2008-12-19|Estimate|September 2004||2004-09-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Alteplase for Blood Flow Restoration in Hemodialysis Catheters|Alteplase for Blood Flow Restoration in Hemodialysis Catheters: A Randomized Prospective Clinical Trial|Terminated||Phase 4|180|Anticipated|University of Manitoba||2||Unable to enrol enough people to achieve the full sample size|f||||t||||||||||2018-06-01 04:07:03.634557|2018-06-01 04:07:03.634557
NCT00303589|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2016-11-01|2006-03-16|2006-03-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2005||2005-12-31|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections|A Phase II Prospective, Open Label, Randomized, Active-controlled, Parallel Group, Multi-center 'Proof of Concept' Trial in Adult Patients With Complicated Skin or Skin Structure Infections Requiring Hospitalization.|Completed||Phase 2|313|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 04:06:57.152458|2018-06-01 04:06:57.152458
NCT00303576|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2006-07-28|2006-03-15|2006-03-17|Estimate|||||||2006-07-28|2006-07-31|Estimate|October 2005||2005-10-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel|A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.|Completed||Phase 1/Phase 2|112||International Partnership for Microbicides, Inc.|||||f||||||||||||||2018-06-01 04:06:57.301496|2018-06-01 04:06:57.301496
NCT00303563|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2016-11-01|2006-03-16|2006-03-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis|A Randomized, Double-blind Study to Compare the Effect of RO4402257 Monotherapy and Methotrexate Monotherapy on Disease Response in Patients With Active Rheumatoid Arthritis.|Completed||Phase 2|204|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 04:06:57.37591|2018-06-01 04:06:57.37591
NCT00303550|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2007-03-26|2006-03-15|2006-03-17|Estimate|||||||2007-03-26|2007-03-27|Estimate|March 2006||2006-03-31|March 2006|2006-03-31||||||||Interventional|||Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)|Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections (ASSIST-2)|Completed||Phase 3|||Arpida AG|||||||||||||||||||2018-06-01 04:06:57.510929|2018-06-01 04:06:57.510929
NCT00303537|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2007-06-29|2006-03-16|2006-03-17|Estimate|||||||2007-06-29|2007-07-02|Estimate|November 2004||2004-11-30|June 2007|2007-06-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Metformin in Non-Alcoholic Fatty Liver Disease|Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)|Unknown status|Active, not recruiting|Phase 2/Phase 3|90|Anticipated|University Hospital, Aker|||||f||||f||||||||||2018-06-01 04:06:57.72838|2018-06-01 04:06:57.72838
NCT00303524|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|||2009-12-20|2006-03-16|2006-03-17|Estimate|||||||2009-12-20|2009-12-23|Estimate|February 2006||2006-02-28|December 2009|2009-12-31|February 2009|Actual|2009-02-28|August 2007|Actual|2007-08-31||Interventional|||Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients|An Open-label, Randomized, Parallel Group, Multicentre Study to Compare Oestradiol Suppression Between ZOLADEX 10.8 mg Depot Given 3 Monthly and ZOLADEX 3.6 mg Depot Given Monthly in Pre-menopausal Patients With ER Positive Early Breast Cancer|Completed||Phase 2|170|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:06:57.80291|2018-06-01 04:06:57.80291
NCT00303511|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2013-11-08||2014-07-16|2006-03-16|2006-03-17|Estimate|2014-07-16|2014-08-08|Estimate||||2014-07-16|2014-08-08|Estimate|January 1996||1996-01-31|July 2014|2014-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Pacemaker Therapy in Adults With Congenital Heart Defects|Pacemaker Therapy in Adults With Congenital Heart Defects|Completed|||10|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:06:57.910963|2018-06-01 04:06:57.910963
NCT00303498|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16||2012-10-08|2012-10-08|2006-03-16|2006-03-17|Estimate||||2012-10-08|2012-10-11|Estimate|2012-10-08|2012-10-11|Estimate|March 2006||2006-03-31|October 2012|2012-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure|A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure|Completed||Phase 2|192|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:06:58.06286|2018-06-01 04:06:58.06286
NCT00303485|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2016-02-23||2016-03-30|2006-03-16|2006-03-17|Estimate|2016-03-30|2016-05-02|Estimate||||2016-03-30|2016-05-02|Estimate|February 2006||2006-02-28|March 2016|2016-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional||The Intent-to-Treat (ITT) Population included all randomized participants who received at least 1 dose of study medication.|A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)|A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis|Completed||Phase 4|67|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:06:58.283248|2018-06-01 04:06:58.283248
NCT00303472|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2010-10-22||2013-11-21|2006-03-16|2006-03-17|Estimate|2010-10-22|2010-11-19|Estimate||||2013-11-21|2013-12-16|Estimate|February 2006||2006-02-28|November 2013|2013-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)|An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 2|72|Actual|Amgen||7|||f||||||||||||||2018-06-01 04:06:59.003042|2018-06-01 04:06:59.003042
NCT00303459|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-16|2015-01-02||2015-10-16|2006-03-16|2006-03-17|Estimate|2015-01-22|2015-01-26|Estimate||||2015-10-16|2015-11-11|Estimate|May 2006||2006-05-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Compass-2|All randomized set|Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)|Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study|Completed||Phase 4|334|Actual|Actelion||2|||f||||t||||||||||2018-06-01 04:07:01.422375|2018-06-01 04:07:01.422375
NCT00303446|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|2009-12-09||2011-01-25|2006-03-15|2006-03-16|Estimate|2010-06-21|2010-06-22|Estimate||||2011-01-25|2011-01-27|Estimate|March 2006||2006-03-31|January 2011|2011-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)|Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy)|Completed||Phase 2|57|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 04:07:02.86981|2018-06-01 04:07:02.86981
NCT00303433|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2015-06-02|2006-03-14|2006-03-16|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2006||2006-03-31|December 2009|2009-12-31|September 2006||2006-09-30|||||Interventional|||Namenda to Prevent Post-Operative Delirium|Namenda as Prevention for Post-Operative Delirium|Terminated||Phase 4|30||University of Rochester|||||f||||||||||||||2018-06-01 04:07:03.528798|2018-06-01 04:07:03.528798
NCT00303381|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2013-08-04|2006-03-14|2006-03-16|Estimate|||||||2013-08-04|2013-08-06|Estimate|December 2001||2001-12-31|August 2013|2013-08-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis|A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding Phase II Study of Subcutaneously Administered IFN-beta-1a in the Treatment of Patients With Moderately Active Ulcerative Colitis|Completed||Phase 2|194|Actual|EMD Serono||3|||f||||||||||||||2018-06-01 04:07:03.898249|2018-06-01 04:07:03.898249
NCT00303368|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2008-05-20|2006-03-14|2006-03-16|Estimate|||||||2008-05-20|2008-05-23|Estimate|March 2004||2004-03-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|||||Observational|NF1TD||Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia|Multicenter Study of Tibial Dysplasia in Neurofibromatosis Type I (NF1) Patients|Unknown status|Recruiting||420|Anticipated|Shriners Hospitals for Children|||||f||||t||||||Samples With DNA|"~     If the enrollee's private physician includes surgery in the management of his/her disorder,~     and if tissue is removed to be discarded, permission is obtained to store the specimen in a~     tissue repository for future research.~   "|||2018-06-01 04:07:04.054602|2018-06-01 04:07:04.054602
NCT00303355|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2013-09-04|2006-03-14|2006-03-16|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2002||2002-09-30|September 2013|2013-09-30|September 2004||2004-09-30|||||Observational|||Measurement of Jugular Venous Pulse in Critically Ill Patients.|An Evaluation of the Utility of Clinical Examination for the Measurement of Jugular Venous Pulse in Critically Ill Patients.|Terminated|||36||University of Chicago||||Study completed|f||||||||||||||2018-06-01 04:07:04.126782|2018-06-01 04:07:04.126782
NCT00303342|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2010-01-12|2006-03-14|2006-03-16|Estimate|||||||2010-01-12|2010-01-14|Estimate|March 2006||2006-03-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Neuroendocrine Mechanisms in Behavioral Treatment of Insomnia|Neuroendocrine Mechanisms in Behavioral Treatment of Insomnia|Completed||Phase 2|60|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 04:07:04.179179|2018-06-01 04:07:04.179179
NCT00303329|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|2010-12-15||2011-04-15|2006-03-15|2006-03-16|Estimate|2011-04-15|2011-05-09|Estimate||||2011-04-15|2011-05-09|Estimate|March 2004||2004-03-31|April 2011|2011-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients|Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload|Completed||Phase 2|184|Actual|Novartis||1|||f||||t||||||||||2018-06-01 04:07:04.307092|2018-06-01 04:07:04.307092
NCT00303316|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|2012-12-11||2013-01-18|2006-03-13|2006-03-16|Estimate|2013-01-18|2013-02-22|Estimate||||2013-01-18|2013-02-22|Estimate|February 2006||2006-02-28|January 2013|2013-01-31|September 2007|Actual|2007-09-30|April 2007|Actual|2007-04-30||Interventional|||Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants|Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants|Completed||Phase 3|458|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:07:05.314362|2018-06-01 04:07:05.314362
NCT00303303|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2008-07-16|2006-03-14|2006-03-16|Estimate|||||||2008-07-16|2008-07-18|Estimate|April 2005||2005-04-30|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations|The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations|Terminated||Phase 4|25|Anticipated|Carolinas Healthcare System||3||Study terminated due to declining enrollment; data analysis proceeding.|f||||t||||||||||2018-06-01 04:07:05.693303|2018-06-01 04:07:05.693303
NCT00303290|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-15|||2015-11-25|2006-03-15|2006-03-16|Estimate|||||||2015-11-25|2015-11-26|Estimate|January 2000||2000-01-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With SCH54031 (PEG Interferon Alpha 2B/PEG Intron) and Low-Dose Cytosine Arabinoside (Ara-C)|Completed||Phase 1|76|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:07:05.782222|2018-06-01 04:07:05.782222
NCT00303277|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2010-04-12|2006-03-14|2006-03-16|Estimate|||||||2010-04-12|2010-04-13|Estimate|August 2002||2002-08-31|April 2010|2010-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Do HMG CoA Reductase Inhibitors Affect Abeta Levels?|Do HMG CoA Reductase Inhibitors Affect Abeta Levels?|Completed||Phase 4|35|Actual|Seattle Institute for Biomedical and Clinical Research||2|||f||||t||||||||||2018-06-01 04:07:05.97347|2018-06-01 04:07:05.97347
NCT00303264|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2012-03-01|2006-03-14|2006-03-16|Estimate|||||||2012-03-01|2012-03-05|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.|A Phase II Study to Investigate the Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.|Completed||Phase 2|48|Actual|Forest Laboratories|||||||||||||||||||2018-06-01 04:07:06.049221|2018-06-01 04:07:06.049221
NCT00303251|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14||2013-02-09|2013-02-09|2006-03-15|2006-03-16|Estimate||||2013-02-09|2013-02-12|Estimate|2013-02-09|2013-02-12|Estimate|April 2006||2006-04-30|February 2013|2013-02-28||||September 2009|Actual|2009-09-30||Interventional|||Safety of TKI258 in Advanced/Metastatic Melanoma Subjects|A Phase I/II Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of TKI258 (CHIR-258) in Patients With Locally Advanced or Metastatic Melanoma|Completed||Phase 1/Phase 2|47|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:07:06.13124|2018-06-01 04:07:06.13124
NCT00303238|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-03-14|2006-03-14|2006-03-16|Estimate|||||||2006-03-14|2006-03-16|Estimate|October 2004||2004-10-31|March 2006|2006-03-31|December 2005||2005-12-31|||||Interventional|||Study to Evaluate the Effect of Botanical Dietary Supplements on Inflammation in Healthy People|Double-Blind Trial to Evaluate the Effect of Botanical Dietary Supplements on C-Reactive Protein, Ex-Vivo IL-1 Production, and In-Vivo IL-1 Gene Expression in Healthy Human Subjects|Completed||N/A|200||Access Business Group|||||f||||||||||||||2018-06-01 04:07:06.217908|2018-06-01 04:07:06.217908
NCT00303225|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2017-06-30|2006-03-14|2006-03-15|Estimate|||||||2017-06-30|2017-07-02|Actual|March 13, 2006||2006-03-13|August 4, 2006|2006-08-04|August 4, 2006||2006-08-04|||||Interventional|||SIGA-246 to Treat Smallpox|A Double-Blind, Randomized, Placebo-Controlled, Ascending Single-Dose, Phase I Trial of the Anti-Orthopoxvirus Compound SIGA-246 in Healthy Volunteers|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:07:06.316855|2018-06-01 04:07:06.316855
NCT00303212|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2010-09-16|2006-03-13|2006-03-15|Estimate|||||||2010-09-16|2010-09-17|Estimate|March 2006||2006-03-31|September 2010|2010-09-30|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|||Tele-HF: Yale Heart Failure Telemonitoring Study|A Study of Telemonitoring to Improve Heart Failure Outcomes|Completed||N/A|1660|Actual|Yale University||2|||f||||t||||||||||2018-06-01 04:07:06.377226|2018-06-01 04:07:06.377226
NCT00303186|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|2012-06-25||2012-06-25|2006-03-14|2006-03-15|Estimate|2012-06-25|2012-07-30|Estimate||||2012-06-25|2012-07-30|Estimate|February 2005||2005-02-28|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy|An Observational Study to Evaluate the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy|Completed|||107|Actual|Pfizer|Results were not summarized for Month 6, 18 and 24 due to insufficient data collected and small sample size achieved at the time points.||||f||||f||||||||||2018-06-01 04:07:06.616033|2018-06-01 04:07:06.616033
NCT00303173|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2008-06-23|2006-03-14|2006-03-15|Estimate|||||||2008-06-23|2008-06-25|Estimate|August 2004||2004-08-31|June 2008|2008-06-30|February 2007|Actual|2007-02-28|December 2006|Actual|2006-12-31||Interventional|||The Relaxation and Blood Pressure in Pregnancy (REBIP) Study|A Randomized Controlled Trial of The Effectiveness of Guided Imagery on Blood Pressure in Hypertensive Pregnant Women: The Relaxation and Blood Pressure in Pregnancy (REBIP) Pilot Study|Completed||N/A|69|Actual|University of Toronto|||||f||||f||||||||||2018-06-01 04:07:08.232182|2018-06-01 04:07:08.232182
NCT00303160|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2007-08-13|2006-03-14|2006-03-15|Estimate|||||||2007-08-13|2007-08-14|Estimate|March 2006||2006-03-31|August 2007|2007-08-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Effect of Helicobacter Pylori on the Availability of Vitamin E and C|Effect of Helicobacter Pylori on the Availability of Vitamin E and C|Unknown status|Active, not recruiting|Phase 4|72|Anticipated|University of Toronto|||||f||||||||||||||2018-06-01 04:07:08.304132|2018-06-01 04:07:08.304132
NCT00303147|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-03-14|2006-03-14|2006-03-15|Estimate|||||||2006-03-14|2006-03-15|Estimate|May 2003||2003-05-31|March 2006|2006-03-31|July 2005||2005-07-31|||||Interventional|||Cognitive and Health Benefits of Expressive Writing for Family Caregivers Under Stress||Unknown status|Active, not recruiting|Phase 1|120||University of Toronto|||||f||||||||||||||2018-06-01 04:07:08.453826|2018-06-01 04:07:08.453826
NCT00303134|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2008-12-04|2006-03-13|2006-03-15|Estimate|||||||2008-12-04|2008-12-05|Estimate|August 2003||2003-08-31|September 2007|2007-09-30||||||||Interventional|||Islet Cell Transplants for Diabetes|Human Islet Cell Transplantation in Type 1 Diabetic Patients|Suspended||Phase 1|8|Anticipated|Weill Medical College of Cornell University|||||||||||||||||||2018-06-01 04:07:08.524354|2018-06-01 04:07:08.524354
NCT00303121|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-10-10|2006-03-14|2006-03-15|Estimate|||||||2006-10-10|2006-10-11|Estimate|November 2005||2005-11-30|June 2006|2006-06-30|June 2006||2006-06-30|||||Observational|||Compliance and Administration Technique in Topical Drug Therapy of Glaucoma||Completed|||120||University of Toronto|||||f||||||||||||||2018-06-01 04:07:08.592875|2018-06-01 04:07:08.592875
NCT00303108|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|2016-02-02||2016-09-15|2006-03-13|2006-03-15|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|December 2005||2005-12-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional||ITT population|Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer|Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer|Completed||Phase 2|136|Actual|US Oncology Research||1|||f||||||||||||||2018-06-01 04:07:08.687647|2018-06-01 04:07:08.687647
NCT00303082|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2011-06-14|2006-03-13|2006-03-15|Estimate|||||||2011-06-14|2011-06-15|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity|Clinical Trial for the Prevention of Premature Birth and Neonatal Related Morbidity|Terminated||Phase 3|645|Actual|Oswaldo Cruz Foundation||||Limitation of funding|f||||t||||||||||2018-06-01 04:07:09.17853|2018-06-01 04:07:09.17853
NCT00303069|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|2010-09-23||2015-06-29|2006-03-13|2006-03-15|Estimate|2010-09-23|2010-10-20|Estimate||||2015-06-29|2015-07-22|Estimate|November 2005||2005-11-30|June 2015|2015-06-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||V710 First-In-Man (FIM) Study (V710-001)|A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age|Completed||Phase 1|124|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-06-01 04:07:09.279258|2018-06-01 04:07:09.279258
NCT00303056|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2012-02-15|2006-03-14|2006-03-15|Estimate|||||||2012-02-15|2012-02-17|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis|Efficacy and Safety of Intra-articular Multiple Doses of 500 µg Icatibant Including 40 mg Triamcinolone as Calibrator in a Randomized, Double-blind, Parallel-group, Placebo-controlled 13-week Multi-centre Study in Patients With Symptomatic Knee Osteoarthritis|Completed||Phase 2|590|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:07:09.937262|2018-06-01 04:07:09.937262
NCT00303043|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2009-12-29|2006-03-14|2006-03-15|Estimate|||||||2009-12-29|2009-12-30|Estimate|March 2006||2006-03-31|March 2009|2009-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Hemodynamic Monitoring With Mixed Venous Saturation|Hemodynamic Monitoring. The Continuous Measurement of Mixed Venous Saturation Compared to Clinical Valuation: A Pilot Study|Completed|||30|Actual|Policlinico Hospital|||1||f||||f||||||||||2018-06-01 04:07:10.014365|2018-06-01 04:07:10.014365
NCT00303030|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2011-11-16|2006-03-14|2006-03-15|Estimate|||||||2011-11-16|2011-11-17|Estimate|May 2006||2006-05-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Randomized, Controlled, Clinical Trial of Biofeedback and Anal Injections as First Treatment of Fecal Incontinence|A Randomized, Controlled, Clinical Trial of Biofeedback and Anal Injections as First Treatment of Fecal Incontinence.|Completed||Phase 1|126|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-06-01 04:07:10.077735|2018-06-01 04:07:10.077735
NCT00303017|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2015-10-19|2006-03-13|2006-03-15|Estimate|||||||2015-10-19|2015-10-21|Estimate|March 2006||2006-03-31|November 2008|2008-11-30|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study|Safety, Efficacy and Acceptability of Flavocoxid (Limbrel) Compared With Naproxen in Subjects With Osteoarthritis of the Knee. A Pilot Study|Completed||N/A|60|Actual|Primus Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:07:10.169054|2018-06-01 04:07:10.169054
NCT00303004|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2008-01-23|2006-03-14|2006-03-15|Estimate|||||||2008-01-23|2008-01-24|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome|Combination Treatment With Bosentan and Sildenafil to Patients With Eisenmengers Syndrome|Completed||Phase 3|20|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||||||2018-06-01 04:07:10.250715|2018-06-01 04:07:10.250715
NCT00302991|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2008-01-29|2006-03-13|2006-03-15|Estimate|||||||2008-01-29|2008-01-30|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)|Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA)|Completed|||180||UCB Pharma|||||f||||f||||||||||2018-06-01 04:07:10.328934|2018-06-01 04:07:10.328934
NCT00302978|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2011-12-14|2006-03-14|2006-03-15|Estimate|||||||2011-12-14|2011-12-15|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Interventional|||Changes in Brain Activity (Functional MRI Study) Before and After Behavioral Therapy of Height Phobia|The Effects of in Vivo Exposure Therapy on the Neural Correlates of Height Phobia: a Functional Magnetic Resonance Imaging Study Using a Fear Provocation Paradigm.|Completed||N/A|40||New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 04:07:10.404401|2018-06-01 04:07:10.404401
NCT00302965|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-17|2006-03-13|2006-03-15|Estimate|||||||2008-10-17|2008-10-21|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effectiveness of Plasma Transfusions in Critical Care Patients|Effectiveness of Fresh Frozen Plasma in Critical Care (EPICC) Trial|Completed||Phase 1/Phase 2|70|Anticipated|Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 04:07:10.469935|2018-06-01 04:07:10.469935
NCT00302952|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|2013-12-18||2017-04-05|2006-03-13|2006-03-15|Estimate|2014-02-06|2014-02-12|Estimate||||2017-04-05|2017-05-11|Actual|August 2006||2006-08-31|April 2017|2017-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Completed Intent-to-Treat (ITT)|Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis|A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis|Completed||Phase 2|64|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Enrollment was slow and the full sample size was not obtained.|2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 04:07:10.567796|2018-06-01 04:07:10.567796
NCT00302939|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2010-04-21|2006-03-14|2006-03-15|Estimate|||||||2010-04-21|2010-04-22|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Etiology of Anemia|Studies in the Etiology of Anemia in an Unselected Sequential Referral Population|Terminated|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||Samples Without DNA|"~     Bone marrow aspirate, urine, blood serum~   "|||2018-06-01 04:07:11.195204|2018-06-01 04:07:11.195204
NCT00302926|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-03-14|2006-03-14|2006-03-15|Estimate|||||||2006-03-14|2006-03-15|Estimate|September 2002||2002-09-30|March 2006|2006-03-31|June 2003||2003-06-30|||||Interventional|||B195: Effect of Diet-Induced Energy Deficit and Body Fat Reduction on Inflammatory Markers in Obese Subjects|B195: Effect of Diet-Induced Energy Deficit and Body Fat Reduction on Inflammatory Markers in Obese Subjects|Completed||N/A|50||University of Copenhagen|||||f||||||||||||||2018-06-01 04:07:11.252334|2018-06-01 04:07:11.252334
NCT00302913|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-06-29|2006-03-14|2006-03-15|Estimate|||||||2006-06-29|2006-07-04|Estimate|December 2005||2005-12-31|February 2006|2006-02-28|June 2006||2006-06-30|||||Interventional|||Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition|Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition After Elective Coronary Stenting|Completed||N/A|120||Heart Center Bad Krozingen|||||f||||||||||||||2018-06-01 04:07:11.312464|2018-06-01 04:07:11.312464
NCT00302900|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2016-10-04|2006-03-14|2006-03-15|Estimate|||||||2016-10-04|2016-10-06|Estimate|January 2006||2006-01-31|February 2009|2009-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Preventing Negative Reactions in First Time Blood Donors to Encourage Subsequent Blood Donations|Preventing Adverse Reactions in Novice Blood Donors|Completed||Phase 2|441|Actual|Ohio University||4|||f||||t||||||||Yes|Deidentified data is available upon request from the primary investigator.|2018-06-01 04:07:11.386386|2018-06-01 04:07:11.386386
NCT00302887|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-03-14|2006-03-14|2006-03-15|Estimate|||||||2006-03-14|2006-03-15|Estimate|August 2003||2003-08-31|March 2006|2006-03-31|December 2004||2004-12-31|||||Observational|||Connective Tissue Manipulation and Combined Ultrasound Therapy in Patients With Fibromyalgia|Short and Long Term Results of Connective Tissue Manipulation and Combined Ultrasound Therapy in Patients With Fibromyalgia|Completed|||20||Hacettepe University|||||f||||||||||||||2018-06-01 04:07:11.456392|2018-06-01 04:07:11.456392
NCT00302874|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2007-03-23|2006-03-14|2006-03-15|Estimate|||||||2007-03-23|2007-03-26|Estimate|February 2003||2003-02-28|October 2002|2002-10-31|October 2004||2004-10-31|||||Interventional|||In-Hospital Hyperglycemia: Effects of Treatment on Glycemic Control and Clinical Outcome|In-Hospital Hyperglycemia: Effects of Treatment on Glycemic Control and Clinical Outcome|Completed||N/A|400||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:07:11.506971|2018-06-01 04:07:11.506971
NCT00302861|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2008-03-14|2006-03-13|2006-03-15|Estimate|||||||2008-03-14|2008-03-18|Estimate|March 2006||2006-03-31|March 2008|2008-03-31||||||||Interventional|||A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Phase 1/2 Study to Evaluate the Feasibility and Tolerability of Treatment of Previously Untreated B-CLL Chronic Lymphocytic Leukemia (B-CLL) Patients With Recombinant Idiotype Conjugated to KLH (Id-KLH) Administered With GM-CSF|Terminated||Phase 1/Phase 2|86||Genitope Corporation|||||||||||||||||||2018-06-01 04:07:11.559492|2018-06-01 04:07:11.559492
NCT00302848|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|2009-06-23||2009-11-06|2006-03-13|2006-03-15|Estimate|2009-11-06|2009-11-20|Estimate||||2009-11-06|2009-11-20|Estimate|November 2000||2000-11-30|November 2009|2009-11-30|December 2005||2005-12-31|||||Observational|||European Active Surveillance Study (EURAS)|The European Active Surveillance Study on OC Prescribing Practice, Benefits and Safety (EURAS)|Completed|||59510|Actual|Center for Epidemiology and Health Research, Germany|This is an observational study. The possibility of bias and residual confounding cannot be entirely eliminated.||3||f||||t||||||||||2018-06-01 04:07:11.696883|2018-06-01 04:07:11.696883
NCT00302835|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-04-21|2006-03-14|2006-03-15|Estimate|||||||2006-04-21|2006-04-24|Estimate|January 2001||2001-01-31|April 2006|2006-04-30|December 2004||2004-12-31|||||Observational|||Case-Control Study on Analgesics and Nephropathy (SAN)|Case-Control Study on Analgesics and Nephropathy (SAN)|Completed|||4200||Center for Epidemiology and Health Research, Germany|||||f||||||||||||||2018-06-01 04:07:12.046061|2018-06-01 04:07:12.046061
NCT00302822|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2013-07-09|2006-03-14|2006-03-15|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 2006||2006-04-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)|Enfuvirtide for the Initial Phase of Antiretroviral Therapy in HIV-infected Patients With High Risk of Clinical Progression : ANRS 130 APOLLO|Completed||Phase 3|195|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 04:07:12.10968|2018-06-01 04:07:12.10968
NCT00302809|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2009-06-16|2006-03-13|2006-03-15|Estimate|||||||2009-06-16|2009-06-18|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|||||Interventional|||Blood Pressure Lowering Effects of Grape Juice|Effect of Concord Grape Juice on Blood Pressure and Vascular Function in Subjects With Pre-Hypertension and Stage 1 Hypertension|Completed||N/A|60|Anticipated|Boston University|||||f||||f||||||||||2018-06-01 04:07:12.194726|2018-06-01 04:07:12.194726
NCT00302796|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2010-05-26|2006-03-14|2006-03-15|Estimate|||||||2010-05-26|2010-05-27|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Antibiotic Treatment to Patients With Low Back Pain|Antibiotic Treatment to Patients With Low Back Pain Associated With Modic Changes Following Disc Herniation. A Randomized Clinical Controlled Trial|Completed||Phase 4|162|Actual|The Back Research Center, Denmark||4|||f||||t||||||||||2018-06-01 04:07:12.26456|2018-06-01 04:07:12.26456
NCT00302783|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-14|||2006-03-14|2006-03-14|2006-03-15|Estimate|||||||2006-03-14|2006-03-15|Estimate|June 2004||2004-06-30|January 2006|2006-01-31|September 2005||2005-09-30|||||Interventional|||Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents|Randomized Controlled Trial of Multi-Source Feedback to Pediatric Residents: The Formative Value of an ACGME Competency-Based Assessment Tool.|Completed||N/A|36||Children's Hospital Medical Center, Cincinnati|||||f||||||||||||||2018-06-01 04:07:12.32942|2018-06-01 04:07:12.32942
NCT00302770|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2011-01-25|2006-03-13|2006-03-15|Estimate|||||||2011-01-25|2011-01-27|Estimate|June 2006||2006-06-30|January 2011|2011-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy of Quetiapine in Generalised Social Anxiety Disorder|Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study|Terminated||Phase 3|50|Anticipated|AstraZeneca||||This study was terminated due to poor enrollment|f||||||||||||||2018-06-01 04:07:12.379775|2018-06-01 04:07:12.379775
NCT00302757|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2014-05-28|2006-03-10|2006-03-14|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2006||2006-03-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|||||Interventional|||Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma|Multicenter Phase I/II Study of Radioimmunotherapy With 90Y-ibritumomab Tiuxetan in a Nonmyeloablative Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation From HLA-identical Donors in Patients With Advanced Non-Hodgkin Lymphoma|Completed||Phase 1/Phase 2|60|Anticipated|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:07:12.442967|2018-06-01 04:07:12.442967
NCT00302744|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2013-01-28|2006-03-13|2006-03-14|Estimate|||||||2013-01-28|2013-01-29|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety|Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety|Completed||Phase 1|12|Actual|Los Angeles Biomedical Research Institute||1|||f||||t||||||||||2018-06-01 04:07:12.526222|2018-06-01 04:07:12.526222
NCT00302731|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|2017-04-27||2018-04-17|2006-03-10|2006-03-14|Estimate|2018-04-17|2018-05-16|Actual||||2018-04-17|2018-05-16|Actual|February 2006||2006-02-28|April 2018|2018-04-30|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|||Bioidentical 'Natural' Hormone Evaluation in Early Menopause|Prospective Double Blind Evaluation of Bioidentical Hormones|Terminated||Phase 2|21|Actual|University of Kansas Medical Center||4|||f||||t|t|f||||||Undecided|"Limited sample size and high drop out rate make data obtained of marginal value. We will decide on a case by case review if data will be made available to requesting researchers. We recognize that data sharing includes protected health information and the deserved rights of individuals who participate in research. We will make every effort to protect these data at all times. Such data intended for broader use will be free of identifiers that would permit linkages to individuals, research participants or variables that could lead to deductive disclosure of the identify of individual subjects. This is in accordance for Standards for Privacy of Individually Identifiable Health Information - The Privacy Rule - HHS dated August 14, 2002. The Privacy Rule is a Federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information."|2018-06-01 04:07:12.619543|2018-06-01 04:07:12.619543
NCT00302718|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|2014-11-21||2015-04-06|2006-03-10|2006-03-14|Estimate|2014-12-04|2014-12-15|Estimate||||2015-04-06|2015-04-24|Estimate|February 2007||2007-02-28|October 2014|2014-10-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional||Distribution of Physician Characteristics Across Study Groups|Financial Incentives to Translate ALLHAT Into Practice: A Randomized Trial|RCT of Financial Incentives to Translate ALLHAT Into Practice|Completed||N/A|83|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 04:07:13.047625|2018-06-01 04:07:13.047625
NCT00302705|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2009-01-02|2006-03-13|2006-03-14|Estimate|||||||2009-01-02|2009-01-05|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose|Prospective, Randomized, Open-Label Study in Patients With Mild-to-Moderate Essential Hypertension to Compare the Antihypertensive Efficacy Determined by Ambulatory Blood Pressure Monitoring of Valsartan and Enalapril After Missing One Dose|Completed||Phase 4|150|Actual|University of Vigo||2|||f||||t||||||||||2018-06-01 04:07:13.506438|2018-06-01 04:07:13.506438
NCT00302692|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2007-05-09|2006-03-10|2006-03-14|Estimate|||||||2007-05-09|2007-05-10|Estimate|December 2005||2005-12-31|May 2007|2007-05-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Use of Beta Blockers in Elderly Trauma Patients|"Effects of Beta-Blockade on Cardiovascular Morbidity and Mortality in Elderly Trauma Patients: A Prospective Randomized Clinical Trial"|Unknown status|Recruiting|Phase 2|148|Anticipated|University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:07:13.572197|2018-06-01 04:07:13.572197
NCT00302679|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-12|||2006-03-13|2006-03-13|2006-03-14|Estimate|||||||2006-03-13|2006-03-14|Estimate|January 2006||2006-01-31|February 2006|2006-02-28|June 2006||2006-06-30|||||Observational|||Comparison of Colonoscopy and Sigmoidoscopy in Terms of Pain, Acceptance and Procedure Time|Comparison of Colonoscopy and Sigmoidoscopy in Terms of Pain, Acceptance and Procedure Time|Unknown status|Recruiting||400||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:07:13.64256|2018-06-01 04:07:13.64256
NCT00302666|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2009-05-15|2006-03-13|2006-03-14|Estimate|||||||2009-05-15|2009-05-18|Estimate|June 2003||2003-06-30|May 2009|2009-05-31|February 2005|Actual|2005-02-28|||||Interventional|||Bleeding Pattern Study|Comparative, Prospective, Multi-Center, Open, Randomized Study to Investigate Bleeding Patterns, Metabolic Effects, Contraceptive Efficacy, Acceptance, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 2 mg Dienogest, in Two Different Regimens of Intake (Four Extended Cycles of 84 Days Each Versus the Conventional Regimen of 21 Days) in Healthy Volunteers|Completed||Phase 3|1315|Actual|Bayer||2|||f||||||||||||||2018-06-01 04:07:13.696428|2018-06-01 04:07:13.696428
NCT00302653|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2009-09-24|2006-03-13|2006-03-14|Estimate|||||||2009-09-24|2009-09-25|Estimate|February 2006||2006-02-28|September 2009|2009-09-30||||November 2006|Actual|2006-11-30||Interventional|||Rasburicase in Tumor Lysis Syndrome|Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.|Completed||Phase 4|33|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:07:13.910089|2018-06-01 04:07:13.910089
NCT00302640|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2012-05-30|2006-03-13|2006-03-14|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|September 2005||2005-09-30|||||Interventional|||Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children|Multi-center, Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children|Completed||Phase 2/Phase 3|50|Actual|Romark Laboratories L.C.||2|||f||||||||||||||2018-06-01 04:07:13.984948|2018-06-01 04:07:13.984948
NCT00302627|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2010-08-25|2006-03-10|2006-03-14|Estimate|||||||2010-08-25|2010-08-26|Estimate|January 1999||1999-01-31|December 2002|2002-12-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation|Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation|Completed||N/A|43|Actual|Providence Health & Services||1|||f||||f||||||||||2018-06-01 04:07:14.048194|2018-06-01 04:07:14.048194
NCT00302614|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-12|||2006-03-12|2006-03-12|2006-03-14|Estimate|||||||2006-03-12|2006-03-14|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|June 2006||2006-06-30|||||Observational|||The Role of Clinical Parameters in Predicting the Severity of Obstructive Sleep Apnea||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:07:14.133677|2018-06-01 04:07:14.133677
NCT00302601|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2016-04-15|2006-03-13|2006-03-14|Estimate|||||||2016-04-15|2016-04-18|Estimate|April 2006||2006-04-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of Diagnosis and Pathophysiology of Pulmonary Embolism (APE 1 Trial)|The Acute Pulmonary Embolism 1 (APE 1) Trial: Prospective Investigation of Scintigraphic Diagnosis and Pathophysiology of Right Heart Strain|Terminated||N/A|15|Actual|Odense University Hospital||1||Logistics failure and staff/scanner shortage|f||||f||||||||No||2018-06-01 04:07:14.194879|2018-06-01 04:07:14.194879
NCT00302588|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-12|||2006-03-12|2006-03-12|2006-03-14|Estimate|||||||2006-03-12|2006-03-14|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|February 2006||2006-02-28|||||Observational|||The Final Diagnosis and Treatment Result of Metastatic Cervical Carcinoma of Unknown Primary||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:07:14.262354|2018-06-01 04:07:14.262354
NCT00302575|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2017-01-10|2006-03-13|2006-03-14|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2005||2005-02-28|August 2006|2006-08-31|August 2007|Anticipated|2007-08-31|||||Interventional|||Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved Parolees|Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved Parolees|Unknown status|Recruiting|N/A|420|Anticipated|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:07:14.32885|2018-06-01 04:07:14.32885
NCT00302562|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-12|||2006-03-12|2006-03-12|2006-03-14|Estimate|||||||2006-03-12|2006-03-14|Estimate|August 2006||2006-08-31|December 2005|2005-12-31|July 2007||2007-07-31|||||Observational|||The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma||Unknown status|Not yet recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:07:14.421949|2018-06-01 04:07:14.421949
NCT00302549|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2010-05-25|2006-03-13|2006-03-14|Estimate|||||||2010-05-25|2010-05-27|Estimate|May 2004||2004-05-31|July 2008|2008-07-31|February 2006|Actual|2006-02-28|May 2005|Actual|2005-05-31||Interventional|||To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN|To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class|Completed||N/A|61|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 04:07:14.48472|2018-06-01 04:07:14.48472
NCT00302536|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2012-02-08|2006-03-13|2006-03-14|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2006||2006-03-31|September 2010|2010-09-30|September 2010|Anticipated|2010-09-30|May 2010|Anticipated|2010-05-31||Interventional|||Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis|Tacrolimus Treatment of Patients With Idiopathic Focal Segmental|Withdrawn||N/A|0|Actual|Nanjing University School of Medicine||1||There was less patients recruited.|f||||t||||||||||2018-06-01 04:07:14.564366|2018-06-01 04:07:14.564366
NCT00302523|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2012-02-02|2006-03-13|2006-03-14|Estimate|||||||2012-02-02|2012-02-03|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy|Tacrolimus Treatment of Patients With Idiopathic|Completed||N/A|16|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 04:07:14.645397|2018-06-01 04:07:14.645397
NCT00302510|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2010-05-25|2006-03-13|2006-03-14|Estimate|||||||2010-05-25|2010-05-27|Estimate|January 2000||2000-01-31|July 2008|2008-07-31|August 2003|Actual|2003-08-31|March 2002|Actual|2002-03-31||Interventional|||Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein Glomerulopathy|Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein|Completed||N/A|20|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 04:07:14.719095|2018-06-01 04:07:14.719095
NCT00302497|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2007-04-11|2006-03-10|2006-03-14|Estimate|||||||2007-04-11|2007-04-12|Estimate|April 2007||2007-04-30|February 2006|2006-02-28|April 2008|Anticipated|2008-04-30|||||Interventional|||EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function|12 Month, Prospective, Randomised, Open-Label Comparative Study to Evaluate the Protection of Kidney Function by Basiliximab in a CNI-Free Regimen in Newly Kidney Transplanted Patients (Three Months Post-Transplant) Who Are Recipient of One Kidney From Expanded Donor Criteria (UNOS Criteria)|Unknown status|Not yet recruiting|Phase 3|50||McGill University Health Center|||||f||||||||||||||2018-06-01 04:07:14.789101|2018-06-01 04:07:14.789101
NCT00302484|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2006-07-25|2006-03-13|2006-03-14|Estimate|||||||2006-07-25|2006-07-26|Estimate|April 2002||2002-04-30|January 2006|2006-01-31||||||||Interventional|||Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation|Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation, a Prospective Randomised Study|Unknown status|Active, not recruiting|N/A|96||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:07:14.848234|2018-06-01 04:07:14.848234
NCT00302471|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2015-04-24|2006-03-10|2006-03-14|Estimate|||||||2015-04-24|2015-04-27|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||MK0429 Study in Prostate Cancer Patients With Metastatic Bone Disease (0429-011)|A Phase I, Randomized, Multicenter, Double-Blind Study of MK0429 in the Treatment of Men With Hormone Refractory Prostate Cancer and Metastatic Bone Disease|Completed||Phase 1|29|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 04:07:14.906304|2018-06-01 04:07:14.906304
NCT00302458|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|2013-11-18||2016-02-01|2006-03-13|2006-03-14|Estimate|2013-11-18|2014-01-07|Estimate||||2016-02-01|2016-02-29|Estimate|January 2006||2006-01-31|February 2016|2016-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional||One subject was ineligible, one subject was lost to follow-up, one withdrew, and twenty six subjects completed the study.|A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults|A Double-blind, Randomized, Placebo-controlled, Crossover Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults|Completed||Phase 4|44|Actual|Massachusetts General Hospital||5|||f||||f||||||||||2018-06-01 04:07:14.992542|2018-06-01 04:07:14.992542
NCT00302445|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2007-07-12|2006-03-10|2006-03-14|Estimate|||||||2007-07-12|2007-07-13|Estimate|March 2006||2006-03-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis|An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Raptiva (Efalizumab)in Combination With Narrow Band Phototherapy for the Treatment of Moderate to Severe Plaque Psoriasis.|Completed||Phase 4|20||Derm Research, PLLC|||||f||||t||||||||||2018-06-01 04:07:15.184795|2018-06-01 04:07:15.184795
NCT00302432|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2010-07-21|2006-03-13|2006-03-14|Estimate|||||||2010-07-21|2010-07-22|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study|The Effect of Cigarette Holders, Plastic Menthol Cigarettes, and Cognitive Behavioral Therapy for Smoking Reduction Among Schizophrenia Inpatients: A Comparative Study|Completed||N/A|37|Actual|Lev-Hasharon Mental Healtlh Center|||||f||||||||||||||2018-06-01 04:07:15.259364|2018-06-01 04:07:15.259364
NCT00302419|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2008-07-30|2006-03-13|2006-03-14|Estimate|||||||2008-07-30|2008-08-01|Estimate|October 2004||2004-10-31|July 2008|2008-07-31|February 2008|Actual|2008-02-29|February 2006|Actual|2006-02-28||Interventional|||Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction|Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction|Completed||Phase 4|95|Actual|Istanbul University||2|||f||||||||||||||2018-06-01 04:07:15.331434|2018-06-01 04:07:15.331434
NCT00302406|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2011-07-11|2006-03-10|2006-03-14|Estimate|||||||2011-07-11|2011-07-12|Estimate|July 2003||2003-07-31|July 2011|2011-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate|Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate|Completed||Phase 4|50|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:07:15.406628|2018-06-01 04:07:15.406628
NCT00302393|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2013-10-21|2006-03-10|2006-03-14|Estimate|||||||2013-10-21|2013-10-22|Estimate|June 2006||2006-06-30|October 2013|2013-10-31|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Interventional|||Study Examining Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults|A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy of Repeat Dosing of OROS® Methylphenidate (CONCERTA®) and Immediate Release Methylphenidate in Healthy Adults|Completed||Phase 3|20|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 04:07:15.461787|2018-06-01 04:07:15.461787
NCT00302380|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2011-06-27|2006-03-10|2006-03-14|Estimate|||||||2011-06-27|2011-06-28|Estimate|October 2000||2000-10-31|June 2011|2011-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD|An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD|Completed|||300|Actual|Massachusetts General Hospital|||2||f||||t||||||Samples With DNA|"~     A sample of blood (2 tablespoons) will be drawn from all subjects.~   "|||2018-06-01 04:07:15.522244|2018-06-01 04:07:15.522244
NCT00302367|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2011-07-11|2006-03-10|2006-03-14|Estimate|||||||2011-07-11|2011-07-12|Estimate|January 2004||2004-01-31|July 2011|2011-07-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects|An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects|Completed||Phase 4|20||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:07:15.582827|2018-06-01 04:07:15.582827
NCT00302354|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2011-07-11|2006-03-13|2006-03-14|Estimate|||||||2011-07-11|2011-07-12|Estimate|December 2004||2004-12-31|July 2011|2011-07-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults|A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults|Completed||Phase 4|50||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:07:15.636924|2018-06-01 04:07:15.636924
NCT00302341|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2013-03-06|2006-03-10|2006-03-14|Estimate|||||||2013-03-06|2013-03-07|Estimate|May 2006||2006-05-31|March 2013|2013-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)|International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS|Terminated||Phase 3|48|Actual|Immtech Pharmaceuticals, Inc||2||FDA Clinical Hold as of 12/21/07 due to safety concerns|f||||t||||||||||2018-06-01 04:07:15.749141|2018-06-01 04:07:15.749141
NCT00302328|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|2012-10-04||2014-03-13|2006-03-13|2006-03-14|Estimate|2014-03-13|2014-04-16|Estimate||||2014-03-13|2014-04-16|Estimate|August 2005||2005-08-31|March 2014|2014-03-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes|A Randomised Clinical Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes|Completed||N/A|78|Actual|Glostrup University Hospital, Copenhagen|non-closure of macular hole after surgical procedure in 18 patients led to re-operation. Data included in main published papers.|3|||f||||f||||||||||2018-06-01 04:07:15.848807|2018-06-01 04:07:15.848807
NCT00302315|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2006-03-13|2006-03-13|2006-03-14|Estimate|||||||2006-03-13|2006-03-14|Estimate|December 2004||2004-12-31|March 2006|2006-03-31|May 2005||2005-05-31|||||Interventional|||Effectiveness of Physiotherapy on Postcesarean Pain and Functional Activities|Effectiveness of Physiotherapy on Postcesarean Pain and Functional Activities|Completed||N/A|50||Hacettepe University|||||f||||||||||||||2018-06-01 04:07:16.107032|2018-06-01 04:07:16.107032
NCT00302302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-02-25|2006-03-13|2006-03-14|Estimate|||||||2014-02-25|2014-02-26|Estimate|September 2005||2005-09-30|February 2014|2014-02-28|January 2006|Actual|2006-01-31|November 2005|Actual|2005-11-30||Interventional|||The Effects of L-arabinose on Intestinal Sucrase Activity in Man|The Effects of Increasing Doses of L-arabinose in a Sucrose Rich Meal on Intestinal Sucrase Activity in Man|Completed||Phase 1|15|Actual|University of Copenhagen|||||f||||f||||||||||2018-06-01 04:07:16.160157|2018-06-01 04:07:16.160157
NCT00302263|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2006-03-13|2006-03-13|2006-03-14|Estimate|||||||2006-03-13|2006-03-14|Estimate|January 2005||2005-01-31|August 2005|2005-08-31|April 2005||2005-04-30|||||Interventional|||B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)|B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)|Completed||Phase 2/Phase 3|22||University of Copenhagen|||||f||||||||||||||2018-06-01 04:07:16.398115|2018-06-01 04:07:16.398115
NCT00302250|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2006-03-21|2006-03-13|2006-03-14|Estimate|||||||2006-03-21|2006-03-22|Estimate|February 2006||2006-02-28|March 2006|2006-03-31|December 2006||2006-12-31|||||Interventional|||The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension|Study of The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension Before and After Receiving Oral Alagebrium or Placebo for 8 Weeks (STRETCH)|Completed||Phase 2|70||Synvista Therapeutics, Inc|||||||||||||||||||2018-06-01 04:07:16.473634|2018-06-01 04:07:16.473634
NCT00302237|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2012-12-12|2006-03-10|2006-03-14|Estimate|||||||2012-12-12|2012-12-13|Estimate|March 2006||2006-03-31|December 2012|2012-12-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|CAPTURE 2||CAPTURE 2 Post-Marketing Registry|"Second Phase of Carotid RX ACCULINK/RX ACCUNET Post-Approval Trial to Uncover Unanticipated or Rare Events"|Completed|||6426|Actual|Abbott Vascular|||1||f||||f||||||||||2018-06-01 04:07:16.557472|2018-06-01 04:07:16.557472
NCT00302224|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2008-02-20|2006-03-10|2006-03-14|Estimate|||||||2008-02-20|2008-02-22|Estimate|February 2005||2005-02-28|February 2008|2008-02-29|August 2006||2006-08-31|||||Interventional|||A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus|A Phase 1/2a, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Study of Safety, Tolerability, Pharmacokinetics and Activity of 14 Days of Oral Dosing With the 2S,4R Enantiomer of Ketoconazole (DIO-902) in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|50||DiObex|||||||||||||||||||2018-06-01 04:07:16.653203|2018-06-01 04:07:16.653203
NCT00302211|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|2010-05-27|2010-03-05|2011-05-12|2006-03-10|2006-03-14|Estimate|2010-07-20|2010-08-13|Estimate|2010-03-05|2010-03-09|Estimate|2011-05-12|2011-05-16|Estimate|February 2006||2006-02-28|May 2011|2011-05-31|November 2009|Actual|2009-11-30|December 2007|Actual|2007-12-31||Interventional|VISION||"The VISION Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension"|A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of Inhaled Iloprost in Patients With Pulmonary Arterial Hypertension Receiving Oral Sildenafil|Terminated||Phase 3|67|Actual|Actelion|Primary purpose was to evaluate the efficacy of iloprost in PAH patients. Slow patient recruitment led to early study closure. In addition there were factors regarding the conduct of the study which preclude conclusions from this limited dataset.|3||Terminated due to slow enrollment|f||||||||||||||2018-06-01 04:07:16.785177|2018-06-01 04:07:16.785177
NCT00302198|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2010-03-01|2006-03-10|2006-03-14|Estimate|||||||2010-03-01|2010-03-02|Estimate|January 2006||2006-01-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org|Amyotrophic Lateral Sclerosis Web Based Patient Care Database|Completed|||15000|Anticipated|Forbes Norris MDA/ALS Research Center|||||f||||||||||||||2018-06-01 04:07:17.804747|2018-06-01 04:07:17.804747
NCT00302185|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-13|||2010-10-19|2006-03-13|2006-03-14|Estimate|||||||2010-10-19|2010-10-20|Estimate|June 2007||2007-06-30|October 2010|2010-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Acupuncture in Palliative Cancer Care|A Feasibility Study in Acupuncture for Symptom Management in Palliative Care.|Completed||Phase 3|20|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-06-01 04:07:17.860792|2018-06-01 04:07:17.860792
NCT00302172|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2009-08-25|2006-03-10|2006-03-14|Estimate|||||||2009-08-25|2009-08-26|Estimate|January 2006||2006-01-31|August 2009|2009-08-31||||||||Interventional|||ARQ 197 in Subjects With Metastatic Solid Tumors|A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Metastatic Solid Tumors|Completed||Phase 1|78|Anticipated|ArQule||1|||f||||f||||||||||2018-06-01 04:07:17.918857|2018-06-01 04:07:17.918857
NCT00302159|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-11|2014-05-22||2016-07-19|2006-03-11|2006-03-13|Estimate|2014-05-22|2014-06-24|Estimate||||2016-07-19|2016-08-18|Estimate|March 2006||2006-03-31|July 2016|2016-07-31|November 2014|Actual|2014-11-30|June 2013|Actual|2013-06-30||Interventional|||Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors|A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial|Completed||Phase 2|43|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||Undecided||2018-06-01 04:07:18.067173|2018-06-01 04:07:18.067173
NCT00302146|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-11|||2018-05-23|2006-03-11|2006-03-13|Estimate|||||||2018-05-23|2018-05-24|Actual|March 10, 2006||2006-03-10|November 24, 2017|2017-11-24||||||||Observational|||Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations|Functional Imaging in Subjects With Glucocerebrosidase Mutations|Completed|||64|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:07:18.399963|2018-06-01 04:07:18.399963
NCT00302133|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2014-10-20||2016-04-16|2006-03-09|2006-03-13|Estimate|2014-11-04|2014-11-05|Estimate||||2016-04-16|2016-05-17|Estimate|May 2006||2006-05-31|April 2016|2016-04-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Optimizing Pharmacotherapy for Bipolar Alcoholics|Optimizing Pharmacotherapy for Bipolar Alcoholics|Completed||Phase 1/Phase 2|88|Actual|University of Miami|High early drop-out rate leading to small number of subjects analyzed.|2|||f||||f||||||||||2018-06-01 04:07:18.461675|2018-06-01 04:07:18.461675
NCT00302120|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2008-06-09|2006-03-10|2006-03-13|Estimate|||||||2008-06-09|2008-06-10|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|March 2010|Anticipated|2010-03-31|March 2009|Anticipated|2009-03-31||Interventional|MONET||The MONET - Study: MR Mammography of Nonpalpable Breast Tumors|MR Mammography: Randomized Controlled Trial to Study Efficiency of MR Mammography in Reducing the Number of Invasive Interventions in Nonpalpable Suspicious Breast Lesions. The MONET - Study|Unknown status|Recruiting|Phase 4|440|Anticipated|UMC Utrecht|||||f||||||||||||||2018-06-01 04:07:18.72644|2018-06-01 04:07:18.72644
NCT00302107|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2014-01-03||2014-11-25|2006-03-09|2006-03-13|Estimate|2014-11-25|2014-11-26|Estimate||||2014-11-25|2014-11-26|Estimate|April 2006||2006-04-30|November 2014|2014-11-30|June 2012|Actual|2012-06-30|May 2011|Actual|2011-05-31||Interventional||Seventy-three (94%) were male; mean age 38.1 +/- 9.5 (SD) years in placebo group and 37.7 +/- 10.3 (SD) in mirtazapine group.|A Placebo-Controlled Study of Mirtazapine for PTSD|A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans|Completed||Phase 4|78|Actual|VA Office of Research and Development|Small sample of predominantly male combat veterans limits generalizability of findings.|2|||f||||t||||||||||2018-06-01 04:07:18.785988|2018-06-01 04:07:18.785988
NCT00302094|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2012-11-29|2006-03-10|2006-03-13|Estimate|||||||2012-11-29|2012-12-03|Estimate|June 2006||2006-06-30|November 2012|2012-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Image Fusion PET, CT and 3D-ultrasound Examinations|Image Fusion PET, CT and 3D-ultrasound Examinations in Treatment of Anal Cancer|Completed|||10|Actual|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:07:18.947738|2018-06-01 04:07:18.947738
NCT00302081|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|2009-04-29||2017-03-08|2006-03-10|2006-03-13|Estimate|2009-06-24|2009-08-11|Estimate||||2017-03-08|2017-04-05|Actual|August 2003||2003-08-31|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)|Comparison of Three Regimens of PEG-Intron and Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients|Completed||Phase 3|696|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:07:19.003626|2018-06-01 04:07:19.003626
NCT00302068|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2012-11-01||2015-06-01|2006-03-09|2006-03-13|Estimate|2012-12-14|2013-01-24|Estimate||||2015-06-01|2015-06-29|Estimate|July 2006||2006-07-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|UPBEAT||Exercise to Treat Depression in Individuals With Coronary Heart Disease|Understanding the Prognostic Benefits of Exercise and Anti-depressant Therapy (UPBEAT)|Completed||Phase 3|101|Actual|Duke University|Relatively small sample size. Participants had to be willing to accept the condition to which they were randomly assigned, and patients who were not interested in exercise or taking an antidepressant were unlikely to have volunteered.|3|||f||||t||||||||||2018-06-01 04:07:20.400628|2018-06-01 04:07:20.400628
NCT00302055|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|2014-12-10||2016-10-06|2006-03-10|2006-03-13|Estimate|2014-12-10|2014-12-18|Estimate||||2016-10-06|2016-12-01|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Feasibility of a Partnered Approach to Prevent Diabetes|Feasibility of a Partnered Approach to Prevent Diabetes|Completed||N/A|72|Actual|Northwestern University||2|||f||||f||||||||No||2018-06-01 04:07:20.781687|2018-06-01 04:07:20.781687
NCT00302042|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|2013-05-23||2017-06-20|2006-03-10|2006-03-13|Estimate|2013-05-23|2013-07-12|Estimate||||2017-06-20|2017-07-18|Actual|May 2005||2005-05-31|August 2014|2014-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Translating the DPP Into the Community|Translating the DPP Into the Community|Completed||N/A|92|Actual|Northwestern University||2|||f||||f||||||||No||2018-06-01 04:07:21.069987|2018-06-01 04:07:21.069987
NCT00302029|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2011-11-10|2006-03-09|2006-03-13|Estimate|||||||2011-11-10|2011-11-11|Estimate|June 2006||2006-06-30|November 2009|2009-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||CMV Infection in Adolescent Males|Seroprevalence and Prospective Risk Factor Analysis of Cytomegalovirus (CMV) Infection in Adolescent Males|Terminated|||411|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Blood, urine and salvia samples.~   "|||2018-06-01 04:07:21.304623|2018-06-01 04:07:21.304623
NCT00302016|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2011-08-25|2006-03-09|2006-03-13|Estimate|||||||2011-08-25|2011-08-26|Estimate|January 2006||2006-01-31|August 2011|2011-08-31||||November 2008|Actual|2008-11-30||Expanded Access|||Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia|An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.|No longer available|||||Novartis|||||||||||||||||||2018-06-01 04:07:21.438447|2018-06-01 04:07:21.438447
NCT00302003|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2016-06-29||2016-12-16|2006-03-09|2006-03-13|Estimate|2016-12-16|2017-02-09|Estimate||||2016-12-16|2017-02-09|Estimate|February 2006||2006-02-28|August 2016|2016-08-31||||March 2012|Actual|2012-03-31||Interventional|||Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma|A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease|Active, not recruiting||Phase 3|287|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 04:07:22.059783|2018-06-01 04:07:22.059783
NCT00301990|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2014-01-09|2006-03-10|2006-03-13|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2005||2005-09-30|April 2007|2007-04-30||||||||Interventional|||Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study|Unknown status|Recruiting|Phase 2|65|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:07:22.425551|2018-06-01 04:07:22.425551
NCT00301964|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2014-11-19||2018-01-10|2006-03-09|2006-03-13|Estimate|2014-11-19|2014-11-26|Estimate||||2018-01-10|2018-02-06|Actual|March 2006||2006-03-31|January 2018|2018-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Total number of eligible and evaluable participants|Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC# 704865, IND # 7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:07:22.565241|2018-06-01 04:07:22.565241
NCT00301951|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2017-10-10|2006-03-09|2006-03-13|Estimate|||||||2017-10-10|2017-10-12|Actual|September 2004||2004-09-30|October 2017|2017-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer|Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients With Advanced Hematopoietic Malignancies|Completed||Phase 1|7|Actual|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-06-01 04:07:23.139623|2018-06-01 04:07:23.139623
NCT00301938|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-09-27|2006-03-09|2006-03-13|Estimate|||||||2013-09-27|2013-09-30|Estimate|December 2005||2005-12-31|September 2013|2013-09-30||||May 2012|Actual|2012-05-31||Interventional|||7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes|A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:07:23.227217|2018-06-01 04:07:23.227217
NCT00301925|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2010-11-25|2006-03-09|2006-03-13|Estimate|||||||2010-11-25|2010-11-29|Estimate|December 2005||2005-12-31|July 2009|2009-07-31||||September 2024|Anticipated|2024-09-30||Interventional|||Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery|Trial of Accelerated Adjuvant Chemotherapy With Capecitabine in Early Breast Cancer (TACT2)|Active, not recruiting||Phase 3|4400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:07:23.404565|2018-06-01 04:07:23.404565
NCT00301912|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2012-10-01|2006-03-09|2006-03-13|Estimate|||||||2012-10-01|2012-10-02|Estimate|January 2002||2002-01-31|October 2012|2012-10-31||||November 2007|Actual|2007-11-30||Interventional|||Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation|Withdrawn||Phase 2|0|Actual|University of California, San Francisco||||Withdrawn because study never opened to accrual|f||||||||||||||2018-06-01 04:07:23.652602|2018-06-01 04:07:23.652602
NCT00301899|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2012-03-07|2006-03-09|2006-03-13|Estimate|||||||2012-03-07|2012-03-08|Estimate|December 2005||2005-12-31|March 2012|2012-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab|A Phase II Study to Evaluate the Efficacy and Safety Using Combined Monoclonal Antibodies, Trastuzumab and Pertuzumab in Subjects With Her-2 Overexpressed Locally Advanced and Metastatic Breast Cancer|Completed||Phase 2|37|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 04:07:23.762607|2018-06-01 04:07:23.762607
NCT00301886|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-11-11|2006-03-09|2006-03-13|Estimate|||||||2013-11-11|2013-11-13|Estimate|May 2006||2006-05-31|November 2013|2013-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone|A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer|Withdrawn||Phase 3|0|Actual|Southwest Oncology Group||2||withdrawn support for study|f||||t||||||||||2018-06-01 04:07:23.837056|2018-06-01 04:07:23.837056
NCT00301873|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2012-10-15||2013-02-13|2006-03-09|2006-03-13|Estimate|2012-12-10|2013-01-16|Estimate||||2013-02-13|2013-02-18|Estimate|May 2006||2006-05-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|February 2011|Actual|2011-02-28||Interventional|||Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma|Phase II Study of Zometa (Zoledronic Acid) to Prevent Osteoporosis in Patients With Brain Tumors|Completed||Phase 2|60|Actual|Duke University|Limitations include early pt termination leading to small numbers of subjects analyzed (eg no BMD study at 6 and/or 12 mos)secondary to the poor overall survival (eg median survival 3-9 mos)associated with recurrent glioblastoma multiforme(GBM) pts.|1|||f||||t||||||||||2018-06-01 04:07:23.929537|2018-06-01 04:07:23.929537
NCT00301860|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-07-11|2006-03-09|2006-03-13|Estimate|||||||2013-07-11|2013-07-15|Estimate|January 2003||2003-01-31|July 2013|2013-07-31|November 2007|Actual|2007-11-30|March 2007|Actual|2007-03-31||Interventional|||Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer|Feasibility of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions for Children at High Risk for Complications With Conventional Transplantation|Terminated||N/A|8|Actual|University of California, San Francisco||||lack of efficacy|f||||t||||||||||2018-06-01 04:07:24.207426|2018-06-01 04:07:24.207426
NCT00301847|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-02-08|2006-03-09|2006-03-13|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 2005||2005-11-30|April 2006|2006-04-30||||June 2007|Actual|2007-06-30||Interventional|||Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain|A Phase 2 Study of Sorafenib (BAY 43-9006) in Metastatic Renal Cell Cancer to the Brain|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||||||||||||||||2018-06-01 04:07:24.276716|2018-06-01 04:07:24.276716
NCT00301834|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2013-01-31||2017-08-30|2006-03-09|2006-03-13|Estimate|2013-04-22|2013-05-16|Estimate||||2017-08-30|2017-09-28|Actual|January 2005||2005-01-31|August 2017|2017-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Thirty-five children undergoing allogeneic hemotopoietic stem cell transplants (HSCTs) for malignant and nonmalignant diseases; 12 with HLA-matched related donors (MRDs), 16 with 10 of 10 HLA allele-matched unrelated donors (MUDs), 7 with 9 of 10 allele MUDs.|Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders|Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia|Completed||Phase 2|35|Actual|University of California, San Francisco||1|||f||||||||||||||2018-06-01 04:07:24.458665|2018-06-01 04:07:24.458665
NCT00301821|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2015-03-13||2016-07-01|2006-03-09|2006-03-13|Estimate|2015-03-13|2015-03-24|Estimate||||2016-07-01|2016-08-01|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|October 2008|Actual|2008-10-31||Interventional|||Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|A Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients With Previously Untreated Diffuse Large B-Cell Lymphoma|Completed||Phase 2|107|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 04:07:24.731021|2018-06-01 04:07:24.731021
NCT00301808|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2014-04-12||2017-11-15|2006-03-09|2006-03-13|Estimate|2014-04-12|2014-05-13|Estimate||||2017-11-15|2017-12-14|Actual|November 2005||2005-11-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer|Phase II Study of Concurrent Cisplatin/Pemetrexed and RT Followed by Docetaxel in Stage III NSCLC (Non Small Cell Lung Cancer)|Completed||Phase 2|29|Actual|Barbara Ann Karmanos Cancer Institute|Study being a single institution, single arm study.|1|||f||||t||||||||||2018-06-01 04:07:25.387019|2018-06-01 04:07:25.387019
NCT00301795|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-01-04|2006-03-09|2006-03-13|Estimate|||||||2013-01-04|2013-01-07|Estimate|March 2006||2006-03-31|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma|A Phase II Trial of Rituximab + Oblimersen Sodium (GenasenseTM, G3139, NSC #683428, IND #58842) in Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)|Terminated||Phase 2|52|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:07:25.643431|2018-06-01 04:07:25.643431
NCT00301782|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-08-23|2006-03-09|2006-03-13|Estimate|||||||2013-08-23|2013-08-26|Estimate|June 2005||2005-06-30|May 2007|2007-05-31|June 2010|Actual|2010-06-30|||||Interventional|||Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors|Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP Chemotherapy in Poor Prognosis Male Germ Cell Tumors|Completed||Phase 2|88|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:07:25.732436|2018-06-01 04:07:25.732436
NCT00301769|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-09-27|2006-03-09|2006-03-13|Estimate|||||||2013-09-27|2013-09-30|Estimate|December 2005||2005-12-31|September 2013|2013-09-30||||February 2009|Actual|2009-02-28||Interventional|||SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia|A Phase I Study of SJG-136 in Patients With Advanced Leukemia|Terminated||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:07:25.838829|2018-06-01 04:07:25.838829
NCT00301756|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2015-04-01||2016-10-20|2006-03-09|2006-03-13|Estimate|2016-10-20|2016-12-14|Estimate||||2016-10-20|2016-12-14|Estimate|September 2006||2006-09-30|October 2016|2016-10-31|December 2012|Actual|2012-12-31|August 2009|Actual|2009-08-31||Interventional|||Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors|A Phase 2 Study of PXD101 in Platinum Resistant Epithelial Ovarian Tumors and Micropapillary/Borderline (LMP) Ovarian Tumors|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:07:25.919098|2018-06-01 04:07:25.919098
NCT00301730|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2015-04-27|2006-03-09|2006-03-13|Estimate|||||||2015-04-27|2015-04-28|Estimate|October 2005||2005-10-31|April 2006|2006-04-30||||||||Interventional|||Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung|Adoptive Immunotherapy With Costimulated Tumor-Derived T Cells After Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 1|1|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:07:26.10107|2018-06-01 04:07:26.10107
NCT00301691|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-07-09|2006-03-09|2006-03-13|Estimate|||||||2013-07-09|2013-07-10|Estimate|September 2000||2000-09-30|May 2006|2006-05-31|May 2006|Actual|2006-05-31|||||Interventional|||Nutrition Education for Low-Income Healthy Participants Who Eat an Unhealthy Diet|Tailoring Nutrition Education for Low-Income Audiences|Completed||N/A|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:07:26.154256|2018-06-01 04:07:26.154256
NCT00301678|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-09-16|2006-03-09|2006-03-13|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2001||2001-06-30|May 2007|2007-05-31||||||||Interventional|||Personalized Nutrition Education in Improving Eating Habits of Healthy Participants Who Eat an Unhealthy Diet|Innovative Video Tailoring for Dietary Change|Unknown status|Active, not recruiting|N/A|2520|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:07:26.202394|2018-06-01 04:07:26.202394
NCT00301665|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2007-09-12|2006-03-09|2006-03-13|Estimate|||||||2007-09-12|2007-09-14|Estimate|February 2003||2003-02-28|September 2007|2007-09-30|March 2005|Actual|2005-03-31|||||Interventional|||Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis|A Phase II, Multicentre, Randomised, Double-Blind, Parallel Groups, Placebo Controlled Clinical Study of Efficacy and Safety of Dysport® for Migraine Prophylaxis|Completed||Phase 2|120||Ipsen|||||f||||||||||||||2018-06-01 04:07:26.342927|2018-06-01 04:07:26.342927
NCT00301652|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2010-06-07|2006-03-10|2006-03-13|Estimate|||||||2010-06-07|2010-06-08|Estimate|June 2003||2003-06-30|March 2009|2009-03-31|December 2005|Actual|2005-12-31|April 2004|Actual|2004-04-30||Interventional|||MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis|Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Treatment of ANCA Associated Vasculitis|Completed||N/A|60|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 04:07:26.424417|2018-06-01 04:07:26.424417
NCT00301639|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2011-07-11|2006-03-10|2006-03-13|Estimate|||||||2011-07-11|2011-07-12|Estimate|March 2005||2005-03-31|July 2011|2011-07-31|December 2005||2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults|A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults|Completed||Phase 3|40||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:07:26.495263|2018-06-01 04:07:26.495263
NCT00301626|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2008-10-23|2006-03-10|2006-03-13|Estimate|||||||2008-10-23|2008-10-24|Estimate|October 2000||2000-10-31|April 2005|2005-04-30|January 2005||2005-01-31|||||Interventional|||ROSCAP: Reduction of Smoking in Cardiac Patients Study||Completed||N/A|180||Minneapolis Veterans Affairs Medical Center|||||||||||||||||||2018-06-01 04:07:26.549191|2018-06-01 04:07:26.549191
NCT00301613|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2010-05-25|2006-03-10|2006-03-13|Estimate|||||||2010-05-25|2010-05-27|Estimate|January 2003||2003-01-31|July 2008|2008-07-31|January 2006|Actual|2006-01-31|May 2005|Actual|2005-05-31||Interventional|||Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN|MMF Versus Intravenous CTX Pulses in the Treatment of Adult Severe Henoch-Schonlein Purpura Nephritis|Completed||N/A|60|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 04:07:26.670726|2018-06-01 04:07:26.670726
NCT00301600|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2010-05-25|2006-03-10|2006-03-13|Estimate|||||||2010-05-25|2010-05-27|Estimate|January 2003||2003-01-31|July 2008|2008-07-31|January 2006|Actual|2006-01-31|May 2005|Actual|2005-05-31||Interventional|||Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy|Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy|Completed||N/A|40|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 04:07:26.7395|2018-06-01 04:07:26.7395
NCT00301587|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2016-09-19|2006-03-10|2006-03-13|Estimate|||||||2016-09-19|2016-09-20|Estimate||||July 2011|2011-07-31|December 2004|Anticipated|2004-12-31|||||Interventional|||A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives|A Randomized, Double-Blind, Two-Part, Parallel-Group, Comparative Study to Evaluate Blood Folate Levels in Women Taking an Oral Contraceptive With and Without Folic Acid|Withdrawn||Phase 3|0|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"Company decision to not fund further development of women's health new drug development~   programs."|||||f||||||||||2018-06-01 04:07:26.80782|2018-06-01 04:07:26.80782
NCT00301574|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2011-05-16|2006-03-10|2006-03-13|Estimate|||||||2011-05-16|2011-05-17|Estimate|April 2001||2001-04-30|January 2011|2011-01-31|February 2004|Actual|2004-02-29|||||Interventional|||An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.|Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.|Completed||Phase 3|398|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 04:07:26.870035|2018-06-01 04:07:26.870035
NCT00301561|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2016-07-20|2006-03-10|2006-03-13|Estimate|||||||2016-07-20|2016-07-22|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|October 2010|Actual|2010-10-31|April 2010|Actual|2010-04-30||Interventional|||Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL)|Expanded Access to Antiretroviral Therapy in Africa: Assessment of the Patients' Management in District Hospitals With a Simplified Follow-up Approach (ANRS 12110 STRATALL)|Completed||Phase 3|459|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 04:07:26.932093|2018-06-01 04:07:26.932093
NCT00301548|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2006-03-09|2006-03-09|2006-03-13|Estimate|||||||2006-03-09|2006-03-13|Estimate|February 2000||2000-02-29|January 2006|2006-01-31|June 2005||2005-06-30|||||Interventional|||Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer|Primary Chemotherapy Combined With Perioperative Chemotherapy In Operable Breast Cancer|Completed||Phase 2|172||European Institute of Oncology|||||f||||||||||||||2018-06-01 04:07:27.0151|2018-06-01 04:07:27.0151
NCT00301535|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2008-05-15|2006-03-10|2006-03-13|Estimate|||||||2008-05-15|2008-05-16|Estimate|February 2006||2006-02-28|May 2008|2008-05-31|September 2008|Anticipated|2008-09-30|July 2008|Anticipated|2008-07-31||Interventional|||A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery|Enhancement of Tissue Preservation During Cardiopulmonary Bypass With HBOC-201 (Registry Study)|Unknown status|Recruiting|Phase 2|60|Anticipated|Biopure Corporation||2|||f||||t||||||||||2018-06-01 04:07:27.069263|2018-06-01 04:07:27.069263
NCT00301522|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2010-08-05|2006-03-09|2006-03-13|Estimate|||||||2010-08-05|2010-08-06|Estimate|February 2003||2003-02-28|August 2010|2010-08-31|April 2009|Actual|2009-04-30|December 2004|Actual|2004-12-31||Interventional|||Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions|TAXUS V: De Novo Lesion: A Randomized, Double-blind Trial to Assess TAXUS Paclitaxel-Eluting Coronary Stents, SR Formulation, in the Treatment of De Novo Coronary Lesions|Completed||Phase 2/Phase 3|1108|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-06-01 04:07:27.168479|2018-06-01 04:07:27.168479
NCT00301509|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2006-03-10|2006-03-10|2006-03-13|Estimate|||||||2006-03-10|2006-03-13|Estimate|January 2002||2002-01-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis|Outcome of Decompensated Hepatitis C Virus-Related Cirrhotic Patients Treated With Peginterferon Alfa-2b and Ribavirin: Results of a Controlled Study|Completed||Phase 2/Phase 3|||Casa Sollievo della Sofferenza IRCCS|||||f||||||||||||||2018-06-01 04:07:27.33555|2018-06-01 04:07:27.33555
NCT00301496|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2007-10-10|2006-03-10|2006-03-13|Estimate|||||||2007-10-10|2007-10-11|Estimate|March 2006||2006-03-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Randomized Controlled 8-Week Crossover Evaluation of Compression Bandage Systems for Venous Leg Ulcers|Randomized Controlled Eight Week Cross-Over Clinical Evaluation of the 3M Coban 2-Layer Compression System to Evaluate the Product Performance in Patients With Venous Leg Ulcers|Completed||N/A|80||3M|||||f||||||||||||||2018-06-01 04:07:27.408309|2018-06-01 04:07:27.408309
NCT00301483|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2008-03-05|2006-03-10|2006-03-13|Estimate|||||||2008-03-05|2008-03-06|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|December 2008|Anticipated|2008-12-31|September 2008|Anticipated|2008-09-30||Interventional|||A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects|A Single-Center, Study to Evaluate the Safety and Tolerability of Hemoglobin-Based Oxygen Carrier-201 (HBOC 201) in Trauma Subjects. (Phase II - Safety and Tolerability)|Unknown status|Recruiting|Phase 2|53|Anticipated|Biopure Corporation||2|||f||||t||||||||||2018-06-01 04:07:27.475924|2018-06-01 04:07:27.475924
NCT00301470|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-10|||2011-07-21|2006-03-10|2006-03-13|Estimate|||||||2011-07-21|2011-07-22|Estimate|March 2006||2006-03-31|October 2006|2006-10-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Functional MR Urography|Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults|Completed||Phase 4|550|Actual|Central Hospital, Nancy, France|||||f||||f||||||||||2018-06-01 04:07:27.554777|2018-06-01 04:07:27.554777
NCT00301457|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2017-08-22|2006-03-09|2006-03-13|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2006||2006-06-30|July 2017|2017-07-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|DATA||Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer|A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.|Active, not recruiting||Phase 3|1914|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-06-01 04:07:27.642953|2018-06-01 04:07:27.642953
NCT00301444|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2007-06-13|2006-03-09|2006-03-10|Estimate|||||||2007-06-13|2007-06-14|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|June 2008|Anticipated|2008-06-30|||||Interventional|||A Study to Test the Effectiveness of Mirror-Box and Mental Visualization Treatments on Phantom Limb Pain|A Pilot Study to Assess the Efficacy of Mirror-Box and Mental Visualization Treatments on Phantom Limb Pain|Unknown status|Recruiting|N/A|48|Anticipated|Walter Reed Army Medical Center|||||f||||f||||||||||2018-06-01 04:07:27.802937|2018-06-01 04:07:27.802937
NCT00301431|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2007-12-03|2006-03-09|2006-03-10|Estimate|||||||2007-12-03|2007-12-05|Estimate|August 2006||2006-08-31|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Study Evaluating the Efficacy of DVS-233 in Fibromyalgia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design, Efficacy and Tolerability Study of 4 Fixed Doses of DVS-233 in Adult Outpatients With Fibromyalgia Syndrome|Terminated||Phase 2/Phase 3|1050||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:07:27.903214|2018-06-01 04:07:27.903214
NCT00301418|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|2016-01-12||2016-01-12|2006-03-09|2006-03-10|Estimate|2016-01-12|2016-02-10|Estimate||||2016-01-12|2016-02-10|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma|Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma|Completed||Phase 1/Phase 2|11|Actual|Northwell Health||1|||f||||f||||||||||2018-06-01 04:07:28.152658|2018-06-01 04:07:28.152658
NCT00301405|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2013-08-01|2006-03-09|2006-03-10|Estimate|||||||2013-08-01|2013-08-05|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain|Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain|Terminated||Phase 2|9|Actual|William Beaumont Hospitals||1||Study closed. Difficult enrollment of patients with prostatitis.|f||||f||||||||||2018-06-01 04:07:28.287623|2018-06-01 04:07:28.287623
NCT00301392|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-05|||2013-09-05|2006-03-09|2006-03-10|Estimate|||||||2013-09-05|2013-09-06|Estimate|April 2006||2006-04-30|September 2013|2013-09-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)|Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)|Completed||Phase 4|1240|Actual|Tokyo University||1|||f||||f||||||||||2018-06-01 04:07:28.353073|2018-06-01 04:07:28.353073
NCT00301379|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2018-03-22|2006-03-08|2006-03-10|Estimate|||||||2018-03-22|2018-03-26|Estimate|August 2005||2005-08-31|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients|Prospective Registry Study of Neoadjuvant Chemoradiation in Conjunction With Liver Transplantation for Cholangiocarcinoma With Induction Gemcitabine, Followed by 3D Conformal Radiation With 5-FU as a Radiosensitizer, and Maintenance Xeloda Therapy Until Liver Transplantation|Recruiting|||30|Anticipated|Washington University School of Medicine|||1||f||||f|f|f||||||No||2018-06-01 04:07:28.437308|2018-06-01 04:07:28.437308
NCT00301366|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|2009-08-28||2014-07-30|2006-03-08|2006-03-10|Estimate|2014-07-30|2014-08-19|Estimate||||2014-07-30|2014-08-19|Estimate|June 2006||2006-06-30|July 2014|2014-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|STAMP||The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency|Multi-center, Open-label Trial to Evaluate the Safety and Tolerability of Alpha-1 MP in Subjects With Alpha-1-antitrypsin (AAT) Deficiency|Completed||Phase 3|38|Actual|Grifols Therapeutics LLC||1|||f||||f||||||||||2018-06-01 04:07:28.534679|2018-06-01 04:07:28.534679
NCT00301353|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2015-05-20|2006-03-08|2006-03-10|Estimate|||||||2015-05-20|2015-05-21|Estimate|October 2002||2002-10-31|October 2002|2002-10-31|July 2004||2004-07-31|||||Interventional|||Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women|Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women|Completed||N/A|300||TNO|||||f||||||||||||||2018-06-01 04:07:28.82757|2018-06-01 04:07:28.82757
NCT00301340|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2007-05-25|2006-03-08|2006-03-10|Estimate|||||||2007-05-25|2007-05-30|Estimate|March 2006||2006-03-31|May 2007|2007-05-31||||||||Interventional|||Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice|An Open Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice|Completed||Phase 3|200||Summers Laboratories|||||||||||||||||||2018-06-01 04:07:28.904111|2018-06-01 04:07:28.904111
NCT00301327|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2007-05-25|2006-03-08|2006-03-10|Estimate|||||||2007-05-25|2007-05-30|Estimate|January 2006||2006-01-31|May 2007|2007-05-31||||||||Interventional|||Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice.|A Multi-Center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice.|Completed||Phase 3|120||Summers Laboratories|||||||||||||||||||2018-06-01 04:07:28.983615|2018-06-01 04:07:28.983615
NCT00301314|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2010-01-11|2006-03-09|2006-03-10|Estimate|||||||2010-01-11|2010-01-12|Estimate||||January 2010|2010-01-31||||||||Observational|||A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).||Completed|||||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:07:29.061818|2018-06-01 04:07:29.061818
NCT00301301|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2010-01-11|2006-03-09|2006-03-10|Estimate|||||||2010-01-11|2010-01-12|Estimate||||January 2010|2010-01-31||||||||Observational|||A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)||Completed|||39||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:07:29.115806|2018-06-01 04:07:29.115806
NCT00301288|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2010-01-11|2006-03-09|2006-03-10|Estimate|||||||2010-01-11|2010-01-12|Estimate||||January 2010|2010-01-31||||||||Observational|||A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL).||Completed|||152||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:07:29.180805|2018-06-01 04:07:29.180805
NCT00301275|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-03-09|2006-03-09|2006-03-10|Estimate|||||||2006-03-09|2006-03-10|Estimate|June 2002||2002-06-30|March 2006|2006-03-31|December 2005||2005-12-31|||||Observational|||Assessing Free Immunoglobulin Light Chains in Patients With Myeloma||Completed|||||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:07:29.237285|2018-06-01 04:07:29.237285
NCT00301262|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2008-11-12||2017-03-07|2006-03-09|2006-03-10|Estimate|2008-12-08|2008-12-09|Estimate||||2017-03-07|2017-04-05|Actual|November 2005||2005-11-30|March 2017|2017-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied|A Multi-Center, Parallel Group, Flexible Dose Trial With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Assess The Impact Of Viagra On The Sexual Satisfaction Of Men With Mild Erectile Dysfunction|Completed||Phase 4|183|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:07:29.401247|2018-06-01 04:07:29.401247
NCT00301249|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2010-01-12|2006-03-09|2006-03-10|Estimate|||||||2010-01-12|2010-01-14|Estimate|October 1999||1999-10-31|January 2010|2010-01-31|November 2005||2005-11-30|||||Observational|||Linkage Consortium for End-Stage Renal Disease|The Family Investigation of Nephropathy and Diabetes (FIND) Study|Completed|||7000||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:07:30.774047|2018-06-01 04:07:30.774047
NCT00301236|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2007-12-17|2006-03-09|2006-03-10|Estimate|||||||2007-12-17|2007-12-21|Estimate|February 2006||2006-02-28|December 2007|2007-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder|A 5-Week Treatment, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of the Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules Administered Once Daily in Pediatric Children With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|252||Novartis|||||||||||||||||||2018-06-01 04:07:30.837914|2018-06-01 04:07:30.837914
NCT00301223|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2011-05-04|2006-03-09|2006-03-10|Estimate|||||||2011-05-04|2011-05-05|Estimate|February 2006||2006-02-28|May 2011|2011-05-31|September 2007|Actual|2007-09-30|||||Interventional|||A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain|An 8-Week Multi-Center, Randomized, Double Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150mg-600mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Symptoms Of Neuropathic Pain|Completed||Phase 3|309|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:07:30.917691|2018-06-01 04:07:30.917691
NCT00301210|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2015-04-16|2006-03-09|2006-03-10|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Assessment of Tramadol as a Treatment for Opioid Addiction|Assessment of the Level of Physical Dependence and Blockade Efficacy Produced by Tramadol|Completed||Phase 1/Phase 2|9|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 04:07:30.986097|2018-06-01 04:07:30.986097
NCT00301197|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-03-08|2006-03-08|2006-03-10|Estimate|||||||2006-03-08|2006-03-10|Estimate|August 1999||1999-08-31|March 2006|2006-03-31|April 2004||2004-04-30|||||Interventional|||Childhood Obesity Treatment: A Maintenance Approach|Childhood Obesity Treatment: A Maintenance Approach|Completed||N/A|216||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:07:31.06492|2018-06-01 04:07:31.06492
NCT00301184|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2013-05-30|2006-03-08|2006-03-10|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|December 2008|Actual|2008-12-31|||||Interventional|||Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of pGA2/JS7 DNA Vaccine and Recombinant Modified Vaccinia Ankara/HIV62 Vaccine in Healthy, HIV-1-Uninfected Adult Participants|Completed||Phase 1|120|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:07:31.122727|2018-06-01 04:07:31.122727
NCT00301171|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2016-07-28|2006-03-09|2006-03-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Treatment of Persistent Wheezing in Infants and Children|Respiratory Function in Infants With Persistent Wheezing|Completed||N/A|54|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:07:31.226882|2018-06-01 04:07:31.226882
NCT00301158|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2013-09-16|2006-03-08|2006-03-10|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2004||2004-09-30|June 2009|2009-06-30||||August 2008|Anticipated|2008-08-31||Interventional|||Promoting Physical Activity In After-School Programs for Urban Adolescents|Involving Adolescents in Physical Activity Promotion|Unknown status|Recruiting|N/A|420|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:07:32.322214|2018-06-01 04:07:32.322214
NCT00301145|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2013-12-18|2006-03-08|2006-03-10|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 2005||2005-10-31|September 2007|2007-09-30|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking|Treatment of Nicotine Dependence in a Health Care Setting|Completed||N/A|1200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:07:32.396066|2018-06-01 04:07:32.396066
NCT00301119|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2017-10-12|2006-03-08|2006-03-10|Estimate|||||||2017-10-12|2017-10-13|Actual|May 2000||2000-05-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|NYULCBC||Lung Cancer Biomarkers and Screening|NYU Lung Cancer Biomarker Center|Recruiting|||6860|Anticipated|New York University School of Medicine|||2||f||||t|f|f||||Samples With DNA|"~     blood serum, plasma, urine, sputum, BAL, lung tissue, buccal swab~   "|||2018-06-01 04:07:32.470817|2018-06-01 04:07:32.470817
NCT00301106|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2017-01-31|2006-03-08|2006-03-10|Estimate|||||||2017-01-31|2017-02-02|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver|Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patients With Metastatic Breast Cancer to the Liver|Terminated||Phase 1|2|Actual|Icahn School of Medicine at Mount Sinai||1||"protocol underwent significant revisions, decision made to terminate study and open as new~   study listed NCT00849459"|f||||t||||||||||2018-06-01 04:07:32.542344|2018-06-01 04:07:32.542344
NCT00301093|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2018-01-30|2006-03-08|2006-03-10|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2005||2005-09-30|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|May 2007|Actual|2007-05-31||Interventional|||Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate|Active, not recruiting||Phase 1|30|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:07:32.627087|2018-06-01 04:07:32.627087
NCT00301080|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|2013-11-25||2013-11-25|2006-03-08|2006-03-10|Estimate|2013-11-25|2013-12-02|Estimate||||2013-11-25|2013-12-02|Estimate|February 2006||2006-02-28|November 2013|2013-11-30|May 2008|Actual|2008-05-31|February 2007|Actual|2007-02-28||Interventional|||D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain|A Phase III Study of D-Cycloserine in the Management of Paclitaxel-Induced Peripheral Neuropathic Pain in Breast Cancer Patients|Terminated||Phase 3|7|Actual|Northwestern University|Early termination resulted from a change in funding source (which ultimately fell through) along with drug manufacturing delays. Data could not be analyzed based on only 7 patients, all of whom were enrolled under the original design version.|5||Funding for the study fell through.|f||||t||||||||||2018-06-01 04:07:32.712905|2018-06-01 04:07:32.712905
NCT00301067|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2017-12-19|2006-03-08|2006-03-10|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2005||2005-05-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma|A Phase I/II Study of High-Dose Calcitriol in Combination With Temozolomide for Patients With Metastatic Melanoma|Active, not recruiting||Phase 1/Phase 2|28|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 04:07:33.081927|2018-06-01 04:07:33.081927
NCT00301054|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2006-05-26|2006-03-09|2006-03-10|Estimate|||||||2006-05-26|2006-05-29|Estimate|June 2005||2005-06-30|July 2005|2005-07-31|April 2006||2006-04-30|||||Interventional|||Study on Preventing Anemia in Children in Ghana|Preventing Anemia in Children (6months-30months) in a Malaria Endemic Rural Area in Ghana - A Randomized Double Blind Study|Completed||N/A|872||Ghana Health Services|||||f||||||||||||||2018-06-01 04:07:33.17414|2018-06-01 04:07:33.17414
NCT00301041|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2013-08-19|2006-03-08|2006-03-10|Estimate|||||||2013-08-19|2013-08-21|Estimate|April 2004||2004-04-30|August 2013|2013-08-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Radiation Therapy in Treating Women With Invasive Breast Cancer|The Relationship Between Plasma Transforming Growth Factor-beta 1 (TGF-β) and Fractionation in Radiotherapy for Breast Cancer: A Randomized Study|Completed||Early Phase 1|20|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:07:33.252721|2018-06-01 04:07:33.252721
NCT00301028|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|2013-02-26||2013-02-26|2006-03-08|2006-03-10|Estimate|2013-02-26|2013-04-05|Estimate||||2013-02-26|2013-04-05|Estimate|April 2006||2006-04-30|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer|Phase II Trial of Induction Therapy With Cetuximab (C225) and Carboplatin/Paclitaxel Chemotherapy in Previously Untreated Patients With Advanced (Stage IV) Head & Neck Squamous Cell Carcinoma|Completed||Phase 2|48|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:07:33.338049|2018-06-01 04:07:33.338049
NCT00301015|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2007-10-31|2006-03-08|2006-03-10|Estimate|||||||2007-10-31|2007-11-01|Estimate|March 2006||2006-03-31|October 2007|2007-10-31|August 2006|Actual|2006-08-31|||||Interventional|||Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers|Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers|Completed||Phase 4|3005|Actual|Karolinska University Hospital||2|||f||||||||||||||2018-06-01 04:07:33.540457|2018-06-01 04:07:33.540457
NCT00301002|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-11-21|2006-03-08|2006-03-10|Estimate|||||||2006-11-21|2006-11-23|Estimate|June 2005||2005-06-30|November 2006|2006-11-30|October 2006||2006-10-31|||||Interventional|||Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis|A Pilot Open-Label Study to Evaluate the Safety and Observe the Effectiveness of 16 Weeks of Alefacept in Palmar Plantar Pustulosis (IST 92)|Completed||Phase 2|15||The Guenther Dermatology Research Centre|||||f||||||||||||||2018-06-01 04:07:33.612139|2018-06-01 04:07:33.612139
NCT00300989|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2007-10-04|2006-03-09|2006-03-10|Estimate|||||||2007-10-04|2007-10-05|Estimate|December 2005||2005-12-31|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Inion OTPS Biodegradable Fixation System for the Ankle|A Double-Blind,Randomised,Prospective Clinical Investigation to Compare Post-Operative Fracture Healing Using the Inion OTPS Biodegradable Fixation System Versus Conventional Metal Screws and Plates in the Treatment of Ankle Fractures.|Completed||Phase 2|43|Actual|Inion Oy|||||f||||||||||||||2018-06-01 04:07:33.673766|2018-06-01 04:07:33.673766
NCT00300976|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2017-08-02|2006-03-09|2006-03-10|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2006|Actual|2006-05-31|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|March 2016|Actual|2016-03-31||Interventional|J-DOIT3||The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases|(Intervention Study) A Randomized Controlled Study of the Intensive Therapy and the Conventional Therapy for the Suppression of the Vascular Complications in the Type 2 Diabetic Patients (Follow-up Study) A Randomized Controlled Study Comparing Intensive Therapy and Conventional Therapy in the Reduction of Vascular Complications in Type 2 Diabetic Patients: A Follow-up Study After Intervention|Active, not recruiting||N/A|2542|Actual|Japan Foundation for the Promotion of International Medical Research Cooperation||2|||f||||t||||||||||2018-06-01 04:07:33.746218|2018-06-01 04:07:33.746218
NCT00300963|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2013-02-13|2006-03-07|2006-03-10|Estimate|||||||2013-02-13|2013-02-15|Estimate|December 2004||2004-12-31|February 2013|2013-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients|A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia|Completed||Phase 2|275||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:07:33.823776|2018-06-01 04:07:33.823776
NCT00300950|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2015-04-02|2006-03-08|2006-03-10|Estimate|||||||2015-04-02|2015-04-06|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer|A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With a Gemcitabine Regimen Versus a Gemcitabine Regimen With Placebo, in Patients With Post-resection R0/R1 Pancreatic Cancer With Tumor Sequence Confirmation of Ras Mutations.|Completed||Phase 2|176|Actual|GlobeImmune||2|||f||||||||||||||2018-06-01 04:07:33.914634|2018-06-01 04:07:33.914634
NCT00300937|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2007-11-21|2006-03-08|2006-03-10|Estimate|||||||2007-11-21|2007-11-26|Estimate|July 2004||2004-07-31|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Coenzyme Q10 Supplementation and Development of Preeclampsia|Coenzyme Q10 Supplementation in Pregnant Women as Strategy to Reduce Maternal Morbidity Due to Preeclampsia|Completed||Phase 3|235|Actual|Teran, Enrique, MD, PhD||1|||f||||f||||||||||2018-06-01 04:07:34.106962|2018-06-01 04:07:34.106962
NCT00300924|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2008-05-27|2006-03-09|2006-03-10|Estimate|||||||2008-05-27|2008-05-28|Estimate|March 2006||2006-03-31|May 2008|2008-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine|A Double-Blind, Double-Dummy, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10mg Co-Administered With Acetaminophen for the Treatment of Acute Migraine.|Completed||Phase 3|200||Diamond Headache Clinic|||||f||||t||||||||||2018-06-01 04:07:34.180165|2018-06-01 04:07:34.180165
NCT00300911|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-09|||2006-03-09|2006-03-09|2006-03-10|Estimate|||||||2006-03-09|2006-03-10|Estimate|December 2005||2005-12-31|November 2005|2005-11-30||||||||Interventional|||Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction|A Study of PPAR-Gamma Agonist-Rosiglitazone for Determining Cardiac Adverse Effects in Type 2 Diabetic Patients|Completed||Phase 4|45||Baskent University|||||f||||||||||||||2018-06-01 04:07:34.256481|2018-06-01 04:07:34.256481
NCT00300898|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2017-03-14|2006-03-08|2006-03-10|Estimate|||||||2017-03-14|2017-03-16|Actual|July 2006|Actual|2006-07-31|March 2017|2017-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Radiofrequency Nucleoplasty vs Percutaneous Nucleotomy vs Decompression Catheter in Lumbar Disc Herniation|Radiofrequency Nucleoplasty vs Percutaneous Nucleotomy (Dekompressor) vs Decompression Catheter for the Treatment of Painful Contained Lumbar Disc Herniation: A Prospective Randomized Controlled Study|Withdrawn||N/A|0|Actual|The Cleveland Clinic||4||Unable to enroll|f||||||||||||No||2018-06-01 04:07:34.329444|2018-06-01 04:07:34.329444
NCT00300885|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|2009-11-04||2014-10-28|2006-03-08|2006-03-10|Estimate|2010-08-26|2010-09-20|Estimate||||2014-10-28|2014-11-04|Estimate|February 2006||2006-02-28|October 2014|2014-10-31|February 2009|Actual|2009-02-28|October 2007|Actual|2007-10-31||Interventional|||A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|926|Actual|Bayer|Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early. The planned biomarker analysis was suspended due to early termination.|2||"Based on the results of the interim analysis, it was determined that the study would not meet~   its primary efficacy endpoint and the study was terminated early."|f||||f||||||||||2018-06-01 04:07:34.499875|2018-06-01 04:07:34.499875
NCT00300872|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2011-06-22|2006-03-08|2006-03-10|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2005||2005-01-31|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|January 2013|Anticipated|2013-01-31||Interventional|||Effect of Nasal Continuous Positive Airway Pressure (CPAP) Blood Pressure and Vascular Endothelial Growth Factor in Obstructive Sleep Apnea Syndrome|A Randomized, Placebo-controlled Study of the Medium-term Effect of Nasal CPAP on 24 Hour Blood Pressure and Vascular Endothelial Growth Factor in Obstructive Sleep Apnea Syndrome|Unknown status|Recruiting|N/A|140|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 04:07:35.771054|2018-06-01 04:07:35.771054
NCT00300859|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-03-09|2006-03-09|2006-03-10|Estimate|||||||2006-03-09|2006-03-10|Estimate|February 2006||2006-02-28|March 2006|2006-03-31|October 2006||2006-10-31|||||Interventional|||Brief Intervention to Increase Safety Belt Use Among ED Patients|Brief Intervention to Increase Safety Belt Use Among ED Patients|Unknown status|Not yet recruiting|Phase 4|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:07:35.861487|2018-06-01 04:07:35.861487
NCT00300846|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2013-11-07|2006-03-08|2006-03-10|Estimate|||||||2013-11-07|2013-11-08|Estimate|December 2005||2005-12-31|June 2008|2008-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients|A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.|Completed||Phase 4|200||Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 04:07:35.931697|2018-06-01 04:07:35.931697
NCT00300833|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2011-08-10|2006-03-09|2006-03-10|Estimate|||||||2011-08-10|2011-08-11|Estimate|January 2006||2006-01-31|January 2009|2009-01-31||||January 2012|Anticipated|2012-01-31||Interventional|||Treating Acute MI Patients With Aggrastat on Their Way to Hospital||Unknown status|Recruiting|Phase 4|200|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||||||||||||2018-06-01 04:07:36.110369|2018-06-01 04:07:36.110369
NCT00300820|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2017-06-30|2006-03-08|2006-03-09|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2, 2006||2006-03-02|February 6, 2008|2008-02-06|February 6, 2008||2008-02-06|||||Observational|||Perspectives of Individuals With Bipolar Disorder and Siblings of Individuals With Bipolar Disorder; A Telephone Interview Study|Seeking Genetic Counseling: What Motivates Families At Risk For Psychiatric Illness?|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:07:36.181417|2018-06-01 04:07:36.181417
NCT00300807|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2007-03-06|2006-03-07|2006-03-09|Estimate|||||||2007-03-06|2007-03-07|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|April 2007||2007-04-30|||||Interventional|||Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection|A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection|Unknown status|Active, not recruiting|Phase 1|36||XTL Biopharmaceuticals|||||||||||||||||||2018-06-01 04:07:36.244647|2018-06-01 04:07:36.244647
NCT00300794|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2006-11-13|2006-03-07|2006-03-09|Estimate|||||||2006-11-13|2006-11-14|Estimate|February 2003||2003-02-28|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia||Completed||Phase 4|60||Vilnius University|||||f||||||||||||||2018-06-01 04:07:36.309797|2018-06-01 04:07:36.309797
NCT00300781|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2017-08-10|2011-02-17|2017-08-10|2006-03-07|2006-03-09|Estimate|2017-08-10|2017-09-13|Actual|2011-02-17|2011-02-23|Estimate|2017-08-10|2017-09-13|Actual|August 2006|Actual|2006-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2008|Actual|2008-04-30||Interventional||All treated subjects|Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer|Phase 2 Study of HKI-272 In Subjects With Advanced Breast Cancer|Active, not recruiting||Phase 2|137|Actual|Puma Biotechnology, Inc.||2|||f||||f|t|f||||||||2018-06-01 04:07:36.425595|2018-06-01 04:07:36.425595
NCT00300768|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2017-11-15|2006-03-07|2006-03-09|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2006||2006-09-30|February 2012|2012-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection|A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection|Completed||Phase 2|172|Actual|Medicines Development Limited||4|||f||||t||||||||||2018-06-01 04:07:36.855398|2018-06-01 04:07:36.855398
NCT00300755|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2009-11-30|2009-03-09|2010-04-14|2006-03-07|2006-03-09|Estimate|2010-04-14|2010-05-19|Estimate|2010-04-14|2010-05-19|Estimate|2010-04-14|2010-05-19|Estimate|May 2006||2006-05-31|April 2010|2010-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)|A Multicenter, Randomized, Double-Blind Study of the Clinical Outcomes, Safety and Tolerability of Multiple Doses of Pantoprazole Sodium Enteric-Coated Spheroids in Children Ages 1 to 5 With Endoscopically Proven Symptomatic Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|60|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||f||||||||||2018-06-01 04:07:37.057272|2018-06-01 04:07:37.057272
NCT00300742|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2017-03-31||2017-06-15|2006-03-07|2006-03-09|Estimate|2017-03-31|2017-05-11|Actual||||2017-06-15|2017-07-12|Actual|March 2006||2006-03-31|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals|Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual|Completed||Phase 2|5|Actual|University of Virginia||1|||f||||t|t|f||||||No||2018-06-01 04:07:37.619485|2018-06-01 04:07:37.619485
NCT00300729|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2009-06-29|2006-03-08|2006-03-09|Estimate|||||||2009-06-29|2009-06-30|Estimate|May 2006||2006-05-31|June 2009|2009-06-30|September 2010|Anticipated|2010-09-30|May 2010|Anticipated|2010-05-31||Interventional|CYCLUS||Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy|Cox-2-Inhibitor and Chemotherapy in Non-Small Cell Lung Cancer. A Prospective Randomized Double-Blind Study|Unknown status|Active, not recruiting|Phase 3|319|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-06-01 04:07:37.840014|2018-06-01 04:07:37.840014
NCT00300716|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2009-08-27|2006-03-08|2006-03-09|Estimate|||||||2009-08-27|2009-08-28|Estimate|April 2004||2004-04-30|April 2007|2007-04-30||||||||Interventional|||Trial of Memantine for Cognitive Impairment in Multiple Sclerosis|Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis|Unknown status|Recruiting|Phase 2/Phase 3|146|Anticipated|Oregon Health and Science University|||||f||||||||||||||2018-06-01 04:07:37.973928|2018-06-01 04:07:37.973928
NCT00300703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-10-13|2006-03-08|2006-03-09|Estimate|||||||2010-10-13|2010-10-15|Estimate|January 2006||2006-01-31|October 2010|2010-10-31|September 2007|Actual|2007-09-30|||||Observational|||OPALS Cardiac Arrest Database (OCAD)|Ontario Prehospital Advanced Life Support (OPALS) Study Cardiac Arrest Database|Completed|||1538|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:07:38.074977|2018-06-01 04:07:38.074977
NCT00300690|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-03-08|2006-03-08|2006-03-09|Estimate|||||||2006-03-08|2006-03-09|Estimate|October 1993||1993-10-31|March 2006|2006-03-31|January 1999||1999-01-31|||||Interventional|||Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp)|Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex).|Completed||Phase 4|400||University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:07:38.156|2018-06-01 04:07:38.156
NCT00300677|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2009-08-26||2009-10-05|2006-03-07|2006-03-09|Estimate|2009-10-05|2009-10-14|Estimate||||2009-10-05|2009-10-14|Estimate|March 2007||2007-03-31|October 2009|2009-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days|Assessment Of Voriconazole Penetration Into The Brain By Fluorine-Magnetic Resonance Spectroscopy|Completed||Phase 4|12|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:07:38.245132|2018-06-01 04:07:38.245132
NCT00300664|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-10-12|2006-03-08|2006-03-09|Estimate|||||||2006-10-12|2006-10-13|Estimate|July 2002||2002-07-31|March 2006|2006-03-31|April 2005||2005-04-30|||||Interventional|||A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients.||Completed||Phase 2/Phase 3|150||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:07:38.471462|2018-06-01 04:07:38.471462
NCT00300651|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-03-08|2006-03-08|2006-03-09|Estimate|||||||2006-03-08|2006-03-09|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|August 2009||2009-08-31|||||Interventional|||Trial of Cognitive Behavioral Therapy for Schizophrenia|Phase 3 Randomized Controlled Trial of Cognitive Behavioural Therapy for Patients With Schizophrenia|Unknown status|Recruiting|Phase 3|70||Philipps University Marburg Medical Center|||||f||||||||||||||2018-06-01 04:07:38.518514|2018-06-01 04:07:38.518514
NCT00300638|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2018-03-15|2006-03-07|2006-03-09|Estimate|||||||2018-03-15|2018-03-19|Actual|August 2001||2001-08-31|March 2018|2018-03-31|May 2023|Anticipated|2023-05-31|May 2020|Anticipated|2020-05-31||Observational|||Alcoholism: Emotion and Thinking|Affective and Conative Changes in Alcoholism|Recruiting|||700|Anticipated|Boston University|||1||f||||f|f|f|||f|||||2018-06-01 04:07:38.584731|2018-06-01 04:07:38.584731
NCT00300625|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2018-05-09|2006-03-07|2006-03-09|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2005||2005-01-31|May 2018|2018-05-31||||||||Observational|||Validation of the San Francisco Syncope Rule|Validation of the San Francisco Syncope Rule|Completed|||||Albert Einstein College of Medicine, Inc.|||||f||||||||||||||2018-06-01 04:07:38.662615|2018-06-01 04:07:38.662615
NCT00300612|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2015-05-29|2006-03-07|2006-03-09|Estimate|||||||2015-05-29|2015-06-01|Estimate|March 2006||2006-03-31|May 2015|2015-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Vaccine Treatment for Advanced Malignant Melanoma|A Phase I/II Study of Dorgenmeltucel-L (HyperAcute Melanoma) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Malignant Melanoma|Completed||Phase 1/Phase 2|6|Actual|NewLink Genetics Corporation||1|||f||||f||||||||||2018-06-01 04:07:38.735742|2018-06-01 04:07:38.735742
NCT00300274|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|2012-07-06||2012-07-10|2006-03-06|2006-03-08|Estimate|2012-07-10|2012-08-16|Estimate||||2012-07-10|2012-08-16|Estimate|January 2006||2006-01-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection|A 24-month, Multi-center, Randomized, Open-label, Non-inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-controlled Everolimus With Reduced Cyclosporine Versus 3.0 g Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Heart Transplant Recipients|Completed||Phase 3|721|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:07:44.929671|2018-06-01 04:07:44.929671
NCT00300599|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2011-06-22|2006-03-08|2006-03-09|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|December 2013|Anticipated|2013-12-31|February 2013|Anticipated|2013-02-28||Interventional|||Effect of Continuous Positive Airway Pressure (CPAP) on Systemic Blood Pressure, Coagulability and Carotid Intima-media Thickness in Patients With Sleep Apnea|A Randomized Controlled Study of the Long-term Effects of Nasal Continuous Positive Airway Pressure on Systemic Blood Pressure, Coagulability and Carotid Intima-media Thickness in Obstructive Sleep Apnea Syndrome|Unknown status|Recruiting|N/A|100|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 04:07:38.801596|2018-06-01 04:07:38.801596
NCT00300586|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2011-12-28|2006-03-06|2006-03-09|Estimate|||||||2011-12-28|2011-12-30|Estimate|June 2006||2006-06-30|December 2011|2011-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer|A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer Not Progressing on First Line Cisplatin-gemcitabine Chemotherapy Maintenance Chemotherapy With Gemcitabine or Sequential Treatment With Erlotinib|Completed||Phase 3|842|Actual|Hospices Civils de Lyon||3|||f||||t||||||||||2018-06-01 04:07:38.885113|2018-06-01 04:07:38.885113
NCT00300573|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2012-06-01|2006-03-08|2006-03-09|Estimate|||||||2012-06-01|2012-06-04|Estimate|April 2006||2006-04-30|June 2012|2012-06-30|April 2006|Actual|2006-04-30|||||Interventional|DECLARE||Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs|A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimized Background Therapy in HIV-1 Infected Subjects Who Have Failed and/or Harbor HIV With Resistance Mutations to NRTIs, PIs, and NNRTIs|Terminated||Phase 2|250|Actual|Incyte Corporation||2||"Development program ended due to inability to pair with other cytidine analogs and higher risk~   of hyperlipasemia when not used with 3TC/FTC."|f||||t||||||||||2018-06-01 04:07:38.956816|2018-06-01 04:07:38.956816
NCT00300560|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2006-05-19|2006-03-08|2006-03-09|Estimate|||||||2006-05-19|2006-05-22|Estimate|February 2006||2006-02-28|March 2006|2006-03-31|December 2006||2006-12-31|||||Interventional|||Efficacy and Safety of Colistin for Therapy of Infections Caused by ESBL Producing K.Pneumoniae or E.Coli|Efficacy and Safety of Colistin for Therapy of Infections Caused by Extended Spectrum Beta-Lactamase(ESBL) Producing Klebsiella Pneumoniae or Escherichia Coli|Unknown status|Recruiting|Phase 3|152||Mahidol University|||||f||||||||||||||2018-06-01 04:07:39.031135|2018-06-01 04:07:39.031135
NCT00300547|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2010-08-17|2006-03-08|2006-03-09|Estimate|||||||2010-08-17|2010-08-18|Estimate|March 2007||2007-03-31|March 2006|2006-03-31||||April 2008|Actual|2008-04-30||Interventional|||Preoperative Assessment for Synchronous Carcinoma or Polyps With Magnetic Resonance (MR) Colonography|Preoperative Assessment for Synchronous Carcinoma or Polyps With MR Colonography in Patients With Obstructing Cancer. A Prospective Study.|Completed||Phase 4|50|Actual|Herlev Hospital|||||f||||||||||||||2018-06-01 04:07:39.087447|2018-06-01 04:07:39.087447
NCT00300534|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2012-09-06|2006-03-02|2006-03-09|Estimate|||||||2012-09-06|2012-09-07|Estimate|August 2002||2002-08-31|September 2012|2012-09-30|July 2009|Actual|2009-07-31|December 2005|Actual|2005-12-31||Interventional|||Multi-site Study of Rapid Diagnostic Syphilis Assays|Multi-site Study of Rapid Diagnostic Syphilis Assays of Persons Attending STD Clinics in High Syphilis Morbidity Areas|Completed||N/A|1000|Actual|Centers for Disease Control and Prevention||1|||f||||||||||||||2018-06-01 04:07:39.222949|2018-06-01 04:07:39.222949
NCT00300521|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|||2006-03-08|2006-03-08|2006-03-09|Estimate|||||||2006-03-08|2006-03-09|Estimate|September 2000||2000-09-30|September 2000|2000-09-30|November 2005||2005-11-30|||||Interventional|||Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma|Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 2|40||Beijing Chao Yang Hospital|||||f||||||||||||||2018-06-01 04:07:39.287126|2018-06-01 04:07:39.287126
NCT00300508|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2009-04-30|2006-03-07|2006-03-09|Estimate|||||||2009-04-30|2009-05-01|Estimate|January 1996||1996-01-31|April 2009|2009-04-30||||||||Interventional|||3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer|A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.|Completed||Phase 3|856||AstraZeneca|||||f||||||||||||||2018-06-01 04:07:39.393982|2018-06-01 04:07:39.393982
NCT00300495|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-08|2017-03-20||2017-03-20|2006-03-08|2006-03-09|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|February 2006|Actual|2006-02-28|March 2017|2017-03-31|October 13, 2009|Actual|2009-10-13|October 13, 2009|Actual|2009-10-13||Interventional|||Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection|Phase III Study of Preoperative Amiodarone for Prevention of Atrial Fibrillation After Lung Resection|Terminated||Phase 3|19|Actual|Beth Israel Deaconess Medical Center||2||Unable to accrual total number of participants during study period.|f|||||t|f||||||No||2018-06-01 04:07:39.527155|2018-06-01 04:07:39.527155
NCT00300482|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2009-01-14||2009-06-03|2006-03-07|2006-03-09|Estimate|2009-03-24|2009-03-25|Estimate||||2009-06-03|2009-06-10|Estimate|March 2006||2006-03-31|June 2009|2009-06-30||||December 2006|Actual|2006-12-31||Interventional|||Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia|Completed||Phase 3|1445|Actual|Abbott||6|||f||||f||||||||||2018-06-01 04:07:39.722843|2018-06-01 04:07:39.722843
NCT00300469|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2009-01-14||2009-06-01|2006-03-07|2006-03-09|Estimate|2009-03-24|2009-03-25|Estimate||||2009-06-01|2009-06-03|Estimate|March 2006||2006-03-31|June 2009|2009-06-30||||February 2007|Actual|2007-02-28||Interventional|||Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia|Completed||Phase 3|613|Actual|Abbott||6|||f||||f||||||||||2018-06-01 04:07:40.707564|2018-06-01 04:07:40.707564
NCT00300456|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2009-01-14||2009-05-29|2006-03-07|2006-03-09|Estimate|2009-02-20|2009-03-25|Estimate||||2009-05-29|2009-06-03|Estimate|March 2006||2006-03-31|May 2009|2009-05-31||||March 2007|Actual|2007-03-31||Interventional|||Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood|A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 and Simvastatin Combination Therapy to ABT-335 and Simvastatin Monotherapy in Subjects With Mixed Dyslipidemia|Completed||Phase 3|657|Actual|Abbott||6|||f||||f||||||||||2018-06-01 04:07:41.580998|2018-06-01 04:07:41.580998
NCT00300430|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2009-03-10||2009-06-03|2006-03-07|2006-03-09|Estimate|2009-06-03|2009-07-23|Estimate||||2009-06-03|2009-07-23|Estimate|September 2006||2006-09-30|June 2009|2009-06-30||||March 2008|Actual|2008-03-31||Interventional|||Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.|A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects With Mixed Dyslipidemia|Completed||Phase 3|1911|Actual|Abbott|This was an open-label study designed to assess the longer-term safety of the combination therapies. Evaluation of efficacy outcomes was a secondary objective.|3|||f||||f||||||||||2018-06-01 04:07:42.613385|2018-06-01 04:07:42.613385
NCT00300417|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2017-06-30|2006-03-07|2006-03-08|Estimate|||||||2017-06-30|2017-07-02|Actual|March 3, 2006||2006-03-03|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Interventional|||Phase I Study of West Nile Virus Vaccine|A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA020-00-VP, in Healthy Adult Subjects|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:07:43.553126|2018-06-01 04:07:43.553126
NCT00300404|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2006-05-19|2006-03-07|2006-03-08|Estimate|||||||2006-05-19|2006-05-22|Estimate|January 2002||2002-01-31|March 2006|2006-03-31|September 2005||2005-09-30|||||Interventional|||Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression|Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study|Completed||Phase 3|40||Zentrum für Integrative Psychiatrie|||||f||||||||||||||2018-06-01 04:07:43.610905|2018-06-01 04:07:43.610905
NCT00300391|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|2016-12-01||2017-11-21|2006-03-06|2006-03-08|Estimate|2017-11-21|2017-12-20|Actual||||2017-11-21|2017-12-20|Actual|March 2006||2006-03-31|November 2017|2017-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium|ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium|Terminated||Phase 3|40|Actual|University of Pittsburgh|This study was pre-maturely terminated. Although sincere efforts were made to locate the relevant and accurate data, limited data could be obtained. Also, conflicting information was available with respect to participant enrollment.|2||Insufficient recruitment to meet aims.|f||||t||||||||No||2018-06-01 04:07:43.694982|2018-06-01 04:07:43.694982
NCT00300378|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2007-12-03|2006-03-07|2006-03-08|Estimate|||||||2007-12-03|2007-12-05|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|480|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:07:44.026167|2018-06-01 04:07:44.026167
NCT00300365|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|2017-04-04||2017-06-29|2006-03-06|2006-03-08|Estimate|2017-06-29|2017-07-28|Actual||||2017-06-29|2017-07-28|Actual|November 2005||2005-11-30|June 2017|2017-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL|A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-diabetic Patients With Metabolic Syndrome|Completed||Phase 2|38|Actual|University of Pennsylvania||2|||f||||||||||||Undecided||2018-06-01 04:07:44.134189|2018-06-01 04:07:44.134189
NCT00300352|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2008-08-06|2006-03-07|2006-03-08|Estimate|||||||2008-08-06|2008-08-07|Estimate|May 2004||2004-05-31|January 2007|2007-01-31||||May 2006|Actual|2006-05-31||Interventional|||Effect of Folic Acid Treatment in Coronary Artery Disease|Effect of Folic Acid Treatment in Coronary Artery Disease|Unknown status|Recruiting|Phase 2|60|Anticipated|University of Oxford|||||f||||||||||||||2018-06-01 04:07:44.369949|2018-06-01 04:07:44.369949
NCT00300339|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2008-12-18|2006-03-07|2006-03-08|Estimate|||||||2008-12-18|2008-12-19|Estimate|February 2006||2006-02-28|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|MASCOT||Mixed Antagonist of Serotonin for Claudication Optimal Therapy|Double-Blind, Double-Dummy, Randomized, Parallel Group Trial of SL650472 (Three Dose Regimens Versus Placebo and Cilostazol), for 24-Week Improvement of Walking Distance in Patients With Stage II Peripheral Arterial Disease Who Benefit From Optimal Prevention Strategy Including Clopidogrel|Completed||Phase 2|599|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:07:44.431197|2018-06-01 04:07:44.431197
NCT00300326|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2016-09-26|2006-03-07|2006-03-08|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|||Computer-assisted Total Knee Arthroplasty (TKA) With Zimmer LPS Flex Knee System|An Investigation of Total Knee Arthroplasty Kinematics on Patient Performance - The Zimmer Legacy® LPS Flex Knee System|Terminated||Phase 4|7|Actual|Queen's University||2||problems with planned computer|f||||t||||||||||2018-06-01 04:07:44.554726|2018-06-01 04:07:44.554726
NCT00300313|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2013-12-30|2006-03-07|2006-03-08|Estimate|||||||2013-12-30|2013-12-31|Estimate|June 2005||2005-06-30|December 2013|2013-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||PTSD Prevention Using Escitalopram||Completed||N/A|450|Anticipated|Sheba Medical Center||2|||f||||||||||||||2018-06-01 04:07:44.609165|2018-06-01 04:07:44.609165
NCT00300300|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2015-09-09|2006-03-06|2006-03-08|Estimate|||||||2015-09-09|2015-09-10|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|January 2029|Anticipated|2029-01-31|January 2028|Anticipated|2028-01-31||Interventional|||Anterior Cruciate Ligament (ACL) Reconstruction Using Different Grafts and Surgical Techniques|Anterior Cruciate Ligament Reconstruction: Comparison of Patellar With Hamstring Tendon Using a Computer-assisted Versus a Conventional Surgical Technique.|Terminated||Phase 4|125|Actual|Queen's University||4||Study temporarily suspended until funding can be secured.|f||||f||||||||||2018-06-01 04:07:44.67496|2018-06-01 04:07:44.67496
NCT00300287|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2017-07-31|2006-03-06|2006-03-08|Estimate|||||||2017-07-31|2017-08-02|Actual|February 20, 2006|Actual|2006-02-20|July 2017|2017-07-31|June 26, 2007|Actual|2007-06-26|June 26, 2007|Actual|2007-06-26||Interventional|||A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia|A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia|Completed||Phase 3|150||Novartis|||||f||||||||||||||2018-06-01 04:07:44.747514|2018-06-01 04:07:44.747514
NCT00300261|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2015-11-30|2006-03-06|2006-03-08|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Testing the Effects of Telehealth Monitoring on Rehospitalization and Self Care for Heart Failure Patients in Home Care|Promoting Self Care Using Telehomecare: Impact on Outcomes|Completed||Phase 3|216|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 04:07:47.300704|2018-06-01 04:07:47.300704
NCT00300248|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2015-08-31|2006-03-07|2006-03-08|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2004||2004-10-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome|The Improving Care of Acute Lung Injury Patients (ICAP) Study|Completed|||520|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 04:07:47.363514|2018-06-01 04:07:47.363514
NCT00300235|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|2009-03-13||2015-12-22|2006-03-07|2006-03-08|Estimate|2009-06-15|2009-08-03|Estimate||||2015-12-22|2016-01-28|Estimate|August 2005||2005-08-31|December 2015|2015-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence|The Epidemiology of Priapism (Sickle Cell Disease)|Completed|||1464|Actual|University of Texas Southwestern Medical Center|||5||f||||t||||||||||2018-06-01 04:07:47.433039|2018-06-01 04:07:47.433039
NCT00300222|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2008-03-04|2006-03-06|2006-03-08|Estimate|||||||2008-03-04|2008-03-06|Estimate|March 2006||2006-03-31|March 2008|2008-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|Completed||Phase 3|400||NeurogesX|||||f||||||||||||||2018-06-01 04:07:47.835779|2018-06-01 04:07:47.835779
NCT00300209|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2016-03-16|2006-03-07|2006-03-08|Estimate|||||||2016-03-16|2016-03-17|Estimate|September 1998||1998-09-30|March 2016|2016-03-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Observational|||Manhattan HIV/Hepatology Brain Bank|Manhattan HIV/Hepatology Brain Bank|Completed|||187|Actual|Icahn School of Medicine at Mount Sinai|||||f||||||||||Samples Without DNA|"~     plasma and serum blood~   "|||2018-06-01 04:07:47.890193|2018-06-01 04:07:47.890193
NCT00300196|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2010-01-11|2006-03-06|2006-03-08|Estimate|||||||2010-01-11|2010-01-12|Estimate|March 2006||2006-03-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke|ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute Ischemic Stroke|Terminated||Phase 3|311|Actual|Neurobiological Technologies||2||Futility|f||||t||||||||||2018-06-01 04:07:47.945211|2018-06-01 04:07:47.945211
NCT00300183|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2006-03-31|2006-03-07|2006-03-08|Estimate|||||||2006-03-31|2006-04-03|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|July 2005||2005-07-31|||||Observational|||Evaluation of an HIV Outreach Program|Evaluation of an Outreach and Intervention Program to Reach HIV- Positive Persons Living in Bronx, NY Single Room Occupancy Hotels|Completed|||150||Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:07:48.236369|2018-06-01 04:07:48.236369
NCT00300170|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2006-03-31|2006-03-07|2006-03-08|Estimate|||||||2006-03-31|2006-04-03|Estimate|October 2004||2004-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Observational|||Engagement in HIV Primary Care Services|Determinants of Engagement in HIV Primary Care Services Among Black and Hispanic Single Room Occupancy Hotel Residents in New York City|Completed|||500||Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:07:48.300385|2018-06-01 04:07:48.300385
NCT00300157|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2011-01-03|2006-03-07|2006-03-08|Estimate|||||||2011-01-03|2011-01-04|Estimate|December 2005||2005-12-31|January 2011|2011-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Left Main Coronary Artery Stenosis and Angioplasty With Taxus Stent|French Multicenter Study Assessing Angioplasty With Taxus Drug Eluting Stent in Unprotected Left Main Coronary Artery Associated to Other Coronary Lesions or Not|Completed||Phase 3|155|Actual|French Cardiology Society|||||f||||t||||||||||2018-06-01 04:07:48.367841|2018-06-01 04:07:48.367841
NCT00300131|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2011-09-09|2006-03-07|2006-03-08|Estimate|||||||2011-09-09|2011-09-13|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|ABSORB A||ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation|Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions|Completed|||30|Actual|Abbott Vascular|||1||f||||t||||||||||2018-06-01 04:07:48.485542|2018-06-01 04:07:48.485542
NCT00300118|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2014-05-16|2006-03-07|2006-03-08|Estimate|||||||2014-05-16|2014-05-19|Estimate|September 2004||2004-09-30|May 2014|2014-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)|Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients|Completed||Phase 3|311|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-06-01 04:07:48.588425|2018-06-01 04:07:48.588425
NCT00300105|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2008-03-14|2006-03-07|2006-03-08|Estimate|||||||2008-03-14|2008-03-17|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|December 2006|Actual|2006-12-31|||||Interventional|||GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes|A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar Therapy in Patients With Type 2 Diabetes|Terminated||Phase 3|400||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:07:48.682735|2018-06-01 04:07:48.682735
NCT00300092|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2015-04-16|2006-03-06|2006-03-08|Estimate|||||||2015-04-16|2015-04-20|Estimate|September 2000||2000-09-30|April 2015|2015-04-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Pediatric Fingertip Injuries:Are Antibiotics Required?|Pediatric Fingertip Injuries: Do Prophylactic Antibiotics Alter Infection Rates?|Completed||Phase 2|146|Actual|Children's Hospital Los Angeles||2|||f||||f||||||||||2018-06-01 04:07:48.814002|2018-06-01 04:07:48.814002
NCT00300079|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2016-11-17|2006-03-06|2006-03-08|Estimate|||||||2016-11-17|2016-11-18|Estimate|September 2006||2006-09-30|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension|A Multiple-Dose Study of the IOP-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% When Added to a PGA as Adjunctive Therapy Over a 24 Hour Period in Patients With Glaucoma or Ocular Hypertension|Completed||Phase 4|30|Anticipated|Alcon Research|||||f||||||||||||||2018-06-01 04:07:48.886379|2018-06-01 04:07:48.886379
NCT00300066|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2010-05-27|2006-03-06|2006-03-08|Estimate|||||||2010-05-27|2010-05-28|Estimate|March 2006||2006-03-31|May 2010|2010-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Assessment of Serum Cystatin C as a Marker of Kidney Function in Children|Prediction Equations for Glomerular Filtration Rate in Children Based on Serum Cystatin C and Body Cell Mass|Completed|||200|Anticipated|Aalborg Universitetshospital|||||f||||||||||||||2018-06-01 04:07:48.98903|2018-06-01 04:07:48.98903
NCT00297661|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2006-10-19|2006-02-27|2006-02-28|Estimate|||||||2006-10-19|2006-10-20|Estimate|April 2003||2003-04-30|February 2006|2006-02-28||||||||Interventional|||Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization|Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization: SIRTAX Trial|Completed||Phase 4|1012||University of Bern|||||f||||||||||||||2018-06-01 04:08:28.054982|2018-06-01 04:08:28.054982
NCT00300053|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06||2009-10-28|2010-09-01|2006-03-06|2006-03-08|Estimate||||2009-10-28|2009-10-30|Estimate|2010-09-01|2010-09-06|Estimate|March 2006||2006-03-31|September 2010|2010-09-30|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||ACT34-CMI -- Adult Autologous CD34+ Stem Cells|A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto--CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)|Completed||Phase 2|150|Anticipated|Baxter Healthcare Corporation|||||f||||t||||||||||2018-06-01 04:07:49.133436|2018-06-01 04:07:49.133436
NCT00300040|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2008-05-15|2006-03-06|2006-03-08|Estimate|||||||2008-05-15|2008-05-16|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia|Phase II, Multi-Center,Single-Blind,Placebo-Controlled Study,Evaluating Safety & Feasibility of HBOC-201 (Wound Healing Patients With Peripheral Vascular Disease & Undergoing Lower Limb Amputation Due to Critical Lower Limb Ischemia|Terminated||Phase 2|16|Actual|Biopure Corporation||2||Very slow enrollment.Study entry criteria not in line w/local standards of care|f||||f||||||||||2018-06-01 04:07:49.255266|2018-06-01 04:07:49.255266
NCT00300027|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06||2010-02-27|2010-02-27|2006-03-06|2006-03-08|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|April 2006||2006-04-30|September 2007|2007-09-30||||December 2006|Actual|2006-12-31||Interventional|||Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies|A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With 5-Fluorouracil/Leucovorin and Irinotecan or Oxaliplatin for Patients With Advanced or Metastatic Cancer|Terminated||Phase 1|50||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:07:49.363988|2018-06-01 04:07:49.363988
NCT00300014|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-07|||2007-06-12|2006-03-07|2006-03-08|Estimate|||||||2007-06-12|2007-06-13|Estimate|January 2006||2006-01-31|June 2007|2007-06-30|May 2007||2007-05-31|||||Interventional|||Efficacy and Safety of Intravitreal Triamcinolone Acetonide in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage|Comparative,Randomized Study Between Intravitreal Triamcinolone Acetonide and Air-Fluid Exchange in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage|Unknown status|Recruiting|N/A|30|Anticipated|Asan Medical Center|||||f||||||||||||||2018-06-01 04:07:49.460267|2018-06-01 04:07:49.460267
NCT00300001|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2006-08-23|2006-03-03|2006-03-07|Estimate|||||||2006-08-23|2006-08-25|Estimate|March 2006||2006-03-31|August 2006|2006-08-31||||||||Observational|||Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes|Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes|Unknown status|Recruiting||300||Community Cancer Care|||||f||||||||||||||2018-06-01 04:07:49.543683|2018-06-01 04:07:49.543683
NCT00299988|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2010-11-08|2006-03-03|2006-03-07|Estimate|||||||2010-11-08|2010-11-10|Estimate|February 2006||2006-02-28|November 2010|2010-11-30|April 2010|Actual|2010-04-30|January 2009|Actual|2009-01-31||Interventional|||Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease|A Placebo-controlled, Randomized, Double-Blind Phase II Clinical Study of Gammagard Intravenous Immunoglobulin (IVIg) for Treatment of Mild to Moderate Alzheimer's Disease|Completed||Phase 2|24|Anticipated|Weill Medical College of Cornell University|||||f||||t||||||||||2018-06-01 04:07:49.617462|2018-06-01 04:07:49.617462
NCT00299975|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|2011-08-02||2015-04-08|2006-03-06|2006-03-07|Estimate|2011-11-14|2011-12-16|Estimate||||2015-04-08|2015-04-24|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||A Dose Determination Study of Chinese Herbal Medicine for Functional Constipation|A Randomized Controlled Trial of Chinese Herbal Medicine in Three-dose Regimen for the Treatment of Functional Constipation|Completed||Phase 2|97|Actual|Hong Kong Baptist University||3|||f||||t||||||||||2018-06-01 04:07:49.740138|2018-06-01 04:07:49.740138
NCT00299962|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2018-02-26|2006-03-03|2006-03-07|Estimate|||||||2018-02-26|2018-02-28|Actual|March 2006||2006-03-31|February 2018|2018-02-28|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Gene Therapy for Pleural Malignancies|A Phase I Clinical Trial of Repeated Dose Intrapleural Adenoviral-Mediated Interferon-beta (BG00001, Ad.hIFN-β for Pleural Malignancies|Active, not recruiting||Phase 1|18|Anticipated|University of Pennsylvania||5|||f||||f||||||||||2018-06-01 04:07:50.532611|2018-06-01 04:07:50.532611
NCT00299949|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2013-02-06|2006-03-06|2006-03-07|Estimate|||||||2013-02-06|2013-02-08|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Thrombin Generation and Thromboelastography in Non-overt DIC|Use of Whole Blood and Cell-rich Coagulation Assays for the Detection of Non-Overt DIC in Sepsis|Terminated|||2|Actual|The University of Texas Health Science Center, Houston||||Insufficient subject enrollment|f||||f||||||Samples Without DNA|"~     Samples will be discarded after the study is completed.~   "|||2018-06-01 04:07:50.620585|2018-06-01 04:07:50.620585
NCT00299936|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2006-03-03|2006-03-03|2006-03-07|Estimate|||||||2006-03-03|2006-03-07|Estimate||||March 2006|2006-03-31||||||||Interventional|||Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve Subjects|Comparison of PEG Interferon Alfa-2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects|Completed||Phase 3|5000||Weill Medical College of Cornell University|||||||||||||||||||2018-06-01 04:07:50.677269|2018-06-01 04:07:50.677269
NCT00299923|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2007-03-08|2006-03-06|2006-03-07|Estimate|||||||2007-03-08|2007-03-09|Estimate|November 2005||2005-11-30|March 2007|2007-03-31||||||||Interventional|||Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy|Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy.|Unknown status|Active, not recruiting|Phase 3|300||Universitätsklinikum Hamburg-Eppendorf|||||f||||||||||||||2018-06-01 04:07:50.747679|2018-06-01 04:07:50.747679
NCT00299910|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2008-05-20|2006-03-06|2006-03-07|Estimate|||||||2008-05-20|2008-05-21|Estimate|March 2005||2005-03-31|May 2008|2008-05-31||||||||Interventional|||Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing|Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing|Unknown status|Recruiting|Phase 4|50|Anticipated|Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:07:50.838241|2018-06-01 04:07:50.838241
NCT00299897|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2006-10-25|2006-03-03|2006-03-07|Estimate|||||||2006-10-25|2006-10-27|Estimate|March 2006||2006-03-31|October 2006|2006-10-31||||||||Interventional|||SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Orally Administered SP01A for 28 Days as Monotherapy Treatment in HIV-Infected Patients With Evidence of Resistance to Currently Available Antiretroviral Therapy|Unknown status|Active, not recruiting|Phase 2|60||Samaritan Pharmaceuticals, Inc|||||||||||||||||||2018-06-01 04:07:50.893239|2018-06-01 04:07:50.893239
NCT00299884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-03-28|2006-03-06|2006-03-07|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2005||2005-01-31|March 2016|2016-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy|The Comparison of the Efficacy of Ezetimibe and Fenofibrate Versus Atorvastatin Alone in the Lowering of LDL Cholesterol|Completed|||45|Actual|Queen's University|||2||f||||f||||||Samples Without DNA|"~     Apo-lipo B~   "|||2018-06-01 04:07:50.99352|2018-06-01 04:07:50.99352
NCT00299871|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2014-01-27|2006-03-06|2006-03-07|Estimate|||||||2014-01-27|2014-01-28|Estimate|February 2006||2006-02-28|January 2014|2014-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus|A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|542|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:07:51.086322|2018-06-01 04:07:51.086322
NCT00299858|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2017-07-05|2006-03-03|2006-03-07|Estimate|||||||2017-07-05|2017-07-07|Actual|October 2006||2006-10-31|July 2017|2017-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Theophylline in Chronic Obstructive Pulmonary Disease|Effect of Theophylline on Exercise Capacity and Lung Function in COPD Patients Receiving Long-acting Inhaled Bronchodilator Therapy|Completed||Phase 2/Phase 3|24|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 04:07:51.156785|2018-06-01 04:07:51.156785
NCT00299845|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2012-10-10|2006-03-06|2006-03-07|Estimate|||||||2012-10-10|2012-10-11|Estimate||||September 2006|2006-09-30||||||||Interventional|||Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children||Withdrawn||Phase 4|0|Actual|Osaka University|||||f||||||||||||||2018-06-01 04:07:52.306011|2018-06-01 04:07:52.306011
NCT00299832|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2016-11-16|2006-03-03|2006-03-07|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction|A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction|Completed||Phase 3|40|Actual|Novartis|||||f||||f||||||||||2018-06-01 04:07:52.385433|2018-06-01 04:07:52.385433
NCT00299819|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2007-12-17|2006-03-06|2006-03-07|Estimate|||||||2007-12-17|2007-12-18|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)|A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lupus Erythematosus (SLE)|Completed||Phase 1|45|Actual|MedImmune LLC||5|||f||||||||||||||2018-06-01 04:07:52.483226|2018-06-01 04:07:52.483226
NCT00299806|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2016-11-16|2006-03-03|2006-03-07|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension|A Multi-center, Open-label Study Assessing the Safety and Efficacy of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension|Completed||Phase 3|39|Actual|Novartis|||||f||||||||||||||2018-06-01 04:07:52.607555|2018-06-01 04:07:52.607555
NCT00299793|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2007-03-22|2006-03-03|2006-03-07|Estimate|||||||2007-03-22|2007-03-23|Estimate|October 2001||2001-10-31|March 2007|2007-03-31||||||||Observational|||Observational Study of Lamotrigine|Observational Study of Lamotrigine|Completed|||60||Northwell Health|||||f||||||||||||||2018-06-01 04:07:52.687882|2018-06-01 04:07:52.687882
NCT00299780|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2007-04-23|2006-03-03|2006-03-07|Estimate|||||||2007-04-23|2007-04-24|Estimate|July 2004||2004-07-31|April 2007|2007-04-30|April 2007||2007-04-30|||||Interventional|||Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.|Phase I Study of Parathyroid Hormone in Combination With G-CSF in Patients Requiring Additional Stem Cell Mobilization|Completed||Phase 1|12||Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:07:52.752422|2018-06-01 04:07:52.752422
NCT00299767|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2016-05-09|2006-03-03|2006-03-07|Estimate|||||||2016-05-09|2016-05-11|Estimate|May 2003||2003-05-31|May 2016|2016-05-31|May 2009|Actual|2009-05-31|May 2005|Actual|2005-05-31||Interventional|||Phase I Study of Sequential Cord Blood Transplants|Phase I Study of Sequential Cord Blood Transplants|Completed||Phase 1|21|Actual|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:07:52.835947|2018-06-01 04:07:52.835947
NCT00299754|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2006-03-06|2006-03-06|2006-03-07|Estimate|||||||2006-03-06|2006-03-07|Estimate|January 2003||2003-01-31|June 2005|2005-06-30|December 2004||2004-12-31|||||Interventional|||Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)|The Randomised-Controlled Trial Of Misoprostol And Dinoprostone Vaginal Pessaries for Cervical Priming (TROMAD Study)|Completed||Phase 3|171||KK Women's and Children's Hospital|||||f||||||||||||||2018-06-01 04:07:53.769774|2018-06-01 04:07:53.769774
NCT00299741|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|2012-05-09||2012-12-14|2006-03-03|2006-03-07|Estimate|2012-11-14|2012-12-13|Estimate||||2012-12-14|2012-12-19|Estimate|March 2006||2006-03-31|December 2012|2012-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of SU11248 in Men With Advanced Prostate Cancer|A Phase II Study of SU011248 in Men With Advanced Prostate Cancer|Completed||Phase 2|36|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 04:07:53.853596|2018-06-01 04:07:53.853596
NCT00299728|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2009-01-28|2006-03-06|2006-03-07|Estimate|||||||2009-01-28|2009-01-29|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors|A Phase I Study Using Vaccination With NY-ESO-1 Recombinant Protein Mixed With CpG7909 and Montanide® ISA-51 in Patients With Cancers That Often Express NY-ESO-1.|Completed||Phase 1|20||Ludwig Institute for Cancer Research|||||||||||||||||||2018-06-01 04:07:54.174981|2018-06-01 04:07:54.174981
NCT00299715|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03||2011-06-02|2011-06-02|2006-03-03|2006-03-07|Estimate||||2011-06-02|2011-06-09|Estimate|2011-06-02|2011-06-09|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-Release Paliperidone in the Treatment of Subjects With Acute Manic and Mixed Episodes Associated With Bipolar I Disorder|Completed||Phase 3|473|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:07:54.25806|2018-06-01 04:07:54.25806
NCT00299533|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2013-08-14|2006-03-03|2006-03-07|Estimate|||||||2013-08-14|2013-08-16|Estimate|February 2004||2004-02-29|August 2013|2013-08-31|September 2006|Actual|2006-09-30|||||Interventional|||Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy|A Randomized, Double-blind, Placebo-controlled, Prospective Study Evaluating the Usefulness of Polyunsaturated Fatty Acids (PUFA) in Patients Wtih Uncontrolled Epilepsy|Completed||Phase 3|40||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:07:58.129313|2018-06-01 04:07:58.129313
NCT00299702|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|2010-01-26||2011-12-22|2006-03-03|2006-03-07|Estimate|2010-03-04|2010-03-16|Estimate||||2011-12-22|2011-12-30|Estimate|February 2006||2006-02-28|December 2011|2011-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia|A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia|Completed||Phase 4|355|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|15% of subjects did not meet stability inclusion criteria; many received supplemental antipsychotics post-randomization; biweekly visits may have increased aripiprazole adherence; numerous early dropouts may have led to dependent censoring and bias.|2|||f||||t||||||||||2018-06-01 04:07:54.345605|2018-06-01 04:07:54.345605
NCT00299689|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|2014-08-26||2014-08-26|2006-03-03|2006-03-07|Estimate|2014-08-26|2014-09-05|Estimate||||2014-08-26|2014-09-05|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Phase II Trial of Ontak With Metastatic Melanoma|Phase II Trial of ONTAK With Metastatic Melanoma|Completed||Phase 2|69|Actual|James Graham Brown Cancer Center||1|||f||||t||||||||||2018-06-01 04:07:55.209793|2018-06-01 04:07:55.209793
NCT00299676|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2014-05-22|2006-03-03|2006-03-07|Estimate|||||||2014-05-22|2014-05-23|Estimate|May 2005||2005-05-31|May 2014|2014-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period|An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period|Completed|||61|Actual|Janssen-Cilag Pty Ltd|||1||f||||||||||||||2018-06-01 04:07:55.464003|2018-06-01 04:07:55.464003
NCT00299663|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-05|||2012-01-15|2006-03-05|2006-03-07|Estimate|||||||2012-01-15|2012-01-18|Estimate|February 2006||2006-02-28|January 2012|2012-01-31|October 2011|Actual|2011-10-31|||||Observational|||Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract|Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract|Completed|||61|Actual|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 04:07:55.717123|2018-06-01 04:07:55.717123
NCT00299650|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2008-10-09|2006-03-06|2006-03-07|Estimate|||||||2008-10-09|2008-10-10|Estimate|March 2006||2006-03-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients|Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients|Completed||Phase 4|340|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-06-01 04:07:55.816765|2018-06-01 04:07:55.816765
NCT00299637|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-05|||2006-11-29|2006-03-05|2006-03-07|Estimate|||||||2006-11-29|2006-11-30|Estimate|October 2006||2006-10-31|March 2006|2006-03-31|December 2007|Anticipated|2007-12-31|||||Observational|||Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis|Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis During Labor Comparing to Fetuses to Healthy Mothers.|Unknown status|Recruiting||34|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:07:55.920785|2018-06-01 04:07:55.920785
NCT00299624|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2010-09-13|2006-03-06|2006-03-07|Estimate|||||||2010-09-13|2010-09-14|Estimate|October 2005||2005-10-31|September 2010|2010-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Effect of Aging on Haemostasis Parameters|Identifying Morphological and Biological Biomarkers of the Venous Thromboembolic Risk Risk Related to Aging|Completed|||100|Anticipated|Hopital Lariboisière|||||f||||t||||||||||2018-06-01 04:07:55.978116|2018-06-01 04:07:55.978116
NCT00299611|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-06|||2013-04-09|2006-03-06|2006-03-07|Estimate|||||||2013-04-09|2013-04-11|Estimate|November 2005||2005-11-30|June 2010|2010-06-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder|A Double-Blind Augmentation Study of LEvetiracetam in Obsessive Compulsive Disorder|Terminated||Phase 2/Phase 3|12|Actual|Duke University||2||Sponsor decided to terminate the study due to budget consideration|f||||t||||||||||2018-06-01 04:07:56.050009|2018-06-01 04:07:56.050009
NCT00299598|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-05|||2010-01-05|2006-03-05|2006-03-07|Estimate|||||||2010-01-05|2010-01-06|Estimate|September 2006||2006-09-30|October 2009|2009-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Clinical Study of Antibacterial Nanoparticles Incorporated in Composite Restorations|phase2 Safety and Efficacy of Antibacterial Nano Particles Incorporated in Dental Composite.|Completed|||10|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:07:56.15958|2018-06-01 04:07:56.15958
NCT00299585|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-05|||2010-01-05|2006-03-05|2006-03-07|Estimate|||||||2010-01-05|2010-01-06|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|November 2008|Anticipated|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||A Clinical Study of the Use of Brushite as Primary Stabilizer in Immediate Dental Implantation|Phase 2 Clinical Study on the Efficacy of Injectable Brushite Bone Cement in Bone Augmentation and Dental Implant Stabilization|Suspended||Phase 2|40|Anticipated|Hadassah Medical Organization||||manufacturer could not finance the study|f||||||||||||||2018-06-01 04:07:56.325312|2018-06-01 04:07:56.325312
NCT00299572|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-05|||2006-03-05|2006-03-05|2006-03-07|Estimate|||||||2006-03-05|2006-03-07|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|December 2006||2006-12-31|||||Interventional|||Alendronate for Vascular Calcification in Peritoneal Dialysis Patients?|Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients?|Unknown status|Not yet recruiting|Phase 4|50||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:07:56.402901|2018-06-01 04:07:56.402901
NCT00299559|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2009-02-12|2006-03-03|2006-03-07|Estimate|||||||2009-02-12|2009-02-13|Estimate|March 2006||2006-03-31|November 2007|2007-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Kinetics of Etheric Oils, Smart Textiles vs. Ointment|An Open Clinical Cross-Over Trial to Compare the Kinetics of Etheric Oils Applied Onto the Skin or Via Smart Textiles|Completed||Phase 1|6|Actual|Technische Universität Dresden||1|||f||||f||||||||||2018-06-01 04:07:56.495928|2018-06-01 04:07:56.495928
NCT00299546|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|2009-05-21||2014-01-27|2006-03-03|2006-03-07|Estimate|2011-08-23|2011-09-28|Estimate||||2014-01-27|2014-02-27|Estimate|February 2006||2006-02-28|January 2014|2014-01-31|May 2012|Actual|2012-05-31|August 2007|Actual|2007-08-31||Interventional|||A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)|Completed||Phase 3|461|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|3|||f||||t||||||||||2018-06-01 04:07:56.6569|2018-06-01 04:07:56.6569
NCT00299520|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2008-04-02|2006-03-03|2006-03-07|Estimate|||||||2008-04-02|2008-04-04|Estimate|June 2005||2005-06-30|April 2008|2008-04-30|July 2006||2006-07-31|||||Interventional|||Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)|Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections.(ASSIST-1)|Completed||Phase 3|||Arpida AG|||||||||||||||||||2018-06-01 04:07:58.305578|2018-06-01 04:07:58.305578
NCT00299507|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03||2012-11-27|2012-11-27|2006-03-03|2006-03-07|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|March 2005||2005-03-31|September 2009|2009-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)|Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD)|Completed||Phase 3|240|Actual|Alcon Research||4|||f||||t||||||||||2018-06-01 04:07:58.489077|2018-06-01 04:07:58.489077
NCT00299494|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|2017-07-24|2015-07-21|2018-02-06|2006-03-02|2006-03-06|Estimate|2018-02-06|2018-03-08|Actual|2015-07-21|2015-08-11|Estimate|2018-02-06|2018-03-08|Actual|May 4, 2006|Actual|2006-05-04|February 2018|2018-02-28|June 2, 2014|Actual|2014-06-02|May 19, 2014|Actual|2014-05-19||Interventional||Intent-to-Treat (ITT) population: All participants enrolled into the intended dose scheme.|Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)|A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma|Completed||Phase 1/Phase 2|119|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 04:07:58.826174|2018-06-01 04:07:58.826174
NCT00299481|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2008-06-26|2006-03-02|2006-03-06|Estimate|||||||2008-06-26|2008-06-30|Estimate|March 2006||2006-03-31|June 2008|2008-06-30|January 2011||2011-01-31|||||Observational|||Tissue Bank of Biological Specimens From Patients With Gynecologic Disease|Tissue and Data Acquisition Activity for the Study of Gynecological Disease|Unknown status|Recruiting||7000|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 04:08:01.807811|2018-06-01 04:08:01.807811
NCT00299468|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2008-03-12|2006-03-02|2006-03-06|Estimate|||||||2008-03-12|2008-03-17|Estimate|April 2006||2006-04-30|May 2006|2006-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Effect of the Patient Activation Measure on Chronic Care|Using the Patient Activation Measure (PAM) to Improve Patient Self-Management of Hypertension|Completed||Phase 1|283|Actual|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:08:02.026108|2018-06-01 04:08:02.026108
NCT00299455|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2009-02-10|2006-03-03|2006-03-06|Estimate|||||||2009-02-10|2009-02-11|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|March 2009|Anticipated|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Amoxicillin Clavulanate in Treatment of Acute Otitis Media|Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children|Unknown status|Active, not recruiting|Phase 4|320|Anticipated|University of Turku||2|||f||||f||||||||||2018-06-01 04:08:02.128161|2018-06-01 04:08:02.128161
NCT00299442|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2009-03-10|2006-03-03|2006-03-06|Estimate|||||||2009-03-10|2009-03-12|Estimate|July 2007||2007-07-31|November 2008|2008-11-30|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|||Self-Help Parent Training for Conduct Problems in Children|Can Self−Help Parent Training Reduce Conduct Problems in Children on NHS Waiting Lists for Child Mental Health Services?|Unknown status|Recruiting|Phase 3|70|Anticipated|University of Oxford||2|||f||||||||||||||2018-06-01 04:08:02.259725|2018-06-01 04:08:02.259725
NCT00299429|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-07-07|2006-03-03|2006-03-06|Estimate|||||||2008-07-07|2008-07-08|Estimate|January 2003||2003-01-31|March 2007|2007-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||MIDCAB Versus DES in Proximal LAD Lesions|Randomised Comparison of Minimally Invasive Direct Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Proximal Stenosis of the Left Anterior Descending Coronary Artery|Completed||Phase 4|130|Actual|University of Leipzig|||||f||||t||||||||||2018-06-01 04:08:02.424677|2018-06-01 04:08:02.424677
NCT00299416|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|2010-08-16||2011-04-05|2006-03-02|2006-03-06|Estimate|2011-04-05|2011-05-03|Estimate||||2011-04-05|2011-05-03|Estimate|February 2003||2003-02-28|April 2011|2011-04-30|August 2009|Actual|2009-08-31|January 2009|Actual|2009-01-31||Interventional|||Caffeinol Hypothermia Protocol|Combined Neuroprotective Modalities Coupled With Thrombolysis in Acute Ischemic Stroke: A Pilot Study of Caffeinol and Mild Hypothermia|Completed||Phase 1/Phase 2|30|Actual|The University of Texas Health Science Center, Houston|||||f||||t||||||||||2018-06-01 04:08:02.527241|2018-06-01 04:08:02.527241
NCT00299403|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2008-06-30|2006-03-03|2006-03-06|Estimate|||||||2008-06-30|2008-07-02|Estimate|May 2002||2002-05-31|June 2008|2008-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Antidepressant Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)Compared to ECT|The Antidepressant Effect of Repetitive Transcranial Magnetic Stimulation (rTMS)Compared to Electroconvulsive Therapy (ECT).An Open Randomized Noninferiority Trial.|Completed||Phase 2/Phase 3|60|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 04:08:02.753244|2018-06-01 04:08:02.753244
NCT00299390|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2015-12-30|2006-03-03|2006-03-06|Estimate|||||||2015-12-30|2015-12-31|Estimate|April 2006||2006-04-30|December 2015|2015-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer|Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)|Terminated||Phase 2|10|Actual|Bayer||1||"Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop~   the trial due to lack of efficacy ."|f||||||||||||||2018-06-01 04:08:02.849608|2018-06-01 04:08:02.849608
NCT00299377|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2008-07-02|2006-03-03|2006-03-06|Estimate|||||||2008-07-02|2008-07-03|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|February 2008|Actual|2008-02-29|November 2007||2007-11-30||Interventional|||Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI|Randomized Comparison of Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI and Effects on Infarct Size and Microvascular Obstruction|Completed||Phase 2/Phase 3|150||University of Leipzig|||||f||||||||||||||2018-06-01 04:08:03.000022|2018-06-01 04:08:03.000022
NCT00299364|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2006-03-02|2006-03-02|2006-03-06|Estimate|||||||2006-03-02|2006-03-06|Estimate|September 2004||2004-09-30|March 2006|2006-03-31|May 2005||2005-05-31|||||Interventional|||Comparison of the Efficacy and Tolerability of Black Cohosh Vs Tibolone in Patients With Menopausal Symptoms|Multi-Center, Randomized, Double-Blind, Parallel-Controlled Study on the Efficacy and Tolerability of Black Cohosh Vs Tibolone in Patients With Menopausal Symptoms|Completed||Phase 3|240||Schaper & Bruemmer GmbH & Co KG|||||f||||||||||||||2018-06-01 04:08:03.152236|2018-06-01 04:08:03.152236
NCT00299351|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2006-03-03|2006-03-03|2006-03-06|Estimate|||||||2006-03-03|2006-03-06|Estimate||||November 2005|2005-11-30||||||||Interventional|||A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.||Unknown status|Not yet recruiting|Phase 2|8||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:08:03.256419|2018-06-01 04:08:03.256419
NCT00299338|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2006-03-31|2006-03-02|2006-03-06|Estimate|||||||2006-03-31|2006-04-03|Estimate|September 1997||1997-09-30|March 2006|2006-03-31|September 2001||2001-09-30|||||Interventional|||A Dose Response and Safety Study of Procaine HCl in HIV-Infected Patients|A Pharmacokinetic and Safety Study of Procaine HCl in HIV-1 Infected Patients|Completed||Phase 1/Phase 2|24||Samaritan Pharmaceuticals, Inc|||||||||||||||||||2018-06-01 04:08:03.328486|2018-06-01 04:08:03.328486
NCT00299325|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03||2016-04-21|2016-06-01|2006-03-03|2006-03-06|Estimate||||2016-04-21|2016-05-20|Estimate|2016-06-01|2016-06-06|Estimate|February 2006||2006-02-28|June 2016|2016-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|VICTORIA||VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt|A Randomized, Double Blind, Two-arm Placebo Controlled, 12-Month Study of the Effects of Rimonabant 20mg Once Daily on the Amount and the Activity of Visceral Fat in Abdominally Obese Patients With Metabolic Syndrome.|Completed||Phase 3|254|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:08:03.451203|2018-06-01 04:08:03.451203
NCT00299312|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2017-03-14|2006-03-03|2006-03-06|Estimate|||||||2017-03-14|2017-03-16|Actual|March 2006||2006-03-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Genetic and Physical Characteristics of Rett Syndrome|Rett Syndrome Natural History: Genetic and Physical Characteristics of Rett Syndrome|Completed|||10|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 04:08:03.586335|2018-06-01 04:08:03.586335
NCT00299299|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2010-01-11|2006-03-03|2006-03-06|Estimate|||||||2010-01-11|2010-01-12|Estimate|June 2006||2006-06-30|January 2010|2010-01-31||||||||Observational|||Modelling Internal Hepatic Movement With an External Abdominal Marker|Modelling Internal Hepatic Movement With an External Abdominal Marker Block for Use With a Real Time Position Monitoring System for Respiratory Gating|Unknown status|Recruiting||10|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:08:03.696798|2018-06-01 04:08:03.696798
NCT00299286|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2012-08-03|2006-03-03|2006-03-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|June 2007||2007-06-30|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MAPLE||Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer|A Double Blind Short-Term Presurgical Study Assessing the Molecular Antiproliferative Predictors of Lapatinib's Effects in Breast Cancer|Completed||Phase 2|121|Actual|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-06-01 04:08:03.781091|2018-06-01 04:08:03.781091
NCT00299273|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2015-06-04|2006-03-02|2006-03-06|Estimate|||||||2015-06-04|2015-06-08|Estimate|March 2006||2006-03-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||High Fat - High Protein Diet in the Treatment of Obesity|Exploratory Feasibility Study: High Fat/Protein Diet in the Treatment of Obesity|Terminated||N/A|8|Actual|Rockefeller University||1||PI left institution|f||||t||||||||||2018-06-01 04:08:03.905478|2018-06-01 04:08:03.905478
NCT00299260|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2010-04-16|2006-03-03|2006-03-06|Estimate|||||||2010-04-16|2010-04-19|Estimate|August 2006||2006-08-31|January 2008|2008-01-31|September 2011|Anticipated|2011-09-30|September 2009|Actual|2009-09-30||Interventional|||CMV Glycoprotein B Vaccine in Allograft Recipients|A Phase II Immunogenicity Trial of Cytomegalovirus Glycoprotein B Vaccine in Allograft Candidate Recipients|Unknown status|Active, not recruiting|Phase 2|140|Actual|University College, London||2|||f||||t||||||||||2018-06-01 04:08:04.014106|2018-06-01 04:08:04.014106
NCT00299247|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2010-08-26|2006-03-03|2006-03-06|Estimate|||||||2010-08-26|2010-08-27|Estimate||||January 2010|2010-01-31|December 2006|Anticipated|2006-12-31|December 2006|Anticipated|2006-12-31||Interventional|||SP Resistance and Falciparum Malaria Transmission|SP Resistance Markers and Falciparum Malaria Transmission|Withdrawn||Phase 3|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:08:04.121541|2018-06-01 04:08:04.121541
NCT00299234|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2012-04-25|2006-03-02|2006-03-06|Estimate|||||||2012-04-25|2012-04-26|Estimate|June 2006||2006-06-30|April 2007|2007-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL|Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia|Terminated||Phase 4|1|Actual|Monarch Medical Research||2||Insufficient number of interested potentital subjects|f||||f||||||||||2018-06-01 04:08:04.233312|2018-06-01 04:08:04.233312
NCT00299221|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|2010-09-10||2015-05-26|2006-03-02|2006-03-06|Estimate|2015-05-26|2015-05-28|Estimate||||2015-05-26|2015-05-28|Estimate|April 2004||2004-04-30|May 2015|2015-05-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|TICTAC||Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients|Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients|Completed||Phase 4|150|Actual|Newark Beth Israel Medical Center|This trial enrolled 150 patients, but cannot be used to generalize care to other patients without careful consideration of risks and benefits. All patients had corticosteorids weaned so this trial doesn't assess the risk of steroid weaning.|2|||f||||f||||||||||2018-06-01 04:08:04.513056|2018-06-01 04:08:04.513056
NCT00299208|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2010-08-26|2006-03-03|2006-03-06|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2010|2010-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Azithromycin Combination Therapy for Malaria|Phase II, Open Label, Randomized Study of Azithromycin Combination Therapy for the Treatment of Acute, Uncomplicated Falciparum Malaria|Completed||Phase 2|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:08:05.204969|2018-06-01 04:08:05.204969
NCT00299195|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2017-06-07|2006-03-02|2006-03-06|Estimate|||||||2017-06-07|2017-06-08|Actual|February 2006||2006-02-28|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Randomized Study of Sulindac in Oral Premalignant Lesions|A Pilot Multi-Center International Double-Blind Placebo Controlled Randomized Study of Sulindac, a Pan-Cox Inhibitor, in Oral Premalignant Lesions|Active, not recruiting||N/A|66|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:08:05.361544|2018-06-01 04:08:05.361544
NCT00299182|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2014-09-04|2006-03-03|2006-03-06|Estimate|||||||2014-09-04|2014-09-05|Estimate|March 2006||2006-03-31|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma|Phase 1/2 Study of AMG 531 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Patients With Aggressive Non-Hodgkin's Lymphoma Receiving R-HyperCVAD Alternating With R-Ara-C/MTX|Completed||Phase 1/Phase 2|50|Actual|M.D. Anderson Cancer Center||7|||f||||f||||||||||2018-06-01 04:08:05.47159|2018-06-01 04:08:05.47159
NCT00299169|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2008-01-04|2006-03-02|2006-03-06|Estimate|||||||2008-01-04|2008-01-08|Estimate|September 2006||2006-09-30|September 2006|2006-09-30|November 2007|Actual|2007-11-30|||||Interventional|||Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes|Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes|Terminated||Phase 4|6|Actual|Lawson Health Research Institute||2||insufficient recruitment/enrollment|f||||f||||||||||2018-06-01 04:08:05.621146|2018-06-01 04:08:05.621146
NCT00299156|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|2015-08-19||2015-10-08|2006-03-03|2006-03-06|Estimate|2015-08-19|2015-09-18|Estimate||||2015-10-08|2015-11-03|Estimate|March 2006||2006-03-31|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Oral Clofarabine Study in Patients With Myelodysplastic Syndrome|Phase II Study of Oral Clofarabine in Myelodysplastic Syndrome (MDS)|Completed||Phase 2|65|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:08:05.720203|2018-06-01 04:08:05.720203
NCT00299143|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2011-12-27|2006-03-02|2006-03-06|Estimate|||||||2011-12-27|2011-12-29|Estimate|June 2005||2005-06-30|December 2011|2011-12-31|June 2010|Actual|2010-06-30|September 2009|Actual|2009-09-30||Observational|REACS||Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes|Pilot Study on Shear-induced Platelet Aggregation in Acute Coronary Syndromes|Completed|||97|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||Samples Without DNA|"~     serum, plasma, urines~   "|||2018-06-01 04:08:06.448626|2018-06-01 04:08:06.448626
NCT00299130|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|2013-02-21||2017-03-21|2006-03-03|2006-03-06|Estimate|2013-05-23|2013-06-28|Estimate||||2017-03-21|2017-04-17|Actual|October 2005||2005-10-31|March 2017|2017-03-31|July 2013|Actual|2013-07-31|June 2008|Actual|2008-06-30||Interventional|SERENE|Safety population included all randomized participants who received any part of an infusion.|A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis|A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|511|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 04:08:06.732617|2018-06-01 04:08:06.732617
NCT00299117|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2009-01-30|2006-03-03|2006-03-06|Estimate|||||||2009-01-30|2009-02-02|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Brief Smoking Intervention for Women Undergoing Breast Cancer Surgery|Effect of a Brief Preoperative Smoking Intervention on Postoperative Complications in Women Undergoing Breast Cancer Surgery: A Randomised Clinical Trial|Completed||N/A|130|Actual|Herlev Hospital|||||f||||t||||||||||2018-06-01 04:08:09.146396|2018-06-01 04:08:09.146396
NCT00299104|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|2009-11-16||2017-06-29|2006-03-03|2006-03-06|Estimate|2011-07-13|2011-08-10|Estimate||||2017-06-29|2017-07-28|Actual|January 2006||2006-01-31|June 2017|2017-06-30|July 2013|Actual|2013-07-31|September 2008|Actual|2008-09-30||Interventional|IMAGE||A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis|A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis|Completed||Phase 3|755|Actual|Genentech, Inc.||3|||f||||||||||||||2018-06-01 04:08:09.267205|2018-06-01 04:08:09.267205
NCT00299091|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2018-02-13|2006-03-03|2006-03-06|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2006||2006-09-30|February 2018|2018-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Modification of Doses of Efavirenz According to Its Blood Concentration in HIV Patients|Open, Parallel and Randomised Pilot Clinical Trial to Evaluate the Utility of the Therapeutic Monitoring of Plasma Levels of Efavirenz in Hiv-Infected Patients Initiating an Antiretroviral Treatment Regimen With Sustiva|Completed||Phase 4|31|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-06-01 04:08:10.844474|2018-06-01 04:08:10.844474
NCT00299065|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2007-09-24|2006-03-02|2006-03-06|Estimate|||||||2007-09-24|2007-09-26|Estimate|January 2006||2006-01-31|September 2007|2007-09-30|June 2006||2006-06-30|||||Interventional|||Safety Study of Zileuton Injection in Patients With Asthma|Assessment of Safety, Tolerability, and Pharmacokinetics of Zileuton Injection in Patients With Asthma|Completed||Phase 1/Phase 2|60||Critical Therapeutics|||||||||||||||||||2018-06-01 04:08:10.92454|2018-06-01 04:08:10.92454
NCT00299052|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2013-09-23|2006-03-02|2006-03-06|Estimate|||||||2013-09-23|2013-09-24|Estimate|March 2006||2006-03-31|September 2013|2013-09-30|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Interventional|||Efficacy of DBM on Fractures of the Shinbone (Tibia)|The Efficacy of Demineralized Bone Matrix and Autogenous Bone Graft in Accelerated Fracture Healing in Closed Tibia Fracture|Completed||Phase 4|16|Actual|Emory University||2|||f||||f||||||||||2018-06-01 04:08:10.999002|2018-06-01 04:08:10.999002
NCT00299039|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2009-01-30|2006-03-03|2006-03-06|Estimate|||||||2009-01-30|2009-02-02|Estimate|May 2006||2006-05-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|T3AI||T3AI-Pain After Breast Surgery|A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery.|Completed||Phase 3|150|Anticipated|Nova Scotia Health Authority||2|||f||||||||||||||2018-06-01 04:08:11.074771|2018-06-01 04:08:11.074771
NCT00299026|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-03|||2017-03-01|2006-03-03|2006-03-06|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2001||2001-06-30|March 2017|2017-03-31|February 2007|Actual|2007-02-28|May 2003|Actual|2003-05-31||Interventional|||A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent|TAXUS II: A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent|Completed||Phase 2|532||Boston Scientific Corporation|||||f|||||f|f||||||No||2018-06-01 04:08:11.153166|2018-06-01 04:08:11.153166
NCT00299013|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2008-04-24|2006-03-02|2006-03-06|Estimate|||||||2008-04-24|2008-04-25|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis|A Multicentre, Randomised, Double Blind, Double Dummy, Active Comparator Controlled, Parallel Group Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis|Completed||Phase 3|796|Actual|Alizyme||4|||f||||f||||||||||2018-06-01 04:08:11.234588|2018-06-01 04:08:11.234588
NCT00299000|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|2010-05-07||2011-07-19|2006-03-02|2006-03-06|Estimate|2010-09-28|2010-10-15|Estimate||||2011-07-19|2011-07-22|Estimate|May 2006||2006-05-31|July 2011|2011-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI|A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI)|Completed||Phase 4|4|Actual|BioMarin Pharmaceutical|Given the small number of patients (4) represented in this study, the outcomes observed in this study may not reflect or predict outcomes observed by physicians in clinical practice.|2|||f||||f||||||||||2018-06-01 04:08:11.551558|2018-06-01 04:08:11.551558
NCT00298987|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02||2010-02-04|2010-02-04|2006-03-03|2006-03-06|Estimate||||2010-02-04|2010-02-08|Estimate|2010-02-04|2010-02-08|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate|Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate|Completed||Phase 2|400|Anticipated|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 04:08:11.889771|2018-06-01 04:08:11.889771
NCT00298974|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2011-01-24|2006-03-02|2006-03-06|Estimate|||||||2011-01-24|2011-01-25|Estimate|February 2006||2006-02-28|January 2011|2011-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study of Pain Relief in Osteoarthritis|A Phase 3, Randomized, Multicenter, Double-blind Study Comparing the Analgesic Efficacy of Extended Release Hydrocodone/Acetaminophen Tablets (Vicodin CR) to Placebo in Subjects With Osteoarthritis|Completed||Phase 3|873|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:08:12.066385|2018-06-01 04:08:12.066385
NCT00298961|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2008-05-20|2006-03-02|2006-03-03|Estimate|||||||2008-05-20|2008-05-21|Estimate|May 2006||2006-05-31|May 2008|2008-05-31|November 2007|Anticipated|2007-11-30|||||Interventional|||Psychiatric Consultation Through Videoconference in a Primary Care Setting|Telepsychiatry: Cost Analysis, Quality of Life, Satisfaction and Effectiveness of Psychiatric Consultation Through Videoconference in a Primary Care Setting|Unknown status|Not yet recruiting|N/A|160|Anticipated|Sha’ar Menashe Mental Health Center|||||f||||||||||||||2018-06-01 04:08:12.23603|2018-06-01 04:08:12.23603
NCT00298935|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2013-06-21|2006-03-02|2006-03-03|Estimate|||||||2013-06-21|2013-06-24|Estimate|July 2003||2003-07-31|June 2013|2013-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Study of the Effectiveness of Osteopathic Manipulative Treatment in Pregnant Women|Pilot Clinical Trial of Osteopathic Manipulative Treatment (OMT) in Pregnancy|Completed||Phase 2|146||University of North Texas Health Science Center|||||f||||||||||||||2018-06-01 04:08:12.316803|2018-06-01 04:08:12.316803
NCT00298922|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2009-07-30|2006-03-02|2006-03-03|Estimate|||||||2009-07-30|2009-07-31|Estimate|February 2006||2006-02-28|July 2009|2009-07-31|October 2009|Anticipated|2009-10-31|February 2009|Anticipated|2009-02-28||Interventional|||Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex|Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Azithromycin in Patients With CF, Chronically Infected With Burkholderia Cepacia Complex|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-06-01 04:08:12.371|2018-06-01 04:08:12.371
NCT00298909|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2012-07-29|2006-03-02|2006-03-03|Estimate|||||||2012-07-29|2012-07-31|Estimate|March 2006||2006-03-31|July 2012|2012-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)|Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function|Completed||Phase 4|48|Actual|University of Leipzig||3|||f||||||||||||||2018-06-01 04:08:12.437163|2018-06-01 04:08:12.437163
NCT00298896|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2009-03-05|2006-03-01|2006-03-03|Estimate|||||||2009-03-05|2009-03-06|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|June 2008|Actual|2008-06-30|August 2007|Actual|2007-08-31||Interventional|||Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer|Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)|Completed||Phase 2|80|Anticipated|Sunesis Pharmaceuticals|||||f||||||||||||||2018-06-01 04:08:12.506368|2018-06-01 04:08:12.506368
NCT00298883|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2012-07-24|2006-03-01|2006-03-03|Estimate|||||||2012-07-24|2012-07-25|Estimate|February 2006||2006-02-28|July 2012|2012-07-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Desensitization of Renal Transplant Candidates|Desensitization of Renal Transplant Candidates|Completed||Phase 1|9|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 04:08:12.595207|2018-06-01 04:08:12.595207
NCT00298870|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2012-10-17|2006-03-02|2006-03-03|Estimate|||||||2012-10-17|2012-10-18|Estimate|June 2005||2005-06-30|May 2011|2011-05-31||||||||Interventional|||Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)||Completed||Phase 4|172|Actual|Osaka University||2|||f||||t||||||||||2018-06-01 04:08:12.672797|2018-06-01 04:08:12.672797
NCT00298857|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2012-06-29|2006-03-02|2006-03-03|Estimate|||||||2012-06-29|2012-07-03|Estimate|March 2006||2006-03-31|June 2012|2012-06-30|March 2007|Actual|2007-03-31|||||Interventional|||A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights|An Open-label, Prospective Trial to Determine the Effect(s) of Obesity on the Pharmacokinetic Parameters of Valproic Acid|Terminated||Phase 4|22||Northwell Health||||Lack of funding|f||||||||||||||2018-06-01 04:08:12.737084|2018-06-01 04:08:12.737084
NCT00298844|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2007-03-22|2006-03-01|2006-03-03|Estimate|||||||2007-03-22|2007-03-23|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|January 2010|Anticipated|2010-01-31|||||Observational|||Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus|Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus: Left Ventricular Diastolic Dysfunction, Myocardial Ischemia and Peripheral Vascular Insufficient|Unknown status|Recruiting||350||Odense University Hospital|||||f||||||||||||||2018-06-01 04:08:13.060642|2018-06-01 04:08:13.060642
NCT00298831|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2017-08-18|2006-03-01|2006-03-03|Estimate|||||||2017-08-18|2017-08-22|Actual|October 27, 2005|Actual|2005-10-27|August 2017|2017-08-31|May 22, 2006|Actual|2006-05-22|May 22, 2006|Actual|2006-05-22||Interventional|||Use of Sugammadex at the End of Case in Routine Anesthesia (19.4.311)(P05943)|A Multicenter, Open Label, Phase IIIa Trial to Evaluate the Efficacy and Safety of Org 25969 When Used at the End of Surgical Procedure to Reverse the Neuromuscular Block Induced by Rocuronium Following Routine Anesthesia|Completed||Phase 3|224|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 04:08:13.121168|2018-06-01 04:08:13.121168
NCT00298818|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2008-05-19|2006-03-02|2006-03-03|Estimate|||||||2008-05-19|2008-05-20|Estimate|August 2002||2002-08-31|May 2008|2008-05-31|March 2008|Actual|2008-03-31|December 2005|Actual|2005-12-31||Observational|||Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation|Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation / Developmental Disabilities|Completed|||25|Actual|Northwell Health|||||f||||f||||||||||2018-06-01 04:08:13.183651|2018-06-01 04:08:13.183651
NCT00298805|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2013-08-08|2006-03-01|2006-03-03|Estimate|||||||2013-08-08|2013-08-12|Estimate|January 2006||2006-01-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|June 2009|Actual|2009-06-30||Observational|||A Quality of Life Study in Patients With Migraines|Dysphoric-like Disorder of Epilepsy, Is It Unique?|Terminated|||52|Actual|Northwell Health||||Study terminated due to expiration of IRB approval|f||||f||||||||||2018-06-01 04:08:13.248194|2018-06-01 04:08:13.248194
NCT00298792|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2009-04-14|2006-03-01|2006-03-03|Estimate|||||||2009-04-14|2009-04-15|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|IATP||Individualized Treatment Program for Alcohol Problems|Individualized Treatment Program for Alcohol Problems|Completed||Phase 1|110|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||f||||||||||2018-06-01 04:08:13.305335|2018-06-01 04:08:13.305335
NCT00298779|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2008-06-04|2006-03-02|2006-03-03|Estimate|||||||2008-06-04|2008-06-06|Estimate||||June 2008|2008-06-30||||||||Interventional|||Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.|An Open-Label Study to Assess the Effect of Omeprazole Administration on the Pharmacokinetics of VELCADE in Subjects With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Completed||Phase 1|20|Anticipated|Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 04:08:13.380297|2018-06-01 04:08:13.380297
NCT00298766|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|2010-07-16||2012-06-19|2006-03-02|2006-03-03|Estimate|2010-07-16|2010-08-13|Estimate||||2012-06-19|2012-06-25|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis|An Open-Label Phase 1/2 Study of VELCADE for Injection in Subjects With Light-Chain (AL)-Amyloidosis|Completed||Phase 1/Phase 2|70|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||||||||||||2018-06-01 04:08:13.461417|2018-06-01 04:08:13.461417
NCT00298753|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2015-09-14|2006-03-01|2006-03-03|Estimate|||||||2015-09-14|2015-09-15|Estimate|May 2005||2005-05-31|September 2006|2006-09-30||||||||Interventional|||Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine|Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine|Withdrawn||Phase 4|0|Actual|Regional Hospital Holstebro||||no patients could be recruited|f||||||||||||||2018-06-01 04:08:13.861134|2018-06-01 04:08:13.861134
NCT00298740|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|2017-08-10||2017-09-08|2006-03-01|2006-03-03|Estimate|2017-09-08|2017-09-12|Actual||||2017-09-08|2017-09-12|Actual|February 2003|Actual|2003-02-28|September 2017|2017-09-30|September 24, 2009|Actual|2009-09-24|September 24, 2009|Actual|2009-09-24||Interventional|||Medtronic MiniMed Implantable Insulin Pump|Reimplantation of Subjects With Implantable Insulin Pump Therapy|Completed||N/A|12|Actual|Johns Hopkins University||1|||f||||t|f|t|f|f||||||2018-06-01 04:08:13.930712|2018-06-01 04:08:13.930712
NCT00298727|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2011-05-03|2006-03-01|2006-03-03|Estimate|||||||2011-05-03|2011-05-04|Estimate|January 2007||2007-01-31|May 2011|2011-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Effect and Mediators of Two Knowledge Translation Strategies|Defining the Effect and Mediators of Two Knowledge Translation Strategies Designed to Alter Knowledge, Intent and Clinical Utilization of Rehabilitation Outcome Measures|Completed||Phase 3|131|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 04:08:14.103981|2018-06-01 04:08:14.103981
NCT00298714|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2007-11-21|2006-03-02|2006-03-03|Estimate|||||||2007-11-21|2007-11-22|Estimate|March 2003||2003-03-31|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C|Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.|Completed||Phase 4|20||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 04:08:14.183669|2018-06-01 04:08:14.183669
NCT00298701|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2006-05-03|2006-03-01|2006-03-03|Estimate|||||||2006-05-03|2006-05-04|Estimate|February 2006||2006-02-28|May 2006|2006-05-31|April 2006||2006-04-30|||||Interventional|||Tolerability of Grazax-R in Children|A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase I Trial Investigating the Safety of GRAZAX-R in Children Aged 5-12 Years With Grass Pollen Induced Rhinoconjunctivitis (With/Without Asthma)|Completed||Phase 1|50||ALK-Abelló A/S|||||f||||||||||||||2018-06-01 04:08:14.238798|2018-06-01 04:08:14.238798
NCT00298688|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2008-06-11|2006-03-01|2006-03-03|Estimate|||||||2008-06-11|2008-06-12|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|March 2007|Actual|2007-03-31|||||Interventional|||A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer|Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer|Completed||Phase 2|56||AstraZeneca|||||f||||||||||||||2018-06-01 04:08:14.292184|2018-06-01 04:08:14.292184
NCT00298675|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2012-08-01|2006-03-02|2006-03-03|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 2006||2006-03-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|July 2010|Actual|2010-07-31||Interventional|||Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors|A Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors|Completed||Phase 1|59|Actual|Sanofi||2|||t||||||||||||||2018-06-01 04:08:14.359953|2018-06-01 04:08:14.359953
NCT00298662|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-02|||2006-03-02|2006-03-02|2006-03-03|Estimate|||||||2006-03-02|2006-03-03|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|September 2006||2006-09-30|||||Interventional|||Combination Therapy of Betaseron-Prograf in Multiple Sclerosis|A Pilot Safety and Tolerability Open-Label Study of Interferon Beta-1b in Combination With Tacrolimus in Patients Suffering From Multiple Sclerosis Who Have Failed Treatment With Approved Disease Modifying Agents|Unknown status|Active, not recruiting|Phase 2|30||Clinique de sclérose en plaques et neuromusculaire de l'Outaouais|||||f||||||||||||||2018-06-01 04:08:14.431033|2018-06-01 04:08:14.431033
NCT00298649|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2015-10-05|2006-03-01|2006-03-02|Estimate|||||||2015-10-05|2015-10-06|Estimate|July 2002||2002-07-31|March 2006|2006-03-31|October 2004||2004-10-31|||||Interventional|||Reducing Farmworkers Exposure to Agricultural Chemicals||Terminated||N/A|400||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 04:08:14.487444|2018-06-01 04:08:14.487444
NCT00298636|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2006-08-01|2006-02-28|2006-03-02|Estimate|||||||2006-08-01|2006-08-02|Estimate|October 2005||2005-10-31|August 2006|2006-08-31||||||||Interventional|||Dose-Response of Adenosine for Perioperative Pain|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Escalating Dose-Response Trial of Intravenous Adenosine for Perioperative Analgesia in Females Undergoing Abdominal Hysterectomy or Myomectomy|Completed||Phase 2|160||Xsira Pharmaceuticals|||||||||||||||||||2018-06-01 04:08:14.537306|2018-06-01 04:08:14.537306
NCT00298623|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2013-05-10|2006-02-28|2006-03-02|Estimate|||||||2013-05-10|2013-05-14|Estimate|March 2006||2006-03-31|May 2011|2011-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 in Patients With Restless Legs Syndrome.|Completed||Phase 3|222|Actual|XenoPort, Inc.||2|||f||||t||||||||||2018-06-01 04:08:14.590047|2018-06-01 04:08:14.590047
NCT00298610|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|2016-11-30||2017-02-01|2006-03-01|2006-03-02|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|March 2006||2006-03-31|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy Study of IV Artesunate to Treat Malaria|A Phase II, Open Label, Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Artesunate in Adults With Uncomplicated Malaria|Completed||Phase 2|30|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||t||||||||No||2018-06-01 04:08:14.682307|2018-06-01 04:08:14.682307
NCT00298597|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2009-04-22|2006-03-01|2006-03-02|Estimate|||||||2009-04-22|2009-04-23|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Influence of G-CSF and EPO on Associative Learning and Motor Skills|Influence of G-CSF and EPO on Associative Learning and Motor Skills|Completed||Phase 2|180|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:08:15.104902|2018-06-01 04:08:15.104902
NCT00298584|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2007-02-22|2006-02-28|2006-03-02|Estimate|||||||2007-02-22|2007-02-23|Estimate|February 2006||2006-02-28|August 2006|2006-08-31||||||||Interventional|||Comparison of Infant Pain Responses Between Two Different Methods of Urine Collection|Comparison of Infant Pain Responses Between Two Different Methods of Urine Collection for Diagnosis of Infection: Suprapubic Aspiration and Urinary Catheterization|Unknown status|Recruiting|Phase 3|50||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:08:15.183345|2018-06-01 04:08:15.183345
NCT00298558|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|2013-04-24||2014-03-24|2006-02-28|2006-03-02|Estimate|2014-01-02|2014-02-24|Estimate||||2014-03-24|2014-04-16|Estimate|March 1998||1998-03-31|January 2014|2014-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ACTIVE|Of 2832 randomized subjects, 30 subjects were randomized inappropriately in violation of the protocol and excluded from the analysis. Therefore, 2802 subjects were used for the baseline analysis.|ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly|Trial of a Cognitive Intervention for Older Adults|Completed||Phase 2/Phase 3|2832|Actual|New England Research Institutes||4|||f||||t||||||||||2018-06-01 04:08:15.411678|2018-06-01 04:08:15.411678
NCT00298545|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2011-11-17|2006-03-01|2006-03-02|Estimate|||||||2011-11-17|2011-11-18|Estimate|November 2005||2005-11-30|November 2011|2011-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Vitamin D and Calcium on Genes in the Colon|High vs. Low Calcium Intake in the Presence of High Vitamin D: Effect on Gene Expression in the Colon|Completed||Phase 1|10|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 04:08:15.996253|2018-06-01 04:08:15.996253
NCT00298532|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2010-10-13|2006-03-01|2006-03-02|Estimate|||||||2010-10-13|2010-10-15|Estimate|July 1992||1992-07-31|October 2010|2010-10-31|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||OPALS Pediatric Study|The Ontario Prehospital Advanced Life Support (OPALS) Study for Critically Ill and Injured Pediatric Patients|Completed||N/A|9000||Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-06-01 04:08:16.069024|2018-06-01 04:08:16.069024
NCT00298519|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2009-09-18|2006-03-01|2006-03-02|Estimate|||||||2009-09-18|2009-09-21|Estimate|June 2003||2003-06-30|September 2009|2009-09-30|February 2006|Actual|2006-02-28|||||Observational|||Maternal Ethnic Group,Diet,Breast Milk Fatty Acid and Potential Effect Development of Allergy in the Offspring|The Influence of Maternal Ethnic Group and Diet on Breast Milk Fatty Acid Content and Its Potential Effect on Development of Allergy in the Offspring.|Completed|||300|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:08:16.158375|2018-06-01 04:08:16.158375
NCT00298506|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2011-09-28|2006-03-01|2006-03-02|Estimate|||||||2011-09-28|2011-09-29|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)|An Open, Prospective Study to Assess the Efficacy and Safety of FK506 Combined MMF in the Treatment of Class III，IV，V + IV or V + III Lupus Nephritis|Completed||N/A|120|Actual|Nanjing University School of Medicine||1|||f||||t||||||||||2018-06-01 04:08:16.211074|2018-06-01 04:08:16.211074
NCT00298493|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2006-02-28|2006-02-28|2006-03-02|Estimate|||||||2006-02-28|2006-03-02|Estimate|February 2001||2001-02-28|February 2006|2006-02-28|September 2004||2004-09-30|||||Interventional|||Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol|A Randomized Trial of Daily Sedative Interruption in Critically Ill Patients Being Managed With a Sedation Protocol - A Pilot Study|Completed||Phase 2|65||Mount Sinai Hospital, Canada|||||f||||||||||||||2018-06-01 04:08:16.297429|2018-06-01 04:08:16.297429
NCT00298480|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2007-04-18|2006-03-01|2006-03-02|Estimate|||||||2007-04-18|2007-04-19|Estimate|February 2005||2005-02-28|April 2007|2007-04-30|July 2007|Anticipated|2007-07-31|||||Observational|||Dynamic Cervical Change: Prediction of Preterm Labor in Symptomatic Patients||Unknown status|Recruiting||220||Memorial Health Services Research Council|||||f||||||||||||||2018-06-01 04:08:16.356896|2018-06-01 04:08:16.356896
NCT00298467|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2010-04-23|2006-03-01|2006-03-02|Estimate|||||||2010-04-23|2010-04-26|Estimate|February 2006||2006-02-28|April 2010|2010-04-30||||||||Interventional|||MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma|An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma|Withdrawn||Phase 2|45|Anticipated|Bristol-Myers Squibb||||sponsor decision|||||||||||||||2018-06-01 04:08:16.419809|2018-06-01 04:08:16.419809
NCT00298454|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2007-04-18|2006-03-01|2006-03-02|Estimate|||||||2007-04-18|2007-04-19|Estimate|December 2005||2005-12-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Forced Diuresis Versus Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients|Forced Diuresis Vs Observation in Resolving Renal Failure After Haemofiltration in Critically Ill Patients (Fodorefh)|Terminated||Phase 3|72||Medical Centre Leeuwarden||||Number included has been reached|f||||||||||||||2018-06-01 04:08:16.497775|2018-06-01 04:08:16.497775
NCT00298441|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2008-05-08|2006-02-28|2006-03-02|Estimate|||||||2008-05-08|2008-05-12|Estimate|June 2005||2005-06-30|May 2008|2008-05-31|March 2007|Actual|2007-03-31|May 2006|Actual|2006-05-31||Interventional|||Efficacy of Intravenous Iron Administration in Hemodialysis Patients|Effect of IVIR Frequency on Anemia Correction and Oxidative Stress Formation and in Hemodialysis Patients|Completed||Phase 4|50||Kumamoto University|||||f||||t||||||||||2018-06-01 04:08:16.565124|2018-06-01 04:08:16.565124
NCT00298428|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2011-09-23|2006-03-01|2006-03-02|Estimate|||||||2011-09-23|2011-09-26|Estimate|May 2006||2006-05-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|SPACE||Biological Efficacy of Clopidogrel After Implantation of Drug-eluting Stents (SPACE)|Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)|Completed||N/A|159|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 04:08:16.651063|2018-06-01 04:08:16.651063
NCT00298415|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2013-10-24|2006-03-01|2006-03-02|Estimate|||||||2013-10-24|2013-10-25|Estimate|March 2006||2006-03-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)|Phase III Study of Monotherapy by Gemcitabine or Vinorelbine Comparing to Doublet by Carboplatin and Paclitaxel Among Elderly Patients With Stage IIIB/IV NSCLC (Obligatory Second-line by Erlotinib)|Completed||Phase 3|451|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||||2018-06-01 04:08:16.739542|2018-06-01 04:08:16.739542
NCT00298402|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2015-05-27|2006-03-01|2006-03-02|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2005||2005-10-31|March 2006|2006-03-31|October 2007||2007-10-31|||||Observational|||Macrophages in Smokers' Lung|The Role of Macrophages in the Pathophysiology of Smokers' Lung|Withdrawn|||0|Actual|Imperial College London|||||f||||||||||||||2018-06-01 04:08:16.821851|2018-06-01 04:08:16.821851
NCT00298389|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2014-03-19|2006-03-01|2006-03-02|Estimate|||||||2014-03-19|2014-03-20|Estimate|October 2005||2005-10-31|March 2006|2006-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Macrophage Phagocytosis in COPD|Macrophage Phagocytosis in Chronic Obstructive Pulmonary Disease|Completed|||90|Actual|Imperial College London|||||f||||||||||||||2018-06-01 04:08:16.87404|2018-06-01 04:08:16.87404
NCT00298376|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2007-04-26|2006-03-01|2006-03-02|Estimate|||||||2007-04-26|2007-04-27|Estimate|March 2006||2006-03-31|April 2007|2007-04-30||||||||Observational|||Oral Tolerance in Cow’s Milk Allergy in the Infant|Oral Tolerance in Cow’s Milk Allergy in the Infant: Role of CD4+CD25+ T Cells and Intestinal Microflora|Unknown status|Recruiting||50||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:08:16.931962|2018-06-01 04:08:16.931962
NCT00298363|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|2012-04-10||2013-04-19|2006-02-28|2006-03-02|Estimate|2013-04-19|2013-04-25|Estimate||||2013-04-19|2013-04-25|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.|A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation|Completed||Phase 2|112|Actual|Gilead Sciences||3|||f||||t||||||||||2018-06-01 04:08:17.063063|2018-06-01 04:08:17.063063
NCT00298350|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2008-07-28|2006-02-28|2006-03-02|Estimate|||||||2008-07-28|2008-07-29|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.|Phase 2 Study of the Treatment of Antiretroviral Treatment-Experienced Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) vs. a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination With Background ART.|Completed||Phase 2|278|Actual|Gilead Sciences|||||f||||t||||||||||2018-06-01 04:08:19.411405|2018-06-01 04:08:19.411405
NCT00298337|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2006-10-17|2006-03-01|2006-03-02|Estimate|||||||2006-10-17|2006-10-18|Estimate|October 1999||1999-10-31|March 2006|2006-03-31|December 2007||2007-12-31|||||Interventional|||Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008||Unknown status|Active, not recruiting|Phase 2/Phase 3|||Helsinki University|||||f||||||||||||||2018-06-01 04:08:19.546841|2018-06-01 04:08:19.546841
NCT00298324|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2015-04-02|2006-03-01|2006-03-02|Estimate|||||||2015-04-02|2015-04-03|Estimate|September 2006||2006-09-30|April 2015|2015-04-30|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|||Myfortic - Treatment for Extensive cGvHD|A Randomized Double Blinded Placebo-Controlled Phase III Trial Comparing Cyclosporine Plus Steroids With or Without Myfortic as Primary Treatment for Extensive Chronic Graft Versus Host Disease|Terminated||Phase 3|34|Actual|European Group for Blood and Marrow Transplantation||2||Due to slow accrual|f||||t||||||||||2018-06-01 04:08:19.606653|2018-06-01 04:08:19.606653
NCT00298311|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2017-08-03|2006-03-01|2006-03-02|Estimate|||||||2017-08-03|2017-08-07|Actual|November 2005||2005-11-30|August 2017|2017-08-31|July 2010|Actual|2010-07-31|February 2009|Actual|2009-02-28||Interventional|||Effect of Home-Based Peer Support on Maternal-Infant Interaction and Postpartum Depression|An RCT to Evaluate the Effect of Home-Based Peer Support on Maternal-Infant Interaction, Infant Health Outcomes, and Postpartum Depression|Completed||N/A|60|Actual|Canadian Research Institute for Social Policy||2|||f||||f||||||||||2018-06-01 04:08:19.715264|2018-06-01 04:08:19.715264
NCT00298298|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2015-12-02|2006-03-01|2006-03-02|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer|L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|6|Actual|AVAX Technologies||3||Suspended until capitalization is completed|f||||t||||||||||2018-06-01 04:08:19.77824|2018-06-01 04:08:19.77824
NCT00298285|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2007-11-07|2006-02-28|2006-03-02|Estimate|||||||2007-11-07|2007-11-09|Estimate||||January 2006|2006-01-31|October 2006||2006-10-31|||||Interventional|||ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement|ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement. A Pilot Study|Completed||Phase 4|100||The Cleveland Clinic|||||||||||||||||||2018-06-01 04:08:19.867975|2018-06-01 04:08:19.867975
NCT00298272|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|2010-04-20||2015-08-27|2006-03-01|2006-03-02|Estimate|2010-10-21|2010-11-17|Estimate||||2015-08-27|2015-09-28|Estimate|May 2006||2006-05-31|August 2015|2015-08-31|July 2011|Actual|2011-07-31|April 2009|Actual|2009-04-30||Interventional||Safety Population|Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis|A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis|Terminated||Phase 2|54|Actual|Biogen|Sponsor made a business decision to terminate study on 28 July 2011, after completion of the primary endpoint and during the long-term extension phase. One participant was still in extended safety follow-up and was referred for appropriate care.|2||Sponsor decided to end long term extension phase for business reasons unrelated to safety.|f||||f||||||||||2018-06-01 04:08:19.978618|2018-06-01 04:08:19.978618
NCT00298259|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2012-12-09|2006-03-01|2006-03-02|Estimate|||||||2012-12-09|2012-12-11|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Trial of Operative Fixation of Fractured Ribs in Patients With Flail Chest|Prospective Randomised Trial of Operative Fixation of Fractured Ribs in Patients With Flail Chest|Completed||Phase 2|48|Actual|The Alfred||2|||f||||f||||||||||2018-06-01 04:08:20.94211|2018-06-01 04:08:20.94211
NCT00298246|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|||2017-10-05|2006-02-28|2006-03-01|Estimate|||||||2017-10-05|2017-10-06|Actual|February 22, 2006||2006-02-22|March 15, 2017|2017-03-15|March 15, 2017||2017-03-15|||||Observational|||Clinical and Immunological Investigations of Subtypes of Autism|Clinical and Immunological Investigations of Subtypes of Autism|Completed|||557|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:08:21.007312|2018-06-01 04:08:21.007312
NCT00298233|ClinicalTrials.gov processed this data on May 31, 2018|2006-03-01|2014-01-17||2014-05-26|2006-02-28|2006-03-01|Estimate|2014-04-28|2014-05-22|Estimate||||2014-05-26|2014-06-06|Estimate|February 2006||2006-02-28|May 2014|2014-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||All participants that were randomized|High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza|High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial|Completed||Phase 2|326|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 04:08:21.09109|2018-06-01 04:08:21.09109
NCT00298220|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2009-09-21|2006-02-21|2006-03-01|Estimate|||||||2009-09-21|2009-09-22|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|April 2009|Actual|2009-04-30|May 2008|Actual|2008-05-31||Interventional|||Engaging General Practice in the Prevention of Patients With Alcohol Problems|Engaging General Practice in the Prevention of Patients With Alcohol Problems|Completed||N/A|77|Actual|Radboud University||2|||f||||||||||||||2018-06-01 04:08:21.406144|2018-06-01 04:08:21.406144
NCT00298207|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-02-27|2006-02-27|2006-03-01|Estimate|||||||2006-02-27|2006-03-01|Estimate|April 2001||2001-04-30|April 2001|2001-04-30|February 2004||2004-02-29|||||Interventional|||Walking Intervention in African American Adults With Newly Diagnosed Hypertension|Walking Intervention in African American Adults With Newly Diagnosed Hypertension|Completed||N/A|20||University of Illinois at Chicago|||||f||||||||||||||2018-06-01 04:08:21.488321|2018-06-01 04:08:21.488321
NCT00298194|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2009-01-12|2006-02-28|2006-03-01|Estimate|||||||2009-01-12|2009-01-14|Estimate|February 2006||2006-02-28|January 2009|2009-01-31||||July 2008|Actual|2008-07-31||Interventional|||The Effects of Z-338 in Subjects With and Without Functional Dyspepsia|The Effects of Z-338 on the Symptomatic Response to a Nutrient Challenge and Gastric Nutrient Distribution and Emptying in Subjects With and Without Functional Dyspepsia|Completed||Phase 2|52|Anticipated|Zeria Pharmaceutical|||||f||||f||||||||||2018-06-01 04:08:21.551388|2018-06-01 04:08:21.551388
NCT00298181|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2008-01-24|2006-02-27|2006-03-01|Estimate|||||||2008-01-24|2008-01-29|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|November 2006|Actual|2006-11-30||Observational|||YSPSL for Prevention of Delayed Graft Function Part A|Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation|Completed|||15|Actual|Y's Therapeutics, Inc.|||||f||||t||||||||||2018-06-01 04:08:21.60638|2018-06-01 04:08:21.60638
NCT00298168|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2008-01-24|2006-02-27|2006-03-01|Estimate|||||||2008-01-24|2008-01-29|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||YSPSL for Prevention of Delayed Graft Function Part B|Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation|Completed||Phase 1/Phase 2|60|Actual|Y's Therapeutics, Inc.||3|||t||||t||||||||||2018-06-01 04:08:22.71987|2018-06-01 04:08:22.71987
NCT00298155|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2017-03-26||2017-03-26|2006-02-27|2006-03-01|Estimate|2017-03-26|2017-05-08|Actual||||2017-03-26|2017-05-08|Actual|July 2006||2006-07-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|June 2010|Actual|2010-06-30||Interventional|TAPS||Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer|Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer|Completed||Phase 2|35|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 04:08:22.832827|2018-06-01 04:08:22.832827
NCT00298142|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2009-10-05|2006-02-27|2006-03-01|Estimate|||||||2009-10-05|2009-10-06|Estimate|February 2006||2006-02-28|October 2009|2009-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Management of Headache Disorders: A Clinical Trial Screening for Prognostic Patient Characteristics|A Prospective Randomised Clinical Trial to Investigate the Management of Headache Disorders. Study to Identify Prognostic Patient Characteristics and to Investigate the Additional Value of Physio-/Manual Therapy|Terminated||N/A|120|Anticipated|Vrije Universiteit Brussel||||Insufficient enrollment|f||||||||||||||2018-06-01 04:08:23.108404|2018-06-01 04:08:23.108404
NCT00298129|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2007-05-08|2006-02-28|2006-03-01|Estimate|||||||2007-05-08|2007-05-09|Estimate|February 2004||2004-02-29|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Observational|||Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease|Autonomic Imbalance and 24-h Blood Pressure Change in Patients With Chronic Renal Disease|Completed|||278|Actual|Yokohama City University Medical Center|||||f||||t||||||||||2018-06-01 04:08:23.187297|2018-06-01 04:08:23.187297
NCT00298116|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2014-12-05|2006-02-27|2006-03-01|Estimate|||||||2014-12-05|2014-12-08|Estimate|September 2000||2000-09-30|December 2014|2014-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Molecular Associations With Reproductive Failure|Molecular Associations With Reproductive Failure|Completed|||475|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:08:23.242906|2018-06-01 04:08:23.242906
NCT00298103|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2015-12-16|2006-02-27|2006-03-01|Estimate|||||||2015-12-16|2015-12-17|Estimate|February 2006||2006-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||Antibiotic Resistant Community-Acquired E. Coli|Antibiotic Resistant Community-Acquired E. Coli|Completed|||1000|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 04:08:23.417231|2018-06-01 04:08:23.417231
NCT00298090|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2012-05-04||2014-11-14|2006-02-27|2006-03-01|Estimate|2013-06-28|2013-08-02|Estimate||||2014-11-14|2014-11-26|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Evaluation of a Radial Arterial Line's Effect on StO2 Monitoring|An Evaluation of a Radial Arterial Line's Effect on StO2 Monitoring Using the InSpectra® Tissue Spectrometer|Completed|||47|Actual|The University of Texas Health Science Center at San Antonio|Eighteen subjects were not included in final analysis due to incomplete data sets; unsuccessful arterial line placement, technical problems in applying StO2 device, unreliable data or partial data.||1||f||||f||||||||||2018-06-01 04:08:23.489611|2018-06-01 04:08:23.489611
NCT00298077|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2017-06-08|2006-02-27|2006-03-01|Estimate|||||||2017-06-08|2017-06-12|Actual|August 2006||2006-08-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|November 2025|Anticipated|2025-11-30||Observational|||A Retrospective Review of Infections Usually Observed in Transplant Recipients|A Retrospective Review of Infections Usually Observed in Transplant Recipients|Recruiting|||500|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 04:08:23.646402|2018-06-01 04:08:23.646402
NCT00298064|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2016-05-10|2006-02-28|2006-03-01|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2005||2005-12-31|May 2016|2016-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer|Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer|Completed||N/A|300|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:08:23.719508|2018-06-01 04:08:23.719508
NCT00298038|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2011-07-17|2006-02-28|2006-03-01|Estimate|||||||2011-07-17|2011-07-19|Estimate|December 2005||2005-12-31|July 2011|2011-07-31|April 2009|Actual|2009-04-30|August 2008|Actual|2008-08-31||Interventional|||A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy|Completed||Phase 3|299|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||t||||||||||2018-06-01 04:08:23.887579|2018-06-01 04:08:23.887579
NCT00298025|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2014-03-24|2006-02-27|2006-03-01|Estimate|||||||2014-03-24|2014-03-26|Estimate|September 2003||2003-09-30|March 2014|2014-03-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation|A Phase IV, Multicenter, Open-label, Randomized Study to Compare the Safety and Efficacy of Cetrotide® 3 mg Versus Antagon™ in the Inhibition of a Premature LH Surge in a r-hFSH/hMG Stimulation Cycle With OCP Programming in Women Undergoing Ovarian Stimulation Prior to ART|Completed||Phase 4|185|Actual|EMD Serono||2|||f||||||||||||||2018-06-01 04:08:23.984095|2018-06-01 04:08:23.984095
NCT00298012|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2009-01-02|2006-02-28|2006-03-01|Estimate|||||||2009-01-02|2009-01-05|Estimate|March 2006||2006-03-31|January 2009|2009-01-31||||||||Interventional|||Methotrexate in the Treatment of Axial Spondyloarthritis|Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study.|Withdrawn||Phase 4|120|Anticipated|Rheumatism Foundation Hospital|||||f||||||||||||||2018-06-01 04:08:24.114729|2018-06-01 04:08:24.114729
NCT00297986|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2015-04-27|2006-02-27|2006-03-01|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2004||2004-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Evaluation of Different Interfaces for Noninvasive Positive Pressure Ventilation (NPPV)|Evaluation of Different Interfaces for NPPV|Completed|||10|Actual|Policlinico Hospital|||1||f||||f||||||||||2018-06-01 04:08:24.188495|2018-06-01 04:08:24.188495
NCT00297973|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2009-03-27|2006-02-27|2006-03-01|Estimate|||||||2009-03-27|2009-03-30|Estimate|February 2006||2006-02-28|April 2008|2008-04-30|April 2007|Actual|2007-04-30|||||Interventional|RIGHT||Cardiovascular Risk Assessment in Patients Treated With Caduet|Cardiovascular Risk Assessment In Patients With Hypertension And At Least Three Other Risk Factors, Treated With Caduet Compared To Usual Care: The Right Study|Completed||Phase 4|1442|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:08:24.328438|2018-06-01 04:08:24.328438
NCT00297960|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2006-10-17|2006-02-28|2006-03-01|Estimate|||||||2006-10-17|2006-10-18|Estimate|April 2005||2005-04-30|October 2005|2005-10-31||||||||Interventional|||Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle|Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle|Completed||Phase 4|||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:08:24.971936|2018-06-01 04:08:24.971936
NCT00297947|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2015-04-16|2006-02-27|2006-03-01|Estimate|||||||2015-04-16|2015-04-17|Estimate|December 2004||2004-12-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|HDQ||High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder|A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder|Completed||Phase 2/Phase 3|60|Actual|Manhattan Psychiatric Center||2|||f||||t||||||||||2018-06-01 04:08:25.03041|2018-06-01 04:08:25.03041
NCT00297934|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2008-12-17|2006-02-27|2006-03-01|Estimate|||||||2008-12-17|2008-12-18|Estimate|March 2006||2006-03-31|October 2006|2006-10-31|March 2006||2006-03-31|||||Interventional|||Spinal Manipulative Therapy: Dual-Task Performance|Influence of Instrument-Applied Spinal Manipulative Therapy on Dual-Task Performance Involving Complex Postural and Cognitive Tasks|Completed||N/A|20||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 04:08:25.114919|2018-06-01 04:08:25.114919
NCT00297921|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2013-11-04|2006-02-27|2006-03-01|Estimate|||||||2013-11-04|2013-11-06|Estimate||||November 2013|2013-11-30||||||||Interventional|||A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy||Withdrawn||Phase 1/Phase 2|0|Actual|Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 04:08:25.165179|2018-06-01 04:08:25.165179
NCT00297908|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2015-06-02|2006-02-27|2006-03-01|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2006||2006-02-28|February 2007|2007-02-28|February 2006||2006-02-28|||||Observational|||Alcohol Based Hand Sanitizer: Can Frequent Use Cause an Elevated Blood Alcohol Level?|Alcohol Based Hand Sanitizer: Can Frequent Use Cause an Elevated Blood Alcohol Level?|Completed|||5||C.R.Darnall Army Medical Center|||||f||||||||||||||2018-06-01 04:08:25.213669|2018-06-01 04:08:25.213669
NCT00297895|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2018-02-05|2006-02-28|2006-03-01|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2004||2004-09-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Multicenter Selective Lymphadenectomy Trial II (MSLT-II)|A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node|Active, not recruiting||N/A|1925|Anticipated|John Wayne Cancer Institute||2|||f||||t|f|f||||||Undecided||2018-06-01 04:08:25.280712|2018-06-01 04:08:25.280712
NCT00297882|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2013-04-28|2006-02-28|2006-03-01|Estimate|||||||2013-04-28|2013-04-30|Estimate|July 2006||2006-07-31|April 2013|2013-04-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon|Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon|Completed||Phase 3|900|Actual|Gates Malaria Partnership||2|||f||||t||||||||||2018-06-01 04:08:25.548875|2018-06-01 04:08:25.548875
NCT00297869|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2016-10-04|2006-02-27|2006-03-01|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Using Informatics to Enhance Care of Older Emergency Department Patients|Computer-Assisted Decision Support to Increase the Safety of Prescribing to Older Emergency Department Patients|Completed||N/A|1350|Actual|Indiana University||2|||f||||f||||||||||2018-06-01 04:08:25.639949|2018-06-01 04:08:25.639949
NCT00297856|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2014-01-09|2006-02-28|2006-03-01|Estimate|||||||2014-01-09|2014-01-13|Estimate|March 2006||2006-03-31|January 2014|2014-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine|Open, Prospective Study of the Safety of GSK Biologicals' Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO)|Completed|||10000|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-06-01 04:08:25.717655|2018-06-01 04:08:25.717655
NCT00297427|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2016-01-14||2016-08-31|2006-02-27|2006-02-28|Estimate|2016-06-20|2016-08-01|Estimate||||2016-08-31|2016-10-24|Estimate|October 2005||2005-10-31|August 2016|2016-08-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Acupuncture for Urinary Incontinence|Efficacy of Acupuncture in Treating Urinary Incontinence|Completed||Phase 2|127|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:08:30.798467|2018-06-01 04:08:30.798467
NCT00297843|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2007-06-18|2006-02-28|2006-03-01|Estimate|||||||2007-06-18|2007-06-19|Estimate|March 2006||2006-03-31|June 2007|2007-06-30|May 2006||2006-05-31|||||Observational|||A Pilot Monocenter Study to Assess Cellular and Soluble Biomarkers in Nasal Secretions|A Pilot Monocenter Study to Assess the Reproducibility and Specificity of Cellular and Soluble Biomarkers in Nasal Secretions in Patients With Allergic Rhinitis and Healthy Volunteers Following Pollen Exposure in the Fraunhofer Environmental Challenge Chamber (ECC)|Completed|||40||Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||||||||||||2018-06-01 04:08:25.815376|2018-06-01 04:08:25.815376
NCT00297830|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2013-02-15||2016-07-28|2006-02-27|2006-03-01|Estimate|2016-07-28|2016-09-15|Estimate||||2016-07-28|2016-09-15|Estimate|November 2005||2005-11-30|July 2016|2016-07-31|January 2014|Actual|2014-01-31|April 2010|Actual|2010-04-30||Interventional|CTX|Based on preliminary data that total hip BMD would decrease by 1.5 ± 3.7% on alendronate and increase by 1.0 ± 3.7% on zoledronate, we estimated that 35 subjects per group would provide 80% power and 5% α to detect a 2.5 ± 3.7% difference between randomized groups. Anticipating a 20% dropout, 84 subjects were randomized.|Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation|Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation|Completed||Phase 2/Phase 3|111|Actual|Columbia University|Heart and liver transplant recipients differ in pretransplant bone disease and exposure to prednisone. Not powered to detect differences in fracture rates,an important clinical outcome,one that would require a large comparative effectiveness trial.|2|||f||||f||||||||Undecided||2018-06-01 04:08:25.899114|2018-06-01 04:08:25.899114
NCT00297817|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2016-11-30|2006-02-27|2006-03-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|February 2006||2006-02-28|January 2012|2012-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents|A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age|Completed||Phase 2|203|Actual|Novartis||3|||||||f||||||||||2018-06-01 04:08:26.272225|2018-06-01 04:08:26.272225
NCT00297804|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2017-04-20|2006-02-27|2006-03-01|Estimate|||||||2017-04-20|2017-04-21|Actual|May 2002||2002-05-31|April 2017|2017-04-30|February 2008|Actual|2008-02-29|October 2003|Actual|2003-10-31||Interventional|TAXUS VI||A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions|TAXUS VI - A Randomized, Double-blind Study to Assess Paclitaxel-eluting Stents in Treatment of Longer Lesions|Completed||Phase 2/Phase 3|448|Actual|Boston Scientific Corporation||2|||f||||t|f|f||||||No||2018-06-01 04:08:26.361812|2018-06-01 04:08:26.361812
NCT00297791|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2013-07-29|2006-02-27|2006-03-01|Estimate|||||||2013-07-29|2013-07-30|Estimate|June 2004||2004-06-30|July 2013|2013-07-31|October 2017|Anticipated|2017-10-31|April 2013|Actual|2013-04-30||Interventional|COLORII||COLOR II: Laparoscopic Versus Open Rectal Cancer Removal|A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Rectal Cancer.|Unknown status|Active, not recruiting|Phase 3|1100|Anticipated|Nova Scotia Health Authority||1|||f||||t||||||||||2018-06-01 04:08:26.467613|2018-06-01 04:08:26.467613
NCT00297778|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|2009-05-22||2014-06-03|2006-02-28|2006-03-01|Estimate|2009-08-21|2009-09-24|Estimate||||2014-06-03|2014-06-09|Estimate|March 2006||2006-03-31|April 2014|2014-04-30||||May 2008|Actual|2008-05-31||Interventional|||Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms|A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms|Completed||Phase 4|296|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 04:08:26.668331|2018-06-01 04:08:26.668331
NCT00297765|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2008-08-25|2006-02-28|2006-03-01|Estimate|||||||2008-08-25|2008-08-26|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|OPTIMA||Optimizing Prograf® Therapy in Renal Transplant Patients|OPTIMA (Optimizing Prograf® Therapy in Renal Transplant Patients)|Completed||Phase 4|323|Actual|Astellas Pharma Inc|||||f||||t||||||||||2018-06-01 04:08:27.394406|2018-06-01 04:08:27.394406
NCT00297752|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2009-08-07|2006-02-28|2006-03-01|Estimate|||||||2009-08-07|2009-08-10|Estimate|March 2006||2006-03-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|||||Interventional|||Treatment of Facial Burns With Flammacerium Compared to Flammazine and the Impact of Facial Burns on Psychosocial Wellbeing|A Randomised Multicentre Clinical Trial on the Efficacy of Flammacerium in the Treatment of Facial Burns and the Impact of Facial Burns on Psychosocial Wellbeing|Completed||Phase 4|180|Anticipated|Association of Dutch Burn Centres|||||f||||||||||||||2018-06-01 04:08:27.548532|2018-06-01 04:08:27.548532
NCT00297739|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-28|||2006-03-15|2006-02-28|2006-03-01|Estimate|||||||2006-03-15|2006-03-16|Estimate|January 2003||2003-01-31|March 2006|2006-03-31|April 2005||2005-04-30|||||Interventional|||Risperidone Augmentation for Treatment-Resistant Aggression in ADHD|Risperidone Augmentation for Treatment-Resistant Aggression in ADHD|Completed||Phase 4|25||Armenteros, Jorge L., M.D., P.A.|||||f||||||||||||||2018-06-01 04:08:27.632179|2018-06-01 04:08:27.632179
NCT00297726|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-02-27|2006-02-27|2006-03-01|Estimate|||||||2006-02-27|2006-03-01|Estimate|October 2004||2004-10-31|February 2006|2006-02-28|April 2006||2006-04-30|||||Interventional|||A Study to Examine the Efficacy of the Arthritis Self Management Program|A Prospective Study to Examine the Efficacy of the Arthritis Self Management Program (ASMP) in Patients With Osteoarthritis (OA) in Alberta|Completed||N/A|64||Alberta Bone and Joint Health Institute|||||f||||||||||||||2018-06-01 04:08:27.701331|2018-06-01 04:08:27.701331
NCT00297713|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-12-11|2006-02-27|2006-03-01|Estimate|||||||2006-12-11|2006-12-13|Estimate|July 2005||2005-07-31|December 2006|2006-12-31|June 2006||2006-06-30|||||Interventional|||Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety|A Phase II, Multi-Center, Multi-Dose, Randomized, Open-Label, Parallel Group Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety|Completed||Phase 2|12||Altus Pharmaceuticals|||||||||||||||||||2018-06-01 04:08:27.758067|2018-06-01 04:08:27.758067
NCT00297700|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2017-01-10|2006-02-24|2006-02-28|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2004||2004-05-31|July 2006|2006-07-31|April 2007||2007-04-30|||||Interventional|||Implementing Tobacco Control in Dental Practice|Implementing Tobacco Control in Dental Practice|Unknown status|Active, not recruiting|Phase 3|2800||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:08:27.815252|2018-06-01 04:08:27.815252
NCT00297687|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2007-12-03|2006-02-27|2006-02-28|Estimate|||||||2007-12-03|2007-12-05|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults|A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults|Completed||Phase 1|108||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:08:27.90787|2018-06-01 04:08:27.90787
NCT00297648|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2009-12-10||2011-08-30|2006-02-27|2006-02-28|Estimate|2009-12-10|2010-01-18|Estimate||||2011-08-30|2011-08-31|Estimate|February 2006||2006-02-28|February 2011|2011-02-28|December 2009|Actual|2009-12-31|January 2008|Actual|2008-01-31||Interventional|MUSIC||Mucosal Healing Study in Crohn's Disease (CD)|A Phase IIIB Multicentre Open Label 54 Weeks Clinical Trial Evaluating Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNFα) on Endoscopic and Mucosal Healing in Patients Suffering From Active Crohn's Disease.|Completed||Phase 3|89|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:08:28.16172|2018-06-01 04:08:28.16172
NCT00297635|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2017-01-11|2006-02-27|2006-02-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2006||2006-03-31|January 2017|2017-01-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy||Withdrawn||Phase 2|0|Actual|Thomas Jefferson University||||Decided not to participate in study per Leslie Padron-Massaro|f||||||||||||||2018-06-01 04:08:28.751618|2018-06-01 04:08:28.751618
NCT00297609|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-02-27|2006-02-27|2006-02-28|Estimate|||||||2006-02-27|2006-02-28|Estimate|January 2002||2002-01-31|February 2006|2006-02-28||||||||Observational|||Prevention of Errors in Resuscitation Medications Orders by Means of a Computerized Physician Order Entry|Prevention of Potential Errors in Resuscitation Medications Orders by Means of a Computerized Physician Order Entry With Clinical Decision Support System in Pediatric Critical Care – a Prospective Cohort Study.|Completed|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:08:28.803604|2018-06-01 04:08:28.803604
NCT00297596|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2012-11-15||2013-01-24|2006-02-24|2006-02-28|Estimate|2012-11-15|2012-12-13|Estimate||||2013-01-24|2013-01-31|Estimate|February 2006||2006-02-28|January 2013|2013-01-31|October 2010|Actual|2010-10-31|October 2008|Actual|2008-10-31||Interventional|||Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer|A Phase II Trial of Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer|Completed||Phase 2|25|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:08:28.858554|2018-06-01 04:08:28.858554
NCT00297583|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2009-12-04|2006-02-27|2006-02-28|Estimate|||||||2009-12-04|2009-12-07|Estimate|April 2004||2004-04-30|December 2009|2009-12-31||||May 2004|Actual|2004-05-31||Interventional|||Insulin Glulisine in Type 1 Diabetes Mellitus|A Single-center, Randomized, Double-blind, 3-period Cross-over Trial to Compare the Effect of Insulin Glulisine, Insulin Lispro and Unmodified Human Insulin on the Endogenous Glucose Production in Type 1 Diabetic Patients.|Completed||Phase 1|||Sanofi|||||f||||||||||||||2018-06-01 04:08:29.03424|2018-06-01 04:08:29.03424
NCT00297570|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2007-10-07|2006-02-27|2006-02-28|Estimate|||||||2007-10-07|2007-10-10|Estimate|February 2006||2006-02-28|October 2007|2007-10-31||||||||Interventional|||Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy||Unknown status|Recruiting|Phase 3|90|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:08:29.08629|2018-06-01 04:08:29.08629
NCT00297557|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-10-10|2006-02-27|2006-02-28|Estimate|||||||2006-10-10|2006-10-11|Estimate||||January 2006|2006-01-31||||||||Observational|||Dual Time Point PET Imaging in Lymphoma||Unknown status|Not yet recruiting||||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:08:29.142939|2018-06-01 04:08:29.142939
NCT00297544|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-02-27|2006-02-27|2006-02-28|Estimate|||||||2006-02-27|2006-02-28|Estimate|October 2005||2005-10-31|November 2005|2005-11-30||||||||Interventional|||Effect of Sildenafil on Endothelial Function|Effect of Sildenafil on Endothelial Function|Unknown status|Recruiting|N/A|60||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:08:29.187789|2018-06-01 04:08:29.187789
NCT00297531|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2007-05-17|2006-02-24|2006-02-28|Estimate|||||||2007-05-17|2007-05-21|Estimate|April 2006||2006-04-30|May 2007|2007-05-31|October 2007|Anticipated|2007-10-31|||||Interventional|||Study of Scaling and Root Planing With PerioWave Versus Scaling and Root Planing Alone in Chronic Periodontitis|Photodynamic Disinfection in Combination With Scaling and Root Planing in the Treatment of Chronic Periodontitis|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Ondine Research Laboratories|||||f||||||||||||||2018-06-01 04:08:29.350965|2018-06-01 04:08:29.350965
NCT00297518|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2007-05-17|2006-02-24|2006-02-28|Estimate|||||||2007-05-17|2007-05-21|Estimate|March 2006||2006-03-31|May 2007|2007-05-31|January 2007|Actual|2007-01-31|||||Interventional|||Study of Scaling and Root Planing (SRP) With PerioWave vs. SRP Alone in Chronic Periodontitis|A Multicenter, Randomized, Examiner Blinded Study of Photoactivated Disinfection With Scaling and Root Planing in the Treatment of Chronic Periodontitis|Completed||Phase 4|40|Actual|Ondine Research Laboratories|||||f||||||||||||||2018-06-01 04:08:29.457232|2018-06-01 04:08:29.457232
NCT00297505|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2017-01-11|2006-02-27|2006-02-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|February 2006|2006-02-28|November 2004||2004-11-30|||||Interventional|||Serotonin, Impulsivity, and Cocaine Dependence Treatment|Serotonin, Impulsivity, and Cocaine Dependence Treatment|Completed||Phase 2|120||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:08:29.550281|2018-06-01 04:08:29.550281
NCT00297492|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2012-05-31||2013-09-17|2006-02-24|2006-02-28|Estimate|2012-08-02|2012-09-05|Estimate||||2013-09-17|2013-09-20|Estimate|January 2006||2006-01-31|September 2013|2013-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Gradual vs. Abrupt Cessation Treatment for Smoking|Gradual vs. Abrupt Cessation Treatment for Smoking|Completed||Phase 2|750|Actual|University of Vermont|Our projected incidence of abstinence was higher than what was actually observed, leading to lower statistical power than expected.|3|||f||||f||||||||||2018-06-01 04:08:29.647057|2018-06-01 04:08:29.647057
NCT00297479|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2016-10-24|2006-02-24|2006-02-28|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2005||2005-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Group Therapy for Nicotine Dependence: Mindfulness and Smoking|Group Therapy for Nicotine Dependence|Completed||N/A|650|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-06-01 04:08:29.968618|2018-06-01 04:08:29.968618
NCT00297466|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2017-01-10|2006-02-24|2006-02-28|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2006||2006-01-31|February 2006|2006-02-28|May 2008|Actual|2008-05-31|April 2007|Actual|2007-04-30||Interventional|||Strategies to Help Adult ED Patients Quit Smoking|Strategies to Help Adult ED Patients Quit Smoking|Completed||N/A|336|Anticipated|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:08:30.318702|2018-06-01 04:08:30.318702
NCT00297453|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2012-06-25|2006-02-24|2006-02-28|Estimate|||||||2012-06-25|2012-06-27|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Smoking Treatment in HIV Clinical Care Settings||Completed||Phase 3|207|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-06-01 04:08:30.590018|2018-06-01 04:08:30.590018
NCT00297440|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2010-07-22|2006-02-27|2006-02-28|Estimate|||||||2010-07-22|2010-07-23|Estimate|March 2006||2006-03-31|July 2010|2010-07-31|August 2011|Anticipated|2011-08-31|August 2009|Actual|2009-08-31||Interventional|||Exercise, Smoking Cessation and Adolescents|Exercise to Aid Smoking Cessation in Adolescent Girls|Unknown status|Active, not recruiting|Phase 1/Phase 2|80|Anticipated|Temple University|||||f||||f||||||||||2018-06-01 04:08:30.680559|2018-06-01 04:08:30.680559
NCT00297414|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2012-04-11|2006-02-24|2006-02-28|Estimate|||||||2012-04-11|2012-04-12|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Observational|||An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine|An Analysis of Mortality in Subjects Who Participated in Three Studies of Galantamine in Mild Cognitive Impairment|Completed|||1083|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||f||||f||||||||||2018-06-01 04:08:31.658851|2018-06-01 04:08:31.658851
NCT00297401|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24||2009-01-30|2016-08-25|2006-02-24|2006-02-28|Estimate||||2009-10-05|2009-10-07|Estimate|2016-08-25|2016-08-29|Estimate|March 2006||2006-03-31|August 2016|2016-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus|The Effect of Protein Kinase C Inhibition on Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|20|Actual|Chromaderm, Inc.||2|||f||||f||||||||||2018-06-01 04:08:31.893274|2018-06-01 04:08:31.893274
NCT00297388|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2011-05-17|2006-02-24|2006-02-28|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|September 2004|Actual|2004-09-30|||||Interventional|||A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder|A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|40|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:08:31.965461|2018-06-01 04:08:31.965461
NCT00297375|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2011-06-08|2006-02-24|2006-02-28|Estimate|||||||2011-06-08|2011-06-10|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|August 2003|Actual|2003-08-31|||||Interventional|||A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache|A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Acute Treatment of Migraine Headache Pain|Completed||Phase 4|375|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:08:32.030041|2018-06-01 04:08:32.030041
NCT00297362|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2012-03-23|2006-02-24|2006-02-28|Estimate|||||||2012-03-23|2012-03-26|Estimate|June 2004||2004-06-30|March 2012|2012-03-31|October 2005|Actual|2005-10-31|||||Observational|||A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease|Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type|Completed|||344|Actual|Janssen Cilag Pharmaceutica S.A.C.I., Greece|||1||f||||||||||||||2018-06-01 04:08:32.115063|2018-06-01 04:08:32.115063
NCT00297349|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2010-04-26|2006-02-24|2006-02-28|Estimate|||||||2010-04-26|2010-04-27|Estimate|November 2003||2003-11-30|April 2010|2010-04-30|June 2005|Actual|2005-06-30|||||Observational|||A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures|An Open-label Observation Study of Topiramate Administration as Adjuvant Therapy for Focal Epilepsy, Lennox-Gastaut Syndrome Epileptic Seizures and Generalized Tonoclonic Seizures in Adults and Children Aged 2 Years and Older|Completed|||153|Actual|Janssen Cilag Pharmaceutica S.A.C.I., Greece|||1||f||||||||||||||2018-06-01 04:08:32.176338|2018-06-01 04:08:32.176338
NCT00297336|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2010-04-26|2006-02-24|2006-02-28|Estimate|||||||2010-04-26|2010-04-27|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|February 2007|Actual|2007-02-28|||||Observational|||An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine|An Open-label Observational Safety Study During Administration of Topiramate, for the Prophylaxis of Migraine|Completed|||80|Actual|Janssen Cilag Pharmaceutica S.A.C.I., Greece|||1||f||||||||||||||2018-06-01 04:08:32.333922|2018-06-01 04:08:32.333922
NCT00297323|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2010-04-26|2006-02-24|2006-02-28|Estimate|||||||2010-04-26|2010-04-27|Estimate|June 2005||2005-06-30|April 2010|2010-04-30|February 2007|Actual|2007-02-28|||||Observational|||An Observational Study of the Safety of Topiramate in Adults and Children With Epilepsy|An Open Observational Safety Study During Administration of Topamac, as Monotherapy in Epileptic Patients With no Prior Treatment or Unsuccessfully Treated With Other Antiepileptic Drug|Completed|||80|Actual|Janssen Cilag Pharmaceutica S.A.C.I., Greece|||1||f||||||||||||||2018-06-01 04:08:32.415458|2018-06-01 04:08:32.415458
NCT00297310|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24||2011-06-06|2011-06-06|2006-02-24|2006-02-28|Estimate||||2011-06-06|2011-06-20|Estimate|2011-06-06|2011-06-20|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|April 2007|Actual|2007-04-30|October 2006|Actual|2006-10-31||Interventional|||Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation|Pre-transplant Pharmacokinetics as a Predictor of the Tacrolimus Dose Requirement Post Renal Transplantation|Completed||Phase 4|89|Actual|Janssen-Cilag Pty Ltd|||||f||||||||||||||2018-06-01 04:08:32.502849|2018-06-01 04:08:32.502849
NCT00297297|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2010-02-24|2006-02-27|2006-02-28|Estimate|||||||2010-02-24|2010-02-25|Estimate|December 2008||2008-12-31|October 2007|2007-10-31|March 2011|Anticipated|2011-03-31|||||Observational|||Improved Preoperative Selection of Cold Thyroid Nodules|Preoperative Selection of Solitary Solid Cold Thyroid Nodules - A Prospective Study on the Value of Sonography, Cytology, Immunostaining and Molecular Profiling|Unknown status|Enrolling by invitation||100|Anticipated|Herlev Hospital|||||f||||||||||||||2018-06-01 04:08:32.567333|2018-06-01 04:08:32.567333
NCT00297284|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2009-01-27|2006-02-24|2006-02-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|February 2006||2006-02-28|September 2006|2006-09-30|February 2007||2007-02-28|||||Interventional|||Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil|Pilot and Feasibility Study of Modafinil Treatment to Improve Cognitive Efficiency in SLE Patients|Terminated||N/A|20||Hospital for Special Surgery, New York|||||f||||||||||||||2018-06-01 04:08:32.636756|2018-06-01 04:08:32.636756
NCT00297271|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2013-11-28|2006-02-24|2006-02-28|Estimate|||||||2013-11-28|2013-12-02|Estimate|August 2005||2005-08-31|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Prospective Research in Memory Clinics (PRIME)|Prospective Research in Memory Clinics (PRIME)|Completed|||970|Actual|Janssen-Cilag Pty Ltd|||1||f||||f||||||||||2018-06-01 04:08:32.73488|2018-06-01 04:08:32.73488
NCT00297258|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2009-12-02||2016-01-04|2006-02-24|2006-02-28|Estimate|2009-12-02|2010-01-06|Estimate||||2016-01-04|2016-02-03|Estimate|November 2005||2005-11-30|December 2015|2015-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma|Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma|Completed||Phase 2|148|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:08:32.887151|2018-06-01 04:08:32.887151
NCT00297245|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2006-02-27|2006-02-27|2006-02-28|Estimate|||||||2006-02-27|2006-02-28|Estimate|February 2006||2006-02-28|January 2006|2006-01-31|May 2006||2006-05-31|||||Interventional|||Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass||Unknown status|Recruiting|Phase 4|200||Huazhong University of Science and Technology|||||f||||||||||||||2018-06-01 04:08:33.349483|2018-06-01 04:08:33.349483
NCT00297232|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2015-04-21||2016-06-16|2006-02-27|2006-02-28|Estimate|2015-05-08|2015-05-29|Estimate||||2016-06-16|2016-07-15|Estimate|March 2006||2006-03-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|STRATA||Natalizumab (Tysabri) Re-Initiation of Dosing|An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation|Terminated||Phase 3|1094|Actual|Biogen|Sponsor decided to terminate the study prior to all subjects reaching Week 480 as the primary objective was deemed to have been met and only approximately 45% of the original STRATA population remained in the study at the time of study termination.|1|||f||||f||||||||||2018-06-01 04:08:33.487126|2018-06-01 04:08:33.487126
NCT00297219|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2009-08-03|2006-02-27|2006-02-28|Estimate|||||||2009-08-03|2009-08-04|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry|The Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry: Prospective, Randomized, Controlled Study|Completed||N/A|457|Actual|Ege University||2|||f||||t||||||||||2018-06-01 04:08:34.112841|2018-06-01 04:08:34.112841
NCT00297206|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2017-09-08|2006-02-24|2006-02-28|Estimate|||||||2017-09-08|2017-09-11|Actual|January 25, 2003|Actual|2003-01-25|September 2017|2017-09-30|February 28, 2007|Actual|2007-02-28|February 28, 2007|Actual|2007-02-28||Interventional|||A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children|An Open-label, Single-dose, Multicenter, Pharmacokinetic, Safety and Tolerability Study of Valaciclovir Oral Suspension in Infants and Children.|Completed||Phase 1|36|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:08:34.20228|2018-06-01 04:08:34.20228
NCT00297193|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2013-08-29|2006-02-27|2006-02-28|Estimate|||||||2013-08-29|2013-08-30|Estimate|June 2006||2006-06-30|August 2013|2013-08-31|March 2017|Anticipated|2017-03-31|March 2013|Actual|2013-03-31||Interventional|||ASTIC Autologous Stem Cell Transplantation for Crohn's Disease|Autologous Stem Cell Transplantation for Crohn's Disease: ASTIC|Terminated||Phase 3|45|Actual|European Group for Blood and Marrow Transplantation||2||"For safety reasons the recruitment was halted prematurely. Patients on the trial continute to~   receive treatment and are being followed up as part the protocol."|f||||t||||||||||2018-06-01 04:08:34.302948|2018-06-01 04:08:34.302948
NCT00297180|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2015-04-14|2006-02-24|2006-02-28|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks|A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor|Completed||Phase 2|136|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:08:34.394054|2018-06-01 04:08:34.394054
NCT00297167|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2014-02-24||2017-02-07|2006-02-27|2006-02-28|Estimate|2014-02-24|2014-04-04|Estimate||||2017-02-07|2017-03-16|Actual|May 2006||2006-05-31|February 2017|2017-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional||Safety population included all participants who received at least 1 dose of study treatment.|Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|A Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients With Cystic Fibrosis and Exocrine Pancreatic Insufficiency|Completed||Phase 3|34|Actual|Forest Laboratories||2|||f||||||||||||||2018-06-01 04:08:34.46593|2018-06-01 04:08:34.46593
NCT00297154|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2010-12-02|2006-02-27|2006-02-28|Estimate|||||||2010-12-02|2010-12-06|Estimate|March 2005||2005-03-31|December 2010|2010-12-31||||||||Interventional|||The Effect of Diet and Exercise in Heart Failure|Lifestyle Modification in the Treatment of Heart Failure|Unknown status|Recruiting|N/A|60|Anticipated|Baylor College of Medicine|||||f||||||||||||||2018-06-01 04:08:35.815334|2018-06-01 04:08:35.815334
NCT00297141|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2013-12-30|2006-02-27|2006-02-28|Estimate|||||||2013-12-30|2013-12-31|Estimate|October 2004||2004-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma|Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum|Completed||Phase 2|60|Actual|Austrian Breast & Colorectal Cancer Study Group||1|||f||||f||||||||||2018-06-01 04:08:35.881615|2018-06-01 04:08:35.881615
NCT00297128|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|||2011-12-29|2006-02-27|2006-02-28|Estimate|||||||2011-12-29|2011-12-30|Estimate|October 2005||2005-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Preoperative Chemoradiation With Capecitabine and Cetuximab|Preoperative Chemoradiation With Capecitabine and Cetuximab Within a Multidisciplinary Therapeutic Approach in Patients With Operable T3-T4 Rectal Cancer: a Phase II Study|Completed||Phase 2|31|Actual|Austrian Breast & Colorectal Cancer Study Group||1|||f||||f||||||||||2018-06-01 04:08:35.967093|2018-06-01 04:08:35.967093
NCT00297115|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2011-03-17||2016-10-03|2006-02-27|2006-02-28|Estimate|2011-04-20|2011-05-19|Estimate||||2016-10-03|2016-11-07|Estimate|March 2006||2006-03-31|September 2016|2016-09-30|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)|Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The HERMES Study|Completed||Phase 3|1568|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:08:36.266262|2018-06-01 04:08:36.266262
NCT00297102|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27|2011-03-17||2016-11-29|2006-02-27|2006-02-28|Estimate|2011-04-20|2011-05-19|Estimate||||2016-11-29|2017-01-16|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)|Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study|Completed||Phase 3|1523|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:08:37.681473|2018-06-01 04:08:37.681473
NCT00297089|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-27||2011-12-07|2013-01-29|2006-02-27|2006-02-28|Estimate||||2011-12-07|2011-12-22|Estimate|2013-01-29|2013-01-31|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer|A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT 751 in Combination With Pemetrexed Versus Pemetrexed Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|165|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 04:08:38.817961|2018-06-01 04:08:38.817961
NCT00297076|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2009-05-15|2006-02-24|2006-02-27|Estimate|||||||2009-05-15|2009-05-18|Estimate|July 2005||2005-07-31|May 2009|2009-05-31|October 2007|Anticipated|2007-10-31|October 2007|Anticipated|2007-10-31||Interventional|||Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-Containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.|Terminated||Phase 3|406||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:08:38.968768|2018-06-01 04:08:38.968768
NCT00297063|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2017-01-16|2006-02-24|2006-02-27|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2006||2006-01-31|January 2017|2017-01-31|May 2007|Actual|2007-05-31|||||Interventional|||BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-|Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo -|Completed||Phase 3|350|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:08:39.03775|2018-06-01 04:08:39.03775
NCT00297050|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-25|||2017-06-30|2006-02-24|2006-02-27|Estimate|||||||2017-06-30|2017-07-02|Actual|February 23, 2006||2006-02-23|August 5, 2009|2009-08-05|November 14, 2006|Actual|2006-11-14|November 14, 2006|Actual|2006-11-14||Interventional|||Safety and Dose Study of Peramivir for Influenza Treatment|A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Intravenous Peramivir in Healthy Subjects|Completed||Phase 1|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:08:39.122964|2018-06-01 04:08:39.122964
NCT00297037|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2011-03-01||2012-09-14|2006-02-23|2006-02-27|Estimate|2012-09-14|2012-10-17|Estimate||||2012-09-14|2012-10-17|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pimecrolimus Cream for Oral Lichen Planus|A 6-week Randomized, Double-blind, Vehicle-controlled Pilot Study With a 6-week Open Label Extension to Assess the Efficacy and Safety of Pimecrolimus 1% Cream in the Treatment of Oral Lichen Planus|Completed||Phase 2|21|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 04:08:39.179401|2018-06-01 04:08:39.179401
NCT00297024|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2014-01-03|2006-02-23|2006-02-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 2005||2005-02-28|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Radiotherapy - Cerebrovascular Reactivity (RT-CVR Study)|MRI Changes With Administered Oxygen and Carbon Dioxide in Patients With Brain Tumors Receiving Radiotherapy: A Pilot Study|Completed||Phase 2|14|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:08:39.473685|2018-06-01 04:08:39.473685
NCT00297011|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2008-04-30|2006-02-23|2006-02-27|Estimate|||||||2008-04-30|2008-05-06|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|January 2008|Actual|2008-01-31|March 2007|Actual|2007-03-31||Interventional|||Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis|Valacyclovir+Temovate Gel for the Episodic Treatment of Herpes Labialis: A Patient-Initiated Double-Blind, Placebo-Controlled Study, Randomized Study.|Completed||Phase 2|300||University of Utah|||||f||||f||||||||||2018-06-01 04:08:39.601332|2018-06-01 04:08:39.601332
NCT00296985|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2013-11-25|2006-02-23|2006-02-27|Estimate|||||||2013-11-25|2013-11-27|Estimate|December 2001||2001-12-31|November 2013|2013-11-30|January 2007|Actual|2007-01-31|January 2005|Actual|2005-01-31||Interventional|||Continuous Cellsaver and Neurocognitive Decline Post Cardiac Surgery|The Impact of Continuous Flow Cellsaver on Neurocognitive Decline After Cardiac Surgery|Completed||Phase 4|312||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:08:39.680225|2018-06-01 04:08:39.680225
NCT00296972|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-04-19|2006-02-23|2006-02-27|Estimate|||||||2007-04-19|2007-04-23|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication|A Randomized, Multicenter, phaseIIIB, Two Arm Study Evaluating the Tolerability of Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection co-Infected With Human Immunodeficiency Virus Receiving HAART Versus Not Receiving HAART|Terminated||Phase 3|100||University Health Network, Toronto||||not funded|f||||||||||||||2018-06-01 04:08:39.742825|2018-06-01 04:08:39.742825
NCT00296959|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-09-19|2006-02-23|2006-02-27|Estimate|||||||2007-09-19|2007-09-20|Estimate|September 2004||2004-09-30|August 2007|2007-08-31|March 2007|Actual|2007-03-31|||||Interventional|||Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease|Anti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced Dyskinesias|Terminated||Phase 2|20|Anticipated|University Health Network, Toronto||||early termination due to slow recruitment|f||||||||||||||2018-06-01 04:08:39.820061|2018-06-01 04:08:39.820061
NCT00296946|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2018-02-16|2006-02-23|2006-02-27|Estimate|||||||2018-02-16|2018-02-20|Actual|November 2004||2004-11-30|October 2004|2004-10-31|June 2006||2006-06-30|||||Interventional|||Ipratropium Spray for Drooling Saliva in Parkinson's Disease|Phase II Clinical Trial of Ipratropium Bromide Spray as a Treatment for Sialorrhea in Patients With Parkinson's Disease|Completed||Phase 2|20||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:08:39.884682|2018-06-01 04:08:39.884682
NCT00296933|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2009-02-16|2006-02-23|2006-02-27|Estimate|||||||2009-02-16|2009-02-17|Estimate|December 2005||2005-12-31|February 2009|2009-02-28||||||||Interventional|||Memory Functioning and Antidepressant Treatment|Memory Functioning and Antidepressant Treatment: A Randomized Controlled Trial Comparing Escitalopram and Bupropion XL|Completed||Phase 3|60|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:08:39.95228|2018-06-01 04:08:39.95228
NCT00296920|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2009-02-16|2006-02-23|2006-02-27|Estimate|||||||2009-02-16|2009-02-17|Estimate|June 2002||2002-06-30|September 2005|2005-09-30||||November 2007|Actual|2007-11-30||Interventional|||Deep Brain Stimulation for Refractory Major Depression|Deep Brain Stimulation for Refractory Major Depression|Completed||Phase 3|10||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:08:40.025896|2018-06-01 04:08:40.025896
NCT00296907|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2012-07-27|2006-02-24|2006-02-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Psychological Interventions in Siblings of Children With Cancer|Psychological Interventions in Siblings of Children With Cancer: a Randomized Controlled Study|Completed||N/A|30|Actual|University Children's Hospital, Zurich||1|||f||||||||||||||2018-06-01 04:08:40.103042|2018-06-01 04:08:40.103042
NCT00296712|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2012-04-26|2006-02-24|2006-02-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|February 2005||2005-02-28|April 2012|2012-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Are Two Antidepressants a Good Initial Treatment for Depression?|Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.|Completed||Phase 4|55|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 04:08:42.049126|2018-06-01 04:08:42.049126
NCT00296894|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2009-02-06|2006-02-24|2006-02-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints|TNF-Blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints: Randomized, Double Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of Adalimumab 40 mg SC Every Other Week in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints|Completed||Phase 2|60|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 04:08:40.207655|2018-06-01 04:08:40.207655
NCT00296881|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-05-17|2006-02-24|2006-02-27|Estimate|||||||2007-05-17|2007-05-21|Estimate|April 2006||2006-04-30|May 2007|2007-05-31|December 2007|Anticipated|2007-12-31|||||Interventional|||SRP in Combination With PERIOWAVE in Comparison to SRP Alone in Chronic Periodontitis|Clinical Outcomes Following Non-Surgical Treatment of Chronic Periodontitis, Using Scaling and Root Planing (SRP) in Conjunction With PerioWave, Compared to SRP Alone|Unknown status|Active, not recruiting|Phase 4|80|Actual|Ondine Research Laboratories|||||f||||||||||||||2018-06-01 04:08:40.294597|2018-06-01 04:08:40.294597
NCT00296868|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2006-02-24|2006-02-24|2006-02-27|Estimate|||||||2006-02-24|2006-02-27|Estimate|January 2001||2001-01-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Prophylactic Administration of Vitamin C in Wrist Fractures|Prophylactic Administration of Vitamin C in Wrist Fractures; a Randomized Placebo Controlled Multicentre Dose-Finding Study of the Incidence of Complex Regional Pain Syndrome|Completed||Phase 4|300||Stichting Achmea Slachtoffer en Samenleving|||||f||||||||||||||2018-06-01 04:08:40.395047|2018-06-01 04:08:40.395047
NCT00296855|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2010-04-22|2006-02-24|2006-02-27|Estimate|||||||2010-04-22|2010-04-23|Estimate|February 2006||2006-02-28|April 2010|2010-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease|Intra-individual Open-label Multicenter Comparison Study of Magnetic Resonance Angiography (MRA) With the Blood Pool Contrast Agent Vasovist® and a Conventional Extracellular Contrast Agent With Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients With Peripheral Artery Disease|Completed||Phase 3|261|Actual|Bayer||1|||f||||||||||||||2018-06-01 04:08:40.471929|2018-06-01 04:08:40.471929
NCT00296842|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2011-12-08|2006-02-24|2006-02-27|Estimate|||||||2011-12-08|2011-12-09|Estimate|November 2004||2004-11-30|December 2011|2011-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Prevention of Posttraumatic Stress Symptoms and Behavioral Problems in Children After Road Traffic Accidents: a Randomized Controlled Trial|Prevention of Posttraumatic Stress Symptoms and Behavioral Problems in Children and Adolescents After Road Traffic Accidents: a Randomized Controlled Trial|Completed||N/A|99|Actual|University Children's Hospital, Zurich|||||f||||||||||||||2018-06-01 04:08:40.584152|2018-06-01 04:08:40.584152
NCT00296829|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2014-01-10|2006-02-24|2006-02-27|Estimate|||||||2014-01-10|2014-01-14|Estimate|January 2006||2006-01-31|January 2014|2014-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly||Completed||Phase 2|1080||Sanofi|||||f||||f||||||||||2018-06-01 04:08:40.665512|2018-06-01 04:08:40.665512
NCT00296816|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2012-06-18||2012-07-20|2006-02-23|2006-02-27|Estimate|2012-07-20|2012-08-23|Estimate||||2012-07-20|2012-08-23|Estimate|March 2006||2006-03-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TEACO||TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary|A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel With Bevacizumab as First Line Therapy in Patients With FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma|Completed||Phase 2|132|Actual|Sanofi|One site closed prematurely during the study. Every effort was made to collect, at minimum, any outstanding safety data for the participants at this site. As a result, participants from this site were included only in the safety analysis.|1|||f||||f||||||||||2018-06-01 04:08:40.902633|2018-06-01 04:08:40.902633
NCT00296803|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2011-01-10|2006-02-23|2006-02-27|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2005||2005-11-30|January 2011|2011-01-31|August 2006|Actual|2006-08-31|||||Interventional|||PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome|PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome|Completed||Phase 4|216||Sanofi|||||f||||||||||||||2018-06-01 04:08:41.423849|2018-06-01 04:08:41.423849
NCT00296790|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-10-11|2006-02-23|2006-02-27|Estimate|||||||2007-10-11|2007-10-12|Estimate|February 2006||2006-02-28|October 2007|2007-10-31|February 2007||2007-02-28|||||Interventional|||Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)||Completed||Phase 4|372||Sanofi|||||f||||||||||||||2018-06-01 04:08:41.537139|2018-06-01 04:08:41.537139
NCT00296777|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2012-04-26|2006-02-23|2006-02-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Interventional|||Treatment of Depression Following Multiple Brain Tests|Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment|Completed||Phase 4|28|Actual|New York State Psychiatric Institute||3|||f||||f||||||||||2018-06-01 04:08:41.595995|2018-06-01 04:08:41.595995
NCT00296764|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2016-11-29|2006-02-24|2006-02-27|Estimate|||||||2016-11-29|2016-11-30|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Characterization of Angelman Syndrome|Angelman Syndrome Natural History Study|Active, not recruiting|||400|Anticipated|University of California, San Diego|||||f||||f||||||Samples With DNA|"~     Blood and cheek swab samples~   "|No||2018-06-01 04:08:41.70554|2018-06-01 04:08:41.70554
NCT00296751|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2010-06-30|2006-02-24|2006-02-27|Estimate|||||||2010-06-30|2010-07-01|Estimate|March 2006||2006-03-31|April 2008|2008-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Epidural Analgesia Versus IV Meperidine for Labor Pain Control|Epidural Analgesia Versus IV Meperidine for Labor Pain Control. Objective Evaluation of the Pain Intensity Influence on the Autonomic Nervous System.|Completed||N/A|60|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:08:41.791459|2018-06-01 04:08:41.791459
NCT00296738|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2011-08-17|2006-02-24|2006-02-27|Estimate|||||||2011-08-17|2011-08-18|Estimate|May 2007||2007-05-31|August 2011|2011-08-31|May 2010|Actual|2010-05-31|August 2009|Actual|2009-08-31||Observational|||123I-MIBG SPECT/CT for Assessment of Cardiac Sympathetic Innervation|Quantitative 123I-MIBG SPECT/CT Assessment of Cardiac Sympathetic Innervation|Completed|||50|Actual|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:08:41.858316|2018-06-01 04:08:41.858316
NCT00296725|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2012-04-26|2006-02-24|2006-02-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|April 1994||1994-04-30|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Dichotic Listening as a Predictor of Medication Response in Depression|Dichotic Listening as a Predictor of Placebo and Medication Response in Depression|Completed||Phase 4|130|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 04:08:41.924995|2018-06-01 04:08:41.924995
NCT00296699|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2008-01-14|2006-02-23|2006-02-27|Estimate|||||||2008-01-14|2008-01-15|Estimate|March 2005||2005-03-31|January 2008|2008-01-31||||June 2007|Actual|2007-06-30||Interventional|||A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression|A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression|Completed||Phase 4|20|Actual|New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 04:08:42.15809|2018-06-01 04:08:42.15809
NCT00296686|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2012-04-26|2006-02-23|2006-02-27|Estimate|||||||2012-04-26|2012-04-27|Estimate|September 2001||2001-09-30|April 2012|2012-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression|A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine.|Terminated||Phase 4|31|Actual|New York State Psychiatric Institute||1||Study is no longer funded.|f||||f||||||||||2018-06-01 04:08:42.298319|2018-06-01 04:08:42.298319
NCT00296673|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2006-10-25|2006-02-24|2006-02-27|Estimate|||||||2006-10-25|2006-10-26|Estimate||||October 2006|2006-10-31|October 2006||2006-10-31|||||Interventional|||Reactive Neuromuscular Training Effects on Side Bridge Endurance Test||Completed||N/A|20||Logan College of Chiropractic|||||f||||||||||||||2018-06-01 04:08:42.382027|2018-06-01 04:08:42.382027
NCT00296660|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2013-11-18|2006-02-24|2006-02-27|Estimate|||||||2013-11-18|2013-11-19|Estimate|June 2006||2006-06-30|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Acute HIV Infection Observational Study|Acute HIV-1 Infection Prospective Cohort Study|Completed|||1300|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||||||||||||2018-06-01 04:08:42.442147|2018-06-01 04:08:42.442147
NCT00296647|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2011-10-21||2015-10-09|2006-02-24|2006-02-27|Estimate|2011-10-21|2011-11-30|Estimate||||2015-10-09|2015-10-14|Estimate|September 2004||2004-09-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Interventional|||Smoking Cessation Intervention: Effectiveness in Primary Care|Tobacco Dependence: Treatment and Outcomes; Pharmacotherapies: Effectiveness in Primary Care|Completed||Phase 4|1346|Actual|University of Wisconsin, Madison|The present study is limited to some extent by the fact that self-reported abstinence was not biochemically confirmed. However, there is evidence that self-reported abstinence rates are generally accurate in low-contact effectiveness studies.|5|||f||||f||||||||||2018-06-01 04:08:42.53324|2018-06-01 04:08:42.53324
NCT00296634|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2010-08-26|2006-02-23|2006-02-27|Estimate|||||||2010-08-26|2010-08-27|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||H5 Vaccine Alone or With Adjuvant in Healthy Adults|A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Adults|Completed||Phase 1/Phase 2|600|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:08:42.850091|2018-06-01 04:08:42.850091
NCT00296621|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-12-20|2006-02-23|2006-02-27|Estimate|||||||2007-12-20|2007-12-21|Estimate|February 2006||2006-02-28|December 2007|2007-12-31|November 2007|Actual|2007-11-30|February 2008|Anticipated|2008-02-29||Interventional|MDB-GLN||Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy|Efficacy Study of Oral Glutamine Supplementation in Duchenne Muscular Dystrophy|Completed||Phase 2|30|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 04:08:42.918258|2018-06-01 04:08:42.918258
NCT00296608|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2016-05-27|2006-02-24|2006-02-27|Estimate|||||||2016-05-27|2016-05-30|Estimate|April 1993||1993-04-30|May 2016|2016-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer|Preoperative Radiotherapy With or Without Concurrent Chemotherapy (5-Fluorouracil and Leucovorin) in T3-4 Rectal Cancers - Randomized Trial|Completed||Phase 3|762|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||f||||||||||2018-06-01 04:08:42.985942|2018-06-01 04:08:42.985942
NCT00296595|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2015-09-21|2006-02-24|2006-02-27|Estimate|||||||2015-09-21|2015-09-22|Estimate|February 2006||2006-02-28|September 2015|2015-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of n-3 Polyunsaturated Fatty Acids and Antioxidants on Postprandial Hyperlipidemia and Vascular Function in Men|Physiological Mechanisms Underlying the Effects of PUFA and Antioxidants on Postprandial Lipemia, Oxidative Stress, Endothelial Dysfunction and Inflammation in Men|Completed||Phase 2/Phase 3|99|Actual|Laval University||4|||f||||||||||||||2018-06-01 04:08:43.060141|2018-06-01 04:08:43.060141
NCT00296582|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2011-05-20|2006-02-24|2006-02-27|Estimate|||||||2011-05-20|2011-05-23|Estimate|January 2006||2006-01-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Gastric Motor Function Measurement in Dyspepsia and Normal Subjects|Simultaneous Gastric Motor Function Measurement in Dyspepsia And Normal Subjects Ingesting a Solid-Liquid Meal|Completed||N/A|30|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 04:08:43.117719|2018-06-01 04:08:43.117719
NCT00296569|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2014-12-23|2006-02-24|2006-02-27|Estimate|||||||2014-12-23|2014-12-24|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)|A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MK0686 in Patients With Osteoarthritis of the Knee or Hip|Completed||Phase 2|150|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:08:43.173977|2018-06-01 04:08:43.173977
NCT00296556|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2009-04-27|2006-02-24|2006-02-27|Estimate|||||||2009-04-27|2009-04-28|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|March 2008|Actual|2008-03-31|December 2007|Anticipated|2007-12-31||Interventional|||Therapeutic Study of ONO-4819CD for Ulcerative Colitis|A Randomized, Placebo-Controlled Trial of ONO-4819CD for Treatment of Mild to Moderate Ulcerative Colitis.|Terminated||Phase 2|7|Actual|Kyoto University, Graduate School of Medicine||||terminated|f||||t||||||||||2018-06-01 04:08:43.329544|2018-06-01 04:08:43.329544
NCT00296543|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2011-06-17|2006-02-23|2006-02-27|Estimate|||||||2011-06-17|2011-06-20|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|August 2008|Actual|2008-08-31|||||Observational|||T Wave Alternans in Hemodialysis|Pilot Study of a Noninvasive Predictor of Sudden Cardiac Death in Hemodialysis Patients|Completed|||30|Anticipated|Indiana University|||||f||||||||||||||2018-06-01 04:08:43.397596|2018-06-01 04:08:43.397596
NCT00296530|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2016-10-27|2006-02-23|2006-02-27|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study Of Patients With Allergic Rhinitis And Asthma|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID|Completed||Phase 4|600|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:08:43.47036|2018-06-01 04:08:43.47036
NCT00296517|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2009-03-19||2017-04-18|2006-02-23|2006-02-27|Estimate|2009-05-27|2009-07-16|Estimate||||2017-04-18|2017-05-22|Actual|January 19, 2006||2006-01-19|March 2011|2011-03-31|March 28, 2008|Actual|2008-03-28|March 1, 2008|Actual|2008-03-01||Interventional|||Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors|Clinical Evaluation of 323U66 SR in Patients With Depression - Placebo-controlled, Double-blind, Comparative Study in Patients With Depression Who Did Not Respond Sufficiently to Selective Serotonin Re-uptake Inhibitors|Completed||Phase 3|325|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:08:43.793001|2018-06-01 04:08:43.793001
NCT00296504|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2011-09-30||2013-04-11|2006-02-24|2006-02-27|Estimate|2011-09-30|2011-11-08|Estimate||||2013-04-11|2013-04-19|Estimate|November 2001||2001-11-30|June 2012|2012-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects|An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects|Completed||Phase 3|753|Actual|ViiV Healthcare|||||||||f||||||||||2018-06-01 04:08:45.832914|2018-06-01 04:08:45.832914
NCT00296491|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2008-10-31||2016-11-03|2006-02-23|2006-02-27|Estimate|2009-03-26|2009-05-13|Estimate||||2016-11-03|2016-12-16|Estimate|September 2005||2005-09-30|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study Of Allergic Rhinitis In Patients Who Also Have Asthma|A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID|Completed||Phase 4|725|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:08:50.693064|2018-06-01 04:08:50.693064
NCT00296478|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2011-05-18|2006-02-23|2006-02-27|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 2005||2005-07-31|May 2011|2011-05-31|July 2006|Actual|2006-07-31|April 2006|Actual|2006-04-30||Interventional|||Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet (Endometrin®) Compared to Crinone 8% Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization (IVF)|Multi-Center, Randomized, Open-Label, Parallel Group Study of a Vaginal Micronized Progesterone Tablet (Endometrin®) Compared to Crinone 8% Vaginal Gel in Female Patients Undergoing In-Vitro Fertilization (IVF)|Completed||Phase 3|1211|Actual|Ferring Pharmaceuticals||3|||f||||||||||||||2018-06-01 04:08:52.561844|2018-06-01 04:08:52.561844
NCT00296465|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2011-05-18|2006-02-23|2006-02-27|Estimate|||||||2011-05-18|2011-05-19|Estimate|February 2005||2005-02-28|May 2011|2011-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Administered Intravenously or Subcutaneously (Via Portable Infusion Pump) Compared to Oral Treatment With Clomiphene Citrate in Anovulatory or Oligoovulatory Infertile Females|Completed||Phase 2/Phase 3|132|Actual|Ferring Pharmaceuticals||7|||t||||t||||||||||2018-06-01 04:08:52.626405|2018-06-01 04:08:52.626405
NCT00296452|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2006-02-23|2006-02-23|2006-02-27|Estimate|||||||2006-02-23|2006-02-27|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Effect of a Nutritional Supplement on H&N Cancer Patients|The Effect of an Enhanced Nutritional Supplement on Head and Neck Cancer Patients|Unknown status|Recruiting|N/A|40||Edward Hines Jr. VA Hospital|||||f||||||||||||||2018-06-01 04:08:52.712827|2018-06-01 04:08:52.712827
NCT00296439|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2006-02-23|2006-02-23|2006-02-27|Estimate|||||||2006-02-23|2006-02-27|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Nutrition Counseling to Lower Serum Phosphorus Levels|Comparison of Different Counseling Methods on Serum Phosphorus Levels in Renal Patients at Hines VA Hospital|Unknown status|Recruiting|N/A|44||Edward Hines Jr. VA Hospital|||||f||||||||||||||2018-06-01 04:08:52.773918|2018-06-01 04:08:52.773918
NCT00296426|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|||2010-01-13|2006-02-24|2006-02-27|Estimate|||||||2010-01-13|2010-01-14|Estimate|May 2006||2006-05-31|January 2010|2010-01-31|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Interventional|||Implementation and Evaluation of a Medical Reconciliation Protocol at Brigham and Women's Hospital|Implementation and Evaluation of a Medical Reconciliation Protocol|Unknown status|Active, not recruiting|N/A|500|Anticipated|Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:08:52.827583|2018-06-01 04:08:52.827583
NCT00296413|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2017-03-10|2006-02-23|2006-02-27|Estimate|||||||2017-03-10|2017-03-14|Actual|February 2006||2006-02-28|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||A Study to Look at Antiepileptic Drug Levels While on Lamictal or Depakote With or Without an Oral Contraceptive|Variation of Serum Valproate and Lamotrigine Levels in Relation to The Menstrual Cycle and Oral Contraceptive Use|Completed|||48|Anticipated|Beth Israel Deaconess Medical Center|||4||f||||f||||||Samples Without DNA|"~     Serum Samples for hormone testing~   "|||2018-06-01 04:08:52.888327|2018-06-01 04:08:52.888327
NCT00296400|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2010-03-22||2011-06-14|2006-02-24|2006-02-27|Estimate|2010-11-30|2010-12-30|Estimate||||2011-06-14|2011-06-16|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|PLANET II||Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease|Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Non-diabetic Patients With Moderate Proteinuria|Completed||Phase 2|237|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:08:53.075422|2018-06-01 04:08:53.075422
NCT00296387|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-12-12|2006-02-23|2006-02-27|Estimate|||||||2007-12-12|2007-12-17|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome|Comparison of the Effects Noted in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome - CENTAURUS|Completed||Phase 3|1160|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:08:55.700279|2018-06-01 04:08:55.700279
NCT00296374|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2010-03-03||2011-08-30|2006-02-23|2006-02-27|Estimate|2010-11-30|2010-12-30|Estimate||||2011-08-30|2011-09-01|Estimate|February 2006||2006-02-28|August 2011|2011-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|PLANET 1||Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease|Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria|Completed||Phase 2|353|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:08:56.042587|2018-06-01 04:08:56.042587
NCT00296361|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2014-08-28|2006-02-23|2006-02-27|Estimate|||||||2014-08-28|2014-09-01|Estimate|October 2004||2004-10-31|August 2014|2014-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|RESTORE||To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.|A Multicentre, Randomised, Open Clinical Study to Compare the Efficacy and Safety of a Combination Therapy of Tacrolimus With Sirolimus Versus Tacrolimus With Mycophenolate Mofetil in Kidney Transplantation.|Completed||Phase 3|634|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:08:58.399263|2018-06-01 04:08:58.399263
NCT00296348|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2015-06-25|2006-02-23|2006-02-27|Estimate|||||||2015-06-25|2015-06-26|Estimate|November 2005||2005-11-30|June 2015|2015-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|TWIST||Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation|An Open, Randomised, Multicentre Clinical Study to Investigate the Safety and Efficacy of Steroid Withdrawal With Tacrolimus, Mycophenolate Mofetil and Daclizumab Against Tacrolimus, Mycophenolate Mofetil and Steroids in Children After Kidney Transplantation|Completed||Phase 3|198|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:08:58.630316|2018-06-01 04:08:58.630316
NCT00296335|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2013-11-12||2014-01-13|2006-02-24|2006-02-27|Estimate|2014-01-13|2014-02-27|Estimate||||2014-01-13|2014-02-27|Estimate|February 2002||2002-02-28|January 2014|2014-01-31|December 2009|Actual|2009-12-31|November 2007|Actual|2007-11-30||Interventional||All enrolled patients were included in the analysis.|Trial of Adjuvant Chemotherapy for Gastric Cancer|A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma|Completed||Phase 3|855|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 04:08:58.757195|2018-06-01 04:08:58.757195
NCT00296322|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-24|2012-07-19||2013-08-07|2006-02-24|2006-02-27|Estimate|2012-08-01|2012-09-06|Estimate||||2013-08-07|2013-08-14|Estimate|October 2001||2001-10-31|August 2013|2013-08-31|March 2010|Actual|2010-03-31|December 2007|Actual|2007-12-31||Interventional|||Trial of Adjuvant Chemotherapy for Gastric Cancer|A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin|Completed||Phase 3|528|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 04:08:59.099657|2018-06-01 04:08:59.099657
NCT00296309|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2014-08-28|2006-02-23|2006-02-27|Estimate|||||||2014-08-28|2014-09-01|Estimate|October 2004||2004-10-31|August 2014|2014-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|SENIOR||Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.|A Multicentre, Randomised, Open Clinical Study to Compare the Efficacy and Safety of a Combination of Tacrolimus and Mycophenolate Mofetil Based Regimen With or Without Induction in Elderly Recipients Undergoing Kidney Transplantation|Completed||Phase 3|267|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:08:59.392713|2018-06-01 04:08:59.392713
NCT00296296|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|2017-09-06||2017-10-04|2006-02-22|2006-02-24|Estimate|2017-10-04|2017-10-06|Actual||||2017-10-04|2017-10-06|Actual|June 2005||2005-06-30|October 2017|2017-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)|Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen.|Completed||Phase 4|29|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 04:08:59.564566|2018-06-01 04:08:59.564566
NCT00296283|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-05-22|2006-02-23|2006-02-24|Estimate|||||||2007-05-22|2007-05-23|Estimate|August 2005||2005-08-31|May 2007|2007-05-31||||||||Interventional|||Family Workshops for Bipolar Disorder|An Acceptance Based Psychoeducation Intervention to Reduce Expressed Emotion in Family Members of Bipolar Patients|Completed||Phase 1|40|Anticipated|University of Miami|||||f||||||||||||||2018-06-01 04:08:59.797911|2018-06-01 04:08:59.797911
NCT00296270|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2006-02-23|2006-02-23|2006-02-24|Estimate|||||||2006-02-23|2006-02-24|Estimate|March 2005||2005-03-31|February 2006|2006-02-28|June 2005||2005-06-30|||||Interventional|||Memory for Flu Facts and Myths and Effects on Vaccine Intentions|"Myths and Facts About the Flu: Health Education Campaigns Can Reduce Vaccination Intentions"|Completed||N/A|175||University of Michigan|||||f||||||||||||||2018-06-01 04:08:59.856567|2018-06-01 04:08:59.856567
NCT00296257|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2009-03-12|2006-02-22|2006-02-24|Estimate|||||||2009-03-12|2009-03-13|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|April 2008|Actual|2008-04-30|||||Interventional|||Assessment of Safety, Pharmacokinetics and Efficacy in a Combination Treatment With SMP-114|A Phase 2, Multi-Centre, Randomised, Double Blind, Placebo Controlled Study Evaluating the Efficacy, Safety and Pharmacokinetics of Two Doses of a Candidate Disease Modifying Anti-Rheumatic Drug (DMARD), (SMP-114 120 mg and 240 mg Once Daily), Administered in Combination With Ongoing Methotrexate Treatment in Patients With Active Rheumatoid Arthritis.|Terminated||Phase 2|312|Actual|Dainippon Sumitomo Pharma Europe LTd.|||||f||||t||||||||||2018-06-01 04:08:59.919989|2018-06-01 04:08:59.919989
NCT00296244|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2011-07-21||2012-10-18|2006-02-23|2006-02-24|Estimate|2012-10-18|2012-11-19|Estimate||||2012-10-18|2012-11-19|Estimate|February 2006||2006-02-28|October 2012|2012-10-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Steroid Free Immunosuppression in Liver Transplantation|Steroid Free Immunosuppression in Liver Transplantation|Completed||Phase 4|40|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-06-01 04:09:00.034173|2018-06-01 04:09:00.034173
NCT00296231|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|2010-10-29||2018-01-14|2006-02-22|2006-02-24|Estimate|2010-11-23|2010-12-22|Estimate||||2018-01-14|2018-02-09|Actual|February 2006||2006-02-28|January 2018|2018-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study|Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study|Completed||Phase 1|14|Actual|University of Iowa||1|||f||||||||||||||2018-06-01 04:09:00.350906|2018-06-01 04:09:00.350906
NCT00296218|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2009-10-14|2006-02-22|2006-02-24|Estimate|||||||2009-10-14|2009-10-15|Estimate|February 2006||2006-02-28|October 2009|2009-10-31||||March 2007|Actual|2007-03-31||Interventional|||ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation|Randomized Comparison of a Two-month Regimen of Irbesartan Versus Enalapril on Cardiovascular Markers in Patients With Acute Coronary Syndrome Without ST Segment Elevation.|Completed||Phase 3|440||Sanofi|||||f||||||||||||||2018-06-01 04:09:00.653439|2018-06-01 04:09:00.653439
NCT00296205|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2009-07-21|2006-02-23|2006-02-24|Estimate|||||||2009-07-21|2009-07-22|Estimate|October 2003||2003-10-31|October 2006|2006-10-31|February 2006|Anticipated|2006-02-28|||||Interventional|||Phase II High-Dose Cyclophosphamide for Multiple Sclerosis|Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis|Withdrawn||Phase 2|25|Anticipated|Stony Brook University||||I am changing locations to Johns Hopkins Medical Center|||||||||||||||2018-06-01 04:09:00.728412|2018-06-01 04:09:00.728412
NCT00295685|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2009-02-24|2006-02-22|2006-02-24|Estimate|||||||2009-02-24|2009-02-25|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|December 2007||2007-12-31|||||Interventional|||Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD|Single Dose Nexium 40MG QAM vs Lansoprazole 30mg BID for Control of Symptomatic GERD-A Double Blind Cross-Over Study|Completed||Phase 4|50|Anticipated|Digestive & Liver Disease Specialists|||||||||||||||||||2018-06-01 04:09:07.34658|2018-06-01 04:09:07.34658
NCT00296192|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|2009-07-30||2014-09-24|2006-02-22|2006-02-24|Estimate|2010-01-05|2010-01-29|Estimate||||2014-09-24|2014-10-02|Estimate|February 2006||2006-02-28|February 2011|2011-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms|"A Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Trial to Assess the Tolerability, Safety, and Efficacy of Rotigotine Nasal Spray for the Acute Treatment of OFF Symptoms in Subjects With Advanced-Stage, Idiopathic Parkinson Disease"|Completed||Phase 2|82|Actual|UCB Pharma||5|||f||||f||||||||||2018-06-01 04:09:00.840041|2018-06-01 04:09:00.840041
NCT00296179|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2008-07-25|2006-02-23|2006-02-24|Estimate|||||||2008-07-25|2008-07-28|Estimate|February 2006||2006-02-28|July 2008|2008-07-31||||June 2007|Actual|2007-06-30||Interventional|||Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro|Comparison of Zolpidem Tartrate Extended-Release vs. Placebo in Treatment of Insomnia Associated With Newly Diagnosed Major Depressive Disorder(MDD) or Untreated MDD Relapse, When Used Concomitantly With Escitalopram|Completed||Phase 4|372||Sanofi|||||f||||||||||||||2018-06-01 04:09:01.600521|2018-06-01 04:09:01.600521
NCT00296166|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2010-09-01|2006-02-23|2006-02-24|Estimate|||||||2010-09-01|2010-09-02|Estimate|November 2006||2006-11-30|July 2007|2007-07-31|November 2010|Anticipated|2010-11-30|||||Interventional|||Catheter Ablation Versus Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation|A Randomized Study That Will Show the Effects of Catheter Ablation Compared to the Effects of Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation.|Terminated||N/A|200|Anticipated|Rigshospitalet, Denmark||||"Patients with permanent AF are seldomly symptomatic enough to justify intervention. We decided~   to stop inclusion due to low recruitment rate."|f||||t||||||||||2018-06-01 04:09:01.654069|2018-06-01 04:09:01.654069
NCT00296153|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2008-03-10|2006-02-23|2006-02-24|Estimate|||||||2008-03-10|2008-03-11|Estimate|February 2006||2006-02-28|March 2008|2008-03-31|October 2007|Actual|2007-10-31|November 2006|Actual|2006-11-30||Interventional|||Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment|Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids|Completed||Phase 4|51|Actual|Pronova BioPharma||2|||f||||f||||||||||2018-06-01 04:09:01.715547|2018-06-01 04:09:01.715547
NCT00296140|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2017-09-08|2006-02-22|2006-02-24|Estimate|||||||2017-09-08|2017-09-11|Actual|December 13, 2006|Actual|2006-12-13|September 2017|2017-09-30|December 31, 2009|Actual|2009-12-31|June 30, 2009|Actual|2009-06-30||Interventional|||Implementing Evidence in the Detection and Treatment of Post Stroke Depression|Implementation Evidence in the Detection and Treatment of Post-stroke Depression|Completed||N/A|45|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-06-01 04:09:01.789034|2018-06-01 04:09:01.789034
NCT00296127|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2007-02-01|2006-02-22|2006-02-24|Estimate|||||||2007-02-01|2007-02-05|Estimate|February 2006||2006-02-28|June 2006|2006-06-30|March 2006||2006-03-31|||||Interventional|||Study of Celecoxib Bioavailability in Healthy Subjects|A Relative Bioavailability Study Of Celecoxib Administered As Capsule Contents Sprinkled On Applesauce In Healthy Adult Volunteers|Completed||Phase 1|24||Pfizer|||||||||||||||||||2018-06-01 04:09:01.875652|2018-06-01 04:09:01.875652
NCT00296114|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2013-04-29|2006-02-22|2006-02-24|Estimate|||||||2013-04-29|2013-05-01|Estimate|February 2004||2004-02-29|December 2011|2011-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Pancreatic Cancer Serum and DNA Repository|Pancreatic Cancer Serum and DNA Repository|Completed|||690|Actual|Pancreatic Cancer Research Team|||||f||||||||||Samples With DNA|"~     Whole Blood and Serum Samples~   "|||2018-06-01 04:09:01.930596|2018-06-01 04:09:01.930596
NCT00296101|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2016-08-05|2006-02-23|2006-02-24|Estimate|||||||2016-08-05|2016-08-08|Estimate|February 2000||2000-02-29|February 2006|2006-02-28|May 2005|Actual|2005-05-31|||||Interventional|||School-Based Intervention to Increase Physical Activity Among Adolescent Females|Interventions to Increase Adolescent Physical Activity|Completed||N/A|300||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:09:01.994555|2018-06-01 04:09:01.994555
NCT00296088|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2013-07-29|2006-02-23|2006-02-24|Estimate|||||||2013-07-29|2013-07-30|Estimate|February 2006||2006-02-28|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Effects of Obesity on Care and Outcomes in Mechanically Ventilated Individuals in the Intensive Care Unit|A Prospective Observational Study of the Association Between Excess Body Weight and Outcome and Process Measures in Mechanically Ventilated Medical Intensive Care Unit Patients|Terminated|||582|Actual|Ohio State University||||PI left institution|f||||||||||||||2018-06-01 04:09:02.055138|2018-06-01 04:09:02.055138
NCT00296062|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2012-01-13|2006-02-23|2006-02-24|Estimate|||||||2012-01-13|2012-01-16|Estimate|March 2006||2006-03-31|January 2012|2012-01-31|May 2011|Actual|2011-05-31|October 2009|Actual|2009-10-31||Interventional|||Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer|Dose-Dense and Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in Solid Tumors and Phase II With Bevacizumab a First-Line Therapy of Advanced Colorectal Cancer|Terminated||Phase 1|12|Actual|Case Comprehensive Cancer Center||||Trial did not move to Phase II portion due to poor tolerance of treatment|f||||t||||||||||2018-06-01 04:09:02.108232|2018-06-01 04:09:02.108232
NCT00296049|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2017-01-18|2006-02-23|2006-02-24|Estimate|||||||2017-01-18|2017-01-19|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy|An Open-Label, Pilot Study of Daptomycin vs. Vancomycin for Treatment of Gram-Positive Bacteremia in Neutropenic Cancer Patients|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 04:09:02.173302|2018-06-01 04:09:02.173302
NCT00296036|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2017-01-23||2017-01-23|2006-02-23|2006-02-24|Estimate|2017-01-23|2017-03-16|Actual||||2017-01-23|2017-03-16|Actual|June 2006||2006-06-30|January 2017|2017-01-31||||July 2009|Actual|2009-07-31||Interventional||Arms I (18), II (18), and IV (31) were combined and analyzed as patients treated with Urea/Lactic Acid Cream. Arms III (16), IV (16), and VI (28) were combined as patients treated with placebo in place of Urea/Lactic Acid Cream.|Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer|A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome|Completed||Phase 3|137|Actual|Alliance for Clinical Trials in Oncology||6|||f||||t||||||||||2018-06-01 04:09:02.281467|2018-06-01 04:09:02.281467
NCT00296023|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2012-10-02|2006-02-23|2006-02-24|Estimate|||||||2012-10-02|2012-10-04|Estimate|January 1999||1999-01-31|October 2012|2012-10-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer|Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies|Completed||N/A|25|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:09:03.044593|2018-06-01 04:09:03.044593
NCT00296010|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2015-08-25|2006-02-23|2006-02-24|Estimate|||||||2015-08-25|2015-08-26|Estimate|August 2005||2005-08-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CASA||Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer|"Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (Age 66 Years or Older) With Endocrine Nonresponsive Breast Cancer Who Are Not Suitable for Being Offered a  Standard Chemotherapy Regimen"|Terminated||Phase 3|77|Actual|International Breast Cancer Study Group||4||Accrual rate was too low|f||||t||||||||||2018-06-01 04:09:03.206051|2018-06-01 04:09:03.206051
NCT00295997|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2014-01-03|2006-02-23|2006-02-24|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 2005||2005-05-31|April 2007|2007-04-30||||||||Interventional|||Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia|Non-myeloablative Allogeneic Stem Cell Transplantation With Match Unrelated Donors for Treatment of Hematologic Malignancies and Renal Cell Carcinoma and Aplastic Anemia|Unknown status|Active, not recruiting|N/A|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:09:03.329715|2018-06-01 04:09:03.329715
NCT00295984|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2013-06-18|2006-02-23|2006-02-24|Estimate|||||||2013-06-18|2013-06-20|Estimate|March 2006||2006-03-31|August 2006|2006-08-31|August 2006|Actual|2006-08-31|||||Interventional|||Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma|Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial|Completed||Phase 2|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:09:03.420309|2018-06-01 04:09:03.420309
NCT00295971|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2012-11-08|2006-02-23|2006-02-24|Estimate|||||||2012-11-08|2012-11-12|Estimate|April 2005||2005-04-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease|Stem Cell Enriched, T Cell Depleted Haplocompatible Peripheral Blood Transplantation for Children With Myelodysplastic Disease, Leukemia, Marrow Failure Syndromes, or Severe Immunodeficiency Diseases|Completed||Phase 1|21|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:09:03.4805|2018-06-01 04:09:03.4805
NCT00295958|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2012-06-12|2006-02-23|2006-02-24|Estimate|||||||2012-06-12|2012-06-14|Estimate|December 2005||2005-12-31|June 2012|2012-06-30|July 2008|Actual|2008-07-31|June 2006|Actual|2006-06-30||Interventional|||LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery|Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma|Completed||Phase 2|26|Actual|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 04:09:03.581449|2018-06-01 04:09:03.581449
NCT00295945|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2014-05-19|2006-02-23|2006-02-24|Estimate|||||||2014-05-19|2014-05-20|Estimate|March 2005||2005-03-31|May 2014|2014-05-31|December 2009|Actual|2009-12-31|April 2008|Actual|2008-04-30||Observational|||Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer|Outcomes of Perioperative Epidural Analgesia in Gynecologic Oncology Patients: A Parallel Prospective Cohort and Randomized Clinical Study|Completed|||240|Actual|University of California, San Francisco|||2||f||||||||||||||2018-06-01 04:09:03.647385|2018-06-01 04:09:03.647385
NCT00295932|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2018-03-12|2006-02-23|2006-02-24|Estimate|||||||2018-03-12|2018-03-14|Actual|December 13, 2005|Actual|2005-12-13|March 2018|2018-03-31|March 11, 2018|Actual|2018-03-11|March 11, 2018|Actual|2018-03-11||Interventional|||Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)|Completed||Phase 1/Phase 2|79|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:09:03.766181|2018-06-01 04:09:03.766181
NCT00295919|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2016-02-11|2006-02-23|2006-02-24|Estimate|||||||2016-02-11|2016-02-15|Estimate|December 2005||2005-12-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Interventional|||N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma|Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma|Completed||Phase 1|68|Anticipated|Children's Hospital Los Angeles|||||f||||t||||||||||2018-06-01 04:09:03.88966|2018-06-01 04:09:03.88966
NCT00295906|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2013-12-17|2006-02-23|2006-02-24|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 2004||2004-06-30|November 2008|2008-11-30||||January 2008|Anticipated|2008-01-31||Interventional|||Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control|Efficacy of Web-Based Instruction on Skin Cancer Triage|Unknown status|Recruiting|N/A|4550|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:09:03.979101|2018-06-01 04:09:03.979101
NCT00295893|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2018-02-09|2006-02-23|2006-02-24|Estimate|||||||2018-02-09|2018-02-12|Actual|September 14, 2005||2005-09-14|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer|Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer|Active, not recruiting||Phase 2|105|Anticipated|City of Hope Medical Center||3|||f||||t||||||||||2018-06-01 04:09:04.050571|2018-06-01 04:09:04.050571
NCT00295880|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|2009-03-25||2017-12-03|2006-02-23|2006-02-24|Estimate|2009-09-02|2009-09-03|Estimate||||2017-12-03|2017-12-28|Actual|June 2005||2005-06-30|December 2017|2017-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer|A Phase I/II Study of Double Unit Umbilical Cord Blood (UCB) Transplantation Utilizing Graft Administration Via Intra-Bone Marrow Injection (Companion Protocol to MT2000-25)|Terminated||Phase 1/Phase 2|12|Actual|Masonic Cancer Center, University of Minnesota|This study was terminated early based on interim statistical analysis that indicated time to engraftment will not be improved compared to historical controls. While safe, lack of faster marrow recovery supports early discontinuation.|1||Time to engraftment would not be improved compared to historical controls.|f||||t||||||||||2018-06-01 04:09:04.186837|2018-06-01 04:09:04.186837
NCT00295867|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2012-10-09|2006-02-23|2006-02-24|Estimate|||||||2012-10-09|2012-10-10|Estimate|December 2005||2005-12-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|June 2011|Actual|2011-06-30||Interventional|||Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer|Pilot Study to Evaluate the Effect of Zoledronic Acid (Zometa) on Occult Malignant Bone Marrow Cells in Patients With High Risk Early Stage Breast Cancer|Unknown status|Active, not recruiting|N/A|45|Anticipated|University of California, San Francisco||1|||f||||||||||||||2018-06-01 04:09:04.409|2018-06-01 04:09:04.409
NCT00295854|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|2011-02-16||2011-12-16|2006-02-22|2006-02-24|Estimate|2011-12-16|2012-01-19|Estimate||||2011-12-16|2012-01-19|Estimate|May 2005||2005-05-31|December 2011|2011-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis|A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis|Completed||Phase 2|296|Actual|MediciNova||2|||f||||t||||||||||2018-06-01 04:09:04.487574|2018-06-01 04:09:04.487574
NCT00295841|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2017-04-17|2006-02-23|2006-02-24|Estimate|||||||2017-04-17|2017-04-19|Actual|February 2005||2005-02-28|September 2015|2015-09-30|January 7, 2015|Actual|2015-01-07|January 7, 2015|Actual|2015-01-07||Interventional|||Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia|Completed||Phase 1|53|Actual|Wake Forest University Health Sciences|||||f||||t|t|f||||||||2018-06-01 04:09:04.769851|2018-06-01 04:09:04.769851
NCT00295828|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2008-09-03|2006-02-22|2006-02-24|Estimate|||||||2008-09-03|2008-09-04|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Pilot Study for the Treatment of Iris Neovascularization With Macugen|A Pilot Study for the Treatment of Iris Neovascularization With Macugen|Completed||Phase 1|10|Actual|Hermann Eye Center||2|||f||||f||||||||||2018-06-01 04:09:04.828261|2018-06-01 04:09:04.828261
NCT00295815|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2016-11-21|2006-02-22|2006-02-24|Estimate|||||||2016-11-21|2016-11-22|Estimate|January 2006||2006-01-31|November 2016|2016-11-30|May 2014|Actual|2014-05-31|August 2007|Actual|2007-08-31||Interventional|||Enzastaurin Versus Lomustine in Glioblastoma|Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma|Completed||Phase 3|397|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 04:09:05.043263|2018-06-01 04:09:05.043263
NCT00295802|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2014-02-06|2006-02-22|2006-02-24|Estimate|||||||2014-02-06|2014-02-07|Estimate|April 2006||2006-04-30|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|August 2012|Actual|2012-08-31||Interventional|||Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer|Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer|Unknown status|Active, not recruiting|Phase 2/Phase 3|141|Actual|EDAP TMS S.A.||2|||f||||f||||||||||2018-06-01 04:09:05.233588|2018-06-01 04:09:05.233588
NCT00295789|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2016-09-20|2006-02-23|2006-02-24|Estimate|||||||2016-09-20|2016-09-22|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)|A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Carboplatin in Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)|Completed||Phase 3|253|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:09:05.423172|2018-06-01 04:09:05.423172
NCT00295776|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2013-03-11|2006-02-22|2006-02-24|Estimate|||||||2013-03-11|2013-03-13|Estimate|February 2005||2005-02-28|February 2005|2005-02-28||||December 2007|Actual|2007-12-31||Interventional|||Lamictal in the Treatment of Post-Herpetic Neuralgia|Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study|Terminated||Phase 2/Phase 3|||George Washington University||||enrollment difficult due to inclusion/exclusion criteria/protocol requirements|f||||||||||||||2018-06-01 04:09:05.563785|2018-06-01 04:09:05.563785
NCT00295763|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2015-03-17|2006-02-22|2006-02-24|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2006||2006-05-31|March 2015|2015-03-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.|Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method.|Completed||Phase 3|61|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:09:05.638397|2018-06-01 04:09:05.638397
NCT00295750|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|2009-01-05||2012-12-17|2006-02-22|2006-02-24|Estimate|2009-03-13|2009-04-16|Estimate||||2012-12-17|2012-12-19|Estimate|February 2006||2006-02-28|December 2012|2012-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer|An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy|Completed||Phase 3|620|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-06-01 04:09:05.789144|2018-06-01 04:09:05.789144
NCT00295737|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2008-01-15|2006-02-23|2006-02-24|Estimate|||||||2008-01-15|2008-01-16|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of an Immunotoxin on Activated Human Macrophages in Those With Allergic Rhinitis or Mild Intermittent Asthma|05/04 IMHOTEP-1 FHG: Ex Vivo Effect of an Immunotoxin on Activated Human Macrophages From Atopics After Segmental Instillation of Allergen and Endotoxin|Terminated||N/A|8|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine||||proof of mechanism achieved with fewer subjects than anticipated|f||||||||||||||2018-06-01 04:09:07.023335|2018-06-01 04:09:07.023335
NCT00295724|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2007-01-26|2006-02-23|2006-02-24|Estimate|||||||2007-01-26|2007-01-30|Estimate|October 2005||2005-10-31|January 2007|2007-01-31||||||||Interventional|||Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain|A Multi-Center, Double-Blind, Placebo-Controlled Randomized Study of Bicifadine 200 mg BID in the Treatment of Chronic Low Back Pain|Completed||Phase 3|||DOV Pharmaceutical, Inc.|||||f||||||||||||||2018-06-01 04:09:07.177298|2018-06-01 04:09:07.177298
NCT00295711|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2006-06-22|2006-02-23|2006-02-24|Estimate|||||||2006-06-22|2006-06-23|Estimate|September 2004||2004-09-30|June 2006|2006-06-30||||||||Interventional|||Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain|A Multi-Center Double-Blind, Placebo-Controlled Randomized Study of Bicifadine 200 Mg BID, Bicifadine 300 Mg BID, and Bicifadine 400 Mg BID in the Treatment of Chronic Low Back Pain|Completed||Phase 3|532||DOV Pharmaceutical, Inc.|||||||||||||||||||2018-06-01 04:09:07.235073|2018-06-01 04:09:07.235073
NCT00295698|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2006-02-23|2006-02-23|2006-02-24|Estimate|||||||2006-02-23|2006-02-24|Estimate|August 2001||2001-08-31|February 2006|2006-02-28|November 2002||2002-11-30|||||Interventional|||Interaction Between HIV and Lymphatic Filariasis|Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine|Completed||N/A|||DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 04:09:07.287702|2018-06-01 04:09:07.287702
NCT00295672|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2009-07-24|2006-02-23|2006-02-24|Estimate|||||||2009-07-24|2009-07-28|Estimate|February 2006||2006-02-28|July 2009|2009-07-31|June 2007|Actual|2007-06-30|||||Interventional|VINCR||Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.|Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy With Cisplatin-docetaxel in Patients With Locally Advanced Non-small-cell Lung Cancer. A Multicenter Phase II Trial|Completed||Phase 2|60|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-06-01 04:09:07.409066|2018-06-01 04:09:07.409066
NCT00295659|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2006-10-17|2006-02-22|2006-02-24|Estimate|||||||2006-10-17|2006-10-18|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|September 2004||2004-09-30|||||Observational|||An RCT to Evaluate Incidence, Cost and Clinical Outcomes Using 75 vs 100g. Screening Methods for Gestational Diabetes|What is the Optimal Method for Screening and Diagnosis of Gestational Diabetes? An RCT to Evaluate Incidence, Cost-Effectiveness and Clinical Outcomes Using Three Methods|Completed|||5800||Canadian Diabetes Association|||||f||||||||||||||2018-06-01 04:09:07.475135|2018-06-01 04:09:07.475135
NCT00295646|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2015-08-03|2006-02-23|2006-02-24|Estimate|||||||2015-08-03|2015-08-04|Estimate|June 1999||1999-06-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid|Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)|Unknown status|Active, not recruiting|Phase 3|1803|Actual|Austrian Breast & Colorectal Cancer Study Group||4|||f||||t||||||||||2018-06-01 04:09:07.546468|2018-06-01 04:09:07.546468
NCT00295633|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|2009-08-17||2015-03-18|2006-02-22|2006-02-24|Estimate|2009-08-17|2009-09-25|Estimate||||2015-03-18|2015-04-07|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone|A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone|Completed||Phase 3|565|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:09:07.724752|2018-06-01 04:09:07.724752
NCT00295620|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2018-03-12|2006-02-23|2006-02-24|Estimate|||||||2018-03-12|2018-03-13|Actual|March 1, 2004|Actual|2004-03-01|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|SALSA||Secondary Adjuvant Long Term Study With Arimidex|A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy|Completed||Phase 3|3486|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 04:09:09.352458|2018-06-01 04:09:09.352458
NCT00295607|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2013-04-09|2006-02-22|2006-02-24|Estimate|||||||2013-04-09|2013-04-11|Estimate|June 2005||2005-06-30|September 2011|2011-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|CHASE||Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients|Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in HCV Positive in Liver Transplantation|Completed||Phase 2|138|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:09:09.603847|2018-06-01 04:09:09.603847
NCT00295594|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2014-08-25|2006-02-22|2006-02-24|Estimate|||||||2014-08-25|2014-08-26|Estimate|March 2005||2005-03-31|August 2014|2014-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|MARSILEA||Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.|An Open, Randomised, Multicenter, Clinical Study to Compare the Safety and Efficacy of Tacrolimus and Minimal Steroids in Combination With Either a Monoclonal Anti-IL2R Antibody (Daclizumab) or Mycophenolate Mofetil in Liver Allograft Transplantation.|Completed||Phase 3|627|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:09:09.750515|2018-06-01 04:09:09.750515
NCT00295581|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2017-06-30|2006-02-22|2006-02-23|Estimate|||||||2017-06-30|2017-07-02|Actual|March 7, 2005||2005-03-07|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Interventional|||PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria|Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria|Completed||Phase 1|0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:09:09.886127|2018-06-01 04:09:09.886127
NCT00295568|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-23|||2017-06-30|2006-02-22|2006-02-23|Estimate|||||||2017-06-30|2017-07-02|Actual|February 17, 2006||2006-02-17|January 12, 2009|2009-01-12|January 12, 2009||2009-01-12|||||Observational|||Interaction of Right and Left Brain Hemispheres in Learning Precision Hand Movements|Contribution of Interhemispheric Inhibition to Motor Learning|Completed|||46||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:09:09.95095|2018-06-01 04:09:09.95095
NCT00295555|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2007-05-08|2006-02-21|2006-02-23|Estimate|||||||2007-05-08|2007-05-10|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy|Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy|Completed||Phase 4|98|Actual|Yokohama City University Medical Center|||||f||||t||||||||||2018-06-01 04:09:10.000183|2018-06-01 04:09:10.000183
NCT00295542|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2009-04-27|2006-02-22|2006-02-23|Estimate|||||||2009-04-27|2009-04-28|Estimate|March 2000||2000-03-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|MAPEC||Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy|Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study).|Completed||Phase 4|3344|Actual|University of Vigo||2|||f||||t||||||||||2018-06-01 04:09:10.092399|2018-06-01 04:09:10.092399
NCT00295529|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2014-12-03|2006-02-22|2006-02-23|Estimate|||||||2014-12-03|2014-12-05|Estimate|April 2005||2005-04-30|December 2014|2014-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||GenetiKiT: Evaluation of an Educational Intervention on the Delivery of Genetics Services by Family Physicians|GenetiKiT: Evaluation of the Impact of a Multifaceted Intervention to Enhance the Delivery of Genetics Services by Family Physicians.|Completed||N/A|125|Actual|University of Toronto||2|||f||||f||||||||||2018-06-01 04:09:10.170736|2018-06-01 04:09:10.170736
NCT00295516|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2006-05-19|2006-02-22|2006-02-23|Estimate|||||||2006-05-19|2006-05-24|Estimate|October 2000||2000-10-31|February 2006|2006-02-28|August 2004||2004-08-31|||||Interventional|||Doppler or Amniocentesis to Predict Fetal Anemia|Minimally Invasive Management of Rh Alloimmunization: Can Amniotic Fluid DeltaOD450 Measurements Be Replaced by Doppler Studies?|Completed||Phase 3|157||University of Toronto|||||f||||||||||||||2018-06-01 04:09:10.233477|2018-06-01 04:09:10.233477
NCT00295503|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|2013-10-18||2016-11-04|2006-02-22|2006-02-23|Estimate|2016-11-04|2017-01-05|Estimate||||2016-11-04|2017-01-05|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional||one patient excluded due to ineligibility. That patient is included in the toxicity analysis|Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma|A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma|Completed||Phase 2|53|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-06-01 04:09:10.318114|2018-06-01 04:09:10.318114
NCT00295490|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|2009-06-19||2011-09-09|2006-02-21|2006-02-23|Estimate|2011-08-08|2011-09-09|Estimate||||2011-09-09|2011-09-12|Estimate|December 2004||2004-12-31|September 2011|2011-09-30|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Trial Evaluating Devil's Claw for the Treatment of Hip and Knee Osteoarthritis|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Two- Centre Study to Evaluate the Efficacy and Safety of Devil's Claw in the Treatment of Knee and Hip Osteoarthritis|Terminated||Phase 2|67|Actual|University of Southampton||4||unexpected withdrawal of funding|f||||f||||||||||2018-06-01 04:09:10.639052|2018-06-01 04:09:10.639052
NCT00295477|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2016-08-17|2006-02-21|2006-02-23|Estimate|||||||2016-08-17|2016-08-19|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV|A Phase I/II, Open-label, Single Center Study to Evaluate the Tolerability, Trafficking and Therapeutic Effects of Repeated Doses of Autologous T Cells Transduced With VRX496 in HIV Infected Subjects|Active, not recruiting||Phase 1/Phase 2|25|Anticipated|University of Pennsylvania|||||f||||t||||||||||2018-06-01 04:09:11.112762|2018-06-01 04:09:11.112762
NCT00295464|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-05-01|2006-02-22|2006-02-23|Estimate|||||||2006-05-01|2006-05-03|Estimate|May 2001||2001-05-31|February 2006|2006-02-28||||||||Interventional|||Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth|Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial)|Terminated||Phase 4|440||University of Oulu|||||f||||||||||||||2018-06-01 04:09:11.187038|2018-06-01 04:09:11.187038
NCT00295438|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2016-09-14|2006-02-21|2006-02-23|Estimate|||||||2016-09-14|2016-09-15|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Robot-based Tele-echography II - A Comparative Study|Robot-based Tele-echography II - A Comparative Study Using Two Echographic Modalities for Diagnosis of Thoracoabdominal Injuries at the Trauma Center of the Grenoble University Hospital.|Terminated||N/A|18|Actual|University Hospital, Grenoble||2||"No diagnosis of visceral lesion was placed on 18 included patients. The study is thus stopped~   prematurely for ethical reasons."|f||||t||||||||||2018-06-01 04:09:11.267993|2018-06-01 04:09:11.267993
NCT00295425|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2006-10-04|2006-02-22|2006-02-23|Estimate|||||||2006-10-04|2006-10-05|Estimate|May 2000||2000-05-31|October 2006|2006-10-31|October 2006||2006-10-31|||||Interventional|||CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.|Open, Multicenter, Randomized Clinical Trial in Patients With Moderate-Severe Psoriasis (PASI > 10) to Compare the Efficacy of Mycophenolate Mofetil Versus Cyclosporine A.|Unknown status|Active, not recruiting|Phase 2|50||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:09:11.347313|2018-06-01 04:09:11.347313
NCT00295412|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-23|Estimate|||||||2006-02-21|2006-02-23|Estimate||||September 2005|2005-09-30||||||||Interventional|||The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients|The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients|Completed||Phase 4|||Université de Montréal|||||f||||||||||||||2018-06-01 04:09:11.426602|2018-06-01 04:09:11.426602
NCT00295399|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2008-08-11|2006-02-21|2006-02-23|Estimate|||||||2008-08-11|2008-08-13|Estimate||||August 2008|2008-08-31||||||||Interventional|||Telerehabilitation for the Hand and Arm After Stroke and Traumatic Brain Injury||Unknown status|Not yet recruiting|N/A|||Ono Academic College|||||f||||||||||||||2018-06-01 04:09:11.476821|2018-06-01 04:09:11.476821
NCT00295386|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2009-01-02|2006-02-21|2006-02-23|Estimate|||||||2009-01-02|2009-01-06|Estimate|January 2004||2004-01-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|January 2006|Actual|2006-01-31||Interventional|||Cognitive-Behavioural and Hypnotic Treatment of Chronic Primary Insomnia Among the Elderly||Completed||Phase 4|||University of Bergen|||||f||||||||||||||2018-06-01 04:09:11.54421|2018-06-01 04:09:11.54421
NCT00295373|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2007-04-19|2006-02-21|2006-02-23|Estimate|||||||2007-04-19|2007-04-20|Estimate|February 2006||2006-02-28|April 2007|2007-04-30|August 2007|Anticipated|2007-08-31|||||Interventional|||Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?|Phase 4 Clinical Trial to Examine the Role of Rosuvastatin and Exercise Treatment in Modulating Inflammatory Response in Hypercholesterolemic Subjects|Unknown status|Active, not recruiting|Phase 4|48||Purdue University|||||f||||||||||||||2018-06-01 04:09:11.596527|2018-06-01 04:09:11.596527
NCT00295360|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-22|2006-02-22|2006-02-23|Estimate|||||||2006-02-22|2006-02-23|Estimate|June 2003||2003-06-30|March 2005|2005-03-31|August 2004||2004-08-31|||||Observational|||Expression of BCRP in Icteric Patients|Influence of Cholestasis on Intestinal BCRP Expression|Completed|||40||University Hospital, Basel, Switzerland|||||f||||||||||||||2018-06-01 04:09:11.662896|2018-06-01 04:09:11.662896
NCT00295347|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2017-05-24|2006-02-22|2006-02-23|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2005||2005-12-31|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Mineralocorticoid Receptor in the Treatment of Severe Depression|Mineralocorticoid Receptor in the Treatment of Severe Depression: A Randomized, Double Blind, and Placebo Controlled Trial|Completed||N/A|65|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||||||||||||2018-06-01 04:09:11.713029|2018-06-01 04:09:11.713029
NCT00295334|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-09-11|2006-02-21|2006-02-23|Estimate|||||||2006-09-11|2006-09-13|Estimate|February 2006||2006-02-28|September 2006|2006-09-30|December 2006||2006-12-31|||||Interventional|||Moderate Alcohol Intake Among Patients With Type 2 Diabetes||Unknown status|Active, not recruiting|Phase 2|100||The S. Daniel Abraham International Center for Health and Nutrition|||||f||||||||||||||2018-06-01 04:09:11.762521|2018-06-01 04:09:11.762521
NCT00295308|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2018-05-19|2006-02-22|2006-02-23|Estimate|||||||2018-05-19|2018-05-22|Actual|November 8, 2005||2005-11-08|September 17, 2014|2014-09-17|July 30, 2014|Actual|2014-07-30|||||Interventional|||Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients|Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients|Completed||Phase 1|208|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 04:09:11.814367|2018-06-01 04:09:11.814367
NCT00295295|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2013-06-19|2006-02-21|2006-02-23|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 2004||2004-09-30|May 2013|2013-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Vibration Intervention to Improve Bone and Muscle in Children With Cerebral Palsy|Mechanical Intervention in Children With Cerebral Palsy|Completed||Phase 2|34||Children's Hospital Los Angeles||2|||f||||||||||||||2018-06-01 04:09:11.900399|2018-06-01 04:09:11.900399
NCT00295100|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2007-06-20|2006-02-20|2006-02-22|Estimate|||||||2007-06-20|2007-06-21|Estimate|September 2000||2000-09-30|June 2007|2007-06-30|July 2006||2006-07-31|||||Interventional|||Tamoxifen-MRI Study|Cancer Risk and Biomarkers of Tamoxifen Chemoprevention|Completed||Phase 2|78||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:09:13.224851|2018-06-01 04:09:13.224851
NCT00295282|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2010-04-22|2006-02-21|2006-02-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis|A Phase I, Multicenter, Dose-escalation Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Patients With Active Ulcerative Colitis|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:09:12.029927|2018-06-01 04:09:12.029927
NCT00295269|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-05-08|2006-02-21|2006-02-23|Estimate|||||||2006-05-08|2006-05-09|Estimate|March 1997||1997-03-31|April 2006|2006-04-30|September 2005||2005-09-30|||||Interventional|||Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome|Late Steroid Rescue Study (LaSRS): The Efficacy of Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome|Completed||Phase 3|200||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:09:12.1288|2018-06-01 04:09:12.1288
NCT00295256|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2017-12-05|2006-02-22|2006-02-23|Estimate|||||||2017-12-05|2017-12-07|Actual|February 2006||2006-02-28|December 2017|2017-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Randomized Trial to Evaluate the Effectiveness of Nurse Case Management|Randomized Trial to Evaluate the Effectiveness of Nurse Case Management on High-Risk Pregnancy Outcomes|Completed||N/A|100|Anticipated|Johns Hopkins University|||||f||||||||||||||2018-06-01 04:09:12.193628|2018-06-01 04:09:12.193628
NCT00295243|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2011-01-12|2006-02-21|2006-02-23|Estimate|||||||2011-01-12|2011-01-13|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|November 2006|Actual|2006-11-30|||||Interventional|||Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies|A Phase I Trial of the Dual Kinase Inhibitor GW572016 in Combination With Topotecan in Patients With Advanced Solid Malignancies|Completed||Phase 1|25|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 04:09:12.250408|2018-06-01 04:09:12.250408
NCT00295230|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2007-11-06|2006-02-21|2006-02-23|Estimate|||||||2007-11-06|2007-11-07|Estimate|February 2006||2006-02-28|November 2007|2007-11-30|September 2007|Anticipated|2007-09-30|||||Observational|||Effects of Volume Guarantee With Pressure Supported vs. Synchronized Intermittent Mandatory Ventilation in VLBW Infants|The Effects of Volume Guarantee Combined With Pressure Supported Ventilation (PSV+VG) Versus Synchronized Intermittent Mandatory Ventilation (SIMV+VG) in Very Low Birth Weight Infants|Suspended|||16|Anticipated|Children's Hospitals and Clinics of Minnesota||||suboptimal enrollment after 18 months.|f||||||||||||||2018-06-01 04:09:12.308019|2018-06-01 04:09:12.308019
NCT00295217|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2009-01-13|2006-02-21|2006-02-23|Estimate|||||||2009-01-13|2009-01-14|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|October 2006||2006-10-31|||||Interventional|||MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation|MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device|Completed||Phase 3|15||InSightec|||||||||||||||||||2018-06-01 04:09:12.368717|2018-06-01 04:09:12.368717
NCT00295204|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-08-02|2006-02-21|2006-02-23|Estimate|||||||2006-08-02|2006-08-03|Estimate|April 2005||2005-04-30|February 2006|2006-02-28|October 2006||2006-10-31|||||Observational|||Evaluation of a Mobile Cardiac Outpatient Telemetry System Versus Standard Loop Event Monitor|Evaluation of a Mobile Cardiac Outpatient Telemetry System (CardioNet) Versus Standard Loop Event Monitor: A Multi-Center Randomized Study|Unknown status|Active, not recruiting||300||Cardionet|||||f||||||||||||||2018-06-01 04:09:12.435075|2018-06-01 04:09:12.435075
NCT00295191|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-22|||2011-10-03|2006-02-22|2006-02-23|Estimate|||||||2011-10-03|2011-10-04|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in HD Patients(EGESTUDY)|Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Prospective, Randomized, Controlled Study|Completed||Phase 4|704|Actual|Ege University||4|||f||||t||||||||||2018-06-01 04:09:12.500082|2018-06-01 04:09:12.500082
NCT00295178|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2017-09-06|2006-02-21|2006-02-23|Estimate|||||||2017-09-06|2017-09-07|Actual|February 20, 2006|Actual|2006-02-20|September 2017|2017-09-30|August 9, 2006|Actual|2006-08-09|August 9, 2006|Actual|2006-08-09||Interventional|||Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas|A Multicenter, Randomized Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in the Treatment of Cellulitis or Erysipelas|Completed||Phase 4|80||Cubist Pharmaceuticals LLC|||||f||||||||||||||2018-06-01 04:09:12.58248|2018-06-01 04:09:12.58248
NCT00295165|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2013-12-02|2006-02-21|2006-02-23|Estimate|||||||2013-12-02|2013-12-04|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease|Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim (Leukine) Administered Subcutaneously Once Daily for 8 Weeks in Patients With Active Crohn's Disease|Terminated||Phase 3|33|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:09:12.669963|2018-06-01 04:09:12.669963
NCT00295152|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2011-11-16|2006-02-21|2006-02-22|Estimate|||||||2011-11-16|2011-11-17|Estimate|April 2001||2001-04-30|February 2006|2006-02-28|February 2005||2005-02-28|||||Interventional|||Effects of Community Occupational Therapy in Older Patients With Dementia and Their Caregivers.|Effects of Community Occupational Therapy on the Daily Performance of Older Patients With Mild to Moderate Dementia and on the Sense of Competence of Their Primary Caregivers.|Unknown status|Active, not recruiting|N/A|135||Radboud University|||||f||||||||||||||2018-06-01 04:09:12.923031|2018-06-01 04:09:12.923031
NCT00295139|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2017-04-20|2006-02-19|2006-02-22|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2005||2005-01-31|April 2017|2017-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients|Behavioral Treatment of Drug Abuse in SPMI Patients|Completed||Phase 2|307|Anticipated|University of Maryland||3|||f||||f||||||||||2018-06-01 04:09:13.010793|2018-06-01 04:09:13.010793
NCT00295126|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2008-03-11|2006-02-20|2006-02-22|Estimate|||||||2008-03-11|2008-03-14|Estimate|May 2003||2003-05-31|March 2008|2008-03-31|November 2007|Actual|2007-11-30|||||Interventional|||REPI : a Randomized Open Label Trial Evaluating the Use of APC in Pre-Implantation Reconstruction of Maxilla|Use of Autologous Platelet Concentrate in Pre-Implantation Reconstruction of Maxilla.|Terminated||Phase 2/Phase 3|20||University Hospital, Grenoble|||||f||||f||||||||||2018-06-01 04:09:13.102652|2018-06-01 04:09:13.102652
NCT00295113|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-28|2006-02-21|2006-02-22|Estimate|||||||2007-11-28|2007-11-29|Estimate|November 2001||2001-11-30|November 2007|2007-11-30|June 2003||2003-06-30|||||Interventional|||Interest of a 30 Minutes' Intermittent Work Exercise Test in Patients With Chronic Obstructive Pulmonary Disease: Cardiac and Pulmonary Functions|Interest of a 30 Minutes' Intermittent Work Exercise Test in Patients With Chronic Obstructive Pulmonary Disease: Cardiac and Pulmonary Functions|Completed||N/A|10|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:09:13.166589|2018-06-01 04:09:13.166589
NCT00295087|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2014-12-05|2006-02-17|2006-02-22|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2005||2005-11-30|December 2014|2014-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||X-Chromosome Inactivation Status and Premature Ovarian Failure|X-Chromosome Inactivation Status and Premature Ovarian Failure|Completed|||13|Actual|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     DNA that is extracted from the blood specimen~   "|||2018-06-01 04:09:13.287639|2018-06-01 04:09:13.287639
NCT00295074|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2008-02-07|2006-02-17|2006-02-22|Estimate|||||||2008-02-07|2008-02-11|Estimate|October 2004||2004-10-31|February 2008|2008-02-29|September 2007|Actual|2007-09-30|||||Interventional|||The Effect of Mild Traumatic Brain Injury on Recovery From Injury|The Effect of Mild Traumatic Brain Injury on Recovery From Injury|Completed||N/A|800|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:09:13.339994|2018-06-01 04:09:13.339994
NCT00295061|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|2009-08-28||2014-08-28|2006-02-20|2006-02-22|Estimate|2014-08-28|2014-09-09|Estimate||||2014-08-28|2014-09-09|Estimate|May 2006||2006-05-31|August 2014|2014-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|ChAMP||Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults|Multi-center, Randomized, Double-blind, Crossover Trial to Evaluate the Pharmacokinetic Comparability of Alpha-1 MP to Prolastin in Subjects With Alpha1-antitrypsin Deficiency.|Completed||Phase 3|24|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-06-01 04:09:13.408544|2018-06-01 04:09:13.408544
NCT00295048|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2017-04-18|2006-02-19|2006-02-22|Estimate|||||||2017-04-18|2017-04-20|Actual|November 2004|Actual|2004-11-30|April 2017|2017-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Cognitive Remediation for Schizophrenia|Cognitive Remediation for Schizophrenia|Completed||N/A|50|Actual|University of Maryland|||||f||||f||||||||||2018-06-01 04:09:13.754362|2018-06-01 04:09:13.754362
NCT00295035|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-22|Estimate|||||||2006-02-21|2006-02-22|Estimate|March 2006||2006-03-31|February 2006|2006-02-28|March 2007||2007-03-31|||||Interventional|||Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer|Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer|Unknown status|Not yet recruiting|Phase 3|100||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 04:09:13.821371|2018-06-01 04:09:13.821371
NCT00295022|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2013-12-13|2006-02-20|2006-02-22|Estimate|||||||2013-12-13|2013-12-16|Estimate|August 2006||2006-08-31|September 2009|2009-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects|Double-blind, 3 Parallel Randomized Groups, Therapeutic Confirmatory. Clinical Trial to Compare the Efficacy of Levocetirizine 5 mg and Montelukast 10 mg to Placebo in Reducing SAR Symptoms in Ragweed Sensitive Subjects in an EEU.|Completed||Phase 4|403||UCB Pharma|||||f||||||||||||||2018-06-01 04:09:13.880067|2018-06-01 04:09:13.880067
NCT00295009|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|2014-06-18|2013-05-06|2014-07-31|2006-02-21|2006-02-22|Estimate|2014-07-03|2014-08-01|Estimate|2013-05-06|2013-05-14|Estimate|2014-07-31|2014-08-06|Estimate|September 2001||2001-09-30|July 2014|2014-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|PDL|Enrolled and treated|Safety and Effectiveness Study of Prodisc to Spinal Fusion Surgery|A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc to Spinal Fusion Surgery in the Treatment of Discogenic Pain Associated With DDD in the Lumbosacral Spine|Completed||N/A|852|Actual|Synthes USA HQ, Inc.||6|||f||||f||||||||||2018-06-01 04:09:13.969848|2018-06-01 04:09:13.969848
NCT00294996|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2009-03-30|2006-02-17|2006-02-22|Estimate|||||||2009-03-30|2009-03-31|Estimate|January 2006||2006-01-31|March 2009|2009-03-31||||||||Interventional|||Trial of Myocet in Metastatic Breast Cancer|A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 3|363|Actual|Sopherion Therapeutics|||||f||||||||||||||2018-06-01 04:09:14.656579|2018-06-01 04:09:14.656579
NCT00294983|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2008-01-28|2006-02-19|2006-02-22|Estimate|||||||2008-01-28|2008-01-29|Estimate||||January 2008|2008-01-31||||||||Observational|||OCD Among Patients With Burns||Withdrawn|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:09:14.849583|2018-06-01 04:09:14.849583
NCT00294970|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2010-01-31|2006-02-19|2006-02-22|Estimate|||||||2010-01-31|2010-02-02|Estimate|February 2006||2006-02-28|January 2010|2010-01-31|August 2006|Actual|2006-08-31|||||Observational|||Cognitive Characteristics of PTSD Patients With OCD|Cognitive Characteristics of PTSD Patients With OCD|Completed|||76|Actual|Sheba Medical Center|||3||f||||f||||||||||2018-06-01 04:09:14.895139|2018-06-01 04:09:14.895139
NCT00294957|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2008-01-28|2006-02-19|2006-02-22|Estimate|||||||2008-01-28|2008-01-29|Estimate||||January 2008|2008-01-31||||||||Observational|||Psychological and Physiological Status of Former Prisoners of War||Withdrawn|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:09:14.942476|2018-06-01 04:09:14.942476
NCT00294944|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2008-01-28|2006-02-19|2006-02-22|Estimate|||||||2008-01-28|2008-01-29|Estimate||||January 2008|2008-01-31||||||||Interventional|||The Effectiveness of Idazoxan in Treating TRD||Withdrawn||Phase 3|||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:09:14.982449|2018-06-01 04:09:14.982449
NCT00294931|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2010-06-24|2006-02-20|2006-02-22|Estimate|||||||2010-06-24|2010-06-28|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|January 2009|Actual|2009-01-31|May 2007|Actual|2007-05-31||Interventional|||Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer|A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|50|Anticipated|SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:09:15.032585|2018-06-01 04:09:15.032585
NCT00294918|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2014-03-24|2006-02-17|2006-02-22|Estimate|||||||2014-03-24|2014-03-26|Estimate|September 2001||2001-09-30|March 2014|2014-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome|Multicenter Open-label, Randomized, Dose-finding, Parallel-group, Safety and Efficacy Trial of Subcutaneous Administration of Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)|Completed||Phase 2/Phase 3|142|Actual|EMD Serono||3|||f||||||||||||||2018-06-01 04:09:15.096471|2018-06-01 04:09:15.096471
NCT00294905|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2010-09-22|2006-02-21|2006-02-22|Estimate|||||||2010-09-22|2010-09-23|Estimate|March 2006||2006-03-31|February 2007|2007-02-28|June 2008|Anticipated|2008-06-30|||||Interventional|||Implementation of an Evidence Based Smoking Cessation Strategy (SMOCC) for Patients With COPD in Primary Care|Implementation of an Evidence Based Smoking Cessation Strategy (SMOCC) for Patients With COPD in Primary Care|Terminated||N/A|2700|Anticipated|Radboud University||||recruitment of patients did not reach sufficient numbers|f||||||||||||||2018-06-01 04:09:15.161452|2018-06-01 04:09:15.161452
NCT00294892|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2012-05-30|2006-02-21|2006-02-22|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|June 2010|Actual|2010-06-30|September 2009|Actual|2009-09-30||Interventional|||Pharmacokinetics Study on Nevirapine Resistance in Tanzania|The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)|Completed||Phase 2|144|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 04:09:15.302104|2018-06-01 04:09:15.302104
NCT00294879|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2008-05-30|2006-02-21|2006-02-22|Estimate|||||||2008-05-30|2008-06-02|Estimate|February 2006||2006-02-28|May 2008|2008-05-31|March 2008|Actual|2008-03-31|||||Interventional|||Effects of Inspiration Rise Time on Work of Breathing and Comfort of Conscious Patients on Mechanical Ventilation||Completed||N/A|10|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:09:15.369669|2018-06-01 04:09:15.369669
NCT00294866|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2010-04-07|2006-02-17|2006-02-22|Estimate|||||||2010-04-07|2010-04-08|Estimate|March 2006||2006-03-31|April 2010|2010-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients|An Open Label, Multi-Center Study of the Effect of Paricalcitol on Markers of Inflammation in Patients With Stage 5 Chronic Kidney Disease on Hemodialysis.|Completed||Phase 4|64|Actual|Fresenius Medical Care North America||2|||f||||f||||||||||2018-06-01 04:09:15.434121|2018-06-01 04:09:15.434121
NCT00294853|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2011-07-03|2006-02-21|2006-02-22|Estimate|||||||2011-07-03|2011-07-06|Estimate|December 2005||2005-12-31|April 2008|2008-04-30|June 2007||2007-06-30|||||Interventional|||Multi Detector-Row Computed Tomography (MDCT) Calcium Score of Heart Transplanted Patients|MDCT Calcium Score of Heart Transplanted Patients|Completed||N/A|240|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:09:15.523521|2018-06-01 04:09:15.523521
NCT00294840|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2010-07-28|2006-02-20|2006-02-22|Estimate|||||||2010-07-28|2010-07-29|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|April 2010|Actual|2010-04-30|September 2009|Actual|2009-09-30||Observational|||Dynamic PET acquisition-a Quantitative Technique for Grading of Malignant Tumors and Prediction of Response to Treatment|Dynamic FDG-PET in Aggressive Lymphoma and Pancreas Cancer|Completed|||70|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:09:15.610331|2018-06-01 04:09:15.610331
NCT00294827|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2017-05-24|2006-02-21|2006-02-22|Estimate|||||||2017-05-24|2017-05-25|Actual|February 2006||2006-02-28|May 2017|2017-05-31|May 2023|Anticipated|2023-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Liver Transplantation and Metastatic Colo-rectal Cancer.|Liver Transplantation and Metastatic Colo-rectal Cancer.|Active, not recruiting||Phase 2|25|Anticipated|Oslo University Hospital||1|||f||||||||||||||2018-06-01 04:09:15.669313|2018-06-01 04:09:15.669313
NCT00294814|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2007-03-19|2006-02-20|2006-02-22|Estimate|||||||2007-03-19|2007-03-20|Estimate||||May 2006|2006-05-31||||||||Interventional|||TCD Detection of Gas and Solid Micro-Emboli in Patients Undergoing Coronary Artery Bypass Grafting (CABG): The Influence of Proximal Anastomosis Technique|Gas and Solid Brain Microembolization Detected by the EmbodopR TCD System During Proximal Coronary Graft Anastomosis Done With Aortic Cross Clamping, Partial Occlusion or the HeartstringR Device and Their Effect on Neurocognitive Performance After Coronary Bypass Operation|Unknown status|Recruiting|N/A|100||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:09:15.744444|2018-06-01 04:09:15.744444
NCT00294801|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-22|Estimate|||||||2006-02-21|2006-02-22|Estimate|January 2006||2006-01-31|February 2006|2006-02-28|December 2007||2007-12-31|||||Interventional|||Effect of Flex-a-New on Osteoarthritis of the Knee||Unknown status|Recruiting|Phase 4|80||Rabin Medical Center|||||f||||||||||||||2018-06-01 04:09:15.812869|2018-06-01 04:09:15.812869
NCT00294788|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2007-01-08|2006-02-21|2006-02-22|Estimate|||||||2007-01-08|2007-01-09|Estimate|March 2006||2006-03-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines|Phase I/II Placebo-Controlled Study of Consumption of a Probiotic on HAI Titre Following Influenza Vaccination of Healthy Adult Subjects|Unknown status|Active, not recruiting|Phase 1/Phase 2|300||Probiomics Ltd|||||f||||||||||||||2018-06-01 04:09:15.871117|2018-06-01 04:09:15.871117
NCT00294775|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2009-06-26|2006-02-21|2006-02-22|Estimate|||||||2009-06-26|2009-06-30|Estimate|February 2006||2006-02-28|June 2009|2009-06-30|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Interventional|||Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis|Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis - Effect of Blockade of the Angiotensin-II Receptor|Unknown status|Active, not recruiting|Phase 3|140|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:09:15.933817|2018-06-01 04:09:15.933817
NCT00294762|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|2010-10-05||2012-08-06|2006-02-17|2006-02-22|Estimate|2011-01-17|2011-02-14|Estimate||||2012-08-06|2012-08-09|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC|A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With Newly Diagnosed Advanced Non-small Cell Lung Cancer Who Have Tumors With EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers|Completed||Phase 2|143|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 04:09:16.033329|2018-06-01 04:09:16.033329
NCT00294749|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2009-01-26|2006-02-19|2006-02-22|Estimate|||||||2009-01-26|2009-01-27|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy|Comparison Between Short and Long Schemes of Antibiotic Prophylaxis for Transrectal Prostate Biopsy. A Multicentre Prospective Randomised Study|Terminated||Phase 3|300|Anticipated|Poitiers University Hospital|||||f||||f||||||||||2018-06-01 04:09:16.851228|2018-06-01 04:09:16.851228
NCT00294736|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2012-08-06|2006-02-17|2006-02-22|Estimate|||||||2012-08-06|2012-08-08|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens|A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens|Completed||Phase 1|57|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:09:16.923333|2018-06-01 04:09:16.923333
NCT00294567|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2011-06-02|2006-02-21|2006-02-22|Estimate|||||||2011-06-02|2011-06-03|Estimate|December 2005||2005-12-31|October 2008|2008-10-31|January 2011|Actual|2011-01-31|May 2009|Actual|2009-05-31||Interventional|||Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)|Azelnidipine and Amlodipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Junten Medical University (ALPS-J)|Completed||Phase 4|200|Anticipated|Juntendo University Hospital||2|||f||||f||||||||||2018-06-01 04:09:22.553166|2018-06-01 04:09:22.553166
NCT00294723|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|2010-02-23|2009-11-09|2017-01-24|2006-02-20|2006-02-22|Estimate|2010-02-23|2010-03-12|Estimate|2009-11-09|2009-11-11|Estimate|2017-01-24|2017-03-07|Actual|February 2006||2006-02-28|January 2017|2017-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|LEAD-3||To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c|Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes|Terminated||Phase 3|746|Actual|Novo Nordisk A/S|Trial terminated due to an insufficient number of subjects remaining to obtain reasonable statistical power. Efficacy data was not analysed after week 156. Safety data was collected through week 195. No data was available from week 195 to 260|4||"The trial was terminated at week 195 due to an insufficient number of subjects remaining to~   obtain reasonable statistical power"|f||||f||||||||||2018-06-01 04:09:17.083604|2018-06-01 04:09:17.083604
NCT00294710|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-18|||2011-11-07|2006-02-18|2006-02-22|Estimate|||||||2011-11-07|2011-11-08|Estimate|March 2005||2005-03-31|November 2011|2011-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine|A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension|Completed||Phase 3|976|Actual|Novartis|||||||||||||||||||2018-06-01 04:09:18.805036|2018-06-01 04:09:18.805036
NCT00294697|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2010-08-23|2006-02-21|2006-02-22|Estimate|||||||2010-08-23|2010-08-24|Estimate|August 2003||2003-08-31|August 2010|2010-08-31|October 2011|Anticipated|2011-10-31|||||Observational|||Genetic Variation and Immune Responses After Injury|Genetics of Innate Immune Response After Burn Trauma|Unknown status|Recruiting||2000|Anticipated|National Institute of General Medical Sciences (NIGMS)|||||f||||t||||||Samples With DNA|"~     Blood, Tissue, Fluids~   "|||2018-06-01 04:09:18.858043|2018-06-01 04:09:18.858043
NCT00294684|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|2014-12-29||2017-03-27|2006-02-21|2006-02-22|Estimate|2017-03-27|2017-05-05|Actual||||2017-03-27|2017-05-05|Actual|November 2005||2005-11-30|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Intent to Treat|A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy|A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy in Infants With Biliary Atresia|Completed||N/A|141|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||Yes|Archived dataset will be entered into NIDDK Repository|2018-06-01 04:09:19.045818|2018-06-01 04:09:19.045818
NCT00294671|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|2013-12-26||2017-01-30|2006-02-21|2006-02-22|Estimate|2017-01-30|2017-03-17|Actual||||2017-01-30|2017-03-17|Actual|February 2006||2006-02-28|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Diflunisal on Familial Amyloidosis|The Effect of Diflunisal on Familial Amyloidosis|Completed||Phase 2/Phase 3|130|Actual|Boston University||2|||f||||t||||||||No|A manuscript analyzing cardiac outcomes is being prepared. We will consider IPD after the manuscript is complete and accepted.|2018-06-01 04:09:19.692062|2018-06-01 04:09:19.692062
NCT00294658|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|2016-09-19||2017-04-12|2006-02-21|2006-02-22|Estimate|2016-11-17|2017-01-16|Estimate||||2017-04-12|2017-05-23|Actual|June 2006||2006-06-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy|A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone|Completed||Phase 3|126|Actual|University of Alabama at Birmingham|Potential weakness of this trial include the single-blinded and pill count methodology.|2|||f||||t||||||||Yes||2018-06-01 04:09:20.380197|2018-06-01 04:09:20.380197
NCT00294645|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|2009-04-01||2010-10-01|2006-02-20|2006-02-22|Estimate|2010-10-01|2010-10-19|Estimate||||2010-10-01|2010-10-19|Estimate|April 2004||2004-04-30|October 2010|2010-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||PREFER (Pacemaker Remote Follow-Up Evaluation and Review)|Pacemaker Remote Follow-up Evaluation and Review|Completed||N/A|980|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-06-01 04:09:21.744028|2018-06-01 04:09:21.744028
NCT00294632|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2016-02-03|2006-02-20|2006-02-22|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2006||2006-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma|Lenalidomide and Rituximab Treatment of Relapsed Mantle Cell Lymphoma and Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Transformed Large Cell Lymphoma, and/or Grade 3 Follicular Lymphoma (Follicular Cleaved Large Cell Lymphoma or Follicular Non-Cleaved Large Cell Lymphoma (RV-LYM-PI-0056)|Completed||Phase 1/Phase 2|112|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:09:22.161124|2018-06-01 04:09:22.161124
NCT00294619|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2012-10-04|2006-02-20|2006-02-22|Estimate|||||||2012-10-04|2012-10-05|Estimate|April 2006||2006-04-30|October 2012|2012-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Treatment of Adults With Growth Hormone Deficiency|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.|Completed||Phase 3|147|Actual|LG Life Sciences||2|||f||||t||||||||||2018-06-01 04:09:22.236465|2018-06-01 04:09:22.236465
NCT00294606|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-17|2006-02-17|2006-02-22|Estimate|||||||2006-02-17|2006-02-22|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Comparison of the Effects of Phenylephrine and Norepinephrine on Cardiac Function During Carotid Artery Surgery|Comparison of the Effects of Phenylephrine and Norepinephrine on Cardiac Function During Carotid Cross-Clamping During Carotid Endarterectomy Under General Anesthesia|Unknown status|Recruiting|N/A|86||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:09:22.364194|2018-06-01 04:09:22.364194
NCT00294593|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2009-12-16|2006-02-21|2006-02-22|Estimate|||||||2009-12-16|2009-12-17|Estimate|October 2000||2000-10-31|December 2009|2009-12-31|December 2003||2003-12-31|||||Interventional|||Efficacy Study of Folinic Acid to Improve Mental Development of Children With Down Syndrome|One-year Double-blind Placebo-controlled Phase 2-3 Study to Evaluate the Effect of Oral Folinic Acid Treatment (1mg/kg/d) on the Psychomotor Development of Young Down Syndrome Patients|Completed||Phase 2/Phase 3|120||Institut Jerome Lejeune|||||f||||||||||||||2018-06-01 04:09:22.432627|2018-06-01 04:09:22.432627
NCT00294580|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2015-05-27|2006-02-20|2006-02-22|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 1982||1982-04-30|March 2006|2006-03-31|September 2001||2001-09-30|||||Interventional|||Early Childhood Malaria Prevention With Maloprim in The Gambia|Comparison of Two Strategies for Control of Malaria Within A Primary Health Care Programme in the Gambia|Completed||Phase 4|2253||Imperial College London|||||f||||||||||||||2018-06-01 04:09:22.489857|2018-06-01 04:09:22.489857
NCT00294554|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|2017-04-14||2017-08-10|2006-02-21|2006-02-22|Estimate|2017-08-10|2017-09-12|Actual||||2017-08-10|2017-09-12|Actual|April 2006||2006-04-30|August 2017|2017-08-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia|Double-Blind Placebo-Controlled Trial of Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia|Completed||N/A|20|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-06-01 04:09:22.639405|2018-06-01 04:09:22.639405
NCT00294541|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2007-09-10|2006-02-21|2006-02-22|Estimate|||||||2007-09-10|2007-09-11|Estimate|February 2006||2006-02-28|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|||A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy|An Open-Label Extension Study Evaluating the Long-Term Safety of ICA-17043 With or Without Hydroxyurea Therapy in Subjects With Sickle Cell Disease|Terminated||Phase 3|51|Actual|Icagen||||Lack of efficacy demonstrated in study ICA-17043-10|f||||t||||||||||2018-06-01 04:09:23.017594|2018-06-01 04:09:23.017594
NCT00294528|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-22|Estimate|||||||2006-02-21|2006-02-22|Estimate|January 2004||2004-01-31|October 2003|2003-10-31|January 2010||2010-01-31|||||Interventional|||Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC|Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex and AGC|Unknown status|Recruiting|Phase 4|100||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:09:23.12587|2018-06-01 04:09:23.12587
NCT00294515|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|2010-06-02||2018-02-28|2006-02-21|2006-02-22|Estimate|2010-06-02|2010-07-05|Estimate||||2018-02-28|2018-03-29|Actual|March 31, 2006|Actual|2006-03-31|February 2018|2018-02-28|August 31, 2009|Actual|2009-08-31|August 31, 2008|Actual|2008-08-31||Interventional|IMPACT||IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients|Completed||Phase 3|326|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-06-01 04:09:23.216788|2018-06-01 04:09:23.216788
NCT00294502|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-22|Estimate|||||||2006-02-21|2006-02-22|Estimate|September 2003||2003-09-30|September 2003|2003-09-30|May 2004||2004-05-31|||||Interventional|||Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia||Completed||Phase 4|120||Henry Ford Health System|||||f||||||||||||||2018-06-01 04:09:23.903143|2018-06-01 04:09:23.903143
NCT00294489|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-22|Estimate|||||||2006-02-21|2006-02-22|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|December 2006|Anticipated|2006-12-31|||||Observational|||Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT|Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT|Unknown status|Recruiting||500|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:09:23.958668|2018-06-01 04:09:23.958668
NCT00294476|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-19|||2006-10-11|2006-02-19|2006-02-22|Estimate|||||||2006-10-11|2006-10-12|Estimate|July 2005||2005-07-31|September 2006|2006-09-30||||||||Interventional|||IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma|A One Arm, Open Label,Multi - Center Phase II Study to Evaluate the Safety and Efficacy of IVIG in the Treatment of Various Metastatic Solid Tumors for Which There is no Better Alternate Treatment|Unknown status|Recruiting|Phase 2|30||GammaCan|||||f||||||||||||||2018-06-01 04:09:24.020361|2018-06-01 04:09:24.020361
NCT00294463|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-17|2006-02-17|2006-02-22|Estimate|||||||2006-02-17|2006-02-22|Estimate|February 2003||2003-02-28|February 2006|2006-02-28|March 2005||2005-03-31|||||Interventional|||Effects of Tibolone Treatment on the Endometrium|Effects of Tibolone Treatment on the Endometrium|Completed||Phase 4|35||Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:09:24.088255|2018-06-01 04:09:24.088255
NCT00294450|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2012-01-31|2006-02-20|2006-02-22|Estimate|||||||2012-01-31|2012-02-01|Estimate|February 2006||2006-02-28|January 2012|2012-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Feasibility Study of a New Fistula Pouching System|Pouching of Fistula - a Non-comparative, Multi-center Investigation|Completed||Phase 2/Phase 3|22|Actual|Coloplast A/S|||||f||||f||||||||||2018-06-01 04:09:24.174257|2018-06-01 04:09:24.174257
NCT00294437|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2012-04-30|2006-02-20|2006-02-22|Estimate|||||||2012-04-30|2012-05-01|Estimate|December 2003||2003-12-31|April 2012|2012-04-30|November 2007|Actual|2007-11-30|December 2003|Actual|2003-12-31||Interventional|||ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases|Randomised Open-label Multicenter Prosp. Clinical Study to Show the Efficacy of IV ZOMETA® 4mg for Prevention of Bone Metastases in Hormone-naïve High Risk Patients With Locally Advanced Prostate Cancer|Terminated||Phase 3|376|Actual|Central European Cooperative Oncology Group||2||underfunding|f||||f||||||||||2018-06-01 04:09:24.234573|2018-06-01 04:09:24.234573
NCT00294424|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-22|Estimate|||||||2006-02-21|2006-02-22|Estimate|September 2002||2002-09-30|January 2006|2006-01-31|April 2006||2006-04-30|||||Interventional|||Study on Costs and Effects of Waiting Time in Total Hip and Knee Replacements|A Prospective, Multi-Centre Study on Costs and Effects of Waiting Time in Patients Undergoing Total Hip and Knee Replacement Surgery. A Randomized Controlled Trial.|Unknown status|Active, not recruiting|N/A|833||Academy of Finland|||||f||||||||||||||2018-06-01 04:09:24.477324|2018-06-01 04:09:24.477324
NCT00294411|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2006-02-21|2006-02-21|2006-02-22|Estimate|||||||2006-02-21|2006-02-22|Estimate|December 2003||2003-12-31|February 2006|2006-02-28||||||||Interventional|||Vaginal Birth After Caesarean Section – Effect on Maternal Psychosocial Function||Completed||N/A|||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:09:24.545354|2018-06-01 04:09:24.545354
NCT00294398|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|2013-05-20||2015-04-23|2006-02-21|2006-02-22|Estimate|2015-04-07|2015-04-24|Estimate||||2015-04-23|2015-05-13|Estimate|March 2006||2006-03-31|April 2015|2015-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma|Inhaled Corticosteroids After a Pediatric Emergency Visit for Asthma|Completed||N/A|152|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-06-01 04:09:24.601215|2018-06-01 04:09:24.601215
NCT00294385|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2011-06-22|2006-02-20|2006-02-22|Estimate|||||||2011-06-22|2011-06-23|Estimate|June 2002||2002-06-30|June 2011|2011-06-30|October 2005|Actual|2005-10-31|||||Interventional|||Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine|A Randomized Phase III Study Comparing Concomitant Docetaxel Plus Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine in Anthracycline-Pretreated Metastatic or Locally Recurrent Breast Cancer Patients|Completed||Phase 3|430|Actual|Central European Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 04:09:24.904418|2018-06-01 04:09:24.904418
NCT00294177|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-17|2006-02-17|2006-02-20|Estimate|||||||2006-02-17|2006-02-20|Estimate|August 2006||2006-08-31|February 2006|2006-02-28|July 2008||2008-07-31|||||Observational|||Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma|Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Persistent Gestational Trophoblastic Tumors Using Atomic Force Microscopy and Dual Polarisation Interferometry|Unknown status|Not yet recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:09:26.191863|2018-06-01 04:09:26.191863
NCT00294372|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-20|||2013-11-13|2006-02-20|2006-02-22|Estimate|||||||2013-11-13|2013-11-14|Estimate|February 2006||2006-02-28|November 2013|2013-11-30||||September 2007|Actual|2007-09-30||Interventional|||Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients|Randomised, Double-blind, Placebo-controlled 7 Day Monotherapy Phase IIa Study to Evaluate the Antiviral Activity and Safety of Increasing Doses of Oral Administered RTV-boosted BILR 355 BS (75 mg and 150 mg Twice Daily) in HIV-1-infected, NNRTI-experienced Patients, Followed by 28 Day Combination Therapy With Tipranavir or Lopinavir Based HAART-regimen|Terminated||Phase 2|36||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:09:25.026103|2018-06-01 04:09:25.026103
NCT00294359|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2007-08-21|2006-02-21|2006-02-22|Estimate|||||||2007-08-21|2007-08-22|Estimate|June 2005||2005-06-30|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer|The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer|Completed||Phase 2/Phase 3|333|Anticipated|Australasian Gastro-Intestinal Trials Group|||||f||||||||||||||2018-06-01 04:09:25.147319|2018-06-01 04:09:25.147319
NCT00294346|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2008-02-15|2006-02-17|2006-02-22|Estimate|||||||2008-02-15|2008-02-25|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder|A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Social Anxiety Disorder|Completed||Phase 2|180||Avera Pharmaceuticals|||||f||||||||||||||2018-06-01 04:09:25.283399|2018-06-01 04:09:25.283399
NCT00294320|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-21|||2008-09-24|2006-02-21|2006-02-22|Estimate|||||||2008-09-24|2008-09-26|Estimate|February 2006||2006-02-28|September 2008|2008-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Evaluation of Two Different Non-Invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions|Pilot Study to Evaluate Two Different Non-Invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions (Clinical and Sub-Clinical), When Treated With Aldara 5% (Imiquimod) Cream|Completed||Phase 3|12|Actual|MEDA Pharma GmbH & Co. KG||2|||f||||||||||||||2018-06-01 04:09:25.371795|2018-06-01 04:09:25.371795
NCT00294307|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2016-01-13|2006-02-16|2006-02-20|Estimate|||||||2016-01-13|2016-01-14|Estimate|February 2006||2006-02-28|January 2016|2016-01-31|August 2012|Actual|2012-08-31|July 2010|Actual|2010-07-31||Observational|||Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers|Hospital to Home: Cognitively Impaired Elders/Caregivers|Completed|||814|Actual|University of Pennsylvania|||3||f||||f||||||||||2018-06-01 04:09:25.456502|2018-06-01 04:09:25.456502
NCT00294294|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2013-02-20|2006-02-17|2006-02-20|Estimate|||||||2013-02-20|2013-02-21|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa|A Randomized Controlled Open-Label Phase IV Multi Center Study to Assess the Effect of Antipyretic Prophylactic Treatment on the Rate of Febrile Reactions Following Concomitant Contralateral Administration of a 7-Valent Pneumococcal Conjugate Vaccine (Prevenar®) and DTPa-HBV-IPV+Hib Vaccine (Infanrix Hexa®) in Children at 2, 3, 4 and 11-14 Months of Age|Completed||Phase 4|300||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:09:25.553343|2018-06-01 04:09:25.553343
NCT00294281|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2011-09-19|2006-02-16|2006-02-20|Estimate|||||||2011-09-19|2011-09-20|Estimate|October 2006||2006-10-31|July 2010|2010-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Vagus Nerve Stimulation for Treating Adults With Severe Fibromyalgia|A Pilot Study to Assess the Tolerability and Exploratory Efficacy of Vagus Nerve Stimulation (VNS) Using the VNS Therapy System in Patients With Refractory Fibromyalgia With and Without Major Depression|Completed||Phase 1|14|Actual|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-06-01 04:09:25.606716|2018-06-01 04:09:25.606716
NCT00294268|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2008-07-01|2006-02-16|2006-02-20|Estimate|||||||2008-07-01|2008-07-03|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Cognitive Behavioural Therapy for Obesity|A Maintenance-Oriented Cognitive Behavioural Therapy in the Treatment of Obesity|Completed||Phase 2|24|Actual|University of Sydney||1|||f||||t||||||||||2018-06-01 04:09:25.675175|2018-06-01 04:09:25.675175
NCT00294255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-02-27|2006-02-16|2006-02-20|Estimate|||||||2013-02-27|2013-03-01|Estimate|March 2003||2003-03-31|February 2013|2013-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Risperidone Plus Mood Stabilizer in Treatment of Mixed Mania|Risperidone Plus Mood Stabilizer in the Treatment of Mixed Mania|Completed||Phase 4|45|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-06-01 04:09:25.751765|2018-06-01 04:09:25.751765
NCT00294242|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-17|2006-02-17|2006-02-20|Estimate|||||||2006-02-17|2006-02-20|Estimate|February 2006||2006-02-28|February 2006|2006-02-28||||||||Interventional|||Safety Study of Membrane Sweeping in Pregnancy|Does Routine Membrane Sweeping in Uncomplicated Term Pregnancies Increase the Rate of Prelabour Rupture of Membranes|Unknown status|Not yet recruiting|Phase 3|300||Tripler Army Medical Center|||||f||||||||||||||2018-06-01 04:09:25.822494|2018-06-01 04:09:25.822494
NCT00294229|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2011-09-30|2006-02-16|2006-02-20|Estimate|||||||2011-09-30|2011-10-03|Estimate|March 2003||2003-03-31|September 2011|2011-09-30|October 2006|Actual|2006-10-31|April 2006|Actual|2006-04-30||Interventional|||Spinal Manipulative Therapy for Low Back Pain|Spinal Manipulative Therapy for Low Back Pain: Randomised Controlled Trial|Completed||Phase 4|104|Actual|University of Bern|||||f||||f||||||||||2018-06-01 04:09:25.891576|2018-06-01 04:09:25.891576
NCT00294216|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-17|2006-02-17|2006-02-20|Estimate|||||||2006-02-17|2006-02-20|Estimate|August 2003||2003-08-31|February 2006|2006-02-28|July 2005||2005-07-31|||||Interventional|||Omacor and Placebo in Carotid Plaque Stability|A Double Blind Comparison of Omacor and Placebo in Patients Awaiting Endarterectomy to Investigate the Effect on Carotid Plaque Stability|Completed||Phase 3|121||Pronova BioPharma|||||f||||||||||||||2018-06-01 04:09:25.954587|2018-06-01 04:09:25.954587
NCT00294203|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2014-04-14|2006-02-17|2006-02-20|Estimate|||||||2014-04-14|2014-04-15|Estimate|February 2006||2006-02-28|April 2014|2014-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer|Placebo-Controlled Pilot Study to Assess the Post-Operative Administration of Epoetin Alfa on Patients Undergoing Abdominal or Pelvic Surgery for Malignancy|Completed||Phase 1|40|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 04:09:26.024839|2018-06-01 04:09:26.024839
NCT00294190|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2012-12-06|2006-02-16|2006-02-20|Estimate|||||||2012-12-06|2012-12-10|Estimate|February 2006||2006-02-28|May 2011|2011-05-31|July 2009|Actual|2009-07-31|September 2007|Actual|2007-09-30||Interventional|||Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer|A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer|Completed||Phase 2|38|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:09:26.113747|2018-06-01 04:09:26.113747
NCT00294164|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2014-03-24|2006-02-16|2006-02-20|Estimate|||||||2014-03-24|2014-03-26|Estimate|March 2001||2001-03-31|March 2014|2014-03-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)|Phase 2/3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Safety and Efficacy Trial of Subcutaneously Administered Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Treatment of Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)|Completed||Phase 2/Phase 3|245|Actual|EMD Serono||3|||f||||||||||||||2018-06-01 04:09:26.255497|2018-06-01 04:09:26.255497
NCT00294151|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2007-07-12|2006-02-17|2006-02-20|Estimate|||||||2007-07-12|2007-07-13|Estimate|September 2005||2005-09-30|January 2006|2006-01-31||||||||Interventional|||Potential Vertebroplasty Use in the Treatment of Vertebral Metastasis From Breast and Prostate Cancer|Challenging the Paradigm in Pain Relief for Advanced Breast and Prostate Cancer Patients With Vertebral Metastasis: Vertebral Augmentation With Cement Plus Radiotherapy Versus Radiotherapy. A Randomized, Prospective, Double Blind Pilot Study|Unknown status|Recruiting|Phase 3|30|Anticipated|McGill University Health Center|||||f||||||||||||||2018-06-01 04:09:26.370863|2018-06-01 04:09:26.370863
NCT00294125|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2013-04-19|2006-02-16|2006-02-20|Estimate|||||||2013-04-19|2013-04-22|Estimate|February 2006||2006-02-28|April 2013|2013-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Flavocoxid, A Plant-Derived Therapy, for the Treatment of Knee Osteoarthritis|Flavocoxid: A Medical Food Therapy for Osteoarthritis|Completed||Phase 1|59|Actual|University of Alabama at Birmingham||2|||f||||||||||||||2018-06-01 04:09:26.430463|2018-06-01 04:09:26.430463
NCT00294112|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2014-12-02|2006-02-17|2006-02-20|Estimate|||||||2014-12-02|2014-12-04|Estimate|February 2006||2006-02-28|December 2014|2014-12-31|September 2008|Actual|2008-09-30|August 2006|Actual|2006-08-31||Interventional|||Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease|A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants|Completed||Phase 2|10|Actual|Mesoblast, Ltd.||2|||f||||f||||||||||2018-06-01 04:09:26.51534|2018-06-01 04:09:26.51534
NCT00294099|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2013-05-30|2006-02-16|2006-02-20|Estimate|||||||2013-05-30|2013-06-03|Estimate|March 2006||2006-03-31|September 2008|2008-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults|A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Elderly Adults|Completed||Phase 1/Phase 2|600|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||||||||||||2018-06-01 04:09:26.597402|2018-06-01 04:09:26.597402
NCT00294086|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2011-06-07|2006-02-17|2006-02-20|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2005||2005-12-31|June 2011|2011-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure|A 12-Week Multicenter, 2-Arm Regimen, Exploratory Study to Evaluate the Tolerability and Safety of Valsartan Administered Once Daily vs Daily, in Patients With Stable, Chronic Heart Failure (NYHA Class Ll-lll)|Completed||Phase 2|160||Novartis|||||f||||||||||||||2018-06-01 04:09:26.838113|2018-06-01 04:09:26.838113
NCT00294073|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2007-06-18|2006-02-17|2006-02-20|Estimate|||||||2007-06-18|2007-06-19|Estimate|July 2005||2005-07-31|August 2005|2005-08-31||||||||Interventional|||Defining the Best Approach to Block the Pain After Knee Surgery|Defining the Best Approach to Block the Pain After Knee Surgery|Unknown status|Recruiting|Phase 3|60|Anticipated|McGill University Health Center|||||f||||||||||||||2018-06-01 04:09:26.912483|2018-06-01 04:09:26.912483
NCT00294060|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|2009-07-01||2011-04-06|2006-02-16|2006-02-20|Estimate|2011-04-06|2011-05-06|Estimate||||2011-04-06|2011-05-06|Estimate|March 2004||2004-03-31|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||P3: Pacemaker Patient Profiling Study|Pacemaker Patient Profiling (P3) Study|Terminated|||2013|Actual|Medtronic Cardiac Rhythm and Heart Failure|Characterization of objectives also encompassed 8 device features (Capture Management, MVP, APP, ARS, PMOP, Rate Response, Mode Switch, Sinus Preference) and 10 additional clinical outcomes. More information is available through the point of contact.|||"Preliminary analysis determined there was sufficient data to support objectives and allow early~   completion. The last patient visit occurred on November 6, 2007."|f||||f||||||||||2018-06-01 04:09:27.013706|2018-06-01 04:09:27.013706
NCT00294047|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|2011-12-08||2016-09-22|2006-02-17|2006-02-20|Estimate|2012-02-23|2012-03-27|Estimate||||2016-09-22|2016-09-23|Estimate|February 2006||2006-02-28|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older|A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above|Completed||Phase 3|5752|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:09:27.362905|2018-06-01 04:09:27.362905
NCT00294034|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2007-03-26|2006-02-16|2006-02-20|Estimate|||||||2007-03-26|2007-03-27|Estimate|October 2002||2002-10-31|March 2007|2007-03-31|May 2006|Actual|2006-05-31|||||Observational|||VIBRANT Registry: Value of Information Based From Pacemaker Recordings and New Technologies|VIBRANT Registry: Value of Information Based From Pacemaker Recordings and New Technologies|Completed|||950||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:09:32.539856|2018-06-01 04:09:32.539856
NCT00294021|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2012-09-25|2006-02-17|2006-02-20|Estimate|||||||2012-09-25|2012-09-26|Estimate|March 2006||2006-03-31|September 2012|2012-09-30|April 2008|Actual|2008-04-30|||||Observational|||Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage|Long-term Impact of the Pneumococcal Conjugate Vaccine on Pneumococcal Nasopharyngeal Colonization and Immune Correlates for Disease Protection|Completed|||1000|Anticipated|Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||Samples Without DNA|"~     Nasopharyngeal specimens will be collected for isolation of pneumococcus; saliva and serum~     specimens will be collected for antibody assays~   "|||2018-06-01 04:09:32.629048|2018-06-01 04:09:32.629048
NCT00294008|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2014-04-02|2006-02-16|2006-02-20|Estimate|||||||2014-04-02|2014-04-03|Estimate|December 2004||2004-12-31|April 2014|2014-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)|Electronic Schizophrenia Treatment Adherence Registry(e-STAR): An Observational, International Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres|Completed|||230|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-06-01 04:09:32.701095|2018-06-01 04:09:32.701095
NCT00293969|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2006-02-17|2006-02-17|2006-02-20|Estimate|||||||2006-02-17|2006-02-20|Estimate|March 2005||2005-03-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||A Trial Comparing Different Dosing Regimens of Morphine in Patients With Moderate to Severe Pain|A Randomized Clinical Trial Comparing Different Dosing Regimens of Intravenous Morphine in the Treatment of Adult Patients Presenting to the Emergency Department With Moderate to Severe Pain|Completed||N/A|280||Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:09:32.896067|2018-06-01 04:09:32.896067
NCT00293956|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2008-01-16|2006-02-16|2006-02-20|Estimate|||||||2008-01-16|2008-01-18|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Thyroid Function in Term Infants With Respiratory Distress|Thyroid Function in Term and Near Term Infants With Respiratory Distress and Its' Relation to Severity of Illness|Completed|||20|Actual|Christiana Care Health Services|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-06-01 04:09:32.959415|2018-06-01 04:09:32.959415
NCT00293943|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2012-09-07|2006-02-17|2006-02-20|Estimate|||||||2012-09-07|2012-09-10|Estimate|February 2006||2006-02-28|September 2012|2012-09-30|August 2010|Actual|2010-08-31|March 2010|Actual|2010-03-31||Interventional|||Randomized Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation|A Randomized Trial to Investigate the Significance of Complete Versus Incomplete Electrical Isolation of Pulmonary Veins by Radiofrequency-induced Linear Lesions|Completed||N/A|232|Actual|Atrial Fibrillation Network|||||f||||||||||||||2018-06-01 04:09:33.037135|2018-06-01 04:09:33.037135
NCT00293930|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2007-12-19|2006-02-16|2006-02-20|Estimate|||||||2007-12-19|2007-12-24|Estimate||||December 2007|2007-12-31|November 2006|Actual|2006-11-30|||||Interventional|||A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis||Completed||Phase 3|645|Actual|Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:09:33.108689|2018-06-01 04:09:33.108689
NCT00293917|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2008-02-11|2006-02-16|2006-02-20|Estimate|||||||2008-02-11|2008-02-13|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis|A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis|Completed||Phase 3|658|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-06-01 04:09:33.271786|2018-06-01 04:09:33.271786
NCT00293904|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2007-09-19|2006-02-17|2006-02-20|Estimate|||||||2007-09-19|2007-09-20|Estimate|February 2006||2006-02-28|September 2007|2007-09-30|February 2007|Actual|2007-02-28|||||Interventional|||Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy|Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (CYT005-AllQbG10) in Subjects With Seasonal Rhinoconjunctivitis Due to Grass-Pollen Allergy|Completed||Phase 1/Phase 2|36|Anticipated|Cytos Biotechnology AG|||||f||||||||||||||2018-06-01 04:09:33.45368|2018-06-01 04:09:33.45368
NCT00293891|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2007-12-19|2006-02-16|2006-02-20|Estimate|||||||2007-12-19|2007-12-24|Estimate||||December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis||Completed||Phase 3|658|Actual|Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:09:33.515522|2018-06-01 04:09:33.515522
NCT00293878|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2007-02-22|2006-02-16|2006-02-20|Estimate|||||||2007-02-22|2007-02-26|Estimate|November 2005||2005-11-30|February 2007|2007-02-28||||||||Interventional|||Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of FM-VP4 in Subjects With Primary Hypercholesterolemia|Completed||Phase 2|150||Forbes Medi-Tech|||||||||||||||||||2018-06-01 04:09:33.629255|2018-06-01 04:09:33.629255
NCT00293865|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2016-04-18|2006-02-17|2006-02-20|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2006||2006-03-31|April 2016|2016-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|GATA||Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast Cancer|Prospective Multicentric Study of Sentinel Lymph Node Assessment Following Previous Surgical Biopsy for Early Breast Cancer|Completed||N/A|203|Actual|Institut Cancerologie de l'Ouest|||||f||||||||||||||2018-06-01 04:09:33.700795|2018-06-01 04:09:33.700795
NCT00293852|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2010-12-02|2006-02-17|2006-02-20|Estimate|||||||2010-12-02|2010-12-06|Estimate|February 2006||2006-02-28|December 2010|2010-12-31||||||||Interventional|||Collaborative Care for Heart Failure Patients With the Metabolic Syndrome|Collaborative Care for Heart Failure Patients With the Metabolic Syndrome|Unknown status|Recruiting|N/A|380|Anticipated|Baylor College of Medicine|||||f||||||||||||||2018-06-01 04:09:33.766197|2018-06-01 04:09:33.766197
NCT00293839|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2010-12-07|2006-02-16|2006-02-20|Estimate|||||||2010-12-07|2010-12-09|Estimate||||December 2010|2010-12-31|December 2002|Actual|2002-12-31|||||Interventional|||Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder|Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder|Completed||Phase 3|790|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:09:33.82004|2018-06-01 04:09:33.82004
NCT00293826|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2010-03-04|2006-02-17|2006-02-20|Estimate|||||||2010-03-04|2010-03-05|Estimate|March 2006||2006-03-31|March 2010|2010-03-31|February 2008|Actual|2008-02-29|November 2007|Actual|2007-11-30||Interventional|||A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis.|Completed||Phase 2|813|Actual|Amgen||4|||f||||||||||||||2018-06-01 04:09:33.876062|2018-06-01 04:09:33.876062
NCT00293813|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|2009-12-22|2009-11-23|2014-07-18|2006-02-17|2006-02-20|Estimate|2009-12-22|2010-01-27|Estimate|2009-11-23|2009-11-25|Estimate|2014-07-18|2014-07-25|Estimate|May 2006||2006-05-31|July 2014|2014-07-31|August 2008|Actual|2008-08-31|March 2008|Actual|2008-03-31||Interventional|||A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density|A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 2|247|Actual|Amgen||3|||f||||||||||||||2018-06-01 04:09:34.152036|2018-06-01 04:09:34.152036
NCT00293800|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2012-02-11|2006-02-17|2006-02-20|Estimate|||||||2012-02-11|2012-02-14|Estimate|July 2004||2004-07-31|February 2012|2012-02-29|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|173|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 04:09:34.497779|2018-06-01 04:09:34.497779
NCT00293787|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2012-02-13|2006-02-17|2006-02-20|Estimate|||||||2012-02-13|2012-02-14|Estimate|June 2004||2004-06-30|February 2012|2012-02-29|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|156|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 04:09:34.578113|2018-06-01 04:09:34.578113
NCT00293774|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2018-01-08|2006-02-16|2006-02-20|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2004||2004-06-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|January 2011|Actual|2011-01-31||Observational|||Alberta Hip Improvement Project|A Provincial Initiative to Examine the Efficacy, Cost-effectiveness and Long-term Safety of Alternative Hip Bearing Surfaces Versus Conventional Therapy for Degenerative Joint Disease of the Hip|Active, not recruiting|||1000|Anticipated|Alberta Bone and Joint Health Institute|||2||f||||t||||||Samples Without DNA|"~     Blood samples retained for cobalt and chromium metal ion level analysis on select cohort.~   "|||2018-06-01 04:09:34.64348|2018-06-01 04:09:34.64348
NCT00293761|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2016-11-17|2006-02-17|2006-02-20|Estimate|||||||2016-11-17|2016-11-18|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 3|109|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 04:09:34.694299|2018-06-01 04:09:34.694299
NCT00293748|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-17|||2017-06-30|2006-02-16|2006-02-17|Estimate|||||||2017-06-30|2017-07-02|Actual|February 13, 2006||2006-02-13|December 15, 2008|2008-12-15|December 15, 2008||2008-12-15|||||Observational|||Effect of Atorvastatin (Lipitor) on Gene Expression in People With Vascular Disease|Dose-Response Study of Modulation of Gene Expression in Peripheral Blood Mononuclear Cells by Atorvastatin|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:09:34.761804|2018-06-01 04:09:34.761804
NCT00293735|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2017-01-12|2006-02-16|2006-02-17|Estimate|||||||2017-01-12|2017-01-13|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|LAMPET||Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial|Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET)|Withdrawn||Phase 2/Phase 3|0|Actual|Baylor College of Medicine||2||Lack of funding|f||||t||||||||||2018-06-01 04:09:34.890483|2018-06-01 04:09:34.890483
NCT00293722|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2014-01-10||2014-01-10|2006-02-15|2006-02-17|Estimate|2014-01-10|2014-02-26|Estimate||||2014-01-10|2014-02-26|Estimate|January 2006||2006-01-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational||Safety analysis set included all participants who were enrolled in this study and had safety data available. Out of a total of 1285 participants included in the safety analysis set, data for baseline measure (age) was available only for 1274 participants.|Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists|Prospective Post Marketing Surveillance to Evaluate the Safety and Efficacy of Etanercept Under Usual Care Settings in Patients With Psoriatic Arthritis (PsA) Treated by Rheumatologists|Completed|||1308|Actual|Pfizer|Results for Psoriasis Area and Severity Index (PASI) was not reported since it was not to be analyzed by rheumatologists as part of this study, as per planned analysis.||1||f||||f||||||||||2018-06-01 04:09:35.056834|2018-06-01 04:09:35.056834
NCT00293709|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2014-01-10||2014-01-10|2006-02-15|2006-02-17|Estimate|2014-01-10|2014-02-26|Estimate||||2014-01-10|2014-02-26|Estimate|January 2006||2006-01-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational||Safety analysis set included all participants who were enrolled in this study. Out of a total of 149 participants, data for baseline measure (age) was available only for 146 participants.|Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists|Prospective Post Marketing Surveillance To Evaluate The Safety And Efficacy Of Etanercept Under Usual Care Settings In Patients With Psoriatic Arthritis (Psa) Treated By Dermatologists|Completed|||129|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 04:09:35.751188|2018-06-01 04:09:35.751188
NCT00293696|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2007-05-07|2006-02-16|2006-02-17|Estimate|||||||2007-05-07|2007-05-08|Estimate|October 2004||2004-10-31|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Interventional|||Casodex/Zoladex Biomarkers in Localised Prostate Cancer|A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma|Completed||Phase 4|30|Actual|University of Tampere|||||f||||||||||||||2018-06-01 04:09:36.127955|2018-06-01 04:09:36.127955
NCT00293683|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2014-07-28|2006-02-16|2006-02-17|Estimate|||||||2014-07-28|2014-07-29|Estimate|December 2004||2004-12-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||A Study Comparing Two Different Techniques for Closing the Skin After a Cesarean Delivery|Cesarean Delivery Skin Closure: A Randomized Controlled Trial of Standard Staples Versus Absorbable Staples|Unknown status|Active, not recruiting|N/A|120||Thomas Jefferson University|||||f||||t||||||||||2018-06-01 04:09:36.182881|2018-06-01 04:09:36.182881
NCT00293670|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2006-02-16|2006-02-16|2006-02-17|Estimate|||||||2006-02-16|2006-02-17|Estimate|May 1997||1997-05-31|February 2006|2006-02-28|April 2015||2015-04-30|||||Interventional|||FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer|Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer|Unknown status|Active, not recruiting|Phase 4|573||University of Tampere|||||f||||||||||||||2018-06-01 04:09:36.249046|2018-06-01 04:09:36.249046
NCT00293657|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2012-11-29|2006-02-15|2006-02-17|Estimate|||||||2012-11-29|2012-12-03|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.|A Randomized, Double-Blind, Single-Dose Study, Placebo-Controlled Evaluation of the Safety and Efficacy of Intravenous Lornoxicam in the Acute Treatment of the Headache of Migraine.|Completed||Phase 2|150||POZEN|||||||||||||||||||2018-06-01 04:09:36.307713|2018-06-01 04:09:36.307713
NCT00293644|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2016-07-20|2006-02-15|2006-02-17|Estimate|||||||2016-07-20|2016-07-22|Estimate|February 2006||2006-02-28|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2012|Actual|2012-06-30||Interventional|||Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy|A Randomized, Open-Label, Study of Pre-emptive Diclectin® Treatment for Severe Nausea and Vomiting of Pregnancy|Completed||Phase 3|76|Actual|The Hospital for Sick Children||3|||f||||f||||||||No||2018-06-01 04:09:36.394692|2018-06-01 04:09:36.394692
NCT00293631|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2012-11-29|2006-02-15|2006-02-17|Estimate|||||||2012-11-29|2012-12-03|Estimate|November 2005||2005-11-30|November 2012|2012-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy|A Randomized, Parallel-Group, Double-Blind, Single-Dose Study Evaluating the Efficacy and Safety of Intravenous Lornoxicam (8 mg and 16 mg) Compared to Intravenous Placebo and Ketorolac 30 mg in Management of Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy).|Completed||Phase 2|100||POZEN|||||||||||||||||||2018-06-01 04:09:36.459113|2018-06-01 04:09:36.459113
NCT00293618|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2009-01-15|2006-02-16|2006-02-17|Estimate|||||||2009-01-15|2009-01-16|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Implementation Study of the PostOperative Nausea and Vomiting Prediction Rule|IMplementation of a Prediction Rule in Anesthesia Practice to Improve Cost-Effectiveness of Treatment of Postoperative Nausea and Vomiting|Completed||N/A|11970|Actual|UMC Utrecht||2|||f||||f||||||||||2018-06-01 04:09:36.58015|2018-06-01 04:09:36.58015
NCT00293605|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2011-05-06|2006-02-16|2006-02-17|Estimate|||||||2011-05-06|2011-05-09|Estimate|January 2004||2004-01-31|May 2011|2011-05-31|April 2011|Actual|2011-04-30|November 2008|Actual|2008-11-30||Observational|||Effect of Cemented Stem Design on Periprosthetic Bone Mass Following Primary Total Hip Arthroplasty|Effect of Cemented Stem Design on Periprosthetic Bone Mass Following Primary Total Hip Arthroplasty|Completed|||120|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||3||f||||f||||||Samples Without DNA|"~     Blood and Urine only~   "|||2018-06-01 04:09:36.664452|2018-06-01 04:09:36.664452
NCT00293592|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2015-04-18|2006-02-16|2006-02-17|Estimate|||||||2015-04-18|2015-04-21|Estimate|May 2006||2006-05-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||Dexamethasone for Cardiac Surgery Trial|Dexamethasone for Cardiac Surgery Trial|Completed||N/A|4500|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 04:09:36.742916|2018-06-01 04:09:36.742916
NCT00293579|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2015-10-30||2016-02-11|2006-02-15|2006-02-17|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|February 2006||2006-02-28|February 2016|2016-02-29|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer|A Phase II Study of Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer|Completed||Phase 2|5|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:09:36.844342|2018-06-01 04:09:36.844342
NCT00293553|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2010-03-17|2006-02-16|2006-02-17|Estimate|||||||2010-03-17|2010-03-18|Estimate||||March 2010|2010-03-31|December 2007|Actual|2007-12-31|||||Interventional|||Clinical Approaches to Ileal Pouch Dysfunction||Completed||Phase 3|64|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:09:37.018616|2018-06-01 04:09:37.018616
NCT00293540|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2016-05-19||2016-06-28|2006-02-15|2006-02-17|Estimate|2016-05-19|2016-06-28|Estimate||||2016-06-28|2016-07-27|Estimate|February 2006||2006-02-28|June 2016|2016-06-30|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|||Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer|Phase III Randomized Study of Luteal Phase vs. Follicular Phase Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor-Positive Breast Cancer|Completed||Phase 3|249|Actual|International Breast Cancer Research Foundation||2|||f||||t||||||||||2018-06-01 04:09:37.081752|2018-06-01 04:09:37.081752
NCT00293527|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2013-05-22|2006-02-15|2006-02-17|Estimate|||||||2013-05-22|2013-05-23|Estimate||||May 2013|2013-05-31|November 2006||2006-11-30|||||Interventional|||Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma|A Phase II Dose Escalation Study of Continuous Daily Subcutaneous Administration of Interferon Alpha-2b in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|Ohio State University Comprehensive Cancer Center||||Withdrawn in October 2006, no longer of interest|f||||t||||||||||2018-06-01 04:09:37.3853|2018-06-01 04:09:37.3853
NCT00293514|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2012-05-04|2006-02-15|2006-02-17|Estimate|||||||2012-05-04|2012-05-07|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)|An Open, Randomised, Prospective, Multi-centre, Parallel-group Trial of TachoSil Versus Standard Surgical Treatment in Patients Undergoing Pulmonary Lobectomy for Lung Malignancy and Requiring Treatment for Air Leakage|Completed||Phase 3|||Nycomed|||||f||||t||||||||||2018-06-01 04:09:37.436383|2018-06-01 04:09:37.436383
NCT00293501|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2013-11-05|2006-02-16|2006-02-17|Estimate|||||||2013-11-05|2013-11-06|Estimate|December 2005||2005-12-31|February 2007|2007-02-28||||February 2007|Anticipated|2007-02-28||Interventional|||Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery|A Phase I/II Trial of Tinzaparin (Innohep), a Low Molecular Weight Heparin (LMWH) for Treatment of Advanced Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:09:37.487586|2018-06-01 04:09:37.487586
NCT00293488|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2016-06-21|2006-02-16|2006-02-17|Estimate|||||||2016-06-21|2016-06-23|Estimate|January 2006||2006-01-31|June 2016|2016-06-30||||September 2008|Actual|2008-09-30||Interventional|||SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma|An Open Label Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of SL-11047 in Patients With Refractory Lymphoma|Completed||Phase 1|20|Anticipated|Progen Pharmaceuticals|||||f||||||||||||||2018-06-01 04:09:37.544949|2018-06-01 04:09:37.544949
NCT00293475|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2018-05-02|2006-02-16|2006-02-17|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2005||2005-10-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|A Phase I/II Study of Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen|Recruiting||Phase 1/Phase 2|81|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 04:09:37.602527|2018-06-01 04:09:37.602527
NCT00293462|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|2013-03-27||2013-05-14|2006-02-16|2006-02-17|Estimate|2013-05-14|2013-05-16|Estimate||||2013-05-14|2013-05-16|Estimate|May 2005||2005-05-31|May 2013|2013-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer|Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol|Completed||N/A|91|Actual|University of California, San Francisco|Of 532 potential subjects that were screened, 374 were excluded as they did not meet the inclusion criteria, 45 refused to participate and 22 were no-shows (declined radiation therapy), thereby reducing our original target sample population to 91.|3|||f||||f||||||||||2018-06-01 04:09:37.749483|2018-06-01 04:09:37.749483
NCT00293436|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2012-09-13|2006-02-16|2006-02-17|Estimate|||||||2012-09-13|2012-09-17|Estimate|January 2005||2005-01-31|September 2012|2012-09-30||||||||Interventional|||Celecoxib and Erlotinib in Treating Patients With Liver Cancer|A Phase I/II Study of Celecoxib and Erlotinib Hydrochloride as Adjuvant Therapy for High Risk Patients With a History of Hepatocellular Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:09:38.287482|2018-06-01 04:09:38.287482
NCT00293423|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16||2014-11-12|2017-08-17|2006-02-16|2006-02-17|Estimate||||2014-11-12|2014-11-24|Estimate|2017-08-17|2017-08-21|Actual|October 2005||2005-10-31|August 2017|2017-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma|Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma|Completed||Phase 1/Phase 2|41|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:09:38.342179|2018-06-01 04:09:38.342179
NCT00292578|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2008-10-16|2006-02-15|2006-02-16|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2005||2005-01-31|October 2008|2008-10-31|January 2006||2006-01-31|||||Interventional|||NAET® Testing Devices in Detection of Hypersensitivity to Cane Sugar|NAET® Testing Devices in Detection of Hypersensitivity to Cane Sugar|Completed||Phase 1/Phase 2|75||Nambudripad's Allergy Research Foundation|||||f||||||||||||||2018-06-01 04:09:48.944237|2018-06-01 04:09:48.944237
NCT00293410|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2010-05-05|2006-02-16|2006-02-17|Estimate|||||||2010-05-05|2010-05-06|Estimate|November 2005||2005-11-30|May 2010|2010-05-31||||April 2010|Actual|2010-04-30||Interventional|||Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders|Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Adults and Children With Relapsed or Refractory Acute Leukemias|Completed||Phase 1|70|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:09:38.417219|2018-06-01 04:09:38.417219
NCT00293397|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2011-07-19|2006-02-16|2006-02-17|Estimate|||||||2011-07-19|2011-07-20|Estimate|November 2005||2005-11-30|July 2011|2011-07-31||||April 2011|Actual|2011-04-30||Interventional|||Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Treatment of Patients With Hepatocellular Carcinoma Using Drug-Eluting Bead Embolization|Completed||Phase 2|20|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:09:38.603067|2018-06-01 04:09:38.603067
NCT00293384|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|2014-05-12||2016-02-12|2006-02-16|2006-02-17|Estimate|2014-09-26|2014-10-03|Estimate||||2016-02-12|2016-03-15|Estimate|October 2004||2004-10-31|February 2016|2016-02-29|February 2012|Actual|2012-02-29|June 2009|Actual|2009-06-30||Interventional||Patients who received all doses of the study drug were considered evaluable patients.|Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant|Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation|Completed||N/A|40|Actual|Barbara Ann Karmanos Cancer Institute|There were no other significant limitations except for the details provided.|1|||f||||t||||||||||2018-06-01 04:09:38.698971|2018-06-01 04:09:38.698971
NCT00293371|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2012-10-09|2006-02-16|2006-02-17|Estimate|||||||2012-10-09|2012-10-11|Estimate|February 2005||2005-02-28|October 2012|2012-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer|A Phase I/II Study of Docetaxel/Prednisone and PTK 787/ZK 222584 in Previously Untreated Metastatic Hormone Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|6|Actual|University of California, San Francisco||||low accrual|f||||||||||||||2018-06-01 04:09:38.953896|2018-06-01 04:09:38.953896
NCT00293358|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2013-09-16|2006-02-16|2006-02-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|January 1997||1997-01-31|July 2008|2008-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain|SIOP Intracranial Germ Cell Tumours Protocol|Completed||Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:09:39.046983|2018-06-01 04:09:39.046983
NCT00293345|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2013-09-27|2006-02-16|2006-02-17|Estimate|||||||2013-09-27|2013-09-30|Estimate|June 2006||2006-06-30|September 2013|2013-09-30||||October 2012|Actual|2012-10-31||Interventional|||3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of a Prolonged Infusion of Triapine in Combination With a Fixed Dose Rate of Gemcitabine in Patients With Advanced Solid Tumors and Lymphomas|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:09:39.204243|2018-06-01 04:09:39.204243
NCT00293332|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2011-02-08|2006-02-16|2006-02-17|Estimate|||||||2011-02-08|2011-02-09|Estimate|December 2005||2005-12-31|June 2007|2007-06-30|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery|A Phase II Study of Neoadjuvant Therapy With Docetaxel, Carboplatin, and Bevacizumab in Patients With Resectable Early Stage Non-Small Cell Lung Cancer|Terminated||Phase 2|1|Actual|University of California, San Francisco||||Terminated due to low subject accrual|f||||t||||||||||2018-06-01 04:09:39.341001|2018-06-01 04:09:39.341001
NCT00293319|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2014-08-14|2006-02-16|2006-02-17|Estimate|||||||2014-08-14|2014-08-18|Estimate|April 2005||2005-04-30|August 2014|2014-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma|I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma, A Phase II Study|Completed||Phase 2|164|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:09:39.432194|2018-06-01 04:09:39.432194
NCT00293293|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|2011-08-22||2017-12-03|2006-02-16|2006-02-17|Estimate|2012-05-02|2012-06-06|Estimate||||2017-12-03|2017-12-28|Actual|May 2005||2005-05-31|December 2017|2017-12-31|January 2010|Actual|2010-01-31|April 2009|Actual|2009-04-30||Interventional|||Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine|Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine|Completed||N/A|43|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||f||||||||||2018-06-01 04:09:39.535597|2018-06-01 04:09:39.535597
NCT00293280|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2013-05-03|2006-02-16|2006-02-17|Estimate|||||||2013-05-03|2013-05-06|Estimate|July 2005||2005-07-31|May 2013|2013-05-31||||July 2007|Actual|2007-07-31||Interventional|||Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene|Completed||Phase 2|42|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:09:39.945812|2018-06-01 04:09:39.945812
NCT00293267|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|2009-08-18||2015-09-04|2006-02-15|2006-02-17|Estimate|2009-09-25|2009-09-28|Estimate||||2015-09-04|2015-09-07|Estimate|February 2006||2006-02-28|September 2015|2015-09-30|May 2011|Actual|2011-05-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiviral Therapies|Completed||Phase 3|352|Actual|Merck Sharp & Dohme Corp.|Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 94 of 118 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.|2|||f||||t||||||||||2018-06-01 04:09:40.06432|2018-06-01 04:09:40.06432
NCT00293085|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2011-06-22|2006-02-16|2006-02-17|Estimate|||||||2011-06-22|2011-06-23|Estimate|December 2001||2001-12-31|June 2011|2011-06-30|September 2003|Actual|2003-09-30|||||Interventional|||An Open, Randomized, Multicentre, Phase II Pilot Study|An Open, Randomized, Multicentre, Phase II Pilot Study of Docetaxel and Cisplatin in the Adjuvant Treatment of Non-Small Cell Lung Cancer (NSCLC) Stage I-II|Completed||Phase 2|37|Actual|Central European Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 04:09:44.789438|2018-06-01 04:09:44.789438
NCT00291993|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2008-04-17|2006-02-13|2006-02-15|Estimate|||||||2008-04-17|2008-04-21|Estimate|January 2004||2004-01-31|April 2008|2008-04-30||||||||Observational|||Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea and Healthy Controls.||Completed|||||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:09:57.203515|2018-06-01 04:09:57.203515
NCT00293254|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2009-08-20||2017-02-14|2006-02-15|2006-02-17|Estimate|2009-09-29|2009-09-30|Estimate||||2017-02-14|2017-03-21|Actual|February 2006||2006-02-28|February 2017|2017-02-28|May 2011|Actual|2011-05-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies|Completed||Phase 3|351|Actual|Merck Sharp & Dohme Corp.|Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 83 of 119 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:09:41.312646|2018-06-01 04:09:41.312646
NCT00293241|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|2014-10-09||2016-05-23|2006-02-16|2006-02-17|Estimate|2015-06-26|2015-06-30|Estimate||||2016-05-23|2016-06-24|Estimate|February 2006||2006-02-28|June 2015|2015-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||PreFER Managed Ventricular Pacing (MVP) For Elective Replacement|PreFER MVP for Elective Replacement|Completed||Phase 4|630|Actual|Medtronic Cardiac Rhythm and Heart Failure|Atrial pacing % was not collected at implant, device programming in the MVP off arm was more often non-compliant than in MVP on arm, and 25% of the case report forms were sent without device data, possibly influencing device data related objectives|2|||f||||t||||||||||2018-06-01 04:09:42.275353|2018-06-01 04:09:42.275353
NCT00293228|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2010-05-25|2006-02-16|2006-02-17|Estimate|||||||2010-05-25|2010-05-26|Estimate|February 2007||2007-02-28|May 2010|2010-05-31|June 2009|Actual|2009-06-30|March 2008|Actual|2008-03-31||Interventional|||Treatment of Latent Tuberculosis Infection With Isoniazid|Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB|Completed||Phase 4|200|Anticipated|Instituto Nacional de Salud Publica, Mexico||4|||f||||t||||||||||2018-06-01 04:09:43.79885|2018-06-01 04:09:43.79885
NCT00293215|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2007-05-11|2006-02-15|2006-02-17|Estimate|||||||2007-05-11|2007-05-15|Estimate|February 2006||2006-02-28|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen|A Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen|Completed||Phase 1|9|Actual|Ludwig Institute for Cancer Research|||||||||||||||||||2018-06-01 04:09:43.926769|2018-06-01 04:09:43.926769
NCT00293202|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2012-04-04|2006-02-15|2006-02-17|Estimate|||||||2012-04-04|2012-04-05|Estimate|March 2005||2005-03-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients|The Effect of Etanercept in Suppression of the Systemic Inflammatory Response in Hemodialysis Patients|Terminated||Phase 2|10|Actual|Kaysen, George A., M.D., Ph.D.||2||We were unable to recruit sufficient patients within the confines of our budget|f||||||||||||||2018-06-01 04:09:44.057558|2018-06-01 04:09:44.057558
NCT00293189|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2006-05-19|2006-02-16|2006-02-17|Estimate|||||||2006-05-19|2006-05-24|Estimate|December 2005||2005-12-31|August 2005|2005-08-31||||||||Observational|||Gene-Polymorphies in the P2X7 Gene in Patients With Osteoporotic Fractures|Gene-Polymorphies in the P2X7 Gene in Patients With Osteoporotic Fractures|Unknown status|Recruiting||700||Kolding Sygehus|||||f||||||||||||||2018-06-01 04:09:44.131564|2018-06-01 04:09:44.131564
NCT00293176|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2011-03-31|2006-02-16|2006-02-17|Estimate|||||||2011-03-31|2011-04-01|Estimate|December 2003||2003-12-31|March 2011|2011-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)|A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)|Completed||Phase 4|821|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:09:44.19671|2018-06-01 04:09:44.19671
NCT00293163|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2015-03-04|2006-02-16|2006-02-17|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2006||2006-02-28|March 2015|2015-03-31|October 2006|Actual|2006-10-31|||||Interventional|||A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.||Completed||Phase 4|120||Sanofi|||||f||||||||||||||2018-06-01 04:09:44.328873|2018-06-01 04:09:44.328873
NCT00293150|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2017-01-26|2006-02-16|2006-02-17|Estimate|||||||2017-01-26|2017-01-27|Estimate|September 2003||2003-09-30|January 2017|2017-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|PREDICT||Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure|Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study)|Terminated||Phase 4|11|Actual|The Cleveland Clinic||2||Lack of eligible patients|f||||f|t|f||||||No||2018-06-01 04:09:44.383797|2018-06-01 04:09:44.383797
NCT00293137|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2008-09-18|2006-02-16|2006-02-17|Estimate|||||||2008-09-18|2008-09-19|Estimate|February 2006||2006-02-28|September 2008|2008-09-30|August 2007|Actual|2007-08-31|||||Observational|NORDIC||NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy|Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy|Terminated|||60|Anticipated|The Cleveland Clinic|||1|safety concerns regarding use of rosiglitazone|f||||||||||||||2018-06-01 04:09:44.464174|2018-06-01 04:09:44.464174
NCT00293124|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2015-08-11|2006-02-16|2006-02-17|Estimate|||||||2015-08-11|2015-08-13|Estimate|March 2004||2004-03-31|May 2012|2012-05-31|July 2008|Actual|2008-07-31|July 2006|Actual|2006-07-31||Interventional|||Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors|An Open-label Trial of Glivec in Patients With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors Expressing C-kit.|Completed||Phase 3|125|Actual|Central European Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 04:09:44.545894|2018-06-01 04:09:44.545894
NCT00293111|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2014-05-08|2006-02-16|2006-02-17|Estimate|||||||2014-05-08|2014-05-12|Estimate|February 2002||2002-02-28|May 2014|2014-05-31||||October 2003|Actual|2003-10-31||Interventional|||Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)|An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)|Terminated||Phase 2|30||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:09:44.652101|2018-06-01 04:09:44.652101
NCT00293098|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2012-02-08|2006-02-16|2006-02-17|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2006||2006-03-31|February 2012|2012-02-29||||||||Expanded Access|||Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease|Compassionate Use of Deferiprone in Patients With Thalassemia and Iron-Induced Heart Disease|Approved for marketing|||||Children's Hospital of Philadelphia|||||||||||||||||||2018-06-01 04:09:44.725812|2018-06-01 04:09:44.725812
NCT00293072|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2006-02-16|2006-02-16|2006-02-17|Estimate|||||||2006-02-16|2006-02-17|Estimate|March 2002||2002-03-31|October 2005|2005-10-31|May 2005||2005-05-31|||||Interventional|||Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis|Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Resistant to Conventional Therapy|Completed||Phase 2|20||Cambridge University Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:09:44.861968|2018-06-01 04:09:44.861968
NCT00293059|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2011-02-23||2013-11-05|2006-02-16|2006-02-17|Estimate|2011-05-04|2011-06-06|Estimate||||2013-11-05|2013-11-27|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.|Completed||Phase 3|190|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:09:45.105507|2018-06-01 04:09:45.105507
NCT00293046|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-16|||2008-09-29|2006-02-16|2006-02-17|Estimate|||||||2008-09-29|2008-09-30|Estimate|February 2006||2006-02-28|September 2008|2008-09-30|October 2007|Actual|2007-10-31|September 2006|Actual|2006-09-30||Interventional|||Assessment of Grazax® Treatment Compliance|A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis|Completed||Phase 3|500||ALK-Abelló A/S|||||f||||||||||||||2018-06-01 04:09:46.208793|2018-06-01 04:09:46.208793
NCT00293033|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2008-01-16|2006-02-15|2006-02-17|Estimate|||||||2008-01-16|2008-01-18|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects|A Double-Blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects|Completed||Phase 3|152|Actual|BioDelivery Sciences International|||||f||||f||||||||||2018-06-01 04:09:46.257548|2018-06-01 04:09:46.257548
NCT00293020|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2012-02-13||2012-09-06|2006-02-15|2006-02-17|Estimate|2012-09-06|2012-10-05|Estimate||||2012-09-06|2012-10-05|Estimate|February 2006||2006-02-28|September 2012|2012-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy|An Open Label, Long-term Treatment Evaluation of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy|Completed||Phase 3|244|Actual|BioDelivery Sciences International||1|||f||||f||||||||||2018-06-01 04:09:46.346601|2018-06-01 04:09:46.346601
NCT00292994|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2006-02-15|2006-02-15|2006-02-16|Estimate|||||||2006-02-15|2006-02-16|Estimate|April 2004||2004-04-30|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||Study of How Exercise or Weight Loss Effects Metabolic Syndrome|Exercise and Diet With Weight Loss in Metabolic Syndrome|Unknown status|Active, not recruiting|N/A|130||Yankton Clinical Research Alliance|||||f||||||||||||||2018-06-01 04:09:46.746485|2018-06-01 04:09:46.746485
NCT00292981|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2011-05-25||2015-04-20|2006-02-15|2006-02-16|Estimate|2011-05-25|2011-06-23|Estimate||||2015-04-20|2015-05-07|Estimate|August 2005||2005-08-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)|Open-label Extension Study of CE1145 (Human Pasteurized C1 Esterase Inhibitor Concentrate) in Subjects With Congenital C1-INH Deficiency and Acute HAE Attacks|Completed||Phase 3|57|Actual|CSL Behring||1|||f||||||||||||||2018-06-01 04:09:46.829411|2018-06-01 04:09:46.829411
NCT00292968|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2012-07-18|2006-02-15|2006-02-16|Estimate|||||||2012-07-18|2012-07-20|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|August 2007|Actual|2007-08-31|February 2007|Actual|2007-02-28||Interventional|||A Comprehensive Practice-Friendly Model for Promoting Healthy Behaviors|A Comprehensive Practice-Friendly Model for Promoting Healthy Behaviors|Completed||N/A|5670|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 04:09:47.069614|2018-06-01 04:09:47.069614
NCT00292955|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2011-05-26|2006-02-14|2006-02-16|Estimate|||||||2011-05-26|2011-05-30|Estimate|February 2006||2006-02-28|May 2011|2011-05-31||||February 2012|Anticipated|2012-02-29||Interventional|||Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma|An Exploratory Pharmacogenomic Study of Neoadjuvant Cetuximab Followed by Cisplatin, Radiotherapy, and Cetuximab in Women With Newly Diagnosed Locally Advanced or Metastatic Cervical Carcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|University of Virginia|||||f||||||||||||||2018-06-01 04:09:47.13755|2018-06-01 04:09:47.13755
NCT00292942|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2016-10-25|2006-02-14|2006-02-16|Estimate|||||||2016-10-25|2016-10-27|Estimate||||March 2007|2007-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Study of the Safety of Intravenous Artesunate|A Phase 1 Double-Blind, Placebo-Controlled, Randomized Multiple Dose Escalation Study to Evaluate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of a New GMP Formulation of Intravenous Artesunate if Healthy Subjects|Completed||Phase 1|40||U.S. Army Medical Research and Materiel Command|||||||||t||||||||||2018-06-01 04:09:47.210274|2018-06-01 04:09:47.210274
NCT00292929|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2016-10-25|2006-02-14|2006-02-16|Estimate|||||||2016-10-25|2016-10-26|Estimate||||March 2007|2007-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Study of the Safety of Intravenous Artesunate|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of Artesunate Administered to Healthy Subjects|Completed||Phase 1|40||U.S. Army Medical Research and Materiel Command|||||||||||||||||||2018-06-01 04:09:47.282921|2018-06-01 04:09:47.282921
NCT00292916|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2015-05-27|2006-02-15|2006-02-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Effect of Whole Body Vibration on Bone and Fall Related Parameters|Effect of Whole Body Vibration on Bone and Fall Related Parameters - the Erlangen Longitudinal Vibration Study (ELVIS)|Terminated||Phase 3|150||University of Erlangen-Nürnberg Medical School|||||f||||||||||||||2018-06-01 04:09:47.345798|2018-06-01 04:09:47.345798
NCT00292903|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2012-09-06|2006-02-15|2006-02-16|Estimate|||||||2012-09-06|2012-09-10|Estimate|March 2004||2004-03-31|September 2012|2012-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluating the Effectiveness of Brief Interpersonal Psychotherapy for Pregnant Women With Depression|Culturally Relevant Brief Interpersonal Psychotherapy (IPT-B) for Perinatal Depression|Completed||N/A|60|Anticipated|University of Pittsburgh||2|||f||||||||||||||2018-06-01 04:09:47.413801|2018-06-01 04:09:47.413801
NCT00292890|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2006-02-15|2006-02-15|2006-02-16|Estimate|||||||2006-02-15|2006-02-16|Estimate|January 2004||2004-01-31|January 2005|2005-01-31|October 2004||2004-10-31|||||Interventional|||Which Needle Length for Injecting Insulin||Completed||N/A|50||University Medical Center Groningen|||||f||||||||||||||2018-06-01 04:09:47.482462|2018-06-01 04:09:47.482462
NCT00292877|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2011-01-21|2006-02-15|2006-02-16|Estimate|||||||2011-01-21|2011-01-24|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)|The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control|Completed||Phase 2|20||St. Joseph's Healthcare Hamilton|||||f||||f||||||||||2018-06-01 04:09:47.539332|2018-06-01 04:09:47.539332
NCT00292864|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2012-06-05|2006-02-15|2006-02-16|Estimate|||||||2012-06-05|2012-06-07|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|December 2007|Actual|2007-12-31|||||Interventional|||Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors|Phase 1 Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Select Advanced Solid Tumors|Completed||Phase 1|25|Anticipated|Sunesis Pharmaceuticals|||||f||||||||||||||2018-06-01 04:09:47.60253|2018-06-01 04:09:47.60253
NCT00292851|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2011-07-19|2006-02-15|2006-02-16|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2004||2004-07-31|July 2011|2011-07-31|June 2005||2005-06-30|||||Observational|||Blown Nasal Secretion Measurements in Rhinosinusitis: Repeatability and Validity Compared to Nasal Lavage|Repeatability and Validity of Measurements in Blown Nasal Secretion in Patients With Rhinosinusitis|Completed|||15||St. Joseph's Healthcare Hamilton|||||f||||f||||||||||2018-06-01 04:09:47.665375|2018-06-01 04:09:47.665375
NCT00292838|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2011-07-19|2006-02-14|2006-02-16|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2001||2001-01-31|July 2011|2011-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Relative Potency of Inhaled Corticosteroids|Relative Potency of Inhaled Corticosteroids: Validation of a Clinical Model|Completed||Phase 4|40||St. Joseph's Healthcare Hamilton|||||f||||||||||||||2018-06-01 04:09:47.712773|2018-06-01 04:09:47.712773
NCT00292825|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2010-03-31|2006-02-15|2006-02-16|Estimate|||||||2010-03-31|2010-04-01|Estimate|February 2006||2006-02-28|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effect of Closed Loop Pacemaker Treatment on Recurrent Vasovagal Syncope|SCANdinavian Vasovagal SYNCope Pacemaker Investigation (SCANSYNC)|Completed||N/A|100|Anticipated|Aarhus University Hospital Skejby|||||f||||||||||||||2018-06-01 04:09:47.7657|2018-06-01 04:09:47.7657
NCT00292812|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2007-10-22|2006-02-15|2006-02-16|Estimate|||||||2007-10-22|2007-10-23|Estimate|March 2006||2006-03-31|May 2007|2007-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Clinical Effects of a Nucleotides-Supplemented Infant Formula|The Clinical Effects of an Infant Formula Supplemented With Various Concentrations of Nucleotides|Completed||N/A|150|Anticipated|Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:09:47.822529|2018-06-01 04:09:47.822529
NCT00292799|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2008-07-15|2006-02-15|2006-02-16|Estimate|||||||2008-07-15|2008-07-16|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||An RCT of Metformin Vs Orlistat in Obese Anovulatory Women|A Randomised Controlled Clinical Trial of Metformin Versus Orlistat for the Management of Obese Anovulatory Women.|Completed||N/A|36|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:09:47.873371|2018-06-01 04:09:47.873371
NCT00292786|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2008-02-04|2006-02-15|2006-02-16|Estimate|||||||2008-02-04|2008-02-05|Estimate|June 2005||2005-06-30|February 2008|2008-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||The Effects of Electrical Stimulation Gait Training on Walking and Posture for Children With Cerebral Palsy|Electrical Stimulation Gait Training to Effect Improvements in Walking Function and Posture for Children With Cerebral Palsy|Completed||N/A|60|Anticipated|Shriners Hospitals for Children|||||f||||f||||||||||2018-06-01 04:09:47.927854|2018-06-01 04:09:47.927854
NCT00292773|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2011-07-19|2006-02-15|2006-02-16|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 2006||2006-02-28|July 2011|2011-07-31|February 2008|Actual|2008-02-29|||||Observational|||Weight Reduction Surgery and Ovarian Function|The Effect of Weight Reduction Surgery on Ovarian Function in Obese Anovulatory Patients|Completed|||30|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:09:47.980145|2018-06-01 04:09:47.980145
NCT00292760|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2009-12-15|2006-02-15|2006-02-16|Estimate|||||||2009-12-15|2009-12-16|Estimate||||December 2009|2009-12-31||||||||Interventional|||A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion|A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion|Completed||Phase 2|||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:09:48.041575|2018-06-01 04:09:48.041575
NCT00292747|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2017-08-04|2006-02-15|2006-02-16|Estimate|||||||2017-08-04|2017-08-08|Actual|May 25, 2005|Actual|2005-05-25|August 2017|2017-08-31|February 28, 2006|Actual|2006-02-28|February 28, 2006|Actual|2006-02-28||Interventional|||Drotaverine in Dysmenorrhoea Treatment|Comparison of the Efficacy and Tolerability of Drotaverine 80 mg, Ibuprofen 400 mg and Their Combination in a Calendar Packaging for the Treatment of Primary and Secondary Dysmenorrhoea|Terminated||Phase 4|480||Sanofi||3||early termination due to loss of interest and low enrollment of patient|f||||||||||||||2018-06-01 04:09:48.08802|2018-06-01 04:09:48.08802
NCT00292734|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2007-12-04|2006-02-15|2006-02-16|Estimate|||||||2007-12-04|2007-12-06|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|June 2006||2006-06-30|||||Interventional|||STILDEP: Zolpidem in Depressive and Dysthimic Patients|Additive Beneficial Effect of Zolpidem Onto the Antidepressant Therapy in Depressive and Dysthimic Patients in the Acute Phase of the Disease|Completed||Phase 4|120||Sanofi|||||f||||||||||||||2018-06-01 04:09:48.386831|2018-06-01 04:09:48.386831
NCT00292721|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2011-07-20|2006-02-15|2006-02-16|Estimate|||||||2011-07-20|2011-07-21|Estimate|August 2004||2004-08-31|July 2011|2011-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effects of Celecoxib After Percutaneous Coronary Intervention|Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial|Completed||Phase 4|260|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 04:09:48.458755|2018-06-01 04:09:48.458755
NCT00292708|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2006-02-15|2006-02-15|2006-02-16|Estimate|||||||2006-02-15|2006-02-16|Estimate|May 2004||2004-05-31|February 2006|2006-02-28|July 2005||2005-07-31|||||Interventional|||Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery|Randomized Multicenter Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery: Single-Dose Vs. Three Doses of Second-Generation Cephalosporin|Completed||Phase 3|500||National Cancer Center, Japan|||||f||||||||||||||2018-06-01 04:09:48.514137|2018-06-01 04:09:48.514137
NCT00292695|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2013-10-28|2006-02-15|2006-02-16|Estimate|||||||2013-10-28|2013-10-30|Estimate|May 2006||2006-05-31|October 2013|2013-10-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||A Phase II Study of Nasal NK/T-cell Lymphoma|A Phase II Study of Concurrent Chemoradiation for The Localized Nasal NK/T-cell Lymphoma|Completed||Phase 2|33|Actual|National Health Research Institutes, Taiwan||1|||f||||t||||||||||2018-06-01 04:09:48.586223|2018-06-01 04:09:48.586223
NCT00292656|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2006-04-02|2006-02-15|2006-02-16|Estimate|||||||2006-04-02|2006-04-04|Estimate|December 2005||2005-12-31|February 2006|2006-02-28|December 2005||2005-12-31|||||Interventional|||Importance of Hand Washing After Each NAET® Treatment|Importance of Hand Washing After Each NAET® Treatment|Completed||Phase 1/Phase 2|60||Nambudripad's Allergy Research Foundation|||||f||||||||||||||2018-06-01 04:09:48.66388|2018-06-01 04:09:48.66388
NCT00292591|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|2016-06-28||2016-08-09|2006-02-15|2006-02-16|Estimate|2016-06-28|2016-08-09|Estimate||||2016-08-09|2016-09-19|Estimate|January 2004||2004-01-31|August 2016|2016-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of Vitamin D Requirements During Pregnancy|Evaluation of Vitamin D Requirements During Pregnancy|Completed||Phase 3|501|Actual|Medical University of South Carolina||3|||f||||||||||||||2018-06-01 04:09:48.73355|2018-06-01 04:09:48.73355
NCT00292552|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2017-03-21|2006-02-14|2006-02-16|Estimate|||||||2017-03-21|2017-03-23|Actual|December 2005||2005-12-31|March 2017|2017-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|ECLIPSE||Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints|A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time|Completed|||2747|Actual|GlaxoSmithKline|||3||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, urine sputum~   "|||2018-06-01 04:09:49.0185|2018-06-01 04:09:49.0185
NCT00292539|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2009-04-22|2006-02-14|2006-02-16|Estimate|||||||2009-04-22|2009-04-23|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|September 2006|Actual|2006-09-30|||||Observational|||Prospective Registry of Pacemaker Patients Concerning Percentage of Right Ventricular Pacing, LVEF and NYHA Class|Preserve Registry: Prospective Registry of Pacemaker Patients Concerning Percentage of Right Ventricular Pacing, LVEF and NYHA Class|Completed|||600||Guidant Corporation|||||f||||||||||||||2018-06-01 04:09:49.14246|2018-06-01 04:09:49.14246
NCT00292526|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2017-02-07|2006-02-15|2006-02-16|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 2000|Actual|2000-11-30|February 2017|2017-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients|Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients|Completed||Phase 4|114|Actual|European Institute of Oncology||1|||f||||||||||||No||2018-06-01 04:09:49.197497|2018-06-01 04:09:49.197497
NCT00292513|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2006-02-15|2006-02-15|2006-02-16|Estimate|||||||2006-02-15|2006-02-16|Estimate||||May 2005|2005-05-31||||||||Interventional|||Clinical Trial Comparing Tissue Adhesive Vs. Absorbable Suture Vs. Non-Absorbable Suture|A Randomized Clinical Trial Comparing Tissue Adhesive (2-Octylcyanoacrylate) Vs. Absorbable Suture Vs. Non-Absorbable Suture for the Closure of Low Tension Facial and Neck Wounds in Children and Adolescents|Unknown status|Recruiting|N/A|||Rady Children's Hospital, San Diego|||||f||||||||||||||2018-06-01 04:09:49.264307|2018-06-01 04:09:49.264307
NCT00292500|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2013-08-19|2006-02-14|2006-02-16|Estimate|||||||2013-08-19|2013-08-21|Estimate|January 2006||2006-01-31|August 2013|2013-08-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II|Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II|Terminated||N/A|170|Actual|Cardica, Inc||1||Cardica has terminated the development of the product for Business Reason.|f||||f||||||||||2018-06-01 04:09:49.327376|2018-06-01 04:09:49.327376
NCT00292487|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2012-02-07|2006-02-14|2006-02-16|Estimate|||||||2012-02-07|2012-02-08|Estimate|November 2004||2004-11-30|August 2006|2006-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Patients With Renal Impairment Undergoing CT|Isovue and Visipaque in Renally Impaired Patients Undergoing CT|Completed||Phase 4|150||Bracco Diagnostics, Inc|||||f||||||||||||||2018-06-01 04:09:49.392901|2018-06-01 04:09:49.392901
NCT00292474|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2008-10-07|2006-02-14|2006-02-16|Estimate|||||||2008-10-07|2008-10-08|Estimate|March 2002||2002-03-31|October 2008|2008-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent|TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent|Completed||Phase 2/Phase 3|1326|Actual|Boston Scientific Corporation||2|||f||||||||||||||2018-06-01 04:09:49.444433|2018-06-01 04:09:49.444433
NCT00292461|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|2010-09-27||2013-05-13|2006-02-14|2006-02-16|Estimate|2011-07-20|2011-08-15|Estimate||||2013-05-13|2013-05-20|Estimate|March 2006||2006-03-31|August 2009|2009-08-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures|A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures|Completed||Phase 3|64|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:09:49.534823|2018-06-01 04:09:49.534823
NCT00292448|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2013-10-28|2006-02-15|2006-02-16|Estimate|||||||2013-10-28|2013-10-29|Estimate|February 2006||2006-02-28|October 2013|2013-10-31|March 2007||2007-03-31|||||Interventional|||A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Ba 679 BR Respimat® 5 μg and Tiotropium Inhalation Capsule 18 μg in Patients With COPD|Completed||Phase 2|157||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:09:49.954506|2018-06-01 04:09:49.954506
NCT00292435|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2013-10-28|2006-02-15|2006-02-16|Estimate|||||||2013-10-28|2013-10-29|Estimate|March 2006||2006-03-31|October 2013|2013-10-31||||October 2006|Actual|2006-10-31||Interventional|||Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)|A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency.|Completed||Phase 3|202||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:09:50.032232|2018-06-01 04:09:50.032232
NCT00292422|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-15|||2007-12-26|2006-02-15|2006-02-16|Estimate|||||||2007-12-26|2007-12-31|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis|A Randomized, Blinded, Placebo-Controlled, Multicenter, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD Therapy|Completed||Phase 2|50|Actual|Biogen|||||f||||||||||||||2018-06-01 04:09:50.090431|2018-06-01 04:09:50.090431
NCT00292409|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-07|2006-02-15|2006-02-16|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2005||2005-03-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices|A Prospective Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices|Completed||Phase 3|400|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.|||||f||||f||||||||||2018-06-01 04:09:50.235802|2018-06-01 04:09:50.235802
NCT00292396|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14||2011-08-22|2013-01-10|2006-02-14|2006-02-16|Estimate||||2011-08-22|2011-08-25|Estimate|2013-01-10|2013-01-18|Estimate|November 2005||2005-11-30|January 2013|2013-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Subcutaneous Injections of ABT-874 vs. Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|180|Actual|AbbVie||6|||f||||t||||||||||2018-06-01 04:09:50.327246|2018-06-01 04:09:50.327246
NCT00292383|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2011-08-01|2006-02-14|2006-02-15|Estimate|||||||2011-08-01|2011-08-02|Estimate||||October 2007|2007-10-31|December 2008||2008-12-31|||||Interventional|||Ventricular Pacing Site Selection (V-PASS)|A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy.|Unknown status|Recruiting|Phase 4|100|Anticipated|Medtronic BRC|||||f||||||||||||||2018-06-01 04:09:50.457705|2018-06-01 04:09:50.457705
NCT00292370|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|2014-02-14||2014-06-27|2006-02-13|2006-02-15|Estimate|2014-06-27|2014-07-01|Estimate||||2014-06-27|2014-07-01|Estimate|January 2006||2006-01-31|June 2014|2014-06-30|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional||"Period 1 or Phase I, 124 patients enrolled in Arm 1/Open-Label Paroxetene for 8 weeks.~Period 2 or Phase II (intervention period), 50 patients enrolled from week 8 to week 16; 25 in Arm 2/OL paroxetene & DB Placebo, 25 in Arm 3/OL paroxetene & DB quetiapine."|Quetiapine Augmentation for Treatment-resistant PTSD|A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD|Completed||Phase 4|124|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 04:09:50.578612|2018-06-01 04:09:50.578612
NCT00292357|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2010-01-15|2006-02-14|2006-02-15|Estimate|||||||2010-01-15|2010-01-18|Estimate||||April 2007|2007-04-30||||||||Interventional|||Local Application of Autologous Bone Marrow Cells for Treatment of Chronic Diabetic Ulcers||Unknown status|Recruiting|Phase 1|40|Anticipated|Heidelberg University|||||f||||||||||||||2018-06-01 04:09:51.05596|2018-06-01 04:09:51.05596
NCT00292344|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2009-04-17|2006-02-13|2006-02-15|Estimate|||||||2009-04-17|2009-04-20|Estimate|June 2004||2004-06-30|February 2006|2006-02-28|August 2005||2005-08-31|||||Interventional|||Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea|Rifaximin in Standard Three-Day Dosing With and Without the Antimotility Drug, Loperamide, in the Treatment of Travelers' Diarrhea|Completed||Phase 4|316||The University of Texas Health Science Center, Houston|||||||||||||||||||2018-06-01 04:09:51.122143|2018-06-01 04:09:51.122143
NCT00292331|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2006-02-14|2006-02-14|2006-02-15|Estimate|||||||2006-02-14|2006-02-15|Estimate||||February 2006|2006-02-28||||||||Interventional|||N-Butyl-2-Cyanoacrylate Injection Versus Band Ligation for Gastric Variceal Hemorrhage|A Randomized Trial of Endoscopic Treatment of Acute Gastric Variceal Hemorrhage: N-Butyl-2-Cyanoacrylate Injection Versus Band Ligation|Completed||Phase 3|120||Taipei Veterans General Hospital, Taiwan|||||f||||||||||||||2018-06-01 04:09:51.202433|2018-06-01 04:09:51.202433
NCT00292318|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|2015-08-13||2015-08-13|2006-02-13|2006-02-15|Estimate|2015-08-13|2015-08-19|Estimate||||2015-08-13|2015-08-19|Estimate|January 2008||2008-01-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2012|Actual|2012-09-30||Interventional|||Treatment of Patients With Fecal Incontinence|Biofeedback Therapy for Fecal Incontinence a Randomized Control Trial|Terminated||N/A|7|Actual|VA Office of Research and Development||2||"Unable to continue due to medical equipment necessary for research study was removed from~   facility."|f||||f||||||||||2018-06-01 04:09:51.271183|2018-06-01 04:09:51.271183
NCT00292305|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2016-09-23|2006-02-14|2006-02-15|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2005||2005-09-30|September 2016|2016-09-30|December 2012|Actual|2012-12-31|February 2007|Actual|2007-02-28||Interventional|BIF II||Nordic Bifurcation Stent Technique Study (BIF II)|Crush- or Culotte Stenting of Bifurcation Lesions Using Drug Eluting Stents? A Randomized Nordic Multicenter Study (BIF II)|Completed||Phase 4|425|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-06-01 04:09:51.495106|2018-06-01 04:09:51.495106
NCT00292292|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13||2011-07-19|2013-08-31|2006-02-14|2006-02-15|Estimate||||2011-07-19|2011-07-22|Estimate|2013-08-31|2013-09-13|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2009|Actual|2009-05-31||Interventional|||Kineflex Artificial Disc System to Treat Degenerative Disc Disease (DDD)|Clinical Study Protocol for the Investigation of the Kineflex Spinal System - a Pivotal Study in Continued Access Stage|Terminated||N/A|514|Actual|SpinalMotion||2||Economic and business reasons|f||||f||||||||||2018-06-01 04:09:51.61872|2018-06-01 04:09:51.61872
NCT00292279|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2008-05-12|2006-02-13|2006-02-15|Estimate|||||||2008-05-12|2008-05-14|Estimate|June 2002||2002-06-30|May 2008|2008-05-31|February 2004|Actual|2004-02-29|November 2003|Actual|2003-11-30||Interventional|||The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients|The Impact of Omega-3 Fat Emulsion on Clinical Outcome of Post-Operative Cancer Patients: A Randomized, Double Blind, Controlled, Multi-Center Clinical Trial.|Completed||Phase 3|206|Actual|Sino-Swed Pharmaceutical Corporation||2|||f||||t||||||||||2018-06-01 04:09:51.707921|2018-06-01 04:09:51.707921
NCT00292266|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2013-08-02|2006-02-13|2006-02-15|Estimate|||||||2013-08-02|2013-08-05|Estimate|November 1999||1999-11-30|August 2013|2013-08-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)|An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif® 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex® 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis|Completed||Phase 3|677|Actual|EMD Serono||2|||||||||||||||||2018-06-01 04:09:51.776055|2018-06-01 04:09:51.776055
NCT00292253|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2013-08-04|2006-02-13|2006-02-15|Estimate|||||||2013-08-04|2013-08-06|Estimate|January 2001||2001-01-31|August 2013|2013-08-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects|A Randomized, Multicenter, Parallel Group, Open-label Study Comparing the Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing Remitting MS Patients|Completed||Phase 3|1883|Actual|EMD Serono||2|||f||||||||||||||2018-06-01 04:09:51.832147|2018-06-01 04:09:51.832147
NCT00292240|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2011-07-20|2006-02-13|2006-02-15|Estimate|||||||2011-07-20|2011-07-21|Estimate|October 2004||2004-10-31|July 2011|2011-07-31|April 2007|Actual|2007-04-30|||||Interventional|||Brief Youth Substance Use Intervention for Primary Care||Completed||N/A|60||RAND|||||f||||||||||||||2018-06-01 04:09:51.916008|2018-06-01 04:09:51.916008
NCT00292227|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|2009-09-09||2014-10-17|2006-02-14|2006-02-15|Estimate|2010-02-02|2010-02-04|Estimate||||2014-10-17|2014-10-27|Estimate|January 2006||2006-01-31|February 2011|2011-02-28|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease|Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.|Completed||Phase 1|130|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 04:09:52.01727|2018-06-01 04:09:52.01727
NCT00292214|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2007-03-08|2006-02-13|2006-02-15|Estimate|||||||2007-03-08|2007-03-09|Estimate|October 2005||2005-10-31|February 2006|2006-02-28|October 2006||2006-10-31|||||Interventional|||Comparing Intravenous and Oral Paracetamol for Cholecystectomy|Comparative Pharmacokinetics of Intravenous and Oral Paracetamol in the Peri-Operative Period of Laparoscopic Cholecystectomy|Completed||Phase 4|30||Melbourne Health|||||f||||||||||||||2018-06-01 04:09:53.896019|2018-06-01 04:09:53.896019
NCT00292201|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2015-09-14|2006-02-14|2006-02-15|Estimate|||||||2015-09-14|2015-09-16|Estimate|February 2006||2006-02-28|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|||Statin Treatment in Patients With Asthma|Pilot Study of Statin Treatment in Patients With Stable Moderate to Severe Asthma|Terminated||Phase 2|10|Actual|Queen's University||2||Lack of funding to complete subject recruitment and testing|f||||f||||||||||2018-06-01 04:09:54.050043|2018-06-01 04:09:54.050043
NCT00292188|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|2009-05-27||2011-04-22|2006-02-13|2006-02-15|Estimate|2009-08-31|2009-10-05|Estimate||||2011-04-22|2011-04-26|Estimate|January 2006||2006-01-31|April 2011|2011-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|P4||P4 (Pregabalin for Peripheral Posttraumatic Pain)|A 9 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study Of Pregabalin (BID) In Subject With Posttraumatic Peripheral Neuropathic Pain|Completed||Phase 4|255|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:09:54.271439|2018-06-01 04:09:54.271439
NCT00292175|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2007-09-21|2006-02-14|2006-02-15|Estimate|||||||2007-09-21|2007-09-24|Estimate|February 2006||2006-02-28|September 2007|2007-09-30||||||||Interventional|||NBI With Magnification for Dysplasia Detection in Ulcerative Colitis|Randomised,Controlled Trial of Narrow Band Imaging With Magnification (NBI) Versus White Light Endoscopy for Dysplasia Detection in Ulcerative Colitis Surveillance|Unknown status|Recruiting|N/A|110|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:09:56.050057|2018-06-01 04:09:56.050057
NCT00292162|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|2011-08-01||2012-05-29|2006-02-14|2006-02-15|Estimate|2012-05-29|2012-06-01|Estimate||||2012-05-29|2012-06-01|Estimate|January 2007||2007-01-31|May 2012|2012-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Curing Atrial Fibrillation in Heart Failure|Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure|Completed||N/A|41|Actual|NHS Greater Glasgow and Clyde||2|||f||||||||||||||2018-06-01 04:09:56.144159|2018-06-01 04:09:56.144159
NCT00292136|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2018-04-04|2006-02-14|2006-02-15|Estimate|||||||2018-04-04|2018-04-05|Actual|August 15, 2003||2003-08-15|June 11, 2013|2013-06-11|June 11, 2013||2013-06-11|||||Observational|||Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study|Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study|Completed|||230|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:09:56.389729|2018-06-01 04:09:56.389729
NCT00292123|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2017-01-11|2006-02-14|2006-02-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 1999||1999-06-30|December 2007|2007-12-31|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|||Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse||Completed||Phase 1|200|Actual|National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 04:09:56.44823|2018-06-01 04:09:56.44823
NCT00292110|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2018-05-18|2006-02-14|2006-02-15|Estimate|||||||2018-05-18|2018-05-21|Actual|February 1, 2004||2004-02-01|August 9, 2013|2013-08-09|August 9, 2013|Actual|2013-08-09|August 9, 2013|Actual|2013-08-09||Interventional|||Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management|Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management|Completed||Phase 1|140|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-06-01 04:09:56.501208|2018-06-01 04:09:56.501208
NCT00292097|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2008-06-04|2006-02-13|2006-02-15|Estimate|||||||2008-06-04|2008-06-05|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Prospective, Randomized Trial of Early Versus Late Tracheostomy in Trauma Patients With Severe Brain Injury|A Prospective, Randomized Trial of Early Versus Conventional Conversion From Endotracheal Intubation to Percutaneous Tracheostomy for Ventilatory Support of Trauma Patients With Severe Brain Injury|Terminated||N/A|5|Actual|Memorial Medical Center||2||Difficulty obtaining enrollment|f||||f||||||||||2018-06-01 04:09:56.604399|2018-06-01 04:09:56.604399
NCT00292084|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2008-01-17|2006-02-13|2006-02-15|Estimate|||||||2008-01-17|2008-01-21|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|October 2007|Actual|2007-10-31|||||Interventional|||An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase II, Multi-Center, Extension Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With or Without Ribavirin, for an Additional 36 Weeks|Completed||Phase 2|60||BioWest Therapeutics Inc|||||f||||||||||||||2018-06-01 04:09:56.665172|2018-06-01 04:09:56.665172
NCT00292071|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2017-02-20|2006-02-14|2006-02-15|Estimate|||||||2017-02-20|2017-02-23|Actual|May 2004||2004-05-31|February 2017|2017-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)|A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 24 Months With New Onset Fever and Neutropenia|Completed||Phase 2|16|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:09:56.721112|2018-06-01 04:09:56.721112
NCT00292058|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2006-02-14|2006-02-14|2006-02-15|Estimate|||||||2006-02-14|2006-02-15|Estimate|August 2001||2001-08-31|February 2006|2006-02-28|August 2004||2004-08-31|||||Interventional|||Comparing Telepsychiatry and in-Person Outcomes|Comparing Patient Outcomes and Cost of Psychiatric Care Provided Through Videoconferencing With Psychiatric Care Provided in-Person.|Completed||N/A|495||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:09:56.823012|2018-06-01 04:09:56.823012
NCT00292045|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2009-06-19|2006-02-13|2006-02-15|Estimate|||||||2009-06-19|2009-06-22|Estimate|December 2004||2004-12-31|June 2009|2009-06-30|January 2006||2006-01-31|||||Interventional|||Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer|Phase 1 Study of Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With High-Risk Stage D1 or Advanced Prostate Cancer|Completed||Phase 1|12||Ludwig Institute for Cancer Research|||||||||||||||||||2018-06-01 04:09:56.971017|2018-06-01 04:09:56.971017
NCT00292032|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2018-04-30|2006-02-14|2006-02-15|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2004||2004-05-31|April 2018|2018-04-30|January 2027|Anticipated|2027-01-31|January 2025|Anticipated|2025-01-31||Observational|||Registry of Unexplained Cardiac Arrest|Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER)|Recruiting|||2500|Anticipated|University of British Columbia|||2||f||||t||||||Samples With DNA|"~     blood~   "|No||2018-06-01 04:09:57.029448|2018-06-01 04:09:57.029448
NCT00292019|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2017-08-25|2006-02-14|2006-02-15|Estimate|||||||2017-08-25|2017-08-28|Actual|March 4, 2004|Actual|2004-03-04|August 2017|2017-08-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Robotic Laparoscopic Radical Prostatectomy|Robotic Laparoscopic Radical Prostatectomy|Completed|||20|Actual|Lawson Health Research Institute|||1||f||||f||||||||||2018-06-01 04:09:57.097873|2018-06-01 04:09:57.097873
NCT00292006|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2017-08-22|2006-02-14|2006-02-15|Estimate|||||||2017-08-22|2017-08-23|Actual||||February 2006|2006-02-28|June 2007||2007-06-30|||||Interventional|||Computerized Tomography to Help Diagnosis Pediatrics Scaphoid Fractures.|The Efficiency of Computerized Tomography to Aid in the Diagnosis of Pediatrics Scaphoid Fractures|Withdrawn||Phase 1|0|Actual|Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:09:57.151644|2018-06-01 04:09:57.151644
NCT00291980|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2008-08-27|2006-02-14|2006-02-15|Estimate|||||||2008-08-27|2008-08-28|Estimate|March 2006||2006-03-31|August 2008|2008-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.|A Phase III, Multicentric, Multinational, Controlled, Randomised, Open Study Comparing the Immunogenicity, Reactogenicity and Safety of Henogen's New Adjuvanted Hepatitis B Vaccine, HB-AS02V, to That of Aventis Pasteur MSD's Hepatitis B Vaccine, HBVAXPRO® , Administered as a Booster Dose in Pre-Dialysis, Peritoneal Dialysis and Haemodialysis Subjects (³ 15 Years of Age) Who Previously Responded to Hepatitis B Primary Vaccination But Have Lost Antibody.|Completed||Phase 3|185|Actual|Henogen||2|||f||||f||||||||||2018-06-01 04:09:57.281353|2018-06-01 04:09:57.281353
NCT00291967|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2006-12-07|2006-02-14|2006-02-15|Estimate|||||||2006-12-07|2006-12-08|Estimate|November 2002||2002-11-30|December 2006|2006-12-31||||||||Interventional|||Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants|Evaluate the Feasibility of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC Vaccine Administered as a 3 Dose Primary Vaccination Course at 6, 10 & 14 Weeks of Age|Completed||Phase 2|525||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:09:57.389028|2018-06-01 04:09:57.389028
NCT00291954|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2008-08-27|2006-02-14|2006-02-15|Estimate|||||||2008-08-27|2008-08-28|Estimate|March 2006||2006-03-31|August 2008|2008-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Compare the Immune Response & Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine vs Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis & Dialysis Patients Who Did Not Respond to Previous Hepatitis B Vaccination|A Multicentric, Randomised Study Comparing the Immunogenicity and Safety of Henogen's Adjuvanted Hepatitis B Vaccine Given at 0, 1months to That of Aventis Pasteur MSD's Hepatitis B Given at 0, 1 Months in Pre-Dialysis, and Dialysis Patients Did Not Respond to Previous Hepatitis B Vaccination|Completed||Phase 3|257|Actual|Henogen||2|||f||||f||||||||||2018-06-01 04:09:57.444718|2018-06-01 04:09:57.444718
NCT00291941|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2008-08-27|2006-02-14|2006-02-15|Estimate|||||||2008-08-27|2008-08-28|Estimate|February 2006||2006-02-28|August 2008|2008-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.|A Multicentric, Randomised Study Comparing the Immunogenicity and Safety of Henogen's Adjuvanted Hepatitis B Vaccine Given at 0, 1, 6 Months to That of GSK Biologicals' Adjuvanted Hepatitis B Vaccine Given at 0, 1, 2, 6 Moths in Pre-Dialysis, and Dialysis Patients Who Are Hepatitis B Naive.|Completed||Phase 3|300|Actual|Henogen||2|||f||||f||||||||||2018-06-01 04:09:57.690499|2018-06-01 04:09:57.690499
NCT00291928|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2012-11-08|2006-02-14|2006-02-15|Estimate|||||||2012-11-08|2012-11-12|Estimate|February 2005||2005-02-28|November 2012|2012-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II|A Double-blind, Randomized, Placebo Controlled, Dose Escalation, Multi-centerphase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20antibody, in Patients With Active Rheumatoid Arthritis Who Have Previously Failedone or More Disease Modifying Anti-rheumatic Drugs|Completed||Phase 2|201|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:09:57.800818|2018-06-01 04:09:57.800818
NCT00291915|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2006-02-14|2006-02-14|2006-02-15|Estimate|||||||2006-02-14|2006-02-15|Estimate|May 2004||2004-05-31|February 2006|2006-02-28|March 2007||2007-03-31|||||Interventional|||Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis|Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis|Unknown status|Recruiting|Phase 4|80||Goupe d'Etudes et de Recherche Clinique En Rhumatologie|||||f||||||||||||||2018-06-01 04:09:57.877005|2018-06-01 04:09:57.877005
NCT00291902|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2012-05-31|2006-02-13|2006-02-15|Estimate|||||||2012-05-31|2012-06-04|Estimate|March 2006||2006-03-31|September 2011|2011-09-30||||||||Interventional|||A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention|A 28-day, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Anti-inflammatory Effect and Steady-state Pharmacokinetics of SB-681323 (7.5 mg) in Subjects With Coronary Heart Disease (CHD) Undergoing Elective Percutaneous Coronary Interventions (PCI)|Completed||Phase 2|80||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:09:57.955514|2018-06-01 04:09:57.955514
NCT00291889|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2017-05-24|2006-02-14|2006-02-15|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2004||2004-07-31|May 2017|2017-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.|Evaluate the Safety, Reactogenicity & Immunogenicity of 2 Antigen Dose Levels of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02 to Healthy PPD-negative Volunteers Aged 18 to 45 Yrs|Completed||Phase 1|50|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:09:58.037711|2018-06-01 04:09:58.037711
NCT00291876|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|2009-12-10||2017-10-23|2006-02-14|2006-02-15|Estimate|2010-02-18|2010-03-08|Estimate||||2017-10-23|2017-11-29|Actual|January 1, 2004||2004-01-01|January 2017|2017-01-31|March 1, 2013|Actual|2013-03-01|March 1, 2013|Actual|2013-03-01||Interventional||Baseline Measures are given for each of the follow-up time points- Months 138, 150, 162, 174, 186, 198, 210, 222, 234 and 246. Note that not all subjects returned and participated in each of the intermediate follow-up time points.|Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule|Double-blind Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Two Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 12 Month Schedule in Healthy Adult Volunteers|Completed||Phase 4|135|Actual|GlaxoSmithKline|For 5 subjects at Month 234, serum sample tubes were broken. Due to risk of contamination, anti-HAV concentrations analyses were not performed for these subjects, who were excluded in the LT-ATP cohort for immunogenicity analysis at Month 234.|1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:09:58.137295|2018-06-01 04:09:58.137295
NCT00291863|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2006-02-15|2006-02-14|2006-02-15|Estimate|||||||2006-02-15|2006-02-16|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Simvastatin Effect on End Stage Renal Failure Patients Treated by Peritoneal Dialysis|Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis|Unknown status|Recruiting|Phase 4|30||Federal University of São Paulo|||||f||||||||||||||2018-06-01 04:09:58.642608|2018-06-01 04:09:58.642608
NCT00291850|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2012-04-30|2006-02-14|2006-02-15|Estimate|||||||2012-04-30|2012-05-01|Estimate|June 2005||2005-06-30|April 2012|2012-04-30||||||||Interventional|||Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC|Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA Non-Small Cell Lung Cancer|Terminated||Phase 2|50|Actual|Central European Cooperative Oncology Group||||no patient recruitment|f||||f||||||||||2018-06-01 04:09:58.729913|2018-06-01 04:09:58.729913
NCT00291837|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2010-02-24|2006-02-14|2006-02-15|Estimate|||||||2010-02-24|2010-02-26|Estimate|November 2004||2004-11-30|February 2010|2010-02-28|December 2007|Actual|2007-12-31|June 2006|Actual|2006-06-30||Interventional|||CT-2106 for the Second Line Treatment of Ovarian Cancer|Phase II Open Label Study of CT-2106 as a Single Agent in Patients With Advanced Metastatic Ovarian Cancer Who Have Failed One Prior Platinum and Taxane Based Regimen|Completed||Phase 2|40||CTI BioPharma|||||||||||||||||||2018-06-01 04:09:58.80044|2018-06-01 04:09:58.80044
NCT00291824|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2006-02-13|2006-02-13|2006-02-15|Estimate|||||||2006-02-13|2006-02-15|Estimate|August 2004||2004-08-31|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Cardiovascular Lifestyle Study: Effects and Expense of a Cardiovascular Risk Reduction Clinic in Primary Care|A Randomized Controlled Trial of the Effects and Expense of a Primary and Secondary Cardiovascular Risk Reduction Clinic in Primary Care|Unknown status|Recruiting|Phase 1|670||Caroline Medical Group|||||f||||||||||||||2018-06-01 04:09:58.865576|2018-06-01 04:09:58.865576
NCT00291811|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2014-02-10|2006-02-13|2006-02-15|Estimate|||||||2014-02-10|2014-02-11|Estimate|October 2003||2003-10-31|February 2014|2014-02-28||||||||Expanded Access|CUP||Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization|Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation|Approved for marketing|||||Sanofi|||||||||||||||||||2018-06-01 04:09:58.934989|2018-06-01 04:09:58.934989
NCT00291798|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2006-09-18|2006-02-14|2006-02-15|Estimate|||||||2006-09-18|2006-09-19|Estimate|September 2000||2000-09-30|February 2006|2006-02-28|March 2009||2009-03-31|||||Interventional|||Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane|Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane|Completed||Phase 2|98||Austrian Breast & Colorectal Cancer Study Group|||||f||||||||||||||2018-06-01 04:09:58.986418|2018-06-01 04:09:58.986418
NCT00291785|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2011-06-06|2006-02-14|2006-02-15|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 2004||2004-01-31|June 2011|2011-06-30|September 2008|Actual|2008-09-30|August 2007|Actual|2007-08-31||Interventional|||Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer|Phase I/II Study of CT-2106 in Combination With Infusional 5-fluorouracil/Folinic Acid (5-FU/FA)(de Gramont Schedule) as Second Line in Patients With Metastatic Colorectal Cancer Failing an Oxaliplatin Plus 5-FU/FA Regimen|Completed||Phase 1/Phase 2|48|Actual|CTI BioPharma|||||f||||f||||||||||2018-06-01 04:09:59.05799|2018-06-01 04:09:59.05799
NCT00291772|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2016-07-12|2006-02-13|2006-02-15|Estimate|||||||2016-07-12|2016-07-14|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Continuous Subcutaneous Infusion of Pramlintide and Insulin|Continuous Subcutaneous Infusion of Pramlintide and Insulin: A Randomized, Crossover Design Study|Completed||Phase 4|13|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 04:09:59.109763|2018-06-01 04:09:59.109763
NCT00291759|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2013-01-29|2006-02-13|2006-02-15|Estimate|||||||2013-01-29|2013-01-30|Estimate|January 1996||1996-01-31|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.|Adjuvant Endocrine Therapy in Postmenopausal Patients With HR +ve BC With Good to Moderate Differentiation - ARNO (Arimidex + Nolvadex). Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to: Tamoxifen 3 Years or Anastrozole 3 Years.|Completed||Phase 3|3858|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:09:59.170421|2018-06-01 04:09:59.170421
NCT00291746|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2009-03-11|2006-02-14|2006-02-15|Estimate|||||||2009-03-11|2009-03-12|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|November 2006|Actual|2006-11-30|||||Interventional|||Validation of RDQ Questionnaire|A Single-Blind Single Arm Study to Validate the Reflux Disease Questionnaire (RDQ) for the Diagnosis of Reflux Disease in Primary Care in Patients Treated With Esomeprazole 40 mg o.d.|Completed||Phase 4|350||AstraZeneca|||||f||||||||||||||2018-06-01 04:09:59.409766|2018-06-01 04:09:59.409766
NCT00291733|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-14|||2007-11-14|2006-02-14|2006-02-15|Estimate|||||||2007-11-14|2007-11-15|Estimate|May 2006||2006-05-31|November 2007|2007-11-30|October 2007|Anticipated|2007-10-31|||||Interventional|||Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease|Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|1st Hospital of Social Security Services||4|||f||||||||||||||2018-06-01 04:09:59.513818|2018-06-01 04:09:59.513818
NCT00291720|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2008-05-20|2006-02-13|2006-02-14|Estimate|||||||2008-05-20|2008-05-21|Estimate|April 2005||2005-04-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?|Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?|Completed||Phase 2|120|Actual|University Hospital Birmingham||2|||f||||t||||||||||2018-06-01 04:09:59.588126|2018-06-01 04:09:59.588126
NCT00291707|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2013-05-02|2006-02-10|2006-02-14|Estimate|||||||2013-05-02|2013-05-06|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|January 2009|Actual|2009-01-31|March 2008|Actual|2008-03-31||Interventional|||Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer|A Phase I Trial of Cetuximab (C225) and Pemetrexed With Concurrent Radiation in Head and Neck Cancer|Completed||Phase 1|40|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:09:59.663526|2018-06-01 04:09:59.663526
NCT00291694|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2013-06-24||2016-09-16|2006-02-10|2006-02-14|Estimate|2013-06-24|2013-09-05|Estimate||||2016-09-16|2016-11-07|Estimate|April 2003||2003-04-30|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Protocol for Women at Increased Risk of Developing Breast Cancer|A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo|Completed||Phase 2|72|Actual|University of Kansas Medical Center||2|||f||||f||||||||No||2018-06-01 04:09:59.809503|2018-06-01 04:09:59.809503
NCT00291681|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-12|||2006-02-12|2006-02-12|2006-02-14|Estimate|||||||2006-02-12|2006-02-14|Estimate|September 2005||2005-09-30|January 2006|2006-01-31||||||||Observational|||Differences in Human Germinal Center B Cell Selection Revealed by Analysis of IgVH Gene Hypermutation and Lineage Trees in Inflammatory Bowel Disease|Studying the Role of B Cells in Inflammatory Bowel Disease (IBD), Using a Combination of Experimental and Bioinformatical Techniques.|Unknown status|Active, not recruiting||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:10:00.134488|2018-06-01 04:10:00.134488
NCT00291668|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2015-03-05|2006-02-10|2006-02-14|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease|A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Active Crohn's Disease|Completed||Phase 2|94|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 04:10:00.192991|2018-06-01 04:10:00.192991
NCT00291655|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2009-08-25||2015-04-29|2006-02-10|2006-02-14|Estimate|2009-10-09|2009-11-13|Estimate||||2015-04-29|2015-05-18|Estimate|June 2006||2006-06-30|April 2015|2015-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).|A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam, for Patients Suffering From Epilepsy and Coming From the Study N01175 (NCT00175903).|Completed||Phase 3|130|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:10:00.324566|2018-06-01 04:10:00.324566
NCT00291642|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2017-02-09|2006-02-13|2006-02-14|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2006||2006-01-31|February 2017|2017-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen|Five Parallel Groups, Exploratory Clinical Trial to Compare the Efficacy of Single Dose Levocetirizine 2.5 and 5 mg, Cetirizine 5 mg and 10 mg to Placebo in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen in a EEU.|Completed||Phase 2|541||UCB Pharma|||||f||||||||||||||2018-06-01 04:10:00.547951|2018-06-01 04:10:00.547951
NCT00291629|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2007-09-06|2006-02-13|2006-02-14|Estimate|||||||2007-09-06|2007-09-10|Estimate|March 2004||2004-03-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES|Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES (MAGIC Cell-3-DES)|Completed||Phase 2|96|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-06-01 04:10:00.609434|2018-06-01 04:10:00.609434
NCT00291616|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2011-07-20|2006-02-13|2006-02-14|Estimate|||||||2011-07-20|2011-07-21|Estimate|December 2005||2005-12-31|July 2011|2011-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B|A Multicenter, Randomized, Controlled Trial of Combination Therapy for HBeAg Positive Chronic Hepatitis B: Comparing Thymosin Alpha 1 and Pegylated Interferon-alpha2a With Pegylated Interferon-alpha2a Alone.|Completed||Phase 4|52|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-06-01 04:10:00.668278|2018-06-01 04:10:00.668278
NCT00291603|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2007-04-24|2006-02-13|2006-02-14|Estimate|||||||2007-04-24|2007-04-25|Estimate|February 2006||2006-02-28|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Short Term Effects of FX Dialysers on QOL and Inflammation|Short-Term Effects of the FX-Class of Haemodialyser on Quality of Life and Inflammatory Markers in Stable Dialysis Patients|Completed||Phase 4|50||Sir Charles Gairdner Hospital|||||f||||f||||||||||2018-06-01 04:10:00.735211|2018-06-01 04:10:00.735211
NCT00291590|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2006-02-13|2006-02-13|2006-02-14|Estimate|||||||2006-02-13|2006-02-14|Estimate|July 2001||2001-07-31|June 2005|2005-06-30|August 2003||2003-08-31|||||Interventional|||Diabetes Health Enhancement Program to Improve Health of People With Diabetes|Phase 3 Randomized Controlled Trial of the Diabetes Health Enhancement Program for Medicaid and Dual Eligibles in South King County, Washington|Completed||Phase 3|146||VA Puget Sound Health Care System|||||f||||||||||||||2018-06-01 04:10:00.794348|2018-06-01 04:10:00.794348
NCT00291577|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|2009-10-01||2009-11-19|2006-02-13|2006-02-14|Estimate|2009-11-19|2009-12-23|Estimate||||2009-11-19|2009-12-23|Estimate|July 2006||2006-07-31|November 2009|2009-11-30|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer|Exploratory Evaluation Of A Sequential Administration Of Docetaxel And SU011248 In Women With Advanced Breast Cancer|Completed||Phase 1|22|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:10:00.873586|2018-06-01 04:10:00.873586
NCT00291564|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2007-12-17|2006-02-10|2006-02-14|Estimate|||||||2007-12-17|2007-12-21|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|February 2006|Actual|2006-02-28|||||Observational|||Ensure Cardiac Resynchronization Therapy Study|Ensure Cardiac Resynchronization Therapy Study|Completed|||430||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:10:01.360932|2018-06-01 04:10:01.360932
NCT00291551|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2011-04-14||2012-05-14|2006-02-10|2006-02-14|Estimate|2011-05-10|2011-06-10|Estimate||||2012-05-14|2012-05-21|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|April 2007|Actual|2007-04-30||Interventional|PEERLESS-HF||Paracor Ventricular Support System (PVSS) for Patients With Heart Failure|Paracor Ventricular Support System: United States Clinical Investigational Plan|Terminated||Phase 1|39|Actual|Paracor Medical, Inc|Insufficient resources to continue study follow-up.|||Resources unavailable to continue study follow-up.|f||||t||||||||||2018-06-01 04:10:01.598664|2018-06-01 04:10:01.598664
NCT00291538|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-02-03|2006-02-10|2006-02-14|Estimate|||||||2009-02-03|2009-02-04|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|October 2008|Actual|2008-10-31|June 2007|Actual|2007-06-30||Interventional|||Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma|Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma|Completed||Phase 1|20|Anticipated|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:10:01.887502|2018-06-01 04:10:01.887502
NCT00291525|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2017-09-24|2006-02-10|2006-02-14|Estimate|||||||2017-09-24|2017-09-26|Actual|July 2006||2006-07-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PROACT||Randomized On-X Anticoagulation Trial|Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT)|Recruiting||N/A|1200|Anticipated|On-X Life Technologies, Inc.||6|||f||||t||||||||No||2018-06-01 04:10:02.063789|2018-06-01 04:10:02.063789
NCT00291512|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2011-10-12|2006-02-10|2006-02-14|Estimate|||||||2011-10-12|2011-10-13|Estimate||||November 2008|2008-11-30||||||||Interventional|||Promoting Safer Sex in HIV+ Homosexual and Bisexual Men Who Use Methamphetamine|Promoting Safer Sex in HIV+ MSM Methamphetamine Users|Completed||Phase 2|||University of California, San Diego|||||f||||||||||||||2018-06-01 04:10:02.333962|2018-06-01 04:10:02.333962
NCT00291499|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2012-11-27|2006-02-13|2006-02-14|Estimate|||||||2012-11-27|2012-11-28|Estimate|June 2005||2005-06-30|November 2012|2012-11-30|August 2010|Actual|2010-08-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand|Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study|Completed||Phase 3|162|Actual|IBSA Institut Biochimique SA||2|||f||||||||||||||2018-06-01 04:10:02.410204|2018-06-01 04:10:02.410204
NCT00291486|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-03-02|2006-02-10|2006-02-14|Estimate|||||||2009-03-02|2009-03-03|Estimate|October 2003||2003-10-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer|Phase I Trial of Oral Capecitabine Combined With 131I-huA33 in Patients With Metastatic Colorectal Cancer|Completed||Phase 1|30|Anticipated|Ludwig Institute for Cancer Research||1|||f||||f||||||||||2018-06-01 04:10:02.520951|2018-06-01 04:10:02.520951
NCT00291473|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-03-02|2006-02-10|2006-02-14|Estimate|||||||2009-03-02|2009-03-03|Estimate|July 2005||2005-07-31|March 2009|2009-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers|Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers|Completed||Phase 1|9|Anticipated|Ludwig Institute for Cancer Research|||||f||||||||||||||2018-06-01 04:10:02.597082|2018-06-01 04:10:02.597082
NCT00291460|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2006-08-18|2006-02-13|2006-02-14|Estimate|||||||2006-08-18|2006-08-21|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|March 2008||2008-03-31|||||Interventional|||Inspiratory Muscle Training in Hypercapnic COPD|Randomized Controlled Trial of Inspiratory Muscle Training in Patients With Stable Hypercapnic Respiratory Failure Due to COPD|Unknown status|Recruiting|Phase 4|40||Krankenhaus Kloster Grafschaft|||||f||||||||||||||2018-06-01 04:10:02.67583|2018-06-01 04:10:02.67583
NCT00291447|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2006-08-11|2006-02-10|2006-02-14|Estimate|||||||2006-08-11|2006-08-15|Estimate|May 2005||2005-05-31|August 2006|2006-08-31|May 2006||2006-05-31|||||Interventional|||111-In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen|A Phase 1 Single Dose Escalation Trial of ch806 in Patients With Advanced Tumours Expressing the 806 Antigen|Completed||Phase 1|12||Ludwig Institute for Cancer Research|||||f||||||||||||||2018-06-01 04:10:02.7826|2018-06-01 04:10:02.7826
NCT00291434|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2006-05-03|2006-02-13|2006-02-14|Estimate|||||||2006-05-03|2006-05-04|Estimate|March 1999||1999-03-31|January 2005|2005-01-31|June 2005||2005-06-30|||||Observational|||Altered and Conventional Fractionated Radiotherapy in Patients With Head and Neck Cancer|Hyperfractionation and Accelerated Fractionation in Comparison With Conventional Fractionation in Definitive Radiotherapy of Squamous Cell Carcinoma of Larynx, Oropharynx and Hypopharynx|Completed|||152||Institute of Radiotherapy and Oncology, Macedonia|||||f||||||||||||||2018-06-01 04:10:02.842176|2018-06-01 04:10:02.842176
NCT00291421|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2013-04-15|2006-02-10|2006-02-14|Estimate|||||||2013-04-15|2013-04-16|Estimate|July 2002||2002-07-31|April 2013|2013-04-30|May 2006|Actual|2006-05-31|||||Observational|||A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease|International Outcomes Survey In Dementia (IOSID)|Completed|||2360|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:10:02.89005|2018-06-01 04:10:02.89005
NCT00291408|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2015-05-28|2006-02-13|2006-02-14|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2006||2006-04-30|April 2008|2008-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD|A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Symbicort® and Pulmicort® on HAT and HDAC Expression and Activity in Induced Sputum Cells Obtained From COPD Patients.|Completed||Phase 4|48|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:10:02.938101|2018-06-01 04:10:02.938101
NCT00291395|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2006-10-25|2006-02-13|2006-02-14|Estimate|||||||2006-10-25|2006-10-26|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Interventional|||PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers||Terminated||Phase 1|12||Danish Headache Center|||||f||||||||||||||2018-06-01 04:10:02.998767|2018-06-01 04:10:02.998767
NCT00291382|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2017-05-24|2006-02-13|2006-02-14|Estimate|||||||2017-05-24|2017-05-30|Actual|November 2005|Actual|2005-11-30|May 2017|2017-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product|A Multicentre, Stratified, Randomised, Double Blind, Parallel Group Trial to Evaluate Whether a Treatment Strategy Based on Aiming for Total Control Results in Better AHR Than a Treatment Strategy Based on Maintaining Well Control|Completed||Phase 4|150|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:10:03.063238|2018-06-01 04:10:03.063238
NCT00291369|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2006-02-15|2006-02-13|2006-02-14|Estimate|||||||2006-02-15|2006-02-16|Estimate|December 1999||1999-12-31|February 2006|2006-02-28|February 2005||2005-02-28|||||Interventional|||Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis|PERCY QUATTRO: Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis|Completed||Phase 3|456||Centre Leon Berard|||||f||||||||||||||2018-06-01 04:10:03.149655|2018-06-01 04:10:03.149655
NCT00291356|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2015-04-14|2006-02-13|2006-02-14|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients|A Double-blind, Randomized, Placebo-controlled, Repeat Dose Study to Compare the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK189075 With GW869682 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|45|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:10:03.206038|2018-06-01 04:10:03.206038
NCT00291343|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|2017-01-12||2017-04-21|2006-02-13|2006-02-14|Estimate|2017-04-21|2017-08-03|Actual||||2017-04-21|2017-08-03|Actual|February 1, 2006||2006-02-01|January 2017|2017-01-31|March 15, 2007|Actual|2007-03-15|March 15, 2007|Actual|2007-03-15||Interventional|||Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study|Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study|Completed||Phase 3|296|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:03.296637|2018-06-01 04:10:03.296637
NCT00291330|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|2010-11-18||2014-06-03|2006-02-13|2006-02-14|Estimate|2011-01-17|2011-02-11|Estimate||||2014-06-03|2014-06-06|Estimate|February 2006||2006-02-28|April 2014|2014-04-30||||May 2009|Actual|2009-05-31||Interventional|RE-COVER I||Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism|A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate 150 mg Twice Daily Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (VTE), Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication.|Completed||Phase 3|2564|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 04:10:04.012442|2018-06-01 04:10:04.012442
NCT00291317|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2011-06-21||2012-08-10|2006-02-10|2006-02-14|Estimate|2012-08-10|2012-08-13|Estimate||||2012-08-10|2012-08-13|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|January 2011|Actual|2011-01-31|September 2008|Actual|2008-09-30||Interventional|||The Effect of FES on Children With Spinal Cord Injury|The Effect of FES on Children With Spinal Cord Dysfunction|Completed||N/A|6|Actual|Children's Specialized Hospital|Difficulty for participants to attend sessions. Difficulties with recruitment.|1|||f||||f||||||||||2018-06-01 04:10:06.482865|2018-06-01 04:10:06.482865
NCT00291304|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-13|||2016-02-23|2006-02-13|2006-02-14|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2006||2006-03-31|December 2011|2011-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma|Magnetic Resonance Imaging (MRI) Correlation to Standard of Care Imaging and Pathology Correlation in Breast Carcinoma|Terminated||Phase 2|72|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:10:06.630919|2018-06-01 04:10:06.630919
NCT00291278|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-11|||2017-06-30|2006-02-11|2006-02-13|Estimate|||||||2017-06-30|2017-07-02|Actual|February 7, 2006||2006-02-07|February 10, 2009|2009-02-10|February 10, 2009||2009-02-10|||||Observational|||Effects of Endometriosis on Bone Mineral Density|The Effects of Endometriosis on Bone Mineral Density|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:10:06.709474|2018-06-01 04:10:06.709474
NCT00291265|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-11|||2017-06-30|2006-02-11|2006-02-13|Estimate|||||||2017-06-30|2017-07-02|Actual|February 9, 2006||2006-02-09|February 2, 2010|2010-02-02|February 2, 2010||2010-02-02|||||Observational|||Measures of Motor Impairment in Early Parkinson's Disease|Testing Objective Measures of Motor Impairment in Early Parkinson's Disease|Completed|||10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:10:06.763558|2018-06-01 04:10:06.763558
NCT00291239|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2009-04-02|2006-02-10|2006-02-13|Estimate|||||||2009-04-02|2009-04-03|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|July 2009|Anticipated|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression|Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Zentrum für Integrative Psychiatrie|||||f||||||||||||||2018-06-01 04:10:06.816425|2018-06-01 04:10:06.816425
NCT00291226|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2016-09-06||2016-11-01|2006-02-10|2006-02-13|Estimate|2016-11-01|2016-12-29|Estimate||||2016-11-01|2016-12-29|Estimate|March 2006||2006-03-31|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Glycine vs Placebo for the Schizophrenia Prodrome|Glycine vs Placebo for the Schizophrenia Prodrome|Completed||Phase 2/Phase 3|8|Actual|Yale University||2|||f||||t||||||||No||2018-06-01 04:10:06.887154|2018-06-01 04:10:06.887154
NCT00291213|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2014-06-05|2006-02-10|2006-02-13|Estimate|||||||2014-06-05|2014-06-06|Estimate||||June 2014|2014-06-30||||April 2006|Actual|2006-04-30||Interventional|||Levetiracetam Treatment of Tardive Dyskinesia||Completed||Phase 3|50|Actual|Yale University||2|||f||||||||||||||2018-06-01 04:10:07.161039|2018-06-01 04:10:07.161039
NCT00291200|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2014-06-09|2006-02-10|2006-02-13|Estimate|||||||2014-06-09|2014-06-10|Estimate|August 2003||2003-08-31|June 2014|2014-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Enhancing the Prospective Prediction of Psychosis|Enhancing the Prospective Prediction of Psychosis|Completed|||268|Actual|Yale University|||2||f||||||||||Samples With DNA|"~     Blood samples for routine laboratory studies~   "|||2018-06-01 04:10:07.229398|2018-06-01 04:10:07.229398
NCT00291187|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|2014-02-28||2014-10-08|2006-02-09|2006-02-13|Estimate|2014-10-08|2014-10-15|Estimate||||2014-10-08|2014-10-15|Estimate|February 2006||2006-02-28|October 2014|2014-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional||Modified Intent-to-Treat. A total of 411 subjects received treatment.|VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia|Completed||Phase 3|411|Actual|Vanda Pharmaceuticals||4|||f||||f||||||||||2018-06-01 04:10:07.336472|2018-06-01 04:10:07.336472
NCT00291174|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2016-08-15|2006-02-10|2006-02-13|Estimate|||||||2016-08-15|2016-08-16|Estimate|April 2006||2006-04-30|August 2016|2016-08-31|January 2008|Actual|2008-01-31|July 2006|Actual|2006-07-31||Observational|||Measuring Electrical Resistance of Different Tissues on the Outer Surface of the Heart|Impedance Measurement of Epicardial Substrate for Ventricular Arrhythmias: Case Control Series of Patients With and Without Myocardial Scarring|Terminated|||8|Actual|University of Pennsylvania||||Unforeseen difficulty identifying and enrolling eligible subjects|f||||||||||||||2018-06-01 04:10:07.770533|2018-06-01 04:10:07.770533
NCT00291161|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2015-03-18||2016-05-10|2006-02-10|2006-02-13|Estimate|2016-05-10|2016-05-19|Estimate||||2016-05-10|2016-05-19|Estimate|December 2006||2006-12-31|May 2016|2016-05-31|February 2011|Actual|2011-02-28|September 2010|Actual|2010-09-30||Interventional|PDC||Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters|Partners in Dementia Care|Completed||N/A|994|Actual|VA Office of Research and Development||2|||f||||f||||||||Undecided||2018-06-01 04:10:07.854924|2018-06-01 04:10:07.854924
NCT00291148|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2012-07-26|2006-02-10|2006-02-13|Estimate|||||||2012-07-26|2012-07-27|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain|A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine|Completed||Phase 3|75|Anticipated|University of Manitoba||2|||f||||||||||||||2018-06-01 04:10:08.27083|2018-06-01 04:10:08.27083
NCT00291135|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2013-06-24||2016-05-11|2006-02-10|2006-02-13|Estimate|2014-01-08|2014-02-07|Estimate||||2016-05-11|2016-06-15|Estimate|January 2003||2003-01-31|May 2016|2016-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Protocol for Women at Increased Risk of Developing Breast Cancer|Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy|Completed||Phase 2|42|Actual|University of Kansas Medical Center||1|||f||||f||||||||No|Global results will be published.|2018-06-01 04:10:08.3613|2018-06-01 04:10:08.3613
NCT00291122|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2008-09-15|2006-02-10|2006-02-13|Estimate|||||||2008-09-15|2008-09-16|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|December 2005||2005-12-31|||||Observational|||An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer|Quantitative Real Time PCR in Formalin Fixed Breast Tissue From Biopsy and Re-Excision Specimens: An Ancillary Protocol to a Chemoprevention Trial of Celecoxib|Completed|||100||University of Kansas Medical Center|||||f||||||||||||||2018-06-01 04:10:08.518661|2018-06-01 04:10:08.518661
NCT00291109|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2008-09-15|2006-02-10|2006-02-13|Estimate|||||||2008-09-15|2008-09-16|Estimate|January 2003||2003-01-31|September 2008|2008-09-30|July 2005||2005-07-31|||||Observational|||An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg|Quantitative Real Time PCR in Cytolytic Formalin Fixed Breast Cells Obtained by Periareolar Fine Needle Aspiration. An Ancillary Protocol to a Chemoprevention Trial of Letrozole|Completed|||40||University of Kansas Medical Center|||||f||||||||||||||2018-06-01 04:10:08.574561|2018-06-01 04:10:08.574561
NCT00290914|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2012-05-08|2006-02-09|2006-02-13|Estimate|||||||2012-05-08|2012-05-09|Estimate||||May 2012|2012-05-31||||||||Interventional|||Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder||Completed||Phase 2|||Pharmacology Research Institute|||||||||||||||||||2018-06-01 04:10:10.517471|2018-06-01 04:10:10.517471
NCT00291096|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2018-01-15|2006-02-10|2006-02-13|Estimate|||||||2018-01-15|2018-01-17|Actual|January 1989||1989-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Protocol for Women at Increased Risk of Developing Breast Cancer|High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer|Recruiting|||3000|Anticipated|University of Kansas Medical Center|||||f||||f||||||Samples Without DNA|"~     RPFNA specimens, serum, NAF~   "|No||2018-06-01 04:10:08.632923|2018-06-01 04:10:08.632923
NCT00291083|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2012-02-06|2006-02-10|2006-02-13|Estimate|||||||2012-02-06|2012-02-07|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer|Study of Manual Nipple Fluid Aspiration IN Post-Menopausal Women|Completed|||229|Actual|University of Kansas Medical Center|||||f||||f||||||||||2018-06-01 04:10:08.700313|2018-06-01 04:10:08.700313
NCT00291070|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2008-04-28|2006-02-09|2006-02-13|Estimate|||||||2008-04-28|2008-05-06|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effects of L-Theanine in Boys With ADHD|A Double Blind, Randomized Placebo Controlled Clinical Trial Examining the Effects of L-Theanine (Suntheanine®) in Male Child Subjects With Attention Deficit Hyperactivity Disorder|Completed||Phase 2|100|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:10:08.751612|2018-06-01 04:10:08.751612
NCT00291057|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2013-12-19|2006-02-10|2006-02-13|Estimate|||||||2013-12-19|2013-12-23|Estimate|February 2006||2006-02-28|November 2013|2013-11-30|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice|Phase II, Multi-center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis|Terminated||Phase 2|30|Anticipated|Taro Pharmaceuticals USA||1||Lack of enrollment|f||||f||||||||||2018-06-01 04:10:08.811699|2018-06-01 04:10:08.811699
NCT00291044|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2010-11-18|2006-02-09|2006-02-13|Estimate|||||||2010-11-18|2010-11-19|Estimate|September 2005||2005-09-30|November 2010|2010-11-30|September 2009|Actual|2009-09-30|||||Observational|||HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women|HSV Seroprevalence and Diagnosis of Genital Herpes in Pregnant Women|Completed|||300|Actual|Stony Brook University|||||f||||||||||||||2018-06-01 04:10:08.900761|2018-06-01 04:10:08.900761
NCT00291031|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2013-10-16|2006-02-10|2006-02-13|Estimate|||||||2013-10-16|2013-10-17|Estimate|February 2006||2006-02-28|October 2013|2013-10-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Study of the Effect of Imagery Rehearsal Therapy (IRT) of Nightmares|A Randomised Controlled Trial of Imagery Rehearsal Therapy (IRT) of Nightmares in a Psychiatric Population|Completed||Phase 1/Phase 2|112|Actual|GGZ Centraal||2|||f||||t||||||||||2018-06-01 04:10:09.028146|2018-06-01 04:10:09.028146
NCT00291018|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2016-11-17||2017-10-17|2006-02-10|2006-02-13|Estimate|2017-01-17|2017-03-08|Actual||||2017-10-17|2017-11-20|Actual|August 1, 2003|Actual|2003-08-01|October 2017|2017-10-31|March 1, 2015|Actual|2015-03-01|March 1, 2015|Actual|2015-03-01||Interventional||Number of subjects enrolled and treated|Safety and Efficacy Study Comparing ProDisc-C to ACDF Surgery to Treat SCDD|A Multi-Center, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of ProDisc-C to Anterior Cervical Discectomy and Fusion (ACDF) Surgery in the Treatment of Symptomatic Cervical Disc Disease (SCDD)|Completed||N/A|368|Actual|Synthes USA HQ, Inc.||2|||f||||f||||||||||2018-06-01 04:10:09.149237|2018-06-01 04:10:09.149237
NCT00291005|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-03-26|2006-02-10|2006-02-13|Estimate|||||||2009-03-26|2009-03-27|Estimate|August 2004||2004-08-31|March 2009|2009-03-31||||||||Interventional|||PhII One Label Non-Comparative Trial in Metastatic Hormone Refractory Prostate Cancer in Combination With Prednisolone|A Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|42||Sanofi|||||f||||||||||||||2018-06-01 04:10:09.964145|2018-06-01 04:10:09.964145
NCT00290992|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-03-27|2006-02-10|2006-02-13|Estimate|||||||2009-03-27|2009-03-30|Estimate|June 2005||2005-06-30|March 2009|2009-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Rasburicase for Hyperuricemia|Open-Label, Multi-Center Study of SR29142 as Uricolytic Therapy/Prophylaxis for Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematological Malignancies at High Risk for Tumor Lysis Syndrome|Completed||Phase 2|30|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:10:10.036092|2018-06-01 04:10:10.036092
NCT00290979|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-08-25|2006-02-10|2006-02-13|Estimate|||||||2009-08-25|2009-08-26|Estimate|December 2004||2004-12-31|March 2009|2009-03-31||||||||Interventional|||Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus|Evaluation of Efficacy and Safety of HMR1964 (Insulin Glulisine) in Subjects With Type 1 Diabetes Mellitus; Insulin Lispro Controlled, Open, Randomized, Parallel Group, Non-inferiority Study, for 28 Weeks|Completed||Phase 3|250||Sanofi|||||f||||||||||||||2018-06-01 04:10:10.116848|2018-06-01 04:10:10.116848
NCT00290966|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2009-04-28|2006-02-10|2006-02-13|Estimate|||||||2009-04-28|2009-04-29|Estimate|October 1998||1998-10-31|April 2009|2009-04-30|May 2003||2003-05-31|||||Interventional|||Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer|Open Label, Randomized Multicentre Phase II/III Study of Docetaxel in Combination With Cisplatin (CDDP) or Docetaxel in Combination With 5-Fluorouracil (5-FU) and CDDP Compared to the Combination of CDDP and 5-FU in Patients With Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease|Completed||Phase 2/Phase 3|610||Sanofi|||||f||||||||||||||2018-06-01 04:10:10.174957|2018-06-01 04:10:10.174957
NCT00290953|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2008-12-22|2006-02-10|2006-02-13|Estimate|||||||2008-12-22|2008-12-23|Estimate|October 2002||2002-10-31|December 2008|2008-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|SESAME||Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide|A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide|Completed||Phase 2/Phase 3|432|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:10:10.233722|2018-06-01 04:10:10.233722
NCT00290940|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2007-09-10|2006-02-10|2006-02-13|Estimate|||||||2007-09-10|2007-09-11|Estimate|January 2006||2006-01-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of CS-917 as Monotherapy for Type 2 Diabetes|Completed||Phase 2|400|Anticipated|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:10:10.333526|2018-06-01 04:10:10.333526
NCT00290927|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-08-25|2006-02-10|2006-02-13|Estimate|||||||2009-08-25|2009-08-26|Estimate|December 2003||2003-12-31|March 2009|2009-03-31||||||||Interventional|||Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus|Evaluation of Efficacy and Safety of HMR1964 Intensive Therapy in Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled With Oral Hypoglycemic Agents (OHA); OHA Therapy Controlled, Open, Randomized, Parallel Group, Comparative (Superiority), 16-week, Multinational, Multicenter Study|Completed||Phase 3|390||Sanofi|||||f||||||||||||||2018-06-01 04:10:10.46658|2018-06-01 04:10:10.46658
NCT00290901|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2008-03-21|2006-02-09|2006-02-13|Estimate|||||||2008-03-21|2008-03-24|Estimate|March 2006||2006-03-31|March 2008|2008-03-31||||December 2006|Actual|2006-12-31||Interventional|||Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.|A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in Subjects With Chronic Low Back Pain|Completed||Phase 4|754||Pfizer|||||||||||||||||||2018-06-01 04:10:10.567075|2018-06-01 04:10:10.567075
NCT00290888|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2014-03-05||2015-03-09|2006-02-10|2006-02-13|Estimate|2014-04-11|2014-05-09|Estimate||||2015-03-09|2015-03-27|Estimate|April 2004||2004-04-30|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Arthroscopic Rotator Cuff Repair of Full Thickness Tears With and Without Arthroscopic Acromioplasty|Arthroscopic Rotator Cuff Repair With and Without Arthroscopic Acromioplasty in the Treatment of Full Thickness Rotator Cuff|Completed||N/A|86|Actual|Panam Clinic|Variation in surgical technique and post-op rehabilitation. We do not have confirmation of cuff healing status as no imaging was carried out post-operatively. Assessment of AC morphology is subjective & based solely on pre-operative radiographs.|2|||f||||f||||||||||2018-06-01 04:10:10.671168|2018-06-01 04:10:10.671168
NCT00290875|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2015-04-20|2006-02-09|2006-02-13|Estimate|||||||2015-04-20|2015-04-22|Estimate|January 2003||2003-01-31|April 2015|2015-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Implementation of the Canadian C-Spine Rule|Implementation of the Canadian C-Spine Rule: Phase III|Completed||Phase 3|11824|Actual|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-06-01 04:10:10.958808|2018-06-01 04:10:10.958808
NCT00290862|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2008-10-13|2006-02-10|2006-02-13|Estimate|||||||2008-10-13|2008-10-15|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|March 2009||2009-03-31|||||Interventional|||A Safety and Efficacy Study for Treatment of Painful Vertebral Compression Fractures Caused by Osteoporosis|A Randomized, Controlled Clinical Study to Evaluate the Safety and Effectiveness of CORTOSS® Synthetic Cortical Bone Void Filler in Vertebral Augmentation|Unknown status|Active, not recruiting|N/A|256|Actual|Orthovita d/b/a Stryker||2|||f||||||||||||||2018-06-01 04:10:11.027439|2018-06-01 04:10:11.027439
NCT00290849|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2012-05-04|2006-02-10|2006-02-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|September 2007|Actual|2007-09-30|June 2006|Actual|2006-06-30||Observational|||ImproveR International (BI-001-IM)|European Registry of Consecutive Patients Undergoing PCI Evaluating the Use of the Thrombin-specific Anticoagulant Bivalirudin With Focus on Patient Selection, Convenience and Safety Aspects.|Completed|||4000||Nycomed|||||f||||t||||||||||2018-06-01 04:10:11.13755|2018-06-01 04:10:11.13755
NCT00290836|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2012-05-04|2006-02-10|2006-02-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2004||2004-05-31|May 2012|2012-05-31|August 2007|Actual|2007-08-31|||||Interventional|||Assess Efficacy and Safety of TachoComb H vs. Standard Surgical Treatment (i.e. Suturing) in Patients Undergoing Prostatectomy (TC-017-AU)|An Open, Randomised, Prospective, Single-centre Phase IV Trial to Assess Efficacy and Safety of TachoComb H Versus Standard Surgical Treatment (i.e. Suture) in Patients Undergoing Prostatectomy|Completed||Phase 4|120||Nycomed|||||f||||t||||||||||2018-06-01 04:10:11.187848|2018-06-01 04:10:11.187848
NCT00290823|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2017-02-02|2006-02-09|2006-02-13|Estimate|||||||2017-02-02|2017-02-03|Estimate|April 2006||2006-04-30|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients|Treatment of Intraparenchymal Neurocysticercosis: Effect of Increased Dosing of Corticosteroids on Seizure Frequency|Completed||Phase 3|110|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:10:11.239503|2018-06-01 04:10:11.239503
NCT00290810|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2013-03-22||2014-04-21|2006-02-09|2006-02-13|Estimate|2013-03-22|2013-05-14|Estimate||||2014-04-21|2014-05-09|Estimate|December 2005||2005-12-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|October 2008|Actual|2008-10-31||Interventional|||Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase II Trial of Bevacizumab to Prevent or Delay Disease Progression in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:10:11.323316|2018-06-01 04:10:11.323316
NCT00290771|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2010-12-20||2011-04-20|2006-02-10|2006-02-13|Estimate|2011-04-20|2011-05-16|Estimate||||2011-04-20|2011-05-16|Estimate|February 2006||2006-02-28|April 2011|2011-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)|A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)|Terminated||Phase 2|231|Actual|Novartis||2||Lack of efficacy|f||||f||||||||||2018-06-01 04:10:11.530647|2018-06-01 04:10:11.530647
NCT00290758|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2016-02-10||2016-12-14|2006-02-09|2006-02-13|Estimate|2016-12-14|2017-02-08|Estimate||||2016-12-14|2017-02-08|Estimate|January 2006||2006-01-31|December 2016|2016-12-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional||Participants who had >4000 epithelial cells in the first and the second rFNA sample.|Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer|Phase IIB Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer|Completed||Phase 2|126|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||No||2018-06-01 04:10:12.295083|2018-06-01 04:10:12.295083
NCT00290745|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2014-03-28|2006-02-09|2006-02-13|Estimate|||||||2014-03-28|2014-04-01|Estimate|January 2004||2004-01-31|March 2014|2014-03-31|June 2011|Actual|2011-06-30|July 2009|Actual|2009-07-31||Interventional|||Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ|Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer|Completed||N/A|56|Actual|University of California, San Francisco||1|||f||||||||||||||2018-06-01 04:10:12.933586|2018-06-01 04:10:12.933586
NCT00290732|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2013-03-01||2013-10-07|2006-02-09|2006-02-13|Estimate|2013-07-17|2013-09-26|Estimate||||2013-10-07|2013-10-31|Estimate|November 2005||2005-11-30|October 2013|2013-10-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer|A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer|Completed||Phase 1|20|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Duct cannulation was not successful in all participants; possibly due to extensive disease or prior excisional biopsy (2 subjects).|2|||f||||f||||||||||2018-06-01 04:10:13.00967|2018-06-01 04:10:13.00967
NCT00290550|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2015-07-24|2006-02-09|2006-02-13|Estimate|||||||2015-07-24|2015-07-27|Estimate|June 2006||2006-06-30|July 2015|2015-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)|A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|22|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 04:10:15.54723|2018-06-01 04:10:15.54723
NCT00290719|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2014-05-07|2006-02-09|2006-02-13|Estimate|||||||2014-05-07|2014-05-09|Estimate|November 2005||2005-11-30|May 2014|2014-05-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery|A Phase I/II Study to Evaluate Safety and Efficacy in Patients Who Have Resectable Esophageal Cancer and Are Treated With Neoadjuvant Cisplatin, Irinotecan (CPT-11) ZD1839 (IRESSA), and Radiotherapy Followed by Surgical Resection|Terminated||Phase 1|6|Actual|University of California, San Francisco||||low enrollment|f||||t||||||||||2018-06-01 04:10:13.312444|2018-06-01 04:10:13.312444
NCT00290706|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2016-08-11|2006-02-09|2006-02-13|Estimate|||||||2016-08-11|2016-08-12|Estimate|September 2005||2005-09-30|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma|A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|32|Actual|Northwestern University||1||"Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients~   resulting in poor data."|f||||t||||||||||2018-06-01 04:10:13.461074|2018-06-01 04:10:13.461074
NCT00290693|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2013-02-20||2017-10-26|2006-02-09|2006-02-13|Estimate|2013-03-29|2013-05-13|Estimate||||2017-10-26|2017-12-02|Actual|July 2004|Actual|2004-07-31|October 2017|2017-10-31|June 2010|Actual|2010-06-30|August 2008|Actual|2008-08-31||Interventional||The 43 study participants who completed baseline assessments and received at least one dose of protocol therapy.|Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer|"A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients CapTere"|Completed||Phase 2|45|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 04:10:13.552506|2018-06-01 04:10:13.552506
NCT00290680|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2018-04-06|2006-02-09|2006-02-13|Estimate|||||||2018-04-06|2018-04-10|Actual|March 2005||2005-03-31|April 2018|2018-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors|Phase I Trial of Bortezomib (VELCADE™) and Celecoxib in Patients With Advanced Solid Tumors|Completed||Phase 1|36|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 04:10:13.773167|2018-06-01 04:10:13.773167
NCT00290667|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2015-11-25|2006-02-09|2006-02-13|Estimate|||||||2015-11-25|2015-11-26|Estimate|February 2004||2004-02-29|November 2015|2015-11-30|November 2015|Actual|2015-11-30|December 2013|Actual|2013-12-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma|2-Weekly CHOP Chemotherapy With Dose-Dense Rituximab for the Treatment of Patients Aged 61 to 80 Years With Aggressive CD-20 Positive B-Cell Lymphomas: A Phase-II/Pharmacokinetic Study (CHOP-R-ESC)|Completed||Phase 2|586|Actual|German High-Grade Non-Hodgkin's Lymphoma Study Group||2|||f||||t||||||||||2018-06-01 04:10:13.881633|2018-06-01 04:10:13.881633
NCT00290654|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2015-04-29||2017-12-03|2006-02-09|2006-02-13|Estimate|2015-04-29|2015-05-15|Estimate||||2017-12-03|2017-12-28|Actual|December 2002||2002-12-31|December 2017|2017-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ|Twin Cities Brachytherapy Study for Ductal Carcinoma in Situ A Phase II Trial|Terminated||Phase 2|45|Actual|Masonic Cancer Center, University of Minnesota||1||Unable to recruit further patients.|f||||t||||||||||2018-06-01 04:10:14.57276|2018-06-01 04:10:14.57276
NCT00290641|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2017-11-27|2006-02-09|2006-02-13|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2001||2001-04-30|November 2017|2017-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer|A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation|Completed||N/A|68|Actual|Masonic Cancer Center, University of Minnesota|||||f||||t||||||||||2018-06-01 04:10:14.764567|2018-06-01 04:10:14.764567
NCT00290628|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2017-11-27|2006-02-09|2006-02-13|Estimate|||||||2017-11-27|2017-11-29|Actual|October 1999||1999-10-31|November 2017|2017-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer|Transplantation of Umbilical Cord Blood From Related and Unrelated Donors|Terminated||N/A|43|Actual|Masonic Cancer Center, University of Minnesota||||Replaced with another study|f||||t||||||||||2018-06-01 04:10:14.920189|2018-06-01 04:10:14.920189
NCT00290615|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2013-02-12||2013-03-25|2006-02-09|2006-02-13|Estimate|2013-03-25|2013-05-07|Estimate||||2013-03-25|2013-05-07|Estimate|January 2006||2006-01-31|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2009|Actual|2009-01-31||Interventional|||Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery|Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Bevacizumab in the Treatment of Metastatic Colorectal Cancer|Completed||Phase 2|30|Actual|Duke University||1|||f||||t||||||||||2018-06-01 04:10:15.028195|2018-06-01 04:10:15.028195
NCT00290602|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2007-01-16|2006-02-10|2006-02-13|Estimate|||||||2007-01-16|2007-01-17|Estimate|February 2004||2004-02-29|January 2007|2007-01-31|December 2006||2006-12-31|||||Interventional|||Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome|Prospective Phase II Study of Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome (ARDS) After Thoracic Surgery (E-START)|Completed||Phase 2|40||National Cancer Center, Korea|||||f||||||||||||||2018-06-01 04:10:15.273434|2018-06-01 04:10:15.273434
NCT00290589|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2009-10-26|2006-02-09|2006-02-13|Estimate|||||||2009-10-26|2009-10-27|Estimate|June 2003||2003-06-30|October 2009|2009-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Trial of Corticosteroids for Low Back Pain|Utility of Intramuscular Corticosteroids for Radicular Low Back Pain|Completed||Phase 3|76|Anticipated|Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:10:15.349847|2018-06-01 04:10:15.349847
NCT00290576|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2008-06-06|2006-02-10|2006-02-13|Estimate|||||||2008-06-06|2008-06-09|Estimate|April 2004||2004-04-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|April 2007|Actual|2007-04-30||Interventional|||Digestive and Nutritional Effects of Probiotics Supplementation in Premature Newborns|Digestive and Nutritional Effects of Probiotics (Bifidobacterium Longum and Lactobacillus GG) Supplementation in Premature Newborns|Completed||N/A|127|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:10:15.427747|2018-06-01 04:10:15.427747
NCT00290563|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2009-12-14|2006-02-10|2006-02-13|Estimate|||||||2009-12-14|2009-12-15|Estimate|February 2006||2006-02-28|December 2009|2009-12-31||||August 2007|Actual|2007-08-31||Interventional|||A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder|A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK0594 in Patients With Overactive Bladder|Completed||Phase 2|557|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:10:15.489982|2018-06-01 04:10:15.489982
NCT00290537|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2009-03-18||2016-04-13|2006-02-10|2006-02-13|Estimate|2009-05-04|2009-06-23|Estimate||||2016-04-13|2016-05-19|Estimate|January 2006||2006-01-31|August 2009|2009-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase II Study of ZD6474 in Advanced NSCLC|A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC|Terminated||Phase 2|4|Actual|M.D. Anderson Cancer Center||3||Accrual was suboptimal and increasing the number of patients was not feasible.|f||||f||||||||||2018-06-01 04:10:15.638515|2018-06-01 04:10:15.638515
NCT00290524|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2006-04-06|2006-02-09|2006-02-13|Estimate|||||||2006-04-06|2006-04-07|Estimate|January 2006||2006-01-31|April 2006|2006-04-30||||||||Interventional|||Early Alimentation Following Colorectal Surgery|Prospective, Multicentric, Randomized Phase III Study Comparing Early Oral Alimentation to Nil Per Os Diet After Colorectal Surgery|Unknown status|Recruiting|Phase 3|800||Maisonneuve-Rosemont Hospital|||||f||||||||||||||2018-06-01 04:10:15.841379|2018-06-01 04:10:15.841379
NCT00290511|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2017-09-28|2006-02-10|2006-02-13|Estimate|||||||2017-09-28|2017-09-29|Actual|June 29, 2004|Actual|2004-06-29|September 2017|2017-09-30|August 24, 2018|Anticipated|2018-08-24|August 24, 2018|Anticipated|2018-08-24||Interventional|||Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma|A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features|Active, not recruiting||Phase 2|49|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 04:10:15.922246|2018-06-01 04:10:15.922246
NCT00290498|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2017-08-15|2006-02-10|2006-02-13|Estimate|||||||2017-08-15|2017-08-18|Actual|August 1, 2005|Actual|2005-08-01|August 2017|2017-08-31|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger|A Phase II Randomized Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger|Completed||Phase 2|67|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 04:10:16.007171|2018-06-01 04:10:16.007171
NCT00290485|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2006-04-06|2006-02-09|2006-02-13|Estimate|||||||2006-04-06|2006-04-07|Estimate|August 2005||2005-08-31|April 2006|2006-04-30||||||||Interventional|||Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)|A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor|Unknown status|Recruiting|Phase 2|50||Maisonneuve-Rosemont Hospital|||||f||||||||||||||2018-06-01 04:10:16.099299|2018-06-01 04:10:16.099299
NCT00290472|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2013-08-19||2014-05-07|2006-02-10|2006-02-13|Estimate|2014-01-10|2014-02-11|Estimate||||2014-05-07|2014-05-23|Estimate|March 2004||2004-03-31|February 2013|2013-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase II Study of CCI-779 in B-cell Lymphoma and CLL|Completed||Phase 2|89|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:10:16.186077|2018-06-01 04:10:16.186077
NCT00290459|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2017-12-29|2006-02-09|2006-02-13|Estimate|||||||2017-12-29|2018-01-03|Actual|December 2003||2003-12-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Prognostic Markers of Gynecologic Cancers|Prognostic Markers of Gynecologic Cancers|Recruiting|||5000|Anticipated|University of Louisville|||||f||||||||||||||2018-06-01 04:10:16.61573|2018-06-01 04:10:16.61573
NCT00290433|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2015-07-13|2006-02-10|2006-02-13|Estimate|||||||2015-07-13|2015-07-14|Estimate|September 2003||2003-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma|A Phase II Study of the Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T Cell Lymphoma|Completed||Phase 2|55|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:10:16.674639|2018-06-01 04:10:16.674639
NCT00290420|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2013-05-21|2006-02-09|2006-02-13|Estimate|||||||2013-05-21|2013-05-22|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|November 2007|Anticipated|2007-11-30|November 2007|Anticipated|2007-11-30||Interventional|||Prevention of P. Vivax Malaria During Pregnancy in Bolivia|Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine.|Withdrawn||Phase 4|0|Actual|Institut de Recherche pour le Developpement||2||important delays and malaria season missed, due to political changes|f||||f||||||||||2018-06-01 04:10:16.783291|2018-06-01 04:10:16.783291
NCT00290407|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2013-05-03||2018-04-02|2006-02-09|2006-02-13|Estimate|2013-05-03|2013-06-24|Estimate||||2018-04-02|2018-05-04|Actual|March 2006||2006-03-31|April 2018|2018-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)|Phase II Study of Rituximab Plus B-Glucan in Patients With Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)|Terminated||Phase 2|2|Actual|University of Louisville|Study terminated, results data not available|||terminated due to lack of accrual|f||||t||||||||||2018-06-01 04:10:16.86452|2018-06-01 04:10:16.86452
NCT00290394|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2006-02-09|2006-02-09|2006-02-13|Estimate|||||||2006-02-09|2006-02-13|Estimate|March 2004||2004-03-31|March 2004|2004-03-31|August 2004||2004-08-31|||||Interventional|||Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients|Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring|Completed||Phase 4|25||Baskent University|||||f||||||||||||||2018-06-01 04:10:16.983645|2018-06-01 04:10:16.983645
NCT00290381|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2015-05-27|2006-02-10|2006-02-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2006||2006-02-28|September 2006|2006-09-30|June 2006||2006-06-30|||||Interventional|||The Effects of OC000459 on Nasal Mediators|The Effects of OC000459 on Nasal Th2 Cytokine Release, Eosinophil Responses, and Nasal Symptoms After Nasal Allergen Challenge (NAC) With Timothy Grass Pollen in Subjects With Allergic Rhinitis Out of Season|Completed||Phase 1|20||Imperial College London|||||f||||||||||||||2018-06-01 04:10:17.115654|2018-06-01 04:10:17.115654
NCT00290368|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2015-10-21|2006-02-10|2006-02-13|Estimate|||||||2015-10-21|2015-10-22|Estimate|February 2006||2006-02-28|September 2006|2006-09-30|May 2006||2006-05-31|||||Interventional|||Repeat Nasal Allergen Challenge|Assessment of Inflammatory Mediator and Cellular Changes Following Repeated Nasal Allergen Challenge in Subjects With Allergic Rhinitis Sensitive to Timothy Grass Pollen - a Validation Study|Completed||Phase 2|22||Imperial College London|||||f||||||||||||||2018-06-01 04:10:17.182726|2018-06-01 04:10:17.182726
NCT00289861|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2013-10-29|2006-02-08|2006-02-10|Estimate|||||||2013-10-29|2013-10-31|Estimate|February 2003||2003-02-28|October 2013|2013-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Risperidone Augmentation in Patients With Schizophrenia|Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine|Completed||Phase 4|24|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:10:28.44068|2018-06-01 04:10:28.44068
NCT00290355|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10||2011-05-13|2014-11-20|2006-02-10|2006-02-13|Estimate||||2011-05-13|2011-05-18|Estimate|2014-11-20|2014-12-10|Estimate|May 2002||2002-05-31|November 2014|2014-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery|A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection|Completed||Phase 2|182|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:10:17.256558|2018-06-01 04:10:17.256558
NCT00290342|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2016-10-11|2006-02-10|2006-02-13|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2006||2006-01-31|October 2016|2016-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants|A Multicentric Study to Compare the Immunogenicity, Safety & Reactogenicity of GSK Biologicals' DTPa-IPV Vaccine vs. Co-administration of GSK's DTPa Vaccine & Sanofi-Pasteurs' IPV Vaccine at Different Injection Sites, to Healthy Children|Completed||Phase 3|452|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:17.423989|2018-06-01 04:10:17.423989
NCT00290329|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2017-01-23||2017-01-23|2006-02-10|2006-02-13|Estimate|2017-01-23|2017-03-14|Actual||||2017-01-23|2017-03-14|Actual|January 2006||2006-01-31|November 2012|2012-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years|Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged Above 2 Years When Administered According to the Prescribing Information.|Completed||Phase 4|249|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:10:17.562655|2018-06-01 04:10:17.562655
NCT00290316|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2006-06-05|2006-02-10|2006-02-13|Estimate|||||||2006-06-05|2006-06-07|Estimate|July 2004||2004-07-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver|Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver – A Prospective Study|Unknown status|Active, not recruiting|Phase 2|||Central Texas Veterans Health Care System|||||f||||||||||||||2018-06-01 04:10:17.914523|2018-06-01 04:10:17.914523
NCT00290303|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2016-09-15|2006-02-10|2006-02-13|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2004||2004-05-31|September 2016|2016-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants|Study to Show Non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- Hepatitis B Vaccine at Birth) Versus Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vacc. at Birth for Antibody Response to All Vaccine Antigens Given in Healthy Infants|Completed||Phase 3|996|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:17.971063|2018-06-01 04:10:17.971063
NCT00290290|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2012-11-15||2014-09-10|2006-02-09|2006-02-13|Estimate|2014-07-18|2014-08-11|Estimate||||2014-09-10|2014-09-18|Estimate|September 2003||2003-09-30|September 2014|2014-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections|Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical-Site Antisepsis:A Prospective, Randomized, Multicenter Clinical Trial|Completed||Phase 3|849|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 04:10:18.071039|2018-06-01 04:10:18.071039
NCT00290277|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|||2016-09-27|2006-02-10|2006-02-13|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2005||2005-11-30|September 2016|2016-09-30|August 2006|Actual|2006-08-31|||||Interventional|||Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years|Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs|Completed||Phase 3|300|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:18.316398|2018-06-01 04:10:18.316398
NCT00290264|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2011-01-21|2006-02-09|2006-02-13|Estimate|||||||2011-01-21|2011-01-24|Estimate|December 2004||2004-12-31|January 2011|2011-01-31|August 2006|Actual|2006-08-31|||||Interventional|||SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma|A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbohaler 160/4.5 μg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open-label, Parallel-group, Multi-centre Study (SALTO)|Completed||Phase 3|1000||AstraZeneca|||||f||||||||||||||2018-06-01 04:10:18.422286|2018-06-01 04:10:18.422286
NCT00290251|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-10|2011-10-28||2012-11-14|2006-02-09|2006-02-10|Estimate|2012-11-14|2012-12-18|Estimate||||2012-11-14|2012-12-18|Estimate|February 2006||2006-02-28|November 2012|2012-11-30|August 2010|Actual|2010-08-31|July 2009|Actual|2009-07-31||Interventional|||Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914|Evaluation of Whether the Selective Progesterone Receptor Modulator CDB-2914 Can Shrink Leiomyomata|Completed||Phase 2|72|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||t||||||||||2018-06-01 04:10:18.851663|2018-06-01 04:10:18.851663
NCT00290238|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2008-11-25||2009-05-08|2006-02-08|2006-02-10|Estimate|2009-02-06|2009-03-09|Estimate||||2009-05-08|2009-06-01|Estimate|December 2005||2005-12-31|May 2009|2009-05-31|September 2008|Actual|2008-09-30|November 2007|Actual|2007-11-30||Interventional|||Percutaneous Neuromodulation Therapy (PNT) With Chronic Low Back Pain Patients|Percutaneous Neuromodulation Therapy With Chronic Low Back Pain Patients With or Without Lower Extremity Pain - A Randomized, Controlled, Parallel Groups Study|Terminated||Phase 4|122|Actual|RS Medical||2||Slow recruitment and high dropout rates|f||||f||||||||||2018-06-01 04:10:19.163394|2018-06-01 04:10:19.163394
NCT00290225|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2007-05-02|2006-02-08|2006-02-10|Estimate|||||||2007-05-02|2007-05-03|Estimate|June 2005||2005-06-30|May 2007|2007-05-31|December 2005|Actual|2005-12-31|||||Interventional|||Yoga Breath Program and Client-Centered Exposure for Relief of PTSD in Tsunami Victims|Controlled Trial of Yoga Breath Based Group Intervention and Client-Centered Exposure Treatment for Relief of Traumatic Stress and Depression in Tsunami Victims|Completed||Phase 3|180|Actual|Victim Services Center, Miami|||||f||||f||||||||||2018-06-01 04:10:19.574413|2018-06-01 04:10:19.574413
NCT00290212|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2008-01-23|2006-02-09|2006-02-10|Estimate|||||||2008-01-23|2008-01-24|Estimate|January 2006||2006-01-31|December 2006|2006-12-31|June 2007||2007-06-30|||||Interventional|||Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause|Phase II Study of Natto Supplementation to Prevent Loss of Bone Mass in Women Immediately After Menopause: a Randomised Double Blind Placebo-Controlled Trial|Completed||Phase 2|304|Actual|University Hospital of North Norway|||||f||||||||||||||2018-06-01 04:10:19.660354|2018-06-01 04:10:19.660354
NCT00290199|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2012-06-01||2017-04-12|2006-02-09|2006-02-10|Estimate|2012-09-29|2012-10-31|Estimate||||2017-04-12|2017-05-23|Actual|December 2005||2005-12-31|April 2017|2017-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Foley Catheter for Labor Induction in Women With Term and Near Term Membrane Rupture|A Randomized Controlled Trial of Foley Catheter for Labor Induction in Women With Term and Near Term Prelabor Rupture of Membranes (PROM)|Terminated||N/A|169|Actual|University of Alabama at Birmingham||2||Gathering information from the PI records to provide this response.|f||||t||||||||||2018-06-01 04:10:19.740398|2018-06-01 04:10:19.740398
NCT00290186|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2014-02-27||2014-08-13|2006-02-08|2006-02-10|Estimate|2014-08-13|2014-08-28|Estimate||||2014-08-13|2014-08-28|Estimate|August 2005||2005-08-31|August 2014|2014-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||An Evaluation of Hyperbaric Treatments for Children With Cerebral Palsy|An Evaluation of the Therapeutic Effectiveness of Hyperbaric Oxygen Treatments and Hyperbaric Air Treatments for Children With Cerebral Palsy|Terminated||N/A|49|Actual|Dayton Children's Hospital||2||Terminated for futility.|f||||t||||||||||2018-06-01 04:10:20.101947|2018-06-01 04:10:20.101947
NCT00290173|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2006-05-03|2006-02-08|2006-02-10|Estimate|||||||2006-05-03|2006-05-04|Estimate||||February 2006|2006-02-28|August 2005||2005-08-31|||||Interventional|||Ritodrine in Oral Maintenance of Tocolysis After Active Preterm Labor|Ritodrine in Oral Maintenance of Tocolysis After Active Preterm Labor: Randomized Controlled Trial|Completed||N/A|||University of Zagreb|||||f||||||||||||||2018-06-01 04:10:20.682632|2018-06-01 04:10:20.682632
NCT00290160|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2012-12-06|2006-02-08|2006-02-10|Estimate|||||||2012-12-06|2012-12-10|Estimate|December 2002||2002-12-31|December 2012|2012-12-31|July 2007|Actual|2007-07-31|September 2005|Actual|2005-09-30||Interventional|||Early Protein Supplementation on Prevention of Hyperkalemia|The Effect of Early Protein Supplementation on Prevention of Hyperkalemia in Extremely Low Birth Weight Infants|Completed||N/A|62||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 04:10:20.736424|2018-06-01 04:10:20.736424
NCT00290147|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2017-03-02||2017-05-23|2006-02-09|2006-02-10|Estimate|2017-03-02|2017-04-14|Actual||||2017-05-23|2017-06-20|Actual|January 2006||2006-01-31|May 2017|2017-05-31|April 2009|Actual|2009-04-30|December 2006|Actual|2006-12-31||Interventional|||Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine|An Open-Label, Dose Escalation, Phase I Safety, and Immunogenicity Trial of a Dengue Serotype 1 (DEN-1) Premembrane (prM) and Envelope (E) DNA Vaccine (D1ME100) in Healthy Adults Volunteers|Completed||Phase 1|22|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f|t|f||||||No||2018-06-01 04:10:20.809877|2018-06-01 04:10:20.809877
NCT00290134|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2008-02-29|2006-02-09|2006-02-10|Estimate|||||||2008-02-29|2008-03-03|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|October 2007|Actual|2007-10-31|||||Interventional|||A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism|Preliminary Efficacy and Safety of Fispemifene in the Treatment of Hypogonadism: A 4 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Daily Oral Doses of 100, 200, and 300 mg Fispemifene and Placebo|Completed||Phase 2|100||QuatRx Pharmaceuticals Company|||||||||||||||||||2018-06-01 04:10:21.383347|2018-06-01 04:10:21.383347
NCT00290121|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2013-03-13|2006-02-08|2006-02-10|Estimate|||||||2013-03-13|2013-03-14|Estimate|September 2006||2006-09-30|October 2005|2005-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics|Cerebral Mechanism Involved in Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics (IIT)|Completed||Phase 4|25|Actual|Université de Montréal||1|||f||||||||||||||2018-06-01 04:10:21.469205|2018-06-01 04:10:21.469205
NCT00290108|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2006-02-09|2006-02-09|2006-02-10|Estimate|||||||2006-02-09|2006-02-10|Estimate|March 2003||2003-03-31|June 1998|1998-06-30|December 2003||2003-12-31|||||Interventional|||The Influence of Injection Rate on EEG Propofol Peak Effect as Measured by Bispectral Index|The Influence of Injection Rate on EEG Propofol Peak Effect as Measured by Bispectral Index|Completed||N/A|99||Technische Universität München|||||f||||||||||||||2018-06-01 04:10:21.546526|2018-06-01 04:10:21.546526
NCT00290095|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2011-03-07|2006-02-09|2006-02-10|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2006||2006-01-31|March 2011|2011-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Quality of Life in Patients With Multiple Myeloma|Quality of Life in Patients With Multiple Myeloma|Completed|||260|Actual|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:10:21.601584|2018-06-01 04:10:21.601584
NCT00290082|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2015-03-10|2006-02-09|2006-02-10|Estimate|||||||2015-03-10|2015-03-11|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients|Comparison Between Midazolam and Loxapine in the Treatment of Agitated Patients in the Emergency Department|Terminated||Phase 3|120|Anticipated|University Hospital, Rouen||2||2 complications with midazolam|f||||t||||||||||2018-06-01 04:10:21.667804|2018-06-01 04:10:21.667804
NCT00290069|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2007-05-14|2006-02-09|2006-02-10|Estimate|||||||2007-05-14|2007-05-15|Estimate||||February 2006|2006-02-28||||||||Interventional|||Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)|Comparative Study of Tacrolimus and Rapamycin to Evaluate the Renal Function in Patients Older Than 50 Years, Receptors of a Kidney From a Donor Older Than 55 Years in a Mycophenolate Mofetil and Daclizumab Immunosuppressor Regime|Unknown status|Not yet recruiting|Phase 4|94|Anticipated|Sociedad Andaluza de Trasplantes de Organos y Tejidos|||||f||||||||||||||2018-06-01 04:10:21.766715|2018-06-01 04:10:21.766715
NCT00290056|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2009-11-03|2006-02-09|2006-02-10|Estimate|||||||2009-11-03|2009-11-04|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|June 2010|Anticipated|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Supplemental Intake of Omega-3 Polyunsaturated Fatty Acids on the Rate and Complexity of Spontaneously Occurring Ventricular and Supraventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillator (ICD) - A Randomized Clinical Trial||Unknown status|Active, not recruiting|Phase 4|105|Actual|Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:10:21.836092|2018-06-01 04:10:21.836092
NCT00290043|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2010-12-03|2006-02-09|2006-02-10|Estimate|||||||2010-12-03|2010-12-06|Estimate|December 2001||2001-12-31|December 2010|2010-12-31|March 2002||2002-03-31|||||Interventional|||Glulisine Pre- and Postmeal|Glucodynamic Response to Pre- and Postmeal Subcutaneous Injection of 0.15 IU/kg HMR1964 Insulin and RHI in Type 1 Diabetic Subjects in an Open, Randomized, Four-way Crossover Study|Completed||Phase 1|20||Sanofi|||||f||||||||||||||2018-06-01 04:10:21.895249|2018-06-01 04:10:21.895249
NCT00290030|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2009-03-10|2006-02-09|2006-02-10|Estimate|||||||2009-03-10|2009-03-12|Estimate|May 2001||2001-05-31|March 2009|2009-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH|A Double-Blind Randomized Parallel Group Study of Alfuzosin 10mg OD Versus Placebo in the Management of Acute Urinary Retention in Patients With a First Episode Due to Benign Prostatic Hyperplasia (BPH)|Completed||Phase 3|800|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:10:21.94176|2018-06-01 04:10:21.94176
NCT00290017|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2007-06-07|2006-02-09|2006-02-10|Estimate|||||||2007-06-07|2007-06-08|Estimate|February 2006||2006-02-28|June 2007|2007-06-30||||||||Interventional|||Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy|A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy|Terminated||Phase 3|400|Anticipated|Point Therapeutics||||FDA Hold May 2007|||||||||||||||2018-06-01 04:10:21.999264|2018-06-01 04:10:21.999264
NCT00290004|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2008-09-10|2006-02-08|2006-02-10|Estimate|||||||2008-09-10|2008-09-11|Estimate|November 2005||2005-11-30|September 2008|2008-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I/II Trial of Weekly Motexafin Gadolinium (MGd) for Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Completed||Phase 1/Phase 2|35||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 04:10:23.146281|2018-06-01 04:10:23.146281
NCT00289991|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2010-02-09||2015-10-16|2006-02-09|2006-02-10|Estimate|2010-02-09|2010-03-10|Estimate||||2015-10-16|2015-11-20|Estimate|March 2006||2006-03-31|October 2015|2015-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|IMPROVIT||Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)|Prospective, Open-Label, Comparative, Multi-Center Study Of Voriconazole Compared To Itraconazole For The Primary Prophylaxis Of Invasive Fungal Infection (IFI) With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)|Completed||Phase 3|489|Actual|Pfizer|Data was excluded from 1 site due to Good Clinical Practices deviations.|2|||f||||t||||||||||2018-06-01 04:10:23.267775|2018-06-01 04:10:23.267775
NCT00289978|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2011-01-04||2012-04-09|2006-02-09|2006-02-10|Estimate|2011-02-22|2011-03-16|Estimate||||2012-04-09|2012-04-11|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|FREEDOMS||Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis|A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 3|1272|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:10:24.442755|2018-06-01 04:10:24.442755
NCT00289965|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2011-07-25|2006-02-08|2006-02-10|Estimate|||||||2011-07-25|2011-07-26|Estimate|September 2005||2005-09-30|July 2011|2011-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Substance Use Risk Education (SURE) Project|Brief Alcohol Interventions by Counselor vs Computer|Completed||Phase 2|703|Actual|Syracuse University||3|||f||||t||||||||||2018-06-01 04:10:25.623261|2018-06-01 04:10:25.623261
NCT00289952|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2009-03-30|2006-02-09|2006-02-10|Estimate|||||||2009-03-30|2009-04-01|Estimate|June 2006||2006-06-30|January 2008|2008-01-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Valproic Acid and Its Effects on HIV Latent Reservoirs|Use of Valproic Acid to Purge HIV From Resting CD4+ Memory Cells/ A Proof-of-Concept Study|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-06-01 04:10:25.710967|2018-06-01 04:10:25.710967
NCT00289939|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2006-02-27|2006-02-09|2006-02-10|Estimate|||||||2006-02-27|2006-02-28|Estimate|September 2000||2000-09-30|July 2005|2005-07-31|January 2005||2005-01-31|||||Interventional|||Reducing HIV & Domestic Violence Risk in Women Offenders|Reducing HIV & Domestic Violence Risk in Women Offenders|Completed||Phase 3|530||Multnomah County Health Department|||||f||||||||||||||2018-06-01 04:10:25.78767|2018-06-01 04:10:25.78767
NCT00289926|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2016-03-15|2006-02-09|2006-02-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 2006||2006-02-28|March 2016|2016-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms|A Randomised, Double-blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms|Completed||Phase 3|240|Actual|Monash University||2|||f||||t||||||||No||2018-06-01 04:10:25.849978|2018-06-01 04:10:25.849978
NCT00289913|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2011-06-09||2017-03-16|2006-02-08|2006-02-10|Estimate|2011-06-09|2011-07-07|Estimate||||2017-03-16|2017-04-13|Actual|April 2006||2006-04-30|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)|An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA™ Given Concomitantly With PedvaxHIB™ and Infanrix™ in Healthy Children 15 Months of Age|Completed||Phase 4|1274|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:10:25.939776|2018-06-01 04:10:25.939776
NCT00289900|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2015-12-17||2017-03-03|2006-02-08|2006-02-10|Estimate|2015-12-17|2016-01-26|Estimate||||2017-03-03|2017-03-31|Actual|January 2006||2006-01-31|March 2017|2017-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)|A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia|Completed||Phase 3|2340|Actual|Merck Sharp & Dohme Corp.||6|||f||||||||||||||2018-06-01 04:10:26.670172|2018-06-01 04:10:26.670172
NCT00289887|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2009-09-21||2015-07-21|2006-02-08|2006-02-10|Estimate|2010-04-29|2010-05-27|Estimate||||2015-07-21|2015-07-28|Estimate|February 2006||2006-02-28|July 2015|2015-07-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Obese Hypertension Study (0954-315)|A Double-Blind, Randomized, Parallel, Efficacy Study Evaluating Losartan Potassium Alone or in Combination With Hydrochlorothiazide Versus Placebo in Obese Patients With Elevated Systolic and Diastolic Blood Pressure|Completed||Phase 3|261|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:10:27.954599|2018-06-01 04:10:27.954599
NCT00289874|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2009-09-09||2016-01-20|2006-02-08|2006-02-10|Estimate|2010-09-10|2010-10-01|Estimate||||2016-01-20|2016-02-17|Estimate|March 2006||2006-03-31|January 2016|2016-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)|A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients With Seasonal Aeroallergen Sensitivity|Completed||Phase 3|421|Actual|Merck Sharp & Dohme Corp.|Safety is reported in the literature.|2|||f||||||||||||||2018-06-01 04:10:28.244332|2018-06-01 04:10:28.244332
NCT00289848|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2010-03-18||2015-05-20|2006-02-08|2006-02-10|Estimate|2010-03-18|2010-04-02|Estimate||||2015-05-20|2015-06-15|Estimate|March 2006||2006-03-31|May 2015|2015-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 3|530|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:10:28.589523|2018-06-01 04:10:28.589523
NCT00289835|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2011-11-23|2006-02-09|2006-02-10|Estimate|||||||2011-11-23|2011-11-24|Estimate|February 2006||2006-02-28|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|VELETI||Treatment of Moderate Vein Graft Lesions With Paclitaxel Drug Eluting Stents: The VELETI Trial|Sealing Moderate Coronary Saphenous VEin Graft LEsions With the Paclitaxel-eluting Stent (Taxus) as a New Approach to Maintain Vein Graft Patency and Reduce Cardiac Events: a Pilot Intravascular Ultrasound Study.|Completed||Phase 4|57|Actual|Laval University||2|||f||||f||||||||||2018-06-01 04:10:28.91158|2018-06-01 04:10:28.91158
NCT00289822|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2006-11-29|2006-02-08|2006-02-10|Estimate|||||||2006-11-29|2006-11-30|Estimate|January 2002||2002-01-31|February 2006|2006-02-28|January 2005||2005-01-31|||||Interventional|||Cell Therapy for Coronary Heart Disease|Cell Therapy for Coronary Heart Disease: Infusion of Autologous Ex Vivo Cultivated Endothelial Progenitor Cells (EPCs)” and Autologous Bone Marrow Progenitor Cells in Crossover Design for Improvement of Vascularization and Cardiac Function|Terminated||Phase 2|75||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:10:28.973135|2018-06-01 04:10:28.973135
NCT00289809|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2009-12-17|2006-02-09|2006-02-10|Estimate|||||||2009-12-17|2009-12-18|Estimate|September 2006||2006-09-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients|A Perspective Phase I and II Trial of Liposome-encapsulated Doxorubicin (TLC D-99) in Combination With Ifosfamide in Patients With Metastatic Soft Tissue Sarcoma|Completed||Phase 1/Phase 2|36|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||||||2018-06-01 04:10:29.046849|2018-06-01 04:10:29.046849
NCT00289796|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2017-02-06|2006-02-09|2006-02-10|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2004||2004-07-31|February 2017|2017-02-28|December 2006|Actual|2006-12-31|April 2006|Actual|2006-04-30||Interventional|||Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine|Assess the Feasibility of an Investigational Vaccination Regimen, Compared to a 3-dose Primary Vaccination With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib Vaccine) Following Hepatitis B Vaccination at Birth. Primary Vaccination is Followed in the 2nd Year of Life by a Booster Dose of Infanrix-hexa|Completed||Phase 2|121|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:29.112082|2018-06-01 04:10:29.112082
NCT00289783|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2012-06-15|2009-05-29|2016-11-03|2006-02-09|2006-02-10|Estimate|2012-06-28|2012-08-06|Estimate|2009-09-28|2009-09-30|Estimate|2016-11-03|2016-12-16|Estimate|February 2006||2006-02-28|November 2016|2016-11-30|February 2008|Actual|2008-02-29|August 2007|Actual|2007-08-31||Interventional|||Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine|A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.|Completed||Phase 3|4441|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:29.297988|2018-06-01 04:10:29.297988
NCT00289770|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2010-11-30||2016-09-20|2006-02-09|2006-02-10|Estimate|2011-02-22|2011-02-23|Estimate||||2016-09-20|2016-10-20|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults|A Double Blind Randomised, Comparative Study of the Immunogenicity and Reactogenicity of Three Different Lots of GlaxoSmithKline Biologicals' Combined Hepatitis A - Hepatitis B Vaccine When Administered in Healthy Adults|Completed||Phase 3|50|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following complete retesting and reanalysis.|3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:31.3872|2018-06-01 04:10:31.3872
NCT00289757|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2009-12-10||2016-09-06|2006-02-09|2006-02-10|Estimate|2010-02-18|2010-03-04|Estimate||||2016-09-06|2016-10-20|Estimate|January 2004||2004-01-31|September 2016|2016-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule|Double-blind, Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Three Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 6 Month Schedule in Healthy Adult Subjects|Completed||Phase 4|78|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:31.764298|2018-06-01 04:10:31.764298
NCT00289744|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2010-04-08||2014-10-02|2006-02-09|2006-02-10|Estimate|2010-07-29|2010-08-26|Estimate||||2014-10-02|2014-10-10|Estimate|February 2004||2004-02-29|October 2011|2011-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule|Long-Term Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Children|Completed||Phase 3|171|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 04:10:32.091382|2018-06-01 04:10:32.091382
NCT00289731|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2016-09-15|2006-02-09|2006-02-10|Estimate|||||||2016-09-15|2016-09-16|Estimate|November 2003||2003-11-30|September 2016|2016-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc|Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals' Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines|Completed||Phase 4|577|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:32.382293|2018-06-01 04:10:32.382293
NCT00289718|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2010-01-11||2017-09-01|2006-02-09|2006-02-10|Estimate|2010-07-29|2010-08-26|Estimate||||2017-09-01|2018-02-15|Actual|November 1, 2004||2004-11-01|November 2016|2016-11-30|March 2, 2005|Actual|2005-03-02|March 2, 2005|Actual|2005-03-02||Interventional|||Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule|Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers|Completed||Phase 3|51|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following complete retesting and reanalysis|1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:32.506593|2018-06-01 04:10:32.506593
NCT00289705|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2017-02-01|2006-02-09|2006-02-10|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2006||2006-02-28|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Surgical Intervention for Morbidly Obese Adolescents|Surgical Intervention With Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity in Adolescence - a Matched Control Study|Active, not recruiting||Phase 3|80|Anticipated|Göteborg University||2|||f||||t||||||||||2018-06-01 04:10:32.868468|2018-06-01 04:10:32.868468
NCT00289679|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2015-03-17|2006-02-09|2006-02-10|Estimate|||||||2015-03-17|2015-03-18|Estimate||||July 2007|2007-07-31||||||||Interventional|||Cytokine Profile and Metal Ion Concentrations at Patients Undergoing a Revision THR||Unknown status|Recruiting|Phase 4|||Frederiksberg University Hospital|||||f||||||||||||||2018-06-01 04:10:32.938417|2018-06-01 04:10:32.938417
NCT00289666|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2016-07-07|2006-02-09|2006-02-10|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2003||2003-07-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|March 2007|Actual|2007-03-31||Observational|||The Effect of Positive Airway Pressure on Heart Rate Variability|A Prospective Study to Determine the Effect of Positive Airway Pressure on Heart Rate Variability in Individuals With Obstructive Sleep Apnea|Completed|||38|Anticipated|Christiana Care Health Services|||||f||||f||||||Samples Without DNA|"~     Serum, Plasma, Urine~   "|||2018-06-01 04:10:32.986262|2018-06-01 04:10:32.986262
NCT00289653|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2009-05-09|2006-02-08|2006-02-10|Estimate|||||||2009-05-09|2009-05-12|Estimate|September 2005||2005-09-30|May 2009|2009-05-31|June 2006||2006-06-30|||||Interventional|||Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation|Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation|Completed||N/A|60||Centre for Addiction and Mental Health|||||f||||||||||||||2018-06-01 04:10:33.047071|2018-06-01 04:10:33.047071
NCT00289640|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09||2010-02-27|2010-02-27|2006-02-09|2006-02-10|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|April 2006||2006-04-30|January 2009|2009-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma|A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma|Completed||Phase 2|210|Anticipated|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 04:10:33.119272|2018-06-01 04:10:33.119272
NCT00289627|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2016-09-27|2006-02-09|2006-02-10|Estimate|||||||2016-09-27|2016-09-28|Estimate|April 2006||2006-04-30|September 2016|2016-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma|A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma|Completed||Phase 2|155|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 04:10:33.346279|2018-06-01 04:10:33.346279
NCT00289614|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2008-01-03|2006-02-08|2006-02-10|Estimate|||||||2008-01-03|2008-01-07|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)|Patients With Renal Impairment and Diabetes Undergoing Computed Tomography|Completed||Phase 4|350|Anticipated|Bracco Diagnostics, Inc|||||f||||||||||||||2018-06-01 04:10:33.50136|2018-06-01 04:10:33.50136
NCT00289601|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2007-07-19|2006-02-08|2006-02-10|Estimate|||||||2007-07-19|2007-07-20|Estimate|March 2006||2006-03-31|July 2007|2007-07-31|December 2007||2007-12-31|||||Interventional|||Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty|Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance|Terminated||Phase 4|1200|Anticipated|Brigham and Women's Hospital||||Sponsor support withdrawn|f||||t||||||||||2018-06-01 04:10:33.561416|2018-06-01 04:10:33.561416
NCT00289588|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2006-02-13|2006-02-09|2006-02-10|Estimate|||||||2006-02-13|2006-02-16|Estimate|January 2005||2005-01-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers|An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus Infection in Soldiers: a Controlled Trial|Completed||N/A|3000||Brooke Army Medical Center|||||f||||||||||||||2018-06-01 04:10:33.639692|2018-06-01 04:10:33.639692
NCT00289575|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2007-03-01|2006-02-09|2006-02-10|Estimate|||||||2007-03-01|2007-03-02|Estimate|February 2006||2006-02-28|March 2007|2007-03-31|February 2008||2008-02-29|||||Interventional|||MBCP Safety and Performance in the Osteonecrosis of Femur Head|Evaluation of Safety and Performance of Macroporous Biphasic Calcium Phosphate Granules Combined With Cellulosic-Derived Gel, in Filling Bones Gap After Aseptic Osteonecrosis Biopsy of Femur Head.|Unknown status|Recruiting|Phase 2|12||Biomatlante|||||f||||f||||||||||2018-06-01 04:10:33.726182|2018-06-01 04:10:33.726182
NCT00289562|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2012-01-19|2006-02-08|2006-02-10|Estimate|||||||2012-01-19|2012-01-20|Estimate|September 2004||2004-09-30|January 2012|2012-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia|A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Extended Use of Forodesine Hydrochloride|Completed||Phase 1/Phase 2|20||BioCryst Pharmaceuticals|||||f||||||||||||||2018-06-01 04:10:33.816747|2018-06-01 04:10:33.816747
NCT00289549|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08||2012-01-19|2012-02-06|2006-02-08|2006-02-10|Estimate||||2012-01-19|2012-01-23|Estimate|2012-02-06|2012-02-08|Estimate|June 2005||2005-06-30|February 2012|2012-02-29|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)|Phase II Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|8|Actual|BioCryst Pharmaceuticals|||||f||||||||||||||2018-06-01 04:10:33.897327|2018-06-01 04:10:33.897327
NCT00289367|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2008-05-19|2006-02-07|2006-02-09|Estimate|||||||2008-05-19|2008-05-20|Estimate|February 2006||2006-02-28|May 2008|2008-05-31|May 2008|Actual|2008-05-31|August 2006|Actual|2006-08-31||Interventional|||Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery|Randomized Prospective Study of T3 on the Incidence of Post-Operative Atrial Fibrillation in Patients Undergoing Cardiac Surgery|Completed||Phase 1|280|Anticipated|Northwell Health|||||f||||||||||||||2018-06-01 04:10:35.573088|2018-06-01 04:10:35.573088
NCT00289536|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|2010-09-30||2017-10-19|2006-02-09|2006-02-10|Estimate|2010-12-08|2011-01-13|Estimate||||2017-10-19|2017-11-22|Actual|February 2006||2006-02-28|May 2011|2011-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A|Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM|Completed||Phase 4|38|Actual|Shire||3|||f||||t||||||||||2018-06-01 04:10:34.003967|2018-06-01 04:10:34.003967
NCT00289523|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2012-03-06|2006-02-08|2006-02-10|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||EEG Biomarkers for Predicting Response to Antidepressant Therapy|Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD), a Prospective, Randomized, Multi-center Study to Determine the Efficacy of Selected EEG and Genotype Biomarkers for Predicting Response to Antidepressant Therapy With Escitalopram, Bupropion XL, or a Combination Treatment Regimen.|Completed|||375|Actual|Medtronic - MITG|||3||f||||t||||||||||2018-06-01 04:10:34.422727|2018-06-01 04:10:34.422727
NCT00289510|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-09|||2015-10-07|2006-02-09|2006-02-10|Estimate|||||||2015-10-07|2015-10-09|Estimate|January 2006||2006-01-31|October 2007|2007-10-31||||||||Interventional|||Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)|Single-Blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) With a License Egg Derived Influenza Vaccine|Completed||Phase 1/Phase 2|423||Ology Bioservices|||||f||||||||||||||2018-06-01 04:10:34.487787|2018-06-01 04:10:34.487787
NCT00289497|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-02-08|2006-02-08|2006-02-09|Estimate|||||||2006-02-08|2006-02-09|Estimate|June 2000||2000-06-30|February 2006|2006-02-28|July 2003||2003-07-31|||||Interventional|||TempTouch IR Thermometry & Diabetic Patient Self-Care|Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home|Completed||Phase 2/Phase 3|180||Diabetica Solutions Inc.|||||f||||||||||||||2018-06-01 04:10:34.538938|2018-06-01 04:10:34.538938
NCT00289484|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-09-11|2006-02-07|2006-02-09|Estimate|||||||2006-09-11|2006-09-13|Estimate|February 2006||2006-02-28|September 2006|2006-09-30||||||||Interventional|||A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression|A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acid as an Augmentor of Antidepressant Medication for Major Depression.|Unknown status|Recruiting|Phase 2|52||The University of New South Wales|||||f||||||||||||||2018-06-01 04:10:34.604987|2018-06-01 04:10:34.604987
NCT00289471|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2014-08-11||2015-04-10|2006-02-08|2006-02-09|Estimate|2014-08-11|2014-08-26|Estimate||||2015-04-10|2015-05-01|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Observational|GEMS||Identifying Patients With Dementia in Primary Care|Dementia in Primary Care: Setting the Stage for Quality Improvement|Completed|||630|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:10:34.68086|2018-06-01 04:10:34.68086
NCT00289458|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2009-02-13||2010-07-06|2006-02-07|2006-02-09|Estimate|2010-07-06|2010-08-03|Estimate||||2010-07-06|2010-08-03|Estimate|October 2005||2005-10-31|July 2010|2010-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Aquatic Exercise and Efficacy Enhancement to Decrease Fall Risk in Older Adults With Hip Osteoarthritis|The Effect of Aquatic Exercise and Aquatic Exercise Combined With Education and Efficacy Enhancement on Improving Indices of Fall Risk in Older Adults With Hip Osteoarthritis: a Randomized Controlled Clinical Trial|Completed||Phase 1|79|Actual|University of Saskatchewan||3|||f||||||||||||||2018-06-01 04:10:34.903127|2018-06-01 04:10:34.903127
NCT00289445|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2013-01-25|2006-02-08|2006-02-09|Estimate|||||||2013-01-25|2013-01-28|Estimate|September 1999||1999-09-30|January 2013|2013-01-31|March 2006||2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)|Open, Multi-center Phase I/II Trial With Mitomycin C in Combination With 5-Fluorouracil and Folinic Acid in Pretreated Patients With Metastatic Gastrointestinal Cancer|Completed||Phase 1/Phase 2|||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:10:35.200393|2018-06-01 04:10:35.200393
NCT00289432|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2015-04-29|2006-02-08|2006-02-09|Estimate|||||||2015-04-29|2015-04-30|Estimate|April 2006||2006-04-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|February 2009|Actual|2009-02-28||Interventional|||Hospital Based Group Intervention for Breast Cancer Patients.|Effects of Group Intervention on Anxiety, Depression and Quality of Life Among Women Operated for Breast Cancer. A Randomized, Prospective Study.|Completed||N/A|450|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 04:10:35.249699|2018-06-01 04:10:35.249699
NCT00289419|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2008-05-06|2006-02-08|2006-02-09|Estimate|||||||2008-05-06|2008-05-07|Estimate|February 2005||2005-02-28|May 2008|2008-05-31|March 2006|Actual|2006-03-31|February 2006|Actual|2006-02-28||Interventional|||Intraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study|Postoperative Analgesia After Total Hip Arthroplasty. A Comparison of Continuous Epidural Infusion and Wound Infiltration With Intraarticular Bolus Injection.|Completed||Phase 4|80|Actual|University of Aarhus||2|||f||||||||||||||2018-06-01 04:10:35.312579|2018-06-01 04:10:35.312579
NCT00289406|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2007-03-05|2006-02-07|2006-02-09|Estimate|||||||2007-03-05|2007-03-06|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|February 2006||2006-02-28|||||Interventional|||Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension|An 8 Weeks, Multi-Center, Randomized, Double Blinded, Comparative Phase 3 Clinical Trial to Assess the Efficacy and Safety of S-Amlodipine Gentisate Compared to Amlodipine Besylate in Patients With Mild-to-Moderate Hypertension|Completed||Phase 3|110||SK Chemicals Co.,Ltd.|||||f||||||||||||||2018-06-01 04:10:35.370811|2018-06-01 04:10:35.370811
NCT00289393|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2006-09-11|2006-02-08|2006-02-09|Estimate|||||||2006-09-11|2006-09-13|Estimate||||September 2006|2006-09-30||||||||Observational|||Response Shift in Patient Expectations and Functional Outcome|Response Shift in Patient Expectations and Functional Outcome Following Posterior Lumbar Spinal Surgery for Degenerative Spinal Disorders|Unknown status|Recruiting||||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:10:35.41743|2018-06-01 04:10:35.41743
NCT00289380|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2017-11-24|2006-02-08|2006-02-09|Estimate|||||||2017-11-24|2017-11-28|Actual|January 2005||2005-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk|1. Prevalence of Nutritional Risk-undernutrition-support in China-Euro-USA. 2. Impact of Nutrition Support on Outcome for Patient at Risk. 3. Impact of Nutrition Support on Outcome,Cost/Effectiveness for Patient at Risk.|Recruiting|||2000|Anticipated|Peking Union Medical College|||2||f||||f||||||||||2018-06-01 04:10:35.468468|2018-06-01 04:10:35.468468
NCT00289029|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-08-17|2006-02-07|2006-02-09|Estimate|||||||2006-08-17|2006-08-18|Estimate|July 2005||2005-07-31|August 2006|2006-08-31|June 2006||2006-06-30|||||Interventional|||A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography|Visipaque and Isovue in Cardiac Angiography in Renally Impaired Patients|Completed||Phase 4|400||Bracco Diagnostics, Inc|||||f||||||||||||||2018-06-01 04:10:43.222818|2018-06-01 04:10:43.222818
NCT00289354|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-02-07|2006-02-07|2006-02-09|Estimate|||||||2006-02-07|2006-02-09|Estimate|March 2003||2003-03-31|February 2006|2006-02-28|November 2005||2005-11-30|||||Interventional|||Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM|Randomized, Double Blinded, Placebo Controlled, Study to Evaluate Improvements in Glycemic Control, Lipid Levels, Quality of Life and Healthcare Costs After Daily Administration of Chromium Picolinate and Biotin in Patients With T2DM|Completed||N/A|600||Nutrition 21, Inc.|||||f||||||||||||||2018-06-01 04:10:35.633036|2018-06-01 04:10:35.633036
NCT00289341|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2011-08-08||2013-01-11|2006-02-07|2006-02-09|Estimate|2012-12-03|2013-01-08|Estimate||||2013-01-11|2013-01-18|Estimate|March 2002||2002-03-31|January 2013|2013-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.|A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/LNCaP) Administered Subcutaneously to Prostate Cancer Patients.|Completed||Phase 1/Phase 2|24|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 04:10:35.698781|2018-06-01 04:10:35.698781
NCT00289328|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2010-03-01|2006-02-08|2006-02-09|Estimate|||||||2010-03-01|2010-03-02|Estimate|November 2001||2001-11-30|March 2010|2010-03-31|April 2006|Actual|2006-04-30|||||Observational|||Glucocorticoid-induced Osteopenia in Children||Completed|||550||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:10:36.915321|2018-06-01 04:10:36.915321
NCT00289315|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2017-06-08|2006-02-08|2006-02-09|Estimate|||||||2017-06-08|2017-06-12|Actual|August 2005||2005-08-31|June 2017|2017-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||LA Health Project HIPTeens Project (a Secondary Prevention Program) and the Wise Mind Project (a Primary Prevention Program).|LA Health: A Prospective Study of Primary and Secondary Obesity Prevention in Children and Adolescents|Completed||N/A|2709|Actual|Pennington Biomedical Research Center||3|||f||||t||||||||||2018-06-01 04:10:36.985988|2018-06-01 04:10:36.985988
NCT00289302|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2007-10-03|2006-02-07|2006-02-09|Estimate|||||||2007-10-03|2007-10-05|Estimate|January 2003||2003-01-31|September 2006|2006-09-30|December 2006|Actual|2006-12-31|||||Observational|||InSync Implantable Cardioverter Defibrillator Registry: Cardiac Resynchronization Therapy|InSync Implantable Cardioverter Defibrillator Registry: Cardiac Resynchronization Therapy|Completed|||600||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:10:37.075928|2018-06-01 04:10:37.075928
NCT00289289|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2011-12-21||2012-06-25|2006-02-07|2006-02-09|Estimate|2012-06-25|2012-08-08|Estimate||||2012-06-25|2012-08-08|Estimate|February 2004||2004-02-29|June 2012|2012-06-30|July 2011|Actual|2011-07-31|November 2010|Actual|2010-11-30||Interventional|||Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)|Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)|Completed||N/A|400|Actual|Medtronic Cardiac Rhythm and Heart Failure|The effect of ON programming was not consistent across randomized study period, violating a key assumption of the cross-over study design.|3|||f||||f||||||||||2018-06-01 04:10:37.228306|2018-06-01 04:10:37.228306
NCT00289276|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2009-04-01||2010-10-05|2006-02-07|2006-02-09|Estimate|2010-09-27|2010-09-28|Estimate||||2010-10-05|2010-10-13|Estimate|November 2003||2003-11-30|October 2010|2010-10-31||||April 2008|Actual|2008-04-30||Interventional|||FAST (Fluid Accumulation Status Trial)|FAST (Fluid Accumulation Status Trial)|Completed||N/A|156|Actual|Medtronic Cardiac Rhythm and Heart Failure|This was a characterization study with no descriptive statistical analysis. The results reported were counts of subjects with impedance data available as applicable for each objective.||||f||||f||||||||||2018-06-01 04:10:38.432571|2018-06-01 04:10:38.432571
NCT00289263|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2006-02-08|2006-02-08|2006-02-09|Estimate|||||||2006-02-08|2006-02-09|Estimate|April 1998||1998-04-30|November 2003|2003-11-30|October 2003||2003-10-31|||||Interventional|||Maintenance Chemotherapy in Metastatic Breast Cancer|Maintenance Paclitaxel Vs Control After Anthracycline/Paclitaxel Combined First-Line Chemotherapy in Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 3|524||MANTA 1 Study Italian Collaborative Group|||||f||||||||||||||2018-06-01 04:10:38.998371|2018-06-01 04:10:38.998371
NCT00289250|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2006-02-28|2006-02-08|2006-02-09|Estimate|||||||2006-02-28|2006-03-01|Estimate|May 2001||2001-05-31|December 2002|2002-12-31|December 2001||2001-12-31|||||Interventional|||Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum|Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum: A Randomized Controlled Trial|Completed||Phase 3|360||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:10:39.076645|2018-06-01 04:10:39.076645
NCT00289237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2012-10-02|2006-02-08|2006-02-09|Estimate|||||||2012-10-02|2012-10-03|Estimate|March 1999||1999-03-31|October 2012|2012-10-31|March 2011|Actual|2011-03-31|March 2006|Actual|2006-03-31||Interventional|||Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease|A Randomised Non-pharmacological Intervention Study for Prevention of Ischaemic Heart Disease Inter99|Completed||N/A|61301|Actual|Glostrup University Hospital, Copenhagen||3|||f||||||||||||||2018-06-01 04:10:39.146958|2018-06-01 04:10:39.146958
NCT00289224|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2014-07-30|2006-02-07|2006-02-09|Estimate|||||||2014-07-30|2014-07-31|Estimate|July 2006||2006-07-31|March 2012|2012-03-31|May 2013|Actual|2013-05-31|December 2011|Actual|2011-12-31||Interventional|||Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata|A Randomized Controlled Trial of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Eastern Kolkata, West Bengal, India|Completed||Phase 3|69329|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-06-01 04:10:39.225137|2018-06-01 04:10:39.225137
NCT00289211|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2010-03-17||2014-03-19|2006-02-07|2006-02-09|Estimate|2010-05-03|2010-06-02|Estimate||||2014-03-19|2014-04-15|Estimate|June 2005||2005-06-30|March 2014|2014-03-31|September 2007|Actual|2007-09-30|December 2006|Actual|2006-12-31||Interventional|||C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks|LEVP2005-1/Part A: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) for the Treatment of HAE in Acute Attacks|Completed||Phase 3|83|Actual|Shire||2|||f||||t||||||||||2018-06-01 04:10:39.332384|2018-06-01 04:10:39.332384
NCT00289198|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2017-04-17||2017-09-11|2006-02-08|2006-02-09|Estimate|2017-09-11|2018-04-13|Actual||||2017-09-11|2018-04-13|Actual|February 7, 2006||2006-02-07|September 2017|2017-09-30|July 4, 2006|Actual|2006-07-04|July 1, 2006|Actual|2006-07-01||Interventional||The ITT Population included all participants who were randomized and received at least one dose of the study drug.|Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 6 Weeks in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|301|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:39.769212|2018-06-01 04:10:39.769212
NCT00288834|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2006-02-06|2006-02-06|2006-02-08|Estimate|||||||2006-02-06|2006-02-08|Estimate|August 2001||2001-08-31|February 2006|2006-02-28|July 2006||2006-07-31|||||Interventional|||Outcomes of Swallowing Rehabilitation After Stroke|Outcomes of Swallowing Rehabilitation After Stroke|Completed||N/A|||University of Canterbury|||||f||||||||||||||2018-06-01 04:10:45.34554|2018-06-01 04:10:45.34554
NCT00289185|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2012-11-08|2009-09-03|2017-04-24|2006-02-08|2006-02-09|Estimate|2013-04-25|2013-07-08|Estimate|2009-09-03|2009-09-04|Estimate|2017-04-24|2017-06-05|Actual|September 27, 2006||2006-09-27|April 2017|2017-04-30|January 15, 2009|Actual|2009-01-15|February 11, 2008|Actual|2008-02-11||Interventional|||Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants|A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region.|Completed||Phase 2|340|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:40.880651|2018-06-01 04:10:40.880651
NCT00289172|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2017-05-26|2006-02-08|2006-02-09|Estimate|||||||2017-05-26|2017-05-30|Actual|February 10, 2006||2006-02-10|May 2017|2017-05-31|September 8, 2006|Actual|2006-09-08|||||Interventional|||Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India|A Multicenter Study of the Immunogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8 Wks at the Time of the First Dose|Completed||Phase 3|360||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:10:41.39586|2018-06-01 04:10:41.39586
NCT00289159|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2006-02-08|2006-02-08|2006-02-09|Estimate|||||||2006-02-08|2006-02-09|Estimate||||September 2005|2005-09-30||||||||Observational|||Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up|Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).|Unknown status|Active, not recruiting||||Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:10:41.55149|2018-06-01 04:10:41.55149
NCT00289146|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2013-09-23|2006-02-07|2006-02-09|Estimate|||||||2013-09-23|2013-09-24|Estimate|November 2005||2005-11-30|September 2013|2013-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Comparison of Immune Response Following Surgical Management of Renal Tumors|Comparison of Immune Response Following Surgical Management of Renal Tumors|Terminated|||50|Anticipated|Emory University|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-06-01 04:10:41.590085|2018-06-01 04:10:41.590085
NCT00289133|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2014-05-30||2017-03-23|2006-02-07|2006-02-09|Estimate|2016-05-31|2016-07-15|Estimate||||2017-03-23|2017-04-24|Actual|February 1, 2005|Actual|2005-02-01|March 2017|2017-03-31|May 1, 2013|Actual|2013-05-01|May 1, 2013|Actual|2013-05-01||Interventional||Enrolled Subjects|Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study|Prospective, Comparative, Randomized Study of GVF Versus Cross-linked Polyethylene in Total Knee Arthroplasty|Completed||N/A|938|Actual|DePuy Orthopaedics|Serious adverse events were not collected in this study per the modern definition. All adverse events collected for this study will be reported in the 'Other Adverse Events' table. MedDRA was used to classify each AE into SOC, but not Preferred Term.|2|||f||||f||||||||||2018-06-01 04:10:41.659558|2018-06-01 04:10:41.659558
NCT00289120|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2013-08-14||2016-05-05|2006-02-07|2006-02-09|Estimate|2014-06-05|2014-07-08|Estimate||||2016-05-05|2016-06-08|Estimate|November 2003||2003-11-30|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Thirteen subjects, including 10 normal subjects and 3 calcium oxalate stone-formers were enrolled in this prospective cross-over study.|Effect of Cola on Urinary Stone Risk Factors|Effect of Cola on Urinary Stone Risk Factors|Completed||N/A|13|Actual|Emory University||2|||f||||f||||||||||2018-06-01 04:10:42.194588|2018-06-01 04:10:42.194588
NCT00289107|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2010-09-29||2013-08-06|2006-02-07|2006-02-09|Estimate|2010-11-12|2010-12-10|Estimate||||2013-08-06|2013-08-14|Estimate|April 2001||2001-04-30|August 2013|2013-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA|Multi-center, Prospective, Clinical Evaluation of the P.F.C.® Sigma™ Rotating Platform Cruciate Substituting vs P.F.C.® Sigma™ Cruciate Substituting Knee Primary Cases|Completed||N/A|149|Actual|DePuy Orthopaedics||2|||f||||f||||||||||2018-06-01 04:10:42.488699|2018-06-01 04:10:42.488699
NCT00289094|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2010-09-29||2013-08-06|2006-02-07|2006-02-09|Estimate|2010-11-12|2010-12-10|Estimate||||2013-08-06|2013-08-14|Estimate|March 2001||2001-03-31|August 2013|2013-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKA|Multi-center, Prospective, Clinical Evaluation of the PFC Sigma Rotating Platform Cruciate Retaining Versus PFC Sigma Cruciate Retaining Knee Primary Cases|Completed||N/A|99|Actual|DePuy Orthopaedics||2|||f||||f||||||||||2018-06-01 04:10:42.770481|2018-06-01 04:10:42.770481
NCT00289081|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2014-05-12|2006-02-07|2006-02-09|Estimate|||||||2014-05-12|2014-05-13|Estimate|February 2001||2001-02-28|May 2014|2014-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Primary TKA Cruciate Retaining vs Cruciate Substituting With Rotating Platform Knee Prostheses|Multi-center Prospective Clinical Evaluation of the P.F.C.® Sigma™ Rotating Platform Knee Primary Cases Cruciate Retaining Versus Cruciate Substituting|Terminated||N/A|399|Actual|DePuy Orthopaedics||2||Business reasons|f||||f||||||||||2018-06-01 04:10:42.965112|2018-06-01 04:10:42.965112
NCT00289068|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2011-07-08|2006-02-07|2006-02-09|Estimate|||||||2011-07-08|2011-07-11|Estimate|January 2006||2006-01-31|July 2011|2011-07-31|September 2007|Actual|2007-09-30|April 2006|Actual|2006-04-30||Observational|||Phacoemulsification Sleeves|Determination of Surgical Efficacy and Most Efficient Surgical Parameters for Use With the 2.2, 2.8, and 3.0mm Phacoemulsification Sleeves Used With the Alcon Infinity 1.1mm ABS Flared Tip|Completed|||44|Actual|University of Oklahoma|||3||f||||t||||||||||2018-06-01 04:10:43.048442|2018-06-01 04:10:43.048442
NCT00289055|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2009-02-20|2006-02-08|2006-02-09|Estimate|||||||2009-02-20|2009-02-24|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|DURAVEST||The Study to Compare the Treatment of Angioplasty and Stents in SFA Occlusions.|A Clinical Investigation of the SMART™ Nitinol Self-Expandable Stent Versus Balloon Angioplasty for the Treatment of Superficial Femoral Artery Occlusions|Terminated||Phase 4|10|Actual|Cordis Corporation||2||lack of enrollment|f||||t||||||||||2018-06-01 04:10:43.111839|2018-06-01 04:10:43.111839
NCT00289042|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2007-01-30|2006-02-08|2006-02-09|Estimate|||||||2007-01-30|2007-01-31|Estimate|December 1999||1999-12-31|May 2005|2005-05-31|November 2004||2004-11-30|||||Interventional|||Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)|The Use of Enoxaparin Compared to Unfractionated Heparin for Short Term Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing TEE Guided Cardioversion: Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) II Randomized Multicenter Study|Completed||Phase 4|200||The Cleveland Clinic|||||||||||||||||||2018-06-01 04:10:43.171171|2018-06-01 04:10:43.171171
NCT00289016|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|2015-11-12||2015-11-12|2006-02-08|2006-02-09|Estimate|2015-11-12|2015-12-18|Estimate||||2015-11-12|2015-12-18|Estimate|December 2005||2005-12-31|November 2015|2015-11-30|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma|A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma|Completed||Phase 2|50|Actual|BioVex Limited||1|||f||||t||||||||||2018-06-01 04:10:43.27856|2018-06-01 04:10:43.27856
NCT00289003|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2007-01-15|2006-02-08|2006-02-09|Estimate|||||||2007-01-15|2007-01-17|Estimate|October 2003||2003-10-31|May 2006|2006-05-31|July 2006||2006-07-31|||||Interventional|||The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients|An Exploratory, Randomised, Parallel Group Study, Comparing the Protective Effect of Soluble Beta-1,3/1,6-Glucan or Placebo in Oral Mucositis in Head and Neck Cancer Patients Receiving Radiation Therapy or Chemoradiotherapy|Completed||Phase 2|40||Biotec Pharmacon ASA|||||f||||||||||||||2018-06-01 04:10:43.58991|2018-06-01 04:10:43.58991
NCT00288990|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2007-12-20|2006-02-08|2006-02-09|Estimate|||||||2007-12-20|2007-12-24|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Observational|||A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis|Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response.|Completed|||300|Anticipated|Biogen|||3||f||||f||||||Samples With DNA|"~     whole blood and serum~   "|||2018-06-01 04:10:43.651332|2018-06-01 04:10:43.651332
NCT00288977|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2017-03-14|2006-02-08|2006-02-09|Estimate|||||||2017-03-14|2017-03-16|Actual|September 2000||2000-09-30|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Islet Transplantation in Type 1 Diabetic Recipients of Kidney Transplants|Islet Transplantation in Type 1 Diabetic Recipients of Renal Allografts, Using the Edmonton Protocol|Completed||N/A|8|Actual|Beth Israel Deaconess Medical Center||1|||f||||||||||||No||2018-06-01 04:10:43.742751|2018-06-01 04:10:43.742751
NCT00288964|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2015-12-28|2006-02-08|2006-02-09|Estimate|||||||2015-12-28|2015-12-29|Estimate|November 2005||2005-11-30|December 2015|2015-12-31||||||||Interventional|||Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure|Compassionate Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure - A Clinical Trial|Withdrawn||Phase 3|0|Actual|Alung Technologies||||Sponsor no longer pursuing regulatory approval of investigational device|f||||||||||||||2018-06-01 04:10:43.810491|2018-06-01 04:10:43.810491
NCT00288951|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2012-08-16|2006-02-07|2006-02-09|Estimate|||||||2012-08-16|2012-08-17|Estimate|October 2004||2004-10-31|September 2009|2009-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients||Completed||Phase 3|690|Actual|Alcon Research|||||f||||||||||||||2018-06-01 04:10:43.875522|2018-06-01 04:10:43.875522
NCT00288938|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-08|||2017-06-30|2006-02-07|2006-02-08|Estimate|||||||2017-06-30|2017-07-02|Actual|February 3, 2006||2006-02-03|October 31, 2011|2011-10-31|October 31, 2011||2011-10-31|||||Observational|||Natural History Study of Moles and Suspicious Melanoma|Dermoscopic Diagnosis, Histopathological Correlation, and Cellular Immortalization of Melanocytic Nevi and Primary Cutaneous Melanoma|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:10:43.92384|2018-06-01 04:10:43.92384
NCT00288925|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-05-29|2006-02-06|2006-02-08|Estimate|||||||2009-05-29|2009-06-01|Estimate|September 2005||2005-09-30|May 2009|2009-05-31||||December 2007|Actual|2007-12-31||Interventional|||Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment|Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment|Completed||Phase 1/Phase 2|30||Zeria Pharmaceutical|||||f||||||||||||||2018-06-01 04:10:43.971679|2018-06-01 04:10:43.971679
NCT00288912|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2014-08-01||2015-04-06|2006-02-06|2006-02-08|Estimate|2014-09-04|2014-09-12|Estimate||||2015-04-06|2015-04-24|Estimate|October 2006||2006-10-31|April 2015|2015-04-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|SeMOA|Among n=523 who consented and were randomized 8 were excluded from analyses because subsequent review of VA medical records revealed there was no documentation of radiographic evidence of knee or hip OA and therefore these participants did not meet initial eligibility requirements.|Self-Management of Osteoarthritis|Self-Management of Osteoarthritis: A Tailored, Telephone-based Intervention|Completed||N/A|523|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:10:44.035318|2018-06-01 04:10:44.035318
NCT00288899|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-06-02|2006-02-06|2006-02-08|Estimate|||||||2017-06-02|2017-06-06|Actual|August 7, 2006|Actual|2006-08-07|June 2017|2017-06-30|March 31, 2009|Actual|2009-03-31|March 31, 2009|Actual|2009-03-31||Interventional|||Benefits of 'Repeat Back' Protocols Within A Computer-Based Informed Consent Program|Benefits of 'Repeat Back' Protocols Within A Computer-Based Informed Consent Program|Completed||Phase 1|575|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:10:44.517776|2018-06-01 04:10:44.517776
NCT00288886|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2014-10-17||2015-04-06|2006-02-06|2006-02-08|Estimate|2014-10-28|2014-10-29|Estimate||||2015-04-06|2015-04-24|Estimate|March 2007||2007-03-31|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2009|Actual|2009-06-30||Interventional|||Reinforcement of Abstinence and Continuing Care in Substance Abuse Treatment|Reinforcement of Abstinence and Attendance in Substance Abuse Treatment|Completed||Phase 2|183|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:10:44.622195|2018-06-01 04:10:44.622195
NCT00288873|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2007-07-19|2006-02-06|2006-02-08|Estimate|||||||2007-07-19|2007-07-20|Estimate|February 2006||2006-02-28|July 2007|2007-07-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity|Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:10:44.914974|2018-06-01 04:10:44.914974
NCT00288860|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2014-10-03||2016-03-22|2006-02-07|2006-02-08|Estimate|2016-03-22|2016-04-25|Estimate||||2016-03-22|2016-04-25|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|TCM-PTSD|Veterans entering residential treatment for posttraumatic stress disorder.|Telephone Case Monitoring (TCM) for Veterans With Post-Traumatic Stress Disorder (PTSD)|Telephone Case Monitoring for Veterans With PTSD|Completed||N/A|837|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:10:44.985033|2018-06-01 04:10:44.985033
NCT00288847|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2015-09-21|2006-02-07|2006-02-08|Estimate|||||||2015-09-21|2015-09-22|Estimate|November 2005||2005-11-30|September 2015|2015-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Functional Surface Electromyogram of Knee Extensors in Healthy Humans and Patients With Patella-dislocation.|Functional Surface Electromyogram of Knee Extensors in Healthy Humans and Patients With Patella-dislocation.|Completed|||15|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 04:10:45.290603|2018-06-01 04:10:45.290603
NCT00288821|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2012-02-08|2006-02-07|2006-02-08|Estimate|||||||2012-02-08|2012-02-09|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Diagnostic Imaging of Lymph Nodes in Gynaecologic Oncology|The Diagnostic Accuracy of Non-invasive Lymph Node Imaging in Gynaecologic Malignancies|Completed|||84|Actual|UMC Utrecht|||||f||||||||||||||2018-06-01 04:10:45.407813|2018-06-01 04:10:45.407813
NCT00288808|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2015-04-24|2006-02-06|2006-02-08|Estimate|||||||2015-04-24|2015-04-27|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.|Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements for Pediatric Patients on Anticoagulation Therapy.|Terminated||Phase 1|200|Anticipated|University of Rochester||||insufficient enrollment|f||||||||||||||2018-06-01 04:10:45.457785|2018-06-01 04:10:45.457785
NCT00288795|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2011-11-30|2006-02-07|2006-02-08|Estimate|||||||2011-11-30|2011-12-01|Estimate|January 2006||2006-01-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Randomized Study of Polarity or Massage Therapy to Reduce Fatigue in Breast Cancer Patients During Radiation Therapy|A Randomized Study of Polarity or Massage Therapy to Reduce Fatigue in Breast Cancer Patients During Radiation Therapy|Completed||Phase 1/Phase 2|45|Actual|University of Rochester||3|||f||||||||||||||2018-06-01 04:10:45.514089|2018-06-01 04:10:45.514089
NCT00288782|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2007-04-18|2006-02-07|2006-02-08|Estimate|||||||2007-04-18|2007-04-19|Estimate|February 2006||2006-02-28|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||PET Neuroimaging of [11C]Mirtazapine|Receptor Occupancy Determined by PET Neuroimaging of [11C]Mirtazapine in Healthy Humans|Completed||Phase 4|24||University of Aarhus|||||f||||f||||||||||2018-06-01 04:10:45.568768|2018-06-01 04:10:45.568768
NCT00288769|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2009-01-22|2006-02-07|2006-02-08|Estimate|||||||2009-01-22|2009-01-23|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis||Completed||N/A|||Soroka University Medical Center||1|||f||||||||||||||2018-06-01 04:10:45.618669|2018-06-01 04:10:45.618669
NCT00288756|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-09-11|2006-02-07|2006-02-08|Estimate|||||||2006-09-11|2006-09-13|Estimate|July 2006||2006-07-31|September 2006|2006-09-30|August 2006||2006-08-31|||||Observational|||The V-Tachogram:Decreasing Ventricular Arrythmias When Injecting Contrast in the Left Ventricle||Unknown status|Active, not recruiting||156||Trillium Health Centre|||||f||||||||||||||2018-06-01 04:10:45.689476|2018-06-01 04:10:45.689476
NCT00288743|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2007-12-19|2006-02-07|2006-02-08|Estimate|||||||2007-12-19|2007-12-28|Estimate|September 2002||2002-09-30|December 2007|2007-12-31|December 2002|Actual|2002-12-31|||||Interventional|||Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study|Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study|Completed||Phase 2|30||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:10:45.733927|2018-06-01 04:10:45.733927
NCT00288730|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2011-06-09|2006-02-03|2006-02-08|Estimate|||||||2011-06-09|2011-06-10|Estimate|October 1996||1996-10-31|June 2011|2011-06-30|August 1997|Actual|1997-08-31|||||Interventional|||A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest|A Randomized, Double-Blinded, Placebo-Controlled Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in Subjects With Decompensated CHF|Completed||Phase 3|127|Actual|Scios, Inc.||1|||f||||||||||||||2018-06-01 04:10:45.776442|2018-06-01 04:10:45.776442
NCT00288717|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2007-01-09|2006-02-07|2006-02-08|Estimate|||||||2007-01-09|2007-01-11|Estimate|February 2006||2006-02-28|January 2007|2007-01-31|September 2007||2007-09-30|||||Interventional|||Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients|A Randomized, Comparative Study of the Effects of Candesartan and Telmisartan on the Home Blood Pressure, Glucose and Lipid Metabolism in the Hypertensive Patients With the Accumulation of Visceral Fat by the Central Registration System|Unknown status|Recruiting|N/A|300||Saitama Medical University|||||f||||||||||||||2018-06-01 04:10:45.83053|2018-06-01 04:10:45.83053
NCT00288704|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2009-09-30||2011-12-01|2006-02-06|2006-02-08|Estimate|2009-09-30|2009-11-13|Estimate||||2011-12-01|2011-12-06|Estimate|December 2005||2005-12-31|December 2011|2011-12-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)|IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs|Completed||Phase 3|104|Actual|Regeneron Pharmaceuticals|Cryopyrin Associated Periodic Syndrome (CAPS) is a rare disease with only a few hundred cases in the US.|3|||f||||t||||||||||2018-06-01 04:10:46.029191|2018-06-01 04:10:46.029191
NCT00288691|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2014-12-29|2006-02-07|2006-02-08|Estimate|||||||2014-12-29|2014-12-30|Estimate|November 2001||2001-11-30|December 2014|2014-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Menorrhagia Study in Women With Treatment-resistant Menorrhagia|A Multi-center, Double-blind, Placebo-controlled, Randomized, Parallel Group Study to Evaluate the Effects of Different Doses of SH T 00127B in Women With Treatment-resistant Menorrhagia Aged 30 to 55 Years After Daily Oral Administration of Multiple Doses for 35 up to 50 Days|Completed||Phase 2|26|Actual|Bayer||4|||f||||f||||||||||2018-06-01 04:10:46.852714|2018-06-01 04:10:46.852714
NCT00288678|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2010-01-26|2006-02-07|2006-02-08|Estimate|||||||2010-01-26|2010-01-27|Estimate|July 2003||2003-07-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|DMIDS||A Prospective Study on Diabetes Management Through an Integrated Delivery System|A Prospective Study on Diabetes Management Through an Integrated Delivery System|Completed||Phase 3|1222|Actual|National Health Research Institutes, Taiwan|||||f||||f||||||||||2018-06-01 04:10:46.932192|2018-06-01 04:10:46.932192
NCT00288665|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2006-02-06|2006-02-06|2006-02-08|Estimate|||||||2006-02-06|2006-02-08|Estimate|April 2004||2004-04-30|February 2006|2006-02-28|December 2005||2005-12-31|||||Interventional|||Thrombectomy and Improvement of Left Ventricular Function in AMI|Thrombectomy Before Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Improves Left Ventricular Function at 3 Months|Completed||Phase 4|50||R&D Cardiologie|||||f||||||||||||||2018-06-01 04:10:47.017551|2018-06-01 04:10:47.017551
NCT00288652|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2011-06-07|2006-02-07|2006-02-08|Estimate|||||||2011-06-07|2011-06-08|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|February 2007|Actual|2007-02-28|||||Interventional|||[S,S]-Reboxetine Dose-Range Finding Trial|[S,S]-Reboxetine Dose-Range Finding Trial: A 16-Week, Randomized, Double-Blind, Placebo And An Active Comparator Controlled, Multi-Center Trial Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN)|Completed||Phase 2|280||Pfizer|||||||||||||||||||2018-06-01 04:10:47.112228|2018-06-01 04:10:47.112228
NCT00288288|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2012-09-24|2006-02-03|2006-02-07|Estimate|||||||2012-09-24|2012-09-25|Estimate|March 2006||2006-03-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|||||Observational|||Prospective Registry of Epicardial LV Leads Placed During Cardiac Surgery Procedures|Prospective Registry of Epicardial LV Leads Placed During Cardiac Surgery Procedures|Completed|||40|Actual|University of Kansas Medical Center|||2||f||||f||||||||||2018-06-01 04:10:52.132069|2018-06-01 04:10:52.132069
NCT00288639|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2008-12-16||2009-08-28|2006-02-07|2006-02-08|Estimate|2009-05-13|2009-07-08|Estimate||||2009-08-28|2009-09-02|Estimate|December 2005||2005-12-31|August 2009|2009-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|LEADER||Lyrica (Pregabalin) Administered as an Add-on Therapy for Partial Seizures (LEADER).|Lyrica (Pregabalin) Administered As An Add-On Therapy For Partial Seizures (LEADER) An Open-Label, Multicenter Add-On Therapy Trial|Completed||Phase 4|98|Actual|Pfizer|||||f||||f||||||||||2018-06-01 04:10:47.298345|2018-06-01 04:10:47.298345
NCT00288626|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2016-12-06||2017-08-21|2006-02-07|2006-02-08|Estimate|2017-02-17|2017-04-04|Actual||||2017-08-21|2017-09-19|Actual|July 2006||2006-07-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Participants who received High-Dose Immunosuppressive Therapy (HDIT)and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT)|High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study|A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis|Completed||Phase 2|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|24 of the 25 planned transplants occurred. One of the enrolled participants developed adverse events that caused withdrawal from the study before the planned transplant.|1|||f||||t||||||||Yes|Data access is provided to the public in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers.|2018-06-01 04:10:47.656505|2018-06-01 04:10:47.656505
NCT00288613|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2014-07-22|2006-02-06|2006-02-08|Estimate|||||||2014-07-22|2014-07-24|Estimate|January 2006||2006-01-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study|FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study|Completed|||501|Actual|NxStage Medical|||||f||||t||||||||||2018-06-01 04:10:49.093515|2018-06-01 04:10:49.093515
NCT00288600|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2015-07-20||2015-12-02|2006-02-06|2006-02-08|Estimate|2015-12-02|2016-01-08|Estimate||||2015-12-02|2016-01-08|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy of High-dose Intravenous Immunoglobulin Therapy for Hyperbilirubinemia Due Rh Hemolytic Disease|Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants|Completed||Phase 4|92|Actual|Oswaldo Cruz Foundation|We calculated the sample size using a expected rate of 30% reduction in exchange using incidence of exchange transfusion at our department and data from a meta-analysis (relative risk, 0.21; 95% CI 0.10-0.45).|2|||f||||t||||||||||2018-06-01 04:10:49.222616|2018-06-01 04:10:49.222616
NCT00288587|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2012-05-16||2012-05-16|2006-02-07|2006-02-08|Estimate|2012-05-16|2012-06-19|Estimate||||2012-05-16|2012-06-19|Estimate|October 2003||2003-10-31|May 2012|2012-05-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)|CP0007: Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)|Completed||Phase 4|36|Actual|NxStage Medical||2|||f||||||||||||||2018-06-01 04:10:49.456002|2018-06-01 04:10:49.456002
NCT00288574|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2015-09-08||2017-12-11|2006-02-06|2006-02-08|Estimate|2016-05-26|2016-07-11|Estimate||||2017-12-11|2017-12-13|Actual|January 2000||2000-01-31|December 2017|2017-12-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa|Fluoxetine After Weight Restoration in Anorexia Nervosa|Completed||Phase 4|93|Actual|New York State Psychiatric Institute||2|||f||||||||||||||2018-06-01 04:10:49.845562|2018-06-01 04:10:49.845562
NCT00288561|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2008-06-18|2006-02-07|2006-02-08|Estimate|||||||2008-06-18|2008-06-19|Estimate|November 2004||2004-11-30|June 2008|2008-06-30|July 2007|Actual|2007-07-31|||||Interventional|||Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration|Open-Label, Multicenter, Phase II Study Assessing the Safety of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Occult or Predominately Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (ARMD)|Completed||Phase 2|||Novartis|||||f||||||||||||||2018-06-01 04:10:50.279815|2018-06-01 04:10:50.279815
NCT00288548|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-02-17|2006-02-07|2006-02-08|Estimate|||||||2006-02-17|2006-02-20|Estimate|February 2006||2006-02-28|February 2006|2006-02-28||||||||Interventional|||Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)|Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD|Unknown status|Recruiting|Phase 4|45||Martini Hospital Groningen|||||f||||||||||||||2018-06-01 04:10:50.342192|2018-06-01 04:10:50.342192
NCT00288535|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2007-09-17|2006-02-07|2006-02-08|Estimate|||||||2007-09-17|2007-09-18|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|February 2007||2007-02-28|||||Interventional|||Treatment of Bifurcated Coronary Lesions With Cypher™-Stent|Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions|Unknown status|Recruiting|Phase 4|200|Anticipated|Heart Center Bad Krozingen|||||f||||||||||||||2018-06-01 04:10:50.409988|2018-06-01 04:10:50.409988
NCT00288522|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2015-09-29|2006-02-07|2006-02-08|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment|A Phase II, Single Centre, Randomized, Double-blind, Parallel and Placebo Controlled, Pilot Study to Evaluate the Efficacy and Safety of Somatuline Autogel 60mg in Patients With Active Thyroid-associated Ophthalmopathy of Moderate Intensity.|Terminated||Phase 2|20||Ipsen|||||f||||||||||||||2018-06-01 04:10:50.486285|2018-06-01 04:10:50.486285
NCT00288509|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|2010-01-06||2010-06-17|2006-02-07|2006-02-08|Estimate|2010-03-18|2010-04-02|Estimate||||2010-06-17|2010-06-22|Estimate|February 2006||2006-02-28|June 2010|2010-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia|A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia|Completed||Phase 3|108|Actual|Ipsen|||||f||||f||||||||||2018-06-01 04:10:50.564641|2018-06-01 04:10:50.564641
NCT00288496|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-02-07|2006-02-07|2006-02-08|Estimate|||||||2006-02-07|2006-02-08|Estimate|April 1998||1998-04-30|April 2000|2000-04-30|February 2004||2004-02-29|||||Interventional|||Mechanical Bowel Preparation for Elective Colorectal Surgery|Mechanical Bowel Preparation for Elective Colorectal Surgery. A Multicenter Randomized Study|Completed||N/A|1400||Ikazia Hospital, Rotterdam|||||f||||||||||||||2018-06-01 04:10:50.917022|2018-06-01 04:10:50.917022
NCT00288483|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2006-07-20|2006-02-06|2006-02-08|Estimate|||||||2006-07-20|2006-07-21|Estimate|September 2000||2000-09-30|November 2005|2005-11-30|July 2001||2001-07-31|||||Interventional|||Cholesterol-Lowering Effects of Policosanol|Placebo-Controlled, Randomised, Double-Blind, Multi-Centre Clinical Trial on Dose-Dependent Cholesterol-Lowering Effects of Policosanol in Patients With Hypercholesterolaemia With 10 to 80 Mg Policosanol for 12 Weeks|Terminated||Phase 3|||Drug Commission of the German Medical Association|||||f||||||||||||||2018-06-01 04:10:50.9816|2018-06-01 04:10:50.9816
NCT00288470|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2015-03-17|2006-02-07|2006-02-08|Estimate|||||||2015-03-17|2015-03-18|Estimate|June 2002||2002-06-30|March 2015|2015-03-31|August 2003||2003-08-31|||||Interventional|||A Double-blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast.||Completed||N/A|||Sanofi|||||||||||||||||||2018-06-01 04:10:51.045942|2018-06-01 04:10:51.045942
NCT00288457|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-12-23|2006-02-06|2006-02-08|Estimate|||||||2013-12-23|2013-12-24|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|October 2006|Actual|2006-10-31|||||Observational|||Ureteral Stent Length and Patient Symptoms||Terminated|||1|Actual|Emory University||||Because no staff to consent or enroll subjects|f||||||||||||||2018-06-01 04:10:51.103551|2018-06-01 04:10:51.103551
NCT00288444|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2012-12-17|2006-02-06|2006-02-08|Estimate|||||||2012-12-17|2012-12-18|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|March 2009|Actual|2009-03-31|May 2008|Actual|2008-05-31||Interventional|||Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer|Defining the Interaction of Docetaxel and Lonafarnib in Patients With Advanced Malignancies|Terminated||Phase 1|38|Actual|Emory University||4|||f||||||||||||||2018-06-01 04:10:51.170705|2018-06-01 04:10:51.170705
NCT00288431|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2015-07-21|2006-02-06|2006-02-08|Estimate|||||||2015-07-21|2015-07-22|Estimate|February 2006||2006-02-28|July 2015|2015-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)|A Phase 1B, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin|Completed||Phase 1|37|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 04:10:51.257846|2018-06-01 04:10:51.257846
NCT00288418|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-01-22|2006-02-06|2006-02-08|Estimate|||||||2013-01-22|2013-01-23|Estimate|December 2005||2005-12-31|January 2013|2013-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization|A Controlled, Randomized, Single-Blind, Multi-Center Pivotal Clinical Study Using Angiotech CVC to Prevent Bacterial Colonization on Short-Term Central Venous Catheters|Completed||Phase 3|960|Actual|Angiotech Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:10:51.335407|2018-06-01 04:10:51.335407
NCT00288405|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2012-04-30|2006-02-06|2006-02-08|Estimate|||||||2012-04-30|2012-05-02|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|December 2005|Actual|2005-12-31|||||Interventional|||The ENTERPRISE Study - Study of the Enterprise Self-Expanding Stent System|Cordis Neurovascular Feasibility Study of the Enterprise Self-Expanding Stent System to Facilitate Endovascular Coil Embolization of Wide- Neck Saccular Intracranial Artery Aneurysms|Completed||Phase 1|31|Actual|Codman & Shurtleff|||||f||||t||||||||||2018-06-01 04:10:51.442084|2018-06-01 04:10:51.442084
NCT00288392|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2006-10-17|2006-02-07|2006-02-08|Estimate|||||||2006-10-17|2006-10-18|Estimate|June 2005||2005-06-30|May 2006|2006-05-31|September 2006||2006-09-30|||||Interventional|||Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients|A Double-Blind Therapeutic Exploratory Clinical Study to Evaluate the Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients|Completed||Phase 2|60||Biotec Pharmacon ASA|||||f||||||||||||||2018-06-01 04:10:51.515124|2018-06-01 04:10:51.515124
NCT00288379|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-07|||2011-01-21|2006-02-07|2006-02-08|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2004||2004-10-31|January 2011|2011-01-31|May 2006|Actual|2006-05-31|||||Interventional|||SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma|A Comparative, Placebo-controlled, Double Blind, Double Dummy, Cross-over, Single Centre, Phase IIIb Study Between Formoterol Alone (Oxis® Turbuhaler® 4.5 µg) and the Fixed Combination of Formoterol and Budesonide (Symbicort® Turbuhaler®160/4.5 µg) on Airway Responsiveness and Airway Inflammation Induced by Repeated Low-dose Allergen Challenge in Allergic Patients With Mild Asthma|Completed||Phase 3|16||AstraZeneca|||||f||||||||||||||2018-06-01 04:10:51.590113|2018-06-01 04:10:51.590113
NCT00288366|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-01-23|2006-02-06|2006-02-07|Estimate|||||||2009-01-23|2009-01-27|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome|Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome|Completed||N/A|250|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:10:51.669957|2018-06-01 04:10:51.669957
NCT00288353|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-05-23|2006-02-06|2006-02-07|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2006||2006-01-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes|Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes|Terminated||Phase 3|250|Actual|Northwestern University||2||unable to secure additional funding|f||||f||||||||||2018-06-01 04:10:51.762101|2018-06-01 04:10:51.762101
NCT00288340|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-04-17|2006-02-06|2006-02-07|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2006||2006-01-31|April 2017|2017-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging|Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging|Completed||N/A|60|Anticipated|Vanderbilt University||1|||f||||f||||||||||2018-06-01 04:10:51.841478|2018-06-01 04:10:51.841478
NCT00288327|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-03-12|2006-02-06|2006-02-07|Estimate|||||||2009-03-12|2009-03-13|Estimate|March 2003||2003-03-31|March 2009|2009-03-31|January 2005|Actual|2005-01-31|December 2004|Actual|2004-12-31||Interventional|||NC Enhanced WISEWOMAN Project|Testing Lifestyle Interventions for CVD Risk Reduction in Older, Underserved Women; Enhanced WISEWOMAN Project|Completed||N/A|258|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 04:10:51.917118|2018-06-01 04:10:51.917118
NCT00288314|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2010-03-16|2006-02-03|2006-02-07|Estimate|||||||2010-03-16|2010-03-17|Estimate|January 2007||2007-01-31|March 2010|2010-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|METRAPI||fMRI in Posttraumatic Stress Disorder (PTSD) During Working Memory Updating|Working Memory Updating in Posttraumatic Stress Disorder (PTSD): Study of Neural Correlates Using fMRI|Completed|||34|Actual|University Hospital, Tours|||2||f||||t||||||||||2018-06-01 04:10:52.002046|2018-06-01 04:10:52.002046
NCT00288301|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2010-06-09|2006-02-06|2006-02-07|Estimate|||||||2010-06-09|2010-06-10|Estimate|February 2005||2005-02-28|June 2010|2010-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||North Carolina WISEWOMAN: Weight-Wise Pilot Study|North Carolina WISEWOMAN Study - Weight-Wise Program|Completed||N/A|151|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 04:10:52.067812|2018-06-01 04:10:52.067812
NCT00288275|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2012-10-04|2006-02-03|2006-02-07|Estimate|||||||2012-10-04|2012-10-05|Estimate|July 2004||2004-07-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|||||Observational|||Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer|A Non-Interventional Prospective Study of the Correlation of the Precision Therapeutics, Inc. Chemoresponse Assay With Progression-Free Survival in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer.|Terminated|||256|Anticipated|Precision Therapeutics|||||f||||||||||Samples With DNA|"~     Leftover tumor cells from the test, pathology slides, and blood samples will be collected and~     stored to look for potential genetic variations related to drug pathway genes to identify~     patterns associated with clinical outcome.~   "|||2018-06-01 04:10:52.208563|2018-06-01 04:10:52.208563
NCT00288262|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2006-02-06|2006-02-06|2006-02-07|Estimate|||||||2006-02-06|2006-02-07|Estimate|June 2004||2004-06-30|October 2005|2005-10-31|February 2005||2005-02-28|||||Interventional|||Melatonin Effects on Luteinizing Hormone|Melatonin Effects on Luteinizing Hormone|Terminated||Phase 1/Phase 2|20||Scripps Health|||||f||||||||||||||2018-06-01 04:10:52.305308|2018-06-01 04:10:52.305308
NCT00288249|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2014-11-27|2006-02-06|2006-02-07|Estimate|||||||2014-11-27|2014-12-02|Estimate|December 2005||2005-12-31|November 2014|2014-11-30|January 2009|Actual|2009-01-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer|Prospective, Multicenter, Randomized, Independent-group, Open-label Phase II Study to Investigate the Efficacy, Safety and Tolerability of 4 Regimen With 3 Doses of ZK 219477 (16 and 12 mg/m2 Body Surface Area as 3-hour Infusion or 22 mg/m2 Body Surface Area as 30-minute or 3-hour Infusion) in Patients With Metastatic Breast Cancer|Completed||Phase 2|82|Actual|Bayer||4|||f||||f||||||||||2018-06-01 04:10:52.458979|2018-06-01 04:10:52.458979
NCT00288236|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-04-06|2006-02-06|2006-02-07|Estimate|||||||2009-04-06|2009-04-07|Estimate|January 2006||2006-01-31|April 2009|2009-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed-Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/Day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled With Insulin|Completed||Phase 3|368|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:10:52.577532|2018-06-01 04:10:52.577532
NCT00288223|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-12-08|2006-02-06|2006-02-07|Estimate|||||||2009-12-08|2009-12-09|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Telithromycin in Acute Exacerbation of Chronic Bronchitis|Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults|Terminated||Phase 4|54|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:10:52.658247|2018-06-01 04:10:52.658247
NCT00288210|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2006-02-09|2006-02-06|2006-02-07|Estimate|||||||2006-02-09|2006-02-10|Estimate|March 2003||2003-03-31|February 2006|2006-02-28|March 2006||2006-03-31|||||Interventional|||Sirolimus Eluting Stenting in Acute Myocardial Infarction|Randomized Study Of Sirolimus Eluting Stent Vs Conventional Stent In Acute Myocardial Infarction Acronym SESAMI|Unknown status|Active, not recruiting|Phase 4|||San Camillo Hospital, Rome|||||f||||||||||||||2018-06-01 04:10:52.721838|2018-06-01 04:10:52.721838
NCT00288197|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2008-06-10|2006-02-06|2006-02-07|Estimate|||||||2008-06-10|2008-06-12|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections|An Open, Prospective, Uncontrolled, Multi-Center Study To Evaluate The Efficacy And Safety Of Voriconazole In Chinese Subjects With Proven Or Probable Serious Invasive Fungal Infections|Completed||Phase 4|77|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:10:52.788366|2018-06-01 04:10:52.788366
NCT00288184|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-09-12|2006-02-06|2006-02-07|Estimate|||||||2017-09-12|2017-09-14|Actual|September 2004|Actual|2004-09-30|September 2017|2017-09-30|August 2007|Actual|2007-08-31|March 2007|Actual|2007-03-31||Interventional|||Uric Acid in Essential Hypertension in Children|Randomized Double-blinded, Placebo-controlled, Cross-over Trial of Allopurinol for the Treatment of Newly Diagnosed Essential Hypertension in Adolescents|Completed||Phase 2|30|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 04:10:52.872371|2018-06-01 04:10:52.872371
NCT00288171|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-09-12|2006-02-06|2006-02-07|Estimate|||||||2017-09-12|2017-09-13|Actual|February 2006||2006-02-28|September 2017|2017-09-30|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Allopurinol for Renal Transplant Associated Hypertension in Children|Randomized Double-blinded, Placebo-controlled, Cross-over Trial of Allopurinol for the Treatment of Post-renal-transplant Hypertension in Children|Withdrawn||Phase 1/Phase 2|0|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||insufficient number of eligible subjects|f||||f|t|f||||||||2018-06-01 04:10:52.954177|2018-06-01 04:10:52.954177
NCT00288158|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-09-12|2006-02-06|2006-02-07|Estimate|||||||2017-09-12|2017-09-14|Actual|September 2008|Actual|2008-09-30|September 2017|2017-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Primary Prevention of Hypertension in Obese Adolescents||Completed||Phase 2|60|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||f|t|f||||||||2018-06-01 04:10:53.05236|2018-06-01 04:10:53.05236
NCT00288145|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-04-30|2006-02-06|2006-02-07|Estimate|||||||2013-04-30|2013-05-01|Estimate|June 2006||2006-06-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Statewide (Rhode Island and Neighboring States) Partnerships for Worksite Weight Management|Statewide Partnerships for Worksite Weight Management|Completed||Phase 2|1700|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t||||||||||2018-06-01 04:10:53.135963|2018-06-01 04:10:53.135963
NCT00288132|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2018-02-28|2006-02-06|2006-02-07|Estimate|||||||2018-02-28|2018-03-02|Actual|September 2005|Actual|2005-09-30|February 2018|2018-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|DTC||The Diabetes TeleCare Study|Bridging Barriers to Diabetes Care With Telemedicine: The Diabetes TeleCare Study (DTC)|Completed||N/A|165|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|f|f||||||||2018-06-01 04:10:53.212801|2018-06-01 04:10:53.212801
NCT00288119|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-11-10|2006-02-06|2006-02-07|Estimate|||||||2017-11-10|2017-11-14|Actual|October 2005||2005-10-31|November 2017|2017-11-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|FBE||Familial Barrett's Esophagus|Familial Barrett's Esophagus|Recruiting|||1000|Anticipated|University Hospitals Cleveland Medical Center|||||f||||t||||||Samples With DNA|"~     Blood Samples are required to be sent to our NIH approved Biorepository and this repository~     is designed to help all researchers performing studies on the genetic basis of diseases.~   "|||2018-06-01 04:10:53.300689|2018-06-01 04:10:53.300689
NCT00288106|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2015-09-28|2006-02-06|2006-02-07|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2005||2005-09-30|September 2015|2015-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT|Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed With Prostate Cancer|Terminated|||961|Actual|Southwest Oncology Group|||1|Poor accrual resulted in lack of feasibility to evaluate endpoints.|f||||t||||||||||2018-06-01 04:10:53.438339|2018-06-01 04:10:53.438339
NCT00288093|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-08-17|2006-02-06|2006-02-07|Estimate|||||||2017-08-17|2017-08-18|Actual|December 20, 2006|Actual|2006-12-20|August 2017|2017-08-31|December 28, 2012|Actual|2012-12-28|December 28, 2012|Actual|2012-12-28||Interventional|||3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase I Study of Triapine® in Combination With Radiation Therapy in Locally Advanced Pancreas Cancer|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:10:53.576389|2018-06-01 04:10:53.576389
NCT00288080|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2016-11-28||2018-03-14|2006-02-06|2006-02-07|Estimate|2016-11-28|2017-01-23|Estimate||||2018-03-14|2018-04-12|Actual|December 2005||2005-12-31|March 2018|2018-03-31||||April 2014|Actual|2014-04-30||Interventional||Eligible patients who have not withdrawn consent.|Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer|A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer|Active, not recruiting||Phase 3|612|Actual|Radiation Therapy Oncology Group|Due to insufficient number of events, local control analysis was not conducted.|2|||f||||t||||||||||2018-06-01 04:10:53.726744|2018-06-01 04:10:53.726744
NCT00288067|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2014-01-08||2014-09-30|2006-02-06|2006-02-07|Estimate|2014-09-30|2014-10-06|Estimate||||2014-09-30|2014-10-06|Estimate|October 2005||2005-10-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma|A Phase I-II Trial of Fenretinide (4-HPR) + Rituximab in Patients With B-cell Lymphoma|Terminated||Phase 1/Phase 2|32|Actual|National Cancer Institute (NCI)||1||NCI stopped supplying fenretinide in November of 2012.|f||||t||||||||||2018-06-01 04:10:55.066868|2018-06-01 04:10:55.066868
NCT00288054|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2012-11-26||2013-01-02|2006-02-06|2006-02-07|Estimate|2012-11-26|2012-12-25|Estimate||||2013-01-02|2013-01-04|Estimate|April 2006||2006-04-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer|Terminated||Phase 1|24|Actual|Southwest Oncology Group||2||Study closed early due to poor accrual.|f||||t||||||||||2018-06-01 04:10:55.624651|2018-06-01 04:10:55.624651
NCT00288041|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-03-04|2006-02-06|2006-02-07|Estimate|||||||2013-03-04|2013-03-05|Estimate|October 2005||2005-10-31|March 2013|2013-03-31||||September 2007|Actual|2007-09-30||Interventional|||Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma|A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for the Treatment of Metastatic Melanoma|Completed||Phase 2|36|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:10:56.124579|2018-06-01 04:10:56.124579
NCT00288028|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-11-18|2006-02-06|2006-02-07|Estimate|||||||2013-11-18|2013-11-19|Estimate|July 2005||2005-07-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|November 2010|Actual|2010-11-30||Interventional|||Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant|A Phase I Study of Bortezomib During Maintenance Phase After High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma|Completed||Phase 1|15|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||f||||||||||2018-06-01 04:10:56.227407|2018-06-01 04:10:56.227407
NCT00288015|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-08-09|2006-02-06|2006-02-07|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2005||2005-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Bevacizumab in Treating Patients With Angiosarcoma|An Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma|Active, not recruiting||Phase 2|30|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 04:10:56.307145|2018-06-01 04:10:56.307145
NCT00288002|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-08-23|2006-02-06|2006-02-07|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2005||2005-01-31|July 2009|2009-07-31||||||||Interventional|||Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer|A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer|Completed||Phase 3|1500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:10:56.391083|2018-06-01 04:10:56.391083
NCT00287989|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2010-08-05|2006-02-06|2006-02-07|Estimate|||||||2010-08-05|2010-08-09|Estimate|November 2004||2004-11-30|August 2010|2010-08-31||||August 2007|Actual|2007-08-31||Interventional|||Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Randomized Phase II Trial Comparing Two Doses of Pulsed Erlotinib Prechemotherapy (PEP-C) in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Completed||Phase 2|58|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||||||||||||||||2018-06-01 04:10:56.454125|2018-06-01 04:10:56.454125
NCT00287976|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-09-16|2006-02-06|2006-02-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2003||2003-04-30|June 2009|2009-06-30||||December 2008|Anticipated|2008-12-31||Interventional|||Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma|Irinotecan Single-Drug Treatment For Children With Refractory or Recurrent Hepatoblastoma|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:10:56.520392|2018-06-01 04:10:56.520392
NCT00287963|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2018-05-14|2006-02-06|2006-02-07|Estimate|||||||2018-05-14|2018-05-17|Actual|February 2004||2004-02-29|May 2018|2018-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer|A Phase I Study of Topotecan in Combination With Vinorelbine in Recurrent Lung Cancer|Completed||Phase 1|18|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-06-01 04:10:56.60893|2018-06-01 04:10:56.60893
NCT00287950|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-09-16|2006-02-06|2006-02-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 1992||1992-09-30|December 2006|2006-12-31||||||||Interventional|||Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma|Protocol for Infants With Neuroblastoma Diagnosed Under the Age of One Year|Unknown status|Active, not recruiting|N/A|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:10:56.703033|2018-06-01 04:10:56.703033
NCT00286650|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2006-02-02|2006-02-02|2006-02-03|Estimate|||||||2006-02-02|2006-02-03|Estimate|May 2005||2005-05-31|June 2004|2004-06-30|October 2005||2005-10-31|||||Interventional|||Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief|Comparison of Two Different Doses of Paracetamol for Post-Operative Pain Relief|Completed||Phase 4|18||University of Otago|||||f||||||||||||||2018-06-01 04:11:13.285642|2018-06-01 04:11:13.285642
NCT00287937|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-02-06|2006-02-06|2006-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2005||2005-07-31|February 2013|2013-02-28||||June 2007|Actual|2007-06-30||Interventional|||Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors|Phase I Study Of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) in Combination With Paclitaxel /Carboplatin for Advanced and Refractory Solid Malignancies|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:10:56.804669|2018-06-01 04:10:56.804669
NCT00287924|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-09-16|2006-02-06|2006-02-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2005||2005-03-31|June 2009|2009-06-30||||March 2010|Anticipated|2010-03-31||Interventional|||High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma|Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma|Unknown status|Active, not recruiting|Phase 2|29|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:10:56.894849|2018-06-01 04:10:56.894849
NCT00287911|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-11-29|2006-02-06|2006-02-07|Estimate|||||||2017-11-29|2017-12-02|Actual|February 2005||2005-02-28|November 2017|2017-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer|A Phase I Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer|Completed||Phase 1|18|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 04:10:57.003111|2018-06-01 04:10:57.003111
NCT00287898|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-04-05|2006-02-06|2006-02-07|Estimate|||||||2017-04-05|2017-04-07|Actual|May 2005|Actual|2005-05-31|February 2017|2017-02-28|January 2014|Actual|2014-01-31|December 2012|Actual|2012-12-31||Interventional|||Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation|Telephone-Based Genetic Counseling; An Equivalence Trial|Completed||N/A|669|Actual|Georgetown University||2|||f||||f||||||||||2018-06-01 04:10:57.091439|2018-06-01 04:10:57.091439
NCT00287885|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-11-27|2006-02-06|2006-02-07|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2004||2004-03-31|November 2017|2017-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer|Phase I Study of Metronomic Daily Dosing of Docetaxel in Women With Progressive or Recurrent Gynecologic Cancer|Completed||Phase 1|18|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 04:10:57.340724|2018-06-01 04:10:57.340724
NCT00287872|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2014-06-25||2018-01-31|2006-02-06|2006-02-07|Estimate|2014-06-25|2014-07-23|Estimate||||2018-01-31|2018-03-01|Actual|September 2004||2004-09-30|June 2014|2014-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma|VELCADE (Bortezomib) and Thalidomide in Newly Diagnosed Patients With Multiple Myeloma|Completed||Phase 2|30|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 04:10:57.440459|2018-06-01 04:10:57.440459
NCT00287859|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2017-11-27|2006-02-06|2006-02-07|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2004||2004-08-31|November 2017|2017-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|Phase I Study of Weekly Topotecan in Women With Progressive or Recurrent Ovarian Cancer and a Poor Performance Status|Terminated||Phase 1|5|Actual|Masonic Cancer Center, University of Minnesota||1||Withdrawn due to low accrual|f||||t||||||||||2018-06-01 04:10:57.65437|2018-06-01 04:10:57.65437
NCT00287846|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2016-08-29|2006-02-06|2006-02-07|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2004||2004-09-30|August 2016|2016-08-31|June 2010|Actual|2010-06-30|February 2006|Actual|2006-02-28||Interventional|||Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis|Multicentric Phase I/II Study Evaluating the Efficacy and Toxicity of Imatinib in Adult Patients With Aggressive Fibromatosis That Cannot be Treated by Surgery or Curative Radiotherapy|Completed||Phase 1/Phase 2|40|Actual|UNICANCER||1|||f||||f||||||||No|Individual Participant data will not be shared at an individual level.|2018-06-01 04:10:57.744959|2018-06-01 04:10:57.744959
NCT00287833|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2013-05-01|2006-02-06|2006-02-07|Estimate|||||||2013-05-01|2013-05-03|Estimate|January 2006||2006-01-31|May 2013|2013-05-31||||April 2007|Actual|2007-04-30||Interventional|||Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men|Phase I Single Dose Safety and Pharmacokinetic Study of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:10:57.850124|2018-06-01 04:10:57.850124
NCT00287820|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2011-07-22|2006-02-06|2006-02-07|Estimate|||||||2011-07-22|2011-07-25|Estimate|February 2004||2004-02-29|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism|Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism|Completed||Phase 4|46|Anticipated|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-06-01 04:10:57.983025|2018-06-01 04:10:57.983025
NCT00287807|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2011-09-23|2006-02-06|2006-02-07|Estimate|||||||2011-09-23|2011-09-26|Estimate|February 2006||2006-02-28|September 2011|2011-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effect of Self-monitoring of Blood Glucose in Patients With Type 2 Diabetes Mellitus Not Using Insulin|Self-monitoring of Blood Glucose in Patients With Type 2 Diabetes Mellitus Who Are Not Using Insulin. A Randomized Controlled Trial|Completed||Phase 3|60|Anticipated|Medical Research Foundation, The Netherlands|||||f||||||||||||||2018-06-01 04:10:58.0985|2018-06-01 04:10:58.0985
NCT00287794|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-03-13|2006-02-06|2006-02-07|Estimate|||||||2009-03-13|2009-03-16|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Quality of Sleep in Patients With Rheumatoid Arthritis|Study on the Quality of Sleep in Patients With Rheumatoid Arthritis|Unknown status|Recruiting||1000|Anticipated|Kobe University|||||f||||||||||Samples Without DNA|"~     Samples for Western blot for inflammatory cytokines and transcription factors responsible for~     arthritis.~   "|||2018-06-01 04:10:58.167954|2018-06-01 04:10:58.167954
NCT00287781|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2008-01-23|2006-02-06|2006-02-07|Estimate|||||||2008-01-23|2008-01-25|Estimate|January 2002||2002-01-31|January 2008|2008-01-31|April 2006||2006-04-30|||||Interventional|||A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache|A Double Blind Randomized Controlled of Placebo and Nebulized Lidocaine for Migraine Headache|Completed||N/A|150||Kern Medical Center|||||f||||||||||||||2018-06-01 04:10:58.235538|2018-06-01 04:10:58.235538
NCT00287768|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2011-06-27|2006-02-03|2006-02-07|Estimate|||||||2011-06-27|2011-06-28|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|October 2010|Actual|2010-10-31|September 2008|Actual|2008-09-30||Interventional|||Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer|A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer|Completed||Phase 3|628|Anticipated|Japan Clinical Cancer Research Organization||2|||f||||t||||||||||2018-06-01 04:10:58.319206|2018-06-01 04:10:58.319206
NCT00287755|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2011-06-28|2006-02-03|2006-02-07|Estimate|||||||2011-06-28|2011-06-29|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Trial of Chemosensitivity Test|Chemosensitivity Test to Evaluate the Effect of Adjuvant Cancer Chemotherapy (S-1) After Gastric Surgery|Completed||Phase 2|300|Anticipated|Japan Clinical Cancer Research Organization||1|||f||||t||||||||||2018-06-01 04:10:58.550292|2018-06-01 04:10:58.550292
NCT00287742|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2011-05-20|2006-02-03|2006-02-07|Estimate|||||||2011-05-20|2011-05-24|Estimate|March 2002||2002-03-31|November 2010|2010-11-30|March 2003|Actual|2003-03-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease|Double-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease|Terminated||Phase 3|33|Actual|Janssen Pharmaceutical K.K.||||"A decision was made to discontinue the study due to a change in the strategic direction of the~   company."|f||||f||||||||||2018-06-01 04:10:58.681302|2018-06-01 04:10:58.681302
NCT00287729|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2010-06-02|2009-08-25|2017-03-20|2006-02-06|2006-02-07|Estimate|2011-05-12|2011-06-13|Estimate|2009-08-25|2009-08-27|Estimate|2017-03-20|2017-04-17|Actual|April 2006||2006-04-30|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 3|344|Actual|Genentech, Inc.||2|||f||||t||||||||||2018-06-01 04:10:58.768559|2018-06-01 04:10:58.768559
NCT00287716|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2010-06-02|2009-08-25|2017-04-18|2006-02-06|2006-02-07|Estimate|2011-05-12|2011-06-13|Estimate|2009-08-25|2009-08-27|Estimate|2017-04-18|2017-05-22|Actual|July 14, 2006|Actual|2006-07-14|April 2017|2017-04-30|November 10, 2008|Actual|2008-11-10|November 10, 2008|Actual|2008-11-10||Interventional|||Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 3|435|Actual|Genentech, Inc.||3|||f||||t||||||||||2018-06-01 04:10:59.466864|2018-06-01 04:10:59.466864
NCT00287703|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-05-28|2006-02-06|2006-02-07|Estimate|||||||2009-05-28|2009-05-29|Estimate|March 2006||2006-03-31|May 2009|2009-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression|Pulsed Electro Magnetic Fields (PEMF) Treatment in Patients With Treatment-Resistant Major Depression in Ongoing Pharmacological Treatment of Depression|Completed||Phase 3|50|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-06-01 04:11:00.694935|2018-06-01 04:11:00.694935
NCT00287690|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2015-10-21|2006-02-06|2006-02-07|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 1999||1999-10-31|February 2006|2006-02-28|April 2003||2003-04-30|||||Interventional|||Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease|The Effect of Genistein (Supro®) on Coronary Artery Diameter and Blood Flow in Men and Women With Coronary Heart Disease|Completed||Phase 2/Phase 3|26|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 04:11:00.82395|2018-06-01 04:11:00.82395
NCT00287677|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-11-03|2006-02-06|2006-02-07|Estimate|||||||2009-11-03|2009-11-04|Estimate|January 2006||2006-01-31|November 2009|2009-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients|Double Strategy to Induce and Expand the T Cell Repertoire by the Administration of Growth Hormone and Vaccination in HIV-1 Infected Patients|Completed||Phase 4|33|Actual|Germans Trias i Pujol Hospital||4|||f||||f||||||||||2018-06-01 04:11:00.929866|2018-06-01 04:11:00.929866
NCT00287664|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2007-04-10|2006-02-06|2006-02-07|Estimate|||||||2007-04-10|2007-04-11|Estimate|February 2002||2002-02-28|April 2007|2007-04-30|September 2006||2006-09-30|||||Interventional|||Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin|Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study|Suspended||Phase 4|100||Hospital Clinic of Barcelona||||"because in a preliminary analysis we would need 1000 patients per group to achieve~   significative differences in the main end point."|f||||||||||||||2018-06-01 04:11:01.028767|2018-06-01 04:11:01.028767
NCT00287651|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2016-08-08|2006-02-06|2006-02-07|Estimate|||||||2016-08-08|2016-08-10|Estimate|November 2005||2005-11-30|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus|Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy|Terminated||Phase 2/Phase 3|150|Actual|Florida Atlantic University||2||Administrative|f||||t||||||||||2018-06-01 04:11:01.1195|2018-06-01 04:11:01.1195
NCT00287638|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2010-01-21|2006-02-06|2006-02-07|Estimate|||||||2010-01-21|2010-01-22|Estimate|January 2006||2006-01-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Markers in Exhaled Breath Condensate in Obstructive Sleep Apnoea (OSA) Patients|To Assess the Differences in Chemokines and Oxidative Stress Markers in Exhaled Breath Condensate of Obstructive Sleep Apnoea Patients|Completed||N/A|60|Anticipated|Chinese University of Hong Kong||2|||f||||||||||||||2018-06-01 04:11:01.23693|2018-06-01 04:11:01.23693
NCT00287625|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2011-06-22|2006-02-06|2006-02-07|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Early Pulmonary Rehabilitation for Hospitalized Patients With Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|To Study the Effect of Early Pulmonary Rehabilitation on Exacerbations, Hospitalization Rates and Quality of Life in Patients Admitted to Hospital With Acute Exacerbation of Chronic Obstructive Pulmonary Disease.|Completed||N/A|60|Anticipated|Chinese University of Hong Kong||2|||f||||||||||||||2018-06-01 04:11:01.329024|2018-06-01 04:11:01.329024
NCT00287612|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-09-21|2006-02-06|2006-02-07|Estimate|||||||2009-09-21|2009-09-22|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Necessity of Esophageal Dissection During Laparoscopic Fundoplication|Prospective Trial Comparing Utility of Esophageal Crural Dissection During Laparoscopic Fundoplication in Children|Completed||N/A|177|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-06-01 04:11:01.417491|2018-06-01 04:11:01.417491
NCT00287599|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2012-02-07|2006-02-03|2006-02-07|Estimate|||||||2012-02-07|2012-02-08|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|September 2009|Actual|2009-09-30||Observational|||Rapid Identification of Key Pathogens in Wound Infection by Molecular Means|Rapid Identification of Key Pathogens in Wound Infection by Molecular Means|Completed|||400|Actual|Brentwood Biomedical Research Institute|||||f||||f||||||Samples With DNA|"~     Pus and tissue specimens~   "|||2018-06-01 04:11:01.495082|2018-06-01 04:11:01.495082
NCT00287586|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|2017-03-28||2017-05-29|2006-02-06|2006-02-07|Estimate|2017-05-29|2017-06-29|Actual||||2017-05-29|2017-06-29|Actual|September 2004|Actual|2004-09-30|May 2017|2017-05-31|May 12, 2012|Actual|2012-05-12|February 7, 2012|Actual|2012-02-07||Interventional|TEAAM|Intent-to-treat Population included all randomized participants who received at least 1 dose of study drug.|Testosterone Replacement in Older Men and Atherosclerosis Progression|Effects of Testosterone Replacement on Atherosclerosis Progression in Older Men With Low Testosterone Levels|Completed||Phase 4|308|Actual|Brigham and Women's Hospital||2|||f||||t|t|f||||||||2018-06-01 04:11:01.613633|2018-06-01 04:11:01.613633
NCT00287573|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2010-08-05|2006-02-03|2006-02-07|Estimate|||||||2010-08-05|2010-08-06|Estimate|June 2003||2003-06-30|August 2010|2010-08-31|January 2010|Actual|2010-01-31|December 2004|Actual|2004-12-31||Interventional|TAXUS V ISR||Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis|A Prospective, Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis|Completed||Phase 2/Phase 3|488|Actual|Boston Scientific Corporation||2|||f||||||||||||||2018-06-01 04:11:02.27326|2018-06-01 04:11:02.27326
NCT00287560|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2008-02-22|2006-02-06|2006-02-07|Estimate|||||||2008-02-22|2008-02-25|Estimate|August 2003||2003-08-31|February 2008|2008-02-29|February 2005||2005-02-28|||||Interventional|||Effect of a Modified Propofol Preparation on Injection Pain During Induction of Anesthesia in Children|A Comparison of Venous Tolerability and Injection Pain of a Modified Propofol Preparation and Standard Propofol in the Induction of Anesthesia in Children|Completed||Phase 3|64||B. Braun Melsungen AG|||||f||||||||||||||2018-06-01 04:11:02.383628|2018-06-01 04:11:02.383628
NCT00287547|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06||2011-04-11|2011-04-11|2006-02-06|2006-02-07|Estimate||||2011-04-11|2011-04-25|Estimate|2011-04-11|2011-04-25|Estimate|March 1997||1997-03-31|April 2011|2011-04-30|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris|Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris|Completed||Phase 2|144||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:11:02.42338|2018-06-01 04:11:02.42338
NCT00287534|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-06|||2009-06-07|2006-02-06|2006-02-07|Estimate|||||||2009-06-07|2009-06-09|Estimate|November 1996||1996-11-30|June 2009|2009-06-30|September 2004|Actual|2004-09-30|||||Interventional|ARNO-95||Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.|A Prospective, Multi-Centre, Randomised, Open Parallel Group Study to Compare the Effectiveness and Compatibility of ARIMIDEX (ZD 1033) With NOLVADEX After a Prior 2 Years' Treatment With Tamoxifen in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.|Completed||Phase 2|1059|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 04:11:02.589689|2018-06-01 04:11:02.589689
NCT00287521|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2012-03-02|2006-02-03|2006-02-07|Estimate|||||||2012-03-02|2012-03-05|Estimate|November 2005||2005-11-30|March 2012|2012-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension||Completed||Phase 2|87|Actual|Alcon Research||4|||f||||||||||||||2018-06-01 04:11:02.703642|2018-06-01 04:11:02.703642
NCT00287508|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2008-10-16|2006-02-03|2006-02-07|Estimate|||||||2008-10-16|2008-10-17|Estimate|November 2005||2005-11-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Emboshield® and Xact® Post Approval Carotid Stent Trial (The EXACT Study)|Emboshield and Xact Post Approval Carotid Stent Trial Using the Emboshield® BareWire™ Rapid Exchange Embolic Protection System and Xact® Rapid Exchange Carotid Stent System|Completed||Phase 4|1500||Abbott Vascular|||||f||||||||||||||2018-06-01 04:11:02.781229|2018-06-01 04:11:02.781229
NCT00287495|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-04|||2018-05-22|2006-02-03|2006-02-06|Estimate|||||||2018-05-22|2018-05-23|Actual|February 2, 2006||2006-02-02|October 18, 2017|2017-10-18|October 18, 2017|Actual|2017-10-18|September 21, 2012|Actual|2012-09-21||Interventional|||BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma|Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma|Terminated||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 04:11:02.844065|2018-06-01 04:11:02.844065
NCT00287482|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2007-02-08|2006-02-03|2006-02-06|Estimate|||||||2007-02-08|2007-02-12|Estimate|October 2005||2005-10-31|February 2007|2007-02-28|July 2007||2007-07-31|||||Interventional|||Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.|A Pilot Study of the Herbal Remedy Essiac (ESIAK ®) Versus Placebo in Improving the Quality of Life in Women Completing Adjuvant Treatment for Breast or Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers.|Terminated||N/A|20||Women and Infants Hospital of Rhode Island|||||f||||||||||||||2018-06-01 04:11:02.922454|2018-06-01 04:11:02.922454
NCT00287469|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2016-12-27|2006-02-02|2006-02-06|Estimate|||||||2016-12-27|2016-12-28|Estimate|February 2000||2000-02-29|December 2016|2016-12-31|January 2004||2004-01-31|||||Interventional|||A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.|A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal.|Withdrawn||Phase 2|0|Actual|U.S. Army Medical Research and Materiel Command||||IND was inactivated|||||||||||||||2018-06-01 04:11:02.985875|2018-06-01 04:11:02.985875
NCT00287456|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2006-02-02|2006-02-02|2006-02-06|Estimate|||||||2006-02-02|2006-02-06|Estimate||||January 2006|2006-01-31||||||||Interventional|||Use of the Insulin Pump in Cystic Fibrosis Patients With Impaired Glucose Tolerance or CFRD and in Type 1 Diabetes Patients.||Unknown status|Active, not recruiting|N/A|16||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:11:03.064544|2018-06-01 04:11:03.064544
NCT00287443|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2006-02-02|2006-02-02|2006-02-06|Estimate|||||||2006-02-02|2006-02-06|Estimate||||January 2006|2006-01-31||||||||Interventional|||Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis||Unknown status|Active, not recruiting|N/A|48||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:11:03.114508|2018-06-01 04:11:03.114508
NCT00287430|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2006-02-02|2006-02-02|2006-02-06|Estimate|||||||2006-02-02|2006-02-06|Estimate||||January 2006|2006-01-31||||||||Interventional|||Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis||Unknown status|Active, not recruiting|N/A|12||University of Texas Southwestern Medical Center|||||||||||||||||||2018-06-01 04:11:03.164757|2018-06-01 04:11:03.164757
NCT00287417|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-13|2006-02-03|2006-02-06|Estimate|||||||2011-05-13|2011-05-16|Estimate|July 2003||2003-07-31|May 2011|2011-05-31|February 2011|Actual|2011-02-28|||||Observational|||Early Ultrasound and Maternal Biochemical Markers to Evaluate the Risk of Down Syndrome During the First Trimester|Nuchal Translucency Study - PAPP-A|Completed|||20000|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:11:03.215236|2018-06-01 04:11:03.215236
NCT00287404|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2007-12-19|2006-02-03|2006-02-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|September 2006||2006-09-30|||||Observational|||Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes|A Comparison of NMR and Chemical Lipid Analysis in the Fasting and Postprandial State in Patients With Type 2 Diabetes|Completed|||30||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 04:11:03.267489|2018-06-01 04:11:03.267489
NCT00287391|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2007-04-25|2006-02-03|2006-02-06|Estimate|||||||2007-04-25|2007-04-27|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Sleep Disorders and Gastroesophageal Reflux Disease (GERD)|The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia.|Completed||Phase 4|20||University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 04:11:03.316541|2018-06-01 04:11:03.316541
NCT00287378|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2009-06-26|2006-02-03|2006-02-06|Estimate|||||||2009-06-26|2009-06-30|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab|Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab|Terminated||N/A|1|Actual|University of North Carolina, Chapel Hill||1||lack of enrollment|f||||t||||||||||2018-06-01 04:11:04.37853|2018-06-01 04:11:04.37853
NCT00287365|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|2017-02-15||2017-09-12|2006-02-03|2006-02-06|Estimate|2017-05-12|2017-05-15|Actual||||2017-09-12|2017-10-13|Actual|January 2006||2006-01-31|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Glutoz|Analysis population only includes those who could produce sputum after ozone challenge. 2 of the original 25 volunteers did not produce adequate sputum|Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers|Glutathione S Transferase M1 (GSTM1) Genotype Associated Susceptibility to Airway Response to Ozone in Mild Asthmatic Volunteers.|Completed||N/A|25|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-06-01 04:11:04.497975|2018-06-01 04:11:04.497975
NCT00287352|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2011-04-29|2006-02-03|2006-02-06|Estimate|||||||2011-04-29|2011-05-02|Estimate|May 2005||2005-05-31|April 2011|2011-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Amantadine for Weight Stabilization During Olanzapine Treatment|Double Blind Placebo Controlled Investigation of Amantadine for Retarding Weight Gain in First Episode Adlt Psychotic Subjects Beginning Therapy With Olanzapine.|Completed||Phase 1|40|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 04:11:04.720178|2018-06-01 04:11:04.720178
NCT00287339|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|2011-05-11||2012-01-06|2006-02-03|2006-02-06|Estimate|2011-05-11|2011-06-02|Estimate||||2012-01-06|2012-01-10|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||The Utility of Nexium in Chronic Cough and Reflux Disease|Chronic Cough and Reflux Disease: A Randomized, Double-Blinded, Placebo Controlled Trial of High Dose Proton Pump Inhibition|Completed||Phase 4|40|Actual|University of North Carolina, Chapel Hill|This study was performed at a single center, and participants were mostly female and white, which may limit generalizability. The number of subjects in some patient subgroups was small.|2|||f||||f||||||||||2018-06-01 04:11:04.869101|2018-06-01 04:11:04.869101
NCT00287326|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2016-04-15|2006-02-03|2006-02-06|Estimate|||||||2016-04-15|2016-04-19|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone|Comparison of Epidural Bupivacaine-Clonidine With Intravenous Morphine Versus Intravenous Morphine Alone for Post-Operative Pain Relief in Pediatric Patients Undergoing Lower Extremity or Pelvic Osteotomy.|Terminated||Phase 3|40|Anticipated|University of North Carolina, Chapel Hill||||terminated by PI|f||||||||||||||2018-06-01 04:11:05.264265|2018-06-01 04:11:05.264265
NCT00287313|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2010-01-11|2006-02-03|2006-02-06|Estimate|||||||2010-01-11|2010-01-12|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Daily Vitamin K in Patients on Warfarin With Unstable INRs|Use of Daily Vitamin K Supplementation in Patients on Warfarin With a History of Frequent Dose Changes or Variable INRs|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 04:11:05.343047|2018-06-01 04:11:05.343047
NCT00287300|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2006-02-03|2006-02-03|2006-02-06|Estimate|||||||2006-02-03|2006-02-06|Estimate|September 2003||2003-09-30|January 2006|2006-01-31|August 2005||2005-08-31|||||Interventional|||Efficacy and Safety of Azithromycin and Artesunate in Pregnant Women|A Pilot Randomized Controlled Trial of Azithromycin or Artesunate Added to Sulphadoxine Pyrimethamine as Therapy for Malaria in Pregnancy|Completed||N/A|141||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 04:11:05.600249|2018-06-01 04:11:05.600249
NCT00287287|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2017-12-11|2006-02-03|2006-02-06|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2006||2006-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas|Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas|Active, not recruiting||Phase 2|25|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-06-01 04:11:05.736729|2018-06-01 04:11:05.736729
NCT00287274|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2007-12-19|2006-02-03|2006-02-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|April 2004|Actual|2004-04-30|||||Interventional|||Impact of Computerized Physician Order Entry on Medication Prescription Errors in the Intensive Care Unit: a Controlled Cross-Sectional Trial.|Impact of Computerized Physician Order Entry on Medication Prescription Errors in the Intensive Care Unit: a Controlled Cross-Sectional Trial.|Completed||N/A|160||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:05.873677|2018-06-01 04:11:05.873677
NCT00287261|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2014-12-08|2006-02-02|2006-02-06|Estimate|||||||2014-12-08|2014-12-09|Estimate|February 2006||2006-02-28|December 2014|2014-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)|A Prospective Multicentre Phase II Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)|Completed||Phase 2|17|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-06-01 04:11:05.980722|2018-06-01 04:11:05.980722
NCT00287248|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2014-03-06|2006-02-02|2006-02-06|Estimate|||||||2014-03-06|2014-03-07|Estimate|February 2006||2006-02-28|March 2014|2014-03-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain|Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease|Completed||Phase 1|38|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 04:11:06.123105|2018-06-01 04:11:06.123105
NCT00287235|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2017-04-04|2006-02-02|2006-02-06|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2000||2000-09-30|April 2017|2017-04-30|April 2004|Actual|2004-04-30|November 2003|Actual|2003-11-30||Interventional|||Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)|A Prospective, Controlled Study Of The Clinical Efficacy Of Albumin Dialysis Using The Molecular Adsorbent Recirculating System (MARS®) For The Treatment Of Patients With Hepatic Encephalopathy|Completed||N/A|70|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-06-01 04:11:06.256679|2018-06-01 04:11:06.256679
NCT00287222|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|2011-03-22||2011-06-17|2006-02-03|2006-02-06|Estimate|2011-06-17|2011-07-15|Estimate||||2011-06-17|2011-07-15|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma|Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma|Completed||Phase 2|21|Actual|University of Arkansas|Two subjects withdrew consent.|1|||f||||f||||||||||2018-06-01 04:11:06.454511|2018-06-01 04:11:06.454511
NCT00287209|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2006-02-03|2006-02-03|2006-02-06|Estimate|||||||2006-02-03|2006-02-06|Estimate|January 2004||2004-01-31|February 2006|2006-02-28|August 2005||2005-08-31|||||Interventional|||Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)|Reduction of Atrial Fibrillation Study in Patients Undergoing Coronary Artery Bypass Grafting. (RASCABG 1 Study)|Completed||Phase 4|250||University of Aarhus|||||f||||||||||||||2018-06-01 04:11:06.694659|2018-06-01 04:11:06.694659
NCT00287196|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2013-06-23|2006-02-03|2006-02-06|Estimate|||||||2013-06-23|2013-06-25|Estimate|March 2002||2002-03-31|September 2009|2009-09-30|December 2011|Actual|2011-12-31|November 2008|Actual|2008-11-30||Interventional|||Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes|Randomised Clinical Trial of Surgery Versus Surgery Plus Adjuvant Radiotherapy for Regional Control in Patients With Completely Resected Macroscopic Nodal Metastatic Melanoma|Completed||Phase 3|250|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||f||||||||||2018-06-01 04:11:06.79313|2018-06-01 04:11:06.79313
NCT00287183|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2009-09-30|2006-02-02|2006-02-06|Estimate|||||||2009-09-30|2009-10-01|Estimate|February 2006||2006-02-28|September 2009|2009-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria|Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multicenter Study In Patients With Type 2 Diabetes And Persistent Albuminuria To Evaluate The Safety And Efficacy Of A Six Month Regimen Of Orally-Administered TTP488|Completed||Phase 2|110|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:11:06.911359|2018-06-01 04:11:06.911359
NCT00287170|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2008-07-03|2006-02-02|2006-02-06|Estimate|||||||2008-07-03|2008-07-08|Estimate|July 2006||2006-07-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|||||Interventional|||Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease|Pilot, Open-Label, Randomized, Parallel Group Study to Evaluate Clinical/ and Immunological Efficacy/Safety of Locally Delivered 6-MP or Calcitriol vs Purinethol in Non-Steroid Dependent Patients With Active CD|Completed||Phase 1/Phase 2|15|Actual|Teva GTC|||||f||||||||||||||2018-06-01 04:11:07.047115|2018-06-01 04:11:07.047115
NCT00287157|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2009-01-20|2006-02-03|2006-02-06|Estimate|||||||2009-01-20|2009-01-21|Estimate|December 2006||2006-12-31|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)|A Double-Blind, Randomized, Two-Way Crossover, Comparative Study to Evaluate the Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl Versus Placebo in Children With Chronic Traumatic Brain Injury|Completed||Phase 1|5|Actual|Teva GTC|||||f||||||||||||||2018-06-01 04:11:07.254587|2018-06-01 04:11:07.254587
NCT00287144|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2006-02-02|2006-02-02|2006-02-06|Estimate|||||||2006-02-02|2006-02-06|Estimate|November 2002||2002-11-30|December 2005|2005-12-31|December 2005||2005-12-31|||||Observational|||Post Partum Thyroiditis 2: Long Term Observations|Observations of Leng Term Effects From Post Partum Thyroiditis.|Unknown status|Active, not recruiting||||Sykehuset Telemark|||||f||||||||||||||2018-06-01 04:11:07.400751|2018-06-01 04:11:07.400751
NCT00287131|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2012-03-28|2006-02-02|2006-02-06|Estimate|||||||2012-03-28|2012-03-29|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|November 2013|Anticipated|2013-11-30|December 2012|Anticipated|2012-12-31||Interventional|||Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients|Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients|Unknown status|Recruiting|Phase 2|70|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:11:07.451118|2018-06-01 04:11:07.451118
NCT00287118|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|2017-08-29||2017-08-29|2006-02-02|2006-02-06|Estimate|2017-08-29|2018-04-03|Actual||||2017-08-29|2018-04-03|Actual|October 27, 2004|Actual|2004-10-27|August 2017|2017-08-31|May 30, 2006|Actual|2006-05-30|May 30, 2006|Actual|2006-05-30||Interventional|||A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis|A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 4|189|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 04:11:07.564219|2018-06-01 04:11:07.564219
NCT00287105|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2017-10-18|2006-02-03|2006-02-06|Estimate|||||||2017-10-18|2017-10-20|Actual|December 2005|Actual|2005-12-31|February 2017|2017-02-28|March 3, 2017|Actual|2017-03-03|March 30, 2016|Actual|2016-03-30||Interventional|ESPHALL||Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children|An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)|Completed||Phase 2|49|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 04:11:07.963088|2018-06-01 04:11:07.963088
NCT00287092|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2015-01-06|2006-02-03|2006-02-06|Estimate|||||||2015-01-06|2015-01-07|Estimate|February 2006||2006-02-28|January 2015|2015-01-31|September 2008|Actual|2008-09-30|May 2007|Actual|2007-05-31||Interventional|||Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants|"A Randomised, Controlled, Double-Blind Study of the Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed) Compared To Infanrix®-IPV+Hib When Both Vaccines Are Given to Infants Using a Three Dose Immunisation Schedule (Nordic Schedule 3-5-12 Months)"|Completed||Phase 3|807|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:11:08.144545|2018-06-01 04:11:08.144545
NCT00287079|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|2012-02-02||2013-12-02|2006-02-02|2006-02-06|Estimate|2012-03-07|2012-04-04|Estimate||||2013-12-02|2013-12-27|Estimate|October 2005||2005-10-31|December 2013|2013-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|CIS-ON||A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome|A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebif®) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS)|Completed||Phase 3|35|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 04:11:08.280626|2018-06-01 04:11:08.280626
NCT00287066|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2008-02-20|2006-02-02|2006-02-06|Estimate|||||||2008-02-20|2008-02-21|Estimate|February 2006||2006-02-28|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition|Open-Label Randomized Two-Way Crossover Pilot Study To Estimate The Effects Of Inhaled Versus IV Infusion Of Human Insulin With Regards To Glucose Disposal In Subjects With Type 1 Diabetes Mellitus|Terminated||Phase 3|22||Pfizer||||See termination reason in detailed description.|||||||||||||||2018-06-01 04:11:08.606166|2018-06-01 04:11:08.606166
NCT00287053|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|2009-04-21||2016-01-15|2006-02-03|2006-02-06|Estimate|2009-04-21|2009-06-10|Estimate||||2016-01-15|2016-02-08|Estimate|February 2006||2006-02-28|January 2016|2016-01-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|VPA||Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation|Phase IV Study of the Effects of Divalproex Sodium on Food Intake and Energy Expenditure.|Completed||Phase 4|57|Actual|Pennington Biomedical Research Center|This was a short-term study; the long-term effects of this compound on energy balance require further study.|2|||f||||f||||||||||2018-06-01 04:11:08.694944|2018-06-01 04:11:08.694944
NCT00287040|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2012-05-16|2006-02-03|2006-02-06|Estimate|||||||2012-05-16|2012-05-17|Estimate|September 2007||2007-09-30|August 2008|2008-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Breast Cancer Screening Via Computer V. Phone|Breast Cancer Screening Via Computer V. Phone|Completed||Phase 3|1686|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 04:11:09.034501|2018-06-01 04:11:09.034501
NCT00287027|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2007-01-04|2006-02-02|2006-02-06|Estimate|||||||2007-01-04|2007-01-05|Estimate|February 2006||2006-02-28|January 2007|2007-01-31|December 2006||2006-12-31|||||Observational|||Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication|Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication|Terminated|||60||National Alliance on Mental Illness New Hampshire|||||f||||||||||||||2018-06-01 04:11:09.101324|2018-06-01 04:11:09.101324
NCT00287014|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2010-08-26|2006-02-02|2006-02-06|Estimate|||||||2010-08-26|2010-08-27|Estimate|March 2006||2006-03-31|October 2007|2007-10-31|April 2006||2006-04-30|||||Observational|||Rift Valley Fever in Kenya|Late Outcomes of Rift Valley Fever in Kenya: Ijara Clinical Survey|Completed|||250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:11:09.197754|2018-06-01 04:11:09.197754
NCT00287001|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2008-05-21|2006-02-02|2006-02-06|Estimate|||||||2008-05-21|2008-05-22|Estimate|December 2005||2005-12-31|February 2007|2007-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Effect of Cold Air Cooling on the Incidence of Post Inflammatory Hyperpigmentation Following Laser Treatment|Effect of Cold Air Cooling on the Incidence of Post Inflammatory Hyperpigmentation Following a Q-Switched Nd:YAG Laser Treatment of Acquired Bilateral Nevus of Ota-Like Macules|Completed||N/A|20|Actual|Mahidol University||1|||f||||f||||||||||2018-06-01 04:11:09.330162|2018-06-01 04:11:09.330162
NCT00286988|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2011-01-05|2006-02-01|2006-02-06|Estimate|||||||2011-01-05|2011-01-06|Estimate|March 2006||2006-03-31|April 2007|2007-04-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children|Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children|Terminated||Phase 4|12|Anticipated|Monarch Medical Research||||Insufficient potential subjects|f||||||||||||||2018-06-01 04:11:09.48724|2018-06-01 04:11:09.48724
NCT00286975|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2008-10-16|2006-02-03|2006-02-06|Estimate|||||||2008-10-16|2008-10-17|Estimate||||November 2005|2005-11-30||||||||Interventional|||Growing Future Physician Leaders: A Randomized Trial of an Educational Intervention in Postgraduate Trainees|Growing Future Physician Leaders: A Randomized, Controlled Trial of an Educational Intervention in Postgraduate Trainees|Completed||Phase 4|||McGill University Health Center|||||f||||||||||||||2018-06-01 04:11:09.563224|2018-06-01 04:11:09.563224
NCT00286962|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2008-04-10|2006-02-03|2006-02-06|Estimate|||||||2008-04-10|2008-04-11|Estimate|February 2006||2006-02-28|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus|A Randomized Cross-Over Single Centre Study Comparing the Effects of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus Patients|Completed||Phase 3|24|Actual|Medical Research Foundation, The Netherlands||2|||f||||||||||||||2018-06-01 04:11:09.637314|2018-06-01 04:11:09.637314
NCT00286949|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|2014-03-11||2017-10-02|2006-02-03|2006-02-06|Estimate|2017-09-12|2017-09-18|Actual||||2017-10-02|2017-11-06|Actual|January 6, 2005|Actual|2005-01-06|October 2017|2017-10-31|June 30, 2008|Actual|2008-06-30|June 30, 2008|Actual|2008-06-30||Interventional||All enrolled subjects|Treatment of Executive Dysfunction in Parkinson's Disease|Atomoxetine for the Treatment of Executive Dysfunction in Patients With Parkinson's Disease: A Pilot Open-label Study|Completed||N/A|12|Actual|Johns Hopkins University|Data interpretation limited by open-label uncontrolled design, small sample size, subjects young (< age 65 years); multiple comparisons, intersubject variability, possible inclusion bias, ceiling and practice effects for neuropsychological data.|1|||f||||f||||||||No||2018-06-01 04:11:09.720081|2018-06-01 04:11:09.720081
NCT00286936|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2011-08-29|2006-02-03|2006-02-06|Estimate|||||||2011-08-29|2011-08-30|Estimate|February 2004||2004-02-29|September 2006|2006-09-30|January 2007|Actual|2007-01-31|||||Interventional|||Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo|Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo|Terminated||Phase 4|96|Anticipated|Hvidovre University Hospital||||Slow inclusion resulting in premature termination due to logistics|f||||||||||||||2018-06-01 04:11:09.975331|2018-06-01 04:11:09.975331
NCT00286923|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2006-02-13|2006-02-02|2006-02-06|Estimate|||||||2006-02-13|2006-02-14|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|August 2006||2006-08-31|||||Observational|||Does Topiramate Adjust the Excitability of the Brain in Migraine Sufferers?|Modulation of the Excitability of the Occipital Cerebral Cortex Using Topiramate|Unknown status|Not yet recruiting||10||Emerald City Headache Organization|||||f||||||||||||||2018-06-01 04:11:10.046252|2018-06-01 04:11:10.046252
NCT00286910|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2010-03-17|2006-02-03|2006-02-06|Estimate|||||||2010-03-17|2010-03-18|Estimate|May 2005||2005-05-31|March 2010|2010-03-31||||||||Observational|||Urinary Aquaporin 2 and Expression of the NPHS2 Gene in Adults Suffering From Nephrotic Syndrome|Urinary Aquaporin 2 and Expression of the NPHS2 Gene in Adults Suffering From Nephrotic Syndrome|Completed|||150|Anticipated|Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:11:10.130496|2018-06-01 04:11:10.130496
NCT00286897|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2015-11-02|2006-02-03|2006-02-06|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2006||2006-02-28|November 2015|2015-11-30|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|||The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|Completed||Phase 3|702|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:11:10.244439|2018-06-01 04:11:10.244439
NCT00286884|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2006-09-08|2006-02-03|2006-02-06|Estimate|||||||2006-09-08|2006-09-11|Estimate||||September 2006|2006-09-30||||||||Observational|||Heart Rate Variability in White Coat Hypertension and Essential Hypertension||Completed|||65||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:11:10.47178|2018-06-01 04:11:10.47178
NCT00286871|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2014-09-18|2006-02-02|2006-02-06|Estimate|||||||2014-09-18|2014-09-22|Estimate|February 2006||2006-02-28|February 2006|2006-02-28|February 2009||2009-02-28|||||Interventional|||Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen|Steroid Avoidance in Hep C OLT|Completed||Phase 1|40||Duke University|||||f||||||||||||||2018-06-01 04:11:10.538865|2018-06-01 04:11:10.538865
NCT00286858|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2016-01-05|2006-02-02|2006-02-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|September 2006||2006-09-30|February 2011|2011-02-28|December 2010|Actual|2010-12-31|September 2009|Actual|2009-09-30||Observational|||Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing|Clinical Observations of Automatic Algorithms for Cardiac Pacing|Completed|||903|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 04:11:10.620197|2018-06-01 04:11:10.620197
NCT00286845|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2012-01-25|2006-02-03|2006-02-06|Estimate|||||||2012-01-25|2012-01-26|Estimate|January 2006||2006-01-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|||||Observational|||Use of the MiCK Assay for Apoptosis in AML|Use of the MiCK Assay for Apoptosis to Predict Complete Remission in Acute Myeloid Leukemia|Completed|||50|Anticipated|Pierian Biosciences|||2||f||||f||||||||||2018-06-01 04:11:10.721516|2018-06-01 04:11:10.721516
NCT00286832|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2011-07-02|2006-02-03|2006-02-06|Estimate|||||||2011-07-02|2011-07-06|Estimate|August 2005||2005-08-31|July 2011|2011-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV|Evaluation of Response to Treatment Using 18F-FDG Positron Emission Tomography Imaging (PET) With Special Emphasize on the Prognostic Significance of Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV|Completed|||100|Actual|Copenhagen University Hospital at Herlev|||1||f||||t||||||||||2018-06-01 04:11:10.820149|2018-06-01 04:11:10.820149
NCT00286819|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2012-05-15|2006-02-03|2006-02-06|Estimate|||||||2012-05-15|2012-05-16|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|September 2006|Actual|2006-09-30|||||Interventional|||Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer|Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin 75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin 90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Breast Cancer|Completed||Phase 2|50|Actual|Central European Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 04:11:10.890947|2018-06-01 04:11:10.890947
NCT00286806|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03||2010-08-12|2010-08-20|2006-02-03|2006-02-06|Estimate||||2010-08-12|2010-08-17|Estimate|2010-08-20|2010-08-24|Estimate|December 2005||2005-12-31|August 2010|2010-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer|An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy|Completed||Phase 1/Phase 2|27||Ascenta Therapeutics|||||||||||||||||||2018-06-01 04:11:10.973519|2018-06-01 04:11:10.973519
NCT00286793|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03||2011-06-27|2011-06-27|2006-02-03|2006-02-06|Estimate||||2011-06-27|2011-06-29|Estimate|2011-06-27|2011-06-29|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC|An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)|Completed||Phase 1/Phase 2|76|Actual|Ascenta Therapeutics||1|||f||||f||||||||||2018-06-01 04:11:11.031847|2018-06-01 04:11:11.031847
NCT00286780|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2010-08-12|2006-02-03|2006-02-06|Estimate|||||||2010-08-12|2010-08-13|Estimate|January 2006||2006-01-31|August 2010|2010-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia|A Phase 2, Open Label Study of AT-101 in Combination With Rituximab in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 2|19|Actual|Ascenta Therapeutics||1|||f||||f||||||||||2018-06-01 04:11:11.15319|2018-06-01 04:11:11.15319
NCT00286767|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-03|||2018-05-23|2006-02-02|2006-02-03|Estimate|||||||2018-05-23|2018-05-24|Actual|February 1, 2006||2006-02-01|November 21, 2017|2017-11-21||||||||Observational|||Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy|A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy|Active, not recruiting|||565|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:11:11.36174|2018-06-01 04:11:11.36174
NCT00286754|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2015-01-21||2015-05-08|2006-02-01|2006-02-03|Estimate|2015-04-08|2015-04-09|Estimate||||2015-05-08|2015-06-01|Estimate|July 2006||2006-07-31|May 2015|2015-05-31|September 2011|Actual|2011-09-30|January 2010|Actual|2010-01-31||Interventional|||A Behavioral Intervention To Improve Hypertension Control In Veterans|A Behavioral Intervention to Improve Hypertension Control in Veterans|Completed||N/A|533|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:11:11.463676|2018-06-01 04:11:11.463676
NCT00286741|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2014-07-31||2015-04-06|2006-02-01|2006-02-03|Estimate|2014-09-03|2014-09-11|Estimate||||2015-04-06|2015-04-24|Estimate|June 2006||2006-06-30|May 2014|2014-05-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Can Group Visits Improve Outcomes of Veterans With Diabetes|Can Group Visits Improve Outcomes of Veterans With Diabetes|Completed||Phase 3|239|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:11:12.551416|2018-06-01 04:11:12.551416
NCT00286728|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2014-09-15||2015-04-06|2006-02-01|2006-02-03|Estimate|2014-10-02|2014-10-06|Estimate||||2015-04-06|2015-04-24|Estimate|April 2006||2006-04-30|August 2014|2014-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Dual Diagnosis Self-Help Referral|Dual Diagnosis Self-Help Group Referral: Outcomes and Services Use|Completed||N/A|287|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:11:12.879334|2018-06-01 04:11:12.879334
NCT00286702|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2006-02-01|2006-02-01|2006-02-03|Estimate|||||||2006-02-01|2006-02-03|Estimate|October 2002||2002-10-31|January 2006|2006-01-31|September 2004||2004-09-30|||||Interventional|||Does Splinting Prevent Contractures Following Stroke?||Completed||N/A|63||University of Western Sydney|||||f||||||||||||||2018-06-01 04:11:13.065687|2018-06-01 04:11:13.065687
NCT00286689|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2006-02-01|2006-02-01|2006-02-03|Estimate|||||||2006-02-01|2006-02-03|Estimate||||January 2006|2006-01-31||||||||Interventional|||Effects of Growth Hormone in Chronically Ill Children||Unknown status|Active, not recruiting|N/A|18||University of Texas Southwestern Medical Center|||||||||||||||||||2018-06-01 04:11:13.111642|2018-06-01 04:11:13.111642
NCT00286676|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2006-02-01|2006-02-01|2006-02-03|Estimate|||||||2006-02-01|2006-02-03|Estimate||||January 2006|2006-01-31||||||||Interventional|||The Use of Nutropin Depot in HIV-Infected Adult Males||Unknown status|Active, not recruiting|Phase 2/Phase 3|20||University of Texas Southwestern Medical Center|||||||||||||||||||2018-06-01 04:11:13.173847|2018-06-01 04:11:13.173847
NCT00286663|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2008-07-08|2006-02-01|2006-02-03|Estimate|||||||2008-07-08|2008-07-09|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|||||Observational|||Autoimmune Hepatitis Study|Evaluation of the Cellular Immune Response in Patients With Anti-SLA/LP- or Anti-LKM-Positive Autoimmune Hepatitis|Terminated|||100|Anticipated|University of Rochester||||Principal Investigator moving out of state, no other staff to lead research.|f||||||||||||||2018-06-01 04:11:13.234011|2018-06-01 04:11:13.234011
NCT00286637|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2018-02-07|2006-02-02|2006-02-03|Estimate|||||||2018-02-07|2018-02-08|Actual|January 1995||1995-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|May 2018|Anticipated|2018-05-31||Observational|||Novel Diagnostics for Ocular Structure|Optical Coherence Tomography Domain Reflectometry & Optical Coherence Tomography Measurements of Intraocular Structure|Active, not recruiting|||2767|Actual|New York University School of Medicine|||||f||||t|f|f||||||Undecided||2018-06-01 04:11:13.364183|2018-06-01 04:11:13.364183
NCT00286624|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2008-05-02|2006-02-02|2006-02-03|Estimate|||||||2008-05-02|2008-05-08|Estimate|March 2003||2003-03-31|May 2008|2008-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|NITA||Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation|A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients|Completed||Phase 1/Phase 2|6|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 04:11:13.42485|2018-06-01 04:11:13.42485
NCT00286611|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-06-09|2006-01-31|2006-02-03|Estimate|||||||2008-06-09|2008-06-10|Estimate|October 2004||2004-10-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|||||Observational|||Determination of Amifostine Levels During Radiation Therapy|Serial Blood and Salivary Sampling for Validation of Quantitative Amifostine Assays|Completed|||13|Actual|University of Iowa|||1||f||||t||||||||||2018-06-01 04:11:13.494222|2018-06-01 04:11:13.494222
NCT00286598|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2016-10-04|2006-02-01|2006-02-03|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Feet First: Promoting Physical Activity Among People With Diabetes Mellitus and Insensate Feet|Feet First: Increasing Activity Without Increasing the Risk of Foot Ulcers in People With Diabetes and Insensate Feet|Completed||Phase 1|79|Actual|University of Missouri-Columbia||2|||f||||t||||||||No||2018-06-01 04:11:13.556579|2018-06-01 04:11:13.556579
NCT00286585|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2012-08-24|2006-02-02|2006-02-03|Estimate|||||||2012-08-24|2012-08-27|Estimate|February 2006||2006-02-28|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||TEAM-Project: Trial on the Effect of Anesthetics on Morbidity and Mortality|Multi-Center Trial on the Effect of Anesthetics on Morbidity and Mortality in Patients Undergoing Major Non-cardiac Surgery|Completed||Phase 4|385|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 04:11:13.622565|2018-06-01 04:11:13.622565
NCT00286572|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2015-03-09|2006-02-02|2006-02-03|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2004||2004-01-31|March 2015|2015-03-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Observational|||Long-term Mortality in Diabetics Undergoing Major Surgery|Comparison in Survival in Patients With Insulin-dependent and Non-insulin-dependent Diabetes Mellitus With Known or Suspected Coronary Artery Disease Undergoing Major Non-cardiac Surgery|Completed|||380|Actual|University Hospital, Basel, Switzerland|||||f||||t||||||||||2018-06-01 04:11:13.790198|2018-06-01 04:11:13.790198
NCT00286559|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2015-03-24|2006-02-02|2006-02-03|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 2006||2006-08-31|March 2015|2015-03-31|December 2008||2008-12-31|||||Interventional|||Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)|Feasibility and Accuracy of Transoesophageal Harmonic Contrast Echocardiography in Assessing Myocardial Blood Flow and Blood Flow Reserve|Withdrawn||Phase 1/Phase 2|0|Actual|University Hospital, Basel, Switzerland||||echo contrast agents no longer allowed in CAD patients.|f||||t||||||||||2018-06-01 04:11:13.85515|2018-06-01 04:11:13.85515
NCT00286546|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2006-09-08|2006-02-01|2006-02-03|Estimate|||||||2006-09-08|2006-09-11|Estimate|January 2001||2001-01-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Testosterone and Major Depression|The Role of Testosterone in Major Depression|Completed|||100||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:11:13.912717|2018-06-01 04:11:13.912717
NCT00286533|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2014-12-04|2006-02-01|2006-02-03|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2006||2006-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of Implants Placed in the Regular Dentist's Practice|Retrospective Evaluation of Implants Placed in the Regular Dentist's Practice. A Study to Evaluate Implant Success, Prosthetic Complications, Opinion of the Patient, and Quality of Care|Unknown status|Recruiting|N/A|500|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:11:13.969929|2018-06-01 04:11:13.969929
NCT00286520|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2006-02-02|2006-02-02|2006-02-03|Estimate|||||||2006-02-02|2006-02-03|Estimate|December 2003||2003-12-31|February 2006|2006-02-28|August 2005||2005-08-31|||||Interventional|||Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury|Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury - a Prospective, Randomized, Controlled, Multicentre Trial of Transanal Irrigation Vs. Conservative Bowel Management|Completed||Phase 4|80||University of Aarhus|||||f||||||||||||||2018-06-01 04:11:14.042448|2018-06-01 04:11:14.042448
NCT00286507|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2012-06-05|2006-02-02|2006-02-03|Estimate|||||||2012-06-05|2012-06-06|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Interventional|FILMS||Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study|Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study: Randomised Comparison of Macular Hole Surgery With or Without Internal Limiting Membrane Peeling|Completed||N/A|141|Actual|University of Aberdeen||2|||f||||||||||||||2018-06-01 04:11:14.112116|2018-06-01 04:11:14.112116
NCT00286494|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2011-06-08||2012-02-01|2006-02-01|2006-02-03|Estimate|2011-08-23|2011-09-27|Estimate||||2012-02-01|2012-02-03|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Pioglitazone in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|493|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:11:14.275902|2018-06-01 04:11:14.275902
NCT00286481|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2012-05-23|2006-02-01|2006-02-03|Estimate|||||||2012-05-23|2012-05-24|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy of Lapaquistat Acetate Alone or Combined With Simvastatin in Subjects With Hypercholesterolemia|A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of Lapaquistat and Simvastatin Alone and in Combination in Subjects With Hypercholesterolemia|Completed||Phase 3|1362|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:11:16.224638|2018-06-01 04:11:16.224638
NCT00286468|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2011-06-08||2012-02-01|2006-02-01|2006-02-03|Estimate|2011-07-27|2011-08-25|Estimate||||2012-02-01|2012-02-03|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes|Completed||Phase 3|500|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:11:16.603019|2018-06-01 04:11:16.603019
NCT00286455|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2011-06-08||2012-02-01|2006-02-01|2006-02-03|Estimate|2011-07-28|2011-08-29|Estimate||||2012-02-01|2012-02-03|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared With Placebo in Subjects With Type 2 Diabetes|Completed||Phase 3|329|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:11:18.409359|2018-06-01 04:11:18.409359
NCT00286442|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2011-06-08||2012-02-01|2006-02-01|2006-02-03|Estimate|2011-07-27|2011-08-25|Estimate||||2012-02-01|2012-02-03|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes|Completed||Phase 3|527|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:11:20.539801|2018-06-01 04:11:20.539801
NCT00286429|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2011-06-08||2012-02-01|2006-02-01|2006-02-03|Estimate|2011-07-19|2011-08-12|Estimate||||2012-02-01|2012-02-03|Estimate|February 2006||2006-02-28|February 2012|2012-02-29|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Insulin in Subjects With Type 2 Diabetes|Completed||Phase 3|390|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:11:23.286742|2018-06-01 04:11:23.286742
NCT00286416|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2006-11-06|2006-02-01|2006-02-03|Estimate|||||||2006-11-06|2006-11-07|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|July 2008||2008-07-31|||||Interventional|||Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma|Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With the Co-Morbid Conditions of Aspirin Exacerbated Respiratory Disease(AERD) and Allergic Asthma and Rhinitis.|Unknown status|Recruiting|N/A|60||Scripps Health|||||f||||||||||||||2018-06-01 04:11:24.601874|2018-06-01 04:11:24.601874
NCT00286403|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2016-03-25|2006-02-01|2006-02-03|Estimate|||||||2016-03-25|2016-03-28|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Vasodilators and Anti-Oxidant Therapy in Early ATN|Combination Fenoldopam Mesylate and Intravenous MESNA (2-mercaptoethane Sulphonate)in Early Acute Kidney Injury (AKD): A Randomized, Double-Blind Placebo Controlled Clinical Trial|Withdrawn||Phase 2/Phase 3|0|Actual|Southeast Renal Research Institute||||The study was terminated due to logistics at a local hospital.|f||||t||||||||||2018-06-01 04:11:24.673493|2018-06-01 04:11:24.673493
NCT00286390|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-09-04|2006-02-01|2006-02-03|Estimate|||||||2007-09-04|2007-09-05|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|February 2006|Actual|2006-02-28|||||Interventional|||Acupuncture for Acute and Chronic Pain in Air Force Personnel|Outcomes and Cost Assessment of Acupuncture in the Treatment (OCAT) of Pain Patients at Malcolm Grow USAF Medical Center|Completed||N/A|200||Samueli Institute for Information Biology|||||f||||||||||||||2018-06-01 04:11:24.782829|2018-06-01 04:11:24.782829
NCT00286377|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2006-02-02|2006-02-02|2006-02-03|Estimate|||||||2006-02-02|2006-02-03|Estimate|September 2003||2003-09-30|January 2006|2006-01-31|December 2004||2004-12-31|||||Interventional|||Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of Prosaptide Over 6 Weeks of Treatment for the Relief of Neuropathic Pain Associated With HIV-1|Terminated||Phase 2|350||Savient Pharmaceuticals|||||||||||||||||||2018-06-01 04:11:24.912529|2018-06-01 04:11:24.912529
NCT00286364|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-04-20|2006-02-02|2006-02-03|Estimate|||||||2007-04-20|2007-04-23|Estimate||||April 2007|2007-04-30||||||||Interventional|||Short-Term Androgen Priming Before COS Using Aromatase Inhibitor and hCG During Early-Follicular-Phase GnRH Antagonist Administration - a Randomized Controlled Trial||Completed||Phase 4|||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:11:24.971644|2018-06-01 04:11:24.971644
NCT00286351|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-04-20|2006-02-01|2006-02-03|Estimate|||||||2007-04-20|2007-04-23|Estimate|January 2005||2005-01-31|April 2007|2007-04-30||||||||Interventional|||Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis||Completed||Phase 4|20||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:11:25.024551|2018-06-01 04:11:25.024551
NCT00286338|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2009-01-13|2006-02-01|2006-02-03|Estimate|||||||2009-01-13|2009-01-14|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|April 2006|Actual|2006-04-30|||||Observational|||Comparison of Monitors of Fluid Therapy|Comparison of Monitors of Fluid Therapy|Completed|||12||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:11:25.100157|2018-06-01 04:11:25.100157
NCT00286325|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2011-04-04||2013-04-09|2006-02-01|2006-02-03|Estimate|2012-09-19|2012-10-22|Estimate||||2013-04-09|2013-04-11|Estimate|March 2005||2005-03-31|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Rituximab in the Treatment of Patients With Bullous Pemphigoid|Rituximab in the Treatment of Patients With Bullous Pemphigoid|Completed||Phase 1/Phase 2|8|Actual|Duke University|Open label trial of rituximab in the treatment of 7 patients with the autoimmune blistering disease bullous pemphigoid.|1|||f||||f||||||||||2018-06-01 04:11:25.171461|2018-06-01 04:11:25.171461
NCT00286312|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2008-05-20|2006-02-02|2006-02-03|Estimate|||||||2008-05-20|2008-05-21|Estimate|February 2006||2006-02-28|May 2008|2008-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Myocardial Infarction Size Reduction With Atorvastatin|Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study|Completed||Phase 4|50|Anticipated|R&D Cardiologie|||||f||||f||||||||||2018-06-01 04:11:25.396718|2018-06-01 04:11:25.396718
NCT00286299|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2017-03-28|2006-02-02|2006-02-03|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2005|Actual|2005-10-31|March 2017|2017-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Treatment Effects From Aerobic Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia|Physiological and Psychiatric Effects From Aerobic High Intensity Endurance Training and Maximal Strength Training in Patients Suffering From Schizophrenia: A Controlled Clinical Trial.|Completed||N/A|33|Actual|Norwegian University of Science and Technology||3|||f||||f|f|f||||||Undecided||2018-06-01 04:11:25.469348|2018-06-01 04:11:25.469348
NCT00286286|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-01-09|2006-02-01|2006-02-03|Estimate|||||||2007-01-09|2007-01-11|Estimate|February 2006||2006-02-28|January 2007|2007-01-31|August 2006||2006-08-31|||||Interventional|||Intraperitoneal Aerosolized Delivery of a Local Anesthetic for Post Operative Pain Management. A Double Blind, Randomised Controlled Clinical Trial.|Clinical Protocol for the Prospective Double Blind Randomised Controlled Trial for the Use of Intraperitoneal Aerosolized Local Anesthetic|Unknown status|Active, not recruiting|N/A|50||Northgate Technologies|||||f||||||||||||||2018-06-01 04:11:25.552709|2018-06-01 04:11:25.552709
NCT00286273|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2009-08-25|2006-02-01|2006-02-03|Estimate|||||||2009-08-25|2009-08-26|Estimate|March 2003||2003-03-31|August 2009|2009-08-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration|Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin|Completed||Phase 4|215|Actual|Onze Lieve Vrouwe Gasthuis||2|||f||||t||||||||||2018-06-01 04:11:25.619187|2018-06-01 04:11:25.619187
NCT00286260|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2009-12-17|2006-02-01|2006-02-03|Estimate|||||||2009-12-17|2009-12-18|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Levetiracetam for Painful Polyneuropathy|Double-blind, Randomised, Placebo-controlled Trial of the Effect of Levetiracetam on Painful Polyneuropathy|Completed||Phase 4|40|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:11:25.709677|2018-06-01 04:11:25.709677
NCT00286247|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2008-03-28|2006-02-01|2006-02-03|Estimate|||||||2008-03-28|2008-04-01|Estimate||||March 2008|2008-03-31||||||||Interventional|||Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer||Completed||Phase 2|60||Introgen Therapeutics|||||||||||||||||||2018-06-01 04:11:25.785227|2018-06-01 04:11:25.785227
NCT00286234|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2013-04-30|2006-02-02|2006-02-03|Estimate|||||||2013-04-30|2013-05-01|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Niacin, N-3 Fatty Acids and Insulin Resistance|Niacin, N-3 Fatty Acids and Insulin Resistance|Completed||Phase 4|10|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||t||||||||||2018-06-01 04:11:25.839753|2018-06-01 04:11:25.839753
NCT00286221|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2017-07-24||2017-08-28|2006-02-01|2006-02-03|Estimate|2017-08-28|2017-09-26|Actual||||2017-08-28|2017-09-26|Actual|March 2006|Actual|2006-03-31|August 2017|2017-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||IVPCA in the Management of Pain Following Major Intracranial Surgery|The Safety and Efficacy of IVPCA in the Management of Adult Postoperative Craniotomy Pain: A Prospective, Randomized Controlled Trial|Completed||Phase 2/Phase 3|159|Actual|Johns Hopkins University||4|||f||||||||||||||2018-06-01 04:11:25.927339|2018-06-01 04:11:25.927339
NCT00286208|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2014-02-18|2006-02-01|2006-02-03|Estimate|||||||2014-02-18|2014-02-19|Estimate|August 2005||2005-08-31|February 2014|2014-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation|A Randomized Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation|Completed||N/A|1443|Actual|Gynuity Health Projects||2|||f||||||||||||||2018-06-01 04:11:26.2084|2018-06-01 04:11:26.2084
NCT00286195|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2015-05-12|2006-02-02|2006-02-03|Estimate|||||||2015-05-12|2015-05-13|Estimate|December 2004||2004-12-31|May 2015|2015-05-31|December 2006||2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Frontier Registry II Bifurcation Stent System Registry|The Abbott Vascular MULTI -LINK FRONTIER Coronary Bifurcation Stent System Registry II|Withdrawn||Phase 4|0|Actual|Abbott Vascular||1||Study was withdrawn due to a business decision.|f||||||||||||||2018-06-01 04:11:26.276532|2018-06-01 04:11:26.276532
NCT00286182|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2015-08-17||2017-01-30|2006-02-01|2006-02-03|Estimate|2016-05-03|2016-06-10|Estimate||||2017-01-30|2017-03-10|Actual|July 2007||2007-07-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)|Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status|Completed||Phase 2|56|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-06-01 04:11:26.343012|2018-06-01 04:11:26.343012
NCT00286169|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2010-08-09|2006-02-01|2006-02-03|Estimate|||||||2010-08-09|2010-08-10|Estimate|April 2006||2006-04-30|August 2010|2010-08-31||||||||Interventional|||Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)|Randomized Phase III Trial of Amrubicin Versus Carboplatin Plus Etoposide in Elderly Patients With Extensive-disease Small-cell Lung Cancer|Terminated||Phase 3|130|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.|||||f||||||||||||||2018-06-01 04:11:26.524552|2018-06-01 04:11:26.524552
NCT00286156|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2015-03-31||2015-03-31|2006-02-01|2006-02-03|Estimate|2015-03-31|2015-04-06|Estimate||||2015-03-31|2015-04-06|Estimate|October 2006||2006-10-31|March 2014|2014-03-31|December 2014|Actual|2014-12-31|March 2012|Actual|2012-03-31||Interventional|||Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 1/Phase 2|30|Actual|The Cleveland Clinic||3|||f||||t||||||||||2018-06-01 04:11:26.621929|2018-06-01 04:11:26.621929
NCT00286143|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2009-09-14|2006-02-01|2006-02-03|Estimate|||||||2009-09-14|2009-09-16|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates|Evaluation of Effects of Additional Fentanyl to Epidural Bupivacaine for Post-Thoracotomy Pain in Neonates on Perioperative Outcome|Completed||Phase 3|32|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-06-01 04:11:27.481149|2018-06-01 04:11:27.481149
NCT00286130|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2012-04-30|2006-02-02|2006-02-03|Estimate|||||||2012-04-30|2012-05-01|Estimate|July 2005||2005-07-31|April 2012|2012-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer|A Randomised, Open-label Phase II Study Evaluating the Efficacy and Safety of Folfox6 + Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|150|Actual|Central European Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 04:11:27.82963|2018-06-01 04:11:27.82963
NCT00286117|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|||2009-04-30|2006-02-02|2006-02-03|Estimate|||||||2009-04-30|2009-05-01|Estimate|March 1998||1998-03-31|April 2009|2009-04-30|May 2006|Actual|2006-05-31|||||Interventional|||ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years|An Open Randomised Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ as Adjuvant Therapies in Post-Menopausal Women With Breast Cancer Already Being Treated With NOLVADEX for at Least Two Years|Completed||Phase 3|448|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:11:28.234394|2018-06-01 04:11:28.234394
NCT00286104|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2009-12-21|2006-02-01|2006-02-03|Estimate|||||||2009-12-21|2009-12-23|Estimate|April 2004||2004-04-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Impact of Ventricular Catheter Used With Antimicrobial Agents on Patients With a Ventricular Catheter|The Impact of Ventricular Catheter Impregnated With Antimicrobial Agents on Infection in Patients With Ventricular Catheter: A Prospective Randomized Study|Completed||Phase 3|184|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 04:11:28.605063|2018-06-01 04:11:28.605063
NCT00286091|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-02|2015-03-25|2011-05-26|2017-06-09|2006-02-02|2006-02-03|Estimate|2015-03-25|2015-04-06|Estimate|2011-05-26|2011-06-03|Estimate|2017-06-09|2017-07-11|Actual|February 2006||2006-02-28|June 2017|2017-06-30|April 2014|Actual|2014-04-30|July 2010|Actual|2010-07-31||Interventional|||Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer|Completed||Phase 3|1435|Actual|Amgen||2|||f||||t||||||||||2018-06-01 04:11:28.792472|2018-06-01 04:11:28.792472
NCT00286078|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|2016-04-06||2018-02-06|2006-02-01|2006-02-03|Estimate|2016-06-28|2016-08-09|Estimate||||2018-02-06|2018-02-08|Actual|February 2006||2006-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|April 2009|Actual|2009-04-30||Interventional||1 subject excluded from analysis because HIPAA authorization was not obtained; randomized to active group, received percutaneous trial only|Treatment for Migraines With an Implantable Device|Precision Implantable Stimulator for Migraine (PRISM) Study- Occipital Nerve Stimulation (ONS) for Migraine|Active, not recruiting||Phase 3|179|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-06-01 04:11:32.063207|2018-06-01 04:11:32.063207
NCT00286065|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2007-06-26|2006-01-31|2006-02-02|Estimate|||||||2007-06-26|2007-06-27|Estimate|January 2006||2006-01-31|June 2007|2007-06-30||||||||Interventional|||Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-op Pain in Adult Patients Undergoing Elective Orthopedic Surgery|Multi-Centre Placebo-Controlled Randomized 2 Part Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-Op Pain in Adult Patients Undergoing Elective Orthopedic Surgery|Completed||Phase 2|123||YM BioSciences|||||f||||||||||||||2018-06-01 04:11:32.350261|2018-06-01 04:11:32.350261
NCT00286052|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-01-31|2006-01-31|2006-02-02|Estimate|||||||2006-01-31|2006-02-02|Estimate|December 2002||2002-12-31|September 2005|2005-09-30|August 2004||2004-08-31|||||Interventional|||Impact of Low Dose Naloxone on Fentanyl Requirements in Pediatric ICU Patients|The Impact of Concomitant Ultra Low Dose Infusion Naloxone and Therapeutic Infusion Opioid on Opioid Requirements in Pediatric ICU Patients|Completed||Phase 3|128||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:11:32.422734|2018-06-01 04:11:32.422734
NCT00286039|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2011-09-29|2006-02-01|2006-02-02|Estimate|||||||2011-09-29|2011-09-30|Estimate|August 2005||2005-08-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Plasma Citrulline Level in Relation to Absorptive Surface|Plasma Citrulline Level in Relation to Absorptive Surface|Completed||N/A|200|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:32.487553|2018-06-01 04:11:32.487553
NCT00286026|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2012-04-12|2006-01-31|2006-02-02|Estimate|||||||2012-04-12|2012-04-16|Estimate|June 2005||2005-06-30|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2007|Actual|2007-08-31||Interventional|||Azithromycin in Control of Trachoma II|Azithromycin in Control of Trachoma II|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||2||Prevalence of infection for screened population too low (<7%) to enroll anyone.|f||||f||||||||||2018-06-01 04:11:32.552552|2018-06-01 04:11:32.552552
NCT00286013|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-12-19|2006-02-01|2006-02-02|Estimate|||||||2007-12-19|2007-12-28|Estimate|May 2004||2004-05-31|December 2007|2007-12-31||||||||Interventional|||Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma|Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma|Suspended||Phase 2|30||University Hospital, Ghent||||Study suspended because of safety reasons|f||||f||||||||||2018-06-01 04:11:32.644095|2018-06-01 04:11:32.644095
NCT00286000|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-12-19|2006-02-01|2006-02-02|Estimate|||||||2007-12-19|2007-12-28|Estimate|June 2004||2004-06-30|December 2007|2007-12-31|December 2005|Actual|2005-12-31|||||Interventional|||High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study|High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study|Completed||Phase 2|106||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:32.76126|2018-06-01 04:11:32.76126
NCT00285987|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-12-19|2006-02-01|2006-02-02|Estimate|||||||2007-12-19|2007-12-28|Estimate||||December 2007|2007-12-31||||||||Interventional|||Quality of Life After an Ambulatory Reconstruction of the Cruciate Ligament|Quality of Life After an Ambulatory Reconstruction of the Cruciate Ligament|Withdrawn||N/A|500||University Hospital, Ghent||||Study has never started|f||||f||||||||||2018-06-01 04:11:32.891354|2018-06-01 04:11:32.891354
NCT00285974|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2014-12-04|2006-02-01|2006-02-02|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2003||2003-12-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Dosage of Metal Ions in the Blood of Different Metal-on-metal Prostheses, in Correlation With Physical Activity|Dosage of Metal Ions in the Blood of Different Metal-on-metal Prostheses, in Correlation With Physical Activity|Unknown status|Active, not recruiting|N/A|120|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:11:32.944824|2018-06-01 04:11:32.944824
NCT00285961|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2009-05-11|2006-02-01|2006-02-02|Estimate|||||||2009-05-11|2009-05-12|Estimate||||February 2009|2009-02-28|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Evaluation of Cork Splint Materials Instead of Plaster Splint for Children|Evaluation of Cork Splint Materials Instead of Plaster Splint for Children|Completed||N/A|50|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:33.032788|2018-06-01 04:11:33.032788
NCT00285948|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2009-02-17|2006-02-01|2006-02-02|Estimate|||||||2009-02-17|2009-02-18|Estimate|November 1998||1998-11-30|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Primary Birmingham Hip Resurfacing Arthroplasty Using a Metal-on-Metal Couple in the Young Active Patient|Primary Birmingham Hip Resurfacing Arthroplasty Using a Metal-on-Metal Couple in the Young Active Patient|Completed||N/A|250|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:33.094165|2018-06-01 04:11:33.094165
NCT00285935|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2016-11-07|2006-01-31|2006-02-02|Estimate|||||||2016-11-07|2016-11-09|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|CAN-D||Cellular Aging and Neurobiology of Depression Study|Neurosteroid Metabolism and the Antidepressant Effects of Serotonin Specific Reuptake Inhibitors (SSRI's)|Recruiting||Phase 4|228|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:11:33.148194|2018-06-01 04:11:33.148194
NCT00285922|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-01-31|2006-01-31|2006-02-02|Estimate|||||||2006-01-31|2006-02-02|Estimate|August 2001||2001-08-31|July 2005|2005-07-31|December 2005||2005-12-31|||||Observational|||Novel Method to Diagnose Acute Myocardial Ischemia|Comparison of Estimated Body Surface Potential Mapping With Standard Electrocardiography in Patients Presenting to the Emergency Department With Chest Pain|Completed|||1320||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:11:33.233692|2018-06-01 04:11:33.233692
NCT00285909|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-08-15|2006-01-31|2006-02-02|Estimate|||||||2006-08-15|2006-08-16|Estimate|March 2006||2006-03-31|August 2006|2006-08-31|June 2006||2006-06-30|||||Interventional|||Moderate Alcohol Consumption, Risk of Cardiovascular Disease and Type 2 Diabetes: Influence of Alcohol Oxidation|Effect of Moderate Alcohol Consumption on PPAR-γ Activity and Risk Markers of Metabolic Disease: Influence of Genetic Variation in Alcohol Oxidation|Completed||N/A|36||TNO|||||f||||||||||||||2018-06-01 04:11:33.295481|2018-06-01 04:11:33.295481
NCT00285896|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2008-07-10|2006-02-01|2006-02-02|Estimate|||||||2008-07-10|2008-07-11|Estimate|December 2005||2005-12-31|July 2008|2008-07-31|May 2007|Actual|2007-05-31|October 2006|Actual|2006-10-31||Interventional|||GLP-1 Infusion and Long-Time Fasting|The Effect of 48 Hours of GLP-1 Infusion During Long-Time Fasting on Glycaemia and Counterregulatory Hormones|Completed||N/A|8|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 04:11:33.352179|2018-06-01 04:11:33.352179
NCT00285883|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-02-27|2006-01-31|2006-02-02|Estimate|||||||2006-02-27|2006-02-28|Estimate|April 2004||2004-04-30|January 2006|2006-01-31|May 2006||2006-05-31|||||Interventional|||Directly Observed Therapy in High Risk Populations in Newark, NJ|Directly Observed Therapy in High Risk Populations in Newark, NJ|Completed||Phase 3|30||Saint Michael's Medical Center|||||||||||||||||||2018-06-01 04:11:33.417649|2018-06-01 04:11:33.417649
NCT00285870|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2013-03-11|2006-01-31|2006-02-02|Estimate|||||||2013-03-11|2013-03-12|Estimate|January 2006||2006-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Quantification of Upper Extremity Hypertonia|Quantification of Upper Extremity Hypertonia|Completed|||60|Actual|University of Southern California|||||f||||||||||||||2018-06-01 04:11:33.473961|2018-06-01 04:11:33.473961
NCT00285857|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2016-11-17||2017-01-19|2006-01-31|2006-02-02|Estimate|2017-01-19|2017-03-09|Actual||||2017-01-19|2017-03-09|Actual|November 2005||2005-11-30|January 2017|2017-01-31|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention|A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer|Terminated||Phase 2|30|Actual|Stanford University||1||Slow accrual|f||||t||||||||No||2018-06-01 04:11:33.5354|2018-06-01 04:11:33.5354
NCT00285844|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2016-11-03|2006-01-31|2006-02-02|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2005||2005-10-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Integrating the Genetic and Metabolic Faces of Obesity|Integrating the Genetic and Metabolic Faces of Obesity|Completed||Phase 1|88|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 04:11:34.012411|2018-06-01 04:11:34.012411
NCT00285831|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-10-23|2006-01-31|2006-02-02|Estimate|||||||2008-10-23|2008-10-27|Estimate|December 2005||2005-12-31|October 2008|2008-10-31||||||||Observational|||Mild Depression 2 Week Observational Study|Dysphoric-Like Disorder of Epilepsy, Is it Unique?|Unknown status|Active, not recruiting||120||Stanford University|||||f||||||||||||||2018-06-01 04:11:34.094706|2018-06-01 04:11:34.094706
NCT00285818|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2016-10-20||2016-12-23|2006-01-31|2006-02-02|Estimate|2016-12-23|2017-02-16|Actual||||2016-12-23|2017-02-16|Actual|January 2003||2003-01-31|December 2016|2016-12-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT|A Double-blind, Placebo-controlled Study of Mifepristone in Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT)|Completed||N/A|11|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 04:11:34.155137|2018-06-01 04:11:34.155137
NCT00285805|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2010-08-23|2006-02-01|2006-02-02|Estimate|||||||2010-08-23|2010-08-24|Estimate|February 2006||2006-02-28|October 2008|2008-10-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride|The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride. A Double-blind Placebo Controlled Cross Over Study.|Completed||N/A|13|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 04:11:34.450547|2018-06-01 04:11:34.450547
NCT00285792|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-10-04|2006-01-31|2006-02-02|Estimate|||||||2006-10-04|2006-10-05|Estimate|December 2005||2005-12-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Stanford Preschool Physical Activity Project|Stanford Preschool Physical Activity Project|Completed||Phase 1/Phase 2|60||Stanford University|||||f||||||||||||||2018-06-01 04:11:34.534179|2018-06-01 04:11:34.534179
NCT00285779|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2015-01-28||2018-03-20|2006-01-31|2006-02-02|Estimate|2015-02-16|2015-03-03|Estimate||||2018-03-20|2018-03-21|Actual|August 2006||2006-08-31|March 2018|2018-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus|A Double-Blind, Randomized, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Etanercept 50mg SC Twice Weekly in the Treatment of Moderate to Severe Lichen Planus|Terminated||Phase 2|27|Actual|Stanford University|Trial was terminated early due to low recruitment rates.|2||Slow recruitment|f||||t||||||||||2018-06-01 04:11:34.647958|2018-06-01 04:11:34.647958
NCT00285766|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-04-21|2006-01-31|2006-02-02|Estimate|||||||2008-04-21|2008-04-22|Estimate|August 2002||2002-08-31|April 2008|2008-04-30|July 2005||2005-07-31|||||Interventional|||Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression|A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression|Completed||Phase 3|300||Somerset Pharmaceuticals|||||||||||||||||||2018-06-01 04:11:35.483623|2018-06-01 04:11:35.483623
NCT00285753|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2008-05-20|2006-02-01|2006-02-02|Estimate|||||||2008-05-20|2008-05-21|Estimate|November 2003||2003-11-30|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Support Groups for Patients With Mild Cognitive Impairment and Their Partners|Development and Evaluation of Support Groups for Patients With Mild Cognitive Impairment and Their Partners|Completed||Phase 2|110|Actual|Radboud University|||||f||||t||||||||||2018-06-01 04:11:35.559491|2018-06-01 04:11:35.559491
NCT00285740|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2007-12-14|2006-01-31|2006-02-02|Estimate|||||||2007-12-14|2007-12-19|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|January 2007||2007-01-31|||||Interventional|||Group Cognitive Behavioral Therapy to Treat Depression in an Epilepsy Clinic Setting||Unknown status|Active, not recruiting|N/A|60||Stanford University|||||f||||||||||||||2018-06-01 04:11:35.617615|2018-06-01 04:11:35.617615
NCT00285727|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-05-16|2006-02-01|2006-02-02|Estimate|||||||2008-05-16|2008-05-19|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|October 2007||2007-10-31|||||Interventional|||Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression|Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression|Completed||N/A|60||Stanford University|||||||||||||||||||2018-06-01 04:11:35.68467|2018-06-01 04:11:35.68467
NCT00285714|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2007-07-26|2006-02-01|2006-02-02|Estimate|||||||2007-07-26|2007-07-27|Estimate|February 2006||2006-02-28|July 2007|2007-07-31|December 2010|Anticipated|2010-12-31|||||Interventional|||3D Imaging of Hard and Soft Tissue in Orthognathic Surgery|An Analysis of the Clinical Applicability of a Three-Dimensional Imaging Platform Used to Register the Influence of Orthognathic Surgery on Facial Hard and Soft Tissue in Patients With Congenital Maxillofacial Deformities.|Unknown status|Recruiting|N/A|450|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:11:35.743333|2018-06-01 04:11:35.743333
NCT00285701|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2010-01-14|2006-01-31|2006-02-02|Estimate|||||||2010-01-14|2010-01-15|Estimate|July 2006||2006-07-31|January 2010|2010-01-31|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study|Early Detection of Pre-malignant and Malignant Conditions in the Colon by Means of Fluorescence Endoscopy Using Local and Oral Sensitisation With Hexaminolevulinate (HAL) - a Dose Finding Study|Completed||Phase 1/Phase 2|38|Actual|Photocure|||||f||||||||||||||2018-06-01 04:11:35.811734|2018-06-01 04:11:35.811734
NCT00285688|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2008-08-02|2006-02-01|2006-02-02|Estimate|||||||2008-08-02|2008-08-05|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|December 2008|Anticipated|2008-12-31|||||Observational|||Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital|Antibiotic Resistance Helicobacter Pylori and Clarithromycin Resistance Mutation in Helicobacter Pylori in Rajavithi Hospital|Unknown status|Recruiting||200|Anticipated|Rajavithi Hospital|||2||f||||t||||||Samples With DNA|"~     Gastric Biopsy tissue and H. pylori DNA~   "|||2018-06-01 04:11:35.864743|2018-06-01 04:11:35.864743
NCT00285675|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-05-30|2006-01-31|2006-02-02|Estimate|||||||2006-05-30|2006-05-31|Estimate|April 2006||2006-04-30|January 2006|2006-01-31|January 2008||2008-01-31|||||Interventional|||Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004|A Continuation Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004|Unknown status|Active, not recruiting|Phase 2|25||Novacea|||||||||||||||||||2018-06-01 04:11:35.929183|2018-06-01 04:11:35.929183
NCT00285662|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2011-07-22|2006-02-01|2006-02-02|Estimate|||||||2011-07-22|2011-07-25|Estimate|June 2006||2006-06-30|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants|Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants|Completed||N/A|1100|Anticipated|Papua New Guinea Institute of Medical Research||3|||f||||t||||||||||2018-06-01 04:11:36.141237|2018-06-01 04:11:36.141237
NCT00285649|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2017-04-18||2017-07-07|2006-01-31|2006-02-02|Estimate|2017-04-18|2017-07-05|Actual||||2017-07-07|2017-08-16|Actual|July 2004||2004-07-31|July 2017|2017-07-31|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|||Predicting Patients' Response to Spinal Manipulation|Predicting Patients' Response to Spinal Manipulation|Completed||N/A|192|Actual|Palmer College of Chiropractic||3|||f||||t||||||||No||2018-06-01 04:11:36.240464|2018-06-01 04:11:36.240464
NCT00285636|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2013-05-06|2006-01-31|2006-02-02|Estimate|||||||2013-05-06|2013-05-08|Estimate|June 1992||1992-06-30|September 2009|2009-09-30|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Observational|||Long Term Follow-Up of Burn Injuries|Long Term Follow-Up of Burn Injuries|Completed|||1000|Anticipated|National Institute of General Medical Sciences (NIGMS)|||||f||||f||||||||||2018-06-01 04:11:36.484705|2018-06-01 04:11:36.484705
NCT00285623|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2012-05-04|2006-02-01|2006-02-02|Estimate|||||||2012-05-04|2012-05-07|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Observational|||Observational Cohort Study of TachoSil (TC-018-IN)|An Non-interventional, Prospective, Non-controlled Study of the Use of TachoSil in Supportive Treatment in Surgery for Improvement of Haemostasis Where Standard Techniques Are Insufficient.|Completed|||3000|Actual|Nycomed|||||f||||t||||||||||2018-06-01 04:11:36.540454|2018-06-01 04:11:36.540454
NCT00285610|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2014-11-17|2006-02-01|2006-02-02|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2001||2001-11-30|November 2014|2014-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Early Exposure to Lead and Adult Antisocial Outcomes||Completed|||225|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 04:11:36.600696|2018-06-01 04:11:36.600696
NCT00285597|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-10-08|2006-01-31|2006-02-02|Estimate|||||||2009-10-08|2009-10-09|Estimate|May 2004||2004-05-31|October 2009|2009-10-31|January 2006||2006-01-31|||||Interventional|||Ursodeoxycholic Acid in Chronic Heart Failure|Ursodeoxycholic Acid Therapy in Chronic Heart Failure: A Placebo-controlled Study Evaluating the Effects of Ursodeoxycholic Acid on Peripheral Blood Flow and Immune Function|Unknown status|Active, not recruiting|Phase 2|||National Heart and Lung Institute|||||f||||||||||||||2018-06-01 04:11:36.652642|2018-06-01 04:11:36.652642
NCT00285584|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2012-03-13||2017-11-14|2006-01-31|2006-02-02|Estimate|2012-05-17|2012-06-20|Estimate||||2017-11-14|2017-12-12|Actual|September 2002||2002-09-30|November 2017|2017-11-30|September 2004|Actual|2004-09-30|March 2004|Actual|2004-03-31||Interventional|||Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)|Drug Abuse, Depression and Responses to HIV Counseling|Completed||Phase 1|41|Actual|New York University School of Medicine|We achieved substantially lower recruitment than needed to adequately test the study hypothesis. We also experienced substantial losses-to-follow-up.|2|||f||||t|t|f|||f|||||2018-06-01 04:11:36.815282|2018-06-01 04:11:36.815282
NCT00285571|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2010-03-17|2006-02-01|2006-02-02|Estimate|||||||2010-03-17|2010-03-18|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|September 2007|Actual|2007-09-30|||||Interventional|||Dietary Variety Versus Dietary Fat Effects in Energy Intake|Dietary Variety vs Dietary Fat Effects on Energy Intake|Completed||Phase 1/Phase 2|64|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:11:37.243035|2018-06-01 04:11:37.243035
NCT00285558|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2017-10-05|2006-01-31|2006-02-02|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2003|Actual|2003-08-31|October 2017|2017-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Peer-enhanced Intervention to Support Teen Weight Loss|Peer-Enhanced Intervention to Support Teen Weight Loss|Completed||N/A|118|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||||||||||||2018-06-01 04:11:37.296149|2018-06-01 04:11:37.296149
NCT00285545|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2013-06-29|2006-01-31|2006-02-02|Estimate|||||||2013-06-29|2013-07-02|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Biomagnetic Signals of Intestinal Ischemia|Biomagnetic Signals of Intestinal Ischemia II|Completed|||60|Actual|University of South Alabama|||2||f||||f||||||||||2018-06-01 04:11:37.374049|2018-06-01 04:11:37.374049
NCT00285532|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2014-11-17|2006-02-01|2006-02-02|Estimate|||||||2014-11-17|2014-11-18|Estimate|October 2001||2001-10-31|November 2014|2014-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Identifying Residential Hazards Using Home Test Kits||Completed|||150|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||1||f||||||||||||||2018-06-01 04:11:37.449143|2018-06-01 04:11:37.449143
NCT00285519|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2006-02-01|2006-02-01|2006-02-02|Estimate|||||||2006-02-01|2006-02-02|Estimate|August 2003||2003-08-31|February 2006|2006-02-28|August 2005||2005-08-31|||||Interventional|||Japan Morning Surge-1 Study|The Effects of Controlling Morning Hypertension on Target Organ Damage With Adrenergic Blockers, Based on Self-Measured Morning Blood Pressure Readings|Completed||Phase 4|600||Japan Heart Foundation|||||f||||||||||||||2018-06-01 04:11:37.504124|2018-06-01 04:11:37.504124
NCT00285506|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-05-25|2006-01-31|2006-02-02|Estimate|||||||2006-05-25|2006-05-29|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||The Effect of Contrast Media on Erythrocytes in Healthy Volunteers|The Effect of Low-Osmolar and Iso-Osmolar Contrast Media on Erythrocytes in Healthy Volunteers.|Completed|||20||Medical University of South Carolina|||||f||||||||||||||2018-06-01 04:11:37.56632|2018-06-01 04:11:37.56632
NCT00285493|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2014-03-12|2006-02-01|2006-02-02|Estimate|||||||2014-03-12|2014-03-13|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Low Back Pain and Antibiotic Treatment|Phase 1 Study of Antibiotic Treatment for Low Back Pain|Withdrawn||Phase 1|0|Actual|Loewenstein Hospital||||Withdrawn: study halted prematurely, prior to enrollment of first participant|f||||||||||||||2018-06-01 04:11:37.624159|2018-06-01 04:11:37.624159
NCT00285467|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2012-03-27||2016-04-18|2006-01-31|2006-02-02|Estimate|2016-04-18|2016-05-02|Estimate||||2016-04-18|2016-05-02|Estimate|January 2006||2006-01-31|April 2016|2016-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||47 subjects had at least one follow up visit after taking medications and were included in results.|Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease|Comparison of Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in CKD|Completed||N/A|55|Actual|Indiana University|Larger, long term studies are needed to demonstrate efficacy of mineral-related and non-mineral-related endpoints and safety.|2|||f||||t||||||||No||2018-06-01 04:11:37.702742|2018-06-01 04:11:37.702742
NCT00285454|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2015-03-30|2006-02-01|2006-02-02|Estimate|||||||2015-03-30|2015-03-31|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|December 2008|Anticipated|2008-12-31|February 2006|Anticipated|2006-02-28||Interventional|||Cell Repair in Heart Failure|A Phase I/II, Randomised, Double-blind, Placebo Controlled, Single-centre Study of Bone Marrow Mononuclear Cells by Percutaneous Retrograde Coronary Venous Delivery to Patients With Ischaemic Heart Failure and no Standard Revascularisation Options.|Withdrawn||Phase 1/Phase 2|0|Actual|Imperial College London||||no funding|f||||||||||||||2018-06-01 04:11:37.913811|2018-06-01 04:11:37.913811
NCT00285441|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-02-27|2006-01-31|2006-02-02|Estimate|||||||2006-02-27|2006-02-28|Estimate|November 2005||2005-11-30|December 2005|2005-12-31|September 2008||2008-09-30|||||Observational|||Identification of Cytokine Profiles and T Cell Subsets Among Immunosuppressed Patients at Risk of Developing Active Tuberculosis||Unknown status|Recruiting||60||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:11:37.970269|2018-06-01 04:11:37.970269
NCT00285428|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2012-02-02|2006-01-31|2006-02-02|Estimate|||||||2012-02-02|2012-02-06|Estimate|September 2004||2004-09-30|February 2012|2012-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma|A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|82|Actual|Immunomedics, Inc.||4|||f||||f||||||||||2018-06-01 04:11:38.036598|2018-06-01 04:11:38.036598
NCT00285415|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2013-10-24|2006-01-31|2006-02-02|Estimate|||||||2013-10-24|2013-10-28|Estimate|April 2005||2005-04-30|October 2013|2013-10-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation|A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation for Stage III/IV Endometrial Carcinoma|Completed||Phase 2|46|Actual|Carilion Clinic||1|||f||||||||||||||2018-06-01 04:11:38.229811|2018-06-01 04:11:38.229811
NCT00285402|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-02-06|2006-01-31|2006-02-02|Estimate|||||||2008-02-06|2008-02-08|Estimate|May 2007||2007-05-31|February 2008|2008-02-29|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine|Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study|Unknown status|Active, not recruiting|Phase 2|198|Anticipated|Ariston Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-06-01 04:11:38.305265|2018-06-01 04:11:38.305265
NCT00285389|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-02-11|2006-01-31|2006-02-02|Estimate|||||||2009-02-11|2009-02-12|Estimate|February 2002||2002-02-28|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2005|Actual|2005-12-31||Interventional|||Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years|Treatment in First Line of Mantle Cell Lymphoma for Patients Under 66 Years by the VAD-CHLORAMBUCIL -Rituximab Regimen Followed by Intensification and Autologous PBSC Transplantation After Marrow Purging With Rituximab|Completed||Phase 2|39|Actual|French Innovative Leukemia Organisation||1|||f||||t||||||||||2018-06-01 04:11:38.392439|2018-06-01 04:11:38.392439
NCT00285376|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-02-12|2006-01-31|2006-02-02|Estimate|||||||2008-02-12|2008-02-21|Estimate|February 2006||2006-02-28|February 2008|2008-02-29|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response|A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder|Completed||Phase 3|410|Actual|Genaissance Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:11:38.471383|2018-06-01 04:11:38.471383
NCT00285363|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-01-31|2006-01-31|2006-02-02|Estimate|||||||2006-01-31|2006-02-02|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||Quality of Life Among Children and Adolescents With Cancer|Quality of Life Among Children and Adolescents With Cancer|Unknown status|Active, not recruiting||75||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:11:38.66855|2018-06-01 04:11:38.66855
NCT00285350|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2015-03-24|2006-01-31|2006-02-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2002||2002-09-30|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Mycophenolate Mofetil in Myasthenia Gravis|A Trial of Mycophenolate Mofetil in Myasthenia Gravis|Completed||Phase 3|80||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 04:11:38.71943|2018-06-01 04:11:38.71943
NCT00285337|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2017-10-30|2006-02-01|2006-02-02|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2005||2005-12-31|October 2017|2017-10-31|November 2007|Actual|2007-11-30|||||Observational|CSM||Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy|An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy|Completed|||321|Anticipated|AOSpine North America Research Network|||||f||||f||||||||||2018-06-01 04:11:38.779182|2018-06-01 04:11:38.779182
NCT00285324|ClinicalTrials.gov processed this data on May 31, 2018|2006-02-01|||2017-10-05|2006-01-31|2006-02-01|Estimate|||||||2017-10-05|2017-10-06|Actual|January 27, 2006||2006-01-27|August 20, 2013|2013-08-20|August 20, 2013||2013-08-20|||||Observational|||Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis|Two-Compartment Model of Diffusion Tensor Magnetic Resonance Imaging (DT-MRI) for the Diagnosis of Glioma Tumor Recurrence Versus Radiation Necrosis|Completed|||29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:11:38.895352|2018-06-01 04:11:38.895352
NCT00285298|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2011-07-28|2006-01-31|2006-02-01|Estimate|||||||2011-07-28|2011-07-29|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients|Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients: a Pilot Randomized, Placebo-controlled, Double-blind Trial.|Completed||Phase 3|39|Actual|Walter Reed Army Medical Center||2|||f||||||||||||||2018-06-01 04:11:38.990389|2018-06-01 04:11:38.990389
NCT00285285|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-01-31|2006-01-31|2006-02-01|Estimate|||||||2006-01-31|2006-02-01|Estimate|January 2004||2004-01-31|January 2006|2006-01-31|August 2004||2004-08-31|||||Interventional|||Point of Care Device Use in the Pediatric Emergency Department|A Randomized Trial to Assess the Efficacy of Point-of-Care Testing in Decreasing Length of Stay in a Pediatric Emergency Department|Completed||N/A|200||Yale University|||||f||||||||||||||2018-06-01 04:11:39.063448|2018-06-01 04:11:39.063448
NCT00285259|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30||2013-07-31|2013-07-31|2006-01-30|2006-02-01|Estimate||||2013-07-31|2013-08-07|Estimate|2013-07-31|2013-08-07|Estimate|January 2006||2006-01-31|July 2013|2013-07-31|November 2010|Actual|2010-11-30|November 2009|Actual|2009-11-30||Interventional|||Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)|A Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity, and Clinical Benefit of a CMV Immunotherapeutic Vaccine in Donors and CMV-Seropositive Recipients Undergoing Allogeneic, Matched Hematopoietic Cell Transplant (HCT)|Completed||Phase 2|108|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:11:39.121688|2018-06-01 04:11:39.121688
NCT00285246|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2014-08-28||2015-04-23|2006-01-30|2006-02-01|Estimate|2014-10-01|2014-10-06|Estimate||||2015-04-23|2015-05-12|Estimate|December 2005||2005-12-31|April 2015|2015-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational||All enrolled participants|Prospective Study of Veteran Health in Previously Deployed Soldiers|Prospective Study of Functional Status in Veterans at Risk for Unexplained Illnesses|Completed|||838|Actual|VA Office of Research and Development|The sample was comprised of only Army National Guard and Reserve military personnel, and therefore results may not generalize to the broader population of military personnel from other Service branches or components.||1||f||||f||||||None Retained|"~     Saliva~   "|||2018-06-01 04:11:39.316411|2018-06-01 04:11:39.316411
NCT00285233|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-07-31|2006-01-31|2006-02-01|Estimate|||||||2012-07-31|2012-08-02|Estimate|September 2000||2000-09-30|July 2012|2012-07-31|March 2005|Actual|2005-03-31|September 2004|Actual|2004-09-30||Interventional|||Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes|An Open-label Pilot Study of Delayed Mycophenolate Mofetil Instead of Tacrolimus Combined With Anti-thymocyte Globulin, Daclizumab, Etanercept, and Sirolimus in Single-donor, Solitary Islet Allograft Recipients With Type 1 Diabetes|Completed||Phase 1/Phase 2|8|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 04:11:39.517087|2018-06-01 04:11:39.517087
NCT00285220|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-02-17|2006-01-31|2006-02-01|Estimate|||||||2009-02-17|2009-02-19|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|||||Interventional|||Safety and Efficacy of Laparoscopic Truncal Vagotomy for the Treatment of Obesity|A Prospective, Multi-Center Study to Evaluate the Safety and Effectiveness of Laparoscopic Truncal Vagotomy for the Treatment of Obesity|Completed||N/A|30||University of Rochester|||||f||||t||||||||||2018-06-01 04:11:39.589433|2018-06-01 04:11:39.589433
NCT00285207|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2010-08-30||2010-09-23|2006-01-30|2006-02-01|Estimate|2010-09-23|2010-10-11|Estimate||||2010-09-23|2010-10-11|Estimate|January 2006||2006-01-31|September 2010|2010-09-30|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial of the Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenyl-hydrazone (A-007) Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix|Completed||Phase 2|147|Actual|Tigris Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:11:39.65939|2018-06-01 04:11:39.65939
NCT00285194|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-07-31|2006-01-30|2006-02-01|Estimate|||||||2012-07-31|2012-08-02|Estimate|April 2000||2000-04-30|July 2012|2012-07-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients|hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients|Completed||Phase 1/Phase 2|6||University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 04:11:39.961264|2018-06-01 04:11:39.961264
NCT00285181|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2007-08-08|2006-01-31|2006-02-01|Estimate|||||||2007-08-08|2007-08-09|Estimate|November 2005||2005-11-30|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Effects of Statins on Pro- and Antioxidant Status : Link With Statin-Associated Myopathy.|Effects of Statins on Pro- and Antioxidant Status : Link With Statin-Associated Myopathy. A Randomized, Placebo-Controlled, Double-Blind Study.|Completed||N/A|24|Anticipated|University Hospital, Montpellier|||||f||||f||||||||||2018-06-01 04:11:40.040604|2018-06-01 04:11:40.040604
NCT00285168|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-07-18|2006-01-30|2006-02-01|Estimate|||||||2012-07-18|2012-07-20|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|March 2010|Actual|2010-03-31|March 2008|Actual|2008-03-31||Observational|||A Randomized Controlled Trial of a Bone Density Decision Aide|A Randomized Controlled Trial of a Bone Density Decision Aide in the Pharmacological Management of Osteoporosis|Terminated|||200|Actual|University of Manitoba|||2|Inadequate recruitment|f||||||||||||||2018-06-01 04:11:40.108289|2018-06-01 04:11:40.108289
NCT00285155|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2007-08-08|2006-01-31|2006-02-01|Estimate|||||||2007-08-08|2007-08-09|Estimate|November 2004||2004-11-30|August 2007|2007-08-31|February 2006|Actual|2006-02-28|||||Interventional|||Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers|Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers|Completed||N/A|12|Anticipated|University Hospital, Montpellier|||||f||||||||||||||2018-06-01 04:11:40.171595|2018-06-01 04:11:40.171595
NCT00285142|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-10-05|2006-01-31|2006-02-01|Estimate|||||||2006-10-05|2006-10-06|Estimate|June 2004||2004-06-30|January 2006|2006-01-31|November 2004||2004-11-30|||||Interventional|||Effect of Rosiglitazone|Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers|Completed||N/A|12||University Hospital, Montpellier|||||f||||||||||||||2018-06-01 04:11:40.225614|2018-06-01 04:11:40.225614
NCT00285129|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2007-12-19|2006-01-31|2006-02-01|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|December 2004|Actual|2004-12-31|||||Interventional|||Primary Ceramic-on-Ceramic Total Hip Replacement Versus Metal-on-Metal Hip Resurfacing in Young Active Patients|Primary Ceramic-on-Ceramic Total Hip Replacement Versus Metal-on-Metal Hip Resurfacing in Young Active Patients|Completed||N/A|400||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:40.279927|2018-06-01 04:11:40.279927
NCT00285116|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-05-18|2006-01-31|2006-02-01|Estimate|||||||2009-05-18|2009-05-19|Estimate||||February 2009|2009-02-28||||||||Interventional|||The Correlation Between Fasicitis Plantaris and Hallux Rigidus|The Correlation Between Fasicitis Plantaris and Hallux Rigidus|Withdrawn||N/A|60|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:40.327598|2018-06-01 04:11:40.327598
NCT00285103|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-01|2006-01-31|2006-02-01|Estimate|||||||2011-02-01|2011-02-02|Estimate|June 2005||2005-06-30|February 2011|2011-02-28|December 2007|Actual|2007-12-31|||||Interventional|||SPC2996 in Chronic Lymphocytic Leukaemia|An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia|Completed||Phase 1/Phase 2|46|Anticipated|Santaris Pharma A/S|||||f||||t||||||||||2018-06-01 04:11:40.383701|2018-06-01 04:11:40.383701
NCT00285090|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2011-12-19|2006-01-31|2006-02-01|Estimate|||||||2011-12-19|2011-12-20|Estimate|February 2005||2005-02-28|December 2011|2011-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Bone Mineral Density, Body Composition and Growth Following Severe Burn Injury|Bone Mineral Density, Body Composition and Growth Following Severe Burn Injury|Terminated||Phase 1|60|Anticipated|Shriners Hospitals for Children||4||Lack of volunteers|f||||||||||||||2018-06-01 04:11:40.457647|2018-06-01 04:11:40.457647
NCT00285077|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-12-22|2006-01-31|2006-02-01|Estimate|||||||2008-12-22|2008-12-23|Estimate|March 2004||2004-03-31|December 2008|2008-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease|Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease|Completed||Phase 2|390|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:11:40.539847|2018-06-01 04:11:40.539847
NCT00285064|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2008-10-11|2006-01-30|2006-02-01|Estimate|||||||2008-10-11|2008-10-15|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|May 2008|Actual|2008-05-31|August 2007|Actual|2007-08-31||Interventional|||Assessment of Myocardial Viability Using Multidetector Computed Tomography|Non-Invasive Assessment of Myocardial Viability Using Multidetector Computed Tomography Post Acute Myocardial Infarction|Completed||N/A|20|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:11:40.611105|2018-06-01 04:11:40.611105
NCT00285051|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2017-04-27|2006-01-31|2006-02-01|Estimate|||||||2017-04-27|2017-04-28|Actual|November 2005||2005-11-30|April 2017|2017-04-30|November 2005||2005-11-30|||||Interventional|||Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy|Study to Compare the Safety and Efficacy of 2 Different Doses of Inhaled D8-THC to Standard Therapy With Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy|Suspended||Phase 2|108||Rafa Laboratories||||Study drug expiry date not extended|f||||||||||||||2018-06-01 04:11:40.667367|2018-06-01 04:11:40.667367
NCT00285038|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2010-12-13|2006-01-30|2006-02-01|Estimate|||||||2010-12-13|2010-12-14|Estimate|March 2006||2006-03-31|January 2006|2006-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Ultrasound (US)-Doppler for the Diagnosis of Asymptomatic Deep Vein Thrombosis (DVT) in Gynecologic Cancer Patients|US-Doppler for the Diagnosis of Asymptomatic DVT in Gynecologic Cancer Patients|Completed|||100|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:11:40.729879|2018-06-01 04:11:40.729879
NCT00285025|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-01-31|2006-01-31|2006-02-01|Estimate|||||||2006-01-31|2006-02-01|Estimate|March 2005||2005-03-31|January 2006|2006-01-31|September 2005||2005-09-30|||||Interventional|||Study of the Effect of SR57667B in Patients With Alzheimer's Disease|A Phase II, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease|Completed||Phase 2|500||Sanofi|||||f||||||||||||||2018-06-01 04:11:40.779753|2018-06-01 04:11:40.779753
NCT00285012|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2009-10-30||2010-04-15|2006-01-30|2006-02-01|Estimate|2009-10-30|2009-12-03|Estimate||||2010-04-15|2010-04-20|Estimate|May 2006||2006-05-31|April 2010|2010-04-30|April 2009|Actual|2009-04-30|July 2008|Actual|2008-07-31||Interventional|||Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease|Completed||Phase 3|504|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:11:40.858931|2018-06-01 04:11:40.858931
NCT00284999|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-08-21|2006-01-31|2006-02-01|Estimate|||||||2006-08-21|2006-08-22|Estimate||||August 2006|2006-08-31|August 2006||2006-08-31|||||Interventional|||Soothe Versus Refresh||Completed||Phase 4|33||Pharmaceutical Research Network|||||f||||||||||||||2018-06-01 04:11:41.554141|2018-06-01 04:11:41.554141
NCT00284986|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2014-12-02|2006-01-31|2006-02-01|Estimate|||||||2014-12-02|2014-12-04|Estimate|November 2005||2005-11-30|December 2014|2014-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients|A Phase II Open Label Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Salvage of Treatment-Refractory Acute GVHD Patients|Completed||Phase 2|15|Actual|Mesoblast, Ltd.||1|||f||||f||||||||||2018-06-01 04:11:41.606421|2018-06-01 04:11:41.606421
NCT00284973|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2015-04-13|2006-01-30|2006-02-01|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2006||2006-01-31|April 2007|2007-04-30||||||||Interventional|||A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate|Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers|Completed||Phase 1|70||PATH|||||f||||||||||||||2018-06-01 04:11:41.761592|2018-06-01 04:11:41.761592
NCT00284960|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2017-08-01|2006-01-31|2006-02-01|Estimate|||||||2017-08-01|2017-08-03|Actual|June 2005||2005-06-30|August 2017|2017-08-31|March 2007|Actual|2007-03-31|||||Observational|||The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction|The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction|Completed|||30||Milton S. Hershey Medical Center|||||f||||||||||||||2018-06-01 04:11:41.833903|2018-06-01 04:11:41.833903
NCT00284947|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2017-03-27|2006-01-30|2006-02-01|Estimate|||||||2017-03-27|2017-03-29|Actual|January 2006||2006-01-31|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids|REPLACE: Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids|Completed||Phase 4|7|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:11:41.896901|2018-06-01 04:11:41.896901
NCT00284934|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2010-12-20||2011-03-31|2006-01-30|2006-02-01|Estimate|2011-03-31|2011-05-02|Estimate||||2011-03-31|2011-05-02|Estimate|December 2005||2005-12-31|March 2011|2011-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|OLYMPE||Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients|A Multicenter, National, Open-label, Prospective, Randomized Study to Evaluate Efficacy and Tolerability of Enteric-coated Mycophenolate Sodium 1440 mg/Day With Tacrolimus Reduced Dose Versus Enteric-coated Mycophenolate Sodium 720 mg/Day With Tacrolimus Standard Dose, in Maintenance, Stable, Adult, Kidney Transplant Recipients|Completed||Phase 3|94|Actual|Novartis||2|||f||||f||||||||||2018-06-01 04:11:42.026217|2018-06-01 04:11:42.026217
NCT00284921|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2011-11-01|2006-01-30|2006-02-01|Estimate|||||||2011-11-01|2011-11-02|Estimate|April 2004||2004-04-30|November 2011|2011-11-30||||August 2006|Actual|2006-08-31||Interventional|||MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive|A Twelve-month, Randomized, Multicenter, Open-label, Exploratory Study to Investigate the Clinical Outcomes of an Immunosuppressive Regimen of Basiliximab, Cyclosporine Microemulsion (CsA-ME) and Enteric-coated Mycophenolate Sodium (EC-MPS) Free of Steroids Compared With a Regimen of EC-MPS With Standard Steroids in de Novo Kidney Recipients Who Are Hepatitis C Positive|Terminated||Phase 3|60||Novartis|||||f||||||||||||||2018-06-01 04:11:42.463855|2018-06-01 04:11:42.463855
NCT00284908|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-03-21|2006-01-31|2006-02-01|Estimate|||||||2008-03-21|2008-03-24|Estimate|September 2006||2006-09-30|March 2008|2008-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers|Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers|Completed||Phase 1|32|Actual|STEBA France||1|||f||||f||||||||||2018-06-01 04:11:42.535209|2018-06-01 04:11:42.535209
NCT00284895|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2017-03-27|2006-01-31|2006-02-01|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2005||2005-11-30|March 2017|2017-03-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Observational|||The Effect of Obesity on Lung Functioning|The Effect of Medical and Surgical Weight Loss on Pulmonary Physiology and Airway|Completed|||40|Actual|National Jewish Health|||||f||||||||||||||2018-06-01 04:11:42.627424|2018-06-01 04:11:42.627424
NCT00284882|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2008-01-24|2006-01-30|2006-02-01|Estimate|||||||2008-01-24|2008-01-25|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|November 2006||2006-11-30|||||Observational|||Incidence of Group A Strep Pharyngitis in School Children in Fiji|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 3: The Incidence of Group A Streptococcal Pharyngitis and the Prevalence of Pyoderma and Scabies in School Children in Fiji, and Establishing Immunologic Correlates of Protection for a J8 Vaccine|Completed|||1000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:11:42.692094|2018-06-01 04:11:42.692094
NCT00284869|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-09-11|2006-01-31|2006-02-01|Estimate|||||||2006-09-11|2006-09-13|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|April 2006||2006-04-30|||||Interventional|||Ethnic Differences in the Inflammatory Response in Systemic Inflammation|Ethnic Differences in the Inflammatory Response in Systemic Inflammation|Completed||Phase 1|32||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:11:42.745108|2018-06-01 04:11:42.745108
NCT00284856|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2011-04-06||2017-03-09|2006-01-31|2006-02-01|Estimate|2011-04-06|2011-05-03|Estimate||||2017-03-09|2017-04-06|Actual|May 2006||2006-05-31|March 2017|2017-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients With Chronic Asthma Who Smoke Cigarettes|Completed||Phase 3|1640|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:11:42.848149|2018-06-01 04:11:42.848149
NCT00284843|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2008-01-24|2006-01-30|2006-02-01|Estimate|||||||2008-01-24|2008-01-25|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|June 2007||2007-06-30|||||Observational|||Prevalence of RHD, Pyoderma and Scabies in Children in Fiji|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 1: The Prevalence of Rheumatic Heart Disease, Pyoderma and Scabies in School Children in Fiji|Completed|||5200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:11:43.220674|2018-06-01 04:11:43.220674
NCT00284830|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-02-26|2006-01-31|2006-02-01|Estimate|||||||2008-02-26|2008-02-29|Estimate|January 2003||2003-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|December 2006|Actual|2006-12-31||Interventional|SAVEPACe||SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction|Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction (SAVE PACe)|Completed||N/A|1070|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-06-01 04:11:43.276503|2018-06-01 04:11:43.276503
NCT00284817|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2008-05-27|2006-01-31|2006-02-01|Estimate|||||||2008-05-27|2008-05-29|Estimate|July 2001||2001-07-31|May 2008|2008-05-31|May 2005|Actual|2005-05-31|January 2005|Actual|2005-01-31||Interventional|||Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer|Phase I Study of MEDI522, a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer or Other Solid Tumors Refractory to Standard Therapy|Completed||Phase 1/Phase 2|17|Actual|MedImmune LLC||5|||f||||||||||||||2018-06-01 04:11:43.561106|2018-06-01 04:11:43.561106
NCT00284804|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30||2015-09-23|2015-09-23|2006-01-30|2006-02-01|Estimate||||2010-09-10|2010-09-14|Estimate|2015-09-23|2015-10-12|Estimate|November 2005||2005-11-30|September 2015|2015-09-30|October 2009|Actual|2009-10-31|May 2008|Actual|2008-05-31||Interventional|||A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease|An Open-label, Randomized, Multicenter, Phase II Study of MDX-060 in Combination With Gemcitabine, MDX060 in Combination With Dexamethasone, and Gemcitabine Monotherapy in Patients With Relapsed or Refractory Hodgkin's Disease|Completed||Phase 2|74|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 04:11:43.660782|2018-06-01 04:11:43.660782
NCT00284791|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2017-05-16|2006-01-30|2006-02-01|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2006|Actual|2006-01-31|May 2017|2017-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Lamotrigine in Treatment Resistant Depression in Adolescents|Lamotrigine Use in Treatment Refractory Depression in Adolescents|Terminated||N/A|50||Maine Medical Center|||||f||||||||||||||2018-06-01 04:11:43.770479|2018-06-01 04:11:43.770479
NCT00284778|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2010-03-26|2006-01-31|2006-02-01|Estimate|||||||2010-03-26|2010-03-29|Estimate|February 2006||2006-02-28|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer|A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Français de Pneumo-Cancérologie (GFPC).|Completed||Phase 3|150|Anticipated|University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:11:43.865663|2018-06-01 04:11:43.865663
NCT00284765|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-03-10|2006-01-31|2006-02-01|Estimate|||||||2006-03-10|2006-03-13|Estimate|February 2006||2006-02-28|January 2006|2006-01-31|May 2006||2006-05-31|||||Interventional|||Management of the Sprained Ankle by Help of NSAID-Plaster|Optimation of Treatment of the Sprained Ankle by Help of NSAID-Plaster (Flector). A Questionnaire.|Unknown status|Recruiting|N/A|200||Kolding Sygehus|||||f||||||||||||||2018-06-01 04:11:44.013627|2018-06-01 04:11:44.013627
NCT00284752|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-09-28|2006-01-30|2006-02-01|Estimate|||||||2012-09-28|2012-10-01|Estimate|August 2005||2005-08-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|October 2007|Actual|2007-10-31||Interventional|||Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer|Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer|Completed||Phase 2|56|Actual|Kaiser Permanente||1|||f||||||||||||||2018-06-01 04:11:44.09251|2018-06-01 04:11:44.09251
NCT00284739|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2013-12-16||2015-02-24|2006-01-31|2006-02-01|Estimate|2015-02-24|2015-02-26|Estimate||||2015-02-24|2015-02-26|Estimate|February 2006||2006-02-28|February 2015|2015-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses|Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses|Completed||Phase 2|20|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 04:11:44.161595|2018-06-01 04:11:44.161595
NCT00284726|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2017-12-05|2006-01-31|2006-02-01|Estimate|||||||2017-12-05|2017-12-07|Actual|December 2000||2000-12-31|December 2017|2017-12-31|September 2005||2005-09-30|||||Interventional|||The Effect of Cold Storage Solutions on Ischemic Injury in Lung Transplantation|A Prospective, Controlled, Randomized Study on the Effect of Cold Storage Solutions on Complement Activation and Other Mediators of Ischemic Injury in Lung Transplantation|Completed||Phase 3|||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:11:44.369285|2018-06-01 04:11:44.369285
NCT00284713|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-02-17|2006-01-31|2006-02-01|Estimate|||||||2009-02-17|2009-02-18|Estimate|May 2004||2004-05-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Progenitor Cell Therapy in Dilative Cardiomyopathy|Transplantation Of Progenitor Cells And Recovery Of Left Ventricular Function In Patients With Nonischemic Dilatative Cardiomyopathy|Completed||Phase 1/Phase 2|30|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-06-01 04:11:44.416031|2018-06-01 04:11:44.416031
NCT00284700|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2006-01-31|2006-01-31|2006-02-01|Estimate|||||||2006-01-31|2006-02-01|Estimate|December 1997||1997-12-31|January 2006|2006-01-31|May 2001||2001-05-31|||||Interventional|||Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh?|Is Helicobacter Pylori Infection a Cause or Treatment Failure of Iron Deficiency Anemia in Children in Bangladesh?|Completed||N/A|260||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:11:44.458132|2018-06-01 04:11:44.458132
NCT00284687|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2010-06-09|2006-01-31|2006-02-01|Estimate|||||||2010-06-09|2010-06-10|Estimate|July 2006||2006-07-31|August 2009|2009-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients|Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients|Completed||Phase 3|20|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:11:44.52145|2018-06-01 04:11:44.52145
NCT00284674|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2017-03-22|2006-01-31|2006-02-01|Estimate|||||||2017-03-22|2017-03-24|Actual|March 2006|Actual|2006-03-31|March 2017|2017-03-31||||November 2007|Actual|2007-11-30||Interventional|||Prospective Clinical Evaluation of Three Prosthesis Re-cap, M2a-Magnum and C2a-taper.||Completed||Phase 4|||Frederiksberg University Hospital|||||f||||||||||||||2018-06-01 04:11:44.593228|2018-06-01 04:11:44.593228
NCT00284661|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2015-11-26|2006-01-31|2006-02-01|Estimate|||||||2015-11-26|2015-11-30|Estimate|June 2005||2005-06-30|November 2015|2015-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Meniscal Repair: A Randomized Prospective Trial of FAST-FIX vs. Meniscal Suturing|Meniscal Repair: A Randomized Prospective Trial of FAST-FIX vs. Meniscal Suturing|Completed||N/A|132|Actual|Fowler Kennedy Sport Medicine Clinic||2|||f||||f||||||||||2018-06-01 04:11:45.571697|2018-06-01 04:11:45.571697
NCT00284648|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2015-11-26|2006-01-31|2006-02-01|Estimate|||||||2015-11-26|2015-11-30|Estimate|December 2000||2000-12-31|November 2015|2015-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Operative Versus Non-operative Treatment of Achilles Tendon Rupture|Operative Versus Non-operative Treatment of Achilles Tendon Rupture: A Multicentre, Prospective Randomized Study.|Completed||N/A|150||Fowler Kennedy Sport Medicine Clinic|||||f||||f||||||||||2018-06-01 04:11:45.675513|2018-06-01 04:11:45.675513
NCT00284635|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2007-07-03|2006-01-31|2006-02-01|Estimate|||||||2007-07-03|2007-07-04|Estimate||||July 2007|2007-07-31||||||||Interventional|||Fast-Track vs Conventional for UKA||Completed||Phase 4|||Frederiksberg University Hospital|||||f||||||||||||||2018-06-01 04:11:45.754163|2018-06-01 04:11:45.754163
NCT00284622|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-01-28|2006-01-31|2006-02-01|Estimate|||||||2009-01-28|2009-01-29|Estimate|December 2009||2009-12-31|January 2009|2009-01-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||HTO With and Without Arthroscopy|A Randomized Clinical Trial to Compare the Effectiveness of High Tibial Osteotomy With or Without Arthroscopy of the Knee Joint on Quality of Life, Functional Ability and Pain for Patients With Medical Compartment Osteoarthritis of the Knee|Unknown status|Not yet recruiting|Phase 2|98|Anticipated|Fowler Kennedy Sport Medicine Clinic|||||f||||||||||||||2018-06-01 04:11:45.802098|2018-06-01 04:11:45.802098
NCT00284609|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2010-03-25|2006-01-31|2006-02-01|Estimate|||||||2010-03-25|2010-03-26|Estimate|August 2006||2006-08-31|January 2009|2009-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Rehabilitation of Type 2 Diabetes Patients.|"The Effect of Rehabilitation of Type 2 Diabetes Mellitus Versus Standard Outpatient Care. A Randomized Controlled Trial."|Completed||N/A|180|Anticipated|Bispebjerg Hospital||2|||f||||f||||||||||2018-06-01 04:11:45.890759|2018-06-01 04:11:45.890759
NCT00284596|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2009-01-28|2006-01-31|2006-02-01|Estimate|||||||2009-01-28|2009-01-29|Estimate|February 2005||2005-02-28|January 2009|2009-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Fixation Stability and Bony Healing Following Open Wedge High Tibial Osteotomy|Fixation Stability and Progress of Bony Healing Following Open-Wedge High- Tibial Osteotomy A 24-Subject Clinical Pilot Study Using Radio Stereometric Analysis|Completed||N/A|24|Actual|Fowler Kennedy Sport Medicine Clinic|||||f||||f||||||||||2018-06-01 04:11:45.979683|2018-06-01 04:11:45.979683
NCT00284583|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2006-01-30|2006-01-30|2006-02-01|Estimate|||||||2006-01-30|2006-02-01|Estimate|May 2005||2005-05-31|January 2006|2006-01-31||||||||Interventional|||Comparison of Alcohol and Steroid Injection for Treating Morton's Neuroma|Comparison of Corticosteroid and Ethanol Injection Therapy in the Treatment of Morton's Neuroma|Unknown status|Recruiting|N/A|120||Brown University|||||f||||||||||||||2018-06-01 04:11:46.050641|2018-06-01 04:11:46.050641
NCT00284570|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2013-11-26|2006-01-30|2006-02-01|Estimate|||||||2013-11-26|2013-11-27|Estimate|January 2006||2006-01-31|November 2013|2013-11-30|March 2007|Actual|2007-03-31|||||Observational|||Pro-Calcitonin Levels Following Pediatric Cardiac Surgery|ProCalcitonin in the Pediatric Surgical Patient, Evaluation of a New Marker of Infection|Completed|||49|Actual|Emory University|||||f||||f||||||Samples With DNA|"~     Blood samples are collected in order to get the procalcitonin level.~   "|||2018-06-01 04:11:46.207081|2018-06-01 04:11:46.207081
NCT00284557|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2012-05-25||2012-06-29|2006-01-30|2006-02-01|Estimate|2012-05-25|2012-06-28|Estimate||||2012-06-29|2012-07-11|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||A Primary Care Behavioral Approach for Addressing Childhood Overweight|Evaluation of a Primary Care-Based Behavioral Intervention for Improving Physical Activity and Nutrition Behaviors Among High-Risk African-American Youth|Completed||Phase 3|130|Actual|Emory University||2|||f||||f||||||||||2018-06-01 04:11:46.285579|2018-06-01 04:11:46.285579
NCT00284531|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|||2015-10-14|2006-01-31|2006-02-01|Estimate|||||||2015-10-14|2015-10-16|Estimate|October 2003||2003-10-31|October 2015|2015-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients|Use of Zenapax (Daclizumab) for the Prevention of Primary Acute Cardiac Rejection in Children and Adolescents. Ind Number: 10100|Terminated||Phase 1/Phase 2|1|Actual|Baylor College of Medicine||||Slow enrollment|f||||f||||||||||2018-06-01 04:11:46.59532|2018-06-01 04:11:46.59532
NCT00284518|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-31|2012-11-16|2010-02-03|2012-11-16|2006-01-31|2006-02-01|Estimate|2012-11-16|2012-12-17|Estimate|2010-02-03|2010-02-08|Estimate|2012-11-16|2012-12-17|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia||Completed||Phase 2|380|Actual|Allergan||4|||f||||t||||||||||2018-06-01 04:11:46.705334|2018-06-01 04:11:46.705334
NCT00284505|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2008-12-04|2006-01-30|2006-01-31|Estimate|||||||2008-12-04|2008-12-05|Estimate|July 2005||2005-07-31|December 2008|2008-12-31|July 2006|Actual|2006-07-31|||||Interventional|||Use of Thalidomide in Patients With Arachnoiditis|Prospective Study of the Use of Thalidomide in Patients With Arachnoiditis|Completed||Phase 2|3|Anticipated|Washington University School of Medicine|||||||||||||||||||2018-06-01 04:11:47.399653|2018-06-01 04:11:47.399653
NCT00284492|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-05-11|2006-01-30|2006-01-31|Estimate|||||||2012-05-11|2012-05-14|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|May 2008|Actual|2008-05-31|May 2007|Actual|2007-05-31||Interventional|ACUFLASH||Acupuncture for Hot Flushes in Menopause|Effectiveness of Acupuncture-care for Treatment of Hot Flushes Among Postmenopausal Women|Completed||N/A|286|Actual|University Hospital of North Norway||2|||f||||||||||||||2018-06-01 04:11:47.455168|2018-06-01 04:11:47.455168
NCT00284479|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2006-07-20|2006-01-27|2006-01-31|Estimate|||||||2006-07-20|2006-07-21|Estimate|May 2002||2002-05-31|January 2003|2003-01-31|January 2003||2003-01-31|||||Interventional|||The Effect of Walking on Cardiovascular Risk|The Effect of a Worksite Based Walking Programme on Cardiovascular Risk in Previously Sedentary Civil Servants|Completed||N/A|40||University of Ulster|||||f||||||||||||||2018-06-01 04:11:47.539745|2018-06-01 04:11:47.539745
NCT00284466|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2012-08-28|2006-01-27|2006-01-31|Estimate|||||||2012-08-28|2012-08-29|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Comparing Angiography: Multislice CT Versus Invasive Heart Catheterization (CACTI)|Comparing Angiography: Multislice CT vs. Invasive Heart Catheterization (CACTI)|Completed||N/A|50|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:11:47.663276|2018-06-01 04:11:47.663276
NCT00284453|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2017-05-09|2006-01-27|2006-01-31|Estimate|||||||2017-05-09|2017-05-11|Actual|October 2005||2005-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Ventricular Tachyarrhythmia (VT) Storm, Gene Expression in Implantable Cardioverter Defibrillator (ICD) Patients With Electrical Storm|Gene Expression in ICD Patients With Electrical Storm|Active, not recruiting|||75|Anticipated|University of Pittsburgh|||3||f||||f||||||Samples With DNA|"~     6 RNA samples are obtained and kept frozen on-site to be evalauted at a later date. A portion~     of this DNA will be used to analyze the structure of certain genes that are known to play a~     role in cardiac arrhythmias. We cannot at this time know exatly what genes will be tested.~   "|||2018-06-01 04:11:47.727874|2018-06-01 04:11:47.727874
NCT00284440|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2015-03-09|2006-01-30|2006-01-31|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma|Relationship Between Visual Field Progression in Glaucoma and Choroidal Blood Flow Response to the Hand-grip Test|Withdrawn|||0|Actual|University Hospital, Basel, Switzerland||||enrollment problems|f||||f||||||||||2018-06-01 04:11:47.79109|2018-06-01 04:11:47.79109
NCT00284427|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2016-02-09|2006-01-27|2006-01-31|Estimate|||||||2016-02-09|2016-02-10|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety of Antioxidants During GYN Cancer Care|Safety of Oral Antioxidants and Intravenous Vitamin C During GYN Cancer Care|Completed||Phase 2|25|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 04:11:47.85053|2018-06-01 04:11:47.85053
NCT00284414|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2009-05-18|2006-01-30|2006-01-31|Estimate|||||||2009-05-18|2009-05-19|Estimate||||February 2009|2009-02-28||||||||Interventional|||Is Ultrasonography Comparable to MRI for the Detection of Morton Neuroma of the Foot?|Is Ultrasonography Comparable to MRI for the Detection of Morton Neuroma of the Foot?|Withdrawn||N/A|40|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:47.934727|2018-06-01 04:11:47.934727
NCT00284401|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2007-12-19|2006-01-30|2006-01-31|Estimate|||||||2007-12-19|2007-12-28|Estimate|February 2004||2004-02-29|December 2007|2007-12-31|July 2004|Actual|2004-07-31|||||Interventional|||Prosthetic Component Relationship of the Reversed Delta III Total Shoulder Prosthesis in the Transverse Plane of the Body|Prosthetic Component Relationship of the Reversed Delta III Total Shoulder Prosthesis in the Transverse Plane of the Body|Completed||N/A|50||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:47.988318|2018-06-01 04:11:47.988318
NCT00284388|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2009-02-13|2006-01-30|2006-01-31|Estimate|||||||2009-02-13|2009-02-16|Estimate||||February 2009|2009-02-28||||||||Interventional|||Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs|Incorporation of Muscle Qualities in Biomechanical Models of the Upper Limbs|Withdrawn||N/A|20|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:48.075351|2018-06-01 04:11:48.075351
NCT00284375|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2014-12-04|2006-01-30|2006-01-31|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Systematic Registration of All Big Toe Prostheses Placed in Ghent University Hospital|Systematic Registration of All Big Toe Prostheses Placed in Ghent University Hospital|Unknown status|Recruiting||500|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:48.136704|2018-06-01 04:11:48.136704
NCT00284362|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2009-05-18|2006-01-30|2006-01-31|Estimate|||||||2009-05-18|2009-05-19|Estimate||||February 2009|2009-02-28||||||||Interventional|||Prospective and Comparative Analysis of Arthroscopic and Open Surgery for Hallux Rigidus|Prospective and Comparative Analysis of Arthroscopic and Open Surgery for Hallux Rigidus|Withdrawn||N/A|60|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:48.201337|2018-06-01 04:11:48.201337
NCT00284349|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2009-05-18|2006-01-30|2006-01-31|Estimate|||||||2009-05-18|2009-05-19|Estimate||||April 2009|2009-04-30||||||||Interventional|||Study to Investigate the Added Value of a Rehabilitation Brace in the Treatment at Home After a Fracture of the Ankle|Study to Investigate the Added Value of a Rehabilitation Brace in the Treatment at Home After a Fracture of the Ankle|Withdrawn||N/A|100|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:48.26413|2018-06-01 04:11:48.26413
NCT00284336|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2014-12-08|2006-01-30|2006-01-31|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2006||2006-01-31|December 2014|2014-12-31|April 2007||2007-04-30|||||Interventional|||Caelyx Adjuvant in Elderly Breast Cancer|An Open Label Phase II Trial to Investigate the Cardiac Effects of Pegylated Liposomal Doxorubicine (Caelyx) in Elderly Breast Cancer Patients With New Imaging and Biochemical Techniques.|Completed||Phase 2|16||Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-06-01 04:11:48.380175|2018-06-01 04:11:48.380175
NCT00284323|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2006-01-27|2006-01-27|2006-01-31|Estimate|||||||2006-01-27|2006-01-31|Estimate|January 2006||2006-01-31|January 2006|2006-01-31||||||||Interventional|||Salvage: Postconditioning With Adenosine for STEMI|Beneficial Effect of Intracoronary Adenosine on Microvascular and Myocardial Salvage in Patients With Acute Myocardial Infarction (SALVAGE)|Unknown status|Recruiting|Phase 2|100||University Hospital, Gasthuisberg|||||f||||||||||||||2018-06-01 04:11:48.499254|2018-06-01 04:11:48.499254
NCT00284310|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2014-12-04|2006-01-30|2006-01-31|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2005||2005-10-31|December 2014|2014-12-31|December 2020|Anticipated|2020-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Follow-up of Patients After 4-row Arthrodesis or Proximal Row Carpectomy|Follow-up of Patients After 4-row Arthrodesis or Proximal Row Carpectomy|Recruiting||N/A|40|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:11:48.590814|2018-06-01 04:11:48.590814
NCT00284297|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2014-12-04|2006-01-30|2006-01-31|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Follow-up of Patients After Knee Arthrodesis With an Intramedullary Nail|Follow-up of Patients After Knee Arthrodesis With an Intramedullary Nail|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:11:48.660292|2018-06-01 04:11:48.660292
NCT00284284|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2009-05-11|2006-01-30|2006-01-31|Estimate|||||||2009-05-11|2009-05-12|Estimate||||April 2009|2009-04-30||||||||Interventional|||Investigation of the Added Value of a Big Toe Hinged Brace for the Treatment of Hallux Rigidus|Investigation of the Added Value of a Big Toe Hinged Brace for the Treatment of Hallux Rigidus|Withdrawn||N/A|50|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:11:48.743326|2018-06-01 04:11:48.743326
NCT00284271|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2011-07-28|2006-01-27|2006-01-31|Estimate|||||||2011-07-28|2011-07-29|Estimate|January 2004||2004-01-31|July 2011|2011-07-31||||December 2005|Actual|2005-12-31||Interventional|||Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma||Completed||Phase 2|65|Actual|University of Cologne|||||f||||||||||||||2018-06-01 04:11:48.797554|2018-06-01 04:11:48.797554
NCT00284258|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-11-01|2006-01-30|2006-01-31|Estimate|||||||2012-11-01|2012-11-02|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer|Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer|Completed||Phase 2/Phase 3|426|Actual|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 04:11:48.941937|2018-06-01 04:11:48.941937
NCT00284245|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2011-06-24|2006-01-30|2006-01-31|Estimate|||||||2011-06-24|2011-06-28|Estimate|June 2004||2004-06-30|September 2006|2006-09-30||||||||Observational|||Evaluation of Pain Location, Pain Quality and Pain Patterns in Subjects With Chronic Pain|Internet-based Study of 10,000 Subjects With Chronic Pain, Including Subject-drawn Pain Diagrams, and Computer-generated Composite Images of Pain Patterns|Unknown status|Recruiting||1000|Anticipated|Taylor MicroTechnology|||||f||||||||||||||2018-06-01 04:11:49.006226|2018-06-01 04:11:49.006226
NCT00284232|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2015-07-27|2006-01-27|2006-01-31|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2004||2004-10-31|July 2015|2015-07-31|December 2006|Actual|2006-12-31|August 2006|Actual|2006-08-31||Interventional|||Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes|Randomized Controlled Trial Studying the Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes|Completed||Phase 4|140||Helse Stavanger HF|||||f||||f||||||||||2018-06-01 04:11:49.069096|2018-06-01 04:11:49.069096
NCT00284219|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2011-06-29|2006-01-30|2006-01-31|Estimate|||||||2011-06-29|2011-06-30|Estimate|July 2005||2005-07-31|June 2011|2011-06-30||||||||Interventional|||High-Frequency Repetitive Transcranial Magnetic Stimulation Assists In Smoking Cessation||Completed||N/A|50|Anticipated|Sheba Medical Center||2|||f||||||||||||||2018-06-01 04:11:49.13055|2018-06-01 04:11:49.13055
NCT00284206|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2008-01-03|2006-01-27|2006-01-31|Estimate|||||||2008-01-03|2008-01-11|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence|An Open-Label Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence|Completed||Phase 2|20|Anticipated|Seattle Institute for Biomedical and Clinical Research|||||f||||||||||||||2018-06-01 04:11:49.256136|2018-06-01 04:11:49.256136
NCT00284193|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2012-07-26|2006-01-29|2006-01-31|Estimate|||||||2012-07-26|2012-07-27|Estimate|January 2005||2005-01-31|July 2012|2012-07-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII|Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII|Completed||Phase 4|5|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-06-01 04:11:49.325616|2018-06-01 04:11:49.325616
NCT00284180|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|2013-03-25||2013-07-09|2006-01-27|2006-01-31|Estimate|2013-07-09|2013-08-09|Estimate||||2013-07-09|2013-08-09|Estimate|January 2006||2006-01-31|July 2013|2013-07-31|November 2010|Actual|2010-11-30|February 2008|Actual|2008-02-29||Interventional|||Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer|Phase II Trial of Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer|Completed||Phase 2|32|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 04:11:49.41731|2018-06-01 04:11:49.41731
NCT00284167|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2011-07-25|2006-01-27|2006-01-31|Estimate|||||||2011-07-25|2011-07-27|Estimate|September 2003||2003-09-30|July 2011|2011-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Efficacy of a Web-based Tailored Weight Management Program|Efficacy of a Web-based Tailored Weight Management Program With and Without Tailored Nutrition and Goal Setting Support|Completed||Phase 2/Phase 3|1848||Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:11:49.820659|2018-06-01 04:11:49.820659
NCT00284154|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|2013-02-08||2013-02-08|2006-01-27|2006-01-31|Estimate|2013-02-08|2013-03-13|Estimate||||2013-02-08|2013-03-13|Estimate|January 2006||2006-01-31|February 2013|2013-02-28|November 2009|Actual|2009-11-30|May 2009|Actual|2009-05-31||Interventional|||Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer|A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer|Completed||Phase 2|51|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:11:49.911154|2018-06-01 04:11:49.911154
NCT00284141|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2012-08-17|2011-07-21|2012-11-12|2006-01-30|2006-01-31|Estimate|2012-11-12|2012-12-10|Estimate|2011-07-21|2011-07-25|Estimate|2012-11-12|2012-12-10|Estimate|January 2006||2006-01-31|July 2011|2011-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma|A Multicenter, Open-label, Single-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-resistant Locally Advanced or Metastatic Non-small-cell Lung Adenocarcinoma|Completed||Phase 2|98|Actual|Sanofi||1|||f||||t||||||||||2018-06-01 04:11:50.200792|2018-06-01 04:11:50.200792
NCT00283933|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27||2010-08-17|2018-01-09|2006-01-27|2006-01-31|Estimate||||2010-08-17|2010-08-19|Estimate|2018-01-09|2018-01-16|Actual|January 2006||2006-01-31|January 2018|2018-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease|A Phase 2, Open-Label, Single Dose Level, 24-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease|Completed||Phase 2|5|Actual|Amicus Therapeutics||1|||f||||t||||||||||2018-06-01 04:11:53.411236|2018-06-01 04:11:53.411236
NCT00284128|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30||2016-04-19|2016-04-19|2006-01-30|2006-01-31|Estimate||||2016-04-19|2016-05-18|Estimate|2016-04-19|2016-05-18|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|RAVEL-1||AVE7688 in Patients With Mild to Moderate Blood Pressure|Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With Mild to Moderate Hypertension|Completed||Phase 2/Phase 3|1940|Actual|Sanofi||5|||f||||f||||||||No||2018-06-01 04:11:50.685257|2018-06-01 04:11:50.685257
NCT00284115|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-07-03|2006-01-30|2006-01-31|Estimate|||||||2012-07-03|2012-07-04|Estimate|March 2006||2006-03-31|July 2012|2012-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Efficacy of a Mechanical Gait Repetitive Training Technique in Hemiparetic Stroke Patients (AVC)|Efficacy of a Mechanical Gait Repetitive Training Technique Compared With a Usual Rehabilitation Program on Gait Recovery in Hemiparetic Stroke Patients|Terminated||N/A|122|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-06-01 04:11:50.849928|2018-06-01 04:11:50.849928
NCT00284102|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2008-09-24|2006-01-30|2006-01-31|Estimate|||||||2008-09-24|2008-09-25|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||PEEP Test and Gas Exchange in ALI/ARDS Patients|Positive End Expiratory Pressure (PEEP) Test and Gas Exchange in ALI/ARDS Patients|Completed||N/A|50|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:11:50.930146|2018-06-01 04:11:50.930146
NCT00284089|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2011-01-20||2011-02-22|2006-01-30|2006-01-31|Estimate|2011-01-20|2011-02-11|Estimate||||2011-02-22|2011-02-24|Estimate|April 2005||2005-04-30|February 2011|2011-02-28|January 2009|Actual|2009-01-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Open-label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|Completed||Phase 1/Phase 2|88|Actual|Novartis||4|||f||||||||||||||2018-06-01 04:11:51.026732|2018-06-01 04:11:51.026732
NCT00284076|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2014-03-04|2006-01-30|2006-01-31|Estimate|||||||2014-03-04|2014-03-05|Estimate|February 2000||2000-02-29|March 2014|2014-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||L-Arginine in the Treatment of Peripheral Arterial Disease||Completed||N/A|||Stanford University|||||f||||||||||||||2018-06-01 04:11:52.045378|2018-06-01 04:11:52.045378
NCT00284063|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2015-04-14|2006-01-30|2006-01-31|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|||Z-Joint Changes in Low Back Pain Following Adjusting|Z-Joint Changes in Low Back Pain Following Adjusting|Completed||N/A|112|Actual|National University of Health Sciences||4|||f||||t||||||||||2018-06-01 04:11:52.10457|2018-06-01 04:11:52.10457
NCT00284050|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|2010-12-20||2011-02-22|2006-01-30|2006-01-31|Estimate|2010-12-21|2011-01-20|Estimate||||2011-02-22|2011-02-24|Estimate|October 2005||2005-10-31|February 2011|2011-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|RESOLVE||Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement|A Randomized, Double-masked, Multi-center, Phase II Study Assessing the Safety and Efficacy of Two Concentrations of Ranibizumab (Intravitreal Injections) Compared With Non-treatment Control for the Treatment of Diabetic Macular Edema With Center Involvement|Completed||Phase 2|151|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:11:52.202683|2018-06-01 04:11:52.202683
NCT00284037|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2006-01-27|2006-01-27|2006-01-31|Estimate|||||||2006-01-27|2006-01-31|Estimate||||May 2005|2005-05-31||||||||Interventional|||Improvement in Baroreflex Sensitivity in OSAS||Unknown status|Recruiting|N/A|||Nagoya University|||||f||||||||||||||2018-06-01 04:11:52.721484|2018-06-01 04:11:52.721484
NCT00284024|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2007-10-11|2006-01-27|2006-01-31|Estimate|||||||2007-10-11|2007-10-15|Estimate|September 2006||2006-09-30|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||Effectiveness of Domperidone to Increase Breastmilk Supply in Mothers With Low Supply|Assessing the Feasibility of Testing Domperidone's Effect on Breastfeeding in Women With Insufficient Breast Milk: An RCT Pilot Study|Terminated||Phase 2|45|Anticipated|McMaster University||||Unable to recruit participants|f||||f||||||||||2018-06-01 04:11:52.785043|2018-06-01 04:11:52.785043
NCT00284011|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2012-01-04|2006-01-30|2006-01-31|Estimate|||||||2012-01-04|2012-01-06|Estimate|June 2005||2005-06-30|January 2012|2012-01-31|May 2006|Actual|2006-05-31|April 2006|Actual|2006-04-30||Interventional|||Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels|Effect of the Dietary Supplement S-Adenosyl-L-Methionine on Plasma Homocysteine Levels in Healthy Human Subjects|Completed||N/A|52|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:11:52.852348|2018-06-01 04:11:52.852348
NCT00283998|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2014-03-25|2006-01-30|2006-01-31|Estimate|||||||2014-03-25|2014-03-26|Estimate|January 2006||2006-01-31|March 2014|2014-03-31|March 2012|Actual|2012-03-31|October 2010|Actual|2010-10-31||Interventional|||Comparing Surgical to Conservative Management in the Treatment of Type II Odontoid Fractures Among the Elderly|Phase 4 Study Comparing Surigcal to Conservative Management of Type 2 Odontoid Fractures|Completed||Phase 4|166|Anticipated|AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-06-01 04:11:52.927244|2018-06-01 04:11:52.927244
NCT00283985|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2013-02-27|2006-01-30|2006-01-31|Estimate|||||||2013-02-27|2013-02-28|Estimate|February 2006||2006-02-28|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma|Phase II Study of an Association of L-asparaginase-Methotrexate-Dexamethasone for Relapsing and/or Refractory Nasal and Nasal-type NK-T-cell Lymphoma|Completed||Phase 2|40|Actual|University Hospital, Limoges|||||f||||t||||||||||2018-06-01 04:11:53.009651|2018-06-01 04:11:53.009651
NCT00283972|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2006-01-30|2006-01-30|2006-01-31|Estimate|||||||2006-01-30|2006-01-31|Estimate|June 2005||2005-06-30|January 2006|2006-01-31|December 2006||2006-12-31|||||Observational|||LAP-BAND Observational Cohort|Health Outcome Study of LAP-BAND Adjustable Gastric Banding System|Unknown status|Active, not recruiting||240||Inamed|||||f||||||||||||||2018-06-01 04:11:53.122669|2018-06-01 04:11:53.122669
NCT00283959|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27||2010-08-17|2015-03-25|2006-01-27|2006-01-31|Estimate||||2010-08-17|2010-08-19|Estimate|2015-03-25|2015-04-15|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease|A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease|Completed||Phase 2|4|Actual|Amicus Therapeutics||1|||f||||||||||||||2018-06-01 04:11:53.228527|2018-06-01 04:11:53.228527
NCT00283946|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-30|||2014-08-19|2006-01-30|2006-01-31|Estimate|||||||2014-08-19|2014-08-20|Estimate|February 2006||2006-02-28|August 2014|2014-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia|FK199B (Zolpidem MR Tablet) Phase III Clinical Study -A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia -|Completed||Phase 3|876|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 04:11:53.310362|2018-06-01 04:11:53.310362
NCT00283920|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-29|||2017-06-30|2006-01-28|2006-01-30|Estimate|||||||2017-06-30|2017-07-02|Actual|January 26, 2006||2006-01-26|October 2, 2007|2007-10-02|October 2, 2007||2007-10-02|||||Interventional|||PET Imaging of Brain Peripheral Benzodiazepine Receptors|PET Imaging of Brain Peripheral Type Benzodiazepine Receptors|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:11:53.489776|2018-06-01 04:11:53.489776
NCT00283907|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-29|||2017-06-30|2006-01-28|2006-01-30|Estimate|||||||2017-06-30|2017-07-02|Actual|January 27, 2006||2006-01-27|December 16, 2008|2008-12-16|December 16, 2008||2008-12-16|||||Observational|||Brain Networks Responsible for Sense of Agency|Brain Networks Responsible for Sense of Agency: An EEG Study|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:11:53.626842|2018-06-01 04:11:53.626842
NCT00283894|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-29|||2017-10-05|2006-01-28|2006-01-30|Estimate|||||||2017-10-05|2017-10-06|Actual|January 20, 2006||2006-01-20|June 19, 2013|2013-06-19|June 19, 2013||2013-06-19|||||Observational|||Body Weight Regulation in Patients With Narcolepsy|The Role of the Orexin System in Body Weight Regulation: Patients With Narcolepsy|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:11:53.674736|2018-06-01 04:11:53.674736
NCT00283881|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-29|||2017-06-30|2006-01-28|2006-01-30|Estimate|||||||2017-06-30|2017-07-02|Actual|January 25, 2006||2006-01-25|October 7, 2009|2009-10-07||||October 7, 2009|Actual|2009-10-07||Observational|||Tactile Learning in Stroke Patients|Implicit Tactile Learning in Chronic Stroke Enhanced by Non-Invasive Brain Stimulation of the Somatosensory Cortex|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:11:53.737112|2018-06-01 04:11:53.737112
NCT00283868|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2009-03-27||2015-06-02|2006-01-26|2006-01-30|Estimate|2009-11-18|2009-11-19|Estimate||||2015-06-02|2015-06-03|Estimate|January 2004||2004-01-31|September 2009|2009-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|STRokE DOC||Stroke Team Remote Evaluation Using a Digital Observation Camera|A Prospective Study to Evaluate the Efficacy of a Remote Digital Observation Camera Protocol in the Evaluation and Thrombolytic Treatment of Acute Stroke Patients in the Remote Hospital Setting|Completed|||234|Actual|University of California, San Diego|||2||f||||t||||||||||2018-06-01 04:11:53.815311|2018-06-01 04:11:53.815311
NCT00283855|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2016-09-29|2006-01-26|2006-01-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|October 2003||2003-10-31|September 2016|2016-09-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||RAHelp.Org: An Online Self Management Program for Adults With Rheumatoid Arthritis|An Online Self Management Program for Adults With Rheumatoid Arthritis|Completed||N/A|200|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-06-01 04:11:54.102754|2018-06-01 04:11:54.102754
NCT00283842|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2009-06-30||2011-10-20|2006-01-26|2006-01-30|Estimate|2009-06-30|2009-08-13|Estimate||||2011-10-20|2011-10-24|Estimate|March 2006||2006-03-31|October 2011|2011-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, 13-Week, Adaptive-Design Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy|Terminated||Phase 3|408|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||5||business reasons|f||||f||||||||||2018-06-01 04:11:54.379414|2018-06-01 04:11:54.379414
NCT00283829|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2007-11-28|2006-01-26|2006-01-30|Estimate|||||||2007-11-28|2007-11-29|Estimate|September 2002||2002-09-30|November 2007|2007-11-30|July 2006|Actual|2006-07-31|||||Interventional|||Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer|Immunotherapy With Low Dose Interleukin-2 After Cytoreductive Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer: A Phase I/II Study|Completed||Phase 1/Phase 2|30|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:11:55.753371|2018-06-01 04:11:55.753371
NCT00283816|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|2011-04-08||2015-04-28|2006-01-27|2006-01-30|Estimate|2011-06-13|2011-07-13|Estimate||||2015-04-28|2015-05-15|Estimate|January 2006||2006-01-31|April 2011|2011-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy|Metabolic Impact of Oral Contraceptives With or Without Metformin in Obese Adolescents With Polycystic Ovary Syndrome (PCOS)|Completed||Phase 3|36|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 04:11:55.836396|2018-06-01 04:11:55.836396
NCT00283803|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2017-10-17||2018-04-10|2006-01-26|2006-01-30|Estimate|2018-04-10|2018-05-14|Actual||||2018-04-10|2018-05-14|Actual|March 12, 2002|Actual|2002-03-12|April 2018|2018-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer|"Evaluation of the Effect of Exisulind on the Duration of the Off-Treatment Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression (ADT)"|Completed||Phase 2|32|Actual|University of Washington|Enrollment goal was 35 evaluable patients. Of the 40+ considered, 32 consented and enrolled. However 13 withdrew, leaving only 19 evaluable patients. Due to small sample size, results were primarily descriptive in nature.|1|||f||||f||||||||No||2018-06-01 04:11:56.118718|2018-06-01 04:11:56.118718
NCT00283790|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2008-04-01|2006-01-27|2006-01-30|Estimate|||||||2008-04-01|2008-04-03|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|April 2006||2006-04-30|||||Interventional|||Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo|Investigation of Psycliomotor and Cognitive Residual Effects After Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopielone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Plurazepam 30 mg As An External Comparator|Completed||Phase 4|36||Sanofi|||||f||||||||||||||2018-06-01 04:11:56.296779|2018-06-01 04:11:56.296779
NCT00283777|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2016-04-07|2006-01-26|2006-01-30|Estimate|||||||2016-04-07|2016-04-08|Estimate|August 1998||1998-08-31|April 2016|2016-04-30|April 2003|Actual|2003-04-30|January 2003|Actual|2003-01-31||Interventional|||Chromium and Insulin Action|Effect of Chromium Picolinate on Metabolic and Physiologic Parameters in Type 2 Diabetes|Completed||Phase 4|30||Pennington Biomedical Research Center|||||f||||||||||||||2018-06-01 04:11:56.409436|2018-06-01 04:11:56.409436
NCT00283764|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2015-03-04|2006-01-26|2006-01-30|Estimate|||||||2015-03-04|2015-03-05|Estimate||||March 2015|2015-03-31||||||||Interventional|||Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device|A Phase 3, 12-Week, Parallel-Design Study Comparing The Safety, Efficacy, and Ease Of Use Of Xalatan When Self-Administered By Subjects With Open-Angle Glaucoma Or Ocular Hypertension Using Either A Conventional Dropper Bottle Or A Forced-Flow Delivery Device|Withdrawn||Phase 3|0|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:11:56.469607|2018-06-01 04:11:56.469607
NCT00283751|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2017-01-26|2006-01-27|2006-01-30|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2003||2003-03-31|January 2017|2017-01-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine as Add-on to Current Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes|Completed||Phase 3|583|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:11:56.570163|2018-06-01 04:11:56.570163
NCT00283738|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2008-01-23|2006-01-27|2006-01-30|Estimate|||||||2008-01-23|2008-01-25|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|March 2008|Anticipated|2008-03-31|||||Interventional|||MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant|A Prospective, Multi-Center, Double-Blinded, Placebo-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With the BioSTAR Septal Repair Implant to Reduce Refractory Migraine Headache With Aura.|Unknown status|Active, not recruiting|Phase 2/Phase 3|610|Anticipated|NMT Medical||2|||f||||t||||||||||2018-06-01 04:11:56.878961|2018-06-01 04:11:56.878961
NCT00283725|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2013-01-24|2006-01-27|2006-01-30|Estimate|||||||2013-01-24|2013-01-25|Estimate|June 2003||2003-06-30|January 2013|2013-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|REMIND||Use of Different Treatment Care Methods in Patients With Dementia Associated With Alzheimer's Disease|Review of Management Strategies in Dementia|Completed|||573|Actual|Ortho-McNeil Neurologics, Inc.|||2||f||||f||||||||||2018-06-01 04:11:56.949763|2018-06-01 04:11:56.949763
NCT00283712|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2012-12-21||2017-11-01|2006-01-26|2006-01-30|Estimate|2012-12-21|2013-01-31|Estimate||||2017-11-01|2017-12-06|Actual|March 2006||2006-03-31|November 2017|2017-11-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Use of Infliximab for the Treatment of Pemphigus Vulgaris|A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Infliximab in Subjects With Pemphigus Vulgaris Receiving Prednisone|Completed||Phase 2|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:11:57.062339|2018-06-01 04:11:57.062339
NCT00283699|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2010-02-05|2006-01-26|2006-01-30|Estimate|||||||2010-02-05|2010-02-08|Estimate|February 2001||2001-02-28|March 2008|2008-03-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Pilot Study of Neurocysticercosis Treatment|A Pilot Study of Neurocysticercosis Treatment|Completed||Phase 3|178|Actual|National Institute of Neurological Disorders and Stroke (NINDS)||2|||f||||t||||||||||2018-06-01 04:11:57.863384|2018-06-01 04:11:57.863384
NCT00283686|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2015-02-09||2015-03-18|2006-01-26|2006-01-30|Estimate|2015-02-25|2015-02-27|Estimate||||2015-03-18|2015-03-19|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||HALT Progression of Polycystic Kidney Disease (HALT PKD) Study A|Polycystic Kidney Disease-Treatment Network|Completed||Phase 3|558|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||t||||||||||2018-06-01 04:11:57.972716|2018-06-01 04:11:57.972716
NCT00283673|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2011-06-03|2006-01-27|2006-01-30|Estimate|||||||2011-06-03|2011-06-06|Estimate|September 1995||1995-09-30|June 2011|2011-06-30|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Effect of Exercise Intervention on Various Physiologic Factors That Change With Increasing Age|Impact of Aerobic Exercise Training on Age Related Changes in Insulin Sensitivity and Muscle Oxidative Capacity|Completed||N/A|102||Mayo Clinic|||||f||||||||||||||2018-06-01 04:11:59.140431|2018-06-01 04:11:59.140431
NCT00283660|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2015-11-16|2006-01-26|2006-01-30|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2006||2006-01-31|November 2015|2015-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Zinc, Mental Health, and School Performance in Guatemalan Schoolchildren|Zinc, Mental Health, and School Performance|Completed||N/A|750|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:11:59.255423|2018-06-01 04:11:59.255423
NCT00283647|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2015-04-13|2006-01-27|2006-01-30|Estimate|||||||2015-04-13|2015-04-14|Estimate|October 2002||2002-10-31|April 2015|2015-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||MR Assessment of Brain Function Altered by Lead Exposure|MR Assessment of Brain Function Altered by Lead Exposure|Completed|||150||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 04:11:59.32454|2018-06-01 04:11:59.32454
NCT00283634|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2011-02-16|2006-01-27|2006-01-30|Estimate|||||||2011-02-16|2011-02-17|Estimate|August 2005||2005-08-31|February 2011|2011-02-28|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer|A Randomized, Non-comparative, Multicenter, Open-Label, Phase 2 Study of Tarceva™ (Erlotinib) Alone and of Tarceva Plus VELCADE* (Bortezomib) for Injection in Patients With Relapsed or Refractory, Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Terminated||Phase 2|||Millennium Pharmaceuticals, Inc.||||insufficient efficacy|||||||||||||||2018-06-01 04:11:59.367318|2018-06-01 04:11:59.367318
NCT00283621|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2012-07-31|2006-01-27|2006-01-30|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2002||2002-11-30|July 2012|2012-07-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide|A Pilot Study of Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta) in Patients With Sarcoma Receiving Adriamycin and Ifosfamide|Completed||N/A|51|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:11:59.412822|2018-06-01 04:11:59.412822
NCT00283608|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2011-05-13|2006-01-27|2006-01-30|Estimate|||||||2011-05-13|2011-05-16|Estimate|July 2005||2005-07-31|May 2011|2011-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer|Pharmacogenetics of Aromatase Inhibitors|Completed|||1000|Anticipated|Mayo Clinic|||2||f||||t||||||Samples With DNA|"~     Anastrozole treatment group samples will be used as described for this study, and then will~     be destroyed.~      Exemestane treatment group samples of blood will be stored at Mayo Clinic Rochester.~   "|||2018-06-01 04:11:59.477254|2018-06-01 04:11:59.477254
NCT00283595|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|2012-08-16||2012-09-15|2006-01-27|2006-01-30|Estimate|2012-09-15|2012-10-16|Estimate||||2012-09-15|2012-10-16|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa|Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa|Completed||Phase 2|21|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:11:59.898124|2018-06-01 04:11:59.898124
NCT00283582|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2012-02-22|2006-01-27|2006-01-30|Estimate|||||||2012-02-22|2012-02-24|Estimate|June 2001||2001-06-30|February 2012|2012-02-29|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy|Randomized Double-blind Placebo-controlled Trial of Primary Prophylaxis With Recombinant Human Thrombopoietin Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy|Completed||Phase 3|50|Actual|M.D. Anderson Cancer Center|||||f||||||||||||||2018-06-01 04:12:00.731353|2018-06-01 04:12:00.731353
NCT00283569|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2010-01-18|2006-01-26|2006-01-30|Estimate|||||||2010-01-18|2010-01-20|Estimate|May 2004||2004-05-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Genetic Epidemiology of Adult Onset Glioma|Genetic Epidemiology of Adult-Onset Glioma|Completed|||100|Anticipated|Kentuckiana Cancer Institute|||||f||||||||||Samples With DNA|"~     Saliva, Toe Nail Clippings~   "|||2018-06-01 04:12:01.109456|2018-06-01 04:12:01.109456
NCT00283556|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2010-01-18|2006-01-26|2006-01-30|Estimate|||||||2010-01-18|2010-01-20|Estimate|August 2001||2001-08-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma|Phase I/II Study of High Dose Irinotecan (Camptosar, CPT-11) in Patients With Recurrent Unresectable Malignant Glioma on Steroids/Anti-epileptics|Completed||Phase 1/Phase 2|30|Anticipated|Kentuckiana Cancer Institute||3|||f||||||||||||||2018-06-01 04:12:01.244085|2018-06-01 04:12:01.244085
NCT00283543|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2007-10-30|2006-01-26|2006-01-30|Estimate|||||||2007-10-30|2007-10-31|Estimate|September 2002||2002-09-30|October 2007|2007-10-31|April 2008|Anticipated|2008-04-30|||||Interventional|||Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma|A Phase II Study of Radiation With Concomitant and Then Sequential Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Who Have Undergone Surgery With Gliadel Wafer Insertion|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Kentuckiana Cancer Institute|||||f||||||||||||||2018-06-01 04:12:01.313442|2018-06-01 04:12:01.313442
NCT00283530|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2010-01-18|2006-01-26|2006-01-30|Estimate|||||||2010-01-18|2010-01-20|Estimate|May 2003||2003-05-31|January 2010|2010-01-31|July 2009|Actual|2009-07-31|||||Observational|||Tumor Phenotypes and Correlation to Clinical Outcomes in Cancer|Identification of Tumor Phenotypes and Correlation to Clinical Outcomes in Patients Diagnosed With Cancer|Terminated|||1000|Anticipated|Kentuckiana Cancer Institute||||"The PI is no longer with Kentuckiana Cancer Institute. All current subjects completed. No~   further subjects will be enrolled. Terminated with IRB."|f||||||||||||||2018-06-01 04:12:01.388138|2018-06-01 04:12:01.388138
NCT00283517|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2010-04-26|2006-01-27|2006-01-30|Estimate|||||||2010-04-26|2010-04-27|Estimate|September 2003||2003-09-30|April 2010|2010-04-30|May 2006|Actual|2006-05-31|||||Observational|||A Registry of Treatment Adherence for Patients With Schizophrenia|Electronic Schizophrenia Treatment Adherence Registry, eSTAR|Completed|||2046|Actual|Janssen-Cilag, S.A.|||1||f||||||||||||||2018-06-01 04:12:01.446878|2018-06-01 04:12:01.446878
NCT00283504|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2018-02-07||2018-02-07|2006-01-26|2006-01-30|Estimate|2018-02-07|2018-02-16|Estimate||||2018-02-07|2018-02-16|Estimate|January 2006||2006-01-31|February 2018|2018-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy|A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair)|Completed||Phase 4|13|Actual|Children's Hospital of The King's Daughters|Difficulty enrolling patients and therefore had a small study population, limiting the results of the study.|1|||f||||||||||||||2018-06-01 04:12:01.521565|2018-06-01 04:12:01.521565
NCT00283491|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2009-01-20|2006-01-27|2006-01-30|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|November 2005|Actual|2005-11-30|||||Interventional|||The Effect of Lactobacillus Cultures on Iron Bioavailability.|The Effect of a Lactic Acid Fermented Oat Gruel on Iron Absorption in the Proximal and Distal Small Intestine From a Phytate Rich Meal in Healthy Women of Childbearing Age.|Completed||N/A|18|Actual|University of Copenhagen||2|||f||||||||||||||2018-06-01 04:12:01.867723|2018-06-01 04:12:01.867723
NCT00283478|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2007-10-30|2006-01-26|2006-01-30|Estimate|||||||2007-10-30|2007-10-31|Estimate|May 2004||2004-05-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer|Randomized Pilot Study of Supplemental Iscar in Combination With Gemcitabine vs. Gemcitabine Alone as Second Line Treatment for Advanced Non-Small Cell Lung Cancer.|Completed||N/A|20|Anticipated|Kentuckiana Cancer Institute|||||||||||||||||||2018-06-01 04:12:01.941108|2018-06-01 04:12:01.941108
NCT00283465|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2011-01-13|2006-01-27|2006-01-30|Estimate|||||||2011-01-13|2011-01-14|Estimate|November 1999||1999-11-30|January 2011|2011-01-31|April 2004|Actual|2004-04-30|||||Interventional|||A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy|An Open-label, Randomized Study to Evaluate the Effect of Early Treatment of Anemia With Epoetin Alfa on Hemoglobin, the Incidence of Blood Transfusions and Quality of Life in Patients Receiving Platinum-containing Chemotherapy|Completed||Phase 4|316|Actual|Janssen-Cilag B.V.|||||f||||||||||||||2018-06-01 04:12:02.012135|2018-06-01 04:12:02.012135
NCT00283452|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2010-03-09|2006-01-27|2006-01-30|Estimate|||||||2010-03-09|2010-03-10|Estimate|September 2003||2003-09-30|March 2010|2010-03-31|September 2009|Actual|2009-09-30|January 2008|Actual|2008-01-31||Interventional|||Keep Active Minnesota|Maintaining Physical Activity in Older Adult MCO Members|Completed||N/A|1049|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-06-01 04:12:02.087631|2018-06-01 04:12:02.087631
NCT00283439|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2010-08-13||2011-06-16|2006-01-26|2006-01-30|Estimate|2010-08-13|2010-09-13|Estimate||||2011-06-16|2011-06-20|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma|An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects With Lymphoma.|Completed||Phase 1/Phase 2|39|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:12:02.191754|2018-06-01 04:12:02.191754
NCT00283426|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2007-03-16|2006-01-27|2006-01-30|Estimate|||||||2007-03-16|2007-03-19|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|March 2007||2007-03-31|||||Interventional|||Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns|An Open Clinical Feasibility Study to Evaluate Efficacy and Safety of Soluble Beta-1,3/1,6-Glucan in Thermal Burns|Terminated||Phase 1|10||Biotec Pharmacon ASA||||Slow patient recruitment|f||||||||||||||2018-06-01 04:12:02.937824|2018-06-01 04:12:02.937824
NCT00283413|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-27|||2009-10-30|2006-01-27|2006-01-30|Estimate|||||||2009-10-30|2009-11-02|Estimate|March 2002||2002-03-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|May 2004|Actual|2004-05-31||Interventional|||Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts|Symbiot III: A Prospective Randomized Trial Evaluating the Symbiot Covered Stent System in Saphenous Vein Grafts|Completed||N/A|514|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 04:12:03.014818|2018-06-01 04:12:03.014818
NCT00283400|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2013-02-05||2015-03-18|2006-01-26|2006-01-27|Estimate|2015-03-18|2015-04-01|Estimate||||2015-03-18|2015-04-01|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||Treatment of Subarachnoid Hemorrhage With Human Albumin|Treatment of Subarachnoid Hemorrhage With Human Albumin|Terminated||N/A|47|Actual|Baylor College of Medicine|Our study has several limitations. ALISAH is an early phase design and we do not have concurrent controls. In addition, the study was neither randomized nor powered to test for efficacy effects.|4||Study met safety endpoints|f||||t||||||||||2018-06-01 04:12:03.173896|2018-06-01 04:12:03.173896
NCT00283387|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2012-11-01||2013-11-21|2006-01-26|2006-01-27|Estimate|2012-11-29|2013-01-01|Estimate||||2013-11-21|2013-12-16|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria|Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria|Completed||Phase 2|15|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 04:12:03.602677|2018-06-01 04:12:03.602677
NCT00283374|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2006-05-17|2006-01-25|2006-01-27|Estimate|||||||2006-05-17|2006-05-18|Estimate|October 2005||2005-10-31|May 2006|2006-05-31||||||||Observational|||Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome|A Prospective, Longitudinal Multicenter, Nontreatment, Exploratory Biomarker Study of Metabolic Syndrome in Subjects Undergoing Laparoscopic Roux-En-Y Gastric Bypass Bariatric Syndrome|Terminated|||120||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:12:03.802185|2018-06-01 04:12:03.802185
NCT00283361|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-02-27|2006-01-25|2006-01-27|Estimate|||||||2007-02-27|2007-02-28|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure|A Phase II,Randomized, Double-Blind, Flexible Dose Study of ZP120 I.V. Infusion as Add-On Therapy in Patients With Acute or Sub-Acute Decompensated Chronic Heart Failure NYHA Class III-IV Treated With Furosemide|Terminated||Phase 2|130||Zealand Pharma|||||f||||||||||||||2018-06-01 04:12:03.890182|2018-06-01 04:12:03.890182
NCT00283348|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2017-03-16|2006-01-25|2006-01-27|Estimate|||||||2017-03-16|2017-03-20|Actual|January 2006||2006-01-31|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||New Strategies for Non-invasive Detection of Chronic Allograft Nephropathy|New Strategies for Non-invasive Detection of Chronic Allograft Nephropathy|Completed|||121|Actual|Virginia Commonwealth University|||||f||||f||||||Samples With DNA|"~     Blood, Urine~   "|||2018-06-01 04:12:03.966959|2018-06-01 04:12:03.966959
NCT00283335|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2015-10-20|2006-01-26|2006-01-27|Estimate|||||||2015-10-20|2015-10-21|Estimate|June 1991||1991-06-30|October 2015|2015-10-31|August 1999|Actual|1999-08-31|September 1998|Actual|1998-09-30||Interventional|HIT||The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol|CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol|Completed||Phase 3|2531|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:12:04.018792|2018-06-01 04:12:04.018792
NCT00283322|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-12-03|2006-01-25|2006-01-27|Estimate|||||||2007-12-03|2007-12-06|Estimate|November 2004||2004-11-30|December 2007|2007-12-31|May 2006|Actual|2006-05-31|||||Observational|||Heparin Antibodies in Intensive Care Unit Patients (HAICU)|Heparin Antibodies in Intensive Care Unit Patients (HAICU)|Completed|||185|Actual|The University of Texas Health Science Center, Houston|||3||f||||f||||||Samples Without DNA|"~     Plasma. Patients consented for use to look for heparin antibodies in this study only.~   "|||2018-06-01 04:12:04.102109|2018-06-01 04:12:04.102109
NCT00283309|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2013-04-19|2006-01-25|2006-01-27|Estimate|||||||2013-04-19|2013-04-23|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes||Terminated||Phase 4|20|Actual|University of Texas Southwestern Medical Center||3||Study finished enrollment but data was never sent for publishing.|f||||||||||||||2018-06-01 04:12:04.165171|2018-06-01 04:12:04.165171
NCT00283296|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2013-06-11||2014-12-23|2006-01-24|2006-01-27|Estimate|2014-12-23|2015-01-06|Estimate||||2014-12-23|2015-01-06|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|April 2011|Actual|2011-04-30|July 2008|Actual|2008-07-31||Interventional|||Development of a Collapsible Folding Manual Wheelchair|Development of a Collapsible Folding Manual Wheelchair|Completed||Phase 2|14|Actual|VA Pittsburgh Healthcare System|Limited number of Endeavor prototypes.|1|||f||||f||||||||||2018-06-01 04:12:05.209522|2018-06-01 04:12:05.209522
NCT00283283|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2015-06-05|2006-01-24|2006-01-27|Estimate|||||||2015-06-05|2015-06-09|Estimate|November 2004||2004-11-30|June 2015|2015-06-30|May 2006|Actual|2006-05-31|November 2004|Actual|2004-11-30||Interventional|||Half vs Full Dose Influenza Vaccine|Clinical Study to Compare the Immune Response of Half Dose Trivalent Inactivated Influenza Vaccine (TIV) to Full Dose|Completed||Phase 2|1316|Actual|U.S. Army Medical Research and Materiel Command||8|||f||||f||||||||||2018-06-01 04:12:05.362552|2018-06-01 04:12:05.362552
NCT00283270|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2006-01-26|2006-01-26|2006-01-27|Estimate|||||||2006-01-26|2006-01-27|Estimate|November 2002||2002-11-30|December 2005|2005-12-31|August 2005||2005-08-31|||||Interventional|||Effectiveness of Screening and Counselling for Elderly With Psychological Problems|A Randomised Controlled Trial on the Effectiveness of Screening and Brief Counselling for Elderly Patients With Psychological Problems in Primary Care.|Completed||Phase 4|450||The University of Hong Kong|||||f||||||||||||||2018-06-01 04:12:05.454916|2018-06-01 04:12:05.454916
NCT00283257|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2017-06-26|2006-01-25|2006-01-27|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2002|Actual|2002-02-28|June 2017|2017-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Simultaneous Care: Linking Palliation to Clinical Trials|A Randomized Control Trial That Teaches Oncology Clinical Trial Patients and Their Caregivers Problem Solving Skills.|Completed||N/A|441|Actual|University of California, Davis|||||f||||||||||||||2018-06-01 04:12:05.532388|2018-06-01 04:12:05.532388
NCT00283244|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2016-08-25||2017-03-09|2006-01-24|2006-01-27|Estimate|2017-03-09|2017-04-24|Actual||||2017-03-09|2017-04-24|Actual|March 2006||2006-03-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC|Randomized Phase II Study of First-Line Treatment With Gemcitabine vs. Erlotinib vs. Gemcitabine and Erlotinib in Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 2|147|Actual|UNC Lineberger Comprehensive Cancer Center||3|||f||||t||||||||No|There is no plan to share any individual participant data.|2018-06-01 04:12:05.644469|2018-06-01 04:12:05.644469
NCT00283231|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2008-05-06|2006-01-25|2006-01-27|Estimate|||||||2008-05-06|2008-05-07|Estimate|October 2005||2005-10-31|July 2005|2005-07-31|February 2006||2006-02-28|||||Interventional|||RESPeRATE for Treatment of Hot Flashes|RESPeRATE (Paced Respiration) for Treatment of Hot Flashes and Menopausal Symptoms|Completed||N/A|12||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:12:06.732198|2018-06-01 04:12:06.732198
NCT00283218|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2006-08-07|2006-01-26|2006-01-27|Estimate|||||||2006-08-07|2006-08-08|Estimate|January 2006||2006-01-31|August 2006|2006-08-31|August 2006||2006-08-31|||||Interventional|||A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.|A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. - A Randomised, Quadruple Cross-Over Trial|Completed||N/A|24||University of Aarhus|||||f||||||||||||||2018-06-01 04:12:06.802936|2018-06-01 04:12:06.802936
NCT00283205|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2006-01-25|2006-01-25|2006-01-27|Estimate|||||||2006-01-25|2006-01-27|Estimate|September 2005||2005-09-30|March 2005|2005-03-31|December 2005||2005-12-31|||||Interventional|||Yoga for Treatment of Hot Flashes|Yoga for Treatment of Hot Flashes and Menopausal Symptoms|Completed||N/A|12||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:12:06.87147|2018-06-01 04:12:06.87147
NCT00283192|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2006-08-02|2006-01-25|2006-01-27|Estimate|||||||2006-08-02|2006-08-04|Estimate|July 2003||2003-07-31|August 2005|2005-08-31|January 2006||2006-01-31|||||Interventional|||Flushes and Sertraline Trial|A Randomized, Double-Blinded, Placebo Controlled, Trial of the Effect of Sertraline Vs. Placebo in Reducing the Incidence and Severity of Hot Flashes in Healthy Women|Completed||N/A|100||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:12:06.925401|2018-06-01 04:12:06.925401
NCT00283179|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2008-05-14|2006-01-26|2006-01-27|Estimate|||||||2008-05-14|2008-05-15|Estimate|March 2004||2004-03-31|January 2006|2006-01-31|December 2004|Actual|2004-12-31|||||Interventional|||Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia|Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control|Completed||Phase 3|83|Actual|Taiwan Otsuka Pharm. Co., Ltd|||||f||||||||||||||2018-06-01 04:12:06.988752|2018-06-01 04:12:06.988752
NCT00283166|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2017-06-07|2006-01-25|2006-01-27|Estimate|||||||2017-06-07|2017-06-09|Actual|November 2006||2006-11-30|June 2017|2017-06-30|December 2011|Actual|2011-12-31|March 2009|Actual|2009-03-31||Interventional|||Coaching to Improve Care of Cancer Pain|Coaching to Improve Care of Cancer Pain|Completed||N/A|258|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 04:12:07.05198|2018-06-01 04:12:07.05198
NCT00283153|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2014-08-01|2006-01-24|2006-01-27|Estimate|||||||2014-08-01|2014-08-04|Estimate|October 2008||2008-10-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|September 2012|Actual|2012-09-30||Interventional|||Affect Recognition: Enhancing Performance of Persons With Acquired Brain Injury (ABI)|Controlled Study of Affect Recognition Training for Individuals With Acquired Brain Injury|Completed||Phase 2/Phase 3|71|Actual|University at Buffalo||2|||f||||f||||||||||2018-06-01 04:12:07.214862|2018-06-01 04:12:07.214862
NCT00283127|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2010-03-02|2006-01-26|2006-01-27|Estimate|||||||2010-03-02|2010-03-03|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|September 2006||2006-09-30|||||Interventional|||Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women.|Home Sampling Versus Conventional Sampling for Screening of Urogenital Chlamydia Trachomatis in Young Men and Women. - A Randomised Control Trial|Completed||N/A|41719||Norwegian Institute of Public Health|||||f||||||||||||||2018-06-01 04:12:07.318793|2018-06-01 04:12:07.318793
NCT00283114|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2014-12-17|2006-01-25|2006-01-27|Estimate|||||||2014-12-17|2014-12-18|Estimate|November 2005||2005-11-30|December 2014|2014-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome|A Phase 1, Multi-Dose Study of SGN-33 (Anti-huCD33 mAb; HuM195; Lintuzumab) in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome|Completed||Phase 1|82|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 04:12:07.395918|2018-06-01 04:12:07.395918
NCT00283101|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2014-12-17|2006-01-25|2006-01-27|Estimate|||||||2014-12-17|2014-12-18|Estimate|July 2005||2005-07-31|December 2014|2014-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Safety Study in Patients With Chronic Lymphocytic Leukemia|A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|12|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 04:12:07.49048|2018-06-01 04:12:07.49048
NCT00283088|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2011-01-11|2006-01-26|2006-01-27|Estimate|||||||2011-01-11|2011-01-12|Estimate|October 2003||2003-10-31|January 2009|2009-01-31|May 2009|Actual|2009-05-31|October 2008|Actual|2008-10-31||Interventional|||Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke|Phase 1 Study of Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke|Completed||Phase 1|130|Anticipated|University of California, San Diego||6|||f||||t||||||||||2018-06-01 04:12:07.581254|2018-06-01 04:12:07.581254
NCT00283075|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2015-10-26||2016-02-11|2006-01-26|2006-01-27|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|January 2005||2005-01-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|December 2012|Actual|2012-12-31||Interventional|||Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer|Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer|Completed||Phase 1|56|Actual|The Rogosin Institute||1|||f||||t||||||||||2018-06-01 04:12:07.684987|2018-06-01 04:12:07.684987
NCT00283062|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2011-12-16||2012-01-25|2006-01-26|2006-01-27|Estimate|2011-12-16|2012-01-23|Estimate||||2012-01-25|2012-01-26|Estimate|December 2005||2005-12-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy|A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- Leuprolide Acetate) in Combination With TAXOTERE® (Docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients With Prostate Cancer at High Risk of Relapse After Radical Prostatectomy|Completed||Phase 3|228|Actual|Sanofi|The study had difficulties in meeting enrollment goals within a reasonable time frame. The final sample size allowed for the safety analyses but was underpowered for drawing conclusions regarding efficacy and quality of life (QoL) endpoints.|4|||f||||||||||||||2018-06-01 04:12:08.041857|2018-06-01 04:12:08.041857
NCT00283049|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2009-12-16||2011-01-07|2006-01-26|2006-01-27|Estimate|2010-01-27|2010-02-19|Estimate||||2011-01-07|2011-01-13|Estimate|February 2006||2006-02-28|January 2011|2011-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control|Safety and Efficacy of Insulin Glargine Injection [rDNA Origin] Treatment in Place of the TZD or the Sulfonylurea or Metformin in Triple Agent Therapy for T2DM Adult Subjects With Unsatisfactory Control|Terminated||Phase 4|390|Actual|Sanofi|The study was terminated prematurely due to technical issues with electronic diary data. Consequently, some of the initially planned efficacy analyses, based directly or indirectly on the e-diary data, were not performed.|3||Due to technical issues relating to the Electronic diary data.|f||||||||||||||2018-06-01 04:12:09.69518|2018-06-01 04:12:09.69518
NCT00283036|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2008-04-01|2006-01-26|2006-01-27|Estimate|||||||2008-04-01|2008-04-03|Estimate|April 2005||2005-04-30|April 2008|2008-04-30||||||||Interventional|||APROVE : Irbesartan in Hypertension|Efficacy and Tolerability of Posology Adaptation of Irbesartan in Ambulatory Hypertensive Patients|Completed||Phase 4|200||Sanofi|||||f||||||||||||||2018-06-01 04:12:10.374133|2018-06-01 04:12:10.374133
NCT00283023|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2008-08-02|2006-01-26|2006-01-27|Estimate|||||||2008-08-02|2008-08-05|Estimate|December 2007||2007-12-31|August 2008|2008-08-31||||December 2010|Anticipated|2010-12-31||Interventional|||Oligodendrocyte Progenitor Cell Culture From Human Brain|Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain|Unknown status|Recruiting|Phase 1|100|Anticipated|Rajavithi Hospital||1|||f||||t||||||||||2018-06-01 04:12:10.423379|2018-06-01 04:12:10.423379
NCT00283010|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2015-10-29|2006-01-25|2006-01-27|Estimate|||||||2015-10-29|2015-11-02|Estimate|January 2006||2006-01-31|October 2015|2015-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|IMPACT||Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT)|Improvement in Memory With Plasticity-Based Adaptive Cognitive Training (IMPACT)|Completed||N/A|487|Actual|Posit Science Corporation||2|||f||||||||||||||2018-06-01 04:12:10.507176|2018-06-01 04:12:10.507176
NCT00282997|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2008-03-21|2006-01-26|2006-01-27|Estimate|||||||2008-03-21|2008-03-25|Estimate|February 2006||2006-02-28|October 2007|2007-10-31|October 2006|Actual|2006-10-31|||||Interventional|||A Safety Study Of Pregabalin In Fibromyalgia|A 12-Week, Open-Label, Safety Trial Of Pregabalin In Patients With Fibromyalgia|Completed||Phase 3|500||Pfizer|||||||||||||||||||2018-06-01 04:12:10.622519|2018-06-01 04:12:10.622519
NCT00282984|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2009-02-13||2017-03-07|2006-01-26|2006-01-27|Estimate|2009-03-17|2009-04-29|Estimate||||2017-03-07|2017-04-05|Actual|February 2006||2006-02-28|March 2017|2017-03-31|August 2008|Actual|2008-08-31|November 2007|Actual|2007-11-30||Interventional|||Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking|A 12-Week, Double-Blind, Placebo-Controlled, Multicenter Study With A 40 Week Follow Up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 Milligram (Mg) Twice Daily (BID) for Smoking Cessation in Subjects With Cardiovascular Disease|Completed||Phase 3|714|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:12:10.804972|2018-06-01 04:12:10.804972
NCT00282971|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2009-02-11||2018-02-02|2006-01-26|2006-01-27|Estimate|2009-07-17|2009-08-26|Estimate||||2018-02-02|2018-03-02|Actual|March 6, 2006|Actual|2006-03-06|February 2018|2018-02-28|February 19, 2008|Actual|2008-02-19|February 19, 2008|Actual|2008-02-19||Interventional|||A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus|A Six Month, Open-label Outpatient, Parallel Group Trial Assessing The Impact Of Inhaled Insulin (Exubera(Registered)) On Glycemic Control In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On Two Oral Anti-diabetic Agents|Terminated||Phase 3|354|Actual|Pfizer|Study terminated prematurely since the sponsor stopped marketing and manufacturing of EXUBERA and withdrew Market Authorization in Europe in September 2008. No efficacy, safety, or quality reason was associated with the premature halt of this study.|2||Terminated as marketing of this product will be discontinued|||||f||||||||||2018-06-01 04:12:11.487698|2018-06-01 04:12:11.487698
NCT00282958|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2015-03-04|2006-01-25|2006-01-27|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2003||2003-02-28|March 2015|2015-03-31|July 2006||2006-07-31|||||Interventional|||The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain|The Therapeutic Use of Botulinum Toxin Type A in Subacute Cervical/Upper Back Pain|Completed||N/A|||Palo Alto Veterans Institute for Research|||||f||||||||||||||2018-06-01 04:12:12.105963|2018-06-01 04:12:12.105963
NCT00282945|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2008-10-09|2006-01-25|2006-01-27|Estimate|||||||2008-10-09|2008-10-13|Estimate|January 2006||2006-01-31|October 2008|2008-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone|Analyzing Beta Cell Function Tests Over Time In Patients With Type 2 Diabetes Mellitus Randomized To Metformin Or Rosiglitazone|Terminated||N/A|29|Actual|Pfizer||||See statement in Detailed Description.|f||||||||||||||2018-06-01 04:12:12.165659|2018-06-01 04:12:12.165659
NCT00282932|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2007-09-05|2006-01-26|2006-01-27|Estimate|||||||2007-09-05|2007-09-06|Estimate|January 2006||2006-01-31|September 2007|2007-09-30||||||||Interventional|||Detrol LA In Men With Overactive Bladder.|"A Randomized, Double Blind, Placebo Controlled Detrol LA Add-On To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker."|Completed||Phase 4|600||Pfizer|||||||||||||||||||2018-06-01 04:12:12.25267|2018-06-01 04:12:12.25267
NCT00282919|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2014-05-27|2009-08-12|2014-05-27|2006-01-26|2006-01-27|Estimate|2014-05-27|2014-06-26|Estimate|2009-08-12|2009-08-14|Estimate|2014-05-27|2014-06-26|Estimate|March 2006||2006-03-31|May 2014|2014-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||All treated population included participants who received at least 1 dose of study medication.|A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria|A Phase 2, Open Label, Non-Comparative Trial Of Azithromycin 2000 mg Plus Chloroquine 600 Mg Base Daily For Three Days For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 2|110|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 04:12:12.504734|2018-06-01 04:12:12.504734
NCT00282906|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2017-04-14|2006-01-25|2006-01-27|Estimate|||||||2017-04-14|2017-04-18|Actual|October 3, 2005|Actual|2005-10-03|April 2017|2017-04-30|August 19, 2014|Actual|2014-08-19|December 19, 2013|Actual|2013-12-19||Interventional|||FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer|[F-18]-Fluorodeoxyglucose (FDG) Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer|Completed||N/A|257|Actual|University of Southern California||1|||f||||t|f|f||||||||2018-06-01 04:12:12.734312|2018-06-01 04:12:12.734312
NCT00282893|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2017-02-13|2006-01-26|2006-01-27|Estimate|||||||2017-02-13|2017-02-15|Actual|October 2000||2000-10-31|March 2014|2014-03-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Balloon Prophylaxis of Aneurysmal Vasospasm|Balloon Prophylaxis of Aneurysmal Vasospasm|Completed||Phase 2|170|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 04:12:12.810578|2018-06-01 04:12:12.810578
NCT00282867|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2009-07-14||2009-07-15|2006-01-26|2006-01-27|Estimate|2009-07-15|2009-08-21|Estimate||||2009-07-15|2009-08-21|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||Glucose Regulation in Acute Stroke Patients (GRASP) Study|Glucose Regulation in Acute Stroke Patients (GRASP) Study|Completed||Phase 2|74|Actual|University of Virginia||3|||f||||t||||||||||2018-06-01 04:12:12.896986|2018-06-01 04:12:12.896986
NCT00282854|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2011-12-05|2006-01-26|2006-01-27|Estimate|||||||2011-12-05|2011-12-06|Estimate|January 2005||2005-01-31|August 2011|2011-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Genetics of Rolandic Epilepsy|Genetics of Rolandic Epilepsy|Unknown status|Recruiting||1000|Anticipated|King's College London|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 04:12:13.176568|2018-06-01 04:12:13.176568
NCT00282841|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2009-09-10|2006-01-26|2006-01-27|Estimate|||||||2009-09-10|2009-09-11|Estimate|May 2005||2005-05-31|July 2008|2008-07-31|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||Visualization of the Cerebral Arterial Circulation Using Contrast-Enhanced Transcranial Ultrasound in Code Stroke Patients|Visualization of the Cerebral Arterial Circulation Using Contrast-Enhanced Transcranial Ultrasound in Code Stroke Patients|Unknown status|Active, not recruiting|N/A|403|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-06-01 04:12:13.241419|2018-06-01 04:12:13.241419
NCT00282828|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|2013-04-22||2013-08-08|2006-01-25|2006-01-27|Estimate|2013-08-08|2013-10-14|Estimate||||2013-08-08|2013-10-14|Estimate|March 2006||2006-03-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder|Improving Outcomes in Pharmacotherapy of Social Phobia|Completed||Phase 4|397|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 04:12:13.34598|2018-06-01 04:12:13.34598
NCT00282815|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|2011-06-21||2013-01-31|2006-01-26|2006-01-27|Estimate|2013-01-31|2013-03-11|Estimate||||2013-01-31|2013-03-11|Estimate|September 2004||2004-09-30|December 2012|2012-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Sleep Apnea Treatment After Stroke (SATS)|Treatment of Obstructive Sleep Apnea After Stroke|Terminated||Phase 2|32|Actual|University of Michigan|Attrition pre-randomization and while in randomized treatment led to small numbers.|2||Poor recruitment. Funding expired.|f||||f||||||||||2018-06-01 04:12:13.649221|2018-06-01 04:12:13.649221
NCT00282802|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2009-07-01|2006-01-26|2006-01-27|Estimate|||||||2009-07-01|2009-07-02|Estimate|April 2001||2001-04-30|July 2009|2009-07-31|July 2010|Anticipated|2010-07-31|||||Observational|||Twins and the Risk of Parkinson's Disease: A Clinical and Imaging Study|Twins and the Risk of PD: A Clinical and Imaging Study|Unknown status|Active, not recruiting||250|Anticipated|The Parkinson's Institute|||1||f||||f||||||||||2018-06-01 04:12:13.846608|2018-06-01 04:12:13.846608
NCT00282789|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2006-01-27|2006-01-26|2006-01-27|Estimate|||||||2006-01-27|2006-01-30|Estimate|June 2000||2000-06-30|June 2000|2000-06-30||||||||Interventional|||BiPAP for Cardiomyopathy With Central Sleep Apnea||Completed||N/A|||Nagoya University|||||f||||||||||||||2018-06-01 04:12:14.043128|2018-06-01 04:12:14.043128
NCT00282776|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2013-09-30|2006-01-25|2006-01-27|Estimate|||||||2013-09-30|2013-10-07|Estimate|August 2006||2006-08-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Identification and Therapy of Postpartum Depression|Identification and Therapy of Postpartum Depression|Completed||Phase 3|628|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:12:14.093258|2018-06-01 04:12:14.093258
NCT00282763|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2015-11-20|2006-01-25|2006-01-27|Estimate|||||||2015-11-20|2015-11-23|Estimate|December 2005||2005-12-31|November 2015|2015-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)|Proprietary Information - Exploratory (Non-confirmatory) Trial|Terminated||Phase 2|12|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:12:14.16207|2018-06-01 04:12:14.16207
NCT00282750|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2010-01-13|2006-01-26|2006-01-27|Estimate|||||||2010-01-13|2010-01-14|Estimate|March 2006||2006-03-31|January 2010|2010-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||The Bar Coded Sponge Study|A Randomised Clinical Trial of a Bar-Coded Safety Sponge System|Completed||N/A|350||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:12:14.220289|2018-06-01 04:12:14.220289
NCT00282724|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2011-09-23|2006-01-25|2006-01-27|Estimate|||||||2011-09-23|2011-09-26|Estimate|January 2006||2006-01-31|September 2011|2011-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis|A Randomized, Double-blind, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg od and 150 mg od) Given During 12 Weeks in Lamellar Ichthyosis|Completed||Phase 2/Phase 3|98|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:12:14.296564|2018-06-01 04:12:14.296564
NCT00282711|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2012-07-31|2006-01-25|2006-01-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|June 2004||2004-06-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Observational|||The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?|"The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?A Multi-Center, Prospective, Randomized Study to Establish the Optimal Method for Detection of CAD Risk in Women at an Intermediate-High Pre-Test Likelihood CAD"|Completed|||824|Actual|Hartford Hospital|||2||f||||t||||||||||2018-06-01 04:12:14.405473|2018-06-01 04:12:14.405473
NCT00282698|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2011-05-20|2006-01-26|2006-01-27|Estimate|||||||2011-05-20|2011-05-23|Estimate|July 2004||2004-07-31|May 2011|2011-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Outcomes With Tight Control of Hyperglycemia in Cardiac Surgery Patients|Outcomes With Use Of Intensive Insulin Therapy In Intraoperative Management Of Hyperglycemia In Adult Patients Undergoing Cardiac Surgery|Completed||Phase 3|400||Mayo Clinic|||||f||||||||||||||2018-06-01 04:12:14.612229|2018-06-01 04:12:14.612229
NCT00282685|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-11-21|2006-01-25|2006-01-27|Estimate|||||||2007-11-21|2007-11-22|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|October 2008|Anticipated|2008-10-31|||||Interventional|||Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy|(Restoration of Nerve Functions by Intra-Arterial Transplantation of Bone Marrow Progenitor Cells in Patients With Diabetic Poly Neuropathy (PNP)|Unknown status|Recruiting|Phase 1|20|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-06-01 04:12:14.715284|2018-06-01 04:12:14.715284
NCT00282672|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|2015-09-11||2017-10-05|2006-01-25|2006-01-27|Estimate|2015-12-28|2015-12-30|Estimate||||2017-10-05|2017-11-06|Actual|February 2006||2006-02-28|October 2017|2017-10-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Ablation of Intestinal Metaplasia Containing Dysplasia|Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years|Completed||N/A|127|Actual|Medtronic - MITG||4|||f||||t||||||||||2018-06-01 04:12:14.845288|2018-06-01 04:12:14.845288
NCT00282659|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-11-02|2006-01-25|2006-01-27|Estimate|||||||2007-11-02|2007-11-05|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|June 2008|Anticipated|2008-06-30|||||Interventional|||The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control|The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag|Unknown status|Recruiting|Phase 4|240|Anticipated|Hartford Hospital|||||f||||||||||||||2018-06-01 04:12:15.477478|2018-06-01 04:12:15.477478
NCT00282646|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2011-08-23|2006-01-25|2006-01-27|Estimate|||||||2011-08-23|2011-08-24|Estimate|October 2005||2005-10-31|March 2011|2011-03-31|March 2011|Actual|2011-03-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)|(Intraarterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells for Induction of Neovascularization in Patients With Peripheral Arterial Occlusive Disease)|Completed||Phase 1/Phase 2|40|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-06-01 04:12:15.570658|2018-06-01 04:12:15.570658
NCT00282633|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-10-30|2006-01-25|2006-01-27|Estimate|||||||2007-10-30|2007-10-31|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Wound Closure Techniques|A Comparison of Skin Closure Techniques After Primary Cesarean Delivery|Unknown status|Recruiting|N/A|120|Anticipated|Hartford Hospital|||||f||||||||||||||2018-06-01 04:12:15.696357|2018-06-01 04:12:15.696357
NCT00282620|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-11-16|2006-01-25|2006-01-27|Estimate|||||||2007-11-16|2007-11-20|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|June 2008|Anticipated|2008-06-30|||||Interventional|||Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.|The Adjuvant Magnesium Trial (AdMag): Assessment if the Impact of Oral Magnesium on ICD Firing and Quality of Life|Unknown status|Recruiting|Phase 4|240|Anticipated|Hartford Hospital|||||f||||||||||||||2018-06-01 04:12:15.758161|2018-06-01 04:12:15.758161
NCT00282607|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-02-27|2006-01-25|2006-01-27|Estimate|||||||2007-02-27|2007-02-28|Estimate|May 2005||2005-05-31|February 2007|2007-02-28|June 2006||2006-06-30|||||Interventional|||A Study of DA-8159 in Subjects With Erectile Dysfunction|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 2 Dose Ranging Trial To Assess The Safety and Efficacy of DA-8159 Tablets in Male Subjects With Erectile Dysfunction.|Completed||Phase 2|300||Dong-A PharmTech Co., Ltd.|||||f||||t||||||||||2018-06-01 04:12:15.840808|2018-06-01 04:12:15.840808
NCT00282594|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2006-01-26|2006-01-26|2006-01-27|Estimate|||||||2006-01-26|2006-01-27|Estimate|July 2003||2003-07-31|November 2005|2005-11-30|October 2005||2005-10-31|||||Interventional|||The Effect of Intensive Insulin Therapy in the Surgical Critical Care Unit|No Outcome Benefit for the Use of Intensive Insulin Therapy in the Critically Ill General and Vascular Surgical Patient. A Randomized Prospective Trial.|Completed||N/A|317||Genesys|||||f||||||||||||||2018-06-01 04:12:15.942357|2018-06-01 04:12:15.942357
NCT00282581|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-26|||2014-01-17|2006-01-26|2006-01-27|Estimate|||||||2014-01-17|2014-01-22|Estimate|October 2006||2006-10-31|January 2014|2014-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive|A Phase 1, Double-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia-Naive Human Immunodeficiency Virus (HIV)-Seropositive Subjects|Terminated||Phase 1|2|Actual|Sanofi||1||Senior managemnt decision|f||||t||||||||||2018-06-01 04:12:16.007416|2018-06-01 04:12:16.007416
NCT00282568|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|2013-07-25|2010-09-22|2013-07-25|2006-01-25|2006-01-27|Estimate|2013-07-25|2013-09-26|Estimate|2011-11-10|2011-11-16|Estimate|2013-07-25|2013-09-26|Estimate|August 2002||2002-08-31|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Pharmacokinetic evaluable set defined as all patients with all five complete pharmacokinetic profiles (two tacrolimus and three tacrolimus MR).|A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients|A Phase 2, Open-Label, Multi-center Study to Assess the Pharmacokinetics, Safety and Tolerability of Tacrolimus in Stable Kidney Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen|Completed||Phase 2|70|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|1|||f||||f||||||||||2018-06-01 04:12:16.11134|2018-06-01 04:12:16.11134
NCT00282555|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2008-03-18|2006-01-25|2006-01-26|Estimate|||||||2008-03-18|2008-03-19|Estimate|February 2006||2006-02-28|March 2008|2008-03-31||||||||Interventional|||Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis|Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.|Suspended||Phase 2|450||STEBA France|||||f||||||||||||||2018-06-01 04:12:16.85169|2018-06-01 04:12:16.85169
NCT00282542|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2017-01-30|2006-01-25|2006-01-26|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2000||2000-05-31|January 2017|2017-01-31|January 2006||2006-01-31|||||Interventional|||Hepatocyte Transplantation as a Life Support Bridge|The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure|Withdrawn||N/A|0|Actual|Virginia Commonwealth University|||||f||||||||||||||2018-06-01 04:12:16.92612|2018-06-01 04:12:16.92612
NCT00282529|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2017-01-23|2006-01-24|2006-01-26|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2006|Actual|2006-01-31|January 2017|2017-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study|Identification of a Screening Tool and Treatment of Lymphedema Secondary to the Management of Breast Cancer Study|Terminated||N/A|400|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:12:17.050535|2018-06-01 04:12:17.050535
NCT00282516|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2006-01-25|2006-01-25|2006-01-26|Estimate|||||||2006-01-25|2006-01-26|Estimate|April 2003||2003-04-30|January 2006|2006-01-31|February 2005||2005-02-28|||||Interventional|||Asthma In-Home Monitoring (AIM) Trial|“Internet-Based Home Monitoring and Education of Children With Asthma is Comparable to Ideal, Office-Based Care: Results of a One-Year, Asthma In-Home Monitoring (AIM) Trial”|Unknown status|Active, not recruiting|N/A|120||Tripler Army Medical Center|||||f||||||||||||||2018-06-01 04:12:17.14306|2018-06-01 04:12:17.14306
NCT00282503|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2017-08-14|2006-01-24|2006-01-26|Estimate|||||||2017-08-14|2017-08-16|Actual|January 2006||2006-01-31|August 2017|2017-08-31||||June 2007|Actual|2007-06-30||Interventional|||Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease|A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease|Terminated||Phase 3|19|Actual|Mallinckrodt||2||Lack of recruitment|f||||||||||||||2018-06-01 04:12:17.243245|2018-06-01 04:12:17.243245
NCT00282490|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2008-06-13|2006-01-25|2006-01-26|Estimate|||||||2008-06-13|2008-06-17|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Surface Nerve Stimulation Treatment for OAB in Children|Sacral Transcutaneous Nerve Stimulation Treatment for Functional Daytime Incontinence in Children With Over Active Bladder Syndrome|Completed||N/A|30|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 04:12:17.456457|2018-06-01 04:12:17.456457
NCT00282477|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2007-08-06|2006-01-25|2006-01-26|Estimate|||||||2007-08-06|2007-08-07|Estimate|February 2006||2006-02-28|August 2007|2007-08-31||||||||Observational|||Trial to Evaluate Erectile Function, Fertility and Sperm Count in Male Cyclists Compared to Age Matched Controls|Prospective Controlled Trial to Evaluate Erectile Function, Fertility and Sperm Count in Male Cyclists Compared to Age Matched Controls|Unknown status|Recruiting||30|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-06-01 04:12:17.530191|2018-06-01 04:12:17.530191
NCT00282464|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2009-03-03||2009-06-01|2006-01-24|2006-01-26|Estimate|2009-04-06|2009-06-02|Estimate||||2009-06-01|2009-06-03|Estimate|February 2006||2006-02-28|June 2009|2009-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.|A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression|Completed||Phase 3|392|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:12:17.677556|2018-06-01 04:12:17.677556
NCT00282139|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2011-10-04|2006-01-23|2006-01-25|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2004||2004-01-31|October 2011|2011-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Aripiprazole in the Treatment of Tourette's Syndrome|Aripiprazole in the Treatment of Tourette's Syndrome|Terminated||N/A|40|Anticipated|University of Florida|||||f||||||||||||||2018-06-01 04:12:27.34053|2018-06-01 04:12:27.34053
NCT00282451|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2016-10-27|2006-01-25|2006-01-26|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2006||2006-02-28|October 2016|2016-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes|Comparison of Biphasic Insulin Aspart 30 Twice Daily With Biphasic Insulin Aspart 30 Twice Daily Plus Lunchtime Injection of Insulin Aspart, in Combination With or Without Metformin (for Both Treatment Groups) in Subjects With Type 2 Diabetes. A Multi-center, Randomized, Open-labeled, Two-armed Parallel Group Trial in Subjects With Type 2 Diabetes Previously Treated With Conventional Biphasic Human Insulin 30/70|Completed||Phase 4|79|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:12:18.768744|2018-06-01 04:12:18.768744
NCT00282438|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2016-09-12||2017-01-03|2006-01-24|2006-01-26|Estimate|2017-01-03|2017-02-24|Actual||||2017-01-03|2017-02-24|Actual|December 2003||2003-12-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis|Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial|Terminated||Phase 1/Phase 2|2|Actual|Northwestern University|Two patients had been enrolled on trial. One underwent autologous HSCT and relapsed early after the transplant. The second participant underwent allogeneic HSCT and died 70 days after the transplant and the study has been terminated.|2||No plan to continue enrollment|f||||f||||||||Undecided||2018-06-01 04:12:18.862968|2018-06-01 04:12:18.862968
NCT00282425|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2012-12-14|2006-01-24|2006-01-26|Estimate|||||||2012-12-14|2012-12-18|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis|Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis|Terminated||Phase 1|8|Actual|Northwestern University||1||No subject enrolled since 2009|f||||t||||||||||2018-06-01 04:12:19.126978|2018-06-01 04:12:19.126978
NCT00282412|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2016-07-11|2006-01-24|2006-01-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2002||2002-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism|Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism|Terminated||Phase 1|4|Actual|Northwestern University||1||No participant enrolled for three years. No plan to continue study.|f||||t||||||||No||2018-06-01 04:12:19.189195|2018-06-01 04:12:19.189195
NCT00282399|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2015-10-27|2006-01-25|2006-01-26|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2006||2006-10-31|October 2015|2015-10-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome|Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.|Terminated||Phase 1|41|Actual|Eisai Inc.||3|||f||||f||||||||||2018-06-01 04:12:19.263917|2018-06-01 04:12:19.263917
NCT00282386|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2017-05-05|2006-01-24|2006-01-26|Estimate|||||||2017-05-05|2017-05-09|Actual|December 23, 1999|Actual|1999-12-23|May 2017|2017-05-31|September 1, 2004|Actual|2004-09-01|September 1, 2004|Actual|2004-09-01||Interventional|||A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)|A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas|Completed||Phase 3|2586|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:12:19.326563|2018-06-01 04:12:19.326563
NCT00282373|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2007-09-10|2006-01-24|2006-01-26|Estimate|||||||2007-09-10|2007-09-11|Estimate|November 2004||2004-11-30|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients|Randomized Controlled Pilot Study: Induction of Mild Hypothermia in Resuscitated Cardiac Arrest Patients Using Traditional Surface Cooling Techniques vs. the Medivance® Arctic Sun® System|Completed||Phase 2/Phase 3|64|Anticipated|Medivance, Inc.|||||f||||t||||||||||2018-06-01 04:12:19.388311|2018-06-01 04:12:19.388311
NCT00282360|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2006-01-24|2006-01-24|2006-01-26|Estimate|||||||2006-01-24|2006-01-26|Estimate|February 1999||1999-02-28|May 2004|2004-05-31|October 2003||2003-10-31|||||Interventional|||Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease|Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease|Completed||Phase 4|30||IRCCS San Raffaele|||||f||||||||||||||2018-06-01 04:12:19.440083|2018-06-01 04:12:19.440083
NCT00282347|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2010-02-01||2015-01-06|2006-01-24|2006-01-26|Estimate|2010-02-01|2010-02-23|Estimate||||2015-01-06|2015-01-15|Estimate|January 2006||2006-01-31|January 2015|2015-01-31|January 2013|Actual|2013-01-31|January 2009|Actual|2009-01-31||Interventional|LUNAR||A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis|Completed||Phase 3|144|Actual|Genentech, Inc.||2|||f||||f||||||||||2018-06-01 04:12:19.510854|2018-06-01 04:12:19.510854
NCT00282334|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2010-02-18||2011-07-29|2006-01-24|2006-01-26|Estimate|2011-07-27|2011-07-29|Estimate||||2011-07-29|2011-08-01|Estimate|May 2004||2004-05-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Comparison of Telemedical and Conventional Antihypertensive Treatment|A Comparison of Telemedical and Conventional Antihypertensive Treatment|Completed||Phase 4|236|Actual|Regional Hospital Holstebro|Technical difficulties with telemedical equipment,referral bias,unblinded study|2|||f||||f||||||||||2018-06-01 04:12:21.432725|2018-06-01 04:12:21.432725
NCT00282321|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2010-02-19|2006-01-24|2006-01-26|Estimate|||||||2010-02-19|2010-02-22|Estimate|May 2007||2007-05-31|February 2010|2010-02-28|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||High-protein and High-carbohydrate Diets' Effect on Urinary Concentrating Ability||Completed||Phase 4|20|Anticipated|Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:12:21.609821|2018-06-01 04:12:21.609821
NCT00282308|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2013-06-05||2017-07-11|2006-01-24|2006-01-26|Estimate|2013-08-19|2013-10-21|Estimate||||2017-07-11|2017-08-10|Actual|January 23, 2006|Actual|2006-01-23|July 2017|2017-07-31|May 28, 2012|Actual|2012-05-28|January 31, 2008|Actual|2008-01-31||Interventional|SIERRA|Safety population: All patients who received any amount of rituximab or any vaccine.|A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate|A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate|Completed||Phase 2|103|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 04:12:21.719546|2018-06-01 04:12:21.719546
NCT00282126|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2014-08-08|2006-01-23|2006-01-25|Estimate|||||||2014-08-08|2014-08-11|Estimate|January 2006||2006-01-31|August 2014|2014-08-31||||January 2011|Actual|2011-01-31||Interventional|||Potassium Citrate to Prevent Age Related Bone Loss|Potassium Citrate to Prevent Age Related Bone Loss: Pilot Study|Completed||N/A|52|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-06-01 04:12:27.417478|2018-06-01 04:12:27.417478
NCT00282295|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|2017-01-23||2017-01-23|2006-01-25|2006-01-26|Estimate|2017-01-23|2017-03-16|Actual||||2017-01-23|2017-03-16|Actual|January 2006||2006-01-31|January 2017|2017-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease|Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents|Completed||Phase 4|1376|Actual|GlaxoSmithKline|None reported.|3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:12:23.320194|2018-06-01 04:12:23.320194
NCT00282282|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2013-01-11||2014-04-29|2006-01-24|2006-01-26|Estimate|2014-03-03|2014-04-08|Estimate||||2014-04-29|2014-05-12|Estimate|January 2006||2006-01-31|March 2014|2014-03-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|||Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation|Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis After Allogeneic Non-myeloablative Peripheral Blood Stem Cell Transplantation|Completed||Phase 2|31|Actual|Dana-Farber Cancer Institute|This study is a single-institution study, and as such the data are limited by the small study population.||||f||||t||||||||||2018-06-01 04:12:24.56029|2018-06-01 04:12:24.56029
NCT00282269|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-25|||2010-06-18|2006-01-25|2006-01-26|Estimate|||||||2010-06-18|2010-06-22|Estimate|November 2006||2006-11-30|June 2009|2009-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Hypothermia in Traumatic Brain Injury in Children (HiTBIC)|Pilot Study of Early and Prolonged Hypothermia in Severe Traumatic Brain Injury in Children|Completed||Phase 2/Phase 3|50|Anticipated|Australia and New Zealand Intensive Care Society|||||f||||t||||||||||2018-06-01 04:12:24.723464|2018-06-01 04:12:24.723464
NCT00282256|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2013-08-12|2010-09-22|2013-08-12|2006-01-24|2006-01-26|Estimate|2013-08-12|2013-10-17|Estimate|2011-11-10|2011-11-16|Estimate|2013-08-12|2013-10-17|Estimate|January 2004||2004-01-31|August 2013|2013-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||The pharmacokinetic evaluable set was defined as all patients who completed both pharmacokinetic profiles: one for tacrolimus, and one for tacrolimus MR.|A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients|A Phase 2, Open-Label, Multi-center Study to Assess the Pharmacokinetics, Long-Term Safety and Tolerability of Tacrolimus in Stable Pediatric Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen|Completed||Phase 2|19|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|1|||f||||f||||||||||2018-06-01 04:12:24.814605|2018-06-01 04:12:24.814605
NCT00282243|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2013-08-01|2010-09-22|2013-08-01|2006-01-24|2006-01-26|Estimate|2013-08-01|2013-09-30|Estimate|2011-11-10|2011-11-16|Estimate|2013-08-01|2013-09-30|Estimate|February 2003||2003-02-28|August 2013|2013-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Pharmacokinetic evaluable set, defined as all patients with four complete pharmacokinetic profiles (two tacrolimus and two tacrolimus MR).|A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients|A Phase 2, Open-Label, Multi-Center Study to Assess the Pharmacokinetics, Long-term Safety and Tolerability of Tacrolimus in Stable Liver Transplant Patients Converted From a Prograf® Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen|Completed||Phase 2|70|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 04:12:25.415687|2018-06-01 04:12:25.415687
NCT00282230|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2012-06-06|2006-01-24|2006-01-26|Estimate|||||||2012-06-06|2012-06-07|Estimate|November 2003||2003-11-30|June 2012|2012-06-30|October 2005|Actual|2005-10-31|||||Interventional|||A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients|A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Prograf®/FK778 and Prograf®/MMF in De Novo Kidney Transplant Recipients|Terminated||Phase 2|150||Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:12:26.064266|2018-06-01 04:12:26.064266
NCT00282217|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2007-03-21|2006-01-24|2006-01-25|Estimate|||||||2007-03-21|2007-03-22|Estimate|August 2006||2006-08-31|March 2007|2007-03-31||||||||Interventional|||Study Evaluating Sirolimus in the Treatment of Kidney Transplant|Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy|Completed||Phase 4|100||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:12:26.166726|2018-06-01 04:12:26.166726
NCT00282204|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2012-06-28|2006-01-24|2006-01-25|Estimate|||||||2012-06-28|2012-06-29|Estimate|December 2005||2005-12-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Hypnosis Antenatal Training for Childbirth (HATCh): a Randomised Controlled Trial|Hypnosis Antenatal Training for Childbirth (HATCh): a Randomised Controlled Trial|Completed||Phase 2/Phase 3|448|Actual|Women's and Children's Hospital, Australia||3|||f||||t||||||||||2018-06-01 04:12:26.256942|2018-06-01 04:12:26.256942
NCT00282191|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2008-03-26|2006-01-23|2006-01-25|Estimate|||||||2008-03-26|2008-03-28|Estimate|August 2006||2006-08-31|March 2008|2008-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Prevalence of Spasticity in Adults With Mental Retardation Living in the Community|Prevalence of Spasticity in Adults With Mental Retardation Residing in a Community Setting|Completed|||7|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:12:26.350046|2018-06-01 04:12:26.350046
NCT00282178|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2008-10-15|2006-01-24|2006-01-25|Estimate|||||||2008-10-15|2008-10-16|Estimate|April 2005||2005-04-30|June 2008|2008-06-30|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo|A 36 Week Three-Center Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo|Completed||Phase 2|26|Actual|Umeå University||3|||f||||f||||||||||2018-06-01 04:12:26.42727|2018-06-01 04:12:26.42727
NCT00282165|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2015-01-23|2006-01-24|2006-01-25|Estimate|||||||2015-01-23|2015-01-26|Estimate|November 2006||2006-11-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order|Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order|Terminated||Phase 4|8|Actual|UMC Utrecht||2||Required number of subjects to be included could not be accomplished|f||||f||||||||||2018-06-01 04:12:26.51087|2018-06-01 04:12:26.51087
NCT00282152|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2017-04-19|2014-12-11|2017-04-19|2006-01-23|2006-01-25|Estimate|2017-04-19|2017-05-30|Actual|2015-04-08|2015-04-30|Estimate|2017-04-19|2017-05-30|Actual|March 2006||2006-03-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|January 2012|Actual|2012-01-31||Interventional|||Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)|Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease|Completed||N/A|37|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-06-01 04:12:26.713191|2018-06-01 04:12:26.713191
NCT00282113|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2009-11-19||2009-12-31|2006-01-23|2006-01-25|Estimate|2009-12-31|2010-01-28|Estimate||||2009-12-31|2010-01-28|Estimate|October 2004||2004-10-31|December 2009|2009-12-31|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Interventional|||Effects of Probiotic and Prebiotic Combinations on Premature Infants|Efficacy of a Prebiotic and Probiotic Combination in Preterm Infants|Completed||N/A|90|Actual|University of California, Davis|Smaller sample size than anticipated due to the number of infants enrolled who were discharged home prior to completing five weeks of treatment.|3|||f||||t||||||||||2018-06-01 04:12:27.502134|2018-06-01 04:12:27.502134
NCT00282100|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2008-12-16|2006-01-24|2006-01-25|Estimate|||||||2008-12-16|2008-12-17|Estimate|December 2005||2005-12-31|December 2008|2008-12-31|December 2012|Anticipated|2012-12-31|||||Interventional|||A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma||Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:12:27.823543|2018-06-01 04:12:27.823543
NCT00282087|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2013-07-19||2014-11-23|2006-01-24|2006-01-25|Estimate|2014-11-23|2014-12-01|Estimate||||2014-11-23|2014-12-01|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma|Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial|Completed||Phase 2|47|Actual|Sarcoma Alliance for Research through Collaboration||1|||f||||t||||||||||2018-06-01 04:12:27.935239|2018-06-01 04:12:27.935239
NCT00282074|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2007-01-23|2006-01-24|2006-01-25|Estimate|||||||2007-01-23|2007-01-24|Estimate|January 2006||2006-01-31|January 2007|2007-01-31||||||||Interventional|||Evaluating Changes in Spermatogram Following Bilateral Laparoscopic Inguinal Hernia Repair in Fertile Males|Prospective Trial to Evaluate Changes in Spermatogram Following Bilateral Laparoscopic Inguinal Hernia Repair in Males in the Fertility Age|Terminated||Phase 2/Phase 3|30||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:12:28.258394|2018-06-01 04:12:28.258394
NCT00282061|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2006-12-14|2006-01-24|2006-01-25|Estimate|||||||2006-12-14|2006-12-15|Estimate||||January 2006|2006-01-31||||||||Interventional|||Synchronization and Desynchronization Between Circadian Rhythms in Patients With Delayed Sleep Phase Syndrome (DSPS)||Unknown status|Recruiting|Phase 1|||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:12:28.311225|2018-06-01 04:12:28.311225
NCT00282048|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2012-02-25|2009-05-20|2012-07-23|2006-01-23|2006-01-25|Estimate|2012-02-25|2012-04-03|Estimate|2009-09-24|2009-09-28|Estimate|2012-07-23|2012-07-31|Estimate|March 2006||2006-03-31|July 2012|2012-07-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer|Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer|Completed||Phase 2|62|Actual|Pfizer|Population pharmacokinetics was not presented, as the data was not available for the single study and data of other axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.|1|||f||||f||||||||||2018-06-01 04:12:28.411876|2018-06-01 04:12:28.411876
NCT00282035|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2018-04-03|2006-01-23|2006-01-25|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2006||2006-01-31|March 2018|2018-03-31|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||RAPID: Randomized Trial of Accelerated Partial Breast Irradiation|A Multi-centre Randomized Trial to Determine if Accelerated Partial Breast Irradiation, Utilizing 3D CRT, is as Effective as Whole Breast Irradiation Following Breast Conserving Surgery in Women With Ductal Carcinoma in Situ or Invasive Breast Cancer With Negative Axillary Lymph Nodes|Completed||Phase 3|2128|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 04:12:29.360114|2018-06-01 04:12:29.360114
NCT00282022|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2013-11-05|2006-01-24|2006-01-25|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2005||2005-09-30|January 2009|2009-01-31||||May 2008|Actual|2008-05-31||Interventional|||VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer|A Phase II Trial of Cloretazine™ (VNP40101M) for Patients With Relapsed or Refractory Small Cell Lung Cancer|Completed||Phase 2|87|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:12:29.58406|2018-06-01 04:12:29.58406
NCT00282009|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2016-02-09|2006-01-24|2006-01-25|Estimate|||||||2016-02-09|2016-02-10|Estimate|August 2004||2004-08-31|August 2014|2014-08-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Internet and Telephone Counseling for Smoking Cessation|Internet and Telephone Counseling for Smoking Cessation|Completed||N/A|2205|Actual|Georgetown University||3|||f||||t||||||||No||2018-06-01 04:12:29.648111|2018-06-01 04:12:29.648111
NCT00281996|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2011-08-24|2006-01-24|2006-01-25|Estimate|||||||2011-08-24|2011-08-26|Estimate|March 2005||2005-03-31|August 2011|2011-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer|Phase I/II Study of Gleevec (Imatinib Mesylate, Formerly Known as STI571) and Gemcitabine for Advanced Pancreas Cancer|Terminated||Phase 1|19|Actual|Northwestern University||||Closed to accrual to allow enrollment on another more promising trial.|f||||t||||||||||2018-06-01 04:12:29.721073|2018-06-01 04:12:29.721073
NCT00281983|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2017-07-20|2006-01-24|2006-01-25|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2000||2000-06-30|April 2007|2007-04-30|July 2010|Actual|2010-07-31|||||Interventional|||Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia|Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|100|Actual|German CLL Study Group||1|||f||||||||||||No||2018-06-01 04:12:29.807937|2018-06-01 04:12:29.807937
NCT00281970|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2009-02-06|2006-01-24|2006-01-25|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2004||2004-08-31|July 2007|2007-07-31||||||||Interventional|||Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery|Phase II Trial of Weekly Docetaxel (Taxotere®) and Monthly Cisplatin Chemotherapy as Adjuvant Treatment for Patients With Completely Resected Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:12:29.956597|2018-06-01 04:12:29.956597
NCT00281957|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2012-06-05||2014-05-02|2006-01-24|2006-01-25|Estimate|2012-06-05|2012-07-10|Estimate||||2014-05-02|2014-05-20|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery|A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) With Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma|Completed||Phase 2|109|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:12:30.069075|2018-06-01 04:12:30.069075
NCT00281749|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2011-08-17|2006-01-23|2006-01-25|Estimate|||||||2011-08-17|2011-08-18|Estimate||||August 2011|2011-08-31|October 2006|Actual|2006-10-31|||||Interventional|||Telephone Call From Acute Care Physicians to Long Term Care Physicians: Impact on Transitional Care of Elderly Patients||Completed||Phase 1|||Maimonides Medical Center|||||f||||||||||||||2018-06-01 04:12:34.985519|2018-06-01 04:12:34.985519
NCT00281944|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2013-05-01|2006-01-24|2006-01-25|Estimate|||||||2013-05-01|2013-05-03|Estimate|September 2005||2005-09-30|May 2013|2013-05-31||||May 2009|Actual|2009-05-31||Interventional|||Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors|A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination With Fluorouracil and Leucovorin in Pediatric Patients With Advanced Solid Tumors|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:12:31.009475|2018-06-01 04:12:31.009475
NCT00281931|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2016-09-23|2006-01-24|2006-01-25|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 1999||1999-09-30|September 2016|2016-09-30|October 2006|Actual|2006-10-31|April 2006|Actual|2006-04-30||Interventional|||Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia|Phase II Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients With B-PLL|Terminated||Phase 2|21|Anticipated|German CLL Study Group|||||f||||||||||||No||2018-06-01 04:12:31.095173|2018-06-01 04:12:31.095173
NCT00281918|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2009-12-21||2013-09-09|2006-01-24|2006-01-25|Estimate|2011-03-03|2011-03-29|Estimate||||2013-09-09|2013-09-19|Estimate|July 2003||2003-07-31|September 2013|2013-09-30|October 2011|Actual|2011-10-31|July 2007|Actual|2007-07-31||Interventional|CLL-8||Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia|Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia|Completed||Phase 3|817|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:12:31.207244|2018-06-01 04:12:31.207244
NCT00281905|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2013-09-19|2006-01-24|2006-01-25|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 1992||1992-06-30|June 2007|2007-06-30||||||||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors|Management of Children Aged Less Than 3 Years With Brain Tumors|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:12:32.394337|2018-06-01 04:12:32.394337
NCT00281892|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2018-05-09|2006-01-24|2006-01-25|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2004||2004-09-30|May 2018|2018-05-31|October 2010|Actual|2010-10-31|May 2008|Actual|2008-05-31||Interventional|||Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia|Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity|Completed||Phase 3|97|Actual|German CLL Study Group||2|||f||||f||||||||No||2018-06-01 04:12:32.657828|2018-06-01 04:12:32.657828
NCT00281879|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2012-05-17||2017-09-25|2006-01-24|2006-01-25|Estimate|2012-05-17|2012-06-19|Estimate||||2017-09-25|2017-09-27|Actual|February 2006||2006-02-28|September 2017|2017-09-30|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer|Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies|Terminated||Phase 2|200|Actual|OHSU Knight Cancer Institute|Early termination|8|||f||||t||||||||||2018-06-01 04:12:32.848056|2018-06-01 04:12:32.848056
NCT00281866|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2016-10-10|2006-01-24|2006-01-25|Estimate|||||||2016-10-10|2016-10-12|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|||Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer|Genotypic-Based Pharmacodynamic Evaluation of Erlotinib (Erlotinib (Tarceva™, OSI Pharmaceuticals, Uniondale, NY) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|37|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:12:33.807402|2018-06-01 04:12:33.807402
NCT00281853|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2010-06-10|2006-01-24|2006-01-25|Estimate|||||||2010-06-10|2010-06-11|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer|Characterization of Chemotherapy/Biotherapy-Induced Peripheral Neuropathy: Refinement of Clinical Measures|Completed|||15|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:12:33.893352|2018-06-01 04:12:33.893352
NCT00281840|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2014-07-14||2015-05-19|2006-01-24|2006-01-25|Estimate|2015-05-19|2015-06-09|Estimate||||2015-05-19|2015-06-09|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase II Study of Bevacizumab in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|30|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:12:33.984508|2018-06-01 04:12:33.984508
NCT00281827|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2009-06-23||2017-12-03|2006-01-24|2006-01-25|Estimate|2009-10-29|2009-12-03|Estimate||||2017-12-03|2017-12-28|Actual|May 2002||2002-05-31|December 2017|2017-12-31|July 2008|Actual|2008-07-31|March 2008|Actual|2008-03-31||Interventional|||Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer|Phase II Trial of Neoadjuvant Therapy With Carboplatin and Gemcitabine With Thalidomide in Patients With Stage II and IIIA Non-Small Cell Lung Cancer|Terminated||Phase 2|22|Actual|Masonic Cancer Center, University of Minnesota||1||Due to drug unavailability|f||||t||||||||||2018-06-01 04:12:34.459379|2018-06-01 04:12:34.459379
NCT00281814|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2018-01-25|2006-01-24|2006-01-25|Estimate|||||||2018-01-25|2018-01-26|Actual|February 1, 2006|Actual|2006-02-01|January 2018|2018-01-31|January 4, 2017|Actual|2017-01-04|December 31, 2008|Actual|2008-12-31||Observational|||Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant|Adjustment to Illness by Survival Rates in Allogeneic Bone Marrow Transplant (BMT): The Relative Importance of Lay Care-Partner Support|Completed|||36|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-06-01 04:12:34.735946|2018-06-01 04:12:34.735946
NCT00281801|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2012-03-13|2006-01-24|2006-01-25|Estimate|||||||2012-03-13|2012-03-15|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|April 2010|Actual|2010-04-30|December 2008|Actual|2008-12-31||Observational|||Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation|Survival in Allogeneic Bone Marrow Transplantation: The Relative Importance of Inpatient Lay Care-Partner Support|Completed|||168|Actual|Case Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 04:12:34.806203|2018-06-01 04:12:34.806203
NCT00281788|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2013-03-20|2006-01-24|2006-01-25|Estimate|||||||2013-03-20|2013-03-21|Estimate|September 2003||2003-09-30|April 2008|2008-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer|A Phase I Study of Oral Capecitabine in Combination With Weekly IV Carboplatin/Paclitaxel and Radiation Therapy for Patients|Completed||Phase 1|13|Actual|Duke University|||||f||||||||||||||2018-06-01 04:12:34.871425|2018-06-01 04:12:34.871425
NCT00281762|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2008-05-06|2006-01-23|2006-01-25|Estimate|||||||2008-05-06|2008-05-09|Estimate||||May 2008|2008-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human|Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human|Completed||Phase 4|20||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:12:34.919092|2018-06-01 04:12:34.919092
NCT00281736|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2013-12-31|2006-01-24|2006-01-25|Estimate|||||||2013-12-31|2014-01-03|Estimate|February 2004||2004-02-29|December 2013|2013-12-31|December 2013|Actual|2013-12-31|July 2007|Actual|2007-07-31||Interventional|||Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer|A Phase II Study of HPPH Photodynamic Therapy for Treatment of High Grade Dysplasia, Carcinoma In-Situ or Early Intramucosal Adenocarcinoma in Barrett's Esophagus. Randomization to Two PDT Treatment Regimens of HPPH (2-1 [Hexyloxyethyl]-2devinylpyropheophorbide-a) and Light|Completed||Phase 2|60|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 04:12:35.036541|2018-06-01 04:12:35.036541
NCT00281723|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2007-05-06|2006-01-24|2006-01-25|Estimate|||||||2007-05-06|2007-05-08|Estimate||||May 2007|2007-05-31|May 2007|Anticipated|2007-05-31|||||Interventional|||Efficacy of Adhesive Tablets in Treating Oral Ulcers (Aphthous)|Phase 2 Study of Efficacy of Adhesive Tablets in Treating Oral Ulcers (Aphthous)|Suspended||Phase 2|50|Anticipated|Hadassah Medical Organization||||The company which holds the patent was not interested.|f||||f||||||||||2018-06-01 04:12:35.092104|2018-06-01 04:12:35.092104
NCT00281710|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2008-05-06|2006-01-23|2006-01-25|Estimate|||||||2008-05-06|2008-05-09|Estimate|October 2005||2005-10-31|May 2008|2008-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans|Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans|Completed||Phase 4|20||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:12:35.145701|2018-06-01 04:12:35.145701
NCT00281697|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2012-08-23||2013-07-05|2006-01-23|2006-01-25|Estimate|2012-08-23|2012-09-24|Estimate||||2013-07-05|2013-07-26|Estimate|February 2006||2006-02-28|July 2013|2013-07-31|September 2012|Actual|2012-09-30|March 2009|Actual|2009-03-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)|A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer|Completed||Phase 3|684|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 04:12:35.325425|2018-06-01 04:12:35.325425
NCT00281684|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2017-08-29|2006-01-23|2006-01-25|Estimate|||||||2017-08-29|2017-08-30|Actual|December 7, 2005|Actual|2005-12-07|August 2017|2017-08-31|October 3, 2007|Actual|2007-10-03|October 3, 2007|Actual|2007-10-03||Interventional|||SB-705498 Dental Pain Study After Tooth Extraction|A Multi-centre, Randomised, Single Blind, Placebo Controlled, Parallel Group Study to Examine the Effect of Single Doses of SB-705498, a TRPV1 Receptor Antagonist, on Pain Following Third Molar Tooth Extraction|Completed||Phase 2|145|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-06-01 04:12:35.863159|2018-06-01 04:12:35.863159
NCT00281671|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2009-01-28|2006-01-23|2006-01-25|Estimate|||||||2009-01-28|2009-01-29|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Nesiritide Use Following Cardiac Surgery in Infants|Pilot Study of the Effects of Nesiritide on Hemodynamics and Urine Output Following Cardiopulmonary Bypass in Infants|Terminated||Phase 1/Phase 2|9|Actual|Boston Children’s Hospital||1||Slow patient enrollment.|f||||t||||||||||2018-06-01 04:12:35.949878|2018-06-01 04:12:35.949878
NCT00281658|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2011-05-05||2018-01-08|2006-01-24|2006-01-25|Estimate|2011-05-05|2011-06-01|Estimate||||2018-01-08|2018-02-01|Actual|January 2, 2006|Actual|2006-01-02|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|June 18, 2010|Actual|2010-06-18||Interventional|||Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination With Paclitaxel Versus Paclitaxel Plus Placebo in Subjects With ErbB2 Amplified Metastatic Breast Cancer|Active, not recruiting||Phase 3|443|Actual|Novartis|Some participants (PAR) are captured as withdrawing from the study due to death. Per protocol, PAR who died were considered to be study completers and did not withdraw from the study; for the purposes of this report, they are classified as withdrawn.|3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 04:12:36.064882|2018-06-01 04:12:36.064882
NCT00281645|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2007-03-26|2006-01-23|2006-01-25|Estimate|||||||2007-03-26|2007-03-27|Estimate|December 2004||2004-12-31|March 2007|2007-03-31||||||||Interventional|||Long-Term Safety Study of Bicifadine for the Treatment of Chronic Low Back Pain|A Multicenter Standard of Care-Controlled Study to Evaluate the Long-Term Safety of Bicifadine for the Treatment of Chronic Low Back Pain|Completed||Phase 3|1250||DOV Pharmaceutical, Inc.|||||||||||||||||||2018-06-01 04:12:37.864739|2018-06-01 04:12:37.864739
NCT00281632|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2009-11-25||2011-03-17|2006-01-23|2006-01-25|Estimate|2011-01-03|2011-01-04|Estimate||||2011-03-17|2011-03-21|Estimate|March 2006||2006-03-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|April 2008|Actual|2008-04-30||Interventional|||A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer|This Study is a Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer.|Completed||Phase 2|35|Actual|GlaxoSmithKline||1|||t||||||||||||||2018-06-01 04:12:37.990904|2018-06-01 04:12:37.990904
NCT00281619|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2013-12-18|2006-01-23|2006-01-25|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients|Development of Population Pharmacokinetic-Pharmacodynamic (PK-PD) Models of Mycophenolic Acid for Bayesian Dose Individualization in Pediatric Kidney Transplant Patients|Completed|||29|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-06-01 04:12:38.679493|2018-06-01 04:12:38.679493
NCT00281606|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2013-09-10|2006-01-23|2006-01-25|Estimate|||||||2013-09-10|2013-09-12|Estimate|February 2006||2006-02-28|September 2013|2013-09-30||||October 2008|Actual|2008-10-31||Interventional|||A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules|A Phase IV, Randomized, Open-label Study of the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules|Completed||Phase 4|65|Actual|California Collaborative Treatment Group||2|||f||||||||||||||2018-06-01 04:12:38.755146|2018-06-01 04:12:38.755146
NCT00281593|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2017-12-27|2006-01-24|2006-01-25|Estimate|||||||2017-12-27|2017-12-28|Actual|April 2006||2006-04-30|December 2017|2017-12-31||||April 2007|Actual|2007-04-30||Interventional|||Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension|A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study|Completed||Phase 3|1354|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:12:38.875042|2018-06-01 04:12:38.875042
NCT00281580|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2009-11-18||2014-02-10|2006-01-24|2006-01-25|Estimate|2010-03-26|2010-04-28|Estimate||||2014-02-10|2014-03-27|Estimate|April 2006||2006-04-30|February 2014|2014-02-28||||March 2007|Actual|2007-03-31||Interventional||Treated set including all 1461 patients who were randomised to receive double-blind treatment and took at least one dose.|Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension|A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to Evaluate Telmisartan 20, 40 and 80 mg Tablets in Combination With Amlodipine 2.5, 5 and 10 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study|Completed||Phase 3|1461|Actual|Boehringer Ingelheim||16|||f||||||||||||||2018-06-01 04:12:39.56536|2018-06-01 04:12:39.56536
NCT00281567|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2013-10-31|2006-01-24|2006-01-25|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2002||2002-08-31|October 2013|2013-10-31||||July 2003|Actual|2003-07-31||Interventional|||Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|76|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:12:42.759313|2018-06-01 04:12:42.759313
NCT00281554|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2008-04-01|2006-01-24|2006-01-25|Estimate|||||||2008-04-01|2008-04-03|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|ACT 4||Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation|A Phase 3, Multi-Center, Open Label, Safety Study of RSD1235 in Subjects With Atrial Fibrillation|Completed||Phase 3|254|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 04:12:42.840294|2018-06-01 04:12:42.840294
NCT00281541|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2012-06-06|2006-01-23|2006-01-25|Estimate|||||||2012-06-06|2012-06-07|Estimate|November 2005||2005-11-30|June 2012|2012-06-30|June 2007|Actual|2007-06-30|||||Interventional|||A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma|A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma|Completed||Phase 2|29|Anticipated|Astellas Pharma Inc|||||f||||f||||||||||2018-06-01 04:12:42.947558|2018-06-01 04:12:42.947558
NCT00281528|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|2012-02-17||2016-10-25|2006-01-24|2006-01-25|Estimate|2012-02-17|2012-03-13|Estimate||||2016-10-25|2016-12-07|Estimate|February 2006||2006-02-28|October 2016|2016-10-31|March 2011|Actual|2011-03-31|July 2010|Actual|2010-07-31||Interventional|||Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer|A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.|Terminated||Phase 2|208|Actual|Celgene Corporation||3||sufficient mature data to complete a final analysis|f||||f||||||||||2018-06-01 04:12:43.067434|2018-06-01 04:12:43.067434
NCT00281515|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-24|||2012-06-28|2006-01-24|2006-01-25|Estimate|||||||2012-06-28|2012-06-29|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer|An Open-label, Multicenter, Randomized Phase II Study to Compare the Effects of Paclitaxel/Carboplatin and Lonafarnib to Those of Paclitaxel/Carboplatin for First-line Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages IIB-IV|Completed||Phase 2|105|Actual|AGO Study Group||2|||f||||||||||||||2018-06-01 04:12:44.434199|2018-06-01 04:12:44.434199
NCT00281502|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2010-11-04|2006-01-20|2006-01-24|Estimate|||||||2010-11-04|2010-11-05|Estimate|December 2005||2005-12-31|November 2010|2010-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy|The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy|Unknown status|Recruiting|Phase 2|50|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:12:44.537959|2018-06-01 04:12:44.537959
NCT00281489|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2012-07-20|2006-01-20|2006-01-24|Estimate|||||||2012-07-20|2012-07-23|Estimate|August 2005||2005-08-31|July 2012|2012-07-31||||October 2006|Actual|2006-10-31||Interventional|||Study Evaluating Ways of Preventing Patients From Being Awake During High-Risk Surgery and Anesthesia|B-Unaware Study: Comparison of BIS-guided Anesthesia With End-Tidal Volatile-Guided Anesthesia to Decrease The Incidence of Awareness During High-Risk Surgery|Completed||Phase 2/Phase 3|2000|Actual|Washington University School of Medicine||2|||f||||||||||||||2018-06-01 04:12:44.630975|2018-06-01 04:12:44.630975
NCT00281476|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2011-10-31|2006-01-23|2006-01-24|Estimate|||||||2011-10-31|2011-11-01|Estimate|February 2006||2006-02-28|October 2011|2011-10-31|November 2007|Actual|2007-11-30|||||Interventional|||The Effect of High Dose Simvastatine on Multiple Myeloma|The Effect of High Dose Simvastatine on Multiple Myeloma|Completed||Phase 1/Phase 2|10|Anticipated|Vejle Hospital|||||f||||||||||||||2018-06-01 04:12:44.720399|2018-06-01 04:12:44.720399
NCT00281463|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2014-11-06||2014-11-06|2006-01-23|2006-01-24|Estimate|2014-11-06|2014-11-18|Estimate||||2014-11-06|2014-11-18|Estimate|November 2001||2001-11-30|November 2014|2014-11-30|January 2008|Actual|2008-01-31|March 2007|Actual|2007-03-31||Interventional|||Impact of Pushrim Activated Power Assist Wheelchairs on Mobility Among People With Tetraplegia|Impact of Pushrim Activated Power Assist Wheelchairs on Mobility Among People With Tetraplegia|Completed||N/A|45|Actual|VA Pittsburgh Healthcare System||1|||f||||f||||||||||2018-06-01 04:12:44.881797|2018-06-01 04:12:44.881797
NCT00281450|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2010-04-27|2006-01-20|2006-01-24|Estimate|||||||2010-04-27|2010-04-28|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||An Intervention to Reduce Inappropriate Prescriptions for Elderly Patients in General Practice|A Cluster Randomized Educational Intervention to Reduce Inappropriate Prescription Patterns for Elderly Patients in General Practice|Completed||Phase 1/Phase 2|85836|Actual|University of Oslo|||||f||||||||||||||2018-06-01 04:12:45.027762|2018-06-01 04:12:45.027762
NCT00281437|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2006-10-11|2006-01-20|2006-01-24|Estimate|||||||2006-10-11|2006-10-12|Estimate||||January 2006|2006-01-31||||||||Interventional|||Health First-Study 2|Health First: Health and Psychological Outcomes of Physical Activity- Study 2|Completed||Phase 2/Phase 3|200||University of Alberta, Physical Education|||||f||||||||||||||2018-06-01 04:12:45.097106|2018-06-01 04:12:45.097106
NCT00281424|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-10-26|2006-01-20|2006-01-24|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2005||2005-06-30|October 2016|2016-10-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Increasing Walking Following Cardiac Rehabilitation|Increasing Walking Following Completion of Cardiac Rehabilitation|Completed||Phase 2/Phase 3|100|Actual|University of Alberta, Physical Education||2|||f||||f||||||||No||2018-06-01 04:12:45.146691|2018-06-01 04:12:45.146691
NCT00281398|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2013-06-19|2006-01-20|2006-01-24|Estimate|||||||2013-06-19|2013-06-20|Estimate|August 2005||2005-08-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Attitudes of Medical Trainees Towards Homeless Persons Presenting for Care in the Emergency Department|Attitudes of Medical Trainees Towards Homeless Persons Presenting for Care in the Emergency Department|Completed||N/A|100|Anticipated|St. Michael's Hospital, Toronto|||||f||||t||||||||||2018-06-01 04:12:45.304104|2018-06-01 04:12:45.304104
NCT00281385|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2006-10-10|2006-01-20|2006-01-24|Estimate|||||||2006-10-10|2006-10-11|Estimate||||January 2006|2006-01-31||||||||Interventional|||Health and Psychological Outcomes of Lifestyle Versus Traditional Physical Activity|Health and Psychological Outcomes of Lifestyle Versus Traditional Physical Activity- Study 1|Completed||Phase 1/Phase 2|300||University of Alberta, Physical Education|||||f||||||||||||||2018-06-01 04:12:45.355448|2018-06-01 04:12:45.355448
NCT00281372|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2008-07-28|2006-01-23|2006-01-24|Estimate|||||||2008-07-28|2008-07-29|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|June 2008|Actual|2008-06-30|||||Observational|||Sexual Dysfunction and Dental Care|Association Between Sexual Dysfunction in Adults and Behavioral Dysfunctions in Achieving Proper Dental Care|Completed|||448|Actual|Sheba Medical Center|||||f||||||||||||||2018-06-01 04:12:45.462566|2018-06-01 04:12:45.462566
NCT00281359|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2014-11-04|2006-01-23|2006-01-24|Estimate|||||||2014-11-04|2014-11-05|Estimate|April 2003||2003-04-30|November 2014|2014-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Comparative Study of the Effectiveness of Treatment of Contractures With Mechanically Applied Stretch and Heat.|A Comparative Study of the Effectiveness of Treatment of Contractures With Mechanically Applied Stretch and Heat.|Completed||N/A|20|Actual|Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust||2|||f||||f||||||||||2018-06-01 04:12:45.509325|2018-06-01 04:12:45.509325
NCT00281346|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2016-07-15|2006-01-23|2006-01-24|Estimate|||||||2016-07-15|2016-07-18|Estimate|December 2005||2005-12-31|July 2016|2016-07-31|August 2008|Actual|2008-08-31|January 2008|Actual|2008-01-31||Interventional|||Non-invasive Diagnosis of Coronary Artery Stenoses by Doppler Echocardiography|Non-invasive Evaluation of Coronary Pathology by Transthoracic Doppler Echocardiography. A Comparative Study to Coronary Angiography.|Completed||N/A|110|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-06-01 04:12:45.575409|2018-06-01 04:12:45.575409
NCT00281333|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2011-08-28|2006-01-23|2006-01-24|Estimate|||||||2011-08-28|2011-08-30|Estimate||||August 2011|2011-08-31|October 2006|Actual|2006-10-31|||||Interventional|||"The Influence of Karate on Bleeding in Hemophilic Patients."|"The Influence of Karate on Bleeding in Hemophilic Patients."|Terminated||N/A|12|Anticipated|Sheba Medical Center||||logistics|f||||f||||||||||2018-06-01 04:12:45.685913|2018-06-01 04:12:45.685913
NCT00281320|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2010-08-12|2009-04-17|2015-02-20|2006-01-23|2006-01-24|Estimate|2010-08-12|2010-09-09|Estimate|2009-10-02|2009-10-06|Estimate|2015-02-20|2015-03-10|Estimate|February 2006||2006-02-28|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)|A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects With Psychosis.|Completed||Phase 3|122|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:12:45.74527|2018-06-01 04:12:45.74527
NCT00281307|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2017-07-13|2006-01-23|2006-01-24|Estimate|||||||2017-07-13|2017-07-18|Actual|December 7, 2005|Actual|2005-12-07|July 2017|2017-07-31|September 1, 2007|Actual|2007-09-01|September 1, 2007|Actual|2007-09-01||Interventional|||Treatment of Rhinitis With Intranasal Vitamin E|DBPCR Clinical Trial for Treatment of Rhinitis With Intranasal Vitamin E|Terminated||N/A|10|Actual|Milton S. Hershey Medical Center||||"Due to a substantial response to placebo an interim analysis indicated the need for a larger~   than expected study population to achieve the level of significance"|f||||||||||||||2018-06-01 04:12:46.054179|2018-06-01 04:12:46.054179
NCT00281294|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2008-08-02|2006-01-20|2006-01-24|Estimate|||||||2008-08-02|2008-08-05|Estimate|December 2005||2005-12-31|August 2008|2008-08-31|December 2006||2006-12-31|||||Interventional|||A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis|A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis|Terminated||Phase 2|40||Facet Biotech||||Terminated early because the first phase didn't meet the endpoint.|||||||||||||||2018-06-01 04:12:46.149527|2018-06-01 04:12:46.149527
NCT00281281|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-22|||2012-12-04|2006-01-23|2006-01-24|Estimate|||||||2012-12-04|2012-12-06|Estimate|December 2005||2005-12-31|December 2012|2012-12-31|April 2007||2007-04-30|||||Interventional|||Pharmacokinetics of Vancomycin in Adults Receiving ECMO|Pharmacokinetics and Posology of Vancomycin in Adults Receiving ECMO|Completed||Phase 4|24|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:12:46.230548|2018-06-01 04:12:46.230548
NCT00281268|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2008-01-18|2006-01-20|2006-01-24|Estimate|||||||2008-01-18|2008-01-21|Estimate||||January 2008|2008-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Fluids and Catheters Treatment Trial (FACTT) - ARDS Clinical Research Network||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:12:46.288332|2018-06-01 04:12:46.288332
NCT00281255|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2013-06-17|2006-01-20|2006-01-24|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2003||2003-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy|Allopurinol and Cardiac Function Pilot Study in Idiopathic Dilated Cardiomyopathy|Withdrawn||Phase 1/Phase 2|0|Actual|University of Pennsylvania||2||Infeasible|f||||f||||||||||2018-06-01 04:12:46.348287|2018-06-01 04:12:46.348287
NCT00281242|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-01-28|2006-01-20|2006-01-24|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2005||2005-09-30|January 2016|2016-01-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Observational|||Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Innate and Adaptive Immunity in COPD Exacerbations: Severe AE-COPD Clinical Course Study|Completed|||37|Actual|University of Michigan|||1||f||||f||||||||||2018-06-01 04:12:46.433376|2018-06-01 04:12:46.433376
NCT00281229|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-01-28|2006-01-20|2006-01-24|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2005||2005-09-30|January 2016|2016-01-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Observational|||T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Innate and Adaptive Immunity in COPD Exacerbations: Surgical Volunteers|Completed|||481|Actual|University of Michigan|||||f||||f||||||||||2018-06-01 04:12:46.516859|2018-06-01 04:12:46.516859
NCT00281216|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-01-28|2006-01-20|2006-01-24|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2005||2005-09-30|January 2016|2016-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations|Innate and Adaptive Immunity in COPD Exacerbations: Prospective Cohort Study|Completed|||10|Actual|University of Michigan|||||f||||f||||||Samples Without DNA|"~     serum, sputum~   "|||2018-06-01 04:12:46.589394|2018-06-01 04:12:46.589394
NCT00281203|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2013-07-15|2006-01-20|2006-01-24|Estimate|||||||2013-07-15|2013-07-16|Estimate|September 2005||2005-09-30|July 2013|2013-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Comparison of Alveolar Macrophages in Healthy Individuals Versus Individuals With COPD|Innate and Adaptive Immunity in COPD Exacerbations: Bronchoscopies on Healthy Volunteers|Completed|||32|Actual|University of Michigan|||1||f||||f||||||||||2018-06-01 04:12:46.690578|2018-06-01 04:12:46.690578
NCT00281190|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2014-12-12|2006-01-20|2006-01-24|Estimate|||||||2014-12-12|2014-12-16|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function|Innate and Adaptive Immunity in COPD Exacerbations: Clinically-Indicated Bronchoscopies|Completed|||32|Actual|University of Michigan|||2||f||||f||||||||||2018-06-01 04:12:46.987219|2018-06-01 04:12:46.987219
NCT00281177|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-07-11|2006-01-20|2006-01-24|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2002||2002-09-30|June 2006|2006-06-30|August 2009|Actual|2009-08-31|||||Interventional|||Center for Reducing Asthma Disparities - Northwestern University/Cook County Hospital Centers|Center for Reducing Asthma Disparities - Northwestern University/Cook County Hospital Centers|Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:12:47.143953|2018-06-01 04:12:47.143953
NCT00281151|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2014-12-10|2006-01-20|2006-01-24|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2002||2002-09-30|February 2009|2009-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Center for Reducing Asthma Disparities - Meharry/Vanderbilt Centers|Center for Reducing Asthma Disparities - Meharry/Vanderbilt Centers|Completed|||180|Actual|Vanderbilt University|||||f||||t||||||||||2018-06-01 04:12:47.202633|2018-06-01 04:12:47.202633
NCT00281138|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2013-11-05|2006-01-20|2006-01-24|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2002||2002-09-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Center for Reducing Asthma Disparities - Rhode Island/Puerto Rico Centers|Pediatric Asthma Disparities: Perceptions and Management|Completed|||983|Actual|Rhode Island Hospital|||||f||||f||||||||||2018-06-01 04:12:47.270938|2018-06-01 04:12:47.270938
NCT00281125|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2012-03-15|2006-01-20|2006-01-24|Estimate|||||||2012-03-15|2012-03-19|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|August 2008|Actual|2008-08-31|September 2006|Actual|2006-09-30||Interventional|||Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer|A Two-Cohort Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin in Patients With Advanced Non-Small Cell Lung Cancers and Malignant Pleural Mesotheliomas|Terminated||Phase 1/Phase 2|20||Nevada Cancer Institute||||"Suspended due to data issues revealed at DSMB meeting. Planned amendment but was never~   submitted. Study was then closed."|f||||t||||||||||2018-06-01 04:12:47.320599|2018-06-01 04:12:47.320599
NCT00281112|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-07-11|2006-01-20|2006-01-24|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2002||2002-09-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Center for Reducing Asthma Disparities - Howard/Hopkins Centers||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:12:47.390127|2018-06-01 04:12:47.390127
NCT00281099|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|2009-06-30||2010-07-30|2006-01-20|2006-01-24|Estimate|2010-07-30|2010-08-03|Estimate||||2010-07-30|2010-08-03|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|MVP||"Managed Ventricular Pacing (MVP) Trial"|"MVP Trial (Managed Ventricular Pacing (MVP) Versus Backup Ventricular Pacing at a Rate of 40 Beats Per Minute (VVI 40) Pacing Trial)"|Terminated||N/A|1031|Actual|Medtronic Cardiac Rhythm and Heart Failure||2||Inability to reach statistical significance toward primary endpoint|f||||t||||||||||2018-06-01 04:12:47.52688|2018-06-01 04:12:47.52688
NCT00281086|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-07-28|2006-01-20|2006-01-24|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2002||2002-09-30|April 2008|2008-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Center for Reducing Asthma Disparities - Harvard University/Boston Area Community Health Centers||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:12:49.036789|2018-06-01 04:12:49.036789
NCT00281073|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2011-05-09|2006-01-23|2006-01-24|Estimate|||||||2011-05-09|2011-05-11|Estimate|March 2005||2005-03-31|May 2011|2011-05-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|ICE-CHIP||Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study|A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation|Completed||Phase 1/Phase 2|95|Actual|EP MedSystems||2|||f||||t||||||||||2018-06-01 04:12:49.090272|2018-06-01 04:12:49.090272
NCT00281060|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2006-07-26|2006-01-20|2006-01-24|Estimate|||||||2006-07-26|2006-07-27|Estimate|June 2003||2003-06-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Vienna Absolute Trial: Balloon Angioplasty Versus Stenting in the Superficial Femoral Artery|Balloon Angioplasty Versus Stenting With Nitinol Stents in the Superficial Femoral Artery|Completed||Phase 4|110||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:12:49.187111|2018-06-01 04:12:49.187111
NCT00281047|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2006-01-26|2006-01-23|2006-01-24|Estimate|||||||2006-01-26|2006-01-27|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|May 2006||2006-05-31|||||Interventional|||The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy|The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin|Unknown status|Recruiting|Phase 2/Phase 3|138||Hamamatsu University|||||f||||||||||||||2018-06-01 04:12:49.377657|2018-06-01 04:12:49.377657
NCT00281034|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2012-04-10|2006-01-23|2006-01-24|Estimate|||||||2012-04-10|2012-04-12|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|July 2007|Actual|2007-07-31|||||Observational|||OASIS STUDY Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS STUDY)|Outcome Assessment Using SF-36 v2 in Stroke Patient Study(OASIS Study)|Completed|||2069|Actual|Kyorin Pharmaceutical Co.,Ltd|||1||f||||t||||||||||2018-06-01 04:12:49.484516|2018-06-01 04:12:49.484516
NCT00281021|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2013-04-12||2018-03-01|2006-01-23|2006-01-24|Estimate|2014-11-06|2014-11-10|Estimate||||2018-03-01|2018-03-29|Actual|February 2006||2006-02-28|March 2018|2018-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer|Phase II Trial of Second Line Erlotinib + Digoxin in Patients With Non-Small Cell Lung Cancer|Terminated||Phase 2|26|Actual|University of Louisville||1||Interim analysis revealed that only 1 patient had a partial response.|f||||t||||||||||2018-06-01 04:12:49.568262|2018-06-01 04:12:49.568262
NCT00281008|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-08-01|2006-01-20|2006-01-24|Estimate|||||||2016-08-01|2016-08-03|Estimate|February 2006||2006-02-28|August 2016|2016-08-31|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy|A Phase 2, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects|Completed||Phase 2|44|Actual|Kastle Therapeutics, LLC||4|||f||||||||||||||2018-06-01 04:12:49.754418|2018-06-01 04:12:49.754418
NCT00280995|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-08-01|2006-01-20|2006-01-24|Estimate|||||||2016-08-01|2016-08-03|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy|A Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects|Completed||Phase 2|12|Actual|Kastle Therapeutics, LLC||4|||f||||||||||||||2018-06-01 04:12:49.832776|2018-06-01 04:12:49.832776
NCT00280982|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2010-11-15|2006-01-20|2006-01-24|Estimate|||||||2010-11-15|2010-11-16|Estimate|January 2006||2006-01-31|November 2010|2010-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Dendritic Cell-based Immunotherapy in Mesothelioma|Vaccination With Autologous Dendritic Cells Pulsed With Tumor Lysate for Treatment of Patients With Malignant Pleural Mesothelioma|Completed||Phase 1|10|Actual|Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:12:49.98129|2018-06-01 04:12:49.98129
NCT00280969|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-22|||2015-03-27|2006-01-23|2006-01-24|Estimate|||||||2015-03-27|2015-03-30|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment|Open-label Randomized Multicenter Study of Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir Boosted Atazanavir to Efavirenz|Completed||Phase 3|71|Actual|International Medical Center of Japan||2|||f||||t||||||||||2018-06-01 04:12:50.057181|2018-06-01 04:12:50.057181
NCT00280956|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-21|||2016-06-14|2006-01-21|2006-01-24|Estimate|||||||2016-06-14|2016-06-16|Estimate|July 2002||2002-07-31|March 2012|2012-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease|A Phase III, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who Have Previously Participated in Antegren Crohn's Disease Studies|Completed||Phase 4|2000|Anticipated|Biogen|||||f||||||||||||||2018-06-01 04:12:50.163973|2018-06-01 04:12:50.163973
NCT00280943|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2007-10-16|2006-01-23|2006-01-24|Estimate|||||||2007-10-16|2007-10-17|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|March 2007|Actual|2007-03-31|||||Interventional|||Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities|Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities Written for FDA Approved Medications for Osteoporosis Treatment.|Completed||Phase 2/Phase 3|64||Duke University|||||f||||||||||||||2018-06-01 04:12:50.231658|2018-06-01 04:12:50.231658
NCT00280930|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|||2007-01-18|2006-01-23|2006-01-24|Estimate|||||||2007-01-18|2007-01-19|Estimate|October 2005||2005-10-31|January 2007|2007-01-31||||||||Interventional|||Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer|A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density|Unknown status|Active, not recruiting|Phase 2|60||Dana-Farber Cancer Institute|||||||||||||||||||2018-06-01 04:12:50.30996|2018-06-01 04:12:50.30996
NCT00280917|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-23|2015-02-24||2015-03-10|2006-01-23|2006-01-24|Estimate|2015-03-10|2015-03-17|Estimate||||2015-03-10|2015-03-17|Estimate|June 2006||2006-06-30|June 2011|2011-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis|Completed||Phase 2|254|Actual|Can-Fite BioPharma|||||||||||||||||||2018-06-01 04:12:50.408332|2018-06-01 04:12:50.408332
NCT00280904|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|2010-11-17||2013-02-05|2006-01-20|2006-01-24|Estimate|2013-02-05|2013-03-08|Estimate||||2013-02-05|2013-03-08|Estimate|January 2006||2006-01-31|February 2013|2013-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus|A Registry for Comparing Catheter-Related Infection Rates Among Various Shunt Systems in the Treatment of Hydrocephalus|Completed|||433|Actual|Codman & Shurtleff|||||f||||f||||||||||2018-06-01 04:12:50.797361|2018-06-01 04:12:50.797361
NCT00280891|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2013-01-24|2006-01-20|2006-01-24|Estimate|||||||2013-01-24|2013-01-28|Estimate|January 2006||2006-01-31|July 2006|2006-07-31|June 2006|Actual|2006-06-30|||||Observational|||Review of Palliative Radiotherapy in the Management of Advanced Head and Neck Cancer|Review of Palliative Radiotherapy in the Management of Advanced Head and Neck Cancer|Completed|||100|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:12:50.943828|2018-06-01 04:12:50.943828
NCT00280878|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-22|||2016-01-13|2006-01-22|2006-01-24|Estimate|||||||2016-01-13|2016-01-15|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma|A Pilot Study of Rituximab in Combination With Out-patient Based VGF/F-GIV Salvage Therapies for Relapsed/Refractory CD20+ Lymphomas|Completed||Phase 2|12|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:12:50.996805|2018-06-01 04:12:50.996805
NCT00280865|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2006-07-27|2006-01-20|2006-01-24|Estimate|||||||2006-07-27|2006-07-31|Estimate|April 2002||2002-04-30|July 2006|2006-07-31|June 2003||2003-06-30|||||Interventional|||GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes|Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes|Completed||Phase 2|500||AstraZeneca|||||||||||||||||||2018-06-01 04:12:51.086859|2018-06-01 04:12:51.086859
NCT00280852|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2011-11-18|2006-01-20|2006-01-24|Estimate|||||||2011-11-18|2011-11-21|Estimate|January 2006||2006-01-31|July 2011|2011-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Review of Multimodality Management of Anaplastic Thyroid Cancer|A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer|Completed|||5|Actual|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:12:51.277501|2018-06-01 04:12:51.277501
NCT00280826|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-21|2010-07-15||2011-01-28|2006-01-20|2006-01-23|Estimate|2011-01-05|2011-01-27|Estimate||||2011-01-28|2011-02-02|Estimate|January 2006||2006-01-31|January 2011|2011-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efalizumab to Treat Uveitis|Treatment of Non-Infectious Intermediate and Posterior Uveitis Associated Macular Edema With Humanized Anti-CD11a Antibody Therapy|Completed||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 04:12:51.338711|2018-06-01 04:12:51.338711
NCT00280813|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2008-10-24|2006-01-19|2006-01-23|Estimate|||||||2008-10-24|2008-10-27|Estimate|March 2004||2004-03-31|October 2008|2008-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Alcohol Use Disorders in Schizophrenia|Treatment of Alcohol Use Disorders in Schizophrenia|Completed||N/A|54|Actual|University of Maryland||1|||f||||f||||||||||2018-06-01 04:12:51.514262|2018-06-01 04:12:51.514262
NCT00280800|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2017-10-26|2006-01-20|2006-01-23|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2006||2006-01-31|October 2017|2017-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Sleep Apnea|Effectiveness of Auto-adjusted Continuous Positive Airway Pressure for Long-term Treatment of Obstructive Sleep Apnea Syndrome|Completed||N/A|208|Actual|University of Zurich||2|||f||||f||||||||||2018-06-01 04:12:51.705002|2018-06-01 04:12:51.705002
NCT00280787|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2013-02-01|2006-01-19|2006-01-23|Estimate|||||||2013-02-01|2013-02-05|Estimate|November 2003||2003-11-30|February 2013|2013-02-28|October 2010|Actual|2010-10-31|January 2006|Actual|2006-01-31||Interventional|||Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim|LCCC 0215: Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim Support Followed by Conformal Radiotherapy and Paclitaxel/Carboplatin/ZD1839 in Locally Advanced Unresectable Stage IIIA/B Non-Small Cell Carcinoma of the Lung|Completed||Phase 2|24|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:12:51.783827|2018-06-01 04:12:51.783827
NCT00280774|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2008-01-23|2006-01-19|2006-01-23|Estimate|||||||2008-01-23|2008-01-25|Estimate|March 2006||2006-03-31|July 2007|2007-07-31|February 2007|Actual|2007-02-28|||||Interventional|||Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes|Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes: A Pilot Study|Completed||Phase 4|20||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:12:51.86071|2018-06-01 04:12:51.86071
NCT00280761|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2018-03-22|2006-01-19|2006-01-23|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2003||2003-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy|A Biologic Study of Global Gene Expression, NF-Kappa B and p53 in Adenocarcinoma of the Rectum.|Recruiting|||60|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Adenocarcinoma of the Rectum~   "|||2018-06-01 04:12:51.927655|2018-06-01 04:12:51.927655
NCT00280748|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|2017-04-03||2017-06-22|2006-01-19|2006-01-23|Estimate|2017-06-22|2017-06-23|Actual||||2017-06-22|2017-06-23|Actual|May 2005||2005-05-31|June 2017|2017-06-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|NRR||Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer|A Phase II Study of Treatment of Brain Metastases From Non-Small Cell Lung Cancer With Concurrent Whole Brain Radiation Therapy and Pemetrexed|Terminated||Phase 2|10|Actual|UNC Lineberger Comprehensive Cancer Center||1||Slow accrual|f||||t||||||||No||2018-06-01 04:12:52.047302|2018-06-01 04:12:52.047302
NCT00280735|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|2017-03-24||2017-06-09|2006-01-19|2006-01-23|Estimate|2017-05-05|2017-06-12|Actual||||2017-06-09|2017-07-11|Actual|May 2004|Actual|2004-05-31|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC|Phase II Trial Exploring the Feasibility of Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA Non-Small Cell Lung Cancer|Completed||Phase 2|75|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||No||2018-06-01 04:12:52.35967|2018-06-01 04:12:52.35967
NCT00280722|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2017-11-02|2006-01-20|2006-01-23|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2006||2006-01-31|January 2006|2006-01-31|November 2006|Anticipated|2006-11-30|||||Interventional|||RAW Study Version 3.4|Does Increasing Research Awareness Impact on Accrual? A Feasibility Study. Protocol Version 3.4 Dated April 2005.|Withdrawn||N/A|0|Actual|Oxford University Hospitals NHS Trust|||||f||||||||||||||2018-06-01 04:12:52.682367|2018-06-01 04:12:52.682367
NCT00280709|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2011-08-09|2006-01-20|2006-01-23|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2006||2006-01-31|December 2010|2010-12-31|August 2010|Actual|2010-08-31|October 2008|Actual|2008-10-31||Interventional|||Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction|Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study.|Completed||Phase 4|400|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-06-01 04:12:53.716042|2018-06-01 04:12:53.716042
NCT00280696|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2015-02-10|2006-01-20|2006-01-23|Estimate|||||||2015-02-10|2015-02-11|Estimate|November 2005||2005-11-30|February 2015|2015-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures|A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam Used as add-on Therapy at Doses of 0.5 to 3 g/Day in Patients From 16 to 65 Years With Epilepsy With Partial Onset Seizures Under Treatment With 1 to 3 Anti-epileptic Drug(s)|Completed||Phase 3|352|Actual|UCB Pharma||5|||f||||f||||||||||2018-06-01 04:12:53.802552|2018-06-01 04:12:53.802552
NCT00280683|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|2012-12-06||2017-05-25|2006-01-19|2006-01-23|Estimate|2013-04-26|2013-06-05|Estimate||||2017-05-25|2017-05-30|Actual|December 2004||2004-12-31|May 2017|2017-05-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma|Phase 2 Study: GCRC: Effects of L-arginine Supplementation on Exhaled Nitric Oxide and Clinical Exacerbations in Adults With Moderate to Severe Asthma|Completed||Phase 2|20|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 04:12:54.00151|2018-06-01 04:12:54.00151
NCT00280670|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2012-03-28|2006-01-20|2006-01-23|Estimate|||||||2012-03-28|2012-04-02|Estimate|January 2005||2005-01-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|BIACA||CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS||Completed||Phase 2|20|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 04:12:54.296622|2018-06-01 04:12:54.296622
NCT00280657|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2014-12-17|2006-01-20|2006-01-23|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2004||2004-03-31|December 2014|2014-12-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa|Multicenter, Double-blind, Double-dummy, Randomized Parallel Group Study to Evaluate the Safety and Efficacy of SH D 00659 E for 6 Treatment Cycles in Female Patients With Acne Papulopustulosa in Comparison to SH D 00659 G and Placebo.|Completed||Phase 3|1326|Actual|Bayer||3|||f||||f||||||||||2018-06-01 04:12:54.382633|2018-06-01 04:12:54.382633
NCT00280644|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2011-01-10|2006-01-19|2006-01-23|Estimate|||||||2011-01-10|2011-01-11|Estimate|April 2004||2004-04-30|January 2011|2011-01-31||||||||Interventional|||Leflunomide in Rheumatoid Arthritis|Efficacy of Leflunomide on Joint Inflammation and Destruction of Joint Integrity in Active Rheumatoid Arthritis (RA) Patients|Completed||Phase 4|60||Sanofi|||||f||||f||||||||||2018-06-01 04:12:55.620161|2018-06-01 04:12:55.620161
NCT00280631|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2012-05-30|2006-01-19|2006-01-23|Estimate|||||||2012-05-30|2012-05-31|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)|Phase 1-2a Dose-Ranging Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)|Completed||Phase 1/Phase 2|49|Actual|Telik||1|||f||||f||||||||||2018-06-01 04:12:55.685375|2018-06-01 04:12:55.685375
NCT00280618|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2009-09-14|2006-01-20|2006-01-23|Estimate|||||||2009-09-14|2009-09-15|Estimate|July 2004||2004-07-31|September 2009|2009-09-30||||November 2006|Actual|2006-11-30||Interventional|||Oxaliplatin in Unresectable Hepatocellular Carcinoma|Phase II Study of Eloxatin + 5-Fluorouracil/Leucovorin in Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 2|||Sanofi|||||f||||||||||||||2018-06-01 04:12:55.757437|2018-06-01 04:12:55.757437
NCT00280605|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2010-08-30|2006-01-20|2006-01-23|Estimate|||||||2010-08-30|2010-08-31|Estimate|August 2005||2005-08-31|August 2010|2010-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||ALF-ONE : ALFuzosin ONcE Daily|Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China|Completed||Phase 4|200||Sanofi|||||f||||||||||||||2018-06-01 04:12:55.810879|2018-06-01 04:12:55.810879
NCT00280592|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2012-05-18|2006-01-20|2006-01-23|Estimate|||||||2012-05-18|2012-05-21|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|October 2008|Actual|2008-10-31|March 2008|Actual|2008-03-31||Interventional|CANNEBERGE||Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients|Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.|Completed||Phase 3|171|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 04:12:55.966703|2018-06-01 04:12:55.966703
NCT00280579|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2014-11-06|2006-01-20|2006-01-23|Estimate|||||||2014-11-06|2014-11-07|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|January 2007||2007-01-31|||||Observational|||Cyanide Poisoning in Fire Victims||Withdrawn|||0|Actual|Rigshospitalet, Denmark|||1|Not sufficient time to conduct the study|f||||||||||||||2018-06-01 04:12:56.100281|2018-06-01 04:12:56.100281
NCT00280566|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|2009-05-06||2010-01-05|2006-01-19|2006-01-23|Estimate|2009-11-11|2009-12-14|Estimate||||2010-01-05|2010-01-12|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)|A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects With Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment With Both Agents|Completed||Phase 3|584|Actual|Pfizer|This is a maintenance of effect design using a survival analysis methodology. In such a design it may be difficult to interpret timepoint by timepoint treatment group comparisons in MRS, CGI-S, CGI-I, MADRS, and PANSS.|2|||f||||f||||||||||2018-06-01 04:12:56.261972|2018-06-01 04:12:56.261972
NCT00280553|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2012-05-14|2006-01-20|2006-01-23|Estimate|||||||2012-05-14|2012-05-15|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||A Pilot Study of Bupivacaine Infusion in Abdominal Surgery|A Pilot Study of Bupivacaine Infusion in Abdominal Surgery|Unknown status|Recruiting|Phase 2|60|Anticipated|McMaster University||3|||f||||||||||||||2018-06-01 04:12:57.41439|2018-06-01 04:12:57.41439
NCT00280540|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2010-11-05|2006-01-19|2006-01-23|Estimate|||||||2010-11-05|2010-11-09|Estimate|December 2005||2005-12-31|March 2008|2008-03-31||||August 2006|Actual|2006-08-31||Interventional|||Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension|A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension|Completed||Phase 4|648||Novartis|||||||||||||||||||2018-06-01 04:12:57.51258|2018-06-01 04:12:57.51258
NCT00280527|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2011-12-16|2006-01-19|2006-01-23|Estimate|||||||2011-12-16|2011-12-20|Estimate|September 2006||2006-09-30|December 2011|2011-12-31|September 2008|Actual|2008-09-30|||||Observational|||Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.|Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.|Completed|||43|Actual|Northwestern University|||||f||||f||||||||||2018-06-01 04:12:57.577977|2018-06-01 04:12:57.577977
NCT00280514|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2010-08-03|2006-01-20|2006-01-23|Estimate|||||||2010-08-03|2010-08-04|Estimate|January 2006||2006-01-31|November 2005|2005-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration|Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration|Completed||Phase 4|20|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-06-01 04:12:57.663986|2018-06-01 04:12:57.663986
NCT00280501|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2008-07-08|2006-01-19|2006-01-23|Estimate|||||||2008-07-08|2008-07-09|Estimate|August 2005||2005-08-31|July 2008|2008-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Dopaminergic Modulation of Choroidal Blood Flow Changes During Dark/Light Transitions|Dopaminergic Modulation of Choroidal Blood Flow Changes During Dark/Light Transitions|Completed||N/A|21|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 04:12:57.745278|2018-06-01 04:12:57.745278
NCT00280488|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2010-06-24|2006-01-19|2006-01-23|Estimate|||||||2010-06-24|2010-06-25|Estimate|May 2005||2005-05-31|June 2010|2010-06-30|April 2011|Anticipated|2011-04-30|April 2011|Anticipated|2011-04-30||Interventional|||Enhanced Motivational Interviewing With Alcohol Positive Trauma Patients|Enhanced MI With Alcohol Positive Trauma Patients|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|Brown University||3|||f||||t||||||||||2018-06-01 04:12:57.822031|2018-06-01 04:12:57.822031
NCT00280475|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2016-09-20|2006-01-20|2006-01-23|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 2006||2006-01-31|September 2016|2016-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis|Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504)|Completed||Phase 3|270|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:12:57.906586|2018-06-01 04:12:57.906586
NCT00280462|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2008-07-08|2006-01-19|2006-01-23|Estimate|||||||2008-07-08|2008-07-09|Estimate|August 2005||2005-08-31|July 2008|2008-07-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade|Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade|Completed||N/A|21|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 04:12:58.003877|2018-06-01 04:12:58.003877
NCT00280449|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2006-01-20|2006-01-20|2006-01-23|Estimate|||||||2006-01-20|2006-01-23|Estimate|March 2006||2006-03-31|November 2005|2005-11-30|February 2007||2007-02-28|||||Interventional|||Two Approaches to Providing HIV/AIDS Services in the Community to People Living With HIV/AIDS|Two Approaches to Providing HIV/AIDS Services in the Community to People Living With HIV/AIDS (PHAs): The Comparative Impact on Quality of Life, Access to and Expenditures for All Health and Social Services|Unknown status|Not yet recruiting|Phase 1|120||McMaster University|||||f||||||||||||||2018-06-01 04:12:58.093176|2018-06-01 04:12:58.093176
NCT00280254|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2006-01-19|2006-01-19|2006-01-20|Estimate|||||||2006-01-19|2006-01-20|Estimate|November 1999||1999-11-30|January 2006|2006-01-31|December 2004||2004-12-31|||||Interventional|||A Hemodynamically Oriented Echocardiography-Based Strategy in the Treatment of Congestive Heart Failure|A Hemodynamically Oriented Echocardiography-Based Strategy in the Treatment of Congestive Heart Failure|Terminated||Phase 2|102||Federal University of Rio Grande do Sul|||||f||||||||||||||2018-06-01 04:13:00.533091|2018-06-01 04:13:00.533091
NCT00280436|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2015-04-14|2006-01-20|2006-01-23|Estimate|||||||2015-04-14|2015-04-16|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia|A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of GW679769 on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Non-elderly Subjects With Primary Insomnia|Completed||Phase 2|122|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:12:58.154823|2018-06-01 04:12:58.154823
NCT00280423|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2015-04-14|2006-01-19|2006-01-23|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia|A 28 Day, Polysomnographic and Subjective Assessment of GW679769 for the Treatment of Primary Insomnia: A Randomized, Double-blind, Parallel-Group, Placebo-Controlled Trial.|Completed||Phase 2|342|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:12:58.354549|2018-06-01 04:12:58.354549
NCT00280410|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2010-01-28|2006-01-20|2006-01-23|Estimate|||||||2010-01-28|2010-01-29|Estimate|February 2006||2006-02-28|January 2010|2010-01-31||||October 2006|Actual|2006-10-31||Interventional|||Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver|Multicenter, Randomized, Open-Label Study Investigating The Superiority Of The Contrast Enhancement Effect Of E7337 On Tumor Like Lesion In The Dynamic CT Of The Liver Of Patients With Tumor Like Lesions In The Liver|Completed||Phase 2/Phase 3|192||Eisai Inc.|||||f||||||||||||||2018-06-01 04:12:58.510401|2018-06-01 04:12:58.510401
NCT00280397|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|2015-02-21||2016-08-29|2006-01-20|2006-01-23|Estimate|2015-02-21|2015-03-06|Estimate||||2016-08-29|2016-10-07|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors|An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors|Completed||Phase 1|27|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 04:12:58.603525|2018-06-01 04:12:58.603525
NCT00280384|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|2013-03-12||2013-04-23|2006-01-20|2006-01-23|Estimate|2013-04-23|2013-04-25|Estimate||||2013-04-23|2013-04-25|Estimate|January 2006||2006-01-31|April 2013|2013-04-30||||August 2006|Actual|2006-08-31||Interventional|||An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects|An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects|Completed||Phase 2|48|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:12:58.87801|2018-06-01 04:12:58.87801
NCT00280371|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2010-11-09|2006-01-19|2006-01-23|Estimate|||||||2010-11-09|2010-11-11|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|May 2007|Actual|2007-05-31|July 2006|Actual|2006-07-31||Interventional|||A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate 20 Mcg/0.5 mL in the Treatment of Patients With COPD|A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg/0.5 mL Delivered by OMRON MicroAir NE-U22V Nebulizer in the Treatment of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|345||Dey|||||||||||||||||||2018-06-01 04:12:59.455027|2018-06-01 04:12:59.455027
NCT00280358|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2008-03-05|2006-01-20|2006-01-23|Estimate|||||||2008-03-05|2008-03-07|Estimate||||March 2008|2008-03-31|December 2005|Actual|2005-12-31|||||Interventional|||A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.||Completed||Phase 1|30||Dey|||||||||||||||||||2018-06-01 04:12:59.579947|2018-06-01 04:12:59.579947
NCT00280345|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2011-07-08|2006-01-19|2006-01-23|Estimate|||||||2011-07-08|2011-07-11|Estimate|February 2006||2006-02-28|July 2011|2011-07-31|May 2009|Actual|2009-05-31|September 2007|Actual|2007-09-30||Interventional|||Autoimmune Dysregulation in Pigmentary Glaucoma|Autoimmune Dysregulation in Pigmentary Glaucoma|Completed||N/A|23|Actual|University of Oklahoma|||||f||||t||||||||||2018-06-01 04:12:59.650219|2018-06-01 04:12:59.650219
NCT00280332|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2008-05-09|2006-01-20|2006-01-23|Estimate|||||||2008-05-09|2008-05-12|Estimate|March 2006||2006-03-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||A Follow-up Colonoscopy Examination in Patients Who Had Previously Undergone Screening Colonoscopy|A Follow-up Colonoscopy Examination in Patients Who Had Previously Undergone Screening Colonoscopy|Completed|||560|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-06-01 04:12:59.710771|2018-06-01 04:12:59.710771
NCT00280319|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-20|||2017-03-10|2006-01-20|2006-01-23|Estimate|||||||2017-03-10|2017-03-14|Actual|May 2005||2005-05-31|March 2017|2017-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study of Treatments for Depression Among Displaced Adolescents in Northern Uganda.|Randomized Controlled Study of Non-pharmacologic Treatments for Depression Among Displaced Adolescents in Northern Uganda.|Completed||N/A|338|Actual|Boston University||3|||f||||f||||||||No||2018-06-01 04:12:59.776831|2018-06-01 04:12:59.776831
NCT00280306|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-06-02|2006-01-19|2006-01-20|Estimate|||||||2015-06-02|2015-06-04|Estimate|November 2005||2005-11-30|June 2015|2015-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||White Matter Fiber Tracking and Assessment of White Matter Integrity in the Cervical Spinal Cord|White Matter Fiber Tracking and Assessment of White Matter Integrity in the Cervical Spinal Cord - Pilot Study|Completed|||35|Actual|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:12:59.842479|2018-06-01 04:12:59.842479
NCT00280293|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|2013-05-13||2013-07-30|2006-01-19|2006-01-20|Estimate|2013-07-30|2013-09-26|Estimate||||2013-07-30|2013-09-26|Estimate|March 2006||2006-03-31|July 2013|2013-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency|A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence|Completed||Phase 4|112|Actual|University of Texas Southwestern Medical Center|The weekly UDS (rather than thrice weekly as is customary in cocaine trials) design feature decreased our number of observations and statistical power, and did not provide us with a complete picture of cocaine use between weekly visits.|2|||f||||f||||||||||2018-06-01 04:13:00.032919|2018-06-01 04:13:00.032919
NCT00280280|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-01-19|2006-01-18|2006-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|February 2006||2006-02-28|January 2012|2012-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Botox vs. Baclofen for Upper Limb Spasticity|Double-blind Comparison of Botox Versus Baclofen for the Treatment of Subjects With Upper Limb Spasticity - Pilot Study|Terminated||Phase 1|8|Actual|Vanderbilt University||1||low patient accrual|f||||f||||||||||2018-06-01 04:13:00.375338|2018-06-01 04:13:00.375338
NCT00280267|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2009-02-03|2006-01-19|2006-01-20|Estimate|||||||2009-02-03|2009-02-04|Estimate|August 2004||2004-08-31|February 2009|2009-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Testosterone Therapy After Hip Fracture in Elderly Women|Testosterone Therapy After Hip Fracture in Elderly Women|Completed||Phase 2|15|Actual|Washington University School of Medicine|||||||||t||||||||||2018-06-01 04:13:00.460163|2018-06-01 04:13:00.460163
NCT00280241|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|2016-01-05||2016-01-05|2006-01-19|2006-01-20|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|January 2013|Actual|2013-01-31|February 2008|Actual|2008-02-29||Interventional|||Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia|Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 2|65|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:13:00.6108|2018-06-01 04:13:00.6108
NCT00280228|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2011-05-25|2006-01-18|2006-01-20|Estimate|||||||2011-05-25|2011-05-26|Estimate|January 2006||2006-01-31|May 2011|2011-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Home Based Treatment for Drug Use in Early Adolescents|Home-based Behavioral Therapy (HBT): Psychosocial Intervention Project for Early Adolescents With Pre- or Early Substance Use Disorder: Phase II|Completed||Phase 2|36|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:13:00.901425|2018-06-01 04:13:00.901425
NCT00280215|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2015-04-06|2006-01-19|2006-01-20|Estimate|||||||2015-04-06|2015-04-07|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria|Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria|Withdrawn||Phase 3|0|Actual|Mayo Clinic||2||Inadequate number of patients, lack of funding|f||||f||||||||||2018-06-01 04:13:00.978194|2018-06-01 04:13:00.978194
NCT00280202|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2017-10-01|2006-01-18|2006-01-20|Estimate|||||||2017-10-01|2017-10-04|Actual|June 1996||1996-06-30|October 2017|2017-10-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|||Detection of Genetic Markers of Lung Cancer|Detection of Genetic Markers of Lung Cancer Initiation and Progression|Recruiting|||4000|Anticipated|University of Pittsburgh|||||f||||t|f|f||||Samples With DNA|"~     Blood, tissue, and lymph nodes~   "|Undecided||2018-06-01 04:13:01.072949|2018-06-01 04:13:01.072949
NCT00280189|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2017-07-13|2006-01-18|2006-01-20|Estimate|||||||2017-07-13|2017-07-18|Actual|September 2003||2003-09-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Study of Outcomes of Radiofrequency Ablation of Lung Tumors|A Prospective Study of Outcomes of Radiofrequency Ablation of Lung Tumors|Suspended|||72|Anticipated|University of Pittsburgh|||||f||||||||||||Undecided||2018-06-01 04:13:01.164749|2018-06-01 04:13:01.164749
NCT00280176|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-02-12|2006-01-19|2006-01-20|Estimate|||||||2012-02-12|2012-02-14|Estimate|April 2003||2003-04-30|February 2012|2012-02-29|September 2010|Actual|2010-09-30|November 2008|Actual|2008-11-30||Interventional|||Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer|Phase I Study of PS-341 in Combination With 5-Fluorouracil and External Beam Radiotherapy For The Treatment Of Locally Advanced And Metastatic Rectal Cancer|Completed||Phase 1|11|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:13:01.232544|2018-06-01 04:13:01.232544
NCT00280163|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2016-02-11|2006-01-18|2006-01-20|Estimate|||||||2016-02-11|2016-02-12|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Genomics and Postoperative Atrial Fibrillation|Genomics and Postoperative Atrial Fibrillation|Completed|||336|Actual|University of Pittsburgh|||||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 04:13:01.309833|2018-06-01 04:13:01.309833
NCT00280150|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|2017-03-24||2017-05-19|2006-01-19|2006-01-20|Estimate|2017-05-19|2017-06-19|Actual||||2017-05-19|2017-06-19|Actual|January 2006||2006-01-31|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|||Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer|Phase I/II Trial of Induction Carboplatin/Paclitaxel With Bevacizumab Followed by Concurrent Thoracic Conformal Radiation Therapy With Carboplatin/Paclitaxel, Bevacizumab and Erlotinib in Stage IIIA/B Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|46|Actual|UNC Lineberger Comprehensive Cancer Center||4|||f||||t||||||||||2018-06-01 04:13:01.405444|2018-06-01 04:13:01.405444
NCT00280137|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2016-04-08|2006-01-18|2006-01-20|Estimate|||||||2016-04-08|2016-04-11|Estimate|June 2004||2004-06-30|April 2016|2016-04-30|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Observational|||Health-related Quality of Life Measure in Pediatric Lupus|Health-related Quality of Life Measure in Pediatric Lupus|Completed|||31|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:13:02.075761|2018-06-01 04:13:02.075761
NCT00280111|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2008-07-01|2006-01-19|2006-01-20|Estimate|||||||2008-07-01|2008-07-02|Estimate|January 2005||2005-01-31|July 2008|2008-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants|Reactogenicity and Immunogenicity of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Healthy Non-Malnourished Infants 8-12 Weeks of Age|Completed||Phase 1|90|Actual|Society for Applied Studies||3|||f||||t||||||||||2018-06-01 04:13:02.149847|2018-06-01 04:13:02.149847
NCT00280098|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2009-12-04|2006-01-18|2006-01-20|Estimate|||||||2009-12-04|2009-12-07|Estimate|January 2006||2006-01-31|December 2009|2009-12-31||||October 2007|Actual|2007-10-31||Interventional|||Docetaxel in the Treatment of Hormone Refractory Prostate Cancer|Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment|Completed||Phase 4|30|Anticipated|Sanofi||1|||f||||||||||||||2018-06-01 04:13:02.212294|2018-06-01 04:13:02.212294
NCT00280085|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2009-08-06|2006-01-18|2006-01-20|Estimate|||||||2009-08-06|2009-08-07|Estimate|December 2005||2005-12-31|September 2008|2008-09-30|July 2007|Actual|2007-07-31|||||Interventional|||The Aim is to Estimate the Total Amount of Insulin-producing Cells in the Pancreas by MRI.|Pancreatic Beta-Cell Mass And Function Quantification By Means Of Perfusion Imaging|Terminated||N/A|29|Actual|Pfizer||||Explanation provided in detailed descriptiong section of record.|f||||||||||||||2018-06-01 04:13:02.353245|2018-06-01 04:13:02.353245
NCT00280072|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-11-29|2006-01-18|2006-01-20|Estimate|||||||2012-11-29|2012-12-03|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure|A Multi-Center, Randomized, Controlled, Double-Blind, Phase II Study To Assess Safety and Efficacy With the Renal Assist Device (RAD) in Patients With Acute Renal Failure|Terminated||Phase 2|||RenaMed Biologics|||||||||||||||||||2018-06-01 04:13:02.41693|2018-06-01 04:13:02.41693
NCT00280059|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|2010-12-16||2015-03-04|2006-01-18|2006-01-20|Estimate|2011-10-20|2011-10-24|Estimate||||2015-03-04|2015-03-24|Estimate|August 2006||2006-08-31|March 2015|2015-03-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy|A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures|Completed||Phase 3|660|Actual|Pfizer|Cox proportional hazards model for time to event (TTE) analyses; three summary statistics were not generated as median TTE will not exist if survival function (Kaplan-Meier product limit estimates) does not fall below 0.5 (post-hoc analysis).|2|||f||||f||||||||||2018-06-01 04:13:02.535275|2018-06-01 04:13:02.535275
NCT00280046|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2017-01-05|2006-01-19|2006-01-20|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2003||2003-11-30|January 2017|2017-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Biphasic Insulin Aspart 30 on Glycaemic Control in Subjects With Type 2 Diabetes|Completed||Phase 3|307|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:13:03.801917|2018-06-01 04:13:03.801917
NCT00280033|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2013-09-12|2006-01-19|2006-01-20|Estimate|||||||2013-09-12|2013-09-13|Estimate|February 2006||2006-02-28|January 2009|2009-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||H5 Adult - Chiron Study of Bird Flu Vaccine|A Randomized, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or Combined With Adjuvants in Healthy Adults|Completed||Phase 1/Phase 2|394|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||9|||f||||||||||||||2018-06-01 04:13:03.898851|2018-06-01 04:13:03.898851
NCT00280020|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-07-09|2006-01-18|2006-01-20|Estimate|||||||2012-07-09|2012-07-11|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Behavioral Treatment of Insomnia in Aging|Aging: Cytokine Mechanisms and Treatment of Insomnia|Completed||N/A|123|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-06-01 04:13:03.994938|2018-06-01 04:13:03.994938
NCT00280007|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2010-04-21|2006-01-19|2006-01-20|Estimate|||||||2010-04-21|2010-04-22|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma|AVATACE-1: Bevacizumab (Avastin®) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial|Terminated||Phase 2|32|Actual|Medical University of Vienna||2||Safety concerns in the treatment arm|f||||f||||||||||2018-06-01 04:13:04.099137|2018-06-01 04:13:04.099137
NCT00279994|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2008-05-06|2006-01-19|2006-01-20|Estimate|||||||2008-05-06|2008-05-09|Estimate|December 2005||2005-12-31|May 2008|2008-05-31|May 2009|Anticipated|2009-05-31|||||Interventional|EXITPAD||(Cost) Effectiveness Study of Exercise Therapy in Patients With Peripheral Arterial Disease|"Exercise Therapy in Patients With Peripheral Arterial Disease: the Costs and Effectiveness of Physiotherapeutic Supervision With or Without Therapy Feedback Versus a go Home and Walk Advice"|Unknown status|Active, not recruiting|N/A|300|Anticipated|Atrium Medical Center|||||f||||||||||||||2018-06-01 04:13:04.183469|2018-06-01 04:13:04.183469
NCT00279981|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2008-12-10|2006-01-18|2006-01-20|Estimate|||||||2008-12-10|2008-12-11|Estimate|November 2003||2003-11-30|December 2008|2008-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics|TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics|Completed|||3100||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:13:04.274781|2018-06-01 04:13:04.274781
NCT00279968|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2007-12-26|2006-01-19|2006-01-20|Estimate|||||||2007-12-26|2007-12-28|Estimate|February 2004||2004-02-29|December 2007|2007-12-31|January 2006||2006-01-31|||||Observational|||INSIGHTS ICD Registry|Investigating Significant ICD Heart Therapies Registry Study (INSIGHTS ICD Registry)|Completed|||1326||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:13:04.423129|2018-06-01 04:13:04.423129
NCT00279955|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|2011-07-20||2012-06-11|2006-01-18|2006-01-20|Estimate|2011-11-03|2011-12-08|Estimate||||2012-06-11|2012-06-15|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Observational|||PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure|Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure|Completed|||1024|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:13:04.676448|2018-06-01 04:13:04.676448
NCT00279942|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-01-04|2006-01-18|2006-01-20|Estimate|||||||2012-01-04|2012-01-06|Estimate|May 2006||2006-05-31|January 2012|2012-01-31|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||Effect of Revival Soy on Fibromyalgia Pain|Effect of Revival Soy on Fibromyalgia Pain|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:13:06.986249|2018-06-01 04:13:06.986249
NCT00279929|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2011-05-20|2006-01-18|2006-01-20|Estimate|||||||2011-05-20|2011-05-23|Estimate|July 2002||2002-07-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||DHEA Replacement in Adrenalectomized/Hypoadrenal Patients|Assessing the Effects of Dehydroepiandrosterone Replacement on the Mood of Adrenalectomised/Hypoadrenal Subjects|Completed||N/A|32||Mayo Clinic|||||f||||||||||||||2018-06-01 04:13:07.127423|2018-06-01 04:13:07.127423
NCT00279916|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|2011-07-20||2017-04-19|2006-01-18|2006-01-20|Estimate|2011-07-20|2011-08-15|Estimate||||2017-04-19|2017-05-30|Actual|September 1, 2005|Actual|2005-09-01|April 2017|2017-04-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays|Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays: a Randomized Placebo-controlled Study|Completed||Phase 3|91|Actual|Mayo Clinic||2|||f||||t|t|f|||f|||No||2018-06-01 04:13:07.292136|2018-06-01 04:13:07.292136
NCT00279903|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-11-06|2006-01-18|2006-01-20|Estimate|||||||2012-11-06|2012-11-07|Estimate|November 2005||2005-11-30|November 2012|2012-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Is Botox Effective in Relieving Pain From Knee Osteoarthritis?|Intra-articular Botulinum Toxin Type-A in Knee Osteoarthritis - a Randomized, Cortisone Controlled, Double Blind Study.|Completed||Phase 1|62|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 04:13:07.886222|2018-06-01 04:13:07.886222
NCT00279890|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2011-05-20|2006-01-18|2006-01-20|Estimate|||||||2011-05-20|2011-05-23|Estimate|July 2005||2005-07-31|May 2011|2011-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Topical Agent for Treatment of Red Skin|Proof of Concept Trial:SR-01 for the Treatment of Rosacea|Completed||Phase 1|20||Mayo Clinic|||||f||||||||||||||2018-06-01 04:13:07.986295|2018-06-01 04:13:07.986295
NCT00279877|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2016-08-17|2006-01-18|2006-01-20|Estimate|||||||2016-08-17|2016-08-18|Estimate|May 2005||2005-05-31|August 2016|2016-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Cost Effectiveness and Efficacy of Kyphoplasty and Vertebroplasty Trial|Cost Effectiveness and Efficacy of Kypho and Vertebro Plasty Trial|Completed||Phase 3|112|Actual|University of Virginia||2|||f||||||||||||||2018-06-01 04:13:08.088107|2018-06-01 04:13:08.088107
NCT00279864|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2015-04-29|2006-01-18|2006-01-20|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection|Prolonged Oral Levofloxacin-Rifampin for Staphylococcus Aureus Prosthetic Joint Infection (PJI) Treated With Debridement And Retention Of Components: A Prospective Observational Cohort Study. Mayo PJI Study Group (MPSG)*|Completed|||15|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:13:08.234116|2018-06-01 04:13:08.234116
NCT00279851|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2006-09-06|2006-01-18|2006-01-20|Estimate|||||||2006-09-06|2006-09-11|Estimate|February 2006||2006-02-28|September 2006|2006-09-30|August 2007||2007-08-31|||||Observational|||Blood Sugars in Children With Idiopathic Seizures.|Prevalence of Hypoglycemia and/or Hyperinsulinism/Hyperammonemia Syndrome in Patients With Idiopathic Seizures.|Unknown status|Recruiting||225||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:13:08.284107|2018-06-01 04:13:08.284107
NCT00279838|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2011-03-22|2006-01-18|2006-01-20|Estimate|||||||2011-03-22|2011-03-23|Estimate|June 2004||2004-06-30|March 2011|2011-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Computer Assisted Total Knee Replacement|Computer Assisted Navigation in Total Knee Arthroplasty|Completed||Phase 4|200|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 04:13:08.363159|2018-06-01 04:13:08.363159
NCT00279825|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2017-01-31|2006-01-18|2006-01-20|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2006||2006-01-31|January 2017|2017-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's Disease|Completed||Phase 2|16|Actual|IMPAX Laboratories, Inc.||4|||f||||f||||||||No||2018-06-01 04:13:08.450194|2018-06-01 04:13:08.450194
NCT00279812|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2011-03-18|2006-01-19|2006-01-20|Estimate|||||||2011-03-18|2011-03-21|Estimate|April 2005||2005-04-30|March 2011|2011-03-31|August 2008|Actual|2008-08-31|||||Interventional|||Selenium and Immune Function|Selenium and Immune Function|Completed||N/A|144|Anticipated|Quadram Institute|||||f||||||||||||||2018-06-01 04:13:08.5727|2018-06-01 04:13:08.5727
NCT00279799|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2013-11-18|2006-01-18|2006-01-20|Estimate|||||||2013-11-18|2013-11-19|Estimate|February 2005||2005-02-28|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||HIV Prevention for African American Teens|HIV Prevention Maintenance for African American Teens|Completed||Phase 3|701|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:13:08.644615|2018-06-01 04:13:08.644615
NCT00279786|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2009-07-27|2006-01-18|2006-01-20|Estimate|||||||2009-07-27|2009-07-28|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||B2-Adrenergic Receptor Polymorphisms|B2-Adrenergic Receptor Polymorphisms: Implications For The Treatment Of Status Asthmaticus In Children|Completed|||126|Actual|Connecticut Children's Medical Center|||||f||||f||||||||||2018-06-01 04:13:08.747573|2018-06-01 04:13:08.747573
NCT00279773|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2010-06-29|2006-01-18|2006-01-20|Estimate|||||||2010-06-29|2010-06-30|Estimate|September 2004||2004-09-30|June 2010|2010-06-30||||October 2007|Actual|2007-10-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia|A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia|Terminated||Phase 1|34|Actual|Novartis||2||Study was stopped due to time dependent drug accumulation|f||||||||||||||2018-06-01 04:13:08.824281|2018-06-01 04:13:08.824281
NCT00279760|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2016-09-15|2006-01-18|2006-01-20|Estimate|||||||2016-09-15|2016-09-16|Estimate||||September 2016|2016-09-30||||March 2002|Actual|2002-03-31||Interventional|||Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis|A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis|Completed||Phase 1/Phase 2|210||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:13:08.906512|2018-06-01 04:13:08.906512
NCT00279747|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2013-10-31|2006-01-19|2006-01-20|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2000||2000-09-30|October 2013|2013-10-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)|A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.|Completed||Phase 3|226||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:13:10.053646|2018-06-01 04:13:10.053646
NCT00279734|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-19|||2011-04-11|2006-01-19|2006-01-20|Estimate|||||||2011-04-11|2011-04-13|Estimate|August 2004||2004-08-31|April 2011|2011-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers|An Exploratory Study to Evaluate the Effect of Abatacept (BMS-188667) on the Antibody Response Following Tetanus Toxoid and 23-Valent Pneumococcal Vaccinations in Healthy Subjects|Completed||Phase 1|80|Anticipated|Bristol-Myers Squibb||4|||f||||||||||||||2018-06-01 04:13:10.187741|2018-06-01 04:13:10.187741
NCT00279721|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-01-18|2006-01-18|2006-01-20|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2006||2006-01-31|July 2011|2011-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.|Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.|Completed||Phase 2|40|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:13:10.271955|2018-06-01 04:13:10.271955
NCT00279708|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|2016-06-30||2017-04-19|2006-01-18|2006-01-19|Estimate|2016-06-30|2016-08-12|Estimate||||2017-04-19|2017-05-22|Actual|January 2006||2006-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Atorvastatin to Treat Pulmonary Sarcoidosis|Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 2|55|Actual|National Institutes of Health Clinical Center (CC)|The recruitment goal of 96 subjects was not met due to slow accrual. The primary endpoint analysis was based on the available subject data.|2|||f||||t||||||||No||2018-06-01 04:13:10.356436|2018-06-01 04:13:10.356436
NCT00279695|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2010-01-19|2006-01-17|2006-01-19|Estimate|||||||2010-01-19|2010-01-20|Estimate|January 1996||1996-01-31|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|||||Observational|||Ultrasonic Evaluation of Ocular Tissues|Ultrasonic Evaluation of Ocular Tissues|Unknown status|Active, not recruiting||150|Anticipated|Weill Medical College of Cornell University|||4||f||||f||||||||||2018-06-01 04:13:10.848806|2018-06-01 04:13:10.848806
NCT00279682|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|May 1999||1999-05-31|January 2006|2006-01-31|August 2003||2003-08-31|||||Interventional|||Prevention of Suicide in Primary Care Elderly: Collaborative Trial (PROSPECT)|Prevention of Suicide in Primary Care Elderly: Collaborative Trial|Completed||Phase 4|1200||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:13:10.96298|2018-06-01 04:13:10.96298
NCT00279669|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2008-05-07|2006-01-17|2006-01-19|Estimate|||||||2008-05-07|2008-05-08|Estimate|December 2004||2004-12-31|May 2008|2008-05-31|July 2008|Anticipated|2008-07-31|||||Observational|||Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity|Ultrasound to Detect Evidence for Retinal Detachment in Retinopathy of Prematurity|Suspended|||30|Anticipated|Weill Medical College of Cornell University||||Studies are suspended until a new ultrasound scanner is acquired.|f||||f||||||||||2018-06-01 04:13:11.057783|2018-06-01 04:13:11.057783
NCT00279656|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|November 2003||2003-11-30|June 2004|2004-06-30|June 2005||2005-06-30|||||Interventional|||Benefit of a Collaborative Approach to Improve the Quality of Medicines Use in Elderly Inpatients|Collaborative Approach to Improve the Quality of Medicines Use in Elderly Inpatients - Randomized Controlled Trial|Completed||Phase 4|180||Université Catholique de Louvain|||||f||||||||||||||2018-06-01 04:13:11.135324|2018-06-01 04:13:11.135324
NCT00279643|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-04-29|2006-01-17|2006-01-19|Estimate|||||||2015-04-29|2015-04-30|Estimate|January 2005||2005-01-31|April 2015|2015-04-30|June 2006|Actual|2006-06-30|||||Interventional|||The Effect of Laser Hair Removal on Permanent Hair Reduction|The Effect of Laser Hair Removal on Markers of Follicular Stem Cells|Completed||Phase 1/Phase 2|60||University of Michigan|||||f||||f||||||||||2018-06-01 04:13:11.203942|2018-06-01 04:13:11.203942
NCT00279630|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2014-12-02|2006-01-17|2006-01-19|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2002||2002-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Exercise and Shoe Orthoses in Treatment of Posterior Tibial Tendon Dysfunction|Phase 1 Study on Effectiveness of Exercise on Function, Quality of Life and Disability in Patients With Posterior Tibial Tendon Dysfunction|Completed||Phase 1|45|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 04:13:11.266179|2018-06-01 04:13:11.266179
NCT00279617|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2011-12-12|2006-01-18|2006-01-19|Estimate|||||||2011-12-12|2011-12-13|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks|Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks|Completed||Phase 3|15|Actual|Lindner Center of HOPE||1|||f||||||||||||||2018-06-01 04:13:11.348527|2018-06-01 04:13:11.348527
NCT00279604|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2007-04-19|2006-01-18|2006-01-19|Estimate|||||||2007-04-19|2007-04-20|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|October 2007|Anticipated|2007-10-31|||||Interventional|||INCA - Intervention and Neuropsychology in Cannabis Abuse|Targeted Interventions in Cannabis Abuse: Focus on Decision Making (INCA)|Unknown status|Recruiting|N/A|160||University Hospital, Bonn|||||f||||||||||||||2018-06-01 04:13:11.422501|2018-06-01 04:13:11.422501
NCT00279591|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2011-03-28||2012-04-03|2006-01-17|2006-01-19|Estimate|2012-04-03|2012-04-30|Estimate||||2012-04-03|2012-04-30|Estimate|June 2006||2006-06-30|April 2012|2012-04-30|January 2008|Actual|2008-01-31|June 2007|Actual|2007-06-30||Interventional|||Near-Continuous, Noninvasive Blood Pressure Monitoring to Improve Outcomes in Pediatric Transport|Near-Continuous, Noninvasive Blood Pressure Monitoring to Improve Outcomes in Pediatric Transport|Terminated||N/A|94|Actual|University of Arkansas|Small Sample Size. Halted prior to projected enrollment secondary to lack of technical support and supplies for near continuous BP measuring device.|2||Lack of technical support and supplies|f||||f||||||||||2018-06-01 04:13:11.500936|2018-06-01 04:13:11.500936
NCT00279578|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-11-15|2006-01-17|2006-01-19|Estimate|||||||2006-11-15|2006-11-16|Estimate|January 2006||2006-01-31|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||Clot Formation and Clot Stability in Patients With Severe Haemophilia A|Clot Formation and Clot Stability in Patients With Severe Haemophilia A - Effect of Recombinant Factor VIII and Tranexamic Acid|Completed||N/A|8||University of Aarhus|||||f||||||||||||||2018-06-01 04:13:11.774783|2018-06-01 04:13:11.774783
NCT00279565|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2012-11-21|2006-01-17|2006-01-19|Estimate|||||||2012-11-21|2012-11-22|Estimate|August 2005||2005-08-31|February 2007|2007-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED)|Randomized, Controlled Study of Buprenorphine and Methadone in Hepatitis C Patients in Need of Treatment|Terminated||Phase 4|128||Indivior Inc.||||The trial was terminated because of deviations from the protocol.|f||||f||||||||||2018-06-01 04:13:11.940822|2018-06-01 04:13:11.940822
NCT00279552|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|April 2004||2004-04-30|January 2006|2006-01-31|December 2004||2004-12-31|||||Interventional|||Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?|Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption?|Completed||Phase 2|37||University of Aarhus|||||f||||||||||||||2018-06-01 04:13:12.013506|2018-06-01 04:13:12.013506
NCT00279539|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-03-30|2006-01-17|2006-01-19|Estimate|||||||2015-03-30|2015-04-01|Estimate|July 2008||2008-07-31|June 2009|2009-06-30||||||||Interventional|||Stem Cell Mobilization and VEGF Gene Transfer for Heart Failure|phVEGF165 GENE TRANSFER TO PROMOTE ANGIOGENESIS IN PATIENTS WITH ISCHEMIC HEART FAILURE|Withdrawn||Phase 1|0|Actual|Losordo, Douglas, M.D.||||Study never started.|||||f||||||||||2018-06-01 04:13:12.087395|2018-06-01 04:13:12.087395
NCT00279526|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2007-05-24|2006-01-18|2006-01-19|Estimate|||||||2007-05-24|2007-05-25|Estimate|April 2006||2006-04-30|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Observational|||Depression and Increased Health Services Utilization Among Elderly Primary Care Patients||Completed|||450||Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:13:12.164219|2018-06-01 04:13:12.164219
NCT00279513|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2011-04-03|2006-01-17|2006-01-19|Estimate|||||||2011-04-03|2011-04-05|Estimate|September 2006||2006-09-30|April 2011|2011-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||TRAUMEEL S in Reducing Pain After Correction of Hallux Valgus-Clinical Trial|A Randomised, Double- Blind, Placebo Controlled, Clinical Trial to Assess the Efficacy of the Homeopathic Medication TRAUMEEL S in Reducing Pain After Surgical Correction of Hallux Valgus|Completed||Phase 3|||Shaare Zedek Medical Center|||||f||||||||||||||2018-06-01 04:13:12.232418|2018-06-01 04:13:12.232418
NCT00279500|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2017-06-14||2018-05-18|2006-01-17|2006-01-19|Estimate|2018-04-16|2018-05-17|Actual||||2018-05-18|2018-05-22|Actual|February 27, 2002|Actual|2002-02-27|April 2018|2018-04-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|(A16)||Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa|Chronic Retinal Electrodes to Provide Electrical Stimulation of the Retina to Elicit Visual Percepts in Blind Subjects|Completed||N/A|6|Actual|Second Sight Medical Products||1|||f||||f||||||||No||2018-06-01 04:13:12.31716|2018-06-01 04:13:12.31716
NCT00279487|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2016-10-24|2006-01-16|2006-01-19|Estimate|||||||2016-10-24|2016-10-26|Estimate||||October 2016|2016-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Preanalgesic Effect of Gabapentin in Total Knee Repair|Preanalgesic Effect of Gabapentin in Total Knee Repair|Completed||N/A|24|Actual|Texas Health Resources||2|||f||||f||||||||No||2018-06-01 04:13:12.523129|2018-06-01 04:13:12.523129
NCT00279474|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|July 2004||2004-07-31|October 2005|2005-10-31|December 2005||2005-12-31|||||Interventional|||The Effect of Cognitive Behavior Intervention on Psychological Distress of Cancer Patients and Their Family Members|Evaluation of the Effect of Cognitive Behavior Intervention on Psychological Distress of Cancer Patients and Their Family Members|Unknown status|Recruiting|N/A|320||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:13:12.60214|2018-06-01 04:13:12.60214
NCT00279071|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2008-07-01|2006-01-18|2006-01-19|Estimate|||||||2008-07-01|2008-07-04|Estimate|October 2002||2002-10-31|July 2008|2008-07-31|March 2007|Actual|2007-03-31|||||Interventional|||Use of Acupuncture for Stimulation of Labour|Use of Acupuncture for Stimulation of Labour|Terminated||Phase 2|100|Actual|Herning Hospital||||exhausted personel after a long recruiting period|f||||f||||||||||2018-06-01 04:13:24.21769|2018-06-01 04:13:24.21769
NCT00279461|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-07-31|2006-01-17|2006-01-19|Estimate|||||||2015-07-31|2015-08-04|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|May 2011|Anticipated|2011-05-31|May 2011|Anticipated|2011-05-31||Interventional|||Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis|Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells|Withdrawn||Phase 2|0|Actual|Indiana University||2||"Dr. Levy terminated from IU in December 2009. Indiana University has no record that this study~   was initiated prior to his termination."|f||||f||||||||||2018-06-01 04:13:12.692764|2018-06-01 04:13:12.692764
NCT00279448|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2011-12-22|2006-01-18|2006-01-19|Estimate|||||||2011-12-22|2011-12-23|Estimate|January 2002||2002-01-31|December 2011|2011-12-31|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|TEAM||Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer|Multicenter, Randomized, Open-Label Study To Compare The Efficacy, Tolerance And Quality Of Life Of 5 Years Of Adjuvant Exemestane (Aromasin) Therapy With 2.5 To 3 Years Of Adjuvant Tamoxifen Therapy, Followed By 2 To 2.5 Years Of Exemestane For A Total Duration Of 5 Years To Treat HR+ Post-Menopausal Patients With Non-Metastatic Breast Cancer|Completed||Phase 3|9779|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:13:12.817508|2018-06-01 04:13:12.817508
NCT00279435|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2012-03-08|2006-01-17|2006-01-19|Estimate|||||||2012-03-08|2012-03-12|Estimate|August 2006||2006-08-31|March 2012|2012-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study|A Randomized, Double-blind, Multicenter Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study|Terminated||Phase 2/Phase 3|25|Actual|Facet Biotech||2||company decision based on other studies|f||||t||||||||||2018-06-01 04:13:12.989071|2018-06-01 04:13:12.989071
NCT00279422|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2012-03-08|2006-01-17|2006-01-19|Estimate|||||||2012-03-08|2012-03-12|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis|A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis|Terminated||Phase 2/Phase 3|127|Actual|Facet Biotech||2||DMC recommendation, no efficacy|f||||t||||||||||2018-06-01 04:13:13.141716|2018-06-01 04:13:13.141716
NCT00279409|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2013-09-20|2006-01-18|2006-01-19|Estimate|||||||2013-09-20|2013-09-23|Estimate|July 2006||2006-07-31|September 2013|2013-09-30|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|TREAT||Treatment of Children With ADHD Who do Not Fully Respond to Stimulants|"Developing More Efficacious Treatments for Children With ADHD Who Are Partial or Non-responders to Stimulants"|Terminated||Phase 2|10|Actual|New York State Psychiatric Institute||2||Recruitment Rate too slow|f||||t||||||||||2018-06-01 04:13:13.404006|2018-06-01 04:13:13.404006
NCT00279383|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2012-05-04|2006-01-18|2006-01-19|Estimate|||||||2012-05-04|2012-05-07|Estimate|August 2005||2005-08-31|January 2009|2009-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||OSHES - Observational Study on Hemostasis in Surgery (TC-022-IT)|OSHES (Observational Study on Hemostasis in Surgery ). A Non Interventional Study on the Hemostasis Supportive Methods in Surgery|Completed|||800|Anticipated|Nycomed|||||f||||t||||||||||2018-06-01 04:13:13.659414|2018-06-01 04:13:13.659414
NCT00279370|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2013-09-30|2006-01-17|2006-01-19|Estimate|||||||2013-09-30|2013-10-07|Estimate|September 1999||1999-09-30|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Antidepressant Use During Pregnancy|Antidepressant Use During Pregnancy|Completed|||283|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 04:13:13.724502|2018-06-01 04:13:13.724502
NCT00279357|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2007-06-28|2006-01-17|2006-01-19|Estimate|||||||2007-06-28|2007-06-29|Estimate|January 2006||2006-01-31|June 2007|2007-06-30||||||||Interventional|||Randomised Trial of NBI for Adenoma Detection|Randomised, Controlled Trial of Narrow Band Imaging (NBI) Versus Standard Endoscopy for Adenoma Detection|Unknown status|Recruiting|N/A|214|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:13:13.788594|2018-06-01 04:13:13.788594
NCT00279344|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2012-05-04|2006-01-17|2006-01-19|Estimate|||||||2012-05-04|2012-05-07|Estimate|September 2004||2004-09-30|May 2012|2012-05-31|August 2007|Actual|2007-08-31|||||Interventional|||Efficacy and Safety of FITpatch Compared to Standard Opioid Treatment in Cancer Pain (FT-015-IN)|A Randomised, Open, Parallel-group, Multi-centre Trial to Investigate Analgesic Efficacy and Safety of Transdermal Fentanyl (FITpatch) Compared to Standard Opioid Treatment in Cancer Pain.|Completed||Phase 3|220||Nycomed|||||f||||f||||||||||2018-06-01 04:13:13.866025|2018-06-01 04:13:13.866025
NCT00279331|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2013-09-20|2006-01-18|2006-01-19|Estimate|||||||2013-09-20|2013-09-23|Estimate||||September 2013|2013-09-30|November 2006|Actual|2006-11-30|||||Observational|||Estimating the Incidence of HIV Infection Among Men Who Have Sex With Men in Peru and Ecuador|Implementation of a Third Generation Sentinel Surveillance Approach Among Men Who Have Sex With Men at High Risk for HIV, Type-1 Acquisition in the Andean Region|Completed|||2608|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:13:13.92614|2018-06-01 04:13:13.92614
NCT00279318|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2017-08-17|2006-01-17|2006-01-19|Estimate|||||||2017-08-17|2017-08-22|Actual|September 2004||2004-09-30|August 2017|2017-08-31|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Observational|||TEDDY - The Environmental Determinants of Diabetes in the Young|Consortium for Identification of Environmental Triggers of Type 1 Diabetes|Active, not recruiting|||8668|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||1||f||||t||||||Samples With DNA|"~     Serum, plasma, PBMCs, stool, urine, saliva, nasal swabs, nail clippings, water~   "|||2018-06-01 04:13:14.007297|2018-06-01 04:13:14.007297
NCT00279305|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2016-05-12||2016-09-27|2006-01-17|2006-01-19|Estimate|2016-07-08|2016-08-18|Estimate||||2016-09-27|2016-11-02|Estimate|August 2005||2005-08-31|September 2016|2016-09-30|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|||Rituximab in New Onset Type 1 Diabetes|Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects|Completed||Phase 2|87|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||Yes||2018-06-01 04:13:14.116115|2018-06-01 04:13:14.116115
NCT00279292|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-10-13|2006-01-17|2006-01-19|Estimate|||||||2015-10-13|2015-10-14|Estimate|August 2004||2004-08-31|October 2015|2015-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Randomized Trial of EUS Neurolysis in Pancreas Cancer|Phase III Randomized Placebo Controlled Trial of EUS Guided Celiac Plexus Neurolysis for Pancreatic Cancer Pain|Completed||Phase 3|26|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:13:14.464313|2018-06-01 04:13:14.464313
NCT00279279|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-10-25|2006-01-17|2006-01-19|Estimate|||||||2006-10-25|2006-10-26|Estimate|October 2003||2003-10-31|October 2006|2006-10-31|May 2006||2006-05-31|||||Interventional|||PREPARE - Primary Prevention Parameters Evaluation|PREPARE - Primary Prevention Parameters Evaluation|Completed||N/A|700||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:13:14.534299|2018-06-01 04:13:14.534299
NCT00279266|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2015-05-11|2006-01-18|2006-01-19|Estimate|||||||2015-05-11|2015-05-13|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Oral Thiamine for the Treatment of Painful Diabetic Peripheral Neuropathy|A Randomized Double Blinded Pilot Study of Oral Thiamine in the Symptomatic Treatment of Painful Diabetic Peripheral Neuropathy|Withdrawn||N/A|0|Actual|Loma Linda University||||inadequate recruitment|f||||t||||||||||2018-06-01 04:13:14.638137|2018-06-01 04:13:14.638137
NCT00279253|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2006-01-18|2006-01-18|2006-01-19|Estimate|||||||2006-01-18|2006-01-19|Estimate|March 2004||2004-03-31|January 2006|2006-01-31|January 2005||2005-01-31|||||Interventional|||Effects of Intravenous Clonidine on Ocular Blood Flow and Intraocular Pressure||Completed||Phase 4|12||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:13:14.719908|2018-06-01 04:13:14.719908
NCT00279240|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2006-01-23|2006-01-18|2006-01-19|Estimate|||||||2006-01-23|2006-01-24|Estimate|March 2001||2001-03-31|July 2002|2002-07-31|December 2004||2004-12-31|||||Interventional|||Life Style Modifications Prevents Type 2 Diabetes in Asian Indians|The Indian Diabetes Prevention Programme Shows That Lifestyle Modification and Metformin Prevent Type 2 Diabetes in Asian Indian Subjects With Impaired Glucose Tolerance (IDPP1)|Completed||Phase 1|||M.V. Hospital for Diabetes|||||f||||||||||||||2018-06-01 04:13:14.76814|2018-06-01 04:13:14.76814
NCT00279227|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-08-09|2006-01-17|2006-01-19|Estimate|||||||2006-08-09|2006-08-15|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|December 2006||2006-12-31|||||Observational|||Role of Epicardial Adipose Tissue in Coronary Artery Disease|Role of Epicardial Adipose Tissue in Coronary Artery Disease|Unknown status|Recruiting||50||McMaster University|||||f||||||||||||||2018-06-01 04:13:14.827397|2018-06-01 04:13:14.827397
NCT00279214|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2008-10-31||2009-08-26|2006-01-17|2006-01-19|Estimate|2009-07-01|2009-08-17|Estimate||||2009-08-26|2009-09-02|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|November 2007|Actual|2007-11-30|||||Interventional|||Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock|An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock|Completed||Phase 4|43|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 04:13:14.908201|2018-06-01 04:13:14.908201
NCT00279201|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2010-11-11||2011-01-24|2006-01-17|2006-01-19|Estimate|2011-01-24|2011-02-21|Estimate||||2011-01-24|2011-02-21|Estimate|December 2005||2005-12-31|January 2011|2011-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|IOOV||The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)|The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine When Added to Existing Oral Therapy in Patients With Type 2 Diabetes and Inadequate Glycemic Control|Completed||Phase 4|2091|Actual|Eli Lilly and Company||6|||f||||t||||||||||2018-06-01 04:13:15.935599|2018-06-01 04:13:15.935599
NCT00279188|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|May 1992||1992-05-31|September 2004|2004-09-30|September 2008||2008-09-30|||||Interventional|||Asthma Management Project University Leiden|Asthma Management Project University Leiden|Completed||N/A|75||Leiden University Medical Center|||||f||||||||||||||2018-06-01 04:13:23.361405|2018-06-01 04:13:23.361405
NCT00279175|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2012-09-19|2006-01-18|2006-01-19|Estimate|||||||2012-09-19|2012-09-20|Estimate|April 2004||2004-04-30|September 2012|2012-09-30|December 2010|Actual|2010-12-31|October 2005|Actual|2005-10-31||Interventional|||REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI)|Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR - AMI)|Completed||Phase 3|204|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||||||||||||2018-06-01 04:13:23.432156|2018-06-01 04:13:23.432156
NCT00279162|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-03-25|2006-01-17|2006-01-19|Estimate|||||||2015-03-25|2015-03-26|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|July 2007|Actual|2007-07-31|||||Interventional|||Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis|Calcipotriene Plus Betamethasone Dipropionate Gel Compared to the Gel Vehicle in Scalp Psoriasis, in Patients Receiving Calcipotriene Plus Betamethasone Dipropionate Ointment for Psoriasis Vulgaris of Trunk/Limbs|Completed||Phase 3|160|Anticipated|LEO Pharma|||||||||||||||||||2018-06-01 04:13:23.661237|2018-06-01 04:13:23.661237
NCT00279149|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2011-02-16|2006-01-17|2006-01-19|Estimate|||||||2011-02-16|2011-02-17|Estimate|March 2006||2006-03-31|February 2007|2007-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||TRUST-tPA: Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) of Patients With Acute Stroke|Therapeutic Trial Evaluating Efficacy of Telemedicine (TELESTROKE) in the Management of Patient With Acute Stroke Within 3-hour After Their Symptom Onset Who Are Admitted to a Remote Hospital With no Stroke Unit Facility|Completed||Phase 4|400|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:13:23.735083|2018-06-01 04:13:23.735083
NCT00279136|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|September 2004||2004-09-30|September 2005|2005-09-30|March 2006||2006-03-31|||||Observational|||Towards Restoring the Physiological Inhibition of Airway Narrowing in Asthma|Towards Restoring the Physiological Inhibition of Airway Narrowing in Asthma|Unknown status|Recruiting||36||Leiden University Medical Center|||||f||||||||||||||2018-06-01 04:13:23.819532|2018-06-01 04:13:23.819532
NCT00279123|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|January 2002||2002-01-31|January 2006|2006-01-31||||||||Interventional|||Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers||Completed||Phase 4|||Kwong Wah Hospital|||||f||||||||||||||2018-06-01 04:13:23.908866|2018-06-01 04:13:23.908866
NCT00279110|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-04-14|2006-01-17|2006-01-19|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2006||2006-04-30|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Directly Administered HIV Therapy in Methadone Clinics|Directly Administered vs. Self-administered Antiretroviral Therapy in Methadone Clinics|Completed||Phase 2/Phase 3|107|Actual|Johns Hopkins University||2|||f||||||||||||||2018-06-01 04:13:23.970603|2018-06-01 04:13:23.970603
NCT00279097|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-11-15|2006-01-17|2006-01-19|Estimate|||||||2006-11-15|2006-11-16|Estimate|January 2006||2006-01-31|November 2006|2006-11-30|September 2006||2006-09-30|||||Interventional|||Safety Study to Evaluate Intracranial Pressure During High Frequency Chest Wall Oscillation|A Safety Study to Evaluate Intracranial Pressure With the Utilization of High Frequency Chest Wall Oscillation (HFCWO) Using the Vest™ on Mechanically Ventilated Neurosurgical Patients|Terminated||N/A|20||Hill-Rom|||||f||||||||||||||2018-06-01 04:13:24.058784|2018-06-01 04:13:24.058784
NCT00279084|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2007-10-03|2006-01-18|2006-01-19|Estimate|||||||2007-10-03|2007-10-04|Estimate|January 2004||2004-01-31|October 2007|2007-10-31||||||||Interventional|||NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels|Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels (110- 129 g/L and 130 - 149 g/L) on Progression of Chronic Kidney Disease in Patients With Type 2 Diabetes and With Chronic Kidney Disease|Unknown status|Active, not recruiting|N/A|204||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:13:24.152483|2018-06-01 04:13:24.152483
NCT00279058|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2015-04-19|2006-01-17|2006-01-19|Estimate|||||||2015-04-19|2015-04-21|Estimate|December 2005||2005-12-31|April 2007|2007-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2|The Role of Autologous Dendritic Cells Pulsed by Melanoma Associated Peptides to Augment the Therapeutic Effect of Interleukin-2|Completed||Phase 1/Phase 2|24|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:13:24.272401|2018-06-01 04:13:24.272401
NCT00279045|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2017-11-27|2006-01-17|2006-01-19|Estimate|||||||2017-11-27|2017-11-29|Actual|January 3, 2000||2000-01-03|November 2017|2017-11-30|June 19, 2006|Actual|2006-06-19|June 1, 2006|Actual|2006-06-01||Interventional|||Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide|A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus|Completed||Phase 3|4426|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:13:24.60058|2018-06-01 04:13:24.60058
NCT00279032|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2009-02-19|2006-01-17|2006-01-19|Estimate|||||||2009-02-19|2009-02-23|Estimate|September 2003||2003-09-30|February 2009|2009-02-28||||||||Interventional|||GW406381 In Patients With Peripheral Nerve Injury|A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Study to Investigate the Effects of Chronic Dose Oral GW406381 on Pain and Areas of Hyperalgesia and Allodynia in Patients With Peripheral Nerve Injury as a Result of Trauma or Surgery.|Completed||Phase 1|40||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:13:25.501568|2018-06-01 04:13:25.501568
NCT00279019|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2017-09-21|2006-01-17|2006-01-19|Estimate|||||||2017-09-21|2017-09-25|Actual|December 12, 2005|Actual|2005-12-12|September 2017|2017-09-30|June 13, 2006|Actual|2006-06-13|June 13, 2006|Actual|2006-06-13||Interventional|||Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double Blind, Placebo-controlled, Double Dummy, 4-way Cross-over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Inhaled Doses of GSK233705 and Tiotropium Bromide (18µg) Via DPI in COPD Patients|Completed||Phase 1|31|Actual|GlaxoSmithKline||16|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:13:25.569731|2018-06-01 04:13:25.569731
NCT00279006|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2006-01-17|2006-01-17|2006-01-19|Estimate|||||||2006-01-17|2006-01-19|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|March 2007||2007-03-31|||||Interventional|||Adhesiveness of Coronary Drug-Eluting Stents to the Delivery Balloon-Catheter: A Randomized Comparison|Adhesiveness of Coronary Drug-Eluting Stents to the Delivery Balloon-Catheter: A Randomized Comparison|Unknown status|Not yet recruiting|N/A|150||Foundation for Cardiovascular Research, Zurich|||||f||||||||||||||2018-06-01 04:13:25.687375|2018-06-01 04:13:25.687375
NCT00278993|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2011-12-22||2014-06-30|2006-01-17|2006-01-19|Estimate|2012-04-16|2012-05-15|Estimate||||2014-06-30|2014-07-14|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy|A Phase II, Multicenter, Open Label, Two Stage Design Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy|Completed||Phase 2|108|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 04:13:25.7682|2018-06-01 04:13:25.7682
NCT00278980|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2006-01-12|2006-01-12|2006-01-19|Estimate|||||||2006-01-12|2006-01-19|Estimate|October 2003||2003-10-31|January 2006|2006-01-31|December 2004||2004-12-31|||||Interventional|||Effect of C-Peptide on Diabetic Peripheral Neuropathy|Effect of C-Peptide on Diabetic Peripheral Neuropathy, a 6 Months Randomized Double-Blind, Placebo Controlled, Dose-Finding, Multicenter Study, With Parallel Groups|Completed||Phase 2|180||Creative Peptides Sweden Inc.|||||f||||||||||||||2018-06-01 04:13:26.245574|2018-06-01 04:13:26.245574
NCT00278967|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2006-10-18|2006-01-13|2006-01-19|Estimate|||||||2006-10-18|2006-10-19|Estimate|February 2006||2006-02-28|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|Completed||Phase 4|450||Braintree Laboratories|||||||||||||||||||2018-06-01 04:13:26.315711|2018-06-01 04:13:26.315711
NCT00278954|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|2009-05-29|2009-05-05|2013-01-23|2006-01-18|2006-01-19|Estimate|2010-01-04|2010-01-28|Estimate|2010-01-04|2010-01-28|Estimate|2013-01-23|2013-01-24|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.|A Phase III, Multicenter, Open-Label Study To Evaluate The Efficacy, Safety, and Pharmacokinetics of Gammaplex® in Primary Immunodeficiency Diseases|Completed||Phase 3|50|Actual|Bio Products Laboratory||1|||f||||f||||||||||2018-06-01 04:13:26.422411|2018-06-01 04:13:26.422411
NCT00278941|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2009-03-24|2006-01-17|2006-01-19|Estimate|||||||2009-03-24|2009-03-25|Estimate|December 2005||2005-12-31|March 2009|2009-03-31|August 2007|Actual|2007-08-31|||||Interventional|AMETHYST||Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder|A Multi-Centre, Double-Blind, Randomised-Withdrawal, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) As Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder|Completed||Phase 3|3000||AstraZeneca|||||f||||||||||||||2018-06-01 04:13:26.758581|2018-06-01 04:13:26.758581
NCT00278928|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-18|||2017-03-13|2006-01-18|2006-01-19|Estimate|||||||2017-03-13|2017-03-14|Actual|January 2006||2006-01-31|March 2017|2017-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic|Prospective, Randomized Study of Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic Containers.|Terminated||N/A|82|Anticipated|Beth Israel Deaconess Medical Center||||Manufacturing change in one of the two lipid emulsion products being studied.|f||||||||||||||2018-06-01 04:13:27.165713|2018-06-01 04:13:27.165713
NCT00278915|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2010-12-06||2018-03-05|2006-01-17|2006-01-19|Estimate|2011-06-21|2011-07-19|Estimate||||2018-03-05|2018-03-06|Actual|January 31, 2006|Actual|2006-01-31|March 2018|2018-03-31|July 3, 2023|Anticipated|2023-07-03|December 8, 2009|Actual|2009-12-08||Interventional|FMAS||Faslodex in McCune Albright Syndrome|An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome|Active, not recruiting||Phase 2|30|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 04:13:27.277104|2018-06-01 04:13:27.277104
NCT00278902|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2012-09-28|2006-01-17|2006-01-19|Estimate|||||||2012-09-28|2012-10-01|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study of ARRY-334543 in Patients With Advanced Cancer||Completed||Phase 1|96|Actual|Array BioPharma||1|||f||||||||||||||2018-06-01 04:13:27.88377|2018-06-01 04:13:27.88377
NCT00278889|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2012-07-26|2011-04-06|2012-09-24|2006-01-17|2006-01-19|Estimate|2012-09-24|2012-10-24|Estimate|2011-04-06|2011-04-12|Estimate|2012-09-24|2012-10-24|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|October 2009|Actual|2009-10-31|November 2007|Actual|2007-11-30||Interventional|HORIZON I||Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)|A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer|Completed||Phase 2|215|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:13:28.01729|2018-06-01 04:13:28.01729
NCT00278876|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2013-11-19||2015-06-30|2006-01-17|2006-01-19|Estimate|2015-06-30|2015-07-27|Estimate||||2015-06-30|2015-07-27|Estimate|April 2005||2005-04-30|June 2015|2015-06-30|March 2011|Actual|2011-03-31|August 2007|Actual|2007-08-31||Interventional||All enrolled patients were included for baseline analysis.|Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation|Phase II Study of Imatinib Mesylate as Adjuvant Treatment in High-relapse Risk Localized Gastrointestinal Stromal Tumors With C-kit Mutation|Completed||Phase 2|47|Actual|Asan Medical Center||1|||f||||f||||||||||2018-06-01 04:13:28.885605|2018-06-01 04:13:28.885605
NCT00278863|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|2014-01-13||2014-01-13|2006-01-17|2006-01-19|Estimate|2014-01-13|2014-02-25|Estimate||||2014-01-13|2014-02-25|Estimate|November 2004||2004-11-30|January 2014|2014-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial|Randomized Multicenter Phase II Trial of Capecitabine Versus S-1 as First-line Treatment in Elderly Patients With Advanced or Recurrent Unresectable Gastric Cancer|Completed||Phase 2|96|Actual|Asan Medical Center||2|||f||||f||||||||||2018-06-01 04:13:29.066521|2018-06-01 04:13:29.066521
NCT00278850|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2015-06-11|2006-01-16|2006-01-18|Estimate|||||||2015-06-11|2015-06-15|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||"Vestibulitis Educational Seminar Trial Study"|"Vestibulitis Educational Seminar Trial Study"|Completed|||500|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:13:29.455129|2018-06-01 04:13:29.455129
NCT00278837|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2017-02-17|2006-01-13|2006-01-18|Estimate|||||||2017-02-17|2017-02-23|Actual|May 2003|Actual|2003-05-31|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors|Contemplative Self-Healing to Improve Quality of Life in Breast Cancer Survivors: the Avon Foundation Program to Reach Medically Underserved Populations|Completed||N/A|94|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No|No Plan to Share IPD|2018-06-01 04:13:29.545079|2018-06-01 04:13:29.545079
NCT00278824|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2012-06-04|2006-01-16|2006-01-18|Estimate|||||||2012-06-04|2012-06-05|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain|A Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy of CHADD™ Applied Over a Transdermal Fentanyl Patch for the Treatment of Breakthrough Pain in Patients With Moderate to Severe Non-malignant Chronic Pain|Terminated||Phase 2|109|Actual|ZARS Pharma Inc.||2||Difficulty identifying and enrolling eligible patients|f||||f||||||||||2018-06-01 04:13:29.673387|2018-06-01 04:13:29.673387
NCT00278811|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2015-10-20|2006-01-16|2006-01-18|Estimate|||||||2015-10-20|2015-10-22|Estimate|April 2003||2003-04-30|October 2015|2015-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Emergency Linkage to Outpatient Psychiatric Services|Emergency Linkage to Outpatient Psychiatric Services|Completed||Phase 1|120|Actual|University of Rochester|||||f||||t||||||||||2018-06-01 04:13:29.82435|2018-06-01 04:13:29.82435
NCT00278798|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2017-05-30|2006-01-16|2006-01-18|Estimate|||||||2017-05-30|2017-06-01|Actual|January 2006||2006-01-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Observational|||TRAIL-CC: Trachelectomy, Radical Hysterectomy, and Intimate Life After Cervical Cancer Study||Completed|||33|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:13:29.984877|2018-06-01 04:13:29.984877
NCT00278785|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2018-02-12|2006-01-13|2006-01-18|Estimate|||||||2018-02-12|2018-02-13|Actual|March 2006||2006-03-31|February 2018|2018-02-28|January 24, 2027|Anticipated|2027-01-24|January 24, 2027|Anticipated|2027-01-24||Interventional|||Brief Intervention for Alcohol Use Among Injured Patients|Brief Intervention for Alcohol Use Among Injured Patients: A Prospective, Randomized Trial|Active, not recruiting||N/A|830|Actual|University of California, Davis||2|||f||||f||||||||||2018-06-01 04:13:30.181356|2018-06-01 04:13:30.181356
NCT00278772|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2010-05-24|2006-01-13|2006-01-18|Estimate|||||||2010-05-24|2010-05-26|Estimate|August 2003||2003-08-31|May 2010|2010-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania|"A Randomized, Double-Blind, Placebo-Controlled Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania"|Completed||Phase 3|62|Actual|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 04:13:30.387242|2018-06-01 04:13:30.387242
NCT00278759|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2009-02-17|2006-01-16|2006-01-18|Estimate|||||||2009-02-17|2009-02-19|Estimate|December 2005||2005-12-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Unclogging the Pediatric Emergency Room: Impact of Rapid Viral Diagnostics|Unclogging the Pediatric Emergency Room: Impact of Rapid Viral Diagnostics. A Randomized Controlled Trial of Decision Making Based Upon Early (at Triage) Rapid Diagnosis of Respiratory Viral Infections (VIRAP) in Children 3-36 Months of Age Presenting to the Emergency Department (ED) With a Flu-Like Illness.|Completed||N/A|275|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:13:30.503018|2018-06-01 04:13:30.503018
NCT00278746|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2015-06-15|2006-01-13|2006-01-18|Estimate|||||||2015-06-15|2015-06-16|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Addition of Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting|An Effectiveness Trial Examining the Addition of Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting.|Completed||N/A|20032|Actual|Society for Applied Studies||2|||f||||f||||||||||2018-06-01 04:13:30.600765|2018-06-01 04:13:30.600765
NCT00278733|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2007-03-07|2006-01-16|2006-01-18|Estimate|||||||2007-03-07|2007-03-09|Estimate|February 2006||2006-02-28|March 2007|2007-03-31|May 2008||2008-05-31|||||Interventional|||Campus Health Intervention Projects UBC Site|Campus Health Intervention Projects to Reduce High Risk Drinking Among University Students by Means of Brief Physician Advice|Completed||N/A|150||University of British Columbia|||||f||||||||||||||2018-06-01 04:13:30.710962|2018-06-01 04:13:30.710962
NCT00278707|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2006-08-11|2006-01-15|2006-01-18|Estimate|||||||2006-08-11|2006-08-15|Estimate|January 2006||2006-01-31|August 2006|2006-08-31|July 2006||2006-07-31|||||Interventional|||GTA-Glyceryltriacetate for Canavan Disease|Phase 1 Treatment With GTA in Two Infant With Canavan Disease|Unknown status|Active, not recruiting|Phase 1|5||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:13:30.792961|2018-06-01 04:13:30.792961
NCT00278694|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2016-09-28|2006-01-16|2006-01-18|Estimate|||||||2016-09-28|2016-09-29|Estimate|September 2005||2005-09-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|LARC-RRP||Oxaliplatin and 5-FU Based Preoperative Chemoradiation|Oxaliplatin and 5-FU Based Preoperative Chemoradiation|Completed||Phase 2|109|Actual|Oslo University Hospital||1|||f||||||||||||||2018-06-01 04:13:30.872419|2018-06-01 04:13:30.872419
NCT00278681|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2008-07-01|2006-01-13|2006-01-18|Estimate|||||||2008-07-01|2008-07-02|Estimate|August 2003||2003-08-31|July 2008|2008-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Effectiveness of Adding Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting|An Effectiveness Trial Examining the Addition of Zinc to the Current Case Management Package of Diarrhoea in a Primary Health Care Setting. Phase I|Completed||Phase 1|2364|Actual|Society for Applied Studies||1|||f||||f||||||||||2018-06-01 04:13:30.9612|2018-06-01 04:13:30.9612
NCT00278668|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2008-05-20|2006-01-16|2006-01-18|Estimate|||||||2008-05-20|2008-05-21|Estimate|October 2006||2006-10-31|May 2008|2008-05-31|October 2006|Anticipated|2006-10-31|||||Observational|||ECT Schizophrenia Serotonin Study|Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy|Unknown status|Not yet recruiting||15|Anticipated|Sha’ar Menashe Mental Health Center|||||f||||||||||||||2018-06-01 04:13:31.080622|2018-06-01 04:13:31.080622
NCT00278655|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|2013-04-09||2014-03-31|2006-01-16|2006-01-18|Estimate|2014-03-31|2014-05-01|Estimate||||2014-03-31|2014-05-01|Estimate|June 2003||2003-06-30|March 2014|2014-03-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis|Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Interferon Therapy: A Phase II Multi-Center Trial|Terminated||Phase 1/Phase 2|21|Actual|Northwestern University|The study had following limitations: small number of enrolled participants and no randomization.|1|||f||||f||||||||||2018-06-01 04:13:31.189566|2018-06-01 04:13:31.189566
NCT00278642|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-04-04|2006-01-16|2006-01-18|Estimate|||||||2013-04-04|2013-04-08|Estimate|September 2002||2002-09-30|April 2013|2013-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders|High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial|Terminated||Phase 1|1|Actual|Northwestern University||1||sponsor stopped the study because of lack of elligible participants|f||||f||||||||||2018-06-01 04:13:31.350694|2018-06-01 04:13:31.350694
NCT00278629|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2017-07-17|2006-01-16|2006-01-18|Estimate|||||||2017-07-17|2017-07-21|Actual|March 2005||2005-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy|Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial|Active, not recruiting||Phase 2|80|Actual|Northwestern University||1|||f||||f||||||||No||2018-06-01 04:13:31.425529|2018-06-01 04:13:31.425529
NCT00278616|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2012-04-09|2006-01-16|2006-01-18|Estimate|||||||2012-04-09|2012-04-11|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome|High Dose Cyclophosphamide & CAMPATH-1H With Hematopoietic Stem Cell Transplantation in Patients With Refractory Antiphospholipid Syndrome (APS): A Phase I Trial|Withdrawn||Phase 1|0|Actual|Northwestern University|||||f||||f||||||||||2018-06-01 04:13:31.493236|2018-06-01 04:13:31.493236
NCT00278603|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2012-04-09|2006-01-15|2006-01-18|Estimate|||||||2012-04-09|2012-04-11|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Interventional|||Stem Cell Injection for Peripheral Vascular Disease|Hematopoietic Stem Cell Injection for Peripheral Vascular Disease: Induction of Neoangiogenesis. A Phase I Study|Completed||Phase 1|10|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 04:13:31.566985|2018-06-01 04:13:31.566985
NCT00278590|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2017-01-12|2006-01-16|2006-01-18|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2004||2004-07-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus|Allogeneic Stem Cell Transplantation in Patients With Systemic Lupus Erythematosus|Withdrawn||Phase 1|0|Actual|Northwestern University||1||No participants enrolled|f||||f||||||||||2018-06-01 04:13:31.633165|2018-06-01 04:13:31.633165
NCT00278577|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2014-02-04|2006-01-15|2006-01-18|Estimate|||||||2014-02-04|2014-02-06|Estimate|April 2001||2001-04-30|April 2013|2013-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease|Terminated||Phase 1|25|Actual|Northwestern University||1|||f||||f||||||||||2018-06-01 04:13:31.705572|2018-06-01 04:13:31.705572
NCT00278564|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2016-07-13|2006-01-15|2006-01-18|Estimate|||||||2016-07-13|2016-07-15|Estimate|September 2005||2005-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases|High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial|Terminated||Phase 1|7|Actual|Northwestern University||1||high relapse rate|f||||f||||||||No||2018-06-01 04:13:31.776968|2018-06-01 04:13:31.776968
NCT00278551|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2013-04-04|2006-01-15|2006-01-18|Estimate|||||||2013-04-04|2013-04-08|Estimate|June 1997||1997-06-30|April 2013|2013-04-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Stem Cell Support in Patients With Rheumatoid Arthritis|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Rheumatoid Arthritis and High Risk Factors|Terminated||Phase 1|10|Actual|Northwestern University||1|||f||||f||||||||||2018-06-01 04:13:31.846293|2018-06-01 04:13:31.846293
NCT00278538|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2017-07-17|2006-01-15|2006-01-18|Estimate|||||||2017-07-17|2017-07-19|Actual|August 2005||2005-08-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus|Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial|Active, not recruiting||Phase 2|33|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 04:13:31.935086|2018-06-01 04:13:31.935086
NCT00278525|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|2013-04-09||2014-03-28|2006-01-15|2006-01-18|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|September 2005||2005-09-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|September 2011|Actual|2011-09-30||Interventional|||Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma|Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial|Completed||Phase 2|19|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 04:13:32.03142|2018-06-01 04:13:32.03142
NCT00278512|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2016-07-11|2006-01-15|2006-01-18|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2003||2003-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Hematopoietic Stem Cell Support in Vasculitis|High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome|Terminated||Phase 1|7|Actual|Northwestern University||2||No participant enrolled over five years. No plan to continue the study.|f||||f||||||||No||2018-06-01 04:13:32.489825|2018-06-01 04:13:32.489825
NCT00278499|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2011-01-12|2006-01-16|2006-01-18|Estimate|||||||2011-01-12|2011-01-13|Estimate|March 2006||2006-03-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Prevalence of HIV and Other Sexually Transmitted Infections Among Female Sex Workers and Miners in Honghe Prefecture, Yunnan Province, China|Epidemiology of HIV-1 and Other Sexually Transmitted Infections in Honghe Prefecture, Yunnan Province, China|Completed|||3800|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||||||2018-06-01 04:13:32.639583|2018-06-01 04:13:32.639583
NCT00278486|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2013-04-04|2006-01-15|2006-01-18|Estimate|||||||2013-04-04|2013-04-08|Estimate|August 2004||2004-08-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)|Immune Ablation and Hematopoietic Stem Cell Transplantation in Patients With Autoimmune-Related Retinopathy and Optic Neuropathy (ARRON) Syndrome (Not Associated With Cancer)|Terminated||Phase 1|2|Actual|Northwestern University||1||"First subject over five years after the transplant. The second subject is not in compliance~   with follow ups. We do not plan to enroll more subjects."|f||||f||||||||||2018-06-01 04:13:32.732825|2018-06-01 04:13:32.732825
NCT00278473|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|2013-10-17||2017-02-16|2006-01-13|2006-01-18|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|May 2005||2005-05-31|February 2017|2017-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults|Treatment of Meta-Cognitive Deficits in Adults With ADHD|Completed||N/A|88|Actual|Icahn School of Medicine at Mount Sinai|"participants were required to meet minimum levels of severity of symptoms and may select nonresponders or suboptimal responders to medication.~Small sample may affects potential moderating and mediating variables"|2|||f||||f||||||||||2018-06-01 04:13:32.807711|2018-06-01 04:13:32.807711
NCT00278460|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2017-01-18|2006-01-16|2006-01-18|Estimate|||||||2017-01-18|2017-01-19|Estimate|November 2000||2000-11-30|July 2012|2012-07-31|September 2007|Actual|2007-09-30|February 2006|Actual|2006-02-28||Interventional|||Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer|Completed||Phase 2|49|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 04:13:33.071514|2018-06-01 04:13:33.071514
NCT00278447|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2014-10-01|2006-01-13|2006-01-18|Estimate|||||||2014-10-01|2014-10-02|Estimate|April 2006||2006-04-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|January 2010|Actual|2010-01-31||Interventional|||Addiction Health Evaluation And Disease Management (AHEAD) Study|Linkage of Alcohol Abusers to Primary Care|Completed||Phase 3|569|Actual|Boston Medical Center||2|||f||||f||||||||||2018-06-01 04:13:33.206935|2018-06-01 04:13:33.206935
NCT00278434|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2017-11-21|2006-01-16|2006-01-18|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2005||2005-04-30|November 2017|2017-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3|An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3|Terminated||Phase 1|12|Actual|University of California, San Francisco||2||Accrual was insufficient to meet study endpoints|f||||t|t|f|||t|||||2018-06-01 04:13:33.325535|2018-06-01 04:13:33.325535
NCT00278421|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2016-10-25|2006-01-16|2006-01-18|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2005||2005-11-30|November 2015|2015-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma|Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study]|Completed||Phase 3|592|Actual|German High-Grade Non-Hodgkin's Lymphoma Study Group||2|||f||||t||||||||||2018-06-01 04:13:33.64268|2018-06-01 04:13:33.64268
NCT00278408|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2016-01-20|2006-01-16|2006-01-18|Estimate|||||||2016-01-20|2016-01-21|Estimate|November 2005||2005-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study]|Completed||Phase 3|700|Actual|German High-Grade Non-Hodgkin's Lymphoma Study Group||4|||f||||f||||||||||2018-06-01 04:13:34.231838|2018-06-01 04:13:34.231838
NCT00278395|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|2012-12-07||2017-10-13|2006-01-16|2006-01-18|Estimate|2013-08-28|2013-08-30|Estimate||||2017-10-13|2017-11-14|Actual|October 2005||2005-10-31|October 2017|2017-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Vorinostat in Treating Patients With Kidney Cancer|A Phase II, Pharmacokinetic and Biologic Correlative Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Renal Cell Carcinoma (RCC)|Completed||Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:13:34.69162|2018-06-01 04:13:34.69162
NCT00278382|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-02-06|2006-01-16|2006-01-18|Estimate|||||||2013-02-06|2013-02-07|Estimate|October 2005||2005-10-31|February 2013|2013-02-28||||December 2007|Actual|2007-12-31||Interventional|||Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|A Phase 2 Study of BAY 43-9006 (IND 69896) in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphomas|Completed||Phase 2|33|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:13:34.92486|2018-06-01 04:13:34.92486
NCT00278369|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-05-20|2006-01-16|2006-01-18|Estimate|||||||2013-05-20|2013-05-22|Estimate|April 2005||2005-04-30|May 2013|2013-05-31|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional|||Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer|A Pilot Study of Denileukin Diftitox in Combination With High-Dose IL-2 for Patients With Metastatic Renal Cell Carcinoma|Completed||Early Phase 1|20|Actual|Northwestern University||3|||f||||t||||||||||2018-06-01 04:13:35.003222|2018-06-01 04:13:35.003222
NCT00277940|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2011-07-05|2006-01-13|2006-01-18|Estimate|||||||2011-07-05|2011-07-06|Estimate||||May 2007|2007-05-31||||||||Observational|||Aortic Arch Reconstruction|Neoaortic Elastic Properties After Aortic Arch Reconstruction|Terminated|||36|Actual|Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:13:37.797482|2018-06-01 04:13:37.797482
NCT00278343|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|2015-09-23||2017-05-31|2006-01-16|2006-01-18|Estimate|2017-05-31|2017-07-02|Actual||||2017-05-31|2017-07-02|Actual|April 2006||2006-04-30|May 2017|2017-05-31||||June 2010|Actual|2010-06-30||Interventional||Platinum sensitive: 39 Platinum resistant: 35 Total # treated: 74|Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer|A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer|Active, not recruiting||Phase 2|74|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:13:35.099332|2018-06-01 04:13:35.099332
NCT00278330|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-04-01|2006-01-16|2006-01-18|Estimate|||||||2013-04-01|2013-04-02|Estimate|January 2006||2006-01-31|April 2013|2013-04-30||||October 2009|Actual|2009-10-31||Interventional|||Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia|Phase I Trial of Vorinostat (SAHA) in Combination With Alvocidib (Flavopiridol) in Patients With Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia With Excess Blasts-2|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:13:35.339297|2018-06-01 04:13:35.339297
NCT00278304|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-06-18|2006-01-16|2006-01-18|Estimate|||||||2013-06-18|2013-06-20|Estimate|September 2005||2005-09-30|April 2006|2006-04-30|June 2006|Actual|2006-06-30|||||Interventional|||Radiation Therapy in Treating Patients With Cervical Cancer|A Pilot Study of MR-Guided High Dose Rate Brachytherapy With MR Image Acquisition for Patients With Cervical Cancer|Completed||Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:35.431393|2018-06-01 04:13:35.431393
NCT00278278|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-12-18|2006-01-16|2006-01-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2003||2003-09-30|November 2008|2008-11-30||||March 2010|Anticipated|2010-03-31||Interventional|||Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas|Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:13:35.500273|2018-06-01 04:13:35.500273
NCT00278265|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2016-09-30|2006-01-16|2006-01-18|Estimate|||||||2016-09-30|2016-10-03|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia|First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL)|Terminated||Phase 2|12|Actual|German CLL Study Group||1||slow recruitment|f||||f||||||||No||2018-06-01 04:13:35.587429|2018-06-01 04:13:35.587429
NCT00278252|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-08-06|2006-01-16|2006-01-18|Estimate|||||||2013-08-06|2013-08-07|Estimate|July 2001||2001-07-31|June 2009|2009-06-30||||July 2010|Anticipated|2010-07-31||Interventional|||Etoposide in Treating Young Patients With Relapsed Ependymoma|Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma|Unknown status|Recruiting|Phase 2|14|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:35.685922|2018-06-01 04:13:35.685922
NCT00278239|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-09-19|2006-01-16|2006-01-18|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 2002||2002-06-30|April 2006|2006-04-30||||||||Observational|||Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors|Study of Outcome of Children Previously Enrolled in European Trials of Treatment for Primitive Neuroectodermal Tumour (PNET)|Unknown status|Active, not recruiting||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:35.746557|2018-06-01 04:13:35.746557
NCT00278226|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2010-03-23|2006-01-16|2006-01-18|Estimate|||||||2010-03-23|2010-03-24|Estimate|June 2001||2001-06-30|March 2010|2010-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Motivational Program for Smokers Enrolled in a Methadone Maintenance Program|Smoking Cessation Among Methadone Maintained Patients|Completed||N/A|398|Actual|Butler Hospital|||||f||||f||||||||||2018-06-01 04:13:35.975281|2018-06-01 04:13:35.975281
NCT00278213|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2018-05-09|2006-01-16|2006-01-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2002||2002-09-30|May 2018|2018-05-31|December 2009|Actual|2009-12-31|February 2007|Actual|2007-02-28||Interventional|||Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia|Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia|Completed||Phase 2|17|Anticipated|German CLL Study Group|||||f||||||||||||No||2018-06-01 04:13:36.049225|2018-06-01 04:13:36.049225
NCT00278200|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2015-10-30|2006-01-16|2006-01-18|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2002||2002-09-30|October 2015|2015-10-31|December 2022||2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Vaccine Therapy in Treating Patients Who Are Being Considered For a Solid Organ Transplant and Are at Risk For Post-Transplant Lymphoproliferative Disorder|Vaccination of Patients at High Risk for Post-Transplant Lymphoproliferative Disorder With a Photochemically Inactivated EBV-Infected B-Cell Vaccine|Active, not recruiting||Phase 1|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:13:36.161462|2018-06-01 04:13:36.161462
NCT00278187|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-12-18|2006-01-16|2006-01-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2005||2005-07-31|February 2006|2006-02-28||||||||Interventional|||Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Open-Label Study of Volociximab (M200) in Combination With Erlotinib (Tarceva™) in Previously Treated Patients With Locally Advanced (Stage IIIb) or Metastatic (Stage IV) Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:36.227227|2018-06-01 04:13:36.227227
NCT00278174|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2011-05-02|2006-01-16|2006-01-18|Estimate|||||||2011-05-02|2011-05-04|Estimate|February 2005||2005-02-28|May 2011|2011-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer|A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma|Completed||Phase 2|7|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:13:36.293913|2018-06-01 04:13:36.293913
NCT00278161|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2014-04-16|2006-01-16|2006-01-18|Estimate|||||||2014-04-16|2014-04-17|Estimate|January 2005||2005-01-31|April 2014|2014-04-30|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|||Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma|Phase II Study of High Dose Cyclophosphamide and Rituximab in Low Grade and Mantle Cell Lymphoma|Completed||Phase 2|82|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:13:36.359955|2018-06-01 04:13:36.359955
NCT00277927|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2011-07-05|2006-01-13|2006-01-18|Estimate|||||||2011-07-05|2011-07-06|Estimate|January 1984||1984-01-31|November 2007|2007-11-30|December 2007|Actual|2007-12-31|||||Observational|||Mild Valvar Pulmonary Stenosis|Clinical Management of Children With Mild Valvar Pulmonary Stenosis|Terminated|||146|Actual|Children's Healthcare of Atlanta||||sufficient data collected for significant study results|f||||f||||||||||2018-06-01 04:13:37.852827|2018-06-01 04:13:37.852827
NCT00278148|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2012-02-08|2006-01-16|2006-01-18|Estimate|||||||2012-02-08|2012-02-09|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|February 2011|Actual|2011-02-28||Interventional|||Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer|A Phase I/II Trial of Neoadjuvant Paclitaxel, Carboplatin and OSI-774 (Tarceva) With Concurrent Accelerated Hyperfractionation Radiation Followed by Maintenance Therapy With OSI-774 for Stage III Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|32|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:13:36.502679|2018-06-01 04:13:36.502679
NCT00278135|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2014-05-16|2006-01-13|2006-01-18|Estimate|||||||2014-05-16|2014-05-19|Estimate|December 2005||2005-12-31|May 2014|2014-05-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|MIDAS||Memory Improvement With Docosahexaenoic Acid Study (MIDAS)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in the Elderly|Completed||N/A|485|Actual|DSM Nutritional Products, Inc.||2|||f||||f||||||||||2018-06-01 04:13:36.602238|2018-06-01 04:13:36.602238
NCT00278122|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2013-12-09|2006-01-16|2006-01-18|Estimate|||||||2013-12-09|2013-12-10|Estimate|July 2005||2005-07-31|December 2013|2013-12-31||||December 2015|Anticipated|2015-12-31||Interventional|||Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|Evaluation of the Clinical Efficacy of Leukine® Administered in Conjunction With Paclitaxel in Patients With Advanced Melanoma|Suspended||Phase 2|42|Anticipated|University of Virginia|||||||||||||||||||2018-06-01 04:13:36.727941|2018-06-01 04:13:36.727941
NCT00278109|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2014-03-28|2006-01-16|2006-01-18|Estimate|||||||2014-03-28|2014-03-31|Estimate|July 2004||2004-07-31|March 2014|2014-03-31||||May 2015|Anticipated|2015-05-31||Interventional|||Radiation Therapy, Cyclophosphamide, and Doxorubicin in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery|Phase I/II Partial Breast Irradiation With Concurrent Chemotherapy|Unknown status|Active, not recruiting|Phase 1/Phase 2|42|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 04:13:36.835007|2018-06-01 04:13:36.835007
NCT00278096|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2006-01-13|2006-01-13|2006-01-18|Estimate|||||||2006-01-13|2006-01-18|Estimate|March 2000||2000-03-31|January 2006|2006-01-31|May 2004||2004-05-31|||||Interventional|||Randomised Controlled Trial of Unsolicited Occupational Therapy in Community-Dwelling Elderly|Randomised Controlled Trial of Unsolicited Occupational Therapy in Community-Dwelling Elderly|Completed||N/A|400||Leiden University Medical Center|||||f||||||||||||||2018-06-01 04:13:36.959235|2018-06-01 04:13:36.959235
NCT00278083|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2016-02-23|2006-01-17|2006-01-18|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2001||2001-10-31|January 2006|2006-01-31|April 2004||2004-04-30|||||Interventional|||TNF-alpha Directed Therapy in Asthma|A Randomised, Double Blind, Placebo-controlled, Parallel Group Pilot Study to Determine the Effect of REMICADE on Safety, Efficacy and Biomarkers of Inflammation in Patients With Asthma Receiving Inhaled Corticosteroids|Completed||Phase 2|40||Imperial College London|||||f||||||||||||||2018-06-01 04:13:37.022006|2018-06-01 04:13:37.022006
NCT00278070|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2008-02-27|2006-01-17|2006-01-18|Estimate|||||||2008-02-27|2008-02-29|Estimate|January 2006||2006-01-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|||||Interventional|||Metronomic Oral Vinorelbine in Patients With Metastatic Tumors|Metronomic Vinorelbine in Patients With Metastatic Tumors: Phase II Translational Study|Completed||Phase 2|||Hellenic Cooperative Oncology Group||3|||f||||t||||||||||2018-06-01 04:13:37.124|2018-06-01 04:13:37.124
NCT00278057|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2006-01-16|2006-01-16|2006-01-18|Estimate|||||||2006-01-16|2006-01-18|Estimate|May 2003||2003-05-31|January 2006|2006-01-31|May 2003||2003-05-31|||||Interventional|||STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE|PHASE 4 STUDY OT THE EFFECT OF GLUCOSE ADDED TO THE DIALYSIS FLUID ON BLOOD PRESSURE, BLOOD GLUCOSE AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS.|Completed||Phase 4|55||Regional Hospital Holstebro|||||f||||||||||||||2018-06-01 04:13:37.239362|2018-06-01 04:13:37.239362
NCT00278044|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2009-02-06|2006-01-17|2006-01-18|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children|Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children|Unknown status|Recruiting|N/A|20|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:13:37.318911|2018-06-01 04:13:37.318911
NCT00278031|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-17|||2016-10-01|2006-01-17|2006-01-18|Estimate|||||||2016-10-01|2016-10-04|Estimate|March 2006||2006-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Quality of Life in Children Cured of Retinoblastoma|Quality of Life in Children Cured of Retinoblastoma|Recruiting|||35|Anticipated|Hadassah Medical Organization|||||f||||f||||||||Yes||2018-06-01 04:13:37.387136|2018-06-01 04:13:37.387136
NCT00278018|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2015-04-19|2006-01-16|2006-01-18|Estimate|||||||2015-04-19|2015-04-21|Estimate|December 2005||2005-12-31|April 2007|2007-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors|Peritumoral Injection of Immature Dendritic Cels to Irradiated Metastases of Solid Tumors|Terminated||Phase 1/Phase 2|20|Anticipated|Hadassah Medical Organization||||Because there were no responses|f||||||||||||||2018-06-01 04:13:37.460651|2018-06-01 04:13:37.460651
NCT00278005|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2012-03-14|2006-01-13|2006-01-18|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 1998||1998-01-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Infection in DiGeorge Following CHD Surgery|Incidence of Infection in the Patient With DiGeorge Syndrome Following Surgery for Congenital Heart Disease|Terminated|||400|Actual|Children's Healthcare of Atlanta||||completed|f||||f||||||||||2018-06-01 04:13:37.521316|2018-06-01 04:13:37.521316
NCT00277992|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2007-05-22|2006-01-13|2006-01-18|Estimate|||||||2007-05-22|2007-05-23|Estimate|January 2001||2001-01-31|May 2007|2007-05-31||||||||Observational|||Growth in Children With HLHS|Growth in Children With HLHS|Terminated|||100||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:13:37.596899|2018-06-01 04:13:37.596899
NCT00277979|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2012-03-14|2006-01-13|2006-01-18|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||3D Echocardiography Managing Infantile Pompe's Disease|Utilization of 3D Echocardiography in the Management of Infantile Pompe's Disease: Two Case Reports|Terminated|||2|Actual|Children's Healthcare of Atlanta||||project withdrawn|f||||f||||||||||2018-06-01 04:13:37.646762|2018-06-01 04:13:37.646762
NCT00277966|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2016-08-05|2006-01-13|2006-01-18|Estimate|||||||2016-08-05|2016-08-09|Estimate|January 2004||2004-01-31|August 2016|2016-08-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Observational|||Cath Lab Performance Improvement|Cardiac Catheterization Laboratory Radiology Performance Improvement|Withdrawn|||0|Actual|Children's Healthcare of Atlanta||||No enrollment as this was a retrospective review, not a clinical trial.|f||||||||||||||2018-06-01 04:13:37.695103|2018-06-01 04:13:37.695103
NCT00277953|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2007-05-02|2006-01-13|2006-01-18|Estimate|||||||2007-05-02|2007-05-04|Estimate||||May 2007|2007-05-31||||||||Observational|||MRI Review of Tracheal Dimensions|A Review of Tracheal Dimensions in the Pediatric Population Using MRI|Terminated|||75||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:13:37.743236|2018-06-01 04:13:37.743236
NCT00277914|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-16|||2012-03-14|2006-01-16|2006-01-18|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2006||2006-01-31|March 2012|2012-03-31||||July 2007|Actual|2007-07-31||Interventional|||Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women|12-month Sustained Efficacy of Flibanserin v Placebo n Younger Women With HSDD in NA|Completed||Phase 3|749|Actual|Sprout Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 04:13:37.915834|2018-06-01 04:13:37.915834
NCT00277901|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2014-11-26|2006-01-13|2006-01-18|Estimate|||||||2014-11-26|2014-12-02|Estimate|March 2002||2002-03-31|November 2014|2014-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||MRI Assessment of RV Function: Patients With TOF or Aortic Coarctation|MRI Assessment of Two Congenital Heart Disease States: Assessment of Right Ventricular Function: Predictor of Optimal Timing of Pulmonary Valve Replacement in Patients With TOF; Assessment of Flow Dynamics in Patients With Aortic Coarctation|Completed|||390|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 04:13:38.22584|2018-06-01 04:13:38.22584
NCT00277888|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2014-11-13|2006-01-13|2006-01-18|Estimate|||||||2014-11-13|2014-11-14|Estimate|April 2004||2004-04-30|November 2014|2014-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|CATHEDIA||Comparison of Femoral Versus Jugular Routes for Temporary Hemodialysis in Seriously Ill Patients|Complications of Jugular and Femoral Venous Catheterization in Critically Ill Patients Requiring Hemodialysis: A Randomized Controlled Trial|Completed||N/A|750|Actual|University Hospital, Caen||2|||f||||||||||||||2018-06-01 04:13:38.331869|2018-06-01 04:13:38.331869
NCT00277875|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2009-08-26|2006-01-13|2006-01-18|Estimate|||||||2009-08-26|2009-08-27|Estimate|February 2004||2004-02-29|January 2006|2006-01-31|January 2006|Actual|2006-01-31|December 2004|Actual|2004-12-31||Interventional|||STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH|The Effect of Vascular Distensibility on Endothelial-Dependent Vasoreactivity in Patients With Systolic Hypertension Before and After Receiving Oral Alagebrium for 8 Weeks.|Completed||Phase 2|25||Synvista Therapeutics, Inc|||||f||||f||||||||||2018-06-01 04:13:38.433418|2018-06-01 04:13:38.433418
NCT00277862|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-15|||2008-02-25|2006-01-15|2006-01-18|Estimate|||||||2008-02-25|2008-02-26|Estimate|April 2002||2002-04-30|February 2008|2008-02-29|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|||Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4|Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4|Completed||Phase 4|280|Actual|Ain Shams University||4|||f||||t||||||||||2018-06-01 04:13:38.532668|2018-06-01 04:13:38.532668
NCT00277849|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-14|||2017-06-30|2006-01-13|2006-01-16|Estimate|||||||2017-06-30|2017-07-02|Actual|January 11, 2006||2006-01-11|July 20, 2010|2010-07-20|July 20, 2010||2010-07-20|||||Observational|||Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research|Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research|Completed|||130|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:13:38.634247|2018-06-01 04:13:38.634247
NCT00277836|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2006-12-07|2006-01-13|2006-01-16|Estimate|||||||2006-12-07|2006-12-08|Estimate||||December 2006|2006-12-31||||||||Interventional|||Study Evaluating MST-997 in Advanced Malignant Solid Tumors|A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors|Terminated||Phase 1|60||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:13:38.689728|2018-06-01 04:13:38.689728
NCT00277823|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2007-12-19|2006-01-12|2006-01-16|Estimate|||||||2007-12-19|2007-12-28|Estimate|February 2006||2006-02-28|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|480||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:13:38.758682|2018-06-01 04:13:38.758682
NCT00277810|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12||2013-02-14|2013-02-14|2006-01-12|2006-01-16|Estimate||||2013-02-14|2013-02-21|Estimate|2013-02-14|2013-02-21|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease|A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor|Completed||Phase 2/Phase 3|250|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||t||||||||||2018-06-01 04:13:38.900346|2018-06-01 04:13:38.900346
NCT00277797|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-06-13|2006-01-12|2006-01-16|Estimate|||||||2013-06-13|2013-06-17|Estimate|February 2001||2001-02-28|June 2013|2013-06-30|October 2008|Actual|2008-10-31|March 2006|Actual|2006-03-31||Interventional|||"Non-Invasive Targeted Electronic Pain Control Device (Biowave System) Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain"|"A Randomized, Single-Blinded, Comparative Crossover Trial of the Safety and Efficacy of a Non-Invasive Targeted Electronic Pain Control Device (Biowave System) Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain."|Completed||Phase 3|50|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 04:13:39.079383|2018-06-01 04:13:39.079383
NCT00277784|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2008-03-04|2006-01-12|2006-01-16|Estimate|||||||2008-03-04|2008-03-07|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||High-Resolution Ultrasound Imaging of the Retina and Choroid for Detection on Age Related Macular Degeneration|High-Resolution Ultrasound Imaging of the Retina and Choroid|Completed|||40|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-06-01 04:13:40.242332|2018-06-01 04:13:40.242332
NCT00277771|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2015-07-02|2006-01-13|2006-01-16|Estimate|||||||2015-07-02|2015-07-07|Estimate|February 2006||2006-02-28|July 2015|2015-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Improving Self-Monitoring in Weight Loss With Technology|Improving Self-Monitoring in Weight Loss With Technology|Completed||N/A|210|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 04:13:40.402745|2018-06-01 04:13:40.402745
NCT00277758|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2008-03-06|2006-01-12|2006-01-16|Estimate|||||||2008-03-06|2008-03-07|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I|A Phase I Study of Low Dose Interleukin 2 (IL-2)Monotherapy, Followed by IL-2 Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I Infection|Terminated||Phase 1|18|Actual|Weill Medical College of Cornell University||2||Insufficient rate of volunteer accrual.|f||||t||||||||||2018-06-01 04:13:40.582121|2018-06-01 04:13:40.582121
NCT00276952|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2006-01-12|2006-01-12|2006-01-13|Estimate|||||||2006-01-12|2006-01-13|Estimate|September 2004||2004-09-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Gonyautoxin in the Treatment of Chronic Tension-Type Headache|Phase 2 Study of Treatment of Chronic Tension-Type Headache Using Gonyautoxins|Terminated||Phase 2|27||University of Chile|||||f||||||||||||||2018-06-01 04:13:49.964006|2018-06-01 04:13:49.964006
NCT00277745|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2015-12-11|2006-01-12|2006-01-16|Estimate|||||||2015-12-11|2015-12-14|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Observational|||Integrated Microfluidic System for Oral Diagnostics|Integrated Microfluidic System for Oral Diagnostics|Completed|||100|Actual|University of Michigan|||||f||||t||||||Samples Without DNA|"~     Saliva, serum, dental plaque and gingival crevicular fluid~   "|||2018-06-01 04:13:40.676096|2018-06-01 04:13:40.676096
NCT00277732|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2007-12-19|2006-01-13|2006-01-16|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|November 2006||2006-11-30|||||Interventional|||Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial|Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial|Completed||N/A|288|Actual|University Ghent|||||f||||f||||||||||2018-06-01 04:13:40.74238|2018-06-01 04:13:40.74238
NCT00277706|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2009-10-06|2006-01-13|2006-01-16|Estimate|||||||2009-10-06|2009-10-07|Estimate|August 2004||2004-08-31|October 2009|2009-10-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Impact of Parathyroid Hormone (PTH) on Osseous Cavity|Impact of Parathyroid Hormone (1-34) on Osseous Regeneration in the Oral Cavity|Completed||Phase 1|40|Anticipated|University of Michigan||2|||||||||||||||||2018-06-01 04:13:40.805629|2018-06-01 04:13:40.805629
NCT00277693|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2006-01-12|2006-01-12|2006-01-16|Estimate|||||||2006-01-12|2006-01-16|Estimate||||December 2005|2005-12-31||||||||Interventional|||Cardiovascular Protective Effect of Spironolactone in Hemodialysis|Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies|Unknown status|Recruiting|Phase 4|||Universidad Los Andes, Chile|||||f||||||||||||||2018-06-01 04:13:40.897362|2018-06-01 04:13:40.897362
NCT00277680|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2011-07-03|2006-01-13|2006-01-16|Estimate|||||||2011-07-03|2011-07-06|Estimate|December 2000||2000-12-31|January 2006|2006-01-31|April 2010||2010-04-30|||||Interventional|||Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids|A Randomized Trial Comparing Laparoscopic Bilateral Occlusion of Uterine Vessels to Uterine Fibroid Embolization for the Treatment of Symptomatic Uterine Fibroids|Unknown status|Active, not recruiting|N/A|60||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:13:40.970663|2018-06-01 04:13:40.970663
NCT00277667|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2009-03-12|2006-01-12|2006-01-16|Estimate|||||||2009-03-12|2009-03-13|Estimate|February 2004||2004-02-29|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms|A Randomized, Double-Blind, Placebo-Controlled Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms|Completed||Phase 3|40|Anticipated|Lindner Center of HOPE|||||f||||||||||||||2018-06-01 04:13:41.147377|2018-06-01 04:13:41.147377
NCT00277654|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2011-12-12|2006-01-12|2006-01-16|Estimate|||||||2011-12-12|2011-12-13|Estimate|February 2004||2004-02-29|December 2011|2011-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder|Completed||Phase 3|111|Actual|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 04:13:41.232624|2018-06-01 04:13:41.232624
NCT00277641|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2011-06-21|2006-01-12|2006-01-16|Estimate|||||||2011-06-21|2011-06-22|Estimate|March 2006||2006-03-31|June 2011|2011-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity|Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients|Completed||Phase 3|70|Anticipated|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 04:13:41.332018|2018-06-01 04:13:41.332018
NCT00277615|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2012-01-20|2006-01-13|2006-01-16|Estimate|||||||2012-01-20|2012-01-23|Estimate|October 2005||2005-10-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|||||Observational|||Evaluation Study of Ultrasound Bladder Scanner for Monitoring Bladder Function|Clinical Evaluation of a Portable Ultrasound Bladder Scanner for Continuous Monitoring of Bladder Function in Children.|Unknown status|Active, not recruiting||30|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 04:13:41.436083|2018-06-01 04:13:41.436083
NCT00277602|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2012-02-15|2006-01-13|2006-01-16|Estimate|||||||2012-02-15|2012-02-17|Estimate|November 1999||1999-11-30|February 2012|2012-02-29|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Riluzole in Huntington's Disease|A Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's Disease|Completed||Phase 3|537|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:13:41.514221|2018-06-01 04:13:41.514221
NCT00277589|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2009-12-03|2006-01-13|2006-01-16|Estimate|||||||2009-12-03|2009-12-04|Estimate|May 2004||2004-05-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||LISA-study : Levothyroxin in Nodular Goiter|TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter|Completed||Phase 4|1024|Actual|Sanofi||4|||f||||||||||||||2018-06-01 04:13:41.60025|2018-06-01 04:13:41.60025
NCT00277576|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2008-11-20|2006-01-13|2006-01-16|Estimate|||||||2008-11-20|2008-11-21|Estimate|January 2006||2006-01-31|November 2008|2008-11-30|December 2007|Actual|2007-12-31|||||Interventional|||Safety Study of HBV DNA Vaccine to Treat Patients With Chronic Hepatitis B Infection|Phase I, Multi-Centre, Randomised, Placebo-Controlled, Dose Escalation Study to Assess Local & Systemic Tolerability of Therapeutic DNA Plasmid pdpSC18 Vaccine Administered by Particle Mediated Epidermal Delivery Using PowderJect ND10 Delivery System in Subjects With Chronic Hepatitis B Infection|Completed||Phase 1|48|Anticipated|PowderMed|||||||||||||||||||2018-06-01 04:13:41.779794|2018-06-01 04:13:41.779794
NCT00277563|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2007-09-20|2006-01-13|2006-01-16|Estimate|||||||2007-09-20|2007-09-21|Estimate|June 2004||2004-06-30|September 2007|2007-09-30|July 2005||2005-07-31|||||Interventional|||Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome|Short and Long Term Exposure to Unique, Time-Varying Pulsed Electro-Magnetic Fields in Refractory Carpal Tunnel Syndrome (Cts): A Randomized, Placebo-Controlled Trial With Secondary Bayesian Modification|Completed||Phase 4|50||Weintraub, Michael I., MD, FACP, FAAN|||||f||||||||||||||2018-06-01 04:13:41.902526|2018-06-01 04:13:41.902526
NCT00277550|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2016-03-02|2006-01-13|2006-01-16|Estimate|||||||2016-03-02|2016-03-04|Estimate||||March 2016|2016-03-31||||||||Interventional|||The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia|A Randomized, Double-blind, Placebo-controlled Evaluation of the Effects of Tegaserod (6 mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia|Withdrawn||Phase 4|0|Actual|Novartis|||||||||||||||||||2018-06-01 04:13:41.982719|2018-06-01 04:13:41.982719
NCT00277537|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2008-08-27|2006-01-13|2006-01-16|Estimate|||||||2008-08-27|2008-08-29|Estimate|March 2006||2006-03-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy of Bronchitol in Bronchiectasis|A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis.|Completed||Phase 3|354|Anticipated|Pharmaxis||2|||f||||t||||||||||2018-06-01 04:13:42.072719|2018-06-01 04:13:42.072719
NCT00277524|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|2012-07-13||2013-05-21|2006-01-12|2006-01-16|Estimate|2013-05-21|2013-08-28|Estimate||||2013-05-21|2013-08-28|Estimate|August 2005||2005-08-31|May 2013|2013-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|OMNI|Subjects implanted with an IPG, ICD or CRT-D and age 18 years or older were eligible for the OMNI study. Clinical data and device programming at baseline from all subjects was summarized for categorical and continuous variables using descriptive statistics.|OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.|OMNI Study--Assessing Therapies in Medtronic Pacemaker, Defibrillator, and Cardiac Resynchronization Therapy Devices.|Terminated|||3032|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1|Ended follow-up after four years|f||||f||||||||||2018-06-01 04:13:42.273759|2018-06-01 04:13:42.273759
NCT00277511|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2007-10-11|2006-01-13|2006-01-16|Estimate|||||||2007-10-11|2007-10-12|Estimate|March 2003||2003-03-31|October 2007|2007-10-31||||||||Interventional|||Levofloxacin, Chronic Bacterial Prostatitis|Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP)|Completed||Phase 3|120||Sanofi|||||f||||||||||||||2018-06-01 04:13:43.225088|2018-06-01 04:13:43.225088
NCT00277498|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2011-03-15|2006-01-13|2006-01-16|Estimate|||||||2011-03-15|2011-03-16|Estimate|December 2005||2005-12-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|||||Interventional|||A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma|A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension In The United States.|Completed||Phase 3|528||Pfizer|||||f||||||||||||||2018-06-01 04:13:43.323726|2018-06-01 04:13:43.323726
NCT00277472|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2011-06-06|2006-01-12|2006-01-16|Estimate|||||||2011-06-06|2011-06-07|Estimate|November 2005||2005-11-30|March 2008|2008-03-31||||November 2005|Actual|2005-11-30||Interventional|||Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension|A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy|Completed||Phase 4|300|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:13:43.480297|2018-06-01 04:13:43.480297
NCT00277446|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|2011-01-14||2011-02-23|2006-01-13|2006-01-16|Estimate|2011-01-21|2011-02-24|Estimate||||2011-02-23|2011-02-25|Estimate|January 2006||2006-01-31|February 2011|2011-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Dietary Supplementation With Soy Isoflavones in Asthma|Dietary Supplementation With Soy Isoflavones in Asthma|Completed||N/A|13|Actual|Northwestern University|||||f||||f||||||||||2018-06-01 04:13:43.564505|2018-06-01 04:13:43.564505
NCT00277433|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2017-03-16|2006-01-12|2006-01-16|Estimate|||||||2017-03-16|2017-03-20|Actual|June 2004||2004-06-30|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Histamine Pharmacogenetics in Children With Atopic Dermatitis|Histamine Pharmacogenetics in Children With Atopic Dermatitis|Completed|||751|Actual|Virginia Commonwealth University|||2||f||||f||||||Samples With DNA|"~     buccal-derived DNA~   "|||2018-06-01 04:13:43.782705|2018-06-01 04:13:43.782705
NCT00277420|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2015-08-21|2006-01-12|2006-01-16|Estimate|||||||2015-08-21|2015-08-25|Estimate|August 2005||2005-08-31|August 2015|2015-08-31|August 2008|Anticipated|2008-08-31|||||Interventional|||Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children|A Randomized Controlled Trial of a Culturally-Appropriate Weight Loss Intervention for Overweight Latino Children|Withdrawn||N/A|0|Actual|Medical College of Wisconsin||||PI has left institution after losing funding for this PI-initiated study|f||||||||||||||2018-06-01 04:13:43.925325|2018-06-01 04:13:43.925325
NCT00277407|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2007-05-04|2006-01-12|2006-01-16|Estimate|||||||2007-05-04|2007-05-07|Estimate|June 2006||2006-06-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Treatment of Autistic Children Using NAET Procedures|An Investigation Into the Outcome of NAET Treatment on Children With Allergy-Related Autism Spectrum Disorders in a Multi-Clinical Setting.|Completed||N/A|48|Actual|Nambudripad's Allergy Research Foundation|||||f||||t||||||||||2018-06-01 04:13:44.085532|2018-06-01 04:13:44.085532
NCT00277394|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|2010-11-23||2015-03-25|2006-01-13|2006-01-16|Estimate|2010-11-23|2010-12-21|Estimate||||2015-03-25|2015-04-14|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis|Safety Profile of Innohep Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis|Completed||Phase 4|541|Actual|LEO Pharma||2|||f||||t||||||||||2018-06-01 04:13:44.260587|2018-06-01 04:13:44.260587
NCT00277381|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2013-02-27|2006-01-13|2006-01-16|Estimate|||||||2013-02-27|2013-03-01|Estimate|July 2006||2006-07-31|February 2013|2013-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology|Improving Adherence in Patients With Hypertension - A Novel Use of Communication Technology|Completed||N/A|84|Actual|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:13:45.024433|2018-06-01 04:13:45.024433
NCT00277368|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2010-04-26|2006-01-13|2006-01-16|Estimate|||||||2010-04-26|2010-04-27|Estimate|July 2005||2005-07-31|April 2010|2010-04-30|March 2006|Actual|2006-03-31|||||Observational|||A Study of the Prevalence of Headache in Epileptic Patients|Headache in Epileptic Patients|Completed|||719|Actual|Janssen Korea, Ltd., Korea|||1||f||||||||||||||2018-06-01 04:13:45.101516|2018-06-01 04:13:45.101516
NCT00277355|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|2013-03-07||2013-04-17|2006-01-12|2006-01-16|Estimate|2013-04-17|2013-04-19|Estimate||||2013-04-17|2013-04-19|Estimate|April 2006||2006-04-30|April 2013|2013-04-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Pilot Study of Minocycline in Huntington's Disease|A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease|Completed||Phase 2/Phase 3|114|Actual|Huntington Study Group||2|||f||||t||||||||||2018-06-01 04:13:45.20917|2018-06-01 04:13:45.20917
NCT00277342|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2012-05-03|2006-01-12|2006-01-16|Estimate|||||||2012-05-03|2012-05-04|Estimate|January 2006||2006-01-31|August 2006|2006-08-31|April 2006||2006-04-30|||||Interventional|||Potential Association of a Common L-FABP Polymorphism With Lipid-induced Hepatic Insulin Resistance||Completed||N/A|18||German Institute of Human Nutrition|||||f||||||||||||||2018-06-01 04:13:45.560171|2018-06-01 04:13:45.560171
NCT00277329|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-02-18|2006-01-12|2006-01-16|Estimate|||||||2010-02-18|2010-02-22|Estimate|December 2005||2005-12-31|February 2010|2010-02-28|July 2008|Actual|2008-07-31|August 2007|Actual|2007-08-31||Interventional|||Study of XL999 in Patients With Non-small Cell Lung Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer|Terminated||Phase 2|9|Actual|Symphony Evolution, Inc.||||Study was terminated due to cardiac toxicities in the subejcts|f||||t||||||||||2018-06-01 04:13:45.643348|2018-06-01 04:13:45.643348
NCT00277316|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-02-18|2006-01-12|2006-01-16|Estimate|||||||2010-02-18|2010-02-19|Estimate|December 2005||2005-12-31|February 2010|2010-02-28|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Interventional|||Study of XL999 in Patients With Metastatic Renal Cell Carcinoma|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|11|Actual|Symphony Evolution, Inc.||||Development of XL999 was stopped due to cardiac toxicities in the subjects|f||||t||||||||||2018-06-01 04:13:45.71497|2018-06-01 04:13:45.71497
NCT00277303|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-02-18|2006-01-12|2006-01-16|Estimate|||||||2010-02-18|2010-02-22|Estimate|December 2005||2005-12-31|February 2010|2010-02-28|February 2007|Actual|2007-02-28|August 2006|Actual|2006-08-31||Interventional|||Study of XL999 in Patients With Metastatic Colorectal Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer|Terminated||Phase 2|17|Actual|Symphony Evolution, Inc.||||Study was terminated due to cardiac toxicities in the subjects|f||||t||||||||||2018-06-01 04:13:45.785702|2018-06-01 04:13:45.785702
NCT00277290|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-02-18|2006-01-12|2006-01-16|Estimate|||||||2010-02-18|2010-02-22|Estimate|January 2006||2006-01-31|February 2010|2010-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study of XL999 in Patients With Previously Treated Ovarian Cancer|A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer|Terminated||Phase 2|24|Actual|Symphony Evolution, Inc.||||Study was terminated due to cardiac toxicities in the subjects|t||||t||||||||||2018-06-01 04:13:45.865033|2018-06-01 04:13:45.865033
NCT00277277|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2007-10-29|2006-01-12|2006-01-16|Estimate|||||||2007-10-29|2007-10-31|Estimate|August 2004||2004-08-31|October 2007|2007-10-31|September 2005||2005-09-30|||||Interventional|||In-Home Weight Loss Program for Adults With Type 2 Diabetes Delivered by Interactive Cable Television Technology|Telehealth Delivery of a Weight Loss Program in Diabetes|Completed||N/A|19||Bastyr University|||||f||||||||||||||2018-06-01 04:13:46.023055|2018-06-01 04:13:46.023055
NCT00277264|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-11-05|2006-01-13|2006-01-16|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 2002||2002-01-31|November 2013|2013-11-30|May 2004||2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Spiriva® Assessment of FEV1 (SAFE)|Spiriva® Assessment of FEV1 (SAFE). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Long-term Treatment in Patients With COPD. A One-year Parallel Group, Double-blind, Randomised, Placebo-controlled Study|Completed||Phase 3|914||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:13:46.112436|2018-06-01 04:13:46.112436
NCT00277251|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2017-04-10|2006-01-13|2006-01-16|Estimate|||||||2017-04-10|2017-04-11|Actual|March 2003|Actual|2003-03-31|April 2017|2017-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Alendronate Osteoporosis Study|Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis|Completed||Phase 2/Phase 3|20||Boston Children’s Hospital|||||||||||||||||||2018-06-01 04:13:46.303541|2018-06-01 04:13:46.303541
NCT00277238|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13||2011-01-03|2017-03-07|2006-01-13|2006-01-16|Estimate||||2011-01-03|2011-01-05|Estimate|2017-03-07|2017-03-08|Actual|February 2006||2006-02-28|March 2017|2017-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects|CPG 10101 Combination Therapy for the Treatment of Hepatitis C: A Phase II Randomized, Open Label, Multi-Center, Parallel Arm, Controlled Trial of CPG 10101 at Two Different Dose Levels With Pegylated-Interferon-Alpha 2B (PEG-IFN) Plus Ribavirin (RBV) or PEG-IFN Plus RBV Without CPG 10101 in the Treatment of Non-Responder (Null and Partial Responder) HCV Genotype 1 Infected Subjects|Completed||Phase 2|113|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 04:13:46.410107|2018-06-01 04:13:46.410107
NCT00277225|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2011-04-11|2006-01-12|2006-01-16|Estimate|||||||2011-04-11|2011-04-13|Estimate|November 1995||1995-11-30|April 2011|2011-04-30|June 1996|Actual|1996-06-30|June 1996|Actual|1996-06-30||Interventional|||A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris|A Phase I,Randomized, Double Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris|Completed||Phase 1|32||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:13:46.504597|2018-06-01 04:13:46.504597
NCT00277212|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|2010-09-20||2013-11-07|2006-01-13|2006-01-16|Estimate|2010-09-20|2010-10-20|Estimate||||2013-11-07|2013-12-02|Estimate|December 2005||2005-12-31|November 2010|2010-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode|A Multicenter, Double-blind, Study of the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode|Completed||Phase 4|1169|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-06-01 04:13:46.631024|2018-06-01 04:13:46.631024
NCT00277199|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2011-04-11|2006-01-12|2006-01-16|Estimate|||||||2011-04-11|2011-04-13|Estimate|September 2002||2002-09-30|April 2011|2011-04-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Comparability DE vs CD-CHO1|Study to Compare the Pharmacokinetics of CD-CHO1 Process BMS-188667 to DE Process BMS188667 in Healthy Subjects|Completed||Phase 1|30||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:13:48.284823|2018-06-01 04:13:48.284823
NCT00277186|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2008-07-28|2006-01-13|2006-01-16|Estimate|||||||2008-07-28|2008-07-29|Estimate|April 2005||2005-04-30|July 2008|2008-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Alberta Hip and Knee Replacement Project|A Randomized Controlled Prospective Study to Examine the Effectiveness of a New Evidence Based Arthroplasty Care Model for Patients With Severe Degenerative Joint Disease (DJD) of the Hip or Knee in Alberta|Completed||N/A|3434|Actual|Alberta Bone and Joint Health Institute||2|||f||||t||||||||||2018-06-01 04:13:48.340284|2018-06-01 04:13:48.340284
NCT00277173|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-13|||2006-01-13|2006-01-13|2006-01-16|Estimate|||||||2006-01-13|2006-01-16|Estimate|January 2006||2006-01-31|January 2006|2006-01-31||||||||Interventional|||Improving Geriatric Drug Safety in Underserved Practices|Improving Geriatric Drug Safety in Underserved Practices|Unknown status|Recruiting|N/A|4800||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:13:48.403288|2018-06-01 04:13:48.403288
NCT00276939|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2012-08-06|2006-01-11|2006-01-13|Estimate|||||||2012-08-06|2012-08-07|Estimate|September 2003||2003-09-30|August 2012|2012-08-31|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Plant-Based Dietary Intervention in Type 2 Diabetes|Plant-Based Dietary Intervention in Type 2 Diabetes|Completed||N/A|99|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-06-01 04:13:50.037729|2018-06-01 04:13:50.037729
NCT00277160|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-10-07|2006-01-12|2006-01-16|Estimate|||||||2010-10-07|2010-10-08|Estimate|June 2002||2002-06-30|October 2010|2010-10-31|January 2005|Actual|2005-01-31|November 2004|Actual|2004-11-30||Interventional|||A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer|A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer|Completed||Phase 4|852|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:13:48.462763|2018-06-01 04:13:48.462763
NCT00277147|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2017-06-30|2006-01-12|2006-01-13|Estimate|||||||2017-06-30|2017-07-02|Actual|January 9, 2006||2006-01-09|September 17, 2008|2008-09-17|September 17, 2008||2008-09-17|||||Interventional|||Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine|Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine, Phase 1 Trial in Adults at NIH CC|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:13:48.517996|2018-06-01 04:13:48.517996
NCT00277121|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2006-01-12|2006-01-12|2006-01-13|Estimate|||||||2006-01-12|2006-01-13|Estimate|January 2006||2006-01-31|January 2006|2006-01-31||||||||Observational|||Genetic Origin of Lipid Disorders|Genetic Origin of Lipid Disorders|Unknown status|Not yet recruiting||||University of Oslo|||||f||||||||||||||2018-06-01 04:13:48.685771|2018-06-01 04:13:48.685771
NCT00277108|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2008-11-05|2006-01-12|2006-01-13|Estimate|||||||2008-11-05|2008-11-06|Estimate|February 2004||2004-02-29|November 2008|2008-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Lexapro in the Treatment of Patients With Postpartum Depression|Open Label Variable Dose Escitalopram (Lexapro) in the Treatment of Patients With Postpartum Major Depression: A Pilot Study|Completed||N/A|20|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:13:48.748769|2018-06-01 04:13:48.748769
NCT00277095|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|2013-01-30||2018-04-30|2006-01-11|2006-01-13|Estimate|2016-01-04|2016-02-03|Estimate||||2018-04-30|2018-05-31|Estimate|August 2005||2005-08-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|February 2009|Actual|2009-02-28||Interventional|ProACT||ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males|Clinical Investigation of the ProACT Adjustable Continence Therapy for Treatment of Post-Prostatectomy Stress Urinary Incontinence|Completed||N/A|123|Actual|Uromedica||1|||f||||f||||||||||2018-06-01 04:13:48.822349|2018-06-01 04:13:48.822349
NCT00277082|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-01-06|2006-01-12|2006-01-13|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2003||2003-08-31|April 2008|2008-04-30|June 2005|Actual|2005-06-30|||||Observational|||Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung|Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung (NSCLC)|Completed|||24|Actual|University of New Mexico|||||f||||t||||||Samples Without DNA|"~     Blood, lung tissue, lung cancer tissue.~   "|||2018-06-01 04:13:49.027811|2018-06-01 04:13:49.027811
NCT00277069|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-01-06|2006-01-12|2006-01-13|Estimate|||||||2010-01-06|2010-01-07|Estimate|May 2000||2000-05-31|October 2008|2008-10-31|March 2006|Actual|2006-03-31|March 2005|Actual|2005-03-31||Interventional|||Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer|INST: Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|33|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:13:49.132853|2018-06-01 04:13:49.132853
NCT00277056|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2010-01-06|2006-01-11|2006-01-13|Estimate|||||||2010-01-06|2010-01-07|Estimate|May 2002||2002-05-31|April 2008|2008-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|||Dysregulated Tyrosine Kinase Signaling in Leukemia|Dysregulated Tyrosine Kinase Signaling in Leukemia|Completed|||30|Actual|University of New Mexico|||||f||||t||||||Samples With DNA|"~     blood bone marrow~   "|||2018-06-01 04:13:49.196694|2018-06-01 04:13:49.196694
NCT00277043|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2011-09-23|2006-01-11|2006-01-13|Estimate|||||||2011-09-23|2011-09-27|Estimate|June 2002||2002-06-30|December 2009|2009-12-31|September 2005|Actual|2005-09-30|July 2004|Actual|2004-07-31||Interventional|||A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes|A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes|Completed||Phase 3|200|Actual|New Mexico Cancer Care Alliance||2|||f||||t||||||||||2018-06-01 04:13:49.32911|2018-06-01 04:13:49.32911
NCT00277030|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2006-08-22|2006-01-11|2006-01-13|Estimate|||||||2006-08-22|2006-08-24|Estimate|January 2006||2006-01-31|December 2005|2005-12-31||||||||Interventional|||Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams|Comparative Trial of Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams|Unknown status|Recruiting|Phase 4|110||Pontificia Universidad Catolica de Chile|||||f||||||||||||||2018-06-01 04:13:49.423097|2018-06-01 04:13:49.423097
NCT00277017|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2011-09-23|2006-01-11|2006-01-13|Estimate|||||||2011-09-23|2011-09-27|Estimate|September 2000||2000-09-30|December 2009|2009-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma|A Phase I/II Trial of Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, and Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma.|Completed||Phase 1/Phase 2|15|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||||||2018-06-01 04:13:49.573488|2018-06-01 04:13:49.573488
NCT00277004|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2010-01-06|2006-01-11|2006-01-13|Estimate|||||||2010-01-06|2010-01-07|Estimate|February 1999||1999-02-28|March 2008|2008-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Observational|||Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.|Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.|Completed|||22|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:13:49.656264|2018-06-01 04:13:49.656264
NCT00276991|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2015-11-02|2006-01-12|2006-01-13|Estimate|||||||2015-11-02|2015-11-04|Estimate|November 2007||2007-11-30|November 2015|2015-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Traditional CAM Therapy in the Treatment of HIV/AIDS|Modest Phase 1 and Phase II Clinical Studies on Traditional CAM Therapy in the Treatment of HIV/AIDS|Terminated||Phase 1/Phase 2|40|Actual|Traditional Alternative Medicine Research, India||1||Lack of funding prevented the recruitment of 1000 HIV Patients all over India|f||||t||||||||||2018-06-01 04:13:49.723349|2018-06-01 04:13:49.723349
NCT00276978|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2016-05-12|2006-01-11|2006-01-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2005||2005-06-30|May 2016|2016-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Aripiprazole Augmentation Therapy in Treatment-resistant Depression|Aripiprazole Augmentation Therapy in Treatment-resistant Depression|Terminated||Phase 3|20|Actual|University Hospital Freiburg||1|||f||||f||||||||||2018-06-01 04:13:49.794819|2018-06-01 04:13:49.794819
NCT00276965|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-05-08|2006-01-12|2006-01-13|Estimate|||||||2013-05-08|2013-05-10|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Bipolar II Depression: Lithium, SSRI, or the Combination|Comparing the Safety and Effectiveness of a Mood Stabilizing Medication, an Antidepressant Medication, and a Combination of Both Medications to Treat Symptoms of Bipolar Type II Depression|Completed||Phase 3|139|Actual|Lindner Center of HOPE||3|||f||||t||||||||||2018-06-01 04:13:49.871204|2018-06-01 04:13:49.871204
NCT00276926|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2009-09-14|2006-01-12|2006-01-13|Estimate|||||||2009-09-14|2009-09-15|Estimate|March 2003||2003-03-31|September 2009|2009-09-30||||||||Interventional|||Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias|Open Label Pilot Phase II Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias|Unknown status|Recruiting|Phase 2|||University of Bologna|||||f||||||||||||||2018-06-01 04:13:50.141466|2018-06-01 04:13:50.141466
NCT00276913|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2014-01-31|2006-01-11|2006-01-13|Estimate|||||||2014-01-31|2014-02-03|Estimate|June 2004||2004-06-30|January 2014|2014-01-31||||||||Interventional|||A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors|A Phase I Study of STA-5312 Administered Weekly in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|30||Synta Pharmaceuticals Corp.|||||f||||||||||||||2018-06-01 04:13:50.2669|2018-06-01 04:13:50.2669
NCT00276900|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2013-09-30|2006-01-11|2006-01-13|Estimate|||||||2013-09-30|2013-10-07|Estimate|December 2003||2003-12-31|September 2013|2013-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Sertraline for the Prevention of Recurrent Postpartum Depression|Prevention of Recurrent Postpartum Depression|Completed||Phase 3|300||University of Pittsburgh|||||f||||f||||||||||2018-06-01 04:13:50.523549|2018-06-01 04:13:50.523549
NCT00276887|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2014-02-19|2006-01-11|2006-01-13|Estimate|||||||2014-02-19|2014-02-20|Estimate|September 1999||1999-09-30|February 2014|2014-02-28|April 2004|Actual|2004-04-30|April 2003|Actual|2003-04-30||Interventional|||Cognitive Behavior Therapy for Somatization Disorder|Cognitive Behavior Therapy for Somatization Disorder|Completed||Phase 2|84|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:13:50.592684|2018-06-01 04:13:50.592684
NCT00276874|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2017-04-05|2006-01-11|2006-01-13|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2006||2006-01-31|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Aripiprazole to Reduce Cocaine Relapse|Preventing Cocaine Relapse: Developing Pharmacotherapies|Completed||Phase 1|41|Actual|University of Kentucky||2|||f||||t||||||||||2018-06-01 04:13:50.670482|2018-06-01 04:13:50.670482
NCT00276861|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|2013-01-22||2016-12-14|2006-01-12|2006-01-13|Estimate|2013-01-22|2013-02-26|Estimate||||2016-12-14|2017-02-08|Estimate|September 2005||2005-09-30|December 2016|2016-12-31|May 2008|Actual|2008-05-31|September 2006|Actual|2006-09-30||Interventional|||Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer|Phase II Study of Oxaliplatin And Fixed Rate Infusion Gemcitabine as Second Line Therapy for Patients With Metastatic Colon Cancer|Terminated||Phase 2|10|Actual|University of Miami|Protocol closed prematurely due to low accrual. Only 10 of 27 anticipated patients were enrolled.|||Low Accrual|f||||t||||||||||2018-06-01 04:13:50.769372|2018-06-01 04:13:50.769372
NCT00276848|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2016-09-23|2006-01-12|2006-01-13|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 1999||1999-07-31|September 2016|2016-09-30|July 2007|Actual|2007-07-31|July 2003|Actual|2003-07-31||Interventional|||Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia|Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 3|375|Actual|German CLL Study Group||2|||f||||f||||||||No||2018-06-01 04:13:51.015055|2018-06-01 04:13:51.015055
NCT00276835|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2015-04-08|2006-01-12|2006-01-13|Estimate|||||||2015-04-08|2015-04-10|Estimate|November 2005||2005-11-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|July 2007|Actual|2007-07-31||Interventional|||Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer|A Pilot Study of the Effect of Genistein in Combination With High-Dose Interleukin-2 on Cell Expansion and Gene Expression in Patients With Metastatic Melanoma or Renal Cell Carcinoma|Completed||Early Phase 1|15|Actual|Northwestern University||1|||f||||||||||||||2018-06-01 04:13:51.363759|2018-06-01 04:13:51.363759
NCT00276822|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2012-06-08|2006-01-12|2006-01-13|Estimate|||||||2012-06-08|2012-06-11|Estimate|October 2005||2005-10-31|June 2012|2012-06-30||||November 2006|Actual|2006-11-30||Interventional|||Improving Communication With Patients With Breast Cancer|Facilitating Caring Communication for People With Cancer: The Case of Breast Cancer|Terminated||N/A|30|Actual|Northwestern University||||Preliminary findings did not support purpose.|f||||||||||||||2018-06-01 04:13:51.453004|2018-06-01 04:13:51.453004
NCT00276809|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2016-09-23|2006-01-12|2006-01-13|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2001||2001-06-30|September 2016|2016-09-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia|Campath 1H (Alemtuzumab) Combined With High-Dose Therapy and Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia|Completed||Phase 2|30|Anticipated|German CLL Study Group|||||f||||||||||||||2018-06-01 04:13:51.527621|2018-06-01 04:13:51.527621
NCT00276796|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-05-24|2006-01-12|2006-01-13|Estimate|||||||2013-05-24|2013-05-27|Estimate||||February 2009|2009-02-28||||January 2007|Actual|2007-01-31||Interventional|||Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix|Completed||Phase 2|66|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 04:13:51.632331|2018-06-01 04:13:51.632331
NCT00276783|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2018-02-28|2006-01-12|2006-01-13|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2005||2005-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases|A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases|Active, not recruiting||Phase 2|31|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 04:13:51.70574|2018-06-01 04:13:51.70574
NCT00276770|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2012-12-12|2006-01-12|2006-01-13|Estimate|||||||2012-12-12|2012-12-13|Estimate|February 2006||2006-02-28|December 2012|2012-12-31||||May 2007|Actual|2007-05-31||Interventional|||Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas|NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy Using [F18] Fluorothymidine (FLT) As a Marker of Proliferation in Patients With Primary Brain Tumors|Completed||N/A|12|Actual|University of Washington|||||f||||||||||||||2018-06-01 04:13:51.786609|2018-06-01 04:13:51.786609
NCT00276757|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2014-01-09|2006-01-12|2006-01-13|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2001||2001-04-30|May 2007|2007-05-31|June 2013|Actual|2013-06-30|||||Interventional|||Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis|Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis|Completed||N/A|376|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:51.854155|2018-06-01 04:13:51.854155
NCT00276367|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2015-05-11|2006-01-11|2006-01-13|Estimate|||||||2015-05-11|2015-05-13|Estimate|October 2006||2006-10-31|May 2015|2015-05-31||||||||Observational|||The Impact of Post Discharge One-Time Home Visit: Bridging the Gap Between Hospital and Home.||Withdrawn|||0|Actual|Maimonides Medical Center||||is involved in NIH study|f||||||||||||||2018-06-01 04:13:59.907296|2018-06-01 04:13:59.907296
NCT00276744|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2012-06-06|2006-01-12|2006-01-13|Estimate|||||||2012-06-06|2012-06-08|Estimate|October 2005||2005-10-31|June 2012|2012-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Individualized Drug Treatment Selection Process for Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery|A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer|Completed||Phase 2|85|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:13:51.956656|2018-06-01 04:13:51.956656
NCT00276731|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-09-16|2006-01-12|2006-01-13|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 1995||1995-03-31|January 2006|2006-01-31||||||||Interventional|||Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma|Randomized Study of Radiotherapy in Patients With Stage 2B/3 (INSS) Neuroblastoma in Children Over 1 Year of Age|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:52.030986|2018-06-01 04:13:52.030986
NCT00276718|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-09-16|2006-01-12|2006-01-13|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 1989||1989-04-30|February 2006|2006-02-28||||||||Interventional|||Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors|Germ Cell Tumour Study II|Unknown status|Active, not recruiting|N/A|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:52.115208|2018-06-01 04:13:52.115208
NCT00276705|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-09-16|2006-01-12|2006-01-13|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2005||2005-06-30|June 2009|2009-06-30||||April 2009|Anticipated|2009-04-30||Interventional|||Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer|Hepatocellular Carcinoma Family of Tumours In Children / Adolescents and Young Adults|Unknown status|Active, not recruiting|Phase 2|47|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:52.327761|2018-06-01 04:13:52.327761
NCT00276692|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-06-25|2006-01-12|2006-01-13|Estimate|||||||2013-06-25|2013-06-26|Estimate|August 2003||2003-08-31|June 2009|2009-06-30|July 2009|Actual|2009-07-31|September 2008|Actual|2008-09-30||Interventional|||Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma|Phase II Study of Irinotecan (CPT-11) in Children and Adolescents With High Risk Ewing's Sarcoma|Completed||Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:52.429324|2018-06-01 04:13:52.429324
NCT00276679|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-09-16|2006-01-12|2006-01-13|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2003||2003-04-30|January 2006|2006-01-31|November 2006|Actual|2006-11-30|||||Interventional|||Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma|Phase II Study of Temozolomide (Temodal) in Children Over 1 Year of Age With Relapsed or Refractory High Risk Neuroblastoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:52.52724|2018-06-01 04:13:52.52724
NCT00276666|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-09-16|2006-01-12|2006-01-13|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 2001||2001-11-30|June 2009|2009-06-30||||March 2010|Anticipated|2010-03-31||Interventional|||Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery|Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma|Unknown status|Active, not recruiting|Phase 2|29|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:13:52.617205|2018-06-01 04:13:52.617205
NCT00276640|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2018-04-19|2006-01-12|2006-01-13|Estimate|||||||2018-04-19|2018-04-20|Actual|April 1, 2004|Actual|2004-04-01|April 2018|2018-04-30|May 31, 2017|Actual|2017-05-31|December 31, 2015|Actual|2015-12-31||Interventional|SIOP-LGG-2004||Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas|Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma|Completed||N/A|3417|Actual|Societe Internationale d'Oncologie Pediatrique||4|||f||||t||||||||||2018-06-01 04:13:52.781001|2018-06-01 04:13:52.781001
NCT00276627|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2014-02-05|2006-01-12|2006-01-13|Estimate|||||||2014-02-05|2014-02-06|Estimate|February 2003||2003-02-28|February 2014|2014-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer|Enhancing Patient-Oncologist Communication|Completed||N/A|800|Actual|Duke University||2|||f||||f||||||||||2018-06-01 04:13:52.905421|2018-06-01 04:13:52.905421
NCT00276614|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|2012-03-27||2015-10-28|2006-01-12|2006-01-13|Estimate|2012-03-27|2012-04-19|Estimate||||2015-10-28|2015-11-24|Estimate|April 2006||2006-04-30|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Bortezomib in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients|Completed||Phase 2|4|Actual|Jonsson Comprehensive Cancer Center|Approval of several agents for management of renal cell carcinoma rendered accrual to this trial quite difficult.|1|||f||||t||||||||||2018-06-01 04:13:53.004254|2018-06-01 04:13:53.004254
NCT00276601|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2014-04-16|2006-01-12|2006-01-13|Estimate|||||||2014-04-16|2014-04-17|Estimate|October 2004||2004-10-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|December 2007|Actual|2007-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia|A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia|Completed||Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:13:53.227456|2018-06-01 04:13:53.227456
NCT00276588|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2010-08-05|2006-01-12|2006-01-13|Estimate|||||||2010-08-05|2010-08-09|Estimate|July 2005||2005-07-31|August 2010|2010-08-31||||March 2007|Actual|2007-03-31||Interventional|||Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel) in Patients With Performance Status = 2,3 or Other Significant Co-Morbidity (HIV Infection or s/p Organ Transplantation) in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|46|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:13:53.315544|2018-06-01 04:13:53.315544
NCT00276575|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2014-11-18|2006-01-12|2006-01-13|Estimate|||||||2014-11-18|2014-11-19|Estimate|March 2005||2005-03-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|October 2012|Actual|2012-10-31||Interventional|||Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors|Phase I Study of Bevacizumab in Combination With Everolimus and Erlotinib in Advanced Cancer|Completed||Phase 1|65|Actual|Duke University||1|||f||||||||||||||2018-06-01 04:13:53.401089|2018-06-01 04:13:53.401089
NCT00276549|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|2012-04-26||2013-01-24|2006-01-12|2006-01-13|Estimate|2012-04-26|2012-06-06|Estimate||||2013-01-24|2013-01-31|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer|Phase II Trial of Gemcitabine And Docetaxel In Androgen-Independent Metastatic Prostate Cancer|Completed||Phase 2|35|Actual|Case Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 04:13:53.500516|2018-06-01 04:13:53.500516
NCT00276536|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2015-10-11|2006-01-12|2006-01-13|Estimate|||||||2015-10-11|2015-10-14|Estimate|January 2001||2001-01-31|October 2015|2015-10-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|IFNa||Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma|Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma|Completed||Phase 1|35|Actual|The Cleveland Clinic||1|||f||||t||||||||||2018-06-01 04:13:53.709955|2018-06-01 04:13:53.709955
NCT00276523|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2012-10-29|2006-01-12|2006-01-13|Estimate|||||||2012-10-29|2012-10-31|Estimate|February 2004||2004-02-29|October 2012|2012-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery|A Randomized Phase II Study of SCH 54031 in Surgically Resectable Squamous Cell Tumors of the Head and Neck|Completed||Phase 2|3|Actual|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-06-01 04:13:53.80433|2018-06-01 04:13:53.80433
NCT00276510|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2009-12-14|2006-01-12|2006-01-13|Estimate|||||||2009-12-14|2009-12-15|Estimate|February 2002||2002-02-28|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints|Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70|Completed||Phase 4|2878|Actual|Ipsen||2|||f||||||||||||||2018-06-01 04:13:53.985035|2018-06-01 04:13:53.985035
NCT00276497|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2009-04-03|2006-01-12|2006-01-13|Estimate|||||||2009-04-03|2009-04-06|Estimate|October 2003||2003-10-31|April 2009|2009-04-30|May 2008||2008-05-31|||||Interventional|||Role of Pioglitazone in Preventing Diabetes||Completed||Phase 1|||M.V. Hospital for Diabetes|||||f||||t||||||||||2018-06-01 04:13:55.363913|2018-06-01 04:13:55.363913
NCT00276484|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|2009-02-06||2017-03-08|2006-01-11|2006-01-13|Estimate|2009-03-10|2009-04-13|Estimate||||2017-03-08|2017-04-05|Actual|February 2006||2006-02-28|March 2017|2017-03-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)|A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at High Risk for CHD Not Adequately Controlled on Atorvastatin 40 Mg|Completed||Phase 3|579|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:13:55.44507|2018-06-01 04:13:55.44507
NCT00276471|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2012-01-31|2006-01-12|2006-01-13|Estimate|||||||2012-01-31|2012-02-02|Estimate|December 2005||2005-12-31|January 2012|2012-01-31|June 2007|Actual|2007-06-30|January 2007|Actual|2007-01-31||Interventional|||Evaluation of the Tantalus System in Type 2 Diabetic Subjects|Evaluation of the Tantalus System in Type 2 Diabetic Subjects|Completed||Phase 1|18|Anticipated|Metacure|||||f||||||||||||||2018-06-01 04:13:56.217063|2018-06-01 04:13:56.217063
NCT00276458|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2008-12-18||2017-03-07|2006-01-11|2006-01-13|Estimate|2009-05-14|2009-07-08|Estimate||||2017-03-07|2017-04-04|Actual|February 2006||2006-02-28|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)|A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 Mg|Completed||Phase 3|196|Actual|Merck Sharp & Dohme Corp.|194 out of 196 randomized patients took at least one dose of blinded study therapy and were included in the safety analysis|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:13:56.29382|2018-06-01 04:13:56.29382
NCT00276445|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2006-11-06|2006-01-12|2006-01-13|Estimate|||||||2006-11-06|2006-11-07|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|June 2004||2004-06-30|||||Interventional|||Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan|Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study|Terminated||Phase 4|60||Meiji University of Oriental Medicine|||||f||||||||||||||2018-06-01 04:13:56.856301|2018-06-01 04:13:56.856301
NCT00276432|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2010-01-27|2006-01-11|2006-01-13|Estimate|||||||2010-01-27|2010-01-28|Estimate|November 2005||2005-11-30|January 2010|2010-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Diagnosis and Treatment of Acute Coronary Syndrome in the ED & the Impact of Rapid Bedside cTnl on Outcome.|Diagnosis and Treatment of Acute Coronary Syndrome in the Emergency Department- The Impact of Rapid Bedside cTnl on Outcome.|Completed||Phase 4|350|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:13:56.915549|2018-06-01 04:13:56.915549
NCT00276419|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|2012-11-16||2012-12-13|2006-01-11|2006-01-13|Estimate|2012-11-16|2012-12-13|Estimate||||2012-12-13|2012-12-20|Estimate|June 2005||2005-06-30|December 2012|2012-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin|Topical Diclofenac for the Treatment of Noncyclic Breast Pain|Terminated||Phase 2/Phase 3|25|Actual|Mayo Clinic|This study was terminated early due to lack of funds; the FDA approved a topical form of diclofenac during study, therefore there was no need to continue study of pharmacy-compounded drug.|2||"Lack of funds; FDA approved a topical form of diclofenac during study, no need to continue~   study of pharmacy-compounded drug."|f||||f||||||||||2018-06-01 04:13:56.973803|2018-06-01 04:13:56.973803
NCT00276406|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|2012-11-02||2012-11-02|2006-01-11|2006-01-13|Estimate|2012-11-02|2012-11-30|Estimate||||2012-11-02|2012-11-30|Estimate|May 2006||2006-05-31|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Use of Pyridostigmine for Constipation in Diabetics|Pyridostigmine in Diabetics With Constipation: Randomized, Placebo-controlled, Double-blind Trial|Completed||Phase 1/Phase 2|30|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:13:57.211899|2018-06-01 04:13:57.211899
NCT00276393|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2011-05-20|2006-01-11|2006-01-13|Estimate|||||||2011-05-20|2011-05-23|Estimate|July 2002||2002-07-31|May 2011|2011-05-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes|Randomized Trial Comparing Insulin Glargine to Ultra-Lente Insulin in Type I Diabetes|Completed||Phase 4|22||Mayo Clinic|||||f||||||||||||||2018-06-01 04:13:58.546943|2018-06-01 04:13:58.546943
NCT00276380|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|2017-03-27||2018-02-16|2006-01-12|2006-01-13|Estimate|2018-02-16|2018-02-19|Actual||||2018-02-16|2018-02-19|Actual|February 2003||2003-02-28|February 2018|2018-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke|A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke|Completed||Phase 3|204|Actual|Ipsen||2|||f||||f||||||||No||2018-06-01 04:13:58.650186|2018-06-01 04:13:58.650186
NCT00276354|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2006-05-15|2006-01-12|2006-01-13|Estimate|||||||2006-05-15|2006-05-16|Estimate|December 1999||1999-12-31|May 2006|2006-05-31||||||||Interventional|||Study of Long-Term Use of Forlax® in Elderly Patients With Chronic Constipation|Tolerance of Long Term Administration of Forlax® 10g in Elderly Ambulatory or Institutionalized Patients Suffering From Chronic Constipation. Single Blind Randomised Lactulose-Controlled Study With Individual Expected Benefit.|Completed||Phase 4|240||Ipsen|||||f||||||||||||||2018-06-01 04:13:59.984481|2018-06-01 04:13:59.984481
NCT00276341|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2006-05-15|2006-01-12|2006-01-13|Estimate|||||||2006-05-15|2006-05-16|Estimate|August 2003||2003-08-31|May 2006|2006-05-31||||||||Interventional|||Study on the Effectiveness of EGb 761® Vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis|Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-Blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.|Completed||Phase 3|240||Ipsen|||||f||||||||||||||2018-06-01 04:14:00.341899|2018-06-01 04:14:00.341899
NCT00276328|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2007-01-16|2006-01-12|2006-01-13|Estimate|||||||2007-01-16|2007-01-18|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults|Efficacy of Diosmectite (Smecta®) in the Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomised, Double Blind, Placebo Controlled, Parallel Groups Study.|Completed||Phase 4|280||Ipsen|||||f||||||||||||||2018-06-01 04:14:00.469784|2018-06-01 04:14:00.469784
NCT00276315|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2007-07-23|2006-01-12|2006-01-13|Estimate|||||||2007-07-23|2007-07-25|Estimate|December 2005||2005-12-31|July 2007|2007-07-31|January 2007|Actual|2007-01-31|||||Interventional|||Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm|A Phase III, Multicentre, Randomised, Assessor-Blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm|Completed||Phase 3|348||Ipsen|||||f||||||||||||||2018-06-01 04:14:00.591182|2018-06-01 04:14:00.591182
NCT00276302|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2011-01-05|2006-01-11|2006-01-13|Estimate|||||||2011-01-05|2011-01-06|Estimate|December 2005||2005-12-31|January 2011|2011-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)|A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Either Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) or Advanced or Metastatic Soft Tissue Sarcomas (STS)|Completed||Phase 1|63|Actual|Infinity Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 04:14:00.658152|2018-06-01 04:14:00.658152
NCT00276289|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2009-12-02|2006-01-11|2006-01-13|Estimate|||||||2009-12-02|2009-12-03|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics|Spironolactone to Decrease Potassium Wasting in Hypercalciuric Patients Treated With Thiazide Diuretics|Completed||N/A|10|Anticipated|Indiana University|||||f||||||||||||||2018-06-01 04:14:00.731829|2018-06-01 04:14:00.731829
NCT00276276|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2013-04-11|2006-01-11|2006-01-13|Estimate|||||||2013-04-11|2013-04-15|Estimate|November 2000||2000-11-30|November 2012|2012-11-30||||||||Interventional|||Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer|An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control Alone or in Combination With Oral Topotecan in Patients With Relapsed Resistant SCLC|Completed||Phase 3|141||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:14:00.792828|2018-06-01 04:14:00.792828
NCT00276263|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2014-06-03|2006-01-12|2006-01-13|Estimate|||||||2014-06-03|2014-06-04|Estimate|August 2006||2006-08-31|June 2014|2014-06-30|June 2009||2009-06-30|||||Interventional|||Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia|Sarcosine (N-methylglycine) Trial for Individuals At Risk for Developing Schizophrenia and Related Disorders|Withdrawn||Phase 2|0|Actual|Herzog Hospital||1||lack of participants|f||||t||||||||||2018-06-01 04:14:00.881368|2018-06-01 04:14:00.881368
NCT00276250|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|2016-04-25||2016-06-16|2006-01-12|2006-01-13|Estimate|2016-06-16|2016-07-27|Estimate||||2016-06-16|2016-07-27|Estimate|December 2005||2005-12-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Islet Transplantation Using Abatacept|Development of Immunosuppression Regimens to Facilitate Single Donor Islet Transplantation Using Abatacept|Completed||Phase 2|5|Actual|Emory University|Enrollment in this study was limited by the removal of Efalizumab from the market in 2009 after patients (external to this study) being treated for plaque psoriasis were diagnosed with Progressive Multifocal Leukoencephalopathy (PML).|3|||f||||t||||||||||2018-06-01 04:14:01.105844|2018-06-01 04:14:01.105844
NCT00276237|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2013-11-25|2006-01-12|2006-01-13|Estimate|||||||2013-11-25|2013-11-26|Estimate|July 2005||2005-07-31|November 2013|2013-11-30|November 2005|Actual|2005-11-30|||||Observational|||Outcomes Following Pulmonary Valve Replacement in Adults|Review of Outcomes Following Pulmonary Valve Replacement for Congenital Heart Disease in Adults|Completed|||300||Emory University|||||f||||||||||||||2018-06-01 04:14:01.577814|2018-06-01 04:14:01.577814
NCT00276224|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2007-10-30|2006-01-12|2006-01-13|Estimate|||||||2007-10-30|2007-10-31|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|April 2006||2006-04-30|||||Interventional|||Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia|Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia|Completed||N/A|480||DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 04:14:01.636855|2018-06-01 04:14:01.636855
NCT00276211|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2009-01-27|2006-01-12|2006-01-13|Estimate|||||||2009-01-27|2009-01-28|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|December 2006|Actual|2006-12-31|||||Observational|||Diffusion Weighted MRI for Lymphnodes in the Axilla|Diffusionsvægtet MR Skanning Med Henblik på axillære Lymfeknudemetastaser Hos Patienter Med primær Mammacancer - et Pilotstudie|Completed|||10|Anticipated|Copenhagen University Hospital at Herlev|||||f||||||||||||||2018-06-01 04:14:01.711524|2018-06-01 04:14:01.711524
NCT00276198|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2008-04-15|2006-01-11|2006-01-13|Estimate|||||||2008-04-15|2008-04-16|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants|Controlled Clinical Trial to Assess the Effect of Multiple Micronutrient Supplementation (Iron, Vitamins A, C, D, Folic Acid and Zinc) on Nutritional and Health Indicators in Infants in Southern Israel.|Completed||Phase 3|771|Anticipated|Soroka University Medical Center||3|||f||||f||||||||||2018-06-01 04:14:01.767997|2018-06-01 04:14:01.767997
NCT00276185|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-12|||2011-01-18|2006-01-12|2006-01-13|Estimate|||||||2011-01-18|2011-01-19|Estimate|December 2005||2005-12-31|January 2011|2011-01-31|December 2009|Anticipated|2009-12-31|January 2009|Anticipated|2009-01-31||Interventional|||HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke|Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke|Unknown status|Recruiting|Phase 3|180|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 04:14:01.865682|2018-06-01 04:14:01.865682
NCT00276172|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2009-06-19|2006-01-12|2006-01-13|Estimate|||||||2009-06-19|2009-06-22|Estimate|December 2003||2003-12-31|June 2009|2009-06-30|January 2006|Actual|2006-01-31|October 2005|Actual|2005-10-31||Interventional|||Open-Label Natalizumab Safety Extension Study|An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803|Completed||Phase 3|1615|Actual|Biogen||1|||f||||f||||||||||2018-06-01 04:14:01.964123|2018-06-01 04:14:01.964123
NCT00276159|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|2010-03-02|2009-04-06|2017-12-03|2006-01-11|2006-01-13|Estimate|2010-04-14|2010-05-05|Estimate|2010-04-14|2010-05-05|Estimate|2017-12-03|2017-12-28|Actual|January 2006||2006-01-31|July 2010|2010-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Immune Response Modifier in the Treatment of Hematologic Malignancies|Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment|Terminated||Phase 2|6|Actual|Masonic Cancer Center, University of Minnesota||1||Drug was not available.|f||||t||||||||||2018-06-01 04:14:02.038381|2018-06-01 04:14:02.038381
NCT00276146|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2013-08-05|2006-01-11|2006-01-13|Estimate|||||||2013-08-05|2013-08-07|Estimate|May 2005||2005-05-31|August 2013|2013-08-31||||||||Interventional|||Dipyridamole/Magnesium To Improve Sickle Cell Hydration|Dipyridamole/Magnesium To Improve Sickle Cell Hydration|Withdrawn||Phase 2|0|Actual|Children's Hospital Medical Center, Cincinnati||||The NHLBI BSMB recommended closure due to poor enrollment.|f||||t||||||||||2018-06-01 04:14:02.208135|2018-06-01 04:14:02.208135
NCT00276133|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2007-05-08|2006-01-11|2006-01-12|Estimate|||||||2007-05-08|2007-05-09|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Effects of Atorvastatin Versus Probucol on Small Dense LDL|Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy|Completed||Phase 4|24|Actual|Yokohama City University Medical Center|||||f||||t||||||||||2018-06-01 04:14:02.275469|2018-06-01 04:14:02.275469
NCT00276120|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2018-04-05|2006-01-10|2006-01-12|Estimate|||||||2018-04-05|2018-04-09|Actual|March 2005||2005-03-31|February 2018|2018-02-28|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Observational|||Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer|Identification of Novel Genetic Risk Factors That Contribute to the Risk for Breast Cancer|Recruiting|||5000|Anticipated|Ohio State University Comprehensive Cancer Center|||||f||||f||||||Samples With DNA|"~     Blood specimens.~   "|||2018-06-01 04:14:02.332512|2018-06-01 04:14:02.332512
NCT00276107|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2009-07-28|2006-01-11|2006-01-12|Estimate|||||||2009-07-28|2009-07-29|Estimate|December 2004||2004-12-31|July 2009|2009-07-31|December 2005||2005-12-31|||||Interventional|||Study Evaluating Prevenar Vaccine in Healthy Infants|An Open-Label Trial of the Immunogenicity and Safety of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine [Diphteria CRM197 Protein Conjugate]) in Healthy Infants at 2, 4 and 6 Months of Age|Completed||Phase 4|200||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:14:02.39329|2018-06-01 04:14:02.39329
NCT00276094|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2013-03-20||2013-05-21|2006-01-10|2006-01-12|Estimate|2013-05-21|2013-06-28|Estimate||||2013-05-21|2013-06-28|Estimate|January 2006||2006-01-31|March 2013|2013-03-31|December 2007|Actual|2007-12-31|||||Interventional|||A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women|Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo|Completed||Phase 3|826|Actual|Shionogi Inc.||3|||||||||||||||||2018-06-01 04:14:02.479709|2018-06-01 04:14:02.479709
NCT00276081|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2006-11-27|2006-01-11|2006-01-12|Estimate|||||||2006-11-27|2006-11-28|Estimate|May 2002||2002-05-31|January 2006|2006-01-31|September 2004||2004-09-30|||||Interventional|||Gabapentin Versus Estrogen for the Treatment of Hot Flashes|A Randomized Trial of Gabapentin, Estrogen and Placebo for the Treatment of Postmenopausal Hot Flashes|Completed||Phase 4|60||University of Rochester|||||||||||||||||||2018-06-01 04:14:03.946962|2018-06-01 04:14:03.946962
NCT00276068|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2007-11-12|2006-01-11|2006-01-12|Estimate|||||||2007-11-12|2007-11-14|Estimate|August 2002||2002-08-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Vulvar Vestibulitis Clinical Trial: Desipramine-Lidocaine|Vulvar Vestibulitis Trial: Desipramine-Lidocaine|Completed||N/A|128|Anticipated|University of Rochester|||||f||||t||||||||||2018-06-01 04:14:04.017975|2018-06-01 04:14:04.017975
NCT00276055|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2015-06-17|2006-01-11|2006-01-12|Estimate|||||||2015-06-17|2015-06-19|Estimate|November 2005||2005-11-30|June 2015|2015-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma|Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma|Completed||Phase 1|38|Actual|New Mexico Cancer Care Alliance||3|||f||||t||||||||||2018-06-01 04:14:04.10548|2018-06-01 04:14:04.10548
NCT00276042|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2008-02-01|2006-01-10|2006-01-12|Estimate|||||||2008-02-01|2008-02-08|Estimate|January 2006||2006-01-31|February 2008|2008-02-29||||January 2007|Actual|2007-01-31||Interventional|||A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media|Prospective, Randomized, Investigator-Blind Trial to Evaluate the Bacteriologic Eradication, Safety and Tolerability, and Pharmacokinetics of Different Dosages of Faropenem Medoxomil BID for 10 Days in the Treatment of Acute Otitis Media|Completed||Phase 2|328|Actual|Replidyne|||||f||||f||||||||||2018-06-01 04:14:04.18492|2018-06-01 04:14:04.18492
NCT00276029|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2006-05-03|2006-01-10|2006-01-12|Estimate|||||||2006-05-03|2006-05-04|Estimate|December 2003||2003-12-31|September 2004|2004-09-30|September 2004||2004-09-30|||||Interventional|||TNF Alpha in Refractory Asthma|The Efficacy of a Soluble Ligand Binding Tumour Necrosis Factor Receptor, Etanercept, in Severe, Steroid Dependant Asthma: a Randomised Controlled Study|Completed||N/A|10||University Hospitals, Leicester|||||f||||||||||||||2018-06-01 04:14:04.243102|2018-06-01 04:14:04.243102
NCT00276016|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|2010-04-01||2015-09-25|2006-01-11|2006-01-12|Estimate|2010-07-02|2010-07-29|Estimate||||2015-09-25|2015-09-28|Estimate|January 2006||2006-01-31|September 2015|2015-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)|Crossover Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber|Completed||Phase 3|39|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 04:14:04.324852|2018-06-01 04:14:04.324852
NCT00276003|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2010-01-06|2006-01-11|2006-01-12|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2002||2002-08-31|December 2009|2009-12-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.|INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.|Completed||Phase 2|22|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:14:04.622783|2018-06-01 04:14:04.622783
NCT00275990|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2014-10-08|2006-01-11|2006-01-12|Estimate|||||||2014-10-08|2014-10-09|Estimate|December 2005||2005-12-31|October 2014|2014-10-31|August 2010|Actual|2010-08-31|October 2009|Actual|2009-10-31||Interventional|||AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction|AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients Undergoing Primary PCI for Acute Myocardial Infarction: [JETSTENT] Study|Completed||Phase 4|501|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 04:14:04.784687|2018-06-01 04:14:04.784687
NCT00275977|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-07-22|2006-01-10|2006-01-12|Estimate|||||||2010-07-22|2010-07-23|Estimate|February 2006||2006-02-28|January 2006|2006-01-31|March 2007||2007-03-31|||||Interventional|||Treatment of Myocardial Infarction With Bone Marrow Derived Stem Cells|Treatment of Myocardial Infarction With Autologous Bone Marrow Derived Stem Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:14:04.864488|2018-06-01 04:14:04.864488
NCT00275964|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2008-10-23|2006-01-11|2006-01-12|Estimate|||||||2008-10-23|2008-10-24|Estimate|February 2004||2004-02-29|June 2005|2005-06-30|September 2004||2004-09-30|||||Observational|||Development of Active Safety Surveillance System for Traditional Chinese Medicine||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:14:04.934198|2018-06-01 04:14:04.934198
NCT00275951|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2012-11-15|2006-01-11|2006-01-12|Estimate|||||||2012-11-15|2012-11-16|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|FLAG||Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer|Phase II Study of Cetuximab Plus P-HDFL(Cisplatin and Weekly 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin)for the First-line Treatment of Advanced Gastric Cancer|Completed||Phase 2|39|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 04:14:04.981148|2018-06-01 04:14:04.981148
NCT00275938|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2006-01-11|2006-01-11|2006-01-12|Estimate|||||||2006-01-11|2006-01-12|Estimate|October 1998||1998-10-31|January 2006|2006-01-31|June 2001||2001-06-30|||||Interventional|||Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B|A Pilot Study Of Interferon Alpha 2b Plus Ribavirin In The Treatment Of Patients With Chronic Hepatitis B|Completed||Phase 2/Phase 3|120||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:14:05.050368|2018-06-01 04:14:05.050368
NCT00275925|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2007-11-29|2006-01-11|2006-01-12|Estimate|||||||2007-11-29|2007-11-30|Estimate|December 2005||2005-12-31|November 2007|2007-11-30|March 2007|Actual|2007-03-31|||||Interventional|||Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures|A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures|Completed||Phase 4|80||Novartis|||||f||||||||||||||2018-06-01 04:14:05.103999|2018-06-01 04:14:05.103999
NCT00275912|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2017-02-20|2006-01-11|2006-01-12|Estimate|||||||2017-02-20|2017-02-23|Actual|September 11, 2006|Actual|2006-09-11|February 2017|2017-02-28|September 28, 2007|Actual|2007-09-28|September 28, 2007|Actual|2007-09-28||Interventional|||Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures|A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures|Completed||Phase 4|60|Actual|Novartis|||||f||||f||||||||||2018-06-01 04:14:05.167163|2018-06-01 04:14:05.167163
NCT00275899|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2006-01-11|2006-01-11|2006-01-12|Estimate|||||||2006-01-11|2006-01-12|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|December 2007||2007-12-31|||||Observational|||Role of DcR3 in T Cell Activation in SLE and RA|Role of DcR3 in T Cell Activation in SLE and RA|Unknown status|Recruiting||450||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:14:05.226264|2018-06-01 04:14:05.226264
NCT00275886|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2006-01-11|2006-01-11|2006-01-12|Estimate|||||||2006-01-11|2006-01-12|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|December 2008||2008-12-31|||||Observational|||Activation and Recruitment of GIL During Hp Infection|Activation and Recruitment of Gastric Infiltrating Lymphocytes During H. Pylori Infection|Unknown status|Recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:14:05.274401|2018-06-01 04:14:05.274401
NCT00275834|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2012-12-10||2016-11-15|2006-01-11|2006-01-12|Estimate|2012-12-10|2013-01-16|Estimate||||2016-11-15|2017-01-12|Estimate|January 2006||2006-01-31|November 2016|2016-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Zonisamide for Weight Reduction in Obese Adults|Zonisamide for Weight Reduction in Obese Adults|Completed||N/A|225|Actual|Duke University||3|||f||||t||||||||||2018-06-01 04:14:05.541163|2018-06-01 04:14:05.541163
NCT00275821|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|2010-12-20||2011-02-22|2006-01-11|2006-01-12|Estimate|2011-02-22|2011-03-16|Estimate||||2011-02-22|2011-03-16|Estimate|December 2005||2005-12-31|February 2011|2011-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|EXCITE||Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|A Randomized, Double-masked, Active-controlled, Multi-center Study Comparing the Efficacy and Safety of Ranibizumab Administered as Two Dosing Regimens in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Completed||Phase 3|353|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:14:05.99525|2018-06-01 04:14:05.99525
NCT00275795|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2006-10-31|2006-01-10|2006-01-12|Estimate|||||||2006-10-31|2006-11-01|Estimate|July 2005||2005-07-31|April 2006|2006-04-30|January 2006||2006-01-31|||||Observational|||NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®|Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST-NAET®|Completed|||42||Nambudripad's Allergy Research Foundation|||||f||||||||||||||2018-06-01 04:14:06.713813|2018-06-01 04:14:06.713813
NCT00275769|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2008-12-10|2006-01-11|2006-01-12|Estimate|||||||2008-12-10|2008-12-11|Estimate|March 2004||2004-03-31|December 2008|2008-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||CAPTURE - Complete Automatic Pacing Threshold Utilization Recorded by EnPulse|Complete Automatic Pacing Threshold Utilization Recorded by EnPulse|Completed||N/A|860||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:14:06.805225|2018-06-01 04:14:06.805225
NCT00275756|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2014-11-20|2006-01-11|2006-01-12|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2008||2008-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans|Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans|Withdrawn||N/A|0|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-06-01 04:14:06.940604|2018-06-01 04:14:06.940604
NCT00275743|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2009-04-27|2006-01-10|2006-01-12|Estimate|||||||2009-04-27|2009-04-29|Estimate|October 2005||2005-10-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Use of MRI for Assessing Stomach Relaxation in Response to a Meal|Dynamic MRI - A Novel Approach for Measuring Gastric Accommodation|Completed||Phase 1|50|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:07.017984|2018-06-01 04:14:07.017984
NCT00275730|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2007-02-09|2006-01-11|2006-01-12|Estimate|||||||2007-02-09|2007-02-12|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|August 2006||2006-08-31|||||Interventional|||Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers|Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers|Completed||N/A|12||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:14:07.077343|2018-06-01 04:14:07.077343
NCT00275717|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-12-20|2006-01-10|2006-01-12|Estimate|||||||2010-12-20|2010-12-22|Estimate|March 2005||2005-03-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||A Study That Will Look at the Impact of Immunosuppression on Antibody Production in Kidney Transplant Recipients.|The Effects of Thymoglobulin on Antibody Screening Cells.|Completed|||60|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:07.132105|2018-06-01 04:14:07.132105
NCT00275704|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-06-09|2006-01-10|2006-01-12|Estimate|||||||2011-06-09|2011-06-10|Estimate|May 2005||2005-05-31|June 2011|2011-06-30||||June 2006|Actual|2006-06-30||Interventional|||Flaxseed for the Treatment of Hot Flashes|Phase II Evaluation of Flaxseed for the Treatment of Hot Flashes|Completed||Phase 2|30||Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:07.183687|2018-06-01 04:14:07.183687
NCT00275691|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-01-15|2006-01-10|2006-01-12|Estimate|||||||2010-01-15|2010-01-18|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR|Evaluation of Respiratory Specimens for Bacterial and Viral Pathogens by Real-Time PCR|Completed|||867|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:07.23795|2018-06-01 04:14:07.23795
NCT00275678|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-06-02|2006-01-10|2006-01-12|Estimate|||||||2010-06-02|2010-06-03|Estimate|November 2003||2003-11-30|June 2010|2010-06-30||||September 2009|Actual|2009-09-30||Interventional|||Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies|A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From HLA Compatible Unrelated Donors.|Completed||Phase 3|15|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:07.285953|2018-06-01 04:14:07.285953
NCT00275665|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-12-16|2006-01-10|2006-01-12|Estimate|||||||2011-12-16|2011-12-19|Estimate|November 2001||2001-11-30|December 2011|2011-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.|A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.|Completed||Phase 3|20|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 04:14:07.34097|2018-06-01 04:14:07.34097
NCT00275652|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-03-22|2006-01-10|2006-01-12|Estimate|||||||2011-03-22|2011-03-23|Estimate|June 2004||2004-06-30|March 2011|2011-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.|A Randomized, Double-Blind Trial of Telbivudine (LdT) Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.|Completed||Phase 3|6||Mayo Clinic|||||||||||||||||||2018-06-01 04:14:07.402142|2018-06-01 04:14:07.402142
NCT00275639|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2012-01-04|2006-01-10|2006-01-12|Estimate|||||||2012-01-04|2012-01-06|Estimate|December 2004||2004-12-31|January 2012|2012-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant|A Randomized, Double-blinded, Placebo-controlled Study of Angiotensin II Receptor Blockade to Prevent Renal Dysfunction Following Liver Transplantation.|Completed||Phase 4|62|Anticipated|Mayo Clinic|||||||||||||||||||2018-06-01 04:14:07.461665|2018-06-01 04:14:07.461665
NCT00275613|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-01-15|2006-01-10|2006-01-12|Estimate|||||||2013-01-15|2013-01-16|Estimate|November 2005||2005-11-30|January 2013|2013-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis|Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis|Completed||Phase 1|10|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 04:14:07.669558|2018-06-01 04:14:07.669558
NCT00275600|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2009-11-25|2006-01-10|2006-01-12|Estimate|||||||2009-11-25|2009-11-26|Estimate|January 2003||2003-01-31|November 2009|2009-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Randomized Clinical Trial of Vitamin E and Evening Oil of Primrose for the Managment of Breast Pain|Randomized Clinical Trial of Vitamin E and Evening Oil of Primrose for the Managment of Cyclical Breast Pain|Completed||Phase 2/Phase 3|82|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:07.747298|2018-06-01 04:14:07.747298
NCT00275587|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-03-21|2006-01-10|2006-01-12|Estimate|||||||2011-03-21|2011-03-23|Estimate|January 2005||2005-01-31|March 2011|2011-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Development of a Hospital Service That Uses Critical Pathway (Protocolized) Care Plans to Provide High-Quality, High-Reliability, Evidence-Based Medical Care|Development of Critical Pathway Care for Hospitalized Patients Using Principles of Patient-Centered Quality Care, Evidence-Based Medicine, and High Reliability Organizational Structure|Completed|||348|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:07.80774|2018-06-01 04:14:07.80774
NCT00275574|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2015-12-30|2006-01-10|2006-01-12|Estimate|||||||2015-12-30|2016-01-01|Estimate|April 2003||2003-04-30|December 2015|2015-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Acupuncture for Non-cyclical Breast Pain|Acupuncture for the Treatment of Non-Cyclical Breast Pain|Completed||N/A|30|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 04:14:07.862994|2018-06-01 04:14:07.862994
NCT00275561|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2011-11-03||2012-05-01|2006-01-10|2006-01-12|Estimate|2011-11-03|2011-12-08|Estimate||||2012-05-01|2012-05-08|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Topical Steroid Treatment for Eosinophilic Esophagitis|A Randomized Placebo-controlled Trial of Swallowed Fluticasone in Treatment of Eosinophilic Esophagitis|Completed||Phase 2|42|Actual|Mayo Clinic|The relatively small sample size; unexpected high dropout rate in the placebo group; study commenced before the consensus definition of EoE advising exclusion of gastroesophageal reflux disease (GERD) was established.|2|||f||||f||||||||||2018-06-01 04:14:07.947345|2018-06-01 04:14:07.947345
NCT00275548|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-11-09|2006-01-10|2006-01-12|Estimate|||||||2011-11-09|2011-11-11|Estimate|July 2004||2004-07-31|November 2011|2011-11-30|April 2009|Actual|2009-04-30|June 2007|Actual|2007-06-30||Interventional|||Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C|A Prospective, Randomized, Multi-center, Open-label, Comparative Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon Alfa-2a(Pegasys) Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C.|Completed||Phase 4|12|Actual|Mayo Clinic||2|||f||||||||||||||2018-06-01 04:14:08.239203|2018-06-01 04:14:08.239203
NCT00275340|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2009-01-28||2009-06-05|2006-01-10|2006-01-11|Estimate|2009-06-05|2009-06-08|Estimate||||2009-06-05|2009-06-08|Estimate|February 2006||2006-02-28|April 2009|2009-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Cardiac Home Education and Support Trial (CHEST): A Pilot Study|A Pilot Trial of a Home-Based Peer Support Program After Coronary Artery Bypass Graft Surgery|Completed||Phase 1|101|Actual|University of Toronto|||||f||||f||||||||||2018-06-01 04:14:10.143649|2018-06-01 04:14:10.143649
NCT00275535|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-12-06|2006-01-10|2006-01-12|Estimate|||||||2011-12-06|2011-12-08|Estimate|April 2001||2001-04-30|December 2011|2011-12-31|December 2008|Actual|2008-12-31|November 2007|Actual|2007-11-30||Interventional|||The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients|A Prospective, Randomized Trial of Calcineurin-Inhibitor Withdrawal in Renal Allograft Recipients|Completed||Phase 4|165|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:14:08.378597|2018-06-01 04:14:08.378597
NCT00275522|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-01-19|2006-01-10|2006-01-12|Estimate|||||||2010-01-19|2010-01-20|Estimate|December 2005||2005-12-31|January 2010|2010-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.|A Randomized Open-label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens With a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients.|Completed||Phase 4|16|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:08.49404|2018-06-01 04:14:08.49404
NCT00275509|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2017-11-20||2017-12-19|2006-01-10|2006-01-12|Estimate|2017-11-20|2017-12-20|Actual||||2017-12-19|2018-01-18|Actual|January 2007|Actual|2007-01-31|December 2017|2017-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch|Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch|Completed||Phase 3|56|Actual|Johns Hopkins University||2|||f||||||||||||||2018-06-01 04:14:08.614645|2018-06-01 04:14:08.614645
NCT00275496|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2015-09-01|2006-01-10|2006-01-12|Estimate|||||||2015-09-01|2015-09-02|Estimate|November 1993||1993-11-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Multicenter Selective Lymphadenectomy Trial (MSLT)|A Clinical Study of Wide Excision Alone Versus Wide Excision With Intraoperative Lymphatic Mapping and Selective Lymph Node Dissection in the Treatment of Patients With Cutaneous Invasive Melanoma.|Completed||Phase 3|2001|Actual|John Wayne Cancer Institute||3|||f||||t||||||||||2018-06-01 04:14:08.996196|2018-06-01 04:14:08.996196
NCT00275483|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2008-05-27|2006-01-10|2006-01-12|Estimate|||||||2008-05-27|2008-05-28|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|February 2007|Actual|2007-02-28|October 2005|Actual|2005-10-31||Interventional|||Prevention of Postoperative Nausea and Vomiting (PONV) by Acupressure|Prevention of PONV by Acupressure. A Study of the Effect of a Recently Generated Danish Bracelet Vital-Band(R) Which Stimulates the Acupressure Point P6|Completed||Phase 4|132|Actual|Herlev Hospital|||||f||||||||||||||2018-06-01 04:14:09.063734|2018-06-01 04:14:09.063734
NCT00275457|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-11|||2013-10-30|2006-01-11|2006-01-12|Estimate|||||||2013-10-30|2013-10-31|Estimate|October 2002||2002-10-31|October 2013|2013-10-31|April 2004||2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients|A Randomised, Double-blind, Placebo-controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Followed by 46 Weeks Open-label or Double-blind Treatment Period|Completed||Phase 3|346||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:09.125744|2018-06-01 04:14:09.125744
NCT00275444|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-11-04|2006-01-11|2006-01-12|Estimate|||||||2013-11-04|2013-11-05|Estimate|March 2002||2002-03-31|November 2013|2013-11-30||||January 2003|Actual|2003-01-31||Interventional|||3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study|Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects|Completed||Phase 2|216|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:09.244218|2018-06-01 04:14:09.244218
NCT00275431|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10||2010-08-12|2011-06-24|2006-01-10|2006-01-12|Estimate||||2010-08-12|2010-08-17|Estimate|2011-06-24|2011-06-29|Estimate|November 2005||2005-11-30|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies|A Phase II, Open Label, Multicenter Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)|Completed||Phase 2|50|Actual|Ascenta Therapeutics|||||f||||||||||||||2018-06-01 04:14:09.374115|2018-06-01 04:14:09.374115
NCT00275418|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2006-01-10|2006-01-10|2006-01-12|Estimate|||||||2006-01-10|2006-01-12|Estimate|July 2002||2002-07-31|January 2006|2006-01-31||||||||Interventional|||Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease|Double-Blind Randomized Prospective Trial of Treatment With Natural Beta Carotene Vs. Placebo for Patients With Crohn's Disease in Remission|Unknown status|Recruiting|Phase 3|300||Bnai Zion Medical Center|||||f||||||||||||||2018-06-01 04:14:09.446207|2018-06-01 04:14:09.446207
NCT00275405|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2007-03-19|2006-01-10|2006-01-12|Estimate|||||||2007-03-19|2007-03-20|Estimate|April 2006||2006-04-30|March 2007|2007-03-31|March 2007|Anticipated|2007-03-31|||||Interventional|||Effect of Garlic on Inflammatory Mediators|Effect of Garlic Oil Macerate on Inflammatory Mediators in Healthy Normal Weight and Obese Subjects.|Suspended||Phase 4|34||Albany Medical College||||Results inconclusive|f||||||||||||||2018-06-01 04:14:09.506022|2018-06-01 04:14:09.506022
NCT00275392|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2014-09-17||2014-12-05|2006-01-10|2006-01-11|Estimate|2014-10-09|2014-10-17|Estimate||||2014-12-05|2014-12-09|Estimate|April 2006||2006-04-30|December 2014|2014-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Vestibular Rehabilitation and Dizziness in Geriatric Patients|Vestibular Rehabilitation and Dizziness in Geriatric Patients|Completed||N/A|39|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:14:09.56222|2018-06-01 04:14:09.56222
NCT00275379|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2007-03-14|2006-01-09|2006-01-11|Estimate|||||||2007-03-14|2007-03-15|Estimate|August 2006||2006-08-31|March 2007|2007-03-31||||||||Interventional|||Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Exploratory Study of Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis|Terminated||N/A|60||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:14:09.777521|2018-06-01 04:14:09.777521
NCT00275366|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2008-03-10|2006-01-10|2006-01-11|Estimate|||||||2008-03-10|2008-03-11|Estimate|July 2005||2005-07-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Arm Robotics in Musculoskeletal Rehabilitation|Upper Extremity Robotics in Musculoskeletal Rehabilitation|Completed||N/A|20|Anticipated|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 04:14:09.846916|2018-06-01 04:14:09.846916
NCT00275353|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2006-05-25|2006-01-10|2006-01-11|Estimate|||||||2006-05-25|2006-05-26|Estimate|July 2003||2003-07-31|January 2006|2006-01-31|February 2006||2006-02-28|||||Interventional|||Effectiveness of an Individualized Symptom Education Program (ISEP)|Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer.|Completed||Phase 2|144||University of Toronto|||||f||||||||||||||2018-06-01 04:14:10.062943|2018-06-01 04:14:10.062943
NCT00275327|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2015-12-16|2006-01-09|2006-01-11|Estimate|||||||2015-12-16|2015-12-17|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria|Mechanisms of Resistance and Molecular Epidemiology of Commonly Encountered Multi-Resistant Bacteria|Completed|||300|Anticipated|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 04:14:10.450212|2018-06-01 04:14:10.450212
NCT00275314|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2015-12-16|2006-01-09|2006-01-11|Estimate|||||||2015-12-16|2015-12-17|Estimate|February 2006||2006-02-28|December 2015|2015-12-31|April 2006||2006-04-30|||||Interventional|||WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients|WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients, Sponsor Protocol Dated 8/11/2005 and Investigator Brochure Version August 2005|Terminated||Phase 3|5||University of Pittsburgh||||Study never started at our site Funding issue|||||||||||||||2018-06-01 04:14:10.512573|2018-06-01 04:14:10.512573
NCT00275301|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2013-08-14||2017-04-17|2006-01-10|2006-01-11|Estimate|2017-04-17|2017-05-23|Actual||||2017-04-17|2017-05-23|Actual|December 2005||2005-12-31|April 2017|2017-04-30|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional||19 subjects were enrolled.|PET Imaging and Olanzapine Treatment in Borderline Personality Disorder|Brain Correlates of Olanzapine Treatment Response in BPD|Completed||N/A|19|Actual|University of Minnesota - Clinical and Translational Science Institute|Small number of subjects (14) analyzed. 19 subjects were enrolled but 5 subjects withdrew early from the study.|1|||f||||f||||||||||2018-06-01 04:14:10.597018|2018-06-01 04:14:10.597018
NCT00275288|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-11-01|2006-01-10|2006-01-11|Estimate|||||||2010-11-01|2010-11-02|Estimate|January 2005||2005-01-31|November 2010|2010-11-30|June 2007|Actual|2007-06-30|||||Observational|||MRI Imaging in Borderline Personality Disorder|"Brain Correlates Of Affect Regulation In BPD"|Completed|||20|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-06-01 04:14:10.837146|2018-06-01 04:14:10.837146
NCT00275275|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|2012-05-02||2012-07-21|2006-01-09|2006-01-11|Estimate|2012-07-21|2012-08-24|Estimate||||2012-07-21|2012-08-24|Estimate|January 2006||2006-01-31|July 2012|2012-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pramipexole Conversion to Ropinirole Controlled Release (CR)|An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease.|Completed||Phase 3|61|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-06-01 04:14:10.919659|2018-06-01 04:14:10.919659
NCT00275262|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|2010-02-05||2010-04-09|2006-01-10|2006-01-11|Estimate|2010-04-09|2010-05-06|Estimate||||2010-04-09|2010-05-06|Estimate|February 2006||2006-02-28|April 2010|2010-04-30||||February 2009|Actual|2009-02-28||Interventional|||A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation|Leuprolide Acetate to Enhance Immune Function Post-Autologous Stem Cell Transplantation|Terminated||Phase 2|25|Actual|Abbott|The study was terminated early because of slow enrollment. For the primary endpoint, changes from baseline within each treatment group were analyzed. Between treatment group comparisons were not performed because the sample size was too small.|2|||f||||f||||||||||2018-06-01 04:14:11.22135|2018-06-01 04:14:11.22135
NCT00275249|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2011-04-12|2006-01-09|2006-01-11|Estimate|||||||2011-04-12|2011-04-14|Estimate|March 2001||2001-03-31|March 2011|2011-03-31|December 2005|Actual|2005-12-31|October 2004|Actual|2004-10-31||Interventional|||Evolution of Analgesic Tolerance With Opioids|Evolution of Analgesic Tolerance During Long Term Treatment of Chronic Pain With Opioids|Completed||N/A|60||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:14:11.661804|2018-06-01 04:14:11.661804
NCT00275236|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2014-09-24|2006-01-10|2006-01-11|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2005||2005-11-30|September 2009|2009-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|A Multi-center, Double-blind, Randomized, Placebo-controlled, Two-arm, Parallel-group, Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|Completed||Phase 3|60||UCB Pharma|||||f||||||||||||||2018-06-01 04:14:11.726406|2018-06-01 04:14:11.726406
NCT00275223|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-03-17|2006-01-10|2006-01-11|Estimate|||||||2010-03-17|2010-03-18|Estimate|September 2004||2004-09-30|March 2010|2010-03-31||||||||Observational|||Insulin Resistance in Severely Obese Patients|Insulin Resistance in Severely Obese Patients|Completed|||48|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:14:11.787151|2018-06-01 04:14:11.787151
NCT00275210|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-04-17|2006-01-10|2006-01-11|Estimate|||||||2009-04-17|2009-04-20|Estimate|October 1998||1998-10-31|April 2009|2009-04-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer|Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer|Completed||Phase 3|2246|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:14:11.838955|2018-06-01 04:14:11.838955
NCT00275197|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2008-10-30|2006-01-09|2006-01-11|Estimate|||||||2008-10-30|2008-11-03|Estimate|December 2005||2005-12-31|October 2008|2008-10-31|July 2007|Actual|2007-07-31|||||Interventional|||A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)|An Eight-Week, Double-Blind, Group-Sequential Design, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of The Co- Administration Of Sertraline And Elzasonan (CP-448,187) In Outpatients With Major Depressive Disorder|Completed||Phase 2|262|Actual|Pfizer|||||||||||||||||||2018-06-01 04:14:11.927603|2018-06-01 04:14:11.927603
NCT00275184|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2007-09-21|2006-01-10|2006-01-11|Estimate|||||||2007-09-21|2007-09-24|Estimate|January 2006||2006-01-31|September 2007|2007-09-30||||||||Interventional|||Bowel Preparation and Prokinetics in Capsule Endoscopy|A Randomised Study of the Optimal Bowel Preparation for Routine Capsule Endoscopy Using Citramag and Senna or Metoclopramide|Unknown status|Recruiting|Phase 3|150|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:14:12.006534|2018-06-01 04:14:12.006534
NCT00275171|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-12-03|2006-01-09|2006-01-11|Estimate|||||||2013-12-03|2013-12-04|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|September 2009|Actual|2009-09-30|April 2009|Actual|2009-04-30||Interventional|||rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter|The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial.|Completed||Phase 2|90|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 04:14:12.073231|2018-06-01 04:14:12.073231
NCT00275158|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-01-12|2006-01-10|2006-01-11|Estimate|||||||2010-01-12|2010-01-14|Estimate|January 2000||2000-01-31|January 2010|2010-01-31|December 2003|Actual|2003-12-31|||||Interventional|||Glomerular Injury of Preeclampsia|Effect of L-Arginine Therapy on the Glomerular Injury of Pre-Eclampsia: A Randomized Controlled Trial|Completed||N/A|45||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:14:12.142674|2018-06-01 04:14:12.142674
NCT00275145|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-05-23|2006-01-10|2006-01-11|Estimate|||||||2013-05-23|2013-05-24|Estimate|May 2004||2004-05-31|November 2011|2011-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|STRRIDE2||Effects of Resistance and Aerobic Exercise on Cardiovascular Health|Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE II)|Completed||Phase 2|261|Actual|Duke University||4|||f||||f||||||||||2018-06-01 04:14:12.198807|2018-06-01 04:14:12.198807
NCT00275132|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2014-12-01|2006-01-10|2006-01-11|Estimate|||||||2014-12-01|2014-12-03|Estimate|April 2005||2005-04-30|December 2011|2011-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|TOPICAL||Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy|Completed||Phase 3|670|Actual|University College, London||2|||f||||t||||||||||2018-06-01 04:14:12.267669|2018-06-01 04:14:12.267669
NCT00275119|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2009-02-06|2006-01-10|2006-01-11|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2003||2003-11-30|January 2006|2006-01-31||||||||Interventional|||Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|Protocole de Phase II: Etude de Faisabilite de L'Oxaliplatine en Association Chimio-Radiotherapie Concomitante Dans le Traitement Des Cancers du Pancreas Localement Avances Non Resecables|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:12.336117|2018-06-01 04:14:12.336117
NCT00275106|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-07-09|2006-01-10|2006-01-11|Estimate|||||||2013-07-09|2013-07-10|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|August 2012|Actual|2012-08-31|December 2009|Actual|2009-12-31||Interventional|||Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma|Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)|Terminated||Phase 3|600|Anticipated|National Cancer Institute (NCI)||||Withdrawn due to an excess of toxic deaths|f||||||||||||||2018-06-01 04:14:12.416669|2018-06-01 04:14:12.416669
NCT00275093|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-01-29|2006-01-10|2006-01-11|Estimate|||||||2013-01-29|2013-01-30|Estimate|December 2005||2005-12-31|January 2013|2013-01-31||||March 2008|Actual|2008-03-31||Interventional|||Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function|A Phase I Pharmacokinetic and Pharmacodynamic Study of Temsirolimus (CCI-779) in Patients With Advanced Malignancies and Normal and Impaired Liver Function: An NCI Organ Dysfunction Working Group Study|Completed||Phase 1|130|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:14:12.515928|2018-06-01 04:14:12.515928
NCT00275080|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2014-08-26|2006-01-10|2006-01-11|Estimate|||||||2014-08-26|2014-08-27|Estimate|February 2006||2006-02-28|June 2014|2014-06-30|August 2014|Actual|2014-08-31|November 2009|Actual|2009-11-30||Interventional|||Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia|A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis|Completed||Phase 1|80|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:14:12.589181|2018-06-01 04:14:12.589181
NCT00275067|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2018-02-02|2006-01-10|2006-01-11|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2005||2005-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery|A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 04:14:12.835958|2018-06-01 04:14:12.835958
NCT00275054|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2018-05-09|2006-01-10|2006-01-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2005||2005-10-31|May 2018|2018-05-31|June 2015|Actual|2015-06-30|July 2007|Actual|2007-07-31||Interventional|||Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia|Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression|Completed||Phase 3|825|Actual|German CLL Study Group||3|||f||||||||||||No||2018-06-01 04:14:12.946864|2018-06-01 04:14:12.946864
NCT00275041|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2016-12-09|2006-01-10|2006-01-11|Estimate|||||||2016-12-09|2016-12-13|Estimate|February 2006||2006-02-28|December 2016|2016-12-31|February 2009|Actual|2009-02-28|February 2007|Actual|2007-02-28||Interventional|||Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Concurrent Irinotecan Plus Cetuximab in Patients With Advanced Breast Cancer With Prior Anthracycline and/or Taxane-Containing Therapy|Completed||Phase 2|21|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:14:13.217856|2018-06-01 04:14:13.217856
NCT00275028|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2015-04-21||2015-10-09|2006-01-10|2006-01-11|Estimate|2015-10-09|2015-11-09|Estimate||||2015-10-09|2015-11-09|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|March 2010|Actual|2010-03-31||Interventional||The number of patients analyzed reflects the intent-to-treat population.|AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer|Completed||Phase 2|47|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:14:13.320883|2018-06-01 04:14:13.320883
NCT00268099|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-03-15|2005-12-20|2005-12-22|Estimate|||||||2012-03-15|2012-03-16|Estimate|May 2005||2005-05-31|June 2007|2007-06-30|November 2006|Actual|2006-11-30|||||Observational|||Optimal Timing for Repair of Right-to-Left Shunt Lesions|Optimal Timing for Repair of Right-to-Left Shunt Lesions|Terminated|||75|Anticipated|Children's Healthcare of Atlanta||||study not started|f||||f||||||||||2018-06-01 04:15:59.122301|2018-06-01 04:15:59.122301
NCT00275015|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2018-05-09|2006-01-10|2006-01-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 1998||1998-01-31|May 2018|2018-05-31|April 2012|Actual|2012-04-30|||||Interventional|||Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia|Pivotal Study for High Dose Therapy and Autologous Stem Cell Transplantation in Early Stages of CLL|Completed||Phase 2|169|Actual|German CLL Study Group||1|||f||||||||||||||2018-06-01 04:14:13.702282|2018-06-01 04:14:13.702282
NCT00275002|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2011-07-13||2014-07-25|2006-01-10|2006-01-11|Estimate|2011-07-13|2011-08-09|Estimate||||2014-07-25|2014-07-31|Estimate|February 2006||2006-02-28|February 2013|2013-02-28|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors|A Phase II Trial of O6-Benzylguanine and Temozolomide in Pediatric Patients With Recurrent or Progressive High-Grade Gliomas and Recurrent or Progressive Brainstem Tumors|Completed||Phase 2|41|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:14:13.921261|2018-06-01 04:14:13.921261
NCT00274989|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2017-07-28|2006-01-10|2006-01-11|Estimate|||||||2017-07-28|2017-08-01|Actual|November 2005||2005-11-30|September 2016|2016-09-30|March 2011|Actual|2011-03-31|March 2008|Actual|2008-03-31||Interventional|||Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia|Multicentre Phase II Trial of Bendamustine in Combination With Rituximab for Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia. CLL2M Protocol of the German CLL-Study Group (GCLLSG)|Completed||Phase 2|195|Actual|German CLL Study Group||1|||f||||f||||||||No||2018-06-01 04:14:14.351212|2018-06-01 04:14:14.351212
NCT00274976|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-11-05|2006-01-10|2006-01-11|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2002||2002-09-30|May 2006|2006-05-31|August 2009|Actual|2009-08-31|||||Interventional|||Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine|Subcutaneous Campath-1H in Fludarabine-Refractory CLL|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:14.521931|2018-06-01 04:14:14.521931
NCT00274963|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2018-05-09|2006-01-10|2006-01-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2004||2004-10-31|May 2018|2018-05-31|October 2009|Actual|2009-10-31|November 2007|Actual|2007-11-30||Interventional|||Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM)|Completed||Phase 2|60|Anticipated|German CLL Study Group|||||f||||||||||||||2018-06-01 04:14:14.618547|2018-06-01 04:14:14.618547
NCT00274950|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-09-16|2006-01-10|2006-01-11|Estimate|||||||2013-09-16|2013-09-17|Estimate|May 2005||2005-05-31|June 2009|2009-06-30||||May 2010|Anticipated|2010-05-31||Interventional|||Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors|Protocol for the Treatment of Extracranial Germ Cell Tumours in Children and Adolescents (GC III)|Unknown status|Active, not recruiting|Phase 3|105|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:14.852594|2018-06-01 04:14:14.852594
NCT00274937|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2016-10-24||2017-05-15|2006-01-10|2006-01-11|Estimate|2016-11-23|2017-01-19|Estimate||||2017-05-15|2017-06-08|Actual|February 2006||2006-02-28|May 2017|2017-05-31||||March 2016|Actual|2016-03-31||Interventional|||Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer|Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study|Completed||Phase 3|111|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 04:14:15.008052|2018-06-01 04:14:15.008052
NCT00274924|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2014-01-09||2017-10-19|2006-01-10|2006-01-11|Estimate|2014-01-09|2014-02-24|Estimate||||2017-10-19|2017-11-21|Actual|April 2006||2006-04-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|June 2013|Actual|2013-06-30||Interventional||Eligible and treated patients|Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning|Active, not recruiting||Phase 2|100|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 04:14:15.524573|2018-06-01 04:14:15.524573
NCT00274911|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-08-01|2006-01-10|2006-01-11|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2004||2004-02-29|June 2009|2009-06-30||||March 2010|Anticipated|2010-03-31||Interventional|||Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors|Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:17.345044|2018-06-01 04:14:17.345044
NCT00274898|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2009-02-06|2006-01-10|2006-01-11|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 2004||2004-05-31|September 2006|2006-09-30||||||||Interventional|||Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer|Phase II Randomized Study Evaluting the Effect of Celecoxib as Maintenance Treatment of Stage IIIb Non-Small Cell Lung Cancer That Reponded or is Stable After Radiochemotherapy|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:17.481556|2018-06-01 04:14:17.481556
NCT00274885|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-12-02|2006-01-10|2006-01-11|Estimate|||||||2011-12-02|2011-12-05|Estimate|October 2005||2005-10-31|May 2007|2007-05-31||||||||Interventional|||Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer|Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin|Unknown status|Recruiting|Phase 4|58|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:17.588539|2018-06-01 04:14:17.588539
NCT00274872|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-01-29|2006-01-10|2006-01-11|Estimate|||||||2010-01-29|2010-02-01|Estimate|January 2004||2004-01-31|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2|Unknown status|Active, not recruiting|Phase 2/Phase 3|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:17.700432|2018-06-01 04:14:17.700432
NCT00274859|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2008-07-23|2006-01-10|2006-01-11|Estimate|||||||2008-07-23|2008-07-24|Estimate|August 2005||2005-08-31|May 2007|2007-05-31||||||||Interventional|||Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer|Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:14:17.832686|2018-06-01 04:14:17.832686
NCT00274846|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2009-07-24||2017-12-03|2006-01-10|2006-01-11|Estimate|2009-07-31|2009-09-07|Estimate||||2017-12-03|2017-12-28|Actual|March 2005||2005-03-31|December 2017|2017-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia|Allogeneic Natural Killer Cells in Patients With Relapsed Acute Myelogenous Leukemia|Completed||Phase 2|21|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 04:14:17.93549|2018-06-01 04:14:17.93549
NCT00274833|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2012-12-05|2006-01-10|2006-01-11|Estimate|||||||2012-12-05|2012-12-06|Estimate|October 2005||2005-10-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|October 2007|Actual|2007-10-31||Interventional|||Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Trial of Erlotinib With Temozolomide and Concurrent Radiation Therapy Post-Operatively in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|27|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:14:18.156312|2018-06-01 04:14:18.156312
NCT00274820|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2012-09-26|2006-01-10|2006-01-11|Estimate|||||||2012-09-26|2012-09-28|Estimate|October 2005||2005-10-31|September 2012|2012-09-30|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder|A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders|Completed||Phase 2|15|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:14:18.241906|2018-06-01 04:14:18.241906
NCT00274807|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-02-09|2006-01-10|2006-01-11|Estimate|||||||2011-02-09|2011-02-11|Estimate|June 2001||2001-06-30|February 2011|2011-02-28|May 2008|Actual|2008-05-31|April 2007|Actual|2007-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Intensive Induction for Newly Diagnosed Acute Myelogenous Leukemia|Completed||Phase 2|40|Actual|The Cleveland Clinic|||||f||||||||||||||2018-06-01 04:14:18.320628|2018-06-01 04:14:18.320628
NCT00274794|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2011-03-28|2006-01-10|2006-01-11|Estimate|||||||2011-03-28|2011-03-29|Estimate|February 2000||2000-02-29|March 2011|2011-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL|A Prospective Randomized Trial of VP-16 Plus G-CSF Plus Rituximab vs VP-16 Plus G-CSF Alone for Peripheral Blood Progenitor Cell Mobilization Prior to Autologous Stem Cell Transplantation for B Cell Lymphoid Malignancies|Completed||N/A|55|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-06-01 04:14:18.486076|2018-06-01 04:14:18.486076
NCT00274781|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2015-06-03||2015-07-06|2006-01-10|2006-01-11|Estimate|2015-07-06|2015-07-10|Estimate||||2015-07-06|2015-07-10|Estimate|February 2004||2004-02-29|July 2015|2015-07-31|November 2010|Actual|2010-11-30|December 2008|Actual|2008-12-31||Interventional|||Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes|A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome|Completed||Phase 2|30|Actual|The Cleveland Clinic||1|||f||||f||||||||||2018-06-01 04:14:18.605481|2018-06-01 04:14:18.605481
NCT00274768|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2012-11-21||2015-10-09|2006-01-10|2006-01-11|Estimate|2012-11-21|2012-12-21|Estimate||||2015-10-09|2015-10-14|Estimate|April 2004||2004-04-30|October 2015|2015-10-31|November 2012|Actual|2012-11-30|December 2009|Actual|2009-12-31||Interventional|||Capecitabine in Treating Patients With Metastatic Breast Cancer|Phase II Study of Fixed-Dose Capecitabine in Metastatic Breast Cancer|Completed||Phase 2|26|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The small sample size limited a number of the secondary objectives.|1|||f||||f||||||||||2018-06-01 04:14:18.900689|2018-06-01 04:14:18.900689
NCT00274755|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2014-05-19|2006-01-10|2006-01-11|Estimate|||||||2014-05-19|2014-05-20|Estimate|November 2003||2003-11-30|May 2014|2014-05-31||||April 2007|Actual|2007-04-30||Interventional|||Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas|Improved Characterization of Brain Tumors By MRI and MRS|Completed||Phase 2|250|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:14:19.109305|2018-06-01 04:14:19.109305
NCT00274742|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2014-12-23||2015-01-15|2006-01-10|2006-01-11|Estimate|2015-01-15|2015-01-16|Estimate||||2015-01-15|2015-01-16|Estimate|June 2004||2004-06-30|January 2015|2015-01-31|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Interventional|||Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL|An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 1|76|Actual|Amgen Research (Munich) GmbH||1|||f||||t||||||||||2018-06-01 04:14:19.288958|2018-06-01 04:14:19.288958
NCT00274729|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2010-03-24|2006-01-10|2006-01-11|Estimate|||||||2010-03-24|2010-03-25|Estimate|January 2004||2004-01-31|January 2006|2006-01-31|June 2008||2008-06-30|||||Interventional|||Mono Unsaturated Fatty Acids in Obesity - Weight Maintenance and Prevention of Lifestyle Diseases in Obese Subjects.|MUFObes: MonoUnsaturated Fatty Acids in Obesity - a Comparison Between 3 Different Diets in Weight Maintenance and the Prevention of Lifestyle Diseases in Obese Subjects. A Randomised, Long-term Intervention Study.|Completed||N/A|125||University of Copenhagen|||||f||||||||||||||2018-06-01 04:14:21.752795|2018-06-01 04:14:21.752795
NCT00274716|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2013-12-23||2015-06-08|2006-01-10|2006-01-11|Estimate|2013-12-23|2014-02-14|Estimate||||2015-06-08|2015-07-03|Estimate|November 2005||2005-11-30|June 2015|2015-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety and Efficacy of MK0736 & MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK0736 and MK0916 in Hypertensive Patients|Completed||Phase 2|249|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 04:14:21.882596|2018-06-01 04:14:21.882596
NCT00274703|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2016-12-02|2006-01-10|2006-01-11|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2005||2005-12-31|December 2016|2016-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Provide a Preliminary Evaluation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Intravenous Anti-human Interleukin-5 (Mepolizumab, 750mg and 1500mg) in the Treatment of Eosinophilic Oesophagitis in Adults|Completed||Phase 2|10|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:14:23.070318|2018-06-01 04:14:23.070318
NCT00274560|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-11-08|2006-01-09|2006-01-11|Estimate|||||||2013-11-08|2013-11-11|Estimate|May 2002||2002-05-31|November 2013|2013-11-30||||March 2003|Actual|2003-03-31||Interventional|||A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.|A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol in a 12 Week, Randomized, Double-Blind, Double-Dummy Parallel Group Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|653|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:14:25.642156|2018-06-01 04:14:25.642156
NCT00274690|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2017-01-19|2006-01-09|2006-01-11|Estimate|||||||2017-01-19|2017-01-20|Estimate|February 2005||2005-02-28|January 2017|2017-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Post-Operative Nausea And Vomiting Study In Female Patients|A Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Efficacy of Oral Dosing With GW679769 (50 mg or 150 mg) for Three Consecutive Days When Administered With a Single Intravenous Dose of Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects With Known Risk Factors for Post-operative Nausea and Vomiting Who Are Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated With an Increased Emetogenic Risk|Completed||Phase 2|435|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:14:23.163354|2018-06-01 04:14:23.163354
NCT00274677|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2016-09-13|2006-01-10|2006-01-11|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2003||2003-11-30|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Depression And Bipolar Disorder|A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients With Type II Bipolar Disorder|Completed||Phase 3|221|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:14:23.289939|2018-06-01 04:14:23.289939
NCT00274664|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2006-01-09|2006-01-09|2006-01-11|Estimate|||||||2006-01-09|2006-01-11|Estimate|February 2002||2002-02-28|December 2005|2005-12-31|May 2005||2005-05-31|||||Interventional|||Patching for Lazy Eye: Trial to Evaluate Daily Patching Amounts|Randomised Occlusion Treatment of Amblyopia Study (ROTAS): Trial of Maximal Vs Substantial Doses of Occlusion to Evaluate Visual Outcome for Children With Amblyopia|Completed||Phase 1|100||City, University of London|||||f||||||||||||||2018-06-01 04:14:23.403296|2018-06-01 04:14:23.403296
NCT00274651|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2014-06-30|2012-12-18|2015-07-07|2006-01-10|2006-01-11|Estimate|2014-10-21|2014-10-27|Estimate|2012-12-18|2012-12-21|Estimate|2015-07-07|2015-07-28|Estimate|January 2006||2006-01-31|July 2015|2015-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|PXD101-CLN-6|Patients received PXD101, 1000 mg/m2/day over 30 minutes days 1-5 of a 21-day cycle. Patients with OR or stable disease were permitted to continue with PXD101 for up to 8 cycles or until progressive disease. Patients with PR or SD could continue therapy beyond 8 cycles until progression in consultation with Investigators and Sponsor.|A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas|A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas|Terminated||Phase 2|53|Actual|Onxeo||2||"Enrollment stopped prior to reaching expected number of patients, study had accumulated~   sufficient data to allow a registration study in PTCL (PXD101-CLN-19)"|f||||f||||||||||2018-06-01 04:14:23.481565|2018-06-01 04:14:23.481565
NCT00274638|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-12-06|2006-01-10|2006-01-11|Estimate|||||||2013-12-06|2013-12-09|Estimate|July 2002||2002-07-31|December 2013|2013-12-31||||July 2003|Actual|2003-07-31||Interventional|||PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)|A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group 6-week Treatment Study Comparing Telmisartan Combined With Hydrochlorothiazide (40 mg/12.5 mg or 80 mg/12.5 mg) Tablets With Losartan Combined With Hydrochlorothiazide (50 mg/12.5 mg) Tablets Using Ambulatory Blood Pressure Monitoring in Patients With Mild-to-Moderate Hypertension|Completed||Phase 4|805|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:14:24.295594|2018-06-01 04:14:24.295594
NCT00274625|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|2014-10-24||2014-11-10|2006-01-09|2006-01-11|Estimate|2014-11-10|2014-11-12|Estimate||||2014-11-10|2014-11-12|Estimate|August 2005||2005-08-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||14 patients in Surgisis Gold group and 8 patients in Suture Closure group were excluded from the analysis, because prior to procedure, either they were found not to meet the inclusion/exclusion criteria, or they chose not to participate.|Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery||Completed||N/A|402|Actual|Cook Group Incorporated||2|||f||||f||||||||||2018-06-01 04:14:24.542078|2018-06-01 04:14:24.542078
NCT00274612|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-10-31|2006-01-10|2006-01-11|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2002||2002-10-31|October 2013|2013-10-31|November 2003||2003-11-30|November 2003|Actual|2003-11-30||Interventional|PRISMA||Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM|A Prospective Randomised Open- Label Blinded-Endpoint (PROBE) Trial Comparing Telmisartan (MICARDIS®) (40-80-80mg QD) and Ramipril (2.5-5--10mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. PRISMA = Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM|Completed||Phase 4|801||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:24.801063|2018-06-01 04:14:24.801063
NCT00274599|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-11-07|2006-01-10|2006-01-11|Estimate|||||||2013-11-07|2013-11-08|Estimate|October 2002||2002-10-31|November 2013|2013-11-30||||December 2003|Actual|2003-12-31||Interventional|||PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN|A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing MICARDIS® (Telmisartan 40-80-80 mg, QD) and ALTACE® (Ramipril 2.5-5-10 mg, QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring|Completed||Phase 4|812|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:24.986917|2018-06-01 04:14:24.986917
NCT00274586|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2013-10-30|2006-01-10|2006-01-11|Estimate|||||||2013-10-30|2013-10-31|Estimate|September 2002||2002-09-30|October 2013|2013-10-31|April 2003||2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Headache Study to Compare Aggrenox Full Dose and Reduced Dose|Tolerability of a Four Weeks Treatment With Aggrenox® Modified Release Capsules b.i.d, Compared to Reduced Dose During the First Two Weeks of Treatment in a Double-Blind, Randomized Controlled Parallel Group Comparison Trial Among Taiwanese Patients With Previous TIAs or Ischemic Stroke|Completed||Phase 3|100||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:25.122447|2018-06-01 04:14:25.122447
NCT00274573|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-11-20|2006-01-09|2006-01-11|Estimate|||||||2013-11-20|2013-11-21|Estimate|March 2002||2002-03-31|November 2013|2013-11-30||||October 2002|Actual|2002-10-31||Interventional|||Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity|Acute and Long-term Effects of Once Daily Oral Inhalation of Tiotropium 18 Mcg Dry Powder Inhalation Capsules in a Placebo Controlled Parallel Group Design Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity|Completed||Phase 3|1639|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:25.199126|2018-06-01 04:14:25.199126
NCT00273845|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2009-02-23|2006-01-05|2006-01-09|Estimate|||||||2009-02-23|2009-02-24|Estimate|May 2003||2003-05-31|February 2009|2009-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|RBP||Reducing Barriers to Drug Abuse Treatment Services|Reducing Barriers to Drug Abuse Treatment Services|Completed||Phase 2/Phase 3|678|Actual|Wright State University||2|||f||||t||||||||||2018-06-01 04:14:35.123606|2018-06-01 04:14:35.123606
NCT00274547|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-11|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2001||2001-09-30|October 2013|2013-10-31||||February 2003|Actual|2003-02-28||Interventional|||Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Proportion of Patients Experiencing an Exacerbation and Proportion of Patients Hospitalized for an Exacerbation Over 6 Months During Treatment With Tiotropium 18 Mcg Capsule Once Daily in Patients With COPD in a Veterans Affairs Setting|Completed||Phase 3|1829|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:14:25.867489|2018-06-01 04:14:25.867489
NCT00274534|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-11-04|2006-01-09|2006-01-11|Estimate|||||||2013-11-04|2013-11-05|Estimate|December 2000||2000-12-31|November 2013|2013-11-30|July 2003||2003-07-31|||||Interventional|||A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.|A Comparison of the Effects of Tiotropium (18 Mcg) Inhalation Capsule q.d. and Salmeterol (50 Mcg) Inhalation Aerosol b.i.d. on Arterial Blood Gases in a Double-blind, Double-dummy, 4-week Crossover Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|36||Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:14:25.973738|2018-06-01 04:14:25.973738
NCT00274521|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-11|Estimate|||||||2013-10-31|2013-11-01|Estimate|May 2001||2001-05-31|October 2013|2013-10-31||||February 2003|Actual|2003-02-28||Interventional|||Tiotropium (Spiriva) Rehabilitation Study|A Randomized, Double-blind, Placebo Controlled 25-week Trial to Compare the Effect of Tiotropium Inhalation Capsuled (18 Mcg) Once Daily on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 8 Weeks of Pulmonary Rehabilitation.|Completed||Phase 3|108||Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:14:26.048955|2018-06-01 04:14:26.048955
NCT00274508|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-11|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2000||2000-10-31|October 2013|2013-10-31||||January 2003|Actual|2003-01-31||Interventional|||Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients|Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study)|Completed||Phase 3|261|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:26.146311|2018-06-01 04:14:26.146311
NCT00274495|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2007-10-31|2006-01-10|2006-01-11|Estimate|||||||2007-10-31|2007-11-01|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver|Randomized Placebo-Control Pilot Study Evaluating the Efficacy and Safety of Rosiglitazone Combined With Pegylated Interferon Plus Ribavirin Versus Pegylated Interferon Plus Ribavirin Alone in Genotype 1 Hepatitis C With Steatosis|Terminated||Phase 4|30|Anticipated|Beth Israel Medical Center|||||||||||||||||||2018-06-01 04:14:26.239195|2018-06-01 04:14:26.239195
NCT00274469|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2009-01-27||2017-02-01|2006-01-10|2006-01-11|Estimate|2009-06-26|2009-08-12|Estimate||||2017-02-01|2017-03-13|Actual|February 2006||2006-02-28|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2008|Actual|2008-01-31||Interventional|FIRST||A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer|A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Anastrozole (ARIMIDEX™) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer|Completed||Phase 2|233|Actual|AstraZeneca|One patient in the ITT population was randomized to Fulvestrant 500 but did not receive drug and was excluded from the safety population. Hence, the safety population for Fulvestrant contained 101 patients.|2|||f||||||||||||||2018-06-01 04:14:26.328355|2018-06-01 04:14:26.328355
NCT00274456|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|2011-02-07||2016-12-14|2006-01-10|2006-01-11|Estimate|2013-05-28|2013-07-02|Estimate||||2016-12-14|2016-12-16|Estimate|November 2005||2005-11-30|December 2016|2016-12-31|July 2011|Actual|2011-07-31|March 2008|Actual|2008-03-31||Interventional|||Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer|A Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 Versus Every 3 Weeks Taxotere as First Line Therapy of Stage IV (Metastatic) Breast Cancer|Completed||Phase 2|302|Actual|Celgene Corporation||4|||f||||f||||||||||2018-06-01 04:14:26.776728|2018-06-01 04:14:26.776728
NCT00274443|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-10|||2016-11-16|2006-01-10|2006-01-11|Estimate|||||||2016-11-16|2016-11-17|Estimate|March 2005||2005-03-31|November 2016|2016-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin|An Open -Label, Phase II Trial of Increasing Doses of ABI-007 and Carboplatin in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|250|Actual|Celgene Corporation||1|||f||||f||||||||||2018-06-01 04:14:28.514373|2018-06-01 04:14:28.514373
NCT00274430|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2006-11-30|2006-01-09|2006-01-10|Estimate|||||||2006-11-30|2006-12-04|Estimate|July 2003||2003-07-31|December 2003|2003-12-31|September 2003||2003-09-30|||||Interventional|||Prevention of High Altitude Pulmonary Edema|A Randomized Controlled Trial of the Effects of Tadalafil and Dexamethasone Versus Placebo on Pulmonary Edema Formation and Cerebral Blood Flow Autoregulation in High Altitude Newcomers With a Previous History of High Altitude Pulmonary Edema|Completed||Phase 1/Phase 2|30||University of Zurich|||||f||||||||||||||2018-06-01 04:14:28.604841|2018-06-01 04:14:28.604841
NCT00274417|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2007-04-17|2006-01-09|2006-01-10|Estimate|||||||2007-04-17|2007-04-18|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|May 2009|Anticipated|2009-05-31|||||Interventional|||Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)|A Randomized, Placebo-Controlled, Double-Blind Study of the Use of Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP Study)|Unknown status|Active, not recruiting|N/A|60||Urology of Virginia|||||f||||||||||||||2018-06-01 04:14:28.694068|2018-06-01 04:14:28.694068
NCT00274404|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2011-10-26|2006-01-06|2006-01-10|Estimate|||||||2011-10-26|2011-10-27|Estimate|February 2004||2004-02-29|October 2011|2011-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Controlled Trial of Valacyclovir in Infectious Mononucleosis|Randomized Study Assessing the Antiviral Activity and Safety of Valacyclovir in Primary Infectious Mononucleosis|Completed||Phase 1/Phase 2|20||University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 04:14:28.789457|2018-06-01 04:14:28.789457
NCT00274391|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2006-01-09|2006-01-09|2006-01-10|Estimate|||||||2006-01-09|2006-01-10|Estimate|July 2001||2001-07-31|December 2005|2005-12-31|April 2004||2004-04-30|||||Interventional|||Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis|Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis|Completed||Phase 2|24||University of North Carolina, Chapel Hill|||||||||||||||||||2018-06-01 04:14:28.869298|2018-06-01 04:14:28.869298
NCT00273832|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-01-04|2006-01-04|2006-01-09|Estimate|||||||2006-01-04|2006-01-09|Estimate|March 2005||2005-03-31|December 2005|2005-12-31|November 2005||2005-11-30|||||Interventional|||Study of Coronary Artery Computed Tomography to Diagnose Emergency Chest Pain|Randomized Controlled Trial of Multi-Slice Coronary Computed Tomography for Evaluation of Acute Chest Pain|Completed||Phase 2|200||William Beaumont Hospitals|||||f||||||||||||||2018-06-01 04:14:35.191784|2018-06-01 04:14:35.191784
NCT00274378|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2009-07-29|2006-01-06|2006-01-10|Estimate|||||||2009-07-29|2009-07-30|Estimate|June 2005||2005-06-30|July 2009|2009-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Allomatrix Injectable Putty in Distal Radius Fractures|Allomatrix Injectable Putty in Distal Radius Fractures. Protocol for a Randomised, Controlled Clinical Study in Unstable Fractures of the Distal Radius|Completed||Phase 4|50|Anticipated|Université Catholique de Louvain|||||f||||||||||||||2018-06-01 04:14:28.929955|2018-06-01 04:14:28.929955
NCT00274365|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2009-01-28|2006-01-09|2006-01-10|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 2005||2005-11-30|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Consultations in Psychiatry Through Videoconference|Consultations in Psychiatry Given to GP's Through Videoconference|Completed||N/A|250||Sha’ar Menashe Mental Health Center|||||f||||||||||||||2018-06-01 04:14:28.992161|2018-06-01 04:14:28.992161
NCT00274352|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2013-05-20|2006-01-06|2006-01-10|Estimate|||||||2013-05-20|2013-05-22|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study of Adalimumab to Treat Sarcoidosis of the Skin|A Double-Blind, Randomized, Placebo-Controlled Study of Adalimumab in the Treatment of Cutaneous Sarcoidosis|Completed||Phase 2|16|Actual|Pariser, Robert J., M.D.|||||f||||f||||||||||2018-06-01 04:14:29.05222|2018-06-01 04:14:29.05222
NCT00274339|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2007-06-22|2006-01-06|2006-01-10|Estimate|||||||2007-06-22|2007-06-25|Estimate|December 2005||2005-12-31|June 2007|2007-06-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Prevacid vs Lifestyle Modifications for the Treatment of LPR|A Comparison of Prevacid 30mg BID Plus Lifestyle Modifications Versus Lifestyle Modifications Alone for the Treatment of Laryngopharyngeal Reflux (LPR) in Adults|Unknown status|Recruiting|N/A|135|Anticipated|Hodge, Kenneth M., M.D.|||||f||||f||||||||||2018-06-01 04:14:29.123726|2018-06-01 04:14:29.123726
NCT00274326|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2008-09-12|2006-01-09|2006-01-10|Estimate|||||||2008-09-12|2008-09-15|Estimate|May 2005||2005-05-31|September 2008|2008-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||DILIPO (DILutIonal HyPOnatremia)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia|Completed||Phase 3|150||Sanofi|||||f||||||||||||||2018-06-01 04:14:29.235648|2018-06-01 04:14:29.235648
NCT00274313|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2009-01-12|2006-01-06|2006-01-10|Estimate|||||||2009-01-12|2009-01-14|Estimate|January 2006||2006-01-31|January 2009|2009-01-31|August 2006||2006-08-31|||||Interventional|||Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients|A Study of the Safety and Pharmacokinetics of 552-02 Following 14 Days of Dosing By Inhalation in Patients With Cystic Fibrosis|Completed||Phase 1/Phase 2|40||Parion Sciences|||||f||||||||||||||2018-06-01 04:14:29.31711|2018-06-01 04:14:29.31711
NCT00274300|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2007-01-25|2006-01-09|2006-01-10|Estimate|||||||2007-01-25|2007-01-29|Estimate|August 2004||2004-08-31|January 2006|2006-01-31|July 2005||2005-07-31|||||Interventional|||Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2|A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2|Completed||Phase 1|36||PowderMed|||||||||||||||||||2018-06-01 04:14:29.383297|2018-06-01 04:14:29.383297
NCT00274287|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|2011-10-06||2017-10-19|2006-01-06|2006-01-10|Estimate|2012-05-07|2012-05-09|Estimate||||2017-10-19|2017-11-22|Actual|January 2006||2006-01-31|October 2017|2017-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere|A Phase II Pilot Study Investigating the Efficacy and Activity of Single Agent GM-CSF (Leukine) Maintenance Approach in Androgen-independent Prostate Cancer (AIPC) Patients Responding to Taxotere Chemotherapy|Completed||Phase 2|15|Actual|Oncology Specialists, S.C.||1|||f||||f||||||||||2018-06-01 04:14:29.451731|2018-06-01 04:14:29.451731
NCT00274274|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2014-11-20|2006-01-09|2006-01-10|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2005||2005-09-30|November 2014|2014-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes|Efficacy and Safety of Insulin Aspart in a Fixed or Flexible Supplementary Insulin Therapy Regimen, With or Without Insulin Detemir in Type 2 Diabetes|Completed||Phase 4|373|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:14:29.65053|2018-06-01 04:14:29.65053
NCT00274261|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|2012-12-14||2018-04-27|2006-01-06|2006-01-10|Estimate|2013-04-30|2013-06-06|Estimate||||2018-04-27|2018-05-01|Actual|June 2004||2004-06-30|April 2018|2018-04-30|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®|A Phase II/III Multicenter, Randomized, Double-masked, Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®|Completed||Phase 3|1565|Actual|Health Decisions||2|||f||||t||||||||||2018-06-01 04:14:29.724133|2018-06-01 04:14:29.724133
NCT00274248|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2008-02-07|2006-01-09|2006-01-10|Estimate|||||||2008-02-07|2008-02-11|Estimate|March 2005||2005-03-31|February 2008|2008-02-29||||May 2007|Actual|2007-05-31||Interventional|||MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia|A Phase 1 Study of MLN518 Given in Combination With Standard Induction Chemotherapy for the Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia|Completed||Phase 1|||Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 04:14:30.183251|2018-06-01 04:14:30.183251
NCT00274235|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2008-10-30|2006-01-09|2006-01-10|Estimate|||||||2008-10-30|2008-10-31|Estimate|July 2005||2005-07-31|October 2008|2008-10-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Intermittent Preventive Treatment During Pregnancy in Benin|Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine|Completed||Phase 3|1600|Anticipated|Institut de Recherche pour le Developpement|||||f||||t||||||||||2018-06-01 04:14:30.237789|2018-06-01 04:14:30.237789
NCT00274222|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2006-01-09|2006-01-09|2006-01-10|Estimate|||||||2006-01-09|2006-01-10|Estimate|January 2003||2003-01-31|January 2006|2006-01-31|October 2005||2005-10-31|||||Observational|||The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD||Terminated|||120||Inonu University|||||f||||||||||||||2018-06-01 04:14:30.299175|2018-06-01 04:14:30.299175
NCT00274209|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2011-11-21|2006-01-06|2006-01-10|Estimate|||||||2011-11-21|2011-11-22|Estimate|December 2005||2005-12-31|November 2011|2011-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Chromoendoscopy for Ulcerative Colitis Surveillance|Impact of Chromoendoscopy on the Detection of Neoplasia in Ulcerative Colitis|Completed|||100|Actual|Indiana University|||1||f||||t||||||Samples Without DNA|"~     endoscopic biopsies~   "|||2018-06-01 04:14:30.33818|2018-06-01 04:14:30.33818
NCT00274196|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2007-11-12|2006-01-09|2006-01-10|Estimate|||||||2007-11-12|2007-11-14|Estimate|February 2006||2006-02-28|November 2007|2007-11-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Ultrasound as a Diagnostic Tool for Occult Hip Fractures|A Prospective Study of the Specificity and Sensitivity of Ultrasound in Diagnosing Occult Hip Fractures|Unknown status|Recruiting|N/A|30|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 04:14:30.398561|2018-06-01 04:14:30.398561
NCT00274183|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2017-03-29|2006-01-02|2006-01-10|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2006||2006-01-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|||Nonalcoholic Fatty Liver Disease in Taiwanese Children|Prevalence, Clinicopathological Characteristics, Biomarkers and Genetics of Nonalcoholic Steatohepatitis in Taiwanese Children|Recruiting|||800|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||Samples With DNA|"~     Serum, WBC DNA~   "|Undecided||2018-06-01 04:14:30.474789|2018-06-01 04:14:30.474789
NCT00274170|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2007-02-27|2006-01-09|2006-01-10|Estimate|||||||2007-02-27|2007-03-01|Estimate|January 2006||2006-01-31|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache|Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache|Unknown status|Recruiting|Phase 1/Phase 2|56||C.R.Darnall Army Medical Center|||||f||||||||||||||2018-06-01 04:14:30.526645|2018-06-01 04:14:30.526645
NCT00274157|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2008-06-26|2006-01-09|2006-01-10|Estimate|||||||2008-06-26|2008-06-27|Estimate|March 2007||2007-03-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||FIRE-PAD: Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease|Functional Improvement Through Revascularization of the Extremities for Peripheral Arterial Disease (FIRE-PAD). Effects of Catheter-Based Revascularization on Functional Capacity, Quality of Life, and the Cardiovascular Risk Profile of Patients With Intermittent Claudication|Terminated|||37|Anticipated|The Cleveland Clinic||||Low enrollment|f||||||||||||||2018-06-01 04:14:30.581215|2018-06-01 04:14:30.581215
NCT00274144|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2001||2001-12-31|October 2013|2013-10-31|May 2004||2004-05-31|March 2004|Actual|2004-03-31||Interventional|||Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism|Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism|Completed||Phase 4|42||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:30.632748|2018-06-01 04:14:30.632748
NCT00274131|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2012-05-18|2006-01-09|2006-01-10|Estimate|||||||2012-05-18|2012-05-21|Estimate|December 1998||1998-12-31|May 2012|2012-05-31|February 2004||2004-02-29|||||Interventional|||Long-term Administration Study of SND 919 Tablets in Parkinson's Disease|Long-term Administration Study of SND 919 Tablets in Parkinson's Disease|Completed||Phase 3|170||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:30.68061|2018-06-01 04:14:30.68061
NCT00274118|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 1997||1997-07-31|October 2013|2013-10-31|January 2004||2004-01-31|January 2004|Actual|2004-01-31||Interventional|||DETAIL Study: Diabetes Exposed to Telmisartan and Enalapril|DETAIL = Diabetics Exposed to Telmisartan And enalapIL: A Randomised, Double-blind, Parallel-group Comparison of the Renal and Antihypertensive Effects of Telmisartan and Enalapril in Subjects With Mild to Moderate Hypertension and Concurrent Type II Diabetes Mellitus and Diabetic Nephropathy|Completed||Phase 3|250||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:30.730368|2018-06-01 04:14:30.730368
NCT00274105|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|March 2001||2001-03-31|October 2013|2013-10-31|October 2004||2004-10-31|October 2004|Actual|2004-10-31||Interventional|||SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients|A Double Blind, 2:1 Randomised Monocentre Study to Investigate the Efficacy and Safety of Telmisartan (80 mg qd) Concerning the Amelioration of Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients)|Terminated||Phase 4|22||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:30.816649|2018-06-01 04:14:30.816649
NCT00274092|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-11-04|2006-01-09|2006-01-10|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2002||2002-09-30|November 2013|2013-11-30|October 2003||2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Comparison of 18 Mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 Mcg) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|132|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:31.934035|2018-06-01 04:14:31.934035
NCT00274079|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2002||2002-10-31|October 2013|2013-10-31|October 2003||2003-10-31|October 2003|Actual|2003-10-31||Interventional|||SPIRIVA in Ususal Care|A Randomised, Double-blind, Parallel Group, 12 Week Study, Comparing the Effect of Once Daily Tiotropium Lactose Capsule With Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD), naïve to Anticholinergic Agents in Addition to Receiving Their Usual COPD Care|Completed||Phase 4|395||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.058259|2018-06-01 04:14:32.058259
NCT00274066|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2002||2002-10-31|October 2013|2013-10-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva|The Acute Bronchodilator Effects of a Single Dose (2 Puffs) of the Shortacting Anticholinergic Ipratropium Bromide (40μg) and the Short-acting Beta-adrenergic Fenoterol (200μg) in Comparison to Placebo on Top of Pharmacodynamic Steady State of Once Daily Tiotropium (18μg) Inhalation Capsule in Patients With Chronic Pulmonary Disease (COPD)|Completed||Phase 3|65||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.184682|2018-06-01 04:14:32.184682
NCT00274053|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|April 2002||2002-04-30|October 2013|2013-10-31|April 2004||2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD|Effect of a 9-month Treatment of SPIRIVA® on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. Validation of a New HRQoL Questionnaire Appropriate to Common Daily Practice. (TIPHON Study)|Completed||Phase 3|555|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.266733|2018-06-01 04:14:32.266733
NCT00274040|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2002||2002-07-31|October 2013|2013-10-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD|A Comparison of 18 μg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 μg, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|141||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.472471|2018-06-01 04:14:32.472471
NCT00273819|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2009-01-24|2006-01-05|2006-01-09|Estimate|||||||2009-01-24|2009-01-27|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|June 2007|Actual|2007-06-30|||||Interventional|||Study of Coronary Artery Disease by Two Types of Angiography|Non-Invasive Detection of Revascularizable Cardiomyopathy|Completed||N/A|30|Anticipated|VA Connecticut Healthcare System|||||f||||||||||||||2018-06-01 04:14:35.257619|2018-06-01 04:14:35.257619
NCT00274027|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2001||2001-01-31|October 2013|2013-10-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)|Randomised, Double-Blind, Placebo-Controlled, Cross-Over Study to Examine the Effects of Tiotropium on Lung Hyperinflation, Respiratory Mechanics and Dyspnea During Exercise in Patients With COPD|Completed||Phase 3|19|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.583371|2018-06-01 04:14:32.583371
NCT00274014|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2000||2000-10-31|October 2013|2013-10-31|October 2003||2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders|Effects of Inhaled Tiotropium Bromide on Severity of Airflow Obstruction During Long-term Treatment in Patients With Moderately Severe Copd. Impact on Severity and Incidence of Exacerbations.|Completed||Phase 3|1000||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.693783|2018-06-01 04:14:32.693783
NCT00274001|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-31|2006-01-09|2006-01-10|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2001||2001-09-30|October 2013|2013-10-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Quality of Life and Changes in Metabolism of Lipids and Glucose After Switching to a Nevirapine-based Regimen in HIV+ Patients|An Open, Randomised, Multicentre, Comparative Trial, to Evaluate the Benefit of Switching From a PI-based Regimen to a Nevirapine-based Regimen on the Quality of Life, Patient Adherence, Patient's Perception of Fat Redistribution and Metabolic Changes, in HIV+ Patients Suffering From Fat Abnormalities|Completed||Phase 4|158|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.875116|2018-06-01 04:14:32.875116
NCT00273988|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-30|2006-01-09|2006-01-10|Estimate|||||||2013-10-30|2013-10-31|Estimate|April 2002||2002-04-30|October 2013|2013-10-31|October 2003||2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults|A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy|Completed||Phase 4|10||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:32.976471|2018-06-01 04:14:32.976471
NCT00273975|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-30|2006-01-09|2006-01-10|Estimate|||||||2013-10-30|2013-10-31|Estimate|January 2002||2002-01-31|October 2013|2013-10-31|December 2004||2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients|A Randomised Open Label Multi-centre Trial to Evaluate the Pharmacokinetic, Efficacy and Safety Parameters of Nevirapine 150mg/m2 and Nevirapine 4 or 7 mg/kg When Administered in Combination With AZT and 3TC for 48 Weeks in Antiretroviral naïve Paediatric Patients.|Completed||Phase 2|123||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:33.047338|2018-06-01 04:14:33.047338
NCT00273962|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2013-10-28|2006-01-09|2006-01-10|Estimate|||||||2013-10-28|2013-10-29|Estimate|May 2002||2002-05-31|October 2013|2013-10-31|November 2003||2003-11-30|November 2003|Actual|2003-11-30||Interventional|||A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)|A Comparison of Combivent® UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg) in a Double-Blind Efficacy and Safety Study in Asthmatic Children With Severe Acute Exacerbation|Completed||Phase 4|500|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:14:33.147174|2018-06-01 04:14:33.147174
NCT00273949|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-09|||2008-02-05|2006-01-09|2006-01-10|Estimate|||||||2008-02-05|2008-02-06|Estimate|January 2006||2006-01-31|September 2005|2005-09-30|January 2007||2007-01-31|||||Interventional|||Lactulose for the Prevention of Nosocomial Infections in Children|Lactulose for the Prevention of Nosocomial Infections in Children|Unknown status|Active, not recruiting|N/A|100||Bnai Zion Medical Center|||||f||||f||||||||||2018-06-01 04:14:33.213995|2018-06-01 04:14:33.213995
NCT00273936|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2011-08-02|2006-01-06|2006-01-10|Estimate|||||||2011-08-02|2011-08-04|Estimate|January 2006||2006-01-31|August 2011|2011-08-31||||||||Interventional|||Trial of AVN-944 in Patients With Advanced Hematologic Malignancies|A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies|Completed||Phase 1|72|Anticipated|Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 04:14:33.384098|2018-06-01 04:14:33.384098
NCT00273910|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-07|2012-03-30||2012-10-17|2006-01-07|2006-01-09|Estimate|2012-07-06|2012-08-14|Estimate||||2012-10-17|2012-10-19|Estimate|January 2006||2006-01-31|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma|Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma|Completed||Phase 2|104|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||f||||||||||2018-06-01 04:14:33.506383|2018-06-01 04:14:33.506383
NCT00273897|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-07|||2017-06-30|2006-01-06|2006-01-09|Estimate|||||||2017-06-30|2017-07-02|Actual|December 30, 2005||2005-12-30|December 16, 2008|2008-12-16||||December 11, 2007|Actual|2007-12-11||Interventional|||Electrical Polarization of the Brain in Corticobasal Syndrome|Direct Current Brain Polarization for Apraxia in Corticobasal Syndrome|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:14:34.225311|2018-06-01 04:14:34.225311
NCT00273884|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2007-02-16|2006-01-05|2006-01-09|Estimate|||||||2007-02-16|2007-02-19|Estimate|August 2005||2005-08-31|February 2007|2007-02-28|April 2009||2009-04-30|||||Interventional|||Amonafide in Combination With Cytarabine in Secondary AML|Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)|Completed||Phase 2|80||Xanthus Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:14:34.29771|2018-06-01 04:14:34.29771
NCT00273871|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2011-03-07|2006-01-05|2006-01-09|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 2002||2002-01-31|May 2007|2007-05-31|September 2006|Actual|2006-09-30|||||Interventional|||Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients|A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency.|Completed||Phase 3|190||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:14:34.396368|2018-06-01 04:14:34.396368
NCT00273858|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|2011-06-30||2011-09-08|2006-01-04|2006-01-09|Estimate|2011-06-30|2011-07-28|Estimate||||2011-09-08|2011-09-12|Estimate|March 2006||2006-03-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis|Open Label Study To Evaluate The Safety Profile And The Quality Of Life In Patients Receiving Etanercept For The Treatment Of Rheumatoid Arthritis, Ankylosing Spondylitis And Psoriatic Arthritis|Terminated|||880|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1|"The study was terminated because at least one year follow-up was achieved for each patient and~   the achievement of 965 exposure years to the drug."|f||||f||||||||||2018-06-01 04:14:34.50652|2018-06-01 04:14:34.50652
NCT00273806|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2008-08-26|2006-01-04|2006-01-09|Estimate|||||||2008-08-26|2008-08-27|Estimate|December 2005||2005-12-31|August 2008|2008-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Medical Assistant-Based Program to Promote Healthy Behaviors in Primary Care|Engaging the Team: A Multilevel Program to Promote Healthy Behaviors|Completed||N/A|864|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||||||||||||2018-06-01 04:14:35.318906|2018-06-01 04:14:35.318906
NCT00273793|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|2012-03-09||2012-06-14|2006-01-04|2006-01-09|Estimate|2012-05-04|2012-06-07|Estimate||||2012-06-14|2012-06-21|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Increasing Contingency Management Success in Smoking Cessation|Increasing Contingency Management Success Using Shaping|Completed||N/A|328|Actual|The University of Texas Health Science Center at San Antonio|The study was conducted largely as planned. However the study was not designed to adequately test post-treatment outcomes, as this would not be justifiable unless during treatment differences were observed.|6|||f||||||||||||||2018-06-01 04:14:35.41564|2018-06-01 04:14:35.41564
NCT00273780|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2012-08-23|2006-01-05|2006-01-09|Estimate|||||||2012-08-23|2012-08-27|Estimate|May 2006||2006-05-31|August 2012|2012-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Highly Active Antiretroviral Therapy (HAART) Adherence Interventions|HAART Adherence Interventions in Africa: An RCT|Completed||N/A|400|Actual|University of Washington||4|||f||||t||||||||||2018-06-01 04:14:35.874979|2018-06-01 04:14:35.874979
NCT00273767|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2009-12-04|2006-01-06|2006-01-09|Estimate|||||||2009-12-04|2009-12-07|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|EPOetCEC||Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB|Double-blind Phase II Pilot Monocentric Randomized Clinical Trial Evaluating the Effect of a Preliminary Administration of Erythropoietin on Different Markers of Cardiac Ischemia Induced by Cardiopulmonary Bypass|Completed||Phase 2|50|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-06-01 04:14:35.969014|2018-06-01 04:14:35.969014
NCT00273754|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|2009-06-05||2016-05-12|2006-01-04|2006-01-09|Estimate|2010-10-14|2010-11-10|Estimate||||2016-05-12|2016-06-16|Estimate|September 2003||2003-09-30|May 2016|2016-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|OSA||The Effect of Caffeine on Postextubation Adverse Respiratory Events in Children With Obstructive Sleep Apnea (OSA).|A Pilot Study to Evaluate if Caffeine Helps Children With Obstructive Sleep Apnea Recover Faster From Anesthesia, and With Less Complications After General Anesthesia for Tonsillectomy and Adenoidectomy.|Completed||Phase 2|74|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 04:14:36.074714|2018-06-01 04:14:36.074714
NCT00273741|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2009-12-04|2006-01-06|2006-01-09|Estimate|||||||2009-12-04|2009-12-07|Estimate|January 2007||2007-01-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|Ritaline||Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients|Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients|Terminated||Phase 3|39|Actual|University Hospital, Grenoble||2||difficulty of recrutement|f||||t||||||||||2018-06-01 04:14:36.376062|2018-06-01 04:14:36.376062
NCT00273728|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2011-08-11|2006-01-06|2006-01-09|Estimate|||||||2011-08-11|2011-08-12|Estimate|May 2005||2005-05-31|August 2011|2011-08-31|May 2011|Actual|2011-05-31|June 2010|Actual|2010-06-30||Interventional|BaSES||BaSES Trial: Basel Starch Evaluation in Sepsis|Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BaSES (130;0.4) Trial|Completed||Phase 4|231|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-06-01 04:14:36.478159|2018-06-01 04:14:36.478159
NCT00273715|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2013-07-30|2006-01-05|2006-01-09|Estimate|||||||2013-07-30|2013-07-31|Estimate|December 2005||2005-12-31|July 2013|2013-07-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Study of Sutures Versus Staples for Skin Closure After Surgical Procedures of Hip|A Comparative Randomized Efficacy Study of Sutures Versus Staples in Hip Surgical Procedures|Completed||Phase 4|93|Actual|University of Kentucky||1|||f||||f||||||||||2018-06-01 04:14:36.545966|2018-06-01 04:14:36.545966
NCT00273702|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2007-04-27|2006-01-06|2006-01-09|Estimate|||||||2007-04-27|2007-04-30|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|||An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling|An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling|Completed||Phase 1|36|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:14:36.60499|2018-06-01 04:14:36.60499
NCT00273689|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2008-05-01|2006-01-06|2006-01-09|Estimate|||||||2008-05-01|2008-05-07|Estimate|December 2005||2005-12-31|May 2008|2008-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Exercise Induced Bronchospasm in Children|"Pretreatment With Albuterol vs. Montelukast in Exercise Induced Bronchospasm in Children."|Completed||Phase 4|13|Actual|University of New Mexico||1|||f||||t||||||||||2018-06-01 04:14:36.661563|2018-06-01 04:14:36.661563
NCT00273676|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2006-01-05|2006-01-05|2006-01-09|Estimate|||||||2006-01-05|2006-01-09|Estimate|July 2000||2000-07-31|January 2006|2006-01-31|March 2004||2004-03-31|||||Interventional|||Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia|Costs and Effects of Early Switch of Intravenous to Oral Antibiotics in Severe Community-Acquired Pneumonia: a Multicenter Randomized Trial|Completed||Phase 4|500||UMC Utrecht|||||f||||||||||||||2018-06-01 04:14:36.83127|2018-06-01 04:14:36.83127
NCT00273663|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2007-06-28|2006-01-06|2006-01-09|Estimate|||||||2007-06-28|2007-06-29|Estimate|January 2006||2006-01-31|June 2007|2007-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Transcranial Electrical Stimulation (TCES) / Cerebral Blood Flow (CBF) / Xenon Under Computerized Tomography (Xe/CT)|The Effects of Transcranial Electrical Stimulation (TCES) on Cerebral Blood Flow (CBF) With Xenon Under Computerized Tomography (Xe/CT)|Completed||N/A|44|Actual|University Hospital, Bordeaux|||||f||||t||||||||||2018-06-01 04:14:36.902583|2018-06-01 04:14:36.902583
NCT00273650|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2012-10-30|2006-01-06|2006-01-09|Estimate|||||||2012-10-30|2012-11-01|Estimate|July 2005||2005-07-31|October 2012|2012-10-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism|Double-Blind Placebo Controlled, Cross-over Trial of Subcutaneous B12 on Behavioral and Metabolic Measures in Children With Autism.|Completed||Phase 2/Phase 3|35|Actual|University of California, Davis||2|||f||||t||||||||||2018-06-01 04:14:36.967848|2018-06-01 04:14:36.967848
NCT00273637|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2006-05-25|2006-01-05|2006-01-09|Estimate|||||||2006-05-25|2006-05-26|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|January 2006||2006-01-31|||||Observational|||Registry and Survey of Women With Pregnancy Related Cardiomyopathy|Pregnancy Related Cardiomyopathy Enrollment and Lessons in Web-Based Recruitment (PRiCELESS)|Unknown status|Recruiting||175||St. Vincent's Medical Center|||||f||||||||||||||2018-06-01 04:14:37.053951|2018-06-01 04:14:37.053951
NCT00273429|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2007-01-08|2006-01-06|2006-01-09|Estimate|||||||2007-01-08|2007-01-09|Estimate|April 2005||2005-04-30|January 2007|2007-01-31|December 2005||2005-12-31|||||Interventional|||Cosopt Versus Xalatan||Completed||Phase 4|||Pharmaceutical Research Network|||||f||||||||||||||2018-06-01 04:14:38.198394|2018-06-01 04:14:38.198394
NCT00273624|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2016-05-12|2006-01-04|2006-01-09|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2005||2005-06-30|May 2016|2016-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial|Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial|Terminated||Phase 3|60|Actual|University Hospital Freiburg||2|||f||||f||||||||||2018-06-01 04:14:37.120304|2018-06-01 04:14:37.120304
NCT00273611|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2013-11-18|2006-01-04|2006-01-09|Estimate|||||||2013-11-18|2013-11-20|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Vitamin D Levels and Vitamin D Education in Geriatric Patients|Characterization of Vitamin D Levels and Affect of Pharmacist-initiated Vitamin D Education in Geriatric Outpatients.|Completed||N/A|80|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 04:14:37.198861|2018-06-01 04:14:37.198861
NCT00273598|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2017-10-11|2006-01-04|2006-01-09|Estimate|||||||2017-10-11|2017-10-12|Actual|September 1997||1997-09-30|October 2017|2017-10-31|September 2002|Actual|2002-09-30|||||Interventional|||Comparing Two Instrumentation Systems for the Treatment of Adolescent Scoliosis|Comparing the Moss Miami and Universal Spinal Instrumentation Systems for the Treatment of Adolescent Idiopathic Scoliosis|Completed||Phase 2|126||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:14:37.277234|2018-06-01 04:14:37.277234
NCT00273585|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2006-09-06|2006-01-06|2006-01-09|Estimate|||||||2006-09-06|2006-09-08|Estimate|August 2005||2005-08-31|September 2006|2006-09-30|February 2006||2006-02-28|||||Interventional|||Study of Using Computerized Education to Increase Patients' Confidence in Their Ability to Be Screened for Colon Cancer|Randomized Controlled Trial of Software-Based Enhancement of Colorectal Cancer Screening Self-Efficacy|Completed||Phase 3|100||University of California, Davis|||||f||||||||||||||2018-06-01 04:14:37.361004|2018-06-01 04:14:37.361004
NCT00273572|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2008-10-27|2006-01-05|2006-01-09|Estimate|||||||2008-10-27|2008-10-29|Estimate|December 2004||2004-12-31|October 2008|2008-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Lifestyle Intervention in Obese Arab Women|The Effect of a Lifestyle Intervention Program on Parameters of the Metabolic Syndrome Among Non-Diabetic Obese Arab Women|Completed||N/A|200|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 04:14:37.428583|2018-06-01 04:14:37.428583
NCT00273559|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2008-05-08|2006-01-05|2006-01-09|Estimate|||||||2008-05-08|2008-05-12|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|December 2008|Anticipated|2008-12-31|||||Observational|||A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids|A Single Center, Open Label, Comparative, Controlled Trial to Assess the Risks and Benefits of Steroid Elimination vs. Steroid Therapy After Renal Transplantation|Unknown status|Active, not recruiting||60|Anticipated|Florida Hospital Transplant Center|||2||f||||t||||||||||2018-06-01 04:14:37.51461|2018-06-01 04:14:37.51461
NCT00273546|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2009-04-28|2006-01-06|2006-01-09|Estimate|||||||2009-04-28|2009-04-29|Estimate|May 1999||1999-05-31|April 2009|2009-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer|A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progression Free Survival in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|500|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:14:37.58864|2018-06-01 04:14:37.58864
NCT00273533|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2008-07-21|2006-01-06|2006-01-09|Estimate|||||||2008-07-21|2008-07-22|Estimate|June 2004||2004-06-30|October 2006|2006-10-31|July 2006||2006-07-31|||||Interventional|||Ramipril in Rheumatoid Arthritis|Effects of Ramipril on Endothelial Function in Patients With Rheumatoid Arthritis|Completed||Phase 2/Phase 3|13|Actual|University of Zurich|||||f||||||||||||||2018-06-01 04:14:37.660349|2018-06-01 04:14:37.660349
NCT00273520|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2009-09-14|2006-01-06|2006-01-09|Estimate|||||||2009-09-14|2009-09-15|Estimate|January 2003||2003-01-31|September 2009|2009-09-30|May 2004|Actual|2004-05-31|April 2004|Actual|2004-04-30||Interventional|||TELICAST : Telithromycin in Acute Exacerbations of Asthma|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Telithromycin 800 mg (Once Daily for 10 Days) as a Supplement to the Standard of Care for Patients With Acute Exacerbations of Asthma|Completed||Phase 3|||Sanofi|||||f||||f||||||||||2018-06-01 04:14:37.713735|2018-06-01 04:14:37.713735
NCT00273507|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2009-09-17|2006-01-05|2006-01-09|Estimate|||||||2009-09-17|2009-09-18|Estimate|January 1998||1998-01-31|September 2009|2009-09-30|January 2006||2006-01-31|||||Interventional|||Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3|Neoadjuvant Chemotherapy in Resectable NSCLC Stages IB, IIA, IIB, and IIIA/T3 But Not IIIA/N2|Terminated||Phase 3|270||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:14:37.767791|2018-06-01 04:14:37.767791
NCT00273494|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2008-05-21|2006-01-05|2006-01-09|Estimate|||||||2008-05-21|2008-05-22|Estimate|January 1998||1998-01-31|May 2008|2008-05-31|January 2008||2008-01-31|||||Interventional|||Neoadjuvant Chemotherapy Plus/Minus Surgery in Non-Small-Cell Lung Cancer (NSCLC) Stage IIIA/N2|Scandinavian Neoadjuvant Phase III Study of Induction Chemotherapy Followed by Irradiation Alone or Surgery Plus Irradiation in NSCLC Stage IIIA/N2 (T1N2, T2N2, T3/N2).|Unknown status|Recruiting|Phase 3|406|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:14:37.827201|2018-06-01 04:14:37.827201
NCT00273481|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2008-11-18|2006-01-06|2006-01-09|Estimate|||||||2008-11-18|2008-11-19|Estimate|September 2005||2005-09-30|November 2008|2008-11-30|April 2007|Actual|2007-04-30|||||Interventional|||Cosopt Versus Xalacom||Completed||Phase 4|33||Pharmaceutical Research Network|||||f||||||||||||||2018-06-01 04:14:37.905434|2018-06-01 04:14:37.905434
NCT00273468|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2008-05-02|2006-01-06|2006-01-09|Estimate|||||||2008-05-02|2008-05-06|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|October 2006|Actual|2006-10-31|||||Interventional|||To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)|A Randomised, Active Control, Double-Blind, Double-Dummy, Parallel-Group, Multi-National Study to Assess the Efficacy, Tolerability and Safety of the Granisetron Transdermal Delivery System in Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Administration of Moderately or Highly Emetogenic Multi-Day Chemotherapy|Completed||Phase 3|630||Prostrakan Pharmaceuticals|||||f||||||||||||||2018-06-01 04:14:37.970491|2018-06-01 04:14:37.970491
NCT00273455|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2008-11-18|2006-01-06|2006-01-09|Estimate|||||||2008-11-18|2008-11-19|Estimate|January 2006||2006-01-31|November 2008|2008-11-30|May 2007|Actual|2007-05-31|||||Interventional|||Lumigan Versus Cosopt||Completed||Phase 4|34||Pharmaceutical Research Network|||||f||||||||||||||2018-06-01 04:14:38.037344|2018-06-01 04:14:38.037344
NCT00273442|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2008-11-18|2006-01-06|2006-01-09|Estimate|||||||2008-11-18|2008-11-19|Estimate|November 2005||2005-11-30|November 2008|2008-11-30|April 2007|Actual|2007-04-30|||||Interventional|||Assessing Cosopt Switch Patients||Completed||Phase 4|60||Pharmaceutical Research Network|||||f||||||||||||||2018-06-01 04:14:38.125592|2018-06-01 04:14:38.125592
NCT00273416|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-08-23|2006-01-04|2006-01-09|Estimate|||||||2006-08-23|2006-08-24|Estimate|January 2006||2006-01-31|August 2006|2006-08-31||||||||Interventional|||A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses|A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses Of PF-00592379 On Erectile Function, Using 100mg Sildenafil As A Positive Control|Completed||Phase 2|32||Pfizer|||||f||||||||||||||2018-06-01 04:14:38.359878|2018-06-01 04:14:38.359878
NCT00273403|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-09-21|2006-01-04|2006-01-09|Estimate|||||||2006-09-21|2006-09-22|Estimate|November 1999||1999-11-30|September 2006|2006-09-30|November 2006||2006-11-30|||||Interventional|||Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA|Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA|Unknown status|Recruiting|N/A|5100||The New York Academy of Medicine|||||f||||||||||||||2018-06-01 04:14:38.437561|2018-06-01 04:14:38.437561
NCT00273390|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2011-07-01|2006-01-05|2006-01-09|Estimate|||||||2011-07-01|2011-07-04|Estimate|August 2001||2001-08-31|January 2008|2008-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Clinical Trial of Infliximab for Uveitis|The Use of Remicade (Infliximab) in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression|Completed||N/A|32||Oregon Health and Science University|||||f||||||||||||||2018-06-01 04:14:38.54385|2018-06-01 04:14:38.54385
NCT00273377|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2016-06-27|2006-01-05|2006-01-09|Estimate|||||||2016-06-27|2016-06-29|Estimate|May 2002||2002-05-31|June 2016|2016-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection|The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection|Completed||Phase 3|2000|Anticipated|The Cleveland Clinic|||||f||||t||||||||||2018-06-01 04:14:38.592307|2018-06-01 04:14:38.592307
NCT00273364|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2017-07-17|2006-01-05|2006-01-09|Estimate|||||||2017-07-17|2017-07-19|Actual|January 2006||2006-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study|Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study|Active, not recruiting||Phase 3|110|Anticipated|Northwestern University||2|||f||||t||||||||||2018-06-01 04:14:38.660637|2018-06-01 04:14:38.660637
NCT00273351|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04||2014-04-21|2014-04-21|2006-01-04|2006-01-09|Estimate||||2014-04-21|2014-05-09|Estimate|2014-04-21|2014-05-09|Estimate|January 2006||2006-01-31|April 2014|2014-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families|Assessment of Pre-symptomatic and Symptomatic Patients With Parkinson Disease to Identify and Characterize Genetic and Phenotypic Biomarkers for Disease Onset and Progression.|Completed||Phase 2|62|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 04:14:38.738362|2018-06-01 04:14:38.738362
NCT00273338|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2007-11-02|2006-01-05|2006-01-09|Estimate|||||||2007-11-02|2007-11-06|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])|A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)|Terminated||Phase 3|1200|Anticipated|Novacea||||DSMB|||||||||||||||2018-06-01 04:14:38.903593|2018-06-01 04:14:38.903593
NCT00273325|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-09-22|2006-01-05|2006-01-09|Estimate|||||||2017-09-22|2017-09-26|Actual|July 2004||2004-07-31|September 2017|2017-09-30|March 2009|Actual|2009-03-31|July 2007|Actual|2007-07-31||Observational|PCV-7||Immunogenicity of PCV-7 Vaccine in VLBW Infants|Observational Study of the Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Very-low-birth-weight Infants|Completed|||368|Actual|NICHD Neonatal Research Network|||||f||||t||||||Samples With DNA|"~     Serum was separated from blood samples. After all study assays were completed on all~     subjects, if a subject's parents asked that his/her serum not be stored, the serum was~     destroyed. For subjects whose parents permit it, leftover serum was re-labeled with a new,~     randomly-generated unique de-identifier, linked only to the subject's gestational age, birth~     weight, and chronologic age at the time of sampling. The link to any other subject~     identifiers will then be destroyed. The serum will be stored indefinitely at the University~     of Rochester for other, non-genetic-testing-related research.~   "|||2018-06-01 04:14:39.268318|2018-06-01 04:14:39.268318
NCT00273312|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2017-02-03|2006-01-04|2006-01-09|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 2006||2006-01-31|February 2017|2017-02-28||||October 2006|Actual|2006-10-31||Interventional|||Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma|An Open-label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC)|Completed||Phase 2|25|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:14:39.388603|2018-06-01 04:14:39.388603
NCT00273299|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2011-11-07|2006-01-04|2006-01-09|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2005||2005-11-30|November 2011|2011-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension|A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension|Completed||Phase 3|607|Actual|Novartis|||||||||||||||||||2018-06-01 04:14:39.484708|2018-06-01 04:14:39.484708
NCT00273286|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2011-05-11|2006-01-05|2006-01-09|Estimate|||||||2011-05-11|2011-05-13|Estimate|January 2006||2006-01-31|April 2011|2011-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Family Management of Type 1 Diabetes in Children|Family Management of Childhood Diabetes Study|Completed||Phase 2|422|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||t||||||||||2018-06-01 04:14:39.551596|2018-06-01 04:14:39.551596
NCT00273273|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2017-02-27|2006-01-05|2006-01-09|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2006||2006-02-28|February 2016|2016-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir|Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults With HIV Infection|Completed|||30||University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 04:14:39.628065|2018-06-01 04:14:39.628065
NCT00273260|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2006-05-08|2006-01-05|2006-01-09|Estimate|||||||2006-05-08|2006-05-09|Estimate|January 2000||2000-01-31|January 2006|2006-01-31|December 2002||2002-12-31|||||Interventional|||The Effectiveness of Individualised Bone Density Feedback and Osteoporosis Education in Premenopausal Women|The Effect on Behavior and Bone Mineral Density of Individualized Bone Mineral Density Feedback and Educational Interventions in Premenopausal Women: a Randomized Controlled Trial.|Completed||Phase 2|400||Menzies Institute for Medical Research|||||f||||||||||||||2018-06-01 04:14:39.724528|2018-06-01 04:14:39.724528
NCT00273247|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2006-01-05|2006-01-05|2006-01-09|Estimate|||||||2006-01-05|2006-01-09|Estimate|June 1998||1998-06-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis|Adjuvant α-Interferon Treatment After Resection of Hepatocellular Carcinoma in HCV-Related Cirrhosis: a Randomized Trial on Prevention of Cancer Recurrence|Completed||Phase 3|150||National Cancer Institute, Milan|||||f||||||||||||||2018-06-01 04:14:39.799369|2018-06-01 04:14:39.799369
NCT00273234|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2007-03-04|2006-01-04|2006-01-09|Estimate|||||||2007-03-04|2007-03-06|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|November 2006||2006-11-30|||||Interventional|||Clinical Effectiveness of Topical Autologous Platelet Gel for the Treatment of Venous Ulcers|Clinical Evaluation of the Safety and Effectiveness of Topical Autologous Platelet Gel (APG) for the Treatment of Lower Extremity Chronic Venous Insufficiency Ulcers. A Multicenter, Randomized, Controlled Clinical Trial|Withdrawn||Phase 3|70||National Healing Corporation||||Lack of financial support. Study criteria severly limited enrollment.|||||||||||||||2018-06-01 04:14:39.895679|2018-06-01 04:14:39.895679
NCT00273221|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2008-05-21|2006-01-06|2006-01-09|Estimate|||||||2008-05-21|2008-05-22|Estimate|July 2005||2005-07-31|May 2008|2008-05-31|July 2006|Anticipated|2006-07-31|||||Interventional|||Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial|Combined Phacoemulsification and Glaucoma Implant Surgery Versus Combined Phacoemulsification and Trabeculectomy: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|50|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:14:39.969116|2018-06-01 04:14:39.969116
NCT00273208|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2007-08-01|2006-01-05|2006-01-09|Estimate|||||||2007-08-01|2007-08-02|Estimate|September 2005||2005-09-30|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||An Intervention to Decrease Fatigue Among Breast Cancer Survivors|Being Well, Staying Healthy: An Integrated Mind-Body Medicine Intervention to Decrease Fatigue Among Breast Cancer Survivors, PILOT STUDY|Completed||N/A|25||Mercy Medical Center|||||f||||f||||||||||2018-06-01 04:14:40.09566|2018-06-01 04:14:40.09566
NCT00273195|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-10-11|2006-01-04|2006-01-09|Estimate|||||||2006-10-11|2006-10-13|Estimate|April 2004||2004-04-30|October 2006|2006-10-31|June 2005||2005-06-30|||||Interventional|||Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG|Clinical Investigation of the Medtronic EnTrust™ Implantable Cardioverter Defibrillator (ICD), Model D153ATG|Completed||N/A|500||Medtronic Cardiac Rhythm and Heart Failure|||||||||||||||||||2018-06-01 04:14:40.187009|2018-06-01 04:14:40.187009
NCT00273182|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|2012-04-13||2013-07-01|2006-01-04|2006-01-09|Estimate|2013-07-01|2013-08-05|Estimate||||2013-07-01|2013-08-05|Estimate|March 2002||2002-03-31|July 2013|2013-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry|InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Systems for Cardiac Resynchronization Therapy (CRT) - InSync Registry|Completed|||1999|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||||2018-06-01 04:14:40.318614|2018-06-01 04:14:40.318614
NCT00273169|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2010-01-14|2006-01-06|2006-01-09|Estimate|||||||2010-01-14|2010-01-15|Estimate|July 2005||2005-07-31|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Use of the PSA 4000 Monitor in the Post-Operative Period in Patients Undergoing Major Surgery|Use of the PSA 4000 Monitor in the Post-Operative Period in Patients Undergoing Major Surgery|Completed|||50|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:40.709874|2018-06-01 04:14:40.709874
NCT00273156|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2013-04-22|2006-01-06|2006-01-09|Estimate|||||||2013-04-22|2013-04-23|Estimate|February 2005||2005-02-28|April 2013|2013-04-30|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Interventional|||A Brief Dental Office Intervention With Tobacco Quitline|A Brief Dental Office Intervention With Tobacco Quitline|Completed||Phase 3|90|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:40.775027|2018-06-01 04:14:40.775027
NCT00273143|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2011-05-20|2006-01-06|2006-01-09|Estimate|||||||2011-05-20|2011-05-24|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.|Kinetics of Cytomegalovirus (CMV) Replication and CMV-specific Immune Reconstitution After Hematopoietic Stem Cell Transplantation.|Completed|||50||Mayo Clinic|||||f||||||||||||||2018-06-01 04:14:40.923243|2018-06-01 04:14:40.923243
NCT00273130|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2006-09-11|2006-01-05|2006-01-09|Estimate|||||||2006-09-11|2006-09-13|Estimate|March 1999||1999-03-31|December 2003|2003-12-31|August 2002||2002-08-31|||||Interventional|||Stress Response Using Thin and Standard Size Endoscopy.|Randomised Evaluation of Neuroendocrine Stress Response During Upper Gastrointestinal Endoscopy With Standard or Ultrathin Endoscope.|Terminated||Phase 2/Phase 3|60||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:14:41.012101|2018-06-01 04:14:41.012101
NCT00273117|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2006-01-06|2006-01-06|2006-01-09|Estimate|||||||2006-01-06|2006-01-09|Estimate|February 2002||2002-02-28|January 2006|2006-01-31|August 2003||2003-08-31|||||Observational|||Transnasal and Oral Gastroscopy.|Transnasal and Conventional Oral Diagnostic Gastroscopy. A Prospective Randomised Study.|Terminated|||100||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:14:41.084009|2018-06-01 04:14:41.084009
NCT00273104|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2018-04-18|2006-01-05|2006-01-09|Estimate|||||||2018-04-18|2018-04-19|Actual|December 2005||2005-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Lifestyle Intervention Versus Gastric Bypass on Various Comorbidities in Morbidly Obese Subjects|The Effect of Lifestyle Intervention vs Gastric Bypass on Various Comorbidities|Completed||N/A|180|Actual|The Hospital of Vestfold||2|||f||||f||||||||||2018-06-01 04:14:41.165295|2018-06-01 04:14:41.165295
NCT00273091|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2017-02-17|2006-01-05|2006-01-09|Estimate|||||||2017-02-17|2017-02-23|Actual|August 2003||2003-08-31|February 2017|2017-02-28|May 2007|Actual|2007-05-31|||||Observational|||MODULA Modul 5 BEAT-HF|MODULA-Study: Modul 5 / BEAT HF: Detektion and Registration of Atrial Tachyarrhythmias at Patients With Heart Failure|Completed|||100|Anticipated|Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:14:41.257593|2018-06-01 04:14:41.257593
NCT00273078|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2007-04-26|2006-01-06|2006-01-09|Estimate|||||||2007-04-26|2007-04-27|Estimate|January 2006||2006-01-31|April 2007|2007-04-30||||||||Observational|||Tongue Pressure Recording During Speech|Experimental Study About Tongue Interactions With Teeth and Palate During Speech, Using Strain Gauge Transducer and Complete Denture. Comparison of Adaptation Phenomenon’s Between Patients With New Complete Denture.|Unknown status|Recruiting||20||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:14:41.382175|2018-06-01 04:14:41.382175
NCT00273065|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2007-02-16|2006-01-04|2006-01-09|Estimate|||||||2007-02-16|2007-02-19|Estimate|May 2005||2005-05-31|February 2007|2007-02-28|September 2005||2005-09-30|||||Interventional|||Local Anesthetic Properties of Neosaxitoxin|Phase 1 Study of Local Infiltration of Neosaxitoxin as a Local Anesthetic|Completed||Phase 1|10||University of Chile|||||f||||||||||||||2018-06-01 04:14:41.448181|2018-06-01 04:14:41.448181
NCT00272363|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2018-05-19|2006-01-04|2006-01-05|Estimate|||||||2018-05-19|2018-05-22|Actual|December 29, 2005||2005-12-29|July 29, 2016|2016-07-29|July 29, 2016||2016-07-29|||||Observational|||Clinical and Molecular Studies in Families With Glaucoma and Related Diseases|Clinical and Molecular Studies in Families With Glaucoma and Related Diseases|Completed|||484|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:14:55.553793|2018-06-01 04:14:55.553793
NCT00273052|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|2008-12-19||2016-12-02|2006-01-05|2006-01-09|Estimate|2010-01-06|2010-02-01|Estimate||||2016-12-02|2017-02-02|Estimate|January 2006||2006-01-31|December 2016|2016-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension|A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) With Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients|Completed||Phase 3|514|Actual|GlaxoSmithKline||2|||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:14:41.606839|2018-06-01 04:14:41.606839
NCT00273039|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2016-10-24|2006-01-06|2006-01-09|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2005||2005-08-31|October 2016|2016-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder|Completed||Phase 2|242|Actual|GlaxoSmithKline|||||||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:14:42.290839|2018-06-01 04:14:42.290839
NCT00273026|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2018-03-19|2006-01-05|2006-01-09|Estimate|||||||2018-03-19|2018-03-21|Actual|November 8, 2004||2004-11-08|March 2018|2018-03-31|March 28, 2006|Actual|2006-03-28|||||Interventional|||Study In Asthma Control|An Open-label, Multi-centre, Randomized, Parallel Group Clinical Effectiveness Study to Determine the Level of Asthma Control in Adolescent and Adult Patients With ADVAIR Versus Usual Care for 24 Weeks.|Terminated||Phase 4|680||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:14:42.416055|2018-06-01 04:14:42.416055
NCT00273013|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2017-10-17|2006-01-05|2006-01-09|Estimate|||||||2017-10-17|2017-10-18|Actual|November 15, 2004|Actual|2004-11-15|October 2017|2017-10-31|October 28, 2005|Actual|2005-10-28|October 28, 2005|Actual|2005-10-28||Interventional|||Study With GW274150 In Patients With Mild Asthma|Single Centre Allergen Challenge Study of GW274150 in Mild Asthmatic Subjects|Completed||Phase 1|28|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-06-01 04:14:42.703124|2018-06-01 04:14:42.703124
NCT00273000|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2006-09-07|2006-01-06|2006-01-09|Estimate|||||||2006-09-07|2006-09-11|Estimate|January 2006||2006-01-31|October 2005|2005-10-31||||||||Interventional|||The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans|The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans|Unknown status|Recruiting|N/A|10||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 04:14:42.804759|2018-06-01 04:14:42.804759
NCT00272987|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|2014-07-28|2010-08-12|2018-01-09|2006-01-05|2006-01-09|Estimate|2014-08-18|2014-08-20|Estimate|2011-11-03|2011-11-10|Estimate|2018-01-09|2018-02-05|Actual|December 13, 2005|Actual|2005-12-13|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2009|Actual|2009-07-31||Interventional|||ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib|A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women With ErbB2 Overexpressing Metastatic Breast Cancer|Active, not recruiting||Phase 3|63|Actual|Novartis||1|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 04:14:42.944093|2018-06-01 04:14:42.944093
NCT00272974|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-01-04|2006-01-04|2006-01-09|Estimate|||||||2006-01-04|2006-01-09|Estimate|February 2001||2001-02-28|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||Madagascar Female Condom Study|Measuring the Impact of Male and Female Condom Promotion Among Commercial Sex Workers in Madagascar|Completed||Phase 3|1000||FHI 360|||||f||||||||||||||2018-06-01 04:14:46.565558|2018-06-01 04:14:46.565558
NCT00272961|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|2013-01-28|2012-01-26|2013-01-28|2006-01-04|2006-01-09|Estimate|2013-01-28|2013-03-05|Estimate|2012-08-23|2012-08-30|Estimate|2013-01-28|2013-03-05|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.|A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension|Terminated||Phase 2|60|Actual|Pfizer|Results for ‘change from standing to sitting SBP and DBP’ and ‘change from pre-dose to post-dose SBP and DBP’ are reported only at Week 10 as per changes in planned analysis because of early termination of the study and clinical development program.|5||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:14:46.718763|2018-06-01 04:14:46.718763
NCT00272948|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2011-06-08|2006-01-04|2006-01-09|Estimate|||||||2011-06-08|2011-06-09|Estimate|December 2005||2005-12-31|June 2011|2011-06-30|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|VOD-DF||Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide|Prospective Randomized Study of the Incidence and Outcome of Veno-Occlusive Disease (VOD) With the Prophylactic Use of Defibrotide (DF) in Pediatric Stem Cell Transplantation|Completed||Phase 2/Phase 3|360|Anticipated|European Group for Blood and Marrow Transplantation||2|||f||||t||||||||||2018-06-01 04:14:48.057688|2018-06-01 04:14:48.057688
NCT00272935|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2012-06-29|2006-01-04|2006-01-09|Estimate|||||||2012-06-29|2012-07-03|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes|A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Demonstrate the Safety and Efficacy of Daily 0.3 mg Synthetic Conjugated Estrogens, A (Cenestin) for the Treatment of Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 3|400|Anticipated|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:14:48.213294|2018-06-01 04:14:48.213294
NCT00272922|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2007-10-17|2006-01-04|2006-01-09|Estimate|||||||2007-10-17|2007-10-18|Estimate|July 2002||2002-07-31|October 2007|2007-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Randomized, Prospective Controlled Trial of Paraesophageal Hernia Repair With Small Intestinal Submucosa (SIS)|Randomized, Prospective Controlled Trial of Paraesophageal Hernia Repair With Small Intestinal Submucosa (SIS)|Completed||N/A|150||Cook Group Incorporated|||||f||||||||||||||2018-06-01 04:14:48.432463|2018-06-01 04:14:48.432463
NCT00269243|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2006-02-06|2005-12-22|2005-12-23|Estimate|||||||2006-02-06|2006-02-08|Estimate|November 1999||1999-11-30|December 2005|2005-12-31|May 2005||2005-05-31|||||Interventional|||Management With Accupril Post Bypass Graft|The Ischemia Management With Accupril Post Bypass Graft Via Inhibition of the coNverting Enzyme (IMAGINE) Trial|Completed||Phase 4|||Montreal Heart Institute|||||f||||||||||||||2018-06-01 04:15:39.37518|2018-06-01 04:15:39.37518
NCT00272909|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2015-10-19|2006-01-05|2006-01-09|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2004||2004-09-30|October 2015|2015-10-31|January 2007|Actual|2007-01-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)|A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI|Terminated||Phase 2|43|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-06-01 04:14:48.493187|2018-06-01 04:14:48.493187
NCT00272896|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-01-04|2006-01-04|2006-01-09|Estimate|||||||2006-01-04|2006-01-09|Estimate|October 2004||2004-10-31|October 2004|2004-10-31|September 2005||2005-09-30|||||Interventional|||Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in Migraineurs|Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide (VIP) in Migraineurs|Completed||N/A|12||Danish Headache Center|||||f||||||||||||||2018-06-01 04:14:48.633881|2018-06-01 04:14:48.633881
NCT00272883|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2018-03-21|2006-01-05|2006-01-09|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2003||2003-08-31|March 2018|2018-03-31|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31||Observational|||Molecular and Genetic Studies of Congenital Myopathies|Molecular Analysis of Neuromuscular Disease|Recruiting|||4000|Anticipated|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     The primary biospecimens retained are blood, saliva and muscle tissue samples. Other~     specimens are retained on a case-by-case basis.~   "|||2018-06-01 04:14:48.709204|2018-06-01 04:14:48.709204
NCT00272870|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2012-08-28|2006-01-04|2006-01-09|Estimate|||||||2012-08-28|2012-08-29|Estimate|December 2005||2005-12-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|December 2008|Actual|2008-12-31||Interventional|||Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy|A Pilot Study of Temozolomide and 06Benzylguanine for Treatment of Newly Diagnosed High Grade Glioma, Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection|Terminated||Phase 1|1|Actual|Children's Hospital Medical Center, Cincinnati||||Slow accrual; drug availability|f||||t||||||||||2018-06-01 04:14:48.80515|2018-06-01 04:14:48.80515
NCT00272857|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2017-06-21|2006-01-04|2006-01-09|Estimate|||||||2017-06-21|2017-06-23|Actual|August 2004||2004-08-31|June 2017|2017-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia|Gene Transfer From Patients With Fanconi Anemia, Genotype A: A Pilot Study|Completed||Phase 1|3|Actual|Boston Children’s Hospital||1|||f||||t||||||||No||2018-06-01 04:14:48.87947|2018-06-01 04:14:48.87947
NCT00272844|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|2013-07-29||2017-09-21|2006-01-04|2006-01-09|Estimate|2017-09-21|2017-10-20|Actual||||2017-09-21|2017-10-20|Actual|January 1998||1998-01-31|September 2017|2017-09-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional||All patients had elevation of 7-DHC diagnostic of SLOS|Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome|Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome|Completed||Phase 1/Phase 2|23|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-06-01 04:14:48.969559|2018-06-01 04:14:48.969559
NCT00272831|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2009-05-21|2006-01-05|2006-01-09|Estimate|||||||2009-05-21|2009-05-22|Estimate|December 2005||2005-12-31|May 2009|2009-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Use of Cilostazol in Patients With Diabetic Nephropathy|A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese|Completed||Phase 4|62|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 04:14:49.128744|2018-06-01 04:14:49.128744
NCT00272818|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2016-01-26|2006-01-04|2006-01-09|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2004||2004-09-30|January 2016|2016-01-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Observational|||Study to Identify Non-Invasive Markers of Gastrointestinal Allergy|Non Invasive Markers in the Diagnosis and Interval Assessment of Children and Adults With Known or Suspected Allergic Disease|Completed|||110|Actual|Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:14:49.200875|2018-06-01 04:14:49.200875
NCT00272805|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2013-02-15|2006-01-05|2006-01-09|Estimate|||||||2013-02-15|2013-02-18|Estimate|October 2005||2005-10-31|February 2013|2013-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg|Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate Release(IR)on Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction|Completed||Phase 3|400||Cardiovascular Clinical Studies|||||f||||||||||||||2018-06-01 04:14:49.264476|2018-06-01 04:14:49.264476
NCT00272792|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|2009-01-29||2015-07-23|2006-01-05|2006-01-09|Estimate|2009-05-18|2009-07-09|Estimate||||2015-07-23|2015-08-13|Estimate|February 2006||2006-02-28|July 2015|2015-07-31|November 2006|Actual|2006-11-30|||||Interventional|||Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet|A Phase 3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet|Completed||Phase 3|45|Actual|BioMarin Pharmaceutical||2|||||||||||||||||2018-06-01 04:14:49.415701|2018-06-01 04:14:49.415701
NCT00272779|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|2010-12-03||2011-04-07|2006-01-05|2006-01-09|Estimate|2011-04-07|2011-05-09|Estimate||||2011-04-07|2011-05-09|Estimate|November 2005||2005-11-30|April 2011|2011-04-30|October 2008|Actual|2008-10-31|June 2007|Actual|2007-06-30||Interventional|||BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada|A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects|Completed||Phase 3|1057|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 04:14:50.008233|2018-06-01 04:14:50.008233
NCT00272766|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-10-25|2006-01-05|2006-01-09|Estimate|||||||2006-10-25|2006-10-27|Estimate|February 2006||2006-02-28|October 2006|2006-10-31|May 2007||2007-05-31|||||Interventional|||Macugen for Histoplasmosis|Macugen for Histoplasmosis-An Open-Label, Single-Site, Comparative, Prospective Case Series|Terminated||N/A|24||Barnes Retina Institute|||||||||||||||||||2018-06-01 04:14:52.66907|2018-06-01 04:14:52.66907
NCT00272753|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2011-05-31|2006-01-05|2006-01-09|Estimate|||||||2011-05-31|2011-06-01|Estimate|April 2004||2004-04-30|May 2011|2011-05-31|November 2005|Actual|2005-11-30|||||Interventional|||Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations|A Randomized Double Blind Comparison Between Single Doses of Symbicort Turbuhaler (Budesonide/Formoterol Combination), Formoterol, Salbutamol and Placebo in Repeated AMP-challenges in Patients With Mild - to Moderate Asthma. Investigating the Supplementary Value of the Budesonide Component Within Symbicort When Tested in a Model of Slow Onset Acute Asthma|Completed||Phase 4|20||AstraZeneca|||||f||||f||||||||||2018-06-01 04:14:52.811954|2018-06-01 04:14:52.811954
NCT00272740|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2007-02-08|2006-01-04|2006-01-09|Estimate|||||||2007-02-08|2007-02-09|Estimate|March 2000||2000-03-31|February 2007|2007-02-28||||||||Interventional|||SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer|An Open, Multicenter Phase II Trial Evaluating the Antitumour Efficacy of Faslodex® (Fulvestrant) in Postmenopausal Women With Advanced Breast Cancer Failing Non-Steroidal or Steroidal Aromatase Inhibitors|Completed||Phase 2|93||AstraZeneca|||||f||||||||||||||2018-06-01 04:14:52.901112|2018-06-01 04:14:52.901112
NCT00272727|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2011-01-21|2006-01-04|2006-01-09|Estimate|||||||2011-01-21|2011-01-24|Estimate|February 2006||2006-02-28|January 2011|2011-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver|Improved Quality of the Treatment and Increased Compliance in Asthmatics Through the Dialog Tool Soren - Between Patient and Caregiver|Completed||N/A|100||AstraZeneca|||||f||||||||||||||2018-06-01 04:14:52.999233|2018-06-01 04:14:52.999233
NCT00272714|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2013-07-11|2006-01-05|2006-01-09|Estimate|||||||2013-07-11|2013-07-15|Estimate|March 2003||2003-03-31|July 2013|2013-07-31|April 2005|Actual|2005-04-30|March 2004|Actual|2004-03-31||Interventional|||Study of Afimoxifene Gel to Treat Cyclic Mastalgia in Premenopausal Women|A Phase II, Randomized, Double-Blind, Two-Dose, Placebo-Controlled Multicentre Study of 4-Hydroxy Tamoxifen Gel for Cyclical Mastalgia in Otherwise Healthy Pre-Menopausal Women With Regular Menstrual Cycles.|Completed||Phase 2|146|Actual|ASCEND Therapeutics|||||f||||f||||||||||2018-06-01 04:14:53.078473|2018-06-01 04:14:53.078473
NCT00272701|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2009-03-05|2006-01-04|2006-01-09|Estimate|||||||2009-03-05|2009-03-06|Estimate|December 2005||2005-12-31|August 2007|2007-08-31|February 2007|Actual|2007-02-28|||||Interventional|||Esomeprazole in PPI Failures - IMPROVE|A Randomised, Open, Phase IV, Parallel Group Multicentre Study to Evaluate a Change of Management in Gastroesophageal Reflux Disease (GERD) Patients by Treatment With Esomeprazole 40 mg or Any Other Proton Pump Inhibitor (PPI), After Initial Treatment Failure, in Ordinary Clinical Practice During 4 Weeks.|Completed||Phase 4|450|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:14:53.160826|2018-06-01 04:14:53.160826
NCT00272688|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06|||2015-12-29|2006-01-06|2006-01-09|Estimate|||||||2015-12-29|2015-12-30|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit|Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation|Completed||Phase 4|10|Actual|University Hospital, Akershus|||||f||||||||||||||2018-06-01 04:14:53.322333|2018-06-01 04:14:53.322333
NCT00272675|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-01-06|2006-01-06|2006-01-09|Estimate|||||||2006-01-06|2006-01-09|Estimate|August 2003||2003-08-31|January 2006|2006-01-31|September 2005||2005-09-30|||||Interventional|||Prevention of Nosocomial Infection by Decontamination of the Naso- and Oropharynx With Chlorhexidine (NONI Trial)|Prevention of Nosocomial Infection in Cardiac Surgery by Decontamination of the Naso- and Oropharynx With Chlorhexidine. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.|Completed||Phase 2/Phase 3|1000||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||||||||||||2018-06-01 04:14:53.397112|2018-06-01 04:14:53.397112
NCT00272662|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2012-12-19|2006-01-05|2006-01-09|Estimate|||||||2012-12-19|2012-12-21|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy|A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy|Completed||Phase 2|60|Actual|Affymax||4|||f||||f||||||||||2018-06-01 04:14:53.476447|2018-06-01 04:14:53.476447
NCT00272649|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-06||2013-03-06|2013-03-06|2006-01-06|2006-01-09|Estimate||||2013-03-06|2013-03-14|Estimate|2013-03-06|2013-03-14|Estimate|January 2006||2006-01-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer|A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma|Completed||Phase 1/Phase 2|22|Actual|Argos Therapeutics||1|||f||||t||||||||||2018-06-01 04:14:53.592783|2018-06-01 04:14:53.592783
NCT00272636|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2015-06-02|2006-01-03|2006-01-06|Estimate|||||||2015-06-02|2015-06-03|Estimate|November 2002||2002-11-30|January 2006|2006-01-31|February 2005||2005-02-28|||||Interventional|||Radiofrequency Catheter Ablation for Chronic Atrial Fibrillation|Randomized Comparison of Radiofrequency Catheter Ablation vs. Antiarrhythmic Therapy With Amiodarone for Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation|Completed||N/A|140||University of Michigan|||||f||||||||||||||2018-06-01 04:14:53.691477|2018-06-01 04:14:53.691477
NCT00272623|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-06-02|2006-01-03|2006-01-06|Estimate|||||||2009-06-02|2009-06-03|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Seldinger Technique Versus Venous Cut-Down for Placement of Totally Implantable Venous Access Ports|A Prospective, Randomized Trial Comparing Seldinger Technique Versus Venous Cut-Down for Placement of Totally Implantable Venous Access Ports|Completed||N/A|152|Actual|University of Zurich|||||f||||||||||||||2018-06-01 04:14:53.757498|2018-06-01 04:14:53.757498
NCT00272610|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2015-06-23|2006-01-03|2006-01-06|Estimate|||||||2015-06-23|2015-06-24|Estimate|September 2000||2000-09-30|September 2006|2006-09-30|February 2002||2002-02-28|||||Interventional|||Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin|Topical Vitamin A (All-trans Retinol) Versus Vehicle Cream in the Treatment of Aged Skin|Completed||Phase 2|50||University of Michigan|||||f||||||||||||||2018-06-01 04:14:53.816837|2018-06-01 04:14:53.816837
NCT00272597|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2017-11-27|2006-01-03|2006-01-06|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2005||2005-09-30|November 2017|2017-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Risperidone LA Heathcare Resource Study|Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study|Completed||Phase 4|30|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 04:14:53.890361|2018-06-01 04:14:53.890361
NCT00272584|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2006-05-05|2006-01-03|2006-01-06|Estimate|||||||2006-05-05|2006-05-08|Estimate|June 2001||2001-06-30|January 2006|2006-01-31|January 2004||2004-01-31|||||Interventional|||CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia|International Study of Improving Treatment for the Most Severely Ill With Schizophrenia|Completed||Phase 4|100||University of British Columbia|||||f||||||||||||||2018-06-01 04:14:53.990324|2018-06-01 04:14:53.990324
NCT00272571|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-01-29|2006-01-04|2006-01-06|Estimate|||||||2006-01-29|2006-01-31|Estimate|August 2004||2004-08-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||The Effects of External Counter Pulsation Therapy on Circulating Endothelial Progenitor Cells|The Effects of External Counter Pulsation Therapy (ECPT) on the Number and Function of Circulating Endothelial Progenitor Cells in Patients With Angina Pectoris|Completed||N/A|25||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:14:54.097639|2018-06-01 04:14:54.097639
NCT00272558|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-09-17|2006-01-03|2006-01-06|Estimate|||||||2009-09-17|2009-09-18|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma|Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma|Completed||Phase 2|40|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:14:54.237579|2018-06-01 04:14:54.237579
NCT00272545|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2013-09-04|2006-01-04|2006-01-06|Estimate|||||||2013-09-04|2013-09-06|Estimate|January 2006||2006-01-31|September 2013|2013-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effectiveness of a Normalization of Eating Intervention Program for Treating Women With Eating Disorders|Adaptation of a CBT Intervention for Eating Disorders|Completed||N/A|280|Actual|Drexel University||2|||f||||||||||||||2018-06-01 04:14:54.378225|2018-06-01 04:14:54.378225
NCT00272532|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2008-02-18|2006-01-04|2006-01-06|Estimate|||||||2008-02-18|2008-02-20|Estimate|April 2005||2005-04-30|February 2008|2008-02-29||||||||Interventional|||EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes|The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study|Completed||Phase 4|65||Sanofi|||||f||||||||||||||2018-06-01 04:14:54.45009|2018-06-01 04:14:54.45009
NCT00272519|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2017-02-27|2006-01-03|2006-01-06|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2006||2006-06-30|February 2016|2016-02-29|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Life Skills Intervention for Adolescents Perinatally Infected With HIV|Life Skills Intervention for Young Adolescents Perinatally Infected With HIV and Their Caregivers|Completed||N/A|16|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 04:14:54.526735|2018-06-01 04:14:54.526735
NCT00272506|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2016-07-11|2006-01-03|2006-01-06|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2002||2002-08-31|January 2006|2006-01-31|September 2004|Actual|2004-09-30|||||Interventional|||Pediatric Asthma Controller Trial (PACT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:14:54.611025|2018-06-01 04:14:54.611025
NCT00272493|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04||2009-09-08|2012-05-17|2006-01-04|2006-01-06|Estimate||||2009-09-08|2009-09-09|Estimate|2012-05-17|2012-05-28|Estimate||||May 2012|2012-05-31|September 2008|Actual|2008-09-30|November 2007|Actual|2007-11-30||Interventional|||Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals|Improving Immune Response to Hepatitis B Vaccine in HIV-positive Subjects Using Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as a Vaccine Adjuvant: A Phase II Open-Label Pilot Study|Completed||Phase 2|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:14:54.765222|2018-06-01 04:14:54.765222
NCT00272480|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2015-05-27|2006-01-04|2006-01-06|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 1999||1999-11-30|January 2006|2006-01-31|November 2001||2001-11-30|||||Interventional|||Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial|Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial|Completed||Phase 2/Phase 3|24||Imperial College London|||||f||||||||||||||2018-06-01 04:14:54.87061|2018-06-01 04:14:54.87061
NCT00272467|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2015-04-27|2006-01-04|2006-01-06|Estimate|||||||2015-04-27|2015-04-29|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy|A Comparative Study on the Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy|Completed||Phase 4|132|Actual|Korea Otsuka International Asia Arab||2|||f||||t||||||||||2018-06-01 04:14:54.962408|2018-06-01 04:14:54.962408
NCT00272454|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-12-15|2006-01-05|2006-01-06|Estimate|||||||2009-12-15|2009-12-16|Estimate|January 2006||2006-01-31|December 2009|2009-12-31|September 2008|Actual|2008-09-30|||||Interventional|||Cilostazol in Acute Ischemic Stroke Treatment (CAIST)|The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke|Completed||Phase 4|468|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-06-01 04:14:55.075253|2018-06-01 04:14:55.075253
NCT00272441|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2016-07-11|2006-01-03|2006-01-06|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2001||2001-01-31|January 2008|2008-01-31|September 2004|Actual|2004-09-30|||||Interventional|||Prevention of Early Asthma in Kids (PEAK)||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:14:55.157727|2018-06-01 04:14:55.157727
NCT00272428|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-12-16|2006-01-04|2006-01-06|Estimate|||||||2009-12-16|2009-12-17|Estimate|October 1994||1994-10-31|October 2007|2007-10-31|September 2005|Actual|2005-09-30|||||Interventional|||Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.|The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.|Completed||Phase 3|13000||Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-06-01 04:14:55.217937|2018-06-01 04:14:55.217937
NCT00272415|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-03-09|2006-01-03|2006-01-06|Estimate|||||||2009-03-09|2009-03-11|Estimate|October 2005||2005-10-31|November 2007|2007-11-30||||||||Interventional|||A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma|A Phase Ib, Open-Label, Multicenter Trial of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate the Tolerability, Safety, and Pharmacokinetics in Subjects With Newly-Diagnosed or Recurrent Unresectable Stage III or Stage IV Melanoma|Terminated||Phase 1|39|Anticipated|Genentech, Inc.||1|||f||||||||||||||2018-06-01 04:14:55.286217|2018-06-01 04:14:55.286217
NCT00272402|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2012-09-04|2006-01-03|2006-01-06|Estimate|||||||2012-09-04|2012-09-05|Estimate|February 2006||2006-02-28|September 2012|2012-09-30|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Reducing Clinical Inertia in Diabetes Care|Reducing Clinical Inertia in Diabetes Care|Completed||N/A|61|Actual|HealthPartners Institute||3|||f||||t||||||||||2018-06-01 04:14:55.367669|2018-06-01 04:14:55.367669
NCT00272389|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-01-04|2006-01-04|2006-01-06|Estimate|||||||2006-01-04|2006-01-06|Estimate|March 2006||2006-03-31|January 2006|2006-01-31|May 2006|Anticipated|2006-05-31|||||Observational|||Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile|Prediction of Response to PEGINTERFERON and RIBAVIRIN Treatment in Patients With Chronic HCV Infection by Genetic Profile|Unknown status|Not yet recruiting||150|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:14:55.437856|2018-06-01 04:14:55.437856
NCT00272376|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2018-05-10|2006-01-04|2006-01-05|Estimate|||||||2018-05-10|2018-05-11|Actual|December 21, 2005||2005-12-21|July 29, 2016|2016-07-29|July 29, 2016||2016-07-29|||||Observational|||Clinical and Genetic Studies in Families With Myopia and Related Diseases|Clinical and Molecular Studies in Families With Myopia and Related Diseases|Completed|||851|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:14:55.488922|2018-06-01 04:14:55.488922
NCT00269230|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-11-18|2005-12-21|2005-12-23|Estimate|||||||2008-11-18|2008-11-20|Estimate|July 2004||2004-07-31|October 2008|2008-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Attain StarFix™ Model 4195 Left Ventricular Lead|Attain StarFix™ Model 4195 Left Ventricular Lead|Completed||N/A|441|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||t||||f||||||||||2018-06-01 04:15:39.437483|2018-06-01 04:15:39.437483
NCT00272350|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-05|||2018-05-18|2006-01-04|2006-01-05|Estimate|||||||2018-05-18|2018-05-21|Actual|December 29, 2005||2005-12-29|February 27, 2014|2014-02-27|February 27, 2014|Actual|2014-02-27|February 27, 2014|Actual|2014-02-27||Interventional|||ZD6474 to Treat Advanced Brain Cancer in Patients|A Phase I/II Trial of ZD6474 for Patients With Recurrent High-Grade and Progressive Low-Grade Gliomas|Completed||Phase 1|83|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:14:55.609646|2018-06-01 04:14:55.609646
NCT00272337|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|2012-05-16||2012-06-20|2006-01-03|2006-01-05|Estimate|2012-05-16|2012-06-18|Estimate||||2012-06-20|2012-06-25|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TAD||Aspirin Dose and Atherosclerosis in Patients With Heart Disease|A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)|Completed||Phase 4|37|Actual|Florida Atlantic University||5|||f||||t||||||||||2018-06-01 04:14:56.774009|2018-06-01 04:14:56.774009
NCT00272324|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2006-01-03|2006-01-03|2006-01-05|Estimate|||||||2006-01-03|2006-01-05|Estimate|February 1992||1992-02-29|November 2005|2005-11-30|January 2007||2007-01-31|||||Interventional|||Aspirin/Folate Prevention of Large Bowel Polyps|Aspirin/Folate Prevention of Large Bowel Polyps|Completed||Phase 2/Phase 3|1121||Dartmouth-Hitchcock Medical Center|||||||||||||||||||2018-06-01 04:14:57.193476|2018-06-01 04:14:57.193476
NCT00272311|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|2012-05-16||2012-06-20|2006-01-04|2006-01-05|Estimate|2012-05-16|2012-06-19|Estimate||||2012-06-20|2012-06-25|Estimate|October 2006||2006-10-31|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|PAD||Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome|A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)|Completed||Phase 4|70|Actual|Florida Atlantic University||5|||f||||t||||||||||2018-06-01 04:14:57.294723|2018-06-01 04:14:57.294723
NCT00272285|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2017-03-07|2006-01-03|2006-01-05|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2006||2006-01-31|March 2017|2017-03-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea|A Double-blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron Plus Dexamethasone Injection for the Prevention of Chemotherapy-Induced Vomiting and Nausea|Completed||Phase 3|287|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 04:14:57.63852|2018-06-01 04:14:57.63852
NCT00272272|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2016-01-26|2006-01-03|2006-01-05|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2005||2005-12-31|January 2016|2016-01-31|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|||Fall Prevention in a Geriatric Nursing Home Setting Using the Music of Nolwenn Leroy|The Nolwenn Effect in a Geriatric Nursing Home Setting|Completed||N/A|200|Actual|Carrick Institute for Graduate Studies||1|||f||||f||||||||No||2018-06-01 04:14:58.60469|2018-06-01 04:14:58.60469
NCT00272259|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2007-01-04|2006-01-03|2006-01-05|Estimate|||||||2007-01-04|2007-01-05|Estimate||||January 2007|2007-01-31||||||||Interventional|||Robots for Stroke Survivors||Terminated||Phase 1|||Carnegie Mellon University|||||f||||||||||||||2018-06-01 04:14:58.690076|2018-06-01 04:14:58.690076
NCT00272246|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-04|||2006-01-04|2006-01-04|2006-01-05|Estimate|||||||2006-01-04|2006-01-05|Estimate|February 2005||2005-02-28|January 2006|2006-01-31|December 2007||2007-12-31|||||Interventional|||Bilateral Internal Pallidum Stimulation in Primary Generalized Dystonia||Unknown status|Recruiting|Phase 2/Phase 3|24||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||||||||||||2018-06-01 04:14:58.749403|2018-06-01 04:14:58.749403
NCT00272233|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2007-03-19|2006-01-03|2006-01-04|Estimate|||||||2007-03-19|2007-03-20|Estimate|December 2004||2004-12-31|January 2006|2006-01-31|June 2005||2005-06-30|||||Observational|||Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents|Effects of Sleep Loss on Endothelial Function and Cytokine Levels in Internal Medicine Residents|Completed|||22||Yale University|||||f||||||||||||||2018-06-01 04:14:58.843013|2018-06-01 04:14:58.843013
NCT00272220|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2007-11-06|2005-12-30|2006-01-04|Estimate|||||||2007-11-06|2007-11-07|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|June 2006|Actual|2006-06-30|||||Interventional|||Longitudinal Study of HAART, Social Networks, & Adherence|Longitudinal Randomized Controlled Study of Modified Directly Observed HAART in Mozambique|Completed||N/A|350|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:14:58.911631|2018-06-01 04:14:58.911631
NCT00272207|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2011-08-24|2006-01-03|2006-01-04|Estimate|||||||2011-08-24|2011-08-25|Estimate|April 2006||2006-04-30|August 2011|2011-08-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia|A Randomized Double-blinded Placebo Controlled Trial Assessing the Effect of the Oral Cannabinoid Nabilone on Pain and Quality of Life in Patients With Fibromyalgia|Completed||Phase 2|40|Actual|Winnipeg Regional Health Authority|||||f||||f||||||||||2018-06-01 04:14:58.983331|2018-06-01 04:14:58.983331
NCT00272194|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2016-03-22|2006-01-02|2006-01-04|Estimate|||||||2016-03-22|2016-03-23|Estimate|December 2005||2005-12-31|March 2016|2016-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Ambu® Laryngeal Mask as an Intubation Conduit|The Ambu® Laryngeal Mask as an Intubation Conduit For Patients Undergoing Routine General Anesthesia|Completed||Phase 4|160||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:14:59.060458|2018-06-01 04:14:59.060458
NCT00272181|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2015-12-22|2006-01-03|2006-01-04|Estimate|||||||2015-12-22|2015-12-23|Estimate|January 2006||2006-01-31|December 2015|2015-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer|A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Proxinium in Patients With Advanced SCCHN Who Have Received at Least One Anti-Cancer Treatment Regimen for Advanced Disease|Terminated||Phase 2|15|Actual|Viventia Bio||1||Slow accrual in North America|f||||f||||||||||2018-06-01 04:14:59.229594|2018-06-01 04:14:59.229594
NCT00272168|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|2015-11-13||2016-05-10|2005-12-30|2006-01-04|Estimate|2016-05-10|2016-06-17|Estimate||||2016-05-10|2016-06-17|Estimate|October 2005||2005-10-31|May 2016|2016-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|MPROVE||The Use of Skills Training to Augment Compensated Work Therapy (CWT)/VI for Veterans With SMI|The Use of Skills Training to Augment CWT/VI for Veterans With SMI|Completed||N/A|88|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:14:59.374677|2018-06-01 04:14:59.374677
NCT00272155|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2010-04-26|2006-01-03|2006-01-04|Estimate|||||||2010-04-26|2010-04-27|Estimate|January 2006||2006-01-31|December 2005|2005-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||An Intervention to Reduce Inappropriate Prescriptions of Antibiotics for Respiratory Infections in General Practice|Can Antibiotic Prescriptions in Respiratory Tract Infections be Improved? A Cluster Randomized Educational Intervention in General Practice|Completed||Phase 1/Phase 2|118621|Actual|University of Oslo|||||f||||||||||||||2018-06-01 04:14:59.724543|2018-06-01 04:14:59.724543
NCT00272142|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-09-02|2006-01-03|2006-01-04|Estimate|||||||2009-09-02|2009-09-03|Estimate|January 2005||2005-01-31|September 2009|2009-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial|Impact of Zinc Supplementation in Low Birth Weight Infants on Severe Morbidity, Mortality and Zinc Status: A Randomized Controlled Trial|Completed||N/A|2000|Anticipated|Society for Applied Studies|||||f||||f||||||||||2018-06-01 04:14:59.802626|2018-06-01 04:14:59.802626
NCT00272116|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2012-04-02|2006-01-02|2006-01-04|Estimate|||||||2012-04-02|2012-04-03|Estimate|February 1998||1998-02-28|April 2012|2012-04-30|September 2000|Actual|2000-09-30|February 2000|Actual|2000-02-29||Interventional|||Effect of Zinc and Vitamin A Supplementation on Diarrhea, Physical Growth and Immune Response in Malnourished Children|Effect of Zinc and Vitamin A Supplementation on Diarrhea, Physical Growth and Immune Response in Malnourished Children|Completed||N/A|2482|Actual|Society for Applied Studies||2|||f||||f||||||||||2018-06-01 04:14:59.899425|2018-06-01 04:14:59.899425
NCT00272103|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2006-05-03|2006-01-03|2006-01-04|Estimate|||||||2006-05-03|2006-05-04|Estimate|December 2000||2000-12-31|November 2005|2005-11-30|January 2002||2002-01-31|||||Interventional|||Itopride in Functional Dyspepsia:a Dose Finding Study|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Dose Finding Study in 4 Parallel Groups to Establish the Efficacy and Safety of an Eight Week Treatment With Itopride Three Times Daily Compared to Placebo in Patients Suffering From Functional Dyspepsia|Completed||Phase 2/Phase 3|500||Royal Adelaide Hospital|||||f||||||||||||||2018-06-01 04:14:59.9935|2018-06-01 04:14:59.9935
NCT00272090|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2011-06-07|2006-01-02|2006-01-04|Estimate|||||||2011-06-07|2011-06-08|Estimate|November 2002||2002-11-30|June 2011|2011-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Insulin Glargine in Type 1 Diabetes Mellitus|Italian Experience Trial for the Implementation of the Use of Lantus in Basal - Bolus Regimen in Type I Diabetes Mellitus Patients.|Completed||Phase 3|489|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:15:00.101444|2018-06-01 04:15:00.101444
NCT00272077|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2009-12-04|2006-01-02|2006-01-04|Estimate|||||||2009-12-04|2009-12-07|Estimate|April 2005||2005-04-30|December 2009|2009-12-31||||May 2006|Actual|2006-05-31||Interventional|||Insulin Glargine in Type 2 Diabetes Mellitus|Pilot Study on Glycaemic Variability in Type 2 Diabetes Mellitus Patients With Basal Insulin and Fixed Combo Oral Antidiabetic Treatment.|Completed||Phase 4|||Sanofi|||||f||||||||||||||2018-06-01 04:15:00.186079|2018-06-01 04:15:00.186079
NCT00272064|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2009-12-04|2006-01-02|2006-01-04|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.|Optimisation of Insulin Treatment of Type 2 Diabetes Mellitus by Telecare Assistance for Self Monitoring of Blood Glucose (SMBG).|Completed||Phase 3|352|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:15:00.262509|2018-06-01 04:15:00.262509
NCT00272051|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2006-09-11|2006-01-03|2006-01-04|Estimate|||||||2006-09-11|2006-09-13|Estimate|July 2002||2002-07-31|September 2006|2006-09-30|May 2004||2004-05-31|||||Interventional|||XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy|A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)|Completed||Phase 3|620||Sanofi|||||f||||||||||||||2018-06-01 04:15:00.345406|2018-06-01 04:15:00.345406
NCT00272038|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|2013-05-06||2018-02-01|2006-01-03|2006-01-04|Estimate|2013-08-12|2013-10-17|Estimate||||2018-02-01|2018-03-05|Actual|December 2005||2005-12-31|February 2018|2018-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer|Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer|Completed||Phase 2|29|Actual|Oncology Specialists, S.C.||1|||f||||f||||||||||2018-06-01 04:15:00.423364|2018-06-01 04:15:00.423364
NCT00272025|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2015-12-14|2006-01-03|2006-01-04|Estimate|||||||2015-12-14|2015-12-16|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Treatment Resistant Bipolar Depression|Six Week Double Blind, Randomized Trial of Escitalopram Add On for Treatment Resistant Bipolar Depression|Terminated||Phase 1|1|Actual|Queen's University||2||Lundbeck withdrew committment - expiring patents and prolonged inactivity|f||||f||||||||||2018-06-01 04:15:00.807304|2018-06-01 04:15:00.807304
NCT00272012|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2009-12-04|2006-01-02|2006-01-04|Estimate|||||||2009-12-04|2009-12-07|Estimate|July 2004||2004-07-31|December 2009|2009-12-31||||September 2006|Actual|2006-09-30||Interventional|||OPAL - Insulin Glulisine, Diabetes Mellitus|Efficacy and Safety of Insulin Glulisine Given as a Single Injection at Breakfast + Insulin Glargine+OAD (Oral Antidiabetic Drug) vs Insulin Glulisine Given as a Single Injection at Main Meal+Insulin Glargine+OAD in Type 2 Diabetic Patients for Which Glycemic Control is Suboptimal Using Insulin Glargine+ OAD Alone|Completed||Phase 3|396|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:15:00.896852|2018-06-01 04:15:00.896852
NCT00271999|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2010-03-02|2006-01-03|2006-01-04|Estimate|||||||2010-03-02|2010-03-03|Estimate|January 2006||2006-01-31|March 2010|2010-03-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Frequent Hemodialysis Network: Nocturnal Trial|Frequent Hemodialysis Network: Nocturnal Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|150|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 04:15:00.969685|2018-06-01 04:15:00.969685
NCT00271986|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2011-07-20|2006-01-03|2006-01-04|Estimate|||||||2011-07-20|2011-07-22|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Observational|||Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection (LAR) for Recto-sigmoid Cancer|Intraperitoneal Microdialysis Monitoring of Patients During the Early Postoperative Period After LAR With Reference to Early Diagnosis of Anastomotic Leakage|Completed|||60|Actual|Odense University Hospital|||||f||||f||||||||||2018-06-01 04:15:01.110767|2018-06-01 04:15:01.110767
NCT00271973|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2007-01-29|2006-01-03|2006-01-04|Estimate|||||||2007-01-29|2007-01-30|Estimate|February 2006||2006-02-28|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models|The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models|Completed||Phase 4|32||Odense University Hospital|||||f||||||||||||||2018-06-01 04:15:01.222859|2018-06-01 04:15:01.222859
NCT00271960|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2016-07-25|2005-12-30|2006-01-04|Estimate|||||||2016-07-25|2016-07-27|Estimate|April 2001||2001-04-30|July 2016|2016-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women|Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women|Completed||Phase 3|1047|Actual|Yale University||3|||f||||f||||||||||2018-06-01 04:15:01.359093|2018-06-01 04:15:01.359093
NCT00268086|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2007-06-12|2005-12-20|2005-12-22|Estimate|||||||2007-06-12|2007-06-13|Estimate||||June 2007|2007-06-30||||||||Observational|||Constrictive Pericarditis in the Adult Congenital Cardiac Population|Constrictive Pericarditis in the Adult Congenital Cardiac Population|Terminated|||15||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:15:59.175837|2018-06-01 04:15:59.175837
NCT00271947|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|2013-05-08||2014-02-10|2006-01-02|2006-01-04|Estimate|2014-02-10|2014-03-27|Estimate||||2014-02-10|2014-03-27|Estimate|April 2005||2005-04-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|||Crohn's Disease Stem Cell Transplantation|Crohn's Disease Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation (CDNST) Versus Standard Therapy|Terminated||Phase 2|1|Actual|Northwestern University|Potential participants refused to be randomized. Just one participant was enrolled on study, the study is terminated early.|1||The PI, who was sponsor got retired|f||||t||||||||||2018-06-01 04:15:01.618428|2018-06-01 04:15:01.618428
NCT00271934|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-02|||2012-04-09|2006-01-03|2006-01-04|Estimate|||||||2012-04-09|2012-04-11|Estimate|September 2002||2002-09-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|November 2007|Actual|2007-11-30||Interventional|||Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Poor Prognostic Indicators and Systemic Lupus Erythematosus:A Phase II Study|Completed||Phase 2|52|Actual|Northwestern University|||||f||||f||||||||||2018-06-01 04:15:02.18773|2018-06-01 04:15:02.18773
NCT00271921|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2012-12-17|2006-01-03|2006-01-04|Estimate|||||||2012-12-17|2012-12-18|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Does Metabolic Syndrome Exist in Anorexia Nervosa?|Does Metabolic Syndrome Exist in Anorexia Nervosa?|Completed|||50|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||||2018-06-01 04:15:02.483982|2018-06-01 04:15:02.483982
NCT00271908|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2017-02-27|2005-12-30|2006-01-04|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2007||2007-02-28|March 2016|2016-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions|Connect to Protect® Partnerships for Youth Prevention Interventions Phase III: Full Evaluation|Completed|||4472|Actual|University of North Carolina, Chapel Hill|||2||f||||t||||||||||2018-06-01 04:15:02.676714|2018-06-01 04:15:02.676714
NCT00271882|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2017-02-27|2005-12-30|2006-01-04|Estimate|||||||2017-02-27|2017-02-28|Actual|March 2006||2006-03-31|February 2016|2016-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||PTSD and Risk Behavior in HIV Positive Female Adolescents|PTSD and Risk Behavior in HIV Positive Female Adolescents|Completed|||40|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 04:15:03.050775|2018-06-01 04:15:03.050775
NCT00271869|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2006-01-03|2006-01-03|2006-01-04|Estimate|||||||2006-01-03|2006-01-04|Estimate|December 2005||2005-12-31|December 2005|2005-12-31||||||||Interventional|||Treatment of Chronic GVHD of Liver or Lungs by ECP|Phase II Study for Treatment of Chronic Graft-Versus-Host Disease of the Liver or Lungs With Adjunct Extracorporeal Photoimmunotherapy|Unknown status|Recruiting|Phase 2|20||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:15:03.212333|2018-06-01 04:15:03.212333
NCT00271856|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|2011-08-03||2012-04-11|2005-12-30|2006-01-04|Estimate|2012-02-02|2012-03-06|Estimate||||2012-04-11|2012-04-17|Estimate|May 2005||2005-05-31|April 2012|2012-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV|Mindfulness-Based Stress Reduction (MBSR), Stress Arousal and Immune Response in Early HIV|Completed||Phase 2|177|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:15:03.327989|2018-06-01 04:15:03.327989
NCT00271843|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2017-01-10|2006-01-03|2006-01-04|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2005||2005-10-31|December 2008|2008-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Smoking and Alcohol Initiation|Predicting Tobacco and Alcohol Initiation|Completed|||2600|Anticipated|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:15:03.74378|2018-06-01 04:15:03.74378
NCT00271830|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2007-12-10|2006-01-03|2006-01-04|Estimate|||||||2007-12-10|2007-12-11|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Observational|||Sexual Function in Male Renal Transplant Patients|Sexual Function in Male Renal Transplant Patients|Terminated|||110|Anticipated|Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:15:03.827434|2018-06-01 04:15:03.827434
NCT00271817|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|2009-02-13||2017-03-13|2006-01-03|2006-01-04|Estimate|2009-06-15|2009-08-03|Estimate||||2017-03-13|2017-04-11|Actual|December 2005||2005-12-31|March 2017|2017-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)|Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia|Completed||Phase 3|1220|Actual|Merck Sharp & Dohme Corp.|Part 1 population is all patients enrolled in Part 1 of the study. Part 2 is those patients who received either niacin, ezetimibe/simvastatin, or ezetimibe/simvastatin + niacin during Part 1 until they finished the study at week 64 or discontinued.|5|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:15:04.059437|2018-06-01 04:15:04.059437
NCT00271804|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2008-03-07|2005-12-30|2006-01-04|Estimate|||||||2008-03-07|2008-03-13|Estimate|June 2005||2005-06-30|March 2008|2008-03-31|April 2007||2007-04-30|||||Interventional|||Study of Velcade and Thalidomide in Patients With Myelodysplasia|Phase I Dose Escalation Trial of Bortezomib in Combination With Thalidomide in Patients With Myelodysplasia|Terminated||Phase 1|28||Massachusetts General Hospital||||New study with lenalidomide pending|f||||||||||||||2018-06-01 04:15:05.547394|2018-06-01 04:15:05.547394
NCT00271791|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-01|||2007-11-04|2006-01-01|2006-01-04|Estimate|||||||2007-11-04|2007-11-06|Estimate|September 2005||2005-09-30|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Interventional|||Prednisone Treatment for Vestibular Neuronitis|Prednisone Treatment for Vestibular Neuronitis|Completed||Phase 2|17|Actual|Carmel Medical Center||2|||f||||f||||||||||2018-06-01 04:15:05.655778|2018-06-01 04:15:05.655778
NCT00271778|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2006-01-03|2006-01-03|2006-01-04|Estimate|||||||2006-01-03|2006-01-04|Estimate|July 2003||2003-07-31|December 2005|2005-12-31|June 2006||2006-06-30|||||Interventional|||A Comparative Study of the Outcomes of 2 Surgical Procedures for Safe Type of Chronic Otitis Media|A Randomized Control Study of the Outcomes of Mastoidotympanoplasty Versus Tympanoplasty in Quiescent Tubotympanic Otitis Media|Unknown status|Active, not recruiting|Phase 3|60||Karnataka Institute of Medical Sciences|||||f||||||||||||||2018-06-01 04:15:05.773627|2018-06-01 04:15:05.773627
NCT00271765|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2006-11-27|2006-01-03|2006-01-04|Estimate|||||||2006-11-27|2006-11-29|Estimate|January 2004||2004-01-31|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention|A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Completed||Phase 2|40||Inotek Pharmaceuticals Corporation|||||f||||||||||||||2018-06-01 04:15:05.838305|2018-06-01 04:15:05.838305
NCT00271752|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-01|||2010-03-03|2006-01-01|2006-01-04|Estimate|||||||2010-03-03|2010-03-04|Estimate|January 2006||2006-01-31|March 2010|2010-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|PASS||The Procalcitonin and Survival Study|The Procalcitonin and Survival Study - A Multicentre Single Blinded Randomized Controlled Trial to Investigate if Treatment Guided by Daily Procalcitonin Measurements Can Reduce Mortality in the Intensive Care Unit|Completed||N/A|1200|Actual|Danish Procalcitonin Study Group||2|||f||||t||||||||||2018-06-01 04:15:05.929392|2018-06-01 04:15:05.929392
NCT00271739|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|2011-02-28||2012-11-19|2005-12-30|2006-01-04|Estimate|2011-07-13|2011-08-10|Estimate||||2012-11-19|2012-11-22|Estimate|December 2000||2000-12-31|November 2012|2012-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|IDEATel||Randomized Trial of Telemedicine for Diabetes Care|Informatics for Diabetes Education and Telemedicine (IDEATel)|Completed||N/A|1665|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 04:15:06.039687|2018-06-01 04:15:06.039687
NCT00271726|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2007-04-25|2006-01-03|2006-01-04|Estimate|||||||2007-04-25|2007-04-27|Estimate|November 2005||2005-11-30|April 2007|2007-04-30||||||||Interventional|||Operative Treatment of Extraarticular Colles' Fractures of the Distal Radius (OTEC)|Prospective, Randomized, Multi-Center Pilot Study on the Treatment of Unstable, Extraarticular Colles Fractures of the Distal Radius by Palmar Locking Plate, External Fixator or Kirschner Wires|Unknown status|Recruiting|N/A|90||Heinrich-Heine University, Duesseldorf|||||f||||||||||||||2018-06-01 04:15:06.398818|2018-06-01 04:15:06.398818
NCT00271713|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2009-01-27|2006-01-03|2006-01-04|Estimate|||||||2009-01-27|2009-01-28|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)|Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures|Completed||Phase 4|70|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-06-01 04:15:06.483442|2018-06-01 04:15:06.483442
NCT00271700|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2010-05-03|2005-12-30|2006-01-04|Estimate|||||||2010-05-03|2010-05-05|Estimate|May 2010||2010-05-31|May 2010|2010-05-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Improving Glycemic Control on GMS: A Quality Improvement Study|Improving Glycemic Control on GMS: A Quality Improvement Study|Unknown status|Not yet recruiting|N/A|1100|Anticipated|Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:15:06.568946|2018-06-01 04:15:06.568946
NCT00271687|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2016-02-24|2005-12-30|2006-01-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer|A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer|Completed||Phase 2|30|Anticipated|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:15:06.69387|2018-06-01 04:15:06.69387
NCT00271674|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2008-06-02|2006-01-03|2006-01-04|Estimate|||||||2008-06-02|2008-06-03|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|||||Interventional|||YAG Laser Versus Punch Biopsy for the Treatment of Tattoo Skin Markers||Completed||N/A|||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:15:06.832937|2018-06-01 04:15:06.832937
NCT00271661|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2011-12-08|2005-12-30|2006-01-04|Estimate|||||||2011-12-08|2011-12-09|Estimate|August 2005||2005-08-31|December 2011|2011-12-31|May 2006||2006-05-31|||||Observational|||Presbyopia in Breast Cancer Survivors|Presbyopia in Breast Cancer Survivors|Withdrawn|||0|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:15:06.981095|2018-06-01 04:15:06.981095
NCT00271635|ClinicalTrials.gov processed this data on May 31, 2018|2006-01-03|||2008-07-02|2006-01-03|2006-01-04|Estimate|||||||2008-07-02|2008-07-04|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|AATIC||Ascorbic Acid Treatment in CMT1A Trial (AATIC)|Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A|Completed||Phase 2|13|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-06-01 04:15:07.04992|2018-06-01 04:15:07.04992
NCT00271622|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-31|||2018-04-03|2005-12-31|2006-01-02|Estimate|||||||2018-04-03|2018-04-04|Estimate|December 29, 2005||2005-12-29|March 28, 2018|2018-03-28||||||||Observational|||The Neurodevelopmental and Behavioral Phenotyping Screening Protocol|The Neurodevelopmental and Behavioral Phenotyping Screening Protocol|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:15:07.15701|2018-06-01 04:15:07.15701
NCT00271609|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-31|2012-04-30||2014-04-13|2005-12-31|2006-01-02|Estimate|2012-04-30|2012-06-08|Estimate||||2014-04-13|2014-04-29|Estimate|December 2005||2005-12-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|March 2011|Actual|2011-03-31||Interventional|||Bevacizumab for Recurrent Malignant Glioma|A Phase II Trial of Bevacizumab for Patients With Recurrent High-Grade Gliomas|Completed||Phase 2|88|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 04:15:07.25669|2018-06-01 04:15:07.25669
NCT00271596|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|2012-12-19||2013-02-08|2005-12-30|2006-01-02|Estimate|2013-02-08|2013-03-13|Estimate||||2013-02-08|2013-03-13|Estimate|November 2005||2005-11-30|February 2013|2013-02-28|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|CIT-HD||Citalopram to Enhance Cognition in HD|A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)|Completed||Phase 2|33|Actual|University of Iowa|Statistical power was limited.|2|||f||||t||||||||||2018-06-01 04:15:08.07726|2018-06-01 04:15:08.07726
NCT00271583|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2007-12-13|2005-12-29|2006-01-02|Estimate|||||||2007-12-13|2007-12-17|Estimate|September 1999||1999-09-30|December 2007|2007-12-31|September 2001|Actual|2001-09-30|||||Interventional|||Efficacy Trial of CDB 2914 for Emergency Contraception|A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerance of CDB-2914 With Levonorgestrel as Emergency Contraception|Completed||Phase 2/Phase 3|1672|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:15:08.465057|2018-06-01 04:15:08.465057
NCT00271570|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|2009-05-01||2010-06-11|2005-12-30|2006-01-02|Estimate|2009-11-23|2009-12-29|Estimate||||2010-06-11|2010-06-14|Estimate|April 2004||2004-04-30|November 2009|2009-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Infliximab (Remicade) for Patients With Acute Kawasaki Disease|Infliximab (Remicade) for Patients With Acute Kawasaki Disease Who Fail to Become Afebrile After Intravenous Gamma Globulin Therapy|Completed||Phase 1|24|Actual|University of California, San Diego||2|||f||||t||||||||||2018-06-01 04:15:08.542682|2018-06-01 04:15:08.542682
NCT00271557|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2011-03-03|2005-12-30|2006-01-02|Estimate|||||||2011-03-03|2011-03-04|Estimate|January 1997||1997-01-31|March 2011|2011-03-31|December 1997|Actual|1997-12-31|||||Interventional|||A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels|A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF|Completed||Phase 3|305|Actual|Scios, Inc.|||||||||||||||||||2018-06-01 04:15:08.928832|2018-06-01 04:15:08.928832
NCT00271544|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|2009-04-30|2009-09-24|2009-09-24|2005-12-30|2006-01-02|Estimate|2009-07-09|2009-08-25|Estimate|2009-09-24|2009-09-28|Estimate|2009-09-24|2009-09-28|Estimate|February 2007||2007-02-28|September 2009|2009-09-30|December 2008|Actual|2008-12-31|August 2007|Actual|2007-08-31||Interventional|||Attain Model 4196 Left Ventricular (LV) Lead|Attain Model 4196 Left Ventricular (LV) Lead|Completed||N/A|190|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-06-01 04:15:09.023911|2018-06-01 04:15:09.023911
NCT00271531|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2011-08-11|2005-12-29|2006-01-02|Estimate|||||||2011-08-11|2011-08-12|Estimate|April 2006||2006-04-30|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Bacterial Pulmonary Infection in PICU|Derivation of a Clinical Prediction Rule for Bacterial Pulmonary Infection in Mechanically Ventilated Children|Completed|||21|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Nasal aspirate, tracheal aspirate, and non bronchoscopic bronchoalveolar lavage.~   "|||2018-06-01 04:15:09.489924|2018-06-01 04:15:09.489924
NCT00271518|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2010-03-16|2005-12-29|2006-01-02|Estimate|||||||2010-03-16|2010-03-17|Estimate|September 2005||2005-09-30|March 2010|2010-03-31||||December 2013|Anticipated|2013-12-31||Interventional|BPLG-004||Treatment of Children With Insufficient Secretion of Growth Hormone|A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily Therapy in Treatment Naive Children With Growth Failure Due to Insufficient Secretion of Endogenous Growth Hormone|Unknown status|Active, not recruiting|Phase 3|144|Anticipated|LG Life Sciences||1|||t||||t||||||||||2018-06-01 04:15:09.55704|2018-06-01 04:15:09.55704
NCT00271505|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2017-08-01|2005-12-29|2006-01-02|Estimate|||||||2017-08-01|2017-08-03|Actual|December 5, 2005|Actual|2005-12-05|August 2017|2017-08-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer|A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|43|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 04:15:09.637929|2018-06-01 04:15:09.637929
NCT00271492|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2010-04-28|2005-12-29|2006-01-02|Estimate|||||||2010-04-28|2010-04-30|Estimate|July 2001||2001-07-31|April 2010|2010-04-30|January 2008|Actual|2008-01-31|June 2006|Actual|2006-06-30||Interventional|||Correlation of Endothelial Function and Early Coronary Artery Disease in Humans|Endothelin in the Coronary Circulation in Early Atherosclerosis in Humans|Completed||Phase 3|200|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:15:09.737844|2018-06-01 04:15:09.737844
NCT00271479|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2006-12-21|2005-12-30|2006-01-02|Estimate|||||||2006-12-21|2006-12-22|Estimate|June 2004||2004-06-30|December 2006|2006-12-31|November 2006||2006-11-30|||||Interventional|||Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine|Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa|Completed||Phase 4|720||Epicentre|||||f||||||||||||||2018-06-01 04:15:09.833592|2018-06-01 04:15:09.833592
NCT00271466|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2011-05-17|2005-12-30|2006-01-02|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 2000||2000-02-29|April 2010|2010-04-30|April 2002|Actual|2002-04-30|||||Interventional|||A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief Therapy|A Study to Assess the Safety, Dose Conversion and Titration of DURAGESIC® (Fentanyl Transdermal System) in Pediatric Subjects With Chronic Pain Requiring Opioid Therapy|Completed||Phase 3|199|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:09.927355|2018-06-01 04:15:09.927355
NCT00271453|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2011-05-17|2005-12-30|2006-01-02|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 1996||1996-02-29|April 2010|2010-04-30|October 1998|Actual|1998-10-31|||||Interventional|||A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief Therapy|A Study to Assess the Safety, Efficacy and Pharmacokinetics of Durogesic (Fentanyl Transdermal Drug Delivery System) in the Treatment of Pediatric Patients With Chronic Pain Requiring Long-term Opioid Therapy|Completed||Phase 3|41|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:15:10.008849|2018-06-01 04:15:10.008849
NCT00271440|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2010-04-02|2005-12-29|2006-01-02|Estimate|||||||2010-04-02|2010-04-05|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|NNIPS-SFS||Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal|Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal|Completed||Phase 1/Phase 2|286|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||||2018-06-01 04:15:10.075448|2018-06-01 04:15:10.075448
NCT00271427|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2006-08-22|2005-12-30|2006-01-02|Estimate|||||||2006-08-22|2006-08-23|Estimate|December 2004||2004-12-31|December 2004|2004-12-31|August 2005||2005-08-31|||||Interventional|||Selenium Treatment in Autoimmune Thyroiditis (AIT)|Selenium Treatment in Autoimmune Thyroiditis: Long Term Follow-Up With Variable Doses|Completed||N/A|100||Ege University|||||f||||||||||||||2018-06-01 04:15:10.145328|2018-06-01 04:15:10.145328
NCT00271414|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2011-05-16|2005-12-30|2006-01-02|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 1999||1999-03-31|April 2010|2010-04-30|March 2001|Actual|2001-03-31|||||Interventional|||A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy|A 15-day Trial to Document the Safety, Clinical Utility and Pharmacokinetics of Duragesic (TTS Fentanyl) in the Treatment of Pediatric Subjects With Continuous Pain Requiring Opioid Therapy|Completed||Phase 3|53|Actual|Janssen Pharmaceutica N.V., Belgium|||||||||||||||||||2018-06-01 04:15:10.198794|2018-06-01 04:15:10.198794
NCT00271401|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-30|||2015-05-22|2005-12-30|2006-01-02|Estimate|||||||2015-05-22|2015-05-25|Estimate|July 1996||1996-07-31|May 2015|2015-05-31|September 1997|Actual|1997-09-30|September 1997|Actual|1997-09-30||Interventional|||A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab|A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percutaneous Coronary Intervention|Completed||Phase 3|2399|Actual|Centocor, Inc.||3|||f||||f||||||||||2018-06-01 04:15:10.247293|2018-06-01 04:15:10.247293
NCT00271388|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2014-10-01|2005-12-28|2005-12-30|Estimate|||||||2014-10-01|2014-10-03|Estimate|January 2006||2006-01-31|October 2014|2014-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Vestibular Stimulation to Treat Hemispatial Neglect|Noise Enhanced Galvanic Vestibular Stimulation in Hemispatial Neglect|Completed||N/A|2|Actual|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:15:10.312098|2018-06-01 04:15:10.312098
NCT00268073|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2007-05-03|2005-12-20|2005-12-22|Estimate|||||||2007-05-03|2007-05-07|Estimate|January 2002||2002-01-31|May 2007|2007-05-31||||||||Observational|||Incidence of Neo-Aortic Insufficiency|Comparison of the Incidence of Neo-Aortic Insufficiency After Classic Norwood I and Norwood I-Sano Procedures|Terminated|||||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:15:59.227261|2018-06-01 04:15:59.227261
NCT00271375|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|2014-10-16||2016-04-22|2005-12-29|2005-12-30|Estimate|2016-04-22|2016-05-30|Estimate||||2016-04-22|2016-05-30|Estimate|October 2005||2005-10-31|April 2016|2016-04-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Evaluating the Carter Institute Caregiver Education Program at the VA|Evaluating the Carter Institute Caregiver Education Program at the VA|Completed||N/A|254|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:15:10.525342|2018-06-01 04:15:10.525342
NCT00271362|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2017-04-19|2005-12-28|2005-12-30|Estimate|||||||2017-04-19|2017-04-21|Actual|January 2006|Actual|2006-01-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Bone Physiology & Mechanics in Osteomyoplasty Amputation Rehabilitation|Bone Physiology & Mechanics in Osteomyoplasty Amputation Rehabilitation|Terminated||N/A|95|Anticipated|VA Office of Research and Development||1||This project is no longer active with DVA.|f||||f||||||||||2018-06-01 04:15:11.103196|2018-06-01 04:15:11.103196
NCT00271349|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2015-05-21|2005-12-29|2005-12-30|Estimate|||||||2015-05-21|2015-05-22|Estimate|December 2005||2005-12-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|BEE||Budesonide for Eosinophilic Esophagitis|Budesonide for Eosinophilic Esophagitis: a Randomized, Placebo-controlled, Double-blind Treatment Study|Completed||Phase 2|28|Actual|Swiss EE Study Group|||||f||||||||||||||2018-06-01 04:15:11.183127|2018-06-01 04:15:11.183127
NCT00271336|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2008-05-22|2005-12-29|2005-12-30|Estimate|||||||2008-05-22|2008-05-23|Estimate|January 2005||2005-01-31|December 2005|2005-12-31|March 2010|Anticipated|2010-03-31|March 2009|Anticipated|2009-03-31||Interventional|||Pentoxifylline in the Treatment of NEC in Premature Neonates|Pentoxifylline in the Treatment of Necrotizing Enterocolitis in Premature Neonates|Unknown status|Recruiting|Phase 2|50|Anticipated|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-06-01 04:15:11.252468|2018-06-01 04:15:11.252468
NCT00271323|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2009-12-21|2005-12-29|2005-12-30|Estimate|||||||2009-12-21|2009-12-23|Estimate|May 2005||2005-05-31|December 2009|2009-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients|A Two Arm Phase II Study Assessing Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-multiple cN2 or IIIB)|Terminated||Phase 2|14|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:15:11.397799|2018-06-01 04:15:11.397799
NCT00271310|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2006-10-06|2005-12-29|2005-12-30|Estimate|||||||2006-10-06|2006-10-09|Estimate|September 2000||2000-09-30|October 2006|2006-10-31|November 2003||2003-11-30|||||Interventional|||The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis|The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis|Completed||Phase 3|164||Royal Prince Alfred Hospital, Sydney, Australia|||||f||||||||||||||2018-06-01 04:15:11.472267|2018-06-01 04:15:11.472267
NCT00271297|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2009-09-18|2005-12-29|2005-12-30|Estimate|||||||2009-09-18|2009-09-21|Estimate|December 2005||2005-12-31|September 2009|2009-09-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Pelvic Floor Muscle Training (PFMT) in Treatment and Prevention of POP (POP Study)|Effect of Pelvic Floor Muscle Training (PFMT) in Prevention and Treatment of Female Pelvic Organ Prolapse (POP).|Completed||N/A|168|Anticipated|Norwegian School of Sport Sciences|||||f||||||||||||||2018-06-01 04:15:11.535099|2018-06-01 04:15:11.535099
NCT00271284|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2009-12-04|2005-12-29|2005-12-30|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|VARIABILITE||Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients|A Crossover, Multicentre, Randomised Trial Comparing the Effect on the Control of Blood Glucose Concentration of Insulin Glargine and Insulin Detemir, Combined With Insulin Glulisine, Used as a Bolus, in Type 1 Diabetic Patients|Completed||Phase 3|88|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:15:11.618512|2018-06-01 04:15:11.618512
NCT00271271|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2009-12-04|2005-12-29|2005-12-30|Estimate|||||||2009-12-04|2009-12-07|Estimate|June 2003||2003-06-30|December 2009|2009-12-31|October 2006|Actual|2006-10-31|||||Interventional|GON||Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients|Phase II Clinical Trial With the Combination Gemcitabine, Oxaliplatin and Vinorelbine as First Line Treatment in Patients With Non-small Cell Bronchopulmonary Cancer|Completed||Phase 2|40||Sanofi|||||f||||f||||||||||2018-06-01 04:15:11.72321|2018-06-01 04:15:11.72321
NCT00271258|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2011-01-10|2005-12-29|2005-12-30|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|January 2007|Actual|2007-01-31|||||Interventional|ADOKOT||Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents|STUDY OF THE TOLERANCE OF SODIUM DIVALPROATE (DEPAKOTE) IN ADOLESCENTS IN MANIC, MIXED OR HYPOMANIC EPISODES OF BIPOLAR DISORDER|Completed||Phase 3|200||Sanofi|||||f||||f||||||||||2018-06-01 04:15:11.784583|2018-06-01 04:15:11.784583
NCT00271245|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2012-03-06|2005-12-29|2005-12-30|Estimate|||||||2012-03-06|2012-03-07|Estimate|February 2006||2006-02-28|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Selenium Supplementation of Patients With Cirrhosis|Selenium Supplementation of Patients With Cirrhosis|Terminated||N/A|99|Actual|Vanderbilt University||4||Insufficient funds to complete study.|f||||t||||||||||2018-06-01 04:15:11.854361|2018-06-01 04:15:11.854361
NCT00271232|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2007-12-20|2005-12-28|2005-12-30|Estimate|||||||2007-12-20|2007-12-21|Estimate|March 2003||2003-03-31|December 2007|2007-12-31|April 2005||2005-04-30|||||Interventional|||InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System|InSync III Marquis Model 7279 Cardioverter Defibrillator Cardiac Resynchronization System|Completed||N/A|238||Medtronic Cardiac Rhythm and Heart Failure|||||||||||||||||||2018-06-01 04:15:11.947977|2018-06-01 04:15:11.947977
NCT00271219|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|2013-03-11||2015-07-30|2005-12-28|2005-12-30|Estimate|2015-07-30|2015-08-05|Estimate||||2015-07-30|2015-08-05|Estimate|July 2005||2005-07-31|July 2015|2015-07-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Interventional|||RCT Comparing Methadone and Buprenorphine in Pregnant Women|Maternal Opioid Treatment: Human Experimental Research|Completed||Phase 3|175|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 04:15:12.07288|2018-06-01 04:15:12.07288
NCT00271206|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2012-07-24|2005-12-28|2005-12-30|Estimate|||||||2012-07-24|2012-07-25|Estimate|September 2004||2004-09-30|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Effect of Progesterone on Smoking Behavior in Male and Female Smokers|Progesterone and the Effects of Nicotine|Completed||Phase 1|65|Actual|Yale University||2|||f||||t||||||||||2018-06-01 04:15:12.699588|2018-06-01 04:15:12.699588
NCT00271193|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2017-10-16|2005-12-29|2005-12-30|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2005||2005-09-30|October 2017|2017-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Primary Care Intervention for Weight Management|A Primary Care Intervention for Weight Management|Completed||Phase 3|50|Actual|Kaiser Permanente||2|||f||||||||||||||2018-06-01 04:15:12.777248|2018-06-01 04:15:12.777248
NCT00271180|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2017-11-29|2005-12-28|2005-12-30|Estimate|||||||2017-11-29|2017-12-02|Actual|January 1983||1983-01-31|November 2017|2017-11-30|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|PPR||Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products|Medtronic CRDM Product Performance Report|Recruiting|||13000|Anticipated|Medtronic|||||f||||f|f|t|f|f||||||2018-06-01 04:15:12.882596|2018-06-01 04:15:12.882596
NCT00271167|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2015-03-23|2005-12-29|2005-12-30|Estimate|||||||2015-03-23|2015-03-25|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|June 2006|Actual|2006-06-30|||||Interventional|||A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass|A Phase II Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Tolerability, Safety, Pharmacokinetics and Efficacy of Intravenous INO-1001 in High Risk Subjects Undergoing Cardiopulmonary Bypass for Coronary Revascularization and/or Valve Surgery.|Terminated||Phase 2|162||Inotek Pharmaceuticals Corporation||||"It was determined that the study was not appropriate for demonstrating therapeutic benefit in~   the cardiopulmonary bypass patient population."|f||||||||||||||2018-06-01 04:15:13.335685|2018-06-01 04:15:13.335685
NCT00271154|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|2008-12-24||2012-01-26|2005-12-28|2005-12-30|Estimate|2009-03-26|2009-05-13|Estimate||||2012-01-26|2012-01-30|Estimate|September 2004||2004-09-30|January 2012|2012-01-31|November 2011|Actual|2011-11-30|October 2007|Actual|2007-10-31||Interventional|||REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)|REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)|Completed||N/A|684|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-06-01 04:15:13.483729|2018-06-01 04:15:13.483729
NCT00271141|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2005-12-29|2005-12-29|2005-12-30|Estimate|||||||2005-12-29|2005-12-30|Estimate|May 2005||2005-05-31|December 2005|2005-12-31|December 2015||2015-12-31|||||Observational|||Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease|Multifunctional Substrate for Early Detection of Oxidative Stress Susceptibility and Application to Parkinson's Disease|Unknown status|Recruiting||500||Hillel Yaffe Medical Center|||||f||||||||||||||2018-06-01 04:15:15.178327|2018-06-01 04:15:15.178327
NCT00271128|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2008-03-19|2005-12-29|2005-12-30|Estimate|||||||2008-03-19|2008-03-20|Estimate|October 2005||2005-10-31|December 2005|2005-12-31|September 2007|Anticipated|2007-09-30|||||Observational|||NT-proBNP for Evaluation of the Dyspneic Patient in the Emergency Room and the Medical Ward|NT-proBNP for Evaluation of the Dyspneic Patient in the Emergency Room and the Medical Ward (BNP4EVER)|Unknown status|Active, not recruiting||500|Anticipated|Hillel Yaffe Medical Center|||||f||||||||||||||2018-06-01 04:15:15.232777|2018-06-01 04:15:15.232777
NCT00271115|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2012-02-16|2005-12-29|2005-12-30|Estimate|||||||2012-02-16|2012-02-17|Estimate|September 2005||2005-09-30|February 2012|2012-02-29|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||Kangaroo Holding and Maternal Stress|The Effect of Kangaroo Holding on Maternal Stress Levels|Completed||N/A|20|Actual|Christiana Care Health Services||1|||f||||f||||||||||2018-06-01 04:15:15.289743|2018-06-01 04:15:15.289743
NCT00271102|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2010-07-09|2005-12-29|2005-12-30|Estimate|||||||2010-07-09|2010-07-12|Estimate|December 2005||2005-12-31|July 2010|2010-07-31|February 2012|Anticipated|2012-02-29|February 2010|Actual|2010-02-28||Interventional|||Surgical Study Comparing 2 Procedures for the Treatment of a Dropped Bladder|Randomized Trial Comparing Anterior Colporrhaphy to Paravaginal Defect Repair for Anterior Vaginal Wall Prolapse|Unknown status|Active, not recruiting|N/A|70|Anticipated|Geisinger Clinic||2|||f||||f||||||||||2018-06-01 04:15:15.478929|2018-06-01 04:15:15.478929
NCT00271089|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2016-07-11|2005-12-29|2005-12-30|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2004||2004-08-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Blood Cell Collection for Future Use in Individuals With Fanconi Anemia|Collection of Hematopoietic Cells From Patients With Fanconi Anemia (FA) for Future Autologous Reinfusion and Research|Completed||N/A|40|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||||||||||||||||2018-06-01 04:15:15.584071|2018-06-01 04:15:15.584071
NCT00271076|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2007-10-24|2005-12-29|2005-12-30|Estimate|||||||2007-10-24|2007-10-25|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||CAPITAL: Carotid Artery Plaque Intravascular Ultrasound Evaluation|Carotid Artery Plaque Intravascular Ultrasound Evaluation|Completed||Phase 1|31|Actual|Arizona Heart Institute|||||||||||||||||||2018-06-01 04:15:15.656067|2018-06-01 04:15:15.656067
NCT00271063|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-29|||2007-12-17|2005-12-29|2005-12-30|Estimate|||||||2007-12-17|2007-12-21|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|April 2008|Anticipated|2008-04-30|||||Interventional|||Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia|Phase I/II Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|34|Anticipated|Callisto Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:15:15.73703|2018-06-01 04:15:15.73703
NCT00271050|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2010-12-20|2005-12-28|2005-12-29|Estimate|||||||2010-12-20|2010-12-21|Estimate|December 2005||2005-12-31|December 2010|2010-12-31|June 2010|Actual|2010-06-30|December 2007|Actual|2007-12-31||Interventional|||External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma|The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma|Completed||Phase 1|12|Anticipated|The Cleveland Clinic||1|||f||||||||||||||2018-06-01 04:15:15.840181|2018-06-01 04:15:15.840181
NCT00271037|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2011-01-09|2005-12-27|2005-12-29|Estimate|||||||2011-01-09|2011-01-11|Estimate|July 2004||2004-07-31|October 2010|2010-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Colpocleisis for Advanced Pelvic Organ Prolapse|Pelvic Symptoms and Patient Satisfaction After Colpocleisis for Advanced Pelvic Organ Prolapse|Completed|||152|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||||||2018-06-01 04:15:15.947458|2018-06-01 04:15:15.947458
NCT00271024|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|2012-12-19||2013-03-13|2005-12-28|2005-12-29|Estimate|2013-03-13|2013-04-26|Estimate||||2013-03-13|2013-04-26|Estimate|December 2005||2005-12-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Naltrexone in Women's Smoking Cessation|Efficacy of Naltrexone in Women's Smoking Cessation|Completed||Phase 2|333|Actual|University of Chicago||4|||f||||f||||||||||2018-06-01 04:15:16.074137|2018-06-01 04:15:16.074137
NCT00271011|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|2014-06-04||2015-11-04|2005-12-27|2005-12-29|Estimate|2014-07-08|2014-07-10|Estimate||||2015-11-04|2015-12-03|Estimate|December 2005||2005-12-31|November 2015|2015-11-30|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of Mitomycin C, Irinotecan, and Cetuximab|A Phase II Study of Mitomycin C, Irinotecan and Cetuximab in Patients With Previously Treated, Metastatic Colorectal Cancer|Terminated||Phase 2|13|Actual|University of Michigan Cancer Center|The study was discontinued and not completed due to the death of a co-investigator and a second co-investigator leaving the institution.|1||"The study was discontinued due to the death of a co-investigator and a second co-investigator~   leaving the institution."|f||||t||||||||||2018-06-01 04:15:16.811526|2018-06-01 04:15:16.811526
NCT00270998|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|2017-04-18||2018-04-30|2005-12-27|2005-12-29|Estimate|2017-08-08|2017-08-10|Actual||||2018-04-30|2018-05-30|Actual|June 2005||2005-06-30|April 2018|2018-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||ATLAS: Ambulatory Treatments for Leakage Associated With Stress|ATLAS: Ambulatory Treatments for Leakage Associated With Stress, A Randomized Trial of Pelvic Muscle Exercise Versus Incontinence Pessary Versus Both for Women With Stress or Mixed Urinary Incontinence|Completed||Phase 3|445|Actual|NICHD Pelvic Floor Disorders Network||3|||f||||t||||||||Yes||2018-06-01 04:15:18.096559|2018-06-01 04:15:18.096559
NCT00270985|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2016-06-20|2005-12-27|2005-12-29|Estimate|||||||2016-06-20|2016-06-22|Estimate|January 2006||2006-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2007|Actual|2007-05-31||Interventional|||The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes|The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes|Completed||Phase 1|66|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||No|No plan to make individual participant data (IPD) available.|2018-06-01 04:15:19.252184|2018-06-01 04:15:19.252184
NCT00270972|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2006-06-02|2005-12-28|2005-12-29|Estimate|||||||2006-06-02|2006-06-05|Estimate|September 2005||2005-09-30|June 2006|2006-06-30||||||||Interventional|||The Evaluation of OrCel for the Treatment of Venous Ulcers|A Confirmatory Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (ORCEL) for the Treatment of Venous Ulcers|Unknown status|Active, not recruiting|N/A|60||Ortec International|||||||||||||||||||2018-06-01 04:15:19.371263|2018-06-01 04:15:19.371263
NCT00270959|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2012-06-19|2005-12-28|2005-12-29|Estimate|||||||2012-06-19|2012-06-20|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|September 2010|Actual|2010-09-30||Interventional|||Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury|Early Combined Intervention After Traumatic Injury|Unknown status|Active, not recruiting|Phase 1|300|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 04:15:19.443282|2018-06-01 04:15:19.443282
NCT00270946|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2005-12-28|2005-12-28|2005-12-29|Estimate|||||||2005-12-28|2005-12-29|Estimate|April 2002||2002-04-30|December 2005|2005-12-31|December 2003||2003-12-31|||||Interventional|||Evaluation of Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers|A Pivotal Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers|Completed||N/A|130||Ortec International|||||||||||||||||||2018-06-01 04:15:19.55809|2018-06-01 04:15:19.55809
NCT00270933|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2007-12-26|2005-12-28|2005-12-29|Estimate|||||||2007-12-26|2007-12-28|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|December 2005||2005-12-31|||||Observational|||MAVRIC VR ICD Registry|Marquis/Maximo VR ICD Programming Practices Registry (MAVRIC VR ICD Registry)|Completed|||742||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:15:19.636075|2018-06-01 04:15:19.636075
NCT00270920|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2008-07-10|2005-12-28|2005-12-29|Estimate|||||||2008-07-10|2008-07-15|Estimate|February 2004||2004-02-29|July 2008|2008-07-31|March 2006||2006-03-31|||||Interventional|||A Randomised Controlled Trial to Compare Antenatal Preparation and Postnatal Counseling|A Randomised Controlled Trial to Compare Antenatal Preparation and Postnatal Counseling Strategies for Improving Breastfeeding Rates|Completed||N/A|450||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:15:19.875777|2018-06-01 04:15:19.875777
NCT00270907|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2013-02-11|2005-12-28|2005-12-29|Estimate|||||||2013-02-11|2013-02-13|Estimate|December 2005||2005-12-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer|A Phase I Study of CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer|Completed||Phase 1|13|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:15:19.959655|2018-06-01 04:15:19.959655
NCT00270894|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|2011-11-18||2012-03-15|2005-12-28|2005-12-29|Estimate|2012-02-09|2012-03-12|Estimate||||2012-03-15|2012-03-20|Estimate|November 2005||2005-11-30|March 2012|2012-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients|Pilot Trial of Sequential Dose-Dense Neoadjuvant Chemotherapy Plus Herceptin in HER2 Positive Stage II-III Breast Cancer Patients|Completed||Phase 2|30|Actual|Accelerated Community Oncology Research Network||1|||f||||f||||||||||2018-06-01 04:15:20.150755|2018-06-01 04:15:20.150755
NCT00270881|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-28|||2012-04-05|2005-12-28|2005-12-29|Estimate|||||||2012-04-05|2012-04-06|Estimate|January 2006||2006-01-31|April 2012|2012-04-30|January 2011|Actual|2011-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies|Phase 1/2 Study of Cord Blood Transplantation From Unrelated Donor for Adult Patients With Hematologic Malignancies Using Myeloablative Conditioning Regimen|Completed||Phase 1/Phase 2|33|Actual|Keio University|||||f||||t||||||||||2018-06-01 04:15:20.751586|2018-06-01 04:15:20.751586
NCT00270868|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2006-10-17|2005-12-27|2005-12-28|Estimate|||||||2006-10-17|2006-10-18|Estimate|November 2004||2004-11-30|October 2006|2006-10-31|November 2006||2006-11-30|||||Interventional|||Efficacy of Double Wire Technique in Difficult Cases of Common Bile Duct Cannulation in ERCP (UDOGUIA-04)|Double Guide Wire Placement Compared With Conventional Method in Cases of Difficult Common Bile Duct Cannulation in Endoscopic Retrograde Cholangiopancreatography Procedures. A Controlled Multicentred Randomized Trial.|Unknown status|Active, not recruiting|N/A|1050||Puerta de Hierro University Hospital|||||f||||||||||||||2018-06-01 04:15:20.844896|2018-06-01 04:15:20.844896
NCT00270855|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|2016-10-07||2017-10-13|2005-12-23|2005-12-28|Estimate|2017-10-13|2017-11-17|Actual||||2017-10-13|2017-11-17|Actual|May 2008||2008-05-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Exercise to Reduce Obesity in Spinal Cord Injury|Exercise to Reduce Obesity in Spinal Cord Injury|Completed||N/A|29|Actual|VA Office of Research and Development|The number of subjects that withdrew lead to small numbers of subjects analyzed.|2|||f||||f||||||||No||2018-06-01 04:15:20.996779|2018-06-01 04:15:20.996779
NCT00270842|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|2014-10-14||2015-04-07|2005-12-23|2005-12-28|Estimate|2015-04-07|2015-04-08|Estimate||||2015-04-07|2015-04-08|Estimate|January 2006||2006-01-31|April 2015|2015-04-30|September 2012|Actual|2012-09-30|January 2009|Actual|2009-01-31||Interventional||101 subjects were enrolled, however, 2 subjects dropped after completion of baseline assessments. Only 99 are included in the data.|Effect of Exercise on Gait and Balance in Peripheral Neuropathy|Effect of Exercise on Gait and Balance in Peripheral Neuropathy|Completed||N/A|101|Actual|VA Office of Research and Development|Due to the large number of drop outs following the 10 week data point, maintenance of gait and balance changes is uncertain.|3|||f||||f||||||||||2018-06-01 04:15:21.911582|2018-06-01 04:15:21.911582
NCT00270829|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2008-02-08|2005-12-27|2005-12-28|Estimate|||||||2008-02-08|2008-02-21|Estimate|December 2005||2005-12-31|February 2008|2008-02-29|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Renal Effects of Intrarenal Nesiritide|Renal Effects of Intrarenal Nesiritide|Terminated||Phase 4|2|Actual|University of Maryland||2||Funding not available|f||||||||||||||2018-06-01 04:15:22.130919|2018-06-01 04:15:22.130919
NCT00268060|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2007-05-03|2005-12-20|2005-12-22|Estimate|||||||2007-05-03|2007-05-07|Estimate|September 2004||2004-09-30|May 2007|2007-05-31||||||||Observational|||Infant Medical Records: Case Report Proposal|Baby R. Case Report Proposal|Terminated|||1||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:15:59.299877|2018-06-01 04:15:59.299877
NCT00270816|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2018-01-05|2005-12-27|2005-12-28|Estimate|||||||2018-01-05|2018-01-08|Actual|November 2005|Actual|2005-11-30|January 2018|2018-01-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||Interferon ß-1b Treatment by Cyclical Administration|Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose.|Completed||Phase 2/Phase 3|60|Actual|S. Andrea Hospital||2|||f||||t||||||||||2018-06-01 04:15:22.19548|2018-06-01 04:15:22.19548
NCT00270803|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-25|||2008-05-06|2005-12-25|2005-12-28|Estimate|||||||2008-05-06|2008-05-07|Estimate|July 2004||2004-07-31|December 2005|2005-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana|The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana.|Completed||N/A|12|Actual|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-06-01 04:15:22.387504|2018-06-01 04:15:22.387504
NCT00270790|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|2015-12-11||2016-12-05|2005-12-23|2005-12-28|Estimate|2016-06-27|2016-08-08|Estimate||||2016-12-05|2017-02-01|Estimate|May 2002||2002-05-31|December 2016|2016-12-31|February 2009|Actual|2009-02-28|December 2005|Actual|2005-12-31||Interventional|||EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)|A SINGLE SITE EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CONCURRENT CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH ADVANCED LOCOREGIONAL SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK.|Completed||Phase 2|21|Actual|University of Maryland||1|||f||||t||||||||No||2018-06-01 04:15:22.486061|2018-06-01 04:15:22.486061
NCT00270777|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2008-06-04|2005-12-27|2005-12-28|Estimate|||||||2008-06-04|2008-06-05|Estimate|March 2005||2005-03-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Improving Safety of Antivenom in People Bitten by Snakes|Low Dose Adrenaline, Promethazine, & Hydrocortisone (Alone and in Combination) to Prevent Acute Adverse Reactions to Antivenom in People Bitten by Snakes: Randomised, Double Blind, Placebo-Controlled Trial|Completed||Phase 4|1000|Anticipated|University of Kelaniya|||||f||||t||||||||||2018-06-01 04:15:22.715442|2018-06-01 04:15:22.715442
NCT00270764|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2013-11-19|2005-12-27|2005-12-28|Estimate|||||||2013-11-19|2013-11-20|Estimate|July 2005||2005-07-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|June 2011|Actual|2011-06-30||Observational|||Social and Economic Outcomes of HIV/AIDS Care and Treatment in HIV Infected South African Adults|Economic Outcomes of HIV/AIDS Care and Treatment in South Africa|Completed|||1065|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||||||2018-06-01 04:15:22.786397|2018-06-01 04:15:22.786397
NCT00270751|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-26|||2006-08-04|2005-12-26|2005-12-28|Estimate|||||||2006-08-04|2006-08-07|Estimate|April 2005||2005-04-30|August 2006|2006-08-31|May 2009||2009-05-31|||||Interventional|||Pleural Abrasion Plus Minocycline Versus Apical Pleurectomy for Primary Spontaneous Pneumothorax|Comparison of Pleural Abrasion Plus Minocycline Pleurodesis Versus Apical Pleurectomy After Thoracoscopic Bullectomy for High Recurrent Risk Patients With Primary Spontaneous Pneumothorax: A Prospective Randomized Trial.|Unknown status|Recruiting|Phase 2/Phase 3|200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:15:22.861744|2018-06-01 04:15:22.861744
NCT00270738|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-26|||2012-12-04|2005-12-26|2005-12-28|Estimate|||||||2012-12-04|2012-12-06|Estimate|December 2005||2005-12-31|December 2012|2012-12-31|March 2010|Actual|2010-03-31|December 2006|Actual|2006-12-31||Interventional|||Treatment for Female Stress Urinary Incontinence|Treatment for Stress Urinary Incontinence—Indirect Training of Pelvic Floor Muscle Via Transversus Abdominis Muscle Contraction|Completed||N/A|168|Actual|National Taiwan University Hospital||3|||f||||t||||||||||2018-06-01 04:15:22.952327|2018-06-01 04:15:22.952327
NCT00270725|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2017-02-26|2005-12-27|2005-12-28|Estimate|||||||2017-02-26|2017-02-28|Actual|July 1, 2005|Actual|2005-07-01|February 2017|2017-02-28|July 1, 2005|Actual|2005-07-01|July 1, 2005|Actual|2005-07-01||Observational|||Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa|The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS|Withdrawn|||0|Actual|Boston University||||Enrollment never initiated, study withdrawn.|f||||||||||||||2018-06-01 04:15:23.038553|2018-06-01 04:15:23.038553
NCT00270712|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2017-01-19|2005-12-27|2005-12-28|Estimate|||||||2017-01-19|2017-01-23|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|DeKAF||A Study of Factors That Affect Long-Term Kidney Transplant Function|Study of Long-term Deterioration of Kidney Allograft Function (DeKAF)|Active, not recruiting|||3175|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||Samples With DNA|"~     Blood and urine specimens.~   "|||2018-06-01 04:15:23.130322|2018-06-01 04:15:23.130322
NCT00270699|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2012-12-31|2005-12-27|2005-12-28|Estimate|||||||2012-12-31|2013-01-03|Estimate|June 2006||2006-06-30|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4|Completed||Phase 1|56|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 04:15:23.20914|2018-06-01 04:15:23.20914
NCT00270686|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2018-04-04|2005-12-27|2005-12-28|Estimate|||||||2018-04-04|2018-04-05|Actual|January 21, 2003||2003-01-21|January 2, 2015|2015-01-02|January 2, 2015||2015-01-02|||||Observational|||Studies of Heritable Disorders of Connective Tissue|Clinical and Molecular Manifestations of Heritable Disorders of Connective Tissue|Completed|||929|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:15:23.298794|2018-06-01 04:15:23.298794
NCT00270673|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2008-04-24|2005-12-23|2005-12-28|Estimate|||||||2008-04-24|2008-04-25|Estimate|February 2006||2006-02-28|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Early Lactate-Directed Therapy in the Intensive Care Unit (ICU)|Early Lactate-Directed Therapy on the ICU: A Randomized Controlled Trial|Completed||Phase 3|350|Anticipated|Erasmus Medical Center|||||f||||t||||||||||2018-06-01 04:15:23.373267|2018-06-01 04:15:23.373267
NCT00270660|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2006-11-29|2005-12-23|2005-12-28|Estimate|||||||2006-11-29|2006-11-30|Estimate|July 2003||2003-07-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Observational|||A Study of the Clinicopathologic Behaviour of the Different Types of Unsafe Chronic Otitis Media|A Cross Sectional Study of Clinicopathologic Behaviour of Primary, Secondary and Mixed Types of Atticoantral Chronic Otitis Media|Unknown status|Active, not recruiting||192||Karnataka Institute of Medical Sciences|||||f||||||||||||||2018-06-01 04:15:23.454673|2018-06-01 04:15:23.454673
NCT00270647|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-27|||2018-02-26|2005-12-27|2005-12-28|Estimate|||||||2018-02-26|2018-02-28|Actual|July 1997||1997-07-31|February 2018|2018-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PHS II||Physicians' Health Study II|Physicians' Health Study II: Trial of Vitamins in the Chemoprevention of Cancer, CVD, and Eye Disease|Completed||N/A|14641|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-06-01 04:15:23.514722|2018-06-01 04:15:23.514722
NCT00270634|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|2012-10-10||2013-02-11|2005-12-23|2005-12-28|Estimate|2013-02-11|2013-02-12|Estimate||||2013-02-11|2013-02-12|Estimate|January 2006||2006-01-31|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|PROMISE||Study of ISA247 (Voclosporin) in De Novo Renal Transplantation|A Phase IIb, Randomized, Multicenter, Open-Label, Concentration Controlled, Safety Study of ISA247 (Voclosporin) and Tacrolimus (Prograf®) in De Novo Renal Transplant Patients|Completed||Phase 2|334|Actual|Aurinia Pharmaceuticals Inc.|By limiting access to patients at relatively low risk for rejection and no delayed graft function, the results observed may not be applicable to all renal transplant recipients.|4|||f||||t||||||||||2018-06-01 04:15:23.648496|2018-06-01 04:15:23.648496
NCT00270621|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2016-09-01|2005-12-23|2005-12-28|Estimate|||||||2016-09-01|2016-09-02|Estimate|June 2003||2003-06-30|September 2016|2016-09-30|April 2008|Actual|2008-04-30|October 2006|Actual|2006-10-31||Interventional|||Family Help Program: Nighttime Enuresis Treatment Program|Family Help Program: Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Enuresis)|Completed||Phase 2|56|Actual|IWK Health Centre||2|||f||||f||||||||No|Aggregate summary data would be made available but not individual data.|2018-06-01 04:15:25.013496|2018-06-01 04:15:25.013496
NCT00270608|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-26|||2007-11-25|2005-12-26|2005-12-28|Estimate|||||||2007-11-25|2007-11-27|Estimate|March 2007||2007-03-31|November 2007|2007-11-30|November 2008|Anticipated|2008-11-30|||||Observational|||How Does Early Age Life Style Affect Bone Strength and General Health Parameters at Middle Age?|How Does Early Age Life Style Affect Bone Strength and General Health at Middle Age? Twenty-Five Year Follow-up Health Status Comparison of a Sedentary Versus Extremely Physically Active Population From an Early Age|Unknown status|Recruiting||100|Anticipated|Hadassah Medical Organization|||||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 04:15:25.095285|2018-06-01 04:15:25.095285
NCT00270582|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-26|||2009-02-06|2005-12-26|2005-12-28|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2005||2005-11-30|September 2005|2005-09-30||||||||Interventional|||A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer|A Randomized Phase II Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|58|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:15:25.178899|2018-06-01 04:15:25.178899
NCT00270569|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-26|||2009-02-06|2005-12-26|2005-12-28|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 2005||2005-10-31|August 2005|2005-08-31||||February 2007|Actual|2007-02-28||Interventional|||An Effective and Compliance Regimen of Paclitaxel Plus Cisplatin to Treat Metastatic Breast Cancer|A Phase II Study of Weekly Low-Dose Paclitaxel Plus 24-Hour Infusion of Cisplatin as First-Line Chemotherapy for Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|43|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:15:25.259467|2018-06-01 04:15:25.259467
NCT00270556|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2008-04-07|2005-12-23|2005-12-28|Estimate|||||||2008-04-07|2008-04-10|Estimate|January 2003||2003-01-31|April 2008|2008-04-30|October 2004||2004-10-31|||||Interventional|||Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART.|Phase II, Open-Label,Randomised, Comparator Study of Substitution w/Tenofovir or Abacavir in HIV-1 Infected Individuals, w/Viral Load Less 50 Copies/mL, Receiving a Thymidine Analogue (Zidovudine or Stavudine) as Part of HAART.|Completed||Phase 2|100||Gilead Sciences|||||f||||||||||||||2018-06-01 04:15:25.333945|2018-06-01 04:15:25.333945
NCT00270543|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-26|||2009-02-06|2005-12-26|2005-12-28|Estimate|||||||2009-02-06|2009-02-09|Estimate||||September 2004|2004-09-30||||||||Interventional|||An Effective and Well-Tolerated Regimen of Docetaxel Plus High-Dose 5-Fluorouracil and Leucovorin(HDFL)to Treat Inoperable Advanced or Metastatic Gastric Cancer|A Phase II Study of Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin(HDFL)for Inoperable Advanced or Metastatic Gastric Cancer|Unknown status|Not yet recruiting|Phase 2|54|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:15:25.392613|2018-06-01 04:15:25.392613
NCT00270530|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2006-01-30|2005-12-23|2005-12-28|Estimate|||||||2006-01-30|2006-01-31|Estimate|November 2002||2002-11-30|November 2004|2004-11-30|October 2004||2004-10-31|||||Interventional|||Intermittent Preventive Treatment of Malaria in HIV-Seropositive Pregnant Women in Zambia|Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia|Completed||Phase 4|454||Center for International Health and Development|||||f||||||||||||||2018-06-01 04:15:25.45976|2018-06-01 04:15:25.45976
NCT00270517|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2006-09-18|2005-12-23|2005-12-28|Estimate|||||||2006-09-18|2006-09-19|Estimate|December 2005||2005-12-31|September 2006|2006-09-30|July 2007||2007-07-31|||||Interventional|||Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia|A Randomized, Double-Blinded, Parallel Group, Multicenter Study of EDP-420 Versus Telithromycin for the Treatment of Community Acquired Pneumonia|Unknown status|Recruiting|Phase 2|250||Enanta Pharmaceuticals|||||||||||||||||||2018-06-01 04:15:25.540055|2018-06-01 04:15:25.540055
NCT00270504|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2009-11-17|2005-12-23|2005-12-28|Estimate|||||||2009-11-17|2009-11-18|Estimate|December 2002||2002-12-31|December 2008|2008-12-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Memokath® 044TW Stent for Treatment of Urethral Stricture|Prospective, Randomized, Controlled, Multicenter Trial of the Memokath® 044TW Thermo-Expandable Stent for Maintaining Urethral Patency in Patients After Dilation or Internal Urethrotomy of Recurrent Stricture of the Bulbar Urethra|Completed||Phase 3|92|Actual|Pnn Medical DK|||||f||||f||||||||||2018-06-01 04:15:25.629641|2018-06-01 04:15:25.629641
NCT00270491|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-26|||2011-02-24|2005-12-26|2005-12-28|Estimate|||||||2011-02-24|2011-02-25|Estimate|December 2005||2005-12-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2009|Actual|2009-10-31||Interventional|||Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.|A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.|Completed||Phase 2|130|Anticipated|ARCAGY/ GINECO GROUP|||||f||||||||||||||2018-06-01 04:15:25.703239|2018-06-01 04:15:25.703239
NCT00270478|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-25|||2018-05-24|2005-12-24|2005-12-26|Estimate|||||||2018-05-24|2018-05-25|Actual|December 21, 2005||2005-12-21|January 27, 2016|2016-01-27|August 31, 2009|Actual|2009-08-31|August 31, 2009|Actual|2009-08-31||Interventional|||Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia|Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia|Completed||Phase 1|7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:15:25.757228|2018-06-01 04:15:25.757228
NCT00268294|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-12-16|2005-12-21|2005-12-22|Estimate|||||||2008-12-16|2008-12-18|Estimate|May 2003||2003-05-31|December 2008|2008-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Restoring Sinus Rhythm With Cardiac Resynchronization in Patients With Atrial Fibrillation (ReSync AF)|Restoring Sinus Rhythm With Cardiac Resynchronization in Patients With Atrial Fibrillation|Completed||N/A|20||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:15:56.04697|2018-06-01 04:15:56.04697
NCT00270465|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-24|||2017-06-30|2005-12-23|2005-12-26|Estimate|||||||2017-06-30|2017-07-02|Actual|December 21, 2005||2005-12-21|June 25, 2009|2009-06-25|June 25, 2009|Actual|2009-06-25|June 25, 2009|Actual|2009-06-25||Interventional|||Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients|VRC101: A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-Boost HIV-1 Vaccination Schedule of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by a Recombinant Multiclade Adenoviral Vector HIV Vaccine|Completed||Phase 1|17||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:15:25.834633|2018-06-01 04:15:25.834633
NCT00270452|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-24|||2017-06-30|2005-12-23|2005-12-26|Estimate|||||||2017-06-30|2017-07-02|Actual|December 22, 2005||2005-12-22|February 9, 2012|2012-02-09|October 26, 2007|Actual|2007-10-26|October 26, 2007|Actual|2007-10-26||Interventional|||Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome|Safety of WT1 and PR1 Peptide Vaccination for Patients With Myeloid Malignancies|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:15:25.896067|2018-06-01 04:15:25.896067
NCT00270439|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2009-09-10|2005-12-22|2005-12-26|Estimate|||||||2009-09-10|2009-09-14|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Omentectomy for the Treatment of Diabetes Mellitus Type 2|Omentectomy for Treatment of Diabetes Mellitus Type 2|Completed||Phase 1|10|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 04:15:25.96376|2018-06-01 04:15:25.96376
NCT00270426|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2006-05-04|2005-12-23|2005-12-26|Estimate|||||||2006-05-04|2006-05-05|Estimate||||March 1999|1999-03-31||||||||Interventional|||Benazepril for Advanced Chronic Renal Insufficiency||Terminated||N/A|||Southern Medical University, China|||||f||||||||||||||2018-06-01 04:15:26.036812|2018-06-01 04:15:26.036812
NCT00270413|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2014-12-08|2005-12-23|2005-12-26|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2006||2006-01-31|December 2014|2014-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer|A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction|Completed||Phase 2|55|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-06-01 04:15:26.099465|2018-06-01 04:15:26.099465
NCT00270400|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-09|2005-12-22|2005-12-26|Estimate|||||||2011-06-09|2011-06-10|Estimate|August 1998||1998-08-31|June 2011|2011-06-30|February 1999|Actual|1999-02-28|||||Interventional|||A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure|Natrecor (Nesiritide) Versus Dobutamine Therapy for Symptomatic, Decompensated CHF: A Safety Study Using 24-Hour Holter Monitoring - The PRECEDENT Trial: Prospective, Randomized Evaluation of Cardiac Ectopy With Dobutamine or Natrecor Therapy|Completed||Phase 3|255|Actual|Scios, Inc.||1|||f||||||||||||||2018-06-01 04:15:26.211808|2018-06-01 04:15:26.211808
NCT00270387|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2012-12-12|2005-12-22|2005-12-26|Estimate|||||||2012-12-12|2012-12-13|Estimate|January 2001||2001-01-31|December 2012|2012-12-31|January 2002|Actual|2002-01-31|||||Interventional|||A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy|Prospective Randomized Outcomes Study of Acutely Decompensated Congestive Heart Failure Treated Initially in Outpatients With Natrecor (Nesiritide) - The PROACTION Trial|Completed||Phase 3|250|Actual|Scios, Inc.||1|||f||||||||||||||2018-06-01 04:15:26.269824|2018-06-01 04:15:26.269824
NCT00270374|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-09|2005-12-22|2005-12-26|Estimate|||||||2011-06-09|2011-06-10|Estimate|October 1999||1999-10-31|June 2011|2011-06-30|August 2000|Actual|2000-08-31|||||Interventional|||A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acute Congestive Heart Failure|Completed||Phase 3|498|Actual|Scios, Inc.||1|||f||||||||||||||2018-06-01 04:15:26.333589|2018-06-01 04:15:26.333589
NCT00270361|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-07-25|2005-12-22|2005-12-26|Estimate|||||||2011-07-25|2011-07-26|Estimate|December 2001||2001-12-31|July 2011|2011-07-31|January 2003|Actual|2003-01-31|||||Interventional|||FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.|Management of Patients With CHF After Hospitalization-Follow up Serial Infusions of NATRECOR (Nesiritide) - FUSION I, A Pilot Study|Completed||Phase 3|214|Actual|Scios, Inc.||3|||f||||||||||||||2018-06-01 04:15:26.397323|2018-06-01 04:15:26.397323
NCT00270348|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2005-12-27|2005-12-22|2005-12-26|Estimate|||||||2005-12-27|2005-12-28|Estimate|December 2000||2000-12-31|December 2005|2005-12-31|September 2004||2004-09-30|||||Interventional|||Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma|A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 Mg/Day and 200 Mg/Day (Ex-Valve) Administered Once Daily on Growth in Children With Mild Persistent Asthma|Completed||Phase 3|450||Sanofi|||||||||||||||||||2018-06-01 04:15:26.467361|2018-06-01 04:15:26.467361
NCT00270335|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2009-10-15|2005-12-23|2005-12-26|Estimate|||||||2009-10-15|2009-10-16|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Optimizing Propofol in Obese Patients|Optimizing Propofol in Obese Patients|Completed||Phase 4|38|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 04:15:26.522753|2018-06-01 04:15:26.522753
NCT00270322|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2007-04-10|2005-12-23|2005-12-26|Estimate|||||||2007-04-10|2007-04-11|Estimate|January 2006||2006-01-31|May 2006|2006-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Pain Treatment After Total Knee Replacement - Continuous Epidural Versus Intravenous Patient Controlled Analgesia With Morphine|Pain Treatment After Total Knee Replacement - Continuous Epidural Versus Intravenous Patient Controlled Analgesia With Morphine|Terminated||Phase 4|80||Rambam Health Care Campus||||"We believe regional anesth better for TKR,90% patients got epidural. Last year we started~   spinal morphine one shot, and found it very promissing."|f||||||||||||||2018-06-01 04:15:26.629252|2018-06-01 04:15:26.629252
NCT00270309|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2015-05-05|2005-12-22|2005-12-26|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2004||2004-01-31|December 2005|2005-12-31|October 2006|Actual|2006-10-31|April 2004|Actual|2004-04-30||Interventional|||Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms|Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms. A Randomised Controlled Trial Against Standard Therapy|Completed||Phase 3|168||The Royal College of Surgeons of England|||||f||||||||||||||2018-06-01 04:15:26.705498|2018-06-01 04:15:26.705498
NCT00270296|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|2017-03-14|2010-03-26|2017-04-27|2005-12-22|2005-12-26|Estimate|2017-04-27|2017-06-05|Actual|2010-03-26|2010-03-30|Estimate|2017-04-27|2017-06-05|Actual|June 2006||2006-06-30|April 2017|2017-04-30|September 2010|Actual|2010-09-30|March 2009|Actual|2009-03-31||Interventional|||Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV|Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana|Completed||Phase 2|730|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|||||||||2018-06-01 04:15:26.852549|2018-06-01 04:15:26.852549
NCT00270283|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|July 1988||1988-07-31|July 2009|2009-07-31|April 1990|Actual|1990-04-30|||||Interventional|||A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||Phase 2|102|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:27.206952|2018-06-01 04:15:27.206952
NCT00270270|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|July 1989|Actual|1989-07-31|||||Interventional|||A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||Phase 2|63|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:27.259501|2018-06-01 04:15:27.259501
NCT00270257|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|2015-11-05||2016-12-08|2005-12-22|2005-12-26|Estimate|2016-10-14|2016-12-08|Estimate||||2016-12-08|2017-02-02|Estimate|May 2008||2008-05-31|December 2016|2016-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users|A Phase III Randomized Controlled Trial to Evaluate the Efficacy of Drug Treatment in Prevention of HIV Infection and Death Among Opiate Dependent Injectors|Terminated||Phase 3|1251|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||DSMB halted the study due to futility as a result of lower than anticipated HIV incidence rates|f||||t||||||||No||2018-06-01 04:15:27.343709|2018-06-01 04:15:27.343709
NCT00270244|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2011-12-27|2005-12-21|2005-12-26|Estimate|||||||2011-12-27|2011-12-30|Estimate|December 2005||2005-12-31|December 2011|2011-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Group Interpersonal Psychotherapy for Depressed Adolescents in School-based Clinics|Group Interpersonal Psychotherapy for Depressed Adolescents (IPT-AG) in School-based Clinics|Completed||Phase 2|16|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 04:15:27.858157|2018-06-01 04:15:27.858157
NCT00270231|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|2009-02-18||2013-11-12|2005-12-23|2005-12-26|Estimate|2013-11-12|2013-12-10|Estimate||||2013-11-12|2013-12-10|Estimate|March 2004||2004-03-31|November 2013|2013-11-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effects of Naltrexone on Nicotine Reinforcement|Pharmacogenetic Investigation of Naltrexone|Completed||Phase 2|64|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 04:15:27.953336|2018-06-01 04:15:27.953336
NCT00270218|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2015-03-03|2005-12-21|2005-12-26|Estimate|||||||2015-03-03|2015-03-04|Estimate|February 2006||2006-02-28|March 2015|2015-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate Immune Response Kinetics and Safety of Two Different Primes, Adenoviral Vector Vaccine (VRC-HIVADV014-00-VP) and DNA Vaccine (VRC-HIVDNA009-00-VP), Each Followed by Adenoviral Vector Boost in Healthy, HIV-1 Uninfected Adults|Completed||Phase 1|66|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:15:28.149814|2018-06-01 04:15:28.149814
NCT00270205|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|2011-09-07|2010-01-30|2017-12-12|2005-12-21|2005-12-26|Estimate|2011-09-07|2011-10-13|Estimate|2010-01-30|2010-02-02|Estimate|2017-12-12|2018-01-10|Actual|January 2006||2006-01-31|December 2017|2017-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART|A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, in HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 1/Phase 2|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|This is a Phase I/II small sample study that was not powered for the secondary efficacy endpoints.|6|||f||||t||||||||||2018-06-01 04:15:28.318598|2018-06-01 04:15:28.318598
NCT00270192|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2006-10-23|2005-12-23|2005-12-26|Estimate|||||||2006-10-23|2006-10-24|Estimate|May 2002||2002-05-31|December 2005|2005-12-31|December 2004||2004-12-31|||||Interventional|||Antenatal Educational Intervention for Improvement of Breastfeeding|The Effects Of Antenatal Breast Preparation On The Successful Initiation And Continuation Of Breastfeeding In Singaporean Mothers|Completed||Phase 3|450||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:15:29.549246|2018-06-01 04:15:29.549246
NCT00270179|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|May 1988|Actual|1988-05-31|||||Interventional|||A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.|A Double-Blind, Placebo-Controlled Study to Determine Whether R-huEPO Can Facilitate Presurgical Autologous Blood Donation and to Determine Its Safety for This Purpose|Completed||Phase 3|17|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:29.608979|2018-06-01 04:15:29.608979
NCT00270166|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 1995||1995-02-28|February 2011|2011-02-28|May 1998|Actual|1998-05-31|||||Interventional|||The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy|A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy|Completed||Phase 3|201|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:15:29.680835|2018-06-01 04:15:29.680835
NCT00270153|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-23|||2011-09-15|2005-12-23|2005-12-26|Estimate|||||||2011-09-15|2011-09-19|Estimate|September 2004||2004-09-30|November 2009|2009-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Use of ACE Inhibitors in the Early Renal Post-transplant Period|The Use of ACE Inhibitors in the Early Renal Post-transplant Period|Completed||N/A|110|Anticipated|Montefiore Medical Center||1|||f||||f||||||||||2018-06-01 04:15:29.779554|2018-06-01 04:15:29.779554
NCT00270140|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|September 1989||1989-09-30|February 2011|2011-02-28|August 1991|Actual|1991-08-31|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.|A Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Multiple Doses of R-HuEPO in Facilitating Presurgical Autologous Blood Donation|Completed||Phase 3|17|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:29.842957|2018-06-01 04:15:29.842957
NCT00270127|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|August 1996||1996-08-31|January 2011|2011-01-31|September 1998|Actual|1998-09-30|||||Interventional|||Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy|Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving Non-Platinum-Containing Chemotherapy|Completed||Phase 3|375|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:15:29.969494|2018-06-01 04:15:29.969494
NCT00270114|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|March 1991|Actual|1991-03-31|||||Interventional|||A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)|Recombinant Human Erythropoietin (r-HuEPO) in Patients With Low Hematocrit Levels to Facilitate Presurgical Autologous Blood Donation in Patients Undergoing Orthopedic Surgery (An Open-label Dose Finding Study)|Completed||Phase 2/Phase 3|55|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:15:30.039139|2018-06-01 04:15:30.039139
NCT00270101|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 1995||1995-01-31|January 2011|2011-01-31|September 1996|Actual|1996-09-30|||||Interventional|||The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma|A Placebo-Controlled Study on the Effect of r-huEPO in Patients With Multiple Myeloma Followed by an Open-Label Extension|Completed||Phase 3|156|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:15:30.088038|2018-06-01 04:15:30.088038
NCT00270088|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|April 1993||1993-04-30|February 2011|2011-02-28|August 1994|Actual|1994-08-31|||||Interventional|||A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.|A Double-Blind, Placebo-Controlled Study to Determine Whether Procrit� (Epoetin Alfa) Can Reduce Peri-Operative Transfusion Requirements in Subjects Undergoing Major Orthopedic Surgery|Completed||Phase 3|316|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.14377|2018-06-01 04:15:30.14377
NCT00270075|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 1990||1990-01-31|February 2011|2011-02-28|May 1992|Actual|1992-05-31|||||Interventional|||A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery|Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Orthopedic or Cardiovascular Surgery, to Facilitate Presurgical Autologous Blood Donation (A Double-blind, Randomized, Dose Finding Study)|Completed||Phase 2/Phase 3|80|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:15:30.20682|2018-06-01 04:15:30.20682
NCT00270062|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|May 1989||1989-05-31|February 2011|2011-02-28|July 1991|Actual|1991-07-31|||||Interventional|||A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.|A Double-Blind, Placebo-Controlled Study to Determine Whether R-HuEPO Can Facilitate Presurgical Autologous Blood Donation in Patients With Low Hematocrit Levels|Completed||Phase 3|77|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.267427|2018-06-01 04:15:30.267427
NCT00270049|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|November 1990||1990-11-30|January 2011|2011-01-31|January 1994|Actual|1994-01-31|||||Interventional|||Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia|The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia|Completed||Phase 2|195|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.33596|2018-06-01 04:15:30.33596
NCT00270036|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate|April 1991||1991-04-30|November 2010|2010-11-30|October 1991|Actual|1991-10-31|||||Interventional|||A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.|A Double-Blind, Placebo-Controlled Study to Determine the Safety of r-HuEPO and Whether r-HuEPO Can Reduce Post-Operative Transfusion Requirements in Subjects Undergoing Major Orthopedic Surgery|Completed||Phase 2|1|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.415277|2018-06-01 04:15:30.415277
NCT00270023|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|November 1991|Actual|1991-11-30|||||Interventional|||A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.|Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Selective Orthopedic and Vascular Surgery or Reductive Mammoplasty to Facilitate Presurgical Autologous Blood Donation Combined With Normo-Volemic Hemodilution (NVHD)|Completed||Phase 2/Phase 3|112|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:15:30.486278|2018-06-01 04:15:30.486278
NCT00270010|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|August 1989|Actual|1989-08-31|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||Phase 2|72|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.560585|2018-06-01 04:15:30.560585
NCT00269997|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|July 1990|Actual|1990-07-31|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug|The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Cisplatin Chemotherapy|Completed||Phase 2|72|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.648065|2018-06-01 04:15:30.648065
NCT00269984|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-06|2005-12-22|2005-12-26|Estimate|||||||2011-06-06|2011-06-08|Estimate||||April 2010|2010-04-30|June 1990|Actual|1990-06-30|||||Interventional|||A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Efficacy of r-HuEPO, Administered Subcutaneously, in Chronic Anemia Induced by Advanced Cancer|Completed||Phase 2|56|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.736603|2018-06-01 04:15:30.736603
NCT00269971|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2016-09-19|2005-12-22|2005-12-26|Estimate|||||||2016-09-19|2016-09-20|Estimate|May 1996||1996-05-31|September 2011|2011-09-30|April 1999|Actual|1999-04-30|||||Interventional|||A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.|A Parallel Group Placebo-Controlled Study to Determine an Effective Dose Regimen for EPREX� (Epoetin Alfa) Sterile Solution to Reduce Transfusion Requirements in Patients Undergoing Major Elective Orthopedic Surgery|Withdrawn||Phase 3|0|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:15:30.833754|2018-06-01 04:15:30.833754
NCT00269958|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-16|2005-12-22|2005-12-26|Estimate|||||||2011-05-16|2011-05-17|Estimate||||April 2010|2010-04-30|December 1991|Actual|1991-12-31|||||Interventional|||A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery|A Double-Blind, Phase II, Placebo-Controlled Study to Determine the Safety and Efficacy of r-HuEPO in Reducing Transfusion Requirements in Patients Undergoing Total Hip Joint Replacement Surgery|Completed||Phase 2|208|Actual|Janssen-Ortho Inc., Canada|||||||||||||||||||2018-06-01 04:15:30.907145|2018-06-01 04:15:30.907145
NCT00269945|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-17|2005-12-22|2005-12-26|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|January 1989|Actual|1989-01-31|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||Phase 2|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:30.964006|2018-06-01 04:15:30.964006
NCT00269932|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-08|2005-12-22|2005-12-26|Estimate|||||||2011-06-08|2011-06-10|Estimate|August 1993||1993-08-31|February 2011|2011-02-28|May 1994|Actual|1994-05-31|||||Interventional|||A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Cefuroxime Axetil in the Treatment of Adults With Persistent Bronchitis Experiencing Rapid Onset of Severe Worsening of Symptoms Caused by Bacteria|A Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With That of Cefuroxime Axetil in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis in Adults|Completed||Phase 3|485|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:15:31.023909|2018-06-01 04:15:31.023909
NCT00269919|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|2013-03-29||2014-03-25|2005-12-22|2005-12-26|Estimate|2013-07-10|2013-08-09|Estimate||||2014-03-25|2014-04-16|Estimate|August 2005||2005-08-31|March 2014|2014-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia|Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia|Completed||Phase 4|40|Actual|Janssen Korea, Ltd., Korea|There is limitation in the study that selection or observer bias may occur because this clinical trial was an open, non-comparative, single-arm study and precaution would be necessary for interpreting change in various scales observed in this study.|1|||f||||f||||||||||2018-06-01 04:15:31.112195|2018-06-01 04:15:31.112195
NCT00269906|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2015-05-22|2005-12-22|2005-12-26|Estimate|||||||2015-05-22|2015-05-25|Estimate|May 1993||1993-05-31|May 2015|2015-05-31|December 1995|Actual|1995-12-31|December 1995|Actual|1995-12-31||Interventional|||A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty|Chimeric Anti-Platelet Therapy (Abciximab) in Unstable Angina Refractory to Standard Medical Therapy Trial (CAPTURE)|Completed||Phase 3|1265|Actual|Centocor, Inc.||2|||f||||||||||||||2018-06-01 04:15:31.479372|2018-06-01 04:15:31.479372
NCT00269893|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2015-06-01|2005-12-22|2005-12-26|Estimate|||||||2015-06-01|2015-06-02|Estimate|November 1991||1991-11-30|June 2015|2015-06-30|November 1992|Actual|1992-11-30|November 1992|Actual|1992-11-30||Interventional|||A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty|A Phase III Double-Blind, Placebo-Controlled Multicenter Study of Abciximab In Patients Undergoing High Risk Coronary Angioplasty (EPIC)|Completed||Phase 3|2038|Actual|Centocor, Inc.||3|||f||||t||||||||||2018-06-01 04:15:31.566635|2018-06-01 04:15:31.566635
NCT00269880|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2015-05-22|2005-12-22|2005-12-26|Estimate|||||||2015-05-22|2015-05-25|Estimate|February 1995||1995-02-28|May 2015|2015-05-31|December 1995|Actual|1995-12-31|December 1995|Actual|1995-12-31||Interventional|||A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Clinical Outcomes Following Percutaneous Coronary Intervention in Patients Treated With an Abciximab Bolus Plus 12-Hour Infusion Given With Either Standard-Dose Weight-Adjusted Heparin or Low-Dose Weight-Adjusted Heparin|Completed||Phase 3|2792|Actual|Centocor, Inc.||3|||f||||||||||||||2018-06-01 04:15:31.661738|2018-06-01 04:15:31.661738
NCT00269867|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2014-11-03|2005-12-22|2005-12-26|Estimate|||||||2014-11-03|2014-11-04|Estimate|March 1997||1997-03-31|November 2014|2014-11-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis|A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment|Completed||Phase 3|428|Actual|Centocor, Inc.||5|||f||||f||||||||||2018-06-01 04:15:31.744362|2018-06-01 04:15:31.744362
NCT00265213|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2008-02-26|2005-12-12|2005-12-14|Estimate|||||||2008-02-26|2008-02-27|Estimate|May 2005||2005-05-31|December 2005|2005-12-31|February 2006|Anticipated|2006-02-28|||||Observational|||How Breast Conservative Surgery (BCS) Affects Women's Daily Activities On Post-Operation 2 Days?||Unknown status|Recruiting||30|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-06-01 04:16:56.927697|2018-06-01 04:16:56.927697
NCT00269854|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2014-11-03|2005-12-22|2005-12-26|Estimate|||||||2014-11-03|2014-11-04|Estimate|June 1995||1995-06-30|November 2014|2014-11-30|October 1996|Actual|1996-10-31|October 1996|Actual|1996-10-31||Interventional|||An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease|A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease|Completed||Phase 2/Phase 3|108|Actual|Centocor, Inc.||4|||f||||f||||||||||2018-06-01 04:15:31.819075|2018-06-01 04:15:31.819075
NCT00269841|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2014-11-03|2005-12-22|2005-12-26|Estimate|||||||2014-11-03|2014-11-04|Estimate|May 1996||1996-05-31|November 2014|2014-11-30|February 1998|Actual|1998-02-28|February 1998|Actual|1998-02-28||Interventional|||An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease|A Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease|Completed||Phase 3|94|Actual|Centocor, Inc.||3|||f||||f||||||||||2018-06-01 04:15:31.89872|2018-06-01 04:15:31.89872
NCT00269828|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2007-02-13|2005-12-22|2005-12-26|Estimate|||||||2007-02-13|2007-02-14|Estimate|December 2005||2005-12-31|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.|Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.|Terminated||Phase 3|600||CTI BioPharma|||||f||||||||||||||2018-06-01 04:15:32.026065|2018-06-01 04:15:32.026065
NCT00269815|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-13|2005-12-22|2005-12-26|Estimate|||||||2011-06-13|2011-06-14|Estimate||||June 2011|2011-06-30|December 1999|Actual|1999-12-31|||||Interventional|||Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder|Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD|Completed||Phase 3|||Alza Corporation, DE, USA||1|||f||||||||||||||2018-06-01 04:15:32.271148|2018-06-01 04:15:32.271148
NCT00269802|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-09|2005-12-22|2005-12-26|Estimate|||||||2011-06-09|2011-06-10|Estimate||||June 2011|2011-06-30|February 1999|Actual|1999-02-28|||||Interventional|||A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder|Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD|Completed||Phase 3|||Alza Corporation, DE, USA||3|||f||||||||||||||2018-06-01 04:15:32.342479|2018-06-01 04:15:32.342479
NCT00269789|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-09|2005-12-22|2005-12-26|Estimate|||||||2011-06-09|2011-06-10|Estimate|March 1998||1998-03-31|June 2011|2011-06-30|May 1998|Actual|1998-05-31|||||Interventional|||A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children|Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD|Completed||Phase 3|||Alza Corporation, DE, USA||3|||f||||||||||||||2018-06-01 04:15:32.407162|2018-06-01 04:15:32.407162
NCT00269776|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-07-08|2005-12-22|2005-12-26|Estimate|||||||2011-07-08|2011-07-11|Estimate|November 1998||1998-11-30|July 2011|2011-07-31|January 1999|Actual|1999-01-31|||||Interventional|||An Effectiveness and Safety Study Evaluating OROS Methylphenidate Hydrochloride (HCl), Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder|Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD|Completed||Phase 3|||Alza Corporation, DE, USA||3|||f||||||||||||||2018-06-01 04:15:32.473847|2018-06-01 04:15:32.473847
NCT00269763|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-18|2005-12-22|2005-12-26|Estimate|||||||2011-05-18|2011-05-19|Estimate|October 1987||1987-10-31|April 2010|2010-04-30|April 1988||1988-04-30|||||Interventional|||Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer|The Clinical Use and Safety of TTS (Fentanyl) in the Management of Pain in Patients With Cancer|Completed||Phase 3|32||Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 04:15:32.547341|2018-06-01 04:15:32.547341
NCT00269750|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-18|2005-12-22|2005-12-26|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 1996||1996-07-31|April 2010|2010-04-30|February 1997||1997-02-28|||||Interventional|||A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.|The Maximum Tolerated Dose and Minimum Effective Dose of OROS® Oxybutynin Compared to Ditropan® (Immediate-release Oxybutynin) in the Treatment of Patients With Urge or Mixed Urinary Incontinence|Completed||Phase 3|100||Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:15:32.607477|2018-06-01 04:15:32.607477
NCT00269737|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-18|2005-12-22|2005-12-26|Estimate|||||||2011-05-18|2011-05-19|Estimate|May 1986||1986-05-31|April 2010|2010-04-30|February 1988||1988-02-29|||||Interventional|||Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer|Efficacy of TTS Fentanyl in the Management of Pain in Patients With Malignancy - Study III|Completed||Phase 3|7||Alza Corporation, DE, USA|||||f||||||||||||||2018-06-01 04:15:32.687782|2018-06-01 04:15:32.687782
NCT00269724|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-05-18|2005-12-22|2005-12-26|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 1997||1997-03-31|April 2010|2010-04-30|September 1997||1997-09-30|||||Interventional|||A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence|Open-Label Safety And Dose Conversion/Determination Study of OROS® Oxybutynin Chloride for Urge Urinary Incontinence|Completed||Phase 3|250||Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:15:32.751775|2018-06-01 04:15:32.751775
NCT00269685|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2006-05-26|2005-12-22|2005-12-23|Estimate|||||||2006-05-26|2006-05-29|Estimate|July 2000||2000-07-31|August 2005|2005-08-31||||||||Interventional|||Comparison of Vasopressin and Other Pressors in Septic Shock|Comparative Prospective Study of Vasopressin and Catecholamine in Septic Shock|Completed||Phase 2/Phase 3|20||Université de Sherbrooke|||||f||||||||||||||2018-06-01 04:15:33.808341|2018-06-01 04:15:33.808341
NCT00269672|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2010-08-04|2005-12-21|2005-12-23|Estimate|||||||2010-08-04|2010-08-05|Estimate|September 2005||2005-09-30|August 2010|2010-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects|A Randomized, Open Label, Controlled Phase II Study to Evaluate Safety, Tolerability and Immunogenicity After Two Different 13-Valent Pneumococcal Conjugate Vaccine Formulations in Elderly Subjects Aged 65 Years and Older Who Are Naive to Previous 23vPS Immunization|Completed||Phase 2|915|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:15:33.871271|2018-06-01 04:15:33.871271
NCT00269659|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2009-02-23|2005-12-22|2005-12-23|Estimate|||||||2009-02-23|2009-02-24|Estimate|January 2004||2004-01-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Evaluating Effects of a Left Bundle Branch Block|Serial Evaluation of Left Bundle Branch Block; Role of New Imaging Techniques. Three-Dimensional Echocardiography, Tissue Doppler Imaging, and Magnetic Resonance Imaging|Completed|||100|Anticipated|VU University Medical Center|||||f||||f||||||||||2018-06-01 04:15:33.953806|2018-06-01 04:15:33.953806
NCT00269646|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2009-02-16|2005-12-21|2005-12-23|Estimate|||||||2009-02-16|2009-02-18|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|August 2009|Anticipated|2009-08-31|February 2008|Actual|2008-02-29||Interventional|||Comparison of Two Different Diets on Health Outcomes|Effect of a Low-Carbohydrate and High-Carbohydrate, High-Fiber Diet on Insulin Sensitivity and Risk Markers for Cardiovascular Disease in Men and Women With the Metabolic Syndrome|Unknown status|Active, not recruiting|N/A|24|Anticipated|University of Virginia|||||f||||f||||||||||2018-06-01 04:15:34.014588|2018-06-01 04:15:34.014588
NCT00269633|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|2015-05-18||2016-03-02|2005-12-22|2005-12-23|Estimate|2016-03-02|2016-03-28|Estimate||||2016-03-02|2016-03-28|Estimate|November 2006||2006-11-30|March 2016|2016-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Research Study of Treatment for Winter Depression With Different Colors of Light|Optimizing Light Wavelength for Treatment of Seasonal Affective Disorder|Completed||Phase 2|9|Actual|Thomas Jefferson University||2|||f||||t||||||||No||2018-06-01 04:15:34.099988|2018-06-01 04:15:34.099988
NCT00269620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-20|2005-12-21|2005-12-23|Estimate|||||||2008-10-20|2008-10-21|Estimate|June 2005||2005-06-30|October 2008|2008-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|PARIS||PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra|An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra|Completed||Phase 4|500|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:15:34.42477|2018-06-01 04:15:34.42477
NCT00269607|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2013-12-10|2005-12-22|2005-12-23|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2005||2005-05-31|December 2005|2005-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Naltrexone Implants as Relapse Prevention|Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction.|Terminated||Phase 2/Phase 3|12|Actual|University of Oslo||||Recruitment difficulties. Reframed as pilot study|f||||||||||||||2018-06-01 04:15:34.592826|2018-06-01 04:15:34.592826
NCT00269594|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2007-04-27|2005-12-22|2005-12-23|Estimate|||||||2007-04-27|2007-04-30|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|||An Open-Label Study Of Lamictal In Neurotic Excoriation|An Open-Label Study of Lamictal In Neurotic Excoriation|Completed||Phase 2|25|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:15:35.555468|2018-06-01 04:15:35.555468
NCT00269581|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2012-09-24|2005-12-22|2005-12-23|Estimate|||||||2012-09-24|2012-09-25|Estimate|August 2004||2004-08-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Headstrong Intervention for Pediatric Headache|Headstrong Intervention for Recurrent Pediatric Headache|Completed||Phase 3|35|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 04:15:35.668932|2018-06-01 04:15:35.668932
NCT00269568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-28|2005-12-21|2005-12-23|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|MAST||Mifepristone at Same Time Multicenter Study|A Multicenter, Randomized Comparison of Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion Through 63 Days|Completed||Phase 4|1128|Actual|University of Pittsburgh|||||f||||f||||||||No||2018-06-01 04:15:35.911243|2018-06-01 04:15:35.911243
NCT00269555|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2010-06-25|2005-12-22|2005-12-23|Estimate|||||||2010-06-25|2010-06-29|Estimate|May 2004||2004-05-31|June 2010|2010-06-30|September 2006|Actual|2006-09-30|January 2006|Actual|2006-01-31||Interventional|||Effects of GCP on Prostate Cancer.|Effects of a Genistein Combined Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.|Completed||N/A|62||University of California, Davis|||||f||||||||||||||2018-06-01 04:15:36.01597|2018-06-01 04:15:36.01597
NCT00269542|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2008-06-30|2005-12-22|2005-12-23|Estimate|||||||2008-06-30|2008-07-01|Estimate|February 2002||2002-02-28|June 2008|2008-06-30|August 2003|Actual|2003-08-31|March 2003|Actual|2003-03-31||Interventional|||Impact of Zinc Supplementation on Mortality and Hospitalizations in Children Aged 1 Months to 23 Months|Impact of Zinc Supplementation on Mortality and Hospitalizations in Children Aged 1 Months to 23 Months|Completed||N/A|94359|Actual|Society for Applied Studies||2|||f||||t||||||||||2018-06-01 04:15:36.102811|2018-06-01 04:15:36.102811
NCT00269529|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2006-10-12|2005-12-22|2005-12-23|Estimate|||||||2006-10-12|2006-10-13|Estimate|February 2005||2005-02-28|October 2006|2006-10-31|March 2006||2006-03-31|||||Interventional|||Intraarticular Analgesia After Total Knee Arthroplasty, a Randomised Study|Postoperative Analgesia After Total Knee Arthroplasty. A Comparison of Continuous Femoral Block and Extensive Intraoperative Infiltration With Local Anesthetic Supplemented With Intraarticular Bolus the Following Day.|Completed||N/A|80||University of Aarhus|||||f||||||||||||||2018-06-01 04:15:36.235471|2018-06-01 04:15:36.235471
NCT00269516|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2008-08-28|2005-12-22|2005-12-23|Estimate|||||||2008-08-28|2008-08-29|Estimate|June 2006||2006-06-30|August 2008|2008-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||SLV308 for Treatment of Patients With Early Parkinson's Disease|A Randomized, Double Blind, Placebo Controlled Parallel-Group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease|Completed||Phase 3|468|Actual|Solvay Pharmaceuticals||4|||f||||t||||||||||2018-06-01 04:15:36.344881|2018-06-01 04:15:36.344881
NCT00269503|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-05-07|2005-12-21|2005-12-23|Estimate|||||||2008-05-07|2008-05-08|Estimate|March 2006||2006-03-31|May 2008|2008-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Chiropractic Prone Distraction for Lower Back Pain|A Pilot Study of Chiropractic Prone Distraction for Subacute Back Pain With Sciatica|Terminated||N/A|60|Anticipated|Samueli Institute for Information Biology|||||f||||||||||||||2018-06-01 04:15:36.755608|2018-06-01 04:15:36.755608
NCT00269490|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-01-24|2005-12-21|2005-12-23|Estimate|||||||2008-01-24|2008-01-28|Estimate|December 2005||2005-12-31|January 2008|2008-01-31|August 2007|Actual|2007-08-31|October 2006|Actual|2006-10-31||Observational|||Yoga as a Therapy for Traumatic Experiences|Yoga as an Adjunctive Therapy for Post-Traumatic Stress Disorder: A Feasibility Study|Completed|||7|Actual|Samueli Institute for Information Biology|||||f||||||||||||||2018-06-01 04:15:36.85872|2018-06-01 04:15:36.85872
NCT00269477|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|2009-11-10||2016-04-12|2005-12-22|2005-12-23|Estimate|2009-11-10|2009-12-14|Estimate||||2016-04-12|2016-04-14|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|December 2007|Actual|2007-12-31|February 2007|Actual|2007-02-28||Interventional|||Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®|Persistence of Bactericidal Antibodies in Adolescents and Adults Aged 15 to 23 Years Who Received a Single Dose of Menactra® or Menomune®-A/C/Y/W-135 Five Years Earlier|Completed||Phase 2|145|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 04:15:36.954249|2018-06-01 04:15:36.954249
NCT00269464|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2007-12-18|2005-12-22|2005-12-23|Estimate|||||||2007-12-18|2007-12-27|Estimate||||December 2007|2007-12-31|March 2007||2007-03-31|||||Observational|||Chronic Schizophrenia With Obsessive-Compulsive Symptoms: Comorbidity or a Subtype?||Completed|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:15:37.522052|2018-06-01 04:15:37.522052
NCT00269451|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2005-12-22|2005-12-22|2005-12-23|Estimate|||||||2005-12-22|2005-12-23|Estimate||||December 2005|2005-12-31||||||||Observational|||Assessing PTSD After Earthquake in Turkey||Unknown status|Active, not recruiting||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:15:37.57599|2018-06-01 04:15:37.57599
NCT00269438|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2009-12-21|2005-12-22|2005-12-23|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis|Phase 3 Study to Establish the Efficacy and Safety of a New Tablet Formulation and Dosing Regimen of Balsalazide Disodium Dosed Twice Daily in Achieving Clinical Improvement in Subjects With Mildly to Moderately Active Ulcerative Colitis After 8 Weeks of Therapy|Completed||Phase 3|225||Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 04:15:37.632593|2018-06-01 04:15:37.632593
NCT00269425|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2010-08-23|2005-12-22|2005-12-23|Estimate|||||||2010-08-23|2010-08-24|Estimate|October 2000||2000-10-31|December 2005|2005-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||The Heart Institute of Spokane Diet Study|The Heart Institute of Spokane Diet Intervention and Evaluation Trial (THIS DIET)|Completed||Phase 3|202|Actual|Providence Health & Services||3|||f||||f||||||||||2018-06-01 04:15:37.89358|2018-06-01 04:15:37.89358
NCT00269412|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2009-12-21|2005-12-22|2005-12-23|Estimate|||||||2009-12-21|2009-12-23|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|September 2008|Actual|2008-09-30|August 2007|Actual|2007-08-31||Interventional|||Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome|Completed||Phase 2|525|Anticipated|Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 04:15:38.007202|2018-06-01 04:15:38.007202
NCT00269399|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-07-17|2005-12-22|2005-12-23|Estimate|||||||2011-07-17|2011-07-19|Estimate|December 2005||2005-12-31|July 2011|2011-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)|A Double-Blind, Randomized, Controlled Trial of Rifaximin Compared to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)|Completed||Phase 3|300|Anticipated|Valeant Pharmaceuticals International, Inc.|||||f||||||||||||||2018-06-01 04:15:38.204811|2018-06-01 04:15:38.204811
NCT00269386|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2009-01-06|2005-12-22|2005-12-23|Estimate|||||||2009-01-06|2009-01-07|Estimate|April 2000||2000-04-30|January 2009|2009-01-31|May 2007|Actual|2007-05-31|December 2006|Actual|2006-12-31||Interventional|||Clarithromycin in Active Crohn's Disease|Randomised Controlled Trial of Clarithromycin in Active Crohn's Disease|Completed||Phase 3|44|Actual|Royal Liverpool University Hospital||2|||f||||t||||||||||2018-06-01 04:15:38.343379|2018-06-01 04:15:38.343379
NCT00269373|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2012-02-20|2005-12-22|2005-12-23|Estimate|||||||2012-02-20|2012-02-22|Estimate|December 2005||2005-12-31|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors|PET-CT Scan as a Diagnostic Method in Unknown Primary Tumors|Completed|||136|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-06-01 04:15:38.444435|2018-06-01 04:15:38.444435
NCT00269360|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2007-11-19|2005-12-22|2005-12-23|Estimate|||||||2007-11-19|2007-11-20|Estimate|March 2001||2001-03-31|November 2007|2007-11-30|February 2005|Actual|2005-02-28|||||Interventional|||Manipulation, Exercise, and Self-Care for Neck Pain|Manipulation, Exercise, and Self-Care for Neck Pain|Completed||Phase 2|270|Actual|Northwestern Health Sciences University||3|||f||||||||||||||2018-06-01 04:15:38.538215|2018-06-01 04:15:38.538215
NCT00269347|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2005-12-22|2005-12-22|2005-12-23|Estimate|||||||2005-12-22|2005-12-23|Estimate|January 2001||2001-01-31|December 2005|2005-12-31|April 2005||2005-04-30|||||Interventional|||Manipulation, Exercise, and Self-Care for Low Back Pain|Manipulation, Exercise, and Self-Care for Low Back Pain|Completed||Phase 2|300||Northwestern Health Sciences University|||||f||||||||||||||2018-06-01 04:15:38.614815|2018-06-01 04:15:38.614815
NCT00269334|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2005-12-22|2005-12-22|2005-12-23|Estimate|||||||2005-12-22|2005-12-23|Estimate|December 2005||2005-12-31|December 2005|2005-12-31|November 2007||2007-11-30|||||Interventional|||Clinical Pharmacogenomics of Antidepressant Response|Phase 4 Study of Clinical Pharmacogenomics of Antidepressant Response|Unknown status|Not yet recruiting|Phase 4|400||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:15:38.693624|2018-06-01 04:15:38.693624
NCT00269321|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2013-06-27|2005-12-22|2005-12-23|Estimate|||||||2013-06-27|2013-06-28|Estimate|October 2003||2003-10-31|June 2013|2013-06-30|March 2008|Actual|2008-03-31|||||Interventional|||Chiropractic and Exercise for Seniors With Low Back Pain|Randomized Clinical Trial of Chiropractic Manual Therapy Plus Home Exercise, Supervised Exercise Plus Home Exercise and Home Exercise Alone For Individuals 65 and Over With Chronic Mechanical Low Back Pain|Completed||Phase 2|240|Actual|Northwestern Health Sciences University||3|||f||||||||||||||2018-06-01 04:15:38.783999|2018-06-01 04:15:38.783999
NCT00269308|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2011-08-22|2005-12-22|2005-12-23|Estimate|||||||2011-08-22|2011-08-23|Estimate|October 2003||2003-10-31|August 2011|2011-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Chiropractic and Exercise for Seniors With Neck Pain|Randomized Clinical Trial of Chiropractic Manual Therapy Plus Home Exercise, Supervised Exercise Plus Home Exercise and Home Exercise Alone For Individual 65 and Over With Chronic Mechanical Neck Pain|Completed||Phase 2|241|Actual|Northwestern Health Sciences University||3|||f||||||||||||||2018-06-01 04:15:38.881766|2018-06-01 04:15:38.881766
NCT00269295|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-09|2005-12-22|2005-12-23|Estimate|||||||2011-06-09|2011-06-10|Estimate|February 2006||2006-02-28|February 2010|2010-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||TY800 Dose Escalation (Typhoid)|A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, In-Patient Phase I/II Study to Determine the Safety and Immunogenicity of Ty800 in Healthy Adult Subjects|Completed||Phase 1/Phase 2|47|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 04:15:39.036823|2018-06-01 04:15:39.036823
NCT00269282|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2013-01-11|2005-12-21|2005-12-23|Estimate|||||||2013-01-11|2013-01-14|Estimate|May 2006||2006-05-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Increasing Adherence to Asthma Medication in Urban Teens|Motivating Asthma Adherence in Urban Teens|Completed||N/A|207|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 04:15:39.156394|2018-06-01 04:15:39.156394
NCT00269269|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2016-02-17|2005-12-21|2005-12-23|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2002||2002-09-30|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Conditioned Placebo Effects and Treatment of Hypertension||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:15:39.232537|2018-06-01 04:15:39.232537
NCT00269256|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2016-02-02|2005-12-21|2005-12-23|Estimate|||||||2016-02-02|2016-02-03|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Stress, Environment, and Genetics in Urban Children With Asthma|Stress, Environment, and Genetics in Urban Asthma|Completed|||959|Actual|Brigham and Women's Hospital|||||f||||f||||||Samples With DNA|"~     Maternal DNA Child DNA~   "|Undecided||2018-06-01 04:15:39.292108|2018-06-01 04:15:39.292108
NCT00269217|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2017-04-05|2005-12-21|2005-12-23|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2006||2006-01-31|March 2017|2017-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Lipid Efficacy Study (0524B-022)(COMPLETED)|"A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia"|Completed||Phase 3|1400|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:15:39.545258|2018-06-01 04:15:39.545258
NCT00269204|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2015-07-24|2005-12-21|2005-12-23|Estimate|||||||2015-07-24|2015-07-27|Estimate|December 2005||2005-12-31|July 2015|2015-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Lipid Efficacy/Tolerability Study (0524A-020)|A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia|Completed||Phase 3|1620|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:15:39.630929|2018-06-01 04:15:39.630929
NCT00269191|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2017-04-06|2005-12-21|2005-12-23|Estimate|||||||2017-04-06|2017-04-10|Actual|February 5, 2003|Actual|2003-02-05|April 2017|2017-04-30|November 21, 2003|Actual|2003-11-21|November 7, 2003|Actual|2003-11-07||Interventional|||A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)|A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)|Completed||Phase 3|528|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:15:39.727379|2018-06-01 04:15:39.727379
NCT00269178|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2017-03-06|2005-12-22|2005-12-23|Estimate|||||||2017-03-06|2017-03-08|Actual|August 2003||2003-08-31|March 2003|2003-03-31|October 2004|Actual|2004-10-31|||||Interventional|||Cluster Randomized Trial of Peer Health Education in Malaria in The Gambia|Cluster Randomized Trial of the Impact of a Peer-health Education Programme on Malaria Knowledge Attitudes and Practice in Students and Their Families|Completed||Phase 3|960||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:15:39.804668|2018-06-01 04:15:39.804668
NCT00269165|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2010-05-28|2005-12-22|2005-12-23|Estimate|||||||2010-05-28|2010-05-31|Estimate|November 2005||2005-11-30|May 2010|2010-05-31||||||||Interventional|||Adjuvant Radiation in Aortic Valvuloplasty - ARAVA||Terminated||Phase 3|60||Medstar Health Research Institute|||||f||||||||||||||2018-06-01 04:15:39.873601|2018-06-01 04:15:39.873601
NCT00269152|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|2008-11-12||2015-07-28|2005-12-21|2005-12-23|Estimate|2009-04-22|2009-06-11|Estimate||||2015-07-28|2015-08-18|Estimate|December 2005||2005-12-31|July 2015|2015-07-31|July 2013|Actual|2013-07-31|November 2007|Actual|2007-11-30||Interventional|||Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer|A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients With Completely Resected Stage Ib or II Non-Small Cell Lung Cancer|Completed||Phase 2|122|Actual|Eli Lilly and Company|A protocol amendment was approved after the trial original completed to allow for collection of additional overall survival data due to number of participants surviving at 3 years.|2|||f||||f||||||||||2018-06-01 04:15:39.971559|2018-06-01 04:15:39.971559
NCT00269139|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2006-02-17|2005-12-22|2005-12-23|Estimate|||||||2006-02-17|2006-02-20|Estimate||||December 2005|2005-12-31||||||||Interventional|||Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder|Study of Outcome With an Intervention From the Cape Cod Model of Psychotherapy for Subjects in a Behavioral Crisis and With the Diagnosis of Borderline Personality Disorder (BPD) or Post-Traumatic Stress Disorder (PTSD)|Unknown status|Not yet recruiting|Phase 1|40||Laddis, Andreas, M.D.|||||f||||||||||||||2018-06-01 04:15:40.673972|2018-06-01 04:15:40.673972
NCT00269126|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2013-04-11|2005-12-21|2005-12-23|Estimate|||||||2013-04-11|2013-04-15|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)|See Detailed Description|Completed||Phase 3|150|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:15:40.738316|2018-06-01 04:15:40.738316
NCT00269113|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|2014-05-20||2015-07-21|2005-12-22|2005-12-23|Estimate|2015-07-21|2015-07-23|Estimate||||2015-07-21|2015-07-23|Estimate|September 1998||1998-09-30|July 2015|2015-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Intent to Treat (ITT) Population: all participants included in the study, who began a therapy and received at least 1 therapy cycle.|A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma|A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma|Completed||Phase 3|360|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:15:40.825898|2018-06-01 04:15:40.825898
NCT00269100|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2007-04-19|2005-12-22|2005-12-23|Estimate|||||||2007-04-19|2007-04-20|Estimate||||April 2007|2007-04-30||||||||Observational|||Prevention of Bacteremia Induced by Debridement of Pressure Ulcer||Terminated|||60||Herzog Hospital|||||f||||||||||||||2018-06-01 04:15:41.424254|2018-06-01 04:15:41.424254
NCT00269087|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2017-03-13|2005-12-21|2005-12-23|Estimate|||||||2017-03-13|2017-03-15|Actual|January 2005||2005-01-31|March 2017|2017-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)|"Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease -"|Completed||Phase 3|122|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:15:41.485438|2018-06-01 04:15:41.485438
NCT00269074|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2009-03-19|2005-12-22|2005-12-23|Estimate|||||||2009-03-19|2009-03-20|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|July 2006||2006-07-31|||||Interventional|||Effect of IDEA-070 on Pain and Inflammation Induced by PDT|Safety and Efficacy of IDEA-070 for the Treatment of Pain and Inflammation Induced by Photodynamic Therapy of Actinic Keratosis|Completed||Phase 2|24||IDEA AG|||||f||||||||||||||2018-06-01 04:15:41.588018|2018-06-01 04:15:41.588018
NCT00269061|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2008-10-15|2005-12-22|2005-12-23|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2006||2006-01-31|October 2008|2008-10-31||||||||Interventional|||Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin|An Exploratory MRI Study in Type 2 Diabetic Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Measurement of Fluid Volumes by MRI in the Lower Extremities of Subjects Receiving Pioglitazone|Completed||Phase 1|32||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:15:41.654672|2018-06-01 04:15:41.654672
NCT00268892|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|2010-11-17||2010-12-08|2005-12-21|2005-12-23|Estimate|2010-11-17|2010-12-06|Estimate||||2010-12-08|2010-12-24|Estimate|January 2006||2006-01-31|December 2010|2010-12-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer|An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens in Patients With Prostate Cancer|Completed||Phase 2/Phase 3|278|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:15:45.441236|2018-06-01 04:15:45.441236
NCT00269048|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2016-08-05|2005-12-22|2005-12-23|Estimate|||||||2016-08-05|2016-08-08|Estimate|November 2005||2005-11-30|August 2016|2016-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||SB-480848 In Subjects With Coronary Heart Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks|Completed||Phase 2|969|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:15:41.755837|2018-06-01 04:15:41.755837
NCT00269035|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2017-08-15|2005-12-22|2005-12-23|Estimate|||||||2017-08-15|2017-08-17|Actual|June 21, 2005|Actual|2005-06-21|August 2017|2017-08-31|May 26, 2007|Actual|2007-05-26|May 26, 2007|Actual|2007-05-26||Interventional|||SPECT Study With SB-773812 In Schizophrenic Patients|A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts.|Completed||Phase 1|95|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:15:42.036633|2018-06-01 04:15:42.036633
NCT00269022|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2009-05-15|2005-12-22|2005-12-23|Estimate|||||||2009-05-15|2009-05-18|Estimate|January 2006||2006-01-31|May 2009|2009-05-31||||||||Interventional|||Use Of SB-705498 In The Acute Treatment Of Migraine|A Single Blind, Placebo Controlled, Multi-Centre Study to Investigate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of the TRPV1 Antagonist SB-705498 Against the Pain of Acute Migraine.|Completed||Phase 2|70||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:15:42.110789|2018-06-01 04:15:42.110789
NCT00269009|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2007-01-10|2005-12-22|2005-12-23|Estimate|||||||2007-01-10|2007-01-11|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|February 2007||2007-02-28|||||Interventional|||CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change|CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change|Unknown status|Recruiting|Phase 1|||Great Lakes Research Into Practice Network|||||f||||||||||||||2018-06-01 04:15:42.171977|2018-06-01 04:15:42.171977
NCT00268996|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|2017-04-27||2018-02-20|2005-12-22|2005-12-23|Estimate|2017-08-14|2018-02-19|Actual||||2018-02-20|2018-03-20|Actual|November 10, 2005|Actual|2005-11-10|August 2017|2017-08-31|August 28, 2007|Actual|2007-08-28|August 28, 2007|Actual|2007-08-28||Interventional|||Integrated Biomarker And Imaging Study - 2|An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects With Angiographically Documented Coronary Heart Disease (CHD) to Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor SB-480848 on Intermediate Cardiovascular Endpoints, Patient Safety and Tolerability|Completed||Phase 2|336|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:15:42.289129|2018-06-01 04:15:42.289129
NCT00268983|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|2010-06-29||2016-11-18|2005-12-22|2005-12-23|Estimate|2010-06-29|2010-08-02|Estimate||||2016-11-18|2017-01-09|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|September 2009|Actual|2009-09-30||Interventional|||Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma|A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma|Completed||Phase 3|14|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:15:43.269068|2018-06-01 04:15:43.269068
NCT00268970|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2012-04-27|2005-12-22|2005-12-23|Estimate|||||||2012-04-27|2012-04-30|Estimate|December 2005||2005-12-31|April 2012|2012-04-30|September 2009|Actual|2009-09-30|April 2007|Actual|2007-04-30||Interventional|||Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer|Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|40|Actual|Agennix|||||f||||||||||||||2018-06-01 04:15:44.097539|2018-06-01 04:15:44.097539
NCT00268957|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2014-03-17|2005-12-22|2005-12-23|Estimate|||||||2014-03-17|2014-03-19|Estimate|January 2006||2006-01-31|March 2014|2014-03-31|May 2007|Actual|2007-05-31|March 2007|Actual|2007-03-31||Interventional|||Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis|A Randomized, Parallel, Open-Label Study to Compare Once Per Day Sevelamer Carbonate Powder Dosing With Three Times Per Day Sevelamer Hydrochloride Tablet Dosing in Chronic Kidney Disease Patients on Hemodialysis|Completed||Phase 3|217|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:15:44.172849|2018-06-01 04:15:44.172849
NCT00268944|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2014-02-04|2005-12-22|2005-12-23|Estimate|||||||2014-02-04|2014-02-05|Estimate|December 2005||2005-12-31|February 2014|2014-02-28|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support|Prospective, Open-label, Single-arm, Exploratory Study of the Effect and Safety of rhGAA in Patients With Advanced Late-onset Pompe Disease Who Are Receiving Respiratory Support|Completed||Phase 3|5|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:15:44.310465|2018-06-01 04:15:44.310465
NCT00268931|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2013-04-12|2005-12-21|2005-12-23|Estimate|||||||2013-04-12|2013-04-16|Estimate|August 2004||2004-08-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Development Training in Babies Born Preterm|Enhanced Developmental Training Experiences in Babies Born Preterm|Completed||N/A|32|Actual|Christiana Care Health Services||3|||f||||f||||||||||2018-06-01 04:15:44.377751|2018-06-01 04:15:44.377751
NCT00268918|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2017-05-04|2005-12-21|2005-12-23|Estimate|||||||2017-05-04|2017-05-05|Actual|September 2005||2005-09-30|May 2017|2017-05-31|January 2011|Actual|2011-01-31|January 2007|Actual|2007-01-31||Interventional|||Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients|A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients|Completed||Phase 1|24|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:15:44.47907|2018-06-01 04:15:44.47907
NCT00268905|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|2012-12-20||2013-02-06|2005-12-21|2005-12-23|Estimate|2012-12-20|2013-01-25|Estimate||||2013-02-06|2013-02-12|Estimate|October 2006||2006-10-31|February 2013|2013-02-28||||November 2011|Actual|2011-11-30||Interventional|||A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors|A Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors|Completed||Phase 1|64|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 04:15:44.602985|2018-06-01 04:15:44.602985
NCT00268281|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2006-10-11|2005-12-21|2005-12-22|Estimate|||||||2006-10-11|2006-10-13|Estimate|December 2004||2004-12-31|October 2006|2006-10-31|July 2005||2005-07-31|||||Interventional|||Left Ventricular Capture Management (LVCM) Software Download Clinical Trial|Left Ventricular Capture Management (LVCM) Software Download Clinical Trial|Completed||N/A|107||Medtronic Cardiac Rhythm and Heart Failure|||||||||||||||||||2018-06-01 04:15:56.120261|2018-06-01 04:15:56.120261
NCT00268879|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2008-02-13|2005-12-22|2005-12-23|Estimate|||||||2008-02-13|2008-02-15|Estimate|December 2005||2005-12-31|February 2008|2008-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)|A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (c-IBS)|Completed||Phase 3|1821|Actual|Alizyme||3|||f||||t||||||||||2018-06-01 04:15:46.593667|2018-06-01 04:15:46.593667
NCT00268866|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2008-04-15|2005-12-22|2005-12-23|Estimate|||||||2008-04-15|2008-04-16|Estimate||||April 2008|2008-04-30|January 2007||2007-01-31|||||Observational|||Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung Clinics|Danish Quality Assurance Project on Diagnosis and Treatment of COPD in Outpatient Lung Clinics|Completed|||1820||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:15:46.703173|2018-06-01 04:15:46.703173
NCT00268853|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2015-01-15|2005-12-21|2005-12-23|Estimate|||||||2015-01-15|2015-01-19|Estimate|November 2005||2005-11-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|RAPID||A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin|Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone Plus Rituximab (CPOP-R) in Patients With Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial|Completed||Phase 2|124|Actual|CTI BioPharma||2|||f||||t||||||||||2018-06-01 04:15:46.790155|2018-06-01 04:15:46.790155
NCT00268840|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2011-06-29|2005-12-22|2005-12-23|Estimate|||||||2011-06-29|2011-06-30|Estimate|August 2001||2001-08-31|June 2011|2011-06-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer|National Trial Phase II to Study the Combination of Gemcitabine and Docetaxel in Patients With Locally Advanced or Metastatic Pancreatic or Biliary Adenocarcinoma That Cannot be Removed by Surgery|Completed||Phase 2|45|Actual|ARCAGY/ GINECO GROUP||1|||f||||f||||||||||2018-06-01 04:15:47.073662|2018-06-01 04:15:47.073662
NCT00268827|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-22|||2007-04-04|2005-12-22|2005-12-23|Estimate|||||||2007-04-04|2007-04-05|Estimate|December 2005||2005-12-31|April 2007|2007-04-30|February 2006|Actual|2006-02-28|||||Interventional|||A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort|A Comparison of Adverse Events and Quality of Life Before and After Switching From Kaletra Soft-Gel Capsules (SGC) to Kaletra Tablets in an African American Cohort|Completed||Phase 4|120||AIDS Arms Inc.|||||f||||t||||||||||2018-06-01 04:15:47.17347|2018-06-01 04:15:47.17347
NCT00268814|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2015-09-07|2005-12-21|2005-12-22|Estimate|||||||2015-09-07|2015-09-09|Estimate|March 2002||2002-03-31|September 2015|2015-09-30|December 2007|Actual|2007-12-31|December 2003|Actual|2003-12-31||Interventional|||The German Project of Heroin Assisted Treatment of Opiate Dependent Patients|Phase III Study of Maintenance Treatment for Opiate Dependence With Heroin (Diamorphine) Compared to Methadone|Completed||Phase 3|1015|Actual|Universitätsklinikum Hamburg-Eppendorf||8|||f||||t||||||||||2018-06-01 04:15:47.268017|2018-06-01 04:15:47.268017
NCT00268788|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-02-19|2005-12-21|2005-12-22|Estimate|||||||2008-02-19|2008-02-21|Estimate|August 2005||2005-08-31|February 2008|2008-02-29|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy|A Controlled Cross-Over Trial of Subcutaneous Versus Intravenous Immunoglobulin for Multifocal Motor Neuropathy|Completed||Phase 2|10|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 04:15:47.388971|2018-06-01 04:15:47.388971
NCT00268775|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2009-08-17|2005-12-21|2005-12-22|Estimate|||||||2009-08-17|2009-08-18|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Implementation Strategies for a Simple Intervention to Reduce Longterm Benzodiazepine Use in Dutch Community Pharmacies|Implementation Strategies Aimed at a Simple Patient-directed Intervention to Reduce Long-term Use of Benzodiazepines in Dutch Community Pharmacies|Completed||N/A|20000||Radboud University|||||f||||||||||||||2018-06-01 04:15:47.487715|2018-06-01 04:15:47.487715
NCT00268762|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2012-08-20||2014-11-03|2005-12-20|2005-12-22|Estimate|2012-08-20|2012-09-19|Estimate||||2014-11-03|2014-11-10|Estimate|February 2003||2003-02-28|November 2014|2014-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Argatroban Stroke Treatment - A Pilot Safety Study|A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke|Completed||Phase 1/Phase 2|65|Actual|The University of Texas Health Science Center, Houston|Possible selection bias and investigators unblinded to treatment. In addition, although 60/65 patients had 24 hour recanalization data, only 47 were available at 2 hours.|1|||f||||t||||||||||2018-06-01 04:15:47.801299|2018-06-01 04:15:47.801299
NCT00268749|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-03-28|2005-12-20|2005-12-22|Estimate|||||||2012-03-28|2012-03-29|Estimate|July 2002||2002-07-31|March 2012|2012-03-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Glycine Treatment of Prodromal Symptoms|Glycine Treatment of Prodromal Symptoms|Completed||Phase 2|10|Actual|Yale University||1|||f||||||||||||||2018-06-01 04:15:48.203583|2018-06-01 04:15:48.203583
NCT00268723|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-02-21|2005-12-20|2005-12-22|Estimate|||||||2012-02-21|2012-02-22|Estimate|December 2005||2005-12-31|February 2012|2012-02-29|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB|An Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Versus Placebo in Prevention of EIB in Subjects 18 Years of Age and Older With EIB|Completed||Phase 3|15|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 04:15:48.275211|2018-06-01 04:15:48.275211
NCT00268710|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2009-12-04|2005-12-21|2005-12-22|Estimate|||||||2009-12-04|2009-12-07|Estimate|February 2004||2004-02-29|December 2009|2009-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]|Multicenter Phase II Study of Taxotere (Docetaxel) Administered Weekly or Every Three Weeks in Combination With Prednisone as Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer (HRPC)|Completed||Phase 2|||Sanofi|||||f||||||||||||||2018-06-01 04:15:48.391656|2018-06-01 04:15:48.391656
NCT00268697|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-05-23|2005-12-20|2005-12-22|Estimate|||||||2012-05-23|2012-05-24|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.|A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia|Completed||Phase 3|1267|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:15:48.444565|2018-06-01 04:15:48.444565
NCT00265031|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2012-06-22|2005-12-12|2005-12-13|Estimate|||||||2012-06-22|2012-06-25|Estimate|January 1999||1999-01-31|August 2007|2007-08-31||||||||Interventional|||HD12 for Advanced Stages||Completed||Phase 3|||University of Cologne|||||f||||||||||||||2018-06-01 04:17:01.487408|2018-06-01 04:17:01.487408
NCT00268684|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2006-02-27|2005-12-21|2005-12-22|Estimate|||||||2006-02-27|2006-02-28|Estimate|May 2005||2005-05-31|December 2005|2005-12-31||||||||Interventional|||Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC|A Phase III Trial Comparing Whole Brain Radiation (WBRT) and Stereotactic Radiosurgery (SRS) Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases|Unknown status|Recruiting|Phase 3|381||Tel-Aviv Sourasky Medical Center|||||||||||||||||||2018-06-01 04:15:48.58594|2018-06-01 04:15:48.58594
NCT00268671|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2009-12-04|2005-12-21|2005-12-22|Estimate|||||||2009-12-04|2009-12-07|Estimate|August 2003||2003-08-31|December 2009|2009-12-31|April 2006||2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)|Phase I/II Trial of Weekly Docetaxel and Cisplatin for Locoregional Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 1/Phase 2|45||Sanofi|||||f||||||||||||||2018-06-01 04:15:48.645213|2018-06-01 04:15:48.645213
NCT00268658|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2007-02-26|2005-12-21|2005-12-22|Estimate|||||||2007-02-26|2007-02-27|Estimate||||November 2005|2005-11-30||||||||Interventional|||Clinical Use of Andante SmartStep System in Gait Rehabilitation|Clinical Use of Andante SmartStep System in Gait Rehabilitation|Unknown status|Not yet recruiting|N/A|60||Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:15:48.712635|2018-06-01 04:15:48.712635
NCT00268645|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2011-01-10|2005-12-21|2005-12-22|Estimate|||||||2011-01-10|2011-01-11|Estimate|September 2004||2004-09-30|January 2011|2011-01-31||||||||Interventional|||Insulin Glargine in Type 2 Diabetes|Open Trial of the Safety and Efficacy of Lantus for Insulin Naive Type 2 Diabetes Mellitus Patients or Patients Who Use Insulin Combined With 1 or More Oral Antidiabetic Drugs and Don't Have Good Glycemic Control.|Completed||Phase 4|534||Sanofi|||||f||||||||||||||2018-06-01 04:15:48.814772|2018-06-01 04:15:48.814772
NCT00268632|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2011-01-10|2005-12-21|2005-12-22|Estimate|||||||2011-01-10|2011-01-11|Estimate|August 1999||1999-08-31|January 2011|2011-01-31||||February 2002|Actual|2002-02-28||Interventional|||"IMPACT Study (Improving Measurements of Persistence on ACtonel Treatment)"|A Multicenter Prospective Study to Assess the Impact of Physician's Reinforcement on the Subject's Compliance and Persistence on Treatment Using Feedback on Bone Markers in Previously Undiagnosed Postmenopausal Osteoporotic Women Treated With Risedronate.|Completed||Phase 3|||Sanofi|||||f||||||||||||||2018-06-01 04:15:48.97257|2018-06-01 04:15:48.97257
NCT00268619|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2011-01-10|2005-12-21|2005-12-22|Estimate|||||||2011-01-10|2011-01-11|Estimate|June 2004||2004-06-30|January 2011|2011-01-31||||July 2005|Actual|2005-07-31||Interventional|||FOCUS:Focus On Coronary Unstable Syndromes|A Placebo-controlled, Double-blind, Randomized, Multicenter Study of Ramipril 5 and 10 mg Capsules and Insulin Infusion in Subjects With Unstable Coronary Syndromes|Completed||Phase 3|||Sanofi|||||f||||||||||||||2018-06-01 04:15:49.046557|2018-06-01 04:15:49.046557
NCT00268606|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-05-20|2005-12-21|2005-12-22|Estimate|||||||2008-05-20|2008-05-21|Estimate|December 2003||2003-12-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Tailored Cognitive-Behavioral Therapy for Fibromyalgia Patients at Risk|Tailored Cognitive-Behavioral Therapy for Fibromyalgia Patients at Risk: A Randomized, Controlled Trial|Completed||N/A|400|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:15:49.12273|2018-06-01 04:15:49.12273
NCT00268593|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2011-06-13|2005-12-20|2005-12-22|Estimate|||||||2011-06-13|2011-06-15|Estimate|August 2005||2005-08-31|June 2011|2011-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer|A Randomised Phase II Study of Two Dose Schedules of PI-88 in Combination With Docetaxel in Patients With Androgen-independent Prostate Cancer|Completed||Phase 2|48|Actual|Progen Pharmaceuticals||2|||f||||||||||||||2018-06-01 04:15:49.210379|2018-06-01 04:15:49.210379
NCT00268580|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2016-03-28|2005-12-20|2005-12-22|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|June 2006|Actual|2006-06-30|January 2006|Actual|2006-01-31||Interventional|||Evaluation of the Emergency Department Asthma Care Project|Evaluation of the Emergency Department Asthma Care Project|Completed||N/A|300|Anticipated|Queen's University||2|||f||||f||||||||||2018-06-01 04:15:49.340388|2018-06-01 04:15:49.340388
NCT00268567|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2005-12-21|2005-12-21|2005-12-22|Estimate|||||||2005-12-21|2005-12-22|Estimate|October 2002||2002-10-31|October 2004|2004-10-31||||||||Interventional|||Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone|Phase 3 Study of Leflunomide Combined With Prednisone Treatment of Proliferative Lupus Nephritis as Induction Therapy|Completed||Phase 2/Phase 3|||Peking University|||||f||||||||||||||2018-06-01 04:15:49.46069|2018-06-01 04:15:49.46069
NCT00268554|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-03-27|2005-12-21|2005-12-22|Estimate|||||||2008-03-27|2008-03-28|Estimate|December 2005||2005-12-31|March 2008|2008-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole|Enhancement of Postocclusive Reactive Hyperaemia|Completed||N/A|12|Anticipated|Radboud University|||||f||||t||||||||||2018-06-01 04:15:49.565242|2018-06-01 04:15:49.565242
NCT00268541|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2007-04-19|2005-12-21|2005-12-22|Estimate|||||||2007-04-19|2007-04-20|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Physical Activity, Insulin Resistance and Function of Fat Tissue in the Offspring of Patients With Type 2 Diabetes|Physical Activity, Insulin Resistance and Adipose Tissue Gene Expression in the Offspring of Patients With Type 2 Diabetes|Completed||N/A|80||NHS Greater Glasgow and Clyde|||||f||||||||||||||2018-06-01 04:15:49.634199|2018-06-01 04:15:49.634199
NCT00268528|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2017-02-07|2005-12-21|2005-12-22|Estimate|||||||2017-02-07|2017-02-09|Estimate|May 2005||2005-05-31|February 2017|2017-02-28|March 5, 2012|Actual|2012-03-05|March 5, 2012|Actual|2012-03-05||Interventional|||Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission|Understanding the Ethnic and Racial Differences in Survival in Children With Acute Lymphoblastic Leukemia|Completed||N/A|755|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 04:15:49.74767|2018-06-01 04:15:49.74767
NCT00268515|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2016-05-12|2005-12-21|2005-12-22|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1998||1998-04-30|December 2005|2005-12-31|March 2003|Actual|2003-03-31|||||Interventional|||Aerosol Cyclosporine for Prevention of Lung Rejection||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:15:50.005434|2018-06-01 04:15:50.005434
NCT00268502|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2015-11-12|2005-12-20|2005-12-22|Estimate|||||||2015-11-12|2015-11-16|Estimate|December 2005||2005-12-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|November 2007|Actual|2007-11-30||Observational|||Quality of Life in African-American or Caucasian Female Breast Cancer Survivors|Survey of the Quality of Life of Women|Completed|||195|Anticipated|Indiana University|||||f||||f||||||||||2018-06-01 04:15:50.059456|2018-06-01 04:15:50.059456
NCT00268489|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2016-07-01|2005-12-20|2005-12-22|Estimate|||||||2016-07-01|2016-07-06|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|April 2010|Actual|2010-04-30|May 2007|Actual|2007-05-31||Interventional|||Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Pemetrexed Disodium (ALIMTA®) Plus Bevacizumab in Patients With Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment)|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:15:50.184439|2018-06-01 04:15:50.184439
NCT00268476|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2018-03-27|2005-12-20|2005-12-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 8, 2005|Actual|2005-07-08|March 2018|2018-03-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|STAMPEDE||Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy|STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial|Recruiting||Phase 2/Phase 3|11200|Anticipated|Medical Research Council||11|||f||||t|f|f||||||||2018-06-01 04:15:50.601957|2018-06-01 04:15:50.601957
NCT00268463|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2013-02-05||2013-05-10|2005-12-20|2005-12-22|Estimate|2013-02-05|2013-03-15|Estimate||||2013-05-10|2013-05-15|Estimate|January 2006||2006-01-31|May 2013|2013-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer|A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients With Resected or Ablated Liver Metastases From Colorectal Cancer|Terminated||Phase 3|22|Actual|NSABP Foundation Inc||2||The study was terminated due to low accrual.|f||||t||||||||||2018-06-01 04:15:50.846171|2018-06-01 04:15:50.846171
NCT00268450|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-04-26|2005-12-20|2005-12-22|Estimate|||||||2012-04-26|2012-04-30|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery|A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder|Completed||Phase 2|25|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 04:15:52.111418|2018-06-01 04:15:52.111418
NCT00268437|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2015-03-09||2016-07-01|2005-12-20|2005-12-22|Estimate|2015-03-16|2015-03-27|Estimate||||2016-07-01|2016-07-06|Estimate|April 2006||2006-04-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|January 2008|Actual|2008-01-31||Interventional|||Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery|A Phase II Trial of Preoperative Radiation and Chemotherapy (Pemetrexed and Carboplatin) for Locally Advanced Esophageal Cancer|Terminated||Phase 2|27|Actual|Alliance for Clinical Trials in Oncology||1||Trial closed early because, during an interim analysis, the primary endpoint fell short.|f||||t||||||||||2018-06-01 04:15:52.24084|2018-06-01 04:15:52.24084
NCT00268411|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2008-05-23|2005-12-20|2005-12-22|Estimate|||||||2008-05-23|2008-05-27|Estimate|September 2004||2004-09-30|May 2007|2007-05-31||||||||Interventional|||Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer|Phase II Randomisee Dans Les Adenocarcinomes Metastatiques Du Pancreas: Gemox Et Gemox Simplifie. [GEMOX]|Unknown status|Active, not recruiting|Phase 3|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:15:54.353733|2018-06-01 04:15:54.353733
NCT00268398|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-05-21|2005-12-20|2005-12-22|Estimate|||||||2012-05-21|2012-05-22|Estimate|July 2002||2002-07-31|May 2012|2012-05-31||||December 2011|Actual|2011-12-31||Interventional|MIROX||Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases|Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX|Completed||Phase 3|284|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||||||||||||2018-06-01 04:15:54.534011|2018-06-01 04:15:54.534011
NCT00268385|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2018-04-20|2005-12-20|2005-12-22|Estimate|||||||2018-04-20|2018-04-23|Actual|December 16, 2005|Actual|2005-12-16|April 2018|2018-04-30||||October 15, 2011|Actual|2011-10-15||Interventional|||Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas|A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas|Active, not recruiting||Phase 1|83|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:15:54.857689|2018-06-01 04:15:54.857689
NCT00268372|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2012-10-03|2005-12-21|2005-12-22|Estimate|||||||2012-10-03|2012-10-04|Estimate|December 2005||2005-12-31|October 2012|2012-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx|A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, With and Without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients With Advanced Oropharyngeal Squamous Cell Cancer|Terminated||Phase 3|6|Actual|Southwest Oncology Group||2||SWOG eliminated its head and neck committee|f||||t||||||||||2018-06-01 04:15:55.006956|2018-06-01 04:15:55.006956
NCT00268359|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2014-07-18|2005-12-20|2005-12-22|Estimate|||||||2014-07-18|2014-07-21|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|October 2009|Actual|2009-10-31|August 2006|Actual|2006-08-31||Interventional|||Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas|Bevacizumab in Combination With Irinotecan for Malignant Gliomas|Completed||Phase 2|68|Anticipated|Duke University|||||f||||||||||||||2018-06-01 04:15:55.270056|2018-06-01 04:15:55.270056
NCT00268346|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2011-10-27||2015-12-04|2005-12-20|2005-12-22|Estimate|2012-02-14|2012-03-16|Estimate||||2015-12-04|2016-01-05|Estimate|October 2005||2005-10-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer|A Phase II Trial of ZD1839 (IRESSA®) for Patients With Recurrent or Metastatic Cancer of the Esophagus or Gastroesophageal Junction|Completed||Phase 2|58|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:15:55.386564|2018-06-01 04:15:55.386564
NCT00268333|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2009-02-06|2005-12-20|2005-12-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2005||2005-08-31|May 2007|2007-05-31||||January 2006|Actual|2006-01-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer|Phase II Study of Recurrent Ganglionic Colorectal Cancer Not Accessible By Surgery Treated Using Chemotherapy With Simplified FOLFOX7 Followed By Radiotherapy Combined With 5FU and Oxaliplatin|Completed||Phase 2|39|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:15:55.598557|2018-06-01 04:15:55.598557
NCT00268320|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2008-09-22|2005-12-21|2005-12-22|Estimate|||||||2008-09-22|2008-09-25|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|July 2007|Actual|2007-07-31|June 2006|Actual|2006-06-30||Interventional|||Clinical Investigation of the Medtronic Concerto™ Device|Clinical Investigation of the Medtronic Concerto™ Cardiac Resynchronization Therapy (CRT) and Implantable Cardioverter Defibrillator (ICD) Therapies (CRT+ICD Device)|Completed||N/A|270||Medtronic Cardiac Rhythm and Heart Failure|||||||||||||||||||2018-06-01 04:15:55.703843|2018-06-01 04:15:55.703843
NCT00268307|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2013-12-03|2005-12-20|2005-12-22|Estimate|||||||2013-12-03|2013-12-05|Estimate|December 2005||2005-12-31|December 2013|2013-12-31|September 2010|Actual|2010-09-30|January 2010|Actual|2010-01-31||Interventional|||Bone Marrow Stem Cell Infusion Following a Heart Attack|Cellular Transplantation of Autologous Bone Marrow-Derived Stem Cells Following Myocardial Infarction|Completed||Phase 1|41|Actual|Minneapolis Heart Institute Foundation||1|||f||||f||||||||||2018-06-01 04:15:55.926185|2018-06-01 04:15:55.926185
NCT00268255|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2013-04-12|2005-12-20|2005-12-22|Estimate|||||||2013-04-12|2013-04-16|Estimate||||April 2013|2013-04-30||||||||Interventional|||Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer|Phase I/II Study of Induction Gefitinib and Concurrent Radiotherapy in Patients With Previously Untreated, Medically Inoperable Stage I or II Non-Small Cell Lung Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Barbara Ann Karmanos Cancer Institute||||Study never moved forward with accrual.|f||||t||||||||||2018-06-01 04:15:56.224598|2018-06-01 04:15:56.224598
NCT00268242|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2015-06-03||2018-01-24|2005-12-20|2005-12-22|Estimate|2015-08-30|2015-10-05|Estimate||||2018-01-24|2018-02-22|Actual|January 2006||2006-01-31|August 2015|2015-08-31|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|||Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse|Terminated||Phase 2|24|Actual|The Cleveland Clinic|If </= 5 of 1st 18 pts had a CR, study would stop (otherwise, another 22 pts would be accrued). Study would stop if >4 of 1st 10 or 10 of 1st 25 pts had unacceptable toxicity per protocol & Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0|1||"If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%)~   of 24 enrolled patients had a CR so the study was terminated."|f||||f||||||||||2018-06-01 04:15:56.312052|2018-06-01 04:15:56.312052
NCT00268229|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2013-02-12|2005-12-20|2005-12-22|Estimate|||||||2013-02-12|2013-02-15|Estimate|July 2003||2003-07-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML|Completed||Phase 1|21|Actual|The Cleveland Clinic|||||f||||||||||||||2018-06-01 04:15:56.55067|2018-06-01 04:15:56.55067
NCT00268216|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2017-01-19|2005-12-21|2005-12-22|Estimate|||||||2017-01-19|2017-01-20|Estimate|September 2000||2000-09-30|January 2017|2017-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment|Completed||Phase 3|6228|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:15:56.753357|2018-06-01 04:15:56.753357
NCT00268203|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2013-10-10||2016-11-18|2005-12-21|2005-12-22|Estimate|2013-10-10|2013-12-09|Estimate||||2016-11-18|2017-01-09|Estimate|September 1998||1998-09-30|November 2016|2016-11-30|February 2013|Actual|2013-02-28|March 2000|Actual|2000-03-31||Interventional|||Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma|Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma|Completed||Phase 2|765|Actual|GlaxoSmithKline|||||||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:15:57.629092|2018-06-01 04:15:57.629092
NCT00268177|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2016-09-13|2005-12-21|2005-12-22|Estimate|||||||2016-09-13|2016-09-15|Estimate|October 2002||2002-10-31|September 2016|2016-09-30|December 2003|Actual|2003-12-31|||||Interventional|||Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease|A 13-week, Double-blind, Parallel Group, Multi-centre Study to Compare the Bronchial Anti-inflammatory Activity of the Combination of Salmeterol/Fluticasone Propionate 50/500mcg Twice Daily Compared With Placebo Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|130||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:15:58.54627|2018-06-01 04:15:58.54627
NCT00268164|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2015-05-05|2005-12-21|2005-12-22|Estimate|||||||2015-05-05|2015-05-06|Estimate|June 2004||2004-06-30|September 2006|2006-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis|Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis|Terminated||Phase 2|48||Hvidovre University Hospital||||Inclusion was difficult and to slow|f||||||||||||||2018-06-01 04:15:58.707921|2018-06-01 04:15:58.707921
NCT00268151|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2018-03-01|2005-12-20|2005-12-22|Estimate|||||||2018-03-01|2018-03-05|Actual|February 2005||2005-02-28|March 2018|2018-03-31||||February 2007|Actual|2007-02-28||Interventional|||Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer|Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer|Terminated||Phase 1|24||University of Louisville||||Study was terminated due to lack of funding.|f||||||||||||||2018-06-01 04:15:58.770494|2018-06-01 04:15:58.770494
NCT00268138|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2009-02-17|2005-12-21|2005-12-22|Estimate|||||||2009-02-17|2009-02-18|Estimate|April 2006||2006-04-30|December 2005|2005-12-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Interventional|||Elmex Gel Efficacy in Preventing White Spot Lesions|Phase 4 Study Prevention of Incipient Carious Lesions (White Spot Lesions) in Patients With Fixed Orthodontic Appliances Following the Application of Elmex Gel|Unknown status|Recruiting|Phase 4|314|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-06-01 04:15:58.85616|2018-06-01 04:15:58.85616
NCT00268125|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2009-03-17|2005-12-21|2005-12-22|Estimate|||||||2009-03-17|2009-03-18|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.|Evaluation of Acupression's Bracelets Associated to an Educational Step Versus Education Only in Nausea and Vomiting's Mastering Induced by FEC100 Chemotherapy's Sort.|Completed||Phase 3|347|Anticipated|Institut Claudius Regaud|||||f||||||||||||||2018-06-01 04:15:58.950964|2018-06-01 04:15:58.950964
NCT00268112|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-03-14|2005-12-20|2005-12-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2004||2004-01-31|December 2006|2006-12-31|December 2006|Actual|2006-12-31|||||Observational|||Resynchronization of Left Ventricular Contraction After Reimplantation of Anomalous Left Coronary Artery|Resynchronization of Left Ventricular Contraction After Re-implantation of Anomalous Left Coronary Artery From the Pulmonary Artery (ALCAPA) Evaluated by Tissue Doppler Imaging|Terminated|||3|Actual|Children's Healthcare of Atlanta||||sufficient data collected for analysis|f||||f||||||||||2018-06-01 04:15:59.045001|2018-06-01 04:15:59.045001
NCT00265018|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2011-07-28|2005-12-12|2005-12-13|Estimate|||||||2011-07-28|2011-07-29|Estimate|May 1998||1998-05-31|July 2011|2011-07-31||||January 2003|Actual|2003-01-31||Interventional|||HD10 for Early Stages||Completed||Phase 3|1370|Actual|University of Cologne||4|||f||||||||||||||2018-06-01 04:17:01.556647|2018-06-01 04:17:01.556647
NCT00268047|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2011-07-05|2005-12-20|2005-12-22|Estimate|||||||2011-07-05|2011-07-06|Estimate||||July 2011|2011-07-31||||||||Observational|||Pulmonary Resistance in Fontan Who Have Undergone Heart Transplantation|Retrospective Assessment of Pulmonary Vascular Resistance in Fontan Patients Who Have Undergone Orthotopic Heart Transplantation|Terminated|||50|Actual|Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:15:59.341131|2018-06-01 04:15:59.341131
NCT00268034|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2007-05-03|2005-12-20|2005-12-22|Estimate|||||||2007-05-03|2007-05-07|Estimate|June 2002||2002-06-30|May 2007|2007-05-31||||||||Observational|||Left Ventricular Aneurysms in Children|Left Ventricular Aneurysms in Children|Terminated|||5||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:15:59.387252|2018-06-01 04:15:59.387252
NCT00268021|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2014-11-26|2005-12-20|2005-12-22|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 1998||1998-01-31|November 2014|2014-11-30||||||||Observational|||Automated Cardioverter Defibrillator in Children|The Use of Automated Cardioverter Defibrillator in Children (AICD)|Completed|||34|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 04:15:59.43828|2018-06-01 04:15:59.43828
NCT00268008|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2007-05-03|2005-12-20|2005-12-22|Estimate|||||||2007-05-03|2007-05-07|Estimate|January 1976||1976-01-31|May 2007|2007-05-31||||||||Observational|||Children and Adolescents Receiving Mechanical and Prosthetic Valves|Retrospective Review of Children and Adolescents Receiving Mechanical and Prosthetic Valves in the Aortic and Mitral Position 1976-2002|Terminated|||300||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:15:59.525174|2018-06-01 04:15:59.525174
NCT00267995|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2011-07-05|2005-12-20|2005-12-22|Estimate|||||||2011-07-05|2011-07-06|Estimate|December 1994||1994-12-31|May 2007|2007-05-31||||||||Observational|||Ross Aortic Valve Replacement Patients|Proposal for Retrospective Review of Ross Aortic Valve Replacement Patients|Terminated|||75|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 04:15:59.595942|2018-06-01 04:15:59.595942
NCT00267982|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2011-07-05|2005-12-20|2005-12-22|Estimate|||||||2011-07-05|2011-07-06|Estimate|August 1992||1992-08-31|June 2011|2011-06-30|February 2008|Actual|2008-02-29|August 2003|Actual|2003-08-31||Observational|||Radiofrequency Ablation of Ectopic Atrial Tachycardia|A Retrospective Review of Outcomes Related to Radiofrequency Ablation of Ectopic Atrial Tachycardia|Terminated|||25|Actual|Children's Healthcare of Atlanta||||significant conclusive data has been collected|f||||f||||||||||2018-06-01 04:15:59.658865|2018-06-01 04:15:59.658865
NCT00267969|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2009-10-23||2013-06-10|2005-12-20|2005-12-22|Estimate|2012-07-23|2012-08-24|Estimate||||2013-06-10|2013-06-17|Estimate|December 2005||2005-12-31|June 2013|2013-06-30|May 2011|Actual|2011-05-31|July 2006|Actual|2006-07-31||Interventional|PHOENIX1||A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis|Completed||Phase 3|766|Actual|Centocor Research & Development, Inc.|The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.|3|||f||||t||||||||||2018-06-01 04:15:59.786698|2018-06-01 04:15:59.786698
NCT00267956|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2009-10-23||2013-05-30|2005-12-20|2005-12-22|Estimate|2012-08-02|2012-09-05|Estimate||||2013-05-30|2013-06-05|Estimate|December 2005||2005-12-31|May 2013|2013-05-31|September 2007|Actual|2007-09-30|March 2007|Actual|2007-03-31||Interventional|||An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis|Completed||Phase 2|146|Actual|Centocor, Inc.|The count of patients with any nonserious adverse event (NAE) excludes patients who only had NAE that occured in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirements of this website.|2|||f||||t||||||||||2018-06-01 04:16:01.611474|2018-06-01 04:16:01.611474
NCT00267943|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2013-11-12|2005-12-21|2005-12-22|Estimate|||||||2013-11-12|2013-11-13|Estimate|January 2006||2006-01-31|November 2013|2013-11-30|January 2007||2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients|An Open-label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80 mg + Hydrochlorothiazide 25 mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension.|Completed||Phase 3|639||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:16:02.04526|2018-06-01 04:16:02.04526
NCT00267930|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2008-12-17|2005-12-20|2005-12-22|Estimate|||||||2008-12-17|2008-12-18|Estimate|December 2005||2005-12-31|December 2008|2008-12-31|August 2006|Actual|2006-08-31|||||Interventional|||Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence|A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF|Completed||Phase 2|221|Actual|Cardiome Pharma||3|||f||||f||||||||||2018-06-01 04:16:02.200189|2018-06-01 04:16:02.200189
NCT00267917|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2017-12-27|2005-12-21|2005-12-22|Estimate|||||||2017-12-27|2017-12-28|Actual|January 2006||2006-01-31|December 2017|2017-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.|A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique.|Completed||Phase 4|13||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:16:02.392051|2018-06-01 04:16:02.392051
NCT00267904|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2018-05-22|2005-12-20|2005-12-21|Estimate|||||||2018-05-22|2018-05-23|Actual|December 15, 2005||2005-12-15|May 4, 2018|2018-05-04||||||||Observational|||Reference Values for Plasma Catechols|Reference Values for Plasma Catechols|Recruiting|||53|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:16:02.455163|2018-06-01 04:16:02.455163
NCT00267891|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2017-06-30|2005-12-20|2005-12-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 14, 2005||2005-12-14|August 12, 2010|2010-08-12|August 12, 2010||2010-08-12|||||Observational|||Brain Changes in Adolescents While Imagining and Observing Aggressive Behavior|Changes in Activation Patterns in the Ventro-Medial Prefrontal Cortex of Healthy Adolescents During the Imagination and Observation of Aggressive Behavior|Completed|||88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:16:02.54195|2018-06-01 04:16:02.54195
NCT00267865|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-21|||2018-04-03|2005-12-20|2005-12-21|Estimate|||||||2018-04-03|2018-04-04|Actual|December 16, 2005||2005-12-16|March 21, 2018|2018-03-21|July 31, 2021|Anticipated|2021-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma|AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy|Recruiting||Phase 2|28|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 04:16:02.5895|2018-06-01 04:16:02.5895
NCT00267852|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2011-09-14|2005-12-19|2005-12-21|Estimate|||||||2011-09-14|2011-09-15|Estimate|April 2006||2006-04-30|September 2011|2011-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|ARPA||Study Evaluating the Clinical Remission in Early Aggressive Rheumatoid Arthritis|An Observational Study To Evaluate The Clinical Remission In Early Aggressive Rheumatoid Arthritis (Artrite Reumatoide Precoce Aggressiva Italian Study)|Completed|||152|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||t||||||||||2018-06-01 04:16:02.734433|2018-06-01 04:16:02.734433
NCT00267839|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2015-05-29|2005-12-20|2005-12-21|Estimate|||||||2015-05-29|2015-06-01|Estimate|January 2006||2006-01-31|May 2015|2015-05-31|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Effect of Exercise on Risk-factors of Elderly Women|Effects of Exercise on Multiple Risk Factors and Health Costs in Community Living Elderly Women. The Senior Fitness and Prevention Study (SEFIP)|Terminated||Phase 3|246|Actual|University of Erlangen-Nürnberg Medical School|||||f||||||||||||||2018-06-01 04:16:02.842584|2018-06-01 04:16:02.842584
NCT00267826|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2008-06-16|2005-12-20|2005-12-21|Estimate|||||||2008-06-16|2008-06-17|Estimate|December 2005||2005-12-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Interventional|||Immunopharmacological Effects of Rituximab in Atopic Dermatitis|Open-Label, Single Center Study to Evaluate the Immunopharmacological Effects of Rituximab in Patients With Atopic Dermatitis|Completed||N/A|6|Actual|University of Bern||1|||f||||f||||||||||2018-06-01 04:16:02.936341|2018-06-01 04:16:02.936341
NCT00267813|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2008-05-06|2005-12-20|2005-12-21|Estimate|||||||2008-05-06|2008-05-07|Estimate|July 2004||2004-07-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers|The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.|Completed||N/A|24|Actual|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-06-01 04:16:03.019932|2018-06-01 04:16:03.019932
NCT00267800|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2008-08-07|2005-12-19|2005-12-21|Estimate|||||||2008-08-07|2008-08-08|Estimate|January 2006||2006-01-31|December 2005|2005-12-31||||||||Observational|||Database of Interstitial Lung Diseases|Registration of Clinical Data and DNA/Serum of Patients With Interstitial Lung Diseases (ILD)|Unknown status|Active, not recruiting||100000||St. Antonius Hospital|||||f||||||||||||||2018-06-01 04:16:03.12914|2018-06-01 04:16:03.12914
NCT00267787|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2012-07-05|2005-12-19|2005-12-21|Estimate|||||||2012-07-05|2012-07-09|Estimate|September 2004||2004-09-30|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|||Molecular Genetic and Pathological Studies of Anal Tumors|Molecular Genetic and Pathological Studies of Anal Tumors|Unknown status|Recruiting||300|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 04:16:03.220582|2018-06-01 04:16:03.220582
NCT00267774|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2016-06-17||2017-10-10|2005-12-19|2005-12-21|Estimate|2016-06-17|2016-07-27|Estimate||||2017-10-10|2017-11-13|Actual|January 2006||2006-01-31|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2008|Actual|2008-09-30||Interventional|||Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)||Completed||N/A|1005|Actual|Stanford University||2|||f||||||||||||||2018-06-01 04:16:03.315197|2018-06-01 04:16:03.315197
NCT00267748|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2011-06-23||2011-08-03|2005-12-20|2005-12-21|Estimate|2011-08-03|2011-09-05|Estimate||||2011-08-03|2011-09-05|Estimate|December 2005||2005-12-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)|A Randomized Phase II Study Of The Efficacy And Safety Of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (Renal EFFECT Trial)|Completed||Phase 2|317|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:16:03.95484|2018-06-01 04:16:03.95484
NCT00267735|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2006-09-08|2005-12-20|2005-12-21|Estimate|||||||2006-09-08|2006-09-11|Estimate|January 2006||2006-01-31|December 2005|2005-12-31||||||||Interventional|||Measuring Preferences for Childbirth After Cesarean|Measuring Preferences for Childbirth After Cesarean|Unknown status|Recruiting|N/A|120||Oregon Health and Science University|||||f||||||||||||||2018-06-01 04:16:05.24025|2018-06-01 04:16:05.24025
NCT00267722|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2012-03-06|2005-12-19|2005-12-21|Estimate|||||||2012-03-06|2012-03-07|Estimate|February 2005||2005-02-28|March 2012|2012-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease|A Phase 2a, Open-label Study of Visilizumab in Patients With Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's Disease|Completed||Phase 2|18||Facet Biotech|||||f||||||||||||||2018-06-01 04:16:05.29936|2018-06-01 04:16:05.29936
NCT00267709|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2012-03-06|2005-12-19|2005-12-21|Estimate|||||||2012-03-06|2012-03-07|Estimate|February 2005||2005-02-28|March 2012|2012-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease|A Phase 2a, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients With Crohn's Disease|Completed||Phase 2|18||Facet Biotech|||||f||||||||||||||2018-06-01 04:16:05.350491|2018-06-01 04:16:05.350491
NCT00267696|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2015-02-09||2015-04-28|2005-12-19|2005-12-21|Estimate|2015-04-28|2015-04-30|Estimate||||2015-04-28|2015-04-30|Estimate|November 2005||2005-11-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Phase II Study of Gemcitabine/Carboplatin/Bevacizumab in Platinum Sensitive Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.|Completed||Phase 2|45|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:16:05.54703|2018-06-01 04:16:05.54703
NCT00267683|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2016-03-03|2005-12-20|2005-12-21|Estimate|||||||2016-03-03|2016-03-04|Estimate|December 2005||2005-12-31|March 2016|2016-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes|A Clinical Trial to Study the Efficacy and Safety of Insulin Aspart Three Times Per Day Compared to Glibenclamide Once or Twice Daily in Type 2 Diabetes by Comparison of Ability to Control Blood Glucose|Terminated||Phase 3|9|Actual|Novo Nordisk A/S||||This trial was terminated due to low recruitment|f||||f||||||||||2018-06-01 04:16:05.797821|2018-06-01 04:16:05.797821
NCT00267670|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2011-01-13||2014-08-27|2005-12-20|2005-12-21|Estimate|2014-08-27|2014-09-09|Estimate||||2014-08-27|2014-09-09|Estimate|March 2005||2005-03-31|August 2014|2014-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH|The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 2/Phase 3|26|Actual|Northwestern University|The most significant limitation of this study is the small sample size, thus the lack of statistical significance may be due to low power.|2|||f||||f||||||||||2018-06-01 04:16:05.87278|2018-06-01 04:16:05.87278
NCT00267475|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2013-09-17|2005-12-19|2005-12-21|Estimate|||||||2013-09-17|2013-09-19|Estimate|May 2001||2001-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Data Bank for Eosinophilic Disorders|Clinical and Immunological Evaluation of Eosinophil Associated Gastrointestinal Disorders (EGID)|Completed|||500|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||||||||||||2018-06-01 04:16:08.123323|2018-06-01 04:16:08.123323
NCT00267657|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2017-01-10|2005-12-20|2005-12-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2004||2004-01-31|December 2005|2005-12-31|November 2004||2004-11-30|||||Interventional|||A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1|Assessment of Interactions Between IV Methamphetamine and Reserpine|Unknown status|Active, not recruiting|Phase 1|30||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 04:16:06.147242|2018-06-01 04:16:06.147242
NCT00267644|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2013-02-27||2013-04-18|2005-12-19|2005-12-21|Estimate|2013-04-18|2013-07-03|Estimate||||2013-04-18|2013-07-03|Estimate|December 2005||2005-12-31|April 2013|2013-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Ultrasound of the Inferior Vena Cava (IVC) and Dehydration Status in Pediatric Emergency Patients|Ultrasound of the Inferior Vena Cava (IVC) and Dehydration Status in Pediatric Emergency Patients|Completed|||76|Actual|Maimonides Medical Center|||2||f||||t||||||||||2018-06-01 04:16:06.209247|2018-06-01 04:16:06.209247
NCT00267631|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2013-02-27||2013-07-29|2005-12-19|2005-12-21|Estimate|2013-04-23|2013-07-18|Estimate||||2013-07-29|2013-08-12|Estimate|April 2005||2005-04-30|July 2013|2013-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Impact of Body Weight on the Immediate Health of the Pediatric Population|The Influence of Childhood Obesity on Presentation to a Pediatric Emergency Department|Completed|||5392|Actual|Maimonides Medical Center|||2||f||||f||||||||||2018-06-01 04:16:06.515682|2018-06-01 04:16:06.515682
NCT00267618|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2015-06-15|2005-12-20|2005-12-21|Estimate|||||||2015-06-15|2015-06-16|Estimate|June 2004||2004-06-30|June 2015|2015-06-30|April 2008|Actual|2008-04-30|June 2007|Actual|2007-06-30||Interventional|||Family Help Program: Pediatric Recurrent Headache and Abdominal Pain|Family Help Program: Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Recurrent Headache and Abdominal Pain)|Completed||Phase 2|10|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 04:16:06.798111|2018-06-01 04:16:06.798111
NCT00267605|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2017-03-07|2005-12-20|2005-12-21|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2003||2003-06-30|March 2017|2017-03-31|April 2008|Actual|2008-04-30|June 2006|Actual|2006-06-30||Interventional|FHPADHD||Strongest Families (Formerly Family Help Program): Pediatric Attention Deficit/Hyperactivity Disorder|Strongest Families (Formerly Family Help Program): Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Attention Deficit/Hyperactivity Disorder)|Completed||Phase 2|72|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 04:16:06.889735|2018-06-01 04:16:06.889735
NCT00267592|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19||2011-08-16|2016-04-20|2005-12-20|2005-12-21|Estimate||||2011-08-16|2011-08-23|Estimate|2016-04-20|2016-05-19|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|February 2011|Actual|2011-02-28|September 2008|Actual|2008-09-30||Interventional|||Safety and Efficacy of Talampanel in Glioblastoma Multiforme|A Phase II Trial of Talampanel in Conjunction With Radiation Therapy With Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|72|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 04:16:06.969381|2018-06-01 04:16:06.969381
NCT00267579|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2013-03-27|2005-12-20|2005-12-21|Estimate|||||||2013-03-27|2013-03-29|Estimate|October 2003||2003-10-31|March 2013|2013-03-31|April 2008|Actual|2008-04-30|September 2006|Actual|2006-09-30||Interventional|||Strongest Families (Formerly Family Help Program): Pediatric Disruptive Behaviour Disorder|Strongest Families (Formerly Family Help Program):Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Disruptive Behaviour Disorder)|Completed||Phase 2|80|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 04:16:07.031072|2018-06-01 04:16:07.031072
NCT00267566|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2013-09-11|2005-12-19|2005-12-21|Estimate|||||||2013-09-11|2013-09-12|Estimate|August 2003||2003-08-31|September 2013|2013-09-30|April 2008|Actual|2008-04-30|September 2007|Actual|2007-09-30||Interventional|FHP-ANX||Strongest Families (Formerly Family Help Program): Pediatric Anxiety|Strongest Families (Formerly Family Help Program): Primary Care Delivery by Telephone for Psychological and Behavioural Problems (Pediatric Anxiety)|Completed||Phase 2|91|Actual|IWK Health Centre||2|||f||||f||||||||||2018-06-01 04:16:07.104911|2018-06-01 04:16:07.104911
NCT00267553|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2007-09-07|2005-12-20|2005-12-21|Estimate|||||||2007-09-07|2007-09-10|Estimate|November 2005||2005-11-30|September 2007|2007-09-30|June 2006|Actual|2006-06-30|||||Interventional|||Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer|Open Label Treatment and Survival Continuation Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer|Terminated||Phase 3|200||Intarcia Therapeutics||||This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint|||||||||||||||2018-06-01 04:16:07.190663|2018-06-01 04:16:07.190663
NCT00267540|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2008-01-29|2005-12-20|2005-12-21|Estimate|||||||2008-01-29|2008-01-30|Estimate|January 2001||2001-01-31|January 2008|2008-01-31|December 2003||2003-12-31|||||Interventional|||The Effect of Vitamin D on Bone Accretion and Turn-Over in Young Girls|Adolescent Girls-Impact of Vitamin D on Bone Accretion Work Package 1 (Danish Part) of OPTIFORD (Towards A Strategy for Optimal Vitamin D Fortification)|Completed||N/A|225||University of Copenhagen|||||f||||||||||||||2018-06-01 04:16:07.309346|2018-06-01 04:16:07.309346
NCT00267527|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2006-10-12|2005-12-20|2005-12-21|Estimate|||||||2006-10-12|2006-10-16|Estimate|December 2005||2005-12-31|October 2006|2006-10-31|September 2006||2006-09-30|||||Interventional|||A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity|Terminated||Phase 2|120||ConjuChem|||||||||||||||||||2018-06-01 04:16:07.374418|2018-06-01 04:16:07.374418
NCT00267514|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2015-03-17|2005-12-20|2005-12-21|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|May 2007|Actual|2007-05-31|March 2007|Actual|2007-03-31||Interventional|||Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients|A Randomized, Cross-over Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer Hydrochloride Tablets Dosed Three Times Per Day in Haemodialysis Patients|Completed||Phase 3|31|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:16:07.45769|2018-06-01 04:16:07.45769
NCT00267501|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2015-11-10|2005-12-19|2005-12-21|Estimate|||||||2015-11-10|2015-11-13|Estimate|May 2005||2005-05-31|September 2014|2014-09-30|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31||Observational|||Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders|Eosinophils and Inflammation, an Expanded Study|Recruiting|||5000|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 04:16:07.540493|2018-06-01 04:16:07.540493
NCT00267488|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|2008-12-05||2012-06-28|2005-12-20|2005-12-21|Estimate|2010-01-04|2010-01-28|Estimate||||2012-06-28|2012-07-11|Estimate|October 2005||2005-10-31|June 2012|2012-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer|An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer|Completed||Phase 2|70|Actual|GlaxoSmithKline|As there was only 1 responder, time to response, and duration of response were not calculated.||||||||f||||||||||2018-06-01 04:16:07.801623|2018-06-01 04:16:07.801623
NCT00267449|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-09-10|2005-12-19|2005-12-21|Estimate|||||||2007-09-10|2007-09-11|Estimate|November 2005||2005-11-30|September 2007|2007-09-30||||||||Observational|||Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System|Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System|Unknown status|Recruiting||950|Anticipated|ART Advanced Research Technologies Inc.|||||f||||||||||||||2018-06-01 04:16:08.318406|2018-06-01 04:16:08.318406
NCT00267436|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-04-12|2005-12-20|2005-12-21|Estimate|||||||2012-04-12|2012-04-13|Estimate|July 2006||2006-07-31|April 2012|2012-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Adopting and Demonstrating the Adaptation of Prevention Techniques: Community PROMISE PLUS|Adopting and Demonstrating the Adaptation of Prevention Techniques: Community PROMISE Positives Leading and Utilizing Strategies (ADAPT CP PLUS)|Completed||Phase 1/Phase 2|574|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:16:08.400961|2018-06-01 04:16:08.400961
NCT00267423|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-05-02|2005-12-19|2005-12-21|Estimate|||||||2007-05-02|2007-05-04|Estimate|January 2002||2002-01-31|May 2007|2007-05-31||||||||Observational|||Biventricular Pacing in the Pediatric Population|A Single Center, Retrospective Study of the Safety and Feasibility of Epicardial Biventricular Pacing in the Pediatric Population|Terminated|||12||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:16:08.478166|2018-06-01 04:16:08.478166
NCT00267410|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-20|||2012-09-10|2005-12-20|2005-12-21|Estimate|||||||2012-09-10|2012-09-11|Estimate|November 2005||2005-11-30|September 2012|2012-09-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center|Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center|Completed||N/A|33|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:16:08.536881|2018-06-01 04:16:08.536881
NCT00267397|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-05-02|2005-12-19|2005-12-21|Estimate|||||||2007-05-02|2007-05-04|Estimate|January 1967||1967-01-31|May 2007|2007-05-31|December 2006||2006-12-31|||||Observational|||Prevalence and Clinical Spectrum of the 22q11 Deletion|Prevalence and Clincial Spectrum of the 22q11 Deletion: A Population Based Study of Children and Congenital Heart Defects|Terminated|||||Children's Healthcare of Atlanta||||sufficient data collected|f||||f||||||||||2018-06-01 04:16:08.598599|2018-06-01 04:16:08.598599
NCT00267384|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2012-06-19|2005-12-16|2005-12-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2006||2006-03-31|June 2012|2012-06-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||N-acetylcysteine Protects From Aminoglycosides Induced Nephrotoxicity||Completed||Phase 2/Phase 3|||Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:16:08.655079|2018-06-01 04:16:08.655079
NCT00267371|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16||2014-03-31|2016-08-23|2005-12-16|2005-12-20|Estimate||||2014-05-19|2014-05-29|Estimate|2016-08-23|2016-08-25|Estimate|November 2005||2005-11-30|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||ESCAPE Migraine Trial|Effect of Septal Closure of Atrial PFO on Events of Migraine With Premere: ESCAPE Migraine Trial|Terminated||Phase 3|168|Actual|St. Jude Medical||2||Insufficient enrollment|f||||t||||||||||2018-06-01 04:16:08.727753|2018-06-01 04:16:08.727753
NCT00267358|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2013-08-30|2005-12-19|2005-12-20|Estimate|||||||2013-08-30|2013-09-02|Estimate|November 2005||2005-11-30|August 2013|2013-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.||Completed||Phase 2|||Helsinn Therapeutics (U.S.), Inc||2|||||||||||||||||2018-06-01 04:16:08.863949|2018-06-01 04:16:08.863949
NCT00267345|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-02-28|2005-12-19|2005-12-20|Estimate|||||||2007-02-28|2007-03-01|Estimate|March 2005||2005-03-31|January 2006|2006-01-31|October 2007||2007-10-31|||||Observational|||Measurement of Hormonal Concentration in Chylothorax Fluid in Infants With Congenital Chylothorax||Unknown status|Recruiting||15||Sheba Medical Center|||||f||||t||||||||||2018-06-01 04:16:08.960245|2018-06-01 04:16:08.960245
NCT00267332|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2018-05-02|2005-12-19|2005-12-20|Estimate|||||||2018-05-02|2018-05-07|Actual|January 2006||2006-01-31|May 2018|2018-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Modafinil in Opioid Induced Sedation|A Randomized Double-Blinded, Placebo Controlled, Crossover Trial Examining the Effectiveness of Modafinil in Opioid Induced Sedation|Terminated||Phase 3|90||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||Low accrual|f||||||||||||||2018-06-01 04:16:09.0269|2018-06-01 04:16:09.0269
NCT00267319|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2009-12-04|2005-12-19|2005-12-20|Estimate|||||||2009-12-04|2009-12-07|Estimate|June 2003||2003-06-30|December 2009|2009-12-31||||October 2006|Actual|2006-10-31||Interventional|||FOCUS Fatigue Outcome in Copaxone USers|Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis|Completed||Phase 4|111|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:16:09.087729|2018-06-01 04:16:09.087729
NCT00267306|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2012-03-08|2005-12-16|2005-12-20|Estimate|||||||2012-03-08|2012-03-09|Estimate|January 2004||2004-01-31|March 2012|2012-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis|A Phase 1/2, Partially Randomized, Open-Label Study of Visilizumab in Patients With Severe Ulcerative Colitis Refractory to Intravenous Corticosteroids|Completed||Phase 1/Phase 2|144||Facet Biotech|||||f||||||||||||||2018-06-01 04:16:09.160913|2018-06-01 04:16:09.160913
NCT00267293|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|2011-07-22||2012-05-08|2005-12-16|2005-12-20|Estimate|2012-05-08|2012-05-09|Estimate||||2012-05-08|2012-05-09|Estimate|January 2006||2006-01-31|May 2012|2012-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever|Ibuprofen Alone and in Combination With Acetaminophen for Treatment of Fever|Completed||Phase 4|60|Actual|Penn State University|Relatively small sample size. Underpowered to evaluate effect oon discomfort and pain. The 6 hour observation allowed for evaluation of single cycle of drug. Did not evaluate the effect of multiple doses over a longer observation period.|3|||f||||f||||||||||2018-06-01 04:16:09.244281|2018-06-01 04:16:09.244281
NCT00267280|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19||2012-02-15|2012-02-15|2005-12-19|2005-12-20|Estimate||||2012-02-15|2012-02-17|Estimate|2012-02-15|2012-02-17|Estimate|January 2006||2006-01-31|February 2012|2012-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).|A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091031)|Terminated||Phase 3|640||Pfizer|||||f||||||||||||||2018-06-01 04:16:09.521969|2018-06-01 04:16:09.521969
NCT00267267|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-12-06|2005-12-19|2005-12-20|Estimate|||||||2007-12-06|2007-12-10|Estimate|January 2006||2006-01-31|December 2006|2006-12-31|January 2007|Actual|2007-01-31|||||Interventional|||A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.|Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects With Dyslipidemia.|Terminated||Phase 3|1784||Pfizer|||||||||||||||||||2018-06-01 04:16:09.666092|2018-06-01 04:16:09.666092
NCT00267254|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-11-20|2005-12-19|2005-12-20|Estimate|||||||2007-11-20|2007-11-21|Estimate|January 2006||2006-01-31|April 2007|2007-04-30|August 2006|Actual|2006-08-31|||||Interventional|||A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.|A Phase 3, Open-Label, Multisite, Randomized, Parallel Group Study of the Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin Administered Once Daily (QD) Compared to Simvastatin for 6 Weeks in Subjects With Hypercholesterolemia (A5091030)|Completed||Phase 3|640||Pfizer|||||||||||||||||||2018-06-01 04:16:10.002675|2018-06-01 04:16:10.002675
NCT00267241|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2015-04-27|2005-12-19|2005-12-20|Estimate|||||||2015-04-27|2015-04-28|Estimate|December 2005||2005-12-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Different Assisted Mechanical Ventilation in Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS) Patients|Effects of Different Assisted Mechanical Ventilation in ALI/ARDS Patients|Completed||N/A|20|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:16:10.186282|2018-06-01 04:16:10.186282
NCT00267228|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-03-22|2005-12-19|2005-12-20|Estimate|||||||2007-03-22|2007-03-23|Estimate|February 2006||2006-02-28|March 2007|2007-03-31||||||||Observational|||Funen Anorexia Nervosa Study - Retrospective Cohort Study and 10 Year Follow-up Study||Unknown status|Active, not recruiting||||Odense University Hospital|||||f||||f||||||||||2018-06-01 04:16:10.258993|2018-06-01 04:16:10.258993
NCT00267215|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2012-05-18|2005-12-16|2005-12-20|Estimate|||||||2012-05-18|2012-05-21|Estimate|November 2000||2000-11-30|May 2012|2012-05-31||||February 2001|Actual|2001-02-28||Interventional|||Efficacy and Safety of Lumiracoxib|A One-week Multicenter, Multiple-dose, Randomized, Double-blind, Double-dummy, Parallel-group Comparison of the Analgesic Efficacy and Safety of Lumiracoxib (COX189), Celecoxib, and Placebo in the Treatment of Osteoarthritis of the Knee|Completed||Phase 3|330||Novartis|||||||||||||||||||2018-06-01 04:16:10.340747|2018-06-01 04:16:10.340747
NCT00267202|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2010-11-22||2016-08-02|2005-12-19|2005-12-20|Estimate|2011-04-20|2011-05-16|Estimate||||2016-08-02|2016-09-14|Estimate|December 2005||2005-12-31|October 2011|2011-10-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma|A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids|Completed||Phase 4|275|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:16:10.443252|2018-06-01 04:16:10.443252
NCT00267189|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2010-12-20||2011-04-11|2005-12-19|2005-12-20|Estimate|2011-03-08|2011-04-07|Estimate||||2011-04-11|2011-04-13|Estimate|November 2005||2005-11-30|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency|A 6-month, Multicenter, Randomized, Open-label Study of Safety and Efficacy of Everolimus-based Regimen Versus Calcineurin Inhibitor (CNI)-Based Regimen in Maintenance Liver Transplant Recipients|Completed||Phase 3|145|Actual|Novartis||2|||f||||t||||||||||2018-06-01 04:16:10.947805|2018-06-01 04:16:10.947805
NCT00267176|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2017-02-03|2005-12-16|2005-12-20|Estimate|||||||2017-02-03|2017-02-07|Estimate|November 2005||2005-11-30|February 2017|2017-02-28||||September 2006|Actual|2006-09-30||Interventional|||Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension|A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to Ibuprofen 600 mg Three Times a Day in Osteoarthritis Patients With Controlled Hypertension|Completed||Phase 4|1020||Novartis|||||||||||||||||||2018-06-01 04:16:11.371967|2018-06-01 04:16:11.371967
NCT00267163|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2008-08-28|2005-12-16|2005-12-20|Estimate|||||||2008-08-28|2008-08-29|Estimate|September 2000||2000-09-30|August 2008|2008-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Brain Imaging and Mental Disorders of Aging Intervention|Brain Imaging and Mental Disorders of Aging Intervention|Completed||Phase 4|64|Actual|National Institute on Aging (NIA)||2|||f||||||||||||||2018-06-01 04:16:11.435495|2018-06-01 04:16:11.435495
NCT00267150|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|2010-12-09||2011-05-17|2005-12-16|2005-12-20|Estimate|2010-12-09|2010-12-24|Estimate||||2011-05-17|2011-05-20|Estimate|November 2005||2005-11-30|May 2011|2011-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants|Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients|Completed||Phase 3|31|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:16:11.505957|2018-06-01 04:16:11.505957
NCT00267137|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2018-05-24|2005-12-19|2005-12-20|Estimate|||||||2018-05-24|2018-05-25|Actual|September 2002||2002-09-30|May 2018|2018-05-31||||||||Interventional|||Study for Atrial Fibrillation Reduction (SAFARI)|Study for Atrial Fibrillation Reduction (SAFARI)|Completed||N/A|540||Medtronic Cardiac Rhythm and Heart Failure|||||||||||||||||||2018-06-01 04:16:11.75525|2018-06-01 04:16:11.75525
NCT00267124|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2017-04-04|2005-12-16|2005-12-20|Estimate|||||||2017-04-04|2017-04-06|Actual|November 2004|Actual|2004-11-30|April 2017|2017-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Brain Aging Project--Kansas University|KU Brain Aging Project|Completed|||172|Actual|University of Kansas Medical Center|||2||f||||||||||Samples With DNA|"~     Blood samples are collected analyzed and banked as whole blood, serum, white blood cells~   "|||2018-06-01 04:16:11.862518|2018-06-01 04:16:11.862518
NCT00267111|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2011-08-10||2012-03-28|2005-12-19|2005-12-20|Estimate|2012-03-28|2012-04-23|Estimate||||2012-03-28|2012-04-23|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Topical Amethocaine Gel for Intramuscular Injection in Term Neonates|Local Anaesthesia [Topical Amethocaine Gel (Ametop)] for Intramuscular Injection in Term Neonates: A Randomized Controlled Trial.|Completed||Phase 2|110|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-06-01 04:16:11.93417|2018-06-01 04:16:11.93417
NCT00267098|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2013-12-18||2014-02-20|2005-12-19|2005-12-20|Estimate|2014-02-20|2014-03-26|Estimate||||2014-02-20|2014-03-26|Estimate|December 2003||2003-12-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|BLOCK HF||Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)|Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)|Completed||N/A|918|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-06-01 04:16:12.250403|2018-06-01 04:16:12.250403
NCT00267085|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2009-09-24||2012-08-01|2005-12-19|2005-12-20|Estimate|2011-01-28|2011-02-25|Estimate||||2012-08-01|2012-08-07|Estimate|December 2005||2005-12-31|August 2012|2012-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease|A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease|Completed||Phase 2|11|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 04:16:16.849476|2018-06-01 04:16:16.849476
NCT00267059|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2009-09-24||2012-08-01|2005-12-19|2005-12-20|Estimate|2011-03-21|2011-04-21|Estimate||||2012-08-01|2012-08-07|Estimate|December 2005||2005-12-31|August 2012|2012-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)|Lenalidomide (Revlimid) in Patients With Previously Treated Chronic Lymphocytic Leukemia|Completed||Phase 2|45|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:16:17.137104|2018-06-01 04:16:17.137104
NCT00267046|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|2012-01-18||2012-04-17|2005-12-19|2005-12-20|Estimate|2012-04-17|2012-05-16|Estimate||||2012-04-17|2012-05-16|Estimate|December 2005||2005-12-31|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma|A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide|Completed||Phase 2|49|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 04:16:17.340243|2018-06-01 04:16:17.340243
NCT00267033|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2008-12-01|2005-12-19|2005-12-20|Estimate|||||||2008-12-01|2008-12-02|Estimate|November 2005||2005-11-30|March 2007|2007-03-31|August 2008|Actual|2008-08-31|February 2008|Actual|2008-02-29||Interventional|||Evaluation of Vertebroplasty Associated With Radiotherapy for Spine Metastases (EVAR)|Randomized Trial of Vertebroplasty and Radiotherapy Versus Radiotherapy Alone for Osseous Spine Metastases|Completed||Phase 3|186|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:16:17.650316|2018-06-01 04:16:17.650316
NCT00267020|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16||2009-06-10|2009-10-05|2005-12-16|2005-12-20|Estimate||||2009-10-05|2009-10-07|Estimate|2009-10-05|2009-10-07|Estimate|December 2005||2005-12-31|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Patients With Advanced or Metastatic Pancreatic Cancer|A Randomized, Open-Label Phase 2 Study of 2 Regimens, Gemcitabine Plus Enzastaurin and Single-Agent Gemcitabine, in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|130|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 04:16:17.719122|2018-06-01 04:16:17.719122
NCT00267007|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|2009-07-31||2014-05-21|2005-12-16|2005-12-20|Estimate|2009-07-31|2009-09-07|Estimate||||2014-05-21|2014-06-04|Estimate|June 2006||2006-06-30|May 2014|2014-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients Receiving Combination Taxane and Platinum-Based Chemotherapy for Cancer|Terminated||Phase 2|32|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|No formal analysis was conducted due to early termination|2||Slow enrollment|f||||t||||||||||2018-06-01 04:16:17.822487|2018-06-01 04:16:17.822487
NCT00266994|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2013-02-20|2005-12-16|2005-12-20|Estimate|||||||2013-02-20|2013-02-21|Estimate|December 2005||2005-12-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||HTRS TE Registry (ThromboEmbolism Registry)|HTRS TE Registry (ThromboEmbolism Registry): Prospective Registry of Demographic and Clinical Data for Patients With Thromboembolic Disease|Completed|||2760|Actual|Nationwide Children's Hospital|||||f||||||||||||||2018-06-01 04:16:18.417449|2018-06-01 04:16:18.417449
NCT00266981|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2005-12-19|2005-12-19|2005-12-20|Estimate|||||||2005-12-19|2005-12-20|Estimate|March 2006||2006-03-31|December 2005|2005-12-31|December 2006|Anticipated|2006-12-31|||||Interventional|||Treatment of Whiplash Associated Disorders by APOS Kit|A Randomized Controlled Trial Which Compare the Effectiveness of an APOS Kit With Short Waves Therapy for Treating Whiplash Associated Disorders|Unknown status|Not yet recruiting|N/A|132|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:16:18.473632|2018-06-01 04:16:18.473632
NCT00266968|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2014-11-26|2005-12-19|2005-12-20|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2000||2000-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Outcomes of Children With Congenital Single Ventricle Heart|Assessment of the Outcomes of Children With Congenital Single Ventricle Heart|Completed|||200|Actual|Children's Healthcare of Atlanta|||||f||||t||||||||||2018-06-01 04:16:18.538578|2018-06-01 04:16:18.538578
NCT00266955|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2011-07-05|2005-12-19|2005-12-20|Estimate|||||||2011-07-05|2011-07-06|Estimate|January 1999||1999-01-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Observational|||Retrospective of Children With ADHD and Cardiac Symptoms|A Retrospective Study of Children With ADHD and Cardiac Symptoms|Terminated|||10|Actual|Children's Healthcare of Atlanta||||insufficient number of eligible subjects|f||||||||||||||2018-06-01 04:16:18.586158|2018-06-01 04:16:18.586158
NCT00266942|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-05-22|2005-12-19|2005-12-20|Estimate|||||||2007-05-22|2007-05-23|Estimate|January 1990||1990-01-31|May 2007|2007-05-31|January 2007||2007-01-31|||||Observational|||Intra-Atrial vs. Extra-Cardiac Technique During Fontan Operation|The Determination of Differences Between Intr-Atrial vs. Extra-Cardiac Technique During the Fontan Operation: A Retrospective Review|Terminated|||400||Children's Healthcare of Atlanta||||data collection ended|f||||f||||||||||2018-06-01 04:16:18.632291|2018-06-01 04:16:18.632291
NCT00266929|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2017-08-09|2005-12-19|2005-12-20|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2005||2005-12-31|August 2017|2017-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Treatment of Type II Odontoid Fractures Among the Elderly|Comparing Surgical to Conservative Management in the Treatment of Type II Odontoid Fractures Among the Elderly|Completed|||159|Actual|AOSpine North America Research Network|||2||f||||f||||||||||2018-06-01 04:16:18.686064|2018-06-01 04:16:18.686064
NCT00266916|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2007-05-22|2005-12-19|2005-12-20|Estimate|||||||2007-05-22|2007-05-23|Estimate|January 1996||1996-01-31|May 2007|2007-05-31|August 2006||2006-08-31|||||Observational|||Percutaneous Interventions in Adults With CHD|Percutaneous Interventions in Adults With Complex Cyanotic Congenital Heart Disease|Terminated|||9||Children's Healthcare of Atlanta||||data collection sufficient|f||||||||||||||2018-06-01 04:16:19.015736|2018-06-01 04:16:19.015736
NCT00266903|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-19|||2014-11-26|2005-12-19|2005-12-20|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 1996||1996-01-31|November 2014|2014-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Eisenmenger's Syndrome in Adults With CHD|Treatment of Eisenmenger's Syndrome in Adults With Congenital Heart Disease With Pulmonary Arterial Vasodilators|Completed|||48|Actual|Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:16:19.068253|2018-06-01 04:16:19.068253
NCT00266877|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|2017-08-10|2009-02-26|2018-04-06|2005-12-16|2005-12-19|Estimate|2018-04-06|2018-04-13|Actual|2009-09-25|2009-09-28|Estimate|2018-04-06|2018-04-13|Actual|December 2005|Actual|2005-12-31|April 2018|2018-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|172|Actual|Puma Biotechnology, Inc.||3|||f||||f||||||||||2018-06-01 04:16:19.165242|2018-06-01 04:16:19.165242
NCT00266864|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2013-12-19||2017-09-29|2005-12-15|2005-12-19|Estimate|2014-02-27|2014-04-07|Estimate||||2017-09-29|2017-11-01|Actual|August 2003||2003-08-31|September 2017|2017-09-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Testosterone Replacement Therapy in Chronic Spinal Cord Injury|Testosterone Replacement Therapy in Chronic Spinal Cord Injury|Completed||Phase 2/Phase 3|31|Actual|VA Office of Research and Development|Compared to similar trials our trial was relatively small. Although there was statistical and clinical changes associated with testosterone replacement therapy, the translation of these findings with regard to functional gain was not addressed.|2|||f||||f||||||||||2018-06-01 04:16:19.982748|2018-06-01 04:16:19.982748
NCT00266851|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2013-12-11|2005-12-15|2005-12-19|Estimate|||||||2013-12-11|2013-12-13|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||AZMATICS: AZithroMycin/Asthma Trial In Community Settings|AZMATICS: Azithromycin Asthma Trial In Community Settings|Completed||Phase 3|97|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:16:20.345699|2018-06-01 04:16:20.345699
NCT00266838|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2010-06-24|2005-12-16|2005-12-19|Estimate|||||||2010-06-24|2010-06-28|Estimate|July 2006||2006-07-31|December 2005|2005-12-31|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Prevention of Docetaxel Induced Dacryostenosis|A Double Blind Interventional Study of the Efficacy of Topical Eye Treatment in the Prevention of Docetaxel Induced Dacryostenosis|Completed||Phase 1|20|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-06-01 04:16:20.479418|2018-06-01 04:16:20.479418
NCT00266825|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2015-06-30||2016-02-11|2005-12-16|2005-12-19|Estimate|2016-01-05|2016-02-04|Estimate||||2016-02-11|2016-03-14|Estimate|January 2006||2006-01-31|February 2016|2016-02-29|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||DHA Supplementation and Pregnancy Outcome|Kansas University DHA Outcome Study (KUDOS)|Completed||Phase 3|350|Actual|University of Kansas Medical Center||2|||f||||t||||||||Undecided||2018-06-01 04:16:20.589567|2018-06-01 04:16:20.589567
NCT00266812|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|2009-07-29||2017-05-12|2005-12-16|2005-12-19|Estimate|2009-07-29|2009-09-04|Estimate||||2017-05-12|2017-06-08|Actual|March 8, 2005|Actual|2005-03-08|May 2017|2017-05-31|January 16, 2008|Actual|2008-01-16|January 16, 2008|Actual|2008-01-16||Interventional|||Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)|Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy Followed by Sequential TMZ in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Central Nervous System (CNS) Metastasis Versus Radiotherapy Alone|Terminated||Phase 2|35|Actual|Merck Sharp & Dohme Corp.||2||Patient target could not be reached within the planned timeframe.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:16:20.98051|2018-06-01 04:16:20.98051
NCT00266799|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2011-10-10||2017-05-12|2005-12-15|2005-12-19|Estimate|2011-10-10|2011-11-16|Estimate||||2017-05-12|2017-06-08|Actual|January 13, 2006|Actual|2006-01-13|May 2017|2017-05-31|October 18, 2010|Actual|2010-10-18|September 29, 2010|Actual|2010-09-29||Interventional|||The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)|A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (PELICAN Trial)|Completed||Phase 3|210|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:16:21.285132|2018-06-01 04:16:21.285132
NCT00266786|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2017-02-06|2005-12-16|2005-12-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2005||2005-12-31|February 2017|2017-02-28||||February 2007|Actual|2007-02-28||Interventional|||Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery|A Phase 3, Double-Blind, Randomized Study of the Safety, Tolerability, and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine Administered Intranasally for Postoperative Pain Following Major Abdominal Surgery|Completed||Phase 3|321|Actual|Egalet Ltd||2|||f||||||||||||||2018-06-01 04:16:22.274929|2018-06-01 04:16:22.274929
NCT00266773|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2013-02-15|2005-12-16|2005-12-19|Estimate|||||||2013-02-15|2013-02-18|Estimate|November 2005||2005-11-30|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Telephone Feedback System for Prevention of Chronic Pain Relapse|Therapeutic Interactive Voice Response (IVR) for Relapse Prevention in Chronic Pain|Completed||N/A|158|Actual|University of Vermont||3|||f||||t||||||||||2018-06-01 04:16:22.362327|2018-06-01 04:16:22.362327
NCT00266760|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2010-07-14|2005-12-16|2005-12-19|Estimate|||||||2010-07-14|2010-07-16|Estimate|May 2006||2006-05-31|July 2010|2010-07-31|July 2011|Anticipated|2011-07-31|July 2011|Anticipated|2011-07-31||Observational|||Characteristics of Episodic Ataxia Syndrome|Episodic Ataxia Syndrome: Genotype-phenotype Correlation and Longitudinal Study|Unknown status|Active, not recruiting||125|Anticipated|Office of Rare Diseases (ORD)|||||f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 04:16:22.436409|2018-06-01 04:16:22.436409
NCT00266747|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2009-03-10|2005-12-16|2005-12-19|Estimate|||||||2009-03-10|2009-03-12|Estimate|December 2005||2005-12-31|March 2009|2009-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|AQUARIUS||An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder|An Eight-Week,Dble-Blind,Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder|Completed||Phase 3|366|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:16:22.508899|2018-06-01 04:16:22.508899
NCT00266734|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2010-02-09|2005-12-16|2005-12-19|Estimate|||||||2010-02-09|2010-02-11|Estimate|December 2004||2004-12-31|February 2010|2010-02-28|September 2005||2005-09-30|||||Interventional|||Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears|A Prospective Blinded Multi-center Clinical Trial to Evaluate the Efficacy of the Recently FDA Approved RPS Adeno Detector for Detecting Adenoviral Conjunctivitis|Completed||N/A|186||Rapid Pathogen Screening|||||f||||f||||||||||2018-06-01 04:16:22.590262|2018-06-01 04:16:22.590262
NCT00266721|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2005-12-15|2005-12-15|2005-12-19|Estimate|||||||2005-12-15|2005-12-19|Estimate|January 2000||2000-01-31|December 2000|2000-12-31|October 2000||2000-10-31|||||Interventional|||Efficacy of Pancrelipase on Postprandial Belching and Bloating.||Completed||Phase 3|45||Minneapolis Veterans Affairs Medical Center|||||f||||||||||||||2018-06-01 04:16:22.659486|2018-06-01 04:16:22.659486
NCT00266708|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2012-10-22|2005-12-15|2005-12-19|Estimate|||||||2012-10-22|2012-10-23|Estimate|October 2002||2002-10-31|October 2012|2012-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.|Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant|Completed||N/A|60|Actual|Montefiore Medical Center||2|||f||||||||||||||2018-06-01 04:16:22.72063|2018-06-01 04:16:22.72063
NCT00266695|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2015-12-22|2009-10-16|2016-08-25|2005-12-15|2005-12-19|Estimate|2015-12-22|2016-01-28|Estimate|2009-10-16|2009-10-19|Estimate|2016-08-25|2016-10-06|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||All enrolled participants.|Treatment for Completers of the Study B7A-MC-MBCM|Open-Label Treatment for Patients Completing Study B7A-MC-MBCM|Completed||Phase 3|203|Actual|Chromaderm, Inc.|A participant could have one or both eyes meet the criteria for a diabetic retinopathy (DR) study eye as defined in study B7A-MC-MBCM.|1|||f||||f||||||||||2018-06-01 04:16:22.8056|2018-06-01 04:16:22.8056
NCT00266682|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2006-10-11|2005-12-16|2005-12-19|Estimate|||||||2006-10-11|2006-10-13|Estimate|August 2002||2002-08-31|October 2006|2006-10-31|August 2005||2005-08-31|||||Interventional|||Clinical Investigation of the SelectSecure Pacing Lead|Clinical Investigation of the SelectSecure Pacing Lead|Completed||N/A|365||Medtronic Cardiac Rhythm and Heart Failure|||||||||||||||||||2018-06-01 04:16:23.241379|2018-06-01 04:16:23.241379
NCT00266669|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2007-08-06|2005-12-15|2005-12-19|Estimate|||||||2007-08-06|2007-08-08|Estimate|December 2005||2005-12-31|August 2007|2007-08-31|May 2006||2006-05-31|||||Interventional|||Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon|"Phase III in-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon"|Completed||Phase 3|200||MediQuest Therapeutics|||||||||||||||||||2018-06-01 04:16:23.322588|2018-06-01 04:16:23.322588
NCT00266656|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2016-07-13||2017-03-03|2005-12-15|2005-12-19|Estimate|2016-07-13|2016-08-23|Estimate||||2017-03-03|2017-03-31|Actual|December 2005||2005-12-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All enrolled/started participants.|Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome|Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome|Completed||Phase 4|69|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:16:23.602638|2018-06-01 04:16:23.602638
NCT00266643|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2007-08-01|2005-12-15|2005-12-19|Estimate|||||||2007-08-01|2007-08-03|Estimate|December 2005||2005-12-31|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain|A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain|Completed||Phase 4|205||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:16:24.413099|2018-06-01 04:16:24.413099
NCT00266630|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2010-05-26||2010-12-10|2005-12-15|2005-12-19|Estimate|2010-05-26|2010-06-29|Estimate||||2010-12-10|2010-12-28|Estimate|November 2005||2005-11-30|December 2010|2010-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder|Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder|Completed||Phase 3|139|Actual|Eli Lilly and Company|Identified errors were corrected.|2|||f||||||||||||||2018-06-01 04:16:24.535416|2018-06-01 04:16:24.535416
NCT00266617|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2011-05-17|2005-12-16|2005-12-19|Estimate|||||||2011-05-17|2011-05-18|Estimate||||April 2010|2010-04-30|June 1990|Actual|1990-06-30|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy|The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Chemotherapy|Completed||Phase 2|86|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:16:25.271878|2018-06-01 04:16:25.271878
NCT00266604|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2011-06-08|2005-12-16|2005-12-19|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 2005||2005-12-31|April 2010|2010-04-30|June 2007|Actual|2007-06-30|||||Interventional|||A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy|TOPAMAX� (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX� as Monotherapy in the Treatment of Epilepsy in Clinical Practice|Completed||Phase 4|409|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:16:25.341472|2018-06-01 04:16:25.341472
NCT00266591|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2011-06-06|2005-12-16|2005-12-19|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 1992||1992-10-31|January 2011|2011-01-31|April 1997|Actual|1997-04-30|||||Interventional|||A Study of the Efficacy and Safety of Topiramate Treatment in Patients With Epilepsy|Single Center TOPAMAX� (Topiramate) Monotherapy Trial in Subjects With Refractory Partial Onset Seizures|Completed||Phase 3|51|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:16:25.398531|2018-06-01 04:16:25.398531
NCT00266578|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2013-04-10|2005-12-15|2005-12-19|Estimate|||||||2013-04-10|2013-04-11|Estimate|October 2002||2002-10-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|November 2006|Actual|2006-11-30||Interventional|||A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders|Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial|Completed||Phase 3|30|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||||||||||||2018-06-01 04:16:25.446591|2018-06-01 04:16:25.446591
NCT00266565|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2017-01-20|2005-12-15|2005-12-19|Estimate|||||||2017-01-20|2017-01-23|Estimate|December 2001||2001-12-31|January 2017|2017-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome|A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes|Completed||Phase 1/Phase 2|24|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 04:16:25.511428|2018-06-01 04:16:25.511428
NCT00266552|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2011-01-20|2005-12-16|2005-12-19|Estimate|||||||2011-01-20|2011-01-24|Estimate||||January 2011|2011-01-31|October 1998|Actual|1998-10-31|||||Interventional|||A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation|The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years|Completed||Phase 3|118|Actual|Janssen Pharmaceutica N.V., Belgium|||||||||||||||||||2018-06-01 04:16:25.566741|2018-06-01 04:16:25.566741
NCT00266539|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2011-05-18|2005-12-16|2005-12-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|April 2004||2004-04-30|April 2010|2010-04-30|April 2005|Actual|2005-04-30|||||Interventional|||A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Scheduled Abdominal or Pelvic Surgery: The Fentanyl Transdermal System Versus the Morphine Intravenous Pump|Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by Fentanyl HCl Transdermal System Versus Morphine IV Pump for Pain Management After Non-emergent Abdominal or Pelvic Surgery|Completed||Phase 3|506|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:16:25.619649|2018-06-01 04:16:25.619649
NCT00265980|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2015-03-30|2005-12-14|2005-12-15|Estimate|||||||2015-03-30|2015-04-01|Estimate|July 2002||2002-07-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|September 2015|Anticipated|2015-09-30||Interventional|||Leptin in Human Energy and Neuroendocrine Homeostasis|Leptin in Human Energy and Neuroendocrine Homeostasis|Unknown status|Active, not recruiting|N/A|60|Anticipated|Columbia University||5|||f||||t||||||||||2018-06-01 04:16:34.23141|2018-06-01 04:16:34.23141
NCT00266526|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2013-03-01|2005-12-16|2005-12-19|Estimate|||||||2013-03-01|2013-03-04|Estimate|July 2003||2003-07-31|March 2013|2013-03-31|July 2005|Actual|2005-07-31|July 2004|Actual|2004-07-31||Interventional|||Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV|A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen|Completed||Phase 2|||Allergopharma GmbH & Co. KG|||||f||||||||||||||2018-06-01 04:16:25.669168|2018-06-01 04:16:25.669168
NCT00266513|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2017-10-05|2005-12-15|2005-12-16|Estimate|||||||2017-10-05|2017-10-06|Actual|December 14, 2005||2005-12-14|July 11, 2013|2013-07-11|July 11, 2013||2013-07-11|||||Observational|||Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States|Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States|Terminated|||119|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:16:25.717185|2018-06-01 04:16:25.717185
NCT00266500|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-16|||2018-05-12|2005-12-15|2005-12-16|Estimate|||||||2018-05-12|2018-05-15|Actual|December 12, 2005||2005-12-12|October 28, 2014|2014-10-28|October 28, 2014||2014-10-28|||||Observational|||Body Heat Content and Dissipation in Obese and Normal Weight Adults|Body Heat Content and Dissipation in Obese and Normal Weight Adults|Completed|||80|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:16:25.768989|2018-06-01 04:16:25.768989
NCT00266487|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2017-05-03|2005-12-15|2005-12-16|Estimate|||||||2017-05-03|2017-05-08|Actual|December 1998||1998-12-31|May 2017|2017-05-31|March 2004||2004-03-31|||||Interventional|||The Norwegian Vitamin Trial (NORVIT)|Randomized Trial of Homocysteine-lowering With B Vitamins for Secondary Prevention of Cardiovascular Disease After Acute Myocardial Infarction. The Norwegian Vitamin Trial (NORVIT)|Completed||N/A|3750||University of Tromso|||||f||||t|f|f||||||No||2018-06-01 04:16:25.824853|2018-06-01 04:16:25.824853
NCT00266474|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2014-12-03|2005-12-15|2005-12-16|Estimate|||||||2014-12-03|2014-12-04|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|September 2007|Actual|2007-09-30|||||Observational|||Prevalence of Chronic Rhinosinusitis in Cystic Fibrosis|Prevalence of Chronic Rhinosinusitis in Cystic Fibrosis|Completed|||187|Actual|University of Jena|||1||f||||||||||Samples With DNA|"~     Pseudomonas aeruginosa and Staphylococcus aureus cultures (SNPS)~   "|||2018-06-01 04:16:26.04913|2018-06-01 04:16:26.04913
NCT00266461|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14||2013-07-11|2013-07-11|2005-12-14|2005-12-16|Estimate||||2013-07-11|2013-07-12|Estimate|2013-07-11|2013-07-12|Estimate|December 2005||2005-12-31|June 2012|2012-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Tolerability and Efficacy Study of TU-100 For The Treatment of Postoperative Ileus|A Randomized, Controlled, Open-Label Tolerability And Efficacy Study Of TU-100 For The Treatment Of Postoperative Ileus In Patients Undergoing Laparotomy For Large Bowel Resection|Completed||Phase 2|24|Actual|Tsumura USA||3|||f||||f||||||||||2018-06-01 04:16:26.11829|2018-06-01 04:16:26.11829
NCT00266448|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2005-12-15|2005-12-15|2005-12-16|Estimate|||||||2005-12-15|2005-12-16|Estimate|January 2001||2001-01-31|April 2004|2004-04-30|April 2004||2004-04-30|||||Interventional|||Whole Body Washing With Chlorhexidine for the Eradication of MRSA|The Value of Whole Body Washing With Chlorhexidine for the Eradication of MRSA – a Randomized, Placebo-Controlled, Double-Blinded Clinical Trial|Completed||Phase 2|100||Heidelberg University|||||f||||||||||||||2018-06-01 04:16:26.193469|2018-06-01 04:16:26.193469
NCT00266435|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2008-03-25|2005-12-15|2005-12-16|Estimate|||||||2008-03-25|2008-03-26|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||The Usefulness of the HyperQ Stress System in Routine Annual Screening Testing|The Usefulness of the HyperQ Stress System in Routine Annual Screening Testing|Completed|||371|Actual|Sheba Medical Center|||||f||||||||||||||2018-06-01 04:16:26.249692|2018-06-01 04:16:26.249692
NCT00266422|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2006-01-28|2005-12-15|2005-12-16|Estimate|||||||2006-01-28|2006-01-31|Estimate|January 2005||2005-01-31|January 2006|2006-01-31|December 2005||2005-12-31|||||Observational|||Neurological Outcome of VLBW Infants With Early Hypotension||Completed|||250||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:16:26.294523|2018-06-01 04:16:26.294523
NCT00266409|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2009-05-05||2014-10-17|2005-12-15|2005-12-16|Estimate|2009-08-25|2009-10-02|Estimate||||2014-10-17|2014-10-27|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder|A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder|Completed||Phase 4|418|Actual|UCB Pharma|Originally it was planned to enrol and randomize 848 subjects. The smaller than planned sample size was a result of an unusually high rate of screening failure (results published in Psychiatry 2006, Vol. 3, Issue 12 , pages 39 - 59).|4|||f||||||||||||||2018-06-01 04:16:26.498225|2018-06-01 04:16:26.498225
NCT00266396|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2016-04-04|2005-12-15|2005-12-16|Estimate|||||||2016-04-04|2016-04-06|Estimate|January 2002||2002-01-31|April 2016|2016-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Weight-bearing Recommendation After Replacement of the Hip or Knee Joint|A Randomized Trial of Weight-bearing Recommendations After Total Hip or Total Knee Arthroplasty|Completed||Phase 1/Phase 2|352||Verein zur Förderung der Rehabilitationsforschung in Schleswig-Holstein||1|||f||||t||||||||No||2018-06-01 04:16:29.253208|2018-06-01 04:16:29.253208
NCT00266383|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2005-12-16|2005-12-15|2005-12-16|Estimate|||||||2005-12-16|2005-12-19|Estimate|January 2005||2005-01-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Observational|||The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population|The Molecular Mechanism and the Role of NRAMP 1gene on Tuberculosis in Taiwan Aboriginal Tribes Population|Completed|||250||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:16:29.321563|2018-06-01 04:16:29.321563
NCT00266370|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2005-12-16|2005-12-15|2005-12-16|Estimate|||||||2005-12-16|2005-12-19|Estimate|January 2005||2005-01-31|December 2005|2005-12-31|December 2009||2009-12-31|||||Observational|||A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma|A Pathology Reference Laboratory for the Study of Infectious Diseases and Malignant Lymphoma|Unknown status|Recruiting||100||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:16:29.361904|2018-06-01 04:16:29.361904
NCT00266357|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2015-01-13|2005-12-14|2005-12-16|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2005||2005-11-30|January 2015|2015-01-31||||March 2007|Actual|2007-03-31||Interventional|||Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)|MK0928 Phase II Sleep Laboratory Study - Primary Insomnia|Terminated||Phase 2|50||H. Lundbeck A/S|||||f||||||||||||||2018-06-01 04:16:29.409177|2018-06-01 04:16:29.409177
NCT00266344|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2015-01-13|2005-12-14|2005-12-16|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2005||2005-11-30|January 2015|2015-01-31|October 2006|Actual|2006-10-31|||||Interventional|||MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)|MK0928 Phase IIb Dose-range Finding Study -Primary Insomnia|Completed||Phase 2|520||H. Lundbeck A/S|||||f||||||||||||||2018-06-01 04:16:29.459421|2018-06-01 04:16:29.459421
NCT00266331|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2013-08-27|2005-12-14|2005-12-16|Estimate|||||||2013-08-27|2013-08-28|Estimate|October 2004||2004-10-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||RayGel-An Alternative for Skin Care During External Beam Radiation|Prospective Blinded Randomized Study; RayGel Versus Placebo-an Alternative for Skin Care During External Beam Radiation.|Completed||Phase 2|150|Actual|Legacy Health System||2|||f||||t||||||||||2018-06-01 04:16:29.511623|2018-06-01 04:16:29.511623
NCT00266318|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2008-04-16|2005-12-14|2005-12-16|Estimate|||||||2008-04-16|2008-04-17|Estimate|December 2005||2005-12-31|April 2008|2008-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy|A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy|Completed||Phase 4|40||Beth Israel Medical Center|||||||||||||||||||2018-06-01 04:16:29.579751|2018-06-01 04:16:29.579751
NCT00266305|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2008-08-12|2005-12-15|2005-12-16|Estimate|||||||2008-08-12|2008-08-14|Estimate|December 1998||1998-12-31|August 2008|2008-08-31|January 2007||2007-01-31|||||Interventional|||Fish Oil Supplementation in Lactation||Completed||N/A|150||University of Copenhagen||3|||f||||||||||||||2018-06-01 04:16:29.710323|2018-06-01 04:16:29.710323
NCT00266292|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2010-05-27|2005-12-15|2005-12-16|Estimate|||||||2010-05-27|2010-05-28|Estimate|September 2005||2005-09-30|December 2005|2005-12-31|April 2006||2006-04-30|||||Interventional|||The Effect of n-3 LCPUFA on Immune Function and Cardiovascular Risk Factors||Unknown status|Active, not recruiting|N/A|60||University of Copenhagen|||||f||||||||||||||2018-06-01 04:16:29.808025|2018-06-01 04:16:29.808025
NCT00266279|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|2013-05-03||2017-12-27|2005-12-15|2005-12-16|Estimate|2014-10-30|2014-10-31|Estimate||||2017-12-27|2017-12-29|Actual|April 2005||2005-04-30|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies|Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies|Completed||Phase 2|17|Actual|University of Louisville|Results data not available, PI not longer at institution|1|||f||||t||||||||||2018-06-01 04:16:29.898928|2018-06-01 04:16:29.898928
NCT00266266|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2017-12-27|2005-12-15|2005-12-16|Estimate|||||||2017-12-27|2017-12-29|Actual|January 2004||2004-01-31|December 2017|2017-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|HPV||Human Papilloma Virus DNA Self-Test|Human Papilloma Virus DNA Self-Test|Completed|||171|Actual|University of Louisville|||||f||||t||||||||||2018-06-01 04:16:30.056832|2018-06-01 04:16:30.056832
NCT00266253|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2016-11-01|2005-12-15|2005-12-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2005||2005-11-30|November 2016|2016-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin|A Randomized Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.|Completed||Phase 2|220|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 04:16:30.135025|2018-06-01 04:16:30.135025
NCT00266240|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2016-11-01|2005-12-15|2005-12-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2005||2005-11-30|November 2016|2016-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|267|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-06-01 04:16:30.295182|2018-06-01 04:16:30.295182
NCT00266227|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2008-10-24||2013-09-20|2005-12-14|2005-12-16|Estimate|2009-03-31|2009-05-25|Estimate||||2013-09-20|2013-10-25|Estimate|January 2006||2006-01-31|September 2013|2013-09-30||||October 2007|Actual|2007-10-31||Interventional|SUNRISE||A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate|Completed||Phase 3|559|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 04:16:30.460485|2018-06-01 04:16:30.460485
NCT00266214|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2011-06-13|2005-12-15|2005-12-16|Estimate|||||||2011-06-13|2011-06-14|Estimate|November 2005||2005-11-30|June 2011|2011-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome|A Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine Patch 5% With Placebo in Patients With Pain From Carpal Tunnel Syndrome|Terminated||Phase 3|210|Actual|Endo Pharmaceuticals||2||Sponsor decision|f||||||||||||||2018-06-01 04:16:31.245825|2018-06-01 04:16:31.245825
NCT00266201|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2011-08-17|2005-12-15|2005-12-16|Estimate|||||||2011-08-17|2011-08-18|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Observational|||Right Ventricular Failure in Congenital Heart Defects|Evaluation of Biochemical Markers of Neurohumoral Activity and Correlation With Clinically Significant Parameters in Patients With Right Ventricular Failure and Congenital Heart Defects|Completed|||150||Competence Network for Congenital Heart Defects|||||f||||f||||||||||2018-06-01 04:16:31.319269|2018-06-01 04:16:31.319269
NCT00266188|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2011-09-20|2005-12-15|2005-12-16|Estimate|||||||2011-09-20|2011-09-21|Estimate|January 2005||2005-01-31|September 2011|2011-09-30|June 2008|Actual|2008-06-30|||||Observational|||Follow up of Post-repair Tetralogy of Fallot|Non-invasive Imaging and Exercise Tolerance Tests in Post-repair Tetralogy of Fallot - Intervention and Course in Patients Over 8 Years Old|Completed|||406|Actual|Competence Network for Congenital Heart Defects|||||f||||f||||||||||2018-06-01 04:16:31.375116|2018-06-01 04:16:31.375116
NCT00266175|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2008-10-14|2005-12-15|2005-12-16|Estimate|||||||2008-10-14|2008-10-15|Estimate|May 2005||2005-05-31|October 2008|2008-10-31|July 2008|Actual|2008-07-31|||||Observational|||Pulmonary Arteriopathy-Diagnostics and Therapy|Pulmonary Arteriopathy; Evaluation of Invasive Treatments of Peripheral Pulmonary Stenosis in Terms of Right Ventricular Function and Patient Exercise Tolerance|Completed|||53|Actual|Competence Network for Congenital Heart Defects|||||f||||f||||||||||2018-06-01 04:16:31.441251|2018-06-01 04:16:31.441251
NCT00266162|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-15|||2008-05-06|2005-12-15|2005-12-16|Estimate|||||||2008-05-06|2008-05-07|Estimate|August 2004||2004-08-31|May 2008|2008-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Bosentan in Treatment of Pulmonary Arterial Hypertension|Therapy of Pulmonary Arterial Hypertension (PAH) With Bosentan in Patients With Eisenmenger Syndrome|Completed||Phase 4|60||Competence Network for Congenital Heart Defects|||||f||||f||||||||||2018-06-01 04:16:31.501774|2018-06-01 04:16:31.501774
NCT00266149|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2008-04-23|2005-12-14|2005-12-15|Estimate|||||||2008-04-23|2008-04-24|Estimate|June 2003||2003-06-30|December 2005|2005-12-31|May 2005||2005-05-31|||||Interventional|||Lamotrigine and Oral Contraceptives|Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives|Terminated||Phase 3|10||University of Aarhus|||||f||||||||||||||2018-06-01 04:16:31.564082|2018-06-01 04:16:31.564082
NCT00266136|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2012-10-25|2005-12-14|2005-12-15|Estimate|||||||2012-10-25|2012-10-26|Estimate|June 1999||1999-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|January 2007|Actual|2007-01-31||Interventional|||Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)|Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose Chemotherapy With Stem Cell Transplantation|Completed||Phase 3|3500|Actual|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:16:31.746148|2018-06-01 04:16:31.746148
NCT00266123|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2007-12-18|2005-12-14|2005-12-15|Estimate|||||||2007-12-18|2007-12-27|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients|A Randomized Open-Label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens With a Tacrolimus + Mycophenolate Mofetil Regimen in De Novo Renal Allograft Recipients|Completed||Phase 4|420||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:16:31.812939|2018-06-01 04:16:31.812939
NCT00266110|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|2017-03-28||2017-05-10|2005-12-13|2005-12-15|Estimate|2017-03-28|2017-05-09|Actual||||2017-05-10|2017-06-09|Actual|December 2005||2005-12-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|February 2013|Actual|2013-02-28||Interventional|||Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|Phase II Trial Evaluating the Toxicity and Efficacy of a Multiepitope Dendritic Cell Vaccine Given With Trastuzumab and Vinorelbine Ditartrate for the Treatment of Women With Metastatic Breast Cancer That Express HLA-A0201 and Whose Tumors Overexpress HER-2/NEU|Active, not recruiting||Phase 2|17|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:16:31.881908|2018-06-01 04:16:31.881908
NCT00266097|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2012-03-05|2005-12-13|2005-12-15|Estimate|||||||2012-03-05|2012-03-07|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|September 2011|Actual|2011-09-30|March 2009|Actual|2009-03-31||Interventional|||Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer|A Two-Part Phase I Study of the Addition of Oxaliplatin to Gemcitabine, and Then Erlotinib Plus Oxaliplatin to Gemcitabine as Radiosensitizers for Pancreatic and Biliary Adenocarcinoma|Completed||Phase 1|23|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:16:32.064999|2018-06-01 04:16:32.064999
NCT00266084|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2016-05-10|2005-12-14|2005-12-15|Estimate|||||||2016-05-10|2016-05-11|Estimate|August 1999||1999-08-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Observational|||Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix|Double-Blinded Multicenter Clinical Study Assessing the Equivalence of the InPath Cervical Cell Collector to the Standard Endocervical Brush and Spatula in Patients Seeking Primary Pap Screening or Follow-up Screening|Completed|||85||University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-06-01 04:16:32.18177|2018-06-01 04:16:32.18177
NCT00266071|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2005-12-14|2005-12-14|2005-12-15|Estimate|||||||2005-12-14|2005-12-15|Estimate|December 2005||2005-12-31|December 2005|2005-12-31||||||||Observational|||Study of the Cutaneous Microcirculation in Elderly People||Unknown status|Not yet recruiting||||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:16:32.264303|2018-06-01 04:16:32.264303
NCT00266058|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2013-06-04|2005-12-14|2005-12-15|Estimate|||||||2013-06-04|2013-06-06|Estimate|December 2005||2005-12-31|May 2013|2013-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Drug Interaction Study Between Antimalarial and Anti-HIV Medications|Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine|Completed||Phase 1|33|Actual|University of California, San Francisco||2|||f||||||||||||||2018-06-01 04:16:32.316295|2018-06-01 04:16:32.316295
NCT00266045|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2012-08-31|2005-12-13|2005-12-15|Estimate|||||||2012-08-31|2012-09-05|Estimate|August 2005||2005-08-31|August 2012|2012-08-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Observational|||D-dimer Levels During and After Anticoagulation in Patients With a Previous Venous Thromboembolism: Effects on the Risk of Recurrence|A Multicentre, Prospective, Observational Study on the Predictive Role for Recurrence of D-dimer Levels Measured During and After Anticoagulation in Patients With a First Venous Thromboembolism Episode (the PROLONG-II Study)|Completed|||355|Actual|St. Orsola Hospital|||||f||||||||||Samples Without DNA|"~     Plasma samples for D-dimer assays or other coagulation tests~   "|||2018-06-01 04:16:32.397752|2018-06-01 04:16:32.397752
NCT00266032|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2009-10-28||2014-10-27|2005-12-14|2005-12-15|Estimate|2010-02-02|2010-03-03|Estimate||||2014-10-27|2014-11-03|Estimate|December 2005||2005-12-31|October 2014|2014-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles|A Multicenter, Open, Randomized, Parallel Group Comparison to Assess the Safety and Efficacy of the Oral Contraceptive SH T00186D (0.02 mg Ethinylestradiol as Betadex Clathrate and 3 mg Drospirenone) in Two Variations of an Extended Regimen vs. a Standard Regimen (24 + 4 Days) in 1122 Healthy Female Volunteers for One Year, Followed by a One Year Safety Extension|Completed||Phase 3|1166|Actual|Bayer|Data for center no. 1148 was included in “all randomized” set of subjects, but not in FAS, as during medical monitoring of laboratory data a suspicion of potential misconduct was found. An audit was made, but the suspicion could not be resolved.|3|||f||||f||||||||||2018-06-01 04:16:32.460019|2018-06-01 04:16:32.460019
NCT00266019|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2010-01-12|2005-12-14|2005-12-15|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Weight Management in Nonalcoholic Steatohepatitis|Weight Management in Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 2|30|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:16:34.052582|2018-06-01 04:16:34.052582
NCT00266006|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2016-11-16|2005-12-14|2005-12-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2006||2006-01-31|November 2016|2016-11-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Factor VIIa in Acute Intracerebral Haemorrhage|Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.|Completed||Phase 2|90|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:16:34.11811|2018-06-01 04:16:34.11811
NCT00265993|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2010-02-02|2005-12-14|2005-12-15|Estimate|||||||2010-02-02|2010-02-03|Estimate|December 2004||2004-12-31|February 2010|2010-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Enoxaparin in Acute Venous Thromboembolic Disease|The Efficacy of Subcutaneous Enoxaparin Once Daily in the Treatment of Acute Venous Thromboembolic Disease: an Open-labelled, Non-comparative, Multicentric, Phase IV Trial|Completed||Phase 4|251|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:16:34.17468|2018-06-01 04:16:34.17468
NCT00265967|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2009-12-04|2005-12-14|2005-12-15|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 2005||2005-09-30|December 2009|2009-12-31||||February 2007|Actual|2007-02-28||Interventional|||Irbesartan in Hypertension|Missed Dose Effect of Irbesartan in Hypertensive Patients and Cardiovascular Risk Profile Monitoring Under Irbesartan Treatment|Completed||Phase 4|88|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:16:34.3075|2018-06-01 04:16:34.3075
NCT00265954|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2010-01-21|2005-12-14|2005-12-15|Estimate|||||||2010-01-21|2010-01-22|Estimate|February 2006||2006-02-28|January 2010|2010-01-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|iReach||Internet Assisted Obesity Treatment|A Randomized Trial of an Internet Versus In-person Behavioral Weight Loss Treatment Program.|Completed||Phase 3|488|Anticipated|University of Vermont||3|||f||||||||||||||2018-06-01 04:16:35.118224|2018-06-01 04:16:35.118224
NCT00265941|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2017-09-26||2017-12-20|2005-12-14|2005-12-15|Estimate|2017-12-20|2017-12-21|Actual||||2017-12-20|2017-12-21|Actual|November 2005||2005-11-30|December 2017|2017-12-31||||January 2011|Actual|2011-01-31||Interventional||Eligible patients with follow-up|Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas|Active, not recruiting||Phase 3|940|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 04:16:35.36316|2018-06-01 04:16:35.36316
NCT00265928|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2008-01-24|2005-12-14|2005-12-15|Estimate|||||||2008-01-24|2008-01-28|Estimate||||January 2007|2007-01-31||||||||Interventional|||Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma|VELCADE (Bortezomib) for Injection - Phase II Study of Bortezomib and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma|Terminated||Phase 2|46|Anticipated|National Cancer Institute (NCI)||||Withdrawn for poor accrual|f||||||||||||||2018-06-01 04:16:37.608794|2018-06-01 04:16:37.608794
NCT00265915|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2014-08-11|2005-12-14|2005-12-15|Estimate|||||||2014-08-11|2014-08-12|Estimate|July 2005||2005-07-31|August 2014|2014-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia|A CRC Trial of Rituximab in Combination With Sargramostim (GM-CSF) in Patients With Chronic Lymphocytic Leukemia|Terminated||Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:16:37.682096|2018-06-01 04:16:37.682096
NCT00265902|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2009-02-06|2005-12-14|2005-12-15|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2004||2004-11-30|June 2006|2006-06-30||||||||Interventional|||Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma|Ultra-Sensitive, Infra-Red Thermographic Analysis of Kaposi's Sarcoma Skin Lesions|Unknown status|Active, not recruiting|N/A|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:16:37.749569|2018-06-01 04:16:37.749569
NCT00265889|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2013-06-10||2013-10-28|2005-12-14|2005-12-15|Estimate|2013-06-10|2013-08-26|Estimate||||2013-10-28|2013-11-20|Estimate|February 2002||2002-02-28|October 2013|2013-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma|Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Poor Risk Recurrent Hodgkin's Disease|Completed||Phase 2|42|Actual|Case Comprehensive Cancer Center||2|||f||||f||||||||||2018-06-01 04:16:37.820847|2018-06-01 04:16:37.820847
NCT00265876|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2016-11-25|2005-12-14|2005-12-15|Estimate|||||||2016-11-25|2016-11-28|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase I/II Study of AZD0530 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|34|Actual|Canadian Cancer Trials Group|||||f||||f||||||||||2018-06-01 04:16:38.046242|2018-06-01 04:16:38.046242
NCT00265863|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2017-11-27|2005-12-14|2005-12-15|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2004||2004-08-31|November 2017|2017-11-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites|Phase II Study of Laparoscopic Hyperthermic Peritoneal Chemotherapy for Malignant Ascites|Terminated||Phase 2|1|Actual|Masonic Cancer Center, University of Minnesota||1||Withdrawn due to slow accrual|f||||t||||||||||2018-06-01 04:16:38.115063|2018-06-01 04:16:38.115063
NCT00265850|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2017-03-13||2017-03-13|2005-12-14|2005-12-15|Estimate|2017-03-13|2017-04-26|Actual||||2017-03-13|2017-04-26|Actual|November 2005||2005-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|February 2015|Actual|2015-02-28||Interventional||During the trial, it was learned that KRAS mutation predicted for lack of efficacy of EGFR antibodies; also studies showed no benefit from chemo combined with both Bevacizumab and an EGFR antibody. The trial was amended to 2 arms limited to KRAS wild type patients. Only confirmed and consented KRAS wild type patients were analyzed.|Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum|Active, not recruiting||Phase 3|2334|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-06-01 04:16:38.516958|2018-06-01 04:16:38.516958
NCT00265837|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2014-04-16|2005-12-14|2005-12-15|Estimate|||||||2014-04-16|2014-04-17|Estimate|December 2002||2002-12-31|April 2014|2014-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer|Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation|Completed||Phase 3|72|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||||||||||||||||2018-06-01 04:16:40.69993|2018-06-01 04:16:40.69993
NCT00265824|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2015-12-10|2005-12-14|2005-12-15|Estimate|||||||2015-12-10|2015-12-11|Estimate|May 2005||2005-05-31|March 2014|2014-03-31||||March 2012|Actual|2012-03-31||Interventional|DREAM||Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)|Phase III Study of an Optimized Chemotherapy Followed by Maintenance With Bevacizumab Strategy With or Without Erlotinib in Unresectable Metastatic Colorectal Cancer. DREAM OPTIMOX 3. C04-2|Completed||Phase 3|700|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||f||||||||||2018-06-01 04:16:40.783332|2018-06-01 04:16:40.783332
NCT00265811|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2016-05-26|2005-12-14|2005-12-15|Estimate|||||||2016-05-26|2016-05-30|Estimate|November 2005||2005-11-30|December 2006|2006-12-31||||November 2009|Actual|2009-11-30||Interventional|||Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery|Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab|Completed||Phase 3|2559|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||||2018-06-01 04:16:40.980058|2018-06-01 04:16:40.980058
NCT00265798|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2013-12-06||2018-04-10|2005-12-14|2005-12-15|Estimate|2013-12-06|2014-01-21|Estimate||||2018-04-10|2018-05-09|Actual|September 14, 2005|Actual|2005-09-14|March 2018|2018-03-31||||February 11, 2010|Actual|2010-02-11||Interventional|||Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate|A Phase 2 Study of BAY 43-9006 for Imatinib- and Sunitinib Resistant Gastrointestinal Stromal Tumor|Active, not recruiting||Phase 2|38|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:16:41.0773|2018-06-01 04:16:41.0773
NCT00265785|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2012-07-12||2012-10-03|2005-12-14|2005-12-15|Estimate|2012-10-03|2012-11-01|Estimate||||2012-10-03|2012-11-01|Estimate|July 2006||2006-07-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Pemetrexed in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)|Terminated||Phase 2|27|Actual|Southwest Oncology Group||1||Closed due to poor accrual|f||||t||||||||||2018-06-01 04:16:41.300715|2018-06-01 04:16:41.300715
NCT00265772|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2005-12-14|2005-12-14|2005-12-15|Estimate|||||||2005-12-14|2005-12-15|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|April 2008||2008-04-30|||||Interventional|||Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis|Phase IV Study Comparing a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis|Unknown status|Recruiting|Phase 4|24||Hôpital Necker-Enfants Malades|||||f||||||||||||||2018-06-01 04:16:41.887142|2018-06-01 04:16:41.887142
NCT00265759|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|2017-02-14||2018-04-06|2005-12-14|2005-12-15|Estimate|2017-02-14|2017-03-30|Actual||||2018-04-06|2018-05-08|Actual|January 2006||2006-01-31|April 2018|2018-04-30||||August 2012|Actual|2012-08-31||Interventional|||Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer|A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer|Active, not recruiting||Phase 3|622|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-06-01 04:16:42.013364|2018-06-01 04:16:42.013364
NCT00265746|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2006-02-27|2005-12-14|2005-12-15|Estimate|||||||2006-02-27|2006-02-28|Estimate|November 2005||2005-11-30|December 2005|2005-12-31||||||||Interventional|||Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes|Program for the Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes. Evaluation of the Efficacy of the Life-Style Modification and the Life-Style Modification in Conjunction With Metformin, in the Prevention of Diabetes Mellitus Development in a Population of Women Who Had Expired a Gestational Diabetes - a Multicenter, Randomized, Double Blind Study.|Unknown status|Recruiting|Phase 4|300||Medical Universtity of Lodz|||||f||||||||||||||2018-06-01 04:16:43.471246|2018-06-01 04:16:43.471246
NCT00265733|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2016-12-02|2005-12-14|2005-12-15|Estimate|||||||2016-12-02|2016-12-06|Estimate|February 2006||2006-02-28|December 2016|2016-12-31|May 2013|Actual|2013-05-31|August 2007|Actual|2007-08-31||Interventional|||Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer|Phase II Trial of CT-2103 (Xyotax™) With Capecitabine as First-Line Chemotherapy for Patients With Metastatic Breast Cancer|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:16:43.529173|2018-06-01 04:16:43.529173
NCT00265720|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2009-02-03|2005-12-13|2005-12-15|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2003||2003-03-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Colorectal Cancer Screening Intervention Trial|Research on Community Cancer Control: Study of Colorectal Cancer Screening in the African American Population|Completed||N/A|360|Actual|Morehouse School of Medicine||4|||f||||f||||||||||2018-06-01 04:16:43.609464|2018-06-01 04:16:43.609464
NCT00265707|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2006-10-06|2005-12-14|2005-12-15|Estimate|||||||2006-10-06|2006-10-09|Estimate|September 2005||2005-09-30|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Evaluation of a New Blood Pressure Measuring Device.|A Study to Evaluate the Safety and Effectiveness (Overall Performance) of the Press-O-Sense Non-Invasive Blood Pressure Measuring Device.|Unknown status|Recruiting|N/A|120||Maaynei Hayesha Medical Center|||||f||||||||||||||2018-06-01 04:16:43.670406|2018-06-01 04:16:43.670406
NCT00265694|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2005-12-14|2005-12-14|2005-12-15|Estimate|||||||2005-12-14|2005-12-15|Estimate||||June 2005|2005-06-30||||||||Interventional|||Random Trial for Elderly Patients With NSCLC|A Randomized Phase III Trial of Vinorelbine Versus Gemcitabine and Carboplatin for Elderly Patients With Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 3|||Inje University|||||f||||||||||||||2018-06-01 04:16:43.722356|2018-06-01 04:16:43.722356
NCT00265681|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2007-04-03|2005-12-13|2005-12-15|Estimate|||||||2007-04-03|2007-04-04|Estimate|November 2004||2004-11-30|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Telephone Counseling for Snuff Users|Proactive Telephone Counseling With Rural Smokeless Tobacco Users|Completed||N/A|400||HealthPartners Institute|||||f||||f||||||||||2018-06-01 04:16:43.768964|2018-06-01 04:16:43.768964
NCT00265655|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01||2012-03-21|2012-03-22|2005-12-13|2005-12-15|Estimate||||2012-03-22|2012-03-28|Estimate|2012-03-22|2012-03-28|Estimate|November 2005||2005-11-30|March 2012|2012-03-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Satraplatin for Patients With Metastatic Breast Cancer (MBC)|Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)|Completed||Phase 2|40|Actual|Agennix|||||f||||||||||||||2018-06-01 04:16:43.93334|2018-06-01 04:16:43.93334
NCT00265642|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2014-02-06|2005-12-14|2005-12-15|Estimate|||||||2014-02-06|2014-02-07|Estimate|October 2006||2006-10-31|July 2012|2012-07-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|Fibrosar||Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C|Study of the Effects of a Sartan on Hepatic Fibrosis Progression in Chronic Viral Hepatitis C|Completed||Phase 3|166|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 04:16:43.987737|2018-06-01 04:16:43.987737
NCT00265629|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2013-06-18|2005-12-14|2005-12-15|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 2005||2005-08-31|June 2013|2013-06-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||RF Ablation of Atrial Fibrillation|A Clinical Investigation of Radiofrequency Ablation for the Treatment of Atrial Fibrillation Using the High Density Mesh Bard Ablation System|Completed||Phase 1|20|Actual|C. R. Bard||1|||f||||f||||||||||2018-06-01 04:16:44.067459|2018-06-01 04:16:44.067459
NCT00265616|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|2010-10-27||2013-04-02|2005-12-13|2005-12-15|Estimate|2013-02-22|2013-04-04|Estimate||||2013-04-02|2013-04-09|Estimate|May 2006||2006-05-31|April 2013|2013-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Treatment of Refractory Status Epilepticus|A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus|Terminated||Phase 3|23|Actual|Brigham and Women's Hospital||2||Insufficient recruitment|f||||t||||||||||2018-06-01 04:16:44.134206|2018-06-01 04:16:44.134206
NCT00265603|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2014-01-15|2005-12-14|2005-12-15|Estimate|||||||2014-01-15|2014-01-16|Estimate|October 2004||2004-10-31|January 2014|2014-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer|Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer|Terminated||Phase 1|16|Anticipated|Atlantic Health System||1|||f||||t||||||||||2018-06-01 04:16:44.373997|2018-06-01 04:16:44.373997
NCT00265590|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-14|||2017-06-30|2005-12-13|2005-12-14|Estimate|||||||2017-06-30|2017-07-02|Actual|December 7, 2005||2005-12-07|October 3, 2008|2008-10-03|October 3, 2008||2008-10-03|||||Observational|||Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia|Phenotype-Genotype Correlation in Aniridia|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:16:44.491729|2018-06-01 04:16:44.491729
NCT00265564|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2014-11-06|2005-12-13|2005-12-14|Estimate|||||||2014-11-06|2014-11-07|Estimate|July 2006||2006-07-31|November 2014|2014-11-30|July 2011|Actual|2011-07-31|April 2011|Actual|2011-04-30||Interventional|||SUPER Study (Substance Use and PTSD Treatment Effectiveness Research Study)|Effectiveness of Screening and Treatment for PTSD in SUD Patients|Completed||N/A|125|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:16:44.537092|2018-06-01 04:16:44.537092
NCT00265551|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2007-12-07|2005-12-12|2005-12-14|Estimate|||||||2007-12-07|2007-12-10|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Olanzapine-Referenced, Parallel Group Safety, Efficacy, and Tolerability Study of SCA-136 in Subjects With Acute Exacerbations of Schizophrenia|Completed||Phase 2|300||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:16:44.627794|2018-06-01 04:16:44.627794
NCT00265538|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2014-08-06|2005-12-12|2005-12-14|Estimate|||||||2014-08-06|2014-08-08|Estimate|July 2006||2006-07-31|August 2014|2014-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Implementing Evidence Based Treatment of Hypertension|Implementing Evidence-based Treatment of Hypertension|Completed||N/A|900|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:16:44.723066|2018-06-01 04:16:44.723066
NCT00265525|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2015-04-07|2005-12-13|2005-12-14|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2004||2004-11-30|March 2009|2009-03-31|August 2007|Actual|2007-08-31|June 2007|Actual|2007-06-30||Interventional|||Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease.|Evaluation of a Web-Based Intervention to Promote Physical Activity in Patients With Heart Disease: A Randomize Control Trial|Completed||Phase 3|223|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-06-01 04:16:44.800535|2018-06-01 04:16:44.800535
NCT00265512|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2014-10-02||2015-04-06|2005-12-12|2005-12-14|Estimate|2014-10-16|2014-10-17|Estimate||||2015-04-06|2015-04-24|Estimate|November 2006||2006-11-30|July 2014|2014-07-31|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||LINK: Aftercare Monitoring Project|Improving Longterm SUD Outcomes With Telephone Case Monitoring|Completed||N/A|667|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:16:44.879173|2018-06-01 04:16:44.879173
NCT00265499|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2005-12-13|2005-12-13|2005-12-14|Estimate|||||||2005-12-13|2005-12-14|Estimate||||November 2005|2005-11-30||||||||Interventional|||The Internal Thoracic Artery Skeletonization Study: A Paired, Within-Patient Comparison|Skeletonized Versus Non-Skeletonized Internal Thoracic Artery Harvest for Coronary Artery Bypass Grafting|Completed||N/A|48||University of Ottawa|||||f||||||||||||||2018-06-01 04:16:45.049671|2018-06-01 04:16:45.049671
NCT00265486|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2012-05-23|2005-12-12|2005-12-14|Estimate|||||||2012-05-23|2012-05-24|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|July 2012|Anticipated|2012-07-31|June 2012|Anticipated|2012-06-30||Observational|||Can Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?|Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?|Unknown status|Recruiting||12|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:16:45.103852|2018-06-01 04:16:45.103852
NCT00265473|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2011-04-01||2017-01-26|2005-12-12|2005-12-14|Estimate|2011-08-16|2011-09-21|Estimate||||2017-01-26|2017-03-09|Actual|November 2005||2005-11-30|January 2017|2017-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||MGA031, Sirolimus and Tacrolimus in Islet Transplantation|hOKT3γ1 (Ala-Ala), Sirolimus and Low Dose Tacrolimus Therapy in Type 1 Diabetic Islet Allograft Recipients|Completed||Phase 1/Phase 2|5|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|t|f||||||||2018-06-01 04:16:45.17352|2018-06-01 04:16:45.17352
NCT00265460|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2009-09-14|2005-12-13|2005-12-14|Estimate|||||||2009-09-14|2009-09-15|Estimate|March 2005||2005-03-31|September 2009|2009-09-30|November 2006|Actual|2006-11-30|||||Interventional|||Smoking Cessation in Groups and With Tobacco Pastils|Phase 2 Study of Smoke Free Tobacco and Group Support for Smoking Cessation|Completed||Phase 2|240||University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:16:45.531768|2018-06-01 04:16:45.531768
NCT00265447|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2016-09-26|2005-12-13|2005-12-14|Estimate|||||||2016-09-26|2016-09-28|Estimate|December 2005||2005-12-31|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Exercise and Physical Fitness for Persons With Knee Osteoarthritis|Exercise and Physical Fitness for Persons With Knee Osteoarthritis: Does One Size Fit All|Completed||Phase 3|55|Actual|University of Missouri-Columbia||3|||f||||||||||||||2018-06-01 04:16:45.602062|2018-06-01 04:16:45.602062
NCT00265434|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2014-12-03|2005-12-13|2005-12-14|Estimate|||||||2014-12-03|2014-12-04|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Completed||Phase 3|5|Actual|University of Jena||2|||f||||t||||||||||2018-06-01 04:16:45.673953|2018-06-01 04:16:45.673953
NCT00265421|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2009-09-29|2005-12-13|2005-12-14|Estimate|||||||2009-09-29|2009-09-30|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|April 2006||2006-04-30|||||Interventional|||Study of Different Suturing Techniques for Perineal Repair After Delivery|The Danish Suture Trial: a Randomized Trial on Perineal Sutures Following Vaginal Birth.|Completed||N/A|400||University of Aarhus|||||f||||t||||||||||2018-06-01 04:16:45.737879|2018-06-01 04:16:45.737879
NCT00265408|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2014-12-05|2005-12-12|2005-12-14|Estimate|||||||2014-12-05|2014-12-08|Estimate|December 2005||2005-12-31|March 2007|2007-03-31|March 2007|Anticipated|2007-03-31|||||Interventional|||Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection|Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection|Withdrawn||Phase 1|0|Actual|University of California, San Diego||2|||f||||||||||||||2018-06-01 04:16:45.802765|2018-06-01 04:16:45.802765
NCT00265226|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2014-01-03|2005-12-13|2005-12-14|Estimate|||||||2014-01-03|2014-01-06|Estimate|March 2005||2005-03-31|July 2011|2011-07-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients|Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters|Completed||Phase 3|1020|Actual|Ministry of Science and Technology, India||2|||f||||t||||||||||2018-06-01 04:16:56.809436|2018-06-01 04:16:56.809436
NCT00265395|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|2009-05-15||2017-03-08|2005-12-13|2005-12-14|Estimate|2009-05-15|2009-07-08|Estimate||||2017-03-08|2017-04-05|Actual|December 2004||2004-12-31|March 2017|2017-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)|A Study to Assess Treatment With PEG-Intron® and Rebetol® in Naïve Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response|Completed||Phase 3|1428|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:16:45.883508|2018-06-01 04:16:45.883508
NCT00265382|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2010-04-16||2011-12-02|2005-12-12|2005-12-14|Estimate|2010-04-16|2010-05-19|Estimate||||2011-12-02|2011-12-06|Estimate|June 2006||2006-06-30|December 2011|2011-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia|26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia|Terminated||Phase 3|221|Actual|Pfizer|The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators.|1||Please see Detailed Description for termination reason.|f||||t||||||||||2018-06-01 04:16:46.3766|2018-06-01 04:16:46.3766
NCT00265369|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-01-10|2005-12-13|2005-12-14|Estimate|||||||2011-01-10|2011-01-11|Estimate|May 2004||2004-05-31|January 2011|2011-01-31||||||||Interventional|||TEDDY: Spores of Bacillus Clausii in Acute Diarrhoea in Children|Comparative Efficacy and Safety of a Bacillus Clausii Probiotic Strain Versus Placebo in the Treatment of Acute Diarrhoea in Children|Completed||Phase 3|420||Sanofi|||||f||||||||||||||2018-06-01 04:16:47.133458|2018-06-01 04:16:47.133458
NCT00265356|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2013-10-18|2005-12-12|2005-12-14|Estimate|||||||2013-10-18|2013-10-21|Estimate|November 2005||2005-11-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2010|Actual|2010-04-30||Interventional|PETCAM||Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases|The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial|Completed||Phase 3|404|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 04:16:47.188935|2018-06-01 04:16:47.188935
NCT00265343|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2010-02-17|2009-04-23|2015-02-20|2005-12-12|2005-12-14|Estimate|2010-02-17|2010-02-23|Estimate|2009-10-02|2009-10-06|Estimate|2015-02-20|2015-03-10|Estimate|December 2005||2005-12-31|February 2015|2015-02-28|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)|A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed the Protocol 25543 (NCT 00212836; P05817)|Completed||Phase 3|306|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:16:47.279898|2018-06-01 04:16:47.279898
NCT00265330|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2009-01-22||2011-12-02|2005-12-12|2005-12-14|Estimate|2009-03-02|2009-04-03|Estimate||||2011-12-02|2011-12-06|Estimate|March 2006||2006-03-31|December 2011|2011-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)|26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)|Completed||Phase 3|169|Actual|Pfizer|The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators.|1|||f||||t||||||||||2018-06-01 04:16:47.590678|2018-06-01 04:16:47.590678
NCT00265317|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2011-01-21||2013-01-31|2005-12-12|2005-12-14|Estimate|2011-05-10|2011-06-10|Estimate||||2013-01-31|2013-02-06|Estimate|June 2006||2006-06-30|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2010|Actual|2010-01-31||Interventional|SUN1058||A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone|Randomized, Double-Blind, Phase 2 Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|162|Actual|Pfizer|Due to rounding some percentages will not equal 100%|2|||f||||f||||||||||2018-06-01 04:16:48.66262|2018-06-01 04:16:48.66262
NCT00265304|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2009-03-19|2005-12-13|2005-12-14|Estimate|||||||2009-03-19|2009-03-20|Estimate|July 2005||2005-07-31|March 2009|2009-03-31||||July 2007|Actual|2007-07-31||Interventional|||A Long-Term Safety Study of IDEA-033 in Comparison to Oral Naproxen for the Treatment of Osteoarthritis of the Knee|A Double-Blind, Long-Term Evaluation of the Safety of IDEA-033 in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of Osteoarthritis of the Knee|Completed||Phase 2|550||IDEA AG|||||f||||||||||||||2018-06-01 04:16:56.062682|2018-06-01 04:16:56.062682
NCT00265291|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2008-10-09|2005-12-13|2005-12-14|Estimate|||||||2008-10-09|2008-10-10|Estimate|November 1999||1999-11-30|September 2008|2008-09-30|October 2008|Actual|2008-10-31|May 2006|Actual|2006-05-31||Interventional|||Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group||Completed||Phase 2|700|Actual|National Institute of General Medical Sciences (NIGMS)|||||f||||t||||||||||2018-06-01 04:16:56.224592|2018-06-01 04:16:56.224592
NCT00265278|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2017-01-10|2005-12-13|2005-12-14|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2005||2005-03-31|December 2005|2005-12-31|March 2006||2006-03-31|||||Interventional|||Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1|Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil|Unknown status|Active, not recruiting|Phase 1|16||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 04:16:56.286914|2018-06-01 04:16:56.286914
NCT00265265|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2017-01-11|2005-12-13|2005-12-14|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2005||2005-08-31|August 2016|2016-08-31||||September 2006|Actual|2006-09-30||Interventional|||Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1|Phase 1, Double-Blind, Placebo-Controlled Multiple Dose Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine|Completed||Phase 1|16||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:16:56.341871|2018-06-01 04:16:56.341871
NCT00265252|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2008-02-26|2005-12-12|2005-12-14|Estimate|||||||2008-02-26|2008-02-27|Estimate|June 2005||2005-06-30|April 2007|2007-04-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis|Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis|Unknown status|Active, not recruiting|Phase 4|60||Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-06-01 04:16:56.517624|2018-06-01 04:16:56.517624
NCT00265239|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|2014-05-19||2014-09-12|2005-12-13|2005-12-14|Estimate|2014-09-12|2014-09-15|Estimate||||2014-09-12|2014-09-15|Estimate|April 2001||2001-04-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Pilot Study of Edaravone to Treat Acute Myocardial Infarction|Effects of Edaravone in Patients With Acute Myocardial Infarction|Completed||Phase 4|104|Actual|Kumamoto University||2|||f||||||||||||||2018-06-01 04:16:56.612563|2018-06-01 04:16:56.612563
NCT00265200|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2013-04-08||2018-03-01|2005-12-12|2005-12-14|Estimate|2017-04-04|2017-04-06|Actual||||2018-03-01|2018-03-05|Actual|February 2005||2005-02-28|March 2018|2018-03-31|December 2010|Actual|2010-12-31|August 2009|Actual|2009-08-31||Interventional|||Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer|Bone Metabolic Markers, TRAP, and Zometa's Effect on Bone Metastasis Due to Lung Cancer|Terminated||Phase 2|28|Actual|University of Louisville||1||funding discontinued by sponsor|f||||t||||||||||2018-06-01 04:16:56.990187|2018-06-01 04:16:56.990187
NCT00265187|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2013-01-02|2005-12-13|2005-12-14|Estimate|||||||2013-01-02|2013-01-03|Estimate|December 2005||2005-12-31|August 2006|2006-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis.|The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis in Northern Israel.|Completed|||200|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 04:16:57.195738|2018-06-01 04:16:57.195738
NCT00265174|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2005-12-13|2005-12-13|2005-12-14|Estimate|||||||2005-12-13|2005-12-14|Estimate|January 2006||2006-01-31|November 2005|2005-11-30||||||||Observational|||Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer.|Serum DNA Analysis: Potential Application for Diagnosis and Prognosis in Brain Cancer.|Unknown status|Not yet recruiting||60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:16:57.248596|2018-06-01 04:16:57.248596
NCT00265161|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2007-05-31|2005-12-13|2005-12-14|Estimate|||||||2007-05-31|2007-06-01|Estimate|December 2005||2005-12-31|August 2006|2006-08-31|March 2007|Actual|2007-03-31|||||Observational|||The Effectiveness of Influenza Vaccine Among Health Care Workers in a Hospital Setting.||Completed|||40||HaEmek Medical Center, Israel|||||f||||f||||||||||2018-06-01 04:16:57.300364|2018-06-01 04:16:57.300364
NCT00265148|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12||2010-10-13|2016-11-15|2005-12-13|2005-12-14|Estimate||||2010-10-13|2010-11-18|Estimate|2016-11-15|2016-11-16|Estimate|May 2004||2004-05-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease|A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD)|Completed||Phase 2|80|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:16:57.354156|2018-06-01 04:16:57.354156
NCT00265135|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2014-07-01|2005-12-13|2005-12-14|Estimate|||||||2014-07-01|2014-07-03|Estimate|August 2003||2003-08-31|July 2014|2014-07-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma|A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|68|Actual|Centocor, Inc.||3|||f||||t||||||||||2018-06-01 04:16:57.467235|2018-06-01 04:16:57.467235
NCT00265122|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|2009-10-23||2014-01-20|2005-12-13|2005-12-14|Estimate|2013-06-25|2013-07-31|Estimate||||2014-01-20|2014-02-13|Estimate|April 2004||2004-04-30|January 2014|2014-01-31|October 2006|Actual|2006-10-31|November 2005|Actual|2005-11-30||Interventional|||A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease|A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn's Disease|Completed||Phase 2|131|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|6|||f||||f||||||||||2018-06-01 04:16:57.582623|2018-06-01 04:16:57.582623
NCT00265109|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2010-10-18||2018-04-16|2005-12-12|2005-12-14|Estimate|2010-10-18|2010-11-16|Estimate||||2018-04-16|2018-05-15|Actual|December 2004||2004-12-31|April 2018|2018-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder|Open-Label Study of Levetiracetam in Body Dysmorphic Disorder|Completed||Phase 4|17|Actual|Butler Hospital|This is a small open-label trial.|1|||f||||||||||||No||2018-06-01 04:16:58.966686|2018-06-01 04:16:58.966686
NCT00265096|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2009-05-21||2013-07-12|2005-12-12|2005-12-14|Estimate|2012-03-20|2012-04-16|Estimate||||2013-07-12|2013-07-19|Estimate|December 2005||2005-12-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|May 2007|Actual|2007-05-31||Interventional|GO-REVEAL||A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis|Completed||Phase 3|407|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|3|||f||||t||||||||||2018-06-01 04:16:59.192992|2018-06-01 04:16:59.192992
NCT00265083|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2009-05-21||2013-07-12|2005-12-12|2005-12-14|Estimate|2009-05-21|2009-07-13|Estimate||||2013-07-12|2013-07-19|Estimate|December 2005||2005-12-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|March 2007|Actual|2007-03-31||Interventional|||A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalpha MonoclonalAntibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis|Completed||Phase 3|356|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|3|||f||||t||||||||||2018-06-01 04:17:00.205113|2018-06-01 04:17:00.205113
NCT00265070|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2013-02-04|2005-12-12|2005-12-14|Estimate|||||||2013-02-04|2013-02-05|Estimate|January 2003||2003-01-31|February 2013|2013-02-28|August 2011|Actual|2011-08-31|||||Interventional|||Trial of Iressa in Prostate Cancer Patients|An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy|Completed||Phase 2|80|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:17:01.290206|2018-06-01 04:17:01.290206
NCT00265057|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-13|||2010-12-27|2005-12-13|2005-12-14|Estimate|||||||2010-12-27|2010-12-28|Estimate|June 2005||2005-06-30|December 2010|2010-12-31|January 2008|Actual|2008-01-31|||||Interventional|||Study of ADH-1 Given Intravenously to Patients With Solid Tumors|Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004)|Completed||Phase 1/Phase 2|||Adherex Technologies, Inc.|||||||||||||||||||2018-06-01 04:17:01.358301|2018-06-01 04:17:01.358301
NCT00265044|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2015-04-06|2005-12-12|2005-12-13|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2004||2004-01-31|May 2006|2006-05-31|December 2004|Actual|2004-12-31|||||Interventional|||Improving Practice Patterns for the Treatment of Hypertension|Innovations to Implementing Evidence-based Clinical Practice|Completed||N/A|1300|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:17:01.413398|2018-06-01 04:17:01.413398
NCT00265005|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2018-04-02|2005-12-12|2005-12-13|Estimate|||||||2018-04-02|2018-04-04|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2009|Actual|2009-12-31||Interventional|||Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants|Dose-Ranging, Safety And Efficacy Of Cathflo(TM) Activase(R) (Alteplase) For The Treatment Of Central Catheter Occlusion In Neonates And Infants; Phase I|Terminated||Phase 1|12|Actual|University of Louisville||1||difficulty in recruiting subjects|f||||t||||||||||2018-06-01 04:17:01.632964|2018-06-01 04:17:01.632964
NCT00264992|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-05-27|2005-12-09|2005-12-13|Estimate|||||||2008-05-27|2008-05-29|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Implantation and Cytokine Expression|The Cytokine Paired Footprint of Successful Implantation|Completed|||160||UMC Utrecht|||||f||||||||||||||2018-06-01 04:17:01.700837|2018-06-01 04:17:01.700837
NCT00264979|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2017-08-21|2005-12-12|2005-12-13|Estimate|||||||2017-08-21|2017-08-22|Actual|December 2005||2005-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|METASYNC||Evaluation of 2 Resection Strategies of Synchronous Colorectal Cancer Metastases|Prospective Randomized Study Comparing the Morbidity and Mortality After Liver Resection for Synchronous Colorectal Cancer Metastases When Performed Either During or 12 to 14 Weeks After the Primary Resection|Terminated||N/A|105|Actual|Rennes University Hospital||2||Stop recommended following the last sequential analysis|f||||t||||||||||2018-06-01 04:17:01.750403|2018-06-01 04:17:01.750403
NCT00264966|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2012-11-30|2005-12-12|2005-12-13|Estimate|||||||2012-11-30|2012-12-03|Estimate|December 2005||2005-12-31|November 2012|2012-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Multiple Dose ASM8 in Mild Asthmatics|A Double-blind, Placebo-controled, Crossover Study To Evaluate the Efficacy, Safety and Tolerability of Inhaled ASM8-003 in Subjects With Mild Allergic Asthma.|Completed||Phase 1/Phase 2|15||Pharmaxis|||||f||||f||||||||||2018-06-01 04:17:01.985152|2018-06-01 04:17:01.985152
NCT00264953|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2011-08-03|2005-12-12|2005-12-13|Estimate|||||||2011-08-03|2011-08-04|Estimate|May 1998||1998-05-31|July 2011|2011-07-31||||January 2003|Actual|2003-01-31||Interventional|||HD11 for Intermediate Stages||Completed||Phase 3|1395|Actual|University of Cologne||4|||f||||||||||||||2018-06-01 04:17:02.067243|2018-06-01 04:17:02.067243
NCT00264940|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2005-12-12|2005-12-12|2005-12-13|Estimate|||||||2005-12-12|2005-12-13|Estimate||||December 2005|2005-12-31||||||||Observational|||Diagnosis of Insulin Resistance: 13C-Glucose Breath Test Vs HOMA Index.||Unknown status|Not yet recruiting||||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 04:17:02.147273|2018-06-01 04:17:02.147273
NCT00264927|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2008-12-09|2005-12-12|2005-12-13|Estimate|||||||2008-12-09|2008-12-10|Estimate|May 2004||2004-05-31|December 2008|2008-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|SIADH||Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|Completed||Phase 3|77|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:17:02.203042|2018-06-01 04:17:02.203042
NCT00264914|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2009-01-19|2005-12-12|2005-12-13|Estimate|||||||2009-01-19|2009-01-21|Estimate|July 2005||2005-07-31|January 2009|2009-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|SIADH Safety||Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|Completed||Phase 3|57|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:17:02.283218|2018-06-01 04:17:02.283218
NCT00264901|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2017-01-30|2005-12-12|2005-12-13|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|PREDICTIVE™||Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes|Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir® (Insulin Detemir [rDNA Origin] Injection) (PREDICTIVE™ 303)|Completed||Phase 4|5652|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:17:02.359249|2018-06-01 04:17:02.359249
NCT00264888|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2009-01-09|2005-12-09|2005-12-13|Estimate|||||||2009-01-09|2009-01-14|Estimate|December 2005||2005-12-31|January 2009|2009-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy|Completed||Phase 2|38||PTC Therapeutics|||||f||||||||||||||2018-06-01 04:17:02.422195|2018-06-01 04:17:02.422195
NCT00264875|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2009-02-20||2009-03-20|2005-12-12|2005-12-13|Estimate|2009-02-20|2009-03-23|Estimate||||2009-03-20|2009-04-02|Estimate|February 2006||2006-02-28|March 2009|2009-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy|An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy|Completed||Phase 3|220|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:17:02.578852|2018-06-01 04:17:02.578852
NCT00264862|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2014-02-27|2005-12-12|2005-12-13|Estimate|||||||2014-02-27|2014-02-28|Estimate|December 2005||2005-12-31|February 2014|2014-02-28|March 2007|Actual|2007-03-31|||||Interventional|||DynaCT Imaging in EVAR: Comparing Clinical Benefit of DynaCT to Multidetector CT as the Current Gold Standard.|Use of DynaCT in Endovascular Treatment of Abdominal Aortic Aneurysm. Evaluation of Image Quality.|Completed||N/A|20|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:17:02.987938|2018-06-01 04:17:02.987938
NCT00264849|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2010-12-03||2011-06-24|2005-12-12|2005-12-13|Estimate|2011-06-24|2011-07-25|Estimate||||2011-06-24|2011-07-25|Estimate|November 2005||2005-11-30|June 2011|2011-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma|A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy|Completed||Phase 4|406|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:17:03.257696|2018-06-01 04:17:03.257696
NCT00264823|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-10-03|2005-12-12|2005-12-13|Estimate|||||||2008-10-03|2008-10-06|Estimate|June 2003||2003-06-30|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Nursing Intervention for HIV Regime Adherence Among People With Serious Mental Illness (SMI)|Nursing Intervention for HIV Regimen Adherence Among Serious Mental Illness (SMI)|Completed||Phase 2|273|Actual|National Institute of Nursing Research (NINR)||2|||f||||t||||||||||2018-06-01 04:17:05.508451|2018-06-01 04:17:05.508451
NCT00264810|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|2013-08-23|2012-01-17|2013-08-23|2005-12-09|2005-12-13|Estimate|2013-08-23|2013-08-28|Estimate|2012-01-17|2012-01-19|Estimate|2013-08-23|2013-08-28|Estimate|December 2005||2005-12-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|October 2009|Actual|2009-10-31||Interventional||Baseline characteristics and primary endpoints were calculated using the Intent-to-Treat population, which includes all subjects that underwent RNS® System implantation (191 subjects). Individuals that did not undergo initial implant (49 subjects) were withdrawn from the study and are considered screen failures.|RNS® System Pivotal Study|RNS® System Pivotal-A Clinical Investigation|Completed||Phase 3|240|Actual|NeuroPace||2|||f||||t||||||||||2018-06-01 04:17:05.89624|2018-06-01 04:17:05.89624
NCT00264797|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-10|2013-01-18||2013-05-02|2005-12-10|2005-12-13|Estimate|2013-05-02|2013-06-07|Estimate||||2013-05-02|2013-06-07|Estimate|February 2006||2006-02-28|May 2013|2013-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)|Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)|Completed||Phase 3|303|Actual|University of Cincinnati||2|||f||||t||||||||||2018-06-01 04:17:08.11127|2018-06-01 04:17:08.11127
NCT00264784|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2007-12-19|2005-12-09|2005-12-13|Estimate|||||||2007-12-19|2007-12-28|Estimate|December 2005||2005-12-31|October 2007|2007-10-31|May 2006||2006-05-31|||||Observational|||GAS Epi Study to Measure Age-Related Antibody Titers to J8 Vaccine|The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) - Part 5: Establishing Natural Age-Related Titers of Antibodies to the J8 Group A Streptococcal Epitope in Fiji|Completed|||300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:17:08.496056|2018-06-01 04:17:08.496056
NCT00264771|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-05-01|2005-12-09|2005-12-13|Estimate|||||||2008-05-01|2008-05-02|Estimate|December 2005||2005-12-31|October 2007|2007-10-31|December 2007||2007-12-31|||||Observational|||Hospital Based Incidence of Group A Streptococcal Disease in Fiji|The Hospital Based Incidence of Acute Rheumatic Fever and Rheumatic Heart Disease, Acute Post Streptococcal Glomerulonephritis and Invasive Group A Streptococcal Disease in Fiji|Completed|||550||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:17:08.55747|2018-06-01 04:17:08.55747
NCT00264758|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2014-07-02|2005-12-12|2005-12-13|Estimate|||||||2014-07-02|2014-07-03|Estimate|January 2006||2006-01-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Frequent Hemodialysis Network: Daily Trial|Frequent Hemodialysis Network: Daily Trial|Completed||Phase 2/Phase 3|245|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 04:17:08.626282|2018-06-01 04:17:08.626282
NCT00264745|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2011-01-11|2005-12-09|2005-12-13|Estimate|||||||2011-01-11|2011-01-12|Estimate|June 2004||2004-06-30|October 2008|2008-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Telephone Assessment and Skill-Building Kit (TASK): A New Program for Family Caregivers of Stroke Survivors|Caregiver Telephone Assessment and Skill-Building Kit|Completed||Phase 1|50|Actual|Indiana University||2|||f||||||||||||||2018-06-01 04:17:08.758746|2018-06-01 04:17:08.758746
NCT00264732|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12||2013-05-21|2013-05-21|2005-12-12|2005-12-13|Estimate||||2013-05-21|2013-05-29|Estimate|2013-05-21|2013-05-29|Estimate|July 2005||2005-07-31|May 2012|2012-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix|Completed||Phase 2/Phase 3|251|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 04:17:08.883625|2018-06-01 04:17:08.883625
NCT00264719|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-11|||2009-09-18|2005-12-11|2005-12-13|Estimate|||||||2009-09-18|2009-09-21|Estimate|January 2006||2006-01-31|September 2009|2009-09-30|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Metoclopramide to Aid Establishment of Breastfeeding:a Randomised Controlled Trial|Metoclopramide to Aid Establishment of Breastfeeding After Delivery: a Randomized Controlled Trial|Completed||N/A|160|Anticipated|National University Hospital, Singapore||4|||f||||t||||||||||2018-06-01 04:17:09.014193|2018-06-01 04:17:09.014193
NCT00264706|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-11|||2016-09-07|2005-12-11|2005-12-13|Estimate|||||||2016-09-07|2016-09-08|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||PolyArginine Treated vEiN grafTs (PATENT)|PolyArginine Treated vEiN grafTs (PATENT)|Terminated||Phase 1/Phase 2|25|Actual|Lumen Therapeutics||1||Reformulation of test compound|f||||||||||||||2018-06-01 04:17:09.101247|2018-06-01 04:17:09.101247
NCT00264693|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-11|||2010-01-25|2005-12-11|2005-12-13|Estimate|||||||2010-01-25|2010-01-26|Estimate|January 2006||2006-01-31|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function|Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function|Completed|||96|Actual|Luzerner Kantonsspital|||8||f||||||||||||||2018-06-01 04:17:09.168034|2018-06-01 04:17:09.168034
NCT00264680|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2017-10-26|2005-12-12|2005-12-13|Estimate|||||||2017-10-26|2017-10-30|Actual|October 1, 2003|Actual|2003-10-01|October 2017|2017-10-31|March 1, 2006|Actual|2006-03-01|March 1, 2006|Actual|2006-03-01||Observational|||Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For Epilepsy|Validation Of Qolie-10 For Epilepsy, Comparison Of Quality Of Life In Patients Treated With Lamotrigine Or Valproic Acid|Completed|||333|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:17:09.237235|2018-06-01 04:17:09.237235
NCT00264667|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2016-10-26|2005-12-12|2005-12-13|Estimate|||||||2016-10-26|2016-10-28|Estimate|December 2005||2005-12-31|October 2016|2016-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Study In Patients With Dyslipidaemia|A Randomised,Double-blind, Parallel Group, Placebo-controlled, Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of Oral GW677954 Capsules 2.5mg, 5mg, 10mg and 20mg a Day for 24 Weeks in Overweight Dyslipidaemic Subjects|Completed||Phase 2|290||GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:17:09.322577|2018-06-01 04:17:09.322577
NCT00264654|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2013-04-11|2005-12-12|2005-12-13|Estimate|||||||2013-04-11|2013-04-15|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|SAD||Long-term Study Of Paroxetine in Women and Men|Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- <Phase III Study>|Completed||Phase 3|50|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:17:09.482414|2018-06-01 04:17:09.482414
NCT00264641|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2016-01-22||2017-03-28|2005-12-12|2005-12-13|Estimate|2017-03-28|2017-03-29|Actual||||2017-03-28|2017-03-29|Actual|January 2006||2006-01-31|March 2017|2017-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study|The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study|Completed||N/A|20|Actual|Hypoglycaemia Research Group||2|||f||||f||||||||No||2018-06-01 04:17:09.565463|2018-06-01 04:17:09.565463
NCT00264628|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2015-04-15|2005-12-12|2005-12-13|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||GW679769 In Fibromyalgia|An Outpatient, Randomised, Double-blind, Placebo Controlled, Parallel Group Exploratory Study to Evaluate Safety, Tolerability and Efficacy of GW679769 in Patients With Fibromyalgia Syndrome Comorbid With Depression.|Completed|||8|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:17:09.783574|2018-06-01 04:17:09.783574
NCT00264615|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2016-09-22|2005-12-12|2005-12-13|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2005||2005-10-31|September 2016|2016-09-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa|An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa|Completed||Phase 3|45||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:17:09.83597|2018-06-01 04:17:09.83597
NCT00264602|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2017-12-18|2005-12-12|2005-12-13|Estimate|||||||2017-12-18|2017-12-20|Actual|February 18, 2009|Actual|2009-02-18|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|September 1, 2017|Actual|2017-09-01||Interventional|||Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer|Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer|Active, not recruiting||Phase 1|57|Actual|Dana-Farber Cancer Institute||1|||f||||f||||||||No||2018-06-01 04:17:09.943799|2018-06-01 04:17:09.943799
NCT00264589|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2015-03-26|2005-12-12|2005-12-13|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes|Effects of an Individualized Training Program on Cardiovascular Function at Rest and During Exercise in Obese and in Type 2 Diabetic Subjects|Completed||Phase 4|59|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-06-01 04:17:10.006457|2018-06-01 04:17:10.006457
NCT00264576|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|2012-12-20||2017-02-21|2005-12-09|2005-12-13|Estimate|2012-12-20|2013-01-28|Estimate||||2017-02-21|2017-03-24|Actual|October 2005||2005-10-31|December 2012|2012-12-31|May 2006|Actual|2006-05-31|December 2005|Actual|2005-12-31||Interventional|||Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults|A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs|Completed||Phase 2|613|Actual|Novartis||2|||||||f||||||||||2018-06-01 04:17:10.093271|2018-06-01 04:17:10.093271
NCT00264563|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2011-06-16|2005-12-12|2005-12-13|Estimate|||||||2011-06-16|2011-06-17|Estimate|November 2005||2005-11-30|August 2005|2005-08-31|April 2006||2006-04-30|||||Observational|||"Iatrogenesis Imperfecta- Extent and Characteristic in NICU in Israel."||Completed|||750|Anticipated|Bnai Zion Medical Center|||1||f||||||||||||||2018-06-01 04:17:10.697003|2018-06-01 04:17:10.697003
NCT00264550|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-11|2009-05-21||2014-04-14|2005-12-11|2005-12-13|Estimate|2014-02-04|2014-03-21|Estimate||||2014-04-14|2014-04-29|Estimate|December 2005||2005-12-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|September 2007|Actual|2007-09-30||Interventional|GO-FORWARD||An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Subjects With ActiveRheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 3|444|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|4|||f||||t||||||||||2018-06-01 04:17:10.805742|2018-06-01 04:17:10.805742
NCT00264537|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-11|2009-05-21||2014-08-27|2005-12-11|2005-12-13|Estimate|2009-05-21|2009-07-13|Estimate||||2014-08-27|2014-09-05|Estimate|December 2005||2005-12-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|April 2008|Actual|2008-04-30||Interventional|||A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive|A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Methotrexate-naive Subjects With Active Rheumatoid Arthritis|Completed||Phase 3|637|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in less than or equal to 5% of patients. This information may vary from existing approved labeling and publications.|4|||f||||t||||||||||2018-06-01 04:17:13.124977|2018-06-01 04:17:13.124977
NCT00264524|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2010-11-26|2005-12-12|2005-12-13|Estimate|||||||2010-11-26|2010-11-29|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|July 2005||2005-07-31|||||Interventional|||DNA Typing of HLA-DR/DQ Alleles in Taiwan Chinese With Rheumatic Heart Disease||Completed||N/A|||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:17:15.346281|2018-06-01 04:17:15.346281
NCT00264511|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2016-01-13|2005-12-12|2005-12-13|Estimate|||||||2016-01-13|2016-01-15|Estimate|February 2006||2006-02-28|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|August 2014|Actual|2014-08-31||Interventional|||Hyperbaric Oxygen in Lower Leg Trauma|Does Hyperbaric Oxygen Reduce Complications and Improve Outcomes After Open Tibial Fractures With Severe Soft Tissue Injury? An International Multi-centre Randomized Controlled Trial.|Unknown status|Active, not recruiting|Phase 2/Phase 3|120|Anticipated|Bayside Health||2|||f||||t||||||||||2018-06-01 04:17:15.400065|2018-06-01 04:17:15.400065
NCT00264498|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|2009-06-11||2009-06-11|2005-12-12|2005-12-13|Estimate|2009-06-11|2009-08-03|Estimate||||2009-06-11|2009-08-03|Estimate|October 2004||2004-10-31|June 2009|2009-06-30|June 2008|Actual|2008-06-30|||||Interventional|||Phase II Iressa & Carbo/Gem in NSCLC|A Randomized, Open-Label Phase II Study Of ZD1839 (IRESSA™) Versus Gemcitabine And Carboplatin In Chemotherapy-Naive Patients With Advanced (Stage IIIB OR IV) Non-Small Cell Lung Cancer And ECOG Performance Status 2|Completed||Phase 2|38|Actual|AstraZeneca|"No analysis of the efficacy results was performed as the study was prematurely terminated with only 35 out of the planned 122 subjects randomized.~Serious and Other adverse event data for Periods 1 and 2 were combined by treatment for this report."|2|||f||||||||||||||2018-06-01 04:17:15.504508|2018-06-01 04:17:15.504508
NCT00264485|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2011-05-18|2005-12-09|2005-12-13|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|April 2005|Actual|2005-04-30|||||Interventional|||A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump|Comparison of the Safety and Efficacy of Patient Controlled Analgesia Delivered by the E-TRANS Fentanyl HCl Transdermal System Versus Morphine IV Pump for Pain Management After Primary Unilateral Total Hip Replacement|Completed||Phase 3|799|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:17:15.822584|2018-06-01 04:17:15.822584
NCT00264472|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2008-12-12|2005-12-12|2005-12-13|Estimate|||||||2008-12-12|2008-12-15|Estimate|January 2006||2006-01-31|December 2008|2008-12-31||||June 2009|Anticipated|2009-06-30||Interventional|||A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors|A 2-Part Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ADH300004 (Eniluracil) Administered With 5-Fluorouracil (5-FU), and the Pharmacokinetics of 5-FU Given as: 5.0 mg ADH300004 With Escalating Doses of 5-FU Administered Orally 3 Weeks Out of 4 in Subjects With Refractory Solid Tumors (Part 1); or 5.0 mg ADH300004 With 5 FU Administered Orally as a Split Dose for 3 Weeks Out of 4 in Subjects With Hepatocellular Carcinoma, Non-Small Cell Lung Carcinoma, Gastric Cancer, Cervical Cancer, Prostate Cancer, or Breast Cancer (Part 2) (Adherex Protocol Number AHX-03-104)|Suspended||Phase 1|60|Anticipated|Adherex Technologies, Inc.||||Lack of funds|f||||||||||||||2018-06-01 04:17:15.935496|2018-06-01 04:17:15.935496
NCT00264459|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2014-01-23|2005-12-12|2005-12-13|Estimate|||||||2014-01-23|2014-01-24|Estimate|February 2003||2003-02-28|January 2014|2014-01-31|September 2011|Actual|2011-09-30|August 2008|Actual|2008-08-31||Interventional|||Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture|A Multicentre, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of a Perennial Sublingual Specific Immunotherapy With a Liquid Formulation of an Extract of a Six Grass Pollen-mixture in Patients With Clinically Relevant Grass Pollen Sensitivity.|Completed||Phase 3|160|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 04:17:16.05843|2018-06-01 04:17:16.05843
NCT00264446|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2007-08-03|2005-12-12|2005-12-13|Estimate|||||||2007-08-03|2007-08-06|Estimate||||August 2007|2007-08-31||||||||Interventional|||A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection|Phase 1 Study of the Evaluation of Dihydropyrimidine Dehydrogenase (DPD), Uridine Phosphorylase (UP), Orotate Phosphoribosyl Transferase (OPRT), and Thymidine Phosphorylase (TP) Activity in Tissue Resected From Subjects Undergoing Planned Resection of Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection, Following Administration of Oral ADH300004 (Adherex Protocol Number AHX-03-101)|Completed||Phase 1|||Adherex Technologies, Inc.|||||||||||||||||||2018-06-01 04:17:16.131263|2018-06-01 04:17:16.131263
NCT00264433|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-12|||2007-08-03|2005-12-12|2005-12-13|Estimate|||||||2007-08-03|2007-08-06|Estimate||||August 2007|2007-08-31||||||||Interventional|||A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent|An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201)|Completed||Phase 2|||Adherex Technologies, Inc.|||||||||||||||||||2018-06-01 04:17:16.186018|2018-06-01 04:17:16.186018
NCT00264420|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2010-12-20|2005-12-09|2005-12-12|Estimate|||||||2010-12-20|2010-12-21|Estimate|December 2005||2005-12-31|December 2010|2010-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation|A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer|Completed||Phase 1|4|Actual|The Cleveland Clinic||1|||f||||||||||||||2018-06-01 04:17:16.259338|2018-06-01 04:17:16.259338
NCT00264407|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2005-12-08|2005-12-08|2005-12-12|Estimate|||||||2005-12-08|2005-12-12|Estimate|January 2001||2001-01-31|December 2005|2005-12-31|February 2005||2005-02-28|||||Observational|||Neural Changes in the Aging Auditory System|Age-Related Hearing Loss: Presbycusis & Its Neural Bases|Completed|||126||University of Rochester|||||f||||||||||||||2018-06-01 04:17:16.376371|2018-06-01 04:17:16.376371
NCT00264394|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2015-05-27|2005-12-09|2005-12-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 2006||2006-07-31|May 2015|2015-05-31|February 2010|Actual|2010-02-28|October 2008|Actual|2008-10-31||Interventional|||Cardiovascular Risk Factor Management in HIV Infection|Efficacy of a Computerised Physician Reminder System to Control Cardiovascular Risk Factors in HIV-infected Patients Receiving Antiretroviral Therapy: A Nested Randomised Controlled Cluster Trial Within the Swiss HIV Cohort Study|Completed||Phase 4|4097|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-06-01 04:17:16.440837|2018-06-01 04:17:16.440837
NCT00264381|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|2013-11-14||2013-11-14|2005-12-08|2005-12-12|Estimate|2013-11-14|2013-11-18|Estimate||||2013-11-14|2013-11-18|Estimate|October 2002||2002-10-31|November 2013|2013-11-30|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Interventional|||Management of Superficial Thrombophlebitis|Management of Superficial Thrombophlebitis|Completed||Phase 4|72|Actual|University of Oklahoma||1|||f||||f||||||||||2018-06-01 04:17:16.540718|2018-06-01 04:17:16.540718
NCT00264368|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2007-06-27|2005-12-09|2005-12-12|Estimate|||||||2007-06-27|2007-06-28|Estimate|December 2005||2005-12-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy|Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy|Terminated||Phase 4|6|Anticipated|University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:17:16.804568|2018-06-01 04:17:16.804568
NCT00264355|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2007-09-05|2005-12-09|2005-12-12|Estimate|||||||2007-09-05|2007-09-06|Estimate|December 2005||2005-12-31|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|||Metabolic Pattern of Cyclosporine A and Acute Renal Failure|Metabolic Pattern of Cyclosporine A - Association of Secondary- and Cyclic Metabolites With Acute Renal Failure in Heart Transplant Recipients|Completed||Phase 4|30|Anticipated|University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:17:16.860312|2018-06-01 04:17:16.860312
NCT00264342|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2013-05-21|2005-12-09|2005-12-12|Estimate|||||||2013-05-21|2013-05-23|Estimate|July 2005||2005-07-31|May 2013|2013-05-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Observational|||Effectiveness of Using Reduced Nicotine Cigarettes in Men and Women Smokers to Combat Nicotine Addiction|Safety of Nicotine Reduction Strategy|Completed|||135|Actual|University of California, San Francisco|||||f||||t||||||Samples Without DNA|"~     Tissue (blood) and urine~   "|||2018-06-01 04:17:17.050087|2018-06-01 04:17:17.050087
NCT00264329|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2016-11-16|2005-12-08|2005-12-12|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2004||2004-11-30|November 2016|2016-11-30|May 2008|Actual|2008-05-31|April 2006|Actual|2006-04-30||Interventional|||Transitional Case Management Study|Transitional Case Management Study|Completed||Phase 3|812|Actual|University of California, Los Angeles|||||f||||||||||||||2018-06-01 04:17:17.114731|2018-06-01 04:17:17.114731
NCT00264316|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2013-01-16|2005-12-09|2005-12-12|Estimate|||||||2013-01-16|2013-01-17|Estimate|May 2003||2003-05-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Bone Marrow-Derived Stem Cell Transfer in Acute Myocardial Infarctions|A Double-blind, Randomised, Controlled Study of Autologous Bone Marrow-Derived Stem Cell Transfer In Patients With ST-Segment Elevation Myocardial Infarction.|Completed||Phase 2|68||Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-06-01 04:17:17.186745|2018-06-01 04:17:17.186745
NCT00264303|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|2009-05-18||2011-08-30|2005-12-08|2005-12-12|Estimate|2009-05-18|2009-07-09|Estimate||||2011-08-30|2011-08-31|Estimate|December 2005||2005-12-31|June 2011|2011-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||CUTE (Chronic Urticaria Treatment Evaluation)|A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU)|Completed||Phase 4|886|Actual|UCB Pharma||2|||f||||||||||||||2018-06-01 04:17:17.274066|2018-06-01 04:17:17.274066
NCT00264290|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|2013-08-13||2013-11-07|2005-12-09|2005-12-12|Estimate|2013-08-27|2013-11-08|Estimate||||2013-11-07|2013-12-03|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Valganciclovir to Reduce T Cell Activation in HIV Infection|Valganciclovir to Reduce T Cell Activation in HIV Infection|Completed||Phase 4|30|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:17:17.933087|2018-06-01 04:17:17.933087
NCT00264277|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2016-11-22|2005-12-09|2005-12-12|Estimate|||||||2016-11-22|2016-11-23|Estimate|September 2002||2002-09-30|November 2016|2016-11-30|September 2005||2005-09-30|December 2004|Actual|2004-12-31||Interventional|||D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism|"D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized Prolong Study"|Completed||Phase 4|600||St. Orsola Hospital|||||f||||||||||||||2018-06-01 04:17:18.207927|2018-06-01 04:17:18.207927
NCT00264264|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2013-05-15|2005-12-08|2005-12-12|Estimate|||||||2013-05-15|2013-05-16|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Arterial Closure vs Direct Compression for Hemostasis After PCI - The ACDC Trial|Arterial Closure vs Direct Compression for Hemostasis After Percutaneous Coronary Interventions|Completed||N/A|572|Actual|St. Michael's Hospital, Toronto||2|||f||||||||||||||2018-06-01 04:17:18.278428|2018-06-01 04:17:18.278428
NCT00264251|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2007-10-26|2005-12-09|2005-12-12|Estimate|||||||2007-10-26|2007-10-29|Estimate|July 2005||2005-07-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance|Effect of Diet, Exercise and Rosiglitazone on Regional Fat and Insulin Resistance in HIV-Infected and Uninfected Men and Women|Completed||N/A|48|Anticipated|St. Luke's-Roosevelt Hospital Center|||||f||||t||||||||||2018-06-01 04:17:18.350646|2018-06-01 04:17:18.350646
NCT00264238|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|2016-11-07||2017-04-19|2005-12-09|2005-12-12|Estimate|2017-01-17|2017-03-07|Actual||||2017-04-19|2017-05-30|Actual|January 2006||2006-01-31|April 2017|2017-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Memantine Augmentation in Obsessive-Compulsive Disorder|An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder|Completed||Phase 1/Phase 2|15|Actual|Stanford University|This study is limited by its open-label design, small size, and the presence of comorbidities and concurrent psychotropic medications|1|||f||||f||||||||No||2018-06-01 04:17:18.423284|2018-06-01 04:17:18.423284
NCT00264225|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-02-15|2005-12-09|2005-12-12|Estimate|||||||2008-02-15|2008-02-20|Estimate|December 2005||2005-12-31|February 2008|2008-02-29||||||||Interventional|||Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)|A Randomized, Double-Blind, Comparative Parallel Group Study of Analgesic Effectiveness and Safety of Three Different Doses of Lamaline® New Formulation vs Dafalgan® Codeine, After 10 Days Administration in Subjects With Painful Gonarthrosis.|Completed||Phase 3|||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:17:18.67173|2018-06-01 04:17:18.67173
NCT00264212|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2007-12-17|2005-12-09|2005-12-12|Estimate|||||||2007-12-17|2007-12-21|Estimate|August 2004||2004-08-31|December 2007|2007-12-31||||||||Interventional|||AMISH : Aprovel for Management of Isolated Systolic Hypertension|A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension|Completed||Phase 4|436||Sanofi|||||f||||||||||||||2018-06-01 04:17:19.012279|2018-06-01 04:17:19.012279
NCT00264199|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2007-12-18|2005-12-09|2005-12-12|Estimate|||||||2007-12-18|2007-12-27|Estimate|December 2005||2005-12-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure|The Effect of 48 Hours GLP-1 Infusion on Left Ventricular Function, Exercise Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure|Completed||N/A|20|Actual|Aarhus University Hospital Skejby||2|||f||||f||||||||||2018-06-01 04:17:19.078643|2018-06-01 04:17:19.078643
NCT00264186|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-05-21|2005-12-09|2005-12-12|Estimate|||||||2008-05-21|2008-05-22|Estimate|June 2005||2005-06-30|May 2008|2008-05-31||||||||Interventional|||Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity|Impact of rhCu/Zn SOD on Inflammation-Induced Impairment of Vascular Reactivity|Completed||Phase 1|43||Medical University of Vienna|||||f||||f||||||||||2018-06-01 04:17:19.148278|2018-06-01 04:17:19.148278
NCT00264173|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2007-11-15|2005-12-09|2005-12-12|Estimate|||||||2007-11-15|2007-11-16|Estimate|February 2004||2004-02-29|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||VALID : VAlproate Versus LIthium in Bipolar Disorders|A Twelve-Week, Open, Randomized Trial Comparing Valproate to Lithium in Bipolar I Patients Suffering From a Manic Episode|Completed||Phase 4|270||Sanofi|||||f||||||||||||||2018-06-01 04:17:19.197793|2018-06-01 04:17:19.197793
NCT00264160|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2017-03-02|2005-12-09|2005-12-12|Estimate|||||||2017-03-02|2017-03-06|Actual|May 2006||2006-05-31|August 2012|2012-08-31|August 2009|Actual|2009-08-31|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy|Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy|Completed||Phase 2/Phase 3|36|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:17:19.298509|2018-06-01 04:17:19.298509
NCT00264147|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|2009-03-19||2015-01-29|2005-12-09|2005-12-12|Estimate|2009-05-22|2009-07-07|Estimate||||2015-01-29|2015-02-16|Estimate|January 2006||2006-01-31|January 2015|2015-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)|A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel-Group, 12-Week Study to Assess the Clinically Effective Dose Range of Etoricoxib and to Assess Its Safety and Tolerability in Patients With Rheumatoid Arthritis|Completed||Phase 2|761|Actual|Merck Sharp & Dohme Corp.||7|||f||||||||||||||2018-06-01 04:17:19.407105|2018-06-01 04:17:19.407105
NCT00264134|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2010-01-18|2005-12-08|2005-12-12|Estimate|||||||2010-01-18|2010-01-20|Estimate|June 2003||2003-06-30|January 2010|2010-01-31|October 2005||2005-10-31|||||Interventional|||Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer|A Phase I/II Trial: Docetaxel, Irinotecan, and Carboplatin in the Treatment of Extensive Stage Small Cell Lung Carcinoma|Terminated||Phase 1/Phase 2|40||Kentuckiana Cancer Institute|||||f||||||||||||||2018-06-01 04:17:21.743683|2018-06-01 04:17:21.743683
NCT00264121|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-05-21|2005-12-09|2005-12-12|Estimate|||||||2008-05-21|2008-05-22|Estimate|June 2005||2005-06-30|May 2008|2008-05-31|June 2008||2008-06-30|||||Observational|||The Incidence of Congenital Undescended Testis Among Dutch Infants|The Incidence of Congenital Undescended Testis Among Dutch Infants in the Medical Centre Alkmaar|Unknown status|Recruiting||3000|Anticipated|Medical Center Alkmaar|||||f||||||||||||||2018-06-01 04:17:21.826831|2018-06-01 04:17:21.826831
NCT00264108|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2014-05-06|2005-12-09|2005-12-12|Estimate|||||||2014-05-06|2014-05-07|Estimate|June 2005||2005-06-30|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia|EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE).|Completed|||492|Actual|Janssen-Cilag B.V.|||2||f||||||||||||||2018-06-01 04:17:21.896256|2018-06-01 04:17:21.896256
NCT00264095|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2014-04-25|2005-12-09|2005-12-12|Estimate|||||||2014-04-25|2014-04-28|Estimate|July 2004||2004-07-31|April 2014|2014-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||An Observational Study of Blood Management Techniques in Oncology Surgical Treatment|Blood Management Observation in Oncology Surgical Treatment (BOOST)|Completed|||488|Actual|Janssen-Cilag B.V.|||1||f||||||||||||||2018-06-01 04:17:21.98744|2018-06-01 04:17:21.98744
NCT00264082|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2017-12-27|2005-12-09|2005-12-12|Estimate|||||||2017-12-27|2017-12-29|Actual|September 2004||2004-09-30|December 2017|2017-12-31||||May 2006|Actual|2006-05-31||Observational|||Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis|"Tartrate-Resistant Acid Phosphatase as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis During Zometa Treatment: A Pilot Study"|Completed|||30|Anticipated|University of Louisville|||||f||||||||||||||2018-06-01 04:17:22.17881|2018-06-01 04:17:22.17881
NCT00264069|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2011-05-18|2005-12-09|2005-12-12|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2005||2005-06-30|April 2010|2010-04-30|June 2006|Actual|2006-06-30|||||Observational|||ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry|"Study ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: Mental Health Registry"|Completed|||2622|Actual|Janssen-Cilag, S.A.|||2||f||||||||||||||2018-06-01 04:17:22.237593|2018-06-01 04:17:22.237593
NCT00264056|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2005-12-08|2005-12-08|2005-12-12|Estimate|||||||2005-12-08|2005-12-12|Estimate|December 2005||2005-12-31|November 2005|2005-11-30|June 2007||2007-06-30|||||Interventional|||Efficacy of Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Progressive Soft Tissue Metastases|Evaluation of the Safety and Efficacy of Systemic Chemotherapy Combined With Regional Hypothermia in Advanced Malignant Melanoma Patients With Locally Inoperable Progressive Soft Tissue Metastases|Unknown status|Recruiting|N/A|26||Fachklinik Hornheide an der Universität Münster|||||f||||||||||||||2018-06-01 04:17:22.311564|2018-06-01 04:17:22.311564
NCT00264043|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-08-05|2005-12-09|2005-12-12|Estimate|||||||2008-08-05|2008-08-06|Estimate|May 2000||2000-05-31|August 2008|2008-08-31|June 2002|Actual|2002-06-30|February 2002|Actual|2002-02-28||Interventional|DISCOVER||The Study to Evaluate Patient Outcome Using Distal Protection Combined With the BX Velocity.|Distal Protection Combined With Velocity in Coronary Arteries and SVBG Registry.|Completed||Phase 2/Phase 3|100|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:17:22.372044|2018-06-01 04:17:22.372044
NCT00264030|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-01-04|2005-12-09|2005-12-12|Estimate|||||||2008-01-04|2008-01-07|Estimate|March 2002||2002-03-31|January 2008|2008-01-31|August 2004|Actual|2004-08-31|||||Interventional|DIPLOMAT||Distal Protection Combined With PTCA in AMI Patients|Distal Protection Combined With PTCA in AMI Patients -- The DIPLOMAT Study.|Completed||Phase 2|56|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:17:22.436123|2018-06-01 04:17:22.436123
NCT00264017|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2005-12-06|2005-12-06|2005-12-12|Estimate|||||||2005-12-06|2005-12-12|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis|Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis|Completed|||60||Dattoli Cancer Center and Brachytherapy Research Institute|||||f||||||||||||||2018-06-01 04:17:22.531071|2018-06-01 04:17:22.531071
NCT00264004|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|2012-07-26|2011-04-06|2012-07-26|2005-12-09|2005-12-12|Estimate|2012-07-26|2012-08-29|Estimate|2011-04-06|2011-04-12|Estimate|2012-07-26|2012-08-29|Estimate|November 2005||2005-11-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|January 2007|Actual|2007-01-31||Interventional|||Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours|A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients With Advanced Solid Tumours|Completed||Phase 2|119|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:17:22.611193|2018-06-01 04:17:22.611193
NCT00263991|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2005-12-09|2005-12-09|2005-12-12|Estimate|||||||2005-12-09|2005-12-12|Estimate||||August 2005|2005-08-31||||||||Observational|||Cortical Reorganisation in Patients With Primary Headache Disorders|Cortical Reorganisation in Patients With Primary Headache Disorders|Unknown status|Active, not recruiting||||Danish Headache Center|||||f||||||||||||||2018-06-01 04:17:23.532406|2018-06-01 04:17:23.532406
NCT00263978|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2014-06-27|2005-12-09|2005-12-12|Estimate|||||||2014-06-27|2014-07-01|Estimate|November 2005||2005-11-30|June 2014|2014-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Expanded Access|||Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver|Defibrotide Compassionate Use Protocol for Patients With Life Threatening Veno-Occlusive Disease of the Liver|No longer available|||||Emory University||||poor enrollment|f||||f||||||||||2018-06-01 04:17:23.581075|2018-06-01 04:17:23.581075
NCT00263965|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2008-03-14|2005-12-09|2005-12-12|Estimate|||||||2008-03-14|2008-03-17|Estimate|August 2005||2005-08-31|March 2008|2008-03-31|July 2006|Actual|2006-07-31|||||Interventional|||ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity|A 16-Week Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo- and Active- (Metformin) Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 2|105||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:17:23.638603|2018-06-01 04:17:23.638603
NCT00263952|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2013-03-01|2005-12-09|2005-12-12|Estimate|||||||2013-03-01|2013-03-04|Estimate|March 2003||2003-03-31|March 2013|2013-03-31|April 2010|Actual|2010-04-30|January 2005|Actual|2005-01-31||Interventional|||Efficacy and Safety of a Purified Standardised Bee Venom Preparation|Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.|Completed||Phase 3|||Allergopharma GmbH & Co. KG|||||f||||f||||||||||2018-06-01 04:17:23.708136|2018-06-01 04:17:23.708136
NCT00263939|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2010-10-04|2005-12-09|2005-12-12|Estimate|||||||2010-10-04|2010-10-05|Estimate|July 2004||2004-07-31|February 2010|2010-02-28|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Interventional|||Homing in on Health: Study of a Home Delivered Chronic Disease Self Management Program|A Randomized Trial of Home Self-Efficacy Enhancement|Completed||N/A|415|Actual|Agency for Healthcare Research and Quality (AHRQ)||3|||f||||t||||||||||2018-06-01 04:17:23.788174|2018-06-01 04:17:23.788174
NCT00263926|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-09|||2013-03-08|2005-12-09|2005-12-12|Estimate|||||||2013-03-08|2013-03-11|Estimate|March 2001||2001-03-31|March 2013|2013-03-31|November 2010|Actual|2010-11-30|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety of a Purified Standardised Wasp Venom Preparation|Immunotherapy of Wasp Venom Allergy: Comparison of a Purified Preparation to Conventional Aqueous Wasp Venom in an Open Controlled Study|Completed||Phase 3|||Allergopharma GmbH & Co. KG|||||f||||||||||||||2018-06-01 04:17:23.869182|2018-06-01 04:17:23.869182
NCT00263900|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2011-04-20|2005-12-08|2005-12-09|Estimate|||||||2011-04-20|2011-04-21|Estimate|December 2005||2005-12-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|||TGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit|Exploratory Study of the Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency Unit and Their Impact on the Assumption of Responsibility of the Suspect Children of a Viral Infection|Completed||N/A|377|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:17:23.937323|2018-06-01 04:17:23.937323
NCT00263887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-09-24||2014-08-05|2005-12-07|2005-12-09|Estimate|2014-08-05|2014-08-21|Estimate||||2014-08-05|2014-08-21|Estimate|December 2003||2003-12-31|August 2014|2014-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)|Multi-center, Randomized Trial With I.V. Prolastin® to Evaluate Frequency of Exacerbations and Progression of Emphysema by Means of Multi-slice CT Scans in Patients With Congenital Alpha-1-antitrypsin Deficiency.|Completed||Phase 2|77|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-06-01 04:17:24.074169|2018-06-01 04:17:24.074169
NCT00263874|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2007-07-20|2005-12-08|2005-12-09|Estimate|||||||2007-07-20|2007-07-23|Estimate|November 2005||2005-11-30|July 2007|2007-07-31|September 2006||2006-09-30|||||Interventional|||Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of UK-500,001 Dry Powder For Inhalation (DPI) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).|Terminated||Phase 2|324||Pfizer||||The decision to terminate was completely related to efficacy and there were no safety concerns.|f||||||||||||||2018-06-01 04:17:24.541368|2018-06-01 04:17:24.541368
NCT00263861|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2010-06-10|2005-12-07|2005-12-09|Estimate|||||||2010-06-10|2010-06-11|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors|Impact of Treatment With Taxane or Platinum-Containing Regimens on Peripheral Nerve Functioning in Older Cancer Patients With Diabetes: An Exploratory Study|Completed||N/A|14|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:17:24.623759|2018-06-01 04:17:24.623759
NCT00263835|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2010-03-01|2005-12-08|2005-12-09|Estimate|||||||2010-03-01|2010-03-02|Estimate|October 2004||2004-10-31|March 2010|2010-03-31|May 2006||2006-05-31|||||Interventional|||A Self-care Intervention for Latino Adults With Diabetes|A Self-care Intervention for Latino Adults With Diabetes|Completed||Phase 2|300||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:17:24.774584|2018-06-01 04:17:24.774584
NCT00263822|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2013-08-26|2005-12-07|2005-12-09|Estimate|||||||2013-08-26|2013-08-27|Estimate|September 2005||2005-09-30|August 2013|2013-08-31||||February 2008|Actual|2008-02-29||Interventional|||Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer|A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|Completed||Phase 3|835|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:17:24.856196|2018-06-01 04:17:24.856196
NCT00263809|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2009-10-06|2005-12-07|2005-12-09|Estimate|||||||2009-10-06|2009-10-07|Estimate|December 2005||2005-12-31|October 2009|2009-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products|Evaluation of the Safety and Performance of Platelet Transfusion Products Treated With MIRASOL® Pathogen Reduction Technology. A Study in Human Thrombocytopenic Subjects.|Completed||Early Phase 1|118|Actual|Terumo BCTbio||2|||f||||||||||||||2018-06-01 04:17:25.042056|2018-06-01 04:17:25.042056
NCT00263796|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2014-04-28|2005-12-08|2005-12-09|Estimate|||||||2014-04-28|2014-04-30|Estimate|March 2006||2006-03-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|October 2010|Actual|2010-10-31||Interventional|||An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism|An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism|Completed||Phase 1|16|Actual|Anagnostou, Evdokia, M.D.||2|||f||||t||||||||||2018-06-01 04:17:25.1788|2018-06-01 04:17:25.1788
NCT00263783|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2009-01-28|2005-12-08|2005-12-09|Estimate|||||||2009-01-28|2009-01-29|Estimate|March 2001||2001-03-31|January 2009|2009-01-31|June 2002|Actual|2002-06-30|April 2002|Actual|2002-04-30||Interventional|||Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors|Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors|Completed||Phase 1|24||MedImmune LLC||1|||f||||||||||||||2018-06-01 04:17:25.243798|2018-06-01 04:17:25.243798
NCT00263770|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2011-05-18|2005-12-07|2005-12-09|Estimate|||||||2011-05-18|2011-05-20|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Treatment Study of Soft Palatal Implants in Obstructive Sleep Apnea|A Randomized, Controlled Treatment Trial of Soft Palatal Implants and Positive Airway Pressure in Mild to Moderate Obstructive Sleep Apnea and Snoring|Completed||N/A|64|Actual|Mayo Clinic||3|||f||||f||||||||||2018-06-01 04:17:25.301679|2018-06-01 04:17:25.301679
NCT00263757|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|2014-05-30||2014-07-07|2005-12-07|2005-12-09|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Atrial Fibrillation Recurrence in Sleep Apnea|A Randomized Trial of Positive Airway Pressure Therapy In Atrial Fibrillation Recurrence In Sleep Apnea|Completed||N/A|25|Actual|Mayo Clinic|The primary barrier to enrollment was the high rate of subjects who were previously diagnosed with sleep apnea and were already prescribed treatment.|2|||f||||t||||||||||2018-06-01 04:17:25.376002|2018-06-01 04:17:25.376002
NCT00263744|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2009-01-07|2005-12-08|2005-12-09|Estimate|||||||2009-01-07|2009-01-08|Estimate|November 1999||1999-11-30|January 2009|2009-01-31|June 2001|Actual|2001-06-30|April 2001|Actual|2001-04-30||Interventional|||Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive|A Phase I/II Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus (HPV) Types 16 and 18, in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive|Completed||Phase 1/Phase 2|60|Actual|MedImmune LLC||2|||f||||||||||||||2018-06-01 04:17:25.587195|2018-06-01 04:17:25.587195
NCT00263731|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2016-11-21|2005-12-08|2005-12-09|Estimate|||||||2016-11-21|2016-11-23|Estimate|December 2005||2005-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Metabolomic Analysis of Lung Cancer|Preoperative Metabolomic Analysis of Primary Lung Cancer: A Translational Clinical Trial of the Brown Cancer Center|Recruiting|||750|Anticipated|James Graham Brown Cancer Center|||3||f||||t||||||||||2018-06-01 04:17:25.637391|2018-06-01 04:17:25.637391
NCT00263718|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2015-03-25|2005-12-08|2005-12-09|Estimate|||||||2015-03-25|2015-03-26|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|May 2006||2006-05-31|||||Interventional|||Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle Alone in Psoriasis Vulgaris|Completed||Phase 2|360||LEO Pharma|||||f||||||||||||||2018-06-01 04:17:25.715215|2018-06-01 04:17:25.715215
NCT00263705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-23|2005-12-08|2005-12-09|Estimate|||||||2011-02-23|2011-02-24|Estimate|January 2003||2003-01-31|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study|Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study|Completed||Phase 2|43|Actual|Jules Bordet Institute||1|||f||||f||||||||||2018-06-01 04:17:25.778148|2018-06-01 04:17:25.778148
NCT00263692|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2016-09-14|2005-12-08|2005-12-09|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2002||2002-11-30|September 2016|2016-09-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety|Open, Randomized, Phase II, Clinical Trial to Compare the Immunogenicity and Safety of a Booster Dose of GSK Biologicals' DTaP-IPV Vaccine (Infanrix®-IPV) Co-administered With a Booster Dose of Merck and Company's M-M-R®II, to That of Separate Injections of GSK Biologicals' DTaP Vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II Administered as Booster Doses to Healthy Children 4 to 6 Years of Age.|Completed||Phase 2|401|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:17:25.845378|2018-06-01 04:17:25.845378
NCT00263679|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2016-09-14|2005-12-08|2005-12-09|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2003||2003-11-30|September 2016|2016-09-30|October 2004|Actual|2004-10-31|May 2004|Actual|2004-05-31||Interventional|||Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.|A Phase III, Double-blinded, Randomized, Multicenter, Clinical Study to Assess the Safety and Immunogenicity of GSK Biologicals' Tdap 0.3 mg Candidate Vaccine When Given as a Booster Dose to Healthy School Children and Adolescents (9-13 Years of Age), Previously Vaccinated With a 5th Consecutive Dose of Acellular Pertussis-containing Vaccine, in Studies APV-118 or APV-120|Completed||Phase 3|321|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:17:25.958833|2018-06-01 04:17:25.958833
NCT00263666|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|2009-02-13||2016-11-09|2005-12-08|2005-12-09|Estimate|2009-03-12|2009-03-13|Estimate||||2016-11-09|2017-01-09|Estimate|March 2005||2005-03-31|November 2016|2016-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa|A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine|Completed||Phase 2|100|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:17:26.351531|2018-06-01 04:17:26.351531
NCT00263653|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2016-09-20|2005-12-08|2005-12-09|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|September 2005|Actual|2005-09-30|March 2005|Actual|2005-03-31||Interventional|||Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197|Study to Evaluate the Safety, Reactogenicity & Immunogenicity of a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™, vs Hib-MenC or Priorix™ Only, in Toddlers (13-14 m) Primed With 3 Doses of Hib (as Part of a DTPa -Containing Vaccine) & MenC-CRM197 Conjugate Vaccines.|Completed||Phase 3|297|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:17:27.204966|2018-06-01 04:17:27.204966
NCT00263640|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2015-01-14|2005-12-08|2005-12-09|Estimate|||||||2015-01-14|2015-01-15|Estimate|May 2005||2005-05-31|January 2015|2015-01-31|August 2012|Actual|2012-08-31|April 2009|Actual|2009-04-30||Interventional|||Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis|Completed||Phase 3|130|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 04:17:27.309687|2018-06-01 04:17:27.309687
NCT00263627|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2014-07-02|2005-12-08|2005-12-09|Estimate|||||||2014-07-02|2014-07-03|Estimate|June 2005||2005-06-30|November 2013|2013-11-30|March 2010|Actual|2010-03-31|June 2007|Actual|2007-06-30||Interventional|||Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens|A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens|Completed||Phase 3|253|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 04:17:27.384742|2018-06-01 04:17:27.384742
NCT00263614|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2009-01-30|2005-12-08|2005-12-09|Estimate|||||||2009-01-30|2009-02-03|Estimate|December 2005||2005-12-31|January 2009|2009-01-31|June 2007|Actual|2007-06-30|||||Observational|||Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.|A Cross Sectional and Retrospective Evaluation in HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)Patients With Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases(The MELT Study).|Completed|||100|Anticipated|Gilead Sciences|||||f||||||||||||||2018-06-01 04:17:27.479091|2018-06-01 04:17:27.479091
NCT00263419|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2011-10-26|2005-12-07|2005-12-08|Estimate|||||||2011-10-26|2011-10-27|Estimate|January 2005||2005-01-31|October 2011|2011-10-31|June 2012|Anticipated|2012-06-30|March 2012|Anticipated|2012-03-31||Interventional|HEIDIS||Stress-relief Management for Treatment of Late Complications in Type 2 Diabetes|Psychosoziale Intervention Zur Reduktion Diabetischer Spätschäden Bei Diabetes Mellitus Typ 2|Unknown status|Active, not recruiting|N/A|110|Actual|Heidelberg University|||||f||||||||||||||2018-06-01 04:17:28.763721|2018-06-01 04:17:28.763721
NCT00263601|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2014-06-04|2005-12-08|2005-12-09|Estimate|||||||2014-06-04|2014-06-05|Estimate|November 2001||2001-11-30|June 2014|2014-06-30|August 2010|Actual|2010-08-31|May 2004|Actual|2004-05-31||Interventional|||Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis|A Multicentre, Placebo Controlled, Double-Blind Study for Evaluation of Safety and Efficacy of Preseasonal Specific Immunotherapy With an Allergoid Preparation of an Extract of a 6 Grass Pollen Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity|Completed||Phase 3|154|Actual|Allergopharma GmbH & Co. KG||2|||f||||f||||||||||2018-06-01 04:17:27.530881|2018-06-01 04:17:27.530881
NCT00263588|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2018-04-27|2005-12-08|2005-12-09|Estimate|||||||2018-04-27|2018-05-01|Actual|December 2, 2005|Actual|2005-12-02|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|September 25, 2007|Actual|2007-09-25||Interventional|||Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer|A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy|Completed||Phase 2|244|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 04:17:27.619947|2018-06-01 04:17:27.619947
NCT00263575|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2013-01-31|2005-12-08|2005-12-09|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2005||2005-01-31|January 2013|2013-01-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients|A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakthrough Pain in Cancer Patients|Completed||Phase 3|97|Actual|Prostrakan Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:17:27.761354|2018-06-01 04:17:27.761354
NCT00263562|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2010-11-30|2005-12-08|2005-12-09|Estimate|||||||2010-11-30|2010-12-01|Estimate|December 2005||2005-12-31|November 2010|2010-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Steroid Treatment for Sickle Cell Pain Crisis|Randomized Trial of High-dose Intravenous Methylprednisolone and Steroid Taper for Vaso-occlusive Crises in Sickle Cell Disease|Completed||Phase 3|80|Anticipated|Baylor College of Medicine|||||f||||||||||||||2018-06-01 04:17:27.82331|2018-06-01 04:17:27.82331
NCT00263549|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2013-02-08|2005-12-08|2005-12-09|Estimate|||||||2013-02-08|2013-02-11|Estimate|September 2002||2002-09-30|February 2013|2013-02-28|February 2006|Actual|2006-02-28|February 2005|Actual|2005-02-28||Interventional|||Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis|Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity|Completed||Phase 4|||Allergopharma GmbH & Co. KG|||||f||||f||||||||||2018-06-01 04:17:27.888587|2018-06-01 04:17:27.888587
NCT00263536|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2017-10-05|2005-12-07|2005-12-08|Estimate|||||||2017-10-05|2017-10-06|Actual|December 5, 2005||2005-12-05|August 16, 2016|2016-08-16|August 16, 2016|Actual|2016-08-16|August 16, 2016|Actual|2016-08-16||Interventional|||Pilot Program for Targeted Prevention of Child or Adolescent Weight Gain|Pilot Program for Targeted Prevention of Child or Adolescent Weight Gain|Completed||Phase 1|147|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:17:27.941058|2018-06-01 04:17:27.941058
NCT00263523|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-08|||2017-06-30|2005-12-07|2005-12-08|Estimate|||||||2017-06-30|2017-07-02|Actual|December 5, 2005||2005-12-05|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY|PET Imaging of Brain 5-HT1A Receptors Using [11C](-)-RWAY|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:17:28.145658|2018-06-01 04:17:28.145658
NCT00263497|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2012-05-11|2005-12-07|2005-12-08|Estimate|||||||2012-05-11|2012-05-14|Estimate|March 2006||2006-03-31|May 2012|2012-05-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Temporary Prosthesis in Traumatic Below-knee Amputation|Immediate Temporary Prosthesis Fitting in Traumatic Trans-tibial Amputation: a Controlled Clinical Study in Rural Cambodia|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital of North Norway|||||f||||t||||||||||2018-06-01 04:17:28.219836|2018-06-01 04:17:28.219836
NCT00263484|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2011-07-19|2005-12-07|2005-12-08|Estimate|||||||2011-07-19|2011-07-21|Estimate|December 2005||2005-12-31|July 2011|2011-07-31|October 2010|Actual|2010-10-31|October 2008|Actual|2008-10-31||Interventional|dtZ||Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma|An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma|Completed||Phase 2|56|Actual|Gleneagles Hospital||1|||f||||t||||||||||2018-06-01 04:17:28.291981|2018-06-01 04:17:28.291981
NCT00263471|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2005-12-13|2005-12-06|2005-12-08|Estimate|||||||2005-12-13|2005-12-14|Estimate|October 2003||2003-10-31|October 2003|2003-10-31|March 2006||2006-03-31|||||Interventional|||Myopia Progression and the Effect of 7-Methylxanthine|Phase 2 Study of the Effect of 7-Methylxanthine on the Progression of Childhood Myopia|Unknown status|Active, not recruiting|Phase 2|90||Trier Research Laboratories|||||f||||||||||||||2018-06-01 04:17:28.392244|2018-06-01 04:17:28.392244
NCT00263458|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2011-09-08|2005-12-06|2005-12-08|Estimate|||||||2011-09-08|2011-09-12|Estimate|December 2005||2005-12-31|September 2011|2011-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|BHIVES-SF||Integrating Buprenorphine Into the SFGH AIDS Program|Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study)|Completed||Phase 4|37|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:17:28.496794|2018-06-01 04:17:28.496794
NCT00263445|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2014-12-01|2005-12-07|2005-12-08|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2004||2004-08-31|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Constructing an Insulin-Like Growth Factor-based Prediction Model|Constructing an Insulin-Like Growth Factor-based Prediction Model|Terminated|||30|Actual|University of California, Los Angeles||||Insufficient recruitment|f||||||||||||||2018-06-01 04:17:28.586501|2018-06-01 04:17:28.586501
NCT00263432|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2014-12-04|2005-12-06|2005-12-08|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Reparation of Cartilage Injuries in the Human Knee by Implantation of Fresh Human Allogenic Chondrocytes|Reparation of Cartilage Injuries in the Human Knee by Implantation of Fresh Human Allogenic Chondrocytes|Unknown status|Recruiting|N/A|10|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:17:28.639298|2018-06-01 04:17:28.639298
NCT00263406|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2007-12-19|2005-12-06|2005-12-08|Estimate|||||||2007-12-19|2007-12-28|Estimate|December 2002||2002-12-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation|Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation|Completed||Phase 2|40||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:17:28.834882|2018-06-01 04:17:28.834882
NCT00263393|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2012-06-21|2005-12-06|2005-12-08|Estimate|||||||2012-06-21|2012-06-22|Estimate|December 2005||2005-12-31|June 2012|2012-06-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|RAPCAPS||Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)|Evaluation of a Primary Health Care Intervention for the Prevention of Cardiovascular Disease in Rural Andhra Pradesh|Completed||Phase 4|3712|Actual|The George Institute||2|||f||||||||||||||2018-06-01 04:17:28.892011|2018-06-01 04:17:28.892011
NCT00263380|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2006-09-08|2005-12-07|2005-12-08|Estimate|||||||2006-09-08|2006-09-11|Estimate|October 2005||2005-10-31|July 2005|2005-07-31||||||||Observational|||Investigation on the Role of Corticosteroids and Beta-Agonists on Cytokine Production in COPD Patients|Experimental Study on the Role of Corticosteroids and Beta-Agonists on Cytokine Production in COPD Patients|Unknown status|Recruiting||90||St. Antonius Hospital|||||f||||||||||||||2018-06-01 04:17:28.972566|2018-06-01 04:17:28.972566
NCT00263367|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2011-06-21|2005-12-07|2005-12-08|Estimate|||||||2011-06-21|2011-06-22|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism|Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism: A Pilot Study|Completed||N/A|10|Actual|The International Child Development Resource Center||1|||f||||t||||||||||2018-06-01 04:17:29.039324|2018-06-01 04:17:29.039324
NCT00263354|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2010-11-05|2005-12-07|2005-12-08|Estimate|||||||2010-11-05|2010-11-09|Estimate|October 2003||2003-10-31|August 2010|2010-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Oxaliplatin in Gastric Cancer|Oxaliplatin Phase II Trial in Association With 5FU and Folinic Acid in the Treatment of Advanced Unresectable or Metastatic Gastric Cancer.|Completed||Phase 2|20||Sanofi|||||f||||||||||||||2018-06-01 04:17:29.102771|2018-06-01 04:17:29.102771
NCT00263341|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06||2012-07-10|2017-10-02|2005-12-06|2005-12-08|Estimate||||2012-09-25|2012-10-01|Estimate|2017-10-02|2017-10-06|Actual|December 2005||2005-12-31|October 2017|2017-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol|A Multicenter, Open-label Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of 150 ug of Nestorone® and 15 ug of Ethinyl Estradiol|Completed||Phase 3|1135|Actual|Population Council|||||f||||||||||||||2018-06-01 04:17:29.17074|2018-06-01 04:17:29.17074
NCT00263328|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2015-04-02||2015-06-16|2005-12-06|2005-12-08|Estimate|2015-06-16|2015-07-13|Estimate||||2015-06-16|2015-07-13|Estimate|December 2005||2005-12-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional||Safety population: all participants who received at least 1 dose of study medication in the study.|Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient|A Multicenter, Phase 2, Open-label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 Versus Tacrolimus, When Co-administered With Mycophenolate Mofetil In Renal Allograft Recipients|Completed||Phase 2|46|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 04:17:29.427244|2018-06-01 04:17:29.427244
NCT00263315|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2006-08-17|2005-12-07|2005-12-08|Estimate|||||||2006-08-17|2006-08-18|Estimate|January 2000||2000-01-31|August 2006|2006-08-31|May 2006||2006-05-31|||||Interventional|||Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis|Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial.|Completed||Phase 2/Phase 3|320||Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:17:35.848801|2018-06-01 04:17:35.848801
NCT00263302|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2008-07-02|2005-12-07|2005-12-08|Estimate|||||||2008-07-02|2008-07-04|Estimate|March 2006||2006-03-31|January 2005|2005-01-31|December 2006||2006-12-31|||||Interventional|||Diuretic Efficacy of Dexamethasone in Heart Failure|Diuretic Efficacy of Dexamethasone in Congestive Heart Failure Patients|Suspended||Phase 1|60||Hebei Medical University|||||f||||||||||||||2018-06-01 04:17:35.936702|2018-06-01 04:17:35.936702
NCT00263289|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2005-12-07|2005-12-07|2005-12-08|Estimate|||||||2005-12-07|2005-12-08|Estimate|January 2006||2006-01-31|December 2005|2005-12-31||||||||Observational|||Preprocedural Fasting and Nitrous Oxide -Oxygen Inhalation Analgesia for Dental Treatment of Children|The Effect of Preprocedural Fasting on Vomiting Frequency in Children Administered Nitrous Oxide -Oxygen Inhalation Analgesia for Dental Treatment|Unknown status|Not yet recruiting||100|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:17:36.009178|2018-06-01 04:17:36.009178
NCT00263276|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2016-11-16|2005-12-07|2005-12-08|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2005||2005-12-31|November 2016|2016-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Control on Diet and Exercise|Completed||Phase 2|389|Actual|AstraZeneca||7|||f||||f||||||||||2018-06-01 04:17:36.108016|2018-06-01 04:17:36.108016
NCT00263263|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2007-03-12|2005-12-07|2005-12-08|Estimate|||||||2007-03-12|2007-03-14|Estimate|September 2003||2003-09-30|March 2007|2007-03-31|December 2005||2005-12-31|||||Interventional|||RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.|Phase 2 Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Degenerated Saphenous Vein Grafts|Completed||Phase 2|75||Antwerp Cardiovascular Institute Middelheim|||||f||||t||||||||||2018-06-01 04:17:36.540814|2018-06-01 04:17:36.540814
NCT00263250|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2013-06-28|2005-12-06|2005-12-08|Estimate|||||||2013-06-28|2013-07-01|Estimate|February 1999||1999-02-28|June 2013|2013-06-30|February 2005|Actual|2005-02-28|December 2004|Actual|2004-12-31||Interventional|||Watchful Waiting Versus Open Tension-free Repair of Inguinal Hernia in Asymptomatic or Minimally Symptomatic Men|Watchful Waiting Versus Open Tension-free Repair of Inguinal Hernia in Asymptomatic or Minimally Symptomatic Men|Completed||N/A|724||Creighton University|||||f||||f||||||||||2018-06-01 04:17:36.609486|2018-06-01 04:17:36.609486
NCT00263237|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-07|||2017-06-30|2005-12-06|2005-12-07|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2, 2005||2005-12-02|July 23, 2008|2008-07-23|July 23, 2008||2008-07-23|||||Interventional|||STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency|A Pilot Study of Safety and Efficacy of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:17:36.705548|2018-06-01 04:17:36.705548
NCT00263211|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2016-07-21||2017-01-24|2005-12-06|2005-12-07|Estimate|2017-01-24|2017-03-15|Actual||||2017-01-24|2017-03-15|Actual|January 2006||2006-01-31|January 2017|2017-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients|The Impact Of Platelet Function Inhibition On Circulating Cancer Cells In Metastatic Breast Cancer Patients|Terminated||Phase 2|48|Actual|Washington University School of Medicine|"Inclusion of patients with no or few CTC's limited ability to distinguish anti-platelet therapeutic effect.~Early termination because of low probability of reaching statistical significance for primary outcome"|2||Stopped due to low percentage of patients with detectable CTCs at baseline.|f||||f||||||||||2018-06-01 04:17:36.800853|2018-06-01 04:17:36.800853
NCT00263198|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2013-05-06|2005-12-06|2005-12-07|Estimate|||||||2013-05-06|2013-05-07|Estimate|March 2006||2006-03-31|May 2013|2013-05-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer|Phase II Study of the Combination of PTK787/ZK222584 and Letrozole in Postmenopausal Women With Advanced Hormone Receptor Positive Breast Cancer|Terminated||Phase 2|4|Actual|Washington University School of Medicine||1||unacceptable toxicity|f||||||||||||||2018-06-01 04:17:37.451831|2018-06-01 04:17:37.451831
NCT00263185|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2014-09-18|2005-12-06|2005-12-07|Estimate|||||||2014-09-18|2014-09-22|Estimate|November 2005||2005-11-30|September 2014|2014-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status|A Double-Blind, Randomized, Placebo Controlled Trial of High Dose Vitamin D Therapy On Musculoskeletal Symptoms and Bone Mineral Density in Anastrozole-Treated Early Stage Breast Cancer Patients With Marginal Vitamin D Status|Completed||Early Phase 1|63|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 04:17:37.526839|2018-06-01 04:17:37.526839
NCT00263172|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2010-01-21|2005-12-05|2005-12-07|Estimate|||||||2010-01-21|2010-01-22|Estimate|February 2003||2003-02-28|December 2005|2005-12-31|March 2005||2005-03-31|||||Interventional|||Weight Loss on the Web: A Pilot Study Comparing a Commercial Website to a Structured Behavioral Intervention||Completed||N/A|||University of Vermont|||||f||||||||||||||2018-06-01 04:17:37.600986|2018-06-01 04:17:37.600986
NCT00263159|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2007-12-19|2005-12-06|2005-12-07|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study|Pharmaceutical Care for Asthma Control Improvement|Completed||N/A|221|Actual|University Ghent|||||f||||f||||||||||2018-06-01 04:17:37.729004|2018-06-01 04:17:37.729004
NCT00263146|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2017-01-13|2005-12-05|2005-12-07|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2005||2005-09-30|February 2010|2010-02-28|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers.|Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory (ARAMIS: Apport d'un Recrutement Alveolaire Sur Les Marqueurs de l'Inflammation Dans le SDRA)|Terminated||N/A|30|Anticipated|University Hospital, Tours||||Lack of inclusion due to changed medical practice|f||||t||||||||||2018-06-01 04:17:37.800453|2018-06-01 04:17:37.800453
NCT00263133|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2007-06-01|2005-12-06|2005-12-07|Estimate|||||||2007-06-01|2007-06-04|Estimate|December 2005||2005-12-31|May 2007|2007-05-31|January 2006||2006-01-31|||||Interventional|||Modulation of Visually Evoked Potentials by an Antidepressant|Modulation of Visually Evoked Potentials by an Antidepressant|Completed||N/A|12||University Hospital Freiburg|||||f||||||||||||||2018-06-01 04:17:37.876073|2018-06-01 04:17:37.876073
NCT00263120|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2016-08-23|2005-12-05|2005-12-07|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2006||2006-03-31|August 2016|2016-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Effects of Thymectomy During Cardiothoracic Surgery||Completed|||124|Actual|University of California, Los Angeles|||||f||||f||||||||No||2018-06-01 04:17:38.087384|2018-06-01 04:17:38.087384
NCT00263107|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2006-05-30|2005-12-05|2005-12-07|Estimate|||||||2006-05-30|2006-05-31|Estimate|August 2004||2004-08-31|December 2005|2005-12-31|June 2005||2005-06-30|||||Observational|||Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction.|Remote Post-Operative Rounding and the Physician Ability to Identify Morbidity|Completed|||270||University of California, Davis|||||f||||||||||||||2018-06-01 04:17:38.164617|2018-06-01 04:17:38.164617
NCT00263094|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2006-01-25|2005-12-06|2005-12-07|Estimate|||||||2006-01-25|2006-01-27|Estimate|September 2004||2004-09-30|January 2006|2006-01-31|November 2004||2004-11-30|||||Interventional|||An End to the Yom Kippur (and Ramadan) Headache|: An End to the Yom Kippur (and Ramadan) Headache: A Double Blind Placebo Controlled Trial of Prophylactic Rofecoxib in Preventing Ritual Fasting Headache.|Completed||N/A|220||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:17:38.237077|2018-06-01 04:17:38.237077
NCT00263081|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2012-05-23|2005-12-06|2005-12-07|Estimate|||||||2012-05-23|2012-05-24|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia|A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Co-administered With Current Lipid-lowering Therapy in Subjects With Homozygous Familial Hypercholesterolemia.|Terminated||Phase 3|44|Actual|Takeda||2||"Overall profile of the compound does not offer significant clinical advantage to patients over~   currently available lipid lowering agents"|f||||f||||||||||2018-06-01 04:17:38.316914|2018-06-01 04:17:38.316914
NCT00263068|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2014-09-24|2005-12-05|2005-12-07|Estimate|||||||2014-09-24|2014-09-25|Estimate|December 2005||2005-12-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome|An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|Completed||Phase 3|279|Actual|UCB Pharma||1|||f||||||||||||||2018-06-01 04:17:38.423203|2018-06-01 04:17:38.423203
NCT00263055|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2009-09-14|2005-12-06|2005-12-07|Estimate|||||||2009-09-14|2009-09-15|Estimate|August 2004||2004-08-31|September 2009|2009-09-30||||June 2005|Actual|2005-06-30||Interventional|||MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV|Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV|Completed||Phase 4|||Sanofi|||||f||||||||||||||2018-06-01 04:17:38.512424|2018-06-01 04:17:38.512424
NCT00263042|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06||2016-04-21|2016-04-21|2005-12-06|2005-12-07|Estimate||||2016-04-21|2016-05-20|Estimate|2016-04-21|2016-05-20|Estimate|December 2005||2005-12-31|April 2016|2016-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|CRESCENDO||Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes|Randomized, Multinational, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors|Terminated||Phase 3|18695|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 04:17:38.677842|2018-06-01 04:17:38.677842
NCT00263029|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2009-09-17|2005-12-06|2005-12-07|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2002||2002-06-30|September 2008|2008-09-30||||March 2007|Actual|2007-03-31||Interventional|PROCTFUL||Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer|Pre-operative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer (PROCTFUL)|Completed||Phase 2|18|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:17:38.832325|2018-06-01 04:17:38.832325
NCT00263016|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2008-03-18|2005-12-06|2005-12-07|Estimate|||||||2008-03-18|2008-03-20|Estimate|May 2005||2005-05-31|March 2008|2008-03-31||||||||Interventional|||Docetaxel in Non Small Cell Lung Cancer (NSCLC)|A Phase II Pilot Study of Combination of Irinotecan and Cisplatin in Docetaxel/Cisplatin-Responsive Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|50|Anticipated|Sanofi||||Slow recruitment|f||||||||||||||2018-06-01 04:17:38.894624|2018-06-01 04:17:38.894624
NCT00263003|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2007-12-06|2005-12-06|2005-12-07|Estimate|||||||2007-12-06|2007-12-07|Estimate|June 2005||2005-06-30|December 2007|2007-12-31||||||||Interventional|||Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension|A Randomized, Open Label Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension|Completed||Phase 3|40||Sanofi|||||f||||||||||||||2018-06-01 04:17:38.962476|2018-06-01 04:17:38.962476
NCT00262990|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06||2012-05-01|2012-05-02|2005-12-06|2005-12-07|Estimate||||2012-05-01|2012-05-03|Estimate|2012-05-02|2012-05-04|Estimate|November 2005||2005-11-30|May 2012|2012-05-31||||February 2010|Actual|2010-02-28||Interventional|||Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer|A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer|Completed||Phase 3|829|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:17:39.046206|2018-06-01 04:17:39.046206
NCT00262977|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2010-07-21|2005-12-05|2005-12-07|Estimate|||||||2010-07-21|2010-07-22|Estimate|September 2004||2004-09-30|July 2010|2010-07-31|May 2005||2005-05-31|||||Interventional|||Improving Aspirin Use in Diabetes: A Cluster Randomized Trial|Improving Appropriate Aspirin Use Among Adults With Diabetes in a Primary Care Setting: Using an Electronic Medical Record to Target a Physician-supervised Nurse Practitioner Intervention|Completed||N/A|300||Northwestern University|||||f||||||||||||||2018-06-01 04:17:39.440755|2018-06-01 04:17:39.440755
NCT00262964|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2010-03-15||2010-07-02|2005-12-06|2005-12-07|Estimate|2010-05-20|2010-06-28|Estimate||||2010-07-02|2010-07-07|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Obesity and Nonalcoholic Fatty Liver Disease|Obesity and Nonalcoholic Fatty Liver Disease|Completed||N/A|51|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 04:17:39.549898|2018-06-01 04:17:39.549898
NCT00262951|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2011-11-14||2017-12-03|2005-12-06|2005-12-07|Estimate|2012-01-03|2012-02-03|Estimate||||2017-12-03|2017-12-28|Actual|January 2005||2005-01-31|December 2017|2017-12-31|August 2011|Actual|2011-08-31|April 2011|Actual|2011-04-30||Interventional|||Chemoradiation in Locally Advanced Pancreatic Cancer|A Phase II Pilot Study of Multi-Agent Neo-Adjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Adenocarcinoma|Terminated||Phase 2|23|Actual|Masonic Cancer Center, University of Minnesota||1||Closed at a planned interim analysis by meeting a predefined toxicity endpoint|f||||t||||||||||2018-06-01 04:17:40.185957|2018-06-01 04:17:40.185957
NCT00262938|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2012-01-17|2005-12-06|2005-12-07|Estimate|||||||2012-01-17|2012-01-18|Estimate|February 2005||2005-02-28|January 2012|2012-01-31|August 2011|Actual|2011-08-31|January 2006|Actual|2006-01-31||Interventional|||Lifestyle Change and Quality of Life in Obese Patients With Stage I/II Endometrial Cancer in Remission|Lifestyle Change and Quality of Life in Obese Endometrial Cancer Survivors|Completed||N/A|47|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:17:40.493225|2018-06-01 04:17:40.493225
NCT00262925|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2014-04-25||2015-04-14|2005-12-06|2005-12-07|Estimate|2014-04-25|2014-05-23|Estimate||||2015-04-14|2015-05-05|Estimate|June 2006||2006-06-30|October 2013|2013-10-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional||All enrolled patients, and 7 were entered to the first step with 5mg Campath dose, 5 entered to the second step with 10mg Campath dose|Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL)|Terminated||Phase 2|12|Actual|National Cancer Institute (NCI)||1||slow accrual|f||||f||||||||||2018-06-01 04:17:40.621936|2018-06-01 04:17:40.621936
NCT00262899|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2013-01-04|2005-12-06|2005-12-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Interventional|||Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions|Genetic Counseling for Newly Diagnosed Breast Cancer Patients|Completed||Phase 3|331|Actual|Georgetown University||2|||f||||f||||||||||2018-06-01 04:17:41.823157|2018-06-01 04:17:41.823157
NCT00262886|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2013-06-05|2005-12-06|2005-12-07|Estimate|||||||2013-06-05|2013-06-06|Estimate|August 2001||2001-08-31|June 2013|2013-06-30||||July 2007|Actual|2007-07-31||Interventional|||Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer|Non-Myeloablative HLA-Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma|Completed||Phase 2|35|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:17:42.115262|2018-06-01 04:17:42.115262
NCT00262873|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2016-02-29||2016-04-04|2005-12-06|2005-12-07|Estimate|2016-04-04|2016-05-09|Estimate||||2016-04-04|2016-05-09|Estimate|May 2005||2005-05-31|April 2016|2016-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Bortezomib in Treating Patients With Myelodysplastic Syndromes|A Phase II Pilot Study of VELCADE in Patients With MDS|Completed||Phase 2|8|Actual|University of Rochester|All study visits were completed and the trial concluded normally for the limited number of enrolled participants; therefore, the study was considered to have been completed. However, the study is under-powered.|1|||f||||t||||||||||2018-06-01 04:17:42.325604|2018-06-01 04:17:42.325604
NCT00262860|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2016-02-25||2016-03-30|2005-12-06|2005-12-07|Estimate|2016-02-25|2016-03-28|Estimate||||2016-03-30|2016-05-09|Estimate|April 2005||2005-04-30|March 2016|2016-03-31||||May 2008|Actual|2008-05-31||Interventional|||Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|Phase II Pilot Study of Bortezomib (VELCADE®) and Gemcitabine for Patients With Relapsed or Refractory Hodgkin's Lymphoma|Completed||Phase 2|18|Actual|University of Rochester|Trial was stopped early by the Data Safety Monitoring Committee due to unexpected toxicity with no improvement in the response rate compared with gemcitabine alone. Trial was prespecified to be stopped early if these criteria were met.|1|||f||||t||||||||||2018-06-01 04:17:42.754956|2018-06-01 04:17:42.754956
NCT00262847|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2013-07-09||2017-10-23|2005-12-06|2005-12-07|Estimate|2013-09-16|2013-09-18|Estimate||||2017-10-23|2017-11-28|Actual|September 2005||2005-09-30|October 2017|2017-10-31|April 2015|Actual|2015-04-30|November 2010|Actual|2010-11-30||Interventional|||Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Completed||Phase 3|1873|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 04:17:43.145101|2018-06-01 04:17:43.145101
NCT00262834|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2013-07-10||2018-04-18|2005-12-06|2005-12-07|Estimate|2014-08-28|2014-09-08|Estimate||||2018-04-18|2018-05-17|Actual|October 2005||2005-10-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|October 2008|Actual|2008-10-31||Interventional|||Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer|A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With Newly Diagnosed Breast Cancer|Completed||N/A|54|Actual|National Cancer Institute (NCI)|The main limitation of the trial is the unexpectedly low proportion of matched evaluable samples available for the biomarkers studied, ranging from 44% to 92%.|1|||f||||||||||||||2018-06-01 04:17:46.087318|2018-06-01 04:17:46.087318
NCT00262821|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2015-10-09||2017-05-30|2005-12-06|2005-12-07|Estimate|2017-05-30|2017-07-02|Actual||||2017-05-30|2017-07-02|Actual|February 2006||2006-02-28|May 2017|2017-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||Eligible and evaluable patients.|Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer|A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis|Terminated||Phase 3|402|Actual|National Cancer Institute (NCI)|Premature closure due to lack of study drug leading to small number of subjects analyzed.|2||Study drug no longer available resulting in lack of study drug for participants.|f||||||||||||||2018-06-01 04:17:46.409547|2018-06-01 04:17:46.409547
NCT00262808|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2013-10-14|2005-12-06|2005-12-07|Estimate|||||||2013-10-14|2013-10-16|Estimate|March 2004||2004-03-31|October 2013|2013-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer|A PHASE II Study of GM-CSF As Pre- And Post-operative Adjuvant Therapy For Stage II And III Colon Cancer|Completed||Phase 2|50|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:17:48.052758|2018-06-01 04:17:48.052758
NCT00262795|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2018-05-09|2005-12-06|2005-12-07|Estimate|||||||2018-05-09|2018-05-15|Actual|September 2003||2003-09-30|May 2018|2018-05-31|October 2005|Actual|2005-10-31|January 2005|Actual|2005-01-31||Interventional|||Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia|Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia|Completed||Phase 3|206|Actual|German CLL Study Group||2|||f||||||||||||||2018-06-01 04:17:48.147062|2018-06-01 04:17:48.147062
NCT00262782|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2017-09-12|2005-12-06|2005-12-07|Estimate|||||||2017-09-12|2017-09-13|Actual|April 1997||1997-04-30|September 2017|2017-09-30|June 2010|Actual|2010-06-30|December 2004|Actual|2004-12-31||Interventional|||Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia|Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia|Completed||Phase 3|877|Actual|German CLL Study Group||2|||f||||||||||||No||2018-06-01 04:17:48.502981|2018-06-01 04:17:48.502981
NCT00262769|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2012-07-16|2005-12-06|2005-12-07|Estimate|||||||2012-07-16|2012-07-17|Estimate|May 2005||2005-05-31|July 2012|2012-07-31||||August 2008|Actual|2008-08-31||Interventional|ABC-02||Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors|Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study|Completed||Phase 3|324|Actual|University College, London||2|||f||||t||||||||||2018-06-01 04:17:48.815173|2018-06-01 04:17:48.815173
NCT00262743|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2011-12-07||2013-05-03|2005-12-06|2005-12-07|Estimate|2012-02-10|2012-03-13|Estimate||||2013-05-03|2013-05-30|Estimate|August 2005||2005-08-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|May 2010|Actual|2010-05-31||Interventional|||Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia|A Phase I/II Study of Daily Oral Polyphenon E in Asymptomatic, Rai Stage 0-II Patients With Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|73|Actual|Mayo Clinic||1|||f||||||||||||||2018-06-01 04:17:48.959396|2018-06-01 04:17:48.959396
NCT00262730|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2013-03-22||2014-06-16|2005-12-06|2005-12-07|Estimate|2014-06-16|2014-07-16|Estimate||||2014-06-16|2014-07-16|Estimate|January 2006||2006-01-31|June 2014|2014-06-30|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Interventional|||Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|97|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|"Other Adverse Events not reported for this study. Only serious(grade 3/4)related to either TMZ and/or Poly were reported. Subjects may have experienced grade 1 and grade 2 other adverse event but they have no bearing on clinical outcome of agent"|1|||f||||t||||||||||2018-06-01 04:17:49.419103|2018-06-01 04:17:49.419103
NCT00262717|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2006-06-08|2005-12-06|2005-12-07|Estimate|||||||2006-06-08|2006-06-09|Estimate|March 2001||2001-03-31|June 2006|2006-06-30|August 2002||2002-08-31|||||Interventional|||Can Resistance Enhance Selection of Treatment? (CREST)|A Randomised Comparator Study to Assess the Relative Efficacy of Genotypic Versus Virtual Phenotypic Resistance Tests in Treatment Experienced Patients With HIV Infection for Whom a Change in Therapy is Indicated|Completed||Phase 4|300||Kirby Institute|||||f||||||||||||||2018-06-01 04:17:49.641984|2018-06-01 04:17:49.641984
NCT00262704|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2014-08-20|2005-12-06|2005-12-07|Estimate|||||||2014-08-20|2014-08-21|Estimate|December 2001||2001-12-31|August 2014|2014-08-31|September 2002|Actual|2002-09-30|August 2002|Actual|2002-08-31||Interventional|||SimCare: Physician Intervention to Improve Diabetes Care|SimCare: Physician Intervention to Improve Diabetes Care|Completed||N/A|2020|Actual|HealthPartners Institute||3|||f||||f||||||||||2018-06-01 04:17:49.71939|2018-06-01 04:17:49.71939
NCT00262691|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2007-09-20|2005-12-06|2005-12-07|Estimate|||||||2007-09-20|2007-09-21|Estimate|May 2005||2005-05-31|September 2007|2007-09-30||||||||Observational|||Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study|Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study, the Kitanagoya Genome (KING) Study for the Local Residents of Kitanagoya, Japan|Unknown status|Recruiting||7000|Anticipated|Nagoya University|||||f||||f||||||||||2018-06-01 04:17:49.79117|2018-06-01 04:17:49.79117
NCT00262678|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2009-06-02|2005-12-06|2005-12-07|Estimate|||||||2009-06-02|2009-06-04|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.|Completed||Phase 3|||Prostrakan Pharmaceuticals|||||f||||||||||||||2018-06-01 04:17:49.858528|2018-06-01 04:17:49.858528
NCT00262665|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2012-12-10|2005-12-06|2005-12-07|Estimate|||||||2012-12-10|2012-12-11|Estimate|March 2005||2005-03-31|December 2012|2012-12-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder|Randomized, Placebo-controlled Trial of an AMPAkine in Major Depressive Disorder|Withdrawn||Phase 2|0|Actual|Icahn School of Medicine at Mount Sinai||2||protocol cancelled|f||||t||||||||||2018-06-01 04:17:49.912421|2018-06-01 04:17:49.912421
NCT00262652|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2011-06-24|2005-12-06|2005-12-07|Estimate|||||||2011-06-24|2011-06-27|Estimate|January 2006||2006-01-31|November 2005|2005-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics|Sodium Pyruvate Bronchodilation in Asthmatics|Terminated||Phase 1/Phase 2|20|Actual|Emphycorp||||Patients did not respond to therapy|f||||t||||||||||2018-06-01 04:17:49.980715|2018-06-01 04:17:49.980715
NCT00262639|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|2009-07-06||2009-12-09|2005-12-05|2005-12-07|Estimate|2009-07-06|2009-08-14|Estimate||||2009-12-09|2009-12-15|Estimate|December 2005||2005-12-31|December 2009|2009-12-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Prometa Protocol for Alcohol Dependence|A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention|Completed||Phase 2/Phase 3|60|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 04:17:50.073915|2018-06-01 04:17:50.073915
NCT00262626|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2005-12-05|2005-12-05|2005-12-07|Estimate|||||||2005-12-05|2005-12-07|Estimate|February 1995||1995-02-28|June 2003|2003-06-30|June 1995||1995-06-30|||||Interventional|||The Canadian Glaucoma Study|A Multicentre Study on the Risk Factors for the Progression of Open-Angle Glaucoma|Terminated||N/A|430||Dalhousie University|||||f||||||||||||||2018-06-01 04:17:50.365722|2018-06-01 04:17:50.365722
NCT00262613|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2006-05-25|2005-12-06|2005-12-07|Estimate|||||||2006-05-25|2006-05-29|Estimate|September 2004||2004-09-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Sodium Pyruvate Therapy in COPD Patients|Long-Term Use of Inhaled Sodium Pyruvate for the Treatment of Chronic Obstructive Pulmonary Disease|Completed||Phase 2|60||Emphycorp|||||||||||||||||||2018-06-01 04:17:50.586675|2018-06-01 04:17:50.586675
NCT00262600|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|2010-11-18||2014-11-05|2005-12-06|2005-12-07|Estimate|2011-01-17|2011-02-10|Estimate||||2014-11-05|2014-11-18|Estimate|November 2005||2005-11-30|April 2014|2014-04-30||||April 2009|Actual|2009-04-30||Interventional|||Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate|Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)|Completed||Phase 3|18113|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 04:17:51.210602|2018-06-01 04:17:51.210602
NCT00262587|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2012-05-15|2005-12-06|2005-12-07|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Elite Sport and Development of Asthma|Elite Sport and Development of Asthma|Completed||Phase 4|18|Actual|Bispebjerg Hospital||2|||f||||||||||||||2018-06-01 04:18:00.766301|2018-06-01 04:18:00.766301
NCT00262574|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2011-08-08|2005-12-06|2005-12-07|Estimate|||||||2011-08-08|2011-08-09|Estimate|July 2005||2005-07-31|December 2010|2010-12-31|June 2013|Anticipated|2013-06-30|April 2012|Anticipated|2012-04-30||Interventional|||Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty|Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1|Unknown status|Recruiting|Phase 4|500|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||f||||||||||2018-06-01 04:18:01.057186|2018-06-01 04:18:01.057186
NCT00262561|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-06|||2014-01-25|2005-12-06|2005-12-07|Estimate|||||||2014-01-25|2014-01-28|Estimate|January 2006||2006-01-31|January 2014|2014-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Resistance to Aspirin and/or Clopidogrel Among Patients With PAD.|Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin|Completed||Phase 4|263|Actual|Aalborg Universitetshospital||1|||f||||t||||||||||2018-06-01 04:18:01.270147|2018-06-01 04:18:01.270147
NCT00262548|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-08-24|2005-12-06|2005-12-07|Estimate|||||||2007-08-24|2007-08-28|Estimate|October 2005||2005-10-31|August 2007|2007-08-31||||||||Interventional|||C-Reactive Protein (CRP) in Obese Diabetic Women|Interventions Study for the Control of Diabetes Mellitus Type 2 in Obese Women|Completed||Phase 4|100|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:18:01.357207|2018-06-01 04:18:01.357207
NCT00262522|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|2009-07-09||2012-02-03|2005-12-05|2005-12-07|Estimate|2009-08-19|2009-08-20|Estimate||||2012-02-03|2012-02-06|Estimate|November 2005||2005-11-30|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects|A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects|Completed||Phase 3|664|Actual|Abbott||4|||f||||f||||||||||2018-06-01 04:18:01.54445|2018-06-01 04:18:01.54445
NCT00262509|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2013-09-17||2014-01-14|2005-12-02|2005-12-06|Estimate|2014-01-14|2014-02-11|Estimate||||2014-01-14|2014-02-11|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional||Includes groups randomized to do either baseline tests first or Intervention tests first|Emergency Egress and Information System for Persons With Vision Loss|Emergency Egress and Information System for Persons With Vision Loss|Terminated||N/A|17|Actual|VA Office of Research and Development|Trials were terminated early with just 17 Participants of the planned 24, as the intervention was NOT providing measurable benefit.|2||Intervention worsened performance for first 17 of 24 planned participants.|f||||f||||||||||2018-06-01 04:18:03.583793|2018-06-01 04:18:03.583793
NCT00262496|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2015-06-25|2005-12-02|2005-12-06|Estimate|||||||2015-06-25|2015-06-26|Estimate||||June 2015|2015-06-30||||||||Interventional|||Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.|Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.|Withdrawn||Phase 2|0|Actual|VA Office of Research and Development|||||||||||||||||||2018-06-01 04:18:04.04088|2018-06-01 04:18:04.04088
NCT00262483|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2007-12-17|2005-12-02|2005-12-06|Estimate|||||||2007-12-17|2007-12-21|Estimate|December 2005||2005-12-31|December 2007|2007-12-31|April 2006|Actual|2006-04-30|||||Interventional|||Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C|A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C|Completed||Phase 2|12||Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 04:18:04.115479|2018-06-01 04:18:04.115479
NCT00262470|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2017-09-13|2005-12-05|2005-12-06|Estimate|||||||2017-09-13|2017-09-14|Actual|April 1997|Actual|1997-04-30|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Treatment of Orthostatic Intolerance|Treatment of Orthostatic Intolerance|Active, not recruiting||Phase 1/Phase 2|150|Anticipated|Vanderbilt University Medical Center||20|||f||||f||||||||||2018-06-01 04:18:04.219981|2018-06-01 04:18:04.219981
NCT00262457|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2013-09-16|2005-12-02|2005-12-06|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2004||2004-04-30|September 2013|2013-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||BIONs, for Improved Tissue Health and Pressure Sore Prevention|BIONs, for Improved Tissue Health and Pressure Sore Prevention|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1||It was found that the devices were not suitable for the application.|f||||f||||||||||2018-06-01 04:18:04.416348|2018-06-01 04:18:04.416348
NCT00262444|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2007-12-19|2005-12-04|2005-12-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|May 2005|Actual|2005-05-31|||||Interventional|||Effectivity and Efficiency of Turning Frequencies: a Randomised Controlled Trial|Effectivity and Efficiency of Turning Frequencies: a Randomised Controlled Trial|Completed||N/A|500|Actual|University Ghent|||||f||||f||||||||||2018-06-01 04:18:04.492439|2018-06-01 04:18:04.492439
NCT00262431|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2012-06-07|2005-12-05|2005-12-06|Estimate|||||||2012-06-07|2012-06-08|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||Efficacy of Early Tracheostomy to Reduce Incidence of Ventilator Acquired Pneumonia (VAP)||Completed||Phase 3|320|Actual|University of Turin, Italy||2|||f||||||||||||||2018-06-01 04:18:04.601236|2018-06-01 04:18:04.601236
NCT00262418|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2007-12-19|2005-12-04|2005-12-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|July 2004||2004-07-31|December 2007|2007-12-31|May 2005|Actual|2005-05-31|||||Interventional|||Comparison of the Efficacy and Safety of Ivermectin to Permethrin|A Randomised, Double Blind, Double Dummy Study to Compare the Efficacy and Safety of a Single Administration of Ivermectin to a Single Administration of Permethrin for the Treatment of Scabies|Completed||Phase 2|160|Actual|University Ghent|||||f||||f||||||||||2018-06-01 04:18:04.73605|2018-06-01 04:18:04.73605
NCT00262405|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-02|2005-12-02|2005-12-06|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2001||2001-01-31|December 2015|2015-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis|Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis|Completed||Phase 2|44|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 04:18:04.799674|2018-06-01 04:18:04.799674
NCT00262392|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2015-03-09|2005-12-05|2005-12-06|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|June 2010|Anticipated|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Pamidronate for the Prevention of Heterotopic Ossification|Study Into the Effect of Pamidronate for the Prevention of Heterotopic Ossification in High-risk Patients: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 04:18:04.904661|2018-06-01 04:18:04.904661
NCT00262379|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2014-12-11|2005-12-05|2005-12-06|Estimate|||||||2014-12-11|2014-12-12|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C|Multicenter Study, Randomized and Pragmatic, Comparing Two Therapeutic Strategies : Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C and Treated by Combination Therapy Peginterferon Alfa-2a Plus Ribavirin|Completed||Phase 3|229|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-06-01 04:18:05.085942|2018-06-01 04:18:05.085942
NCT00262366|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2007-12-19|2005-12-04|2005-12-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|||Comparison of Automatic CPAP to Fixed CPAP for OSAS Following a Prediction Formula|Titration Efficacy of Automatic CPAP Versus Fixed CPAP, Following a Prediction Formula in Patients With OSAS|Completed||N/A|45||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:18:05.32145|2018-06-01 04:18:05.32145
NCT00262353|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2010-06-28|2005-12-04|2005-12-06|Estimate|||||||2010-06-28|2010-06-29|Estimate||||June 2010|2010-06-30||||||||Interventional|||Elimination of Protein-bound Uremic Retention Solutes by Prometheus Artificial Hepatic System Versus Conventional Dialysis|Elimination of Protein-bound Uremic Retention Solutes by Prometheus Artificial Hepatic System Versus Conventional Dialysis|Suspended||N/A|10|Anticipated|University Hospital, Ghent||||study never started because of safety alerts in literature regarding the topic to be examined|f||||f||||||||||2018-06-01 04:18:05.43703|2018-06-01 04:18:05.43703
NCT00262340|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2015-10-28|2005-12-05|2005-12-06|Estimate|||||||2015-10-28|2015-10-29|Estimate|December 2005||2005-12-31|October 2015|2015-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma|Prospective, Randomised Controlled Trial of the Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma|Completed||N/A|55|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-06-01 04:18:05.572712|2018-06-01 04:18:05.572712
NCT00262327|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2006-06-15|2005-12-02|2005-12-06|Estimate|||||||2006-06-15|2006-06-20|Estimate|May 2005||2005-05-31|December 2005|2005-12-31|February 2006||2006-02-28|||||Interventional|||Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor|Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Human Endostatin for Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|20||Sun Yat-sen University|||||f||||||||||||||2018-06-01 04:18:05.661218|2018-06-01 04:18:05.661218
NCT00262314|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|2010-05-21||2013-10-21|2005-12-05|2005-12-06|Estimate|2010-05-21|2010-06-23|Estimate||||2013-10-21|2013-11-14|Estimate|October 2000||2000-10-31|October 2013|2013-10-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Observational|RENEW||Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients|Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients|Completed|||509|Actual|EMD Serono|||||f||||||||||||||2018-06-01 04:18:05.767749|2018-06-01 04:18:05.767749
NCT00262301|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|2012-07-27||2012-09-27|2005-12-05|2005-12-06|Estimate|2012-07-27|2012-08-30|Estimate||||2012-09-27|2012-10-02|Estimate|June 2004||2004-06-30|September 2012|2012-09-30|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Randomized, Placebo-controlled, Double-blind Phase III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|Completed||Phase 3|75|Actual|Pharming Technologies B.V.||2|||f||||t||||||||||2018-06-01 04:18:06.424277|2018-06-01 04:18:06.424277
NCT00262288|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2013-02-21|2005-12-05|2005-12-06|Estimate|||||||2013-02-21|2013-02-22|Estimate|April 2004||2004-04-30|February 2013|2013-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|Completed||Phase 2/Phase 3|14|Actual|Pharming Technologies B.V.||1|||f||||||||||||||2018-06-01 04:18:07.154357|2018-06-01 04:18:07.154357
NCT00262275|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2016-01-21|2005-12-05|2005-12-06|Estimate|||||||2016-01-21|2016-01-22|Estimate|July 2002||2002-07-31|January 2016|2016-01-31||||July 2004|Actual|2004-07-31||Interventional|||Optimum Platelet Inhibition After Coronary Bypass Surgery|Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel|Completed||N/A|||Papworth Hospital NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:18:07.322864|2018-06-01 04:18:07.322864
NCT00262262|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2007-11-21|2005-12-05|2005-12-06|Estimate|||||||2007-11-21|2007-11-26|Estimate|March 2004||2004-03-31|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||The Effect of Levetiracetam on the Postmastectomy Pain Syndrome|The Effect of Levetiracetam on the Postmastectomy Pain Syndrome|Completed||N/A|25|Actual|Odense University Hospital|||||f||||f||||||||||2018-06-01 04:18:07.568732|2018-06-01 04:18:07.568732
NCT00262249|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2017-01-17|2005-12-05|2005-12-06|Estimate|||||||2017-01-17|2017-01-18|Estimate|August 2000||2000-08-31|January 2017|2017-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Effect of Growth Hormone in Children With Growth Hormone Deficiency|Effect of Growth Hormone in Children With Growth Hormone Deficiency and Idiopathic Short Stature|Completed||Phase 3|173|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:18:07.736274|2018-06-01 04:18:07.736274
NCT00262236|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2016-11-16|2005-12-02|2005-12-06|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2005||2005-11-30|November 2016|2016-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension|A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension|Completed||Phase 3|693|Actual|Novartis|||||||||||||||||||2018-06-01 04:18:08.024402|2018-06-01 04:18:08.024402
NCT00262223|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|2014-08-14||2018-02-13|2005-12-05|2005-12-06|Estimate|2014-09-03|2014-09-16|Estimate||||2018-02-13|2018-03-12|Actual|May 2006||2006-05-31|February 2018|2018-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Combined Treatment for Alcohol-Dependent Individuals With PTSD|Combined Treatment for Alcohol-Dependent Individuals With PTSD|Completed||Phase 2|69|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 04:18:08.322861|2018-06-01 04:18:08.322861
NCT00262210|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2005-12-05|2005-12-05|2005-12-06|Estimate|||||||2005-12-05|2005-12-06|Estimate|June 1995||1995-06-30|December 2005|2005-12-31|December 1999||1999-12-31|||||Interventional|||A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers|A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers|Completed||Phase 2|50||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:18:08.878861|2018-06-01 04:18:08.878861
NCT00262197|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2012-09-04|2005-12-05|2005-12-06|Estimate|||||||2012-09-04|2012-09-05|Estimate|December 2001||2001-12-31|September 2012|2012-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Patient Based Strategy to Reduce Errors in Diabetes Care|Patient Based Strategy to Reduce Errors in Diabetes Care|Completed||N/A|10000||HealthPartners Institute|||||f||||f||||||||||2018-06-01 04:18:08.994279|2018-06-01 04:18:08.994279
NCT00262184|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2005-12-05|2005-12-05|2005-12-06|Estimate|||||||2005-12-05|2005-12-06|Estimate|December 2004||2004-12-31|December 2005|2005-12-31|December 2007||2007-12-31|||||Interventional|||A Taiwan Isoflavone Multicenter Study (TIMS)|A Taiwan Isoflavone Multicenter Study (TIMS)|Unknown status|Recruiting|N/A|420||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:18:09.110123|2018-06-01 04:18:09.110123
NCT00262171|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2016-04-05|2005-12-05|2005-12-06|Estimate|||||||2016-04-05|2016-04-07|Estimate|May 2002||2002-05-31|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Hereditary Nonpolyposis Colorectal Cancer in Taiwan－Related Genetic Study and Clinical Applications|Hereditary Nonpolyposis Colorectal Cancer in Taiwan－Related Genetic Study and Clinical Applications|Unknown status|Active, not recruiting||1014|Actual|National Health Research Institutes, Taiwan|||||f||||f||||||||Undecided||2018-06-01 04:18:09.238681|2018-06-01 04:18:09.238681
NCT00262158|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2005-12-05|2005-12-05|2005-12-06|Estimate|||||||2005-12-05|2005-12-06|Estimate|August 2004||2004-08-31|December 2005|2005-12-31|September 2004||2004-09-30|||||Observational|||Analysis of 'Tobacco and Alcohol Tax Law' and Its Impact on Cigarette Consumption|The Survey of Cigarette Consumption|Completed|||4000||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:18:09.389452|2018-06-01 04:18:09.389452
NCT00262145|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2005-12-05|2005-12-05|2005-12-06|Estimate|||||||2005-12-05|2005-12-06|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|November 2005||2005-11-30|||||Interventional|||Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption|Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Uptake in Human|Completed||Phase 1|20||NatureGen|||||f||||||||||||||2018-06-01 04:18:09.484916|2018-06-01 04:18:09.484916
NCT00262132|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2018-04-06|2005-12-05|2005-12-06|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2003||2003-09-30|April 2018|2018-04-30|August 2006||2006-08-31|||||Interventional|||Mycophenolate for Pulmonary Sarcoidosis|Mycophenolate for Pulmonary Sarcoidosis|Terminated||Phase 3|20||Medical University of South Carolina|||||||||||||||||||2018-06-01 04:18:09.631043|2018-06-01 04:18:09.631043
NCT00262119|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|2014-05-09||2016-03-23|2005-12-04|2005-12-06|Estimate|2014-05-09|2014-06-11|Estimate||||2016-03-23|2016-04-21|Estimate|February 2006||2006-02-28|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|||MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure|MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure|Completed||Phase 4|1300|Actual|Medtronic Bakken Research Center||3|||f||||||||||||||2018-06-01 04:18:09.749279|2018-06-01 04:18:09.749279
NCT00262106|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05||2012-02-08|2012-09-05|2005-12-05|2005-12-06|Estimate||||2012-09-05|2012-09-10|Estimate|2012-09-05|2012-09-10|Estimate|October 2005||2005-10-31|September 2012|2012-09-30|September 2009|Actual|2009-09-30|August 2008|Actual|2008-08-31||Interventional|||Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection|An International Multi-centre, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 0.5% and 2% PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection|Completed||Phase 3|9404|Actual|Endo Pharmaceuticals||2|||f||||t||||||||||2018-06-01 04:18:10.782091|2018-06-01 04:18:10.782091
NCT00262093|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2007-03-19|2005-12-04|2005-12-06|Estimate|||||||2007-03-19|2007-03-20|Estimate|November 2005||2005-11-30|November 2005|2005-11-30||||||||Observational|||Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence|Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence|Unknown status|Recruiting||200|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:18:11.030252|2018-06-01 04:18:11.030252
NCT00262080|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|2009-12-30|2009-12-30|2016-08-01|2005-12-05|2005-12-06|Estimate|2010-04-09|2010-05-11|Estimate|2010-04-09|2010-05-11|Estimate|2016-08-01|2016-09-19|Estimate|December 2005||2005-12-31|August 2016|2016-08-31|February 2007|Actual|2007-02-28|December 2005|Actual|2005-12-31||Interventional|||Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)|A Double-blind, Placebo-controlled Study (72 Patients, Randomized 1:1) Followed by a Repeat-dosing Phase to Assess the Efficacy and Safety of DX-88 (Ecallantide; Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema|Completed||Phase 3|91|Actual|Shire||2|||f||||t||||||||||2018-06-01 04:18:11.141129|2018-06-01 04:18:11.141129
NCT00262067|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2013-08-20|2009-09-01|2013-11-18|2005-12-02|2005-12-06|Estimate|2013-08-20|2013-10-25|Estimate|2009-09-01|2009-09-02|Estimate|2013-11-18|2013-12-13|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|July 2008|Actual|2008-07-31||Interventional||Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.|A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)|A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 3|1237|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 04:18:12.097413|2018-06-01 04:18:12.097413
NCT00262054|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2010-03-12|2005-12-05|2005-12-06|Estimate|||||||2010-03-12|2010-03-15|Estimate|November 2005||2005-11-30|August 2008|2008-08-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)|Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3|Completed||Phase 4|4570|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:18:15.265556|2018-06-01 04:18:15.265556
NCT00262041|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2013-09-09||2016-09-23|2005-12-02|2005-12-06|Estimate|2013-09-09|2013-11-20|Estimate||||2016-09-23|2016-10-27|Estimate|October 2004||2004-10-31|September 2016|2016-09-30|March 2006||2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents|A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age|Completed||Phase 2|524|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:18:15.377207|2018-06-01 04:18:15.377207
NCT00262028|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2013-08-30||2016-01-12|2005-12-02|2005-12-06|Estimate|2016-01-12|2016-02-11|Estimate||||2016-01-12|2016-02-11|Estimate|April 2005||2005-04-30|January 2016|2016-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children|A Phase 2, Randomized, Single-blind, Controlled, Single-Center Study to Compare the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Children 2-10 Years of Age and an Open-label Study to Assess the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine Administered to Healthy Toddlers 12-23 Months of Age|Completed||Phase 2|910|Actual|Novartis||5|||f||||f||||||||||2018-06-01 04:18:15.897396|2018-06-01 04:18:15.897396
NCT00262015|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2005-12-02|2005-12-02|2005-12-06|Estimate|||||||2005-12-02|2005-12-06|Estimate|September 2003||2003-09-30|December 2005|2005-12-31||||||||Interventional|||Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine|A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate®|Unknown status|Active, not recruiting|Phase 4|264||Chiron Corporation|||||f||||||||||||||2018-06-01 04:18:17.450231|2018-06-01 04:18:17.450231
NCT00262002|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2013-09-02||2014-06-16|2005-12-02|2005-12-06|Estimate|2014-06-16|2014-06-18|Estimate||||2014-06-16|2014-06-18|Estimate|September 2004||2004-09-30|June 2014|2014-06-30|October 2006|Actual|2006-10-31|July 2005|Actual|2005-07-31||Interventional|||Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants|A Phase II, Randomized, Open Label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory After Two or Three Doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants at 2, 3, 4 or 2, 4, 6 Months of Age|Completed||Phase 2|601|Actual|Novartis||7|||f||||||||||||||2018-06-01 04:18:17.559908|2018-06-01 04:18:17.559908
NCT00261989|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-07-05|2005-12-02|2005-12-06|Estimate|||||||2011-07-05|2011-07-06|Estimate|November 2005||2005-11-30|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Observational|||Pulse Oximetry Readings and Hourly Variation in Oximetry Readings With CHD|The Retrospective Analysis of Presenting Pulse Oximetry Readings and Hourly Variation in Oximetry Readings in Patients With Known Congenital Heart Disease|Terminated|||1000|Actual|Children's Healthcare of Atlanta||||data insignificant, study terminated|f||||f||||||||||2018-06-01 04:18:19.628959|2018-06-01 04:18:19.628959
NCT00261976|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2014-03-15|2005-12-02|2005-12-06|Estimate|||||||2014-03-15|2014-03-18|Estimate|February 2002||2002-02-28|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||A Long-term Safety Study of Infliximab (Remicade)|Long-term Safety Follow-up of REMICADE (RESULTS)|Completed|||2971|Actual|Centocor, Inc.|||1||f||||t||||||||||2018-06-01 04:18:19.682013|2018-06-01 04:18:19.682013
NCT00261963|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2007-06-04|2005-12-02|2005-12-06|Estimate|||||||2007-06-04|2007-06-05|Estimate|February 2004||2004-02-29|June 2007|2007-06-30|August 2006||2006-08-31|||||Interventional|||The Effect of UV-Irradiation on Cutaneous Cicatrices|The Effect of UV-Irradiation on Cutaneous Cicatrices -A Randomised, Controlled Study With Clinical, Skin Reflectance, Histological and Biochemical Evaluations|Completed||N/A|15||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:18:20.198778|2018-06-01 04:18:20.198778
NCT00261950|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2013-10-07||2014-06-24|2005-12-02|2005-12-06|Estimate|2013-10-07|2013-12-04|Estimate||||2014-06-24|2014-07-21|Estimate|May 2006||2006-05-31|June 2014|2014-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|BONAFIDE||Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease|Bone Histomorphometry Assessment For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease|Completed||Phase 2|110|Actual|Amgen||1|||f||||f||||||||||2018-06-01 04:18:20.317242|2018-06-01 04:18:20.317242
NCT00261937|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2013-02-05|2005-12-05|2005-12-06|Estimate|||||||2013-02-05|2013-02-06|Estimate|December 2005||2005-12-31|December 2005|2005-12-31|April 2006|Actual|2006-04-30|||||Interventional|||Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants|Inhaled Furosemide Versus Placebo for Acute Viral Bronchiolitis in Hospitalized Infants|Completed||Phase 1|||Bnai Zion Medical Center|||||f||||||||||||||2018-06-01 04:18:20.919026|2018-06-01 04:18:20.919026
NCT00261924|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-05|||2010-04-13|2005-12-05|2005-12-06|Estimate|||||||2010-04-13|2010-04-14|Estimate|October 2005||2005-10-31|December 2005|2005-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|TESSI||Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days|Clinical Trial to Evaluate the Therapeutic Efficacy and Safety of INTERCEPT Platelets Stored for up to Seven Days After Collection|Completed||Phase 3|211|Actual|Cerus Corporation||2|||f||||t||||||||||2018-06-01 04:18:20.980908|2018-06-01 04:18:20.980908
NCT00261911|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2007-08-30|2005-12-02|2005-12-06|Estimate|||||||2007-08-30|2007-08-31|Estimate|July 2000||2000-07-31|August 2007|2007-08-31|February 2002||2002-02-28|||||Interventional|||A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.|A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents|Completed||Phase 3|498|Actual|Abbott|||||f||||f||||||||||2018-06-01 04:18:21.050622|2018-06-01 04:18:21.050622
NCT00261898|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-04|||2015-11-03|2005-12-03|2005-12-05|Estimate|||||||2015-11-03|2015-11-04|Estimate|November 2005||2005-11-30|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity|Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity|Terminated||Phase 2|239|Actual|National Institutes of Health Clinical Center (CC)||||"This study has been terminated. (Interim analysis of preliminary results indicated the need for~   protocol re-design)."|f||||||||||||||2018-06-01 04:18:21.107593|2018-06-01 04:18:21.107593
NCT00261872|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-03|||2017-06-30|2005-12-02|2005-12-05|Estimate|||||||2017-06-30|2017-07-02|Actual|December 1, 2005||2005-12-01|April 9, 2007|2007-04-09|April 9, 2007||2007-04-09|||||Interventional|||Treatment of Patients With Alcoholism and Attention Deficit Disorder|Treatment of Patients With Alcoholism and Attention Deficit Disorder|Completed||Phase 4|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:18:21.163433|2018-06-01 04:18:21.163433
NCT00261859|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2016-08-04|2005-12-02|2005-12-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|October 2005||2005-10-31|August 2016|2016-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Enhancing Emergency Practitioner (EP)-Performed Alcohol Interventions in the Emergency Department (ED)|Enhancing EP-Performed Alcohol Interventions in the ED|Completed||Phase 2/Phase 3|900|Actual|Yale University||4|||f||||f||||||||||2018-06-01 04:18:21.218242|2018-06-01 04:18:21.218242
NCT00261846|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2012-10-04|2011-11-15|2017-06-28|2005-12-02|2005-12-05|Estimate|2013-02-06|2013-03-12|Estimate|2011-11-15|2011-11-21|Estimate|2017-06-28|2017-07-27|Actual|January 18, 2006|Actual|2006-01-18|June 2017|2017-06-30|August 6, 2015|Actual|2015-08-06|September 25, 2009|Actual|2009-09-25||Interventional||All-treated population - included all enrolled participants who received at least one dose of bosutinib.|Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias|A Phase 1/2 Study Of Bosutinib (Ski-606) In Philadelphia Chromosome Positive Leukemias|Completed||Phase 2|571|Actual|Pfizer|Analyses of progression free survival and overall survival was based on all-treated population, instead of evaluable population which was the primary efficacy population as per planned analyses.|1|||f||||f||||||||||2018-06-01 04:18:21.475711|2018-06-01 04:18:21.475711
NCT00261833|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2014-11-02|2013-10-06|2015-01-11|2005-12-02|2005-12-05|Estimate|2015-01-11|2015-01-19|Estimate|2013-10-06|2013-10-28|Estimate|2015-01-11|2015-01-19|Estimate|March 2006||2006-03-31|January 2015|2015-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency|A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to Compare the Efficacy and Safety of 60mg/kg Body Weight of Zemaira® Weekly I.V. Administration With Placebo Weekly I.V. Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency|Completed||Phase 4|180|Actual|CSL Behring||2|||f||||t||||||||||2018-06-01 04:18:31.324809|2018-06-01 04:18:31.324809
NCT00261820|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2006-05-17|2005-12-02|2005-12-05|Estimate|||||||2006-05-17|2006-05-19|Estimate||||May 2006|2006-05-31|January 2005||2005-01-31|||||Interventional|||Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients|A Randomized Study To Compare The Safety And Efficacy Of Two Immunosuppressive Regimens In De Novo Renal Allograft Recipients:Sirolimus Plus Mycophenolate Mofetil Plus Corticosteroids Following A Rabbit Anti-Human Thymocyte Globulin Induction (RATG) Vs Tacrolimus Plus Mycophenolate Mofetil Plus Corticosteroids|Completed||Phase 4|160||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:18:32.054684|2018-06-01 04:18:32.054684
NCT00261807|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2018-03-14|2005-12-01|2005-12-05|Estimate|||||||2018-03-14|2018-03-16|Actual|June 2005||2005-06-30|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections|Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.|Completed||N/A|25|Actual|University of Maryland||1|||f||||||||||||||2018-06-01 04:18:32.12408|2018-06-01 04:18:32.12408
NCT00261794|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2010-01-05|2005-12-01|2005-12-05|Estimate|||||||2010-01-05|2010-01-06|Estimate|November 2004||2004-11-30|January 2010|2010-01-31|September 2007|Actual|2007-09-30|June 2007|Actual|2007-06-30||Interventional|||Cognitive Remediation for Schizophrenia|Computer Assisted Cognitive Remediation for Schizophrenia|Completed||N/A|90|Actual|VA Office of Research and Development||2|||f||||||||||||||2018-06-01 04:18:32.298208|2018-06-01 04:18:32.298208
NCT00261781|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2015-05-27|2005-12-01|2005-12-05|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|December 2006|Actual|2006-12-31||Interventional|||Walking Capacity in Parkinson's Disease (PD-Walk)|Does Home-based Treadmill Training Improve Walking Capacity and Quality of Life in People With Early to Mid-stage Parkinson's Disease?|Terminated||N/A|20|Actual|University of Sydney||2||20 subjects completed for a pilot, further funding required to continue study|f||||f||||||||||2018-06-01 04:18:32.367262|2018-06-01 04:18:32.367262
NCT00261768|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2010-03-19|2005-12-01|2005-12-05|Estimate|||||||2010-03-19|2010-03-23|Estimate|June 2004||2004-06-30|March 2010|2010-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial|Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial|Completed||N/A|288|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 04:18:32.434468|2018-06-01 04:18:32.434468
NCT00261755|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2008-05-06|2005-12-02|2005-12-05|Estimate|||||||2008-05-06|2008-05-07|Estimate|March 2001||2001-03-31|May 2008|2008-05-31|May 2004|Actual|2004-05-31|February 2004|Actual|2004-02-29||Interventional|||Acupuncture as Pain Relief and Relaxation During Childbirth|Acupuncture as Pain Relief and Relaxation During Childbirth. A Randomized Controlled Study|Completed||Phase 1/Phase 2|607|Actual|University of Aarhus||3|||f||||f||||||||||2018-06-01 04:18:32.500779|2018-06-01 04:18:32.500779
NCT00261742|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2007-01-16|2005-12-01|2005-12-05|Estimate|||||||2007-01-16|2007-01-17|Estimate|October 2005||2005-10-31|January 2007|2007-01-31|December 2006||2006-12-31|||||Interventional|||Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis|Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Dermatitis - an Open, Randomized, Controlled Trial|Terminated||Phase 4|194||University Children's Hospital Basel|||||f||||||||||||||2018-06-01 04:18:32.690729|2018-06-01 04:18:32.690729
NCT00261729|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2009-12-02|2005-12-01|2005-12-05|Estimate|||||||2009-12-02|2009-12-03|Estimate|July 2004||2004-07-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|August 2007|Actual|2007-08-31||Interventional|||Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees|Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees|Completed||N/A|210|Anticipated|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 04:18:32.758307|2018-06-01 04:18:32.758307
NCT00261716|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|2016-03-17||2016-06-17|2005-12-01|2005-12-05|Estimate|2016-06-17|2016-08-03|Estimate||||2016-06-17|2016-08-03|Estimate|January 2005||2005-01-31|June 2016|2016-06-30|February 2010|Actual|2010-02-28|September 2008|Actual|2008-09-30||Interventional|||Motivational Interviewing to Improve Work Outcomes in Schizophrenia|Motivational Interviewing to Improve Work Outcomes in Schizophrenia|Completed||Phase 3|38|Actual|VA Office of Research and Development|Small sample size reflecting recruitment challenges|2|||f||||f||||||||Yes|Contact PI for access to data|2018-06-01 04:18:32.854376|2018-06-01 04:18:32.854376
NCT00261703|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2012-05-10|2005-12-02|2005-12-05|Estimate|||||||2012-05-10|2012-05-11|Estimate|December 2002||2002-12-31|May 2012|2012-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Docetaxel in Head and Neck Cancer|Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck Cancer (LAHNC).|Completed||Phase 2/Phase 3|439|Actual|Sanofi||3|||f||||||||||||||2018-06-01 04:18:33.302546|2018-06-01 04:18:33.302546
NCT00261690|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2013-04-17|2005-12-02|2005-12-05|Estimate|||||||2013-04-17|2013-04-19|Estimate|February 2002||2002-02-28|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|VRPT/H2O/RT||Virtual Reality Pain Control During Burn Wound Care|Use of Virtual Reality for Adjunctive Treatment of Burn Pain|Completed||Phase 2/Phase 3|184|Actual|National Institute of General Medical Sciences (NIGMS)||1|||f||||f||||||||||2018-06-01 04:18:33.370336|2018-06-01 04:18:33.370336
NCT00261677|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-05-19|2005-12-02|2005-12-05|Estimate|||||||2011-05-19|2011-05-23|Estimate|August 2000||2000-08-31|April 2010|2010-04-30|October 2003|Actual|2003-10-31|||||Interventional|||A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) on Anemia and Quality of Life in Children With Cancer Undergoing Myelosuppressive Chemotherapy|Completed||Phase 3|224|Actual|Ortho Biotech Products, L.P.|||||f||||||||||||||2018-06-01 04:18:33.439838|2018-06-01 04:18:33.439838
NCT00261664|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-07-25|2005-12-02|2005-12-05|Estimate|||||||2011-07-25|2011-07-27|Estimate|September 2003||2003-09-30|July 2011|2011-07-31|July 2005|Actual|2005-07-31|||||Interventional|||Empowering Elders Through Technology|Empowering Elders Through Technology|Completed||Phase 1/Phase 2|290||Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:18:33.497327|2018-06-01 04:18:33.497327
NCT00261638|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2005-12-02|2005-12-02|2005-12-05|Estimate|||||||2005-12-02|2005-12-05|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|May 2006||2006-05-31|||||Observational|||A Study of the Effect of Mental Health Promotion on Mental Health Index|A Study of the Effect of Mental Health Promotion on Mental Health Index|Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:18:33.549622|2018-06-01 04:18:33.549622
NCT00261625|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2009-01-02|2005-12-01|2005-12-05|Estimate|||||||2009-01-02|2009-01-05|Estimate|August 2005||2005-08-31|December 2008|2008-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?|Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients?|Completed||Phase 4|50|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:18:33.606262|2018-06-01 04:18:33.606262
NCT00261612|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2006-10-17|2005-12-01|2005-12-05|Estimate|||||||2006-10-17|2006-10-18|Estimate|January 2005||2005-01-31|October 2006|2006-10-31|January 2007||2007-01-31|||||Interventional|||Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma||Unknown status|Active, not recruiting|Phase 2|16||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:18:33.668271|2018-06-01 04:18:33.668271
NCT00261599|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2008-11-06|2005-12-01|2005-12-05|Estimate|||||||2008-11-06|2008-11-07|Estimate|March 2006||2006-03-31|November 2008|2008-11-30|October 2006|Actual|2006-10-31|||||Interventional|||An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy|A Phase 3, Randomized, Double-Blind, Dose-Controlled Study to Assess the Efficacy and Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal to Moderate Sedation in Patients Undergoing Colonoscopy|Completed||Phase 3|300||Eisai Inc.|||||||||||||||||||2018-06-01 04:18:33.73788|2018-06-01 04:18:33.73788
NCT00261586|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-06-28|2005-12-02|2005-12-05|Estimate|||||||2011-06-28|2011-06-29|Estimate||||June 2011|2011-06-30|March 2004|Actual|2004-03-31|||||Interventional|||A Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach|Effect of Analgesics on the Irreversible Inactivation of Cyclooxygenase-1 Activity by Low Dose Aspirin and Endoscopic Evaluation of the Gastric Mucosal Effect|Completed||Phase 4|92|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|||||f||||||||||||||2018-06-01 04:18:33.816601|2018-06-01 04:18:33.816601
NCT00261573|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-05-17|2005-12-02|2005-12-05|Estimate|||||||2011-05-17|2011-05-18|Estimate|December 1998||1998-12-31|November 2010|2010-11-30|December 2000|Actual|2000-12-31|||||Interventional|||A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia|The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia|Completed||Phase 3|593|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:18:33.863826|2018-06-01 04:18:33.863826
NCT00261560|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-06-28|2005-12-02|2005-12-05|Estimate|||||||2011-06-28|2011-06-29|Estimate||||June 2011|2011-06-30|February 2004|Actual|2004-02-29|||||Interventional|||A Safety and Effectiveness Study of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Pain Associated With Ankle Sprains.|A Randomized, Double-Blind, Parallel-Group Study Comparing the Safety and Effectiveness of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Ankle Sprains.|Completed||Phase 4|260|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|||||||||||||||||||2018-06-01 04:18:33.917609|2018-06-01 04:18:33.917609
NCT00261547|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2008-02-15|2005-12-01|2005-12-05|Estimate|||||||2008-02-15|2008-02-25|Estimate|December 2005||2005-12-31|February 2008|2008-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Rituximab Treatment to Block HLA Antibodies in Renal Transplant Recipients|Pilot Study of Rituximab Treatment to Inhibit HLA Antibodies in Renal Allograft Recipients|Completed||Phase 1/Phase 2|0|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:18:33.974264|2018-06-01 04:18:33.974264
NCT00261534|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2006-09-13|2005-12-01|2005-12-05|Estimate|||||||2006-09-13|2006-09-14|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|July 2006||2006-07-31|||||Observational|||Cancer Related Fatigue in Patients Receiving Chemotherapy|Outcomes Research on the Course of Cancer Related Fatigue Throughout Five Chemotherapy Treatments|Unknown status|Active, not recruiting||90||Medical Center Alkmaar|||||f||||||||||||||2018-06-01 04:18:34.041204|2018-06-01 04:18:34.041204
NCT00261521|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2010-12-02|2005-12-02|2005-12-05|Estimate|||||||2010-12-02|2010-12-03|Estimate|February 2000||2000-02-29|December 2010|2010-12-31|May 2003|Actual|2003-05-31|||||Interventional|||A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients|Double-blind Study to Assess the Impact of Normalization of Hemoglobin Compared to Partial Correction of Hemoglobin With EPREX�/ERYPO� on Left Ventricular Structure in Early Hemodialysis Patients (RWJ-22512)|Completed||Phase 3|596|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:18:34.089308|2018-06-01 04:18:34.089308
NCT00261508|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-01-20|2005-12-02|2005-12-05|Estimate|||||||2011-01-20|2011-01-24|Estimate|August 1999||1999-08-31|January 2011|2011-01-31|December 2001|Actual|2001-12-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)|Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study|Completed||Phase 3|80|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:18:34.2123|2018-06-01 04:18:34.2123
NCT00261495|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|2012-11-20||2014-05-21|2005-12-02|2005-12-05|Estimate|2012-11-20|2012-12-24|Estimate||||2014-05-21|2014-06-03|Estimate|March 2006||2006-03-31|May 2014|2014-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.|Randomized, Open-Label, Comparative Parallel Group Study to Assess Efficacy and Safety on Flexible Dosages of OROS Hydromorphone Once-Daily Compared to Sustained Release Oxycodone Twice Daily in Subjects With Chronic Non-malignant Pain Requiring Continuous Opioid Therapy.|Completed||Phase 3|504|Actual|Janssen Pharmaceutica N.V., Belgium||2|||f||||f||||||||||2018-06-01 04:18:34.433476|2018-06-01 04:18:34.433476
NCT00261482|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2010-11-15|2005-12-02|2005-12-05|Estimate|||||||2010-11-15|2010-11-16|Estimate|July 2003||2003-07-31|November 2010|2010-11-30|December 2004|Actual|2004-12-31|||||Interventional|||Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.|An Open Label, Multicentre Study of the EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch in Europe: Evaluation of Women's Experience With EVRA� and Comparison With Previously Used Methods of Contraception.|Completed||Phase 4|778|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:18:36.577705|2018-06-01 04:18:36.577705
NCT00261469|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-05-16|2005-12-02|2005-12-05|Estimate|||||||2011-05-16|2011-05-17|Estimate|April 2003||2003-04-30|January 2011|2011-01-31|November 2004|Actual|2004-11-30|||||Interventional|||An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans|Efficacy of Topiramate Prophylaxis as add-on to Triptan Therapy for Migraine|Completed||Phase 2|38|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:18:36.629284|2018-06-01 04:18:36.629284
NCT00261456|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2017-09-12|2005-12-02|2005-12-05|Estimate|||||||2017-09-12|2017-09-14|Actual|October 2005||2005-10-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|||The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer|The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer: Targeted Screening in BRCA1/2 Mutation Carriers & Controls|Recruiting|||1700|Anticipated|Institute of Cancer Research, United Kingdom|||2||f||||t||||||Samples With DNA|"~     Whole blood, Serum, Plasma, Urine, Prostate tissue.~   "|Yes|Anonymised data can be applied for via the Data Access Committee|2018-06-01 04:18:36.753203|2018-06-01 04:18:36.753203
NCT00261443|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|2011-01-28||2013-11-07|2005-12-01|2005-12-05|Estimate|2011-04-08|2011-04-27|Estimate||||2013-11-07|2013-12-02|Estimate|September 2005||2005-09-30|April 2011|2011-04-30|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania|Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy|Completed||Phase 4|1270|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-06-01 04:18:37.117077|2018-06-01 04:18:37.117077
NCT00261430|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-05-16|2005-12-02|2005-12-05|Estimate|||||||2011-05-16|2011-05-17|Estimate||||April 2010|2010-04-30|October 2004|Actual|2004-10-31|||||Interventional|||A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.|"Schizophrenia Treatment Acceptance Response Trial: a 20-week, Open-label, Multicenter, Randomized Study Comparing the Effect of the GAIN Acceptance Approach Verses the Approach-as-usual in Supporting Patient Acceptance of Long-acting Risperidone (Risperdal� CONSTA�) in Adults With Schizophrenia"|Completed||Phase 4|650|Actual|Janssen, LP|||||f||||||||||||||2018-06-01 04:18:44.562242|2018-06-01 04:18:44.562242
NCT00261417|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2009-04-21|2005-12-01|2005-12-05|Estimate|||||||2009-04-21|2009-04-22|Estimate|May 2004||2004-05-31|April 2009|2009-04-30|October 2005|Actual|2005-10-31|||||Interventional|||Dose Response Study in Japanese Patients|A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes|Terminated||Phase 2|250||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:18:44.622072|2018-06-01 04:18:44.622072
NCT00261404|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-05-11|2005-12-02|2005-12-05|Estimate|||||||2011-05-11|2011-05-12|Estimate||||May 2011|2011-05-31||||||||Interventional|||TNFerade™ Biologic Plus Radiation for Metastatic Melanoma|"A Phase II, Open Label, Single Arm, Proof of Concept Study of TNFerade™ Plus Radiation in Patients With Metastatic Melanoma"|Completed||Phase 2|||GenVec|||||||||||||||||||2018-06-01 04:18:44.704259|2018-06-01 04:18:44.704259
NCT00261391|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2008-01-08|2005-12-02|2005-12-05|Estimate|||||||2008-01-08|2008-01-09|Estimate|October 2000||2000-10-31|May 2005|2005-05-31|October 2007||2007-10-31|||||Interventional|||Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.|Phase I Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Marimastat in Patients With Disabling Malformations and No Other Treatment Options|Completed||Phase 1|9||Boston Children’s Hospital|||||||||||||||||||2018-06-01 04:18:44.753403|2018-06-01 04:18:44.753403
NCT00261378|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2010-06-14|2005-12-01|2005-12-05|Estimate|||||||2010-06-14|2010-06-15|Estimate|November 2005||2005-11-30|June 2010|2010-06-30|January 2008|Actual|2008-01-31|||||Interventional|PRECISIONV||Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation|Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)|Completed||Phase 2|212|Actual|Biocompatibles UK Ltd|||||f||||||||||||||2018-06-01 04:18:44.812618|2018-06-01 04:18:44.812618
NCT00261365|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2016-09-27|2005-12-01|2005-12-05|Estimate|||||||2016-09-27|2016-09-29|Estimate|November 2005||2005-11-30|August 2008|2008-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)|An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients With Unresectable Stage III or IV Malignant Melanoma Randomized and Treated With Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels|Completed||Phase 1/Phase 2|80|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-06-01 04:18:44.999438|2018-06-01 04:18:44.999438
NCT00261352|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2009-04-21|2005-12-01|2005-12-05|Estimate|||||||2009-04-21|2009-04-22|Estimate|March 2005||2005-03-31|April 2009|2009-04-30|December 2006|Actual|2006-12-31|||||Interventional|||GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy With a Statin|Terminated||Phase 3|1000||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:18:45.119254|2018-06-01 04:18:45.119254
NCT00261339|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2012-05-04|2005-12-02|2005-12-05|Estimate|||||||2012-05-04|2012-05-07|Estimate|August 2005||2005-08-31|December 2006|2006-12-31||||||||Interventional|||Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)|PRISM: Determination of the Performance Characteristics of ReQuest (TradeMark) in Practice in the Stepped Down Management of GORD|Completed||Phase 4|300||Takeda|||||f||||||||||||||2018-06-01 04:18:45.540859|2018-06-01 04:18:45.540859
NCT00261326|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2011-01-07|2005-12-02|2005-12-05|Estimate|||||||2011-01-07|2011-01-10|Estimate|September 2006||2006-09-30|March 2009|2009-03-31|May 2011|Anticipated|2011-05-31|January 2010|Anticipated|2010-01-31||Interventional|||Simvastatin Treatment of Patients With Acute Optic Neuritis|Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial|Unknown status|Active, not recruiting|Phase 3|64|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-06-01 04:18:45.650731|2018-06-01 04:18:45.650731
NCT00261313|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2010-02-25|2005-12-02|2005-12-05|Estimate|||||||2010-02-25|2010-02-26|Estimate|December 2005||2005-12-31|February 2010|2010-02-28|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer|An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer|Completed||Phase 2|80|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:18:45.733491|2018-06-01 04:18:45.733491
NCT00261300|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2012-05-04|2005-12-02|2005-12-05|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2000||2000-10-31|December 2008|2008-12-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)|Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints|Completed||Phase 3|100|Anticipated|Takeda||1|||f||||||||||||||2018-06-01 04:18:45.793487|2018-06-01 04:18:45.793487
NCT00261287|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-02|||2016-11-29|2005-12-02|2005-12-05|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2005||2005-11-30|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age|Completed||Phase 3|102||AstraZeneca|||||f||||||||||||||2018-06-01 04:18:45.862696|2018-06-01 04:18:45.862696
NCT00261274|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2009-05-22|2005-11-30|2005-12-02|Estimate|||||||2009-05-22|2009-05-25|Estimate|November 2005||2005-11-30|May 2009|2009-05-31||||||||Interventional|||Safety Study of ECO Conversion System For Red Blood Cells.|Evaluation of the Safety of Repeated Autologous Infusions of Enzyme-Converted A-to-O (A-ECO) Red Cells Into Group A Volunteers.|Completed||Phase 1|60||Velico Medical|||||f||||t||||||||||2018-06-01 04:18:46.010316|2018-06-01 04:18:46.010316
NCT00261261|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2005-11-30|2005-11-30|2005-12-02|Estimate|||||||2005-11-30|2005-12-02|Estimate|January 2001||2001-01-31|November 2005|2005-11-30|December 2004||2004-12-31|||||Interventional|||Family-Centered Behavioral Preparation for Surgery|Study of the ADVANCE Behavioral Preparation Program for Children and Their Parents|Completed||N/A|400||Yale University|||||f||||||||||||||2018-06-01 04:18:46.091172|2018-06-01 04:18:46.091172
NCT00261248|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2015-10-01|2005-11-30|2005-12-02|Estimate|||||||2015-10-01|2015-10-05|Estimate|November 1996||1996-11-30|September 2003|2003-09-30|December 2003||2003-12-31|||||Interventional|||Vaccine for Recurrent Urinary Tract Infections in Women|Phase 2 Clinical Trial of Vaginal Mucosal Immunization for Recurrent Urinary Tract Infections|Completed||Phase 2|75||University of Wisconsin, Madison|||||||||||||||||||2018-06-01 04:18:46.158894|2018-06-01 04:18:46.158894
NCT00261235|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2009-01-24|2005-12-01|2005-12-02|Estimate|||||||2009-01-24|2009-01-27|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|January 2007|Actual|2007-01-31|January 2006|Actual|2006-01-31||Interventional|||Trial of Supported Employment Versus USES Supported Employment|A Randomized Trial of Supported Employment Versus USES Enhanced Supported Employment in Veterans With Serious Mental Illness|Completed||N/A|300|Anticipated|VA Connecticut Healthcare System|||||f||||||||||||||2018-06-01 04:18:46.228737|2018-06-01 04:18:46.228737
NCT00261222|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2010-02-02|2005-11-30|2005-12-02|Estimate|||||||2010-02-02|2010-02-03|Estimate|September 2005||2005-09-30|October 2006|2006-10-31|November 2005||2005-11-30|||||Interventional|||Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso|Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso|Completed||Phase 2|120||Heidelberg University|||||f||||||||||||||2018-06-01 04:18:46.295722|2018-06-01 04:18:46.295722
NCT00261209|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2016-04-20|2005-11-30|2005-12-02|Estimate|||||||2016-04-20|2016-04-21|Estimate|January 2005||2005-01-31|April 2016|2016-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Collagenase in the Treatment of Zone II Flexor Tendon Adhesions in the Hand|Study of Collagenase Injection Therapy for Treatment of Zone II Flexor Tendon Adhesions in the Hand|Completed||Phase 1/Phase 2|3|Actual|Stony Brook University||1|||f||||f||||||||No||2018-06-01 04:18:46.363436|2018-06-01 04:18:46.363436
NCT00261196|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2011-08-11|2005-11-30|2005-12-02|Estimate|||||||2011-08-11|2011-08-12|Estimate|January 2006||2006-01-31|August 2011|2011-08-31|January 2007|Anticipated|2007-01-31|||||Interventional|||Collagenase in the Treatment of Adhesive Capsulitis (Frozen Shoulder)||Withdrawn||Phase 2|58|Anticipated|Stony Brook University||||IND moved to sponsor.|||||||||||||||2018-06-01 04:18:46.429044|2018-06-01 04:18:46.429044
NCT00261183|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2005-12-01|2005-12-01|2005-12-02|Estimate|||||||2005-12-01|2005-12-02|Estimate|December 2004||2004-12-31|November 2005|2005-11-30|December 2006||2006-12-31|||||Interventional|||The Contribution of Melatonin Vs. Placebo in Benzodiazepine Withdrawal in Methadone Maintenance Treatment Patients||Unknown status|Recruiting|Phase 3|100||Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-06-01 04:18:46.477025|2018-06-01 04:18:46.477025
NCT00261170|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2008-05-22|2005-12-01|2005-12-02|Estimate|||||||2008-05-22|2008-05-23|Estimate|July 2003||2003-07-31|May 2008|2008-05-31|February 2007|Actual|2007-02-28|August 2006|Actual|2006-08-31||Interventional|||Bupropion for Hospital-Based Smoking Cessation|Bupropion for Hospital-Based Smoking Cessation|Completed||Phase 3|85|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:18:46.529856|2018-06-01 04:18:46.529856
NCT00261157|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2005-11-30|2005-11-30|2005-12-02|Estimate|||||||2005-11-30|2005-12-02|Estimate|April 2004||2004-04-30|November 2005|2005-11-30|June 2005||2005-06-30|||||Interventional|||Use of Robotic Telerounding After Operative Procedures|Use of Robotic Telerounding After Operative Procedures: Does It Affect Patient Outcomes?|Completed||N/A|72||University of California, Davis|||||f||||||||||||||2018-06-01 04:18:46.587692|2018-06-01 04:18:46.587692
NCT00261144|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2012-12-11|2005-12-01|2005-12-02|Estimate|||||||2012-12-11|2012-12-12|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|||Collagenase in the Treatment of Cellulite|Collagenase in the Treatment of Cellulite|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Stony Brook University|||||f||||f||||||||||2018-06-01 04:18:46.643027|2018-06-01 04:18:46.643027
NCT00261131|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2009-02-04|2005-11-30|2005-12-02|Estimate|||||||2009-02-04|2009-02-05|Estimate|March 2006||2006-03-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|||||Interventional|||Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy|Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial|Completed||Phase 3|250|Anticipated|Shriners Hospitals for Children|||||f||||||||||||||2018-06-01 04:18:46.707498|2018-06-01 04:18:46.707498
NCT00261118|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2014-11-05|2005-12-01|2005-12-02|Estimate|||||||2014-11-05|2014-11-06|Estimate|April 2004||2004-04-30|November 2014|2014-11-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Rituximab in Active Ulcerative Colitis|Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis|Completed||Phase 2/Phase 3|24|Actual|Royal Liverpool University Hospital||2|||f||||t||||||||||2018-06-01 04:18:46.759329|2018-06-01 04:18:46.759329
NCT00261105|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2009-09-24|2005-12-01|2005-12-02|Estimate|||||||2009-09-24|2009-09-25|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|December 2005|Actual|2005-12-31|October 2005|Actual|2005-10-31||Interventional|||Telithromycin in Respiratory Tract Infections|An Open, Multicenter, Non-comparative, Phase IV Trial of Efficacy and Safety of Ketek(Telithromycin) 800mg|Completed||Phase 4|||Sanofi|||||f||||||||||||||2018-06-01 04:18:46.978258|2018-06-01 04:18:46.978258
NCT00261092|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2008-04-14|2005-12-01|2005-12-02|Estimate|||||||2008-04-14|2008-04-15|Estimate|October 2005||2005-10-31|April 2008|2008-04-30||||||||Interventional|||GEMOX: Oxaliplatin in Pancreatic Cancer|Phase II Multicenter, Open Label Study of Oxaliplatin Combined With Gemcitabine(GEMOX) in Advanced and Metastatic Pancreatic Cancer|Completed||Phase 2|48||Sanofi|||||f||||||||||||||2018-06-01 04:18:47.032355|2018-06-01 04:18:47.032355
NCT00261079|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2007-11-05|2005-12-01|2005-12-02|Estimate|||||||2007-11-05|2007-11-07|Estimate|April 2005||2005-04-30|November 2007|2007-11-30|October 2006|Actual|2006-10-31|||||Interventional|||Fexofenadine in Pruritic Skin Disease|The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease|Completed||Phase 4|435|Actual|Handok Pharmaceuticals Co., Ltd.|||||f||||f||||||||||2018-06-01 04:18:47.086516|2018-06-01 04:18:47.086516
NCT00261066|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2018-03-23|2005-11-30|2005-12-02|Estimate|||||||2018-03-23|2018-03-27|Actual|September 2001||2001-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Outcome Following Orthopaedic Surgery|A Prospective Database for Orthopaedic Surgery|Recruiting|||15000|Anticipated|Ottawa Hospital Research Institute|||||f||||f|f|f||||||Undecided||2018-06-01 04:18:47.142974|2018-06-01 04:18:47.142974
NCT00261053|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2013-04-24|2005-12-01|2005-12-02|Estimate|||||||2013-04-24|2013-04-25|Estimate|June 2003||2003-06-30|April 2013|2013-04-30|December 2005|Actual|2005-12-31|September 2005|Actual|2005-09-30||Interventional|||Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Phase II Exploratory, Open-label Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|Completed||Phase 2|14|Actual|Pharming Technologies B.V.||1|||f||||t||||||||||2018-06-01 04:18:47.214482|2018-06-01 04:18:47.214482
NCT00261040|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2011-10-24|2005-11-30|2005-12-02|Estimate|||||||2011-10-24|2011-10-26|Estimate|June 2003||2003-06-30|October 2011|2011-10-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Minimally Invasive Surgery of the Hip Versus Standard Approach|Minimally Invasive Surgery of the Hip: A Randomized Study|Completed||N/A|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 04:18:47.279789|2018-06-01 04:18:47.279789
NCT00261027|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2010-03-01|2005-11-30|2005-12-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|January 2003||2003-01-31|March 2010|2010-03-31|September 2007|Actual|2007-09-30|July 2007|Actual|2007-07-31||Interventional|||Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer|A Pilot, Phase II, Single Center, Non-comparative, Open-label Study of Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer|Completed||Phase 2|30|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:18:47.346547|2018-06-01 04:18:47.346547
NCT00261014|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2015-11-17|2005-11-30|2005-12-02|Estimate|||||||2015-11-17|2015-11-18|Estimate|October 2002||2002-10-31|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Understanding Risk Factors Involved in Developing a Second Blood Clot.|REcurrent VEnous Thromboembolism Risk Stratification Evaluation A Study to Develop a Clinical Prediction Rule to Predict Low Recurrence Risk in Patients With Idiopathic Venous Thromboembolism.|Unknown status|Active, not recruiting||800|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:18:47.406328|2018-06-01 04:18:47.406328
NCT00261001|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2009-11-24|2005-12-01|2005-12-02|Estimate|||||||2009-11-24|2009-11-25|Estimate|October 2005||2005-10-31|November 2009|2009-11-30|September 2009|Actual|2009-09-30|February 2006|Actual|2006-02-28||Interventional|MANON-05||Safety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular Route|A Randomized Comparative Phase I Study to Evaluate and to Compare the Safety and Immunogenicity of a Transcutaneous Mode of Administration of a Licensed Tetanus/Influenza Vaccine to the Conventional Intramuscular Route of Vaccine Administration in Healthy Volunteers and HIV-infected Patients|Completed||Phase 1|38|Actual|Objectif Recherche Vaccins SIDA||2|||f||||f||||||||||2018-06-01 04:18:47.535734|2018-06-01 04:18:47.535734
NCT00260988|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2014-09-08|2005-11-30|2005-12-02|Estimate|||||||2014-09-08|2014-09-10|Estimate|October 2003||2003-10-31|July 2009|2009-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery|Tinzaparin Versus Dalteparin for Perioperative Thromboembolic Prophylaxis in Patients With Dialysis Dependent Renal Disease- A Canadian Multicentre Trial|Completed||Phase 2/Phase 3|29|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 04:18:47.610476|2018-06-01 04:18:47.610476
NCT00260975|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2017-09-20|2005-11-30|2005-12-02|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2001||2001-06-30|September 2017|2017-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Study of the Effects of Chemotherapy on Memory and Other Mental Functions in Women With Breast Cancer|A Prospective, Longitudinal Investigation of the Neuropsychological and Psychosocial Effects of Cancer Therapy|Completed|||112|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-06-01 04:18:47.683112|2018-06-01 04:18:47.683112
NCT00260962|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|2017-01-26||2018-01-05|2005-11-30|2005-12-02|Estimate|2017-03-19|2017-04-28|Actual||||2018-01-05|2018-01-30|Actual|September 2000||2000-09-30|January 2018|2018-01-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Olanzapine in the Treatment of Patients With Anorexia Nervosa|Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa: A Double Blind Placebo Controlled Study|Completed||Phase 2|34|Actual|Ottawa Hospital Research Institute||2|||f||||||||||||Undecided||2018-06-01 04:18:47.749232|2018-06-01 04:18:47.749232
NCT00260949|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2011-10-24|2005-11-30|2005-12-02|Estimate|||||||2011-10-24|2011-10-26|Estimate|November 2004||2004-11-30|October 2011|2011-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Outcome Following Surgery to Repair Rotator Cuff Tears|Functional and Anatomical Results Following Arthroscopic Cuff Repair|Completed||Phase 4|30|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:18:47.972291|2018-06-01 04:18:47.972291
NCT00260936|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2017-02-27|2005-11-30|2005-12-02|Estimate|||||||2017-02-27|2017-03-01|Actual|March 2006||2006-03-31|February 2016|2016-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Metabolic Abnormalities - HIV Infected and Uninfected Males|Prevalence of Morphologic and Metabolic Anormalities in HIV Infected and Uninfected Young Men|Completed|||250|Actual|University of North Carolina, Chapel Hill|||4||f||||f||||||||||2018-06-01 04:18:48.056402|2018-06-01 04:18:48.056402
NCT00260923|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2011-11-07|2005-12-01|2005-12-02|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2005||2005-11-30|November 2011|2011-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg, 150 mg and 300 mg to Placebo in Patients With Essential Hypertension|Completed||Phase 3|641|Actual|Novartis|||||f||||||||||||||2018-06-01 04:18:48.13866|2018-06-01 04:18:48.13866
NCT00260910|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2016-04-05|2005-12-01|2005-12-02|Estimate|||||||2016-04-05|2016-04-07|Estimate|May 2001||2001-05-31|August 2009|2009-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Progression Evaluation and Genetic Determinants of Hypertension in Chinese - A Follow-up Study of Taiwan SAPPHIRe|Progression Evaluation and Genetic Determinants of Hypertension in Chinese - A Follow-up Study of Taiwan SAPPHIRe|Completed|||1246|Actual|National Health Research Institutes, Taiwan|||||f||||f||||||Samples With DNA|"~     Plasma, serum, urine, and buffy coat~   "|Undecided||2018-06-01 04:18:48.201095|2018-06-01 04:18:48.201095
NCT00260897|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2007-05-07|2005-12-01|2005-12-02|Estimate|||||||2007-05-07|2007-05-08|Estimate|May 2003||2003-05-31|May 2007|2007-05-31|April 2008|Anticipated|2008-04-30|||||Observational|||Molecular Genetic Study of Avascular Necrosis of the Femoral Head|Molecular Genetic Study of Avascular Necrosis of the Femoral Head-Revealing ANFH Pathogenesis Mechanism by Cell and Animal Models|Unknown status|Recruiting||500|Anticipated|National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:18:48.252209|2018-06-01 04:18:48.252209
NCT00260884|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2005-12-01|2005-12-01|2005-12-02|Estimate|||||||2005-12-01|2005-12-02|Estimate|October 1993||1993-10-31|December 2005|2005-12-31|August 2004||2004-08-31|||||Interventional|||Phase III Study OF the Gastric Surgery on Advanced Stage Gastric Cancer|Phase III Study of the Effect of Radical Gastric Surgery Versus Conventional Surgery on Recurrence and Survival in Patients With Advanced Stage Gastric Cancer.|Completed||Phase 3|220||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:18:48.370226|2018-06-01 04:18:48.370226
NCT00260871|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2011-07-27|2005-12-01|2005-12-02|Estimate|||||||2011-07-27|2011-07-29|Estimate|May 2002||2002-05-31|July 2011|2011-07-31||||||||Observational|||Genetic Epidemiological Study of Lung Cancer in Taiwan and Clinical Applications|Genetic Epidemiological Study of Lung Cancer in Taiwan and Clinical Applications-focusing on Female Lung Adenocarcinoma (GEFLAC)|Unknown status|Active, not recruiting||1500|Anticipated|National Health Research Institutes, Taiwan|||||f||||t||||||||||2018-06-01 04:18:48.441825|2018-06-01 04:18:48.441825
NCT00260858|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2006-06-07|2005-11-30|2005-12-02|Estimate|||||||2006-06-07|2006-06-09|Estimate|November 2005||2005-11-30|June 2006|2006-06-30|April 2006||2006-04-30|||||Interventional|||GI Interlab 2 Study: Measuring the Glycaemic Index (GI) of Foods|Measuring the Glycaemic Index of Foods: Interlaboratory Study #2|Completed||N/A|280||Glycaemic Index Testing, Inc.|||||f||||||||||||||2018-06-01 04:18:48.507068|2018-06-01 04:18:48.507068
NCT00260832|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|2011-04-13||2011-09-20|2005-12-01|2005-12-02|Estimate|2011-08-16|2011-09-21|Estimate||||2011-09-20|2011-09-22|Estimate|November 2005||2005-11-30|September 2011|2011-09-30|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||Trial of Decitabine in Patients With Acute Myeloid Leukemia|Randomized Phase 3 Trial of Decitabine Versus Patient's Choice With Physician's Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 3|485|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:18:48.610515|2018-06-01 04:18:48.610515
NCT00260819|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2008-10-16|2005-12-01|2005-12-02|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2006||2006-01-31|March 2007|2007-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia|Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia|Completed||Phase 1|20|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:18:49.130144|2018-06-01 04:18:49.130144
NCT00260806|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2014-03-17|2005-12-01|2005-12-02|Estimate|||||||2014-03-17|2014-03-18|Estimate|August 2004||2004-08-31|March 2014|2014-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children|HAART Associated Cardiotoxicity in HIV-Infected Children|Completed|||71|Actual|University of Miami|||2||f||||t||||||Samples With DNA|"~     Peripheral blood mononuclear cells (PBMCs) were collected from the WITS cohort to investigate~     the presence of mitochondrial DNA (mtDNA) mutations.~   "|||2018-06-01 04:18:49.201802|2018-06-01 04:18:49.201802
NCT00260793|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2006-02-02|2005-12-01|2005-12-02|Estimate|||||||2006-02-02|2006-02-03|Estimate|November 2005||2005-11-30|November 2005|2005-11-30||||||||Interventional|||Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease|Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease|Unknown status|Recruiting|Phase 3|20||Colorado Neurology|||||f||||||||||||||2018-06-01 04:18:49.273618|2018-06-01 04:18:49.273618
NCT00260780|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2005-12-01|2005-12-01|2005-12-02|Estimate|||||||2005-12-01|2005-12-02|Estimate|June 2001||2001-06-30|December 2005|2005-12-31|June 2004||2004-06-30|||||Interventional|||An STD Prevention Intervention for Men Newly Released From Jail|The MISTERS Project: An STD Prevention Intervention for Men Newly Released From Jail|Completed||N/A|300||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:18:49.332738|2018-06-01 04:18:49.332738
NCT00260767|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2005-11-30|2005-11-30|2005-12-02|Estimate|||||||2005-11-30|2005-12-02|Estimate||||November 2005|2005-11-30||||||||Interventional|||Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution|An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution|Unknown status|Not yet recruiting|Phase 1|6||Biosyn|||||f||||||||||||||2018-06-01 04:18:49.453005|2018-06-01 04:18:49.453005
NCT00260754|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2006-05-30|2005-12-01|2005-12-02|Estimate|||||||2006-05-30|2006-05-31|Estimate|October 2002||2002-10-31|December 2005|2005-12-31|July 2005||2005-07-31|||||Interventional|||Utilization of the Community Popular Opinion Leader (C-POL) Model in Alabama|Utilization of the Community Popular Opinion Leader (C-POL) Model to Achieve Syphilis Elimination in Alabama|Completed||N/A|600||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:18:49.519718|2018-06-01 04:18:49.519718
NCT00260741|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2007-04-03|2005-11-30|2005-12-02|Estimate|||||||2007-04-03|2007-04-04|Estimate|March 2003||2003-03-31|April 2007|2007-04-30|January 2006|Actual|2006-01-31|||||Interventional|||Cannabis for Spasticity in Multiple Sclerosis|Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study|Terminated||Phase 1/Phase 2|60||Center for Medicinal Cannabis Research||||Discontinued due to non-enrollment.|||||||||||||||2018-06-01 04:18:49.587247|2018-06-01 04:18:49.587247
NCT00260728|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2012-06-26|2005-11-30|2005-12-02|Estimate|||||||2012-06-26|2012-06-27|Estimate|December 2005||2005-12-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|May 2007|Actual|2007-05-31||Interventional|ACCESS||The Boston Scientific ACCESS Trial|ACCESS: Prospective, Multi-center Trial of the Fusion Vascular Access Graft for Patients Who Require Early Vascular Access for Hemodialysis|Terminated||Phase 2/Phase 3|149|Actual|Maquet Cardiovascular||1|||f||||||||||||||2018-06-01 04:18:49.659079|2018-06-01 04:18:49.659079
NCT00260715|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2005-12-01|2005-12-01|2005-12-02|Estimate|||||||2005-12-01|2005-12-02|Estimate|October 2002||2002-10-31|December 2005|2005-12-31|July 2005||2005-07-31|||||Interventional|||A Community-Based Intervention With Popular Opinion Leaders (C-POL) in Texas|A Community-Based Intervention With Popular Opinion Leaders (C-POL) in Texas to Achieve Syphilis Elimination|Completed||N/A|1200||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:18:49.751578|2018-06-01 04:18:49.751578
NCT00260702|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|||2017-06-30|2005-11-30|2005-12-01|Estimate|||||||2017-06-30|2017-07-02|Actual|November 24, 2005||2005-11-24|March 15, 2010|2010-03-15|March 19, 2010|Actual|2010-03-19|March 19, 2010|Actual|2010-03-19||Interventional|||Omalizumab to Treat Hyper-IgE (Job's) Syndrome|Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome|Completed||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:18:49.8189|2018-06-01 04:18:49.8189
NCT00260689|ClinicalTrials.gov processed this data on May 31, 2018|2005-12-01|2017-05-16||2017-05-16|2005-11-30|2005-12-01|Estimate|2017-05-16|2017-06-08|Actual||||2017-05-16|2017-06-08|Actual|November 28, 2005||2005-11-28|May 15, 2017|2017-05-15|May 4, 2016|Actual|2016-05-04|May 4, 2016|Actual|2016-05-04||Interventional|||Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia|A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab|Completed||Phase 2|136|Actual|National Institutes of Health Clinical Center (CC)|Originally, there were 3 regimens: h-ATG/CsA ; r-ATG/CsA; alemtuzumab. Subjects not responding to r-ATG will cross over to alemtuzumab, and subjects failing alemtuzumab will cross over to r-ATG. Subjects not responding to h-ATG/CsA will go off study.|3|||f|||||t|f||||||Yes|NIH Biomedical Translational Research Information System (BTRIS)|2018-06-01 04:18:49.927823|2018-06-01 04:18:49.927823
NCT00260676|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2009-06-16|2005-11-29|2005-12-01|Estimate|||||||2009-06-16|2009-06-17|Estimate|September 2004||2004-09-30|June 2009|2009-06-30|January 2010|Anticipated|2010-01-31|September 2009|Anticipated|2009-09-30||Interventional|||Protective Ventilatory Strategy in Potential Organ Donors|a Randomised Control Trial on Protective Ventilatory Strategy in Potential Organ Donors|Unknown status|Recruiting|Phase 3|200|Anticipated|University of Turin, Italy||1|||f||||||||||||||2018-06-01 04:18:50.762437|2018-06-01 04:18:50.762437
NCT00260663|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2015-04-06|2005-11-29|2005-12-01|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2006||2006-02-28|January 2008|2008-01-31|June 2008|Actual|2008-06-30|October 2007|Actual|2007-10-31||Interventional|||The Hearing Aid Effectiveness After Aural Rehabilitation (HEAR) Trial|The Hearing Aid Effectiveness After Aural Rehabilitation (HEAR) Trial|Completed||N/A|660|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:18:50.847606|2018-06-01 04:18:50.847606
NCT00260650|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2014-09-29|2005-11-30|2005-12-01|Estimate|||||||2014-09-29|2014-09-30|Estimate|September 2006||2006-09-30|September 2014|2014-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Heart PACT||Patient Activation in High-Risk Patients With Heart Failure|Heart PACT: Patient Activation in High-Risk Patients With Heart Failure|Completed||N/A|84|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:18:50.91597|2018-06-01 04:18:50.91597
NCT00260637|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2006-10-25|2005-11-29|2005-12-01|Estimate|||||||2006-10-25|2006-10-26|Estimate|February 2004||2004-02-29|November 2005|2005-11-30|August 2005||2005-08-31|||||Interventional|||Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis|A Double Blind, Sham Controlled Trial Evaluating the Efficacy of Acupuncture in Relieving Symptoms of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome|Completed||Phase 2/Phase 3|86||University of Science Malaysia|||||f||||||||||||||2018-06-01 04:18:50.971497|2018-06-01 04:18:50.971497
NCT00260624|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2012-02-23|2005-11-29|2005-12-01|Estimate|||||||2012-02-23|2012-02-24|Estimate|February 2003||2003-02-28|February 2012|2012-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Escitalopram Treatment of Patients With Agitated Dementia|Escitalopram in the Treatment of Patients With Agitated Dementia|Completed||Phase 4|20|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:18:51.020682|2018-06-01 04:18:51.020682
NCT00260611|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2015-03-24|2005-11-30|2005-12-01|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2004||2004-11-30|March 2015|2015-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study of Oxaliplatin and Taxotere in Prostate Cancer|Study of Oxaliplatin and Taxotere in Androgen Independent Prostate Cancer|Completed||Phase 2|34|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:18:51.078989|2018-06-01 04:18:51.078989
NCT00260598|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2017-03-31|2005-11-29|2005-12-01|Estimate|||||||2017-03-31|2017-04-04|Actual|August 1998||1998-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|January 2010|Actual|2010-01-31||Interventional|||LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer|LIFE-Lung Fluorescence Endoscopic Surveillance in Patients at High Risk For Developing Lung Cancer|Terminated||Phase 2|142|Actual|University of Pittsburgh||||LIFE Bronchoscopy equipment no longer functioning and cannot be repaired.|f||||||||||||||2018-06-01 04:18:51.142085|2018-06-01 04:18:51.142085
NCT00260585|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2017-11-03|2005-11-28|2005-12-01|Estimate|||||||2017-11-03|2017-11-07|Actual|June 1999||1999-06-30|November 2017|2017-11-30|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|||Esophageal Cancer Risk Registry|Esophageal Cancer Risk Registry|Recruiting|||6000|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     blood, tissue, lymph nodes~   "|Undecided||2018-06-01 04:18:51.341961|2018-06-01 04:18:51.341961
NCT00260572|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2017-07-13|2005-11-28|2005-12-01|Estimate|||||||2017-07-13|2017-07-18|Actual|April 1999||1999-04-30|July 2017|2017-07-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|||Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease|Outcomes After Medical and Surgical Treatment of Gastroesophageal Reflux Disease|Recruiting|||2500|Anticipated|University of Pittsburgh|||||f||||||||||||Undecided||2018-06-01 04:18:51.427162|2018-06-01 04:18:51.427162
NCT00260559|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2017-07-13|2005-11-28|2005-12-01|Estimate|||||||2017-07-13|2017-07-18|Actual|May 1999||1999-05-31|July 2017|2017-07-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|||Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life|Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life|Recruiting|||3500|Anticipated|University of Pittsburgh|||||f||||t||||||||No||2018-06-01 04:18:51.502171|2018-06-01 04:18:51.502171
NCT00260546|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2011-09-29|2005-11-29|2005-12-01|Estimate|||||||2011-09-29|2011-09-30|Estimate|May 2006||2006-05-31|September 2011|2011-09-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||An-Art Study: Atrioventricular (AV) Node Ablation in Cardiac Resynchronisation Therapy|An-Art Study: AV-Node Ablation in Cardiac Resynchronisation Therapy|Withdrawn||Early Phase 1|0|Actual|University Hospital, Basel, Switzerland||||No patients enrolled for 6 months.|f||||f||||||||||2018-06-01 04:18:51.57167|2018-06-01 04:18:51.57167
NCT00260533|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|2012-06-13||2016-05-19|2005-11-29|2005-12-01|Estimate|2014-01-24|2014-03-11|Estimate||||2016-05-19|2016-06-24|Estimate|November 2005||2005-11-30|May 2016|2016-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder|Double Blind Placebo Controlled Parallel Group Comparison of Atomoxetine (Strattera) for Generalized Social Anxiety Disorder (GSAD)|Completed||Phase 2/Phase 3|27|Actual|University of California, San Diego|Small study, with possibility of Type II error. Nonetheless, response rates in both arms were very low, making it unlikely that the failure to see a response to atomoxetine was due to low power compared to placebo.|2|||f||||f||||||||||2018-06-01 04:18:51.636253|2018-06-01 04:18:51.636253
NCT00260520|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2006-03-03|2005-11-30|2005-12-01|Estimate|||||||2006-03-03|2006-03-06|Estimate|January 2002||2002-01-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Observational|||LMWH to Prevent Preeclampsia and Fetal Growth Restriction|Low Molecular Weight Heparin Vs No Treatment in Pregnant Women With Previous Preeclampsia or Fetal Growth Restriction Who Were Heterozygote for Factor V Leiden or Prothrombin Gene G20210A Mutation|Terminated|||||University of Florence|||||f||||||||||||||2018-06-01 04:18:51.811279|2018-06-01 04:18:51.811279
NCT00260494|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2013-07-22|2005-11-29|2005-12-01|Estimate|||||||2013-07-22|2013-07-23|Estimate|March 2005||2005-03-31|July 2013|2013-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Acupuncture and Post-Surgical Wound Healing|Acupuncture and Post-Surgical Wound Healing in Coronary Artery Bypass Graft Patients Undergoing Open Saphenous Vein Graft Harvest|Terminated||N/A|65|Actual|University of California, San Francisco||3||No difference in primary outcomes at interim analysis.|f||||t||||||||||2018-06-01 04:18:51.929177|2018-06-01 04:18:51.929177
NCT00260481|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2016-01-20|2005-11-29|2005-12-01|Estimate|||||||2016-01-20|2016-01-22|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Prometa Pharmacotherapy for Methamphetamine Dependence|Double-Blind, Placebo Controlled Trial of Prometa Pharmacotherapy for the Treatment of Methamphetamine Abuse|Completed||Phase 2/Phase 3|120|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 04:18:51.998316|2018-06-01 04:18:51.998316
NCT00260468|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2009-10-21|2005-11-30|2005-12-01|Estimate|||||||2009-10-21|2009-10-22|Estimate|November 2005||2005-11-30|October 2009|2009-10-31|December 2008|Actual|2008-12-31|||||Observational|||Brain Abnormalities in Late-Onset Major Depression|Structural and Functional Cerebral Findings in Late-Onset Major Depression|Completed|||44|Actual|University of Aarhus|||||f||||f||||||Samples With DNA|"~     Apolipoprotein~   "|||2018-06-01 04:18:52.094328|2018-06-01 04:18:52.094328
NCT00260442|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2015-11-04|2005-11-29|2005-12-01|Estimate|||||||2015-11-04|2015-11-05|Estimate|November 2005||2005-11-30|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|May 2008|Actual|2008-05-31||Interventional|||Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy|Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy|Unknown status|Active, not recruiting|Phase 2|36|Actual|Texas A&M University||3|||f||||||||||||||2018-06-01 04:18:52.160024|2018-06-01 04:18:52.160024
NCT00260429|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|2010-11-05||2010-11-05|2005-11-29|2005-12-01|Estimate|2010-11-05|2010-12-09|Estimate||||2010-11-05|2010-12-09|Estimate|June 2003||2003-06-30|November 2010|2010-11-30|April 2008|Actual|2008-04-30|August 2005|Actual|2005-08-31||Interventional|||Collagenase in the Treatment of Dupuytrens Disease|Double-blind, Randomized Placebo Controlled Study of the Relative Safety and Efficacy of Collagenase Therapy in the Treatment of Residual-type Dupuytren's Disease.|Completed||Phase 3|38|Actual|Stony Brook University||2|||f||||f||||||||||2018-06-01 04:18:52.245451|2018-06-01 04:18:52.245451
NCT00260416|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2008-05-21|2005-11-30|2005-12-01|Estimate|||||||2008-05-21|2008-05-22|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours|Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours|Completed||Phase 2|60|Anticipated|Aarhus University Hospital Skejby|||||f||||||||||||||2018-06-01 04:18:52.491458|2018-06-01 04:18:52.491458
NCT00260403|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2006-02-02|2005-11-29|2005-12-01|Estimate|||||||2006-02-02|2006-02-03|Estimate|June 2003||2003-06-30|June 2004|2004-06-30|January 2008||2008-01-31|||||Interventional|||TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration|Transpupillary Thermotherapy Versus Photodynamic Therapy Treatment of Occult and Minimally Classic Choroidal Neovascularization in Age-Related Macular Degeneration.|Unknown status|Recruiting|Phase 2/Phase 3|140||St. Erik Eye Hospital|||||f||||||||||||||2018-06-01 04:18:52.55458|2018-06-01 04:18:52.55458
NCT00260390|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2006-10-03|2005-11-30|2005-12-01|Estimate|||||||2006-10-03|2006-10-04|Estimate|September 2004||2004-09-30|October 2006|2006-10-31||||||||Interventional|||Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial|The Efficacy of Testosterone Replacement in Treating Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial|Unknown status|Recruiting|Phase 4|||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:18:52.607841|2018-06-01 04:18:52.607841
NCT00260377|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2008-09-08|2005-11-29|2005-12-01|Estimate|||||||2008-09-08|2008-09-09|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|December 2006||2006-12-31|June 2006||2006-06-30||Interventional|||Aspirin Resistance Following Coronary Bypass Surgery||Terminated||N/A|||Sheba Medical Center||||The researcher had left the hospital and the project was stopped|f||||f||||||||||2018-06-01 04:18:52.669304|2018-06-01 04:18:52.669304
NCT00260364|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2016-10-13|2005-11-29|2005-12-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2005||2005-11-30|January 2010|2010-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|TARGET||Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer|A Phase I-II Dose Finding and Early Efficacy Study of Combination Therapy With Erlotinib (Tarceva), Gemcitabine, Bevacizumab (Avastin), and Capecitabine in Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|44|Actual|Royal Marsden NHS Foundation Trust|||||f||||t||||||||||2018-06-01 04:18:52.723302|2018-06-01 04:18:52.723302
NCT00260351|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2014-01-10|2005-11-29|2005-12-01|Estimate|||||||2014-01-10|2014-01-14|Estimate|December 2004||2004-12-31|January 2014|2014-01-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Immunogenicity and Safety of Verorab™ in Indian Population|Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV, Verorab™) Administered for Rabies Post-exposure Treatment. Comparison of Essen-IM, Zagreb-IM, and Thai Red Cross (TRC)-ID Regimens in the Indian Population.|Completed||Phase 4|405|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 04:18:52.803998|2018-06-01 04:18:52.803998
NCT00260338|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2013-05-30|2005-11-29|2005-12-01|Estimate|||||||2013-05-30|2013-05-31|Estimate|December 2005||2005-12-31|May 2013|2013-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia|Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia|Completed||Phase 1/Phase 2|31|Actual|Rigshospitalet, Denmark||1|||f||||||||||||||2018-06-01 04:18:52.873153|2018-06-01 04:18:52.873153
NCT00260325|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2017-11-21|2005-11-29|2005-12-01|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2004||2004-08-31|November 2017|2017-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy Volunteers|Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia: a Randomized Controlled Trial in Healthy Volunteers|Completed||Phase 4|20||Penn State University|||||f||||||||||||||2018-06-01 04:18:52.962319|2018-06-01 04:18:52.962319
NCT00260312|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2005-11-29|2005-11-29|2005-12-01|Estimate|||||||2005-11-29|2005-12-01|Estimate|August 2001||2001-08-31|January 2004|2004-01-31|January 2003||2003-01-31|||||Interventional|||Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals|Randomized Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba|Completed||N/A|300||Pan American Health Organization|||||f||||||||||||||2018-06-01 04:18:53.026622|2018-06-01 04:18:53.026622
NCT00260299|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2012-03-21|2005-11-30|2005-12-01|Estimate|||||||2012-03-21|2012-03-23|Estimate|February 2005||2005-02-28|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|||||Observational|||Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency|Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency|Unknown status|Recruiting||15|Anticipated|Oregon Health and Science University|||||f||||t||||||Samples With DNA|"~     blood samples, cells (fibroblasts) from skin biopsy tissue, DNA, urine and stool~   "|||2018-06-01 04:18:53.088369|2018-06-01 04:18:53.088369
NCT00260286|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2005-12-02|2005-11-30|2005-12-01|Estimate|||||||2005-12-02|2005-12-05|Estimate|August 2001||2001-08-31|November 2005|2005-11-30|May 2004||2004-05-31|||||Interventional|||Effects of Gynecological Age on LH Sensitivity to Energy Availability|Dietary Energy Requirements in Physically Active Men and Women, Objective 4B: Effects of Gynecological Age on LH Sensitivity to Energy Availability|Completed||N/A|18||Ohio University|||||f||||||||||||||2018-06-01 04:18:53.155413|2018-06-01 04:18:53.155413
NCT00260273|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2007-11-07|2005-11-28|2005-12-01|Estimate|||||||2007-11-07|2007-11-08|Estimate|August 2004||2004-08-31|October 2007|2007-10-31|August 2008|Anticipated|2008-08-31|||||Interventional|||Access, Detection and Psychological Treatments|Access, Detection and Psychological Treatments|Unknown status|Active, not recruiting|N/A|56|Actual|Ontario Mental Health Foundation||2|||f||||f||||||||||2018-06-01 04:18:53.394615|2018-06-01 04:18:53.394615
NCT00260260|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2008-01-03|2005-11-30|2005-12-01|Estimate|||||||2008-01-03|2008-01-11|Estimate|June 2005||2005-06-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||OXY-1: The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain|The Pharmacogenetics of Oxycodone Analgesia in Postoperative Pain|Completed||Phase 4|300|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:18:53.453066|2018-06-01 04:18:53.453066
NCT00260247|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2015-04-21|2005-11-28|2005-12-01|Estimate|||||||2015-04-21|2015-04-22|Estimate|April 2005||2005-04-30|March 2005|2005-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine.|Induction of Drug Metabolism: A Comparative, Pharmacokinetic in Vivo Study of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4.|Completed||Phase 4|10|Actual|Odense University Hospital|||||f||||||||||||||2018-06-01 04:18:53.504988|2018-06-01 04:18:53.504988
NCT00260234|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2014-09-08|2005-11-28|2005-12-01|Estimate|||||||2014-09-08|2014-09-09|Estimate|November 2005||2005-11-30|September 2014|2014-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients|A Single-Center Phase I/II Study Of Peg-Encapsulated Islet Allografts Implanted In Patients With Type I Diabetes|Terminated||Phase 1/Phase 2|12||Novocell||1||Stopped in December 2007|f||||||||||||||2018-06-01 04:18:53.557855|2018-06-01 04:18:53.557855
NCT00260221|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2013-05-06|2005-11-30|2005-12-01|Estimate|||||||2013-05-06|2013-05-08|Estimate|January 2002||2002-01-31|March 2011|2011-03-31|November 2011|Actual|2011-11-30|January 2011|Actual|2011-01-31||Interventional|VRH||VRH Pain Reduction During Burn Wound Care and Physical Therapy|Testing Interactions to Adjunctive Pain Control Techniques|Completed||N/A|77|Actual|National Institute of General Medical Sciences (NIGMS)||3|||f||||f||||||||||2018-06-01 04:18:53.632499|2018-06-01 04:18:53.632499
NCT00260026|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2007-01-25|2005-11-29|2005-12-01|Estimate|||||||2007-01-25|2007-01-26|Estimate|November 2004||2004-11-30|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer|Safety and Pharmacokinetic Study of Jin Fu Kang In Combination With Docetaxel for Patients With Previously Treated Non-Small Cell Lung Cancer|Completed||Phase 2|20||Memorial Sloan Kettering Cancer Center|||||||||||||||||||2018-06-01 04:18:57.076102|2018-06-01 04:18:57.076102
NCT00260208|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|2011-09-14||2011-12-02|2005-11-30|2005-12-01|Estimate|2011-09-14|2011-10-26|Estimate||||2011-12-02|2011-12-06|Estimate|January 2006||2006-01-31|December 2011|2011-12-31||||September 2010|Actual|2010-09-30||Interventional|||Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus|A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus|Terminated||Phase 4|361|Actual|Novartis|This study was prematurely discontinued due to poor recruitment. Since only a small patient group could be analyzed for primary outcome measure, robust conclusions on the effect of the two calcineurin inhibitors on the fibrosis score cannot be drawn.|2||Study was prematurely terminated due to poor recruitment.|f||||||||||||||2018-06-01 04:18:53.805852|2018-06-01 04:18:53.805852
NCT00260195|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|2013-11-27||2014-04-28|2005-11-29|2005-12-01|Estimate|2014-04-28|2014-05-22|Estimate||||2014-04-28|2014-05-22|Estimate|July 2005||2005-07-31|April 2014|2014-04-30|July 2009|Actual|2009-07-31|July 2007|Actual|2007-07-31||Interventional|||A School Program for Children Exposed to Violence|A School Program for Children Exposed to Violence|Completed||Phase 2|78|Actual|RAND||2|||f||||f||||||||||2018-06-01 04:18:55.223576|2018-06-01 04:18:55.223576
NCT00260182|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2011-01-03|2005-11-28|2005-12-01|Estimate|||||||2011-01-03|2011-01-04|Estimate|October 2005||2005-10-31|May 2009|2009-05-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Observational|||Genetics of Recurrent Early Onset Major Depression|Genetics of Recurrent Early Onset Major Depression|Unknown status|Active, not recruiting||1500|Anticipated|National Institute of Mental Health (NIMH)|||||f||||||||||Samples With DNA|"~     Blood samples with DNA~   "|||2018-06-01 04:18:55.467236|2018-06-01 04:18:55.467236
NCT00260169|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2013-12-09|2005-11-29|2005-12-01|Estimate|||||||2013-12-09|2013-12-10|Estimate|November 2005||2005-11-30|December 2013|2013-12-31|January 2009|Actual|2009-01-31|October 2007|Actual|2007-10-31||Interventional|||Determining Depression Treatment Preferences of Low-Income Latinos in Primary Care Settings|Patient-Centered Depression Care in the Public Sector|Completed||N/A|432|Actual|University of Southern California||2|||f||||||||||||||2018-06-01 04:18:55.543367|2018-06-01 04:18:55.543367
NCT00260156|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29||2013-01-02|2013-01-02|2005-11-29|2005-12-01|Estimate||||2013-01-02|2013-01-04|Estimate|2013-01-02|2013-01-04|Estimate|November 2005||2005-11-30|January 2013|2013-01-31||||December 2008|Actual|2008-12-31||Interventional|||A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes|A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|59|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:18:55.611225|2018-06-01 04:18:55.611225
NCT00260143|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2018-03-07|2005-11-29|2005-12-01|Estimate|||||||2018-03-07|2018-03-09|Actual|May 2003|Actual|2003-05-31|March 2018|2018-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Testosterone and Physical Function in HIV+ Men|Testosterone and Physical Function in HIV Associate Weight Loss|Completed||Phase 2|61|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f|||||t|f||||||||2018-06-01 04:18:55.694227|2018-06-01 04:18:55.694227
NCT00260130|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2013-05-28|2005-11-29|2005-12-01|Estimate|||||||2013-05-28|2013-05-30|Estimate|February 2005||2005-02-28|May 2013|2013-05-31|July 2009|Actual|2009-07-31|December 2007|Actual|2007-12-31||Interventional|||Food Rheology and Feeding in Lean and Obese Humans|Study 1: Viscosity Study Study 2: Meal Timing Study Study 3:Chronic Fluid and Solid Food Intake in Lean and Overweight Individuals|Completed||N/A|34|Anticipated|Purdue University||2|||f||||||||||||||2018-06-01 04:18:55.889918|2018-06-01 04:18:55.889918
NCT00260117|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2010-02-24|2005-11-29|2005-12-01|Estimate|||||||2010-02-24|2010-02-25|Estimate|January 2005||2005-01-31|February 2010|2010-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Long-Term Exercise Maintenance Via Internet Support|Long-Term Exercise Maintenance Via Internet Support|Completed||Phase 1/Phase 2|16000|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 04:18:55.967122|2018-06-01 04:18:55.967122
NCT00260104|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2008-05-23|2005-11-29|2005-12-01|Estimate|||||||2008-05-23|2008-05-26|Estimate|November 2005||2005-11-30|May 2008|2008-05-31||||||||Observational|||Risk Factors of Individuals With Coronary Artery Disease||Unknown status|Recruiting||||Nanjing Medical University|||||f||||||||||||||2018-06-01 04:18:56.025564|2018-06-01 04:18:56.025564
NCT00260091|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2013-11-15|2005-11-29|2005-12-01|Estimate|||||||2013-11-15|2013-11-18|Estimate|August 1999||1999-08-31|January 2009|2009-01-31|April 2006|Actual|2006-04-30|August 2005|Actual|2005-08-31||Interventional|FASTT||Conventional Infertility Treatment vs. Fast Track to IVF|Conventional Infertility Therapy vs. Fast Track to IVF|Completed||N/A|503|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 04:18:56.10962|2018-06-01 04:18:56.10962
NCT00260078|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29||2010-01-20|2016-07-26|2005-11-29|2005-12-01|Estimate||||2010-01-20|2010-01-22|Estimate|2016-07-26|2016-07-28|Estimate|February 2006||2006-02-28|July 2016|2016-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children|Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children|Completed||Phase 1/Phase 2|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 04:18:56.209757|2018-06-01 04:18:56.209757
NCT00260065|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|2009-04-13||2013-05-13|2005-11-28|2005-12-01|Estimate|2009-07-28|2009-09-04|Estimate||||2013-05-13|2013-05-20|Estimate|May 2005||2005-05-31|June 2010|2010-06-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes|A Phase 2 Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Advanced-Stage Myelodysplastic Syndromes|Completed||Phase 2|99|Actual|Eisai Inc.|Not Specified|1|||f||||||||||||||2018-06-01 04:18:56.351604|2018-06-01 04:18:56.351604
NCT00260052|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2015-08-21|2005-11-29|2005-12-01|Estimate|||||||2015-08-21|2015-08-24|Estimate|July 2003||2003-07-31|August 2015|2015-08-31|January 2010|Actual|2010-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Erythropoietin Effects After Traumatic Brain Injury|Phase II Study of the Effects of Erythropoietin on Neuronal Cell Death in Traumatic Brain Injury Patients|Withdrawn||Phase 2/Phase 3|0|Actual|Medical College of Wisconsin||||PI has left institution|f||||||||||||||2018-06-01 04:18:56.905614|2018-06-01 04:18:56.905614
NCT00260039|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2015-06-05|2005-11-28|2005-12-01|Estimate|||||||2015-06-05|2015-06-08|Estimate|December 2005||2005-12-31|June 2015|2015-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)|A Randomized, International, Double-Blinded (With In-House Blinding), GARDASIL-Controlled, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) L1 Virus-like Particle (VLP) Vaccine Administered to 16- to 23- Year-Old Women|Completed||Phase 2|680|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 04:18:56.983409|2018-06-01 04:18:56.983409
NCT00260013|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2010-03-22|2005-11-29|2005-12-01|Estimate|||||||2010-03-22|2010-03-23|Estimate|January 2005||2005-01-31|March 2010|2010-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Transition Into Primary-care Psychiatry (TIPP)|Transition Into Primary-care Psychiatry (TIPP): A Mental Health Demonstration Project.|Completed||Phase 2/Phase 3|40|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 04:18:57.147799|2018-06-01 04:18:57.147799
NCT00260000|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2006-04-12|2005-11-30|2005-12-01|Estimate|||||||2006-04-12|2006-04-13|Estimate|April 2005||2005-04-30|April 2006|2006-04-30|December 2005||2005-12-31|||||Interventional|||Study of BH4, a New and Simple Treatment of Mild PKU|Study of the Response of Tetrahydrobiopterin on S-Phenylalanine in Patients With PKU Housing the Y414C Mutation|Completed||Phase 2|15||The Kennedy Institute-National Eye Clinic|||||f||||||||||||||2018-06-01 04:18:57.284914|2018-06-01 04:18:57.284914
NCT00259987|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2009-05-15|2005-11-30|2005-12-01|Estimate|||||||2009-05-15|2009-05-18|Estimate|November 2005||2005-11-30|May 2009|2009-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus|A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients With Relapsed Adenocarcinoma of the Esophagus, Including Tumors of the Gastroesophageal Junction and Gastric Cardia|Completed||Phase 2|24|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:18:57.365846|2018-06-01 04:18:57.365846
NCT00259974|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2011-05-05|2005-11-29|2005-12-01|Estimate|||||||2011-05-05|2011-05-06|Estimate|April 2006||2006-04-30|March 2007|2007-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy|Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy|Completed||Phase 3|60|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:18:57.43548|2018-06-01 04:18:57.43548
NCT00259961|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2006-12-22|2005-11-30|2005-12-01|Estimate|||||||2006-12-22|2006-12-25|Estimate||||December 2006|2006-12-31|December 2006||2006-12-31|||||Observational|||Clinical Outcome of Laparoscopic Versus Open Nissen Fundoplication in Children: 3−Year Follow-up Study of Randomized Controlled Trial.||Completed|||||Institute of Child Health|||||f||||||||||||||2018-06-01 04:18:57.50516|2018-06-01 04:18:57.50516
NCT00259948|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2005-11-30|2005-11-30|2005-12-01|Estimate|||||||2005-11-30|2005-12-01|Estimate|January 2006||2006-01-31|October 2005|2005-10-31||||||||Interventional|||Aerobic Exercise Training & the Autonomic System In Patients After Myocardial Infarction or Stroke|The Effect of Aerobic Exercise Training On the Function of the Autonomic System In Patients That Have Suffered Myocardial Infarction or Stroke|Unknown status|Not yet recruiting|Phase 1|230|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:18:57.54657|2018-06-01 04:18:57.54657
NCT00259935|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2017-11-10|2005-11-30|2005-12-01|Estimate|||||||2017-11-10|2017-11-14|Actual|October 4, 2004|Actual|2004-10-04|November 2017|2017-11-30|July 5, 2007|Actual|2007-07-05|July 5, 2007|Actual|2007-07-05||Interventional|||A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors|A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors (4C)|Completed||Phase 1|107|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:18:57.609812|2018-06-01 04:18:57.609812
NCT00259922|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2015-09-01|2005-11-29|2005-12-01|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2005||2005-08-31|September 2009|2009-09-30||||June 2006|Actual|2006-06-30||Interventional|||Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain|Completed||Phase 3|485|Actual|Cubist Pharmaceuticals LLC||3|||||||||||||||||2018-06-01 04:18:57.698975|2018-06-01 04:18:57.698975
NCT00259909|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2017-10-10|2005-11-30|2005-12-01|Estimate|||||||2017-10-10|2017-10-12|Actual|November 2, 2005|Actual|2005-11-02|October 2017|2017-10-31|November 7, 2006|Actual|2006-11-07|November 7, 2006|Actual|2006-11-07||Observational|||Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Prospective Observational Study for the Psychometric Validation of a Patient-reported Questionnaire in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)|Completed|||259|Actual|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-06-01 04:18:58.316468|2018-06-01 04:18:58.316468
NCT00259896|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2012-05-31|2005-11-30|2005-12-01|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 2005||2005-10-31|January 2011|2011-01-31||||||||Interventional|||In-patient Study in Patients With Type 2 Diabetes Mellitus|A Randomized, Open-label, Placebo-controlled, Repeat-dose Study to Assess the Pharmacokinetics and Pharmacodynamics of 5 Micrograms Exenatide Administered Subcutaneously Twice Daily for 7 Days in Healthy Normal Volunteers and in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|30||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:18:58.618405|2018-06-01 04:18:58.618405
NCT00259883|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2017-01-16|2005-11-30|2005-12-01|Estimate|||||||2017-01-16|2017-01-18|Estimate|June 2005||2005-06-30|January 2017|2017-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Combination Of PAXIL Tablet And Benzodiazepines|Post-marketing Clinical Study on PAXIL Tablet in Patients With Depression or Depressive Mood - A Study on Combination of PAXIL Tablet and Benzodiazepines|Completed||Phase 4|150|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:18:58.835865|2018-06-01 04:18:58.835865
NCT00259870|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2017-03-21|2005-11-30|2005-12-01|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2005||2005-09-30|March 2017|2017-03-31|August 2007|Actual|2007-08-31|||||Interventional|||SB-773812 Administered In Adults With Schizophrenia|A Multi Centre, Double-Blind, Double-Dummy, Placebo-Controlled, Randomised, Adaptive, Dose-Range Study To Evaluate the Safety and Efficacy of SB-773812 Administered Once Daily for 12 Weeks in Adults With Schizophrenia|Completed||Phase 2|338|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:18:58.971313|2018-06-01 04:18:58.971313
NCT00259857|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|2010-11-09||2010-12-29|2005-11-29|2005-12-01|Estimate|2010-12-29|2011-01-19|Estimate||||2010-12-29|2011-01-19|Estimate|October 2003||2003-10-31|December 2010|2010-12-31|August 2009|Actual|2009-08-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis|A Randomized, Double-Blind, Placebo-Controlled, Prospective, Cross-Over Phase II Clinical Trial to Determine the Safety and Efficacy of Alendronate (Fosamax) in Juvenile Osteoporosis (IND#60,017)|Completed||Phase 2|22|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-06-01 04:18:59.289847|2018-06-01 04:18:59.289847
NCT00259844|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2006-07-17|2005-11-29|2005-12-01|Estimate|||||||2006-07-17|2006-07-18|Estimate|June 2004||2004-06-30|November 2005|2005-11-30|December 2006||2006-12-31|||||Interventional|||Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed|A Phase 2 Study Immunologically Evaluating 5T4-MVA (TroVax) in Patients Undergoing Surgical Resection of Colorectal Liver Metastases|Completed||Phase 2|20||Cancer Research UK|||||f||||||||||||||2018-06-01 04:18:59.629366|2018-06-01 04:18:59.629366
NCT00259831|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2009-06-04|2005-11-29|2005-12-01|Estimate|||||||2009-06-04|2009-06-08|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|||Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adults|Efficacy of Cold-FX (CVT-E002) in the Prevention of Upper Respiratory Tract Infections in Healthy Adult Employees in Continuing Care Facilities|Completed||Phase 3|500||Afexa Life Sciences Inc|||||f||||||||||||||2018-06-01 04:18:59.698331|2018-06-01 04:18:59.698331
NCT00259818|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2008-01-23|2005-11-30|2005-12-01|Estimate|||||||2008-01-23|2008-01-24|Estimate|December 2005||2005-12-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|||||Interventional|||Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors|An Open-Label Phase I Dose Escalation Study of Intravenous Infusion of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Refractory Malignant Tumors|Completed||Phase 1|30|Anticipated|Erimos Pharmaceuticals|||||||||||||||||||2018-06-01 04:18:59.758375|2018-06-01 04:18:59.758375
NCT00259805|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2013-03-20|2005-11-29|2005-12-01|Estimate|||||||2013-03-20|2013-03-22|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis|A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis|Completed||Phase 1|10|Actual|California Pacific Medical Center Research Institute||1|||f||||f||||||||||2018-06-01 04:18:59.812795|2018-06-01 04:18:59.812795
NCT00259792|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2011-01-21|2005-11-29|2005-12-01|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|January 2006|Actual|2006-01-31|||||Interventional|||SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults|A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26-week, Randomised, Open, Parallel Group Multicentre Study|Completed||Phase 3|1000||AstraZeneca|||||f||||||||||||||2018-06-01 04:18:59.928673|2018-06-01 04:18:59.928673
NCT00259779|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|||2011-01-21|2005-11-29|2005-12-01|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2005||2005-09-30|January 2011|2011-01-31|July 2007|Actual|2007-07-31|||||Interventional|SPACE||Comparison Between Symbicort® and Prednisolone in COPD|A Randomised, Double Blind, Double Dummy, Multicentre Phase III Study Comparing the Efficacy of Budesonide/Formoterol (Symbicort® Forte Turbuhaler®) and Oral Prednisolone + Formoterol (Oxis® Turbuhaler) During Two Weeks, in COPD Patients With an Acute Exacerbation, Followed by Twelve Weeks Open Follow up Period With Budesonide/Formoterol (Symbicort Forte Turbuhaler)|Completed||Phase 3|120|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:19:00.215663|2018-06-01 04:19:00.215663
NCT00259766|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2011-01-21|2005-11-28|2005-12-01|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2004||2004-04-30|January 2011|2011-01-31|May 2007|Actual|2007-05-31|||||Interventional|||SHARE - Symbicort and Health Economics in a Real Life Evaluation|Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised, Open-Label, Parallel-Group, Multicentre Study to Assess the Asthma-Related Health-Care Costs, in Ordinary Clinical Practice During 12 Months|Completed||Phase 3|1970||AstraZeneca|||||f||||||||||||||2018-06-01 04:19:00.356868|2018-06-01 04:19:00.356868
NCT00259753|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-30|||2008-08-04|2005-11-30|2005-12-01|Estimate|||||||2008-08-04|2008-08-05|Estimate|July 2005||2005-07-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration|A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration|Completed||Phase 2|120|Actual|OPKO Health, Inc.||3|||f||||t||||||||||2018-06-01 04:19:00.674242|2018-06-01 04:19:00.674242
NCT00259740|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-29|2010-12-09|2009-11-23|2017-02-07|2005-11-29|2005-12-01|Estimate|2010-12-09|2011-01-06|Estimate|2009-11-23|2009-11-25|Estimate|2017-02-07|2017-03-15|Actual|November 2005||2005-11-30|February 2017|2017-02-28|December 2011|Actual|2011-12-31|August 2007|Actual|2007-08-31||Interventional|||Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab|An Open-Label, Multi-Center Phase 2 Trial of Denosumab in the Treatment of Relapsed or Plateau-Phase Multiple Myeloma|Completed||Phase 2|96|Actual|Amgen||1|||f||||f||||||||||2018-06-01 04:19:00.852194|2018-06-01 04:19:00.852194
NCT00259727|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-09-28|2005-11-28|2005-11-29|Estimate|||||||2009-09-28|2009-09-30|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|September 2008|Actual|2008-09-30|||||Observational|||The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism|The Effects of HIV Protease Inhibitors on Glucose Metabolism|Completed|||80|Anticipated|VA Office of Research and Development|||1||f||||||||||||||2018-06-01 04:19:01.378467|2018-06-01 04:19:01.378467
NCT00259714|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2016-07-21|2005-11-28|2005-11-29|Estimate|||||||2016-07-21|2016-07-22|Estimate|March 2006||2006-03-31|July 2016|2016-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Dialysate Sodium Individualization in Hemodialysis|Hemodynamic and Hormonal Responses to Dialysate Sodium Individualization in Hemodialysis Patients|Terminated||Phase 1|1|Actual|Yale University||2||Protocol was not feasible - only 1 of 18 enrollees completed procedures.|f||||f||||||||||2018-06-01 04:19:01.476587|2018-06-01 04:19:01.476587
NCT00259701|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2006-10-05|2005-11-28|2005-11-29|Estimate|||||||2006-10-05|2006-10-06|Estimate|June 2005||2005-06-30|November 2005|2005-11-30|September 2005||2005-09-30|||||Observational|||Microvascular Reactivity.|Transdermal Application of Acetylcholine and Nitroglycerin Without Iontophoresis.|Completed|||20||Yale University|||||f||||||||||||||2018-06-01 04:19:01.622436|2018-06-01 04:19:01.622436
NCT00259688|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2010-01-07|2005-11-28|2005-11-29|Estimate|||||||2010-01-07|2010-01-08|Estimate|February 2006||2006-02-28|January 2010|2010-01-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Prevalence Study of Sleep Apnea in Women With Preeclampsia|Sleep Disordered Breathing and Preeclampsia|Completed||Phase 2|60|Anticipated|University of Saskatchewan||3|||f||||||||||||||2018-06-01 04:19:01.670852|2018-06-01 04:19:01.670852
NCT00259675|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2007-11-10|2005-11-28|2005-11-29|Estimate|||||||2007-11-10|2007-11-15|Estimate|May 2004||2004-05-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC|Treatment of Stages IIIB and IV, Non Small Cell Lung Cancer With Alternating Cycles of Carboplatin/Taxol and Carboplatin/Gemcitabine.|Completed||Phase 2|100|Anticipated|University of Saskatchewan|||||f||||||||||||||2018-06-01 04:19:01.735176|2018-06-01 04:19:01.735176
NCT00259662|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2016-11-30|2005-11-28|2005-11-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2005||2005-11-30|November 2016|2016-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||High-dose Periop Statins for Prevention of DVT|High-dose Statin Therapy in the Perioperative Period and DVT Prevention.|Completed||N/A|29|Actual|Yale University|||||f||||||||||||||2018-06-01 04:19:01.793836|2018-06-01 04:19:01.793836
NCT00259649|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-26|2011-05-26||2011-07-01|2005-11-26|2005-11-29|Estimate|2011-07-01|2011-07-04|Estimate||||2011-07-01|2011-07-04|Estimate|August 2004||2004-08-31|June 2011|2011-06-30||||August 2008|Actual|2008-08-31||Interventional|||Prospective Survey of Menstrual Migraine & Prevention With Eletriptan|Assessment and Prevention of Menstrual Migraine: Phase 1-prospective Survey of Self-identified Menstrual Migraine. Phase 2-prevention of Menstrual Migraine With Relpax|Completed||Phase 4|71|Actual|University of Pittsburgh|Relatively small sample size and open-label treatment limit Menstrual regulation by hormonal therapy might have affected treatment response;||||f||||||||||||||2018-06-01 04:19:01.863247|2018-06-01 04:19:01.863247
NCT00259636|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-26|||2011-05-31|2005-11-26|2005-11-29|Estimate|||||||2011-05-31|2011-06-01|Estimate|August 2004||2004-08-31|May 2011|2011-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Zonisamide for Fibromyalgia & Migraine|Zonisamide for Fibromyalgia & Migraine|Withdrawn||Phase 4|0|Actual|University of Pittsburgh||||Logistical problems prevented enrollment|f||||t||||||||||2018-06-01 04:19:02.101202|2018-06-01 04:19:02.101202
NCT00259623|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2009-07-16|2005-11-25|2005-11-29|Estimate|||||||2009-07-16|2009-07-17|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Cardiac Surgical Treatment by Radiofrequency Ablation on Valvular Patients: Efficacy at 3 Months|Efficacy at 3 Months on Permanent Atrial Fibrillation in Patients Candidates to Cardiac Surgical Treatment by Epicardial, or Possibly Endocardial, Radiofrequency Ablation|Completed||N/A|13|Actual|University Hospital, Toulouse|||||f||||f||||||||||2018-06-01 04:19:02.167611|2018-06-01 04:19:02.167611
NCT00259610|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|2012-05-31||2014-07-16|2005-11-28|2005-11-29|Estimate|2014-07-16|2014-07-17|Estimate||||2014-07-16|2014-07-17|Estimate|May 2004||2004-05-31|October 2013|2013-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TEAR||Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)|Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)|Completed||Phase 4|755|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-06-01 04:19:02.378186|2018-06-01 04:19:02.378186
NCT00259597|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2012-12-19|2005-11-28|2005-11-29|Estimate|||||||2012-12-19|2012-12-20|Estimate|June 2004||2004-06-30|November 2008|2008-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Nuclear Morphology of Breast Cells in Ductal Lavage|Morphometry of Breast Cells in Ductal Lavage|Completed|||57|Actual|University of Michigan|||||f||||t||||||||||2018-06-01 04:19:03.549362|2018-06-01 04:19:03.549362
NCT00259584|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2010-08-12|2005-11-28|2005-11-29|Estimate|||||||2010-08-12|2010-08-13|Estimate|October 2001||2001-10-31|August 2010|2010-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Superior Vena Caval Obstruction (SVCO) - Management and Outcome|A Prospective Longitudinal Study of the Management and Outcome of Superior Vena Caval Obstruction (SVCO)|Completed||Phase 1/Phase 2|20|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:19:03.619632|2018-06-01 04:19:03.619632
NCT00259571|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2013-12-12|2005-11-28|2005-11-29|Estimate|||||||2013-12-12|2013-12-13|Estimate||||November 2005|2005-11-30|March 2010||2010-03-31|||||Interventional|||Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.|"Prospektive, Randomisierte, Doppelblinde, Mesalazin-kontrollierte (Double-dummy Verfahren) Multizenter-Studie Zur Beurteilung Der Annahme Der äquivalenten Wirkung Von Intestinal Retardiert Freigesetztem Phosphatidylcholin gegenüber Mesalazin (Non-inferiority Study) in Der Remissionserhaltung Der Colitis Ulcerosa."|Withdrawn||Phase 2/Phase 3|0|Actual|Heidelberg University||||Missing financial sponsorship|f||||||||||||||2018-06-01 04:19:03.668354|2018-06-01 04:19:03.668354
NCT00259558|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2007-02-07|2005-11-25|2005-11-29|Estimate|||||||2007-02-07|2007-02-12|Estimate|April 2003||2003-04-30|February 2007|2007-02-28|March 2006||2006-03-31|||||Interventional|||Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis|Prospektive, Randomisierte Doppelblinde Studie Zur Dosisfindung Von Intestinal Redardiert Freigesetztem Phosphatidylcholin Bei Chronisch Aktiver Pancolitis Ulcerosa|Completed||Phase 2|60||Heidelberg University|||||f||||||||||||||2018-06-01 04:19:04.768732|2018-06-01 04:19:04.768732
NCT00259545|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2008-06-04|2005-11-25|2005-11-29|Estimate|||||||2008-06-04|2008-06-05|Estimate|February 2003||2003-02-28|June 2008|2008-06-30|February 2006||2006-02-28|||||Interventional|||Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis|Prospektive, Randomisierte Doppelblinde Studie Zur Wirksamkeit Von Intestinal Retardiert Freigesetztem Phosphatidylcholine Bei therapierefraktärer Colitis Ulcerosa Mit Chronisch Aktivem Verlauf Unter Corticosteroiden|Completed||Phase 2|60||Heidelberg University|||||f||||f||||||||||2018-06-01 04:19:04.88819|2018-06-01 04:19:04.88819
NCT00259532|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2009-02-25|2005-11-25|2005-11-29|Estimate|||||||2009-02-25|2009-02-26|Estimate|February 2005||2005-02-28|February 2009|2009-02-28|January 2009||2009-01-31|||||Interventional|||Three New Methods for Diagnosing Pancreas Cancer|Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer|Unknown status|Recruiting|N/A|80|Anticipated|University of Copenhagen|||||f||||||||||||||2018-06-01 04:19:04.956312|2018-06-01 04:19:04.956312
NCT00259519|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2010-04-05|2005-11-28|2005-11-29|Estimate|||||||2010-04-05|2010-04-06|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|September 2011|Anticipated|2011-09-30|March 2010|Actual|2010-03-31||Interventional|||Safety and Efficacy Study of Intentional Delivery in Women With Preterm and Prelabour Rupture of the Membranes|Effects of Intentional Delivery After Preterm and Prelabor Rupture of Membranes Between 32 and 35 Weeks of Gestation: A Multicentre Randomized and Controlled Trial|Terminated||N/A|152|Actual|University of Alberta||2||The DSMB supported termination of the trial due to slow recruitment.|f||||t||||||||||2018-06-01 04:19:05.023831|2018-06-01 04:19:05.023831
NCT00259506|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-06-02|2005-11-28|2005-11-29|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||"Implementation and Evaluation of Mindfulness-Based Cognitive Therapy in a Health Care Region in Flanders: a Randomized Clinical Trial"|"Implementation and Evaluation of Mindfulness-Based Cognitive Therapy in a Health Care Region in Flanders: a Randomized Clinical Trial"|Completed||N/A|405|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:19:05.10213|2018-06-01 04:19:05.10213
NCT00259493|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2006-09-07|2005-11-25|2005-11-29|Estimate|||||||2006-09-07|2006-09-11|Estimate|December 2005||2005-12-31|September 2005|2005-09-30|October 2007||2007-10-31|||||Interventional|||Graft Patency in Beating Heart Vs. Conventional CABG Using Cardiac CT|Graft Patency Following Off-Pump CABG Vs. On-Pump CABG Using 64 MDCT Bypass Graft CT Angiography|Unknown status|Recruiting|N/A|350||Trillium Health Centre|||||f||||||||||||||2018-06-01 04:19:05.163218|2018-06-01 04:19:05.163218
NCT00259480|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2015-05-12|2005-11-28|2005-11-29|Estimate|||||||2015-05-12|2015-05-13|Estimate|August 2001||2001-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Project ACT: Advancing Caregiving Techniques|Reducing Family Caregiver Upset With Disruptive Behavior|Completed||Phase 3|272|Actual|Thomas Jefferson University|||||f||||||||||||||2018-06-01 04:19:05.225052|2018-06-01 04:19:05.225052
NCT00259467|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2010-08-24|2005-11-28|2005-11-29|Estimate|||||||2010-08-24|2010-08-25|Estimate|February 2004||2004-02-29|August 2010|2010-08-31|January 2007||2007-01-31|||||Interventional|||Project TAP: Tailored Activities Project|Tailored Activity to Improve Affect in Dementia|Completed||Phase 1|60||Thomas Jefferson University|||||f||||f||||||||||2018-06-01 04:19:05.281468|2018-06-01 04:19:05.281468
NCT00259454|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2010-03-15|2005-11-28|2005-11-29|Estimate|||||||2010-03-15|2010-03-16|Estimate|June 2005||2005-06-30|March 2010|2010-03-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Project COPE:Managing Dementia at Home|Managing Problem Behaviors of Alzheimer's Disease|Completed||Phase 3|278|Anticipated|Thomas Jefferson University|||||f||||t||||||||||2018-06-01 04:19:05.438152|2018-06-01 04:19:05.438152
NCT00259441|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2007-07-10|2005-11-25|2005-11-29|Estimate|||||||2007-07-10|2007-07-12|Estimate|February 2005||2005-02-28|July 2007|2007-07-31|March 2006||2006-03-31|||||Interventional|||PROMISS: Simvastatin Prevents the Contrast Induced Acute Renal Failure in Patients With Renal Insufficiency Undergoing Coronary Angiography|Prevention of Radiocontrast Media Induced Nephropathy by Short-Term High-Dose Statin in Renal Insufficiency Undergoing Coronary Angiography (PROMISS)|Completed||Phase 4|320||Seoul National University Hospital|||||f||||||||||||||2018-06-01 04:19:05.514551|2018-06-01 04:19:05.514551
NCT00259428|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2010-02-08|2005-11-25|2005-11-29|Estimate|||||||2010-02-08|2010-02-09|Estimate|November 2001||2001-11-30|February 2010|2010-02-28|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|EURIDIS||EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)|EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)|Completed||Phase 3|615|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:19:05.581984|2018-06-01 04:19:05.581984
NCT00259415|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2015-07-06|2005-11-28|2005-11-29|Estimate|||||||2015-07-06|2015-07-08|Estimate|September 2000||2000-09-30|July 2015|2015-07-31||||||||Interventional|||Telesupport: Evaluation of Professionally Led Support Groups for Caregivers|Evaluation of Professionally Led Support Groups for Caregivers|Completed||Phase 1|||Thomas Jefferson University|||||f||||||||||||||2018-06-01 04:19:05.697524|2018-06-01 04:19:05.697524
NCT00259402|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-12-04|2005-11-28|2005-11-29|Estimate|||||||2009-12-04|2009-12-07|Estimate|February 2000||2000-02-29|December 2009|2009-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Oxaliplatin in Esophagus Cancer (Advanced) 1st Line|Phase II Open-label Single Arm Study of Oxaliplatin Combined With Cisplatin and 5FU in Advanced Esophagus Cancer Patients|Completed||Phase 2|41|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:19:05.771497|2018-06-01 04:19:05.771497
NCT00259389|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2012-09-17|2005-11-28|2005-11-29|Estimate|||||||2012-09-17|2012-09-18|Estimate|April 2006||2006-04-30|September 2012|2012-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Directly Observed Therapy for HIV Infected Adolescents|Directly Observed Therapy (DOT) in HIV-1 Infected Adolescents|Completed||N/A|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:19:05.855511|2018-06-01 04:19:05.855511
NCT00259376|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2010-02-12|2005-11-25|2005-11-29|Estimate|||||||2010-02-12|2010-02-15|Estimate|November 2001||2001-11-30|February 2010|2010-02-28|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|ADONIS||American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm|American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)|Completed||Phase 3|629|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:19:05.949993|2018-06-01 04:19:05.949993
NCT00259363|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-12-04|2005-11-28|2005-11-29|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2002||2002-10-31|December 2009|2009-12-31||||June 2006|Actual|2006-06-30||Interventional|||Oxaliplatin in Rectal Cancer|Phase I-II Study of Preoperative Oxaliplatin-FU and Radiotherapy for Patients With Rectal Cancer|Terminated||Phase 1/Phase 2|46|Actual|Sanofi||||Study cancelled because recruitment rate was too slow|f||||||||||||||2018-06-01 04:19:06.02015|2018-06-01 04:19:06.02015
NCT00259350|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-27|||2009-01-26|2005-11-27|2005-11-29|Estimate|||||||2009-01-26|2009-01-27|Estimate|May 2004||2004-05-31|January 2009|2009-01-31|April 2006||2006-04-30|||||Interventional|||Chlorhexidine vs Povidone Iodine in Alcoholic Solutions for Prevention of Central Venous Catheter Infection|Prevention of Central Venous Catheter Infections : Comparison of the Efficacy of Skin Disinfection With 5% Povidone Iodine in Alcoholic Solution Versus 0.25% Chlorhexidine, 0.025 Benzalkonium and 4% Benzylic Alcohol|Completed||Phase 4|520||Poitiers University Hospital|||||f||||||||||||||2018-06-01 04:19:06.071059|2018-06-01 04:19:06.071059
NCT00259337|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2012-04-13|2005-11-24|2005-11-29|Estimate|||||||2012-04-13|2012-04-16|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|||Immunogenicity and Safety of Pentaxim™ in an Indian Population|Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India.|Completed||Phase 3|226|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 04:19:06.12011|2018-06-01 04:19:06.12011
NCT00259324|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2012-04-19|2005-11-28|2005-11-29|Estimate|||||||2012-04-19|2012-04-20|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Childhood Obesity Treatment Targeting Specific Behaviors|Childhood Obesity Treatment Targeting Specific Behaviors|Completed||N/A|81|Actual|The Miriam Hospital||3|||f||||||||||||||2018-06-01 04:19:06.195799|2018-06-01 04:19:06.195799
NCT00259311|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2007-01-24|2005-11-28|2005-11-29|Estimate|||||||2007-01-24|2007-01-26|Estimate|November 2005||2005-11-30|January 2007|2007-01-31|November 2006||2006-11-30|||||Interventional|||Efficacy Study of LY2422347 to Treat Insomnia|A Randomized, Double-Blind Comparison of 5 mg of LY2422347, 15 mg of LY2422347, and Placebo in the Treatment of Patients With Primary Insomnia|Completed||Phase 2|400||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:19:06.25578|2018-06-01 04:19:06.25578
NCT00259298|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|2010-07-14||2010-07-14|2005-11-28|2005-11-29|Estimate|2010-07-14|2010-08-11|Estimate||||2010-07-14|2010-08-11|Estimate|November 2005||2005-11-30|July 2010|2010-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Evaluation of the Effects of Teriparatide on Skeleton Images in Postmenopausal Women With Osteoporosis|The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women With Osteoporosis|Completed||Phase 4|12|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:19:06.401513|2018-06-01 04:19:06.401513
NCT00259285|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|2008-12-19||2009-04-07|2005-11-28|2005-11-29|Estimate|2009-04-07|2009-06-02|Estimate||||2009-04-07|2009-06-02|Estimate|November 2005||2005-11-30|April 2009|2009-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer|Alimta (Pemetrexed) and Cisplatin Treatment as Neoadjuvant Therapy in Non Small Cell Lung Cancer|Terminated||Phase 2|10|Actual|Eli Lilly and Company|Trial was stopped early due to low enrollment and the relapse-free survival outcome measure was not analyzed.|1||Trial was stopped early due to low enrollment.|f||||f||||||||||2018-06-01 04:19:07.273033|2018-06-01 04:19:07.273033
NCT00259272|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|2009-04-30||2009-04-30|2005-11-28|2005-11-29|Estimate|2009-04-30|2009-06-24|Estimate||||2009-04-30|2009-06-24|Estimate|November 2005||2005-11-30|April 2009|2009-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine|Phase IIIb, Multicenter, Single-Arm Open-Label Study, Supporting the Development and the Validation of the MATHYS Scale (Multidimensional Assessment of THYmic States) in a Population of Bipolar Patients Treated With Olanzapine, Either in-Label (Manic and Mixed Patients) and Off-Label (Hypomanic and Bipolar Depression)|Completed||Phase 3|141|Actual|Eli Lilly and Company|Fewer patients than planned were enrolled in the study. Not all the analyses (Principal Component Analysis, scree plot to define the structure) could be provided due to the specific formatting of the clinicaltrials.gov databank.|1|||f||||f||||||||||2018-06-01 04:19:07.57368|2018-06-01 04:19:07.57368
NCT00259246|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2009-01-20|2005-11-25|2005-11-29|Estimate|||||||2009-01-20|2009-01-21|Estimate|June 2004||2004-06-30|April 2005|2005-04-30|November 2005||2005-11-30|||||Interventional|||The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.|Fasting and Postprandial Response After Infusion of Saline, PYY1-36 and PYY3-36 and Effects on Appetite, Energy Intake and Energy Expenditure in Overweight/Obese Compared to Normalweight Subjects|Completed||N/A|24||University of Copenhagen|||||f||||||||||||||2018-06-01 04:19:09.500203|2018-06-01 04:19:09.500203
NCT00259233|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2009-01-20|2005-11-25|2005-11-29|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2005||2005-03-31|April 2007|2007-04-30|May 2005||2005-05-31|||||Interventional|||The Role of Peptide YY (PYY)in Inhibiting Food Intake.|The Effects of Peripheral Administration of Saline, PYY1-36 and PYY3-36 on ad Libitum Energy Intake and Appetite.|Completed||N/A|24||University of Copenhagen|||||f||||||||||||||2018-06-01 04:19:09.551616|2018-06-01 04:19:09.551616
NCT00259220|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2008-09-30|2005-11-28|2005-11-29|Estimate|||||||2008-09-30|2008-10-01|Estimate|December 2005||2005-12-31|March 2007|2007-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||HDUPE 2004: Gastro-Oesophageal Haemorrhage in Emergency : Gastric Préparation to Endoscopy|In Urgency Hight Digestive Haemorrhage : Gastric Preparation for Endoscopy|Completed||Phase 3|270|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-06-01 04:19:09.59726|2018-06-01 04:19:09.59726
NCT00259207|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-09-29|2005-11-28|2005-11-29|Estimate|||||||2009-09-29|2009-09-30|Estimate|December 2005||2005-12-31|March 2007|2007-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pulmonary Valve Replacement in Large Right Ventricular Outflow Tract|Pulmonary Valve Replacement : Study of Comparison Between a Standard Surgical Approach With Extracorporeal Circulation and an Off-pump Hybrid Strategy.|Completed||Phase 3|8|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:19:09.677672|2018-06-01 04:19:09.677672
NCT00259194|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-06-08|2005-11-28|2005-11-29|Estimate|||||||2009-06-08|2009-06-11|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|OPKAT||Observation and Prediction of Complications After Coronary Angiography|Observation and Prediction of Complications After Coronary Angiography|Completed||N/A|1000|Anticipated|Herning Hospital||2|||f||||f||||||||||2018-06-01 04:19:09.743508|2018-06-01 04:19:09.743508
NCT00259181|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2010-01-05|2005-11-28|2005-11-29|Estimate|||||||2010-01-05|2010-01-06|Estimate|January 2005||2005-01-31|December 2007|2007-12-31||||||||Interventional|||A Protocol for the Use of Chlorhexidine Gluconate Saturation for the Reduction of Dental Biofilm Formation on Polymethylmethacrylate Restoration|Examination of the Immersion of Provisional Crown Material in Chlorhexidine Gluconate on Dental Plaque Formation in Vivo|Completed||Phase 1|12||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:19:09.806564|2018-06-01 04:19:09.806564
NCT00259168|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2005-11-28|2005-11-28|2005-11-29|Estimate|||||||2005-11-28|2005-11-29|Estimate|June 2003||2003-06-30|November 2005|2005-11-30||||||||Interventional|||Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?|Insulin Resistance and Postprandial Endothelial Function: Does Early Intervention Make a Difference?|Unknown status|Recruiting|Phase 4|70||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:19:09.868106|2018-06-01 04:19:09.868106
NCT00259155|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2008-03-17|2005-11-25|2005-11-29|Estimate|||||||2008-03-17|2008-03-18|Estimate|July 2003||2003-07-31|July 2003|2003-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Rifaximin for the Treatment of Irritable Bowel Syndrome|Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth and IBS: Double Blind Randomized Controlled Trial (Multicenter Trial)|Completed||Phase 2|92||Cedars-Sinai Medical Center|||||||||||||||||||2018-06-01 04:19:09.956492|2018-06-01 04:19:09.956492
NCT00259142|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2015-05-12|2005-11-28|2005-11-29|Estimate|||||||2015-05-12|2015-05-13|Estimate|November 2005||2005-11-30|May 2015|2015-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies|Community Acceptability and Cost-effectiveness of Two Drug Distribution Methods for Home Based Management of Fevr in Kayunga District, Uganda|Terminated||N/A|1314|Anticipated|DBL -Institute for Health Research and Development||||Study never started|f||||||||||||||2018-06-01 04:19:10.012625|2018-06-01 04:19:10.012625
NCT00259129|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2014-11-11|2005-11-28|2005-11-29|Estimate|||||||2014-11-11|2014-11-13|Estimate|August 2005||2005-08-31|November 2014|2014-11-30|March 2008|Actual|2008-03-31|February 2007|Actual|2007-02-28||Interventional|||Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients|Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients|Completed||Phase 1|53|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:19:10.073336|2018-06-01 04:19:10.073336
NCT00259116|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2009-04-13|2005-11-28|2005-11-29|Estimate|||||||2009-04-13|2009-04-15|Estimate|November 2005||2005-11-30|April 2009|2009-04-30||||||||Interventional|||A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure|A Pilot Safety and Dose-Finding Trial of Intravenous Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure|Completed||Phase 2|18||Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies|||||f||||||||||||||2018-06-01 04:19:10.179238|2018-06-01 04:19:10.179238
NCT00259103|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2014-05-06|2005-11-28|2005-11-29|Estimate|||||||2014-05-06|2014-05-07|Estimate|November 2005||2005-11-30|May 2014|2014-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Pharmacokinetics and Efficacy of Intravenous Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labour|Completed||Phase 2|72|Actual|Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies||4|||f||||||||||||||2018-06-01 04:19:10.239633|2018-06-01 04:19:10.239633
NCT00259090|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|2009-11-03||2012-07-09|2005-11-25|2005-11-29|Estimate|2012-07-09|2012-08-16|Estimate||||2012-07-09|2012-08-16|Estimate|April 2004||2004-04-30|July 2012|2012-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer|A Double-blind, Randomized, Multicentre Trial to Compare the Anti-tumour Effects and Tolerability of a 500 mg Dose of Faslodex (Fulvestrant) Plus Arimidex (Anastrozole) With a 500 mg Dose of Faslodex(Fulvestrant) Alone and With Arimidex(Anastrozole) Alone, in Postmenopausal Women Prior to Surgery for Primary Breast Cancer|Completed||Phase 2|120|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:19:10.376821|2018-06-01 04:19:10.376821
NCT00259077|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2011-01-21|2005-11-25|2005-11-29|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2003||2003-10-31|January 2011|2011-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population|A Double-blind, Randomised, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy of Omeprazole 20mg and 10mg od for the Four-week Treatment of Non-erosive Reflux Disease (NERD) With That of Placebo od and to Investigate Safety|Completed||Phase 3|270||AstraZeneca|||||f||||||||||||||2018-06-01 04:19:10.698781|2018-06-01 04:19:10.698781
NCT00259064|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2016-06-01|2005-11-25|2005-11-29|Estimate|||||||2016-06-01|2016-06-02|Estimate|September 2004||2004-09-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|February 2007|Actual|2007-02-28||Interventional|INSTEP||Iressa v BSC (Best Supportive Care) in First Line NSCLC|A Phase II Multicentre Randomised, Parallel Group, Double-Blind, Placebo-Controlled Study of ZD1839 (IRESSATM) (250MG Tablet) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Chemotherapy-Naive Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status|Completed||Phase 2/Phase 3|216|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:19:10.78911|2018-06-01 04:19:10.78911
NCT00259051|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2011-01-21|2005-11-25|2005-11-29|Estimate|||||||2011-01-21|2011-01-24|Estimate|January 2004||2004-01-31|January 2011|2011-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population|A Double-blind, Randomised, Parallel-group, Multicentre, Phase III Study to Investigate the Pharmacodynamic Effect by Assessment of the 24 Hours Intraesophageal pH Level, the Efficacy and Safety of Omeprazole 10mg and 20mg od in Patients With Non-erosive Reflux Disease (NERD).|Completed||Phase 3|40||AstraZeneca|||||f||||||||||||||2018-06-01 04:19:10.910536|2018-06-01 04:19:10.910536
NCT00259038|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-28|||2016-11-04|2005-11-28|2005-11-29|Estimate|||||||2016-11-04|2016-11-08|Estimate|January 2004||2004-01-31|November 2016|2016-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure|A Phase II, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects With Congestive Heart Failure|Completed||Phase 2|162|Actual|Daiichi Sankyo, Inc.||2|||f||||||||||||||2018-06-01 04:19:10.984728|2018-06-01 04:19:10.984728
NCT00259025|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2008-08-08|2005-11-25|2005-11-29|Estimate|||||||2008-08-08|2008-08-11|Estimate|September 2006||2006-09-30|April 2008|2008-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Intravenous n-3 Fatty Acids and Sudden Cardiac Death in Hemodialysis Patients|The Effect of Intravenous n-3 Polyunsaturated Fatty Acids on Risk Markers for Sudden Cardiac Death in Hemodialysis Patients|Completed||Phase 2|60|Actual|Aalborg Universitetshospital|||||f||||||||||||||2018-06-01 04:19:11.080861|2018-06-01 04:19:11.080861
NCT00259012|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|2009-11-30|2009-01-21|2010-04-19|2005-11-23|2005-11-28|Estimate|2010-04-19|2010-05-07|Estimate|2010-04-19|2010-05-07|Estimate|2010-04-19|2010-05-07|Estimate|November 2005||2005-11-30|April 2010|2010-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD|A Multicenter, Randomized, Open Label, Single and Multiple Dose Study of the Pharmacokinetics and Pharmacodynamics of 2 Dose Levels of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged 1 Through 11 Months With Presumed GERD|Completed||Phase 3|67|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 04:19:11.327182|2018-06-01 04:19:11.327182
NCT00258999|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2015-10-01|2005-11-23|2005-11-28|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study|Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study|Completed||N/A|600||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:19:11.873564|2018-06-01 04:19:11.873564
NCT00258986|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2006-01-31|2005-11-23|2005-11-28|Estimate|||||||2006-01-31|2006-02-01|Estimate|March 2004||2004-03-31|November 2005|2005-11-30|December 2006||2006-12-31|||||Interventional|||Efficacy Study Comparing Hand-Assisted Laparoscopic and Mini-Incision Muscle Splitting Incision Living Donor Nephrectomy||Unknown status|Recruiting|Phase 3|50||University Medical Center Groningen|||||f||||||||||||||2018-06-01 04:19:11.934011|2018-06-01 04:19:11.934011
NCT00258973|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2015-12-01|2005-11-23|2005-11-28|Estimate|||||||2015-12-01|2015-12-03|Estimate|April 2006||2006-04-30|December 2015|2015-12-31|September 2007|Actual|2007-09-30|||||Observational|||Office Practice Assessment of Carotid Atherosclerosis Using Handheld Ultrasound (OPACA) Study|Office Practice Assessment of Carotid Atherosclerosis Using Handheld Ultrasound (OPACA) Study|Completed|||375|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:19:11.994665|2018-06-01 04:19:11.994665
NCT00258960|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2009-09-25|2005-11-24|2005-11-28|Estimate|||||||2009-09-25|2009-09-28|Estimate|February 2006||2006-02-28|September 2009|2009-09-30|July 2008|Actual|2008-07-31|||||Interventional|||Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer|Phase IV.II, Clinical Trial, With the Combination of Pegylated Liposomal Doxorubicin (Caelyx), Cyclophosphamide and Trastuzumab (Herceptin) in Patients With Metastatic Breast Cancer With Overexpression of HER2/Neu|Completed||Phase 2|49|Anticipated|Spanish Breast Cancer Research Group|||||f||||||||||||||2018-06-01 04:19:12.048552|2018-06-01 04:19:12.048552
NCT00258947|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2012-01-30|2005-11-24|2005-11-28|Estimate|||||||2012-01-30|2012-02-01|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults|Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults.|Completed||Phase 2|230|Actual|Sanofi|||||f||||f||||||||||2018-06-01 04:19:12.108104|2018-06-01 04:19:12.108104
NCT00258934|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2014-01-10|2005-11-24|2005-11-28|Estimate|||||||2014-01-10|2014-01-14|Estimate|September 2005||2005-09-30|January 2014|2014-01-31|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|||Immunogenicity Study of the Influenza Vaccine in Adults||Completed||Phase 2|978|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:19:12.177534|2018-06-01 04:19:12.177534
NCT00258921|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2007-11-21|2005-11-24|2005-11-28|Estimate|||||||2007-11-21|2007-11-22|Estimate|March 2004||2004-03-31|November 2007|2007-11-30|July 2006|Actual|2006-07-31|||||Observational|RIAT||RIAT Registry: Reason for Not Intensifying Antihypertensive Treatment|An International Registry in Essential Hypertension|Completed|||31870||Sanofi|||||f||||||||||||||2018-06-01 04:19:12.259525|2018-06-01 04:19:12.259525
NCT00258908|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|2009-04-07||2016-04-12|2005-11-24|2005-11-28|Estimate|2009-04-07|2009-06-08|Estimate||||2016-04-12|2016-04-14|Estimate|November 2005||2005-11-30|April 2016|2016-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan|Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age.|Completed||Phase 3|115|Actual|Sanofi|||||f||||f||||||||||2018-06-01 04:19:12.323713|2018-06-01 04:19:12.323713
NCT00258895|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|2009-08-18||2016-04-12|2005-11-24|2005-11-28|Estimate|2009-08-18|2009-09-28|Estimate||||2016-04-12|2016-04-14|Estimate|March 2005||2005-03-31|April 2016|2016-04-30|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®|Safety and Immunogenicity of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL® or Pentacel®|Completed||Phase 3|649|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:19:12.560628|2018-06-01 04:19:12.560628
NCT00257582|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2013-05-03|2005-11-22|2005-11-23|Estimate|||||||2013-05-03|2013-05-06|Estimate|August 2005||2005-08-31|May 2013|2013-05-31||||||||Interventional|||Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics|Long-term Study of Cetirizine Dry Syrup in Children Suffering From Various Type of Cutaneous Disease Accompanied With Pruritus.|Completed||Phase 3|60||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:19:29.123071|2018-06-01 04:19:29.123071
NCT00258882|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|2015-11-13||2016-03-10|2005-11-24|2005-11-28|Estimate|2016-03-10|2016-04-13|Estimate||||2016-03-10|2016-04-13|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Observational||Participants who received Adacel vaccine during the study period and age matched participants who received Td vaccine but no live virus vaccine, during the year prior to initiation of study during the same month as the Adacel vaccine recipient, 1 year earlier.|Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine|Post-licensure Safety Surveillance Study of Routine Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|Completed|||327293|Actual|Sanofi|As a result of screening using The Risk Interval and The Historic Cohort methods incident rates for 1030 outcomes were flagged as elevated. In post-hoc manual review no safety signals were identified. Details highlighted in the manuscript.||||f||||f||||||||||2018-06-01 04:19:12.98912|2018-06-01 04:19:12.98912
NCT00258869|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2010-11-05|2005-11-23|2005-11-28|Estimate|||||||2010-11-05|2010-11-09|Estimate|December 2005||2005-12-31|January 2009|2009-01-31|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests|Plasma Protein Biomarker Based Diagnostics of Outcome in Sepsis & CAP|Unknown status|Recruiting||1200|Anticipated|National Center for Genome Resources|||1||f||||t||||||Samples With DNA|"~     PaxGene whole blood tubes (RNA and DNA), EDTA plasma, serum (subset), microbiologic isolates~   "|||2018-06-01 04:19:13.322949|2018-06-01 04:19:13.322949
NCT00258856|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|2009-10-19||2014-01-21|2005-11-24|2005-11-28|Estimate|2009-10-19|2009-11-25|Estimate||||2014-01-21|2014-02-14|Estimate|January 2006||2006-01-31|January 2014|2014-01-31|November 2007|Actual|2007-11-30|March 2007|Actual|2007-03-31||Interventional|||Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®|Persistence of Bactericidal Antibodies in Children Aged 7 to 15 Years Who Received a Single Dose of Menactra® or Menomune®-A/C/Y/W-135 Five Years Earlier|Completed||Phase 2|234|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 04:19:13.601763|2018-06-01 04:19:13.601763
NCT00258843|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2014-01-20|2005-11-24|2005-11-28|Estimate|||||||2014-01-20|2014-01-22|Estimate|November 2005||2005-11-30|January 2014|2014-01-31|April 2006|Actual|2006-04-30|February 2006|Actual|2006-02-28||Interventional|||Safety of Imovax Polio in Chinese Infants and Children|Clinical Safety Evaluation Study of the Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered as a Single Booster Dose at 18 Months of Age in Healthy Chinese Children, and as the First Dose of Primary Vaccination at 2 Months of Age in Healthy Chinese Infants.|Completed||Phase 3|40|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:19:13.956088|2018-06-01 04:19:13.956088
NCT00258830|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|2009-03-05||2016-04-12|2005-11-24|2005-11-28|Estimate|2009-04-09|2009-06-03|Estimate||||2016-04-12|2016-04-14|Estimate|September 2005||2005-09-30|April 2016|2016-04-30|March 2007|Actual|2007-03-31|February 2006|Actual|2006-02-28||Interventional|||Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine|Annual Study of Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2005-2006 Formulation)|Completed||Phase 4|120|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:19:14.034852|2018-06-01 04:19:14.034852
NCT00258817|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|2009-01-21||2016-04-12|2005-11-24|2005-11-28|Estimate|2009-03-24|2009-03-25|Estimate||||2016-04-12|2016-04-14|Estimate|October 2005||2005-10-31|April 2016|2016-04-30|August 2007|Actual|2007-08-31|March 2006|Actual|2006-03-31||Interventional|||Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine|Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2005-2006 Formulation)|Completed||Phase 4|30|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:19:14.41144|2018-06-01 04:19:14.41144
NCT00258804|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2011-06-07|2005-11-24|2005-11-28|Estimate|||||||2011-06-07|2011-06-08|Estimate|May 2005||2005-05-31|June 2011|2011-06-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Insulin Glargine During and After the Period of Fasting in Ramadan|Evaluation (Safety and Efficacy) of Treatment With Insulin Glargine and Glimepiride in Patients With Type 2 Diabetes Before, During and After the Period of Fasting in Ramadan|Completed||Phase 4|450||Sanofi|||||f||||||||||||||2018-06-01 04:19:14.768684|2018-06-01 04:19:14.768684
NCT00258791|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2012-09-21|2005-11-25|2005-11-28|Estimate|||||||2012-09-21|2012-09-25|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Pretreatment With Ibuprofen in Post-Electroconvulsive Therapy (ECT) Headache|Effects of Pretreatment With Ibuprofen in Post- ECT Headache|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||||first postponed then cancelled as national drug authority changed requirements|f||||f||||||||||2018-06-01 04:19:14.844505|2018-06-01 04:19:14.844505
NCT00258778|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2006-12-04|2005-11-23|2005-11-28|Estimate|||||||2006-12-04|2006-12-05|Estimate|November 2005||2005-11-30|December 2006|2006-12-31|January 2006||2006-01-31|||||Interventional|||Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)|A Phase I, Non-Randomized, Open Label, Single Dose-Escalation Safety Study of Recombinant Human Glucocerebrosidase (prGCD) in Healthy Volunteers|Completed||Phase 1|6||Protalix|||||||||||||||||||2018-06-01 04:19:14.899036|2018-06-01 04:19:14.899036
NCT00258765|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2010-04-23|2005-11-24|2005-11-28|Estimate|||||||2010-04-23|2010-04-26|Estimate|May 2006||2006-05-31|April 2010|2010-04-30||||November 2006|Actual|2006-11-30||Interventional|||Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.|A Phase IIb Randomised Clinical Trial of the Tolerability, Safety and Efficacy of Adjuvant Docetaxel-Zoledronic Acid After Prostatectomy for High-risk Early Prostate Cancer (AD-ZAP).|Terminated||Phase 2|1|Actual|Novartis||2||Poor recruitment & not feasible to continue|f||||t||||||||||2018-06-01 04:19:14.951634|2018-06-01 04:19:14.951634
NCT00258752|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2013-04-11|2005-11-23|2005-11-28|Estimate|||||||2013-04-11|2013-04-15|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|June 2009|Actual|2009-06-30|January 2008|Actual|2008-01-31||Interventional|||Comparison of Three Therapy-Based Interventions for Preventing Depression in Adolescents|Prevention of Depression in Adolescents|Completed||N/A|57|Actual|Rutgers University||3|||f||||f||||||||||2018-06-01 04:19:15.016186|2018-06-01 04:19:15.016186
NCT00258739|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2009-12-04|2005-11-23|2005-11-28|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 2001||2001-10-31|December 2009|2009-12-31||||September 2007|Actual|2007-09-30||Interventional|||Docetaxel in Non Small Cell Lung Cancer (NSCLC)|A Phase II, Randomized Study With Docetaxel-gemcitabine Followed by Radiotherapy vs Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) Followed by Docetaxel-gemcitabine Versus Docetaxel-gemcitabine Followed by Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) in Stage III NSCLC|Completed||Phase 2|140|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:19:15.087738|2018-06-01 04:19:15.087738
NCT00258726|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2010-08-26|2005-11-23|2005-11-28|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2005||2005-10-31|April 2010|2010-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Immune Responses to Two Dose Varivax +/- MMR-II|Immunogenicity and Safety of Live Attenuated Varicella Vaccine in 12 and 18 Month-old Children, With and Without Concomitant Administration of Measles-Mumps-Rubella Vaccine|Terminated||Phase 1/Phase 2|105||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:19:15.148141|2018-06-01 04:19:15.148141
NCT00258713|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2008-09-24|2005-11-23|2005-11-28|Estimate|||||||2008-09-24|2008-09-29|Estimate|September 2005||2005-09-30|September 2008|2008-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|SPIRIT||A 36-Week Extension to Protocol ISA04-03|A 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients With Plaque Psoriasis|Completed||Phase 3|309|Actual|Aurinia Pharmaceuticals Inc.||3|||f||||t||||||||||2018-06-01 04:19:15.205326|2018-06-01 04:19:15.205326
NCT00258700|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2016-09-20|2005-11-24|2005-11-28|Estimate|||||||2016-09-20|2016-09-21|Estimate|February 2005||2005-02-28|September 2016|2016-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine|Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix™-IPV Versus a Licensed Men-C Vaccine With Pediacel™ When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months|Completed||Phase 3|478|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:19:15.309767|2018-06-01 04:19:15.309767
NCT00258687|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2018-02-01|2005-11-23|2005-11-28|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2005|Actual|2005-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2006|Actual|2006-07-31||Interventional|||Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma|A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients|Active, not recruiting||Phase 1|12|Actual|Dana-Farber Cancer Institute||2|||f||||||||||||||2018-06-01 04:19:15.390199|2018-06-01 04:19:15.390199
NCT00258674|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|2011-10-21||2017-06-09|2005-11-23|2005-11-28|Estimate|2012-09-21|2012-10-23|Estimate||||2017-06-09|2017-06-14|Actual|January 2000||2000-01-31|June 2017|2017-06-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Improving Diabetes Care:Effectiveness of Physician Profiling and Care Coordination by a Diabetes Resource Nurse|A Randomized Trial of Strategies to Improve Diabetes Care: Effectiveness and Costs of Physician Profiling and Care Coordination by a Diabetes Resource Nurse|Completed||N/A|1891|Actual|Baylor Research Institute|"All participating practices belonged to the same network of fee-for-service practices, which may reduce generalizability.~Neither physicians nor patients could be blinded; but data were collected by individuals blinded to study arm assignments."|3|||f||||t||||||||||2018-06-01 04:19:15.482334|2018-06-01 04:19:15.482334
NCT00258661|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2011-07-22|2005-11-23|2005-11-28|Estimate|||||||2011-07-22|2011-07-26|Estimate|March 2004||2004-03-31|July 2011|2011-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|MOPSE||Is Osteopathic Manipulative Treatment (OMT) Beneficial for Elderly Patients Hospitalized With Pneumonia?|Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE)|Completed||N/A|406|Actual|A.T. Still University of Health Sciences||3|||f||||t||||||||||2018-06-01 04:19:16.298745|2018-06-01 04:19:16.298745
NCT00258635|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-25|||2010-06-16|2005-11-25|2005-11-28|Estimate|||||||2010-06-16|2010-06-17|Estimate|November 2005||2005-11-30|June 2010|2010-06-30||||||||Interventional|||Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test|A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Ragweed Allergoid With MPL® With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Patients Sensitized to Ragweed Pollen.|Completed||Phase 2|69|Actual|Allergy Therapeutics|||||f||||||||||||||2018-06-01 04:19:16.396883|2018-06-01 04:19:16.396883
NCT00258622|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-24|||2007-11-15|2005-11-24|2005-11-28|Estimate|||||||2007-11-15|2007-11-16|Estimate|November 2005||2005-11-30|November 2007|2007-11-30|February 2007|Actual|2007-02-28|||||Interventional|||NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain|NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain: a Randomized, Double-Blind, Placebo-Controlled, Crossover Study|Completed||Phase 2|18|Actual|Danish Pain Research Center|||||f||||||||||||||2018-06-01 04:19:16.468706|2018-06-01 04:19:16.468706
NCT00258609|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2005-12-22|2005-11-23|2005-11-24|Estimate|||||||2005-12-22|2005-12-23|Estimate|February 2003||2003-02-28|December 2005|2005-12-31|June 2004||2004-06-30|||||Interventional|||Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study|A 12-Week Prospective, Double-Blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis.|Completed||Phase 3|128||Rajavithi Hospital|||||f||||||||||||||2018-06-01 04:19:16.53023|2018-06-01 04:19:16.53023
NCT00258596|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2007-03-05|2005-11-23|2005-11-24|Estimate|||||||2007-03-05|2007-03-06|Estimate|January 2003||2003-01-31|January 2007|2007-01-31|September 2006||2006-09-30|||||Interventional|||Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions|Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions: A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Chronic Total Coronary Occlusions (PRISON II)|Completed||Phase 3|200||R&D Cardiologie|||||f||||||||||||||2018-06-01 04:19:16.627597|2018-06-01 04:19:16.627597
NCT00258583|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2017-07-24|2005-11-23|2005-11-24|Estimate|||||||2017-07-24|2017-07-25|Actual|October 2003||2003-10-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|ILDRR||UPMC Simmons Center for Interstitial Lung Disease Pennsylvania Statewide Research Registry|UPMC Simmons Center for Interstitial Lung Disease Pennsylvania Statewide Research Registry|Recruiting|||5000|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:19:16.702993|2018-06-01 04:19:16.702993
NCT00258570|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2017-07-24|2005-11-23|2005-11-24|Estimate|||||||2017-07-24|2017-07-25|Actual|January 2003||2003-01-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|GP||Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)|Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis|Recruiting|||2000|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Blood samples retained for multitude of testing. Consent allows for unrestricted use of~     samples.~   "|||2018-06-01 04:19:16.862866|2018-06-01 04:19:16.862866
NCT00258557|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-06-25|2005-11-22|2005-11-24|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2005||2005-09-30|June 2013|2013-06-30|May 2012|Actual|2012-05-31|June 2007|Actual|2007-06-30||Interventional|||"TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir (TMC114/r) in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications."|Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients.|Completed||Phase 3|692|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||t||||||||||2018-06-01 04:19:16.977518|2018-06-01 04:19:16.977518
NCT00258167|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2008-06-10|2005-11-23|2005-11-24|Estimate|||||||2008-06-10|2008-06-11|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|November 2008|Anticipated|2008-11-30|November 2008|Anticipated|2008-11-30||Interventional|||Family Involvement in The Treatment Of a Mentally Ill Relative|Family Involvement in The Treatment Of a Mentally Ill Relative|Unknown status|Recruiting|N/A|50|Anticipated|Lev-Hasharon Mental Healtlh Center|||||f||||||||||||||2018-06-01 04:19:21.860252|2018-06-01 04:19:21.860252
NCT00258544|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2017-07-24|2005-11-23|2005-11-24|Estimate|||||||2017-07-24|2017-07-26|Actual|October 2001||2001-10-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|MAA||Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)|Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis|Recruiting|||150|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Lung Tissue from a Lung Biopsy ordered by the patients physician. Also, a blood sample may be~     collected at the researchers discretion as listed in the addendum consent form.~   "|||2018-06-01 04:19:17.250877|2018-06-01 04:19:17.250877
NCT00258531|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2006-07-27|2005-11-22|2005-11-24|Estimate|||||||2006-07-27|2006-07-28|Estimate|June 2003||2003-06-30|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Evaluation of 3-Dimensional Magnetic Imaging During Colonoscopy|Evaluation of 3-Dimensional Magnetic Imaging During Colonoscopy for Visualisation of Endoscope Localisation|Completed||Phase 4|360||Sykehuset Telemark|||||f||||||||||||||2018-06-01 04:19:17.345687|2018-06-01 04:19:17.345687
NCT00258518|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2012-03-07|2005-11-23|2005-11-24|Estimate|||||||2012-03-07|2012-03-08|Estimate|November 2005||2005-11-30|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Respiratory Mechanics and Pleural Effusion|Estimation of Respiratory Mechanics (Respiratory System, Chest Wall and Lung Elastance) and Pleural Effusion at the Bedside With CT Scan.|Completed|||60|Actual|Policlinico Hospital|||1||f||||f||||||||||2018-06-01 04:19:17.407866|2018-06-01 04:19:17.407866
NCT00258505|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2007-07-31|2005-11-23|2005-11-24|Estimate|||||||2007-07-31|2007-08-01|Estimate||||October 2005|2005-10-31|September 2007||2007-09-30|||||Observational|||Monitoring Brain Activity in Human Brain Injury|Incidence, Nature and Consequences of Cortical Depolarizations in Human Brain Injury From Trauma and Ischemia: The COSBID Study|Unknown status|Not yet recruiting||100|Anticipated|Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:19:17.478453|2018-06-01 04:19:17.478453
NCT00258492|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2007-01-25|2005-11-23|2005-11-24|Estimate|||||||2007-01-25|2007-01-26|Estimate|December 2005||2005-12-31|July 2006|2006-07-31|January 2007||2007-01-31|||||Interventional|||Restless Legs Syndrome Exercise Intervention|The Prevalence and Outcomes of Restless Legs Syndrome Among Veterans - Exercise Intervention|Unknown status|Active, not recruiting|Phase 1/Phase 2|30||Northeastern Ohio Universities College of Medicine|||||f||||||||||||||2018-06-01 04:19:17.560524|2018-06-01 04:19:17.560524
NCT00258479|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2017-05-10|2005-11-23|2005-11-24|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2003||2003-06-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents|Modafinil and Nicotine in Adolescents: Phase I Trial|Completed||Phase 1|24|Actual|University of Kentucky||3|||f||||t||||||||||2018-06-01 04:19:17.617476|2018-06-01 04:19:17.617476
NCT00258466|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2013-04-05|2005-11-23|2005-11-24|Estimate|||||||2013-04-05|2013-04-08|Estimate|May 2005||2005-05-31|April 2013|2013-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer|Phase III Trial of Neutron + Photon Radiation Versus Photon + Hypofractionated Intensity Modulated Radiation Therapy in Localized Prostate Cancer|Withdrawn||Phase 3|0|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 04:19:17.696883|2018-06-01 04:19:17.696883
NCT00258453|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-08-01|2005-11-22|2005-11-24|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2001||2001-05-31|October 2007|2007-10-31|September 2009|Actual|2009-09-30|September 2007|Actual|2007-09-30||Interventional|||Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma|Prospective, Multi-Center Survey Study of Children and Adolescents With Craniopharyngioma|Completed||N/A|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:19:17.771851|2018-06-01 04:19:17.771851
NCT00258440|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|2010-06-10||2017-05-07|2005-11-23|2005-11-24|Estimate|2011-04-27|2011-05-26|Estimate||||2017-05-07|2017-05-09|Actual|May 2003||2003-05-31|May 2017|2017-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer|A Pilot Trial of Extended Interval Dosing of Epoetin Alfa (Procrit®) for the Treatment of Anemia in Oncology Patients|Terminated||N/A|7|Actual|OHSU Knight Cancer Institute|Due to low accruals the sponsor decided to discontinue the study early. A full analysis was not completed.|3||Sponsor discontinued funding of the study|f||||t||||||||||2018-06-01 04:19:17.965156|2018-06-01 04:19:17.965156
NCT00258427|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2018-02-12|2005-11-22|2005-11-24|Estimate|||||||2018-02-12|2018-02-13|Actual|March 26, 2002|Actual|2002-03-26|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia|Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02|Recruiting||Phase 2|25|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 04:19:18.224813|2018-06-01 04:19:18.224813
NCT00258401|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-01-11|2005-11-22|2005-11-24|Estimate|||||||2011-01-11|2011-01-12|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.|The Effectiveness of a Low-Residue Diet on Diarrhea in Cancer Patients Receiving Pelvic Radiation Therapy|Completed||N/A|11|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:19:18.425179|2018-06-01 04:19:18.425179
NCT00258388|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-09-27|2005-11-22|2005-11-24|Estimate|||||||2011-09-27|2011-09-28|Estimate|June 2005||2005-06-30|September 2011|2011-09-30|January 2011|Actual|2011-01-31|October 2007|Actual|2007-10-31||Interventional|||Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy|A Randomized Phase II Study of OGX-011 in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|82|Actual|Canadian Cancer Trials Group||2|||f||||f||||||||||2018-06-01 04:19:18.497847|2018-06-01 04:19:18.497847
NCT00258375|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2010-11-07|2005-11-22|2005-11-24|Estimate|||||||2010-11-07|2010-11-09|Estimate|June 2005||2005-06-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer|A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer|Completed||Phase 2|42|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 04:19:18.588388|2018-06-01 04:19:18.588388
NCT00258362|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2010-08-20||2017-12-03|2005-11-22|2005-11-24|Estimate|2010-11-10|2010-11-11|Estimate||||2017-12-03|2017-12-28|Actual|July 2005||2005-07-31|December 2017|2017-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer|A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer|Completed||Phase 2|41|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 04:19:18.661275|2018-06-01 04:19:18.661275
NCT00258349|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2012-08-28||2014-05-29|2005-11-22|2005-11-24|Estimate|2012-08-28|2012-09-27|Estimate||||2014-05-29|2014-06-02|Estimate|August 2006||2006-08-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer|A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer|Completed||Phase 1/Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:19:18.895434|2018-06-01 04:19:18.895434
NCT00258336|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2014-01-09|2005-11-22|2005-11-24|Estimate|||||||2014-01-09|2014-01-10|Estimate|August 2004||2004-08-31|August 2008|2008-08-31||||November 2009|Anticipated|2009-11-30||Interventional|||Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma|Phase II Trial of Maintenance Rituximab Plus FavId® and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma|Unknown status|Recruiting|Phase 2|56|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:19:19.087262|2018-06-01 04:19:19.087262
NCT00258323|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2015-09-29|2005-11-22|2005-11-24|Estimate|||||||2015-09-29|2015-09-30|Estimate|October 2005||2005-10-31|September 2015|2015-09-30|February 2010|Actual|2010-02-28|July 2007|Actual|2007-07-31||Interventional|||Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer|A Phase II Trial of Pre- and Postoperative Chemoradiotherapy and ZD1839 (IRESSA) Followed by Maintenance ZD1839 in Patients With Locoregionally Advanced Esophageal and Gastroesophageal Junction Carcinoma|Completed||Phase 2|80|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:19:19.145019|2018-06-01 04:19:19.145019
NCT00258310|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2014-11-20||2015-01-15|2005-11-22|2005-11-24|Estimate|2015-01-15|2015-01-19|Estimate||||2015-01-15|2015-01-19|Estimate|December 2003||2003-12-31|January 2015|2015-01-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy|A Phase II Study Examining the Feasibility of Long Term and Low Dose Oral Capecitabine (Xeloda®) in Newly Diagnosed Head and Neck Squamous Cell Carcinoma (HNSCC) After Surgery, Radiation and/or Chemotherapy|Completed||Phase 2|35|Actual|Barbara Ann Karmanos Cancer Institute|There were no significant limitations.|1|||f||||t||||||||||2018-06-01 04:19:19.223384|2018-06-01 04:19:19.223384
NCT00258297|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-10-14|2005-11-22|2005-11-24|Estimate|||||||2013-10-14|2013-10-16|Estimate|April 2004||2004-04-30|October 2013|2013-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery|A Phase II Safety, Efficacy, and Feasibility Study of Neoadjuvant ZD1839 (IRESSA) in Resectable Esophageal Cancer|Terminated||Phase 2|30|Anticipated|University of Rochester||||Withdrawn for lack of funding and accrual|f||||t||||||||||2018-06-01 04:19:20.330592|2018-06-01 04:19:20.330592
NCT00258284|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2014-03-05|2005-11-22|2005-11-24|Estimate|||||||2014-03-05|2014-03-06|Estimate|August 2003||2003-08-31|March 2014|2014-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer|Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma|Completed||Phase 2|30|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 04:19:20.392322|2018-06-01 04:19:20.392322
NCT00258271|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-10-14|2005-11-22|2005-11-24|Estimate|||||||2013-10-14|2013-10-16|Estimate|March 2005||2005-03-31|October 2013|2013-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia|A Phase I Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Leukemias|Completed||Phase 1|18|Anticipated|University of Rochester|||||f||||t||||||||||2018-06-01 04:19:20.462606|2018-06-01 04:19:20.462606
NCT00258258|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-01-31|2005-11-22|2005-11-24|Estimate|||||||2013-01-31|2013-02-01|Estimate|August 2005||2005-08-31|January 2013|2013-01-31||||March 2009|Actual|2009-03-31||Interventional|||Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders|An Open Label Dose Escalation Study of Intravenous Paricalcitol (ZEMPLAR™) [19-NOR-1 ALPHA, 25 - (OH)D] With Zoledronic Acid (Zometa™) in Patients With Multiple Myeloma|Terminated||Phase 1|7|Actual|Roswell Park Cancer Institute||||Withdrawn due to low accrual|f||||f||||||||||2018-06-01 04:19:20.526092|2018-06-01 04:19:20.526092
NCT00258245|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-04-25|2005-11-22|2005-11-24|Estimate|||||||2013-04-25|2013-04-29|Estimate|May 2005||2005-05-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia|A Phase I Study of Arsenic Trioxide and Ascorbic Acid (ATO/AA) in Combination With Low Dose Velcade-Thalidomide-Dexamethasone (VTD) in Relapsed/Refractory Multiple Myeloma (MM)|Completed||Phase 1|5|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 04:19:20.594072|2018-06-01 04:19:20.594072
NCT00258232|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-04-05|2005-11-22|2005-11-24|Estimate|||||||2013-04-05|2013-04-08|Estimate|January 2002||2002-01-31|April 2013|2013-04-30|August 2007|Actual|2007-08-31|March 2007|Actual|2007-03-31||Interventional|||Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer|Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 04:19:20.711712|2018-06-01 04:19:20.711712
NCT00258206|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2015-05-28||2017-11-01|2005-11-22|2005-11-24|Estimate|2015-05-28|2015-06-11|Estimate||||2017-11-01|2017-12-06|Actual|December 2004||2004-12-31|November 2017|2017-11-30|September 7, 2007|Actual|2007-09-07|September 7, 2007|Actual|2007-09-07||Interventional|||Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma|Phase II Study of High Dose Cyclophosphamide and Rituximab in Multiple Myeloma|Completed||Phase 2|21|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 04:19:20.782461|2018-06-01 04:19:20.782461
NCT00258193|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2006-10-19|2005-11-22|2005-11-24|Estimate|||||||2006-10-19|2006-10-20|Estimate|January 2006||2006-01-31|October 2006|2006-10-31|September 2006||2006-09-30|||||Interventional|||Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS|A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Pharmacodynamic Effects of Orally Administered 100ug and 1000ug QD MD-1100 Acetate on Gastrointestinal Transit in Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)|Completed||Phase 2|36||Ironwood Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:19:21.743006|2018-06-01 04:19:21.743006
NCT00258180|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2012-06-13|2005-11-22|2005-11-24|Estimate|||||||2012-06-13|2012-06-14|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy|High-Dose Cyclophosphamide for the Treatment of Severe Autoimmune Enteropathy|Completed||Phase 2|3|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:19:21.796439|2018-06-01 04:19:21.796439
NCT00258154|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2009-08-10||2015-10-05|2005-11-22|2005-11-24|Estimate|2009-08-10|2009-09-23|Estimate||||2015-10-05|2015-10-06|Estimate|February 2006||2006-02-28|October 2015|2015-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)|Safety and Immunogenicity of Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants|Completed||Phase 3|403|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:19:21.981301|2018-06-01 04:19:21.981301
NCT00258141|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2005-11-23|2005-11-23|2005-11-24|Estimate|||||||2005-11-23|2005-11-24|Estimate||||November 2005|2005-11-30||||||||Interventional|||Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects|A Placebo-Controlled, Double-Blind, Cross-Over Study With Rupatadine 10 Mg in 30 Mosquito-Bite Allergic Adult Subjects|Unknown status|Not yet recruiting|Phase 4|30||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:19:22.74286|2018-06-01 04:19:22.74286
NCT00258128|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2008-11-26|2005-11-22|2005-11-24|Estimate|||||||2008-11-26|2008-11-27|Estimate|January 2000||2000-01-31|November 2008|2008-11-30||||||||Interventional|||Effect of Salicylate on Glucose Metabolism in Insulin Resistance States|Effect of Salicylate on Glucose Metabolism in Insulin Resistance States|Completed||Phase 2/Phase 3|20||Joslin Diabetes Center|||||f||||||||||||||2018-06-01 04:19:22.805966|2018-06-01 04:19:22.805966
NCT00258115|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2018-02-14|2005-11-22|2005-11-24|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2003||2003-12-31|February 2018|2018-02-28||||October 2007|Actual|2007-10-31||Interventional|||The Study of Inflammation on Blood Glucose Levels in Obese People|The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity|Completed||Phase 2|20|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-06-01 04:19:22.870747|2018-06-01 04:19:22.870747
NCT00258102|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-06-08|2005-11-22|2005-11-24|Estimate|||||||2011-06-08|2011-06-10|Estimate|January 1993||1993-01-31|January 2011|2011-01-31|January 1995|Actual|1995-01-31|||||Interventional|||A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections|A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults|Completed||Phase 3|603|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:19:22.935049|2018-06-01 04:19:22.935049
NCT00258089|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-05-19|2005-11-22|2005-11-24|Estimate|||||||2011-05-19|2011-05-23|Estimate|June 1993||1993-06-30|November 2010|2010-11-30|January 1995|Actual|1995-01-31|||||Interventional|||A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections|A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults|Completed||Phase 3|578|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:19:22.986213|2018-06-01 04:19:22.986213
NCT00258076|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2012-12-11|2005-11-22|2005-11-24|Estimate|||||||2012-12-11|2012-12-12|Estimate|April 2004||2004-04-30|December 2012|2012-12-31|September 2004|Actual|2004-09-30|||||Interventional|||A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)|Open-Label, Randomized, Partially Balanced, Incomplete Block Design Sudy to Evaluate the Hormone Exposure From Commercial ORTHO EVRA�|Completed||Phase 1|53|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||||||||||||||||2018-06-01 04:19:23.05168|2018-06-01 04:19:23.05168
NCT00258063|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-06-06|2005-11-22|2005-11-24|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2004||2004-05-31|January 2011|2011-01-31|September 2004|Actual|2004-09-30|||||Interventional|||A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)|Open-Label, Randomized, Partially Balanced, Incomplete Block Design Study to Evaluate the Hormone Exposure From Commercial EVRA (Manufactured by LOHMANN Therapie-Systeme) and an Oral Contraceptive|Completed||Phase 1|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:19:23.104212|2018-06-01 04:19:23.104212
NCT00258050|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2017-12-04|2005-11-23|2005-11-24|Estimate|||||||2017-12-04|2017-12-06|Actual|November 21, 2005|Actual|2005-11-21|December 2017|2017-12-31|February 8, 2007|Actual|2007-02-08|February 8, 2007|Actual|2007-02-08||Interventional|||To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients|A Four-Way Cross-Over Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally and Intravenously Administered Midazolam in Cancer Patients|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:19:23.156032|2018-06-01 04:19:23.156032
NCT00258037|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2010-05-25|2005-11-23|2005-11-24|Estimate|||||||2010-05-25|2010-05-26|Estimate|January 1999||1999-01-31|March 2000|2000-03-31|September 2001||2001-09-30|||||Interventional|||Effect of Pelvic Floor Muscle Training in Stroke|Six Months Follow-Up of Pelvic Floor Muscle Training in Women With Urinary Incontinence After Stroke|Terminated||Phase 2|60||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 04:19:23.221688|2018-06-01 04:19:23.221688
NCT00258024|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2008-02-19|2005-11-23|2005-11-24|Estimate|||||||2008-02-19|2008-02-21|Estimate|November 2005||2005-11-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment|Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment Through Community Involvement in Rural Ghana|Completed||N/A|420|Anticipated|DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 04:19:23.36338|2018-06-01 04:19:23.36338
NCT00258011|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2009-01-13||2014-02-04|2005-11-22|2005-11-24|Estimate|2009-01-13|2009-02-12|Estimate||||2014-02-04|2014-03-07|Estimate|December 2005||2005-12-31|February 2014|2014-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease|A Safety Confirmatory Study of JC0498 (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients|Completed||Phase 3|3|Actual|Sanofi|Due to the rarity of the disease, this study is limited by its small sample size, lack of a control group and patients had variable treatment durations.|1|||f||||||||||||||2018-06-01 04:19:23.438832|2018-06-01 04:19:23.438832
NCT00257998|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2007-10-31|2005-11-23|2005-11-24|Estimate|||||||2007-10-31|2007-11-02|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Effectiveness of Three Manual Physical Therapy Techniques in a Subgroup of Patients With Low Back Pain|Comparison of the Effectiveness of Three Manual Physical Therapy Techniques in a Subgroup of Patients With Low Back Pain Who Satisfy a Clinical Prediction Rule: A Randomized Clinical Trial.|Completed||Phase 1|240|Anticipated|Franklin Pierce University|||||f||||||||||||||2018-06-01 04:19:23.641398|2018-06-01 04:19:23.641398
NCT00257985|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2006-07-31|2005-11-22|2005-11-24|Estimate|||||||2006-07-31|2006-08-01|Estimate|April 2005||2005-04-30|November 2005|2005-11-30|March 2006||2006-03-31|||||Interventional|||Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2|Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2|Completed||N/A|30||Danish Headache Center|||||f||||||||||||||2018-06-01 04:19:23.704118|2018-06-01 04:19:23.704118
NCT00257972|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-23|||2013-11-07|2005-11-23|2005-11-24|Estimate|||||||2013-11-07|2013-11-08|Estimate|October 2004||2004-10-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Aripiprazole in Patients With Bipolar I Disorder|Efficacy of Aripiprazole in Combination With Valproate or Lithium in the Treatment of Mania in Patients With Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy|Completed||Phase 3|400||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||f||||||||||||||2018-06-01 04:19:23.786153|2018-06-01 04:19:23.786153
NCT00257959|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2006-07-26|2005-11-22|2005-11-24|Estimate|||||||2006-07-26|2006-07-27|Estimate|January 2001||2001-01-31|November 2005|2005-11-30|October 2004||2004-10-31|||||Interventional|||Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)||Completed||Phase 4|400||Connolly, Stuart, M.D.|||||f||||||||||||||2018-06-01 04:19:24.016855|2018-06-01 04:19:24.016855
NCT00257946|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-12-14|2005-11-22|2005-11-24|Estimate|||||||2011-12-14|2011-12-15|Estimate|December 2005||2005-12-31|December 2011|2011-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Type of Material in Repair of Congenital Diaphragmatic Hernia|Prospective Randomized Trial Comparing Type of Material in Repair of Congenital Diaphragmatic Hernia|Terminated||Phase 3|50||Children's Mercy Hospital Kansas City||||poor accrual|f||||f||||||||||2018-06-01 04:19:24.078094|2018-06-01 04:19:24.078094
NCT00257933|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2010-07-14||2010-12-23|2005-11-22|2005-11-24|Estimate|2010-07-14|2010-08-11|Estimate||||2010-12-23|2010-12-31|Estimate|February 2006||2006-02-28|December 2010|2010-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Oral Prednisolone Dosing in Children Hospitalized With Asthma|Oral Prednisolone Dosing in Children Hospitalized With Asthma|Completed||Phase 4|152|Actual|Children's Hospital of Philadelphia|"Limited ability to measure pulmonary function in hospitalized children with asthma did not allow measurement of this outcome.~Some protocol violations occurred~Single center study"|2|||f||||f||||||||||2018-06-01 04:19:24.151248|2018-06-01 04:19:24.151248
NCT00257920|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2009-01-26||2009-12-22|2005-11-22|2005-11-24|Estimate|2009-04-06|2009-05-20|Estimate||||2009-12-22|2009-12-24|Estimate|June 2006||2006-06-30|December 2009|2009-12-31||||January 2008|Actual|2008-01-31||Interventional|||A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease|A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis|Completed||Phase 4|41|Actual|Abbott|The null hypothesis was not tested appropriately as a result of measurable differences in parathyroid hormone (PTH) suppression indicating dose exposure was different. Therefore, differences in calcium absorption could not be determined.|2|||f||||||||||||||2018-06-01 04:19:24.379569|2018-06-01 04:19:24.379569
NCT00257907|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2018-04-04|2005-11-22|2005-11-23|Estimate|||||||2018-04-04|2018-04-05|Actual|November 18, 2005||2005-11-18|February 24, 2016|2016-02-24|February 24, 2016||2016-02-24|||||Observational|||Immune Response to Mycobacterium Tuberculosis Infection|Correlation of the Precursor Frequency of CD4 + Effector Memory T Cells With Induration Measured in the Tuberculin Skin Test (TST)|Completed|||157|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:19:24.787987|2018-06-01 04:19:24.787987
NCT00257894|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|2014-01-28||2015-10-05|2005-11-21|2005-11-23|Estimate|2015-10-05|2015-11-04|Estimate||||2015-10-05|2015-11-04|Estimate|December 2005||2005-12-31|October 2015|2015-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Baclofen Effects on Smoking Urge and Withdrawal|Baclofen Effects on Smoking Urge and Withdrawal|Terminated||Phase 2|41|Actual|VA Office of Research and Development||2||Enrollment was completed with insufficient sample size for publishable results|f||||f||||||||||2018-06-01 04:19:24.938983|2018-06-01 04:19:24.938983
NCT00257881|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2007-12-06|2005-11-22|2005-11-23|Estimate|||||||2007-12-06|2007-12-10|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors|Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors|Terminated||Phase 1|46||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:19:25.194083|2018-06-01 04:19:25.194083
NCT00257868|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2007-07-30|2005-11-22|2005-11-23|Estimate|||||||2007-07-30|2007-07-31|Estimate|January 2006||2006-01-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Rivastigmine for the Prevention of Postoperative Delirium in Patients Undergoing Cardiac Surgery|Rivastigmine for the Prevention of Postoperative Delirium After Cardiac Surgery|Completed||Phase 3|120|Actual|University Hospital, Basel, Switzerland|||||f||||||||||||||2018-06-01 04:19:25.248391|2018-06-01 04:19:25.248391
NCT00257855|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2010-02-05|2005-11-22|2005-11-23|Estimate|||||||2010-02-05|2010-02-08|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis|A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial|Completed||Phase 2|120||University College London Hospitals|||||f||||t||||||||||2018-06-01 04:19:25.316735|2018-06-01 04:19:25.316735
NCT00257842|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2014-09-16|2005-11-21|2005-11-23|Estimate|||||||2014-09-16|2014-09-17|Estimate||||September 2014|2014-09-30||||||||Interventional|||Randomized Controlled Trial of Biofeedback Therapy for Dyssynergic Defecation||Terminated||N/A|||Augusta University|||||f||||||||||||||2018-06-01 04:19:25.395721|2018-06-01 04:19:25.395721
NCT00257829|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2008-02-27|2005-11-21|2005-11-23|Estimate|||||||2008-02-27|2008-02-29|Estimate|July 2004||2004-07-31|February 2008|2008-02-29||||||||Interventional|||Improving Tumor Oxygenation in Cervical Cancer|Improving Tumor Oxygenation in Cervical Cancer With Methazolamide|Withdrawn||Phase 2|18||University of California, Irvine||||This study was closed due to lack of funding.|f||||t||||||||||2018-06-01 04:19:25.457091|2018-06-01 04:19:25.457091
NCT00257816|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2018-02-01|2005-11-21|2005-11-23|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2004||2004-01-31|February 2018|2018-02-28|December 17, 2007|Actual|2007-12-17|December 17, 2007|Actual|2007-12-17||Interventional|||Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma|A Pilot Study of Weekly IV Topotecan and Cisplatin With Concurrent Pelvic Radiation in the Treatment of Stages IB2 - IVA Cervical Carcinoma|Completed||Phase 2|12|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 04:19:25.519824|2018-06-01 04:19:25.519824
NCT00257803|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2014-03-14|2005-11-21|2005-11-23|Estimate|||||||2014-03-14|2014-03-17|Estimate|November 2005||2005-11-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|October 2006|Actual|2006-10-31||Interventional|||Does the Rapid Intravenous Administration of Oxytocin After Delivery of the Baby Decrease the Bleeding During Cesarean Section in Women at Risk of Bleeding During Cesarean Section?|A Randomized Double-blind Comparison of a 5 Unit Intravenous Oxytocin Bolus Versus Placebo as a Strategy to Prevent Uterine Atony at Cesarean Section in Women Who Are at Increased Risk of Post-Partum Hemorrhage|Completed||N/A|150|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 04:19:25.602318|2018-06-01 04:19:25.602318
NCT00257777|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-07-03|2005-11-22|2005-11-23|Estimate|||||||2011-07-03|2011-07-06|Estimate|November 2003||2003-11-30|November 2005|2005-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Intermittent Cold Blood vs Crystalloid Cardioplegia in Aortic Valve Surgery|Intermittent Cold Blood vs Crystalloid Cardioplegia in Aortic Valve Surgery|Completed||N/A|350|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:19:25.769707|2018-06-01 04:19:25.769707
NCT00257764|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2006-05-04|2005-11-21|2005-11-23|Estimate|||||||2006-05-04|2006-05-05|Estimate|May 1996||1996-05-31|June 1999|1999-06-30|May 1999||1999-05-31|||||Interventional|||Behavioural Intervention for Dysphagia in Acute Stroke|A Randomised Controlled Trial of Dysphagia Therapies for Swallowing Disorders Following Stroke.|Completed||Phase 2/Phase 3|300||Royal Perth Hospital|||||f||||||||||||||2018-06-01 04:19:25.829679|2018-06-01 04:19:25.829679
NCT00257751|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2011-07-03|2005-11-22|2005-11-23|Estimate|||||||2011-07-03|2011-07-06|Estimate|March 2004||2004-03-31|March 2009|2009-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)|Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving|Completed||N/A|400|Anticipated|Oslo University Hospital|||||f||||f||||||||||2018-06-01 04:19:25.900398|2018-06-01 04:19:25.900398
NCT00257738|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2018-02-26|2005-11-21|2005-11-23|Estimate|||||||2018-02-26|2018-02-28|Actual|November 2005||2005-11-30|February 2018|2018-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck|A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously in Combination With Montanide and GM-CSF on Immunological Response, Safety, Tolerability, and Preliminary Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|17|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 04:19:25.961518|2018-06-01 04:19:25.961518
NCT00257725|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2009-02-04|2005-11-21|2005-11-23|Estimate|||||||2009-02-04|2009-02-05|Estimate|March 2005||2005-03-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Long Duration Stimulant Treatment Study of Preschoolers With ADHD-Feasibility Study||Completed||Phase 4|10|Actual|New York State Psychiatric Institute|||||f||||f||||||||||2018-06-01 04:19:26.040405|2018-06-01 04:19:26.040405
NCT00257712|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2013-12-17|2005-11-21|2005-11-23|Estimate|||||||2013-12-17|2013-12-19|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||SMART: Somatotrophics, Memory, and Aging Research Trial|GHRH: Cognition in Aging and MCI|Completed||Phase 2|151|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:19:26.110761|2018-06-01 04:19:26.110761
NCT00257699|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2008-08-11|2005-11-22|2005-11-23|Estimate|||||||2008-08-11|2008-08-12|Estimate|May 2006||2006-05-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study of Antibiotics in the Treatment of Colonic Crohn's Disease|Metronidazole and Ciprofloxacin in the Treatment of Colonic Crohn's Disease: The MACINTOCC Trial.|Terminated||Phase 2|12|Actual|Mount Sinai Hospital, Canada||2||Inadequate recruitment to meet completion date|f||||||||||||||2018-06-01 04:19:26.19162|2018-06-01 04:19:26.19162
NCT00257686|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|2009-08-26||2010-03-09|2005-11-21|2005-11-23|Estimate|2009-12-11|2010-01-18|Estimate||||2010-03-09|2010-03-16|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients|Study Of Pitavastatin 1 Mg Vs. Pravastatin 10 Mg, Pitavastatin 2 Mg Vs. Pravastatin 20 Mg And Pitavastatin 4 Mg Vs. Pravastatin 40 Mg (Following Up-Titration) In Elderly Patients With Primary Hypercholesterolemia Or Combined Dyslipidemia|Completed||Phase 3|962|Actual|Kowa Research Europe||6|||f||||f||||||||||2018-06-01 04:19:26.291346|2018-06-01 04:19:26.291346
NCT00257673|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2008-05-05|2005-11-22|2005-11-23|Estimate|||||||2008-05-05|2008-05-06|Estimate|November 2005||2005-11-30|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|183|Actual|Memory Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:19:26.843952|2018-06-01 04:19:26.843952
NCT00257660|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2010-01-06||2010-06-17|2005-11-22|2005-11-23|Estimate|2010-04-20|2010-05-10|Estimate||||2010-06-17|2010-06-22|Estimate|October 2005||2005-10-31|June 2010|2010-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia|A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia|Completed||Phase 3|116|Actual|Ipsen||2|||f||||f||||||||||2018-06-01 04:19:27.088718|2018-06-01 04:19:27.088718
NCT00257647|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2009-02-17|2005-11-22|2005-11-23|Estimate|||||||2009-02-17|2009-02-18|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|November 2007|Actual|2007-11-30|||||Observational|||Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)|Use of SV40 siRNA Vectors to Treat CML|Completed|||25|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 04:19:27.64791|2018-06-01 04:19:27.64791
NCT00257634|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2007-04-26|2005-11-21|2005-11-23|Estimate|||||||2007-04-26|2007-04-27|Estimate|December 2004||2004-12-31|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Randomized Trial of Iontophoresis Versus Injection of Corticosteroids for Lateral Epicondylitis|Dexamethasone Delivery for Treatment of Lateral Epicondylitis (IRB #3260)|Completed||Phase 3|80||Henry Ford Health System|||||f||||||||||||||2018-06-01 04:19:27.709239|2018-06-01 04:19:27.709239
NCT00257621|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2017-05-25|2005-11-22|2005-11-23|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2004||2004-10-31|May 2017|2017-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults|A Pilot, Phase II, Open-label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GW640385 When Administered With Ritonavir in Combination With NRTIs for 48 Weeks in HIV-1 Infected Adults|Completed||Phase 2|30|Actual|ViiV Healthcare|||||||||f||||||||||2018-06-01 04:19:27.769908|2018-06-01 04:19:27.769908
NCT00257608|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|2015-11-09||2016-03-18|2005-11-21|2005-11-23|Estimate|2016-02-16|2016-03-15|Estimate||||2016-03-18|2016-04-18|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)|A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|1145|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 04:19:27.928143|2018-06-01 04:19:27.928143
NCT00257556|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|2010-01-08||2010-02-12|2005-11-22|2005-11-23|Estimate|2010-02-12|2010-02-26|Estimate||||2010-02-12|2010-02-26|Estimate|October 2005||2005-10-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|July 2008|Actual|2008-07-31||Interventional|||A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa|A Prospective, Open Label, Randomised, Parallel Group, Comparative Pilot Study to Study the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant FSH (Follitropin Alfa) Administered Subcutaneously to Subfertile Female Patients Undergoing IVF Using Antagonist Downregulation|Completed||Phase 4|80|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:19:29.319475|2018-06-01 04:19:29.319475
NCT00257543|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-09-16|2005-11-22|2005-11-23|Estimate|||||||2013-09-16|2013-09-17|Estimate|January 2006||2006-01-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease|SALT - Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease|Terminated||Early Phase 1|3|Actual|Emory University||1||lack of enrollment|f||||t||||||||||2018-06-01 04:19:30.14424|2018-06-01 04:19:30.14424
NCT00257530|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2008-06-11|2005-11-22|2005-11-23|Estimate|||||||2008-06-11|2008-06-12|Estimate|December 2005||2005-12-31|June 2008|2008-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis|Randomized Double Blind Clinical Trial of Imiquimod (Aldara) Versus Placebo Used in Combination With Pentavalent Antimony (Glucantime) in Peruvian Cutaneous Leishmaniasis Patients|Completed||Phase 3|80||Drugs for Neglected Diseases|||||f||||||||||||||2018-06-01 04:19:30.203935|2018-06-01 04:19:30.203935
NCT00257517|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2014-02-11|2005-11-22|2005-11-23|Estimate|||||||2014-02-11|2014-02-13|Estimate|October 2005||2005-10-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Observational|||Multisite Feeding Study: Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle|Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle|Completed|||20|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:19:30.251322|2018-06-01 04:19:30.251322
NCT00257504|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2006-09-11|2005-11-21|2005-11-23|Estimate|||||||2006-09-11|2006-09-12|Estimate|November 2005||2005-11-30|September 2006|2006-09-30|May 2006||2006-05-31|||||Observational|||Central Blood Volume in Hypotensive Dialysis Patients|Registration of Central Blood Volume in Hypotensive Dialysis Patients - a Comparison of Thoracic Impedance and Central Venous Saturation Monitoring|Completed|||20||Danish State Hospital|||||f||||||||||||||2018-06-01 04:19:30.300037|2018-06-01 04:19:30.300037
NCT00257491|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2013-11-08|2005-11-22|2005-11-23|Estimate|||||||2013-11-08|2013-11-11|Estimate|November 2005||2005-11-30|November 2013|2013-11-30|August 2006||2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension|An Open-label Study to Evaluate the Trough and Peak Effect of Once Daily Micardis Plus (Telmisartan 80mg / Hydrochlorothiazide 12.5 mg) by 24 ABPM in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 3|29|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:19:30.34837|2018-06-01 04:19:30.34837
NCT00257478|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2012-06-06|2005-11-22|2005-11-23|Estimate|||||||2012-06-06|2012-06-07|Estimate||||June 2012|2012-06-30|March 2007|Actual|2007-03-31|||||Interventional|||A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy||Completed||Phase 2|||Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:19:30.399696|2018-06-01 04:19:30.399696
NCT00257465|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-22|||2015-12-02|2005-11-22|2005-11-23|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma|M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma|Completed||Phase 1/Phase 2|82|Actual|AVAX Technologies||4|||f||||t||||||||||2018-06-01 04:19:30.465566|2018-06-01 04:19:30.465566
NCT00257452|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2013-10-31|2005-11-21|2005-11-23|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2004||2004-10-31|October 2013|2013-10-31|July 2005||2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)|A Double-blind, Randomised, Placebo Controlled, Three-way Cross-over Study With an Open Label Positive Control (Moxifloxacin) to Assess the Influence of Inhaled Tiotropium Once Daily Over Twelve Days on the QTC Interval of the ECG in Healthy Male and Female Volunteers|Completed||Phase 1|56||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:19:30.578057|2018-06-01 04:19:30.578057
NCT00257439|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2012-09-24|2005-11-21|2005-11-23|Estimate|||||||2012-09-24|2012-09-25|Estimate|December 2005||2005-12-31|September 2012|2012-09-30||||||||Observational|||Vitamin Metabolism in Kidney Disease|Vitamin Metabolism in Kidney Disease|Unknown status|Recruiting||100|Anticipated|Aalborg Universitetshospital|||2||f||||f||||||||||2018-06-01 04:19:30.634417|2018-06-01 04:19:30.634417
NCT00257426|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2012-02-12|2005-11-18|2005-11-22|Estimate|||||||2012-02-12|2012-02-14|Estimate|July 2005||2005-07-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|February 2007|Actual|2007-02-28||Interventional|||Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer|A Phase II Study of Octreotide Acetate for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|31|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 04:19:30.701477|2018-06-01 04:19:30.701477
NCT00257413|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2005-11-21|2005-11-21|2005-11-22|Estimate|||||||2005-11-21|2005-11-22|Estimate||||December 2003|2003-12-31||||||||Interventional|||Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension||Completed||N/A|||Zhejiang University|||||f||||||||||||||2018-06-01 04:19:30.76094|2018-06-01 04:19:30.76094
NCT00257400|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2013-12-31|2005-11-21|2005-11-22|Estimate|||||||2013-12-31|2014-01-03|Estimate|May 2003||2003-05-31|December 2013|2013-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Comparison of Two Psychotherapy Treatments for Depressed Women With a History of Sexual Abuse|Interpersonal Psychotherapy for Depressed Women With Sexual Abuse Histories|Completed||Phase 1/Phase 2|70|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 04:19:30.808879|2018-06-01 04:19:30.808879
NCT00257387|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-02-01|2005-11-21|2005-11-22|Estimate|||||||2011-02-01|2011-02-02|Estimate|June 2004||2004-06-30|June 2007|2007-06-30|August 2006|Actual|2006-08-31|||||Interventional|||Study Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants|A Nonrandomized, Open-label, Multicenter, Sequential Phase Study to Evaluate the Safety and Efficacy of Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese De Novo Renal Allograft Recipients Receiving Rapamune|Completed||Phase 1/Phase 2|120||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:19:30.876612|2018-06-01 04:19:30.876612
NCT00257374|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2014-01-08|2005-11-21|2005-11-22|Estimate|||||||2014-01-08|2014-01-09|Estimate||||January 2014|2014-01-31||||||||Interventional|||Pedialyte or Gatorade for Viral Gastroenteritis in Adults: a Randomized, Controlled Trial||Completed||N/A|||Augusta University|||||f||||||||||||||2018-06-01 04:19:30.921174|2018-06-01 04:19:30.921174
NCT00257361|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2013-09-27|2005-11-18|2005-11-22|Estimate|||||||2013-09-27|2013-09-30|Estimate|July 2005||2005-07-31|August 2011|2011-08-31||||||||Interventional|||D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder|D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder|Withdrawn||Phase 2|0|Actual|University of Florida||||PI left the university|f||||f||||||||||2018-06-01 04:19:30.967647|2018-06-01 04:19:30.967647
NCT00257348|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2013-02-06|2005-11-21|2005-11-22|Estimate|||||||2013-02-06|2013-02-08|Estimate|March 2004||2004-03-31|February 2013|2013-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer|A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer|Completed||Phase 2|5|Actual|University of California, Irvine|||||f||||t||||||||||2018-06-01 04:19:31.982826|2018-06-01 04:19:31.982826
NCT00257335|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2017-07-26|2005-11-21|2005-11-22|Estimate|||||||2017-07-26|2017-07-31|Actual|October 14, 2004||2004-10-14|July 2017|2017-07-31|June 12, 2007|Actual|2007-06-12|June 12, 2007|Actual|2007-06-12||Interventional|||Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer|A Phase II Protocol of Intensity-Modulated Radiotherapy for Treatment of Previously Irradiated Recurrent Head and Neck Cancer|Withdrawn||Phase 2|0|Actual|University of California, Irvine||||Due to no patient enrollment this study was withdrawn/closed|f||||||||||||||2018-06-01 04:19:32.048011|2018-06-01 04:19:32.048011
NCT00257322|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2009-06-26||2016-03-23|2005-11-18|2005-11-22|Estimate|2016-03-23|2016-04-26|Estimate||||2016-03-23|2016-04-26|Estimate|April 2003||2003-04-30|March 2016|2016-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Cellular Immune Augmentation in Colon and Rectal Cancer|A Pilot Study of Cellular Immune Augmentation in Colon and Rectal Cancer Therapy|Completed||Phase 2|20|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 04:19:32.105235|2018-06-01 04:19:32.105235
NCT00257309|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2016-10-02||2016-11-22|2005-11-18|2005-11-22|Estimate|2016-11-22|2017-01-19|Estimate||||2016-11-22|2017-01-19|Estimate|April 2005||2005-04-30|November 2016|2016-11-30|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|TRIANA||Thrombolysis Versus Primary Angioplasty for AMI in Elderly Patients|TRIANA: A Randomized Trial to Compare the Efficay and Safety of Thrombolysis With Primary Angioplasty as Initial Reperfusion Therapy in Older Patients (>= 75 Years Old) With Acute Myocardial Infarction|Terminated||Phase 4|266|Actual|Spanish Society of Cardiology||2||Slow recruitment|f||||t||||||||||2018-06-01 04:19:32.263305|2018-06-01 04:19:32.263305
NCT00257296|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2018-02-09|2005-11-21|2005-11-22|Estimate|||||||2018-02-09|2018-02-13|Actual|August 1, 2004|Actual|2004-08-01|February 2018|2018-02-28|October 15, 2005|Actual|2005-10-15|October 15, 2005|Actual|2005-10-15||Interventional|||Evaluation of an Intimate Partner Violence Screening-Intervention|Evaluation of an Intimate Partner Violence Screening-Intervention|Completed||N/A|471|Actual|University at Albany||2|||f||||||||||||||2018-06-01 04:19:32.616398|2018-06-01 04:19:32.616398
NCT00257283|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2008-03-10|2005-11-21|2005-11-22|Estimate|||||||2008-03-10|2008-03-11|Estimate|November 2002||2002-11-30|March 2008|2008-03-31|June 2005||2005-06-30|||||Interventional|||Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis|A Double Blind Comparison of Omacor and Placebo as Secondary Prevention Against Cardiovascular Events in Patients Undergoing Chronic Hemodialysis|Completed||Phase 4|200||Pronova BioPharma|||||f||||||||||||||2018-06-01 04:19:32.674775|2018-06-01 04:19:32.674775
NCT00257270|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2005-11-18|2005-11-18|2005-11-22|Estimate|||||||2005-11-18|2005-11-22|Estimate|August 2003||2003-08-31|June 2005|2005-06-30|January 2005||2005-01-31|||||Interventional|||The Effect of Gabapentin on the Sensation and Impact of Tinnitus|The Effect of Gabapentin on the Sensation and Impact of Tinnitus|Completed||Phase 2|40||Tinnitus Research Consortium|||||f||||||||||||||2018-06-01 04:19:32.743483|2018-06-01 04:19:32.743483
NCT00257257|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2009-04-17|2005-11-21|2005-11-22|Estimate|||||||2009-04-17|2009-04-20|Estimate|March 2005||2005-03-31|April 2009|2009-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|SERENADE||Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20 mg) Multicenter Study of Long-Term Glycemic Control With Rimonabant in Treatment-naïve Patients With Type 2 Diabetes|Completed||Phase 3|281|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:19:32.806138|2018-06-01 04:19:32.806138
NCT00257244|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2016-11-08|2005-11-18|2005-11-22|Estimate|||||||2016-11-08|2016-11-09|Estimate|April 2004||2004-04-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2013|Actual|2013-09-30||Observational|||Inflammation and the Host Response to Injury (Burns)|Inflammation and the Host Response to Injury|Active, not recruiting|||280|Anticipated|Massachusetts General Hospital|||||f||||t||||||Samples Without DNA|"~     Plasma, blood leukocyte nucleic acids (RNA), solid tissue nucleic acids (only RNA, no DNA)~   "|Yes|Curated and validated data are available to Consortium Members|2018-06-01 04:19:32.887726|2018-06-01 04:19:32.887726
NCT00257231|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2016-11-08|2005-11-18|2005-11-22|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2003||2003-11-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2013|Actual|2013-09-30||Observational|||Inflammation and the Host Response to Injury (Trauma)|Inflammation and the Host Response to Injury|Active, not recruiting|||610|Anticipated|Massachusetts General Hospital|||||f||||t||||||Samples Without DNA|"~     Plasma, blood leukocyte nucleic acids (only RNA, no DNA)~   "|Yes|Curated and validated data are available to Consortium Members|2018-06-01 04:19:32.968207|2018-06-01 04:19:32.968207
NCT00257218|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2005-11-21|2005-11-21|2005-11-22|Estimate|||||||2005-11-21|2005-11-22|Estimate|January 2006||2006-01-31|November 2005|2005-11-30||||||||Interventional|||A Study on Effect of Health Promotion for Prevention NIDDM in People With Prediabetes||Unknown status|Not yet recruiting|N/A|1000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:19:33.081735|2018-06-01 04:19:33.081735
NCT00257205|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18||2011-01-03|2012-06-25|2005-11-18|2005-11-22|Estimate||||2011-04-26|2011-05-04|Estimate|2012-06-25|2012-07-02|Estimate|March 2006||2006-03-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy|A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma|Completed||Phase 3|655|Actual|AstraZeneca||2|||f||||t||||||||||2018-06-01 04:19:33.179473|2018-06-01 04:19:33.179473
NCT00257192|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|2010-03-23||2011-12-02|2005-11-21|2005-11-22|Estimate|2010-03-23|2010-04-13|Estimate||||2011-12-02|2011-12-06|Estimate|April 2006||2006-04-30|December 2011|2011-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia|Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia|Terminated||Phase 3|284|Actual|Pfizer|The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators.|2||Please see Detailed Description for termination reason.|f||||t||||||||||2018-06-01 04:19:33.644551|2018-06-01 04:19:33.644551
NCT00257166|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|2013-05-24||2013-07-24|2005-11-21|2005-11-22|Estimate|2013-05-24|2013-07-19|Estimate||||2013-07-24|2013-07-31|Estimate|January 2006||2006-01-31|July 2013|2013-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)|Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)|Completed||Phase 3|238|Actual|Pfizer||2|||f||||||||||||||2018-06-01 04:19:35.233922|2018-06-01 04:19:35.233922
NCT00257153|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2006-12-01|2005-11-18|2005-11-22|Estimate|||||||2006-12-01|2006-12-04|Estimate|March 2004||2004-03-31|June 2005|2005-06-30|September 2005||2005-09-30|||||Interventional|||Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction.||Completed||Phase 4|160||Niguarda Hospital|||||f||||||||||||||2018-06-01 04:19:35.652809|2018-06-01 04:19:35.652809
NCT00257140|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2011-06-08|2005-11-18|2005-11-22|Estimate|||||||2011-06-08|2011-06-10|Estimate|June 1931||1931-06-30|January 2011|2011-01-31|July 1994|Actual|1994-07-31|||||Interventional|||A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria|A Multicenter, Active-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Oral Levofloxacin Versus Cefaclor in the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis in Adults|Completed||Phase 2/Phase 3|367|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:19:35.710218|2018-06-01 04:19:35.710218
NCT00257127|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2014-11-10|2005-11-18|2005-11-22|Estimate|||||||2014-11-10|2014-11-11|Estimate|February 2006||2006-02-28|November 2014|2014-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs|Evaluation of Immunologic Memory Following Pneumococcal, Hepatitis B, and Measles Vaccination in HIV Infected Children Treated With Highly Active Antiretroviral Therapy (HAART)|Completed||N/A|101|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:19:35.768618|2018-06-01 04:19:35.768618
NCT00257114|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2008-02-07|2005-11-18|2005-11-22|Estimate|||||||2008-02-07|2008-02-11|Estimate||||February 2008|2008-02-29||||March 2007|Actual|2007-03-31||Interventional|||Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability|Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability|Completed||Phase 4|||Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 04:19:35.872983|2018-06-01 04:19:35.872983
NCT00257101|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2016-02-17|2005-11-18|2005-11-22|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Stepped Intervention for Meds Adherence and Blood Pressure Control||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:19:35.920774|2018-06-01 04:19:35.920774
NCT00257088|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2008-02-13|2005-11-18|2005-11-22|Estimate|||||||2008-02-13|2008-02-14|Estimate|September 2003||2003-09-30|August 2005|2005-08-31||||||||Interventional|||The Whole Day First Grade Program|Prevention Services in Schools for Early Drug Abuse Risk|Completed||Phase 4|2000||American Institutes for Research|||||f||||||||||||||2018-06-01 04:19:35.959865|2018-06-01 04:19:35.959865
NCT00257075|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2011-01-13|2005-11-18|2005-11-22|Estimate|||||||2011-01-13|2011-01-14|Estimate|December 2000||2000-12-31|January 2011|2011-01-31|May 2002|Actual|2002-05-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder|The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.|Completed||Phase 3|267|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:19:36.017664|2018-06-01 04:19:36.017664
NCT00257062|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2011-06-08|2005-11-18|2005-11-22|Estimate|||||||2011-06-08|2011-06-10|Estimate|January 1993||1993-01-31|April 2010|2010-04-30|April 1994|Actual|1994-04-30|||||Interventional|||A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin|A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With That of Ciprofloxacin HCl in the Treatment of Uncomplicated Skin and Skin Structure Infections in Adults|Completed||Phase 3|361|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:19:36.167034|2018-06-01 04:19:36.167034
NCT00257049|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2011-06-08|2005-11-18|2005-11-22|Estimate|||||||2011-06-08|2011-06-10|Estimate|January 1984||1984-01-31|November 2010|2010-11-30|January 1995|Actual|1995-01-31|||||Interventional|||A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia|A Multicenter, Active-Controlled, Randomized Study To Evaluate The Safety And Efficacy Of Levofloxacin Versus Ceftriaxone Sodium Or Cefuroxime Axetil In The Treatment Of Community-Acquired Pneumonia In Adults|Completed||Phase 2/Phase 3|604|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:19:36.219566|2018-06-01 04:19:36.219566
NCT00257036|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2011-06-08|2005-11-18|2005-11-22|Estimate|||||||2011-06-08|2011-06-10|Estimate|July 1991||1991-07-31|January 2011|2011-01-31|February 1993|Actual|1993-02-28|||||Interventional|||A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin|A Multicenter, Active-Controlled, Randomized Study to Evaluate the Safety and Efficacy of Levofloxacin Versus Ciprofloxacin HCl in the Treatment of Mild to Moderate Skin and Skin Structure Infections in Adults|Completed||Phase 2/Phase 3|431|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:19:36.278092|2018-06-01 04:19:36.278092
NCT00257023|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2011-05-16|2005-11-18|2005-11-22|Estimate|||||||2011-05-16|2011-05-17|Estimate|February 2005||2005-02-28|January 2011|2011-01-31|September 2005|Actual|2005-09-30|||||Interventional|||An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia|Exploratory Study of Paliperidone in Patients With Schizophrenia to Investigate the Safety and Efficacy|Completed||Phase 2|52|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 04:19:36.336034|2018-06-01 04:19:36.336034
NCT00257010|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2013-10-11||2014-01-23|2005-11-18|2005-11-22|Estimate|2013-10-11|2013-12-06|Estimate||||2014-01-23|2014-02-21|Estimate|December 2005||2005-12-31|January 2014|2014-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches|Long-Term, Open-Label Safety Study of Oral Almotriptan Malate 12.5 mg in the Treatment of Migraine in Adolescents|Completed||Phase 3|447|Actual|Janssen-Ortho LLC||1|||f||||f||||||||||2018-06-01 04:19:36.418141|2018-06-01 04:19:36.418141
NCT00256997|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2013-02-27||2013-11-12|2005-11-18|2005-11-22|Estimate|2013-07-24|2013-10-07|Estimate||||2013-11-12|2013-12-05|Estimate|January 2006||2006-01-31|November 2013|2013-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Out of a total of 167 participants, Baseline data was available for only 165 participants who were included in intent to treat (ITT) population.|A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication|Pragmatic Randomized Trial of Risperdal Consta Versus Oral Atypical Antipsychotics in Poorly Adherent Subjects With Schizophrenia in a Routine Care Setting|Terminated||Phase 4|167|Actual|Janssen-Ortho Inc., Canada|The study was terminated due to futility.|2||Inability to recruit number of planned patients|f||||f||||||||||2018-06-01 04:19:36.944398|2018-06-01 04:19:36.944398
NCT00256984|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2009-10-27||2011-03-07|2005-11-18|2005-11-22|Estimate|2011-03-07|2011-04-07|Estimate||||2011-03-07|2011-04-07|Estimate|October 2005||2005-10-31|March 2011|2011-03-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)|A Multi-center Study to Assess the Outcomes of Stapled Trans-Anal Rectal Resection (STARR) in the Treatment of Obstructed Defecation Syndrome (ODS)|Completed||Phase 4|75|Actual|Ethicon Endo-Surgery|||||f||||f||||||||||2018-06-01 04:19:37.940869|2018-06-01 04:19:37.940869
NCT00256971|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-20|||2008-05-12|2005-11-20|2005-11-22|Estimate|||||||2008-05-12|2008-05-13|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|January 2008|Anticipated|2008-01-31|||||Observational|||Balance in Patients After Surgery for Torn Meniscus|Functioning Balance in Patients After Surgery for Torn Meniscus: Meniscectomy vs Meniscal Repair; A Prospective Study|Unknown status|Recruiting||150|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:19:38.26025|2018-06-01 04:19:38.26025
NCT00256958|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-20|||2008-05-12|2005-11-20|2005-11-22|Estimate|||||||2008-05-12|2008-05-13|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Static and Dynamic Balance in Correlation With Quality of Life, in Primary Total Knee Replacement|Static and Dynamic Balance During Standing and Walking in Correlation With Quality of Life, in Primary Total Knee Replacement|Unknown status|Recruiting|Phase 1/Phase 2|150|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:19:38.331623|2018-06-01 04:19:38.331623
NCT00256945|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-20|||2010-01-05|2005-11-20|2005-11-22|Estimate|||||||2010-01-05|2010-01-06|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|August 2006||2006-08-31|||||Interventional|||Surface Roughness of a Dental Restorative Material and Biofilm Formation|In Vivo Study of the Relationship Between Surface Roughness of a Dental Restorative Material and Biofilm Formation|Completed||Phase 1|12||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:19:38.408322|2018-06-01 04:19:38.408322
NCT00256932|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2015-09-01|2005-11-21|2005-11-22|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2005||2005-08-31|December 2011|2011-12-31|May 2006|Actual|2006-05-31|||||Interventional|||Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain|Completed||Phase 3|518|Actual|Cubist Pharmaceuticals LLC||3|||||||||||||||||2018-06-01 04:19:38.504685|2018-06-01 04:19:38.504685
NCT00256919|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2012-11-01|2005-11-21|2005-11-22|Estimate|||||||2012-11-01|2012-11-05|Estimate|November 2005||2005-11-30|October 2012|2012-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)|A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship|Completed||Phase 2|51|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:19:38.821392|2018-06-01 04:19:38.821392
NCT00256906|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-20|||2018-03-04|2005-11-21|2005-11-22|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2006|Actual|2006-01-31|June 2007|2007-06-30|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Observational|||Isolated Mild Fetal Ventriculomegaly and Neurodevelopmental Outcome|Isolated Mild Fetal Ventriculomegaly and Neurodevelopmental Outcome|Terminated|||20|Actual|Hadassah Medical Organization||||lack of funding|f||||f||||||||||2018-06-01 04:19:38.912117|2018-06-01 04:19:38.912117
NCT00256893|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2016-09-13|2005-11-21|2005-11-22|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|July 2005|Actual|2005-07-31|||||Interventional|||Fibromyalgia Study In Adults|A Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Investigate the Safety and Efficacy of Controlled-release Ropinirole (CR) (1-24 mg) Administered Once Daily for 12 Weeks in Subjects With Fibromyalgia|Completed||Phase 2|164||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:19:38.972075|2018-06-01 04:19:38.972075
NCT00256880|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2017-01-16|2005-11-21|2005-11-22|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|December 2005|Actual|2005-12-31|||||Interventional|||Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma|A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|100|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:19:39.099101|2018-06-01 04:19:39.099101
NCT00256867|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2017-08-24||2017-08-24|2005-11-21|2005-11-22|Estimate|2017-08-24|2018-03-23|Actual||||2017-08-24|2018-03-23|Actual|August 18, 2005|Actual|2005-08-18|August 2017|2017-08-31|October 31, 2006|Actual|2006-10-31|October 31, 2006|Actual|2006-10-31||Interventional||Safety Population comprised of all participants who were randomized and received at least one dose of study medication. No race information available for one participant in arm SIMV 40mg.|A Study In Patients With Type 2 Diabetes Mellitus|A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|369|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:19:39.22388|2018-06-01 04:19:39.22388
NCT00256854|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2017-09-21|2005-11-21|2005-11-22|Estimate|||||||2017-09-21|2017-09-25|Actual|November 14, 2005|Actual|2005-11-14|September 2017|2017-09-30|September 21, 2006|Actual|2006-09-21|September 21, 2006|Actual|2006-09-21||Interventional|||Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)|A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Patients With Restless Legs Syndrome (RLS)|Completed||Phase 3|135|Actual|GlaxoSmithKline|||||||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:19:40.797981|2018-06-01 04:19:40.797981
NCT00256841|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2014-01-27|2005-11-21|2005-11-22|Estimate|||||||2014-01-27|2014-01-29|Estimate|September 2005||2005-09-30|January 2014|2014-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy|Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study|Withdrawn||Phase 1/Phase 2|0|Actual|Clinical Oncology Research Associates||||Lack of funding|f||||||||||||||2018-06-01 04:19:40.960868|2018-06-01 04:19:40.960868
NCT00256828|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2007-10-15|2005-11-21|2005-11-22|Estimate|||||||2007-10-15|2007-10-16|Estimate|June 2004||2004-06-30|November 2005|2005-11-30|November 2006||2006-11-30|||||Interventional|||Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV|A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03)|Completed||Phase 4|360||Clinical Trial Agency of HIV Study Group|||||f||||||||||||||2018-06-01 04:19:41.058525|2018-06-01 04:19:41.058525
NCT00256815|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2014-02-10|2005-11-21|2005-11-22|Estimate|||||||2014-02-10|2014-02-11|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|September 2005|Actual|2005-09-30|||||Interventional|||Combination of Weekly Chest Radiotherapy and Oral Navelbine for the Palliation of Advanced Non Small Cell Lung Cancer: A Phase I Study||Completed||Phase 1/Phase 2|35||Clinical Oncology Research Associates|||||||||||||||||||2018-06-01 04:19:41.218796|2018-06-01 04:19:41.218796
NCT00256802|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2009-03-30|2005-11-21|2005-11-22|Estimate|||||||2009-03-30|2009-04-01|Estimate|June 2004||2004-06-30|May 2004|2004-05-31|January 2005||2005-01-31|||||Interventional|||The Diameter of the Middle Cerebral Artery Measured With Magnetic Resonance Angiography|The Diameter of the Middle Cerebral Artery Measured With Magnetic Resonance Angiography (MRA) Under Provocation With Glyceryl Trinitrate in Healthy Volunteers.|Completed||N/A|12||Danish Headache Center|||||f||||||||||||||2018-06-01 04:19:41.310611|2018-06-01 04:19:41.310611
NCT00256789|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2014-02-10|2005-11-18|2005-11-22|Estimate|||||||2014-02-10|2014-02-11|Estimate|September 2002||2002-09-30|November 2005|2005-11-30|December 2004|Actual|2004-12-31|December 2003|Actual|2003-12-31||Interventional|||Once Weekly Radiation for Lung Cancer With Chemotherapy|Combination of Weekly Radiation and Docetaxel for Locally Advanced Non Small Cell Lung Cancer: A Feasibility Study|Completed||N/A|26|Actual|Clinical Oncology Research Associates|||||f||||||||||||||2018-06-01 04:19:41.371167|2018-06-01 04:19:41.371167
NCT00256776|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-21|||2012-08-06|2005-11-21|2005-11-22|Estimate|||||||2012-08-06|2012-08-07|Estimate|July 2005||2005-07-31|August 2012|2012-08-31|June 2013|Anticipated|2013-06-30|||||Interventional|||MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation|A Randomized Controlled Study of Velcade (Bortezomib) Plus Thalidomide Plus Dexamethasone Compared to Thalidomide Plus Dexamethasone for the Treatment of Myeloma Patients Progressing or Relapsing After Autologous Transplantation|Unknown status|Active, not recruiting|Phase 3|269|Actual|European Group for Blood and Marrow Transplantation||2|||f||||t||||||||||2018-06-01 04:19:41.453762|2018-06-01 04:19:41.453762
NCT00256750|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2016-05-24|2010-04-29|2016-07-12|2005-11-18|2005-11-22|Estimate|2016-07-12|2016-08-19|Estimate|2010-04-29|2010-05-03|Estimate|2016-07-12|2016-08-19|Estimate|March 2005||2005-03-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|June 2008|Actual|2008-06-30||Interventional|BENEFIT|Baseline characteristics of transplant recipients: All randomized and transplanted participants, intent to treat (ITT) population|Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)|Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)|Completed||Phase 3|738|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 04:19:41.900424|2018-06-01 04:19:41.900424
NCT00256737|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-20|||2011-01-21|2005-11-21|2005-11-22|Estimate|||||||2011-01-21|2011-01-24|Estimate|January 1998||1998-01-31|January 2011|2011-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Sopran - Omeprazole Treatment Versus Surgery|Omeprazole Versus Anti-reflux Surgery in the Long-term Management of Peptic Esophagitis - a 10 Year Follow up Study of Patients Previously Studied for 5 Years - A Nordic Multicentre Study|Completed||Phase 3|219||AstraZeneca|||||f||||||||||||||2018-06-01 04:19:48.93572|2018-06-01 04:19:48.93572
NCT00256724|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2013-05-24||2013-07-24|2005-11-18|2005-11-22|Estimate|2013-05-24|2013-07-18|Estimate||||2013-07-24|2013-07-31|Estimate|June 2005||2005-06-30|July 2013|2013-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy Study of a Facemask Device to Treat Hypotension|Evaluation of an Inspiratory Impedance Threshold Device (ITD) in the Emergency Department for the Treatment of Hypotension|Completed||Phase 2|47|Actual|Advanced Circulatory Systems||2|||f||||f||||||||||2018-06-01 04:19:48.999162|2018-06-01 04:19:48.999162
NCT00256711|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-20|||2009-04-22|2005-11-20|2005-11-22|Estimate|||||||2009-04-22|2009-04-23|Estimate|July 2004||2004-07-31|April 2009|2009-04-30|February 2006|Actual|2006-02-28|||||Interventional|||Phase II Iressa Versus Vinorelbine (INVITE)|A Randomised, Open Label, Parallel Group, Multi-Centre, Phase II Study of Progression Free Survival Comparing ZD1839 (IRESSA™) (250 MG Tablet) Versus Vinorelbine (30 MG/M2 Infusion) in Chemonaive, Elderly Patients With Locally Advanced (Stage IIIB) or Metastatic (Stage IV) NSCLC|Completed||Phase 2|192||AstraZeneca|||||f||||||||||||||2018-06-01 04:19:49.223072|2018-06-01 04:19:49.223072
NCT00256698|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-20|2010-04-29||2012-07-27|2005-11-20|2005-11-22|Estimate|2011-01-12|2011-02-09|Estimate||||2012-07-27|2012-08-01|Estimate|January 2004||2004-01-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|April 2009|Actual|2009-04-30||Interventional|FACT||Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy|FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy; an Open Randomized, Comparative, Phase III Multicentre Study in Postmenopausal Women With Hormone Receptor Positive Breast Cancer in First Relapse After Primary Treatment of Localized Tumor.|Completed||Phase 3|514|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:19:49.355072|2018-06-01 04:19:49.355072
NCT00256685|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2006-05-17|2005-11-17|2005-11-21|Estimate|||||||2006-05-17|2006-05-19|Estimate|September 2004||2004-09-30|May 2006|2006-05-31|July 2005||2005-07-31|||||Interventional|||Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause|A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|568||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:19:50.087382|2018-06-01 04:19:50.087382
NCT00256672|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2008-06-11|2005-11-16|2005-11-21|Estimate|||||||2008-06-11|2008-06-13|Estimate|June 2005||2005-06-30|June 2008|2008-06-30|December 2012|Anticipated|2012-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Effectiveness of Bracing in Preventing Scoliosis in Children With Spinal Cord Injury|Effectiveness of Full-Time Prophylactic Bracing at Preventing or Delaying Curve Progression in Paralytic Scoliosis Secondary to Spinal Cord Injury in the Growing Child: Randomized Trial|Unknown status|Active, not recruiting|N/A|88|Anticipated|Shriners Hospitals for Children||2|||f||||||||||||||2018-06-01 04:19:50.138078|2018-06-01 04:19:50.138078
NCT00256646|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2014-05-21|2005-11-17|2005-11-21|Estimate|||||||2014-05-21|2014-05-23|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Markers and Mechanisms of Vascular Disease in Type II Diabetes|CSP #465D - Markers And Mechanisms of Vascular Disease in Type II Diabetes|Completed|||298|Actual|VA Office of Research and Development|||1||f||||f||||||Samples Without DNA|"~     samples without DNA~   "|||2018-06-01 04:19:50.34912|2018-06-01 04:19:50.34912
NCT00256633|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2014-05-21|2005-11-17|2005-11-21|Estimate|||||||2014-05-21|2014-05-23|Estimate|April 2007||2007-04-30|May 2014|2014-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal|CSP #465C - Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal|Completed|||874|Actual|VA Office of Research and Development|||1||f||||t||||||Samples With DNA|"~     Blood draws of DNA samples.~   "|||2018-06-01 04:19:50.446412|2018-06-01 04:19:50.446412
NCT00256620|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2008-03-31|2005-11-17|2005-11-21|Estimate|||||||2008-03-31|2008-04-03|Estimate|December 1996||1996-12-31|March 2008|2008-03-31|December 1999||1999-12-31|||||Interventional|||Improving Outcomes and Quality of Life After CABG|Improving Outcomes and Quality of Life After CABG|Completed||N/A|412||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:19:50.522738|2018-06-01 04:19:50.522738
NCT00256607|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2014-06-26|2005-11-17|2005-11-21|Estimate|||||||2014-06-26|2014-06-27|Estimate|June 2007||2007-06-30|June 2014|2014-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes|CSP #465A - Non-Traditional Cardiovascular Risk Factors And Atherosclerosis In Type 2 Diabetes|Completed|||301|Actual|VA Office of Research and Development|||1||f||||t||||||||||2018-06-01 04:19:50.586797|2018-06-01 04:19:50.586797
NCT00256594|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2011-12-14|2005-11-17|2005-11-21|Estimate|||||||2011-12-14|2011-12-15|Estimate|August 2005||2005-08-31|December 2011|2011-12-31|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|||Evaluation of an Outpatient Modified Prescription Form|Evaluation of an Outpatient Modified Paper Prescription Form in 4 Rural States to Address the Public Health Problem of Prescribing Error|Completed||N/A|84|Actual|University of Vermont|||||f||||f||||||||||2018-06-01 04:19:50.662012|2018-06-01 04:19:50.662012
NCT00256581|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2012-08-28|2005-11-17|2005-11-21|Estimate|||||||2012-08-28|2012-08-29|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Imaging Studies With GE C-Hawk Gamma Camera Compared to Routine Clinical Exam|Imaging Studies With GE C-Hawk Gamma Camera Compared to Routine Clinical Exam|Completed|||34|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:19:50.726961|2018-06-01 04:19:50.726961
NCT00256568|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2011-12-14|2005-11-17|2005-11-21|Estimate|||||||2011-12-14|2011-12-15|Estimate|September 2003||2003-09-30|December 2011|2011-12-31|August 2008|Actual|2008-08-31|||||Observational|||Outpatient Prescription Errors: Detection, Analysis, and Impact on Safety|Outpatient Prescription Errors: Detection, Analysis, and Impact on Safety|Completed|||103|Actual|University of Vermont|||1||f||||f||||||||||2018-06-01 04:19:50.781156|2018-06-01 04:19:50.781156
NCT00256555|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2005-11-17|2005-11-17|2005-11-21|Estimate|||||||2005-11-17|2005-11-21|Estimate|February 2000||2000-02-29|November 2005|2005-11-30||||||||Interventional|||Growth Hormone Treatment Study in Children With Cystic Fibrosis|GROWTH HORMONE USE IN CYSTIC FIBROSIS - A MULTICENTER STUDY|Unknown status|Active, not recruiting|Phase 2/Phase 3|60||University of Texas Southwestern Medical Center|||||||||||||||||||2018-06-01 04:19:50.845228|2018-06-01 04:19:50.845228
NCT00256542|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2006-09-28|2005-11-17|2005-11-21|Estimate|||||||2006-09-28|2006-09-29|Estimate|January 2006||2006-01-31|August 2006|2006-08-31|September 2006||2006-09-30|||||Interventional|||Study of U101 for Bladder Pain and/or Urgency|A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin|Completed||Phase 2|90||Urigen|||||||||||||||||||2018-06-01 04:19:50.903513|2018-06-01 04:19:50.903513
NCT00256529|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2014-12-12|2005-11-17|2005-11-21|Estimate|||||||2014-12-12|2014-12-15|Estimate|November 2005||2005-11-30|December 2014|2014-12-31|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Observational|||Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia|Prospective Analysis of Eosinophilic Esophagitis in Patients Presenting With Dysphagia|Completed|||483|Actual|University of Utah|||1||f||||f||||||Samples Without DNA|"~     4 quadrant distal and proximal biopsies of the esophagus~   "|||2018-06-01 04:19:50.969252|2018-06-01 04:19:50.969252
NCT00256516|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2013-05-17|2005-11-16|2005-11-21|Estimate|||||||2013-05-17|2013-05-20|Estimate|April 2005||2005-04-30|May 2013|2013-05-31|December 2006||2006-12-31|||||Interventional|||"Low Carbohydrate Portfolio or Eco-Atkins Diet"|"Low Carbohydrate Portfolio or Eco-Atkins Diet"|Completed||Phase 2|30||University of Toronto||2|||f||||||||||||||2018-06-01 04:19:51.034754|2018-06-01 04:19:51.034754
NCT00256503|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2016-01-11|2005-11-16|2005-11-21|Estimate|||||||2016-01-11|2016-01-12|Estimate|December 2005||2005-12-31|January 2016|2016-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Sleep Homeostasis in Primary Insomnia|Sleep Homeostasis in Primary Insomnia Following Behavioral Treatment|Completed||N/A|18|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 04:19:51.10393|2018-06-01 04:19:51.10393
NCT00256490|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2005-11-17|2005-11-17|2005-11-21|Estimate|||||||2005-11-17|2005-11-21|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|November 2009||2009-11-30|||||Interventional|||Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by PET/CT|Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by Positron Emission Tomography Coupled With Computed Tomography (PET/CT)|Unknown status|Recruiting|N/A|82||Université de Sherbrooke|||||f||||||||||||||2018-06-01 04:19:51.173469|2018-06-01 04:19:51.173469
NCT00256477|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2005-11-16|2005-11-16|2005-11-21|Estimate|||||||2005-11-16|2005-11-21|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|October 2005||2005-10-31|||||Interventional|||A Controlled Breathing Course for Social & Emotional Health for Vietnam Veterans With Chronic PTSD-RCT|A Controlled Breathing Course Promoting Social and Emotional Health for Vietnam Veterans With Chronic Posttraumatic Stress Disorder - A Randomised Controlled Trial|Completed||Phase 1|30||The University of Queensland|||||f||||||||||||||2018-06-01 04:19:51.227083|2018-06-01 04:19:51.227083
NCT00256464|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2006-09-07|2005-11-16|2005-11-21|Estimate|||||||2006-09-07|2006-09-08|Estimate|June 2007||2007-06-30|August 2005|2005-08-31|January 2008||2008-01-31|||||Interventional|||Evaluation of a MCYI as Adjunct to Psychiatric Treatment for Vietnam Veterans With PTSD - RCT|Evaluation of a Multi-Component Yoga Intervention as Adjunct to Psychiatric Treatment for Vietnam Veterans With Posttraumatic Stress Disorder (PTSD): A Randomized Controlled Trial (RCT).|Unknown status|Not yet recruiting|Phase 1|30||The University of Queensland|||||f||||||||||||||2018-06-01 04:19:51.278483|2018-06-01 04:19:51.278483
NCT00256451|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2016-12-01|2005-11-17|2005-11-21|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2005||2005-11-30|December 2016|2016-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|DEFINE||Endophenotype for Alcohol Misuse in Healthy Minority Populations|Defining an Endophenotype for Alcohol Misuse: A Focus On Minority Populations|Completed||Phase 4|38|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 04:19:51.33744|2018-06-01 04:19:51.33744
NCT00256438|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2006-07-06|2005-11-17|2005-11-21|Estimate|||||||2006-07-06|2006-07-10|Estimate|February 2006||2006-02-28|July 2006|2006-07-31||||||||Interventional|||Depression and Transcranial Direct Current Stimulation (tDCS)|The Treatment of Depression Using Transcranial Direct Current Stimulation (tDCS): a Pilot Study.|Unknown status|Recruiting|Phase 1/Phase 2|20||The University of New South Wales|||||f||||||||||||||2018-06-01 04:19:51.402192|2018-06-01 04:19:51.402192
NCT00256425|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2008-03-20|2005-11-18|2005-11-21|Estimate|||||||2008-03-20|2008-03-21|Estimate|October 2003||2003-10-31|July 2007|2007-07-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Cognitive Rehabilitation of Glioma Patients|Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study|Unknown status|Active, not recruiting|Phase 3|140|Actual|UMC Utrecht|||||f||||f||||||||||2018-06-01 04:19:51.477074|2018-06-01 04:19:51.477074
NCT00256412|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2008-06-03|2005-11-16|2005-11-21|Estimate|||||||2008-06-03|2008-06-05|Estimate|October 2005||2005-10-31|June 2008|2008-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Essential Fatty Acids for Major Depression|Essential Fatty Acids in Management of MDD - A Pilot Study|Completed||N/A|24|Actual|University of Iowa||3|||f||||f||||||||||2018-06-01 04:19:51.722056|2018-06-01 04:19:51.722056
NCT00256399|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2007-11-26|2005-11-18|2005-11-21|Estimate|||||||2007-11-26|2007-11-27|Estimate|November 2005||2005-11-30|November 2005|2005-11-30||||||||Interventional|||Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)|A Prospective, Open Label, Study to Assess the Efficacy of Alfuzosin 10 mg Tablet Once a Day in Male Subjects Suffering From Benign Prostate Hypertrophy Associated Lower Urinary Tract Symptoms and Erectile Dysfunction|Unknown status|Recruiting|N/A|100|Anticipated|University Hospitals Cleveland Medical Center|||||||||||||||||||2018-06-01 04:19:51.787038|2018-06-01 04:19:51.787038
NCT00256386|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2006-11-29|2005-11-17|2005-11-21|Estimate|||||||2006-11-29|2006-11-30|Estimate|January 2004||2004-01-31|November 2005|2005-11-30|March 2005||2005-03-31|||||Interventional|||LabAlert: Enhancing Medication Safety Through Electronic Interventions to Improve Laboratory Monitoring|LabAlert: Enhancing Medication Safety Through Electronic Interventions to Improve Medication Safety|Completed||N/A|800||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:19:51.857731|2018-06-01 04:19:51.857731
NCT00256373|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2006-04-18|2005-11-16|2005-11-21|Estimate|||||||2006-04-18|2006-04-19|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|November 2005||2005-11-30|||||Interventional|||Treatment of Chronic Low Back Pain: A Trial Comparing Traditional Back School and Individual Therapist-Assisted Exercise||Unknown status|Active, not recruiting|Phase 3|||University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:19:51.929121|2018-06-01 04:19:51.929121
NCT00256360|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2014-12-08|2005-11-16|2005-11-21|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|May 2006||2006-05-31|||||Interventional|||Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer|A Randomized Phase II Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer|Completed||Phase 2|117||Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-06-01 04:19:51.977879|2018-06-01 04:19:51.977879
NCT00256347|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2011-04-12|2005-11-16|2005-11-21|Estimate|||||||2011-04-12|2011-04-14|Estimate|March 2005||2005-03-31|March 2011|2011-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine|Development of Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine Using the Brief Thermal Sensitization Model in Healthy Volunteers|Completed||N/A|30||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:19:52.027151|2018-06-01 04:19:52.027151
NCT00256334|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2014-06-18|2005-11-17|2005-11-21|Estimate|||||||2014-06-18|2014-06-20|Estimate|July 2005||2005-07-31|June 2014|2014-06-30|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Resveratrol for Patients With Colon Cancer|Resveratrol for Patients With Colon Cancer|Completed||Phase 1|11|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 04:19:52.135243|2018-06-01 04:19:52.135243
NCT00256321|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2008-02-27|2005-11-18|2005-11-21|Estimate|||||||2008-02-27|2008-02-29|Estimate|October 2004||2004-10-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|||||Interventional|||Celecoxib/Oxaliplatin/Capecitabine for Gastric/GE Junction Carcinoma|A Phase II Study of Celecoxib/Oxaliplatin/Capecitabine Combination Chemotherapy for Unresectable,Recurrent, or Metastatic Gastric/Gastroesophageal Junction Carcinoma|Completed||Phase 2|20||University of California, Irvine|||||f||||||||||||||2018-06-01 04:19:52.20281|2018-06-01 04:19:52.20281
NCT00256308|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|2013-06-26||2018-04-27|2005-11-17|2005-11-21|Estimate|2018-04-27|2018-05-01|Actual||||2018-04-27|2018-05-01|Actual|February 2005||2005-02-28|April 2018|2018-04-30|October 2011|Actual|2011-10-31|May 2010|Actual|2010-05-31||Interventional|||Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer|A Phase II Study of Adjuvant Chemoradiation With Weekly Oxaliplatin in Patients With High Risk Resected Squamous Cell Carcinoma of the Head and Neck Region|Terminated||Phase 2|6|Actual|University of California, Irvine||1||Halted prematurely due to slow accrual|f||||t||||||||No||2018-06-01 04:19:52.281419|2018-06-01 04:19:52.281419
NCT00256295|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|2013-06-21||2016-12-02|2005-11-17|2005-11-21|Estimate|2014-03-25|2014-04-25|Estimate||||2016-12-02|2017-02-01|Estimate|April 2005||2005-04-30|December 2016|2016-12-31|October 2011|Actual|2011-10-31|February 2008|Actual|2008-02-29||Interventional|||Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of Weekly Oxaliplatin and Gemcitabine Combination Chemotherapy for Recurrent or Metastatic Head and Neck Cancer|Terminated||Phase 2|8|Actual|University of California, Irvine||1||Low accrual|f||||t||||||||||2018-06-01 04:19:52.521137|2018-06-01 04:19:52.521137
NCT00256282|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|2016-12-31||2018-05-01|2005-11-17|2005-11-21|Estimate|2018-05-01|2018-05-03|Actual||||2018-05-01|2018-05-03|Actual|April 2003||2003-04-30|February 2018|2018-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma|A Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in Patients With Metastatic Malignant Melanoma|Completed||Phase 2|52|Actual|University of California, Irvine||1|||f||||t||||||||No||2018-06-01 04:19:52.789324|2018-06-01 04:19:52.789324
NCT00256269|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2018-01-24|2005-11-17|2005-11-21|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2005|Actual|2005-06-30|January 2018|2018-01-31|February 7, 2007|Actual|2007-02-07|February 7, 2007|Actual|2007-02-07||Interventional|||Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma|A Phase II Study of Weekly Oxaliplatin and Irinotecan in the Treatment of Recurrent or Metastatic Esophageal Carcinoma and Carcinoma of the Gastroesophageal (GE) Junction|Terminated||Phase 2|4|Actual|University of California, Irvine||1||Study was terminated by funding entity|f||||t|t|f|||t|||No||2018-06-01 04:19:52.955535|2018-06-01 04:19:52.955535
NCT00255112|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2015-06-10|2005-11-16|2005-11-17|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2004||2004-06-30|June 2015|2015-06-30||||December 2009|Actual|2009-12-31||Interventional|||TAFF-Psychological Treatment of Separation Anxiety Disorder|Psychological Treatment of Separation Anxiety Disorder|Completed||N/A|64|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-06-01 04:20:09.545578|2018-06-01 04:20:09.545578
NCT00256256|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2007-10-29|2005-11-16|2005-11-21|Estimate|||||||2007-10-29|2007-10-30|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|January 2007|Actual|2007-01-31|||||Interventional|||The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men|The Effect of GLP-1 on Glucose Uptake in the CNS and Heart in Healthy Subjects During Normoglycaemia Assessed by Positron Emission Tomografi|Completed||N/A|10|Actual|University of Aarhus|||||f||||||||||||||2018-06-01 04:19:53.041512|2018-06-01 04:19:53.041512
NCT00256243|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|2009-08-28||2018-02-28|2005-11-17|2005-11-21|Estimate|2014-01-28|2014-03-17|Estimate||||2018-02-28|2018-03-02|Actual|April 2004||2004-04-30|February 2018|2018-02-28|July 2012|Actual|2012-07-31|March 2011|Actual|2011-03-31||Interventional|||Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer|A Pilot Study of Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide (AC) With GMCSF Followed by Weekly Carboplatin/Paclitaxel With Plus or Minus Trastuzumab (TC ± H) in the Treatment of Breast Cancer|Completed||Phase 2|48|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 04:19:53.130502|2018-06-01 04:19:53.130502
NCT00256230|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2016-12-06|2005-11-17|2005-11-21|Estimate|||||||2016-12-06|2016-12-08|Estimate|January 2002||2002-01-31|December 2011|2011-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Disulfiram in Patients With Metastatic Melanoma|Evaluation of Disulfiram in Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy, Phase I/II|Completed||Phase 1/Phase 2|7|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 04:19:53.299082|2018-06-01 04:19:53.299082
NCT00256217|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2018-01-11|2005-11-16|2005-11-21|Estimate|||||||2018-01-11|2018-01-16|Actual|September 2004||2004-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women|Phase II Chemoprevention Trial - Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women|Active, not recruiting||Phase 2|42|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 04:19:53.366874|2018-06-01 04:19:53.366874
NCT00256204|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|2010-03-08||2012-01-10|2005-11-18|2005-11-21|Estimate|2011-05-20|2011-06-21|Estimate||||2012-01-10|2012-01-12|Estimate|November 2005||2005-11-30|January 2012|2012-01-31|June 2009|Actual|2009-06-30|April 2008|Actual|2008-04-30||Interventional|ADAGIO||A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease|A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects|Completed||Phase 3|1174|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 04:19:53.468148|2018-06-01 04:19:53.468148
NCT00256191|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2007-10-11|2005-11-16|2005-11-21|Estimate|||||||2007-10-11|2007-10-15|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|February 2007|Actual|2007-02-28|||||Interventional|||Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies|A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies|Completed||Phase 1|45||Cortice Biosciences, Inc.|||||t||||f||||||||||2018-06-01 04:19:54.416365|2018-06-01 04:19:54.416365
NCT00256178|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2012-05-23|2005-11-16|2005-11-21|Estimate|||||||2012-05-23|2012-05-24|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.|A Placebo-controlled, Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 50 mg and 100 mg Versus Placebo, When Co-administered With Simvastatin 20 mg or 40 mg in Subjects With Primary Dyslipidemia.|Completed||Phase 3|411|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:19:54.700415|2018-06-01 04:19:54.700415
NCT00256165|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2009-03-30|2005-11-16|2005-11-21|Estimate|||||||2009-03-30|2009-03-31|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||REST Study: Left Ventricular Regression European Study|Left Ventricular Regression European Study|Completed||Phase 4|150|Anticipated|St. Jude Medical|||||f||||f||||||||||2018-06-01 04:19:54.853913|2018-06-01 04:19:54.853913
NCT00256152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2012-07-27|2005-11-17|2005-11-21|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 2004||2004-09-30|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial|Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial|Completed||Phase 4|2580|Actual|St. Jude Medical||2|||f||||||||||||||2018-06-01 04:19:54.907322|2018-06-01 04:19:54.907322
NCT00256139|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2017-01-13|2005-11-18|2005-11-21|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2003||2003-03-31|January 2017|2017-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||CLEAR Study: Clinical Experience Acquired With Raptiva Study||Completed||Phase 3|793|Actual|Merck KGaA|||||f||||||||||||||2018-06-01 04:19:55.021269|2018-06-01 04:19:55.021269
NCT00256126|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2017-08-24||2017-08-24|2005-11-18|2005-11-21|Estimate|2017-08-24|2018-03-20|Actual||||2017-08-24|2018-03-20|Actual|May 31, 2005|Actual|2005-05-31|August 2017|2017-08-31|September 30, 2007|Actual|2007-09-30|September 30, 2007|Actual|2007-09-30||Interventional|||Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®|A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated With SAIZEN®|Completed||Phase 4|318|Actual|Merck KGaA|Limitations of the trial were short duration of the study treatment, and relatively small sample size|2|||f||||||||||||||2018-06-01 04:19:55.112645|2018-06-01 04:19:55.112645
NCT00256113|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2018-04-18|2005-11-17|2005-11-21|Estimate|||||||2018-04-18|2018-04-20|Actual|December 2004||2004-12-31|April 2018|2018-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder|Completed||Phase 3|467|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:19:55.690855|2018-06-01 04:19:55.690855
NCT00256100|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2017-04-10|2005-11-17|2005-11-21|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2004||2004-06-30|April 2015|2015-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.|Assessment of the Safety and Efficacy of Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Renal Failure.|Terminated||N/A|20|Actual|Melbourne Health||2||Teh Priincipal investigator responsible for the trial no longer employed at the study site.|f||||f||||||||||2018-06-01 04:19:55.766908|2018-06-01 04:19:55.766908
NCT00256087|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2015-11-18|2005-11-17|2005-11-21|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2005||2005-01-31|April 2015|2015-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Effect of Prophylactic Probiotic Lactobacilli in Enteral Feeding on Nosocomial Pneumonia Rates in Critically Ill Patients|The Effect of Prophylactic Probiotic Lactobacilli in Enteral Feeding on Nosocomial Pneumonia Rates in Critically Ill Patients|Completed||N/A|57|Actual|Melbourne Health||3|||f||||||||||||||2018-06-01 04:19:55.834933|2018-06-01 04:19:55.834933
NCT00256074|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2017-04-10|2005-11-17|2005-11-21|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2004||2004-06-30|April 2017|2017-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||The Effects of Nutritional Support of Critically Ill Patients Requiring Mechanical Ventilation|The Effects of Nutritional Support of Critically Ill Patients Requiring Mechanical Ventilation|Terminated||N/A|30|Anticipated|Melbourne Health||2||"Decision was made to terminate the project due to slower than anticipated recruitment and many~   of the investigators no longer being available."|f||||f||||||||||2018-06-01 04:19:55.904788|2018-06-01 04:19:55.904788
NCT00256061|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2015-04-23|2005-11-17|2005-11-21|Estimate|||||||2015-04-23|2015-04-27|Estimate|February 2003||2003-02-28|April 2015|2015-04-30|February 2004||2004-02-29|||||Observational|||Assessment of Electrolyte Values in the Intensive Care Unit:Comparison Between Arterial and Venous Blood Gas Analysis and Formal Laboratory Testing|Assessment of Electrolyte Values in the Intensive Care Unit:Comparison Between Arterial and Venous Blood Gas Analysis and Formal Laboratory Testing|Withdrawn|||0|Actual|Melbourne Health||||"Due to the publication of significant literature in this area since commencement of the project~   which has now rendered the project unnecessary."|f||||f||||||||||2018-06-01 04:19:55.972644|2018-06-01 04:19:55.972644
NCT00256048|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2017-04-10|2005-11-17|2005-11-21|Estimate|||||||2017-04-10|2017-04-12|Actual|May 2003||2003-05-31|April 2015|2015-04-30|July 2005|Actual|2005-07-31|||||Interventional|||Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.|Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.|Completed||N/A|50|Actual|Melbourne Health||2|||f||||f||||||||||2018-06-01 04:19:56.010865|2018-06-01 04:19:56.010865
NCT00256035|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2015-04-23|2005-11-17|2005-11-21|Estimate|||||||2015-04-23|2015-04-27|Estimate||||April 2015|2015-04-30||||||||Interventional|||Interleukin-4 (IL-4) as a Marker of Atherosclerosis|IL-4 as a Marker of Atherosclerosis|Withdrawn||N/A|0|Actual|Melbourne Health||4|||f||||f||||||||||2018-06-01 04:19:56.066942|2018-06-01 04:19:56.066942
NCT00256022|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2015-11-18|2005-11-17|2005-11-21|Estimate|||||||2015-11-18|2015-11-20|Estimate|July 2007||2007-07-31|April 2015|2015-04-30|December 2007|Anticipated|2007-12-31|||||Interventional|||The Effect of Prophylactic Pre Operative Probiotic Therapy on Endotoxin Levels in Cardiac Surgery Patients|The Effect of Prophylactic Pre Operative Probiotic Therapy on Peri Operative Endotoxin Levels in Cardiac Surgery Patients.|Withdrawn||N/A|0|Actual|Melbourne Health||4||Due to delays with logistics and protocol revision not viable to continue.|f||||f||||||||||2018-06-01 04:19:56.122247|2018-06-01 04:19:56.122247
NCT00256009|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2006-05-31|2005-11-18|2005-11-21|Estimate|||||||2006-05-31|2006-06-01|Estimate||||November 2005|2005-11-30|January 2009||2009-01-31|||||Interventional|||Treatment of Late Abortion: Evacuatio Uteri or Conservative Treatment|Evacuatio Uteri or Conservtive Treatment After Late Abortion. A Randomize Trial.|Unknown status|Not yet recruiting|Phase 4|200||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:19:56.173195|2018-06-01 04:19:56.173195
NCT00255996|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2009-07-13|2005-11-18|2005-11-21|Estimate|||||||2009-07-13|2009-07-14|Estimate|May 2006||2006-05-31|July 2009|2009-07-31|January 2007|Actual|2007-01-31|||||Interventional|||Evaluation Of Linezolid Pk Profile In Burns Patients|An Open Label Parallel Group Study To Investigate The Pharmacokinetics Of Intravenous Linezolid, An Oxazolidinone, Administered To Healthy Volunteers And Patients With Major Thermal Injuries|Completed||Phase 1|16|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:19:56.25386|2018-06-01 04:19:56.25386
NCT00255983|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2008-05-30|2005-11-16|2005-11-21|Estimate|||||||2008-05-30|2008-06-03|Estimate|December 2005||2005-12-31|May 2008|2008-05-31|June 2008|Anticipated|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis|Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo In the Treatment of Acute Exacerbation of Chronic Bronchitis|Terminated||Phase 3|491|Actual|Replidyne||2||financial reasons|f||||t||||||||||2018-06-01 04:19:56.30743|2018-06-01 04:19:56.30743
NCT00255970|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|2009-06-09||2011-08-08|2005-11-16|2005-11-21|Estimate|2011-07-12|2011-08-05|Estimate||||2011-08-08|2011-08-10|Estimate|January 2006||2006-01-31|August 2011|2011-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects|Regenerative Therapy for Vertical Defects Comparing Demineralized Freeze Dried Bone Allograft (DFDBA) and Regenafil|Completed||Phase 2/Phase 3|40|Actual|RTI Surgical||2|||f||||f||||||||||2018-06-01 04:19:56.376918|2018-06-01 04:19:56.376918
NCT00255957|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2006-04-17|2005-11-16|2005-11-21|Estimate|||||||2006-04-17|2006-04-19|Estimate|October 2005||2005-10-31|November 2005|2005-11-30|March 2006||2006-03-31|||||Interventional|||Influence of Hydroxyehtyl Starch (HES) on Hemorehology, Coagulation and Elimination Kinetics|Clinical Trial to Study the Effects of HES on Coagulation, Hemorehology and Kinetics Comparing Two Different Products.|Completed||N/A|20||Nizam's Institute of Medical Sciences University, India|||||f||||||||||||||2018-06-01 04:19:56.640791|2018-06-01 04:19:56.640791
NCT00255944|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2013-11-26|2005-11-16|2005-11-21|Estimate|||||||2013-11-26|2013-11-27|Estimate|October 2005||2005-10-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|Youthnet suppl||Effectiveness of an Online Prevention Program in Reducing the Risk of STD Infection in Young Adults|Internet-based Efficacy Trial of an HIV Prevention Program|Completed||Phase 1/Phase 2|1860|Actual|University of Colorado, Denver||2|||f||||||||||||||2018-06-01 04:19:56.689046|2018-06-01 04:19:56.689046
NCT00255931|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2012-06-02|2005-11-16|2005-11-21|Estimate|||||||2012-06-02|2012-06-05|Estimate|July 2004||2004-07-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Impact of a Psychological Biofeedback-Relaxation Intervention on Clinical, Physical and Psychological Outcomes in Patients With Heart Failure|Biobehavioral Intervention in Heart Failure|Completed||Phase 2|380|Actual|University of Kentucky||3|||f||||f||||||||||2018-06-01 04:19:56.757844|2018-06-01 04:19:56.757844
NCT00255918|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2015-06-30|2005-11-16|2005-11-21|Estimate|||||||2015-06-30|2015-07-01|Estimate|March 2004||2004-03-31|June 2015|2015-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients|Phase 1 Trial of 3-2,4 Dimethoxbenzylidene Anabaseine in Schizophrenia|Completed||Phase 1|12|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-06-01 04:19:56.833904|2018-06-01 04:19:56.833904
NCT00255905|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2013-06-27|2005-11-18|2005-11-21|Estimate|||||||2013-06-27|2013-06-28|Estimate|July 2004||2004-07-31|June 2013|2013-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Cognitive Behavioral Therapy for the Treatment of Depression-Related Insomnia|Is Insomnia a Modifiable Risk Factor for Major Depressive Disorder|Completed||N/A|45|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:19:56.911627|2018-06-01 04:19:56.911627
NCT00255892|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2017-02-27|2005-11-16|2005-11-21|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2006||2006-02-28|February 2016|2016-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Intervention Development for Newly Diagnosed Youth With HIV|Intervention Development for Newly Diagnosed Youth With HIV|Completed|||48|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-06-01 04:19:57.072728|2018-06-01 04:19:57.072728
NCT00255879|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2013-06-05|2005-11-16|2005-11-21|Estimate|||||||2013-06-05|2013-06-06|Estimate|January 1999||1999-01-31|November 2005|2005-11-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Movement Disorders Caused by Antipsychotic Drugs in Older Patients|Neuroleptic Induced Movement Disorders in Older Patients|Completed||Phase 1|250||University of California, San Diego|||||f||||||||||||||2018-06-01 04:19:57.131961|2018-06-01 04:19:57.131961
NCT00255866|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2015-11-30|2005-11-16|2005-11-21|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2004||2004-01-31|December 2013|2013-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their Caregivers|Improving Affect and Behavior in Assisted Living Residents|Completed||Phase 2/Phase 3|90||University of Washington|||||f||||||||||||||2018-06-01 04:19:57.20351|2018-06-01 04:19:57.20351
NCT00255840|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|2011-03-02||2011-06-17|2005-11-16|2005-11-21|Estimate|2011-05-16|2011-06-16|Estimate||||2011-06-17|2011-06-21|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities|"Safeguard the Household - A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country"|Completed||N/A|812|Actual|CIPRA SA|The study design did not address nurse-initiated ART because the prescription of ART in South Africa is restricted to doctors. We noted a high rate of loss to follow-up, but this rate was similar to other resource-constrained settings.|2|||f||||f||||||||||2018-06-01 04:19:57.291936|2018-06-01 04:19:57.291936
NCT00255827|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2015-05-29|2005-11-16|2005-11-21|Estimate|||||||2015-05-29|2015-06-01|Estimate|November 2005||2005-11-30|May 2015|2015-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Vaccine Treatment for Surgically Resected Pancreatic Cancer|A Phase I/II Study of Algenpantucel-L (HyperAcute Pancreas) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Pancreatic Cancer|Completed||Phase 1/Phase 2|7|Actual|NewLink Genetics Corporation|||||f||||t||||||||||2018-06-01 04:19:57.759511|2018-06-01 04:19:57.759511
NCT00255814|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2015-11-14|2005-11-18|2005-11-21|Estimate|||||||2015-11-14|2015-11-17|Estimate|November 2005||2005-11-30|November 2015|2015-11-30|November 2013|Actual|2013-11-30|September 2011|Actual|2011-09-30||Interventional|||Radiation Therapy in Treating Patients With Liver Metastases|A Phase I Trial of Highly Conformal Radiation Therapy for Patients With Liver Metastases|Completed||Phase 1|26|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-06-01 04:19:57.810006|2018-06-01 04:19:57.810006
NCT00255801|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2017-10-17|2005-11-18|2005-11-21|Estimate|||||||2017-10-17|2017-10-19|Actual|November 2005||2005-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma|Phase II Trial of Doxorubicin HCl Liposome Injection (Doxil®) in Advanced Stage Cutaneous T-Cell Lymphoma Followed by Bexarotene (Targretin®)|Completed||Phase 2|37|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 04:19:57.876811|2018-06-01 04:19:57.876811
NCT00255788|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2016-11-25|2005-11-18|2005-11-21|Estimate|||||||2016-11-25|2016-11-28|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer|A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients With Recurrent/Metastatic Breast Cancer|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 04:19:57.963919|2018-06-01 04:19:57.963919
NCT00255775|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2010-08-05|2005-11-18|2005-11-21|Estimate|||||||2010-08-05|2010-08-09|Estimate|January 2005||2005-01-31|August 2010|2010-08-31||||May 2009|Actual|2009-05-31||Interventional|||Broccoli Sprout Extract in Preventing Lung Cancer in Smokers|Evaluation of the Biological Effects of Broccoli Sprout Extract in Smokers|Completed||N/A|70|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:19:58.032462|2018-06-01 04:19:58.032462
NCT00255762|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2013-10-25|2005-11-18|2005-11-21|Estimate|||||||2013-10-25|2013-10-28|Estimate|December 2005||2005-12-31|October 2013|2013-10-31||||December 2006|Actual|2006-12-31||Interventional|||Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients With Unresectable Stage IV Melanoma|Completed||Phase 2|47|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:19:58.07675|2018-06-01 04:19:58.07675
NCT00255749|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2012-10-03|2005-11-18|2005-11-21|Estimate|||||||2012-10-03|2012-10-04|Estimate|August 2005||2005-08-31|October 2012|2012-10-31||||April 2007|Actual|2007-04-30||Interventional|||Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer|Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy|Completed||Phase 2|89|Actual|Jonsson Comprehensive Cancer Center||2|||f||||||||||||||2018-06-01 04:19:59.064716|2018-06-01 04:19:59.064716
NCT00255723|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2015-12-22||2015-12-22|2005-11-18|2005-11-21|Estimate|2015-12-22|2016-02-01|Estimate||||2015-12-22|2016-02-01|Estimate|April 2004||2004-04-30|December 2015|2015-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma|Risk-Adapted High Dose Chemoradiotherapy and Autologous Stem Cell Transplantation for Patients With Relapsed and Primary Refractory Hodgkin's Lymphoma|Completed||Phase 2|98|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:19:59.190406|2018-06-01 04:19:59.190406
NCT00255710|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2010-03-16|2005-11-18|2005-11-21|Estimate|||||||2010-03-16|2010-03-17|Estimate|July 2002||2002-07-31|March 2010|2010-03-31||||||||Interventional|||Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer|Nonmyeloablative Bone Marrow Transplants in Hematologic Malignancies: Dose Finding Study for Post-Transplant Immunosuppression|Completed||Phase 1|60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:19:59.449679|2018-06-01 04:19:59.449679
NCT00255697|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2015-10-08|2005-11-18|2005-11-21|Estimate|||||||2015-10-08|2015-10-09|Estimate|July 2005||2005-07-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Observational|||Quality of Life of Older Patients Who Are Undergoing Treatment for Cancer and of Their Family Caregivers|Quality of Life Study Registry for Persons With Cancer and Family Caregivers|Completed|||863|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:19:59.533477|2018-06-01 04:19:59.533477
NCT00255684|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|2016-05-18||2016-09-28|2005-11-18|2005-11-21|Estimate|2016-05-18|2016-06-27|Estimate||||2016-09-28|2016-11-03|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|March 2013|Actual|2013-03-31||Interventional|||Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer|Non-Myeloablative Conditioning and Unrelated Umbilical Cord Blood Transplantation for Children and Adults With Serious Oncohematologic Diseases|Terminated||N/A|16|Actual|University of Rochester||1||low accrual|f||||t||||||||||2018-06-01 04:19:59.61005|2018-06-01 04:19:59.61005
NCT00255671|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2015-10-01|2005-11-18|2005-11-21|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2005||2005-05-31|October 2015|2015-10-31|May 2012|Actual|2012-05-31|April 2008|Actual|2008-04-30||Observational|||Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders|Prospective Study on the Short-Term Adverse Effects From Gamma Knife Radiosurgery|Completed|||76|Actual|Case Comprehensive Cancer Center|||||f||||t||||||None Retained|"~     Determine the incidence and types of acute complications in patients undergoing stereotactic~     radiosurgery for brain tumors or other brain disorders.~   "|||2018-06-01 04:20:00.636705|2018-06-01 04:20:00.636705
NCT00255658|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2015-04-14|2005-11-18|2005-11-21|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2005||2005-09-30|December 2013|2013-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors|Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination With CCI-779 (Temsirolimus) in Advanced Solid Malignancies|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:20:00.706129|2018-06-01 04:20:00.706129
NCT00255645|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2008-03-14|2005-11-18|2005-11-21|Estimate|||||||2008-03-14|2008-03-17|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|December 2006|Actual|2006-12-31|||||Observational|||G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)|A Long-Term, Post-Treatment, Safety Follow-Up, Multi-Center Study in Patients With Type 2 Diabetes Mellitus From the GALLANT, GALLEX or ARMOR Studies.|Terminated|||4500||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:20:00.887746|2018-06-01 04:20:00.887746
NCT00255619|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2006-10-25|2005-11-17|2005-11-21|Estimate|||||||2006-10-25|2006-10-26|Estimate|May 2002||2002-05-31|November 2005|2005-11-30|May 2004||2004-05-31|||||Interventional|||Open Label Trial to Establish the Equivalence Between ANDY-Disc® and Ultrabag® in Patients on CAPD.|A Randomized, Multi-Center, Open Label Trial to Establish the Equivalence Between ANDY-Disc® (Fresenius Medical Care) and Ultrabag® (Baxter) in Patients on CAPD. [CAPD-2 Trial]|Completed||Phase 4|264||Ministry of Health, Malaysia|||||f||||||||||||||2018-06-01 04:20:01.9402|2018-06-01 04:20:01.9402
NCT00255606|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2013-06-25|2005-11-18|2005-11-21|Estimate|||||||2013-06-25|2013-06-26|Estimate|August 2005||2005-08-31|September 2010|2010-09-30|August 2010|Actual|2010-08-31|May 2009|Actual|2009-05-31||Interventional|||Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer|A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial|Completed||Phase 3|360|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:20:02.027727|2018-06-01 04:20:02.027727
NCT00255593|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-18|||2007-11-29|2005-11-18|2005-11-21|Estimate|||||||2007-11-29|2007-11-30|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Safety and Efficacy Study of Rituximab in Renal Transplantation|A Prospective, Randomised, Placebo Controlled, Multicenter Study of the Efficacy and Safety of Rituximab as Induction Therapy Together With Tacrolimus, Mycophenolate Mofetil and Steroids for Patients Undergoing Renal Transplantation|Completed||Phase 1|140|Anticipated|Karolinska University Hospital|||||f||||||||||||||2018-06-01 04:20:02.21133|2018-06-01 04:20:02.21133
NCT00255580|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2008-02-20|2005-11-17|2005-11-21|Estimate|||||||2008-02-20|2008-02-28|Estimate|September 2001||2001-09-30|February 2008|2008-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Medicinal Cannabis for Painful HIV Neuropathy|Placebo-Controlled, Double Blind Trial of Medicinal Cannabis in Painful HIV Neuropathy|Completed||Phase 1/Phase 2|28|Actual|Center for Medicinal Cannabis Research||2|||f||||t||||||||||2018-06-01 04:20:02.357913|2018-06-01 04:20:02.357913
NCT00255567|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2016-03-21|2005-11-18|2005-11-21|Estimate|||||||2016-03-21|2016-03-22|Estimate|November 2004||2004-11-30|March 2016|2016-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis|A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan|Completed||Phase 3|1142|Actual|Drugs for Neglected Diseases||3|||f||||t||||||||||2018-06-01 04:20:02.485943|2018-06-01 04:20:02.485943
NCT00255554|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2005-11-17|2005-11-17|2005-11-21|Estimate|||||||2005-11-17|2005-11-21|Estimate||||November 2005|2005-11-30||||||||Interventional|||DBT and Escitalopram in Borderline Personality Disorder|Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder|Unknown status|Recruiting|N/A|||Bronx VA Medical Center|||||f||||||||||||||2018-06-01 04:20:02.603194|2018-06-01 04:20:02.603194
NCT00255541|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2008-03-14|2005-11-17|2005-11-21|Estimate|||||||2008-03-14|2008-03-17|Estimate|September 2004||2004-09-30|March 2008|2008-03-31|December 2006|Actual|2006-12-31|||||Interventional|||GALLANT 4 Tesaglitazar vs. Glibenclamide|A 52-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 3|580||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:20:02.79786|2018-06-01 04:20:02.79786
NCT00255528|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2007-03-19|2005-11-17|2005-11-21|Estimate|||||||2007-03-19|2007-03-20|Estimate|July 2002||2002-07-31|March 2007|2007-03-31||||||||Interventional|307A||Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects|Dose Ranging, Safety and Tolerability of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study|Completed||Phase 3|144||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:03.018123|2018-06-01 04:20:03.018123
NCT00255515|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2009-03-24|2005-11-17|2005-11-21|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|SCORE||Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia|An Open, Randomised, Parallel, Three Treatment Groups, Multicentre, Phase IV Study - in Real Life - to Compare the Change in Social Outcome of Quetiapine Fumarate (Seroquel®) Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia.|Completed||Phase 4|85|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:20:03.159076|2018-06-01 04:20:03.159076
NCT00255502|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2006-11-20|2005-11-17|2005-11-21|Estimate|||||||2006-11-20|2006-11-22|Estimate|July 2002||2002-07-31|November 2006|2006-11-30||||||||Interventional|||307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects|A Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® (Metoprolol Succinate) Extended-Release Tablets (Metoprolol CR/XL) in Hypertensive Pediatric Subjects: A Multicenter, Open-Label Extension of Protocol 307A|Completed||Phase 3|100||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:03.286274|2018-06-01 04:20:03.286274
NCT00255489|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2011-01-24|2005-11-17|2005-11-21|Estimate|||||||2011-01-24|2011-01-25|Estimate|May 2004||2004-05-31|January 2011|2011-01-31|June 2006|Actual|2006-06-30|||||Interventional|||A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer|A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer|Completed||Phase 1|36||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:03.388965|2018-06-01 04:20:03.388965
NCT00255476|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2009-04-22|2005-11-17|2005-11-21|Estimate|||||||2009-04-22|2009-04-23|Estimate|February 2004||2004-02-29|April 2009|2009-04-30|July 2007|Actual|2007-07-31|||||Interventional|||The IRESSA Novel Head and Neck Chemotherapy Evaluation Study|A Randomised Phase II Study to Investigate the Feasibility and Benefits of Combining ZD1839 and Cisplatin/5FU, as Induction Therapy, in Patients With Locally and Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|64||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:03.447226|2018-06-01 04:20:03.447226
NCT00255463|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2009-04-22|2005-11-17|2005-11-21|Estimate|||||||2009-04-22|2009-04-23|Estimate|January 2004||2004-01-31|April 2009|2009-04-30|November 2005|Actual|2005-11-30|||||Interventional|||Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study|Phase II, Placebo Controlled, Parallel Group, Double Blind, Randomised, Multicentre Trial Comparing the Anastrozole (Arimidex®) Placebo Combination to the Anastrozole - ZD1839 (Iressa™) Combination as Neoadjuvant Treatment in Postmenopausal Women With Stage I-IIIB Breast Cancer and Oestrogen Receptor (ER) and/or Progesterone (PgR) Positive Tumours|Completed||Phase 2|185||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:03.512534|2018-06-01 04:20:03.512534
NCT00255450|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2008-11-10|2005-11-17|2005-11-21|Estimate|||||||2008-11-10|2008-11-11|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|August 2006|Actual|2006-08-31|||||Interventional|||A Crossover Safety Study of Ferumoxytol Versus Placebo|A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared With Placebo|Completed||Phase 3|750||AMAG Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:20:03.647805|2018-06-01 04:20:03.647805
NCT00255437|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2015-01-07|2005-11-17|2005-11-21|Estimate|||||||2015-01-07|2015-01-09|Estimate|June 2004||2004-06-30|October 2007|2007-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients|A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis|Completed||Phase 3|304||AMAG Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:20:03.809397|2018-06-01 04:20:03.809397
NCT00255424|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2015-01-07|2005-11-17|2005-11-21|Estimate|||||||2015-01-07|2015-01-09|Estimate|May 2004||2004-05-31|October 2008|2008-10-31|August 2006|Actual|2006-08-31|||||Interventional|||Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients|A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Chronic Kidney Disease Patients Not on Dialysis|Completed||Phase 3|304||AMAG Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:20:03.949673|2018-06-01 04:20:03.949673
NCT00255411|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2017-06-30|2005-11-17|2005-11-18|Estimate|||||||2017-06-30|2017-07-02|Actual|November 9, 2005||2005-11-09|February 24, 2009|2009-02-24|February 24, 2009||2009-02-24|||||Observational|||Psychiatric Correlates of Psychogenic Movement Disorder and Non-Epileptic Seizure|Neuropsychiatric Correlates of Psychogenic Movement Disorder and Non-Epileptic Seizure|Completed|||190||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:20:04.146979|2018-06-01 04:20:04.146979
NCT00255398|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2018-04-27|2005-11-17|2005-11-18|Estimate|||||||2018-04-27|2018-04-30|Actual|November 10, 2005||2005-11-10|December 3, 2014|2014-12-03|December 3, 2014||2014-12-03|||||Observational|||Kidney Disease Biomarkers|Kidney Disease Biomarkers|Completed|||25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:20:04.217101|2018-06-01 04:20:04.217101
NCT00255385|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2005-11-16|2005-11-16|2005-11-18|Estimate|||||||2005-11-16|2005-11-18|Estimate|April 2002||2002-04-30|April 2005|2005-04-30|April 2004||2004-04-30|||||Interventional|||Efficacy of Bifidus DR10 and Oligo Saccharides / Micronutrient Fortification of Milk|Evaluating Efficacy of Milk Fortified With Bifidus DR10-Oligosaccharides, Zinc and Iron in Reducing Morbidity Due to Diarrhea, Pneumonia and Improving Growth and Development in Children Ages 13-36 Months|Completed||Phase 3|1200||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:20:04.295174|2018-06-01 04:20:04.295174
NCT00255372|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2008-06-03|2005-11-17|2005-11-18|Estimate|||||||2008-06-03|2008-06-04|Estimate|April 2005||2005-04-30|June 2008|2008-06-30||||May 2008|Actual|2008-05-31||Interventional|||To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.|Polyethylene Glycol Laxative (Macrogol 4000;Forlax®) for Treatment of Chronic Constipation in Children : A Phase III, Bicentric, Randomized, Double-Blind, Lactulose Controlled Study.|Completed||Phase 3|84|Anticipated|Ipsen||2|||f||||||||||||||2018-06-01 04:20:04.372983|2018-06-01 04:20:04.372983
NCT00255359|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2007-11-05|2005-11-16|2005-11-18|Estimate|||||||2007-11-05|2007-11-06|Estimate|February 2006||2006-02-28|November 2007|2007-11-30|November 2007||2007-11-30|||||Interventional|||Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Safety and Efficacy of XTL 2125 in Adult HCV-Infected Patients With Compensated Liver Disease, Who Are Interferon-Alpha Non-Responders or Have Relapsed From Interferon-Alpha Therapy|Withdrawn||Phase 1|60|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:20:04.449707|2018-06-01 04:20:04.449707
NCT00255346|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2017-03-07|2005-11-16|2005-11-18|Estimate|||||||2017-03-07|2017-03-09|Actual|November 15, 2005|Actual|2005-11-15|March 2017|2017-03-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)|Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)|Completed||Phase 2|68|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 04:20:04.53788|2018-06-01 04:20:04.53788
NCT00255333|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2007-05-11|2005-11-17|2005-11-18|Estimate|||||||2007-05-11|2007-05-14|Estimate|November 2005||2005-11-30|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||INNO-105 in Patients With Solid Tumors|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Weekly Intravenous INNO-105 in Adult Patients With Advanced Solid Malignancies|Terminated||Phase 1|24||Innovive Pharmaceuticals||||Development of this compound was discontinued.|||||||||||||||2018-06-01 04:20:04.64499|2018-06-01 04:20:04.64499
NCT00255320|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2005-12-07|2005-11-16|2005-11-18|Estimate|||||||2005-12-07|2005-12-09|Estimate|December 2003||2003-12-31|December 2003|2003-12-31|June 2004||2004-06-30|||||Interventional|||Experimental Headache Induced by Vasoactive Intestinal Polypeptide|Experimental Headache Induced by Vasoactive Intestinal Polypeptide|Completed||N/A|12||Danish Headache Center|||||f||||||||||||||2018-06-01 04:20:04.73076|2018-06-01 04:20:04.73076
NCT00255307|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2007-06-14|2005-11-16|2005-11-18|Estimate|||||||2007-06-14|2007-06-18|Estimate|November 2005||2005-11-30|June 2007|2007-06-30|April 2006|Actual|2006-04-30|||||Interventional|||Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection.|A Pilot Evaluation of Two Dosing Schedules of American Ginseng Extract in Pediatric Upper Respiratory Tract Infection.|Completed||Phase 2|75|Actual|Afexa Life Sciences Inc|||||f||||||||||||||2018-06-01 04:20:04.800685|2018-06-01 04:20:04.800685
NCT00255294|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2005-11-17|2005-11-17|2005-11-18|Estimate|||||||2005-11-17|2005-11-18|Estimate|January 2005||2005-01-31|November 2005|2005-11-30|October 2005||2005-10-31|||||Interventional|||Contraceptive Effectiveness Trial of Cellulose Sulfate Gel|Non-Comparative Contraceptive Effectiveness Trial of Cellulose Sulfate (CS) Gel|Completed||Phase 2|200||CONRAD|||||||||||||||||||2018-06-01 04:20:04.867266|2018-06-01 04:20:04.867266
NCT00255281|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2007-12-04|2005-11-17|2005-11-18|Estimate|||||||2007-12-04|2007-12-06|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|May 2006|Actual|2006-05-31|||||Interventional|||Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation|A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase II Study to Assess the Efficacy of AZD7009 (AR H065522XX) Given Intravenously (Infusion for 15 or 30 Minutes) to Patients for Conversion of Atrial Fibrillation|Completed||Phase 2|160|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:04.94106|2018-06-01 04:20:04.94106
NCT00255268|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-08-24|2005-11-17|2005-11-18|Estimate|||||||2007-08-24|2007-08-28|Estimate|August 2004||2004-08-31|August 2007|2007-08-31||||||||Interventional|||CMAB vs IMAB in Metastatic Prostate Cancer|Longitudinal, Randomized, Open and Prospective Clinical Trial to Evaluate the Efficacy of Continuous vs Intermittent Maximum Androgen Blockade (CMAB vs IMAB) With Goserelin-Bicalutamide Combination in the Treatment of Hormonal naïve With Metastatic Prostate Cancer|Withdrawn||Phase 4|15|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:05.050945|2018-06-01 04:20:05.050945
NCT00255255|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-17|||2011-01-21|2005-11-17|2005-11-18|Estimate|||||||2011-01-21|2011-01-24|Estimate|November 2005||2005-11-30|January 2011|2011-01-31|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|||Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma|An Open, Phase III, Multicentre, 52-week Study, Evaluating the Safety and Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma|Completed||Phase 3|120||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:05.12568|2018-06-01 04:20:05.12568
NCT00255242|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2009-07-31|2005-11-16|2005-11-18|Estimate|||||||2009-07-31|2009-08-03|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|May 2009|Actual|2009-05-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Simvastatin on CF Airway Inflammation|Effect of Simvastatin on CF Airway Inflammation|Completed||Phase 1|40|Anticipated|Akron Children's Hospital|||||f||||f||||||||||2018-06-01 04:20:05.218859|2018-06-01 04:20:05.218859
NCT00255229|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2016-02-24|2005-11-16|2005-11-18|Estimate|||||||2016-02-24|2016-02-25|Estimate|December 2002||2002-12-31|January 2012|2012-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea|Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea|Completed||Phase 2|130|Actual|AHS Cancer Control Alberta||2|||f||||t||||||||||2018-06-01 04:20:05.299651|2018-06-01 04:20:05.299651
NCT00255216|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2005-11-17|2005-11-17|2005-11-18|Estimate|||||||2005-11-17|2005-11-18|Estimate|January 2005||2005-01-31|October 2005|2005-10-31|August 2005||2005-08-31|||||Interventional|||Policosanol for the Treatment of Hypercholesterolemia|Policosanol for the Treatment of Hypercholesterolemia|Completed||N/A|40||Carolinas Healthcare System|||||f||||||||||||||2018-06-01 04:20:05.374947|2018-06-01 04:20:05.374947
NCT00255190|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2009-06-24||2016-06-27|2005-11-15|2005-11-17|Estimate|2009-06-24|2009-08-12|Estimate||||2016-06-27|2016-07-27|Estimate|January 2006||2006-01-31|April 2011|2011-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn|A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD)|Completed||Phase 3|591|Actual|Takeda|The incidence of adverse events was considered one of the primary outcome measures of this study. These results are presented in the Adverse Events Section and are not reposted as a separate primary endpoint.|2|||f||||f||||||||||2018-06-01 04:20:05.515831|2018-06-01 04:20:05.515831
NCT00255177|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2009-04-22||2009-10-30|2005-11-15|2005-11-17|Estimate|2009-08-17|2009-09-23|Estimate||||2009-10-30|2009-11-03|Estimate|November 2005||2005-11-30|October 2009|2009-10-31|January 2008|Actual|2008-01-31|September 2007|Actual|2007-09-30||Interventional|||Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients|A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients|Completed||Phase 2|44|Actual|VGX Pharmaceuticals, LLC||4|||f||||f||||||||||2018-06-01 04:20:06.937181|2018-06-01 04:20:06.937181
NCT00255164|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2009-02-20||2012-02-01|2005-11-15|2005-11-17|Estimate|2009-07-20|2009-08-28|Estimate||||2012-02-01|2012-02-03|Estimate|January 2006||2006-01-31|February 2012|2012-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis|A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis|Completed||Phase 3|451|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:20:07.395509|2018-06-01 04:20:07.395509
NCT00255151|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2009-02-20||2012-02-01|2005-11-15|2005-11-17|Estimate|2009-07-20|2009-08-28|Estimate||||2012-02-01|2012-02-03|Estimate|January 2006||2006-01-31|February 2012|2012-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis|A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis|Completed||Phase 3|451|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:20:08.223807|2018-06-01 04:20:08.223807
NCT00255138|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2008-10-28|2005-11-15|2005-11-17|Estimate|||||||2008-10-28|2008-10-31|Estimate|November 2005||2005-11-30|October 2008|2008-10-31||||||||Interventional|||Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects|Efficacy of Atomoxetine Therapy Versus Placebo For Ameliorating Cognitive Late Effects Among Survivors of Childhood Cancers|Withdrawn||Phase 3|60||Temple University|||||f||||||||||||||2018-06-01 04:20:09.194707|2018-06-01 04:20:09.194707
NCT00255125|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2013-12-24||2015-06-12|2005-11-15|2005-11-17|Estimate|2015-06-12|2015-06-17|Estimate||||2015-06-12|2015-06-17|Estimate|September 2005||2005-09-30|June 2015|2015-06-30|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional||Prostate cancer patient, randomized between to study groups; all patients with early stage prostate cancer.|Role of Soy Supplementation in Prostate Cancer Development|Role of Soy Isoflavones in Prostate Cancer Prevention|Completed||Phase 3|86|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:20:09.268235|2018-06-01 04:20:09.268235
NCT00255099|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15||2011-06-02|2011-06-02|2005-11-15|2005-11-17|Estimate||||2011-06-02|2011-06-15|Estimate|2011-06-02|2011-06-15|Estimate|December 2005||2005-12-31|June 2011|2011-06-30|July 2008|Actual|2008-07-31|January 2007|Actual|2007-01-31||Interventional|||TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.|A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treatment to no Treatment Options.|Completed||Phase 3|593|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||||||||||||2018-06-01 04:20:09.611667|2018-06-01 04:20:09.611667
NCT00255086|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2016-08-23||2017-02-23|2005-11-15|2005-11-17|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|May 2005||2005-05-31|February 2017|2017-02-28|February 2010|Actual|2010-02-28|June 2009|Actual|2009-06-30||Interventional||Per protocol, only participants who completed the study were evaluable for baseline characteristics.|The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients|The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial|Completed||Phase 3|17|Actual|Stanford University||2|||f||||f||||||||Undecided||2018-06-01 04:20:09.709491|2018-06-01 04:20:09.709491
NCT00255073|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2014-05-21|2005-11-15|2005-11-17|Estimate|||||||2014-05-21|2014-05-23|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|April 2006||2006-04-30|||||Interventional|||Does Reducing Spasticity Permit an Increase in Strength?|Does Reducing Spasticity Permit an Increase in Strength?|Completed||Phase 2|10||University of Southern California|||||f||||f||||||||||2018-06-01 04:20:09.916853|2018-06-01 04:20:09.916853
NCT00255060|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2010-07-16|2005-11-15|2005-11-17|Estimate|||||||2010-07-16|2010-07-20|Estimate|November 2001||2001-11-30|July 2010|2010-07-31|June 2007|Actual|2007-06-30|July 2006|Actual|2006-07-31||Observational|||Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer|Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer|Completed|||100|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:20:10.012855|2018-06-01 04:20:10.012855
NCT00255047|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2010-09-14||2014-01-21|2005-11-15|2005-11-17|Estimate|2010-10-14|2010-11-10|Estimate||||2014-01-21|2014-02-14|Estimate|November 2005||2005-11-30|January 2014|2014-01-31|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Safety and Immune Response of Different Pediatric Combination Vaccines.|Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on a 5 Component Acellular Pertussis Vaccine in Infants and Toddlers|Completed||Phase 3|2167|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 04:20:10.108222|2018-06-01 04:20:10.108222
NCT00255034|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2009-06-04||2017-03-08|2005-11-15|2005-11-17|Estimate|2009-06-04|2009-07-23|Estimate||||2017-03-08|2017-04-06|Actual|February 2005||2005-02-28|March 2017|2017-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)|Phase IV Study of Tailored Therapy With Peg Interferon Alfa 2b and Ribavirin for Patients With Genotype 3 and High Viral Load. Genotype 3 Extended Treatment for HCV (GET-C Study)|Terminated||Phase 4|146|Actual|Merck Sharp & Dohme Corp.|No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfill the recruitment target.|2||Recruitment targets were unachievable in the currently available population.|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:20:10.965911|2018-06-01 04:20:10.965911
NCT00255021|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2012-04-13|2005-11-15|2005-11-17|Estimate|||||||2012-04-13|2012-04-16|Estimate|December 2005||2005-12-31|April 2012|2012-04-30|January 2009|Actual|2009-01-31|September 2007|Actual|2007-09-30||Interventional|||Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand||Completed||Phase 4|186|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:20:11.33727|2018-06-01 04:20:11.33727
NCT00255008|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2008-12-05||2017-03-08|2005-11-15|2005-11-17|Estimate|2009-12-02|2010-01-06|Estimate||||2017-03-08|2017-04-06|Actual|March 2005||2005-03-31|March 2017|2017-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)|SEASON South East Asian Study Of Novel Genotypes in Hepatitis C Infection: Pegylated-Interferon and Ribavirin Therapy (PEGATRON REDIPEN Combination Therapy (PEG-Intron® REDIPEN Plus REBETOL®)) in Treatment Naive Patients With Genotypes 1, 6, 7, 8, 9: A Comparison of Race and Genotype on Treatment Outcome.|Terminated||Phase 4|121|Actual|Merck Sharp & Dohme Corp.||4||Slow enrollment|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:20:11.440873|2018-06-01 04:20:11.440873
NCT00254995|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2014-09-04||2016-04-15|2005-11-15|2005-11-17|Estimate|2014-11-03|2014-11-11|Estimate||||2016-04-15|2016-04-19|Estimate|July 2005||2005-07-31|April 2016|2016-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational||Subjects who received Menactra vaccine during the study period from the Kaiser Permanente databases.|Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine|Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra ™)|Completed|||62626|Actual|Sanofi|||2||f||||f||||||||||2018-06-01 04:20:11.984475|2018-06-01 04:20:11.984475
NCT00254982|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2010-05-27||2015-10-09|2005-11-16|2005-11-17|Estimate|2010-05-27|2010-07-05|Estimate||||2015-10-09|2015-10-12|Estimate|August 2005||2005-08-31|October 2015|2015-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)|"An Open-Label Study to Determine Equivalence in Efficacy, Organ Safety and Systemic Tolerability Between Infliximab in GROUP I (High Need) and GROUP II (Low Need) Patients Suffering From Chronic Plaque Psoriasis (Psoriasis Vulgaris)"|Completed||Phase 3|593|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:20:12.649398|2018-06-01 04:20:12.649398
NCT00254969|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2012-04-16|2005-11-15|2005-11-17|Estimate|||||||2012-04-16|2012-04-17|Estimate|October 2005||2005-10-31|April 2012|2012-04-30|January 2010|Actual|2010-01-31|May 2008|Actual|2008-05-31||Interventional|||Immunogenicity and Safety of Pentaxim in South African Infants||Completed||Phase 3|212|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 04:20:13.067532|2018-06-01 04:20:13.067532
NCT00254956|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2009-04-07|2005-11-15|2005-11-17|Estimate|||||||2009-04-07|2009-04-08|Estimate|January 2004||2004-01-31|April 2009|2009-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma|A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide Hfa-Mdi 640 μg/Day and Beclomethasone Hfa-Mdi 640 μg/Day on Lens Opacification in Adult Subjects With Moderate to Severe Persistent Asthma|Completed||Phase 3|1568|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:20:13.166874|2018-06-01 04:20:13.166874
NCT00254930|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2011-05-18|2005-11-15|2005-11-17|Estimate|||||||2011-05-18|2011-05-20|Estimate|September 2003||2003-09-30|March 2010|2010-03-31|June 2006|Actual|2006-06-30|||||Interventional|||A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children|Prospective Trial of Risperdal (Risperidone) Following Psychological Therapy for Challenging Behaviour in Learning Disabled Children|Completed||Phase 3|19|Actual|Janssen-Cilag Ltd.|||||f||||||||||||||2018-06-01 04:20:13.25472|2018-06-01 04:20:13.25472
NCT00254917|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2012-04-13|2005-11-15|2005-11-17|Estimate|||||||2012-04-13|2012-04-16|Estimate|October 2003||2003-10-31|April 2012|2012-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines||Completed||Phase 4|387|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:20:13.315073|2018-06-01 04:20:13.315073
NCT00254904|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15||2009-03-20|2015-03-10|2005-11-15|2005-11-17|Estimate||||2009-09-24|2009-09-28|Estimate|2015-03-10|2015-03-30|Estimate|November 2005||2005-11-30|March 2015|2015-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC|International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 3|839|Actual|Pfizer||2||See Termination Reason in Detailed Description|f||||t||||||||||2018-06-01 04:20:13.414815|2018-06-01 04:20:13.414815
NCT00254891|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15||2009-03-20|2015-03-10|2005-11-15|2005-11-17|Estimate||||2009-09-24|2009-09-28|Estimate|2015-03-10|2015-03-30|Estimate|November 2005||2005-11-30|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer|International, Randomized, Open-Label, Phase 3 Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 3|828|Actual|Pfizer||2||See Termination Reason in Detailed Description|f||||t||||||||||2018-06-01 04:20:13.937525|2018-06-01 04:20:13.937525
NCT00254878|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2007-12-17|2005-11-16|2005-11-17|Estimate|||||||2007-12-17|2007-12-21|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|February 2006|Actual|2006-02-28|||||Interventional|||Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14|A 7 Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Cross-Over Evaluation of the Efficacy and Safety of Two Different Brands of Modified-Release Oral Dosage Forms of Methylphenidate-HCl (20 mg, q.d.) in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14|Completed||Phase 3|130||Novartis|||||f||||||||||||||2018-06-01 04:20:14.344162|2018-06-01 04:20:14.344162
NCT00254865|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2011-06-06|2005-11-15|2005-11-17|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2002||2002-08-31|January 2011|2011-01-31|March 2003|Actual|2003-03-31|||||Interventional|||A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers|A Comparative Pharmacokinetic Study of EVRA and CILEST in Healthy Female Volunteers|Completed||Phase 1|34|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:20:14.404201|2018-06-01 04:20:14.404201
NCT00254852|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2013-11-20|2005-11-15|2005-11-17|Estimate|||||||2013-11-20|2013-11-21|Estimate|October 2005||2005-10-31|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft|A Single Blind, Multi-Center, Randomized, Prospective Clinical Study Comparing Optecure™ Autograft Extender to Autograft Only in Fusion of the Lumbar Spine|Terminated||N/A|94|Actual|Exactech||2||Slow enrollment|f||||f||||||||||2018-06-01 04:20:14.472495|2018-06-01 04:20:14.472495
NCT00254839|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-16|||2006-09-14|2005-11-16|2005-11-17|Estimate|||||||2006-09-14|2006-09-15|Estimate|December 2005||2005-12-31|November 2005|2005-11-30||||||||Observational|||Association Between Dental Implants Properties and Malodor Production|Bacterial Accumulation and Malodor Production in Various Types of Dental Implants|Completed|||60||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:20:14.571096|2018-06-01 04:20:14.571096
NCT00254826|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2013-12-03|2005-11-15|2005-11-17|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 2006||2006-06-30|December 2013|2013-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Yellow Fever Virus Vaccine and Immune Globulin Study|Randomized Controlled Double-Blind Trial of the Comparative Viremia, Immunogenicity and Safety of a 17-D Live Attenuated Yellow Fever Vaccine (YF-VAX)Given Alone or in Combination With Human Immune Globulin (Gama STAN S/D)|Completed||Phase 1|80|Actual|Emory University||2|||f||||f||||||||||2018-06-01 04:20:14.629403|2018-06-01 04:20:14.629403
NCT00254813|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2011-01-25|2005-11-15|2005-11-17|Estimate|||||||2011-01-25|2011-01-26|Estimate|October 2004||2004-10-31|January 2011|2011-01-31|September 2005|Actual|2005-09-30|||||Interventional|||Fast Titration Of Quetiapine Versus Currently Approved Titration|Fast Titration Of Quetiapine Versus Currently Approved Titration: A Randomised, Multicentre, Parallel Group Open Trial In Schizophrenia And Schizoaffective Disorder|Completed||Phase 3|150||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:14.773148|2018-06-01 04:20:14.773148
NCT00254800|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2015-08-17|2005-11-15|2005-11-17|Estimate|||||||2015-08-17|2015-08-18|Estimate|November 2005||2005-11-30|August 2015|2015-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females|The Effect of Exenatide on Single and Multiple Doses Oral Contraceptive Pharmacokinetics in Healthy Female Subjects|Completed||Phase 1|38|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 04:20:14.838784|2018-06-01 04:20:14.838784
NCT00254787|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2009-06-09|2005-11-15|2005-11-17|Estimate|||||||2009-06-09|2009-06-11|Estimate|June 2005||2005-06-30|June 2009|2009-06-30|January 2006|Actual|2006-01-31|||||Interventional|||Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients|Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in the Treatment of Patients With Acute Schizophrenia - a Multicentre, Double-Blind, Parallel Group, Randomized Study|Completed||Phase 2|30||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:14.91675|2018-06-01 04:20:14.91675
NCT00254774|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2007-12-14|2005-11-15|2005-11-17|Estimate|||||||2007-12-14|2007-12-18|Estimate|January 2002||2002-01-31|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|||Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling|Pilot Study of the Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling: an Open Trial|Completed||Phase 3|44|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:14.981067|2018-06-01 04:20:14.981067
NCT00254241|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2009-06-09|2005-11-14|2005-11-16|Estimate|||||||2009-06-09|2009-06-11|Estimate|May 2002||2002-05-31|June 2009|2009-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Safety and Efficacy of Seroquel in First Episode Schizophrenia|Safety and Efficacy of Seroquel in First Episode Schizophrenia|Completed||Phase 4|80||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:25.004031|2018-06-01 04:20:25.004031
NCT00254761|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2008-02-27|2005-11-15|2005-11-17|Estimate|||||||2008-02-27|2008-02-28|Estimate|November 2003||2003-11-30|February 2008|2008-02-29|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Effects of Smoked Marijuana on Neuropathic Pain|A Double Blind, Active Placebo Controlled Crossover Trial of the Antinociceptive Effect of Smoked Marijuana on Subjects With Neuropathic Pain; Correlation With Changes in Mood, Cognition, and Psychomotor Performance|Completed||Phase 1/Phase 2|28|Actual|Center for Medicinal Cannabis Research||3|||f||||t||||||||||2018-06-01 04:20:15.040023|2018-06-01 04:20:15.040023
NCT00254748|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2009-06-09|2005-11-15|2005-11-17|Estimate|||||||2009-06-09|2009-06-11|Estimate|June 2004||2004-06-30|June 2009|2009-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients|The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial|Completed||Phase 2|40|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 04:20:15.160735|2018-06-01 04:20:15.160735
NCT00254735|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2007-12-14|2005-11-15|2005-11-17|Estimate|||||||2007-12-14|2007-12-18|Estimate|April 2002||2002-04-30|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|||Quetiapine Augmentation in Severe Obsessive Compulsive Disorder|Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study|Completed||Phase 3|44|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:15.219616|2018-06-01 04:20:15.219616
NCT00254722|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2010-01-04|2005-11-14|2005-11-16|Estimate|||||||2010-01-04|2010-01-05|Estimate|April 2006||2006-04-30|January 2010|2010-01-31|October 2009|Actual|2009-10-31|November 2008|Actual|2008-11-30||Interventional|||Safety of Autologous Stem Cell Treatment for Traumatic Brain Injury in Children|Safety of Autologous Stem Cell Treatment for Traumatic Brain Injury in Children|Completed||Phase 1|10|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-06-01 04:20:15.271359|2018-06-01 04:20:15.271359
NCT00254709|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2012-01-26|2005-11-14|2005-11-16|Estimate|||||||2012-01-26|2012-01-31|Estimate|October 2002||2002-10-31|January 2012|2012-01-31|September 2005|Actual|2005-09-30|||||Interventional|||Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients|Open, Pilot, Comparative Study to Evaluate the Efficacy and Safety of Two Immunosuppressor Regimens, Anti Il-2, Sirolimus Mycophenolate, Mophetyl and Steroids Versus Sirolimus, Cyclosporine, and Withdrawal of Cyclosporine Since the Third Month and Steroids in Elderly Population|Completed||Phase 4|66|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:20:15.473104|2018-06-01 04:20:15.473104
NCT00254696|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2011-04-13|2005-11-14|2005-11-16|Estimate|||||||2011-04-13|2011-04-15|Estimate|June 2004||2004-06-30|April 2011|2011-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)|Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs)|Completed||Phase 4|710|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:20:15.529686|2018-06-01 04:20:15.529686
NCT00254683|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2009-04-13|2005-11-15|2005-11-16|Estimate|||||||2009-04-13|2009-04-14|Estimate|September 2005||2005-09-30|April 2009|2009-04-30|September 2015|Anticipated|2015-09-30|August 2010|Anticipated|2010-08-31||Interventional|||Use of Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Tumor Response to Neoadjuvant Treatment for Distal Rectal Cancer|Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy|Unknown status|Recruiting|Phase 2|100|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-06-01 04:20:15.584907|2018-06-01 04:20:15.584907
NCT00254670|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2011-04-12|2005-11-15|2005-11-16|Estimate|||||||2011-04-12|2011-04-14|Estimate|February 2005||2005-02-28|March 2011|2011-03-31|December 2006|Actual|2006-12-31|December 2005|Actual|2005-12-31||Interventional|||Naltrexone Effects on Alcohol Intake|Naltrexone Effects on Alcohol Intake Using a Laboratory Bar in Asp40 Positive and Negative Alcohol Users Characterized by fMRI and Genetic Screening|Completed||N/A|||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:20:15.677818|2018-06-01 04:20:15.677818
NCT00254657|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2013-05-10|2005-11-15|2005-11-16|Estimate|||||||2013-05-10|2013-05-13|Estimate|March 2004||2004-03-31|May 2013|2013-05-31|April 2005|Actual|2005-04-30|March 2005|Actual|2005-03-31||Interventional|||Levetiracetam for Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled Trial of Levetiracetam for Treatment of Pain Associated With Fibromyalgia|Completed||N/A|66|Actual|University of California, San Francisco||2|||f||||||||||||||2018-06-01 04:20:15.737209|2018-06-01 04:20:15.737209
NCT00254644|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2017-01-13|2005-11-15|2005-11-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|February 2007||2007-02-28|May 2011|2011-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|PHR04-CH/DYS||Morphofunctional Imaging and Developmental Dyslexia|Morphofunctional Imaging and Developmental Dyslexia|Completed|||32|Actual|University Hospital, Tours|||2||f||||f||||||||||2018-06-01 04:20:15.810261|2018-06-01 04:20:15.810261
NCT00254631|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2015-02-04|2005-11-15|2005-11-16|Estimate|||||||2015-02-04|2015-02-05|Estimate|April 2007||2007-04-30|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures|Preemptive Analgesia With OxyContin Versus Placebo Before Surgery for Long Bone Fractures|Completed||Phase 4|65|Actual|Rambam Health Care Campus||2|||f||||||||||||||2018-06-01 04:20:15.885165|2018-06-01 04:20:15.885165
NCT00254618|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2013-04-15|2005-11-14|2005-11-16|Estimate|||||||2013-04-15|2013-04-17|Estimate|October 2005||2005-10-31|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.|Study to Determine the Pharmacokinetics of Mesalamine Following Administration of 30, 60, and 90 mg/kg/Day as 400 mg Delayed-release Tablets Given Every 12 Hours for 28 Days to Children/Adolescents With Active Ulcerative Colitis.|Terminated||Phase 1|34|Actual|Warner Chilcott||3||Slow enrollment.|f||||f||||||||||2018-06-01 04:20:16.042945|2018-06-01 04:20:16.042945
NCT00254605|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2016-10-24|2005-11-14|2005-11-16|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2005||2005-11-30|October 2016|2016-10-31|November 2019|Anticipated|2019-11-30|October 2017|Anticipated|2017-10-31||Observational|||Retinal Imaging in Patients With Inherited Retinal Degenerations|High Resolution Retinal Imaging in Patients With Inherited Retinal Degenerations|Recruiting|||400|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-06-01 04:20:16.16779|2018-06-01 04:20:16.16779
NCT00254592|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2009-08-28||2018-01-11|2005-11-15|2005-11-16|Estimate|2013-09-06|2013-11-11|Estimate||||2018-01-11|2018-02-09|Actual|October 2005||2005-10-31|January 2018|2018-01-31|December 28, 2018|Anticipated|2018-12-28|September 4, 2013|Actual|2013-09-04||Interventional|||Neoadjuvant Treatment of Breast Cancer|Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study|Active, not recruiting||Phase 2|43|Actual|University of California, Irvine||1|||f||||t||||||||||2018-06-01 04:20:16.247038|2018-06-01 04:20:16.247038
NCT00254579|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14||2009-05-09|2012-06-05|2005-11-14|2005-11-16|Estimate||||2009-09-24|2009-09-28|Estimate|2012-06-05|2012-06-07|Estimate|December 2005||2005-12-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study of CP-675,206 in Refractory Melanoma|A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma|Completed||Phase 2|251|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 04:20:16.436312|2018-06-01 04:20:16.436312
NCT00254566|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|2009-07-22||2009-11-03|2005-11-14|2005-11-16|Estimate|2009-07-22|2009-09-02|Estimate||||2009-11-03|2009-11-11|Estimate|February 2006||2006-02-28|November 2009|2009-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)|A Phase 3B Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial To Evaluate The Efficacy and Safety Of Azithromycin SR (Microspheres Formulation) Versus Moxifloxacin For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB).|Completed||Phase 3|398|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:20:16.642356|2018-06-01 04:20:16.642356
NCT00254553|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2015-12-11|2005-11-14|2005-11-16|Estimate|||||||2015-12-11|2015-12-14|Estimate|July 2005||2005-07-31|December 2015|2015-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two Period Cross Over Trial to Validate Patient-Reported Outcome Measures for Use in Men With Late Onset Hypogonadism|Terminated||Phase 2|150|Actual|Merck Sharp & Dohme Corp.||2||Recruitment issues|f||||f||||||||||2018-06-01 04:20:17.101393|2018-06-01 04:20:17.101393
NCT00254540|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|2010-01-15||2010-02-17|2005-11-14|2005-11-16|Estimate|2010-01-19|2010-02-11|Estimate||||2010-02-17|2010-02-23|Estimate|December 2005||2005-12-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of SU011248 in Patients With Advanced Kidney Cancer|Phase II Study Of Single-Agent SU011248 In The Treatment Of Patients With Renal Cell Carcinoma|Completed||Phase 2|51|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:20:17.193599|2018-06-01 04:20:17.193599
NCT00254527|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2007-04-30|2005-11-14|2005-11-16|Estimate|||||||2007-04-30|2007-05-02|Estimate|January 2005||2005-01-31|November 2005|2005-11-30|April 2007|Actual|2007-04-30|||||Observational|||Colonization, Infection, and Molecular Typing of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Children.|Colonization, Infection, and Molecular Typing of Methicillin-Resistant Staphylococcus Aureus (MRSA) in Children.|Completed|||477|Actual|Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:20:17.874235|2018-06-01 04:20:17.874235
NCT00254514|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2017-01-20|2005-11-15|2005-11-16|Estimate|||||||2017-01-20|2017-01-23|Estimate|August 2001||2001-08-31|January 2017|2017-01-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures|A Multi-centre, Randomised, Double-blind, Placebocontrolled, Parallel-group Trial Investigating the Efficacy and Safety of Norditropin® SimpleXx® in Tibia Fractures|Completed||Phase 2|407|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:20:17.950488|2018-06-01 04:20:17.950488
NCT00254501|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|2016-07-14||2016-07-20|2005-11-14|2005-11-16|Estimate|2016-07-20|2016-07-22|Estimate||||2016-07-20|2016-07-22|Estimate|November 2005||2005-11-30|July 2016|2016-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Empowering Patients to Better Manage Diabetes Through Self-Care|Empowering Patients to Better Manage Diabetes Through Self-Care|Completed||Phase 3|69|Actual|Oregon State University||2|||f||||f||||||||No||2018-06-01 04:20:18.099996|2018-06-01 04:20:18.099996
NCT00254488|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2013-07-24|2005-11-14|2005-11-16|Estimate|||||||2013-07-24|2013-07-25|Estimate|November 2005||2005-11-30|July 2013|2013-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|GERI-BD||Treatment of Bipolar Mania in Older Adults|Acute Pharmacotherapy of Late-Life Mania (GERI-BD)|Completed||Phase 4|224|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 04:20:19.218079|2018-06-01 04:20:19.218079
NCT00254475|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2014-08-18|2005-11-15|2005-11-16|Estimate|||||||2014-08-18|2014-08-19|Estimate|November 2005||2005-11-30|August 2014|2014-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia|A Study to Evaluate the Efficacy of the Valsartan/Simvastatin Combinations 160/20mg up Titrated to 320/20mg Versus 160/40mg up Titrated to 320/40mg in Patients With Both Essential Hypertension and Hypercholesterolemia|Completed||Phase 3|871|Actual|Novartis|||||f||||||||||||||2018-06-01 04:20:19.689685|2018-06-01 04:20:19.689685
NCT00254462|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|2011-10-03||2015-12-16|2005-11-14|2005-11-16|Estimate|2013-06-17|2013-07-17|Estimate||||2015-12-16|2015-12-18|Estimate|October 2005||2005-10-31|December 2015|2015-12-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children|Pharmacological Treatment of ADHD in Young Children|Completed||Phase 4|93|Actual|University of Nebraska|Study design does not allow differentiation between placebo response and psychoeducational treatment effect. Eight-week duration does not allow for examination of long-term effectiveness or assessment of adverse effects over time.|2|||f||||t||||||||||2018-06-01 04:20:19.773279|2018-06-01 04:20:19.773279
NCT00254449|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2009-02-12|2005-11-14|2005-11-16|Estimate|||||||2009-02-12|2009-02-16|Estimate|November 2005||2005-11-30|September 2007|2007-09-30|May 2006||2006-05-31|||||Interventional|||Effect of NGX-4010 on ENFD and Sensory Function|A Randomized, Controlled, Open-Label Study to Investigate the Effect of NGX-4010 on Epidermal Nerve Fiber Density and Sensory Function in Healthy Volunteers|Completed||Phase 1|36||NeurogesX|||||||||||||||||||2018-06-01 04:20:20.192925|2018-06-01 04:20:20.192925
NCT00254436|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2012-07-27|2005-11-14|2005-11-16|Estimate|||||||2012-07-27|2012-07-31|Estimate|December 2002||2002-12-31|July 2012|2012-07-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery|Terminated||Phase 3|50|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 04:20:20.241442|2018-06-01 04:20:20.241442
NCT00254423|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2017-11-14|2005-11-14|2005-11-16|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2005|Actual|2005-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Study of Dasatinib in Patients With Chronic Myelogenous Leukemia|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)|Active, not recruiting||Phase 2|150|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-06-01 04:20:20.362565|2018-06-01 04:20:20.362565
NCT00253331|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-13|||2007-05-29|2005-11-13|2005-11-15|Estimate|||||||2007-05-29|2007-05-30|Estimate|November 2004||2004-11-30|May 2007|2007-05-31|September 2005||2005-09-30|||||Interventional|||Lab Study of MQX-503 in Treatment of Raynaud's|Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon|Completed||Phase 2/Phase 3|36||MediQuest Therapeutics|||||||||||||||||||2018-06-01 04:20:35.115522|2018-06-01 04:20:35.115522
NCT00254410|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2017-09-18|2005-11-14|2005-11-16|Estimate|||||||2017-09-18|2017-09-20|Actual|March 14, 2005|Actual|2005-03-14|September 2017|2017-09-30|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years|Phase 2 Study of the Activity and Safety of Fludarabine, Cyclophosphamide, and Mitoxantrone Plus Rituximab (FCM-R) With Pegfilgrastim (Neulasta) as Frontline Therapy for Patients < 70 Years With Chronic Lymphocytic Leukemia|Completed||Phase 2|31|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 04:20:20.453309|2018-06-01 04:20:20.453309
NCT00254397|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2013-02-12|2005-11-14|2005-11-16|Estimate|||||||2013-02-12|2013-02-13|Estimate|November 2005||2005-11-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Melanoma Vaccine With Peptides and Leuprolide|Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients|Completed||Phase 2|98|Actual|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-06-01 04:20:20.527177|2018-06-01 04:20:20.527177
NCT00254384|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2017-09-11|2005-11-14|2005-11-16|Estimate|||||||2017-09-11|2017-09-13|Actual|October 5, 2005|Actual|2005-10-05|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) Surgery for Non-Small Cell Lung Cancer (NSCLC) Following Definitive Surgical Resection|Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection|Active, not recruiting||N/A|50|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 04:20:20.630559|2018-06-01 04:20:20.630559
NCT00254371|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2011-05-20|2005-11-14|2005-11-16|Estimate|||||||2011-05-20|2011-05-23|Estimate|July 1998||1998-07-31|May 2011|2011-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||DHEA and Testosterone Replacement in Elderly|Pathogenesis of Sarcopenia and Metabolic Changes in Aging|Completed||N/A|150||Mayo Clinic|||||f||||||||||||||2018-06-01 04:20:20.71395|2018-06-01 04:20:20.71395
NCT00254358|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2008-07-03|2005-11-15|2005-11-16|Estimate|||||||2008-07-03|2008-07-04|Estimate|April 2007||2007-04-30|June 2008|2008-06-30|April 2007|Actual|2007-04-30|||||Observational|||A Brain Imaging Study of Nicotine Release in Cigarette Smokers|A Brain Imaging Study of Nicotine Release in Cigarette Smokers|Terminated|||0|Actual|Hadassah Medical Organization||||It was decided to use a different protocol with a different radioligand|f||||t||||||||||2018-06-01 04:20:20.890797|2018-06-01 04:20:20.890797
NCT00254345|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2007-12-10|2005-11-15|2005-11-16|Estimate|||||||2007-12-10|2007-12-11|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Effect of Provisional-Crown Surface Coating on Biofilm Formation|Effect of Provisional-Crown Surface Coating on Biofilm Formation|Completed||Phase 1|1||Hadassah Medical Organization|||||f||||f||||||||||2018-06-01 04:20:21.103611|2018-06-01 04:20:21.103611
NCT00254332|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2015-03-24|2005-11-15|2005-11-16|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|September 2007||2007-09-30|||||Observational|||Effect of Denileukin Diftitox on Immune System in CTCL Patients|Effect of Denileukin Diftitox in T-Regulatory Cells in CTCL Patients|Completed|||10|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 04:20:21.187607|2018-06-01 04:20:21.187607
NCT00254319|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2005-11-14|2005-11-14|2005-11-16|Estimate|||||||2005-11-14|2005-11-16|Estimate||||November 2005|2005-11-30||||||||Interventional|||Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)|Phase II Trial of Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 2|||The Cooper Health System|||||||||||||||||||2018-06-01 04:20:21.24079|2018-06-01 04:20:21.24079
NCT00254306|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2011-07-06|2005-11-15|2005-11-16|Estimate|||||||2011-07-06|2011-07-07|Estimate|January 2006||2006-01-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Functional Brain Imaging in Recreational Users of Ecstasy|Functional Brain Imaging in Recreational Users of Ecstasy|Completed|||18|Actual|Hadassah Medical Organization|||2||f||||t||||||||||2018-06-01 04:20:21.295955|2018-06-01 04:20:21.295955
NCT00254293|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|2013-08-20||2014-03-03|2005-11-15|2005-11-16|Estimate|2014-03-03|2014-04-08|Estimate||||2014-03-03|2014-04-08|Estimate|January 2006||2006-01-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|May 2007|Actual|2007-05-31||Interventional||Baseline includes all participants enrolled and treated. Baseline parameters are presented for each arm but the total value for baseline mean age and standard deviation (SD) includes all participants in LTE. Data are presented by treatment the participant actually received, not to what they were randomized to receive.|Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)|A Study to Assess the Steady-State Trough Serum Concentration, Safety, and Immunogenicity of Abatacept (BMS-188667) Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Who Are Receiving Disease Modifying Ant-Rheumatic Drugs (DMARDs)|Completed||Phase 1/Phase 2|87|Actual|Bristol-Myers Squibb|Error resulted in 4 participants being treated with study drug they were not randomized to receive. ST data were summarized by study drug participants actually received while LT data were summarized by what participants were randomized to receive.|6|||f||||||||||||||2018-06-01 04:20:21.43924|2018-06-01 04:20:21.43924
NCT00254280|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-15|||2008-05-30|2005-11-15|2005-11-16|Estimate|||||||2008-05-30|2008-06-02|Estimate|November 2005||2005-11-30|May 2008|2008-05-31|September 2008||2008-09-30|||||Interventional|||Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial|Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light and Paring Versus Paring Alone - a Randomized Controlled Trial With Blinded Response Evaluation|Unknown status|Active, not recruiting|N/A|||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:20:24.603484|2018-06-01 04:20:24.603484
NCT00254267|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2014-02-26|2005-11-14|2005-11-16|Estimate|||||||2014-02-26|2014-02-27|Estimate|November 2005||2005-11-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|February 2007|Actual|2007-02-28||Interventional|||Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors|An Open-label Phase 2 Study of AMG 706 in Japanese Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate|Completed||Phase 2|35|Actual|Amgen||1|||f||||t||||||||||2018-06-01 04:20:24.809388|2018-06-01 04:20:24.809388
NCT00254254|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2015-02-19|2005-11-14|2005-11-16|Estimate|||||||2015-02-19|2015-02-23|Estimate|February 2006||2006-02-28|January 2015|2015-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus|A Randomized, Single-Blind, Dose-Rising, Placebo-Controlled, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|13|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 04:20:24.897772|2018-06-01 04:20:24.897772
NCT00254228|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2008-10-08|2005-11-14|2005-11-15|Estimate|||||||2008-10-08|2008-10-09|Estimate|November 2005||2005-11-30|October 2008|2008-10-31|December 2007||2007-12-31|||||Interventional|||Safety and Efficacy of the BrainPort™ Balance Device to Improve Balance in Bilateral Vestibular Hypofunction|A Clinical Study to Evaluate the Safety and Efficacy of the BrainPort™ Balance Device When Used to Improve Postural Control in Subjects With Bilateral Vestibular Disorders|Terminated||N/A|60||Wicab||||Terminated due to slow recruitment|f||||||||||||||2018-06-01 04:20:25.133761|2018-06-01 04:20:25.133761
NCT00254215|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-13|||2006-11-27|2005-11-13|2005-11-15|Estimate|||||||2006-11-27|2006-11-28|Estimate|March 2002||2002-03-31|July 2005|2005-07-31|October 2004||2004-10-31|||||Interventional|||Glycemic Load, Weight Loss and Cardiovascular Disease Risk|The Effect of 4 Diets Varying in Glycemic Index, Glycemic Load, Carbohydrate and Protein, on Weight, Body Composition and Cardio-Vascular Risk Factors|Completed||Phase 1|120||University of Sydney|||||f||||||||||||||2018-06-01 04:20:25.216762|2018-06-01 04:20:25.216762
NCT00254202|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2012-07-18|2005-11-10|2005-11-15|Estimate|||||||2012-07-18|2012-07-20|Estimate|November 2005||2005-11-30|July 2012|2012-07-31|March 2007||2007-03-31|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.|Completed||Phase 3|600||Vanda Pharmaceuticals|||||||||||||||||||2018-06-01 04:20:25.302084|2018-06-01 04:20:25.302084
NCT00254189|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2006-05-17|2005-11-14|2005-11-15|Estimate|||||||2006-05-17|2006-05-19|Estimate|December 2002||2002-12-31|May 2006|2006-05-31|October 2004||2004-10-31|||||Interventional|||Study Evaluating Effects of Levonorgestrel and Ethinyl Estradiol on Ovulation|A Single Center, Open-Label Study to Evaluate the Effects on Ovulation of Levonorgestrel 90mg and Ethinyl Estradiol 20mg in a Daily, Continuous, Oral Regimen.|Completed||Phase 2|60||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:20:25.423913|2018-06-01 04:20:25.423913
NCT00254176|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2010-02-25|2005-11-14|2005-11-15|Estimate|||||||2010-02-25|2010-02-26|Estimate|September 2006||2006-09-30|February 2010|2010-02-28|July 2011|Anticipated|2011-07-31|March 2011|Anticipated|2011-03-31||Interventional|||Cysteine Supplementation in Critically Ill Neonates|Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates|Unknown status|Active, not recruiting|Phase 2/Phase 3|108|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 04:20:25.478625|2018-06-01 04:20:25.478625
NCT00254163|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2016-02-02||2016-09-15|2005-11-14|2005-11-15|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||ITT population|Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients|A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia|Completed||Phase 3|184|Actual|US Oncology Research||2|||f||||f||||||||||2018-06-01 04:20:25.612673|2018-06-01 04:20:25.612673
NCT00254150|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2005-11-14|2005-11-14|2005-11-15|Estimate|||||||2005-11-14|2005-11-15|Estimate|May 1995||1995-05-31|April 1995|1995-04-30|December 1996||1996-12-31|||||Interventional|||A Therapy to Reduce Morbidity and Hospital Length of Stay of High-Risk Surgical Patients|Goal-Directed Intraoperative Therapy Reduces Morbidity and Length of Hospital Stay in High Risk Surgical Patients|Completed||Phase 2|130||Università Politecnica delle Marche|||||f||||||||||||||2018-06-01 04:20:26.248799|2018-06-01 04:20:26.248799
NCT00254137|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2010-10-27|2005-11-14|2005-11-15|Estimate|||||||2010-10-27|2010-10-28|Estimate|September 2004||2004-09-30|September 2004|2004-09-30|November 2006||2006-11-30|||||Interventional|||Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.|A Randomized Phase II-study to Evaluate the Safety and Efficacy of Capecitabine Plus Irinotecan Plus Cetuximab Compared to Capecitabine Plus Oxaliplatin Plus Cetuximab in First-line Treatment of Patients With Metastatic Colorectal Cancer.|Completed||Phase 2|92||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 04:20:26.30964|2018-06-01 04:20:26.30964
NCT00254124|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2005-11-14|2005-11-14|2005-11-15|Estimate|||||||2005-11-14|2005-11-15|Estimate|April 2004||2004-04-30|November 2005|2005-11-30|December 2004||2004-12-31|||||Interventional|||Use of a Portion Control Food Tool to Induce Weight Loss in Obese Type 2 Diabetics.|Efficacy of a Food Portion Control Tool to Induce Weight Loss and Decrease Hypoglycemic Medication Requirements Amongst Obese Type 2 Diabetics.|Completed||N/A|130||University of Calgary|||||f||||||||||||||2018-06-01 04:20:26.44635|2018-06-01 04:20:26.44635
NCT00254111|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2005-11-14|2005-11-14|2005-11-15|Estimate|||||||2005-11-14|2005-11-15|Estimate|July 2005||2005-07-31|November 2005|2005-11-30|July 2006||2006-07-31|||||Interventional|||Study of the Use of Laser Light to Treat Osteoarthritis of the Hand.|Ultra Probe Laser System Osteoarthritis of the Hand Clinical Study.|Unknown status|Recruiting|N/A|100||TriTech Manufacturing|||||f||||||||||||||2018-06-01 04:20:26.534844|2018-06-01 04:20:26.534844
NCT00254085|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2005-11-14|2005-11-14|2005-11-15|Estimate|||||||2005-11-14|2005-11-15|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|March 2006||2006-03-31|||||Interventional|||Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.|Multiple Substitution of First Phase Insulin Response With a Rapid Action Insuli Analogue in Patient With Newly Diagnosed Type 2 Diabtes.|Unknown status|Recruiting|Phase 4|20||University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:20:26.622835|2018-06-01 04:20:26.622835
NCT00254072|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|2009-11-05||2010-02-11|2005-11-14|2005-11-15|Estimate|2009-12-11|2010-01-18|Estimate||||2010-02-11|2010-02-18|Estimate|January 2007||2007-01-31|February 2010|2010-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|EEA-LGB||Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)|Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)a Prospective Randomized Comparison of the 3.5 mm vs 4.8 mm Circular Stapler for Creation of the Gastrojejunostomy in Prevention of Staple Line Hemorrhage During Laparoscopic Gastric Bypass|Completed||N/A|355|Actual|University of California, Irvine|"Difficulty discerning GI bleeding attributed to the gastrojejunostomy vs gastric pouch staple-line~Technological differences between 3.5mm vs 4.8 mm stapler~Operative techniques varying between study sites~Study size may be underpowered"|2|||f||||f||||||||||2018-06-01 04:20:26.719776|2018-06-01 04:20:26.719776
NCT00254059|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2005-11-10|2005-11-10|2005-11-15|Estimate|||||||2005-11-10|2005-11-15|Estimate||||November 2005|2005-11-30|December 2004||2004-12-31|||||Interventional|||A Randomized Study to Compare Polysomnography With Overnight Home Oximetry and Auto – CPAP for Sleep Apnea|A Randomized Study to Compare Polysomnography With Overnight Home Oximetry and Auto – CPAP for Diagnosis and Nasal CPAP Titration in Patients With a High Probability of Obstructive Sleep Apnea.|Completed||N/A|60||University of British Columbia|||||f||||||||||||||2018-06-01 04:20:27.033409|2018-06-01 04:20:27.033409
NCT00254046|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2014-06-19|2005-11-10|2005-11-15|Estimate|||||||2014-06-19|2014-06-20|Estimate|November 2005||2005-11-30|June 2014|2014-06-30|July 2008|Actual|2008-07-31|February 2007|Actual|2007-02-28||Interventional|||TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.|A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treatment to no Treatment Options.|Completed||Phase 3|616|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||t||||||||||2018-06-01 04:20:27.115412|2018-06-01 04:20:27.115412
NCT00254033|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2017-04-26|2005-11-10|2005-11-15|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2003||2003-10-31|April 2017|2017-04-30|October 2006|Actual|2006-10-31|||||Interventional|||Apathy Associated With Alzheimer's Disease|The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease|Completed||Phase 4|40||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:20:27.263276|2018-06-01 04:20:27.263276
NCT00254020|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2017-04-26|2005-11-10|2005-11-15|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2005||2005-06-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|January 2011|Actual|2011-01-31||Interventional|||The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression|The Role of Cytokine-Serotonin Interactions in Post-Stroke Depression|Completed||Phase 4|138|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-06-01 04:20:27.32306|2018-06-01 04:20:27.32306
NCT00254007|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2017-04-26|2005-11-10|2005-11-15|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2003||2003-07-31|April 2017|2017-04-30|May 2010|Actual|2010-05-31|December 2005|Actual|2005-12-31||Interventional|||Depression and Traumatic Brain Injury|The Serotonin Transporter Gene Polymorphism and Major Depression Following Traumatic Brain Injury|Completed||Phase 4|200|Anticipated|Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:20:27.388214|2018-06-01 04:20:27.388214
NCT00253994|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2007-09-04|2005-11-14|2005-11-15|Estimate|||||||2007-09-04|2007-09-05|Estimate|August 2003||2003-08-31|September 2007|2007-09-30|December 2004|Actual|2004-12-31|||||Interventional|||Auricular Acupuncture for Acute Pain|Auricular Acupuncture in the Treatment of Acute Pain Syndromes (AATAPS) Pilot|Completed||N/A|100||Samueli Institute for Information Biology|||||f||||||||||||||2018-06-01 04:20:27.446497|2018-06-01 04:20:27.446497
NCT00253981|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2013-08-28||2016-05-10|2005-11-14|2005-11-15|Estimate|2014-05-20|2014-06-19|Estimate||||2016-05-10|2016-06-13|Estimate|November 2005||2005-11-30|May 2016|2016-05-31|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|MilCAM||Light Therapy in the Treatment of Leg Pain|Monochromatic Near-Infrared Light Energy (MIRE) in the Treatment of Tibial Stress Reaction|Terminated||N/A|30|Actual|Samueli Institute for Information Biology||2||Enrollment not achieved succesfully|f||||t||||||||||2018-06-01 04:20:27.501276|2018-06-01 04:20:27.501276
NCT00253968|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14||2016-02-02|2016-02-02|2005-11-14|2005-11-15|Estimate||||2016-02-02|2016-03-01|Estimate|2016-02-02|2016-03-01|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|GEMS||Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia|Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 3|967|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:20:27.806061|2018-06-01 04:20:27.806061
NCT00253955|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2008-11-07|2005-11-14|2005-11-15|Estimate|||||||2008-11-07|2008-11-10|Estimate|June 2003||2003-06-30|November 2008|2008-11-30|November 2007|Actual|2007-11-30|May 2007|Actual|2007-05-31||Interventional|||Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia|An Open-Label, Multicenter, Multinational, Centrally Randomized, Two-Arm Parallel-Group Study to Demonstrate the Non-Inferiority in Clinical Efficacy of Levofloxacin 750mg od in Comparison With Piperacillin/Tazobactam 4g/500mg Every 8 Hours in the Treatment of Mild to Moderate Hospital-Acquired Pneumonia Adult Patients in Both General Wards and ICU (Intensive Care Unit)|Completed||Phase 3|460|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:20:27.903181|2018-06-01 04:20:27.903181
NCT00253942|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2005-11-14|2005-11-14|2005-11-15|Estimate|||||||2005-11-14|2005-11-15|Estimate|November 2005||2005-11-30|October 2005|2005-10-31||||||||Interventional|||Safety and Efficacy Study of Bee Venom to Treat Knee Osteoarthritis|A Randomized, Double-Blind, Histamine-Controlled, Phase 3 Study to Determine the Safety and Efficacy of Bee Venom in the Treatment of Knee Osteoarthritis|Unknown status|Recruiting|Phase 3|40||Rheumatology Therapeutics Medical Center|||||f||||||||||||||2018-06-01 04:20:28.008426|2018-06-01 04:20:28.008426
NCT00253929|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2007-04-04|2005-11-11|2005-11-15|Estimate|||||||2007-04-04|2007-04-05|Estimate|November 2005||2005-11-30|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia|The Influence of the 1976T>C Polymorphism in the Adenosine A2A Receptor Gene on Adenosine-Induced Vasodilation and the Influence of the 34C>T Polymorphism in the AMP Deaminase Gene on Post-Occlusive Reactive Hyperemia.|Completed||N/A|100||Radboud University|||||f||||||||||||||2018-06-01 04:20:28.162031|2018-06-01 04:20:28.162031
NCT00253916|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2017-05-09|2005-11-10|2005-11-15|Estimate|||||||2017-05-09|2017-05-11|Actual|June 2002||2002-06-30|May 2017|2017-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Exercise in Men Receiving Radiation Therapy for Prostate Cancer.|Exercise in Men Receiving Radiation Therapy for Prostate Cancer: Effects on Fatigue, Toxicity, Body Composition, Muscular Fitness, Cardiorespiratory Fitness and Quality of Life.|Completed||N/A|121|Actual|Ottawa Hospital Research Institute||3|||f||||||||||||||2018-06-01 04:20:28.25453|2018-06-01 04:20:28.25453
NCT00253903|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2010-11-29|2005-11-14|2005-11-15|Estimate|||||||2010-11-29|2010-11-30|Estimate|November 2005||2005-11-30|November 2010|2010-11-30|September 2008|Actual|2008-09-30|November 2007|Actual|2007-11-30||Interventional|EPLILONG||Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year|Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study Followed by an Open Treatment Phase Extension With Eplivanserin for a 40-week Period|Completed||Phase 3|1155|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:20:28.331219|2018-06-01 04:20:28.331219
NCT00253890|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2012-08-01||2013-10-22|2005-11-14|2005-11-15|Estimate|2013-10-22|2013-12-11|Estimate||||2013-10-22|2013-12-11|Estimate|October 2005||2005-10-31|October 2013|2013-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Insomnia and Drug Relapse Risk|Insomnia and Drug Relapse Risk|Completed||Phase 3|137|Actual|Butler Hospital||2|||f||||t||||||||||2018-06-01 04:20:28.444072|2018-06-01 04:20:28.444072
NCT00253877|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2010-08-19|2005-11-10|2005-11-15|Estimate|||||||2010-08-19|2010-08-23|Estimate|July 2003||2003-07-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Comparison of a Resurfacing Hip System to Standard Total Hip Arthroplasty|A Prospective, Multi-Centre, Historical Control Trial Comparing the Conserve® Plus Resurfacing Hip System to Standard Total Hip Arthroplasty.|Completed||Phase 4|200|Actual|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-06-01 04:20:28.698803|2018-06-01 04:20:28.698803
NCT00253864|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2018-03-29|2005-11-10|2005-11-15|Estimate|||||||2018-03-29|2018-03-30|Actual|November 2004||2004-11-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Functional Outcomes Following Shoulder Surgery: A Prospective Database|Functional Outcome Following Shoulder Surgery: A Prospective Database|Recruiting|||2500|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:20:28.788284|2018-06-01 04:20:28.788284
NCT00253851|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2012-04-13|2005-11-10|2005-11-15|Estimate|||||||2012-04-13|2012-04-17|Estimate|July 2003||2003-07-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery|Multi-centre, Double-blind, Randomized, Controlled Trial Comparing Intra-operative Regional Heparinization to Placebo for the Prevention of Deep Vein Thrombosis Following Total Knee Arthroplasty|Completed||Phase 4|30|Actual|Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 04:20:28.860858|2018-06-01 04:20:28.860858
NCT00253838|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2017-09-20|2005-11-10|2005-11-15|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2001||2001-10-31|September 2017|2017-09-30|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|||A Comparison of Two Type of Stems in Revision Hip Arthroplasty|A Randomized Controlled Trial Comparing a Titanium to a Cobalt Chrome Femoral Stem in Revision Hip Arthroplasty: A Pilot Study|Completed||N/A|39|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-06-01 04:20:28.931477|2018-06-01 04:20:28.931477
NCT00253825|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2005-12-20|2005-11-14|2005-11-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|November 2005||2005-11-30|August 2005|2005-08-31|July 2006||2006-07-31|||||Interventional|||mCIMT and Eye Patching for Neglect Rehabilitation Post Stroke: A Longitudinal Study of Separate and Combined Effects|Modified Constraint-Induced Movement Therapy and Eye Patching for Neglect Rehabilitation Post Stroke: A Longitudinal Study of Separate and Combined Effects|Unknown status|Recruiting|Phase 1/Phase 2|60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:20:29.015784|2018-06-01 04:20:29.015784
NCT00253812|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2007-09-21|2005-11-11|2005-11-15|Estimate|||||||2007-09-21|2007-09-24|Estimate|November 2005||2005-11-30|September 2007|2007-09-30||||||||Interventional|||Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy|Adenoma Detection Rate in Rectal Remnants of Familial Polyposis (FAP) Patients Using Standard (White Light), Auto-Fluorescence (AFI), Narrow Band Imaging (NBI) and Chromoscopic Endoscopy|Unknown status|Recruiting|N/A|60|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:20:29.088424|2018-06-01 04:20:29.088424
NCT00253799|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2007-06-21|2005-11-10|2005-11-15|Estimate|||||||2007-06-21|2007-06-25|Estimate|December 2005||2005-12-31|June 2007|2007-06-30||||||||Interventional|||A Safety Study of Hylan GF-20 to Treat Shoulder Osteoarthritis|Prospective, Single Arm, Pilot Study Evaluating the Safety and Efficacy of Hyaluronan (Hylan GF-20) in Patients With Painful Shoulder Osteoarthritis|Unknown status|Active, not recruiting|Phase 4|35|Anticipated|Northwestern Ophthalmic Institute S.C.|||||f||||t||||||||||2018-06-01 04:20:29.151714|2018-06-01 04:20:29.151714
NCT00253786|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2018-04-02|2005-11-10|2005-11-15|Estimate|||||||2018-04-02|2018-04-03|Actual|May 3, 2005|Actual|2005-05-03|April 2018|2018-04-30|November 27, 2014|Actual|2014-11-27|November 27, 2014|Actual|2014-11-27||Interventional|||Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy|Study for the Effectiveness of Intensive Therapy for Diabetic Nephropathy in Unblinded, Randomized Intergroup Comparison Study.|Completed||N/A|312|Actual|Okayama University||4|||f||||||||||||||2018-06-01 04:20:29.203714|2018-06-01 04:20:29.203714
NCT00253773|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2010-01-12|2005-11-14|2005-11-15|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2005||2005-01-31|January 2010|2010-01-31|November 2007|Actual|2007-11-30|||||Interventional|||Metabolic Effects of Chemical Interactions in Toxicity|Metabolic Effects of Chemical Interactions in Toxicity|Completed||N/A|15|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:20:29.281391|2018-06-01 04:20:29.281391
NCT00253760|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2010-03-17|2005-11-14|2005-11-15|Estimate|||||||2010-03-17|2010-03-18|Estimate|February 2004||2004-02-29|March 2010|2010-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Metabolic Analysis in Human Sulfur Amino Acid Deficiency||Completed||N/A|15|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:20:29.346609|2018-06-01 04:20:29.346609
NCT00253747|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-13|2012-07-16||2012-08-17|2005-11-13|2005-11-15|Estimate|2012-08-17|2012-09-17|Estimate||||2012-08-17|2012-09-17|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers With ADHD|Completed||Phase 3|255|Actual|University of Cincinnati||2|||f||||t||||||||||2018-06-01 04:20:29.419291|2018-06-01 04:20:29.419291
NCT00253734|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-05-30|2005-11-11|2005-11-15|Estimate|||||||2013-05-30|2013-06-03|Estimate|November 2005||2005-11-30|July 2008|2008-07-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||Immunogenicity and Safety of Different Doses of Fluzone® Influenza|Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone® in Healthy Adults|Completed||Phase 2|217|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 04:20:29.775753|2018-06-01 04:20:29.775753
NCT00253721|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2017-04-19|2005-11-11|2005-11-15|Estimate|||||||2017-04-19|2017-04-21|Actual|May 1998||1998-05-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Melphalan With BBBD in Treating Patients With Brain Malignancies|Intra-Arterial Melphalan (L-Phenylalanine Mustard) Administered in Conjunction With Osmotic Blood-Brain Barrier Disruption in Patients With Brain Malignancies: A Phase I Study|Terminated||Phase 1|21|Actual|OHSU Knight Cancer Institute||1||Other competing clinical trials affecting enrollment|f||||t||||||||||2018-06-01 04:20:29.847419|2018-06-01 04:20:29.847419
NCT00253708|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2017-03-30||2017-06-29|2005-11-11|2005-11-15|Estimate|2017-06-29|2017-08-07|Actual||||2017-06-29|2017-08-07|Actual|December 1, 2004|Actual|2004-12-01|June 2017|2017-06-30|January 1, 2013|Actual|2013-01-01|January 1, 2013|Actual|2013-01-01||Interventional|||Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer|Body-Based Complementary Therapies for Patients With Cancer|Completed||N/A|39|Actual|Beth Israel Deaconess Medical Center|Small sample size limited statistical power. Pre–post intervention data collection was not blinded. Patient bias in massage group. Heterogeneity in type and stage of cancer may have resulted in variation of the effects of the interventions.|3|||f||||f|f|f||||||No||2018-06-01 04:20:29.932169|2018-06-01 04:20:29.932169
NCT00253695|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2013-03-26|2005-11-10|2005-11-15|Estimate|||||||2013-03-26|2013-03-28|Estimate|July 2004||2004-07-31|March 2013|2013-03-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Sleep, HIV Disease Progression, and Function in HIV Infected Children and Adolescents|Sleep Studies in HIV+ Older Children/Adolescents|Completed|||90|Actual|Baylor College of Medicine|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 04:20:30.482525|2018-06-01 04:20:30.482525
NCT00253682|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2014-03-17|2005-11-10|2005-11-15|Estimate|||||||2014-03-17|2014-03-18|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|CHAART-1||Effects of Highly Active Anti-Retroviral Therapy on Cardiovascular Health in Infants of HIV-Infected Mothers|Cardiac Status of HAART Exposed Infants of HIV-Infected Mothers (CHAART I)|Completed|||167|Actual|University of Miami|||2||f||||t||||||Samples Without DNA|"~     Blood samples were collected for analysis of cardiac biomarkers high sensitivity C REactive~     PRotein (hsCRP) and N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP).~   "|||2018-06-01 04:20:30.568633|2018-06-01 04:20:30.568633
NCT00253669|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2012-05-24|2005-11-11|2005-11-15|Estimate|||||||2012-05-24|2012-05-28|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas|Pilot Study of Thrombophilic States in Newly Diagnosed Patients With High-Grade Gliomas|Completed|||110|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:20:30.648606|2018-06-01 04:20:30.648606
NCT00253643|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2014-12-19||2017-04-14|2005-11-11|2005-11-15|Estimate|2015-02-13|2015-02-18|Estimate||||2017-04-14|2017-04-18|Actual|July 2005||2005-07-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer|Catechins and Omega-3 Fatty Acids Impact on Fatty Acid Synthase Activity in the Prostate: A Randomized Controlled Trial|Completed||N/A|89|Actual|OHSU Knight Cancer Institute||4|||f||||t||||||||||2018-06-01 04:20:30.80697|2018-06-01 04:20:30.80697
NCT00253630|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2017-12-20||2018-02-05|2005-11-11|2005-11-15|Estimate|2018-02-05|2018-03-06|Actual||||2018-02-05|2018-03-06|Actual|September 2005||2005-09-30|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||Two enrolled patients were ineligible due to diffuse B-cell lymphoma at start of treatment. Treatment was changed for these ineligible patients (within 2 months of enrollment) before a response evaluation. These patients were removed and are not included in the analysis.|Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma|A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)|Two enrolled patients were ineligible due to diffuse B-cell lymphoma at start of treatment. Their treatment was changed (within 2 months of enrollment) before a response evaluation. These patients were removed and are not included in the analysis.|1|||f||||||||||||||2018-06-01 04:20:31.264081|2018-06-01 04:20:31.264081
NCT00253617|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-04-02|2005-11-11|2005-11-15|Estimate|||||||2013-04-02|2013-04-04|Estimate||||December 2006|2006-12-31||||||||Interventional|||Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery|Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma|Withdrawn||Phase 3|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:20:31.668829|2018-06-01 04:20:31.668829
NCT00253591|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-12-18|2005-11-11|2005-11-15|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 2005||2005-06-30|July 2007|2007-07-31|December 2009|Actual|2009-12-31|December 2007|Actual|2007-12-31||Interventional|||Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Randomised Phase II/III Trial of Induction Chemotherapy Followed by Continuous Hyperfractionated Accelerated Radiotherapy (CHART) Versus CHART Alone in Patients With Inoperable Non-Small Cell Lung Cancer|Completed||Phase 2/Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:20:31.747399|2018-06-01 04:20:31.747399
NCT00253578|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-01-04|2005-11-11|2005-11-15|Estimate|||||||2013-01-04|2013-01-07|Estimate|March 2006||2006-03-31|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients With Relapsing or Resistant Multiple Myeloma|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:20:31.833261|2018-06-01 04:20:31.833261
NCT00253565|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-04-04|2005-11-11|2005-11-15|Estimate|||||||2013-04-04|2013-04-08|Estimate|August 2003||2003-08-31|April 2013|2013-04-30|July 2010|Actual|2010-07-31|July 2006|Actual|2006-07-31||Interventional|||Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies|Completed||Phase 1|25|Actual|Duke University|||||f||||||||||||||2018-06-01 04:20:31.916584|2018-06-01 04:20:31.916584
NCT00253552|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2012-05-24|2005-11-11|2005-11-15|Estimate|||||||2012-05-24|2012-05-28|Estimate|May 2004||2004-05-31|June 2010|2010-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders|A Pilot Study of Using Filgrastim-Primed Bone Marrow in Human Leukocyte Antigen (HLA) Matched Related Donor Allogenetic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies|Terminated||N/A|4|Actual|OHSU Knight Cancer Institute||||Terminated at request of PI as study was outdated.|f||||||||||||||2018-06-01 04:20:31.977895|2018-06-01 04:20:31.977895
NCT00253539|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2011-04-11|2005-11-11|2005-11-15|Estimate|||||||2011-04-11|2011-04-13|Estimate|January 2002||2002-01-31|April 2011|2011-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer|A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer|Completed||Phase 2|3|Actual|The Cleveland Clinic||3|||f||||t||||||||||2018-06-01 04:20:32.090669|2018-06-01 04:20:32.090669
NCT00253526|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2015-04-27|2005-11-11|2005-11-15|Estimate|||||||2015-04-27|2015-04-28|Estimate||||December 2006|2006-12-31||||||||Interventional|||Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer|Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:20:32.1625|2018-06-01 04:20:32.1625
NCT00253513|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2010-11-16||2012-05-24|2005-11-11|2005-11-15|Estimate|2011-01-14|2011-02-11|Estimate||||2012-05-24|2012-06-01|Estimate|June 2005||2005-06-30|February 2011|2011-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome|A Study of a Reduced-Intensity Conditioning Regimen With Treosulfan and Fludarabine for Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Leukemia|Completed||Phase 1/Phase 2|60|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 04:20:32.232712|2018-06-01 04:20:32.232712
NCT00253500|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-01-02|2005-11-11|2005-11-15|Estimate|||||||2013-01-02|2013-01-03|Estimate|June 2002||2002-06-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|September 2005|Actual|2005-09-30||Interventional|||Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer|Prediction of Response or Resistance to Dose Intensified Pre-Operative Epirubicin Therapy of Operable Breast Cancer|Completed||Phase 2|15|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:20:32.468034|2018-06-01 04:20:32.468034
NCT00253487|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2014-01-03|2005-11-11|2005-11-15|Estimate|||||||2014-01-03|2014-01-06|Estimate|August 2005||2005-08-31|January 2006|2006-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas|A Pilot Study of Temozolomide and O-Benzylguanine for Treatment of High-Grade Glioma, Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:20:32.588173|2018-06-01 04:20:32.588173
NCT00253474|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2012-03-28|2005-11-11|2005-11-15|Estimate|||||||2012-03-28|2012-03-29|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|||||Interventional|||PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma|A Phase I Trial of Peginterferon Alfa-2b (PEG-Intron) for Plexiform Neurofibromas|Completed||Phase 1|36|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:20:32.654585|2018-06-01 04:20:32.654585
NCT00253461|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2012-03-16|2005-11-11|2005-11-15|Estimate|||||||2012-03-16|2012-03-20|Estimate|December 2004||2004-12-31|March 2012|2012-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||11C Topotecan PET Imaging|Positron Emission Tomography Using 11C Topotecan in Predicting Response to Treatment in Patients With Brain Metastases Due to Ovarian, Small Cell Lung, or Other Cancer|Terminated||Early Phase 1|7|Actual|Case Comprehensive Cancer Center||||Drugs unavailable:unable to make radioactive topotecan|f||||t||||||||||2018-06-01 04:20:32.722152|2018-06-01 04:20:32.722152
NCT00253448|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2011-06-29||2011-08-25|2005-11-11|2005-11-15|Estimate|2011-06-29|2011-07-26|Estimate||||2011-08-25|2011-08-29|Estimate|December 2002||2002-12-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|||Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme|Phase II Trial of Conventional Radiotherapy With Stereotactic Radiosurgery to High Risk Tumor Regions as Determined by Functional Imaging in Patients With Glioblastoma Multiforme|Completed||Phase 2|35|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:20:32.887473|2018-06-01 04:20:32.887473
NCT00253435|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2014-08-25||2016-08-23|2005-11-11|2005-11-15|Estimate|2016-08-23|2016-08-24|Estimate||||2016-08-23|2016-08-24|Estimate|September 2005||2005-09-30|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional||Number of patients who signed the consent form and started treatment.|N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma|I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma|Completed||Phase 2|50|Actual|Children's Hospital Los Angeles||1|||f||||t||||||||||2018-06-01 04:20:33.094067|2018-06-01 04:20:33.094067
NCT00253422|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2011-05-14|2005-11-11|2005-11-15|Estimate|||||||2011-05-14|2011-05-17|Estimate|March 2004||2004-03-31|May 2011|2011-05-31||||May 2016|Anticipated|2016-05-31||Interventional|||Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex™) With or Without Concomitant Anastrozole (Arimidex™) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors|Unknown status|Active, not recruiting|Phase 3|750|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:20:33.974211|2018-06-01 04:20:33.974211
NCT00253409|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2009-07-11|2005-11-11|2005-11-15|Estimate|||||||2009-07-11|2009-07-14|Estimate|May 2005||2005-05-31|July 2009|2009-07-31||||June 2011|Anticipated|2011-06-30||Interventional|||Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery|Mesothelioma and Radical Surgery Trial|Unknown status|Active, not recruiting|N/A|670|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:20:34.054755|2018-06-01 04:20:34.054755
NCT00253396|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2009-03-09|2005-11-14|2005-11-15|Estimate|||||||2009-03-09|2009-03-10|Estimate|October 2005||2005-10-31|May 2007|2007-05-31|January 2007||2007-01-31|||||Interventional|||Patients Preference With Self-Injection: The PRISM Study|THE PRISM Study-Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Perioperative Bridging Anticoagulation: the Patient Preference for Self-Injection Study and Related Measurements|Completed||Phase 4|100|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 04:20:34.149482|2018-06-01 04:20:34.149482
NCT00253383|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2014-12-18|2005-11-11|2005-11-15|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2003||2003-01-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients|Improving Palliative Care for Patients With Cancer|Completed||N/A|329|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 04:20:34.234764|2018-06-01 04:20:34.234764
NCT00253370|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|2014-05-21||2014-11-19|2005-11-11|2005-11-15|Estimate|2014-11-19|2014-11-24|Estimate||||2014-11-19|2014-11-24|Estimate|October 2005||2005-10-31|December 2013|2013-12-31|September 2010|Actual|2010-09-30|May 2008|Actual|2008-05-31||Interventional||All 44 patients started treatment and were considered eligible and hence were included in the analysis.|Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer|A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 04:20:34.360829|2018-06-01 04:20:34.360829
NCT00253357|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-13|||2007-12-17|2005-11-14|2005-11-15|Estimate|||||||2007-12-17|2007-12-21|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Observational|||PROSPECT: Predictors of Response to Cardiac Re-Synchronization Therapy|Predictors of Response to Cardiac Re-Synchronization Therapy|Completed|||450||Medtronic Cardiac Rhythm and Heart Failure|||||f||||||||||||||2018-06-01 04:20:34.948677|2018-06-01 04:20:34.948677
NCT00253344|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2010-06-10|2005-11-11|2005-11-15|Estimate|||||||2010-06-10|2010-06-11|Estimate|June 2005||2005-06-30|June 2010|2010-06-30|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|33|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:20:35.037968|2018-06-01 04:20:35.037968
NCT00253318|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-04-04|2005-11-11|2005-11-15|Estimate|||||||2013-04-04|2013-04-08|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer|Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer|Terminated||Phase 1|15|Actual|M.D. Anderson Cancer Center||1||Toxicity and Lack of Efficacy|f||||f||||||||||2018-06-01 04:20:35.173347|2018-06-01 04:20:35.173347
NCT00253305|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-13|||2007-05-29|2005-11-13|2005-11-15|Estimate|||||||2007-05-29|2007-05-30|Estimate|September 2005||2005-09-30|May 2007|2007-05-31||||||||Interventional|||Topical Gel Anti-Fungal Agent for Tinea Unguium|Phase IIB Efficacy and Safety Study of Four Topical Gel Formulations of Anti-Fungal Agents, MQX-5858, MQX-5859, MQX-5866, and MQX-5867, Versus Vehicle in the Treatment of Tinea Unguium.|Completed||Phase 2|75||MediQuest Therapeutics|||||||||||||||||||2018-06-01 04:20:35.281288|2018-06-01 04:20:35.281288
NCT00253292|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2011-07-27|2005-11-11|2005-11-15|Estimate|||||||2011-07-27|2011-07-28|Estimate|January 1997||1997-01-31|July 2011|2011-07-31|December 2007|Actual|2007-12-31|||||Observational|||Psychometric Study of Outcomes Instruments|Psychometric Study of Outcomes Instruments|Terminated|||40|Actual|Massachusetts General Hospital||||Unable to recruit necessary sample size|f||||f||||||||||2018-06-01 04:20:35.340168|2018-06-01 04:20:35.340168
NCT00253279|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2009-08-12|2005-11-11|2005-11-15|Estimate|||||||2009-08-12|2009-08-13|Estimate|November 2009||2009-11-30|August 2009|2009-08-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|||Alterations in Protein Synthesis Rates of Burn Patients Measured Over Time Using PET Scans|A Quantitative Study of the Metabolic Alterations in Protein Synthesis Rate That Occur in Burn Patients Over the Time Course of Their Injury Using Positron Emission Tomography.|Unknown status|Not yet recruiting||64|Anticipated|National Institute of General Medical Sciences (NIGMS)|||2||f||||t||||||||||2018-06-01 04:20:35.424725|2018-06-01 04:20:35.424725
NCT00253266|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2015-04-07|2005-11-11|2005-11-15|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2008||2008-04-30|April 2015|2015-04-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Venlafaxine Augmentation in Treatment Resistant Depression|Comparison of Venlafaxine Augmentation With Quetiapine v.s. Placebo in Treatment Resistant Depression|Completed||Phase 4|126|Actual|Max-Planck-Institute of Psychiatry||2|||f||||t||||||||||2018-06-01 04:20:35.49766|2018-06-01 04:20:35.49766
NCT00253253|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2008-05-21|2005-11-14|2005-11-15|Estimate|||||||2008-05-21|2008-05-22|Estimate|August 2006||2006-08-31|May 2008|2008-05-31|January 2007||2007-01-31|||||Observational|||Long-Term Outcome in Congenital Undescended Testis After Surgical Treatment by Orchidopexy|Long-Term Outcome in Congenital Undescended Testis After Surgical Treatment by Orchidopexy|Completed|||181|Actual|Medical Center Alkmaar|||||f||||||||||||||2018-06-01 04:20:35.583344|2018-06-01 04:20:35.583344
NCT00253240|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2007-07-20|2005-11-10|2005-11-15|Estimate|||||||2007-07-20|2007-07-23|Estimate|September 2004||2004-09-30|July 2007|2007-07-31|September 2005|Actual|2005-09-30|||||Observational|||Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population|Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population - An Evaluation Project|Completed|||75|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 04:20:35.624458|2018-06-01 04:20:35.624458
NCT00253227|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2011-05-17|2005-11-10|2005-11-15|Estimate|||||||2011-05-17|2011-05-18|Estimate|July 1997||1997-07-31|November 2010|2010-11-30|December 1998|Actual|1998-12-31|||||Interventional|||A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease|Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial|Completed||Phase 3|387|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:20:35.689858|2018-06-01 04:20:35.689858
NCT00253214|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2011-05-19|2005-11-10|2005-11-15|Estimate|||||||2011-05-19|2011-05-23|Estimate|March 2001||2001-03-31|November 2010|2010-11-30|July 2002|Actual|2002-07-31|||||Interventional|||Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation|Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation|Completed||Phase 3|973|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:20:35.772515|2018-06-01 04:20:35.772515
NCT00253201|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2011-05-17|2005-11-10|2005-11-15|Estimate|||||||2011-05-17|2011-05-18|Estimate||||November 2010|2010-11-30|October 1997|Actual|1997-10-31|||||Interventional|||A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease|Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease|Completed||Phase 3|636|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:20:35.821986|2018-06-01 04:20:35.821986
NCT00253188|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2011-05-17|2005-11-10|2005-11-15|Estimate|||||||2011-05-17|2011-05-18|Estimate|February 1997||1997-02-28|November 2010|2010-11-30|December 1998|Actual|1998-12-31|||||Interventional|||A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease|Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease|Completed||Phase 3|653|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:20:36.015898|2018-06-01 04:20:36.015898
NCT00253175|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2010-04-26|2005-11-10|2005-11-15|Estimate|||||||2010-04-26|2010-04-28|Estimate|October 2000||2000-10-31|April 2010|2010-04-30|December 2001|Actual|2001-12-31|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine|A Comparison Of The Efficacy And Safety Of Topamax® (Topiramate) Tablets Versus Placebo For The Prophylaxis Of Migraine|Completed||Phase 3|211|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:20:36.08618|2018-06-01 04:20:36.08618
NCT00253162|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2011-01-27|2005-11-10|2005-11-15|Estimate|||||||2011-01-27|2011-01-28|Estimate|March 2001||2001-03-31|January 2011|2011-01-31|September 2002|Actual|2002-09-30|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol|The Efficacy And Safety Of Flexible Dose Ranges Of Risperidone Versus Placebo Or Haloperidol In The Treatment Of Manic Episodes Associated With Bipolar I Disorder.|Completed||Phase 3|439|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:20:36.139045|2018-06-01 04:20:36.139045
NCT00253149|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2011-01-20|2005-11-10|2005-11-15|Estimate|||||||2011-01-20|2011-01-24|Estimate||||January 2011|2011-01-31|April 1999|Actual|1999-04-30|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder|The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder|Completed||Phase 3|158|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:20:36.193136|2018-06-01 04:20:36.193136
NCT00253136|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2010-12-02|2005-11-10|2005-11-15|Estimate|||||||2010-12-02|2010-12-03|Estimate|November 1999||1999-11-30|December 2010|2010-12-31|December 2000|Actual|2000-12-31|||||Interventional|||A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia|Risperidone Depot (Microspheres) vs. Placebo in the Treatment of Subjects With Schizophrenia|Completed||Phase 3|458|Actual|Janssen, LP|||||||||||||||||||2018-06-01 04:20:36.260591|2018-06-01 04:20:36.260591
NCT00253123|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2010-12-02|2005-11-10|2005-11-15|Estimate|||||||2010-12-02|2010-12-03|Estimate||||December 2010|2010-12-31|March 1997|Actual|1997-03-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia|A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia|Completed||Phase 3|626|Actual|Janssen, LP|||||||||||||||||||2018-06-01 04:20:36.39939|2018-06-01 04:20:36.39939
NCT00253110|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2012-08-03|2005-11-10|2005-11-15|Estimate|||||||2012-08-03|2012-08-06|Estimate|May 1996||1996-05-31|August 2012|2012-08-31|September 1998|Actual|1998-09-30|||||Interventional|||A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder|A Comparison of Risperidone and Haloperidol for Prevention of Relapse in Subjects With Schizophrenia and Schizoaffective Disorders|Completed||Phase 4|396|Actual|Janssen, LP||2|||||||||||||||||2018-06-01 04:20:36.483952|2018-06-01 04:20:36.483952
NCT00253097|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2009-08-10|2005-11-14|2005-11-15|Estimate|||||||2009-08-10|2009-08-11|Estimate|December 2005||2005-12-31|July 2009|2009-07-31|October 2009|Anticipated|2009-10-31|October 2009|Anticipated|2009-10-31||Interventional|PREVENT||The Post Stroke Preventive Trial (PREVENT). A RCT Nested in a Cohort Study|The Post Stroke Preventive Trial (PREVENT) A Randomised Controlled Trial Nested in a Cohort (RIALTO) Study|Unknown status|Active, not recruiting|N/A|353|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 04:20:36.557618|2018-06-01 04:20:36.557618
NCT00253084|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2017-01-31|2005-11-11|2005-11-15|Estimate|||||||2017-01-31|2017-02-02|Estimate|November 2005||2005-11-30|January 2017|2017-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease|A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease|Completed||Phase 2|12|Actual|IMPAX Laboratories, Inc.||2|||f||||f||||||||No||2018-06-01 04:20:36.647461|2018-06-01 04:20:36.647461
NCT00253071|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2015-03-18|2005-11-14|2005-11-15|Estimate|||||||2015-03-18|2015-03-19|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Early Integrated Intervention in Severe Affective Disorders|Early Integrated Intervention in Severe Affective Disorders - a Randomized Controlled Trial.|Completed||N/A|426|Actual|Hovedstadens Sygehusfaelesskab||2|||f||||f||||||||||2018-06-01 04:20:36.747284|2018-06-01 04:20:36.747284
NCT00253058|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2013-05-03|2005-11-14|2005-11-15|Estimate|||||||2013-05-03|2013-05-06|Estimate|July 2005||2005-07-31|May 2013|2013-05-31||||||||Interventional|||Study Of Perennial Allergic Rhinitis In Pediatrics|Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Perennial Allergic Rhinitis-|Completed||Phase 3|286||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:20:36.818206|2018-06-01 04:20:36.818206
NCT00253045|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2013-09-13|2005-11-14|2005-11-15|Estimate|||||||2013-09-13|2013-09-17|Estimate|August 2004||2004-08-31|September 2013|2013-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|KHARMA||Motivating HIV+ Women: Risk Reduction and ART Adherence|Motivating HIV+ Women: Risk Reduction and ART Adherence|Completed||N/A|207|Actual|Emory University||1|||f||||t||||||||||2018-06-01 04:20:36.933465|2018-06-01 04:20:36.933465
NCT00253032|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2006-03-02|2005-11-11|2005-11-15|Estimate|||||||2006-03-02|2006-03-03|Estimate||||March 2006|2006-03-31||||||||Interventional|||Pain Relief Investigation of NeuroModulation Therapy in Adult Humans|PRIMA Study: Pain Relief Investigation of NeuroModulation Therapy in an Adult Population: A Double Blind, Randomized, Multicenter, Placebo Controlled Trial.|Terminated||Phase 3|||Fralex Therapeutics|||||||||||||||||||2018-06-01 04:20:37.093794|2018-06-01 04:20:37.093794
NCT00253019|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|2013-04-09||2013-08-10|2005-11-14|2005-11-15|Estimate|2013-07-09|2013-08-09|Estimate||||2013-08-10|2013-08-21|Estimate|October 2004||2004-10-31|August 2013|2013-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods|A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods (Oral Contraceptive Pills, Depo Provera and Ortho Evra) Among Women Seeking First Trimester Abortion.|Completed|||321|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:20:37.167329|2018-06-01 04:20:37.167329
NCT00253006|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2006-10-06|2005-11-11|2005-11-15|Estimate|||||||2006-10-06|2006-10-09|Estimate|January 2006||2006-01-31|October 2006|2006-10-31|January 2008||2008-01-31|||||Observational|||Analysis of Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium|A Quantitative Analysis of Protein- and mRNA-Expression of Nitric Oxide Syntheses and Their Functional Role in Human Urothelium|Terminated|||60||Copenhagen University Hospital at Herlev|||||f||||||||||||||2018-06-01 04:20:37.693446|2018-06-01 04:20:37.693446
NCT00252993|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2007-10-10|2005-11-11|2005-11-15|Estimate|||||||2007-10-10|2007-10-12|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|March 2006||2006-03-31|||||Interventional|||12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DDP225 in Patients With Chronic Functional Vomiting|Terminated||Phase 2|30||Dynogen Pharmaceuticals|||||||||||||||||||2018-06-01 04:20:37.765685|2018-06-01 04:20:37.765685
NCT00252980|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2007-01-15|2005-11-14|2005-11-15|Estimate|||||||2007-01-15|2007-01-17|Estimate|January 2006||2006-01-31|January 2007|2007-01-31|March 2007||2007-03-31|||||Interventional|||CANDIS - Targeted Treatment for Cannabis Disorders|CANDIS -Targeted Treatment for Cannabis Disorders|Unknown status|Active, not recruiting|Phase 2|210||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:20:37.843749|2018-06-01 04:20:37.843749
NCT00252967|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|2014-04-21||2014-08-21|2005-11-14|2005-11-15|Estimate|2014-08-21|2014-09-03|Estimate||||2014-08-21|2014-09-03|Estimate|October 2005||2005-10-31|August 2014|2014-08-31|October 2009|Actual|2009-10-31|November 2008|Actual|2008-11-30||Interventional|||Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)|Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)|Terminated||Phase 3|64|Actual|Emory University|Limited enrollment; recurrence rate of AF was slightly higher than other trials indicated that the study sample may be a high-risk population.|2||Insufficient power to show therapy difference at interim analysis.|f||||t||||||||||2018-06-01 04:20:37.930418|2018-06-01 04:20:37.930418
NCT00252954|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2009-08-19|2005-11-14|2005-11-15|Estimate|||||||2009-08-19|2009-08-20|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|||Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury|Effects of Levetiracetam on Chronic Neuropathic Pain Following Spinal Cord Injury: a Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study|Completed||Phase 4|36|Actual|Danish Pain Research Center||1|||f||||t||||||||||2018-06-01 04:20:38.410716|2018-06-01 04:20:38.410716
NCT00252941|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2010-12-20|2005-11-14|2005-11-15|Estimate|||||||2010-12-20|2010-12-21|Estimate|November 2005||2005-11-30|December 2010|2010-12-31|November 2006|Actual|2006-11-30|April 2006|Actual|2006-04-30||Interventional|||Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma|The Role Of Prophylactic Urethral Stenting With Memokath® 028SW in Patients Undergoing Prostate 125I Seed Implants For Prostate Carcinoma: A Phase I/II Study|Completed||Phase 1/Phase 2|20||The Cleveland Clinic|||||||||||||||||||2018-06-01 04:20:38.516198|2018-06-01 04:20:38.516198
NCT00252928|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2007-10-29|2005-11-10|2005-11-15|Estimate|||||||2007-10-29|2007-10-30|Estimate|July 2006||2006-07-31|October 2007|2007-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Health Impact Study of Aquatabs in Tamale, Ghana|Health Impact Study of a Water Treatment Tablet, Aquatabs, in Tamale, Ghana|Completed||N/A|240|Actual|Centers for Disease Control and Prevention||2|||f||||||||||||||2018-06-01 04:20:38.694937|2018-06-01 04:20:38.694937
NCT00252915|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2011-05-24|2005-11-14|2005-11-15|Estimate|||||||2011-05-24|2011-05-26|Estimate|November 2005||2005-11-30|July 2009|2009-07-31|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|||Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock|Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock: a Prospective, Randomised, Double-blind, Placebo-controlled Study|Completed||Phase 2|38|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-06-01 04:20:38.925783|2018-06-01 04:20:38.925783
NCT00252902|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2017-01-10|2005-11-11|2005-11-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2005||2005-12-31|October 2013|2013-10-31|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Emergency Department Initiated Tobacco Treatment (EDITT)|Emergency Department Initiated Tobacco Treatment (EDITT)|Completed||Phase 1/Phase 2|75|Anticipated|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:20:38.985361|2018-06-01 04:20:38.985361
NCT00252889|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2009-01-26|2005-11-11|2005-11-15|Estimate|||||||2009-01-26|2009-01-27|Estimate|May 2004||2004-05-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|March 2006|Actual|2006-03-31||Interventional|||Doxil Topotecan Doublet Cancer Study|GSK - Doublet: A Phase I Study of Pegylated Liposomal Doxorubicin (Doxil) and Weekly Intravenous Topotecan in Patients With Advanced Solid Tumors|Completed||Phase 1|20|Actual|Christiana Care Health Services|||||f||||t||||||||||2018-06-01 04:20:39.056867|2018-06-01 04:20:39.056867
NCT00252876|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2008-03-14|2005-11-10|2005-11-15|Estimate|||||||2008-03-14|2008-03-17|Estimate|March 2005||2005-03-31|March 2008|2008-03-31|January 2007|Actual|2007-01-31|||||Interventional|||GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes|An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1 mg in Patients With Type 2 Diabetes Mellitus.|Terminated||Phase 3|2000||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:20:39.164878|2018-06-01 04:20:39.164878
NCT00252863|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2009-03-16|2005-11-14|2005-11-15|Estimate|||||||2009-03-16|2009-03-17|Estimate|December 2004||2004-12-31|March 2009|2009-03-31|May 2006|Actual|2006-05-31|||||Interventional|||DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults|A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 µg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study|Completed||Phase 3|1600||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:40.840967|2018-06-01 04:20:40.840967
NCT00252850|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2016-09-02|2005-11-11|2005-11-15|Estimate|||||||2016-09-02|2016-09-07|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease|A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease|Completed||Phase 1|12||Sangamo Therapeutics|||||f||||t||||||||||2018-06-01 04:20:41.36159|2018-06-01 04:20:41.36159
NCT00252837|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2008-03-14|2005-11-10|2005-11-15|Estimate|||||||2008-03-14|2008-03-17|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|December 2006|Actual|2006-12-31|||||Interventional|||GALLANT 22 Tesaglitazar vs. Placebo|A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes|Terminated||Phase 3|475||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:20:41.488817|2018-06-01 04:20:41.488817
NCT00252824|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2011-01-21|2005-11-10|2005-11-15|Estimate|||||||2011-01-21|2011-01-24|Estimate|July 2005||2005-07-31|January 2011|2011-01-31|December 2006|Actual|2006-12-31|||||Interventional|||STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma|A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26 Weeks, Randomised, Open-label, Parallel-group, Multicentre Study|Completed||Phase 3|1000|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:41.890792|2018-06-01 04:20:41.890792
NCT00252811|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2011-01-27|2005-11-10|2005-11-15|Estimate|||||||2011-01-27|2011-01-28|Estimate|February 2004||2004-02-29|January 2011|2011-01-31||||||||Interventional|||A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer|A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery|Withdrawn||Phase 2|60||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:42.050306|2018-06-01 04:20:42.050306
NCT00252798|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2007-12-16|2005-11-10|2005-11-15|Estimate|||||||2007-12-16|2007-12-19|Estimate|July 2002||2002-07-31|December 2007|2007-12-31|October 2005|Actual|2005-10-31|||||Interventional|||ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer|A Phase I Trial to Evaluate ZD1839(Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer|Completed||Phase 1|44||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:42.16979|2018-06-01 04:20:42.16979
NCT00252785|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-11|||2011-01-21|2005-11-11|2005-11-15|Estimate|||||||2011-01-21|2011-01-24|Estimate|October 2005||2005-10-31|January 2011|2011-01-31|November 2006|Actual|2006-11-30|||||Interventional|||Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients|An 8-week, Randomised, Double Blind, Parallel-group, Multi-centre, Phase III Study Comparing the Efficacy and Safety of Symbicort® Turbuhaler® 160/4.5 µg Twice Daily and Pulmicort® Turbuhaler® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Patients With Asthma|Completed||Phase 3|340||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:42.376753|2018-06-01 04:20:42.376753
NCT00252772|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-04-21|2005-11-10|2005-11-15|Estimate|||||||2009-04-21|2009-04-22|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|November 2006|Actual|2006-11-30|||||Interventional|||GALLANT 2 Tesaglitazar vs. Placebo|A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered as Monotherapy to Drug-Naïve Patients With Type 2 Diabetes|Terminated||Phase 3|80||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:20:42.806627|2018-06-01 04:20:42.806627
NCT00252759|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2011-01-27|2005-11-14|2005-11-15|Estimate|||||||2011-01-27|2011-01-28|Estimate|November 2003||2003-11-30|January 2011|2011-01-31|February 2006|Actual|2006-02-28|||||Observational|||Iressa Case Control Study in Japan|A Nested Case-control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib|Completed|||6000|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:43.292952|2018-06-01 04:20:43.292952
NCT00252746|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2016-08-24|2005-11-14|2005-11-15|Estimate|||||||2016-08-24|2016-08-25|Estimate|December 2004||2004-12-31|August 2016|2016-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||ZD6474 Phase IIa Dose Finding Multicentre Study|A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]|Completed||Phase 2|53|Actual|Sanofi||3|||f||||||||||||||2018-06-01 04:20:43.545813|2018-06-01 04:20:43.545813
NCT00252733|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2009-03-31||2014-05-09|2005-11-14|2005-11-15|Estimate|2012-03-19|2012-04-13|Estimate||||2014-05-09|2014-05-14|Estimate|June 2001||2001-06-30|April 2014|2014-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|DIRECT||Diabetic Retinopathy Candesartan Trials|Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.|Completed||Phase 3|5238|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:20:44.085585|2018-06-01 04:20:44.085585
NCT00252720|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2012-03-19||2014-05-09|2005-11-14|2005-11-15|Estimate|2014-05-09|2014-06-03|Estimate||||2014-05-09|2014-06-03|Estimate|August 2001||2001-08-31|April 2014|2014-04-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|DIRECT||DIabetic Retinopathy Candesartan Trials.|DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.|Completed||Phase 3|1850|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:20:45.337412|2018-06-01 04:20:45.337412
NCT00252707|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-14|||2007-12-14|2005-11-14|2005-11-15|Estimate|||||||2007-12-14|2007-12-18|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Iressa 2nd Line Phase III Study in Japan|A Multicentre, Randomised, Open-Label, Parallel-Group, Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic (Stage IIIB/IV), or Recurrent Non-Small Cell Lung Cancer, Who Have Failed One or Two Chemotherapy Regimens|Completed||Phase 3|484|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:46.397464|2018-06-01 04:20:46.397464
NCT00252694|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2012-03-22||2014-05-09|2005-11-14|2005-11-15|Estimate|2014-05-09|2014-06-06|Estimate||||2014-05-09|2014-06-06|Estimate|August 2001||2001-08-31|April 2014|2014-04-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|DIRECT||DIabetic Retinopathy Candesartan Trials|Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.|Completed||Phase 3|4717|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:20:46.645995|2018-06-01 04:20:46.645995
NCT00252681|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2006-07-20|2005-11-09|2005-11-11|Estimate|||||||2006-07-20|2006-07-21|Estimate|July 1999||1999-07-31|November 2005|2005-11-30|June 2005||2005-06-30|||||Interventional|||Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants|Surgery for Necrotizing Enterocolitis in Human Infants: A Randomized Trial|Completed||N/A|130||Yale University|||||f||||||||||||||2018-06-01 04:20:47.889849|2018-06-01 04:20:47.889849
NCT00252668|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2011-05-17|2005-11-09|2005-11-11|Estimate|||||||2011-05-17|2011-05-18|Estimate|June 2004||2004-06-30|May 2011|2011-05-31|September 2005|Actual|2005-09-30|||||Interventional|||Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects|An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects|Completed||Phase 4|300||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:20:47.965249|2018-06-01 04:20:47.965249
NCT00252655|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2007-04-18|2005-11-09|2005-11-11|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|June 2009||2009-06-30|||||Interventional|||Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients|Use of Sirolimus Vs. Tacrolimus As The Primary Agent In Immunosuppressive Regimen For African-American Renal Allograft Recipients With Immediate Graft Function: A Pilot Study|Unknown status|Active, not recruiting|Phase 4|40||Wayne State University|||||f||||||||||||||2018-06-01 04:20:48.036153|2018-06-01 04:20:48.036153
NCT00252642|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2017-03-16|2005-11-09|2005-11-11|Estimate|||||||2017-03-16|2017-03-20|Actual|November 2005||2005-11-30|March 2017|2017-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C|The Impact of Peginterferon Alpha-2a Maintenance Therapy on Portal Hypertension in Patients With Chronic Hepatitis C Virus Infection and Advanced Fibrosis and Cirrhosis Enrolled in the HALT-C Trial|Completed||N/A|60|Actual|Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 04:20:48.091587|2018-06-01 04:20:48.091587
NCT00252629|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2014-11-14||2014-12-10|2005-11-09|2005-11-11|Estimate|2014-12-10|2014-12-11|Estimate||||2014-12-10|2014-12-11|Estimate|November 2005||2005-11-30|December 2014|2014-12-31|November 2010|Actual|2010-11-30|October 2008|Actual|2008-10-31||Interventional|||Sleep Disordered Breathing in Gulf War Illness and the Effect of Nasal CPAP Treatment|Inspiratory Flow Dynamics During Sleep in Gulf War Syndrome (GWS) and the Effect of Continuous Positive Airway Pressure (CPAP)|Completed||N/A|29|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:20:48.164008|2018-06-01 04:20:48.164008
NCT00252616|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2013-12-16|2005-11-10|2005-11-11|Estimate|||||||2013-12-16|2013-12-17|Estimate|September 2003||2003-09-30|December 2013|2013-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Timing of Target Enteral Feeding in the Mechanically Ventilated Patient|Phase III Study of Early vs. Delayed Goal Enteral Nutrition in Mechanically Ventilated Patients|Completed||Phase 2/Phase 3|200|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-06-01 04:20:48.443225|2018-06-01 04:20:48.443225
NCT00252603|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2007-01-25|2005-11-09|2005-11-11|Estimate|||||||2007-01-25|2007-01-29|Estimate|April 2004||2004-04-30|January 2007|2007-01-31|April 2007||2007-04-30|||||Interventional|||Galantamine Versus Placebo in Childhood Autism|Galantamine Versus Placebo in Childhood Autism|Completed||Phase 3|20||Rutgers, The State University of New Jersey|||||||||||||||||||2018-06-01 04:20:48.534333|2018-06-01 04:20:48.534333
NCT00252421|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2014-05-20|2005-11-10|2005-11-11|Estimate|||||||2014-05-20|2014-05-21|Estimate|October 2005||2005-10-31|May 2014|2014-05-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||The Nitrate and Bone Study: Effects of Nitrates on Osteoporosis|The Effects of Organic Nitrates on Osteoporosis: Part 2|Completed||Phase 3|243|Actual|University of Toronto||2|||f||||t||||||||||2018-06-01 04:20:51.554688|2018-06-01 04:20:51.554688
NCT00252590|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2015-06-25||2016-02-19|2005-11-09|2005-11-11|Estimate|2016-02-19|2016-03-21|Estimate||||2016-02-19|2016-03-21|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Health Focused Motivational Treatment for Alcohol Dependent Veterans|Health Focused Motivational Treatment for Alcohol Dependent Veterans|Completed||N/A|99|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 04:20:48.598083|2018-06-01 04:20:48.598083
NCT00252577|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2016-07-26|2005-11-09|2005-11-11|Estimate|||||||2016-07-26|2016-07-27|Estimate|October 2005||2005-10-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|||Genetic Predictors of Lithium Response in Bipolar Disorder|Genetic Studies of Psychiatric Illness|Completed|||130|Anticipated|VA Office of Research and Development|||1||f||||t||||||Samples With DNA|"~     DNA from patients with bipolar disorder~   "|Undecided||2018-06-01 04:20:49.23584|2018-06-01 04:20:49.23584
NCT00252564|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2011-02-15||2011-02-15|2005-11-10|2005-11-11|Estimate|2011-02-15|2011-03-14|Estimate||||2011-02-15|2011-03-14|Estimate|September 2005||2005-09-30|February 2011|2011-02-28|June 2009|Actual|2009-06-30|June 2007|Actual|2007-06-30||Interventional|||Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer|Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer|Completed||Phase 3|247|Actual|US Oncology Research||2|||f||||f||||||||||2018-06-01 04:20:49.360646|2018-06-01 04:20:49.360646
NCT00252551|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2015-03-15|2005-11-10|2005-11-11|Estimate|||||||2015-03-15|2015-03-17|Estimate|March 2005||2005-03-31|March 2015|2015-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|CLEOS||Vertebral Osteosynthesis in Degenerative Lumbar Stenosis With Spondylolisthesis|Vertebral Osteosynthesis in Degenerative Lumbar Stenosis With Spondylolisthesis - CLEOS Study|Terminated||N/A|11|Actual|University Hospital, Toulouse||2||Insufficient recruitment|f||||f||||||||||2018-06-01 04:20:50.19219|2018-06-01 04:20:50.19219
NCT00252538|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2014-11-17||2014-12-03|2005-11-09|2005-11-11|Estimate|2014-12-03|2014-12-11|Estimate||||2014-12-03|2014-12-11|Estimate|April 2006||2006-04-30|December 2014|2014-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Genetic and Biochemical Markers of Interferon-Induced Depression.|Genetic and Biochemical Markers of Interferon-Induced Depression.|Completed|||133|Actual|VA Office of Research and Development|Limitations include that there are numerous polymorphism in various genes that may influence certain symptoms of depression. The risk for side effects during interferon-alpha treatment likely influenced by many genetic polymorphisms.||1||f||||||||||Samples With DNA|"~     Blood samples are being collected to determine the variability in the development of~     depressive symptoms induced by interferon. Thus, we plan to measure specific genetic~     polymorphisms [i.e., in the serotonin (5-HT) transporter gene-linked polymorphic region~     (5-HTTLPR), in the promoter of the 5-HT1A receptor subtype, and an intronic tryptophan~     hydroxylase polymorphism]. Tryptophan, 5-HT, and cortisol blood levels will also be measured.~   "|||2018-06-01 04:20:50.285135|2018-06-01 04:20:50.285135
NCT00252525|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2014-06-26|2005-11-09|2005-11-11|Estimate|||||||2014-06-26|2014-06-27|Estimate|June 2007||2007-06-30|June 2014|2014-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Correlation of Plasma Endothelial Cell Activity With Cardiovascular Events in Patients With Diabetes Mellitus Type 2|CSP #465B - Correlation of Plasma Endothelial Cell (Basic Fibroblast Growth Factor) Activity With Cardiovascular Events In Patients With Diabetes Mellitus Type 2|Completed|||400|Actual|VA Office of Research and Development|||1||f||||t||||||None Retained|"~     The cohort consisted of patients that participated in the 465 main study.~   "|||2018-06-01 04:20:50.454359|2018-06-01 04:20:50.454359
NCT00252512|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2014-08-18||2015-04-06|2005-11-09|2005-11-11|Estimate|2014-08-18|2014-08-29|Estimate||||2015-04-06|2015-04-24|Estimate|May 2007||2007-05-31|July 2014|2014-07-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|REAP||The Effect of a Contingency Management Intervention on Substance Use|Effectiveness of Contingency Management in VA Addictions Treatment|Completed||N/A|332|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:20:50.541331|2018-06-01 04:20:50.541331
NCT00252499|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2013-11-12||2014-08-18|2005-11-09|2005-11-11|Estimate|2014-03-05|2014-04-11|Estimate||||2014-08-18|2014-08-20|Estimate|October 2005||2005-10-31|August 2014|2014-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Insulin Resistance in Non-alcoholic Fatty Liver Disease|Insulin Resistance in Non-alcoholic Fatty Liver Disease|Terminated||N/A|13|Actual|VA Office of Research and Development|Due to recruitment difficulties and concerns about the safety of thiazolidinediones, recruitment was stopped without achieving adequate sample size (16/arm). Thus, no definitive conclusions can be made about the study medications.|3||Protocol drug change required new clinicaltrails.gov entry|f||||f||||||||||2018-06-01 04:20:50.814014|2018-06-01 04:20:50.814014
NCT00252486|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2013-06-17|2005-11-09|2005-11-11|Estimate|||||||2013-06-17|2013-06-19|Estimate|November 2001||2001-11-30|June 2013|2013-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Omega-3 Fatty Acids in Children and Adolescents With Bipolar Disorder|A Comparison of Omega-3 Fatty Acids vs. Placebo in Children and Adolescents With Bipolar Disorder|Completed||N/A|65|Actual|University of Rochester||1|||f||||t||||||||||2018-06-01 04:20:51.259944|2018-06-01 04:20:51.259944
NCT00252473|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2010-08-12|2005-11-09|2005-11-11|Estimate|||||||2010-08-12|2010-08-13|Estimate|January 2005||2005-01-31|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||S-Frame CT Immobilization Masks For Patients Undergoing Radiation Therapy For Head and Neck Cancer|Evaluation of Setup Accuracy in Med Tec S-Frame Immobilization Masks For Patients Undergoing Radiation Therapy For Head and Neck Cancer|Completed||Phase 2|30|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:20:51.330798|2018-06-01 04:20:51.330798
NCT00252460|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2016-03-24|2005-11-09|2005-11-11|Estimate|||||||2016-03-24|2016-03-25|Estimate|November 2003||2003-11-30|March 2016|2016-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||CT/MRI Co-registration Prostate Cancer|Evaluation of Planning Computed Tomography Scan and Magnetic Resonance Imaging Simulator Scan Co-Registration for Delineation of Gross Tumour Volume in Radiotherapy Treatment of Localized Prostate Cancer|Completed|||31|Actual|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:20:51.385059|2018-06-01 04:20:51.385059
NCT00252447|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2010-08-10|2005-11-09|2005-11-11|Estimate|||||||2010-08-10|2010-08-11|Estimate|May 2000||2000-05-31|August 2010|2010-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Preop Conformal Radiotherapy - Prostate|A Pilot Study of Pre-Operative Conformal Radiotherapy in Patients With Radical Prostatectomy|Completed||Phase 1/Phase 2|15||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:20:51.439323|2018-06-01 04:20:51.439323
NCT00252434|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2016-01-26|2005-11-10|2005-11-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|August 2004||2004-08-31|January 2016|2016-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Behavioral Therapy Development for Methamphetamine Abuse|Behavioral Therapy Development for Methamphetamine Abuse|Terminated||Phase 1|||University of California, Los Angeles||||Slow enrollment|f||||f||||||||||2018-06-01 04:20:51.493373|2018-06-01 04:20:51.493373
NCT00252395|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2005-11-09|2005-11-09|2005-11-11|Estimate|||||||2005-11-09|2005-11-11|Estimate|August 2005||2005-08-31|November 2005|2005-11-30|August 2006||2006-08-31|||||Interventional|||Evaluation of Electronic Prescribing in Hospital Ambulatory Care Clinics|Effects of Electronic Prescribing on Safety and Quality in Hospital-Based Ambulatory Are: a Randomised Controlled Trial|Completed||Phase 4|40||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:20:51.752303|2018-06-01 04:20:51.752303
NCT00252382|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2017-04-14||2017-04-14|2005-11-09|2005-11-11|Estimate|2017-04-14|2017-06-29|Actual||||2017-04-14|2017-06-29|Actual|December 27, 2005|Actual|2005-12-27|April 2017|2017-04-30|November 29, 2007|Actual|2007-11-29|March 5, 2007|Actual|2007-03-05||Interventional|||Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC|Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of the Intravenous Administration of SNS-595 as Second-Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|31|Actual|Sunesis Pharmaceuticals|Statistical fields are not included here because no statistical testings were performed to compare any treatment group. No p-values or odds ratios were reported.|1|||f||||f|t|||||||No||2018-06-01 04:20:51.922906|2018-06-01 04:20:51.922906
NCT00252369|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-04-23|2005-11-10|2005-11-11|Estimate|||||||2009-04-23|2009-04-24|Estimate||||April 2009|2009-04-30||||||||Interventional|||Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.|Instillation of Fibrin Glue After Induction of Local Conditions Using Infliximab, in the Treatment of Perianal Crohn's Disease.|Terminated||N/A|||Sheba Medical Center||||Low accrual rate|f||||f||||||||||2018-06-01 04:20:52.217672|2018-06-01 04:20:52.217672
NCT00252356|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-03-10|2005-11-10|2005-11-11|Estimate|||||||2009-03-10|2009-03-12|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Interventional|ORION||Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder|An Eight-Week, Double-Blind, Placebo Controlled, Multicenter Study With Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With MDD|Completed||Phase 3|468|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:20:52.291974|2018-06-01 04:20:52.291974
NCT00252343|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-03-10|2005-11-10|2005-11-11|Estimate|||||||2009-03-10|2009-03-12|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|LIBRA||Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder|An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Escitalopram (10mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder|Completed||Phase 3|360|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:20:52.380895|2018-06-01 04:20:52.380895
NCT00252330|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-03-10|2005-11-10|2005-11-11|Estimate|||||||2009-03-10|2009-03-12|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|PHOENIX||Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder|An Eight-Week, Double-Blind, Placebo Controlled, Multicenter Study With Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With MDD|Completed||Phase 3|476|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:20:52.456003|2018-06-01 04:20:52.456003
NCT00252317|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2008-09-02|2005-11-10|2005-11-11|Estimate|||||||2008-09-02|2008-09-03|Estimate|November 2005||2005-11-30|November 2007|2007-11-30|October 2008|Anticipated|2008-10-31|||||Interventional|||Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis|Acute Haemodynamic Effects of Treatment With ACE-Inhibitors in Patients With Symptomatic Aortic Stenosis (ACCESS)|Unknown status|Recruiting|Phase 4|64|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-06-01 04:20:52.557213|2018-06-01 04:20:52.557213
NCT00252304|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-10-02|2005-11-10|2005-11-11|Estimate|||||||2009-10-02|2009-10-06|Estimate|January 2006||2006-01-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Therapeutic Zinc in Childhood Pneumonia|Efficacy of Zinc as Adjuvant Therapy in the Treatment of Severe Pneumonia in Nepalese Children at the Kanti Children's Hospital|Completed||Phase 2/Phase 3|641|Actual|Centre For International Health||2|||f||||f||||||||||2018-06-01 04:20:52.675617|2018-06-01 04:20:52.675617
NCT00252291|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-11-29|2005-11-10|2005-11-11|Estimate|||||||2009-11-29|2009-12-01|Estimate|November 2005||2005-11-30|November 2009|2009-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Ability of Aridol to Detect Bronchial Hyperresponsiveness in Suspected Asthmatics|A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting With Signs and Symptoms Suggestive of Asthma But Without a Definitive Diagnosis|Completed||Phase 3|240||Pharmaxis|||||||||||||||||||2018-06-01 04:20:52.772469|2018-06-01 04:20:52.772469
NCT00252278|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2006-07-05|2005-11-10|2005-11-11|Estimate|||||||2006-07-05|2006-07-07|Estimate|November 2005||2005-11-30|November 2005|2005-11-30||||||||Interventional|||Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents|The Effect of a Once Daily Evening Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents|Unknown status|Recruiting|Phase 4|36||Rhode Island Hospital|||||f||||||||||||||2018-06-01 04:20:52.879288|2018-06-01 04:20:52.879288
NCT00252252|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2008-06-20|2005-11-09|2005-11-11|Estimate|||||||2008-06-20|2008-06-24|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation|Crossover Trial of VPAP (Variable Positive Airway Pressure) Ventilation Versus AutoVPAP in Neuromuscular and Chest Wall Disease: Effects on Nocturnal Hypoventilation, Sleep Quality and Tolerance|Completed||Phase 1|20|Actual|ResMed|||||f||||||||||||||2018-06-01 04:20:52.951814|2018-06-01 04:20:52.951814
NCT00252239|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2015-01-12||2015-02-26|2005-11-10|2005-11-11|Estimate|2015-01-12|2015-01-19|Estimate||||2015-02-26|2015-03-17|Estimate|November 2005||2005-11-30|February 2015|2015-02-28|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)|Phase 2B Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)|Terminated||Phase 2|112|Actual|University of Virginia|Premature termination limits any conclusions from the trial.|2||Slow enrollment|f||||t||||||||||2018-06-01 04:20:53.058364|2018-06-01 04:20:53.058364
NCT00252226|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2008-06-02|2005-11-09|2005-11-11|Estimate|||||||2008-06-02|2008-06-04|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders|Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders: An Open Prospective Longitudinal Study of the Effectiveness of Quetiapine Monotherapy in Preventing Relapse and Minimizing Neurocognitive Dysfunction Among Adolescents Manifesting Bipolar Spectrum Disorders|Completed||Phase 3|100|Anticipated|Mood Disorders Center of Ottawa|||||f||||||||||||||2018-06-01 04:20:53.86173|2018-06-01 04:20:53.86173
NCT00252213|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-12-09|2005-11-10|2005-11-11|Estimate|||||||2009-12-09|2009-12-11|Estimate|August 2002||2002-08-31|December 2009|2009-12-31|January 2006||2006-01-31|||||Interventional|||BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling|B-Type Natriuretic Peptide (Nesiritide) and Post Myocardial Infarction Left Ventricular Remodeling: Pilot Study Assessing Safety|Terminated||Phase 1|24||Mayo Clinic||||recruitment of subjects was halted prematurely. recruiting subjects halted prematurely|||||||||||||||2018-06-01 04:20:53.988949|2018-06-01 04:20:53.988949
NCT00252200|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2009-09-22|2005-11-10|2005-11-11|Estimate|||||||2009-09-22|2009-09-23|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.|Low Dose Continuous Infusion of BNP (Nesiritide) in the Prevention of Renal Insufficiency Post Cardiopulmonary Bypass Cardiac Surgery.|Completed||Phase 1/Phase 2|40|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 04:20:54.051331|2018-06-01 04:20:54.051331
NCT00252187|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2012-11-20||2012-12-19|2005-11-10|2005-11-11|Estimate|2012-12-19|2012-12-20|Estimate||||2012-12-19|2012-12-20|Estimate|January 2000||2000-01-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|July 2008|Actual|2008-07-31||Interventional|SubqBNP||Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure|Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strategy|Completed||Phase 1/Phase 2|45|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:20:54.338817|2018-06-01 04:20:54.338817
NCT00252174|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2017-01-20||2017-10-12|2005-11-09|2005-11-11|Estimate|2017-03-27|2017-05-05|Actual||||2017-10-12|2017-11-14|Actual|February 2007||2007-02-28|October 2017|2017-10-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer|Phase II Dose-response Pilot Study of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Anxiety Associated With Advanced-stage Cancer.|Terminated||Phase 2|2|Actual|Brigham and Women's Hospital||3||Lack of funds and insufficient patient population for study enrollment.|f||||t||f||||||No||2018-06-01 04:20:55.414401|2018-06-01 04:20:55.414401
NCT00252161|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2016-09-20|2005-11-10|2005-11-11|Estimate|||||||2016-09-20|2016-09-22|Estimate|November 2005||2005-11-30|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer|Randomized Phase III Trial of Surgery Plus Neoadjuvant TS-1 and Cisplatin Compared With Surgery Alone for Type 4 and Large Type 3 Gastric Cancer: Japan Clinical Oncology Group Study (JCOG 0501)|Completed||Phase 3|316|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:20:55.899508|2018-06-01 04:20:55.899508
NCT00252148|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2013-02-08|2005-11-09|2005-11-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|January 2005||2005-01-31|June 2010|2010-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults|Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of a Modified Vaccinia Ankara (MVA) Vectored HIV-1 (ADMVA) Vaccine Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers|Completed||Phase 1|48|Anticipated|International AIDS Vaccine Initiative||2|||f||||t||||||||||2018-06-01 04:20:56.046585|2018-06-01 04:20:56.046585
NCT00252135|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2017-05-11|2005-11-09|2005-11-11|Estimate|||||||2017-05-11|2017-05-12|Actual|June 2004|Actual|2004-06-30|May 2017|2017-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma|An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma (EXCELS)|Completed|||8023|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 04:20:56.181454|2018-06-01 04:20:56.181454
NCT00252122|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2009-03-12|2005-11-09|2005-11-11|Estimate|||||||2009-03-12|2009-03-13|Estimate|June 2004||2004-06-30|March 2009|2009-03-31|January 2007|Actual|2007-01-31|November 2005|Actual|2005-11-30||Interventional|||Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease|A Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease|Terminated||Phase 4|3|Actual|Children's Hospital of Philadelphia||1||Recruitment was very slow.|f||||f||||||||||2018-06-01 04:20:56.256007|2018-06-01 04:20:56.256007
NCT00252109|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2012-08-15|2005-11-10|2005-11-11|Estimate|||||||2012-08-15|2012-08-16|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|January 2009|Actual|2009-01-31|September 2007|Actual|2007-09-30||Observational|||ADAPT-POL New Orleans: Adaptation of Prevention Techniques With Popular Opinion Leader|New Orleans AIDS Task Force Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT) With Popular Opinion Leader (POL)|Completed|||27|Actual|Centers for Disease Control and Prevention|||||f||||t||||||||||2018-06-01 04:20:56.330756|2018-06-01 04:20:56.330756
NCT00252096|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2012-09-26|2005-11-10|2005-11-11|Estimate|||||||2012-09-26|2012-09-27|Estimate|June 2003||2003-06-30|September 2012|2012-09-30|June 2010|Actual|2010-06-30|January 2006|Actual|2006-01-31||Interventional|||Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections|Nucleic Acid Amplification Tests for the Diagnosis of Pharyngeal and Rectal Chlamydia Trachomatis and Neisseria Gonorrhoeae Infections|Completed||N/A|3900|Anticipated|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:20:56.395029|2018-06-01 04:20:56.395029
NCT00252083|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2012-04-04|2005-11-10|2005-11-11|Estimate|||||||2012-04-04|2012-04-05|Estimate|July 2004||2004-07-31|April 2012|2012-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||ADAPT-POL: Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques|Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques With Popular Opinion Leader (ADAPT-POL)|Completed||N/A|41|Actual|Centers for Disease Control and Prevention|||||f||||t||||||||||2018-06-01 04:20:56.459113|2018-06-01 04:20:56.459113
NCT00252070|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2007-09-06|2005-11-10|2005-11-11|Estimate|||||||2007-09-06|2007-09-10|Estimate|November 2005||2005-11-30|September 2007|2007-09-30|January 2007|Actual|2007-01-31|||||Interventional|||Fitness and Exercise for People With Arthritis|Fitness and Functional Exercise for People With Arthritis|Completed||Phase 2/Phase 3|154|Actual|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:20:56.515663|2018-06-01 04:20:56.515663
NCT00252057|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|2009-02-10||2017-02-27|2005-11-10|2005-11-11|Estimate|2009-03-10|2009-04-13|Estimate||||2017-02-27|2017-03-28|Actual|December 2005||2005-12-31|February 2017|2017-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Testing the Re-Engineered Hospital Discharge|Testing the Re-Engineered Hospital Discharge|Completed||N/A|749|Actual|Boston University||2|||f||||f||||||||No||2018-06-01 04:20:56.596104|2018-06-01 04:20:56.596104
NCT00252044|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2005-11-17|2005-11-09|2005-11-11|Estimate|||||||2005-11-17|2005-11-21|Estimate|October 2000||2000-10-31|November 2005|2005-11-30||||||||Interventional|||Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder|The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder|Unknown status|Recruiting|N/A|||Bronx VA Medical Center|||||f||||||||||||||2018-06-01 04:20:56.815219|2018-06-01 04:20:56.815219
NCT00252018|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2008-05-13|2005-11-10|2005-11-11|Estimate|||||||2008-05-13|2008-05-14|Estimate|January 2006||2006-01-31|May 2008|2008-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease|The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease.|Completed||N/A|160|Anticipated|Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:20:56.977105|2018-06-01 04:20:56.977105
NCT00252005|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09||2010-02-27|2010-02-27|2005-11-09|2005-11-11|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|November 2005||2005-11-30|August 2008|2008-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study|Protocol CV185017: A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis|Completed||Phase 2|520||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:20:57.043445|2018-06-01 04:20:57.043445
NCT00251992|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2011-01-21|2005-11-09|2005-11-11|Estimate|||||||2011-01-21|2011-01-24|Estimate|December 2002||2002-12-31|January 2011|2011-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Nexium Dyspepsia/AST|Supportive Test for Acid-Related Symptoms (STARS II) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Uninvestigated Subjects With Upper Gastrointestinal Symptoms.|Completed||Phase 3|1200||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:57.249186|2018-06-01 04:20:57.249186
NCT00251979|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2008-12-12||2011-05-18|2005-11-09|2005-11-11|Estimate|2011-05-18|2011-06-17|Estimate||||2011-05-18|2011-06-17|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer|A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.|Completed||Phase 3|1312|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:20:57.688388|2018-06-01 04:20:57.688388
NCT00251966|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2009-03-11|2005-11-09|2005-11-11|Estimate|||||||2009-03-11|2009-03-12|Estimate|May 2004||2004-05-31|March 2009|2009-03-31|September 2005|Actual|2005-09-30|||||Interventional|||ASTERIX: Low Dose ASA and Nexium|A Randomized Double-Blind Placebo-Controlled Study to Assess the Prevention of Low-Dose Acetylsalicylic Acid (ASA) Associated Gastroduodenal Lesions and Upper Gastrointestinal Symptoms in Patients Taking Esomeprazole 20 mg Once Daily for 26 Weeks.|Completed||Phase 3|960||AstraZeneca|||||f||||||||||||||2018-06-01 04:20:59.263402|2018-06-01 04:20:59.263402
NCT00251953|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2009-04-21|2005-11-09|2005-11-11|Estimate|||||||2009-04-21|2009-04-22|Estimate|July 2004||2004-07-31|April 2009|2009-04-30|March 2006|Actual|2006-03-31|||||Interventional|||GALLANT 8 Tesaglitazar Add-on to Metformin|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Metformin Alone|Terminated||Phase 3|555||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:21:00.299831|2018-06-01 04:21:00.299831
NCT00251940|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2008-03-14|2005-11-09|2005-11-11|Estimate|||||||2008-03-14|2008-03-17|Estimate|July 2004||2004-07-31|March 2008|2008-03-31|March 2006|Actual|2006-03-31|||||Interventional|||GALLANT 7 Tesaglitazar Add-on to Sulphonylurea|A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone|Terminated||Phase 3|555||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:21:00.629921|2018-06-01 04:21:00.629921
NCT00251927|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2010-07-08||2012-08-07|2005-11-09|2005-11-11|Estimate|2012-08-07|2012-08-08|Estimate||||2012-08-07|2012-08-08|Estimate|October 2001||2001-10-31|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|LOTUS||Esomeprazole (NEXIUM) vs. Surgery|An Open, Randomized, Multicenter, Phase IIIB Study During 5 Years to Assess Long-term Efficacy and Tolerability of Esomeprazole Compared to Laparoscopic Anti-reflux Surgery in Adult Subjects With Gastroesophageal Reflux Disease - LOTUS.|Completed||Phase 3|626|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:21:00.910474|2018-06-01 04:21:00.910474
NCT00251914|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2011-01-21|2005-11-09|2005-11-11|Estimate|||||||2011-01-21|2011-01-24|Estimate|December 2002||2002-12-31|January 2011|2011-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Nexium Dyspepsia/AST|Supportive Test for Acid-Related Symptoms (STARS I) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Subjects With Upper Gastrointestinal Symptoms and With Normal Findings at Esophagogastroduodenoscopy.|Completed||Phase 3|1500||AstraZeneca|||||f||||||||||||||2018-06-01 04:21:02.052125|2018-06-01 04:21:02.052125
NCT00251901|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2011-01-21|2005-11-09|2005-11-11|Estimate|||||||2011-01-21|2011-01-24|Estimate|May 2004||2004-05-31|January 2011|2011-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Chest Pain Pilot Study|A Randomized Double-Blind Placebo-Controlled Multi-Centre Pilot Study to Assess Symptom Response in Subjects With Pain or Discomfort in the Chest Receiving Oral Treatment With Esomeprazole 40 mg Bid for 4 Weeks.|Completed||Phase 3|600||AstraZeneca|||||f||||||||||||||2018-06-01 04:21:02.452005|2018-06-01 04:21:02.452005
NCT00251888|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-10|||2017-01-24|2005-11-10|2005-11-11|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2002||2002-11-30|February 2011|2011-02-28|November 2005|Actual|2005-11-30|||||Interventional|||CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto|Etude de Recherche de Dose de l'Association Irinotecan (Campto(R)) - Cisplatine (Cisplatyl(R)) Avec la radiothérapie Pelvienne Dans Les Cancers avancés du Col de l'utérus.|Completed||Phase 1|15||ARCAGY/ GINECO GROUP|||||f||||||||||||||2018-06-01 04:21:02.70808|2018-06-01 04:21:02.70808
NCT00251875|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2005-11-09|2005-11-09|2005-11-11|Estimate|||||||2005-11-09|2005-11-11|Estimate|July 2005||2005-07-31|November 2005|2005-11-30|September 2007||2007-09-30|||||Interventional|||Shared Online Health Records for Patient Safety and Care|Shared Online Health Records for Patient Safety and Care|Unknown status|Recruiting|N/A|5400||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:21:02.770807|2018-06-01 04:21:02.770807
NCT00251862|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2013-07-23||2013-12-02|2005-11-09|2005-11-11|Estimate|2013-09-30|2013-12-02|Estimate||||2013-12-02|2013-12-27|Estimate|January 2005||2005-01-31|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Shared Decision-Making for Colorectal Cancer Screening|Shared Decision-Making for Colorectal Cancer Screening|Completed||N/A|825|Actual|Agency for Healthcare Research and Quality (AHRQ)||3|||f||||f||||||||||2018-06-01 04:21:02.869609|2018-06-01 04:21:02.869609
NCT00251849|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2008-08-20|2005-11-09|2005-11-11|Estimate|||||||2008-08-20|2008-08-21|Estimate|November 2005||2005-11-30|October 2006|2006-10-31|December 2007||2007-12-31|||||Interventional|||PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients|Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients|Unknown status|Active, not recruiting|Phase 3|274||ActivBiotics|||||||||||||||||||2018-06-01 04:21:03.397226|2018-06-01 04:21:03.397226
NCT00251836|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2016-12-28|2005-11-08|2005-11-10|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2007||2007-01-31|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Adrenal Function After Living Kidney Donation|Prospective Evaluation of Adrenal Function After Living Donor Nephrectomy With or Without Ligation of the Adrenal Vein|Completed|||30|Actual|University of Zurich|||2||f||||f||||||||No||2018-06-01 04:21:03.55033|2018-06-01 04:21:03.55033
NCT00251823|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2008-09-03|2005-11-08|2005-11-10|Estimate|||||||2008-09-03|2008-09-04|Estimate|July 2005||2005-07-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|||||Interventional|||Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)|The Safety and Efficacy of Eptifibatide-Facilitated Percutaneous Coronary Angioplasty Versus Primary Percutaneous Coronary Angioplasty Alone|Completed||Phase 3|400|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||||||||||||2018-06-01 04:21:03.630333|2018-06-01 04:21:03.630333
NCT00251810|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2011-08-15|2005-11-09|2005-11-10|Estimate|||||||2011-08-15|2011-08-16|Estimate|November 2004||2004-11-30|August 2011|2011-08-31||||||||Observational|||Can CSM Monitor Depth of Anaesthesia Just as Good as BIS?|Can CSM Monitor Depth of Anaesthesia Just as Good as BIS?|Unknown status|Active, not recruiting||60|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-06-01 04:21:03.697087|2018-06-01 04:21:03.697087
NCT00251797|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2010-01-06|2005-11-08|2005-11-10|Estimate|||||||2010-01-06|2010-01-07|Estimate|March 2000||2000-03-31|October 2008|2008-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors|A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors.|Completed||Phase 1|10|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:21:03.767964|2018-06-01 04:21:03.767964
NCT00251784|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2005-11-09|2005-11-09|2005-11-10|Estimate|||||||2005-11-09|2005-11-10|Estimate|February 2002||2002-02-28|December 2003|2003-12-31|June 2003||2003-06-30|||||Interventional|||Healthy Volunteer Study of Sildenafil Effects Upon Vision|A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil|Completed||Phase 4|||University of Cambridge|||||f||||||||||||||2018-06-01 04:21:03.832622|2018-06-01 04:21:03.832622
NCT00251771|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2015-04-29|2005-11-09|2005-11-10|Estimate|||||||2015-04-29|2015-04-30|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CaVenT||Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis|Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial|Completed||N/A|209|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 04:21:03.886401|2018-06-01 04:21:03.886401
NCT00251758|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2009-02-26||2010-05-12|2005-11-08|2005-11-10|Estimate|2009-03-20|2009-03-23|Estimate||||2010-05-12|2010-05-18|Estimate|December 2005||2005-12-31|May 2010|2010-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn|A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|908|Actual|Takeda||3|||t||||f||||||||||2018-06-01 04:21:04.002114|2018-06-01 04:21:04.002114
NCT00251745|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2009-02-26||2011-04-25|2005-11-08|2005-11-10|Estimate|2009-02-26|2009-03-23|Estimate||||2011-04-25|2011-04-28|Estimate|December 2005||2005-12-31|April 2011|2011-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn|A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|908|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:21:04.799675|2018-06-01 04:21:04.799675
NCT00251732|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2010-08-18|2005-11-08|2005-11-10|Estimate|||||||2010-08-18|2010-08-19|Estimate|March 2005||2005-03-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)|Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI.|Completed||Phase 4|150|Actual|Southern Arizona VA Health Care System||3|||f||||f||||||||||2018-06-01 04:21:05.51726|2018-06-01 04:21:05.51726
NCT00251719|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2009-02-20||2012-02-01|2005-11-08|2005-11-10|Estimate|2009-03-20|2009-03-23|Estimate||||2012-02-01|2012-02-03|Estimate|December 2005||2005-12-31|February 2012|2012-02-29|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis|A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis|Completed||Phase 3|2054|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:21:05.661334|2018-06-01 04:21:05.661334
NCT00251706|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2006-05-04|2005-11-08|2005-11-10|Estimate|||||||2006-05-04|2006-05-05|Estimate|February 1999||1999-02-28|November 2005|2005-11-30|September 2004||2004-09-30|||||Interventional|||Amiodarone to Prevent Post-Operative Arrhythmias|Prophylactic Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valve Replacement, or Repair - PAPABEAR|Completed||Phase 3|600||University of Calgary|||||f||||||||||||||2018-06-01 04:21:06.517462|2018-06-01 04:21:06.517462
NCT00251693|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2009-02-20||2012-02-01|2005-11-08|2005-11-10|Estimate|2009-03-20|2009-03-23|Estimate||||2012-02-01|2012-02-03|Estimate|December 2005||2005-12-31|February 2012|2012-02-29|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis|A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis|Completed||Phase 3|2038|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:21:06.63278|2018-06-01 04:21:06.63278
NCT00251680|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-05-23|2005-11-08|2005-11-10|Estimate|||||||2012-05-23|2012-05-24|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.|A Placebo-Controlled, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in Subjects With Type 2 Diabetes Currently Treated With Lipid-Lowering Therapy|Completed||Phase 3|400|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:21:07.646585|2018-06-01 04:21:07.646585
NCT00251654|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2009-09-30|2005-11-09|2005-11-10|Estimate|||||||2009-09-30|2009-10-01|Estimate|January 2002||2002-01-31|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Complications and Adverse Effects in Continuous Peripheral Regional Anesthesia|Complications and Adverse Effects in Continuous Peripheral Regional Anesthesia Results of Investigations on 3,491 Catheters|Completed|||9000|Actual|Rechbergklinik Bretten|||||f||||f||||||||||2018-06-01 04:21:07.820159|2018-06-01 04:21:07.820159
NCT00251641|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2009-05-21||2017-04-04|2005-11-08|2005-11-10|Estimate|2009-05-21|2009-07-14|Estimate||||2017-04-04|2017-05-10|Actual|September 1, 2005|Actual|2005-09-01|April 2017|2017-04-30|June 1, 2008|Actual|2008-06-01|June 1, 2008|Actual|2008-06-01||Interventional|||The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)|An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis|Completed||Phase 3|868|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:21:07.920752|2018-06-01 04:21:07.920752
NCT00251628|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-06-07|2005-11-08|2005-11-10|Estimate|||||||2012-06-07|2012-06-08|Estimate|June 2000||2000-06-30|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Home Care Management of Pediatric Pain|Home Care Management of Pediatric Pain|Completed||Phase 4|211|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-06-01 04:21:08.450405|2018-06-01 04:21:08.450405
NCT00251615|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-08-03|2005-11-08|2005-11-10|Estimate|||||||2012-08-03|2012-08-06|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging|Calcium Channel Splice Variant Expression in Cardiovascular Disease and Aging|Completed|||18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||Samples With DNA|"~     Vascular tissue obtained from the surgical site that would have otherwise been discarded and~     Blood Serum~   "|||2018-06-01 04:21:08.513615|2018-06-01 04:21:08.513615
NCT00251602|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-08-03|2005-11-08|2005-11-10|Estimate|||||||2012-08-03|2012-08-06|Estimate|March 2003||2003-03-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Analysis of Atropine and Propranolol Induced Changes|Wavelet Transform and Pharmacodynamic Analysis of Atropine and Propranolol Induced Changes in Human Heart Rate Variability|Completed||Phase 1|24|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-06-01 04:21:08.573923|2018-06-01 04:21:08.573923
NCT00251589|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|2008-10-27||2015-02-17|2005-11-08|2005-11-10|Estimate|2009-03-09|2009-03-10|Estimate||||2015-02-17|2015-03-06|Estimate|January 2006||2006-01-31|February 2015|2015-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)|A Phase I/II Clinical Trial of Oral Vorinostat (MK0683) in Combination With Erlotinib in Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer|Terminated||Phase 1/Phase 2|23|Actual|Merck Sharp & Dohme Corp.|Due to the slow pace of patient accrual, failure to observe meaningful efficacy in treated patients, and overall intolerance of the combination regimen, the study was terminated prematurely on 12-Oct-2007.|4||"This trial is being closed based on lack of substantive efficacy, slow accrual and overall~   tolerance in patients treated to date."|f||||f||||||||||2018-06-01 04:21:08.677221|2018-06-01 04:21:08.677221
NCT00251576|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2017-04-06|2005-11-09|2005-11-10|Estimate|||||||2017-04-06|2017-04-10|Actual|November 1, 1999|Actual|1999-11-01|April 2017|2017-04-30|March 23, 2004|Actual|2004-03-23|March 23, 2004|Actual|2004-03-23||Interventional|||Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)|A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction With Aspirin|Completed||Phase 3|4497|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:21:10.075461|2018-06-01 04:21:10.075461
NCT00251563|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2006-10-12|2005-11-09|2005-11-10|Estimate|||||||2006-10-12|2006-10-13|Estimate|August 2005||2005-08-31|November 2005|2005-11-30||||||||Observational|||Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Cancer.||Unknown status|Recruiting||||Nanjing Medical University|||||f||||||||||||||2018-06-01 04:21:10.334969|2018-06-01 04:21:10.334969
NCT00251550|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2007-11-05|2005-11-08|2005-11-10|Estimate|||||||2007-11-05|2007-11-06|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|August 2006|Actual|2006-08-31|||||Interventional|||Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma|Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma|Completed||Phase 1/Phase 2|12||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:21:10.600024|2018-06-01 04:21:10.600024
NCT00251537|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2006-07-07|2005-11-09|2005-11-10|Estimate|||||||2006-07-07|2006-07-10|Estimate|November 2005||2005-11-30|July 2006|2006-07-31|August 2006||2006-08-31|||||Interventional|||A Pilot Study of LTB4 in HIV-1 Infected Adults|A Pilot Study Assessing Safety and Antiretroviral Activity of Intravenously Administered LTB4 in HIV-1 Infected Adults With a CD4 Count Greater Than 250 Cells/mm3 and a Viral Load Greater Than 5,000 Copies/mL, and Who Have Not Received Antiretroviral Therapy Within Two Months|Completed||Phase 2|40||LTB4 Sweden AB|||||f||||||||||||||2018-06-01 04:21:10.866017|2018-06-01 04:21:10.866017
NCT00251524|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-05-09|2005-11-09|2005-11-10|Estimate|||||||2012-05-09|2012-05-11|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC|A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC|Completed||Phase 2|69|Actual|Veeda Oncology|||||f||||f||||||||||2018-06-01 04:21:11.124713|2018-06-01 04:21:11.124713
NCT00251511|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-05-09|2005-11-08|2005-11-10|Estimate|||||||2012-05-09|2012-05-11|Estimate|August 2004||2004-08-31|May 2012|2012-05-31|May 2007|Actual|2007-05-31|January 2006|Actual|2006-01-31||Interventional|||A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome|A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome|Terminated||Phase 2|60|Actual|Veeda Oncology||||Sponsor terminated trial|f||||f||||||||||2018-06-01 04:21:11.238928|2018-06-01 04:21:11.238928
NCT00251498|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2008-08-20|2005-11-08|2005-11-10|Estimate|||||||2008-08-20|2008-08-21|Estimate||||August 2008|2008-08-31|October 2007|Actual|2007-10-31|||||Interventional|||Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|82|Actual|Veeda Oncology|||||f||||||||||||||2018-06-01 04:21:11.325881|2018-06-01 04:21:11.325881
NCT00251485|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2008-08-20|2005-11-08|2005-11-10|Estimate|||||||2008-08-20|2008-08-21|Estimate|March 2004||2004-03-31|August 2008|2008-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer|A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer|Completed||Phase 2|82|Actual|Veeda Oncology|||||f||||f||||||||||2018-06-01 04:21:11.428491|2018-06-01 04:21:11.428491
NCT00251472|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-05-09|2005-11-09|2005-11-10|Estimate|||||||2012-05-09|2012-05-11|Estimate|March 2005||2005-03-31|May 2012|2012-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer|A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer|Completed||Phase 2|72|Actual|Veeda Oncology|||||f||||f||||||||||2018-06-01 04:21:11.493017|2018-06-01 04:21:11.493017
NCT00251459|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2014-03-06|2005-11-08|2005-11-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|November 2005||2005-11-30|March 2014|2014-03-31|September 2007|Actual|2007-09-30|||||Interventional|||A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naive and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|Completed||Phase 3|5000||Genentech, Inc.|||||||||||||||||||2018-06-01 04:21:11.55087|2018-06-01 04:21:11.55087
NCT00251446|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-05-09|2005-11-08|2005-11-10|Estimate|||||||2012-05-09|2012-05-11|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer|A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|70|Actual|Veeda Oncology|||||f||||f||||||||||2018-06-01 04:21:11.611917|2018-06-01 04:21:11.611917
NCT00251433|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2017-06-06|2005-11-09|2005-11-10|Estimate|||||||2017-06-06|2017-06-08|Actual|September 26, 2005|Actual|2005-09-26|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer|An Open-label, Multicenter, Phase I/II Dose Escalation Study of Oral GW572016 in Combination With Docetaxel (Taxotere) Plus Trastuzumab (Herceptin) in Subjects Previously Untreated for ErbB2-overexpressing Metastatic Breast Cancer|Active, not recruiting||Phase 1|53|Actual|Novartis||3|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 04:21:11.672275|2018-06-01 04:21:11.672275
NCT00251420|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2009-05-06|2005-11-09|2005-11-10|Estimate|||||||2009-05-06|2009-05-07|Estimate|December 2005||2005-12-31|May 2009|2009-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Writing About Disease: Effect on Rehabilitation?|Writing About Disease: Effect on Rehabilitation?|Completed||N/A|180|Anticipated|LHL Helse|||||f||||f||||||||||2018-06-01 04:21:11.749109|2018-06-01 04:21:11.749109
NCT00251407|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-08-07|2005-11-08|2005-11-10|Estimate|||||||2012-08-07|2012-08-09|Estimate|September 1999||1999-09-30|August 2012|2012-08-31|April 2009|Actual|2009-04-30|January 2003|Actual|2003-01-31||Interventional|||Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies|Phase I Study of Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies|Completed||Phase 1|46|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 04:21:11.797737|2018-06-01 04:21:11.797737
NCT00251394|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2010-01-28|2005-11-08|2005-11-10|Estimate|||||||2010-01-28|2010-01-29|Estimate|July 2004||2004-07-31|July 2009|2009-07-31|July 2009|Actual|2009-07-31|December 2006|Actual|2006-12-31||Interventional|||Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma|A Phase 2, Open-Label Study of the Efficacy, Safety, and Tolerability of Dynavax's Immunostimulatory Phosphorothiolate Oligodeoxyribonucleotide, 1018 ISS, Following Rituxan (Rituximab) Treatment in Patients With CD20+, B-Cell Follicular Non-Hodgkin's Lymphoma.|Completed||Phase 2|30|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:21:11.872434|2018-06-01 04:21:11.872434
NCT00251381|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2006-10-25|2005-11-09|2005-11-10|Estimate|||||||2006-10-25|2006-10-26|Estimate|November 2005||2005-11-30|October 2006|2006-10-31|November 2009||2009-11-30|||||Interventional|||Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.|Open Label Randomized Phase II, Multicentre, Pilot Study to Evaluate Safety and Efficacy of the Combination of Cetuximab and Concomitant-Boost Accelerated Radiotherapy Followed or Not by a Complementary Treatment With Cetuximab in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.|Unknown status|Recruiting|Phase 2|90||Trial Form Support S.L.|||||f||||||||||||||2018-06-01 04:21:11.975799|2018-06-01 04:21:11.975799
NCT00251368|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2011-03-09|2005-11-08|2005-11-10|Estimate|||||||2011-03-09|2011-03-10|Estimate|January 1995||1995-01-31|March 2011|2011-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia|Multicenter Study of 9-AC in Refractory Leukemia|Completed||Phase 1|52|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:21:12.110325|2018-06-01 04:21:12.110325
NCT00251355|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2016-12-19|2005-11-08|2005-11-10|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 1998||1998-01-31|December 2016|2016-12-31|August 2008|Actual|2008-08-31|June 2007|Actual|2007-06-30||Interventional|||Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer|A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer|Completed||Phase 1|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:21:12.167936|2018-06-01 04:21:12.167936
NCT00251342|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|||2007-04-04|2005-11-09|2005-11-10|Estimate|||||||2007-04-04|2007-04-05|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|January 2008|Anticipated|2008-01-31|||||Interventional|||Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale|Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale|Unknown status|Recruiting|Phase 2/Phase 3|460||Chinese University of Hong Kong|||||f||||f||||||||||2018-06-01 04:21:12.234148|2018-06-01 04:21:12.234148
NCT00251329|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2007-04-03|2005-11-08|2005-11-10|Estimate|||||||2007-04-03|2007-04-04|Estimate|May 2003||2003-05-31|April 2007|2007-04-30||||||||Interventional|||Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery|Phase II Neoadjuvant Trial of Docetaxel (Taxotere), Carboplatin, and Capecitabine (Xeloda) in the Treatment of Early Stage Locally Advanced and Inflammatory Breast Cancer|Unknown status|Active, not recruiting|Phase 2|48||Cancer Research Network|||||f||||||||||||||2018-06-01 04:21:12.290665|2018-06-01 04:21:12.290665
NCT00251316|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2012-11-20||2013-01-29|2005-11-08|2005-11-09|Estimate|2012-11-20|2012-12-27|Estimate||||2013-01-29|2013-02-04|Estimate|November 2005||2005-11-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer|The Effects of Lithium Carbonate on Low Dose Radioiodine Ablation in Early Thyroid Cancer Treatment|Completed||Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 04:21:12.362058|2018-06-01 04:21:12.362058
NCT00251303|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-09|2013-05-16||2014-07-14|2005-11-08|2005-11-09|Estimate|2014-07-14|2014-07-15|Estimate||||2014-07-14|2014-07-15|Estimate|August 2005||2005-08-31|July 2014|2014-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||These data apply only to double-blind phase.|Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders|An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent|Completed||Phase 2|78|Actual|National Institutes of Health Clinical Center (CC)|Only treatment-refractory subjects were eligible for study participation. This may have decreased treatment response. Further, 98% were taking psychotropic drugs at baseline, which may have reduced between-group differences.|2|||f||||f||||||||||2018-06-01 04:21:13.567823|2018-06-01 04:21:13.567823
NCT00251290|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2009-03-02|2005-11-07|2005-11-09|Estimate|||||||2009-03-02|2009-03-03|Estimate|November 2004||2004-11-30|March 2009|2009-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack|Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack|Completed||Phase 2|62|Actual|Yale University|||||f||||||||||||||2018-06-01 04:21:13.807359|2018-06-01 04:21:13.807359
NCT00251277|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2012-11-14|2005-11-07|2005-11-09|Estimate|||||||2012-11-14|2012-11-15|Estimate|November 2005||2005-11-30|November 2012|2012-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura|Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura|Withdrawn||Phase 1/Phase 2|0|Actual|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:21:13.887007|2018-06-01 04:21:13.887007
NCT00251264|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2015-07-09|2005-11-08|2005-11-09|Estimate|||||||2015-07-09|2015-07-13|Estimate|November 2001||2001-11-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2010|Actual|2010-12-31||Interventional|||Arthroscopic Versus Open Stabilization for Traumatic Shoulder Instability|Arthroscopic Versus Open Stabilization of Traumatic Unidirectional Anterior Shoulder Instability: A Randomized Clinical Trial|Completed||N/A|194|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 04:21:13.955939|2018-06-01 04:21:13.955939
NCT00251251|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-06-15|2005-11-08|2005-11-09|Estimate|||||||2012-06-15|2012-06-18|Estimate|April 2003||2003-04-30|June 2012|2012-06-30|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|RAFT||Resynchronization/Defibrillation for Ambulatory Heart Failure Trial|Resynchronization/Defibrillation for Ambulatory Heart Failure Trial|Completed||N/A|1798|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-06-01 04:21:14.051193|2018-06-01 04:21:14.051193
NCT00251238|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2015-01-12||2017-05-16|2005-11-08|2005-11-09|Estimate|2017-05-16|2017-05-22|Actual||||2017-05-16|2017-05-22|Actual|November 2005||2005-11-30|May 2017|2017-05-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon|Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon|Completed||Phase 2|41|Actual|VSM Geneesmiddelen b.v.||2|||f||||t||||||||Undecided||2018-06-01 04:21:14.270931|2018-06-01 04:21:14.270931
NCT00251225|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2016-01-15||2017-07-10|2005-11-08|2005-11-09|Estimate|2017-07-10|2017-08-09|Actual||||2017-07-10|2017-08-09|Actual|August 2005||2005-08-31|July 2017|2017-07-31|March 2014|Actual|2014-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Imatinib and Docetaxel in Prostate Cancer|A Phase II Study of Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer|Completed||Phase 2|49|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:21:14.519406|2018-06-01 04:21:14.519406
NCT00251212|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2014-04-09|2005-11-07|2005-11-09|Estimate|||||||2014-04-09|2014-04-10|Estimate|September 2006||2006-09-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2010|Actual|2010-10-31||Interventional|||Tailored Teen Alcohol and Violence Prevention in the Emergency Room (ER)|Tailored Teen Alcohol and Violence Prevention in the ER|Completed||N/A|3694|Actual|University of Michigan||3|||f||||f||||||||||2018-06-01 04:21:14.832019|2018-06-01 04:21:14.832019
NCT00251199|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2007-12-17|2005-11-07|2005-11-09|Estimate|||||||2007-12-17|2007-12-21|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|||VX-950 and Peginterferon for Hepatitis C|A Phase 1b Viral Kinetic Study of VX-950 and Peginterferon in Hepatitis C|Completed||Phase 1|20||Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 04:21:14.934519|2018-06-01 04:21:14.934519
NCT00251186|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2010-01-25|2005-11-08|2005-11-09|Estimate|||||||2010-01-25|2010-01-26|Estimate|April 2006||2006-04-30|January 2010|2010-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients|Phase II Study of First-Line Capecitabine and Cetuximab for Treatment of Metastatic Colorectal Cancer in Elderly Patients and/or Those With Multiple Comorbidities Unable to Receive Chemotherapy Doublets|Terminated||Phase 2|18||Rutgers, The State University of New Jersey||||Funding unavailable|f||||||||||||||2018-06-01 04:21:14.988107|2018-06-01 04:21:14.988107
NCT00251173|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2016-04-07|2005-11-07|2005-11-09|Estimate|||||||2016-04-07|2016-04-08|Estimate|November 2005||2005-11-30|April 2016|2016-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Project Health Link: Connecting Patients With Services|Services Interventions for Injured ED Substance Abusers|Completed||N/A|755|Actual|University of Michigan||3|||f||||f||||||||No||2018-06-01 04:21:15.049441|2018-06-01 04:21:15.049441
NCT00251160|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2015-07-09|2005-11-07|2005-11-09|Estimate|||||||2015-07-09|2015-07-13|Estimate|December 1999||1999-12-31|July 2015|2015-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Electrothermal Arthroscopic Capsulorrhaphy (ETAC) and Open Inferior Capsular Shift in Patients With Shoulder Instability|Arthroscopic Electrothermal Capsulorrhaphy, ETAC, Versus Open Inferior Capsular Shift, ICS in Patients With Shoulder Instability: A Multicentre Randomized Clinical Trial|Completed||N/A|58|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 04:21:15.114664|2018-06-01 04:21:15.114664
NCT00251147|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2008-01-14|2005-11-07|2005-11-09|Estimate|||||||2008-01-14|2008-01-17|Estimate|March 1999||1999-03-31|January 2008|2008-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Randomized Clinical Trial Comparing Open to Mini-Open Rotator Cuff Repair for Full-Thickness Rotator Cuff Tears.|Prospective Randomized Study Comparing Open Acromioplasty and Rotator Cuff Repair Versus Arthroscopic Acromioplasty and Mini-Open Rotator Cuff Repair.|Completed||N/A|73|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 04:21:15.198984|2018-06-01 04:21:15.198984
NCT00251134|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2008-09-11|2005-11-08|2005-11-09|Estimate|||||||2008-09-11|2008-09-12|Estimate|October 2003||2003-10-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|June 2008|Actual|2008-06-30||Interventional|OMEGA||OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction|OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.|Completed||Phase 3|3800|Actual|Stiftung Institut fuer Herzinfarktforschung||2|||f||||t||||||||||2018-06-01 04:21:15.364856|2018-06-01 04:21:15.364856
NCT00251121|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2012-02-08|2005-11-07|2005-11-09|Estimate|||||||2012-02-08|2012-02-09|Estimate|November 2005||2005-11-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Routine Mini-invasive Electrophysiology Study for Patients Feeling Tachycardia, With a Negative Holter ECG|Mini-invasive Electrophysiology Study as a Routine Examination for Patients Complaining of Tachycardia, But With a Negative Holter ECG.|Completed||N/A|51|Actual|Sykehuset Telemark||1|||f||||f||||||||||2018-06-01 04:21:15.467532|2018-06-01 04:21:15.467532
NCT00251108|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2007-02-28|2005-11-08|2005-11-09|Estimate|||||||2007-02-28|2007-03-01|Estimate|October 2003||2003-10-31|February 2007|2007-02-28|March 2007||2007-03-31|||||Interventional|||Fitness Training After Traumatic Brain Injury|The Efficacy of a Supervised Fitness Centre-Based Exercise Programme Compared to an Unsupervised Home-Based Exercise Programme on Improving Fitness and Psychosocial Outcomes in a Traumatic Brain Injured Population|Completed||N/A|60||Sydney South West Area Health Service|||||f||||||||||||||2018-06-01 04:21:15.553778|2018-06-01 04:21:15.553778
NCT00251095|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2009-06-02|2005-11-08|2005-11-09|Estimate|||||||2009-06-02|2009-06-04|Estimate|September 2005||2005-09-30|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer|A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer|Terminated||Phase 3|821|Actual|Achieve Life Sciences||2||Failed primary endpoint|f||||||||||||||2018-06-01 04:21:15.617103|2018-06-01 04:21:15.617103
NCT00251082|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2008-03-11|2005-11-08|2005-11-09|Estimate|||||||2008-03-11|2008-03-12|Estimate|December 2005||2005-12-31|March 2008|2008-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Vasomotoric Symptoms Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination|A Randomized, Placebo-Controlled, Double-Blind, Multi-National Study to Demonstrate Efficacy of Continuous Combined 0.5 mg Estradiol and 2.5 mg Dydrogesterone in the Treatment of Vasomotor Symptoms in Postmenopausal Women in Comparison to Placebo Over 3 Months, and to Investigate the Bleeding Pattern Over a Double-Blind Treatment Period of One Year Compared With Continuous Combined 1 mg Estradiol and 5 mg Dydrogesterone|Completed||Phase 3|391|Actual|Solvay Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:21:15.713866|2018-06-01 04:21:15.713866
NCT00251069|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2005-11-07|2005-11-07|2005-11-09|Estimate|||||||2005-11-07|2005-11-09|Estimate|April 2005||2005-04-30|July 2005|2005-07-31|August 2005||2005-08-31|||||Interventional|||Glucosamine Sulphate and Increased Level of Blood Cholesterol|Glucosamine Sulphate and Hypercholesterolaemia|Completed||Phase 4|66||Slidgigtinstituttet|||||f||||||||||||||2018-06-01 04:21:15.809039|2018-06-01 04:21:15.809039
NCT00251056|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-08-27|2005-11-07|2005-11-09|Estimate|||||||2008-08-27|2008-08-29|Estimate|October 2005||2005-10-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Mannitol Dose Response Study in Cystic Fibrosis|A Phase IIa Randomised, Open Label, Dose Response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement In Patients With Cystic Fibrosis|Completed||Phase 2|48|Actual|Pharmaxis||4|||f||||t||||||||||2018-06-01 04:21:15.877736|2018-06-01 04:21:15.877736
NCT00251043|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2012-03-23|2005-11-07|2005-11-09|Estimate|||||||2012-03-23|2012-03-26|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Site|Antepartum Study on Use of Interpersonal Psychotherapy at 3 New York City Sites|Completed||Phase 4|142|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 04:21:15.976569|2018-06-01 04:21:15.976569
NCT00251030|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2009-02-13|2005-11-08|2005-11-09|Estimate|||||||2009-02-13|2009-02-16|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|January 2006|Actual|2006-01-31|||||Interventional|||A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects|A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects|Completed||Phase 4|20|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:21:16.046508|2018-06-01 04:21:16.046508
NCT00251017|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2012-12-25|2005-11-08|2005-11-09|Estimate|||||||2012-12-25|2012-12-27|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs|Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs|Completed||N/A|34|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:21:16.104365|2018-06-01 04:21:16.104365
NCT00251004|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|2010-12-17||2011-04-07|2005-11-07|2005-11-09|Estimate|2011-04-07|2011-05-10|Estimate||||2011-04-07|2011-05-10|Estimate|October 2005||2005-10-31|April 2011|2011-04-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients|Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients|Completed||Phase 3|833|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:21:16.256967|2018-06-01 04:21:16.256967
NCT00250991|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2009-05-07|2005-11-07|2005-11-09|Estimate|||||||2009-05-07|2009-05-08|Estimate|July 2003||2003-07-31|May 2009|2009-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial|Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial|Completed||Phase 1/Phase 2|94|Actual|University of Cincinnati|||||f||||t||||||||||2018-06-01 04:21:18.554211|2018-06-01 04:21:18.554211
NCT00250978|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2008-04-29|2005-11-08|2005-11-09|Estimate|||||||2008-04-29|2008-04-30|Estimate|November 2005||2005-11-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC|Phase I of Bevacizumab Plus Chemotherapy in Patients With Malignant Pleural Effusion Due to Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|15|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:21:18.641463|2018-06-01 04:21:18.641463
NCT00250965|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2010-11-03|2005-11-07|2005-11-09|Estimate|||||||2010-11-03|2010-11-04|Estimate|July 2004||2004-07-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional|||MPAACS: Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery|Magnesium for the Prevention of Atrial Arrhythmias After Cardiac Surgery|Terminated||Phase 3|927|Actual|University of British Columbia||||Terminated by DSMB; futility analysis showing Mg treatment not efficacious|f||||f||||||||||2018-06-01 04:21:18.70643|2018-06-01 04:21:18.70643
NCT00250952|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2005-11-08|2005-11-08|2005-11-09|Estimate|||||||2005-11-08|2005-11-09|Estimate|February 2005||2005-02-28|November 2005|2005-11-30|June 2005||2005-06-30|||||Interventional|||Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection Affects Its Overall Effect and Duration.|A Randomized, Evaluator-Blinded, Two Centre Study of the Safety and Effect of Volume on the Diffusion and Efficacy of BOTOX Cosmetic™ (Botulinum Toxin Type A) in the Treatment of Lateral Orbital Rhytides.|Completed||N/A|20||Carruthers Dermatology Centre|||||f||||||||||||||2018-06-01 04:21:18.760939|2018-06-01 04:21:18.760939
NCT00250939|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|||2014-02-04|2005-11-08|2005-11-09|Estimate|||||||2014-02-04|2014-02-06|Estimate|February 2005||2005-02-28|February 2014|2014-02-28|November 2006|Actual|2006-11-30|July 2006|Actual|2006-07-31||Interventional|||A Study of rhGAA in Patients With Late-Onset Pompe Disease|Single-center, Open-label Study of Safety, Pharmacokinetics and Efficacy of rhGAA in Patients With Late-Onset Pompe Disease|Completed||Phase 2|5|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:21:18.813109|2018-06-01 04:21:18.813109
NCT00250926|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-08|2012-12-19||2016-03-10|2005-11-08|2005-11-09|Estimate|2016-03-10|2016-04-08|Estimate||||2016-03-10|2016-04-08|Estimate|October 2005||2005-10-31|March 2016|2016-03-31|February 2009|Actual|2009-02-28|March 2007|Actual|2007-03-31||Interventional|||Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia|A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia|Completed||Phase 2|23|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:21:18.904064|2018-06-01 04:21:18.904064
NCT00250913|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2010-11-05|2005-11-07|2005-11-08|Estimate|||||||2010-11-05|2010-11-09|Estimate|August 2005||2005-08-31|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Efficacy and Cost-Effectiveness of Behavioral Counseling for Exercise in Men and Women Following Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI)|Efficacy and Cost-Effectiveness of Behavioral Counseling For Exercise Behavior in Men and Women Following AMI and PCI|Completed||Phase 1|304|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||||||||||||2018-06-01 04:21:19.214923|2018-06-01 04:21:19.214923
NCT00250900|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2006-11-29|2005-11-07|2005-11-08|Estimate|||||||2006-11-29|2006-11-30|Estimate|July 2004||2004-07-31|November 2005|2005-11-30|August 2005||2005-08-31|||||Interventional|||Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial|Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial|Completed||N/A|240||Yale University|||||f||||||||||||||2018-06-01 04:21:19.295699|2018-06-01 04:21:19.295699
NCT00250887|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2007-10-22|2005-11-04|2005-11-08|Estimate|||||||2007-10-22|2007-10-23|Estimate|July 2005||2005-07-31|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research|A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research|Completed||Phase 2|22|Actual|University of Zurich|||||f||||f||||||||||2018-06-01 04:21:19.365802|2018-06-01 04:21:19.365802
NCT00250874|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2005-11-07|2005-11-07|2005-11-08|Estimate|||||||2005-11-07|2005-11-08|Estimate|December 2003||2003-12-31|November 2005|2005-11-30||||||||Interventional|||Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer|Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|45||Zeneus Pharma|||||f||||||||||||||2018-06-01 04:21:19.440052|2018-06-01 04:21:19.440052
NCT00250861|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2008-04-17|2005-11-07|2005-11-08|Estimate|||||||2008-04-17|2008-04-21|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma|A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue|Terminated||Phase 2|110||US Oncology Research||||Study terminated due to lack of enrollment.|f||||||||||||||2018-06-01 04:21:19.497823|2018-06-01 04:21:19.497823
NCT00250848|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2016-06-09|2005-11-04|2005-11-08|Estimate|||||||2016-06-09|2016-06-13|Estimate|March 2004||2004-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Observational|||Lung Cancer Case Registry and Tissue Resource|Lung Cancer Case Registry and Tissue Resource|Completed|||750|Actual|University of New Mexico|||||f||||f||||||Samples With DNA|"~     Blood samples, and sputum (phlegm) samples.~   "|||2018-06-01 04:21:19.577296|2018-06-01 04:21:19.577296
NCT00250835|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2015-06-19||2015-08-03|2005-11-04|2005-11-08|Estimate|2015-08-03|2015-09-01|Estimate||||2015-08-03|2015-09-01|Estimate|April 2005||2005-04-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|December 2012|Actual|2012-12-31||Interventional|||Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer|A Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Patients With Newly Diagnosed Resectable Rectal Cancer|Terminated||Phase 2|38|Actual|New Mexico Cancer Care Alliance||1||Low accrual|f||||t||||||||||2018-06-01 04:21:19.645461|2018-06-01 04:21:19.645461
NCT00250822|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04||2011-07-19|2011-09-23|2005-11-04|2005-11-08|Estimate||||2011-07-19|2011-07-22|Estimate|2011-09-23|2011-10-05|Estimate|October 2005||2005-10-31|September 2011|2011-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter|Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.|Completed||Phase 2|11|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||||||2018-06-01 04:21:19.903102|2018-06-01 04:21:19.903102
NCT00250809|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2010-01-06|2005-11-04|2005-11-08|Estimate|||||||2010-01-06|2010-01-07|Estimate|March 1994||1994-03-31|March 2009|2009-03-31|March 2006|Actual|2006-03-31|December 2005|Actual|2005-12-31||Interventional|||Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study|CVC Pros and Cons of Scheduled Triple-lumen Central Venous Catheter Exchange: A Prospective Controlled Randomized Study|Completed||N/A|15|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:21:20.149477|2018-06-01 04:21:20.149477
NCT00250796|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2010-01-06|2005-11-04|2005-11-08|Estimate|||||||2010-01-06|2010-01-07|Estimate|September 2000||2000-09-30|December 2009|2009-12-31|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma|Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 2|12|Actual|University of New Mexico||2|||f||||t||||||||||2018-06-01 04:21:20.211697|2018-06-01 04:21:20.211697
NCT00250783|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2010-01-06|2005-11-04|2005-11-08|Estimate|||||||2010-01-06|2010-01-07|Estimate|July 2002||2002-07-31|July 2009|2009-07-31|January 2008|Actual|2008-01-31|||||Observational|||Pre-Clinical Models in Gynecological Tumors A Tissue Repository|Pre-Clinical Models in Gynecological Tumors: A Tissue Repository|Completed|||26|Actual|University of New Mexico|||||f||||t||||||Samples Without DNA|"~     Tumor and normal tissues, ascites, and/or serum, and/or urine from women with malignant or~     premalignant gynecological conditions for which they are undergoing medically-indicated~     surgery, and normal tissues from women without malignancy who volunteer to donate serum~     and/or tissue at the time of medically indicated surgery~   "|||2018-06-01 04:21:20.299123|2018-06-01 04:21:20.299123
NCT00250770|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2016-05-10|2005-11-04|2005-11-08|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 1998||1998-01-31|May 2016|2016-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis|CSF-1 and Other Cytokines in Human Endometrial Carcinogenesis|Recruiting|||750|Anticipated|University of New Mexico|||1||f||||t||||||Samples Without DNA|"~     We have collected serum and ascites from approximately 200 patients with endometrial~     carcinoma and 200 controls. We have long term follow-up serum from approximately 60 of these~     patients. Approximately 10% of endometrial carcinoma patients recur. Our goal will be to~     eventually have follow-up serum from up to 60 patients with recurrent endometrial carcinoma~     in our tissue bank, so that we can determine the role of these assays in predicting~     recurrence.~   "|||2018-06-01 04:21:20.362036|2018-06-01 04:21:20.362036
NCT00250757|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2016-01-06|2005-11-04|2005-11-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|October 2005||2005-10-31|January 2016|2016-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions|Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions|Terminated|||101|Actual|New Mexico Cancer Care Alliance||||Study was not renewed timely with IRB of record.|f||||t||||||Samples Without DNA|"~     Semen samples or Prostatic secretions (via prostate massage).~   "|||2018-06-01 04:21:20.428864|2018-06-01 04:21:20.428864
NCT00250744|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-09-23|2005-11-04|2005-11-08|Estimate|||||||2011-09-23|2011-09-27|Estimate|December 2004||2004-12-31|December 2009|2009-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Comparison of Aprepitant Versus Gabapentin in the Prevention of Delayed Nausea and Vomiting|Comparison of Aprepitant vs. Gabapentin in the Prevention of Delayed Nausea and Vomiting|Completed||Phase 2|200|Actual|New Mexico Cancer Care Alliance||2|||f||||t||||||||||2018-06-01 04:21:20.484544|2018-06-01 04:21:20.484544
NCT00250731|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2009-06-15|2005-11-07|2005-11-08|Estimate|||||||2009-06-15|2009-06-16|Estimate|January 2006||2006-01-31|June 2009|2009-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Improving Diabetes Outcomes: a Couples Intervention|Improving Diabetes Outcomes: a Couples Intervention|Completed||Phase 1|45|Anticipated|State University of New York - Upstate Medical University||3|||f||||t||||||||||2018-06-01 04:21:20.558797|2018-06-01 04:21:20.558797
NCT00250718|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2015-06-13||2015-07-06|2005-11-04|2005-11-08|Estimate|2015-07-06|2015-08-03|Estimate||||2015-07-06|2015-08-03|Estimate|October 2004||2004-10-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|November 2008|Actual|2008-11-30||Interventional|||Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach|Phase II Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-angiogenic Approach|Terminated||Phase 2|17|Actual|New Mexico Cancer Care Alliance||1||Low rate of accrual|f||||t||||||||||2018-06-01 04:21:20.668631|2018-06-01 04:21:20.668631
NCT00250705|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2017-03-28||2017-07-06|2005-11-04|2005-11-08|Estimate|2017-07-06|2017-07-11|Actual||||2017-07-06|2017-07-11|Actual|November 17, 2004|Actual|2004-11-17|July 2017|2017-07-31|March 23, 2009|Actual|2009-03-23|March 23, 2009|Actual|2009-03-23||Interventional|||Trial of Aripiprazole in the Treatment of CD in Adolescents|Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents|Completed||Phase 4|12|Actual|University of Iowa|12 subjects were recruited for this study but only 10 (83%) completed at least a week of data demonstrating the primary frustrations of the investigators in this study. Conduct disorder was a difficult diagnosis to recruit patients into this study.|1|||f||||f||||||||No||2018-06-01 04:21:20.98347|2018-06-01 04:21:20.98347
NCT00250692|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2017-02-15|2005-11-07|2005-11-08|Estimate|||||||2017-02-15|2017-02-17|Actual||||February 2017|2017-02-28||||||||Interventional|||A Study to Test the Pain-relieving Effect of Laughing Gas in Infants|Analgesic Effect of Nitrous Oxide in Neonates Undergoing Heel Stick|Withdrawn||Phase 3|0|Actual|University of California, Los Angeles||||unknown - no record of study conduct in departmental archive|f||||||||||||||2018-06-01 04:21:21.219376|2018-06-01 04:21:21.219376
NCT00250679|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2008-10-03||2012-05-29|2005-11-04|2005-11-08|Estimate|2009-02-18|2009-02-19|Estimate||||2012-05-29|2012-06-04|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease|Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|443|Actual|Sunovion|Please see dropout rate in participant group. Sunovion is unaware of any other limitations or caveats associated with this study.|3|||f||||t||||||||||2018-06-01 04:21:21.350028|2018-06-01 04:21:21.350028
NCT00250666|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2008-07-07|2005-11-07|2005-11-08|Estimate|||||||2008-07-07|2008-07-08|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|May 2007|Actual|2007-05-31|May 2007||2007-05-31||Interventional|||Procalcitonin-Guided Antimicrobial Discontinuation|Procalcitonin-Guided Antimicrobial Discontinuation Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Sepsis|Completed||Phase 4|70|Anticipated|University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:21:22.984789|2018-06-01 04:21:22.984789
NCT00250653|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2012-02-15|2005-11-07|2005-11-08|Estimate|||||||2012-02-15|2012-02-17|Estimate|May 2005||2005-05-31|February 2012|2012-02-29|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression|A Fifty-two-week, Multicenter, Open-label Study Evaluating the Long-term Safety and Tolerability of Saredutant in Adult and Elderly Patients With Major Depressive Disorder|Completed||Phase 3|365|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:21:23.050119|2018-06-01 04:21:23.050119
NCT00250640|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2015-01-30|2005-11-07|2005-11-08|Estimate|||||||2015-01-30|2015-02-02|Estimate|April 2005||2005-04-30|January 2015|2015-01-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Observational|||Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years|Open-label, Uncontrolled, Prospective Long-term Observation of Ventavis Inhalation Therapy in the Treatment of Patients With Primary Pulmonary Hypertension up to 4 Years|Completed|||106|Actual|Bayer|||1||f||||f||||||None Retained|"~     n.a~   "|||2018-06-01 04:21:23.171091|2018-06-01 04:21:23.171091
NCT00250627|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2008-12-22|2005-11-07|2005-11-08|Estimate|||||||2008-12-22|2008-12-23|Estimate|December 2004||2004-12-31|December 2008|2008-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder|Completed||Phase 3|465|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:21:23.28731|2018-06-01 04:21:23.28731
NCT00250614|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2010-06-08|2005-11-07|2005-11-08|Estimate|||||||2010-06-08|2010-06-09|Estimate|April 2005||2005-04-30|June 2010|2010-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder.|Completed||Phase 3|452|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:21:23.356384|2018-06-01 04:21:23.356384
NCT00250601|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2012-02-15|2005-11-07|2005-11-08|Estimate|||||||2012-02-15|2012-02-17|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression|An Eight-Week, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety, and Tolerability of One Fixed 100 mg Dose of Saredutant in Patients With Major Depressive Disorder.|Completed||Phase 3|460|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:21:23.417293|2018-06-01 04:21:23.417293
NCT00250588|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2012-12-11||2013-04-25|2005-11-04|2005-11-08|Estimate|2013-04-25|2013-06-03|Estimate||||2013-04-25|2013-06-03|Estimate|October 2003||2003-10-31|April 2013|2013-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Problem-Solving Skills Training to Improve Care for Children With Asthma|Reducing Barriers to Care for Vulnerable Children With Asthma|Completed||N/A|252|Actual|RAND|Substantial dropout, particularly from CC+PST, is a limitation. Our sample size was not large enough, nor was there sufficient variability in our secondary outcomes, to detect differences in health care utilization despite the odds ratios.|3|||f||||f||||||||||2018-06-01 04:21:23.498666|2018-06-01 04:21:23.498666
NCT00250575|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2016-04-20|2005-11-07|2005-11-08|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2005||2005-11-30|April 2016|2016-04-30||||December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia|A 24-week, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia|Completed||Phase 3|43|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:21:23.820779|2018-06-01 04:21:23.820779
NCT00250562|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-06|||2017-07-30|2005-11-07|2005-11-08|Estimate|||||||2017-07-30|2017-08-01|Actual|October 2005||2005-10-31|November 2016|2016-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.|A Multicenter, Double-blind, Randomized, Active Controlled, Parallel Group Trial Comparing the Combinations of Valsartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Valsartan 80 mg in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80mg|Completed||Phase 3|1171|Actual|Novartis|||||f||||||||||||||2018-06-01 04:21:23.90104|2018-06-01 04:21:23.90104
NCT00250549|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2014-12-09|2005-11-07|2005-11-08|Estimate|||||||2014-12-09|2014-12-10|Estimate|May 2005||2005-05-31|December 2014|2014-12-31|March 2006|Actual|2006-03-31|October 2005|Actual|2005-10-31||Interventional|||A Theory Based HIV Prevention Video For Rapid HIV Testing: A Randomized Trial|A Randomized Control Trial Evaluating the Educational Effectiveness of a Rapid HIV Post-Test Counseling Video.|Completed||N/A|128|Actual|North Bronx Healthcare Network||2|||f||||f||||||||||2018-06-01 04:21:23.962239|2018-06-01 04:21:23.962239
NCT00250536|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2010-01-12|2005-11-07|2005-11-08|Estimate|||||||2010-01-12|2010-01-14|Estimate|March 2000||2000-03-31|January 2010|2010-01-31|October 2004||2004-10-31|||||Interventional|||Anabolic Steroids and Exercise in Hemodialysis Patients|Anabolic Steroids and Exercise in Hemodialysis Patients|Completed||N/A|80||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:21:24.063583|2018-06-01 04:21:24.063583
NCT00250523|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2017-09-14|2005-11-07|2005-11-08|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2003||2003-02-28|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Observational|||Mathematical Modeling of the Acute Inflammatory Response Following Injury|Mathematical Modeling of the Acute Inflammatory Response Following Injury|Recruiting|||520|Anticipated|National Institute of General Medical Sciences (NIGMS)|||2||f||||t||||||Samples With DNA|"~     For trauma injury cohort: The maximum blood volume collected over the 28 day period, if all~     samples are obtained, is approximately 90 cc. All standard precautions will be undertaken to~     assure minimal risk.~      Blood samples will be obtained for genetic analysis of inflammatory gene polymorphisms. We~     will collect whole blood, serum and white cells.~   "|No||2018-06-01 04:21:24.159835|2018-06-01 04:21:24.159835
NCT00250510|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2010-03-17|2005-11-07|2005-11-08|Estimate|||||||2010-03-17|2010-03-18|Estimate|June 2004||2004-06-30|March 2010|2010-03-31|December 2006|Actual|2006-12-31|||||Interventional|||Reimbursement Effects on Enrollment in Obesity Treatment|A Prospective Study to Determine the Effects of a Reimbursement Incentive on Enrollment and Outcomes in a Community Weight Control Program.|Completed||N/A|401|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 04:21:24.257254|2018-06-01 04:21:24.257254
NCT00250497|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|2012-07-12||2017-02-17|2005-11-07|2005-11-08|Estimate|2015-07-06|2015-08-03|Estimate||||2017-02-17|2017-03-22|Actual|September 2005||2005-09-30|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||New Moves - Obesity Prevention Among Adolescent Girls|New Moves: Obesity Prevention Among Adolescent Girls|Completed||N/A|356|Actual|University of Minnesota - Clinical and Translational Science Institute|Control group also had all-girls PE. Some girls missing body composition data.|2|||f||||t||||||||||2018-06-01 04:21:24.364774|2018-06-01 04:21:24.364774
NCT00250484|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|2015-07-20||2017-09-11|2005-11-07|2005-11-08|Estimate|2016-08-30|2016-10-21|Estimate||||2017-09-11|2017-10-11|Actual|November 2004||2004-11-30|September 2017|2017-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||TMS Treatment for Pain in Chronic Pancreatitis|The Effect of 10-Day Treatment of Repetitive Transcranial Magnetic Stimulation on Abdominal Pain in Patients With Chronic Pancreatitis|Completed||N/A|23|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||No|No plan in protocol to share individual data|2018-06-01 04:21:24.755166|2018-06-01 04:21:24.755166
NCT00250471|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2005-11-07|2005-11-07|2005-11-08|Estimate|||||||2005-11-07|2005-11-08|Estimate|May 2003||2003-05-31|November 2005|2005-11-30|September 2004||2004-09-30|||||Interventional|||PROTECT-TIMI 30 Trial|A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents|Completed||Phase 3|900||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:21:25.129547|2018-06-01 04:21:25.129547
NCT00250458|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|2009-09-21||2015-10-30|2005-11-07|2005-11-08|Estimate|2010-05-25|2010-06-23|Estimate||||2015-10-30|2015-11-02|Estimate|March 2006||2006-03-31|October 2015|2015-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT)|Completed||Phase 3|346|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:21:25.186393|2018-06-01 04:21:25.186393
NCT00250445|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2015-07-29|2005-11-07|2005-11-08|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2003||2003-01-31|July 2015|2015-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)|A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis|Completed||Phase 3|23498|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:21:25.524721|2018-06-01 04:21:25.524721
NCT00250432|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2009-01-13||2017-02-21|2005-11-04|2005-11-08|Estimate|2009-03-23|2009-03-24|Estimate||||2017-02-21|2017-03-24|Actual|January 2006||2006-01-31|February 2017|2017-02-28|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults|Completed||Phase 3|204|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:21:25.619312|2018-06-01 04:21:25.619312
NCT00250419|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2015-02-09|2005-11-07|2005-11-08|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2005||2005-09-30|February 2015|2015-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||V930 First in Man (FIM) Study (V930-002)(COMPLETED)|A Phase I Study to Evaluate the Safety/Tolerability and Immunogenicity of V-930 in Patients With Cancers Expressing HER-2 and/or CEA|Completed||Phase 1|26|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:21:26.369317|2018-06-01 04:21:26.369317
NCT00250406|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2013-12-19|2005-11-04|2005-11-08|Estimate|||||||2013-12-19|2013-12-20|Estimate|November 2005||2005-11-30|December 2013|2013-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation|Assessment of Bacterial Adherence and Biofilm Formation on a Triclosan Loaded Ureteral Stent: A Phase II Study|Completed||Phase 2|20|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:21:26.467481|2018-06-01 04:21:26.467481
NCT00250393|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2012-08-28|2005-11-04|2005-11-08|Estimate|||||||2012-08-28|2012-08-29|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease|Placebo-Controlled , Crossover , Double-Blind Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Monotherapy]|Completed||Phase 2|64||Kyowa Hakko Kirin Co., Ltd|||||f||||f||||||||||2018-06-01 04:21:26.559907|2018-06-01 04:21:26.559907
NCT00250380|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2011-12-12|2005-11-07|2005-11-08|Estimate|||||||2011-12-12|2011-12-13|Estimate|November 2005||2005-11-30|December 2011|2011-12-31|March 2011|Actual|2011-03-31|June 2010|Actual|2010-06-30||Observational|||The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)|The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)－A Prospective Multicenter Cohort Study-|Completed|||583|Actual|Ministry of Health, Labour and Welfare, Japan|||||f||||t||||||Samples With DNA|"~     whole blood, serum, urine~   "|||2018-06-01 04:21:26.65591|2018-06-01 04:21:26.65591
NCT00250367|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2010-11-24|2005-11-04|2005-11-08|Estimate|||||||2010-11-24|2010-11-25|Estimate|October 1997||1997-10-31|November 2010|2010-11-30|November 1999|Actual|1999-11-30|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.|The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder|Completed||Phase 3|151|Actual|Janssen Pharmaceutica N.V., Belgium|||||||||||||||||||2018-06-01 04:21:26.785454|2018-06-01 04:21:26.785454
NCT00250354|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-01-20|2005-11-04|2005-11-08|Estimate|||||||2011-01-20|2011-01-24|Estimate|September 1997||1997-09-30|January 2011|2011-01-31|August 1999|Actual|1999-08-31|||||Interventional|||A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation|The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years|Completed||Phase 3|110|Actual|Janssen Pharmaceutica N.V., Belgium|||||||||||||||||||2018-06-01 04:21:26.859027|2018-06-01 04:21:26.859027
NCT00250341|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2015-03-19|2005-11-07|2005-11-08|Estimate|||||||2015-03-19|2015-03-20|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Non-invasive Measures of Distal Lung Disease in Asthmatics|Non-Invasive Measures of Distal Lung Disease in Asthmatics Before and After Therapy Directed at the Proximal vs. Distal Lung|Completed||Phase 4|34|Anticipated|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:21:26.931769|2018-06-01 04:21:26.931769
NCT00250328|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-06|||2005-11-06|2005-11-06|2005-11-08|Estimate|||||||2005-11-06|2005-11-08|Estimate|January 2006||2006-01-31|November 2005|2005-11-30||||||||Interventional|||Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-Colectomy|Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-Colectomy|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:21:27.046735|2018-06-01 04:21:27.046735
NCT00250315|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2007-10-31|2005-11-04|2005-11-08|Estimate|||||||2007-10-31|2007-11-01|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Observational|||DOCICAR: Cardiac Dysfunction in Cirrhosis|Cardiac Dysfunction in Cirrhosis: Cirrhotic Cardiomyopathy Evaluated by Dobutamin MRI.|Completed|||||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:21:27.134759|2018-06-01 04:21:27.134759
NCT00250302|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-06|||2011-04-27|2005-11-06|2005-11-08|Estimate|||||||2011-04-27|2011-04-28|Estimate|April 2009||2009-04-30|October 2010|2010-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures|Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures|Completed||Phase 1/Phase 2|24|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:21:27.208503|2018-06-01 04:21:27.208503
NCT00250289|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-06|||2010-01-05|2005-11-06|2005-11-08|Estimate|||||||2010-01-05|2010-01-06|Estimate|March 2006||2006-03-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|January 2008|Actual|2008-01-31||Interventional|||Prevention of Oral Malodor With an Oral Sticker Containing Herbal Formula|Invivo Study of the Efficacy of an Innovative Herbal Formula and Delivery System on Oral Malodor|Completed||Phase 1|15|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:21:27.285774|2018-06-01 04:21:27.285774
NCT00250276|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|2017-01-31||2017-01-31|2005-11-07|2005-11-08|Estimate|2017-01-31|2017-03-17|Actual||||2017-01-31|2017-03-17|Actual|October 2005||2005-10-31|January 2017|2017-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.|Assess Lot-to-lot Consistency of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Following Manufacturing Adjustments Administered Intramuscularly According to a 0,1,6-mth Schedule in Healthy Female Subjects (18-25 y)|Completed||Phase 3|798|Actual|GlaxoSmithKline|None reported.|4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:21:27.427908|2018-06-01 04:21:27.427908
NCT00250263|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-06|||2013-02-11|2005-11-06|2005-11-08|Estimate|||||||2013-02-11|2013-02-13|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy|A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy|Completed||Phase 4|30|Actual|Bayside Health||2|||f||||||||||||||2018-06-01 04:21:29.096174|2018-06-01 04:21:29.096174
NCT00250250|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2011-05-19|2005-11-07|2005-11-08|Estimate|||||||2011-05-19|2011-05-20|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|August 2006|Actual|2006-08-31|March 2006|Actual|2006-03-31||Interventional|||An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG|An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG (Recombinant Somatropin) Administered by ZomaJet Vision X|Completed||Phase 3|27|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:21:29.17815|2018-06-01 04:21:29.17815
NCT00250237|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2009-08-06|2005-11-07|2005-11-08|Estimate|||||||2009-08-06|2009-08-07|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery|Randomised Double-blind Placebo-controlled Study of Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery|Completed||Phase 3|220|Actual|Bronovo Hospital||2|||f||||t||||||||||2018-06-01 04:21:29.244407|2018-06-01 04:21:29.244407
NCT00250224|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-07|||2015-06-25|2005-11-07|2005-11-08|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2006||2006-01-31|September 2005|2005-09-30|May 2014|Actual|2014-05-31|May 2009|Actual|2009-05-31||Interventional|||Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II|Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging - Protocol II|Completed||Phase 1|100|Actual|Aalborg Universitetshospital||1|||f||||t||||||||||2018-06-01 04:21:29.315976|2018-06-01 04:21:29.315976
NCT00250211|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2016-02-23|2005-11-04|2005-11-08|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2005||2005-03-31|October 2011|2011-10-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide|Multimodality Functional Imaging (MRS and Tumor Perfusion) Predicts Tumor Migration, Invasiveness, and Patterns of Failure of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide|Completed||Phase 1/Phase 2|26|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:21:29.391877|2018-06-01 04:21:29.391877
NCT00250198|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-05|||2017-06-30|2005-11-05|2005-11-07|Estimate|||||||2017-06-30|2017-07-02|Actual|November 3, 2005||2005-11-03|September 5, 2006|2006-09-05|September 5, 2006||2006-09-05|||||Interventional|||The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease|A Randomized, Double-blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease|Completed||Phase 2|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:21:29.452583|2018-06-01 04:21:29.452583
NCT00250185|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-05|||2017-06-30|2005-11-04|2005-11-07|Estimate|||||||2017-06-30|2017-07-02|Actual|November 1, 2005||2005-11-01|August 22, 2008|2008-08-22|June 9, 2007|Actual|2007-06-09|June 9, 2007|Actual|2007-06-09||Interventional|||The Role of Nitrite in Preconditioning Mediated Tolerance to Ischemic Stress|The Role of Nitrite in Preconditioning Mediated Tolerance to Ischemic Stress|Completed||Phase 1|135||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:21:29.503021|2018-06-01 04:21:29.503021
NCT00250172|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-05|||2018-05-23|2005-11-04|2005-11-07|Estimate|||||||2018-05-23|2018-05-24|Actual|October 31, 2005||2005-10-31|September 15, 2014|2014-09-15|February 5, 2009|Actual|2009-02-05|February 5, 2009|Actual|2009-02-05||Interventional|||PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram|PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram|Completed||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:21:29.570645|2018-06-01 04:21:29.570645
NCT00250159|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-05|||2018-04-18|2005-11-04|2005-11-07|Estimate|||||||2018-04-18|2018-04-19|Actual|November 3, 2005||2005-11-03|April 17, 2018|2018-04-17||||||||Observational|||Natural History Study of Patients With Excess Androgen|Natural History Study of Patients With Excess Androgen|Enrolling by invitation|||741|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:21:29.622303|2018-06-01 04:21:29.622303
NCT00250146|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2005-11-03|2005-11-03|2005-11-07|Estimate|||||||2005-11-03|2005-11-07|Estimate|February 2001||2001-02-28|April 2005|2005-04-30|March 2005||2005-03-31|||||Interventional|||Multicenter Study on the Toxicity of Gluten Traces in the Treatment of Celiac Disease||Terminated||N/A|39||Università Politecnica delle Marche|||||f||||||||||||||2018-06-01 04:21:29.684634|2018-06-01 04:21:29.684634
NCT00250133|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2007-08-31|2005-11-04|2005-11-07|Estimate|||||||2007-08-31|2007-09-03|Estimate||||August 2007|2007-08-31||||||||Observational|||Microbiologic Effect of Selective Decontamination of the Digestive Tract With Colistin, Gentamicin and Nystatin|Microbiologic Effect of Selective Decontamination of the Digestive Tract With Colistin, Gentamicin and Nystatin|Terminated|||40||University of Pittsburgh||||Unable to obtain funding to complete study never started study|f||||||||||||||2018-06-01 04:21:29.743956|2018-06-01 04:21:29.743956
NCT00250120|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2016-05-10|2005-11-03|2005-11-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2003||2003-04-30|May 2016|2016-05-31|August 2007|Actual|2007-08-31|March 2007|Actual|2007-03-31||Interventional|||Pharmacology Study of Aerosolized Liposomal|Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S) - Camptothecin (L9NC)|Withdrawn||Phase 2|0|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:21:29.793741|2018-06-01 04:21:29.793741
NCT00250094|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-09-02|2005-11-03|2005-11-07|Estimate|||||||2011-09-02|2011-09-07|Estimate|May 2004||2004-05-31|September 2011|2011-09-30|March 2006|Actual|2006-03-31|June 2005|Actual|2005-06-30||Interventional|||Clinical Benefit of Topoisomerase Downregulation|Clinical Benefit of Topoisomerase Downregulation: A Phase I Pilot Study|Completed||Phase 1|15|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||||||2018-06-01 04:21:30.902993|2018-06-01 04:21:30.902993
NCT00250081|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2014-11-18|2005-11-03|2005-11-07|Estimate|||||||2014-11-18|2014-11-19|Estimate|February 2005||2005-02-28|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|UECP||Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy|Multi Center Project: Comparison of Functional Outcomes of Tendon Transfer Surgery, Botulinum Toxin Injections and Regular Ongoing Treatment in Hemiplegic Upper Extremity Cerebral Palsy|Terminated||N/A|38|Actual|Shriners Hospitals for Children||3||Accrual is complete.|f||||t||||||||||2018-06-01 04:21:30.983589|2018-06-01 04:21:30.983589
NCT00250068|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2010-05-18|2005-11-03|2005-11-07|Estimate|||||||2010-05-18|2010-05-19|Estimate|April 2003||2003-04-30|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)|Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)|Completed||Phase 2|8|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:21:31.099866|2018-06-01 04:21:31.099866
NCT00250055|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2016-05-10|2005-11-03|2005-11-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2004||2004-04-30|May 2016|2016-05-31|January 2010|Actual|2010-01-31|December 2007|Actual|2007-12-31||Interventional|||Non-Invasive, Real-Time Technology for Diagnosis of Cervical Tissue|Non-Invasive, Real-time Technology for Diagnosis of Cervical Tissue|Completed||N/A|100|Anticipated|University of New Mexico|||||f||||t||||||||||2018-06-01 04:21:31.159774|2018-06-01 04:21:31.159774
NCT00250042|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-09-18|2005-11-03|2005-11-07|Estimate|||||||2011-09-18|2011-09-20|Estimate|April 2004||2004-04-30|December 2009|2009-12-31|March 2006|Actual|2006-03-31|April 2005|Actual|2005-04-30||Interventional|||A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec|A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment|Completed||Phase 2|6|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||||||2018-06-01 04:21:31.219097|2018-06-01 04:21:31.219097
NCT00250029|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-09-23|2005-11-03|2005-11-07|Estimate|||||||2011-09-23|2011-09-27|Estimate|April 2004||2004-04-30|April 2010|2010-04-30|March 2006|Actual|2006-03-31|September 2005|Actual|2005-09-30||Interventional|||Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen|Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy|Completed||N/A|30|Actual|New Mexico Cancer Care Alliance|||||f||||t||||||||||2018-06-01 04:21:31.285265|2018-06-01 04:21:31.285265
NCT00250016|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2010-01-06|2005-11-03|2005-11-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Observational|||Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)|1102C-T. Pharmacology Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium. Tissue Submission for Patients With Endometrial Cancer.|Completed|||6|Actual|University of New Mexico|||||f||||t||||||Samples Without DNA|"~     Blood sample, tumor endometrial tissue, and normal endometrial tissue.~   "|||2018-06-01 04:21:31.355465|2018-06-01 04:21:31.355465
NCT00250003|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2005-11-22|2005-11-04|2005-11-07|Estimate|||||||2005-11-22|2005-11-23|Estimate|February 2000||2000-02-29|September 2005|2005-09-30|December 2001||2001-12-31|||||Interventional|||Preventive Home Visits for Healthy Pensioners- a Randomized Controlled Trial|Preventive Home Visits for Healthy Pensioners- a Randomized Controlled Trial in Nordmaling|Completed||Phase 1|||Umeå University|||||f||||||||||||||2018-06-01 04:21:31.529368|2018-06-01 04:21:31.529368
NCT00249990|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2010-01-06|2005-11-03|2005-11-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|April 2003||2003-04-30|October 2008|2008-10-31|September 2007|Actual|2007-09-30|July 2006|Actual|2006-07-31||Interventional|||Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)|Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium|Completed||Phase 2|39|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:21:31.6095|2018-06-01 04:21:31.6095
NCT00249977|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2010-01-06|2005-11-03|2005-11-07|Estimate|||||||2010-01-06|2010-01-07|Estimate|April 2003||2003-04-30|October 2009|2009-10-31|January 2009|Actual|2009-01-31|August 2007|Actual|2007-08-31||Interventional|||Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan|Phase I Study Of Capecitabine in Combination With Cisplatin and Irinotecan in Patients With Advanced Malignancies.|Completed||Phase 1|21|Actual|University of New Mexico|||||f||||t||||||||||2018-06-01 04:21:31.697248|2018-06-01 04:21:31.697248
NCT00249964|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2016-01-15|2005-11-03|2005-11-07|Estimate|||||||2016-01-15|2016-01-20|Estimate|November 2003||2003-11-30|January 2016|2016-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Combination Paclitaxel, Carboplatin and Temozolomide|Phase I Dose Finding Clinical Trial of Combination Paclitaxel, Carboplatin and Temozolomide for Subjects With Solid Tumor Malignancies.|Completed||Phase 1|15|Actual|New Mexico Cancer Care Alliance||1|||f||||t||||||||||2018-06-01 04:21:31.775208|2018-06-01 04:21:31.775208
NCT00249951|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2012-06-29|2005-11-03|2005-11-07|Estimate|||||||2012-06-29|2012-07-03|Estimate|November 2005||2005-11-30|June 2012|2012-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants||Completed||Phase 3|80|Actual|University of Cologne|||||f||||t||||||||||2018-06-01 04:21:31.87184|2018-06-01 04:21:31.87184
NCT00249938|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-03-24|2005-11-04|2005-11-07|Estimate|||||||2017-03-24|2017-03-28|Actual|March 2005||2005-03-31|March 2017|2017-03-31|August 2006|Actual|2006-08-31|||||Interventional|||Evaluation of Combination Cholesterol Treatments in Patients With High Cholesterol.|Evaluation of Plant Sterol and Placebo on Low-density Lipoprotein Concentrations in Hyperlipidemic Patients Treated With Combination Statin and Colesevelam Therapy.|Completed||Phase 4|60||University of Colorado, Denver|||||f||||||||||||||2018-06-01 04:21:31.949704|2018-06-01 04:21:31.949704
NCT00249925|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2016-04-25|2005-11-04|2005-11-07|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2000||2000-01-31|April 2016|2016-04-30|January 2005|Actual|2005-01-31|June 2004|Actual|2004-06-30||Interventional|||Project ABLE:Advancing Better Living for Elders|Enhancing Function of Frail Elders At Home|Completed||Phase 3|319||Thomas Jefferson University|||||f||||t||||||||||2018-06-01 04:21:32.023978|2018-06-01 04:21:32.023978
NCT00249912|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2012-05-23|2005-11-04|2005-11-07|Estimate|||||||2012-05-23|2012-05-24|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg, 100 mg or Placebo When Coadministered With Rosuvastatin 10 mg or 20 mg in Subjects With Primary Hypercholesterolemia|Completed||Phase 3|415|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:21:32.117217|2018-06-01 04:21:32.117217
NCT00249899|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2012-05-23|2005-11-04|2005-11-07|Estimate|||||||2012-05-23|2012-05-24|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia|A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat or Placebo When Co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia|Terminated||Phase 3|649|Actual|Takeda||2||"Overall profile of the compound does not offer significant clinical advantage to patients over~   currently available lipid lowering agents"|f||||f||||||||||2018-06-01 04:21:32.317493|2018-06-01 04:21:32.317493
NCT00249886|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2006-09-18|2005-11-04|2005-11-07|Estimate|||||||2006-09-18|2006-09-19|Estimate|September 2002||2002-09-30|November 2005|2005-11-30|November 2006||2006-11-30|||||Interventional|||Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents||Withdrawn||Phase 3|60||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:21:32.535414|2018-06-01 04:21:32.535414
NCT00249873|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2010-03-08||2015-05-20|2005-11-04|2005-11-07|Estimate|2010-03-08|2010-03-26|Estimate||||2015-05-20|2015-06-15|Estimate|June 2003||2003-06-30|May 2015|2015-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)|A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation|Completed||Phase 3|7554|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:21:32.728414|2018-06-01 04:21:32.728414
NCT00249860|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2013-08-04|2005-11-04|2005-11-07|Estimate|||||||2013-08-04|2013-08-06|Estimate|September 2002||2002-09-30|August 2013|2013-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects|A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects|Completed||Phase 3|257|Actual|EMD Serono||2|||f||||||||||||||2018-06-01 04:21:35.693682|2018-06-01 04:21:35.693682
NCT00249847|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2014-10-01|2005-11-04|2005-11-07|Estimate|||||||2014-10-01|2014-10-02|Estimate|October 2005||2005-10-31|October 2014|2014-10-31|April 2008|Actual|2008-04-30|July 2007|Actual|2007-07-31||Interventional|||Study of PET Scans and Serotonin in Hot Flashes Treatment|A Feasibility Study of Positron Emission Tomography (PET) of the Serotonin Transporter (SERT) Before and After Treatment With Conjugated Equine Estrogen or Paroxetine for Hot Flashes|Terminated||N/A|5|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||Unable to complete accrual; elected to close the study in April 2008.|f||||t||||||||||2018-06-01 04:21:35.768181|2018-06-01 04:21:35.768181
NCT00249834|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2017-08-29||2017-08-29|2005-11-04|2005-11-07|Estimate|2017-08-29|2018-03-30|Actual||||2017-08-29|2018-03-30|Actual|September 22, 2004|Actual|2004-09-22|August 2017|2017-08-31|January 16, 2006|Actual|2006-01-16|January 16, 2006|Actual|2006-01-16||Interventional|CONSORT||Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)|A Phase IIIB/IV, Open Label Study to Assess the Efficacy and Safety of a Pre-defined, Fixed Dose of Gonal-f® (Filled-by-Mass in a Prefilled Pen) Based on Subject Baseline Characteristics, for Ovarian Stimulation in Subjects Undergoing in Vitro Fertilization (IVF)|Completed||Phase 4|166|Actual|Merck KGaA||8|||f||||||||||||||2018-06-01 04:21:35.877486|2018-06-01 04:21:35.877486
NCT00249821|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2012-06-28||2017-08-28|2005-11-04|2005-11-07|Estimate|2012-10-09|2012-10-10|Estimate||||2017-08-28|2017-09-26|Actual|February 28, 2005|Actual|2005-02-28|August 2017|2017-08-31|September 30, 2007|Actual|2007-09-30|September 30, 2007|Actual|2007-09-30||Interventional|SGA OPTIMIS||Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age|Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Efficacy of a Saizen® Treatment at the Same Dose Versus a Lower Maintenance Dose Prolonged During 1 Additional Year.|Completed||Phase 3|22|Actual|Merck KGaA|Participants’ inclusion period was extended but due to remaining low recruitment rate, it was finally decided to stop enrollment even if only 22 participants were enrolled.|2|||f||||f||||||||||2018-06-01 04:21:36.747191|2018-06-01 04:21:36.747191
NCT00249808|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2017-08-24||2017-08-24|2005-11-04|2005-11-07|Estimate|2017-08-24|2018-03-20|Actual||||2017-08-24|2018-03-20|Actual|December 13, 2004|Actual|2004-12-13|August 2017|2017-08-31|January 25, 2007|Actual|2007-01-25|January 25, 2007|Actual|2007-01-25||Interventional||Intent-to-treat (ITT) population included all participants who received at least one dose of treatment and had at least one post-dose efficacy assessment.|A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies|A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Efalizumab in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Have Failed to Respond to, or Who Have a Contraindication to, or Are Intolerant to Other Systemic Therapies Including Ciclosporin, Methotrexate and PUVA|Completed||Phase 4|1266|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 04:21:37.115292|2018-06-01 04:21:37.115292
NCT00249795|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2010-08-24||2010-09-29|2005-11-04|2005-11-07|Estimate|2010-09-29|2010-10-15|Estimate||||2010-09-29|2010-10-15|Estimate|June 2003||2003-06-30|September 2010|2010-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|ACTIVE I||Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)|A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation|Completed||Phase 3|9016|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:21:37.440846|2018-06-01 04:21:37.440846
NCT00249782|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-05-27|2005-11-03|2005-11-07|Estimate|||||||2011-05-27|2011-05-30|Estimate|November 2005||2005-11-30|May 2011|2011-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.|A Phase II, Randomized, Partial-Blind, Parallel-Group, Active- and Vehicle-Controlled, Multicenter Study of the Safety and Efficacy of ACZONE™ (Dapsone) Gel, 5% in Subjects With Papulopustular Rosacea|Completed||Phase 2|400|Actual|Allergan|||||||||||||||||||2018-06-01 04:21:40.634212|2018-06-01 04:21:40.634212
NCT00249769|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2008-05-05|2005-11-03|2005-11-07|Estimate|||||||2008-05-05|2008-05-07|Estimate|November 2005||2005-11-30|May 2007|2007-05-31|May 2006||2006-05-31|||||Interventional|||Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine|Assessment of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine Given Alone|Completed||Phase 3|600||PATH|||||f||||||||||||||2018-06-01 04:21:40.72942|2018-06-01 04:21:40.72942
NCT00249756|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2013-08-29|2005-11-03|2005-11-07|Estimate|||||||2013-08-29|2013-09-02|Estimate|August 2005||2005-08-31|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Re-Entry MTC for Offenders With MICA Disorders|Re-Entry MTC for Offenders With MICA Disorders|Completed||N/A|610|Actual|National Development and Research Institutes, Inc.||2|||f||||t||||||||||2018-06-01 04:21:40.777806|2018-06-01 04:21:40.777806
NCT00249743|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2006-05-25|2005-11-04|2005-11-07|Estimate|||||||2006-05-25|2006-05-29|Estimate|December 2004||2004-12-31|May 2006|2006-05-31|July 2005||2005-07-31|||||Interventional|||Clinical Evaluation of a Wireless Monitoring Device to Reduce Falls in the Elderly and Others at High Risk of Falling|NIH-NIA SBIR Phase I/II Study: Clinical Evaluation of a Device to Reduce Patient Falls|Completed||Phase 1/Phase 2|50||NOCwatch International|||||f||||||||||||||2018-06-01 04:21:40.84107|2018-06-01 04:21:40.84107
NCT00249730|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2006-12-18|2005-11-04|2005-11-07|Estimate|||||||2006-12-18|2006-12-19|Estimate|October 2005||2005-10-31|December 2006|2006-12-31||||||||Interventional|||Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.|A Prospective Multicenter, Parallel Group Study With A Single Blind Phase And A Double Blind Randomised Phase, To Evaluate The Efficacy And Satisfaction Of Viagra (Sildenafil Citrate) High Dose (100mg) Titration Compared With 50mg Dose, In Men With Erectile Dysfunction|Completed||Phase 4|510||Pfizer|||||f||||||||||||||2018-06-01 04:21:40.999611|2018-06-01 04:21:40.999611
NCT00249717|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-11-17|2005-11-03|2005-11-07|Estimate|||||||2011-11-17|2011-11-21|Estimate|May 2005||2005-05-31|November 2011|2011-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Group-Based Contingency Management for Substance Abuse Treatment - 1|Group-Based Contingency Management for Substance Abuse Treatment|Completed||N/A|312|Actual|UConn Health|||||f||||f||||||||||2018-06-01 04:21:41.094353|2018-06-01 04:21:41.094353
NCT00249704|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2009-01-07|2005-11-04|2005-11-07|Estimate|||||||2009-01-07|2009-01-08|Estimate|October 2005||2005-10-31|January 2009|2009-01-31|January 2008|Actual|2008-01-31|||||Interventional|||Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects|Evaluation of the Effect of a 4-Month Intervention of Exercise and/or Vitamin D on Mobility Function and Strength in Frail Elderly Subjects|Terminated||Phase 1|64|Actual|Pfizer||4||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:21:41.150184|2018-06-01 04:21:41.150184
NCT00249691|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2012-03-06|2005-11-03|2005-11-07|Estimate|||||||2012-03-06|2012-03-08|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|October 2012|Anticipated|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1|Medication Development for Cocaine Dependence|Unknown status|Active, not recruiting|Phase 3|180|Anticipated|University of Virginia||2|||f||||t||||||||||2018-06-01 04:21:41.226331|2018-06-01 04:21:41.226331
NCT00249678|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2018-02-13|2005-11-03|2005-11-07|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2004||2004-09-30|February 2018|2018-02-28|May 2007||2007-05-31|||||Interventional|||Behavioral Therapy Development for Methamphetamine Abusers|Behavioral Therapy Development for Methamphetamine Abuse|Suspended||Phase 2|50||University of California, Los Angeles|||||f||||||||||||||2018-06-01 04:21:41.362861|2018-06-01 04:21:41.362861
NCT00249652|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2015-04-13|2005-11-03|2005-11-07|Estimate|||||||2015-04-13|2015-04-14|Estimate|September 2003||2003-09-30|April 2015|2015-04-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Transplant and Addiction Project (TAP) - 1|Drug Treatment for Transplant Candidates|Completed||Phase 1/Phase 2|41|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-06-01 04:21:41.435202|2018-06-01 04:21:41.435202
NCT00249639|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-01-11|2005-11-03|2005-11-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Contingency Management for Attendance - 2|Contingency Management for Attendance|Completed||N/A|300|Actual|National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 04:21:41.509276|2018-06-01 04:21:41.509276
NCT00249626|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-11-17|2005-11-03|2005-11-07|Estimate|||||||2011-11-17|2011-11-21|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Therapists to Administer Contingency Management-Therapist Phase - 1|Therapists to Administer Contingency Management-Therapist Phase|Completed||N/A|42|Actual|UConn Health|||||f||||f||||||||||2018-06-01 04:21:41.577196|2018-06-01 04:21:41.577196
NCT00249613|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2013-04-10||2014-03-07|2005-11-03|2005-11-07|Estimate|2014-03-07|2014-04-07|Estimate||||2014-03-07|2014-04-07|Estimate|June 2005||2005-06-30|March 2014|2014-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Gender-Responsive Treatment for Women Offenders - 1|Gender-Responsive Treatment for Women Offenders|Completed||N/A|291|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 04:21:41.651699|2018-06-01 04:21:41.651699
NCT00249600|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-11-17|2005-11-03|2005-11-07|Estimate|||||||2011-11-17|2011-11-21|Estimate|March 2003||2003-03-31|November 2011|2011-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Lower-Cost Contingency Management in a Group Setting - 1|Lower-Cost Contingency Management in a Group Setting|Completed||N/A|172|Actual|UConn Health|||||f||||f||||||||||2018-06-01 04:21:41.920304|2018-06-01 04:21:41.920304
NCT00249587|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-01-09|2005-11-03|2005-11-07|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2000||2000-09-30|September 2008|2008-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Medication Adherence Therapy for Opioid Abusing Pain Patients|Medication Adherence Therapy for Opioid Abusing Pain Patients|Completed||Phase 1/Phase 2|36|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:21:41.985267|2018-06-01 04:21:41.985267
NCT00249574|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-01-13|2005-11-03|2005-11-07|Estimate|||||||2017-01-13|2017-01-16|Estimate|June 2003||2003-06-30|December 2008|2008-12-31|June 2006|Actual|2006-06-30|March 2004|Actual|2004-03-31||Interventional|||Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1|HCV Treatment of IDUs After Buprenorphine Stabilization|Completed||N/A|10|Anticipated|National Institute on Drug Abuse (NIDA)||1|||t||||t||||||||||2018-06-01 04:21:42.064256|2018-06-01 04:21:42.064256
NCT00249561|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-07-19|2005-11-03|2005-11-07|Estimate|||||||2011-07-19|2011-07-20|Estimate|September 2001||2001-09-30|July 2011|2011-07-31|September 2007|Actual|2007-09-30|July 2007|Actual|2007-07-31||Interventional|||Colorado Women's TC Project|Women's Prison TC: Outcomes, Process & Economic Analysis|Completed||Phase 1/Phase 2|610|Actual|National Development and Research Institutes, Inc.||2|||f||||t||||||||||2018-06-01 04:21:42.139483|2018-06-01 04:21:42.139483
NCT00249548|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-01-11|2005-11-03|2005-11-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2004||2004-08-31|May 2008|2008-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Low-Cost Contingency Management for Hispanic Outpatients - 3|Low-Cost Contingency Management for Hispanic Outpatients|Completed||N/A|30|Actual|National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 04:21:42.220316|2018-06-01 04:21:42.220316
NCT00249535|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2012-03-29|2005-11-03|2005-11-07|Estimate|||||||2012-03-29|2012-03-30|Estimate|March 2005||2005-03-31|March 2012|2012-03-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Vouchers vs. Prizes for Cocaine-Dependent Methadone Patients - 2|Vouchers vs. Prizes for Cocaine-Dependent Methadone Patients|Completed||N/A|240|Actual|UConn Health||3|||f||||f||||||||||2018-06-01 04:21:42.277392|2018-06-01 04:21:42.277392
NCT00249522|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-01-11|2005-11-03|2005-11-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2003||2003-08-31|May 2008|2008-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Vouchers vs. Prizes for Methadone Patients - 1|Vouchers vs. Prizes for Methadone Patients|Completed||N/A|76|Actual|National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 04:21:42.347412|2018-06-01 04:21:42.347412
NCT00249509|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-01-13|2005-11-03|2005-11-07|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2000||2000-09-30|March 2011|2011-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals|Marijuana Pharmacotherapies: Controlled Clinical Trials With Nefazodone and Bupropion|Completed||Phase 2|132||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:21:42.403529|2018-06-01 04:21:42.403529
NCT00249496|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2016-08-31||2017-08-18|2005-11-03|2005-11-07|Estimate|2016-10-25|2016-12-16|Estimate||||2017-08-18|2017-09-18|Actual|October 2003||2003-10-31|August 2017|2017-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1|Therapeutic Workplace Maintenance Study|Completed||N/A|51|Actual|Johns Hopkins University||2|||f||||f||||||||No|The results were published in a peer-reviewed journal.|2018-06-01 04:21:42.482446|2018-06-01 04:21:42.482446
NCT00249483|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-07-06|2005-11-03|2005-11-07|Estimate|||||||2017-07-06|2017-07-11|Actual|October 1999||1999-10-31|July 2017|2017-07-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals|Placebo-Controlled Venlafaxine Treatment for Depressed Cocaine Abusers|Completed||Phase 2|150|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 04:21:42.823145|2018-06-01 04:21:42.823145
NCT00249470|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2016-09-02||2017-12-01|2005-11-03|2005-11-07|Estimate|2016-10-25|2016-12-16|Estimate||||2017-12-01|2017-12-27|Actual|April 2003||2003-04-30|December 2017|2017-12-31|October 2004|Actual|2004-10-31|May 2004|Actual|2004-05-31||Interventional|||The Therapeutic Workplace Initiation Study|The Therapeutic Workplace Initiation Study|Completed||N/A|117|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-06-01 04:21:42.929543|2018-06-01 04:21:42.929543
NCT00249457|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-10-26|2005-11-03|2005-11-07|Estimate|||||||2017-10-26|2017-10-30|Actual|October 1996||1996-10-31|October 2017|2017-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2|A Therapeutic Workplace for Drug Abusers|Completed||N/A|40|Actual|Johns Hopkins University||2|||f||||f||||||||No|The data for this study have been published in a peer-reviewed journal.|2018-06-01 04:21:43.201733|2018-06-01 04:21:43.201733
NCT00249444|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2016-04-12||2017-09-25|2005-11-03|2005-11-07|Estimate|2017-09-25|2017-10-25|Actual||||2017-09-25|2017-10-25|Actual|May 2006||2006-05-31|September 2017|2017-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression|A Placebo Controlled Trial of Mirtazapine for Patients With Depression and Cocaine Dependence|Completed||Phase 2|86|Actual|New York State Psychiatric Institute|Early cocaine responders were the most likely to achieve three weeks of continuous abstinence. 20% of patients on mirtazapine did not have any detectable blood level, therefore, poor compliance may have prevented detection of a medication effect.|2|||f||||t||||||||No||2018-06-01 04:21:43.27441|2018-06-01 04:21:43.27441
NCT00249431|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-10-26|2005-11-03|2005-11-07|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2001|Actual|2001-12-31|October 2017|2017-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1|A Pilot Study of Sertraline Plus Relapse Prevention Therapy (RP) for the Treatment of Pathological Gambling With Comorbid Abuse or Dependence|Terminated||Phase 2|9|Actual|New York State Psychiatric Institute||2||Inability to recruit patients.|f||||||||||||||2018-06-01 04:21:43.502603|2018-06-01 04:21:43.502603
NCT00249418|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-11-17|2005-11-03|2005-11-07|Estimate|||||||2011-11-17|2011-11-21|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Training Therapists to Administer Contingency Management-Patient Phase - 3|Training Therapists to Administer Contingency Management-Patient Phase|Completed||N/A|180|Actual|UConn Health|||||f||||f||||||||||2018-06-01 04:21:43.560557|2018-06-01 04:21:43.560557
NCT00249405|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2010-11-02|2005-11-04|2005-11-07|Estimate|||||||2010-11-02|2010-11-03|Estimate|February 2005||2005-02-28|November 2010|2010-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)|Predicting Alcoholics' Treatment Responses to an SSRI|Completed||Phase 2|200|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-06-01 04:21:43.696058|2018-06-01 04:21:43.696058
NCT00249392|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2008-05-22|2005-11-04|2005-11-07|Estimate|||||||2008-05-22|2008-05-23|Estimate|October 2004||2004-10-31|May 2008|2008-05-31||||||||Observational|||Epidemiologic, Laboratory, and Clinical Characterization of Individuals With Ocular Diseases||Unknown status|Active, not recruiting||800|Anticipated|Nanjing Medical University|||||f||||||||||||||2018-06-01 04:21:43.763334|2018-06-01 04:21:43.763334
NCT00249379|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2012-01-03||2016-04-29|2005-11-04|2005-11-07|Estimate|2016-04-29|2016-05-11|Estimate||||2016-04-29|2016-05-11|Estimate|June 2005||2005-06-30|April 2016|2016-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees|The Use of Acamprosate for Preventing Alcohol Relapse Among Alcohol Dependent Drug Treatment Court Participants|Terminated||Phase 4|26|Actual|Virginia Commonwealth University|Small numbers of subjects, significant number withdrew or were lost to follow-up|2||Not enough sugjects enrolled before funding ran out|f||||f||||||||||2018-06-01 04:21:43.826961|2018-06-01 04:21:43.826961
NCT00249366|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2016-04-08|2005-11-03|2005-11-07|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2001||2001-04-30|April 2016|2016-04-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Treatment of Alcohol Withdrawal in Hospital Patients|Acute Drug Withdrawal in a General Medical Setting|Completed||Phase 4|183|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-06-01 04:21:44.038714|2018-06-01 04:21:44.038714
NCT00249353|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2010-04-26|2005-11-04|2005-11-07|Estimate|||||||2010-04-26|2010-04-28|Estimate|March 2002||2002-03-31|April 2010|2010-04-30|October 2002|Actual|2002-10-31|||||Interventional|||An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder|An Evaluation of the Safety and Effectiveness of CONCERTA® (Methylphenidate Hydrochloride), up to 72 mg Daily, in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|220|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||||||||||||||||2018-06-01 04:21:44.110313|2018-06-01 04:21:44.110313
NCT00249340|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2007-04-10|2005-11-04|2005-11-07|Estimate|||||||2007-04-10|2007-04-11|Estimate|November 2005||2005-11-30|August 2005|2005-08-31|July 2006|Actual|2006-07-31|||||Interventional|||Brief Behavioral Weight Loss Treatment vs. Weight Watchers|Comparison of a Brief Behavioral Weight Loss Intervention With the Weight Watchers Program|Completed||N/A|60||The Miriam Hospital|||||f||||||||||||||2018-06-01 04:21:44.157737|2018-06-01 04:21:44.157737
NCT00249327|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2007-04-18|2005-11-04|2005-11-07|Estimate|||||||2007-04-18|2007-04-19|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|February 2006|Actual|2006-02-28|||||Interventional|||Online HIV Prevention Vignette Evaluation|Online HIV Prevention Vignette Evaluation|Completed||N/A|1000||Public Health Solutions|||||f||||||||||||||2018-06-01 04:21:44.208212|2018-06-01 04:21:44.208212
NCT00249314|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2007-04-18|2005-11-03|2005-11-07|Estimate|||||||2007-04-18|2007-04-19|Estimate|November 2005||2005-11-30|April 2007|2007-04-30|December 2007|Anticipated|2007-12-31|||||Observational|||(Mol-SHARE) Molecular Study of Health Assessment and Risk in Ethnic Groups|A Prospective, Cross-Sectional, Case-Control, Molecular Study of Health Assessment and Risk in Ethnic Groups|Unknown status|Recruiting||120||McMaster University|||||f||||||||||||||2018-06-01 04:21:44.270491|2018-06-01 04:21:44.270491
NCT00249301|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2008-03-28|2005-11-04|2005-11-07|Estimate|||||||2008-03-28|2008-04-01|Estimate|October 2005||2005-10-31|March 2008|2008-03-31||||January 2008|Actual|2008-01-31||Interventional|||A Study of MLN8054 in Patients With Advanced Solid Tumors|An Open-Label, Dose Escalation Phase 1 Study of MLN8054, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors|Terminated||Phase 1|63|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 04:21:44.32414|2018-06-01 04:21:44.32414
NCT00249288|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2014-06-11||2018-03-09|2005-11-03|2005-11-07|Estimate|2014-07-14|2014-08-06|Estimate||||2018-03-09|2018-04-05|Actual|December 2003||2003-12-31|March 2018|2018-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Folate Supplementation in Schizophrenia|Folate Supplementation in Schizophrenia|Completed||Phase 4|46|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:21:44.386093|2018-06-01 04:21:44.386093
NCT00249275|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2005-11-03|2005-11-03|2005-11-07|Estimate|||||||2005-11-03|2005-11-07|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|August 2004||2004-08-31|||||Interventional|||Effectiveness of Alternative Approaches to Providing Spectacles in Tanzanian Secondary School Students|Evaluation of the Effectiveness of Alternative Approaches to Providing Spectacles in Secondary School Students in Dar Es Salaam, Tanzania|Completed||N/A|250||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:21:44.754374|2018-06-01 04:21:44.754374
NCT00249262|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2018-01-22|2005-11-03|2005-11-07|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2005||2005-10-31|January 2018|2018-01-31|April 2007||2007-04-30|||||Interventional|||Taxoprexin Treatment for Advanced Skin Melanoma|Phase II Open-Label Study of Weekly Taxoprexin (DHA-paclitaxel) Injection as First Line Treatment of Patients With Metastatic Non-choroidal Melanoma|Completed||Phase 2|30||Luitpold Pharmaceuticals|||||||||||||||||||2018-06-01 04:21:45.860398|2018-06-01 04:21:45.860398
NCT00249249|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|2009-08-26||2010-01-07|2005-11-04|2005-11-07|Estimate|2009-11-13|2009-12-16|Estimate||||2010-01-07|2010-01-12|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|November 2006|Actual|2006-11-30|||||Interventional|||Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels|Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia|Completed||Phase 3|830|Actual|Kowa Research Europe|||||f||||||||||||||2018-06-01 04:21:46.01925|2018-06-01 04:21:46.01925
NCT00249236|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-01-13|2005-11-04|2005-11-07|Estimate|||||||2011-01-13|2011-01-14|Estimate|March 2001||2001-03-31|January 2011|2011-01-31|December 2001|Actual|2001-12-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder|The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder|Completed||Phase 3|291|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:21:47.607579|2018-06-01 04:21:47.607579
NCT00249223|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-01-13|2005-11-04|2005-11-07|Estimate|||||||2011-01-13|2011-01-14|Estimate|January 2000||2000-01-31|January 2011|2011-01-31|December 2000|Actual|2000-12-31|||||Interventional|||A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia|Risperidone Depot (Microspheres) vs. Risperidone Tablets - a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia|Completed||Phase 3|641|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:21:47.769613|2018-06-01 04:21:47.769613
NCT00249210|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-06-08|2005-11-04|2005-11-07|Estimate|||||||2011-06-08|2011-06-10|Estimate|August 1993||1993-08-31|February 2011|2011-02-28|July 1994|Actual|1994-07-31|||||Interventional|||A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses|A Multicenter, Randomized Study to Compare the Safety and Efficacy of Oral Levofloxacin With Amoxicillin/Clavulanate Potassium in the Treatment of Acute Sinusitis in Adults|Completed||Phase 3|614|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:21:47.843441|2018-06-01 04:21:47.843441
NCT00249197|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-06-08|2005-11-04|2005-11-07|Estimate|||||||2011-06-08|2011-06-10|Estimate|January 1997||1997-01-31|January 2011|2011-01-31|July 1998|Actual|1998-07-31|||||Interventional|||A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin Infections|A Multicenter, Randomized, Open-Label Study to Compare the Safety and Efficacy of i.v. And/Or Oral Levofloxacin With That of Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Bacterial Skin and Skin Structure Infections|Completed||Phase 3|413|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:21:47.918992|2018-06-01 04:21:47.918992
NCT00249171|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-01-13|2005-11-04|2005-11-07|Estimate|||||||2011-01-13|2011-01-14|Estimate|June 2001||2001-06-30|January 2011|2011-01-31|February 2003|Actual|2003-02-28|||||Interventional|||A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients|Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients|Completed||Phase 4|226|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:21:47.990068|2018-06-01 04:21:47.990068
NCT00249158|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2010-11-18|2005-11-04|2005-11-07|Estimate|||||||2010-11-18|2010-11-19|Estimate|March 1998||1998-03-31|November 2010|2010-11-30|February 2001|Actual|2001-02-28|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia|Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial|Completed||Phase 3|344|Actual|Janssen-Cilag Pty Ltd|||||f||||||||||||||2018-06-01 04:21:48.063573|2018-06-01 04:21:48.063573
NCT00249145|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-01-13|2005-11-04|2005-11-07|Estimate|||||||2011-01-13|2011-01-14|Estimate|April 1995||1995-04-30|January 2011|2011-01-31|December 1996|Actual|1996-12-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia|Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference|Completed||Phase 3|349|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:21:48.122078|2018-06-01 04:21:48.122078
NCT00249132|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-02-10|2005-11-04|2005-11-07|Estimate|||||||2011-02-10|2011-02-11|Estimate||||February 2011|2011-02-28|July 1991|Actual|1991-07-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia|Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia|Completed||Phase 3|523|Actual|Janssen, LP|||||f||||||||||||||2018-06-01 04:21:48.184059|2018-06-01 04:21:48.184059
NCT00249119|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2011-02-10|2005-11-04|2005-11-07|Estimate|||||||2011-02-10|2011-02-11|Estimate||||February 2011|2011-02-28|December 1991|Actual|1991-12-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia|Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.|Completed||Phase 3|1579|Actual|Janssen, LP|||||f||||||||||||||2018-06-01 04:21:48.249022|2018-06-01 04:21:48.249022
NCT00249106|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2013-02-08|2005-11-03|2005-11-07|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2003||2003-12-31|September 2011|2011-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|C001||Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults|Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of Clade C DNA Vaccine ADVAX e/g + ADVAX p/N-t (ADVAX) Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers.|Completed||Phase 1|45|Actual|International AIDS Vaccine Initiative||2|||f||||t||||||||||2018-06-01 04:21:48.329111|2018-06-01 04:21:48.329111
NCT00249093|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2007-04-12|2005-11-04|2005-11-07|Estimate|||||||2007-04-12|2007-04-13|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Effects of Supplementary Oxygen on Dyspnoea and Exercise Tolerance in COPD Patients Given LTOT||Completed||N/A|20||LHL Helse|||||f||||f||||||||||2018-06-01 04:21:48.404878|2018-06-01 04:21:48.404878
NCT00249080|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2009-08-21|2005-11-03|2005-11-07|Estimate|||||||2009-08-21|2009-08-24|Estimate|June 2005||2005-06-30|August 2009|2009-08-31|August 2007|Actual|2007-08-31|||||Observational|||Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease|High Field MRI of Brain Iron in Neurodegenerative Disease|Completed|||182|Actual|Albany Medical College|||||f||||t||||||||||2018-06-01 04:21:48.466463|2018-06-01 04:21:48.466463
NCT00249067|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2007-06-12|2005-11-04|2005-11-07|Estimate|||||||2007-06-12|2007-06-13|Estimate|October 2005||2005-10-31|June 2007|2007-06-30|October 2005||2005-10-31|||||Observational|||Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients|The Retrospective Evaluation of Carvedilol Versus Captopril and Digoxin/Lasix Therapy in Congestive Heart Failure Due to Left-to-Right Shunt Lesions|Terminated|||50||Children's Healthcare of Atlanta||||data collection completed|f||||f||||||||||2018-06-01 04:21:48.527864|2018-06-01 04:21:48.527864
NCT00249054|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-03-22|2005-11-04|2005-11-07|Estimate|||||||2017-03-22|2017-03-24|Actual|November 2005||2005-11-30|March 2017|2017-03-31||||November 2012|Actual|2012-11-30||Interventional|||Prospective Clinical Evaluation of ASR and ReCap Resurfacing Arthroplasty|Clinical Performance of the ASR and ReCap Resurfacing Implants-7Years Follow-Up.|Completed||N/A|46|Actual|Frederiksberg University Hospital||2|||f||||||||||||||2018-06-01 04:21:48.590338|2018-06-01 04:21:48.590338
NCT00249041|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2010-07-29|2005-11-03|2005-11-07|Estimate|||||||2010-07-29|2010-07-30|Estimate|October 2005||2005-10-31|July 2010|2010-07-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Enbrel Liquid Immunogenicity Protocol|Open-label Study to Assess the Antibody Response to Etanercept Liquid in Subjects With Rheumatoid Arthritis (RA)|Completed||Phase 3|447|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:21:48.659342|2018-06-01 04:21:48.659342
NCT00249015|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-04|||2016-07-14|2005-11-04|2005-11-07|Estimate|||||||2016-07-14|2016-07-18|Estimate|January 2008||2008-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors|Randomized Controlled Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors. The CARE Trial.|Completed||Phase 3|301|Actual|AHS Cancer Control Alberta||3|||f||||t||||||||||2018-06-01 04:21:48.82404|2018-06-01 04:21:48.82404
NCT00249002|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2012-02-21||2016-03-30|2005-11-03|2005-11-07|Estimate|2012-02-21|2012-03-13|Estimate||||2016-03-30|2016-05-04|Estimate|November 2005||2005-11-30|March 2016|2016-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis|A Pilot Phase II Trial Of ABI-007 (A Cremophor El-Free, Protein Stabilized, Nanoparticle Paclitaxel) For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis|Terminated||Phase 2|9|Actual|Celgene Corporation||1||Terminated due to pipeline prioritization|f||||f||||||||||2018-06-01 04:21:48.936913|2018-06-01 04:21:48.936913
NCT00248989|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2017-04-06|2005-11-02|2005-11-04|Estimate|||||||2017-04-06|2017-04-07|Actual|November 1, 2004|Actual|2004-11-01|April 2017|2017-04-30|November 13, 2008|Actual|2008-11-13|November 24, 2005|Actual|2005-11-24||Interventional|||Effect of DHEA on Skin Aging in Postmenopausal Women|Effect of DHEA on Skin Aging - Placebo-Controlled and Randomized Phase III Study in Postmenopausal Women.|Completed||Phase 3|150|Actual|CHU de Quebec-Universite Laval||2|||f||||f|f|f||||||No||2018-06-01 04:21:49.308523|2018-06-01 04:21:49.308523
NCT00248976|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2008-03-28|2005-11-03|2005-11-04|Estimate|||||||2008-03-28|2008-03-31|Estimate|April 1999||1999-04-30|March 2008|2008-03-31|March 2004||2004-03-31|||||Interventional|||Improving Health Behavior and Outcomes After Angioplasty|Improving Health Behavior and Outcomes After Angioplasty|Completed||N/A|660|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 04:21:49.410641|2018-06-01 04:21:49.410641
NCT00248963|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2006-05-17|2005-11-02|2005-11-04|Estimate|||||||2006-05-17|2006-05-19|Estimate||||May 2006|2006-05-31|October 2004||2004-10-31|||||Interventional|||Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception|A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 Mg and Ethinyl Estradiol 20 Mg in a Continuous 28-Day Regimen for Oral Contraception Versus a Cyclic 21-Day Regimen Oral Contraceptive|Completed||Phase 3|600||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:21:49.484475|2018-06-01 04:21:49.484475
NCT00248950|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2008-04-01|2005-11-03|2005-11-04|Estimate|||||||2008-04-01|2008-04-03|Estimate|February 2004||2004-02-29|April 2008|2008-04-30|June 2004||2004-06-30|||||Interventional|||A Pilot Study: Changing Multiple Behaviors in Post-Angioplasty Patients|A Pilot Study: Changing Multiple Behaviors in Post-Angioplasty Patients|Completed||N/A|40||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:21:49.540478|2018-06-01 04:21:49.540478
NCT00248937|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2008-04-01|2005-11-03|2005-11-04|Estimate|||||||2008-04-01|2008-04-03|Estimate|February 2004||2004-02-29|April 2008|2008-04-30|June 2004||2004-06-30|||||Interventional|||A Pilot Study of Changing Medication Adherence In Hypertensive African-American Patients|A Pilot Study of Changing Medication Adherence In Hypertensive African-American Patients|Completed||N/A|40||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:21:49.602872|2018-06-01 04:21:49.602872
NCT00248924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-03-31|2005-11-03|2005-11-04|Estimate|||||||2008-03-31|2008-04-03|Estimate|April 2001||2001-04-30|March 2008|2008-03-31|February 2003||2003-02-28|||||Observational|||Outcomes Of Social Service Programs For Homebound Older Adults|Outcomes Of Social Service Programs For Homebound Older Adults|Completed|||56||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:21:49.670792|2018-06-01 04:21:49.670792
NCT00248911|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-02-17|2005-11-03|2005-11-04|Estimate|||||||2017-02-17|2017-02-23|Actual|May 2003||2003-05-31|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers|The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers:Avon Program for Meditation and Healing|Completed||N/A|94|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No|No Plan to Share IPD|2018-06-01 04:21:49.745436|2018-06-01 04:21:49.745436
NCT00248898|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-01-18|2005-11-03|2005-11-04|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2005||2005-03-31|January 2017|2017-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Quality of Life After Open Heart Surgery in Older Patients|Quality of Life After Open Heart Surgery in Older Patients|Completed|||49|Actual|Weill Medical College of Cornell University|||||f||||f||||||||Yes|Investigators may contact the PI for access to the data, with their planned analyses|2018-06-01 04:21:49.827188|2018-06-01 04:21:49.827188
NCT00248885|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2008-04-10|2005-11-03|2005-11-04|Estimate|||||||2008-04-10|2008-04-11|Estimate|September 1991||1991-09-30|April 2008|2008-04-30|September 1994|Actual|1994-09-30|||||Interventional|||Peri-Operative Morbidity and Quality of Life After Coronary Artery Bypass Graft (CABG)|Peri-Operative Morbidity and Quality of Life After CABG|Completed||N/A|248|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 04:21:49.893214|2018-06-01 04:21:49.893214
NCT00248872|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-02-17|2005-11-03|2005-11-04|Estimate|||||||2017-02-17|2017-02-23|Actual|October 2004|Actual|2004-10-31|February 2017|2017-02-28|July 2008|Actual|2008-07-31|September 2006|Actual|2006-09-30||Interventional|||A Randomized Trial of Changing Medication Adherence In Hypertensive African-American Patients|A Randomized Trial of Changing Medication Adherence In Hypertensive African-American Patients|Completed||N/A|278|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No|No Plan to Share IPD|2018-06-01 04:21:49.958182|2018-06-01 04:21:49.958182
NCT00248859|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-02-17|2005-11-03|2005-11-04|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2004||2004-08-31|February 2017|2017-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Determinants of Cardiac Risk Factor Modification in Latinos With Coronary Artery Disease|Determinants of Cardiac Risk Factors Modification|Completed|||198|Actual|Weill Medical College of Cornell University|||||f||||f||||||||No|No plan to share IPD|2018-06-01 04:21:50.031298|2018-06-01 04:21:50.031298
NCT00248846|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-02-17|2005-11-03|2005-11-04|Estimate|||||||2017-02-17|2017-02-23|Actual|October 2004|Actual|2004-10-31|February 2017|2017-02-28|July 2011|Actual|2011-07-31|January 2008|Actual|2008-01-31||Interventional|||A Randomized Trial: Changing Behavior in Post-Angioplasty Patients|A Randomized Trial: Changing Behavior in Post-Angioplasty Patients|Completed||N/A|242|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No|No Plan to Share IPD|2018-06-01 04:21:50.088272|2018-06-01 04:21:50.088272
NCT00248833|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2016-10-25|2005-11-02|2005-11-04|Estimate|||||||2016-10-25|2016-10-27|Estimate|December 2005||2005-12-31|April 2010|2010-04-30|December 2007|Actual|2007-12-31|||||Interventional|||Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.|Phase 1 Dose Esc Study of Safety and Immun of 3 Injections, Given at 0, 6 and 24 Wks, of Grp B Meningococcal 44/76 MOS NOMV 5D Vaccine Admin to Healthy Subjs IM With and Without Adjuvant|Completed||Phase 1|30||U.S. Army Medical Research and Materiel Command|||||||||||||||||||2018-06-01 04:21:50.149717|2018-06-01 04:21:50.149717
NCT00248820|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2007-11-21|2005-11-02|2005-11-04|Estimate|||||||2007-11-21|2007-11-22|Estimate|September 2002||2002-09-30|November 2007|2007-11-30|February 2009|Anticipated|2009-02-28|||||Interventional|||Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses|Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Tours|||||f||||f||||||||||2018-06-01 04:21:50.218366|2018-06-01 04:21:50.218366
NCT00248807|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|2013-09-12||2014-05-21|2005-11-02|2005-11-04|Estimate|2014-05-21|2014-06-23|Estimate||||2014-05-21|2014-06-23|Estimate|October 2005||2005-10-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|May 2009|Actual|2009-05-31||Interventional|||A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.|Systemic Hemodynamics and Cerebral Blood Flow in Persons With Tetraplegia|Completed||N/A|30|Actual|VA Office of Research and Development|Did not assess carbon dioxide levels or the severity of spinal cord injury, which may have contributed to the results.|4|||f||||||||||||||2018-06-01 04:21:50.385974|2018-06-01 04:21:50.385974
NCT00248794|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|2015-09-02||2016-04-25|2005-11-02|2005-11-04|Estimate|2016-03-14|2016-04-14|Estimate||||2016-04-25|2016-05-25|Estimate|June 2004||2004-06-30|April 2016|2016-04-30|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|||Cognitive Rehabilitation in Schizophrenia|The Effects of Cognitive Rehabilitation on Function in Schizophrenia|Completed||N/A|59|Actual|VA Office of Research and Development||3|||f||||f||||||||No|Data to be written up in peer review journal and possibly presented at regional and national conferences, but there is no plan to de-identify and share|2018-06-01 04:21:50.670149|2018-06-01 04:21:50.670149
NCT00248781|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|2013-09-24||2013-12-10|2005-11-03|2005-11-04|Estimate|2013-12-10|2014-01-10|Estimate||||2013-12-10|2014-01-10|Estimate|September 2003||2003-09-30|December 2013|2013-12-31|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|||Home-based Exercise Via a Telecommunications System|Home-based Exercise Via a Telecommunications System|Completed||Phase 3|103|Actual|VA Office of Research and Development||2|||f||||||||||||||2018-06-01 04:21:51.021336|2018-06-01 04:21:51.021336
NCT00248768|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2014-09-18|2005-11-02|2005-11-04|Estimate|||||||2014-09-18|2014-09-19|Estimate|February 2005||2005-02-28|September 2014|2014-09-30|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|ATMS||Accelerated Transcranial Magnetic Stimulation (TMS) for Depression|Accelerated Transcranial Magnetic Stimulation for Depression|Completed||Phase 1|20|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 04:21:51.37041|2018-06-01 04:21:51.37041
NCT00248755|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2017-07-24|2005-11-02|2005-11-04|Estimate|||||||2017-07-24|2017-07-25|Actual|November 2005||2005-11-30|July 2017|2017-07-31|August 2006|Actual|2006-08-31|||||Interventional|||Assessing Mucociliary Clearance and Airway Liquid Volume in the CF Airway|Pilot Study of a New Technique for Assessing Mucociliary Clearance and Airway Surface Liquid Volume in Cystic Fibrosis|Completed||N/A|14||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:21:51.435971|2018-06-01 04:21:51.435971
NCT00248742|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-07-03|2005-11-03|2005-11-04|Estimate|||||||2011-07-03|2011-07-06|Estimate|February 2001||2001-02-28|March 2009|2009-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|INSPIRE||Psychobiology in Inflammatory Bowel Disease(IBD)|The Impact of Psychobiological Factors in Inflammatory Bowel Disease|Completed||N/A|114|Actual|Oslo University Hospital|||||f||||f||||||||||2018-06-01 04:21:51.498934|2018-06-01 04:21:51.498934
NCT00248729|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2006-08-28|2005-11-02|2005-11-04|Estimate|||||||2006-08-28|2006-08-29|Estimate|October 2002||2002-10-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.|Etomidate Versus Midazolam for Pre-Hospital Intubation: A Prospective, Randomized Trial|Completed||Phase 2|||St. Luke's Hospital, Pennsylvania|||||f||||||||||||||2018-06-01 04:21:51.565226|2018-06-01 04:21:51.565226
NCT00248716|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2008-04-29|2005-11-03|2005-11-04|Estimate|||||||2008-04-29|2008-05-06|Estimate|February 2007||2007-02-28|April 2008|2008-04-30||||April 2009|Anticipated|2009-04-30||Interventional|||Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations.||Unknown status|Recruiting|Phase 4|200|Anticipated|Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:21:51.633139|2018-06-01 04:21:51.633139
NCT00248703|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2017-10-16|2005-11-03|2005-11-04|Estimate|||||||2017-10-16|2017-10-17|Actual|October 2003|Actual|2003-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|November 2012|Actual|2012-11-30||Interventional|||Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow|Secondary Adjuvant (Rescue) Treatment With Docetaxel (Taxotere) and Detection of Isolated Tumor Cells in Bone Marrow as a Surrogate Marker for Effect in Node Positive and High Risk Node Negative Breast Cancer After Standard Adjuvant Epirubicin-containing Treatment|Active, not recruiting||Phase 2|1128|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-06-01 04:21:51.721326|2018-06-01 04:21:51.721326
NCT00248690|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2011-01-17|2005-11-03|2005-11-04|Estimate|||||||2011-01-17|2011-01-19|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||ICP Versus Intracranial Compliance Guided Management in SAH|Intracranial Pressure (ICP) Versus Intracranial Compliance (ICC) Guided Management in Subarachnoid Hemorrhage; - a Prospective, Randomized Trial.|Completed||N/A|100|Actual|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:21:51.787643|2018-06-01 04:21:51.787643
NCT00248677|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-12-09|2005-11-03|2005-11-04|Estimate|||||||2011-12-09|2011-12-13|Estimate|September 2005||2005-09-30|February 2011|2011-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Sensible Treatment of Obesity in Rural Youth . . .|Sensible Treatment of Obesity in Rural Youth|Completed||Early Phase 1|93|Actual|University of Florida||3|||f||||||||||||||2018-06-01 04:21:51.84715|2018-06-01 04:21:51.84715
NCT00248664|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2010-03-02|2005-11-03|2005-11-04|Estimate|||||||2010-03-02|2010-03-03|Estimate|March 2004||2004-03-31|March 2010|2010-03-31|November 2008|Actual|2008-11-30|||||Observational|EPIC||Events Preceding Interstitial Cystitis (EPIC)|A Case Control Study of Interstitial Cystitis|Completed|||400|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:21:51.91494|2018-06-01 04:21:51.91494
NCT00248651|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2014-06-26||2014-06-26|2005-11-03|2005-11-04|Estimate|2014-06-26|2014-07-25|Estimate||||2014-06-26|2014-07-25|Estimate|October 2006||2006-10-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|FDTT||Functional Dyspepsia Treatment Trial|Antidepressant Therapy for Functional Dyspepsia|Completed||Phase 2/Phase 3|292|Actual|Mayo Clinic||3|||f||||t||||||||||2018-06-01 04:21:51.978626|2018-06-01 04:21:51.978626
NCT00248638|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2013-12-19||2018-01-18|2005-11-03|2005-11-04|Estimate|2013-12-19|2014-02-13|Estimate||||2018-01-18|2018-01-23|Actual|September 2006||2006-09-30|January 2018|2018-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GLND|Adults following CABG, cardiac valve, vascular (non-neurosurgical), or small bowel and/or colonic surgery who are deemed likely to require PN for ≥ 7 subsequent days by the attending physicians and investigators are eligible. Potentially eligible subjects admitted to the SICU and deemed to require PN.|Efficacy and Mechanisms of GLN Dipeptide in the SICU|Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients|Completed||Phase 3|150|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:21:52.491175|2018-06-01 04:21:52.491175
NCT00248625|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2016-02-19||2016-06-16|2005-11-03|2005-11-04|Estimate|2016-06-16|2016-07-28|Estimate||||2016-06-16|2016-07-28|Estimate|January 2000||2000-01-31|June 2016|2016-06-30|October 2010|Actual|2010-10-31|September 2009|Actual|2009-09-30||Interventional||All participants who were randomized were included in the baseline analysis.|N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure|A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen.|Completed||Phase 3|184|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-06-01 04:21:52.83773|2018-06-01 04:21:52.83773
NCT00248612|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|2017-05-24||2018-01-21|2005-11-02|2005-11-04|Estimate|2017-07-19|2017-08-17|Actual||||2018-01-21|2018-01-24|Actual|September 2003|Actual|2003-09-30|January 2018|2018-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Psychosocial and Medication Treatment for Anxiety in Alcoholism|CBT And Venlafaxine Treatments For Anxiety In Alcoholism|Completed||Phase 2/Phase 3|162|Actual|Boston Medical Center|Small size of treatment groups leading to diminished meaningful difference between comparison groups at follow-up; Failure of randomization leading to unequal number of subjects in each treatment group.|4|||f||||t|t|f|||t|||No||2018-06-01 04:21:53.494291|2018-06-01 04:21:53.494291
NCT00248586|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2017-10-11|2005-11-02|2005-11-04|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2005|Actual|2005-02-28|October 2017|2017-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Development of Limited Contact CBT Treatment for IBS|Development of Limited Contact CBT Treatment for IBS|Completed||N/A|75|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f|||||f|f||||||||2018-06-01 04:21:54.38514|2018-06-01 04:21:54.38514
NCT00248573|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2013-12-16|2005-11-03|2005-11-04|Estimate|||||||2013-12-16|2013-12-17|Estimate|October 2004||2004-10-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Observational|||Mechanisms of Adaptation in Human Short Bowel Syndrome||Completed|||32|Actual|Emory University|||||f||||||||||Samples With DNA|"~     Intestinal biopsy samples~   "|||2018-06-01 04:21:54.471479|2018-06-01 04:21:54.471479
NCT00248560|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2014-08-18||2014-09-24|2005-11-03|2005-11-04|Estimate|2014-08-18|2014-08-28|Estimate||||2014-09-24|2014-10-03|Estimate|January 2005||2005-01-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|December 2009|Actual|2009-12-31||Interventional|||Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer|Phase II Study of Gemcitabine and Docetaxel (GEMDOC) Combination in Patients With Previously Treated Recurrent or Metatstatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|36|Actual|Barbara Ann Karmanos Cancer Institute|The trial design was changed during accrual to allow for study continuation although response rate was lower than predicted. The trial was completed but it did not meet the specified end points.|1|||f||||t||||||||||2018-06-01 04:21:54.546643|2018-06-01 04:21:54.546643
NCT00248547|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2011-11-21||2017-05-07|2005-11-03|2005-11-04|Estimate|2011-11-21|2011-12-21|Estimate||||2017-05-07|2017-05-09|Actual|May 2004||2004-05-31|May 2017|2017-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant|A Pilot Study of Aprepitant vs. Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplatation(HCT)|Completed||N/A|40|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 04:21:54.759595|2018-06-01 04:21:54.759595
NCT00248534|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2012-10-11|2005-11-03|2005-11-04|Estimate|||||||2012-10-11|2012-10-12|Estimate|September 2005||2005-09-30|October 2008|2008-10-31||||September 2012|Actual|2012-09-30||Interventional|||Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma|A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:21:55.00209|2018-06-01 04:21:55.00209
NCT00248521|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2013-08-01|2005-11-03|2005-11-04|Estimate|||||||2013-08-01|2013-08-02|Estimate|October 2005||2005-10-31|March 2008|2008-03-31||||January 2007|Anticipated|2007-01-31||Interventional|||17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery|A Cancer Research UK Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:21:55.100838|2018-06-01 04:21:55.100838
NCT00248495|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|2017-04-10||2017-06-15|2005-11-03|2005-11-04|Estimate|2017-04-10|2017-05-19|Actual||||2017-06-15|2017-07-12|Actual|June 8, 2005|Actual|2005-06-08|June 2017|2017-06-30|April 5, 2017|Actual|2017-04-05|April 29, 2011|Actual|2011-04-29||Interventional||All treated and eligible patients|Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Molecular and Genetic Changes in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Cisplatin and Alimta - Phase II Study|Completed||Phase 2|38|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 04:21:55.266086|2018-06-01 04:21:55.266086
NCT00248482|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2013-04-25|2005-11-03|2005-11-04|Estimate|||||||2013-04-25|2013-04-29|Estimate|February 2002||2002-02-28|April 2013|2013-04-30|January 2008|Actual|2008-01-31|April 2005|Actual|2005-04-30||Interventional|||Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Imatinib Mesylate Maintenance Therapy in Patients With C-Kit (+) Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|6|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 04:21:55.589912|2018-06-01 04:21:55.589912
NCT00248469|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2006-10-19|2005-11-02|2005-11-04|Estimate|||||||2006-10-19|2006-10-20|Estimate|July 1998||1998-07-31|November 2005|2005-11-30|April 2002||2002-04-30|||||Interventional|||MEMA Kwa Vijana Trial: Impact of an Adolescent Sexual and Reproductive Health Intervention in Mwanza, Tanzania|Strategies for the Prevention of HIV Infection and the Enhancement of Reproductive Health Among Adolescents in Rural Tanzania: MEMA Kwa Vijana Trial|Completed||Phase 3|10000||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:21:55.687668|2018-06-01 04:21:55.687668
NCT00248456|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2008-02-20|2005-11-03|2005-11-04|Estimate|||||||2008-02-20|2008-02-21|Estimate|October 2005||2005-10-31|February 2008|2008-02-29|February 2006||2006-02-28|||||Interventional|||Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris|A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris|Completed||Phase 4|320||LEO Pharma|||||f||||||||||||||2018-06-01 04:21:55.765317|2018-06-01 04:21:55.765317
NCT00248443|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2011-02-17|2005-11-03|2005-11-04|Estimate|||||||2011-02-17|2011-02-18|Estimate|August 2005||2005-08-31|March 2007|2007-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Réa-MiniMax: Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage|Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage. A Multicentric Randomized Controlled Trial|Completed||Phase 3|206|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:21:55.830446|2018-06-01 04:21:55.830446
NCT00248430|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2010-09-20|2005-11-03|2005-11-04|Estimate|||||||2010-09-20|2010-09-21|Estimate|August 2003||2003-08-31|September 2010|2010-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer|A Phase I-II Trial of Adoptive Immunotherapy Using Haploidentical, Related Donor-Lymphocyte Infusions and IL-2 After Autologous Stem Cell Transplantation for Advanced Lymphoid Malignancies|Completed||Phase 1/Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:21:55.911447|2018-06-01 04:21:55.911447
NCT00248404|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2012-09-26|2005-11-03|2005-11-04|Estimate|||||||2012-09-26|2012-09-27|Estimate|September 2005||2005-09-30|January 2008|2008-01-31||||||||Interventional|||NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)|A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase|Completed||Phase 1/Phase 2|155|Anticipated|Kiadis Pharma|||||f||||||||||||||2018-06-01 04:21:55.993927|2018-06-01 04:21:55.993927
NCT00248391|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2007-10-25|2005-11-03|2005-11-04|Estimate|||||||2007-10-25|2007-10-26|Estimate||||October 2006|2006-10-31|January 2008|Anticipated|2008-01-31|||||Interventional|||The Influence of Feeding Position on Pulmonary Morbidity in Young Children|The Influence of Feeding Position on Pulmonary Morbidity in Young Children|Unknown status|Not yet recruiting|N/A|2000|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:21:56.095288|2018-06-01 04:21:56.095288
NCT00248378|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2006-06-21|2005-11-02|2005-11-04|Estimate|||||||2006-06-21|2006-06-23|Estimate|September 2001||2001-09-30|June 2006|2006-06-30|March 2005||2005-03-31|||||Interventional|||Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis|Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis|Completed||Phase 1/Phase 2|30||Center for Medicinal Cannabis Research|||||||||||||||||||2018-06-01 04:21:56.184281|2018-06-01 04:21:56.184281
NCT00248365|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-03|||2016-02-24|2005-11-03|2005-11-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|August 2007|Actual|2007-08-31|||||Interventional|||Theralux Extracorporeal Photochemotherapy (ECP) in Patients With Extensive Chronic Graft Versus Host Disease (GvHD)|Safety, Biological and Clinical Efficacy of Two Intensity Levels of Theralux Extracorporeal Photochemotherapy in Subjects With Extensive Chronic GvHD Refractory or Intolerant to Standard Therapy: A Randomized, Open-label Phase I/II Clinical Trial|Completed||Phase 1/Phase 2|20|Actual|Kiadis Pharma||2|||||||||||||||||2018-06-01 04:21:56.255631|2018-06-01 04:21:56.255631
NCT00248352|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2007-10-25|2005-11-01|2005-11-03|Estimate|||||||2007-10-25|2007-10-26|Estimate|February 2005||2005-02-28|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||A Study Comparing Standard Care for Diabetes to Case-Managed Care for Diabetes in Patients With Coronary Artery Disease|GLUCOSE : Glucose Lowering by Usual Care Or Specialized Endocrinology Team|Completed||N/A|212|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||||||||||||2018-06-01 04:21:56.341693|2018-06-01 04:21:56.341693
NCT00248339|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2017-03-16|2005-11-02|2005-11-03|Estimate|||||||2017-03-16|2017-03-20|Actual|May 2002||2002-05-31|March 2017|2017-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection|An Open-label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-alfa-2b Plus Ribavirin to Peginterferon-alfa-2b Plus Epoetin-alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection|Completed||Phase 3|150|Actual|Virginia Commonwealth University||3|||f||||t||||||||||2018-06-01 04:21:56.438339|2018-06-01 04:21:56.438339
NCT00248313|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2010-03-09|2005-11-02|2005-11-03|Estimate|||||||2010-03-09|2010-03-10|Estimate|July 2000||2000-07-31|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus|A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporin Dose Reduction With Cyclosporin Elimination in de Novo Renal Allograft Recipients Receiving Rapamune|Completed||Phase 3|470||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:21:56.785101|2018-06-01 04:21:56.785101
NCT00248300|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2015-11-09|2005-11-02|2005-11-03|Estimate|||||||2015-11-09|2015-11-11|Estimate|August 2005||2005-08-31|November 2015|2015-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Peri-intubation Oral Intervention to Reduce Oral Flora and VAP|A Peri-intubation Oral Intervention to Reduce Oral Flora and VAP|Completed||Phase 4|156|Actual|Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 04:21:56.833976|2018-06-01 04:21:56.833976
NCT00248287|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|2016-02-02||2016-09-15|2005-11-02|2005-11-03|Estimate|2016-09-15|2016-11-03|Estimate||||2016-09-15|2016-11-03|Estimate|July 2005||2005-07-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|May 2014|Actual|2014-05-31||Interventional|CA225200|ITT population|PhII ICb With/Without Erbitux in MBC Pts|Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 2|154|Actual|US Oncology Research||2|||f||||||||||||||2018-06-01 04:21:57.062011|2018-06-01 04:21:57.062011
NCT00248274|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2011-11-21|2005-11-02|2005-11-03|Estimate|||||||2011-11-21|2011-11-22|Estimate|January 2005||2005-01-31|November 2011|2011-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Atrial Tissue Banking: Atrial Tissue Obtained From Patients Undergoing Heart Surgery|Assessment of Atrial Tissue Obtained From Patients Undergoing Heart Surgery|Terminated|||300|Actual|University of Pittsburgh||||Staffing and departmental changes at our site made it difficult to enroll subjects.|f||||t||||||Samples With DNA|"~     1. myocardial tissue~        2. DNA~   "|||2018-06-01 04:21:57.481017|2018-06-01 04:21:57.481017
NCT00248261|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2013-12-12|2005-11-02|2005-11-03|Estimate|||||||2013-12-12|2013-12-13|Estimate|November 2005||2005-11-30|December 2013|2013-12-31|June 2010|Actual|2010-06-30|August 2009|Actual|2009-08-31||Observational|||Ziprasidone and Sertraline in PTSD|Effects of Ziprasidone vs. Placebo During the First Four Weeks of Eight Weeks Sertraline Treatment in Patients With Post-traumatic Stress Disorder (PTSD)|Terminated|||7|Actual|Universitätsklinikum Hamburg-Eppendorf||||High rate of early drop-outs|f||||||||||||||2018-06-01 04:21:57.619913|2018-06-01 04:21:57.619913
NCT00248248|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2011-10-07|2005-11-01|2005-11-03|Estimate|||||||2011-10-07|2011-10-12|Estimate|October 2005||2005-10-31|October 2011|2011-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||DOXIL for Consolidation Therapy in Ovarian Cancer.|A Phase II Non-randomized Study of DOXIL Consolidation Treatment for Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneal Carcinoma.|Completed||Phase 2|45|Anticipated|Southeastern Gynecologic Oncology|||||f||||f||||||||||2018-06-01 04:21:57.686975|2018-06-01 04:21:57.686975
NCT00248235|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2016-05-10|2005-11-01|2005-11-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|January 2009|Actual|2009-01-31|May 2008|Actual|2008-05-31||Interventional|||Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer|Randomized Controlled Trial of Progressive Resistance Exercise Training for Spinal Accessory Neurapraxia/ Neurectomy in Head and Neck Cancer Survivors|Completed||Phase 2/Phase 3|64|Actual|University of Alberta, Physical Education||2|||f||||||||||||||2018-06-01 04:21:57.7613|2018-06-01 04:21:57.7613
NCT00248222|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2009-10-26|2005-11-02|2005-11-03|Estimate|||||||2009-10-26|2009-10-27|Estimate|October 2005||2005-10-31|October 2009|2009-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Early Aerobic Training Program After Ischemic Stroke||Completed||Phase 2|||Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:21:57.876647|2018-06-01 04:21:57.876647
NCT00248209|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2011-07-19|2005-11-02|2005-11-03|Estimate|||||||2011-07-19|2011-07-20|Estimate|May 2004||2004-05-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Female Orgasmic Disorder (FOD) and Wellbutrin XL|A Multi-center, Double-blind, Placebo-controlled Study of Bupropion XL in Females With Orgasmic Disorder|Completed||Phase 2/Phase 3|48|Actual|Segraves, R., T., M.D., Ph.D.||1|||f||||f||||||||||2018-06-01 04:21:57.955868|2018-06-01 04:21:57.955868
NCT00248196|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2008-03-20|2005-11-01|2005-11-03|Estimate|||||||2008-03-20|2008-03-21|Estimate|October 2005||2005-10-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||COOL MI II: Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|COOL MI II: Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|Terminated||Phase 2/Phase 3|225|Anticipated|Radiant Medical|||||||||||||||||||2018-06-01 04:21:58.040692|2018-06-01 04:21:58.040692
NCT00248183|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2008-04-02|2005-11-02|2005-11-03|Estimate|||||||2008-04-02|2008-04-03|Estimate|August 2005||2005-08-31|April 2008|2008-04-30|June 2006|Actual|2006-06-30|||||Interventional|||A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)|A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)|Completed||Phase 3|310||Epix Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 04:21:58.115314|2018-06-01 04:21:58.115314
NCT00248170|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|2015-09-08||2016-03-20|2005-11-02|2005-11-03|Estimate|2015-09-08|2015-10-09|Estimate||||2016-03-20|2016-04-19|Estimate|December 2005||2005-12-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|FACE||Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer|Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer|Completed||Phase 3|4172|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:21:58.287647|2018-06-01 04:21:58.287647
NCT00248157|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2012-04-30|2005-11-02|2005-11-03|Estimate|||||||2012-04-30|2012-05-01|Estimate|November 2005||2005-11-30|April 2012|2012-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)|Terminated||Phase 3|105|Actual|Novartis||||Inconsistent treatment benefit|f||||||||||||||2018-06-01 04:22:01.133086|2018-06-01 04:22:01.133086
NCT00248144|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2007-12-07|2005-11-02|2005-11-03|Estimate|||||||2007-12-07|2007-12-10|Estimate|October 2003||2003-10-31|August 2006|2006-08-31|July 2007|Actual|2007-07-31|||||Interventional|||A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis|A Randomized, Multicenter, Double-Blinded Controlled Study to Compare the Effectiveness of a Single Dose (1500 mg) of Famciclovir, One Day (750 mg q12) of Famciclovir and Placebo in Patient-Initiated Episodic Treatment of Recurrent Herpes Labialis|Completed||Phase 4|||Novartis|||||||||||||||||||2018-06-01 04:22:01.404855|2018-06-01 04:22:01.404855
NCT00248131|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2012-04-08|2005-11-02|2005-11-03|Estimate|||||||2012-04-08|2012-04-10|Estimate|November 2005||2005-11-30|April 2012|2012-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)|Terminated||Phase 3|260||Novartis|||||f||||||||||||||2018-06-01 04:22:01.522157|2018-06-01 04:22:01.522157
NCT00248118|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2016-09-22|2005-11-01|2005-11-03|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|May 2008|Actual|2008-05-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking|Neurocognitive and Affective Correlates of Tobacco Dependence in Adolescent Smokers and Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking|Terminated||Phase 2/Phase 3|72|Actual|National Institutes of Health Clinical Center (CC)||2||PI left NIH|f||||t||||||||||2018-06-01 04:22:01.959251|2018-06-01 04:22:01.959251
NCT00248105|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2013-10-31|2005-11-02|2005-11-03|Estimate|||||||2013-10-31|2013-11-04|Estimate|September 2005||2005-09-30|October 2013|2013-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|IMPAACT||Improving Motivation for Physical Activity in Arthritis Clinical Trial|Physical Activity in Persons With Arthritis|Completed||N/A|889|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 04:22:02.423608|2018-06-01 04:22:02.423608
NCT00248092|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2007-11-01|2005-11-01|2005-11-03|Estimate|||||||2007-11-01|2007-11-05|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse|A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse|Completed||Phase 1/Phase 2|36||New River Pharmaceuticals|||||||||||||||||||2018-06-01 04:22:02.912864|2018-06-01 04:22:02.912864
NCT00248079|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2011-10-18|2005-11-01|2005-11-03|Estimate|||||||2011-10-18|2011-10-20|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|October 2011|Actual|2011-10-31|June 2007|Actual|2007-06-30||Interventional|||The Medtronic RESOLUTE Clinical Trial|The Clinical Response Evaluation of the Medtronic Endeavor CR ABT-578 Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|Completed||Phase 1/Phase 2|139|Actual|Medtronic Vascular|||||f||||t||||||||||2018-06-01 04:22:03.236207|2018-06-01 04:22:03.236207
NCT00248066|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2007-02-06|2005-11-01|2005-11-03|Estimate|||||||2007-02-06|2007-02-08|Estimate|September 2005||2005-09-30|February 2007|2007-02-28||||||||Interventional|||Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries|APPRAISAL Trial: A Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of RESTEN-MP® When Used in Conjunction With a Bare Metal Stent in de Novo Native Coronary Artery Lesions|Completed||Phase 2|50||Sarepta Therapeutics|||||f||||||||||||||2018-06-01 04:22:03.396001|2018-06-01 04:22:03.396001
NCT00248053|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2012-09-18|2005-11-01|2005-11-03|Estimate|||||||2012-09-18|2012-09-20|Estimate|November 2005||2005-11-30|September 2012|2012-09-30||||June 2008|Actual|2008-06-30||Interventional|||Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients|Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis (FAP) Patients|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||1||"Subsequent data generated by our collaborators have shown efficacy with curcumin and quercetin~   in 5 patients in a non placebo controlled trial."|f||||f||||||||||2018-06-01 04:22:03.55441|2018-06-01 04:22:03.55441
NCT00248040|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-02|||2011-06-07|2005-11-02|2005-11-03|Estimate|||||||2011-06-07|2011-06-08|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Reparixin in Prevention of Delayed Graft Dysfunction After Kidney Transplantation|A Phase 2, Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group (3 Arms) Pilot Study to Assess the Efficacy, the Safety and the Pharmacokinetics of Two Treatment Schedules of Reparixin in the Prevention of Delayed Graft Function After Kidney Transplantation in High Risk Patients|Completed||Phase 2|80|Actual|Dompé Farmaceutici S.p.A||3|||||||||||||||||2018-06-01 04:22:03.79785|2018-06-01 04:22:03.79785
NCT00248027|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2006-09-12|2005-11-01|2005-11-03|Estimate|||||||2006-09-12|2006-09-13|Estimate|January 2004||2004-01-31|September 2006|2006-09-30||||||||Observational|||Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders Clinic|Tracking Service Use and Outcomes II:First Episode Psychosis and Psychotic Disorders Clinic|Terminated|||||McMaster University|||||f||||||||||||||2018-06-01 04:22:04.026759|2018-06-01 04:22:04.026759
NCT00248014|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2012-01-18|2005-11-01|2005-11-03|Estimate|||||||2012-01-18|2012-01-19|Estimate|October 2005||2005-10-31|January 2012|2012-01-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||Response of Individuals With Class II Malocclusion|Cephalometric Indicators of Biological Responsiveness to Orthodontic Treatment of Class II/I in Growing Patients|Completed||Phase 2|63|Actual|Aristotle University Of Thessaloniki|||||f||||t||||||||||2018-06-01 04:22:04.172157|2018-06-01 04:22:04.172157
NCT00247988|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2007-04-20|2005-11-01|2005-11-02|Estimate|||||||2007-04-20|2007-04-24|Estimate|October 2003||2003-10-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers|Phase II Study of Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers|Terminated||Phase 2|38||University of Saskatchewan||||"Regulatory issues(trial temporarily suspended December 28, 2005. Permanently suspended January~   19, 2007. Institutional Reveiw Board informed April 18, 2007"|f||||||||||||||2018-06-01 04:22:04.251251|2018-06-01 04:22:04.251251
NCT00247975|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2012-02-06|2005-10-31|2005-11-02|Estimate|||||||2012-02-06|2012-02-07|Estimate|March 2006||2006-03-31|February 2012|2012-02-29|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy|Primary Prevention of Anthracycline-Induced Cardiotoxicity With L-Carnitine in Patients With Breast Cancer (PPACC)-Pilot Study|Completed||Phase 2/Phase 3|144|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||t||||||||||2018-06-01 04:22:04.393561|2018-06-01 04:22:04.393561
NCT00247962|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|2009-01-30||2012-10-09|2005-10-31|2005-11-02|Estimate|2012-10-09|2012-11-08|Estimate||||2012-10-09|2012-11-08|Estimate|December 2005||2005-12-31|October 2012|2012-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis|A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis|Completed||Phase 4|566|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 04:22:05.820066|2018-06-01 04:22:05.820066
NCT00247949|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2009-11-09|2005-11-01|2005-11-02|Estimate|||||||2009-11-09|2009-11-10|Estimate|July 2004||2004-07-31|November 2009|2009-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||Accuracy of Non-invasive Continuous CO2-Monitoring|The Accuracy of Non-invasive Continuous Carbon Dioxide Monitoring by the Sentec V-Sign Digital Monitor System|Terminated|||150|Actual|University Hospital, Basel, Switzerland||||We had got enough data, therefore we stopped the study and published the data.|f||||t||||||||||2018-06-01 04:22:08.710521|2018-06-01 04:22:08.710521
NCT00247936|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2009-11-04|2005-10-31|2005-11-02|Estimate|||||||2009-11-04|2009-11-06|Estimate|May 2004||2004-05-31|November 2009|2009-11-30|April 2010|Anticipated|2010-04-30|April 2010|Anticipated|2010-04-30||Interventional|||Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.|Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.|Withdrawn||N/A|40|Anticipated|University of California, Irvine||2||Prior to recruitment, study terminated lack of recruitment interest.|f||||f||||||||||2018-06-01 04:22:08.961754|2018-06-01 04:22:08.961754
NCT00247923|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2011-07-03|2005-10-31|2005-11-02|Estimate|||||||2011-07-03|2011-07-06|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|||||Interventional|||Endometrial Polyps: Pathophysiology and Clinical Consequences|Endometrial Polyps. Pathophysiology and Clinical Consequences.|Completed||N/A|1186|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:22:09.344878|2018-06-01 04:22:09.344878
NCT00247910|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2011-09-16|2005-11-01|2005-11-02|Estimate|||||||2011-09-16|2011-09-19|Estimate|October 2001||2001-10-31|September 2011|2011-09-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Behavioural Treatment of Hypertension|Behavioural Treatment of Hypertension|Completed||N/A|150|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:22:09.450828|2018-06-01 04:22:09.450828
NCT00247897|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2011-04-11|2005-11-01|2005-11-02|Estimate|||||||2011-04-11|2011-04-12|Estimate|November 2005||2005-11-30|April 2011|2011-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Comparing Skin Disinfectants Before Labour Epidural Analgesia|What is the Best Skin Preparation Solution for Labour Epidural Analgesia? A Randomized Prospective Trial Comparing ChloraprepTM, DuraprepTM, and Chlorhexidine 0.5% in 70% Alcohol.|Completed||N/A|195|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:22:09.548144|2018-06-01 04:22:09.548144
NCT00247884|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2009-10-09|2005-10-31|2005-11-02|Estimate|||||||2009-10-09|2009-10-14|Estimate|June 2005||2005-06-30|October 2009|2009-10-31|October 2009|Actual|2009-10-31|||||Observational|||Pender Assisted Therapy (PATh) - Prospective Study of the Treatment of HCV|Directly Observed Therapy for the Treatment of Hepatitis C Virus Infection in Injection Drug Users|Completed|||50|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:22:09.702508|2018-06-01 04:22:09.702508
NCT00247871|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2011-09-28|2005-10-31|2005-11-02|Estimate|||||||2011-09-28|2011-09-29|Estimate|October 2005||2005-10-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|||||Observational|||Microbiological Characterization and Nasal Carriage Rates of Methicillin Resistant Staphylococcus Aureus (MRSA) in Vancouver Downtown Eastside|The Prevalence of Panton Valentine Leukocidin, Exfoliative Toxin and Agr Genotypes in Staphylococcus Aureus Nasal Colonization in Vancouver's Eastside Community|Unknown status|Active, not recruiting||600|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:22:09.907939|2018-06-01 04:22:09.907939
NCT00247858|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2011-09-28|2005-11-01|2005-11-02|Estimate|||||||2011-09-28|2011-09-29|Estimate|January 2005||2005-01-31|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Analysis of Methicillin Resistant Staphylococcus Aureus (MRSA) Obtained Through the Emergency Department in a Tertiary Care Hospital in Vancouver Canada From 2001-2005|Analysis of Methicillin Resistant Staphylococcus Aureus (MRSA) Obtained Through the Emergency Department in a Tertiary Care Hospital in Vancouver Canada From 2001-2005|Unknown status|Active, not recruiting||97|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:22:09.960516|2018-06-01 04:22:09.960516
NCT00247845|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2014-08-20|2005-10-31|2005-11-02|Estimate|||||||2014-08-20|2014-08-22|Estimate|July 2004||2004-07-31|August 2014|2014-08-31|September 2007|Actual|2007-09-30|||||Observational|||Evaluation of Atazanavir Substitution Intervention (EASI) Study|Evaluation of Atazanavir Substitution Intervention (EASI) Study: An Observational Phase IV Study to Evaluate the Impact of Atazanavir Substitution on the Quality of Life and Maintenance of Virologic Suppression in HIV-Infected Patients Intolerant to Current Successful HAART|Completed|||100|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:22:10.033025|2018-06-01 04:22:10.033025
NCT00247832|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2011-11-15|2005-10-31|2005-11-02|Estimate|||||||2011-11-15|2011-11-16|Estimate|October 2005||2005-10-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Readiness for Discharge Following Lobectomy|Readiness for Discharge Following Lobectomy: Effects of the Thoracic Risk Intervention and Management (T.R.I.M.) Protocol|Unknown status|Recruiting|N/A|99|Anticipated|University of British Columbia||3|||f||||f||||||||||2018-06-01 04:22:10.114199|2018-06-01 04:22:10.114199
NCT00247819|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2017-01-11|2005-10-31|2005-11-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1992||1992-08-31|October 2005|2005-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||The Genetic Basis for Vulnerability to Substance Abuse|Allelic Linkage in Substance Abuse|Completed|||8000|Anticipated|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:22:10.216861|2018-06-01 04:22:10.216861
NCT00247806|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2008-09-24|2005-10-31|2005-11-02|Estimate|||||||2008-09-24|2008-09-25|Estimate|October 2008||2008-10-31|October 2005|2005-10-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Prevalence of Lactose Intolerance Following Stem Cell Transplantation|Prevalence of Lactose Intolerance Following Stem Cell Transplantation in Pediatric Patients.|Terminated|||20|Anticipated|University of British Columbia||||Too few patients completed the study once enrolled.|f||||||||||||||2018-06-01 04:22:10.296949|2018-06-01 04:22:10.296949
NCT00247793|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2005-11-01|2005-11-01|2005-11-02|Estimate|||||||2005-11-01|2005-11-02|Estimate|July 1996||1996-07-31|November 2005|2005-11-30|December 1998||1998-12-31|||||Interventional|||Immunonutrition in Cardiac Surgery|The Effect of Pre- and Postoperative Supplemental Enteral Nutrition in High-Risk Patients Undergoing Elective Cardiac Surgery. A Prospective Double Blind Study.|Completed||N/A|||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||||||||||||2018-06-01 04:22:10.375081|2018-06-01 04:22:10.375081
NCT00247780|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2008-02-13|2005-11-01|2005-11-02|Estimate|||||||2008-02-13|2008-02-18|Estimate|November 2004||2004-11-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation|Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation|Completed||Phase 4|149|Actual|University of Aarhus|||||f||||||||||||||2018-06-01 04:22:10.450808|2018-06-01 04:22:10.450808
NCT00247754|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2005-10-31|2005-10-31|2005-11-02|Estimate|||||||2005-10-31|2005-11-02|Estimate|November 2002||2002-11-30|October 2005|2005-10-31|June 2005||2005-06-30|||||Interventional|||VP3: Vancouver Primary Prevention Program (Anxiety Disorders Prevention in School Children)|VP3: Vancouver Primary Prevention Program (Anxiety Disorders Prevention in School Children)|Completed||N/A|281||University of British Columbia|||||f||||||||||||||2018-06-01 04:22:10.598039|2018-06-01 04:22:10.598039
NCT00247741|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2013-12-18|2005-11-01|2005-11-02|Estimate|||||||2013-12-18|2013-12-19|Estimate|November 2005||2005-11-30|October 2005|2005-10-31|May 2006||2006-05-31|||||Interventional|||Spinal Anesthesia With Articaine and Lidocaine for Outpatient Surgery.|Spinal Anesthesia With Articaine and Lidocaine for Outpatient Surgery: A Double Blind Randomized Clinical Trial.|Completed||Phase 3|80||St. Antonius Hospital||2|||f||||f||||||||||2018-06-01 04:22:10.674437|2018-06-01 04:22:10.674437
NCT00247728|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2007-10-16|2005-11-01|2005-11-02|Estimate|||||||2007-10-16|2007-10-18|Estimate|June 2004||2004-06-30|October 2007|2007-10-31|June 2008||2008-06-30|||||Interventional|||PI-88 in Hepatocellular Carcinoma After Hepatectomy|A Randomized, Multi-Centre, Efficacy Evaluation of PI-88 in Patients With Hepatocellular Carcinoma After Hepatectomy - A Phase II Study|Completed||Phase 2|343||Progen Pharmaceuticals|||||||||||||||||||2018-06-01 04:22:10.771363|2018-06-01 04:22:10.771363
NCT00247715|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2007-08-28|2005-11-01|2005-11-02|Estimate|||||||2007-08-28|2007-08-29|Estimate|October 2003||2003-10-31|August 2007|2007-08-31|January 2007|Actual|2007-01-31|||||Interventional|||"Comparison of a Step-Up Versus a Step-Down Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)"|Comparison of an Antacid/H2-Receptor Antagonist/Proton Pump Inhibitor Versus a Proton Pump Inhibitor/H2-Receptor Antagonist/Antacid Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)|Completed||N/A|664|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 04:22:10.920474|2018-06-01 04:22:10.920474
NCT00247702|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2005-11-01|2005-11-01|2005-11-02|Estimate|||||||2005-11-01|2005-11-02|Estimate|July 2005||2005-07-31|July 2005|2005-07-31|June 2006||2006-06-30|||||Interventional|||The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR|Study of the Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR|Unknown status|Recruiting|N/A|120||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:22:11.029462|2018-06-01 04:22:11.029462
NCT00247689|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2018-05-19|2005-10-31|2005-11-02|Estimate|||||||2018-05-19|2018-05-22|Actual|December 22, 2004||2004-12-22|February 27, 2015|2015-02-27|February 27, 2015||2015-02-27|||||Observational|||Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics|Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics|Terminated|||31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:11.103987|2018-06-01 04:22:11.103987
NCT00247676|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|2010-01-06||2010-02-04|2005-11-01|2005-11-02|Estimate|2010-01-06|2010-02-02|Estimate||||2010-02-04|2010-02-18|Estimate|February 2006||2006-02-28|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer|An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 2|37|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:22:11.206328|2018-06-01 04:22:11.206328
NCT00247663|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2012-04-18|2005-11-01|2005-11-02|Estimate|||||||2012-04-18|2012-04-19|Estimate|December 1999||1999-12-31|April 2012|2012-04-30||||December 2005|Actual|2005-12-31||Interventional|||Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer|Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer|Completed||Phase 2|17|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:22:12.072055|2018-06-01 04:22:12.072055
NCT00247650|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2017-02-28|2005-11-01|2005-11-02|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2005||2005-09-30|November 2009|2009-11-30||||March 2007|Actual|2007-03-31||Interventional|||Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy|Randomized Multi-Center Study Comparing Prolonged Primary Systemic Endocrine Therapy With Letrozole Alone or in Combination With Zoledronic Acid in Early Breast Cancer (NEOadjuvant Study in CANada)|Completed||Phase 2|190|Anticipated|Novartis|||||f||||||||||||||2018-06-01 04:22:12.15031|2018-06-01 04:22:12.15031
NCT00247637|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2013-07-01|2005-10-31|2005-11-02|Estimate|||||||2013-07-01|2013-07-03|Estimate|May 2003||2003-05-31|July 2013|2013-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||The Genetic Basis of Inherited Neurologic Deficits in People With Schizophrenia|The Genetics of Endophenotypes and Schizophrenia|Completed|||2025|Actual|University of California, San Diego|||||f||||||||||Samples With DNA|"~     Whole blood was sent to the Cell Repository at Rutgers toestablish cell lines.~   "|||2018-06-01 04:22:12.295272|2018-06-01 04:22:12.295272
NCT00247624|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|2011-08-05||2017-11-10|2005-10-31|2005-11-02|Estimate|2017-11-10|2017-12-13|Actual||||2017-11-10|2017-12-13|Actual|October 2005||2005-10-31|November 2017|2017-11-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Improving Sleep and Psychological Functioning in People With Depression and Insomnia|Hypnotics in the Treatment of Psychiatric Disorders|Completed||Phase 4|60|Actual|Wake Forest University Health Sciences||2|||f|||||t|f||||||||2018-06-01 04:22:12.40247|2018-06-01 04:22:12.40247
NCT00247611|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|2013-08-01||2013-11-26|2005-10-31|2005-11-02|Estimate|2013-11-26|2013-12-20|Estimate||||2013-11-26|2013-12-20|Estimate|October 2005||2005-10-31|November 2013|2013-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||Baseline characteristics provided for randomized sample. Analyses were conducted on those with >=2 adherence assessments for ITT.|Improving Treatment Adherence in HIV-Infected Individuals|Changing ART Adherence Behavior: The Lifewindows Project|Completed||Phase 2|594|Actual|University of Connecticut|"The only empirical demonstration of LifeWindows outcomes to date~OP sample was defined a posteriori~Under-powered to detect changes in Viral Load"|2|||f||||t||||||||||2018-06-01 04:22:12.732489|2018-06-01 04:22:12.732489
NCT00247585|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2006-12-04|2005-11-01|2005-11-02|Estimate|||||||2006-12-04|2006-12-06|Estimate|September 2003||2003-09-30|December 2006|2006-12-31|June 2006||2006-06-30|||||Interventional|||Hangover, Congeners, Sleep and Occupational Performance|Hangover, Congeners, Sleep and Occupational Performance|Completed||Phase 2|140||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 04:22:13.575744|2018-06-01 04:22:13.575744
NCT00247572|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2007-11-01|2005-10-31|2005-11-02|Estimate|||||||2007-11-01|2007-11-05|Estimate|September 2005||2005-09-30|November 2007|2007-11-30|November 2005|Actual|2005-11-30|||||Interventional|||Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories|A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse|Completed||Phase 2|12||New River Pharmaceuticals|||||||||||||||||||2018-06-01 04:22:13.776234|2018-06-01 04:22:13.776234
NCT00247559|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2006-05-15|2005-11-01|2005-11-02|Estimate|||||||2006-05-15|2006-05-16|Estimate|May 2004||2004-05-31|May 2006|2006-05-31|May 2005||2005-05-31|||||Interventional|||Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)|A Phase II, Multi-Centre, Randomised, Double-Blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15 U, 30 U or 45 U of Botulinum Type A Toxin to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow’s Feet)|Completed||Phase 2|220||Ipsen|||||f||||||||||||||2018-06-01 04:22:13.896853|2018-06-01 04:22:13.896853
NCT00247546|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2006-10-17|2005-11-01|2005-11-02|Estimate|||||||2006-10-17|2006-10-18|Estimate|March 2003||2003-03-31|September 2006|2006-09-30|March 2005||2005-03-31|||||Interventional|||Prevention of Falls and Injurious Falls Among Elderly People||Completed||N/A|592||The Hospital District of Satakunta|||||f||||||||||||||2018-06-01 04:22:13.99606|2018-06-01 04:22:13.99606
NCT00247533|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2009-02-06|2005-10-31|2005-11-02|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 2005||2005-10-31|August 2005|2005-08-31|August 2007|Anticipated|2007-08-31|||||Interventional|||Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia|The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography|Unknown status|Recruiting|Phase 4|30|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:22:14.189535|2018-06-01 04:22:14.189535
NCT00247520|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2005-11-01|2005-11-01|2005-11-02|Estimate|||||||2005-11-01|2005-11-02|Estimate|May 2005||2005-05-31|November 2005|2005-11-30|August 2005||2005-08-31|||||Interventional|||Safety and Efficacy Study of rEV131 in Allergic Rhinitis|Two Center Evaluation of the Safety and Efficacy of Topical Nasal rEV131 Versus rEV131 Vehicle (Placebo)in the Prevention of the Signs and Symptoms of Allergic Rhinitis Induced by Nasal Allergen Challenge|Unknown status|Active, not recruiting|Phase 1/Phase 2|112||Evolutec Group|||||||||||||||||||2018-06-01 04:22:14.352947|2018-06-01 04:22:14.352947
NCT00247507|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2006-10-17|2005-10-31|2005-11-02|Estimate|||||||2006-10-17|2006-10-18|Estimate|September 2005||2005-09-30|October 2005|2005-10-31|December 2005||2005-12-31|||||Interventional|||The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients||Unknown status|Active, not recruiting|Phase 4|||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:22:14.548689|2018-06-01 04:22:14.548689
NCT00247494|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2009-07-21|2005-11-01|2005-11-02|Estimate|||||||2009-07-21|2009-07-22|Estimate|April 2005||2005-04-30|November 2005|2005-11-30||||||||Interventional|||Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients|Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients|Unknown status|Recruiting|Phase 4|90|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||t||||||||||2018-06-01 04:22:14.711829|2018-06-01 04:22:14.711829
NCT00247481|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2009-04-22|2005-11-01|2005-11-02|Estimate|||||||2009-04-22|2009-04-23|Estimate|September 2002||2002-09-30|April 2009|2009-04-30|June 2005|Actual|2005-06-30|||||Interventional|||ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer|A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer|Completed||Phase 2|77||AstraZeneca|||||f||||||||||||||2018-06-01 04:22:14.79932|2018-06-01 04:22:14.79932
NCT00247468|ClinicalTrials.gov processed this data on May 31, 2018|2005-11-01|||2017-01-19|2005-11-01|2005-11-02|Estimate|||||||2017-01-19|2017-01-23|Estimate|December 2004|Actual|2004-12-31|January 2017|2017-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Strict Glucose Control of Pediatric Intensive Care Unit (ICU) Patients|Strict Glucose Control of Pediatric ICU Patients to Reduce Mortality and Morbidity|Withdrawn||N/A|0|Actual|Children's Hospital of Philadelphia||||Never received IRB approval|f||||f|f|f||||||No||2018-06-01 04:22:14.900305|2018-06-01 04:22:14.900305
NCT00247455|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-06-20|2005-10-31|2005-11-01|Estimate|||||||2011-06-20|2011-06-21|Estimate|March 2002||2002-03-31|August 2007|2007-08-31|August 2005|Actual|2005-08-31|||||Interventional|||Fibre and Appetite Regulation Trial (FART)|Long-term Effect of Cereal Fibre on Abdominal Fat in Insulin Resistant Subjects|Completed||N/A|32||University of Toronto|||||f||||f||||||||||2018-06-01 04:22:14.99028|2018-06-01 04:22:14.99028
NCT00247442|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-30|||2006-09-27|2005-10-30|2005-11-01|Estimate|||||||2006-09-27|2006-09-28|Estimate|January 2006||2006-01-31|June 2005|2005-06-30|April 2006||2006-04-30|||||Interventional|||Australian Screening Mammography Decision Aid Trial (ASMDAT)|An Evaluation of a Decision Aid for Women Aged Over 70 Considering Whether to Stop or Continue Having Mammography Screening.|Completed||N/A|670||University of Sydney|||||f||||||||||||||2018-06-01 04:22:15.080084|2018-06-01 04:22:15.080084
NCT00247429|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2009-08-31|2005-10-28|2005-11-01|Estimate|||||||2009-08-31|2009-09-01|Estimate|July 2004||2004-07-31|August 2009|2009-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|||Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients|Vandral Retard (Venlafaxine Extended Release) in Depressive Syndrome With Anxiety and Painful Symptoms in Elderly Patients. Observational Study in Primary Care|Completed|||59|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||None Retained|"~     No specimen retained~   "|||2018-06-01 04:22:15.163746|2018-06-01 04:22:15.163746
NCT00247416|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2013-08-02||2014-01-16|2005-10-28|2005-11-01|Estimate|2014-01-16|2014-03-07|Estimate||||2014-01-16|2014-03-07|Estimate|August 2005||2005-08-31|January 2014|2014-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer|Randomized Phase II Trail of Carboplatin and Gemcitabine Untreated Stage IIIB-pleural Effusion and Stage IV Lung Cancer|Completed||Phase 2|60|Actual|University of Kentucky||2|||f||||t||||||||||2018-06-01 04:22:15.248872|2018-06-01 04:22:15.248872
NCT00247403|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2015-04-09|2005-10-28|2005-11-01|Estimate|||||||2015-04-09|2015-04-10|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Interventional|||Safety Study of 2DG With Stereotactic Radiosurgery|Phase I Clinical Trial: 2DG + Stereotactic Radiosurgery (SRS) Protocol for Treatment of Intracranial Metastases|Withdrawn||Phase 1|0|Actual|University of Iowa||1||Pharmaceutical company no longer manufactures drug|f||||t||||||||||2018-06-01 04:22:15.713595|2018-06-01 04:22:15.713595
NCT00247390|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2010-06-02|2005-10-28|2005-11-01|Estimate|||||||2010-06-02|2010-06-03|Estimate|July 2005||2005-07-31|June 2010|2010-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.|A Randomised, Double-blind, Placebo-controlled Study to Determine the Long-term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.|Completed||Phase 3|451|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:22:15.796569|2018-06-01 04:22:15.796569
NCT00247377|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|2010-01-19||2010-05-11|2005-10-31|2005-11-01|Estimate|2010-03-22|2010-04-06|Estimate||||2010-05-11|2010-05-18|Estimate|October 2002||2002-10-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Laparoscopic Gastric Bypass vs LAP-BAND for Treatment of Morbid Obesity|A Prospective Randomized Trial of Laparoscopic Gastric Bypass vs Laparoscopic Adjustable Gastric Banding (LAP-BAND) for Treatment of Morbid Obesity|Completed||N/A|197|Actual|University of California, Irvine||2|||f||||f||||||||||2018-06-01 04:22:15.930701|2018-06-01 04:22:15.930701
NCT00247364|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2005-10-28|2005-10-28|2005-11-01|Estimate|||||||2005-10-28|2005-11-01|Estimate|November 2003||2003-11-30|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)|A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)|Completed||Phase 2|20||Sleep Health Centers|||||f||||||||||||||2018-06-01 04:22:16.37794|2018-06-01 04:22:16.37794
NCT00247351|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2006-10-18|2005-10-31|2005-11-01|Estimate|||||||2006-10-18|2006-10-19|Estimate|September 2003||2003-09-30|September 2003|2003-09-30|June 2005||2005-06-30|||||Interventional|||Prevention of Atrial Tachycardia After a Right Atriotomy|Prevention of Atrial Tachycardia After a Right Atriotomy|Completed||N/A|15||Aarhus University Hospital Skejby|||||f||||||||||||||2018-06-01 04:22:16.427483|2018-06-01 04:22:16.427483
NCT00247338|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2008-05-09|2005-10-31|2005-11-01|Estimate|||||||2008-05-09|2008-05-12|Estimate|April 2005||2005-04-30|May 2008|2008-05-31|May 2006|Actual|2006-05-31|April 2006|Actual|2006-04-30||Interventional|||The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients|Comparing With Traditional Nitrogen Calorie Parenteral Nutrition Support, the Impact of Low Calorie and Low Nitrogen Intake on the Clinical Outcome of Gastrointestinal Postoperative Patients, Multicentre Post-Marketing Clinical Study|Completed||Phase 4|120|Anticipated|Sino-Swed Pharmaceutical Corporation|||||f||||||||||||||2018-06-01 04:22:16.476551|2018-06-01 04:22:16.476551
NCT00247325|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2006-11-29|2005-10-31|2005-11-01|Estimate|||||||2006-11-29|2006-11-30|Estimate|January 2004||2004-01-31|January 2005|2005-01-31|December 2004||2004-12-31|||||Interventional|||RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography|Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Renal Insufficiency Undergoing Coronary Angiography: The RECOVER Study, A Randomized Controlled Trial|Completed||Phase 4|||Seoul National University Hospital|||||f||||||||||||||2018-06-01 04:22:16.535197|2018-06-01 04:22:16.535197
NCT00247312|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2015-11-16|2005-10-28|2005-11-01|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2005||2005-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial|Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial|Completed||Phase 3|319|Actual|Schiffler Cancer Center||2|||f||||t||||||||||2018-06-01 04:22:16.590997|2018-06-01 04:22:16.590997
NCT00247299|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-30|||2005-10-30|2005-10-30|2005-11-01|Estimate|||||||2005-10-30|2005-11-01|Estimate|May 2005||2005-05-31|October 2005|2005-10-31||||||||Interventional|||Evaluation and Optimization of the Technical and Clinical Performance of the Lumenis ONE Platform|Evaluation and Optimization of the Technical and Clinical Performance of the Lumenis ONE Platform|Unknown status|Active, not recruiting|N/A|30||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:22:16.670116|2018-06-01 04:22:16.670116
NCT00247286|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2016-01-25|2005-10-31|2005-11-01|Estimate|||||||2016-01-25|2016-01-27|Estimate|September 2001||2001-09-30|January 2016|2016-01-31|October 2007|Actual|2007-10-31|January 2007|Actual|2007-01-31||Interventional|||Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial.|A Randomised, Single-Blind Comparison of Pelvic Floor Muscle Exercises With Biofeedback Versus Weighted Vaginal Cones in the Management of Genuine Stress Incontinence : A Pilot Study|Terminated||Phase 4|36|Actual|Queen's University||2||slow recruitment|f||||f||||||||Undecided||2018-06-01 04:22:16.723244|2018-06-01 04:22:16.723244
NCT00247273|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2011-03-04||2013-04-15|2005-10-28|2005-11-01|Estimate|2011-05-23|2011-06-21|Estimate||||2013-04-15|2013-04-22|Estimate|October 2005||2005-10-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||A Study of Monthly Risedronate for Osteoporosis|A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)|Completed||Phase 3|1294|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 04:22:16.833734|2018-06-01 04:22:16.833734
NCT00247260|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2007-03-13|2005-10-31|2005-11-01|Estimate|||||||2007-03-13|2007-03-15|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|February 2007||2007-02-28|||||Interventional|||Safety of 32P BioSilicon in Patients With Hepatocellular Carcinoma|A Study of the Safety Profile of Three Escalating Radioactivity Levels of 32P BioSilicon Delivered With the SIMPL Needle as Intratumoural Implantations in Patients With Unresectable Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 2|50||pSiVida Limited|||||f||||||||||||||2018-06-01 04:22:18.905551|2018-06-01 04:22:18.905551
NCT00247247|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2007-06-22|2005-10-31|2005-11-01|Estimate|||||||2007-06-22|2007-06-25|Estimate|December 2002||2002-12-31|June 2007|2007-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.|Efficacy and Tolerability of Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon|Completed||Phase 4|300||Orion Corporation, Orion Pharma|||||f||||||||||||||2018-06-01 04:22:18.973848|2018-06-01 04:22:18.973848
NCT00247234|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2017-09-20|2005-10-31|2005-11-01|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2004|Actual|2004-09-30|September 2017|2017-09-30|January 2015|Actual|2015-01-31|June 2011|Actual|2011-06-30||Interventional|||Effectiveness of Group Based Schema Therapy in the Treatment of Personality Disorders|Effectiveness of Group Based Schema Therapy in the Treatment of Borderline Personality Disorder and Avoidant Personality Disorder|Completed||N/A|90|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 04:22:19.040684|2018-06-01 04:22:19.040684
NCT00247221|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2012-07-28|2005-10-28|2005-11-01|Estimate|||||||2012-07-28|2012-07-31|Estimate|October 2002||2002-10-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Brief Intervention for Families of Teens Treated in the Emergency Department for an Alcohol-Related Event|Family Motivational Interviews for ETOH+ Teens in the ER|Completed||Phase 1|208|Actual|Brown University||2|||f||||t||||||||||2018-06-01 04:22:19.112829|2018-06-01 04:22:19.112829
NCT00247208|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2012-04-25|2005-10-31|2005-11-01|Estimate|||||||2012-04-25|2012-04-26|Estimate|May 2005||2005-05-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|October 2008|Actual|2008-10-31||Interventional|||The SOS (Stenting Of Saphenous Vein Grafts) Trial|The SOS (Stenting Of Saphenous Vein Grafts) Randomized-controlled Trial of a Paclitaxel-eluting Stent vs. a Bare Metal Stent in Saphenous Vein Graft Lesions|Completed||Phase 3|80|Actual|North Texas Veterans Healthcare System||2|||f||||t||||||||||2018-06-01 04:22:19.18872|2018-06-01 04:22:19.18872
NCT00247195|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2012-10-24|2005-10-28|2005-11-01|Estimate|||||||2012-10-24|2012-10-25|Estimate|November 2005||2005-11-30|October 2012|2012-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder|Culturally Congruent Care for Hispanic Outpatients With Major Depressive Disorder (MDD)|Completed||N/A|113|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 04:22:19.283617|2018-06-01 04:22:19.283617
NCT00247182|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2016-09-20|2005-10-28|2005-11-01|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2006||2006-10-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|April 2010|Actual|2010-04-30||Interventional|||Stepped Care for Mandated College Students|Stepped Care for Mandated College Students|Completed||Phase 1|598|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||3|||f||||t||||||||||2018-06-01 04:22:19.366335|2018-06-01 04:22:19.366335
NCT00247169|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2012-03-08|2005-10-31|2005-11-01|Estimate|||||||2012-03-08|2012-03-09|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II|Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II: A Phase II Trial|Completed||Phase 2|40|Actual|Medical University of Vienna|||||f||||||||||||||2018-06-01 04:22:19.45337|2018-06-01 04:22:19.45337
NCT00247156|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2008-06-25|2005-10-31|2005-11-01|Estimate|||||||2008-06-25|2008-06-26|Estimate|November 2004||2004-11-30|April 2006|2006-04-30|November 2005||2005-11-30|||||Interventional|||An Autism Study Using Nambudripad's Food Allergy Elimination Treatments|An Investigation Into the Effectiveness of NAET on Autism Spectrum Disorders|Completed||Phase 1/Phase 2|60||Nambudripad's Allergy Research Foundation|||||f||||||||||||||2018-06-01 04:22:19.508721|2018-06-01 04:22:19.508721
NCT00247143|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2006-09-18|2005-10-28|2005-11-01|Estimate|||||||2006-09-18|2006-09-20|Estimate|October 2005||2005-10-31|September 2006|2006-09-30||||||||Interventional|||High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease|Prospective Open Label Non-Comparative Study of the Safety, Efficacy and Tolerability of High Dose Ritonavir/Lopinavir Liquid in Salvage Therapy for PI Resistant HIV & a PK Equivalence Sub-Study of High Dose Ritonavir/Lopinavir Capsules|Unknown status|Recruiting|N/A|20||Lampiris, Harry W., M.D.|||||f||||||||||||||2018-06-01 04:22:19.567558|2018-06-01 04:22:19.567558
NCT00247130|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2015-03-31|2005-10-31|2005-11-01|Estimate|||||||2015-03-31|2015-04-03|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer|A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer|Withdrawn||Phase 4|0|Actual|Keio University||2||Superiority of iv omeprazole to ranitidine has already been proven by others.|f||||f||||||||||2018-06-01 04:22:19.628166|2018-06-01 04:22:19.628166
NCT00247117|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2006-10-06|2005-10-31|2005-11-01|Estimate|||||||2006-10-06|2006-10-09|Estimate|January 2004||2004-01-31|October 2003|2003-10-31|August 2005||2005-08-31|||||Interventional|||Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)|Study of the Effect of Metformin in Patients With Non-Alcoholic Fatty Liver Disease|Unknown status|Recruiting|N/A|15||Kaplan Medical Center|||||f||||||||||||||2018-06-01 04:22:19.781467|2018-06-01 04:22:19.781467
NCT00247104|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2007-04-10|2005-10-31|2005-11-01|Estimate|||||||2007-04-10|2007-04-11|Estimate|May 2007||2007-05-31|March 2006|2006-03-31|February 2008|Anticipated|2008-02-29|||||Interventional|||The Use of Cranberries in Women With Preterm Premature Rupture of Membranes|The Use of Cranberries in Women With Preterm Premature Rupture of Membranes|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:22:19.837734|2018-06-01 04:22:19.837734
NCT00247091|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2005-10-28|2005-10-28|2005-11-01|Estimate|||||||2005-10-28|2005-11-01|Estimate|May 2000||2000-05-31|October 2005|2005-10-31|September 2004||2004-09-30|||||Observational|||Impact of HIV on Measles and Measles Immunisation|Impact of HIV on Measles and Measles Immunisation|Completed|||700||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:22:19.926639|2018-06-01 04:22:19.926639
NCT00247078|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2016-03-18|2005-10-28|2005-11-01|Estimate|||||||2016-03-18|2016-03-22|Estimate|October 2005||2005-10-31|March 2016|2016-03-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism|The Efficacy and Safety of Aracmyn® [Antivenin Latrodectus (Black Widow)Equine Immune F(ab)2], in Patients With Systemic Latrodectism: A Phase II, Multi-center, Randomized, Double-Blind Trial|Completed||Phase 2|24|Actual|Instituto Bioclon S.A. de C.V.||2|||f||||t||||||||||2018-06-01 04:22:19.984685|2018-06-01 04:22:19.984685
NCT00247052|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2009-07-31|2005-10-28|2005-11-01|Estimate|||||||2009-07-31|2009-08-03|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Interventional|||Non Steroidal Anti Inflammatory Treatment for Post Operative Pericardial Effusion|the Post Operative Pericardial Effusion (POPE) Treatment Study|Completed||Phase 4|200|Anticipated|French Cardiology Society||2|||f||||||||||||||2018-06-01 04:22:20.096436|2018-06-01 04:22:20.096436
NCT00247039|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2013-07-04|2005-10-31|2005-11-01|Estimate|||||||2013-07-04|2013-07-08|Estimate|June 2006||2006-06-30|July 2013|2013-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Garlic in Patients With Febrile Neutropenia|A Controlled Study to Determine The Clinical Efficacy Of Garlic Compounds In Patients With Chemotherapy Related Febrile Neutropenia|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 04:22:20.189654|2018-06-01 04:22:20.189654
NCT00247026|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2007-04-10|2005-10-31|2005-11-01|Estimate|||||||2007-04-10|2007-04-11|Estimate|April 2007||2007-04-30|April 2007|2007-04-30||||||||Interventional|||The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes|A Pilot Study to Determine the Clinical Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes|Withdrawn||Phase 1/Phase 2|50||Hadassah Medical Organization||||No funding|f||||||||||||||2018-06-01 04:22:20.278614|2018-06-01 04:22:20.278614
NCT00247013|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2016-02-19|2005-10-28|2005-11-01|Estimate|||||||2016-02-19|2016-02-22|Estimate|January 1996||1996-01-31|September 2010|2010-09-30|January 2006||2006-01-31|||||Interventional|||Automated Tele Counseling for Screening Mammography|Automated Tele Counseling for Screening Mammography|Completed||Phase 1|2120||Boston Medical Center|||||f||||||||||||||2018-06-01 04:22:20.345803|2018-06-01 04:22:20.345803
NCT00247000|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-30|||2007-06-27|2005-10-30|2005-11-01|Estimate|||||||2007-06-27|2007-06-28|Estimate|September 2007||2007-09-30|February 2006|2006-02-28|November 2007||2007-11-30|||||Interventional|||A Strategy of Home Telehealth for Management of Congestive Heart Failure(STARTEL)|A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Nova Scotia Health Authority|||||f||||||||||||||2018-06-01 04:22:20.413609|2018-06-01 04:22:20.413609
NCT00246987|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2012-04-26|2005-10-28|2005-11-01|Estimate|||||||2012-04-26|2012-04-27|Estimate|June 2003||2003-06-30|April 2012|2012-04-30|April 2004|Actual|2004-04-30|||||Interventional|||A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 3|341||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:22:20.528781|2018-06-01 04:22:20.528781
NCT00246974|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2008-10-14|2005-10-31|2005-11-01|Estimate|||||||2008-10-14|2008-10-15|Estimate|May 2003||2003-05-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT|An Open Randomised Phase II Study Of Gemcitabine Plus Cisplatin +/- Concomitant or Sequential ZD1839 in Patients With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|125|Anticipated|AstraZeneca||2|||f||||||||||||||2018-06-01 04:22:20.790665|2018-06-01 04:22:20.790665
NCT00246961|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2007-10-11|2005-10-31|2005-11-01|Estimate|||||||2007-10-11|2007-10-12|Estimate|July 2004||2004-07-31|June 2007|2007-06-30||||||||Observational|ARREST||Arimidex Observational: Reason for and Effect of Change From Tamoxifen|Arimidex: Reason for and Effect of Change From Tamoxifen|Completed|||200||AstraZeneca|||||f||||f||||||||||2018-06-01 04:22:20.900252|2018-06-01 04:22:20.900252
NCT00246948|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2008-10-16|2005-10-31|2005-11-01|Estimate|||||||2008-10-16|2008-10-17|Estimate|November 2001||2001-11-30|October 2005|2005-10-31|August 2003||2003-08-31|||||Interventional|||The Efficacy of Active Conservative Treatment for Patients With Severe Sciatica. A Randomized Clinical Controlled Trial|The Efficacy of Active Conservative Treatment for Patients With Severe Sciatica. A Randomized Clinical Controlled Trial|Completed||N/A|181||The Back Research Center, Denmark|||||f||||||||||||||2018-06-01 04:22:21.074325|2018-06-01 04:22:21.074325
NCT00246935|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2016-10-24|2005-10-31|2005-11-01|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2005||2005-05-31|September 2016|2016-09-30|October 2007|Actual|2007-10-31|January 2007|Actual|2007-01-31||Interventional|||Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)|A Long-term Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|150||AstraZeneca|||||f||||||||||||||2018-06-01 04:22:21.133015|2018-06-01 04:22:21.133015
NCT00246922|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2016-12-01|2005-10-31|2005-11-01|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2004||2004-12-31|September 2016|2016-09-30|October 2007|Actual|2007-10-31|January 2007|Actual|2007-01-31||Interventional|||Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)|A Long-term Study of APTA-2217 in Adult Patients With Bronchial Asthma|Completed||Phase 3|150||AstraZeneca|||||f||||||||||||||2018-06-01 04:22:21.199104|2018-06-01 04:22:21.199104
NCT00246909|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-31|||2012-05-04|2005-10-31|2005-11-01|Estimate|||||||2012-05-04|2012-05-07|Estimate|November 2005||2005-11-30|June 2011|2011-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)|Determination of the Minimal Clinically Important Difference (MCID) of the Patient Orientated Self Assessment Scale ReQuest TradeMark in Patients Suffering From Endoscopically Confirmed Gastroesophageal Reflux Disease (GERD), Grade A-D According to Los Angeles Classification Treated With Pantoprazole 40 mg o.d. or Placebo o.d. Over One Week.|Completed||Phase 4|600||Takeda|||||f||||||||||||||2018-06-01 04:22:21.277431|2018-06-01 04:22:21.277431
NCT00246896|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2006-07-26|2005-10-28|2005-11-01|Estimate|||||||2006-07-26|2006-07-27|Estimate|August 2001||2001-08-31|October 2005|2005-10-31|August 2005||2005-08-31|||||Interventional|||Care Management for Patients With Alzheimer Disease and Their Family Caregivers|A Program of Collaborative Care for Alzheimer Disease|Completed||N/A|220||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:22:21.413142|2018-06-01 04:22:21.413142
NCT00246883|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-29|||2017-06-30|2005-10-29|2005-10-31|Estimate|||||||2017-06-30|2017-07-02|Actual|October 26, 2005||2005-10-26|April 15, 2009|2009-04-15|April 15, 2009||2009-04-15|||||Interventional|||Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force|"Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force: The NHLBI Keep the Beat Program"|Completed||Phase 2|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:21.478829|2018-06-01 04:22:21.478829
NCT00246870|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-29|||2017-06-30|2005-10-29|2005-10-31|Estimate|||||||2017-06-30|2017-07-02|Actual|October 24, 2005||2005-10-24|October 19, 2010|2010-10-19|October 19, 2010||2010-10-19|||||Observational|||PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency|PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency|Completed|||42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:21.550651|2018-06-01 04:22:21.550651
NCT00246857|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-29|||2018-04-24|2005-10-29|2005-10-31|Estimate|||||||2018-04-24|2018-04-25|Actual|October 26, 2005||2005-10-26|April 17, 2018|2018-04-17||||||||Observational|||Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death|Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:21.620516|2018-06-01 04:22:21.620516
NCT00246844|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-29|||2017-06-30|2005-10-28|2005-10-31|Estimate|||||||2017-06-30|2017-07-02|Actual|October 26, 2005||2005-10-26|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Observational|||Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants|Assessing Arginine-Stimulated Native Pancreas Insulin Production Via Selective Venous Sampling in Patients With Long-Functioning Pancreas Allografts|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:21.710434|2018-06-01 04:22:21.710434
NCT00246831|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-29|||2017-06-30|2005-10-28|2005-10-31|Estimate|||||||2017-06-30|2017-07-02|Actual|October 27, 2005||2005-10-27|October 28, 2008|2008-10-28|October 28, 2008||2008-10-28|||||Observational|||Brain Networks Responsible for Self-Agency|Brain Networks Responsible for Self-Agency: An fMRI Study|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:21.768776|2018-06-01 04:22:21.768776
NCT00246818|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-29|||2017-06-30|2005-10-28|2005-10-31|Estimate|||||||2017-06-30|2017-07-02|Actual|October 26, 2005||2005-10-26|February 25, 2011|2011-02-25|February 25, 2011|Actual|2011-02-25|July 31, 2007|Actual|2007-07-31||Interventional|||Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors|A Randomized Study of the Effect of Tai Chi Chuan Compared to a Structured Exercise Program on Parameters of Physical Fitness and Stress in Adult Cancer Survivors|Completed||Phase 2|76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:21.830129|2018-06-01 04:22:21.830129
NCT00246805|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2009-11-06||2011-08-23|2005-10-28|2005-10-31|Estimate|2011-08-23|2011-09-28|Estimate||||2011-08-23|2011-09-28|Estimate|January 2006||2006-01-31|March 2010|2010-03-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|RARE-PEARL||Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study|Post Marketing Study on Heart Rate Regularization in Patients With Permanent Atrial Fibrillation|Completed||Phase 4|67|Actual|Medtronic BRC||2|||f||||t||||||||||2018-06-01 04:22:21.929295|2018-06-01 04:22:21.929295
NCT00246792|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2006-02-16|2005-10-28|2005-10-31|Estimate|||||||2006-02-16|2006-02-17|Estimate|September 2004||2004-09-30|November 2005|2005-11-30|December 2006||2006-12-31|||||Interventional|||Enhancing Self-Understanding and Social Integration of Middle School Students With Learning Disabilities|Enhancing Self-Understanding and Social Integration of Middle School Students With Learning Disabilities|Unknown status|Recruiting|Phase 2/Phase 3|||University of Toronto|||||f||||||||||||||2018-06-01 04:22:22.211899|2018-06-01 04:22:22.211899
NCT00246779|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2007-10-26|2005-10-27|2005-10-31|Estimate|||||||2007-10-26|2007-10-30|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|June 2007|Actual|2007-06-30|||||Interventional|||A Study of the Effect of Blinding in a Trial of Blood Filtration During Heart Surgery|Transfusion Reduction and Modified Ultrafiltration After Cardiopulmonary Bypass (TRAM Trial) - A Pilot Feasibility Trial|Completed||Phase 1|78|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||||||||||||2018-06-01 04:22:22.285787|2018-06-01 04:22:22.285787
NCT00246766|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2007-11-21|2005-10-28|2005-10-31|Estimate|||||||2007-11-21|2007-11-22|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|June 2010|Anticipated|2010-06-30|||||Observational|||Study of Fetal Movements Using Multichannel Ultrasound Pulsed Doppler in Normal and Pathologic Pregnancy|Qualitative and Quantitative Study of Fetal Movements Using Multichannel Ultrasound Pulsed Doppler in Normal and Pathologic Pregnancy|Unknown status|Recruiting||90|Anticipated|University Hospital, Tours|||||f||||f||||||||||2018-06-01 04:22:22.343744|2018-06-01 04:22:22.343744
NCT00246753|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2017-03-08||2017-05-26|2005-10-28|2005-10-31|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|October 2005||2005-10-31|May 2017|2017-05-31|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Interventional|NRR||Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Study of Oral Once Daily GW572016 (Lapatinib) In Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|29|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:22:22.416932|2018-06-01 04:22:22.416932
NCT00246740|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2017-01-16||2017-05-09|2005-10-28|2005-10-31|Estimate|2017-05-09|2017-12-15|Actual||||2017-05-09|2017-12-15|Actual|October 2005||2005-10-31|May 2017|2017-05-31|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting|Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting: A Pilot Study|Completed||Phase 2|56|Actual|University of Alberta|Small sample size. LVSWI does not estimate diastolic dysfunction. Right atrial biopsies may not reflect changes in left ventricular MMP activity. Doxycycline dose- and time-response analyses is required to better assess the protective effects|2|||f||||f||||||||Undecided||2018-06-01 04:22:22.740217|2018-06-01 04:22:22.740217
NCT00246727|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2011-10-28|2005-10-27|2005-10-31|Estimate|||||||2011-10-28|2011-10-31|Estimate|December 2005||2005-12-31|October 2011|2011-10-31||||December 2014|Anticipated|2014-12-31||Interventional|||Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer|Study 1: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Chemotherapy: A Randomized Double Blind Placebo Controlled Study; Study 2: Effects of a Dietary Supplement (SV) on Advanced NSCLC Treated With Best Supportive Care: A Randomized Double Blind Placebo Controlled Study|Unknown status|Recruiting|Phase 3|300|Anticipated|Sun Farm Corporation||2|||f||||t||||||||||2018-06-01 04:22:23.240386|2018-06-01 04:22:23.240386
NCT00246714|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2008-04-14|2005-10-28|2005-10-31|Estimate|||||||2008-04-14|2008-04-15|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans|Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans|Completed||Phase 1|16|Anticipated|Radboud University|||||f||||f||||||||||2018-06-01 04:22:23.326223|2018-06-01 04:22:23.326223
NCT00246701|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2017-03-24|2005-10-28|2005-10-31|Estimate|||||||2017-03-24|2017-03-28|Actual|November 1, 2005|Actual|2005-11-01|March 2017|2017-03-31|June 1, 2006|Actual|2006-06-01|June 1, 2006|Actual|2006-06-01||Interventional|COMBOS||Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Omacor and Simvastatin Therapy in Hypertriglyceridemic Subjects|Completed||Phase 3|256|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:22:23.405815|2018-06-01 04:22:23.405815
NCT00246688|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2015-12-30|2005-10-28|2005-10-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|November 2005||2005-11-30|December 2015|2015-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer|Randomized, Multicenter, Prospective Two-arm, Open-label Phase II Study to Investigate the Efficacy and Safety of Two ZK219477 i.v. Infusions (3-hour Infusion of 16mg/m2 Versus 0.5-hour Infusion of 16 mg/m2) in Patients With Recurrent Ovarian Cancer Progressing During, or Within 6 Months of the End of Platinum-based Chemotherapy|Completed||Phase 2|63|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:22:23.487819|2018-06-01 04:22:23.487819
NCT00246675|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2015-04-23|2005-10-27|2005-10-31|Estimate|||||||2015-04-23|2015-04-27|Estimate||||April 2015|2015-04-30||||||||Interventional|||Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.|Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery|Withdrawn||N/A|0|Actual|Melbourne Health||2||"The study has ceased recruiting as Ethics approval has lapsed and the investigator availability~   reduced."|f||||f||||||||||2018-06-01 04:22:23.574795|2018-06-01 04:22:23.574795
NCT00246662|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-03-28|2005-10-27|2005-10-31|Estimate|||||||2017-03-28|2017-03-30|Actual|November 14, 2005||2005-11-14|March 2017|2017-03-31|April 2009|Actual|2009-04-30|December 23, 2008|Actual|2008-12-23||Interventional|||Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies|Phase 1b Open-Label, Multicenter Clinical Study of the Safety and Activity of Intravenous Administration of SNS-595 in Patients With Advanced Hematologic Malignancies|Completed||Phase 1|75|Actual|Sunesis Pharmaceuticals||2|||f||||f||||||||No|Aggregate data of participants experiencing Adverse Events|2018-06-01 04:22:23.673079|2018-06-01 04:22:23.673079
NCT00246636|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2009-12-10|2005-10-28|2005-10-31|Estimate|||||||2009-12-10|2009-12-14|Estimate|October 2005||2005-10-31|December 2009|2009-12-31|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Omacor Therapy in Hypertriglyceridemic Subjects Treated With Antara, Followed by an 8-week Extension|Completed||Phase 4|167|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 04:22:23.775934|2018-06-01 04:22:23.775934
NCT00246623|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2008-02-06|2005-10-28|2005-10-31|Estimate|||||||2008-02-06|2008-02-08|Estimate|November 2005||2005-11-30|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||US Inhaled Insulin Dose Titration Study|A Randomized, Open-Label, Multicenter Study Assessing the Effects of Forced Exubera Dose Titration on Glycemic Control in Patients With Suboptimally Controlled Type 2 Diabetes on Two or More Oral Antidiabetic Agents|Completed||Phase 3|120||Pfizer|||||||||||||||||||2018-06-01 04:22:23.867751|2018-06-01 04:22:23.867751
NCT00246610|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-04-26|2005-10-28|2005-10-31|Estimate|||||||2011-04-26|2011-04-28|Estimate|March 2006||2006-03-31|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy|A Phase IV, Non-Randomized, Open-Label Trial Evaluating The Safety Of 625 mg Formulation Of VIRACEPT When Administered To HIV-Infected Women During Pregnancy|Completed||Phase 4|16|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 04:22:23.975011|2018-06-01 04:22:23.975011
NCT00246597|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-05-17|2005-10-28|2005-10-31|Estimate|||||||2011-05-17|2011-05-19|Estimate|December 2002||2002-12-31|March 2010|2010-03-31|June 2004|Actual|2004-06-30|||||Interventional|||A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer|A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer|Terminated||Phase 3|37|Actual|Ortho Biotech Products, L.P.||||"Study stopped to avoid treating enrolled subjects to hemoglobin levels higher than those~   specified in current labeling."|f||||f||||||||||2018-06-01 04:22:24.095145|2018-06-01 04:22:24.095145
NCT00246584|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2006-07-27|2005-10-28|2005-10-31|Estimate|||||||2006-07-27|2006-07-28|Estimate|October 2004||2004-10-31|July 2006|2006-07-31||||||||Interventional|||A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)|Long-Term Treatment, Multicenter, Open-Label Study With SPP100 in Patients With Essential Hypertension|Completed||Phase 2|300||Novartis|||||f||||||||||||||2018-06-01 04:22:24.158063|2018-06-01 04:22:24.158063
NCT00246571|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|2011-05-31||2012-07-02|2005-10-27|2005-10-31|Estimate|2011-05-31|2011-06-27|Estimate||||2012-07-02|2012-07-12|Estimate|January 2006||2006-01-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer|A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer|Completed||Phase 2|217|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:22:24.31064|2018-06-01 04:22:24.31064
NCT00246558|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2014-04-02|2005-10-28|2005-10-31|Estimate|||||||2014-04-02|2014-04-03|Estimate|November 2005||2005-11-30|April 2014|2014-04-30|November 2005||2005-11-30|||||Observational|||Tight Achilles Tendon, Hyperpronation and Anterior Knee Pains|Is There a Connection Between a Tight Achilles Tendon, Hyperpronation of the Foot and Pain in the Anterior Part of the Knee|Withdrawn|||0|Actual|Northern Orthopaedic Division, Denmark||||The study stopped due to unforeseen circumstances.|f||||||||||||||2018-06-01 04:22:25.946353|2018-06-01 04:22:25.946353
NCT00246545|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-08-25|2005-10-28|2005-10-31|Estimate|||||||2011-08-25|2011-08-26|Estimate|October 2005||2005-10-31|August 2011|2011-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect Evaluation of Early Exercise Training After Myocardial Infarction|Effect Evaluation of Early Exercise Training After Myocardial Infarction|Completed||Phase 2|39|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:22:26.009217|2018-06-01 04:22:26.009217
NCT00246532|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2012-04-26|2005-10-27|2005-10-31|Estimate|||||||2012-04-26|2012-04-30|Estimate|October 2005||2005-10-31|April 2012|2012-04-30|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||Opiate-Induced Tolerance & Hyperalgesia in Pain Patients|Opiate-Induced Tolerance & Hyperalgesia in Pain Patients|Completed||Phase 4|139|Actual|National Institute of General Medical Sciences (NIGMS)||2|||f||||t||||||||||2018-06-01 04:22:26.076268|2018-06-01 04:22:26.076268
NCT00246519|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|2013-05-20||2018-04-04|2005-10-27|2005-10-31|Estimate|2013-07-08|2013-07-10|Estimate||||2018-04-04|2018-05-07|Actual|October 2005||2005-10-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pharmacogenomic Evaluation of Antihypertensive Responses|Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)|Completed||Phase 4|1701|Actual|University of Florida|The trial has limited number of hypertensive patients of African ancestry, therefore power is limited to those patients.|2|||f||||t|f|f||||||||2018-06-01 04:22:26.183934|2018-06-01 04:22:26.183934
NCT00246506|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2013-01-14|2005-10-27|2005-10-31|Estimate|||||||2013-01-14|2013-01-15|Estimate|July 2003||2003-07-31|December 2012|2012-12-31|April 2013|Anticipated|2013-04-30|April 2012|Actual|2012-04-30||Interventional|FORT-T||Infertility Therapy for Women Age Thirty-eight and Older|Optimal Infertility Therapy RCT: Women 40 and Older|Unknown status|Active, not recruiting|N/A|450|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||3|||f||||t||||||||||2018-06-01 04:22:26.791202|2018-06-01 04:22:26.791202
NCT00246493|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2018-04-28|2005-10-27|2005-10-31|Estimate|||||||2018-04-28|2018-05-01|Actual|June 22, 2004||2004-06-22|November 1, 2017|2017-11-01|November 1, 2017||2017-11-01|||||Observational|||Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)|Vascular Aging: The Link That Bridges Age to Atherosclerosis (The VALIDATE Study)|Terminated|||495|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:27.097842|2018-06-01 04:22:27.097842
NCT00246480|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2010-08-26|2005-10-27|2005-10-31|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|October 2009||2009-10-31|||||Observational|||RSV Disease in the Elderly|Pathogenesis of RSV Disease in the Elderly|Unknown status|Recruiting||2000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:22:27.321275|2018-06-01 04:22:27.321275
NCT00246467|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2008-09-12|2005-10-27|2005-10-31|Estimate|||||||2008-09-12|2008-09-15|Estimate|October 2005||2005-10-31|September 2008|2008-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)|A Phase 1b, Multi-Centre, Parallel Group, Single Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Plague Vaccine (rF1 and rV Antigens) in Healthy Subjects|Completed||Phase 1|123|Actual|PharmAthene UK Limited|||||f||||t||||||||||2018-06-01 04:22:27.463198|2018-06-01 04:22:27.463198
NCT00246454|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2016-09-22|2005-10-27|2005-10-31|Estimate|||||||2016-09-22|2016-09-26|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Circadian Rhythms and Sleep in Familial DSPS and ASPS|Circadian Rhythms and Sleep in Familial Delayed Sleep Phase Syndrome (DSPS) and Advanced Sleep Phase Syndrome (ASPS)|Recruiting|||156|Anticipated|Northwestern University|||3||f||||f||||||Samples Without DNA|"~     plasma~   "|No||2018-06-01 04:22:27.6747|2018-06-01 04:22:27.6747
NCT00246441|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2016-12-01|2005-10-28|2005-10-31|Estimate|||||||2016-12-01|2016-12-02|Estimate|March 2002||2002-03-31|November 2009|2009-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism|Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism|Completed||Phase 4|42|Actual|Medical University of South Carolina||2|||f||||f||||||||No||2018-06-01 04:22:27.806506|2018-06-01 04:22:27.806506
NCT00246428|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2007-12-06|2005-10-27|2005-10-31|Estimate|||||||2007-12-06|2007-12-07|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|July 2003|Anticipated|2003-07-31|||||Interventional|||Motivational Interviewing for Alcohol-Positive Teens in the Emergency Room|Motivational Interviewing (MI) for ETOH+ Teens in the ER|Unknown status|Active, not recruiting|Phase 3|198|Anticipated|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||1|||f||||||||||||||2018-06-01 04:22:28.093249|2018-06-01 04:22:28.093249
NCT00246415|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2008-10-07|2005-10-27|2005-10-31|Estimate|||||||2008-10-07|2008-10-08|Estimate|November 2002||2002-11-30|October 2008|2008-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Placebo-Controlled Trial of Memantine for Alcohol Dependence|Medications Development for Alcohol Abuse: NMDA Agents -- A Placebo-Controlled Trial of Memantine for Alcohol Dependence|Completed||Phase 2|90||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 04:22:28.318492|2018-06-01 04:22:28.318492
NCT00246402|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2014-05-14|2005-10-27|2005-10-31|Estimate|||||||2014-05-14|2014-05-15|Estimate|September 2002||2002-09-30|December 2007|2007-12-31|August 2006|Actual|2006-08-31|||||Interventional|||Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV|Anti-Lipolytic Strategy for HIV Lipodystrophy|Completed||N/A|30||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:22:28.502258|2018-06-01 04:22:28.502258
NCT00246389|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-02-17|2005-10-28|2005-10-31|Estimate|||||||2011-02-17|2011-02-18|Estimate||||February 2011|2011-02-28|July 2004|Actual|2004-07-31|||||Interventional|||An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm|Flexeril� (Cyclobenzaprine Hydrochloride) Community Based Study - An Evaluation of Cyclobenzaprine HCl Monotherapy and in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm|Completed||Phase 4|1000|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||f||||||||||||||2018-06-01 04:22:28.77832|2018-06-01 04:22:28.77832
NCT00246376|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|2015-10-20||2016-02-25|2005-10-27|2005-10-31|Estimate|2016-02-25|2016-03-21|Estimate||||2016-02-25|2016-03-21|Estimate|January 2004||2004-01-31|February 2016|2016-02-29|February 2012|Actual|2012-02-29|September 2009|Actual|2009-09-30||Interventional|HeartPositive||Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia|Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy|Completed||N/A|221|Actual|Baylor College of Medicine|High dropout rate, especially by loss to follow-up (with no explanation). Flushing was common among patients taking niacin, and this (with transportation and socio-economc problems) could have contributed to the high drop-out rate.|5|||f||||t||||||||||2018-06-01 04:22:28.984632|2018-06-01 04:22:28.984632
NCT00246363|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2011-09-14|2005-10-27|2005-10-31|Estimate|||||||2011-09-14|2011-09-15|Estimate|January 2005||2005-01-31|September 2011|2011-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C|A Pilot Randomized Placebo-Controlled Trial Designed to Determine the Tolerability and Efficacy of Silymarin (Milk Thistle) vs. Placebo for the Treatment of Chronic Hepatitis C in HIV Infected Patients|Completed||Phase 1/Phase 2|40|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 04:22:30.380554|2018-06-01 04:22:30.380554
NCT00246350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-19|2005-10-27|2005-10-31|Estimate|||||||2010-11-19|2010-11-22|Estimate|September 2004||2004-09-30|November 2010|2010-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Spinal Manipulation for Treatment of Chronic Headaches|Dose-Response of Manipulation for Chronic Headache|Completed||Phase 2|80|Actual|University of Western States||4|||f||||f||||||||||2018-06-01 04:22:30.687086|2018-06-01 04:22:30.687086
NCT00246337|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|2010-07-19||2015-10-30|2005-10-27|2005-10-31|Estimate|2010-08-17|2010-09-15|Estimate||||2015-10-30|2015-11-02|Estimate|November 2005||2005-11-30|October 2015|2015-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)|A Multicenter, Double-Blind, Placebo and Active-Controlled, Dose-Finding Study of MK0974 in the Treatment of Acute Migraine|Completed||Phase 2|420|Actual|Merck Sharp & Dohme Corp.||9|||f||||||||||||||2018-06-01 04:22:30.820669|2018-06-01 04:22:30.820669
NCT00246324|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|2011-05-05||2018-03-08|2005-10-27|2005-10-31|Estimate|2011-10-07|2011-11-17|Estimate||||2018-03-08|2018-04-04|Actual|December 2003||2003-12-31|March 2018|2018-03-31|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis|An Open Label Trial of Safety and Efficacy of Combination Therapy With Interferon-B-1a and Oral Doxycycline in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)|Completed||Phase 4|16|Actual|Louisiana State University Health Sciences Center Shreveport||1|||f||||f||||||||||2018-06-01 04:22:32.906605|2018-06-01 04:22:32.906605
NCT00246298|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-06-08|2005-10-28|2005-10-31|Estimate|||||||2011-06-08|2011-06-10|Estimate|October 2005||2005-10-31|March 2010|2010-03-31|September 2006|Actual|2006-09-30|||||Interventional|||A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients|A Randomized, Open-Label Study Assessing the Efficacy of Initiating PROCRIT (Epoetin Alfa) Dosing at Q2W vs. PROCRIT Dosing at QW in Anemic HIV-infected Subjects|Terminated||Phase 2|31|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||OBI business decision not to complete any additional research in HIV.|||||f||||||||||2018-06-01 04:22:33.328351|2018-06-01 04:22:33.328351
NCT00246285|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-06-06|2005-10-28|2005-10-31|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2001||2001-04-30|March 2010|2010-03-31|December 2006|Actual|2006-12-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia|The Efficacy And Safety Of Risperidone In The Treatment Of Adolescents With Schizophrenia: A Six-Month Open-Label Study.|Completed||Phase 3|381|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:22:33.41692|2018-06-01 04:22:33.41692
NCT00246272|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2010-04-26|2005-10-28|2005-10-31|Estimate|||||||2010-04-26|2010-04-27|Estimate|October 2004||2004-10-31|April 2010|2010-04-30|May 2006|Actual|2006-05-31|||||Interventional|||An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone|An Open-label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL® Tablets (Risperidone) to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone|Completed||Phase 3|82|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:22:33.555898|2018-06-01 04:22:33.555898
NCT00246259|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2013-03-20||2013-11-15|2005-10-28|2005-10-31|Estimate|2013-09-09|2013-11-12|Estimate||||2013-11-15|2013-12-11|Estimate|October 2004||2004-10-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||Analysis was based on the Intent-to-treat (ITT) population.|A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis|An Open-Label Randomized Trial Comparing Risperdal Consta With Oral Antipsychotic Care in the Treatment of Early Psychosis|Completed||Phase 4|77|Actual|Janssen-Ortho Inc., Canada||2|||f||||f||||||||||2018-06-01 04:22:33.684711|2018-06-01 04:22:33.684711
NCT00246246|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-02-10|2005-10-28|2005-10-31|Estimate|||||||2011-02-10|2011-02-11|Estimate|January 2004||2004-01-31|February 2011|2011-02-28|April 2006|Actual|2006-04-30|||||Interventional|||A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder|A Randomized, Open-label Trial of RISPERDAL® CONSTA™ Versus Oral Antipsychotic Care in Subjects With Bipolar Disorder|Completed||Phase 3|48|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:22:34.573722|2018-06-01 04:22:34.573722
NCT00245856|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|2013-02-01||2013-02-15|2005-10-26|2005-10-28|Estimate|2013-02-01|2013-02-04|Estimate||||2013-02-15|2013-02-21|Estimate|September 2002||2002-09-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|March 2009|Actual|2009-03-31||Interventional|||Treatment of Upper Extremity Deep-Vein Thrombosis|Treatment of Upper Extremity Deep-Vein Thrombosis|Completed||Phase 4|67|Actual|University of Oklahoma||1|||f||||||||||||||2018-06-01 04:22:42.7715|2018-06-01 04:22:42.7715
NCT00246233|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-05-16|2005-10-28|2005-10-31|Estimate|||||||2011-05-16|2011-05-17|Estimate|June 2005||2005-06-30|April 2010|2010-04-30|April 2006|Actual|2006-04-30|||||Interventional|||CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.|A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.|Completed||Phase 3|145|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:22:34.636118|2018-06-01 04:22:34.636118
NCT00246220|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-05-16|2005-10-28|2005-10-31|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|November 2006|Actual|2006-11-30|||||Interventional|||A Study of the Effectiveness and Safety of Prolonged-release Methylphenidate Hydrochloride in Adult Patients With Attention Deficit/Hyperactivity Disorder.|A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study To Evaluate the Safety And Efficacy Of Prolonged Release OROS Methylphenidate Hydrochloride (18, 36 and 72 mg/Day), With Open-Label Extension, In Adults With Attention Deficit/Hyperactivity Disorder|Completed||Phase 3|402|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:22:34.747224|2018-06-01 04:22:34.747224
NCT00246207|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2012-02-09|2005-10-28|2005-10-31|Estimate|||||||2012-02-09|2012-02-10|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|December 2005|Actual|2005-12-31|||||Interventional|||CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults|An Open-label Study Evaluating the Safety and Effectiveness of OROS Methylphenidate Hydrochloride (CONCERTA) in Adults With Attention Deficit Hyperactivity Disorder|Completed||Phase 3|32|Actual|Janssen-Ortho Inc., Canada|||||f||||||||||||||2018-06-01 04:22:34.967746|2018-06-01 04:22:34.967746
NCT00246194|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2014-04-02|2005-10-28|2005-10-31|Estimate|||||||2014-04-02|2014-04-04|Estimate|September 2004||2004-09-30|April 2014|2014-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|SOURCE||Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)|The SOURCE Study: Schizophrenia Outcomes-utilization, Relapse, and Clinical Evaluation: a Prospective 2-year Observational Study of Patients With Schizophrenia Who Initiate Treatment With Injectable Risperidone Long-acting Microspheres (RISPERDAL CONSTA)|Completed|||532|Actual|Janssen, LP|||1||f||||f||||||||||2018-06-01 04:22:35.050036|2018-06-01 04:22:35.050036
NCT00246181|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2014-01-10|2005-10-27|2005-10-31|Estimate|||||||2014-01-10|2014-01-13|Estimate|December 1999||1999-12-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|SBF-NSCLC||Phase I and II Study Of Stereotactic Body Radiotherapy in Medically Unresectable Patients With Stage 1 NSCLC|Phase I and II Study Of Stereotactic Body Radiotherapy in Medically Unresectable Patients With Stage 1 NSCLC|Completed||Phase 1/Phase 2|117|Actual|Indiana University|||||f||||t||||||||||2018-06-01 04:22:35.175171|2018-06-01 04:22:35.175171
NCT00246168|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2010-11-29|2005-10-28|2005-10-31|Estimate|||||||2010-11-29|2010-11-30|Estimate||||November 2010|2010-11-30|June 2005|Actual|2005-06-30|||||Interventional|||ULTRACET (Tramadol Hydrochloride and Acetaminophen) for the Treatment of Rheumatoid Arthritis Pain.|ULTRACET (Tramadol Hydrochloride and Acetaminophen) add-on Therapy for the Treatment of the Pain of Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 4|277|Actual|Janssen Korea, Ltd., Korea|||||f||||||||||||||2018-06-01 04:22:35.368337|2018-06-01 04:22:35.368337
NCT00246155|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2006-10-10|2005-10-27|2005-10-31|Estimate|||||||2006-10-10|2006-10-11|Estimate|January 2005||2005-01-31|October 2006|2006-10-31||||||||Interventional|||Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain|A Prospective Study to Evaluate the Potential Effects on Function and Size in Back Muscle After Injection of Botulinum Toxin Type A (Dysport®) in the Treatment of Chronic Low Back Pain|Completed||Phase 3|35||Ipsen|||||f||||||||||||||2018-06-01 04:22:35.450362|2018-06-01 04:22:35.450362
NCT00246142|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2007-10-11|2005-10-27|2005-10-31|Estimate|||||||2007-10-11|2007-10-12|Estimate|April 2005||2005-04-30|October 2007|2007-10-31||||||||Interventional|||A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.|A 16-Week Prospective Randomised Double-Blind Study on Facilitation of DYSPORT® Effect on Myofascial Pain Syndrome (MPS) by Electrical Stimulation.|Completed||Phase 3|68||Ipsen|||||f||||||||||||||2018-06-01 04:22:35.516407|2018-06-01 04:22:35.516407
NCT00246129|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2008-05-09|2005-10-28|2005-10-31|Estimate|||||||2008-05-09|2008-05-12|Estimate|October 2005||2005-10-31|May 2008|2008-05-31|April 2011|Anticipated|2011-04-30|April 2009|Anticipated|2009-04-30||Interventional|||Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation|A Randomised Controlled Comparison of Campath−Tacrolimus vs IL2R MoAb−Tacrolimus/MMMF in Kidney Transplantation|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Hammersmith Hospitals NHS Trust||2|||f||||t||||||||||2018-06-01 04:22:35.637945|2018-06-01 04:22:35.637945
NCT00246116|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2017-01-27|2005-10-28|2005-10-31|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 2002||2002-02-28|January 2017|2017-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|SBF Companion||Functional Imaging of Treatment Effects: A Companion Protocol to a Study of Extracranial Stereotactic Radioablation in Early Stage Non-Small Cell Lung Cancer|Functional Imaging of Treatment Effects: A Companion Protocol to a Phase II Study of Extracranial Stereotactic Radioablation (a.k.a. Stereotactic Body Radiotherapy) in Early Stage Non-Small Cell Lung Cancer.|Completed||N/A|15|Actual|Indiana University|||||f||||t||||||||||2018-06-01 04:22:35.754492|2018-06-01 04:22:35.754492
NCT00246103|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2017-02-20|2005-10-28|2005-10-31|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2004||2004-03-31|January 2009|2009-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies|Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies|Completed||Phase 1|82|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||||||||||||2018-06-01 04:22:35.902732|2018-06-01 04:22:35.902732
NCT00246090|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|2011-12-22||2014-06-30|2005-10-27|2005-10-31|Estimate|2012-04-16|2012-05-15|Estimate||||2014-06-30|2014-07-14|Estimate|October 2005||2005-10-31|April 2012|2012-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine|A Phase II Open Label Single-Arm Study of E7389 in Patients With Locally Advanced or Metastatic Breast Cancer, Previously Treated With Anthracycline, Taxane, and Capecitabine Therapy, Refractory to the Last Prior Therapy for Their Disease|Completed||Phase 2|298|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 04:22:36.135082|2018-06-01 04:22:36.135082
NCT00246077|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2007-04-10|2005-10-27|2005-10-31|Estimate|||||||2007-04-10|2007-04-11|Estimate|October 2005||2005-10-31|November 2005|2005-11-30|December 2005|Actual|2005-12-31|||||Observational|||Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport|Quality of Life of Children With Sickle Cell Disease Who Are Receiving Chronic Transfusion Therapy With a Lifeport Device|Completed|||5||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:22:36.598388|2018-06-01 04:22:36.598388
NCT00246064|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|||2011-05-18|2005-10-28|2005-10-31|Estimate|||||||2011-05-18|2011-05-19|Estimate|December 2001||2001-12-31|January 2011|2011-01-31|November 2003|Actual|2003-11-30|||||Interventional|||The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol|The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol. Tapering Methotrexate in Patients With Rheumatoid Arthritis Beginning Therapy With Infliximab|Completed||Phase 4|210|Actual|Centocor Ortho Biotech Services, L.L.C.|||||f||||||||||||||2018-06-01 04:22:36.907539|2018-06-01 04:22:36.907539
NCT00246051|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-13|2005-10-27|2005-10-31|Estimate|||||||2013-08-13|2013-08-15|Estimate|November 2005||2005-11-30|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Comprehensive Police Fatigue Management Program|Testing the Effectiveness of a Comprehensive Fatigue Management for the Police|Completed||N/A|683|Actual|Brigham and Women's Hospital||3|||f||||||||||||||2018-06-01 04:22:37.020479|2018-06-01 04:22:37.020479
NCT00246038|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2015-08-27|2005-10-27|2005-10-31|Estimate|||||||2015-08-27|2015-08-31|Estimate||||August 2015|2015-08-31||||||||Interventional|||The Boston Scientific ENOVUS Trial|A Phase II Evaluation of the Safety and Efficacy of the Boston Scientific ENOVUS AAA Endograft in the Treatment of Abdominal Aortic Aneurysms|Withdrawn||Phase 2|0|Actual|Boston Scientific Corporation||||Sponsor cancelled the development program, and never conducted the study.|f||||f||||||||||2018-06-01 04:22:37.110506|2018-06-01 04:22:37.110506
NCT00246025|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2010-11-18||2014-06-03|2005-10-28|2005-10-31|Estimate|2010-11-18|2010-12-17|Estimate||||2014-06-03|2014-06-09|Estimate|October 2005||2005-10-31|February 2014|2014-02-28||||June 2007|Actual|2007-06-30||Interventional|||A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.|A Randomised, Parallel-group, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery|Completed||Phase 2|512|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 04:22:37.310192|2018-06-01 04:22:37.310192
NCT00246012|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-28|2013-05-01||2013-07-17|2005-10-28|2005-10-31|Estimate|2013-07-17|2013-08-19|Estimate||||2013-07-17|2013-08-19|Estimate|May 2005||2005-05-31|July 2013|2013-07-31|February 2009|Actual|2009-02-28|June 2008|Actual|2008-06-30||Interventional|||A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma|A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma|Completed||Phase 1/Phase 2|144|Actual|Centocor, Inc.||9|||f||||t||||||||||2018-06-01 04:22:38.521437|2018-06-01 04:22:38.521437
NCT00245986|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2017-06-30|2005-10-27|2005-10-28|Estimate|||||||2017-06-30|2017-07-02|Actual|October 18, 2005||2005-10-18|May 20, 2008|2008-05-20|May 20, 2008||2008-05-20|||||Interventional|||Effect of Genetics on Metabolism of Efavirenz|Pharmacogenetics of Efavirenz Metabolism: Association of CYP2B6 Genotype and Prolonged Drug Exposure|Completed||Phase 4|350||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:22:40.996766|2018-06-01 04:22:40.996766
NCT00245973|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2007-12-03|2005-10-27|2005-10-28|Estimate|||||||2007-12-03|2007-12-05|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Study Evaluating Bifeprunox in Bipolar Depression|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients With Bipolar Disorder|Completed||Phase 3|380||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:22:41.098692|2018-06-01 04:22:41.098692
NCT00245960|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|2009-03-31||2009-03-31|2005-10-27|2005-10-28|Estimate|2009-03-31|2009-05-27|Estimate||||2009-03-31|2009-05-27|Estimate|December 2005||2005-12-31|March 2009|2009-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis|A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis.|Completed||Phase 4|752|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 04:22:41.360922|2018-06-01 04:22:41.360922
NCT00245947|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2009-09-09|2005-10-26|2005-10-28|Estimate|||||||2009-09-09|2009-09-10|Estimate|April 2004||2004-04-30|September 2009|2009-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study Evaluating ERB-041 in Active Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Exploratory Pharmacogenomic, Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohn's Disease|Completed||Phase 1|22|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:22:42.125825|2018-06-01 04:22:42.125825
NCT00245934|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-12-12|2005-10-26|2005-10-28|Estimate|||||||2007-12-12|2007-12-14|Estimate|June 2003||2003-06-30|December 2007|2007-12-31|July 2005|Actual|2005-07-31|||||Observational|||Study Evaluating Enbrel in Patients With Rheumatoid Arthritis|Observational Study With Enbrel in Patients With Rheumatoid Arthritis|Completed|||1500||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:22:42.228028|2018-06-01 04:22:42.228028
NCT00245921|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2013-02-07|2005-10-26|2005-10-28|Estimate|||||||2013-02-07|2013-02-08|Estimate|February 2003||2003-02-28|May 2006|2006-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception|A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception|Completed||Phase 3|2000||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:22:42.274982|2018-06-01 04:22:42.274982
NCT00245908|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2005-10-27|2005-10-27|2005-10-28|Estimate|||||||2005-10-27|2005-10-28|Estimate|September 1999||1999-09-30|January 2002|2002-01-31|September 2002||2002-09-30|||||Interventional|||ASTHMA (AntibioticS To Help Manage Asthma) Pilot Study||Completed||Phase 3|100||Wisconsin Research Network|||||f||||||||||||||2018-06-01 04:22:42.365144|2018-06-01 04:22:42.365144
NCT00245895|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-11-27|2005-10-26|2005-10-28|Estimate|||||||2007-11-27|2007-11-29|Estimate|April 2003||2003-04-30|November 2007|2007-11-30|February 2005|Actual|2005-02-28|||||Interventional|||Study of Aranesp to Treat Anemia in Prostate Cancer Patients.|Phase II Study of Aranesp (Darbepoetin Alfa) to Treat Anemia in Prostate Cancer Patients.|Completed||Phase 2|20|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:22:42.429409|2018-06-01 04:22:42.429409
NCT00245882|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2012-09-17|2005-10-27|2005-10-28|Estimate|||||||2012-09-17|2012-09-18|Estimate|October 2005||2005-10-31|September 2012|2012-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|DiaTel||The Diabetes Telemonitoring (DiaTel) Study|The Diabetes Telemonitoring (DiaTel) Study|Completed||N/A|150|Actual|VA Pittsburgh Healthcare System||2|||f||||f||||||||||2018-06-01 04:22:42.55973|2018-06-01 04:22:42.55973
NCT00245869|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-02-19|2005-10-26|2005-10-28|Estimate|||||||2007-02-19|2007-02-21|Estimate|March 2004||2004-03-31|July 2006|2006-07-31|February 2007||2007-02-28|||||Interventional|||Ultrasound and Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response|Contrast-Enhanced Ultrasound and Neoadjuvant Chemotherapy of Breast Cancer: Relationship Between Early Vascular Changes of the Tumor and Late Tumoral Response|Completed||N/A|30||University Hospital, Tours|||||f||||||||||||||2018-06-01 04:22:42.66365|2018-06-01 04:22:42.66365
NCT00245843|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2009-03-31|2005-10-27|2005-10-28|Estimate|||||||2009-03-31|2009-04-01|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|February 2010|Anticipated|2010-02-28|February 2008|Actual|2008-02-29||Interventional|||Vermont Intervention: Effect on Joint Attention Skills Between Parents and Moderate/Late Preterm Infants in the First Year of Life|Vermont Intervention: Effect on Joint Attention Skills Between Parents and Moderate/Late Preterm Infants Int the First Year of Life|Unknown status|Active, not recruiting|N/A|170|Actual|Ullevaal University Hospital|||||f||||t||||||||||2018-06-01 04:22:43.233139|2018-06-01 04:22:43.233139
NCT00245830|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2015-01-16|2005-10-27|2005-10-28|Estimate|||||||2015-01-16|2015-01-19|Estimate|October 2003||2003-10-31|January 2015|2015-01-31|March 2007|Actual|2007-03-31|July 2006|Actual|2006-07-31||Interventional|||Ischemic Preconditioning of Liver in Cadaver Donors|Ischemic Preconditioning of Liver in Cadaver Donors|Completed||N/A|100|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 04:22:43.316468|2018-06-01 04:22:43.316468
NCT00245817|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2011-03-10|2005-10-27|2005-10-28|Estimate|||||||2011-03-10|2011-03-11|Estimate|August 2003||2003-08-31|December 2010|2010-12-31|July 2005|Actual|2005-07-31|January 2005|Actual|2005-01-31||Interventional|||HINCAB-study. Home Based Intervention in Nursing for Coronary Artery Bypass Patients|Coronary Artery Bypass Grafting (CABG) Patients in the Rehabilitation Phase. A Randomised Controlled Trial.|Completed||N/A|203|Actual|Oslo University Hospital|||||f||||t||||||||||2018-06-01 04:22:43.415474|2018-06-01 04:22:43.415474
NCT00245804|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2010-06-29|2005-10-26|2005-10-28|Estimate|||||||2010-06-29|2010-06-30|Estimate|March 2003||2003-03-31|January 2005|2005-01-31|February 2005||2005-02-28|||||Observational|DYS-AUT||Developmental Dyslexia and Functional Maturation of Auditory Cortex||Completed|||60||University Hospital, Tours|||4||f||||t||||||||||2018-06-01 04:22:43.5042|2018-06-01 04:22:43.5042
NCT00245791|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2015-06-02|2005-10-27|2005-10-28|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2004||2004-10-31|August 2005|2005-08-31|July 2005||2005-07-31|||||Interventional|||Urinary Tract Infection Study With the Antibiotic Levofloxacin Given at a Higher Dose Over a Shorter Period of Time|TREATMENT OF COMPLICATED URINARY INFECTION WITH FIVE DAY HIGH DOSE LEVOFLOXACIN|Terminated||Phase 4|30||University of Manitoba|||||f||||||||||||||2018-06-01 04:22:43.595066|2018-06-01 04:22:43.595066
NCT00245778|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-05-25|2005-10-26|2005-10-28|Estimate|||||||2007-05-25|2007-05-28|Estimate|March 2004||2004-03-31|May 2007|2007-05-31|February 2007|Actual|2007-02-28|||||Observational|||fMRI Study of Grasping in Autistic Patients|fMRI Study of Grasping in Autistic Patients|Terminated|||30|Actual|University Hospital, Tours||||All the patients were included|f||||||||||||||2018-06-01 04:22:43.739357|2018-06-01 04:22:43.739357
NCT00245765|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2013-09-06|2005-10-26|2005-10-28|Estimate|||||||2013-09-06|2013-09-09|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy|Multicenter, Dose Response, Randomized, Double Blind, Parallel, Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy|Completed||Phase 2|176|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:22:43.900327|2018-06-01 04:22:43.900327
NCT00245752|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2009-02-04|2005-10-27|2005-10-28|Estimate|||||||2009-02-04|2009-02-05|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Can Acupuncture be Used as Preparation for Induction of Labour|Randomised Study of the Effect of Acupuncture as Induction of Labour|Completed||Phase 2|125|Actual|Aarhus University Hospital Skejby||2|||f||||f||||||||||2018-06-01 04:22:44.209186|2018-06-01 04:22:44.209186
NCT00245739|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2014-04-10|2005-10-27|2005-10-28|Estimate|||||||2014-04-10|2014-04-11|Estimate||||April 2014|2014-04-30||||||||Expanded Access|||TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.|Early Access of TMC114 in Combination With Low-dose Ritonavir (TMC/r)) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to no Treatment Options.|Approved for marketing|||||Tibotec Pharmaceuticals, Ireland|||||||||f||||||||||2018-06-01 04:22:44.394672|2018-06-01 04:22:44.394672
NCT00245726|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2009-01-29|2005-10-27|2005-10-28|Estimate|||||||2009-01-29|2009-02-02|Estimate|March 2004||2004-03-31|January 2009|2009-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Functional Electrical Stimulation (FES) Cycling for Children With Spinal Cord Injuries (SCI)|Lower Extremity Cycling With Functional Electrical Stimulation to Improve the Health and Fitness of Children With Spinal Cord Injuries|Completed||N/A|30|Actual|Shriners Hospitals for Children||3|||f||||f||||||||||2018-06-01 04:22:45.419499|2018-06-01 04:22:45.419499
NCT00245713|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2013-11-25|2005-10-26|2005-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.|9-11 Week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Determine Effects of Adjunctive Levetiracetam on Sleep Architecture of Adults With Partial Onset Epilepsy Receiving a First Generation Anti-epileptic Drug.|Completed||Phase 4|40||UCB Pharma|||||f||||||||||||||2018-06-01 04:22:45.535314|2018-06-01 04:22:45.535314
NCT00245700|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2008-05-22|2005-10-27|2005-10-28|Estimate|||||||2008-05-22|2008-05-23|Estimate|April 2005||2005-04-30|May 2008|2008-05-31|July 2006|Actual|2006-07-31|||||Observational|||Adherence of Stalevo, Entacapone and Levodopa|Study of Adherence of Stalevo, Entacapone and Levodopa|Completed|||14||South Glasgow University Hospitals NHS Trust|||||f||||||||||||||2018-06-01 04:22:45.627558|2018-06-01 04:22:45.627558
NCT00245687|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2014-03-13|2005-10-27|2005-10-28|Estimate|||||||2014-03-13|2014-03-14|Estimate|June 2005||2005-06-30|March 2014|2014-03-31|June 2007|Actual|2007-06-30|||||Interventional|||A Research Study to Test (2) Two Different Types of Feeding Tubes Used in the Intensive Care Unit|A Comparative Study of the Tiger Tube Frictional Nasal Jejunal Feeding Tube and the Dubhoff Tube|Completed||N/A|60|Anticipated|Thomas Jefferson University|||||f||||||||||||||2018-06-01 04:22:45.787169|2018-06-01 04:22:45.787169
NCT00245674|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2008-04-08|2005-10-27|2005-10-28|Estimate|||||||2008-04-08|2008-04-10|Estimate|June 2005||2005-06-30|April 2008|2008-04-30||||||||Interventional|||SOLIACS: Solian Solution in the Acute Setting|Solian Solution to Treat Schizophrenic Patients During an Acute Episode|Completed||Phase 4|300||Sanofi|||||f||||||||||||||2018-06-01 04:22:45.881869|2018-06-01 04:22:45.881869
NCT00245661|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2007-10-31|2005-10-27|2005-10-28|Estimate|||||||2007-10-31|2007-11-02|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Effects of Temazepam in Patients With Chronic Pulmonary Obstructive Disease|Effects of Temazepam on Dyspnea, Gas Exchange and Sleep Quality in Chronic Obstructive Pulmonary Disease.|Completed||Phase 3|14|Anticipated|Rijnstate Hospital|||||f||||||||||||||2018-06-01 04:22:46.050123|2018-06-01 04:22:46.050123
NCT00245284|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2006-06-05|2005-10-26|2005-10-27|Estimate|||||||2006-06-05|2006-06-06|Estimate|September 2005||2005-09-30|June 2006|2006-06-30|May 2006||2006-05-31|||||Observational|||Predictor of Advanced Subclinical Atherosclerosis||Completed|||600||PreMD|||||f||||||||||||||2018-06-01 04:22:53.551835|2018-06-01 04:22:53.551835
NCT00245648|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2012-10-03|2005-10-27|2005-10-28|Estimate|||||||2012-10-03|2012-10-04|Estimate|June 2001||2001-06-30|October 2012|2012-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI|Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial|Completed||Phase 3|||New York University School of Medicine|||||f||||||||||||||2018-06-01 04:22:46.268782|2018-06-01 04:22:46.268782
NCT00245635|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|2015-04-21||2018-03-30|2005-10-26|2005-10-28|Estimate|2015-06-09|2015-06-29|Estimate||||2018-03-30|2018-04-27|Actual|November 2004||2004-11-30|March 2018|2018-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|FDA BDD||Fluoxetine in Pediatric Body Dysmorphic Disorder|Fluoxetine in Pediatric Body Dysmorphic Disorder|Completed||Phase 4|43|Actual|Montefiore Medical Center||2|||f||||t|t|f|||t|||||2018-06-01 04:22:46.529862|2018-06-01 04:22:46.529862
NCT00245622|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20||2011-06-27|2014-02-06|2005-10-27|2005-10-28|Estimate||||2011-06-27|2011-06-29|Estimate|2014-02-06|2014-03-10|Estimate|May 2006||2006-05-31|February 2014|2014-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|TERMS||Autologous T Cell Vaccine (TCV) for Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS|Completed||Phase 2|150|Actual|Opexa Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 04:22:47.096507|2018-06-01 04:22:47.096507
NCT00245609|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2008-03-19|2005-10-26|2005-10-28|Estimate|||||||2008-03-19|2008-03-21|Estimate|January 2006||2006-01-31|March 2008|2008-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Of The Anxiolytic Efficacy Of Pregabalin And Alprazolam IR In Subjects With Anxiety Prior To Dental Procedure|Completed||Phase 2|90||Pfizer|||||f||||||||||||||2018-06-01 04:22:47.272325|2018-06-01 04:22:47.272325
NCT00245596|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2008-02-22|2005-10-27|2005-10-28|Estimate|||||||2008-02-22|2008-02-25|Estimate|October 2005||2005-10-31|February 2008|2008-02-29||||||||Interventional|||Evaluation of the Index of Sexual Life Questionnaire|An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)|Completed||Phase 4|120||Pfizer|||||f||||||||||||||2018-06-01 04:22:47.406406|2018-06-01 04:22:47.406406
NCT00245583|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2010-05-19|2005-10-26|2005-10-28|Estimate|||||||2010-05-19|2010-05-20|Estimate||||May 2008|2008-05-31||||||||Interventional|||Topiramate in the Treatment of Pathological Gambling|Topiramate in the Treatment of Pathological Gambling: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study|Unknown status|Active, not recruiting|Phase 4|120||Icahn School of Medicine at Mount Sinai|||||f||||||||||||||2018-06-01 04:22:47.511329|2018-06-01 04:22:47.511329
NCT00245570|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|2009-09-25||2015-06-22|2005-10-27|2005-10-28|Estimate|2010-04-29|2010-05-27|Estimate||||2015-06-22|2015-07-15|Estimate|December 2005||2005-12-31|June 2015|2015-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)|A Double-Blind, Randomized Multicenter, 3-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast Compared With Placebo and Salmeterol on Exercise-Induced Bronchoconstriction|Completed||Phase 3|47|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-06-01 04:22:47.687235|2018-06-01 04:22:47.687235
NCT00245557|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|2009-09-16||2017-03-01|2005-10-27|2005-10-28|Estimate|2010-02-08|2010-02-26|Estimate||||2017-03-01|2017-03-30|Actual|November 2004||2004-11-30|March 2017|2017-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Magnetic Resonance Imaging Study of Geriatric Depression|Nuclear Magnetic Resonance Imaging Study of Treatment With Sertraline in Geriatric Depression|Completed||N/A|43|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 04:22:48.23088|2018-06-01 04:22:48.23088
NCT00245544|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2015-05-20|2005-10-27|2005-10-28|Estimate|||||||2015-05-20|2015-05-21|Estimate|November 2005||2005-11-30|May 2015|2015-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)|A Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Explore the Safety and Preliminary Efficacy of Oral MK0759 in the Treatment of Postherpetic Neuralgia|Terminated||Phase 2|20|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:22:48.735757|2018-06-01 04:22:48.735757
NCT00245531|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-03-30|2005-10-26|2005-10-28|Estimate|||||||2015-03-30|2015-04-01|Estimate|August 2004||2004-08-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Observational|||Effects of Endocrine Health on Mental Performance of Men and Women Using Drugs|Effects of Endocrine Health on the Cognitive Function of Men and Women Using Drugs: A Cross-sectional Investigation|Completed|||300|Anticipated|Johns Hopkins University|||2||f||||t||||||||||2018-06-01 04:22:48.78836|2018-06-01 04:22:48.78836
NCT00245518|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|2017-08-14||2017-09-12|2005-10-26|2005-10-28|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|June 2005||2005-06-30|September 2017|2017-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Baseline characteristics were only recorded for the 33 participants who completed the study.|Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy|Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy|Completed||Phase 4|39|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 04:22:48.909986|2018-06-01 04:22:48.909986
NCT00245505|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2012-03-09|2005-10-26|2005-10-28|Estimate|||||||2012-03-09|2012-03-12|Estimate|February 2009||2009-02-28|March 2012|2012-03-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||"The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active Drug: Crohn's Disease"|The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s Disease, Evaluated by Video Capsule Endoscopy After 6 and 12 Weeks Treatment. A Pilot Study|Terminated||Phase 3|3|Actual|Ferring Pharmaceuticals||||Study terminated due to lack of eligible patients|f||||f||||||||||2018-06-01 04:22:50.20953|2018-06-01 04:22:50.20953
NCT00245492|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2009-01-27|2005-10-26|2005-10-28|Estimate|||||||2009-01-27|2009-01-28|Estimate|May 2006||2006-05-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.|Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.|Completed||N/A|792|Anticipated|Indiana University||1|||f||||||||||||||2018-06-01 04:22:50.368262|2018-06-01 04:22:50.368262
NCT00245479|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-18|2005-10-26|2005-10-28|Estimate|||||||2011-05-18|2011-05-19|Estimate|April 2002||2002-04-30|May 2011|2011-05-31|November 2006|Actual|2006-11-30|September 2005|Actual|2005-09-30||Interventional|DRIP||A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis|An Open Label, Multi-national Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis|Completed||Phase 4|802|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:22:50.511936|2018-06-01 04:22:50.511936
NCT00245466|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|2009-01-22||2011-05-18|2005-10-26|2005-10-28|Estimate|2009-04-23|2009-06-11|Estimate||||2011-05-18|2011-05-20|Estimate|October 2001||2001-10-31|May 2011|2011-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients|An Open-Label, Multi-Centre, Extension Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients.|Terminated||Phase 2|88|Actual|Ferring Pharmaceuticals||3||The maintenance doses were too low to maintain testosterone suppression|f||||f||||||||||2018-06-01 04:22:50.681643|2018-06-01 04:22:50.681643
NCT00245453|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2015-07-27|2005-10-26|2005-10-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2005||2005-10-31|July 2015|2015-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Outpatient Registry Trial of Respiratory Tract Infections in Adults|Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT)|Withdrawn||Phase 4|0|Actual|CPL Associates||3||Terminated by sponsor|f||||||||||||||2018-06-01 04:22:51.940763|2018-06-01 04:22:51.940763
NCT00245440|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-10-29|2005-10-26|2005-10-28|Estimate|||||||2007-10-29|2007-10-31|Estimate|December 2005||2005-12-31|October 2007|2007-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis|Influence of Oral Telithromycin vs. Azithromycin on the Endogenous Microflora in Adults With Acute Sinusitis|Terminated||Phase 4|192|Actual|CPL Associates||2||Sponsor Terminated|f||||||||||||||2018-06-01 04:22:52.043277|2018-06-01 04:22:52.043277
NCT00245427|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-10-29|2005-10-26|2005-10-28|Estimate|||||||2007-10-29|2007-10-31|Estimate|December 2005||2005-12-31|October 2007|2007-10-31|March 2006|Actual|2006-03-31|||||Interventional|||Outcomes of Patients Not Responding to Antibiotics in the Community|Outcomes of Patients Not Responding to Outpatient Macrolide or b-Lactam Therapy for the Treatment of Community Acquired Pneumonia: Expansion to Include Acute Exacerbations of Chronic Bronchitis and Acute Sinusitis|Completed||N/A|200|Actual|CPL Associates||2|||f||||||||||||||2018-06-01 04:22:52.130098|2018-06-01 04:22:52.130098
NCT00245414|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2010-11-16|2005-10-27|2005-10-28|Estimate|||||||2010-11-16|2010-11-17|Estimate|October 2005||2005-10-31|November 2010|2010-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Trial of Pegasys® in Patients With Chronic Hepatitis C|Post-marketing Clinical Trial of Pegasys® 180μg for Subcutaneous Injection in Patients With Chronic Hepatitis C. General Clinical Study in Interferon (IFN)-Treated and IFN-untreated Chronic Hepatitis C Patients, Except for Those Infected With High Viral Load of Genotype 1b|Completed||Phase 4|108|Actual|Chugai Pharmaceutical||4|||f||||f||||||||||2018-06-01 04:22:52.22322|2018-06-01 04:22:52.22322
NCT00245401|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-04-03|2005-10-27|2005-10-28|Estimate|||||||2007-04-03|2007-04-04|Estimate|August 2003||2003-08-31|April 2007|2007-04-30|December 2004|Actual|2004-12-31|||||Interventional|||CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)|CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)|Completed||Phase 4|2070||Cordis Corporation|||||f||||t||||||||||2018-06-01 04:22:52.322354|2018-06-01 04:22:52.322354
NCT00245388|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2012-04-20|2005-10-26|2005-10-28|Estimate|||||||2012-04-20|2012-04-23|Estimate|April 2002||2002-04-30|April 2012|2012-04-30|July 2002|Actual|2002-07-31|||||Interventional|||Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia|A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Trial to Determine the Lipid-Lowering Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia|Completed||Phase 2/Phase 3|330||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:22:52.384942|2018-06-01 04:22:52.384942
NCT00245375|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2008-03-28|2005-10-26|2005-10-28|Estimate|||||||2008-03-28|2008-04-01|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|December 2005|Actual|2005-12-31|||||Interventional|||A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery|A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery|Completed||N/A|150||Nova Scotia Health Authority|||||f||||||||||||||2018-06-01 04:22:52.689731|2018-06-01 04:22:52.689731
NCT00245362|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-27|||2005-10-27|2005-10-27|2005-10-28|Estimate|||||||2005-10-27|2005-10-28|Estimate|June 2002||2002-06-30|October 2005|2005-10-31|June 2004||2004-06-30|||||Interventional|||A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer|A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer|Completed||Phase 2|50||Cell Genesys|||||||||||||||||||2018-06-01 04:22:52.786378|2018-06-01 04:22:52.786378
NCT00245349|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2008-06-09|2005-10-26|2005-10-27|Estimate|||||||2008-06-09|2008-06-10|Estimate|October 2005||2005-10-31|June 2008|2008-06-30|April 2008|Actual|2008-04-30|||||Observational|||Study to Calculate the Radiation Dosimetry in Subjects With Head and Neck Cancer|Biodistribution and Radiation Dosimetry of F-18 Fluorothymidine (FLT) Imaged With Positron Emission Tomography (PET) in Patients With Head and Neck Cancer: A Radioactive Drug Research Committee (RDRC) Study|Completed|||9|Actual|University of Iowa|||1||f||||t||||||Samples With DNA|"~     Tumor biopsy, blood samples~   "|||2018-06-01 04:22:52.877335|2018-06-01 04:22:52.877335
NCT00245336|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2009-03-06|2005-10-25|2005-10-27|Estimate|||||||2009-03-06|2009-03-09|Estimate|October 2005||2005-10-31|March 2009|2009-03-31|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Study of Recombinant Human Thrombin for Bleeding During Surgery|A Phase 3, Randomized, Double-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Recombinant Human Thrombin (rhThrombin) and Thrombin-JMI (Bovine Thrombin) in Surgical Hemostasis|Completed||Phase 3|401|Actual|ZymoGenetics||2|||f||||t||||||||||2018-06-01 04:22:52.988561|2018-06-01 04:22:52.988561
NCT00245323|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2005-10-25|2005-10-25|2005-10-27|Estimate|||||||2005-10-25|2005-10-27|Estimate|November 2003||2003-11-30|October 2005|2005-10-31|August 2004||2004-08-31|||||Interventional|||Checking Smoking Status as a Routine Vital Sign: A Cluster-Randomized Trial of Its Effect on Cessation Counseling|Does Checking Smoking Status as a Vital Sign Increase Physician Counseling? A Practice-Level Randomized Controlled Trial|Completed||N/A|2000||Virginia Commonwealth University|||||f||||||||||||||2018-06-01 04:22:53.234229|2018-06-01 04:22:53.234229
NCT00245310|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2010-10-08|2005-10-25|2005-10-27|Estimate|||||||2010-10-08|2010-10-11|Estimate|October 2005||2005-10-31|November 2008|2008-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Indocyangreen Elimination in Cirrhosis and Acute Liver Failure|Evaluation of the Indocyangreen Elimination as a Prognostic Marker in Decompensated Cirrhosis and Acute Liver Failure|Completed|||40|Anticipated|Heidelberg University|||||f||||||||||||||2018-06-01 04:22:53.325808|2018-06-01 04:22:53.325808
NCT00245297|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2007-10-15|2005-10-26|2005-10-27|Estimate|||||||2007-10-15|2007-10-16|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|April 2006|Actual|2006-04-30|||||Interventional|||Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.|A Patient-Blinded, Randomized, Comparative, Multicenter, Crossover, (Liposome) Dose Finding Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.|Completed||Phase 2|16|Actual|Recoly N.V.|||||f||||f||||||||||2018-06-01 04:22:53.432748|2018-06-01 04:22:53.432748
NCT00245271|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26||2011-06-17|2011-06-17|2005-10-26|2005-10-27|Estimate||||2011-06-17|2011-06-27|Estimate|2011-06-17|2011-06-27|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction|Double-Blind, Multicenter Study Evaluating the Safety of OMS103HP and Vehicle in Subjects Undergoing Anterior Cruciate Ligament Reconstruction With an Open-Label Phase Containing a PK Analysis in a Subset of Subjects|Completed||Phase 3|480|Anticipated|Omeros Corporation||2|||f||||f||||||||||2018-06-01 04:22:53.67648|2018-06-01 04:22:53.67648
NCT00245258|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2006-10-05|2005-10-25|2005-10-27|Estimate|||||||2006-10-05|2006-10-06|Estimate|November 2005||2005-11-30|October 2006|2006-10-31|September 2006||2006-09-30|||||Interventional|||Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction|A Multicenter, Double-Blind Placebo Controlled, Fixed Dose Study With An Open-Label, Flexible Dose Phase To Assess The Efficacy Of Sildenafil Citrate In Providing A Better Sexual Experience Including Quality Of Erections And Satisfaction In Men With Erectile Dysfunction|Completed||Phase 4|312||Pfizer|||||f||||||||||||||2018-06-01 04:22:53.824399|2018-06-01 04:22:53.824399
NCT00245245|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2007-10-02|2005-10-25|2005-10-27|Estimate|||||||2007-10-02|2007-10-04|Estimate|May 2005||2005-05-31|October 2007|2007-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII|An Open-Label Study of the Hemostatic Activity, Pharmacokinetics and Safety of OBI-1 (B-Domain Deleted Recombinant Porcine FVIII), When Administered by Intravenous Injection, to Control Non-Life and Non-Limb Threatening Bleeding Episodes in Congenital Hemophilia A Patients With an Inhibitor to Human FVIII|Completed||Phase 2|12|Anticipated|Octagen Corporation|||||||||||||||||||2018-06-01 04:22:54.036653|2018-06-01 04:22:54.036653
NCT00245232|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-03-30|2005-10-25|2005-10-27|Estimate|||||||2015-03-30|2015-03-31|Estimate|August 2000||2000-08-31|March 2015|2015-03-31|April 2005||2005-04-30|||||Interventional|||Cognitive Processing Therapy Versus Its Individual Components in the Treatment of Post-Traumatic Stress Disorder and Depression in Women Who Have Been Sexually Abused|Cognitive Processes in PTSD: Treatment|Completed||N/A|228||University of Missouri, St. Louis|||||f||||||||||||||2018-06-01 04:22:54.158869|2018-06-01 04:22:54.158869
NCT00245219|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|2015-08-25||2016-02-03|2005-10-26|2005-10-27|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|September 1999||1999-09-30|December 2015|2015-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Understanding Shared Psychobiological Pathways|Understanding Shared Psychobiological Pathways--Project 4. Psychobiological Pathways: Breast Cancer Interventions|Completed||N/A|245|Actual|Carnegie Mellon University|The study was originally planned as a 2(early stage, late stage) X 3(education intervention, peer support intervention, control condition) design; however, the education condition for the late stage cancer group was dropped, due to slow recruitment.|3|||f||||t||||||||||2018-06-01 04:22:54.283215|2018-06-01 04:22:54.283215
NCT00245206|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-06-11|2005-10-25|2005-10-27|Estimate|||||||2013-06-11|2013-06-12|Estimate|August 2005||2005-08-31|April 2009|2009-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Side Effects of Newer Antipsychotics in Older Adults|Metabolic Effects of Newer Antipsychotics in Older Patients|Completed||Phase 4|406|Actual|Veterans Medical Research Foundation||3|||f||||t||||||||||2018-06-01 04:22:54.925411|2018-06-01 04:22:54.925411
NCT00245193|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-06-21|2005-10-25|2005-10-27|Estimate|||||||2013-06-21|2013-06-25|Estimate|April 2003||2003-04-30|June 2013|2013-06-30|March 2006|Actual|2006-03-31|||||Interventional|||Motivationally-Enhanced Brief Interpersonal Psychotherapy for Depressed Mothers of Ill Children|Motivationally-Enhanced Brief Interpersonal Psychotherapy for Depressed Mothers of Ill Children (MI-IPT-B-II)|Completed||Phase 4|50||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:22:55.082541|2018-06-01 04:22:55.082541
NCT00245180|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2014-03-10|2005-10-26|2005-10-27|Estimate|||||||2014-03-10|2014-03-12|Estimate|May 2006||2006-05-31|April 2006|2006-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Preventing American Indian Children From Becoming Overweight|Primordial Prevention of Overweight in American Indian Children|Completed||N/A|577|Actual|Kaiser Permanente||1|||f||||f||||||||||2018-06-01 04:22:55.181321|2018-06-01 04:22:55.181321
NCT00245167|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2016-07-28|2005-10-26|2005-10-27|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2002||2002-01-31|March 2008|2008-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Possible Relation of Toll-Like Receptors and Nitric Oxide to Chronic Lung Disease|TLR's, Nitric Oxide and Chronic Lung Disease: Any Connections?|Completed|||120||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:22:55.306839|2018-06-01 04:22:55.306839
NCT00245154|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2016-11-25|2005-10-25|2005-10-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|January 2013|Actual|2013-01-31|February 2008|Actual|2008-02-29||Interventional|||Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II/III Double Blind Randomized Trial of AZD2171 Versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2/Phase 3|296|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 04:22:55.536041|2018-06-01 04:22:55.536041
NCT00245141|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-08-09|2005-10-25|2005-10-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|May 2004||2004-05-31|July 2009|2009-07-31||||April 2011|Anticipated|2011-04-30||Interventional|||Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma|Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma|Unknown status|Recruiting|Phase 2|32|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:22:55.729045|2018-06-01 04:22:55.729045
NCT00245128|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2011-10-25||2011-12-01|2005-10-25|2005-10-27|Estimate|2011-12-01|2012-01-13|Estimate||||2011-12-01|2012-01-13|Estimate|August 2005||2005-08-31|December 2011|2011-12-31|October 2011|Actual|2011-10-31|March 2007|Actual|2007-03-31||Interventional|||Imatinib Mesylate in Treating Patients With Myelofibrosis|A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia|Terminated||Phase 2|10|Actual|OHSU Knight Cancer Institute|Early termination/results were never analyzed due to negative study results from other similar studies.|||"Per PI, results from another similar study were published prior to study analysis. Negative~   study results were published therefore analysis was not completed"|f||||t||||||||||2018-06-01 04:22:55.968521|2018-06-01 04:22:55.968521
NCT00245115|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2016-10-14|2005-10-25|2005-10-27|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2005||2005-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|December 2007|Actual|2007-12-31||Interventional|||Autologous Peripheral Stem Cell or Bone Marrow Transplant Using Laboratory-Treated Cells in Treating Patients With Acute Leukemia|Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia|Active, not recruiting||N/A|25|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:22:56.286719|2018-06-01 04:22:56.286719
NCT00245102|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2013-11-19||2014-05-07|2005-10-25|2005-10-27|Estimate|2013-11-19|2014-01-20|Estimate||||2014-05-07|2014-05-23|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma|A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas|Completed||Phase 2|147|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:22:56.412407|2018-06-01 04:22:56.412407
NCT00245089|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-08-09|2005-10-25|2005-10-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|May 2004||2004-05-31|July 2009|2009-07-31||||April 2011|Anticipated|2011-04-30||Interventional|||Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma|Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma|Unknown status|Recruiting|Phase 2|41|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:22:57.701622|2018-06-01 04:22:57.701622
NCT00245076|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-04-30|2005-10-25|2005-10-27|Estimate|||||||2015-04-30|2015-05-01|Estimate|April 2005||2005-04-30|April 2006|2006-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking|Evaluation of the Impact of a Bulletin Board on a Web-Based Smoking Cessation Intervention|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:22:57.84435|2018-06-01 04:22:57.84435
NCT00245063|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2014-07-21||2014-10-01|2005-10-25|2005-10-27|Estimate|2014-10-01|2014-10-02|Estimate||||2014-10-01|2014-10-02|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer|Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)|The 45 mg PO dose on arm 1 was deemed undeliverable since 7 of 12 patients were unable to complete one cycle due to treatment intolerance. Study was ammended and re-started at 30 mg (arm 2) after discussions with coinvestigators at CTEP.|1|||f||||||||||||||2018-06-01 04:22:57.911377|2018-06-01 04:22:57.911377
NCT00245050|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2010-10-26||2011-12-28|2005-10-25|2005-10-27|Estimate|2010-11-29|2010-12-22|Estimate||||2011-12-28|2011-12-30|Estimate|April 2004||2004-04-30|December 2011|2011-12-31|September 2011|Actual|2011-09-30|April 2008|Actual|2008-04-30||Interventional|||Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer|A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome)|Completed||Phase 3|34|Actual|Case Comprehensive Cancer Center|Interim analysis was conducted after 30 patients were enrolled and had evaluable PPE assessment data. Due to decreased accrual and similar PPE rates between groups, the trial was closed for enrollment after the interim analyses was completed.|2|||f||||t||||||||||2018-06-01 04:22:58.422189|2018-06-01 04:22:58.422189
NCT00245037|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2017-04-20|2016-11-28|2017-09-25|2005-10-25|2005-10-27|Estimate|2017-05-31|2017-07-02|Actual|2016-11-28|2016-12-29|Estimate|2017-09-25|2017-09-27|Actual|June 2005||2005-06-30|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Bu Flu TBI||Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation|Completed||Phase 1/Phase 2|147|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 04:22:58.748511|2018-06-01 04:22:58.748511
NCT00245024|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-05-01|2005-10-25|2005-10-27|Estimate|||||||2013-05-01|2013-05-03|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|January 2010|Actual|2010-01-31|August 2007|Actual|2007-08-31||Interventional|||Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer|Phase IB Sulindac Study for Women at High Risk for Breast Cancer|Completed||Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:22:59.155481|2018-06-01 04:22:59.155481
NCT00245011|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2015-02-03||2016-07-26|2005-10-25|2005-10-27|Estimate|2015-04-15|2015-05-01|Estimate||||2016-07-26|2016-08-30|Estimate|October 2004||2004-10-31|July 2016|2016-07-31|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|||Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma|High Dose Samarium-153 With Peripheral Blood Stem Cell Support in High Risk Osteogenic Sarcoma|Completed||Phase 2|11|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|"Future work will focus on better understanding the factors that contribute to drug delivery and improving efficacy be combination with chemotherapy, biologics, or external beam radiotherapy. (See Publication section of this entry)."|1|||f||||t||||||||||2018-06-01 04:22:59.226807|2018-06-01 04:22:59.226807
NCT00244998|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-03-07|2005-10-25|2005-10-27|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 2005||2005-09-30|March 2013|2013-03-31|June 2012|Actual|2012-06-30|October 2006|Actual|2006-10-31||Interventional|||Fulvestrant in Treating Patients With Advanced Prostate Cancer|Phase II Study of Fulvestrant (Faslodex®) in Androgen Independent Prostate Cancer|Completed||Phase 2|20|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 04:22:59.383612|2018-06-01 04:22:59.383612
NCT00244985|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2017-06-19||2017-07-14|2005-10-25|2005-10-27|Estimate|2017-06-19|2017-07-14|Actual||||2017-07-14|2017-08-17|Actual|September 2005||2005-09-30|July 2017|2017-07-31|December 2012|Actual|2012-12-31|August 2008|Actual|2008-08-31||Interventional||All treated and eligible patients|Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I/II Pilot Study of the Safety and Efficacy of Rituxan (Chimeric Anti-CD20 Antibody) in Combination With Doxil (Liposomal Doxorubicin) Chemotherapy in Patients With Relapsing or Refractory Indolent or Aggressive B-Cell Lymphoma|Completed||Phase 1/Phase 2|42|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 04:22:59.453795|2018-06-01 04:22:59.453795
NCT00244972|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2017-04-26|2005-10-25|2005-10-27|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2005||2005-10-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer|Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers|Completed||Phase 1|74|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:22:59.723327|2018-06-01 04:22:59.723327
NCT00244959|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-03-18|2005-10-25|2005-10-27|Estimate|||||||2013-03-18|2013-03-19|Estimate|January 2004||2004-01-31|March 2013|2013-03-31|November 2011|Actual|2011-11-30|September 2007|Actual|2007-09-30||Interventional|||Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer|Surrogate Markers of Response: A Phase II Study of Changes in Breast Density Among Postmenopausal Women Receiving Adjuvant Anastrozole Therapy|Completed||Phase 2|54|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-06-01 04:22:59.794877|2018-06-01 04:22:59.794877
NCT00244764|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2009-11-19||2017-02-23|2005-10-26|2005-10-27|Estimate|2011-01-06|2011-01-25|Estimate||||2017-02-23|2017-03-27|Actual|October 2005||2005-10-31|September 2015|2015-09-30|September 2013|Actual|2013-09-30|March 2008|Actual|2008-03-31||Interventional|||GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma|A Phase II Study of GW786034 Using a Randomised Discontinuation Design in Subjects With Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma|Completed||Phase 2|225|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 04:23:01.769473|2018-06-01 04:23:01.769473
NCT00244946|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-03-25|2005-10-25|2005-10-27|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2004||2004-03-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|January 2010|Actual|2010-01-31||Interventional|||Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma|Immune Consolidation With Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) After Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin's Lymphomas|Completed||Phase 1|15|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||f||||||||||2018-06-01 04:22:59.874875|2018-06-01 04:22:59.874875
NCT00244933|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2015-01-12||2018-04-13|2005-10-25|2005-10-27|Estimate|2015-01-30|2015-02-02|Estimate||||2018-04-13|2018-05-14|Actual|February 2004||2004-02-29|December 2017|2017-12-31|October 2009|Actual|2009-10-31|November 2008|Actual|2008-11-30||Interventional|||Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer|Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays|Completed||Phase 2|19|Actual|Barbara Ann Karmanos Cancer Institute|Although the study is designed to accrue 18 response evaluable participants in the first stage, the decision was made to close the study after 17 patients because of lack of efficacy.|1|||f||||t||||||||||2018-06-01 04:22:59.963267|2018-06-01 04:22:59.963267
NCT00244920|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2012-05-24|2005-10-25|2005-10-27|Estimate|||||||2012-05-24|2012-05-28|Estimate|January 2002||2002-01-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer|An Open Label Randomized Phase 2 Study To Evaluate The Activity, Tolerability, And Toxicity Of Combined Neoadjuvant Anti-angiogenesis and Androgen Ablation Therapy in Men Undergoing Radical Prostatectomy|Withdrawn||Phase 2|0|Actual|OHSU Knight Cancer Institute||||Sponsor withdrew drug.|f||||f||||||||||2018-06-01 04:23:00.360339|2018-06-01 04:23:00.360339
NCT00244907|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2018-05-03|2005-10-25|2005-10-27|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2006||2006-01-31|May 2018|2018-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women|Metabolism and Bone Health|Completed||Phase 1|23|Actual|Purdue University||2|||f||||t||||||||||2018-06-01 04:23:00.430794|2018-06-01 04:23:00.430794
NCT00244894|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2017-04-26|2005-10-25|2005-10-27|Estimate|||||||2017-04-26|2017-04-28|Actual|September 2002||2002-09-30|April 2017|2017-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer|Acupuncture for Hot Flashes in Prostate Cancer Patients|Terminated||N/A|22|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 04:23:00.516779|2018-06-01 04:23:00.516779
NCT00244881|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2013-11-04||2015-12-03|2005-10-25|2005-10-27|Estimate|2013-11-04|2013-12-23|Estimate||||2015-12-03|2015-12-07|Estimate|September 2005||2005-09-30|November 2013|2013-11-30|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)|A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)|Completed||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:23:00.608683|2018-06-01 04:23:00.608683
NCT00244868|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2013-01-28|2005-10-25|2005-10-27|Estimate|||||||2013-01-28|2013-01-29|Estimate|July 2003||2003-07-31|January 2013|2013-01-31||||April 2007|Actual|2007-04-30||Interventional|||Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer|Facilitating Decision Making in Advanced Cancer Patients|Completed||Phase 3|720|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 04:23:00.7791|2018-06-01 04:23:00.7791
NCT00244855|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2017-04-14||2017-04-14|2005-10-25|2005-10-27|Estimate|2017-04-14|2017-05-22|Actual||||2017-04-14|2017-05-22|Actual|May 2004||2004-05-31|April 2017|2017-04-30|August 29, 2011|Actual|2011-08-29|December 2008|Actual|2008-12-31||Interventional|||Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma|Rituximab and Dexamethasone in CD20 Positive Low Grade and Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|32|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-06-01 04:23:00.932625|2018-06-01 04:23:00.932625
NCT00244842|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2008-09-24|2005-10-25|2005-10-27|Estimate|||||||2008-09-24|2008-09-29|Estimate|December 2004||2004-12-31|September 2008|2008-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|SPIRIT||Randomized Placebo-Controlled Study of ISA247 in Plaque Psoriasis|A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients|Completed||Phase 3|451|Actual|Aurinia Pharmaceuticals Inc.||4|||f||||t||||||||||2018-06-01 04:23:01.292812|2018-06-01 04:23:01.292812
NCT00244829|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2011-11-28|2005-10-25|2005-10-27|Estimate|||||||2011-11-28|2011-11-30|Estimate|January 2004||2004-01-31|November 2011|2011-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia|A Multicenter Pilot Study Evaluating the Safety and Efficacy of Imatinib as Post-Transplant Therapy for High- Risk Philadelphia Chromosome-Positive Leukemias|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:23:01.425441|2018-06-01 04:23:01.425441
NCT00244816|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2018-01-22|2005-10-25|2005-10-27|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2005||2005-10-31|January 2018|2018-01-31|April 2007||2007-04-30|||||Interventional|||Taxoprexin® Treatment for Advanced Eye Melanoma|Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma|Completed||Phase 2|30||Luitpold Pharmaceuticals|||||||||||||||||||2018-06-01 04:23:01.490512|2018-06-01 04:23:01.490512
NCT00244803|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2016-08-30|2005-10-25|2005-10-27|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2005||2005-01-31|August 2016|2016-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)|Redistribution and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)|Completed|||101|Actual|Johns Hopkins University|||1||f||||t||||||||||2018-06-01 04:23:01.554519|2018-06-01 04:23:01.554519
NCT00244790|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-08-26|2005-10-25|2005-10-27|Estimate|||||||2015-08-26|2015-08-28|Estimate|April 2004||2004-04-30|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Effects of Obesity and Protein Intake on the Kidney|The Effects of Obesity and Protein Intake on the Kidney|Completed||N/A|50|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 04:23:01.614455|2018-06-01 04:23:01.614455
NCT00244777|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2015-06-11|2005-10-26|2005-10-27|Estimate|||||||2015-06-11|2015-06-12|Estimate|December 2002||2002-12-31|October 2005|2005-10-31|February 2004||2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Introduction of Hypo-osmolar ORS for Routine Use|Introduction of New Hypo-osmolar ORS Into Routine Use in the Management of Diarrhoeal Disease: a Phase IV Clinical Surveillance.|Completed||Phase 4|75000||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:23:01.67752|2018-06-01 04:23:01.67752
NCT00242268|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2005-12-06|2005-10-19|2005-10-20|Estimate|||||||2005-12-06|2005-12-07|Estimate|October 2005||2005-10-31|September 2005|2005-09-30||||||||Interventional|||A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis||Unknown status|Recruiting|Phase 3|30||Alabama Neurology Associates, PC|||||f||||||||||||||2018-06-01 04:23:44.065753|2018-06-01 04:23:44.065753
NCT00244751|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2017-09-26|2009-07-22|2017-11-08|2005-10-26|2005-10-27|Estimate|2017-11-08|2017-12-11|Actual|2009-07-22|2009-08-10|Estimate|2017-11-08|2017-12-11|Actual|November 2, 2005|Actual|2005-11-02|November 2017|2017-11-30|March 13, 2008|Actual|2008-03-13|March 13, 2008|Actual|2008-03-13||Interventional|||Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects|A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy|Completed||Phase 2|265|Actual|GlaxoSmithKline||3|||||||f||||||||||2018-06-01 04:23:02.236222|2018-06-01 04:23:02.236222
NCT00244738|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2012-03-18|2005-10-26|2005-10-27|Estimate|||||||2012-03-18|2012-03-20|Estimate|February 2006||2006-02-28|November 2005|2005-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||The Use of Castor Oil as a Labor Initiator in Post-date Pregnancies|The Use of Castor Oil as a Labor Initiator in Post-date Pregnancies|Completed||N/A|82|Actual|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 04:23:03.942779|2018-06-01 04:23:03.942779
NCT00244725|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2017-03-21||2017-03-21|2005-10-26|2005-10-27|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|September 2005||2005-09-30|March 2017|2017-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Odiparcil For The Prevention Of Venous Thromboembolism|A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery|Completed||Phase 2|961|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:23:04.095428|2018-06-01 04:23:04.095428
NCT00244712|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2009-04-23||2010-06-03|2005-10-26|2005-10-27|Estimate|2009-08-07|2009-09-15|Estimate||||2010-06-03|2010-06-08|Estimate|July 2005||2005-07-31|June 2010|2010-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|HEAT||Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV|A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects|Completed||Phase 4|688|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:23:05.441781|2018-06-01 04:23:05.441781
NCT00244699|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2009-05-09|2005-10-25|2005-10-27|Estimate|||||||2009-05-09|2009-05-12|Estimate|October 2005||2005-10-31|May 2009|2009-05-31|April 2007||2007-04-30|||||Interventional|||Integrating Mindfulness-Based Skills Training Into Brief Outpatient Treatment for Substance Abusing Youth|A Mindfulness-Based Intervention for Youth With Concurrent Disorders|Completed||N/A|40||Centre for Addiction and Mental Health|||||f||||||||||||||2018-06-01 04:23:06.58996|2018-06-01 04:23:06.58996
NCT00244686|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2018-04-11|2005-10-26|2005-10-27|Estimate|||||||2018-04-11|2018-04-13|Actual||||April 2018|2018-04-30||||||||Expanded Access|||This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic|104317: An Open-Label Compassionate Use Access and Long-Term Access Study of Anti IL-5 (Mepolizumab) Treatment in Subjects With Hypereosinophilic Syndrome. 201956: A Long-term Access Programme for Subjects With Severe Asthma Who Participated in a GSK-sponsored Mepolizumab Clinical Study. 112562: Expanded Access to Mepolizumab for Patients With Hypereosinophilic Syndrome|Available|||||GlaxoSmithKline||||||t|||||||||||||2018-06-01 04:23:06.754861|2018-06-01 04:23:06.754861
NCT00244673|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2012-02-25|2005-10-25|2005-10-27|Estimate|||||||2012-02-25|2012-02-28|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination|Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination|Completed||Phase 4|6534|Actual|Bandim Health Project|||||f||||||||||||||2018-06-01 04:23:07.301589|2018-06-01 04:23:07.301589
NCT00244660|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2008-01-17|2005-10-26|2005-10-27|Estimate|||||||2008-01-17|2008-01-21|Estimate|November 2005||2005-11-30|January 2008|2008-01-31|June 2007||2007-06-30|||||Interventional|||Blood Pressure Reduction in Danish General Practice (BRIDGE)|Blood Pressure Reduction in Danish General Practice (BRIDGE)|Completed||Phase 4|1000||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:23:07.38872|2018-06-01 04:23:07.38872
NCT00244647|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2008-04-09|2005-10-25|2005-10-27|Estimate|||||||2008-04-09|2008-04-10|Estimate|August 2003||2003-08-31|April 2008|2008-04-30||||||||Interventional|||A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis|A Phase 1b, Randomized, Single Blind Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis|Terminated||Phase 1|40||Sarepta Therapeutics|||||f||||||||||||||2018-06-01 04:23:07.436444|2018-06-01 04:23:07.436444
NCT00244634|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2007-12-17|2005-10-25|2005-10-27|Estimate|||||||2007-12-17|2007-12-19|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|November 2005|Actual|2005-11-30|||||Interventional|||Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age|A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6 to <17 Years of Age: A 4-Week, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study|Completed||Phase 3|238||AstraZeneca|||||||||||||||||||2018-06-01 04:23:07.670673|2018-06-01 04:23:07.670673
NCT00244621|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2009-08-07||2011-08-29|2005-10-25|2005-10-27|Estimate|2009-08-07|2009-09-15|Estimate||||2011-08-29|2011-08-31|Estimate|November 2004||2004-11-30|August 2011|2011-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age|A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period.|Completed||Phase 3|95|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 04:23:07.816663|2018-06-01 04:23:07.816663
NCT00244608|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2011-01-21|2005-10-25|2005-10-27|Estimate|||||||2011-01-21|2011-01-24|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|March 2007|Actual|2007-03-31|||||Interventional|||A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®|A Comparison of the Inflammatory Control of Asthma Provided by One Inhalation of Symbicort® Turbuhaler® 160/4.5 µg/Inhalation b.i.d. Plus As-needed Versus One Inhalation of Symbicort® Turbuhaler® 320/9 µg/Inhalation b.i.d. + One Inhalation of Pulmicort® Turbuhaler® 400 µg/Dose b.i.d. Plus Terbutaline Turbuhaler® 0.4 mg/Inhalation As-needed. A 12-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational, Phase IIIB Study in Adult Patients With Asthma, EOS|Completed||Phase 3|100||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:08.34644|2018-06-01 04:23:08.34644
NCT00244595|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2009-12-08|2005-10-25|2005-10-27|Estimate|||||||2009-12-08|2009-12-09|Estimate|September 2003||2003-09-30|December 2009|2009-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age|A Multicenter, Multinational, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age|Completed||Phase 3|235||AstraZeneca|||||||||||||||||||2018-06-01 04:23:08.457384|2018-06-01 04:23:08.457384
NCT00244582|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-26|||2017-06-30|2005-10-25|2005-10-26|Estimate|||||||2017-06-30|2017-07-02|Actual|October 22, 2005||2005-10-22|November 3, 2006|2006-11-03|November 3, 2006||2006-11-03|||||Observational|||Convection-Enhanced Delivery of Glucocerebrosidase to Treat Type 2 Gaucher Disease|Direct Convection-Enhanced Delivery of Glucocerebrosidase for the Treatment of Type 2 (Acute Neuronopathic) Gaucher Disease|Completed|||1||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:23:08.597049|2018-06-01 04:23:08.597049
NCT00244569|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2017-03-16|2005-10-24|2005-10-26|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2005||2005-09-30|March 2017|2017-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Development of a Breath Test for Monitoring Patients With Liver Disease|Development of a Breath Test for Monitoring Liver Metabolic Function in Patients With Chronic Liver Disease and Cirrhosis|Completed||Phase 3|120|Anticipated|Virginia Commonwealth University|||||f||||||||||||||2018-06-01 04:23:08.677384|2018-06-01 04:23:08.677384
NCT00244556|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-02-20|2005-10-25|2005-10-26|Estimate|||||||2013-02-20|2013-02-21|Estimate|March 2003||2003-03-31|February 2013|2013-02-28|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy|A Randomized Comparison of the Safety and Efficacy of Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Patients With Active Rheumatoid Arthritis Despite Current Methotrexate Therapy|Completed||Phase 4|300||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:23:08.791128|2018-06-01 04:23:08.791128
NCT00244543|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2011-09-26|2005-10-25|2005-10-26|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2005||2005-10-31|September 2011|2011-09-30||||November 2005|Actual|2005-11-30||Interventional|||Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis|A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|Completed||Phase 3|110||Vistakon Pharmaceuticals|||||f||||||||||||||2018-06-01 04:23:08.860691|2018-06-01 04:23:08.860691
NCT00244530|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2006-12-20|2005-10-25|2005-10-26|Estimate|||||||2006-12-20|2006-12-22|Estimate|June 2001||2001-06-30|December 2006|2006-12-31|October 2005||2005-10-31|||||Interventional|||Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery|Postoperative Renal Function After Open-Heart Surgery in Patients With Impaired Renal Function Preoperatively. A Study of the Calcium Channel Blocker Nifedipine's Prophylactic Effect on Further Decline in Renal Function.|Completed||Phase 4|20||University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:23:08.928837|2018-06-01 04:23:08.928837
NCT00244517|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2010-06-30|2005-10-25|2005-10-26|Estimate|||||||2010-06-30|2010-07-01|Estimate|June 2004||2004-06-30|June 2010|2010-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||DIAFAX I+II-Effects of Inhalative Anesthetics on Left Ventricular Diastolic Function|The Effects of Remifentanil, Sevoflurane, Isoflurane and Desflurane on Left Ventricular Diastolic Function in Humans|Terminated||Phase 4|60|Actual|University Hospital, Basel, Switzerland||3||"Part II was not performed as we could not include enough patients fulfilling the inclusion~   criteria."|f||||t||||||||||2018-06-01 04:23:08.989956|2018-06-01 04:23:08.989956
NCT00244504|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2009-11-09|2005-10-25|2005-10-26|Estimate|||||||2009-11-09|2009-11-10|Estimate|November 2002||2002-11-30|November 2009|2009-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Moxonidine in Patients Undergoing Vascular Surgery|The Effects of Small Doses of Moxonidine in Patients Undergoing Vascular Surgery|Terminated||Phase 3|141|Actual|University Hospital, Basel, Switzerland||2||Study was stopped after pre-definied interim analysis because of no effects|f||||t||||||||||2018-06-01 04:23:09.071329|2018-06-01 04:23:09.071329
NCT00244491|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2015-08-10|2005-10-24|2005-10-26|Estimate|||||||2015-08-10|2015-08-13|Estimate|September 2002||2002-09-30|August 2015|2015-08-31|August 2003||2003-08-31|||||Interventional|||The Care Transitions Intervention|The Care Transitions Intervention|Completed||N/A|1400||University of Colorado, Denver|||||f||||||||||||||2018-06-01 04:23:09.142101|2018-06-01 04:23:09.142101
NCT00244478|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-09-23|2005-10-25|2005-10-26|Estimate|||||||2015-09-23|2015-09-25|Estimate|October 2005||2005-10-31|September 2015|2015-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Soy, Bone and Health in College Females|Influence of Soy on Bone Turnover and Body Composition in College Females|Completed||N/A|120|Actual|University of Georgia||2|||f||||t||||||||||2018-06-01 04:23:09.229524|2018-06-01 04:23:09.229524
NCT00244465|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2016-09-05|2005-10-24|2005-10-26|Estimate|||||||2016-09-05|2016-09-07|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription|Post Marketing Non-interventional Surveillance Pharmacoepidemiology Study (PMSS) to Evaluate Long-term Safety, Tolerability and Compliance in Administration of Xyrem® (Sodium Oxybate) Oral Solution in Patients Who Receive Treatment With This Medication in Regular Clinical Practice.|Completed|||750|Actual|UCB Pharma|||||f||||f||||||||||2018-06-01 04:23:09.302254|2018-06-01 04:23:09.302254
NCT00244452|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2008-03-28|2005-10-25|2005-10-26|Estimate|||||||2008-03-28|2008-03-31|Estimate|November 2005||2005-11-30|March 2008|2008-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Multinational, Randomized, Double-Blind, Placebo‑Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis|A Multinational, Randomized, Double-Blind, Placebo‑Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis|Completed||Phase 2|||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:23:09.408425|2018-06-01 04:23:09.408425
NCT00244439|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2013-12-19|2005-10-24|2005-10-26|Estimate|||||||2013-12-19|2013-12-23|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice|A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05%Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis|Completed||Phase 3|360|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-06-01 04:23:09.513193|2018-06-01 04:23:09.513193
NCT00244426|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2009-10-29|2005-10-24|2005-10-26|Estimate|||||||2009-10-29|2009-10-30|Estimate|December 2000||2000-12-31|October 2009|2009-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|SIFA||S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation|II Italian Study on Atrial Fibrillation (S.I.F.A. II): Prevention of Thromboembolic Events in Patients With Non Valvular Atrial Fibrillation.|Completed||Phase 3|1372|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:23:09.593252|2018-06-01 04:23:09.593252
NCT00242255|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2018-04-24|2005-10-18|2005-10-19|Estimate|||||||2018-04-24|2018-04-25|Actual|October 14, 2005||2005-10-14|April 11, 2018|2018-04-11||||||||Observational|||Epigenetics in the Aging Process|Remodeling of Chromatin-Based Epigenetic Structures in Development and Aging|Completed|||90|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:23:44.375511|2018-06-01 04:23:44.375511
NCT00244413|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2013-03-05|2005-10-24|2005-10-26|Estimate|||||||2013-03-05|2013-03-06|Estimate|February 2006||2006-02-28|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Characteristics of Nondystrophic Myotonias|Nondystrophic Myotonias: Genotype-phenotype Correlation and Longitudinal Study|Completed|||94|Actual|University of Kansas Medical Center|||||f||||||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 04:23:09.946241|2018-06-01 04:23:09.946241
NCT00244400|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2006-10-16|2005-10-25|2005-10-26|Estimate|||||||2006-10-16|2006-10-17|Estimate|November 2002||2002-11-30|October 2006|2006-10-31|January 2006||2006-01-31|||||Observational|||Examine the Possible Association of Hepatic CYP3A Activity and the Susceptibility to Femur Head Necrosis||Completed|||200||Osaka City University|||||f||||||||||||||2018-06-01 04:23:10.012299|2018-06-01 04:23:10.012299
NCT00244387|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2014-09-24|2005-10-24|2005-10-26|Estimate|||||||2014-09-24|2014-09-25|Estimate|March 2004||2004-03-31|February 2010|2010-02-28|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa|A Multi-centre, Multi-national, Phase 3, Randomized, Double-blind, Double-dummy, 3- Arm Parallel Group, Placebo- and Pramipexole- Controlled Trial of the Efficacy and Safety of Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa|Completed||Phase 3|506|Actual|UCB Pharma|||||||||||||||||||2018-06-01 04:23:10.058869|2018-06-01 04:23:10.058869
NCT00244374|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|2013-04-25||2013-07-25|2005-10-25|2005-10-26|Estimate|2013-05-15|2013-07-19|Estimate||||2013-07-25|2013-09-30|Estimate|August 2004||2004-08-31|July 2013|2013-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|UFO VAX||A Randomized Trial of Vaccine Adherence in Young Injection Drug Users|A Randomized Trial of Vaccine Adherence in Young IDU|Completed||N/A|546|Actual|University of California, San Francisco||4|||f||||f||||||||||2018-06-01 04:23:10.123451|2018-06-01 04:23:10.123451
NCT00244361|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2011-05-06|2005-10-24|2005-10-26|Estimate|||||||2011-05-06|2011-05-10|Estimate|June 2005||2005-06-30|May 2011|2011-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effectiveness of Rituximab in Pediatric OMS Patients.|A Phase I Clinical Trial of Rituximab for Pediatric Opsoclonus-Myoclonus Syndrome|Completed||Phase 1/Phase 2|25|Actual|National Pediatric Neuroinflammation Organization, Inc.|||||f||||t||||||||||2018-06-01 04:23:11.478268|2018-06-01 04:23:11.478268
NCT00244348|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-08-26|2005-10-25|2005-10-26|Estimate|||||||2015-08-26|2015-08-27|Estimate|October 2005||2005-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Hepatic Artery Infusion With Oxaliplatin|Hepatic Arterial Infusion of Oxaliplatin Clinical Trial|Withdrawn||Phase 1/Phase 2|0|Actual|Medical College of Wisconsin||||Investigator has left institution|f||||||||||||||2018-06-01 04:23:11.603406|2018-06-01 04:23:11.603406
NCT00244335|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2017-01-09|2005-10-25|2005-10-26|Estimate|||||||2017-01-09|2017-01-10|Estimate|October 2000||2000-10-31|August 2008|2008-08-31|July 2008|Actual|2008-07-31|February 2006|Actual|2006-02-28||Observational|||Examining the Role of Negative Emotional States on Sedative Drug Use in Individuals With Post-Traumatic Stress Disorder|Emotional Control of Sedative Self-Medication in Post-Traumatic Stress Disorder|Completed|||39|Actual|National Institute on Drug Abuse (NIDA)|||2||f||||t||||||||||2018-06-01 04:23:11.671701|2018-06-01 04:23:11.671701
NCT00244322|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2007-05-24|2005-10-24|2005-10-26|Estimate|||||||2007-05-24|2007-05-28|Estimate|October 2005||2005-10-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease|LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|45||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:23:11.741875|2018-06-01 04:23:11.741875
NCT00244309|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2011-05-03|2005-10-24|2005-10-26|Estimate|||||||2011-05-03|2011-05-04|Estimate|November 2005||2005-11-30|May 2011|2011-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer|A Randomized Trial of Tamsulosin and/or Dutasteride Versus Placebo to Relieve Urinary Symptoms After Brachytherapy for the Treatment of Localized Prostate Cancer|Completed||Phase 3|348|Anticipated|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:23:11.806518|2018-06-01 04:23:11.806518
NCT00244296|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2007-01-24|2005-10-24|2005-10-26|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2005||2005-10-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms|A Double-Blind, Stratified, Randomised, Parallel, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of Duloxetine (20 mg Bid for 2 Weeks Escalating to 40 mg Bid) for up to 12 Weeks, Compared to Placebo, in Community-Dwelling Elderly Women > or = 65 Years of Age With Symptoms of Stress Urinary Incontinence or Stress-Predominant Mixed Urinary Incontinence.|Completed||Phase 4|276||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:23:11.969938|2018-06-01 04:23:11.969938
NCT00244283|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2005-10-24|2005-10-24|2005-10-26|Estimate|||||||2005-10-24|2005-10-26|Estimate|January 2006||2006-01-31|October 2005|2005-10-31|January 2008||2008-01-31|||||Interventional|||A Comparison of Two Anaesthetic Methods of Protecting Heart Tissue During Cardiac Surgery|A Comparison of Myocardial Protection Using Preconditioning With Sevoflurane Against High Thoracic Epidural Analgesia for CABG Surgery|Unknown status|Not yet recruiting|Phase 4|150||Golden Jubilee National Hospital|||||f||||||||||||||2018-06-01 04:23:12.883874|2018-06-01 04:23:12.883874
NCT00244270|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2011-08-26|2005-10-25|2005-10-26|Estimate|||||||2011-08-26|2011-08-29|Estimate|December 2005||2005-12-31|September 2005|2005-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|RITHM||Cystic Fibrosis and Totally Implantable Vascular Access Devices|Cystic Fibrosis and Totally Implantable Vascular Access Devices: Evaluation of the Incidence of Venous Thrombosis Related to the Catheter and Study of the Genetic and Acquired Risk Factors|Completed||Phase 4|97|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 04:23:12.964307|2018-06-01 04:23:12.964307
NCT00244257|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2015-04-08|2005-10-25|2005-10-26|Estimate|||||||2015-04-08|2015-04-09|Estimate|August 2005||2005-08-31|April 2015|2015-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|Phase I, Open-Label, Multi-center, Single-Dose, Dose-Escalating, Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamic Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)|Terminated||Phase 1|10|Actual|Sanofi||5||Study terminated due to low enrollment.|f||||t||||||||||2018-06-01 04:23:13.038414|2018-06-01 04:23:13.038414
NCT00244244|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2012-02-08|2005-10-25|2005-10-26|Estimate|||||||2012-02-08|2012-02-09|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS|A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|80||CytRx|||||f||||||||||||||2018-06-01 04:23:13.125194|2018-06-01 04:23:13.125194
NCT00244231|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2007-02-27|2005-10-25|2005-10-26|Estimate|||||||2007-02-27|2007-03-01|Estimate|October 2003||2003-10-31|February 2007|2007-02-28|August 2005||2005-08-31|||||Interventional|||Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia|A Placebo-Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Nidadd in the Management of Hyperlipidemia|Completed||Phase 3|70||Genovate Biotechnology Co., Ltd.,|||||f||||f||||||||||2018-06-01 04:23:13.206373|2018-06-01 04:23:13.206373
NCT00244218|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2009-01-15|2005-10-25|2005-10-26|Estimate|||||||2009-01-15|2009-01-16|Estimate|April 2005||2005-04-30|January 2009|2009-01-31||||March 2009|Anticipated|2009-03-31||Interventional|||Response to Phenylketonuria to Tetrahydrobiopterin (BH4)|Response to Phenylketonuria to Tetrahydrobiopterin (BH4)|Unknown status|Recruiting|Phase 1|36|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 04:23:13.260256|2018-06-01 04:23:13.260256
NCT00244205|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2005-11-14|2005-10-24|2005-10-26|Estimate|||||||2005-11-14|2005-11-15|Estimate|November 2005||2005-11-30|November 2005|2005-11-30||||||||Observational|||Identifying Methylation Biomarkers for Monitoring Bladder Tumors|Using PCR Technology (Polymerase Chain Reaction Technology) for Monitoring Patients With Bladder Tumors - Optimizing Genanalyses for Clinical Use.|Unknown status|Recruiting||120||Copenhagen University Hospital at Herlev|||||f||||||||||||||2018-06-01 04:23:13.43226|2018-06-01 04:23:13.43226
NCT00244192|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2005-12-08|2005-10-25|2005-10-26|Estimate|||||||2005-12-08|2005-12-09|Estimate|October 2003||2003-10-31|October 2005|2005-10-31|December 2005||2005-12-31|||||Interventional|||Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia|Completed||Phase 2|16||Center for Integrated Rehabilitation and Organ Failure Horn|||||f||||||||||||||2018-06-01 04:23:13.516636|2018-06-01 04:23:13.516636
NCT00244179|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2006-09-07|2005-10-25|2005-10-26|Estimate|||||||2006-09-07|2006-09-08|Estimate|January 2003||2003-01-31|September 2006|2006-09-30||||||||Interventional|||New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis|New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis: Immunostimulation Plus Antibiotic Versus Immunosuppression Plus Antibiotic Versus Conventional Standardtherapy|Unknown status|Recruiting|Phase 2|40||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:23:13.639877|2018-06-01 04:23:13.639877
NCT00244166|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2006-09-07|2005-10-25|2005-10-26|Estimate|||||||2006-09-07|2006-09-11|Estimate|May 2002||2002-05-31|September 2006|2006-09-30|August 2008||2008-08-31|||||Interventional|||Prednisolone in Active Ankylosing Spondylitis (AS)|Threecenter Placebo Controlled Three Arm Trial in Patients With Active Ankylosing Spondylitis With Prednisolone|Unknown status|Recruiting|Phase 2/Phase 3|75||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:23:13.763602|2018-06-01 04:23:13.763602
NCT00244153|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-25|||2006-09-07|2005-10-25|2005-10-26|Estimate|||||||2006-09-07|2006-09-11|Estimate|June 2004||2004-06-30|February 2004|2004-02-29|August 2007||2007-08-31|||||Interventional|||Intraarticular Opioids Vs Glucocorticosteroids in Gonarthritis|Intraarticular Application of Opioids Versus Glucocorticosteroids Versus Placebo in Rheumatoid Arthritis|Unknown status|Recruiting|Phase 1/Phase 2|120||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:23:13.873781|2018-06-01 04:23:13.873781
NCT00244140|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|2009-05-29||2014-01-28|2005-10-24|2005-10-26|Estimate|2009-05-29|2009-07-20|Estimate||||2014-01-28|2014-02-28|Estimate|October 2005||2005-10-31|January 2014|2014-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Ultravist: Safety and Efficacy in Computed Tomography of Head and Body|Ultravist 370 Milligrams of Iodine Per Milliliter (mg I/mL): Safety and Efficacy in Computed Tomography of Head and Body|Completed||Phase 3|435|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:23:14.018475|2018-06-01 04:23:14.018475
NCT00244127|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2005-10-26|2005-10-24|2005-10-25|Estimate|||||||2005-10-26|2005-10-28|Estimate|October 2002||2002-10-31|October 2005|2005-10-31||||||||Interventional|||Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.|Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.|Unknown status|Active, not recruiting|Phase 2|75||Zeneus Pharma|||||f||||||||||||||2018-06-01 04:23:14.375575|2018-06-01 04:23:14.375575
NCT00244114|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2013-02-14|2005-10-24|2005-10-25|Estimate|||||||2013-02-14|2013-02-18|Estimate|February 2006||2006-02-28|February 2013|2013-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients|In Vitro Evaluation Of Allergic Reactions In Hemophilia B Subjects Who Have Exhibited A Systemic Allergic Response After Exposure To BeneFIX (Nonacog Alfa; Recombinant Factor IX)|Completed|||20|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||2||f||||f||||||||||2018-06-01 04:23:14.43302|2018-06-01 04:23:14.43302
NCT00244101|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|2012-08-16||2012-08-16|2005-10-24|2005-10-25|Estimate|2012-08-16|2012-09-14|Estimate||||2012-08-16|2012-09-14|Estimate|August 2003||2003-08-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2009|Actual|2009-06-30||Interventional|||Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome|Delivery Room Management of Premature Infants at High Risk of Respiratory Distress Syndrome|Completed||Phase 3|648|Actual|Vermont Oxford Network||3|||f||||t||||||||||2018-06-01 04:23:14.510263|2018-06-01 04:23:14.510263
NCT00244088|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2009-08-31|2005-10-21|2005-10-25|Estimate|||||||2009-08-31|2009-09-01|Estimate|April 2004||2004-04-30|August 2009|2009-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||Study Evaluating the Etiology of Intra-Abdominal Infections|Study of the Etiology of Intra-Abdominal Infections|Completed|||340||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||Samples Without DNA|"~     Intra-abdominal fluid~   "|||2018-06-01 04:23:14.93285|2018-06-01 04:23:14.93285
NCT00244075|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2015-05-22|2005-10-21|2005-10-25|Estimate|||||||2015-05-22|2015-05-25|Estimate|July 1998||1998-07-31|May 2015|2015-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients|Effects of Nutritional Supplementation on Protein and Energy Homeostasis in Malnourished Chronic Hemodialysis Patients|Completed||Phase 2|46|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:23:14.986189|2018-06-01 04:23:14.986189
NCT00244062|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2015-10-01|2005-10-21|2005-10-25|Estimate|||||||2015-10-01|2015-10-05|Estimate|April 2001||2001-04-30|April 2011|2011-04-30|June 2007|Actual|2007-06-30|||||Interventional|||Healthy Moms Alcohol Intervention|"Brief Alcohol Intervention: The Healthy Moms Project."|Completed||N/A|250||University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:23:15.090493|2018-06-01 04:23:15.090493
NCT00244049|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2014-12-05|2005-10-21|2005-10-25|Estimate|||||||2014-12-05|2014-12-08|Estimate|May 2004||2004-05-31|December 2014|2014-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||CHIPs or College Health Intervention Projects|"Primary Care Alcohol Intervention in College Students"|Completed||Phase 3|1000|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 04:23:15.14981|2018-06-01 04:23:15.14981
NCT00241293|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2005-10-14|2005-10-14|2005-10-18|Estimate|||||||2005-10-14|2005-10-18|Estimate||||July 2005|2005-07-31||||||||Observational|||Influence of Age on Hemispheric Lateralization of Language : a Longitudinal Study||Completed|||||University Hospital, Tours|||||f||||||||||||||2018-06-01 04:23:58.268608|2018-06-01 04:23:58.268608
NCT00244023|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-23|||2008-08-22|2005-10-23|2005-10-25|Estimate|||||||2008-08-22|2008-08-25|Estimate|October 2005||2005-10-31|August 2008|2008-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone|Double-Blind, Placebo Controlled Randomized Study of Co-Administering Testosterone With PDE5 Inhibitors in Patients Non-Responders to PDE5 Inhibitors Alone|Completed||Phase 3|173|Actual|SELARL du Dr Jacques BUVAT||2|||f||||t||||||||||2018-06-01 04:23:15.222456|2018-06-01 04:23:15.222456
NCT00244010|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|2012-02-02||2017-04-24|2005-10-24|2005-10-25|Estimate|2012-05-01|2012-05-02|Estimate||||2017-04-24|2017-05-30|Actual|October 2005||2005-10-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias|Hematopoietic Stem Cell Transplantation (HSCT) From Partially Matched Family Donors for Patients With Refractory Severe Aplastic Anemia or Refractory Cytopenias: A Pilot Study|Completed||N/A|4|Actual|St. Jude Children's Research Hospital|This study has terminated due to the PI leaving the institution. An insufficient number of subjects were enrolled to answer the primary objective.|1|||f||||f||||||||||2018-06-01 04:23:15.339025|2018-06-01 04:23:15.339025
NCT00243997|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2008-10-13|2005-10-21|2005-10-25|Estimate|||||||2008-10-13|2008-10-15|Estimate|February 2002||2002-02-28|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Evaluation of the Efficacy of the Becoming Parents Program|Study of the Effects of the Becoming Parents Program on Couples Becoming Parents for the First Time|Completed||N/A|940|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:23:15.584046|2018-06-01 04:23:15.584046
NCT00243984|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2007-12-07|2005-10-21|2005-10-25|Estimate|||||||2007-12-07|2007-12-10|Estimate|March 2005||2005-03-31|December 2007|2007-12-31|November 2007|Anticipated|2007-11-30|||||Interventional|||Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome|Suspended||Phase 3|90|Anticipated|Northeastern Ohio Universities College of Medicine||||Study was discontinued because of high drop out rate.|f||||||||||||||2018-06-01 04:23:15.654446|2018-06-01 04:23:15.654446
NCT00243971|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2014-09-24|2005-10-24|2005-10-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2004||2004-11-30|September 2009|2009-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease|A Phase 3, Randomized, Open-Label, Two-Arm, Parallel-Group, Multicenter, Multinational Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease|Completed||Phase 3|||UCB Pharma|||||f||||||||||||||2018-06-01 04:23:15.743698|2018-06-01 04:23:15.743698
NCT00243958|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-23|||2005-10-23|2005-10-23|2005-10-25|Estimate|||||||2005-10-23|2005-10-25|Estimate|October 2005||2005-10-31|October 2005|2005-10-31||||||||Observational|||Aluminum and Auditory Function in ESRD||Unknown status|Recruiting||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:23:15.805073|2018-06-01 04:23:15.805073
NCT00243945|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2014-09-24|2005-10-24|2005-10-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|December 2004||2004-12-31|September 2009|2009-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease|A Phase 3b, Open-Label, Multicenter, Multinational Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders in Patients With Idiopathic Parkinson's Disease|Completed||Phase 3|58|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:23:15.873421|2018-06-01 04:23:15.873421
NCT00243932|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|2010-03-29||2014-01-28|2005-10-24|2005-10-25|Estimate|2011-02-22|2011-03-17|Estimate||||2014-01-28|2014-02-28|Estimate|April 2005||2005-04-30|February 2013|2013-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Clinical Trial of High Dose CoQ10 in ALS|Clinical Trial of High Dose CoQ10 in ALS|Completed||Phase 2|185|Actual|Columbia University||3|||f||||t||||||||||2018-06-01 04:23:15.963818|2018-06-01 04:23:15.963818
NCT00243919|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|2011-03-29||2014-07-09|2005-10-24|2005-10-25|Estimate|2011-09-08|2011-09-22|Estimate||||2014-07-09|2014-07-16|Estimate|April 2006||2006-04-30|December 2012|2012-12-31|June 2012|Actual|2012-06-30|April 2010|Actual|2010-04-30||Interventional|LEAPS||Locomotor Experience Applied Post Stroke Trial|Locomotor Experience Applied Post Stroke (LEAPS) Trial|Completed||Phase 3|408|Actual|Duke University||3|||f||||||||||||||2018-06-01 04:23:16.371734|2018-06-01 04:23:16.371734
NCT00243906|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24||2012-07-18|2012-07-18|2005-10-24|2005-10-25|Estimate||||2012-07-18|2012-07-25|Estimate|2012-07-18|2012-07-25|Estimate|January 2003||2003-01-31|July 2012|2012-07-31|May 2007|Actual|2007-05-31|May 2006|Actual|2006-05-31||Interventional|||Interventional Management of Stroke (IMS) II Study|Interventional Management of Stroke (IMS) II Study|Completed||Phase 2|81|Actual|University of Cincinnati|||||f||||t||||||||||2018-06-01 04:23:17.558771|2018-06-01 04:23:17.558771
NCT00243893|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2013-10-08|2005-10-24|2005-10-25|Estimate|||||||2013-10-08|2013-10-09|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms|Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms|Completed||Phase 1|26|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:23:17.646211|2018-06-01 04:23:17.646211
NCT00243880|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2016-05-05|2005-10-24|2005-10-25|Estimate|||||||2016-05-05|2016-05-09|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|Neu-START||Neuroprotection With Statin Therapy for Acute Recovery Trial (Neu-START)|SPOTRIAS: Neuroprotection With Statin Therapy for Acute Recovery Trial|Completed||Phase 1|33|Actual|Columbia University||1|||f||||t||||||||Undecided||2018-06-01 04:23:17.744869|2018-06-01 04:23:17.744869
NCT00243867|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21||2017-07-27|2018-01-22|2005-10-21|2005-10-25|Estimate||||2018-01-22|2018-01-26|Actual|2018-01-22|2018-01-26|Actual|November 2005|Actual|2005-11-30|January 2018|2018-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer|A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|519|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||No||2018-06-01 04:23:17.836165|2018-06-01 04:23:17.836165
NCT00243854|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2014-03-17|2005-10-24|2005-10-25|Estimate|||||||2014-03-17|2014-03-18|Estimate|November 2005||2005-11-30|March 2014|2014-03-31|October 2011|Actual|2011-10-31|August 2010|Actual|2010-08-31||Interventional|||Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer|Pilot Study Using Neoadjuvant Chemo-Radiotherapy and EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer|Completed||Phase 1|8|Actual|Indiana University|||||f||||t||||||||||2018-06-01 04:23:17.926402|2018-06-01 04:23:17.926402
NCT00243841|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2017-03-20|2005-10-21|2005-10-25|Estimate|||||||2017-03-20|2017-03-22|Actual|May 2004||2004-05-31|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|SBF-HCC||Dose Escalation Study for Primary Hepatocellular Carcinoma|Multi-institution Phase I/II Dose Escalation Study of Hypofractionated Stereotactic Body Radiation Therapy for Primary Hepatocellular Carcinoma|Completed||N/A|72|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 04:23:17.999522|2018-06-01 04:23:17.999522
NCT00243828|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2015-09-14|2005-10-24|2005-10-25|Estimate|||||||2015-09-14|2015-09-15|Estimate|November 2005||2005-11-30|March 2007|2007-03-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure|Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure: a Randomized Controlled Trial.|Terminated||Phase 4|300||Corporacion Parc Tauli||||Very low rate of recruitment anticipated futility of pursuing the study|f||||f||||||||||2018-06-01 04:23:18.078804|2018-06-01 04:23:18.078804
NCT00243815|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2006-10-16|2005-10-24|2005-10-25|Estimate|||||||2006-10-16|2006-10-17|Estimate|June 2002||2002-06-30|October 2005|2005-10-31|November 2004||2004-11-30|||||Interventional|||Use of Ibuprofen to Prevent IUD Site Effects|Prophylactic Ibuprofen: Effect on IUD Continuation Rates|Completed||Phase 3|2019||FHI 360|||||f||||||||||||||2018-06-01 04:23:18.136389|2018-06-01 04:23:18.136389
NCT00243802|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2013-09-26|2005-10-24|2005-10-25|Estimate|||||||2013-09-26|2013-09-27|Estimate|May 2005||2005-05-31|September 2013|2013-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Markers of Oxidative Stress Present in Left Atrial Appendage Tissue in Patients With Atrial Fibrillation|Comparison of Markers of Oxidative Stress Present in Left Atrial Appendage Tissue From Subjects With and Without Atrial Fibrillation|Terminated|||23|Actual|Emory University||||Terminated.|f||||f||||||||||2018-06-01 04:23:18.195522|2018-06-01 04:23:18.195522
NCT00243789|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2011-10-26|2005-10-21|2005-10-25|Estimate|||||||2011-10-26|2011-10-27|Estimate|September 2005||2005-09-30|October 2011|2011-10-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy|A Double-Blinded Randomized Placebo Controlled Study of Daily Pentoxifylline as a Rescue Treatment in DMD|Completed||Phase 1/Phase 2|64|Actual|Cooperative International Neuromuscular Research Group||2|||f||||t||||||||||2018-06-01 04:23:18.261573|2018-06-01 04:23:18.261573
NCT00243776|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2017-08-15|2005-10-24|2005-10-25|Estimate|||||||2017-08-15|2017-08-17|Actual|April 2005||2005-04-30|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Calcium Current in Human Heart Cells|Calcium Current in Human Atrial Myocytes|Recruiting|||600|Anticipated|Emory University|||||f||||f||||||Samples Without DNA|"~     tissue obtained from surgical waste tissue~   "|||2018-06-01 04:23:18.346027|2018-06-01 04:23:18.346027
NCT00243763|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2009-11-20|2005-10-21|2005-10-25|Estimate|||||||2009-11-20|2009-11-23|Estimate||||November 2009|2009-11-30||||||||Interventional|||TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma|Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma|Terminated||Phase 1|64|Anticipated|Novartis|||||||||||||||||||2018-06-01 04:23:18.405682|2018-06-01 04:23:18.405682
NCT00243750|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2005-12-08|2005-10-24|2005-10-25|Estimate|||||||2005-12-08|2005-12-09|Estimate|September 2003||2003-09-30|August 2003|2003-08-31|November 2005||2005-11-30|||||Interventional|||Methotrexate in Ankylosing Spondylitis (MTX in AS)|Open Study for the Evaluation of the Efficacy of Methotrexate 20mg Given Subcutaneously in Patients With Active Ankylosing Spondylitis|Unknown status|Active, not recruiting|Phase 2|20||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:23:18.460958|2018-06-01 04:23:18.460958
NCT00243737|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2013-01-23|2005-10-24|2005-10-25|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|April 2006||2006-04-30|||||Interventional|||Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria|Open-label, Stratified Study on the Efficacy, Safety and Pharmacokinetic Characteristics of Two Paediatric Formulations of ArtequinTM in Children With Acute Uncomplicated P. Falciparum Malaria|Completed||Phase 2|70||Albert Schweitzer Hospital|||||f||||||||||||||2018-06-01 04:23:18.510498|2018-06-01 04:23:18.510498
NCT00243724|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-24|||2009-03-25|2005-10-24|2005-10-25|Estimate|||||||2009-03-25|2009-03-26|Estimate|April 2005||2005-04-30|March 2009|2009-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease|An Open-Label, Parallel-Group, Multi-Centre Study to Determine the Effect of Treatment With Esomeprazole for Six Months on Histological Markers of Esophageal Epithelial Acid-Related Disease in Patients With Upper GI Symptoms.|Completed||Phase 3|350|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:23:18.571197|2018-06-01 04:23:18.571197
NCT00243711|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2011-05-27|2005-10-21|2005-10-25|Estimate|||||||2011-05-27|2011-05-30|Estimate|September 2005||2005-09-30|May 2011|2011-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop||Completed||Phase 2/Phase 3|286|Actual|Allergan|||||f||||||||||||||2018-06-01 04:23:18.633441|2018-06-01 04:23:18.633441
NCT00243698|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2007-11-21|2005-10-21|2005-10-24|Estimate|||||||2007-11-21|2007-11-22|Estimate|May 2004||2004-05-31|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions|A Pilot Study Evaluation of the Efficacy of SonoVue to Detect and Characterise Breast Lesions|Completed||N/A|59|Actual|University Hospital, Tours|||||f||||f||||||||||2018-06-01 04:23:18.694065|2018-06-01 04:23:18.694065
NCT00243685|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2012-01-25|2005-10-21|2005-10-24|Estimate|||||||2012-01-25|2012-01-26|Estimate|September 2006||2006-09-30|January 2012|2012-01-31|May 2009|Actual|2009-05-31|||||Interventional|||Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis|Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Drug Testing Sensitivity of Solid Tumors|Completed||Phase 2/Phase 3|150|Anticipated|Pierian Biosciences||1|||f||||f||||||||||2018-06-01 04:23:18.750799|2018-06-01 04:23:18.750799
NCT00243672|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2007-11-16|2005-10-21|2005-10-24|Estimate|||||||2007-11-16|2007-11-19|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|October 2007||2007-10-31|||||Interventional|||Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques|Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques: a Randomised Microarray-Study on Endarterectomy Specimens of Human Carotid Arteries|Withdrawn||Phase 4|100|Anticipated|University Hospital Muenster||||The study chair changed his employment, the realization of the study was not possible|f||||||||||||||2018-06-01 04:23:18.869473|2018-06-01 04:23:18.869473
NCT00243659|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|2009-05-29||2011-06-02|2005-10-20|2005-10-24|Estimate|2009-05-29|2009-07-20|Estimate||||2011-06-02|2011-06-03|Estimate|April 2006||2006-04-30|June 2011|2011-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery|An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery|Completed||Phase 3|30|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 04:23:18.988593|2018-06-01 04:23:18.988593
NCT00243646|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2016-04-12|2005-10-20|2005-10-24|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2004||2004-08-31|April 2016|2016-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial|Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial|Terminated||Phase 3|6|Actual|Schiffler Cancer Center||2||poor accrual|f||||t||||||||||2018-06-01 04:23:19.291448|2018-06-01 04:23:19.291448
NCT00243633|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2008-03-18|2005-10-21|2005-10-24|Estimate|||||||2008-03-18|2008-03-20|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|August 2007|Actual|2007-08-31|December 2006|Actual|2006-12-31||Interventional|||Characterization of Focal Liver Lesions by Real-Time Contrast-Enhanced Ultrasound Imaging (CEUS)|Characterization of Focal Liver Lesions by Real-Time Contrast-Enhanced Ultrasound Imaging (CEUS)|Completed||N/A|878|Actual|University Hospital, Tours|||||f||||f||||||||||2018-06-01 04:23:19.391921|2018-06-01 04:23:19.391921
NCT00243620|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2017-01-12|2005-10-21|2005-10-24|Estimate|||||||2017-01-12|2017-01-13|Estimate|May 2001||2001-05-31|May 2001|2001-05-31|May 2004||2004-05-31|||||Interventional|||A Randomised Controlled Trial Comparing Vacuum Assisted Closure (V.A.C.®) With Modern Wound Dressings|State-of-the Art Treatment of Chronic Leg Ulcers: a Randomised Controlled Trial Comparing Vacuum Assisted Closure (V.A.C.®) With Modern Wound Dressings|Completed||N/A|60||Maastricht University Medical Center|||||f||||||||||||||2018-06-01 04:23:19.489729|2018-06-01 04:23:19.489729
NCT00243607|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2017-05-03|2005-10-21|2005-10-24|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2006||2006-05-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Hydrotherapy Against Menopausal Symptoms in Breast Cancer Survivors|Prospective Randomized Feasibility Study on the Self Application of Hydrotherapy to Treat Menopausal Symptoms Caused by Breast Cancer Therapy|Completed||N/A|45|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 04:23:19.569377|2018-06-01 04:23:19.569377
NCT00243594|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2009-02-18|2005-10-21|2005-10-24|Estimate|||||||2009-02-18|2009-02-19|Estimate|September 1999||1999-09-30|February 2009|2009-02-28||||January 2009|Actual|2009-01-31||Interventional|||Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection|Active Immunization of Patients With Stage III and IV Melanoma in Whom a Regional Lymph Node Dissection is Planned, With Peptide-Pulsed Dendritic Cells: Evaluation of in Vivo Immune and Clinical Response and Migration|Completed||Phase 1/Phase 2|40|Anticipated|Radboud University|||||f||||f||||||||||2018-06-01 04:23:19.648346|2018-06-01 04:23:19.648346
NCT00243581|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2005-10-28|2005-10-21|2005-10-24|Estimate|||||||2005-10-28|2005-10-31|Estimate|August 2000||2000-08-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||The Effects of an Intensive Lifestyle Modification Program on Carotid Artery Intima-Media Thickness|The Effects of an Intensive Lifestyle Modification Program on Carotid Artery Intima-Media Thickness|Completed||Phase 4|||SwedishAmerican Health System|||||f||||||||||||||2018-06-01 04:23:19.720334|2018-06-01 04:23:19.720334
NCT00243568|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20||2009-06-09|2009-10-21|2005-10-20|2005-10-24|Estimate||||2009-10-21|2009-10-23|Estimate|2009-10-21|2009-10-23|Estimate|September 2005||2005-09-30|October 2009|2009-10-31||||||||Interventional|||Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285)(TERMINATED)|Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E2)|Terminated||Phase 3|500||Schering-Plough|||||f||||||||||||||2018-06-01 04:23:19.766059|2018-06-01 04:23:19.766059
NCT00243555|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2007-01-31|2005-10-20|2005-10-24|Estimate|||||||2007-01-31|2007-02-01|Estimate|September 2002||2002-09-30|September 2006|2006-09-30||||||||Observational|||Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut|Molecular Analysis of Immuno-Regulatory Genes Expressed by Mononuclear Cells From Peanut Skin Test Positive Individuals With and Without a History of Peanut Ingestion|Unknown status|Recruiting||60||McMaster University|||||f||||||||||||||2018-06-01 04:23:19.818609|2018-06-01 04:23:19.818609
NCT00243542|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2011-05-27|2005-10-21|2005-10-24|Estimate|||||||2011-05-27|2011-05-30|Estimate|November 2005||2005-11-30|May 2011|2011-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency|ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%.|Completed||Phase 4|64|Actual|Allergan|||||||||||||||||||2018-06-01 04:23:19.910597|2018-06-01 04:23:19.910597
NCT00243529|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2009-09-28|2005-10-21|2005-10-24|Estimate|||||||2009-09-28|2009-09-29|Estimate|April 2004||2004-04-30|February 2009|2009-02-28||||February 2009|Actual|2009-02-28||Interventional|||Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients|In Vivo Responses of DC Vaccines Presenting HLA Class I and II Restricted Tumor Epitopes Either by Peptide-pulsing or mRNA Transfection in Melanoma Patients|Completed||Phase 1/Phase 2|64|Actual|Radboud University||3|||f||||f||||||||||2018-06-01 04:23:20.022837|2018-06-01 04:23:20.022837
NCT00243516|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2007-11-08|2005-10-21|2005-10-24|Estimate|||||||2007-11-08|2007-11-09|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|October 2007||2007-10-31|||||Interventional|||Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain|Randomized, Controlled Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain|Unknown status|Recruiting|Phase 3|400|Anticipated|PREtest Consult|||||f||||||||||||||2018-06-01 04:23:20.130756|2018-06-01 04:23:20.130756
NCT00243503|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|2010-04-20||2011-07-20|2005-10-20|2005-10-24|Estimate|2010-04-20|2010-05-19|Estimate||||2011-07-20|2011-07-22|Estimate|February 2006||2006-02-28|July 2011|2011-07-31|July 2010|Actual|2010-07-31|April 2009|Actual|2009-04-30||Interventional|||Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer|A Phase 2 Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer|Completed||Phase 2|60|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:23:20.266948|2018-06-01 04:23:20.266948
NCT00243490|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2010-01-11|2005-10-20|2005-10-24|Estimate|||||||2010-01-11|2010-01-12|Estimate||||January 2010|2010-01-31|January 2009||2009-01-31|||||Interventional|||Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors|Prospective, Open-labeled, Clinical Trial in Compassionate Use to Evaluate the Efficacy and Safety of Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors|Withdrawn||Phase 2|5|Anticipated|National Taiwan University Hospital||||"The Trial could not get permit from Department of Health, Taiwan; Furthermore, no research fund~   could support the expensive (photosensitizer) photosan"|f||||||||||||||2018-06-01 04:23:20.749835|2018-06-01 04:23:20.749835
NCT00243477|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2012-03-16|2005-10-20|2005-10-24|Estimate|||||||2012-03-16|2012-03-19|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||MOTIV Study- Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting|MOTIV Study. Effect of Antidepressive Treatment by Escitalopram Started Preoperatively in Patients Undergoing Coronary Artery Bypass Grafting|Completed||Phase 4|368|Actual|Hopital Jean Minjoz||2|||f||||t||||||||||2018-06-01 04:23:20.811434|2018-06-01 04:23:20.811434
NCT00243464|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2015-03-25|2005-10-21|2005-10-24|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|May 2006||2006-05-31|||||Interventional|||Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients With Scalp Psoriasis|Completed||Phase 3|300||LEO Pharma|||||f||||||||||||||2018-06-01 04:23:20.880746|2018-06-01 04:23:20.880746
NCT00243451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-09-02|2005-10-20|2005-10-24|Estimate|||||||2011-09-02|2011-09-07|Estimate|September 2003||2003-09-30|September 2011|2011-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Early Detection of Mild Cognitive Impairment in Individual Patients|Early Detection of Mild Cognitive Impairment in Individual Patients|Completed|||34|Anticipated|Louisiana State University Health Sciences Center Shreveport|||||f||||f||||||||||2018-06-01 04:23:20.937199|2018-06-01 04:23:20.937199
NCT00243438|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2009-01-27|2005-10-21|2005-10-24|Estimate|||||||2009-01-27|2009-01-28|Estimate|July 2003||2003-07-31|January 2009|2009-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Observational|||DaVinci Registry(Distinctly Assess Vision in Coronary Intervention)|Distinctly Access Vision In Coronary Interventions|Completed|||1300||Abbott Vascular|||1||f||||t||||||||||2018-06-01 04:23:21.062966|2018-06-01 04:23:21.062966
NCT00243425|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2005-10-21|2005-10-21|2005-10-24|Estimate|||||||2005-10-21|2005-10-24|Estimate|March 2004||2004-03-31|October 2005|2005-10-31|March 2007||2007-03-31|||||Interventional|||Patient-Centered Depression Care for African Americans|Patient-Centered Depression Care for African Americans|Unknown status|Recruiting|N/A|250||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:23:21.156694|2018-06-01 04:23:21.156694
NCT00243412|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|2011-03-24||2011-09-06|2005-10-21|2005-10-24|Estimate|2011-09-06|2011-10-07|Estimate||||2011-09-06|2011-10-07|Estimate|August 2005||2005-08-31|September 2011|2011-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|RUMBA||A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate|A Double-Blind, Randomized, Multicenter, Phase II Study of the Safety and Efficacy of Two Rituximab Regimens in Subjects With Moderate to Severe Active Rheumatoid Arthritis Receiving Stable Doses of Methotrexate|Completed||Phase 2|42|Actual|Genentech, Inc.|Because of the limited sample size, interpretation of these results should be made with caution and therefore definitive conclusions cannot be made regarding differences between the two retreatment regimens studied.|2|||f||||||||||||||2018-06-01 04:23:21.325205|2018-06-01 04:23:21.325205
NCT00243399|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2011-07-14|2005-10-20|2005-10-24|Estimate|||||||2011-07-14|2011-07-15|Estimate|July 2004||2004-07-31|July 2011|2011-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia|A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia|Completed||Phase 1|10|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 04:23:21.871055|2018-06-01 04:23:21.871055
NCT00243386|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|2012-03-14|2011-06-27|2017-10-18|2005-10-21|2005-10-24|Estimate|2012-10-19|2012-11-20|Estimate|2011-06-27|2011-06-29|Estimate|2017-10-18|2017-11-20|Actual|January 2006||2006-01-31|October 2012|2012-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A|Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A|Completed||Phase 4|82|Actual|Shire||2|||f||||t||||||||||2018-06-01 04:23:22.018723|2018-06-01 04:23:22.018723
NCT00243373|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2012-01-18|2005-10-21|2005-10-24|Estimate|||||||2012-01-18|2012-01-19|Estimate|April 2005||2005-04-30|January 2012|2012-01-31|March 2008|Actual|2008-03-31|December 2005|Actual|2005-12-31||Interventional|||Using Barcode Technology to Improve Medication Safety|Using Barcode Technology to Improve Medication Safety|Completed||N/A|6700|Anticipated|Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:23:22.912861|2018-06-01 04:23:22.912861
NCT00243360|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2005-10-21|2005-10-21|2005-10-24|Estimate|||||||2005-10-21|2005-10-24|Estimate|January 2001||2001-01-31|October 2005|2005-10-31|July 2003||2003-07-31|||||Interventional|||Optimizing Antibiotic Use in Long Term Care|Optimizing Antibiotic Use in Long Term Care|Completed||N/A|||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:23:23.008646|2018-06-01 04:23:23.008646
NCT00243347|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|2013-03-22||2013-08-09|2005-10-21|2005-10-24|Estimate|2013-08-09|2013-10-17|Estimate||||2013-08-09|2013-10-17|Estimate|December 2005||2005-12-31|August 2013|2013-08-31|July 2009|Actual|2009-07-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer|An Exploratory, Open-Lael Study to Assess the Effects of AZD2171 on Tumors and Biomarkers in Patients With Previously Untreated or Recurrent Non-small Cell Lung Cancer (NSCLC) or Patients With Metastatic or Recurrent Head and Neck Cancer (HNC)|Completed||Phase 1|19|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:23:23.097326|2018-06-01 04:23:23.097326
NCT00243334|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-21|||2013-02-14|2005-10-21|2005-10-24|Estimate|||||||2013-02-14|2013-02-18|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|December 2009|Actual|2009-12-31||Interventional|||Improving Safety and Quality With Outpatient Order Entry|Improving Safety and Quality With Outpatient Order Entry|Unknown status|Active, not recruiting|N/A|800|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 04:23:23.329111|2018-06-01 04:23:23.329111
NCT00243321|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2017-07-10|2005-10-19|2005-10-21|Estimate|||||||2017-07-10|2017-07-13|Actual|February 2003||2003-02-28|July 2017|2017-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer|Phase I Examination of Combination High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Therapy for the Comprehensive Local Treatment of Patients With Locally Confined Adenocarcinoma of the Prostate|Completed||N/A|27|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-06-01 04:23:23.39088|2018-06-01 04:23:23.39088
NCT00243308|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2009-02-05|2005-10-19|2005-10-21|Estimate|||||||2009-02-05|2009-02-06|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Serp-1 for the Treatment of Acute Coronary Syndrome|A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)|Terminated||Phase 2|72|Anticipated|Viron Therapeutics Inc||||Third dose group not recruited due to slow enrollment.|||||||||||||||2018-06-01 04:23:23.458531|2018-06-01 04:23:23.458531
NCT00243295|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2006-10-05|2005-10-19|2005-10-21|Estimate|||||||2006-10-05|2006-10-06|Estimate|November 2003||2003-11-30|October 2006|2006-10-31|March 2005||2005-03-31|||||Interventional|||Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies|A Pilot Study to Validate the Feasibility of Injecting and Monitoring Recombinant Human Bone Morphogenetic Protein-2/Calcium Phosphate Matrix (rhBMP-2/CPM) in Subjects With Open Wedge Osteotomies|Completed||Phase 1|6||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:23:23.521184|2018-06-01 04:23:23.521184
NCT00243282|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2009-01-20|2005-10-19|2005-10-21|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|October 2006||2006-10-31|||||Interventional|||Randomized Controlled Trial of Mind-Body Breathing Therapy (in Chronic Obstructive Pulmonary Disease) To Improve Palliation of Dyspnea and Health-Related Quality of Life|Randomized Controlled Trial of Mind-Body Breathing Therapy (in Chronic Obstructive Pulmonary Disease) To Improve Palliation of Dyspnea and Health-Related Quality of Life|Completed||N/A|120||VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:23:23.567443|2018-06-01 04:23:23.567443
NCT00243269|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2010-03-22||2015-05-21|2005-10-20|2005-10-21|Estimate|2010-12-20|2011-01-21|Estimate||||2015-05-21|2015-06-18|Estimate|November 2005||2005-11-30|March 2010|2010-03-31|January 2010|Actual|2010-01-31|May 2009|Actual|2009-05-31||Interventional|||Acupressure and Relaxation for Nausea Control|Acupressure and Relaxation for Nausea Control|Completed||Phase 1/Phase 2|83|Actual|University of Rochester|Limitations include a small sample size and the fact that we ceased recruitment to two of the treatment arms and changed our planned primary analysis mid-study based upon an interim analysis that was not specified at the time the study began.|4|||f||||t||||||||||2018-06-01 04:23:23.631571|2018-06-01 04:23:23.631571
NCT00243256|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2008-05-08|2005-10-20|2005-10-21|Estimate|||||||2008-05-08|2008-05-14|Estimate|November 2005||2005-11-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Treatment of Obesity With Vitamin D (40.000 IE Per Week for 1 Year)||Completed||Phase 2|450|Anticipated|University of Tromso|||||f||||||||||||||2018-06-01 04:23:25.012839|2018-06-01 04:23:25.012839
NCT00243243|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2012-08-28||2016-04-26|2005-10-19|2005-10-21|Estimate|2013-01-29|2013-03-06|Estimate||||2016-04-26|2016-05-26|Estimate|January 2006||2006-01-31|April 2016|2016-04-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn|Effect of Recombinant Coagulation Factor VIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn Excision and Grafting|Completed||Phase 3|20|Actual|United States Army Institute of Surgical Research||2|||f||||f||||||||No||2018-06-01 04:23:25.089848|2018-06-01 04:23:25.089848
NCT00243230|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2015-09-24|2005-10-20|2005-10-21|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2005||2005-09-30|September 2015|2015-09-30|March 2011|Actual|2011-03-31|October 2007|Actual|2007-10-31||Interventional|||Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1) (Study P03672AM6)|Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1)|Completed||Phase 2|120|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:23:25.334272|2018-06-01 04:23:25.334272
NCT00243217|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2014-09-24|2005-10-20|2005-10-21|Estimate|||||||2014-09-24|2014-09-25|Estimate|April 2003||2003-04-30|September 2009|2009-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Rotigotine Restless Legs Syndrome Dose Finding Trial|Multi-center, Double-blind, Randomized, Placebo-controlled, Six-arm, Parallel-group, Dose-finding Trial to Determine Efficacy, Safety and Tolerability of Five Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome|Completed||Phase 2|341|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:23:25.40703|2018-06-01 04:23:25.40703
NCT00243204|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2007-06-07|2005-10-19|2005-10-21|Estimate|||||||2007-06-07|2007-06-08|Estimate|January 2006||2006-01-31|June 2007|2007-06-30||||||||Interventional|||Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy||Terminated||Phase 3|400|Anticipated|Point Therapeutics||||FDA Hold May 2007|||||||||||||||2018-06-01 04:23:25.48707|2018-06-01 04:23:25.48707
NCT00243191|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|2011-03-14||2012-02-14|2005-10-20|2005-10-21|Estimate|2012-02-14|2012-03-29|Estimate||||2012-02-14|2012-03-29|Estimate|May 2006||2006-05-31|February 2012|2012-02-29|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans|Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans|Completed||Phase 2|18|Actual|Sarcoma Alliance for Research through Collaboration|Dermatofibrosarcoma protuberans (DFSP)is a rare tumor type. During the the trial the drug manufacturer obtained approval for DSFP indication.The other limitation is limited funding; SARC is actively seeking funding for secondary outcome goal 12/2012.|1|||f||||t||||||||||2018-06-01 04:23:25.793967|2018-06-01 04:23:25.793967
NCT00243178|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2009-10-16|2005-10-20|2005-10-21|Estimate|||||||2009-10-16|2009-10-19|Estimate|July 2003||2003-07-31|October 2009|2009-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)|A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation|Terminated||Phase 3|6706|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:23:26.171958|2018-06-01 04:23:26.171958
NCT00243165|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2009-12-04|2005-10-20|2005-10-21|Estimate|||||||2009-12-04|2009-12-07|Estimate|November 2005||2005-11-30|October 2005|2005-10-31||||||||Interventional|||Lifemel Honey to Reduce Leucopenia During Chemotherapy|Lifemel Honey During Adjuvant Chemotherapy for Breast Cancer Patients to Prevent Leucopenia|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:23:26.324821|2018-06-01 04:23:26.324821
NCT00243152|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2012-11-29|2005-10-19|2005-10-21|Estimate|||||||2012-11-29|2012-11-30|Estimate|October 2005||2005-10-31|November 2012|2012-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI|Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI|Completed||N/A|6|Actual|Pain and Analgesia Imaging and Neuroscience Group||1|||f||||f||||||||||2018-06-01 04:23:26.407041|2018-06-01 04:23:26.407041
NCT00243139|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2006-09-14|2005-10-20|2005-10-21|Estimate|||||||2006-09-14|2006-09-15|Estimate|July 1999||1999-07-31|September 2006|2006-09-30|February 2004||2004-02-29|||||Interventional|||Mandibular Advancement Device for Obstructive Sleep Apnea|A Randomized Controlled Trial of a Mandibular Advancement Device for Obstructive Sleep Apnea|Completed||Phase 2/Phase 3|90||Nykøbing Falster County Hospital|||||f||||||||||||||2018-06-01 04:23:26.519083|2018-06-01 04:23:26.519083
NCT00243126|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2017-02-27|2005-10-19|2005-10-21|Estimate|||||||2017-02-27|2017-03-01|Actual|November 2005||2005-11-30|February 2016|2016-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Family-based HIV Prevention for Adolescent Girls|Family-based HIV Prevention for Adolescent Females|Completed||N/A|168|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 04:23:26.59739|2018-06-01 04:23:26.59739
NCT00243113|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2013-03-25|2005-10-20|2005-10-21|Estimate|||||||2013-03-25|2013-03-26|Estimate|June 2004||2004-06-30|March 2008|2008-03-31|November 2008|Actual|2008-11-30|March 2008|Actual|2008-03-31||Interventional|||Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx|Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:23:26.677815|2018-06-01 04:23:26.677815
NCT00243100|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2013-12-13|2005-10-20|2005-10-21|Estimate|||||||2013-12-13|2013-12-16|Estimate|November 2005||2005-11-30|December 2013|2013-12-31||||August 2011|Actual|2011-08-31||Interventional|||Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase 1 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Gemcitabine in Patients With Epithelial Tumors|Completed||Phase 1|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:23:26.78722|2018-06-01 04:23:26.78722
NCT00243087|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2013-10-31|2005-10-20|2005-10-21|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2005||2005-07-31|October 2013|2013-10-31||||August 2008|Actual|2008-08-31||Interventional|||Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)|An Open Phase I Single Dose Escalation Study of BI 2536 Administered Intravenously in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma|Completed||Phase 1|41|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:23:26.96833|2018-06-01 04:23:26.96833
NCT00243074|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|2012-10-30||2017-12-27|2005-10-20|2005-10-21|Estimate|2015-09-21|2015-10-21|Estimate||||2017-12-27|2018-01-23|Actual|November 2005||2005-11-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|April 2010|Actual|2010-04-30||Interventional||Only eligible patients who received protocol treatment are included in the analysis. Of the 54 patients enrolled, 6 were ineligible and 1 addtional patients refused protocol treatment.|S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery|A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma|Completed||Phase 2|54|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:23:27.128924|2018-06-01 04:23:27.128924
NCT00243061|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|2014-07-09||2015-06-01|2005-10-20|2005-10-21|Estimate|2015-06-01|2015-06-23|Estimate||||2015-06-01|2015-06-23|Estimate|January 2006||2006-01-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma|A Phase II Study of AZD2171 in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma|Completed||Phase 2|24|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:23:27.693394|2018-06-01 04:23:27.693394
NCT00243048|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2013-04-03|2005-10-20|2005-10-21|Estimate|||||||2013-04-03|2013-04-05|Estimate|May 2002||2002-05-31|April 2013|2013-04-30|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Interventional|||Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer|Phase II Randomized Study of Soy Isoflavones in Patients With Localized Prostate Cancer Treated With Radiation Therapy|Completed||Phase 2|70|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 04:23:27.9702|2018-06-01 04:23:27.9702
NCT00243035|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2013-10-07|2005-10-20|2005-10-21|Estimate|||||||2013-10-07|2013-10-08|Estimate|August 2005||2005-08-31|October 2013|2013-10-31||||February 2007|Actual|2007-02-28||Interventional|||Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma|A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade® (PS-341) in Patients With Relapsed Multiple Myeloma.|Terminated||Phase 1/Phase 2|64|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:23:28.051328|2018-06-01 04:23:28.051328
NCT00243022|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|2012-10-11||2013-06-21|2005-10-20|2005-10-21|Estimate|2013-06-21|2013-07-30|Estimate||||2013-06-21|2013-07-30|Estimate|September 2004||2004-09-30|June 2013|2013-06-30|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme|Phase II Randomized Evaluation of 5-Lipoxygenase Inhibition by Herbal Complementary and Alternative Medicine Approach Compared to Control as an Adjuvant Therapy in Newly Diagnosed and Recurrent High-grade Gliomas|Terminated||Phase 2|12|Actual|Case Comprehensive Cancer Center|Certain outcome analysis not done due to low patient accrual.|2||Slow accrual|f||||t||||||||||2018-06-01 04:23:28.159806|2018-06-01 04:23:28.159806
NCT00243009|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2012-05-24|2005-10-20|2005-10-21|Estimate|||||||2012-05-24|2012-05-28|Estimate|June 2005||2005-06-30|June 2010|2010-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery|Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma|Terminated||Phase 2|1|Actual|OHSU Knight Cancer Institute||||Due to a lack of a referal base, study was terminated.|f||||t||||||||||2018-06-01 04:23:28.598239|2018-06-01 04:23:28.598239
NCT00242996|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2017-09-27|2005-10-20|2005-10-21|Estimate|||||||2017-09-27|2017-09-28|Actual|March 2004||2004-03-31|September 2017|2017-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma|Phase II Trial of Rituximab and Autologous Stem Cell Transplantation for Refractory B Cell Large Cell Lymphoma|Completed||Phase 2|44|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:23:28.671748|2018-06-01 04:23:28.671748
NCT00242983|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2013-12-17|2005-10-20|2005-10-21|Estimate|||||||2013-12-17|2013-12-18|Estimate|April 2004||2004-04-30|December 2005|2005-12-31||||||||Observational|||Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer|"Assessment of Quality of Life (QOL) in Patients Registered With Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer (JMTO LC00-03)"|Unknown status|Active, not recruiting||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:23:28.742045|2018-06-01 04:23:28.742045
NCT00242970|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2015-03-31|2005-10-20|2005-10-21|Estimate|||||||2015-03-31|2015-04-03|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Hypertrophic Scarring After Facial Burn|Hypertrophic Scarring After Facial Burn: A Pilot, Observational Study of Static and Dynamic Measurements of Facial Scars With the 3-D Scanner Through the Scar Maturation Process|Completed|||15|Actual|Legacy Health System|||||f||||f||||||||||2018-06-01 04:23:28.924113|2018-06-01 04:23:28.924113
NCT00242957|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2009-02-05|2005-10-20|2005-10-21|Estimate|||||||2009-02-05|2009-02-09|Estimate|June 2001||2001-06-30|December 2008|2008-12-31|April 2005||2005-04-30|||||Interventional|||The Intervention With Microfinance for AIDS and Gender Equity (IMAGE) Study||Completed||N/A|||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:23:29.172513|2018-06-01 04:23:29.172513
NCT00242944|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2009-12-16|2005-10-20|2005-10-21|Estimate|||||||2009-12-16|2009-12-17|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)|Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome|Completed||Phase 4|307|Actual|Kyoto University||2|||f||||t||||||||||2018-06-01 04:23:29.303732|2018-06-01 04:23:29.303732
NCT00240747|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2012-05-24|2005-10-14|2005-10-18|Estimate|||||||2012-05-24|2012-05-25|Estimate|June 2000||2000-06-30|May 2012|2012-05-31|January 2005||2005-01-31|||||Interventional|||Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients||Terminated||Phase 3|||Pfizer|||||||||||||||||||2018-06-01 04:24:03.546345|2018-06-01 04:24:03.546345
NCT00242931|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2012-05-31|2005-10-20|2005-10-21|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2005||2005-01-31|September 2010|2010-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy|Pilot Trial of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Hormone-Refractory Prostate Cancer|Withdrawn||Phase 2|0|Actual|OHSU Knight Cancer Institute||1||Unable to successfully recruit subjects to this study.|f||||t||||||||||2018-06-01 04:23:29.429979|2018-06-01 04:23:29.429979
NCT00242918|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2012-02-03|2005-10-20|2005-10-21|Estimate|||||||2012-02-03|2012-02-07|Estimate|May 2003||2003-05-31|June 2006|2006-06-30|November 2007|Actual|2007-11-30|||||Interventional|||Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer|Phase II Trial of Neoadjuvant Docetaxel and ZD 1839 (Iressa) Followed by Radical Prostatectomy in Patients With High Risk, Locally Advanced Prostate Cancer|Completed||Phase 2|29||Benaroya Research Institute|||||||||||||||||||2018-06-01 04:23:29.536428|2018-06-01 04:23:29.536428
NCT00242905|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2011-04-29|2005-10-20|2005-10-21|Estimate|||||||2011-04-29|2011-05-02|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Functional Magnetic Resonance Imaging (fMRI) Study of Memory in Children|Anatomical and Functional MRI Study of Episodic Memory in Epileptic Compared to Normal Children|Completed|||52|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:23:29.747447|2018-06-01 04:23:29.747447
NCT00242892|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2011-11-25|2005-10-20|2005-10-21|Estimate|||||||2011-11-25|2011-11-29|Estimate|November 2001||2001-11-30|March 2007|2007-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||FROST 4: Study of the Optimal Spreading of a Coronary Stent Guided With Pressure Into the Coronary Arteries|Prospective Study Randomized Multicentric On the Optimization Of the Installation Of Stent By Measurement Of the Intra-Coronary Pressure|Completed||N/A|800|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:23:29.875172|2018-06-01 04:23:29.875172
NCT00242879|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2017-05-25|2005-10-19|2005-10-21|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2005||2005-08-31|May 2017|2017-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults|Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen|Terminated||Phase 2|130|Actual|ViiV Healthcare|||||f||||||||||||||2018-06-01 04:23:29.98349|2018-06-01 04:23:29.98349
NCT00242866|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2016-05-05|2005-10-19|2005-10-21|Estimate|||||||2016-05-05|2016-05-09|Estimate|October 2005||2005-10-31|September 2015|2015-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Use Of GW274150 In The Prophylactic Treatment Of Migraine|A Multicentre, Two-part, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up to 120mg Daily for 12 Weeks in the Prophylactic Treatment of Migraine.|Completed||Phase 2|430|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:23:30.180541|2018-06-01 04:23:30.180541
NCT00242853|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2008-10-09|2005-10-19|2005-10-21|Estimate|||||||2008-10-09|2008-10-13|Estimate|October 2004||2004-10-31|October 2008|2008-10-31||||||||Observational|||A Study To Investigate Markers Of Inflammation In Rheumatoid Arthritis|An Enabling Study to Investigate the Correlation of Biomarkers of the Activity of Inducible Nitric Oxide Synthase (iNOS) With Disease Activity and Treatment Response in Patients With Rheumatoid Arthritis(RA)|Completed|||48||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:23:30.555348|2018-06-01 04:23:30.555348
NCT00242840|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2017-05-25|2005-10-19|2005-10-21|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2003||2003-06-30|May 2017|2017-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)|A 24 Week Phase IIIb/IV Single Arm Open Label Observational Study to Explore the Efficacy of Protease Inhibitors Given in Combination With Reverse Transcriptase Inhibitors to HIV-1 Infected Subjects With Protease Mutations Selected During Therapy With GW433908 Containing Antiretroviral Therapy|Completed||Phase 3|20|Actual|ViiV Healthcare|||||f||||||||||||||2018-06-01 04:23:30.647429|2018-06-01 04:23:30.647429
NCT00242827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-08-22|2005-10-20|2005-10-21|Estimate|||||||2012-08-22|2012-08-23|Estimate|April 2006||2006-04-30|September 2006|2006-09-30|May 2007||2007-05-31|||||Interventional|||Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma|An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma|Terminated||Phase 2|||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:23:30.707027|2018-06-01 04:23:30.707027
NCT00242814|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2012-05-18|2005-10-20|2005-10-21|Estimate|||||||2012-05-18|2012-05-21|Estimate|October 2005||2005-10-31|May 2012|2012-05-31||||March 2007|Actual|2007-03-31||Interventional|||Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities|A Phase IV Study, Prospective, Randomised, Open Label, Blinded Endpoint, Parallel Group, 9 Weeks of Comparison Between Oral Administration of Telmisartan Tablet (80mg Once Daily) and Amlodipine Tablet (10 mg Once Daily) on Biological PPAR Gamma Activities in Non Controlled Hypertensive Male Patients With Metabolic Syndrome|Completed||Phase 4|100|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:23:30.789958|2018-06-01 04:23:30.789958
NCT00242801|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2009-04-22|2005-10-20|2005-10-21|Estimate|||||||2009-04-22|2009-04-23|Estimate|July 2003||2003-07-31|April 2009|2009-04-30|April 2005|Actual|2005-04-30|||||Interventional|||Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study|A Double Blind,Placebo Controlled,Parallel Group,Multicentre,Randomised,Phase Iii Survival Study Comparing ZD1839 (IRESSA™)(250mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced NSCLC Who Have Received One Or Two Prior Chemotherapy Regimens And Are Refractory Or Intolerant To Their Most Recent Regimen|Completed||Phase 3|1692||AstraZeneca|||||||||||||||||||2018-06-01 04:23:30.98338|2018-06-01 04:23:30.98338
NCT00242788|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2009-04-22|2005-10-20|2005-10-21|Estimate|||||||2009-04-22|2009-04-23|Estimate|February 2004||2004-02-29|April 2009|2009-04-30|November 2005|Actual|2005-11-30|||||Interventional|||IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo Failure|A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of First-Line Chemotherapy|Completed||Phase 1/Phase 2|40||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:31.396881|2018-06-01 04:23:31.396881
NCT00242775|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2011-01-21|2005-10-20|2005-10-21|Estimate|||||||2011-01-21|2011-01-24|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|May 2006|Actual|2006-05-31|||||Interventional|||Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg|Efficacy and Safety of Symbicort ®Turbuhaler® 160/4.5 µg/Inhalation, Two Inhalations Twice Daily Plus As-needed Compared With Seretide™ Diskus™ 50/500 µg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation As-needed - a 6-month, Randomised, Double-blind, Parallel-group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD).|Completed||Phase 3|2100||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:31.528794|2018-06-01 04:23:31.528794
NCT00242762|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2011-01-25|2005-10-20|2005-10-21|Estimate|||||||2011-01-25|2011-01-27|Estimate|July 2003||2003-07-31|January 2011|2011-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer|A Phase II Study to Evaluate the Safety and Efficacy of the Combination of ZD1839 (IRESSA™), Docetaxel and Cisplatin in Subjects With Recurrent and/or Metastatic Head and Neck Cancer|Completed||Phase 2|36||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:31.807069|2018-06-01 04:23:31.807069
NCT00242749|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2009-04-22|2005-10-20|2005-10-21|Estimate|||||||2009-04-22|2009-04-23|Estimate|December 2002||2002-12-31|April 2009|2009-04-30|July 2007|Actual|2007-07-31|||||Interventional|||IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma|A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable)|Completed||Phase 2|47||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:31.957214|2018-06-01 04:23:31.957214
NCT00242736|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2009-03-05|2005-10-19|2005-10-21|Estimate|||||||2009-03-05|2009-03-06|Estimate|October 2005||2005-10-31|March 2009|2009-03-31|January 2006|Actual|2006-01-31|||||Interventional|||An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)|An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship Between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution After 4 Weeks of Treatment|Completed||Phase 4|350||AstraZeneca|||||||||||||||||||2018-06-01 04:23:32.116757|2018-06-01 04:23:32.116757
NCT00242723|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-20|||2018-05-22|2005-10-19|2005-10-20|Estimate|||||||2018-05-22|2018-05-23|Actual|October 18, 2005||2005-10-18|May 3, 2018|2018-05-03||||||||Observational|||Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining|Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies|Recruiting|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:23:32.307247|2018-06-01 04:23:32.307247
NCT00242710|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|2013-10-30|2009-02-26|2013-10-30|2005-10-19|2005-10-20|Estimate|2013-10-30|2013-12-20|Estimate|2009-09-24|2009-09-28|Estimate|2013-10-30|2013-12-20|Estimate|September 2005||2005-09-30|October 2013|2013-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Safety analysis set included all randomly assigned participants who took at least 1 dose of test article.|Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women|A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women|Completed||Phase 3|1083|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 04:23:32.479166|2018-06-01 04:23:32.479166
NCT00242697|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2005-10-19|2005-10-19|2005-10-20|Estimate|||||||2005-10-19|2005-10-20|Estimate|April 2002||2002-04-30|October 2005|2005-10-31|July 2003||2003-07-31|||||Interventional|||Double-Blind Comparison of Combined General-Spinal Anesthesia to General Anesthesia for Coronary Artery Surgery|A Randomized Double-Blind Comparison of Combined General-Spinal Anesthesia to General Anesthesia for Coronary Artery Surgery|Completed||Phase 3|63||University of Calgary|||||f||||||||||||||2018-06-01 04:23:34.700563|2018-06-01 04:23:34.700563
NCT00242684|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|2014-11-24||2015-04-06|2005-10-18|2005-10-20|Estimate|2014-11-24|2014-12-02|Estimate||||2015-04-06|2015-04-24|Estimate|March 2006||2006-03-31|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational||Elderly patients admitted to TCU|PEU in Elderly TCU Residents|Manifestations, Causes, and Consequences of PEU in Elderly TCU Residents|Completed|||446|Actual|VA Office of Research and Development|This was an observational study designed to develop a better understanding of the interrelationships among nutrient intake, weight change, serum concentration of albumins, illness severity, and mortality. For more details, see cited references.||1||f||||f||||||Samples Without DNA|"~     serum and plasma samples~   "|||2018-06-01 04:23:34.790008|2018-06-01 04:23:34.790008
NCT00242671|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2010-08-03|2005-10-18|2005-10-20|Estimate|||||||2010-08-03|2010-08-05|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||The Efficacy of Isocapnic Hyperpnoea to Accelerate Recovery After General Anesthesia With Sevoflurane|The Efficacy of Isocapnic Hyperpnoea to Accelerate Recovery After General Anesthesia With Sevoflurane.|Completed||Phase 3|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:34.953227|2018-06-01 04:23:34.953227
NCT00242658|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2010-12-16||2012-11-07|2005-10-19|2005-10-20|Estimate|2011-05-04|2011-06-06|Estimate||||2012-11-07|2012-11-12|Estimate|May 2005||2005-05-31|November 2012|2012-11-30|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Computerized Health Education to Promote Physical Activity|Computerized Physical Activity Promotion in Primary Care|Completed||Phase 1|394|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 04:23:35.024608|2018-06-01 04:23:35.024608
NCT00242645|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2010-08-24|2005-10-19|2005-10-20|Estimate|||||||2010-08-24|2010-08-25|Estimate|June 2004||2004-06-30|August 2010|2010-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Computer-Assisted Cancer Risk Behavior Counseling|Computer-Assisted Cancer Risk Behavior Counseling|Terminated||Phase 1|200|Actual|Thomas Jefferson University||||Administratively terminated.|f||||f||||||||||2018-06-01 04:23:35.269284|2018-06-01 04:23:35.269284
NCT00242632|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2016-10-10||2017-05-16|2005-10-19|2005-10-20|Estimate|2017-04-14|2017-05-17|Actual||||2017-05-16|2017-06-14|Actual|June 2004||2004-06-30|May 2017|2017-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Treatment With Namenda in Women at Risk for Cognitive Decline|Cognitive Effects of Memantine in Postmenopausal Women at Risk of Dementia: a Pilot Study|Completed||N/A|22|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 04:23:35.391308|2018-06-01 04:23:35.391308
NCT00242619|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2016-10-10||2016-12-20|2005-10-19|2005-10-20|Estimate|2016-12-20|2017-02-14|Actual||||2016-12-20|2017-02-14|Actual|July 2007||2007-07-31|December 2016|2016-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Insulin Resistance in Patients With Mood Disorder|Rosiglitazone Add-On in Treatment of Depressed Patients With Insulin Resistance: a Pilot Study|Completed||N/A|12|Actual|Stanford University||1|||f||||f||||||||No||2018-06-01 04:23:35.636056|2018-06-01 04:23:35.636056
NCT00242606|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2012-05-08|2005-10-19|2005-10-20|Estimate|||||||2012-05-08|2012-05-09|Estimate|March 2005||2005-03-31|May 2012|2012-05-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy|Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study|Completed||Phase 3|409|Actual|Philipps University Marburg Medical Center||2|||f||||t||||||||||2018-06-01 04:23:35.885919|2018-06-01 04:23:35.885919
NCT00242593|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2011-08-04|2005-10-19|2005-10-20|Estimate|||||||2011-08-04|2011-08-05|Estimate|June 2006||2006-06-30|August 2011|2011-08-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|RECALL||Rosiglitazone Effects on Cognition for Adults in Later Life|The Effects of Rosiglitazone on Cognition in Patients With MCI|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 04:23:35.967099|2018-06-01 04:23:35.967099
NCT00242580|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2011-01-24||2016-03-03|2005-10-19|2005-10-20|Estimate|2011-04-01|2011-05-02|Estimate||||2016-03-03|2016-03-31|Estimate|September 2005||2005-09-30|March 2016|2016-03-31||||January 2008|Actual|2008-01-31||Interventional|VERITAS||A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib|A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne® Plus Intravitreal Pegaptanib(Macugen®) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Completed||Phase 3|111|Actual|Novartis|Secondary outcome measures were to be assessed at Month 6 and at 24 months. However, this study was not completed but terminated after all patients completed 12 months. Original safety was COSTART now mapped to SOC MedDRA.|3|||f||||||||||||||2018-06-01 04:23:36.065088|2018-06-01 04:23:36.065088
NCT00242567|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2013-01-29||2014-04-14|2005-10-19|2005-10-20|Estimate|2013-01-29|2013-03-06|Estimate||||2014-04-14|2014-05-07|Estimate|December 2005||2005-12-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer|A Phase III, Parallel Group, Randomized, Open-label, Multi-centre Clinical Trial of Zoledronic Acid in Males Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer.|Completed||Phase 3|522|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:23:37.786395|2018-06-01 04:23:37.786395
NCT00242554|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2017-02-21|2005-10-19|2005-10-20|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2002||2002-10-31|February 2017|2017-02-28||||July 2007|Actual|2007-07-31||Interventional|||Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases|Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases|Completed||Phase 4|150||Novartis|||||f||||||||||||||2018-06-01 04:23:39.949795|2018-06-01 04:23:39.949795
NCT00242541|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2012-04-25|2005-10-19|2005-10-20|Estimate|||||||2012-04-25|2012-04-26|Estimate|March 2003||2003-03-31|April 2012|2012-04-30||||August 2005|Actual|2005-08-31||Interventional|||Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas|Open Label Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas|Terminated||Phase 4|50|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:23:40.093668|2018-06-01 04:23:40.093668
NCT00242528|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2015-04-13|2005-10-19|2005-10-20|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2004||2004-04-30|April 2015|2015-04-30||||||||Interventional|||Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.|Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.|Withdrawn||Phase 4|0|Actual|Novartis|||||f||||||||||||||2018-06-01 04:23:40.179383|2018-06-01 04:23:40.179383
NCT00242515|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2014-01-07|2005-10-19|2005-10-20|Estimate|||||||2014-01-07|2014-01-08|Estimate|March 2005||2005-03-31|January 2014|2014-01-31|March 2008||2008-03-31|||||Interventional|||T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)|Preemptive CD8+ T-cell Depleted Donor Lymphocyte Infusion (DLI) Following Nonmyeloablative Stem Cell Transplantation (NMT) for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)|Unknown status|Recruiting|Phase 1/Phase 2|16|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:23:40.232413|2018-06-01 04:23:40.232413
NCT00242502|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|2013-02-19||2013-03-25|2005-10-18|2005-10-20|Estimate|2013-03-25|2013-05-06|Estimate||||2013-03-25|2013-05-06|Estimate|October 2005||2005-10-31|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery|A Phase II Study of the Combination of Bevacizumab and Erlotinib in Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 2|62|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:23:40.310188|2018-06-01 04:23:40.310188
NCT00242489|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2015-02-24|2005-10-18|2005-10-20|Estimate|||||||2015-02-24|2015-02-25|Estimate|June 1998||1998-06-30|February 2015|2015-02-28|July 2002|Actual|2002-07-31|February 1999|Actual|1999-02-28||Interventional|||Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)|A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.|Completed||Phase 2|1167|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:23:40.510658|2018-06-01 04:23:40.510658
NCT00242476|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2015-05-13|2005-10-18|2005-10-20|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Study to Assess the Effect of Vitamin D3 8400IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Aged 70 Years or Older|Completed||Phase 2|216|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:23:40.584979|2018-06-01 04:23:40.584979
NCT00242463|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2011-01-04|2005-10-19|2005-10-20|Estimate|||||||2011-01-04|2011-01-05|Estimate|October 2005||2005-10-31|January 2011|2011-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Anabolic Steroids for Nutritional Rehabilitation of Critically Ill Patients|The Efficacy of Anabolic Steroids for the Nutritional Rehabilitation of Critically Ill Patients|Terminated||Phase 2|20|Anticipated|Lawson Health Research Institute||2||drug no longer available in canada|f||||f||||||||||2018-06-01 04:23:40.646021|2018-06-01 04:23:40.646021
NCT00242450|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2017-08-24|2005-10-19|2005-10-20|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2002|Actual|2002-03-31|May 2005|2005-05-31|July 2005|Actual|2005-07-31|||||Interventional|||Metoclopramide Use in Very Low Birth Weight Newborns|The Effect of Metoclopramide on Feeding in Very Low Birthweight Newborns : a Randomized, Double Blind, Placebo Controlled Pilot Study and a Proposal for a Multicentre Trial|Completed||Phase 4|30||Lawson Health Research Institute|||||f||||f|f|f||||||||2018-06-01 04:23:40.732258|2018-06-01 04:23:40.732258
NCT00242437|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2006-07-11|2005-10-19|2005-10-20|Estimate|||||||2006-07-11|2006-07-13|Estimate|October 2005||2005-10-31|July 2006|2006-07-31|February 2006||2006-02-28|||||Interventional|||Hemostatic Matrix in Endoscopic Sinus Surgery|A Prospective, Multicenter Study to Evaluate Hemostatic Matrix With Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Endoscopic Sinus Surgery|Completed||Phase 4|30||Ethicon, Inc.|||||f||||||||||||||2018-06-01 04:23:40.795965|2018-06-01 04:23:40.795965
NCT00242424|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2009-01-27|2005-10-19|2005-10-20|Estimate|||||||2009-01-27|2009-01-28|Estimate|September 2005||2005-09-30|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Interventional|GRC28||Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age|Safety and Immunogenicity of Fluzone Influenza Virus Vaccine (2005-2006 Formulation) Among Healthy Children 6 to 12 Weeks of Age|Completed||Phase 2/Phase 3|1375|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-06-01 04:23:40.885025|2018-06-01 04:23:40.885025
NCT00242411|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2011-01-21|2005-10-19|2005-10-20|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults|A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults. A Randomized, Open, Parallel-group, Multicentre 26-weeks Study|Completed||Phase 4|1900||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:41.235767|2018-06-01 04:23:41.235767
NCT00242398|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2007-10-02|2005-10-18|2005-10-20|Estimate|||||||2007-10-02|2007-10-03|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|April 2008|Anticipated|2008-04-30|||||Interventional|||Hemodialysis Without Anticoagulation in Intensive Care Unit|Heparin Free Hemodialysis for Patients With Bleeding High Risk in ICU. Randomized Study: Heparin Free Dialysis With Intermittent Saline Flushes Versus Heparin Free Dialysis With Nephral 400ST (AN69ST, Hospal, France)|Unknown status|Recruiting|Phase 3|120|Anticipated|Centre Hospitalier Départemental|||||f||||t||||||||||2018-06-01 04:23:41.625824|2018-06-01 04:23:41.625824
NCT00242385|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|2011-02-15||2017-10-19|2005-10-19|2005-10-20|Estimate|2011-07-18|2011-07-20|Estimate||||2017-10-19|2017-11-24|Actual|December 2005||2005-12-31|July 2011|2011-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Pharmacokinetic Study of ARALAST (Human Alpha1- PI)|Single-Dose, Double-Blind, Crossover Study to Evaluate the Pharmacokinetic Comparability of ARALAST Fraction IV-1 Alpha1-Proteinase Inhibitor (ARALAST Fr. IV-1) and ARALAST|Completed||Phase 1|25|Actual|Shire||2|||f||||||||||||||2018-06-01 04:23:41.806202|2018-06-01 04:23:41.806202
NCT00242372|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2009-04-21|2005-10-19|2005-10-20|Estimate|||||||2009-04-21|2009-04-22|Estimate|August 2004||2004-08-31|April 2009|2009-04-30|March 2006|Actual|2006-03-31|||||Interventional|||GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin|A 24-Week Randomised, Double-Blind, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Added to the Therapy of Patients With Type 2 Diabetes Poorly Controlled on Insulin|Terminated||Phase 3|370||AstraZeneca||||The development program has been terminated|||||||||||||||2018-06-01 04:23:42.445252|2018-06-01 04:23:42.445252
NCT00242359|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2009-01-27|2005-10-17|2005-10-20|Estimate|||||||2009-01-27|2009-01-28|Estimate|November 2005||2005-11-30|January 2009|2009-01-31||||||||Interventional|||A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma|A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma|Withdrawn||Phase 4|16|Anticipated|Bernstein Clinical Research Center||||could not find subject population|||||f||||||||||2018-06-01 04:23:42.664191|2018-06-01 04:23:42.664191
NCT00242346|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2007-12-17|2005-10-18|2005-10-20|Estimate|||||||2007-12-17|2007-12-19|Estimate|April 2003||2003-04-30|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||High Doses of Candesartan Cilexetil on the Reduction of Proteinuria|A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria|Completed||Phase 3|270||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:42.717063|2018-06-01 04:23:42.717063
NCT00242333|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2006-05-15|2005-10-19|2005-10-20|Estimate|||||||2006-05-15|2006-05-16|Estimate|October 2005||2005-10-31|May 2006|2006-05-31||||||||Interventional|||A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD|A Multi-Center Randomized, Double-Blind, Parallel Group, Placebo Controlled Study, Including an Additional Open Label Tiotropium Group, to Assess the Efficacy, Safety and Tolerability of 4 Doses of AD 237 Inhaled Once Daily for 28 Days in Subjects With COPD.|Completed||Phase 2|300||Sosei|||||f||||||||||||||2018-06-01 04:23:42.836159|2018-06-01 04:23:42.836159
NCT00242320|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2016-12-01|2005-10-19|2005-10-20|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2005||2005-08-31|September 2016|2016-09-30|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety of Oral Roflumilast Taken Once Daily in Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (BY217/M2-119)|The JADE Study: A 12-week, Double-blind, Randomized Study to Investigate the Effect of 500 mcg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|551|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:23:43.067113|2018-06-01 04:23:43.067113
NCT00242307|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2016-10-31|2005-10-19|2005-10-20|Estimate|||||||2016-10-31|2016-11-02|Estimate|May 2004||2004-05-31|September 2016|2016-09-30|June 2007|Actual|2007-06-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)|A Confirmatory Study of APTA-2217 in Adult Patients With Bronchial Asthma (A Placebo-controlled Double-blind Comparative Study)|Completed||Phase 2/Phase 3|450|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:23:43.249718|2018-06-01 04:23:43.249718
NCT00242294|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2016-10-24|2005-10-19|2005-10-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|March 2007|Actual|2007-03-31|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)|A Confirmatory Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease (A Placebo-controlled Double-blind Comparative Study)|Completed||Phase 2/Phase 3|570||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:43.493729|2018-06-01 04:23:43.493729
NCT00242281|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2006-10-23|2005-10-18|2005-10-20|Estimate|||||||2006-10-23|2006-10-25|Estimate|November 2005||2005-11-30|January 2006|2006-01-31|July 2006||2006-07-31|||||Interventional|||APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat|A Phase III, Multicenter Study to Evaluate the Safety/Efficacy of APC-111 MP Tablet QD vs. Penicillin VK QID Both for 10 Days Treatment of Pharyngitis Secondary to S.Pyogenes in Adolescents/Adults|Completed||Phase 3|600||Advancis Pharmaceutical Corporation|||||||||||||||||||2018-06-01 04:23:43.604165|2018-06-01 04:23:43.604165
NCT00242242|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-19|||2018-05-23|2005-10-18|2005-10-19|Estimate|||||||2018-05-23|2018-05-24|Actual|October 17, 2005||2005-10-17|July 23, 2013|2013-07-23|July 23, 2013||2013-07-23|||||Observational|||Moving a Paralyzed Hand Through Use of a Brain-Computer Interface|Moving a Paralyzed Hand Through a Brain-Computer Interface Controlled by the Affected Hemisphere After Stroke or Traumatic Brain Injury|Terminated|||110|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:23:44.655149|2018-06-01 04:23:44.655149
NCT00242229|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2009-08-18|2005-10-17|2005-10-19|Estimate|||||||2009-08-18|2009-08-19|Estimate|October 2004||2004-10-31|August 2009|2009-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder|A 6 Month, Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Elderly Outpatients With Major Depressive Disorder (MDD)|Completed||N/A|52|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:23:44.879828|2018-06-01 04:23:44.879828
NCT00242216|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|2013-05-02||2013-12-12|2005-10-18|2005-10-19|Estimate|2013-08-12|2013-10-17|Estimate||||2013-12-12|2014-01-15|Estimate|May 2004||2004-05-31|December 2013|2013-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||"The Once A Day Protease Inhibitor Regimens"|"PIQD: The Once a Day Protease Inhibitor Regimens. Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients."|Completed||Phase 4|76|Actual|The University of Texas Health Science Center, Houston|High porportion of subject did not complete the study.|2|||f||||f||||||||||2018-06-01 04:23:45.125981|2018-06-01 04:23:45.125981
NCT00242203|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2013-08-09|2005-10-17|2005-10-19|Estimate|||||||2013-08-09|2013-08-13|Estimate|October 2002||2002-10-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|August 2007|Actual|2007-08-31||Interventional|||Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer|Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer|Completed||Phase 2|120|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 04:23:46.189645|2018-06-01 04:23:46.189645
NCT00242190|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2010-11-10|2005-10-18|2005-10-19|Estimate|||||||2010-11-10|2010-11-15|Estimate|June 2004||2004-06-30|November 2010|2010-11-30|February 2010|Actual|2010-02-28|March 2006|Actual|2006-03-31||Interventional|||Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer|Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer|Completed||Phase 1/Phase 2|40||University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:23:46.54444|2018-06-01 04:23:46.54444
NCT00242177|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2005-10-24|2005-10-18|2005-10-19|Estimate|||||||2005-10-24|2005-10-26|Estimate|October 2003||2003-10-31|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability|Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability|Completed||Phase 1|30||University of Illinois at Chicago|||||f||||||||||||||2018-06-01 04:23:46.772115|2018-06-01 04:23:46.772115
NCT00242164|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2014-12-08|2005-10-17|2005-10-19|Estimate|||||||2014-12-08|2014-12-09|Estimate|November 2005||2005-11-30|July 2005|2005-07-31|November 2006|Actual|2006-11-30|June 2006|Actual|2006-06-30||Interventional|||Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis|Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis|Completed||Phase 2|25|Anticipated|University of Michigan|||||f||||||||||||||2018-06-01 04:23:47.046552|2018-06-01 04:23:47.046552
NCT00242151|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2006-10-11|2005-10-18|2005-10-19|Estimate|||||||2006-10-11|2006-10-12|Estimate||||September 2006|2006-09-30||||||||Observational|||Prevalence of Delirium in Patients Undergoing Cardiac Surgery|Prevalence of Delirium in Patients Undergoing Cardiac Surgery|Unknown status|Recruiting||100||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:47.33774|2018-06-01 04:23:47.33774
NCT00242138|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2016-02-08|2005-10-18|2005-10-19|Estimate|||||||2016-02-08|2016-02-09|Estimate|March 2000||2000-03-31|February 2016|2016-02-29|April 2004||2004-04-30|||||Interventional|||Erectile Dysfunction/Prostate/RT/Androgen|A Cross-Sectional Study of Erectile Dysfunction in Patients With Locally Advanced Prostate Cancer Who Have Undergone Radiotherapy and Prolonged Pharmacological Androgen Ablation|Completed||Phase 2|50||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:47.56134|2018-06-01 04:23:47.56134
NCT00242125|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2006-01-13|2005-10-18|2005-10-19|Estimate|||||||2006-01-13|2006-01-16|Estimate|October 2005||2005-10-31|October 2005|2005-10-31||||||||Observational|||Family Studies in Primary Biliary Cirrhosis (PBC)|Family Studies in Primary Biliary Cirrhosis|Unknown status|Recruiting||3000||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:47.662939|2018-06-01 04:23:47.662939
NCT00242112|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2017-04-24|2005-10-18|2005-10-19|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2005||2005-06-30|April 2017|2017-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI|Defining the Extent and Grade of Prostate Cancer Using Dynamic Contrast Enhanced Diffusion Weighted and BOLD MRI|Completed||N/A|31|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:23:47.722683|2018-06-01 04:23:47.722683
NCT00242099|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2008-04-15|2005-10-18|2005-10-19|Estimate|||||||2008-04-15|2008-04-16|Estimate|February 2005||2005-02-28|February 2005|2005-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant|The Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant: A Randomized Trial|Completed||Phase 4|160||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:47.778638|2018-06-01 04:23:47.778638
NCT00242086|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2016-05-31|2005-10-18|2005-10-19|Estimate|||||||2016-05-31|2016-06-01|Estimate|October 2004||2004-10-31|May 2016|2016-05-31||||March 2010|Actual|2010-03-31||Interventional|||Comparison of Triphasic CT, PET and MR Tumour With Pathological Findings in Colorectal Cancer Liver Metastases|Comparison of Triphasic CT, CT/PET and MR Defined Gross Tumour With Pathological Findings in Patients With Colorectal Cancer Liver Metastases|Completed||N/A|7|Actual|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:47.823212|2018-06-01 04:23:47.823212
NCT00242073|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2017-09-19|2005-10-18|2005-10-19|Estimate|||||||2017-09-19|2017-09-21|Actual|October 2001||2001-10-31|September 2017|2017-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||The Potential Use of BOLD MRI as a Noninvasive Measure of Tumor Hypoxia in Prostate Cancer|The Potential Use of BOLD MRI as a Noninvasive Measure of Tumor Hypoxia in Prostate Cancer|Completed||N/A|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:47.871929|2018-06-01 04:23:47.871929
NCT00242060|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2010-07-14|2005-10-18|2005-10-19|Estimate|||||||2010-07-14|2010-07-15|Estimate|November 2002||2002-11-30|July 2010|2010-07-31|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|||Functional and Morphologic MRI in the Detection of Prostate Cancer in Patients With Prior Negative Biopsy|The Utility of Functional and Morphologic MRI in the Detection of Prostate Cancer for Patients With Elevated PSA and Prior Negative Biopsy|Completed||N/A|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:47.916852|2018-06-01 04:23:47.916852
NCT00242047|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2005-10-18|2005-10-18|2005-10-19|Estimate|||||||2005-10-18|2005-10-19|Estimate|March 2001||2001-03-31|November 2004|2004-11-30|August 2006||2006-08-31|||||Interventional|||Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination.|Randomized, Controlled Trial Comparing Efficacy of Percutaneous and Intradermal Vaccination With Japanese (Tokyo) 172 BCG in the Prevention of Tuberculosis In Infants Vaccinated at Birth|Unknown status|Active, not recruiting|Phase 4|12000||University of Cape Town|||||f||||||||||||||2018-06-01 04:23:47.960125|2018-06-01 04:23:47.960125
NCT00242034|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2008-09-02|2005-10-18|2005-10-19|Estimate|||||||2008-09-02|2008-09-03|Estimate||||August 2008|2008-08-31||||||||Interventional|||Investigation of Cervix Tumor Oxygenation and Microvasculature Using Magnetic Resonance Techniques|Investigation of Cervix Tumor Oxygenation and Microvasculature Using Magnetic Resonance Techniques|Completed||N/A|60|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:23:48.022535|2018-06-01 04:23:48.022535
NCT00242021|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2009-10-13|2005-10-18|2005-10-19|Estimate|||||||2009-10-13|2009-10-14|Estimate|October 2005||2005-10-31|October 2009|2009-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||The Effect of Fatty Acid Composition on Energy Intake and Satiety|Fatty Acid Composition of a Fat Supplement on Energy Intake, Satiety and Fat Metabolism in Lean and Obese Men|Completed||N/A|20||TNO|||||f||||||||||||||2018-06-01 04:23:48.064725|2018-06-01 04:23:48.064725
NCT00242008|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2014-09-24|2005-10-18|2005-10-19|Estimate|||||||2014-09-24|2014-09-25|Estimate|December 2004||2004-12-31|September 2009|2009-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease|A Phase 3b, Open-Label, Multicenter, Multinational Trial To Assess The Tolerability Of Switching Subjects From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System And Its Effect On Symptoms In Subjects With Idiopathic Parkinson's Disease|Completed||Phase 3|||UCB Pharma|||||f||||||||||||||2018-06-01 04:23:48.124158|2018-06-01 04:23:48.124158
NCT00241995|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2006-10-17|2005-10-17|2005-10-19|Estimate|||||||2006-10-17|2006-10-18|Estimate||||October 2005|2005-10-31||||||||Interventional|||Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome||Completed||N/A|||St. Petersburg State Pavlov Medical University|||||f||||||||||||||2018-06-01 04:23:48.278551|2018-06-01 04:23:48.278551
NCT00241982|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2008-05-28|2005-10-18|2005-10-19|Estimate|||||||2008-05-28|2008-05-30|Estimate|October 2005||2005-10-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis|Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis|Completed||Phase 2|22|Actual|Radboud University|||||f||||f||||||||||2018-06-01 04:23:48.327224|2018-06-01 04:23:48.327224
NCT00241969|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|2017-08-21||2018-04-23|2005-10-18|2005-10-19|Estimate|2018-03-19|2018-04-17|Actual||||2018-04-23|2018-05-22|Actual|January 2006|Actual|2006-01-31|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2012|Actual|2012-06-30||Interventional|||Behavioral & Nutritional Treatment to Help CF Preschoolers Grow|A Multi-Site Randomized Clinical Trial of Behavioral and Nutrition Treatment Designed to Help Preschoolers With Cystic Fibrosis Optimize Growth|Completed||N/A|78|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No||2018-06-01 04:23:48.408286|2018-06-01 04:23:48.408286
NCT00241956|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2011-07-19|2005-10-18|2005-10-19|Estimate|||||||2011-07-19|2011-07-21|Estimate|October 2005||2005-10-31|July 2011|2011-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Impact of Diabetes and Glucose Control During Rehabilitation After Stroke|Impact of Diabetes and Glucose Control During Rehabilitation After Stroke|Terminated|||20|Actual|Melbourne Health||||poor data collection|f||||f||||||||||2018-06-01 04:23:48.714817|2018-06-01 04:23:48.714817
NCT00241943|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2008-12-08|2005-10-18|2005-10-19|Estimate|||||||2008-12-08|2008-12-09|Estimate|November 2005||2005-11-30|December 2008|2008-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Video-Based HCV Curriculum for Active Injection Drug Users|Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training|Completed||N/A|103|Actual|Organization to Achieve Solutions in Substance Abuse (OASIS)|||||f||||f||||||||||2018-06-01 04:23:48.763877|2018-06-01 04:23:48.763877
NCT00241930|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2005-10-24|2005-10-17|2005-10-19|Estimate|||||||2005-10-24|2005-10-25|Estimate|September 2005||2005-09-30|August 2005|2005-08-31|February 2009||2009-02-28|||||Interventional|||Integrating Buprenorphine Into HIV Treatment|SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model|Unknown status|Recruiting|Phase 4|60||Organization to Achieve Solutions in Substance Abuse (OASIS)|||||f||||||||||||||2018-06-01 04:23:48.819727|2018-06-01 04:23:48.819727
NCT00241917|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2008-12-05|2005-10-18|2005-10-19|Estimate|||||||2008-12-05|2008-12-09|Estimate|November 2005||2005-11-30|December 2008|2008-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Video-Based HCV Curriculum for Drug Users|Cooperative Agreement to Develop, Implement, and Evaluate Viral Hepatitis and Training|Completed||N/A|450|Actual|Organization to Achieve Solutions in Substance Abuse (OASIS)||2|||f||||f||||||||||2018-06-01 04:23:48.960003|2018-06-01 04:23:48.960003
NCT00241904|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|2017-04-14||2017-08-18|2005-10-17|2005-10-19|Estimate|2017-08-18|2017-09-15|Actual||||2017-08-18|2017-09-15|Actual|May 2006||2006-05-31|August 2017|2017-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|COACH||Reducing Total Cardiovascular Risk in an Urban Community|Reducing Total Cardiovascular Risk in an Urban Community|Completed||Phase 4|525|Actual|Johns Hopkins University||2|||f||||t|t|f||||||No|Researchers can contact the PI for access to the data set|2018-06-01 04:23:49.068688|2018-06-01 04:23:49.068688
NCT00241891|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2015-04-06|2005-10-17|2005-10-19|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|May 2011|Actual|2011-05-31||Interventional|||Behavior Change Family Counseling to Reduce Rate of Weight Gain in At-Risk Children|Primary Care Obesity Prevention: One or Multiple Targets|Completed||N/A|158|Actual|Children's Hospital of Philadelphia||3|||f||||f||||||||||2018-06-01 04:23:49.389992|2018-06-01 04:23:49.389992
NCT00241878|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2016-05-04|2005-10-17|2005-10-19|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2006||2006-09-30|December 2007|2007-12-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Preschool Based Obesity Prevention Effectiveness Trial|Preschool Based Obesity Prevention Effectiveness Trial|Completed||N/A|648|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||||||||||||2018-06-01 04:23:49.475447|2018-06-01 04:23:49.475447
NCT00241852|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2014-01-09|2005-10-17|2005-10-19|Estimate|||||||2014-01-09|2014-01-10|Estimate|May 2005||2005-05-31|January 2014|2014-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Family Approach to Managing Asthma in Early Teens|Family Approach to Managing Asthma in Early Teens|Completed||Phase 3|392|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 04:23:49.553872|2018-06-01 04:23:49.553872
NCT00239213|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2006-10-28|2005-10-13|2005-10-14|Estimate|||||||2006-10-28|2006-10-31|Estimate|November 2005||2005-11-30|October 2006|2006-10-31|April 2006||2006-04-30|||||Interventional|||Catechin Gargling for Influenza Infection|A Randomized Clinical Study of Catechin Gargling Effects on the Prevention of Influenza Infection|Completed||N/A|400||University of Shizuoka|||||f||||||||||||||2018-06-01 04:24:29.836201|2018-06-01 04:24:29.836201
NCT00241839|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|2013-03-28|2012-08-29|2013-07-18|2005-10-17|2005-10-19|Estimate|2013-07-15|2013-07-17|Estimate|2012-08-29|2012-09-05|Estimate|2013-07-18|2013-07-26|Estimate|August 2005||2005-08-31|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||African Americans with borderline high Blood Pressure|Uric Acid and Hypertension in African Americans|Uric Acid and Hypertension in African Americans|Completed||Phase 3|150|Actual|University of Florida|For all 4 outcomes analyzed, patients required to have data at both baseline and 8-10 weeks on that field to be included. Thus, the numbers of subjects varies slightly from analysis to analysis.|2|||f||||t||||||||||2018-06-01 04:23:49.666029|2018-06-01 04:23:49.666029
NCT00241826|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2013-08-19|2005-10-17|2005-10-19|Estimate|||||||2013-08-19|2013-08-20|Estimate|April 2006||2006-04-30|July 2009|2009-07-31|April 2009||2009-04-30|September 2008|Actual|2008-09-30||Observational|||Prospective Investigation of Pulmonary Embolism Diagnosis III|Prospective Investigation of Pulmonary Embolism Diagnosis III (PIOPED III)|Completed|||1256|Anticipated|George Washington University|||||f||||||||||||||2018-06-01 04:23:49.991721|2018-06-01 04:23:49.991721
NCT00241813|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2012-12-13|2005-10-17|2005-10-19|Estimate|||||||2012-12-13|2012-12-17|Estimate|January 2005||2005-01-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Behavioral Stress Reduction Programs on Blood Pressure in African American Youth|Stress Reduction: Impact on Blood Pressure in African American Youth|Completed||N/A|283|Actual|Medical University of South Carolina||4|||f||||f||||||||||2018-06-01 04:23:50.081621|2018-06-01 04:23:50.081621
NCT00241800|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2017-06-02|2005-10-17|2005-10-19|Estimate|||||||2017-06-02|2017-06-05|Actual|September 2005|Actual|2005-09-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Medications and the Risk of Sudden Cardiac Death||Completed|||1200|Actual|Vanderbilt University Medical Center|||||f||||f|f|f||||||No||2018-06-01 04:23:50.144122|2018-06-01 04:23:50.144122
NCT00241787|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2015-11-30|2005-10-17|2005-10-19|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2005||2005-09-30|November 2015|2015-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Progression of Sub-Clinical Atherosclerosis||Completed|||2900|Actual|Tufts Medical Center|||||f||||||||||||||2018-06-01 04:23:50.1967|2018-06-01 04:23:50.1967
NCT00241774|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2016-02-04|2005-10-17|2005-10-19|Estimate|||||||2016-02-04|2016-02-05|Estimate|August 2005||2005-08-31|February 2016|2016-02-29|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Observational|||Coronary Heart Disease Incidence: Depression & Inflammation Risk|Coronary Heart Disease Incidence: Depression & Inflammation Risk|Completed|||3227|Actual|Columbia University|||1||f||||f||||||Samples With DNA|"~     In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the~     time of enrollment, epidemiologic data as well as blood samples were obtained. The~     participants have since been followed prospectively for a variety of health outcomes. We plan~     to assay stored blood samples collected in 1995 for markers of inflammation and link these~     results to existing epidemiologic and outcomes data, specifically the 7-year incidence of CAD~     events. Buffy coats were also obtained from the blood samples of the SAME participants for~     future DNA analysis.~   "|||2018-06-01 04:23:50.24026|2018-06-01 04:23:50.24026
NCT00241761|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2016-08-05|2005-10-17|2005-10-19|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|August 2010|Actual|2010-08-31|||||Observational|||Epidemiology of Depression and Heart Failure in Aging||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:23:50.292569|2018-06-01 04:23:50.292569
NCT00241748|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2012-01-04|2005-10-17|2005-10-19|Estimate|||||||2012-01-04|2012-01-05|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event|Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event|Completed|||187|Actual|University of Washington|||3||f||||f||||||Samples With DNA|"~     DNA is extracted from swish and spit samples. DNA is retained.~   "|||2018-06-01 04:23:50.333239|2018-06-01 04:23:50.333239
NCT00241735|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2017-09-13|2005-10-17|2005-10-19|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2005||2005-09-30|September 2017|2017-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Soy Food and Coronary Heart Disease in Women||Completed|||135896|Actual|Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 04:23:50.506447|2018-06-01 04:23:50.506447
NCT00241722|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2017-08-29|2005-10-17|2005-10-19|Estimate|||||||2017-08-29|2017-08-30|Actual|August 1, 2005|Actual|2005-08-01|August 2017|2017-08-31|February 1, 2007|Actual|2007-02-01|February 1, 2007|Actual|2007-02-01||Interventional|||Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate Long-Term Safety and Efficacy of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain|Completed||Phase 3|805|Actual|Cubist Pharmaceuticals LLC||2|||||||||||||||||2018-06-01 04:23:50.626294|2018-06-01 04:23:50.626294
NCT00241709|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2013-03-08|2005-10-17|2005-10-19|Estimate|||||||2013-03-08|2013-03-11|Estimate|August 2005||2005-08-31|March 2013|2013-03-31||||June 2010|Actual|2010-06-30||Observational|GALA 1||Optimal Approach for Analysis of Case-Control Genetic Association Studies|Case-Control Association Studies and Genetic Confounding|Completed|||800|Actual|University of California, San Francisco|||||f||||f||||||Samples With DNA|"~     Retrospective genetic analysis of DNA; samples collected between 1998-2001~   "|||2018-06-01 04:23:50.95021|2018-06-01 04:23:50.95021
NCT00241696|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2016-08-05|2005-10-17|2005-10-19|Estimate|||||||2016-08-05|2016-08-08|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|June 2010|Actual|2010-06-30|||||Observational|||Air Pollution, Inflammation, and New Onset Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:23:50.997581|2018-06-01 04:23:50.997581
NCT00241683|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2013-01-18|2005-10-17|2005-10-19|Estimate|||||||2013-01-18|2013-01-21|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Fetal Growth Restriction & Maternal Cardiovascular Risk|Fetal Growth Restriction & Maternal Cardiovascular Risk|Completed|||704|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-06-01 04:23:51.995719|2018-06-01 04:23:51.995719
NCT00241670|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2012-04-25|2005-10-18|2005-10-19|Estimate|||||||2012-04-25|2012-04-26|Estimate|October 1999||1999-10-31|April 2012|2012-04-30||||July 2004|Actual|2004-07-31||Interventional|||Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid|Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection|Completed||Phase 3|415|Actual|medac GmbH||2|||f||||||||||||||2018-06-01 04:23:52.099996|2018-06-01 04:23:52.099996
NCT00241657|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2005-12-14|2005-10-18|2005-10-19|Estimate|||||||2005-12-14|2005-12-15|Estimate||||December 2002|2002-12-31||||||||Interventional|||Immune Responses to BCG Vaccination in Malawi and the UK||Completed||Phase 2|||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:23:52.160261|2018-06-01 04:23:52.160261
NCT00241644|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|2009-06-18||2016-10-27|2005-10-18|2005-10-19|Estimate|2009-06-18|2009-08-04|Estimate||||2016-10-27|2016-12-09|Estimate|October 2005||2005-10-31|October 2016|2016-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants|Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants|Completed||Phase 3|2089|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:23:52.290177|2018-06-01 04:23:52.290177
NCT00241631|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2015-05-27|2005-10-18|2005-10-19|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2006||2006-04-30|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Enhancement of in−Vitro GC Function in Patients With COPD|Enhancement of In-vitro GC Function in Patients With COPD. A Randomised, Double Blind, Placebo Controlled, Parallel-group Study to Investigate the Effect of Theophylline and Fluticasone on Induced Sputum Cells Obtained Form COPD Patients|Completed||Phase 2|31|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 04:23:53.823639|2018-06-01 04:23:53.823639
NCT00241618|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2006-09-07|2005-10-18|2005-10-19|Estimate|||||||2006-09-07|2006-09-11|Estimate|January 2002||2002-01-31|September 2006|2006-09-30|January 2006||2006-01-31|||||Interventional|||Timing and Duration of Acute Hepatitis C Treatment|Phase IV Study of Treatment of Acute Hepatitis C With Pegylated Interferon|Completed||Phase 4|180||Ain Shams University|||||f||||||||||||||2018-06-01 04:23:53.89898|2018-06-01 04:23:53.89898
NCT00241605|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2018-03-19|2005-10-17|2005-10-19|Estimate|||||||2018-03-19|2018-03-21|Actual|June 25, 2003||2003-06-25|March 2018|2018-03-31|December 16, 2005|Actual|2005-12-16|December 1, 2005|Actual|2005-12-01||Interventional|||AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus|AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, Multicenter Study to Compare the Efficacy and Tolerability of AVANDAMET to Metformin Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Control on Submaximal Metformin.|Completed||Phase 4|600||GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:23:54.1514|2018-06-01 04:23:54.1514
NCT00241592|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2007-06-12|2005-10-18|2005-10-19|Estimate|||||||2007-06-12|2007-06-14|Estimate|August 2004||2004-08-31|June 2007|2007-06-30|May 2005||2005-05-31|||||Interventional|||Vaporization as a Smokeless Cannabis Delivery System|Vaporization as a Smokeless Cannabis Delivery System: A Pilot Study|Completed||Phase 1|18||Center for Medicinal Cannabis Research|||||||||||||||||||2018-06-01 04:23:54.473222|2018-06-01 04:23:54.473222
NCT00241579|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2006-06-21|2005-10-17|2005-10-19|Estimate|||||||2006-06-21|2006-06-23|Estimate|February 2002||2002-02-28|June 2006|2006-06-30|January 2004||2004-01-31|||||Interventional|||Analgesic Efficacy of Smoked Cannabis|Analgesic Efficacy of Smoked Cannabis|Completed||Phase 1/Phase 2|15||Center for Medicinal Cannabis Research|||||||||||||||||||2018-06-01 04:23:54.535711|2018-06-01 04:23:54.535711
NCT00241566|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2010-01-19|2005-10-18|2005-10-19|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2003||2003-08-31|January 2010|2010-01-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Economic Medical Evaluation of Treatment of the Neuropathic Pain Rebel by Cortical Stimulation|Economic Medical Evaluation of Treatment of the Neuropathic Pain Rebel by Cortical Stimulation|Completed||Phase 4|200|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-06-01 04:23:54.601529|2018-06-01 04:23:54.601529
NCT00241553|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2011-01-21|2005-10-18|2005-10-19|Estimate|||||||2011-01-21|2011-01-24|Estimate|April 2001||2001-04-30|January 2011|2011-01-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs|Completed||Phase 3|276||AstraZeneca|||||||||||||||||||2018-06-01 04:23:54.679099|2018-06-01 04:23:54.679099
NCT00241540|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2011-01-21|2005-10-18|2005-10-19|Estimate|||||||2011-01-21|2011-01-24|Estimate|January 2001||2001-01-31|January 2011|2011-01-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo & Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs|Completed||Phase 3|808||AstraZeneca|||||||||||||||||||2018-06-01 04:23:55.070712|2018-06-01 04:23:55.070712
NCT00241527|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2011-01-21|2005-10-18|2005-10-19|Estimate|||||||2011-01-21|2011-01-24|Estimate|December 2000||2000-12-31|January 2011|2011-01-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo and Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs|Completed||Phase 3|556||AstraZeneca|||||||||||||||||||2018-06-01 04:23:55.388193|2018-06-01 04:23:55.388193
NCT00241514|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2011-01-20|2005-10-18|2005-10-19|Estimate|||||||2011-01-20|2011-01-21|Estimate|February 2001||2001-02-28|January 2011|2011-01-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs|Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs|Completed||Phase 3|334||AstraZeneca|||||||||||||||||||2018-06-01 04:23:55.660578|2018-06-01 04:23:55.660578
NCT00241501|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2010-11-18|2005-10-18|2005-10-19|Estimate|||||||2010-11-18|2010-11-19|Estimate|February 2004||2004-02-29|November 2010|2010-11-30|April 2005|Actual|2005-04-30|||||Interventional|||Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients|A Phase III, Multicentre, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GERD) in Pediatric and Adolescent Patients 12 to 17 Years of Age, Inclusive.|Completed||Phase 3|140||AstraZeneca|||||||||||||||||||2018-06-01 04:23:55.825546|2018-06-01 04:23:55.825546
NCT00241488|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2008-02-05|2005-10-18|2005-10-19|Estimate|||||||2008-02-05|2008-02-07|Estimate|June 2003||2003-06-30|February 2008|2008-02-29|February 2007|Actual|2007-02-28|December 2005|Actual|2005-12-31||Interventional|||DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia|: An Open-Label, Randomised, Multi-Centre, Phase IIIb/IV, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia (DISCOVERY)|Completed||Phase 3|1362|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:23:56.059754|2018-06-01 04:23:56.059754
NCT00241475|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2009-04-22|2005-10-18|2005-10-19|Estimate|||||||2009-04-22|2009-04-23|Estimate|December 2003||2003-12-31|April 2009|2009-04-30|October 2005|Actual|2005-10-31|||||Interventional|||Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy|An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy|Completed||Phase 2|30||AstraZeneca|||||f||||||||||||||2018-06-01 04:23:56.156484|2018-06-01 04:23:56.156484
NCT00241462|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-18|||2009-04-21|2005-10-18|2005-10-19|Estimate|||||||2009-04-21|2009-04-22|Estimate|June 2005||2005-06-30|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|||||Observational|FORUM||Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients|Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients|Terminated|||150|Anticipated|AstraZeneca||||Due to poor patient enrollment|f||||||||||||||2018-06-01 04:23:56.223598|2018-06-01 04:23:56.223598
NCT00241449|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2012-06-05|2005-10-17|2005-10-19|Estimate|||||||2012-06-05|2012-06-06|Estimate|November 1998||1998-11-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|March 2007|Actual|2007-03-31||Interventional|||A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer|A Double-blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer|Completed||Phase 3|51|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:23:56.417871|2018-06-01 04:23:56.417871
NCT00241436|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2011-01-25|2005-10-17|2005-10-19|Estimate|||||||2011-01-25|2011-01-27|Estimate|June 2005||2005-06-30|January 2011|2011-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Open Label Arimidex in Gynecomastia|An Open-Label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (Arimidex™) Used to Treat Pubertal Boys With Gynecomastia of Recent Onset|Completed||Phase 2|35||AstraZeneca|||||||||||||||||||2018-06-01 04:23:56.681392|2018-06-01 04:23:56.681392
NCT00241423|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2015-02-20|2005-10-17|2005-10-19|Estimate|||||||2015-02-20|2015-02-23|Estimate|October 2005||2005-10-31|January 2015|2015-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes|Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes Using Metformin or Metformin Plus a Thiazolidinedione|Completed||Phase 2|30|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:23:56.736597|2018-06-01 04:23:56.736597
NCT00241410|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2010-06-16|2005-10-17|2005-10-19|Estimate|||||||2010-06-16|2010-06-17|Estimate|December 2005||2005-12-31|September 2009|2009-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen|Investigation of the Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen|Completed||Phase 1|86|Actual|Allergy Therapeutics||2|||f||||f||||||||||2018-06-01 04:23:56.817915|2018-06-01 04:23:56.817915
NCT00241397|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2007-03-14|2005-10-17|2005-10-18|Estimate|||||||2007-03-14|2007-03-15|Estimate|November 2005||2005-11-30|March 2007|2007-03-31||||||||Observational|||Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety|An Observational Study on the Presence of Depression and/or Anxiety Disorder in Patients Consulting the General Practitioner With Painful Physical Symptoms in Belgium and Luxemburg.|Completed|||2560||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:23:56.923644|2018-06-01 04:23:56.923644
NCT00241384|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-11-16|2005-10-14|2005-10-18|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2005||2005-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer|Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer|Completed||Phase 3|396|Actual|Schiffler Cancer Center||2|||f||||t||||||||||2018-06-01 04:23:57.078112|2018-06-01 04:23:57.078112
NCT00241371|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2013-08-09|2005-10-17|2005-10-18|Estimate|||||||2013-08-09|2013-08-13|Estimate|March 2005||2005-03-31|August 2013|2013-08-31|December 2007|Actual|2007-12-31|November 2005|Actual|2005-11-30||Interventional|||A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 2|8|Actual|Washington University School of Medicine||1||No response seen in patients|f||||||||||||||2018-06-01 04:23:57.182752|2018-06-01 04:23:57.182752
NCT00241358|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|2017-04-30||2017-06-05|2005-10-17|2005-10-18|Estimate|2017-06-05|2017-06-06|Actual||||2017-06-05|2017-06-06|Actual|May 2004||2004-05-31|June 2017|2017-06-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies|A Phase I/II Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies|Completed||Phase 1/Phase 2|92|Actual|Washington University School of Medicine||3|||f||||t|t|f||||||No||2018-06-01 04:23:57.296262|2018-06-01 04:23:57.296262
NCT00241345|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2013-07-22|2005-10-17|2005-10-18|Estimate|||||||2013-07-22|2013-07-23|Estimate|June 2004||2004-06-30|July 2013|2013-07-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant|Randomized Trial of Preemptive Treatment With Oral Valganciclovir Compared With IV Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant|Terminated||Phase 3|39|Actual|Washington University School of Medicine||2||Due to low accrual|f||||||||||||||2018-06-01 04:23:58.007771|2018-06-01 04:23:58.007771
NCT00241332|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2011-07-03|2005-10-17|2005-10-18|Estimate|||||||2011-07-03|2011-07-06|Estimate|October 2005||2005-10-31|September 2005|2005-09-30|July 2006|Actual|2006-07-31|||||Interventional|||Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil Based Anesthesia?|Prophylaxis Against Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil/Propofol Based Anesthesia?|Completed||Phase 3|100||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:23:58.098191|2018-06-01 04:23:58.098191
NCT00241319|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-09-26|2005-10-14|2005-10-18|Estimate|||||||2011-09-26|2011-09-27|Estimate|October 2005||2005-10-31|September 2011|2011-09-30||||December 2005|Actual|2005-12-31||Interventional|||Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Evaluation of the Onset and Duration of Action of R89674 0.25% Ophthalmic Solution in Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|Completed||Phase 3|150||Vistakon Pharmaceuticals|||||f||||||||||||||2018-06-01 04:23:58.159588|2018-06-01 04:23:58.159588
NCT00241306|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2005-10-14|2005-10-14|2005-10-18|Estimate|||||||2005-10-14|2005-10-18|Estimate||||July 2005|2005-07-31||||||||Observational|||Variations of Hemispheric Lateralisation of Language Depending of Gender and Age.|Variations of Hemispheric Lateralisation of Language Depending of Gender and Age.|Unknown status|Active, not recruiting||||University Hospital, Tours|||||f||||||||||||||2018-06-01 04:23:58.221465|2018-06-01 04:23:58.221465
NCT00241280|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|2015-12-04||2016-02-24|2005-10-14|2005-10-18|Estimate|2016-01-28|2016-02-25|Estimate||||2016-02-24|2016-03-24|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional||The baseline population consists of subjects that were randomized to receive either the Test or Control lens.|Study Intended to Evaluate the Safety and Effectiveness of a Johnson & Johnson Vision Care Inc, (JJVCI) Contact Lens for Use on an Extended-wear Basis for up to 7 Days (6 Nights).||Completed||N/A|504|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||||||||||||2018-06-01 04:23:58.385164|2018-06-01 04:23:58.385164
NCT00241267|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2006-10-05|2005-10-14|2005-10-18|Estimate|||||||2006-10-05|2006-10-06|Estimate|March 2005||2005-03-31|May 2006|2006-05-31|March 2006||2006-03-31|||||Observational|||Bronchial Ultrasonography Via a Fibrescope: Pilot Study in Tumoral Disease|Bronchial Ultrasonography Via a Fibrescope: Pilot Study in Tumoral Disease|Terminated|||20||University Hospital, Tours|||||f||||||||||||||2018-06-01 04:23:58.790368|2018-06-01 04:23:58.790368
NCT00241254|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2012-03-14|2005-10-17|2005-10-18|Estimate|||||||2012-03-14|2012-03-15|Estimate|December 2005||2005-12-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2010|Actual|2010-03-31||Interventional|PROMESS||Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis|A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study|Completed||Phase 3|138|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 04:23:58.870411|2018-06-01 04:23:58.870411
NCT00241241|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2015-10-20|2005-10-17|2005-10-18|Estimate|||||||2015-10-20|2015-10-21|Estimate|September 2004||2004-09-30|October 2015|2015-10-31|January 2008|Actual|2008-01-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera|Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients|Completed||Phase 2|40||PV-Nord|||||f||||||||||||||2018-06-01 04:23:59.005761|2018-06-01 04:23:59.005761
NCT00241228|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2010-10-12|2005-10-17|2005-10-18|Estimate|||||||2010-10-12|2010-10-13|Estimate|October 2005||2005-10-31|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|IVOIRE||Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care)|Impact of High-volume Veno-venous Continuous Hemofiltration in the Early Management of Septic Shock Patients With Acute Renal Failure|Completed||N/A|139|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 04:23:59.088095|2018-06-01 04:23:59.088095
NCT00241215|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2016-06-19|2005-10-17|2005-10-18|Estimate|||||||2016-06-19|2016-06-21|Estimate|June 2003||2003-06-30|June 2016|2016-06-30||||November 2005|Actual|2005-11-30||Interventional|||Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome|Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome|Completed||Phase 4|132|Actual|University of California, Los Angeles|||||f||||||||||||||2018-06-01 04:23:59.187581|2018-06-01 04:23:59.187581
NCT00241202|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2008-01-14|2005-10-14|2005-10-18|Estimate|||||||2008-01-14|2008-01-17|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||The Efficacy of the HIV/AIDS Symptom Management Manual|The Efficacy of the HIV/AIDS Symptom Management Manual|Completed||N/A|775|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 04:23:59.256239|2018-06-01 04:23:59.256239
NCT00241189|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2016-04-08|2005-10-14|2005-10-18|Estimate|||||||2016-04-08|2016-04-11|Estimate|August 2002||2002-08-31|April 2016|2016-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Rapamycin vs Methotrexate in Diffuse SSc|A 48-week, Double-blind, Randomized, Parallel Phase I/II Study of Oral Rapamycin Versus Methotrexate in Systemic Sclerosis (Scleroderma)|Completed||Phase 1/Phase 2|17|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 04:23:59.33236|2018-06-01 04:23:59.33236
NCT00241176|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|2012-06-07||2016-10-26|2005-10-14|2005-10-18|Estimate|2012-12-14|2013-01-25|Estimate||||2016-10-26|2016-12-09|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|February 2010|Actual|2010-02-28|August 2008|Actual|2008-08-31||Interventional|||Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder|Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder|Completed||Phase 4|11|Actual|New York University School of Medicine|All subjects failed to respond to previous tic medications so could have unique tic symptoms, small sample size, and this was an open-label study, so we did not have a comparison group nor were we blinded to treatment.|1|||f||||t||||||||||2018-06-01 04:23:59.416403|2018-06-01 04:23:59.416403
NCT00241163|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2012-08-01|2005-10-16|2005-10-18|Estimate|||||||2012-08-01|2012-08-03|Estimate||||May 2012|2012-05-31||||||||Interventional|||TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN)|An Open, Randomised, Prospective, Multicentre, Parallel-group Trial to Compare Efficacy and Safety of TachoComb S Versus Standard Surgical Treatment in Patients Undergoing Surgical Resection of Superficial Renal Tumour.|Completed||Phase 3|170||Takeda|||||f||||t||||||||||2018-06-01 04:23:59.591122|2018-06-01 04:23:59.591122
NCT00241150|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-11-07|2005-10-17|2005-10-18|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2002||2002-11-30|June 2006|2006-06-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome|A Multicenter, Double Blind, Randomized Study With Two Parallel Groups Comparing The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome|Completed||Phase 4|80|Actual|Novartis|||||||||||||||||||2018-06-01 04:23:59.63885|2018-06-01 04:23:59.63885
NCT00241137|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-11-22|2005-10-14|2005-10-18|Estimate|||||||2011-11-22|2011-11-23|Estimate|September 2003||2003-09-30|June 2006|2006-06-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg|A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg|Completed||Phase 3|3790|Actual|Novartis|||||f||||||||||||||2018-06-01 04:23:59.819881|2018-06-01 04:23:59.819881
NCT00241124|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-11-22|2005-10-17|2005-10-18|Estimate|||||||2011-11-22|2011-11-23|Estimate|April 2004||2004-04-30|November 2011|2011-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Comparison Of Morning And Evening Dosing Of Valsartan And Lisinopril In Patients With Diabetes|A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension And Non-Insulin Dependent Diabetes|Completed||Phase 4|1099|Actual|Novartis|||||f||||||||||||||2018-06-01 04:23:59.885572|2018-06-01 04:23:59.885572
NCT00241111|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2017-03-02|2005-10-17|2005-10-18|Estimate|||||||2017-03-02|2017-03-06|Actual|September 2003||2003-09-30|April 2010|2010-04-30||||January 2006|Actual|2006-01-31||Interventional|||Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis|Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis|Completed||Phase 4|148|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:23:59.949941|2018-06-01 04:23:59.949941
NCT00241098|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-11-07|2005-10-14|2005-10-18|Estimate|||||||2011-11-07|2011-11-08|Estimate|May 2003||2003-05-31|February 2006|2006-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure|A Randomized, Double Blind, Parallel Group Study to Evaluate the Effects of Valsartan Versus Placebo in Patients With Early Stage Heart Failure Due to Diastolic Dysfunction Already Evidenced by an Elevated B-type Natriuretic Peptide Level: the VALIDATE Study|Completed||Phase 4|37|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:00.030658|2018-06-01 04:24:00.030658
NCT00241085|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-11-07|2005-10-14|2005-10-18|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2002||2002-11-30|June 2006|2006-06-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Effect of Valsartan on Proteinuria in Patients With Hypertension and Diabetes Mellitus|A Multi-center, Double Blind, Randomized, Parallel Group Study to Evaluate the Effects of Valsartan on Proteinuria in Hypertensive Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|392|Actual|Novartis|||||||||||||||||||2018-06-01 04:24:00.097297|2018-06-01 04:24:00.097297
NCT00241072|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2012-05-03|2005-10-17|2005-10-18|Estimate|||||||2012-05-03|2012-05-04|Estimate|September 2002||2002-09-30|May 2012|2012-05-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance|A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt)|Completed||Phase 4|27|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:00.186726|2018-06-01 04:24:00.186726
NCT00241059|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-01-28|2005-10-14|2005-10-18|Estimate|||||||2011-01-28|2011-01-31|Estimate|August 2002||2002-08-31|January 2011|2011-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients|A Prospective, Open-label, Multicenter, International Follow-up Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients|Completed||Phase 4|183|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:00.268822|2018-06-01 04:24:00.268822
NCT00241046|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2012-04-18|2005-10-17|2005-10-18|Estimate|||||||2012-04-18|2012-04-19|Estimate|April 2002||2002-04-30|April 2012|2012-04-30||||March 2005|Actual|2005-03-31||Interventional|||Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment|Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment|Terminated||Phase 4|13|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:00.327601|2018-06-01 04:24:00.327601
NCT00241020|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2016-04-11|2005-10-16|2005-10-18|Estimate|||||||2016-04-11|2016-04-12|Estimate|June 2002||2002-06-30|April 2016|2016-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma|Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 3|270|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:00.38074|2018-06-01 04:24:00.38074
NCT00241007|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-11-07|2005-10-14|2005-10-18|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2003||2003-12-31|October 2005|2005-10-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension|A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension|Completed||Phase 3|836|Actual|Novartis|||||||||||||||||||2018-06-01 04:24:00.432733|2018-06-01 04:24:00.432733
NCT00240994|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|2012-09-13||2016-11-15|2005-10-14|2005-10-18|Estimate|2012-09-13|2012-10-25|Estimate||||2016-11-15|2017-01-02|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients|A Phase II Exploratory Study to Determine the Safety and Study the Immunomodulatory Functions of Induction Therapy With Campath, Combined With Chronic Immunosuppression With Mycophenolate Mofetil and Sirolimus|Completed||Phase 2|35|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 04:24:00.497382|2018-06-01 04:24:00.497382
NCT00240981|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|2017-02-08||2017-02-22|2005-10-14|2005-10-18|Estimate|2017-02-22|2017-02-23|Actual||||2017-02-22|2017-02-23|Actual|January 2005||2005-01-31|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter or a free serum testosterone level of less than 50 pg per milliliter were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months.|TOM: Testosterone in Older Men With Sarcopenia|Testosterone Replacement for Older Men With Sarcopenia|Terminated||Phase 4|209|Actual|Boston Medical Center||2||"Higher incidence of cardiovascular events in the testosterone arm of the trial. Decision taken~   by the DSMB on December 31st, 2009."|f||||t||||||||||2018-06-01 04:24:00.795269|2018-06-01 04:24:00.795269
NCT00240968|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-08-15|2005-10-14|2005-10-18|Estimate|||||||2013-08-15|2013-08-16|Estimate|October 2005||2005-10-31|July 2008|2008-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||H5 Booster After a Two Dose Schedule|Evaluation of a Booster Dose of A/Vietnam/1203/04 (H5N1) Vaccine Administered at 6 Months to Healthy Adult Subjects After a Two Dose Schedule at 0 and 1 Months|Completed||Phase 2|337|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:24:02.227744|2018-06-01 04:24:02.227744
NCT00240955|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2017-02-21|2005-10-14|2005-10-18|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2004||2004-03-31|February 2017|2017-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients|Efficacy and Safety of Two Immunosuppressive Regimens Mycophenolate Sodium (EC-MPS) With Short-term Steroid Use or Free of Steroids Compared With a Regimen of EC-MPS With Standard Steroids in de Novo Kidney Recipients|Completed||Phase 4|79|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:02.300042|2018-06-01 04:24:02.300042
NCT00240942|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2012-04-25|2005-10-14|2005-10-18|Estimate|||||||2012-04-25|2012-04-26|Estimate|October 2002||2002-10-31|April 2012|2012-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Letrozole in the Treatment of Severe and Recurrent Endometriosis|Letrozole in the Treatment of Severe and Recurrent Endometriosis|Completed||Phase 2|40||Novartis|||||f||||||||||||||2018-06-01 04:24:02.354817|2018-06-01 04:24:02.354817
NCT00238862|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2007-03-05|2005-10-12|2005-10-14|Estimate|||||||2007-03-05|2007-03-06|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|September 2006||2006-09-30|||||Interventional|||Treatment of PED With AMT and Autologous Serum|Efficacy of Amniotic Membrane Transplantation and Autologous Serum in Treatment of Persistent Epithelial Defects|Completed||N/A|180||King Khaled Eye Specialist Hospital|||||f||||t||||||||||2018-06-01 04:24:32.162402|2018-06-01 04:24:32.162402
NCT00240929|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2010-11-12|2005-10-14|2005-10-18|Estimate|||||||2010-11-12|2010-11-15|Estimate|September 2002||2002-09-30|November 2010|2010-11-30|April 2003|Actual|2003-04-30|||||Interventional|||A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)|A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis), A Humanized Respiratory Syncytial Virus Monoclonal Antibody, in Children With a History of Prematurity|Completed||Phase 2|150|Actual|MedImmune LLC|||||f||||||||||||||2018-06-01 04:24:02.501382|2018-06-01 04:24:02.501382
NCT00240916|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2009-11-05|2005-10-14|2005-10-18|Estimate|||||||2009-11-05|2009-11-09|Estimate|July 1993||1993-07-31|November 2009|2009-11-30|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|||Ontogeny of Measles Immunity in Infants|Ontogeny of Vaccine-Induced Measles Immunity Child Participant-6 and 9 Months|Unknown status|Recruiting||555|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     white cells, serum~   "|||2018-06-01 04:24:02.565361|2018-06-01 04:24:02.565361
NCT00240903|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-08-11|2005-10-14|2005-10-18|Estimate|||||||2011-08-11|2011-08-12|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|March 2006||2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine|Revaccination of Healthy Subjects With Intramuscular Inactivated Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine Representing a Drifted Variant|Completed||Phase 1|37|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:24:02.649472|2018-06-01 04:24:02.649472
NCT00240877|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2008-11-19|2005-10-14|2005-10-18|Estimate|||||||2008-11-19|2008-11-20|Estimate|August 2002||2002-08-31|November 2008|2008-11-30|April 2004|Actual|2004-04-30|August 2003|Actual|2003-08-31||Interventional|||Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)|Completed||Phase 3|330|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 04:24:02.7158|2018-06-01 04:24:02.7158
NCT00240864|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-06-18|2005-10-14|2005-10-18|Estimate|||||||2015-06-18|2015-06-19|Estimate||||June 2015|2015-06-30|February 2004|Actual|2004-02-29|||||Interventional|||An Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain|Completed||Phase 4|224|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||||||||||||2018-06-01 04:24:02.786897|2018-06-01 04:24:02.786897
NCT00240851|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-06-18|2005-10-14|2005-10-18|Estimate|||||||2015-06-18|2015-06-19|Estimate||||June 2015|2015-06-30|February 2004|Actual|2004-02-29|||||Interventional|||An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in Treating Muscle Aches and Soreness That Occur After a Marathon Race|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) in the Treatment of Post-Race Muscle Aching and Pain (Soreness)|Completed||Phase 4|665|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||||||||||||2018-06-01 04:24:02.868298|2018-06-01 04:24:02.868298
NCT00240838|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-06-28|2005-10-14|2005-10-18|Estimate|||||||2011-06-28|2011-06-29|Estimate|May 2003||2003-05-31|June 2011|2011-06-30|June 2003|Actual|2003-06-30|||||Interventional|||An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.|A Randomized, Double-Blind Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.|Completed||Phase 4|483|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|||||||||||||||||||2018-06-01 04:24:03.056097|2018-06-01 04:24:03.056097
NCT00240825|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-06-18|2005-10-14|2005-10-18|Estimate|||||||2015-06-18|2015-06-19|Estimate||||June 2015|2015-06-30|February 2004|Actual|2004-02-29|||||Interventional|||An Effectiveness and Safety Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain.|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study of Acetaminophen 1000 mg and Ibuprofen 400 mg in Postoperative Dental Pain|Completed||Phase 4|222|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||||||||||||2018-06-01 04:24:03.133595|2018-06-01 04:24:03.133595
NCT00240812|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-06-28|2005-10-14|2005-10-18|Estimate|||||||2011-06-28|2011-06-29|Estimate||||June 2011|2011-06-30|November 2002|Actual|2002-11-30|||||Interventional|||A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting|A Comparative Study of Coadministered Doses of Ibuprofen and Pseudoephedrine HCl and Each Drug Alone in the Treatment of Primary Nocturnal Enuresis in Children|Completed||Phase 2|318|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|||||||||||||||||||2018-06-01 04:24:03.203625|2018-06-01 04:24:03.203625
NCT00240799|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-06-18|2005-10-14|2005-10-18|Estimate|||||||2015-06-18|2015-06-19|Estimate||||June 2015|2015-06-30|October 2004|Actual|2004-10-31|||||Interventional|||An Effectiveness and Safety Study of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee.|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (3900 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee.|Completed||Phase 3|542|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||||||||||||2018-06-01 04:24:03.268567|2018-06-01 04:24:03.268567
NCT00240786|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-06-28|2005-10-14|2005-10-18|Estimate|||||||2011-06-28|2011-06-29|Estimate|April 2002||2002-04-30|June 2011|2011-06-30|March 2003|Actual|2003-03-31|||||Interventional|||An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee|A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release (1950 mg/Day or 3900 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee|Completed||Phase 3|483|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|||||||||||||||||||2018-06-01 04:24:03.346394|2018-06-01 04:24:03.346394
NCT00240773|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-06-18|2005-10-14|2005-10-18|Estimate|||||||2015-06-18|2015-06-19|Estimate||||June 2015|2015-06-30|June 2003|Actual|2003-06-30|||||Interventional|||A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee|A Randomized, Double-Blind, Long-Term Comparative Study Evaluating the Safety and Efficacy of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee|Completed||Phase 3|581|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||||||||||||2018-06-01 04:24:03.406315|2018-06-01 04:24:03.406315
NCT00240760|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2006-02-17|2005-10-14|2005-10-18|Estimate|||||||2006-02-17|2006-02-20|Estimate|October 2005||2005-10-31|October 2005|2005-10-31||||||||Interventional|||Memantine and Down's Syndrome|Efficacy and Safety of Memantine Hydrochloride, a Low Affinity Antagonist to N-Methyl-D-Aspartate (NMDA) Type Receptors, in the Prevention of Cognitive Decline and Disease Progression in Down’s Syndrome|Unknown status|Recruiting|N/A|180||King's College London|||||f||||||||||||||2018-06-01 04:24:03.475788|2018-06-01 04:24:03.475788
NCT00240734|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-06-08|2005-10-14|2005-10-18|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2005||2005-03-31|March 2010|2010-03-31|September 2005|Actual|2005-09-30|||||Interventional|||Treatment of Anemia in Diabetic Subjects With CKD|A Randomized, Double-blind, Placebo-Controlled Study Evaluating Weekly Epoetin Alfa (PROCRIT�) Administration on Hemoglobin Response and Safety in Diabetic Subjects With the Anemia of Chronic Kidney Disease (CKD)|Terminated||Phase 2|11|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"This study was stopped for slow enrollment after enrolling only 11 of 180 patients in six~   months time."|||||f||||||||||2018-06-01 04:24:03.605731|2018-06-01 04:24:03.605731
NCT00240721|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-06-06|2005-10-14|2005-10-18|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2000||2000-10-31|November 2010|2010-11-30|September 2002|Actual|2002-09-30|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension|Completed||Phase 3|363|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:03.74646|2018-06-01 04:24:03.74646
NCT00240708|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-05-16|2005-10-14|2005-10-18|Estimate|||||||2011-05-16|2011-05-17|Estimate|June 2004||2004-06-30|March 2010|2010-03-31|April 2006|Actual|2006-04-30|||||Interventional|||A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia|A Parallel-Group Comparative Open-Label Study of Long-Acting Injectible Risperidone Versus Risperidone Tablets in Patients With Schizophrenia.|Completed||Phase 3|205|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 04:24:03.81758|2018-06-01 04:24:03.81758
NCT00240695|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-05-17|2005-10-14|2005-10-18|Estimate|||||||2011-05-17|2011-05-18|Estimate|May 2003||2003-05-31|April 2010|2010-04-30|May 2004|Actual|2004-05-31|||||Interventional|||A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment|An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment|Completed||Phase 3|724|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:03.916246|2018-06-01 04:24:03.916246
NCT00240682|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2012-02-18|2005-10-17|2005-10-18|Estimate|||||||2012-02-18|2012-02-22|Estimate|October 2005||2005-10-31|August 2009|2009-08-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|CTXSCC||Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR|Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR.|Completed||Phase 2|37|Actual|Centre Hospitalier of Chartres||1|||f||||t||||||||||2018-06-01 04:24:04.004769|2018-06-01 04:24:04.004769
NCT00240669|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2007-04-26|2005-10-14|2005-10-18|Estimate|||||||2007-04-26|2007-04-27|Estimate|November 2005||2005-11-30|April 2007|2007-04-30||||||||Interventional|||RESTIT : Evaluation of Resorbable Osteosynthesis Devices Versus Titanium in Maxillofacial Surgery|RESTIT : Evaluation of Resorbable Osteosynthesis Devices Versus Titanium in Maxillofacial Surgery – A Prospective Randomized Trial in Therapeutic Strategy|Unknown status|Recruiting|N/A|308||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:24:04.12121|2018-06-01 04:24:04.12121
NCT00240656|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17|||2008-06-27|2005-10-17|2005-10-18|Estimate|||||||2008-06-27|2008-06-30|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|May 2006||2006-05-31|||||Interventional|||Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension|Official Title: Spironolactone Combined With Captopril and Carvedilol for the Treatment of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease—Focus on Pulmonary Artery Remodeling|Completed||Phase 1|||Hebei Medical University|||||f||||||||||||||2018-06-01 04:24:04.20652|2018-06-01 04:24:04.20652
NCT00240643|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2017-01-13|2005-10-14|2005-10-18|Estimate|||||||2017-01-13|2017-01-16|Estimate|November 2005||2005-11-30|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke|A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke|Completed||Phase 2|640|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:24:04.320748|2018-06-01 04:24:04.320748
NCT00240630|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-04-15|2005-10-14|2005-10-18|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks|A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks|Completed||Phase 3|646|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:24:04.608169|2018-06-01 04:24:04.608169
NCT00240617|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2016-10-24|2005-10-14|2005-10-18|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2005||2005-10-31|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks|A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima* (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks (*Treximet)|Completed||Phase 3|623|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:24:04.770964|2018-06-01 04:24:04.770964
NCT00240604|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2011-09-13|2005-10-16|2005-10-18|Estimate|||||||2011-09-13|2011-09-14|Estimate|April 2005||2005-04-30|September 2011|2011-09-30|October 2015|Anticipated|2015-10-31|December 2013|Anticipated|2013-12-31||Interventional|||Prevention of Corticosteroid-induced Glucose Intolerance|Treatment With Rosiglitazone for the Prevention of Glucose Intolerance in Patients Treated With Corticosteroids|Unknown status|Recruiting|Phase 3|100|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:24:04.958192|2018-06-01 04:24:04.958192
NCT00240591|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-11-09|2005-10-14|2005-10-18|Estimate|||||||2015-11-09|2015-11-11|Estimate|October 2003||2003-10-31|November 2015|2015-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab|A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH TOSITUMOMAB AND/OR IODINE I 131 TOSITUMOMAB IN STUDIES RIT-I-000, RIT-II-001, RIT-II-002, RIT-II-004, or CP-97-012|Completed|||150|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:24:05.025542|2018-06-01 04:24:05.025542
NCT00240578|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2016-01-28|2005-10-14|2005-10-18|Estimate|||||||2016-01-28|2016-02-01|Estimate|November 2003||2003-11-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab|A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036|Completed|||88|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:24:05.1644|2018-06-01 04:24:05.1644
NCT00240565|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2012-08-09|2005-10-14|2005-10-18|Estimate|||||||2012-08-09|2012-08-13|Estimate|April 2004||2004-04-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|February 2007|Actual|2007-02-28||Interventional|||Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma|A Single Arm, Open-label, Multicentre, Phase II Study of Tositumomab and Iodine 131-Tositumomab in Subjects With Indolent Non-Hodgkin's Lymphoma Who Have Previously Received Rituximab.|Completed||Phase 2|93|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:24:05.235105|2018-06-01 04:24:05.235105
NCT00240552|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2016-09-09|2005-10-14|2005-10-18|Estimate|||||||2016-09-09|2016-09-12|Estimate|July 2003||2003-07-31|September 2016|2016-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Fosamprenavir Expanded Access|An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options|Completed||Phase 4|85|Actual|ViiV Healthcare|||||f||||||||||||||2018-06-01 04:24:05.337501|2018-06-01 04:24:05.337501
NCT00240539|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2009-07-16||2016-10-26|2005-10-17|2005-10-18|Estimate|2009-11-12|2009-11-17|Estimate||||2016-10-26|2016-12-08|Estimate|October 2003||2003-10-31|October 2016|2016-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Long Term Follow-Up Study 16-20 Years After Hepatitis B Vaccination in Newborns of Mothers Who Were Seropositive for Hepatitis B Envelope Antigen (HBeAg) & Hepatitis B Surface Antigen (HBsAg)|Long-term Follow-Up Studies at Years 16-20, to Evaluate the Persistence of Immune Response of GSK Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers in Comparison With a Historical Control Group|Completed||Phase 4|36|Actual|GlaxoSmithKline|No safety data were collected during this long-term follow-up study.|4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:24:05.440496|2018-06-01 04:24:05.440496
NCT00240526|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2010-06-14||2016-10-14|2005-10-17|2005-10-18|Estimate|2010-06-14|2010-07-15|Estimate||||2016-10-14|2016-12-07|Estimate|October 2003||2003-10-31|October 2016|2016-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers|Comparative Study of the Immunogenicity and Protective Efficacy of GlaxoSmithKline Biologicals' Rec-DNA Hepatitis B Vaccine With or Without Hepatitis B Immunoglobulins (HBIg) in Newborns of HBeAg+ Mothers.|Completed||Phase 4|79|Actual|GlaxoSmithKline|A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). Additional tables have been generated following partial retesting and reanalysis of the results at Years 19 and 20.|4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:24:06.023405|2018-06-01 04:24:06.023405
NCT00240513|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2012-02-22|2005-10-16|2005-10-18|Estimate|||||||2012-02-22|2012-02-24|Estimate|August 2004||2004-08-31|February 2012|2012-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin|A Randomized Study to Compare the Acne Relapse Rate After a 3-mo Course of Oral Minocycline, to a 3-mo Course of Oral Minocycline in Combination With a Daily Dose of Topical Tretinoin 0.01% Followed by 3 mo of Topical Tretinoin Alone|Terminated||Phase 4|38|Actual|Derm Research @ 888 Inc.||2||Too much difficulty recruiting and retaining patients, PI decided to stop.|f||||f||||||||||2018-06-01 04:24:06.691863|2018-06-01 04:24:06.691863
NCT00240500|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2008-10-30||2016-11-03|2005-10-17|2005-10-18|Estimate|2009-03-19|2009-05-01|Estimate||||2016-11-03|2016-12-21|Estimate|October 2003||2003-10-31|November 2016|2016-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers|Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers|Completed||Phase 4|109|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:24:06.79533|2018-06-01 04:24:06.79533
NCT00240487|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|2013-01-10||2015-04-23|2005-10-14|2005-10-18|Estimate|2015-04-23|2015-04-24|Estimate||||2015-04-23|2015-04-24|Estimate|September 2000||2000-09-30|April 2015|2015-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Nitric Oxide Administration for Acute Respiratory Distress Syndrome|Nitric Oxide Administration for Acute Respiratory Distress Syndrome|Completed||Phase 3|52|Actual|Children's Hospital of Philadelphia|There may be some confounding of effects of lung recruitment from high mean airway pressures over the duration of the observation period.|2|||f||||f||||||||||2018-06-01 04:24:07.362091|2018-06-01 04:24:07.362091
NCT00240474|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-17|2005-10-18|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2002||2002-12-31|October 2013|2013-10-31|March 2004||2004-03-31|March 2004|Actual|2004-03-31||Interventional|||A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)|A Comparison of Telmisartan 80 mg + Hydrochlorothiazide 12.5 mg With Amlodipine 10 mg + Hydrochlorothiazide 12.5 mg in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension. A Prospective, Randomised, Open-label, Blinded End-point Evaluation. (ATHOS Study)|Completed||Phase 4|1000||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:07.694976|2018-06-01 04:24:07.694976
NCT00240461|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-07-06|2005-10-14|2005-10-18|Estimate|||||||2011-07-06|2011-07-07|Estimate|September 2005||2005-09-30|July 2011|2011-07-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors|Efficacy and Safety of COLD-fX in the Prevention of Respiratory Infections in Community-dwelling Seniors: a Multi-center, Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 3|780|Actual|Capital Health, Canada||3|||f||||f||||||||||2018-06-01 04:24:07.874598|2018-06-01 04:24:07.874598
NCT00240305|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2009-03-13|2005-10-17|2005-10-18|Estimate|||||||2009-03-13|2009-03-16|Estimate|April 2004||2004-04-30|March 2009|2009-03-31|May 2006|Actual|2006-05-31|||||Interventional|||A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome|A Randomised, Double-Blind, Placebo Controlled, Crossover Dose-Ranging Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome|Completed||Phase 3|15||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:14.405751|2018-06-01 04:24:14.405751
NCT00240448|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-11-04|2005-10-14|2005-10-18|Estimate|||||||2013-11-04|2013-11-05|Estimate|September 2003||2003-09-30|November 2013|2013-11-30||||June 2004|Actual|2004-06-30||Interventional|||A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pressure in Patients With Stage 1 and Stage 2 Hypertension|Completed||Phase 4|1109|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:24:08.001773|2018-06-01 04:24:08.001773
NCT00240435|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-14|2005-10-18|Estimate|||||||2013-10-31|2013-11-01|Estimate|November 2002||2002-11-30|October 2013|2013-10-31||||December 2003|Actual|2003-12-31||Interventional|||12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD|A Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Comparison of 12-week Treatment of Two Doses (5 Mcg and 10 Mcg) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) i|Completed||Phase 3|491||Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:24:08.25727|2018-06-01 04:24:08.25727
NCT00240422|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-11-07|2005-10-14|2005-10-18|Estimate|||||||2013-11-07|2013-11-08|Estimate|February 2003||2003-02-28|November 2013|2013-11-30|July 2004||2004-07-31|||||Interventional|||Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes|A Prospective, Randomized, Double-blind, Double-dummy, Forced Titration, Parallel Group Comparison, Multicenter Trial to Compare the Effects of Either Telmisartan (40-80 mg p.o. Once Daily) or Ramipril (5-10 mg p.o. Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes|Completed||Phase 4|96|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:08.380749|2018-06-01 04:24:08.380749
NCT00240409|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-11-01|2005-10-14|2005-10-18|Estimate|||||||2013-11-01|2013-11-04|Estimate|July 2003||2003-07-31|November 2013|2013-11-30|August 2004||2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease|A Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole Tablets and Bromocriptine Tablets in Patients With Parkinson's Disease.|Completed||Phase 3|208|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:08.60319|2018-06-01 04:24:08.60319
NCT00240396|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2017-03-21|2005-10-14|2005-10-18|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2005||2005-10-31|March 2017|2017-03-31|September 24, 2007|Actual|2007-09-24|September 24, 2007|Actual|2007-09-24||Interventional|||Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture|Bimodal Analgesia as Form of Pain Control Post Long Bone Fracture|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center||||We were not able to enroll patients.|f||||||||||||No||2018-06-01 04:24:08.806752|2018-06-01 04:24:08.806752
NCT00240383|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17||2010-09-10|2010-09-10|2005-10-17|2005-10-18|Estimate||||2010-09-10|2010-09-14|Estimate|2010-09-10|2010-09-14|Estimate|May 2002||2002-05-31|June 2008|2008-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Dose Ranging Study With LT, Monotherapy, PPAR|A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes|Completed||Phase 2/Phase 3|1260||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:24:08.949045|2018-06-01 04:24:08.949045
NCT00240370|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-17||2010-09-10|2010-09-10|2005-10-17|2005-10-18|Estimate||||2010-09-10|2010-09-14|Estimate|2010-09-10|2010-09-14|Estimate|October 2003||2003-10-31|June 2008|2008-06-30||||March 2005|Actual|2005-03-31||Interventional|||A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics|A Phase 3, Randomized, Double-Blind, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Metformin Compared to Pioglitazone in Combination With Metformin in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone|Completed||Phase 3|1159||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:24:09.455091|2018-06-01 04:24:09.455091
NCT00240357|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2009-03-25|2005-10-16|2005-10-18|Estimate|||||||2009-03-25|2009-03-26|Estimate|February 2003||2003-02-28|March 2009|2009-03-31||||||||Interventional|||Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia|Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement of LDL Goals. - Denmark|Withdrawn||Phase 4|1175||AstraZeneca||||Study cancelled prior to FSI|f||||||||||||||2018-06-01 04:24:09.664308|2018-06-01 04:24:09.664308
NCT00240344|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2011-08-29|2005-10-16|2005-10-18|Estimate|||||||2011-08-29|2011-08-30|Estimate|September 2004||2004-09-30|August 2011|2011-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal|REALISTIC: Protocol for an Observational Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New EAS LDL-C Target Goal|Completed|||2650|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:24:09.861034|2018-06-01 04:24:09.861034
NCT00240331|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|2009-09-29||2011-05-17|2005-10-16|2005-10-18|Estimate|2009-09-29|2009-11-04|Estimate||||2011-05-17|2011-05-19|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)|A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events (AURORA). A Double Blind, Randomised, Phase 3b, Parallel-group Study to Compare the Effects of Rosuvastatin With Placebo on Assessment of Survival & Cardiovascular Events When Given to Subjects With End-stage Renal Failure on Chronic Haemodialysis Treatment|Completed||Phase 3|2776|Actual|AstraZeneca|The endpoints were originally intended to be time to event endpoints, however we are unable to report the data as intended due to the nature of time to event endpoints. Therefore we have reported the number of participants who reached the event.|2|||f||||||||||||||2018-06-01 04:24:10.236149|2018-06-01 04:24:10.236149
NCT00240318|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2010-11-18|2005-10-16|2005-10-18|Estimate|||||||2010-11-18|2010-11-19|Estimate|November 2002||2002-11-30|November 2010|2010-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)|A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment With Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography Who Have Coronary Artery Disease|Completed||Phase 3|450||AstraZeneca|||||||||||||||||||2018-06-01 04:24:14.26515|2018-06-01 04:24:14.26515
NCT00239226|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2009-11-06||2013-09-20|2005-10-13|2005-10-14|Estimate|2013-09-20|2013-11-25|Estimate||||2013-09-20|2013-11-25|Estimate|November 2005||2005-11-30|April 2012|2012-04-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|EPASS||Electrophysiologically Guided PAcing Site Selection Study|Investigational New Drug Application/ Investigational Device Exemption Information|Completed||Phase 4|102|Actual|Medtronic BRC||4|||f||||t||||||||||2018-06-01 04:24:29.418586|2018-06-01 04:24:29.418586
NCT00240292|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2010-11-18|2005-10-16|2005-10-18|Estimate|||||||2010-11-18|2010-11-19|Estimate|February 2003||2003-02-28|November 2010|2010-11-30||||||||Interventional|||Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines|A Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre, Phase III Study to Assess the Impact of Rosuvastatin Treatment for 26 Weeks (Titrated to a Maximum Dose of 40mg Once Daily) on Left Ventricular Function, Cytokines and Lipid Parameters in Patients With Established Systolic Chronic Heart Failure.|Completed||Phase 3|160||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:14.462562|2018-06-01 04:24:14.462562
NCT00240279|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2010-11-18|2005-10-16|2005-10-18|Estimate|||||||2010-11-18|2010-11-19|Estimate|January 2003||2003-01-31|November 2010|2010-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study|The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study|Completed||Phase 3|10||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:14.540689|2018-06-01 04:24:14.540689
NCT00240266|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-16|||2010-11-18|2005-10-16|2005-10-18|Estimate|||||||2010-11-18|2010-11-19|Estimate|August 2003||2003-08-31|November 2010|2010-11-30|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)|A Randomised, Double-blind, Placebo-controlled, Crossover Pilot Study to Define the High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)|Completed||Phase 3|15||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:14.690844|2018-06-01 04:24:14.690844
NCT00240253|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2015-03-26|2005-10-14|2005-10-18|Estimate|||||||2015-03-26|2015-03-31|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Who Are Not Achieving Glycemic Targets|Completed||Phase 4|200|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 04:24:14.820793|2018-06-01 04:24:14.820793
NCT00240227|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2013-11-25||2016-03-11|2005-10-13|2005-10-17|Estimate|2016-03-11|2016-03-14|Estimate||||2016-03-11|2016-03-14|Estimate|April 2004||2004-04-30|March 2016|2016-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Prazosin for ETOH or Cocaine Craving|The Role of the Alpha 1-adrenergic Antagonist, Prazosin, in the Reduction of Craving and Relapse in Alcohol and Cocaine-dependent Individuals: a Double-blind, Randomized, Controlled Clinical Trial|Terminated||N/A|8|Actual|VA Office of Research and Development|The study procedure intended to induce substance craving failed to induce craving. Thus, any difference between placebo and active medication conditions could not be measured and so the study was terminated.|2||"Experimental procedure did not induce sufficient craving to determine any possible effect of~   medication."|f||||f||||||||||2018-06-01 04:24:14.972297|2018-06-01 04:24:14.972297
NCT00240214|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2008-03-13|2005-10-13|2005-10-17|Estimate|||||||2008-03-13|2008-03-14|Estimate|April 2001||2001-04-30|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Study Evaluating Rapamune in Patients After Kidney Transplantation|An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime|Terminated|||500|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||||||||||||2018-06-01 04:24:15.169218|2018-06-01 04:24:15.169218
NCT00240188|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2010-09-15|2005-10-13|2005-10-17|Estimate|||||||2010-09-15|2010-09-16|Estimate|February 2004||2004-02-29|September 2010|2010-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Study to Compare Ventral Incisional Hernia by Laparoscopic vs Open Repair With Mesh|Ventral Incisional Hernia Repair: Comparison Of Laparoscopic and Open Repair With Mesh|Completed||N/A|110|Anticipated|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 04:24:15.240147|2018-06-01 04:24:15.240147
NCT00240175|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2012-02-29|2005-10-13|2005-10-17|Estimate|||||||2012-02-29|2012-03-01|Estimate|August 2005||2005-08-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluating the Effects of Foot Orthotics on Plantar Pressures in the Diabetic Population|Evaluating the Effects of Foot Orthotics on Plantar Pressures in the Diabetic Population|Completed||Phase 1|65|Actual|The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 04:24:15.315403|2018-06-01 04:24:15.315403
NCT00240162|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2014-08-22||2014-09-05|2005-10-13|2005-10-17|Estimate|2014-08-22|2014-09-04|Estimate||||2014-09-05|2014-09-17|Estimate|September 2005||2005-09-30|September 2014|2014-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma|A Phase II Study of PTK787/ZK 222584, a Novel, Oral Angiogenesis Inhibitor as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma Following High Dose Chemotherapy and Autologous Stem Cell Transplant|Terminated||Phase 2|21|Actual|Washington University School of Medicine|In November 2008, it was reported that the drug might have carcinogenic potential in animal models. At that time, the remaining three patients were taken off study.|1||"investigator letter from drug manufacturer stating animal studies showed increased risk of~   cancer which was an unknown adverse event"|f||||||||||||||2018-06-01 04:24:15.396825|2018-06-01 04:24:15.396825
NCT00240149|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2007-12-19|2005-10-13|2005-10-17|Estimate|||||||2007-12-19|2007-12-20|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|March 2006||2006-03-31|||||Interventional|||Pilot Study to Evaluate a Method of Controlling High Blood Sugar in the Pediatric Intensive Care Unit|Pilot Study Evaluating Use of Insulin-Glucose Algorithm and Glucose Monitoring Techniques to Control Hyperglycemia in the Pediatric Intensive Care Unit|Completed||N/A|0||Stanford University|||||f||||||||||||||2018-06-01 04:24:15.682227|2018-06-01 04:24:15.682227
NCT00240136|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2016-02-17|2005-10-13|2005-10-17|Estimate|||||||2016-02-17|2016-02-19|Estimate|January 1993||1993-01-31|February 2016|2016-02-29|July 2023|Anticipated|2023-07-31|December 2022|Anticipated|2022-12-31||Observational|||Long-term Observation of Patients With Early Rheumatoid Arthritis|Long-term Observation of Patients With Early Rheumatoid Arthritis|Active, not recruiting|||372|Actual|University of California, Los Angeles|||||f||||t||||||||||2018-06-01 04:24:15.836689|2018-06-01 04:24:15.836689
NCT00240123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-16|2005-10-13|2005-10-17|Estimate|||||||2015-09-16|2015-09-18|Estimate|July 2005||2005-07-31|September 2015|2015-09-30|July 2007||2007-07-31|||||Interventional|||Effect of Benadryl Sedation During ERCP or EUS|Effect of Diphenhydramine Sedation During Endoscopic Retrograde Cholangio-pancreatography (ERCP) or Endoscopic Ultrasound (EUS)|Withdrawn||Phase 1|0|Actual|University of Rochester|||||f||||||||||||||2018-06-01 04:24:15.906967|2018-06-01 04:24:15.906967
NCT00240110|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2015-06-30||2016-08-24|2005-10-13|2005-10-17|Estimate|2016-08-24|2016-10-17|Estimate||||2016-08-24|2016-10-17|Estimate|March 2006||2006-03-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Valproate Efficacy in Cocaine-Bipolar Comorbidity|Valproate Efficacy in Cocaine-Bipolar Comorbidity|Completed||Phase 1/Phase 2|152|Actual|University of Miami||2|||f||||t||||||||No||2018-06-01 04:24:15.982026|2018-06-01 04:24:15.982026
NCT00240097|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2012-06-08||2014-11-26|2005-10-13|2005-10-17|Estimate|2014-11-26|2014-11-27|Estimate||||2014-11-26|2014-11-27|Estimate|June 2005||2005-06-30|November 2014|2014-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)|Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin-Etoposide/Carboplatin in Extensive SCLC|Completed||Phase 2|30|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 04:24:16.407742|2018-06-01 04:24:16.407742
NCT00240084|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2013-06-17|2005-10-13|2005-10-17|Estimate|||||||2013-06-17|2013-06-19|Estimate|July 2003||2003-07-31|June 2013|2013-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Nesiritide and Vo2 Max in Heart Failure Patients|Nesiritide and Vo2 Max in Heart Failure Patients|Completed||Phase 2|20|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 04:24:16.720326|2018-06-01 04:24:16.720326
NCT00240071|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2011-04-20||2018-02-20|2005-10-13|2005-10-17|Estimate|2011-08-21|2011-09-27|Estimate||||2018-02-20|2018-03-19|Actual|October 2005||2005-10-31|February 2018|2018-02-28|April 2011|Actual|2011-04-30|March 2009|Actual|2009-03-31||Interventional|||Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.|The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial|Completed||Phase 2|30|Actual|University of Alabama at Birmingham|A Phase II trial.|1|||f||||t||||||||||2018-06-01 04:24:16.801941|2018-06-01 04:24:16.801941
NCT00240058|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2017-06-01|2005-10-13|2005-10-17|Estimate|||||||2017-06-01|2017-06-05|Actual|July 2005||2005-07-31|June 2017|2017-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Pilot Study On The Role Of Nitric Oxide In Alpha 1-Adrenergic Vasoreactivity|Pilot Study On The Role Of Nitric Oxide In Alpha 1-Adrenergic Vasoreactivity|Completed||N/A|22|Actual|University of Michigan||1|||f||||||||||||||2018-06-01 04:24:17.019045|2018-06-01 04:24:17.019045
NCT00240045|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2007-12-03|2005-10-13|2005-10-17|Estimate|||||||2007-12-03|2007-12-06|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|July 2007|Actual|2007-07-31|||||Interventional|||The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction|The Use of Midodrine, Octreotide and Albumin in Refractory Ascites|Completed||Phase 2/Phase 3|9|Actual|University of Alberta||1|||f||||f||||||||||2018-06-01 04:24:17.095345|2018-06-01 04:24:17.095345
NCT00240032|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2011-04-07|2005-10-13|2005-10-17|Estimate|||||||2011-04-07|2011-04-11|Estimate|October 2004||2004-10-31|April 2011|2011-04-30|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.|A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.|Completed||Phase 4|80|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:24:17.180407|2018-06-01 04:24:17.180407
NCT00240019|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2006-10-16|2005-10-13|2005-10-17|Estimate|||||||2006-10-16|2006-10-17|Estimate|December 2003||2003-12-31|June 2006|2006-06-30|April 2006||2006-04-30|||||Interventional|||Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.|Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy|Completed||N/A|30||Stanford University|||||f||||||||||||||2018-06-01 04:24:17.245857|2018-06-01 04:24:17.245857
NCT00240006|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2011-04-08|2005-10-13|2005-10-17|Estimate|||||||2011-04-08|2011-04-11|Estimate|January 2006||2006-01-31|April 2011|2011-04-30|September 2007|Actual|2007-09-30|January 2007|Actual|2007-01-31||Interventional|||A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone|An Open Label, Prospective Parallel Cohort Study Comparing A 90-day Copaxone® Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions® Alone or in Partnership With Their MS Center|Completed||Phase 4|307|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:24:17.308609|2018-06-01 04:24:17.308609
NCT00239993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2017-02-02|2005-10-13|2005-10-17|Estimate|||||||2017-02-02|2017-02-06|Estimate|August 2005||2005-08-31|February 2017|2017-02-28|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®|An Open-Label, Randomized, Single Cross-over Study of Warm Compress Versus Usual Injection Site Preparation on Local Injection Site Reactions Among Persons With MS Who Perform Daily Injections of Copaxone®.|Completed||Phase 4|50|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:24:17.375824|2018-06-01 04:24:17.375824
NCT00239980|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2010-02-02|2005-10-13|2005-10-17|Estimate|||||||2010-02-02|2010-02-03|Estimate|October 2005||2005-10-31|February 2010|2010-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)|A Phase II Randomized Study of Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)|Completed||Phase 2|77|Actual|Ontario Clinical Oncology Group (OCOG)||3|||f||||t||||||||||2018-06-01 04:24:17.455453|2018-06-01 04:24:17.455453
NCT00239967|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2009-04-06|2005-10-13|2005-10-17|Estimate|||||||2009-04-06|2009-04-07|Estimate|May 2005||2005-05-31|April 2009|2009-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|ADAGIO-lipids||An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients|A Randomized, Double-Blind, Two-Arm Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients|Completed||Phase 3|803|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:24:17.538492|2018-06-01 04:24:17.538492
NCT00239954|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2012-05-08|2005-10-13|2005-10-17|Estimate|||||||2012-05-08|2012-05-09|Estimate|March 2005||2005-03-31|May 2012|2012-05-31||||||||Interventional|||Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder|Fixed Dose Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder|Unknown status|Active, not recruiting|Phase 3|||Pharmacology Research Institute|||||||||||||||||||2018-06-01 04:24:17.622497|2018-06-01 04:24:17.622497
NCT00239928|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2009-11-04||2011-05-11|2005-10-13|2005-10-17|Estimate|2011-04-05|2011-05-04|Estimate||||2011-05-11|2011-05-12|Estimate|September 2005||2005-09-30|May 2011|2011-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration|Long-Term Study For Pegaptanib Sodium In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration (Extension Study From A5751010)|Completed||Phase 2|61|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:24:17.696063|2018-06-01 04:24:17.696063
NCT00239915|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2012-05-08|2005-10-13|2005-10-17|Estimate|||||||2012-05-08|2012-05-09|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|December 2006||2006-12-31|||||Interventional|||Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)|An 8-week, Double-Blind, Randomized, Multicenter, Flexible-Dose, Placebo-Controlled Pilot Study of Pagoclone in Patients With Persistent Developmental Stuttering Followed by a 52-week Open-Label Extension.|Completed||Phase 2|||Pharmacology Research Institute|||||||||||||||||||2018-06-01 04:24:18.167704|2018-06-01 04:24:18.167704
NCT00239902|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2011-11-01|2005-10-13|2005-10-17|Estimate|||||||2011-11-01|2011-11-02|Estimate|May 2002||2002-05-31|November 2011|2011-11-30||||November 2004|Actual|2004-11-30||Interventional|||Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|Two-year Extension of a One-year, Multicenter, Randomized, Partially-blinded Study of the Safety and Efficacy of FTY720 Combined With Corticosteroids and Full or Reduced-dose Cyclosporine, USP [Modified] (Novartis Brand) in de Novo Adult Renal Transplant Recipients|Completed||Phase 2|396||Novartis|||||||||||||||||||2018-06-01 04:24:18.217998|2018-06-01 04:24:18.217998
NCT00239889|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2006-11-29|2005-10-13|2005-10-17|Estimate|||||||2006-11-29|2006-11-30|Estimate|March 2002||2002-03-31|March 2006|2006-03-31||||||||Interventional|||Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women|Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women|Completed||Phase 4|300||Novartis|||||f||||||||||||||2018-06-01 04:24:18.273841|2018-06-01 04:24:18.273841
NCT00239876|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2011-11-01|2005-10-13|2005-10-17|Estimate|||||||2011-11-01|2011-11-02|Estimate|May 2005||2005-05-31|November 2011|2011-11-30||||December 2005|Actual|2005-12-31||Interventional|||Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A Two-year Extension to a One-year, Multicenter, Open-label, Randomised Study to Evaluate the Safety and Efficacy of FTY720 Combined With Tacrolimus and Steroids Versus Mycophenolate Mofetyl Combined With Tacrolimus and Steroids, in de Novo Adult Renal Transplant Recipients|Completed||Phase 3|140||Novartis|||||||||||||||||||2018-06-01 04:24:18.3315|2018-06-01 04:24:18.3315
NCT00239863|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2017-02-21|2005-10-13|2005-10-17|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2004||2004-05-31|February 2017|2017-02-28||||May 2006|Actual|2006-05-31||Interventional|||Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients|A Two-year Extension to a One-year, Multicenter, Partially Blinded, Double-dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients.|Completed||Phase 3|684||Novartis|||||||||||||||||||2018-06-01 04:24:18.389493|2018-06-01 04:24:18.389493
NCT00239850|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2017-03-21|2005-10-14|2005-10-17|Estimate|||||||2017-03-21|2017-03-24|Actual|August 2005|Actual|2005-08-31|March 2017|2017-03-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Morbid Obesity: Effects of Conservative Treatments and Gastric Bypass Surgery|Morbid Obesity: Effects of Conservative Treatments and Gastric Bypass Surgery|Completed||N/A|209|Actual|Norwegian University of Science and Technology|||||f|||||f|f||||||||2018-06-01 04:24:18.469897|2018-06-01 04:24:18.469897
NCT00239837|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2013-05-06||2015-12-04|2005-10-13|2005-10-17|Estimate|2014-02-14|2014-03-31|Estimate||||2015-12-04|2016-01-08|Estimate|December 2003||2003-12-31|December 2015|2015-12-31|April 2013|Actual|2013-04-30|December 2009|Actual|2009-12-31||Interventional|||Prevention Program for Problem Behaviors in Girls in Foster Care|Preventing Problems for Girls in Foster Care|Completed||Phase 1|100|Actual|Oregon Social Learning Center|Sample is relatively small in size, and limited to girls in foster care in two Oregon Counties|2|||f||||f||||||||||2018-06-01 04:24:18.585601|2018-06-01 04:24:18.585601
NCT00239824|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2016-07-15|2005-10-14|2005-10-17|Estimate|||||||2016-07-15|2016-07-18|Estimate|October 2005||2005-10-31|July 2016|2016-07-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Pelvic Floor Muscle Training to Treat Urinary Incontinence After Radical Prostatectomy|Urinary Incontinence After Radical Prostatectomy. - Effect of Pelvic Floor Muscle Training. A Randomised Controlled Trial|Completed||N/A|80|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:24:19.017561|2018-06-01 04:24:19.017561
NCT00239811|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2011-11-01|2005-10-13|2005-10-17|Estimate|||||||2011-11-01|2011-11-02|Estimate|April 2004||2004-04-30|November 2011|2011-11-30||||May 2006|Actual|2006-05-31||Interventional|||Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A Two-year Extension to a One-year, Multicenter, Partially Blinded, Double Dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients|Completed||Phase 3|684||Novartis|||||f||||||||||||||2018-06-01 04:24:19.130916|2018-06-01 04:24:19.130916
NCT00239798|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2017-02-21|2005-10-13|2005-10-17|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2004||2004-11-30|February 2017|2017-02-28||||November 2006|Actual|2006-11-30||Interventional|||Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A 24-month Extension of a One-year, Multicenter, Double Blinded Double Dummy, Randomized Study to Evaluate the Safety and Efficacy of Two Doses of FTY720 Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids, in Adult de Novo Renal Transplant Recipients|Completed||Phase 2|255||Novartis|||||||||||||||||||2018-06-01 04:24:19.230405|2018-06-01 04:24:19.230405
NCT00239785|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2017-08-18|2005-10-13|2005-10-17|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2003||2003-04-30|August 2017|2017-08-31||||April 2005|Actual|2005-04-30||Interventional|||Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients|A One-year, Multicenter, Partially Blinded, Double-dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients|Completed||Phase 3|684||Novartis|||||f||||||||||||||2018-06-01 04:24:19.296308|2018-06-01 04:24:19.296308
NCT00239772|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2014-06-04|2005-10-13|2005-10-17|Estimate|||||||2014-06-04|2014-06-05|Estimate|May 1994||1994-05-31|June 2014|2014-06-30||||||||Interventional|||Cognitive Processing Therapy Versus Prolonged Exposure for Treating Women With Post-Traumatic Stress Disorder Brought on by Sexual Assault|Cognitive Processes in PTSD: Treatment|Completed||N/A|120||University of Missouri, St. Louis|||||f||||||||||||||2018-06-01 04:24:19.35871|2018-06-01 04:24:19.35871
NCT00239759|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2009-02-24|2005-10-13|2005-10-17|Estimate|||||||2009-02-24|2009-02-25|Estimate|September 2002||2002-09-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|||||Observational|||MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology|Genetic Epidemiological Studies of Apolipoprotein E and Alzheimer's Disease|Completed|||2000|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:24:19.419017|2018-06-01 04:24:19.419017
NCT00239746|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2009-04-28|2005-10-13|2005-10-17|Estimate|||||||2009-04-28|2009-04-29|Estimate|October 2005||2005-10-31|April 2009|2009-04-30|August 2009|Anticipated|2009-08-31|August 2009|Anticipated|2009-08-31||Interventional|||BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories|Biomarkers of Nonsteroidal Anti-Inflammatories|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 04:24:19.489872|2018-06-01 04:24:19.489872
NCT00239733|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2017-01-05||2017-04-14|2005-10-13|2005-10-17|Estimate|2017-04-14|2017-05-16|Actual||||2017-04-14|2017-05-16|Actual|March 2005||2005-03-31|April 2017|2017-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection|The Safety and Efficacy of Intravenous Anti-D for the Treatment of Thrombocytopenia in Patients With HCV Infection Prior to or During Treatment With Pegylated-interferon and Ribavirin|Terminated||Phase 4|6|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1||failure to enroll additional subjects|f||||f||||||||No||2018-06-01 04:24:19.597769|2018-06-01 04:24:19.597769
NCT00239720|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2012-02-15||2017-03-27|2005-10-13|2005-10-17|Estimate|2012-02-15|2012-03-21|Estimate||||2017-03-27|2017-04-27|Actual|March 16, 2006|Actual|2006-03-16|March 2017|2017-03-31|June 25, 2008|Actual|2008-06-25|December 2006|Actual|2006-12-31||Interventional|PART||PsA Treatment With hOKT3γ1 (Ala-Ala)|Treatment of Psoriatic Arthritis With hOKT3γ1 (Ala-Ala)|Terminated||Phase 2|4|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|This study was put on voluntary clinical hold after a serious adverse event occurred. After a review of the data, the team decided to close the study to further enrollment. Due to limited participants, no formal statistical analyses were performed|2||Study team decision-impact(s) of change in hOKT3γ1 (Ala-Ala) manufacturer during study.|f||||t||||||||Yes|Data access is provided in TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.|2018-06-01 04:24:19.837383|2018-06-01 04:24:19.837383
NCT00239707|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2013-11-27|2005-10-13|2005-10-17|Estimate|||||||2013-11-27|2013-11-28|Estimate|February 2003||2003-02-28|November 2013|2013-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||GIP: Glucose-dependent Insulinotropic Peptide|Effect of GIP / GIP Analog in Type 2 Diabetes After a Meal|Completed||Phase 1|41|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||||2018-06-01 04:24:20.13311|2018-06-01 04:24:20.13311
NCT00239694|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13||2015-07-14|2015-07-14|2005-10-13|2005-10-17|Estimate||||2015-07-14|2015-08-04|Estimate|2015-07-14|2015-08-04|Estimate|April 2001||2001-04-30|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||PPV: Pneumococcal Polysaccharide Vaccine in Older Adults|Immunogenicity of Pneumococcal Vaccination and Revaccination in Older Adults|Completed||Phase 4|100|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 04:24:20.206953|2018-06-01 04:24:20.206953
NCT00239681|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2009-08-20||2014-02-06|2005-10-13|2005-10-17|Estimate|2014-02-06|2014-03-24|Estimate||||2014-02-06|2014-03-24|Estimate|February 2003||2003-02-28|February 2014|2014-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events|A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein|Terminated||Phase 3|17802|Actual|AstraZeneca||2||See detailed description for reason.|f||||t||||||||||2018-06-01 04:24:20.604329|2018-06-01 04:24:20.604329
NCT00239668|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2012-05-02|2005-10-13|2005-10-17|Estimate|||||||2012-05-02|2012-05-03|Estimate|March 2000||2000-03-31|May 2012|2012-05-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors|Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors|Unknown status|Recruiting||3000|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:24:24.654053|2018-06-01 04:24:24.654053
NCT00239655|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2016-07-29|2005-10-13|2005-10-17|Estimate|||||||2016-07-29|2016-08-01|Estimate|August 2004||2004-08-31|July 2016|2016-07-31|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)|A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI|Terminated||Phase 2|120|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:24:24.721489|2018-06-01 04:24:24.721489
NCT00239642|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2011-12-05||2018-01-22|2005-10-13|2005-10-17|Estimate|2011-12-05|2012-01-10|Estimate||||2018-01-22|2018-02-20|Estimate|July 2005||2005-07-31|January 2018|2018-01-31|April 2010|Actual|2010-04-30|January 2009|Actual|2009-01-31||Interventional|||Safety and Efficacy of Iron Sucrose in Children|Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients|Completed||Phase 4|141|Actual|Luitpold Pharmaceuticals||3|||f||||||||||||||2018-06-01 04:24:24.782259|2018-06-01 04:24:24.782259
NCT00239629|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2007-06-11|2005-10-13|2005-10-17|Estimate|||||||2007-06-11|2007-06-12|Estimate|September 2005||2005-09-30|June 2007|2007-06-30|January 2007|Actual|2007-01-31|||||Interventional|||Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial|Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis|Completed||Phase 4|73||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:24:25.341153|2018-06-01 04:24:25.341153
NCT00239616|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2018-01-22|2005-10-13|2005-10-17|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2002||2002-06-30|January 2018|2018-01-31|November 2003||2003-11-30|||||Interventional|||Pharmacokinetic Study of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin|Open-label Multicenter, Pharmacokinetic Study of a Single Dose of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin|Completed||Phase 4|8||Luitpold Pharmaceuticals|||||||||||||||||||2018-06-01 04:24:25.432121|2018-06-01 04:24:25.432121
NCT00239603|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2007-04-16|2005-10-13|2005-10-17|Estimate|||||||2007-04-16|2007-04-17|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|June 2007||2007-06-30|||||Observational|||Efficacy Study of the OV-Watch™ Personal Fertility Monitor for Women Using Clomiphene Citrate.|Clinical Investigation of the OV-Watch™ Personal Fertility Monitor for Women Undergoing Ovulation Induction With Clomiphene Citrate.|Completed|||40||Emory University|||||f||||||||||||||2018-06-01 04:24:25.479974|2018-06-01 04:24:25.479974
NCT00239590|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2015-03-25|2005-10-13|2005-10-17|Estimate|||||||2015-03-25|2015-03-26|Estimate|June 2001||2001-06-30|October 2005|2005-10-31|April 2004||2004-04-30|||||Interventional|||Testosterone and Myocardial Perfusion in CHD|Effects of Chronic Testosterone on Myocardial Ischaemia and Endothelial Function in Men With Documented Coronary Heart Disease|Completed||Phase 2|||Imperial College London|||||f||||f||||||||||2018-06-01 04:24:25.532327|2018-06-01 04:24:25.532327
NCT00239577|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2008-10-09|2005-10-14|2005-10-17|Estimate|||||||2008-10-09|2008-10-13|Estimate|April 2006||2006-04-30|October 2008|2008-10-31||||June 2007|Actual|2007-06-30||Interventional|||A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults|Observer-Blind, Single Center, Controlled Study of 2 Doses of Various Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6-Mth Schedule, to Healthy Adults|Completed||Phase 2|132||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:24:25.588988|2018-06-01 04:24:25.588988
NCT00239564|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2017-01-31|2005-10-13|2005-10-17|Estimate|||||||2017-01-31|2017-02-02|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease|An Open-Label Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease|Completed||Phase 1/Phase 2|12|Actual|IMPAX Laboratories, Inc.||1|||f||||f|t|f||||||No||2018-06-01 04:24:25.723376|2018-06-01 04:24:25.723376
NCT00239551|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2013-07-29|2005-10-13|2005-10-17|Estimate|||||||2013-07-29|2013-07-31|Estimate|October 2005||2005-10-31|July 2013|2013-07-31|December 2007|Actual|2007-12-31|October 2006|Actual|2006-10-31||Interventional|||Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer|Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer|Completed||Phase 4|30|Actual|Emory University||1|||f||||t||||||||||2018-06-01 04:24:25.815631|2018-06-01 04:24:25.815631
NCT00239538|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-11-07|2005-10-14|2005-10-17|Estimate|||||||2013-11-07|2013-11-08|Estimate|January 2003||2003-01-31|November 2013|2013-11-30|December 2004||2004-12-31|December 2004|Actual|2004-12-31||Interventional|||SMOOTH - Blood Pressure Control in Diabetic/Obese Patients|Prospective, Randomized, Open-label, Blinded Endpoint, Forced Titration Study to Compare Telmisartan Combined With HCTZ (80mg/12.5mg), to Valsartan Combined With HCTZ (160mg/12.5mg), for the Control of Mild-to-moderate Hypertension in Obese Patients With Type 2 Diabetes Mellitus Using ABPM.|Completed||Phase 4|840|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:25.918544|2018-06-01 04:24:25.918544
NCT00239525|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2014-04-09|2005-10-13|2005-10-17|Estimate|||||||2014-04-09|2014-04-11|Estimate|May 2006||2006-05-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|April 2007|Actual|2007-04-30||Interventional|Definity||3-D Transcranial Ultrasound Analysis Study|3-D Transcranial Ultrasound Analysis Using Definity Injectable Suspension|Completed||N/A|28|Actual|Duke University|||||f||||t||||||||||2018-06-01 04:24:26.12155|2018-06-01 04:24:26.12155
NCT00239512|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2006-06-23|2005-10-14|2005-10-17|Estimate|||||||2006-06-23|2006-06-26|Estimate|March 2005||2005-03-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Interventional|||New Management Strategy of PDA for VLBW Preterm Infants|New Management Strategy of PDA for VLBW Preterm--Comparison of Indomethacin and Ibuprofen|Terminated||N/A|60||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:24:26.200351|2018-06-01 04:24:26.200351
NCT00239499|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-11-08|2005-10-14|2005-10-17|Estimate|||||||2013-11-08|2013-11-11|Estimate|September 2003||2003-09-30|November 2013|2013-11-30|August 2004||2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)|A Six-Week, Randomised, Double-Blind, Triple-Dummy, Parallel Group, Multiple Dose, Pilot Study Comparing Tiotropium Inhalation Capsules to Salmeterol Inhalation Aerosol Combined With Fluticasone Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 4|107||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:26.317366|2018-06-01 04:24:26.317366
NCT00239486|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-14|2005-10-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2002||2002-10-31|October 2013|2013-10-31|April 2004||2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)|Evaluation of the Effect of Different Doses of Pramipexole on Subjective and Objective Symptoms of Idiopathic Restless Legs Syndrome (RLS).|Completed||Phase 2|109||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:26.388285|2018-06-01 04:24:26.388285
NCT00239473|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-14|2005-10-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|November 2002||2002-11-30|October 2013|2013-10-31||||December 2003|Actual|2003-12-31||Interventional|||12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD|A Randomised, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Comparison of 12-Week Treatment of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Placebo and Ipratropium Bromide Inhalation Aerosol (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|429||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:26.451599|2018-06-01 04:24:26.451599
NCT00239460|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-14|2005-10-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2003||2003-07-31|October 2013|2013-10-31||||March 2004|Actual|2004-03-31||Interventional|||Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD|Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With Chronic Obstructive Pulmonary Disease (a 12-week, Parallel Group, Randomized, Placebo-cotrolled, Double-blind Study).|Completed||Phase 3|196||Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:24:26.838915|2018-06-01 04:24:26.838915
NCT00239447|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-14|2005-10-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|November 2002||2002-11-30|October 2013|2013-10-31|April 2004||2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD|Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|131||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:26.923768|2018-06-01 04:24:26.923768
NCT00239434|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2012-05-11|2005-10-14|2005-10-17|Estimate|||||||2012-05-11|2012-05-14|Estimate|June 2003||2003-06-30|May 2012|2012-05-31|March 2004||2004-03-31|||||Interventional|||A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)|Comparison of 18 mg of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20 mg, Four Times Daily) in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|200||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:27.008169|2018-06-01 04:24:27.008169
NCT00239421|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-14|2005-10-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|November 2003||2003-11-30|October 2013|2013-10-31|September 2004||2004-09-30|September 2004|Actual|2004-09-30||Interventional|||A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)|A Six-Week, Randomized, Double-Blind, Quadruple-Dummy Parallel Group Multiple Dose Study Comparing the Efficacy and Safety of Tiotropium Inhalation Capsules Plus Formoterol Inhalation Capsules to Salmeterol Inhalation Aerosol Plus Fluticasone Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|605||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:27.094361|2018-06-01 04:24:27.094361
NCT00239408|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2013-10-31|2005-10-14|2005-10-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2002||2002-12-31|October 2013|2013-10-31|April 2004||2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).|Spiriva Assessment of FEV1 - (SAFE-Portugal). The Effect of Inhaled Tiotropium Bromide (18 Mcg Once Daily) on the Change in FEV1 During Treatment in Patients With COPD. A Three-month Parallel Group, Double-blind, Randomised, Placebo-controlled Study.|Completed||Phase 4|311||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:27.319934|2018-06-01 04:24:27.319934
NCT00239395|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2013-10-31|2005-10-13|2005-10-17|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|December 2004||2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis|A Randomised, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 7.5 mg IM Ampoules Once Daily and Meloxicam 7.5 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With Osteoarthritis (OA)|Completed||Phase 3|168||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:27.446158|2018-06-01 04:24:27.446158
NCT00239382|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2012-05-11|2005-10-13|2005-10-17|Estimate|||||||2012-05-11|2012-05-14|Estimate|July 2004||2004-07-31|May 2012|2012-05-31|December 2004||2004-12-31|||||Interventional|||A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis|A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.|Completed||Phase 3|150||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:27.530548|2018-06-01 04:24:27.530548
NCT00239369|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2017-12-27|2005-10-13|2005-10-17|Estimate|||||||2017-12-27|2017-12-28|Actual|October 2005||2005-10-31|December 2017|2017-12-31|August 2006||2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5|A Prospective Randomised Study to Compare a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 25 mg With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Uncontrolled Hypertension Who Fail to Respond Adequately to Treatment With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg|Completed||Phase 3|713||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:24:27.631227|2018-06-01 04:24:27.631227
NCT00239356|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|2013-11-05||2014-12-04|2005-10-13|2005-10-17|Estimate|2013-11-22|2014-01-10|Estimate||||2014-12-04|2014-12-19|Estimate|March 2003||2003-03-31|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||All treated participants.|Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials|Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol|Completed||Phase 3|119|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-06-01 04:24:27.859971|2018-06-01 04:24:27.859971
NCT00239343|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-14|||2011-01-25|2005-10-14|2005-10-17|Estimate|||||||2011-01-25|2011-01-27|Estimate|October 2004||2004-10-31|January 2011|2011-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer|Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa®/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer|Completed||Phase 2|160|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:24:28.435062|2018-06-01 04:24:28.435062
NCT00239330|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2010-11-18|2005-10-13|2005-10-17|Estimate|||||||2010-11-18|2010-11-19|Estimate|June 2003||2003-06-30|November 2010|2010-11-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy|An Open-label, Randomised, Multi-centre, Phase IIIb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia|Completed||Phase 3|824||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:28.606726|2018-06-01 04:24:28.606726
NCT00239317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-10-18|2005-10-13|2005-10-17|Estimate|||||||2007-10-18|2007-10-22|Estimate||||October 2007|2007-10-31||||||||Interventional|||Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome||Completed||Phase 3|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:24:28.703596|2018-06-01 04:24:28.703596
NCT00239304|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2007-12-14|2005-10-13|2005-10-17|Estimate|||||||2007-12-14|2007-12-18|Estimate|June 2003||2003-06-30|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|||Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer|A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer|Completed||Phase 1/Phase 2|40||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:28.793981|2018-06-01 04:24:28.793981
NCT00239291|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2009-04-22|2005-10-13|2005-10-17|Estimate|||||||2009-04-22|2009-04-23|Estimate|January 2003||2003-01-31|April 2009|2009-04-30|May 2006|Actual|2006-05-31|||||Interventional|||Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer|A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer|Completed||Phase 1/Phase 2|42|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:24:28.858331|2018-06-01 04:24:28.858331
NCT00239278|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2011-01-21|2005-10-13|2005-10-17|Estimate|||||||2011-01-21|2011-01-24|Estimate|January 2001||2001-01-31|January 2011|2011-01-31|January 2005|Actual|2005-01-31|||||Interventional|||Budesonide / Formoterol in Treatment of Exacerbations of COPD|Effects of High Dose Inhaled Budesonide+ Formoterol Versus Placebo and Oral Prednisolone on Biomarkers of Airway Inflammation in the Treatment of Exacerbations in Non-hospitalised Patients With Mild to Moderate COPD.|Completed||Phase 2|120||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:29.093694|2018-06-01 04:24:29.093694
NCT00239265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-18|2005-10-13|2005-10-17|Estimate|||||||2007-10-18|2007-10-22|Estimate||||October 2007|2007-10-31||||||||Interventional|||Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome||Completed||Phase 3|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:24:29.167711|2018-06-01 04:24:29.167711
NCT00239252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-08-25|2005-10-13|2005-10-17|Estimate|||||||2014-08-25|2014-08-26|Estimate||||August 2014|2014-08-31||||||||Interventional|||Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C||Completed||Phase 3|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:24:29.233832|2018-06-01 04:24:29.233832
NCT00239239|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2010-03-04|2005-10-13|2005-10-17|Estimate|||||||2010-03-04|2010-03-05|Estimate|August 2005||2005-08-31|March 2010|2010-03-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies|An Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Darbepoetin Alfa Administered Three Times Per Week for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy|Completed||Phase 2|44|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:24:29.321825|2018-06-01 04:24:29.321825
NCT00239200|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-07-28|2005-10-12|2005-10-14|Estimate|||||||2008-07-28|2008-07-30|Estimate|October 2005||2005-10-31|July 2008|2008-07-31|September 2007|Actual|2007-09-30|June 2006|Actual|2006-06-30||Interventional|||Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus|Lapatinib (GW572016) a Dual Inhibitor of EGFR and ErbB2, for Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus|Terminated||Phase 2|29|Anticipated|University of Michigan Cancer Center||||notification from sponsor|f||||||||||||||2018-06-01 04:24:29.922487|2018-06-01 04:24:29.922487
NCT00239187|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-07-17|2005-10-12|2005-10-14|Estimate|||||||2008-07-17|2008-07-21|Estimate|September 2005||2005-09-30|July 2006|2006-07-31|January 2007|Actual|2007-01-31|||||Interventional|||A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Response of Repeated Subcutaneous Doses of E1 in Combination With G1 in Patients With Type 2 Diabetes|Completed||Phase 1|30||Transition Therapeutics|||||||||||||||||||2018-06-01 04:24:29.987385|2018-06-01 04:24:29.987385
NCT00239174|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2008-12-09|2005-10-13|2005-10-14|Estimate|||||||2008-12-09|2008-12-10|Estimate|November 2004||2004-11-30|December 2008|2008-12-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study Evaluating the Efficacy and Safety of Four Doses of SR147778 in Obese Patients|Completed||Phase 2|394|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:24:30.047494|2018-06-01 04:24:30.047494
NCT00239161|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2005-10-12|2005-10-12|2005-10-14|Estimate|||||||2005-10-12|2005-10-14|Estimate|September 2004||2004-09-30|August 2005|2005-08-31|July 2005||2005-07-31|||||Interventional|||Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin|TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot Study|Terminated||Phase 4|30||University of Manitoba|||||f||||||||||||||2018-06-01 04:24:30.109414|2018-06-01 04:24:30.109414
NCT00239148|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2009-05-25|2005-10-12|2005-10-14|Estimate|||||||2009-05-25|2009-05-27|Estimate|June 2005||2005-06-30|July 2006|2006-07-31|December 2006|Actual|2006-12-31|||||Interventional|||A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1|A Randomized, Double-Blind, Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Effects of Repeated Subcutaneous Doses of E1 in Combination With G1 in Type 1 Diabetes|Completed||Phase 1|20||Transition Therapeutics|||||||||||||||||||2018-06-01 04:24:30.191676|2018-06-01 04:24:30.191676
NCT00239135|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2015-03-24|2005-10-13|2005-10-14|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel|An Open-label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks|Completed||Phase 2|34||Peplin|||||||||||||||||||2018-06-01 04:24:30.25624|2018-06-01 04:24:30.25624
NCT00239122|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2005-10-12|2005-10-12|2005-10-14|Estimate|||||||2005-10-12|2005-10-14|Estimate|June 2000||2000-06-30|October 2005|2005-10-31|February 2004||2004-02-29|||||Interventional|||Recovery Therapy Trial|Applicability of CBT to Unselected Mental Health Service Clients With Psychotic Disorders|Completed||N/A|94||Melbourne Health|||||f||||||||||||||2018-06-01 04:24:30.316284|2018-06-01 04:24:30.316284
NCT00239109|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-03-17|2005-10-12|2005-10-14|Estimate|||||||2008-03-17|2008-03-18|Estimate|April 2003||2003-04-30|March 2008|2008-03-31|February 2007||2007-02-28|||||Interventional|||Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.|Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia: A Six Months, Double Blind Randomized, Parallel Group Study.|Completed||Phase 4|112||Pfizer|||||f||||||||||||||2018-06-01 04:24:30.376853|2018-06-01 04:24:30.376853
NCT00239096|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2005-10-13|2005-10-13|2005-10-14|Estimate|||||||2005-10-13|2005-10-14|Estimate|September 2005||2005-09-30|October 2005|2005-10-31|September 2011||2011-09-30|||||Interventional|||Prevention of Decompensation in Liver Cirrhosis|Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis – a Prospective Randomized Long-Term Study|Unknown status|Recruiting|Phase 4|100||Odense University Hospital|||||f||||||||||||||2018-06-01 04:24:30.439257|2018-06-01 04:24:30.439257
NCT00239083|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2017-02-21|2005-10-12|2005-10-14|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2005||2005-01-31|February 2017|2017-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients|Phase IV Study of Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Kidney Transplant Patients|Completed||Phase 4|40|Anticipated|Novartis||1|||f||||||||||||||2018-06-01 04:24:30.506356|2018-06-01 04:24:30.506356
NCT00239070|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-28|2005-10-12|2005-10-14|Estimate|||||||2011-01-28|2011-01-31|Estimate|April 2003||2003-04-30|January 2011|2011-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients|A Prospective, Open-label, Multicenter, International Follow-up Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients|Completed||Phase 3|69|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:30.570767|2018-06-01 04:24:30.570767
NCT00239057|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-28|2005-10-12|2005-10-14|Estimate|||||||2011-01-28|2011-01-31|Estimate|May 2002||2002-05-31|January 2011|2011-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,|Enteric-Coated Mycophenolate Sodium (EC-MPS) Administration in Maintenance Renal Transplant Patients Receiving Cyclosporine Microemulsion (CsA-ME) and Steroids, for the Withdrawal of Concomitant Steroid Therapy: a Prospective, Open-label, Exploratory Study|Completed||Phase 3|23|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:30.622407|2018-06-01 04:24:30.622407
NCT00239044|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-11-01|2005-10-12|2005-10-14|Estimate|||||||2011-11-01|2011-11-02|Estimate|December 2002||2002-12-31|November 2011|2011-11-30||||July 2005|Actual|2005-07-31||Interventional|||An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients|An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients|Completed||Phase 3|40||Novartis|||||f||||||||||||||2018-06-01 04:24:30.69273|2018-06-01 04:24:30.69273
NCT00238875|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2016-09-21|2005-10-13|2005-10-14|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2004||2004-07-31|September 2016|2016-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-small Cell Lung Cancer (JCOG0403)|A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-small Cell Lung Cancer (JCOG0403)|Completed||Phase 2|167|Actual|Japan Clinical Oncology Group||1|||f||||t||||||||||2018-06-01 04:24:32.059328|2018-06-01 04:24:32.059328
NCT00239031|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-28|2005-10-12|2005-10-14|Estimate|||||||2011-01-28|2011-01-31|Estimate|March 2002||2002-03-31|January 2011|2011-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids|Multicentre, Controlled, Prospective, Randomized, Open-label Clinical Trial to Compare Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced Dose Cyclosporine Microemulsion (CsA-ME) Vs EC-MPS Plus Standard Dose CsA-ME in Elderly de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids|Completed||Phase 3|117|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:30.737391|2018-06-01 04:24:30.737391
NCT00239018|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-28|2005-10-12|2005-10-14|Estimate|||||||2011-01-28|2011-01-31|Estimate|April 2003||2003-04-30|January 2011|2011-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients|A Prospective, Open-label, Multicenter, Follow-up Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients|Completed||Phase 4|144|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:30.901002|2018-06-01 04:24:30.901002
NCT00239005|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2010-12-08||2017-02-28|2005-10-12|2005-10-14|Estimate|2011-02-23|2011-03-24|Estimate||||2017-02-28|2017-03-30|Actual|September 2005||2005-09-30|February 2017|2017-02-28||||March 2008|Actual|2008-03-31||Interventional|||Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation|A Study of the Effect of Conversion to Enteric-Coated Mycophenolate Sodium (EC-MPS) on Quality of Life in Patients With Gastrointestinal (GI) Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation (MYQOL)|Completed||Phase 4|134|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:24:30.972702|2018-06-01 04:24:30.972702
NCT00238992|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-11-01|2005-10-12|2005-10-14|Estimate|||||||2011-11-01|2011-11-02|Estimate|December 2002||2002-12-31|November 2011|2011-11-30||||July 2005|Actual|2005-07-31||Interventional|||Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.|A Prospective, Randomized, Open Label, Multicenter Trial of EC-MPS With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen for the Prevention of Acute Rejection Episodes in de Novo Renal Transplant Recipients.|Completed||Phase 3|144||Novartis|||||f||||||||||||||2018-06-01 04:24:31.275172|2018-06-01 04:24:31.275172
NCT00238979|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-11-01|2005-10-12|2005-10-14|Estimate|||||||2011-11-01|2011-11-02|Estimate|January 2003||2003-01-31|November 2011|2011-11-30||||February 2005|Actual|2005-02-28||Interventional|||A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)|A 6-month, 1-arm, Open-label Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)|Completed||Phase 4|50||Novartis|||||f||||||||||||||2018-06-01 04:24:31.413812|2018-06-01 04:24:31.413812
NCT00238966|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-28|2005-10-12|2005-10-14|Estimate|||||||2011-01-28|2011-01-31|Estimate|November 2002||2002-11-30|January 2011|2011-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil|A One Arm, Open-label Study to Investigate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Recipients Who Received Mycophenolate Mofetil (MMF)|Completed||Phase 4|187|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:31.488653|2018-06-01 04:24:31.488653
NCT00238953|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2017-02-21|2005-10-12|2005-10-14|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2005||2005-02-28|February 2017|2017-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients|A Prospective, Open Label Protocol to Assess the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients|Completed||Phase 4|30|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:31.569428|2018-06-01 04:24:31.569428
NCT00238940|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-28|2005-10-12|2005-10-14|Estimate|||||||2011-01-28|2011-01-31|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants|A One-year, Randomized, Open Label, Parallel Group Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Either Full Dose or Reduced Dose Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients|Completed||Phase 3|55|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:31.653511|2018-06-01 04:24:31.653511
NCT00238927|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2014-03-25|2005-10-12|2005-10-14|Estimate|||||||2014-03-25|2014-03-27|Estimate|November 1999||1999-11-30|March 2014|2014-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma|Multicenter Randomised Controlled Trial of Episodic Fluticasone Versus Placebo in Viral-induced Asthma in Children|Completed||Phase 4|150||McGill University Health Center|||||f||||f||||||||||2018-06-01 04:24:31.725215|2018-06-01 04:24:31.725215
NCT00238914|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-13|||2012-01-12|2005-10-13|2005-10-14|Estimate|||||||2012-01-12|2012-01-13|Estimate|August 1999||1999-08-31|January 2012|2012-01-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1|Opiate Dependence: Combined Naltrexone/Behavior Therapy|Completed||Phase 2|12|Actual|New York State Psychiatric Institute||2|||t||||t||||||||||2018-06-01 04:24:31.817561|2018-06-01 04:24:31.817561
NCT00238901|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2010-08-31|2005-10-12|2005-10-14|Estimate|||||||2010-08-31|2010-09-01|Estimate|December 2002||2002-12-31|August 2010|2010-08-31||||July 2005|Actual|2005-07-31||Interventional|||Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation|Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF)|Completed||Phase 3|194|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:31.909915|2018-06-01 04:24:31.909915
NCT00238888|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2017-04-18|2005-10-12|2005-10-14|Estimate|||||||2017-04-18|2017-04-20|Actual|August 2002||2002-08-31|April 2017|2017-04-30|December 2011|Actual|2011-12-31|April 2007|Actual|2007-04-30||Interventional|||Randomised Controlled Trial of a Multi-faceted Community-based Intervention to Improve Asthma in Children|Randomised Controlled Trial of a Multi-faceted Community-based Intervention to Improve Pediatric Morbidity: a PRIISME Project (Program to Integrate Information Service and Manage Education)|Completed||Phase 4|298|Actual|McGill University Health Center||2|||f||||f||||||||Undecided||2018-06-01 04:24:31.97283|2018-06-01 04:24:31.97283
NCT00238849|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2005-10-13|2005-10-13|2005-10-14|Estimate|||||||2005-10-13|2005-10-14|Estimate||||October 2005|2005-10-31||||||||Interventional|||Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.|Phase II Study of Oxaliplatin in Combination With Navelbine for the Second-Line Treatment of Advanced and Metastatic Non-Small Cell Lung Cancer|Unknown status|Not yet recruiting|Phase 2|40||Integrated Community Oncology Network|||||f||||||||||||||2018-06-01 04:24:32.228966|2018-06-01 04:24:32.228966
NCT00238836|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2006-10-12|2005-10-12|2005-10-14|Estimate|||||||2006-10-12|2006-10-13|Estimate||||June 2005|2005-06-30|March 2006||2006-03-31|||||Interventional|||Anticipatory & Preventive Team Care (APTCare): At Risk Patients of Family Health Networks||Unknown status|Active, not recruiting|Phase 2/Phase 3|240||C. T. Lamont Primary Care Research Centre|||||f||||||||||||||2018-06-01 04:24:32.314572|2018-06-01 04:24:32.314572
NCT00238823|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2007-05-22|2005-10-13|2005-10-14|Estimate|||||||2007-05-22|2007-05-23|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|December 2004||2004-12-31|||||Observational|||Cryoablation Versus Radiofrequency Ablation|A Review and Comparison of Cryoablation and Radiofrequency Ablation in Children|Terminated|||50||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:24:32.364793|2018-06-01 04:24:32.364793
NCT00238810|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2014-11-26|2005-10-13|2005-10-14|Estimate|||||||2014-11-26|2014-12-02|Estimate|April 2005||2005-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome|Retrospective Evaluation of Serum B-type Natriuretic Peptide Hormone Levels in Post-operative Patients and the Relationship of BNP Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome|Completed|||20|Actual|Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:24:32.407739|2018-06-01 04:24:32.407739
NCT00238797|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-20|2005-10-12|2005-10-14|Estimate|||||||2011-01-20|2011-01-21|Estimate|February 2003||2003-02-28|January 2011|2011-01-31|March 2006|Actual|2006-03-31|||||Interventional|||A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme|A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme|Completed||Phase 2|36||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:32.460406|2018-06-01 04:24:32.460406
NCT00238784|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-01-11|2005-10-12|2005-10-14|Estimate|||||||2008-01-11|2008-01-14|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults|A Comparison of Symbicort® Single Inhaler Therapy (Symbicort® 200 Turbuhaler® 1 Inhalation b.i.d. Plus as Needed) & Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents & Adults-a 26-Week, Randomised, Open-Label, Parallel Group, Multicentre Study|Completed||Phase 3|1300||AstraZeneca|||||||||||||||||||2018-06-01 04:24:32.514255|2018-06-01 04:24:32.514255
NCT00238758|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2006-09-11|2005-10-11|2005-10-13|Estimate|||||||2006-09-11|2006-09-13|Estimate|October 2005||2005-10-31|September 2006|2006-09-30||||||||Interventional|||A Study of Omega-3 as a Treatment for Major Depression|A Randomised, Double-Blind, Placebo Controlled Trial of Omega-3 Polyunsaturated Fatty Acids as a Monotherapy for Major Depression|Unknown status|Recruiting|Phase 2|128||The University of New South Wales|||||f||||||||||||||2018-06-01 04:24:32.572628|2018-06-01 04:24:32.572628
NCT00238745|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2007-12-17|2005-10-12|2005-10-13|Estimate|||||||2007-12-17|2007-12-20|Estimate|August 2003||2003-08-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.|Bone Mineral Density Increase and Safety of TSE-424 Compared to Placebo in Osteoporotic Postmenopausal Women|Completed||Phase 2|375||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:24:32.646819|2018-06-01 04:24:32.646819
NCT00238732|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2007-12-19|2005-10-12|2005-10-13|Estimate|||||||2007-12-19|2007-12-28|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause|A Double-Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogens Combinations for Treatment of Moderate to Severe Vulvar/Vaginal Atrophy in Postmenopausal Women|Completed||Phase 3|650||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:24:32.701132|2018-06-01 04:24:32.701132
NCT00238719|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2006-05-17|2005-10-12|2005-10-13|Estimate|||||||2006-05-17|2006-05-19|Estimate|December 1999||1999-12-31|May 2006|2006-05-31|June 2003||2003-06-30|||||Interventional|||Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder|A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder|Completed||Phase 3|293||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:24:32.928974|2018-06-01 04:24:32.928974
NCT00238706|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2006-05-04|2005-10-12|2005-10-13|Estimate|||||||2006-05-04|2006-05-05|Estimate|December 2001||2001-12-31|October 2005|2005-10-31|November 2004||2004-11-30|||||Interventional|||Use of Radiofrequency Ablation to Eliminate Continuous Atrial Fibrillation in Patients Undergoing Mitral Valve Surgery|Left Atrial Radiofrequency Ablation During Mitral Valve Surgery for Continuous Atrial Fibrillation: A Prospective Randomized Clinical Trial|Completed||N/A|||University Hospitals, Leicester|||||f||||||||||||||2018-06-01 04:24:32.984432|2018-06-01 04:24:32.984432
NCT00238693|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2017-07-27|2005-10-11|2005-10-13|Estimate|||||||2017-07-27|2017-07-28|Actual|April 2003||2003-04-30|July 2017|2017-07-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||Transplant Patient Registry of Liver, Kidney and/or Pancreas|Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas|Recruiting|||15000|Anticipated|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 04:24:33.069625|2018-06-01 04:24:33.069625
NCT00238680|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-06-13|2005-10-12|2005-10-13|Estimate|||||||2008-06-13|2008-06-17|Estimate|March 2005||2005-03-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|September 2006|Actual|2006-09-30||Interventional|||Programmable Timer in the Bladder Rehabilitation Treatment of OAB|The Effect of Programmable Timer in Bladder Rehabilitation Treatment of Idiopathic Overactive Bladder in Children|Completed||N/A|100||University of Aarhus|||||f||||||||||||||2018-06-01 04:24:33.138514|2018-06-01 04:24:33.138514
NCT00238667|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2015-05-19|2005-10-12|2005-10-13|Estimate|||||||2015-05-19|2015-05-20|Estimate|November 2005||2005-11-30|September 2005|2005-09-30|May 2014|Actual|2014-05-31|||||Interventional|CADISS||To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection|Cervical Artery Dissection in Stroke Study|Completed||Phase 3|250|Actual|St George's, University of London||2|||f||||||||||||||2018-06-01 04:24:33.197221|2018-06-01 04:24:33.197221
NCT00237315|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2017-10-30|2005-10-10|2005-10-12|Estimate|||||||2017-10-30|2017-11-01|Actual|February 2006||2006-02-28|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|||Longitudinal Study of Urea Cycle Disorders|Longitudinal Study of Urea Cycle Disorders|Recruiting|||1100|Anticipated|Children's Research Institute|||||f||||t||||||||||2018-06-01 04:24:49.352987|2018-06-01 04:24:49.352987
NCT00238654|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-04-08|2005-10-12|2005-10-13|Estimate|||||||2011-04-08|2011-04-12|Estimate|May 2003||2003-05-31|April 2011|2011-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy|"A Multicenter, Open-Label, Two-Arm Prospective Study to Evaluate the Impact of Patient Readiness to Self-Inject on Outcomes When Using the Copaxone® Prefilled Syringes [The READY Trial]"|Completed|||257|Actual|Teva Pharmaceutical Industries|||||f||||f||||||||||2018-06-01 04:24:33.270265|2018-06-01 04:24:33.270265
NCT00238641|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2005-10-11|2005-10-11|2005-10-13|Estimate|||||||2005-10-11|2005-10-13|Estimate|January 2002||2002-01-31|October 2005|2005-10-31|May 2005||2005-05-31|||||Interventional|||“DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?”|“DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?”|Completed||Phase 1/Phase 2|10||Stanford University|||||f||||||||||||||2018-06-01 04:24:33.341156|2018-06-01 04:24:33.341156
NCT00238628|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2010-07-16|2005-10-11|2005-10-13|Estimate|||||||2010-07-16|2010-07-20|Estimate|April 2004||2004-04-30|July 2010|2010-07-31|December 2005|Actual|2005-12-31|April 2005|Actual|2005-04-30||Interventional|||A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer|A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|12|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:24:33.392306|2018-06-01 04:24:33.392306
NCT00238615|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|2012-09-24||2015-04-21|2005-10-11|2005-10-13|Estimate|2013-05-29|2013-07-04|Estimate||||2015-04-21|2015-05-12|Estimate|March 2003||2003-03-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|September 2009|Actual|2009-09-30||Interventional|||Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC|A Phase II Trial of Concurrent Docetaxel (Taxotere) / Carboplatin / Radiotherapy Followed by Surgical Resection Followed by Consolidation Taxotere / Carboplatin in Stage III Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|13|Actual|Stanford University|Accrual was very slow. The study was halted with accrual of only 13 patients. These results were published.|1||low accrual|f||||t||||||||||2018-06-01 04:24:33.451828|2018-06-01 04:24:33.451828
NCT00238602|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2012-07-12|2005-10-11|2005-10-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|March 2000||2000-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2007|Actual|2007-06-30||Interventional|||Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer|Evaluation of the Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Tumors - A Phase I/II Study|Completed||Phase 1/Phase 2|48|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:24:34.609011|2018-06-01 04:24:34.609011
NCT00238576|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2016-04-19|2005-10-11|2005-10-13|Estimate|||||||2016-04-19|2016-04-21|Estimate|May 2008||2008-05-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Observational|||Lamotrigine in the Treatment of Bipolar Disorder in Women of Reproductive Age|Lamotrigine in the Treatment of Bipolar Disorder in Women of Reproductive Age|Completed|||30|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:24:34.669545|2018-06-01 04:24:34.669545
NCT00238563|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2008-02-22|2005-10-11|2005-10-13|Estimate|||||||2008-02-22|2008-02-26|Estimate||||August 2007|2007-08-31||||||||Interventional|||Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery|Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery|Unknown status|Recruiting|N/A|200||Stanford University|||||f||||||||||||||2018-06-01 04:24:34.731086|2018-06-01 04:24:34.731086
NCT00238550|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-07-19|2005-10-12|2005-10-13|Estimate|||||||2011-07-19|2011-07-20|Estimate|October 2003||2003-10-31|October 2005|2005-10-31|March 2006||2006-03-31|||||Interventional|||Study of CBME in the Relief of Painful Diabetic Neuropathy|Randomised Control Trial Studying the Addition of CBME to Conventional Treatment for the Relief of Painful Diabetic Neuropathy|Completed||Phase 2|36|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:24:34.800275|2018-06-01 04:24:34.800275
NCT00238537|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2013-05-28|2005-10-11|2005-10-13|Estimate|||||||2013-05-28|2013-05-30|Estimate|August 2001||2001-08-31|May 2009|2009-05-31|April 2007||2007-04-30|||||Interventional|||Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET)|Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET) in Acute Stroke|Completed||Phase 2|100||Melbourne Health|||||f||||||||||||||2018-06-01 04:24:34.876569|2018-06-01 04:24:34.876569
NCT00238524|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2014-09-19|2005-10-11|2005-10-13|Estimate|||||||2014-09-19|2014-09-22|Estimate|December 2003||2003-12-31|April 2010|2010-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy|A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy|Completed||Phase 3|357|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:24:34.970186|2018-06-01 04:24:34.970186
NCT00238511|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2014-09-19|2005-10-11|2005-10-13|Estimate|||||||2014-09-19|2014-09-22|Estimate|November 2002||2002-11-30|September 2009|2009-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)|An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)|Completed||Phase 2|||UCB Pharma|||||f||||||||||||||2018-06-01 04:24:35.03793|2018-06-01 04:24:35.03793
NCT00238498|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2012-04-30|2005-10-12|2005-10-13|Estimate|||||||2012-04-30|2012-05-02|Estimate|July 2004||2004-07-31|April 2012|2012-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes|A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes|Completed||Phase 2|291|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:35.184469|2018-06-01 04:24:35.184469
NCT00238485|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2017-03-24|2005-10-12|2005-10-13|Estimate|||||||2017-03-24|2017-03-28|Actual|January 2005||2005-01-31|March 2017|2017-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder|A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder.|Completed||Phase 3|251|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:35.269359|2018-06-01 04:24:35.269359
NCT00238472|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2012-04-25|2005-10-12|2005-10-13|Estimate|||||||2012-04-25|2012-04-27|Estimate|May 2003||2003-05-31|April 2012|2012-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion|A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion|Completed||Phase 4|24||Novartis|||||||||||||||||||2018-06-01 04:24:35.326671|2018-06-01 04:24:35.326671
NCT00229450|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2008-06-02|2005-09-28|2005-09-29|Estimate|||||||2008-06-02|2008-06-04|Estimate|October 2004||2004-10-31|June 2008|2008-06-30||||||||Interventional|||Estrogen and Perimenopausal Depression|Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression|Unknown status|Recruiting|Phase 4|20|Anticipated|University of California, Los Angeles|||||f||||||||||||||2018-06-01 04:26:38.678229|2018-06-01 04:26:38.678229
NCT00238459|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2013-11-19|2005-10-11|2005-10-13|Estimate|||||||2013-11-19|2013-11-20|Estimate|July 2005||2005-07-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|March 2011|Actual|2011-03-31||Observational|||Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised|Immunopathogenesis of Acute and Early HIV Infection and the Role of HIV-Specific CD4 T Cell Responses and the Effect of Their Enhancement by Potent Antiretroviral Drugs and an HIV Vaccine Adequate Vaccine Was Not Provided.|Completed|||58|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||Samples Without DNA|"~     Sequential samples from patients with acute and recent HIV infection~   "|||2018-06-01 04:24:35.392315|2018-06-01 04:24:35.392315
NCT00238446|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2017-02-22|2005-10-11|2005-10-13|Estimate|||||||2017-02-22|2017-02-24|Actual|April 2003||2003-04-30|February 2017|2017-02-28||||June 2006|Actual|2006-06-30||Interventional|||Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients|A Prospective, Open-label, Multicenter Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Heart Transplant Recipients|Completed||Phase 3|||Novartis|||||||||||||||||||2018-06-01 04:24:35.49406|2018-06-01 04:24:35.49406
NCT00238433|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2017-03-31|2016-11-28|2017-09-25|2005-10-12|2005-10-13|Estimate|2017-03-31|2017-05-11|Actual|2016-11-28|2016-12-29|Estimate|2017-09-25|2017-09-27|Actual|March 2005||2005-03-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|August 2015|Actual|2015-08-31||Interventional|||Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma|A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma|Completed||Phase 2|37|Actual|OHSU Knight Cancer Institute||1|||f||||||||||||||2018-06-01 04:24:35.58675|2018-06-01 04:24:35.58675
NCT00238420|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2015-12-10||2018-01-04|2005-10-12|2005-10-13|Estimate|2016-04-15|2016-05-23|Estimate||||2018-01-04|2018-01-30|Actual|July 26, 2005|Actual|2005-07-26|January 2018|2018-01-31|February 5, 2014|Actual|2014-02-05|October 1, 2013|Actual|2013-10-01||Interventional||Eligible patients who started protocol treatment.|Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer|A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer|Completed||Phase 1/Phase 2|70|Actual|National Cancer Institute (NCI)|Accrual of patients with her2/neu overexpression stopped early due to unmet targeted accrual goals, with 22 subject accrued out of 40 planned.|2|||f||||||||||||||2018-06-01 04:24:35.928036|2018-06-01 04:24:35.928036
NCT00238407|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2012-06-04|2005-10-12|2005-10-13|Estimate|||||||2012-06-04|2012-06-05|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|August 2010|Actual|2010-08-31|February 2008|Actual|2008-02-29||Interventional|||Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery|Docetaxel and Cisplatin Chemotherapy Followed by Radiochemotherapy in Patients With Inoperable, Locally Advanced Esophageal Cancer, A Multicenter Phase II Trial|Completed||Phase 2|21|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||||2018-06-01 04:24:36.841498|2018-06-01 04:24:36.841498
NCT00238394|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-06-04|2005-10-12|2005-10-13|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2005||2005-12-31|June 2013|2013-06-30||||March 2007|Actual|2007-03-31||Interventional|||Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer|A Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:24:36.947815|2018-06-01 04:24:36.947815
NCT00238381|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2016-08-11|2005-10-12|2005-10-13|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2005||2005-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2014|Actual|2014-05-31||Interventional|||Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer|Clinical Function After Total Mesorectal Excision and Rectal Replacement. A Prospective Randomized Trial Comparing Side-to-End Anastomosis, Colon-J-Pouch and Straight Coloanal Anastomosis|Completed||Phase 3|336|Actual|Swiss Group for Clinical Cancer Research||3|||f||||t||||||||||2018-06-01 04:24:37.030403|2018-06-01 04:24:37.030403
NCT00238368|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2017-11-01|2005-10-12|2005-10-13|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2004|Actual|2004-02-29|November 2017|2017-11-30|September 17, 2007|Actual|2007-09-17|September 17, 2007|Actual|2007-09-17||Interventional|||Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant|Autologous Blood or Marrow Transplantation for Aggressive Non-Hodgkin's Lymphoma Based on Early [18F] FDG-PET Scanning|Completed||Phase 2|59|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:24:37.138623|2018-06-01 04:24:37.138623
NCT00238355|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2011-11-07||2011-12-12|2005-10-12|2005-10-13|Estimate|2011-11-07|2011-12-09|Estimate||||2011-12-12|2011-12-19|Estimate|August 2003||2003-08-31|December 2011|2011-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems|Phase II Trial of Voriconazole Plus Caspofungin for the Initial Treatment of Invasive Fungal Infections|Terminated||Phase 2|13|Actual|OHSU Knight Cancer Institute||1||competing study at site|f||||t||||||||||2018-06-01 04:24:37.231224|2018-06-01 04:24:37.231224
NCT00238342|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2010-02-06|2005-10-12|2005-10-13|Estimate|||||||2010-02-06|2010-02-09|Estimate|October 2005||2005-10-31|April 2007|2007-04-30||||October 2007|Anticipated|2007-10-31||Interventional|||Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass|Pelvic Mass Study to Develop Serum Proteomic Profiles (SIGNATURES) for Epithelial Ovarian Cancer Diagnosis and Prognosis|Unknown status|Active, not recruiting|N/A|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:24:37.434357|2018-06-01 04:24:37.434357
NCT00238329|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-04-05|2005-10-12|2005-10-13|Estimate|||||||2013-04-05|2013-04-08|Estimate|January 2001||2001-01-31|April 2013|2013-04-30|June 2007||2007-06-30|December 2005|Actual|2005-12-31||Interventional|||PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma|Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma|Completed||Phase 2|32|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 04:24:37.74265|2018-06-01 04:24:37.74265
NCT00238316|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-05-30|2005-10-12|2005-10-13|Estimate|||||||2013-05-30|2013-06-03|Estimate|December 2000||2000-12-31|September 2011|2011-09-30|February 2009|Actual|2009-02-28|April 2006|Actual|2006-04-30||Interventional|||Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density|A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density|Completed||Phase 2|68|Actual|Canadian Cancer Trials Group||2|||f||||||||||||||2018-06-01 04:24:37.8321|2018-06-01 04:24:37.8321
NCT00238303|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2012-12-11||2014-05-07|2005-10-12|2005-10-13|Estimate|2013-05-29|2013-07-10|Estimate||||2014-05-07|2014-05-23|Estimate|September 2005||2005-09-30|October 2011|2011-10-31|March 2010|Actual|2010-03-31|July 2008|Actual|2008-07-31||Interventional|||Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Recurrent Glioblastoma|Completed||Phase 2|103|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:24:37.970737|2018-06-01 04:24:37.970737
NCT00238290|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2012-06-04|2005-10-12|2005-10-13|Estimate|||||||2012-06-04|2012-06-05|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|January 2010|Actual|2010-01-31||Interventional|||Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer|Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial|Completed||Phase 2|13|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||||2018-06-01 04:24:38.765475|2018-06-01 04:24:38.765475
NCT00238277|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-01-30|2005-10-12|2005-10-13|Estimate|||||||2008-01-30|2008-01-31|Estimate|March 2005||2005-03-31|December 2007|2007-12-31||||December 2007|Actual|2007-12-31||Interventional|||Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme|Phase II Study of Temozolomide and Radiation in Newly Diagnosed GBM Patients After Resection and Insertion of Gliadel® Wafers|Terminated||Phase 2|72||National Cancer Institute (NCI)||||Withdrawn - due to lack of accrual|f||||||||||||||2018-06-01 04:24:38.846901|2018-06-01 04:24:38.846901
NCT00238264|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2017-01-05||2017-01-05|2005-10-12|2005-10-13|Estimate|2017-01-05|2017-02-23|Actual||||2017-01-05|2017-02-23|Actual|November 2006||2006-11-30|November 2016|2016-11-30||||December 2013|Actual|2013-12-31||Interventional|||Radiation Therapy in Treating Young Patients With Gliomas|A Phase II Study of Conformal Radiotherapy In Patients With Low-Grade Gliomas|Active, not recruiting||Phase 2|92|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 04:24:38.95314|2018-06-01 04:24:38.95314
NCT00238251|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2012-06-04|2005-10-12|2005-10-13|Estimate|||||||2012-06-04|2012-06-05|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|November 2010|Actual|2010-11-30|April 2009|Actual|2009-04-30||Interventional|||Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases|Whole Brain Radiotherapy in Combination With Gefitinib (Iressa) or Temozolomide (Temodal) for Brain Metastases From Non-Small Lung Cancer (NSCLC) A Randomized Phase II Trial|Completed||Phase 2|59|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 04:24:39.50561|2018-06-01 04:24:39.50561
NCT00238238|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2016-12-15||2017-02-06|2005-10-12|2005-10-13|Estimate|2016-12-15|2017-02-07|Estimate||||2017-02-06|2017-03-15|Actual|March 2006||2006-03-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|June 2012|Actual|2012-06-30||Interventional||Three participants assigned to the lenalidomide arm alone arm never began treatment. Participants on the rituximab arm was discontinued early; in order to avoid potential identification of patients, no results will be entered for this arm.|Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab|A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory|Completed||Phase 2|97|Actual|Alliance for Clinical Trials in Oncology||3|||f||||f||||||||||2018-06-01 04:24:39.66755|2018-06-01 04:24:39.66755
NCT00238225|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-01-30|2005-10-12|2005-10-13|Estimate|||||||2013-01-30|2013-01-31|Estimate|November 2004||2004-11-30|January 2013|2013-01-31||||June 2006|Actual|2006-06-30||Interventional|||Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Oral Calcitriol in Combination With Ketoconazole in Refractory Advanced Malignancies|Completed||Phase 1|15|Actual|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 04:24:40.759778|2018-06-01 04:24:40.759778
NCT00238212|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-01-11|2005-10-12|2005-10-13|Estimate|||||||2013-01-11|2013-01-14|Estimate|October 2005||2005-10-31|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma|Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:24:40.81209|2018-06-01 04:24:40.81209
NCT00238199|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2015-04-22|2005-10-12|2005-10-13|Estimate|||||||2015-04-22|2015-04-24|Estimate|June 2002||2002-06-30|April 2015|2015-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer|Phase II Study of Calcitriol-Enhanced Docetaxel in Patients With Previously Untreated Metastatic or Locally Advanced Pancreatic Cancer|Completed||Phase 2|25|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 04:24:40.89294|2018-06-01 04:24:40.89294
NCT00238173|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2017-04-19|2005-10-12|2005-10-13|Estimate|||||||2017-04-19|2017-04-21|Actual|December 2004||2004-12-31|April 2017|2017-04-30|February 17, 2006|Actual|2006-02-17|February 17, 2006|Actual|2006-02-17||Interventional|||Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors|Phase I Dose Escalation Study of N-Acetylcysteine Administered in Conjunction With Carboplatin, Cyclophosphamide, and Etoposide Phosphate BBBD, in Children With Malignant Brain Tumors|Terminated||Phase 1|2|Actual|OHSU Knight Cancer Institute||||OHSU IRB closed study to further enrollment 2/17/2006|f||||t||||||||||2018-06-01 04:24:40.95184|2018-06-01 04:24:40.95184
NCT00238160|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-05-29|2005-10-12|2005-10-13|Estimate|||||||2013-05-29|2013-05-30|Estimate||||July 2006|2006-07-31||||||||Interventional|||Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer|Phase III Randomized Study of Surgical Resection With Versus Without Postoperative Hepatic Arterial Chemotherapy in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus|Withdrawn||Phase 3|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:24:41.016724|2018-06-01 04:24:41.016724
NCT00238147|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2013-05-15|2005-10-12|2005-10-13|Estimate|||||||2013-05-15|2013-05-17|Estimate|September 2004||2004-09-30|May 2013|2013-05-31|August 2008|Actual|2008-08-31|||||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer|Phase I Trial With Weekly Docetaxel, Capecitabine and Carboplatin as Induction Chemotherapy Followed by Concomitant Capecitabine and Radiotherapy in Patients With Locally Advanced Esophageal Cancer|Completed||Phase 1|18|Anticipated|University of Washington|||||f||||||||||||||2018-06-01 04:24:41.071277|2018-06-01 04:24:41.071277
NCT00238121|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|2013-12-23||2015-11-17|2005-10-12|2005-10-13|Estimate|2014-05-30|2014-06-10|Estimate||||2015-11-17|2015-11-20|Estimate|February 2005||2005-02-28|January 2014|2014-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer|A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:24:41.232704|2018-06-01 04:24:41.232704
NCT00238108|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|2012-06-18||2017-10-13|2005-10-11|2005-10-13|Estimate|2012-08-24|2012-09-25|Estimate||||2017-10-13|2017-11-14|Actual|October 2005||2005-10-31|October 2017|2017-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Melatonin Supplements for Improving Sleep in Individuals With Hypertension|Melatonin Supplementation in Hypertensive Patients|Completed||Phase 2|16|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 04:24:41.708325|2018-06-01 04:24:41.708325
NCT00238082|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2017-03-27|2005-10-11|2005-10-13|Estimate|||||||2017-03-27|2017-03-29|Actual|November 1999|Actual|1999-11-30|March 2017|2017-03-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease|The Effect of HFA-beclomethasone Dipropionate on Static Lung Volumes in COPD|Terminated||N/A|20|Actual|National Jewish Health|||||f||||||||||||||2018-06-01 04:24:41.953059|2018-06-01 04:24:41.953059
NCT00238069|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2017-03-27|2005-10-11|2005-10-13|Estimate|||||||2017-03-27|2017-03-29|Actual|December 2004||2004-12-31|March 2017|2017-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Effect of CPAP (Continuous Positive Airway Pressure) on Lung Function in Asthmatics With Sleep Apnea|Effect of CPAP (Continuous Positive Airway Pressure) on Airway Inflammation in Asthmatics With Sleep-Disordered Breathing: A Pilot Study|Completed||N/A|20|Actual|National Jewish Health|||||f||||||||||||||2018-06-01 04:24:42.027664|2018-06-01 04:24:42.027664
NCT00238056|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2015-01-26|2005-10-11|2005-10-13|Estimate|||||||2015-01-26|2015-01-27|Estimate||||October 2005|2005-10-31||||||||Interventional|||Effect of Domperidone on QT Interval in Premature Infants|Effect of Domperidone on QT Interval in Premature Infants|Completed||Phase 2|||Nantes University Hospital|||||f||||||||||||||2018-06-01 04:24:42.086001|2018-06-01 04:24:42.086001
NCT00238043|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-06-12|2005-10-12|2005-10-13|Estimate|||||||2008-06-12|2008-06-17|Estimate|August 2005||2005-08-31|October 2005|2005-10-31|April 2011|Anticipated|2011-04-30|||||Interventional|||Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia||Unknown status|Active, not recruiting|Phase 3|2000|Anticipated|Ministry of Health, Malaysia|||||f||||f||||||||||2018-06-01 04:24:42.137348|2018-06-01 04:24:42.137348
NCT00238030|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2011-01-04|2005-10-12|2005-10-13|Estimate|||||||2011-01-04|2011-01-05|Estimate|December 2004||2004-12-31|January 2011|2011-01-31|October 2010|Actual|2010-10-31|May 2009|Actual|2009-05-31||Interventional|||Thyroxine Replacement in Organ Donors|Efficacy and Pharmacokinetics of Oral Thyroid Replacement Therapy in Organ Donors|Completed||Phase 1/Phase 2|34|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:24:42.222535|2018-06-01 04:24:42.222535
NCT00238017|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2006-02-01|2005-10-11|2005-10-13|Estimate|||||||2006-02-01|2006-02-02|Estimate|October 2005||2005-10-31|July 2005|2005-07-31|December 2005||2005-12-31|||||Interventional|||Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate|A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria|Unknown status|Active, not recruiting|Phase 4|400||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:24:42.304012|2018-06-01 04:24:42.304012
NCT00238004|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2006-09-11|2005-10-12|2005-10-13|Estimate|||||||2006-09-11|2006-09-13|Estimate|November 2005||2005-11-30|September 2006|2006-09-30||||||||Interventional|||The Low HDL On Six Weeks Statin Therapy (LOW) Study|The Low HDL On Six Weeks Statin Therapy (LOW) Study|Unknown status|Active, not recruiting|Phase 4|60||Craigavon Area Hospital|||||f||||||||||||||2018-06-01 04:24:42.365452|2018-06-01 04:24:42.365452
NCT00237991|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2008-10-15|2005-10-12|2005-10-13|Estimate|||||||2008-10-15|2008-10-16|Estimate|June 2005||2005-06-30|October 2008|2008-10-31||||||||Observational|||Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population|A Multicentric, Post-Marketing Surveillance to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals Hepatitis A Vaccine Administered in Korean Population.|Completed|||600||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:24:42.429117|2018-06-01 04:24:42.429117
NCT00237978|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2009-05-13|2005-10-12|2005-10-13|Estimate|||||||2009-05-13|2009-05-14|Estimate|September 2006||2006-09-30|May 2008|2008-05-31|September 2009|Anticipated|2009-09-30|June 2009|Anticipated|2009-06-30||Interventional|||Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)|Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and / or Adapalen (Differin Gel)|Unknown status|Recruiting|Phase 4|60|Anticipated|Technische Universität Dresden||3|||f||||f||||||||||2018-06-01 04:24:42.480311|2018-06-01 04:24:42.480311
NCT00237965|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2005-10-11|2005-10-11|2005-10-13|Estimate|||||||2005-10-11|2005-10-13|Estimate||||May 2004|2004-05-31||||||||Interventional|||The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy|The Use of Mole Mapping Diagrams to Increase Skin Self Examination Accuracy|Completed||N/A|||Brown University|||||f||||||||||||||2018-06-01 04:24:42.54522|2018-06-01 04:24:42.54522
NCT00237952|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2009-06-21|2005-10-11|2005-10-13|Estimate|||||||2009-06-21|2009-06-23|Estimate|August 2005||2005-08-31|June 2009|2009-06-30||||||||Interventional|||Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy|Environmental Lead Exposure and Progressive Renal Insufficiency in Patients With Type II Diabetes and Diabetic Nephropathy|Completed||N/A|||Chang Gung Memorial Hospital|||||f||||||||||||||2018-06-01 04:24:42.589999|2018-06-01 04:24:42.589999
NCT00237939|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2013-11-07|2005-10-11|2005-10-13|Estimate|||||||2013-11-07|2013-11-08|Estimate|September 2002||2002-09-30|October 2007|2007-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices|A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices (Broad Effectiveness Trial With Aripiprazole- BETA)|Completed||Phase 3|1200||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||f||||||||||||||2018-06-01 04:24:42.658327|2018-06-01 04:24:42.658327
NCT00237926|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2008-07-29|2005-10-11|2005-10-13|Estimate|||||||2008-07-29|2008-08-01|Estimate|November 2005||2005-11-30|July 2008|2008-07-31||||March 2008|Actual|2008-03-31||Interventional|||Comparing Aerobic to Resistance Training in Recovery From Cancer|Comparing Aerobic to Resistance Training in Recovery From Cancer|Completed||N/A|58|Actual|Brooke Army Medical Center||2|||f||||f||||||||||2018-06-01 04:24:42.739778|2018-06-01 04:24:42.739778
NCT00237913|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2013-11-07|2005-10-11|2005-10-13|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 2004||2004-07-31|July 2008|2008-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Schizophrenia Trial of Aripiprazole|A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)|Completed||Phase 3|700||Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 04:24:42.812695|2018-06-01 04:24:42.812695
NCT00237900|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-12|||2009-04-22|2005-10-12|2005-10-13|Estimate|||||||2009-04-22|2009-04-23|Estimate|July 2003||2003-07-31|April 2009|2009-04-30|February 2004|Actual|2004-02-29|||||Interventional|||Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer|An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer|Terminated||Phase 1/Phase 2|34||AstraZeneca|||||f||||||||||||||2018-06-01 04:24:43.007572|2018-06-01 04:24:43.007572
NCT00237887|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2007-08-28|2005-10-11|2005-10-13|Estimate|||||||2007-08-28|2007-08-29|Estimate|December 2004||2004-12-31|August 2007|2007-08-31||||||||Interventional|||Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|1212|Actual|Abbott|||||f||||f||||||||||2018-06-01 04:24:43.071994|2018-06-01 04:24:43.071994
NCT00237874|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2014-06-05|2005-10-07|2005-10-12|Estimate|||||||2014-06-05|2014-06-06|Estimate|February 2004||2004-02-29|June 2014|2014-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Aripiprazole Treatment of Prodromal Patients|Aripiprazole Treatment of Prodromal Patients|Completed||Phase 2/Phase 3|15|Actual|Yale University|||||f||||||||||||||2018-06-01 04:24:43.121951|2018-06-01 04:24:43.121951
NCT00237861|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2014-06-05|2005-10-07|2005-10-12|Estimate|||||||2014-06-05|2014-06-06|Estimate||||June 2014|2014-06-30||||December 2002|Actual|2002-12-31||Interventional|||Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia|Effectiveness of Atypical Vs Conventional Antipsychotics|Completed||Phase 4|||Yale University|||||f||||||||||||||2018-06-01 04:24:43.178539|2018-06-01 04:24:43.178539
NCT00237848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-15|2005-10-07|2005-10-12|Estimate|||||||2012-06-15|2012-06-18|Estimate|February 2005||2005-02-28|April 2008|2008-04-30||||||||Interventional|||D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia|D-Serine Augmentation of Cognitive Retraining in Schizophrenia|Completed||Phase 3|72|Anticipated|Yale University|||||f||||||||||||||2018-06-01 04:24:43.234828|2018-06-01 04:24:43.234828
NCT00237822|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2017-10-13|2005-10-07|2005-10-12|Estimate|||||||2017-10-13|2017-10-17|Actual|September 2003||2003-09-30|October 2005|2005-10-31|December 2007|Actual|2007-12-31|||||Interventional|||Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders|Increasing Treatment Adherence in Co-Occurring Disorders|Completed||Phase 2|75|Anticipated|Yale University|||||f||||||||||||||2018-06-01 04:24:43.293075|2018-06-01 04:24:43.293075
NCT00237809|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-08-22||2017-03-30|2005-10-07|2005-10-12|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|September 2002||2002-09-30|March 2017|2017-03-31|September 2012|Actual|2012-09-30|December 2010|Actual|2010-12-31||Interventional|||D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia|D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia|Completed||Phase 3|104|Actual|Yale University||4|||f||||||||||||||2018-06-01 04:24:43.425645|2018-06-01 04:24:43.425645
NCT00237796|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2014-11-19||2015-03-23|2005-10-07|2005-10-12|Estimate|2015-03-23|2015-04-06|Estimate||||2015-03-23|2015-04-06|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||Participants numbers reported include at least one baseline and at least 1 ILSS assesssment|Functional Rehabilitation of Older Patients With Schizophrenia|Functional Rehabilitation of Older Patients With Schizophrenia|Completed||N/A|116|Actual|VA Office of Research and Development|"Randomization of treatment groups were not matched on the primary outcome (ILSS) at baseline but this was controlled using baseline ILSS as a covariate.~Participant dropout varied across assessments"|2|||f||||t||||||||||2018-06-01 04:24:44.011646|2018-06-01 04:24:44.011646
NCT00237783|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2016-07-25|2005-10-07|2005-10-12|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2005||2005-10-31|July 2016|2016-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Safety of Dialysate Sodium Individualization in Hemodialysis Patients With Intradialytic Hypotension|Hemodynamic Changes During Dialysate Sodium Individualization in Hemodialysis Patients|Terminated||Phase 1|4|Actual|Yale University||2||Unable to recruit enough subjects|f||||f||||||||||2018-06-01 04:24:44.4174|2018-06-01 04:24:44.4174
NCT00237770|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2013-09-24||2014-04-23|2005-10-11|2005-10-12|Estimate|2014-04-23|2014-05-19|Estimate||||2014-04-23|2014-05-19|Estimate|June 2003||2003-06-30|April 2014|2014-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Prevention of Low Blood Pressure in Persons With Tetraplegia|Prevention of Low Blood Pressure in Persons With Tetraplegia|Completed||Phase 2/Phase 3|16|Actual|VA Office of Research and Development|The small sample of subjects tested and the heterogeneity of spinal lesions.|1|||f||||f||||||||||2018-06-01 04:24:44.503807|2018-06-01 04:24:44.503807
NCT00237757|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2013-07-02|2005-10-07|2005-10-12|Estimate|||||||2013-07-02|2013-07-03|Estimate|January 2002||2002-01-31|July 2013|2013-07-31|September 2009|Actual|2009-09-30|January 2004|Actual|2004-01-31||Interventional|||Rehabilitation Team Functioning and Patient Outcomes|Rehabilitation Team Functioning and Patient Outcomes|Completed||N/A|31|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:24:44.793866|2018-06-01 04:24:44.793866
NCT00237744|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2013-11-08||2014-10-03|2005-10-07|2005-10-12|Estimate|2014-07-24|2014-08-15|Estimate||||2014-10-03|2014-10-13|Estimate|April 2005||2005-04-30|October 2014|2014-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Brain and Coordination Changes Induced By Robotics and FES Treatment Following Stroke|CNS Plasticity Induced By Motor Learning Technologies Following Stroke|Completed||N/A|40|Actual|VA Office of Research and Development||3|||f||||||||||||||2018-06-01 04:24:44.878725|2018-06-01 04:24:44.878725
NCT00237731|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2017-05-10|2005-10-07|2005-10-12|Estimate|||||||2017-05-10|2017-05-12|Actual|September 2005||2005-09-30|May 2017|2017-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Pre-hospital Morphine Titration : Comparison of 0,05 Versus 0,1 mg/kg|Pre-hospital Morphine Titration : Comparison of 0,05 Versus 0,1 mg/kg|Completed||Phase 4|106|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-06-01 04:24:45.118655|2018-06-01 04:24:45.118655
NCT00237718|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|2011-09-01||2012-01-09|2005-10-10|2005-10-12|Estimate|2011-09-01|2011-10-05|Estimate||||2012-01-09|2012-01-11|Estimate|April 2006||2006-04-30|January 2012|2012-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Provision of Antioxidant Therapy in Hemodialysis (PATH) Study|Provision of Antioxidant Therapy in Hemodialysis (PATH) Study|Completed||Phase 2|385|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 04:24:45.203607|2018-06-01 04:24:45.203607
NCT00237705|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2006-12-04|2005-10-07|2005-10-12|Estimate|||||||2006-12-04|2006-12-05|Estimate|May 2004||2004-05-31|December 2006|2006-12-31||||||||Interventional|||Intravenous Metoclopramide for the Treatment of Post Concussive Headache: a Randomized Placebo Controlled Trial||Unknown status|Recruiting|N/A|40||Vancouver General Hospital|||||f||||||||||||||2018-06-01 04:24:45.503494|2018-06-01 04:24:45.503494
NCT00237692|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2014-08-29||2015-04-06|2005-10-07|2005-10-12|Estimate|2014-11-21|2014-12-01|Estimate||||2015-04-06|2015-04-24|Estimate|May 2006||2006-05-31|August 2014|2014-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||All data except blood pressure, age, gender were patient-reported.|Hypertension Intervention Nurse Telemedicine Study (HINTS)|Behavioral/Pharmacological Telemedicine Interventions for BP Control|Completed||N/A|591|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 04:24:45.594614|2018-06-01 04:24:45.594614
NCT00237679|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2015-10-13|2005-10-11|2005-10-12|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2004||2004-01-31|October 2015|2015-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Quantifying Effects of Treatment of Pediatric Dysphonia|Quantifying Effects of Treatment of Pediatric Dysphonia|Terminated||N/A|31|Actual|University of Wisconsin, Madison||2||Terminated due to funding loss.|f||||t||||||||||2018-06-01 04:24:46.323648|2018-06-01 04:24:46.323648
NCT00237666|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2012-11-20||2013-05-09|2005-10-07|2005-10-12|Estimate|2013-05-09|2013-06-19|Estimate||||2013-05-09|2013-06-19|Estimate|February 2005||2005-02-28|May 2013|2013-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression|An Open-Label, Flexible-Dose Trial of the Safety and Efficacy of Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression|Completed||Phase 4|30|Actual|The Medical Research Network||1|||f||||t||||||||||2018-06-01 04:24:46.395309|2018-06-01 04:24:46.395309
NCT00237653|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2009-04-02|2005-10-11|2005-10-12|Estimate|||||||2009-04-02|2009-04-03|Estimate|February 2004||2004-02-29|April 2009|2009-04-30|December 2007|Actual|2007-12-31|||||Interventional|||MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus|Relevance of Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus|Terminated||Phase 3|40|Anticipated|University Hospital, Grenoble||||difficulty to include patients|f||||||||||||||2018-06-01 04:24:46.699152|2018-06-01 04:24:46.699152
NCT00237640|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2008-09-19|2005-10-10|2005-10-12|Estimate|||||||2008-09-19|2008-09-22|Estimate|March 2005||2005-03-31|September 2008|2008-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus|Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus|Completed||Phase 2|85|Actual|University of Oklahoma||2|||f||||f||||||||||2018-06-01 04:24:46.798845|2018-06-01 04:24:46.798845
NCT00237627|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2012-05-16|2005-10-07|2005-10-12|Estimate|||||||2012-05-16|2012-05-18|Estimate|May 2001||2001-05-31|May 2012|2012-05-31|January 2010|Actual|2010-01-31|December 2006|Actual|2006-12-31||Interventional|||Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer|A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies|Completed||Phase 1/Phase 2|107|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:24:46.873021|2018-06-01 04:24:46.873021
NCT00237614|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2006-07-17|2005-10-07|2005-10-12|Estimate|||||||2006-07-17|2006-07-18|Estimate|February 2003||2003-02-28|July 2005|2005-07-31|May 2005||2005-05-31|||||Interventional|||Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction||Completed||Phase 2/Phase 3|300||University of Milan|||||f||||||||||||||2018-06-01 04:24:46.99387|2018-06-01 04:24:46.99387
NCT00237601|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-04-01|2005-10-07|2005-10-12|Estimate|||||||2010-04-01|2010-04-02|Estimate|January 2006||2006-01-31|April 2010|2010-04-30|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Observational|||Home or Home-like Hospital Birth|Home or Home-like Hospital Birth for Low-risk Nulliparae: Does it Matter?|Completed|||500|Actual|Maastricht University Medical Center|||2||f||||f||||||||||2018-06-01 04:24:47.077111|2018-06-01 04:24:47.077111
NCT00237588|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2011-07-03|2005-10-10|2005-10-12|Estimate|||||||2011-07-03|2011-07-06|Estimate|December 2004||2004-12-31|October 2005|2005-10-31|July 2005||2005-07-31|||||Interventional|||Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)|Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)|Completed||Phase 4|25||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:24:47.136672|2018-06-01 04:24:47.136672
NCT00237575|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2012-05-22|2005-10-10|2005-10-12|Estimate|||||||2012-05-22|2012-05-23|Estimate|November 2005||2005-11-30|May 2012|2012-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer|A Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin and Gemcitabine for Regionally Advanced or Metastatic Urothelial Cancer|Terminated||Phase 3|100||University of Kentucky|||||f||||||||||||||2018-06-01 04:24:47.206228|2018-06-01 04:24:47.206228
NCT00237562|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2006-05-04|2005-10-10|2005-10-12|Estimate|||||||2006-05-04|2006-05-05|Estimate|July 1999||1999-07-31|October 2005|2005-10-31||||||||Interventional|||Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit|Single Visit Cervical Cancer Prevention Program|Completed||Phase 3|||University of California, Irvine|||||f||||||||||||||2018-06-01 04:24:47.292842|2018-06-01 04:24:47.292842
NCT00237549|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2013-12-19|2005-10-10|2005-10-12|Estimate|||||||2013-12-19|2013-12-20|Estimate|January 2001||2001-01-31|August 2012|2012-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ADDTION||The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care.|The ADDITION Study. Anglo-Danish-Dutch Study of Intensive Treatment In PeOple With screeN Detected Diabetes in Primary Care|Completed||N/A|3057|Actual|University of Aarhus||1|||f||||t||||||||||2018-06-01 04:24:47.365343|2018-06-01 04:24:47.365343
NCT00237536|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2009-04-28|2005-10-10|2005-10-12|Estimate|||||||2009-04-28|2009-04-29|Estimate|June 2005||2005-06-30|April 2009|2009-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia|A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia|Terminated||Phase 2|240||Threshold Pharmaceuticals|||||||||||||||||||2018-06-01 04:24:47.470824|2018-06-01 04:24:47.470824
NCT00237523|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2007-06-15|2005-10-07|2005-10-12|Estimate|||||||2007-06-15|2007-06-18|Estimate|July 2005||2005-07-31|June 2007|2007-06-30|March 2008|Anticipated|2008-03-31|||||Interventional|||"Study for Treatment of Moderate or Severe, Periodic, Cyclic, Breast Pain"|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease|Unknown status|Active, not recruiting|Phase 3|175|Anticipated|Symbollon Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:24:47.793816|2018-06-01 04:24:47.793816
NCT00237510|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2014-03-04|2005-10-11|2005-10-12|Estimate|||||||2014-03-04|2014-03-05|Estimate|May 2005||2005-05-31|March 2014|2014-03-31|May 2007|Actual|2007-05-31|May 2006|Actual|2006-05-31||Interventional|||Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating|A Pilot Study of the Efficacy and Tolerability of Terazosin for the Treatment of Antidepressant-Induced Excessive Sweating|Completed||N/A|15|Anticipated|Thomas Jefferson University|||||f||||t||||||||||2018-06-01 04:24:47.914087|2018-06-01 04:24:47.914087
NCT00237497|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2012-01-31|2005-10-11|2005-10-12|Estimate|||||||2012-01-31|2012-02-02|Estimate|July 2005||2005-07-31|January 2012|2012-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia|A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ramelteon Compared to Placebo With Zopiclone as a Reference Arm in Adults With Chronic Insomnia|Completed||Phase 3|275|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:24:47.983801|2018-06-01 04:24:47.983801
NCT00234767|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2008-11-05|2005-10-06|2005-10-07|Estimate|||||||2008-11-05|2008-11-07|Estimate|September 2001||2001-09-30|November 2008|2008-11-30||||August 2007|Actual|2007-08-31||Observational|||Study of the Economics of Pulmonary Artery Catheter Use in Patients With Acute Respiratory Distress Syndrome (ARDS)|Economic Analysis of Pulmonary Artery Catheter Use (EA-PAC)|Completed|||650||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:25:31.519932|2018-06-01 04:25:31.519932
NCT00237484|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2017-03-08|2005-10-10|2005-10-12|Estimate|||||||2017-03-08|2017-03-09|Actual|July 2005||2005-07-31|March 2017|2017-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|Pegade||Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)|Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy|Completed||Phase 3|89|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:24:48.08399|2018-06-01 04:24:48.08399
NCT00237471|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2011-07-19|2005-10-10|2005-10-12|Estimate|||||||2011-07-19|2011-07-21|Estimate|October 2005||2005-10-31|July 2011|2011-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Impact of Tight Glycaemic Control in Acute Myocardial Infarction|Impact of Tight Glycaemic Control With Insulin on Novel Vascular Disease Risk Factors and Myocardial Function and Perfusion in Acute Myocardial Infarction Patients With Hyperglycaemia|Terminated||Phase 4|40||Melbourne Health||||difficulty recruiting patients|f||||||||||||||2018-06-01 04:24:48.15867|2018-06-01 04:24:48.15867
NCT00237458|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|2012-03-07||2017-07-28|2005-10-11|2005-10-12|Estimate|2012-04-16|2012-05-15|Estimate||||2017-07-28|2017-08-28|Actual|May 2001||2001-05-31|July 2017|2017-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain|An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain|Completed||Phase 2|7|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:24:48.306722|2018-06-01 04:24:48.306722
NCT00237445|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2011-01-10|2005-10-10|2005-10-12|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2005||2005-11-30|January 2011|2011-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|COBRA II||Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days|A Multinational, Multicenter, Randomized, Double-blind, Study in Areas of High Pneumococcal Resistance Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Ketek® Telithromycin Once Daily for 7 Days, or Zithromax® Azithromycin Once Daily for 5 Days|Terminated||Phase 4|110|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:24:48.617124|2018-06-01 04:24:48.617124
NCT00237432|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2010-12-09|2005-10-10|2005-10-12|Estimate|||||||2010-12-09|2010-12-10|Estimate|April 2003||2003-04-30|December 2010|2010-12-31|February 2008|Actual|2008-02-29|||||Observational|||Study of the Immune Response to Hepatitis C Virus|HCV Pathogenesis and Dendritic Cell Immunobiology|Completed|||11|Actual|Rockefeller University|||||f||||f||||||Samples With DNA|"~     White blood cells~   "|||2018-06-01 04:24:48.676058|2018-06-01 04:24:48.676058
NCT00237419|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2008-05-30|2005-10-10|2005-10-12|Estimate|||||||2008-05-30|2008-06-03|Estimate|December 2005||2005-12-31|May 2008|2008-05-31|April 2011|Anticipated|2011-04-30|November 2010|Anticipated|2010-11-30||Interventional|||Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis|An Open Label Extension, Investigator Initiated Trial to Examine Radiographic Progression , Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis. EASIC (European Ankylosing Spondylitis Infliximab Cohort)|Unknown status|Recruiting|N/A|149|Anticipated|Rheumazentrum Ruhrgebiet|||||f||||||||||||||2018-06-01 04:24:48.745019|2018-06-01 04:24:48.745019
NCT00237406|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2010-03-24|2005-10-11|2005-10-12|Estimate|||||||2010-03-24|2010-03-25|Estimate|January 2006||2006-01-31|March 2010|2010-03-31|October 2006|Actual|2006-10-31|||||Observational|||Interactive Voice Response (IVR) for Methadone Patients|Interactive Voice Response for Methadone Patients|Completed|||50||Butler Hospital|||||f||||||||||||||2018-06-01 04:24:48.879185|2018-06-01 04:24:48.879185
NCT00237393|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2008-02-20|2005-10-11|2005-10-12|Estimate|||||||2008-02-20|2008-02-21|Estimate|August 2003||2003-08-31|October 2005|2005-10-31|December 2007|Actual|2007-12-31|||||Interventional|PTSD||Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)|A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD|Completed||Phase 4|80|Actual|Ralph H. Johnson VA Medical Center||2|||f||||f||||||||||2018-06-01 04:24:48.944656|2018-06-01 04:24:48.944656
NCT00237380|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2009-01-09|2005-10-11|2005-10-12|Estimate|||||||2009-01-09|2009-01-14|Estimate|November 2005||2005-11-30|January 2009|2009-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Efficacy of PTC124 for Cystic Fibrosis|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis|Completed||Phase 2|24||PTC Therapeutics|||||f||||||||||||||2018-06-01 04:24:49.03277|2018-06-01 04:24:49.03277
NCT00237367|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-04-26|2005-10-07|2005-10-12|Estimate|||||||2010-04-26|2010-04-28|Estimate||||April 2010|2010-04-30|April 2005|Actual|2005-04-30|||||Interventional|||A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn|A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn|Completed||Phase 4|52|Actual|PriCara, Unit of Ortho-McNeil, Inc.|||||f||||||||||||||2018-06-01 04:24:49.100137|2018-06-01 04:24:49.100137
NCT00237354|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2008-10-22|2005-10-07|2005-10-12|Estimate|||||||2008-10-22|2008-10-24|Estimate|October 2005||2005-10-31|October 2008|2008-10-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||PV-10 Chemoablation of Recurrent Breast Carcinoma|A Phase 1 Safety and Tolerability Study of PV-10 Chemoablation of Recurrent Breast Carcinoma|Completed||Phase 1|15|Anticipated|Provectus Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:24:49.165747|2018-06-01 04:24:49.165747
NCT00237341|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2013-11-19|2005-10-07|2005-10-12|Estimate|||||||2013-11-19|2013-11-20|Estimate|June 2002||2002-06-30|November 2013|2013-11-30|January 2004|Actual|2004-01-31|||||Interventional|||Duragesic® (Fentanyl Transdermal System) Functionality Trial in Chronic Low Back Pain|Assessing Functionality Changes Associated With Patients Who Were Taking Short Acting Opioids Chronically and Who Initiated Treatment With Duragesic® (Fentanyl Transdermal System) for the Management of Chronic Low Back Pain.|Completed||Phase 4|358|Actual|PriCara, Unit of Ortho-McNeil, Inc.|||||f||||||||||||||2018-06-01 04:24:49.234451|2018-06-01 04:24:49.234451
NCT00237328|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2013-02-22|2005-10-11|2005-10-12|Estimate|||||||2013-02-22|2013-02-25|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|March 2009|Actual|2009-03-31||Observational|HIT||Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery|The Incidence of Thromboembolic Events in Patients With Antibodies to Heparin-PF4 After Cardiac Bypass|Completed|||1015|Actual|Duke University|||||f||||f||||||||||2018-06-01 04:24:49.284089|2018-06-01 04:24:49.284089
NCT00237302|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-17|2005-10-07|2005-10-12|Estimate|||||||2011-05-17|2011-05-19|Estimate|July 2001||2001-07-31|April 2010|2010-04-30|September 2003|Actual|2003-09-30|||||Interventional|||A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Preventing Migraine Headaches in Children|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects|Completed||Phase 3|162|Actual|Ortho-McNeil Neurologics, Inc.|||||f||||||||||||||2018-06-01 04:24:49.472295|2018-06-01 04:24:49.472295
NCT00237289|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-17|2005-10-07|2005-10-12|Estimate|||||||2011-05-17|2011-05-19|Estimate|October 2001||2001-10-31|April 2010|2010-04-30|October 2003|Actual|2003-10-31|||||Interventional|||Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting|Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting|Completed||Phase 3|287|Actual|Ortho-McNeil Neurologics, Inc.|||||f||||||||||||||2018-06-01 04:24:49.525157|2018-06-01 04:24:49.525157
NCT00237276|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2007-09-21|2005-10-10|2005-10-12|Estimate|||||||2007-09-21|2007-09-24|Estimate|October 2005||2005-10-31|September 2007|2007-09-30||||||||Interventional|||Experience and Enhancement: Improving Colonoscopic Polyp Detection|Evaluation of Effect of Colonoscopist Experience and Addition of of Mucosal Enhancement Techniques on Detection of Colonic Polyps When Viewing Videotaped Colonoscopic Withdrawals|Unknown status|Recruiting|N/A|30|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:24:49.575315|2018-06-01 04:24:49.575315
NCT00237263|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2017-02-21|2005-10-11|2005-10-12|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2003||2003-02-28|February 2017|2017-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States|An Extension Study to Phase IIb Dose-finding Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off|Completed||Phase 2|285|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:49.65964|2018-06-01 04:24:49.65964
NCT00237250|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2012-05-04|2005-10-09|2005-10-12|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance|Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance|Completed||Phase 3|171|Actual|Novartis|||||f||||||||||||||2018-06-01 04:24:49.846726|2018-06-01 04:24:49.846726
NCT00237237|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2017-02-03|2005-10-09|2005-10-12|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2005||2005-10-31|February 2017|2017-02-28||||February 2007|Actual|2007-02-28||Interventional|||Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes|Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes|Completed||Phase 3|588||Novartis|||||||||||||||||||2018-06-01 04:24:49.920478|2018-06-01 04:24:49.920478
NCT00237224|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2009-11-18|2005-10-09|2005-10-12|Estimate|||||||2009-11-18|2009-11-19|Estimate|February 2003||2003-02-28|November 2009|2009-11-30||||February 2007|Actual|2007-02-28||Interventional|||Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole|Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole|Completed||Phase 4|40|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:49.993055|2018-06-01 04:24:49.993055
NCT00237211|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2017-02-21|2005-10-09|2005-10-12|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2001||2001-06-30|February 2017|2017-02-28||||October 2006|Actual|2006-10-31||Interventional|||Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer|Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer|Completed||Phase 2|31|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:50.073957|2018-06-01 04:24:50.073957
NCT00237198|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2017-02-21|2005-10-09|2005-10-12|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2004||2004-03-31|February 2017|2017-02-28||||July 2006|Actual|2006-07-31||Interventional|||Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment|Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment|Completed||Phase 2|47|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:50.171102|2018-06-01 04:24:50.171102
NCT00237185|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|2014-06-13||2014-08-14|2005-10-09|2005-10-12|Estimate|2014-06-13|2014-07-15|Estimate||||2014-08-14|2014-08-19|Estimate|June 2000||2000-06-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene|Open, Randomized, Phase II Study of Glivec in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Plus 10 Year Extension Study|Completed||Phase 2|148|Actual|Novartis|No safety data was collected in the extension.|2|||f||||f||||||||||2018-06-01 04:24:50.381088|2018-06-01 04:24:50.381088
NCT00237172|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2012-04-29|2005-10-09|2005-10-12|Estimate|||||||2012-04-29|2012-05-01|Estimate|September 2002||2002-09-30|April 2012|2012-04-30||||July 2005|Actual|2005-07-31||Interventional|||Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)|Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)|Completed||Phase 2|72|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:51.257442|2018-06-01 04:24:51.257442
NCT00237159|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2011-03-21|2005-10-09|2005-10-12|Estimate|||||||2011-03-21|2011-03-23|Estimate|October 2002||2002-10-31|March 2011|2011-03-31||||December 2005|Actual|2005-12-31||Interventional|||Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis|Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis|Completed||Phase 4|284|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:51.324399|2018-06-01 04:24:51.324399
NCT00237146|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2017-02-21|2005-10-09|2005-10-12|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2003||2003-11-30|February 2017|2017-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy|Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy.|Completed||Phase 4|38|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:51.402107|2018-06-01 04:24:51.402107
NCT00237133|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-09|||2017-02-22|2005-10-09|2005-10-12|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2003||2003-03-31|February 2017|2017-02-28|January 21, 2009|Actual|2009-01-21|January 2009|Actual|2009-01-31||Interventional|PREDICT||Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women|PREDICT TRIAL- Neoadjuvant Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Expressing Hormonal Receptors ( ER and PR)|Completed||Phase 4|112|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:24:51.492639|2018-06-01 04:24:51.492639
NCT00237120|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2009-11-20|2005-10-07|2005-10-12|Estimate|||||||2009-11-20|2009-11-23|Estimate|November 2002||2002-11-30|November 2009|2009-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)|Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)|Completed||Phase 3|100||Novartis|||||f||||||||||||||2018-06-01 04:24:51.57203|2018-06-01 04:24:51.57203
NCT00237107|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2016-07-18|2005-10-10|2005-10-12|Estimate|||||||2016-07-18|2016-07-19|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Debulking Effect of Curretage on Basal Cell Carcinomas - a Histological Assessment.|Relation of Basal Cell Carcinoma Tumour Thickness, Histologically Estimated, in Punch Biopsies Performed Before and After Curretage.|Completed||N/A|36|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||No||2018-06-01 04:24:51.624018|2018-06-01 04:24:51.624018
NCT00237094|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2010-01-14|2005-10-11|2005-10-12|Estimate|||||||2010-01-14|2010-01-15|Estimate|June 2005||2005-06-30|January 2010|2010-01-31||||||||Interventional|||Use of Midlevel Providers in Diabetes Management|Use of Midlevel Providers in Diabetes Management|Completed||N/A|600|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:24:51.679266|2018-06-01 04:24:51.679266
NCT00237081|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2010-03-02|2005-10-11|2005-10-12|Estimate|||||||2010-03-02|2010-03-03|Estimate|June 2004||2004-06-30|March 2010|2010-03-31|November 2008|Actual|2008-11-30|||||Observational|magic||Genetics of Interstitial Cystitis|Maryland Genetics of Interstitial Cystitis (MaGIC)|Completed|||||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:24:51.726231|2018-06-01 04:24:51.726231
NCT00237068|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2011-03-15|2005-10-11|2005-10-12|Estimate|||||||2011-03-15|2011-03-16|Estimate|March 2006||2006-03-31|March 2011|2011-03-31|December 2010|Anticipated|2010-12-31|December 2009|Anticipated|2009-12-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy.|A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy ( Lansoprazole; Solutab) in the Management of Childhood Asthma|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 04:24:51.775828|2018-06-01 04:24:51.775828
NCT00237055|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2010-03-17|2005-10-11|2005-10-12|Estimate|||||||2010-03-17|2010-03-18|Estimate|August 2004||2004-08-31|March 2010|2010-03-31|September 2006||2006-09-30|||||Observational|||Infectious Agents in Pediatric Crohn's|Infectious Agents in Pediatric Crohn's Disease|Completed|||500|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:24:51.834802|2018-06-01 04:24:51.834802
NCT00237042|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2011-05-02||2011-06-10|2005-10-07|2005-10-12|Estimate|2011-06-10|2011-07-11|Estimate||||2011-06-10|2011-07-11|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Managing Temporomandibular Disorder (TMD) Symptoms|Hormonal Cycles in Women: Effects on TMD Pain & Symptoms|Completed||N/A|252|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 04:24:51.90358|2018-06-01 04:24:51.90358
NCT00237016|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2008-10-23|2005-10-07|2005-10-12|Estimate|||||||2008-10-23|2008-10-24|Estimate|April 2002||2002-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever|Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever|Completed||Phase 2/Phase 3|140||Medical Corps, Israel Defense Force|||||f||||||||||||||2018-06-01 04:24:52.389222|2018-06-01 04:24:52.389222
NCT00237003|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2010-05-10|2005-10-11|2005-10-12|Estimate|||||||2010-05-10|2010-05-12|Estimate|September 2003||2003-09-30|May 2010|2010-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Brief Alcohol Intervention for Incarcerated Women|A Brief Alcohol Intervention for Incarcerated Women|Completed||Phase 3|326|Anticipated|Butler Hospital||1|||f||||||||||||||2018-06-01 04:24:52.443155|2018-06-01 04:24:52.443155
NCT00236990|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-30|2005-10-07|2005-10-12|Estimate|||||||2011-06-30|2011-07-01|Estimate||||June 2011|2011-06-30|September 2005|Actual|2005-09-30|||||Interventional|||An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland|A Double-Blind, Randomized, Placebo-Controlled Trial of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Prostatitis|Completed||Phase 2|283|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.||1|||f||||||||||||||2018-06-01 04:24:52.501954|2018-06-01 04:24:52.501954
NCT00236977|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2009-01-14||2018-01-22|2005-10-11|2005-10-12|Estimate|2010-02-22|2010-03-09|Estimate||||2018-01-22|2018-02-20|Estimate|August 2003||2003-08-31|January 2018|2018-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia|Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia|Completed||Phase 3|182|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:24:52.577504|2018-06-01 04:24:52.577504
NCT00236964|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2018-01-22|2005-10-07|2005-10-12|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2001||2001-02-28|January 2018|2018-01-31|May 2002||2002-05-31|||||Interventional|||Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis|Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis|Completed||Phase 3|78||Luitpold Pharmaceuticals|||||||||||||||||||2018-06-01 04:24:52.986588|2018-06-01 04:24:52.986588
NCT00236951|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|2009-06-24||2018-01-22|2005-10-10|2005-10-12|Estimate|2009-08-14|2009-09-23|Estimate||||2018-01-22|2018-02-20|Estimate|February 2003||2003-02-28|January 2018|2018-01-31|December 2005||2005-12-31|October 2005|Actual|2005-10-31||Interventional|||Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy|A Phase III Randomized Controlled Study Comparing Iron Sucrose Intravenously to No Iron Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy|Completed||Phase 3|224|Actual|Luitpold Pharmaceuticals||4|||f||||||||||||||2018-06-01 04:24:53.085757|2018-06-01 04:24:53.085757
NCT00236938|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|2009-01-14||2018-01-22|2005-10-10|2005-10-12|Estimate|2009-07-31|2009-09-07|Estimate||||2018-01-22|2018-02-20|Estimate|July 2002||2002-07-31|January 2018|2018-01-31|October 2004|Actual|2004-10-31|September 2004|Actual|2004-09-30||Interventional|||Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis|Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis|Completed||Phase 3|121|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:24:53.822443|2018-06-01 04:24:53.822443
NCT00236925|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2015-03-30|2005-10-10|2005-10-12|Estimate|||||||2015-03-30|2015-04-01|Estimate|May 2003||2003-05-31|March 2015|2015-03-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia|A Double-Blind Crossover Within Subject Study on Low-Dose Hydrocortisone for Fibromyalgia|Completed||Early Phase 1|30|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-06-01 04:24:54.17592|2018-06-01 04:24:54.17592
NCT00236912|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-11|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|July 2003||2003-07-31|April 2010|2010-04-30|September 2004|Actual|2004-09-30|||||Interventional|||A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated Appendicitis|A Multi-center, Open-label, Randomized Study to Compare the Safety and Efficacy of Once Daily Levofloxacin Along With Once Daily Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Appendicitis|Terminated||Phase 4|139|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||This study was terminated due to low enrollment.|||||f||||||||||2018-06-01 04:24:54.400025|2018-06-01 04:24:54.400025
NCT00236899|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2011-07-25||2011-08-22|2005-10-07|2005-10-12|Estimate|2011-08-22|2011-09-27|Estimate||||2011-08-22|2011-09-27|Estimate|September 2005||2005-09-30|August 2011|2011-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC|A Randomized Phase III Trial of Gemcitabine and Docetaxel Versus Gemcitabine and Paclitaxel in Patients With Metastatic Breast Cancer: A Comparison of Different Schedules|Completed||Phase 3|241|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 04:24:54.556412|2018-06-01 04:24:54.556412
NCT00236886|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-04-26|2005-10-11|2005-10-12|Estimate|||||||2010-04-26|2010-04-28|Estimate|May 1998||1998-05-31|April 2010|2010-04-30|June 2000|Actual|2000-06-30|||||Interventional|||Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients|Prospective Pilot Study on Metabolism and Weight Changes in Subjects With Diagnosed Partial Onset Epilepsy, With or Without Secondarily Generalized Seizures and Treated With Topiramate.|Completed||Phase 3|49|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:24:55.871796|2018-06-01 04:24:55.871796
NCT00236873|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 1989||1989-10-31|April 2010|2010-04-30|May 1993|Actual|1993-05-31|||||Interventional|||A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.|Double-Blind Parallel Comparison of Topiramate 200 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy|Completed||Phase 2|47|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:55.943384|2018-06-01 04:24:55.943384
NCT00236860|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 1989||1989-05-31|April 2010|2010-04-30|February 1992|Actual|1992-02-29|||||Interventional|||A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures|Double-Blind Parallel Comparison of Topiramate 400 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy|Completed||Phase 2|56|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.009498|2018-06-01 04:24:56.009498
NCT00236847|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 1989||1989-12-31|April 2010|2010-04-30|July 1993|Actual|1993-07-31|||||Interventional|||A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy.|Double-Blind, Parallel Comparison of Topiramate 300 mg Twice Daily to Placebo in Patients With Refractory Partial Epilepsy|Completed||Phase 2|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.07122|2018-06-01 04:24:56.07122
NCT00236834|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 1997||1997-12-31|April 2010|2010-04-30|June 2001|Actual|2001-06-30|||||Interventional|||A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization|A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia|Completed||Phase 3|438|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.125044|2018-06-01 04:24:56.125044
NCT00236821|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2001||2001-03-31|April 2010|2010-04-30|June 2002|Actual|2002-06-30|||||Interventional|||A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia|Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults|Completed||Phase 3|530|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.179332|2018-06-01 04:24:56.179332
NCT00236808|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|May 2000||2000-05-31|April 2010|2010-04-30|November 2001|Actual|2001-11-30|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis|A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis|Completed||Phase 3|383|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.235468|2018-06-01 04:24:56.235468
NCT00236795|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 1997||1997-01-31|November 2010|2010-11-30|March 1999|Actual|1999-03-31|||||Interventional|||A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.|An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil.|Completed||Phase 3|1494|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.364053|2018-06-01 04:24:56.364053
NCT00236782|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 1997||1997-10-31|November 2010|2010-11-30|March 1999|Actual|1999-03-31|||||Interventional|||A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.|An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17dNorgestimate and Ethinyl Estradiol With the Oral Contraceptive Mercilon.|Completed||Phase 3|1517|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.423654|2018-06-01 04:24:56.423654
NCT00236769|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-11-15|2005-10-07|2005-10-12|Estimate|||||||2010-11-15|2010-11-17|Estimate|November 1997||1997-11-30|November 2010|2010-11-30|October 1999|Actual|1999-10-31|||||Interventional|||A Study of Efficacy and Safety With the Transdermal Contraceptive System.|An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17deacetyl-norgestimate and Ethinyl Estradiol.|Completed||Phase 3|1751|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.502334|2018-06-01 04:24:56.502334
NCT00226031|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2015-03-10|2005-09-22|2005-09-26|Estimate|||||||2015-03-10|2015-03-11|Estimate|September 2003||2003-09-30|March 2015|2015-03-31|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Interventional|||Optimal Management of Women With Wrist Fractures|Optimal Management of Older Women With Distal Forearm Fractures|Completed||N/A|270|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 04:27:17.397152|2018-06-01 04:27:17.397152
NCT00236756|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-02|2005-10-07|2005-10-12|Estimate|||||||2011-06-02|2011-06-03|Estimate|August 1993||1993-08-31|January 2011|2011-01-31|February 2001|Actual|2001-02-28|||||Interventional|||A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome|A Double-Blind Trial of Topiramate in Subjects With Lennox-Gastaut Syndrome.|Completed||Phase 3|100|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.5748|2018-06-01 04:24:56.5748
NCT00236743|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 1994||1994-06-30|January 2011|2011-01-31|October 2000|Actual|2000-10-31|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy|Topiramate (RWJ 17021-000) Clinical Trial In Children With Partial Onset Seizures|Completed||Phase 3|90|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.636858|2018-06-01 04:24:56.636858
NCT00236730|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 1988||1988-06-30|January 2011|2011-01-31|December 1990|Actual|1990-12-31|||||Interventional|||A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Difficult to Control Epilepsy|Double-Blind Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy|Completed||Phase 2|178|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.692|2018-06-01 04:24:56.692
NCT00236717|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|September 1997||1997-09-30|January 2011|2011-01-31|November 2000|Actual|2000-11-30|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy|TOPAMAX (Topiramate) Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy (RWJ-17021-000); Phase IIIB|Completed||Phase 3|865|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.752333|2018-06-01 04:24:56.752333
NCT00236704|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 1994||1994-03-31|January 2011|2011-01-31|December 1999|Actual|1999-12-31|||||Interventional|||"A Study of the Efficacy and Safety of Topiramate as Add on Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures"|Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures|Completed||Phase 3|80|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.814341|2018-06-01 04:24:56.814341
NCT00236691|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 1988||1988-07-31|January 2011|2011-01-31|December 1990|Actual|1990-12-31|||||Interventional|||A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.|Double-Blind, Parallel Comparison of Three Doses of Topiramate and Placebo in Refractory Partial Epilepsy|Completed||Phase 2|188|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:56.879574|2018-06-01 04:24:56.879574
NCT00236678|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|January 2006|Actual|2006-01-31|||||Interventional|||Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT|A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT� (Epoetin Alfa)|Terminated||Phase 2|29|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"This study was terminated due to slow enrollment, despite protocol amendments to change the~   entrance criteria."|||||t||||||||||2018-06-01 04:24:56.966304|2018-06-01 04:24:56.966304
NCT00236665|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-04-26|2005-10-07|2005-10-12|Estimate|||||||2010-04-26|2010-04-28|Estimate|March 2001||2001-03-31|April 2010|2010-04-30|June 2002|Actual|2002-06-30|||||Interventional|||A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension|Completed||Phase 3|531|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:24:57.023289|2018-06-01 04:24:57.023289
NCT00236652|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|November 2003||2003-11-30|April 2010|2010-04-30|June 2005|Actual|2005-06-30|||||Interventional|||A Study Evaluating the Safety and Efficacy of Treating Sinus Infection With Levofloxacin 750 mg for 5 Days.|An Open-label, Multi-center, Non-comparative Sinus Puncture Study of 750 mg, Short-course Levofloxacin in the Treatment of Acute Maxillary Sinusitis|Completed||Phase 3|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.086868|2018-06-01 04:24:57.086868
NCT00236639|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-04-26|2005-10-07|2005-10-12|Estimate|||||||2010-04-26|2010-04-28|Estimate|July 2000||2000-07-31|April 2010|2010-04-30|June 2002|Actual|2002-06-30|||||Interventional|||A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity|Completed||Phase 3|1293|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:24:57.143064|2018-06-01 04:24:57.143064
NCT00236626|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2000||2000-04-30|April 2010|2010-04-30|May 2002|Actual|2002-05-31|||||Interventional|||A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes|A 9 Month, Double-Blind, Placebo-Controlled Study With a Blinded Crossover Transition to Open-Label Extension, Evaluating the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Type 2 Diabetes Patients|Completed||Phase 2|38|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:24:57.199189|2018-06-01 04:24:57.199189
NCT00236613|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-12-02|2005-10-07|2005-10-12|Estimate|||||||2010-12-02|2010-12-03|Estimate|September 2000||2000-09-30|December 2010|2010-12-31|July 2001|Actual|2001-07-31|||||Interventional|||A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Dose-Response Study to Assess the Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity|Completed||Phase 2|385|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.261362|2018-06-01 04:24:57.261362
NCT00236600|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-04-26|2005-10-07|2005-10-12|Estimate|||||||2010-04-26|2010-04-28|Estimate|August 2000||2000-08-31|April 2010|2010-04-30|June 2002|Actual|2002-06-30|||||Interventional|||A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Patients Following Participation in an Intensive, Non-Pharmacologic Weight Loss Program|Completed||Phase 3|561|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:24:57.314526|2018-06-01 04:24:57.314526
NCT00236587|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2001||2001-11-30|January 2011|2011-01-31|February 2004|Actual|2004-02-29|||||Interventional|||A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia|An Open Label, Long Term Trial of Risperidone Long Acting Microspheres in the Treatment of Patients Diagnosed With Schizophrenia|Completed||Phase 3|100|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.629905|2018-06-01 04:24:57.629905
NCT00236574|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2001||2001-05-31|November 2010|2010-11-30|November 2003|Actual|2003-11-30|||||Interventional|||A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment|A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease.|Completed||Phase 3|974|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.69155|2018-06-01 04:24:57.69155
NCT00236561|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-11-18|2005-10-07|2005-10-12|Estimate|||||||2010-11-18|2010-11-19|Estimate|April 2001||2001-04-30|November 2010|2010-11-30|December 2002|Actual|2002-12-31|||||Interventional|||A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine|A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine|Completed||Phase 3|786|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.75584|2018-06-01 04:24:57.75584
NCT00236548|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-17|2005-10-07|2005-10-12|Estimate|||||||2011-05-17|2011-05-18|Estimate||||March 2011|2011-03-31|January 2003|Actual|2003-01-31|||||Interventional|||Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection|An Open-label Evaluation of the Utility of the RISPERDAL CONSTA Treatment Guidebook During Transition of Adult Patients With Schizophrenia or Schizoaffective Disorder to RISPERDAL CONSTA (Risperidone) Treatment Over Three Months in the Community Mental Health Center (CMHC) Setting|Completed||Phase 3|1|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.818701|2018-06-01 04:24:57.818701
NCT00236535|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 2003||2003-12-31|April 2010|2010-04-30|October 2004|Actual|2004-10-31|||||Interventional|||A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament|A Comparison of the Efficacy and Safety of Tramadol HCl/Acetaminophen Versus Hydrocodone Bitartrate/Acetaminophen Versus Placebo in Subjects With Acute Musculoskeletal Pain|Completed||Phase 3|603|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.879083|2018-06-01 04:24:57.879083
NCT00236522|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|October 2002||2002-10-31|April 2010|2010-04-30|April 2004|Actual|2004-04-30|||||Interventional|||A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.|A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Levofloxacin 750 mg Once Daily for 5 Days Versus Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults.|Completed||Phase 3|784|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:57.946285|2018-06-01 04:24:57.946285
NCT00236509|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-11-15|2005-10-07|2005-10-12|Estimate|||||||2010-11-15|2010-11-17|Estimate|February 2001||2001-02-28|November 2010|2010-11-30|September 2002|Actual|2002-09-30|||||Interventional|||A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine|Completed||Phase 3|763|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:58.011606|2018-06-01 04:24:58.011606
NCT00236496|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|October 2001||2001-10-31|April 2010|2010-04-30|February 2004|Actual|2004-02-29|||||Interventional|||A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor|Completed||Phase 3|223|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:58.078671|2018-06-01 04:24:58.078671
NCT00236483|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|November 2002||2002-11-30|April 2010|2010-04-30|February 2003|Actual|2003-02-28|||||Interventional|||A Comparison of the Effectiveness and Safety of ULTRACET® (Tramadol Hydrochloride/Acetaminophen) Versus ULTRAM® (Tramadol Hydrochloride) Versus Placebo in Patients With Pain After Oral Surgery|A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus ULTRAM® (Tramadol HCl) Versus Placebo in Subjects With Pain Following Oral Surgery|Completed||Phase 4|456|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:58.199583|2018-06-01 04:24:58.199583
NCT00236470|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 2002||2002-01-31|January 2011|2011-01-31|July 2004|Actual|2004-07-31|||||Interventional|||A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders|Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders - an Open Label Follow-up Trial of CR002020|Completed||Phase 3|232|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:24:58.264743|2018-06-01 04:24:58.264743
NCT00236457|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2000||2000-11-30|November 2010|2010-11-30|December 2002|Actual|2002-12-31|||||Interventional|||A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder|Randomized, Multi-center, Open Label Trial Comparing Risperidone Depot (Microspheres) and Olanzapine Tablets in Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|629|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:24:58.336523|2018-06-01 04:24:58.336523
NCT00236262|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2007-03-23|2005-10-07|2005-10-12|Estimate|||||||2007-03-23|2007-03-26|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|September 2006|Actual|2006-09-30|||||Interventional|||Effect of Positive Expiratory Pressure on Right Ventricular Function in Patients With Respiratory Distress Syndrome|Effect of the Positive Expiratory Pressure on the Right Ventricular Function in Patient With Adult Respiratory Distress Syndrome Ventilated With Limited Plateau Pressure|Completed||N/A|15||Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:24:59.294469|2018-06-01 04:24:59.294469
NCT00236444|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 2001||2001-12-31|November 2010|2010-11-30|September 2003|Actual|2003-09-30|||||Interventional|||A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders|Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders.|Completed||Phase 3|375|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:58.414712|2018-06-01 04:24:58.414712
NCT00236431|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2001||2001-05-31|November 2010|2010-11-30|December 2003|Actual|2003-12-31|||||Interventional|||A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment|A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease|Completed||Phase 3|1063|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:58.487372|2018-06-01 04:24:58.487372
NCT00236418|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-06|2005-10-07|2005-10-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 1994||1994-12-31|April 2010|2010-04-30|December 1996|Actual|1996-12-31|||||Interventional|||A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures|Topiramate Clinical Trial in Primary Generalized Tonic-Clonic Seizures|Completed||Phase 3|80|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:24:58.5534|2018-06-01 04:24:58.5534
NCT00236405|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-06-08|2005-10-07|2005-10-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2005||2005-03-31|March 2010|2010-03-31|October 2005|Actual|2005-10-31|||||Interventional|||PROCRIT and Short-Term Outcomes in Orthopedic Surgery|A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of of PROCRIT� (Epoetin Alfa) on Short-Term Outcomes in Orthopedic Subjects Undergoing Primary Unilateral Knee Arthroplasty|Terminated||Phase 2|6|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||The study was terminated due to poor enrollment.|||||f||||||||||2018-06-01 04:24:58.631671|2018-06-01 04:24:58.631671
NCT00236392|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-11-29|2005-10-07|2005-10-12|Estimate|||||||2010-11-29|2010-11-30|Estimate|October 2001||2001-10-31|November 2010|2010-11-30|October 2002|Actual|2002-10-31|||||Interventional|||"A Study of Efficacy and Safety of On-demand Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)"|"Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week Open Acute Phase"|Completed||Phase 3|422|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:24:58.693659|2018-06-01 04:24:58.693659
NCT00236379|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-16|2005-10-07|2005-10-12|Estimate|||||||2011-05-16|2011-05-17|Estimate||||March 2011|2011-03-31|August 2003|Actual|2003-08-31|||||Interventional|||A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder|A Six-month, Double-blind, Randomized, International, Multicenter Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|59|Actual|Janssen, LP||2|||f||||||||||||||2018-06-01 04:24:58.759899|2018-06-01 04:24:58.759899
NCT00236366|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-16|2005-10-07|2005-10-12|Estimate|||||||2011-05-16|2011-05-17|Estimate|June 2002||2002-06-30|December 2010|2010-12-31|April 2004|Actual|2004-04-30|||||Interventional|||A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With Osteoarthritis|Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Trial To Investigate Durogesic™ In Comparison To Placebo In Subjects With Moderate To Severe Pain Induced By Osteoarthritis Of The Hip Or The Knee, Who Are In Need Of And Waiting For Hip Or Knee Replacement.|Completed||Phase 4|418|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:24:58.840961|2018-06-01 04:24:58.840961
NCT00236353|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-16|2005-10-07|2005-10-12|Estimate|||||||2011-05-16|2011-05-17|Estimate|May 2002||2002-05-31|March 2011|2011-03-31|December 2003|Actual|2003-12-31|||||Interventional|||Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder|An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|86|Actual|Janssen, LP|||||f||||||||||||||2018-06-01 04:24:58.904498|2018-06-01 04:24:58.904498
NCT00236340|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2007-04-18|2005-10-11|2005-10-12|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2002||2002-01-31|October 2005|2005-10-31|February 2005|Actual|2005-02-28|||||Interventional|||Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.|Syringe or Continuous Amnioreduction for Symptomatic Polyhydramnios. A Prospective Randomized Study.|Completed||Phase 3|80||Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-06-01 04:24:58.96286|2018-06-01 04:24:58.96286
NCT00236327|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-16|2005-10-07|2005-10-12|Estimate|||||||2011-05-16|2011-05-17|Estimate|June 2003||2003-06-30|April 2010|2010-04-30|May 2004|Actual|2004-05-31|||||Interventional|||Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain|Evaluation of the Efficacy and Safety of Transdermal Fentanyl in Patients Suffering From Chronic Cancer Pain in an Ambulatory Setting|Terminated||Phase 4|34|Actual|Janssen Cilag S.A.S.||||"Sponsor discontinued the study following the discovery of a number of incompletely sealed~   batches that were unusable."|f||||f||||||||||2018-06-01 04:24:59.035302|2018-06-01 04:24:59.035302
NCT00236301|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2008-01-16|2005-10-11|2005-10-12|Estimate|||||||2008-01-16|2008-01-17|Estimate|March 2004||2004-03-31|October 2005|2005-10-31|January 2007|Actual|2007-01-31|June 2006|Actual|2006-06-30||Interventional|THS||Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers|Pro-Inflammatory Effects of Two Different Doses of 17 Beta Estradiol in Menopausal Women|Terminated||Phase 3|99|Actual|Assistance Publique - Hôpitaux de Paris||3||terminated|f||||f||||||||||2018-06-01 04:24:59.098265|2018-06-01 04:24:59.098265
NCT00236288|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2007-10-29|2005-10-07|2005-10-12|Estimate|||||||2007-10-29|2007-10-31|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||A Feasibility Study of Smoking Cessation Program in Radiation Oncology|A Feasibility Study of Smoking Cessation Program in Radiation Oncology|Completed||N/A|36|Anticipated|Indiana University|||||f||||||||||||||2018-06-01 04:24:59.183253|2018-06-01 04:24:59.183253
NCT00236275|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2011-04-29|2005-10-11|2005-10-12|Estimate|||||||2011-04-29|2011-05-02|Estimate|May 2004||2004-05-31|March 2007|2007-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer|PET and MRI in the Follow-up of Neoadjuvant Chemotherapy of Breast Cancer|Completed||Phase 3|60|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:24:59.237548|2018-06-01 04:24:59.237548
NCT00236249|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2011-02-17|2005-10-10|2005-10-12|Estimate|||||||2011-02-17|2011-02-18|Estimate|May 2005||2005-05-31|March 2007|2007-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety and Efficacy Study of Intravenous Lidocaine After Colorectal Surgery: LIDOREHAB|Evaluation of Lidocaine Continuous Intravenous Administration for Postoperative Recovery After Colorectal Surgery|Completed||Phase 3|110|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:24:59.346984|2018-06-01 04:24:59.346984
NCT00236236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-11-13|2005-10-10|2005-10-12|Estimate|||||||2006-11-13|2006-11-14|Estimate|February 2003||2003-02-28|October 2005|2005-10-31|May 2005||2005-05-31|||||Observational|||The HF-HRV Registry|CONTAK RENEWAL® Heart Failure Heart Rate Variability Registry|Completed|||1400||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:24:59.404046|2018-06-01 04:24:59.404046
NCT00236223|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2008-05-14|2005-10-07|2005-10-12|Estimate|||||||2008-05-14|2008-05-15|Estimate|October 2005||2005-10-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||The Effect of Gabapentin, Ketamine and Dexamethasone on Pain and Opioid Requirements After Hip Surgery|The Effect of Gabapentin, Low Dose Ketamine, Paracetamol, NSAID and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for Primary Total Hip Replacement|Terminated||Phase 4|48|Actual|Glostrup University Hospital, Copenhagen||2||Structural changes that stopped the type of operations used in the study|f||||t||||||||||2018-06-01 04:24:59.442181|2018-06-01 04:24:59.442181
NCT00236210|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2009-07-31|2005-10-07|2005-10-12|Estimate|||||||2009-07-31|2009-08-04|Estimate|August 2004||2004-08-31|July 2009|2009-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program|The Vascular Intervention Project (VIP): a Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program in the Algoma District of Northern Ontario|Completed||N/A|422|Actual|Group Health Centre||2|||f||||f||||||||||2018-06-01 04:24:59.508204|2018-06-01 04:24:59.508204
NCT00236197|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|2009-08-25||2009-11-04|2005-10-10|2005-10-12|Estimate|2009-11-03|2009-11-05|Estimate||||2009-11-04|2009-11-11|Estimate|October 2005||2005-10-31|November 2009|2009-11-30|June 2008|Actual|2008-06-30|March 2006|Actual|2006-03-31||Interventional|||E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers|E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers|Completed||Phase 3|619|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:24:59.57285|2018-06-01 04:24:59.57285
NCT00236184|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|2009-08-26||2010-03-30|2005-10-10|2005-10-12|Estimate|2009-08-26|2009-10-01|Estimate||||2010-03-30|2010-04-06|Estimate|October 2005||2005-10-31|March 2010|2010-03-31|June 2008|Actual|2008-06-30|March 2006|Actual|2006-03-31||Interventional|||E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers|E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers|Completed||Phase 3|629|Actual|Eisai Inc.||2|||f||||t||||||||||2018-06-01 04:24:59.945631|2018-06-01 04:24:59.945631
NCT00236171|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2010-06-07|2005-10-10|2005-10-12|Estimate|||||||2010-06-07|2010-06-08|Estimate|September 2004||2004-09-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|April 2006|Actual|2006-04-30||Interventional|||Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test|Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test|Completed||N/A|14|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 04:25:00.244508|2018-06-01 04:25:00.244508
NCT00236158|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2009-02-20|2005-10-10|2005-10-12|Estimate|||||||2009-02-20|2009-02-24|Estimate|March 1999||1999-03-31|February 2009|2009-02-28|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Interventional|||The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome|The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome|Terminated||Phase 2/Phase 3|1415|Actual|The DANPACE Investigator Group||2||Not able to recruit the estimated number of patients|f||||t||||||||||2018-06-01 04:25:00.304735|2018-06-01 04:25:00.304735
NCT00236145|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2013-01-28|2005-10-07|2005-10-12|Estimate|||||||2013-01-28|2013-01-29|Estimate|June 2004||2004-06-30|October 2005|2005-10-31||||August 2005|Actual|2005-08-31||Interventional|||Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain|A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain|Completed||Phase 3|||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:25:00.375454|2018-06-01 04:25:00.375454
NCT00236132|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2007-10-11|2005-10-10|2005-10-12|Estimate|||||||2007-10-11|2007-10-12|Estimate|August 2001||2001-08-31|October 2007|2007-10-31|December 2008|Anticipated|2008-12-31|||||Observational|||"A Multicenter Study Comparing the Clinical Outcomes of the Nuss and Ravitch Procedures for Repair Of Pediatric Pectus Excavatum"|" A Multicenter Study Comparing the Clinical Outcomes of the Nuss and Ravitch Procedures for Repair of Pediatric Pectus Excavatum"|Unknown status|Active, not recruiting||360|Anticipated|Children's Health System, Inc.|||||f||||||||||||||2018-06-01 04:25:00.429999|2018-06-01 04:25:00.429999
NCT00236119|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2012-08-22|2005-10-11|2005-10-12|Estimate|||||||2012-08-22|2012-08-23|Estimate|June 2005||2005-06-30|August 2012|2012-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis|A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe, Recalcitrant, Plaque Type Psoriasis|Completed||Phase 2|46|Actual|Teva Pharmaceutical Industries||4|||f||||||||||||||2018-06-01 04:25:00.551669|2018-06-01 04:25:00.551669
NCT00236106|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2005-12-08|2005-10-07|2005-10-12|Estimate|||||||2005-12-08|2005-12-09|Estimate|February 2005||2005-02-28|March 2005|2005-03-31|June 2005||2005-06-30|||||Interventional|||Short Term Growth in Children With Atopic Dermatitis||Completed||Phase 4|20||Children´s Clinic, Randers|||||f||||||||||||||2018-06-01 04:25:00.629735|2018-06-01 04:25:00.629735
NCT00236093|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2014-05-08|2005-10-07|2005-10-12|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2006||2006-10-31|May 2014|2014-05-31||||December 2006|Actual|2006-12-31||Interventional|||Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain|A 4-week, Open-Label Extension Study of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain|Completed||Phase 2|||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:25:00.689925|2018-06-01 04:25:00.689925
NCT00236080|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2009-06-01||2013-07-12|2005-10-07|2005-10-12|Estimate|2010-01-08|2010-02-03|Estimate||||2013-07-12|2013-07-19|Estimate|August 2005||2005-08-31|July 2013|2013-07-31|December 2005||2005-12-31|||||Interventional|||Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil (150, 200, and 250 mg) and PROVIGIL® (200 mg) in Patients With Chronic Shift Work Sleep Disorder|Completed||Phase 3|136|Actual|Teva Pharmaceutical Industries|In analyzing the PVT data, it was discovered that data transfer errors had occurred at certain study centers. The ability to interpret the efficacy results from this study is limited, and the findings should be considered inconclusive.|5|||||||||||||||||2018-06-01 04:25:00.808428|2018-06-01 04:25:00.808428
NCT00236067|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2014-05-08|2005-10-07|2005-10-12|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2004||2004-10-31|May 2014|2014-05-31|March 2006||2006-03-31|||||Interventional|||A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril(up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder|Completed||Phase 3|440||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:25:01.294278|2018-06-01 04:25:01.294278
NCT00236054|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2014-05-08|2005-10-07|2005-10-12|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2004||2004-10-31|May 2014|2014-05-31|December 2005||2005-12-31|||||Interventional|||A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril (up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder|Completed||Phase 3|440||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:25:01.419512|2018-06-01 04:25:01.419512
NCT00236041|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2014-05-08|2005-10-07|2005-10-12|Estimate|||||||2014-05-08|2014-05-09|Estimate|April 2004||2004-04-30|May 2014|2014-05-31|August 2006||2006-08-31|||||Interventional|||Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)|A Double-Blind, Placebo-Comparison Study to Evaluate the Efficacy and Safety of ACTIQ® (Oral Transmucosal Fentanyl Citrate [OTFC®]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain|Completed||Phase 2|38||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:25:01.507701|2018-06-01 04:25:01.507701
NCT00236028|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-05-18|2005-10-07|2005-10-12|Estimate|||||||2011-05-18|2011-05-19|Estimate||||March 2010|2010-03-31|April 2003|Actual|2003-04-30|||||Interventional|||A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis|A Randomized, Double-blind, Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared With Methotrexate Alone for the Treatment of Patients With Early Rheumatoid Arthritis|Completed||Phase 3|607|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:25:01.604221|2018-06-01 04:25:01.604221
NCT00236015|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2014-05-08|2005-10-07|2005-10-12|Estimate|||||||2014-05-08|2014-05-09|Estimate|November 2004||2004-11-30|May 2014|2014-05-31|March 2006||2006-03-31|||||Interventional|||A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Gabitril at 4, 8, and 12 mg/Day in the Treatment of Adults With Generalized Anxiety Disorder.|Completed||Phase 3|880||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:25:01.66496|2018-06-01 04:25:01.66496
NCT00236002|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-11|||2009-08-11|2005-10-11|2005-10-12|Estimate|||||||2009-08-11|2009-08-12|Estimate|July 2005||2005-07-31|August 2009|2009-08-31|August 2009|Actual|2009-08-31|November 2007|Actual|2007-11-30||Interventional|||Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )|A Phase III, Double-blind, Randomized, Parallel Group, Placebo-controlled Study of Oral Fosamax, 70 mg Once a Week, for the Prevention of Androgen Deprivation Bone Loss in Non-metastatic Prostate Cancer|Terminated||Phase 3|182|Actual|Canadian Urology Research Consortium||1||Slow accrual than anticipated.|f||||f||||||||||2018-06-01 04:25:01.771197|2018-06-01 04:25:01.771197
NCT00235989|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|2009-01-30||2014-04-25|2005-10-10|2005-10-12|Estimate|2009-05-13|2009-07-03|Estimate||||2014-04-25|2014-05-08|Estimate|June 2003||2003-06-30|April 2014|2014-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis|An Open-label Extension Study of the Double-blind, Randomized, Parallel Group, Multicenter Phase 2 Study 307000A to Further Evaluate the Safety and Tolerability of Betaseron® 500 mcg Subcutaneously Every Other Day and Betaseron® 250 mcg Subcutaneously Every Other Day in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)|Completed||Phase 2|63|Actual|Bayer|The 40 patients in the NAb frequency summaries are the total number of patients with NAb titers at week 234. Official HARTS-to-MedDRA Mapping was used.|4|||f||||f||||||||||2018-06-01 04:25:01.875581|2018-06-01 04:25:01.875581
NCT00235976|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2006-07-20|2005-10-07|2005-10-12|Estimate|||||||2006-07-20|2006-07-21|Estimate|May 2005||2005-05-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||The Efficacy and Safety of Gantacurium Chloride for Injection in Tracheal Intubation in Healthy Adult Patients Undergoing Surgery Under General Anesthesia|A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate the Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patients Undergoing Surgery With General Anesthesia|Completed||Phase 1/Phase 2|200||Avera Pharmaceuticals|||||f||||||||||||||2018-06-01 04:25:03.191266|2018-06-01 04:25:03.191266
NCT00235963|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2008-10-14|2005-10-07|2005-10-12|Estimate|||||||2008-10-14|2008-10-16|Estimate|December 2002||2002-12-31|October 2008|2008-10-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm|A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm|Completed||Phase 1/Phase 2|104||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:25:03.252695|2018-06-01 04:25:03.252695
NCT00235950|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2010-11-18|2005-10-07|2005-10-12|Estimate|||||||2010-11-18|2010-11-19|Estimate|January 2004||2004-01-31|November 2010|2010-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease|A Multicentre Study Comparing the Efficacy of Rosuvastatin With Atorvastatin When Given for a Period of 16 Wks to Subjects With Coronary Heart Disease & a Previously Performed Percutaneous Coronary Intervention|Completed||Phase 4|255||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:03.368022|2018-06-01 04:25:03.368022
NCT00235937|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2011-01-20|2005-10-10|2005-10-12|Estimate|||||||2011-01-20|2011-01-21|Estimate|December 2001||2001-12-31|January 2011|2011-01-31|December 2006|Actual|2006-12-31|||||Interventional|||Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex|An Open, Phase II Trial Assessing the Objective Response Rate After Combination of Arimidex® 1mg Per os/Day and Zoladex® 3.6 mg Sub Cut/Monthly as 1st Treatment for Premenopausal Receptor Positive Advanced or Metastatic Breast Cancer|Completed||Phase 2|45|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:25:03.47338|2018-06-01 04:25:03.47338
NCT00235924|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2005-12-07|2005-10-07|2005-10-12|Estimate|||||||2005-12-07|2005-12-08|Estimate|June 2004||2004-06-30|October 2005|2005-10-31||||||||Interventional|||Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women|Study Assessing the Effects on Endometrium and Breast of a Standardized Isoflavone Extract(Phytosoya) in Post Menopausal Women.|Unknown status|Active, not recruiting|Phase 3|300||Laboratoires Arkopharma|||||f||||||||||||||2018-06-01 04:25:03.553678|2018-06-01 04:25:03.553678
NCT00235911|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2011-01-21|2005-10-07|2005-10-12|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2003||2003-09-30|January 2011|2011-01-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting|Effects of Symbicort Single Inhaler Therapy on Bronchial Hyper Responsiveness, Asthma Control and Safety in Mild to Moderate Asthmatics in General Practice, Compared to Usual Care Therapy|Completed||Phase 3|100||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:03.61748|2018-06-01 04:25:03.61748
NCT00235898|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2008-08-22|2005-10-10|2005-10-12|Estimate|||||||2008-08-22|2008-08-25|Estimate|May 2005||2005-05-31|August 2008|2008-08-31||||March 2008|Actual|2008-03-31||Interventional|||Clinical Trial in Patients With Metastatic Colorectal Cancer|A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU Versus Leucovorin and 5-FU in Subjects With Metastatic Colorectal Carcinoma|Completed||Phase 2|300|Actual|Mast Therapeutics, Inc.||2|||f||||t||||||||||2018-06-01 04:25:03.695208|2018-06-01 04:25:03.695208
NCT00235885|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2007-08-28|2005-10-11|2005-10-12|Estimate|||||||2007-08-28|2007-08-29|Estimate|July 2005||2005-07-31|August 2007|2007-08-31||||||||Interventional|STEREO||Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)|Safety and Efficacy of Adalimumab in Patients With Active Psoriatic Arthritis (PsA) - An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy, Including Patients Who Failed Prior Treatment With Other TNF-Inhibitors (STEREO)|Completed||Phase 3|445||Abbott|||||f||||||||||||||2018-06-01 04:25:03.843624|2018-06-01 04:25:03.843624
NCT00235872|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2009-12-09||2011-04-07|2005-10-11|2005-10-12|Estimate|2009-12-09|2010-01-13|Estimate||||2011-04-07|2011-04-11|Estimate|August 2004||2004-08-31|April 2011|2011-04-30||||July 2006|Actual|2006-07-31||Interventional|||Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis|Completed||Phase 3|309|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:25:04.02568|2018-06-01 04:25:04.02568
NCT00235859|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2007-08-28|2005-10-11|2005-10-12|Estimate|||||||2007-08-28|2007-08-29|Estimate|July 2003||2003-07-31|August 2007|2007-08-31||||||||Interventional|||Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Human Anti-TNF Antibody Adalimumab Administered as Subcutaneous Injections in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate|Completed||Phase 3|128|Actual|Abbott|||||f||||f||||||||||2018-06-01 04:25:05.155111|2018-06-01 04:25:05.155111
NCT00235846|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-10|||2015-04-13|2005-10-11|2005-10-12|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2004||2004-12-31|April 2015|2015-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Endoscopic Vessel Harvesting During Coronary Bypass Surgery|Endoscopic Vessel Harvesting During Coronary Bypass Surgery|Completed||N/A|132|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-06-01 04:25:05.208485|2018-06-01 04:25:05.208485
NCT00235833|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|2009-10-12||2011-04-07|2005-10-11|2005-10-12|Estimate|2010-01-05|2010-01-29|Estimate||||2011-04-07|2011-04-11|Estimate|June 2003||2003-06-30|April 2011|2011-04-30||||October 2004|Actual|2004-10-31||Interventional|||Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis|Long-term Continuously Repeated Dose Study of Adalimumab (D2E7) in Patients With Rheumatoid Arthritis|Completed||Phase 2|25|Actual|Abbott|Due to the small population, statistical tests were not performed.|1|||f||||f||||||||||2018-06-01 04:25:05.359517|2018-06-01 04:25:05.359517
NCT00235820|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2008-07-15|2005-10-07|2005-10-12|Estimate|||||||2008-07-15|2008-07-17|Estimate|July 2005||2005-07-31|June 2008|2008-06-30||||May 2006|Actual|2006-05-31||Interventional|CHAMPION||Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|271|Actual|Abbott||3|||f||||f||||||||||2018-06-01 04:25:06.917934|2018-06-01 04:25:06.917934
NCT00235807|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2011-03-23|2005-10-06|2005-10-10|Estimate|||||||2011-03-23|2011-03-24|Estimate|June 2004||2004-06-30|March 2011|2011-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Multi-Site Randomized Clinical Study of Tinnitus Treatment Methods|Multi-Site Randomized Clinical Study of Tinnitus Treatment Methods|Completed||N/A|144|Anticipated|VA Office of Research and Development||3|||f||||||||||||||2018-06-01 04:25:07.041325|2018-06-01 04:25:07.041325
NCT00235794|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2007-12-18|2005-10-06|2005-10-10|Estimate|||||||2007-12-18|2007-12-27|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients|An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse|Completed||N/A|50|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:25:07.117556|2018-06-01 04:25:07.117556
NCT00235781|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2006-10-13|2005-10-06|2005-10-10|Estimate|||||||2006-10-13|2006-10-16|Estimate|January 2006||2006-01-31|October 2006|2006-10-31|February 2006||2006-02-28|||||Interventional|||Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients|Non-Phased Study of the Use of a Single Dose of Thymoglobulin for Immunosuppressive Induction in Renal Transplant Recipients as Compared to a Standard Four Dose Regimen|Terminated||N/A|90||Washington University School of Medicine|||||f||||||||||||||2018-06-01 04:25:07.175731|2018-06-01 04:25:07.175731
NCT00235768|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2005-10-06|2005-10-06|2005-10-10|Estimate|||||||2005-10-06|2005-10-10|Estimate|April 2002||2002-04-30|October 2004|2004-10-31|July 2005||2005-07-31|||||Observational|||The NeXT Study; The Netherlands XTC Toxicity Study|Neurotoxicity of Ecstasy: Causality, Course and Clinical Relevance|Completed|||225||UMC Utrecht|||||f||||||||||||||2018-06-01 04:25:07.237347|2018-06-01 04:25:07.237347
NCT00235755|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|2011-07-07||2017-03-23|2005-10-06|2005-10-10|Estimate|2011-09-30|2011-11-07|Estimate||||2017-03-23|2017-04-21|Actual|December 2005||2005-12-31|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|RESTORE2||Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy|Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures|Completed||Phase 3|539|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-06-01 04:25:07.379966|2018-06-01 04:25:07.379966
NCT00235729|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2009-03-19|2005-10-06|2005-10-10|Estimate|||||||2009-03-19|2009-03-20|Estimate|June 2006||2006-06-30|March 2009|2009-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Lofexidine for Inpatient Opiate Detox|CSP #1024 - A Phase III, Randomized, Multi-Center, Double Blind, Placebo-Controlled Study of Safety and Efficacy of Lofexidine for Relief of Symptoms in Subjects Undergoing Inpatient Opiate Detoxification.|Completed||Phase 3|264|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:25:09.661419|2018-06-01 04:25:09.661419
NCT00235716|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|2013-12-06||2014-07-14|2005-10-06|2005-10-10|Estimate|2014-01-23|2014-01-29|Estimate||||2014-07-14|2014-07-23|Estimate|August 2007||2007-08-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|TEAM-AD||A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease|CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)|Completed||Phase 3|613|Actual|VA Office of Research and Development||4|||f||||t||||||||||2018-06-01 04:25:09.932096|2018-06-01 04:25:09.932096
NCT00235703|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2006-05-04|2005-10-06|2005-10-10|Estimate|||||||2006-05-04|2006-05-05|Estimate|October 2001||2001-10-31|October 2005|2005-10-31|September 2005||2005-09-30|||||Observational|||Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)|Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)|Completed|||13000||University of Utah|||||f||||||||||||||2018-06-01 04:25:13.660909|2018-06-01 04:25:13.660909
NCT00235690|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2015-12-16|2005-10-06|2005-10-10|Estimate|||||||2015-12-16|2015-12-17|Estimate|June 2008||2008-06-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Optimizing Dosing of Colistin for Infections Resistant to All Other Antibiotics, Approved NIH Protocol Dated 12.06.07(DMID Protocol #07-0036)|Pharmacokinetics and Pharmacodynamics of Intravenous Colistin- Pilot Study|Completed||N/A|10|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:25:13.74899|2018-06-01 04:25:13.74899
NCT00235677|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2005-10-06|2005-10-06|2005-10-10|Estimate|||||||2005-10-06|2005-10-10|Estimate|August 2003||2003-08-31|July 2005|2005-07-31|August 2005||2005-08-31|||||Interventional|||Treatment Of Gastroesophageal Reflux Disease By Endoscopic Fundoplication, A Placebo-Controlled Study|A Blinded, Randomized, Sham-Controlled Trial of Endoscopic Gastroplication for the Treatment of Gastroesophageal Reflux Disease|Completed||Phase 3|60||UMC Utrecht|||||f||||||||||||||2018-06-01 04:25:13.82538|2018-06-01 04:25:13.82538
NCT00235664|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2008-12-16|2005-10-06|2005-10-10|Estimate|||||||2008-12-16|2008-12-17|Estimate|October 2005||2005-10-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|||||Observational|||Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients|Prospective Study of Drug Resistant Pathogens Among Liver, Intestinal and Multivisceral Transplant Recipients|Completed|||200|Anticipated|University of Pittsburgh|||||f||||||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. If a subject withdraws and provides the request in writing, samples collected~     and not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 04:25:13.893608|2018-06-01 04:25:13.893608
NCT00235651|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2008-12-16|2005-10-06|2005-10-10|Estimate|||||||2008-12-16|2008-12-17|Estimate|October 2005||2005-10-31|December 2008|2008-12-31|April 2006|Actual|2006-04-30|||||Interventional|||Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients|Pharmacokinetic and Deposition Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet®) in Lung Transplant Recipients (Radiotagging Protocol)|Terminated||Phase 3|12||University of Pittsburgh||||study completed|f||||||||||||||2018-06-01 04:25:13.957606|2018-06-01 04:25:13.957606
NCT00235625|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2007-12-12|2005-10-07|2005-10-10|Estimate|||||||2007-12-12|2007-12-17|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Curcuminoids for the Treatment of Chronic Psoriasis Vulgaris|A Phase II Open Label Study of the Safety and Efficacy of Curcuminoids C3 Complex® in Patients With Chronic Psoriasis Vulgaris.|Completed||Phase 2|12|Actual|University of Pennsylvania|||||f||||t||||||||||2018-06-01 04:25:14.049699|2018-06-01 04:25:14.049699
NCT00235599|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2007-05-15|2005-10-06|2005-10-10|Estimate|||||||2007-05-15|2007-05-17|Estimate|September 2005||2005-09-30|May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Observational|||The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.|The Insulin-Like Growth Factor Binding Protein-3 Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.|Completed|||10|Actual|University of Massachusetts, Worcester|||||f||||f||||||||||2018-06-01 04:25:14.114568|2018-06-01 04:25:14.114568
NCT00235586|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2007-09-18|2005-10-07|2005-10-10|Estimate|||||||2007-09-18|2007-09-20|Estimate|April 2004||2004-04-30|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Vitamin D Deficiency: Bone Loss and Vascular Dysfunction|Vitamin D Deficiency: Bone Loss and Vascular Dysfunction|Completed||N/A|40||University of Kansas Medical Center|||||f||||f||||||||||2018-06-01 04:25:14.178824|2018-06-01 04:25:14.178824
NCT00235573|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|2011-09-30||2011-12-15|2005-10-06|2005-10-10|Estimate|2011-11-08|2011-12-14|Estimate||||2011-12-15|2011-12-22|Estimate|October 2005||2005-10-31|December 2011|2011-12-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption|Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption|Completed||N/A|21|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 04:25:14.256736|2018-06-01 04:25:14.256736
NCT00235560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-06-19|2005-10-06|2005-10-10|Estimate|||||||2008-06-19|2008-06-20|Estimate|June 2005||2005-06-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|LAM-RAPA||Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients|Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)|Completed||Phase 2|50|Actual|University Hospital, Toulouse|||||f||||f||||||||||2018-06-01 04:25:14.397007|2018-06-01 04:25:14.397007
NCT00235547|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2013-07-01|2005-10-06|2005-10-10|Estimate|||||||2013-07-01|2013-07-03|Estimate|August 2005||2005-08-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|May 2006|Actual|2006-05-31||Interventional|||Trial of Immediate Versus Delayed Initiation of Transdermal Hormonal Contraception After Therapeutic Abortion|Immediate Versus Delayed Initiation of Transdermal Hormonal Contraception After Therapeutic Abortion: A Randomized Trial|Completed||N/A|300|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:25:14.466935|2018-06-01 04:25:14.466935
NCT00235534|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2012-11-16|2005-10-06|2005-10-10|Estimate|||||||2012-11-16|2012-11-19|Estimate|October 2005||2005-10-31|November 2012|2012-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Trial of Immediate Versus Delayed Initiation of Oral Contraceptive Pills After Abortion|Immediate Versus Delayed Initiation of Oral Contraceptive Pills After Therapeutic Abortion - A Randomized Trial|Completed||N/A|300|Actual|University of California, San Francisco||2|||f||||||||||||||2018-06-01 04:25:14.618066|2018-06-01 04:25:14.618066
NCT00235521|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2012-12-11|2005-10-06|2005-10-10|Estimate|||||||2012-12-11|2012-12-12|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery|Comparison of Inhaled Nitric Oxide With Aerosolized Iloprost (Ventavis®) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery|Completed||N/A|15|Actual|Heidelberg University|||||f||||t||||||||||2018-06-01 04:25:14.753935|2018-06-01 04:25:14.753935
NCT00235508|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2012-02-21|2005-10-06|2005-10-10|Estimate|||||||2012-02-21|2012-02-22|Estimate|June 2005||2005-06-30|February 2012|2012-02-29|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder|The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.|Completed||Phase 4|420|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 04:25:14.861053|2018-06-01 04:25:14.861053
NCT00235495|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-11-14|2005-10-05|2005-10-10|Estimate|||||||2012-11-14|2012-11-15|Estimate|June 2006||2006-06-30|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|February 2013|Anticipated|2013-02-28||Interventional|ALIAS||Albumin in Acute Ischemic Stroke Trial|A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke|Terminated||Phase 3|843|Actual|University of Miami||2||Recruitment halted by DSMB following interim analysis.|f||||t||||||||||2018-06-01 04:25:15.040313|2018-06-01 04:25:15.040313
NCT00235482|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2018-01-10|2005-10-07|2005-10-10|Estimate|||||||2018-01-10|2018-01-12|Actual|November 21, 2005|Actual|2005-11-21|January 2018|2018-01-31|April 21, 2006|Actual|2006-04-21|April 21, 2006|Actual|2006-04-21||Interventional|PXS-X02||Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)|Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)|Completed||Phase 1|3|Actual|Viralytics|||||f||||||||||||||2018-06-01 04:25:15.15327|2018-06-01 04:25:15.15327
NCT00235469|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2014-09-19|2005-10-06|2005-10-10|Estimate|||||||2014-09-19|2014-09-22|Estimate|April 2004||2004-04-30|February 2010|2010-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety OF 200, 400, AND 600 mg/Day SPM 927 in Subjects With Painful Distal Diabetic Neuropathy|Completed||Phase 2/Phase 3|496|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:25:15.210451|2018-06-01 04:25:15.210451
NCT00235456|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|2016-06-20||2016-12-18|2005-10-06|2005-10-10|Estimate|2016-06-20|2016-07-29|Estimate||||2016-12-18|2017-02-10|Actual|March 2003||2003-03-31|December 2016|2016-12-31|January 2005|Actual|2005-01-31|October 2004|Actual|2004-10-31||Interventional|||Supplemental Oxygen Reduces Surgical Infection|Supplemental Perioperative Oxygen Reduces the Risk of Surgical Wound Infection: A Randomized, Double-blind Trial|Completed||N/A|300|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-06-01 04:25:15.522322|2018-06-01 04:25:15.522322
NCT00235443|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|2009-08-31||2017-07-28|2005-10-06|2005-10-10|Estimate|2009-08-31|2009-10-05|Estimate||||2017-07-28|2017-08-28|Actual|September 2004||2004-09-30|July 2017|2017-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy|A Multi-Center, Open-Label, Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy|Completed||Phase 2/Phase 3|451|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:25:15.918085|2018-06-01 04:25:15.918085
NCT00235417|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2007-06-07|2005-10-06|2005-10-10|Estimate|||||||2007-06-07|2007-06-08|Estimate|October 2005||2005-10-31|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Stem Cell Therapy in Chronic Ischemic Heart Failure||Completed||Phase 2|35|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:25:18.341427|2018-06-01 04:25:18.341427
NCT00235404|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2016-07-28|2005-10-07|2005-10-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2003||2003-09-30|July 2016|2016-07-31|May 2005|Actual|2005-05-31|||||Interventional|||Randomized Controlled Trial of Health Care to Elderly Patients.|Specialized Treatment and Care Intervention at a Primary Level in a Nursing Home Compared to Conventional Treatment at a Hospital: a Randomized Controlled Trial.|Completed||N/A|142|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:25:18.403201|2018-06-01 04:25:18.403201
NCT00235391|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|2010-12-17||2011-06-03|2005-10-06|2005-10-10|Estimate|2011-03-31|2011-05-02|Estimate||||2011-06-03|2011-06-07|Estimate|October 2005||2005-10-31|June 2011|2011-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload|A Study to Provide Expanded Access of (Exjade®) Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload From Blood Transfusions Who Cannot Adequately be Treated With Other Locally Approved Iron Chelators|Completed||Phase 3|1683|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:25:18.518824|2018-06-01 04:25:18.518824
NCT00235378|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2015-10-13|2005-10-06|2005-10-10|Estimate|||||||2015-10-13|2015-10-15|Estimate|July 1996||1996-07-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Genetic Study of Lupus Patients and Their Families|Gene Mapping in Women With SLE|Completed|||2356|Actual|Oklahoma Medical Research Foundation|||3||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 04:25:19.642813|2018-06-01 04:25:19.642813
NCT00235365|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2012-11-21|2005-10-07|2005-10-10|Estimate|||||||2012-11-21|2012-11-22|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Metacognitive Therapy for Comorbid Insomnia|Metacognitive Therapy for Patients With a Psychiatric Disorder and Comorbid Insomnia.|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||2||problems recruiting patients|f||||f||||||||||2018-06-01 04:25:19.706791|2018-06-01 04:25:19.706791
NCT00235352|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2009-02-25|2005-10-06|2005-10-10|Estimate|||||||2009-02-25|2009-02-26|Estimate|February 2002||2002-02-28|February 2009|2009-02-28|February 2007|Actual|2007-02-28|April 2005|Actual|2005-04-30||Interventional|CX516||Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia|A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia|Completed||Phase 2/Phase 3|105|Actual|North Suffolk Mental Health Association|||||f||||t||||||||||2018-06-01 04:25:19.762638|2018-06-01 04:25:19.762638
NCT00235339|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-07|||2012-05-11|2005-10-07|2005-10-10|Estimate|||||||2012-05-11|2012-05-14|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|December 2009|Actual|2009-12-31|February 2008|Actual|2008-02-29||Interventional|||Effect of Standard Care Rehabilitation Versus Interval Treadmill Training After Myocardial Infarction|Comparative Study of Training Modality After Myocardial Infarction; Standard Care Rehabilitation Training or Interval Treadmill Training|Completed||N/A|89|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:25:19.821996|2018-06-01 04:25:19.821996
NCT00235326|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|2009-02-05||2009-03-16|2005-10-06|2005-10-10|Estimate|2009-03-16|2009-04-22|Estimate||||2009-03-16|2009-04-22|Estimate|January 2002||2002-01-31|March 2009|2009-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario|Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario|Completed|||4561|Actual|McMaster University|||2||f||||f||||||||||2018-06-01 04:25:20.108685|2018-06-01 04:25:20.108685
NCT00235313|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2008-03-28|2005-10-06|2005-10-10|Estimate|||||||2008-03-28|2008-04-01|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|ADONIS||Adjustment of DOses of NIcotine in Smoking Cessation (ADONIS)|Does Dose Adjustment of Nicotine Replacement Therapies According to Saliva Cotinine Increase Efficacy of These Treatments of Assistance To the Nicotinic Weaning Of the High-Risk Patients?|Completed||Phase 4|300|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:25:20.292382|2018-06-01 04:25:20.292382
NCT00235300|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2015-03-17|2005-10-06|2005-10-10|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2000||2000-05-31|March 2015|2015-03-31|June 2005|Actual|2005-06-30|April 2003|Actual|2003-04-30||Interventional|||An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.|An Open-Label Prospective, Randomized, Multicenter Phase II Comparative Trial of Thymoglobulin® Versus Simulect® for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients|Completed||Phase 2|240|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:25:20.373409|2018-06-01 04:25:20.373409
NCT00235287|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2009-01-16|2005-10-06|2005-10-10|Estimate|||||||2009-01-16|2009-01-19|Estimate|September 2005||2005-09-30|January 2009|2009-01-31||||||||Interventional|||Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease|Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Herlev Hospital||4|||f||||t||||||||||2018-06-01 04:25:20.481566|2018-06-01 04:25:20.481566
NCT00235274|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2017-03-01|2005-10-06|2005-10-10|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2005||2005-11-30|March 2017|2017-03-31|August 2006||2006-08-31|||||Interventional|||Effects of RG1068 (Secretin) on Information Processing in Schizophrenia|Effects of RG1068 (Secretin) on Information Processing in Schizophrenia|Completed||Phase 2|30||Indiana University|||||||||||||||||||2018-06-01 04:25:20.570918|2018-06-01 04:25:20.570918
NCT00235261|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2007-08-16|2005-10-07|2005-10-10|Estimate|||||||2007-08-16|2007-08-17|Estimate|October 2005||2005-10-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Effect of Paracetamol, Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients After Hip Operations|Effect of Paracetamol Versus Paracetamol Combined With Pregabalin Versus Paracetamol Combined With Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for a Primary Total Hip Replacement|Completed||Phase 4|120|Anticipated|Glostrup University Hospital, Copenhagen|||||f||||t||||||||||2018-06-01 04:25:20.633432|2018-06-01 04:25:20.633432
NCT00235248|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2012-07-06|2005-10-06|2005-10-10|Estimate|||||||2012-07-06|2012-07-10|Estimate|February 2002||2002-02-28|July 2012|2012-07-31|July 2012|Actual|2012-07-31|December 2010|Actual|2010-12-31||Interventional|ARCH||Aortic Arch Related Cerebral Hazard Trial (ARCH)|Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery|Completed||Phase 3|350|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:25:20.77186|2018-06-01 04:25:20.77186
NCT00235235|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2015-12-08|2005-10-06|2005-10-10|Estimate|||||||2015-12-08|2015-12-09|Estimate|September 2005||2005-09-30|December 2015|2015-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer|Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study: Hoosier Oncology Group COE-01|Terminated|||80|Actual|Hoosier Cancer Research Network|||4|Funding terminated|f||||t||||||Samples With DNA|"~     core biopsy, serum, urine~   "|||2018-06-01 04:25:20.877004|2018-06-01 04:25:20.877004
NCT00235222|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2005-10-24|2005-10-06|2005-10-10|Estimate|||||||2005-10-24|2005-10-25|Estimate|June 2004||2004-06-30|October 2005|2005-10-31|March 2006||2006-03-31|||||Interventional|||Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY|Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY|Unknown status|Active, not recruiting|Phase 4|57||Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:25:20.99254|2018-06-01 04:25:20.99254
NCT00235209|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2011-06-08|2005-10-06|2005-10-10|Estimate|||||||2011-06-08|2011-06-09|Estimate|November 2004||2004-11-30|October 2006|2006-10-31|December 2005||2005-12-31|||||Interventional|||A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Venous Leg Ulcers|A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Venous Leg Ulcers|Completed||Phase 4|48||Ethicon, Inc.|||||f||||||||||||||2018-06-01 04:25:21.051496|2018-06-01 04:25:21.051496
NCT00235196|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2006-10-12|2005-10-06|2005-10-10|Estimate|||||||2006-10-12|2006-10-13|Estimate|July 2004||2004-07-31|October 2006|2006-10-31|December 2005||2005-12-31|||||Interventional|||Evaluation of the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers|A Study to Evaluate the Clinical Effectiveness of a Collagen-ORC Antimicrobial Matrix in Full-Thickness, Neuropathic Diabetic Foot Ulcers|Completed||Phase 4|48||Ethicon, Inc.|||||f||||||||||||||2018-06-01 04:25:21.106064|2018-06-01 04:25:21.106064
NCT00235183|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2014-02-14|2005-10-06|2005-10-10|Estimate|||||||2014-02-14|2014-02-17|Estimate|June 2005||2005-06-30|February 2014|2014-02-28|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Plasma Transfusion in Liver Transplantation|Plasma Transfusion in Liver Transplantation : a Randomized, Double Blind, Multicenter Trial of Methylene Blue, Solvent/Detergent and Quarantined Plasma.|Completed||Phase 4|300|Anticipated|Etablissement Français du Sang||3|||f||||||||||||||2018-06-01 04:25:21.162708|2018-06-01 04:25:21.162708
NCT00235170|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2009-05-04|2005-10-07|2005-10-10|Estimate|||||||2009-05-04|2009-05-05|Estimate|February 2003||2003-02-28|May 2009|2009-05-31|April 2009|Actual|2009-04-30|December 2004|Actual|2004-12-31||Interventional|ARTS II||The Arterial Revascularization Therapies Study Part II.|ARTS II: Arterial Revascularization Therapies Study Part II of the Sirolimus-Eluting Bx VELOCITY™ Balloon Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions.|Completed||Phase 3|607|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:21.234651|2018-06-01 04:25:21.234651
NCT00234806|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2015-10-21|2005-10-05|2005-10-07|Estimate|||||||2015-10-21|2015-10-22|Estimate|December 2000||2000-12-31|October 2015|2015-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Health-e-Access Telemedicine in Primary Pediatric Care|Health-e-Access: A Study of Telemedicine in Primary Pediatric Care in Rochester, NY|Completed||N/A|2000|Actual|University of Rochester||2|||f||||||||||||||2018-06-01 04:25:31.256211|2018-06-01 04:25:31.256211
NCT00235157|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2008-08-05|2005-10-07|2005-10-10|Estimate|||||||2008-08-05|2008-08-06|Estimate|November 2001||2001-11-30|August 2008|2008-08-31|July 2005|Actual|2005-07-31|November 2002|Actual|2002-11-30||Interventional|GREAT||A Comparison of Coated and Uncoated Stents in Renal Artery Treatment.|Palmaz Genesis Peripheral Stainless Steel Balloon Expandable Stent, Comparing a Sirolimus Coated Versus an Uncoated Stent in REnal Artery Treatment.|Completed||Phase 2|105|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:21.313491|2018-06-01 04:25:21.313491
NCT00235144|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2009-05-08|2005-10-07|2005-10-10|Estimate|||||||2009-05-08|2009-05-11|Estimate|March 2001||2001-03-31|May 2009|2009-05-31|September 2008|Actual|2008-09-30|October 2002|Actual|2002-10-31||Interventional|E-SIRIUS||The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.|E-Sirius Study: a European, Multi-Center, Randomized, Double-Blind Study of the Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions|Completed||Phase 3|353|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:21.391639|2018-06-01 04:25:21.391639
NCT00235131|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2010-02-03|2005-10-07|2005-10-10|Estimate|||||||2010-02-03|2010-02-04|Estimate|May 2005||2005-05-31|February 2010|2010-02-28|May 2009|Actual|2009-05-31|March 2008|Actual|2008-03-31||Interventional|SUPER SL||The Study to Compare the Cordis SMART™ Stent System With the Bard® Luminexx™ Stent|A Clinical Investigation of the Cordis S.M.A.R.T. ™ CONTROL ™ Nitinol Stent System Versus the Bard® Luminexx™ 6F Vascular Stent for the Treatment of TASC C & D Superficial Femoral Artery Long Lesions|Completed||Phase 4|200|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:21.468642|2018-06-01 04:25:21.468642
NCT00235118|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2005-12-08|2005-10-06|2005-10-10|Estimate|||||||2005-12-08|2005-12-09|Estimate|December 1999||1999-12-31|October 2005|2005-10-31|February 2006||2006-02-28|||||Interventional|||Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)|An Evaluation of the Safety and Effectiveness of the Cordis Bilateral AAA Device Compared to Open Surgical Repair for the Treatment of Abdominal Aortic Aneurysm|Completed||Phase 1/Phase 2|29||Cordis Corporation|||||||||||||||||||2018-06-01 04:25:21.542206|2018-06-01 04:25:21.542206
NCT00235105|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2005-12-08|2005-10-07|2005-10-10|Estimate|||||||2005-12-08|2005-12-09|Estimate|March 2005||2005-03-31|October 2005|2005-10-31|June 2007||2007-06-30|||||Interventional|||D2E7-Early AS|Adalimumab in Early Axial Spondyloarthritis (Without Radiological Sacroiliitis): Placebo Controlled Phase Over 3 Months Followed by a 9 Months Open Extension Phase|Unknown status|Active, not recruiting|Phase 2/Phase 3|46||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:25:21.603965|2018-06-01 04:25:21.603965
NCT00235092|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-04-25|2005-10-07|2005-10-10|Estimate|||||||2007-04-25|2007-04-27|Estimate|August 2003||2003-08-31|April 2007|2007-04-30|March 2006||2006-03-31|||||Interventional|||The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus|A Prospective, Randomized, Multi-Center Comparison of the Cypher Sirolimus-Eluting and the Taxus Paclitaxel-Eluting Stent Systems.|Completed||Phase 4|1335||Cordis Corporation|||||f||||t||||||||||2018-06-01 04:25:21.669192|2018-06-01 04:25:21.669192
NCT00235079|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2013-08-06|2005-10-06|2005-10-10|Estimate|||||||2013-08-06|2013-08-07|Estimate|November 2005||2005-11-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CORP 2||Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP 2 Trial: COlchicine for Recurrent Pericarditis.|Completed||Phase 4|240|Actual|Azienda Sanitaria Locale 3, Torino||2|||f||||t||||||||||2018-06-01 04:25:21.72621|2018-06-01 04:25:21.72621
NCT00235066|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2008-09-15|2005-10-07|2005-10-10|Estimate|||||||2008-09-15|2008-09-16|Estimate|November 2002||2002-11-30|September 2008|2008-09-30|April 2006|Actual|2006-04-30|November 2003|Actual|2003-11-30||Interventional|SVELTE||The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.|A Multicenter, Nonrandomized, Historical Controlled Study In Patients With De Novo Coronary Artery Lesions In Small VessELs Treated With The CYPHER™ STEnt|Completed||Phase 4|100|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:21.797977|2018-06-01 04:25:21.797977
NCT00235053|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2006-01-30|2005-10-06|2005-10-10|Estimate|||||||2006-01-30|2006-01-31|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|November 2005||2005-11-30|||||Interventional|||Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID|A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma|Unknown status|Active, not recruiting|Phase 4|13||Allergy & Asthma Medical Group & Research Center|||||f||||||||||||||2018-06-01 04:25:21.865846|2018-06-01 04:25:21.865846
NCT00235040|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2012-01-24|2005-10-07|2005-10-10|Estimate|||||||2012-01-24|2012-01-26|Estimate|November 2005||2005-11-30|January 2012|2012-01-31|August 2007|Actual|2007-08-31|May 2006|Actual|2006-05-31||Interventional|||Evaluating the Effectiveness of the Acute Respiratory Infection Smart Form|Evaluating Smart Forms and Quality Dashboards in an EHR: Effectiveness of the Acute Respiratory Infection Smart Form|Completed||N/A|18257|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||f||||||||||2018-06-01 04:25:21.927376|2018-06-01 04:25:21.927376
NCT00235027|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2015-07-20|2005-10-06|2005-10-10|Estimate|||||||2015-07-20|2015-07-21|Estimate|August 2000||2000-08-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Improving Safety By Computerizing Outpatient Prescribing|Improving Safety By Computerizing Outpatient Prescribing|Completed||N/A|701|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||||||||||||2018-06-01 04:25:21.982192|2018-06-01 04:25:21.982192
NCT00235014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-11|2005-10-07|2005-10-10|Estimate|||||||2008-07-11|2008-07-15|Estimate|March 1997||1997-03-31|June 2008|2008-06-30||||January 2006|Actual|2006-01-31||Interventional|BENEDICT||A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)|A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)|Completed||Phase 4|1204|Actual|Abbott||4|||f||||f||||||||||2018-06-01 04:25:22.156988|2018-06-01 04:25:22.156988
NCT00235001|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-09|2005-10-07|2005-10-10|Estimate|||||||2008-07-09|2008-07-10|Estimate|June 2004||2004-06-30|July 2008|2008-07-31||||November 2006|Actual|2006-11-30||Interventional|||Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension|A Multicenter, Open, Phase IV, 24-Hour Ambulatory Blood Pressure Monitoring Study of the Efficacy and Safety of Tarka in Patients With Arterial Hypertension|Completed||Phase 4|120|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:25:22.232999|2018-06-01 04:25:22.232999
NCT00234988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-11|2005-10-07|2005-10-10|Estimate|||||||2008-07-11|2008-07-15|Estimate|June 2004||2004-06-30|July 2008|2008-07-31||||January 2006|Actual|2006-01-31||Interventional|||A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.|Safety and Weight Reduction of Sibutramine in the Treatment of Thai Obese and Overweight Subjects|Completed||Phase 4|93|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:25:22.325457|2018-06-01 04:25:22.325457
NCT00234975|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-02|2005-10-07|2005-10-10|Estimate|||||||2013-01-02|2013-01-03|Estimate|October 2002||2002-10-31|January 2013|2013-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score|Evaluation of Clinical Response and Safety in HIV Positive Subjects Co-infected With Hepatitis C Treated With a Kaletra Containing HAART Regimen|Completed||Phase 4|86|Actual|AbbVie||2|||f||||f||||||||||2018-06-01 04:25:22.397125|2018-06-01 04:25:22.397125
NCT00234962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-11-19|2005-10-07|2005-10-10|Estimate|||||||2008-11-19|2008-11-21|Estimate|August 2002||2002-08-31|November 2008|2008-11-30|February 2007|Actual|2007-02-28|||||Interventional|||Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy|Factors Associated With Adherence in a Cohort of HIV Positive Subjects on a First Time PI Containing HAART Regimen: Observational Study of the Impact of Adherence on Viral Load for a HAART Regimen Containing Kaletra vs Other Selected PI Containing HAART.|Terminated||Phase 4|200||Abbott|||||f||||||||||||||2018-06-01 04:25:22.486197|2018-06-01 04:25:22.486197
NCT00234949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-23|2005-10-07|2005-10-10|Estimate|||||||2007-10-23|2007-10-25|Estimate|March 2005||2005-03-31|October 2007|2007-10-31||||||||Interventional|||A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections|A Comparative Study of the Safety, Tolerability, and Efficacy of Cefdinir and Cephalexin for the Treatment of Subjects With Mild to Moderate Uncomplicated Skin and Skin Structure Infections|Completed||Phase 4|380||Abbott|||||f||||||||||||||2018-06-01 04:25:22.538355|2018-06-01 04:25:22.538355
NCT00234936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-10-02|2005-10-07|2005-10-10|Estimate|||||||2007-10-02|2007-10-03|Estimate|December 2003||2003-12-31|October 2007|2007-10-31||||||||Interventional|||Quality of Life Study With Adalimumab in Rheumatoid Arthritis|Quality of Life Study With Adalimumab in Rheumatoid Arthritis|Completed||Phase 3|200|Actual|Abbott|||||f||||||||||||||2018-06-01 04:25:22.584975|2018-06-01 04:25:22.584975
NCT00234923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-01|2005-10-07|2005-10-10|Estimate|||||||2008-04-01|2008-04-03|Estimate|August 2003||2003-08-31|April 2008|2008-04-30||||February 2007|Actual|2007-02-28||Interventional|MONARK||Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients|A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen Versus Lopinavir/Ritonavir in Combination With Lamivudine/Zidovudine in Antiretroviral Naïve Patients|Completed||Phase 3|138|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:25:22.697314|2018-06-01 04:25:22.697314
NCT00234910|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-09|2005-10-07|2005-10-10|Estimate|||||||2008-07-09|2008-07-10|Estimate|January 2005||2005-01-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|KALEAD||Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients|A Phase III, Open Label, Randomized, Comparative Study of the Antiviral Efficacy of ARV Therapy With Lopinavir/Ritonavir (LPV/r-Kaletra) in Combination With Tenofovir (TDF) Versus Standard of Care (Kaletra in Combination With 2 Nucleoside RTIs) in naïve-HIV-1 Positive Patients|Completed||Phase 3|152|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:25:22.767465|2018-06-01 04:25:22.767465
NCT00234897|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-28|2005-10-07|2005-10-10|Estimate|||||||2007-08-28|2007-08-29|Estimate|August 2004||2004-08-31|August 2007|2007-08-31||||||||Interventional|HERO||Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis|Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)|Completed||Phase 4|1938|Actual|Abbott|||||f||||f||||||||||2018-06-01 04:25:22.848614|2018-06-01 04:25:22.848614
NCT00234884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2011-07-15||2011-08-25|2005-10-07|2005-10-10|Estimate|2011-08-25|2011-09-30|Estimate||||2011-08-25|2011-09-30|Estimate|September 2003||2003-09-30|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|ReAlise||Post-marketing Observational Study in Subjects With Rheumatoid Arthritis|A Five-year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis Formerly Treated in Study M02-497 (ReAct) and Subsequently Prescribed Humira|Completed|||3435|Actual|Abbott|||1||f||||f||||||||||2018-06-01 04:25:22.975743|2018-06-01 04:25:22.975743
NCT00234871|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-11|2005-10-07|2005-10-10|Estimate|||||||2008-07-11|2008-07-15|Estimate|January 2004||2004-01-31|July 2008|2008-07-31||||March 2005|Actual|2005-03-31||Interventional|TANDEM||Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)|A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy|Completed||Phase 4|357|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:25:24.468302|2018-06-01 04:25:24.468302
NCT00234858|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-11|2005-10-07|2005-10-10|Estimate|||||||2008-07-11|2008-07-15|Estimate|March 2004||2004-03-31|June 2008|2008-06-30||||April 2006|Actual|2006-04-30||Interventional|STAR||Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)|A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome|Completed||Phase 4|280|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:25:24.547648|2018-06-01 04:25:24.547648
NCT00234845|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-28|2005-10-07|2005-10-10|Estimate|||||||2007-08-28|2007-08-29|Estimate|March 2003||2003-03-31|August 2007|2007-08-31||||||||Interventional|||Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis|A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis|Completed||Phase 3|148|Actual|Abbott|||||f||||f||||||||||2018-06-01 04:25:24.692502|2018-06-01 04:25:24.692502
NCT00234832|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-03-26||2010-05-06|2005-10-07|2005-10-10|Estimate|2010-03-26|2010-04-15|Estimate||||2010-05-06|2010-05-11|Estimate|January 2003||2003-01-31|May 2010|2010-05-31|November 2009|Actual|2009-11-30|March 2009|Actual|2009-03-31||Interventional|SCOUT||A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients|Sibutramine Cardiovascular Morbidity/Mortality Outcomes Study in Overweight or Obese Subjects at Risk of a Cardiovascular Event|Completed||Phase 3|10777|Actual|Abbott|Most subjects not indicated for sibutramine (sbt) due to CV disease. Long-term sbt use (6 yrs) regardless of weight loss, is inconsistent with label (limits use to 1-2 yrs & 5% weight loss). Trial lacked true placebo; all received Lead-in Period sbt.|3|||f||||t||||||||||2018-06-01 04:25:24.870847|2018-06-01 04:25:24.870847
NCT00234819|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2007-12-19|2005-10-05|2005-10-07|Estimate|||||||2007-12-19|2007-12-28|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause|A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogen Combinations for Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|325||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:25:31.077554|2018-06-01 04:25:31.077554
NCT00234793|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-11|2005-10-05|2005-10-07|Estimate|||||||2015-06-11|2015-06-15|Estimate|May 2003||2003-05-31|June 2015|2015-06-30|April 2010||2010-04-30|||||Interventional|||Maternal Problem-Solving in Childhood Cancer|Maternal Problem-Solving in Childhood Cancer|Completed||Phase 3|433|Actual|University of Rochester|||||f||||||||||||||2018-06-01 04:25:31.335505|2018-06-01 04:25:31.335505
NCT00234754|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2016-08-29|2005-10-05|2005-10-07|Estimate|||||||2016-08-29|2016-08-31|Estimate|September 2005||2005-09-30|August 2016|2016-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women|Surgical Management of Stress Urinary Incontinence in Women: A Randomized Clinical Trial (RCT) of TOT vs TVT|Completed||N/A|199|Actual|University of Calgary||2|||f||||f||||||||Undecided|Decision to share will depend on review of IPD protocol|2018-06-01 04:25:31.586324|2018-06-01 04:25:31.586324
NCT00234741|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2008-12-03|2005-10-05|2005-10-07|Estimate|||||||2008-12-03|2008-12-04|Estimate|November 2005||2005-11-30|December 2008|2008-12-31||||||||Interventional|||Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Pilot Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, to Investigate Peripheral Blood and Mucosal Mononuclear Cell Phenotype and Cytokine Responses in Patients With Crohn's Disease|Completed||Phase 2|12||Synta Pharmaceuticals Corp.|||||||||||||||||||2018-06-01 04:25:31.681668|2018-06-01 04:25:31.681668
NCT00234728|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2008-06-30|2005-10-05|2005-10-07|Estimate|||||||2008-06-30|2008-07-02|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Study of a New Dressing for Use With Topical Medications|An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Occlusion of Topical Agents With a Hydrophilic Occlusive Dressing to Treatment With Occlusive Dressing Without the Addition of Topical Agents|Completed||N/A|120|Anticipated|Teikoku Pharma USA, Inc.|||||f||||||||||||||2018-06-01 04:25:31.747411|2018-06-01 04:25:31.747411
NCT00234715|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2007-11-13|2005-10-06|2005-10-07|Estimate|||||||2007-11-13|2007-11-15|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|August 2006|Actual|2006-08-31|||||Observational|||Psychosocial Study on Breast Cancer Risk Assessment|A Pilot Study: Psychosocial and Socio-Demographic Determinants of Accepting Breast Cancer Risk Assessment|Completed|||62|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:25:31.80463|2018-06-01 04:25:31.80463
NCT00234702|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2010-04-29|2005-10-05|2005-10-07|Estimate|||||||2010-04-29|2010-04-30|Estimate|October 2005||2005-10-31|April 2010|2010-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease|A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Lanthanum Carbonate for the Reduction of Serum Phosphorus in Subjects With Stage 3 and 4 Chronic Kidney Disease Who Have Elevated Serum Phosphorus Levels|Completed||Phase 2|84|Anticipated|Shire||2|||f||||||||||||||2018-06-01 04:25:31.865685|2018-06-01 04:25:31.865685
NCT00234689|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2008-01-28|2005-10-06|2005-10-07|Estimate|||||||2008-01-28|2008-01-30|Estimate|January 2002||2002-01-31|January 2008|2008-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients||Completed||N/A|||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:25:32.04646|2018-06-01 04:25:32.04646
NCT00234676|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2007-12-24|2005-10-05|2005-10-07|Estimate|||||||2007-12-24|2008-01-08|Estimate|October 2003||2003-10-31|December 2007|2007-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease|A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study for the Safety, Tolerability and Efficacy of Estrogen Replacement Therapy (Conjugated Equine Estrogens 0.625 mg Daily) in Post Menopausal Women With Parkinson's Disease|Completed||Phase 2|23|Actual|The Parkinson Study Group||1|||f||||||||||||||2018-06-01 04:25:32.109256|2018-06-01 04:25:32.109256
NCT00234663|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-01-09|2005-10-05|2005-10-07|Estimate|||||||2009-01-09|2009-01-13|Estimate|September 2005||2005-09-30|January 2009|2009-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||PTC124 for Cystic Fibrosis|A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis|Completed||Phase 2|24||PTC Therapeutics|||||||||||||||||||2018-06-01 04:25:32.200826|2018-06-01 04:25:32.200826
NCT00234650|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-04-01|2005-10-05|2005-10-07|Estimate|||||||2009-04-01|2009-04-02|Estimate|October 2005||2005-10-31|December 2008|2008-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Adenoma Detection Rate With Position Change at Colonoscopy|Evaluation of the Effect of Position Change During the Withdrawal Phase of Colonoscopy on Adenoma Detection Rate|Completed||N/A|130|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:25:32.264452|2018-06-01 04:25:32.264452
NCT00234637|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2011-11-16|2005-10-05|2005-10-07|Estimate|||||||2011-11-16|2011-11-17|Estimate|November 2003||2003-11-30|November 2011|2011-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment|An Open-label Study to Evaluate the Efficacy and Safety of add-on Memantine [5-10 mg b.i.d (10-20 mg/Day)] to Rivastigmine [1.5-6 mg b.i.d. (3-12 mg/Day)] Treatment in Patients With Alzheimer's Disease Who Continued With Rivastigmine Treatment After a Previous Decline While on Donepezil or Galantamine Treatment|Completed||Phase 4|204|Actual|Novartis|||||f||||||||||||||2018-06-01 04:25:32.327029|2018-06-01 04:25:32.327029
NCT00234624|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2005-10-05|2005-10-05|2005-10-07|Estimate|||||||2005-10-05|2005-10-07|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Observational|||Hepatic Hemodynamic Changes and Simulation in Living-Related Liver Transplantation|Hepatic Hemodynamic Changes and Simulation Before /After Living-Related Liver Transplantation in Donors/Recipients|Unknown status|Recruiting||10||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:25:32.384224|2018-06-01 04:25:32.384224
NCT00234611|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2006-11-02|2005-10-05|2005-10-07|Estimate|||||||2006-11-02|2006-11-06|Estimate|September 2005||2005-09-30|November 2006|2006-11-30|April 2007||2007-04-30|||||Interventional|||Localization of CRT According to Echocardiography: LOCATE-Pilot Study|Localization of CRT According to Echocardiography: LOCATE-Pilot Study|Unknown status|Active, not recruiting|N/A|60||Michigan Heart, PC|||||f||||||||||||||2018-06-01 04:25:32.434259|2018-06-01 04:25:32.434259
NCT00234598|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2015-12-04|2005-10-05|2005-10-07|Estimate|||||||2015-12-04|2015-12-08|Estimate|March 2002||2002-03-31|December 2015|2015-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Strategies to Prevent Pneumonia (SToP Pneumonia)|Oral Care Intervention in Mechanically Ventilated Adults|Completed||Phase 2|547|Actual|Virginia Commonwealth University||4|||f||||f||||||||||2018-06-01 04:25:32.550177|2018-06-01 04:25:32.550177
NCT00234585|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2014-12-09|2005-10-05|2005-10-07|Estimate|||||||2014-12-09|2014-12-10|Estimate|August 2002||2002-08-31|December 2014|2014-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Prospective Randomized Study Comparing Renal Artery Stenting (RESIST)With/Without Distal Protection|A Prospective Randomized Multicenter Study Comparing the Safety and Efficacy of Renal Artery Stenting With/Without Distal Protection Device (AngioGuard) and With/Without the Use of a Platelet Aggregator Inhibitor (Abciximab-Reopro) (RESIST)|Completed||Phase 2|100||University of Toledo Health Science Campus|||||f||||||||||||||2018-06-01 04:25:32.631882|2018-06-01 04:25:32.631882
NCT00234572|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2009-11-16|2005-10-06|2005-10-07|Estimate|||||||2009-11-16|2009-11-17|Estimate|May 2000||2000-05-31|November 2009|2009-11-30|January 2003||2003-01-31|||||Interventional|||Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly|Phase II, Multicentre, Randomized, Double-blind Study in Acromegalic Patients Evaluating the Efficacy and Safety of a Single Deep Subcutaneous Administration of Lanreotide Autogel (60, 90 or 120mg) Versus Placebo Followed by a Single Blind Fixed Dose Phase Evaluating the Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Profile of Multiple Deep Subcutaneous Administrations of Lanreotide Autogel (60, 90 & 120mg) Ending in Open Label Dose Titration Phase.|Completed||Phase 2/Phase 3|96||Ipsen|||||||||||||||||||2018-06-01 04:25:32.710042|2018-06-01 04:25:32.710042
NCT00234559|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2013-08-19|2005-10-05|2005-10-07|Estimate|||||||2013-08-19|2013-08-21|Estimate|September 2005||2005-09-30|August 2013|2013-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Trial of Vacuum Assisted Closure® Therapy Versus Control Therapy in Angiogenesis|A Randomized Controlled Study Comparing Vacuum Assisted Closure® Therapy to Moist Wound Therapy in Angiogenesis|Withdrawn||N/A|0|Actual|KCI USA, Inc.||||Study terminated due to no subject enrollment.|f||||||||||||||2018-06-01 04:25:32.824073|2018-06-01 04:25:32.824073
NCT00234546|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-06|||2012-06-18|2005-10-06|2005-10-07|Estimate|||||||2012-06-18|2012-06-19|Estimate|February 2003||2003-02-28|June 2012|2012-06-30|October 2007|Actual|2007-10-31|||||Interventional|||Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity|A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke.|Completed||Phase 4|162|Actual|Ipsen||2|||f||||||||||||||2018-06-01 04:25:32.884237|2018-06-01 04:25:32.884237
NCT00234533|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-05-14|2005-10-05|2005-10-07|Estimate|||||||2009-05-14|2009-05-15|Estimate|June 2004||2004-06-30|May 2009|2009-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|OPTIMA||Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq|Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method|Completed||Phase 3|250|Actual|Ipsen|||||f||||f||||||||||2018-06-01 04:25:32.974971|2018-06-01 04:25:32.974971
NCT00234520|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2008-06-26|2005-10-05|2005-10-07|Estimate|||||||2008-06-26|2008-06-27|Estimate|May 2003||2003-05-31|June 2008|2008-06-30||||||||Observational|||A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide|A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide|Completed|||200||Ipsen|||||||||||||||||||2018-06-01 04:25:33.13422|2018-06-01 04:25:33.13422
NCT00234507|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2006-04-12|2005-10-05|2005-10-07|Estimate|||||||2006-04-12|2006-04-13|Estimate|January 2003||2003-01-31|April 2006|2006-04-30|May 2004||2004-05-31|||||Interventional|||Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm|Phase II, Multi-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection, of Three Doses of Dysport (40 Units/Eye, 80 Units/Eye, and 120 Units/Eye) for the Treatment of Benign Essential Blepharospasm|Completed||Phase 2|120||Ipsen|||||||||||||||||||2018-06-01 04:25:33.250532|2018-06-01 04:25:33.250532
NCT00234494|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|2016-01-19||2016-02-16|2005-10-05|2005-10-07|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer|A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75|Completed||Phase 2|45|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-06-01 04:25:33.346681|2018-06-01 04:25:33.346681
NCT00234481|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2008-06-02|2005-10-05|2005-10-07|Estimate|||||||2008-06-02|2008-06-04|Estimate||||June 2008|2008-06-30||||||||Interventional|||Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia|A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia|Terminated||Phase 1|||Exelixis||||Study closed due to slow enrollment|||||||||||||||2018-06-01 04:25:33.840093|2018-06-01 04:25:33.840093
NCT00234468|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2011-05-19|2005-10-05|2005-10-07|Estimate|||||||2011-05-19|2011-05-20|Estimate|January 2004||2004-01-31|May 2011|2011-05-31|August 2007|Actual|2007-08-31|||||Interventional|||Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC|A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy|Terminated||Phase 3|490|Anticipated|AstraZeneca||||Closed due to insufficient recruitment|f||||||||||||||2018-06-01 04:25:33.907208|2018-06-01 04:25:33.907208
NCT00234455|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2008-04-28|2005-10-06|2005-10-07|Estimate|||||||2008-04-28|2008-04-30|Estimate|June 2001||2001-06-30|April 2008|2008-04-30|April 2007|Actual|2007-04-30|October 2002|Actual|2002-10-31||Interventional|BIFURCATION||A Study of the Cypher Sirolimus-Eluting Stent to Treat Bifurcation Lesions.|An Evaluation of the Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With Bifurcation Lesions.|Completed||Phase 2|86|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:34.000979|2018-06-01 04:25:34.000979
NCT00234442|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-06-29|2005-10-05|2005-10-07|Estimate|||||||2009-06-29|2009-06-30|Estimate|July 2004||2004-07-31|June 2009|2009-06-30|February 2006||2006-02-28|||||Interventional|||Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer|A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy|Terminated||Phase 2|47||AstraZeneca||||Closed due to insufficient recruitment.|f||||||||||||||2018-06-01 04:25:34.138838|2018-06-01 04:25:34.138838
NCT00234429|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2007-12-14|2005-10-05|2005-10-07|Estimate|||||||2007-12-14|2007-12-18|Estimate|November 2003||2003-11-30|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma|A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma|Completed||Phase 2/Phase 3|74||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:34.203916|2018-06-01 04:25:34.203916
NCT00234416|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-04-22|2005-10-05|2005-10-07|Estimate|||||||2009-04-22|2009-04-23|Estimate|August 2002||2002-08-31|April 2009|2009-04-30|March 2005|Actual|2005-03-31|||||Interventional|||IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer|A Trial to Evaluate ZD1839 (IRESSA) in Combination With Radiotherapy & Gemcitabine as First-Line Treatment in Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|45||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:34.287922|2018-06-01 04:25:34.287922
NCT00234403|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-04-22|2005-10-05|2005-10-07|Estimate|||||||2009-04-22|2009-04-23|Estimate|May 2004||2004-05-31|April 2009|2009-04-30|October 2007|Actual|2007-10-31|||||Interventional|||A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer|A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer|Completed||Phase 2|60||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:34.359095|2018-06-01 04:25:34.359095
NCT00234390|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2011-01-21|2005-10-05|2005-10-07|Estimate|||||||2011-01-21|2011-01-24|Estimate|November 1998||1998-11-30|January 2011|2011-01-31|December 2004|Actual|2004-12-31|||||Interventional|||PreAsthmaControl (PAC)|Prevention of Asthma in Infants/Young Children - PAC|Completed||Phase 4|400||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:34.432734|2018-06-01 04:25:34.432734
NCT00234377|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2013-01-03|2005-10-05|2005-10-07|Estimate|||||||2013-01-03|2013-01-04|Estimate|November 2004||2004-11-30|January 2013|2013-01-31|May 2006|Actual|2006-05-31|||||Interventional|||Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia|A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia|Completed||Phase 3|550||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:34.507838|2018-06-01 04:25:34.507838
NCT00234364|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-09-19|2005-10-05|2005-10-07|Estimate|||||||2007-09-19|2007-09-20|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Observational|||Pergolide Treatment and Valvular Heart Disease||Completed|||155|Actual|Århus Amt|||||f||||f||||||||||2018-06-01 04:25:34.610605|2018-06-01 04:25:34.610605
NCT00234338|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-12-07|2005-10-05|2005-10-06|Estimate|||||||2007-12-07|2007-12-10|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Observational|||Study Evaluating Prevenar in High-Risk Children|Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years|Completed|||5000|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:25:34.688176|2018-06-01 04:25:34.688176
NCT00234312|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2006-09-07|2005-10-04|2005-10-06|Estimate|||||||2006-09-07|2006-09-11|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|October 2006||2006-10-31|||||Interventional|||Medications for the Treatment of Dysthymic Disorder and Double Depression|Escitalopram Vs. Sertraline in the Treatment of Dysthymic Disorder and Double Depression|Unknown status|Active, not recruiting|Phase 4|40||Oregon Health and Science University|||||f||||||||||||||2018-06-01 04:25:34.746568|2018-06-01 04:25:34.746568
NCT00234299|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2016-05-24|2005-10-04|2005-10-06|Estimate|||||||2016-05-24|2016-05-25|Estimate|December 2005||2005-12-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of ASA on Prostate Tissue|In Vivo Molecular Effects of Aspirin on Prostate Tissue|Completed||N/A|60|Anticipated|University of Washington||2|||f||||t||||||||||2018-06-01 04:25:34.803679|2018-06-01 04:25:34.803679
NCT00234286|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|2015-01-13||2015-04-23|2005-10-04|2005-10-06|Estimate|2015-04-23|2015-04-27|Estimate||||2015-04-23|2015-04-27|Estimate|August 2005||2005-08-31|April 2015|2015-04-30|September 2013|Actual|2013-09-30|March 2011|Actual|2011-03-31||Interventional|BEACON|Deceased veterans|Intervention to Improve Care at Life's End|Intervention to Improve Care at Life's End in VA Medical Centers|Completed||N/A|78|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:25:34.897441|2018-06-01 04:25:34.897441
NCT00234273|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2013-06-18|2005-10-05|2005-10-06|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 2004||2004-11-30|June 2013|2013-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||APAD2: Effects of Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics|Effects Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics Persons|Terminated||Phase 2|10|Actual|University Hospital, Grenoble||2||recrutment|f||||f||||||||||2018-06-01 04:25:35.304718|2018-06-01 04:25:35.304718
NCT00234260|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-07-15|2005-10-04|2005-10-06|Estimate|||||||2008-07-15|2008-07-16|Estimate|April 1995||1995-04-30|October 2005|2005-10-31||||||||Observational|||Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)|Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)|Terminated|||||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:25:35.382339|2018-06-01 04:25:35.382339
NCT00234247|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2016-05-12|2005-10-05|2005-10-06|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 2002||2002-12-31|May 2016|2016-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Prolonged Outcomes After Nitric Oxide (PrONOx)|Study of the Long-term Outcomes of Nitric Oxide for Ventilated Premature Babies|Completed|||652|Actual|University of Pittsburgh|||||f||||t||||||||No||2018-06-01 04:25:35.443063|2018-06-01 04:25:35.443063
NCT00234234|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2012-02-08|2005-10-05|2005-10-06|Estimate|||||||2012-02-08|2012-02-09|Estimate|January 2006||2006-01-31|February 2012|2012-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Predictors of the Response to Adalimumab in Rheumatoid Arthritis|Predictors of the Response to Adalimumab in Rheumatoid Arthritis|Completed||Phase 4|200|Actual|University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:25:35.497119|2018-06-01 04:25:35.497119
NCT00234221|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2016-04-11|2005-10-04|2005-10-06|Estimate|||||||2016-04-11|2016-04-13|Estimate|November 2005||2005-11-30|April 2016|2016-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Project Health Link: Connecting Patients With Services|Services Interventions for Injured ED Problem Drinkers|Completed||N/A|686|Actual|University of Michigan||3|||f||||f||||||||No||2018-06-01 04:25:35.555192|2018-06-01 04:25:35.555192
NCT00234208|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2016-05-23|2005-10-05|2005-10-06|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2005||2005-10-31|May 2016|2016-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Early Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Parapneumonic Effusion and Pleural Empyema|A Randomized Controlled Study of Early Mini-invasive Medical Thoracoscopy Versus Simple Chest Tube Drainage in Complicated Parapneumonic Effusions or Pleural Empyema - ESMITE (European Study on Mini-invasive Thoracoscopy in Empyema)|Terminated||Phase 3|2|Actual|University Hospital, Basel, Switzerland||2||insufficient enrollment|f||||f||||||||||2018-06-01 04:25:35.614488|2018-06-01 04:25:35.614488
NCT00234195|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-04-16|2005-10-04|2005-10-06|Estimate|||||||2007-04-16|2007-04-17|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Wellbutrin XL, Major Depressive Disorder and Breast Cancer|A Pilot Study of the Efficacy and Tolerability of Bupropion Extended Release (Wellbutrin XL) for the Treatment of Major Depressive Disorder in Women With Breast Cancer|Completed||Phase 4|25||Thomas Jefferson University|||||f||||f||||||||||2018-06-01 04:25:35.795928|2018-06-01 04:25:35.795928
NCT00234182|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2005-11-29|2005-10-05|2005-10-06|Estimate|||||||2005-11-29|2005-12-01|Estimate|January 2000||2000-01-31|October 2005|2005-10-31|December 2004||2004-12-31|||||Interventional|||Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC|Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of Hepatocellular Carcinoma: a Randomized Controlled Trial|Completed||Phase 1/Phase 2|84||The University of Hong Kong|||||f||||||||||||||2018-06-01 04:25:35.862331|2018-06-01 04:25:35.862331
NCT00234169|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2012-05-09|2005-10-05|2005-10-06|Estimate|||||||2012-05-09|2012-05-10|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone|A Phase I/II Study of Peripheral Blood Progenitor Cells Mobilisation With VTP195183 Plus G-CSF Compared to Mobilisation With G-CSF Alone in Patients With Multiple Myeloma and Lymphoma.|Completed||Phase 1/Phase 2|30|Actual|Peter MacCallum Cancer Centre, Australia|||||f||||t||||||||||2018-06-01 04:25:35.917921|2018-06-01 04:25:35.917921
NCT00234156|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2012-01-10|2005-10-05|2005-10-06|Estimate|||||||2012-01-10|2012-01-11|Estimate|September 2004||2004-09-30|January 2012|2012-01-31|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers|Sensitivity to Fructose-Induced Palmitate Synthesis in End-Stage Renal Disease|Completed||N/A|30|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 04:25:35.979205|2018-06-01 04:25:35.979205
NCT00234143|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-03-11|2005-10-05|2005-10-06|Estimate|||||||2009-03-11|2009-03-12|Estimate|October 2004||2004-10-31|March 2009|2009-03-31||||||||Interventional|||Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)|A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha With or Without Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Versus Best Supportive Care in Patients With Low-Risk Myelodysplastic Syndromes|Unknown status|Active, not recruiting|Phase 2/Phase 3|360|Anticipated|St. Bartholomew's Hospital||3|||f||||t||||||||||2018-06-01 04:25:36.050339|2018-06-01 04:25:36.050339
NCT00234130|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-06-02|2005-10-05|2005-10-06|Estimate|||||||2009-06-02|2009-06-03|Estimate|July 2002||2002-07-31|June 2009|2009-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||The Effect of Nighttime Dialysis on the Inflammation of Kidney Failure|A Comparison of the Effects of Conventional and Nocturnal Hemodialysis on the Inflammatory Response of Chronic Renal Failure|Terminated||N/A|20||Rockefeller University||||The patient population was not enough to complete enrollment|f||||f||||||||||2018-06-01 04:25:36.118184|2018-06-01 04:25:36.118184
NCT00234117|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2011-07-20|2005-10-05|2005-10-06|Estimate|||||||2011-07-20|2011-07-22|Estimate|July 2005||2005-07-31|October 2005|2005-10-31||||||||Interventional|||Improvement in Bronchial Asthma in Patients With Extraesophageal Reflux After Acid Suppression|Overall Assessment of Improvement in Bronchial Asthma Patients With Extraesophageal Reflux After Effective Acid Suppression|Completed||N/A|40|Anticipated|Ponce Gastroenterology Research|||||f||||||||||||||2018-06-01 04:25:36.177589|2018-06-01 04:25:36.177589
NCT00234104|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|2013-11-01||2013-11-06|2005-10-04|2005-10-06|Estimate|2013-11-06|2013-12-25|Estimate||||2013-11-06|2013-12-25|Estimate|August 2004||2004-08-31|November 2013|2013-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional||1 Subject of each arm were excluded form the analysis set because emergency codes were lost.|A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of OPC-41061 in Congestive Heart Failure Patients With Extracellular Volume Expansion|Completed||Phase 2|122|Actual|Otsuka Pharmaceutical Co., Ltd.|||||f||||f||||||||||2018-06-01 04:25:36.314006|2018-06-01 04:25:36.314006
NCT00234091|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2013-12-02|2005-10-04|2005-10-06|Estimate|||||||2013-12-02|2013-12-04|Estimate|April 2006||2006-04-30|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)|An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression|Completed||Phase 3|300|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:25:36.817349|2018-06-01 04:25:36.817349
NCT00234078|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|2014-01-20||2014-01-20|2005-10-04|2005-10-06|Estimate|2014-01-20|2014-02-28|Estimate||||2014-01-20|2014-02-28|Estimate|January 2005||2005-01-31|January 2014|2014-01-31|March 2007|Actual|2007-03-31|April 2006|Actual|2006-04-30||Interventional|||Dose-response Study of OPC-12759 Ophthalmic Suspension|Dose-response Study of OPC-12759 Ophthalmic Suspension|Completed||Phase 2|290|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-06-01 04:25:36.967679|2018-06-01 04:25:36.967679
NCT00234065|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|2011-04-19||2011-06-09|2005-10-04|2005-10-06|Estimate|2011-04-19|2011-05-13|Estimate||||2011-06-09|2011-06-10|Estimate|December 2003||2003-12-31|June 2011|2011-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)|Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin|Completed||Phase 4|2800|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-06-01 04:25:37.44496|2018-06-01 04:25:37.44496
NCT00234052|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2018-01-24|2005-10-05|2005-10-06|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2005||2005-06-30|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|50|Actual|Northwestern University||1|||f||||||||||||||2018-06-01 04:25:38.692577|2018-06-01 04:25:38.692577
NCT00234039|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|2012-11-19||2015-12-08|2005-10-05|2005-10-06|Estimate|2012-11-19|2012-12-18|Estimate||||2015-12-08|2016-01-08|Estimate|November 2006||2006-11-30|December 2015|2015-12-31|April 2013|Actual|2013-04-30|November 2011|Actual|2011-11-30||Interventional|||S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin|Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG|Completed||Phase 2|58|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 04:25:38.794765|2018-06-01 04:25:38.794765
NCT00234026|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2012-06-04|2005-10-05|2005-10-06|Estimate|||||||2012-06-04|2012-06-05|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma|Master Protocol for Mantle Cell Lymphoma A Multicenter Phase II Trial Testing Gemcitabine for the Treatment of Patients With Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma|Completed||Phase 2|||Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 04:25:40.251235|2018-06-01 04:25:40.251235
NCT00234000|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2015-09-30|2005-10-05|2005-10-06|Estimate|||||||2015-09-30|2015-10-02|Estimate|February 2007||2007-02-28|August 2012|2012-08-31||||February 2009|Actual|2009-02-28||Interventional|||Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes|A Phase I Multicenter Study of Arsenic Trioxide and Azacitidine in Patients With Myelodysplastic Syndromes|Terminated||Phase 1|1|Actual|Jonsson Comprehensive Cancer Center||1||The study was closed due to poor enrollment|f||||t||||||||||2018-06-01 04:25:40.336554|2018-06-01 04:25:40.336554
NCT00233987|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|2013-01-02||2018-01-31|2005-10-05|2005-10-06|Estimate|2013-01-02|2013-02-05|Estimate||||2018-01-31|2018-03-01|Actual|October 2005||2005-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2014|Actual|2014-11-30||Interventional|||S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma|Tandem Autologous Stem Cell Transplantation for Patients With Primary Progressive or Recurrent Hodgkin's Disease (A BMT Study), Phase II|Completed||Phase 2|98|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 04:25:40.46272|2018-06-01 04:25:40.46272
NCT00233974|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2012-03-05|2005-10-05|2005-10-06|Estimate|||||||2012-03-05|2012-03-07|Estimate|May 2002||2002-05-31|March 2012|2012-03-31|March 2006|Actual|2006-03-31|February 2005|Actual|2005-02-28||Interventional|||Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery|Axillary Lymph Nodes and PET (Positron Emission Tomography) Probe-Guided Surgical Resection in Locally Advanced Breast Cancer Patients: Molecular Marker Profile and Response to Neoadjuvant Chemotherapy|Completed||Phase 2|15|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:25:41.180464|2018-06-01 04:25:41.180464
NCT00233961|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2013-02-01|2005-10-05|2005-10-06|Estimate|||||||2013-02-01|2013-02-04|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission|Peripheral Blood Stem Cell Mobilization With Filgrastim in Patients With Chronic Myeloid Leukemia in Cytogenetic Response|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:25:41.249625|2018-06-01 04:25:41.249625
NCT00233948|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|2015-02-02||2015-03-30|2005-10-05|2005-10-06|Estimate|2015-02-02|2015-02-23|Estimate||||2015-03-30|2015-04-01|Estimate|March 2006||2006-03-31|March 2015|2015-03-31||||July 2013|Actual|2013-07-31||Interventional|||Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma|A Phase I/II Study of Nelfinavir in Liposarcoma|Terminated||Phase 1/Phase 2|29|Actual|City of Hope Medical Center|After 12 patients were accrued to the Phase II portion, the study was terminated…protocol objectives for the Phase II portion not met. Closed prematurely due to drug availability issues.|1||Drug availability issues|f||||t||||||||||2018-06-01 04:25:41.410953|2018-06-01 04:25:41.410953
NCT00233935|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2014-09-10|2005-10-05|2005-10-06|Estimate|||||||2014-09-10|2014-09-11|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus|Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients With Barrett's Esophagus|Completed||Phase 1|55|Actual|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-06-01 04:25:43.590489|2018-06-01 04:25:43.590489
NCT00233922|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2008-05-12|2005-10-05|2005-10-06|Estimate|||||||2008-05-12|2008-05-13|Estimate|July 2004||2004-07-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Reconstruction of the Orbit With a Bioresorbable Polycaprolactone Implant|Reconstruction of the Orbit With a Bioresorbable Polycaprolactone Implant|Completed||Phase 2|80|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:25:43.679102|2018-06-01 04:25:43.679102
NCT00233909|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-03-28|2005-10-04|2005-10-06|Estimate|||||||2008-03-28|2008-04-01|Estimate|October 2005||2005-10-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia|An Open-Label, Phase I/II Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|55|Anticipated|Kanisa Pharmaceuticals|||||||||||||||||||2018-06-01 04:25:43.740288|2018-06-01 04:25:43.740288
NCT00233896|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2005-10-04|2005-10-04|2005-10-06|Estimate|||||||2005-10-04|2005-10-06|Estimate|July 2001||2001-07-31|December 2004|2004-12-31|December 2004||2004-12-31|||||Interventional|||Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD|A Randomized, Placebo-Controlled, Multi-Center Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal Graft Vs. Host Disease|Completed||Phase 3|130||Enteron Pharmaceuticals|||||||||||||||||||2018-06-01 04:25:43.80612|2018-06-01 04:25:43.80612
NCT00233883|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2015-11-02|2005-10-04|2005-10-06|Estimate|||||||2015-11-02|2015-11-03|Estimate|August 2005||2005-08-31|November 2015|2015-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.|An Open-label Study of the Tolerability of a Subcutaneous Needle-free Injection Device Used to Administer Fuzeon, Compared With the Standard Needle/Syringe Supplied With Commercial Fuzeon in HIV-1 Infected, ARV Treatment-experienced Adults|Completed||Phase 4|58|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:25:43.883959|2018-06-01 04:25:43.883959
NCT00233870|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2015-05-07|2005-10-05|2005-10-06|Estimate|||||||2015-05-07|2015-05-08|Estimate|June 2004||2004-06-30|May 2015|2015-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.|Special Survey in Long-Term Use of Fabrazyme|Completed|||405|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:25:43.972741|2018-06-01 04:25:43.972741
NCT00233857|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2011-02-25|2005-10-05|2005-10-06|Estimate|||||||2011-02-25|2011-02-28|Estimate|August 2003||2003-08-31|February 2011|2011-02-28|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||Auricular Acupuncture for Pain Relief After Ambulatory Knee Arthroscopy|Auricular Acupuncture Versus Placebo (Sham Acupuncture) for Postoperative Pain Relief After Ambulatory Knee Arthroscopy - a Randomized Controlled Trial|Completed||Phase 2/Phase 3|120||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:25:44.030278|2018-06-01 04:25:44.030278
NCT00233844|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2005-10-05|2005-10-05|2005-10-06|Estimate|||||||2005-10-05|2005-10-06|Estimate|February 2004||2004-02-29|October 2005|2005-10-31||||||||Interventional|||"Studying the Analgesic Mechanism of the Cough-Trick"|"Studying the Analgesic Mechanism of the Cough-Trick - Randomized Crossover Volunteer Study"|Completed||Phase 2|21||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:25:44.084697|2018-06-01 04:25:44.084697
NCT00233831|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2011-02-25|2005-10-04|2005-10-06|Estimate|||||||2011-02-25|2011-02-28|Estimate|March 2004||2004-03-31|February 2011|2011-02-28|October 2007|Actual|2007-10-31|October 2006|Actual|2006-10-31||Interventional|||Millimeter Wave Therapy (MWT) for Analgesia After Total Knee Replacement|Millimeter Wave Therapy (MWT) Versus Placebo for Analgesia and Wound Healing After Elective Total Knee Arthroplasty - a Randomized Controlled Trial|Completed||Phase 2/Phase 3|80||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:25:44.144654|2018-06-01 04:25:44.144654
NCT00233259|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-10-24|2005-10-03|2005-10-05|Estimate|||||||2011-10-24|2011-10-25|Estimate|March 2006||2006-03-31|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Lifestyle Modification Program to Reduce Risk of Coronary Heart Disease in Latina Women With Diabetes|CHD Lifestyle Modification for Latinas With Diabetes|Completed||N/A|273|Actual|Oregon Research Institute||2|||f||||t||||||||||2018-06-01 04:25:49.63737|2018-06-01 04:25:49.63737
NCT00233818|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-10-11|2005-10-05|2005-10-06|Estimate|||||||2007-10-11|2007-10-12|Estimate|February 2000||2000-02-29|October 2007|2007-10-31|June 2005|Actual|2005-06-30|||||Interventional|||FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent|An Evaluation of Sirolimus-Coated Modified BX VELOCITY Balloon-Expandable Stents for the Treatment of Patients With de Novo Native Coronary Artery Lesions|Completed||Phase 1/Phase 2|15|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:44.214165|2018-06-01 04:25:44.214165
NCT00233805|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-08-05|2005-10-05|2005-10-06|Estimate|||||||2008-08-05|2008-08-06|Estimate|August 2000||2000-08-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|||||Interventional|RAVEL||The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.|A Randomized Study With the Sirolimus Coated Modified BX Velocity Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions|Completed||Phase 2|220|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:44.279905|2018-06-01 04:25:44.279905
NCT00233792|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-10-11|2005-10-05|2005-10-06|Estimate|||||||2007-10-11|2007-10-12|Estimate|December 1999||1999-12-31|October 2007|2007-10-31|March 2005|Actual|2005-03-31|||||Interventional|||FIM-BR - First-in-Man Study (Brazil Part) With Sirolimus-Coated BX VELOCITY Stent|An Evaluation of the Sirolimus Coated Modified BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo or Restenotic Native Coronary Artery Lesions.|Completed||Phase 1/Phase 2|30|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:44.354842|2018-06-01 04:25:44.354842
NCT00233779|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-06-26|2005-10-04|2005-10-06|Estimate|||||||2007-06-26|2007-06-27|Estimate|October 2003||2003-10-31|June 2007|2007-06-30|December 2004|Actual|2004-12-31|||||Interventional|||Evaluation of Sirolimus-Eluting, Heparin-Coated CoCr Stent in the Treatment of de Novo Coronary Artery Lesions in Small Vessels(EVOLUTION)|Sirolimus-Eluting, Heparin-Coated Cobalt Chromium Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions in Small Vessels (EVOLUTION)|Completed||Phase 2|52|Actual|Cordis Corporation|||||f||||f||||||||||2018-06-01 04:25:44.517478|2018-06-01 04:25:44.517478
NCT00233766|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-04-17|2005-10-04|2005-10-06|Estimate|||||||2008-04-17|2008-04-24|Estimate|September 2002||2002-09-30|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of Two Reduced Sirolimus Doses in Treatment of de Novo Coronary Artery Lesions (REDOX)|An Evaluation of Two Reduced Sirolimus Doses on the BX VELOCITY Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions(REDOX)|Completed||Phase 1/Phase 2|60||Cordis Corporation|||||f||||f||||||||||2018-06-01 04:25:44.577145|2018-06-01 04:25:44.577145
NCT00233753|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-01-05|2005-10-05|2005-10-06|Estimate|||||||2009-01-05|2009-01-07|Estimate|January 2004||2004-01-31|January 2009|2009-01-31|December 2005||2005-12-31|||||Interventional|||Study of the Enterprise Self-Expanding Stent System With Endovascular Coil Embolization of Wide- Neck Saccular Intracranial Artery Aneurysms|Cordis Neurovascular Feasibility Study of the Enterprise Self-Expanding Stent System to Facilitate Endovascular Coil Embolization of Wide- Neck Saccular Intracranial Artery Aneurysms|Completed||Phase 1|30||Codman & Shurtleff|||||||||||||||||||2018-06-01 04:25:44.670818|2018-06-01 04:25:44.670818
NCT00233740|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-08-04|2005-10-04|2005-10-06|Estimate|||||||2008-08-04|2008-08-05|Estimate|September 2003||2003-09-30|August 2008|2008-08-31|May 2005|Actual|2005-05-31|||||Interventional|||Protection From Pulmonary Embolism With the Permanent OptEase™ Filter (PROOF)|The Cordis Protection From Pulmonary Embolism With the Permanent OptEase™ Filter - A Post Marketing Surveillance Study (PROOF Study)|Completed||Phase 4|150||Cordis Corporation|||||f||||f||||||||||2018-06-01 04:25:44.714963|2018-06-01 04:25:44.714963
NCT00233727|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2015-07-07|2005-10-04|2005-10-06|Estimate|||||||2015-07-07|2015-07-09|Estimate|January 2000||2000-01-31|July 2015|2015-07-31|May 2013|Actual|2013-05-31|April 2006|Actual|2006-04-30||Interventional|SAT||Screen and Treat for Cervical Cancer Prevention|Safety and Efficacy of Two Screen-and-Treat Approaches for the Prevention of Cervical Cancer|Terminated||Phase 3|7123|Actual|Columbia University||3||PI left University|f||||f||||||||||2018-06-01 04:25:44.769526|2018-06-01 04:25:44.769526
NCT00233714|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2009-11-17|2005-10-04|2005-10-06|Estimate|||||||2009-11-17|2009-11-19|Estimate|May 2003||2003-05-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|July 2004|Actual|2004-07-31||Interventional|3D||Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary Artery Lesions|A Randomized Feasibility Study of the Double Dose or Single Dose Sirolimus-Eluting BX VELOCITY Balloon-Expandable Stent for the Treatment of Diabetic Patients With de Novo Native Coronary Artery Lesions(3D)|Completed||Phase 1/Phase 2|56|Actual|Cordis Corporation||2|||f||||f||||||||||2018-06-01 04:25:44.834869|2018-06-01 04:25:44.834869
NCT00233701|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2010-02-05|2005-10-04|2005-10-06|Estimate|||||||2010-02-05|2010-02-08|Estimate|October 2004||2004-10-31|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Normal Pressure Hydrocephalus (NPH) Registry|Normal Pressure Hydrocephalus (NPH) Registry|Completed|||343|Actual|Codman & Shurtleff|||||f||||f||||||||||2018-06-01 04:25:44.914165|2018-06-01 04:25:44.914165
NCT00233688|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2009-04-30|2005-10-05|2005-10-06|Estimate|||||||2009-04-30|2009-05-01|Estimate|November 2001||2001-11-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|December 2004|Actual|2004-12-31||Interventional|||Study of the Endovascular QUANTUM LP™ Stent Graft System in Abdominal Aortic Aneurysms (AAA)|A Prospective, Multicenter Study of the Cordis Endovascular QUANTUM LP™ Stent Graft System for the Treatment of Abdominal Aortic Aneurysms (AAA)-FORTRON|Completed||Phase 3|300|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:45.212789|2018-06-01 04:25:45.212789
NCT00233675|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2014-05-08|2005-09-27|2005-10-06|Estimate|||||||2014-05-08|2014-05-09|Estimate|August 2003||2003-08-31|May 2014|2014-05-31||||February 2005|Actual|2005-02-28||Interventional|||Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder|A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder|Completed||Phase 3|||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:25:45.284911|2018-06-01 04:25:45.284911
NCT00233662|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2005-10-04|2005-10-04|2005-10-06|Estimate|||||||2005-10-04|2005-10-06|Estimate|December 2002||2002-12-31|October 2005|2005-10-31|June 2005||2005-06-30|||||Interventional|||Safety and Tolerability of Repeat Courses of IM Alefacept|An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Repeat Courses of Intramuscular Administration of Alefacept (LFA-3/IgG1 Fusion Protein) in Patients With Chronic Plaque Psoriasis|Completed||Phase 3|400||Biogen|||||||||||||||||||2018-06-01 04:25:45.400113|2018-06-01 04:25:45.400113
NCT00233649|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-05|||2010-11-18|2005-10-05|2005-10-06|Estimate|||||||2010-11-18|2010-11-19|Estimate|May 2004||2004-05-31|November 2010|2010-11-30||||||||Observational|||DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines|DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines|Completed|||2500||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:45.567648|2018-06-01 04:25:45.567648
NCT00233038|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2013-10-28|2005-10-03|2005-10-05|Estimate|||||||2013-10-28|2013-10-29|Estimate|January 2005||2005-01-31|October 2013|2013-10-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial|EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial|Completed||Phase 2/Phase 3|50|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:25:51.651575|2018-06-01 04:25:51.651575
NCT00233636|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2011-01-25|2005-10-04|2005-10-06|Estimate|||||||2011-01-25|2011-01-27|Estimate|July 2003||2003-07-31|January 2011|2011-01-31||||||||Interventional|||Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck|A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck|Withdrawn||Phase 2|28||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:46.003574|2018-06-01 04:25:46.003574
NCT00233623|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2011-01-25|2005-10-04|2005-10-06|Estimate|||||||2011-01-25|2011-01-27|Estimate|July 2004||2004-07-31|January 2011|2011-01-31|January 2006|Anticipated|2006-01-31|January 2006|Anticipated|2006-01-31||Interventional|||Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer|A Randomised, Non-Comparative, Multicentre, Phase II, Parallel-Group Trial Of ZD1839 (Iressa™) In Combination With 5 Fluorouracil, Leucovorin And Cpt-11 (Irinotecan) In Patients With Metastatic Colorectal Cancer|Withdrawn||Phase 2|190||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:46.067191|2018-06-01 04:25:46.067191
NCT00233610|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2011-01-25|2005-10-04|2005-10-06|Estimate|||||||2011-01-25|2011-01-27|Estimate|December 2003||2003-12-31|January 2011|2011-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer|A Comparative Trial of the Efficacy of Two Different Nolvadex (NDX) Dosing and Scheduling Regimens in Preventing Gynecomastia Induced by Casodex (CDX) 150 Monotherapy in Prostate Cancer Patients. An Open, Multicenter, Phase III Trial.|Completed||Phase 3|180||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:46.131953|2018-06-01 04:25:46.131953
NCT00233597|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2009-02-26|2005-10-04|2005-10-06|Estimate|||||||2009-02-26|2009-02-27|Estimate|August 2004||2004-08-31|October 2007|2007-10-31|March 2007|Actual|2007-03-31|||||Interventional|||Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients|A Phase III Study of the Safety and Efficacy of Ferumoxytol (Compared With Oral Iron) as an Iron Replacement Therapy in Hemodialysis Patients Who Are Receiving Supplemental EPO Therapy|Completed||Phase 3|230||AMAG Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:25:46.198354|2018-06-01 04:25:46.198354
NCT00233584|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-01-11|2005-10-04|2005-10-06|Estimate|||||||2008-01-11|2008-01-14|Estimate|July 2001||2001-07-31|January 2008|2008-01-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Pulmicort Asthma Prevention (Post-PAC)|A Study to Evaluate the Feasibility of a Treatment Algorithm in Newly Diagnosed Asthmatic Children. An Open Follow-up to Asthma Prevention in Infants/Young Children (PAC)|Completed||N/A|400||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:46.45068|2018-06-01 04:25:46.45068
NCT00233571|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-21|2005-10-05|2005-10-06|Estimate|||||||2011-11-21|2011-11-22|Estimate|June 2000||2000-06-30|November 2011|2011-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis|A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab)|Completed||Phase 3|796|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:25:46.508041|2018-06-01 04:25:46.508041
NCT00233558|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-23|2005-10-05|2005-10-06|Estimate|||||||2007-04-23|2007-04-24|Estimate|June 2005||2005-06-30|April 2007|2007-04-30||||||||Interventional|||Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis|Multicentre, Randomised, Open Label Study Comparing a “Scheduled Steroid Reduction Strategy” Versus a Free Steroid Reduction Strategy (Physician’s Usual Practice for Reducing Steroids) in Patients With Active RA Treated With Humira 40 mg Eow + MTX During 9 Months|Terminated||Phase 4|160||Abbott||||Study terminated due to low subject enrollment. Safety results consistent with product label.|f||||||||||||||2018-06-01 04:25:46.568829|2018-06-01 04:25:46.568829
NCT00233545|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2010-05-29|2005-10-05|2005-10-06|Estimate|||||||2010-05-29|2010-06-02|Estimate|September 2005||2005-09-30|May 2010|2010-05-31|September 2007||2007-09-30|||||Interventional|||Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia|Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia|Completed||Phase 2|80||AB Foundation|||||f||||||||||||||2018-06-01 04:25:46.628024|2018-06-01 04:25:46.628024
NCT00233532|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-18|2005-10-05|2005-10-06|Estimate|||||||2008-07-18|2008-07-22|Estimate|March 2004||2004-03-31|July 2008|2008-07-31||||June 2005|Actual|2005-06-30||Interventional|TRAIL||Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)|A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)|Completed||Phase 4|2000|Actual|Abbott||3|||f||||f||||||||||2018-06-01 04:25:46.686757|2018-06-01 04:25:46.686757
NCT00233519|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2009-08-13||2012-06-20|2005-10-03|2005-10-05|Estimate|2010-01-06|2010-02-01|Estimate||||2012-06-20|2012-06-25|Estimate|November 2005||2005-11-30|June 2012|2012-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)|Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)|Completed||Phase 1/Phase 2|17|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 04:25:46.780644|2018-06-01 04:25:46.780644
NCT00233506|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2017-02-02|2005-10-03|2005-10-05|Estimate|||||||2017-02-02|2017-02-06|Estimate|July 2004||2004-07-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated|A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia|Completed||Phase 1|41|Actual|University of Iowa||2|||f||||||||||||||2018-06-01 04:25:47.187933|2018-06-01 04:25:47.187933
NCT00233493|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2005-10-03|2005-10-03|2005-10-05|Estimate|||||||2005-10-03|2005-10-05|Estimate|March 2005||2005-03-31|November 2004|2004-11-30|February 2006||2006-02-28|||||Observational|||Spread of Dermatophytes Among Families|Demonstration of the Spread of Dermatophytes Through Casual Contact Among Family Household Members|Unknown status|Recruiting||150||University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-06-01 04:25:47.266518|2018-06-01 04:25:47.266518
NCT00233480|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2012-03-29|2005-10-04|2005-10-05|Estimate|||||||2012-03-29|2012-04-02|Estimate|August 2005||2005-08-31|March 2012|2012-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Statin Therapy in Heart Failure: Potential Mechanisms of Benefit|A Double-blind Randomized, Placebo-Controlled, Single-Center Study to Assess the Impact of Statins on the Autonomic Nervous System and Cardiac Structure/Function in Non-Ischemic Heart Failure|Completed||Phase 4|27|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 04:25:47.33216|2018-06-01 04:25:47.33216
NCT00233467|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2017-09-12|2005-10-03|2005-10-05|Estimate|||||||2017-09-12|2017-09-14|Actual|September 1, 2005|Actual|2005-09-01|September 2017|2017-09-30|September 30, 2005|Actual|2005-09-30|September 30, 2005|Actual|2005-09-30||Observational|||Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade|Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade|Withdrawn|||0|Actual|Tuscaloosa Research & Education Advancement Corporation||||Funding expired; no subjects enrolled as this was a retrospective chart review|f||||||||||||||2018-06-01 04:25:47.408513|2018-06-01 04:25:47.408513
NCT00233454|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2015-06-16||2018-03-28|2005-10-03|2005-10-05|Estimate|2015-06-16|2015-07-09|Estimate||||2018-03-28|2018-04-26|Actual|March 2005|Actual|2005-03-31|March 2018|2018-03-31|April 16, 2011|Actual|2011-04-16|June 18, 2010|Actual|2010-06-18||Interventional|||Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia|A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 <Midostaurin> Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)|Completed||Phase 2|26|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 04:25:47.49836|2018-06-01 04:25:47.49836
NCT00233441|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2012-05-07|2005-10-04|2005-10-05|Estimate|||||||2012-05-07|2012-05-08|Estimate|December 2004||2004-12-31|May 2012|2012-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|MAIA||Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter|Placebo Controlled Double Blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200, or 300 mg OD, With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter|Completed||Phase 2/Phase 3|673|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:25:47.868309|2018-06-01 04:25:47.868309
NCT00233428|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2015-05-11|2005-10-04|2005-10-05|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Study to Determine Racial and Gender Differences in Platelet Aggregation|Phase 1 Study to Determine Racial and Gender Differences in Platelet Aggregation|Completed|||60||Texas Tech University Health Sciences Center|||||f||||||||||||||2018-06-01 04:25:47.946591|2018-06-01 04:25:47.946591
NCT00233415|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2010-06-01|2005-10-03|2005-10-05|Estimate|||||||2010-06-01|2010-06-02|Estimate|July 2003||2003-07-31|June 2010|2010-06-30|May 2007|Actual|2007-05-31|March 2006|Actual|2006-03-31||Interventional|||Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer|Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer|Completed||Phase 2|100|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:25:47.994393|2018-06-01 04:25:47.994393
NCT00233402|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|2013-08-05||2013-08-05|2005-10-04|2005-10-05|Estimate|2013-08-05|2013-10-11|Estimate||||2013-08-05|2013-10-11|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy|A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection Of Papillary Bladder Cancer and the Early Recurrence Rate in Patients With Bladder Cancer|Completed||Phase 3|789|Actual|Photocure||2|||f||||t||||||||||2018-06-01 04:25:48.074955|2018-06-01 04:25:48.074955
NCT00233389|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-05-25|2005-10-04|2005-10-05|Estimate|||||||2007-05-25|2007-05-28|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|September 2005||2005-09-30|||||Interventional|||Post-Marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer|A Post-Marketing Clinical Study of Rebamipide to Investigate the Gastric Ulcer Healing Effect of Continued Dosing Following Helicobacter Pylori Eradication Therapy|Completed||Phase 4|300||Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-06-01 04:25:48.593798|2018-06-01 04:25:48.593798
NCT00233376|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2006-07-17|2005-10-04|2005-10-05|Estimate|||||||2006-07-17|2006-07-18|Estimate|May 2004||2004-05-31|October 2005|2005-10-31|November 2004||2004-11-30|||||Interventional|||Computerized Decision Support System for Antibiotic Treatment|Improving Empirical Antibiotic Treatment Using TREAT,a Computerized Decision Support System. Cluster Randomized Trial|Completed||Phase 3|1500||Rabin Medical Center|||||f||||||||||||||2018-06-01 04:25:48.648809|2018-06-01 04:25:48.648809
NCT00233363|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-05-25|2005-10-04|2005-10-05|Estimate|||||||2007-05-25|2007-05-28|Estimate|March 2005||2005-03-31|May 2007|2007-05-31|January 2006||2006-01-31|||||Interventional|||Exploratory Study for Dry Mouth in Patients With Sjögren’s Syndrome|An Exploratory Study of Rebamipide to Evaluate Efficacy and Safety in the Treatment of Dry Mouth in Patients With Sjögren’s Syndrome|Completed||Phase 2|100||Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-06-01 04:25:48.736241|2018-06-01 04:25:48.736241
NCT00233350|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2015-09-30|2005-10-04|2005-10-05|Estimate|||||||2015-09-30|2015-10-01|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Clinical Evaluation of Navigated 3D Ultrasound Multicentre Study|Clinical Evaluation of Navigated 3D Ultrasound Multicentre Study|Completed|||142|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:25:48.785282|2018-06-01 04:25:48.785282
NCT00233337|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2012-04-25|2005-10-04|2005-10-05|Estimate|||||||2012-04-25|2012-04-27|Estimate|May 2001||2001-05-31|April 2012|2012-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers|Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 04:25:48.871191|2018-06-01 04:25:48.871191
NCT00233324|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2014-11-16||2017-09-22|2005-10-03|2005-10-05|Estimate|2014-11-28|2014-12-05|Estimate||||2017-09-22|2017-10-25|Actual|February 2005||2005-02-28|September 2017|2017-09-30|August 2016|Actual|2016-08-31|February 2009|Actual|2009-02-28||Interventional|SUPPORT||Surfactant Positive Airway Pressure and Pulse Oximetry Trial|Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants|Completed||Phase 3|1316|Actual|NICHD Neonatal Research Network||4|||f||||t||||||||||2018-06-01 04:25:48.996434|2018-06-01 04:25:48.996434
NCT00233311|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2012-08-03|2005-10-03|2005-10-05|Estimate|||||||2012-08-03|2012-08-06|Estimate|March 2004||2004-03-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Fast Food Study: Assessment of the Effects of Fast-Food on Inflammatory Markers|Assessment of the Postprandial Effects of a Fast-food on Inflammatory Markers|Completed|||61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||f||||||Samples With DNA|"~     Serum, Whole Blood~   "|||2018-06-01 04:25:49.380014|2018-06-01 04:25:49.380014
NCT00233298|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2018-04-04|2005-10-03|2005-10-05|Estimate|||||||2018-04-04|2018-04-05|Actual|May 26, 2005||2005-05-26|January 2, 2015|2015-01-02|January 2, 2015||2015-01-02|||||Observational|||A Study of the Function of Hormones Present In Taste Buds|A Study of the Function of Hormones Present In Taste Buds|Completed|||225|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:25:49.432691|2018-06-01 04:25:49.432691
NCT00233285|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2016-07-11|2005-10-03|2005-10-05|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1999||1999-09-30|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Factors in Childhood Lung Susceptibility to Pollution||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:25:49.493326|2018-06-01 04:25:49.493326
NCT00233272|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2018-05-08|2005-10-03|2005-10-05|Estimate|||||||2018-05-08|2018-05-09|Actual|January 21, 2003||2003-01-21|May 2, 2018|2018-05-02||||||||Observational|||Baltimore Longitudinal Study of Aging|Longitudinal Studies of Human Physiology, Biochemistry, and Psychology (The Baltimore Longitudinal Syudy of Aging - BLSA)|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:25:49.542559|2018-06-01 04:25:49.542559
NCT00233246|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2014-06-05|2005-10-03|2005-10-05|Estimate|||||||2014-06-05|2014-06-06|Estimate|March 2006||2006-03-31|June 2014|2014-06-30||||||||Interventional|||Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures|Study of Hemostasis and Invasive Procedures (SHIP: A TMH CTN Study)|Withdrawn||Phase 3|0|Actual|Massachusetts General Hospital||||Study never activated|f||||||||||||||2018-06-01 04:25:49.716148|2018-06-01 04:25:49.716148
NCT00233233|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2017-12-11|2005-10-03|2005-10-05|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2002||2002-08-31|December 2017|2017-12-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Influence of Data Collection Mode on Self-Report Validity of Asthma Therapy Adherence|Assessment Mode and Validity of Self-Reports in Adults|Completed||N/A|139|Actual|Johns Hopkins University|||||f||||||||||||||2018-06-01 04:25:49.794128|2018-06-01 04:25:49.794128
NCT00233220|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2014-02-12|2005-10-03|2005-10-05|Estimate|||||||2014-02-12|2014-02-13|Estimate|September 2004||2004-09-30|February 2014|2014-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Blood Pressure Control in African Americans|Multi-site Randomized Controlled Trial for Blood Pressure Control in Hypertensive African Americans|Completed||N/A|1039|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 04:25:49.846158|2018-06-01 04:25:49.846158
NCT00233207|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2017-05-12|2005-10-03|2005-10-05|Estimate|||||||2017-05-12|2017-05-16|Actual|September 2005||2005-09-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||IC14 Antibodies to Treat Individuals With Acute Lung Injury|Acute Lung Injury Clinical Trials Incubator Unit|Terminated||Phase 2|13|Actual|University of Washington||||Unable to meet enrollment number to complete study, study stopped June 30, 2007|f||||||||||||||2018-06-01 04:25:49.911652|2018-06-01 04:25:49.911652
NCT00233194|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2016-12-03|2005-10-03|2005-10-05|Estimate|||||||2016-12-03|2016-12-06|Estimate|January 2005||2005-01-31|December 2016|2016-12-31|July 2011|Actual|2011-07-31|November 2009|Actual|2009-11-30||Observational|||Identification of Sleep-Disordered Breathing in Children|Identification of Sleep-Disordered Breathing in Children|Completed|||160|Actual|University of Michigan|||1||f||||f||||||||||2018-06-01 04:25:49.967016|2018-06-01 04:25:49.967016
NCT00233181|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2016-02-17|2005-10-03|2005-10-05|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2000||2000-04-30|December 2005|2005-12-31|March 2005|Actual|2005-03-31|||||Interventional|||Adherence Intervention for Minority Children With Asthma||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:25:50.03604|2018-06-01 04:25:50.03604
NCT00233168|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2014-06-24|2005-10-03|2005-10-05|Estimate|||||||2014-06-24|2014-06-25|Estimate|September 2003||2003-09-30|June 2014|2014-06-30|August 2008|Actual|2008-08-31|August 2007|Actual|2007-08-31||Interventional|||Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents|Promoting Adherence to TB Regimens in High Risk Youth|Completed||N/A|263|Actual|San Diego State University||2|||f||||t||||||||||2018-06-01 04:25:50.078591|2018-06-01 04:25:50.078591
NCT00233155|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2008-03-04|2005-10-03|2005-10-05|Estimate|||||||2008-03-04|2008-03-06|Estimate|August 2005||2005-08-31|March 2008|2008-03-31|December 2006||2006-12-31|||||Interventional|||Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)|A Multicenter, Open-Label, Phase 2 Study of NGX-4010 for the Treatment of Neuropathic Pain in Patients With Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)|Completed||Phase 2|100||NeurogesX|||||||||||||||||||2018-06-01 04:25:50.137392|2018-06-01 04:25:50.137392
NCT00233142|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-04-13|2005-10-03|2005-10-05|Estimate|||||||2016-04-13|2016-04-15|Estimate|September 2005||2005-09-30|November 2009|2009-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Expressive Writing for Reducing Stress and Diabetic Symptoms in Diabetes Patients|Expressive Writing: Complementary Treatment for Diabetes|Completed||Phase 2|187|Actual|Syracuse University||2|||f||||t||||||||||2018-06-01 04:25:50.186032|2018-06-01 04:25:50.186032
NCT00233129|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2013-09-23|2005-10-03|2005-10-05|Estimate|||||||2013-09-23|2013-09-24|Estimate|October 2005||2005-10-31|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||"Improving Executive Functions After Traumatic Brain Injury (TBI): A Clinical Trial of the Executive Plus Program"|"Improving Executive Functions After TBI: A Randomized Clinical Trial of the Executive Plus Program"|Completed||N/A|77|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 04:25:50.257303|2018-06-01 04:25:50.257303
NCT00233103|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2013-07-29||2015-10-14|2005-10-03|2005-10-05|Estimate|2015-10-14|2015-11-13|Estimate||||2015-10-14|2015-11-13|Estimate|June 2003||2003-06-30|October 2015|2015-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Post-Traumatic Brain Injury (TBI) Depression|Treatment of Post-TBI Depression|Completed||Phase 2|52|Actual|Icahn School of Medicine at Mount Sinai|"Sample size was small - those who dropped out could have reduced the differential effect.~Sample was heterogeneous for severity and time since injury."|2|||f||||t||||||||||2018-06-01 04:25:50.33171|2018-06-01 04:25:50.33171
NCT00233090|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2013-08-07||2016-03-16|2005-10-03|2005-10-05|Estimate|2016-03-16|2016-04-15|Estimate||||2016-03-16|2016-04-15|Estimate|July 2005||2005-07-31|March 2016|2016-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Post-Traumatic Brain Injury (Post-TBI) Fatigue and Its Treatment|Post-TBI Fatigue and Its Treatment|Terminated||Phase 2|21|Actual|Icahn School of Medicine at Mount Sinai|Study was terminated due to insufficient recruitment. Data analysis not available.|2||Insufficient recruitment|f||||||||||||||2018-06-01 04:25:50.528603|2018-06-01 04:25:50.528603
NCT00233077|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2013-12-02|2005-10-03|2005-10-05|Estimate|||||||2013-12-02|2013-12-03|Estimate|October 2006||2006-10-31|December 2013|2013-12-31|January 2011|Actual|2011-01-31|June 2010|Actual|2010-06-30||Interventional|||Patient Centered Randomized Controlled Trial|Patient Assistance to Reduce Breast Cancer Disparities|Completed||N/A|374|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 04:25:50.901331|2018-06-01 04:25:50.901331
NCT00233064|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2008-10-02||2010-01-07|2005-10-03|2005-10-05|Estimate|2008-10-27|2008-10-28|Estimate||||2010-01-07|2010-01-13|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)|A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease|Completed||Phase 4|417|Actual|MedImmune LLC|Only serious adverse events were collected as part of the safety evaluation. One death (asphyxia) occurred in the Lyophilized Palivizumab group; this event was judged not related to study drug.|2|||f||||f||||||||||2018-06-01 04:25:51.011132|2018-06-01 04:25:51.011132
NCT00233051|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2017-03-27|2005-10-03|2005-10-05|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2003||2003-04-30|March 2017|2017-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Evaluating Genes in Sputum to Measure Drug Response in COPD|Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD|Terminated||N/A|20|Actual|National Jewish Health|||||f||||||||||||||2018-06-01 04:25:51.573398|2018-06-01 04:25:51.573398
NCT00233012|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2010-05-24|2005-10-03|2005-10-05|Estimate|||||||2010-05-24|2010-05-25|Estimate|June 2005||2005-06-30|May 2010|2010-05-31|October 2007|Actual|2007-10-31|||||Interventional|||A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures|A Randomized, Open-label (OL), Multicenter Study With OL Extension of the Pharmacokinetics and Safety of Topiramate Administered as Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy in Infants (Aged 1-24 Months, Inclusive) With Refractory Partial-onset Seizures|Completed||Phase 1|16|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:25:51.873631|2018-06-01 04:25:51.873631
NCT00232999|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2012-07-03|2005-10-04|2005-10-05|Estimate|||||||2012-07-03|2012-07-04|Estimate|October 2005||2005-10-31|September 2008|2008-09-30|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma||Completed||Phase 2|15|Actual|Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:25:51.933533|2018-06-01 04:25:51.933533
NCT00232986|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2005-10-03|2005-10-03|2005-10-05|Estimate|||||||2005-10-03|2005-10-05|Estimate|September 2004||2004-09-30|October 2005|2005-10-31|November 2004||2004-11-30|||||Observational|||A Comparison of Survey Methodologies to Elicit Sensitive Information From Adolescents in Urban India|A Comparison of Survey Methodologies to Elicit Information on Sexual and Reproductive Health From Adolescents in Urban India|Completed|||960||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:25:52.00123|2018-06-01 04:25:52.00123
NCT00232973|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-02-04|2005-10-04|2005-10-05|Estimate|||||||2008-02-04|2008-02-05|Estimate|July 2005||2005-07-31|February 2008|2008-02-29||||||||Interventional|||Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers|A Prospective, Multi-Centre, Double Blind, Randomized, Placebo Controlled Trial to Evaluate the Safety and Efficacy of ICXP007 in a Phase III Trial With Four-Layer Therapeutic Compression, for the Treatment of Non-Infected Skin Leg Ulcers, Due to Venous-Insufficiency|Unknown status|Recruiting|Phase 3|396|Anticipated|Intercytex|||||f||||t||||||||||2018-06-01 04:25:52.071103|2018-06-01 04:25:52.071103
NCT00232960|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2012-03-27|2005-10-04|2005-10-05|Estimate|||||||2012-03-27|2012-03-28|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC|Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Early Stages Oral and Oropharyngeal Squamous Cell Carcinomas: A Prospective Study|Unknown status|Active, not recruiting|N/A|310|Actual|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:25:52.264664|2018-06-01 04:25:52.264664
NCT00232947|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2007-01-19|2005-10-03|2005-10-05|Estimate|||||||2007-01-19|2007-01-22|Estimate|October 2005||2005-10-31|October 2005|2005-10-31|February 2006||2006-02-28|||||Interventional|||Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over|A Non-Inferiority Comparison of Fluviral™ Influenza Vaccine to a U.S. Licensed Inactivated Split-Virion Vaccine (Fluzone®) in Adults ≥ 50 Years Old Living in the Community|Completed||Phase 3|900||ID Biomedical Corporation, Quebec|||||||||||||||||||2018-06-01 04:25:52.32208|2018-06-01 04:25:52.32208
NCT00232934|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2005-10-04|2005-10-04|2005-10-05|Estimate|||||||2005-10-04|2005-10-05|Estimate|January 2002||2002-01-31|October 2005|2005-10-31|May 2010||2010-05-31|||||Interventional|||Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients|Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.|Completed||Phase 3|400||Gruppo Italiano per lo Studio del Mieloma Multiplo|||||f||||||||||||||2018-06-01 04:25:52.385925|2018-06-01 04:25:52.385925
NCT00232921|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2006-12-22|2005-10-04|2005-10-05|Estimate|||||||2006-12-22|2006-12-25|Estimate||||December 2006|2006-12-31|February 2003||2003-02-28|||||Interventional|||The Effect of Caudal Volumes on the Anatomical Spread of Caudals in Children||Completed||Phase 1|||Institute of Child Health|||||f||||||||||||||2018-06-01 04:25:52.44796|2018-06-01 04:25:52.44796
NCT00232908|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2016-11-01|2005-10-04|2005-10-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2004||2004-06-30|November 2016|2016-11-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection|An Open-label Study of a HAART (Highly Active Antiretroviral Therapy) Regimen Containing Subcutaneous Injection of Fuzeon on Quality of Life in Clinically Stable, Treatment-experienced Patients With HIV-1 Infection|Completed||Phase 4|361|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 04:25:52.503431|2018-06-01 04:25:52.503431
NCT00232895|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-03-27|2005-10-04|2005-10-05|Estimate|||||||2007-03-27|2007-03-28|Estimate||||March 2007|2007-03-31|August 2005||2005-08-31|||||Interventional|||Pain of Injection of Lipuro Propofol in Children Aged 1-7 Years||Completed||N/A|||Institute of Child Health|||||f||||||||||||||2018-06-01 04:25:52.799336|2018-06-01 04:25:52.799336
NCT00232882|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2013-08-30|2005-10-03|2005-10-05|Estimate|||||||2013-08-30|2013-09-04|Estimate|December 2003||2003-12-31|August 2013|2013-08-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.|Neurohumoral and Oxidative Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Essential Hypertensive Patients.|Completed||Phase 4|86|Actual|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||||2018-06-01 04:25:52.853373|2018-06-01 04:25:52.853373
NCT00232869|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2010-02-03|2005-10-04|2005-10-05|Estimate|||||||2010-02-03|2010-02-04|Estimate|February 2001||2001-02-28|February 2010|2010-02-28|May 2009|Actual|2009-05-31|June 2003|Actual|2003-06-30||Interventional|SIROCCO||A Study of the SMART Stent in the Treatment SFA Disease.|A Clinical Investigation of the SIROlimus Coated Cordis SMART™ Nitinol Selfexpandable Stent for the Treatment of Obstructive Superficial Femoral Artery Disease.|Completed||Phase 2|93|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:52.936582|2018-06-01 04:25:52.936582
NCT00232856|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-04-29|2005-10-04|2005-10-05|Estimate|||||||2008-04-29|2008-04-30|Estimate|December 2002||2002-12-31|April 2008|2008-04-30|August 2006|Actual|2006-08-31|December 2003|Actual|2003-12-31||Interventional|TROPICAL||A Study of the Cypher SES to Treat Restenotic Native Coronary Artery Lesions.|A Multi-Center, Non-Randomised Study of the CYPHER™ Sirolimus-Eluting Stent in the Treatment of Patient With an in-Stent Restenotic Native Coronary Artery Lesion|Completed||Phase 4|162|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:52.999059|2018-06-01 04:25:52.999059
NCT00232843|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2009-06-02|2005-10-04|2005-10-05|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2005||2005-03-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|SUPER UK||The Study to Treat Superficial Femoral Artery Occlusions.|A Clinical Investigation of the SMART™ Nitinol Self-Expandable Stent Versus Balloon Angioplasty Only for the Treatment of SUPERficial Femoral Artery Occlusions|Completed||Phase 4|150|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:53.076806|2018-06-01 04:25:53.076806
NCT00232830|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2009-09-15|2005-10-04|2005-10-05|Estimate|||||||2009-09-15|2009-09-16|Estimate|October 2003||2003-10-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|TYPHOON||The Study to Assess AMI Treated With Balloon Angioplasty.|Trial to Assess the Use of the Cypher TM Stent in Acute Myocardial Infarction Treated With Balloon Angioplasty|Completed||Phase 3|715|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:53.144722|2018-06-01 04:25:53.144722
NCT00232817|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-01-12|2005-10-03|2005-10-05|Estimate|||||||2011-01-12|2011-01-14|Estimate|July 2003||2003-07-31|January 2011|2011-01-31|March 2006|Actual|2006-03-31|July 2005|Actual|2005-07-31||Interventional|||Anesthesia and Postoperative Pain|Intranasal Nicotine for Postoperative Pain Treatment: A Comparison of Its Effects in the Context of Isoflurane-induced Anesthesia Versus Propofol Anesthesia|Completed||Phase 4|80|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 04:25:53.208213|2018-06-01 04:25:53.208213
NCT00232804|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-10-08|2005-10-04|2005-10-05|Estimate|||||||2007-10-08|2007-10-10|Estimate|June 2002||2002-06-30|October 2007|2007-10-31|February 2004|Actual|2004-02-29|||||Interventional|||The BRIDGE Registry: Safety and Efficacy Registry of Bx Cypher Stent|Safety and Efficacy Registry of Bx Cypher Stent in the Revascularisation of Patients With Significant Risk of Restenosis|Completed||Phase 4|639|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:53.275511|2018-06-01 04:25:53.275511
NCT00232791|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2008-08-05|2005-10-04|2005-10-05|Estimate|||||||2008-08-05|2008-08-06|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|March 2005|Actual|2005-03-31|August 2004|Actual|2004-08-31||Interventional|DOMINO||The Study to Compare Cypher Versus Cypher Select in Treating Cornary Artery Lesions.|A Randomized Study With the CYPHER SELECT™ Sirolimus-Eluting Balloon-Expandable Coronary Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions.|Completed||Phase 2/Phase 3|102|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:53.326019|2018-06-01 04:25:53.326019
NCT00232778|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2008-04-17|2005-10-03|2005-10-05|Estimate|||||||2008-04-17|2008-04-24|Estimate|May 2000||2000-05-31|April 2008|2008-04-30|June 2006|Actual|2006-06-30|||||Interventional|||A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis (GAMMA V)|A Multicenter Trial of Localized Radiation Therapy to Inhibit Restenosis (GAMMA V)|Completed||Phase 1/Phase 2|579||Cordis Corporation|||||f||||||||||||||2018-06-01 04:25:53.38385|2018-06-01 04:25:53.38385
NCT00232765|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2009-09-15|2005-10-03|2005-10-05|Estimate|||||||2009-09-15|2009-09-16|Estimate|February 2001||2001-02-28|September 2009|2009-09-30|November 2008|Actual|2008-11-30|May 2002|Actual|2002-05-31||Interventional|||Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions (SIRIUS)|A Multicenter, Randomized, Double-Blind Study of the Sirolimus-Coated BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions|Completed||Phase 3|1058|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:25:54.441413|2018-06-01 04:25:54.441413
NCT00232752|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03||2009-11-16|2009-12-01|2005-10-03|2005-10-05|Estimate||||2009-11-16|2009-11-18|Estimate|2009-12-01|2009-12-02|Estimate|September 2003||2003-09-30|December 2009|2009-12-31|November 2009|Actual|2009-11-30|January 2005|Actual|2005-01-31||Interventional|||Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions|A Multicenter, Non-Randomized Study of the 4.0mm Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions|Completed||Phase 3|100|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:54.660291|2018-06-01 04:25:54.660291
NCT00232739|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2009-10-19||2010-03-11|2005-10-03|2005-10-05|Estimate|2010-01-14|2010-02-08|Estimate||||2010-03-11|2010-03-16|Estimate|September 2003||2003-09-30|March 2010|2010-03-31|August 2009|Actual|2009-08-31|November 2004|Actual|2004-11-30||Interventional|||Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions|A Multicenter, Non-Randomized Study of the 2.25mm Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions|Completed||Phase 3|100|Actual|Cordis Corporation||1|||f||||t||||||||||2018-06-01 04:25:54.759933|2018-06-01 04:25:54.759933
NCT00232726|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2007-07-09|2005-10-04|2005-10-05|Estimate|||||||2007-07-09|2007-07-10|Estimate|September 2005||2005-09-30|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Clinical Study of Previously Untreated Patients With Malignant Melanoma|A Non-Randomised, Multicentre, Phase II Clinical Study of CP-4055 in Chemotherapy-Naïve Patients With Metastatic Malignant Melanoma|Completed||Phase 2|42|Anticipated|Clavis Pharma|||||f||||t||||||||||2018-06-01 04:25:55.043555|2018-06-01 04:25:55.043555
NCT00232713|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2006-08-29|2005-10-03|2005-10-05|Estimate|||||||2006-08-29|2006-08-30|Estimate|December 2005||2005-12-31|February 2006|2006-02-28|December 2005||2005-12-31|||||Observational|||Uterine Fibroid Pregnancy Registry||Terminated|||2360||INC Research|||||f||||||||||||||2018-06-01 04:25:55.103545|2018-06-01 04:25:55.103545
NCT00232700|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2011-06-22|2005-10-04|2005-10-05|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2005||2005-09-30|September 2007|2007-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Investigation of a Combination Treatment of Escitalopram and rTMS|Investigation of Efficacy and Response Speed of a Combination Treatment of Escitalopram and Repetitive Transcranial Magnetic Stimulation|Completed||N/A|42|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:25:55.248195|2018-06-01 04:25:55.248195
NCT00232687|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2013-11-07|2005-10-03|2005-10-05|Estimate|||||||2013-11-07|2013-11-08|Estimate|June 2005||2005-06-30|February 2012|2012-02-29|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Switch Study of BMS-337039 in Schizophrenic Out-patients|A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone|Completed||Phase 4|450|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 04:25:55.32818|2018-06-01 04:25:55.32818
NCT00232674|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2011-01-21|2005-10-04|2005-10-05|Estimate|||||||2011-01-21|2011-01-24|Estimate|July 1999||1999-07-31|January 2011|2011-01-31|February 2004|Actual|2004-02-29|||||Interventional|||Efficacy Study of the Effect of Budesonide on Emphysema|The Effect of Inhaled Corticosteroids on the Development of Emphysema in Smokers Assessed by Computed Tomography (CT).|Completed||Phase 4|240||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:55.506345|2018-06-01 04:25:55.506345
NCT00232661|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2010-02-02|2005-09-30|2005-10-05|Estimate|||||||2010-02-02|2010-02-03|Estimate|August 2000||2000-08-31|February 2010|2010-02-28|December 2007|Actual|2007-12-31|January 2003|Actual|2003-01-31||Interventional|||PROACT - Pre-Operative Arimidex Compared To Tamoxifen|A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer.|Completed||Phase 3|452|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:25:55.583465|2018-06-01 04:25:55.583465
NCT00226018|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2008-04-16|2005-09-22|2005-09-26|Estimate|||||||2008-04-16|2008-04-17|Estimate|March 2005||2005-03-31|April 2008|2008-04-30|October 2006||2006-10-31|||||Interventional|||Performance of Acceleromyography With and Without Preload|Performance of Acceleromyography With and Without Preload During Neuromuscular Blockade|Completed||Phase 4|60||Rigshospitalet, Denmark||4|||f||||f||||||||||2018-06-01 04:27:17.471531|2018-06-01 04:27:17.471531
NCT00232648|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2009-03-24|2005-09-30|2005-10-05|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2004||2004-01-31|March 2009|2009-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma|Investigation of Safety and Efficacy of Budesonide Inhalation Suspension in the Long-Term Use in Japanese Children With Bronchial Asthma (Open Long-Term Extension Study Following Study SD-004-0765|Completed||Phase 3|54||AstraZeneca|||||f||||||||||||||2018-06-01 04:25:55.748001|2018-06-01 04:25:55.748001
NCT00232635|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-04|||2010-02-11|2005-10-04|2005-10-05|Estimate|||||||2010-02-11|2010-02-12|Estimate|September 2005||2005-09-30|February 2010|2010-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT|A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of A-60444 in Adults With RSV Infection Following Stem Cell Transplantation|Completed||Phase 2|27|Actual|Arrow Therapeutics|||||f||||t||||||||||2018-06-01 04:25:55.804064|2018-06-01 04:25:55.804064
NCT00232622|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2013-10-23|2005-10-03|2005-10-05|Estimate|||||||2013-10-23|2013-10-24|Estimate|November 2004||2004-11-30|October 2013|2013-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|RAFT-PVT||A Study Comparing a New Dosing Regimen of Clot-dissolving Drug for Mechanical Heart Valves Which Show Clots|A Prospective Randomized Trial of a Rapid Fibrinolytic Protocol for Left-sided Prosthetic Valve Thrombosis|Completed||Phase 3|120|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-06-01 04:25:55.859283|2018-06-01 04:25:55.859283
NCT00232609|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2012-09-17|2005-09-30|2005-10-04|Estimate|||||||2012-09-17|2012-09-18|Estimate|August 2005||2005-08-31|September 2012|2012-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Development of the GameCycle Exercise System: Phase II|Development of the GameCycle Exercise System: Phase II|Completed||Phase 2|14|Actual|VA Pittsburgh Healthcare System|||||f||||f||||||||||2018-06-01 04:25:56.012864|2018-06-01 04:25:56.012864
NCT00232596|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2011-07-07||2016-10-26|2005-09-30|2005-10-04|Estimate|2011-09-15|2011-10-25|Estimate||||2016-10-26|2016-12-08|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|RESTORE1||Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures|Completed||Phase 3|306|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:25:56.147603|2018-06-01 04:25:56.147603
NCT00232583|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2013-10-15||2017-11-17|2005-09-30|2005-10-04|Estimate|2015-05-26|2015-05-28|Estimate||||2017-11-17|2017-12-14|Actual|November 2003||2003-11-30|November 2017|2017-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Preservation of Beta-cell Function in Type 2 Diabetes Mellitus|Preservation of Beta-cell Function in Type 2 Diabetes Mellitus|Completed||N/A|58|Actual|University of Texas Southwestern Medical Center|Relatively small trial, but longest (6-year) follow-up.|2|||f||||f||||||||||2018-06-01 04:25:57.207638|2018-06-01 04:25:57.207638
NCT00232570|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2009-05-04|2005-09-30|2005-10-04|Estimate|||||||2009-05-04|2009-05-05|Estimate|November 2005||2005-11-30|May 2009|2009-05-31|January 2010|Anticipated|2010-01-31|December 2009|Anticipated|2009-12-31||Interventional|||Quetiapine for the Treatment of Insomnia in Alzheimer's Disease|Quetiapine for the Treatment of Insomnia Associated With Alzheimer's Disease|Unknown status|Recruiting|N/A|18|Anticipated|University of Vermont|||||||||||||||||||2018-06-01 04:25:57.610172|2018-06-01 04:25:57.610172
NCT00232557|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2013-11-27||2015-04-06|2005-09-30|2005-10-04|Estimate|2014-01-16|2014-02-13|Estimate||||2015-04-06|2015-04-24|Estimate|August 2004||2004-08-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional||Subject with baseline examination|Telecommunications System in Asthma|Effectiveness of a Telecommunications System in Asthma Management|Completed||Phase 3|136|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:25:57.710101|2018-06-01 04:25:57.710101
NCT00232544|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2013-11-04||2015-04-06|2005-09-30|2005-10-04|Estimate|2013-12-31|2014-02-17|Estimate||||2015-04-06|2015-04-24|Estimate|October 2004||2004-10-31|October 2013|2013-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Telecommunications System in Sleep Apnea|RCT of a Telecommunications System in Sleep Apnea|Completed||N/A|250|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:25:57.877825|2018-06-01 04:25:57.877825
NCT00232531|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2007-01-26|2005-10-03|2005-10-04|Estimate|||||||2007-01-26|2007-01-29|Estimate|September 2004||2004-09-30|September 2006|2006-09-30|February 2009||2009-02-28|||||Interventional|||Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function|Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function|Unknown status|Active, not recruiting|N/A|70||University of Oxford|||||f||||||||||||||2018-06-01 04:25:58.081941|2018-06-01 04:25:58.081941
NCT00232518|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-05-04|2005-09-30|2005-10-04|Estimate|||||||2007-05-04|2007-05-07|Estimate|September 2005||2005-09-30|April 2005|2005-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis|Randomised Controlled Clinical Trial of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis|Completed||N/A|30||University of Nottingham|||||f||||||||||||||2018-06-01 04:25:58.139138|2018-06-01 04:25:58.139138
NCT00232505|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2017-04-07||2017-05-25|2005-10-03|2005-10-04|Estimate|2017-05-25|2017-06-28|Actual||||2017-05-25|2017-06-28|Actual|November 2005|Actual|2005-11-30|May 2017|2017-05-31|August 12, 2012|Actual|2012-08-12|June 21, 2010|Actual|2010-06-21||Interventional|||Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer|Phase II Trial of Cetuximab Alone and in Combination With Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer|Completed||Phase 2|112|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||No||2018-06-01 04:25:58.249622|2018-06-01 04:25:58.249622
NCT00232492|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-07-03|2005-10-02|2005-10-04|Estimate|||||||2011-07-03|2011-07-06|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Ketamine on Acute Pain in Females and Males|Effect of Racemic Ketamine on Pain in Females and Males After Surgical Removal of Third Molars|Completed||Phase 4|128|Actual|Oslo University Hospital||8|||f||||f||||||||||2018-06-01 04:25:59.184407|2018-06-01 04:25:59.184407
NCT00232479|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2012-06-12||2012-07-16|2005-09-30|2005-10-04|Estimate|2012-07-16|2012-08-21|Estimate||||2012-07-16|2012-08-21|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer|Phase II Study of Dose Dense Carboplatin and Taxotere With Herceptin As Primary Systemic Therapy in Breast Cancer|Completed||Phase 2|48|Actual|University of Miami||1|||f||||t||||||||||2018-06-01 04:25:59.265984|2018-06-01 04:25:59.265984
NCT00232466|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2018-02-14|2005-09-30|2005-10-04|Estimate|||||||2018-02-14|2018-02-15|Actual|February 2006||2006-02-28|June 2008|2008-06-30|June 2010|Actual|2010-06-30|||||Interventional|||VERTOS-II. Percutaneous Vertebroplasty Versus Conservative Therapy|VERTOS II. Percutaneous Vertebroplasty Versus Conservative Therapy in Patients With Osteoporotic Vertebral Fractures|Completed||N/A|200|Actual|UMC Utrecht||2|||f||||||||||||||2018-06-01 04:25:59.382288|2018-06-01 04:25:59.382288
NCT00232453|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-02-11|2005-10-03|2005-10-04|Estimate|||||||2011-02-11|2011-02-15|Estimate|March 2001||2001-03-31|February 2011|2011-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Preoperative Combined Radiation and Chemotherapy - Rectal Cancer|A Phase II Protocol of Preoperative Combined Radiation and Chemotherapy for Resectable Primary Rectal Cancer|Completed||Phase 2|34||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:25:59.439084|2018-06-01 04:25:59.439084
NCT00232440|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2010-08-10|2005-10-03|2005-10-04|Estimate|||||||2010-08-10|2010-08-11|Estimate|January 2003||2003-01-31|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma|A Study to Examine the Reproducibility of an Immobilization Device (BodyFIX ) to Deliver High Precision Radiation Therapy for Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|20||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:25:59.479127|2018-06-01 04:25:59.479127
NCT00232427|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-10-02|2005-09-30|2005-10-04|Estimate|||||||2007-10-02|2007-10-03|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||PiCCO Guided Therapy in Liver Cirrhosis|Optimized Therapy of Decompensated Liver Cirrhosis by Hemodynamic Monitoring Using the PiCCO System|Completed||N/A|20|Actual|Heidelberg University|||||f||||||||||||||2018-06-01 04:25:59.518445|2018-06-01 04:25:59.518445
NCT00232414|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2013-12-09|2005-09-30|2005-10-04|Estimate|||||||2013-12-09|2013-12-10|Estimate|October 2005||2005-10-31|December 2013|2013-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder|A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder|Completed||Phase 3|30|Anticipated|University of Cincinnati|||||f||||t||||||||||2018-06-01 04:25:59.565569|2018-06-01 04:25:59.565569
NCT00232401|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2009-02-13|2005-10-03|2005-10-04|Estimate|||||||2009-02-13|2009-02-16|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|||||Observational|||The Circadian Rhythm of Urine Output in Healthy Infants|The Circadian Rhythm of Urine Output in Healthy Infants|Completed|||60|Anticipated|University of Aarhus|||||f||||||||||||||2018-06-01 04:25:59.705237|2018-06-01 04:25:59.705237
NCT00232388|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2015-10-06|2005-10-03|2005-10-04|Estimate|||||||2015-10-06|2015-10-07|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|September 2007|Actual|2007-09-30|||||Observational|||Association of PICP Serum Marker in Patients With LVSD|Phase 1 Study of PICP Serum Marker of Myocardial Fibrosis and Diastolic Function in Patients With Systolic Dysfunction|Terminated|||45|Actual|Texas Tech University Health Sciences Center||||PI left institution; Data collected from 45 participants, but no results are available.|f||||f||||||None Retained|"~     PLEASE NOTE THAT THE INVESTIGATOR LEFT THE INSTITUION WITHOUT PROVIDING ANY INFORMATION~     REGARDING THIS PROJECT. NO FORWARDING INFORMATION IS AVAILABLE FROM THE INVESTIGATOR.~   "|||2018-06-01 04:25:59.756695|2018-06-01 04:25:59.756695
NCT00232375|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2005-09-30|2005-09-30|2005-10-04|Estimate|||||||2005-09-30|2005-10-04|Estimate|January 1996||1996-01-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Interventional|||Intervention to Preserve Beta-Cell Function in GAD Ab-Positive Diabetes||Completed||N/A|42||Tokyo Study Group|||||f||||||||||||||2018-06-01 04:25:59.810358|2018-06-01 04:25:59.810358
NCT00232362|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2015-04-09|2005-09-30|2005-10-04|Estimate|||||||2015-04-09|2015-04-13|Estimate|June 2007||2007-06-30|April 2015|2015-04-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus|Effect of Pioglitazone on Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus|Withdrawn||Phase 1|0|Actual|Texas Tech University Health Sciences Center||||This study was not conducted as the Principal Investigator left the institution|f||||||||||||||2018-06-01 04:25:59.861495|2018-06-01 04:25:59.861495
NCT00232349|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2008-07-30|2005-09-30|2005-10-04|Estimate|||||||2008-07-30|2008-07-31|Estimate|February 2005||2005-02-28|July 2008|2008-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy of Galantamine to Treat Schizophrenia|An Open-Label Trial of Adjunctive Galantamine Maintenance Therapy to Treat Functional Impairments in Chronic Outpatients With Schizophrenia|Terminated||Phase 4|21|Actual|Seattle Institute for Biomedical and Clinical Research||1||Study terminated due to no apparent benefit.|f||||t||||||||||2018-06-01 04:25:59.919063|2018-06-01 04:25:59.919063
NCT00232336|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2008-07-29|2005-09-30|2005-10-04|Estimate|||||||2008-07-29|2008-07-30|Estimate|October 2003||2003-10-31|July 2008|2008-07-31|January 2006|Actual|2006-01-31|||||Interventional|||Quetiapine for Cocaine Use and Cravings|Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence|Completed||Phase 4|42|Actual|Seattle Institute for Biomedical and Clinical Research|||||f||||f||||||||||2018-06-01 04:25:59.99098|2018-06-01 04:25:59.99098
NCT00232323|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-02|||2007-01-23|2005-10-02|2005-10-04|Estimate|||||||2007-01-23|2007-01-24|Estimate|January 2006||2006-01-31|January 2007|2007-01-31|June 2006||2006-06-30|||||Interventional|||Simulation Training as a Tool to Decrease Occupational Stress in ICU Personnel|Experimental Like Study of Stress Reduction in Intensive Care Teams by Use of Simulation Training|Suspended||N/A|40||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:00.050599|2018-06-01 04:26:00.050599
NCT00232310|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2012-05-07|2005-10-03|2005-10-04|Estimate|||||||2012-05-07|2012-05-08|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|CORYFEE||Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr|Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 300 or 600 mg for the Conversion of Atrial Fibrillation / Flutter|Completed||Phase 2|150|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:26:00.104976|2018-06-01 04:26:00.104976
NCT00232297|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2012-05-07|2005-10-03|2005-10-04|Estimate|||||||2012-05-07|2012-05-08|Estimate|June 2005||2005-06-30|May 2012|2012-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|ICARIOS||Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS|Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 100 OR 300 mg for the Prevention of Ventricular Arrhythmia-Triggered ICD Interventions|Completed||Phase 2|153|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:26:00.183046|2018-06-01 04:26:00.183046
NCT00232284|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-02|||2015-06-24|2005-10-02|2005-10-04|Estimate|||||||2015-06-24|2015-06-26|Estimate|September 2004||2004-09-30|June 2015|2015-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Treatment of Comorbid Depression and Substance Abuse in Young People|An Integrated Pharmacological and Psychological Approach to Young People With Comorbid Depression and Substance Abuse|Completed||Phase 2|60|Actual|Melbourne Health||2|||f||||f||||||||||2018-06-01 04:26:00.273853|2018-06-01 04:26:00.273853
NCT00232271|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-02|||2013-05-28|2005-10-02|2005-10-04|Estimate|||||||2013-05-28|2013-05-30|Estimate|August 2005||2005-08-31|October 2005|2005-10-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.|The Effect of Enoxaparin Sodium (Clexane) on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.|Terminated||Phase 4|35|Actual|Melbourne Health||2||Slow recruitment|f||||||||||||||2018-06-01 04:26:00.348698|2018-06-01 04:26:00.348698
NCT00232258|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2008-12-09|2005-10-03|2005-10-04|Estimate|||||||2008-12-09|2008-12-10|Estimate|April 2005||2005-04-30|December 2008|2008-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|NICE||Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study|Nolpitantium Besylate in Patients With Mild to Moderate Ulcerative Colitis, a Double-Blind, Placebo Controlled Efficacy and Safety, 8 Week Study|Completed||Phase 2|307|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:26:00.412215|2018-06-01 04:26:00.412215
NCT00232245|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-02|||2013-05-28|2005-10-02|2005-10-04|Estimate|||||||2013-05-28|2013-05-30|Estimate|December 2003||2003-12-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Use of Fish Oils to Reduce the Frequency and Duration of Episodes of Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation.||Completed||Phase 4|80|Actual|Melbourne Health||2|||f||||t||||||||||2018-06-01 04:26:00.485905|2018-06-01 04:26:00.485905
NCT00232232|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-02|||2015-05-08|2005-10-02|2005-10-04|Estimate|||||||2015-05-08|2015-05-12|Estimate|September 2003||2003-09-30|May 2015|2015-05-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia||Completed||Phase 4|100|Anticipated|Melbourne Health||2|||f||||||||||||||2018-06-01 04:26:00.551977|2018-06-01 04:26:00.551977
NCT00232219|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-02|||2015-05-04|2005-10-02|2005-10-04|Estimate|||||||2015-05-04|2015-05-05|Estimate|January 2003||2003-01-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion|Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.|Completed||Phase 4|200|Actual|Melbourne Health||2|||f||||||||||||||2018-06-01 04:26:00.613132|2018-06-01 04:26:00.613132
NCT00232206|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-05-17|2005-10-03|2005-10-04|Estimate|||||||2011-05-17|2011-05-18|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|November 2007||2007-11-30|April 2007|Actual|2007-04-30||Interventional|||Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer|A Phase II Study of Cisplatin Plus Docetaxel as Neoadjuvant Therapy for Stages IB Through Selected IIIA NSCLC|Terminated||Phase 2|40|Anticipated|Providence Health & Services||||study terminated due to slow accrual|f||||||||||||||2018-06-01 04:26:00.667605|2018-06-01 04:26:00.667605
NCT00232193|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-07-20|2005-09-30|2005-10-04|Estimate|||||||2011-07-20|2011-07-22|Estimate|December 2003||2003-12-31|July 2011|2011-07-31|August 2010|Actual|2010-08-31|December 2008|Actual|2008-12-31||Observational|||Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS|Steroid Adjunctive Treatment at Initiation of Avonex Therapy for Patients With Mono-Symptomatic or Relapsing-Remitting Multiple Sclerosis|Completed|||40|Actual|Providence Multiple Sclerosis Center|||2||f||||f||||||||||2018-06-01 04:26:00.722749|2018-06-01 04:26:00.722749
NCT00232180|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2011-05-20||2013-03-28|2005-09-30|2005-10-04|Estimate|2011-05-20|2011-06-27|Estimate||||2013-03-28|2013-04-22|Estimate|March 2006||2006-03-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|May 2010|Actual|2010-05-31||Interventional|EMPHASIS-HF||A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines|The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure|Completed||Phase 3|2743|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 04:26:01.066129|2018-06-01 04:26:01.066129
NCT00232167|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-10-01|2005-09-30|2005-10-04|Estimate|||||||2007-10-01|2007-10-02|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|April 2006||2006-04-30|||||Interventional|||Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Tolerability Of Indiplon Therapy Initiated With Sertraline Versus Sertraline Monotherapy In Subjects With Insomnia And Co-Existing Major Depressive Disorder|Terminated||Phase 3|380||Neurocrine Biosciences||||Please see Detailed Description below for termination reason.|||||f||||||||||2018-06-01 04:26:06.176264|2018-06-01 04:26:06.176264
NCT00232154|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-04-20|2005-10-03|2005-10-04|Estimate|||||||2011-04-20|2011-04-21|Estimate|November 2005||2005-11-30|April 2011|2011-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To|An Open-Label Study Of Azithromycin Pharmacokinetics In Sinus Mucosal Tissue And Plasma In Subjects With Chronic Rhinosinusitis Following A Single 2g Dose Of Azithromycin Extended Release For Oral Suspension Or Azithromycin 500mg Tablet Formulation Once Daily For A Maximum Of Three Days|Completed||Phase 2|72|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:26:06.229652|2018-06-01 04:26:06.229652
NCT00232141|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2008-11-25||2009-06-22|2005-09-30|2005-10-04|Estimate|2009-06-22|2009-08-11|Estimate||||2009-06-22|2009-08-11|Estimate|October 2005||2005-10-31|June 2009|2009-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With HIV Neuropathy.|Completed||Phase 3|302|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:26:06.426258|2018-06-01 04:26:06.426258
NCT00232128|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2007-01-11|2005-10-03|2005-10-04|Estimate|||||||2007-01-11|2007-01-12|Estimate|June 2003||2003-06-30|May 2006|2006-05-31||||||||Interventional|||Protocol for Radiofrequency Ablation of Pulmonary Neoplasms|Protocol for Radiofrequency Ablation of Pulmonary Neoplasms|Terminated||N/A|||Oncology Specialties, Alabama|||||f||||||||||||||2018-06-01 04:26:08.83526|2018-06-01 04:26:08.83526
NCT00232115|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2008-01-15|2005-10-03|2005-10-04|Estimate|||||||2008-01-15|2008-01-17|Estimate|September 2005||2005-09-30|January 2008|2008-01-31|July 2006|Actual|2006-07-31|||||Interventional|||Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis|Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis|Completed||Phase 3|124|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:26:08.897961|2018-06-01 04:26:08.897961
NCT00232102|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-01-31|2005-10-03|2005-10-04|Estimate|||||||2008-01-31|2008-02-01|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia|Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia|Completed||Phase 3|423||Novartis|||||||||||||||||||2018-06-01 04:26:08.982602|2018-06-01 04:26:08.982602
NCT00232089|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-11-16|2005-10-03|2005-10-04|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2004||2004-05-31|November 2016|2016-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia|Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia|Completed||Phase 3|1296||Novartis|||||||||||||||||||2018-06-01 04:26:09.041335|2018-06-01 04:26:09.041335
NCT00232076|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-11-01|2005-10-03|2005-10-04|Estimate|||||||2011-11-01|2011-11-02|Estimate|May 2004||2004-05-31|November 2011|2011-11-30||||March 2005|Actual|2005-03-31||Interventional|||Verification Study of Ciclosporin for Atopic Dermatitis|Verification Study of Ciclosporin for Atopic Dermatitis|Completed||Phase 3|||Novartis|||||f||||||||||||||2018-06-01 04:26:09.109736|2018-06-01 04:26:09.109736
NCT00232063|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-11-01|2005-10-03|2005-10-04|Estimate|||||||2011-11-01|2011-11-02|Estimate|May 2004||2004-05-31|November 2011|2011-11-30||||November 2005|Actual|2005-11-30||Interventional|||Long-term Study of Ciclosporin for Atopic Dermatitis|Long-term Study of Ciclosporin for Atopic Dermatitis|Completed||Phase 3|||Novartis|||||f||||||||||||||2018-06-01 04:26:09.160089|2018-06-01 04:26:09.160089
NCT00232050|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-10-24|2005-10-03|2005-10-04|Estimate|||||||2011-10-24|2011-10-25|Estimate|October 2002||2002-10-31|October 2011|2011-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study of Omalizumab in Moderate to Severe Bronchial Asthma|Study of Omalizumab in Moderate to Severe Bronchial Asthma|Completed||Phase 3|327|Actual|Novartis|||||f||||||||||||||2018-06-01 04:26:09.208761|2018-06-01 04:26:09.208761
NCT00232037|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-01-31|2005-10-03|2005-10-04|Estimate|||||||2008-01-31|2008-02-01|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia|Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia|Completed||Phase 3|359||Novartis|||||||||||||||||||2018-06-01 04:26:09.381287|2018-06-01 04:26:09.381287
NCT00232024|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-01-31|2005-10-03|2005-10-04|Estimate|||||||2008-01-31|2008-02-01|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|May 2006|Actual|2006-05-31|||||Interventional|||Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia|Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia|Completed||Phase 3|1296||Novartis|||||||||||||||||||2018-06-01 04:26:09.441129|2018-06-01 04:26:09.441129
NCT00232011|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2007-12-13|2005-10-03|2005-10-04|Estimate|||||||2007-12-13|2007-12-17|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|May 2005|Actual|2005-05-31|||||Interventional|||Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis|A Clinical Study Continued From the Confirmatory Study to Assess the Efficacy and Safety of ASM981 Cream in Adult Atopic Dermatitis Patients|Completed||Phase 3|160||Novartis||1|||f||||||||||||||2018-06-01 04:26:09.499198|2018-06-01 04:26:09.499198
NCT00231998|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2007-12-13|2005-10-03|2005-10-04|Estimate|||||||2007-12-13|2007-12-17|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|June 2005|Actual|2005-06-30|||||Interventional|||Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis|A Clinical Study Continued From the Confirmatory Study to Validate the Efficacy and Safety of Pimecrolimus Cream in Pediatric Atopic Dermatitis Patients|Completed||Phase 3|240||Novartis||1|||f||||||||||||||2018-06-01 04:26:09.566299|2018-06-01 04:26:09.566299
NCT00231985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2012-02-08|2005-09-30|2005-10-04|Estimate|||||||2012-02-08|2012-02-09|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder|Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder|Completed||Phase 2|122|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 04:26:09.63907|2018-06-01 04:26:09.63907
NCT00231972|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-04-07|2005-09-30|2005-10-04|Estimate|||||||2011-04-07|2011-04-08|Estimate|December 2003||2003-12-31|February 2011|2011-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|Enhance||Enhancing HIV Prevention by Using Behavioral Intervention Among HIV-Infected Men|Enhancing HIV Prevention Among HIV Infected Men|Completed||N/A|201|Actual|Fenway Community Health||2|||f||||f||||||||||2018-06-01 04:26:09.740384|2018-06-01 04:26:09.740384
NCT00231959|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2012-04-25|2005-09-30|2005-10-04|Estimate|||||||2012-04-25|2012-04-26|Estimate|September 2003||2003-09-30|April 2012|2012-04-30|April 2008|Actual|2008-04-30|September 2007|Actual|2007-09-30||Interventional|||Effectiveness of Pramipexole for Treatment-Resistant Depression|A Double-Blind Placebo-Controlled Trial of Adjunctive Pramipexole, a Dopamine Receptor Agonist, for Treatment Resistant Major Depressive Episodes|Completed||Phase 4|65|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:26:09.812354|2018-06-01 04:26:09.812354
NCT00231946|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-09-18|2005-09-30|2005-10-04|Estimate|||||||2007-09-18|2007-09-20|Estimate|September 2005||2005-09-30|September 2007|2007-09-30||||||||Interventional|||ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)|A Double-Blind Placebo-Controlled Study of VP4896 For the Treatment of Mild-to-Moderate Alzheimer's Disease|Completed||Phase 3|555||National Institute on Aging (NIA)|||||||||||||||||||2018-06-01 04:26:09.975845|2018-06-01 04:26:09.975845
NCT00231933|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2012-04-09|2005-09-30|2005-10-04|Estimate|||||||2012-04-09|2012-04-11|Estimate|October 2005||2005-10-31|April 2012|2012-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Culturally Responsive Person-Centered Care for Psychosis|Culturally-responsive, Person-centered Care for Psychosis|Completed||Phase 1|290|Actual|Yale University||3|||f||||f||||||||||2018-06-01 04:26:10.12998|2018-06-01 04:26:10.12998
NCT00231920|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-08-11|2005-09-30|2005-10-04|Estimate|||||||2011-08-11|2011-08-12|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|October 2006||2006-10-31|August 2006|Actual|2006-08-31||Interventional|||Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age|Prospective Pilot Safety Study Administering Two Doses of Inactivated Influenza Vaccine to Infants 10-22 Weeks of Age|Completed||Phase 1|23|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:26:10.204469|2018-06-01 04:26:10.204469
NCT00231907|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2010-08-26|2005-09-30|2005-10-04|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2005||2005-09-30|February 2010|2010-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist|Influenza Vaccines: Mix and Match of Trivalent Inactivated Influenza (TIV) and Live Attenuated Influenza Vaccine (LAIV), a Phase I Safety, Immunogenicity, and Viral Shedding Study|Completed||Phase 1|56|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:26:10.259417|2018-06-01 04:26:10.259417
NCT00231725|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-06-26|2005-09-30|2005-10-04|Estimate|||||||2007-06-26|2007-06-27|Estimate|September 2005||2005-09-30|June 2007|2007-06-30|April 2006|Actual|2006-04-30|||||Interventional|||Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin|Complaints Associated With Use of Pre-Filled Pen B When Used by Patients With Type 2 Diabetes on Twice-Daily Insulin Therapy|Completed||Phase 3|370||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:26:12.479026|2018-06-01 04:26:12.479026
NCT00231894|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2016-12-15||2017-11-09|2005-10-03|2005-10-04|Estimate|2017-11-09|2017-12-11|Actual||||2017-11-09|2017-12-11|Actual|May 2005||2005-05-31|November 2017|2017-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia|Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function|Completed||Phase 4|56|Actual|Nathan Kline Institute for Psychiatric Research|Sufficient RBANS data at baseline and 3 months followup for China sample was not available for analysis. Subjects failed to complete scales or complete scales with sufficient data.|2|||f||||f|t|f|||f|||No||2018-06-01 04:26:10.339483|2018-06-01 04:26:10.339483
NCT00231881|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2007-04-27|2005-10-03|2005-10-04|Estimate|||||||2007-04-27|2007-04-30|Estimate||||April 2007|2007-04-30||||||||Observational|||Functional and Molecular Characterisation of Oesophageal Distal Epithelium: Correlations With Acid and Non Acid Reflux|Functional and Molecular Characterisation of Oesophageal Distal Epithelium: Correlations With Acid and Non Acid Reflux|Unknown status|Recruiting||60|Anticipated|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:26:10.842366|2018-06-01 04:26:10.842366
NCT00231868|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2012-04-22|2005-10-03|2005-10-04|Estimate|||||||2012-04-22|2012-04-24|Estimate|December 2001||2001-12-31|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma|"A Pilot Phase II Trial of Radiation Therapy Sandwiched Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma"|Completed||Phase 2|81|Actual|Montefiore Medical Center||1|||f||||t||||||||||2018-06-01 04:26:10.910134|2018-06-01 04:26:10.910134
NCT00231855|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2012-04-22|2005-09-30|2005-10-04|Estimate|||||||2012-04-22|2012-04-24|Estimate|November 2004||2004-11-30|April 2012|2012-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers|Phase II Trial- Weekly Taxotere and Topotecan for Recurrent Ovarian, Primary Peritoneal, Endometrial and Uterine Cancers|Completed||Phase 2|31||Montefiore Medical Center|||||f||||t||||||||||2018-06-01 04:26:10.981944|2018-06-01 04:26:10.981944
NCT00231842|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2012-04-22|2005-10-03|2005-10-04|Estimate|||||||2012-04-22|2012-04-24|Estimate|February 2003||2003-02-28|April 2012|2012-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Phase II Trial of Adjuvant Radiation Therapy With Ifosfamide in Patients With MMT of the Uterus|"A Pilot Phase II Trial of Adjuvant Radiation Therapy Sandwiched Between Ifosfamide in Patients With Mixed Mesodermal Tumors"|Completed||Phase 2|27|Actual|Montefiore Medical Center||1|||f||||t||||||||||2018-06-01 04:26:11.065492|2018-06-01 04:26:11.065492
NCT00231829|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2012-04-22|2005-09-30|2005-10-04|Estimate|||||||2012-04-22|2012-04-24|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers|A Pilot Phase II Trial of Celecoxib in Patients With Grade 2 or 3 Endometrioid-type, Clear Cell, and Papillary Serous Uterine Cancers|Terminated||Phase 2|23||Montefiore Medical Center||||Due to reported toxicity of Celecoxib at high doses|f||||t||||||||||2018-06-01 04:26:11.138584|2018-06-01 04:26:11.138584
NCT00231816|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2010-05-12||2015-09-02|2005-09-30|2005-10-04|Estimate|2010-11-17|2010-12-15|Estimate||||2015-09-02|2015-09-21|Estimate|September 2005||2005-09-30|September 2015|2015-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)|A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V211 Administered Concomitantly Versus Nonconcomitantly With Influenza Virus Vaccine (Inactivated)|Completed||Phase 3|763|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:26:11.220621|2018-06-01 04:26:11.220621
NCT00231803|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2005-10-06|2005-10-03|2005-10-04|Estimate|||||||2005-10-06|2005-10-10|Estimate|April 2005||2005-04-30|October 2005|2005-10-31|December 2007||2007-12-31|||||Interventional|||The Canadian Prevention of Renal and Cardiovascular Endpoints Trial|Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial|Unknown status|Recruiting|Phase 4|500||Memorial University of Newfoundland|||||f||||||||||||||2018-06-01 04:26:11.702626|2018-06-01 04:26:11.702626
NCT00231790|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2015-12-16|2005-09-30|2005-10-04|Estimate|||||||2015-12-16|2015-12-17|Estimate|August 2005||2005-08-31|December 2015|2015-12-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of MK0634 in Postmenopausal Women With Overactive Bladder|Completed||Phase 2|848|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 04:26:11.793143|2018-06-01 04:26:11.793143
NCT00231777|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2010-05-10||2015-08-18|2005-09-30|2005-10-04|Estimate|2010-05-10|2010-06-08|Estimate||||2015-08-18|2015-08-19|Estimate|July 2005||2005-07-31|August 2015|2015-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)|A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety and Tolerability of IV MK0517 for the Prevention of Postoperative Nausea and Vomiting (PONV)|Completed||Phase 3|216|Actual|Merck Sharp & Dohme Corp.|The formulation of MK0517 used in this study was a non polysorbate (PS80) formulation which was not further developed and is not available for use.|2|||f||||f||||||||||2018-06-01 04:26:11.894765|2018-06-01 04:26:11.894765
NCT00231764|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2008-04-22|2005-09-30|2005-10-04|Estimate|||||||2008-04-22|2008-04-24|Estimate|November 2002||2002-11-30|April 2008|2008-04-30|February 2008|Actual|2008-02-29|May 2006|Actual|2006-05-31||Interventional|||MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients|Evaluating Safety and Efficacy of MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Combination With Low-Dose CsA, Tac or Sir in Comparison to Current Standard Immunosuppression (MMF, CsA and Corticosteroids) in Renal Tx|Completed||Phase 4|1760||Ekberg, Henrik, M.D.|||||f||||||||||||||2018-06-01 04:26:12.329128|2018-06-01 04:26:12.329128
NCT00231751|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2005-09-30|2005-09-30|2005-10-04|Estimate|||||||2005-09-30|2005-10-04|Estimate|November 2002||2002-11-30|September 2005|2005-09-30|June 2004||2004-06-30|||||Observational|||The Malmö International Brother Study (MIBS)|The Malmö International Brother Study (MIBS)|Completed|||||Skane University Hospital|||||f||||||||||||||2018-06-01 04:26:12.377309|2018-06-01 04:26:12.377309
NCT00231738|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2015-11-19|2005-10-03|2005-10-04|Estimate|||||||2015-11-19|2015-11-20|Estimate|November 1996||1996-11-30|October 2005|2005-10-31|November 2004||2004-11-30|||||Interventional|||Protective Effect of EPA on Cardiovascular Events|Effect of Eicosapentaenoic Acid (EPA) on Major Cardiovascular Events in Hypercholesterolemic Patients: the Japan EPA Lipid Intervention Study (JELIS)|Completed||Phase 4|18000||Kobe University|||||f||||||||||||||2018-06-01 04:26:12.422274|2018-06-01 04:26:12.422274
NCT00231712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2006-08-22|2005-09-30|2005-10-04|Estimate|||||||2006-08-22|2006-08-23|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|February 2009||2009-02-28|||||Observational|||Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant|Prospective Analysis of the Patterns of Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Autologous/Allogeneic Stem Cell Transplant|Unknown status|Recruiting||50||Julius-Maximilians University|||||f||||||||||||||2018-06-01 04:26:12.537316|2018-06-01 04:26:12.537316
NCT00231699|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2005-10-03|2005-10-03|2005-10-04|Estimate|||||||2005-10-03|2005-10-04|Estimate|January 2004||2004-01-31|October 2005|2005-10-31|December 2004||2004-12-31|||||Interventional|||A Comparison of Prevention of Hypothermia in Pediatric Patient Between Wrapping With Cotton and Plastic.|A Comparison of Prevention of Hypothermia in Pediatric Patient Between Wrapping With Cotton (Webril) and Plastic (Mwrap).|Completed||N/A|42||Khon Kaen University|||||f||||||||||||||2018-06-01 04:26:12.602094|2018-06-01 04:26:12.602094
NCT00231686|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2005-09-30|2005-09-30|2005-10-04|Estimate|||||||2005-09-30|2005-10-04|Estimate|November 2000||2000-11-30|September 2005|2005-09-30|May 2003||2003-05-31|||||Interventional|||Effects of a 6-Months Physical Conditioning Program in Patients With Cystic Fibrosis|Effects of a 6-Months Physical Conditioning Program on Health Status and Physical Activity in Youths and Young Adults With Cystic Fibrosis - MUKOTRAIN|Completed||Phase 2/Phase 3|80||Julius-Maximilians University|||||f||||||||||||||2018-06-01 04:26:12.656599|2018-06-01 04:26:12.656599
NCT00231673|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-09-30|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 2001||2001-07-31|April 2011|2011-04-30|January 2003|Actual|2003-01-31|||||Interventional|||A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy|A Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Topiramate on Electrophysiological Parameters in Subjects With Diabetic Peripheral Polyneuropathy|Completed||Phase 2|72|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||||||||||||2018-06-01 04:26:12.862413|2018-06-01 04:26:12.862413
NCT00231660|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-10-03|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2000||2000-10-31|January 2011|2011-01-31|June 2002|Actual|2002-06-30|||||Interventional|||A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Treated With Metformin|Completed||Phase 3|211|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:26:12.921159|2018-06-01 04:26:12.921159
NCT00231647|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-09-30|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|February 2004||2004-02-29|January 2011|2011-01-31|October 2004|Actual|2004-10-31|||||Interventional|||A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Assess the Efficacy and Safety of Topiramate OROS Controlled-Release in the Treatment of Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin|Completed||Phase 2|113|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:26:12.974613|2018-06-01 04:26:12.974613
NCT00231634|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-09-30|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2001||2001-05-31|January 2011|2011-01-31|November 2002|Actual|2002-11-30|||||Interventional|||A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy|Terminated||Phase 3|31|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||Program discontinued|f||||f||||||||||2018-06-01 04:26:13.046551|2018-06-01 04:26:13.046551
NCT00231621|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-09-30|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|May 2001||2001-05-31|April 2010|2010-04-30|June 2002|Actual|2002-06-30|||||Interventional|||A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, One-year Study of the Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Dyslipidemia|Terminated||Phase 3|179|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"The study was terminated prior to completion to focus on the development of a controlled~   release formulation."|f||||f||||||||||2018-06-01 04:26:13.100754|2018-06-01 04:26:13.100754
NCT00231608|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-09-30|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 1998||1998-12-31|April 2010|2010-04-30|January 2002|Actual|2002-01-31|||||Interventional|||A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity|The Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity: A 6-Month Double-Blind, Randomized, Placebo-Controlled Study With a 6-Month Open-Label Extension|Completed||Phase 2|68|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:26:13.154949|2018-06-01 04:26:13.154949
NCT00231595|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2010-11-18|2005-09-30|2005-10-04|Estimate|||||||2010-11-18|2010-11-19|Estimate|March 2001||2001-03-31|November 2010|2010-11-30|November 2002|Actual|2002-11-30|||||Interventional|||A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine|Completed||Phase 3|768|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:26:13.213128|2018-06-01 04:26:13.213128
NCT00231582|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-02-24|2005-10-03|2005-10-04|Estimate|||||||2011-02-24|2011-02-25|Estimate|September 2004||2004-09-30|March 2007|2007-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II|Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation|Completed||Phase 2|50|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:26:13.270798|2018-06-01 04:26:13.270798
NCT00231569|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2016-08-01|2005-10-03|2005-10-04|Estimate|||||||2016-08-01|2016-08-03|Estimate|September 2005||2005-09-30|December 2013|2013-12-31|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Dose-escalating Safety Study in Subjects on Stable Statin Therapy|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose‑Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy|Completed||Phase 2|74|Actual|Kastle Therapeutics, LLC||7|||f||||t||||||||||2018-06-01 04:26:13.42803|2018-06-01 04:26:13.42803
NCT00230425|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2006-10-10|2005-09-28|2005-09-30|Estimate|||||||2006-10-10|2006-10-11|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|June 2004||2004-06-30|||||Observational|||The Measurement of Mood Variability and Sustained Attention in Women With Alcohol Dependence.|The Measurement of Mood Variability and Sustained Attention in Women With Alcohol Dependence.|Completed|||30||University of Saskatchewan|||||f||||||||||||||2018-06-01 04:26:25.268442|2018-06-01 04:26:25.268442
NCT00231556|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-09-30|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 1999||1999-07-31|January 2010|2010-01-31|September 2003|Actual|2003-09-30|||||Interventional|||A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy|A Randomized, Double-Blind, Parallel-Group, Monotherapy Study to Compare the Safety and Efficacy of Two Doses of Topiramate in the Treatment of Newly Diagnosed or Recurrent Epilepsy|Completed||Phase 3|750|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:26:13.51505|2018-06-01 04:26:13.51505
NCT00231543|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2006-10-11|2005-10-03|2005-10-04|Estimate|||||||2006-10-11|2006-10-12|Estimate||||October 2005|2005-10-31||||||||Interventional|||Laparoscopy in Children: Does it Decrease the Metabolic, Endocrine and Inflammatory Stress Response to Surgery||Completed||N/A|||Institute of Child Health|||||f||||||||||||||2018-06-01 04:26:13.574734|2018-06-01 04:26:13.574734
NCT00231530|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-06|2005-09-30|2005-10-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 2001||2001-01-31|April 2010|2010-04-30|May 2002|Actual|2002-05-31|||||Interventional|||A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients on a Controlled Diet|Completed||Phase 3|541|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:26:13.632918|2018-06-01 04:26:13.632918
NCT00231517|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2006-10-11|2005-10-03|2005-10-04|Estimate|||||||2006-10-11|2006-10-12|Estimate||||October 2005|2005-10-31||||||||Interventional|||Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa||Completed||Phase 4|||Institute of Child Health|||||f||||||||||||||2018-06-01 04:26:13.702807|2018-06-01 04:26:13.702807
NCT00231504|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2010-01-05|2005-10-03|2005-10-04|Estimate|||||||2010-01-05|2010-01-06|Estimate|October 2005||2005-10-31|March 2007|2007-03-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Observational|||Study of Follicle Stimulating Hormone (FSH) Receptor in Women With Low Antral Follicle Count|Study of Follicle Stimulating Hormone (FSH) Receptor in Women With Low Antral Follicle Count|Completed|||82|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     DNA~   "|||2018-06-01 04:26:13.756418|2018-06-01 04:26:13.756418
NCT00231491|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2011-02-16|2005-10-03|2005-10-04|Estimate|||||||2011-02-16|2011-02-17|Estimate|November 2005||2005-11-30|March 2007|2007-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder.|Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder (OAB). A Multicenter Phase II, Randomized, Double-blind, Placebo Controlled 6 Month Study . VESITOX|Completed||Phase 2|160|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:26:13.812204|2018-06-01 04:26:13.812204
NCT00231478|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2011-03-30||2018-02-26|2005-09-30|2005-10-04|Estimate|2011-03-30|2011-04-28|Estimate||||2018-02-26|2018-03-27|Actual|April 2007||2007-04-30|February 2018|2018-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy|A Randomized, Double-blind Study of 2 Dose Levels of Kytril on the Prevention of Post-operative Nausea and Vomiting in Pediatric Patients Undergoing Surgery With General Anesthesia|Completed||Phase 4|171|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:26:13.902532|2018-06-01 04:26:13.902532
NCT00231465|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2012-11-01||2017-01-20|2005-10-03|2005-10-04|Estimate|2012-11-01|2012-11-30|Estimate||||2017-01-20|2017-03-03|Actual|July 2003||2003-07-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer|Phase II Study of Taxotere® (Docetaxel) + ZD1839 (IRESSA®) in Previously Untreated Elderly Patients (≥70 Years Old) With Stage III-b (With Malignant Pleural Effusion [MPE+]) or Stage IV Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|44|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 04:26:14.154818|2018-06-01 04:26:14.154818
NCT00231452|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-10-27|2005-09-30|2005-10-04|Estimate|||||||2011-10-27|2011-10-28|Estimate|September 2005||2005-09-30|October 2011|2011-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Age of Exposure and Immunity to Malaria in Infants|Age of Exposure and Immunity to Malaria in Infants|Completed||N/A|349|Actual|Hospital Clinic of Barcelona||3|||f||||t||||||||||2018-06-01 04:26:14.378317|2018-06-01 04:26:14.378317
NCT00231439|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2005-12-12|2005-09-30|2005-10-04|Estimate|||||||2005-12-12|2005-12-13|Estimate|August 2003||2003-08-31|July 2003|2003-07-31|July 2004||2004-07-31|||||Interventional|||Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)|Post-Polio Syndrome Treated With Intravenous Immunoglobulin (IvIg)|Completed||Phase 2/Phase 3|40||Haukeland University Hospital|||||f||||||||||||||2018-06-01 04:26:14.44446|2018-06-01 04:26:14.44446
NCT00231426|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2006-11-20|2005-09-30|2005-10-04|Estimate|||||||2006-11-20|2006-11-22|Estimate|June 2003||2003-06-30|November 2006|2006-11-30|November 2005||2005-11-30|||||Interventional|||ASSURE Study - Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICD Implantations|Arrhythmia Single Shock DFT Versus ULV: Risk Reduction Evaluation With ICDs Study|Completed||Phase 4|||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:26:14.498192|2018-06-01 04:26:14.498192
NCT00231413|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2016-09-22|2005-10-03|2005-10-04|Estimate|||||||2016-09-22|2016-09-23|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.|A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)|Completed||Phase 2|383|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:26:14.554259|2018-06-01 04:26:14.554259
NCT00231400|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2017-08-10|2005-09-30|2005-10-04|Estimate|||||||2017-08-10|2017-08-14|Actual|August 21, 2004|Actual|2004-08-21|August 2017|2017-08-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Observational|||Pompe Disease Registry|Pompe Disease Registry|Recruiting|||2000|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 04:26:14.669305|2018-06-01 04:26:14.669305
NCT00231387|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2017-01-20|2005-10-03|2005-10-04|Estimate|||||||2017-01-20|2017-01-23|Estimate|September 2002|Actual|2002-09-30|January 2017|2017-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus|Rosiglitazone and Plaque Study: A 12 Month Randomised, Double-blind, Placebo-controlled, Magnetic Resonance Imaging Study to Evaluate the Effect of Rosiglitazone on the Structure and Composition of Carotid Atherosclerotic Plaques in Subjects With Type 2 Diabetes Mellitus and Coexisting Vascular Disease or Hypertension|Completed||Phase 3|60||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:26:14.778987|2018-06-01 04:26:14.778987
NCT00231374|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2014-01-08|2005-10-03|2005-10-04|Estimate|||||||2014-01-08|2014-01-09|Estimate|September 2005||2005-09-30|January 2014|2014-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Measure of Cerebrospinal Fluid (CSF) Pressure Variation With Patient Positioning|In Vivo Analysis of Intradural Pressure Variation With Patient Positioning|Withdrawn||N/A|0|Actual|Emory University||||Difficulty in recruiting patients for the study.|f||||||||||||||2018-06-01 04:26:14.95426|2018-06-01 04:26:14.95426
NCT00231348|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2013-11-08|2005-10-03|2005-10-04|Estimate|||||||2013-11-08|2013-11-13|Estimate||||November 2013|2013-11-30|April 2000|Actual|2000-04-30|||||Interventional|||Nefazodone in the Treatment of Social Phobia|Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates|Completed||Phase 4|24||Emory University|||||f||||||||||||||2018-06-01 04:26:15.012153|2018-06-01 04:26:15.012153
NCT00231335|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2010-12-06|2005-10-03|2005-10-04|Estimate|||||||2010-12-06|2010-12-07|Estimate|March 2006||2006-03-31|March 2006|2006-03-31|July 2007|Actual|2007-07-31|||||Interventional|||Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia|The Efficacy and Safety of Escitalopram Augmentation of Risperidone and Olanzapine in Treatment Resistant Schizophrenia: a Double Blind Placebo Controlled Pilot Study|Completed||Phase 4|30|Anticipated|Emory University|||||f||||||||||||||2018-06-01 04:26:15.086575|2018-06-01 04:26:15.086575
NCT00231322|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-04-19|2005-09-30|2005-10-04|Estimate|||||||2007-04-19|2007-04-20|Estimate|March 2004||2004-03-31|April 2007|2007-04-30|March 2006||2006-03-31|||||Interventional|||Influence of Transmission Season on Outcome of Treatment of Schistosoma Haematobium Infection in Mozambique|The Influence of Transmission Season on Outcome of Schistosoma Haematobium Infection Treatment Among School Children in Urban and Peri-Urban Areas of Maputo and Matola, Mozambique|Completed||N/A|520||DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 04:26:15.147821|2018-06-01 04:26:15.147821
NCT00231309|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2013-08-14||2014-08-19|2005-10-03|2005-10-04|Estimate|2014-07-31|2014-08-19|Estimate||||2014-08-19|2014-08-22|Estimate|July 2003||2003-07-31|August 2014|2014-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)|Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies|Completed||N/A|10|Actual|Emory University|Our study is also limited by its small patient population and short follow-up time.|1|||f||||t||||||||||2018-06-01 04:26:15.21586|2018-06-01 04:26:15.21586
NCT00231296|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2017-05-02|2005-09-30|2005-10-04|Estimate|||||||2017-05-02|2017-05-04|Actual|November 2004|Actual|2004-11-30|May 2017|2017-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety and Efficacy of CryoCor™ Cryoablation for PAF|A Clinical Study to Evaluate the Safety and Efficacy of the CryoCor(TM)Cardiac Cryoablation System for the Treatment of Paroxysmal Atrial Fibrillation|Completed||N/A|174|Actual|Boston Scientific Corporation||2|||f||||f|f|t|t|f||||No||2018-06-01 04:26:15.373667|2018-06-01 04:26:15.373667
NCT00231283|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2008-11-18||2010-04-13|2005-09-30|2005-10-04|Estimate|2010-03-11|2010-03-23|Estimate||||2010-04-13|2010-04-20|Estimate|April 2004||2004-04-30|April 2010|2010-04-30|July 2005|Actual|2005-07-31|||||Interventional|||NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions|A Multicenter, Non-Randomized Study of the CYPHER NxT Sirolimus-Eluting Coronary Stent on BX SONIC OVER-THE-WIRE (OTW) Stent Delivery System(SDS)for the Treatment of de Novo Native Coronary Artery Lesions|Completed||Phase 3|100|Actual|Cordis Corporation||1|||f||||f||||||||||2018-06-01 04:26:15.542319|2018-06-01 04:26:15.542319
NCT00231270|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2008-04-17|2005-10-03|2005-10-04|Estimate|||||||2008-04-17|2008-04-24|Estimate|August 2000||2000-08-31|July 2007|2007-07-31|August 2005|Actual|2005-08-31|||||Interventional|||Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE)|Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy|Completed||Phase 3|1300||Cordis Corporation|||||f||||t||||||||||2018-06-01 04:26:15.777974|2018-06-01 04:26:15.777974
NCT00231257|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30||2009-11-17|2009-11-17|2005-09-30|2005-10-04|Estimate||||2009-11-17|2009-11-19|Estimate|2009-11-17|2009-11-19|Estimate|February 2003||2003-02-28|November 2009|2009-11-30|September 2009|Actual|2009-09-30|January 2005|Actual|2005-01-31||Interventional|||Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)|A Multicenter, Randomized Study of the Sirolimus-Eluting Bx VELOCITY® BALLOON Expandable Stent vs. Intravascular Brachytherapy in the Treatment of Patients With In-Stent Restenotic Coronary Artery Lesions|Completed||Phase 3|384|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:26:15.846882|2018-06-01 04:26:15.846882
NCT00231244|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2009-12-04|2005-10-03|2005-10-04|Estimate|||||||2009-12-04|2009-12-07|Estimate|March 2002||2002-03-31|December 2009|2009-12-31|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE)|Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry|Completed||Phase 3|252|Actual|Cordis Corporation||1|||f||||f||||||||||2018-06-01 04:26:15.931139|2018-06-01 04:26:15.931139
NCT00231231|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-07-19|2005-09-30|2005-10-04|Estimate|||||||2007-07-19|2007-07-20|Estimate|September 2004||2004-09-30|July 2007|2007-07-31|November 2006|Actual|2006-11-30|||||Interventional|||Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)|Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)|Completed||Phase 3|1500||Cordis Corporation|||||f||||t||||||||||2018-06-01 04:26:16.001006|2018-06-01 04:26:16.001006
NCT00231218|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2006-12-13|2005-09-30|2005-10-04|Estimate|||||||2006-12-13|2006-12-14|Estimate|January 2006||2006-01-31|December 2006|2006-12-31|March 2006||2006-03-31|||||Interventional|||Echinacea, Propolis and Vitamin C for URI Prevention in Preschoolers|the Effectiveness of Echinacea, Propolis and Vitamin C in the Prevention of Respiratory Tract Infections and Gastroenteritis in Preschool Age Children: a Prospective Study|Completed||Phase 3|104||The Cleveland Clinic|||||f||||||||||||||2018-06-01 04:26:16.066198|2018-06-01 04:26:16.066198
NCT00231205|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2005-09-30|2005-09-30|2005-10-04|Estimate|||||||2005-09-30|2005-10-04|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|December 2009||2009-12-31|||||Observational|||TDI Preejection Velocities and Myocardial Viability|TDI-Derived Myocardial Preejection Velocities in Patients With Chronic Ischemic Left Ventricular Dysfunction Undergoing Surgical Revascularization|Unknown status|Recruiting||200||Charles University, Czech Republic|||||f||||||||||||||2018-06-01 04:26:16.127327|2018-06-01 04:26:16.127327
NCT00231192|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2015-03-11|2005-10-03|2005-10-04|Estimate|||||||2015-03-11|2015-03-12|Estimate|October 2005||2005-10-31|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes|Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes|Withdrawn||N/A|0|Actual|Children's Hospital of Philadelphia||||Unable to recruit any subjects|f||||t||||||||||2018-06-01 04:26:16.195741|2018-06-01 04:26:16.195741
NCT00229866|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-05|2005-09-28|2005-09-30|Estimate|||||||2011-07-05|2011-07-06|Estimate|August 2005||2005-08-31|July 2011|2011-07-31|June 2006|Actual|2006-06-30|||||Observational|||Feeding After Neonate Surgery Review|Feeding After Neonatal Surgery Chart Review|Terminated|||90|Actual|Children's Healthcare of Atlanta||||sufficient data gathered for study conclusion|f||||f||||||||||2018-06-01 04:26:32.518191|2018-06-01 04:26:32.518191
NCT00231179|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2010-03-01||2015-10-26|2005-09-30|2005-10-04|Estimate|2010-06-01|2010-07-02|Estimate||||2015-10-26|2015-11-23|Estimate|February 2004||2004-02-29|October 2015|2015-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|MOM Program||The MOM Program: 5 Year Follow-up Study of a Home Visiting Program at The Children's Hospital of Philadelphia|The MOM Program Continuation - 5 Year Follow-up|Completed||Phase 3|302|Actual|Children's Hospital of Philadelphia|The initial high rate of refusal to participate in the study may affect the generalizability of our results. Those who refused study participation were older and did not elaborate on their lack of interest.|2|||f||||f||||||||||2018-06-01 04:26:16.274483|2018-06-01 04:26:16.274483
NCT00231166|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2017-03-27|2005-09-30|2005-10-04|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2005||2005-09-30|March 2017|2017-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma|A Phase I, Dose-finding Trial of HCD122, an Anti-CD40 Monoclonal Antibody, in Patients With Multiple Myeloma That is Relapsed or Has Not Responded to Prior Therapy (CHIR1212-C12101)|Completed||Phase 2|33|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:26:16.506608|2018-06-01 04:26:16.506608
NCT00231153|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|2009-06-30||2009-06-30|2005-10-03|2005-10-04|Estimate|2009-06-30|2009-08-13|Estimate||||2009-06-30|2009-08-13|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters|A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Omiganan 1% Gel in Preventing Local Catheter Site Infections/Colonization in Patients Undergoing Central Venous Catheterization|Completed||Phase 3|1859|Actual|Mallinckrodt||2|||f||||f||||||||||2018-06-01 04:26:16.589038|2018-06-01 04:26:16.589038
NCT00231140|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2007-01-18|2005-09-30|2005-10-04|Estimate|||||||2007-01-18|2007-01-19|Estimate|December 2005||2005-12-31|January 2007|2007-01-31|August 2006||2006-08-31|||||Interventional|||Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)|Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)|Terminated||Phase 2|40||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:26:16.993746|2018-06-01 04:26:16.993746
NCT00231127|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-03|||2009-11-09|2005-10-03|2005-10-04|Estimate|||||||2009-11-09|2009-11-10|Estimate|April 2005||2005-04-30|November 2009|2009-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Osteoporosis and Chronic Obstructive Pulmonary Disease (COPD)|Osteoporosis and COPD (Making of a Database)|Completed|||250|Anticipated|Catharina Ziekenhuis Eindhoven|||||f||||f||||||||||2018-06-01 04:26:17.061285|2018-06-01 04:26:17.061285
NCT00231114|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2010-08-31|2010-02-10|2017-06-29|2005-09-30|2005-10-04|Estimate|2010-10-28|2010-11-29|Estimate|2010-02-10|2010-02-12|Estimate|2017-06-29|2017-07-27|Actual|September 2005||2005-09-30|March 2014|2014-03-31|April 2013|Actual|2013-04-30|August 2008|Actual|2008-08-31||Interventional|||Asthma Intervention Research 2 (AIR2) Trial|Safety and Effectiveness of the Alair® System for the Treatment of Asthma: A Multicenter Randomized Clinical Trial(Asthma Intervention Research (AIR2) Trial)|Completed||N/A|297|Actual|Boston Scientific Corporation||2|||f||||t||||||||Undecided||2018-06-01 04:26:17.1597|2018-06-01 04:26:17.1597
NCT00231101|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2006-10-16|2005-09-30|2005-10-04|Estimate|||||||2006-10-16|2006-10-17|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia|Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia|Unknown status|Recruiting|N/A|40||Arthur P. Noyes Research Foundation|||||f||||||||||||||2018-06-01 04:26:17.745732|2018-06-01 04:26:17.745732
NCT00231075|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2005-11-02|2005-09-30|2005-10-04|Estimate|||||||2005-11-02|2005-11-03|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|May 2007||2007-05-31|||||Interventional|||Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV|National, Phase II Study Designed to Evaluate the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III and IV. FAG-2|Completed||Phase 2|75||ARCAGY/ GINECO GROUP|||||f||||||||||||||2018-06-01 04:26:17.806192|2018-06-01 04:26:17.806192
NCT00231062|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2011-04-29||2011-06-10|2005-09-30|2005-10-04|Estimate|2011-06-10|2011-07-08|Estimate||||2011-06-10|2011-07-08|Estimate|April 2005||2005-04-30|June 2011|2011-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)|Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)|Completed||Phase 3|115|Actual|Acclarent|||||f||||t||||||||||2018-06-01 04:26:17.863551|2018-06-01 04:26:17.863551
NCT00231049|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2008-10-24|2005-09-30|2005-10-04|Estimate|||||||2008-10-24|2008-10-27|Estimate|March 2006||2006-03-31|October 2008|2008-10-31||||||||Interventional|||Trial Evaluating Safety, Tolerability and Immune Response of AG-707|A Phase 1 Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Compared to Placebo in HSV-2 Seropositive Patients|Completed||Phase 1|35|Actual|Agenus Inc.|||||f||||||||||||||2018-06-01 04:26:17.996694|2018-06-01 04:26:17.996694
NCT00231023|ClinicalTrials.gov processed this data on May 31, 2018|2005-10-02|||2008-03-03|2005-10-01|2005-10-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2005||2005-09-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema|Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema|Completed||Phase 2|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:26:19.037988|2018-06-01 04:26:19.037988
NCT00231010|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2018-04-04|2005-09-30|2005-10-03|Estimate|||||||2018-04-04|2018-04-05|Actual|September 26, 2005||2005-09-26|June 23, 2016|2016-06-23|June 23, 2016||2016-06-23|||||Observational|||Molecular Genetics of Retinal Degenerations|Molecular Genetics of Retinal Degenerations|Completed|||3549|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:26:19.098403|2018-06-01 04:26:19.098403
NCT00230997|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2005-12-15|2005-09-29|2005-10-03|Estimate|||||||2005-12-15|2005-12-16|Estimate|December 2002||2002-12-31|September 2005|2005-09-30|August 2004||2004-08-31|||||Interventional|||Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies|An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies|Completed||Phase 3|50||Neurological Research Center|||||f||||||||||||||2018-06-01 04:26:19.168374|2018-06-01 04:26:19.168374
NCT00230984|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2009-07-07|2005-09-30|2005-10-03|Estimate|||||||2009-07-07|2009-07-08|Estimate|April 2003||2003-04-30|July 2006|2006-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||IRAD2 : Patients With Respiratory Failure at Home|Effects of Home Pulmonary Rehabilitation in Patients With Chronic Respiratory Failure and Nutritional Depletion.|Completed||Phase 3|200||University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:26:19.252934|2018-06-01 04:26:19.252934
NCT00229853|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-05|2005-09-28|2005-09-30|Estimate|||||||2011-07-05|2011-07-06|Estimate|August 2004||2004-08-31|July 2011|2011-07-31|July 2007|Actual|2007-07-31|||||Observational|||Thoracoscopic Vascular Rings Chart Review|Thoracoscopic Vascular Rings Chart Review|Terminated|||47|Actual|Children's Healthcare of Atlanta||||sufficient data gathered to support hypothesis|f||||f||||||||||2018-06-01 04:26:32.561059|2018-06-01 04:26:32.561059
NCT00230971|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|2009-09-30||2013-02-20|2005-09-30|2005-10-03|Estimate|2010-04-05|2010-04-26|Estimate||||2013-02-20|2013-02-25|Estimate|October 2005||2005-10-31|February 2013|2013-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)|A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection|Completed||Phase 4|473|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 04:26:19.377425|2018-06-01 04:26:19.377425
NCT00230958|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2012-06-21|2005-09-29|2005-10-03|Estimate|||||||2012-06-21|2012-06-22|Estimate|December 2003||2003-12-31|June 2012|2012-06-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive|Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C|Completed||Phase 3|900||Valeant Pharmaceuticals International, Inc.|||||f||||||||||||||2018-06-01 04:26:20.062147|2018-06-01 04:26:20.062147
NCT00230945|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2008-03-27|2005-09-29|2005-10-03|Estimate|||||||2008-03-27|2008-03-28|Estimate|January 2000||2000-01-31|March 2008|2008-03-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Couples-Oriented Psychosocial Intervention for Osteoarthritis|Psychobiological Pathways: Osteoarthritis Interventions|Completed||N/A|543|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:26:20.122199|2018-06-01 04:26:20.122199
NCT00230932|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2015-04-06|2005-09-29|2005-10-03|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2005||2005-10-31|November 2008|2008-11-30|September 2008|Actual|2008-09-30|June 2007|Actual|2007-06-30||Observational|HELP-Vets||Help Veterans Experience Less Pain Study (HELP-Vets)|Validation of Pain as a Vital Sign Among Veterans With Advanced Illness|Completed|||654|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:26:20.187504|2018-06-01 04:26:20.187504
NCT00230919|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-30|||2011-06-30|2005-09-30|2005-10-03|Estimate|||||||2011-06-30|2011-07-01|Estimate|April 2004||2004-04-30|February 2004|2004-02-29|November 2006|Actual|2006-11-30|June 2006|Actual|2006-06-30||Interventional|||Weight Loss and Changes in Cardiovascular Risk Markers With a Low Glycemic Diet Compared With a Standard Diet|Weight Loss and Changes in Cardiovascular Risk Markers With a Low Glycemic Load Diet Compared With a Standard National Nutrition Council-recommended Diet: a Randomized Trial|Completed||N/A|200||Oslo University Hospital|||||f||||f||||||||||2018-06-01 04:26:20.255159|2018-06-01 04:26:20.255159
NCT00230906|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2007-12-19|2005-09-29|2005-10-03|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2001||2001-01-31|December 2007|2007-12-31|April 2002|Actual|2002-04-30|||||Interventional|||Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane|Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane|Completed||N/A|12||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:26:20.316595|2018-06-01 04:26:20.316595
NCT00230893|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2006-09-20|2005-09-29|2005-10-03|Estimate|||||||2006-09-20|2006-09-21|Estimate|July 2005||2005-07-31|September 2006|2006-09-30|September 2005||2005-09-30|||||Observational|||Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years|Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years|Completed|||99||Tuscaloosa Research & Education Advancement Corporation|||||f||||||||||||||2018-06-01 04:26:20.368594|2018-06-01 04:26:20.368594
NCT00230880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2012-12-03|2005-09-29|2005-10-03|Estimate|||||||2012-12-03|2012-12-05|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|REACH||The Young Woman's Reach Project: Trial of an Intervention to Impact Contraceptive Behavior, Unintended Pregnancy, and Sexually Transmitted Infections (STIs) Among Adolescent Females|Randomized Trial of an Intervention to Impact Contraceptive Behavior, Unintended Pregnancy, and STIs Among Adolescent Females Receiving Family Planning Clinic Services|Completed||N/A|800|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:26:20.429909|2018-06-01 04:26:20.429909
NCT00230867|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2006-06-30|2005-09-29|2005-10-03|Estimate|||||||2006-06-30|2006-07-04|Estimate|April 2005||2005-04-30|June 2006|2006-06-30|December 2005||2005-12-31|||||Interventional|||Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis|A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical Iontophoretic Application of Acyclovir 5% Cream With an Open Label Conventional Therapy Treatment Arm, and a Blinded Evaluator, for the Treatment of Recurrent Herpes Labialis|Completed||Phase 2|1800||Transport Pharmaceuticals|||||||||||||||||||2018-06-01 04:26:20.597143|2018-06-01 04:26:20.597143
NCT00230854|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2013-06-04|2005-09-29|2005-10-03|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2005||2005-08-31|June 2013|2013-06-30|July 2007||2007-07-31|||||Interventional|||Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin|An Open Label, Dose Escalation Study of EMZ702 in Combination With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Non-responsive to Prior Therapy With Pegylated Interferon and Ribavirin|Completed||Phase 1|28||Transition Therapeutics|||||f||||||||||||||2018-06-01 04:26:20.706805|2018-06-01 04:26:20.706805
NCT00230841|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2013-07-31|2005-09-29|2005-10-03|Estimate|||||||2013-07-31|2013-08-02|Estimate|September 2001||2001-09-30|July 2013|2013-07-31|April 2004||2004-04-30|||||Interventional|||Comparing Different Ways of Delivering Humidity to Children With Croup|Efficacy of Optimal Versus 'Traditional' Delivery of Humidity in Children With Croup|Completed||Phase 2|129||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:26:20.776848|2018-06-01 04:26:20.776848
NCT00230828|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-11|2005-09-30|2005-10-03|Estimate|||||||2013-09-11|2013-09-12|Estimate|May 2005||2005-05-31|September 2007|2007-09-30||||January 2006|Actual|2006-01-31||Interventional|||Patient-reported Outcomes in the Treatment of Schizophrenia|Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials|Completed||Phase 3|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:26:20.83837|2018-06-01 04:26:20.83837
NCT00230815|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2013-11-27|2005-09-29|2005-10-03|Estimate|||||||2013-11-27|2013-11-28|Estimate|July 2004||2004-07-31|November 2013|2013-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction|A Phase IIIb, Prospective, Multicenter Trial to Evaluate Subject Satisfaction With Follitropin Alfa Injection Applied by Pen Device Compared With Other Injectable Gonadotropins in Oligoanovulatory Infertile Women Undergoing Ovulation Induction|Completed||Phase 3|62|Actual|EMD Serono||1|||f||||||||||||||2018-06-01 04:26:20.885582|2018-06-01 04:26:20.885582
NCT00230802|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|2012-05-29||2016-10-31|2005-09-29|2005-10-03|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Thyroid Hormone Dose Adjustment in Pregnancy|Thyroid Hormone Dose Adjustments During Pregnancy in Women With Primary Hypothyroidism.|Completed||N/A|48|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 04:26:20.970036|2018-06-01 04:26:20.970036
NCT00230789|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2013-04-09|2005-09-29|2005-10-03|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2005||2005-10-31|April 2013|2013-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.|A Multicenter, Multiphase, Single Arm, Open Label Study To Evaluate The Effects Of Tolterodine ER In Conjunction With Behavioral Intervention On Subject Satisfaction And Over- Active Bladder Symptoms (Urgency Urinary Incontinence (UUI), Urgency, Frequency) In Overactive Bladder Subjects Who Were Dissatisfied With Their Most Recent Antimuscarinic OAB Medication Therapy.|Completed||Phase 4|417||Pfizer|||||||||||||||||||2018-06-01 04:26:21.238187|2018-06-01 04:26:21.238187
NCT00230776|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2012-10-08|2005-09-29|2005-10-03|Estimate|||||||2012-10-08|2012-10-10|Estimate|October 2005||2005-10-31|October 2012|2012-10-31|July 2006|Actual|2006-07-31|||||Interventional|||A Controlled Pregabalin Trial In Fibromyalgia|A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia|Completed||Phase 3|740||Pfizer|||||||||||||||||||2018-06-01 04:26:21.414283|2018-06-01 04:26:21.414283
NCT00230763|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2015-03-04|2005-09-29|2005-10-03|Estimate|||||||2015-03-04|2015-03-05|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|PREDICOM||Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure|Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension|Completed||Phase 3|396|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:26:21.604318|2018-06-01 04:26:21.604318
NCT00230750|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2013-08-22|2005-09-29|2005-10-03|Estimate|||||||2013-08-22|2013-08-23|Estimate|October 2005||2005-10-31|September 2008|2008-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Inactivated Influenza A/H5N1 Vaccine in the Elderly|A Randomized, Double-Blinded, Placebo-Controlled Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Elderly Adults|Completed||Phase 1/Phase 2|261|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 04:26:21.899768|2018-06-01 04:26:21.899768
NCT00230737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-01-17||2017-01-17|2005-09-29|2005-10-03|Estimate|2017-01-17|2017-03-08|Actual||||2017-01-17|2017-03-08|Actual|October 2004||2004-10-31|January 2017|2017-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Melatonin on Insomnia Symptoms in Older Adults|Melatonin Randomized Trial for Insomnia in the Elderly|Completed||Phase 2|27|Actual|University of Pennsylvania|Study did not meet total recruitment targets|3|||f||||t||||||||||2018-06-01 04:26:21.989487|2018-06-01 04:26:21.989487
NCT00230724|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2005-09-29|2005-09-29|2005-10-03|Estimate|||||||2005-09-29|2005-10-03|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|April 2007||2007-04-30|||||Interventional|||Maintaining Exercise After Cardiac Rehabilitation|Maintaining Exercise After Cardiac Rehabilitation|Unknown status|Recruiting|Phase 3|180||The Miriam Hospital|||||f||||||||||||||2018-06-01 04:26:22.217462|2018-06-01 04:26:22.217462
NCT00230711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2012-11-29|2005-09-29|2005-10-03|Estimate|||||||2012-11-29|2012-11-30|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Physical Activity Promotion in Cancer Follow-Up Care|Physical Activity Promotion In Cancer Follow-up Care|Completed||Phase 3|300|Anticipated|The Miriam Hospital||2|||f||||||||||||||2018-06-01 04:26:22.286248|2018-06-01 04:26:22.286248
NCT00230698|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2010-11-12|2005-09-29|2005-10-03|Estimate|||||||2010-11-12|2010-11-15|Estimate|November 1995||1995-11-30|November 2010|2010-11-30|August 2002|Actual|2002-08-31|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure|Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures|Completed||Phase 3|451|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:26:22.363148|2018-06-01 04:26:22.363148
NCT00230685|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2015-05-28|2005-09-29|2005-10-03|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2000||2000-01-31|August 2008|2008-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia|Hammersmith Hospital Patients With Pulmonary Arteriovenous Malformations (PAVMs) and Hereditary Haemorrhagic Telangiectasia|Unknown status|Recruiting||500|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:26:22.459314|2018-06-01 04:26:22.459314
NCT00230672|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2008-08-12|2005-09-29|2005-10-03|Estimate|||||||2008-08-12|2008-08-13|Estimate|March 2005||2005-03-31|August 2008|2008-08-31||||||||Observational|||Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs|Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients|Unknown status|Recruiting||70|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:26:22.562388|2018-06-01 04:26:22.562388
NCT00230659|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2015-05-28|2005-09-29|2005-10-03|Estimate|||||||2015-05-28|2015-05-29|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Observational|||Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia|Investigation of Coagulation Parameters in Hereditary Haemorrhagic|Completed|||100||Imperial College London|||2||f||||||||||||||2018-06-01 04:26:22.636834|2018-06-01 04:26:22.636834
NCT00230646|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2010-10-04|2005-09-29|2005-10-03|Estimate|||||||2010-10-04|2010-10-05|Estimate|July 2005||2005-07-31|September 2005|2005-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Promoting Physical Activity After Colorectal Cancer|Promoting Physical Activity After Colorectal Cancer|Completed||Phase 3|46|Actual|The Miriam Hospital|||||f||||||||||||||2018-06-01 04:26:22.735419|2018-06-01 04:26:22.735419
NCT00230633|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2008-08-12|2005-09-29|2005-10-03|Estimate|||||||2008-08-12|2008-08-13|Estimate|April 2002||2002-04-30|August 2008|2008-08-31||||||||Observational|||Studies of White Blood Cells Derived From HHT Patients|Studies of White Blood Cells Derived From HHT Patients|Unknown status|Recruiting||200|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:26:22.797918|2018-06-01 04:26:22.797918
NCT00230620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2015-05-28|2005-09-29|2005-10-03|Estimate|||||||2015-05-28|2015-05-29|Estimate|December 1998||1998-12-31|August 2008|2008-08-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Observational|||Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families|Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families With Pulmonary Arteriovenous Malformations|Recruiting|||250|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:26:22.858239|2018-06-01 04:26:22.858239
NCT00230438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2014-01-03|2005-09-28|2005-09-30|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2005||2005-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||External Beam Radiation Therapy - Target Volume|A Pilot Study to Develop a Technique for External Beam Radiotherapy After Radical Prostatectomy Based on MRI-Delineation of the Clinical Target Volume|Completed||Phase 2|27|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:26:25.142635|2018-06-01 04:26:25.142635
NCT00230607|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2017-08-03|2005-09-29|2005-10-03|Estimate|||||||2017-08-03|2017-08-07|Actual|May 28, 2006|Actual|2006-05-28|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of the Effects of Fabrazyme Treatment on Lactation and Infants|A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants|Recruiting||Phase 4|20|Anticipated|Sanofi||1|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-06-01 04:26:22.973932|2018-06-01 04:26:22.973932
NCT00230594|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2011-05-18|2005-09-29|2005-10-03|Estimate|||||||2011-05-18|2011-05-19|Estimate|July 2004||2004-07-31|May 2011|2011-05-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|DRY||Desmopressin Response in the Young|Desmopressin Response in the Young: A Double-blind, Randomised, Placebo-controlled, Dose-titration Study With Three Different Doses (120 Mcg, 240 Mcg and 360 Mcg) of Desmopressin Administered as a New Melt Tablet in Children and Adolescents With Primary Nocturnal Enuresis (PNE).|Completed||Phase 3|132|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:26:23.141414|2018-06-01 04:26:23.141414
NCT00230581|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2007-10-12|2005-09-29|2005-10-03|Estimate|||||||2007-10-12|2007-10-15|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS|A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP225 in Female Patients With Irritable Bowel Syndrome With Diarrhea|Completed||Phase 2|88|Anticipated|Dynogen Pharmaceuticals|||||f||||||||||||||2018-06-01 04:26:23.240753|2018-06-01 04:26:23.240753
NCT00230568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2011-03-31|2005-09-29|2005-10-03|Estimate|||||||2011-03-31|2011-04-01|Estimate|December 2005||2005-12-31|March 2011|2011-03-31|December 2007|Actual|2007-12-31|April 2007|Actual|2007-04-30||Interventional|||EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)|A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 4|100|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:26:23.332927|2018-06-01 04:26:23.332927
NCT00230555|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2005-09-29|2005-09-29|2005-10-03|Estimate|||||||2005-09-29|2005-10-03|Estimate|July 2001||2001-07-31|April 2005|2005-04-30|November 2004||2004-11-30|||||Interventional|||The MOM Program at the Children's Hospital of Philadelphia|The MOM Program at the Children's Hospital of Philadelphia|Completed||Phase 3|300||Children's Hospital of Philadelphia|||||f||||||||||||||2018-06-01 04:26:23.527253|2018-06-01 04:26:23.527253
NCT00230542|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2017-03-22|2005-09-29|2005-10-03|Estimate|||||||2017-03-22|2017-03-23|Actual|September 2005||2005-09-30|March 2017|2017-03-31|April 2011|Actual|2011-04-30|July 2007|Actual|2007-07-31||Interventional|||Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer|Phase II Study of Carboplatin and Pemetrexed in Patients With Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 2|44|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:26:23.657083|2018-06-01 04:26:23.657083
NCT00230529|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2011-06-08|2005-09-29|2005-10-03|Estimate|||||||2011-06-08|2011-06-09|Estimate||||August 2010|2010-08-31|January 2003|Actual|2003-01-31|||||Interventional|||A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis|A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE�) Induction Therapy in Patients With Plaque-type Psoriasis|Completed||Phase 2|249|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:26:23.758169|2018-06-01 04:26:23.758169
NCT00230516|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2013-01-03|2005-09-29|2005-10-03|Estimate|||||||2013-01-03|2013-01-04|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|February 2006|Actual|2006-02-28|||||Interventional|||Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects|A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects on Days 1 and 5 of Intravenous Treatment|Completed||Phase 4|100||AstraZeneca|||||||||||||||||||2018-06-01 04:26:23.992106|2018-06-01 04:26:23.992106
NCT00230503|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2012-06-21|2005-09-28|2005-09-30|Estimate|||||||2012-06-21|2012-06-22|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B|Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B|Completed||Phase 2|220||Valeant Pharmaceuticals International, Inc.|||||f||||||||||||||2018-06-01 04:26:24.110857|2018-06-01 04:26:24.110857
NCT00230490|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2012-06-21|2005-09-28|2005-09-30|Estimate|||||||2012-06-21|2012-06-22|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201|Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201|Terminated||Phase 2|150||Valeant Pharmaceuticals International, Inc.||||Adverse findings from nonclinical carcinogenicity studies.|f||||||||||||||2018-06-01 04:26:24.283036|2018-06-01 04:26:24.283036
NCT00230477|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-14|2005-09-28|2005-09-30|Estimate|||||||2007-11-14|2007-11-15|Estimate|April 2003||2003-04-30|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT|Efficacy of Adefovir Dipivoxil Versus Adefovir Dipivoxil Plus Lamivudine for the Treatment of Chronic Hepatitis B in Patients With Normal Baseline ALT|Completed||Phase 4|19|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:26:24.368595|2018-06-01 04:26:24.368595
NCT00230464|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2006-01-03|2005-09-28|2005-09-30|Estimate|||||||2006-01-03|2006-01-04|Estimate|November 2004||2004-11-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Acute Metabolic Effects of LAF 237 in Type 2 Diabetics|A Double-Blind, Placebo-Controlled, Randomized, Crossover Study to Explore the Acute Effects of LAF 237 on the Rate of Appearance and Disappearance of Glucose During the Overnight Post-Absorptive Period in Type 2 Diabetics|Completed||Phase 3|16||The University of Texas Health Science Center at San Antonio|||||||||||||||||||2018-06-01 04:26:24.736445|2018-06-01 04:26:24.736445
NCT00230451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2010-01-14|2005-09-28|2005-09-30|Estimate|||||||2010-01-14|2010-01-15|Estimate|November 1997||1997-11-30|January 2010|2010-01-31|July 2008|Actual|2008-07-31|December 1999|Actual|1999-12-31||Interventional|||Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma|A Phase II Trial of Preoperative Chemotherapy and Radiation Therapy Followed by Adjuvant Combination Chemotherapy for Patients With Loco-Regional Esophageal Carcinoma|Completed||Phase 2|||University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:26:24.979809|2018-06-01 04:26:24.979809
NCT00230412|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2010-02-01|2005-09-28|2005-09-30|Estimate|||||||2010-02-01|2010-02-02|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|December 2010|Anticipated|2010-12-31|||||Observational|HSP||Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)|Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)|Unknown status|Recruiting||120|Anticipated|University of Munich Children's Clinic|||||f||||f||||||Samples With DNA|"~     Whole blood, serum and urine.~   "|||2018-06-01 04:26:25.345343|2018-06-01 04:26:25.345343
NCT00230399|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-04-20|2005-09-28|2005-09-30|Estimate|||||||2015-04-20|2015-04-21|Estimate|June 2003||2003-06-30|April 2015|2015-04-30|March 2008||2008-03-31|January 2006|Actual|2006-01-31||Interventional|||Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer|C-2424: Phase II Study of Celecoxib, Capecitabine, and Irinotecan in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|15||University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:26:25.565868|2018-06-01 04:26:25.565868
NCT00230386|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2009-07-10|2005-09-28|2005-09-30|Estimate|||||||2009-07-10|2009-07-14|Estimate|May 2003||2003-05-31|September 2005|2005-09-30||||||||Interventional|||Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma|The Role of MRI Perfusion to Detect Locally Recurrent or Persistent Disease in Prostate Carcinoma Treated With Radiation Therapy - A Pilot Study|Completed||Phase 1/Phase 2|50|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:26:25.638179|2018-06-01 04:26:25.638179
NCT00230373|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2015-04-22|2005-09-28|2005-09-30|Estimate|||||||2015-04-22|2015-04-23|Estimate|November 2005||2005-11-30|April 2015|2015-04-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study|Evaluation of the Efficacy and Safety of Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study|Withdrawn||Phase 3|0|Actual|University of Alberta||||Study never started.|f||||t||||||||||2018-06-01 04:26:25.717616|2018-06-01 04:26:25.717616
NCT00230360|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2007-02-01|2005-09-29|2005-09-30|Estimate|||||||2007-02-01|2007-02-02|Estimate|June 2005||2005-06-30|February 2007|2007-02-28|April 2006||2006-04-30|||||Observational|||Diagnosis of Functional Defecation Disorders in Childhood|Diagnosis of Functional Defecation Disorders in Childhood|Completed|||90||University of Aarhus|||||f||||||||||||||2018-06-01 04:26:25.845478|2018-06-01 04:26:25.845478
NCT00230347|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2010-03-30|2005-09-28|2005-09-30|Estimate|||||||2010-03-30|2010-04-01|Estimate|October 2003||2003-10-31|March 2010|2010-03-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||Evaluation of Stereotactic Radiosurgery For Liver Malignancies|Dose Escalation Study Evaluating Stereotactic Radiosurgery for Liver Malignancies|Completed||Phase 1|20|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:26:25.900549|2018-06-01 04:26:25.900549
NCT00230334|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2011-04-11|2005-09-28|2005-09-30|Estimate|||||||2011-04-11|2011-04-13|Estimate|June 2003||2003-06-30|April 2011|2011-04-30||||||||Interventional|||Phase II Gleevec Idiopathic Hypereosinophilic Syndrome|Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)|Withdrawn||Phase 2|25||Stanford University||||Withdrawn by PI due to insufficient accrual|||||||||||||||2018-06-01 04:26:25.997385|2018-06-01 04:26:25.997385
NCT00230321|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2013-01-31|2005-09-28|2005-09-30|Estimate|||||||2013-01-31|2013-02-04|Estimate|February 2002||2002-02-28|January 2013|2013-01-31|January 2008|Actual|2008-01-31|November 2007|Actual|2007-11-30||Interventional|||A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)|A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)|Completed||Phase 1/Phase 2|21|Actual|Stanford University||1|||f||||||||||||||2018-06-01 04:26:26.052089|2018-06-01 04:26:26.052089
NCT00230308|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2016-11-08|2005-09-28|2005-09-30|Estimate|||||||2016-11-08|2016-11-10|Estimate|April 2002||2002-04-30|November 2016|2016-11-30|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Observational|||Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer|Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer|Recruiting|||500|Anticipated|Stanford University|||||f||||t||||||Samples With DNA|"~     At the time of biospy or surgery, a small amount of tumor tissue (approximately 1 cc) will be~     taken from the main tumor specimen and stored until analysis.~   "|||2018-06-01 04:26:26.121968|2018-06-01 04:26:26.121968
NCT00230295|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2010-07-23|2005-09-28|2005-09-30|Estimate|||||||2010-07-23|2010-07-27|Estimate|February 2003||2003-02-28|July 2010|2010-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast|Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast|Completed||N/A|20|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:26:26.236983|2018-06-01 04:26:26.236983
NCT00230282|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2014-08-27||2014-09-25|2005-09-28|2005-09-30|Estimate|2014-08-27|2014-09-08|Estimate||||2014-09-25|2014-10-06|Estimate|July 2004||2004-07-31|September 2014|2014-09-30|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia|A Multi-Center Phase 2 Efficacy and Pharmacokinetic Study Evaluating Fludarabine, Cyclophosphamide, and Subcutaneous Campath (FCCam, Alemtuzumab) for Previously Untreated B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|25|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 04:26:26.431728|2018-06-01 04:26:26.431728
NCT00230269|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2012-07-10|2005-09-28|2005-09-30|Estimate|||||||2012-07-10|2012-07-12|Estimate|May 2003||2003-05-31|July 2012|2012-07-31|November 2007|Actual|2007-11-30|June 2006|Actual|2006-06-30||Observational|||The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers|The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers|Completed|||5|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:26:26.627228|2018-06-01 04:26:26.627228
NCT00230256|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2012-07-11|2005-09-28|2005-09-30|Estimate|||||||2012-07-11|2012-07-12|Estimate|April 2003||2003-04-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Treatment Outcomes and Quality of Life After IMRT Treatments of Head and Neck Cancers|Treatment Outcomes and Quality of Life After IMRT Treatments of Head and Neck Cancers|Completed|||61|Actual|Stanford University|||||f||||t||||||||||2018-06-01 04:26:26.683628|2018-06-01 04:26:26.683628
NCT00230243|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2017-03-07|2005-09-28|2005-09-30|Estimate|||||||2017-03-07|2017-03-10|Actual|March 1997||1997-03-31|March 2017|2017-03-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Observational|||Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387)|A Retrospective Study to Establish an Historical Database on the Efficacy of Standard Antifungal Therapy in Patients With Invasive Fungal Infections|Completed|||330||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:26:26.731361|2018-06-01 04:26:26.731361
NCT00230230|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2015-09-15|2005-09-29|2005-09-30|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2005||2005-10-31|September 2015|2015-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Comparison of SCH 486757 to Codeine and Placebo in Subjects With Persistent Postviral Cough (Study P03069AM2)(COMPLETED)|SCH 486757 vs Codeine and Placebo in Subjects With Persistent Postviral Cough|Completed||Phase 2|91|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:26:26.786107|2018-06-01 04:26:26.786107
NCT00230217|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2009-03-27|2005-09-28|2005-09-30|Estimate|||||||2009-03-27|2009-03-30|Estimate|March 2004||2004-03-31|March 2009|2009-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy|Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease|Completed||Phase 4|94|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:26:26.833429|2018-06-01 04:26:26.833429
NCT00230204|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2006-02-15|2005-09-29|2005-09-30|Estimate|||||||2006-02-15|2006-02-16|Estimate|September 2005||2005-09-30|January 2006|2006-01-31|April 2006||2006-04-30|||||Interventional|||Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis|Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.|Unknown status|Recruiting|Phase 1|100||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:26.904046|2018-06-01 04:26:26.904046
NCT00230191|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2007-01-12|2005-09-28|2005-09-30|Estimate|||||||2007-01-12|2007-01-15|Estimate|January 2003||2003-01-31|October 2005|2005-10-31|December 2005||2005-12-31|||||Interventional|||Safety and Efficacy of RK0202 in Oral Mucositis|Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region|Completed||Phase 2|110||RxKinetix|||||||||||||||||||2018-06-01 04:26:27.004998|2018-06-01 04:26:27.004998
NCT00230178|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2009-07-22||2010-01-08|2005-09-28|2005-09-30|Estimate|2009-11-30|2009-12-31|Estimate||||2010-01-08|2010-01-12|Estimate|April 2004||2004-04-30|January 2010|2010-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome|Evaluation of Single Agent Rasburicase for 5 Days Versus Sequential Treatment With Rasburicase From Day 1 Through 3 Followed by Oral Allopurinol From Day 3 Through 5 (Overlap on Day 3) Versus Single Agent Oral Allopurinol for 5 Days in the Management of Plasma Uric Acid in Adult Patients With Leukemia, Lymphoma, and Solid Tumor Malignancies at Risk for Hyperuricemia and Tumor Lysis Syndrome|Completed||Phase 3|280|Actual|Sanofi||3|||f||||||||||||||2018-06-01 04:26:27.096225|2018-06-01 04:26:27.096225
NCT00230165|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2017-09-05|2005-09-28|2005-09-30|Estimate|||||||2017-09-05|2017-09-08|Actual|September 2005||2005-09-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.|Studies of Interactions Among Normal and Abnormal Blood Cells, and the Vessel Wall, and Studies of Genetic and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell and Coagulation Disorders|Recruiting|||60|Anticipated|Rockefeller University|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 04:26:28.24229|2018-06-01 04:26:28.24229
NCT00230152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2010-10-21|2005-09-29|2005-09-30|Estimate|||||||2010-10-21|2010-10-22|Estimate|February 2006||2006-02-28|September 2005|2005-09-30|March 2009|Actual|2009-03-31|April 2007|Actual|2007-04-30||Interventional|||Hybrid Imaging Modalities for the Evaluation of Infection|Nuclear Medicine for the Evaluation of Infection-the Added Value of Hybrid Imaging Modalities|Completed||N/A|300|Actual|Rambam Health Care Campus|||||f||||f||||||||||2018-06-01 04:26:28.331414|2018-06-01 04:26:28.331414
NCT00230139|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2008-10-11|2005-09-29|2005-09-30|Estimate|||||||2008-10-11|2008-10-15|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|January 2006|Actual|2006-01-31|January 2004|Actual|2004-01-31||Interventional|||SPECT/CT in Endocrine and Neuroendocrine Tumors|The Added Value of SPECT/CT in the Evaluation of Endocrine and Neuroendocrine Tumors|Completed||N/A|200|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:26:28.431414|2018-06-01 04:26:28.431414
NCT00230126|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2014-04-15||2017-11-28|2005-09-28|2005-09-30|Estimate|2014-11-04|2014-11-07|Estimate||||2017-11-28|2017-12-26|Actual|October 2005||2005-10-31|November 2017|2017-11-30|July 2013|Actual|2013-07-31|September 2011|Actual|2011-09-30||Interventional||Fifty-eight patients . 31 men, 24 women.|OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer|A Phase II Randomized Study of OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|57|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:26:28.516136|2018-06-01 04:26:28.516136
NCT00230113|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2013-07-09|2005-09-29|2005-09-30|Estimate|||||||2013-07-09|2013-07-10|Estimate|September 2005||2005-09-30|July 2013|2013-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Omega-3 PUFA Supplementation in NAFLD Patients|A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Diet Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease|Completed||Phase 2|30|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 04:26:28.780847|2018-06-01 04:26:28.780847
NCT00230100|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|2014-09-15||2016-12-16|2005-09-29|2005-09-30|Estimate|2016-12-16|2017-02-08|Estimate||||2016-12-16|2017-02-08|Estimate|March 2003||2003-03-31|December 2016|2016-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||The Women's Recovery Group Study: Stage I Trial|Recovery Group for Women With Substance Use Disorders - Stage I|Completed||Phase 1|46|Actual|Mclean Hospital|"small sample~small proportion had drug dependence; majority had alcohol dependence (questionable generalizability)~sample was almost all white and well-educated (questionable generalizability)~therapists not blind to study"|2|||f||||f||||||||No||2018-06-01 04:26:28.869436|2018-06-01 04:26:28.869436
NCT00230087|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2012-11-06|2005-09-29|2005-09-30|Estimate|||||||2012-11-06|2012-11-07|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Iron Depletion Therapy for Type 2 DM and NAFLD|Iron Depletion Therapy for Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease|Completed||Phase 2|15|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 04:26:29.283983|2018-06-01 04:26:29.283983
NCT00230074|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2011-11-22|2005-09-28|2005-09-30|Estimate|||||||2011-11-22|2011-11-23|Estimate|November 2004||2004-11-30|November 2011|2011-11-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)|A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)|Completed||Phase 2|350|Actual|Novartis|||||f||||||||||||||2018-06-01 04:26:29.340063|2018-06-01 04:26:29.340063
NCT00230061|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2010-06-01|2005-09-28|2005-09-30|Estimate|||||||2010-06-01|2010-06-02|Estimate|April 2004||2004-04-30|June 2010|2010-06-30|February 2010|Actual|2010-02-28|May 2008|Actual|2008-05-31||Interventional|||Hepatitis B Vaccination in HIV-infected Persons|Randomised Open Label Clinical Trial of the Immune Response to Hepatitis B Vaccination in HIV-infected Persons.|Completed||Phase 4|800|Anticipated|Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:26:29.393387|2018-06-01 04:26:29.393387
NCT00230048|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|2011-10-12||2012-10-29|2005-09-29|2005-09-30|Estimate|2012-07-09|2012-08-16|Estimate||||2012-10-29|2012-10-31|Estimate|September 2001||2001-09-30|October 2012|2012-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Interactive Motivational Media for Perinatal Drug Abuse - 3|Interactive Motivational Media for Perinatal Drug Abuse|Completed||Phase 2|107|Actual|Wayne State University|Generalizability limited by relatively small sample, attrition of 29%, and restriction to low-income mothers. Second, power limitations prevented verification of effects on the dichotomous outcomes, despite effects in the small-moderate range.|2|||f||||f||||||||||2018-06-01 04:26:29.469145|2018-06-01 04:26:29.469145
NCT00230035|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2013-01-31|2005-09-28|2005-09-30|Estimate|||||||2013-01-31|2013-02-01|Estimate|September 2005||2005-09-30|January 2013|2013-01-31||||||||Interventional|||Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)|A Randomized, Open Label, Phase II Multicenter Study of Non-Myeloablative Autologous Transplantation With Auto-CD34+HPC Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Systemic Lupus Erythematosus|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||Recommended by DSMB due to lack of accrual|f||||t||||||||||2018-06-01 04:26:29.68545|2018-06-01 04:26:29.68545
NCT00230022|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|2011-10-12||2013-06-10|2005-09-29|2005-09-30|Estimate|2013-06-06|2013-06-10|Estimate||||2013-06-10|2013-06-20|Estimate|October 2004||2004-10-31|June 2013|2013-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Pilot Clinical Trial of Computer-based Motivational Intervention - 1|Pilot Clinical Trial of Computer-based Motivational Intervention|Completed||Phase 1|30|Actual|Wayne State University|Small sample size in the pilot clinical trial. Because of this lack of power, a statistically significant difference between groups was not demonstrated, and the 95% Confidence Interval (CI) for the effect size estimate included zero.|2|||f||||f||||||||||2018-06-01 04:26:30.742338|2018-06-01 04:26:30.742338
NCT00230009|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|2013-03-19||2013-08-06|2005-09-29|2005-09-30|Estimate|2013-08-06|2013-08-08|Estimate||||2013-08-06|2013-08-08|Estimate|April 2004||2004-04-30|August 2013|2013-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Brief Intervention in At-Risk First-time Mothers|Brief Intervention in At-Risk First-time Mothers|Completed||Phase 1/Phase 2|100|Actual|Wayne State University|This study is limited by the relatively small sample size and the restriction to low-income, urban women, thus limiting generalizability to other populations.|2|||f||||f||||||||||2018-06-01 04:26:30.96034|2018-06-01 04:26:30.96034
NCT00229996|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2014-01-23|2005-09-28|2005-09-30|Estimate|||||||2014-01-23|2014-01-24|Estimate|July 2004||2004-07-31|January 2014|2014-01-31||||||||Interventional|||Medical Treatment of Endometriosis-Associated Pelvic Pain|Oral Contraceptives Versus Depot-Leuprolide Taken After Surgery for Endometriosis-Associated Pelvic Pain|Completed||Phase 3|194|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:26:31.210236|2018-06-01 04:26:31.210236
NCT00229983|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2016-10-06|2005-09-29|2005-09-30|Estimate|||||||2016-10-06|2016-10-07|Estimate|June 2004||2004-06-30|October 2016|2016-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Medical Office Intervention for Adolescent Drug Use|Medical Office Intervention for Adolescent Drug Use|Completed||Phase 2|170|Actual|Boston Children’s Hospital||2|||f||||t||||||||No||2018-06-01 04:26:31.284385|2018-06-01 04:26:31.284385
NCT00229970|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2009-05-22||2015-05-05|2005-09-28|2005-09-30|Estimate|2009-05-22|2009-07-17|Estimate||||2015-05-05|2015-05-21|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|June 2007|Actual|2007-06-30|October 2006|Actual|2006-10-31||Interventional|||MK0476 Study in Adult Patients With Acute Asthma (0476-322)|MK0476 Phase II/III Placebo Controlled Double Blind Study|Completed||Phase 3|225|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 04:26:31.365197|2018-06-01 04:26:31.365197
NCT00229957|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2009-05-18||2010-07-13|2005-09-28|2005-09-30|Estimate|2010-06-07|2010-07-07|Estimate||||2010-07-13|2010-07-20|Estimate|June 2004||2004-06-30|September 2009|2009-09-30|October 2006|Actual|2006-10-31|August 2006|Actual|2006-08-31||Interventional|||Rehabilitation in Primary Care: A Project to Maximize the Health Status of Adults With Chronic Illness|Rehabilitation in Primary Care: A Project to Maximize the Health Status of Adults With Chronic Illness|Completed||N/A|303|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 04:26:31.772714|2018-06-01 04:26:31.772714
NCT00229944|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2006-07-20|2005-09-29|2005-09-30|Estimate|||||||2006-07-20|2006-07-21|Estimate|December 2002||2002-12-31|September 2005|2005-09-30|May 2004||2004-05-31|||||Interventional|||Single Dose Azithromycin in the Treatment of Adult Cholera|Randomized, Double-Blind, Controlled Clinical Trial to Compare Efficacy of a Single Dose of Azithromycin Versus a Single Dose of Ciprofloxacin in the Treatment of Adults With Clinically Severe Cholera Due to V. Cholerae O1 or O139|Completed||Phase 3|220||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:26:31.994847|2018-06-01 04:26:31.994847
NCT00229931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2017-04-10||2017-06-29|2005-09-28|2005-09-30|Estimate|2017-06-29|2017-07-28|Actual||||2017-06-29|2017-07-28|Actual|November 2005||2005-11-30|June 2017|2017-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|IVTA||Triamcinolone vs. Laser for Diabetic Macular Edema|The Role of Triamcinolone Injection During Cataract Extraction for Diabetic Patients With Pre-Operative Macular Edema|Completed||N/A|11|Actual|University of Oklahoma|Due to lack of patient follow up on this study, sufficient data was not available for analysis|2|||f||||t||||||||||2018-06-01 04:26:32.0708|2018-06-01 04:26:32.0708
NCT00229918|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2005-09-28|2005-09-28|2005-09-30|Estimate|||||||2005-09-28|2005-09-30|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|September 2006||2006-09-30|||||Interventional|||PST/Laser v. Laser Alone for CSME|Combined Posterior Sub-Tenon Injection of Triamcinolone Acetonide and Laser Photocoagulation for the Treatment of Clinically Significant Macular Edema|Unknown status|Recruiting|Phase 2|60||Edward Hines Jr. VA Hospital|||||f||||||||||||||2018-06-01 04:26:32.303174|2018-06-01 04:26:32.303174
NCT00229905|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-14|2005-09-28|2005-09-30|Estimate|||||||2012-03-14|2012-03-16|Estimate|March 2005||2005-03-31|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Observational|||Child With Anomalous Drainage of IVC to Left Atrium|A Case Report of a Child With Anomalous Drainage of the Inferior Vena Cava to the Left Atrium|Terminated|||1|Actual|Children's Healthcare of Atlanta||||sufficient data|f||||f||||||||||2018-06-01 04:26:32.373706|2018-06-01 04:26:32.373706
NCT00229892|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-16|2005-09-28|2005-09-30|Estimate|||||||2011-11-16|2011-11-18|Estimate|February 2005||2005-02-28|May 2007|2007-05-31|September 2006|Actual|2006-09-30|||||Observational|||Incisions for Cardiac Surgery|Small Incisions for Cardiac Surgery|Terminated|||90|Actual|Children's Healthcare of Atlanta||||after 90 charts reviewed, insufficient data to support conclusion|f||||f||||||||||2018-06-01 04:26:32.418521|2018-06-01 04:26:32.418521
NCT00229879|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-14|2005-09-28|2005-09-30|Estimate|||||||2012-03-14|2012-03-16|Estimate|December 2004||2004-12-31|May 2007|2007-05-31|September 2006|Actual|2006-09-30|||||Observational|||Rare Tumor Case Review|Rare Tumor Case Review|Terminated|||||Children's Healthcare of Atlanta||||sufficient data gathered to support conclusion|f||||f||||||||||2018-06-01 04:26:32.470162|2018-06-01 04:26:32.470162
NCT00224809|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-02-18|2005-09-21|2005-09-23|Estimate|||||||2014-02-18|2014-02-19|Estimate|September 2002||2002-09-30|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation|Functional Mitral Regurgitation in STICH|Completed||N/A|250|Anticipated|Baylor Research Institute|||||f||||||||||||||2018-06-01 04:27:30.566443|2018-06-01 04:27:30.566443
NCT00229840|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-24|2005-09-28|2005-09-30|Estimate|||||||2011-06-24|2011-06-27|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of Functional MRI and DTI (Imaging Techniques) in Children With Epilepsy and Focal Brain Lesions|Advanced MR Imaging Evaluation Of Neurosurgical Candidates With Focal Abnormalities|Completed||N/A|30|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 04:26:32.613345|2018-06-01 04:26:32.613345
NCT00229827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-14|2005-09-28|2005-09-30|Estimate|||||||2012-03-14|2012-03-16|Estimate|May 2005||2005-05-31|May 2007|2007-05-31|August 2007|Actual|2007-08-31|||||Observational|||Optimal Timing for Repair of Left to Right Shunt Lesions|Optimal Timing for Repair of Left-to-Right Shunt Lesions|Terminated|||200||Children's Healthcare of Atlanta||||sufficient data was collected|f||||||||||||||2018-06-01 04:26:32.663143|2018-06-01 04:26:32.663143
NCT00229814|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-09-20|2005-09-28|2005-09-30|Estimate|||||||2012-09-20|2012-09-24|Estimate|August 2005||2005-08-31|September 2012|2012-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Study of Brain Tumors (Tectal Tumors) Using Magnetic Resonance Imaging|Magnetic Resonance Spectroscopic Analysis of Pediatric Tectal Tumors: Insight Into Pathology and Behavior|Withdrawn|||0|Actual|Children's Healthcare of Atlanta||||There were technical difficulties and the study was terminated in 2008|f||||||||||||||2018-06-01 04:26:32.709237|2018-06-01 04:26:32.709237
NCT00229801|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-20|2005-09-28|2005-09-30|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2004||2004-06-30|September 2012|2012-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Kidney Function in Children With Brain Tumors|Evaluation of Renal Function in Children With Brain Tumors|Withdrawn||N/A|0|Actual|Children's Healthcare of Atlanta||1||No funds available, hard to enroll patients-Terminated in 2008|f||||||||||||||2018-06-01 04:26:32.856127|2018-06-01 04:26:32.856127
NCT00229788|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-12|2005-09-28|2005-09-30|Estimate|||||||2007-06-12|2007-06-13|Estimate|March 2005||2005-03-31|June 2007|2007-06-30||||||||Observational|||Impact of Race and Re-Transplantation|Impact of Race and Re-Transplantation in Childhood: Analysis of Data From the United Network of Organ Sharing|Terminated|||||Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:26:32.932574|2018-06-01 04:26:32.932574
NCT00229775|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2012-09-10|2005-09-28|2005-09-30|Estimate|||||||2012-09-10|2012-09-11|Estimate|July 2003||2003-07-31|September 2012|2012-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines|Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines|Completed||N/A|560|Actual|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:26:32.977865|2018-06-01 04:26:32.977865
NCT00229762|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2005-09-28|2005-09-28|2005-09-30|Estimate|||||||2005-09-28|2005-09-30|Estimate|March 2004||2004-03-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Racial Disparities in Pneumococcal Vaccination in Managed Care|Racial Disparities in Pneumococcal Vaccination in Managed Care: the Effects of Randomized Telephone Outreach|Completed||N/A|7000||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:26:33.065934|2018-06-01 04:26:33.065934
NCT00229749|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2008-04-09|2005-09-28|2005-09-30|Estimate|||||||2008-04-09|2008-04-10|Estimate|September 2005||2005-09-30|April 2008|2008-04-30|January 2007|Actual|2007-01-31|October 2006|Actual|2006-10-31||Interventional|||Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients|Exploratory Study of AVI-4065 Injection to Design Therapeutic Dosing for Chronic Active HCV Patients|Terminated||Phase 1/Phase 2|80|Anticipated|Sarepta Therapeutics||||Limited viral load reduction in HCV subjects|f||||||||||||||2018-06-01 04:26:33.123234|2018-06-01 04:26:33.123234
NCT00229736|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2013-12-02|2005-09-28|2005-09-30|Estimate|||||||2013-12-02|2013-12-04|Estimate|November 2004||2004-11-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease|A Phase1 Open Label Safety Study of Intrastriatal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV-hAADC-2) in Subjects With Parkinson's Disease [AAV-hAADC-2-003]|Completed||Phase 1|10|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:26:33.179904|2018-06-01 04:26:33.179904
NCT00229723|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2009-06-17||2009-06-17|2005-09-28|2005-09-30|Estimate|2009-06-17|2009-08-04|Estimate||||2009-06-17|2009-08-04|Estimate|November 2004||2004-11-30|June 2009|2009-06-30|June 2008|Actual|2008-06-30|||||Interventional|||IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma|A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multicentre Comparative Study of Gefitinib 250 mg or 500 mg (IRESSA™) Given Either Continuously or Concomitantly With Cisplatin Plus Radiotherapy for the Treatment of Patients With Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma|Completed||Phase 2|224|Actual|AstraZeneca||7|||f||||||||||||||2018-06-01 04:26:33.339281|2018-06-01 04:26:33.339281
NCT00229710|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2010-11-18|2005-09-28|2005-09-30|Estimate|||||||2010-11-18|2010-11-19|Estimate|February 2005||2005-02-28|November 2010|2010-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes|An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 0.5mg When Added to Insulin Therapy in Patients With Type 2 Diabetes Mellitus (GALLEX 9)|Terminated||Phase 3|270||AstraZeneca||||The development program has been terminated|||||||||||||||2018-06-01 04:26:35.868685|2018-06-01 04:26:35.868685
NCT00229697|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2015-10-02|2005-09-28|2005-09-30|Estimate|||||||2015-10-02|2015-10-05|Estimate|October 2003||2003-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|December 2006|Actual|2006-12-31||Interventional|||Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study|A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours|Completed||Phase 2|317|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:26:36.051878|2018-06-01 04:26:36.051878
NCT00229684|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2011-08-29|2005-09-28|2005-09-30|Estimate|||||||2011-08-29|2011-08-30|Estimate|September 2004||2004-09-30|August 2011|2011-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)|A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 2|100||AstraZeneca||||The development program has been terminated|||||||||||||||2018-06-01 04:26:36.211975|2018-06-01 04:26:36.211975
NCT00229671|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2005-09-28|2005-09-28|2005-09-30|Estimate|||||||2005-09-28|2005-09-30|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics|Ambulatory Medication Errors and Adverse Drug Events (ADEs) in Pediatrics|Unknown status|Recruiting|N/A|30000||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:26:36.371136|2018-06-01 04:26:36.371136
NCT00229658|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|2009-05-05||2015-03-05|2005-09-28|2005-09-30|Estimate|2009-05-05|2009-06-24|Estimate||||2015-03-05|2015-03-25|Estimate|September 2005||2005-09-30|February 2015|2015-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes|A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace|Completed|||1297|Actual|AstraZeneca|||2||f||||f||||||||||2018-06-01 04:26:36.493206|2018-06-01 04:26:36.493206
NCT00229645|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2016-07-11|2005-09-28|2005-09-30|Estimate|||||||2016-07-11|2016-07-13|Estimate|November 2003||2003-11-30|July 2016|2016-07-31|April 2005||2005-04-30|||||Interventional|||A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety|A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and Tolerability of Immediate-Release Formulation of Quetiapine Fumarate as Potentiation of Selective Serotonin Reuptake Inhibitors, and Serotonin Norepinephrine Reuptake Inhibitors Treatment in Major Depression With Comorbid Anxiety Symptoms|Completed||Phase 4|60||Dr Alexander McIntyre Inc.|||||f||||||||||||||2018-06-01 04:26:37.227625|2018-06-01 04:26:37.227625
NCT00229632|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|||2018-03-27|2005-09-28|2005-09-29|Estimate|||||||2018-03-27|2018-03-29|Actual|September 27, 2005||2005-09-27|March 14, 2018|2018-03-14|December 17, 2007|Actual|2007-12-17|December 17, 2007|Actual|2007-12-17||Interventional|||Idebenone to Treat Friedreich's Ataxia|A Six Month Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Determine the Safety and Efficacy of Idebenone Administered to Patients With Friedreich's Ataxia|Completed||Phase 2|51|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:26:37.514346|2018-06-01 04:26:37.514346
NCT00229619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-29|2013-01-28||2014-07-01|2005-09-28|2005-09-29|Estimate|2014-07-01|2014-07-28|Estimate||||2014-07-01|2014-07-28|Estimate|September 2005||2005-09-30|July 2014|2014-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia|A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia|Completed||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 04:26:37.59521|2018-06-01 04:26:37.59521
NCT00229593|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2014-12-03|2005-09-27|2005-09-29|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|NES-1||NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel|A Randomized, Open Label Clinical Trial to Evaluate if Nestorone Gel Has Gonadotropin Suppressive Activity and if Nestorone in Combination With Testosterone Will Have an Additive Effect on Gonadotropin Suppression When Applied Transdermally in Healthy Men|Completed||Phase 1|140|Actual|University of Washington||7|||f||||t||||||||||2018-06-01 04:26:37.791812|2018-06-01 04:26:37.791812
NCT00229580|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2007-11-28|2005-09-27|2005-09-29|Estimate|||||||2007-11-28|2007-11-30|Estimate|December 2003||2003-12-31|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||Health Behavior Feedback Study for Veterans With Hepatitis C|Health Behavior Feedback Study for Veterans With Hepatitis C|Completed||Phase 1|12|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:26:37.90453|2018-06-01 04:26:37.90453
NCT00229567|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2007-04-18|2005-09-27|2005-09-29|Estimate|||||||2007-04-18|2007-04-19|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function|A Randomised Controlled Trial of Lidocaine Infusion Plus Ketamine Injection Versus Placebo to Decrease Postoperative Ileus|Terminated||N/A|60||University of Saskatchewan||||"insufficient numbers of eligible patients as laparscopic surgery increased and open surgery~   decreased."|f||||||||||||||2018-06-01 04:26:37.984661|2018-06-01 04:26:37.984661
NCT00229554|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2015-04-06|2005-09-27|2005-09-29|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2006||2006-03-31|January 2009|2009-01-31|March 2008|Actual|2008-03-31|May 2007|Actual|2007-05-31||Observational|SCREEN||Survey of ColoRectal Cancer Education and Environment Needs|Assessing and Addressing Patient Colorectal Cancer Screening Barriers|Completed|||4644|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:26:38.067185|2018-06-01 04:26:38.067185
NCT00229541|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2007-10-26|2005-09-27|2005-09-29|Estimate|||||||2007-10-26|2007-10-29|Estimate|October 2003||2003-10-31|October 2007|2007-10-31|March 2006|Actual|2006-03-31|||||Interventional|||Medical In-Patient Rehabilitation in Rheumatoid Arthritis|Medical In-Patient Rehabilitation in Rheumatoid Arthritis: Acceptance and Outcomes in Insurants of Compulsory Health Insurances and Statutory Pension Insurances (VERA)|Completed||Phase 3|129|Actual|University of Luebeck||2|||f||||t||||||||||2018-06-01 04:26:38.202182|2018-06-01 04:26:38.202182
NCT00229528|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2008-09-19|2005-09-27|2005-09-29|Estimate|||||||2008-09-19|2008-09-22|Estimate|March 2004||2004-03-31|September 2008|2008-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease|Dose Ranging Study of the Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease|Completed||Phase 4|25||University of Oklahoma|||||f||||||||||||||2018-06-01 04:26:38.29109|2018-06-01 04:26:38.29109
NCT00229515|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2011-10-26|2005-09-27|2005-09-29|Estimate|||||||2011-10-26|2011-10-27|Estimate|November 2004||2004-11-30|October 2011|2011-10-31|March 2012|Anticipated|2012-03-31|April 2007|Actual|2007-04-30||Interventional|||Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI|Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Administered With the Single High-Dose Bolus Versus Abciximab and Sirolimus Eluting Stent Versus Bare Metal Stent in Acute Myocardial Infarction - MULTI-STRATEGY Trial|Unknown status|Active, not recruiting|Phase 4|744|Actual|Università degli Studi di Ferrara||4|||f||||t||||||||||2018-06-01 04:26:38.367084|2018-06-01 04:26:38.367084
NCT00229502|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-03-21|2005-09-27|2005-09-29|Estimate|||||||2012-03-21|2012-03-23|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Cognitive Effects of Immunomodulatory Drugs in MS|Comparison of the Cognitive Effects of Three Immunomodulatory Drugs in Relapsing-Remitting Multiple Sclerosis: A Longitudinal Study|Completed|||96|Actual|University of Kansas Medical Center|||4||f||||f||||||||||2018-06-01 04:26:38.459375|2018-06-01 04:26:38.459375
NCT00229476|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2016-11-03|2005-09-28|2005-09-29|Estimate|||||||2016-11-03|2016-11-07|Estimate|December 2003||2003-12-31|November 2016|2016-11-30||||March 2006|Actual|2006-03-31||Interventional|||Study of Medication and Placebo Response in Major Depression||Completed||Phase 4|60||University of California, Los Angeles|||||f||||||||||||||2018-06-01 04:26:38.524705|2018-06-01 04:26:38.524705
NCT00229463|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2016-11-16|2005-09-28|2005-09-29|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2002||2002-01-31|October 2016|2016-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|Genetics||Study of Genetic Differences in People With Depression|Study of Genetic Differences in People With Depression|Completed|||200|Anticipated|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 04:26:38.604942|2018-06-01 04:26:38.604942
NCT00229437|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-02-27|2005-09-27|2005-09-29|Estimate|||||||2012-02-27|2012-02-28|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy|Completed||Phase 2|343|Actual|Takeda||4|||f||||f||||||||||2018-06-01 04:26:38.762777|2018-06-01 04:26:38.762777
NCT00229424|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2011-07-06|2005-09-28|2005-09-29|Estimate|||||||2011-07-06|2011-07-07|Estimate|April 2005||2005-04-30|July 2011|2011-07-31|January 2007|Actual|2007-01-31|October 2006|Actual|2006-10-31||Interventional|||Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -|Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -|Completed||Phase 3|325||Taiho Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-06-01 04:26:38.891782|2018-06-01 04:26:38.891782
NCT00229411|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2007-01-23|2005-09-28|2005-09-29|Estimate|||||||2007-01-23|2007-01-24|Estimate|January 2006||2006-01-31|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Simulation Training as a Tool for Teamwork Improvement in Multidisciplinary Intensive Care Team|Experimental Like Observational Study of Teamwork Improvement in Multidisciplinary Intensive Care Team Before and After Simulation Training.|Withdrawn||N/A|40||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:38.96315|2018-06-01 04:26:38.96315
NCT00229398|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2008-01-28|2005-09-28|2005-09-29|Estimate|||||||2008-01-28|2008-01-31|Estimate|November 1998||1998-11-30|January 2008|2008-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder||Completed|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:39.010863|2018-06-01 04:26:39.010863
NCT00229385|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2013-12-30|2005-09-28|2005-09-29|Estimate|||||||2013-12-30|2013-12-31|Estimate|January 2006||2006-01-31|December 2013|2013-12-31|April 2010|Actual|2010-04-30|April 2008|Actual|2008-04-30||Interventional|||Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)|Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)|Completed||N/A|45|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 04:26:39.052294|2018-06-01 04:26:39.052294
NCT00229372|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2008-01-28|2005-09-28|2005-09-29|Estimate|||||||2008-01-28|2008-01-29|Estimate|November 2006||2006-11-30|January 2008|2008-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Prolonged Exposure Versus Treatment as Usual in Chronic Posttraumatic Stress Disorder Combat and Terror Related Patients||Completed||N/A|||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:39.245392|2018-06-01 04:26:39.245392
NCT00229359|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2007-12-18|2005-09-28|2005-09-29|Estimate|||||||2007-12-18|2007-12-27|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|December 2002||2002-12-31|||||Observational|||Characteristics of Post-Traumatic Stress Disorder (PTSD) and Non-PTSD Subjects|Risk Factors for PTSD|Completed|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:39.297018|2018-06-01 04:26:39.297018
NCT00229346|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2007-12-18|2005-09-28|2005-09-29|Estimate|||||||2007-12-18|2007-12-27|Estimate|October 2004||2004-10-31|December 2007|2007-12-31|January 2006||2006-01-31|||||Observational|||Fibromyalgia and Psychiatric Symptoms Among PMS and PMDD Patients||Completed|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:39.33493|2018-06-01 04:26:39.33493
NCT00229333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2006-08-28|2005-09-27|2005-09-29|Estimate|||||||2006-08-28|2006-08-29|Estimate|December 2004||2004-12-31|August 2006|2006-08-31||||||||Interventional|||Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia|Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia|Unknown status|Recruiting|Phase 4|40||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:39.38272|2018-06-01 04:26:39.38272
NCT00229320|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2008-01-28|2005-09-28|2005-09-29|Estimate|||||||2008-01-28|2008-01-30|Estimate|February 2005||2005-02-28|January 2008|2008-01-31|November 2005||2005-11-30|||||Interventional|||Short Term Group Therapy for OCD||Completed||N/A|||Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:26:39.452721|2018-06-01 04:26:39.452721
NCT00229307|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2013-01-26|2005-09-28|2005-09-29|Estimate|||||||2013-01-26|2013-01-29|Estimate|December 2005||2005-12-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Prolonged Exposure (PE) Treatment for Post Traumatic Stress Disorder (PTSD) 20 Minutes Versus 40 Minutes||Completed||N/A|39|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-06-01 04:26:39.506845|2018-06-01 04:26:39.506845
NCT00229294|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2007-12-18|2005-09-28|2005-09-29|Estimate|||||||2007-12-18|2007-12-27|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|March 2005||2005-03-31|||||Observational|||Fibromyalgia in Men Suffering From PTSD||Completed|||||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:39.588676|2018-06-01 04:26:39.588676
NCT00229281|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2007-12-18|2005-09-28|2005-09-29|Estimate|||||||2007-12-18|2007-12-27|Estimate|February 2004||2004-02-29|December 2007|2007-12-31||||||||Interventional|||Short Term Group Therapy for Anxiety Disorder||Completed||N/A|30||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:39.641496|2018-06-01 04:26:39.641496
NCT00229268|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-05-31|2005-09-27|2005-09-29|Estimate|||||||2012-05-31|2012-06-01|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|April 2010|Actual|2010-04-30|||||Observational|||Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes|FOXA2 Expression in Adipose Tissue of Human Subjects With Obesity/Insulin-Resistance|Completed|||14|Anticipated|Rockefeller University|||||f||||t||||||||||2018-06-01 04:26:39.689785|2018-06-01 04:26:39.689785
NCT00229255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-05-31|2005-09-27|2005-09-29|Estimate|||||||2012-05-31|2012-06-01|Estimate|March 2005||2005-03-31|May 2012|2012-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Relation of Obesity With Frequency of Meals (MST 0557)|Relation of Obesity With Frequency of Meals (MST 0557)|Completed||N/A|22|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 04:26:39.809165|2018-06-01 04:26:39.809165
NCT00229242|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-12-11|2005-09-27|2005-09-29|Estimate|||||||2009-12-11|2009-12-14|Estimate|November 2003||2003-11-30|December 2009|2009-12-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures|Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures|Completed||N/A|38|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 04:26:39.882962|2018-06-01 04:26:39.882962
NCT00229229|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-27|2005-09-28|2005-09-29|Estimate|||||||2009-01-27|2009-01-28|Estimate|September 2004||2004-09-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease|Comparison of a Low Glycemic Load Diet With a Canada Food Guide Diet in the Management of Overweight Patients With Cardiovascular Disease|Terminated||Phase 4|90|Actual|Queen's University||4||Lack of funding|f||||t||||||||||2018-06-01 04:26:39.973785|2018-06-01 04:26:39.973785
NCT00229216|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-03-21|2005-09-27|2005-09-29|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2005||2005-01-31|March 2017|2017-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Treatment of Bacterial Vaginosis With Oral Tinidazole|A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets.|Completed||Phase 3|200|Actual|Mission Pharmacal|||||||||||||||||||2018-06-01 04:26:40.062214|2018-06-01 04:26:40.062214
NCT00229203|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|2009-08-31||2009-12-14|2005-09-27|2005-09-29|Estimate|2009-11-11|2009-12-14|Estimate||||2009-12-14|2009-12-24|Estimate|February 2005||2005-02-28|December 2009|2009-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma|"Phase II Multicenter, Open-Label, Clinical and Pharmacokinetic Study of Aplidin® As A 3-Hour Infusion Every 2 Weeks Alone or in Combination With Dexamethasone, in Pre-Treated Patients With Relapsing or Refractory Multiple Myeloma."|Completed||Phase 2|51|Actual|PharmaMar|32 patients were treated with plitidepsin as single agent;afterwards 19 of them were treated with plitidepsin+dexamethasone combination.Therefore 32+19=51 is the no. patients at risk for plitidepsin and 19 is no. of patients at risk for dexamethasone||||f||||f||||||||||2018-06-01 04:26:40.148748|2018-06-01 04:26:40.148748
NCT00229190|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2007-04-23|2005-09-28|2005-09-29|Estimate|||||||2007-04-23|2007-04-24|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|May 2005|Actual|2005-05-31|||||Interventional|||Nasal Lavage Study: Comparing Single Versus Multi Sample Lavages|Reproducibility of Cell Counts in Nasal Lavage: A Comparison of Pooled Versus Non-Pooled Nasal Lavage Samples|Completed||N/A|21||McMaster University|||||f||||f||||||||||2018-06-01 04:26:40.648199|2018-06-01 04:26:40.648199
NCT00229177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-06-12|2005-09-27|2005-09-29|Estimate|||||||2012-06-12|2012-06-13|Estimate|September 2005||2005-09-30|June 2012|2012-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study of ONO-2506 in Patients With Acute Ischemic Stroke|Controlled Study of ONO-2506 in Patients With Acute Ischemic Stroke|Completed||Phase 2/Phase 3|757|Actual|Ono Pharmaceutical Co. Ltd||3|||f||||||||||||||2018-06-01 04:26:40.722322|2018-06-01 04:26:40.722322
NCT00229164|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-12-26|2005-09-27|2005-09-29|Estimate|||||||2012-12-26|2012-12-27|Estimate|October 2005||2005-10-31|November 2012|2012-11-30|January 2006||2006-01-31|||||Interventional|||The Effect of Transcutaneous Electric Nerve Stimulation on Primary Dysmenorrhea-a Randomized Control Study|The Effect of Transcutaneous Electric Nerve Stimulation on Primary Dysmenorrhea-a Randomized Control Study|Completed||Phase 1/Phase 2|20|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 04:26:40.7956|2018-06-01 04:26:40.7956
NCT00229151|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-04-06|2005-09-28|2005-09-29|Estimate|||||||2012-04-06|2012-04-09|Estimate|October 2005||2005-10-31|April 2012|2012-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Sleep Deprivation and Advancement of Sleep Period as Treatment for Bipolar Depression.|Sleep Deprivation and Three Days Sleep Phase Advancement as Treatment for Bipolar Depression.|Terminated||N/A|5|Actual|Norwegian University of Science and Technology||2||recruiting problems|f||||f||||||||||2018-06-01 04:26:40.872311|2018-06-01 04:26:40.872311
NCT00229138|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-02-03|2005-09-27|2005-09-29|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2005||2005-09-30|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients|A Six-month, Prospective, Multicenter, Open Label, Parallel, Randomized Study of the Safety, Tolerability and Efficacy of EC-MPS With Basiliximab, Corticosteroids and Two Different Levels of Tacrolimus in de Novo Renal Transplant Recipients|Completed||Phase 4|291|Actual|Novartis||2|||||||||||||||||2018-06-01 04:26:40.926072|2018-06-01 04:26:40.926072
NCT00229125|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2005-09-27|2005-09-27|2005-09-29|Estimate|||||||2005-09-27|2005-09-29|Estimate|July 2001||2001-07-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam|Gabapentin Vs. Lorazepam in Alcohol Withdrawal|Completed||Phase 2|160||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 04:26:40.985751|2018-06-01 04:26:40.985751
NCT00229112|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-02-16|2005-09-27|2005-09-29|Estimate|||||||2017-02-16|2017-02-17|Actual|April 2001||2001-04-30|February 2017|2017-02-28|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)|A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.|Completed||Phase 3|400||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:26:41.052008|2018-06-01 04:26:41.052008
NCT00229099|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2006-10-25|2005-09-28|2005-09-29|Estimate|||||||2006-10-25|2006-10-26|Estimate|April 2005||2005-04-30|December 2005|2005-12-31|November 2005||2005-11-30|||||Interventional|||Efficacy and Safety Study of GerEPO|A Randomized, Multi-Center, Open Label Trial to Establish the Therapeutic Equivalence Between GerEpo and Eprex® and to Determine the Long Term Safety Profile of GerEpo in Patients on Hemodialysis.|Completed||Phase 3|270||Ministry of Health, Malaysia|||||f||||||||||||||2018-06-01 04:26:41.303097|2018-06-01 04:26:41.303097
NCT00229086|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2008-07-24|2005-09-28|2005-09-29|Estimate|||||||2008-07-24|2008-07-28|Estimate||||July 2008|2008-07-31||||||||Observational|||Gatekeeper European 005|Long Term Follow-up European Gatekeeper Study 005|Terminated|||55||MedtronicNeuro|||||f||||||||||||||2018-06-01 04:26:41.421141|2018-06-01 04:26:41.421141
NCT00229073|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2011-06-06|2005-09-28|2005-09-29|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 2004||2004-12-31|March 2010|2010-03-31|October 2006|Actual|2006-10-31|||||Interventional|||A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation|A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study Of The Efficacy And Safety Of Dapoxetine In The Treatment Of Subjects With Premature Ejaculation|Completed||Phase 3|1116|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:26:41.500164|2018-06-01 04:26:41.500164
NCT00229060|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2011-06-08|2005-09-27|2005-09-29|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Doripenem in the Treatment of Complicated Intra-Abdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Versus Comparator Antibiotic in the Treatment of Complicated Intra-Abdominal Infections|Completed||Phase 3|483|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:26:41.581792|2018-06-01 04:26:41.581792
NCT00229047|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-08-24|2005-09-27|2005-09-29|Estimate|||||||2017-08-24|2017-08-25|Actual|April 2005|Actual|2005-04-30|August 2017|2017-08-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|||Ischemia and Reperfusion Injury in the Human: An Observational Study|Ischemia and Reperfusion Injury in the Human: An Observational Study|Completed|||20|Actual|Lawson Health Research Institute|||1||f||||t||||||||||2018-06-01 04:26:41.65488|2018-06-01 04:26:41.65488
NCT00229034|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-08-24|2005-09-27|2005-09-29|Estimate|||||||2017-08-24|2017-08-25|Actual|September 2005|Actual|2005-09-30|August 2017|2017-08-31|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Observational|||Effect of APC and Epo on the Inflammatory Response During Sepsis|Effect of Activated Protein C and Erythropoietin on the Microvascular Inflammatory Response During Severe Sepsis.|Completed|||40|Actual|Lawson Health Research Institute|||||f||||t||||||||||2018-06-01 04:26:41.726601|2018-06-01 04:26:41.726601
NCT00229021|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2011-06-08|2005-09-27|2005-09-29|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 2003||2003-12-31|April 2010|2010-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis|A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis|Completed||Phase 3|741|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:26:41.845914|2018-06-01 04:26:41.845914
NCT00229008|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27||2011-06-02|2012-08-27|2005-09-27|2005-09-29|Estimate||||2011-06-02|2011-06-09|Estimate|2012-08-27|2012-09-03|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Ceftobiprole in Hospital Acquired Pneumonia|A Phase 3 Randomized Double-Blind Study Of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia|Completed||Phase 3|106|Actual|Basilea Pharmaceutica||2|||f||||t||||||||||2018-06-01 04:26:41.955363|2018-06-01 04:26:41.955363
NCT00228995|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2011-06-08|2005-09-27|2005-09-29|Estimate|||||||2011-06-08|2011-06-10|Estimate|June 2004||2004-06-30|April 2010|2010-04-30|September 2005|Actual|2005-09-30|||||Interventional|||A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia|A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Idiopathic Anemia of Aging (IAA) Receiving Epoetin Alfa (PROCRIT�)|Terminated||Phase 2|9|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"This study was stopped due to slow enrollment after enrolling only 9 of 80 patients over 14~   months time."|||||t||||||||||2018-06-01 04:26:42.04468|2018-06-01 04:26:42.04468
NCT00228982|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-07-25|2005-09-27|2005-09-29|Estimate|||||||2012-07-25|2012-07-26|Estimate|October 2004||2004-10-31|July 2012|2012-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections|A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections|Completed||Phase 3|784|Actual|Basilea Pharmaceutica||2|||||||f||||||||||2018-06-01 04:26:42.182287|2018-06-01 04:26:42.182287
NCT00228969|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2012-08-01|2005-09-27|2005-09-29|Estimate|||||||2012-08-01|2012-08-02|Estimate|February 2005||2005-02-28|August 2012|2012-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy||Completed||Phase 2|||SK Life Science|||||f||||||||||||||2018-06-01 04:26:42.307173|2018-06-01 04:26:42.307173
NCT00228956|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2008-09-24|2005-09-27|2005-09-29|Estimate|||||||2008-09-24|2008-09-25|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|February 2009|Anticipated|2009-02-28|||||Observational|||Aromatase Inhibitor Clinical Trial|A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism|Unknown status|Recruiting||500|Anticipated|National Institute of General Medical Sciences (NIGMS)|||||f||||||||||Samples With DNA|"~     Whole blood Serum and Plasma Urine~   "|||2018-06-01 04:26:42.444943|2018-06-01 04:26:42.444943
NCT00228943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2008-11-13||2015-03-24|2005-09-27|2005-09-29|Estimate|2008-12-08|2008-12-10|Estimate||||2015-03-24|2015-04-14|Estimate|July 2005||2005-07-31|March 2015|2015-03-31|November 2008|Actual|2008-11-30|October 2007|Actual|2007-10-31||Interventional|||The Role of Serotonin in Hot Flashes After Breast Cancer|The Role of Serotonin in Hot Flashes After Breast Cancer|Completed||N/A|28|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 04:26:42.547009|2018-06-01 04:26:42.547009
NCT00228930|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2008-09-24|2005-09-27|2005-09-29|Estimate|||||||2008-09-24|2008-09-25|Estimate|September 2002||2002-09-30|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Observational|||Tamoxifen Pharmacogenetics and Clinical Effects|A Pilot Trial Correlating Metabolic Profile of Tamoxifen With Pharmacogenetic Predictors and Clinical Effects|Completed|||297|Actual|National Institute of General Medical Sciences (NIGMS)|||||f||||||||||Samples With DNA|"~     Whole Blood Serum Plasma~   "|||2018-06-01 04:26:42.787866|2018-06-01 04:26:42.787866
NCT00228917|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|2017-02-10||2017-05-09|2005-09-27|2005-09-29|Estimate|2017-02-10|2017-03-29|Actual||||2017-05-09|2017-06-09|Actual|June 1, 2005|Actual|2005-06-01|May 2017|2017-05-31|January 20, 2006|Actual|2006-01-20|January 1, 2006|Actual|2006-01-01||Interventional|||Safety Study of Tritanrix™-HepB/Hib-MenAC, Tritanrix™-HepB/Hiberix™, and Mencevax™ ACWY Vaccines in Children|Assess Reactogenicity & Safety of a Booster of Either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) & a Dose of Mencevax™ ACWY at 24-30 Mths (Open Label)|Completed||Phase 3|1290|Actual|GlaxoSmithKline||4|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:26:42.876502|2018-06-01 04:26:42.876502
NCT00228904|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2016-08-08|2005-09-27|2005-09-29|Estimate|||||||2016-08-08|2016-08-10|Estimate|February 2005||2005-02-28|August 2016|2016-08-31|October 2011|Anticipated|2011-10-31|May 2011|Anticipated|2011-05-31||Interventional|||Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes|Effects of Pulsatile IV Insulin Delivery on Peripheral Diabetic Neuropathy|Withdrawn||Phase 2/Phase 3|0|Actual|Florida Atlantic University||2||Administrative|f||||t||||||||||2018-06-01 04:26:43.540134|2018-06-01 04:26:43.540134
NCT00228891|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2016-08-08|2005-09-27|2005-09-29|Estimate|||||||2016-08-08|2016-08-10|Estimate|February 2004||2004-02-29|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus|Effects of Pulsatile Insulin Delivery on Peripheral Diabetic Neuropathy|Terminated||Phase 2/Phase 3|152|Actual|Florida Atlantic University||2||Administrative|f||||t||||||||||2018-06-01 04:26:43.672808|2018-06-01 04:26:43.672808
NCT00228878|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2016-08-08|2005-09-27|2005-09-29|Estimate|||||||2016-08-08|2016-08-10|Estimate|March 2003||2003-03-31|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes|Quality of Life With and Without Pulsatile IV Insulin Therapy in Diabetes.|Terminated||Phase 2/Phase 3|152|Actual|Florida Atlantic University||1||Administrative|f||||t||||||||||2018-06-01 04:26:43.771962|2018-06-01 04:26:43.771962
NCT00228865|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2016-08-08|2005-09-27|2005-09-29|Estimate|||||||2016-08-08|2016-08-10|Estimate|June 2003||2003-06-30|August 2016|2016-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Clinical Effects of Pulsatile Insulin Delivery on Cognitive Function- Phase 1|Effects of Pulsatile IV Insulin on Cognitive Deficits in Diabetic Patients|Terminated||Phase 2/Phase 3|75|Actual|Florida Atlantic University||1||Administrative|f||||t||||||||||2018-06-01 04:26:43.897397|2018-06-01 04:26:43.897397
NCT00228852|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2009-06-29|2005-09-27|2005-09-29|Estimate|||||||2009-06-29|2009-06-30|Estimate||||September 2005|2005-09-30|November 2006|Actual|2006-11-30|||||Interventional|||IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency|Phase I/II Trial of De-Escalation of Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency|Completed||Phase 1/Phase 2|||Emory University|||||f||||||||||||||2018-06-01 04:26:44.022478|2018-06-01 04:26:44.022478
NCT00228839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2009-06-29|2005-09-27|2005-09-29|Estimate|||||||2009-06-29|2009-06-30|Estimate||||December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease|A Pediatric Phase I Pharmacokinetic Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease|Completed||Phase 1|||Emory University|||||f||||f||||||||||2018-06-01 04:26:44.090763|2018-06-01 04:26:44.090763
NCT00228813|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|2016-03-23||2017-08-10|2005-09-27|2005-09-29|Estimate|2016-05-25|2016-07-06|Estimate||||2017-08-10|2017-09-11|Actual|April 2004||2004-04-30|August 2017|2017-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|G-CSF PMRD||G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome|Feasibility Study of Using G-CSF Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome With Partially Mismatched Related Donors|Terminated||N/A|8|Actual|Emory University|There was a small number of participants and a short follow up time period for this trial.|1||lack of enrollment|f||||t||||||||||2018-06-01 04:26:44.182153|2018-06-01 04:26:44.182153
NCT00228696|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2013-11-23|2005-09-27|2005-09-29|Estimate|||||||2013-11-23|2013-11-26|Estimate|September 2005||2005-09-30|November 2013|2013-11-30|December 2011|Anticipated|2011-12-31|December 2010|Anticipated|2010-12-31||Interventional|||National Wilm's Tumor Study Late Effects|National Wilm's Tumor Study Late Effects|Withdrawn||N/A|0|Actual|Emory University||1||national study, local site not responsible for results/analysis|f||||t||||||||||2018-06-01 04:26:44.366687|2018-06-01 04:26:44.366687
NCT00228683|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2013-11-23|2005-09-27|2005-09-29|Estimate|||||||2013-11-23|2013-11-26|Estimate|September 2005||2005-09-30|November 2013|2013-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Hepatoblastoma Biology Study and Tissue Bank|Hepatoblastoma Biology Study and Tissue Bank|Withdrawn||N/A|0|Actual|Emory University||||national study, local site not responsible for any analysis/results/etc|f||||t||||||||||2018-06-01 04:26:44.560897|2018-06-01 04:26:44.560897
NCT00228670|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-05-10|2005-09-27|2005-09-29|Estimate|||||||2017-05-10|2017-05-11|Actual|July 2005||2005-07-31|May 2017|2017-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Herpesvirus in Idiopathic Pulmonary Fibrosis|Herpesvirus in Idiopathic Pulmonary Fibrosis|Completed|||41|Actual|Emory University|||4||f||||f||||||Samples Without DNA|"~     Lung tissue at the time of lung transplantation. Saliva, induced sputum, and blood at clinic~     visitis~   "|||2018-06-01 04:26:44.655907|2018-06-01 04:26:44.655907
NCT00228657|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-28|||2013-11-25|2005-09-28|2005-09-29|Estimate|||||||2013-11-25|2013-11-27|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride|The Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride Administration (Substudy of SAFE Protocol 153711)|Completed||Phase 1/Phase 2|1100||Bayside Health|||||f||||f||||||||||2018-06-01 04:26:44.76677|2018-06-01 04:26:44.76677
NCT00228644|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2009-01-29|2005-09-27|2005-09-29|Estimate|||||||2009-01-29|2009-01-30|Estimate|July 2005||2005-07-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|||||Observational|||Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione|Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione and Cysteine.|Completed|||15|Anticipated|Emory University|||||f||||||||||||||2018-06-01 04:26:44.898605|2018-06-01 04:26:44.898605
NCT00228631|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2014-05-23|2005-09-27|2005-09-29|Estimate|||||||2014-05-23|2014-05-26|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Observational|||Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic BMT for Severe SCD|Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease (ImmuneReconstSCD)|Completed|||7|Actual|Emory University|||1||f||||t||||||||||2018-06-01 04:26:44.973603|2018-06-01 04:26:44.973603
NCT00228618|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2009-01-29|2005-09-27|2005-09-29|Estimate|||||||2009-01-29|2009-01-30|Estimate|January 2005||2005-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|||||Observational|||Dietary Effects of Sulfur Amino Acids|Dietary Effects of Sulfur Amino Acid Depletion and Repletion on Glutathione and Cysteine Pools.|Completed|||20|Anticipated|Emory University|||||f||||||||||||||2018-06-01 04:26:45.088528|2018-06-01 04:26:45.088528
NCT00228605|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2014-05-08|2005-09-27|2005-09-29|Estimate|||||||2014-05-08|2014-05-09|Estimate|March 2005||2005-03-31|May 2014|2014-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain|An Open-Label 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Noncancer Pain|Completed||Phase 3|500||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:26:45.246423|2018-06-01 04:26:45.246423
NCT00228592|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2007-02-12|2005-09-27|2005-09-29|Estimate|||||||2007-02-12|2007-02-13|Estimate||||February 2007|2007-02-28|August 2005||2005-08-31|||||Interventional|||HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection|A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-Bä, a Mixture of Two Monoclonal Antibodies, as Compared to Hepatitis B Immune Globulin in Patients Who Have Received Hepatic Allografts for Treatment of End-Stage Liver Disease Due to Hepatitis B Virus Infection|Terminated||Phase 2|||Cubist Pharmaceuticals LLC|||||||||||||||||||2018-06-01 04:26:45.557514|2018-06-01 04:26:45.557514
NCT00228579|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-04-18|2005-09-27|2005-09-29|Estimate|||||||2017-04-18|2017-04-19|Actual|June 2003||2003-06-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Assessment of Changes in Abdominal Fat|Assessment of Changes in Abdominal Fat and Metabolic and Tissue Biomarkers During a Bariatric Surgery Weight Loss Intervention Program|Active, not recruiting|||60|Anticipated|Purdue University|||1||f||||f||||||||||2018-06-01 04:26:45.790345|2018-06-01 04:26:45.790345
NCT00228397|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-02-11|2005-09-16|2005-09-28|Estimate|||||||2013-02-11|2013-02-13|Estimate|November 2003||2003-11-30|February 2013|2013-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study Evaluating CCI-779 in Relapsing Multiple Sclerosis|A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.|Completed||Phase 2|221|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:26:48.305148|2018-06-01 04:26:48.305148
NCT00228566|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|2009-06-01||2013-07-12|2005-09-27|2005-09-29|Estimate|2010-06-01|2010-06-25|Estimate||||2013-07-12|2013-07-19|Estimate|October 2005||2005-10-31|July 2013|2013-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome|A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome|Completed||Phase 3|247|Actual|Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:26:45.997362|2018-06-01 04:26:45.997362
NCT00228553|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|2009-06-01||2013-07-12|2005-09-27|2005-09-29|Estimate|2010-03-18|2010-03-31|Estimate||||2013-07-12|2013-07-19|Estimate|May 2004||2004-05-31|July 2013|2013-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness|A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)|Completed||Phase 3|743|Actual|Teva Pharmaceutical Industries||1|||||||||||||||||2018-06-01 04:26:46.395448|2018-06-01 04:26:46.395448
NCT00228540|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2014-05-08|2005-09-27|2005-09-29|Estimate|||||||2014-05-08|2014-05-09|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|September 2006|Actual|2006-09-30|||||Interventional|||Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD|An 8 Week, Open-Label Study to Characterize the Response to Modafinil (85 mg Film Coated Tablet) Treatment at Dosages Up to 425 mg/Day in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD) (With an Open Ended Extension Period)|Completed||Phase 3|||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:26:46.940629|2018-06-01 04:26:46.940629
NCT00228527|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2010-11-18|2005-09-27|2005-09-29|Estimate|||||||2010-11-18|2010-11-19|Estimate|October 2004||2004-10-31|November 2009|2009-11-30|October 2005|Actual|2005-10-31|||||Interventional|||Esomeprazole for Treatment of GERD in Pediatric Patients|A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive.|Completed||Phase 4|100||AstraZeneca|||||f||||||||||||||2018-06-01 04:26:47.051786|2018-06-01 04:26:47.051786
NCT00228514|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2010-11-11|2005-09-27|2005-09-29|Estimate|||||||2010-11-11|2010-11-15|Estimate|February 2004||2004-02-29|November 2010|2010-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Dutch Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA). PET Sub Study|Sub Study: Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) PET Sub Study|Completed||Phase 3|40||AstraZeneca|||||f||||||||||||||2018-06-01 04:26:47.15768|2018-06-01 04:26:47.15768
NCT00228488|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2007-12-16|2005-09-27|2005-09-29|Estimate|||||||2007-12-16|2007-12-19|Estimate|June 2004||2004-06-30|December 2007|2007-12-31|December 2005|Actual|2005-12-31|||||Interventional|||Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma|Phase II Study of Iressa With/Without Concurrent Chemoradiotherapy in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma and to Study the Effect of Iressa™ (ZD1839) on Tumour Gene Expression Profiles ®|Completed||Phase 2|60||AstraZeneca|||||f||||||||||||||2018-06-01 04:26:47.383929|2018-06-01 04:26:47.383929
NCT00228475|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2011-01-21|2005-09-27|2005-09-29|Estimate|||||||2011-01-21|2011-01-24|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|October 2005|Actual|2005-10-31|||||Interventional|||A Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women|An Open Single Centre Study to Assess the Concentration of Budesonide in Breast Milk From Asthmatic Women on Maintenance Treatment w/Pulmicort ® Turbuhaler ® at the Dose Levels 200/400 µg Bid|Completed||Phase 4|8||AstraZeneca|||||f||||||||||||||2018-06-01 04:26:47.466623|2018-06-01 04:26:47.466623
NCT00228462|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2013-01-03|2005-09-27|2005-09-29|Estimate|||||||2013-01-03|2013-01-04|Estimate|March 2005||2005-03-31|January 2013|2013-01-31|April 2006|Actual|2006-04-30|||||Interventional|||Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo|A 1-year, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo (Abbreviated)|Completed||Phase 3|197|Actual|AstraZeneca|||||||||||||||||||2018-06-01 04:26:47.556949|2018-06-01 04:26:47.556949
NCT00228449|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-12-19|2005-09-27|2005-09-29|Estimate|||||||2012-12-19|2012-12-21|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Peginesatide for Anemia in Chronic Hemodialysis Patients|A Phase 2, Open-label, Multi-center, Sequential, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Peginesatide Administered Intravenously for the Maintenance Treatment of Anemia in Chronic Hemodialysis Patients|Completed||Phase 2|165|Actual|Affymax||8|||f||||f||||||||||2018-06-01 04:26:47.693962|2018-06-01 04:26:47.693962
NCT00228436|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2012-12-19|2005-09-27|2005-09-29|Estimate|||||||2012-12-19|2012-12-21|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients|A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of Subcutaneously Administered Peginesatide in Chronic Kidney Disease Patients Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment|Completed||Phase 2|139|Actual|Affymax||8|||f||||f||||||||||2018-06-01 04:26:47.848163|2018-06-01 04:26:47.848163
NCT00228423|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2016-11-02|2005-09-26|2005-09-28|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)|Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?|Completed||Phase 2|91|Actual|Ottawa Heart Institute Research Corporation||2|||f||||||||||||||2018-06-01 04:26:48.00673|2018-06-01 04:26:48.00673
NCT00228410|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-02-07|2005-09-26|2005-09-28|Estimate|||||||2013-02-07|2013-02-08|Estimate|November 2002||2002-11-30|February 2013|2013-02-28|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections|A Multicenter, Randomized, Double-Blind Comparison of the Safety and Efficacy of Tigecycline With Those of Vancomycin With Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients.|Completed||Phase 3|503|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:26:48.222136|2018-06-01 04:26:48.222136
NCT00228384|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|2012-01-27||2012-05-25|2005-09-26|2005-09-28|Estimate|2012-04-25|2012-05-28|Estimate||||2012-05-25|2012-06-04|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study|GORE VIABAHN Endoprosthesis Versus Bare Nitinol Stent in the Treatment of Long Lesion (>8cm) Superficial Femoral Artery Occlusive Disease|Completed||Phase 4|148|Actual|W.L.Gore & Associates||2|||f||||f||||||||||2018-06-01 04:26:48.432868|2018-06-01 04:26:48.432868
NCT00228371|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2015-05-27|2005-09-26|2005-09-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy|Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.|Terminated||Phase 2/Phase 3|4|Actual|University Hospital, Grenoble||2||insufficent enrolement|f||||t||||||||||2018-06-01 04:26:50.153129|2018-06-01 04:26:50.153129
NCT00228358|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-11-07|2005-09-26|2005-09-28|Estimate|||||||2014-11-07|2014-11-11|Estimate|June 2003||2003-06-30|November 2014|2014-11-30||||May 2011|Actual|2011-05-31||Interventional|||Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine|A Phase I Study of Infusion of HER-2/Neu Specific T Cells in Patients With Advanced Stage HER-2/Neu Expressing Cancers Who Have Received a HER-2/Neu Vaccine|Completed||Phase 1|8|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:26:50.305339|2018-06-01 04:26:50.305339
NCT00228345|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-09-04|2005-09-26|2005-09-28|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2004||2004-01-31|September 2013|2013-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy|The Significance of Glucose Intolerance in the Pathogenesis of Idiopathic Axonal Polyneuropathy|Terminated||Phase 1|40||University of Chicago||||Study Completed|f||||||||||||||2018-06-01 04:26:50.415907|2018-06-01 04:26:50.415907
NCT00228332|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-19|2005-09-26|2005-09-28|Estimate|||||||2007-12-19|2007-12-28|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|March 2006|Actual|2006-03-31|||||Interventional|||A Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares|A Double-Blind, Placebo-Controlled Trial Investigating the Effect of a Treatment With Zinkgluconaat for Verrucae Vulgares|Completed||Phase 2|70||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:26:50.54027|2018-06-01 04:26:50.54027
NCT00228319|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2016-02-09|2005-09-27|2005-09-28|Estimate|||||||2016-02-09|2016-02-10|Estimate|October 2002||2002-10-31|February 2016|2016-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants|Antioxidant Effects on the Outcome of Ovarian Cancer|Completed||Phase 1/Phase 2|27|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 04:26:50.6334|2018-06-01 04:26:50.6334
NCT00228306|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2012-04-27|2005-09-26|2005-09-28|Estimate|||||||2012-04-27|2012-05-01|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of Aerobic Exercise on Learning After Stroke|Effect of Cardiovascular Fitness on Motor Learning and Executive Function in Individuals After Stroke|Completed||Phase 1|38|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-06-01 04:26:50.736938|2018-06-01 04:26:50.736938
NCT00228293|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2013-09-20|2005-09-23|2005-09-28|Estimate|||||||2013-09-20|2013-09-23|Estimate|December 2002||2002-12-31|September 2013|2013-09-30|September 2005||2005-09-30|||||Interventional|||Assessing CPR Quality During In-Hospital Cardiac Arrest|Assessment of Cardiopulmonary Resuscitation Quality During In-Hospital Cardiac Arrest|Terminated||Phase 2/Phase 3|200||University of Chicago|||||||||||||||||||2018-06-01 04:26:51.571742|2018-06-01 04:26:51.571742
NCT00228280|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-12-03|2005-09-23|2005-09-28|Estimate|||||||2008-12-03|2008-12-04|Estimate|January 2005||2005-01-31|December 2008|2008-12-31|September 2008|Anticipated|2008-09-30|||||Interventional|||Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling|Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling|Unknown status|Active, not recruiting|Phase 1/Phase 2|54|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 04:26:51.680774|2018-06-01 04:26:51.680774
NCT00228267|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2017-05-02|2005-09-23|2005-09-28|Estimate|||||||2017-05-02|2017-05-04|Actual|September 2004||2004-09-30|May 2017|2017-05-31|November 2007|Actual|2007-11-30|||||Interventional|||Propofol Injection for Daily Headache|The Effect of Single-dose Propofol Injection on Pain and Quality of Life in Chronic Daily Headache: a Randomized Double-blind Controlled Trial|Completed||Phase 2|28|Anticipated|University of Alberta|||||f||||f||||||||No||2018-06-01 04:26:51.78108|2018-06-01 04:26:51.78108
NCT00228254|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2005-09-23|2005-09-23|2005-09-28|Estimate|||||||2005-09-23|2005-09-28|Estimate|January 2000||2000-01-31|September 2005|2005-09-30|June 2004||2004-06-30|||||Interventional|||Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study|Vitamin A and Zinc: Prevention of Pneumonia (VAZPOP) Study|Completed||Phase 4|2582||Tufts University|||||f||||||||||||||2018-06-01 04:26:51.88493|2018-06-01 04:26:51.88493
NCT00228241|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2006-10-25|2005-09-26|2005-09-28|Estimate|||||||2006-10-25|2006-10-26|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|July 2006||2006-07-31|||||Interventional|||Left Ventricular Function and Remodelling During Permanent Pacing|Left Ventricular Function and Remodelling During Permanent Pacing|Unknown status|Active, not recruiting|N/A|100||Aarhus University Hospital Skejby|||||f||||||||||||||2018-06-01 04:26:51.991229|2018-06-01 04:26:51.991229
NCT00228228|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2006-08-27|2005-09-27|2005-09-28|Estimate|||||||2006-08-27|2006-08-29|Estimate|May 2002||2002-05-31|August 2006|2006-08-31|December 2006||2006-12-31|||||Interventional|||TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis|T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis|Unknown status|Recruiting|Phase 3|80||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:52.067494|2018-06-01 04:26:52.067494
NCT00228215|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2014-11-18|2005-09-26|2005-09-28|Estimate|||||||2014-11-18|2014-11-19|Estimate|September 2005||2005-09-30|November 2014|2014-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Tips for Infant and Parent Sleep (TIPS)|Tips for Infant and Parent Sleep (TIPS) Pilot Study|Completed||N/A|30|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 04:26:52.176541|2018-06-01 04:26:52.176541
NCT00228202|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2006-08-17|2005-09-26|2005-09-28|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2005||2005-09-30|January 2006|2006-01-31||||||||Observational|||Genotyping of Cytomegalovirus From Patients in Israel|Cytomegalovirus Glycoprotein B Genotypes in Israeli Patients: Relationship Between CMV Genotype, Clinical and Demographic Factors|Unknown status|Recruiting||100||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:26:52.384652|2018-06-01 04:26:52.384652
NCT00228007|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-08-20|2005-09-26|2005-09-28|Estimate|||||||2013-08-20|2013-08-22|Estimate|September 2000||2000-09-30|August 2013|2013-08-31|September 2004|Actual|2004-09-30|||||Interventional|||Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users|Maintaining HIV Risk Reduction Among Needle Exchangers|Completed||Phase 3|265||Butler Hospital|||||f||||||||||||||2018-06-01 04:26:54.314665|2018-06-01 04:26:54.314665
NCT00228189|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2010-11-26|2005-09-27|2005-09-28|Estimate|||||||2010-11-26|2010-11-30|Estimate|December 2003||2003-12-31|November 2010|2010-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients|Induction of Specific T Cell Responses in Colorectal Cancer Patients With Liver Metastases Upon Vaccination With Autologous Dendritic Cells Pulsed With CEA-peptide or Electroporated With CEA-RNA: Evaluation of in Vivo Immune Response.|Completed||Phase 1/Phase 2|30|Anticipated|Radboud University||3|||f||||||||||||||2018-06-01 04:26:52.521685|2018-06-01 04:26:52.521685
NCT00228176|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26||2016-04-21|2016-04-21|2005-09-26|2005-09-28|Estimate||||2016-04-21|2016-05-20|Estimate|2016-04-21|2016-05-20|Estimate|August 2005||2005-08-31|April 2016|2016-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|AUDITOR||Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant|Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors|Terminated||Phase 3|661|Actual|Sanofi||2||Company decision taken in light of demands by certain national health authorities|f||||t||||||||||2018-06-01 04:26:52.717695|2018-06-01 04:26:52.717695
NCT00228163|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2015-03-24|2005-09-26|2005-09-28|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2002||2002-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses|Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses|Completed||Phase 2|147|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:26:52.927711|2018-06-01 04:26:52.927711
NCT00228150|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2008-12-22|2005-09-26|2005-09-28|Estimate|||||||2008-12-22|2008-12-23|Estimate|July 2003||2003-07-31|December 2008|2008-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease|A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease|Completed||Phase 2|564|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:26:53.128176|2018-06-01 04:26:53.128176
NCT00228137|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-08|2005-09-27|2005-09-28|Estimate|||||||2007-08-08|2007-08-09|Estimate|November 2002||2002-11-30|August 2007|2007-08-31|November 2012|Anticipated|2012-11-30|||||Observational|||Randomised Controlled Trial PFC Versus CKS Total Knee Prostheses|A Prospective Randomized Double-Blind Study to Assess the Functional Differences Between the PFC and CKS Knee Prostheses|Unknown status|Active, not recruiting||90||Radboud University|||||f||||||||||||||2018-06-01 04:26:53.22441|2018-06-01 04:26:53.22441
NCT00228124|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2006-01-25|2005-09-27|2005-09-28|Estimate|||||||2006-01-25|2006-01-26|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|April 2008||2008-04-30|||||Observational|||PR.7 Companion Trial: Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition|Effect of Intermittent Versus Continuous Androgen Suppression on Bone Loss and Body Composition in a Phase III Randomized Trial|Unknown status|Recruiting||300||Ontario Cancer Research Network|||||f||||||||||||||2018-06-01 04:26:53.277205|2018-06-01 04:26:53.277205
NCT00228111|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2009-09-23|2005-09-27|2005-09-28|Estimate|||||||2009-09-23|2009-09-24|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Observational|||TRACT Study: Evaluation of the Value of Routine Thoraco-abdominal CT in Blunt Trauma Patients|Prospective Evaluation of the Additional Value of Routine Thoraco-abdominal CT in Patients That Suffered Severe Blunt Trauma of the Abdomen/Thorax|Completed|||1000|Anticipated|Radboud University|||||f||||f||||||||||2018-06-01 04:26:53.374222|2018-06-01 04:26:53.374222
NCT00228098|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2005-09-27|2005-09-27|2005-09-28|Estimate|||||||2005-09-27|2005-09-28|Estimate|February 2005||2005-02-28|September 2005|2005-09-30|February 2007||2007-02-28|||||Interventional|||Smoking Cessation Intervention After Stroke or Transient Ischaemic Attack.|Smoking Cessation Intervention After Stroke or Transient Ischaemic Attack. A Randomised Controlled Trial|Unknown status|Recruiting|N/A|300||Odense University Hospital|||||f||||||||||||||2018-06-01 04:26:53.476614|2018-06-01 04:26:53.476614
NCT00228085|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2005-09-26|2005-09-26|2005-09-28|Estimate|||||||2005-09-26|2005-09-28|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Observational|||Changes of Parameters of Transcranial Magnetic Stimulation in Patients With Spinal Cord Injury|Reorganization of Cortical Motor Activation in Patients With Spinal Cord Injury: a Study of Motor Evoked Potential|Unknown status|Not yet recruiting||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:26:53.571323|2018-06-01 04:26:53.571323
NCT00228072|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2008-05-28|2005-09-26|2005-09-28|Estimate|||||||2008-05-28|2008-05-29|Estimate||||May 2008|2008-05-31||||February 2008|Actual|2008-02-29||Interventional|||Liposuction as Treatment for Excessive Axillary Sweat|Suction-Curettage vs. Standard Excision in Axillary Hyperhidrosis|Completed||Phase 2/Phase 3|50|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:26:53.632565|2018-06-01 04:26:53.632565
NCT00228059|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2017-02-21|2005-09-26|2005-09-28|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2005||2005-01-31|February 2017|2017-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.|A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750- 2000 mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder|Completed||Phase 3|132|Actual|Novartis|||||f||||||||||||||2018-06-01 04:26:53.724553|2018-06-01 04:26:53.724553
NCT00228046|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-10-29|2005-09-26|2005-09-28|Estimate|||||||2013-10-29|2013-10-31|Estimate|January 2004||2004-01-31|October 2013|2013-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder|Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder|Completed||Phase 4|40|Anticipated|Stony Brook University|||||f||||||||||||||2018-06-01 04:26:53.796961|2018-06-01 04:26:53.796961
NCT00228033|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2014-03-19|2005-09-26|2005-09-28|Estimate|||||||2014-03-19|2014-03-20|Estimate|April 2002||2002-04-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|December 2005|Actual|2005-12-31||Interventional|||Effectiveness of Supplemental Calcium in Preventing Postpartum Depression|Calcium for the Prevention of Postpartum Depression|Completed||Phase 4|238||Oregon Health and Science University|||||f||||||||||||||2018-06-01 04:26:53.948461|2018-06-01 04:26:53.948461
NCT00228020|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2010-08-24|2005-09-26|2005-09-28|Estimate|||||||2010-08-24|2010-08-25|Estimate|May 2001||2001-05-31|August 2010|2010-08-31||||January 2006|Actual|2006-01-31||Interventional|||Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients|A Randomized, Placebo-controlled, Double-blind, Multicenter Study Investigating Basiliximab in Combination With MMF, Cyclosporine Microemulsion and Prednisone in the Prevention of Acute Rejection in Pediatric Renal Allograft Recipients|Completed||Phase 3|212|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:26:54.181059|2018-06-01 04:26:54.181059
NCT00227994|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|2016-05-02||2017-11-09|2005-09-26|2005-09-28|Estimate|2016-10-30|2016-12-28|Estimate||||2017-11-09|2017-12-11|Actual|April 2003||2003-04-30|November 2017|2017-11-30|March 2005|Actual|2005-03-31|January 2005|Actual|2005-01-31||Interventional|||Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke|Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly|Completed||Phase 4|40|Actual|University of Pittsburgh||2|||f||||f||||||||Yes|study has small sample size and is unlikely to be useful for data sharing efforts; however, interested researchers can contact the first author via email.|2018-06-01 04:26:54.403653|2018-06-01 04:26:54.403653
NCT00227981|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-06-21|2005-09-26|2005-09-28|Estimate|||||||2013-06-21|2013-06-25|Estimate|March 1995||1995-03-31|June 2013|2013-06-30|March 2001||2001-03-31|||||Interventional|||Maintenance Interpersonal Psychotherapy for Sustaining Remission of Depression|Maintenance Psychotherapies in Recurrent Depression: Study II|Completed||N/A|93||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:26:54.781288|2018-06-01 04:26:54.781288
NCT00227968|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-06-21|2005-09-26|2005-09-28|Estimate|||||||2013-06-21|2013-06-25|Estimate|March 1995||1995-03-31|June 2013|2013-06-30|April 2002||2002-04-30|||||Interventional|||Psychosocial Therapy Plus Maintenance Pharmacotherapy for Treating Bipolar Disorder|Maintenance Therapies in Bipolar Disorder|Completed||Phase 4|181||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:26:54.914563|2018-06-01 04:26:54.914563
NCT00227955|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-06-21|2005-09-26|2005-09-28|Estimate|||||||2013-06-21|2013-06-25|Estimate|December 1987||1987-12-31|June 2013|2013-06-30|December 1993||1993-12-31|||||Interventional|||Comparing Various Treatments for Achieving and Maintaining Remission of Depression|Maintenance Therapies in Recurrent Depression-Study I|Completed||Phase 4|200||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:26:55.022754|2018-06-01 04:26:55.022754
NCT00227942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2014-05-23|2005-09-26|2005-09-28|Estimate|||||||2014-05-23|2014-05-26|Estimate|August 2003||2003-08-31|May 2014|2014-05-31|November 2007|Actual|2007-11-30|||||Interventional|||Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia|Understanding the Role That Hot Flashes and Sleep Disruption Play in the Effect of Estrogen Replacement Therapy on Mood in Perimenopausal and Postmenopausal Women|Completed||Phase 4|86|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-06-01 04:26:55.128735|2018-06-01 04:26:55.128735
NCT00227929|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-12-09|2005-09-26|2005-09-28|Estimate|||||||2013-12-09|2013-12-10|Estimate|July 2003||2003-07-31|December 2013|2013-12-31|June 2008|Actual|2008-06-30|September 2007|Actual|2007-09-30||Interventional|||Culturally Sensitive Collaborative Treatment for Depressed Chinese Americans|Effectiveness of Culturally Sensitive Collaborative Treatment (CSCT) of Depressed Chinese Americans in Primary Care|Completed||N/A|120|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:26:55.218227|2018-06-01 04:26:55.218227
NCT00227916|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2014-09-24|2005-09-27|2005-09-28|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2000||2000-11-30|September 2014|2014-09-30|July 2004|Actual|2004-07-31|May 2004|Actual|2004-05-31||Interventional|||Motivational Interviews for Incarcerated Teens - 1|Motivational Interviews for Incarcerated Teens|Completed||N/A|200|Anticipated|Brown University|||||f||||||||||||||2018-06-01 04:26:55.28106|2018-06-01 04:26:55.28106
NCT00227903|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|2013-06-14||2016-11-22|2005-09-27|2005-09-28|Estimate|2013-06-14|2013-08-21|Estimate||||2016-11-22|2017-01-23|Estimate|September 2004||2004-09-30|September 2016|2016-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|PRIDE-P|Analysis excluded women with no follow-up assessments.|Therapeutic Substance Abuse Treatment in Pregnancy - 1|Psychosocial Research to Improve Drug Treatment in Pregnancy (PRIDE-P)|Completed||Phase 2|168|Actual|Yale University|Did not acheive desired sample size; results were averaged across substances; women were not seeking substance abuse treatment (i.e. they were attending for prenatal care); treatment was brief|2|||f||||t||||||||No|only aggregate de-identified data|2018-06-01 04:26:55.465538|2018-06-01 04:26:55.465538
NCT00227890|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-03-01|2005-09-27|2005-09-28|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2005||2005-03-31|March 2017|2017-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Skills and Motivation at the Rhode Island Training School (Project SMART) - 1|Motivation and Skills for THC/ETOH+ Teens in Jail|Completed||Phase 2|205|Actual|University of Rhode Island||2|||f||||t||||||||Yes|With appropriate request and procedure.|2018-06-01 04:26:56.73957|2018-06-01 04:26:56.73957
NCT00227877|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2016-10-06|2005-09-27|2005-09-28|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2004||2004-09-30|October 2016|2016-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Screening and Brief Advice to Reduce Teen Substance Use|Screening and Brief Advice to Reduce Teen Substance Use|Completed||Phase 2|2145|Actual|Boston Children’s Hospital||2|||f||||t||||||||No||2018-06-01 04:26:56.827042|2018-06-01 04:26:56.827042
NCT00227864|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2015-11-10|2005-09-27|2005-09-28|Estimate|||||||2015-11-10|2015-11-11|Estimate|September 2004||2004-09-30|November 2015|2015-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Brief Marijuana Intervention for Adolescent Women - 1|A Brief Marijuana Intervention for Adolescent Women|Completed||Phase 3|326|Actual|Butler Hospital||2|||f||||||||||||||2018-06-01 04:26:56.928648|2018-06-01 04:26:56.928648
NCT00227838|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-01-11|2005-09-27|2005-09-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2003||2003-07-31|September 2005|2005-09-30|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Modifying Group Therapy for Bipolar Substance Abusers - 1|Modifying Group Therapy for Bipolar Abusers|Completed||N/A|60|Anticipated|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:26:57.018217|2018-06-01 04:26:57.018217
NCT00227825|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-01-10|2005-09-27|2005-09-28|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||The Aim of This Study is to Determine the Effectiveness of a Motivational Enhancement Intervention in Reducing Risk Behaviors (Drug and Alcohol Use, Sexual Risk Behavior, Poor Adherence to Medications) Among HIV+ Youth. - 1|Motivational Enhancement Therapy to Reduce Risk Behaviors in HIV Infected Youth|Unknown status|Not yet recruiting|Phase 2|60||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||No||2018-06-01 04:26:57.131092|2018-06-01 04:26:57.131092
NCT00227812|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2017-01-11|2005-09-27|2005-09-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|January 2009|2009-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Integrated Treatment for Cocaine and Mood Disorders - 1|ERP-8654 - Integrated Treatment for Cocaine and Mood Disorders|Completed||Phase 2|140||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:26:57.218017|2018-06-01 04:26:57.218017
NCT00227786|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-08-15|2005-09-26|2005-09-28|Estimate|||||||2013-08-15|2013-08-16|Estimate|January 2003||2003-01-31|November 2005|2005-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Primary Care Physicians' Use of Stop-Smoking Plans to Help Patients Who Are Smokers|Using Electronic Medical Records to Measure and Improve Adherence to Tobacco Treatment Guidelines in Primary Care|Completed||N/A|344|Actual|Kaiser Permanente|||||f||||f||||||||||2018-06-01 04:26:57.301295|2018-06-01 04:26:57.301295
NCT00227773|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2015-10-06|2005-09-26|2005-09-28|Estimate|||||||2015-10-06|2015-10-08|Estimate||||October 2015|2015-10-31||||||||Interventional|||Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors|Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors|Withdrawn||Phase 2|0|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 04:26:57.380985|2018-06-01 04:26:57.380985
NCT00227760|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|2016-01-29||2016-01-29|2005-09-26|2005-09-28|Estimate|2016-01-29|2016-02-29|Estimate||||2016-01-29|2016-02-29|Estimate|December 2005||2005-12-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery|A Phase 2 Study of AZD2171 in Progressive Unresectable, Recurrent or Metastatic Renal Cell Carcinoma (RCC)|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:26:57.464084|2018-06-01 04:26:57.464084
NCT00227747|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2010-04-14|2005-09-26|2005-09-28|Estimate|||||||2010-04-14|2010-04-15|Estimate|July 2005||2005-07-31|December 2006|2006-12-31||||||||Interventional|||Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer|Randomized Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine vs 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Carcinomas T3-4 No-2 Mo|Unknown status|Active, not recruiting|Phase 3|590|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:26:57.759954|2018-06-01 04:26:57.759954
NCT00227734|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2012-06-04|2005-09-26|2005-09-28|Estimate|||||||2012-06-04|2012-06-05|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|February 2006|Actual|2006-02-28|October 2005|Actual|2005-10-31||Interventional|||Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Capecitabine and Oxaliplatin Alone or in Combination With Cetuximab as First-Line Treatment for Metastatic EGFR-Positive Colorectal Cancer, A Randomized Multicenter Phase II Trial|Completed||Phase 2|74|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 04:26:57.924118|2018-06-01 04:26:57.924118
NCT00227721|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|2014-11-18||2017-02-22|2005-09-26|2005-09-28|Estimate|2015-02-05|2015-02-09|Estimate||||2017-02-22|2017-03-27|Actual|February 2004||2004-02-29|February 2017|2017-02-28|February 2017|Actual|2017-02-28|June 2011|Actual|2011-06-30||Interventional|||Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer|Phase II Trial of Weekly Gemcitabine and Docetaxel Combination Therapy for Relapsed Ovarian or Peritoneal Cancer|Completed||Phase 2|30|Actual|Barbara Ann Karmanos Cancer Institute|Small sample size|1|||f||||t||||||||||2018-06-01 04:26:58.052755|2018-06-01 04:26:58.052755
NCT00227708|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2009-08-19|2005-09-26|2005-09-28|Estimate|||||||2009-08-19|2009-08-20|Estimate|June 2005||2005-06-30|December 2006|2006-12-31||||||||Interventional|||Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70|Unknown status|Active, not recruiting|Phase 2|58|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:26:58.259408|2018-06-01 04:26:58.259408
NCT00227695|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2018-01-16|2005-09-26|2005-09-28|Estimate|||||||2018-01-16|2018-01-17|Actual|June 8, 2004|Actual|2004-06-08|January 2018|2018-01-31|December 19, 2017|Actual|2017-12-19|May 3, 2013|Actual|2013-05-03||Interventional|||Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma|Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial|Completed||Phase 3|270|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-06-01 04:26:58.347405|2018-06-01 04:26:58.347405
NCT00227682|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2012-05-24|2005-09-26|2005-09-28|Estimate|||||||2012-05-24|2012-05-28|Estimate|June 2004||2004-06-30|June 2010|2010-06-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid|Terminated||Phase 2|2|Actual|OHSU Knight Cancer Institute||1||Terminated early due to funding suspension by grant sponsor.|f||||||||||||||2018-06-01 04:26:58.46756|2018-06-01 04:26:58.46756
NCT00227669|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2016-08-29|2005-09-26|2005-09-28|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2005||2005-10-31|August 2016|2016-08-31|August 2012|Actual|2012-08-31|February 2010|Actual|2010-02-28||Interventional|||Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma|Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas|Completed||Phase 2|90|Actual|UNICANCER||2|||f||||f||||||||No|Individual participant data will not be shared at an individual level.|2018-06-01 04:26:58.68408|2018-06-01 04:26:58.68408
NCT00227656|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2012-12-10|2005-09-26|2005-09-28|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer|Phase II Trial of Capecitabine (Xeloda®) and Pegylated Interferon Alfa-2A(Pegasys®) for Recurrent or Progressive Brain Metastasis From Breast Carcinoma|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Study slow to accrue.|f||||f||||||||||2018-06-01 04:26:58.845274|2018-06-01 04:26:58.845274
NCT00227630|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2012-07-17|2005-09-26|2005-09-28|Estimate|||||||2012-07-17|2012-07-18|Estimate|July 2005||2005-07-31|July 2012|2012-07-31||||August 2007|Actual|2007-08-31||Interventional|||Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma|A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Postoperative Radiotherapy in Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|59|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:26:58.947871|2018-06-01 04:26:58.947871
NCT00227617|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2015-04-07|2005-09-26|2005-09-28|Estimate|||||||2015-04-07|2015-04-09|Estimate|June 2005||2005-06-30|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|January 2012|Actual|2012-01-31||Interventional|||Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors|A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors|Unknown status|Active, not recruiting|Phase 2/Phase 3|70|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:26:59.094099|2018-06-01 04:26:59.094099
NCT00223314|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-12-20|2005-09-14|2005-09-22|Estimate|||||||2007-12-20|2007-12-21|Estimate|November 2000||2000-11-30|December 2007|2007-12-31|February 2004|Actual|2004-02-29|||||Interventional|||Safer Choices 2 - HIV, STD, & Pregnancy Prevention Program|HIV Prevention Among Alternative School Youth|Completed||N/A|1000|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-06-01 04:27:53.765318|2018-06-01 04:27:53.765318
NCT00227591|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|2012-10-11||2014-05-02|2005-09-26|2005-09-28|Estimate|2013-07-23|2013-09-26|Estimate||||2014-05-02|2014-05-21|Estimate|December 2005||2005-12-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Lenalidomide and Prednisone in Treating Patients With Myelofibrosis|A Phase II Study of Lenalidomide (CC-5013) in Combination With Prednisone for the Treatment of Myelofibrosis With Myeloid Metaplasia|Completed||Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:26:59.265358|2018-06-01 04:26:59.265358
NCT00227565|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2016-07-01|2005-09-26|2005-09-28|Estimate|||||||2016-07-01|2016-07-06|Estimate|February 2006||2006-02-28|July 2016|2016-07-31|October 2009|Actual|2009-10-31|December 2007|Actual|2007-12-31||Interventional|||Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|50|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:26:59.579683|2018-06-01 04:26:59.579683
NCT00227539|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|2017-02-14||2017-03-31|2005-09-26|2005-09-28|Estimate|2017-02-14|2017-04-04|Actual||||2017-03-31|2017-05-09|Actual|July 2005||2005-07-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|March 2010|Actual|2010-03-31||Interventional|||Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer|Completed||Phase 2|25|Actual|University of Washington||1|||f||||||||||||||2018-06-01 04:26:59.942393|2018-06-01 04:26:59.942393
NCT00227526|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2010-09-02|2005-09-27|2005-09-28|Estimate|||||||2010-09-02|2010-09-06|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Enhancing Outcomes After Colon Surgery|Enhancing Outcomes After Colon Surgery: Role of Prehabilitation Facilitating the Recovery Process.|Completed||Phase 2|200|Anticipated|McGill University|||||f||||f||||||||||2018-06-01 04:27:00.192705|2018-06-01 04:27:00.192705
NCT00227513|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2014-02-21|2005-09-26|2005-09-28|Estimate|||||||2014-02-21|2014-02-24|Estimate|July 2005||2005-07-31|April 2013|2013-04-30||||June 2010|Actual|2010-06-30||Interventional|||Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Bortezomib in Patients With Advanced Malignancies|Completed||Phase 1|66|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:27:00.320693|2018-06-01 04:27:00.320693
NCT00227500|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2006-06-08|2005-09-27|2005-09-28|Estimate|||||||2006-06-08|2006-06-09|Estimate|July 2001||2001-07-31|June 2006|2006-06-30|October 2004||2004-10-31|||||Interventional|||Pravastatin for Hyperlipidaemia in HIV.|A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV|Completed||Phase 4|40||Kirby Institute|||||f||||||||||||||2018-06-01 04:27:00.405145|2018-06-01 04:27:00.405145
NCT00227487|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2016-09-28|2005-09-26|2005-09-28|Estimate|||||||2016-09-28|2016-09-30|Estimate|October 2005||2005-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|May 2011|Actual|2011-05-31||Interventional|||Intestinal Inflammation and Carbohydrate Digestion in Autistic Children|The Evaluation of Intestinal Inflammation and Carbohydrate Digestion in Children With Autistic Spectrum Disorders|Active, not recruiting||N/A|115|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 04:27:00.467052|2018-06-01 04:27:00.467052
NCT00227474|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-01-23|2005-09-26|2005-09-28|Estimate|||||||2013-01-23|2013-01-24|Estimate||||January 2013|2013-01-31||||||||Interventional|||S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission|S0348: A Phase II Study of 5T4-Modified Vaccinia Ankara (MVA) Vaccine (TROVAX) in Patients With Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||||SWOG has decided to not pursue this trial|f||||t||||||||||2018-06-01 04:27:00.566101|2018-06-01 04:27:00.566101
NCT00227461|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2015-03-31|2005-09-26|2005-09-28|Estimate|||||||2015-03-31|2015-04-01|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.|Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-06-01 04:27:00.621826|2018-06-01 04:27:00.621826
NCT00227448|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2008-04-01|2005-09-26|2005-09-28|Estimate|||||||2008-04-01|2008-04-03|Estimate|June 2003||2003-06-30|April 2008|2008-04-30|April 2005||2005-04-30|||||Interventional|||Induced Hypertension for Acute Ischemic Stroke|Induced Hypertension for Acute Ischemic Stroke|Completed||Phase 2|60||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:27:00.705384|2018-06-01 04:27:00.705384
NCT00227435|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2016-04-25|2005-09-26|2005-09-28|Estimate|||||||2016-04-25|2016-04-27|Estimate|February 2003||2003-02-28|April 2016|2016-04-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C|A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C|Completed||Phase 1/Phase 2|||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:27:00.767269|2018-06-01 04:27:00.767269
NCT00227422|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2016-09-20|2005-09-27|2005-09-28|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|November 2005|Actual|2005-11-30|||||Interventional|||Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs|A Phase IV, Partially Double-blind Study to Demonstrate Non-inferiority of GSK Biologicals' Mencevax™ ACWY (New Process) Versus Mencevax™ ACWY (Current Process) When Administered as a Single Dose to Subjects Aged 2-30 Yrs|Completed||Phase 4|324||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:27:00.821083|2018-06-01 04:27:00.821083
NCT00227409|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2006-10-17|2005-09-26|2005-09-28|Estimate|||||||2006-10-17|2006-10-18|Estimate|November 2001||2001-11-30|September 2005|2005-09-30|October 2005||2005-10-31|||||Interventional|||Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency|Long-Term Repeated Lead Chelation Therapy in Non-Diabetic Patients With Chronic Renal Insufficiency and High-Normal Body Lead Burden|Completed||N/A|||Chang Gung Memorial Hospital|||||f||||||||||||||2018-06-01 04:27:00.91382|2018-06-01 04:27:00.91382
NCT00227383|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2007-01-19|2005-09-27|2005-09-28|Estimate|||||||2007-01-19|2007-01-22|Estimate||||September 2005|2005-09-30||||||||Interventional|||Effect of Electroacupuncture in Diabetic Patients With Gastroparesis||Unknown status|Not yet recruiting|Phase 3|30||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:27:00.967245|2018-06-01 04:27:00.967245
NCT00226824|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2009-08-21|2005-09-23|2005-09-27|Estimate|||||||2009-08-21|2009-08-25|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Safety Study of Galantamine in Tic Disorders|Pilot Examination of Galantamine in the Management of Tic Disorders|Terminated||Phase 4|1|Actual|Parkinson's Disease and Movement Disorders Center||||Unable to recruit subjects into the trial.|f||||||||||||||2018-06-01 04:27:09.380206|2018-06-01 04:27:09.380206
NCT00227370|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|2013-01-24||2013-04-25|2005-09-26|2005-09-28|Estimate|2013-04-25|2013-04-29|Estimate||||2013-04-25|2013-04-29|Estimate|July 2003||2003-07-31|April 2013|2013-04-30|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|Valgan||Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation|A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation|Completed||Phase 3|136|Actual|Duke University||2|||f||||||||||||||2018-06-01 04:27:01.087609|2018-06-01 04:27:01.087609
NCT00227357|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|||2010-06-04|2005-09-27|2005-09-28|Estimate|||||||2010-06-04|2010-06-07|Estimate|July 2005||2005-07-31|September 2005|2005-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|BUP||The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration|SPNS - An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Abuse Treatment in HIV Primary Care|Completed|||101|Actual|Ruth M. Rothstein CORE Center|||2||f||||f||||||||||2018-06-01 04:27:02.101694|2018-06-01 04:27:02.101694
NCT00227344|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2014-05-27||2016-03-10|2005-09-27|2005-09-28|Estimate|2015-01-05|2015-01-14|Estimate||||2016-03-10|2016-04-08|Estimate|December 2004||2004-12-31|March 2016|2016-03-31|May 2009|Actual|2009-05-31|October 2008|Actual|2008-10-31||Interventional|CACAF-2||CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation|Catheter Ablation for Cure of Atrial Fibrillation|Terminated||Phase 4|129|Actual|Biosense Webster, Inc.|The study was terminated early due to randomization imbalance. The relatively small number of subjects enrolled limited the amount of data available for analysis. Because the study did not reach its targeted enrollment, the study is underpowered.|2||Study prematurely terminated due to randomization imbalance.|f||||f||||||||||2018-06-01 04:27:02.281359|2018-06-01 04:27:02.281359
NCT00227331|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2006-05-02|2005-09-26|2005-09-28|Estimate|||||||2006-05-02|2006-05-03|Estimate|January 1998||1998-01-31|September 2005|2005-09-30|January 2000||2000-01-31|||||Interventional|||Equivalency Of Oral Amoxicillin Vs Injectable Penicillin In Children With Severe Pneumonia|A Randomized Multicentre Equivalency Study Of Oral Amoxicillin Versus Injectable Penicillin In Children Aged 3 To 59 Months With Severe Pneumonia|Completed||N/A|||Boston Medical Center|||||f||||||||||||||2018-06-01 04:27:02.698591|2018-06-01 04:27:02.698591
NCT00227318|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2011-08-29|2005-09-26|2005-09-28|Estimate|||||||2011-08-29|2011-08-30|Estimate|July 1998||1998-07-31|August 2011|2011-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial|A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY)|Completed||Phase 3|1000||AstraZeneca|||||f||||||||||||||2018-06-01 04:27:02.76839|2018-06-01 04:27:02.76839
NCT00227305|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-27|2008-12-22||2013-01-03|2005-09-27|2005-09-28|Estimate|2012-09-05|2012-10-05|Estimate||||2013-01-03|2013-01-08|Estimate|August 2004||2004-08-31|January 2013|2013-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|ANCHOR 150||Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder|A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)|Completed||Phase 3|381|Actual|AstraZeneca|No comparator group, open label treatment, duration only 26 weeks - not long enough to assess full impact on growth and development||||f||||||||||||||2018-06-01 04:27:02.930743|2018-06-01 04:27:02.930743
NCT00227292|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2014-06-15|2005-09-26|2005-09-28|Estimate|||||||2014-06-15|2014-06-17|Estimate|November 2007||2007-11-30|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain|Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain|Withdrawn||Phase 4|0|Actual|Martin-Luther-Universität Halle-Wittenberg||2||Mutual agreement between Sponsor and Investigator.|f||||f||||||||||2018-06-01 04:27:03.404328|2018-06-01 04:27:03.404328
NCT00227279|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-01-28|2005-09-26|2005-09-28|Estimate|||||||2013-01-28|2013-01-29|Estimate|October 2004||2004-10-31|January 2013|2013-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Trial of the ALK Grass Tablet in Subjects With Hayfever|A Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Trial Assessing the Efficacy and Safety of ALK Grass Tablet in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis|Completed||Phase 3|634|Actual|ALK-Abelló A/S||2|||f||||||||||||||2018-06-01 04:27:03.478117|2018-06-01 04:27:03.478117
NCT00227266|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|2010-03-19||2011-09-22|2005-09-23|2005-09-27|Estimate|2011-03-31|2011-05-03|Estimate||||2011-09-22|2011-09-26|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy|Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)|Completed||Phase 2|94|Actual|University of Utah||3|||f||||t||||||||||2018-06-01 04:27:03.569166|2018-06-01 04:27:03.569166
NCT00227253|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-09-28|2005-09-23|2005-09-27|Estimate|||||||2017-09-28|2017-09-29|Actual|September 1993||1993-09-30|September 2017|2017-09-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|Chromosome18||Chromosome 18 Clinical Research Center|The Chromosome 18 Clinical Research Center|Recruiting|||1000|Anticipated|The University of Texas Health Science Center at San Antonio|||||f||||f||||||Samples With DNA|"~     blood specimens are collected from study participant and both biological parents if available~     and are processed for DNA and to establish cell lines~   "|||2018-06-01 04:27:05.282165|2018-06-01 04:27:05.282165
NCT00227240|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-20|2005-09-22|2005-09-27|Estimate|||||||2012-03-20|2012-03-21|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis|Observational Study With Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis|Completed|||753|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:27:05.382291|2018-06-01 04:27:05.382291
NCT00227227|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-07|2005-09-22|2005-09-27|Estimate|||||||2007-12-07|2007-12-10|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Observational|||Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis|Observational Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis|Completed|||750|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:27:05.47911|2018-06-01 04:27:05.47911
NCT00227214|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-24|2005-09-22|2005-09-27|Estimate|||||||2010-06-24|2010-06-28|Estimate|January 2004||2004-01-31|June 2010|2010-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.|Prevalence of Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.|Completed|||160|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:27:05.582554|2018-06-01 04:27:05.582554
NCT00227201|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-04-23|2005-09-26|2005-09-27|Estimate|||||||2008-04-23|2008-04-25|Estimate|June 2003||2003-06-30|April 2008|2008-04-30|May 2005||2005-05-31|||||Observational|||The Association Between the Use of Complementary and Alternative Medicine and Medication Adherence in Hypertensive African-Americans|The Association Between the Use of Complementary and Alternative Medicine and Medication Adherence in Hypertensive African-Americans|Completed|||60||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:27:05.813476|2018-06-01 04:27:05.813476
NCT00227188|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-11-28|2005-09-13|2005-09-27|Estimate|||||||2012-11-28|2012-11-29|Estimate|May 2003||2003-05-31|November 2012|2012-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.|Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain|Completed|||408|Actual|Pfizer|||1||f||||f||||||Samples Without DNA|"~     Samples without DNA~   "|||2018-06-01 04:27:05.886333|2018-06-01 04:27:05.886333
NCT00227175|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-03-31|2005-09-26|2005-09-27|Estimate|||||||2008-03-31|2008-04-03|Estimate|April 2003||2003-04-30|March 2008|2008-03-31|September 2003||2003-09-30|||||Observational|||Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study|Cornell Translational Behavioral Science Research Consortium: Hypertension Qualitative Study|Completed|||60||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:27:05.972811|2018-06-01 04:27:05.972811
NCT00227162|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2017-02-17|2005-09-23|2005-09-27|Estimate|||||||2017-02-17|2017-02-23|Actual|February 2004||2004-02-29|February 2017|2017-02-28|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Pilot Study of Changing Exercise and Physical Activity Behavior in Asthma Patients|Pilot Study of Changing Exercise and Physical Activity Behavior in Asthma Patients|Completed||N/A|40|Actual|Weill Medical College of Cornell University||4|||f||||t|f|f||||||No|No Plan to Share IPD|2018-06-01 04:27:06.035792|2018-06-01 04:27:06.035792
NCT00227149|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2009-02-03|2005-09-23|2005-09-27|Estimate|||||||2009-02-03|2009-02-04|Estimate|July 2005||2005-07-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|||||Observational|||Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C|Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C Infection and a Former (Peg)Interferon Alfa-2b-Based Therapy|Completed|||197|Actual|University of Wuerzburg|||||f||||f||||||||||2018-06-01 04:27:06.136533|2018-06-01 04:27:06.136533
NCT00227136|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2018-04-11|2005-09-23|2005-09-27|Estimate|||||||2018-04-11|2018-04-13|Actual|May 2005||2005-05-31|July 2006|2006-07-31|September 2005||2005-09-30|||||Interventional|||Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion|Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion|Terminated||Phase 3|8||Western University, Canada|||||f||||||||||||||2018-06-01 04:27:06.21152|2018-06-01 04:27:06.21152
NCT00227123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-01-03|2005-09-23|2005-09-27|Estimate|||||||2008-01-03|2008-01-04|Estimate|October 2002||2002-10-31|October 2007|2007-10-31|November 2006|Actual|2006-11-30|||||Interventional|||A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence|A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder Outpatients With Current Stimulant Dependence|Completed||N/A|96|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-06-01 04:27:06.317029|2018-06-01 04:27:06.317029
NCT00227110|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2009-10-12|2005-09-23|2005-09-27|Estimate|||||||2009-10-12|2009-10-14|Estimate|October 2002||2002-10-31|October 2009|2009-10-31|January 2006|Actual|2006-01-31|November 2005|Actual|2005-11-30||Interventional|||Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)|Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)|Completed||Phase 4|55|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-06-01 04:27:06.409474|2018-06-01 04:27:06.409474
NCT00227097|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2006-07-06|2005-09-23|2005-09-27|Estimate|||||||2006-07-06|2006-07-07|Estimate|December 2002||2002-12-31|July 2006|2006-07-31|December 2004||2004-12-31|||||Observational|||Educ'Avk: Recommendations for the Antivitamin K's Gestion|Implication of Patient in the Making Ready of Recommendations for the Antivitamin K's Gestion in Case of Thrombosis Embolic Venous's Illness. Randomised Study for Clinical Validation.|Terminated|||300||University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:27:06.511501|2018-06-01 04:27:06.511501
NCT00227084|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2007-08-24|2005-09-23|2005-09-27|Estimate|||||||2007-08-24|2007-08-27|Estimate|September 2005||2005-09-30|August 2007|2007-08-31|October 2006|Actual|2006-10-31|||||Interventional|||Effect of Arista Powder on Bleeding in Reductive Mammary Surgery|Effect of Arista AH-Haemostatic Powder in Plastic Surgery. A Prospective, Consecutive Randomized Study in 30 Women Undergoing Reduction of Both Mamma|Completed||Phase 2|30||University of Oslo|||||f||||t||||||||||2018-06-01 04:27:06.579027|2018-06-01 04:27:06.579027
NCT00227071|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2006-01-03|2005-09-26|2005-09-27|Estimate|||||||2006-01-03|2006-01-04|Estimate|September 1999||1999-09-30|September 2005|2005-09-30|June 2002||2002-06-30|||||Interventional|||Aquatic Verses Land Exercise to Decrease Fall Risk|The Effect of Water Verses Land Exercise to Decrease Fall Risk in Older Women With Osteoporosis|Completed||N/A|73||University of Saskatchewan|||||f||||||||||||||2018-06-01 04:27:06.637745|2018-06-01 04:27:06.637745
NCT00227058|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2007-01-24|2005-09-23|2005-09-27|Estimate|||||||2007-01-24|2007-01-26|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic Rhinitis|Effects of Orotic Acid Derivatives With or Without Glutathione on Allergic|Completed||N/A|100||University of Mississippi Medical Center|||||f||||||||||||||2018-06-01 04:27:06.712109|2018-06-01 04:27:06.712109
NCT00227045|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2007-04-19|2005-09-23|2005-09-27|Estimate|||||||2007-04-19|2007-04-20|Estimate|October 2003||2003-10-31|April 2007|2007-04-30||||||||Observational|||CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients|The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction: A Two Phase Pharmacokinetic Study in Renal Allograft Recipients at the University of Michigan Transplant Program|Completed|||20||University of Michigan|||||f||||||||||||||2018-06-01 04:27:06.766075|2018-06-01 04:27:06.766075
NCT00227032|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2012-03-05|2005-09-23|2005-09-27|Estimate|||||||2012-03-05|2012-03-06|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme|Phase I Study of Erlotinib Administered Every 72 Hours in Patients With Glioblastoma Multiforme With Pharmacokinetic/Pharmacodynamic Correlates|Terminated||Phase 1|10|Actual|UNC Lineberger Comprehensive Cancer Center||2||Loss of funding|f||||t||||||||||2018-06-01 04:27:06.851078|2018-06-01 04:27:06.851078
NCT00226811|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|2009-05-14||2015-03-10|2005-09-23|2005-09-27|Estimate|2009-10-20|2009-11-26|Estimate||||2015-03-10|2015-03-30|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy|An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy|Completed||Phase 2|78|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:27:09.47832|2018-06-01 04:27:09.47832
NCT00227019|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2016-04-20||2017-01-12|2005-09-26|2005-09-27|Estimate|2017-01-12|2017-03-06|Actual||||2017-01-12|2017-03-06|Actual|March 2006||2006-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2010|Actual|2010-11-30||Interventional||Adult patients with advanced stage nonsquamous NSCLC and stable treated metastatic disease in the brain were eligible if they were candidates for second-line therapy after progression on a platinum doublet regimen for advanced disease.|Phase 2 Trial of Bevacizumab in Combination With Pemetrexed|Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma)|Completed||Phase 2|16|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 04:27:06.960213|2018-06-01 04:27:06.960213
NCT00227006|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-18|2005-09-23|2005-09-27|Estimate|||||||2015-05-18|2015-05-20|Estimate|January 1999||1999-01-31|May 2015|2015-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Promoting Long-term Behavior Change to Reduce CVD Risk|Promoting Long-term Dietary Change to Reduce CVD Risk|Completed||N/A|163|Actual|Stanford University||3|||f||||||||||||||2018-06-01 04:27:07.3674|2018-06-01 04:27:07.3674
NCT00226993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-29|2005-09-23|2005-09-27|Estimate|||||||2016-11-29|2016-12-01|Estimate|March 2005||2005-03-31|November 2016|2016-11-30||||December 2006|Anticipated|2006-12-31||Interventional|||Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.|Phase I/II Study of Intratumoral Injection of CPG 7909, A TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides|Withdrawn||Phase 1/Phase 2|0|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:27:07.442123|2018-06-01 04:27:07.442123
NCT00226980|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-10|2005-09-23|2005-09-27|Estimate|||||||2009-04-10|2009-04-14|Estimate|October 2002||2002-10-31|April 2009|2009-04-30|July 2006|Actual|2006-07-31|July 2005|Actual|2005-07-31||Interventional|||A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma|A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma|Completed||Phase 2|30|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:27:07.520282|2018-06-01 04:27:07.520282
NCT00226967|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-11-09|2005-09-23|2005-09-27|Estimate|||||||2012-11-09|2012-11-14|Estimate|September 2002||2002-09-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|November 2004|Actual|2004-11-30||Observational|||Stress, Diurnal Cortisol, and Breast Cancer Survival|Stress, Diurnal Cortisol, and Breast Cancer Survival|Unknown status|Active, not recruiting||115|Anticipated|Stanford University|||||f||||t||||||Samples Without DNA|"~     Saliva~   "|||2018-06-01 04:27:07.581577|2018-06-01 04:27:07.581577
NCT00226954|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-07-27|2005-09-23|2005-09-27|Estimate|||||||2009-07-27|2009-07-28|Estimate|March 2003||2003-03-31|July 2009|2009-07-31|February 2009|Actual|2009-02-28|November 2007|Actual|2007-11-30||Interventional|||Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer|Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer|Completed||Phase 2|30|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:27:07.654955|2018-06-01 04:27:07.654955
NCT00226941|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2017-07-27||2017-11-01|2005-09-23|2005-09-27|Estimate|2017-11-01|2017-12-08|Actual||||2017-11-01|2017-12-08|Actual|June 2004||2004-06-30|November 2017|2017-11-30|February 2009|Actual|2009-02-28|March 2008|Actual|2008-03-31||Interventional|||A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer|A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgical Resection for Locally-Advanced Rectal Cancer|Terminated||Phase 1/Phase 2|23|Actual|Stanford University|"This trial was halted after the phase 1 portion of enrollment, and before the phase 2 portion accrued.~Data reported for phase 2 objectives/outcomes do not include any phase 2 participants, and are only provided for completeness."|4||"The response rate observed in the phase 1 portion of the study did not merit further evaluation~   in phase 2 portion of the study."|f||||t|t|f||||||No||2018-06-01 04:27:07.765146|2018-06-01 04:27:07.765146
NCT00226928|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-02|2005-09-23|2005-09-27|Estimate|||||||2013-12-02|2013-12-04|Estimate||||December 2013|2013-12-31|July 2005|Actual|2005-07-31|||||Interventional|||Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer|Psychosocial Treatment Effects on Cancer Survival|Completed||N/A|125|Actual|Stanford University|||||f||||f||||||||||2018-06-01 04:27:08.735991|2018-06-01 04:27:08.735991
NCT00226915|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2012-04-02|2005-09-26|2005-09-27|Estimate|||||||2012-04-02|2012-04-04|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Interventional|||Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma|Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma|Unknown status|Active, not recruiting|Phase 3|637|Actual|Japanese Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 04:27:08.794152|2018-06-01 04:27:08.794152
NCT00226902|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2015-05-04|2005-09-26|2005-09-27|Estimate|||||||2015-05-04|2015-05-05|Estimate|September 2006||2006-09-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Vascular Reactivity in Kidney Disease Patients|Integrated Studies in Vascular Reactivity and Anaemia Correction Therapy in Endstage Kidney Disease Patients|Completed||N/A|15||Melbourne Health|||||f||||f||||||||||2018-06-01 04:27:08.894322|2018-06-01 04:27:08.894322
NCT00226889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2009-06-11|2005-09-23|2005-09-27|Estimate|||||||2009-06-11|2009-06-12|Estimate|January 2005||2005-01-31|March 2006|2006-03-31|June 2009||2009-06-30|January 2009||2009-01-31||Interventional|TRANOS||Treatment of Early Systemic Sclerosis by Bosentan||Terminated||Phase 1/Phase 2|30|Anticipated|Rikshospitalet University Hospital||||failure of recruiting a sufficient number of patients|f||||||||||||||2018-06-01 04:27:08.987801|2018-06-01 04:27:08.987801
NCT00226876|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2013-05-28|2005-09-26|2005-09-27|Estimate|||||||2013-05-28|2013-05-30|Estimate|February 2005||2005-02-28|September 2005|2005-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||Dreaming During Anaesthesia and Anaesthetic Depth|Dreaming During Anaesthesia and Anaesthetic Depth|Completed|||300|Actual|Melbourne Health|||||f||||f||||||||||2018-06-01 04:27:09.130929|2018-06-01 04:27:09.130929
NCT00226863|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-23|2005-09-23|2005-09-27|Estimate|||||||2005-09-23|2005-09-27|Estimate||||September 2005|2005-09-30||||||||Interventional|||Meditation and Hypnosis for Chronic Depressed Mood||Completed||Phase 3|||Stanford University|||||f||||||||||||||2018-06-01 04:27:09.1866|2018-06-01 04:27:09.1866
NCT00226850|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-23|2005-09-23|2005-09-27|Estimate|||||||2005-09-23|2005-09-27|Estimate||||September 2005|2005-09-30||||||||Interventional|||Using Hypnosis to Help Children Undergoing a Difficult Medical Procedure||Completed||Phase 3|||Stanford University|||||f||||||||||||||2018-06-01 04:27:09.243956|2018-06-01 04:27:09.243956
NCT00226837|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2009-02-03|2005-09-26|2005-09-27|Estimate|||||||2009-02-03|2009-02-05|Estimate|August 2004||2004-08-31|February 2009|2009-02-28|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling|Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling|Completed||Phase 4|60|Actual|Melbourne Health||3|||f||||f||||||||||2018-06-01 04:27:09.306911|2018-06-01 04:27:09.306911
NCT00226798|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2005-12-31|2005-09-26|2005-09-27|Estimate|||||||2005-12-31|2006-01-04|Estimate|December 2003||2003-12-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Immunochemotherapy for Metastatic Renal Cell Carcinoma|Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study|Unknown status|Recruiting|Phase 2|45||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:27:09.917369|2018-06-01 04:27:09.917369
NCT00226785|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2006-11-10|2005-09-23|2005-09-27|Estimate|||||||2006-11-10|2006-11-14|Estimate|October 2005||2005-10-31|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||Dexmedetomidine for Continuous Sedation|A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of Intravenous Dexmedetomidine With Propofol/Midazolam for Continuous Sedation (24 Hours to 14 Days) of Ventilated Patients in Intensive Care Unit|Terminated||Phase 3|900||Orion Corporation, Orion Pharma|||||f||||||||||||||2018-06-01 04:27:10.024422|2018-06-01 04:27:10.024422
NCT00226772|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26||2012-10-10|2012-10-10|2005-09-26|2005-09-27|Estimate||||2012-10-10|2012-10-12|Estimate|2012-10-10|2012-10-12|Estimate|June 2005||2005-06-30|October 2012|2012-10-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction|Double-Blind, Multicenter Phase 3 Study Comparing the Efficacy and Safety of OMS103HP With Vehicle in Patients Undergoing Autograft ACL Reconstruction|Completed||Phase 3|326|Actual|Omeros Corporation||2|||f||||f||||||||||2018-06-01 04:27:10.097999|2018-06-01 04:27:10.097999
NCT00226759|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26||2012-10-10|2012-10-10|2005-09-26|2005-09-27|Estimate||||2012-10-10|2012-10-12|Estimate|2012-10-10|2012-10-12|Estimate|November 2004||2004-11-30|October 2012|2012-10-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction|Double-Blind, Multicenter Phase 3 Study Comparing the Efficacy and Safety of OMS103HP With Vehicle in Patients Undergoing Allograft ACL Reconstruction|Completed||Phase 3|321|Actual|Omeros Corporation||2|||f||||f||||||||||2018-06-01 04:27:10.192231|2018-06-01 04:27:10.192231
NCT00226746|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2018-04-04|2005-09-23|2005-09-27|Estimate|||||||2018-04-04|2018-04-06|Actual|March 2003|Actual|2003-03-31|April 2018|2018-04-30|June 2012|Actual|2012-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer|A Multicenter Phase II Trial of Weekly Gemcitabine, Paclitaxel, and Hyperfractionated External Irradiation (63.80 GY) for Locally Advanced Pancreatic Cancer|Completed||Phase 2|70|Actual|New York Methodist Hospital||1|||f||||t||||||||||2018-06-01 04:27:10.30256|2018-06-01 04:27:10.30256
NCT00226733|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-05-17|2005-09-26|2005-09-27|Estimate|||||||2010-05-17|2010-05-18|Estimate|March 2004||2004-03-31|April 2008|2008-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Training Intensity After Coronary Bypass Grafting|Training Intensity After Coronary Bypass Grafting|Terminated||Phase 2|60||Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:27:10.399082|2018-06-01 04:27:10.399082
NCT00226720|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-05-05|2005-09-23|2005-09-27|Estimate|||||||2008-05-05|2008-05-06|Estimate|September 2002||2002-09-30|April 2007|2007-04-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Outpatient Versus Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence: The IN/OUT Study|Comparison of Efficacy of an Outpatient vs Inpatient Detoxification Program for Alcohol Dependent Patients Seeking Abstinence. A Prospective Randomized Clinical Trial.|Completed||N/A|500|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 04:27:10.47042|2018-06-01 04:27:10.47042
NCT00226707|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-26|||2008-02-13|2005-09-26|2005-09-27|Estimate|||||||2008-02-13|2008-02-15|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|March 2005|Actual|2005-03-31|||||Interventional|||Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis|A 6-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Pimecrolimus Cream 1% in Patients With Mild-to-Moderate Chronic Hand Dermatitis Followed by a 6-Week Open-Label Phase to Assess the Safety of Pimecrolimus Cream 1%|Completed||Phase 3|652||Novartis|||||||||||||||||||2018-06-01 04:27:10.63539|2018-06-01 04:27:10.63539
NCT00226694|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2014-01-03|2005-09-23|2005-09-27|Estimate|||||||2014-01-03|2014-01-07|Estimate|September 2003||2003-09-30|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Alcohol and Gender Effects on Stress Circuit Function|Alcohol and Gender Effects on Stress Circuit Function|Completed||N/A|96|Actual|University of Cincinnati||2|||f||||||||||||||2018-06-01 04:27:10.69431|2018-06-01 04:27:10.69431
NCT00226681|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-09-09|2005-09-23|2005-09-27|Estimate|||||||2008-09-09|2008-09-10|Estimate|September 1999||1999-09-30|September 2008|2008-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Nurses Helping Sudden Cardiac Arrest Survivors Recover After Getting An Implantable Cardioverter Defibrillator (ICD)|Nursing Interventions Following Sudden Cardiac Arrest|Completed||Phase 1|150|Actual|National Institute of Nursing Research (NINR)||2|||f||||t||||||||||2018-06-01 04:27:10.777058|2018-06-01 04:27:10.777058
NCT00226668|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2007-12-27|2005-09-23|2005-09-27|Estimate|||||||2007-12-27|2008-01-03|Estimate|January 2006||2006-01-31|December 2007|2007-12-31|January 2008|Anticipated|2008-01-31|||||Interventional|||XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema|A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma|Withdrawn||Phase 3|120|Anticipated|Celtic Pharma Development Services||2||Alternate study projected to assess imaging endpoints versus clinical endpoints.|f||||t||||||||||2018-06-01 04:27:10.858304|2018-06-01 04:27:10.858304
NCT00226655|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|2012-07-31||2012-07-31|2005-09-23|2005-09-27|Estimate|2012-07-31|2012-08-31|Estimate||||2012-07-31|2012-08-31|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies|An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies|Completed||Phase 3|112|Actual|Celtic Pharma Development Services||1|||f||||t||||||||||2018-06-01 04:27:11.057411|2018-06-01 04:27:11.057411
NCT00226642|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2005-09-23|2005-09-23|2005-09-27|Estimate|||||||2005-09-23|2005-09-27|Estimate||||February 2002|2002-02-28||||||||Interventional|||Treatment of Mild and Subthreshold Depressive Disorders|"Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl (Treatment of Mild and Subthreshold Depressive Disorders. A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT)"|Unknown status|Active, not recruiting|Phase 4|369||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 04:27:11.518557|2018-06-01 04:27:11.518557
NCT00226629|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2017-08-24|2005-09-23|2005-09-27|Estimate|||||||2017-08-24|2017-08-25|Actual|August 2003|Actual|2003-08-31|August 2017|2017-08-31|August 2007|Actual|2007-08-31|June 2006|Actual|2006-06-30||Interventional|||Evaluation of the Endovascular Repair for Aortic Aneurysm (EVAR) Program at LHSC|Evaluation of the Endovascular Repair for Aortic Aneurysm (EVAR) Program at LHSC|Completed||N/A|130||Lawson Health Research Institute|||||f||||f|f|f||||||||2018-06-01 04:27:11.581841|2018-06-01 04:27:11.581841
NCT00226616|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-25|||2005-10-19|2005-09-25|2005-09-27|Estimate|||||||2005-10-19|2005-10-20|Estimate|November 2000||2000-11-30|September 2005|2005-09-30|July 2002||2002-07-31|||||Interventional|||Zinc Supplementation in Cholera Patients|Clinical Trial of Zinc Supplementation in Cholera Patients|Completed||Phase 3|||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:27:11.639312|2018-06-01 04:27:11.639312
NCT00226603|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2005-09-26|2005-09-26|2005-09-27|Estimate|||||||2005-09-26|2005-09-27|Estimate|September 1997||1997-09-30|June 1998|1998-06-30|June 1998||1998-06-30|||||Interventional|||Lyske Trial (Danish) Groin Trial|Prevention of Groin Injuries in Football Players|Unknown status|Active, not recruiting|Phase 2/Phase 3|1600||Hölmich, Per, M.D.|||||f||||||||||||||2018-06-01 04:27:11.704909|2018-06-01 04:27:11.704909
NCT00226590|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|2011-03-11||2017-02-20|2005-09-23|2005-09-27|Estimate|2011-04-22|2011-05-23|Estimate||||2017-02-20|2017-03-23|Actual|April 2003||2003-04-30|May 2011|2011-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Induction Gemcitabine & Carboplatin Followed by Paclitaxel & Carboplatin +XRT in NSCLC|Phase II Trial of Induction Gemcitabine and Carboplatin Followed by Paclitaxel and Carboplatin With Concurrent Thoracic Radiation for Patients With Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer|Completed||Phase 2|39|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 04:27:11.762581|2018-06-01 04:27:11.762581
NCT00226577|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|2010-10-26||2017-02-20|2005-09-23|2005-09-27|Estimate|2010-12-13|2011-01-12|Estimate||||2017-02-20|2017-03-23|Actual|February 2004||2004-02-29|January 2011|2011-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.|Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Pemetrexed in Resectable Non-Small-Cell Lung Cancer (NSCLC) With Pharmacogenomic Correlates.|Completed||Phase 2|52|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 04:27:11.9641|2018-06-01 04:27:11.9641
NCT00226564|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-28|2005-09-26|2005-09-27|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 1997||1997-08-31|October 2008|2008-10-31||||||||Interventional|||Genetic Determinants of Opioids Analgesia|The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy|Completed||N/A|100||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:27:12.178942|2018-06-01 04:27:12.178942
NCT00226551|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-28|2005-09-25|2005-09-27|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 1999||1999-08-31|October 2008|2008-10-31||||||||Interventional|||Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms|ß2 Adrenergic Receptor Polymorphisms and Vasodilation of Internal Mammary Artery Induced by Isoproterenol|Completed||N/A|100||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:27:12.22879|2018-06-01 04:27:12.22879
NCT00226538|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-28|2005-09-25|2005-09-27|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 1999||1999-08-31|October 2008|2008-10-31||||||||Interventional|||Prediction of Drug Interactions With CYP2C9 Substrates|Prediction of Potential Drug Interaction With CYP2C9 Substrate by Using Phenytoin Metabolic Ratio as a Marker of Its Activity in-Vivo.|Completed||N/A|16||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:27:12.284971|2018-06-01 04:27:12.284971
NCT00226525|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-10|||2006-11-06|2005-09-26|2005-09-27|Estimate|||||||2006-11-06|2006-11-07|Estimate|February 2005||2005-02-28|September 2006|2006-09-30|August 2006||2006-08-31|||||Interventional|||Effect of Metal Skin Sensitivity on Restenosis After Stent Implantation|Rate of Metal Skin Allergy in Cohorts of Patients With and Without Coronary Stent Restenosis|Unknown status|Active, not recruiting|N/A|150||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:27:12.338345|2018-06-01 04:27:12.338345
NCT00226512|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-07|2005-09-25|2005-09-27|Estimate|||||||2011-04-07|2011-04-08|Estimate|July 2004||2004-07-31|September 2005|2005-09-30||||||||Interventional|||To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning|Phase III Trial of a Non-myeloablative Preparative Regimen With Fludarabine and Busulfan With or Without Anti-lymphocyte Antibodies (Campath-1H or ATG) for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation From an HLA Compatible Donor|Withdrawn||Phase 3|203|Anticipated|Hadassah Medical Organization||||the PI is no longer work at Hadassah|f||||||||||||||2018-06-01 04:27:12.395359|2018-06-01 04:27:12.395359
NCT00226499|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23||2014-11-24|2015-01-12|2005-09-23|2005-09-27|Estimate||||2014-11-24|2014-12-11|Estimate|2015-01-12|2015-01-26|Estimate|September 2005||2005-09-30|January 2015|2015-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox|Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine|Completed||Phase 3|5735|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 04:27:12.482077|2018-06-01 04:27:12.482077
NCT00226486|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-08-20|2005-09-26|2005-09-27|Estimate|||||||2008-08-20|2008-08-21|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Examination and Treatment of Elderly After a Fall|Examination and Treatment of Elderly After a Fall- an Analysis in a Medical Technology Evaluation Perspective|Completed||N/A|392|Actual|Glostrup University Hospital, Copenhagen||2|||f||||||||||||||2018-06-01 04:27:12.739616|2018-06-01 04:27:12.739616
NCT00226473|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-25|||2006-06-20|2005-09-25|2005-09-27|Estimate|||||||2006-06-20|2006-06-21|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma|Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma|Unknown status|Recruiting|Phase 4|200||Dermatologic Cooperative Oncology Group|||||f||||||||||||||2018-06-01 04:27:12.801608|2018-06-01 04:27:12.801608
NCT00226460|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2015-03-17|2005-09-23|2005-09-27|Estimate|||||||2015-03-17|2015-03-18|Estimate|August 1997||1997-08-31|March 2015|2015-03-31|January 2001||2001-01-31|||||Interventional|||Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.||Completed||Phase 2|||Sanofi|||||||||||||||||||2018-06-01 04:27:12.914021|2018-06-01 04:27:12.914021
NCT00226447|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-10-23|2005-09-23|2005-09-27|Estimate|||||||2008-10-23|2008-10-24|Estimate|December 2002||2002-12-31|October 2008|2008-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients|A Study on the Viral Kinetics of Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in HBeAg Positive Chronic Hepatitis B|Completed||Phase 2|30||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:27:13.023605|2018-06-01 04:27:13.023605
NCT00226434|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2012-03-15|2005-09-23|2005-09-27|Estimate|||||||2012-03-15|2012-03-16|Estimate|January 2006||2006-01-31|March 2012|2012-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA)|Early vs Late Introduction of Antiretroviral Therapy in Naive HIV-infected Patients With Tuberculosis in Cambodia|Completed||Phase 3|661|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 04:27:13.126251|2018-06-01 04:27:13.126251
NCT00226421|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2010-02-12|2005-09-23|2005-09-27|Estimate|||||||2010-02-12|2010-02-15|Estimate|October 2004||2004-10-31|February 2010|2010-02-28|August 2005||2005-08-31|||||Interventional|||Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain|An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Experienced Patients With Chronic Low Back Pain|Completed||Phase 3|120||Endo Pharmaceuticals|||||||||||||||||||2018-06-01 04:27:13.243426|2018-06-01 04:27:13.243426
NCT00226408|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-25|||2006-06-20|2005-09-25|2005-09-27|Estimate|||||||2006-06-20|2006-06-21|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon|Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy|Unknown status|Recruiting|Phase 3|600||Dermatologic Cooperative Oncology Group|||||f||||||||||||||2018-06-01 04:27:13.40876|2018-06-01 04:27:13.40876
NCT00226395|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2010-02-12|2005-09-23|2005-09-27|Estimate|||||||2010-02-12|2010-02-15|Estimate|September 2004||2004-09-30|February 2010|2010-02-28|August 2005||2005-08-31|||||Interventional|||Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain|Randomized, Double-Blind, Placebo- and Active-Control, Single- and Multiple-Dose Evaluation of the Analgesic Efficacy and Safety of Oxymorphone Immediate Release (IR) Tablets in Patients With Moderate/Severe Pain Following Abdominal Surgery|Completed||Phase 3|320||Endo Pharmaceuticals|||||||||||||||||||2018-06-01 04:27:13.566438|2018-06-01 04:27:13.566438
NCT00226382|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2010-06-10|2005-09-23|2005-09-27|Estimate|||||||2010-06-10|2010-06-11|Estimate|January 2005||2005-01-31|October 2008|2008-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment|Treatment With Peginterferon Alfa-2a (40 KD) (PEGASYS®) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment. A Pilot Study.|Completed||Phase 4|50|Actual|Chinese University of Hong Kong|||||f||||f||||||||||2018-06-01 04:27:13.6928|2018-06-01 04:27:13.6928
NCT00226369|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2010-02-11|2005-09-21|2005-09-27|Estimate|||||||2010-02-11|2010-02-12|Estimate|December 1997||1997-12-31|September 2005|2005-09-30|June 2001||2001-06-30|||||Interventional|||Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery|Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy/Safety of CY-1503 (Cylexin) in Prevention of Reperfusion Injury in Neonates/Infants Undergoing Hypothermic Cardiopulmonary Bypass|Completed||Phase 2/Phase 3|242||Boston Children’s Hospital|||||||||||||||||||2018-06-01 04:27:13.780432|2018-06-01 04:27:13.780432
NCT00226356|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-17|2005-09-26|2005-09-27|Estimate|||||||2017-04-17|2017-04-18|Actual|December 2004||2004-12-31|April 2017|2017-04-30|September 17, 2008|Actual|2008-09-17|June 2007|Actual|2007-06-30||Interventional|||Natural Supplements for Unipolar Depression|Phase 4 Study: An Open Study of the Efficacy and Tolerability in Unipolar Depression of Augmentation of the One-carbon Cycle With L-methionine, Betaine and Folate|Completed||Phase 4|20|Actual|Cambridge Health Alliance||1|||f||||||||||||||2018-06-01 04:27:13.857104|2018-06-01 04:27:13.857104
NCT00226343|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-17|2005-09-26|2005-09-27|Estimate|||||||2017-04-17|2017-04-18|Actual|August 2003||2003-08-31|April 2017|2017-04-30|August 2006|Actual|2006-08-31|January 2006|Actual|2006-01-31||Interventional|||Depakote-ER for Depressive and Bipolar Depression|Phase 4 Study: Double-blind Placebo-controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non-refractory Bipolar Depression|Completed||Phase 4|25||Cambridge Health Alliance|||||||||||f||||||||2018-06-01 04:27:13.933958|2018-06-01 04:27:13.933958
NCT00226330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2010-11-18|2005-09-23|2005-09-27|Estimate|||||||2010-11-18|2010-11-19|Estimate|March 2005||2005-03-31|November 2010|2010-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus|A Double-Blind, Multi-Centre, Active-Controlled (15, 30, and 45 mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar (0.5 and 1 mg) in Patients With Type 2 Diabetes Mellitus (GALLEX 6)|Terminated||Phase 3|1100||AstraZeneca||||The development program has been terminated|||||||||||||||2018-06-01 04:27:14.059679|2018-06-01 04:27:14.059679
NCT00226317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-17|2005-09-26|2005-09-27|Estimate|||||||2017-04-17|2017-04-18|Actual|April 2004||2004-04-30|April 2017|2017-04-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Aripiprazole in the Treatment of Bipolar Depression|Phase 4 Study: An Open Prospective Study of the Safety and Effectiveness of Aripiprazole in the Treatment of Bipolar Depression|Completed||N/A|20|Actual|Cambridge Health Alliance||1|||||||||f||||||||2018-06-01 04:27:14.396616|2018-06-01 04:27:14.396616
NCT00226304|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2017-06-30|2005-09-23|2005-09-26|Estimate|||||||2017-06-30|2017-07-02|Actual|September 20, 2005||2005-09-20|April 15, 2009|2009-04-15|April 15, 2009||2009-04-15|||||Observational|||Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma|The Evaluation of Focal Contrast-Enhancing Brain Lesions in HIV-Infected Patients|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:27:14.455218|2018-06-01 04:27:14.455218
NCT00226291|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2014-05-27|2005-09-22|2005-09-26|Estimate|||||||2014-05-27|2014-05-28|Estimate|August 2004||2004-08-31|May 2014|2014-05-31|May 2007|Actual|2007-05-31|February 2006|Actual|2006-02-28||Interventional|||The Clinical Informationist: Does the Model Work|The Clinical Informationist: Does the Model Work|Completed||N/A|299|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:27:14.506926|2018-06-01 04:27:14.506926
NCT00226278|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2008-03-28|2005-09-23|2005-09-26|Estimate|||||||2008-03-28|2008-03-31|Estimate|September 2004||2004-09-30|March 2008|2008-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Safety Study of ORG 34517 for Major Depression With Psychotic Features|"Prospective, Double Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunct"|Completed||Phase 2|25|Anticipated|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:27:14.579364|2018-06-01 04:27:14.579364
NCT00226265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-02-17|2005-09-22|2005-09-26|Estimate|||||||2017-02-17|2017-02-23|Actual|January 1999|Actual|1999-01-31|February 2017|2017-02-28|September 2007|Actual|2007-09-30|December 2006|Actual|2006-12-31||Observational|||The Short Form-36: Pre- Versus Post-Surgical Administration in Cardiac Surgery Patients|The Short Form-36: Pre-vs. Post-Surgical Administration in Cardiac Surgery Patients|Completed|||50|Actual|Weill Medical College of Cornell University|||||f||||f||||||||No|No Plan to Share IPD|2018-06-01 04:27:14.718621|2018-06-01 04:27:14.718621
NCT00226239|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|2016-01-15||2017-07-09|2005-09-22|2005-09-26|Estimate|2017-07-09|2017-07-11|Actual||||2017-07-09|2017-07-11|Actual|October 2005||2005-10-31|April 2017|2017-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer|A Phase II Trial of Docetaxel, Cetuximab (C225), and Cisplatin Followed by Radiation, Cetuximab, and Cisplatin in Locally Advanced Head and Neck Cancer|Completed||Phase 2|39|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:27:14.872728|2018-06-01 04:27:14.872728
NCT00226226|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2008-02-10|2005-09-22|2005-09-26|Estimate|||||||2008-02-10|2008-02-15|Estimate|June 2006||2006-06-30|February 2008|2008-02-29|June 2007|Actual|2007-06-30|||||Interventional|||Peripherally Inserted Central Catheter Placement by IV Team Nurses Using the Sonic Flashlight|Peripherally Inserted Central Catheter Placement by IV Team Nurses Using the Sonic Flashlight|Completed||Phase 1|230|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:15.202877|2018-06-01 04:27:15.202877
NCT00226213|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2007-12-11|2005-09-22|2005-09-26|Estimate|||||||2007-12-11|2007-12-13|Estimate|February 2005||2005-02-28|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Peripherally Inserted Central Catheter Placement by Interventional Radiologists Using the Sonic Flashlight|Peripherally Inserted Central Catheter Placement by Interventional Radiologists Using the Sonic Flashlight|Completed||Phase 1|20|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:16.180159|2018-06-01 04:27:16.180159
NCT00226200|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2008-11-26|2005-09-22|2005-09-26|Estimate|||||||2008-11-26|2008-12-01|Estimate|November 2004||2004-11-30|November 2008|2008-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Soluble CD23 Expression in Asthma Patients Treated With OMA|Soluble CD23 Expression as a Marker of Immunomodulation and CLinical Response in Asthma Patients Treated With Omalizumab|Terminated||N/A|80||University of Mississippi Medical Center||||Completed|||||t||||||||||2018-06-01 04:27:16.245423|2018-06-01 04:27:16.245423
NCT00226187|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2007-02-14|2005-09-23|2005-09-26|Estimate|||||||2007-02-14|2007-02-15|Estimate|December 2003||2003-12-31|September 2005|2005-09-30||||||||Interventional|||A Randomized Clinical Trial on Supplementation of DHA and AA to Preterm Infants||Completed||N/A|140||University of Oslo|||||f||||||||||||||2018-06-01 04:27:16.318115|2018-06-01 04:27:16.318115
NCT00226174|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2005-09-22|2005-09-22|2005-09-26|Estimate|||||||2005-09-22|2005-09-26|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus|A Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Curcuminoids in Oral Lichen Planus|Terminated||Phase 2|||University of California, San Francisco|||||||||||||||||||2018-06-01 04:27:16.373262|2018-06-01 04:27:16.373262
NCT00226161|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2013-01-25|2005-09-22|2005-09-26|Estimate|||||||2013-01-25|2013-01-28|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|September 2013||2013-09-30|September 2013||2013-09-30||Interventional|||Chronic Pain After Inguinal Herniorrhaphy||Terminated||N/A|||University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:27:16.440383|2018-06-01 04:27:16.440383
NCT00226148|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2009-09-08|2005-09-23|2005-09-26|Estimate|||||||2009-09-08|2009-09-10|Estimate|September 2005||2005-09-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Immediate Implant Placement in the Molar Regions|Immediate Implant Placement in the Molar Regions|Completed||Early Phase 1|92|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 04:27:16.502686|2018-06-01 04:27:16.502686
NCT00226135|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2007-04-04|2005-09-23|2005-09-26|Estimate|||||||2007-04-04|2007-04-05|Estimate|March 2001||2001-03-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder|Lamotrigine Versus Lithium in Subjects With Bipolar Affective Disorders - a Randomised Study of Prophylactic Effect|Completed||Phase 3|150||University of Aarhus|||||f||||f||||||||||2018-06-01 04:27:16.563|2018-06-01 04:27:16.563
NCT00226122|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2010-06-24|2005-09-23|2005-09-26|Estimate|||||||2010-06-24|2010-06-25|Estimate|January 2003||2003-01-31|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal|The Effect of Indomethacin in Monosymptomatic Enuresis Nocturnal|Completed||Phase 4|56|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 04:27:16.627871|2018-06-01 04:27:16.627871
NCT00226109|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2010-10-19|2005-09-23|2005-09-26|Estimate|||||||2010-10-19|2010-10-20|Estimate|April 2004||2004-04-30|October 2010|2010-10-31|December 2011|Anticipated|2011-12-31|August 2011|Anticipated|2011-08-31||Interventional|SPICA||Clinical Trial Studying the Effects of Spironolactone on Heart and Skeletal Muscle Function in Chronic Alcoholics|Effect of Spironolactone Treatment on Heart- and Skeletal Muscle in Chronic Alcoholics|Suspended||Phase 4|40|Anticipated|University of Aarhus||1||Problems recruting patients|f||||t||||||||||2018-06-01 04:27:16.805595|2018-06-01 04:27:16.805595
NCT00226096|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-06-25|2005-09-23|2005-09-26|Estimate|||||||2008-06-25|2008-06-26|Estimate|November 2005||2005-11-30|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage|A Randomised Trial to Establish the Effects of Early Intensive Blood Pressure Lowering on Death and Disability in Patients With Stroke Due to Acute Intracerebral Haemorrhage|Completed||N/A|404|Actual|The George Institute|||||f||||t||||||||||2018-06-01 04:27:16.909094|2018-06-01 04:27:16.909094
NCT00226083|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2015-06-05|2005-09-22|2005-09-26|Estimate|||||||2015-06-05|2015-06-09|Estimate|August 2005||2005-08-31|June 2015|2015-06-30|September 2007|Anticipated|2007-09-30|September 2007|Anticipated|2007-09-30||Observational|||Study of Blood Platelets in Sickle Cell Disease|Studies of Large Platelets in Patients With Sickle Cell Disease|Withdrawn|||0|Actual|Rockefeller University||||PI returned to India|f||||f||||||||||2018-06-01 04:27:17.088135|2018-06-01 04:27:17.088135
NCT00226070|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2006-12-18|2005-09-23|2005-09-26|Estimate|||||||2006-12-18|2006-12-19|Estimate|September 2004||2004-09-30|December 2006|2006-12-31|September 2005||2005-09-30|||||Interventional|||Rehabilitation to Patients Over 65 Years Undergoing THA|Cross-Section Study Among Patients Waiting for or Already Undergoing THA Followed by a RCT|Unknown status|Recruiting|Phase 1/Phase 2|160||University of Aarhus|||||f||||||||||||||2018-06-01 04:27:17.15586|2018-06-01 04:27:17.15586
NCT00226057|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2005-09-22|2005-09-22|2005-09-26|Estimate|||||||2005-09-22|2005-09-26|Estimate|June 2005||2005-06-30|August 2005|2005-08-31|November 2005||2005-11-30|||||Interventional|||Efalizumab for Moderate to Severe Atopic Dermatitis|Efalizumab for Moderate to Severe Atopic Dermatitis - A Phase I Pilot Study in Adults|Completed||Phase 1|10||Oregon Health and Science University|||||||||||||||||||2018-06-01 04:27:17.253933|2018-06-01 04:27:17.253933
NCT00226044|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2013-04-25|2005-09-22|2005-09-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|September 2005||2005-09-30|April 2013|2013-04-30|December 2007||2007-12-31|||||Interventional|||Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.|Rectal and Oral Omeprazole Treatment of Gastroesophageal Reflux in Infants With Esophageal Atresia or Congenital Diaphragmatic Hernia; A Pharmacodynamic and Pharmacokinetic Study.|Unknown status|Recruiting|Phase 3|20|Anticipated|Rijnstate Hospital|||||f||||||||||||||2018-06-01 04:27:17.32282|2018-06-01 04:27:17.32282
NCT00226005|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2012-05-08|2005-09-22|2005-09-26|Estimate|||||||2012-05-08|2012-05-09|Estimate|December 2005||2005-12-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|December 2008|Actual|2008-12-31||Interventional|||PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma|Phase II Trial of PTK787/ZK222584 in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Who Failed First-Line Gemcitabine Therapy.|Completed||Phase 2|67|Actual|Pancreatic Cancer Research Team||1|||f||||t||||||||||2018-06-01 04:27:17.534697|2018-06-01 04:27:17.534697
NCT00225992|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2012-10-10|2005-09-23|2005-09-26|Estimate|||||||2012-10-10|2012-10-11|Estimate|February 2004||2004-02-29|October 2012|2012-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)|A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)|Terminated||Phase 2|||Oncology Specialties, Alabama||||terminated due to lack of accrual.|f||||f||||||||||2018-06-01 04:27:17.618685|2018-06-01 04:27:17.618685
NCT00225979|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2012-04-10|2005-09-23|2005-09-26|Estimate|||||||2012-04-10|2012-04-11|Estimate|November 2002||2002-11-30|April 2012|2012-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly|Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly|Completed||Phase 3|100|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:27:17.670867|2018-06-01 04:27:17.670867
NCT00225966|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-14|2005-09-23|2005-09-26|Estimate|||||||2013-11-14|2013-11-15|Estimate|August 2004||2004-08-31|November 2013|2013-11-30|October 2007||2007-10-31|||||Interventional|||Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control|Patient Registry to Study the Tined Lead Used With the InterStim System For Urinary Control|Terminated||N/A|153||MedtronicNeuro||||Study design was changed and is now InSite trial #1634 - See NCT00547378|f||||||||||||||2018-06-01 04:27:17.737739|2018-06-01 04:27:17.737739
NCT00225927|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-02-28|2005-09-23|2005-09-26|Estimate|||||||2011-02-28|2011-03-02|Estimate|June 2004||2004-06-30|March 2010|2010-03-31|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers|A Prospective, Randomized, Controlled Trial of Radioguided Seed Localization Versus Standard Needle Localization of Nonpalpable Breast Cancers|Completed||N/A|333|Actual|McMaster University|||||f||||f||||||||||2018-06-01 04:27:17.792569|2018-06-01 04:27:17.792569
NCT00225914|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2010-11-23|2005-09-22|2005-09-26|Estimate|||||||2010-11-23|2010-11-24|Estimate|September 2004||2004-09-30|November 2010|2010-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Study of Paxil Use in Menopausal Women|Paroxetine Controlled Release in the Treatment of Symptomatic Menopausal Women Following Discontinuation of Hormone Therapy|Completed||Phase 4|64|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:27:17.968473|2018-06-01 04:27:17.968473
NCT00225901|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-22|2005-09-22|2005-09-26|Estimate|||||||2005-09-22|2005-09-26|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Interventional|||Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure|Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant and Late-Onset Hepatic Failure|Unknown status|Recruiting|Phase 1/Phase 2|16||Kyoto University, Graduate School of Medicine|||||f||||||||||||||2018-06-01 04:27:18.083255|2018-06-01 04:27:18.083255
NCT00225888|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2017-04-12|2005-09-22|2005-09-26|Estimate|||||||2017-04-12|2017-04-13|Actual|October 2004||2004-10-31|April 2017|2017-04-30|July 20, 2007|Actual|2007-07-20|July 20, 2007|Actual|2007-07-20||Interventional|||Feasibility Study of Digital Photography and Group Discussion for People With Diabetes|Digital Photography and Group Discussion as a Means of Affecting Dietary Change Among People With Type 2 Diabetes: Feasibility Project|Terminated||N/A|36|Anticipated|Joslin Diabetes Center||||Investigators left Joslin|f||||||||||||||2018-06-01 04:27:18.168175|2018-06-01 04:27:18.168175
NCT00225875|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-10-25|2005-09-22|2005-09-26|Estimate|||||||2005-10-25|2005-10-27|Estimate|September 2003||2003-09-30|March 2005|2005-03-31|July 2007||2007-07-31|||||Interventional|||Study of the Effectiveness of Rituximab in Adults With Chronic and Severe Immune Thrombocytopenic Purpura and Candidate for a Splenectomy|Evaluation De l’Efficacité Du Rituximab (Mabthéra) Chez l'Adulte Atteint d'Un Purpura thrombopénique Auto-Immun Chronique Et sévère Et Candidat à La splénectomie|Terminated||Phase 2|65||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:18.256084|2018-06-01 04:27:18.256084
NCT00225862|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2016-09-13|2005-09-23|2005-09-26|Estimate|||||||2016-09-13|2016-09-15|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|December 2005|Actual|2005-12-31|||||Interventional|||A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)|A 12-week, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Intermittent Dosing of Ropinirole in Patients With Restless Legs Syndrome (RLS)|Completed||Phase 3|140|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:27:18.34223|2018-06-01 04:27:18.34223
NCT00225849|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2005-09-22|2005-09-22|2005-09-26|Estimate|||||||2005-09-22|2005-09-26|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|September 2010||2010-09-30|||||Interventional|||Japanese Primary Prevention Project With Aspirin|Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP|Unknown status|Recruiting|Phase 4|10000||Ministry of Health, Labour and Welfare, Japan|||||f||||||||||||||2018-06-01 04:27:18.494605|2018-06-01 04:27:18.494605
NCT00225836|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2007-01-12|2005-09-22|2005-09-26|Estimate|||||||2007-01-12|2007-01-17|Estimate|September 2005||2005-09-30|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Treatment of Dysmenorrhoea With the OVA TENS Apparatus|Treatment of Dysmenorrhoea With the OVA TENS Apparatus|Completed||N/A|20||The Hospital of Vestfold|||||f||||||||||||||2018-06-01 04:27:18.588772|2018-06-01 04:27:18.588772
NCT00225823|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2016-09-13|2005-09-22|2005-09-26|Estimate|||||||2016-09-13|2016-09-15|Estimate|May 2005||2005-05-31|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study In Adults And Adolescents With Seasonal Allergic Rhinitis.|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis in Europe|Completed||Phase 3|288|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:27:18.677166|2018-06-01 04:27:18.677166
NCT00225810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2011-05-18|2005-09-22|2005-09-26|Estimate|||||||2011-05-18|2011-05-19|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease|Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tbl. 500 mg in Children With Crohn´s Disease|Completed||Phase 4|50|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:27:18.796021|2018-06-01 04:27:18.796021
NCT00225797|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2010-02-12|2005-09-22|2005-09-26|Estimate|||||||2010-02-12|2010-02-15|Estimate|November 2004||2004-11-30|February 2010|2010-02-28|July 2005||2005-07-31|||||Interventional|||Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain|An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naïve Patients With Chronic Low Back Pain|Completed||Phase 3|160||Endo Pharmaceuticals|||||||||||||||||||2018-06-01 04:27:18.869592|2018-06-01 04:27:18.869592
NCT00225784|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|2012-08-22||2014-07-10|2005-09-22|2005-09-26|Estimate|2013-04-16|2013-04-18|Estimate||||2014-07-10|2014-07-16|Estimate|February 2005||2005-02-28|October 2011|2011-10-31|September 2012|Actual|2012-09-30|February 2010|Actual|2010-02-28||Interventional|||Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer|A Phase II Trial of Cetuximab, Radiotherapy and Twice Weekly Gemcitabine in Patients With Adenocarcinoma of the Pancreas|Completed||Phase 2|37|Actual|Dartmouth-Hitchcock Medical Center|Our study suffers limitations common to single institution trials, namely small patient numbers and selection bias. Our cohort of subjects is too small to adequately assess the effect of tumor EGFR and KRAS status on outcome.|1|||f||||t||||||||||2018-06-01 04:27:19.015122|2018-06-01 04:27:19.015122
NCT00225758|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2015-01-12|2005-09-22|2005-09-26|Estimate|||||||2015-01-12|2015-01-14|Estimate|January 2006||2006-01-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy|Lapatinib in Endocrine-Resistant Metastatic Breast Cancer|Terminated||Phase 2|27|Actual|Dartmouth-Hitchcock Medical Center||1||slow accrual|f||||t||||||||||2018-06-01 04:27:19.217011|2018-06-01 04:27:19.217011
NCT00225745|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2015-10-12|2005-09-22|2005-09-26|Estimate|||||||2015-10-12|2015-10-14|Estimate|April 2004||2004-04-30|August 2015|2015-08-31|September 2015|Actual|2015-09-30|October 2013|Actual|2013-10-31||Observational|||Ghrelin Levels in Pancreatic Cancer Patients|Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer|Completed|||72|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||t||||||Samples Without DNA|"~     Whole Blood~   "|||2018-06-01 04:27:19.492787|2018-06-01 04:27:19.492787
NCT00225732|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|2011-04-01||2016-05-17|2005-09-22|2005-09-26|Estimate|2011-08-10|2011-09-15|Estimate||||2016-05-17|2016-06-22|Estimate|January 2005||2005-01-31|May 2016|2016-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Ibuprofen Injection (IVIb) for Treatment of Pain in the Post-Operative Adult Patients|Completed||Phase 3|319|Actual|Cumberland Pharmaceuticals||2|||f||||t||||||||||2018-06-01 04:27:19.581738|2018-06-01 04:27:19.581738
NCT00225719|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-23|||2008-11-06|2005-09-23|2005-09-26|Estimate|||||||2008-11-06|2008-11-10|Estimate|July 2005||2005-07-31|November 2008|2008-11-30||||||||Interventional|||Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL|Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound.|Completed||Phase 2|180|Anticipated|CSL Limited|||||f||||||||||||||2018-06-01 04:27:19.977102|2018-06-01 04:27:19.977102
NCT00225706|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2010-04-08|2005-09-22|2005-09-26|Estimate|||||||2010-04-08|2010-04-12|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of Caldolor in Hospitalized Febrile Pediatric Patients|Efficacy and Safety Study of Caldolor in Hospitalized Febrile Pediatric Patients|Completed||Phase 3|||Cumberland Pharmaceuticals|||||||||||||||||||2018-06-01 04:27:20.047214|2018-06-01 04:27:20.047214
NCT00225693|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-01-30|2005-09-23|2005-09-26|Estimate|||||||2012-01-30|2012-02-01|Estimate|October 2003||2003-10-31|January 2012|2012-01-31|July 2005||2005-07-31|||||Interventional|ELUTES III||V-Flex Plus PTX Drug Eluting Coronary Stent|ELUTES III - V-Flex Plus PTX Drug Eluting Coronary Stent|Completed||N/A|150||Cook Group Incorporated|||||f||||||||||||||2018-06-01 04:27:20.112996|2018-06-01 04:27:20.112996
NCT00225680|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-01-30|2005-09-23|2005-09-26|Estimate|||||||2012-01-30|2012-02-01|Estimate|April 2002||2002-04-30|January 2012|2012-01-31|August 2005||2005-08-31|||||Interventional|ELUTES II||In Stent ELUTES Study|ELUTES II - In Stent ELUTES Study|Completed||N/A|124||Cook Group Incorporated|||||f||||||||||||||2018-06-01 04:27:20.213052|2018-06-01 04:27:20.213052
NCT00225667|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-22|2005-09-12|2005-09-26|Estimate|||||||2005-11-22|2005-11-23|Estimate|December 2005||2005-12-31|November 2005|2005-11-30|July 2007||2007-07-31|||||Interventional|||Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers|Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension, Permanent Pacemakers and Risk Factors for Developing Atrial Fibrillation|Unknown status|Not yet recruiting|Phase 3|200||Connolly, Stuart, M.D.|||||f||||||||||||||2018-06-01 04:27:20.277766|2018-06-01 04:27:20.277766
NCT00225654|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-01-30|2005-09-23|2005-09-26|Estimate|||||||2012-01-30|2012-02-01|Estimate|January 2000||2000-01-31|January 2012|2012-01-31|November 2001||2001-11-30|||||Interventional|ELUTES I||The ELUTES Clinical Trial|The ELUTES Clinical Trial (European Evaluation of Paclitaxel Eluting Stent)|Completed||N/A|192||Cook Group Incorporated|||||f||||||||||||||2018-06-01 04:27:20.361138|2018-06-01 04:27:20.361138
NCT00225641|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2015-12-21|2005-09-23|2005-09-26|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2006||2006-03-31|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer|COLOFOL - A Pragmatic Study to Assess the Frequency of Surveillance Tests After Curative Resection in Patients With Stage II and III Colorectal Cancer - a Randomised Multicentre Trial|Unknown status|Active, not recruiting|N/A|2500|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||||2018-06-01 04:27:20.424973|2018-06-01 04:27:20.424973
NCT00225628|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2005-09-23|2005-09-23|2005-09-26|Estimate|||||||2005-09-23|2005-09-26|Estimate|September 2000||2000-09-30|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||Improving Quality With Outpatient Decision Support|Improving Quality With Outpatient Decision Support|Completed||N/A|3000||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:27:20.51343|2018-06-01 04:27:20.51343
NCT00225615|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2009-08-18|2005-09-22|2005-09-26|Estimate|||||||2009-08-18|2009-08-20|Estimate|November 2005||2005-11-30|August 2009|2009-08-31|June 2006|Actual|2006-06-30|||||Interventional|||A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels|A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels|Completed||Phase 3|100||BioMarin Pharmaceutical|||||||||||||||||||2018-06-01 04:27:20.589169|2018-06-01 04:27:20.589169
NCT00225602|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2005-09-22|2005-09-22|2005-09-26|Estimate|||||||2005-09-22|2005-09-26|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|May 2006||2006-05-31|||||Interventional|||Assertive Community Treatment in Copenhagen|Quasi-Experimental Trial of the Effect of Assertive Community Treatment Among Those With Severe Mental Disorder|Unknown status|Active, not recruiting|N/A|400||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:27:20.676252|2018-06-01 04:27:20.676252
NCT00225589|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2010-11-18|2005-09-22|2005-09-26|Estimate|||||||2010-11-18|2010-11-19|Estimate|August 2002||2002-08-31|November 2010|2010-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)|A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)|Completed||Phase 3|840||AstraZeneca|||||||||||||||||||2018-06-01 04:27:20.754252|2018-06-01 04:27:20.754252
NCT00225576|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2014-01-23|2005-09-23|2005-09-26|Estimate|||||||2014-01-23|2014-01-24|Estimate|September 2005||2005-09-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2007|Actual|2007-11-30||Interventional|||Statewide Implementation of Electronic Health Records|Statewide Implementation of Electronic Health Records|Completed||Phase 2|2030|Anticipated|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||f||||||||||2018-06-01 04:27:20.877027|2018-06-01 04:27:20.877027
NCT00225563|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2007-06-12|2005-09-22|2005-09-26|Estimate|||||||2007-06-12|2007-06-13|Estimate|October 2004||2004-10-31|September 2005|2005-09-30|September 2007|Anticipated|2007-09-30|||||Interventional|||Taconic Health Information Network and Community (THINC)|Transforming Healthcare Quality Through I.T.|Unknown status|Recruiting|N/A|9000|Anticipated|Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:27:20.94019|2018-06-01 04:27:20.94019
NCT00225550|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2007-08-03|2005-09-22|2005-09-26|Estimate|||||||2007-08-03|2007-08-06|Estimate||||August 2007|2007-08-31||||||||Interventional|||A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors|Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Daily for 5 Consecutive Days by Intravenous Infusion in Subjects With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX 01 003)|Terminated||Phase 1/Phase 2|||Adherex Technologies, Inc.|||||||||||||||||||2018-06-01 04:27:21.005299|2018-06-01 04:27:21.005299
NCT00225537|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2006-09-07|2005-09-21|2005-09-23|Estimate|||||||2006-09-07|2006-09-11|Estimate|September 2005||2005-09-30|April 2006|2006-04-30|August 2007||2007-08-31|||||Interventional|||4-Methylumbelliferone as a Treatment for Chronic HBV/HCV|Evaluation of 4-Methylumbelliferone for Treatment of Chronic Hepatitis B (HBV) and Chronic Hepatitis C (HCV)|Unknown status|Active, not recruiting|Phase 2|160||MTmedical Institute of Health|||||f||||||||||||||2018-06-01 04:27:21.050938|2018-06-01 04:27:21.050938
NCT00225524|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-22|2005-09-20|2005-09-23|Estimate|||||||2007-05-22|2007-05-24|Estimate|September 2004||2004-09-30|May 2007|2007-05-31||||||||Interventional|||Study Evaluating Long-Term Safety of Effexor XR in Patients With Major Depression.|Phase III Long-Term Administration Study of Effexor XR for the Treatment of Depression|Completed||Phase 3|150|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:27:21.217521|2018-06-01 04:27:21.217521
NCT00225511|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-22|2005-09-20|2005-09-23|Estimate|||||||2007-05-22|2007-05-24|Estimate|June 2004||2004-06-30|May 2007|2007-05-31||||||||Interventional|||Study Evaluating Effexor XR for Major Depression.|Phase III Multi-Center, Double-Blind, Comparative Study of Effexor XR for the Treatment of Depression|Completed||Phase 3|590|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:27:21.386568|2018-06-01 04:27:21.386568
NCT00225498|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2012-12-12||2015-09-02|2005-09-22|2005-09-23|Estimate|2015-09-02|2015-09-10|Estimate||||2015-09-02|2015-09-10|Estimate|June 2002||2002-06-30|September 2015|2015-09-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Baseline characteristics for all participants prior to randomization are reported because treatment assignment information is not available. That information was not preserved when the orginally planned analyses were not conducted because the enrollment was insufficient for statistically valid results.|Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade|Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade|Completed||N/A|35|Actual|Northwell Health|This is a small sample.|2|||f||||f||||||||||2018-06-01 04:27:21.545227|2018-06-01 04:27:21.545227
NCT00225485|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-25|2005-09-20|2005-09-23|Estimate|||||||2007-05-25|2007-05-28|Estimate|December 2003||2003-12-31|May 2007|2007-05-31||||||||Interventional|||Study Evaluating Effexor XR in Elderly Patients With Major Depression.|Phase III Study of Effexor XR for the Treatment of Elderly Patients With Depression|Completed||Phase 3|100||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:27:21.725096|2018-06-01 04:27:21.725096
NCT00225472|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-10|2005-09-22|2005-09-23|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2004||2004-06-30|May 2016|2016-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Organ Preservation Media Investigation|Organ Preservation Media Investigation|Completed||Phase 1|20|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:27:21.851506|2018-06-01 04:27:21.851506
NCT00225459|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2011-10-04|2005-09-21|2005-09-23|Estimate|||||||2011-10-04|2011-10-05|Estimate|June 2005||2005-06-30|October 2011|2011-10-31|December 2008|Actual|2008-12-31|||||Observational|||Does Spiritual/Religious Commitment Mediate the Relationship Between Mood Variability and Suicidal Ideation.|Does Spiritual/Religious Commitment Mediate the Relationship Between Mood Variability and Suicidal Ideation.|Completed|||200|Anticipated|University of Saskatchewan|||||f||||||||||||||2018-06-01 04:27:21.929814|2018-06-01 04:27:21.929814
NCT00225446|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2008-06-03|2005-09-22|2005-09-23|Estimate|||||||2008-06-03|2008-06-04|Estimate|February 2006||2006-02-28|June 2008|2008-06-30|January 2009|Anticipated|2009-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Micron Tracker: Computer-Assisted Orthognathic Surgery With a Third Generation Optic Repositioning System|Computer-Assisted Orthognathic Surgery With a Third Generation Optic Repositioning System.|Suspended||Phase 1/Phase 2|20|Anticipated|University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:27:21.986083|2018-06-01 04:27:21.986083
NCT00225433|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2015-12-01|2005-09-21|2005-09-23|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2005||2005-09-30|December 2015|2015-12-31|June 2008|Actual|2008-06-30|December 2006|Actual|2006-12-31||Interventional|||Luteal Phase FSH in the IVF Poor Responder|Luteal Phase Recombinant FSH vs. Follicular Phase Recombinant FSH for IVF Stimulation in the Poor Responder|Completed||Phase 4|20|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 04:27:22.053091|2018-06-01 04:27:22.053091
NCT00225420|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2017-03-09||2017-04-26|2005-09-21|2005-09-23|Estimate|2017-04-26|2017-06-01|Actual||||2017-04-26|2017-06-01|Actual|August 2005||2005-08-31|April 2017|2017-04-30|August 2012|Actual|2012-08-31|June 2010|Actual|2010-06-30||Interventional|NRR|All patients included in this trial were high-risk localized (Gleason 8-10 or PSA level >= 20 ng/mL) prostate cancer, or T3 disease.|Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer|A Phase I/II Study of Concurrent Weekly Docetaxel (Taxotere®), Androgen Ablation, and Adaptive External Beam Radiotherapy for Localized High-Risk Adenocarcinoma of the Prostate|Completed||Phase 1/Phase 2|23|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:27:22.152702|2018-06-01 04:27:22.152702
NCT00225407|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-21|2005-09-21|2005-09-23|Estimate|||||||2005-09-21|2005-09-23|Estimate|July 2005||2005-07-31|March 2005|2005-03-31|December 2005||2005-12-31|||||Interventional|||Processing and Effects of Cannabis|A Double-Blind, Randomised, Placebo-Controlled, Cross-Over Study on the Pharmacokinetics and Effects of Cannabis|Unknown status|Recruiting|Phase 1|27||UMC Utrecht|||||f||||||||||||||2018-06-01 04:27:22.465874|2018-06-01 04:27:22.465874
NCT00225394|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-21|2005-09-21|2005-09-23|Estimate|||||||2005-09-21|2005-09-23|Estimate|October 2003||2003-10-31|August 2005|2005-08-31|July 2006||2006-07-31|||||Observational|||Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients|Long-Term Valcyte Therapy in Transplant Patients and the Development of Ganciclovir Resistant CMV|Completed|||100||University of Massachusetts, Worcester|||||||||||||||||||2018-06-01 04:27:22.552175|2018-06-01 04:27:22.552175
NCT00225381|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2011-02-10|2005-09-21|2005-09-23|Estimate|||||||2011-02-10|2011-02-11|Estimate|August 2005||2005-08-31|February 2011|2011-02-28|December 2011|Anticipated|2011-12-31|||||Observational|||Gas Kinetics and Metabolism in Anesthesia During Non Steady State|Gas Kinetics and Metabolism in Anesthesia During Non Steady State|Unknown status|Recruiting||100|Anticipated|University of California, Irvine|||7||f||||f||||||||||2018-06-01 04:27:22.655308|2018-06-01 04:27:22.655308
NCT00225368|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2010-02-05|2005-09-21|2005-09-23|Estimate|||||||2010-02-05|2010-02-08|Estimate||||September 2005|2005-09-30||||||||Interventional|||Effects of Insecticide Treated Bednets on Child Morbidity and Mortality|Long Term Effects of Insecticide Treated Bednets on the Morbidity and Mortality Caused by Malaria and on the Overall Mortality in Young Children of a Rural Population in Burkina Faso|Completed||N/A|||Heidelberg University|||||f||||||||||||||2018-06-01 04:27:22.758506|2018-06-01 04:27:22.758506
NCT00225355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2009-02-18|2005-09-21|2005-09-23|Estimate|||||||2009-02-18|2009-02-19|Estimate|February 2006||2006-02-28|February 2009|2009-02-28|November 2006|Anticipated|2006-11-30|||||Interventional|||Rosiglitazone Versus Placebo in Chronic Stable Angina|Insulin Sensitisation as a Novel Mechanism to Lessen Ischaemic Burden in Overweight Non-Diabetic Patients With Chronic Stable Angina: A Pilot Study|Terminated||Phase 4|80|Anticipated|University of Glasgow|||||f||||||||||||||2018-06-01 04:27:22.810109|2018-06-01 04:27:22.810109
NCT00225342|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2006-09-07|2005-09-21|2005-09-23|Estimate|||||||2006-09-07|2006-09-08|Estimate||||September 2005|2005-09-30||||||||Interventional|||Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina|Effects of Rosiglitazone and Sulphonylureas on Ischaemic Burden, Blood Pressure and Novel Risk Markers Inclusive of Vascular Function in Patients With Chronic Stable Angina and Type 2 Diabetes Mellitus: A Randomised, Double-Blinded Study.|Withdrawn||Phase 4|60||University of Glasgow|||||f||||||||||||||2018-06-01 04:27:22.873248|2018-06-01 04:27:22.873248
NCT00225329|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-21|2005-09-21|2005-09-23|Estimate|||||||2005-09-21|2005-09-23|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|August 2004||2004-08-31|||||Interventional|||Early Labour Assessment and Support at Home|Early Labour Support at Home: RCT of Nurse Visits and Telephone Triage|Completed||N/A|1466||University of British Columbia|||||f||||||||||||||2018-06-01 04:27:22.963271|2018-06-01 04:27:22.963271
NCT00225316|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2011-05-13|2005-09-21|2005-09-23|Estimate|||||||2011-05-13|2011-05-17|Estimate|August 2005||2005-08-31|May 2011|2011-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Maternal Acupuncture for Substance Abuse|Can Maternal Acupuncture for Chemically Dependent Pregnant Women Reduce the Severity of Neonatal Abstinence Syndrome? - A Randomized Controlled Trial|Completed||Phase 3|89|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:27:23.062479|2018-06-01 04:27:23.062479
NCT00225303|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-18|2005-09-22|2005-09-23|Estimate|||||||2011-05-18|2011-05-19|Estimate|March 2005||2005-03-31|October 2010|2010-10-31|June 2006|Actual|2006-06-30|||||Interventional|||TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use|A Phase II, Randomized, Active Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-na�ve and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use.|Completed||Phase 2|116|Actual|Tibotec Pharmaceuticals, Ireland|||||f||||||||||||||2018-06-01 04:27:23.113373|2018-06-01 04:27:23.113373
NCT00225290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2011-10-07|2005-09-21|2005-09-23|Estimate|||||||2011-10-07|2011-10-12|Estimate|February 2003||2003-02-28|September 2005|2005-09-30||||||||Interventional|||Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve|Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve|Terminated||Phase 3|230|Anticipated|TTY Biopharm||||slowly recruitment rate|f||||||||||||||2018-06-01 04:27:23.174761|2018-06-01 04:27:23.174761
NCT00225277|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2008-10-17||2012-02-27|2005-09-21|2005-09-23|Estimate|2009-04-16|2009-06-10|Estimate||||2012-02-27|2012-02-28|Estimate|July 2003||2003-07-31|February 2012|2012-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|PERISCOPE||Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus|A Double-Blind, Randomized, Comparator-Controlled Study In Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultrasound|Completed||Phase 3|547|Actual|Takeda|Composite Endpoints A,B,C include cardiovascular mortality, nonfatal MI and nonfatal stroke. In addition, B: coronary revascularization, carotid endarterectomy/stenting, unstable angina hosp. or CHF; C: hospitalization for unstable angina or CHF.|2|||f||||f||||||||||2018-06-01 04:27:23.362716|2018-06-01 04:27:23.362716
NCT00225264|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2012-02-27|2005-09-21|2005-09-23|Estimate|||||||2012-02-27|2012-02-28|Estimate|October 2003||2003-10-31|February 2012|2012-02-29|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|CHICAGO||Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.|A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus Glimepiride on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickness|Completed||Phase 3|458|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:27:24.484392|2018-06-01 04:27:24.484392
NCT00225251|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2014-05-13||2015-10-29|2005-09-21|2005-09-23|Estimate|2014-11-19|2014-11-24|Estimate||||2015-10-29|2015-11-26|Estimate|November 2004||2004-11-30|October 2014|2014-10-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional||adults with dysthymic disorder, males and females|Wellbutrin XL for Dysthymic Disorder|Double-Blind Treatment of Outpatients With Dysthymic Disorder With Wellbutrin XL|Completed||Phase 4|18|Actual|St. Luke's-Roosevelt Hospital Center|Early termination led to small numbers of subjects analyzed|2|||f||||f||||||||||2018-06-01 04:27:24.578439|2018-06-01 04:27:24.578439
NCT00225238|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2013-06-04|2005-09-21|2005-09-23|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2003||2003-12-31|June 2013|2013-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep|The Effect of Esomeprazole (Nexium) on the Incidence and Severity of Gastrointestinal Adverse Events Associated With a Colonoscopy Purgative|Completed||Phase 4|500|Actual|Thomas Jefferson University|||||f||||f||||||||||2018-06-01 04:27:24.89251|2018-06-01 04:27:24.89251
NCT00225225|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2016-10-18|2005-09-21|2005-09-23|Estimate|||||||2016-10-18|2016-10-20|Estimate|October 2002||2002-10-31|October 2016|2016-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Rosiglitazone-Induced Weight Gain|Rosiglitazone-Induced Weight Gain|Terminated||N/A|45|Actual|Stanford University||2||due to published data on Rosiglitazone|f||||||||||||||2018-06-01 04:27:24.948536|2018-06-01 04:27:24.948536
NCT00225212|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2014-08-26||2014-09-04|2005-09-21|2005-09-23|Estimate|2014-08-26|2014-09-05|Estimate||||2014-09-04|2014-09-15|Estimate|November 1997||1997-11-30|September 2014|2014-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma|Clinical Trial Of C2B8 Monoclonal Antibody Following High Dose Therapy And Autografting In B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|35|Actual|Stanford University||1|||f||||f||||||||||2018-06-01 04:27:25.025082|2018-06-01 04:27:25.025082
NCT00225199|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2010-04-22|2005-09-22|2005-09-23|Estimate|||||||2010-04-22|2010-04-23|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Efficacy and Safety of SH T00660AA in Treatment of Endometriosis|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Oral Administration of SH T00660AA for the Treatment of Endometriosis Over 12 Weeks|Completed||Phase 3|198|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:27:25.247309|2018-06-01 04:27:25.247309
NCT00225186|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2014-01-08|2005-09-22|2005-09-23|Estimate|||||||2014-01-08|2014-01-09|Estimate|July 2004||2004-07-31|January 2014|2014-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety and Efficacy of SH T00660AA in Treatment of Endometriosis|A Multi-center, Open, One-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of T00660AA for the Treatment of Endometriosis Over 52 Weeks (Follow-up to Study 307041)|Completed||Phase 3|168|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:27:25.310578|2018-06-01 04:27:25.310578
NCT00225173|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-08-26|2005-09-21|2005-09-23|Estimate|||||||2014-08-26|2014-08-27|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|September 2006|Actual|2006-09-30|September 2005|Actual|2005-09-30||Interventional|||Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease|A Phase II Trial of Stanford VI ± Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease With 3+ Risk Factors: the G6 Study|Terminated||Phase 2|45|Anticipated|Stanford University||1|||f||||||||||||||2018-06-01 04:27:25.395216|2018-06-01 04:27:25.395216
NCT00225160|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2008-09-17|2005-09-21|2005-09-23|Estimate|||||||2008-09-17|2008-09-18|Estimate|November 2003||2003-11-30|September 2008|2008-09-30||||||||Interventional|||ALCAR Prophylaxis Study|A Randomised Double Blinded Placebo Controlled Pilot Study to Evaluate the Safety and Efficacy of Acetyl L Carnitine in Combination With Antiretroviral Therapy for the Prevention of Distal Symmetric Polyneuropathy and Lipid Abnormalities in Treatment naïve HIV Infected Subjects|Unknown status|Active, not recruiting|Phase 2|50||Royal Free Hampstead NHS Trust|||||f||||||||||||||2018-06-01 04:27:25.477649|2018-06-01 04:27:25.477649
NCT00225147|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2012-02-22||2013-02-20|2005-09-21|2005-09-23|Estimate|2012-07-27|2012-08-31|Estimate||||2013-02-20|2013-02-22|Estimate|July 2005||2005-07-31|February 2013|2013-02-28|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|A Randomized, Placebo-controlled, Double Blind Phase II/III Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema|Completed||Phase 2/Phase 3|77|Actual|Pharming Technologies B.V.||3|||f||||t||||||||||2018-06-01 04:27:25.542441|2018-06-01 04:27:25.542441
NCT00225121|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2012-04-06|2005-09-21|2005-09-23|Estimate|||||||2012-04-06|2012-04-09|Estimate|October 2005||2005-10-31|April 2012|2012-04-30|September 2010|Actual|2010-09-30|April 2007|Actual|2007-04-30||Interventional|||Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors|A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of 2 Dosing Schedules Of PF-00299804 In Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|121|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:27:26.83277|2018-06-01 04:27:26.83277
NCT00225108|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2018-02-05|2005-09-21|2005-09-23|Estimate|||||||2018-02-05|2018-02-07|Actual|July 2002||2002-07-31|February 2018|2018-02-28|September 2006||2006-09-30|||||Interventional|||The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section|The Cesarean Section Thromboprophylaxis Pilot Study:A Randomized Open-Label Controlled Pilot Study of Prophylactic Low Molecular Weight Heparin in High Risk Postpartum Women Following Cesarean Section|Completed||Phase 2/Phase 3|30||Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 04:27:26.909597|2018-06-01 04:27:26.909597
NCT00225095|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-12-02|2005-09-21|2005-09-23|Estimate|||||||2014-12-02|2014-12-04|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy|A Phase I/II, Randomized, Controlled, Double Blind, Study of Chondrogen - Adult Universal Cell Delivered by Intra-Articular Injection Following Meniscectomy in Patients 18-60 Years|Completed||Phase 1/Phase 2|55|Actual|Mesoblast, Ltd.||3|||f||||||||||||||2018-06-01 04:27:26.987301|2018-06-01 04:27:26.987301
NCT00225082|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2010-10-04|2005-09-21|2005-09-23|Estimate|||||||2010-10-04|2010-10-05|Estimate|November 2004||2004-11-30|October 2010|2010-10-31|October 2007|Actual|2007-10-31|December 2006|Actual|2006-12-31||Observational|||SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function|SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial|Completed|||12|Actual|Northwestern University|||||f||||f||||||Samples Without DNA|"~     adipose tissue, blood~   "|||2018-06-01 04:27:27.115119|2018-06-01 04:27:27.115119
NCT00225069|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2012-08-22|2005-09-21|2005-09-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Thoracoscopic Sympathectomy for Blushing|Thoracoscopic Sympathectomy for Blushing. A Prospective Randomised Trial.|Completed||Phase 4|100|Actual|Odense University Hospital||2|||f||||||||||||||2018-06-01 04:27:27.296386|2018-06-01 04:27:27.296386
NCT00225056|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2007-04-18|2005-09-21|2005-09-23|Estimate|||||||2007-04-18|2007-04-20|Estimate|October 2003||2003-10-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma|Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma|Terminated||Phase 2|43||Oncology Specialties, Alabama||||Terminated due to lack of accrual|f||||||||||||||2018-06-01 04:27:27.379917|2018-06-01 04:27:27.379917
NCT00225043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2008-05-30|2005-09-22|2005-09-23|Estimate|||||||2008-05-30|2008-06-02|Estimate|June 2005||2005-06-30|May 2008|2008-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Randomized, Double-Blind, Trial Comparing Epinephrine Versus Phenylephrine as a Vasoconstrictor in Regional Anesthesia for Upper Extremity Surgery||Completed||N/A|60|Actual|New York Methodist Hospital|||||f||||||||||||||2018-06-01 04:27:27.436055|2018-06-01 04:27:27.436055
NCT00225030|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-23|Estimate|||||||2005-09-13|2005-09-23|Estimate|January 1970||1970-01-31|July 2004|2004-07-31|July 2004||2004-07-31|||||Observational|||Observational Study of the Prognosis in Treated Arterial Hypertension|Observational Study of the Prognosis in Treated Arterial Hypertension|Completed|||1000||Odense University Hospital|||||f||||||||||||||2018-06-01 04:27:27.527907|2018-06-01 04:27:27.527907
NCT00225017|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2010-10-04||2012-06-29|2005-09-21|2005-09-23|Estimate|2012-06-29|2012-08-02|Estimate||||2012-06-29|2012-08-02|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|SABAR||Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study|Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study: Endothelial Function in HIV-Infected Subjects Switched to an Atazanavir Regimen|Completed||Phase 3|50|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 04:27:27.598355|2018-06-01 04:27:27.598355
NCT00225004|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-04-02|2005-09-21|2005-09-23|Estimate|||||||2014-04-02|2014-04-03|Estimate|July 2004||2004-07-31|April 2014|2014-04-30||||||||Observational|||Osteoporosis and Colles Fracture|Low-energy Fracture of the Wrist (Colles Fracture) and Osteoporosis. A Ten Year Follow-up and a Prospective Study|Terminated|||||Northern Orthopaedic Division, Denmark||||Recruiting problems|f||||||||||||||2018-06-01 04:27:27.933486|2018-06-01 04:27:27.933486
NCT00224991|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-04-02|2005-09-21|2005-09-23|Estimate|||||||2014-04-02|2014-04-03|Estimate|June 1999||1999-06-30|April 2014|2014-04-30|June 2005||2005-06-30|||||Interventional|||Osteoporosis School|Effect of Training in Prevention of Falls, Compliance to Treatment and Quality of Life: A Randomized, Prospective Investigation.|Completed||N/A|350||Northern Orthopaedic Division, Denmark|||||f||||f||||||||||2018-06-01 04:27:28.011708|2018-06-01 04:27:28.011708
NCT00224978|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2009-11-17|2005-09-22|2005-09-23|Estimate|||||||2009-11-17|2009-11-18|Estimate|January 2005||2005-01-31|November 2009|2009-11-30|August 2005||2005-08-31|||||Interventional|||Chloroquine for Treatment of Glioblastoma Multiforme|Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial|Completed||Phase 3|||National Institute of Neurology and Neurosurgery, Mexico|||||f||||||||||||||2018-06-01 04:27:28.096155|2018-06-01 04:27:28.096155
NCT00224965|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2017-01-11|2005-09-22|2005-09-23|Estimate|||||||2017-01-11|2017-01-12|Estimate||||September 2005|2005-09-30|October 2004||2004-10-31|||||Interventional|||Early Tobacco Abstinence - 5|Early Tobacco Abstinence in High Risk Smokers|Terminated||Phase 1|140||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:27:28.159929|2018-06-01 04:27:28.159929
NCT00224952|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2017-04-18||2017-08-11|2005-09-21|2005-09-23|Estimate|2017-08-11|2017-08-14|Actual||||2017-08-11|2017-08-14|Actual|July 2002||2002-07-31|August 2017|2017-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Pathogenesis of Adverse Drug Reactions|The Role of Drug Metabolizing Enzymes in the Pathogenesis Adverse Drug Reactions in Children|Completed|||274|Actual|Children's Mercy Hospital Kansas City|||1||f||||f||||||Samples With DNA|"~     Urine DNA (source: blood or saliva)~   "|||2018-06-01 04:27:28.241105|2018-06-01 04:27:28.241105
NCT00224939|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2010-01-12|2005-09-21|2005-09-23|Estimate|||||||2010-01-12|2010-01-14|Estimate|July 2002||2002-07-31|January 2010|2010-01-31|December 2006|Actual|2006-12-31|||||Interventional|||Pre-ESRD Syndrome in High Risk African Americans|Pre-ESRD Syndrome in High Risk African American Young Adults|Terminated||N/A|144|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||||"Only apx 1/3 of enrolled subjects (signed consent) participated. Futility analysis to show~   primary endpoint"|f||||||||||||||2018-06-01 04:27:28.631872|2018-06-01 04:27:28.631872
NCT00224926|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2011-09-16|2005-09-21|2005-09-23|Estimate|||||||2011-09-16|2011-09-19|Estimate|September 2003||2003-09-30|September 2011|2011-09-30|September 2005|Actual|2005-09-30|||||Observational|||The Natural Course of Trichophyton Tonsurans Carriage and Infection: A Molecular and Biochemical Evaluation|The Natural Course of Trichophyton Tonsurans Carriage and Infection: A Molecular and Biochemical Evaluation|Completed|||446|Actual|Children's Mercy Hospital Kansas City|||||f||||f||||||Samples With DNA|"~     fungal scalp cultures~   "|||2018-06-01 04:27:28.687606|2018-06-01 04:27:28.687606
NCT00224913|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-10-11|2005-09-21|2005-09-23|Estimate|||||||2005-10-11|2005-10-12|Estimate|March 2002||2002-03-31|October 2005|2005-10-31||||||||Interventional|||Electrical Stimulation After Total Knee Arthroplasty|NMES for Older Individuals After Total Knee Arthroplasty|Unknown status|Recruiting|Phase 1|200||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:27:28.834433|2018-06-01 04:27:28.834433
NCT00224900|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2017-02-27|2005-09-21|2005-09-23|Estimate|||||||2017-02-27|2017-02-28|Actual|September 2005||2005-09-30|February 2016|2016-02-29|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers|Development of a Life Skills Intervention for Young Adolescents Perinatally-Infected With HIV and Their Caregivers Part A: Focus Group And Measurement Evaluation|Terminated|||10|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 04:27:28.919729|2018-06-01 04:27:28.919729
NCT00224887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2008-07-23|2005-09-21|2005-09-23|Estimate|||||||2008-07-23|2008-07-24|Estimate|September 2003||2003-09-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Family-Based Nutrition Intervention for Latino Children||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:27:28.980982|2018-06-01 04:27:28.980982
NCT00224874|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2010-01-29||2017-08-24|2005-09-21|2005-09-23|Estimate|2010-03-23|2010-04-09|Estimate||||2017-08-24|2017-09-25|Actual|September 2005||2005-09-30|August 2017|2017-08-31|June 2012|Actual|2012-06-30|January 2009|Actual|2009-01-31||Interventional|||Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)|Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)|Completed||Phase 2|180|Actual|National Heart, Lung, and Blood Institute (NHLBI)||4|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-06-01 04:27:29.07597|2018-06-01 04:27:29.07597
NCT00224861|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2013-03-21|2005-09-21|2005-09-23|Estimate|||||||2013-03-21|2013-03-25|Estimate|September 2004||2004-09-30|March 2013|2013-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Hypertension Telemanagement in African Americans|Hypertension Telemanagement in African Americans|Completed||N/A|||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:27:30.215792|2018-06-01 04:27:30.215792
NCT00224848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2016-11-04|2005-09-21|2005-09-23|Estimate|||||||2016-11-04|2016-11-07|Estimate|July 2002||2002-07-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|September 2007|Actual|2007-09-30||Interventional|GLAD Heart||Guideline Adherence for Heart Health||Completed||Phase 2|61|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||f||||||||||2018-06-01 04:27:30.291426|2018-06-01 04:27:30.291426
NCT00224835|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2016-05-12|2005-09-21|2005-09-23|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2003||2003-05-31|May 2016|2016-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Mindfulness-Based Stress Reduction and Myocardial Ischemia|Mindfulness-Based Stress Reduction and Myocardial Ischemia|Completed||N/A|150|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 04:27:30.412176|2018-06-01 04:27:30.412176
NCT00224822|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2010-03-23|2005-09-21|2005-09-23|Estimate|||||||2010-03-23|2010-03-24|Estimate|March 2004||2004-03-31|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|||The Effects of Aripiprazole on Patients With Metabolic Syndrome|"The Effects of Aripiprazole on Patients With Metabolic Syndrome: An Open-Label Trial"|Completed||Phase 4|27|Actual|New Mexico VA Healthcare System|||||f||||t||||||||||2018-06-01 04:27:30.487861|2018-06-01 04:27:30.487861
NCT00224796|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2006-07-19|2005-09-21|2005-09-23|Estimate|||||||2006-07-19|2006-07-20|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|October 2005||2005-10-31|||||Interventional|||Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot|A Randomized, Controlled Multicenter Trial of Vacuum Assisted Closure® Therapy in the Treatment and Blinded Evaluation of Amputation Wounds of the Diabetic Foot|Completed||Phase 4|146||KCI USA, Inc.|||||f||||||||||||||2018-06-01 04:27:30.63719|2018-06-01 04:27:30.63719
NCT00224783|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-01-25|2005-09-20|2005-09-23|Estimate|||||||2012-01-25|2012-01-26|Estimate|August 2002||2002-08-31|January 2012|2012-01-31|September 2002|Actual|2002-09-30|||||Interventional|||Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults|Placebo-controlled Double-blind Controlled Trial of Single Intranasal Inoculation of CAIV-T Liquid Formulation in Healthy Japanese Male Adults|Completed||Phase 1|45|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 04:27:30.693632|2018-06-01 04:27:30.693632
NCT00224770|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2014-09-21||2015-06-17|2005-09-21|2005-09-23|Estimate|2015-06-17|2015-06-18|Estimate||||2015-06-17|2015-06-18|Estimate|August 2005||2005-08-31|June 2015|2015-06-30|April 2013|Actual|2013-04-30|August 2012|Actual|2012-08-31||Interventional|MISTIE|The decision was made to exclude the pilot patients from the analysis...|Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation|Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation|Completed||Phase 2|141|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-06-01 04:27:30.892099|2018-06-01 04:27:30.892099
NCT00224757|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2011-09-05|2005-09-21|2005-09-23|Estimate|||||||2011-09-05|2011-09-07|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|TIARA||Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation - TIARA Pilot Study|Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation|Completed||N/A|227|Actual|The Interuniversity Cardiology Institute of the Netherlands||2|||f||||t||||||||||2018-06-01 04:27:31.78058|2018-06-01 04:27:31.78058
NCT00224744|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-22|||2014-09-11|2005-09-22|2005-09-23|Estimate|||||||2014-09-11|2014-09-12|Estimate|November 2005||2005-11-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage|Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage.|Completed||Phase 3|73|Actual|Institut Claudius Regaud||2|||f||||||||||||||2018-06-01 04:27:31.868503|2018-06-01 04:27:31.868503
NCT00224731|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2006-10-25|2005-09-21|2005-09-23|Estimate|||||||2006-10-25|2006-10-26|Estimate|December 2003||2003-12-31|September 2005|2005-09-30||||||||Observational|||Sleep Disorders in Children With ADHD|Sleep Disorders in Children With ADHD|Unknown status|Recruiting||100||Hvolby, Allan, M.D.|||||f||||||||||||||2018-06-01 04:27:31.95966|2018-06-01 04:27:31.95966
NCT00224718|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-03-31|2005-09-19|2005-09-23|Estimate|||||||2009-03-31|2009-04-01|Estimate|January 2003||2003-01-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|ACE||Elective Abdominal Aortic Aneurism - Open Versus Endovascular Repair|"ACE Trial :Not Worn-Out Aneurism of the Abdominal Aorta Under Renal  Surgery Versus Endoprosthesis "|Completed||N/A|306|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:27:32.035486|2018-06-01 04:27:32.035486
NCT00224705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2011-02-16|2005-09-19|2005-09-23|Estimate|||||||2011-02-16|2011-02-17|Estimate|August 2004||2004-08-31|July 2007|2007-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure|Efficacy and Safety of the Albumin Dialysis MARS® Therapy in Patients With Fulminant and Subfulminant Hepatic Failure|Completed||Phase 3|110|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:27:32.131378|2018-06-01 04:27:32.131378
NCT00224692|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2006-10-25|2005-09-19|2005-09-23|Estimate|||||||2006-10-25|2006-10-26|Estimate|February 2003||2003-02-28|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine|MK III Trial: Analgesic Effect in Children of Low-Dose Ketamine for Mucositis Treated by Patient-Controlled Analgesia With Morphine|Terminated||Phase 3|50||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:32.260655|2018-06-01 04:27:32.260655
NCT00224679|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2012-06-04|2005-09-19|2005-09-23|Estimate|||||||2012-06-04|2012-06-05|Estimate|March 1997||1997-03-31|September 2006|2006-09-30|March 1999||1999-03-31|||||Interventional|||APACC Study:Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence|Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence|Terminated||Phase 3|300||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:32.343654|2018-06-01 04:27:32.343654
NCT00224666|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-01-09|2005-09-16|2005-09-23|Estimate|||||||2007-01-09|2007-01-11|Estimate|March 2001||2001-03-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Efficacy of Cortex Stimulation in Neuropathic Pain|Evaluation of the Effectiveness of Stimulation Cortex Sensorimotor for the Treatment of Rebel Neuropathic Pains|Terminated||Phase 2|16||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:32.416622|2018-06-01 04:27:32.416622
NCT00224653|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2006-04-12|2005-09-16|2005-09-23|Estimate|||||||2006-04-12|2006-04-13|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Comparison Between Volume Controlled Ventilation and Pressure Controlled Ventilation||Completed||N/A|36||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:32.478663|2018-06-01 04:27:32.478663
NCT00224640|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-03-03|2005-09-16|2005-09-23|Estimate|||||||2009-03-03|2009-03-04|Estimate|March 2005||2005-03-31|March 2007|2007-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Iron-Chelating Therapy and Friedreich Ataxia|Effect of Iron-Chelating Therapy in Friedreich Ataxia. Study Phase I/II|Completed||Phase 1/Phase 2|15|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:27:32.556104|2018-06-01 04:27:32.556104
NCT00224627|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-03-23|2005-09-16|2005-09-23|Estimate|||||||2007-03-23|2007-03-26|Estimate|March 2002||2002-03-31|March 2007|2007-03-31|June 2005|Actual|2005-06-30|||||Interventional|||Capsule Endoscopy vs. Push Enteroscopy in Occult Gastrointestinal Bleeding OGIB|Efficiency of Capsule Endoscopy and Push Enteroscopy in Obscure Gastrointestinal Bleeding. A Prospective Randomized Study.|Completed||Phase 3|45||Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:27:32.639305|2018-06-01 04:27:32.639305
NCT00224614|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-12-13|2005-09-16|2005-09-23|Estimate|||||||2005-12-13|2005-12-14|Estimate|July 2005||2005-07-31|June 2005|2005-06-30|July 2009||2009-07-31|||||Interventional|||Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia|Randomised Prospective Comparison of the nonmyélo-Ablative Allograft and the Traditional Allograft in Acute Myeloid Leukaemia in Complete Remission of the Adult|Unknown status|Recruiting|Phase 3|100||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:32.738541|2018-06-01 04:27:32.738541
NCT00223119|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-24|2005-09-13|2005-09-22|Estimate|||||||2012-10-24|2012-10-25|Estimate|January 2004||2004-01-31|October 2012|2012-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Comparison of Absorbable Sutures in Perineal Laceration Repair||Terminated||Phase 4|||Medtronic - MITG||||Study recruitment very slow.|f||||||||||||||2018-06-01 04:27:55.702355|2018-06-01 04:27:55.702355
NCT00224601|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-02-17|2005-09-16|2005-09-23|Estimate|||||||2011-02-17|2011-02-18|Estimate|July 2005||2005-07-31|July 2007|2007-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||CHROENDOHNPCC: Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer Syndrome|Early Detection of Pre-cancer Lesions in Adults With Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndrome: Assessment of Coloscopy With Chromoscopy Benefit|Completed||Phase 2|80|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 04:27:32.838456|2018-06-01 04:27:32.838456
NCT00224588|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2006-04-12|2005-09-16|2005-09-23|Estimate|||||||2006-04-12|2006-04-13|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|May 2005||2005-05-31|||||Interventional|||KETOR: Effects of Peri Operative Administration of Ketamine on Long Term Post Thoracotomy Pain|Effects of Peri Operative Administration of Ketamine on Long Term Post Thoracotomy Pain|Completed||Phase 3|80||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:32.918941|2018-06-01 04:27:32.918941
NCT00224575|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-07|2005-09-13|2005-09-23|Estimate|||||||2016-03-07|2016-03-08|Estimate|November 2004||2004-11-30|March 2016|2016-03-31|November 2006|Actual|2006-11-30|November 2005|Actual|2005-11-30||Interventional|IRIDIA||Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly|Therapeutical Impact of a Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly|Terminated||N/A|260|Actual|Assistance Publique - Hôpitaux de Paris||1||End of recruitment period|f||||f||||||||||2018-06-01 04:27:33.143655|2018-06-01 04:27:33.143655
NCT00224562|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-10-25|2005-09-14|2005-09-23|Estimate|||||||2005-10-25|2005-10-26|Estimate|February 2004||2004-02-29|February 2004|2004-02-29||||||||Observational|||The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists|The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists|Unknown status|Recruiting||||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:27:33.300702|2018-06-01 04:27:33.300702
NCT00224549|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-02-25|2005-09-16|2005-09-23|Estimate|||||||2011-02-25|2011-02-28|Estimate|April 2005||2005-04-30|March 2007|2007-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||PHARES Study: Management of Resistant Hypertension|Management of Resistant Hypertension -Pharmacokinetic Assessment of Different Antihypertensive Regimen -Comparison of Two Treatment Strategies: Increase Sodium Depletion or Combined Blockage of Renin-angiotensin System (RAS)|Completed||Phase 4|180|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:27:33.457818|2018-06-01 04:27:33.457818
NCT00224536|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-21|2005-09-21|2005-09-23|Estimate|||||||2005-09-21|2005-09-23|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|October 2003||2003-10-31|||||Interventional|||Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration|Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration-1|Completed||Phase 1|60||Hannover Medical School|||||f||||||||||||||2018-06-01 04:27:33.594457|2018-06-01 04:27:33.594457
NCT00224523|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-10-27|2005-09-21|2005-09-23|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Long Term Safety Of GW685698X Via Nasal Biopsy|A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD Via Nasal Biopsy in Subjects 18 Years of Age With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|125|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:27:33.723871|2018-06-01 04:27:33.723871
NCT00224510|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2017-05-24|2005-09-21|2005-09-23|Estimate|||||||2017-05-24|2017-05-30|Actual|August 2002|Actual|2002-08-31|May 2017|2017-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium|A Mulitcentre, Double-blind, Randomised, Fixed-dose Evaluation of the Safety and Efficacy of Lamictal (Lamotrigine) Compared to Placebo as an add-on Therapy to Lithium or Another Mood Stabiliser in the Treatment of Bipolar Depression, Followed by Long-term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients With Bipolar Disorder|Completed||Phase 3|120|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:27:33.93597|2018-06-01 04:27:33.93597
NCT00224497|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2009-12-23|2005-09-21|2005-09-23|Estimate|||||||2009-12-23|2009-12-24|Estimate|September 2005||2005-09-30|December 2009|2009-12-31||||||||Interventional|||A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease|A Phase IIa/b Double-blind, Randomised, Placebo-controlled, Linear Trend Design Dose-ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|380||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:27:34.114265|2018-06-01 04:27:34.114265
NCT00224484|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2017-02-24||2017-02-24|2005-09-21|2005-09-23|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|April 2004||2004-04-30|February 2017|2017-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old|A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years.|Completed||Phase 3|5960|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:27:34.335746|2018-06-01 04:27:34.335746
NCT00224471|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2016-09-20|2005-09-21|2005-09-23|Estimate|||||||2016-09-20|2016-09-21|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|January 2006|Actual|2006-01-31|September 2005|Actual|2005-09-30||Interventional|||Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine|A Phase III, Double-blind, Randomized, Study to Compare: 1) the Immunogenicity and Safety of 3 Commercial Scale Consistency Lots of GlaxoSmithKline (GSK) Biologicals' Herpes Simplex Candidate Vaccine in Healthy HSV-1 and -2 Seronegative (HSV 1-/2-) Female Subjects Aged 10 - 17 Years, and 2) Vaccine Immunogenicity in Healthy HSV 1-/2- Females Aged 10 - 17 Years With Healthy HSV 1-/2- Adult Females|Completed||Phase 3|671|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:27:37.420692|2018-06-01 04:27:37.420692
NCT00224458|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2008-04-07|2005-09-21|2005-09-23|Estimate|||||||2008-04-07|2008-04-10|Estimate|September 2004||2004-09-30|February 2008|2008-02-29|February 2006|Actual|2006-02-28|||||Interventional|||Combination of Efavirenz and Truvada - COMET Study|Combination of Efavirenz & Truvada (COMET Study): Phase 4 Evaluation of Switching Twice Daily Combivir to Once-Daily Regimen Co-Formulated Truvada in Virologically Suppressed HIV Infected Patients Taking Efavirenz.|Completed||Phase 4|400||Gilead Sciences|||||f||||||||||||||2018-06-01 04:27:37.553444|2018-06-01 04:27:37.553444
NCT00224445|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-01-08|2005-09-21|2005-09-23|Estimate|||||||2013-01-08|2013-01-10|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Boosted Atazanavir and Truvada Given Once-Daily - BATON Study|Boosted Atazanavir and Truvada Given Once-Daily (BATON Study): A Phase 4 Study of Safety, Efficacy & Adherence in HIV Infected, Antiretroviral Naïve Subjects Treated With a Simple Once-Daily Regimen|Completed||Phase 4|100|Actual|Gilead Sciences||1|||f||||||||||||||2018-06-01 04:27:37.61191|2018-06-01 04:27:37.61191
NCT00224432|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-26|2005-09-13|2005-09-23|Estimate|||||||2006-09-26|2006-09-27|Estimate|March 2001||2001-03-31|September 2006|2006-09-30|September 2002||2002-09-30|||||Interventional|||Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis|Double-Blind, Parallel, Randomised Study to Investigate the Clinical and Immunological Effects of Oral Administration of Probiotic Bacteria in Infants With Atopic Dermatitis With and Without Cow’s Milk Allergy.|Completed||N/A|45||Groningen Research Institute for Asthma and COPD|||||f||||||||||||||2018-06-01 04:27:37.744777|2018-06-01 04:27:37.744777
NCT00224419|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-07-18|2005-09-21|2005-09-23|Estimate|||||||2014-07-18|2014-07-21|Estimate|June 2003||2003-06-30|April 2009|2009-04-30||||August 2006|Actual|2006-08-31||Interventional|||Testing Pharmacological Therapies for Pregnant Smokers|Testing Pharmacological Therapies for Pregnant Smokers|Terminated||Phase 4|181|Actual|Duke University||2||was terminated due to meeting a priori stopping rule set by DSMB|f||||t||||||||||2018-06-01 04:27:37.816939|2018-06-01 04:27:37.816939
NCT00224406|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2008-11-26|2005-09-21|2005-09-23|Estimate|||||||2008-11-26|2008-11-27|Estimate|May 2005||2005-05-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|September 2007|Actual|2007-09-30||Interventional|||Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Repertaxin in the Prevention of Primary Graft Dysfunction After Lung Transplantation|Completed||Phase 2|100||Dompé Farmaceutici S.p.A|||||||||||||||||||2018-06-01 04:27:37.980316|2018-06-01 04:27:37.980316
NCT00224393|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-21|2005-09-21|2005-09-23|Estimate|||||||2005-09-21|2005-09-23|Estimate|February 2001||2001-02-28|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis||Suspended||Phase 2|60||The Cleveland Clinic|||||f||||||||||||||2018-06-01 04:27:38.107028|2018-06-01 04:27:38.107028
NCT00224380|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-09-22|2005-09-22|2005-09-23|Estimate|||||||2009-09-22|2009-09-23|Estimate|July 2003||2003-07-31|September 2009|2009-09-30|February 2005||2005-02-28|||||Interventional|||Medication Adherence in Older Adults With Serious Mental Illness|Medication Adherence in Older Adults|Completed||N/A|72||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 04:27:38.218973|2018-06-01 04:27:38.218973
NCT00224367|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-21|2005-09-21|2005-09-23|Estimate|||||||2005-09-21|2005-09-23|Estimate|February 2004||2004-02-29|February 2005|2005-02-28|December 2004||2004-12-31|||||Interventional|||Does Early Ambulation After Hip Fracture Surgery Accelerate Recovery?|Does Early Ambulation After Hip Fracture Surgery Accelerate Recovery?: A Randomised Controlled Trial|Completed||N/A|60||Bayside Health|||||f||||||||||||||2018-06-01 04:27:38.319963|2018-06-01 04:27:38.319963
NCT00224354|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2012-05-18|2005-09-21|2005-09-23|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|CLONTAK||Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells|Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells After Depletion of Regulatory T Cells|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 04:27:38.439283|2018-06-01 04:27:38.439283
NCT00280839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-11|2005-09-13|2005-09-22|Estimate|||||||2012-04-11|2012-04-13|Estimate||||April 2012|2012-04-30||||||||Interventional|||Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation|A Double-Blind, Placebo-Controlled, 11-Week Trial of Topiramate as an Aid to Smoking Cessation|Completed||Phase 3|87|Actual|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 04:27:38.527231|2018-06-01 04:27:38.527231
NCT00224341|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2006-10-17|2005-09-20|2005-09-22|Estimate|||||||2006-10-17|2006-10-18|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|November 2006||2006-11-30|||||Interventional|||Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation||Unknown status|Recruiting|Phase 4|360||Vitatron France|||||f||||||||||||||2018-06-01 04:27:38.642258|2018-06-01 04:27:38.642258
NCT00224328|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-11|2005-09-13|2005-09-22|Estimate|||||||2007-09-11|2007-09-12|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|January 2007|Actual|2007-01-31|||||Observational|||Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia|Measurement of Tissue Oxygen Saturation in Chronic Critical Limb Ischemia: A Phase Iia, Non-Randomized Study Using the ODISsey Tissue Oximeter to Evaluate the Correlation Between Tissue Oxygen Saturation and Symptom Resolution in Patients With Chronic Critical Limb Ischemia Undergoing Treatment Interventions|Terminated|||100|Anticipated|ViOptix Canada||||The results were not able to be consistantly reproduced. Thus the trial was terminated|f||||||||||||||2018-06-01 04:27:38.918676|2018-06-01 04:27:38.918676
NCT00224315|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-06-02|2005-09-15|2005-09-22|Estimate|||||||2008-06-02|2008-06-04|Estimate|November 2003||2003-11-30|June 2008|2008-06-30|September 2006||2006-09-30|||||Interventional|||Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial|Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial|Completed||Phase 4|24||Central Institute of Mental Health, Mannheim|||||f||||||||||||||2018-06-01 04:27:39.003843|2018-06-01 04:27:39.003843
NCT00224302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-06-03|2005-09-15|2005-09-22|Estimate|||||||2008-06-03|2008-06-04|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine|Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine|Completed||Phase 4|20|Anticipated|Central Institute of Mental Health, Mannheim|||||f||||||||||||||2018-06-01 04:27:39.108935|2018-06-01 04:27:39.108935
NCT00224289|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2012-11-09||2012-11-09|2005-09-16|2005-09-22|Estimate|2012-11-09|2012-12-10|Estimate||||2012-11-09|2012-12-10|Estimate|March 2005||2005-03-31|November 2012|2012-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Effect of Age on Latanoprost 0.005% in Patients With Glaucoma|Effect of Age on Efficacy and Response Time of Latanoprost 0.005% in Patients With Glaucoma|Completed||Phase 4|17|Actual|Yale University||1|||f||||f||||||||||2018-06-01 04:27:39.231426|2018-06-01 04:27:39.231426
NCT00224276|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-22|Estimate|||||||2005-09-16|2005-09-22|Estimate||||September 2005|2005-09-30||||||||Observational|||Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics|Prevalence and Incidence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics|Completed|||100||Yale University|||||f||||||||||||||2018-06-01 04:27:39.690136|2018-06-01 04:27:39.690136
NCT00222703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Enhancing Tobacco Abstinence Following Hospitalization|Enhancing Tobacco Abstinence Following Hospitalization|Completed||N/A|80||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:58.200994|2018-06-01 04:27:58.200994
NCT00224263|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2011-08-15|2005-09-20|2005-09-22|Estimate|||||||2011-08-15|2011-08-16|Estimate|September 2005||2005-09-30|August 2011|2011-08-31|February 2008|Actual|2008-02-29|||||Interventional|||Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI|Completed||Phase 2|360||Xuanwu Hospital, Beijing|||||f||||t||||||||||2018-06-01 04:27:39.755309|2018-06-01 04:27:39.755309
NCT00224250|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-09|2005-09-13|2005-09-22|Estimate|||||||2018-03-09|2018-03-13|Actual|January 2005||2005-01-31|March 2018|2018-03-31||||||||Interventional|||Ultrasound Study of the Uterine Healing Process After Cesarean Delivery|Ultrasonographic Assessment of the Uterine Scarring Process Following Closure of the Uterus in One Versus Two Layer Technique.|Completed||N/A|30||Yale University|||||f||||||||||||||2018-06-01 04:27:39.81565|2018-06-01 04:27:39.81565
NCT00224237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-02-17|2005-09-20|2005-09-22|Estimate|||||||2017-02-17|2017-02-23|Actual|December 2005|Actual|2005-12-31|February 2017|2017-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Exploring Folk Health Practices in Latinos With Chronic Medical Conditions|Exploring Folk Health Practices in Latinos With Chronic Medical Conditions|Completed|||54|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||No|No Plan to Share IPD|2018-06-01 04:27:39.909147|2018-06-01 04:27:39.909147
NCT00224224|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-04-02|2005-09-20|2005-09-22|Estimate|||||||2008-04-02|2008-04-03|Estimate|January 1995||1995-01-31|March 2008|2008-03-31|January 2005||2005-01-31|||||Observational|||A Comparison of Primary Care and Traditional Internal Medicine Residents|A Comparison of Primary Care and Traditional Internal Medicine Residents|Completed|||||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:27:39.983436|2018-06-01 04:27:39.983436
NCT00224211|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-03-12|2005-09-20|2005-09-22|Estimate|||||||2008-03-12|2008-03-13|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Music's Effects on Premature Babies.|Effects of Homophonic Sounds on Preterm Infants|Completed|||50|Actual|Weill Medical College of Cornell University|||1||f||||t||||||||||2018-06-01 04:27:40.085759|2018-06-01 04:27:40.085759
NCT00224198|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2016-04-29|2005-09-20|2005-09-22|Estimate|||||||2016-04-29|2016-05-03|Estimate|January 2004||2004-01-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Evaluation of the Lungs of Individuals With Lung Disease|Evaluation of the Lungs of Individuals With Lung Disease With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing and Bronchial Wall Biopsy|Completed|||196|Actual|Weill Medical College of Cornell University|||1||f||||t||||||Samples With DNA|"~     Specimens will be retained from both a blood draw and a bronchoscopy procedure.~   "|Undecided||2018-06-01 04:27:40.156945|2018-06-01 04:27:40.156945
NCT00224185|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2016-04-29|2005-09-20|2005-09-22|Estimate|||||||2016-04-29|2016-05-02|Estimate|January 2004||2004-01-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Evaluation of Lungs of Normal Individuals by Lung Lavage, Brushing and Bronchial Wall Biopsy|Evaluation of the Lungs of Normal Individuals With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing and Bronchial Wall Biopsy|Completed|||196|Actual|Weill Medical College of Cornell University|||||f||||t||||||Samples With DNA|"~     Specimens will be retained from both a blood draw and a bronchial wall biopsy which obtains~     tissue to a depth of 2-3 mm and includes epithelial and subepithelial tissue.~   "|Undecided||2018-06-01 04:27:40.261285|2018-06-01 04:27:40.261285
NCT00224172|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-03-27|2005-09-20|2005-09-22|Estimate|||||||2008-03-27|2008-03-28|Estimate|January 2001||2001-01-31|March 2008|2008-03-31|December 2001||2001-12-31|||||Observational|||Ambulatory Care Characteristics as Predictors of Mortality and Re-Admission|Ambulatory Care Characteristics as Predictors of Mortality and Re-Admission|Completed|||302||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:27:40.329564|2018-06-01 04:27:40.329564
NCT00224159|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2011-02-18|2005-09-20|2005-09-22|Estimate|||||||2011-02-18|2011-02-21|Estimate|February 2005||2005-02-28|February 2011|2011-02-28|June 2006||2006-06-30|||||Observational|||Does Statin Initiation Undermine Dietary Behavior?|Does Statin Initiation Undermine Dietary Behavior?|Completed|||100||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:27:40.495287|2018-06-01 04:27:40.495287
NCT00224146|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-11-29|2005-09-14|2005-09-22|Estimate|||||||2011-11-29|2011-11-30|Estimate|May 2004||2004-05-31|November 2011|2011-11-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|MATRIX||Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder|Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)|Completed||Phase 4|2878|Actual|Watson Pharmaceuticals|||||f||||||||||||||2018-06-01 04:27:40.561461|2018-06-01 04:27:40.561461
NCT00224133|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2009-12-23||2010-04-06|2005-09-14|2005-09-22|Estimate|2010-04-06|2010-04-27|Estimate||||2010-04-06|2010-04-27|Estimate|September 2005||2005-09-30|April 2010|2010-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months|A Multi-Center, Open-Label Evaluation of the Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|661|Actual|Watson Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:27:40.682967|2018-06-01 04:27:40.682967
NCT00224120|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2009-09-08||2009-12-11|2005-09-14|2005-09-22|Estimate|2009-10-30|2009-12-03|Estimate||||2009-12-11|2009-12-15|Estimate|May 2005||2005-05-31|December 2009|2009-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo|A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|462|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:27:41.252519|2018-06-01 04:27:41.252519
NCT00224107|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2009-09-08||2011-07-05|2005-09-14|2005-09-22|Estimate|2009-10-30|2009-12-03|Estimate||||2011-07-05|2011-07-12|Estimate|May 2005||2005-05-31|July 2011|2011-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo|A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 3|461|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:27:41.797155|2018-06-01 04:27:41.797155
NCT00224094|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-10-11|2005-09-14|2005-09-22|Estimate|||||||2012-10-11|2012-10-15|Estimate|January 2002||2002-01-31|October 2012|2012-10-31||||May 2003|Actual|2003-05-31||Interventional|||A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women|A Comparison of Transdermal vs. Oral Estrogen Replacement Therapy on Androgen Levels and Thyroid Function in Naturally Menopausal Women|Completed||Phase 4|27|Actual|Watson Pharmaceuticals||2|||f||||||||||||||2018-06-01 04:27:42.283984|2018-06-01 04:27:42.283984
NCT00224081|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-08|2005-09-13|2005-09-22|Estimate|||||||2015-12-08|2015-12-10|Estimate|September 2004||2004-09-30|December 2015|2015-12-31||||May 2006|Actual|2006-05-31||Interventional|DRIVE||DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)|Dialysis Patients' Response to IV Iron With Elevated Ferritin|Completed||Phase 4|134|Actual|Watson Pharmaceuticals||2|||f||||||||||||||2018-06-01 04:27:42.346755|2018-06-01 04:27:42.346755
NCT00224068|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-29|2005-09-13|2005-09-22|Estimate|||||||2012-02-29|2012-03-02|Estimate|May 2002||2002-05-31|February 2012|2012-02-29|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy|A Multicenter, Randomized, Controlled Prospective Trial of the Safety and Efficacy of Ferrlecit® in Anemic Cancer Patients Who Are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment|Completed||Phase 4|180||Watson Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:27:42.608249|2018-06-01 04:27:42.608249
NCT00224055|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-02-29||2012-02-29|2005-09-13|2005-09-22|Estimate|2012-02-29|2012-03-29|Estimate||||2012-02-29|2012-03-29|Estimate|April 2003||2003-04-30|February 2012|2012-02-29|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients|A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease|Completed||Phase 4|89|Actual|Watson Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:27:42.751469|2018-06-01 04:27:42.751469
NCT00224042|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-12-23||2012-02-29|2005-09-13|2005-09-22|Estimate|2012-02-29|2012-03-29|Estimate||||2012-02-29|2012-03-29|Estimate|April 2003||2003-04-30|February 2012|2012-02-29||||May 2005|Actual|2005-05-31||Interventional|||Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents|A Randomized, Controlled, Open-label Study of the Safety and Efficacy of Ferrlecit® vs Oral Iron in Iron Deficient Patients With Chronic Kidney Disease Being Treated With Erythropoietic Therapy|Completed||Phase 4|52|Actual|Watson Pharmaceuticals||2|||f||||||||||||||2018-06-01 04:27:43.440155|2018-06-01 04:27:43.440155
NCT00224029|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-11-13||2010-04-07|2005-09-13|2005-09-22|Estimate|2010-04-07|2010-04-30|Estimate||||2010-04-07|2010-04-30|Estimate|December 2004||2004-12-31|April 2010|2010-04-30|May 2008|Actual|2008-05-31|December 2005|Actual|2005-12-31||Interventional|||A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition|A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury|Completed||Phase 4|24|Actual|Watson Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:27:44.088133|2018-06-01 04:27:44.088133
NCT00224016|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-11-13||2012-02-07|2005-09-13|2005-09-22|Estimate|2009-11-13|2009-12-23|Estimate||||2012-02-07|2012-02-09|Estimate|December 2004||2004-12-31|February 2012|2012-02-29|September 2008|Actual|2008-09-30|April 2007|Actual|2007-04-30||Interventional|||Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition|A Multi-Center, Open-Label (OL), Active-Controlled, Dose-Titration Study Evaluating the Safety, Efficacy and PK of Oxybutynin Transdermal Systems in the Treatment of Detrusor Overactivity in Pediatric Patients|Completed||Phase 4|57|Actual|Watson Pharmaceuticals|The transdermal groups included more males and younger subjects. The study was not designed to compare the transdermal and oral groups. Advserse event data reported for the titration and maintenance periods.|2|||f||||f||||||||||2018-06-01 04:27:44.295797|2018-06-01 04:27:44.295797
NCT00224003|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-08-18||2009-08-18|2005-09-13|2005-09-22|Estimate|2009-08-18|2009-09-28|Estimate||||2009-08-18|2009-09-28|Estimate|April 2003||2003-04-30|August 2009|2009-08-31|February 2005|Actual|2005-02-28|March 2004|Actual|2004-03-31||Interventional|||Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients|Open-Label, Multi-Center Study of the Safety and Efficacy of Ferrlecit® in the Maintenance of Iron Stores in Pediatric Hemodialysis Patients Receiving Epoetin|Completed||Phase 4|23|Actual|Watson Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:27:44.794687|2018-06-01 04:27:44.794687
NCT00223990|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-02-01|2005-09-13|2005-09-22|Estimate|||||||2013-02-01|2013-02-04|Estimate|March 2005||2005-03-31|February 2013|2013-02-28|April 2006||2006-04-30|||||Interventional|||Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine|A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine|Completed||Phase 2|400||U.S. Army Medical Research and Materiel Command|||||f||||||||||||||2018-06-01 04:27:45.287632|2018-06-01 04:27:45.287632
NCT00223977|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-08-19||2013-05-17|2005-09-13|2005-09-22|Estimate|2009-08-19|2009-09-28|Estimate||||2013-05-17|2013-07-08|Estimate|December 2003||2003-12-31|May 2013|2013-05-31|February 2008|Actual|2008-02-29|November 2004|Actual|2004-11-30||Interventional|||2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.|A Multi-center, Randomized, Open Label Study of the Efficacy and Safety of Two Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peroneal Dialysis Patients Receiving Erythropoietin.|Completed||Phase 2/Phase 3|146|Actual|Watson Pharmaceuticals|Primary endpoint for the 250 mg dose was 4 weeks earlier than the endpoint for the 125 mg dose, which may have contributed to lower Hbg increase with the 250 mg dose at endpoint.|3|||f||||f||||||||||2018-06-01 04:27:45.672602|2018-06-01 04:27:45.672602
NCT00223964|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-10|2005-09-13|2005-09-22|Estimate|||||||2012-08-10|2012-08-14|Estimate|June 2003||2003-06-30|August 2012|2012-08-31||||October 2003|Actual|2003-10-31||Interventional|||Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients|Randomized Double-Blind Parallel Group MultiCenter Study of the Efficacy of Two Doses of Ferrlecit® in Treatment of Iron Deficiency in Pediatric Hemodialysis Patients Receiving Epoetin.|Completed||Phase 4|59|Actual|Watson Pharmaceuticals||2|||f||||||||||||||2018-06-01 04:27:46.391368|2018-06-01 04:27:46.391368
NCT00223951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2015-02-19|2005-09-20|2005-09-22|Estimate|||||||2015-02-19|2015-02-20|Estimate|September 2005||2005-09-30|February 2015|2015-02-28||||December 2005|Actual|2005-12-31||Interventional|||Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers|A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of R89674 0.25% Ophthalmic Solution in Healthy, Normal Volunteers|Completed||Phase 3|900||Vistakon Pharmaceuticals|||||f||||||||||||||2018-06-01 04:27:46.486223|2018-06-01 04:27:46.486223
NCT00223938|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-18|2005-09-13|2005-09-22|Estimate|||||||2008-02-18|2008-02-22|Estimate|May 2004||2004-05-31|February 2008|2008-02-29|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Interventional|||Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.|A Multi-Center, Open-Label, Randomized, Parallel Group Study of the Efficacy and Safety of Ferrlecit in the Maintenance of Iron Stores and Serum Hemoglobin Concentration in Hemodialysis Patients Receiving Erythropoietin.|Unknown status|Active, not recruiting|Phase 4|291|Anticipated|Watson Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:27:46.551566|2018-06-01 04:27:46.551566
NCT00223925|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-25|2005-09-13|2005-09-22|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2004||2004-10-31|March 2014|2014-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Maribavir for Prevention of CMV After Stem Cell Transplants|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants|Completed||Phase 2|111|Actual|Shire||4|||||||||||||||||2018-06-01 04:27:46.629228|2018-06-01 04:27:46.629228
NCT00223912|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-09-15|2005-09-14|2005-09-22|Estimate|||||||2010-09-15|2010-09-16|Estimate|November 2003||2003-11-30|September 2010|2010-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|FES||Effect of Exercise on Blood Coagulation in Persons With Chronic Spinal Cord Injury|Effect of FES- Exercise on Hemostasis in Persons With Chronic Spinal Cord Injury|Completed||N/A|12|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:27:46.715469|2018-06-01 04:27:46.715469
NCT00223899|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-05|2005-09-13|2005-09-22|Estimate|||||||2011-07-05|2011-07-07|Estimate|July 2005||2005-07-31|July 2011|2011-07-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Interventional|||A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma|A Phase 1, Multi-Center, Open-Label, Dose-Escalation Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma|Completed||Phase 1|26|Actual|Vical||1|||f||||f||||||||||2018-06-01 04:27:46.799132|2018-06-01 04:27:46.799132
NCT00223873|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-20|2005-09-13|2005-09-22|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 2002||2002-11-30|May 2006|2006-05-31|July 2006|Actual|2006-07-31|||||Interventional|||The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury|The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury|Completed||N/A|30||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:27:46.871628|2018-06-01 04:27:46.871628
NCT00223860|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-03-05|2005-09-14|2005-09-22|Estimate|||||||2008-03-05|2008-03-11|Estimate|July 2001||2001-07-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.|Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury|Completed||N/A|100|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:27:46.945903|2018-06-01 04:27:46.945903
NCT00223847|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-12-31|2005-09-14|2005-09-22|Estimate|||||||2008-12-31|2009-01-01|Estimate|August 2002||2002-08-31|December 2008|2008-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||An Investigation of Constraint Induced Language Therapy for Aphasia|An Investigation of Constraint Induced Language Therapy for Aphasia|Completed||N/A|48|Actual|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:27:47.013914|2018-06-01 04:27:47.013914
NCT00223834|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-03-11|2005-09-14|2005-09-22|Estimate|||||||2008-03-11|2008-03-14|Estimate|March 2005||2005-03-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|January 2007|Actual|2007-01-31||Interventional|||Pathways to Vocational Rehabilitation: Enhancing Entry and Retention|Pathways to Vocational Rehabilitation: Enhancing Entry and Retention|Completed||N/A|200|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:27:47.077745|2018-06-01 04:27:47.077745
NCT00223821|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2013-10-11||2013-10-29|2005-09-14|2005-09-22|Estimate|2013-10-29|2013-12-19|Estimate||||2013-10-29|2013-12-19|Estimate|September 2003||2003-09-30|October 2013|2013-10-31|December 2009|Actual|2009-12-31|November 2008|Actual|2008-11-30||Interventional|COMBO||Enhancing Conservative Treatment for Urge Incontinence|Enhancing Conservative Treatment for Urge Incontinence|Completed||N/A|166|Actual|VA Office of Research and Development|Secondary objectives could not be achieved because, based on a conditional power calculation, the trial was stopped early for futility.|2|||f||||f||||||||||2018-06-01 04:27:47.153003|2018-06-01 04:27:47.153003
NCT00223808|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2013-10-09||2014-01-03|2005-09-14|2005-09-22|Estimate|2014-01-03|2014-02-17|Estimate||||2014-01-03|2014-02-17|Estimate|January 2002||2002-01-31|January 2014|2014-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial|Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial|Completed||Phase 3|71|Actual|VA Office of Research and Development|Limitations include the relatively small number of subjects in each group and the variation in severity level across subjects. Subjects at the Houston site were enrolled earlier after stroke than in the LA site and the Palo Alto site.|3|||f||||f||||||||||2018-06-01 04:27:48.566286|2018-06-01 04:27:48.566286
NCT00223795|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-09-24||2017-09-29|2005-09-13|2005-09-22|Estimate|2014-03-18|2014-04-22|Estimate||||2017-09-29|2017-11-01|Actual|July 2006||2006-07-31|September 2017|2017-09-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Walking Aids in the Management of Knee Osteoarthritis|Walking Aids in the Management of Obesity-Related Knee Osteoarthritis|Completed||N/A|53|Actual|VA Office of Research and Development|Had high drop out rate leading to small numbers of subjects analyzed.|2|||f||||f||||||||||2018-06-01 04:27:48.973013|2018-06-01 04:27:48.973013
NCT00223782|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-03-21|2005-09-14|2005-09-22|Estimate|||||||2008-03-21|2008-03-24|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Motor Learning in Gait in Subjects With Diabetic Peripheral Neuropathy|Motor Learning in Gait in Subjects With Diabetic Peripheral Neuropathy|Completed||N/A|150|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:27:49.190405|2018-06-01 04:27:49.190405
NCT00223769|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-12|2005-09-13|2005-09-22|Estimate|||||||2008-02-12|2008-02-13|Estimate|January 2004||2004-01-31|May 2006|2006-05-31|May 2006|Actual|2006-05-31|||||Interventional|||The Use of Anabolic Steroids to Improve Function After Spinal Cord Injury|The Use of Oxandrolone to Improve Function in Persons With Chronic Spinal Cord Injury|Completed||N/A|40||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:27:49.346987|2018-06-01 04:27:49.346987
NCT00223756|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-06|2005-09-13|2005-09-22|Estimate|||||||2016-01-06|2016-01-08|Estimate|November 2004||2004-11-30|January 2016|2016-01-31|August 2007|Actual|2007-08-31|July 2006|Actual|2006-07-31||Interventional|LOVIT||VA Low Vision Intervention Trial|VA Low Vision Intervention Trial|Completed||N/A|61|Anticipated|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:27:49.426728|2018-06-01 04:27:49.426728
NCT00223743|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-06-20|2005-09-15|2005-09-22|Estimate|||||||2012-06-20|2012-06-22|Estimate|November 2004||2004-11-30|June 2012|2012-06-30||||September 2008|Actual|2008-09-30||Interventional|||A Safety/Efficacy Trial of Zonisamide for Essential Tremor|Novel Therapies for Essential Tremor - Zonisamide Pilot Study|Completed||Phase 2|25|Actual|VA Greater Los Angeles Healthcare System||1|||f||||||||||||||2018-06-01 04:27:49.51618|2018-06-01 04:27:49.51618
NCT00223730|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2016-11-01|2005-09-19|2005-09-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2001||2001-10-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Chemotherapy Toxicity Reduction Via Urea Cycle Support|Chemotherapy Toxicity Reduction Via Urea Cycle Support|Completed||Phase 2|100|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 04:27:49.609348|2018-06-01 04:27:49.609348
NCT00223717|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-10-12|2005-09-14|2005-09-22|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2001||2001-01-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Treatment of Supine Hypertension in Autonomic Failure|The Pathophysiology and Treatment of Supine Hypertension in Patients With Autonomic Failure|Completed||Phase 1|152|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 04:27:49.703944|2018-06-01 04:27:49.703944
NCT00223704|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|2013-07-29||2013-10-15|2005-09-19|2005-09-22|Estimate|2013-07-29|2013-10-11|Estimate||||2013-10-15|2013-11-25|Estimate|May 2006||2006-05-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|BRAC||Bradykinin Receptor Antagonism During Cardiopulmonary Bypass|Bradykinin Receptor Antagonism During Cardiopulmonary Bypass|Completed||Phase 2/Phase 3|150|Actual|Vanderbilt University|This study was conducted in a population that predominantly underwent valve-only surgery. We cannot exclude the possibility that our results may have been different if we studied only coronary artery bypass graft surgery patients.|3|||f||||t||||||||||2018-06-01 04:27:49.987522|2018-06-01 04:27:49.987522
NCT00223691|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-01-16|2005-09-14|2005-09-22|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2002||2002-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Treatment of Orthostatic Hypotension in Autonomic Failure|Evaluation and Treatment of Autonomic Failure.|Completed||Phase 1|389|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 04:27:50.486657|2018-06-01 04:27:50.486657
NCT00223678|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|2017-02-21||2017-05-24|2005-09-19|2005-09-22|Estimate|2017-02-21|2017-04-06|Actual||||2017-05-24|2017-06-21|Actual|June 2000||2000-06-30|May 2017|2017-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||approximately 30 patients will be randomized in a 2:1 ratio: two patients will be converted to Rapamycin-based immunosuppression for each patient randomized to continue calcineurin inhibitor based immunosuppression.|Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure|Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure|Completed||Phase 4|20|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-06-01 04:27:50.615299|2018-06-01 04:27:50.615299
NCT00223665|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2017-11-25||2018-04-10|2005-09-16|2005-09-22|Estimate|2018-04-10|2018-05-14|Actual||||2018-04-10|2018-05-14|Actual|January 8, 1997|Actual|1997-01-08|April 2018|2018-04-30|September 6, 2012|Actual|2012-09-06|September 6, 2012|Actual|2012-09-06||Interventional|IAS||Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer|A Prospective Study of Intermittent Androgen Suppression (IAS) in Men With Localized Prostate Cancer Who Have Biochemical Relapse After Radiation Therapy or Radical Prostatectomy|Completed||Phase 2|102|Actual|University of Washington||1|||f||||f|t|f|||f|||No||2018-06-01 04:27:50.829514|2018-06-01 04:27:50.829514
NCT00223652|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2014-09-09||2015-04-06|2005-09-20|2005-09-22|Estimate|2014-12-16|2014-12-17|Estimate||||2015-04-06|2015-04-24|Estimate|March 2006||2006-03-31|August 2014|2014-08-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas|Tele-Mental Health Intervention to Improve Depression Outcomes in Community Based Outpatient Clinics (CBOCs)|Completed||Phase 2|85|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:27:51.359588|2018-06-01 04:27:51.359588
NCT00223639|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2012-02-03|2005-09-19|2005-09-22|Estimate|||||||2012-02-03|2012-02-07|Estimate|September 2005||2005-09-30|February 2012|2012-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||New Medications to Treat Alcohol Dependence|New Medications to Treat Alcohol Dependence|Completed||Phase 2|29|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 04:27:51.758175|2018-06-01 04:27:51.758175
NCT00223626|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-17|2005-09-16|2005-09-22|Estimate|||||||2012-04-17|2012-04-19|Estimate|January 2007||2007-01-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Topiramate to Reduce Cocaine Dependence|Lab Trials to Develop Medication for Cocaine Dependence|Completed||Phase 2|25|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 04:27:51.833742|2018-06-01 04:27:51.833742
NCT00223613|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-18|2005-09-13|2005-09-22|Estimate|||||||2006-09-18|2006-09-19|Estimate|August 1997||1997-08-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Intranasal Insulin for Prevention of Type 1 Diabetes|Intranasal Insulin for Prevention of Type 1 Diabetes in Children Carrying Increased HLA-Conferred Genetic Risk|Unknown status|Recruiting|Phase 3|240||University of Turku|||||f||||||||||||||2018-06-01 04:27:51.915313|2018-06-01 04:27:51.915313
NCT00223600|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-18|2005-09-13|2005-09-22|Estimate|||||||2006-09-18|2006-09-19|Estimate|May 1990||1990-05-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Special Turku Atherosclerosis Risk Factor Intervention Project for Children (STRIP)|Special Turku Atherosclerosis Risk Factor Intervention Project for Children (STRIP)|Unknown status|Active, not recruiting|Phase 3|1062||University of Turku|||||f||||||||||||||2018-06-01 04:27:52.000975|2018-06-01 04:27:52.000975
NCT00223587|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-11|2005-09-13|2005-09-22|Estimate|||||||2008-04-11|2008-04-15|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Seasonal Allergic Rhinitis and Driving Ability|Study to Investigate the Effects of Seasonal Allergic Rhinitis on Over-the-Road Driving Performance and Memory Functioning|Terminated||Phase 4|22|Actual|Utrecht Institute for Pharmaceutical Sciences||1||slow recruitment rate|f||||f||||||||||2018-06-01 04:27:52.070001|2018-06-01 04:27:52.070001
NCT00223574|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-09-21|2005-09-21|2005-09-22|Estimate|||||||2005-09-21|2005-09-22|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|October 2004||2004-10-31|||||Interventional|||Canadian Trial of Dietary Carbohydrates in Diabetes|Long-Term Effect of Altering the Source or Amount of Dietary Carbohydrate in Type 2 Diabetes|Completed||N/A|168||University of Toronto|||||f||||||||||||||2018-06-01 04:27:52.184833|2018-06-01 04:27:52.184833
NCT00223561|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-02-28|2005-09-13|2005-09-22|Estimate|||||||2006-02-28|2006-03-01|Estimate|February 2003||2003-02-28|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder|A Double Blind, Placebo-Controlled Crossover Study to Determine the Effects of Methylphenidate on Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder|Completed||Phase 4|18||Utrecht Institute for Pharmaceutical Sciences|||||f||||||||||||||2018-06-01 04:27:52.300488|2018-06-01 04:27:52.300488
NCT00223548|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|October 2002||2002-10-31|September 2002|2002-09-30|December 2004||2004-12-31|||||Interventional|||MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application|MESNA Zur Prophylaxe Der Kontrastmittel-Induzierten Nephropathie|Completed||Phase 2|106||University of Ulm|||||f||||||||||||||2018-06-01 04:27:52.36605|2018-06-01 04:27:52.36605
NCT00223535|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Cognitive Remediation and Social Skills Training in Schizophrenia|Cognitive Remediation and Social Skills Training in Schizophrenia|Completed||N/A|40||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 04:27:52.425867|2018-06-01 04:27:52.425867
NCT00223522|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|March 2005||2005-03-31|||||Observational|||Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?|Do Self-Report and Physician Impressions of Adherence to Oral Antipsychotic Medication Agree With Objective Data?|Completed|||50||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 04:27:52.497534|2018-06-01 04:27:52.497534
NCT00223509|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-19|2005-09-13|2005-09-22|Estimate|||||||2012-06-19|2012-06-20|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Lamictal As Add on Treatment in Mixed States of Bipolar Disorder|Lamictal As Add on Treatment in Mixed States of Bipolar Disorder|Completed||Phase 4|28|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 04:27:52.550782|2018-06-01 04:27:52.550782
NCT00223496|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2013-02-27||2017-04-19|2005-09-14|2005-09-22|Estimate|2013-04-09|2013-05-21|Estimate||||2017-04-19|2017-05-16|Actual|September 2004||2004-09-30|April 2017|2017-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||32 subjects consented, 19 subjects were baselined|12- Week Open Label Treatment of Refractory Bipolar Depression|12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP)|Completed||Phase 4|32|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-06-01 04:27:52.631272|2018-06-01 04:27:52.631272
NCT00223483|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-01-29|2005-09-13|2005-09-22|Estimate|||||||2018-01-29|2018-01-30|Actual|March 2005||2005-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers|Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers|Active, not recruiting|||1000|Anticipated|The University of Texas Health Science Center at San Antonio|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, white cells~   "|||2018-06-01 04:27:52.789555|2018-06-01 04:27:52.789555
NCT00223470|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-07|2005-09-13|2005-09-22|Estimate|||||||2012-03-07|2012-03-09|Estimate|October 2002||2002-10-31|March 2012|2012-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Cytokine Regulation of Periradicular Pain in Humans|Cytokine Regulation of Periradicular Pain in Humans|Completed|||9|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||Samples Without DNA|"~     Sterile paper points are placed in the canal for 30 seconds~   "|||2018-06-01 04:27:52.961788|2018-06-01 04:27:52.961788
NCT00223457|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2007-01-23|2005-09-15|2005-09-22|Estimate|||||||2007-01-23|2007-01-25|Estimate|April 2004||2004-04-30|April 2005|2005-04-30|September 2005||2005-09-30|||||Observational|||Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis|Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis|Completed|||1040||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:27:53.039563|2018-06-01 04:27:53.039563
NCT00223444|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-30|2005-09-13|2005-09-22|Estimate|||||||2009-04-30|2009-05-01|Estimate|August 2002||2002-08-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|GABA-Alcohol||Clinical-Genetic Variation in GABA/Alcohol Sensitivity|Clinical-Genetic Variation in GABA/Alcohol Sensitivity|Completed|||23|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||f||||||Samples With DNA|"~     Specifically, we will determine whether the subject's gene for a brain protein called~     GABA-alpha-6 is of the Pro type or Ser type.~   "|||2018-06-01 04:27:53.101919|2018-06-01 04:27:53.101919
NCT00223431|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|February 1998||1998-02-28|September 2005|2005-09-30|May 2004||2004-05-31|||||Interventional|||Clinical Performance of 3-Unit FPDs|Clinical Performance of Three-Unit Fixed Partial Dentures (FPDs) Made From a Hot-Pressed Ceramic (Five-Year Study)|Completed||Phase 2|30||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 04:27:53.159535|2018-06-01 04:27:53.159535
NCT00223418|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-04-05|2005-09-13|2005-09-22|Estimate|||||||2013-04-05|2013-04-08|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills|Do Patients Taking Aripiprazole Learn More in Vocational Skills Training Than Patients Taking Olanzapine?|Completed||N/A|43|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-06-01 04:27:53.233409|2018-06-01 04:27:53.233409
NCT00223405|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-18|2005-09-13|2005-09-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|April 2003||2003-04-30|April 2013|2013-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Analysis of Enamel Wear Against Ceramic Restorations|Analysis of Clinical Wear Patterns of Tooth Enamel and Ceramic Restorations as a Function of Particle Size, Inter-Particle Spacing and Fracture Toughness of Ceramic Crystals|Completed|||36|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||||||||||||2018-06-01 04:27:53.318154|2018-06-01 04:27:53.318154
NCT00223379|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-06|2005-09-13|2005-09-22|Estimate|||||||2012-03-06|2012-03-08|Estimate|December 2002||2002-12-31|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Longitudinal Endodontic Study of Apical Preparation Size|Longitudinal Endodontic Study of Apical Preparation Size|Completed||N/A|36|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-06-01 04:27:53.387057|2018-06-01 04:27:53.387057
NCT00223366|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-24|2005-09-13|2005-09-22|Estimate|||||||2018-04-24|2018-04-26|Actual|October 2001|Actual|2001-10-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors|Studies on Normal and Inflamed Dental Pulp, NPY Regulation of Peripheral Human Nociceptors, Peripheral Mechanisms of Opioid Analgesia, Cannabinoid-induced Desensitization of TRPV1 Receptors Adrenergic Modulation of Trigeminal Nociceptors|Active, not recruiting|||2000|Anticipated|The University of Texas Health Science Center at San Antonio|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, sputum, oral mucosa tissue, teeth~   "|||2018-06-01 04:27:53.450382|2018-06-01 04:27:53.450382
NCT00223353|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-15|2005-09-13|2005-09-22|Estimate|||||||2012-02-15|2012-02-17|Estimate|November 1998||1998-11-30|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Quantitative Gait Analysis for Clinical Decision Making|Quantitative Gait Analysis for Clinical Decision Making|Completed|||100|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||||||||||||2018-06-01 04:27:53.507269|2018-06-01 04:27:53.507269
NCT00223340|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-28|2005-09-13|2005-09-22|Estimate|||||||2012-06-28|2012-07-02|Estimate|March 2005||2005-03-31|June 2012|2012-06-30|June 2007||2007-06-30|June 2007|Actual|2007-06-30||Interventional|||The ABC Planning Study: Diabetes and Cardiovascular Risks in Primary Care|Diabetes and Cardiovascular Risks in Primary Care|Completed||N/A|400||The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-06-01 04:27:53.58972|2018-06-01 04:27:53.58972
NCT00223327|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-07|2005-09-13|2005-09-22|Estimate|||||||2012-03-07|2012-03-09|Estimate|March 2005||2005-03-31|March 2012|2012-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Measurement of Bite Force in Humans|Measurement of Bite Force in Humans|Completed|||89|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-06-01 04:27:53.658127|2018-06-01 04:27:53.658127
NCT00223301|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-04-18|2005-09-19|2005-09-22|Estimate|||||||2013-04-18|2013-04-22|Estimate|July 2004||2004-07-31|April 2013|2013-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis|A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis|Completed||Phase 2/Phase 3|24||University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-06-01 04:27:53.923705|2018-06-01 04:27:53.923705
NCT00223288|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-08-02|2005-09-15|2005-09-22|Estimate|||||||2011-08-02|2011-08-03|Estimate|March 2003||2003-03-31|August 2011|2011-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||Impact of Caregiver Depression on Asthma in the Child|Caregiver Psychiatric Symptomatology and it's Relationship to Service Utilization by Children With Asthma|Completed|||175||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:27:54.053941|2018-06-01 04:27:54.053941
NCT00223275|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-05-23|2005-09-15|2005-09-22|Estimate|||||||2011-05-23|2011-05-24|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Naltrexone for Bipolar Disorder and Alcohol Dependence|Naltrexone for Bipolar Disorder and Alcohol Dependence|Completed||Phase 4|50|Anticipated|University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:27:54.154575|2018-06-01 04:27:54.154575
NCT00223262|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-08-02|2005-09-15|2005-09-22|Estimate|||||||2011-08-02|2011-08-03|Estimate|August 2002||2002-08-31|January 2010|2010-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients||Completed||Phase 4|||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:27:54.312354|2018-06-01 04:27:54.312354
NCT00223249|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-04-01|2005-09-15|2005-09-22|Estimate|||||||2016-04-01|2016-04-04|Estimate|November 2002||2002-11-30|April 2016|2016-04-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence|A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence.|Completed||Phase 4|115|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-06-01 04:27:54.38391|2018-06-01 04:27:54.38391
NCT00223236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2013-07-08||2014-08-07|2005-09-15|2005-09-22|Estimate|2014-08-07|2014-08-11|Estimate||||2014-08-07|2014-08-11|Estimate|July 2010||2010-07-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Number of paticipants who completed baseline assessment|Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence|A Double-blind, Placebo-controlled Trial of Citicoline add-on Therapy in Patients With a History of Mania or Hypomania and Cocaine Abuse/Dependence|Completed||Phase 3|44|Actual|University of Texas Southwestern Medical Center|Low retention rate in the end of study (12 weeks) leading to a potential underestimation of treatment effectiveness.|2|||f||||f||||||||||2018-06-01 04:27:54.481468|2018-06-01 04:27:54.481468
NCT00223223|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-08-02|2005-09-14|2005-09-22|Estimate|||||||2011-08-02|2011-08-03|Estimate|February 2005||2005-02-28|September 2005|2005-09-30|November 2005||2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study|Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study|Completed||Phase 4|30||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:27:54.96979|2018-06-01 04:27:54.96979
NCT00223210|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-08-16|2005-09-14|2005-09-22|Estimate|||||||2012-08-16|2012-08-20|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence|A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence|Completed||Phase 4|100|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 04:27:55.05149|2018-06-01 04:27:55.05149
NCT00223197|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-04-02|2005-09-14|2005-09-22|Estimate|||||||2012-04-02|2012-04-03|Estimate|February 2004||2004-02-29|August 2006|2006-08-31|April 2006||2006-04-30|||||Interventional|||Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse|A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse|Completed||Phase 4|75||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 04:27:55.124673|2018-06-01 04:27:55.124673
NCT00223184|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-29|2005-09-21|2005-09-22|Estimate|||||||2011-08-29|2011-08-30|Estimate|March 2003||2003-03-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Observational|||Genetic Characterisation of High-grade Paediatric Osteosarcomas|Study of Prognostic Value by Molecular Analysis in Paediatric Osteosarcomas of the Chromosomal Regions Containing Rb, p16, p53, Cycline D1, APC, erbB2 and C-met Genes|Completed|||||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:27:55.239117|2018-06-01 04:27:55.239117
NCT00223171|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-05-09|2005-09-13|2005-09-22|Estimate|||||||2017-05-09|2017-05-11|Actual|October 2000||2000-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PCS IV||Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers|Randomized, Multicentre, Phase III Study: Assessment of the Duration of Androgen Blockade Combined With Pelvic Irradiation in High-risk Prostate Cancers|Active, not recruiting||Phase 3|650|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-06-01 04:27:55.295118|2018-06-01 04:27:55.295118
NCT00223158|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2014-04-08|2005-09-19|2005-09-22|Estimate|||||||2014-04-08|2014-04-09|Estimate|September 2003||2003-09-30|July 2005|2005-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer|L-T3 Preparation for I131 Whole Body Scintigraphy: A Randomized Controlled Trial|Completed||N/A|70|Anticipated|Université de Sherbrooke|||||f||||||||||||||2018-06-01 04:27:55.360314|2018-06-01 04:27:55.360314
NCT00223145|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-05-09|2005-09-15|2005-09-22|Estimate|||||||2017-05-09|2017-05-11|Actual|December 2000||2000-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PCS III||Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone|Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy|Active, not recruiting||Phase 3|600|Actual|Université de Sherbrooke||3|||f||||f||||||||||2018-06-01 04:27:55.413193|2018-06-01 04:27:55.413193
NCT00223132|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-24|2005-09-13|2005-09-22|Estimate|||||||2012-10-24|2012-10-25|Estimate|February 2005||2005-02-28|October 2012|2012-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Suture Granuloma in Body Contouring Surgery||Completed||Phase 4|||Medtronic - MITG|||||f||||||||||||||2018-06-01 04:27:55.595859|2018-06-01 04:27:55.595859
NCT00223106|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-07-23|2005-09-13|2005-09-22|Estimate|||||||2015-07-23|2015-07-27|Estimate|March 2004||2004-03-31|July 2015|2015-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Treatment for Stress and Mixed Urinary Incontinence and Vaginal Vault Prolapse|A Prospective Multicenter Clinical Study on a New Approach in Treating Stress and Mixed Incontinence and Vaginal Vault Prolapse|Completed||N/A|467|Actual|Medtronic - MITG|||||f||||||||||||||2018-06-01 04:27:55.748752|2018-06-01 04:27:55.748752
NCT00223093|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-10-27|2005-09-14|2005-09-22|Estimate|||||||2005-10-27|2005-10-28|Estimate|February 2004||2004-02-29|April 2003|2003-04-30|August 2005||2005-08-31|||||Interventional|||TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)|A Single-Center Open-Labelled Study of the Administration of Transplant-Acceptance Inducing Cells (TAIZ) for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)|Unknown status|Active, not recruiting|Phase 1|10||University of Schleswig-Holstein|||||f||||||||||||||2018-06-01 04:27:55.886907|2018-06-01 04:27:55.886907
NCT00223080|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-04|2005-09-13|2005-09-22|Estimate|||||||2012-09-04|2012-09-06|Estimate|October 2003||2003-10-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|July 2006|Actual|2006-07-31||Interventional|||HIV Vaccine Trial in Thai Adults|A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults|Completed||Phase 3|16402|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-06-01 04:27:55.953805|2018-06-01 04:27:55.953805
NCT00223067|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-10-27|2005-09-14|2005-09-22|Estimate|||||||2005-10-27|2005-10-28|Estimate|March 2005||2005-03-31|April 2004|2004-04-30|May 2006||2006-05-31|||||Interventional|||Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes|A Multi-Center Open-Labeled Study of the Administration of Allogenic and Autologous Regulatory Cells for the Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor)|Unknown status|Recruiting|Phase 1|10||University of Schleswig-Holstein|||||f||||||||||||||2018-06-01 04:27:56.056238|2018-06-01 04:27:56.056238
NCT00223054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-08-03|2005-09-14|2005-09-22|Estimate|||||||2011-08-03|2011-08-04|Estimate|March 2005||2005-03-31|June 2008|2008-06-30|October 2006|Actual|2006-10-31|June 2006|Actual|2006-06-30||Observational|||Polymorphism of the Cytochrome P450-system in Renal Transplants|Polymorphism of the Cytochrome P450-system and the MDR-system in Renal Transplants Receiving the Immunosuppressive Drugs Tacrolimus, Sirolimus, Everolimus or Cyclosporine A|Completed|||200|Actual|University of Schleswig-Holstein|||||f||||t||||||Samples With DNA|"~     DNA samples to analyze polymorphisms~   "|||2018-06-01 04:27:56.122552|2018-06-01 04:27:56.122552
NCT00223041|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-08-04|2005-09-14|2005-09-22|Estimate|||||||2011-08-04|2011-08-08|Estimate|April 2003||2003-04-30|May 2006|2006-05-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Cranoc Lipid Study in Renal Transplantation|Cardiovascular Events in Renal Transplant Recipients With Low LDL-cholesterol Receiving Tacrolimus in Combination With the Statin Fluvastatin|Terminated||Phase 2/Phase 3|200|Anticipated|University of Schleswig-Holstein||2||No possibilty to receive all plened patients for this study|f||||t||||||||||2018-06-01 04:27:56.190458|2018-06-01 04:27:56.190458
NCT00223028|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-10-27|2005-09-14|2005-09-22|Estimate|||||||2005-10-27|2005-10-28|Estimate|April 2005||2005-04-30|July 2004|2004-07-31|July 2005||2005-07-31|||||Interventional|||Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation|Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation|Completed||Phase 4|15||University of Schleswig-Holstein|||||f||||||||||||||2018-06-01 04:27:56.265814|2018-06-01 04:27:56.265814
NCT00223015|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-10-19|2005-09-14|2005-09-22|Estimate|||||||2005-10-19|2005-10-20|Estimate|May 2004||2004-05-31|May 2004|2004-05-31|April 2005||2005-04-30|||||Interventional|||Investigation of the Steady State Pharmacokinetics of Tacrolimus, Mycophenolate Mofetil and Fluvastatin After Renal Transplantation||Completed||Phase 4|15||University of Schleswig-Holstein|||||f||||||||||||||2018-06-01 04:27:56.31905|2018-06-01 04:27:56.31905
NCT00223002|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-02-12|2005-09-21|2005-09-22|Estimate|||||||2009-02-12|2009-02-16|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||Chlorhexidine Versus Povidone-Iodine for Prevention of Epidural Needle Contamination in the Parturient|Chlorhexidine Versus Povidone-Iodine for Prevention of Epidural Needle Contamination in the Parturient|Completed||N/A|400|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 04:27:56.370519|2018-06-01 04:27:56.370519
NCT00222989|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-04-12|2005-09-14|2005-09-22|Estimate|||||||2017-04-12|2017-04-14|Actual|October 2003||2003-10-31|April 2017|2017-04-30|December 1, 2100|Anticipated|2100-12-01|December 1, 2100|Anticipated|2100-12-01||Interventional|||PPI Versus Placebo in Severe Functional Heartburn|PPI Versus Placebo in Severe Functional Heartburn|Withdrawn||N/A|0|Actual|University of Southern California||1||Study never started.|f||||||||||||||2018-06-01 04:27:56.440343|2018-06-01 04:27:56.440343
NCT00222976|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-11-13|2005-09-19|2005-09-22|Estimate|||||||2007-11-13|2007-11-15|Estimate|September 2006||2006-09-30|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||Oral vs Rectal Admin of Naproxen for Post-Vag Perineal Pain Control|Oral vs Rectal Administration of Naproxen for Post-Vaginal Perineal Pain Control: A Randomized Clinical Trial|Completed||Phase 4|60|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 04:27:56.517092|2018-06-01 04:27:56.517092
NCT00222963|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-02-12|2005-09-15|2005-09-22|Estimate|||||||2009-02-12|2009-02-13|Estimate|September 2004||2004-09-30|September 2006|2006-09-30||||||||Observational|||Pilot Study to Assess the Effectiveness of Tonsil and Adenoidectomy (T+A) in Overweight Children and Adolescents|Pilot Study to Assess the Effectiveness of Tonsil and Adenoidectomy (T+A) in Overweight Children and Adolescents|Completed|||250|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 04:27:56.582847|2018-06-01 04:27:56.582847
NCT00222950|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Concentration of Plant Sterols in Serum and Aortic Valve Cusps|Concentrations of Plant Sterols in Serum and Aortic Valve Cusps: a Prospectiv Observational Study|Unknown status|Recruiting||100||University Hospital, Saarland|||||f||||||||||||||2018-06-01 04:27:56.643024|2018-06-01 04:27:56.643024
NCT00222937|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2016-01-21|2005-09-20|2005-09-22|Estimate|||||||2016-01-21|2016-01-25|Estimate|October 2005||2005-10-31|January 2016|2016-01-31|August 2010|Actual|2010-08-31|June 2009|Actual|2009-06-30||Interventional|||Voice Therapy for Teachers With Voice Problems|Efficacy of Voice Therapy for Phonotrauma in Teachers|Completed||Phase 3|105|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:27:56.729723|2018-06-01 04:27:56.729723
NCT00222924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-12-14|2005-09-20|2005-09-22|Estimate|||||||2007-12-14|2007-12-19|Estimate|December 2003||2003-12-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Mitochondrial Impairment in Muscle Insulin Resistance|Mitochondrial Impairment in Muscle Insulin Resistance|Completed||N/A|49||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:56.796955|2018-06-01 04:27:56.796955
NCT00222911|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-05-19|2005-09-20|2005-09-22|Estimate|||||||2008-05-19|2008-05-20|Estimate|August 2005||2005-08-31|May 2008|2008-05-31|November 2006|Actual|2006-11-30|||||Interventional|||Treatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports|Conservative Treatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports: a Prospective Randomized Study|Completed||Phase 4|75|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:56.870227|2018-06-01 04:27:56.870227
NCT00222898|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-02-16|2005-09-20|2005-09-22|Estimate|||||||2007-02-16|2007-02-19|Estimate|June 2004||2004-06-30|February 2007|2007-02-28||||||||Observational|||Cancer Detection in Pancreatic Cysts|Pancreatic Cyst DNA Analysis|Completed|||300||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:56.964756|2018-06-01 04:27:56.964756
NCT00222885|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-12-14|2005-09-20|2005-09-22|Estimate|||||||2007-12-14|2007-12-19|Estimate|December 2002||2002-12-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Observational|||Multi-Tracer PET Quantitation of Insulin Action in Muscle (Phase 1, Phase 2, Phase 3, Phase 4)|Three-Tracer PET Quantitation of Insulin Action in Muscle|Completed|||50||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:57.037483|2018-06-01 04:27:57.037483
NCT00222872|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-04-25|2005-09-19|2005-09-22|Estimate|||||||2014-04-25|2014-04-28|Estimate|July 2005||2005-07-31|April 2014|2014-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women|A Three Week Dose Escalation Study of PTHrP(1-36) in Postmenopausal Women|Completed||Phase 1|61|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:27:57.108015|2018-06-01 04:27:57.108015
NCT00222859|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-29|2005-09-19|2005-09-22|Estimate|||||||2013-07-29|2013-07-30|Estimate|March 2005||2005-03-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Reasons for Non-treatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting|Reasons for Nontreatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting|Completed|||300|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:27:57.188345|2018-06-01 04:27:57.188345
NCT00222846|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-05-14|2005-09-19|2005-09-22|Estimate|||||||2010-05-14|2010-05-17|Estimate|May 2004||2004-05-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|ENHANCE||Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study|Enhancing Adherence in Type 2 Diabetics|Completed||N/A|288|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:27:57.243994|2018-06-01 04:27:57.243994
NCT00222833|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-01-08|2005-09-19|2005-09-22|Estimate|||||||2008-01-08|2008-01-15|Estimate|October 2004||2004-10-31|January 2008|2008-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia|The Effect of Switching to Aripiprazole on Indices of Cardiovascular Health in Overweight and Obese Patients With Schizophrenia|Completed||Phase 4|30||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:57.322408|2018-06-01 04:27:57.322408
NCT00222820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-19|2005-09-19|2005-09-22|Estimate|||||||2005-09-19|2005-09-22|Estimate|April 2002||2002-04-30|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study|Depression: The Search for Treatment-Relevant Phenotypes|Completed||Phase 4|35||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:57.397252|2018-06-01 04:27:57.397252
NCT00222807|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-25|2005-09-19|2005-09-22|Estimate|||||||2017-08-25|2017-08-28|Actual|August 2003||2003-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus|Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus|Completed|||200|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     blood samples are collected, stored at minus 70 degree C and analyzed in batches.~   "|||2018-06-01 04:27:57.456926|2018-06-01 04:27:57.456926
NCT00222794|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-08-30|2005-09-19|2005-09-22|Estimate|||||||2010-08-30|2010-08-31|Estimate|November 2003||2003-11-30|January 2008|2008-01-31|July 2006|Actual|2006-07-31|||||Interventional|||A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia|A Randomized, Parallel Group, Double Blind, Placebo Controlled, Clinical Trial of Augmentation With Atomoxetine for the Treatment of Negative Symptoms in Patients With Schizophrenia and Schizoaffective Disorder|Completed||Phase 4|66||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:57.550664|2018-06-01 04:27:57.550664
NCT00222781|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-12-14|2005-09-19|2005-09-22|Estimate|||||||2007-12-14|2007-12-19|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|December 2006||2006-12-31|||||Observational|||Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus|Three-Tracer PET Quantitation of Insulin Action in Muscle|Completed|||24||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:57.64097|2018-06-01 04:27:57.64097
NCT00222768|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2008-02-15|2005-09-19|2005-09-22|Estimate|||||||2008-02-15|2008-02-18|Estimate|April 2005||2005-04-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|||||Observational|||PET Imaging of Regional Variation in Insulin Sensitivity of Adipose Tissue in Humans|Three-Tracer PET Quantitation of Insulin Action in Muscle|Completed|||20||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:57.697878|2018-06-01 04:27:57.697878
NCT00222755|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2008-01-03|2005-09-19|2005-09-22|Estimate|||||||2008-01-03|2008-01-04|Estimate|January 2006||2006-01-31|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|CIVIC-2||Improving Care for Patients With Bipolar Disorder|Improving Care for Veterans With Bipolar Disorder|Completed||N/A|60|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 04:27:57.747533|2018-06-01 04:27:57.747533
NCT00222742|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-07-10|2005-09-16|2005-09-22|Estimate|||||||2012-07-10|2012-07-11|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||Hypothermia in Children After Trauma|Pediatric Traumatic Brain Injury Consortium: Hypothermia|Terminated||Phase 3|90|Actual|Phoenix Children's Hospital||1||Futility|f||||t||||||||||2018-06-01 04:27:57.829307|2018-06-01 04:27:57.829307
NCT00222729|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2016-01-15||2016-01-15|2005-09-16|2005-09-22|Estimate|2016-01-15|2016-02-15|Estimate||||2016-01-15|2016-02-15|Estimate|November 2005||2005-11-30|January 2016|2016-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer|Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer|Completed||Phase 2|42|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:27:57.951291|2018-06-01 04:27:57.951291
NCT00222716|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-06-22|2005-09-14|2005-09-22|Estimate|||||||2017-06-22|2017-06-26|Actual|January 2004||2004-01-31|June 2017|2017-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MM2||Managing Medications|Improving Adherence to Antiretroviral Therapy|Completed||N/A|349|Actual|University of Pittsburgh||3|||f||||t||||||||No|There is not plan to share data specifically but the data has been shared with the Mach14 Collaborative. Entire data set has been shared with the Collaborative.|2018-06-01 04:27:58.142911|2018-06-01 04:27:58.142911
NCT00222690|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-05-26|2005-09-14|2005-09-22|Estimate|||||||2006-05-26|2006-05-29|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|June 2006||2006-06-30|||||Observational|||Living With Fibromyalgia: Triggers,Subgroups, and a Cognitive-Behavioral and Interactive Technology-Based Intervention|Living With Fibromyalgia (FM): Triggers,Clinical Subgroups, and the Effects Of A Self-Monitored Cognitive-Behavioral and Interactive Technology-Based Intervention on Clinical Subgroups|Completed|||30||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:27:58.267621|2018-06-01 04:27:58.267621
NCT00222677|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-21|2005-09-19|2005-09-22|Estimate|||||||2011-08-21|2011-08-23|Estimate|May 2004||2004-05-31|August 2011|2011-08-31||||January 2012|Anticipated|2012-01-31||Interventional|||Aspirin for the Prevention of Recurrent Venous Thromboembolism|Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.|Unknown status|Active, not recruiting|Phase 2/Phase 3|70|Anticipated|University Of Perugia|||||f||||||||||||||2018-06-01 04:27:58.312208|2018-06-01 04:27:58.312208
NCT00222664|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|September 1983||1983-09-30|August 2005|2005-08-31|December 2004||2004-12-31|||||Interventional|||Qidong Hepatitis B Intervention Study||Completed||Phase 4|80000||University of Oxford|||||f||||||||||||||2018-06-01 04:27:58.477569|2018-06-01 04:27:58.477569
NCT00222651|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2008-04-29|2005-09-19|2005-09-22|Estimate|||||||2008-04-29|2008-05-06|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|July 2006|Anticipated|2006-07-31|||||Interventional|||Tenecteplase Pulmonary Embolism Italian Study|A Phase II Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Single Bolus i.v. Tenecteplase Versus Placebo in Normotensive Patients With Pulmonary Embolism and Right Ventricular Dysfunction|Terminated||Phase 2|180|Anticipated|University Of Perugia||||competitor study about to start|f||||||||||||||2018-06-01 04:27:58.551336|2018-06-01 04:27:58.551336
NCT00222638|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|October 2004||2004-10-31|June 2005|2005-06-30|May 2005||2005-05-31|||||Interventional|||Influenza Vaccination and Oral Anticoagulant Therapy|Randomized Blinded Cross-Over Clinical Trial Investigate the Interactions Between Influenza Vaccination and Oral Anticoagulant Therapy|Completed||Phase 4|100||University Of Perugia|||||f||||||||||||||2018-06-01 04:27:58.684357|2018-06-01 04:27:58.684357
NCT00222625|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-19|2005-09-13|2005-09-22|Estimate|||||||2006-09-19|2006-09-20|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets|Randomized, Open, Prospective, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII in Acute Intracerebral Haemorrhage in Patients Treated With Oral Anticoagulants or Antiplatelets Agents.|Unknown status|Recruiting|Phase 2|32||University Of Perugia|||||f||||||||||||||2018-06-01 04:27:58.758613|2018-06-01 04:27:58.758613
NCT00222612|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-02|2005-09-14|2005-09-22|Estimate|||||||2010-02-02|2010-02-03|Estimate|October 2003||2003-10-31|February 2010|2010-02-28|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003|Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003|Unknown status|Recruiting|Phase 4|2100|Anticipated|University of Oxford||3|||f||||t||||||||||2018-06-01 04:27:58.886791|2018-06-01 04:27:58.886791
NCT00222573|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-05-04|2005-09-13|2005-09-22|Estimate|||||||2006-05-04|2006-05-05|Estimate|July 1999||1999-07-31|March 2005|2005-03-31|February 2005||2005-02-28|||||Interventional|||Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction|Clopidogrel Or Metoprolol in Myocardial Infarction Trial|Completed||Phase 4|46000||University of Oxford|||||f||||||||||||||2018-06-01 04:27:58.992946|2018-06-01 04:27:58.992946
NCT00222560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-04-27|2005-09-16|2005-09-22|Estimate|||||||2007-04-27|2007-04-30|Estimate|May 2005||2005-05-31|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Interventional|PAC||The PAC Project: Integrating a Physical Activity Counsellor in the Primary Health Care Team|The PAC Project: Integrating a Physical Activity Counsellor in the Primary Health Care Team: A Randomized Controlled Trial|Completed||Phase 2|120|Actual|University of Ottawa|||||f||||f||||||||||2018-06-01 04:27:59.123377|2018-06-01 04:27:59.123377
NCT00222547|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-10-27|2005-09-13|2005-09-22|Estimate|||||||2005-10-27|2005-10-28|Estimate|January 1999||1999-01-31|February 2005|2005-02-28|February 2005||2005-02-28|||||Interventional|||Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6|Deworming and Enhanced Vitamin A Supplementation DEVTA Project|Completed||Phase 4|720000||University of Oxford|||||f||||||||||||||2018-06-01 04:27:59.195437|2018-06-01 04:27:59.195437
NCT00222534|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-01-17|2005-09-14|2005-09-22|Estimate|||||||2014-01-17|2014-01-20|Estimate|January 2002||2002-01-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis|Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis|Completed||Phase 4|70|Actual|University of Oslo School of Pharmacy||2|||f||||||||||||||2018-06-01 04:27:59.255863|2018-06-01 04:27:59.255863
NCT00222521|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Insulin Glargine Vs Standard Insulin Therapy|Comparison of Insulin Glargine Vs Standard Insulin Therapy in CFRD Without Fasting Hyperglycemia|Completed||Phase 3|20||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:27:59.335223|2018-06-01 04:27:59.335223
NCT00222508|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-07-31|2005-09-14|2005-09-22|Estimate|||||||2012-07-31|2012-08-02|Estimate|April 2001||2001-04-30|July 2012|2012-07-31|July 2005||2005-07-31|||||Observational|||The Microvascular Complications Study|Microvascular Complications of Cystic Fibrosis Related Diabetes|Completed|||150|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 04:27:59.413606|2018-06-01 04:27:59.413606
NCT00222495|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2006-09-07|2005-09-16|2005-09-22|Estimate|||||||2006-09-07|2006-09-11|Estimate|August 2002||2002-08-31|September 2006|2006-09-30|August 2006||2006-08-31|||||Interventional|||A Comparative Study of New Medications for Psychosis in Adolescents|A Comparative Study of New Medications for Psychosis in Adolescents|Completed||N/A|30||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:27:59.50577|2018-06-01 04:27:59.50577
NCT00222482|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-08-08|2005-09-14|2005-09-22|Estimate|||||||2007-08-08|2007-08-09|Estimate|March 2003||2003-03-31|August 2007|2007-08-31|September 2005|Actual|2005-09-30|||||Interventional|||Depakote ER in Borderline Personality Disorder|A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder|Completed||N/A|15||University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 04:27:59.626245|2018-06-01 04:27:59.626245
NCT00222274|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-02-06|2005-09-15|2005-09-22|Estimate|||||||2015-02-06|2015-02-09|Estimate|July 2004||2004-07-31|February 2015|2015-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||HRV Biofeedback in Fibromyalgia|A Pilot Study of the Efficacy of Biofeedback in Patients With Fibromyalgia Syndrome.|Completed||N/A|80|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 04:28:00.638823|2018-06-01 04:28:00.638823
NCT00222469|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-07-08|2005-09-20|2005-09-22|Estimate|||||||2008-07-08|2008-07-09|Estimate|August 2005||2005-08-31|July 2008|2008-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer|A Phase II Trial of Bevacizumab Plus Gemcitabine™ and Oxaliplatin™ as First Line Therapy in Metastatic or Locally Advanced (Unresectable) Pancreatic Cancer|Completed||Phase 2|50|Actual|University of Oklahoma||1|||f||||||||||||||2018-06-01 04:27:59.705442|2018-06-01 04:27:59.705442
NCT00222456|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2005-09-15|2005-09-15|2005-09-22|Estimate|||||||2005-09-15|2005-09-22|Estimate|March 1999||1999-03-31|September 2005|2005-09-30|September 2008||2008-09-30|||||Interventional|||Project Early Intervention 2000|Can Early Intervention Prevent Developmental Disturbances/Delays and Improve the Health of Children Born Prematurely|Completed||N/A|210||University Hospital of North Norway|||||f||||||||||||||2018-06-01 04:27:59.78579|2018-06-01 04:27:59.78579
NCT00222443|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-09-19|2005-09-20|2005-09-22|Estimate|||||||2008-09-19|2008-09-22|Estimate|September 2004||2004-09-30|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy|Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy|Completed||Phase 1|40||University of Oklahoma|||||f||||||||||||||2018-06-01 04:27:59.843543|2018-06-01 04:27:59.843543
NCT00222430|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-03-27|2005-09-20|2005-09-22|Estimate|||||||2012-03-27|2012-03-28|Estimate|March 2005||2005-03-31|March 2012|2012-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Fluoroscopy Guided Femoral Arterial Access|Fluoroscopy Guided Femoral Arterial Access and the Use of Closure Devices: A Randomized Controlled Trial.|Completed||N/A|990|Actual|University of Oklahoma||2|||f||||f||||||||||2018-06-01 04:27:59.912954|2018-06-01 04:27:59.912954
NCT00222417|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-20|2005-09-13|2005-09-22|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2002||2002-09-30|June 2012|2012-06-30|December 2014|Anticipated|2014-12-31|||||Observational|||Audiometric Parameters in Conductive Hearing Loss and Middle Ear Disease|Audiometric Parameters in Conductive Hearing Loss and Middle Ear Disease|Unknown status|Active, not recruiting||44|Actual|University Hospital of North Norway|||2||f||||f||||||||||2018-06-01 04:27:59.98393|2018-06-01 04:27:59.98393
NCT00222404|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-11-04|2005-09-16|2005-09-22|Estimate|||||||2010-11-04|2010-11-05|Estimate|July 2005||2005-07-31|November 2010|2010-11-30|August 2010|Actual|2010-08-31|||||Observational|Pharmacogenos||"Pharmacogenomic Study Realized on Non-small Cell Lung Carcinoma"|"Pharmacogenomic Study Realized Within the Framework of the Common Care to Non-small Cell Lung Carcinoma at Any Stages Treated by Chemotherapy."|Completed|||556|Actual|University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:28:00.091639|2018-06-01 04:28:00.091639
NCT00222391|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2009-01-06|2005-09-20|2005-09-22|Estimate|||||||2009-01-06|2009-01-07|Estimate|April 2004||2004-04-30|March 2006|2006-03-31|January 2006||2006-01-31|||||Observational|||Influence of Thoracic Epidural Anesthesia on Skin Sympathetic Activity and Heart Rate Variability|Influence of Thoracic Epidural Anesthesia on Skin Sympathetic Activity and Heart Rate Variability in Surgical Patients|Completed|||40||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:28:00.143089|2018-06-01 04:28:00.143089
NCT00222378|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2015-07-28|2005-09-19|2005-09-22|Estimate|||||||2015-07-28|2015-07-30|Estimate|April 2005||2005-04-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease|Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus DNA in Intestinal Mucosa of Patients With Inflammatory Bowel Disease|Completed|||129|Actual|University of Miami|||||f||||t||||||Samples With DNA|"~     Specimens will be discarded upon study completion~   "|||2018-06-01 04:28:00.190687|2018-06-01 04:28:00.190687
NCT00222365|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-11-09|2005-09-14|2005-09-22|Estimate|||||||2006-11-09|2006-11-14|Estimate|December 2003||2003-12-31|July 2006|2006-07-31|May 2006||2006-05-31|||||Interventional|||Homeopathy Assessment in Terms of the Consumption of Analgesics After Knee Ligamentoplasty|Homeopathy Assessment in Terms of the Consumption of Analgesics After Knee Ligamentoplasty|Terminated||Phase 3|165||University Hospital, Grenoble|||||f||||||||||||||2018-06-01 04:28:00.250375|2018-06-01 04:28:00.250375
NCT00222352|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-02-01|2005-09-14|2005-09-22|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2004|Actual|2004-12-31|February 2018|2018-02-28|March 2007|Actual|2007-03-31|November 2006|Actual|2006-11-30||Observational|Dispo-ACS||Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes|Diagnosis and Treatment of Acute Coronary Syndromes in the Emergency Department: The Impact of Rapid Bedside cTnI Testing on Outcomes|Completed|||2000|Actual|University of Cincinnati|||2||f||||f|f|f||||Samples Without DNA|"~     SERUM BANKING Each patient consented and enrolled will have whole blood and plasma saved and~     frozen. The amount of blood drawn for the study is 5 ml (per draw), which is to be placed in~     a lithium heparinzed tube. One ml of whole blood will be alloquoted, frozen at -70ºC, and~     shipped to the Study Coordinating Center. The remainder of the sample will be centrifuged,~     alloquoted, frozen at -70ºC, and shipped to the Study Coordinating Center. These blood~     samples will be de-identified and assigned a study ID #. There will be no genetic testing of~     these samples.~   "|Undecided|Blood samples banked for future use. Must be IRB approved before use.|2018-06-01 04:28:00.306257|2018-06-01 04:28:00.306257
NCT00222339|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|February 2002||2002-02-28|December 2001|2001-12-31|June 2004||2004-06-30|||||Interventional|||Task-Related Training of Arm Use After Stroke|Task-Related Training of Arm Use After Stroke: a Randomised Controlled Trial|Completed||N/A|30||University of Melbourne|||||f||||||||||||||2018-06-01 04:28:00.4005|2018-06-01 04:28:00.4005
NCT00222326|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-17|2005-09-13|2005-09-22|Estimate|||||||2009-02-17|2009-02-18|Estimate|July 2002||2002-07-31|February 2009|2009-02-28|April 2007|Actual|2007-04-30|April 2006|Actual|2006-04-30||Interventional|||The Effect of Physiotherapy Treatment Following Gynaecological Surgery|The Effect of a Physiotherapy Treatment Program on Pelvic Function Following Gynaecological Surgery|Completed||N/A|50|Actual|University of Melbourne||1|||f||||f||||||||||2018-06-01 04:28:00.462832|2018-06-01 04:28:00.462832
NCT00222300|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-08-07|2005-09-13|2005-09-22|Estimate|||||||2006-08-07|2006-08-08|Estimate|May 2003||2003-05-31|October 2003|2003-10-31|December 2005||2005-12-31|||||Interventional|||A Targeted Strengthening Program Following Total Hip Replacement.|A Targeted Strengthening Program Following Total Hip Replacement.|Completed||N/A|30||University of Melbourne|||||f||||||||||||||2018-06-01 04:28:00.524401|2018-06-01 04:28:00.524401
NCT00222287|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-21|2005-09-13|2005-09-22|Estimate|||||||2006-09-21|2006-09-22|Estimate|September 2004||2004-09-30|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||The Effect of Feldenkrais Lessons on Walking and Balance|The Effect of Feldenkrais Lessons on Walking and Balance|Unknown status|Active, not recruiting|Phase 1|60||University of Melbourne|||||f||||||||||||||2018-06-01 04:28:00.575942|2018-06-01 04:28:00.575942
NCT00222261|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-22|2005-09-14|2005-09-22|Estimate|||||||2011-03-22|2011-03-23|Estimate|April 2003||2003-04-30|March 2011|2011-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ASCET||Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.|Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.|Completed||Phase 4|1001|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 04:28:00.712131|2018-06-01 04:28:00.712131
NCT00222248|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-08-07|2005-09-13|2005-09-22|Estimate|||||||2006-08-07|2006-08-08|Estimate|March 2003||2003-03-31|June 2003|2003-06-30|March 2006||2006-03-31|||||Interventional|||Pelvic Floor Muscle Training for Incontinence in Older Women.|The Effect of Pelvic Floor Muscle Training for the Management of Incontinence in Older Women: a Single Blind Randomised Controlled Trial.|Unknown status|Active, not recruiting|N/A|90||University of Melbourne|||||f||||||||||||||2018-06-01 04:28:00.783057|2018-06-01 04:28:00.783057
NCT00222235|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-21|2005-09-14|2005-09-22|Estimate|||||||2013-11-21|2013-11-25|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|June 2004||2004-06-30|||||Interventional|||Adjunctive Treatment for Decreasing Symptoms of Schizophrenia|Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST)|Completed||Phase 2/Phase 3|240||University of Maryland|||||||||||||||||||2018-06-01 04:28:01.765207|2018-06-01 04:28:01.765207
NCT00222222|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-22|Estimate|||||||2012-02-14|2012-02-16|Estimate|March 2003||2003-03-31|February 2012|2012-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis|Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis|Completed||N/A|105|Actual|Universitätsmedizin Mannheim|||||f||||f||||||||||2018-06-01 04:28:01.832274|2018-06-01 04:28:01.832274
NCT00222209|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-08-02|2005-09-13|2005-09-22|Estimate|||||||2006-08-02|2006-08-03|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|November 2007||2007-11-30|||||Interventional|||Clinical Study on Implicit Learning, Comorbidity and Stress Vulnerability in Chronic Functional Pain|Implicit Learning, Comorbidity and Stress Vulnerability in Chronic Functional Pain Syndromes|Unknown status|Recruiting|N/A|64||Universitätsmedizin Mannheim|||||f||||||||||||||2018-06-01 04:28:01.897138|2018-06-01 04:28:01.897138
NCT00222196|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-03|2005-09-13|2005-09-22|Estimate|||||||2011-07-03|2011-07-06|Estimate|November 2000||2000-11-30|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Oslo Balloon Angioplasty Versus Conservative Treatment|Oslo Balloon Angioplasty Versus Conservative Treatment|Completed||N/A|200||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:28:01.964191|2018-06-01 04:28:01.964191
NCT00222183|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-04-05|2005-09-19|2005-09-22|Estimate|||||||2007-04-05|2007-04-06|Estimate|June 2003||2003-06-30|February 2007|2007-02-28||||||||Interventional|||Cutaneous Lupus Erythematosus and Elidel|Evaluation of the Therapeutic Effect and Local Tolerability of Elidel® Cream 1% (Pimecrolimus) in Chronic Discoid Lupus Erythematosus (dLE) or Subacute Cutaneous Lupus Erythematosus (scLE)|Unknown status|Recruiting|N/A|25||University of Leipzig|||||f||||||||||||||2018-06-01 04:28:02.027832|2018-06-01 04:28:02.027832
NCT00222170|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-07|2005-09-13|2005-09-22|Estimate|||||||2009-05-07|2009-05-08|Estimate|May 2005||2005-05-31|August 2007|2007-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)|Esophagoprotection by Rabeprazole Mediated by Restoration of an Impairment in Esophageal Mucin Production: Its Potential Therapeutic Benefit in Patients With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 2|24|Actual|University of Kansas Medical Center|||||f||||f||||||||||2018-06-01 04:28:02.100284|2018-06-01 04:28:02.100284
NCT00222144|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-06|2005-09-13|2005-09-22|Estimate|||||||2012-08-06|2012-08-07|Estimate|September 2004||2004-09-30|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer|Phase II Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer|Completed||Phase 2|23|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-06-01 04:28:02.167821|2018-06-01 04:28:02.167821
NCT00222131|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-01|2005-09-13|2005-09-22|Estimate|||||||2015-05-01|2015-05-05|Estimate|October 2003||2003-10-31|May 2015|2015-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients|Inhibition of Gastric Acid Is the Key To Satisfactory Relief of Symptoms and Restoration of the Quality of Life in Patients With Epigastric Pain Related to Non-Ulcer Dyspepsia During Therapy With Esomeprazole|Completed||Phase 2|77|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-06-01 04:28:02.33047|2018-06-01 04:28:02.33047
NCT00222118|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-11-08|2005-09-13|2005-09-22|Estimate|||||||2012-11-08|2012-11-09|Estimate|October 2003||2003-10-31|November 2012|2012-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Kansas University Teen Mothers Project|Promoting and Supporting Breastfeeding in Adolescents|Completed||N/A|390|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-06-01 04:28:02.437982|2018-06-01 04:28:02.437982
NCT00222105|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-03-21||2017-06-05|2005-09-13|2005-09-22|Estimate|2017-03-21|2017-05-01|Actual||||2017-06-05|2017-07-02|Actual|November 2002||2002-11-30|June 2017|2017-06-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life|Doxil® (Pegylated Liposomal Doxorubicin), Dexamethasone Plus Thalidomide (Ddt) in Previously Untreated Multiple Myeloma: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life|Completed||Phase 2|25|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-06-01 04:28:02.536007|2018-06-01 04:28:02.536007
NCT00222092|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-23|2005-09-13|2005-09-22|Estimate|||||||2011-08-23|2011-08-24|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|September 2006||2006-09-30|||||Observational|||Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers|Effect of Octreotide, Somatostatin, Pentoxyfilline or Placebo in the Prevention and the Course of Post-ERCP Pancreatitis and Study of Molecular Markers in Post-ERCP Pancreatitis|Completed|||300||University of Ioannina|||||f||||||||||||||2018-06-01 04:28:02.701262|2018-06-01 04:28:02.701262
NCT00222079|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-12-12|2005-09-16|2005-09-22|Estimate|||||||2017-12-12|2017-12-14|Actual|November 2004|Actual|2004-11-30|December 2017|2017-12-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy|Pilot Study to Evaluate Esomeprazole (Nexium) in Treating Gastro-esophageal Reflux in Patients With Head and Neck Cancer With Prior External Beam Radiation Therapy: a Randomized, Prospective, Placebo-controlled, Double-blind Study.|Terminated||N/A|40|Actual|University of Iowa||||Project canceled due to the implementation of IMRT, fewer patients reporting xerostomia.|f||||||||||||||2018-06-01 04:28:02.758019|2018-06-01 04:28:02.758019
NCT00222066|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2010-02-02|2005-09-19|2005-09-22|Estimate|||||||2010-02-02|2010-02-03|Estimate|June 2001||2001-06-30|September 2006|2006-09-30|September 2007|Actual|2007-09-30|January 2007|Actual|2007-01-31||Interventional|||Effect of Fetal Ovarian Cyst Aspiration to Prevent Torsion|Comparison Between Abstention and Intrauterine Aspiration in the Treatment of Anechoic Fetal Ovarian Cysts to Prevent Ovarian Torsion|Completed||N/A|61|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-06-01 04:28:02.82284|2018-06-01 04:28:02.82284
NCT00222027|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-06|2005-09-13|2005-09-22|Estimate|||||||2009-01-06|2009-01-07|Estimate|November 2003||2003-11-30|January 2009|2009-01-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|GRAALL2003||Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial|GRAALL 2003 Trial (ALL 15-59 Years). Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial|Completed||Phase 2|300||University Hospital, Toulouse|||||f||||f||||||||||2018-06-01 04:28:03.155041|2018-06-01 04:28:03.155041
NCT00222014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-22|2005-09-13|2005-09-22|Estimate|||||||2013-01-22|2013-01-24|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||TIPS With Coated Stents for Refractory Ascites in Patients With Cirrhosis|TIPS (With Coated Stents) OR PARACENTESIS + ALBUMIN ADMINISTRATION FOR THE TREATMENT OF REFRACTORY ASCITES IN PATIENTS WITH CIRRHOSIS : A RANDOMIZED TRIAL COMPARING SURVIVAL, QUALITY OF LIFE AND NUTRITIONAL STATUS|Completed||N/A|55|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-06-01 04:28:03.214959|2018-06-01 04:28:03.214959
NCT00222001|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-01-27|2005-09-15|2005-09-22|Estimate|||||||2015-01-27|2015-01-28|Estimate|December 2002||2002-12-31|January 2015|2015-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||Telephone Triage Study|Outcome Evaluation of Triage for Health Maintenance Organization (HMO) Patients Performed by Doctors in a Medical Telemedicine Center|Completed|||100|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-06-01 04:28:03.286322|2018-06-01 04:28:03.286322
NCT00221988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-22|Estimate|||||||2005-09-16|2005-09-22|Estimate|March 2004||2004-03-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers|A Randomized, Double-Blind, Cross-Over Study of the Cognitive and Mood Effects of KEPPRA (Levetiracetam) Tablets in Healthy Older Adults.|Unknown status|Recruiting|N/A|40||University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-06-01 04:28:03.337571|2018-06-01 04:28:03.337571
NCT00221975|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-01|2005-09-16|2005-09-22|Estimate|||||||2014-12-01|2014-12-03|Estimate|July 2002||2002-07-31|December 2014|2014-12-31|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling|Combination Therapy in Dual Diagnosis Rapid Cycling Bipolar Disorder|Completed||Phase 3|98|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 04:28:03.418876|2018-06-01 04:28:03.418876
NCT00221962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2014-12-12|2005-09-16|2005-09-22|Estimate|||||||2014-12-12|2014-12-15|Estimate|April 2005||2005-04-30|June 2013|2013-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)|The Cognitive Effects of Aripiprazole in Children|Completed||Phase 4|23|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-06-01 04:28:03.581399|2018-06-01 04:28:03.581399
NCT00221949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-12-04|2005-09-20|2005-09-22|Estimate|||||||2008-12-04|2008-12-05|Estimate||||August 2005|2005-08-31||||||||Observational|||Visualizing Peripheral Nerves Using Ultrasound-Guided Approach|Development of a Comprehensive Study of the Peripheral Nerves in the Lower Arm and Lower Leg Using an Ultrasound Guided Approach|Completed|||16|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:28:03.65866|2018-06-01 04:28:03.65866
NCT00221936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-12-04|2005-09-20|2005-09-22|Estimate|||||||2008-12-04|2008-12-05|Estimate|July 2004||2004-07-31|July 2005|2005-07-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Patient Controlled Oral Analgesia for Postoperative Pain Management After Total Knee Replacement|Patient Controlled Oral Analgesia (PCOA) for Postoperative Pain Management After Total Knee Replacement-A Pilot Study|Completed||N/A|50|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:28:03.711961|2018-06-01 04:28:03.711961
NCT00221923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-08-29|2005-09-14|2005-09-22|Estimate|||||||2011-08-29|2011-08-30|Estimate|September 2002||2002-09-30|August 2011|2011-08-31|February 2015|Anticipated|2015-02-28|||||Observational|ADAGES||African Descent and Glaucoma Evaluation Study|African Descent and Glaucoma Evaluation Study (Formerly African Americans With Glaucoma Study)|Unknown status|Active, not recruiting||1540|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-06-01 04:28:03.771292|2018-06-01 04:28:03.771292
NCT00221910|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-12-04|2005-09-20|2005-09-22|Estimate|||||||2008-12-04|2008-12-05|Estimate|February 2003||2003-02-28|March 2005|2005-03-31|March 2005|Actual|2005-03-31|||||Interventional|||Use of Ultrasound in Lower Extremity Blocks.|Does Ultrasound Guidance Improve the Success of Sciatic Nerve Block at the Popliteal Fossa? A Prospective, Randomized, Controlled Trial.|Completed||N/A|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:28:03.859233|2018-06-01 04:28:03.859233
NCT00221897|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-08-29|2005-09-14|2005-09-22|Estimate|||||||2011-08-29|2011-08-30|Estimate|April 1995||1995-04-30|August 2011|2011-08-31|July 2016|Anticipated|2016-07-31|||||Observational|DIGS||Diagnostic Innovations in Glaucoma Study|Diagnostic Innovations in Glaucoma Study|Unknown status|Recruiting||3000|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-06-01 04:28:03.917008|2018-06-01 04:28:03.917008
NCT00221884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-12-04|2005-09-20|2005-09-22|Estimate|||||||2008-12-04|2008-12-05|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Use of Ultrasound in Upper Extremity Blocks.|Does Ultrasound Guidance Improve the Success of Brachial Plexus Block? A Prospective, Randomized, Controlled Trial.|Completed||N/A|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:28:04.031588|2018-06-01 04:28:04.031588
NCT00221871|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2006-10-10|2005-09-20|2005-09-22|Estimate|||||||2006-10-10|2006-10-11|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Proper Dosage of Ketamine in Intravenous Regional Anesthesia|Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).|Unknown status|Recruiting|N/A|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:28:04.108356|2018-06-01 04:28:04.108356
NCT00221858|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2018-01-17|2005-09-20|2005-09-22|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2002|Actual|2002-08-31|January 2018|2018-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Observational|||Regional Anesthesia Database|Regional Anesthesia Database|Completed|||||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:28:04.173122|2018-06-01 04:28:04.173122
NCT00221845|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2010-01-11|2005-09-15|2005-09-22|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 1998||1998-01-31|January 2010|2010-01-31|January 2010|Actual|2010-01-31|July 2007|Actual|2007-07-31||Interventional|ESCAPE||Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients|Molecular Mechanisms of Disease Progression and Renoprotective Pharmacotherapy in Children With Chronic Renal Failure|Completed||Phase 3|400|Actual|Heidelberg University||2|||f||||t||||||||||2018-06-01 04:28:04.239996|2018-06-01 04:28:04.239996
NCT00221832|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-01-12|2005-09-14|2005-09-22|Estimate|||||||2010-01-12|2010-01-13|Estimate|October 2003||2003-10-31|October 2003|2003-10-31|December 2011|Anticipated|2011-12-31|||||Observational|||Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases|Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases|Unknown status|Recruiting||300|Anticipated|Heidelberg University|||||f||||f||||||Samples With DNA|"~     no biospecimens are to be retained.~   "|||2018-06-01 04:28:04.36739|2018-06-01 04:28:04.36739
NCT00221819|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-05-07|2005-09-20|2005-09-22|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2004||2004-06-30|May 2013|2013-05-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Gases Humidification During Noninvasive Ventilation : Heat and Moisture Exchanger or Heated Humidifier ?|Prospective Study of the Influence of the Humidification Mode on Ventilation Parameters and Arterial Blood Gases in Non Invasive Ventilation|Terminated||N/A|||University Hospital, Bordeaux|||||f||||||||||||||2018-06-01 04:28:04.442383|2018-06-01 04:28:04.442383
NCT00221806|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|June 2004||2004-06-30|September 2005|2005-09-30|June 2012||2012-06-30|||||Interventional|||Comparison of Two Under Knee Lower Limb Bypass Types:Endothelialised Prosthesis Versus Autologous Vein Graft|Randomised Study Comparing Endothelialised Prosthesis and Autologous Vein for Under Knee Revascularisation With Femoro Popliteal Bypass. ePTFE|Unknown status|Recruiting|Phase 2|40||University Hospital, Bordeaux|||||f||||||||||||||2018-06-01 04:28:04.505201|2018-06-01 04:28:04.505201
NCT00221793|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-17|2005-09-13|2005-09-22|Estimate|||||||2008-09-17|2008-09-18|Estimate|December 2002||2002-12-31|September 2008|2008-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation|Study of Ponderal Load in Parkinsonian Patients After Deep Brain Stimulation of the Subthalamic Nucleus|Completed||N/A|20|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-06-01 04:28:04.567133|2018-06-01 04:28:04.567133
NCT00221780|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-28|2005-09-13|2005-09-22|Estimate|||||||2007-06-28|2007-06-29|Estimate|November 2003||2003-11-30|June 2007|2007-06-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Role of Left Ventricular Pacing Site|Importance of Left Ventricular Pacing Site in Biventricular Resynchronization Therapy for Severe Heart Failure|Unknown status|Recruiting|N/A|33|Anticipated|University Hospital, Bordeaux|||||f||||f||||||||||2018-06-01 04:28:04.628348|2018-06-01 04:28:04.628348
NCT00221767|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-13|2005-09-13|2005-09-22|Estimate|||||||2012-06-13|2012-06-14|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|BRINDLEY||Medico-economical Impact of the Brindley Neurosurgical Technique in France|Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord|Completed||N/A|53|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 04:28:04.707519|2018-06-01 04:28:04.707519
NCT00221754|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-12|2005-09-13|2005-09-22|Estimate|||||||2007-06-12|2007-06-13|Estimate|March 2003||2003-03-31|June 2007|2007-06-30|March 2004|Actual|2004-03-31|||||Interventional|||Pravastatin and Protease Inhibitors in HIV-Infected Patients|Pravastatin in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy|Completed||Phase 2|21|Actual|University Hospital, Bordeaux|||||f||||t||||||||||2018-06-01 04:28:04.7796|2018-06-01 04:28:04.7796
NCT00221741|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-17|2005-09-13|2005-09-22|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2004||2004-02-29|March 2015|2015-03-31|March 2006|Actual|2006-03-31|||||Observational|PLASMACARD||Fresh Frozen Plasma in Cardiac Surgery: Descriptive and Prognostic Study|PLASMACARD - Fresh Frozen Plasma in Cardiac Surgery: Descriptive and Prognostic Study|Completed|||1497|Actual|University Hospital, Bordeaux|||||f||||f||||||||||2018-06-01 04:28:04.837683|2018-06-01 04:28:04.837683
NCT00221728|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-27|2005-09-13|2005-09-22|Estimate|||||||2010-05-27|2010-05-28|Estimate|April 2005||2005-04-30|May 2010|2010-05-31|January 2008|Anticipated|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors|Treatment of Renal Tumors With Radiofrequency: Efficacy Evaluation in Comparison With Conservative Surgery (Multicentric Randomized Trial)|Terminated||Phase 2/Phase 3|160|Anticipated|University Hospital, Bordeaux||||lack of patients|f||||t||||||||||2018-06-01 04:28:04.900851|2018-06-01 04:28:04.900851
NCT00221715|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-05-07|2005-09-13|2005-09-22|Estimate|||||||2013-05-07|2013-05-09|Estimate|July 2002||2002-07-31|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|REVA||Comparison of Two Lower Limb Bypass Types : Prosthesis Versus Autologous Vein|Randomised Study Comparing Prosthesis and Autologous Vein for Revascularisation With Above Knee Femoropopliteal Bypass.|Completed||N/A|100|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 04:28:04.961409|2018-06-01 04:28:04.961409
NCT00221702|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-10-12|2005-09-13|2005-09-22|Estimate|||||||2010-10-12|2010-10-13|Estimate|June 2003||2003-06-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|EADO||PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)|Randomized, Multicenter Phase III Trial Comparing Adjuvant Treatment With PegIntron Over 36 Months Versus Reference Treatment With IntronA Over 18 Months in Cutaneous Melanoma Patients AJCC Stage II (>=1.5 mm Clinically Node Negative)|Completed||Phase 3|898|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-06-01 04:28:05.128196|2018-06-01 04:28:05.128196
NCT00221689|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-12|2005-09-13|2005-09-22|Estimate|||||||2007-06-12|2007-06-13|Estimate|March 2003||2003-03-31|June 2007|2007-06-30|February 2004|Actual|2004-02-29|||||Interventional|||Intrathecal Baclofen Therapy and Paroxysmal Dysautonomia in Severe Brain-Injured Patients|Early Treatment of Paroxysmal Dysautonomia and Hypertonia for Severe Brain Injured Patients by Intrathecal Baclofen Therapy|Terminated||Phase 2|4|Actual|University Hospital, Bordeaux||||very slow recruitment and treatments beyond expiry date|f||||t||||||||||2018-06-01 04:28:05.296672|2018-06-01 04:28:05.296672
NCT00221676|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-27|2005-09-13|2005-09-22|Estimate|||||||2006-11-27|2006-11-28|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|June 2004||2004-06-30|||||Interventional|||Effectiveness of Influenza Vaccination Among General Practitioners|Effectiveness of Influenza Vaccination (Alfarix)in Preventing Clinical Influenza Cases Among General Practitioners: Non-Randomized Clinical Trial.|Completed||Phase 4|300||University Hospital, Antwerp|||||f||||||||||||||2018-06-01 04:28:05.600019|2018-06-01 04:28:05.600019
NCT00221663|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-08-14|2005-09-13|2005-09-22|Estimate|||||||2008-08-14|2008-08-15|Estimate|January 2002||2002-01-31|August 2008|2008-08-31|December 2006|Actual|2006-12-31|January 2002|Actual|2002-01-31||Interventional|||Conventional Versus Mini-Sternotomy for Aortic Valve Surgery|Clinical Trial Comparing a Conventional Median Sternotomy Versus a Minimally Invasive Technique for Aortic Valvular Replacement in Adults|Terminated||Phase 2/Phase 3|78|Actual|University Hospital, Bordeaux||||slow recruitment|f||||t||||||||||2018-06-01 04:28:05.832831|2018-06-01 04:28:05.832831
NCT00221650|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-12|2005-09-13|2005-09-22|Estimate|||||||2007-06-12|2007-06-13|Estimate|April 2002||2002-04-30|June 2007|2007-06-30|June 2004|Actual|2004-06-30|||||Interventional|ROCO2||Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients|Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment|Completed||Phase 2|17|Actual|University Hospital, Bordeaux|||||f||||t||||||||||2018-06-01 04:28:06.096623|2018-06-01 04:28:06.096623
NCT00221247|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-13|2005-09-13|2005-09-22|Estimate|||||||2016-05-13|2016-05-16|Estimate|October 2004||2004-10-31|May 2016|2016-05-31|October 2008|Actual|2008-10-31|March 2008|Actual|2008-03-31||Interventional|||Acupuncture as Complementary Therapy for Cerebral Palsy|Acupuncture as Complementary Therapy for Cerebral Palsy|Completed||Phase 2|75|Actual|University of Arizona||2|||f||||f||||||||||2018-06-01 04:28:12.121007|2018-06-01 04:28:12.121007
NCT00221637|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-12|2005-09-13|2005-09-22|Estimate|||||||2007-06-12|2007-06-13|Estimate|March 2002||2002-03-31|June 2007|2007-06-30|July 2005|Actual|2005-07-31|||||Interventional|||Efficacy of Valproate in Peripheral Neuropathic Pain|Efficacy of a Therapeutic Strategy in Peripheral Neuropathic Pain: Intravenous Sodium Valproate Followed by Oral Route Treatment Versus Placebo (Clinical and Neurophysiologic Evaluation)|Terminated||Phase 2/Phase 3|40|Actual|University Hospital, Bordeaux||||slow recruitment and treatments beyond expiry date|f||||t||||||||||2018-06-01 04:28:06.362735|2018-06-01 04:28:06.362735
NCT00221624|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-12|2005-09-13|2005-09-22|Estimate|||||||2007-06-12|2007-06-13|Estimate|November 2001||2001-11-30|June 2007|2007-06-30|April 2004|Actual|2004-04-30|||||Interventional|PEGARI||Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients|Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Interferon and Ribavirin|Completed||Phase 3|131|Actual|University Hospital, Bordeaux|||||f||||t||||||||||2018-06-01 04:28:06.649448|2018-06-01 04:28:06.649448
NCT00221611|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-19|2005-09-21|2005-09-22|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|August 2006|Actual|2006-08-31|||||Interventional|||Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity|Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity|Completed||Phase 2|80||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:28:06.908522|2018-06-01 04:28:06.908522
NCT00221598|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-04|2005-09-14|2005-09-22|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2005||2005-06-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effect of Dialysate Temperature on Haemodynamic Stability and Haemodialysis Efficiency|Effect of Dialysate Temperature on Haemodynamic Stability and Haemodialysis Efficiency|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:28:07.183656|2018-06-01 04:28:07.183656
NCT00221585|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2006-11-06|2005-09-16|2005-09-22|Estimate|||||||2006-11-06|2006-11-07|Estimate|October 1997||1997-10-31|July 1997|1997-07-31|July 2005||2005-07-31|||||Observational|||The National Danish Schizophrenia Project||Unknown status|Active, not recruiting||||University of Copenhagen|||||f||||||||||||||2018-06-01 04:28:07.517224|2018-06-01 04:28:07.517224
NCT00221572|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-12-04|2005-09-14|2005-09-22|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2005||2005-07-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Can Quantitative Ultrasound be Used for the Evaluation of Bone Health in Adolescents and Adults With Cystic Fibrosis|Can Quantitative Ultrasound be Used for the Evaluation of Bone Health in Adolescents and Adults With Cystic Fibrosis|Unknown status|Recruiting||100|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:28:07.75868|2018-06-01 04:28:07.75868
NCT00221559|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-05-07|2005-09-14|2005-09-22|Estimate|||||||2006-05-07|2006-05-09|Estimate|September 2004||2004-09-30|May 2006|2006-05-31||||||||Observational|||Serum Zn Status of Patients With Cystic Fibrosis at Diagnosis and One Year Later, Compared to a Healthy Control Group|Serum Zn Status of Patients With Cystic Fibrosis at Diagnosis and One Year Later, Compared to a Healthy Control Group|Completed|||0||University Hospital, Ghent|||||f||||||||||||||2018-06-01 04:28:08.025552|2018-06-01 04:28:08.025552
NCT00221546|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-09-27|2005-09-14|2005-09-22|Estimate|||||||2011-09-27|2011-09-28|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis|Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis|Completed||Phase 2|17|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 04:28:08.285553|2018-06-01 04:28:08.285553
NCT00221533|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-19|2005-09-13|2005-09-22|Estimate|||||||2007-12-19|2007-12-28|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|August 2006|Actual|2006-08-31|||||Observational|||Relation Between Renin-Angiotensin Gene Polymorphisms, Plasma Adiponectin and Arterial Stiffness in Renal Transplant Recipients|Relation Between Renin-Angiotensin Gene Polymorphisms, Plasma Adiponectin and Arterial Stiffness in Renal Transplant Recipients|Completed|||250||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:28:08.593442|2018-06-01 04:28:08.593442
NCT00221520|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2007-01-09|2005-09-15|2005-09-22|Estimate|||||||2007-01-09|2007-01-11|Estimate|February 2003||2003-02-28|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Sedation in the Intensive Care Unit|Trial on The Efficacy of Sedation in Mechanically Ventilated Critically Ill Patients|Unknown status|Active, not recruiting|Phase 3|126||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:28:08.82981|2018-06-01 04:28:08.82981
NCT00221507|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-07-17|2005-09-16|2005-09-22|Estimate|||||||2007-07-17|2007-07-18|Estimate|February 2004||2004-02-29|January 2007|2007-01-31|June 2007||2007-06-30|||||Interventional|||Increasing Infant Preventive Health Service Delivery in an Inner City Population|Increasing Infant Preventive Health Service Delivery in an Inner City Population|Unknown status|Recruiting|N/A|800|Anticipated|University of Colorado, Denver|||||f||||||||||||||2018-06-01 04:28:09.077556|2018-06-01 04:28:09.077556
NCT00221494|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-29|2005-09-13|2005-09-22|Estimate|||||||2015-05-29|2015-06-01|Estimate|January 2004||2004-01-31|June 2006|2006-06-30||||June 2006|Actual|2006-06-30||Interventional|||Can Additional Drug Therapy Accelerate Response Time to Antidepressants|Can Additional Drug Therapy Accelerate Response Time to Antidepressants: A Double-blind, Placebo-controlled Randomization Research Study for Major Depression|Withdrawn||Phase 4|0|Actual|Mayo Clinic||||PI move|f||||t||||||||||2018-06-01 04:28:09.350294|2018-06-01 04:28:09.350294
NCT00221481|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-29|2005-09-13|2005-09-22|Estimate|||||||2015-05-29|2015-06-01|Estimate||||February 2009|2009-02-28|March 2006||2006-03-31|||||Interventional|||An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder|An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder|Withdrawn||Phase 4|0|Actual|Mayo Clinic||||Lack of recruitment|f||||||||||||||2018-06-01 04:28:09.611724|2018-06-01 04:28:09.611724
NCT00221468|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-07-17|2005-09-21|2005-09-22|Estimate|||||||2012-07-17|2012-07-18|Estimate|June 2003||2003-06-30|March 2007|2007-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents|A Single-Blind Prospective Study of Quetiapine for the Treatment of Mood Disorders in Adolescents|Completed||Phase 3|20|Actual|University of Cincinnati||1|||f||||||||||||||2018-06-01 04:28:09.873188|2018-06-01 04:28:09.873188
NCT00221455|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-07-25|2005-09-15|2005-09-22|Estimate|||||||2011-07-25|2011-07-27|Estimate|September 2004||2004-09-30|July 2011|2011-07-31|September 2007|Actual|2007-09-30|||||Interventional|||The Potential of Technology to Improve Chronic Disease Management and Quality of Care|The Potential of Technology to Improve Chronic Disease Management and Quality of Care|Completed||Phase 1|1000|Anticipated|Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:28:10.205523|2018-06-01 04:28:10.205523
NCT00221442|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-06-21|2005-09-14|2005-09-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|August 2005||2005-08-31|June 2011|2011-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity|Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity: A Single Center, Double-Blind, Placebo-controlled, Flexible-Dose Study in Outpatients|Completed||Phase 3|60|Actual|Lindner Center of HOPE||2|||f||||||||||||||2018-06-01 04:28:10.477822|2018-06-01 04:28:10.477822
NCT00221429|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-02-22|2005-09-21|2005-09-22|Estimate|||||||2006-02-22|2006-02-23|Estimate|March 2001||2001-03-31|November 2002|2002-11-30||||||||Interventional|||Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder|Pediatric Bipolar Collaborative Mood Stabilizer Trial|Unknown status|Active, not recruiting|Phase 3|154||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 04:28:10.783842|2018-06-01 04:28:10.783842
NCT00221416|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-06-26|2005-09-21|2005-09-22|Estimate|||||||2013-06-26|2013-06-27|Estimate|June 2005||2005-06-30|June 2013|2013-06-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder|An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder|Completed||Phase 3|30|Anticipated|University of Cincinnati|||||f||||f||||||||||2018-06-01 04:28:10.905159|2018-06-01 04:28:10.905159
NCT00221403|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-06-24|2005-09-14|2005-09-22|Estimate|||||||2011-06-24|2011-06-27|Estimate|September 2004||2004-09-30|June 2011|2011-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders|Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders|Completed||Phase 3|46|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||||||2018-06-01 04:28:10.962741|2018-06-01 04:28:10.962741
NCT00221390|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2016-10-28|2005-09-19|2005-09-22|Estimate|||||||2016-10-28|2016-11-01|Estimate|October 2003||2003-10-31|October 2016|2016-10-31|May 2007|Actual|2007-05-31|February 2007|Actual|2007-02-28||Interventional|||Trial of Ropinirole in Motor Recovery After Stroke|Randomized, Placebo-controlled, Double-blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery After Stroke|Completed||Phase 2|52|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-06-01 04:28:11.01858|2018-06-01 04:28:11.01858
NCT00221377|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-16|2005-09-13|2005-09-22|Estimate|||||||2012-05-16|2012-05-17|Estimate|April 2005||2005-04-30|December 2011|2011-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||"Cuffed Versus Uncuffed Tracheal Tubes in Small Children"|"Cuffed Versus Uncuffed Tracheal Tubes in Small Children"|Completed||N/A|4000|Anticipated|University Children's Hospital, Zurich|||||f||||||||||||||2018-06-01 04:28:11.080856|2018-06-01 04:28:11.080856
NCT00221364|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-07-13|2005-09-16|2005-09-22|Estimate|||||||2015-07-13|2015-07-15|Estimate|March 2003||2003-03-31|July 2015|2015-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|TEF||Trachoma Elimination Follow-up|Trachoma Elimination With Repeated Mass Azithromycin Treatments|Completed||Phase 4|20000|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-06-01 04:28:11.158646|2018-06-01 04:28:11.158646
NCT00221351|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2011-05-20|2005-09-19|2005-09-22|Estimate|||||||2011-05-20|2011-05-23|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|July 2006|Actual|2006-07-31|March 2006|Actual|2006-03-31||Interventional|||C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough|A Randomized, Controlled Trial of a C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough Illness in the Emergency Department|Completed||N/A|139|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:28:11.333402|2018-06-01 04:28:11.333402
NCT00221338|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2015-07-14|2005-09-19|2005-09-22|Estimate|||||||2015-07-14|2015-07-15|Estimate|January 2006||2006-01-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Clinical Trial of Gabapentin to Improve Postoperative Pain in Surgical Patients|Clinical Trial of Gabapentin to Improve Postoperative Pain in Surgical Patients|Completed||Phase 3|750|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:28:11.408231|2018-06-01 04:28:11.408231
NCT00221325|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-02-12|2005-09-14|2005-09-22|Estimate|||||||2015-02-12|2015-02-16|Estimate|April 2007||2007-04-30|February 2015|2015-02-28|March 2013|Actual|2013-03-31|January 2012|Actual|2012-01-31||Interventional|||A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma|Phase I Study of Intraventricular Administration of Rituximab in Combination With Methotrexate in the Treatment of Recurrent CNS and Intraocular Lymphoma|Completed||Phase 1|14|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:28:11.49633|2018-06-01 04:28:11.49633
NCT00221312|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2008-05-05|2005-09-16|2005-09-22|Estimate|||||||2008-05-05|2008-05-08|Estimate|May 2002||2002-05-31|May 2005|2005-05-31|July 2007|Actual|2007-07-31|||||Observational|||Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss|Alendronate to Prevent Perimenopausal Transition Bone Loss|Completed|||48|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 04:28:11.58366|2018-06-01 04:28:11.58366
NCT00221299|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2014-01-23||2015-06-02|2005-09-14|2005-09-22|Estimate|2015-06-02|2015-06-25|Estimate||||2015-06-02|2015-06-25|Estimate|September 2005||2005-09-30|June 2015|2015-06-30|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional||Study subjects were men and women, greater than 18 years of age with a history of glucocorticoid therapy with prednisone >= 7.5gm a day for 6 months and currently on prednisone or equivalent >= 5mg/day.|Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use|Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis?|Completed||Phase 4|60|Actual|University of California, Davis||4|||f||||f||||||||||2018-06-01 04:28:11.671652|2018-06-01 04:28:11.671652
NCT00221286|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-02-17|2005-09-14|2005-09-22|Estimate|||||||2009-02-17|2009-02-18|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients|Pegylated Interferon Alfa-2a Versus Emtricitabine / Tenofovir +/- Pegylated Interferon Alfa-2a for the Treatment of Chronic HBe-Ag Positive Hepatitis B Infection in HIV-Coinfected Patients - the PEGPLUS Trial|Terminated||Phase 3|2|Actual|University Hospital, Bonn||||Lack of accrual|f||||f||||||||||2018-06-01 04:28:11.902455|2018-06-01 04:28:11.902455
NCT00221273|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2017-03-01|2005-09-18|2005-09-22|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2010||2010-12-31|March 2017|2017-03-31|May 18, 2012|Actual|2012-05-18|May 18, 2012|Actual|2012-05-18||Interventional|||Use of Graft Tensioner Device in ACL (Knee) Repair|Randomized Clinical Trial to Assess the Clinical Effectiveness of a Measured Objective Tensioning in Hamstring ACL Reconstruction|Completed||N/A|130|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:28:11.995426|2018-06-01 04:28:11.995426
NCT00221260|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2008-09-24|2005-09-18|2005-09-22|Estimate|||||||2008-09-24|2008-09-25|Estimate|September 2005||2005-09-30|September 2008|2008-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Perioperative Epidural Trial (POET) Pilot Study|Perioperative Epidural Trial (POET) Pilot Study|Completed||N/A|250|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:28:12.052771|2018-06-01 04:28:12.052771
NCT00221234|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-13|2005-09-13|2005-09-22|Estimate|||||||2009-03-13|2009-03-16|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|July 2007|Actual|2007-07-31|||||Interventional|||Alberta Diabetes and Physical Activity Trial|The Development and Evaluation of Physical Activity Behavioural Strategies for Adults With Type 2 Diabetes: A Population Based Approach|Completed||Phase 2|300|Anticipated|University of Alberta, Physical Education|||||f||||||||||||||2018-06-01 04:28:12.225909|2018-06-01 04:28:12.225909
NCT00221221|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-02|2005-09-13|2005-09-22|Estimate|||||||2007-05-02|2007-05-03|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|March 2006||2006-03-31|||||Interventional|||Physical Activity Promotion in Breast Cancer Survivors|Physical Activity Promotion in Breast Cancer Survivors: A Population Based Randomized Controlled Trial|Completed||Phase 2/Phase 3|300||University of Alberta, Physical Education|||||f||||||||||||||2018-06-01 04:28:12.337532|2018-06-01 04:28:12.337532
NCT00221208|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-16|2005-09-13|2005-09-22|Estimate|||||||2009-03-16|2009-03-17|Estimate|April 2005||2005-04-30|March 2009|2009-03-31|December 2005|Actual|2005-12-31|||||Interventional|||Home Based Resistance Training For Type 2 Diabetes|A Home Based Resistance Training Program for Obese Adults With Type 2 Diabetes|Completed||Phase 1|54||University of Alberta, Physical Education|||||f||||||||||||||2018-06-01 04:28:12.40335|2018-06-01 04:28:12.40335
NCT00221195|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|2016-12-12||2016-12-12|2005-09-19|2005-09-22|Estimate|2016-12-12|2017-02-06|Estimate||||2016-12-12|2017-02-06|Estimate|June 2003||2003-06-30|December 2016|2016-12-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|ProFEIBA||Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors|A Prospective, Randomized, Cross-over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors|Completed||Phase 2/Phase 3|34|Actual|Tulane University|One limitation was the relatively short duration; in addition, due to the small number of children enrolled, it is not possible to draw conclusions regarding the relationship of age and the benefits of prophylaxis.|2|||f||||||||||||||2018-06-01 04:28:12.48376|2018-06-01 04:28:12.48376
NCT00221182|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-21|2005-09-13|2005-09-22|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 2005||2005-09-30|June 2011|2011-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Stem Cell Study for Patients With Heart Disease|Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Myocardial Ischemia|Terminated||Phase 1/Phase 2|1|Actual|Foundation for Biomedical Research and Innovation||||slow recruitment of the study subjects|f||||||||||||||2018-06-01 04:28:12.842444|2018-06-01 04:28:12.842444
NCT00221169|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-04|2005-09-13|2005-09-22|Estimate|||||||2009-02-04|2009-02-05|Estimate|October 2005||2005-10-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||Role of PET CT in Determining Target Volumes in Radiation Therapy for Lung Cancer|Can PET CT Coregistration Imaging Adequately Determine the Gross Tumor Volume and Microscopic Extension in Non-Small Cell Lung Cancer Patients for Radical Radiation Therapy?|Completed||Early Phase 1|31|Actual|Toronto Sunnybrook Regional Cancer Centre||1|||f||||f||||||||||2018-06-01 04:28:12.918784|2018-06-01 04:28:12.918784
NCT00221156|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-23|2005-09-13|2005-09-22|Estimate|||||||2009-06-23|2009-06-25|Estimate|May 2005||2005-05-31|June 2009|2009-06-30|April 2009|Actual|2009-04-30|||||Interventional|||Acarbose and Secondary Prevention After Coronary Stenting|Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study)|Completed||Phase 3|300|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||||||||||||2018-06-01 04:28:12.988378|2018-06-01 04:28:12.988378
NCT00221143|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-06|2005-09-13|2005-09-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2003||2003-11-30|February 2009|2009-02-28|January 2008|Actual|2008-01-31|||||Interventional|||Stem Cell Study for Patients With Leg Ulcer/Gangrene|Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Critical Limb Ischemia|Completed||Phase 1/Phase 2|15|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||t||||||||||2018-06-01 04:28:13.063161|2018-06-01 04:28:13.063161
NCT00221130|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-06|2005-09-13|2005-09-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 2004||2004-07-31|February 2009|2009-02-28|December 2005||2005-12-31|||||Interventional|||Clinical Trials of Regeneration for Periodontal Tissue|Clinical Trial of Regenerative Periodontal Tissue by Transplanting Mesenchymal Stem Cells and Osteoblast Cells - I, II Phase-|Completed||Phase 1/Phase 2|10||Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||||||||||||2018-06-01 04:28:13.123657|2018-06-01 04:28:13.123657
NCT00221117|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-05-08||2017-10-19|2005-09-14|2005-09-22|Estimate|2017-10-19|2017-11-20|Actual||||2017-10-19|2017-11-20|Actual|August 2005||2005-08-31|October 2017|2017-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Benefits of Applying Neuroprosthesis to Improve Grasping and Reaching in Spinal Cord Injury Patients|Neuroprosthesis for Improving Grasping Function in Spinal Cord Injured Patients|Completed||N/A|22|Actual|Toronto Rehabilitation Institute|A limitation of this study is that despite considerable effort we failed to attract the subjects to take part in a 6-month follow- up assessment.|2|||f||||t||||||||No|IPD will not be shared , mean results of the study have been published in the peer reviewed paper.|2018-06-01 04:28:13.183083|2018-06-01 04:28:13.183083
NCT00221104|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-07-06||2017-06-19|2005-09-13|2005-09-22|Estimate|2017-06-19|2018-01-25|Actual||||2017-06-19|2018-01-25|Actual|March 1, 2004||2004-03-01|June 2017|2017-06-30||||July 2014|Actual|2014-07-31||Interventional||intention to treat|Japan Statin Treatment Against Recurrent Stroke (J-STARS)|Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke|Completed||Phase 3|1578|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||||||||||||2018-06-01 04:28:13.429511|2018-06-01 04:28:13.429511
NCT00221091|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-06|2005-09-13|2005-09-22|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|October 2005||2005-10-31|||||Interventional|||Study to Evaluate Efficacy of Shunt Operation for Idiopathic Normal Pressure Hydrocephalus|Clinical Study of Idiopathic Normal Pressure Hydrocephalus for Neurological Improvement|Completed||Phase 2|110||Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||||||||||||2018-06-01 04:28:14.711797|2018-06-01 04:28:14.711797
NCT00221078|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-02-04|2005-09-14|2005-09-22|Estimate|||||||2009-02-04|2009-02-05|Estimate|April 2003||2003-04-30|February 2009|2009-02-28|December 2005|Actual|2005-12-31|June 2005|Actual|2005-06-30||Interventional|||Benefits of Applying Neuroprosthesis for Improving Reaching and Grasping Functions in Stroke Patients|Restoration of Reaching and Grasping Functions in Stroke Patients Using Functional Electrical Stimulation.|Completed||Phase 3|40|Actual|Toronto Rehabilitation Institute|||||f||||t||||||||||2018-06-01 04:28:14.816519|2018-06-01 04:28:14.816519
NCT00220142|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-05-30|2005-09-20|2005-09-22|Estimate|||||||2013-05-30|2013-05-31|Estimate|November 2003||2003-11-30|May 2013|2013-05-31||||||||Observational|||Molecular Markers of Prognosis in Colorectal Cancer Patients|Molecular Markers of Prognosis in Colorectal Cancer Patients|Completed|||103|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:23.7578|2018-06-01 04:28:23.7578
NCT00221065|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-04|2005-09-13|2005-09-22|Estimate|||||||2009-02-04|2009-02-05|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effect of Continuous Positive Airway Pressure (CPAP) on Cognitive and Functional Performance in Stroke Patients With Obstructive Sleep Apnea|Influence of CPAP on Cognitive Function and Outcome of Stroke Patients With Obstructive Apnea|Completed||Phase 3|60|Anticipated|Toronto Rehabilitation Institute||2|||f||||f||||||||||2018-06-01 04:28:14.921229|2018-06-01 04:28:14.921229
NCT00221052|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-10|2005-09-13|2005-09-22|Estimate|||||||2006-10-10|2006-10-11|Estimate|June 2005||2005-06-30|October 2006|2006-10-31|July 2005||2005-07-31|||||Interventional|||Effect of Reduction of Inflammatory Status on Glucose Metabolism in Overweight Men|Relation Between Reduction of the Inflammatory Status and Glucose Metabolism in Healthy Overweight Men|Completed||N/A|20||TNO|||||f||||||||||||||2018-06-01 04:28:15.003984|2018-06-01 04:28:15.003984
NCT00221039|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-23|2005-09-13|2005-09-22|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2004||2004-09-30|May 2016|2016-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A|UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A|Completed||Phase 4|19|Actual|Mallinckrodt||1|||f||||f||||||||||2018-06-01 04:28:15.080031|2018-06-01 04:28:15.080031
NCT00221026|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-18|2005-09-13|2005-09-22|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2004||2004-12-31|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease|A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents|Completed||Phase 2|25|Actual|Mallinckrodt||1|||f||||f||||||||||2018-06-01 04:28:15.195625|2018-06-01 04:28:15.195625
NCT00221013|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-02-25|2005-09-14|2005-09-22|Estimate|||||||2009-02-25|2009-02-27|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||Augmented Vs. Normal Renal Replacement Therapy in Severe Acute Renal Failure (ARF).|Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).|Completed||Phase 4|1508|Actual|The George Institute||2|||f||||t||||||||||2018-06-01 04:28:15.284768|2018-06-01 04:28:15.284768
NCT00221000|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-18|2005-09-13|2005-09-22|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2003||2003-08-31|October 2016|2016-10-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|RA-1||Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis|"A Phase II, Multicenter, Randomized, Double-blind, Sham Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic Drugs and Biological Agents"|Completed||Phase 2|86|Actual|Mallinckrodt|||||f||||f||||||||||2018-06-01 04:28:15.378458|2018-06-01 04:28:15.378458
NCT00220987|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-27|2005-09-14|2005-09-22|Estimate|||||||2009-01-27|2009-01-29|Estimate|April 2005||2005-04-30|January 2009|2009-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE - SUGAR STUDY)|A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients.|Completed||Phase 4|6104|Actual|The George Institute||2|||f||||t||||||||||2018-06-01 04:28:15.50502|2018-06-01 04:28:15.50502
NCT00220974|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-11|2005-09-14|2005-09-22|Estimate|||||||2009-02-11|2009-02-13|Estimate|October 2004||2004-10-31|February 2009|2009-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study to Assess if Internet-Based Tailored Advice Could Modify Behaviour to Improve Health|Internet-Based Cholesterol Assessment Trial|Completed||N/A|3708|Anticipated|The George Institute|||||f||||||||||||||2018-06-01 04:28:15.582976|2018-06-01 04:28:15.582976
NCT00220961|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2016-02-17||2016-06-29|2005-09-14|2005-09-22|Estimate|2016-06-29|2016-08-11|Estimate||||2016-06-29|2016-08-11|Estimate|January 2004||2004-01-31|June 2016|2016-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Actos Now for Prevention of Diabetes (ACT NOW)|Actos Now for Prevention of Diabetes (ACT NOW)|Completed||Phase 3|602|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||||||||||||2018-06-01 04:28:15.66297|2018-06-01 04:28:15.66297
NCT00220948|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|August 2004||2004-08-31|July 2005|2005-07-31|March 2006||2006-03-31|||||Interventional|||Large Array EMG Discriminability in Discogenic Low Back Pain|Large Array EMG Discriminability in Discogenic Low Back Pain|Unknown status|Recruiting|N/A|60||Texas Back Institute|||||f||||||||||||||2018-06-01 04:28:15.965217|2018-06-01 04:28:15.965217
NCT00220935|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-04|2005-09-13|2005-09-22|Estimate|||||||2006-10-04|2006-10-05|Estimate|January 2003||2003-01-31|July 2005|2005-07-31|July 2006||2006-07-31|||||Interventional|||A Randomized, Controlled Trial of Treatment for Disc Herniation With Radiating Leg Pain|Orthotrac Pneumatic Vest: A Randomized, Controlled Trial of Treatment for Disc Herniation With Radiating Leg Pain|Completed||N/A|150||Texas Back Institute|||||f||||||||||||||2018-06-01 04:28:16.076784|2018-06-01 04:28:16.076784
NCT00220922|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2011-04-07|2005-09-20|2005-09-22|Estimate|||||||2011-04-07|2011-04-08|Estimate|August 2004||2004-08-31|April 2011|2011-04-30|February 2006|Actual|2006-02-28|October 2005|Actual|2005-10-31||Interventional|||A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.|An Open-Label, Randomized, Single Cross-Over Study of Isopropyl Alcohol Wipes Versus No Injection Site Preparation on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone®|Completed||Phase 4|50|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:28:16.132703|2018-06-01 04:28:16.132703
NCT00220909|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-01-02|2005-09-20|2005-09-22|Estimate|||||||2008-01-02|2008-01-11|Estimate|September 2005||2005-09-30|January 2008|2008-01-31|January 2006|Actual|2006-01-31|||||Interventional|||Lansoprazole Preventing Gastroduodenal Stress Ulcerations|A Prospective, Randomized, Double-Blind Protocol to Compare the Efficacy of Lansoprazole to Ranitidine in Healing Pre-Existing and/or Preventing the Development of Gastroduodenal Stress Ulceration and Postoperative Bleeding in Patients Undergoing Elective Coronary Artery Bypass Graft or Cardiac Valve Replacement Surgery|Terminated||Phase 4|40|Anticipated|Temple University||||Recruitment slow|||||||||||||||2018-06-01 04:28:16.19437|2018-06-01 04:28:16.19437
NCT00220896|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-09-13|2005-09-14|2005-09-22|Estimate|||||||2011-09-13|2011-09-14|Estimate|January 2006||2006-01-31|September 2011|2011-09-30|March 2009|Actual|2009-03-31|||||Interventional|||Prevention of Postoperative Delirium With Donepezil||Completed||Phase 4|37|Actual|Technische Universität München|||||f||||||||||||||2018-06-01 04:28:16.244674|2018-06-01 04:28:16.244674
NCT00220883|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2006-02-06|2005-09-19|2005-09-22|Estimate|||||||2006-02-06|2006-02-07|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|September 2006||2006-09-30|||||Observational|||Electrogastrogram (EGG) Reproducibility Study: EEG Readings in Normal Subjects and Dyspeptic Patients|Reproducibility and Inter-Reader Reliability of Electrogastrographic Readings in Normal Subjects and Dyspeptic Patients|Unknown status|Recruiting||40||Temple University|||||f||||||||||||||2018-06-01 04:28:16.297448|2018-06-01 04:28:16.297448
NCT00220870|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2010-04-07|2005-09-15|2005-09-22|Estimate|||||||2010-04-07|2010-04-08|Estimate|January 2003||2003-01-31|April 2010|2010-04-30|August 2005||2005-08-31|||||Interventional|||Shared Decision Making for Schizophrenia|Shared Decision Making in the Therapy of Schizophrenia|Completed||N/A|||Technische Universität München|||||f||||||||||||||2018-06-01 04:28:16.347304|2018-06-01 04:28:16.347304
NCT00220857|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-01-02|2005-09-20|2005-09-22|Estimate|||||||2008-01-02|2008-01-11|Estimate|September 2005||2005-09-30|January 2008|2008-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Rabeprazole Protection of Aspirin Induced Gastric Damage.|Rapid Protection of the Gastroduodenal Mucosa Against Aspirin-Induced Damage by Rabeprazole|Completed||Phase 4|30|Anticipated|Temple University|||||f||||||||||||||2018-06-01 04:28:16.405356|2018-06-01 04:28:16.405356
NCT00220844|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2006-02-08|2005-09-19|2005-09-22|Estimate|||||||2006-02-08|2006-02-10|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|September 2007||2007-09-30|||||Interventional|||Tricyclic Antidepressants (TCAs) on Gastric Emptying|Effect of Tricyclic Antidepressant Agents on Gastric Accommodation and Emptying|Unknown status|Recruiting|N/A|60||Temple University|||||f||||||||||||||2018-06-01 04:28:16.474285|2018-06-01 04:28:16.474285
NCT00220831|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-02-28|2005-09-13|2005-09-22|Estimate|||||||2007-02-28|2007-03-01|Estimate|April 2005||2005-04-30|February 2007|2007-02-28|December 2009||2009-12-31|||||Interventional|||Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment|Prevention of Diabetic Cardiovascular Complications With Vitamin E 400 IU Treatment to High Risk Patients by Haptoglobin Phenotype (I CARE – Israel Cardiovascular Atherosclerosis Risk and Vitamin E)|Terminated||Phase 2/Phase 3|2000||Technion, Israel Institute of Technology||||interim analysis showed significant differences between two treatment groups|f||||||||||||||2018-06-01 04:28:17.471274|2018-06-01 04:28:17.471274
NCT00220818|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-07-20|2005-09-19|2005-09-22|Estimate|||||||2010-07-20|2010-07-22|Estimate|January 2005||2005-01-31|July 2010|2010-07-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.|A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Infants With Clinically-Evident Gastroesophageal Reflux Disease.|Completed||Phase 1|24|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:28:17.546463|2018-06-01 04:28:17.546463
NCT00220805|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2009-09-24||2016-02-22|2005-09-14|2005-09-22|Estimate|2016-02-22|2016-03-21|Estimate||||2016-02-22|2016-03-21|Estimate|January 2004||2004-01-31|February 2016|2016-02-29|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional||The intent to treat (ITT) population, which was defined as the primary analysis population, comprised 29 subjects treated with IGIV-C 10% and 24 subjects treated with placebo. A total of 4 subjects were excluded from the ITT population: 1 from IGIV-C 10% and 3 from Placebo.|Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration|Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-C, 10% Treatment in Subjects With Pure Occult Choroidal Neovascularization Due to Age Related Macular Degeneration|Completed||Phase 2|96|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-06-01 04:28:17.672653|2018-06-01 04:28:17.672653
NCT00220792|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2005-09-15|2005-09-15|2005-09-22|Estimate|||||||2005-09-15|2005-09-22|Estimate|June 1993||1993-06-30|September 2005|2005-09-30|June 1998||1998-06-30|||||Interventional|||Group Therapy for Primary Breast Cancer|A Multicenter Trial of Group Therapy for Breast Cancer|Completed||Phase 3|480||Stanford University|||||f||||||||||||||2018-06-01 04:28:18.074353|2018-06-01 04:28:18.074353
NCT00220779|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-09-24||2016-03-28|2005-09-13|2005-09-22|Estimate|2014-03-06|2014-04-11|Estimate||||2016-03-28|2016-04-27|Estimate|December 2002||2002-12-31|March 2016|2016-03-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|PRIVIG||Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis|Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis|Completed||Phase 2|128|Actual|Grifols Therapeutics LLC||3|||f||||f||||||||||2018-06-01 04:28:18.261406|2018-06-01 04:28:18.261406
NCT00220766|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-09-24|2005-09-13|2005-09-22|Estimate|||||||2009-09-24|2009-09-25|Estimate|August 2002||2002-08-31|September 2009|2009-09-30|March 2004|Actual|2004-03-31|August 2002|Actual|2002-08-31||Interventional|||Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients|IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients|Completed||Phase 3|100|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-06-01 04:28:18.896912|2018-06-01 04:28:18.896912
NCT00220753|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-07-21|2005-09-19|2005-09-22|Estimate|||||||2009-07-21|2009-07-23|Estimate|September 2005||2005-09-30|July 2009|2009-07-31|April 2006|Actual|2006-04-30|February 2006|Actual|2006-02-28||Interventional|||Air Cleaners for Children and Adolescents With Asthma and Dog Allergy|Air Cleaners for Children and Adolescents With Asthma and Dog Allergy|Completed||N/A|22|Actual|Sykehuset Innlandet HF||2|||f||||t||||||||||2018-06-01 04:28:19.000978|2018-06-01 04:28:19.000978
NCT00220740|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-09-24||2016-02-23|2005-09-13|2005-09-22|Estimate|2015-08-10|2015-09-10|Estimate||||2016-02-23|2016-03-23|Estimate|April 2004||2004-04-30|February 2016|2016-02-29|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|ICE||Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy|Completed||Phase 3|117|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-06-01 04:28:19.131609|2018-06-01 04:28:19.131609
NCT00220727|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-09-24||2016-03-28|2005-09-13|2005-09-22|Estimate|2014-08-19|2014-08-20|Estimate||||2016-03-28|2016-04-27|Estimate|July 2003||2003-07-31|March 2016|2016-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP|Randomized, Controlled, Open Study Investigating IGIV-C, 10% Given at Different Infusion Rates on Intravascular Hemolysis in Patients With Idiopathic (Immune) Thrombocytopenic Purpura (ITP)|Completed||Phase 2|8|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-06-01 04:28:19.716389|2018-06-01 04:28:19.716389
NCT00220714|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-03-28|2005-09-13|2005-09-22|Estimate|||||||2008-03-28|2008-03-31|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|December 2007|Anticipated|2007-12-31|||||Interventional|||PREvent First Episode Relapse (PREFER)|Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia|Unknown status|Active, not recruiting|Phase 4|80||State University of New York - Downstate Medical Center|||||f||||||||||||||2018-06-01 04:28:20.042843|2018-06-01 04:28:20.042843
NCT00220701|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2014-11-19||2015-10-13|2005-09-21|2005-09-22|Estimate|2014-11-19|2014-11-25|Estimate||||2015-10-13|2015-11-11|Estimate|June 2002||2002-06-30|November 2007|2007-11-30|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|||Escitalopram in the Treatment of Dysthymic Disorder, Double Blind|Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder|Completed||Phase 4|36|Actual|St. Luke's-Roosevelt Hospital Center|Small double blinded study with limited power.|2|||f||||f||||||||||2018-06-01 04:28:20.146513|2018-06-01 04:28:20.146513
NCT00220688|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-10-13|2005-09-16|2005-09-22|Estimate|||||||2009-10-13|2009-10-14|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|October 2006||2006-10-31|||||Interventional|||Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients?|Does Acupressure Help Reduce Nausea and Vomiting in Palliative Care Patients?|Completed||N/A|10||Gloucestershire Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:28:20.416529|2018-06-01 04:28:20.416529
NCT00220675|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-05-21|2005-09-20|2005-09-22|Estimate|||||||2008-05-21|2008-05-22|Estimate|August 2005||2005-08-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Erythropoietin Spinal Cord Compression Randomized Trial|Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study|Terminated||Phase 2/Phase 3|7|Actual|Sunnybrook Health Sciences Centre||||Insufficient accrual|f||||t||||||||||2018-06-01 04:28:20.514002|2018-06-01 04:28:20.514002
NCT00220662|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-22|Estimate|||||||2005-09-16|2005-09-22|Estimate|June 2000||2000-06-30|July 2004|2004-07-31|June 2006||2006-06-30|||||Interventional|||The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa|The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa|Unknown status|Active, not recruiting|Phase 3|100||St. Paul's Hospital, Canada|||||f||||||||||||||2018-06-01 04:28:20.589979|2018-06-01 04:28:20.589979
NCT00220649|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-08-14|2005-09-16|2005-09-22|Estimate|||||||2009-08-14|2009-08-17|Estimate|March 2004||2004-03-31|August 2009|2009-08-31||||||||Interventional|||Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas|Phase I Study to Determine the Safety, Maximum Tolerated Dose, and Efficacy of Biweekly Oxaliplatin (Eloxatin) in Combination With Gemcitabine, Irinotecan, and 5-FU/Leucovorin (G-Flie) in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Exocrine Pancreas|Completed||Phase 1|25|Actual|St. Luke's-Roosevelt Hospital Center|||||f||||t||||||||||2018-06-01 04:28:20.651164|2018-06-01 04:28:20.651164
NCT00220636|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|2009-04-15||2016-04-26|2005-09-21|2005-09-22|Estimate|2015-02-18|2015-02-20|Estimate||||2016-04-26|2016-05-26|Estimate|March 2005||2005-03-31|October 2014|2014-10-31|January 2008|Actual|2008-01-31|March 2007|Actual|2007-03-31||Interventional|||Abilify as an Adjunctive Treatment for Refractory Depression|Abilify (Aripiprazole) as an Adjunctive Treatment for Refractory Unipolar Depression|Completed||Phase 4|15|Actual|St. Luke's-Roosevelt Hospital Center|Open label study without comparison group.|1|||f||||f||||||||||2018-06-01 04:28:20.722618|2018-06-01 04:28:20.722618
NCT00220623|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-22|Estimate|||||||2005-09-16|2005-09-22|Estimate|August 2004||2004-08-31|September 2005|2005-09-30||||||||Interventional|||Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression|Efficacy and Cost-Effectiveness of 18-Months of Antidepressive Medication Plus Either Cognitive-Behavior Therapy or Dynamic Psychotherapy Compared to Supportive Clinical Management for Recurrent Major Depression: a Pilot Study|Unknown status|Recruiting|Phase 3|30||Sir Mortimer B. Davis - Jewish General Hospital|||||f||||||||||||||2018-06-01 04:28:20.939597|2018-06-01 04:28:20.939597
NCT00220610|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|May 2004||2004-05-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN the Treatment of DEPRESSION|Right Parietal Inhibition With rTMS in the Treatment of Depression|Unknown status|Recruiting|Phase 2|40||St. Lucas Andreas Ziekenhuis Hospital|||||f||||||||||||||2018-06-01 04:28:21.024296|2018-06-01 04:28:21.024296
NCT00220597|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-12-02|2005-09-15|2005-09-22|Estimate|||||||2013-12-02|2013-12-03|Estimate|September 1999||1999-09-30|December 2013|2013-12-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Group Therapies for Reducing HIV-risk Behavior in Women Who Have Survived Childhood Sexual Abuse|Group Interventions to Prevent HIV in High Risk Women|Completed||N/A|171|Actual|Stanford University|||||f||||f||||||||||2018-06-01 04:28:21.103237|2018-06-01 04:28:21.103237
NCT00220584|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-12-11|2005-09-15|2005-09-22|Estimate|||||||2012-12-11|2012-12-13|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||An Open-Label Trial of Donepezil in Fragile X Syndrome|An Open-Label Trial of Donepezil in Fragile X Syndrome|Completed||Phase 1|10|Actual|Stanford University||1|||f||||f||||||||||2018-06-01 04:28:21.161455|2018-06-01 04:28:21.161455
NCT00220571|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-02|2005-09-20|2005-09-22|Estimate|||||||2007-07-02|2007-07-03|Estimate|May 2003||2003-05-31|September 2005|2005-09-30|March 2007|Actual|2007-03-31|||||Interventional|||CARESS in Acute Myocardial Infarction|Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction|Completed||Phase 3|600|Actual|Società Italiana di Cardiologia Invasiva|||||f||||t||||||||||2018-06-01 04:28:21.24157|2018-06-01 04:28:21.24157
NCT00220558|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-12-03|2005-09-15|2005-09-22|Estimate|||||||2009-12-03|2009-12-04|Estimate|May 2005||2005-05-31|May 2009|2009-05-31|February 2010|Anticipated|2010-02-28|October 2007|Actual|2007-10-31||Interventional|||GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions|A Randomized Comparison of Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions: The Gruppo Italiano di Studio Sullo Stent Nelle Occlusioni Coronariche. The GISSOC II Study.|Unknown status|Active, not recruiting|Phase 4|150|Actual|Società Italiana di Cardiologia Invasiva|||||f||||f||||||||||2018-06-01 04:28:21.504234|2018-06-01 04:28:21.504234
NCT00220545|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-10-22|2005-09-14|2005-09-22|Estimate|||||||2007-10-22|2007-10-23|Estimate|March 2002||2002-03-31|October 2007|2007-10-31|March 2006||2006-03-31|||||Interventional|||Comparison Between Laparoscopic Ovarian Diathermy and Clomiphene Citrate in Women With Anovulatory PCOS|A Prospective Randomized Controlled Trial to Compare Laparoscopic Ovarian Diathermy With Clomiphene Citrate as a First Line Treatment of Anovulatory Infertility in Patients With Polycystic Ovarian Syndrome|Completed||N/A|72|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:28:21.596983|2018-06-01 04:28:21.596983
NCT00220532|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-11|2005-09-13|2005-09-22|Estimate|||||||2006-09-11|2006-09-13|Estimate|July 2005||2005-07-31|September 2006|2006-09-30|May 2007||2007-05-31|||||Interventional|||Folate and Protection Against Cervical Cancer|A Randomised Placebo-Controlled Trial to Evaluate Interactions Between Riboflavin and Folate Intake and Genotype in Reducing Risk of Cervical Cancer|Terminated||Phase 1/Phase 2|180||Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:28:21.652225|2018-06-01 04:28:21.652225
NCT00220519|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-12-21|2005-09-14|2005-09-22|Estimate|||||||2007-12-21|2008-01-07|Estimate|October 2004||2004-10-31|September 2005|2005-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Lactobacillus GG Supplementation During Pediatric Burn Injuries|Lactobacillus GG Supplementation During Pediatric Burn Injuries|Terminated||N/A|3|Actual|Shriners Hospitals for Children||||Study stopped due to low enrollment|f||||t||||||||||2018-06-01 04:28:21.71566|2018-06-01 04:28:21.71566
NCT00220506|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-02-16|2005-09-14|2005-09-22|Estimate|||||||2006-02-16|2006-02-17|Estimate|September 2005||2005-09-30|February 2006|2006-02-28|December 2006||2006-12-31|||||Interventional|||Fatigue Treatment Using Provigil|Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis|Unknown status|Recruiting|N/A|50||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:28:21.799634|2018-06-01 04:28:21.799634
NCT00220493|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-01-04|2005-09-14|2005-09-22|Estimate|||||||2007-01-04|2007-01-05|Estimate|June 2003||2003-06-30|January 2007|2007-01-31|June 2005||2005-06-30|||||Interventional|||Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients|Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients|Unknown status|Recruiting|Phase 1|80||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:28:21.871871|2018-06-01 04:28:21.871871
NCT00220480|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-02-07|2005-09-14|2005-09-22|Estimate|||||||2010-02-07|2010-02-09|Estimate|February 2005||2005-02-28|February 2010|2010-02-28||||June 2011|Anticipated|2011-06-30||Interventional|||A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression||Unknown status|Recruiting|N/A|60|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:28:21.94112|2018-06-01 04:28:21.94112
NCT00220467|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2008-07-29|2005-09-21|2005-09-22|Estimate|||||||2008-07-29|2008-07-30|Estimate|January 2005||2005-01-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Cognitive Effects of Aerobic Exercise for MCI Adults|Cognitive Effects of Aerobic Exercise for Adults With Mild Cognitive Impairment: A Controlled Trial|Completed||Phase 2|40|Anticipated|Seattle Institute for Biomedical and Clinical Research|||||f||||f||||||||||2018-06-01 04:28:22.016479|2018-06-01 04:28:22.016479
NCT00220454|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-02-26|2005-09-20|2005-09-22|Estimate|||||||2007-02-26|2007-02-27|Estimate|December 2002||2002-12-31|February 2007|2007-02-28|March 2005||2005-03-31|||||Interventional|||Effect of Estrogen & Stress for Postmenopausal Women|Effect of Estrogen on the Stress Response for Postmenopausal Women|Completed||Phase 2|40||Seattle Institute for Biomedical and Clinical Research|||||f||||f||||||||||2018-06-01 04:28:22.083986|2018-06-01 04:28:22.083986
NCT00220441|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2008-07-29|2005-09-21|2005-09-22|Estimate|||||||2008-07-29|2008-07-30|Estimate|July 2004||2004-07-31|July 2008|2008-07-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Cognitive Effects of Aerobic Exercise for IGT Adults|Cognitive Effects of Aerobic Exercise for Adults With Impaired Glucose Tolerance: A Controlled Trial|Completed||Phase 2|40||Seattle Institute for Biomedical and Clinical Research|||||f||||f||||||||||2018-06-01 04:28:22.139316|2018-06-01 04:28:22.139316
NCT00220428|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-01-23|2005-09-14|2005-09-22|Estimate|||||||2007-01-23|2007-01-24|Estimate|July 1998||1998-07-31|January 2007|2007-01-31|December 2007||2007-12-31|||||Interventional|||T-Cell Vaccination in Multiple Sclerosis (MS)|The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial|Unknown status|Recruiting|Phase 1/Phase 2|20||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:28:22.198026|2018-06-01 04:28:22.198026
NCT00220415|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2014-09-19|2005-09-13|2005-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|May 2004||2004-05-31|February 2010|2010-02-28|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization|Completed||Phase 3|||UCB Pharma|||||f||||||||||||||2018-06-01 04:28:22.266022|2018-06-01 04:28:22.266022
NCT00220402|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-11-21|2005-09-13|2005-09-22|Estimate|||||||2008-11-21|2008-11-24|Estimate|July 2004||2004-07-31|November 2008|2008-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome|Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 04:28:22.317725|2018-06-01 04:28:22.317725
NCT00220389|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-10-15|2005-09-14|2005-09-22|Estimate|||||||2008-10-15|2008-10-16|Estimate|June 2003||2003-06-30|October 2008|2008-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase|Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder(OAB): a Double-Blind Phase Followed by an Open-Label Extension Phase|Completed||Phase 2|||Pfizer|||||||||||||||||||2018-06-01 04:28:22.363261|2018-06-01 04:28:22.363261
NCT00220376|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-11-21|2005-09-14|2005-09-22|Estimate|||||||2008-11-21|2008-11-24|Estimate|April 2004||2004-04-30|November 2008|2008-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome|Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome|Completed||Phase 3|||Pfizer|||||||||||||||||||2018-06-01 04:28:22.40796|2018-06-01 04:28:22.40796
NCT00220363|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-04-29|2005-09-13|2005-09-22|Estimate|||||||2008-04-29|2008-05-05|Estimate|January 2004||2004-01-31|April 2008|2008-04-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome|A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 04:28:22.459683|2018-06-01 04:28:22.459683
NCT00220350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-22|Estimate|||||||2005-09-16|2005-09-22|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Lupron Sex Offender Therapy|Leuprolide Acetate Suppresses Pedophilic Urges and Arousability|Unknown status|Active, not recruiting|Phase 2/Phase 3|10||Schober, Justine, M.D.|||||f||||||||||||||2018-06-01 04:28:22.517933|2018-06-01 04:28:22.517933
NCT00220337|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2014-09-19|2005-09-13|2005-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|December 2004||2004-12-31|September 2009|2009-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy|A Multicenter, Open-label Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy|Completed||Phase 3|371|Actual|UCB Pharma||1|||f||||||||||||||2018-06-01 04:28:22.596122|2018-06-01 04:28:22.596122
NCT00220324|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-04-02|2005-09-16|2005-09-22|Estimate|||||||2015-04-02|2015-04-03|Estimate|February 2004||2004-02-29|April 2015|2015-04-30|November 2005|Actual|2005-11-30|||||Interventional|||Pearl Index Study With Low Dose Combined Oral Contraceptive|Prospective, Multicenter, Open-label, Uncontrolled Study to Investigate the Contraceptive Efficacy, Bleeding Patterns, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 0.125 mg Levonorgestrel (SH D00342A) Applied for 13 Cycles to Healthy Female Volunteers|Completed||Phase 3|840|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:28:22.709312|2018-06-01 04:28:22.709312
NCT00220311|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2013-12-02|2005-09-21|2005-09-22|Estimate|||||||2013-12-02|2013-12-04|Estimate|November 2000||2000-11-30|December 2013|2013-12-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia|A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia|Completed||Phase 4|10|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 04:28:22.806778|2018-06-01 04:28:22.806778
NCT00220298|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2014-12-29|2005-09-16|2005-09-22|Estimate|||||||2014-12-29|2014-12-30|Estimate|February 2003||2003-02-28|December 2014|2014-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism|Open One-arm Study to Investigate Safety and Efficacy of Intramuscular Injections of 1000 mg Testosterone Undecanoate (TU) in Hypogonadal Men at Variable Intervals During a 136-week to 192-week Treatment Including Pharmacokinetics|Completed||Phase 3|96|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:28:22.874032|2018-06-01 04:28:22.874032
NCT00220285|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2014-12-29|2005-09-21|2005-09-22|Estimate|||||||2014-12-29|2014-12-30|Estimate|August 2004||2004-08-31|December 2014|2014-12-31|October 2005|Actual|2005-10-31|||||Interventional|||Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma|A Phase II Open-label Study of SH L 749 in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphomas|Completed||Phase 2|45|Actual|Bayer||2|||f||||t||||||||||2018-06-01 04:28:22.94417|2018-06-01 04:28:22.94417
NCT00220272|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2008-12-22|2005-09-16|2005-09-22|Estimate|||||||2008-12-22|2008-12-23|Estimate|January 2004||2004-01-31|December 2008|2008-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease|A Phase II, Randomized, Multicenter, Multinational, Double-Blind, Placebo-Controlled, Study of the Effect of SR57667B on Dopaminergic Nigro-Striatal Function Assessed by 18F-Dopa PET Imaging in Outpatients With Early Parkinson's Disease|Completed||Phase 2|183|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:28:23.028828|2018-06-01 04:28:23.028828
NCT00220259|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-11-07|2005-09-20|2005-09-22|Estimate|||||||2005-11-07|2005-11-08|Estimate|May 2001||2001-05-31|September 2005|2005-09-30|February 2005||2005-02-28|||||Interventional|||Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)|Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)|Completed||N/A|240||Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:28:23.185933|2018-06-01 04:28:23.185933
NCT00220246|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-02-28|2005-09-20|2005-09-22|Estimate|||||||2007-02-28|2007-03-01|Estimate|March 2004||2004-03-31|February 2007|2007-02-28|September 2008||2008-09-30|||||Observational|||Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer||Unknown status|Active, not recruiting||130||Radboud University|||||f||||||||||||||2018-06-01 04:28:23.246853|2018-06-01 04:28:23.246853
NCT00220233|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-12-12|2005-09-16|2005-09-22|Estimate|||||||2007-12-12|2007-12-14|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Olmesartan as an Add-on to Amlodipine in Hypertension|Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone|Completed||Phase 3|632||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:28:23.299451|2018-06-01 04:28:23.299451
NCT00220220|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-10-10|2005-09-16|2005-09-22|Estimate|||||||2007-10-10|2007-10-11|Estimate|April 2005||2005-04-30|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Amlodipine as Add-on to Olmesartan in Hypertension|Efficacy and Safety of Amlodipine Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy|Completed||Phase 3|429|Anticipated|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:28:23.370181|2018-06-01 04:28:23.370181
NCT00220207|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2007-07-31|2005-09-15|2005-09-22|Estimate|||||||2007-07-31|2007-08-01|Estimate|September 2003||2003-09-30|July 2007|2007-07-31|February 2007||2007-02-28|||||Interventional|||Determining the Effect on Patients of Internet-Based Diabetes Disease Management|A Randomized Controlled Trial of Diabetes Disease Management Over the Internet|Completed||N/A|63||Robert Wood Johnson Foundation|||||f||||f||||||||||2018-06-01 04:28:23.46137|2018-06-01 04:28:23.46137
NCT00220194|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-17|||2016-10-13|2005-09-17|2005-09-22|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2003||2003-04-30|October 2016|2016-10-31|June 2005||2005-06-30|||||Interventional|||A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer|A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer|Completed||Phase 4|100||San Bernardino Urological Associates Medical Group Inc|||||f||||||||||||||2018-06-01 04:28:23.521005|2018-06-01 04:28:23.521005
NCT00220181|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2005-09-21|2005-09-21|2005-09-22|Estimate|||||||2005-09-21|2005-09-22|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Prospective Study in Pelvic Radiotherapy Patients|A Prospective Study to Identify Changes in Nutritional Status and Bowel Symptoms in Patients Receiving a Course of Radical Radiotherapy to the Pelvis for Treatment of Gynaecological, Urological or Rectal Cancer.|Completed|||100||Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:28:23.590283|2018-06-01 04:28:23.590283
NCT00220168|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-12-15|2005-09-21|2005-09-22|Estimate|||||||2009-12-15|2009-12-16|Estimate|January 2003||2003-01-31|December 2009|2009-12-31||||||||Interventional|||Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours|A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours|Completed||Phase 4|33|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:23.636725|2018-06-01 04:28:23.636725
NCT00220155|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2009-12-15|2005-09-20|2005-09-22|Estimate|||||||2009-12-15|2009-12-16|Estimate|May 2004||2004-05-31|December 2009|2009-12-31||||||||Interventional|||Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer|A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced or Metastatic Colorectal Cancer.|Completed||Phase 2|16|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:23.703338|2018-06-01 04:28:23.703338
NCT00220129|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-12-15|2005-09-19|2005-09-22|Estimate|||||||2009-12-15|2009-12-16|Estimate|November 2002||2002-11-30|December 2009|2009-12-31||||||||Interventional|||Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus|Neoadjuvant Epirubicin, Cisplatin and Capecitabine (Xeloda) [ECX] Followed by Definitive Chemoradiation With or Without Surgery for Patients With Newly Diagnosed Localized Squamous Cell Carcinoma of the Oesophagus|Completed||Phase 2|16|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:23.798856|2018-06-01 04:28:23.798856
NCT00220116|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2010-01-05|2005-09-19|2005-09-22|Estimate|||||||2010-01-05|2010-01-06|Estimate|August 2002||2002-08-31|January 2010|2010-01-31||||||||Interventional|||Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer|A Phase II Trial Assessing the Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer.|Completed||Phase 2|172|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:23.854905|2018-06-01 04:28:23.854905
NCT00220103|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-12-15|2005-09-19|2005-09-22|Estimate|||||||2009-12-15|2009-12-16|Estimate|November 2002||2002-11-30|December 2009|2009-12-31||||||||Interventional|||Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma|Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma|Completed||Phase 2|80|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:23.91918|2018-06-01 04:28:23.91918
NCT00220090|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-13|2005-09-13|2005-09-22|Estimate|||||||2008-05-13|2008-05-14|Estimate|July 2003||2003-07-31|May 2008|2008-05-31||||September 2006|Actual|2006-09-30||Interventional|||DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)|A 24-wk, Prospective, d/b, Placebo Controlled, Parallel Group, Multicenter, Randomized/Withdrawal Efficacy and Safety Study of Dexloxiglumide for the Relief of Symptoms in Patients With Constipation-Predominant Irritable Bowel Syndrome|Completed||Phase 3|||Rottapharm|||||f||||||||||||||2018-06-01 04:28:24.025727|2018-06-01 04:28:24.025727
NCT00220077|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2015-11-23|2005-09-19|2005-09-22|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2002||2002-06-30|November 2015|2015-11-30||||||||Interventional|||Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer|Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer|Unknown status|Recruiting|N/A|400|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:28:24.089207|2018-06-01 04:28:24.089207
NCT00220064|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-05-30|2005-09-19|2005-09-22|Estimate|||||||2013-05-30|2013-05-31|Estimate|July 2000||2000-07-31|May 2013|2013-05-31|November 2005|Actual|2005-11-30|||||Interventional|||A Phase II Trial Evaluating Irinotecan Plus 5FU/LV in Patients With Relapsed/Refractory Upper GI Tumours|A Phase II Trial Evaluating Irinotecan With 5_fluorouracil Plus Leucovorin in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours|Completed||Phase 2|65|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:24.201944|2018-06-01 04:28:24.201944
NCT00220051|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-05-30|2005-09-19|2005-09-22|Estimate|||||||2013-05-30|2013-05-31|Estimate|November 2001||2001-11-30|May 2013|2013-05-31||||||||Interventional|||A Phase II Study of Oxaliplatin Capecitabine and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer|A Phase II Study of Oxaliplatin (Eloxatin) Capecitabine (Xeloda) and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer.|Completed||Phase 2|109|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-06-01 04:28:24.25055|2018-06-01 04:28:24.25055
NCT00220038|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2012-01-10|2005-09-21|2005-09-22|Estimate|||||||2012-01-10|2012-01-11|Estimate|May 2004||2004-05-31|January 2012|2012-01-31|May 2010|Actual|2010-05-31|January 2007|Actual|2007-01-31||Observational|||Experiments to Test How and Why the Sense of Smell Differs Between People|Genetic Basis of Specific Anosmias|Completed|||500|Actual|Rockefeller University|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 04:28:24.304924|2018-06-01 04:28:24.304924
NCT00220025|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-10-24|2005-09-20|2005-09-22|Estimate|||||||2012-10-24|2012-10-25|Estimate|June 1999||1999-06-30|October 2012|2012-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.|A Study To Determine the Efficacy of Whole Body Narrowband UVB Phototherapy in People With Darker Skin Types|Completed||Phase 1|70|Actual|Rockefeller University||1|||f||||t||||||||||2018-06-01 04:28:24.361636|2018-06-01 04:28:24.361636
NCT00220012|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-11-14|2005-09-19|2005-09-22|Estimate|||||||2013-11-14|2013-11-15|Estimate|June 2003||2003-06-30|November 2013|2013-11-30|September 2008|Actual|2008-09-30|||||Interventional|||Effect of Folate on Colon and Blood Cells|Effect of Folate on Colonic and Blood Cells|Completed||Phase 1|20||Rockefeller University|||||f||||||||||||||2018-06-01 04:28:24.420079|2018-06-01 04:28:24.420079
NCT00219999|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-08-06|2005-09-19|2005-09-22|Estimate|||||||2013-08-06|2013-08-09|Estimate|September 2001||2001-09-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Hepatitis C Virus and the Humoral Immune System|Hepatitis C Virus and the Humoral Immune System|Completed|||161|Actual|Rockefeller University|||5||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 04:28:24.484977|2018-06-01 04:28:24.484977
NCT00219986|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-16|2005-09-20|2005-09-22|Estimate|||||||2007-07-16|2007-07-18|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Phase I/II, Open-Label Trial of Three Monoclonal Antibodies|A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection|Completed||Phase 1/Phase 2|12||Rockefeller University|||||||||||||||||||2018-06-01 04:28:24.557221|2018-06-01 04:28:24.557221
NCT00219973|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2010-04-27|2005-09-19|2005-09-22|Estimate|||||||2010-04-27|2010-04-28|Estimate|May 2005||2005-05-31|April 2010|2010-04-30|April 2009|Actual|2009-04-30|||||Interventional|||CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)|Multicentric, Rand., D-b, Pbo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of the Thromboprophylaxis With Bemiparin 3,500 IU/d for 28 Days Compared to 8 Days, in Patients Undergoing Oncological Abdominal/ Pelvic Surgery|Completed||Phase 3|526|Anticipated|Rovi Pharmaceuticals Laboratories|||||f||||t||||||||||2018-06-01 04:28:24.616352|2018-06-01 04:28:24.616352
NCT00219960|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|April 2001||2001-04-30|June 2004|2004-06-30|October 2003||2003-10-31|||||Interventional|||The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension|The Effect of North American Ginseng on Blood Pressure in Individuals With Hypertension|Completed||Phase 3|52||Risk Factor Modification Centre|||||f||||||||||||||2018-06-01 04:28:24.682819|2018-06-01 04:28:24.682819
NCT00219947|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2018-01-10|2005-09-20|2005-09-22|Estimate|||||||2018-01-10|2018-01-11|Actual|July 2000||2000-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Viral and Host Factors in the Transmission and Pathogenesis of HIV|Viral and Host Factors in the Transmission and Pathogenesis of HIV|Recruiting|||600|Anticipated|Rockefeller University|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|No||2018-06-01 04:28:24.795226|2018-06-01 04:28:24.795226
NCT00219934|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-02-15|2005-09-20|2005-09-22|Estimate|||||||2012-02-15|2012-02-17|Estimate|February 2002||2002-02-28|February 2012|2012-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Observational Study of Treated and Untreated Acute and Early HIV-1 Infection|Observational Study of Treated and Untreated Acute and Early HIV-1 Infection|Completed|||399|Actual|Rockefeller University|||2||f||||t||||||Samples With DNA|"~     PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS~   "|||2018-06-01 04:28:24.871713|2018-06-01 04:28:24.871713
NCT00219921|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-29|2005-09-13|2005-09-22|Estimate|||||||2007-03-29|2007-03-30|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Postoperative Analgesia After Total Hip Replacement|Postoperative Analgesia After Total Hip Replacement|Completed||Phase 3|120||Rijnstate Hospital|||||f||||||||||||||2018-06-01 04:28:24.936105|2018-06-01 04:28:24.936105
NCT00219908|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-12-21|2005-09-16|2005-09-22|Estimate|||||||2005-12-21|2005-12-22|Estimate|July 1999||1999-07-31|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis|Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b|Terminated||Phase 2|124||Rennes University Hospital|||||f||||||||||||||2018-06-01 04:28:24.997702|2018-06-01 04:28:24.997702
NCT00219895|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-12-18|2005-09-16|2005-09-22|Estimate|||||||2007-12-18|2007-12-25|Estimate|August 2004||2004-08-31|August 2006|2006-08-31|March 2006|Actual|2006-03-31|||||Interventional|||Assessment of Inflammatory Mediators (AIM)|Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients With Cystic Fibrosis|Completed||N/A|120||Ramsey, Bonnie, MD|||||f||||||||||||||2018-06-01 04:28:25.081923|2018-06-01 04:28:25.081923
NCT00219882|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-12-18|2005-09-16|2005-09-22|Estimate|||||||2007-12-18|2007-12-25|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|SEER||Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis|A Phase I Safety and Dose Finding Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis Who Are Homozygous for Delta F508 Cystic Fibrosis Transmembrane Conductance Regulator (ΔF508 CFTR) Mutation|Completed||Phase 1|11|Actual|Ramsey, Bonnie, MD||1|||f||||t||||||||||2018-06-01 04:28:25.151011|2018-06-01 04:28:25.151011
NCT00219869|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|July 2005||2005-07-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Galantamine in the Treatment of Post-Traumatic Headache|Galantamine in the Preventive Treatment of Chronic Post-Traumatic Headache|Unknown status|Recruiting|Phase 4|30||Rapoport, Alan, M.D.|||||f||||||||||||||2018-06-01 04:28:25.221708|2018-06-01 04:28:25.221708
NCT00219856|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-25|2005-09-13|2005-09-22|Estimate|||||||2012-06-25|2012-06-26|Estimate|August 2004||2004-08-31|June 2012|2012-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy|Prospective, Randomized, Simple Blind Study Comparing the Effects of an Anaesthesia With Propofol to an Anaesthesia With Desflurane on Oxydative Stress and Liver Function Recovery After Hepatectomy|Completed||Phase 3|34|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-06-01 04:28:25.292574|2018-06-01 04:28:25.292574
NCT00219843|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-08-22|2005-09-15|2005-09-22|Estimate|||||||2007-08-22|2007-08-23|Estimate|August 2005||2005-08-31|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Intralesional PV-10 Chemoablation of Metastatic Melanoma|A Phase 1 Safety and Tolerability Study of Intralesional PV-10 Chemoablation in Subjects With Metastatic Melanoma|Completed||Phase 1|20||Provectus Pharmaceuticals|||||f||||f||||||||||2018-06-01 04:28:25.459603|2018-06-01 04:28:25.459603
NCT00219830|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2018-05-15|2005-09-19|2005-09-22|Estimate|||||||2018-05-15|2018-05-18|Actual|January 2005||2005-01-31|May 2018|2018-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|CRU-SHAL||A Trial of a Home Based Walking Program as an Alternate Program for Non Attenders at Cardiac Rehabilitation|Health and Social Inequalities in the Uptake of Cardiac Rehabilitation in Northern Ireland: an Alternative Program for Non-attenders: (2) a Randomised Controlled Trial.|Completed||N/A|2|Actual|Queen's University, Belfast||2|||f||||f||||||||No|No plan to share individual participant data - these will form an aggregated database for determination of the design of a later definitive study.|2018-06-01 04:28:25.565377|2018-06-01 04:28:25.565377
NCT00219817|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-08-30|2005-09-13|2005-09-22|Estimate|||||||2013-08-30|2013-09-02|Estimate|June 2005||2005-06-30|August 2013|2013-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss||Completed||Phase 2|80||Helsinn Therapeutics (U.S.), Inc|||||||||||||||||||2018-06-01 04:28:25.656533|2018-06-01 04:28:25.656533
NCT00219804|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate||||September 2005|2005-09-30||||||||Interventional|||Efficacy and Safety of Tetrabenazine in Chorea|A Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's Chorea|Completed||Phase 3|||Prestwick Pharmaceuticals|||||||||||||||||||2018-06-01 04:28:25.788027|2018-06-01 04:28:25.788027
NCT00219791|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2014-09-10|2005-09-15|2005-09-22|Estimate|||||||2014-09-10|2014-09-11|Estimate|January 2000||2000-01-31|September 2014|2014-09-30|June 2003||2003-06-30|||||Interventional|||Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance|Study of Recombinant Carboxypeptidase G2 (CPG2) for the Management of Patients With Delayed Methotrexate (MTX) Clearance or Intrathecal MTX Overdosage|Completed||Phase 2|||BTG International Inc.|||||f||||||||||||||2018-06-01 04:28:25.873565|2018-06-01 04:28:25.873565
NCT00219778|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2016-04-04|2005-09-16|2005-09-22|Estimate|||||||2016-04-04|2016-04-06|Estimate|December 2004||2004-12-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|||||Interventional|||A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas|A Placebo Controlled Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas|Terminated||Phase 2|20|Anticipated|Poitiers University Hospital|||||f||||||||||||||2018-06-01 04:28:25.974586|2018-06-01 04:28:25.974586
NCT00219765|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-11-25|2005-09-13|2005-09-22|Estimate|||||||2005-11-25|2005-11-28|Estimate|May 2001||2001-05-31|September 2005|2005-09-30|January 2006||2006-01-31|||||Interventional|||Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients|Phase I/II Trial to Study the Dose, Tolerability and the Effectiveness of Imatinib in Combination With Daunorubicine and Cytarabine for Patients With Chronic Myelogenous Leukemia in Myeloid Acute Phase|Terminated||Phase 1/Phase 2|30||Poitiers University Hospital|||||f||||||||||||||2018-06-01 04:28:26.04326|2018-06-01 04:28:26.04326
NCT00219752|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-21|2005-09-13|2005-09-22|Estimate|||||||2005-12-21|2005-12-22|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|May 2007||2007-05-31|||||Interventional|||Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years|Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase With Age More Than 70, Diagnosis of CML is Being Performed Within 1 Year|Completed||Phase 2|30||Poitiers University Hospital|||||f||||||||||||||2018-06-01 04:28:26.181092|2018-06-01 04:28:26.181092
NCT00219739|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-10|2005-09-13|2005-09-22|Estimate|||||||2016-10-10|2016-10-11|Estimate|September 2003||2003-09-30|June 2016|2016-06-30||||December 2014|Actual|2014-12-31||Interventional|SPIRIT||STI571 ProspectIve RandomIzed Trial: SPIRIT|A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase|Completed||Phase 3|789|Actual|Poitiers University Hospital||4|||f||||||||||||||2018-06-01 04:28:26.292923|2018-06-01 04:28:26.292923
NCT00219726|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-28|2005-09-13|2005-09-22|Estimate|||||||2012-08-28|2012-08-29|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|July 2007||2007-07-31|||||Interventional|||Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation|Phase II Trial to Study the Tolerability and the Effectiveness of Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase in Relapse After Allogeneic Stem Cell Transplantation|Completed||Phase 2|30|Anticipated|Poitiers University Hospital|||||f||||||||||||||2018-06-01 04:28:26.408685|2018-06-01 04:28:26.408685
NCT00219713|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-22|Estimate|||||||2005-09-13|2005-09-22|Estimate|March 2000||2000-03-31|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Evaluation of Pain Intensity During Bone Marrow Biopsy Performed With Inhalation of Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture.|A Randomized Placebo-Controlled Double Blind Trial Comparing Pre-Mixed 50 Per Cent Nitrous Oxide and Oxygen Mixture in Combination With Local Local 1% Xylocaine Anesthetic Versus Placebo in Order to Evaluate Pain Intensity During Bone Marrow Biopsy.|Terminated||Phase 3|280||Poitiers University Hospital|||||f||||||||||||||2018-06-01 04:28:26.589992|2018-06-01 04:28:26.589992
NCT00219700|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-11-25|2005-09-20|2005-09-22|Estimate|||||||2008-11-25|2008-11-26|Estimate|January 2005||2005-01-31|November 2008|2008-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Ibuprofen-PC Compared With Ibuprofen in a GI Safety Trial|Phase II, Randomized, Blinded Study of Ibuprofen-PC and Ibuprofen in Patients With Osteoarthritis to Investigate Efficacy and Gastrointestinal Toxicity|Completed||Phase 2|125||PLx Pharma|||||f||||f||||||||||2018-06-01 04:28:26.703533|2018-06-01 04:28:26.703533
NCT00219687|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-10-28|2005-09-13|2005-09-22|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2004||2004-06-30|October 2014|2014-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Dispatcher-Assisted Resuscitation Trial (DART)|Randomized Trial of Dispatcher-Assisted CPR:Chest Compression Alone Versus Chest Compression Plus Ventilation|Completed||Phase 3|5494|Actual|Public Health - Seattle and King County||2|||f||||t||||||||||2018-06-01 04:28:26.778941|2018-06-01 04:28:26.778941
NCT00219674|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-10-28|2005-09-13|2005-09-22|Estimate|||||||2014-10-28|2014-10-29|Estimate|July 2004||2004-07-31|October 2014|2014-10-31|March 2011|Actual|2011-03-31|March 2009|Actual|2009-03-31||Interventional|||At-Home Automated External Defibrillator (AED) Training Study|Home Automatic External Defibrillator Training for High-Risk Patients|Completed||Phase 2|305|Actual|Public Health - Seattle and King County||4|||f||||t||||||||||2018-06-01 04:28:26.867174|2018-06-01 04:28:26.867174
NCT00219661|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-19|2005-09-22|Estimate|||||||2007-04-20|2007-04-23|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Effect of Drainage of Subglottic Secretions on Pneumonia Acquired Under Mechanical Ventilation|Impact of Drainage of Subglottic Secretions on Ventilator-Associated Pneumonia:a Randomised Multicentre Trial|Completed||Phase 3|440||Poissy-Saint Germain Hospital|||||f||||f||||||||||2018-06-01 04:28:27.008265|2018-06-01 04:28:27.008265
NCT00219648|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-09-20|2005-09-20|2005-09-22|Estimate|||||||2005-09-20|2005-09-22|Estimate|September 2004||2004-09-30|September 2005|2005-09-30||||||||Interventional|||Two-Stage Study to Assess the Efficacy and Safety of 12 Weeks of Treatment With PEP03 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose- Finding, Two-Stage Study to Assess the Efficacy and Safety of 12 Weeks of Treatment With PEP03 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Recruiting|Phase 2|||PharmaEngine|||||||||||||||||||2018-06-01 04:28:27.126233|2018-06-01 04:28:27.126233
NCT00219635|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-11-05|2005-09-14|2005-09-22|Estimate|||||||2012-11-05|2012-11-07|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation|A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation|Completed||Phase 2/Phase 3|138||Pfizer|||||||||||||||||||2018-06-01 04:28:27.220349|2018-06-01 04:28:27.220349
NCT00219622|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2012-11-05|2005-09-14|2005-09-22|Estimate|||||||2012-11-05|2012-11-07|Estimate|May 2004||2004-05-31|November 2012|2012-11-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults Diagnosed With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|300||Pfizer|||||f||||||||||||||2018-06-01 04:28:27.34476|2018-06-01 04:28:27.34476
NCT00219609|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-11-05|2005-09-14|2005-09-22|Estimate|||||||2012-11-05|2012-11-07|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Assessment Of Safety Of UK-390,957|A Phase 2 Multi-Center, Open Label Long-Term Extension Trial To Assess The Safety Of Oral Uk-390,957 Administered As Required In Adult Men With Premature Ejaculation|Completed||Phase 2/Phase 3|1058||Pfizer|||||||||||||||||||2018-06-01 04:28:27.528336|2018-06-01 04:28:27.528336
NCT00219596|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-13|2005-09-14|2005-09-22|Estimate|||||||2007-09-13|2007-09-14|Estimate|June 2005||2005-06-30|November 2006|2006-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension|An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension|Completed||Phase 3|240||Pfizer|||||f||||||||||||||2018-06-01 04:28:27.718689|2018-06-01 04:28:27.718689
NCT00219583|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-11-05|2005-09-14|2005-09-22|Estimate|||||||2012-11-05|2012-11-07|Estimate|August 2004||2004-08-31|November 2012|2012-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation|A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation|Completed||Phase 2/Phase 3|460||Pfizer|||||||||||||||||||2018-06-01 04:28:27.784639|2018-06-01 04:28:27.784639
NCT00219557|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-02-25|2009-03-20|2012-07-23|2005-09-13|2005-09-22|Estimate|2012-07-23|2012-08-24|Estimate|2009-09-24|2009-09-28|Estimate|2012-07-23|2012-08-24|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer|A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combination With Gemcitabine In Patients With Chemotherapy Naive Advanced Pancreatic Cancer Preceded By A Phase 1 Portion|Completed||Phase 2|111|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:28:29.258473|2018-06-01 04:28:29.258473
NCT00219544|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-02-13||2011-04-22|2005-09-13|2005-09-22|Estimate|2009-04-07|2009-06-02|Estimate||||2011-04-22|2011-04-26|Estimate|November 2005||2005-11-30|April 2011|2011-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.|A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain|Completed||Phase 3|158|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 04:28:33.470192|2018-06-01 04:28:33.470192
NCT00219531|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-11-28|2005-09-14|2005-09-22|Estimate|||||||2017-11-28|2017-11-29|Actual|March 1999||1999-03-31|November 2017|2017-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Effect of Menstrual Cycle on Central Nervous System (CNS) Processing of Gut Stimuli in Irritable Bowel Syndrome (IBS) and Control|Effect of Menstrual Cycle and Irritable Bowel Syndrome on the Central Nervous System Processing of Gut Stimuli|Terminated|||48|Actual|Penn State University|||2|inadequate number of patients, study completed with normal subjects|f||||f||||||||||2018-06-01 04:28:34.169206|2018-06-01 04:28:34.169206
NCT00219518|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-05-23|2005-09-14|2005-09-22|Estimate|||||||2018-05-23|2018-05-25|Actual|February 2006||2006-02-28|May 2018|2018-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Mechano-physiological Approach to Anorectal Function|Mechano-physiological Approach to Normal Anorectal Function and the Classification of Defecatory Disorders|Terminated|||17|Actual|Milton S. Hershey Medical Center||||inadequate no of constip patients|f||||||||||||||2018-06-01 04:28:34.256067|2018-06-01 04:28:34.256067
NCT00219505|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-11-21|2005-09-14|2005-09-22|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2001||2001-08-31|November 2017|2017-11-30|January 2004||2004-01-31|||||Interventional|||Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS|Effect of Acupuncture on Symptoms of Diarrhea and Pain in Diarrhea Predominant Irritable Bowel Syndrome (IBS) and Effect on Plasma Beta-endorphin and Serotonin Levels.|Terminated||N/A|36||Penn State University||||no eligible subjects identified during recruitment|f||||||||||||||2018-06-01 04:28:34.335497|2018-06-01 04:28:34.335497
NCT00219492|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-06-16|2005-09-16|2005-09-22|Estimate|||||||2017-06-16|2017-06-20|Actual|September 2005||2005-09-30|June 2017|2017-06-30|August 21, 2014|Actual|2014-08-21|August 21, 2014|Actual|2014-08-21||Observational|||Role of Esophageal Mast Cell Activation in Noncardiac Chest Pain (NCCP)|Role of Esophageal Mast Cell Activation in Noncardiac Chest Pain (NCCP)|Completed|||86|Actual|Milton S. Hershey Medical Center|||||f||||||||||||||2018-06-01 04:28:34.46761|2018-06-01 04:28:34.46761
NCT00219479|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-11-21|2005-09-15|2005-09-22|Estimate|||||||2017-11-21|2017-11-24|Actual|August 1997||1997-08-31|November 2017|2017-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study|Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study|Terminated||Phase 4|3|Actual|Penn State University||||Difficulty recruiting subjects|f||||f||||||||||2018-06-01 04:28:34.531318|2018-06-01 04:28:34.531318
NCT00219466|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-19|2005-09-13|2005-09-22|Estimate|||||||2011-08-19|2011-08-22|Estimate|June 2005||2005-06-30|August 2011|2011-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash|A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash|Completed||Phase 4|112|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 04:28:34.586635|2018-06-01 04:28:34.586635
NCT00219453|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-18|2005-09-13|2005-09-22|Estimate|||||||2007-04-18|2007-04-19|Estimate|October 2004||2004-10-31|April 2007|2007-04-30|January 2006||2006-01-31|||||Interventional|||Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination|A Pilot Safety Study to Determine the Presence of Hepatitis B Virus in Downstream Injection Samples Using the HSI-500 Jet Injector With Protector Cap|Completed||Phase 1|17||PATH|||||f||||||||||||||2018-06-01 04:28:34.685699|2018-06-01 04:28:34.685699
NCT00219440|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-01-22|2005-09-14|2005-09-22|Estimate|||||||2016-01-22|2016-01-25|Estimate|February 2003||2003-02-28|January 2016|2016-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|TAKE II||A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS|A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS|Completed||Phase 4|60|Anticipated|Pennington Biomedical Research Center||3|||f||||t||||||||||2018-06-01 04:28:34.781882|2018-06-01 04:28:34.781882
NCT00219427|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-05-20|2005-09-14|2005-09-22|Estimate|||||||2008-05-20|2008-05-22|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|December 2005|Actual|2005-12-31|November 2005|Actual|2005-11-30||Observational|||Retina Projection System Trials for Low Vision People|Multicenter Clinical Trials of Retina Projection System|Completed|||58|Actual|Osaka City University|||1||f||||t||||||||||2018-06-01 04:28:34.885553|2018-06-01 04:28:34.885553
NCT00219414|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-09-26|2005-09-19|2005-09-22|Estimate|||||||2007-09-26|2007-09-27|Estimate|June 2005||2005-06-30|September 2007|2007-09-30|June 2006||2006-06-30|||||Interventional|||Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205)||Completed||Phase 4|42||Otsuka Frankfurt Research Institute GmbH|||||f||||||||||||||2018-06-01 04:28:34.970955|2018-06-01 04:28:34.970955
NCT00219401|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-07-10|2005-09-16|2005-09-22|Estimate|||||||2011-07-10|2011-07-12|Estimate|May 2005||2005-05-31|July 2011|2011-07-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea|Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea|Completed||Phase 2|318|Actual|Papua New Guinea Institute of Medical Research||3|||f||||t||||||||||2018-06-01 04:28:35.030029|2018-06-01 04:28:35.030029
NCT00219388|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-03-17|2005-09-21|2005-09-22|Estimate|||||||2017-03-17|2017-03-20|Actual|November 2002||2002-11-30|September 2005|2005-09-30|April 2005||2005-04-30|||||Interventional|||Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.|Efficacy and Safety of Short-term Intravenous Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients Treated With Beta-receptor Blocking Agents.|Completed||Phase 4|60||Orion Corporation, Orion Pharma|||||f||||||||||||||2018-06-01 04:28:35.103843|2018-06-01 04:28:35.103843
NCT00218634|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2012-01-03||2017-12-07|2005-09-20|2005-09-22|Estimate|2012-06-22|2012-07-30|Estimate||||2017-12-07|2018-01-02|Actual|February 2005||2005-02-28|December 2017|2017-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1|CBT for Depression & Adherence in HIV Methadone Patients|Completed||N/A|89|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:28:41.317023|2018-06-01 04:28:41.317023
NCT00219375|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-21|2005-09-20|2005-09-22|Estimate|||||||2015-04-21|2015-04-23|Estimate|June 2004||2004-06-30|June 2012|2012-06-30||||July 2007|Actual|2007-07-31||Interventional|||Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan|Efficacy and Safety of Sivelestat Sodium Hydrate in Acute Lung Injury Associated With Systemic Inflammatory Response Syndrome, Compared With the Conventional Treatment in Japan|Completed||Phase 4|649|Actual|Ono Pharmaceutical Co. Ltd||3|||f||||||||||||||2018-06-01 04:28:35.171058|2018-06-01 04:28:35.171058
NCT00219362|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-11-24|2005-09-16|2005-09-22|Estimate|||||||2009-11-24|2009-11-25|Estimate|April 2004||2004-04-30|November 2009|2009-11-30|September 2006|Actual|2006-09-30|November 2005|Actual|2005-11-30||Interventional|MANON 02||Immunogenicity and Safety of 2 Schedules of ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients|A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity and the Safety of 2 Schedules of an Homologous Prime-boost With the ALVAC-HIV vCP1452 in Chronically HIV-Infected Patients|Completed||Phase 2|65|Actual|Objectif Recherche Vaccins SIDA||4|||f||||f||||||||||2018-06-01 04:28:35.246937|2018-06-01 04:28:35.246937
NCT00219349|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-02-29||2017-11-21|2005-09-14|2005-09-22|Estimate|2012-04-11|2012-05-09|Estimate||||2017-11-21|2017-12-19|Actual|January 2005||2005-01-31|November 2017|2017-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)|Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation|Completed||Phase 4|25|Actual|New York State Psychiatric Institute||1|||f||||f||||||||No||2018-06-01 04:28:35.536867|2018-06-01 04:28:35.536867
NCT00219336|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-09-29|2005-09-14|2005-09-22|Estimate|||||||2016-09-29|2016-09-30|Estimate|November 2005||2005-11-30|September 2016|2016-09-30|March 2009|Actual|2009-03-31|July 2008|Actual|2008-07-31||Interventional|||A Media Based Motivational Intervention to Prevent Alcohol Exposed Pregnancies (AEPs)|A Media Based Motivational Intervention to Reduce Alcohol Exposed Pregnancies (AEPs)|Completed||Phase 2|354|Actual|Nova Southeastern University||2|||f||||f||||||||No||2018-06-01 04:28:35.782293|2018-06-01 04:28:35.782293
NCT00219323|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2011-10-24|2005-09-21|2005-09-22|Estimate|||||||2011-10-24|2011-10-25|Estimate|November 2003||2003-11-30|October 2011|2011-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.|Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma|Completed||Phase 3|133|Actual|Novartis|||||f||||||||||||||2018-06-01 04:28:35.875043|2018-06-01 04:28:35.875043
NCT00219310|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2012-04-26|2005-09-21|2005-09-22|Estimate|||||||2012-04-26|2012-04-27|Estimate|June 2003||2003-06-30|April 2012|2012-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir|A Study to Determine the Safety and Efficacy of Famciclovir in the Episodic and Suppressive Treatment of Recurrent Genital Herpes (RGH). The Study Will Also Evaluate Quality of Life and Patient Satisfaction|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 04:28:35.956877|2018-06-01 04:28:35.956877
NCT00219297|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21||2012-05-01|2013-03-14|2005-09-21|2005-09-22|Estimate||||2012-05-01|2012-05-03|Estimate|2013-03-14|2013-03-15|Estimate|November 2005||2005-11-30|March 2013|2013-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer|An Open-label, Multi-center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-small Cell Lung Cancer.|Completed||Phase 2|62|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:28:36.034129|2018-06-01 04:28:36.034129
NCT00219284|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2010-12-07||2017-02-28|2005-09-19|2005-09-22|Estimate|2011-02-16|2011-03-15|Estimate||||2017-02-28|2017-03-30|Actual|January 2005||2005-01-31|February 2017|2017-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease|A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off|Completed||Phase 4|359|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:28:36.202499|2018-06-01 04:28:36.202499
NCT00219271|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-05-28|2005-09-16|2005-09-22|Estimate|||||||2017-05-28|2017-05-31|Actual|September 2003||2003-09-30|May 2017|2017-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer|Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer|Completed||Phase 4|60|Actual|Novartis||1|||f||||||||||||No||2018-06-01 04:28:36.693005|2018-06-01 04:28:36.693005
NCT00219258|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-11-20|2005-09-16|2005-09-22|Estimate|||||||2009-11-20|2009-11-23|Estimate|July 2005||2005-07-31|November 2009|2009-11-30||||||||Interventional|||Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma|A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma|Completed||Phase 3|240||Novartis|||||f||||||||||||||2018-06-01 04:28:36.771495|2018-06-01 04:28:36.771495
NCT00219245|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-11-16|2005-09-14|2005-09-22|Estimate|||||||2011-11-16|2011-11-17|Estimate|November 2002||2002-11-30|November 2011|2011-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits|A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/Day in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits|Completed||Phase 4|157|Actual|Novartis|||||f||||||||||||||2018-06-01 04:28:36.862719|2018-06-01 04:28:36.862719
NCT00219232|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-02-21|2005-09-14|2005-09-22|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2003||2003-02-28|February 2017|2017-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease|An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease|Completed||Phase 3|868|Actual|Novartis|||||f||||||||||||||2018-06-01 04:28:36.921309|2018-06-01 04:28:36.921309
NCT00219219|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-04-13|2005-09-16|2005-09-22|Estimate|||||||2015-04-13|2015-04-14|Estimate|September 2003||2003-09-30|April 2015|2015-04-30|October 2006||2006-10-31|||||Interventional|||Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases|Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 04:28:37.014203|2018-06-01 04:28:37.014203
NCT00219193|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-03|2005-09-14|2005-09-22|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2005||2005-10-31|February 2017|2017-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients|An Eight Week, Multicenter Study to Evaluate Efficacy and Safety of the Triple Combo of Aliskiren /Valsartan/HCTZ (300/320/25 mg), Compared to the Double Combos of Aliskiren/HCTZ (300/25 mg) or Valsartan/HCTZ (320/25 mg) in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg|Completed||Phase 3|641|Actual|Novartis|||||f||||||||||||||2018-06-01 04:28:37.064407|2018-06-01 04:28:37.064407
NCT00219180|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-15|2005-09-14|2005-09-22|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2005||2005-06-30|May 2017|2017-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure|An 8-week Multi-center, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren (150 mg and 300 mg) Administered Alone and in Combination With Valsartan (160 mg and 320 mg) in Patients With Hypertension|Completed||Phase 3|1797|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:37.141569|2018-06-01 04:28:37.141569
NCT00219167|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-16|2005-09-14|2005-09-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2005||2005-04-30|November 2016|2016-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure|An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference|Completed||Phase 3|355|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:37.208494|2018-06-01 04:28:37.208494
NCT00219154|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-14|2005-09-22|Estimate|||||||2011-11-07|2011-11-08|Estimate|March 2005||2005-03-31|November 2011|2011-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine|A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension|Completed||Phase 3|1125|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:37.281901|2018-06-01 04:28:37.281901
NCT00219141|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-01-11||2011-05-20|2005-09-14|2005-09-22|Estimate|2011-04-15|2011-05-10|Estimate||||2011-05-20|2011-05-26|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|ALLAY||Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension|A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension|Completed||Phase 3|460|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:28:37.49844|2018-06-01 04:28:37.49844
NCT00219128|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-14|2005-09-22|Estimate|||||||2011-11-07|2011-11-08|Estimate|November 2004||2004-11-30|June 2006|2006-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.|An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension|Completed||Phase 3|671|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:38.218294|2018-06-01 04:28:38.218294
NCT00219115|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-03|2005-09-14|2005-09-22|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 2005||2005-01-31|February 2017|2017-02-28|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg|A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Responsive to HCTZ 25 mg|Completed||Phase 3|493|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:38.300422|2018-06-01 04:28:38.300422
NCT00219102|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-24|2005-09-14|2005-09-22|Estimate|||||||2011-02-24|2011-02-25|Estimate|June 2005||2005-06-30|February 2011|2011-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients|A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 mg|Completed||Phase 3|336||Novartis|||||f||||||||||||||2018-06-01 04:28:38.447988|2018-06-01 04:28:38.447988
NCT00219089|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-15|2005-09-14|2005-09-22|Estimate|||||||2017-05-15|2017-05-17|Actual|November 2004||2004-11-30|May 2017|2017-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.|An Eight-week, Randomized, Double-blind, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Ramipril in Patients With Hypertension and Diabetes Mellitus|Completed||Phase 3|839|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:38.513963|2018-06-01 04:28:38.513963
NCT00219076|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-16|2005-09-14|2005-09-22|Estimate|||||||2017-05-16|2017-05-18|Actual|February 2005||2005-02-28|May 2017|2017-05-31||||October 2005|Actual|2005-10-31||Interventional|||A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients|A Six-week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren 150 mg and Amlodipine 5 mg Compared to Amlodipine 5 mg and 10 mg in Hypertensive Patients Not Adequately Responsive to Amlodipine 5 mg|Completed||Phase 3|504||Novartis|||||f||||||||||||||2018-06-01 04:28:38.581471|2018-06-01 04:28:38.581471
NCT00219063|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-15|2005-09-14|2005-09-22|Estimate|||||||2017-05-15|2017-05-17|Actual|February 2005||2005-02-28|May 2017|2017-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.|A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patients With Essential Hypertension|Completed||Phase 3|844|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:38.657879|2018-06-01 04:28:38.657879
NCT00219050|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-24|2005-09-14|2005-09-22|Estimate|||||||2011-02-24|2011-02-25|Estimate|February 2005||2005-02-28|February 2011|2011-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension|An Eight-week, Randomized, Double-blind, Multi-center, Active-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of an Aliskiren-based Regimen Compared to a Lisinopril-based Regimen in Patients With Uncomplicated Severe Hypertension|Completed||Phase 3|180||Novartis|||||f||||||||||||||2018-06-01 04:28:38.735812|2018-06-01 04:28:38.735812
NCT00219037|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-14|2005-09-22|Estimate|||||||2011-11-07|2011-11-08|Estimate|June 2004||2004-06-30|June 2006|2006-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension|A 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long Term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.|Completed||Phase 3|1955|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:38.797083|2018-06-01 04:28:38.797083
NCT00219024|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-15|2005-09-14|2005-09-22|Estimate|||||||2017-05-15|2017-05-17|Actual|August 2004||2004-08-31|May 2017|2017-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.|An 8 Week Double-blind, Multicenter, Randomized, Multifactorial, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension|Completed||Phase 3|2775|Actual|Novartis|||||||||||||||||||2018-06-01 04:28:38.859248|2018-06-01 04:28:38.859248
NCT00219011|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-15|2005-09-14|2005-09-22|Estimate|||||||2017-05-15|2017-05-17|Actual|May 2005||2005-05-31|May 2017|2017-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||"ALOFT - Aliskiren Observation of Heart Failure Treatment: Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure"|A Twelve-week, Randomized, Double-blind, Multi-center, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Aliskiren 150 mg When Added to Standard Therapy in Hypertensive Patients With Stable Heart Failure|Completed||Phase 3|280||Novartis|||||f||||||||||||||2018-06-01 04:28:38.962597|2018-06-01 04:28:38.962597
NCT00218998|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-03-29|2005-09-20|2005-09-22|Estimate|||||||2017-03-29|2017-03-31|Actual|January 2004|Actual|2004-01-31|March 2017|2017-03-31||||||||Interventional|||Effective Endurance Training in Metabolic Syndrome|Effective Endurance Training in Metabolic Syndrome|Completed||N/A|30|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-06-01 04:28:39.055065|2018-06-01 04:28:39.055065
NCT00218985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2018-02-16|2005-09-20|2005-09-22|Estimate|||||||2018-02-16|2018-02-20|Estimate|January 2005|Actual|2005-01-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Exercise-training Before Coronary Artery Bypass Graft (CABG)|Exercise-training Before Coronary Artery Bypass Graft (CABG)|Completed||N/A|40|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:28:39.109068|2018-06-01 04:28:39.109068
NCT00218972|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-12-05|2005-09-20|2005-09-22|Estimate|||||||2013-12-05|2013-12-06|Estimate|February 2005||2005-02-28|December 2013|2013-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Physical Exercise in Hypertension, Randomised Clinical Trial|Physical Exercise in Hypertension, Randomised Clinical Trial|Completed||N/A|88|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-06-01 04:28:39.178152|2018-06-01 04:28:39.178152
NCT00218959|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-01-25|2005-09-20|2005-09-22|Estimate|||||||2017-01-25|2017-01-27|Estimate|September 2005||2005-09-30|January 2017|2017-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees|Randomized Controlled Trial of Narrative Exposure Therapy Compared to Treatment as Usual for Traumatized Refugees and Asylum Seekers in Mid-Norway|Completed||N/A|81|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:28:39.281354|2018-06-01 04:28:39.281354
NCT00218946|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2015-04-07|2005-09-20|2005-09-22|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2005||2005-01-31|April 2015|2015-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Nasogastric Tube in Premature Babies - Pain and Treatment|Nasogastric Tube in Premature Babies - Pain and Treatment. A Randomised, Partly Blinded, Placebo-controlled Factorial Clinical Trial of Sucrose and Pacifier|Completed||Phase 2|24|Actual|Norwegian University of Science and Technology||6|||f||||f||||||||||2018-06-01 04:28:39.360279|2018-06-01 04:28:39.360279
NCT00218933|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-02-07|2005-09-20|2005-09-22|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2001|Actual|2001-10-31|February 2017|2017-02-28|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||High-intensity Exercise Training in Patients With Post-infarction Heart Failure|Anti-remodeling Effect of High-intensity Interval Training in Patients With Post-infarction Heart Failure on Optimal Treatment|Completed||N/A|27|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-06-01 04:28:39.433265|2018-06-01 04:28:39.433265
NCT00218920|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-10-13|2005-09-20|2005-09-22|Estimate|||||||2017-10-13|2017-10-16|Actual|September 2005|Actual|2005-09-30|October 2017|2017-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effective Training in Overweight and Obese People|Effective Training in Overweight and Obesity|Completed||N/A|40|Actual|Norwegian University of Science and Technology||3|||f|||||f|f||||||||2018-06-01 04:28:39.500525|2018-06-01 04:28:39.500525
NCT00218907|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2005-10-21|2005-09-19|2005-09-22|Estimate|||||||2005-10-21|2005-10-25|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|August 2003||2003-08-31|||||Interventional|||An Educational HIV Pre-Test Counseling Video Program for Off Hours Testing in the ED: A Randomized Control Trial|An Educational HIV Pre-Test Counseling Video Program for Off Hours Testing in the ED: A Randomized Control Trial|Terminated||N/A|130||North Bronx Healthcare Network|||||f||||||||||||||2018-06-01 04:28:39.591279|2018-06-01 04:28:39.591279
NCT00218894|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-01-16|2005-09-20|2005-09-22|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2004||2004-01-31|January 2017|2017-01-31|December 2009|Actual|2009-12-31|March 2008|Actual|2008-03-31||Observational|||The Influence of Vision on Balance, Gait and Falls|The Effect of Cataract Surgery on Gait, Balance and Falls in Older Persons|Completed|||148|Actual|Norwegian University of Science and Technology|||1||f||||f||||||||||2018-06-01 04:28:39.709365|2018-06-01 04:28:39.709365
NCT00218881|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2005-10-21|2005-09-19|2005-09-22|Estimate|||||||2005-10-21|2005-10-25|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|July 2004||2004-07-31|||||Interventional|||An Effective Alternative to the Standard Referral System for HIV Testing in the Emergency Department During Off Hour Tours: A Randomized Trial|An Effective Alternative to the Standard Referral System for HIV Testing in the ED|Completed||N/A|408||North Bronx Healthcare Network|||||f||||||||||||||2018-06-01 04:28:39.811504|2018-06-01 04:28:39.811504
NCT00218868|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-02-09|2005-09-20|2005-09-22|Estimate|||||||2012-02-09|2012-02-13|Estimate|January 2000||2000-01-31|February 2012|2012-02-29|November 2007|Actual|2007-11-30|February 2006|Actual|2006-02-28||Observational|||Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear|Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunvald-giemsa Stained Cutaneous Tissue Smear in Relation to Photodynamic Therapy|Completed|||66|Actual|Norwegian University of Science and Technology|||1||f||||f||||||||||2018-06-01 04:28:39.864941|2018-06-01 04:28:39.864941
NCT00218855|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-03-06|2005-09-20|2005-09-22|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2002||2002-01-31|March 2014|2014-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Thalidomide to Patients With Previously Untreated Multiple Myeloma|A Phase 3 Study With Randomization to Melphalan/Prednisone/Thalidomide Versus Melphalan/Prednisone/Placebo to Patients With Previously Untreated Multiple Myeloma|Completed||Phase 3|363|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:28:39.941546|2018-06-01 04:28:39.941546
NCT00218842|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-03-06|2005-09-20|2005-09-22|Estimate|||||||2014-03-06|2014-03-07|Estimate|October 2005||2005-10-31|March 2014|2014-03-31|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Interventional|||The Effect on Function of Increasing Activity for Nursing Home Residents|Physical and Daily Activity for Residents in a Nursing Home Setting. -A Nordic Multi-Centre Study|Completed||N/A|125|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:28:40.020784|2018-06-01 04:28:40.020784
NCT00218829|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-03-10|2005-09-20|2005-09-22|Estimate|||||||2017-03-10|2017-03-14|Actual|September 1997|Actual|1997-09-30|March 2017|2017-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||DMSO-PDT of BCC - A 6 Year Follow up|Dimethylsulphoxide-supported Photodynamic Therapy of Basal Cell Carcinoma Combined With Curettage - A 6 Year Clinical and Histological Evaluation.|Completed|||44|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||No||2018-06-01 04:28:40.088603|2018-06-01 04:28:40.088603
NCT00218816|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-09-03|2005-09-20|2005-09-22|Estimate|||||||2008-09-03|2008-09-05|Estimate|August 2000||2000-08-31|September 2008|2008-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Nebulizer Intervention for Minority Children With Asthma|Nebulizer Intervention for Minority Children With Asthma|Completed||Phase 3|221|Actual|National Institute of Nursing Research (NINR)||2|||f||||t||||||||||2018-06-01 04:28:40.134366|2018-06-01 04:28:40.134366
NCT00218803|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-09-03|2005-09-20|2005-09-22|Estimate|||||||2008-09-03|2008-09-05|Estimate|August 2000||2000-08-31|September 2008|2008-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Teaching Children With Asthma and Who Live in a Rural Setting How to Self-Manage Their Asthma|A+ Asthma Rural Partnership|Completed||Phase 3|220|Actual|National Institute of Nursing Research (NINR)||2|||f||||t||||||||||2018-06-01 04:28:40.381245|2018-06-01 04:28:40.381245
NCT00218790|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2014-02-10|2005-09-16|2005-09-22|Estimate|||||||2014-02-10|2014-02-12|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||"The Effects of Cool Dialysate on the Sleep/Wake Cycle in Patients on Chronic Hemodialysis - The Sleep Cool Study"|The Effects of Hemodialysis on the Sleep/Wake Cycle|Completed||N/A|58|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:28:40.466014|2018-06-01 04:28:40.466014
NCT00218777|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2015-12-10|2005-09-21|2005-09-22|Estimate|||||||2015-12-10|2015-12-14|Estimate|December 2004||2004-12-31|December 2015|2015-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|CBIT||Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children|Behavior Therapy for Children With Chronic Tic Disorders|Completed||Phase 2/Phase 3|120|Anticipated|Tourette Association of America|||||f||||||||||||||2018-06-01 04:28:40.545696|2018-06-01 04:28:40.545696
NCT00218751|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-09-23|2005-09-16|2005-09-22|Estimate|||||||2013-09-23|2013-09-24|Estimate|March 2000||2000-03-31|February 2008|2008-02-29|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Early Home Visitation Program to Promote Good Health and Development in Children at Risk for Abuse|Promoting Child Mental Health: RCT of Home Visiting|Completed||Phase 2/Phase 3|1122||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:28:40.614821|2018-06-01 04:28:40.614821
NCT00218725|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2015-09-28|2005-09-21|2005-09-22|Estimate|||||||2015-09-28|2015-09-29|Estimate|May 2005||2005-05-31|September 2015|2015-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effectiveness of Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder|Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder|Completed||Phase 1|2|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 04:28:40.681872|2018-06-01 04:28:40.681872
NCT00218712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-04-30|2005-09-16|2005-09-22|Estimate|||||||2012-04-30|2012-05-02|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Specialized Cognitive-Behavioral Counseling Intervention to Reduce HIV Transmission Risk Behavior in HIV-Infected Men|Reducing HIV Transmission Risk Behavior: a Trial of a Two Session Risk-Reduction Intervention With HIV-Positive Men Who Have Sex With Men|Completed||N/A|488|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:28:40.752628|2018-06-01 04:28:40.752628
NCT00218699|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-08-02|2005-09-16|2005-09-22|Estimate|||||||2013-08-02|2013-08-05|Estimate|August 2002||2002-08-31|August 2013|2013-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Pre-HIV Test Counseling Intervention to Reduce HIV Infection Risk Behavior in Men Who Are Not HIV Infected|Changing Sexual Behavior in Gay Male Repeat HIV Testers: A Randomized Trial of a Single Session Counseling Intervention|Completed||N/A|300|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 04:28:40.821165|2018-06-01 04:28:40.821165
NCT00218686|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-08-31|2005-09-20|2005-09-22|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2003||2003-01-31|August 2015|2015-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Network Intervention for Prevention of HIV Infection in Chennai, India - 1|Supplement to the Long-term Impact of a Network Outreach Intervention|Withdrawn||Phase 2|0|Actual|Johns Hopkins Bloomberg School of Public Health||2||In ability to obtain Indian governmental approval from the study from NACO|f||||f||||||||||2018-06-01 04:28:40.984059|2018-06-01 04:28:40.984059
NCT00218673|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2016-05-11|2005-09-20|2005-09-22|Estimate|||||||2016-05-11|2016-05-13|Estimate|October 2003||2003-10-31|May 2016|2016-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||RCT of Russian IDU Peer Network HIV Prevention Intervention - 1|Randomized Controlled Trial of Russian IDU Peer Network HIV Prevention Intervention|Completed||Phase 3|400|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||||||||||||2018-06-01 04:28:41.099995|2018-06-01 04:28:41.099995
NCT00218660|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2015-10-21|2005-09-20|2005-09-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 1998||1998-04-30|June 2010|2010-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1|Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence|Completed||Phase 3|164|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 04:28:41.19705|2018-06-01 04:28:41.19705
NCT00218621|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-02-20|2005-09-20|2005-09-22|Estimate|||||||2013-02-20|2013-02-21|Estimate|September 2005||2005-09-30|February 2013|2013-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||The Effects of Methadone and Buprenorphine on Fetal Neurobehavior and Infant Neonatal Abstinence Syndrome - 1|Maternal Buprenorphine Administration and Fetal/Infant Neurobehavior|Completed|||20|Actual|Johns Hopkins University|||||f||||t||||||||||2018-06-01 04:28:41.767305|2018-06-01 04:28:41.767305
NCT00218608|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-01-26|2005-09-20|2005-09-22|Estimate|||||||2012-01-26|2012-01-31|Estimate|April 2001||2001-04-30|January 2012|2012-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone|Disulfiram for Cocaine Abuse in Methadone- Patients|Completed||Phase 2|158|Actual|University of Arkansas||4|||f||||t||||||||||2018-06-01 04:28:41.832665|2018-06-01 04:28:41.832665
NCT00218595|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-07-31|2005-09-20|2005-09-22|Estimate|||||||2014-07-31|2014-08-01|Estimate|August 2004||2004-08-31|January 2013|2013-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients. - 1|Evaluation of Dialectical Behavior Therapy in Treatment of Opioid Addiction and Emotional Problems|Completed||N/A|39|Actual|Duke University||2|||f||||t||||||||||2018-06-01 04:28:41.907762|2018-06-01 04:28:41.907762
NCT00218582|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-01-11|2005-09-20|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2003||2003-03-31|October 2008|2008-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effectiveness of Self-Help for Dually-Diagnosed Persons - 1|Effectiveness of Self-Help for Dually-Diagnosed Persons|Completed||Phase 1/Phase 2|229|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:28:41.979019|2018-06-01 04:28:41.979019
NCT00218569|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2016-01-25|2005-09-20|2005-09-22|Estimate|||||||2016-01-25|2016-01-27|Estimate|April 2003||2003-04-30|January 2016|2016-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Combined Treatment for Cocaine-Alcohol Dependence - 1|Combined Treatment for Cocaine-Alcohol Dependence|Completed||Phase 2|87|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 04:28:42.04447|2018-06-01 04:28:42.04447
NCT00218556|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-01-11|2005-09-20|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|October 2015|2015-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1|Preventing Depression in MMT Patients on Interferon|Completed||N/A|42|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||||||||||||2018-06-01 04:28:42.112099|2018-06-01 04:28:42.112099
NCT00218543|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2012-01-12||2018-05-10|2005-09-20|2005-09-22|Estimate|2012-06-25|2012-07-04|Estimate||||2018-05-10|2018-05-15|Actual|June 2004||2004-06-30|May 2018|2018-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|Atom||Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial|Completed||Phase 2|20|Actual|New York State Psychiatric Institute|Clearly, there are limitations of this study including the high drop-out rate, small sample size, and lack of a control group.|1|||f||||t||||||||||2018-06-01 04:28:42.18023|2018-06-01 04:28:42.18023
NCT00218530|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2003||2003-03-31|October 2016|2016-10-31|September 2004||2004-09-30|||||Interventional|||Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1|Naltrexone and Lofexidine in Detoxified Heroin Addicts|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:28:42.423411|2018-06-01 04:28:42.423411
NCT00218517|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1|Selegiline for Treatment of Cannabis Dependence|Completed||Phase 2|19|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 04:28:42.511906|2018-06-01 04:28:42.511906
NCT00218504|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-06-01|2005-09-16|2005-09-22|Estimate|||||||2012-06-01|2012-06-05|Estimate|December 2005||2005-12-31|June 2012|2012-06-30|October 2009|Actual|2009-10-31|||||Observational|||Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2|Cue Reactivity Model for Assessing Pharmacologic Intervention in Treatment of Cannabis Use Disorders (Study 2)|Completed|||20|Anticipated|Wayne State University|||||f||||||||||||||2018-06-01 04:28:42.744627|2018-06-01 04:28:42.744627
NCT00218491|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-11-07|2005-09-16|2005-09-22|Estimate|||||||2011-11-07|2011-11-09|Estimate|November 2005||2005-11-30|September 2010|2010-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|NAC||Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1|A Controlled Trial of N-Acetylcysteine (NAC) for Cocaine Dependence|Completed||Phase 2|235|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-06-01 04:28:42.805581|2018-06-01 04:28:42.805581
NCT00218478|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-06-01|2005-09-16|2005-09-22|Estimate|||||||2012-06-01|2012-06-05|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|July 2008|Actual|2008-07-31|||||Observational|||Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1|Cue Reactivity Model for Assessing Pharmacologic Intervention in Treatment of Cannabis Use Disorders (Study 1)|Completed|||15|Anticipated|Wayne State University|||||f||||||||||||||2018-06-01 04:28:42.885904|2018-06-01 04:28:42.885904
NCT00218465|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2010-08-02||2017-03-22|2005-09-16|2005-09-22|Estimate|2010-11-23|2010-12-20|Estimate||||2017-03-22|2017-03-24|Actual|August 2006||2006-08-31|March 2017|2017-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking|A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking|Completed||Phase 2|264|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:28:42.963599|2018-06-01 04:28:42.963599
NCT00218452|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-04-06|2005-09-16|2005-09-22|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Smoking Cessation for Young Adults Who Binge Drink - 1|Smoking Cessation for Young Adults Who Binge Drink|Completed||Early Phase 1|41|Actual|Mayo Clinic||1|||f||||f||||||||||2018-06-01 04:28:43.244435|2018-06-01 04:28:43.244435
NCT00218439|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2013-10-29||2015-07-28|2005-09-16|2005-09-22|Estimate|2014-04-28|2014-05-23|Estimate||||2015-07-28|2015-08-18|Estimate|October 2005||2005-10-31|July 2015|2015-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional||Includes subjects who completed both laboratory sessions (n=62). One additional subject completed both laboratory sessions but did not have usable measures in the primary outcomes (cardiovascular measures) and was excluded|Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1|Smoking, Antidepressants, and Response to Mental Stress|Completed||N/A|105|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||||||||||||2018-06-01 04:28:43.376835|2018-06-01 04:28:43.376835
NCT00218426|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2018-02-23|2005-09-16|2005-09-22|Estimate|||||||2018-02-23|2018-02-26|Actual|July 2006|Actual|2006-07-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|July 2017|Actual|2017-07-31||Interventional|||Addiction Treatment in Russia: Oral vs. Naltrexone Implant|Addiction Treatment in Russia: Oral and Depot Naltrexone|Active, not recruiting||Phase 2/Phase 3|306|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-06-01 04:28:43.657905|2018-06-01 04:28:43.657905
NCT00218413|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2004||2004-10-31|November 2008|2008-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals|A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers|Completed||Phase 2|51|Actual|National Institute on Drug Abuse (NIDA)||5|||f||||f||||||||||2018-06-01 04:28:43.720265|2018-06-01 04:28:43.720265
NCT00218387|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-11-07|2005-09-16|2005-09-22|Estimate|||||||2011-11-07|2011-11-09|Estimate|April 2004||2004-04-30|September 2010|2010-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1|CBT and Modafinil for Cocaine Addiction|Completed||Phase 2|326|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-06-01 04:28:43.800983|2018-06-01 04:28:43.800983
NCT00218374|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2006||2006-10-31|August 2008|2008-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia|Hyperalgesia in Methadone Patients: Can it be Treated?|Completed||N/A|60|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:28:43.86477|2018-06-01 04:28:43.86477
NCT00218361|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-06-01|2005-09-16|2005-09-22|Estimate|||||||2012-06-01|2012-06-05|Estimate|August 2005||2005-08-31|June 2012|2012-06-30||||||||Observational|||Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals|Biobehavioral Study of Opioid Drug Seeking Behavior: Study 2|Completed|||16|Anticipated|Wayne State University|||||f||||||||||Samples With DNA|"~     Whole Blood~   "|||2018-06-01 04:28:43.918617|2018-06-01 04:28:43.918617
NCT00218348|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-12-16|2005-09-16|2005-09-22|Estimate|||||||2017-12-16|2017-12-19|Actual|September 2003||2003-09-30|December 2017|2017-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo|Pharmacotherapy for Cocaine Dependence - 1|Completed||Phase 2|186|Actual|The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:28:43.972349|2018-06-01 04:28:43.972349
NCT00218335|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2013-01-25||2013-03-07|2005-09-16|2005-09-22|Estimate|2013-03-07|2013-04-18|Estimate||||2013-03-07|2013-04-18|Estimate|June 2003||2003-06-30|March 2013|2013-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Network & Dyad HIV Prevention Intervention for IDU's - 1|A Network & Dyad HIV Prevention Intervention for IDU's|Completed||Phase 2|1024|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 04:28:45.10916|2018-06-01 04:28:45.10916
NCT00218322|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-11-06|2005-09-16|2005-09-22|Estimate|||||||2012-11-06|2012-11-07|Estimate|September 2004||2004-09-30|November 2012|2012-11-30|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Effectiveness of ATMX in Treating Adolescents With ADHD and SUD|Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD)|Completed||Phase 4|108|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:28:45.645243|2018-06-01 04:28:45.645243
NCT00218309|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2003||2003-09-30|May 2006|2006-05-31|July 2005||2005-07-31|||||Observational|||Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals|Biobehavioral Studies of Opioid Drug Seeking Behavior: Study 1|Completed|||16||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:28:45.718757|2018-06-01 04:28:45.718757
NCT00218296|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2013-10-29||2017-09-13|2005-09-16|2005-09-22|Estimate|2013-10-29|2013-12-19|Estimate||||2017-09-13|2017-10-16|Actual|November 2006||2006-11-30|September 2017|2017-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users|Completed||Phase 2|332|Actual|University of Minnesota - Clinical and Translational Science Institute|Sample size was limited.|2|||f||||t||||||||||2018-06-01 04:28:45.79132|2018-06-01 04:28:45.79132
NCT00218283|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-09|2005-09-16|2005-09-22|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Nicotine Lozenge to Reduce Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users|Completed||Phase 2|100|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 04:28:46.267273|2018-06-01 04:28:46.267273
NCT00218270|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-09|2005-09-16|2005-09-22|Estimate|||||||2017-01-09|2017-01-10|Estimate|December 2002||2002-12-31|June 2008|2008-06-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users|Completed||Phase 2|138|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 04:28:46.353826|2018-06-01 04:28:46.353826
NCT00218257|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-11-16|2005-09-16|2005-09-22|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2002||2002-07-31|November 2015|2015-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Progesterone for the Treatment of Cocaine Dependence - 1|Interactions Between Progesterone and Cocaine in Women|Completed||N/A|36|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 04:28:46.472823|2018-06-01 04:28:46.472823
NCT00218244|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-09|2005-09-16|2005-09-22|Estimate|||||||2017-01-09|2017-01-10|Estimate|August 2001||2001-08-31|June 2008|2008-06-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|Brandswitch||Using Smokeless Tobacco Products With Lower Nicotine Levels to Reduce Negative Effects of Smokeless Tobacco Use|Treatment of Smokeless Tobacco Users: Use of Nicotine Replacement Products to Reduce Smokeless Tobacco Use|Completed||Phase 1/Phase 2|56|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 04:28:46.552663|2018-06-01 04:28:46.552663
NCT00218231|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia|Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)|Completed||Phase 2|48|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:28:46.645655|2018-06-01 04:28:46.645655
NCT00218218|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2002||2002-06-30|August 2008|2008-08-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia|Transdermal Nicotine and Bupropion for Smoking in Schizophrenics (Study 1)|Completed||Phase 2|48|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||f||||||||||2018-06-01 04:28:46.754702|2018-06-01 04:28:46.754702
NCT00218205|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-09-20|2005-09-20|2005-09-22|Estimate|||||||2005-09-20|2005-09-22|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer|A Phase II Trial of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Hormone Resistant Prostate Cancer (HRPC)|Unknown status|Recruiting|Phase 2|28||Department of Veterans Affairs, New Jersey|||||||||||||||||||2018-06-01 04:28:46.849959|2018-06-01 04:28:46.849959
NCT00218192|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-05-21|2005-09-16|2005-09-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2000||2000-09-30|April 2013|2013-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Trial to Reduce Hepatitis C Among Injection Drug Users - 1|A Trial to Reduce Hepatitis C Among Injection Drug Users|Completed||Phase 3|277|Actual|Butler Hospital|||||f||||f||||||||||2018-06-01 04:28:46.917327|2018-06-01 04:28:46.917327
NCT00218179|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-19|2005-09-16|2005-09-22|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2005||2005-09-30|January 2017|2017-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1|Prostate, Lung, Colon, and Ovarian Cancer (PLCO) Screen Trial|Completed|||200|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-06-01 04:28:46.976143|2018-06-01 04:28:46.976143
NCT00218166|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-10|2005-09-16|2005-09-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2001||2001-08-31|October 2016|2016-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine|GABA Agonists as Pharmacotherapies for Cocaine Abuse|Completed||Phase 2|78|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||f||||||||||2018-06-01 04:28:47.05457|2018-06-01 04:28:47.05457
NCT00218153|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2000||2000-11-30|September 2005|2005-09-30|April 2004||2004-04-30|||||Interventional|||Naltrexone Augmentation of Nicotine Patch Therapy - 1|Naltrexone Augmentation of Nicotine Patch Therapy|Completed||Phase 3|200||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:28:47.140956|2018-06-01 04:28:47.140956
NCT00218140|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate||||October 2016|2016-10-31|April 2005||2005-04-30|||||Interventional|||Effectiveness of the Nicotine Patch in Suppressing Nicotine Withdrawal Symptoms in Women Versus Men - 1|Effects of Nicotine Patch in Men and Women|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:28:47.282648|2018-06-01 04:28:47.282648
NCT00218127|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2001||2001-11-30|October 2016|2016-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens|Opioid Maintenance: Optimum Stabilization and Withdrawal|Completed||Phase 2|142|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 04:28:47.349002|2018-06-01 04:28:47.349002
NCT00218114|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-08-08|2005-09-16|2005-09-22|Estimate|||||||2017-08-08|2017-08-10|Actual|February 2000|Actual|2000-02-29|August 2017|2017-08-31|February 18, 2005|Actual|2005-02-18|February 18, 2005|Actual|2005-02-18||Interventional|||Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults|Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents|Completed||Phase 3|25|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 04:28:47.43224|2018-06-01 04:28:47.43224
NCT00218101|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2004||2004-05-31|October 2016|2016-10-31|March 2005||2005-03-31|||||Interventional|||Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids|Dose Reduction Strategies in Oral Opioid Dependence Subsequent to Pain Management: An Exploratory Study|Completed||Phase 2|10||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:28:47.517733|2018-06-01 04:28:47.517733
NCT00218075|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2016-01-04|2005-09-16|2005-09-22|Estimate|||||||2016-01-04|2016-01-05|Estimate|March 2000||2000-03-31|January 2016|2016-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence|Behavioral Strategies to Maximize the Efficacy of Pharmacotherapy for Cocaine Dependence: Relapse Prevention With Contingency Management Procedures|Completed||Phase 2|200||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:28:47.57984|2018-06-01 04:28:47.57984
NCT00218062|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2017-05-24||2017-05-24|2005-09-16|2005-09-22|Estimate|2017-05-24|2017-06-21|Actual||||2017-05-24|2017-06-21|Actual|March 2006||2006-03-31|May 2017|2017-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals|Pharmacotherapy Dosing Regimen (Cocaine Dependence Population)|Completed||Phase 2|73|Actual|The University of Texas Health Science Center, Houston|High attrition; Pill-taking burden (3 capsules daily) contributed to medication non-compliance; Small sample size.|4|||f||||t|t|f|||f|||||2018-06-01 04:28:47.673358|2018-06-01 04:28:47.673358
NCT00218049|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals|Phase 1, Double-blind, Placebo-controlled Assessment of Interactions Between 2 Doses of Cocaine and Three Doses of Escalating Vanoxerine (GBR 12909) in Cocaine Using Volunteers|Terminated||Phase 1|3|Actual|National Institute on Drug Abuse (NIDA)||3||Issue of priority of resources|f||||t||||||||||2018-06-01 04:28:48.173972|2018-06-01 04:28:48.173972
NCT00218036|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-12-11|2005-09-16|2005-09-22|Estimate|||||||2009-12-11|2009-12-15|Estimate|July 2006||2006-07-31|December 2009|2009-12-31|July 2011|Anticipated|2011-07-31|July 2010|Anticipated|2010-07-31||Interventional|||Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8|Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals|Unknown status|Recruiting|Phase 2|200|Anticipated|National Institute on Drug Abuse (NIDA)||5|||f||||t||||||||||2018-06-01 04:28:48.277075|2018-06-01 04:28:48.277075
NCT00218023|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2017-02-23||2017-05-11|2005-09-16|2005-09-22|Estimate|2017-02-23|2017-04-07|Actual||||2017-05-11|2017-06-09|Actual|March 2006||2006-03-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Medications for Stopping Cocaine Dependence and Preventing Relapse|Screening Medications for Cocaine Cessation and Relapse Prevention|Completed||Phase 2|101|Actual|The University of Texas Health Science Center, Houston|The sample size was small; however, the main aim of the study was achieved (i.e., to evaluate the feasibility of using a two-phase abstinence induction paradigm to screen candidate medications for cocaine treatment).|4|||f||||t|t|f|||f|||||2018-06-01 04:28:48.399366|2018-06-01 04:28:48.399366
NCT00218010|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2000||2000-11-30|April 2015|2015-04-30|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Observational|||Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2|Breastfeeding Among Methadone Maintained Women|Completed|||25|Actual|National Institute on Drug Abuse (NIDA)|||1||f||||f||||||||||2018-06-01 04:28:48.754698|2018-06-01 04:28:48.754698
NCT00217997|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-05-05|2005-09-16|2005-09-22|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2005||2005-09-30|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals|Impulsivity, Brain Function and Substance Abuse Treatment|Completed|||192|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-06-01 04:28:48.823004|2018-06-01 04:28:48.823004
NCT00217984|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-10-30|2005-09-16|2005-09-22|Estimate|||||||2017-10-30|2017-11-01|Actual|July 2006||2006-07-31|October 2017|2017-10-31|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Intensive Intervention for Smokers - 6|Intensive Intervention for Smokers in Alcohol Treatment|Completed||N/A|162|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:28:48.880255|2018-06-01 04:28:48.880255
NCT00217971|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2011-09-13||2018-05-10|2005-09-16|2005-09-22|Estimate|2011-10-19|2011-11-01|Estimate||||2018-05-10|2018-05-15|Actual|March 2005||2005-03-31|May 2018|2018-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MARINOL||Dronabinol Treatment for Marijuana Addiction|A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction|Completed||Phase 2|156|Actual|New York State Psychiatric Institute|Consequences of use are often long-term and more subtle. Thus, trying to initiate change over a relatively short period (i.e. patients in the present trial were maintained on the maximum dronabinol dose for only 6 weeks), may have been inadequate.|2|||f||||t||||||||||2018-06-01 04:28:48.948779|2018-06-01 04:28:48.948779
NCT00217958|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2014-10-27|2005-09-19|2005-09-22|Estimate|||||||2014-10-27|2014-10-28|Estimate|May 2002||2002-05-31|October 2014|2014-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Better Asthma Outcomes: Lowering Tobacco Smoke Exposure||Completed||N/A|||Palo Alto Medical Foundation|||||f||||||||||||||2018-06-01 04:28:49.210637|2018-06-01 04:28:49.210637
NCT00217945|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2016-07-28|2005-09-19|2005-09-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Does Shared Decision-Making Improve Adherence in Asthma||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:28:49.293664|2018-06-01 04:28:49.293664
NCT00217932|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-01-11|2005-09-16|2005-09-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2000||2000-09-30|April 2006|2006-04-30|August 2005||2005-08-31|||||Interventional|||Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings|Double-Blind, Placebo-Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings|Completed||Phase 2|15||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:28:49.471314|2018-06-01 04:28:49.471314
NCT00217919|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2014-04-07|2005-09-21|2005-09-22|Estimate|||||||2014-04-07|2014-04-09|Estimate|February 2006||2006-02-28|April 2014|2014-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Reducing Risk Factors in Peripheral Arterial Disease|Reducing Risk Factors in Peripheral Arterial Disease|Completed||N/A|355|Actual|Northwestern University||2|||f||||t||||||||||2018-06-01 04:28:49.560537|2018-06-01 04:28:49.560537
NCT00217906|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2016-02-17|2005-09-19|2005-09-22|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 1999||1999-10-31|December 2005|2005-12-31|March 2004|Actual|2004-03-31|||||Interventional|||A+ Asthma Early Intervention in Asthma Management||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:28:49.641207|2018-06-01 04:28:49.641207
NCT00217893|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-10-22|2005-09-19|2005-09-22|Estimate|||||||2013-10-22|2013-10-24|Estimate|February 2003||2003-02-28|October 2013|2013-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Environmental Tobacco Smoke Exposure Reduction in High-Risk Preteens|ETS Reduction in High-Risk Preteens: A Controlled Trial|Completed||N/A|203|Actual|San Diego State University||2|||f||||t||||||||||2018-06-01 04:28:49.72312|2018-06-01 04:28:49.72312
NCT00217880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-08-16|2005-09-19|2005-09-22|Estimate|||||||2013-08-16|2013-08-19|Estimate|July 2004||2004-07-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory Disease|Prognostic Significance of Biological Markers in Patients With ALI/ARDS|Completed||N/A|40|Actual|University of Michigan|||||f||||t||||||||||2018-06-01 04:28:49.815045|2018-06-01 04:28:49.815045
NCT00217867|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2017-07-26|2005-09-19|2005-09-22|Estimate|||||||2017-07-26|2017-07-28|Actual|October 2008||2008-10-31|July 2017|2017-07-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Educational and Supportive Interventions to Prevent Cardiopulmonary Rehospitalization|A RCT to Reduce Cardiopulmonary Rehospitalization|Completed||N/A|832|Actual|Boston Medical Center||2|||f||||t|f|f||||||||2018-06-01 04:28:49.896815|2018-06-01 04:28:49.896815
NCT00217854|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2017-06-23|2005-09-19|2005-09-22|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2001||2001-09-30|June 2017|2017-06-30|February 2011|Actual|2011-02-28|February 2009|Actual|2009-02-28||Interventional|||Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity|Mechanisms of Airway Inflammation: Natural Exacerbation of Asthma Induced by Glucocorticoid Withdrawal|Completed||N/A|27|Actual|Washington University School of Medicine||1|||f||||||||||||||2018-06-01 04:28:49.976943|2018-06-01 04:28:49.976943
NCT00217841|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-09-18|2005-09-14|2005-09-22|Estimate|||||||2006-09-18|2006-09-19|Estimate|January 2004||2004-01-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||Aurograb and Vancomycin in MRSA Infection|A Multi Centre, Double-Blind, Randomised, Placebo Controlled Prospective Study on the Safety and Efficacy of Aurograb in Patients With Severe, Deep-Seated Staphylococcal Infections Receiving Vancomycin|Completed||Phase 3|180||NeuTec Pharma|||||f||||||||||||||2018-06-01 04:28:50.074446|2018-06-01 04:28:50.074446
NCT00217828|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2014-06-10|2005-09-19|2005-09-22|Estimate|||||||2014-06-10|2014-06-11|Estimate|March 2002||2002-03-31|June 2014|2014-06-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Effects of Citalopram on Hostility and CHD Risk||Completed||N/A|||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:28:50.203445|2018-06-01 04:28:50.203445
NCT00217815|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-07-14|2005-09-15|2005-09-22|Estimate|||||||2008-07-14|2008-07-15|Estimate|September 2005||2005-09-30|July 2008|2008-07-31|October 2006||2006-10-31|||||Interventional|||Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer|A Phase Ib, Pharmacokinetic, Multiple Center, Open Label Study Evaluating the Safety and Efficacy of Mycograb Administered IV in Combination With Docetaxel in Metastatic or Recurrent Breast Cancer Patients|Completed||Phase 1/Phase 2|20||NeuTec Pharma|||||f||||||||||||||2018-06-01 04:28:50.262179|2018-06-01 04:28:50.262179
NCT00217802|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2016-07-28|2005-09-19|2005-09-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2000||2000-03-31|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||The Effect of Self-regulatory Education on Women With Asthma||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:28:50.33071|2018-06-01 04:28:50.33071
NCT00217789|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-12-23|2005-09-19|2005-09-22|Estimate|||||||2013-12-23|2013-12-24|Estimate|July 2004||2004-07-31|December 2013|2013-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Pathogen Specific Immunity in Patients With Sarcoidosis|Pathogen Specific Immunity in Sarcoidosis|Completed|||5|Actual|Rutgers, The State University of New Jersey|||||f||||||||||||||2018-06-01 04:28:50.397502|2018-06-01 04:28:50.397502
NCT00217763|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-12-07|2005-09-14|2005-09-22|Estimate|||||||2007-12-07|2007-12-10|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|December 2007|Anticipated|2007-12-31|||||Interventional|||European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients|A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease|Unknown status|Active, not recruiting|Phase 3|930|Anticipated|Bellus Health Inc|||||||||||||||||||2018-06-01 04:28:50.623649|2018-06-01 04:28:50.623649
NCT00217737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2018-05-24|2005-09-20|2005-09-22|Estimate|||||||2018-05-24|2018-05-25|Actual|August 4, 2005|Actual|2005-08-04|January 2018|2018-01-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer|A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers|Active, not recruiting||Phase 3|3610|Anticipated|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 04:28:51.000256|2018-06-01 04:28:51.000256
NCT00217724|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2010-06-10||2017-05-07|2005-09-20|2005-09-22|Estimate|2010-08-25|2010-09-24|Estimate||||2017-05-07|2017-05-09|Actual|July 1999||1999-07-31|May 2017|2017-05-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer|A Double-blinded Pilot Study of Glutamine for the Prevention of Paclitaxel-Induced Myalgias and Arthralgias|Terminated||N/A|18|Actual|OHSU Knight Cancer Institute|We were able to only accrue 18 of the 40 patient target. This, plus confounded results and limited funds, the remaining research funds were returned to the sponsor and no evaluation of serum or dietary glutamine levels was done.|2||Only able to accrue just 18 of the 40 target & funds were limited.|f||||t||||||||||2018-06-01 04:28:52.590579|2018-06-01 04:28:52.590579
NCT00217711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-06-02|2005-09-20|2005-09-22|Estimate|||||||2012-06-02|2012-06-05|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|August 2007|Actual|2007-08-31||Interventional|||Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery|Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|23|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||||2018-06-01 04:28:52.790071|2018-06-01 04:28:52.790071
NCT00217698|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-06-02|2005-09-20|2005-09-22|Estimate|||||||2012-06-02|2012-06-05|Estimate|November 2003||2003-11-30|June 2012|2012-06-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|63|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 04:28:52.871943|2018-06-01 04:28:52.871943
NCT00217672|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2015-09-21||2016-02-25|2005-09-20|2005-09-22|Estimate|2016-02-25|2016-03-29|Estimate||||2016-02-25|2016-03-29|Estimate|May 2005||2005-05-31|February 2016|2016-02-29|November 2010|Actual|2010-11-30|December 2008|Actual|2008-12-31||Interventional|||Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer|A Randomized Phase II Trial of Docetaxel With or Without Bevacizumab as First-Line Therapy for Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer|Completed||Phase 2|76|Actual|Translational Oncology Research International|Small sample size and that it was changed from a 2-arm study to a single arm study. This was necessary with public release of E2100 results(improved progression free survival) and subsequent availability of bevacizumab outside of clinical trial.|2|||f||||t||||||||||2018-06-01 04:28:52.951556|2018-06-01 04:28:52.951556
NCT00217659|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-01-02|2005-09-20|2005-09-22|Estimate|||||||2013-01-02|2013-01-03|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer|A Phase II Study of Goserelin Plus Anastrozole for the Treatment of Male Patients With Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||||poor accrual|f||||t||||||||||2018-06-01 04:28:53.323563|2018-06-01 04:28:53.323563
NCT00217646|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2015-04-27|2005-09-20|2005-09-22|Estimate|||||||2015-04-27|2015-04-28|Estimate|October 2005||2005-10-31|February 2013|2013-02-28||||December 2010|Actual|2010-12-31||Interventional|||Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia|Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:28:53.442769|2018-06-01 04:28:53.442769
NCT00217633|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2015-05-27|2005-09-20|2005-09-22|Estimate|||||||2015-05-27|2015-05-29|Estimate|January 2006||2006-01-31|May 2015|2015-05-31||||January 2013|Actual|2013-01-31||Interventional|||Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer|Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer|Completed||Phase 2|38|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 04:28:53.516547|2018-06-01 04:28:53.516547
NCT00217620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2012-10-03||2014-05-05|2005-09-20|2005-09-22|Estimate|2012-10-03|2012-11-01|Estimate||||2014-05-05|2014-05-15|Estimate|March 2006||2006-03-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|April 2008|Actual|2008-04-30||Interventional|||S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas|Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas|Completed||Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 04:28:53.763284|2018-06-01 04:28:53.763284
NCT00217607|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2016-08-29|2005-09-20|2005-09-22|Estimate|||||||2016-08-29|2016-08-30|Estimate|February 2005||2005-02-28|August 2016|2016-08-31|January 2012|Actual|2012-01-31|April 2008|Actual|2008-04-30||Interventional|||Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery|Multicentric Phase II Study Evaluating the Efficacy and Toxicity of Weekly Paclitaxel in Locally Advanced or Metastatic Soft Tissue Angiosarcomas That Cannot be Treated by Surgery|Completed||Phase 2|30|Actual|UNICANCER||1|||f||||f||||||||No|Individual participant data will not be shared at an individual level.|2018-06-01 04:28:54.631345|2018-06-01 04:28:54.631345
NCT00217594|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-10-26|2005-09-20|2005-09-22|Estimate|||||||2017-10-26|2017-10-27|Actual|July 21, 2005||2005-07-21|October 17, 2017|2017-10-17|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome|A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS)|Completed||Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:28:54.781746|2018-06-01 04:28:54.781746
NCT00217581|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2014-06-05||2018-04-15|2005-09-20|2005-09-22|Estimate|2014-06-05|2014-07-07|Estimate||||2018-04-15|2018-05-21|Actual|October 2004|Actual|2004-10-31|April 2018|2018-04-30|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer|Phase II Trial of Bevacizumab, Docetaxel, and Oxaliplatin in Gastric and Gastroesophageal Junction Cancer|Completed||Phase 2|39|Actual|Barbara Ann Karmanos Cancer Institute|The trial completed its planned accrual. There were no significant limitations.|1|||f||||t||||||||||2018-06-01 04:28:54.87984|2018-06-01 04:28:54.87984
NCT00217568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-09-20|2005-09-20|2005-09-22|Estimate|||||||2010-09-20|2010-09-21|Estimate|May 2005||2005-05-31|September 2010|2010-09-30||||March 2006|Actual|2006-03-31||Interventional|||Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer|A Phase II Trial of Docetaxel and Carboplatin for First Relapsed Platinum-Sensitive Stage III and IV Advanced Ovarian Cancer or Peritoneal Carcinoma|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:28:55.303564|2018-06-01 04:28:55.303564
NCT00217555|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-09-20|2005-09-20|2005-09-22|Estimate|||||||2010-09-20|2010-09-21|Estimate|July 2002||2002-07-31|September 2010|2010-09-30||||February 2006|Actual|2006-02-28||Interventional|||Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer|Phase II Trial for the Treatment of Recurrent or Persistent Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With Gemcitabine and Topotecan|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:28:55.708975|2018-06-01 04:28:55.708975
NCT00217542|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-05-01|2005-09-20|2005-09-22|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2005||2005-07-31|May 2013|2013-05-31||||July 2008|Actual|2008-07-31||Interventional|||Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery|A Phase 1 Study of 5-azacitidine in Combination With Interferon-Alfa 2B in Unresectable or Metastatic Melanoma and Renal Cell Carcinoma|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:28:55.987127|2018-06-01 04:28:55.987127
NCT00217529|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-09-20|2005-09-20|2005-09-22|Estimate|||||||2010-09-20|2010-09-21|Estimate|June 2004||2004-06-30|September 2010|2010-09-30||||November 2005|Actual|2005-11-30||Interventional|||Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer|A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:28:56.29868|2018-06-01 04:28:56.29868
NCT00217516|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-02-08|2005-09-20|2005-09-22|Estimate|||||||2012-02-08|2012-02-09|Estimate|March 2005||2005-03-31|September 2010|2010-09-30|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Interventional|||Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer|Supplementation of L-Selenomethionine in Patients With Prostate Cancer Prior to Brachytherapy. Selenium Brachytherapy Trial: Phase I/Pilot Study|Completed||Phase 1|18|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-06-01 04:28:56.588643|2018-06-01 04:28:56.588643
NCT00217503|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-06-18|2005-09-20|2005-09-22|Estimate|||||||2013-06-18|2013-06-20|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|June 2007|Actual|2007-06-30|||||Interventional|||Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma|Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir|Completed||Phase 2|15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:28:56.902067|2018-06-01 04:28:56.902067
NCT00217490|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2015-09-29||2017-02-16|2005-09-20|2005-09-22|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|March 2005||2005-03-31|February 2017|2017-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Individual Counseling and/or Computer-Based Counseling in Helping Healthy Women Adopt a Cancer Prevention Diet|Helping Women Adopt a Cancer Prevention Diet|Completed||N/A|621|Actual|Kaiser Permanente||4|||f||||f||||||||||2018-06-01 04:28:57.181776|2018-06-01 04:28:57.181776
NCT00217477|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-12-08|2005-09-20|2005-09-22|Estimate|||||||2014-12-08|2014-12-09|Estimate|August 2004||2004-08-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|May 2013|Actual|2013-05-31||Interventional|||Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer|An Open Label, Dose Escalation Study of Paricalcitol (Zemplar™) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies|Completed||Phase 1|34|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 04:28:57.965288|2018-06-01 04:28:57.965288
NCT00217464|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2015-03-17||2015-03-31|2005-09-20|2005-09-22|Estimate|2015-03-31|2015-04-16|Estimate||||2015-03-31|2015-04-16|Estimate|June 2004||2004-06-30|March 2015|2015-03-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional||All treated and eligible patients|Fulvestrant in Treating Patients With Recurrent Prostate Cancer|Multicenter Study of Fulvestrant (Faslodex®) in Early, Recurrent Prostate Cancer Following Local Therapy: A Phase II Trial|Terminated||Phase 2|17|Actual|Roswell Park Cancer Institute||1||Closed for futility|f||||t||||||||||2018-06-01 04:28:58.049699|2018-06-01 04:28:58.049699
NCT00217451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-19|2005-09-19|2005-09-22|Estimate|||||||2005-09-19|2005-09-22|Estimate|June 2002||2002-06-30|September 2005|2005-09-30|March 2003||2003-03-31|||||Interventional|||Treatment of Malaria in Gabon With Fosmidomycin-Clindamycin|Evaluation of Fosmidomycin in Combination With Clindamycin in Children With Acute Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 2|51||Albert Schweitzer Hospital|||||f||||||||||||||2018-06-01 04:28:58.193212|2018-06-01 04:28:58.193212
NCT00217438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2013-11-01||2015-08-04|2005-09-20|2005-09-22|Estimate|2014-09-16|2014-09-19|Estimate||||2015-08-04|2015-08-21|Estimate|July 2005||2005-07-31|August 2015|2015-08-31||||October 2012|Actual|2012-10-31||Interventional|||Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma|A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine|Completed||Phase 3|130|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 04:28:58.254792|2018-06-01 04:28:58.254792
NCT00217425|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2014-02-20||2014-04-08|2005-09-20|2005-09-22|Estimate|2014-04-08|2014-05-07|Estimate||||2014-04-08|2014-05-07|Estimate|July 2006||2006-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|April 2012|Actual|2012-04-30||Interventional||Eligible and treated|Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms|Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms|Completed||Phase 2|46|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 04:28:58.463378|2018-06-01 04:28:58.463378
NCT00217412|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-06-16|2005-09-20|2005-09-22|Estimate|||||||2014-06-16|2014-06-17|Estimate|August 2005||2005-08-31|April 2013|2013-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia|A Phase 1 Study of SAHA (NSC# 701852) in Pediatric Patients With Recurrent or Refractory Solid Tumors (Including Lymphomas) and Leukemia Followed by a Phase I Study of SAHA in Combination With 13-Cis-Retinoic Acid for Patients With Selected Recurrent/Refractory Solid Tumors|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 04:28:59.021765|2018-06-01 04:28:59.021765
NCT00217399|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2011-03-23||2014-05-12|2005-09-20|2005-09-22|Estimate|2013-01-09|2013-02-12|Estimate||||2014-05-12|2014-05-28|Estimate|June 2005||2005-06-30|December 2012|2012-12-31|January 2013|Actual|2013-01-31|July 2009|Actual|2009-07-31||Interventional|||Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:28:59.118847|2018-06-01 04:28:59.118847
NCT00217386|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-09-13|2005-09-20|2005-09-22|Estimate|||||||2010-09-13|2010-09-15|Estimate|March 2004||2004-03-31|September 2010|2010-09-30||||December 2007|Actual|2007-12-31||Interventional|||Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes|Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept|Completed||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:28:59.307143|2018-06-01 04:28:59.307143
NCT00217373|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2015-04-17|2005-09-20|2005-09-22|Estimate|||||||2015-04-17|2015-04-20|Estimate|June 2005||2005-06-30|December 2014|2014-12-31|March 2015|Actual|2015-03-31|January 2013|Actual|2013-01-31||Interventional|||Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)|A Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-Tricom (B7.1/ICAM/LFA3) and Vaccinia-CEA (6D)-Tricom, in Combination With GM-CSF and Interferon-Alfa-2B in Patients With CEA-Expressing Carcinomas|Completed||Phase 1|33|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:28:59.413569|2018-06-01 04:28:59.413569
NCT00217360|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2006-10-03|2005-09-16|2005-09-22|Estimate|||||||2006-10-03|2006-10-04|Estimate|December 2002||2002-12-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||RCT to Reduce Further Falls and Injuries for Older Fallers Presenting to an Emergency Department|RCT to Evaluate the Effectiveness of a Targeted and Personalised Multifactorial Program to Reduce Further Falls and Injuries for Community-Dwelling Older Fallers Presenting to and Being Discharged Directly From an Emergency Department.|Unknown status|Recruiting|N/A|700||National Ageing Research Institute, Australia|||||f||||||||||||||2018-06-01 04:28:59.493561|2018-06-01 04:28:59.493561
NCT00217347|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-06-04|2005-09-20|2005-09-22|Estimate|||||||2008-06-04|2008-06-05|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|July 2006|Actual|2006-07-31|||||Interventional|||Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy||Completed||N/A|150|Anticipated|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:28:59.547735|2018-06-01 04:28:59.547735
NCT00217334|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2005-09-19|2005-09-19|2005-09-22|Estimate|||||||2005-09-19|2005-09-22|Estimate|November 2002||2002-11-30|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Community Hypertension Assessment Trial (CHAT)|A Pragmatic Trial of Community Pharmacy Blood Pressure Clinics Linked With Family Medicine Practices to Improve the Monitoring and Management of High Blood Pressure Among Older Adults|Completed||N/A|28||McMaster University|||||f||||||||||||||2018-06-01 04:28:59.599566|2018-06-01 04:28:59.599566
NCT00217321|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2010-07-20|2005-09-15|2005-09-22|Estimate|||||||2010-07-20|2010-07-21|Estimate|November 2003||2003-11-30|September 2006|2006-09-30|December 2015|Anticipated|2015-12-31|||||Observational|||Parkinson's Disease Registry of the Muhammad Ali Parkinson Center|Parkinson's Disease Registry|Unknown status|Active, not recruiting||20000|Anticipated|Muhammad Ali Parkinson Research Center|||||f||||||||||||||2018-06-01 04:28:59.66558|2018-06-01 04:28:59.66558
NCT00217308|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-08-29|2005-09-14|2005-09-22|Estimate|||||||2017-08-29|2017-08-31|Actual|February 2005|Actual|2005-02-28|August 2017|2017-08-31|September 2007|Actual|2007-09-30|July 2007|Anticipated|2007-07-31||Interventional|||Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery|Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery|Withdrawn||Phase 1|0|Actual|Mount Sinai Hospital, Canada||2||Tightly defined inclusion criteria were making recruitment very slow.|f||||f||||||||No||2018-06-01 04:28:59.71936|2018-06-01 04:28:59.71936
NCT00217295|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|April 2004||2004-04-30|June 2005|2005-06-30|December 2007||2007-12-31|||||Interventional|||A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis|A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis.|Unknown status|Recruiting|Phase 2|30||Multiple Sclerosis Institute|||||f||||||||||||||2018-06-01 04:28:59.781061|2018-06-01 04:28:59.781061
NCT00217282|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-05-20|2005-09-14|2005-09-22|Estimate|||||||2008-05-20|2008-05-22|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|March 2008|Actual|2008-03-31|June 2007|Actual|2007-06-30||Interventional|||Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer|Phase II Trial OF Oxaliplatin and Gemcitabine With Bevacizumab in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|45|Actual|Mt. Sinai Medical Center, Miami|||||f||||f||||||||||2018-06-01 04:28:59.894928|2018-06-01 04:28:59.894928
NCT00217269|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-04-19|2005-09-14|2005-09-22|Estimate|||||||2012-04-19|2012-04-20|Estimate|April 2005||2005-04-30|April 2012|2012-04-30|July 2011|Actual|2011-07-31|March 2007|Actual|2007-03-31||Interventional|ENDEAVOR IV||The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions|A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|Completed||N/A|1548|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-06-01 04:28:59.956825|2018-06-01 04:28:59.956825
NCT00217256|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-06-22|2005-09-14|2005-09-22|Estimate|||||||2011-06-22|2011-06-27|Estimate|February 2004||2004-02-29|June 2011|2011-06-30|December 2010|Actual|2010-12-31|May 2005|Actual|2005-05-31||Interventional|ENDEAVOR III||The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial|A Randomized Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|Completed||N/A|436|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-06-01 04:29:00.019287|2018-06-01 04:29:00.019287
NCT00215280|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2007-04-19|2005-09-21|2005-09-22|Estimate|||||||2007-04-19|2007-04-20|Estimate|November 2005||2005-11-30|April 2007|2007-04-30|February 2006||2006-02-28|||||Interventional|||Epidemiology and Control of Mansonella Perstans Infection in Uganda|Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda|Completed||N/A|1000||DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 04:29:24.548547|2018-06-01 04:29:24.548547
NCT00217243|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-09-17|2005-09-19|2005-09-22|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|June 2007|Actual|2007-06-30|||||Observational|||Evoked Fields After Median and Ulnar Stimulation|Evoked (Magnetic) Cortical Fields for the Comparative Study of Mechanisms Underlying Chronic Non-malignant Pain in Peripheral Nerve Injury (CRPS II) and CRPS I (Chronic Regional Pain Syndrome I)|Completed|||60|Actual|Medical Center Alkmaar|||1||f||||f||||||||||2018-06-01 04:29:00.087495|2018-06-01 04:29:00.087495
NCT00217230|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-02|2005-09-20|2005-09-22|Estimate|||||||2006-10-02|2006-10-03|Estimate|April 2001||2001-04-30|October 2006|2006-10-31|November 2001||2001-11-30|||||Interventional|||Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older CAIV-T, Liquid Formulation|Completed||Phase 3|3000||MedImmune LLC|||||||||||||||||||2018-06-01 04:29:00.154077|2018-06-01 04:29:00.154077
NCT00217217|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-03-13|2005-09-15|2005-09-22|Estimate|||||||2012-03-13|2012-03-14|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Low Field Magnetic Stimulation Treatment for Bipolar Depression|Low Field Magnetic Stimulation in Bipolar Depression|Terminated||Phase 3|13|Actual|Mclean Hospital||2||Study was terminated for lack of recruitment.|f||||t||||||||||2018-06-01 04:29:00.225382|2018-06-01 04:29:00.225382
NCT00217204|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-17|2005-09-13|2005-09-22|Estimate|||||||2011-05-17|2011-05-19|Estimate|July 2005||2005-07-31|April 2010|2010-04-30|February 2006|Actual|2006-02-28|||||Interventional|||An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption|A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Effectiveness of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and Toddlers With Cystic Fibrosis-Related Pancreatic Insufficiency and Fat Malabsorption|Completed||Phase 2|18|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||f||||||||||||||2018-06-01 04:29:00.322804|2018-06-01 04:29:00.322804
NCT00217191|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-09-18|2005-09-19|2005-09-22|Estimate|||||||2006-09-18|2006-09-19|Estimate|September 2004||2004-09-30|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||Ibuprofen and Renal Function in Premature Infants|Ibuprofen and Renal Function in Premature Infants|Completed||Phase 4|120||Maternite Regionale Universitaire|||||f||||||||||||||2018-06-01 04:29:00.374352|2018-06-01 04:29:00.374352
NCT00217178|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-22|Estimate|||||||2005-09-16|2005-09-22|Estimate|January 2000||2000-01-31|October 2004|2004-10-31|October 2005||2005-10-31|||||Interventional|||Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)|Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)|Unknown status|Active, not recruiting|Phase 4|900||McMaster University|||||f||||||||||||||2018-06-01 04:29:00.440198|2018-06-01 04:29:00.440198
NCT00217165|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22||2017-03-17|2017-03-17|2005-09-15|2005-09-22|Estimate||||2017-03-17|2017-03-20|Actual|2017-03-17|2017-03-20|Actual|April 2005||2005-04-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|||Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study|Taurine as an Anti-manic Agent: a Double-blind Placebo-controlled Study.|Completed||Phase 2|60|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 04:29:00.494076|2018-06-01 04:29:00.494076
NCT00217152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2011-12-16|2005-09-20|2005-09-22|Estimate|||||||2011-12-16|2011-12-19|Estimate|March 2005||2005-03-31|December 2011|2011-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors|An Open Label, Prospective, Randomized, Controlled, Multicenter Study Assessing Fixed Dose vs. Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Combination With Full Dose and Reduced Dose Calcineurin Inhibitors|Terminated||Phase 4|12|Actual|Mayo Clinic||||Roche decided to prematurely terminate study.|f||||||||||||||2018-06-01 04:29:00.555312|2018-06-01 04:29:00.555312
NCT00217139|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-27|2005-09-13|2005-09-22|Estimate|||||||2006-09-27|2006-09-29|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase II, Randomized, Active-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Celgosivir in Combination With Peginterferon Alfa-2b, With and Without Ribavirin, for 12 Weeks in Patients With Chronic Hepatitis C Infection (Genotype 1) Who Failed to Respond to Pegylated α Interferon-Based Therapy|Completed||Phase 2|60||BioWest Therapeutics Inc|||||f||||||||||||||2018-06-01 04:29:00.73788|2018-06-01 04:29:00.73788
NCT00217126|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-01-02|2005-09-16|2005-09-22|Estimate|||||||2013-01-02|2013-01-03|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||The Study of Long-term Deterioration of Kidney Transplants.|Long-term Kidney Function (2 Arms-Prospective and Retrospective)|Completed|||870|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 04:29:00.799853|2018-06-01 04:29:00.799853
NCT00217113|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2010-01-20|2005-09-16|2005-09-22|Estimate|||||||2010-01-20|2010-01-21|Estimate|September 2005||2005-09-30|January 2010|2010-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||An Intervention to Preserve Functional Status and Independence Among Community Dwelling Elderly|An Intervention to Preserve Functional Status and Independence Among Community Dwelling Elderly|Completed||N/A|100|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:29:00.849073|2018-06-01 04:29:00.849073
NCT00217100|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-04-23|2005-09-20|2005-09-22|Estimate|||||||2012-04-23|2012-04-25|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Multivitamin Comparison Study in Kidney Transplant Recipients.|Folic Acid for Vascular Outcome Reduction in Transplantation.|Completed||Phase 3|200|Actual|Mayo Clinic||2|||f||||||||||||||2018-06-01 04:29:00.899642|2018-06-01 04:29:00.899642
NCT00217087|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2015-03-02||2015-11-23|2005-09-20|2005-09-22|Estimate|2015-08-26|2015-09-25|Estimate||||2015-11-23|2015-12-24|Estimate|September 2005||2005-09-30|November 2015|2015-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Endoscopic Therapy of Early Cancer in Barretts Esophagus|Endoscopic Therapy of Early Cancer in Barretts Esophagus|Completed||Phase 2|73|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:29:00.979493|2018-06-01 04:29:00.979493
NCT00217074|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-02-01|2005-09-20|2005-09-22|Estimate|||||||2010-02-01|2010-02-02|Estimate|January 2004||2004-01-31|February 2010|2010-02-28|October 2005|Actual|2005-10-31|January 2004|Actual|2004-01-31||Interventional|||Acupuncture and Hot Flashes|Acupuncture for Hot Flashes: A Randomized Sham Controlled Clinical Study|Terminated||Phase 3|103|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:29:01.402155|2018-06-01 04:29:01.402155
NCT00217061|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-05-20|2005-09-16|2005-09-22|Estimate|||||||2011-05-20|2011-05-23|Estimate|April 2005||2005-04-30|May 2011|2011-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus|The Statin Choice Decision Aid and Its Effects on Statin Decisions in Patients With Type 2 Diabetes Mellitus. A Clustered Randomized Trial|Completed||Phase 3|98||Mayo Clinic|||||f||||||||||||||2018-06-01 04:29:01.456776|2018-06-01 04:29:01.456776
NCT00217048|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-04-27|2005-09-16|2005-09-22|Estimate|||||||2009-04-27|2009-04-29|Estimate|June 2005||2005-06-30|April 2009|2009-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effect of Yohimbine on Colon Transit|Effect of Oral Yohimbine on Colonic Transit: Randomized, Placebo-Controlled Trial|Completed||Phase 1/Phase 2|30|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 04:29:01.524275|2018-06-01 04:29:01.524275
NCT00217035|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2017-01-12|2005-09-19|2005-09-22|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 1997||1997-08-31|January 2017|2017-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|||Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients|Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients.|Withdrawn|||0|Actual|National Institute of General Medical Sciences (NIGMS)||||"State of Mass. tightened regulations for making intravenous solutions for research subjects.~   Study was withdrawn and no participants were enrolled."|f||||t||||||||||2018-06-01 04:29:01.591033|2018-06-01 04:29:01.591033
NCT00217022|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2011-07-15||2012-03-16|2005-09-14|2005-09-22|Estimate|2012-03-16|2012-04-12|Estimate||||2012-03-16|2012-04-12|Estimate|June 2003||2003-06-30|March 2012|2012-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis|A Randomized, Double-Blind, Placebo Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis|Terminated||Phase 2/Phase 3|16|Actual|Mayo Clinic|Study closed early, because of low enrollment. Primary physician for patients with lymphocytic colitis would prescribe Budesonide off label for them. Subjects not interested in placebo trial.|2||Study closed early, because of low enrollment.|f||||f||||||||||2018-06-01 04:29:01.688763|2018-06-01 04:29:01.688763
NCT00217009|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-05-18|2005-09-14|2005-09-22|Estimate|||||||2015-05-18|2015-05-20|Estimate|March 2005||2005-03-31|May 2015|2015-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.|A Randomized Controlled Trial of Narrowband Ultraviolet B vs Topical Psoralen Plus Ultraviolet A Photochemotherapy for Hand and Foot Dermatoses|Terminated||Early Phase 1|3|Actual|Mayo Clinic||2||"Unfortunately we had unforeseen difficulty recruiting to this study. Therefore we have decided~   to halt the study and not publish the results."|f||||||||||||||2018-06-01 04:29:01.95465|2018-06-01 04:29:01.95465
NCT00216996|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2016-11-15|2005-09-20|2005-09-22|Estimate|||||||2016-11-15|2016-11-16|Estimate||||November 2016|2016-11-30||||||||Observational|||Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Burns|Study on the Effect of Glutamine Supplemented Nutrition Support on Protein and Glutamine Metabolism in Severely Burned Patients|Withdrawn|||0|Actual|Massachusetts General Hospital|||1|This study was withdrawn (see NCT00181753).|f||||t||||||||Yes|Published data will be shared in our publications and directly with an individual researcher when requested.|2018-06-01 04:29:02.039822|2018-06-01 04:29:02.039822
NCT00216983|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2017-01-12|2005-09-20|2005-09-22|Estimate|||||||2017-01-12|2017-01-13|Estimate|September 1997||1997-09-30|January 2017|2017-01-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|||Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding|Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding.|Withdrawn|||0|Actual|National Institute of General Medical Sciences (NIGMS)|||3|"State of Mass. tightened regulations for making intravenous solutions for research subjects.~   Study was withdrawn and no participants were enrolled."|f||||t||||||||||2018-06-01 04:29:02.107389|2018-06-01 04:29:02.107389
NCT00216970|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-08-12|2005-09-16|2005-09-22|Estimate|||||||2009-08-12|2009-08-13|Estimate|August 1997||1997-08-31|August 2009|2009-08-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients|Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients|Unknown status|Recruiting|N/A|16|Anticipated|National Institute of General Medical Sciences (NIGMS)||2|||f||||t||||||||||2018-06-01 04:29:02.182716|2018-06-01 04:29:02.182716
NCT00216957|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2005-09-19|2005-09-19|2005-09-22|Estimate|||||||2005-09-19|2005-09-22|Estimate|October 1998||1998-10-31|September 2005|2005-09-30|June 2004||2004-06-30|||||Interventional|||Randomized Clinical Trial Comparing Coronary Bypass Grafting With or Without Cardiopulmonary Bypass|Randomized Clinical Trial Comparing Coronary Bypass Grafting With or Without Cardiopulmonary Bypass|Completed||Phase 3|300||Maritime Heart Centre|||||f||||||||||||||2018-06-01 04:29:02.278199|2018-06-01 04:29:02.278199
NCT00216944|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2010-02-12|2005-09-15|2005-09-22|Estimate|||||||2010-02-12|2010-02-15|Estimate|August 2005||2005-08-31|December 2010|2010-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Balanced Anesthesia for Intubation of Premature Infants|Balanced Anesthesia for Intubation of Newborn Premature Infants - a Randomized Intervention Study|Completed||Phase 4|40|Anticipated|Lund University Hospital||2|||f||||||||||||||2018-06-01 04:29:02.340755|2018-06-01 04:29:02.340755
NCT00216931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-02-03|2005-09-15|2005-09-22|Estimate|||||||2009-02-03|2009-02-04|Estimate|May 2006||2006-05-31|February 2009|2009-02-28|October 2008|Anticipated|2008-10-31|||||Interventional|||Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost|Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost|Withdrawn||N/A|40|Anticipated|Lund University Hospital||||No patients enrolled after three years|f||||||||||||||2018-06-01 04:29:02.401039|2018-06-01 04:29:02.401039
NCT00216918|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-01-24|2005-09-20|2005-09-22|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2005||2005-09-30|January 2007|2007-01-31|June 2006||2006-06-30|||||Interventional|||Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.|An Open-Label Pilot Study of Atomoxetine Hydrochloride to Evaluate Neuropsychological Function in Children Ages 6 to 10 Years With Attention-Deficit/Hyperactivity Disorder.|Completed||Phase 4|40||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:29:02.459654|2018-06-01 04:29:02.459654
NCT00216905|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2010-06-01|2005-09-19|2005-09-22|Estimate|||||||2010-06-01|2010-06-02|Estimate|October 2004||2004-10-31|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Simultaneous Measurement of Electroencephalography (EEG) and Functional Magnetic Resonance Imaging (fMRI) in Patients With Alcoholism|Neurobiological Correlates of Disturbed Cognitive Function in Patients With Alcoholism - Simultaneous Measurement With EEG and fMRI|Completed|||25|Actual|Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 04:29:02.511464|2018-06-01 04:29:02.511464
NCT00216892|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-03-25|2005-09-15|2005-09-22|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2005||2005-04-30|March 2015|2015-03-31|December 2005||2005-12-31|||||Interventional|||Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris|Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris|Completed||Phase 4|1032||LEO Pharma|||||f||||||||||||||2018-06-01 04:29:02.557642|2018-06-01 04:29:02.557642
NCT00216879|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-03-25|2005-09-15|2005-09-22|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|July 2006||2006-07-31|||||Interventional|||Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis|Long-term Treatment of Scalp Psoriasis With Calcipotriol Plus Betamethasone Dipropionate Gel|Completed||Phase 3|800||LEO Pharma|||||||||||||||||||2018-06-01 04:29:02.619617|2018-06-01 04:29:02.619617
NCT00216866|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2017-08-25|2005-09-21|2005-09-22|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2002|Actual|2002-09-30|August 2017|2017-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis|A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity|Completed||Phase 2|70||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:29:02.678082|2018-06-01 04:29:02.678082
NCT00216853|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-04-15|2005-09-19|2005-09-22|Estimate|||||||2009-04-15|2009-04-16|Estimate|September 2003||2003-09-30|April 2009|2009-04-30|March 2007|Actual|2007-03-31|June 2006|Actual|2006-06-30||Observational|||A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection|A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection|Completed|||44|Actual|Lawson Health Research Institute|||2||f||||f||||||||||2018-06-01 04:29:02.74762|2018-06-01 04:29:02.74762
NCT00216840|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-03-25|2005-09-15|2005-09-22|Estimate|||||||2015-03-25|2015-03-26|Estimate|December 2004||2004-12-31|March 2015|2015-03-31|September 2005||2005-09-30|||||Interventional|||Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis|Completed||Phase 3|1350||LEO Pharma|||||||||||||||||||2018-06-01 04:29:02.93218|2018-06-01 04:29:02.93218
NCT00216827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-03-25|2005-09-15|2005-09-22|Estimate|||||||2015-03-25|2015-03-26|Estimate|November 2004||2004-11-30|March 2015|2015-03-31|September 2005||2005-09-30|||||Interventional|||Efficacy and Safety of Calcipotriol Plus Betamethasone Gel in the Treatment of Scalp Psoriasis|Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle, and the Gel Vehicle Alone in Scalp Psoriasis|Completed||Phase 3|1485||LEO Pharma|||||||||||||||||||2018-06-01 04:29:02.9964|2018-06-01 04:29:02.9964
NCT00216814|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2008-04-18|2005-09-19|2005-09-22|Estimate|||||||2008-04-18|2008-04-22|Estimate|October 2003||2003-10-31|January 2008|2008-01-31|September 2007|Actual|2007-09-30|||||Observational|||Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors|Intravesically Administered BCG May Have Antiangiogenic Effects on Urinary Concentrations of Basic Fibroblast Growth Factor ( bFGF), Vascular Endothelial Growth Factor (VEGF) and Interleukin (IL-8)|Terminated|||220|Actual|Lawson Health Research Institute||||No funding and data was not appropriate to consider continuing.|f||||||||||||||2018-06-01 04:29:03.078467|2018-06-01 04:29:03.078467
NCT00216801|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-01-20|2005-09-19|2005-09-22|Estimate|||||||2009-01-20|2009-01-21|Estimate|September 2005||2005-09-30|January 2009|2009-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Relationship of Ochratoxin A to Upper Urologic Cancers|The Relationship of Ochratoxin A to Upper Tract TCC Malignancies, Testicular Cancer, and Renal Cell Cancer|Completed|||60|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 04:29:03.177729|2018-06-01 04:29:03.177729
NCT00216788|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2010-03-15|2005-09-19|2005-09-22|Estimate|||||||2010-03-15|2010-03-16|Estimate|January 2006||2006-01-31|November 2005|2005-11-30|January 2006|Anticipated|2006-01-31|||||Interventional|||The Effect of Nexium on Transmucosal Esophageal Leak|The Effect of Proton Pump Inhibitors on Transmucosal Esophageal Leak|Unknown status|Not yet recruiting|Phase 1|35|Anticipated|Main Line Health|||||f||||||||||||||2018-06-01 04:29:03.253603|2018-06-01 04:29:03.253603
NCT00216775|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2015-09-01|2005-09-14|2005-09-22|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2004||2004-12-31|September 2015|2015-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C||Completed|||50|Actual|Kyoto University|||||f||||||||||||||2018-06-01 04:29:03.355727|2018-06-01 04:29:03.355727
NCT00216762|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-08-31|2005-09-16|2005-09-22|Estimate|||||||2015-08-31|2015-09-02|Estimate|January 2006||2006-01-31|August 2015|2015-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Safety Study of Rituximab (Rituxan®) in Chronic Urticaria|"Phase I/II Open Label Evaluation of the Safety and Efficacy of Rituximab in Patients With Chronic Urticaria (The Rituximab Urticaria Study - RUSTY)"|Terminated||Phase 1/Phase 2|15|Anticipated|Johns Hopkins University||||Full Clinical Hold|f||||t||||||||||2018-06-01 04:29:03.412628|2018-06-01 04:29:03.412628
NCT00216749|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-12-15|2005-09-14|2005-09-22|Estimate|||||||2009-12-15|2009-12-17|Estimate|December 2003||2003-12-31|December 2009|2009-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Efficacy and Safety of Cilostazol for the Indication of CSPS|Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS|Completed|||650|Actual|Korea Otsuka Pharmaceutical Co., Ltd.|||1||f||||f||||||||||2018-06-01 04:29:03.482751|2018-06-01 04:29:03.482751
NCT00216736|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2009-05-28||2015-04-13|2005-09-14|2005-09-22|Estimate|2015-04-13|2015-04-30|Estimate||||2015-04-13|2015-04-30|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|July 2007|Actual|2007-07-31|December 2006|Actual|2006-12-31||Interventional|||Oral Dexamethasone for Treatment of Migraine|Does a Single Oral Dose of Dexamethasone After Successful Emergency Treatment of Migraine Reduce the Incidence or Severity of Rebound Headache Within 48 Hours?|Completed||Phase 4|63|Actual|The Joseph Epstein Centre for Emergency Medicine Research||2|||f||||f||||||||||2018-06-01 04:29:03.537654|2018-06-01 04:29:03.537654
NCT00216723|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-10-22|2005-09-14|2005-09-22|Estimate|||||||2013-10-22|2013-10-23|Estimate|April 2004||2004-04-30|October 2013|2013-10-31|December 2009|Actual|2009-12-31|||||Observational|||Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder|Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder|Completed|||3000|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-06-01 04:29:03.764729|2018-06-01 04:29:03.764729
NCT00216710|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-08-29|2005-09-16|2005-09-22|Estimate|||||||2017-08-29|2017-08-30|Actual|July 1999||1999-07-31|August 2017|2017-08-31|January 21, 2005|Actual|2005-01-21|February 21, 2004|Actual|2004-02-21||Interventional|||Evaluation of the Healthy Families Alaska Program|Evaluation of the Healthy Families Alaska Program|Completed||N/A|380|Actual|Johns Hopkins University||2|||f||||||||||||||2018-06-01 04:29:03.827369|2018-06-01 04:29:03.827369
NCT00216697|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-16|2005-09-13|2005-09-22|Estimate|||||||2011-05-16|2011-05-17|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|October 2006|Actual|2006-10-31|||||Interventional|||An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy|An Extension or Re-Treatment Study of Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|13|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 04:29:03.88555|2018-06-01 04:29:03.88555
NCT00216684|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-31|2005-09-13|2005-09-22|Estimate|||||||2011-01-31|2011-02-01|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|September 2006|Actual|2006-09-30|||||Interventional|||Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics|An Open Label Study to Confirm the Effectiveness, and Safety of Fentanyl Transdermal Matrix Patch in Japanese Patients With Chronic Intractable Pain Who Has Prior Therapy of Codeine, Morphine Hydrochloride, or Fentanyl Injectable Preparations.|Completed||Phase 3|139|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 04:29:03.944196|2018-06-01 04:29:03.944196
NCT00216671|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-01-07||2013-07-12|2005-09-14|2005-09-22|Estimate|2011-10-25|2011-12-02|Estimate||||2013-07-12|2013-07-19|Estimate|November 2005||2005-11-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode|Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode|Completed||Phase 4|220|Actual|Janssen Pharmaceutica N.V., Belgium|Due to the substantial number of protocol deviations (mainly due to prohibited medication), the study did not have the required power to demonstrate non-inferiority in the per protocol population|2|||f||||f||||||||||2018-06-01 04:29:05.001482|2018-06-01 04:29:05.001482
NCT00216658|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-20|2005-09-13|2005-09-22|Estimate|||||||2011-01-20|2011-01-24|Estimate|December 2004||2004-12-31|January 2011|2011-01-31|September 2005|Actual|2005-09-30|||||Interventional|||Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -|Open Label Study to Confirm Effectiveness, Safety and Pharmacokinetics of Fentanyl Transdermal Matrix Patch, in Japanese Patients With Cancer Pain Who Have Had a Minimum Amount of Morphine Therapy, Such as Equal to Less Than 45 mg/Day of Oral Morphine or Oxycodone Equal to Less Than 30 mg/Day.|Completed||Phase 2|87|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 04:29:05.411698|2018-06-01 04:29:05.411698
NCT00216645|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-16|2005-09-13|2005-09-22|Estimate|||||||2011-05-16|2011-05-17|Estimate|January 2005||2005-01-31|March 2010|2010-03-31|November 2006|Actual|2006-11-30|||||Interventional|||Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy|Open-label Study to Verify Effectiveness, Safety of Pegylated Liposomal Doxorubicin 50 mg/m2 Administered Every 4 Weeks to Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Who Have Undergone Prior Platinum-based Chemotherapy.|Completed||Phase 2|74|Actual|Janssen Pharmaceutical K.K.|||||f||||||||||||||2018-06-01 04:29:05.487714|2018-06-01 04:29:05.487714
NCT00216632|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-12-06|2005-09-14|2005-09-22|Estimate|||||||2012-12-06|2012-12-07|Estimate|March 2005||2005-03-31|December 2012|2012-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)|Treatment Success in Patients Requiring Treatment Change From Olanzapine to Risperidone Long Acting Injectable (TRESOR)|Completed||Phase 4|99|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:29:05.64795|2018-06-01 04:29:05.64795
NCT00216619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-07-01|2005-09-13|2005-09-22|Estimate|||||||2014-07-01|2014-07-02|Estimate|November 2003||2003-11-30|July 2014|2014-07-31|August 2006|Actual|2006-08-31|||||Interventional|PROMPT||The Prolonged Use of Topiramate for Preventing Migraine Headaches|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention|Completed||Phase 3|834|Actual|Janssen Pharmaceutica N.V., Belgium||2|||f||||f||||||||||2018-06-01 04:29:05.729344|2018-06-01 04:29:05.729344
NCT00216606|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-31|2005-09-13|2005-09-22|Estimate|||||||2011-01-31|2011-02-01|Estimate|December 2003||2003-12-31|January 2011|2011-01-31|July 2005|Actual|2005-07-31|||||Interventional|||The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine|A Randomized Double-Blind Placebo Controlled Trial to Investigate the Efficacy and Tolerability of Topiramate in the Prophylaxis of Chronic Migraine|Completed||Phase 3|59|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:29:05.939239|2018-06-01 04:29:05.939239
NCT00216593|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13||2011-06-07|2011-06-07|2005-09-13|2005-09-22|Estimate||||2011-06-07|2011-06-21|Estimate|2011-06-07|2011-06-21|Estimate|December 2003||2003-12-31|April 2010|2010-04-30|March 2008|Actual|2008-03-31|September 2007|Actual|2007-09-30||Interventional|||Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study|Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.|Completed||Phase 3|415|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||||||||||||2018-06-01 04:29:06.003508|2018-06-01 04:29:06.003508
NCT00216580|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-22|2005-09-13|2005-09-22|Estimate|||||||2013-03-22|2013-03-25|Estimate|February 2004||2004-02-29|March 2013|2013-03-31|December 2006|Actual|2006-12-31|||||Interventional|||A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis|An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis|Completed||Phase 3|50|Actual|Janssen Pharmaceutica N.V., Belgium||1|||f||||f||||||||||2018-06-01 04:29:06.071092|2018-06-01 04:29:06.071092
NCT00216567|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-31|2005-09-13|2005-09-22|Estimate|||||||2011-01-31|2011-02-01|Estimate|December 2002||2002-12-31|January 2011|2011-01-31|February 2006|Actual|2006-02-28|||||Interventional|||Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy|A Randomized, Open Label, Comparative, Multi-center Clinical Trial to Determine the Efficacy and Safety of Topiramate Comparing With Carbamazepine in Benign Rolandic Epilepsy.|Completed||Phase 4|114|Actual|Janssen Korea, Ltd., Korea|||||f||||||||||||||2018-06-01 04:29:06.138333|2018-06-01 04:29:06.138333
NCT00216554|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-20|2005-09-13|2005-09-22|Estimate|||||||2011-01-20|2011-01-24|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|March 2006|Actual|2006-03-31|||||Interventional|||The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania|A Multicenter, Open-Label Study to Evaluate Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania|Completed||Phase 4|118|Actual|Janssen Korea, Ltd., Korea|||||f||||||||||||||2018-06-01 04:29:06.190248|2018-06-01 04:29:06.190248
NCT00216541|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-18|2005-09-13|2005-09-22|Estimate|||||||2011-05-18|2011-05-19|Estimate|August 2003||2003-08-31|June 2010|2010-06-30|September 2006|Actual|2006-09-30|||||Interventional|||A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy|Randomised Study to Evaluate the Effect of Early Intervention to Treat Anemia With Epoetin Alfa Versus Standard Use on Hemoglobin Levels and the Incidence of Blood Transfusions in Cancer Patients Receiving Chemotherapy|Completed||Phase 4|110|Actual|Janssen-Cilag B.V.|||||f||||||||||||||2018-06-01 04:29:06.250817|2018-06-01 04:29:06.250817
NCT00216528|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-26|2005-09-13|2005-09-22|Estimate|||||||2010-04-26|2010-04-27|Estimate|July 2005||2005-07-31|April 2010|2010-04-30|April 2007|Actual|2007-04-30|||||Interventional|||A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres|A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)|Completed||Phase 4|527|Actual|Janssen Korea, Ltd., Korea|||||f||||||||||||||2018-06-01 04:29:06.319001|2018-06-01 04:29:06.319001
NCT00216515|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-20|2005-09-13|2005-09-22|Estimate|||||||2011-01-20|2011-01-24|Estimate|March 2004||2004-03-31|January 2011|2011-01-31|November 2005|Actual|2005-11-30|||||Interventional|||The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type|A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type|Completed||Phase 4|102|Actual|Janssen Korea, Ltd., Korea|||||f||||||||||||||2018-06-01 04:29:06.38135|2018-06-01 04:29:06.38135
NCT00216502|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-20|2005-09-13|2005-09-22|Estimate|||||||2011-01-20|2011-01-24|Estimate|August 2001||2001-08-31|January 2011|2011-01-31|November 2005|Actual|2005-11-30|||||Interventional|||A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease|Long Term Treatment With Galantamine In Dementia|Completed||Phase 3|254|Actual|Janssen-Cilag S.p.A.|||||f||||||||||||||2018-06-01 04:29:06.441911|2018-06-01 04:29:06.441911
NCT00216489|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-22|2005-09-13|2005-09-22|Estimate|||||||2010-04-22|2010-04-26|Estimate|March 2003||2003-03-31|April 2010|2010-04-30|November 2005|Actual|2005-11-30|||||Interventional|||A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)|A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD)|Completed||Phase 4|191|Actual|Janssen Cilag Pharmaceutica S.A.C.I., Greece|||||f||||||||||||||2018-06-01 04:29:06.491029|2018-06-01 04:29:06.491029
NCT00216476|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-07-08||2014-03-25|2005-09-14|2005-09-22|Estimate|2010-07-08|2010-08-10|Estimate||||2014-03-25|2014-04-16|Estimate|October 2004||2004-10-31|March 2014|2014-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder|CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness|Completed||Phase 3|753|Actual|Janssen-Cilag International NV||3|||f||||f||||||||||2018-06-01 04:29:06.627396|2018-06-01 04:29:06.627396
NCT00216463|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2016-08-01|2005-09-19|2005-09-22|Estimate|||||||2016-08-01|2016-08-03|Estimate|August 2005||2005-08-31|August 2016|2016-08-31|August 2007|Actual|2007-08-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels|A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 301012 Administered to Hypercholesterolemic Subjects|Completed||Phase 2|50|Actual|Kastle Therapeutics, LLC||5|||f||||||||||||||2018-06-01 04:29:07.594735|2018-06-01 04:29:07.594735
NCT00216450|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-22|2005-09-13|2005-09-22|Estimate|||||||2010-04-22|2010-04-26|Estimate|October 2004||2004-10-31|April 2010|2010-04-30|February 2006|Actual|2006-02-28|||||Interventional|||Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.|An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection|Completed||Phase 4|80|Actual|Janssen Cilag Pharmaceutica S.A.C.I., Greece|||||f||||||||||||||2018-06-01 04:29:07.661732|2018-06-01 04:29:07.661732
NCT00216437|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-11-09|2005-09-20|2005-09-22|Estimate|||||||2007-11-09|2007-11-12|Estimate|December 2004||2004-12-31|November 2007|2007-11-30|March 2007|Actual|2007-03-31|||||Interventional|||Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma|A Phase I Dose Escalation Study to Assess the Maximum Tolerated Dose and Feasibility of Combining Oral Capecitabine (Xeloda) and Conformal Radiotherapy (CRT) for Patients With Unresectable Hepatocellular Carcinoma, Multiple Hepatic Metastases or Cholangiocarcinoma|Terminated||Phase 1|30|Anticipated|James A. Haley Veterans Administration Hospital||||lack of accrual|f||||||||||||||2018-06-01 04:29:07.728154|2018-06-01 04:29:07.728154
NCT00216424|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2007-11-09|2005-09-21|2005-09-22|Estimate|||||||2007-11-09|2007-11-12|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|January 2007|Actual|2007-01-31|||||Interventional|||Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma|An Open Label, Phase II Study of Capecitabine (Xeloda) Plus Conformal Radiotherapy for Patients With Locally Advanced, Non-Metastatic Rectosigmoid Carcinoma|Terminated||Phase 4|40|Anticipated|James A. Haley Veterans Administration Hospital||||lack of accrual|f||||||||||||||2018-06-01 04:29:07.77639|2018-06-01 04:29:07.77639
NCT00216411|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-11|2005-09-20|2005-09-22|Estimate|||||||2007-10-11|2007-10-12|Estimate|November 2004||2004-11-30|October 2007|2007-10-31|October 2006||2006-10-31|||||Interventional|||Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm|A Prospective Phase IV, Multicentre, Placebo-Controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients|Completed||Phase 4|102||Ipsen|||||f||||||||||||||2018-06-01 04:29:07.828168|2018-06-01 04:29:07.828168
NCT00216398|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-11|2005-09-20|2005-09-22|Estimate|||||||2007-10-11|2007-10-12|Estimate|June 2004||2004-06-30|October 2007|2007-10-31|December 2006||2006-12-31|||||Interventional|||Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR|A Phase IV, Multicentre, Open-Label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR|Completed||Phase 4|8||Ipsen|||||f||||||||||||||2018-06-01 04:29:07.882917|2018-06-01 04:29:07.882917
NCT00216385|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-20|2005-09-20|2005-09-22|Estimate|||||||2005-09-20|2005-09-22|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|December 2008||2008-12-31|||||Interventional|||A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis|A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis|Unknown status|Recruiting|Phase 3|2070||Institut de Recherche pour le Developpement|||||f||||||||||||||2018-06-01 04:29:08.038103|2018-06-01 04:29:08.038103
NCT00216372|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-28|2005-09-20|2005-09-22|Estimate|||||||2009-05-28|2009-05-29|Estimate|September 2003||2003-09-30|May 2009|2009-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis|Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients.|Completed||Phase 3|80|Actual|Ipsen||2|||f||||||||||||||2018-06-01 04:29:08.158407|2018-06-01 04:29:08.158407
NCT00216359|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-10-21|2005-09-14|2005-09-22|Estimate|||||||2005-10-21|2005-10-25|Estimate|May 2003||2003-05-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Observational|||Cohort Study for Patients Using Fuzeon (Enfuvirtide)|The Radata-Fuzeon Cohort - An Observational Cohort-Study in HIV-Infected Patients Using Fuzeon (Enfuvirtide) as Part of Their Antiretroviral Combination Therapy|Unknown status|Active, not recruiting||200||Institute for Interdisciplinary Infectiology|||||f||||||||||||||2018-06-01 04:29:08.29897|2018-06-01 04:29:08.29897
NCT00216346|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-10-02|2005-09-15|2005-09-22|Estimate|||||||2014-10-02|2014-10-03|Estimate|June 2003||2003-06-30|October 2014|2014-10-31|November 2004||2004-11-30|||||Interventional|||Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis|A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis|Completed||Phase 3|667||PATH|||||f||||||||||||||2018-06-01 04:29:08.369815|2018-06-01 04:29:08.369815
NCT00216333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2006-09-12|2005-09-20|2005-09-22|Estimate|||||||2006-09-12|2006-09-13|Estimate|December 2003||2003-12-31|September 2006|2006-09-30|June 2007||2007-06-30|||||Interventional|||Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis|International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis|Unknown status|Recruiting|Phase 4|1500||International Union Against Tuberculosis and Lung Diseases|||||f||||||||||||||2018-06-01 04:29:08.43349|2018-06-01 04:29:08.43349
NCT00216320|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|2013-04-18||2013-04-18|2005-09-19|2005-09-22|Estimate|2013-04-18|2013-04-19|Estimate||||2013-04-18|2013-04-19|Estimate|September 2005||2005-09-30|April 2013|2013-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy of the WalkAide and AFOs for CVA|A Three-Arm, Randomized Crossover Study Comparing the Innovative Neurotronics WalkAide™ System to Ankle-Foot Orthosis [AFO]|Completed||N/A|121|Actual|Innovative Neurotronics||3|||f||||f||||||||||2018-06-01 04:29:08.536609|2018-06-01 04:29:08.536609
NCT00216294|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-07-14|2005-09-19|2005-09-22|Estimate|||||||2006-07-14|2006-07-17|Estimate|February 2005||2005-02-28|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder|An Open-Label, Dose Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG1068 (Synthetic Human Secretin) in Patients With Obsessive Compulsive Disorder (OCD)|Completed||Phase 2|16||Indiana University|||||||||||||||||||2018-06-01 04:29:08.922448|2018-06-01 04:29:08.922448
NCT00216281|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-03-25|2005-09-19|2005-09-22|Estimate|||||||2013-03-25|2013-03-26|Estimate|September 2005||2005-09-30|March 2013|2013-03-31|September 2008|Actual|2008-09-30|October 2006|Actual|2006-10-31||Interventional|||Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia|Correlation of Phenotype, Genotype and Clinical Efficacy/Toxicity of Clozapine Augmented by Atomoxetine for Treatment Refractory Schizophrenia (CAPG Study)|Terminated||Phase 3|126|Actual|Indiana University||2|||f||||f||||||||||2018-06-01 04:29:08.985947|2018-06-01 04:29:08.985947
NCT00216268|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2006-02-08|2005-09-20|2005-09-22|Estimate|||||||2006-02-08|2006-02-09|Estimate|July 2005||2005-07-31|September 2005|2005-09-30|May 2008||2008-05-31|||||Interventional|||Treatment of Japanese Encephalitis|Treatment of Japanese Encephalitis - a Double Blind Placebo Controlled Trial|Unknown status|Recruiting|Phase 2|200||Indian Council of Medical Research|||||f||||||||||||||2018-06-01 04:29:09.049548|2018-06-01 04:29:09.049548
NCT00216255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16||2012-08-20|2012-08-27|2005-09-16|2005-09-22|Estimate||||2012-08-20|2012-08-28|Estimate|2012-08-27|2012-09-03|Estimate|April 2005||2005-04-30|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||EXPRESS: Examining Pagoclone for Persistent Developmental Stuttering Study|An 8-week, Double-blind, Randomized, Multicenter, Flexible-dose, Placebo Controlled Pilot Study of Pagoclone in Patients With PDS Followed by a 52-week Open-label Extension|Completed||Phase 2|120|Actual|Endo Pharmaceuticals||2|||f||||t||||||||||2018-06-01 04:29:09.119252|2018-06-01 04:29:09.119252
NCT00216242|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2006-12-08|2005-09-20|2005-09-22|Estimate|||||||2006-12-08|2006-12-11|Estimate|September 2005||2005-09-30|December 2006|2006-12-31|May 2007||2007-05-31|||||Interventional|||Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.|A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age|Unknown status|Active, not recruiting|Phase 3|7400||ID Biomedical Corporation, Quebec|||||f||||||||||||||2018-06-01 04:29:09.2097|2018-06-01 04:29:09.2097
NCT00216229|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-13|2005-09-16|2005-09-22|Estimate|||||||2005-12-13|2005-12-14|Estimate|September 2004||2004-09-30|September 2005|2005-09-30|February 2006||2006-02-28|||||Interventional|||Twinrix Alternative Schedule Study|A Study Comparing the Effectiveness of Two Different Vaccination Schedules of the Combined Hepatitis A and B Vaccine(Twinrix Adult1440/20)|Unknown status|Active, not recruiting|Phase 4|400||IDEWE Occupational Health Services|||||f||||||||||||||2018-06-01 04:29:09.315619|2018-06-01 04:29:09.315619
NCT00216216|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-28|2005-09-14|2005-09-22|Estimate|||||||2011-04-28|2011-05-02|Estimate|January 2005||2005-01-31|April 2011|2011-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer|Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78)|Terminated||Phase 2|43|Actual|Hoosier Cancer Research Network||1||The results from the interim analysis were not favorable to continue this trial.|f||||t||||||||||2018-06-01 04:29:09.366953|2018-06-01 04:29:09.366953
NCT00216203|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-04-27||2016-08-22|2005-09-14|2005-09-22|Estimate|2016-04-27|2016-06-02|Estimate||||2016-08-22|2016-09-29|Estimate|May 2005||2005-05-31|August 2016|2016-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||33 of 36 consented participants received treatment.|Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer|A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79|Completed||Phase 1/Phase 2|36|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-06-01 04:29:09.496706|2018-06-01 04:29:09.496706
NCT00216190|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-07-22|2005-09-14|2005-09-22|Estimate|||||||2015-07-22|2015-07-23|Estimate|March 2005||2005-03-31|July 2015|2015-07-31|August 2007|Actual|2007-08-31|||||Interventional|||A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation|A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation|Completed||Phase 4|420|Actual|Hospira, now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 04:29:10.146807|2018-06-01 04:29:10.146807
NCT00216177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2009-08-17|2005-09-20|2005-09-22|Estimate|||||||2009-08-17|2009-08-18|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|June 2009|Anticipated|2009-06-30|January 2009|Anticipated|2009-01-31||Interventional|||Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis|Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks|Unknown status|Recruiting|Phase 4|112|Anticipated|Hvidovre University Hospital|||||f||||t||||||||||2018-06-01 04:29:10.333292|2018-06-01 04:29:10.333292
NCT00216164|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-28|2005-09-14|2005-09-22|Estimate|||||||2011-04-28|2011-05-02|Estimate|April 2005||2005-04-30|April 2011|2011-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64|Terminated||Phase 2|8|Actual|Hoosier Cancer Research Network||1||Study terminated due to lack of response at the first efficacy analysis|f||||t||||||||||2018-06-01 04:29:10.418305|2018-06-01 04:29:10.418305
NCT00216151|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-28|2005-09-14|2005-09-22|Estimate|||||||2011-04-28|2011-05-02|Estimate|June 2005||2005-06-30|April 2011|2011-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma|A Randomized Phase II Study of Bisphosphonate: Zoledronic Acid (Zometa) in the Management of Asymptomatic/Early Stage Multiple Myeloma: Hoosier Oncology Group MM02-35|Terminated||Phase 2|3|Actual|Hoosier Cancer Research Network||2||Study terminated due to low patient enrollment.|f||||t||||||||||2018-06-01 04:29:10.497219|2018-06-01 04:29:10.497219
NCT00216138|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-28|2005-09-14|2005-09-22|Estimate|||||||2011-04-28|2011-05-02|Estimate|March 2004||2004-03-31|April 2011|2011-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck|A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): Hoosier Oncology Group HN02-40|Terminated||Phase 2|19|Actual|Hoosier Cancer Research Network||1||Interim analysis results did not meet criteria for second stage of trial|f||||t||||||||||2018-06-01 04:29:10.621087|2018-06-01 04:29:10.621087
NCT00216125|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-11-23||2016-02-17|2005-09-14|2005-09-22|Estimate|2016-02-04|2016-02-08|Estimate||||2016-02-17|2016-03-16|Estimate|February 2002||2002-02-28|February 2016|2016-02-29|March 2008|Actual|2008-03-31|June 2006|Actual|2006-06-30||Interventional|||Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer|A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24|Completed||Phase 3|243|Actual|Hoosier Cancer Research Network||3|||f||||t||||||||No||2018-06-01 04:29:10.760922|2018-06-01 04:29:10.760922
NCT00216112|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-02-17|2005-09-14|2005-09-22|Estimate|||||||2016-02-17|2016-02-19|Estimate|December 2003||2003-12-31|February 2016|2016-02-29|July 2007|Actual|2007-07-31|October 2005|Actual|2005-10-31||Interventional|||Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer|Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62|Completed||Phase 2|23|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-06-01 04:29:11.423271|2018-06-01 04:29:11.423271
NCT00216099|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-12-17||2016-06-18|2005-09-14|2005-09-22|Estimate|2016-06-18|2016-07-29|Estimate||||2016-06-18|2016-07-29|Estimate|February 2005||2005-02-28|June 2016|2016-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer|A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67|Completed||Phase 2|49|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-06-01 04:29:11.504368|2018-06-01 04:29:11.504368
NCT00216086|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2016-01-05||2016-04-27|2005-09-14|2005-09-22|Estimate|2016-04-27|2016-06-06|Estimate||||2016-04-27|2016-06-06|Estimate|May 2005||2005-05-31|April 2016|2016-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer|A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53|Terminated||Phase 2|22|Actual|Hoosier Cancer Research Network||1||Funding withdrawn|f||||t||||||||No||2018-06-01 04:29:12.031071|2018-06-01 04:29:12.031071
NCT00216073|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-29|2005-09-14|2005-09-22|Estimate|||||||2011-04-29|2011-05-02|Estimate|March 2004||2004-03-31|April 2011|2011-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer|A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients With HER-2 Positive Metastatic Breast Cancer: Hoosier Oncology Group BRE03-61|Terminated||Phase 2|11|Actual|Hoosier Cancer Research Network||1||Lack of patient accrual|f||||t||||||||||2018-06-01 04:29:12.368922|2018-06-01 04:29:12.368922
NCT00216060|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-01-05||2016-05-25|2005-09-14|2005-09-22|Estimate|2016-05-25|2016-05-26|Estimate||||2016-05-25|2016-05-26|Estimate|October 2003||2003-10-31|May 2016|2016-05-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41|Terminated||Phase 3|63|Actual|Hoosier Cancer Research Network||2||Terminated due to low accrual|f||||t||||||||No||2018-06-01 04:29:12.505361|2018-06-01 04:29:12.505361
NCT00216047|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-08|2005-09-14|2005-09-22|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2005||2005-01-31|December 2015|2015-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer|A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80|Terminated||Phase 1/Phase 2|7|Actual|Hoosier Cancer Research Network||1||Low patient enrollment; toxicities|f||||t||||||||||2018-06-01 04:29:13.289712|2018-06-01 04:29:13.289712
NCT00216034|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2016-06-06|2005-09-20|2005-09-22|Estimate|||||||2016-06-06|2016-06-07|Estimate|March 2005||2005-03-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK|Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy|Completed||Phase 3|255|Actual|Hokuriku-Kinki Immunochemotherapy Study Group||2|||f||||t||||||||||2018-06-01 04:29:13.368215|2018-06-01 04:29:13.368215
NCT00216021|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-12-08|2005-09-14|2005-09-22|Estimate|||||||2015-12-08|2015-12-09|Estimate|March 2004||2004-03-31|December 2015|2015-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer|A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60|Completed||Phase 2|25|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||||2018-06-01 04:29:13.468637|2018-06-01 04:29:13.468637
NCT00216008|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-11-21|2005-09-19|2005-09-22|Estimate|||||||2013-11-21|2013-11-25|Estimate|July 2005||2005-07-31|July 2009|2009-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.|Phase II Pharmacogenomic Study of Neoadjuvant Pre-irradiation Docetaxel and Cisplatin, Followed by Neoadjuvant Concomitant Docetaxel, Cisplatin and Irradiation, Followed by Surgery (CD-CDR-S) in Adult Patients With Operable Adenocarcinomas of the Esophagus or Gastroesophageal Junction|Terminated||Phase 2|42||H. Lee Moffitt Cancer Center and Research Institute||||IRB Closure|f||||||||||||||2018-06-01 04:29:13.538307|2018-06-01 04:29:13.538307
NCT00215995|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2012-01-12|2005-09-19|2005-09-22|Estimate|||||||2012-01-12|2012-01-13|Estimate|July 2003||2003-07-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas|A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas|Completed||Phase 2|21|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 04:29:13.592842|2018-06-01 04:29:13.592842
NCT00215982|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-11-21|2005-09-19|2005-09-22|Estimate|||||||2013-11-21|2013-11-25|Estimate|December 2004||2004-12-31|September 2010|2010-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer|A Phase II Study of Capecitabine in Combination With Irinotecan and Oxaliplatin (Eloxatin) in Adult Patients With Advanced Colorectal Cancer|Completed||Phase 2|24|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 04:29:13.66186|2018-06-01 04:29:13.66186
NCT00215969|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-02-01|2005-09-14|2005-09-22|Estimate|||||||2006-02-01|2006-02-02|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|October 2007||2007-10-31|||||Observational|||Prospective Study in Pregnant Women With Hypercoagulopathy|Prospective Study of Hypercoagulation in Pregnant Women|Unknown status|Recruiting||600||Hillerod Hospital, Denmark|||||f||||||||||||||2018-06-01 04:29:13.727739|2018-06-01 04:29:13.727739
NCT00215956|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-12-20|2005-09-19|2005-09-22|Estimate|||||||2013-12-20|2013-12-23|Estimate|November 2001||2001-11-30|January 2009|2009-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma|A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma|Completed||Phase 1|31|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||||||||||||2018-06-01 04:29:13.780796|2018-06-01 04:29:13.780796
NCT00215943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2013-08-21||2014-04-01|2005-09-15|2005-09-22|Estimate|2014-01-29|2014-03-04|Estimate||||2014-04-01|2014-04-17|Estimate|June 2003||2003-06-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)|Phase III Randomized Trial of Thalidomide/Dexamethasone vs VAD as Induction Chemotherapy for Newly Diagnosed Myeloma Patients and Evaluation of the Effects of Zoledronate on Chemotherapy Induced Apoptosis and Antigen Presentation.|Terminated||Phase 3|90|Actual|H. Lee Moffitt Cancer Center and Research Institute|Target accrual for planned analysis (176) was not met. Principal Investigator (PI) determined study must close due to changes in the management of newly diagnosed myeloma (emergence of new drugs, more effective regimens).|2||"Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more~   effective regimens."|f||||t||||||||||2018-06-01 04:29:13.932388|2018-06-01 04:29:13.932388
NCT00215930|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2010-10-08||2017-02-20|2005-09-15|2005-09-22|Estimate|2011-01-27|2011-02-23|Estimate||||2017-02-20|2017-03-23|Actual|February 2004||2004-02-29|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer|Phase II Study on the Use of Molecular Analyses-Based Customized Chemotherapy in Patients With Stage IV/IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer (NSCLC)|Completed||Phase 2|53|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-06-01 04:29:14.405743|2018-06-01 04:29:14.405743
NCT00215917|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2006-05-01|2005-09-18|2005-09-22|Estimate|||||||2006-05-01|2006-05-03|Estimate||||May 2006|2006-05-31||||||||Interventional|||D-Serine Monotherapy for Schizophrenia||Unknown status|Recruiting|Phase 1/Phase 2|40||Herzog Hospital|||||f||||||||||||||2018-06-01 04:29:14.725309|2018-06-01 04:29:14.725309
NCT00215904|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2012-07-05|2005-09-18|2005-09-22|Estimate|||||||2012-07-05|2012-07-09|Estimate|August 2003||2003-08-31|July 2012|2012-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||D-serine Adjuvant Treatment for Parkinson's Disease|D-serine Adjuvant Treatment for Parkinson's Disease|Completed||Phase 4|13|Actual|Herzog Hospital||2|||f||||t||||||||||2018-06-01 04:29:14.79213|2018-06-01 04:29:14.79213
NCT00215891|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-10-24|2005-09-20|2005-09-22|Estimate|||||||2005-10-24|2005-10-25|Estimate||||September 2005|2005-09-30||||||||Interventional|||PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon|PEG-Interferon a-2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon|Completed||Phase 3|300||Hepatitis Resource Network|||||||||||||||||||2018-06-01 04:29:14.857908|2018-06-01 04:29:14.857908
NCT00215878|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2012-07-05|2005-09-18|2005-09-22|Estimate|||||||2012-07-05|2012-07-09|Estimate|August 2003||2003-08-31|July 2012|2012-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||D-serine for Posttraumatic Stress Disorder Treatment|D-serine for Posttraumatic Stress Disorder Treatment|Completed||Phase 2|22|Actual|Herzog Hospital||2|||f||||t||||||||||2018-06-01 04:29:14.917804|2018-06-01 04:29:14.917804
NCT00214071|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2004||2004-10-31|August 2009|2009-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Immunological Consequences of Obstructive Sleep Apnea|Influence of Obstructive Sleep Apnea on Humoral and Cell-Mediated Vaccine Responses|Completed||N/A|30||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:37.54267|2018-06-01 04:29:37.54267
NCT00215865|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-09-20|2005-09-20|2005-09-22|Estimate|||||||2005-09-20|2005-09-22|Estimate||||September 2005|2005-09-30||||||||Interventional|||PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy|HRN 003PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy|Completed||Phase 3|600||Hepatitis Resource Network|||||||||||||||||||2018-06-01 04:29:14.986503|2018-06-01 04:29:14.986503
NCT00215852|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16||2013-08-27|2013-08-27|2005-09-16|2005-09-22|Estimate||||2013-08-27|2013-09-04|Estimate|2013-08-27|2013-09-04|Estimate|July 2005||2005-07-31|August 2013|2013-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects|A Randomized, Dose-Ranging Study of Alferon® LDO [Low Dose Interferon Alfa-n3 (Human Leukocyte Derived)] in Asymptomatic HIV+ Subjects|Terminated||Phase 2|17|Actual|Hemispherx Biopharma||3|||f||||f||||||||||2018-06-01 04:29:15.054216|2018-06-01 04:29:15.054216
NCT00215839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-10-24|2005-09-20|2005-09-22|Estimate|||||||2005-10-24|2005-10-25|Estimate||||September 2005|2005-09-30||||||||Interventional|||HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy|A Multi-Center, Randomized, Open-Label, Phase IIIb Study Investigating the Safety and Efficacy of Peginterferon a-2a Plus Ribavirin for the Treatment of Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy|Unknown status|Active, not recruiting|Phase 3|||Hepatitis Resource Network|||||||||||||||||||2018-06-01 04:29:15.135593|2018-06-01 04:29:15.135593
NCT00215826|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-04-16|2005-09-21|2005-09-22|Estimate|||||||2013-04-16|2013-04-17|Estimate|November 2004||2004-11-30|April 2013|2013-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers|A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS|Completed||Phase 2|10|Actual|Hemispherx Biopharma||2|||f||||f||||||||||2018-06-01 04:29:15.196283|2018-06-01 04:29:15.196283
NCT00215813|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-07-21|2005-09-16|2005-09-22|Estimate|||||||2017-07-21|2017-07-25|Actual|March 1997||1997-03-31|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ampligen in Chronic Fatigue Syndrome|An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN®) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)|Active, not recruiting||Phase 3|100|Anticipated|Hemispherx Biopharma||1|||f||||f||||||||No||2018-06-01 04:29:15.267998|2018-06-01 04:29:15.267998
NCT00215800|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-04-16|2005-09-16|2005-09-22|Estimate|||||||2013-04-16|2013-04-17|Estimate|December 1998||1998-12-31|April 2013|2013-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome|A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME)|Completed||Phase 3|234||Hemispherx Biopharma|||||f||||f||||||||||2018-06-01 04:29:15.339091|2018-06-01 04:29:15.339091
NCT00215787|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2010-08-10||2010-09-21|2005-09-21|2005-09-22|Estimate|2010-09-21|2010-09-22|Estimate||||2010-09-21|2010-09-22|Estimate|September 2005||2005-09-30|September 2010|2010-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease|Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease|Completed||N/A|20|Actual|Head and Neck Surgery Associates|||||f||||t||||||||||2018-06-01 04:29:15.393721|2018-06-01 04:29:15.393721
NCT00215774|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-09-10|2005-09-14|2005-09-22|Estimate|||||||2012-09-10|2012-09-11|Estimate|March 2005||2005-03-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|October 2009|Actual|2009-10-31||Interventional|||Flecainide-Short Long Study (Flec-SL)|Targeted Pharmacological Reversal of Electrical Remodeling After Cardioversion.|Completed||N/A|760|Actual|Atrial Fibrillation Network||3|||f||||t||||||||||2018-06-01 04:29:15.510006|2018-06-01 04:29:15.510006
NCT00215761|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-09-07|2005-09-14|2005-09-22|Estimate|||||||2012-09-07|2012-09-10|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Observational|||Recurrence of Atrial Fibrillation in Patients With Dual-chamber Pacemakers and Drug Therapy|A Multicenter Study to Investigate Preventive Pacing in Combination With Antiarrhythmic Beta-Blocker Oder AT-I-/ACE-inhibitor Therapy on the Recurrence of Atrial Fibrillation in Patients With Dual-chamber Pacemakers|Completed|||263|Actual|Atrial Fibrillation Network|||||f||||||||||||||2018-06-01 04:29:15.576519|2018-06-01 04:29:15.576519
NCT00215748|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-11-15|2005-09-19|2005-09-22|Estimate|||||||2007-11-15|2007-11-16|Estimate|August 2004||2004-08-31|November 2007|2007-11-30|April 2007|Actual|2007-04-30|||||Interventional|||Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel|Feasibility of A Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Treated With Weekly Docetaxel|Terminated||Phase 2|40|Anticipated|Geriatric Oncology Consortium||||slow accrual|f||||||||||||||2018-06-01 04:29:15.623401|2018-06-01 04:29:15.623401
NCT00215735|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-03-16|2005-09-14|2005-09-22|Estimate|||||||2012-03-16|2012-03-20|Estimate|June 2004||2004-06-30|March 2012|2012-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Effect of Platelet Concentrate in Treatment of Diabetic Ulcers|Clinical Evaluation of the Safety and Effectiveness of Harvest Autologous Platelet Concentrate and Autologous Thrombin for Treatment of Lower Extremity Chronic Diabetic Ulcers|Terminated||N/A|||Harvest Technologies||1||inconclusive results, market feasiblity|f||||||||||||||2018-06-01 04:29:15.674974|2018-06-01 04:29:15.674974
NCT00215722|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-04-05|2005-09-20|2005-09-22|Estimate|||||||2007-04-05|2007-04-06|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|July 2008|Anticipated|2008-07-31|||||Interventional|||XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer||Unknown status|Active, not recruiting|Phase 2|45||Grupo de Investigacao do Cancro Digestivo|||||f||||||||||||||2018-06-01 04:29:15.740316|2018-06-01 04:29:15.740316
NCT00215709|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-11-15|2005-09-19|2005-09-22|Estimate|||||||2007-11-15|2007-11-19|Estimate|July 2004||2004-07-31|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer|A Pilot Study of Docetaxel on a Bi-Weekly Schedule in the Treatment of Elderly Men With Hormone-Refractory Prostate Cancer (HRPC)|Completed||Phase 1|17|Actual|Geriatric Oncology Consortium|||||f||||||||||||||2018-06-01 04:29:15.841096|2018-06-01 04:29:15.841096
NCT00214279|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-06-22|2005-09-14|2005-09-21|Estimate|||||||2012-06-22|2012-06-26|Estimate|May 2002||2002-05-31|June 2012|2012-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal|MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal|Completed||N/A|32|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-06-01 04:29:35.911024|2018-06-01 04:29:35.911024
NCT00215696|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-05-12|2005-09-15|2005-09-22|Estimate|||||||2011-05-12|2011-05-13|Estimate|April 2005||2005-04-30|May 2011|2011-05-31||||||||Interventional|||A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard Therapies|"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA™-GUIDED/MYOSTAR™ Catheter in No Option Patients With Class II-IV Stable Angina"|Completed||Phase 2|129||GenVec|||||f||||||||||||||2018-06-01 04:29:15.915348|2018-06-01 04:29:15.915348
NCT00215683|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2010-11-12||2015-03-12|2005-09-20|2005-09-22|Estimate|2010-11-12|2010-12-14|Estimate||||2015-03-12|2015-04-01|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer|An Open-Label, Multi-Centre, Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer.|Completed||Phase 2/Phase 3|137|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-06-01 04:29:16.002144|2018-06-01 04:29:16.002144
NCT00215670|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-05-02|2005-09-20|2005-09-22|Estimate|||||||2006-05-02|2006-05-03|Estimate|November 2002||2002-11-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)|A Randomized, Double-Masked, Multi-Center Trial of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Intravitreal Injections of Pegaptanib Sodium (Anti-Vegf Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)|Completed||Phase 2/Phase 3|125||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 04:29:17.934174|2018-06-01 04:29:17.934174
NCT00215657|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2009-01-22||2011-05-18|2005-09-20|2005-09-22|Estimate|2009-04-24|2009-06-12|Estimate||||2011-05-18|2011-05-20|Estimate|March 2003||2003-03-31|May 2011|2011-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|Terminated||Phase 2|131|Actual|Ferring Pharmaceuticals||8||The doses were not effective in maintaining testosterone suppression|f||||f||||||||||2018-06-01 04:29:18.077998|2018-06-01 04:29:18.077998
NCT00215644|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-11-04|2005-09-15|2005-09-22|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2005||2005-08-31|November 2016|2016-11-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer)|Randomized Phase II Open-label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-gastric Adenocarcinoma|Completed||Phase 2|72|Actual|Merck KGaA||2|||f||||f||||||||||2018-06-01 04:29:20.237262|2018-06-01 04:29:20.237262
NCT00215631|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2015-09-14|2005-09-18|2005-09-22|Estimate|||||||2015-09-14|2015-09-15|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|November 2005|Actual|2005-11-30|||||Interventional|||Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?|Can Tadalafil (Cialis)® Maintain Erectile Function In Patients Treated With External-beam Radiotherapy For Prostate Cancer? A Randomized, Double-blind, Placebo-controlled Study|Terminated||Phase 3|100||Erasmus Medical Center||||slow recruitment|f||||||||||||||2018-06-01 04:29:20.430051|2018-06-01 04:29:20.430051
NCT00215618|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2009-01-13|2005-09-19|2005-09-22|Estimate|||||||2009-01-13|2009-01-14|Estimate|March 2003||2003-03-31|January 2009|2009-01-31|September 2008|Actual|2008-09-30|August 2006|Actual|2006-08-31||Interventional|||Uterine Balloon Treatment for Heavy Period Bleeding.|Clinical Evaluation of Uterine Balloon Therapy System for Menorrhagia|Completed||Phase 3|250|Actual|Ethicon, Inc.||2|||f||||f||||||||||2018-06-01 04:29:20.487572|2018-06-01 04:29:20.487572
NCT00215605|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-02-26|2005-09-20|2005-09-22|Estimate|||||||2013-02-26|2013-02-27|Estimate|September 2005||2005-09-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|April 2011|Actual|2011-04-30||Interventional|||Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies|Completed||Phase 1|85|Actual|Exelixis||1|||f||||||||||||||2018-06-01 04:29:20.548297|2018-06-01 04:29:20.548297
NCT00215592|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-01-06|2005-09-14|2005-09-22|Estimate|||||||2016-01-06|2016-01-08|Estimate|October 2005||2005-10-31|November 2015|2015-11-30||||July 2007|Actual|2007-07-31||Interventional|||Open Label, Zonegran (Zonisamide) In Partial Onset Seizures|An Open Label Study Of Zonegran (Zonisamide) In Patients With Partial Onset Seizures|Completed||Phase 4|1000|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:29:20.606622|2018-06-01 04:29:20.606622
NCT00215579|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-09-19|2005-09-14|2005-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|April 2004||2004-04-30|March 2012|2012-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence||Completed||Phase 4|64|Actual|Duke University|||||f||||f||||||||||2018-06-01 04:29:20.690461|2018-06-01 04:29:20.690461
NCT00215566|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-05-25|2005-09-19|2005-09-22|Estimate|||||||2007-05-25|2007-05-28|Estimate|September 2005||2005-09-30|March 2006|2006-03-31||||||||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation|Completed||Phase 2|90||Dynogen Pharmaceuticals|||||f||||||||||||||2018-06-01 04:29:20.738845|2018-06-01 04:29:20.738845
NCT00215553|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-04-02||2012-04-02|2005-09-21|2005-09-22|Estimate|2012-04-02|2012-04-27|Estimate||||2012-04-02|2012-04-27|Estimate|May 2001||2001-05-31|April 2012|2012-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||KL₄Surfactant Treatment in Patients With ARDS|A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of SURFAXIN® (Lucinactant) Delivered Via Bronchopulmonary Segmental Lavage to Standard of Care in Patients With Acute Respiratory Distress Syndrome (ARDS).|Terminated||Phase 2|124|Actual|Windtree Therapeutics||7||Slow enrollment and administrative reasons|f||||t||||||||||2018-06-01 04:29:21.024791|2018-06-01 04:29:21.024791
NCT00215540|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-04-02||2012-05-11|2005-09-21|2005-09-22|Estimate|2012-05-11|2012-06-13|Estimate||||2012-05-11|2012-06-13|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.|A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of SURFAXIN® (Lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dysplasia|Terminated||Phase 2|136|Actual|Windtree Therapeutics||3||Concerns related to availability of drug product|f||||t||||||||||2018-06-01 04:29:22.112731|2018-06-01 04:29:22.112731
NCT00215527|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-02-20|2005-09-19|2005-09-22|Estimate|||||||2013-02-20|2013-02-21|Estimate|November 2005||2005-11-30|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I|A Study of Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis I|Terminated||Phase 1|4|Actual|Dickson, Patricia I., M.D.||1||Due to slow enrolment.|f||||t||||||||||2018-06-01 04:29:22.920973|2018-06-01 04:29:22.920973
NCT00215514|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-07-28|2005-09-20|2005-09-22|Estimate|||||||2014-07-28|2014-07-29|Estimate|September 2000||2000-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|November 2003|Actual|2003-11-30||Interventional|||Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma|A Pilot Study of Adjuvant Chemoradiation After Resection of Gastric Or Gastroesophageal Junction Adenocarcinoma|Completed||Early Phase 1|25|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:29:22.984957|2018-06-01 04:29:22.984957
NCT00215501|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-07-08|2005-09-14|2005-09-22|Estimate|||||||2016-07-08|2016-07-12|Estimate|November 2001||2001-11-30|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2005|Actual|2005-09-30||Interventional|||Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies|A Phase I Trial of Capecitabine or Continuous Infusion 5-Fluorouracil in Combination With Weekly Irinotecan and Cisplatin in Patients With Advanced Solid Tumor Malignancies|Active, not recruiting||Phase 1|68|Anticipated|Dana-Farber Cancer Institute||2|||f||||||||||||||2018-06-01 04:29:23.075244|2018-06-01 04:29:23.075244
NCT00215462|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-04-27|2005-09-14|2005-09-22|Estimate|||||||2009-04-27|2009-04-28|Estimate|June 2000||2000-06-30|April 2009|2009-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma|A Phase II Study of Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma|Completed||Phase 2|32||Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:29:23.148354|2018-06-01 04:29:23.148354
NCT00215449|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-14|2005-09-22|Estimate|||||||2010-11-10|2010-11-11|Estimate||||January 2009|2009-01-31|April 2006|Actual|2006-04-30|December 2005|Actual|2005-12-31||Interventional|||Study in Patients With COPD||Completed||Phase 3|690||Dey|||||||||||||||||||2018-06-01 04:29:23.399643|2018-06-01 04:29:23.399643
NCT00215436|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-09|2005-09-15|2005-09-22|Estimate|||||||2010-11-09|2010-11-10|Estimate|March 2005||2005-03-31|April 2008|2008-04-30|September 2006|Actual|2006-09-30|September 2005|Actual|2005-09-30||Interventional|||A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD|A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|345||Dey|||||||||||||||||||2018-06-01 04:29:23.555663|2018-06-01 04:29:23.555663
NCT00215423|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-14|2005-09-22|Estimate|||||||2010-11-10|2010-11-11|Estimate||||August 2008|2008-08-31|September 2005|Actual|2005-09-30|December 2003|Actual|2003-12-31||Interventional|||Study in Patients With COPD||Completed||Phase 2|49||Dey|||||||||||||||||||2018-06-01 04:29:23.744547|2018-06-01 04:29:23.744547
NCT00215410|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-14|2005-09-22|Estimate|||||||2010-11-10|2010-11-11|Estimate||||February 2008|2008-02-29|October 2005|Actual|2005-10-31|October 2003|Actual|2003-10-31||Interventional|||Study in Patients With Asthma||Completed||Phase 2|36||Dey|||||||||||||||||||2018-06-01 04:29:23.813689|2018-06-01 04:29:23.813689
NCT00215397|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-14|2005-09-22|Estimate|||||||2010-11-10|2010-11-11|Estimate||||February 2008|2008-02-29|December 2005|Actual|2005-12-31|February 2003|Actual|2003-02-28||Interventional|||Study in Patients With Asthma||Completed||Phase 2|16||Dey|||||||||||||||||||2018-06-01 04:29:23.908949|2018-06-01 04:29:23.908949
NCT00215384|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-14|2005-09-22|Estimate|||||||2010-11-10|2010-11-11|Estimate||||February 2008|2008-02-29|October 2005|Actual|2005-10-31|April 2003|Actual|2003-04-30||Interventional|||Study in Patients With COPD||Completed||Phase 2|35||Dey|||||||||||||||||||2018-06-01 04:29:24.000514|2018-06-01 04:29:24.000514
NCT00215371|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-14|2005-09-22|Estimate|||||||2010-11-10|2010-11-11|Estimate|July 2002||2002-07-31|February 2008|2008-02-29|November 2005|Actual|2005-11-30|October 2002|Actual|2002-10-31||Interventional|||Study in Patients With Asthma||Completed||Phase 2|32||Dey|||||||||||||||||||2018-06-01 04:29:24.101733|2018-06-01 04:29:24.101733
NCT00215358|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-14|2005-09-22|Estimate|||||||2010-11-10|2010-11-11|Estimate|July 2002||2002-07-31|February 2008|2008-02-29|December 2005|Actual|2005-12-31|October 2002|Actual|2002-10-31||Interventional|||Study in Patients With Asthma||Completed||Phase 2|32||Dey|||||||||||||||||||2018-06-01 04:29:24.171915|2018-06-01 04:29:24.171915
NCT00215345|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2005-09-20|2005-09-20|2005-09-22|Estimate|||||||2005-09-20|2005-09-22|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer|A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer|Unknown status|Recruiting|Phase 2|66||Department of Veterans Affairs, New Jersey|||||||||||||||||||2018-06-01 04:29:24.228134|2018-06-01 04:29:24.228134
NCT00215332|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-04-10|2005-09-14|2005-09-22|Estimate|||||||2015-04-10|2015-04-13|Estimate|March 2005||2005-03-31|April 2015|2015-04-30|July 2007|Actual|2007-07-31|||||Observational|||CHARITE™ vs. ALIF 5-Year Follow-up|Five-year Follow-up of the CHARITÉ™ Artificial Disc Compared to Anterior Lumbar Interbody Fusion With the BAK Cage.|Completed|||367|Anticipated|DePuy Spine|||3||f||||f||||||||||2018-06-01 04:29:24.296659|2018-06-01 04:29:24.296659
NCT00215319|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-22|2005-09-14|2005-09-22|Estimate|||||||2014-05-22|2014-05-23|Estimate|December 2000||2000-12-31|May 2014|2014-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Titanium Surgical Mesh and MOSS-Miami Screws for Lumbar Fusion.|A Multi-center Study to Evaluate the Safety and Efficacy of DePuy AcroMed Titanium Surgical Mesh and MOSS-Miami Spinal Fixation System Pedicle Screws for Intradiscal Fusion in the Lumbar Spine|Completed||Phase 3|139|Actual|DePuy Spine||1|||f||||f||||||||||2018-06-01 04:29:24.363061|2018-06-01 04:29:24.363061
NCT00215306|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-22|2005-09-14|2005-09-22|Estimate|||||||2014-05-22|2014-05-23|Estimate|March 2000||2000-03-31|May 2014|2014-05-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||CHARITÉ™ Artificial Disc Compared to Anterior Interbody Fusion for Treatment of Degenerative Disc Disease|Clinical Investigation of the SB Charite III Intervertebral Disc Spacer.|Completed||Phase 3|304|Actual|DePuy Spine||2|||f||||||||||||||2018-06-01 04:29:24.425192|2018-06-01 04:29:24.425192
NCT00215293|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-22|2005-09-14|2005-09-22|Estimate|||||||2014-05-22|2014-05-23|Estimate|August 2000||2000-08-31|May 2014|2014-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Cervical I/F Cage for Anterior Cervical Fusion|A Randomized Multi-Center Study to Evaluate the Safety and Efficacy of the Cervical I/F Cage for Anterior Cervical Fusion|Completed||Phase 3|240|Actual|DePuy Spine||2|||f||||f||||||||||2018-06-01 04:29:24.489579|2018-06-01 04:29:24.489579
NCT00213473|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2001||2001-06-30|June 2013|2013-06-30|May 2006||2006-05-31|||||Observational|||Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study|Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA Study|Completed|||81|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:42.58035|2018-06-01 04:29:42.58035
NCT00215267|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-02-19|2005-09-20|2005-09-22|Estimate|||||||2008-02-19|2008-02-21|Estimate|September 2005||2005-09-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda|The Effect of One Versus Two Praziquantel Treatments on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria in Uganda|Completed||N/A|540|Anticipated|DBL -Institute for Health Research and Development|||||f||||||||||||||2018-06-01 04:29:24.607148|2018-06-01 04:29:24.607148
NCT00215254|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2006-12-18|2005-09-20|2005-09-22|Estimate|||||||2006-12-18|2006-12-19|Estimate|March 2004||2004-03-31|March 2006|2006-03-31|February 2006||2006-02-28|||||Interventional|||Quetiapine in Social Anxiety Disorder|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder|Completed||Phase 2/Phase 3|15||Duke University|||||f||||||||||||||2018-06-01 04:29:24.808272|2018-06-01 04:29:24.808272
NCT00215241|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-09-18|2005-09-20|2005-09-22|Estimate|||||||2014-09-18|2014-09-22|Estimate|April 2004||2004-04-30|June 2006|2006-06-30|July 2006||2006-07-31|||||Interventional|||Risperidone Augmentation for PTSD|Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD|Completed||Phase 2/Phase 3|80||Duke University|||||f||||||||||||||2018-06-01 04:29:24.872105|2018-06-01 04:29:24.872105
NCT00215228|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2014-07-18|2005-09-20|2005-09-22|Estimate|||||||2014-07-18|2014-07-21|Estimate|July 2005||2005-07-31|September 2007|2007-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression|Effects of Escitalopram vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control|Completed||Phase 2/Phase 3|26|Anticipated|Duke University|||||f||||||||||||||2018-06-01 04:29:24.943163|2018-06-01 04:29:24.943163
NCT00215215|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2006-02-20|2005-09-16|2005-09-22|Estimate|||||||2006-02-20|2006-02-22|Estimate|February 2005||2005-02-28|February 2006|2006-02-28|November 2007||2007-11-30|||||Interventional|||Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures|Post Marketing Study; Randomized, Parallel-Group Comparison of Treatment With Pharmacotherapy or Adjunctive Vagus Nerve Stimulation Therapy for Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial|Terminated||Phase 4|360||Cyberonics, Inc.|||||f||||||||||||||2018-06-01 04:29:25.013315|2018-06-01 04:29:25.013315
NCT00215202|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2018-05-16|2005-09-15|2005-09-22|Estimate|||||||2018-05-16|2018-05-17|Actual|August 2004||2004-08-31|May 2018|2018-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)|A Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)|Completed||Phase 2|16|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 04:29:25.108512|2018-06-01 04:29:25.108512
NCT00215189|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-09-22|2005-09-15|2005-09-22|Estimate|||||||2009-09-22|2009-09-23|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Evaluation of a Health Promotion Intervention for Persons With Mental Illness|Evaluation of a Health Promotion Intervention for Persons With Mental Illness|Completed|||145|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 04:29:25.16839|2018-06-01 04:29:25.16839
NCT00215176|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-06-17|2005-09-20|2005-09-22|Estimate|||||||2013-06-17|2013-06-19|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|April 2005||2005-04-30|||||Interventional|||Modafinil for Atypical Depression|A Study of Modafinil for Atypical Depression|Completed||Phase 2/Phase 3|65||Duke University|||||f||||||||||||||2018-06-01 04:29:25.216439|2018-06-01 04:29:25.216439
NCT00215163|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2013-05-29|2005-09-20|2005-09-22|Estimate|||||||2013-05-29|2013-05-30|Estimate|December 2002||2002-12-31|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy|Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post-Traumatic Stress Disorder (PTSD) Remaining Symptomatic After Initial Exposure Therapy|Completed||Phase 2/Phase 3|17|Actual|Duke University|||||f||||||||||||||2018-06-01 04:29:25.332325|2018-06-01 04:29:25.332325
NCT00215150|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2012-12-13||2014-10-23|2005-09-20|2005-09-22|Estimate|2013-04-16|2013-05-24|Estimate||||2014-10-23|2014-10-31|Estimate|November 2004||2004-11-30|April 2013|2013-04-30|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|SAD|This is the intent to treat population consisting of subjects completing at least one post baseline visit.|Geodon for the Treatment of Refractory Social Anxiety Disorder|Ziprasidone for the Treatment of Refractory Social Anxiety Disorder|Completed||Phase 2|51|Actual|Duke University||3|||f||||f||||||||||2018-06-01 04:29:25.421521|2018-06-01 04:29:25.421521
NCT00215137|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|2013-04-15||2014-07-14|2005-09-20|2005-09-22|Estimate|2013-08-22|2013-10-29|Estimate||||2014-07-14|2014-07-23|Estimate|October 2004||2004-10-31|August 2013|2013-08-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional||Only the open label treatment phase is being reported per reviewer's instructions. The other arms are for the second phase of the study.|Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder|Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder|Completed||Phase 2|14|Actual|Duke University||3|||f||||f||||||||||2018-06-01 04:29:25.606852|2018-06-01 04:29:25.606852
NCT00215124|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-09-17|2005-09-14|2005-09-22|Estimate|||||||2008-09-17|2008-09-19|Estimate||||September 2008|2008-09-30|February 2007|Actual|2007-02-28|||||Interventional|||A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction|Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction|Completed||Phase 1/Phase 2|||The Cleveland Clinic|||||f||||t||||||||||2018-06-01 04:29:25.78871|2018-06-01 04:29:25.78871
NCT00215111|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-02-04|2005-09-15|2005-09-22|Estimate|||||||2015-02-04|2015-02-05|Estimate|March 2005||2005-03-31|February 2015|2015-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Role of Carbohydrate Modification in Weight Management Among Obese Children|Role of Carbohydrate Modification in Weight Management Among Obese Children|Completed||N/A|102|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||||||||||||2018-06-01 04:29:25.83773|2018-06-01 04:29:25.83773
NCT00215098|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-03-14|2005-09-20|2005-09-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|May 2005||2005-05-31|June 2007|2007-06-30|November 2006|Actual|2006-11-30|||||Observational|||Chylothorax Following Heart Surgery|Chylothorax in Children Following Congenital Heart Surgery|Terminated|||70|Anticipated|Children's Healthcare of Atlanta||||insufficient data|f||||f||||||||||2018-06-01 04:29:25.91362|2018-06-01 04:29:25.91362
NCT00215085|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-03-14|2005-09-20|2005-09-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|May 2005||2005-05-31|May 2007|2007-05-31|November 2006|Actual|2006-11-30|||||Observational|||Cardiac Tumors in Children|Cardiac Tumors in Children|Terminated|||70|Anticipated|Children's Healthcare of Atlanta||||insufficient data|f||||f||||||||||2018-06-01 04:29:25.959194|2018-06-01 04:29:25.959194
NCT00215072|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-03-14|2005-09-20|2005-09-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|February 2007|Actual|2007-02-28|||||Observational|||Death Following Congenital Heart Surgery|Death Following Congenital Heart Surgery|Terminated|||40|Anticipated|Children's Healthcare of Atlanta||||insufficient number of patient charts to support hypothesis|f||||f||||||||||2018-06-01 04:29:26.001289|2018-06-01 04:29:26.001289
NCT00215059|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-08-01|2005-09-15|2005-09-22|Estimate|||||||2012-08-01|2012-08-02|Estimate|August 2000||2000-08-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Measurement of Angiogenic Related Growth Factors in Urine and Blood From Patients With Pulmonary Vein Stenosis|Measurement of Angiogenic Related Growth Factors in Urine and Blood From Patients With Multivessel Pulmonary Vein Stenosis|Terminated|||50|Anticipated|Boston Children’s Hospital||||Lack of funding|f||||f||||||||||2018-06-01 04:29:26.044861|2018-06-01 04:29:26.044861
NCT00215046|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-06-22|2005-09-15|2005-09-22|Estimate|||||||2011-06-22|2011-06-27|Estimate|March 2000||2000-03-31|June 2011|2011-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis|Vinblastine and Methotrexate in Children With Multivessel Pulmonary Vein Stenosis-A Phase II Study|Completed||Phase 2|28|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-06-01 04:29:26.092383|2018-06-01 04:29:26.092383
NCT00215033|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2012-03-14|2005-09-20|2005-09-22|Estimate|||||||2012-03-14|2012-03-16|Estimate|April 2005||2005-04-30|May 2007|2007-05-31|May 2006|Actual|2006-05-31|||||Observational|||Relationship Between EBV and PTLD|Relationship Between Quantitative Epstein-Bar Viral(EBV) Titres and Post-Transplant Lymphoproliferative Disease|Terminated|||160|Actual|Children's Healthcare of Atlanta||||sufficient data gathered to support conclusion|f||||f||||||||||2018-06-01 04:29:26.161542|2018-06-01 04:29:26.161542
NCT00215020|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-01-26|2005-09-15|2005-09-22|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2003||2003-09-30|January 2016|2016-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease|Phase I Evaluation of Urinary Isoprostane Levels in Pediatric Patients With Inflammatory and Non-Inflammatory Gastrointestinal Disease|Completed|||150|Actual|Boston Children’s Hospital|||||f||||f||||||Samples Without DNA|"~     Specimens stored at -80 in the Center for IBD at Boston Children's Hospital.~   "|No||2018-06-01 04:29:26.204894|2018-06-01 04:29:26.204894
NCT00215007|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2007-11-29|2005-09-15|2005-09-22|Estimate|||||||2007-11-29|2007-11-30|Estimate||||February 2004|2004-02-29||||||||Interventional|||Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)|Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem Cells|Unknown status|Recruiting|Phase 2/Phase 3|||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:29:26.24802|2018-06-01 04:29:26.24802
NCT00214994|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-05-08|2005-09-21|2005-09-22|Estimate|||||||2014-05-08|2014-05-09|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|December 2006||2006-12-31|||||Interventional|||Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.|A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment (up to 16 mg/Day) in Adults With Generalized Anxiety Disorder.|Completed||Phase 3|||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:29:26.303926|2018-06-01 04:29:26.303926
NCT00214981|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-07-25|2005-09-14|2005-09-22|Estimate|||||||2012-07-25|2012-07-26|Estimate|September 2003||2003-09-30|July 2012|2012-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Evaluate the Safety and Efficacy of Modafinil in Children and Adolescents With ADHD|A 1-Year, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Continued Efficacy of Modafinil (Film-coated Tablet Formulation) in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (Followed by an Open-Ended Extension Period)|Completed||Phase 3|||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:29:26.565137|2018-06-01 04:29:26.565137
NCT00214968|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14||2012-05-23|2012-05-23|2005-09-14|2005-09-22|Estimate||||2012-05-23|2012-05-31|Estimate|2012-05-23|2012-05-31|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness|A 6-Month Open Label, Flexible-Dosage Study to Assess the Safety and Effectiveness of PROVIGIL (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome|Completed||Phase 3|92|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 04:29:26.69078|2018-06-01 04:29:26.69078
NCT00214955|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-05-08|2005-09-14|2005-09-22|Estimate|||||||2014-05-08|2014-05-09|Estimate|September 2005||2005-09-30|May 2014|2014-05-31||||May 2006|Actual|2006-05-31||Interventional|||Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Neuropathic Pain|Completed||Phase 3|120||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:29:26.750438|2018-06-01 04:29:26.750438
NCT00214942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-05-08|2005-09-14|2005-09-22|Estimate|||||||2014-05-08|2014-05-09|Estimate|September 2005||2005-09-30|May 2014|2014-05-31||||March 2006|Actual|2006-03-31||Interventional|||Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Low Back Pain|Completed||Phase 3|||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:29:26.813869|2018-06-01 04:29:26.813869
NCT00214929|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-12-08|2005-09-16|2005-09-22|Estimate|||||||2005-12-08|2005-12-09|Estimate|December 2004||2004-12-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Home Treatment of Pulmonary Embolism|Cooperative Investigation Plan for Home Treatment of Pulmonary Embolism|Unknown status|Active, not recruiting|Phase 4|||Carlos III Health Institute|||||f||||||||||||||2018-06-01 04:29:26.940306|2018-06-01 04:29:26.940306
NCT00214916|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2017-06-21|2005-09-21|2005-09-22|Estimate|||||||2017-06-21|2017-06-22|Actual|October 2004||2004-10-31|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|February 2008|Actual|2008-02-29||Interventional|||Tight Glycemic Control With Intensive Insulin Therapy in PICU|KULeuven Intensive Insulin Study in Pediatric Intensive Care Patients|Active, not recruiting||Phase 2|700|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-06-01 04:29:27.010312|2018-06-01 04:29:27.010312
NCT00214903|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|2014-11-06||2014-11-13|2005-09-19|2005-09-22|Estimate|2014-11-06|2014-11-14|Estimate||||2014-11-13|2014-12-01|Estimate|November 2004||2004-11-30|November 2014|2014-11-30|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Observational||At baseline, 33% of women were using DRSP/E2, 44% were using ooccHRT, 13% were using ooHRT, and 10% ‘Non-oral HRT’. These proportions only partially reflect the overall exposure in each cohort (AT population) because market authorization for DRSP/E2 was delayed by more than 1.5 years.|European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)|European Active Surveillance Study of Women Taking HRT|Completed|||30597|Actual|Center for Epidemiology and Health Research, Germany|In non-experimental studies like EURAS-HRT the possibility of bias and residual confounding can never be entirely eliminated. The findings may exclude large, but not small relative risks.||2||f||||t||||||||||2018-06-01 04:29:27.103521|2018-06-01 04:29:27.103521
NCT00214890|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2011-08-02|2005-09-20|2005-09-22|Estimate|||||||2011-08-02|2011-08-03|Estimate|April 2005||2005-04-30|August 2011|2011-08-31||||February 2009|Actual|2009-02-28||Interventional|||Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir|CCTG584: Viral Dynamics and Pharmacokinetics of Tenofovir and Abacavir Monotherapy Versus the Combination Therapy of TDF-ABC in HIV-Infected Treatment Naive Patients|Completed||Phase 2|20|Anticipated|California Collaborative Treatment Group||2|||f||||||||||||||2018-06-01 04:29:27.435269|2018-06-01 04:29:27.435269
NCT00214877|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2008-03-28|2005-09-20|2005-09-22|Estimate|||||||2008-03-28|2008-04-01|Estimate|November 2003||2003-11-30|March 2008|2008-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Methylene Blue for Cognitive Dysfunction in Bipolar Disorder|Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder|Completed||Phase 3|40|Anticipated|Nova Scotia Health Authority|||||f||||f||||||||||2018-06-01 04:29:27.524479|2018-06-01 04:29:27.524479
NCT00214864|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-02-13|2005-09-15|2005-09-22|Estimate|||||||2012-02-13|2012-02-14|Estimate|December 2002||2002-12-31|February 2012|2012-02-29||||January 2006|Actual|2006-01-31||Interventional|||A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer|A Pilot Study of Taxotere (Docetaxel) Combined With Xeloda (Capecitabine) in the Treatment of Metastatic Breast Cancer|Completed||Phase 2|18|Actual|Cancer Research Network|||||f||||t||||||||||2018-06-01 04:29:27.586508|2018-06-01 04:29:27.586508
NCT00214851|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2008-05-30|2005-09-21|2005-09-22|Estimate|||||||2008-05-30|2008-06-02|Estimate|September 2005||2005-09-30|May 2008|2008-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria|The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria|Completed||Phase 1|8|Anticipated|Nova Scotia Health Authority|||||f||||f||||||||||2018-06-01 04:29:27.644735|2018-06-01 04:29:27.644735
NCT00214838|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-12-01|2005-09-14|2005-09-22|Estimate|||||||2006-12-01|2006-12-05|Estimate|March 2005||2005-03-31|December 2006|2006-12-31|March 2007||2007-03-31|||||Interventional|||An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer|An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|61||Callisto Pharmaceuticals|||||f||||||||||||||2018-06-01 04:29:27.70868|2018-06-01 04:29:27.70868
NCT00214825|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2007-12-28|2005-09-20|2005-09-22|Estimate|||||||2007-12-28|2008-01-03|Estimate|August 2003||2003-08-31|December 2007|2007-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Aldosterone and Vascular Disease in Diabetes Mellitus|Aldosterone and Vascular Disease in Diabetes Mellitus|Completed||N/A|46|Actual|Brigham and Women's Hospital||2|||f||||||||||||||2018-06-01 04:29:27.77955|2018-06-01 04:29:27.77955
NCT00214812|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-10-24|2005-09-15|2005-09-22|Estimate|||||||2005-10-24|2005-10-25|Estimate|June 2005||2005-06-30|September 2005|2005-09-30||||||||Interventional|||An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots|An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots|Unknown status|Recruiting|Phase 1|6||Biosyn|||||f||||||||||||||2018-06-01 04:29:27.872805|2018-06-01 04:29:27.872805
NCT00214786|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2013-02-11||2017-06-09|2005-09-14|2005-09-22|Estimate|2014-05-15|2014-06-06|Estimate||||2017-06-09|2017-06-14|Actual|April 2005||2005-04-30|June 2017|2017-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Pancreatic Islet Cell Transplantation|Pancreatic Islet Cell Transplantation - A Novel Approach to Immunosuppression and Validation of Remote Site Islet Cell Processing, Islet Cell Culture and Two-Layer Preservation|Completed||Phase 1|4|Actual|Baylor Research Institute|Three of the four patients voluntarily withdrew from the study.|1|||f||||t||||||||||2018-06-01 04:29:27.940153|2018-06-01 04:29:27.940153
NCT00214773|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-19|2005-09-14|2005-09-22|Estimate|||||||2017-04-19|2017-04-21|Actual|July 2005||2005-07-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Observational|||Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)|MPS VI Clinical Surveillance Program (CSP)|Recruiting|||200|Anticipated|BioMarin Pharmaceutical|||1||f||||f||||||Samples Without DNA|"~     Urine and serum~   "|No||2018-06-01 04:29:28.161189|2018-06-01 04:29:28.161189
NCT00214760|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2010-01-29|2005-09-16|2005-09-22|Estimate|||||||2010-01-29|2010-02-01|Estimate|May 2005||2005-05-31|November 2009|2009-11-30|September 2011|Anticipated|2011-09-30|August 2008|Actual|2008-08-31||Interventional|||Polymethyl Methacrylate and (PEGT/PBT) Centralizer by the Uncemented BIHAPRO THP|Phase 3 Randomised, Prospective Study Comparing the PMMA and the Resorbable PEGT/PBT Centralizer by the Uncemented BIHAPRO Total Hip Prosthesis|Terminated||Phase 3|70|Actual|Biomet Nederland BV||2||On of the liners has been taken from the market|f||||f||||||||||2018-06-01 04:29:28.330074|2018-06-01 04:29:28.330074
NCT00214747|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-10-24|2005-09-15|2005-09-22|Estimate|||||||2005-10-24|2005-10-25|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|November 2005||2005-11-30|||||Interventional|||An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina|An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina: Candidate Formulations|Unknown status|Active, not recruiting|Phase 1|6||Biosyn|||||f||||||||||||||2018-06-01 04:29:28.390368|2018-06-01 04:29:28.390368
NCT00214734|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-10-19|2005-09-15|2005-09-22|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2004||2004-08-31|April 2009|2009-04-30|January 2007||2007-01-31|||||Observational|||ADVATE Post Authorization Safety Surveillance|Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study|Completed|||450|Anticipated|Shire|||||f||||||||||||||2018-06-01 04:29:28.437702|2018-06-01 04:29:28.437702
NCT00214721|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-11-28|2005-09-16|2005-09-22|Estimate|||||||2007-11-28|2007-11-29|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|July 2006||2006-07-31|||||Interventional|||A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis|A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis|Completed||Phase 3|120||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 04:29:28.632715|2018-06-01 04:29:28.632715
NCT00214708|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-22|Estimate|||||||2005-09-16|2005-09-22|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|September 2004||2004-09-30|||||Observational|||Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?|Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? A Cluster Randomised Controlled Trial in an East London Primary Care Trust|Unknown status|Active, not recruiting||200||Barts & The London NHS Trust|||||f||||||||||||||2018-06-01 04:29:28.684443|2018-06-01 04:29:28.684443
NCT00214695|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-11-20|2005-09-14|2005-09-22|Estimate|||||||2006-11-20|2006-11-22|Estimate|May 2005||2005-05-31|November 2006|2006-11-30|July 2006||2006-07-31|||||Interventional|||A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis|A Subjective Evaluation of Inflow Pain Associated With the Use of an Experimental Solution for Peritoneal Dialysis|Completed||N/A|20||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 04:29:28.735943|2018-06-01 04:29:28.735943
NCT00214682|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-09-12|2005-09-14|2005-09-22|Estimate|||||||2011-09-12|2011-09-13|Estimate|October 2005||2005-10-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Beyond Ageing Project: A Study for the Prevention of Depression|Beyond Ageing Project: A RCT to Assess the Benefit of Improving Mental Health Literacy as Well as the Effect of Folate and B12, and Physical Activity, in Preventing Major Depression and Cognitive Decline Among Older Australians|Completed||Phase 2|909|Actual|Australian National University||6|||f||||t||||||||||2018-06-01 04:29:28.791608|2018-06-01 04:29:28.791608
NCT00214669|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-06-03|2005-09-14|2005-09-22|Estimate|||||||2009-06-03|2009-06-04|Estimate|November 2005||2005-11-30|May 2009|2009-05-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|OEDIPUS||Can Education for South Asians With Asthma and Their Clinicians Reduce Unscheduled Care? A Randomised Trial|Can Education for South Asians With Asthma and Their Clinicians Reduce Unscheduled Care? A Cluster Randomised Trial|Completed||Phase 1|375|Actual|Barts & The London NHS Trust||2|||f||||||||||||||2018-06-01 04:29:28.882321|2018-06-01 04:29:28.882321
NCT00214656|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-22|Estimate|||||||2005-09-14|2005-09-22|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|June 2008||2008-06-30|||||Interventional|||"Salvage Use of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery"|"Salvage Use of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial"|Unknown status|Recruiting|Phase 3|40||Austin Health|||||f||||||||||||||2018-06-01 04:29:28.95016|2018-06-01 04:29:28.95016
NCT00214643|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2009-02-03|2005-09-19|2005-09-22|Estimate|||||||2009-02-03|2009-02-04|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|July 2006||2006-07-31|||||Interventional|||Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children|A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 3|160||Albert Schweitzer Hospital|||||f||||||||||||||2018-06-01 04:29:29.020713|2018-06-01 04:29:29.020713
NCT00214630|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2010-11-18|2005-09-21|2005-09-22|Estimate|||||||2010-11-18|2010-11-19|Estimate|December 2003||2003-12-31|November 2010|2010-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes|A 12-week Randomized, Open-label 3-arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes|Completed||Phase 3|825|Actual|AstraZeneca|||||||||||||||||||2018-06-01 04:29:29.168717|2018-06-01 04:29:29.168717
NCT00214617|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2017-06-19|2005-09-19|2005-09-22|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2005||2005-01-31|September 2006|2006-09-30|February 2006||2006-02-28|||||Interventional|||Effect of Crestor on Lipoprotein Metabolism in Humans|Effect of Crestor on the Kinetics of Plasma Apolipoproteins: Dose-Response Study|Completed||Phase 4|8||Atlanta Research and Education Foundation|||||f||||||||||||||2018-06-01 04:29:29.313593|2018-06-01 04:29:29.313593
NCT00214604|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-21|||2010-11-18|2005-09-21|2005-09-22|Estimate|||||||2010-11-18|2010-11-19|Estimate|February 2005||2005-02-28|November 2010|2010-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Type III Dysbetalipoproteinemia|An 18-week, Randomized, Multicenter, Phase 3b, Double-blind, Crossover Study, Followed by an 18-week Open-Label Period to Evaluate the Efficacy & Safety of the Lipid-Regulating Agents, Rosuvastatin & Pravastatin in the Treatment of Subjects With Dysbetalipoproteinemia (Frederickson Type III Hyperlipoproteinemia)|Completed||Phase 3|30||AstraZeneca|||||||||||||||||||2018-06-01 04:29:29.387932|2018-06-01 04:29:29.387932
NCT00214591|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-11-18|2005-09-20|2005-09-22|Estimate|||||||2010-11-18|2010-11-19|Estimate|August 2004||2004-08-31|November 2010|2010-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||GALLANT 5 Tesaglitazar Versus Metformin|A 52-wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 3|580||AstraZeneca||||The development program has been terminated|f||||||||||||||2018-06-01 04:29:29.490353|2018-06-01 04:29:29.490353
NCT00214578|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-01-03|2005-09-20|2005-09-22|Estimate|||||||2013-01-03|2013-01-04|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|October 2005|Actual|2005-10-31|||||Interventional|||Seroquel on Glucose Metabolism|Seroquel on Glucose Metabolism|Completed||Phase 4|572||AstraZeneca|||||f||||||||||||||2018-06-01 04:29:29.762453|2018-06-01 04:29:29.762453
NCT00214565|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-11-17|2005-09-20|2005-09-22|Estimate|||||||2010-11-17|2010-11-19|Estimate|August 2004||2004-08-31|November 2010|2010-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||GALLANT 6 Tesaglitazar vs. Pioglitazone|A 24-Wk Randomised, Double-Blind, Multi-Centre, Active-Controlled (Pioglitazone) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes|Terminated||Phase 3|1450||AstraZeneca||||The development program has been terminated|||||||||||||||2018-06-01 04:29:29.903744|2018-06-01 04:29:29.903744
NCT00214552|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-06-22|2005-09-19|2005-09-22|Estimate|||||||2011-06-22|2011-06-23|Estimate|September 2002||2002-09-30|June 2011|2011-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.|A Double-blind Placebo Controlled Clinical Trial to Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.|Completed||Phase 3|80|Anticipated|Associated Scientists to Help Minimize Allergies|||||f||||f||||||||||2018-06-01 04:29:30.031912|2018-06-01 04:29:30.031912
NCT00214539|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2010-09-08|2010-02-10|2011-09-30|2005-09-15|2005-09-22|Estimate|2011-09-30|2011-11-07|Estimate|2010-02-10|2010-02-12|Estimate|2011-09-30|2011-11-07|Estimate|April 2004||2004-04-30|September 2011|2011-09-30|August 2006|Actual|2006-08-31|February 2006|Actual|2006-02-28||Interventional|||Research in Severe Asthma (RISA) Trial|Multicenter Randomized Clinical Trial of Bronchial Thermoplasty With the Alair System for the Treatment of Severe Asthma|Completed||N/A|34|Actual|Asthmatx, Inc.||2|||f||||t||||||||||2018-06-01 04:29:30.28148|2018-06-01 04:29:30.28148
NCT00214526|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2010-09-08|2010-02-10|2015-08-21|2005-09-15|2005-09-22|Estimate|2010-09-30|2010-10-18|Estimate|2010-02-10|2010-02-12|Estimate|2015-08-21|2015-08-28|Estimate|November 2002||2002-11-30|August 2015|2015-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Asthma Intervention Research (AIR) Trial|Multicenter Randomized Clinical Trial of the Alair System for the Bronchial Thermoplasty Treatment of Asthma|Completed||N/A|112|Actual|Asthmatx, Inc.||2|||f||||t||||||||||2018-06-01 04:29:31.252062|2018-06-01 04:29:31.252062
NCT00214513|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-05-16|2005-09-16|2005-09-22|Estimate|||||||2007-05-16|2007-05-17|Estimate|June 2004||2004-06-30|May 2007|2007-05-31|July 2006|Actual|2006-07-31|||||Interventional|||A Randomized Trial of Effect of Low-Cost Maintenance Training on Exercise Capacity, Quality of Life and Morbidity|Maintain. A Randomized Trial of Effect of Low-Cost Maintenance Training on Exercise Capacity, Quality of Life and Morbidity|Completed||Phase 3|160|Anticipated|Amager Hospital|||||f||||||||||||||2018-06-01 04:29:31.904603|2018-06-01 04:29:31.904603
NCT00214500|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13||2010-08-17|2015-05-05|2005-09-14|2005-09-22|Estimate||||2010-08-17|2010-08-19|Estimate|2015-05-05|2015-05-22|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of AT1001 in Patients With Fabry Disease|A Phase 2, Open-Label, Multicenter, Ascending-Dose, 12-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AT1001 in Patients With Fabry Disease|Completed||Phase 2|14|Actual|Amicus Therapeutics||4|||f||||||||||||||2018-06-01 04:29:31.959998|2018-06-01 04:29:31.959998
NCT00214487|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2014-06-23||2014-06-23|2005-09-14|2005-09-22|Estimate|2014-06-23|2014-07-22|Estimate||||2014-06-23|2014-07-22|Estimate|October 2003||2003-10-31|June 2014|2014-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional||Numbers reflect those subjects screened, enrolled, randomized with at least one follow up examination.|Bifocal Soft Contact Lenses and Their Effect on Myopia Progression in Children and Adolescents.|Bifocal Soft Contact Lenses - Do They Slow Progression of Myopia Relative to Single Vision Soft Contact Lenses in Children and Adolescents?|Completed||N/A|78|Actual|Aller, Thomas A., OD||2|||f||||f||||||||||2018-06-01 04:29:33.012552|2018-06-01 04:29:33.012552
NCT00214474|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2013-02-12|2005-09-19|2005-09-22|Estimate|||||||2013-02-12|2013-02-13|Estimate|November 2002||2002-11-30|February 2013|2013-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Improving Diabetes Efforts Across Language and Literacy (IDEALL)|Improving Diabetes Efforts Across Language and Literacy (IDEALL)|Completed||N/A|339|Actual|Agency for Healthcare Research and Quality (AHRQ)||3|||f||||f||||||||||2018-06-01 04:29:33.29314|2018-06-01 04:29:33.29314
NCT00214461|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2012-03-13||2012-04-09|2005-09-16|2005-09-22|Estimate|2012-03-13|2012-04-09|Estimate||||2012-04-09|2012-04-11|Estimate|November 2005||2005-11-30|April 2012|2012-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers|A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Elderly Volunteers (> or =65 Years)|Completed||Phase 1|48|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 04:29:33.425183|2018-06-01 04:29:33.425183
NCT00214448|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2006-07-13|2005-09-20|2005-09-22|Estimate|||||||2006-07-13|2006-07-14|Estimate||||September 2005|2005-09-30||||||||Observational|||Reproducibility of the Array-Based Comparative Genomic Hybridization (aCGH) System Using Whole Blood Samples|Reproducibility of the GeneTrait™ CGH Microarray System DX Using Whole Blood Samples|Unknown status|Not yet recruiting||4||Abbott Molecular|||||||||||||||||||2018-06-01 04:29:34.965394|2018-06-01 04:29:34.965394
NCT00214435|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-10-21|2005-09-16|2005-09-22|Estimate|||||||2005-10-21|2005-10-25|Estimate|May 2004||2004-05-31|September 2005|2005-09-30||||||||Interventional|||Once Daily 3TC, Efavirenz and ddI for HIV Infection|A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily|Unknown status|Recruiting|Phase 4|120||407 Doctors|||||f||||||||||||||2018-06-01 04:29:35.012417|2018-06-01 04:29:35.012417
NCT00214422|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-04-19|2005-09-20|2005-09-21|Estimate|||||||2018-04-19|2018-04-20|Actual|September 19, 2005||2005-09-19|April 18, 2018|2018-04-18|April 18, 2018|Actual|2018-04-18|May 27, 2014|Actual|2014-05-27||Interventional|||Intensity Modulated Radiation Therapy for Prostate Cancer|A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer|Completed||Phase 1|19|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 04:29:35.082755|2018-06-01 04:29:35.082755
NCT00214383|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-04-04||2013-01-16|2005-09-19|2005-09-21|Estimate|2012-06-04|2012-07-09|Estimate||||2013-01-16|2013-01-24|Estimate|May 2004||2004-05-31|January 2013|2013-01-31|May 2009|Actual|2009-05-31|August 2007|Actual|2007-08-31||Interventional|CHESS||Internet Telehealth for Pediatric Asthma Case Management|Internet Telehealth for Pediatric Asthma Case Management|Completed||N/A|301|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:29:35.160962|2018-06-01 04:29:35.160962
NCT00214370|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-10-01|2005-09-15|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|July 2004||2004-07-31|July 2007|2007-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma|Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma|Completed||N/A|40|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:35.383386|2018-06-01 04:29:35.383386
NCT00214357|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-10-01|2005-09-15|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2004||2004-10-31|November 2008|2008-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||The Effects of Mindfulness Training on School Staff|The Effects of Mindfulness Training on School Staff Emotions, Attention, and Stress|Completed||N/A|19||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:35.529912|2018-06-01 04:29:35.529912
NCT00214344|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-10-01|2005-09-15|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|February 2007|Actual|2007-02-28|||||Interventional|||Family Preparation Study For Withdrawal of Mechanical Ventilation From Their Family Member|Evaluating the Usefulness of Preparing Families For Withdrawal of Mechanical Ventilation From Their Family Member: A Pilot Study|Completed||Phase 2|20||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:35.583049|2018-06-01 04:29:35.583049
NCT00214331|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-10-25|2005-09-14|2005-09-21|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2003||2003-04-30|October 2016|2016-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy|Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy|Completed|||150|Actual|University of Wisconsin, Madison|||3||f||||t||||||||||2018-06-01 04:29:35.643303|2018-06-01 04:29:35.643303
NCT00214318|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-10-06|2005-09-14|2005-09-21|Estimate|||||||2015-10-06|2015-10-08|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|February 2007|Actual|2007-02-28|||||Interventional|||Beta-2 Polymorphisms and Beta Receptor Selectivity|The Effects of ß2 Polymorphisms on Beta Selectivity After ß-adrenergic Blockade in Patients With Heart Failure|Completed||N/A|25||University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:29:35.71029|2018-06-01 04:29:35.71029
NCT00214305|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-30|2005-09-14|2005-09-21|Estimate|||||||2015-09-30|2015-10-02|Estimate|August 2005||2005-08-31|September 2015|2015-09-30||||||||Interventional|||Effects of Swallowing Therapy in Head and Neck Cancer|Effects of Swallowing Therapy in Head and Neck Cancer|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||2||low accrual|f||||t||||||||||2018-06-01 04:29:35.781113|2018-06-01 04:29:35.781113
NCT00214292|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-01-28|2005-09-14|2005-09-21|Estimate|||||||2016-01-28|2016-01-29|Estimate|May 2005||2005-05-31|January 2016|2016-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Evaluation of Breast Cancer Surgical Margins Using Optical Spectroscopy|A Pilot Study of Intraoperative Margin Assessment Comparing Optical Spectroscopy and Frozen Section Analysis for Ductal Carcinoma In Situ of the Breast|Completed||N/A|20|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:35.845084|2018-06-01 04:29:35.845084
NCT00214266|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-29|2005-09-13|2005-09-21|Estimate|||||||2018-05-29|2018-05-30|Actual|January 2005||2005-01-31|May 2018|2018-05-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation|A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation|Completed||Phase 2|31|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 04:29:35.981067|2018-06-01 04:29:35.981067
NCT00214253|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-03-29|2005-09-14|2005-09-21|Estimate|||||||2017-03-29|2017-03-31|Actual|February 2002||2002-02-28|March 2017|2017-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Islet Transplantation in Type 1 Diabetic Patients|Islet Transplantation in Type 1 Diabetic Patients Using a Steroid-free Immunosuppression Protocol and Thiazolidinedione Insulin Sensitizers|Completed||Phase 1|14|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-06-01 04:29:36.055515|2018-06-01 04:29:36.055515
NCT00214240|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-07-25|2005-09-13|2005-09-21|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2000||2000-01-31|July 2012|2012-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease|The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease|Completed||N/A|28|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:29:36.125436|2018-06-01 04:29:36.125436
NCT00214227|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-18|2005-09-13|2005-09-21|Estimate|||||||2013-06-18|2013-06-19|Estimate|December 2007||2007-12-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||ATM Variants in Radiotherapy Patients|ATM Variants in Radiotherapy|Completed|||60|Actual|University of Wisconsin, Madison|||||f||||||||||Samples With DNA|"~     direct sequence analysis of all exons and intron-exon junctions of the ATM gene. DNA will be~     isolated from lympocytes using the PAX blood DNA system.~   "|||2018-06-01 04:29:36.201906|2018-06-01 04:29:36.201906
NCT00214214|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-06|2005-09-13|2005-09-21|Estimate|||||||2015-10-06|2015-10-08|Estimate|October 2005||2005-10-31|October 2015|2015-10-31||||||||Interventional|||A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus|A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus|Withdrawn||Phase 1|0|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:36.284676|2018-06-01 04:29:36.284676
NCT00214201|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-08-13||2012-09-21|2005-09-13|2005-09-21|Estimate|2012-08-13|2012-09-12|Estimate||||2012-09-21|2012-10-03|Estimate|May 2003||2003-05-31|September 2012|2012-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation|Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation|Completed||N/A|40|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:29:36.39356|2018-06-01 04:29:36.39356
NCT00214175|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-22|2005-09-13|2005-09-21|Estimate|||||||2012-02-22|2012-02-24|Estimate|June 2004||2004-06-30|February 2012|2012-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy|Determination of Fraction Size Equivalent Dose (FED) Levels for Intracranial Conformal Avoidance Radiotherapy|Completed|||44|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-06-01 04:29:36.728161|2018-06-01 04:29:36.728161
NCT00214162|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-16|2005-09-13|2005-09-21|Estimate|||||||2012-03-16|2012-03-19|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||CHESS Caregivers Study: Web-based Support for Informal Caregivers in Cancer|Web-based Support for Informal Caregivers in Cancer|Completed||N/A|235|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 04:29:36.887824|2018-06-01 04:29:36.887824
NCT00214149|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|October 2004||2004-10-31|June 2013|2013-06-30|October 2010|Actual|2010-10-31|April 2008|Actual|2008-04-30||Interventional|||Multi-catheter High Dose Rate (HDR) Breast Brachytherapy|A UW Phase II Trial of Multi-catheter HDR Brachytherapy Following Lumpectomy for Early Stage Breast Breast Cancer|Terminated||Phase 2|127|Actual|University of Wisconsin, Madison||1||lost funding|f||||t||||||||||2018-06-01 04:29:36.956968|2018-06-01 04:29:36.956968
NCT00214136|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-08-08||2017-09-11|2005-09-13|2005-09-21|Estimate|2017-09-11|2017-10-12|Actual||||2017-09-11|2017-10-12|Actual|March 2005||2005-03-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Participants with histologically confirmed prostate cancer and no evidence of bone or extrapelvic metastases were enrolled.|Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes|A Phase II Prostate Cancer Trial Treating Pelvic Lymph Nodes to High Dose Using Intensity Modulated Radiation Therapy|Completed||Phase 2|30|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 04:29:37.033896|2018-06-01 04:29:37.033896
NCT00214123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-07-22|2005-09-13|2005-09-21|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2004||2004-06-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Hypofractionated Radiotherapy for Lung Cancer|The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer|Completed||Phase 1|79|Actual|University of Wisconsin, Madison||5|||f||||t||||||||||2018-06-01 04:29:37.239286|2018-06-01 04:29:37.239286
NCT00214110|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2001||2001-01-31|August 2008|2008-08-31|January 2005|Actual|2005-01-31|||||Interventional|||Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]|Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]|Completed||Phase 2|100||University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 04:29:37.321202|2018-06-01 04:29:37.321202
NCT00214097|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-17|2005-09-13|2005-09-21|Estimate|||||||2018-05-17|2018-05-22|Actual|October 14, 2002|Actual|2002-10-14|May 2018|2018-05-31|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|||Phase I/II Hypofractionated Radiotherapy for Prostate Cancer|Phase I/II Trial Examining Dose-per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer|Completed||Phase 1/Phase 2|309|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 04:29:37.39761|2018-06-01 04:29:37.39761
NCT00214084|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-06|2005-09-13|2005-09-21|Estimate|||||||2015-10-06|2015-10-08|Estimate||||October 2015|2015-10-31||||||||Interventional|||Vascular Pathophysiology in Obstructive Sleep Apnea|Influence of Xanthine Oxidase Inhibition on Vascular Function in Obstructive Sleep Apnea|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:37.468404|2018-06-01 04:29:37.468404
NCT00214058|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-30|2005-09-13|2005-09-21|Estimate|||||||2015-09-30|2015-10-02|Estimate|August 2002||2002-08-31|June 2008|2008-06-30|February 2006|Actual|2006-02-28|||||Interventional|||Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer|Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma|Completed||Phase 2|36||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:37.606695|2018-06-01 04:29:37.606695
NCT00214045|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-11-19|2005-09-13|2005-09-21|Estimate|||||||2012-11-19|2012-11-21|Estimate|July 2004||2004-07-31|October 2012|2012-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Rigid Versus Flexible Cystoscopy in Women|Rigid Versus Flexible Cystoscopy in Women in Outpatient Clinic|Completed||N/A|36|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 04:29:37.683386|2018-06-01 04:29:37.683386
NCT00214032|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2002||2002-05-31|January 2008|2008-01-31|January 2007|Actual|2007-01-31|November 2006|Actual|2006-11-30||Interventional|||Pycnogenol for the Treatment of Lymphedema|Treatment of Arm Lymphedema in Breast Cancer Survivors: A Double-Blind, Randomized Study of Pycnogenol vs. Placebo|Completed||Phase 2|2|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-06-01 04:29:37.758977|2018-06-01 04:29:37.758977
NCT00214019|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-08-17||2017-10-17|2005-09-13|2005-09-21|Estimate|2016-06-24|2016-08-08|Estimate||||2017-10-17|2017-11-21|Actual|November 2003|Actual|2003-11-30|October 2017|2017-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||This is a randomized/double-blinded/placebo-controlled/four-phase/crossover trial in subjects with a history of mild allergic asthma. Treatment arms included placebo, fluticasone 44 µg twice daily, salmeterol 50 µµg twice daily and combined FT and SA treatment, all given by inhalers. The order of these treatments was randomized for each subject.|The Effect of Salmeterol on Eosinophil (EOS) Function|The Effect of Salmeterol on Eosinophil (EOS) Function|Completed||N/A|36|Actual|University of Wisconsin, Madison|36 subjects were screened, identifying subjects with both a peripheral eosinophil count >0.200x106 cells/ml and a LPR >15% was more difficult than expected. Of the subjects screened, only 12 met criteria and 6 subjects completed.|4|||f||||f||||||||No||2018-06-01 04:29:37.838182|2018-06-01 04:29:37.838182
NCT00214006|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-06|2005-09-13|2005-09-21|Estimate|||||||2013-03-06|2013-03-07|Estimate|November 2001||2001-11-30|March 2013|2013-03-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Observational|||Carotid Atherosclerotic Plaque Study|Carotid Atherosclerotic Plaque Study|Completed|||162|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:29:38.030414|2018-06-01 04:29:38.030414
NCT00213993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|October 2006|Actual|2006-10-31||Interventional|||Topical Antiperspirant for Hand-Foot Syndrome|Topical Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Associated With Capecitabine|Completed||Phase 2|14|Actual|University of Wisconsin, Madison||1|||f||||||||||||||2018-06-01 04:29:38.106632|2018-06-01 04:29:38.106632
NCT00213980|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-08-02||2017-12-06|2005-09-13|2005-09-21|Estimate|2017-12-06|2018-01-05|Actual||||2017-12-06|2018-01-05|Actual|January 2000||2000-01-31|December 2017|2017-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||Postmenopausal women with stage II/III breast cancer diagnosed up to 5 years previous.|Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer|Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer|Completed||Phase 2|68|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:29:38.188723|2018-06-01 04:29:38.188723
NCT00213967|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-21|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2005||2005-10-31|January 2008|2008-01-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||The Effect of Needle Temperature on Pain Ratings Following Intramuscular Injection|The Effect of Needle Temperature on Pain Ratings Following Intramuscular Injection|Completed||N/A|80|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:29:38.634865|2018-06-01 04:29:38.634865
NCT00213954|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-24|2005-09-20|2005-09-21|Estimate|||||||2009-02-24|2009-02-25|Estimate|May 2005||2005-05-31|February 2009|2009-02-28|September 2009|Anticipated|2009-09-30|March 2009|Anticipated|2009-03-31||Interventional|||Ultrasound Guidance in Nerve Block Anaesthesia|Ultrasound Guidance in Nerve Block Anaesthesia: Classic Nerve Stimulation Technique Versus Ultrasound-Neurostimulation Combination in Four Blocks: Interscalene, Humeral, Parasacral and Lumbar Blocks|Unknown status|Active, not recruiting|N/A|1002|Anticipated|University Hospital, Strasbourg, France||4|||f||||f||||||||||2018-06-01 04:29:38.68755|2018-06-01 04:29:38.68755
NCT00213941|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-02|2005-09-13|2005-09-21|Estimate|||||||2006-10-02|2006-10-03|Estimate|November 2004||2004-11-30|October 2006|2006-10-31||||||||Interventional|||Study Protocol Evaluating Transient Tachypnoea of the Newborn in Term and Near Term Neonates|Study Protocol Evaluating Transient Tachypnoea of the Newborn in Term and Near Term Neonates|Unknown status|Recruiting|N/A|100||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:38.869278|2018-06-01 04:29:38.869278
NCT00213928|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-29|2005-09-13|2005-09-21|Estimate|||||||2015-05-29|2015-06-02|Estimate|May 2002||2002-05-31|July 2011|2011-07-31|September 2008|Actual|2008-09-30|September 2004|Actual|2004-09-30||Interventional|||Horse Chestnut Seed Extract for Lymphedema|A Single-blind, Randomized Trial of Horse Chestnut Seed Extract for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors|Completed||Phase 2|56|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 04:29:38.986485|2018-06-01 04:29:38.986485
NCT00213915|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-28|2005-09-20|2005-09-21|Estimate|||||||2007-11-28|2007-11-29|Estimate|February 2004||2004-02-29|November 2007|2007-11-30|December 2004||2004-12-31|||||Interventional|||L-Arginine Supplementation and Exercise; L-Arginine Supplementation and Renal Function|Effects of Oral Chronic L-Arginine Supplementation on Exercise and Renal Function of Heart Transplant Recipients|Completed||Phase 4|30||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.069973|2018-06-01 04:29:39.069973
NCT00213902|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-28|2005-09-13|2005-09-21|Estimate|||||||2007-11-28|2007-11-29|Estimate|April 2004||2004-04-30|November 2007|2007-11-30||||||||Observational|||Clonidine and Left Ventricular Dysfunction|Evaluation of Effects of Central Sympathetic Inhibition in Elderly With Left Ventricular Diastolic Dysfunction and Preserved Ejection Fraction: A Proof-of-Concept Trial With Clonidine|Withdrawn|||70|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.146465|2018-06-01 04:29:39.146465
NCT00213889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-26|2005-09-20|2005-09-21|Estimate|||||||2015-03-26|2015-03-27|Estimate|February 2003||2003-02-28|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||TWIST Human Gene and Cleft Lips and Palates|TWIST Human Gene and Cleft Lips and Palates|Terminated||N/A|45|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.212767|2018-06-01 04:29:39.212767
NCT00213681|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-06-17|2005-09-14|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|November 2002||2002-11-30|June 2013|2013-06-30|March 2005||2005-03-31|||||Interventional|||CPAP Versus Bilevel Pressure Support Ventilation in Cardiogenic Pulmonary Edema|CPAP Boussignac Versus Bilevel Pressure Support Ventilation in Severe Acute Cardiogenic Pulmonary Edema|Completed||Phase 3|||University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:40.29278|2018-06-01 04:29:40.29278
NCT00213876|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-29|2005-09-13|2005-09-21|Estimate|||||||2011-08-29|2011-08-30|Estimate|February 2004||2004-02-29|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Observational|||Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours|Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.|Completed|||189|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.270853|2018-06-01 04:29:39.270853
NCT00213863|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-28|2005-09-13|2005-09-21|Estimate|||||||2012-06-28|2012-07-02|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Interventional|||Implantation of Porous Titanium Prosthesis in Laryngeal Surgery|Implantation of Porous Titanium Prosthesis in Laryngeal Surgery|Unknown status|Recruiting|Phase 2|10|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 04:29:39.320791|2018-06-01 04:29:39.320791
NCT00213850|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-28|2005-09-20|2005-09-21|Estimate|||||||2007-11-28|2007-11-29|Estimate|January 2002||2002-01-31|November 2007|2007-11-30|September 2006||2006-09-30|||||Interventional|||Reference Values for Respiratory Resistance Measured by the Interrupter Technique in Adults|Reference Values for Respiratory Resistance Measured by the Interrupter Technique in Adults|Completed||N/A|122|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.400268|2018-06-01 04:29:39.400268
NCT00213837|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-24|2005-09-13|2005-09-21|Estimate|||||||2009-02-24|2009-02-25|Estimate|October 2003||2003-10-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Reconstruction Implant Bone After Removal Using Porous Titanium Prosthesis|Reconstruction Implant Bone (Anterior Mandibular Arch) After Removing Using Porous Titanium Prosthesis in ENT Surgery|Completed||Phase 2|7|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-06-01 04:29:39.456686|2018-06-01 04:29:39.456686
NCT00213824|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-26|2005-09-13|2005-09-21|Estimate|||||||2015-03-26|2015-03-27|Estimate|February 2004||2004-02-29|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis|A Study of the Expression of Nogo and Reticulon Genes in Skeletal Muscle of Patients With Amyotrophic Lateral Sclerosis|Terminated|||79|Actual|University Hospital, Strasbourg, France|||||f||||||||||None Retained|"~     tissue (skeletal muscle)~   "|||2018-06-01 04:29:39.524761|2018-06-01 04:29:39.524761
NCT00213811|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-08-07|2005-09-13|2005-09-21|Estimate|||||||2008-08-07|2008-08-08|Estimate|June 2003||2003-06-30|August 2008|2008-08-31||||||||Observational|||Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults|Bardet-Biedl Syndrome: Clinical and Genetic Epidemiology Study in the Adults|Completed|||40||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.587804|2018-06-01 04:29:39.587804
NCT00213798|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-29|2005-09-13|2005-09-21|Estimate|||||||2011-08-29|2011-08-30|Estimate|December 2003||2003-12-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Interventional|||Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients|Detection of Plasma DNA by Allelotyping in Non Small Cell and Small Cell Lung Cancer Patients. Evolution During Treatment and Follow-up.|Completed||N/A|200|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.656692|2018-06-01 04:29:39.656692
NCT00213785|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-28|2005-09-13|2005-09-21|Estimate|||||||2007-11-28|2007-11-29|Estimate|November 2001||2001-11-30|November 2007|2007-11-30|March 2004||2004-03-31|||||Observational|||A Study of Plasmatic Concentrations of Endothelin-1 (ET1), Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP) in Acute Ischemic Stroke.|A Study of Plasmatic Concentrations of Endothelin-1 (ET1), Atrial Natriuretic Peptide (ANP) and Brain Natriuretic Peptide (BNP) in Acute Ischemic Stroke.|Completed|||14|Actual|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.721655|2018-06-01 04:29:39.721655
NCT00213772|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|May 1999||1999-05-31|September 2005|2005-09-30||||||||Observational|||Risk Factors of Porphyria Cutanea Tarda (PCT)|“Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus”|Completed|||280||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.788338|2018-06-01 04:29:39.788338
NCT00213759|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-28|2005-09-13|2005-09-21|Estimate|||||||2007-11-28|2007-11-29|Estimate|March 2002||2002-03-31|November 2007|2007-11-30|August 2006|Actual|2006-08-31|||||Interventional|||Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF|Prevention Trial of Nosocomial Infections in Neutropenic Prematures With G-CSF|Completed||Phase 3|200|Actual|University Hospital, Strasbourg, France||2|||f||||||||||||||2018-06-01 04:29:39.839688|2018-06-01 04:29:39.839688
NCT00213746|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-14|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|October 2003||2003-10-31|June 2013|2013-06-30|December 2005||2005-12-31|||||Observational|||Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)|Prediction of Left Ventricular Function Changes Using Low Dose Dobutamine Gated SPECT in Patients Referred for Viability Assessment: The DOGS (DObutamine Gated Spect)Study.|Completed|||75||University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:39.925523|2018-06-01 04:29:39.925523
NCT00213733|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-29|2005-09-13|2005-09-21|Estimate|||||||2011-08-29|2011-08-30|Estimate|June 2004||2004-06-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|||||Observational|||Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer|Research of Molecular Markers for Diagnosis and/or Prognosis in Lymph Node Metastasis of Resected Non-small Cell Lung Cancer|Completed|||150|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:29:39.997699|2018-06-01 04:29:39.997699
NCT00213720|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-09-07|2005-09-13|2005-09-21|Estimate|||||||2017-09-07|2017-09-08|Actual|August 2005||2005-08-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Observational|||Treatment of Subclinical Hyperthyroidism|Place de l'Iode RadioActif Dans l'HyperThyroïdiE Sub-clinique (PIRHATES)/ Evaluation of the Interest of Subclinical Hyperthyroidism Treatment|Active, not recruiting|||300|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||Samples Without DNA|"~     serum~   "|||2018-06-01 04:29:40.083745|2018-06-01 04:29:40.083745
NCT00213707|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-24|2005-09-13|2005-09-21|Estimate|||||||2009-02-24|2009-02-25|Estimate|May 2003||2003-05-31|February 2009|2009-02-28|May 2011|Anticipated|2011-05-31|May 2010|Anticipated|2010-05-31||Observational|||Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution.|Liver Transplanted Patients for HCV Related End Stage Liver Disease.Functional Role of Blood Circulating Dendritic Cells in the Pathogenesis of Hepatitis C Virus Infection During Liver Transplantation.|Unknown status|Active, not recruiting||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||Samples With DNA|"~     Serum peripheral blood mononuclear cells~   "|||2018-06-01 04:29:40.176497|2018-06-01 04:29:40.176497
NCT00213694|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-04|2005-09-14|2005-09-21|Estimate|||||||2013-03-04|2013-03-05|Estimate|November 2003||2003-11-30|March 2013|2013-03-31|June 2006||2006-06-30|||||Observational|||PROSTACOX : Metastatic Prostate Chemotherapy|Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer|Completed|||52||University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:40.22866|2018-06-01 04:29:40.22866
NCT00213668|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2002||2002-04-30|June 2013|2013-06-30||||||||Interventional|||Effect of Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates|Effect of Glutamine on Gastric Emptying and Length of Parenteral Nutrition in Premature Neonates|Completed||Phase 4|||University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:40.357332|2018-06-01 04:29:40.357332
NCT00213655|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-07-30|2005-09-14|2005-09-21|Estimate|||||||2014-07-30|2014-07-31|Estimate|June 2004||2004-06-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|||URO-BCG-4 : Bladder Tumors Immunotherapy|Clinical Evaluation of Maintenance BCG Immunotherapy in Superficial Bladder Tumors|Completed|||146|Actual|University Hospital, Rouen|||2||f||||f||||||||||2018-06-01 04:29:40.593554|2018-06-01 04:29:40.593554
NCT00213642|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|July 2001||2001-07-31|June 2013|2013-06-30|August 2004||2004-08-31|||||Observational|||Tc-99m Renography and Cisplatin-induced Nephrotoxicity|Value of Tc-99m Renography for Early Diagnosis of Cisplatin-induced Renal Toxicity|Terminated|||20||University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:40.853983|2018-06-01 04:29:40.853983
NCT00213629|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-21|Estimate|||||||2012-02-14|2012-02-16|Estimate|November 2004||2004-11-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|MYOARRAY||myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies|Transcriptome Analysis Through a Dedicated Macro-array and TcLandscape Repertoire Analysis for Diagnosis of Myositis.|Completed||N/A|100|Actual|University Hospital, Rouen||1|||f||||t||||||||||2018-06-01 04:29:41.076645|2018-06-01 04:29:41.076645
NCT00213616|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|March 2004||2004-03-31|June 2013|2013-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bilateral Laryngeal Paralysis Reinnervation|Bilateral Laryngeal Paralysis Reinnervation. Speech and Ventilatory Results Analysis|Completed||N/A|10|Actual|University Hospital, Rouen|||||f||||t||||||||||2018-06-01 04:29:41.358204|2018-06-01 04:29:41.358204
NCT00213603|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-17|2005-09-13|2005-09-21|Estimate|||||||2013-01-17|2013-01-18|Estimate|April 2002||2002-04-30|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Follow-up Modalities of Low Grade Precancerous Bronchial Lesions|Endoscopic Follow-up of Low Grade Precancerous Bronchial Lesions in High Risk Patients (SELEPREBB1)|Completed|||365|Actual|University Hospital, Rouen|||||f||||t||||||Samples Without DNA|"~     bronchial biopsies (fixed samples)~   "|||2018-06-01 04:29:41.63378|2018-06-01 04:29:41.63378
NCT00213590|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-21|Estimate|||||||2012-02-14|2012-02-16|Estimate|April 2000||2000-04-30|February 2012|2012-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|DICAM||Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients|A Multicentric, Randomized, Opened Study to Evaluate Efficacy on Renal Function of an Immunosuppressant Regimen Based on Cyclosporine A Dose Reduction in Combination With Mycophenolate Mofetil, From the Second Year of Renal Transplantation|Completed||Phase 3|208|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-06-01 04:29:41.78809|2018-06-01 04:29:41.78809
NCT00213577|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-23|2005-09-13|2005-09-21|Estimate|||||||2015-03-23|2015-03-24|Estimate|December 2003||2003-12-31|March 2015|2015-03-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder|Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment|Terminated||Phase 2|80|Actual|University Hospital, Rouen||||the study has concluded normally;|f||||t||||||||||2018-06-01 04:29:41.966533|2018-06-01 04:29:41.966533
NCT00213564|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-25|2005-09-13|2005-09-21|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2003||2003-04-30|June 2013|2013-06-30|December 2005|Actual|2005-12-31|May 2004|Actual|2004-05-31||Observational|||Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis|Gene Expression Profiling in PBMCs as a Tool for Prediction of Infliximab Responsiveness in Rheumatoid Arthritis|Completed|||40|Anticipated|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:42.057948|2018-06-01 04:29:42.057948
NCT00213551|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2004||2004-04-30|June 2013|2013-06-30|June 2008|Actual|2008-06-30|||||Interventional|||Glutamine and Intestinal Protein Metabolism|Comparative Effects of Glutamine and Glucose on Intestinal Protein Metabolism in Healthy Humans|Completed||Phase 1|30|Anticipated|University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:42.114146|2018-06-01 04:29:42.114146
NCT00213538|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-13|2005-09-13|2005-09-21|Estimate|||||||2017-06-13|2017-06-14|Actual|June 2003||2003-06-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis|Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis|Completed|||341|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:42.189756|2018-06-01 04:29:42.189756
NCT00213525|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-02-04|2005-09-13|2005-09-21|Estimate|||||||2015-02-04|2015-02-05|Estimate|October 2004||2004-10-31|February 2015|2015-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls|Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Healthy Controls|Completed|||300|Actual|University Hospital, Rouen|||2||f||||f||||||||||2018-06-01 04:29:42.253726|2018-06-01 04:29:42.253726
NCT00213512|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2003||2003-06-30|June 2013|2013-06-30|October 2008|Actual|2008-10-31|June 2006|Actual|2006-06-30||Interventional|||Effect of Anti CD20 in Pemphigus Desease|Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera).|Completed||Phase 2/Phase 3|22||University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:42.335462|2018-06-01 04:29:42.335462
NCT00213499|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-21|Estimate|||||||2012-02-14|2012-02-16|Estimate|January 2002||2002-01-31|February 2012|2012-02-29|September 2008|Actual|2008-09-30|April 2006|Actual|2006-04-30||Interventional|VENISE||Non Invasive Ventilation and Weaning : VENISE Trial|Randomized Prospective Multicenter Study of Non Invasive Ventilation Assessment for Weaning From Mechanical Ventilation in Patients With Chronic Respiratory Failure. NIV and Weaning (VENISE)Trial.|Completed||N/A|205||University Hospital, Rouen|||||f||||t||||||||||2018-06-01 04:29:42.428495|2018-06-01 04:29:42.428495
NCT00213486|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-10-27|2005-09-13|2005-09-21|Estimate|||||||2005-10-27|2005-10-28|Estimate|June 2002||2002-06-30|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial|Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial|Completed||Phase 2|43||University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:42.502501|2018-06-01 04:29:42.502501
NCT00213460|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-04-15|2005-09-13|2005-09-21|Estimate|||||||2013-04-15|2013-04-16|Estimate|August 2001||2001-08-31|April 2013|2013-04-30|July 2003|Actual|2003-07-31|||||Observational|||Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up|Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up|Completed|||||University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:42.639906|2018-06-01 04:29:42.639906
NCT00213447|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|November 2002||2002-11-30|June 2013|2013-06-30|December 2005||2005-12-31|||||Observational|||T Cell Response in Hypersensitivity Syndrome|Characterization of T Cell Response in Hypersensitivity Syndrome|Completed|||40|Anticipated|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:42.706864|2018-06-01 04:29:42.706864
NCT00213434|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-25|2005-09-13|2005-09-21|Estimate|||||||2013-06-25|2013-06-26|Estimate|November 2001||2001-11-30|June 2013|2013-06-30|June 2006|Actual|2006-06-30|December 2004|Actual|2004-12-31||Interventional|||Evaluation of a Mandibular Advancement Device in the Treatment of Obstructive Sleep Apnea Syndrome|Prospective Evaluation of Mandibular Advancement by Herbst Device in the Treatment of Moderate Obstructive Sleep Apnea Syndrome|Completed||N/A|||University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:42.75658|2018-06-01 04:29:42.75658
NCT00213421|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|August 2001||2001-08-31|June 2013|2013-06-30|November 2008|Actual|2008-11-30|October 2004|Actual|2004-10-31||Observational|||Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus||Completed|||330|Actual|University Hospital, Rouen|||2||f||||||||||||||2018-06-01 04:29:42.824612|2018-06-01 04:29:42.824612
NCT00213408|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2001||2001-06-30|June 2013|2013-06-30|January 2007|Actual|2007-01-31|||||Interventional|||Catheter Ablation as the First Line Therapy for Typical Atrial Flutter|Catheter Ablation as the First Line Therapy for Symptomatic Typical Atrial Flutter: A Multicenter Randomized Study of Cost/Effectiveness|Terminated||Phase 4|120||University Hospital, Rouen||||end of the follow-up period|f||||||||||||||2018-06-01 04:29:42.895639|2018-06-01 04:29:42.895639
NCT00213395|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-21|Estimate|||||||2012-02-14|2012-02-16|Estimate|October 2004||2004-10-31|February 2012|2012-02-29|February 2006||2006-02-28|||||Interventional|||Clinical Efficacy of a Cephalic Mask for Noninvasive Ventilation During Acute Hypercapnic Respiratory Failure||Terminated||N/A|||University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:42.971478|2018-06-01 04:29:42.971478
NCT00213382|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-23|2005-09-13|2005-09-21|Estimate|||||||2011-02-23|2011-02-24|Estimate|February 2005||2005-02-28|February 2011|2011-02-28||||||||Observational|||Cortical Pharyngeal Area: Excitability, Facilitation and Plasticity in Healthy Subjects|Cortical Pharyngeal Area: Excitability, Facilitation and Plasticity in Healthy Subjects|Completed|||10|Anticipated|University Hospital, Rouen|||||f||||||||||||||2018-06-01 04:29:43.05125|2018-06-01 04:29:43.05125
NCT00213369|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-21|Estimate|||||||2012-02-14|2012-02-16|Estimate|January 2007||2007-01-31|February 2012|2012-02-29|May 2009|Actual|2009-05-31|||||Observational|||Neuromodulation of Aspiration Secondary to Stroke|Neuromodulation of Aspiration Secondary to Stroke|Completed|||20|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:43.100907|2018-06-01 04:29:43.100907
NCT00213356|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2003||2003-04-30|June 2013|2013-06-30|March 2004||2004-03-31|||||Observational|||Study of the Nervous Control of the Anal Sphincter|Evoked Responses of External Anal Sphincter After Cortical and Lombo-sacral Magnetic Stimulations|Withdrawn|||0|Actual|University Hospital, Rouen||||patients with neurological disease not included|f||||f||||||||||2018-06-01 04:29:43.15135|2018-06-01 04:29:43.15135
NCT00213343|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|May 2005||2005-05-31|June 2013|2013-06-30|July 2005|Actual|2005-07-31|June 2005|Actual|2005-06-30||Observational|||Effects of Phrenic Nerve Stimulation During Swallowing : Experimental Model of Aspiration|Effects of Phrenic Nerve Stimulation During Swallowing : Experimental Model of Aspiration|Terminated|||30|Actual|University Hospital, Rouen||||dyspnea|f||||f||||||||||2018-06-01 04:29:43.201554|2018-06-01 04:29:43.201554
NCT00213330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-20|2005-09-13|2005-09-21|Estimate|||||||2012-04-20|2012-04-23|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|February 2006||2006-02-28|||||Observational|||Cerebral Resonance Magnetic Imaging During Rectal Distention|Cerebral Activity During Rectal Pain in Patients With Irritable Bowel Syndrome or Inflammatory Bowel Disease:Resonance Magnetic Imaging Study.|Withdrawn|||0|Actual|University Hospital, Rouen||||patients with inflammatory colitis not included|f||||||||||||||2018-06-01 04:29:43.253138|2018-06-01 04:29:43.253138
NCT00213317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-21|Estimate|||||||2012-02-14|2012-02-16|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Observational|||Effect of Lumbo-sacral Magnetic Stimulation on Colonic Motility|Could Lumbo-sacral Magnetic Stimulation Modify Recto-colonic Motility?|Completed|||30|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:29:43.304165|2018-06-01 04:29:43.304165
NCT00213304|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-08-15|2005-09-14|2005-09-21|Estimate|||||||2013-08-15|2013-08-16|Estimate|June 1999||1999-06-30|August 2013|2013-08-31||||||||Interventional|||The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation|Safety and Immunogenicity of Live Attenuated Oka/Merck Varicella Vaccine in Children Listed to Undergo Solid Organ Transplantation|Unknown status|Active, not recruiting|Phase 3|150||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:29:43.351745|2018-06-01 04:29:43.351745
NCT00213291|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-23|2005-09-13|2005-09-21|Estimate|||||||2013-08-23|2013-08-26|Estimate|April 2005||2005-04-30|August 2013|2013-08-31|October 2005||2005-10-31|September 2005|Actual|2005-09-30||Interventional|||Darbepoetin Treatment of Anemia in Children With Chronic Renal Failure|Extended Dosing of Darbepoetin Alfa (Aranesp) for the Management of Anemia in Children With Chronic Renal Failure|Completed||Phase 3|40|Anticipated|The Hospital for Sick Children||1|||f||||f||||||||||2018-06-01 04:29:43.421603|2018-06-01 04:29:43.421603
NCT00213278|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-11-19|2005-09-13|2005-09-21|Estimate|||||||2014-11-19|2014-11-20|Estimate|January 2002||2002-01-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma|A Phase 2 Study of Vinblastine Sulphate Injection in Children With Recurrent or Refractory Low Grade Glioma|Completed||Phase 2|50|Actual|The Hospital for Sick Children||1|||f||||t||||||||||2018-06-01 04:29:43.486229|2018-06-01 04:29:43.486229
NCT00213265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-15|2005-09-13|2005-09-21|Estimate|||||||2013-08-15|2013-08-16|Estimate|July 2002||2002-07-31|August 2013|2013-08-31||||||||Interventional|||Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants|Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Among Solid Organ Transplant Recipients: Protocol 1A and 1B|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 04:29:43.551009|2018-06-01 04:29:43.551009
NCT00213252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-12|2005-09-13|2005-09-21|Estimate|||||||2014-05-12|2014-05-13|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Use of Montelukast to Treat Children With Mild to Moderate Acute Asthma|Can Montelukast Shorten Corticosteroid Therapy In Children With Mild To Moderate Acute Asthma?|Completed||Phase 2|130|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-06-01 04:29:43.627779|2018-06-01 04:29:43.627779
NCT00213239|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-19|2005-09-13|2005-09-21|Estimate|||||||2013-08-19|2013-08-20|Estimate|September 2005||2005-09-30|August 2013|2013-08-31|January 2008|Actual|2008-01-31|September 2007|Actual|2007-09-30||Interventional|||A Dose Finding Study of Remifentanil and Propofol for Lumbar Punctures in Children|The Minimum Effective Dose of Remifentanil When Co-administered With Propofol for Lumbar Puncture in Children: A Dose-finding Study|Completed||Phase 1/Phase 2|64|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 04:29:43.709242|2018-06-01 04:29:43.709242
NCT00213226|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-12|2005-09-13|2005-09-21|Estimate|||||||2014-05-12|2014-05-13|Estimate|December 2001||2001-12-31|May 2014|2014-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Single Dose Versus Multiple Doses of Dexamethasone in Children With Acute Bronchiolitis|Efficacy of Single Dose Versus Multiple Doses of Dexamethasone in Outpatients With Acute Bronchiolitis|Completed||Phase 3|120|Anticipated|The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:29:43.801654|2018-06-01 04:29:43.801654
NCT00213213|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-11|2005-09-13|2005-09-21|Estimate|||||||2010-03-11|2010-03-15|Estimate|July 2003||2003-07-31|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||Using Sugar Water to Relieve Pain in Infants|Effectiveness of Sucrose Analgesia in Reducing Pain Responses in Infants Born to Diabetic and Non-diabetic Mothers: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|240||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:29:43.863352|2018-06-01 04:29:43.863352
NCT00213200|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-10|2005-09-13|2005-09-21|Estimate|||||||2006-10-10|2006-10-11|Estimate|July 2003||2003-07-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Intravenous and Topical Analgesics for Procedural Pain in Neonates|Systemic Analgesia and Local Anaesthesia for Percutaneous Venous Catheter Placement in Preterm Neonates|Completed||Phase 3|108||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:29:43.91892|2018-06-01 04:29:43.91892
NCT00213187|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-17|2005-09-13|2005-09-21|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2002||2002-08-31|December 2013|2013-12-31|November 2005||2005-11-30|||||Interventional|||PEAK Study (Physical Exercise and Activity in Kids)|The Effect of Vigorous Exercise on Motor Function and Functional Fitness in Juvenile Arthritis|Completed||Phase 2|80||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:29:43.972845|2018-06-01 04:29:43.972845
NCT00213174|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-14|2005-09-13|2005-09-21|Estimate|||||||2013-08-14|2013-08-15|Estimate|January 2005||2005-01-31|August 2013|2013-08-31||||||||Interventional|||Study of Sand Versus Wood Chip Surfaces on School Playgrounds to Minimize Injury in School Children|School Playground Surfacing - A Randomized Prospective Comparison of Injury Rates on Sand Versus Wood Chip Surfaces|Unknown status|Recruiting|Phase 3|34|Anticipated|The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:29:44.036455|2018-06-01 04:29:44.036455
NCT00213161|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-10|2005-09-13|2005-09-21|Estimate|||||||2006-10-10|2006-10-11|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Using Iron Supplementation to Decrease Iron Deficiency Anemia in Infants and Young Children in India|Establishing an Iron Supplementation Strategy to Reduce the Prevalence of Iron Deficiency Anemia Among Infants and Young Children in India.|Completed||N/A|425||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:29:44.112221|2018-06-01 04:29:44.112221
NCT00213148|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-08-05|2005-09-13|2005-09-21|Estimate|||||||2014-08-05|2014-08-06|Estimate|March 2005||2005-03-31|August 2014|2014-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction|A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction|Completed||Phase 2|271|Actual|EMD Serono||4|||f||||||||||||||2018-06-01 04:29:44.185264|2018-06-01 04:29:44.185264
NCT00213135|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-09-30||2014-01-10|2005-09-13|2005-09-21|Estimate|2013-09-30|2013-12-02|Estimate||||2014-01-10|2014-02-07|Estimate|April 2005||2005-04-30|January 2014|2014-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|CLARITY||A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)|A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)|Completed||Phase 3|1326|Actual|EMD Serono||3|||f||||||||||||||2018-06-01 04:29:44.290207|2018-06-01 04:29:44.290207
NCT00213122|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-25|2005-09-13|2005-09-21|Estimate|||||||2006-09-25|2006-09-28|Estimate||||September 2006|2006-09-30||||||||Interventional|||Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin||Completed||Phase 3|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 04:29:45.368973|2018-06-01 04:29:45.368973
NCT00213109|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-20|2005-09-13|2005-09-21|Estimate|||||||2006-09-20|2006-09-21|Estimate||||September 2006|2006-09-30||||||||Interventional|||Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment||Completed||Phase 3|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 04:29:45.462949|2018-06-01 04:29:45.462949
NCT00213096|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-11|2005-09-13|2005-09-21|Estimate|||||||2017-08-11|2017-08-14|Actual|March 2003|Actual|2003-03-31|August 2017|2017-08-31|February 2004|Actual|2004-02-29|||||Interventional|||Effects of Hormonal Contraceptives on Liver Proteins and Coagulation Factors: A Comparison of a Contraceptive Vaginal Ring and an Oral Contraceptive|A Randomized, Open-Label Study Comparing the Effect of a Contraceptive Vaginal Ring Delivering Daily Doses of 150 Micrograms Nestorone and 15 Micrograms Ethinyl Estradiol to an Oral Contraceptive Containing 150 Micrograms of Levonorgestrel and 30 Micrograms of Ethinyl Estradiol Per Tablet on Hepatic Factors Including Coagulation Factors|Completed||Phase 2|50||Population Council|||||||||||||||||||2018-06-01 04:29:45.532369|2018-06-01 04:29:45.532369
NCT00213083|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-11|2005-09-13|2005-09-21|Estimate|||||||2017-08-11|2017-08-15|Actual|April 2004||2004-04-30|August 2017|2017-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission|Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard® in Preventing HIV Seroconversion in Women|Completed||Phase 3|6203|Actual|Population Council|||||f||||||||||||||2018-06-01 04:29:45.594626|2018-06-01 04:29:45.594626
NCT00213070|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-20|2005-09-13|2005-09-21|Estimate|||||||2006-09-20|2006-09-21|Estimate||||September 2006|2006-09-30||||||||Interventional|||Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment||Completed||Phase 3|||Sanwa Kagaku Kenkyusho Co., Ltd.|||||f||||||||||||||2018-06-01 04:29:45.669382|2018-06-01 04:29:45.669382
NCT00213057|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-11|2005-09-13|2005-09-21|Estimate|||||||2017-08-11|2017-08-14|Actual|June 2001|Actual|2001-06-30|August 2017|2017-08-31|June 2002|Actual|2002-06-30|||||Interventional|||Safety and Acceptability of Carraguard™ Among HIV-negative Couples in Thailand|A Randomized, Placebo-controlled, Double-blind Trial to Assess Expanded Safety and Acceptability of Carraguard™ (PC-515) Vaginal Gel Among Heterosexual Couples in Chiang Rai|Completed||Phase 1|110||Population Council|||||||||||||||||||2018-06-01 04:29:45.737592|2018-06-01 04:29:45.737592
NCT00213044|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-11|2005-09-13|2005-09-21|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2003|Actual|2003-03-31|August 2017|2017-08-31|June 2004|Actual|2004-06-30|||||Interventional|||A Randomized, Controlled, Cross-Over Trial of Safety of Vaginal Use of Carraguard by HIV-Infected Women|A Randomized, Controlled, Double-Blind, Cross-Over Trial of Safety, Effect on Genital Tract HIV Shedding, and Acceptability of Vaginal Use of Carraguard by HIV-Infected Women|Completed||Phase 1|60||Population Council|||||||||||||||||||2018-06-01 04:29:45.811443|2018-06-01 04:29:45.811443
NCT00213031|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-11|2005-09-13|2005-09-21|Estimate|||||||2017-08-11|2017-08-14|Actual|February 2000|Actual|2000-02-29|August 2017|2017-08-31|December 2001|Actual|2001-12-31|||||Interventional|||Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide|A Randomized, Placebo-controlled, Double-blind Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of PC-515 (Lambda Carrageenan) for Vaginal Use as a Possible Microbicide|Completed||Phase 2|165||Population Council|||||||||||||||||||2018-06-01 04:29:45.900771|2018-06-01 04:29:45.900771
NCT00213018|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-11|2005-09-13|2005-09-21|Estimate|||||||2017-08-11|2017-08-14|Actual|October 1999|Actual|1999-10-31|August 2017|2017-08-31|January 2002|Actual|2002-01-31|||||Interventional|||Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission|A Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing STI/HIV Transmission|Completed||Phase 2|400||Population Council|||||||||||||||||||2018-06-01 04:29:45.966089|2018-06-01 04:29:45.966089
NCT00213005|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-11|2005-09-13|2005-09-21|Estimate|||||||2017-08-11|2017-08-14|Actual|June 2002|Actual|2002-06-30|August 2017|2017-08-31|August 2003|Actual|2003-08-31|||||Interventional|||Safety and Acceptability of Carraguard® in HIV Positive Women and Men|A Phase 1 Safety and Acceptability Study of Carraguard® Among HIV Positive Women and Men in Durban, South Africa|Completed||Phase 1|60||Population Council|||||||||||||||||||2018-06-01 04:29:46.042654|2018-06-01 04:29:46.042654
NCT00212992|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-23|2005-09-13|2005-09-21|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2001|Actual|2001-03-31|January 2017|2017-01-31|July 2006|Actual|2006-07-31|September 2005|Actual|2005-09-30||Interventional|||Biphasic Defibrillation Study: Trial to Compare Fixed Versus Escalating Energy|A Pilot Randomized Controlled Trial to Compare Fixed Versus Escalating Energy Regimens for Biphasic Waveform Defibrillation|Completed||Phase 3|200||Ottawa Hospital Research Institute|||||f|||||f|f||||||No||2018-06-01 04:29:46.10299|2018-06-01 04:29:46.10299
NCT00212979|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-29|2005-09-13|2005-09-21|Estimate|||||||2016-03-29|2016-03-31|Estimate|April 2004||2004-04-30|February 2009|2009-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Measuring Kidney Function in Kidney Transplantation|The Accurate Prediction of Renal Function in Kidney Transplant Recipients|Completed|||250|Anticipated|Ottawa Hospital Research Institute|||1||f||||||||||||||2018-06-01 04:29:46.173644|2018-06-01 04:29:46.173644
NCT00212966|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-08-19|2005-09-13|2005-09-21|Estimate|||||||2010-08-19|2010-08-23|Estimate|July 2004||2004-07-31|August 2010|2010-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Shared Mental Health Care Linking Mental Health Services With Family Medicine Groups|Shared Mental Health Care Linking General Hospital Acute Care Mental Health Services With Two Comprehensive Family Medicine Groups|Completed|||350|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:29:46.245117|2018-06-01 04:29:46.245117
NCT00212953|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-10-13|2005-09-13|2005-09-21|Estimate|||||||2010-10-13|2010-10-15|Estimate|March 1997||1997-03-31|October 2010|2010-10-31|May 1999|Actual|1999-05-31|||||Interventional|||OPALS Critical Care Sub-Studies|Ontario Prehospital Advanced Life Support (OPALS) Study Phase III Cardiac Arrest and Critical Care Sub-Studies - Chest Pain Sub-Study, Respiratory Sub-Study, and Major Trauma Sub-Study|Completed||N/A|21000||Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:29:46.291222|2018-06-01 04:29:46.291222
NCT00212940|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-25|2005-09-13|2005-09-21|Estimate|||||||2007-07-25|2007-07-26|Estimate|October 2000||2000-10-31|July 2007|2007-07-31|September 2006|Actual|2006-09-30|||||Interventional|||Supportive Therapy for Adherence to ART(STAART)|Increasing Patient Adherence to HIV Medications: A Prospective Intervention Study|Completed||N/A|112|Anticipated|Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 04:29:47.288455|2018-06-01 04:29:47.288455
NCT00212927|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-08-31|2005-09-13|2005-09-21|Estimate|||||||2015-08-31|2015-09-02|Estimate|October 2002||2002-10-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Observational|||Continuity of Care and Outcomes After Discharge From Hospital|The Association of Provider Continuity and Information Continuity With Patient Outcomes After Discharge From Hospital|Completed|||5900|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:29:47.34518|2018-06-01 04:29:47.34518
NCT00212914|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-08|2005-09-13|2005-09-21|Estimate|||||||2008-09-08|2008-09-09|Estimate|May 2002||2002-05-31|September 2008|2008-09-30|January 2006||2006-01-31|||||Interventional|||Increasing Screening for Type 2 Diabetes in Women With Previous Gestational Diabetes.|Mailing Recommendations to the Individual or Physician to Increase Screening for Type 2 Diabetes in Women With Previous Gestational Diabetes: Clinical Trial.|Completed||N/A|268||Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 04:29:47.395267|2018-06-01 04:29:47.395267
NCT00212901|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-25|2005-09-13|2005-09-21|Estimate|||||||2007-07-25|2007-07-26|Estimate|August 2004||2004-08-31|July 2007|2007-07-31|September 2006|Actual|2006-09-30|||||Interventional|||High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy|Addition of Angiotensin Receptor Blockade to ACE Inhibition Versus High Dose ACE Inhibition for Reduction of Proteinuria in Patients With Diabetic Nephropathy|Completed||N/A|30|Anticipated|Ottawa Hospital Research Institute|||||f||||||||||||||2018-06-01 04:29:47.449903|2018-06-01 04:29:47.449903
NCT00212888|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-22|2005-09-13|2005-09-21|Estimate|||||||2012-05-22|2012-05-23|Estimate|April 2004||2004-04-30|May 2012|2012-05-31|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|||Combination Vaccination Before HIV Treatment Interruption|A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression|Completed||Phase 1/Phase 2|60|Actual|Ottawa Hospital Research Institute|||||f||||t||||||||||2018-06-01 04:29:47.52221|2018-06-01 04:29:47.52221
NCT00212706|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-11|2005-09-20|2005-09-21|Estimate|||||||2012-10-11|2012-10-12|Estimate|October 2001||2001-10-31|October 2012|2012-10-31||||November 2002|Actual|2002-11-30||Interventional|||Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan|Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan|Completed||Phase 2|400||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:48.764273|2018-06-01 04:29:48.764273
NCT00212875|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-05-19|2005-09-16|2005-09-21|Estimate|||||||2011-05-19|2011-05-23|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|February 2007|Actual|2007-02-28|||||Interventional|||A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.|An Open-Label, Randomized, Multicenter Study of the Initiation of Four Dosing Regimens of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease (CKD). Protocol Addendum: Due to Space Constraints, See Detailed Description for Full Title of Addendum.|Completed||Phase 2|267|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:29:47.633812|2018-06-01 04:29:47.633812
NCT00212862|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-06-27|2005-09-13|2005-09-21|Estimate|||||||2014-06-27|2014-06-30|Estimate|December 2003||2003-12-31|June 2014|2014-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|DOSE||Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia|Dosing and Outcomes Study of Erythropoietic Stimulating Therapies|Completed|||2130|Actual|Ortho Biotech Products, L.P.|||1||f||||f||||||||||2018-06-01 04:29:47.694847|2018-06-01 04:29:47.694847
NCT00212849|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 1995||1995-01-31|December 2004|2004-12-31|August 2005||2005-08-31|||||Observational|||Autologous Chondrocyte Implantation in the Patellofemoral Joint|Autologous Chondrocyte Implantation in the Patellofemoral Joint|Completed|||35||Orthopaedic Research Foundation|||||f||||||||||||||2018-06-01 04:29:47.752052|2018-06-01 04:29:47.752052
NCT00212836|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-28|2005-09-13|2005-09-21|Estimate|||||||2017-04-28|2017-05-02|Actual|April 21, 2005|Actual|2005-04-21|April 2017|2017-04-30|August 2, 2007|Actual|2007-08-02|June 15, 2007|Actual|2007-06-15||Interventional|||Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)|A Multicenter, Double-Blind, Flexible -Dose, 6-Month Trial Comparing the Efficacy Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia|Completed||Phase 3|481|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:29:47.899133|2018-06-01 04:29:47.899133
NCT00212823|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-17|2005-09-13|2005-09-21|Estimate|||||||2011-05-17|2011-05-19|Estimate|June 2004||2004-06-30|April 2010|2010-04-30|February 2005|Actual|2005-02-28|||||Interventional|||The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain|AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain|Completed||Phase 4|1450|Actual|Ortho-McNeil Neurologics, Inc.|||||f||||||||||||||2018-06-01 04:29:47.980785|2018-06-01 04:29:47.980785
NCT00212810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-17|2005-09-13|2005-09-21|Estimate|||||||2011-05-17|2011-05-19|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.|TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study|Completed||Phase 4|385|Actual|Ortho-McNeil Neurologics, Inc.|||||f||||||||||||||2018-06-01 04:29:48.055583|2018-06-01 04:29:48.055583
NCT00212797|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-11-25|2005-09-15|2005-09-21|Estimate|||||||2015-11-25|2015-11-26|Estimate|July 2004||2004-07-31|November 2015|2015-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|Hermes||A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)|Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).|Completed||Phase 2|273|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:29:48.123168|2018-06-01 04:29:48.123168
NCT00212784|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-18|2005-09-13|2005-09-21|Estimate|||||||2017-08-18|2017-08-22|Actual|September 4, 2003|Actual|2003-09-04|August 2017|2017-08-31|March 15, 2006|Actual|2006-03-15|March 15, 2006|Actual|2006-03-15||Interventional|||Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)|A Phase III, Double-Blind, Randomized, Active-Controlled, Two-Armed, Multicenter, Efficacy and Safety Assessment (ACTAMESA) of Org 5222 and Olanzapine in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|1225|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:29:48.197247|2018-06-01 04:29:48.197247
NCT00212771|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-22|2005-09-13|2005-09-21|Estimate|||||||2014-12-22|2014-12-23|Estimate|September 2004||2004-09-30|December 2014|2014-12-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|ACTAMESA||Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)|Long-Term Efficacy and Safety Evaluation of Asenapine (10-20 mg/Day) in With Schizophrenia or Schizoaffective Disorder, in a Multicenter Trial Using (10-20 mg/Day) as a Control|Completed||Phase 3|440|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:29:48.28633|2018-06-01 04:29:48.28633
NCT00212758|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2011-07-22||2011-10-22|2005-09-14|2005-09-21|Estimate|2011-10-22|2011-10-26|Estimate||||2011-10-22|2011-10-26|Estimate|January 2005||2005-01-31|October 2011|2011-10-31|May 2010|Actual|2010-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood|IGF-1 Generation Test in Children With Chronic Kidney Disease|Completed||Phase 4|17|Actual|Oregon Health and Science University|Slow enrollment and the small number of participants in the study is the main limitation.|2|||f||||f||||||||||2018-06-01 04:29:48.385628|2018-06-01 04:29:48.385628
NCT00212745|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-09-22|2005-09-13|2005-09-21|Estimate|||||||2009-09-22|2009-09-23|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|March 2010|Anticipated|2010-03-31|March 2009|Actual|2009-03-31||Interventional|||Pilot Trial of a Behavioral Treatment for Epilepsy|Nonrandomized Pilot Trial of the Andrews/Reiter Behavioral Treatment for Epilepsy|Unknown status|Active, not recruiting|Phase 1/Phase 2|8|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 04:29:48.570133|2018-06-01 04:29:48.570133
NCT00212732|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-10|2005-09-20|2005-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|October 2003||2003-10-31|October 2012|2012-10-31||||April 2006|Actual|2006-04-30||Interventional|||Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan|Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan|Completed||Phase 3|750||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:48.652469|2018-06-01 04:29:48.652469
NCT00212719|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-10|2005-09-20|2005-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|May 2003||2003-05-31|October 2012|2012-10-31||||April 2006|Actual|2006-04-30||Interventional|||Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Completed||Phase 3|250||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:48.710827|2018-06-01 04:29:48.710827
NCT00212693|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-10|2005-09-20|2005-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|January 2004||2004-01-31|October 2012|2012-10-31||||September 2005|Actual|2005-09-30||Interventional|||Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan|Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan|Completed||Phase 2|165||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:48.817847|2018-06-01 04:29:48.817847
NCT00212680|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-10|2005-09-20|2005-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|December 1996||1996-12-31|October 2012|2012-10-31||||April 2006|Actual|2006-04-30||Interventional|||Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan|Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan|Completed||Phase 2|100||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:48.866122|2018-06-01 04:29:48.866122
NCT00212667|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-10|2005-09-20|2005-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|August 2002||2002-08-31|October 2012|2012-10-31||||September 2006|Actual|2006-09-30||Interventional|||Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Completed||Phase 3|650||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:49.005521|2018-06-01 04:29:49.005521
NCT00212654|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-10|2005-09-20|2005-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|June 2001||2001-06-30|October 2012|2012-10-31||||April 2006|Actual|2006-04-30||Interventional|||Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan|Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan|Completed||Phase 2/Phase 3|165||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:49.065239|2018-06-01 04:29:49.065239
NCT00212641|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-10-10|2005-09-14|2005-09-21|Estimate|||||||2012-10-10|2012-10-11|Estimate|June 2005||2005-06-30|October 2012|2012-10-31||||October 2007|Actual|2007-10-31||Interventional|||A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus|Randomized Double-Blind Placebo-Controlled Pharmacodynamic Evaluation of ONO-5129 in Patients With Treatment Naive Type 2 Diabetes Mellitus|Completed||Phase 2|105||Ono Pharmaceutical Co. Ltd|||||||||||||||||||2018-06-01 04:29:49.147792|2018-06-01 04:29:49.147792
NCT00212628|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-12|2005-09-20|2005-09-21|Estimate|||||||2012-06-12|2012-06-14|Estimate|June 2004||2004-06-30|June 2012|2012-06-30||||||||Interventional|||Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan|Completed||Phase 3|444|Actual|Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:49.31896|2018-06-01 04:29:49.31896
NCT00212615|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-10-16|2005-09-13|2005-09-21|Estimate|||||||2009-10-16|2009-10-19|Estimate|February 2004||2004-02-29|October 2009|2009-10-31|October 2008||2008-10-31|||||Interventional|||XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer|XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|116||Odense University Hospital|||||f||||||||||||||2018-06-01 04:29:49.399205|2018-06-01 04:29:49.399205
NCT00212602|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-12|2005-09-20|2005-09-21|Estimate|||||||2012-06-12|2012-06-14|Estimate|August 2005||2005-08-31|June 2012|2012-06-30||||||||Interventional|||ONO-7436 Phase II Study in Japan|ONO-7436 Phase II Study - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of ONO-7436 for the Prevention of Cancer Chemotherapy-Induced Nausea and Vomiting in Japan|Completed||Phase 2|420||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 04:29:49.481444|2018-06-01 04:29:49.481444
NCT00212589|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|December 2002||2002-12-31|May 2004|2004-05-31|April 2004||2004-04-30|||||Interventional|||Patients Preference for Oral or i.v. Therapy|A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer|Completed||Phase 3|60||Odense University Hospital|||||f||||||||||||||2018-06-01 04:29:49.552229|2018-06-01 04:29:49.552229
NCT00212576|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2018-02-07|2005-09-19|2005-09-21|Estimate|||||||2018-02-07|2018-02-08|Actual|November 2005||2005-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Promoting Early School Readiness in Primary Health Care|Promoting Early School Readiness in Primary Health Care|Active, not recruiting||N/A|675|Actual|New York University School of Medicine||5|||f||||t|f|f||||||||2018-06-01 04:29:49.634782|2018-06-01 04:29:49.634782
NCT00212550|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-29|2005-09-13|2005-09-21|Estimate|||||||2016-03-29|2016-03-31|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|January 2012|Actual|2012-01-31|February 2010|Actual|2010-02-28||Observational|||Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb|Evaluation of the Practice of Three Morning Sputa on Separate Days for Diagnosis of Mtb|Completed|||10|Actual|New York University School of Medicine|||1||f||||t||||||||Undecided||2018-06-01 04:29:49.721672|2018-06-01 04:29:49.721672
NCT00212537|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2018-01-18|2005-09-19|2005-09-21|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2002||2002-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Disease Modifying Genes in Severe Asthma|Disease Modifying Genes in Severe Asthma|Active, not recruiting|||2000|Anticipated|New York University School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     The total amount of blood drawn is approximately 5 tablespoons (75 ml). The blood sample will~     be processed to isolate genetic material (mainly DNA, RNA and protein). This genetic~     material will be used to try to identify the genetic factors or genes that a person~     inherits that make him or her more likely to develop asthma. The blood is used to test for~     allergies to weeds, trees, insects and molds (RAST) and a complete blood count.~   "|||2018-06-01 04:29:49.780896|2018-06-01 04:29:49.780896
NCT00212511|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-26|2005-09-13|2005-09-21|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2004||2004-11-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry|Prospective Evaluation of Patients With Idiopathic Pulmonary Fibrosis Through an IPF Registry|Withdrawn|||0|Actual|New York University School of Medicine||||Pending more information from PI|f||||t|f|f||||||Yes|Data has not been analyzed yet.|2018-06-01 04:29:49.837231|2018-06-01 04:29:49.837231
NCT00212498|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-07|2005-09-13|2005-09-21|Estimate|||||||2015-12-07|2015-12-09|Estimate|November 2006||2006-11-30|December 2015|2015-12-31||||January 2012|Actual|2012-01-31||Observational|||Tuberculosis Research Blood Bank||Withdrawn|||0|Actual|New York University School of Medicine|||1||f||||||||||||||2018-06-01 04:29:49.907396|2018-06-01 04:29:49.907396
NCT00212485|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-30|2005-09-13|2005-09-21|Estimate|||||||2010-06-30|2010-07-01|Estimate|September 2005||2005-09-30|June 2010|2010-06-30|May 2009|Actual|2009-05-31|April 2008|Actual|2008-04-30||Interventional|||Study to Evaluate the Use of Ultrasound in the Diagnosis of Hemophilic Joint Disease|Evaluation of the Role of Power Doppler Sonography in the Diagnosis of Hemophilic Joint Disease|Completed||N/A|43|Actual|New York Presbyterian Hospital|||||f||||f||||||||||2018-06-01 04:29:49.976768|2018-06-01 04:29:49.976768
NCT00212472|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-12-04|2005-09-13|2005-09-21|Estimate|||||||2009-12-04|2009-12-07|Estimate|July 2002||2002-07-31|October 2009|2009-10-31|December 2012|Anticipated|2012-12-31|December 2010|Anticipated|2010-12-31||Interventional|||International Immune Tolerance Study|An International Randomised Controlled Trial Of Immune Tolerance Induction|Terminated||N/A|134|Actual|New York Presbyterian Hospital||2||The DSMB recommended stopping the study due to safety concerns.|f||||t||||||||||2018-06-01 04:29:50.044691|2018-06-01 04:29:50.044691
NCT00212459|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-26|2005-09-13|2005-09-21|Estimate|||||||2013-03-26|2013-03-27|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|April 2008|Actual|2008-04-30|February 2006|Actual|2006-02-28||Interventional|||The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs|A Prospective Randomized Pilot Study on the Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs|Completed||N/A|14|Actual|New York Presbyterian Hospital||2|||f||||f||||||||||2018-06-01 04:29:50.155708|2018-06-01 04:29:50.155708
NCT00212446|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-11-19|2005-09-13|2005-09-21|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pilot Study to Evaluate a Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions|Pilot Study to Evaluate a Prototype Electronic Uterine Inhibitor to Prevent Preterm Contractions|Completed||N/A|8|Actual|St. Luke's-Roosevelt Hospital Center||1|||f||||f||||||||||2018-06-01 04:29:50.415093|2018-06-01 04:29:50.415093
NCT00212433|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-20|2005-09-13|2005-09-21|Estimate|||||||2006-07-20|2006-07-24|Estimate|July 2004||2004-07-31|December 2005|2005-12-31|February 2006||2006-02-28|||||Interventional|||Optimisation and Performance of Reduced Preparation CT Colography|Multidetector-Row CT Colonography: Optimisation of Reduced Bowel Preparation Regimes and Diagnostic Performance in Comparison to Colonoscopy|Completed||Phase 4|120||London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:29:50.496677|2018-06-01 04:29:50.496677
NCT00212420|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-21|2005-09-13|2005-09-21|Estimate|||||||2007-09-21|2007-09-24|Estimate|December 2004||2004-12-31|September 2007|2007-09-30||||||||Interventional|||Nutritional Management of Acute and Chronic Enterocutaneous Fistulae|Nutritional Management of Acute and Chronic Enterocutaneous Fistulae|Unknown status|Recruiting|N/A|150|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:29:50.576932|2018-06-01 04:29:50.576932
NCT00212407|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-24|2005-09-13|2005-09-21|Estimate|||||||2016-03-24|2016-03-25|Estimate|February 1993||1993-02-28|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||New York Blood Center National Cord Blood Program|New York Blood Center National Cord Blood Program|Recruiting||Early Phase 1|5000|Anticipated|New York Blood Center||1|||f||||f||||||||||2018-06-01 04:29:50.648867|2018-06-01 04:29:50.648867
NCT00212394|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-10|2005-09-12|2005-09-21|Estimate|||||||2017-03-10|2017-03-13|Actual|January 2005|Actual|2005-01-31|March 2017|2017-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||Tourniquet Complications in Orthopaedic Surgery|A Prospective, Epidemiological Study of the Incidence and Nature of Tourniquet Complications in Norway|Completed|||10||Norwegian University of Science and Technology|||||f||||||||||||||2018-06-01 04:29:50.736555|2018-06-01 04:29:50.736555
NCT00212381|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-27|2005-09-13|2005-09-21|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2000||2000-09-30|March 2017|2017-03-31|July 2010|Actual|2010-07-31|January 2006|Actual|2006-01-31||Interventional|||Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia|Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN)|Completed||Phase 3|62|Anticipated|New York Presbyterian Hospital||2|||f||||f|f|f||||||||2018-06-01 04:29:50.801548|2018-06-01 04:29:50.801548
NCT00212368|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-09-09|2005-09-13|2005-09-21|Estimate|||||||2010-09-09|2010-09-10|Estimate|October 2004||2004-10-31|September 2010|2010-09-30|December 2005|Actual|2005-12-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.|Phase3,Open-label,Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.|Completed||Phase 3|||Nobelpharma|||||f||||||||||||||2018-06-01 04:29:50.889006|2018-06-01 04:29:50.889006
NCT00212355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-04-09||2014-04-10|2005-09-13|2005-09-21|Estimate|2014-04-10|2014-05-14|Estimate||||2014-04-10|2014-05-14|Estimate|March 2005||2005-03-31|April 2014|2014-04-30|January 2009|Actual|2009-01-31|April 2008|Actual|2008-04-30||Interventional||Analysis was performed subjects comprised 37 patients who were found to have Wilson disease through clnical and biochemical tests.|Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.|Phase3, Open-Label, Clinical Trial of Zinc Acetate for Treatment of Wilson's Disease in Japan.|Completed||Phase 3|37|Actual|Nobelpharma||1|||f||||f||||||||||2018-06-01 04:29:50.955296|2018-06-01 04:29:50.955296
NCT00212342|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-09-06|2005-09-13|2005-09-21|Estimate|||||||2010-09-06|2010-09-08|Estimate|December 2004||2004-12-31|September 2010|2010-09-30|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea|Phase 3,Placebo Controlled,Randomized,Double-Blinded,NSAID-Add-on,Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis.|Completed||Phase 3|100|Actual|Nobelpharma||2|||f||||||||||||||2018-06-01 04:29:51.154557|2018-06-01 04:29:51.154557
NCT00212329|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-12|2005-09-13|2005-09-21|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|September 2007|Actual|2007-09-30|||||Observational|||T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus|A Comparative Study Between the Cytokine Elispot, Tetramer, Immunoblot, and T Cell Proliferation Assays Using Fresh Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus|Completed|||100|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:29:51.226954|2018-06-01 04:29:51.226954
NCT00212316|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2012-08-14|2005-09-20|2005-09-21|Estimate|||||||2012-08-14|2012-08-15|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)|Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's Disease|Completed||Phase 2|60||University of Rochester|||||||||||||||||||2018-06-01 04:29:51.312198|2018-06-01 04:29:51.312198
NCT00212303|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-18|2005-09-13|2005-09-21|Estimate|||||||2013-01-18|2013-01-23|Estimate|May 2004||2004-05-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|SHAPE2||Exercise Training in Type 2 Diabetes and Hypertension|Exercise Training in Type 2 Diabetes and Hypertension|Completed||Phase 4|115|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 04:29:51.398191|2018-06-01 04:29:51.398191
NCT00212290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-02-12|2005-09-20|2005-09-21|Estimate|||||||2010-02-12|2010-02-15|Estimate|November 2002||2002-11-30|February 2010|2010-02-28|December 2006|Actual|2006-12-31|||||Interventional|||Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes||Completed||Phase 4|140|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:29:51.472613|2018-06-01 04:29:51.472613
NCT00212277|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-09-09|2005-09-13|2005-09-21|Estimate|||||||2010-09-09|2010-09-10|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|February 2007|Actual|2007-02-28|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.|Phase3,Open-label,Long-term,NSAID-Add-on,Clinical Trial of Mono-phase Low-dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis.|Completed||Phase 3|||Nobelpharma|||||f||||||||||||||2018-06-01 04:29:51.540416|2018-06-01 04:29:51.540416
NCT00212264|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-10-07||2016-03-21|2005-09-13|2005-09-21|Estimate|2016-03-21|2016-04-11|Estimate||||2016-03-21|2016-04-11|Estimate|August 2003||2003-08-31|March 2016|2016-03-31|August 2011|Actual|2011-08-31|September 2008|Actual|2008-09-30||Interventional|||Conservative Treatment of Postprostatectomy Incontinence|Conservative Treatment of Postprostatectomy Incontinence|Completed||N/A|208|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||f||||||||||2018-06-01 04:29:51.601165|2018-06-01 04:29:51.601165
NCT00212251|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2014-07-14|2005-09-19|2005-09-21|Estimate|||||||2014-07-14|2014-07-15|Estimate|August 2004||2004-08-31|January 2010|2010-01-31|April 2008||2008-04-30|||||Interventional|||Promoting Postpartum Weight Loss in Overweight Women|Promoting Postpartum Weight Loss in Overweight Women|Completed||N/A|450||Duke University||1|||f||||||||||||||2018-06-01 04:29:51.886604|2018-06-01 04:29:51.886604
NCT00212238|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2010-03-17|2005-09-19|2005-09-21|Estimate|||||||2010-03-17|2010-03-18|Estimate|September 2003||2003-09-30|March 2010|2010-03-31|October 2006||2006-10-31|||||Interventional|||Enhanced Internet Behavior Therapy for Treating Obesity|Enhanced Internet Behavior Therapy for Treating Obesity|Completed||N/A|100||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:29:51.948594|2018-06-01 04:29:51.948594
NCT00212225|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-20|||2010-01-12|2005-09-20|2005-09-21|Estimate|||||||2010-01-12|2010-01-13|Estimate|October 1997||1997-10-31|January 2010|2010-01-31|December 2007|Actual|2007-12-31|||||Observational|||Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)|Risk Factors for Gastric Disease in Pediatric H. Pylori|Completed|||755|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:29:52.010624|2018-06-01 04:29:52.010624
NCT00212212|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2012-03-06|2005-09-19|2005-09-21|Estimate|||||||2012-03-06|2012-03-07|Estimate|March 2006||2006-03-31|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Selenium Supplementation of Patients With Cirrhosis|Human Selenium Nutritional Requirement and Biomarkers in Health and Disease|Terminated||N/A|99|Actual|Vanderbilt University||4||Insufficient funds to complete study.|f||||t||||||||||2018-06-01 04:29:52.061621|2018-06-01 04:29:52.061621
NCT00212199|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-17|2005-09-13|2005-09-21|Estimate|||||||2010-03-17|2010-03-18|Estimate|January 2002||2002-01-31|March 2010|2010-03-31|August 2004|Actual|2004-08-31|||||Interventional|||Effectiveness of Brief Counseling for Weight Management|Effectiveness of Brief Counseling for Weight Management|Completed||Phase 4|246||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:29:52.126146|2018-06-01 04:29:52.126146
NCT00212186|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2012-03-06|2005-09-19|2005-09-21|Estimate|||||||2012-03-06|2012-03-07|Estimate|October 1998||1998-10-31|March 2012|2012-03-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Selenium Supplementation of Patients With Cirrhosis||Completed||N/A|48|Actual|Vanderbilt University|||||f||||||||||||||2018-06-01 04:29:52.273153|2018-06-01 04:29:52.273153
NCT00212173|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-16|2005-09-13|2005-09-21|Estimate|||||||2015-04-16|2015-04-17|Estimate||||April 2015|2015-04-30|August 2007|Actual|2007-08-31|||||Interventional|||Adolescent Weight Management Study|Behavioral & Pharmacologic Therapy of Adolescent Obesity|Completed||N/A|120||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 04:29:52.342052|2018-06-01 04:29:52.342052
NCT00212160|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-30|2005-09-13|2005-09-21|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2005|Actual|2005-01-31|January 2017|2017-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Role of the Omentum in the Treatment of Morbid Obesity|The Role of the Omentum in the Treatment of Morbid Obesity|Completed||N/A|66|Actual|Vanderbilt University Medical Center||4|||f||||t||||||||||2018-06-01 04:29:52.410184|2018-06-01 04:29:52.410184
NCT00212147|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-11-06|2005-09-13|2005-09-21|Estimate|||||||2012-11-06|2012-11-07|Estimate|September 2003||2003-09-30|November 2012|2012-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Interaction of Cobalamin Status With Nitrous Oxide in Relation to Postoperative Cognitive Changes in the Elderly|Subtle Disturbances of Cobalamin Status|Completed||N/A|444|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-06-01 04:29:52.484241|2018-06-01 04:29:52.484241
NCT00212134|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-07-15||2018-02-08|2005-09-13|2005-09-21|Estimate|2014-12-18|2015-01-05|Estimate||||2018-02-08|2018-03-09|Actual|December 2004||2004-12-31|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|March 21, 2019|Anticipated|2019-03-21||Interventional|IATS||Infant Aphakia Treatment Study (IATS)|Infant Aphakia Treatment Study (IATS)|Active, not recruiting||N/A|114|Actual|Stanford University||2|||f||||t||||||||No||2018-06-01 04:29:52.588774|2018-06-01 04:29:52.588774
NCT00212121|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-25|2005-09-13|2005-09-21|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2004||2004-07-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Radiation Dose Intensity Study in Breast Cancer in Young Women|Radiation Dose Intensity Study in Breast Cancer in Young Women: a Randomized Phase III Trial of Additional Dose to the Tumor Bed|Active, not recruiting||Phase 3|2400|Anticipated|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-06-01 04:29:53.33239|2018-06-01 04:29:53.33239
NCT00212108|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-29|2005-09-13|2005-09-21|Estimate|||||||2012-03-29|2012-04-02|Estimate|November 2003||2003-11-30|March 2012|2012-03-31|January 2009|Actual|2009-01-31|March 2007|Actual|2007-03-31||Interventional|||A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839|A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839|Completed||Phase 1/Phase 2|22|Actual|National University Hospital, Singapore||1|||f||||||||||||||2018-06-01 04:29:53.421868|2018-06-01 04:29:53.421868
NCT00212095|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-31|2005-09-13|2005-09-21|Estimate|||||||2012-10-31|2012-11-01|Estimate|June 2005||2005-06-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|April 2007|Actual|2007-04-30||Interventional|||Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer|Phase II Study of Docetaxel Combined With Ketoconazole in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor|Completed||Phase 2|30|Actual|National University Hospital, Singapore||1|||f||||t||||||||||2018-06-01 04:29:53.491433|2018-06-01 04:29:53.491433
NCT00212082|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-06-11|2005-09-13|2005-09-21|Estimate|||||||2008-06-11|2008-06-12|Estimate|April 2002||2002-04-30|June 2008|2008-06-30||||||||Interventional|||Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer|Gene Expression Profiles of Breast Cancer Treated With Sequential Adriamycin and Docetaxel in Relation to Tumor Responses|Completed||Phase 2|100||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:29:53.556392|2018-06-01 04:29:53.556392
NCT00212069|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-10|2005-09-13|2005-09-21|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2004||2004-03-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer|Serum Protein Profiling as a Predictor of Gemcitabine Sensitivity in Breast Cancer With Prior Exposure to Anthracyclines and Taxanes|Completed||Phase 2|30|Anticipated|National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:29:53.609382|2018-06-01 04:29:53.609382
NCT00212056|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-31|2005-09-13|2005-09-21|Estimate|||||||2007-10-31|2007-11-01|Estimate|October 2001||2001-10-31|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP|Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP|Completed||N/A|600|Anticipated|National Cerebral and Cardiovascular Center||2|||f||||||||||||||2018-06-01 04:29:53.663951|2018-06-01 04:29:53.663951
NCT00212043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-10-07|2005-09-13|2005-09-21|Estimate|||||||2009-10-07|2009-10-08|Estimate|July 2000||2000-07-31|May 2008|2008-05-31|February 2004||2004-02-29|||||Interventional|||Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma|Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma|Completed||Phase 2|74||National University Hospital, Singapore|||||f||||||||||||||2018-06-01 04:29:53.738585|2018-06-01 04:29:53.738585
NCT00212030|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-31|2005-09-13|2005-09-21|Estimate|||||||2007-10-31|2007-11-01|Estimate|October 2001||2001-10-31|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP|Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP|Completed||N/A|600|Anticipated|National Cerebral and Cardiovascular Center||2|||f||||||||||||||2018-06-01 04:29:53.794628|2018-06-01 04:29:53.794628
NCT00212017|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-07|2005-09-13|2005-09-21|Estimate|||||||2007-11-07|2007-11-08|Estimate|April 2005||2005-04-30|November 2007|2007-11-30|April 2009|Anticipated|2009-04-30|||||Interventional|||Assessment of an Alpha-Glucosidase Inhibitor to Block Cardiac Events in Patients With Myocardial Infarction and IGT (ABC Study)|The Japan Working Group for the Assessment That the Alpha-Glucosidase Inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT|Unknown status|Recruiting|N/A|3000|Anticipated|National Cerebral and Cardiovascular Center|||||f||||||||||||||2018-06-01 04:29:53.864753|2018-06-01 04:29:53.864753
NCT00212004|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-22|2005-09-13|2005-09-21|Estimate|||||||2018-05-22|2018-05-23|Actual|April 2005|Actual|2005-04-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2017|Actual|2017-04-30||Interventional|||Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)|The Japan Working Group for the Assessment That the Pioglitazone Protects DM Patients Against Re-Infarction|Terminated||Phase 4|630|Actual|National Cerebral and Cardiovascular Center||2||Limited budget to continue this study|f||||t|f|f|||f|||||2018-06-01 04:29:54.034595|2018-06-01 04:29:54.034595
NCT00211991|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-10|2005-09-13|2005-09-21|Estimate|||||||2012-05-10|2012-05-14|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Evaluation of Consistency of StaphVAX Manufacturing Lots|A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Compare Immunogenicity and Safety Between Three Commercial Lots of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Normal, Healthy, Adult Volunteers|Completed||Phase 3|354||Nabi Biopharmaceuticals|||||f||||||||||||||2018-06-01 04:29:54.237188|2018-06-01 04:29:54.237188
NCT00211978|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-26|2005-09-16|2005-09-21|Estimate|||||||2007-12-26|2008-01-08|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|June 2006|Actual|2006-06-30||Interventional|||EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)|EPIC (Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease): A Prospective, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel Arm, Study of PhosLo on Phosphorus Levels in Subjects With Chronic Kidney Disease|Completed||Phase 3|110|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-06-01 04:29:54.285136|2018-06-01 04:29:54.285136
NCT00211965|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-26|2005-09-13|2005-09-21|Estimate|||||||2007-12-26|2008-01-04|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|August 2006|Actual|2006-08-31|May 2006|Actual|2006-05-31||Interventional|||StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adult Patients Receiving an Orthopedic Prosthetic Implant|Completed||Phase 3|67|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-06-01 04:29:54.357421|2018-06-01 04:29:54.357421
NCT00211952|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|March 2004||2004-03-31|September 2005|2005-09-30||||||||Interventional|||Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients|A Randomized, Double Blind, Placebo Controlled Phase III Trial Evaluating the Role of Adjuvant Celecoxib in Completely Resected, High-Risk (pN1-2) Non-Small Cell Lung Cancer (NSCLC) Patients|Suspended||Phase 3|542||Medical University of Gdansk|||||f||||||||||||||2018-06-01 04:29:54.412605|2018-06-01 04:29:54.412605
NCT00211939|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-26|2005-09-13|2005-09-21|Estimate|||||||2007-12-26|2008-01-08|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients|CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2)|Completed||Phase 4|203|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-06-01 04:29:54.490501|2018-06-01 04:29:54.490501
NCT00211926|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-21|2005-09-13|2005-09-21|Estimate|||||||2007-12-21|2008-01-04|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|June 2006|Actual|2006-06-30||Interventional|||StaphVAX Immunogenicity in Orthopedic Implant Patients|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Receiving an Orthopaedic Prosthetic Implant|Completed||Phase 3|120|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-06-01 04:29:54.568767|2018-06-01 04:29:54.568767
NCT00211913|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-26|2005-09-13|2005-09-21|Estimate|||||||2007-12-26|2008-01-04|Estimate|June 2004||2004-06-30|December 2007|2007-12-31|January 2006|Actual|2006-01-31|October 2005|Actual|2005-10-31||Interventional|||StaphVAX in Cardiovascular Surgery Patients|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Undergoing Cardiovascular Surgery|Completed||Phase 3|120|Actual|Nabi Biopharmaceuticals||2|||f||||f||||||||||2018-06-01 04:29:54.622417|2018-06-01 04:29:54.622417
NCT00211900|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-26|2005-09-13|2005-09-21|Estimate|||||||2007-12-26|2008-01-04|Estimate|March 2005||2005-03-31|December 2007|2007-12-31|November 2005|Actual|2005-11-30|August 2005|Actual|2005-08-31||Interventional|||Evaluation of Manufacturing Lot of StaphVAX|A Phase 3, Multicenter, Open-Label, Historical Comparative Study to Evaluate Immunogenicity and Safety of a Commercial Lot of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis|Completed||Phase 3|65|Actual|Nabi Biopharmaceuticals||1|||f||||f||||||||||2018-06-01 04:29:54.763638|2018-06-01 04:29:54.763638
NCT00211887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-06-25||2014-03-06|2005-09-13|2005-09-21|Estimate|2014-03-06|2014-04-03|Estimate||||2014-03-06|2014-04-03|Estimate|January 2005||2005-01-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|April 2012|Actual|2012-04-30||Interventional|||Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx|A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)|Completed||Phase 3|1008|Actual|Icahn School of Medicine at Mount Sinai|absence of a comparative randomized placebo only group|3|||f||||t||||||||||2018-06-01 04:29:54.873462|2018-06-01 04:29:54.873462
NCT00211874|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-10-09|2005-09-14|2005-09-21|Estimate|||||||2015-10-09|2015-10-12|Estimate|September 2000||2000-09-30|October 2015|2015-10-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Improving Heart Failure Care in Minority Communities|Improving Heart Failure Care in Minority Communities|Completed||N/A|406|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 04:29:55.473683|2018-06-01 04:29:55.473683
NCT00211848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-26|2005-09-13|2005-09-21|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2000||2000-06-30|April 2007|2007-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers|Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers|Completed||Phase 2|207|Anticipated|Icahn School of Medicine at Mount Sinai|||||||||||||||||||2018-06-01 04:29:55.56268|2018-06-01 04:29:55.56268
NCT00211835|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-09-20|2005-09-13|2005-09-21|Estimate|||||||2013-09-20|2013-09-24|Estimate|November 2005||2005-11-30|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Post-TBI Depression|Treatment of Post-TBI Depression - A Randomized Clinical Trial|Completed||N/A|75|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 04:29:55.629387|2018-06-01 04:29:55.629387
NCT00211822|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-13|2005-09-13|2005-09-21|Estimate|||||||2011-07-13|2011-07-14|Estimate|November 2004||2004-11-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD)|fMRI Studies in Pathological Gambling and Obsessive-Compulsive Disorder|Terminated|||57|Actual|Icahn School of Medicine at Mount Sinai|||3|Enrollments closed after former PI Eric Hollander left institution. There are no results.|f||||f||||||||||2018-06-01 04:29:55.709617|2018-06-01 04:29:55.709617
NCT00211809|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-01-18||2017-01-18|2005-09-13|2005-09-21|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|September 2008||2008-09-30|January 2017|2017-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||CBT as an Adjunct to SRIs in the Treatment of BDD|A Controlled Trial of Cognitive-Behavioral Therapy as an Adjunct to Serotonin Reuptake Inhibitors in Body Dysmorphic Disorder|Terminated||Phase 4|17|Actual|Icahn School of Medicine at Mount Sinai|The primary limitations of this study are the small sample size, the open-label design, and the primarily female sample.|1||low enrollment|f||||f||||||||||2018-06-01 04:29:55.807104|2018-06-01 04:29:55.807104
NCT00211796|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-29|2005-09-13|2005-09-21|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 2005||2005-04-30|May 2018|2018-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Divalproex Sodium ER in Adult Autism|Divalproex Sodium ER in Adult Autism|Completed||Phase 4|10|Anticipated|Montefiore Medical Center|||||||||||||||||||2018-06-01 04:29:56.099061|2018-06-01 04:29:56.099061
NCT00211783|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-26|2005-09-13|2005-09-21|Estimate|||||||2012-06-26|2012-06-28|Estimate|November 2004||2004-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Observational|||Functional Magnetic Resonance Imaging (fMRI) for the Study of Response Inhibition, and Face and Linguistic Processing in Autism|fMRI for the Study of Response Inhibition, and Face and Linguistic Processing in Autism|Completed|||71|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||||||2018-06-01 04:29:56.210805|2018-06-01 04:29:56.210805
NCT00211770|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-11|2005-09-13|2005-09-21|Estimate|||||||2013-06-11|2013-06-12|Estimate|February 2005||2005-02-28|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2005|Actual|2005-12-31||Observational|||Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.|Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism.|Completed|||144|Actual|Icahn School of Medicine at Mount Sinai|||||f||||f||||||||||2018-06-01 04:29:56.281585|2018-06-01 04:29:56.281585
NCT00211757|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-15|2005-09-13|2005-09-21|Estimate|||||||2011-04-15|2011-04-19|Estimate|September 2002||2002-09-30|April 2011|2011-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism|Divalproex Sodium vs. Placebo in Childhood/Adolescent Autism|Completed||Phase 2|55|Anticipated|Montefiore Medical Center||2|||f||||||||||||||2018-06-01 04:29:56.352181|2018-06-01 04:29:56.352181
NCT00211744|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-25|2005-09-13|2005-09-21|Estimate|||||||2018-05-25|2018-05-30|Actual|August 2004||2004-08-31|May 2018|2018-05-31|August 2006|Actual|2006-08-31|||||Interventional|||Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder|Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder|Completed||Phase 4|24|Anticipated|Montefiore Medical Center|||||||||||||||||||2018-06-01 04:29:56.433293|2018-06-01 04:29:56.433293
NCT00211731|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-11-10|2005-09-13|2005-09-21|Estimate|||||||2014-11-10|2014-11-11|Estimate|September 2002||2002-09-30|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Preventing Recurrent Stroke in Minority Populations|Improving the Delivery of Effective Care to Minorities|Completed||N/A|87|Actual|Icahn School of Medicine at Mount Sinai|||||f||||||||||||||2018-06-01 04:29:56.494269|2018-06-01 04:29:56.494269
NCT00211718|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-11-02|2005-09-14|2005-09-21|Estimate|||||||2005-11-02|2005-11-03|Estimate|July 2004||2004-07-31|August 2005|2005-08-31|June 2007||2007-06-30|||||Interventional|||Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain|Intra-Articular Injection of Botulinum Toxin Type A for the Treatment of Shoulder Pain: A Randomized, Double Blinded, Placebo Controlled Trial|Unknown status|Recruiting|Phase 3|40||Minneapolis Veterans Affairs Medical Center|||||||||||||||||||2018-06-01 04:29:56.600804|2018-06-01 04:29:56.600804
NCT00211705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-30|2005-09-13|2005-09-21|Estimate|||||||2006-11-30|2006-12-04|Estimate|February 1994||1994-02-28|June 2005|2005-06-30|March 2004||2004-03-31|||||Interventional|||Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)|Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)|Completed||Phase 4|8000||Mitsukoshi Health and Welfare Foundation|||||f||||||||||||||2018-06-01 04:29:56.688239|2018-06-01 04:29:56.688239
NCT00211497|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|September 2003||2003-09-30|||||Interventional|||Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne|A Phase II, Randomized, Vehicle-Controlled, Double-Blind, Multi-Center Study to Evaluate Safety and Efficacy of MBI 226 1.25% and 2.5% Acne Solutions Applied Topically for 12 Weeks to Subjects With Acne Vulgaris|Completed||Phase 2|255||BioWest Therapeutics Inc|||||||||||||||||||2018-06-01 04:29:59.626022|2018-06-01 04:29:59.626022
NCT00211692|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-08-01||2014-11-20|2005-09-13|2005-09-21|Estimate|2014-11-20|2014-11-21|Estimate||||2014-11-20|2014-11-21|Estimate|July 2005||2005-07-31|November 2014|2014-11-30|September 2009|Actual|2009-09-30|July 2008|Actual|2008-07-31||Interventional|||Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial|Prospective Randomized Pilot Study of Daily Consensus Interferon (CIFN) and Ribavirin for 52 Wks vs Extended Duration 72 Wks Based on Virologic Response for the Initial Treatment of Difficult-to-treat Patients With Chronic HCV Genotype 1|Completed||Phase 3|64|Actual|Minneapolis Veterans Affairs Medical Center||2|||f||||t||||||||||2018-06-01 04:29:56.769037|2018-06-01 04:29:56.769037
NCT00211679|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|June 2004||2004-06-30|July 2005|2005-07-31|June 2007||2007-06-30|||||Interventional|||Intra-articularInjection of Botulinum Toxin Type|Intra-articularInjection of Botulinum Toxin Type a for the Treatment of Chronic Knee Pain: A Randomized, Placebo Controlled, Double Blind Study|Unknown status|Recruiting|Phase 2|40||Minneapolis Veterans Affairs Medical Center|||||||||||||||||||2018-06-01 04:29:57.058518|2018-06-01 04:29:57.058518
NCT00211666|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|September 2002||2002-09-30|September 2005|2005-09-30|August 2006||2006-08-31|||||Interventional|||Improving Hypertension Control in East and Central Harlem|Improving the Delivery of Effective Care to Minorities|Completed||N/A|480||Icahn School of Medicine at Mount Sinai|||||f||||||||||||||2018-06-01 04:29:57.126105|2018-06-01 04:29:57.126105
NCT00211653|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-18|2005-09-13|2005-09-21|Estimate|||||||2007-09-18|2007-09-19|Estimate|April 2003||2003-04-30|September 2007|2007-09-30|November 2006|Actual|2006-11-30|||||Interventional|||Acetylcysteine in the Prevention of Renal Failure After Bypass Surgery|Single Center Randomized Clinical Trial of the Effects of Acetylcysteine in the Prevention of Postoperative Renal Failure|Completed||Phase 1/Phase 2|102|Actual|Minneapolis Veterans Affairs Medical Center|||||f||||f||||||||||2018-06-01 04:29:57.176185|2018-06-01 04:29:57.176185
NCT00211640|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate||||August 2005|2005-08-31||||||||Observational|||Identification and Treatment of Men With BPH in the Primary Care Setting|A Proactive Approach to the Identification and Treatment of Men With BPH Inthe Primary Care Setting|Completed|||1100||Mid Michigan Health Centers|||||f||||||||||||||2018-06-01 04:29:58.194084|2018-06-01 04:29:58.194084
NCT00211627|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|June 2004||2004-06-30|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||Clinical Study to Determine Safety and Effectiveness of KEEPASLEEP Device in Simple Snorers.|Clinical Study to Determine Safety and Effectiveness of KEEPASLEEP Device in Simple Snorers.|Unknown status|Recruiting|Phase 1|30||Miller, Chipp St. Kevin, M.D.|||||f||||||||||||||2018-06-01 04:29:58.24338|2018-06-01 04:29:58.24338
NCT00211614|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-20|2005-09-13|2005-09-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|July 2006||2006-07-31|February 2007|2007-02-28|July 2007||2007-07-31|||||Interventional|||Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea|Proton Pump Inhibitor Therapy for Mild to Moderate Obstructive Sleep Apnea|Terminated||N/A|50||MetroHealth Medical Center|||||f||||||||||||||2018-06-01 04:29:58.303207|2018-06-01 04:29:58.303207
NCT00211601|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-30|2005-09-13|2005-09-21|Estimate|||||||2015-04-30|2015-05-01|Estimate|August 2004||2004-08-31|April 2015|2015-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|C-PHONE||Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)|Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis|Completed||N/A|1500||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:29:58.379653|2018-06-01 04:29:58.379653
NCT00211588|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-04|2005-09-13|2005-09-21|Estimate|||||||2007-05-04|2007-05-07|Estimate|June 2004||2004-06-30|May 2007|2007-05-31|May 2007|Anticipated|2007-05-31|||||Interventional|||Galantamine Executive Function in Parkinson's Disease|Investigator Initiated Study: Galantamine CR Potential Enhancement of Attentional and Executive Function in Non-Demented Patients With Parkinson's Disease|Unknown status|Active, not recruiting|N/A|90|Anticipated|Memorial Hospital of Rhode Island|||||f||||t||||||||||2018-06-01 04:29:58.434851|2018-06-01 04:29:58.434851
NCT00211575|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-01-02|2005-09-13|2005-09-21|Estimate|||||||2015-01-02|2015-01-05|Estimate|May 2003||2003-05-31|January 2015|2015-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Instrument Utility for Suspected Asthma (0000-042)(COMPLETED)|Clinical Utility of an Instrument in the Evaluation of Young Children With Suspected Asthma|Completed||N/A|400|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:29:58.492195|2018-06-01 04:29:58.492195
NCT00211562|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-23|2005-09-13|2005-09-21|Estimate|||||||2012-10-23|2012-10-24|Estimate|October 2005||2005-10-31|October 2012|2012-10-31||||January 2006|Actual|2006-01-31||Interventional|||Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids|Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids|Terminated||Phase 3|20|Actual|Augusta University||3|||f||||||||||||||2018-06-01 04:29:58.544704|2018-06-01 04:29:58.544704
NCT00211549|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-19|2005-09-13|2005-09-21|Estimate|||||||2009-03-19|2009-03-20|Estimate|June 2005||2005-06-30|March 2009|2009-03-31||||||||Interventional|||An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Doses of IDEA-033 in Comparison to Oral Naproxen for the Treatment of the Signs and Symptoms of Osteoarthritis of the Knee|Completed||Phase 2|875||IDEA AG|||||||||||||||||||2018-06-01 04:29:58.64552|2018-06-01 04:29:58.64552
NCT00211536|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-04-25||2011-09-19|2005-09-13|2005-09-21|Estimate|2011-05-24|2011-06-23|Estimate||||2011-09-19|2011-09-21|Estimate|June 2002||2002-06-30|August 2011|2011-08-31|September 2008|Actual|2008-09-30|August 2004|Actual|2004-08-31||Interventional|MIP310||Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration|A Randomized, Active Control, Multi-Center Study Comparing the Effect of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration on Glycemic Control and the Frequency of Severe Hypoglycemia|Completed||Phase 3|107|Actual|Medtronic Diabetes||2|||f||||f||||||||||2018-06-01 04:29:58.975282|2018-06-01 04:29:58.975282
NCT00211523|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|October 2000||2000-10-31|September 2005|2005-09-30|September 2001||2001-09-30|||||Interventional|||Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne|Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of MBI 226 2.5% and 5.0% Acne Solutions Applied Topically for 6 Weeks to Subjects With Acne Vulgaris|Completed||Phase 2|75||BioWest Therapeutics Inc|||||||||||||||||||2018-06-01 04:29:59.296004|2018-06-01 04:29:59.296004
NCT00211510|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-04-01||2017-05-10|2005-09-13|2005-09-21|Estimate|2011-04-04|2011-04-29|Estimate||||2017-05-10|2017-06-12|Actual|June 2005||2005-06-30|May 2017|2017-05-31|February 2007|Actual|2007-02-28|August 2006|Actual|2006-08-31||Interventional|STAR1||Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes|Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes: A Multi-center, Randomized Controlled Trial|Completed||N/A|146|Actual|Medtronic Diabetes||2|||f||||f|f|t|f|f||||No||2018-06-01 04:29:59.362812|2018-06-01 04:29:59.362812
NCT00211484|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-04|2005-09-20|2005-09-21|Estimate|||||||2007-05-04|2007-05-07|Estimate|May 2003||2003-05-31|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.||Completed||Phase 2|5|Actual|Manhattan Eye, Ear & Throat Hospital|||||t||||f||||||||||2018-06-01 04:29:59.677266|2018-06-01 04:29:59.677266
NCT00211471|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-04|2005-09-13|2005-09-21|Estimate|||||||2007-05-04|2007-05-07|Estimate|March 2002||2002-03-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).|Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension (15mg.).|Terminated||Phase 2|0|Actual|Manhattan Eye, Ear & Throat Hospital||||poor enrollment|t||||f||||||||||2018-06-01 04:29:59.813998|2018-06-01 04:29:59.813998
NCT00211458|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-24|2005-09-13|2005-09-21|Estimate|||||||2012-10-24|2012-10-25|Estimate|September 2005||2005-09-30|October 2012|2012-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Treatment of Age-Related Macular Degeneration With Anecortave Acetate|Treatment of Age-Related Macular Degeneration With Open-label Anecortave Acetate Sterile Suspension (15mg) Following Failed Treatment With Photodynamic Therapy With Visudyne|Completed||Phase 2|||Manhattan Eye, Ear & Throat Hospital|||||f||||f||||||||||2018-06-01 04:29:59.885181|2018-06-01 04:29:59.885181
NCT00211445|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-27|2005-09-13|2005-09-21|Estimate|||||||2007-09-27|2007-09-28|Estimate|July 2002||2002-07-31|September 2007|2007-09-30|January 2006|Actual|2006-01-31|||||Interventional|||Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)||Completed||Phase 2|11|Actual|Manhattan Eye, Ear & Throat Hospital|||||f||||f||||||||||2018-06-01 04:29:59.955901|2018-06-01 04:29:59.955901
NCT00211432|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-24|2005-09-13|2005-09-21|Estimate|||||||2012-10-24|2012-10-25|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)||Completed||Phase 2|4|Actual|Manhattan Eye, Ear & Throat Hospital||1|||f||||f||||||||||2018-06-01 04:30:00.0498|2018-06-01 04:30:00.0498
NCT00211419|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-23|2005-09-13|2005-09-21|Estimate|||||||2012-10-23|2012-10-24|Estimate||||September 2005|2005-09-30||||||||Interventional|||Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)|Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)|Completed||Phase 1|||Manhattan Eye, Ear & Throat Hospital|||||||||||||||||||2018-06-01 04:30:00.140903|2018-06-01 04:30:00.140903
NCT00211406|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-06|2005-09-13|2005-09-21|Estimate|||||||2007-05-06|2007-05-08|Estimate||||May 2007|2007-05-31||||||||Interventional|||Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)||Terminated||Phase 1|||Manhattan Eye, Ear & Throat Hospital|||||f||||f||||||||||2018-06-01 04:30:00.207318|2018-06-01 04:30:00.207318
NCT00211393|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-24|2005-09-13|2005-09-21|Estimate|||||||2012-10-24|2012-10-25|Estimate|May 2005||2005-05-31|October 2012|2012-10-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|CSC/Keto||A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole|A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole.|Completed||Phase 2|5|Actual|Manhattan Eye, Ear & Throat Hospital||1|||f||||f||||||||||2018-06-01 04:30:00.260067|2018-06-01 04:30:00.260067
NCT00211380|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-09-02|2005-09-13|2005-09-21|Estimate|||||||2011-09-02|2011-09-07|Estimate|August 2003||2003-08-31|September 2011|2011-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)|Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia, (SFBRI).|Terminated||N/A|8|Actual|Louisiana State University Health Sciences Center Shreveport||||Recruitment was too difficult|f||||f||||||||||2018-06-01 04:30:00.327557|2018-06-01 04:30:00.327557
NCT00211367|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-20|2005-09-13|2005-09-21|Estimate|||||||2007-06-20|2007-06-21|Estimate|April 2004||2004-04-30|June 2007|2007-06-30|March 2007|Actual|2007-03-31|||||Interventional|||Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)||Terminated||Phase 2|2|Actual|Manhattan Eye, Ear & Throat Hospital||||poor enrollment|t||||f||||||||||2018-06-01 04:30:00.394646|2018-06-01 04:30:00.394646
NCT00211354|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-03|2005-09-13|2005-09-21|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2002||2002-03-31|February 2009|2009-02-28|April 2007|Anticipated|2007-04-30|March 2007|Anticipated|2007-03-31||Interventional|||Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)||Withdrawn||Phase 2|0|Actual|Manhattan Eye, Ear & Throat Hospital||1||No subjects enrolled|t||||f||||||||||2018-06-01 04:30:00.458233|2018-06-01 04:30:00.458233
NCT00211341|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-17|2005-09-13|2005-09-21|Estimate|||||||2010-02-17|2010-02-18|Estimate|December 2000||2000-12-31|February 2010|2010-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|ObaapaVitA||Trial of the Impact of Vitamin A on Maternal Mortality|Randomised Double-blind Placebo-controlled Trial to Evaluate the Impact of Vitamin A on Maternal Mortality in Ghana|Completed||Phase 3|100000|Anticipated|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:30:00.534018|2018-06-01 04:30:00.534018
NCT00211328|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-03|2005-09-13|2005-09-21|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2002||2002-03-31|February 2009|2009-02-28|March 2007|Actual|2007-03-31|||||Interventional|||Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).||Completed||Phase 2|5|Actual|Manhattan Eye, Ear & Throat Hospital|||||t||||f||||||||||2018-06-01 04:30:00.627701|2018-06-01 04:30:00.627701
NCT00211315|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-23|2005-09-13|2005-09-21|Estimate|||||||2012-10-23|2012-10-24|Estimate|March 2002||2002-03-31|October 2012|2012-10-31|March 2007||2007-03-31|||||Interventional|||Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)||Completed||Phase 2|4|Actual|Manhattan Eye, Ear & Throat Hospital|||||f||||f||||||||||2018-06-01 04:30:00.701542|2018-06-01 04:30:00.701542
NCT00211302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-09-02|2005-09-13|2005-09-21|Estimate|||||||2011-09-02|2011-09-07|Estimate|August 2003||2003-08-31|September 2011|2011-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)|Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia. (BMS)|Terminated||N/A|8|Actual|Louisiana State University Health Sciences Center Shreveport||||Enrollment too difficult|f||||f||||||||||2018-06-01 04:30:00.777246|2018-06-01 04:30:00.777246
NCT00211289|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-14|2005-09-13|2005-09-21|Estimate|||||||2007-11-14|2007-11-15|Estimate|July 2002||2002-07-31|June 2005|2005-06-30|December 2007||2007-12-31|||||Interventional|||Trial of Education and Compliance in Heart Dysfunction (TEACH)|Trial of Education and Compliance in Heart Dysfunction. A Study Measuring the Impact of Multi-Disciplinary Education as an Intervention to Increase Patient Concordance and the Cost Effectiveness of Treatment in Patients With Heart Dysfunction|Unknown status|Recruiting|Phase 3|383|Anticipated|London Health Sciences Centre|||||f||||||||||||||2018-06-01 04:30:00.868843|2018-06-01 04:30:00.868843
NCT00211276|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-13|2005-09-20|2005-09-21|Estimate|||||||2012-03-13|2012-03-14|Estimate|March 2005||2005-03-31|March 2011|2011-03-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma|A Phase II Multicenter Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non-Hodgkins Lymphoma.|Completed||Phase 2|50|Anticipated|Eisai Inc.|||||f||||||||||||||2018-06-01 04:30:00.95396|2018-06-01 04:30:00.95396
NCT00211263|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-07|2005-09-13|2005-09-21|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2003||2003-11-30|June 2005|2005-06-30|February 2007||2007-02-28|||||Interventional|||Bipolar Disorder Research Study for Ages 12 and Older|Bipolar Disorder Center for Pennsylvanians (BDCP) Research Study|Completed||N/A|750||Kupfer, David J., M.D.||2|||||||||||||||||2018-06-01 04:30:01.02344|2018-06-01 04:30:01.02344
NCT00211250|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-27|2005-09-13|2005-09-21|Estimate|||||||2009-01-27|2009-01-28|Estimate|July 2005||2005-07-31|January 2009|2009-01-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER|An Exploratory Study Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar I and II Patients From Valproic Acid to Depakote ER|Completed||Phase 4|20|Anticipated|Joliet Center for Clinical Research|||||f||||t||||||||||2018-06-01 04:30:01.191485|2018-06-01 04:30:01.191485
NCT00211237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-03-31|2010-02-19|2017-12-06|2005-09-13|2005-09-21|Estimate|2010-04-27|2010-05-14|Estimate|2010-03-22|2010-03-24|Estimate|2017-12-06|2017-12-08|Actual|May 2005||2005-05-31|June 2017|2017-06-30|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|CAFE||CAFE Study - Cancer Patient Fracture Evaluation|A Multicenter, Prospective, Randomized, Controlled Study to Compare Balloon Kyphoplasty to Non-surgical Fracture Management in the Treatment of Painful, Acute Vertebral Body Compression Fractures in Cancer Patients|Completed||N/A|134|Actual|Medtronic Spinal and Biologics||2|||f||||t||||||||||2018-06-01 04:30:01.510176|2018-06-01 04:30:01.510176
NCT00211224|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-14|2005-09-13|2005-09-21|Estimate|||||||2005-12-14|2005-12-15|Estimate|April 2000||2000-04-30|September 2005|2005-09-30|November 2004||2004-11-30|||||Interventional|||Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)|Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)|Terminated||Phase 3|800||King's College London|||||f||||||||||||||2018-06-01 04:30:04.149991|2018-06-01 04:30:04.149991
NCT00211211|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-12-06|2005-09-13|2005-09-21|Estimate|||||||2017-12-06|2017-12-08|Actual|February 2003||2003-02-28|January 2012|2012-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||FREE Study - Fracture Reduction Evaluation|An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures|Completed||Phase 4|300||Medtronic Spinal and Biologics|||||f||||||||||||||2018-06-01 04:30:04.214703|2018-06-01 04:30:04.214703
NCT00211198|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-29|2005-09-13|2005-09-21|Estimate|||||||2008-02-29|2008-03-05|Estimate|May 2001||2001-05-31|February 2008|2008-02-29|January 2006|Actual|2006-01-31|January 2005|Actual|2005-01-31||Interventional|||Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)|Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status|Completed||Phase 4|60||Eisai Inc.|||||f||||t||||||||||2018-06-01 04:30:04.314009|2018-06-01 04:30:04.314009
NCT00211185|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-08-27|2005-09-20|2005-09-21|Estimate|||||||2009-08-27|2009-08-28|Estimate|March 2004||2004-03-31|March 2008|2008-03-31||||August 2008|Anticipated|2008-08-31||Interventional|||A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma|A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma.|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Eisai Inc.||1|||f||||t||||||||||2018-06-01 04:30:04.560025|2018-06-01 04:30:04.560025
NCT00211172|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-08-05||2014-10-07|2005-09-13|2005-09-21|Estimate|2014-10-07|2014-10-09|Estimate||||2014-10-07|2014-10-09|Estimate|October 2003||2003-10-31|July 2011|2011-07-31|May 2009|Actual|2009-05-31|December 2005|Actual|2005-12-31||Interventional|||HMO Research Network CERT: Acute Myocardial Infarction|The HMO Research Network CERT: Acute Myocardial Infarction|Completed||N/A|836|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 04:30:04.756085|2018-06-01 04:30:04.756085
NCT00211159|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-07-27|2005-09-13|2005-09-21|Estimate|||||||2017-07-27|2017-07-31|Actual|December 2000||2000-12-31|April 2005|2005-04-30||||||||Interventional|||OmegAD (Omega-3 and Alzheimer's Disease)|Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial|Completed||N/A|204||Karolinska University Hospital|||||f||||||||||||||2018-06-01 04:30:05.0707|2018-06-01 04:30:05.0707
NCT00211146|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-14|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|April 1998||1998-04-30|April 2010|2010-04-30|May 2006|Actual|2006-05-31|||||Interventional|||A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)|An Open-Label, Randomized, Parallel-Group Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Subjects Undergoing Major Elective Spinal Surgery|Completed||Phase 3|680|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:05.209616|2018-06-01 04:30:05.209616
NCT00211133|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-29|2005-09-13|2005-09-21|Estimate|||||||2010-11-29|2010-11-30|Estimate|June 2000||2000-06-30|November 2010|2010-11-30|December 2006|Actual|2006-12-31|||||Interventional|||A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy|Completed||Phase 3|939|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:30:05.287768|2018-06-01 04:30:05.287768
NCT00211120|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-17|2005-09-13|2005-09-21|Estimate|||||||2011-05-17|2011-05-18|Estimate|March 2002||2002-03-31|March 2010|2010-03-31|August 2005|Actual|2005-08-31|||||Interventional|||Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)|Correction of Hemoglobin and Outcomes In Renal Insufficiency|Terminated||Phase 4|1432|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"Stopped by the DSMB due to a trend toward more adverse events in the higher hemoglobin (Hb) arm~   and <5% chance that the study would show benefit for higher Hb."|f||||t||||||||||2018-06-01 04:30:05.382817|2018-06-01 04:30:05.382817
NCT00211107|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-05-18|2005-09-15|2005-09-21|Estimate|||||||2011-05-18|2011-05-19|Estimate|June 2003||2003-06-30|March 2010|2010-03-31|June 2004|Actual|2004-06-30|||||Interventional|||A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.|A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation|Completed||Phase 3|1294|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:30:05.462687|2018-06-01 04:30:05.462687
NCT00211094|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-02-10|2005-09-15|2005-09-21|Estimate|||||||2011-02-10|2011-02-11|Estimate||||February 2011|2011-02-28|June 2004|Actual|2004-06-30|||||Interventional|||A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation|A Placebo-Controlled, Double-blind, Randomized, Parallel Study of the Efficacy and Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation|Completed||Phase 3|1320|Actual|Alza Corporation, DE, USA|||||||||||||||||||2018-06-01 04:30:05.546947|2018-06-01 04:30:05.546947
NCT00211081|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-12-08||2017-10-03|2005-09-13|2005-09-21|Estimate|2014-12-08|2014-12-16|Estimate||||2017-10-03|2017-11-06|Actual|November 2004||2004-11-30|October 2017|2017-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Spironolactone in Patients With Single Ventricle Heart|Impact of Spironolactone on Endothelial Function in Patients With Single Ventricle Heart|Completed||N/A|12|Actual|Emory University||1|||f||||f||||||||||2018-06-01 04:30:05.621899|2018-06-01 04:30:05.621899
NCT00211068|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-04-29|2005-09-13|2005-09-21|Estimate|||||||2013-04-29|2013-04-30|Estimate|March 2004||2004-03-31|April 2013|2013-04-30|March 2006|Actual|2006-03-31|||||Observational|||A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa|Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa|Completed|||124|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||f||||t||||||Samples With DNA|"~     Blood sample collected for pharmacogenomic analysis~   "|||2018-06-01 04:30:05.933079|2018-06-01 04:30:05.933079
NCT00211055|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-04-15|2005-09-13|2005-09-21|Estimate|||||||2013-04-15|2013-04-16|Estimate|September 2004||2004-09-30|April 2013|2013-04-30|March 2005|Actual|2005-03-31|||||Observational|||A Study to Observe the Causes and Treatment of Anemia in Critically Ill Children|A Multicenter, Epidemiological, Observational Study of the Management of Anemia in Critically Ill Pediatric Patients|Completed|||1201|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:30:06.070459|2018-06-01 04:30:06.070459
NCT00211042|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-04-29|2005-09-13|2005-09-21|Estimate|||||||2013-04-29|2013-04-30|Estimate|February 2004||2004-02-29|April 2013|2013-04-30|December 2006|Actual|2006-12-31|||||Observational|||A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment|Observational, Multicenter Study of Subjects With Pure Red Cell Aplasia Associated With r-HuEPO Treatment|Completed|||52|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||f||||t||||||||||2018-06-01 04:30:06.126198|2018-06-01 04:30:06.126198
NCT00211029|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-07-30|2005-09-13|2005-09-21|Estimate|||||||2015-07-30|2015-07-31|Estimate|January 2003||2003-01-31|July 2015|2015-07-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Observational|||A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins|An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa Therapy or Other Recombinant Erythropoietins|Completed|||4670|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||f||||f||||||||||2018-06-01 04:30:06.347037|2018-06-01 04:30:06.347037
NCT00211016|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|August 2004||2004-08-31|March 2010|2010-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Doripenem in the Treatment of Ventilator-Associated Pneumonia|A Multicenter, Randomized, Open-Label, Phase 3 Study of Doripenem Versus a Comparator Antibiotic in the Treatment of Ventilator-Associated Pneumonia|Completed||Phase 3|318|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:06.417763|2018-06-01 04:30:06.417763
NCT00211003|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|October 2006|Actual|2006-10-31|||||Interventional|||Doripenem in the Treatment of Hospital-Acquired Pneumonia|A Multicenter, Randomized, Open-Label, Phase 3 Study to Compare the Safety and Effectiveness of Doripenem Versus a Comparator Antibiotic in Hospital-Acquired Pneumonia|Completed||Phase 3|240|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:06.509645|2018-06-01 04:30:06.509645
NCT00210990|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|April 2006|Actual|2006-04-30|||||Interventional|||Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis|A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis|Completed||Phase 3|403|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:06.573582|2018-06-01 04:30:06.573582
NCT00210977|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-29|2005-09-13|2005-09-21|Estimate|||||||2013-08-29|2013-09-02|Estimate|December 2005||2005-12-31|August 2013|2013-08-31|January 2010|Anticipated|2010-01-31|January 2010|Anticipated|2010-01-31||Observational|||A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies|An Observational Study of Subjects Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies|Withdrawn|||0|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1|The study never started due to zero enrolment|f||||t||||||Samples With DNA|"~     Blood samples will be collected for pharmacogenomic analysis.~   "|||2018-06-01 04:30:06.645231|2018-06-01 04:30:06.645231
NCT00210964|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13||2011-06-02|2012-08-27|2005-09-13|2005-09-21|Estimate||||2011-06-02|2011-06-09|Estimate|2012-08-27|2012-09-03|Estimate|April 2005||2005-04-30|August 2012|2012-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Ceftobiprole in Hospital Acquired Pneumonia|A Phase III Randomized Double-Blind Study Of Ceftobiprole Versus Linezolid Plus Ceftazidime In The Treatment Of Nosocomial Pneumonia|Completed||Phase 3|781|Actual|Basilea Pharmaceutica||2|||f||||t||||||||||2018-06-01 04:30:06.754942|2018-06-01 04:30:06.754942
NCT00210951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-23|2005-09-13|2005-09-21|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2003||2003-05-31|March 2015|2015-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Observational|||Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin|An Active Safety Surveillance Plan to Conduct Serologic Testing for Anti-erythropoietin Antibodies and Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa or Another Erythropoietin|Completed|||4761|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||1||f||||f||||||||||2018-06-01 04:30:06.840256|2018-06-01 04:30:06.840256
NCT00210938|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|January 2006|Actual|2006-01-31|||||Interventional|||Doripenem in the Treatment of Complicated Intra-Abdominal Infections|A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Versus Comparator Antibiotic in the Treatment of Complicated Intra-Abdominal Infections|Completed||Phase 3|478|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:06.986105|2018-06-01 04:30:06.986105
NCT00210925|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-06|2005-09-13|2005-09-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|August 2006|Actual|2006-08-31|||||Interventional|||An Efficacy and Safety Study of Topiramate in the Treatment of Alcohol Dependence|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence|Completed||Phase 2|371|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.055737|2018-06-01 04:30:07.055737
NCT00210912|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|September 2003||2003-09-30|April 2010|2010-04-30|April 2005|Actual|2005-04-30|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine|Completed||Phase 3|328|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.122966|2018-06-01 04:30:07.122966
NCT00210899|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-07-25|2005-09-13|2005-09-21|Estimate|||||||2012-07-25|2012-07-26|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections|A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections|Completed||Phase 3|828|Actual|Basilea Pharmaceutica||2|||f||||f||||||||||2018-06-01 04:30:07.189093|2018-06-01 04:30:07.189093
NCT00210886|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|October 2004||2004-10-31|April 2010|2010-04-30|April 2006|Actual|2006-04-30|||||Interventional|||A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.|A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis.|Completed||Phase 3|1109|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.290286|2018-06-01 04:30:07.290286
NCT00210873|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|February 2004||2004-02-29|May 2010|2010-05-31|August 2005|Actual|2005-08-31|||||Interventional|||An Open Label Extension of a Study of Topiramate in Chronic Migraine.|An Open-label Study of the Safety and Efficacy of Topiramate for the Prophylaxis of Chronic Migraine: Extension Study to CAPSS-276|Completed||Phase 3|200|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.353706|2018-06-01 04:30:07.353706
NCT00210860|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|September 2004||2004-09-30|April 2010|2010-04-30|March 2006|Actual|2006-03-31|||||Interventional|||An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.|An Open-label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study to CAPSS-277|Completed||Phase 3|142|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.419833|2018-06-01 04:30:07.419833
NCT00210847|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 2003||2003-12-31|April 2010|2010-04-30|May 2005|Actual|2005-05-31|||||Interventional|||A Study Comparing the Effectiveness and Safety of Tramadol HCl/Acetaminophen Versus Placebo for the Treatment of Painful Neuropathy in Diabetic Patients|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Tramadol HCl/Acetaminophen for the Treatment of Painful Diabetic Neuropathy|Completed||Phase 3|313|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.490392|2018-06-01 04:30:07.490392
NCT00210834|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|May 2004||2004-05-31|May 2010|2010-05-31|September 2005|Actual|2005-09-30|||||Interventional|||An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.|A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Initiated At 40,000 Units Every Week Versus 80,000 Units Every Two Weeks In Anemic Patients With Cancer Receiving Chemotherapy|Completed||Phase 2|310|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.55699|2018-06-01 04:30:07.55699
NCT00210821|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|February 2004||2004-02-29|May 2010|2010-05-31|November 2005|Actual|2005-11-30|||||Interventional|||Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches|A Comparison of Topiramate Versus Amitriptyline in Migraine Prophylaxis|Completed||Phase 3|347|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.643646|2018-06-01 04:30:07.643646
NCT00210808|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|September 2003||2003-09-30|April 2010|2010-04-30|March 2005|Actual|2005-03-31|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity|A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity|Completed||Phase 2/Phase 3|407|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.708444|2018-06-01 04:30:07.708444
NCT00210795|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|June 2004||2004-06-30|April 2010|2010-04-30|October 2005|Actual|2005-10-31|||||Interventional|||A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia|A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Anemia of Chronic Disease (ACD) Receiving Epoetin Alfa (PROCRIT�)|Terminated||Phase 2|12|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"This study was stopped due to slow enrollment after enrolling only 12 of 80 patients over 14~   months time."|||||t||||||||||2018-06-01 04:30:07.770588|2018-06-01 04:30:07.770588
NCT00210782|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|June 2004||2004-06-30|March 2010|2010-03-31|August 2007|Actual|2007-08-31|||||Interventional|||A Comparison of the Effectiveness and Safety of Topiramate and Phenytoin in Patients With New Onset Epilepsy Requiring Rapid Initiation of Antiepileptic Drug Treatment|A Double-blind Trial Comparing the Efficacy, Tolerability and Safety of Monotherapy Topiramate Versus Phenytoin in Subjects With Seizures Indicative of New Onset Epilepsy|Completed||Phase 3|262|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.842915|2018-06-01 04:30:07.842915
NCT00209924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-29|2005-09-13|2005-09-21|Estimate|||||||2007-03-29|2007-03-30|Estimate|April 2004||2004-04-30|March 2007|2007-03-31|November 2005|Actual|2005-11-30|||||Interventional|||A Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia|Completed||Phase 3|505||H. Lundbeck A/S|||||f||||f||||||||||2018-06-01 04:30:15.017968|2018-06-01 04:30:15.017968
NCT00210769|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-17|2005-09-13|2005-09-21|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 2004||2004-01-31|April 2010|2010-04-30|December 2005|Actual|2005-12-31|||||Interventional|||A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia|Open-label Extension of A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Extended Release OROS� Paliperidone (6 and 12 mg/Day) and Olanzapine (10 mg/Day), in Patients With Schizophrenia|Completed||Phase 3|203|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.917491|2018-06-01 04:30:07.917491
NCT00210756|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|February 2004||2004-02-29|April 2010|2010-04-30|February 2006|Actual|2006-02-28|||||Interventional|||Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.|Comparative Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days|Completed||Phase 2|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:07.993198|2018-06-01 04:30:07.993198
NCT00210743|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-19|2005-09-13|2005-09-21|Estimate|||||||2011-05-19|2011-05-23|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|October 2005|Actual|2005-10-31|||||Interventional|||Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.|An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week Epoetin Alfa (PROCRIT)in the Treatment of Subjects With the Anemia of Chronic Kidney Disease (CKD)|Completed||Phase 2|67|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:08.091183|2018-06-01 04:30:08.091183
NCT00210730|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|June 2004||2004-06-30|March 2010|2010-03-31|July 2005|Actual|2005-07-31|||||Interventional|||The Duration Study|An Open Label Randomized Study To Evaluate The Response Rate Of Epoetin Alfa (PROCRIT�) Versus No/Delayed PROCRIT Treatment In Patients With Cancer And Persistent Chemotherapy-Induced Myelosuppression (Anemia)|Terminated||Phase 3|2|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||This study was stopped early due to slow enrollment.|||||f||||||||||2018-06-01 04:30:08.155221|2018-06-01 04:30:08.155221
NCT00210717|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-06|2005-09-13|2005-09-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|February 2005||2005-02-28|April 2010|2010-04-30|April 2007|Actual|2007-04-30|||||Interventional|||A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia|A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia|Completed||Phase 3|748|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:30:08.217072|2018-06-01 04:30:08.217072
NCT00210704|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-06|2005-09-13|2005-09-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2005||2005-03-31|March 2010|2010-03-31|June 2006|Actual|2006-06-30|||||Interventional|||A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation|A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation|Completed||Phase 3|1067|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||f||||||||||||||2018-06-01 04:30:08.285309|2018-06-01 04:30:08.285309
NCT00210691|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-18|2005-09-13|2005-09-21|Estimate|||||||2010-11-18|2010-11-19|Estimate|December 1999||1999-12-31|November 2010|2010-11-30|February 2004|Actual|2004-02-29|||||Interventional|||A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder|Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|273|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:08.354036|2018-06-01 04:30:08.354036
NCT00210678|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-09|2005-09-13|2005-09-21|Estimate|||||||2012-10-09|2012-10-10|Estimate|March 2005||2005-03-31|October 2012|2012-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||A Study to Evaluate Intravaginal Ejaculation Time in Men With and Without Premature Ejaculation|An Observational Study to Evaluate Intravaginal Ejaculatory Latency Time and Patient-Reported Outcomes in Men With and Without Premature Ejaculation|Completed|||1115|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||2||f||||f||||||||||2018-06-01 04:30:08.416517|2018-06-01 04:30:08.416517
NCT00210665|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-10-09|2005-09-13|2005-09-21|Estimate|||||||2017-10-09|2017-10-10|Actual||||October 2017|2017-10-31||||||||Expanded Access|||A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment|A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment|No longer available|||||Janssen Research & Development, LLC|||||||||||||||||||2018-06-01 04:30:08.475609|2018-06-01 04:30:08.475609
NCT00210652|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13||2013-01-15|2013-01-15|2005-09-13|2005-09-21|Estimate||||2013-01-15|2013-01-24|Estimate|2013-01-15|2013-01-24|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy|A Double-Blind, Placebo-Controlled, Dose-Titration Study to Determine Safety, Tolerability and Preliminary Efficacy of RWJ-333369 as Adjunctive Therapy in Subjects With Treatment-Resistant Partial Seizures (With or Without Secondary Generalization) or Primarily Generalized Tonic-Clonic Seizures|Completed||Phase 2|47|Actual|SK Life Science||1|||f||||||||||||||2018-06-01 04:30:08.568715|2018-06-01 04:30:08.568715
NCT00210639|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-04-26||2014-04-02|2005-09-13|2005-09-21|Estimate|2011-04-26|2011-05-23|Estimate||||2014-04-02|2014-04-21|Estimate|August 2002||2002-08-31|April 2014|2014-04-30|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Observational|||A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection|A Multicenter, Long-Term, Active-Surveillance Study of Musculoskeletal Disorders That Occur After Initiating a Course of Levofloxacin (RWJ-25213-097) or Non-Fluoroquinolone Therapy for Acute Infectious Diseases in Children Who Were Enrolled in Phase 3 Clinical Trials Involving Levofloxacin Therapy|Completed|||2233|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|This was an observational safety study with no efficacy endpoints. Adverse event data is entered into the appropriate section within this submission.||2||f||||f||||||||||2018-06-01 04:30:08.637876|2018-06-01 04:30:08.637876
NCT00210626|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-06-26||2014-04-02|2005-09-13|2005-09-21|Estimate|2009-11-18|2009-12-22|Estimate||||2014-04-02|2014-04-21|Estimate|August 2005||2005-08-31|April 2014|2014-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT®)) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects|Terminated||Phase 2|192|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|The study was stopped early due to slow enrollment. Four subjects were randomized but withdrew prior to hospital entry and no data were collected|2|||f||||t||||||||||2018-06-01 04:30:09.157768|2018-06-01 04:30:09.157768
NCT00210613|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-06|2005-09-13|2005-09-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2004||2004-11-30|December 2010|2010-12-31|August 2005|Actual|2005-08-31|||||Interventional|||A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation|A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As-Needed Dosing With Dapoxetine in the Treatment of Premature Ejaculation|Completed||Phase 3|199|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:09.708059|2018-06-01 04:30:09.708059
NCT00210600|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|May 2005||2005-05-31|April 2010|2010-04-30|August 2006|Actual|2006-08-31|||||Interventional|||Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy|Assessment of Early and Standard Intervention With PROCRIT (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy.|Completed||Phase 2|186|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:09.788212|2018-06-01 04:30:09.788212
NCT00210587|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|February 2005||2005-02-28|May 2010|2010-05-31|December 2005|Actual|2005-12-31|||||Interventional|||An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation|A Pilot Study to Evaluate the Response Rate of Epoetin Alfa (PROCRIT) at 80,000 Units Every Three Weeks in Anemic Patients With Cancer Not Receiving Chemotherapy or Radiation Therapy|Completed||Phase 3|51|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:09.863494|2018-06-01 04:30:09.863494
NCT00210574|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|October 2006|Actual|2006-10-31|||||Interventional|||A Pilot Study of Topiramate in Childhood Absence Epilepsy|A Pilot Study of Topiramate in Childhood Absence Epilepsy|Completed||Phase 2|12|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:09.937306|2018-06-01 04:30:09.937306
NCT00210561|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-08|2005-09-13|2005-09-21|Estimate|||||||2011-06-08|2011-06-10|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|April 2005|Actual|2005-04-30|||||Interventional|||A Study of the Effectiveness and Safety of Tramadol HCl/Acetaminophen Compared to Placebo in Treating Acute Low Back Pain|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) for the Treatment of Acute Low Back Pain|Terminated||Phase 4|22|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||"Study was stopped shortly after initiation due to change in strategic direction of the company;~   no safety concerns were observed that impacted this decision."|||||f||||||||||2018-06-01 04:30:10.023417|2018-06-01 04:30:10.023417
NCT00210548|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-06|2005-09-13|2005-09-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2005||2005-04-30|April 2010|2010-04-30|June 2006|Actual|2006-06-30|||||Interventional|||A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia|Completed||Phase 3|366|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:10.098831|2018-06-01 04:30:10.098831
NCT00210535|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-06|2005-09-13|2005-09-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 2005||2005-06-30|January 2010|2010-01-31|November 2006|Actual|2006-11-30|||||Interventional|||A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age|Completed||Phase 3|110|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:30:10.170621|2018-06-01 04:30:10.170621
NCT00210522|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13||2013-01-15|2013-01-15|2005-09-13|2005-09-21|Estimate||||2013-01-15|2013-01-24|Estimate|2013-01-15|2013-01-24|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy|A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects With Refractory Partial Seizures (Protocol 333369-EPY-2003 [Double-blind] and Protocol 333369-EPY-2006 [Open-label Extension])|Completed||Phase 2|421|Actual|SK Life Science||1|||f||||||||||||||2018-06-01 04:30:10.241825|2018-06-01 04:30:10.241825
NCT00210509|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-16|2005-09-13|2005-09-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|November 2004||2004-11-30|April 2010|2010-04-30|June 2005|Actual|2005-06-30|||||Interventional|||A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache|AXERT® Early miGraine Intervention Study (AEGIS): Efficacy and Safety of Almotriptan Malate (AXERT®) Versus Placebo for the Acute Treatment of Migraine Headache|Completed||Phase 4|378|Actual|Janssen-Ortho LLC|||||||||||||||||||2018-06-01 04:30:10.314874|2018-06-01 04:30:10.314874
NCT00210496|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-16|2005-09-13|2005-09-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|June 2005||2005-06-30|April 2010|2010-04-30|June 2007|Actual|2007-06-30|||||Interventional|||Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine|Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)|Completed||Phase 4|406|Actual|Janssen-Ortho LLC|||||||||||||||||||2018-06-01 04:30:10.376414|2018-06-01 04:30:10.376414
NCT00210483|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-16|2005-09-13|2005-09-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|July 2003||2003-07-31|April 2010|2010-04-30|July 2005|Actual|2005-07-31|||||Interventional|||A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents|A Randomized, Double-blind, Placebo-controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents|Completed||Phase 3|866|Actual|Janssen-Ortho LLC|||||||||||||||||||2018-06-01 04:30:10.440744|2018-06-01 04:30:10.440744
NCT00210470|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-01-06||2012-05-22|2005-09-13|2005-09-21|Estimate|2012-01-06|2012-02-08|Estimate||||2012-05-22|2012-05-28|Estimate|July 2005||2005-07-31|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer|A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck|Completed||Phase 2|27|Actual|IRX Therapeutics||1|||f||||f||||||||||2018-06-01 04:30:10.534028|2018-06-01 04:30:10.534028
NCT00210457|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2008-06-26|2005-09-19|2005-09-21|Estimate|||||||2008-06-26|2008-06-27|Estimate|September 2000||2000-09-30|June 2008|2008-06-30||||||||Interventional|||Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients|Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues.|Completed||Phase 3|60||Ipsen|||||f||||||||||||||2018-06-01 04:30:10.771948|2018-06-01 04:30:10.771948
NCT00210444|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2007-09-12|2005-09-19|2005-09-21|Estimate|||||||2007-09-12|2007-09-14|Estimate|June 2003||2003-06-30|September 2007|2007-09-30|December 2006|Actual|2006-12-31|||||Interventional|||Efficacy Study of Dysport® in the Treatment of Anal Fissure.|A Phase II, Multicentre, Open, Randomised, Parallel Group, Dose Ranging Study to Define the Efficacy of Dysport® in the Treatment of Anal Fissure.|Completed||Phase 2|152||Ipsen|||||f||||||||||||||2018-06-01 04:30:10.859095|2018-06-01 04:30:10.859095
NCT00210431|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-29|2005-09-13|2005-09-21|Estimate|||||||2015-09-29|2015-10-01|Estimate|October 2004||2004-10-31|September 2007|2007-09-30|June 2006|Actual|2006-06-30|||||Observational|||Post Marketing Surveillance Study of Dysport|A Post Marketing Surveillance Study of Dysport Formulated With a Batch of Bulk Active Substance From a New Primary Manufacturing Facility at the Centre for Applied Microbiology & Research.|Completed|||800||Ipsen|||||f||||||||||||||2018-06-01 04:30:10.926136|2018-06-01 04:30:10.926136
NCT00210418|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-29|2005-09-13|2005-09-21|Estimate|||||||2012-08-29|2012-08-30|Estimate|May 2002||2002-05-31|August 2012|2012-08-31|September 2005|Actual|2005-09-30|||||Interventional|||Effectiveness of Targeting Food Aid to Malnourished Children Compared to Targeting All Children Under Two Years|Prevention or Cure: A Comparison of the Effectiveness of Targeting Food Supplements to Malnourished Children Compared to Universal Targeting of Children Under Two in Haiti|Completed||N/A|1500||International Food Policy Research Institute||2|||f||||||||||||||2018-06-01 04:30:11.116863|2018-06-01 04:30:11.116863
NCT00210405|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-29|2005-09-13|2005-09-21|Estimate|||||||2012-08-29|2012-08-30|Estimate|March 2005||2005-03-31|August 2012|2012-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Feasibility and Effectiveness of Distributing Micronutrient Sprinkles to Reduce Prevalence of Anemia|Assessing the Feasibility and Effectiveness of Distributing Micronutrient Sprinkles Within a Title II Food Aid and Maternal and Child Health Program in Rural Haiti|Completed||N/A|450|Actual|International Food Policy Research Institute||2|||f||||||||||||||2018-06-01 04:30:11.204462|2018-06-01 04:30:11.204462
NCT00210392|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-27|2005-09-13|2005-09-21|Estimate|||||||2015-03-27|2015-03-30|Estimate|July 2005||2005-07-31|March 2015|2015-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy|Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142)|Terminated||Phase 2|12|Actual|International Extranodal Lymphoma Study Group (IELSG)||||"After IELSG25A study amendment, patients subject of the present study were eligible for~   inclusion in the IELSG25A study"|f||||t||||||||||2018-06-01 04:30:11.296124|2018-06-01 04:30:11.296124
NCT00210379|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-07-21|2005-09-13|2005-09-21|Estimate|||||||2009-07-21|2009-07-22|Estimate|November 2000||2000-11-30|July 2009|2009-07-31|March 2007|Actual|2007-03-31|November 2004|Actual|2004-11-30||Interventional|||Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma|A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma|Completed||Phase 2|64|Actual|International Extranodal Lymphoma Study Group (IELSG)|||||f||||||||||||||2018-06-01 04:30:11.363108|2018-06-01 04:30:11.363108
NCT00210366|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-07-29|2005-09-13|2005-09-21|Estimate|||||||2010-07-29|2010-07-30|Estimate|November 2004||2004-11-30|July 2010|2010-07-31||||July 2010|Actual|2010-07-31||Interventional|||Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma|Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas|Terminated||Phase 2|25|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||||due to slow accrual|f||||||||||||||2018-06-01 04:30:11.432862|2018-06-01 04:30:11.432862
NCT00210353|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-07-26|2005-09-13|2005-09-21|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2003||2003-01-31|July 2016|2016-07-31|April 2020|Anticipated|2020-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma|Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)|Active, not recruiting||Phase 3|450|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||3|||f||||t||||||||||2018-06-01 04:30:11.504315|2018-06-01 04:30:11.504315
NCT00210340|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-27|2005-09-13|2005-09-21|Estimate|||||||2015-03-27|2015-03-30|Estimate||||March 2015|2015-03-31||||||||Interventional|||A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis|A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis|Withdrawn||Phase 1|0|Actual|International Extranodal Lymphoma Study Group (IELSG)||||lack of accrual|f||||||||||||||2018-06-01 04:30:11.648159|2018-06-01 04:30:11.648159
NCT00210327|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-07-21|2005-09-13|2005-09-21|Estimate|||||||2009-07-21|2009-07-22|Estimate|July 2005||2005-07-31|July 2009|2009-07-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy|Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142)|Completed||Phase 2|33|Anticipated|International Extranodal Lymphoma Study Group (IELSG)|||||f||||t||||||||||2018-06-01 04:30:11.708732|2018-06-01 04:30:11.708732
NCT00210314|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-27|2005-09-13|2005-09-21|Estimate|||||||2015-03-27|2015-03-30|Estimate|July 2003||2003-07-31|March 2015|2015-03-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma|Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|Completed||Phase 2|79|Actual|International Extranodal Lymphoma Study Group (IELSG)||2|||f||||||||||||||2018-06-01 04:30:11.780336|2018-06-01 04:30:11.780336
NCT00210301|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-06|2005-09-13|2005-09-21|Estimate|||||||2006-09-06|2006-09-07|Estimate|January 2003||2003-01-31|August 2005|2005-08-31||||||||Interventional|||Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS|Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS|Unknown status|Recruiting|N/A|60||Institute for Clinical Research|||||f||||||||||||||2018-06-01 04:30:11.852036|2018-06-01 04:30:11.852036
NCT00210288|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-11|2005-09-13|2005-09-21|Estimate|||||||2010-03-11|2010-03-12|Estimate|May 2005||2005-05-31|March 2010|2010-03-31|April 2007|Actual|2007-04-30|September 2006|Actual|2006-09-30||Interventional|||Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine|A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers|Completed||Phase 2|111|Anticipated|Institut Pasteur|||||f||||||||||||||2018-06-01 04:30:11.919617|2018-06-01 04:30:11.919617
NCT00210275|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-25|2005-09-13|2005-09-21|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2005||2005-07-31|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|OPEMS||Ontario Printed Educational Materials (PEMs) for Physician Behaviour Change|The Ontario Printed Educational Message (OPEM) Trial to Narrow the Evidence-practice Gap With Respect to Prescribing Practices of General and Family Physicians: a Cluster Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|5000|Anticipated|Institute for Clinical Evaluative Sciences||4|||f||||f||||||||||2018-06-01 04:30:12.959502|2018-06-01 04:30:12.959502
NCT00210262|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2005-09-15|2005-09-15|2005-09-21|Estimate|||||||2005-09-15|2005-09-21|Estimate|October 2002||2002-10-31|November 2003|2003-11-30|January 2005||2005-01-31|||||Interventional|||Promoting Blood Pressure Control and Cholesterol Reduction to Prevent Major Complications in Persons With Diabetes|Promoting Blood Pressure Control and Cholesterol Reduction to Prevent Major Complications in Persons With Diabetes|Completed||N/A|||Institute for Clinical Evaluative Sciences|||||f||||||||||||||2018-06-01 04:30:13.041154|2018-06-01 04:30:13.041154
NCT00210249|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|September 2002||2002-09-30|September 2005|2005-09-30|June 2006|Actual|2006-06-30|||||Observational|ONCOGERIATRIE||Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment|Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country.|Completed|||360|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.112371|2018-06-01 04:30:13.112371
NCT00210236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|September 1995||1995-09-30|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|AXIL95||Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women With Breast Cancer|Surgical Resection With or Without Axillary Lymph Node Excision in Treating Menopausal Women With Infiltrative Breast Cancer Smaller Than 10 mm|Terminated||Phase 3|592|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.196237|2018-06-01 04:30:13.196237
NCT00210223|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|April 2004||2004-04-30|October 2007|2007-10-31|July 2006|Actual|2006-07-31|||||Interventional|RF SEIN||Radiofrequency of Breast Cancers in Non Surgical Patients|Radiofrequency of Breast Cancers : Pilot Study in Non Surgical Patients|Completed||N/A|15|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.28124|2018-06-01 04:30:13.28124
NCT00210210|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|February 2004||2004-02-29|October 2007|2007-10-31|December 2005|Actual|2005-12-31|||||Interventional|KETAMINE||Administration of Ketamine to Prevent the Post-operative Pain|Effect of Ketamine, at the Induction and Its Maintenance to Prevent the Post-operative Pain: Clinical Trial in Cancerology|Completed||Phase 3|230|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.341429|2018-06-01 04:30:13.341429
NCT00210197|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|January 2006|Actual|2006-01-31|||||Observational|EHC||Hypercoagulability After Breast Cancer Surgery|Plasma Coagulation Parameters and Hypercoagulability After Breast Cancer Surgery|Completed|||48|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.496993|2018-06-01 04:30:13.496993
NCT00210184|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-12-29|2005-09-13|2005-09-21|Estimate|||||||2011-12-29|2012-01-02|Estimate|July 2004||2004-07-31|October 2007|2007-10-31|July 2009||2009-07-31|||||Interventional|CEPAFIRI||Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer|Multicentric Phase II Trial: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years Old and More Presenting Gastric Cancer Locally Advanced or Metastatic|Completed||Phase 2|43|Anticipated|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.566335|2018-06-01 04:30:13.566335
NCT00210171|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|May 2004||2004-05-31|October 2007|2007-10-31|March 2007|Actual|2007-03-31|||||Interventional|BIB 01||Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer|Multicentric Phase II Study of Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer, With :- Induction Chemotherapy by Cisplatin - Docetaxel- Concomitant Chemo-radiotherapy by Weekly Cisplatin - Docetaxel- Consolidation Chemotherapy by Docetaxel|Terminated||Phase 2|3|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.655239|2018-06-01 04:30:13.655239
NCT00210158|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Interventional|PROTOX||Intraoperative Nitrous Oxide and Postoperative Pain for Patients With Current Opioid Treatment|Effects of Intraoperative Nitrous Oxide on Postoperative Pain for Patients With Current Opioid Treatment After Vertebroplasty.|Completed||N/A|36|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.738634|2018-06-01 04:30:13.738634
NCT00210145|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-12-29|2005-09-13|2005-09-21|Estimate|||||||2011-12-29|2012-01-02|Estimate|October 2003||2003-10-31|October 2007|2007-10-31|June 2006|Actual|2006-06-30|||||Observational|ASE K SEIN||Socio-aesthetic Intervention on Body Image and Quality of Life in Women With Breast Cancer.|Impact of a Socio-aesthetic Intervention on Body Image and Quality of Life in Patients With Mastectomy or Tumorectomy for Breast Cancer.|Completed|||100|Anticipated|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.808646|2018-06-01 04:30:13.808646
NCT00210132|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-11-25|2005-09-13|2005-09-21|Estimate|||||||2015-11-25|2015-11-26|Estimate|October 2003||2003-10-31|November 2015|2015-11-30|February 2008|Actual|2008-02-29|June 2006|Actual|2006-06-30||Interventional|ROPAL 1||Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery|Randomized Trial to Evaluate the Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery|Completed||Phase 2|90|Actual|Institut Bergonié||1|||f||||||||||||||2018-06-01 04:30:13.887967|2018-06-01 04:30:13.887967
NCT00210119|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-07-25|2005-09-13|2005-09-21|Estimate|||||||2013-07-25|2013-07-26|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|AFR22||Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response|Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy|Terminated||Phase 2|17|Actual|Institut Bergonié|||||f||||||||||||||2018-06-01 04:30:13.975905|2018-06-01 04:30:13.975905
NCT00210106|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-03|2005-09-13|2005-09-21|Estimate|||||||2015-03-03|2015-03-04|Estimate|June 2003||2003-06-30|March 2015|2015-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ARF2003||Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.|Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy. A Phase 2 Study.|Completed||Phase 2|53|Anticipated|Institut Bergonié|||||f||||f||||||||||2018-06-01 04:30:14.059174|2018-06-01 04:30:14.059174
NCT00210093|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-15|2005-09-20|2005-09-21|Estimate|||||||2015-10-15|2015-10-16|Estimate|April 2003||2003-04-30|October 2015|2015-10-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||A Pharmacokinetic Evaluation Study in Healthy Volunteers|A Single-Center, Randomized, Crossover Pharmacokinetic Evaluation of the Effect of Single Doses of Intravenous INS37217, Nasally Inhaled INS37217 and Orally Inhaled INS37217 Solution in Healthy Volunteers|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:30:14.128923|2018-06-01 04:30:14.128923
NCT00210080|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-03|2005-09-13|2005-09-21|Estimate|||||||2015-09-03|2015-09-04|Estimate|April 2001||2001-04-30|September 2015|2015-09-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)|A Double-Blind, Placebo-Controlled, Parallel Group Study of Uridine 5'-Triphosphate (UTP) Solution for Inhalation as an Adjunct in the Diagnosis of Lung Cancer by Sputum Cytology|Completed||Phase 3|700||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:30:14.176558|2018-06-01 04:30:14.176558
NCT00210067|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-08|2005-09-13|2005-09-21|Estimate|||||||2015-10-08|2015-10-09|Estimate|May 2001||2001-05-31|October 2015|2015-10-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||A Study in Subjects With Retinal Detachment|A Double-Masked, Randomized, Dose-Ranging Study of a Single Intravitreal (IVT) Injection of INS37217 Intravitreal Injection in Subjects With Retinal Detachment|Completed||Phase 1|14|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:30:14.231667|2018-06-01 04:30:14.231667
NCT00210054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-09|2005-09-20|2005-09-21|Estimate|||||||2015-10-09|2015-10-12|Estimate|November 2002||2002-11-30|October 2015|2015-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Pharmacokinetic Evaluation Study in Healthy Volunteers|Pilot Single-Dose Intravenous Pharmacokinetic Evaluation of INS37217 Solution in Healthy Volunteers|Completed||Phase 1|4|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:30:14.276634|2018-06-01 04:30:14.276634
NCT00210041|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-03-26|2005-09-13|2005-09-21|Estimate|||||||2015-03-26|2015-03-31|Estimate|February 2004||2004-02-29|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma|Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin|Completed||Phase 2|50|Anticipated|Institut Claudius Regaud|||||f||||||||||||||2018-06-01 04:30:14.326522|2018-06-01 04:30:14.326522
NCT00210028|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-10|2005-09-13|2005-09-21|Estimate|||||||2006-11-10|2006-11-14|Estimate|August 2003||2003-08-31|November 2006|2006-11-30|August 2008||2008-08-31|||||Interventional|||Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer|Open, Single-Arm Phase II Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer Expressing the Estrogen and/or Progesterone Receptor|Terminated||Phase 2|40||Institut Claudius Regaud|||||f||||||||||||||2018-06-01 04:30:14.416787|2018-06-01 04:30:14.416787
NCT00210015|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-22|2005-09-13|2005-09-21|Estimate|||||||2016-01-22|2016-01-25|Estimate|December 2002||2002-12-31|January 2016|2016-01-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||A Study in Subjects With Perennial Allergic Rhinitis|A Multi-Center, Randomized, Parallel-Group, Double-Blind, Efficacy and Safety Study of INS37217 Nasal Spray Versus Placebo in Subjects With Perennial Allergic Rhinitis|Completed||Phase 2|630||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:30:14.572769|2018-06-01 04:30:14.572769
NCT00210002|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-13|2005-09-13|2005-09-21|Estimate|||||||2006-11-13|2006-11-14|Estimate|November 2003||2003-11-30|November 2006|2006-11-30|April 2006||2006-04-30|||||Interventional|||Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced|Evaluation of Systematic Intravenous Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced.|Terminated||Phase 2|55||Institut Claudius Regaud|||||f||||||||||||||2018-06-01 04:30:14.636991|2018-06-01 04:30:14.636991
NCT00209989|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-23|2005-09-13|2005-09-21|Estimate|||||||2011-11-23|2011-11-24|Estimate|October 2005||2005-10-31|November 2011|2011-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme|Phase I/II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme|Completed||Phase 2|27|Actual|Institut Claudius Regaud|||||f||||||||||||||2018-06-01 04:30:14.735795|2018-06-01 04:30:14.735795
NCT00209963|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-29|2005-09-13|2005-09-21|Estimate|||||||2007-03-29|2007-03-30|Estimate|June 2003||2003-06-30|March 2007|2007-03-31|March 2005|Actual|2005-03-31|||||Interventional|||A Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia|Completed||Phase 3|600||H. Lundbeck A/S|||||f||||f||||||||||2018-06-01 04:30:14.813349|2018-06-01 04:30:14.813349
NCT00209950|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-29|2005-09-13|2005-09-21|Estimate|||||||2007-03-29|2007-03-30|Estimate|July 2004||2004-07-31|March 2007|2007-03-31|September 2005|Actual|2005-09-30|||||Interventional|||A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia|A Prospective Open-Label Extension Study (to Study 99784) of Gaboxadol in Primary Insomnia|Completed||Phase 3|200||H. Lundbeck A/S|||||f||||f||||||||||2018-06-01 04:30:14.874907|2018-06-01 04:30:14.874907
NCT00209937|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-29|2005-09-13|2005-09-21|Estimate|||||||2007-03-29|2007-03-30|Estimate|January 2003||2003-01-31|March 2007|2007-03-31|June 2004|Actual|2004-06-30|||||Interventional|||A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Active-Reference Study of Gaboxadol in Primary Insomnia|Completed||Phase 3|675||H. Lundbeck A/S|||||f||||f||||||||||2018-06-01 04:30:14.947426|2018-06-01 04:30:14.947426
NCT00209911|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 2001||2001-01-31|January 2001|2001-01-31|January 2003||2003-01-31|||||Observational|||Study of the Effect of Cardioversion on Cardiac Volume in Patients With Persistent Atrial Fibrillation|Atrial and Ventricular Volume and Function In Atrial Fibrillation - A Magnetic Resonance Imaging Study|Terminated|||60||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:30:15.099969|2018-06-01 04:30:15.099969
NCT00209898|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-19|2005-09-13|2005-09-21|Estimate|||||||2015-03-19|2015-03-20|Estimate|August 2003||2003-08-31|June 2003|2003-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|PEGPRI||Hepatitis C Treatment of Inmates|Hepatitis C Treatment of Inmates. A Randomized, Open-label Study Evaluating the Feasibility, Safety and Efficacy of Treatment With Peginterferon Alfa-2a in Combination With Ribavirin in Inmate Patients With Chronic Hepatitis C|Terminated||Phase 4|42|Anticipated|Haukeland University Hospital||2||Low inclusion rate|f||||f||||||||||2018-06-01 04:30:15.171206|2018-06-01 04:30:15.171206
NCT00209885|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-21|Estimate|||||||2005-09-14|2005-09-21|Estimate|October 2005||2005-10-31|September 2005|2005-09-30||||||||Interventional|||Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy||Unknown status|Not yet recruiting|Phase 4|60||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:30:15.2552|2018-06-01 04:30:15.2552
NCT00209872|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-11-06|2005-09-14|2005-09-21|Estimate|||||||2007-11-06|2007-11-07|Estimate|October 2005||2005-10-31|September 2005|2005-09-30||||||||Interventional|||Optimal Multimodal Analgesia in Abdominal Hysterectomy||Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:30:15.345415|2018-06-01 04:30:15.345415
NCT00209859|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-21|Estimate|||||||2005-09-16|2005-09-21|Estimate|October 1998||1998-10-31|September 2005|2005-09-30|November 2007||2007-11-30|||||Interventional|||Methotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis|Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis.|Completed||Phase 4|160||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:30:15.428802|2018-06-01 04:30:15.428802
NCT00209846|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-29|2005-09-13|2005-09-21|Estimate|||||||2007-03-29|2007-03-30|Estimate|June 2004||2004-06-30|March 2007|2007-03-31|November 2006|Actual|2006-11-30|||||Interventional|||A Study of Gaboxadol in Primary Insomnia|A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia|Completed||Phase 3|320||H. Lundbeck A/S|||||f||||f||||||||||2018-06-01 04:30:15.493138|2018-06-01 04:30:15.493138
NCT00209833|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-11-17|2005-09-13|2005-09-21|Estimate|||||||2005-11-17|2005-11-18|Estimate|January 1999||1999-01-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T|Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial)|Unknown status|Active, not recruiting|Phase 2/Phase 3|200||Hannover Medical School|||||f||||||||||||||2018-06-01 04:30:15.551723|2018-06-01 04:30:15.551723
NCT00209820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-10|2005-09-13|2005-09-21|Estimate|||||||2007-04-10|2007-04-11|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Nordic Walking and Chronic Low Back Pain||Unknown status|Recruiting|N/A|150||Human Locomotion Science|||||f||||||||||||||2018-06-01 04:30:15.625007|2018-06-01 04:30:15.625007
NCT00209807|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-26|2005-09-13|2005-09-21|Estimate|||||||2010-05-26|2010-05-27|Estimate|September 2005||2005-09-30|May 2010|2010-05-31|April 2011|Anticipated|2011-04-30|June 2009|Anticipated|2009-06-30||Interventional|||Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder|Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial|Unknown status|Recruiting|Phase 4|42|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||||||||||||2018-06-01 04:30:15.691985|2018-06-01 04:30:15.691985
NCT00209794|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-15|2005-09-20|2005-09-21|Estimate|||||||2006-11-15|2006-11-16|Estimate|September 2002||2002-09-30|November 2006|2006-11-30|December 2005||2005-12-31|||||Interventional|||IPTi in Mozambican Infants for Malaria Prevention|The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children|Unknown status|Active, not recruiting|Phase 1/Phase 2|1498||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 04:30:15.773382|2018-06-01 04:30:15.773382
NCT00209781|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-29|2005-09-13|2005-09-21|Estimate|||||||2008-02-29|2008-03-06|Estimate|August 2003||2003-08-31|February 2008|2008-02-29|December 2006||2006-12-31|||||Interventional|||IPTp Plus ITNs for Malaria Control in Pregnant Women|Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women|Unknown status|Active, not recruiting|N/A|1028||Hospital Clinic of Barcelona|||||f||||||||||||||2018-06-01 04:30:15.834006|2018-06-01 04:30:15.834006
NCT00209768|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-11-28|2005-09-13|2005-09-21|Estimate|||||||2008-11-28|2008-12-01|Estimate|February 2005||2005-02-28|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Use of In-Line Filtration in Critically Ill Children|Randomised, Prospective Study of the Use of In-Line Filtration on the Reduction of Complication Rate in Critically Ill Children|Completed||Phase 4|821|Actual|Hannover Medical School|||||f||||||||||||||2018-06-01 04:30:15.903113|2018-06-01 04:30:15.903113
NCT00209755|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|October 2003||2003-10-31|September 2004|2004-09-30|July 2004||2004-07-31|||||Interventional|||Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C|Diagnostic Value of Plasma Ribavirin Assay During the Combination Therapy « Pegylated Interferon + Ribavirin » in Chronic Hepatitis C.|Terminated||N/A|40||Hopital A Michallon|||||f||||||||||||||2018-06-01 04:30:15.957731|2018-06-01 04:30:15.957731
NCT00209742|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-05-24|2005-09-13|2005-09-21|Estimate|||||||2010-05-24|2010-05-26|Estimate|April 2005||2005-04-30|May 2010|2010-05-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer|Randomized Phase III Clinical Study Comparing Postoperative UFT+LV, UFT+LV/UFT and UFT+LV+PSK/UFT+PSK Therapies for Stage III Colorectal Cancer|Unknown status|Active, not recruiting|Phase 3|340|Anticipated|Hokkaido Gastrointestinal Cancer Study Group||3|||f||||t||||||||||2018-06-01 04:30:16.101726|2018-06-01 04:30:16.101726
NCT00209729|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-24|2005-09-13|2005-09-21|Estimate|||||||2010-05-24|2010-05-26|Estimate|April 2005||2005-04-30|May 2010|2010-05-31|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.|Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer|Suspended||Phase 1/Phase 2|50|Anticipated|Hokkaido Gastrointestinal Cancer Study Group||1||Registration is less|f||||t||||||||||2018-06-01 04:30:16.188523|2018-06-01 04:30:16.188523
NCT00209365|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-13|2005-09-13|2005-09-21|Estimate|||||||2017-02-13|2017-02-15|Actual|September 2005||2005-09-30|February 2017|2017-02-28|December 2005|Actual|2005-12-31|||||Interventional|||The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit||Completed||N/A|24||Fraunhofer-Institute of Toxicology and Experimental Medicine|||||f||||||||||||||2018-06-01 04:30:20.398503|2018-06-01 04:30:20.398503
NCT00209716|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-24|2005-09-13|2005-09-21|Estimate|||||||2010-05-24|2010-05-26|Estimate|December 2003||2003-12-31|May 2010|2010-05-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.|Phase I/II Study of Docetaxel, Cisplatin and 5-fluorouracil(TPF) as Chemotherapy in Pre-treated Patients With Metastatic Esophageal Cancer.|Completed||Phase 1/Phase 2|30|Anticipated|Hokkaido Gastrointestinal Cancer Study Group||1|||f||||t||||||||||2018-06-01 04:30:16.280752|2018-06-01 04:30:16.280752
NCT00209703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-04-19|2005-09-13|2005-09-21|Estimate|||||||2006-04-19|2006-04-21|Estimate|January 2005||2005-01-31|April 2006|2006-04-30|June 2007||2007-06-30|||||Interventional|||Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer|Feasibility Study of mFOLFOX6 (Oxaliplatin Combined With l-Leucovorin (l-LV) and 5-Fluorouracil) in Patients With Advanced Colorectal Cancer|Terminated||Phase 2|30||Hokkaido Gastrointestinal Cancer Study Group|||||f||||||||||||||2018-06-01 04:30:16.362199|2018-06-01 04:30:16.362199
NCT00209690|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-24|2005-09-13|2005-09-21|Estimate|||||||2010-05-24|2010-05-26|Estimate|October 2003||2003-10-31|May 2010|2010-05-31|April 2010|Actual|2010-04-30|December 2009|Actual|2009-12-31||Interventional|||Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.|Phase I/II Study of Docetaxel, Cisplatin and 5-fluorouracil(TPF) as 1st-line Chemotherapy in Patients With Metastatic Esophageal Cancer.|Completed||Phase 1/Phase 2|30|Anticipated|Hokkaido Gastrointestinal Cancer Study Group||1|||f||||t||||||||||2018-06-01 04:30:16.434815|2018-06-01 04:30:16.434815
NCT00209677|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-31|2005-09-13|2005-09-21|Estimate|||||||2007-10-31|2007-11-01|Estimate|December 2004||2004-12-31|October 2007|2007-10-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|Suspended||Phase 1/Phase 2|40|Anticipated|Hokkaido Gastrointestinal Cancer Study Group||||"Unfortunately, other Phase III clinical Study (GEM+S-1 vs GEM vs S-1) have been started in~   Japan.~    h"|f||||t||||||||||2018-06-01 04:30:16.524363|2018-06-01 04:30:16.524363
NCT00209664|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-01-31|2005-09-13|2005-09-21|Estimate|||||||2006-01-31|2006-02-02|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|December 2008||2008-12-31|||||Interventional|||Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer|Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0303|Suspended||Phase 2|40||Hokkaido Gastrointestinal Cancer Study Group|||||f||||||||||||||2018-06-01 04:30:16.616629|2018-06-01 04:30:16.616629
NCT00209651|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-31|2005-09-13|2005-09-21|Estimate|||||||2007-10-31|2007-11-01|Estimate|January 2004||2004-01-31|October 2007|2007-10-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer|Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302|Unknown status|Active, not recruiting|Phase 2|40|Actual|Hokkaido Gastrointestinal Cancer Study Group||1|||f||||t||||||||||2018-06-01 04:30:16.690623|2018-06-01 04:30:16.690623
NCT00209638|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-04-19|2005-09-13|2005-09-21|Estimate|||||||2006-04-19|2006-04-21|Estimate|May 2000||2000-05-31|April 2006|2006-04-30|April 2003||2003-04-30|||||Interventional|||Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer|Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0101|Completed||Phase 1/Phase 2|24||Hokkaido Gastrointestinal Cancer Study Group|||||f||||||||||||||2018-06-01 04:30:16.809509|2018-06-01 04:30:16.809509
NCT00209625|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|April 2000||2000-04-30|April 2000|2000-04-30|November 2004||2004-11-30|||||Interventional|||Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer|Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer：Hokkaido Gastrointestinal Cancer Study Group:HGCSG0001|Completed||Phase 1/Phase 2|23||Hokkaido Gastrointestinal Cancer Study Group|||||f||||||||||||||2018-06-01 04:30:16.900852|2018-06-01 04:30:16.900852
NCT00209612|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-16|2005-09-13|2005-09-21|Estimate|||||||2009-02-16|2009-02-17|Estimate|April 2004||2004-04-30|February 2009|2009-02-28|March 2009|Anticipated|2009-03-31|November 2008|Anticipated|2008-11-30||Interventional|||Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.|Phase I/II Study of Biweekly Administration Regimen of Paclitaxel Combined With CPT-11 in Patients With Second Line Chemotherapy of Inoperable or Recurrent Gastric Cancer(GC).|Withdrawn||Phase 1/Phase 2|40|Anticipated|Hokkaido Gastrointestinal Cancer Study Group||1||due to strong side effect|f||||t||||||||||2018-06-01 04:30:17.05871|2018-06-01 04:30:17.05871
NCT00209599|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-11-06|2005-09-13|2005-09-21|Estimate|||||||2008-11-06|2008-11-07|Estimate|February 2005||2005-02-28|November 2008|2008-11-30|March 2005|Actual|2005-03-31|||||Interventional|||A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy|A Phase II, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Colonoscopy Procedures|Terminated||Phase 2|100||Eisai Inc.|||||||||||||||||||2018-06-01 04:30:17.178805|2018-06-01 04:30:17.178805
NCT00209586|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-31|2005-09-13|2005-09-21|Estimate|||||||2012-01-31|2012-02-01|Estimate|September 2004||2004-09-30|January 2012|2012-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy|A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Flexible Bronchoscopy Procedures|Terminated||Phase 3|55|Actual|Eisai Inc.||||"Patient enrollment was stopped prior to completion of the study in order to re-evaluate the~   dosing regimen."|||||||||||||||2018-06-01 04:30:17.268853|2018-06-01 04:30:17.268853
NCT00209573|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-11-06|2005-09-13|2005-09-21|Estimate|||||||2008-11-06|2008-11-07|Estimate|September 2004||2004-09-30|November 2008|2008-11-30|December 2004|Actual|2004-12-31|||||Interventional|||A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy|A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN Injection Versus Midazolam HCl for Sedation in Patients Undergoing Colonoscopy Procedures|Completed||Phase 3|270||Eisai Inc.|||||||||||||||||||2018-06-01 04:30:17.38951|2018-06-01 04:30:17.38951
NCT00209352|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-17|2005-09-14|2005-09-21|Estimate|||||||2007-12-17|2007-12-21|Estimate|June 1985||1985-06-30|December 2007|2007-12-31|July 2004|Actual|2004-07-31|||||Interventional|||Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant|Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant|Completed||Phase 3|120||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:30:20.509965|2018-06-01 04:30:20.509965
NCT00209560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-03-01||2014-12-22|2005-09-13|2005-09-21|Estimate|2012-05-17|2012-06-19|Estimate||||2014-12-22|2015-01-09|Estimate|October 2004||2004-10-31|July 2014|2014-07-31|March 2005||2005-03-31|||||Interventional|||A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures|A Phase III, Randomized, Open-label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Minor Surgical Procedures|Terminated||Phase 3|168|Actual|Eisai Inc.|Analysis of results from a previous fospropofol study (3000-0410) completed during the enrollment of this study indicated that the dosing regimen needed to be re-evaluated. The study was prematurely terminated after 168 subjects were randomized.||||f||||||||||||||2018-06-01 04:30:17.495856|2018-06-01 04:30:17.495856
NCT00209547|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-11-06|2005-09-13|2005-09-21|Estimate|||||||2008-11-06|2008-11-07|Estimate|February 2004||2004-02-29|November 2008|2008-11-30|March 2005|Actual|2005-03-31|||||Interventional|||Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization|A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Percutaneous Coronary (PC) Procedures|Completed||Phase 3|110||Eisai Inc.|||||||||||||||||||2018-06-01 04:30:18.193812|2018-06-01 04:30:18.193812
NCT00209534|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-12-03|2005-09-13|2005-09-21|Estimate|||||||2009-12-03|2009-12-04|Estimate|January 2003||2003-01-31|December 2009|2009-12-31|February 2004|Actual|2004-02-29|||||Interventional|||A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy|A Phase 2, Two Part Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy|Completed||Phase 2|200||Eisai Inc.|||||||||||||||||||2018-06-01 04:30:18.26204|2018-06-01 04:30:18.26204
NCT00209521|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-10|2005-09-13|2005-09-21|Estimate|||||||2010-06-10|2010-06-11|Estimate|June 2002||2002-06-30|June 2010|2010-06-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery|Phase 2, Randomized Study of AQUAVAN® Injection In Elective Coronary Artery Surgery With Comparison to DISOPRIVAN® Injectable Emulsion|Completed||Phase 2|16|Actual|Eisai Inc.||2|||f||||f||||||||||2018-06-01 04:30:18.339326|2018-06-01 04:30:18.339326
NCT00209508|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-11-06|2005-09-13|2005-09-21|Estimate|||||||2008-11-06|2008-11-07|Estimate|November 2002||2002-11-30|November 2008|2008-11-30|October 2005|Actual|2005-10-31|||||Interventional|||2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.|Completed||Phase 2|200||Eisai Inc.|||||f||||||||||||||2018-06-01 04:30:18.444914|2018-06-01 04:30:18.444914
NCT00209495|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-28|2005-09-13|2005-09-21|Estimate|||||||2008-02-28|2008-02-29|Estimate|June 2005||2005-06-30|February 2008|2008-02-29|February 2008|Actual|2008-02-29|November 2007|Actual|2007-11-30||Interventional|||Effect of Paracetamol,Pregabalin and Dexamethasone on Pain and Opioid Requirements in Postoperative Patients|Effect of Paracetamol Versus Paracetamol Combined With Pregabalin Versus Paracetamol Combined With Pregabalin and Dexamethasone on Pain and Opioid Requirements in Patients Scheduled for Abdominal Hysterectomy.|Completed||Phase 4|130|Actual|Glostrup University Hospital, Copenhagen||3|||f||||t||||||||||2018-06-01 04:30:18.519384|2018-06-01 04:30:18.519384
NCT00209482|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-04|2005-09-13|2005-09-21|Estimate|||||||2006-10-04|2006-10-05|Estimate|October 2003||2003-10-31|November 2005|2005-11-30|November 2007||2007-11-30|||||Interventional|||Glaser Obesity Study|A Multi-Center, Randomized, Placebo Controlled, Double Blind Trial of Metformin in Obese Adolescents.|Unknown status|Active, not recruiting|Phase 2/Phase 3|76||Glaser Pediatric Research Network|||||f||||||||||||||2018-06-01 04:30:18.672842|2018-06-01 04:30:18.672842
NCT00209469|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|February 2007||2007-02-28|||||Interventional|||Network Osteoporosis Study|Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis|Unknown status|Active, not recruiting|Phase 2/Phase 3|90||Glaser Pediatric Research Network|||||||||||||||||||2018-06-01 04:30:18.755466|2018-06-01 04:30:18.755466
NCT00209456|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-15|2005-09-13|2005-09-21|Estimate|||||||2007-05-15|2007-05-16|Estimate|November 2003||2003-11-30|May 2007|2007-05-31||||||||Interventional|||Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title|Completed||Phase 3|326||GE Healthcare|||||f||||||||||||||2018-06-01 04:30:18.928218|2018-06-01 04:30:18.928218
NCT00209443|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-30|2005-09-13|2005-09-21|Estimate|||||||2007-10-30|2007-10-31|Estimate|September 2004||2004-09-30|October 2007|2007-10-31||||||||Interventional|||A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-Iliac Arteries While Using Gadodiamide||Completed||Phase 3|295||GE Healthcare|||||||||||||||||||2018-06-01 04:30:19.010832|2018-06-01 04:30:19.010832
NCT00209430|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-30|2005-09-13|2005-09-21|Estimate|||||||2007-10-30|2007-10-31|Estimate|August 2005||2005-08-31|October 2007|2007-10-31||||||||Interventional|||Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.|Completed||Phase 4|408||GE Healthcare|||||f||||||||||||||2018-06-01 04:30:19.120085|2018-06-01 04:30:19.120085
NCT00209417|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|2014-10-02||2014-10-09|2005-09-13|2005-09-21|Estimate|2014-10-08|2014-10-10|Estimate||||2014-10-09|2014-10-17|Estimate|June 2005||2005-06-30|October 2014|2014-10-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.|Terminated||Phase 4|656|Actual|GE Healthcare||2||"Supported by preliminary interim analysis. Not based on any safety signals in study or any~   quality issues that could affect efficacy of the product."|f||||||||||||||2018-06-01 04:30:19.215802|2018-06-01 04:30:19.215802
NCT00209404|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2007-10-30|2005-09-13|2005-09-21|Estimate|||||||2007-10-30|2007-10-31|Estimate|July 2005||2005-07-31|October 2007|2007-10-31||||||||Interventional|||Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)||Completed||Phase 4|50||GE Healthcare|||||f||||||||||||||2018-06-01 04:30:19.974841|2018-06-01 04:30:19.974841
NCT00209391|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-30|2005-09-13|2005-09-21|Estimate|||||||2007-10-30|2007-10-31|Estimate|September 2003||2003-09-30|October 2007|2007-10-31||||||||Interventional|||A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide|GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title|Completed||Phase 3|270||GE Healthcare|||||||||||||||||||2018-06-01 04:30:20.11433|2018-06-01 04:30:20.11433
NCT00209378|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-04-01|2005-09-13|2005-09-21|Estimate|||||||2013-04-01|2013-04-04|Estimate|May 2005||2005-05-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|CASH-CVVH||Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration|Citrate Versus Heparin Anticoagulation in Continuous Venovenous Hemofiltration in Critically Ill Patients With Acute Renal Failure: A Randomized Clinical Trial|Completed||N/A|139|Actual|Free University Medical Center||2|||f||||f||||||||||2018-06-01 04:30:20.243445|2018-06-01 04:30:20.243445
NCT00209339|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-06-21||2016-10-20|2005-09-13|2005-09-21|Estimate|2016-06-21|2016-08-03|Estimate||||2016-10-20|2016-12-15|Estimate|July 2003||2003-07-31|October 2016|2016-10-31|October 2011|Actual|2011-10-31|February 2006|Actual|2006-02-28||Interventional|EVEREST(I)||Feasibility Study of a Percutaneous Mitral Valve Repair System.|A Study of the Evalve Cardiovascular Valve Repair System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST I).|Completed||Phase 1/Phase 2|55|Actual|Evalve||1|||f||||t||||||||||2018-06-01 04:30:20.847751|2018-06-01 04:30:20.847751
NCT00209326|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-12-15|2005-09-14|2005-09-21|Estimate|||||||2011-12-15|2011-12-16|Estimate|November 2003||2003-11-30|December 2011|2011-12-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor|A Randomised, Double-blind, Parallel Group, Dose-ranging, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 (0.3, 1, 3, 10 mg) and Placebo on Stopping Preterm Labour and Uterine Contractions in Pregnant Women With Advanced Gestational Age|Completed||Phase 2|163|Actual|Ferring Pharmaceuticals|||||f||||||||||||||2018-06-01 04:30:22.706119|2018-06-01 04:30:22.706119
NCT00209313|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-12-14|2005-09-13|2005-09-21|Estimate|||||||2011-12-14|2011-12-16|Estimate|March 2005||2005-03-31|December 2011|2011-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon|A Randomized, Double-blind, Placebo-controlled Crossover Trial of Acyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons in Cameroon|Completed||Phase 2/Phase 3|40|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-06-01 04:30:22.958168|2018-06-01 04:30:22.958168
NCT00209300|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-18|2005-09-19|2005-09-21|Estimate|||||||2011-05-18|2011-05-19|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission|Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission. A European Multi-centre Investigator Blinded Randomized Controlled Study of Pentasa Sachet Comparing One Gram Twice With Two Grams Once Daily|Completed||Phase 3|362|Actual|Ferring Pharmaceuticals|||||f||||t||||||||||2018-06-01 04:30:23.179348|2018-06-01 04:30:23.179348
NCT00209287|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-20|2005-09-19|2005-09-21|Estimate|||||||2012-04-20|2012-04-23|Estimate|June 2005||2005-06-30|April 2012|2012-04-30|September 2007|Actual|2007-09-30|December 2006|Actual|2006-12-31||Interventional|||Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis|Study of Histological Modifications, of Pro-apoptotic Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis (Clinical and Endoscopic Remission) Taking 5-ASA|Terminated||Phase 4|6|Actual|Ferring Pharmaceuticals||||Recruitment problematic|f||||f||||||||||2018-06-01 04:30:23.423214|2018-06-01 04:30:23.423214
NCT00209274|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-12-06|2013-07-31|2018-03-05|2005-09-13|2005-09-21|Estimate|2017-08-02|2017-09-05|Actual|2013-09-17|2013-09-18|Estimate|2018-03-05|2018-04-03|Actual|August 2005||2005-08-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|November 2009|Actual|2009-11-30||Interventional|EVERESTIIRCT||Pivotal Study of a Percutaneous Mitral Valve Repair System|Pivotal Study: A Study of the Evalve Cardiovascular Valve Repair System - Endovascular Valve Edge-to-Edge REpair STudy (EVERESTIIRCT)|Completed||N/A|279|Actual|Evalve||2|||f||||t||||||||||2018-06-01 04:30:23.576243|2018-06-01 04:30:23.576243
NCT00209261|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-18|2005-09-13|2005-09-21|Estimate|||||||2011-05-18|2011-05-19|Estimate|December 2004||2004-12-31|May 2011|2011-05-31|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Interventional|PALAT||A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)|A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate (120 μg and 240 μg) and 2 Different Daily Doses of Minirin® Tablet (0.2 mg and 2 x 0.2 mg) in Children and Adolescents With Primary Nocturnal Enuresis (PNE)|Completed||Phase 4|221|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:30:29.075633|2018-06-01 04:30:29.075633
NCT00209235|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-14|2005-09-13|2005-09-21|Estimate|||||||2017-08-14|2017-08-16|Actual|January 2003||2003-01-31|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments|Natural History Study of Albright Hereditary Osteodystrophy: Includes Substudies on Effects of Growth Hormone in Patients With Pseudohypoparathyroidism Type 1a and Cognitive & Behavioral Studies in Albright Hereditary Osteodystrophy|Recruiting||N/A|600|Anticipated|Connecticut Children's Medical Center||1|||f||||f|f|f||||||||2018-06-01 04:30:29.196604|2018-06-01 04:30:29.196604
NCT00209222|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-07|2005-09-13|2005-09-21|Estimate|||||||2012-09-07|2012-09-10|Estimate|July 2004||2004-07-31|July 2009|2009-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL|Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation|Unknown status|Recruiting|Phase 3|360|Anticipated|European Mantle Cell Lymphoma Network||2|||f||||t||||||||||2018-06-01 04:30:29.34522|2018-06-01 04:30:29.34522
NCT00209209|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-06|2005-09-13|2005-09-21|Estimate|||||||2017-03-06|2017-03-07|Actual|January 14, 2004|Actual|2004-01-14|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MCLelderly||Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL|Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation|Active, not recruiting||Phase 3|570|Anticipated|European Mantle Cell Lymphoma Network||2|||f||||t||||||||No||2018-06-01 04:30:29.540303|2018-06-01 04:30:29.540303
NCT00209196|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-02-10|2005-09-14|2005-09-21|Estimate|||||||2015-02-10|2015-02-11|Estimate|May 2005||2005-05-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|July 2007|Actual|2007-07-31||Observational|||Quality of Life in Pediatric Transplant Recipients|Health Behaviors and Quality of Life in Pediatric Solid Organ Transplant Recipients|Completed|||65|Actual|Emory University|||1||f||||f||||||||||2018-06-01 04:30:29.747158|2018-06-01 04:30:29.747158
NCT00209170|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2015-06-23||2015-07-27|2005-09-14|2005-09-21|Estimate|2015-07-27|2015-07-29|Estimate||||2015-07-27|2015-07-29|Estimate|May 2004||2004-05-31|July 2015|2015-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Depression-Diabetes Mechanisms: Urban African Americans|Depression-Diabetes Mechanisms: Urban African Americans|Completed||Phase 4|20|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:30:29.858091|2018-06-01 04:30:29.858091
NCT00208793|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-22|2005-09-13|2005-09-21|Estimate|||||||2013-11-22|2013-11-26|Estimate|May 2005||2005-05-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|September 2006|Actual|2006-09-30||Interventional|CaDvMAP||Calcium and Vitamin D vs Markers of Adenomatous Polyps|Calcium, Vitamin D, and Colon Cancer Risk Biomarkers|Completed||Phase 2|92|Actual|Emory University||4|||f||||f||||||||||2018-06-01 04:30:36.006879|2018-06-01 04:30:36.006879
NCT00209144|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-06-13|2005-09-14|2005-09-21|Estimate|||||||2014-06-13|2014-06-16|Estimate|October 2004||2004-10-31|June 2014|2014-06-30|December 2006|Actual|2006-12-31|December 2005|Actual|2005-12-31||Interventional|||Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.|Effects of Intense Glycemic Control on Markers of Inflammation and Thrombosis in Patients Treated With Percutaneous Coronary Intervention for Acute Myocardial Infarction.|Completed||Phase 1|58|Actual|Emory University||2|||f||||||||||||||2018-06-01 04:30:30.221668|2018-06-01 04:30:30.221668
NCT00209131|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-06-05||2013-09-23|2005-09-14|2005-09-21|Estimate|2012-06-05|2012-07-09|Estimate||||2013-09-23|2013-10-28|Estimate|April 2005||2005-04-30|September 2013|2013-09-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy|Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy|Terminated||N/A|24|Actual|Emory University|Study was terminated due to turnovers of personnel to assist with recruitment and execution of the study.Recruitment was strained and patients recruited could not be followed up in a timely fashion to adhere to protocol. Thus, no data was generated.|2||Due to frequent turnover of research coordinators and thus poor study accrual.|f||||f||||||||||2018-06-01 04:30:30.339113|2018-06-01 04:30:30.339113
NCT00209118|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-04-07|2005-09-14|2005-09-21|Estimate|||||||2016-04-07|2016-04-11|Estimate||||April 2016|2016-04-30|July 2005||2005-07-31|||||Interventional|||Paroxetine for the Treatment of Interferon Related Side Effects for Hepatitis C|Paroxetine for the Prevention of IFN-Alpha Associated Depression in Patients With Chronic Hepatitis C|Completed||N/A|60||Emory University|||||f||||||||||||||2018-06-01 04:30:30.581239|2018-06-01 04:30:30.581239
NCT00209105|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-11|2005-09-13|2005-09-21|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|March 2011|Actual|2011-03-31|December 2009|Actual|2009-12-31||Observational|||Characterizing Psychological Consequences of Childhood Trauma|Emory Conte Center for the Neuroscience of Mental Disorders: Psychobiology of Childhood Trauma|Completed|||113|Actual|Emory University|||1||f||||t||||||||||2018-06-01 04:30:30.673896|2018-06-01 04:30:30.673896
NCT00209092|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-03-15||2015-03-06|2005-09-14|2005-09-21|Estimate|2012-06-20|2012-06-25|Estimate||||2015-03-06|2015-03-27|Estimate|August 2006||2006-08-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|July 2009|Actual|2009-07-31||Interventional|||Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer|Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer|Completed||Phase 2|51|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:30:30.76135|2018-06-01 04:30:30.76135
NCT00209079|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-12-27|2005-09-14|2005-09-21|Estimate|||||||2007-12-27|2007-12-31|Estimate|September 2004||2004-09-30|September 2007|2007-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma|Phase II Trial of Gleevec (Imatinib Mesylate) and Taxotere (Docetaxel) as a Combined Regimen for Advanced Gastric Adenocarcinoma|Terminated||Phase 2|5|Actual|Emory University||1||Terminated 4/17/07. Drug sponsor withdrew.|f||||t||||||||||2018-06-01 04:30:31.418739|2018-06-01 04:30:31.418739
NCT00209066|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-11-17|2005-09-14|2005-09-21|Estimate|||||||2013-11-17|2013-11-19|Estimate|November 1998||1998-11-30|November 2013|2013-11-30|April 2005||2005-04-30|||||Observational|||Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy|A Means to Enhanced Cardiovascular Outcomes: Reduction of Exaggerated Platelet Activity Through Treatment of Depression.|Completed|||50|Anticipated|Emory University|||||f||||||||||||||2018-06-01 04:30:31.514609|2018-06-01 04:30:31.514609
NCT00209053|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-10-14|2005-09-14|2005-09-21|Estimate|||||||2013-10-14|2013-10-16|Estimate|January 2007||2007-01-31|October 2013|2013-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||SMART Trial Longitudinal Follow-Up:Off-Pump Versus On-Pump Coronary Artery Bypass Surgery|A Prospective, Randomized Comparison of Graft Patency and Clinical Outcomes After Coronary Bypass Surgery Performed With and Without the Use of Cardiopulmonary Bypass:Longitudinal Follow-Up|Completed||N/A|87|Actual|Emory University||2|||f||||||||||||||2018-06-01 04:30:31.672535|2018-06-01 04:30:31.672535
NCT00209040|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-11-27|2005-09-14|2005-09-21|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2001||2001-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Fear Potentiation and Fear Inhibition in Posttraumatic Stress Disorder|Fear Potentiation and Fear Inhibition in Posttraumatic Stress Disorder|Active, not recruiting|||250|Anticipated|Emory University|||3||f||||f||||||||||2018-06-01 04:30:31.802701|2018-06-01 04:30:31.802701
NCT00209027|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-04-13||2013-11-13|2005-09-13|2005-09-21|Estimate|2012-06-15|2012-06-18|Estimate||||2013-11-13|2013-12-06|Estimate|April 2005||2005-04-30|November 2013|2013-11-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Interventional|||The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia|Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia|Terminated||N/A|20|Actual|Emory University|Although the study was planned as a repeated measures study with fMRI testing at baseline and after 3 months, difficulty with recruitment and technical difficulties with obtaining fMRI data relegated the study to a single baseline timepoint.|1||difficulty with technical aspect of fMRI, resources to complete the study ran out|f||||t||||||||||2018-06-01 04:30:31.964537|2018-06-01 04:30:31.964537
NCT00209014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-06|2005-09-13|2005-09-21|Estimate|||||||2009-05-06|2009-05-07|Estimate|July 2003||2003-07-31|May 2009|2009-05-31|June 2006|Actual|2006-06-30|||||Interventional|||Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease|Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease|Terminated||Phase 2|2|Actual|Emory University||||Celgene unable to continue funds.|f||||||||||||||2018-06-01 04:30:32.373431|2018-06-01 04:30:32.373431
NCT00209001|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-07-10|2005-09-13|2005-09-21|Estimate|||||||2015-07-10|2015-07-13|Estimate|July 2003||2003-07-31|July 2015|2015-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer|Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer|Terminated||N/A|7|Actual|Emory University||3||Principal investigator Peter Johnstone, MD relocated to another institution|f||||t||||||||||2018-06-01 04:30:32.482775|2018-06-01 04:30:32.482775
NCT00208988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|May 2003||2003-05-31|September 2005|2005-09-30|August 2003||2003-08-31|||||Interventional|||A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening|A Randomized Controlled Trial to Promote Physician-Patient Discussion of Prostate Cancer Screening|Completed||N/A|250||Emory University|||||f||||||||||||||2018-06-01 04:30:32.554377|2018-06-01 04:30:32.554377
NCT00208780|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-15|2005-09-13|2005-09-21|Estimate|||||||2013-11-15|2013-11-18|Estimate|December 2004||2004-12-31|November 2013|2013-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Effects of Tetrahydrobiopterin on Blood Pressure|Effects of Tetrahydrobiopterin on Blood Pressure|Completed||Early Phase 1|24|Actual|Emory University||2|||f||||f||||||||||2018-06-01 04:30:36.172143|2018-06-01 04:30:36.172143
NCT00208975|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-03-16||2012-05-25|2005-09-13|2005-09-21|Estimate|2012-05-25|2012-06-28|Estimate||||2012-05-25|2012-06-28|Estimate|July 2002||2002-07-31|May 2012|2012-05-31|September 2011|Actual|2011-09-30|December 2009|Actual|2009-12-31||Interventional|||Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab|Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability|Terminated||Phase 2|15|Actual|Emory University|The protocol was closed early due to slow and poor accrual.|1||slow accrual|f||||t||||||||||2018-06-01 04:30:32.641384|2018-06-01 04:30:32.641384
NCT00208962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-08-11|2005-09-13|2005-09-21|Estimate|||||||2014-08-11|2014-08-12|Estimate|September 1998||1998-09-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|September 2007|Actual|2007-09-30||Interventional|||Allogeneic Cell Therapy for Adults With Hematologic Malignancies|Allogeneic Cell Therapy for Adults With Hematologic Malignancies|Completed||Phase 2|32|Actual|Emory University||1|||f||||t||||||||||2018-06-01 04:30:33.967762|2018-06-01 04:30:33.967762
NCT00208949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-03-22||2012-08-17|2005-09-13|2005-09-21|Estimate|2012-08-17|2012-09-14|Estimate||||2012-08-17|2012-09-14|Estimate|September 2002||2002-09-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2010|Actual|2010-05-31||Interventional|||A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSF|A Randomized Comparison of Dendritic Cell Content and T-Cell Phenotype Between G-CSF(Granulocyte Colony-Stimulating Factor)or G-CSF+GM-CSF (Granulocyte Macrophage Colony-Stimulating Factor) for the Mobilization of Normal Allogeneic Peripheral Blood Stem Cell Donors|Terminated||Phase 2|50|Actual|Emory University||2||slow accrual|f||||t||||||||||2018-06-01 04:30:34.165933|2018-06-01 04:30:34.165933
NCT00208936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-09-05|2005-09-13|2005-09-21|Estimate|||||||2014-09-05|2014-09-09|Estimate|January 1996||1996-01-31|September 2014|2014-09-30||||March 2006|Actual|2006-03-31||Interventional|||Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus|Phase II Study of Pre-Operative Chemotherapy With Taxol, Cisplatin, and 5-Fluorouracil Followed by G-CSF in Patients With Resectable Local-Regional Carcinoma of Esophagus|Terminated||Phase 2|20||Emory University|||||f||||||||||||||2018-06-01 04:30:34.508941|2018-06-01 04:30:34.508941
NCT00208923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-05|2005-09-13|2005-09-21|Estimate|||||||2012-04-05|2012-04-06|Estimate|July 1998||1998-07-31|April 2012|2012-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies|Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies Using a Preparative Regimen of Busulfan, Cyclophosphamide, and Fludarabine|Completed||Phase 2|55|Anticipated|Emory University||1|||f||||t||||||||||2018-06-01 04:30:34.621331|2018-06-01 04:30:34.621331
NCT00208910|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-08|2005-09-13|2005-09-21|Estimate|||||||2013-11-08|2013-11-11|Estimate|November 2003||2003-11-30|November 2013|2013-11-30|May 2005||2005-05-31|||||Interventional|||Muscle Relaxation Therapy With Odorant Cue|A Study of Enhancement of Progressive Muscle Relaxation Therapy for Generalized Anxiety Disorder Through Use Of An Odorant Cue.|Completed||N/A|15||Emory University|||||f||||||||||||||2018-06-01 04:30:34.745343|2018-06-01 04:30:34.745343
NCT00208897|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-08|2005-09-13|2005-09-21|Estimate|||||||2013-11-08|2013-11-11|Estimate|December 1997||1997-12-31|November 2013|2013-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?|Does Fluoxetine Reverse the Effects of Early Life Stress on the CNS Corticotropin-Releasing Factor System and Improve Psychological and Neuroendocrine Function?: A Therapy Outcome Study in Women With Childhood Abuse Experiences|Completed||N/A|80|Anticipated|Emory University|||||f||||f||||||||||2018-06-01 04:30:34.945013|2018-06-01 04:30:34.945013
NCT00208884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-25|2005-09-13|2005-09-21|Estimate|||||||2013-11-25|2013-11-27|Estimate|October 2003||2003-10-31|November 2013|2013-11-30|November 2005||2005-11-30|||||Observational|||Terminal Graft Failure|Terminal Graft Failure: A Combined Pathologic and Clinical Study|Terminated|||19||Emory University|||||f||||f||||||||||2018-06-01 04:30:35.151121|2018-06-01 04:30:35.151121
NCT00208871|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-19|2005-09-13|2005-09-21|Estimate|||||||2013-11-19|2013-11-20|Estimate|December 2004||2004-12-31|November 2013|2013-11-30|March 2011|Actual|2011-03-31|December 2007|Actual|2007-12-31||Interventional|||An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall|An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall|Completed||N/A|1467|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:30:35.240019|2018-06-01 04:30:35.240019
NCT00208858|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-06-13|2005-09-13|2005-09-21|Estimate|||||||2014-06-13|2014-06-16|Estimate|December 2004||2004-12-31|June 2014|2014-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Pilot Study of the Neural Correlates of Treatment Effect on Nicotine Craving|Nicotine Craving: Neural Correlates of Treatment Effect - A Pilot Study|Completed||Phase 2|||Emory University|||||f||||||||||||||2018-06-01 04:30:35.391461|2018-06-01 04:30:35.391461
NCT00208845|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-19|2005-09-13|2005-09-21|Estimate|||||||2013-11-19|2013-11-20|Estimate|September 2005||2005-09-30|November 2013|2013-11-30||||||||Observational|||Hypernet- Hypertension Screening|Hypernet- Hypertension ED Surveillance|Terminated|||100|Anticipated|Emory University|||1||f||||f||||||||||2018-06-01 04:30:35.519539|2018-06-01 04:30:35.519539
NCT00208832|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-18|2005-09-13|2005-09-21|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2004||2004-03-31|December 2013|2013-12-31|March 2006||2006-03-31|||||Interventional|||A Randomized Controlled Trial to Improve Medication Compliance Among Patients With Coronary Heart Disease|A Randomized Controlled Trial to Improve Medication Compliance Among Patients With Coronary Heart Disease|Completed||N/A|440||Emory University|||||f||||||||||||||2018-06-01 04:30:35.580136|2018-06-01 04:30:35.580136
NCT00208819|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-12|2005-09-13|2005-09-21|Estimate|||||||2013-11-12|2013-11-13|Estimate|September 2003||2003-09-30|November 2013|2013-11-30|July 2007|Actual|2007-07-31|||||Interventional|||A Comparison of Two Standard Therapies in the Management of Dementia With Agitation|Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies|Completed||Phase 4|50|Anticipated|Emory University|||||f||||||||||||||2018-06-01 04:30:35.722089|2018-06-01 04:30:35.722089
NCT00208806|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-09|2005-09-13|2005-09-21|Estimate|||||||2013-12-09|2013-12-10|Estimate|June 2004||2004-06-30|December 2013|2013-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Resynchronization Therapy in Young Patients With and Without CHD|Clinical Evaluation of Dilated Cardiomyopathy and Cardiac Resynchronization Therapy for Ventricular Dysfunction in Young Patients With and Without Congenital Heart Disease|Completed|||50||Emory University|||1||f||||||||||||||2018-06-01 04:30:35.866423|2018-06-01 04:30:35.866423
NCT00208052|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|July 2005||2005-07-31|||||Observational|||Behavioral Indicators of Pain:Tool Development With Concurrent and Construct Validity||Completed|||10||Cincinnati VA Medical Center|||||f||||||||||||||2018-06-01 04:30:46.265854|2018-06-01 04:30:46.265854
NCT00208767|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-09-12||2015-11-09|2005-09-13|2005-09-21|Estimate|2014-09-12|2014-09-19|Estimate||||2015-11-09|2015-12-08|Estimate|February 2005||2005-02-28|November 2015|2015-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of Valsartan on Carotid Artery Disease|Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT)|Completed||Phase 2|120|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:30:36.473985|2018-06-01 04:30:36.473985
NCT00208754|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-08|2005-09-13|2005-09-21|Estimate|||||||2013-11-08|2013-11-13|Estimate|May 2004||2004-05-31|November 2013|2013-11-30|December 2005||2005-12-31|||||Observational|||Heart Failure in Adult Patients With a History of Congenital Heart Disease|Heart Failure in Adult Patients With a History of Congenital Heart Disease.|Terminated|||350||Emory University|||||f||||||||||||||2018-06-01 04:30:36.884101|2018-06-01 04:30:36.884101
NCT00208741|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-08|2005-09-13|2005-09-21|Estimate|||||||2013-11-08|2013-11-11|Estimate|June 2002||2002-06-30|November 2013|2013-11-30|November 2003||2003-11-30|||||Interventional|||Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder|A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD)|Completed||Phase 4|50||Emory University|||||f||||||||||||||2018-06-01 04:30:37.027853|2018-06-01 04:30:37.027853
NCT00208728|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-25|2005-09-13|2005-09-21|Estimate|||||||2013-11-25|2013-11-27|Estimate|May 2003||2003-05-31|November 2013|2013-11-30|June 2005||2005-06-30|||||Interventional|||Cardiopulmonary Circuits in the Pediatric Population|Prospective Evaluation of Modified Cardiopulmonary Bypass Circuits in the Pediatric Population|Completed||N/A|90||Emory University|||||f||||||||||||||2018-06-01 04:30:37.146355|2018-06-01 04:30:37.146355
NCT00208715|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-08|2005-09-13|2005-09-21|Estimate|||||||2013-11-08|2013-11-11|Estimate|February 2003||2003-02-28|November 2013|2013-11-30|October 2004||2004-10-31|||||Interventional|||Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.|A DOUBLE-BLIND PILOT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PROVIGIL® (MODAFINIL) AT FIXED/FLEXIBLE DOSES, IN CONJUNCTION WITH IDENTIFIED SSRIs FOR THE TREATMENT OF EXCESSIVE SLEEPINESS IN PATIENTS WITH MILD TO MODERATE DEPRESSION WITH ATTENDANT SYMPTOMS OF SLEEPINESS AND FATIGUE|Completed||Phase 4|100||Emory University|||||f||||||||||||||2018-06-01 04:30:37.243999|2018-06-01 04:30:37.243999
NCT00208702|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-11-16|2005-09-13|2005-09-21|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 1996||1996-09-30|November 2015|2015-11-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Thyroid Medication and Antidepressants for Treating Major Depression|Thyroid Axis in Major Depression|Completed||Phase 4|153|Actual|Emory University||2|||f||||f||||||||||2018-06-01 04:30:37.53507|2018-06-01 04:30:37.53507
NCT00208689|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-02-11|2005-09-13|2005-09-21|Estimate|||||||2014-02-11|2014-02-13|Estimate|January 2004||2004-01-31|February 2014|2014-02-28||||May 2006|Actual|2006-05-31||Observational|||Critical Congenital Heart Defect (CHD) Outcomes in Children|A Review of the Diagnosis, Treatment and Outcomes of Children With Critical Congenital Heart Defects|Terminated|||150||Emory University|||||f||||||||||||||2018-06-01 04:30:37.706993|2018-06-01 04:30:37.706993
NCT00208676|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-25|2005-09-13|2005-09-21|Estimate|||||||2013-11-25|2013-11-27|Estimate|September 2005||2005-09-30|November 2013|2013-11-30|January 2006||2006-01-31|||||Observational|||Using Tissue Doppler/Synchronization to Determine Heart Function in Children With Congenital Heart Disease|Non-Invasive Quantitation of Myocardial Dysfunction by Tissue Doppler / Synchronization Imaging in Children With Congenital Heart Defects (CHD)|Terminated|||200||Emory University|||||f||||||||||||||2018-06-01 04:30:37.802124|2018-06-01 04:30:37.802124
NCT00208663|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-10|2005-09-13|2005-09-21|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Validation of an Instrument to Qualitatively and Quantitatively Profile Hospitalist Workflow|Validation of an Instrument to Qualitatively and Quantitatively Profile Hospitalist Workflow|Withdrawn|||0|Actual|Emory University||||Resources|f||||f||||||||||2018-06-01 04:30:37.928482|2018-06-01 04:30:37.928482
NCT00208650|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-25|2005-09-13|2005-09-21|Estimate|||||||2013-11-25|2013-11-27|Estimate|September 2005||2005-09-30|November 2013|2013-11-30|September 2006|Actual|2006-09-30|||||Observational|||Tissue Doppler Echo Imaging of Heart Function After Transplant|Non-Invasive Quantitation of Myocardial Dysfunction by Tissue Doppler/Synchronization Imaging After Orthotopic Heart Transplantation in Children|Completed|||75||Emory University|||||f||||||||||||||2018-06-01 04:30:38.028247|2018-06-01 04:30:38.028247
NCT00208637|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||He Purongo Mo Nga Kai Hei Arai i Te Matehuka – Dietary Diabetes Prevention Study for Maori||Completed||N/A|90||Edgar National Centre for Diabetes Research|||||f||||||||||||||2018-06-01 04:30:38.126847|2018-06-01 04:30:38.126847
NCT00208624|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-01|2005-09-13|2005-09-21|Estimate|||||||2014-05-01|2014-05-05|Estimate|December 2004||2004-12-31|May 2014|2014-05-31|May 2005||2005-05-31|||||Observational|||Rhythm Disturbances After Ventricular Septal Defects|Rhythm Disturbances After Ventricular Septal Defects|Terminated|||30||Emory University|||||f||||||||||||||2018-06-01 04:30:38.241342|2018-06-01 04:30:38.241342
NCT00208611|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-16|2005-09-13|2005-09-21|Estimate|||||||2014-12-16|2014-12-18|Estimate|September 2006||2006-09-30|December 2014|2014-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease|Assessment of Cobalamin Status and Responses to Supplementation in Patients With Parkinson's Disease : a Pilot Study|Terminated||Phase 2/Phase 3|57|Actual|Emory University||1||Funding ended and enrollment not completed within a certain time period|f||||f||||||||||2018-06-01 04:30:38.361397|2018-06-01 04:30:38.361397
NCT00208598|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|December 2005||2005-12-31|||||Observational|||Measures of Obesity and Co-Morbid Conditions in Maori||Completed|||220||Edgar National Centre for Diabetes Research|||||f||||||||||||||2018-06-01 04:30:38.516553|2018-06-01 04:30:38.516553
NCT00208585|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-09|2005-09-20|2005-09-21|Estimate|||||||2007-10-09|2007-10-10|Estimate|February 2000||2000-02-29|October 2007|2007-10-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury|A Randomized Placebo-Controlled Trial of Sertraline for the Neurobehavioral Sequelae of Traumatic Brain Injury|Unknown status|Recruiting|N/A|100|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 04:30:38.662356|2018-06-01 04:30:38.662356
NCT00208572|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-04|2005-09-13|2005-09-21|Estimate|||||||2007-10-04|2007-10-05|Estimate|November 2003||2003-11-30|October 2007|2007-10-31|February 2008|Anticipated|2008-02-29|||||Interventional|||Treatment of Citalopram for Anxiety Disorders Following a Traumatic Brain Injury|A Randomized Placebo-Controlled Trial of Citalopram for Anxiety Disorders Following Traumatic Brain Injury|Unknown status|Recruiting|N/A|104|Anticipated|Walter Reed Army Medical Center|||||f||||||||||||||2018-06-01 04:30:38.794387|2018-06-01 04:30:38.794387
NCT00208559|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-15|2005-09-13|2005-09-21|Estimate|||||||2010-06-15|2010-06-17|Estimate|February 2002||2002-02-28|June 2010|2010-06-30|August 2006|Actual|2006-08-31|June 2005|Actual|2005-06-30||Interventional|||Ziprasidone in Children With Autism: A Pilot Study|Ziprasidone in Children With Autism: A Pilot Study|Completed||Phase 2|15|Actual|Drexel University||1|||f||||t||||||||||2018-06-01 04:30:38.926662|2018-06-01 04:30:38.926662
NCT00208546|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-01|2005-09-13|2005-09-21|Estimate|||||||2012-02-01|2012-02-02|Estimate|June 2005||2005-06-30|February 2012|2012-02-29|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer|Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study|Completed||Phase 3|750|Actual|Dutch Colorectal Cancer Group||2|||f||||t||||||||||2018-06-01 04:30:39.026125|2018-06-01 04:30:39.026125
NCT00208533|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-28|2005-09-13|2005-09-21|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2004||2004-02-29|March 2017|2017-03-31|November 16, 2011|Actual|2011-11-16|November 16, 2011|Actual|2011-11-16||Interventional|||Aripiprazole in Children With Autism: A Pilot Study|Aripiprazole in Children With Autism: A Pilot Study|Completed||Phase 2|11|Actual|Drexel University||1|||f||||t||||||||No|No sharing plan|2018-06-01 04:30:39.152266|2018-06-01 04:30:39.152266
NCT00208520|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-11|2005-09-13|2005-09-21|Estimate|||||||2006-09-11|2006-09-12|Estimate|July 2003||2003-07-31|September 2006|2006-09-30|June 2007||2007-06-30|||||Interventional|||Second-Line Treatment Choice for Epilepsy|Second-Line Treatment Choice for Epilepsy|Unknown status|Active, not recruiting|N/A|60||Dutch Epilepsy Clinics Foundation|||||f||||||||||||||2018-06-01 04:30:39.262239|2018-06-01 04:30:39.262239
NCT00208507|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-01-21||2013-12-18|2005-09-13|2005-09-21|Estimate|2011-01-21|2011-02-16|Estimate||||2013-12-18|2014-01-24|Estimate|April 2003||2003-04-30|December 2013|2013-12-31|December 2010|Actual|2010-12-31|March 2008|Actual|2008-03-31||Interventional|||28 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement Study|Delta Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prosthesis Study (28mm)|Completed||N/A|264|Actual|DePuy Orthopaedics||2|||f||||f||||||||||2018-06-01 04:30:39.397642|2018-06-01 04:30:39.397642
NCT00208494|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-07-11||2013-08-06|2005-09-13|2005-09-21|Estimate|2011-07-11|2011-08-04|Estimate||||2013-08-06|2013-08-14|Estimate|August 2005||2005-08-31|August 2013|2013-08-31|June 2011|Actual|2011-06-30|December 2008|Actual|2008-12-31||Interventional|||Metal on Metal Versus Ceramic on Metal Hip Replacement|Comparative Study to Evaluate the Safety and Efficacy of the DePuy Ceramic-on-metal Total Hip Prosthesis Versus the DePuy Metal-on-metal Total Hip Prosthesis Through Clinical and Radiographical Data|Completed||N/A|392|Actual|DePuy Orthopaedics||2|||f||||f||||||||||2018-06-01 04:30:39.653523|2018-06-01 04:30:39.653523
NCT00208481|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-09-30|2005-09-13|2005-09-21|Estimate|||||||2011-09-30|2011-10-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-06-01 04:30:39.955823|2018-06-01 04:30:39.955823
NCT00208468|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-06|2005-09-13|2005-09-21|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2000||2000-02-29|October 2016|2016-10-31|March 2015|Actual|2015-03-31|June 2005|Actual|2005-06-30||Interventional|||A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement|A Multi-centre, Randomised, Parallel Group, Controlled Study to Compare the Performance of the Future Hip Against Three Currently Used Implants in Total Hip Replacement|Terminated||Phase 3|317|Actual|DePuy International||3||"Slow recruitment, investigators not wishing to continue with randomisation and a decision to~   rationalise this product from the Sponsors portfolio."|f||||f||||||||||2018-06-01 04:30:40.096901|2018-06-01 04:30:40.096901
NCT00208455|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-23|2005-09-13|2005-09-21|Estimate|||||||2017-06-23|2017-06-26|Actual|February 2005||2005-02-28|June 2017|2017-06-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement|An Uncontrolled, Multi-Centre, Prospective, Post Marketing Surveillance Study to Monitor the Long Term Survivorship of the DePuy PROXIMA™ Hip in Subjects Requiring a Total Hip Replacement|Terminated||Phase 4|184|Actual|DePuy International||1||"DePuy discontinued this product in 2013, the clinical program was reviewed and this Study was~   closed."|f||||f||||||||||2018-06-01 04:30:40.22765|2018-06-01 04:30:40.22765
NCT00208442|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-23|2005-09-13|2005-09-21|Estimate|||||||2017-06-23|2017-06-26|Actual|June 1, 2001|Actual|2001-06-01|June 2017|2017-06-30|September 1, 2013|Actual|2013-09-01|September 1, 2006|Actual|2006-09-01||Interventional|||A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement|A Prospective, Randomised, Controlled, Single Centre, Blinded Study of the Wear Characteristics of Two Polyethylene Bearing Surfaces, Enduron vs. Marathon|Completed||Phase 4|122|Actual|DePuy International||2|||f||||f||||||||||2018-06-01 04:30:40.305358|2018-06-01 04:30:40.305358
NCT00208429|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-27|2005-09-13|2005-09-21|Estimate|||||||2017-06-27|2017-06-28|Actual|July 1, 2004|Actual|2004-07-01|June 2017|2017-06-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2009|Anticipated|2009-07-01||Interventional|||A Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle Acetabular Cup System With a Metal on Enduron Polyethylene Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement|Withdrawn||Phase 4|0|Actual|DePuy International||1||"Site Principal Investigator became seriously ill, so study abandoned before the start of~   recruitment"|f||||f||||||||||2018-06-01 04:30:40.398202|2018-06-01 04:30:40.398202
NCT00208416|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-09|2005-09-13|2005-09-21|Estimate|||||||2016-05-09|2016-05-11|Estimate|October 2005||2005-10-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|December 2007|Actual|2007-12-31||Interventional|||A Randomised Multi-centre Study to Compare the Short-term Outcomes of Minimally Invasive and Conventional Surgery in Primary Total Hip Replacement|Randomised, Prospective, Post-Market Surveillance Study Comparing the Outcomes of Minimally Invasive and Conventional Surgical Procedures in Subjects Requiring Primary Total Hip Arthroplasty for Osteoarthritis.|Terminated||Phase 4|58|Actual|DePuy International||2||Combination of departure of Investigator from one site and slow recruitment rate|f||||f||||||||||2018-06-01 04:30:40.487453|2018-06-01 04:30:40.487453
NCT00208403|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-27|2005-09-13|2005-09-21|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2002||2002-10-31|March 2017|2017-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Randomised Single Centre Study to Compare the Long-term Performance of Acryloc™ and Palacos® R Bone Cements in Primary Total Hip Replacement|Randomised, Prospective, RSA, PMS Study Comparing Acryloc™ & Palacos R in Primary Total Hip Arthroplasty|Terminated||Phase 4|36|Actual|DePuy International||2|||f||||f||||||||||2018-06-01 04:30:40.586728|2018-06-01 04:30:40.586728
NCT00208390|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-03|2005-09-13|2005-09-21|Estimate|||||||2016-08-03|2016-08-04|Estimate|February 2003||2003-02-28|July 2016|2016-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement|Prospective, Uncontrolled, Multi-Centre, Post-Marketing Surveillance Study to Evaluate the Long-Term Performance of Summit Tapered Hip in Cementless Total Hip Arthroplasty|Terminated||Phase 4|275|Actual|DePuy International||1||"Study closed after the 5 year end-point was reached after a review of the status further to a~   request from the investigators to discontinue participation."|f||||f||||||||||2018-06-01 04:30:40.657835|2018-06-01 04:30:40.657835
NCT00208377|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-23|2005-09-13|2005-09-21|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2003||2003-07-31|June 2017|2017-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Multi-centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Primary Hip Resurfacing Surgery|Prospective Multi-Centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-Term Performance of the DePuy ASR Hip System in Subjects With Suitable Indications for a Primary Resurfacing Hip Arthroplasty|Terminated||Phase 4|228|Actual|DePuy International||1||"DePuy discontinued this product in 4Q2009. At the time of this decision DePuy reviewed all~   clinical studies for this product and decided to close this Study."|f||||f||||||||||2018-06-01 04:30:40.741725|2018-06-01 04:30:40.741725
NCT00208364|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-06|2005-09-13|2005-09-21|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2004||2004-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|October 2014|Actual|2014-10-31||Interventional|||A Two Centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement|Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle Acetabular Cup Prosthesis With a Metal on Metal Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement|Terminated||Phase 4|163|Actual|DePuy International||1||Study terminated early due to business reasons|f||||f||||||||||2018-06-01 04:30:40.828751|2018-06-01 04:30:40.828751
NCT00208351|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-09|2005-09-13|2005-09-21|Estimate|||||||2016-05-09|2016-05-11|Estimate|May 1997||1997-05-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|November 2004|Actual|2004-11-30||Interventional|||A Randomised Single Centre Study to Compare the Long-term Performance of 4 Designs of the DePuy Ultima LX Stem in Primary Total Hip Replacement|Clinical and Radiographic Evaluation to Compare a Polished and Non-polished Collared Stem and a Polished and Non Polished Collarless Stem in Primary Total Hip Replacement|Terminated||Phase 3|164|Actual|DePuy International||4||"The final assessments were conducted late and in a reduced format due to resource limitations~   at the site."|f||||f||||||||||2018-06-01 04:30:40.924789|2018-06-01 04:30:40.924789
NCT00208338|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-07-01|2005-09-13|2005-09-21|Estimate|||||||2016-07-01|2016-07-04|Estimate|July 2005||2005-07-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|February 2007|Actual|2007-02-28||Interventional|||Pilot Study to Evaluate the Restore Orthobiologic Implant in Rotator Cuff Tear Repair|A Prospective, Randomised Pilot Study to Determine the Variability of Early Clinical Outcome in Subjects Undergoing Full Thickness Rotator Cuff Tear Repair, When Augmented With or Without Porcine Small Intestine Submucosa (RESTORE)|Completed||Phase 4|33|Actual|DePuy International||2|||f||||f||||||||||2018-06-01 04:30:41.032618|2018-06-01 04:30:41.032618
NCT00208325|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2015-06-05||2016-08-01|2005-09-13|2005-09-21|Estimate|2016-06-08|2016-07-20|Estimate||||2016-08-01|2016-09-13|Estimate|May 2000||2000-05-31|August 2016|2016-08-31|September 2010|Actual|2010-09-30|January 2009|Actual|2009-01-31||Interventional||All participants who received treatment and were not mis-randomized.|PFC Sigma Fixed and Mobile Knee Study|Clinical Evaluation of the P.F.C. Sigma (Fixed Bearing) and P.F.C. Sigma RP (Mobile Bearing) Total Knee Systems|Terminated||Phase 4|754|Actual|DePuy International||4||"The study was terminated at the point the primary endpoint and early milestones were reached~   and because long term outcomes were available from other sources"|f||||f||||||||||2018-06-01 04:30:41.23976|2018-06-01 04:30:41.23976
NCT00208312|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-11-24|2005-09-13|2005-09-21|Estimate|||||||2009-11-24|2009-11-26|Estimate|April 2004||2004-04-30|November 2009|2009-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)|A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging|Completed||Phase 3|787|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 04:30:44.225031|2018-06-01 04:30:44.225031
NCT00208299|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-11-24|2005-09-13|2005-09-21|Estimate|||||||2009-11-24|2009-11-26|Estimate|October 2003||2003-10-31|November 2009|2009-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)|A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 Versus Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging|Completed||Phase 3|1231|Actual|Gilead Sciences||2|||f||||f||||||||||2018-06-01 04:30:44.31237|2018-06-01 04:30:44.31237
NCT00208286|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-06-17|2005-09-13|2005-09-21|Estimate|||||||2016-06-17|2016-06-20|Estimate|November 2001||2001-11-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|October 2006|Actual|2006-10-31||Interventional|||P.F.C. Sigma Fixed Versus P.F.C. RP Mobile Bearing Total Knee Systems|Clinical Evaluation of the P.F.C. Sigma (Fixed Bearing) and P.F.C. Sigma Rotating Platform (Mobile Bearing) Total Knee Systems.|Terminated||Phase 4|120|Actual|DePuy International||2||"Primary study outcome achieved; investigator decided to conduct the study without sponsor~   support after 2009."|f||||f||||||||||2018-06-01 04:30:44.457779|2018-06-01 04:30:44.457779
NCT00208273|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-13|2005-09-13|2005-09-21|Estimate|||||||2007-12-13|2007-12-18|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer|A Phase II Randomized Study to Compare Skin Late Toxicities of Concomitant Letrozole-Radiotherapy and Radiotherapy Followed by Letrozole as Adjuvant Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors|Completed||Phase 2|150|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||||||||||||2018-06-01 04:30:44.605827|2018-06-01 04:30:44.605827
NCT00208260|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-15|2005-09-13|2005-09-21|Estimate|||||||2010-06-15|2010-06-16|Estimate|April 2004||2004-04-30|June 2010|2010-06-30|August 2007|Actual|2007-08-31|||||Interventional|||Intensified Chemotherapy in CRC After Resection of Liver Metastases|Randomized Phase II Trial Followed by Phase III Trial With Molecular Biology Study, Comparing a Standard Bi-therapy vs 3 Arms of Intensified Chemotherapy in Patients With Unresectable or Not Optimally Resectable Colorectal Cancer Liver Metastases.|Completed||Phase 2/Phase 3|124|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||5|||f||||||||||||||2018-06-01 04:30:44.71716|2018-06-01 04:30:44.71716
NCT00207441|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-23|2005-09-13|2005-09-21|Estimate|||||||2011-03-23|2011-03-24|Estimate|April 2003||2003-04-30|March 2011|2011-03-31|August 2006|Actual|2006-08-31|October 2004|Actual|2004-10-31||Interventional|||Comparing ASHC and CDSMP Outcomes In Arthritis|Comparing ASHC and CDSMP Outcomes In Arthritis|Completed||N/A|416|Actual|Centers for Disease Control and Prevention||2|||f||||||||||||||2018-06-01 04:30:53.15247|2018-06-01 04:30:53.15247
NCT00208247|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-10|2005-09-13|2005-09-21|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2001||2001-12-31|August 2016|2016-08-31|March 2005|Actual|2005-03-31|January 2003|Actual|2003-01-31||Interventional|||KATHY:Cognitive-behavioural Therapy for Hypochondriasis|Cognitive-behavioural Therapy Versus Short-term Psychodynamic Psychotherapy: a Randomised Clinical Trial|Completed||Phase 2|80|Actual|Copenhagen Trial Unit, Center for Clinical Intervention Research||3|||f||||||||||||||2018-06-01 04:30:44.824384|2018-06-01 04:30:44.824384
NCT00208234|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-09-22|2005-09-14|2005-09-21|Estimate|||||||2011-09-22|2011-09-23|Estimate|January 2004||2004-01-31|September 2011|2011-09-30|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Effect of Xolair on Airway Hyperresponsiveness|The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness|Unknown status|Active, not recruiting|Phase 4|22|Anticipated|Creighton University||2|||f||||f||||||||||2018-06-01 04:30:44.908656|2018-06-01 04:30:44.908656
NCT00208221|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-07|2005-09-13|2005-09-21|Estimate|||||||2007-11-07|2007-11-08|Estimate|August 2006||2006-08-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes|Comparison of a Higher Dose of Ramipril to the Addition of Telmisartan 80 mg+Ramipril 10 mg in Patients With Hypertension and Diabetes|Terminated||Phase 3|50|Anticipated|Institut de Recherches Cliniques de Montreal||||Not enough recruitment|f||||f||||||||||2018-06-01 04:30:44.985688|2018-06-01 04:30:44.985688
NCT00208208|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-09-14|2005-09-14|2005-09-21|Estimate|||||||2006-09-14|2006-09-15|Estimate|December 2002||2002-12-31|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||Geodon (Ziprasidone) for Posttraumatic Stress Disorder|Geodon (Ziprasidone) for Posttraumatic Stress Disorder|Completed||Phase 4|80||Creighton University|||||f||||||||||||||2018-06-01 04:30:45.103337|2018-06-01 04:30:45.103337
NCT00208195|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-12-12|2005-09-14|2005-09-21|Estimate|||||||2007-12-12|2007-12-14|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Depakote ER Therapy for Mania Comorbid With Substance Abuse|Depakote ER Therapy for Mania Comorbid With Substance Abuse|Completed||Phase 4|20|Actual|Creighton University|||||f||||f||||||||||2018-06-01 04:30:45.206936|2018-06-01 04:30:45.206936
NCT00208182|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-03-08|2005-09-13|2005-09-21|Estimate|||||||2006-03-08|2006-03-10|Estimate|July 2001||2001-07-31|March 2006|2006-03-31|August 2004||2004-08-31|||||Interventional|||Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma|Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial|Completed||Phase 4|20||Creighton University|||||||||||||||||||2018-06-01 04:30:45.295311|2018-06-01 04:30:45.295311
NCT00208169|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-22|2005-09-13|2005-09-21|Estimate|||||||2007-08-22|2007-08-24|Estimate|March 2005||2005-03-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Abilify Therapy for Reducing Comorbid Substance Abuse|Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse|Completed||Phase 4|30|Actual|Creighton University||1|||f||||f||||||||||2018-06-01 04:30:45.388912|2018-06-01 04:30:45.388912
NCT00208156|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-14|2005-09-13|2005-09-21|Estimate|||||||2012-02-14|2012-02-15|Estimate|May 2005||2005-05-31|February 2012|2012-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression|An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features|Completed||Phase 3|87|Actual|Corcept Therapeutics||1|||f||||f||||||||||2018-06-01 04:30:45.455931|2018-06-01 04:30:45.455931
NCT00208143|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-11|2005-09-13|2005-09-21|Estimate|||||||2007-12-11|2007-12-13|Estimate|November 2003||2003-11-30|October 2006|2006-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia|Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone|Completed||Phase 4|20||Creighton University|||||f||||f||||||||||2018-06-01 04:30:45.603828|2018-06-01 04:30:45.603828
NCT00208130|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-28|2005-09-13|2005-09-21|Estimate|||||||2009-04-28|2009-04-29|Estimate|October 2001||2001-10-31|April 2009|2009-04-30|March 2004||2004-03-31|||||Interventional|||Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians|Completed||Phase 4|60||Creighton University|||||f||||f||||||||||2018-06-01 04:30:45.677768|2018-06-01 04:30:45.677768
NCT00208117|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-05-30|2005-09-15|2005-09-21|Estimate|||||||2012-05-30|2012-05-31|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|CHIME||A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease|A Randomized Controlled Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease|Terminated||Phase 1|7|Actual|New York State Psychiatric Institute||2||Unable to enroll subjects|f||||f||||||||||2018-06-01 04:30:45.743312|2018-06-01 04:30:45.743312
NCT00208104|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-02-15|2005-09-14|2005-09-21|Estimate|||||||2013-02-15|2013-02-18|Estimate|July 2002||2002-07-31|February 2013|2013-02-28|September 2008|Actual|2008-09-30|May 2006|Actual|2006-05-31||Interventional|||Motivational Interviewing|Motivational Interviewing in Hypertensive African Americans|Terminated||N/A|167|Actual|Columbia University||2||PI left institution|f||||f||||||||||2018-06-01 04:30:45.813466|2018-06-01 04:30:45.813466
NCT00208091|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-08-22||2014-04-11|2005-09-13|2005-09-21|Estimate|2014-04-11|2014-05-09|Estimate||||2014-04-11|2014-05-09|Estimate|April 2003||2003-04-30|April 2014|2014-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia|An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®).|Completed||Phase 4|16|Actual|Columbia University||1|||f||||f||||||||||2018-06-01 04:30:45.920141|2018-06-01 04:30:45.920141
NCT00208078|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-02-12|2005-09-13|2005-09-21|Estimate|||||||2013-02-12|2013-02-13|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.|Evaluation of the Effects of Long Term Non-Invasive Ventilation in Patient With Cystic Fibrosis and Chronic Hypercapnic Respiratory Failure.|Terminated||Phase 4|36|Actual|Cochin Hospital, India||2||Not enough patient recruited|f||||t||||||||||2018-06-01 04:30:46.127386|2018-06-01 04:30:46.127386
NCT00208065|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-05|2005-09-13|2005-09-21|Estimate|||||||2009-05-05|2009-05-06|Estimate|May 2004||2004-05-31|May 2009|2009-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers|"Evaluation of Histamine, CGRP and VIP as Biological Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers in Response to Sinus Symptoms"|Completed||Phase 4|50||Clinvest|||||f||||||||||||||2018-06-01 04:30:46.203292|2018-06-01 04:30:46.203292
NCT00208039|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-19|2005-09-13|2005-09-21|Estimate|||||||2007-11-19|2007-11-22|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates|Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates Less Than or Equal to 1250 gm Birthweight Ver 4.0|Completed||N/A|89|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 04:30:46.317607|2018-06-01 04:30:46.317607
NCT00208026|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-03-09||2017-10-20|2005-09-13|2005-09-21|Estimate|2014-12-06|2014-12-12|Estimate||||2017-10-20|2017-11-24|Actual|September 2005||2005-09-30|October 2017|2017-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome|Exploratory Safety and Systemic Absorption of Elidel (Pimecrolimus) 1% Cream for the Treatment of Netherton Syndrome|Completed||Phase 1/Phase 2|3|Actual|Children's Hospital of Philadelphia|There were no early termination for any of the subjects.|1|||f||||t||||||||||2018-06-01 04:30:46.384806|2018-06-01 04:30:46.384806
NCT00208013|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-26|2005-09-20|2005-09-21|Estimate|||||||2010-11-26|2010-11-29|Estimate|July 2005||2005-07-31|July 2005|2005-07-31||||||||Observational|||The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients|The Survey About Resting Metabolic Rate and Its Related Factors in Terminal Patients|Completed|||100|Anticipated|China Medical University Hospital|||||f||||t||||||||||2018-06-01 04:30:46.785541|2018-06-01 04:30:46.785541
NCT00208000|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2010-11-26|2005-09-16|2005-09-21|Estimate|||||||2010-11-26|2010-11-29|Estimate|July 2004||2004-07-31|September 2005|2005-09-30|April 2006|Anticipated|2006-04-30|||||Interventional|||A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.||Unknown status|Recruiting|Phase 2|||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:30:46.872971|2018-06-01 04:30:46.872971
NCT00207987|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-20|2005-09-13|2005-09-21|Estimate|||||||2007-11-20|2007-11-21|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Observational|||Changes in Cerebral Oxygenation During Deliberate Hypotensive Anesthesia||Unknown status|Recruiting||40|Anticipated|China Medical University Hospital|||||f||||||||||||||2018-06-01 04:30:47.000774|2018-06-01 04:30:47.000774
NCT00207974|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-11-16|2005-09-16|2005-09-21|Estimate|||||||2005-11-16|2005-11-17|Estimate||||September 2005|2005-09-30||||||||Interventional|||Pharmacokinetic Study of Marine Active in Health Men||Unknown status|Active, not recruiting|Phase 1|||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:30:47.061018|2018-06-01 04:30:47.061018
NCT00207961|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-08|2005-09-13|2005-09-21|Estimate|||||||2005-12-08|2005-12-09|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|October 2004||2004-10-31|||||Observational|||The Threshold Value of Regional Cerebral Oxygenation in Detecting Cerebral Ischemia||Completed|||||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:30:47.116181|2018-06-01 04:30:47.116181
NCT00207948|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-08-03|2005-09-20|2005-09-21|Estimate|||||||2015-08-03|2015-08-05|Estimate|November 2004||2004-11-30|August 2015|2015-08-31|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Observational|||Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents|Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents|Terminated|||4|Actual|Children's Research Institute|||1|no measurable response was detected at the 50% increase threshold.|f||||t||||||||||2018-06-01 04:30:47.163229|2018-06-01 04:30:47.163229
NCT00207935|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-05-01|2005-09-14|2005-09-21|Estimate|||||||2008-05-01|2008-05-05|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|March 2007||2007-03-31|||||Interventional|||Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population|Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population|Completed||Phase 4|20|Anticipated|Children's Research Institute|||||f||||||||||||||2018-06-01 04:30:47.280098|2018-06-01 04:30:47.280098
NCT00207922|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|December 2003||2003-12-31|December 2003|2003-12-31||||||||Observational|||The Polarization and Expression of Chemokine Receptors of T Help Cell in the Pathogenesis of Acute and Chronic GVHD||Unknown status|Active, not recruiting||||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:30:47.344097|2018-06-01 04:30:47.344097
NCT00207909|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-06-13|2005-09-13|2005-09-21|Estimate|||||||2016-06-13|2016-06-14|Estimate|February 2005||2005-02-28|June 2016|2016-06-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Study of Patients With Acute Renal Failure on CVVH|The Role of Hemodynamics, Cytokine Response, and Modulators of Apoptosis on Urine Output in Patients With Acute Renal Failure on CVVH|Completed|||39|Actual|Children's Healthcare of Atlanta|||||f||||t||||||||||2018-06-01 04:30:47.460136|2018-06-01 04:30:47.460136
NCT00207896|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-11-25|2005-09-13|2005-09-21|Estimate|||||||2014-11-25|2014-12-02|Estimate|August 2004||2004-08-31|November 2014|2014-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Neuroendocrine Dysfunction in Critically Ill Pediatric Patients|Defining the Prevalence of Acute Neuroendocrine Dysfunction and Correlating the Dysfunction With Outcomes in Critically Ill Pediatric Patients: A Pilot Study|Completed|||73|Actual|Children's Healthcare of Atlanta|||||f||||||||||||||2018-06-01 04:30:47.522799|2018-06-01 04:30:47.522799
NCT00207883|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-06-01||2017-03-22|2005-09-13|2005-09-21|Estimate|2017-02-02|2017-03-23|Actual||||2017-03-22|2017-04-18|Actual|January 2005||2005-01-31|March 2017|2017-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational||Two hundred twelve CVC placements were performed and evaluated: 93 during the LM phase and 119 in the US phase.|Ultrasound Guided Vascular Access in Pediatric Intensive Care Patients|Ultrasound Guided Vascular Access: A Prospective Comparison Study|Completed|||212|Actual|Children's Healthcare of Atlanta|Small sample size. Personnel were aware they were being timed which can bias study.||2||f||||f||||||||No||2018-06-01 04:30:47.596667|2018-06-01 04:30:47.596667
NCT00207870|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-07-21|2005-09-13|2005-09-21|Estimate|||||||2014-07-21|2014-07-22|Estimate|October 2006||2006-10-31|July 2011|2011-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Type II Supracondylar Fractures in Children|Comparison of Crossed Pin Versus Lateral-Entry Pin Fixation for Type II Supracondylar Fractures in Children: A Prospective, Randomized Trial|Withdrawn|||0|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||||2018-06-01 04:30:47.814651|2018-06-01 04:30:47.814651
NCT00207857|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-02-02|2005-09-13|2005-09-21|Estimate|||||||2015-02-02|2015-02-04|Estimate|March 2004||2004-03-31|February 2015|2015-02-28|August 2005|Anticipated|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Test-Retest Reliability of Pulmonary Function Tests in Patients With Duchenne's Muscular Dystrophy|Test-Retest Reliability of Pulmonary Function Tests in Patients With Duchenne's Muscular Dystrophy|Withdrawn|||0|Actual|Children's Healthcare of Atlanta|||1||f||||||||||||||2018-06-01 04:30:47.883679|2018-06-01 04:30:47.883679
NCT00207844|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Selenium, as Sodium Selenite, in the Treatment of Septic Shock|Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of a Therapeutic Administration of Selenium, as Selenite, in Septic Shock Patients.|Completed||Phase 2|60||Centre Hospitalier de Meaux|||||f||||||||||||||2018-06-01 04:30:48.005361|2018-06-01 04:30:48.005361
NCT00207831|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-07-20|2005-09-13|2005-09-21|Estimate|||||||2010-07-20|2010-07-21|Estimate|July 2004||2004-07-31|July 2010|2010-07-31|February 2008|Actual|2008-02-29|June 2007|Actual|2007-06-30||Interventional|UFT RT Phase 3||Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma|Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma|Terminated||Phase 3|219|Anticipated|ICO Paul Papin||2||Terminated after interim analysis|f||||t||||||||||2018-06-01 04:30:48.15648|2018-06-01 04:30:48.15648
NCT00207818|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-02-10|2005-09-13|2005-09-21|Estimate|||||||2014-02-10|2014-02-11|Estimate|September 1999||1999-09-30|February 2014|2014-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatment of Cutaneous Ulcers With a Novel Biological Dressing|Treatment of Cutaneous Ulcers With a Novel Biological Dressing|Completed||Phase 1/Phase 2|6|Actual|CHU de Quebec-Universite Laval|||||f||||f||||||||||2018-06-01 04:30:48.269336|2018-06-01 04:30:48.269336
NCT00207805|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-26|2005-09-13|2005-09-21|Estimate|||||||2009-01-26|2009-01-27|Estimate|May 2003||2003-05-31|January 2009|2009-01-31||||||||Interventional|||The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma||Completed||Phase 3|202||Centre National de Greffe de Moelle Osseuse|||||f||||||||||||||2018-06-01 04:30:48.359309|2018-06-01 04:30:48.359309
NCT00207792|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-05|2005-09-13|2005-09-21|Estimate|||||||2007-11-05|2007-11-06|Estimate|July 2005||2005-07-31|September 2007|2007-09-30||||||||Interventional|||Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation|Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation|Unknown status|Recruiting|Phase 3|160|Anticipated|Centre National de Greffe de Moelle Osseuse|||||f||||||||||||||2018-06-01 04:30:48.41105|2018-06-01 04:30:48.41105
NCT00207779|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-19|2005-09-13|2005-09-21|Estimate|||||||2007-09-19|2007-09-20|Estimate|May 2005||2005-05-31|September 2007|2007-09-30|August 2005||2005-08-31|||||Interventional|||Prevention of Catheter-Related Bloodstream Infection in Patients With Haemato-Oncological Disease||Completed||Phase 3|||Centre National de Greffe de Moelle Osseuse|||||f||||||||||||||2018-06-01 04:30:48.466411|2018-06-01 04:30:48.466411
NCT00207766|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-26|2005-09-13|2005-09-21|Estimate|||||||2010-04-26|2010-04-27|Estimate|June 2000||2000-06-30|January 2009|2009-01-31|August 2006|Actual|2006-08-31|||||Interventional|||A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease|ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease|Completed||Phase 3|306|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:30:48.521458|2018-06-01 04:30:48.521458
NCT00207753|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-11-16|2005-09-13|2005-09-21|Estimate|||||||2005-11-16|2005-11-17|Estimate|February 2005||2005-02-28|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections|Efficacy and Nutritional Assessment Following Albendazole and Combined Albendazole/Ivermectin Treatment for Intestinal Helminth Infections in Rural Guatemalan Schoolchildren|Completed||N/A|550||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:48.568608|2018-06-01 04:30:48.568608
NCT00207740|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-05-21||2012-08-14|2005-09-13|2005-09-21|Estimate|2012-05-01|2012-06-01|Estimate||||2012-08-14|2012-08-20|Estimate|August 2004||2004-08-31|August 2012|2012-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma|Completed||Phase 2|309|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|2|||f||||t||||||||||2018-06-01 04:30:48.678242|2018-06-01 04:30:48.678242
NCT00207727|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-10-25||2012-04-20|2005-09-13|2005-09-21|Estimate|2009-10-25|2009-12-02|Estimate||||2012-04-20|2012-04-23|Estimate|July 2004||2004-07-31|April 2012|2012-04-30|August 2006|Actual|2006-08-31|March 2006|Actual|2006-03-31||Interventional|||A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis|A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|249|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.||||||||||||||||||2018-06-01 04:30:49.965136|2018-06-01 04:30:49.965136
NCT00207714|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-05-21||2012-10-16|2005-09-13|2005-09-21|Estimate|2012-06-28|2012-08-07|Estimate||||2012-10-16|2012-10-18|Estimate|November 2003||2003-11-30|October 2012|2012-10-31|February 2006|Actual|2006-02-28|February 2005|Actual|2005-02-28||Interventional|||An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis|A Randomized, Double-blind, Dose-ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate|Completed||Phase 2|172|Actual|Centocor, Inc.|The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in <= 5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.|3|||||||f||||||||||2018-06-01 04:30:50.675175|2018-06-01 04:30:50.675175
NCT00207701|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-16|2005-09-13|2005-09-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|September 2002||2002-09-30|August 2010|2010-08-31|February 2005|Actual|2005-02-28|||||Interventional|||A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.|A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy|Completed||Phase 3|279|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:30:51.3889|2018-06-01 04:30:51.3889
NCT00207688|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-14|2005-09-13|2005-09-21|Estimate|||||||2016-03-14|2016-03-15|Estimate|August 2004||2004-08-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients|A Multicenter International Study of the Long-term Safety of Infliximab (REMICADE) in Ulcerative Colitis|Completed|||505|Actual|Janssen Research & Development, LLC|||3||f||||f||||||||||2018-06-01 04:30:51.449243|2018-06-01 04:30:51.449243
NCT00207675|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-16|2005-09-13|2005-09-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|February 2003||2003-02-28|March 2010|2010-03-31|August 2007|Actual|2007-08-31|||||Interventional|||A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease|A Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF a Chimeric Monoclonal Antibody (Infliximab, REMICADE) in Pediatric Subjects With Moderate to Severe CROHN'S Disease.|Completed||Phase 3|112|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:30:51.762488|2018-06-01 04:30:51.762488
NCT00207662|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-26|2005-09-13|2005-09-21|Estimate|||||||2010-04-26|2010-04-27|Estimate|July 2000||2000-07-31|April 2010|2010-04-30|November 2005|Actual|2005-11-30|||||Interventional|||A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease|ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease|Completed||Phase 3|580|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:30:51.819378|2018-06-01 04:30:51.819378
NCT00207649|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-03-23|2005-09-14|2005-09-21|Estimate|||||||2011-03-23|2011-03-24|Estimate|November 2005||2005-11-30|March 2011|2011-03-31|February 2011|Anticipated|2011-02-28|March 2010|Actual|2010-03-31||Interventional|||Shared Decision Making: Prostate Cancer Screening|Shared Decision Making: Prostate Cancer Screening|Unknown status|Active, not recruiting|N/A|641|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:30:51.874416|2018-06-01 04:30:51.874416
NCT00207636|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2005-09-15|2005-09-15|2005-09-21|Estimate|||||||2005-09-15|2005-09-21|Estimate|December 2004||2004-12-31|September 2005|2005-09-30|September 2007||2007-09-30|||||Interventional|||Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening|Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Harvard - SIP 21-04|Unknown status|Recruiting|Phase 3|1120||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:51.998722|2018-06-01 04:30:51.998722
NCT00207623|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|July 2003||2003-07-31|||||Interventional|||Evaluation of the Arthritis Basics for Change (ABCs) Self Management Program|Evaluation of the Arthritis Basics for Change (ABCs) Self Management Program|Completed||N/A|300||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:52.144574|2018-06-01 04:30:52.144574
NCT00207610|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2009-01-30|2005-09-16|2005-09-21|Estimate|||||||2009-01-30|2009-02-03|Estimate|June 2003||2003-06-30|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Iron Supplementation Among Low-Income Postpartum Women|Phase 3 Study of the Prevention of Postpartum Anemia by Three Different Strategies|Completed||Phase 3|959|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:30:52.194354|2018-06-01 04:30:52.194354
NCT00207597|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|September 1995||1995-09-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Observational|||Joint Outcome Study|A Clinical Trial of Primary Prophylaxis Against Joint Disease in Children With Severe Hemophilia|Completed|||64||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:52.248895|2018-06-01 04:30:52.248895
NCT00207584|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 1994||1994-01-31|September 2005|2005-09-30|April 1994||1994-04-30|||||Interventional|||Randomized Controlled Trial of Doxycycline to Prevent Acquisition of Mycoplasma Pneumoniae in an Outbreak Setting|A Double-Blind, Randomized Placebo-Controlled Trial of Doxycycline for Chemoprophylaxis in the Setting of an Outbreak of Mycoplasma Pneumoniae|Completed||N/A|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:52.28651|2018-06-01 04:30:52.28651
NCT00207571|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-26|2005-09-13|2005-09-21|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2001||2001-04-30|September 2012|2012-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Partner Notification Intervention for STD Clinics.|Computer-assisted STD Partner Notification|Completed||Phase 1/Phase 2|150||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:30:52.330352|2018-06-01 04:30:52.330352
NCT00207558|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-07-12|2005-09-13|2005-09-21|Estimate|||||||2006-07-12|2006-07-13|Estimate||||September 2005|2005-09-30||||||||Interventional|||Blood Folate and Homocysteine Levels Following Administration of Folic Acid According to Different Daily Dosing Schedules:a Simulation of Food Fortification|Blood Folate and Homocysteine Levels Following Administration of Folic Acid According to Different Daily Dosing Schedules:a Simulation of Food Fortification|Completed||N/A|1100||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:52.393624|2018-06-01 04:30:52.393624
NCT00207532|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Dosage Effects of Folic Acid on Blood Folates of Honduran Women|Dosage Effects of Folic Acid on Blood Folates of Honduran Women|Completed||N/A|100||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:52.4492|2018-06-01 04:30:52.4492
NCT00207519|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-10|2005-09-13|2005-09-21|Estimate|||||||2009-02-10|2009-02-11|Estimate|April 2003||2003-04-30|February 2009|2009-02-28|January 2009|Actual|2009-01-31|August 2004|Actual|2004-08-31||Interventional|||Liquid Meal Replacements in Conjunction With Lifestyle Intervention in Overweight Adolescents|The Use of Liquid Meal Replacements in Conjunction With Lifestyle Intervention in Overweight Adolescents: A 12 Week Safety and Efficacy Study|Completed||Phase 1|40||Boston Medical Center|||||f||||f||||||||||2018-06-01 04:30:52.516682|2018-06-01 04:30:52.516682
NCT00207506|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-10|2005-09-13|2005-09-21|Estimate|||||||2012-09-10|2012-09-11|Estimate|October 2004||2004-10-31|September 2012|2012-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Lay Health Advisors for Sexually Transmitted Disease Prevention|HoMBReS: A Lay Health Advisor Approach to Sexually Transmitted Disease Prevention|Completed||Phase 1/Phase 2|354|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:30:52.598341|2018-06-01 04:30:52.598341
NCT00207493|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-26|2005-09-13|2005-09-21|Estimate|||||||2012-09-26|2012-09-27|Estimate|October 2000||2000-10-31|September 2012|2012-09-30|September 2007|Actual|2007-09-30|September 2005|Actual|2005-09-30||Interventional|||The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services.|The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services.|Completed||Phase 1/Phase 2|494||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:30:52.664834|2018-06-01 04:30:52.664834
NCT00207480|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|October 2004||2004-10-31|September 2005|2005-09-30||||||||Interventional|||Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women|Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women|Suspended||Phase 1|270||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:52.724807|2018-06-01 04:30:52.724807
NCT00207467|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|December 2001||2001-12-31|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Study to Improve Partner Services for STD Prevention|Prospective Study for Cost-Effectiveness Strategies to Improve Partner Notification: Female Trichomonas and Male Urethritis Studies|Completed||Phase 2|1500||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:53.016482|2018-06-01 04:30:53.016482
NCT00207454|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|June 2001||2001-06-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Optimizing Strategies to Improve STD Partner Services|Optimizing Strategies to Improve STD Partner Services|Completed||Phase 1|800||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:53.091217|2018-06-01 04:30:53.091217
NCT00207428|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-05-15|2005-09-13|2005-09-21|Estimate|||||||2006-05-15|2006-05-16|Estimate|August 1999||1999-08-31|July 1999|1999-07-31|April 2000||2000-04-30|||||Interventional|||Antiepileptic Drug Carbamazepine in Treatment of Bronchial Asthma|Randomized, Placebo Controlled, Double Blind Study of Carbamazepine in Treatment of Bronchial Asthma|Completed||Phase 4|65||Centre of Chinese Medicine, Georgia|||||f||||||||||||||2018-06-01 04:30:53.244808|2018-06-01 04:30:53.244808
NCT00207415|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||A Comparison of the ASHC and CDSMP|A Comparison of the ASHC and CDSMP|Completed||N/A|300||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:30:53.301202|2018-06-01 04:30:53.301202
NCT00207402|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-13|2005-09-13|2005-09-21|Estimate|||||||2012-02-13|2012-02-14|Estimate|October 2005||2005-10-31|February 2012|2012-02-29|July 2010|Actual|2010-07-31|January 2010|Actual|2010-01-31||Interventional|||Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin|A Pilot Trial of Combination Therapy With Interferon Alfacon1, Ribavirin, & Rosiglitazone in a Group of Insulin Resistant, Chronic Hepatitis C, GT 1 Patients Who Are Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin|Completed||Phase 4|34|Actual|Brooke Army Medical Center||2|||f||||f||||||||||2018-06-01 04:30:53.366491|2018-06-01 04:30:53.366491
NCT00207389|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-25|2005-09-13|2005-09-21|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2004||2004-03-31|January 2017|2017-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients|A Pilot Study to Examine the Relationship Between Changes in Plasma GIP Levels and Other Gastrointestinal Peptides Following Gastric Bypass Surgery in Obese Patients|Terminated|||5|Actual|Boston Medical Center|||2|Insufficient funding|f||||f|f|f||||||||2018-06-01 04:30:53.441677|2018-06-01 04:30:53.441677
NCT00207376|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-23|2005-09-13|2005-09-21|Estimate|||||||2009-06-23|2009-06-24|Estimate||||February 2007|2007-02-28||||||||Interventional|||Safety and Effectiveness Study of the Solysafe Septal Occluder in Patients With Atrial Septum Defect and Patent Foramen Ovale|Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device in Patients With Atrial Septum Defect (ASD) and Patent Foramen Ovale (PFO)|Completed||N/A|||Carag AG|||||f||||||||||||||2018-06-01 04:30:53.572295|2018-06-01 04:30:53.572295
NCT00207363|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-02-13|2005-09-14|2005-09-21|Estimate|||||||2012-02-13|2012-02-14|Estimate|February 2002||2002-02-28|February 2012|2012-02-29|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC|Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With Chronic Hepatitis C|Completed||Phase 4|610|Actual|Brooke Army Medical Center||2|||f||||f||||||||||2018-06-01 04:30:53.626017|2018-06-01 04:30:53.626017
NCT00207350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-17|2005-09-12|2005-09-21|Estimate|||||||2017-02-17|2017-02-23|Actual|January 2002||2002-01-31|February 2017|2017-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|ILT||Neurosurgical Use of Interstitial Laser Therapy (ILT)|Neurosurgical Use of Interstitial Laser Therapy (ILT)|Completed||N/A|6|Actual|Brigham and Women's Hospital||1|||f||||t||||||||Undecided||2018-06-01 04:30:53.705442|2018-06-01 04:30:53.705442
NCT00207337|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-21|2005-09-12|2005-09-21|Estimate|||||||2008-01-21|2008-01-23|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Exhale (R) Stent for Emphysema|A Prospective Feasibility Study to Evaluate the Safety and Performance of the Exhale(R) Drug-Eluting Stent System in Patients With Emphysema|Completed||Phase 2/Phase 3|60||Broncus Technologies|||||f||||||||||||||2018-06-01 04:30:53.7851|2018-06-01 04:30:53.7851
NCT00207324|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2007-06-26|2005-09-15|2005-09-21|Estimate|||||||2007-06-26|2007-06-27|Estimate|January 2004||2004-01-31|June 2007|2007-06-30|January 2007|Actual|2007-01-31|||||Interventional|||The Use of Silver Leaf Dressing in the Prevention of Radiotherapy Induced Skin Reactions|A Phase III Study of the Efficacy of Silver Leaf Nylon Dressing in the Prevention of Severe Skin Reactions in the Inframammary Skin Fold of Patients Receiving Adjuvant Whole Breast Radiotherapy|Completed||Phase 3|100||British Columbia Cancer Agency|||||f||||f||||||||||2018-06-01 04:30:53.861189|2018-06-01 04:30:53.861189
NCT00207311|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-13|2005-09-13|2005-09-21|Estimate|||||||2012-02-13|2012-02-14|Estimate|August 2005||2005-08-31|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|HCVNASH||Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus|A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus|Completed||Phase 4|30|Actual|Brooke Army Medical Center||2|||f||||f||||||||||2018-06-01 04:30:53.927962|2018-06-01 04:30:53.927962
NCT00207298|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-03|2005-09-13|2005-09-21|Estimate|||||||2010-11-03|2010-11-05|Estimate|June 2005||2005-06-30|November 2010|2010-11-30|November 2008||2008-11-30|||||Interventional|||18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology|Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology|Unknown status|Recruiting|Phase 3|5000|Anticipated|British Columbia Cancer Agency|||||f||||||||||||||2018-06-01 04:30:54.029502|2018-06-01 04:30:54.029502
NCT00207285|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-15|2005-09-20|2005-09-21|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Sleep Disorders Management, Health and Safety in Police|Sleep Disorders Management, Health and Safety in Police|Completed||N/A|731|Actual|Brigham and Women's Hospital||3|||f||||||||||||||2018-06-01 04:30:54.101377|2018-06-01 04:30:54.101377
NCT00207272|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-22|2005-09-13|2005-09-21|Estimate|||||||2008-05-22|2008-05-26|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Use of MCT Oil for Enhancement of Weight Loss in Obese Patients|Use of MCT Oil for Enhancement of Weight Loss in Obese Patients-Preliminary Phase 2002-291G|Completed||N/A|24|Anticipated|Boston Medical Center|||||f||||||||||||||2018-06-01 04:30:54.1825|2018-06-01 04:30:54.1825
NCT00207259|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-07-11|2005-09-13|2005-09-21|Estimate|||||||2017-07-11|2017-07-13|Actual|March 2005||2005-03-31|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Study of Complementary Therapies in Men Receiving Radiation Therapy for Prostate Cancer: A Feasibility Trial|Study of Complementary Therapies in Men Receiving Radiation Therapy for Prostate Cancer: A Feasibility Trial|Completed||N/A|60|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-06-01 04:30:54.280401|2018-06-01 04:30:54.280401
NCT00207233|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-01-24|2005-09-14|2005-09-21|Estimate|||||||2011-01-24|2011-01-25|Estimate|July 2004||2004-07-31|February 2009|2009-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients|Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients 2002-292G|Completed||Phase 1/Phase 2|42|Anticipated|Boston Medical Center||2|||f||||f||||||||||2018-06-01 04:30:54.387792|2018-06-01 04:30:54.387792
NCT00207220|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-07|2005-09-13|2005-09-21|Estimate|||||||2007-11-07|2007-11-09|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|January 2007|Actual|2007-01-31|||||Observational|||Ventricular-Vascular Coupling in Heart Failure|Ventricular-Vascular Coupling in Patients With Heart Failure and Preserved Ejection Fraction|Completed|||53|Actual|Brigham and Women's Hospital|||1||f||||f||||||||||2018-06-01 04:30:54.637381|2018-06-01 04:30:54.637381
NCT00207207|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-10|2005-09-13|2005-09-21|Estimate|||||||2009-02-10|2009-02-11|Estimate|July 2003||2003-07-31|February 2009|2009-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Self Monitoring of Blood Glucose With Finger Tip vs. Alternate Site Sampling: Effect on Long Term Glycemic Control|Randomized Trial to Assess the Effect of Using Alternate Site Blood Glucose Testing Versus Finger-Tip Testing on Long-Term Glycemic Control.|Completed||Phase 1|174||Boston Medical Center|||||f||||f||||||||||2018-06-01 04:30:54.695401|2018-06-01 04:30:54.695401
NCT00207194|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-06-15|2005-09-12|2005-09-21|Estimate|||||||2016-06-15|2016-06-16|Estimate|October 2001||2001-10-31|June 2016|2016-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Interactive Multirisk-Factor Intervention for Hypertension (HTN) Blacks|Interactive Multirisk-Factor Intervention for HTN Blacks|Completed||N/A|337|Actual|Boston Medical Center||2|||f||||t||||||||||2018-06-01 04:30:54.774007|2018-06-01 04:30:54.774007
NCT00207181|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-06-30|2005-09-12|2005-09-21|Estimate|||||||2011-06-30|2011-07-01|Estimate|May 2005||2005-05-31|June 2011|2011-06-30|January 2007|Actual|2007-01-31|||||Observational|||The Development and Testing of an Electronic Tool to Measure Physical Activity in Domestic Settings|Context Sensitive Measurement of Physical Activity|Completed|||40|Actual|Boston Medical Center|||||f||||f||||||||||2018-06-01 04:30:54.830528|2018-06-01 04:30:54.830528
NCT00207168|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2010-02-03|2011-04-08|2005-09-19|2005-09-21|Estimate||||2010-02-03|2010-02-05|Estimate|2011-04-08|2011-04-22|Estimate|April 2004||2004-04-30|April 2011|2011-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine|A Randomized, Multi-center, Open Label Study in Well Controlled Treatment-experienced HIV- Infected Patients to Assess Compliance With a Once-daily Regimen|Completed||Phase 4|120||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:30:54.875587|2018-06-01 04:30:54.875587
NCT00207155|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-26|2005-09-12|2005-09-21|Estimate|||||||2015-10-26|2015-10-28|Estimate|December 2003||2003-12-31|October 2015|2015-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer|An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer|Completed||Phase 1|110||Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:30:54.9177|2018-06-01 04:30:54.9177
NCT00207142|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2009-06-02||2010-01-07|2005-09-20|2005-09-21|Estimate|2009-12-03|2010-01-07|Estimate||||2010-01-07|2010-01-12|Estimate|November 2005||2005-11-30|January 2010|2010-01-31|January 2008|Actual|2008-01-31|August 2007|Actual|2007-08-31||Interventional|INDUMA||Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)|A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase With Unboosted vs. Boosted Reyataz After an Induction Phase With Reyataz and Ritonavir in Treatment Naive HIV Patients (the INDUMA Study)|Completed||Phase 4|252|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 04:30:55.201553|2018-06-01 04:30:55.201553
NCT00207129|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-01-27|2005-09-12|2005-09-21|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2004||2004-10-31|January 2017|2017-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies|Effect of Capecitabine on the Pharmacokinetics of BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies|Completed||Phase 1|25||R-Pharm||2|||f||||||||||||||2018-06-01 04:30:56.161599|2018-06-01 04:30:56.161599
NCT00207116|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-26|2005-09-12|2005-09-21|Estimate|||||||2015-10-26|2015-10-28|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma|An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma|Completed||Phase 1|120||Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:30:56.268824|2018-06-01 04:30:56.268824
NCT00207103|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-11-03|2005-09-12|2005-09-21|Estimate|||||||2008-11-03|2008-11-04|Estimate|September 2004||2004-09-30|November 2008|2008-11-30|September 2008|Actual|2008-09-30|October 2007|Actual|2007-10-31||Interventional|||MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors|Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|68|Actual|Bristol-Myers Squibb||6|||f||||f||||||||||2018-06-01 04:30:56.385286|2018-06-01 04:30:56.385286
NCT00207090|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-09-03||2016-02-09|2005-09-12|2005-09-21|Estimate|2010-09-03|2010-10-01|Estimate||||2016-02-09|2016-03-10|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer|Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer|Completed||Phase 1|19|Actual|R-Pharm||1|||f||||f||||||||||2018-06-01 04:30:56.535317|2018-06-01 04:30:56.535317
NCT00207077|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-26|2005-09-12|2005-09-21|Estimate|||||||2015-10-26|2015-10-28|Estimate|August 2005||2005-08-31|October 2015|2015-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors|A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies|Completed||Phase 1|33|Anticipated|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:30:57.067826|2018-06-01 04:30:57.067826
NCT00207064|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-09-16|2005-09-20|2005-09-21|Estimate|||||||2011-09-16|2011-09-19|Estimate|April 2004||2004-04-30|September 2011|2011-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia|5-HT2A-receptor Binding: Implications for the Pathophysiology of Schizophrenia and Effects of Treatment With Antipsychotic Drugs|Completed||N/A|46|Actual|University of Copenhagen||1|||f||||f||||||||||2018-06-01 04:30:57.128921|2018-06-01 04:30:57.128921
NCT00207051|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-01-24|2005-09-20|2005-09-21|Estimate|||||||2011-01-24|2011-01-25|Estimate|January 2006||2006-01-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies|Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy|Completed||Phase 1|62|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:30:57.199903|2018-06-01 04:30:57.199903
NCT00207038|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-02-10|2005-09-14|2005-09-21|Estimate|||||||2009-02-10|2009-02-11|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|||||Observational|||Airway Inflammation in Swimmers|Airway Inflammation in Swimmers: Development and Risk Factors|Completed|||90|Anticipated|Bispebjerg Hospital|||||f||||||||||Samples Without DNA|"~     Blood samples EBC Sputum~   "|||2018-06-01 04:30:57.268033|2018-06-01 04:30:57.268033
NCT00207025|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2010-02-27|2010-02-27|2005-09-20|2005-09-21|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|October 2004||2004-10-31|July 2008|2008-07-31||||February 2007|Actual|2007-02-28||Interventional|||A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies|A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies|Terminated||Phase 1|60||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:30:57.313031|2018-06-01 04:30:57.313031
NCT00207012|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2010-02-27|2010-02-27|2005-09-20|2005-09-21|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|May 2004||2004-05-31|January 2009|2009-01-31||||February 2006|Actual|2006-02-28||Interventional|||MAD Refractory: Solid Tumor QD w/o Break|Continuous Dosing Phase I Study of BMS-599626 in Patients With HER2-Expressing Advanced Solid Malignancies|Completed||Phase 1|45||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:30:57.360971|2018-06-01 04:30:57.360971
NCT00206999|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-09-19|2005-09-13|2005-09-21|Estimate|||||||2011-09-19|2011-09-20|Estimate|September 2004||2004-09-30|September 2011|2011-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||The Effect of Imipramine on Early Information Processing|Early Information Processing in Healthy Controls: Studies on the Relation Between Two Different Paradigms (PPI and P50ERP) and Effects of Pharmacological Interventions|Completed||N/A|20|Actual|University of Copenhagen||1|||f||||f||||||||||2018-06-01 04:30:57.430058|2018-06-01 04:30:57.430058
NCT00206986|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-19|2005-09-20|2005-09-21|Estimate|||||||2013-12-19|2013-12-20|Estimate|May 2005||2005-05-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?|Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?|Completed||N/A|40|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-06-01 04:30:57.492327|2018-06-01 04:30:57.492327
NCT00206973|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Bronchial Response to Mannitol and Inflammation in Steroid Naive Asthmatics.|Bronchial Response to Mannitol and Inflammation in Steroid Naive Asthmatics|Unknown status|Recruiting||40||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:30:57.693791|2018-06-01 04:30:57.693791
NCT00206960|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-09-16|2005-09-13|2005-09-21|Estimate|||||||2011-09-16|2011-09-19|Estimate|January 1998||1998-01-31|September 2011|2011-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia|Effects of Classical and Atypical Antipsychotics on Dopamine Receptor Binding of 123I-epidepride, Cognition, Startle Response and Extrapyramidal Side-effects in Drug-naive First-episode Schizophrenic Patients|Completed||N/A|56|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 04:30:57.759253|2018-06-01 04:30:57.759253
NCT00206947|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-09-19|2005-09-20|2005-09-21|Estimate|||||||2011-09-19|2011-09-20|Estimate|December 2002||2002-12-31|July 2008|2008-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia|PHARMACOLOGICAL TREATMENT OF COGNITIVE DEFICITS IN SCHIZOPHRENIC PATIENTS: The Effects of Central Cholinergic Augmentation on Cognitive Deficits and Psychopathology|Terminated||Phase 2|50|Anticipated|University of Copenhagen||2||No more funding|f||||f||||||||||2018-06-01 04:30:57.845573|2018-06-01 04:30:57.845573
NCT00206934|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-09-16|2005-09-13|2005-09-21|Estimate|||||||2011-09-16|2011-09-19|Estimate|March 2005||2005-03-31|July 2008|2008-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||The Effects of Increased Central Serotonergic Activity on Information Processing|The Effects of Increased Central Serotonergic Activity on Psychophysiological Parameters of Human Information Processing|Completed||N/A|40|Actual|University of Copenhagen||2|||f||||f||||||||||2018-06-01 04:30:57.928019|2018-06-01 04:30:57.928019
NCT00206921|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-23|2005-09-13|2005-09-21|Estimate|||||||2007-07-23|2007-07-25|Estimate|February 2005||2005-02-28|December 2004|2004-12-31|August 2005||2005-08-31|||||Interventional|||Pulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin Redness|Pulsed Dye Laser and Intense Pulsed Light for the Treatment of Telangiectasia and Skin Redness|Unknown status|Recruiting|N/A|||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:30:58.005235|2018-06-01 04:30:58.005235
NCT00206908|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-07-20|2005-09-13|2005-09-21|Estimate|||||||2015-07-20|2015-07-22|Estimate|July 2002||2002-07-31|July 2015|2015-07-31||||||||Observational|||BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)|BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)|Completed|||900||Biosite|||||f||||||||||||||2018-06-01 04:30:58.102578|2018-06-01 04:30:58.102578
NCT00206895|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-10|2005-09-12|2005-09-21|Estimate|||||||2006-10-10|2006-10-11|Estimate|November 2004||2004-11-30|October 2004|2004-10-31||||||||Interventional|||Photodynamic Therapy of Acne Vulgaris - a Randomized Blinded Controlled Study||Completed||N/A|24||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:30:58.262298|2018-06-01 04:30:58.262298
NCT00206882|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-10|2005-09-12|2005-09-21|Estimate|||||||2006-10-10|2006-10-11|Estimate|September 2005||2005-09-30|August 2005|2005-08-31||||||||Interventional|||The Sun Protection Effect and Efficacy in Treatment of Sunburn Using Topical Corticosteroids.||Unknown status|Recruiting|N/A|20||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:30:58.34915|2018-06-01 04:30:58.34915
NCT00206869|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-10|2005-09-12|2005-09-21|Estimate|||||||2006-10-10|2006-10-11|Estimate|January 2003||2003-01-31|December 2002|2002-12-31||||||||Interventional|||Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria||Unknown status|Recruiting|N/A|||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:30:58.418318|2018-06-01 04:30:58.418318
NCT00206856|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-26|2005-09-13|2005-09-21|Estimate|||||||2013-07-26|2013-07-29|Estimate|July 2003||2003-07-31|July 2013|2013-07-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)|Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)|Terminated||Phase 4|720||Biosite||||Slow enrollment|f||||f||||||||||2018-06-01 04:30:58.506948|2018-06-01 04:30:58.506948
NCT00206843|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-07-23|2005-09-13|2005-09-21|Estimate|||||||2015-07-23|2015-07-27|Estimate|November 2004||2004-11-30|July 2015|2015-07-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT II)|Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT II)|Completed||N/A|630|Actual|Biosite||2|||f||||f||||||||||2018-06-01 04:30:58.613977|2018-06-01 04:30:58.613977
NCT00206830|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-07-23|2005-09-13|2005-09-21|Estimate|||||||2015-07-23|2015-07-27|Estimate|April 2005||2005-04-30|July 2015|2015-07-31|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Interventional|||SHORTness of Breath In the Emergency Department (SHORTIE)|SHORTness of Breath In the Emergency Department (SHORTIE)|Completed||Phase 2/Phase 3|306||Biosite||2|||f||||||||||||||2018-06-01 04:30:58.703904|2018-06-01 04:30:58.703904
NCT00206817|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-07-20|2005-09-13|2005-09-21|Estimate|||||||2015-07-20|2015-07-21|Estimate|October 2003||2003-10-31|July 2015|2015-07-31||||||||Interventional|||Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)|Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)|Withdrawn||Phase 4|0|Actual|Biosite|||||f||||||||||||||2018-06-01 04:30:58.773253|2018-06-01 04:30:58.773253
NCT00206791|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-25|2005-09-12|2005-09-21|Estimate|||||||2006-10-25|2006-10-26|Estimate|May 2006||2006-05-31|October 2006|2006-10-31|May 2008||2008-05-31|||||Interventional|||Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects|Study of Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects From Various Origins|Unknown status|Recruiting|N/A|12||Biomatlante|||||f||||||||||||||2018-06-01 04:30:58.853483|2018-06-01 04:30:58.853483
NCT00206778|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2010-11-24|2005-09-16|2005-09-21|Estimate|||||||2010-11-24|2010-11-25|Estimate|July 2003||2003-07-31|November 2010|2010-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania|A Randomized Open-Label 6 Month Acute and Maintenance Trial of Lamotrigine vs. Standard of Care Sodium Valproate Monotherapy for Treatment of Mixed Mania.|Completed||Phase 2|36|Anticipated|Beth Israel Medical Center|||||f||||||||||||||2018-06-01 04:30:58.926735|2018-06-01 04:30:58.926735
NCT00206765|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-19|2005-09-13|2005-09-21|Estimate|||||||2012-10-19|2012-10-22|Estimate|January 2003||2003-01-31|October 2012|2012-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Risperidone vs. Paroxetine for Panic Attacks|A Single-blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks|Terminated||Phase 2|90|Anticipated|Beth Israel Medical Center|||||f||||||||||||||2018-06-01 04:30:58.99281|2018-06-01 04:30:58.99281
NCT00206752|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-27|2005-09-13|2005-09-21|Estimate|||||||2015-03-27|2015-03-30|Estimate|August 2004||2004-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Unilateral||Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck|A Randomized Prospective Evaluation of Unilateral/Ipsilateral Neck Irradiation in Selected Patients With Squamous Cell Carcinoma of the Head and Neck Who Are Managed by Radiation Therapy|Completed||N/A|45|Actual|Beth Israel Medical Center||1|||f||||||||||||||2018-06-01 04:30:59.050262|2018-06-01 04:30:59.050262
NCT00206739|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-29|2005-09-13|2005-09-21|Estimate|||||||2010-03-29|2010-03-30|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants|Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial|Completed||Phase 4|1070|Actual|Bernhard Nocht Institute for Tropical Medicine|||||f||||t||||||||||2018-06-01 04:30:59.115676|2018-06-01 04:30:59.115676
NCT00206726|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|2009-11-19||2016-07-27|2005-09-19|2005-09-21|Estimate|2010-12-08|2011-01-13|Estimate||||2016-07-27|2016-08-29|Estimate|May 2005||2005-05-31|July 2016|2016-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|ECO-1||Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)|Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)|Completed||Phase 2|60|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:30:59.233456|2018-06-01 04:30:59.233456
NCT00206713|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-02|2005-09-13|2005-09-21|Estimate|||||||2013-12-02|2013-12-04|Estimate|July 2004||2004-07-31|December 2013|2013-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim|Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Retreatment Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease and Prior Treatment Response to Sargramostim|Terminated||Phase 3|264|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:30:59.810295|2018-06-01 04:30:59.810295
NCT00206700|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-02|2005-09-14|2005-09-21|Estimate|||||||2013-12-02|2013-12-04|Estimate|February 2003||2003-02-28|December 2013|2013-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Open-label Trial of Leukine in Active Crohn's Disease|Open-label Trial of Leukine® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease|Terminated||Phase 2|378|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:30:59.89638|2018-06-01 04:30:59.89638
NCT00206687|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13||2015-09-23|2015-09-23|2005-09-13|2005-09-21|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|January 2003||2003-01-31|November 2014|2014-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||STEPS Trial - Spheramine Safety and Efficacy Study|Study of the Safety, Tolerability and Efficacy of Spheramine Implanted Bilaterally Into the Postcommissural Putamen of Patients With Advanced Parkinson's Disease|Terminated||Phase 2|71|Actual|Bayer||2||Study was completed, only life long extended follow-up phase was discontinued after 12 years.|f||||t||||||||||2018-06-01 04:31:00.361337|2018-06-01 04:31:00.361337
NCT00206674|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-02|2005-09-13|2005-09-21|Estimate|||||||2013-12-02|2013-12-04|Estimate|September 2004||2004-09-30|December 2013|2013-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease|Phase 3 Randomized, Double-Blind, Placebo Controlled Induction Study of Sargramostim (Leukine®) in Patients With Active Crohn's Disease|Completed||Phase 3|286|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:31:00.566722|2018-06-01 04:31:00.566722
NCT00206661|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-02|2005-09-12|2005-09-21|Estimate|||||||2013-12-02|2013-12-04|Estimate|December 2004||2004-12-31|December 2013|2013-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease|Phase 1/2 Safety, Pharmacokinetic, and Pharmacodynamic Study of Sargramostim (Leukine®) in Pediatric Patients With Active Crohn's Disease, With One-year Surveillance and Retreatment Extension|Terminated||Phase 1/Phase 2|22|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:31:00.800235|2018-06-01 04:31:00.800235
NCT00206648|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-30|2005-09-13|2005-09-21|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2003||2003-03-31|December 2014|2014-12-31|October 2005|Actual|2005-10-31|||||Interventional|ABOVE||An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS|A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex|Completed||Phase 4|271|Actual|Bayer||2|||f||||t||||||||||2018-06-01 04:31:00.937869|2018-06-01 04:31:00.937869
NCT00206635|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-11-21|2005-09-13|2005-09-21|Estimate|||||||2012-11-21|2012-11-22|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|December 2005|Actual|2005-12-31|||||Observational|||Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis|A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron® (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis|Completed|||432|Actual|Bayer|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-06-01 04:31:01.094805|2018-06-01 04:31:01.094805
NCT00206622|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-28|2005-09-12|2005-09-21|Estimate|||||||2009-05-28|2009-05-29|Estimate|December 2004||2004-12-31|May 2009|2009-05-31|February 2006|Actual|2006-02-28|||||Interventional|||Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Comparing a 2.2mg 17 Beta-Estradiol/0.69mg Levonorgestrel Combination Transdermal Patch, and a 1mg 17 Beta-Estradiol Transdermal Patch With a Placebo Patch in Postmenopausal Women to Determine the Lowest Effective Dose of Estradiol for the Relief of Moderate to Severe Hot Flushes|Completed||Phase 4|425|Actual|Bayer||3|||f||||||||||||||2018-06-01 04:31:01.228429|2018-06-01 04:31:01.228429
NCT00206609|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2005-09-18|2005-09-18|2005-09-21|Estimate|||||||2005-09-18|2005-09-21|Estimate|November 2000||2000-11-30|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||The Role of Oxygen in the Management of Dyspnoea in Advanced Cancer|A Randomised, Double-Blind Cross-Over Trial of the Effect of Oxygen on Dyspnoea in Patients With Advanced Cancer|Completed||Phase 3|50||Bayside Health|||||f||||||||||||||2018-06-01 04:31:01.379152|2018-06-01 04:31:01.379152
NCT00206596|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-02|2005-09-12|2005-09-21|Estimate|||||||2013-12-02|2013-12-04|Estimate|July 2003||2003-07-31|December 2013|2013-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease|Randomized, Stratified, Double-Blind, Placebo-Controlled Phase 2 Study of Steroid-Sparing Properties of Sargramostim (Leukine) Therapy in Patients With Cortico-Dependent Crohn's Disease|Completed||Phase 2|127|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:31:01.440605|2018-06-01 04:31:01.440605
NCT00206583|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-09-30|2005-09-12|2005-09-21|Estimate|||||||2014-09-30|2014-10-01|Estimate|March 2005||2005-03-31|September 2014|2014-09-30|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety Study of an Oral Contraceptive in Healthy Females|A Multicenter, Open-label Uncontrolled Study to Investigate the Efficacy and Safety of a 4-phasic Oral Contraceptive SH T0065 in a 28-day Regimen for 13 Cycles in Healthy Female Subjects|Completed||Phase 3|499|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:31:01.515642|2018-06-01 04:31:01.515642
NCT00206570|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-02-02|2005-09-13|2005-09-21|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2001||2001-01-31|February 2015|2015-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Clinical Estradiol Trial in Women With Schizophrenia|Double Blind Study of Estradiol Plus Neuroleptic Versus Placebo Plus Neuroleptic in the Treatment of Psychotic Symptoms in Women With Schizophrenia|Completed||Phase 2|100|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:31:01.606217|2018-06-01 04:31:01.606217
NCT00206557|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-20|2005-09-13|2005-09-21|Estimate|||||||2007-04-20|2007-04-23|Estimate|October 2002||2002-10-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study|The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study|Completed||Phase 2|60||The Alfred|||||f||||||||||||||2018-06-01 04:31:01.685821|2018-06-01 04:31:01.685821
NCT00206544|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-23|2005-09-13|2005-09-21|Estimate|||||||2008-10-23|2008-10-24|Estimate|January 2004||2004-01-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?|Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?|Completed||Phase 2|51|Actual|The Alfred||3|||f||||||||||||||2018-06-01 04:31:01.753387|2018-06-01 04:31:01.753387
NCT00206531|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-03|2005-09-13|2005-09-21|Estimate|||||||2006-10-03|2006-10-04|Estimate||||June 2005|2005-06-30||||||||Observational|||The Role of Naive T-Cells in HIV Pathogenesis|Role of Naive T-Cells in the Pathogenesis of T-Cell Decline and Long Term Persistence of HIV|Unknown status|Recruiting||75||Bayside Health|||||f||||||||||||||2018-06-01 04:31:01.824761|2018-06-01 04:31:01.824761
NCT00206518|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2017-02-02||2017-05-08|2005-09-14|2005-09-21|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|September 2004||2004-09-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|October 2016|Actual|2016-10-31||Interventional|TACAC||Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients|A Randomized Multicenter Trial of Neoadjuvant Taxotere (T) and Adriamycin/Cytoxan (Ac): A Validation|Active, not recruiting||Phase 2|167|Actual|Baylor Breast Care Center||2|||f||||t||||||||No||2018-06-01 04:31:01.885264|2018-06-01 04:31:01.885264
NCT00206505|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-11-16|2005-09-14|2005-09-21|Estimate|||||||2011-11-16|2011-11-17|Estimate|January 1999||1999-01-31|November 2011|2011-11-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Neoadjuvant Taxotere|A PHASE II STUDY OF THE CLINICAL AND BIOLOGIC EFFECTS OF DOCETAXEL (TAXOTERE) IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER|Completed||Phase 2|40||Baylor Breast Care Center|||||f||||f||||||||||2018-06-01 04:31:02.285466|2018-06-01 04:31:02.285466
NCT00206492|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-07-28|2005-09-14|2005-09-21|Estimate|||||||2017-07-28|2017-08-01|Actual|July 2003||2003-07-31|July 2017|2017-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients|A Neoadjuvant Phase II Trial of ZD1839 (Iressa) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study (AZ #1839US/0303)|Terminated||Phase 2|3|Actual|Baylor Breast Care Center||1||halted by the PI only 3 of 45 subjects were accrued.|f||||f||||||||||2018-06-01 04:31:02.380247|2018-06-01 04:31:02.380247
NCT00206466|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-24|2005-09-14|2005-09-21|Estimate|||||||2012-01-24|2012-01-25|Estimate|April 2002||2002-04-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|April 2006|Actual|2006-04-30||Interventional|TAX/AC||Biologic Correlative Taxotere/AC|A Randomized Multicenter Trial of Neoadjuvant Taxotere and Adriamycin/Cytoxan(AC): A Biologic Correlative Study|Completed||Phase 2|70|Actual|Baylor Breast Care Center||1|||f||||||||||||||2018-06-01 04:31:02.463388|2018-06-01 04:31:02.463388
NCT00206453|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-02-04|2005-09-14|2005-09-21|Estimate|||||||2013-02-04|2013-02-05|Estimate|January 2002||2002-01-31|February 2013|2013-02-28|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer|An Extension Phase II Study of the Clinical and Biologic Effects of Docetaxel (Taxotere) in Patients With Locally Advanced Breast Cancer|Terminated||Phase 2|25|Actual|Baylor Breast Care Center||||accrual too difficult to meet|f||||||||||||||2018-06-01 04:31:02.543347|2018-06-01 04:31:02.543347
NCT00206440|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-02-01||2012-04-27|2005-09-13|2005-09-21|Estimate|2012-02-03|2012-03-07|Estimate||||2012-04-27|2012-05-02|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|February 2009|Actual|2009-02-28||Interventional|NEXIUM||Nexium Study To Suppress Nausea During Chemotherapy|Evaluation of the Efficacy of Esomeprazole in Suppressing Nausea and Vomiting in Patients Undergoing Chemotherapy for Breast Cancer|Terminated||Phase 3|43|Actual|Baylor Breast Care Center||2||Accrual was not optimized|f||||t||||||||||2018-06-01 04:31:02.619435|2018-06-01 04:31:02.619435
NCT00206427|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-02-03||2013-07-26|2005-09-14|2005-09-21|Estimate|2012-02-03|2012-03-07|Estimate||||2013-07-26|2013-07-31|Estimate|August 2004||2004-08-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|GW||Neoadjuvant GW572016 to Treat Breast Cancer|A Neoadjuvant Phase II Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients: Biologic Correlative Study|Completed||Phase 2|49|Actual|Baylor Breast Care Center||1|||f||||t||||||||||2018-06-01 04:31:02.880414|2018-06-01 04:31:02.880414
NCT00206414|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-04|2005-09-12|2005-09-21|Estimate|||||||2013-02-04|2013-02-05|Estimate|January 2003||2003-01-31|February 2013|2013-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer|Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|Terminated||Phase 2|15|Actual|Baylor Breast Care Center||2||Difficulty accruing subjects the study accrual was closed|f||||t||||||||||2018-06-01 04:31:03.055017|2018-06-01 04:31:03.055017
NCT00206401|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-07-12|2005-09-13|2005-09-21|Estimate|||||||2016-07-12|2016-07-14|Estimate|November 2004||2004-11-30|July 2016|2016-07-31|October 2006||2006-10-31|||||Interventional|||Lantus in the Treatment of Type 1 Diabetes Children|Conventional Insulin Therapy Vs Intensive Insulin Management In Children With Type 1 Diabetes Mellitus|Completed||Phase 4|60||Baylor College of Medicine|||||f||||||||||||||2018-06-01 04:31:03.125205|2018-06-01 04:31:03.125205
NCT00206388|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-08-01|2005-09-14|2005-09-21|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2005||2005-04-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|April 2008|Actual|2008-04-30||Interventional|||Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement|A Phase I Study of Zoledronic Acid (Zometa) With Cyclophosphamide in Children With Recurrent or Refractory Neuroblastoma and Cortical Bone Involvement (NANT 2004-01)|Completed||Phase 1|21|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 04:31:03.210938|2018-06-01 04:31:03.210938
NCT00206375|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-18|2005-09-13|2005-09-21|Estimate|||||||2015-09-18|2015-09-22|Estimate|May 2003||2003-05-31|September 2015|2015-09-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism|Concomitant Use of Growth Hormone and GnRH Agonist in Adolescent Patients With Acquired Hypothyroidism|Completed||Phase 4|21|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-06-01 04:31:03.285472|2018-06-01 04:31:03.285472
NCT00206362|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-07-19|2005-09-14|2005-09-21|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2004||2004-07-31|July 2016|2016-07-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Observational|||Ability to Cope With Type 1 Diabetes|Evaluation of Ongoing Management of Type 1 Diabetes|Completed|||100|Actual|Baylor College of Medicine|||||f||||f||||||||No||2018-06-01 04:31:03.357973|2018-06-01 04:31:03.357973
NCT00206349|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-07-12|2005-09-14|2005-09-21|Estimate|||||||2016-07-12|2016-07-14|Estimate|June 2004||2004-06-30|July 2016|2016-07-31|May 2005||2005-05-31|||||Observational|||Ability to Cope With Type 1 Diabetes|Evaluation of Coping Skills in Type 1 Diabetes|Completed|||220||Baylor College of Medicine|||||f||||||||||||||2018-06-01 04:31:04.339227|2018-06-01 04:31:04.339227
NCT00206336|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-02-17||2017-10-05|2005-09-13|2005-09-21|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|October 2004||2004-10-31|October 2017|2017-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.|An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286)|Completed||Phase 3|20|Actual|Baylor College of Medicine|Because of the small sample size and open label design we decided not to pursue publication of the extension study.|1|||f||||f||||||||||2018-06-01 04:31:04.404188|2018-06-01 04:31:04.404188
NCT00206323|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-02-17||2017-10-05|2005-09-13|2005-09-21|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|September 2004||2004-09-30|October 2017|2017-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Randomized, Placebo-controlled, Tourette Syndrome Study.|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Safety and Efficacy of Topiramate in the Treatment of Tourette Syndrome (CAPSS-176)|Completed||Phase 3|29|Actual|Baylor College of Medicine|Joseph Jankovic, Joohi Jimenez-Shahed and Lawrence Brown J. Neurol. Neurosurg. Psychiatry published online 1 Sep 2009; doi:10.1136/jnnp.2009.185348|2|||f||||f||||||||||2018-06-01 04:31:04.580417|2018-06-01 04:31:04.580417
NCT00206310|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2010-11-17|2005-09-16|2005-09-21|Estimate|||||||2010-11-17|2010-11-19|Estimate|September 2003||2003-09-30|November 2010|2010-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Crestor Versus Placebo in Subjects With Heart Failure|Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure|Completed||Phase 3|5013||AstraZeneca|||||f||||||||||||||2018-06-01 04:31:04.920543|2018-06-01 04:31:04.920543
NCT00206297|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-12|2005-09-12|2005-09-21|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 2003||2003-10-31|July 2016|2016-07-31|February 2006||2006-02-28|||||Interventional|||The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes|The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes|Completed||Phase 3|20||Baylor College of Medicine|||||||||||||||||||2018-06-01 04:31:06.308571|2018-06-01 04:31:06.308571
NCT00206284|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-01-03|2005-09-20|2005-09-21|Estimate|||||||2013-01-03|2013-01-04|Estimate|May 2004||2004-05-31|January 2013|2013-01-31|April 2005|Actual|2005-04-30|||||Interventional|||A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.|A 4-week, Randomised, Double-blind, Multicentre, Dose-finding Phase IIb Study With AZD0865 25, 50, 75 mg and Esomeprazole 20 mg, Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification in Adult Subjects.|Completed||Phase 2|1400||AstraZeneca|||||||||||||||||||2018-06-01 04:31:06.404872|2018-06-01 04:31:06.404872
NCT00206271|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-21|Estimate|||||||2005-09-13|2005-09-21|Estimate|May 2001||2001-05-31|September 2005|2005-09-30|October 2004||2004-10-31|||||Interventional|||Comparison of the Effect of Neck Collar, Act-as-Usual, and Active Mobilisation Early After a Whiplash Injury|A Randomized Early Intervention Study Comparing the Effect of Stiff Neck Collar, “Act-as-Usual” and Active Mobilisation on the One Year Outcome Following Whiplash Injury.|Completed||Phase 3|450||The Back Research Center, Denmark|||||f||||||||||||||2018-06-01 04:31:06.843383|2018-06-01 04:31:06.843383
NCT00206258|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-12|2005-09-12|2005-09-21|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 2002||2002-07-31|July 2016|2016-07-31|August 2005||2005-08-31|||||Interventional|||The Role of Amylin and Glucagon in T1DM|The Role of Amylin and Glucagon in the Management of Normalizing Glucose Excursions in Children With Type 1 Diabetes|Completed||Phase 3|30||Baylor College of Medicine|||||||||||||||||||2018-06-01 04:31:06.937499|2018-06-01 04:31:06.937499
NCT00206245|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-03|2005-09-20|2005-09-21|Estimate|||||||2013-01-03|2013-01-04|Estimate|May 2004||2004-05-31|January 2013|2013-01-31|March 2005|Actual|2005-03-31|||||Interventional|||A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.|A Randomised, Double-blind, Multicentre Dose-finding Phase IIb Study for up to 8 Weeks' Treatment With AZD0865 25, 50, 75 mg and Esomeprazole 40 mg, Given Orally Once Daily for the Healing of Erosive Esophagitis in Adult Subjects With GERD With Erosive Esophagitis According to the LA Classification in Adult Subjects.|Completed||Phase 2|1400||AstraZeneca|||||||||||||||||||2018-06-01 04:31:07.057119|2018-06-01 04:31:07.057119
NCT00206232|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-15|2005-09-12|2005-09-21|Estimate|||||||2013-02-15|2013-02-18|Estimate|July 2004||2004-07-31|February 2013|2013-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Novel Treatment for Diastolic Heart Failure in Women|Novel Treatment for Diastolic Heart Failure in Women|Completed||Phase 4|48|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-06-01 04:31:07.440612|2018-06-01 04:31:07.440612
NCT00206219|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-01-25|2005-09-16|2005-09-21|Estimate|||||||2011-01-25|2011-01-27|Estimate|November 2003||2003-11-30|January 2011|2011-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)|A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|477||AstraZeneca|||||||||||||||||||2018-06-01 04:31:07.547588|2018-06-01 04:31:07.547588
NCT00206206|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-02-02|2005-09-13|2005-09-21|Estimate|||||||2006-02-02|2006-02-07|Estimate|July 2005||2005-07-31|September 2005|2005-09-30||||||||Interventional|||Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart|Evaluation of an ICU Hyperglycemia Protocol Using Insulin Aspart.|Terminated||N/A|235||Atlantic Health System|||||f||||||||||||||2018-06-01 04:31:07.785779|2018-06-01 04:31:07.785779
NCT00206193|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-29|2005-09-13|2005-09-21|Estimate|||||||2007-10-29|2007-10-30|Estimate||||September 2005|2005-09-30||||||||Observational|||Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone||Unknown status|Recruiting||||Atrium Medical Center|||||||||||||||||||2018-06-01 04:31:07.86295|2018-06-01 04:31:07.86295
NCT00206180|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-03-25|2005-09-15|2005-09-21|Estimate|||||||2009-03-25|2009-03-26|Estimate|June 2004||2004-06-30|March 2009|2009-03-31|August 2005|Actual|2005-08-31|||||Interventional|||NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis|A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily|Completed||Phase 4|120||AstraZeneca|||||||||||||||||||2018-06-01 04:31:07.942329|2018-06-01 04:31:07.942329
NCT00206167|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-26|2005-09-13|2005-09-21|Estimate|||||||2009-03-26|2009-03-27|Estimate|April 2005||2005-04-30|March 2009|2009-03-31|September 2007|Actual|2007-09-30|||||Interventional|||A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD|A 12-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid Compared to Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD|Completed||Phase 3|1600||AstraZeneca|||||f||||||||||||||2018-06-01 04:31:08.10601|2018-06-01 04:31:08.10601
NCT00206154|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-26|2005-09-13|2005-09-21|Estimate|||||||2009-03-26|2009-03-27|Estimate|April 2005||2005-04-30|March 2009|2009-03-31|December 2006|Actual|2006-12-31|||||Interventional|||A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients|A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT® pMDI 2 x 160/4.5 µg & 80/4.5 µg Bid Compared to Formoterol TBH, Budesonide pMDI (& the Combination) & Placebo in COPD Patients|Completed||Phase 3|1500|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 04:31:08.444771|2018-06-01 04:31:08.444771
NCT00206141|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-03|2005-09-13|2005-09-21|Estimate|||||||2013-01-03|2013-01-04|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Seroquel in Bipolar Depression Versus Lithium|Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)|Completed||Phase 3|672||AstraZeneca|||||f||||||||||||||2018-06-01 04:31:08.87298|2018-06-01 04:31:08.87298
NCT00206128|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-03|2005-09-13|2005-09-21|Estimate|||||||2013-01-03|2013-01-04|Estimate|November 2004||2004-11-30|January 2013|2013-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia|6-week Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Evaluate the Feasibility of Switching From Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate in Outpatients With Schizophrenia (Abbreviated)|Completed||Phase 3|454|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:31:09.065459|2018-06-01 04:31:09.065459
NCT00206115|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-01-03|2005-09-14|2005-09-21|Estimate|||||||2013-01-03|2013-01-04|Estimate|November 2004||2004-11-30|January 2013|2013-01-31|December 2005|Actual|2005-12-31|||||Interventional|||SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia|A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy & Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia|Completed||Phase 3|535||AstraZeneca|||||f||||||||||||||2018-06-01 04:31:09.221698|2018-06-01 04:31:09.221698
NCT00206102|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2009-10-22||2013-01-08|2005-09-14|2005-09-21|Estimate|2011-06-15|2011-07-13|Estimate||||2013-01-08|2013-01-14|Estimate|September 2003||2003-09-30|January 2013|2013-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder|A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|1098|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:31:09.364945|2018-06-01 04:31:09.364945
NCT00205907|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-27|2005-09-13|2005-09-21|Estimate|||||||2008-02-27|2008-03-06|Estimate|January 2005||2005-01-31|February 2008|2008-02-29|April 2007|Actual|2007-04-30|August 2006|Actual|2006-08-31||Interventional|||Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation|Phase 1/Phase 2 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema|Terminated||Phase 1/Phase 2|4|Actual|Aeris Therapeutics||1||Change in Formulation|f||||f||||||||||2018-06-01 04:31:11.611859|2018-06-01 04:31:11.611859
NCT00206089|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-11|2005-09-13|2005-09-21|Estimate|||||||2010-11-11|2010-11-15|Estimate|September 2005||2005-09-30|November 2010|2010-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|EXTEND||Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events|"The EXTEND Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery."|Terminated||Phase 3|3300||AstraZeneca||||"Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006~   in the interest of patient safety."|f||||||||||||||2018-06-01 04:31:10.287014|2018-06-01 04:31:10.287014
NCT00206076|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-02-23||2013-07-31|2005-09-13|2005-09-21|Estimate|2013-07-31|2013-08-02|Estimate||||2013-07-31|2013-08-02|Estimate|August 2006||2006-08-31|July 2013|2013-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation|CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver Disease - A Prospective, Randomized, Multicenter Trial.|Completed||Phase 4|19|Actual|Albert Einstein Healthcare Network||2|||f||||f||||||||||2018-06-01 04:31:10.570495|2018-06-01 04:31:10.570495
NCT00206063|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-13|2005-09-21|Estimate|||||||2010-11-10|2010-11-15|Estimate|August 1999||1999-08-31|November 2010|2010-11-30|April 2006|Actual|2006-04-30|June 2004|Actual|2004-06-30||Interventional|||Long Term Open Follow-up With H376/95 vs. Warfarin|Long-Term Treatment With the Oral Direct Thrombin Inhibitor Ximelagatran, Compared to Warfarin, as Stroke Prophylaxis in Patients With Atrial Fibrillation. A Long Term Follow-Up Study|Terminated||Phase 2|220||AstraZeneca||||"Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006~   in the interest of patient safety."|f||||||||||||||2018-06-01 04:31:10.842423|2018-06-01 04:31:10.842423
NCT00206050|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-01-20|2005-09-20|2005-09-21|Estimate|||||||2011-01-20|2011-01-21|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po|A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-Hour Intragastric pH Profile After 5 Days of Once Daily Oral Administration of Either Esomeprazole 40 mg or Pantoprazole 40 mg Following Once Daily Infusion of Intravenous Pantoprazole 40 mg for 5 Days in Healthy Volunteer Subjects|Completed||Phase 4|40||AstraZeneca|||||||||||||||||||2018-06-01 04:31:10.918659|2018-06-01 04:31:10.918659
NCT00206037|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-11-19|2005-09-14|2005-09-21|Estimate|||||||2007-11-19|2007-11-20|Estimate|May 2005||2005-05-31|November 2007|2007-11-30|February 2007|Actual|2007-02-28|||||Interventional|||Open Wedge High Tibia Osteotomy|Comparison of Open Wedge High Tibia Osteotomy Surgeries Using Colloss E and Tomofix and Tomofix Only, Regarding the Bone Healing|Terminated||Phase 4|49|Actual|AO Clinical Investigation and Documentation||||Interim analysis showed significant results, thus study was stopped|f||||t||||||||||2018-06-01 04:31:10.963253|2018-06-01 04:31:10.963253
NCT00206024|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-11-18|2005-09-13|2005-09-21|Estimate|||||||2010-11-18|2010-11-19|Estimate|November 2004||2004-11-30|November 2010|2010-11-30|July 2005|Actual|2005-07-31|||||Interventional|||Acid-Associated Heartburn Symptoms and Dose of Esomeprazole|A 4-week Study to Investigate the Relationship Between Resolution of Acid-Associated Heartburn Symptoms and Dose of Esomeprazole Magnesium|Completed||Phase 4|330||AstraZeneca|||||||||||||||||||2018-06-01 04:31:11.025572|2018-06-01 04:31:11.025572
NCT00206011|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-01-29|2005-09-14|2005-09-21|Estimate|||||||2009-01-29|2009-01-30|Estimate|April 2003||2003-04-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|October 2008|Actual|2008-10-31||Interventional|||Open Versus Endoscopic Surgery of Craniomaxillofacial (CMF) Condylar Neck Fractures|Open Versus Endoscopic Surgery of Condylar Neck Fractures|Completed||Phase 4|134|Actual|AO Clinical Investigation and Documentation||2|||f||||f||||||||||2018-06-01 04:31:11.103342|2018-06-01 04:31:11.103342
NCT00205998|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-26|2005-09-13|2005-09-21|Estimate|||||||2007-04-26|2007-04-27|Estimate|December 2001||2001-12-31|April 2007|2007-04-30|December 2005|Actual|2005-12-31|||||Interventional|||Surgical Plate Osteosynthesis of Distal Radius Fractures|Surgical Plate Osteosynthesis of Distal Radius Fractures. Prospective Study of the Locking Compression Plate (LCP)|Terminated||Phase 4|450|Actual|AO Clinical Investigation and Documentation||||Study completed|f||||f||||||||||2018-06-01 04:31:11.162061|2018-06-01 04:31:11.162061
NCT00205985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-11-16|2005-09-14|2005-09-21|Estimate|||||||2007-11-16|2007-11-19|Estimate|December 2003||2003-12-31|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Operative Versus Conservative Treatment of Scaphoid Fractures|Comparison of Time to Return to Previous Activity Between Operative Treatment and Cast Immobilization of Complete Fracture of the Middle Part of the Scaphoid Without Dislocation|Completed||Phase 4|100||AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-06-01 04:31:11.222669|2018-06-01 04:31:11.222669
NCT00205972|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-19|2005-09-13|2005-09-21|Estimate|||||||2007-11-19|2007-11-20|Estimate|December 2000||2000-12-31|November 2007|2007-11-30|October 2004||2004-10-31|||||Interventional|||Non Randomized Humerusshaft Fracture|Comparison (Conservative Versus Operative) of Standardized Treatment for Defined Humerusshaft Fractures|Completed||Phase 4|300||AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-06-01 04:31:11.297109|2018-06-01 04:31:11.297109
NCT00205959|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-06|2005-09-13|2005-09-21|Estimate|||||||2006-09-06|2006-09-07|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|August 2006||2006-08-31|||||Interventional|||LPHP-Philos-PHN Conservative Treatment|Comparison of Standard Treatment Methods for Proximal Humerus Fractures|Completed||Phase 4|640||AO Clinical Investigation and Documentation|||||f||||||||||||||2018-06-01 04:31:11.358794|2018-06-01 04:31:11.358794
NCT00205946|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-04|2005-09-13|2005-09-21|Estimate|||||||2007-12-04|2007-12-06|Estimate|April 2005||2005-04-30|November 2007|2007-11-30|July 2007|Actual|2007-07-31|||||Interventional|||The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity|The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity|Completed||Phase 1|32|Actual|Affective Neuroscience Laboratory||2|||f||||t||||||||||2018-06-01 04:31:11.411469|2018-06-01 04:31:11.411469
NCT00205933|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-04|2005-09-13|2005-09-21|Estimate|||||||2007-12-04|2007-12-06|Estimate|April 2004||2004-04-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Observational|||Behavioral Processes Underlying Reward Processing in Depression|Behavioral Processes Underlying Reward Processing in Depression|Completed|||78|Actual|Affective Neuroscience Laboratory|||||f||||t||||||||||2018-06-01 04:31:11.491503|2018-06-01 04:31:11.491503
NCT00205920|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-01-14|2005-09-13|2005-09-21|Estimate|||||||2010-01-14|2010-01-18|Estimate|May 2005||2005-05-31|January 2010|2010-01-31|May 2007|Actual|2007-05-31|September 2006|Actual|2006-09-30||Interventional|||Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation|Dose Escalation Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Emphysema|Terminated||Phase 2|5|Actual|Aeris Therapeutics||1||Change in formulation|f||||f||||||||||2018-06-01 04:31:11.546254|2018-06-01 04:31:11.546254
NCT00205894|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-04|2005-09-15|2005-09-21|Estimate|||||||2008-09-04|2008-09-05|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|September 2007|Actual|2007-09-30|October 2006|Actual|2006-10-31||Interventional|||Occipital Nerve Stimulation to Treat Chronic Headaches|Multicenter Feasibility Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches|Completed||Phase 1/Phase 2|20|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 04:31:11.675094|2018-06-01 04:31:11.675094
NCT00205881|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-09-29||2012-02-28|2005-09-13|2005-09-21|Estimate|2012-01-09|2012-02-10|Estimate||||2012-02-28|2012-03-01|Estimate|October 2004||2004-10-31|February 2012|2012-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System|Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System|Completed||Phase 4|32|Actual|Advanced Bionics||1|||f||||f||||||||||2018-06-01 04:31:11.73074|2018-06-01 04:31:11.73074
NCT00205868|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-10|2005-09-13|2005-09-21|Estimate|||||||2008-10-10|2008-10-13|Estimate|December 2004||2004-12-31|October 2008|2008-10-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||Spinal Cord Stimulation for Low Back Pain|Effectiveness of the Precision Spinal Cord Stimulation System in Patients With Failed Back Surgery Syndrome and Axial Low Back Pain|Completed||Phase 4|304|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 04:31:12.800757|2018-06-01 04:31:12.800757
NCT00205855|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-03-05||2012-09-26|2005-09-13|2005-09-21|Estimate|2012-09-26|2012-10-26|Estimate||||2012-09-26|2012-10-26|Estimate|February 2003||2003-02-28|September 2012|2012-09-30|March 2005|Actual|2005-03-31|October 2003|Actual|2003-10-31||Interventional|||An Implantable Spinal Cord Stimulation Pain Management System|Stimulus Confirmatory Study - An Implantable Spinal Cord Stimulation Pain Management System|Completed||Phase 3|65|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 04:31:12.901172|2018-06-01 04:31:12.901172
NCT00205842|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-07|2005-09-13|2005-09-21|Estimate|||||||2016-01-07|2016-01-11|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus|A Phase IIIb, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus|Completed||Phase 3|660||Cubist Pharmaceuticals LLC|||||f||||f||||||||||2018-06-01 04:31:13.081031|2018-06-01 04:31:13.081031
NCT00205829|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-07-31|2005-09-13|2005-09-21|Estimate|||||||2012-07-31|2012-08-02|Estimate|June 2004||2004-06-30|July 2012|2012-07-31|January 2009|Actual|2009-01-31|August 2007|Actual|2007-08-31||Interventional|||Bion for Occipital Nerve Stimulation|Bion for Occipital Nerve Stimulation|Completed||Phase 1/Phase 2|10|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 04:31:13.22745|2018-06-01 04:31:13.22745
NCT00205816|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-02-07|2005-09-16|2005-09-20|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.|An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens.|Completed||Phase 3|26|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:31:13.294959|2018-06-01 04:31:13.294959
NCT00205803|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|2010-03-26||2012-07-06|2005-09-19|2005-09-20|Estimate|2012-07-06|2012-08-15|Estimate||||2012-07-06|2012-08-15|Estimate|September 2004||2004-09-30|July 2012|2012-07-31|May 2007|Actual|2007-05-31|||||Interventional|||Study Evaluating Pneumococcal Vaccine in Healthy Infants|A Phase I/II, 2-stage, Randomized, Double-Blind Trial of the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in Healthy Infants|Completed||Phase 1/Phase 2|249|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||||||||||||||||2018-06-01 04:31:13.50501|2018-06-01 04:31:13.50501
NCT00205790|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-08-06|2005-09-12|2005-09-20|Estimate|||||||2008-08-06|2008-08-07|Estimate|February 2003||2003-02-28|August 2008|2008-08-31|August 2007|Actual|2007-08-31|||||Interventional|||GORE-TEX PROPATEN Vascular Graft Study|Comparison of Primary Patency Between GORE-TEX PROPATEN Vascular Grafts and Thin Walled GORE-TEX Stretch Vascular Grafts|Completed||N/A|200||W.L.Gore & Associates|||||f||||||||||||||2018-06-01 04:31:15.79713|2018-06-01 04:31:15.79713
NCT00205777|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2012-12-31||2013-02-28|2005-09-16|2005-09-20|Estimate|2013-02-28|2013-04-10|Estimate||||2013-02-28|2013-04-10|Estimate|December 2001||2001-12-31|February 2013|2013-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women|Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women|Completed||Phase 3|7609|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:31:16.141403|2018-06-01 04:31:16.141403
NCT00205764|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-21|2005-09-12|2005-09-20|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 1999||1999-03-31|November 2013|2013-11-30|October 2009|Actual|2009-10-31|||||Interventional|||Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy|Randomised, Non-blind, Parallel Group Study to Compare Tandem High Dose Melphalan (200mg/m²) Versus Triple Intermediate Dose Melphalan (100mg/m²) and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma|Completed||Phase 3|212|Anticipated|Austrian Forum Against Cancer|||||f||||||||||||||2018-06-01 04:31:23.402609|2018-06-01 04:31:23.402609
NCT00205751|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-21|2005-09-12|2005-09-20|Estimate|||||||2013-11-21|2013-11-25|Estimate|August 2001||2001-08-31|November 2013|2013-11-30|October 2009|Actual|2009-10-31|||||Interventional|||Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy|International, Multi-center, Prospective, Double Randomized, Open Phase III Study Evaluating Thalidomide/Dexamethasone Versus Melphalan/Prednisone as Induction Therapy and Thalidomide/Interferon-alpha Versus Interferon-alpha as Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma|Completed||Phase 2/Phase 3|350|Anticipated|Austrian Forum Against Cancer|||||f||||||||||||||2018-06-01 04:31:23.468596|2018-06-01 04:31:23.468596
NCT00205738|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-03-12|2005-09-13|2005-09-20|Estimate|||||||2014-03-12|2014-03-13|Estimate|July 2000||2000-07-31|March 2014|2014-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Janssen - Glucose Regulation/Risp/Olanz|Glucose Regulation During Risperidone and Olanzapine Treatment|Completed||N/A|120|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 04:31:23.535905|2018-06-01 04:31:23.535905
NCT00205725|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-03-12|2005-09-13|2005-09-20|Estimate|||||||2014-03-12|2014-03-13|Estimate|November 2000||2000-11-30|March 2014|2014-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Pfizer/IVGTT/Ziprasidone/Olanzapine|Glucose Regulation During Ziprasidone Treatment|Completed||N/A|120|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 04:31:23.613769|2018-06-01 04:31:23.613769
NCT00205712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-10-27||2016-01-12|2005-09-19|2005-09-20|Estimate|2010-03-24|2010-04-07|Estimate||||2016-01-12|2016-01-14|Estimate|February 2003||2003-02-28|January 2016|2016-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids|Prevention of NMDA Antagonist-induced Psychosis and Memory Impairment in Children|Completed||Phase 4|40|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 04:31:23.702617|2018-06-01 04:31:23.702617
NCT00205699|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-03-12|2005-09-13|2005-09-20|Estimate|||||||2014-03-12|2014-03-13|Estimate|October 2004||2004-10-31|March 2014|2014-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|MEAC||Metabolic Effects of Antipsychotics in Children|Metabolic Effects of Antipsychotics in Children|Completed||Phase 4|240|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 04:31:24.11522|2018-06-01 04:31:24.11522
NCT00205686|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-01-04|2005-09-13|2005-09-20|Estimate|||||||2006-01-04|2006-01-06|Estimate|April 2001||2001-04-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Effects of DHEA and Exercise in the Elderly|DHEA+Exercise-Effect on Sarcopenia and Osteopenia of Aging|Completed||Phase 3|64||Washington University School of Medicine|||||f||||||||||||||2018-06-01 04:31:24.320196|2018-06-01 04:31:24.320196
NCT00205660|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-08|2005-09-12|2005-09-20|Estimate|||||||2012-03-08|2012-03-12|Estimate|February 2005||2005-02-28|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole|Changes in Adiposity and Metabolic Measures During Medication Switches to Aripiprazole From Other Atypical Antipsychotics|Completed||Phase 4|78|Actual|Washington University School of Medicine||4|||f||||f||||||||||2018-06-01 04:31:24.3991|2018-06-01 04:31:24.3991
NCT00205647|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-11-01|2005-09-13|2005-09-20|Estimate|||||||2017-11-01|2017-11-06|Actual|January 1997||1997-01-31|March 2000|2000-03-31|March 2000||2000-03-31|||||Interventional|||Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis|A Phase II Multicenter Efficacy, Safety and Dose-Effect Study of the Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable, Chronic Bronchitis|Completed||Phase 2|240||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 04:31:24.504745|2018-06-01 04:31:24.504745
NCT00205634|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-08|2005-09-12|2005-09-20|Estimate|||||||2017-08-08|2017-08-10|Actual|December 2000|Actual|2000-12-31|August 2017|2017-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis|Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis|Completed||N/A|50||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 04:31:24.797624|2018-06-01 04:31:24.797624
NCT00205621|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-07|2005-09-13|2005-09-20|Estimate|||||||2006-09-07|2006-09-08|Estimate|October 2005||2005-10-31|August 2005|2005-08-31|December 2009||2009-12-31|||||Interventional|||Positron Emission Tomography of Amyloid in Alzheimer's Disease|Positron Emission Tomography of Cerebral Amyloid Load as a Potential Diagnostic Marker for Pre-Symptomatic Alzheimer’s Disease.|Suspended||Phase 1|50||VU University Medical Center|||||f||||||||||||||2018-06-01 04:31:24.915683|2018-06-01 04:31:24.915683
NCT00205608|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-25|2005-09-13|2005-09-20|Estimate|||||||2010-06-25|2010-06-28|Estimate|January 2004||2004-01-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|March 2007|Actual|2007-03-31||Interventional|||Microglia Activation in Schizophrenia|Microglia Activation in Schizophrenia: a Pilot Study|Completed||Phase 1|20|Anticipated|VU University Medical Center|||||f||||f||||||||||2018-06-01 04:31:25.054238|2018-06-01 04:31:25.054238
NCT00205595|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-07-03|2005-09-13|2005-09-20|Estimate|||||||2008-07-03|2008-07-08|Estimate|February 2001||2001-02-28|July 2008|2008-07-31|January 2007||2007-01-31|||||Interventional|||Normal Binding of R-[11C]PK11195 in Human Subjects|The Distribution and Quantification of Specific Binding of the Positron Emission Tomography Tracer R)-[11C]PK11195 in Normal Human Subjects|Unknown status|Active, not recruiting|Phase 1|40||VU University Medical Center|||||f||||||||||||||2018-06-01 04:31:25.186711|2018-06-01 04:31:25.186711
NCT00205582|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-03|2005-09-13|2005-09-20|Estimate|||||||2005-11-03|2005-11-04|Estimate|May 2001||2001-05-31|May 2001|2001-05-31|December 2004||2004-12-31|||||Interventional|||Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study|The Role of Excitatory Amino Acids on Neuronal Damage and Outcome After Traumatic Brain Injury: Assessment in Patients Using Microdialysis and (R)-[11C]PK11195 Positron Emission Tomography|Unknown status|Active, not recruiting|Phase 1|20||VU University Medical Center|||||f||||||||||||||2018-06-01 04:31:25.483272|2018-06-01 04:31:25.483272
NCT00205569|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-16|2005-09-12|2005-09-20|Estimate|||||||2017-03-16|2017-03-17|Actual|October 2002||2002-10-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation|Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)|Completed|||103|Actual|Virginia Commonwealth University|||1||f||||f||||||||||2018-06-01 04:31:25.553275|2018-06-01 04:31:25.553275
NCT00205556|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-01-20|2005-09-12|2005-09-20|Estimate|||||||2011-01-20|2011-01-21|Estimate|June 2004||2004-06-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|CONTRAST||Effect of Increased Convective Clearance by On-Line Hemodiafiltration on All Cause Mortality in Chronic Hemodialysis Patients|Effect of Increased Convective Clearance by On-line Hemodiafiltration on All Cause and Cardiovascular Mortality in Chronic Hemodialysis Patients: The Dutch Convective Transport Study (CONTRAST)|Completed||N/A|715|Actual|VU University Medical Center||2|||f||||t||||||||||2018-06-01 04:31:25.654053|2018-06-01 04:31:25.654053
NCT00205543|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-06-19|2005-09-15|2005-09-20|Estimate|||||||2012-06-19|2012-06-21|Estimate|July 2004||2004-07-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of Effects of Sutures on Results of Palate Surgery for Obstructive Sleep Apnea|Role of Suture Closure in Post-Operative Uvulopalatopharyngoplasty Outcomes|Completed||N/A|16|Actual|Virginia Commonwealth University||3|||f||||f||||||||||2018-06-01 04:31:25.857812|2018-06-01 04:31:25.857812
NCT00205530|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-07-29|2005-09-12|2005-09-20|Estimate|||||||2013-07-29|2013-07-31|Estimate|January 2003||2003-01-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Evaluation of an Intervention Model for Family Crisis and Support|Evaluation of an Intervention Model for Family Crisis and Support (a Research Project Within the Traumatic Brain Injury Model System Grant)|Completed|||160|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 04:31:25.972575|2018-06-01 04:31:25.972575
NCT00205517|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-01-07|2005-09-12|2005-09-20|Estimate|||||||2013-01-07|2013-01-09|Estimate|September 2002||2002-09-30|January 2013|2013-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Sedation and Psychopharmacology in Critical Care|Pharmacokinetics and Dynamics in Patients Randomized to Once Daily Awakening and Sedated According to Standardized Algorithm|Terminated||N/A|75|Actual|Virginia Commonwealth University||||End point reached at interim analysis|f||||||||||||||2018-06-01 04:31:26.068458|2018-06-01 04:31:26.068458
NCT00205504|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-01-25||2018-02-12|2005-09-13|2005-09-20|Estimate|2012-04-10|2012-05-07|Estimate||||2018-02-12|2018-03-12|Actual|June 2005||2005-06-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|June 2009|Actual|2009-06-30||Interventional|||Oral Contraceptives in the Metabolic Syndrome|Oral Contraceptives in the Metabolic Syndrome|Active, not recruiting||Phase 4|36|Actual|Virginia Commonwealth University||3|||f||||||||||||||2018-06-01 04:31:26.149447|2018-06-01 04:31:26.149447
NCT00205491|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-16|2005-09-12|2005-09-20|Estimate|||||||2017-03-16|2017-03-17|Actual|October 2004||2004-10-31|March 2017|2017-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Pharmacological Intervention in Depression After Traumatic Brain Injury|Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System)|Completed||Phase 4|100|Anticipated|Virginia Commonwealth University|||||f||||||||||||||2018-06-01 04:31:26.612807|2018-06-01 04:31:26.612807
NCT00205478|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-05|2005-09-12|2005-09-20|Estimate|||||||2007-12-05|2007-12-07|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|February 2006|Actual|2006-02-28|||||Interventional|||Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702|A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo Controlled Study of Two Doses of VX-702 in Subjects With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 2|300||Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 04:31:26.689327|2018-06-01 04:31:26.689327
NCT00205465|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-03|2005-09-13|2005-09-20|Estimate|||||||2007-12-03|2007-12-05|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|September 2005|Actual|2005-09-30|||||Interventional|||Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765|A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy|Completed||Phase 2|64||Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 04:31:26.822982|2018-06-01 04:31:26.822982
NCT00205452|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-16|2005-09-13|2005-09-20|Estimate|||||||2012-10-16|2012-10-18|Estimate|June 2003||2003-06-30|October 2012|2012-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Quality of Life (QOL) Following Parathyroid Surgery|Does Quality of Life Improve Following Minimally Invasive Parathyroid Surgery?|Completed|||200|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:26.878049|2018-06-01 04:31:26.878049
NCT00205439|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-07-09|2005-09-19|2005-09-20|Estimate|||||||2015-07-09|2015-07-13|Estimate|December 2001||2001-12-31|July 2015|2015-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Surveillance For New Lung Primaries|"Fluorescence Bronchoscopic Surveillance For New Lung Primaries After Curative Therapy for Squamous Cell Carcinoma of the Aerodigestive Tract"|Terminated|||200|Anticipated|University of Wisconsin, Madison|||1|low accrual|f||||||||||||||2018-06-01 04:31:26.918829|2018-06-01 04:31:26.918829
NCT00205426|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-13|2005-09-13|2005-09-20|Estimate|||||||2015-10-13|2015-10-14|Estimate|August 2005||2005-08-31|October 2015|2015-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Natrecor for Pulmonary Hypertension in Lung Transplants|Natrecor® (Nesiritide) as a Nitric Oxide Sparing Agent in Patients Undergoing Lung Transplantation|Completed||Phase 4|7|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-06-01 04:31:26.963925|2018-06-01 04:31:26.963925
NCT00205413|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-30|2005-09-13|2005-09-20|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2002||2002-09-30|September 2015|2015-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Surveillance For New Lung Primaries|Low Dose Helical Computed Tomographic (CT) Screening Followed by Anatomic Co-Registered Computed Tomography With Positron Emission Tomography (CT/PET) for Patients With Indeterminate (5-9 mm) Nodules|Terminated|||250|Anticipated|University of Wisconsin, Madison||||low accrual|f||||||||||||||2018-06-01 04:31:27.033726|2018-06-01 04:31:27.033726
NCT00205400|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-25|2005-09-13|2005-09-20|Estimate|||||||2016-10-25|2016-10-27|Estimate|August 1999||1999-08-31|October 2016|2016-10-31||||March 2005|Actual|2005-03-31||Interventional|||Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care|Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care|Completed||N/A|192||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:27.077827|2018-06-01 04:31:27.077827
NCT00205387|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-08-28|2005-09-19|2005-09-20|Estimate|||||||2012-08-28|2012-08-29|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Cardiac Elastography to Determine Strain and Strain Rates in the Heart|Cardiac Elastography|Completed|||100|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:27.134429|2018-06-01 04:31:27.134429
NCT00205374|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-02-22||2017-10-24|2005-09-13|2005-09-20|Estimate|2017-06-19|2017-07-18|Actual||||2017-10-24|2017-11-30|Actual|November 1999||1999-11-30|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Use of Cidofovir for Recurrent Respiratory Papillomatosis|"Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis."|Completed||Phase 4|19|Actual|University of Wisconsin, Madison||2|||f||||t||||||||No||2018-06-01 04:31:27.186631|2018-06-01 04:31:27.186631
NCT00205361|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-16|2005-09-19|2005-09-20|Estimate|||||||2012-10-16|2012-10-17|Estimate|January 2002||2002-01-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Airway IgA: Respiratory Tract IgA Levels in Anesthetized Patients Undergoing Elective Surgical Procedures|Respiratory Tract IgA Levels in Anesthetized Patients Undergoing Elective Surgical Procedures|Completed|||9|Actual|University of Wisconsin, Madison|||2||f||||||||||||||2018-06-01 04:31:27.643381|2018-06-01 04:31:27.643381
NCT00205348|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-06-22||2017-08-18|2005-09-19|2005-09-20|Estimate|2017-08-18|2018-02-28|Actual||||2017-08-18|2018-02-28|Actual|April 2002||2002-04-30|August 2017|2017-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Swallowing Function Before and After Surgery for Thyroid Goiter|Swallowing Function Before and After Surgery for Thyroid Goiter|Completed|||146|Actual|University of Wisconsin, Madison|There are no limitations or caveats to report.||||f||||f||||||||||2018-06-01 04:31:27.70833|2018-06-01 04:31:27.70833
NCT00205335|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-29|2005-09-13|2005-09-20|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2004||2004-01-31|September 2015|2015-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Free Test Strips and Blood Glucose Control|The Impact of Increased Availability of Test Strips on Blood Glucose Control in Patients With Diabetes|Completed||N/A|22|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-06-01 04:31:27.880621|2018-06-01 04:31:27.880621
NCT00205322|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-12-02|2005-09-13|2005-09-20|Estimate|||||||2011-12-02|2011-12-06|Estimate|April 2004||2004-04-30|December 2011|2011-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer|A Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|45|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 04:31:27.97606|2018-06-01 04:31:27.97606
NCT00205309|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-10-16|2005-09-13|2005-09-20|Estimate|||||||2012-10-16|2012-10-18|Estimate|January 2003||2003-01-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Airway IgA: Respiratory Tract IgA Levels in Critically Ill Intubated Patients|Respiratory Tract IgA Levels in Critically Ill Intubated Patients|Completed|||13|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:28.045607|2018-06-01 04:31:28.045607
NCT00205296|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2002||2002-03-31|October 2008|2008-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Fitness Training in Children|Effect of Fitness Training on Insulin Sensitivity and Body Composition in Children|Completed||N/A|300|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:28.194381|2018-06-01 04:31:28.194381
NCT00205283|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|August 2003||2003-08-31|September 2005|2005-09-30||||||||Interventional|||Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection|Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection|Unknown status|Recruiting|N/A|20|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:28.274116|2018-06-01 04:31:28.274116
NCT00205270|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-20|Estimate|||||||2013-06-17|2013-06-19|Estimate|December 2004||2004-12-31|June 2013|2013-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Influenza Vaccine in Lung Transplant Patients|Influenza Vaccine in Lung Transplant Patients|Completed||N/A|152|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:28.357633|2018-06-01 04:31:28.357633
NCT00205257|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|September 2001||2001-09-30|December 2013|2013-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Prediction of Acute Rejection in Renal Transplant|Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant|Completed|||||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:28.417758|2018-06-01 04:31:28.417758
NCT00205244|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-30|2005-09-19|2005-09-20|Estimate|||||||2017-03-30|2017-03-31|Actual||||March 2017|2017-03-31||||October 2007|Actual|2007-10-31||Interventional|||Preoperative Preparation for Children|Preoperative Preparation for Children: Use of Relaxation and Distraction|Recruiting||N/A|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:28.464116|2018-06-01 04:31:28.464116
NCT00205231|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-25|2005-09-13|2005-09-20|Estimate|||||||2016-10-25|2016-10-27|Estimate|May 2002||2002-05-31|September 2005|2005-09-30||||July 2008|Actual|2008-07-31||Interventional|||A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease|A Pilot Study to Examine the Feasibility and Effect on Tumor Necrosis Factor (TNF) Inhibition on HIV Disease|Completed||N/A|25|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:28.538765|2018-06-01 04:31:28.538765
NCT00205218|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-19|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|November 1998||1998-11-30|April 2007|2007-04-30|August 2006|Actual|2006-08-31|||||Observational|||Validation of Methods to Estimate Body Fat|Validation of Methods to Estimate Body Fat|Completed|||150||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:28.609781|2018-06-01 04:31:28.609781
NCT00205205|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate||||June 2008|2008-06-30||||||||Interventional|||Peer Mentoring for Persons With Spinal Cord Injury (SCI)|Peer Mentoring for Persons With Spinal Cord Injury: Program Satisfaction and Outcome for Mentor/Mentee|Completed||N/A|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:28.672174|2018-06-01 04:31:28.672174
NCT00205192|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-08-28|2005-09-13|2005-09-20|Estimate|||||||2012-08-28|2012-08-29|Estimate|June 2004||2004-06-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Optimizing Cardiac Resynchronization|Optimizing Cardiac Resynchronization|Completed|||100|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:28.739825|2018-06-01 04:31:28.739825
NCT00205179|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2005||2005-01-31|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Alzheimer's Disease: Potential Benefit of Isoflavones|Alzheimer's Disease: Potential Benefit of Isoflavones|Completed||Phase 2|60|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:31:28.806563|2018-06-01 04:31:28.806563
NCT00205166|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-10-25|2005-09-13|2005-09-20|Estimate|||||||2012-10-25|2012-10-29|Estimate|June 1999||1999-06-30|October 2012|2012-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?|Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?|Completed||N/A|50|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 04:31:28.882396|2018-06-01 04:31:28.882396
NCT00205153|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-18|2005-09-13|2005-09-20|Estimate|||||||2014-12-18|2014-12-23|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Team Model of Hypertension Care in African Americans|A Team Model of Hypertension Care in African Americans|Completed||N/A|576|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:31:28.961115|2018-06-01 04:31:28.961115
NCT00205140|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-06|2005-09-19|2005-09-20|Estimate|||||||2015-10-06|2015-10-08|Estimate|July 2005||2005-07-31|October 2015|2015-10-31|May 2007|Actual|2007-05-31|||||Observational|||Effect of Pharmacist Initiated Recommendations On Prescribing For Participants In the Senior MEDS Personalized Medication Review|Participant Characteristics, Medication Utilization, and the Effects of Pharmacist Initiated Recommendations On the Prescribing For Participants In the Senior MEDS Personalized Medication Review for Adults Age 55 and Older|Terminated|||100|Anticipated|University of Wisconsin, Madison||||The program responsible for recruitment was dismantled in 2006.|f||||||||||||||2018-06-01 04:31:29.045409|2018-06-01 04:31:29.045409
NCT00205127|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-08-28|2005-09-13|2005-09-20|Estimate|||||||2012-08-28|2012-08-29|Estimate|January 2004||2004-01-31|August 2012|2012-08-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Cardiac Water and Fluoromethane Cardiac PET|Comparison of Cardiac Perfusion by O15-water and F17-fluoromethane PET|Completed||N/A|10||University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:29.089674|2018-06-01 04:31:29.089674
NCT00205114|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|December 2003||2003-12-31|December 2007|2007-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Dane County Safety Assessment for Elders (SAFE) Research Study|Dane County Safety Assessment for Elders (SAFE) Research Study|Completed||N/A|500|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:29.14116|2018-06-01 04:31:29.14116
NCT00205101|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-14|2005-09-13|2005-09-20|Estimate|||||||2007-12-14|2007-12-19|Estimate|September 2004||2004-09-30|December 2007|2007-12-31||||||||Observational|||Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion|Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion|Completed|||70|Anticipated|University of Wisconsin, Madison|||4||f||||||||||||||2018-06-01 04:31:29.191453|2018-06-01 04:31:29.191453
NCT00205088|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|August 2002||2002-08-31|June 2008|2008-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||The Use of Shunt Tap in Assessing Ventriculoperitoneal (VP) Shunt Malfunction|The Use of Shunt Tap in Assessing Ventriculoperitoneal (VP) Shunt Malfunction|Completed|||100|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:29.388739|2018-06-01 04:31:29.388739
NCT00205075|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-07|2005-09-13|2005-09-20|Estimate|||||||2015-12-07|2015-12-09|Estimate|August 2004||2004-08-31|December 2015|2015-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression|The Use of Validated Measures of Alcohol Intake to Measure the Impact of Moderate Alcohol Consumption on Hepatic Fibrogenesis in Individuals Infected With Hepatitis C|Completed|||47|Actual|University of Wisconsin, Madison|||2||f||||||||||||||2018-06-01 04:31:29.426043|2018-06-01 04:31:29.426043
NCT00205062|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Positron Emission Tomography (PET)-Computed Tomography (CT) in Inflammatory Bowel Disease (IBD)|Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease|Terminated||Phase 4|||University of Wisconsin, Madison||||No Accrual|f||||||||||||||2018-06-01 04:31:29.472189|2018-06-01 04:31:29.472189
NCT00205049|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-08-04||2014-04-10|2005-09-13|2005-09-20|Estimate|2014-04-10|2014-05-13|Estimate||||2014-04-10|2014-05-13|Estimate|March 2005||2005-03-31|April 2014|2014-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Pentoxifylline for Acute Alcoholic Hepatitis (AAH)|A Pilot Study of Pentoxifylline-Therapy for Acute Alcoholic Hepatitis|Terminated||Phase 1|4|Actual|University of Wisconsin, Madison|Study was terminated before any data was gathered/analyzed.|1||lack of funding|f||||f||||||||||2018-06-01 04:31:29.521358|2018-06-01 04:31:29.521358
NCT00205036|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-25|2005-09-19|2005-09-20|Estimate|||||||2016-03-25|2016-03-28|Estimate|January 2005||2005-01-31|March 2016|2016-03-31|April 2008|Actual|2008-04-30|October 2005|Actual|2005-10-31||Observational|||Calcium DXA: Impact of Calcium Supplements on Lumbar Spine Bone Mineral Density|Impact of Calcium Supplements on Lumbar Spine Bone Mineral Density|Completed|||||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:29.769542|2018-06-01 04:31:29.769542
NCT00205023|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-30|2005-09-13|2005-09-20|Estimate|||||||2015-09-30|2015-10-02|Estimate|January 2004||2004-01-31|June 2008|2008-06-30|August 2006|Actual|2006-08-31|February 2006|Actual|2006-02-28||Interventional|||Disseminated Endometrial Cancer Cells During Sonohysterography|The Incidence of Disseminated Endometrial Cancer Cells During Sonohysterography and Their Functional Viability: a Prospective Study|Completed||N/A|25|Actual|University of Wisconsin, Madison||1|||f||||||||||||||2018-06-01 04:31:29.824985|2018-06-01 04:31:29.824985
NCT00205010|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-30|2005-09-13|2005-09-20|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2003||2003-10-31|June 2008|2008-06-30|June 2006|Actual|2006-06-30|February 2006|Actual|2006-02-28||Observational|||Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer|Laparoscopic Sentinel Lymph Node Localization in Patients With Operable Cervical Cancer - A Pilot Study|Completed|||20|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 04:31:29.881019|2018-06-01 04:31:29.881019
NCT00204997|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-30|2005-09-13|2005-09-20|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2002||2002-09-30|June 2008|2008-06-30|February 2008|Actual|2008-02-29|September 2005|Actual|2005-09-30||Interventional|||Preservation of Ovarian Function Via LOT in Squamous Cell Carcinoma of the Cervix|Preservation of Ovarian Function Via Laparoscopic Transposition in Patients With Locally Advanced Squamous Cell Carcinoma of the Cervix|Terminated||N/A|10|Anticipated|University of Wisconsin, Madison||1||slow accrual|f||||t||||||||||2018-06-01 04:31:29.932076|2018-06-01 04:31:29.932076
NCT00204984|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2005||2005-05-31|January 2009|2009-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Heart and Blood Pressure Study: The Effect of Aortic Impedance on Myocardial Relaxation|The Effect of Aortic Impedance on Myocardial Relaxation|Completed||N/A|60|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:29.993488|2018-06-01 04:31:29.993488
NCT00204971|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-29|2005-09-13|2005-09-20|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2003||2003-01-31|September 2015|2015-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Enteral Glutamine in Neurologically-injured Patients|Randomized, Placebo-controlled Clinical Trial of Enteral Glutamine Supplementation in Neurologically-injured Patients|Completed||Phase 4|102|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-06-01 04:31:30.051274|2018-06-01 04:31:30.051274
NCT00204958|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-29|2005-09-13|2005-09-20|Estimate|||||||2015-09-29|2015-10-01|Estimate|February 2004||2004-02-29|September 2015|2015-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Glutamine Popsicles in Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients|Evaluation of Glutamine Popsicles in Adult/Pediatric Bone Marrow Transplant (BMT)/Hematopoietic Stem Cell Transplant (HSCT) Patients|Completed||Phase 4|50|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:30.113565|2018-06-01 04:31:30.113565
NCT00204945|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-15|2005-09-13|2005-09-20|Estimate|||||||2009-01-15|2009-01-16|Estimate|February 2005||2005-02-28|January 2009|2009-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Catheterization Laboratory Study: Acute Responses in Diastolic Heart Failure|Acute Responses in Diastolic Heart Failure|Completed||N/A|65|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:30.163381|2018-06-01 04:31:30.163381
NCT00204932|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-08-04||2017-05-04|2005-09-13|2005-09-20|Estimate|2014-12-18|2014-12-22|Estimate||||2017-05-04|2017-05-31|Actual|July 2004||2004-07-31|May 2017|2017-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects of CLA Supplements on Body Weight and Fat Oxidation|Effects of CLA Supplements on Body Weight and Fat Oxidation|Completed||Phase 2|53|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:31:30.222752|2018-06-01 04:31:30.222752
NCT00204919|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-30|2005-09-13|2005-09-20|Estimate|||||||2015-09-30|2015-10-01|Estimate|June 2001||2001-06-30|September 2015|2015-09-30|November 2004|Actual|2004-11-30|May 2004|Actual|2004-05-31||Interventional|||Vitamin D Administration in the Nursing Home|Intermittent Vitamin D Administration in the Nursing Home: Impact on Vitamin D Status, Falls, Bone Turnover and Bone Density|Completed||N/A|96|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 04:31:30.471834|2018-06-01 04:31:30.471834
NCT00204906|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2005||2005-01-31|June 2015|2015-06-30||||January 2009|Actual|2009-01-31||Interventional|||Correction of Vitamin D Inadequacy in Nursing Home Residents|Effect of Vitamin D Supplementation on Skeletal and Overall Health of Nursing Home Residents|Completed||N/A|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:30.538089|2018-06-01 04:31:30.538089
NCT00204113|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-10|2005-09-12|2005-09-20|Estimate|||||||2008-06-10|2008-06-13|Estimate|June 2002||2002-06-30|June 2008|2008-06-30||||||||Interventional|||Control of Unsupported Paraplegic Standing|Integrated Voluntary Control of Unsupported Paraplegic Standing|Unknown status|Active, not recruiting|N/A|10|Anticipated|University of Glasgow|||||f||||||||||||||2018-06-01 04:31:36.937184|2018-06-01 04:31:36.937184
NCT00204893|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-10-28|2005-09-19|2005-09-20|Estimate|||||||2013-10-28|2013-10-30|Estimate|July 2003||2003-07-31|October 2013|2013-10-31||||March 2007|Actual|2007-03-31||Interventional|||Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects|Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects|Unknown status|Active, not recruiting|Phase 1|12||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:30.587574|2018-06-01 04:31:30.587574
NCT00204880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Aging and Cancer Effects (ACE) Study|Aging and Cancer: The Effects of Comorbidities on Cancer and it's Treatment|Completed|||34|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 04:31:30.664792|2018-06-01 04:31:30.664792
NCT00204867|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-06-17|2005-09-13|2005-09-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|July 2004||2004-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Virtual Colonoscopy (VC) for Primary Colorectal Screening|CT Virtual Colonoscopy for Primary Colorectal Screening|Completed|||272|Actual|University of Wisconsin, Madison|||1||f||||t||||||||||2018-06-01 04:31:30.702561|2018-06-01 04:31:30.702561
NCT00204854|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|December 2001||2001-12-31|January 2011|2011-01-31|November 2004|Actual|2004-11-30|June 2004|Actual|2004-06-30||Interventional|TAMI||Telephone and Mail Intervention for Alcohol Use Disorders|Telephone and Mail Intervention for Alcohol Use Disorders|Completed||Phase 3|900||University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:30.750972|2018-06-01 04:31:30.750972
NCT00204841|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-30|2005-09-13|2005-09-20|Estimate|||||||2017-03-30|2017-03-31|Actual|October 1998||1998-10-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|COAST||Childhood Origins of Asthma (COAST)|Rhinovirus Infection and Asthma in Childhood and Adolescents|Active, not recruiting|||300|Anticipated|University of Wisconsin, Madison|||||f||||f||||||Samples With DNA|"~     nasal mucus samples, cord blood, peripheral blood samples, nasal cell brushing samples, cell~     lines~   "|||2018-06-01 04:31:30.970955|2018-06-01 04:31:30.970955
NCT00204828|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-01-02|2005-09-13|2005-09-20|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2005||2005-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2007|Actual|2007-06-30||Observational|||T Regulatory and Childhood Asthma|T Regulatory and Childhood Asthma|Completed|||58|Actual|University of Wisconsin, Madison|||2||f||||f||||||Samples Without DNA|"~     blood, PBMC culture supes and nasal lavage~   "|No||2018-06-01 04:31:31.978926|2018-06-01 04:31:31.978926
NCT00204815|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-01|2005-09-13|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|October 2007|Actual|2007-10-31|||||Observational|||Bone Mineral Density in Pediatric Epilepsy|Bone Mineral Density in Pediatric Epilepsy: AED-Specific and Duration of Treatment-Specific Effects|Completed|||98|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:32.037787|2018-06-01 04:31:32.037787
NCT00204802|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-01|2005-09-12|2005-09-20|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2004||2004-01-31|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Interventional|||Patient-Centered Advance Care Planning|A Patient-Centered Approach to Advance Care Planning of Patients With End Stage Heart Failure and Renal Disease|Completed||Phase 3|313|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:31:32.093238|2018-06-01 04:31:32.093238
NCT00204789|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-09-30|2005-09-13|2005-09-20|Estimate|||||||2015-09-30|2015-10-02|Estimate|July 2003||2003-07-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients|Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR)|Completed||Phase 2|52|Anticipated|University of Wisconsin, Madison|||||||||||||||||||2018-06-01 04:31:32.152339|2018-06-01 04:31:32.152339
NCT00204776|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-09-30|2005-09-13|2005-09-20|Estimate|||||||2015-09-30|2015-10-02|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|November 2006|Actual|2006-11-30|||||Interventional|||XELOX for Metastatic Breast Cancer|A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer|Completed||Phase 2|37|Anticipated|University of Wisconsin, Madison|||||f||||t||||||||||2018-06-01 04:31:32.207153|2018-06-01 04:31:32.207153
NCT00204763|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-01-11|2005-09-13|2005-09-20|Estimate|||||||2008-01-11|2008-01-16|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Comparison of Esophageal and Anorectal Manometry Catheters|Comparison of Solid-State Esophageal Manometry and Water Perfused Anorectal Manometry Catheters With Air Filled Multi-Balloon Esophageal and Anorectal Manometry Catheters|Terminated||Phase 4|5|Actual|University of Utah||2||We determined that the results would not be worth reporting.|f||||f||||||||||2018-06-01 04:31:32.26288|2018-06-01 04:31:32.26288
NCT00204750|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-23|2005-09-13|2005-09-20|Estimate|||||||2007-12-23|2008-01-04|Estimate|August 2001||2001-08-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Trial of Electrosurgical Incision Versus Bougie Dilation of Symptomatic Lower Esophageal (Schatzki's) Rings|A Randomized, Prospective Trial of Electrosurgical Incision Followed by Rabeprazole Versus Bougie Dilation Followed by Rabeprazole of Symptomatic Lower Esophageal (Schatzki's) Rings|Completed||Phase 2/Phase 3|50|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 04:31:32.331624|2018-06-01 04:31:32.331624
NCT00204737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-09-29|2005-09-12|2005-09-20|Estimate|||||||2015-09-29|2015-10-01|Estimate|December 2004||2004-12-31|September 2015|2015-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Short Course Glucocorticoid Treatment for PTSD|A Placebo-controlled, Randomized, Double-blind Comparison of Placebo vs Short Course Low Dose Corticosteroids on Posttraumatic Stress Disorder (PTSD)|Completed||N/A|12|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 04:31:33.130415|2018-06-01 04:31:33.130415
NCT00204711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-26|2005-09-12|2005-09-20|Estimate|||||||2007-12-26|2008-01-04|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|November 2006|Actual|2006-11-30|June 2008|Anticipated|2008-06-30||Observational|||Use of the SNAP II Electroencephalography (EEG) Monitor in Outpatients Undergoing Surgery/Procedures With Sedation|Use of the SNAP II EEG Monitor in Outpatients Undergoing Surgery/Procedures With Sedation|Completed|||50|Anticipated|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:31:33.208107|2018-06-01 04:31:33.208107
NCT00204698|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-01-11|2005-09-13|2005-09-20|Estimate|||||||2008-01-11|2008-01-16|Estimate|August 2003||2003-08-31|January 2008|2008-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment|Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment|Completed||Phase 2/Phase 3|24|Actual|University of Utah||1|||f||||f||||||||||2018-06-01 04:31:33.28392|2018-06-01 04:31:33.28392
NCT00204685|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-13|2005-09-14|2005-09-20|Estimate|||||||2006-09-13|2006-09-14|Estimate|August 2003||2003-08-31|September 2006|2006-09-30|July 2006||2006-07-31|||||Interventional|||Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa|Beatmungsdauer Und Lungenfunktion Bei Beatmeten Patienten Unter Therapie Mit Dornase Alfa - Randomisierte, Doppel-Blinde, Placebo-Kontrollierte, Multizentrische, Prospektive Klinische Studie|Unknown status|Active, not recruiting|Phase 2/Phase 3|540||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:33.37199|2018-06-01 04:31:33.37199
NCT00204672|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|October 2000||2000-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||The Role of GER in Exercise Triggered Asthma|The Role of GER in Exercise Triggered Asthma|Completed||Phase 2/Phase 3|36||University of Utah|||||f||||||||||||||2018-06-01 04:31:33.486149|2018-06-01 04:31:33.486149
NCT00204659|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-10-17|2005-09-14|2005-09-20|Estimate|||||||2008-10-17|2008-10-20|Estimate|March 2003||2003-03-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma|Phase II Study With Rituximab and CHOP in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma|Completed||Phase 2|30|Actual|University Hospital Tuebingen|||||f||||f||||||||||2018-06-01 04:31:33.538691|2018-06-01 04:31:33.538691
NCT00204646|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-19|2005-09-13|2005-09-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|February 1999||1999-02-28|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)|Phase II Study of Neoadjuvant Dose-Intensive Chemotherapy With Adriamycin and Ifosfamide Followed by High-Dose ICE in Locally Advanced Soft Tissue Sarcomas|Completed||Phase 2|||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:33.691621|2018-06-01 04:31:33.691621
NCT00204633|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-13|2005-09-13|2005-09-20|Estimate|||||||2009-02-13|2009-02-16|Estimate|July 2003||2003-07-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||"Darbepoetin Alfa in Patients With Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)"|"Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic Poor Prognosis Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP Regimen)"|Completed||Phase 2|108|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:33.755251|2018-06-01 04:31:33.755251
NCT00204620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-19|2005-09-13|2005-09-20|Estimate|||||||2007-04-19|2007-04-20|Estimate|March 2002||2002-03-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)|Multicenter Phase II Study With Bendamustin for Patients With Refractory Soft Tissue Sarcoma|Completed||Phase 2|28||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:33.82855|2018-06-01 04:31:33.82855
NCT00204607|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-18|2005-09-13|2005-09-20|Estimate|||||||2007-04-18|2007-04-19|Estimate|July 2004||2004-07-31|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients|Induction of Specific Immune Responses Against Melanoma-Associated Antigens in Vivo by Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial|Completed||Phase 1/Phase 2|20||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:33.885198|2018-06-01 04:31:33.885198
NCT00204594|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-15|2005-09-13|2005-09-20|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28|Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28|Completed||Phase 1/Phase 2|1|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-06-01 04:31:33.948973|2018-06-01 04:31:33.948973
NCT00204581|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-18|2005-09-13|2005-09-20|Estimate|||||||2011-08-18|2011-08-19|Estimate|August 2003||2003-08-31|February 2009|2009-02-28|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional|||Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases|Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases. A Phase II, Prospective, Open, Multicenter Trial|Completed||Phase 2|51|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:34.038035|2018-06-01 04:31:34.038035
NCT00204568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-07|2005-09-13|2005-09-20|Estimate|||||||2013-01-07|2013-01-08|Estimate|August 2004||2004-08-31|January 2013|2013-01-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)|Randomized Phase II Trial of Trofosfamide vs. Adriamycin in Elderly Patients With Previously Untreated Metastatic Soft Tissue Sarcoma|Unknown status|Active, not recruiting|Phase 2|117|Anticipated|University of Schleswig-Holstein||2|||f||||||||||||||2018-06-01 04:31:34.112277|2018-06-01 04:31:34.112277
NCT00204555|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-31|2005-09-13|2005-09-20|Estimate|||||||2011-08-31|2011-09-01|Estimate|January 2002||2002-01-31|April 2007|2007-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma|A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma|Completed||Phase 4|100|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:34.19128|2018-06-01 04:31:34.19128
NCT00204542|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-18|2005-09-13|2005-09-20|Estimate|||||||2011-08-18|2011-08-19|Estimate|June 2005||2005-06-30|March 2009|2009-03-31|December 2010|Actual|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head|Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head|Completed||Phase 4|418|Actual|University Hospital Tuebingen||2|||f||||||||||||||2018-06-01 04:31:34.250399|2018-06-01 04:31:34.250399
NCT00204529|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-02|2005-09-12|2005-09-20|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2004|Actual|2004-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|May 2013|Actual|2013-05-31||Interventional|||Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB|Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002)|Completed||Phase 3|901|Actual|University Hospital Tuebingen||2|||f||||||||||||||2018-06-01 04:31:34.321857|2018-06-01 04:31:34.321857
NCT00204100|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-11|2005-09-12|2005-09-20|Estimate|||||||2006-10-11|2006-10-12|Estimate|January 2003||2003-01-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Paraplegic Cycling: Improving Health After Spinal Cord Injury|The Development of Systems for Paraplegic Cycling: Improving Health After Spinal Cord Injury|Unknown status|Active, not recruiting|N/A|5||University of Glasgow|||||f||||||||||||||2018-06-01 04:31:37.012922|2018-06-01 04:31:37.012922
NCT00204516|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-15|2005-09-13|2005-09-20|Estimate|||||||2013-01-15|2013-01-16|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2011|Actual|2011-08-31||Interventional|||Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens|Pilot Study of Intradermal Vaccination of Melanoma Patients With a Fixed Combination of mRNAs Compared to an Individualized Selection After Analysis of Antigen Expression in Tumor Tissue|Completed||Phase 1/Phase 2|31|Actual|University Hospital Tuebingen||1|||f||||||||||||||2018-06-01 04:31:34.400522|2018-06-01 04:31:34.400522
NCT00204503|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-30|2005-09-13|2005-09-20|Estimate|||||||2015-03-30|2015-03-31|Estimate|June 2003||2003-06-30|March 2015|2015-03-31|May 2005||2005-05-31|||||Interventional|||Open-Label Depakote ER in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence|An Open Label Pilot Study Evaluating Safety and Efficacy of Divalproex Sodium (Depakote ER) in Patients With Bipolar I or II Depression and Alcohol Abuse or Dependence.|Withdrawn||Phase 2|0|Actual|The University of Texas Medical Branch, Galveston|||||f||||||||||||||2018-06-01 04:31:34.479388|2018-06-01 04:31:34.479388
NCT00204490|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-06|2005-09-12|2005-09-20|Estimate|||||||2018-04-06|2018-04-10|Actual|April 2004|Actual|2004-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Soy Isoflavones and Breast Cancer Risk Reduction|Mammographic Density and Soy Isoflavones|Active, not recruiting||Phase 2|197|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-06-01 04:31:34.535017|2018-06-01 04:31:34.535017
NCT00204477|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-05-10|2005-09-13|2005-09-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2002||2002-04-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Soy Protein and Breast Cancer Risk Reduction|Soybean Diet and Breast Density|Unknown status|Active, not recruiting|Phase 2|313|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-06-01 04:31:34.614845|2018-06-01 04:31:34.614845
NCT00204464|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-11-03|2005-09-14|2005-09-20|Estimate|||||||2005-11-03|2005-11-04|Estimate||||December 2004|2004-12-31|December 2004||2004-12-31|||||Interventional|||Study of the Effects Strengthening Exercises in Individuals With ALS|Preliminary Study: The Effects of a Strengthening Program on Maximum Voluntary Isometric Contraction, Functional Abilities, Fatigue and Quality of Life in Individuals With Amyotrophic Lateral Sclerosis|Completed||Phase 2|40||University of Saskatchewan|||||f||||||||||||||2018-06-01 04:31:34.681318|2018-06-01 04:31:34.681318
NCT00204451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-23|2005-09-19|2005-09-20|Estimate|||||||2016-11-23|2016-11-28|Estimate|July 2005||2005-07-31|November 2016|2016-11-30|June 2006||2006-06-30|||||Interventional|||Human Ovarian Follicular Dynamics and Emergency Contraception|Human Ovarian Follicular Dynamics and Emergency Contraception|Completed||Phase 4|40||University of Saskatchewan|||||f||||||||||||||2018-06-01 04:31:34.822903|2018-06-01 04:31:34.822903
NCT00204438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-23|2005-09-12|2005-09-20|Estimate|||||||2016-11-23|2016-11-28|Estimate|February 2002||2002-02-28|November 2016|2016-11-30|December 2002||2002-12-31|||||Interventional|||Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle|Follicular Profiles After Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle|Completed||N/A|45||University of Saskatchewan|||||f||||||||||||||2018-06-01 04:31:34.897878|2018-06-01 04:31:34.897878
NCT00204425|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-09-09|2005-09-12|2005-09-20|Estimate|||||||2011-09-09|2011-09-13|Estimate|December 2004||2004-12-31|September 2011|2011-09-30|April 2010|Actual|2010-04-30|December 2007|Actual|2007-12-31||Interventional|||Effect of Exercise Training and Soy-based Nutritional Supplementation on Prevention of Osteoporosis|Effect of Combined Exercise Therapy and Isoflavone Supplementation on Prevention of Osteoporosis|Completed||Phase 3|351|Actual|University of Saskatchewan||4|||f||||t||||||||||2018-06-01 04:31:34.978414|2018-06-01 04:31:34.978414
NCT00204412|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-01|2005-09-12|2005-09-20|Estimate|||||||2007-11-01|2007-11-05|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Exercise and Flax-Based Nutritional Supplementation for Lowering Cholesterol|Effectiveness of Flax Lignan and Exercise Training for Improving Lipid Profiles|Completed||Phase 3|100|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-06-01 04:31:35.085101|2018-06-01 04:31:35.085101
NCT00204399|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|July 2001||2001-07-31|May 2000|2000-05-31|December 2004||2004-12-31|||||Interventional|||Examining Physician Counseling to Promote Adoption of Physical Activity: A Controlled Trial|Examining Physician Counseling to Promote Adoption of Physical Activity: A Controlled Trial|Completed||Phase 1|200||University of Saskatchewan|||||f||||||||||||||2018-06-01 04:31:35.204748|2018-06-01 04:31:35.204748
NCT00204386|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-29|2005-09-12|2005-09-20|Estimate|||||||2007-05-29|2007-05-30|Estimate|September 2002||2002-09-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Safety & Efficacy Study Using Topiramate in Posttraumatic Stress Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder|Completed||Phase 2/Phase 3|50|Actual|University of Oklahoma|||||f||||t||||||||||2018-06-01 04:31:35.280799|2018-06-01 04:31:35.280799
NCT00204373|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-05-16||2012-10-23|2005-09-13|2005-09-20|Estimate|2012-09-19|2012-10-19|Estimate||||2012-10-23|2012-10-30|Estimate|March 2003||2003-03-31|October 2012|2012-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Zollinger-Ellison Syndrome With Prevacid|Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors|Completed||Phase 4|72|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-06-01 04:31:35.385585|2018-06-01 04:31:35.385585
NCT00204360|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-18|2005-09-13|2005-09-20|Estimate|||||||2007-04-18|2007-04-19|Estimate||||August 2005|2005-08-31||||||||Observational|||Pediatric Epilepsy Database|Pediatric Epilepsy Database|Completed|||||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 04:31:35.581906|2018-06-01 04:31:35.581906
NCT00204347|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-15|2005-09-13|2005-09-20|Estimate|||||||2012-03-15|2012-03-16|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder|Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS)|Completed||Phase 4|20||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 04:31:35.656968|2018-06-01 04:31:35.656968
NCT00204334|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-12|2005-09-12|2005-09-20|Estimate|||||||2010-01-12|2010-01-13|Estimate|June 2005||2005-06-30|May 2008|2008-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients|Effects of Anemia Correction on Vascular Function, Endothelial Cell Markers and Monocyte Apoptosis in Renal Transplant Recipients|Completed||Phase 4|60|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:31:35.725151|2018-06-01 04:31:35.725151
NCT00204321|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-12|2005-09-12|2005-09-20|Estimate|||||||2010-01-12|2010-01-13|Estimate|June 2005||2005-06-30|January 2010|2010-01-31|January 2010|Actual|2010-01-31|January 2008|Actual|2008-01-31||Interventional|||Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients|Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression|Completed||Phase 4|80|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:31:35.805786|2018-06-01 04:31:35.805786
NCT00204308|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-05-30|2005-09-12|2005-09-20|Estimate|||||||2012-05-30|2012-05-31|Estimate|March 2005||2005-03-31|May 2012|2012-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|TD-2||Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP|Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission|Completed||Phase 2|400|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 04:31:35.878952|2018-06-01 04:31:35.878952
NCT00204295|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-13|2005-09-14|2005-09-20|Estimate|||||||2006-09-13|2006-09-14|Estimate|January 2004||2004-01-31|September 2006|2006-09-30||||||||Interventional|||Study on Amino Acid Uptake in Brain Tumors|Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET)|Unknown status|Active, not recruiting|Phase 2|60||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:31:35.955498|2018-06-01 04:31:35.955498
NCT00204282|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-20|2005-09-12|2005-09-20|Estimate|||||||2013-09-20|2013-09-23|Estimate|August 2003||2003-08-31|September 2013|2013-09-30|December 2005||2005-12-31|||||Interventional|||The Effectiveness of Improving Compliance With Diabetic Preventative Services and Modifying Vascular Risk|The Effectiveness of Nurse Practitioner Led Group Visits in Improving Compliance With Diabetic Preventative Services and Modifying Vascular Risk|Completed||N/A|150||University of Chicago|||||f||||||||||||||2018-06-01 04:31:36.011914|2018-06-01 04:31:36.011914
NCT00204269|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-05-12|2005-09-12|2005-09-20|Estimate|||||||2006-05-12|2006-05-15|Estimate|January 2003||2003-01-31|May 2006|2006-05-31|September 2006||2006-09-30|||||Interventional|||Three-Year Trial on a New Testosterone Gel|Three-Year Trial on a New Testosterone Gel: Clinical Efficacy, Tolerability and Compliance|Unknown status|Active, not recruiting|Phase 3|100||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:31:36.07677|2018-06-01 04:31:36.07677
NCT00204256|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|March 2004||2004-03-31|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Intravenous Iron in Patients With Anemia of Chronic Kidney Disease|Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease|Unknown status|Active, not recruiting|Phase 4|50||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:31:36.151769|2018-06-01 04:31:36.151769
NCT00204243|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-18|2005-09-16|2005-09-20|Estimate|||||||2011-05-18|2011-05-19|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|||Naltrexone Implants vs. MMT Among Inmates in the Norwegian Correctional Services|Naltrexone Implants Compared to Methadone Maintenance Treatment (MMT) Among Inmates About to be Released From Prison - a Randomized Controlled Trial|Completed||Phase 2|46|Actual|University of Oslo||2|||f||||t||||||||||2018-06-01 04:31:36.213412|2018-06-01 04:31:36.213412
NCT00204230|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|October 1999||1999-10-31|September 2005|2005-09-30|September 2002||2002-09-30|||||Interventional|||MMF and Calcineurin Inhibitor Withdrawal in CAN|Randomized Controlled Study: Effect of Mycophenolatmofetil in Patients With Histologically Proven Chronic Allograft Nephropathy|Terminated||N/A|86||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:31:36.282132|2018-06-01 04:31:36.282132
NCT00204217|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-24|2005-09-12|2005-09-20|Estimate|||||||2007-08-24|2007-08-27|Estimate|September 2004||2004-09-30|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Monitoring of Intubation and Ventilation During Resuscitation|Monitoring of Intubation and Ventilation During Resuscitation|Completed||Phase 2|15||University of Oslo|||||f||||f||||||||||2018-06-01 04:31:36.338661|2018-06-01 04:31:36.338661
NCT00204204|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-24|2005-09-13|2005-09-20|Estimate|||||||2007-08-24|2007-08-27|Estimate|January 2005||2005-01-31|August 2007|2007-08-31|January 2006|Actual|2006-01-31|||||Observational|||Importance of Forces and Safety Features in Car Crash Multitrauma|The Multitraumatized Patient. What is the Importance of Forces Involved and the Use of Safety Equipment for the Amount of Trauma to the Patient Inside the Vehicle.|Completed|||200||University of Oslo|||||f||||f||||||||||2018-06-01 04:31:36.472578|2018-06-01 04:31:36.472578
NCT00204191|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-18|2005-09-12|2005-09-20|Estimate|||||||2007-10-18|2007-10-19|Estimate|May 2003||2003-05-31|September 2005|2005-09-30|December 2007||2007-12-31|||||Interventional|||Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation|Open, Prospective, Randomized Study to Compare the Efficacy and Safety of Immunosuppression Regimens Based on Cyclosporine (Neoral®) and Tacrolimus (Prograf®) in Renal Transplant Patients|Unknown status|Recruiting|Phase 4|300|Anticipated|Uniwersytet Mikolaja Kopernika w Toruniu|||||f||||||||||||||2018-06-01 04:31:36.528763|2018-06-01 04:31:36.528763
NCT00204178|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-11-30|2005-09-13|2005-09-20|Estimate|||||||2005-11-30|2005-12-01|Estimate|April 2003||2003-04-30|August 2005|2005-08-31|September 2005||2005-09-30|||||Observational|||The Role of Reactive Oxygen Species in Ischaemia-Reperfusion Injury of the Transplanted Kidney|The Role of Reactive Oxygen Species in Ischaemia-Reperfusion Injury of the Transplanted Kidney|Unknown status|Active, not recruiting||60||Uniwersytet Mikolaja Kopernika w Toruniu|||||f||||||||||||||2018-06-01 04:31:36.600442|2018-06-01 04:31:36.600442
NCT00204165|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-07|2005-09-13|2005-09-20|Estimate|||||||2006-09-07|2006-09-11|Estimate|November 2004||2004-11-30|September 2006|2006-09-30|June 2005||2005-06-30|||||Interventional|||Comparison of MR Enteroclysis and MRI With Per Oral Contrast Using a 6 % Mannitol Solution.|MRI of the Small Bowel. Comparison of Different Techniques and Contrast.|Unknown status|Active, not recruiting|Phase 3|40||University of Oslo|||||f||||||||||||||2018-06-01 04:31:36.659566|2018-06-01 04:31:36.659566
NCT00204152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-09-04|2005-09-13|2005-09-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2004||2004-06-30|September 2013|2013-09-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Treatment for Chronic Depression|Treatment for Chronic Depression With Behavioral Interventions|Terminated||Phase 3|30||University of Chicago||||PI left U of C|f||||f||||||||||2018-06-01 04:31:36.712175|2018-06-01 04:31:36.712175
NCT00204139|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|June 2002||2002-06-30|July 2004|2004-07-31|May 2004||2004-05-31|||||Interventional|||Routine Versus Selective Midtrimester Ultrasound in a Poorly Resourced Setting: a Cluster Randomised Controlled Trial||Completed||Phase 3|900||University of Johannesburg|||||f||||||||||||||2018-06-01 04:31:36.799738|2018-06-01 04:31:36.799738
NCT00204126|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-08|2005-09-12|2005-09-20|Estimate|||||||2006-09-08|2006-09-11|Estimate|February 2005||2005-02-28|September 2006|2006-09-30|February 2005||2005-02-28|||||Interventional|||Exercise Testing During Treadmill Gait in Incomplete Spinal Cord Injury|Determination of Novel Methods of Exercise Testing During Treadmill Gait in Incomplete Spinal Cord Injury|Unknown status|Active, not recruiting|N/A|4||University of Glasgow|||||f||||||||||||||2018-06-01 04:31:36.871236|2018-06-01 04:31:36.871236
NCT00204087|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-01-10|2005-09-12|2005-09-20|Estimate|||||||2006-01-10|2006-01-12|Estimate|January 2001||2001-01-31|June 1999|1999-06-30|June 2005||2005-06-30|||||Interventional|||Psychological Intervention for Persons in the Early Initial Prodromal State|Psychological Intervention for Persons at Risk of Psychosis in the Early Initial Prodromal State|Unknown status|Active, not recruiting|Phase 3|126||University of Cologne|||||f||||||||||||||2018-06-01 04:31:37.075928|2018-06-01 04:31:37.075928
NCT00204074|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-28|2005-09-12|2005-09-20|Estimate|||||||2005-12-28|2005-12-29|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||Treatment of Menstrual Migraine With Sequential, Transdermal, 17-Beta-Estradiol. A Double-Blind, Randomised, Cross-Over Trial.||Unknown status|Active, not recruiting|Phase 2/Phase 3|||University Hospital, Linkoeping|||||f||||||||||||||2018-06-01 04:31:37.148211|2018-06-01 04:31:37.148211
NCT00204061|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-12-23|2005-09-12|2005-09-20|Estimate|||||||2014-12-23|2014-12-24|Estimate|January 2001||2001-01-31|December 2014|2014-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis|Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis|Completed||Phase 4|124|Actual|University of Cologne||2|||f||||f||||||||||2018-06-01 04:31:37.213261|2018-06-01 04:31:37.213261
NCT00204048|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-28|2005-09-19|2005-09-20|Estimate|||||||2017-08-28|2017-08-30|Actual|July 2001||2001-07-31|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||A Multicenter Trial of Academic Hospitalists|A Multicenter Trial of Academic Hospitalists|Recruiting|||100000|Anticipated|University of Chicago|||||f||||f|f|f||||||No||2018-06-01 04:31:37.289099|2018-06-01 04:31:37.289099
NCT00204035|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-28|2005-09-19|2005-09-20|Estimate|||||||2017-08-28|2017-08-30|Actual|June 2004||2004-06-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2017|Anticipated|2017-09-30||Observational|||Evaluation of TEACH (Training Early Achievers for Careers in Health) Research|Evaluation of TEACH (Training Early Achievers for Careers in Health) Research|Recruiting|||400|Anticipated|University of Chicago|||||f||||f|f|f||||||No||2018-06-01 04:31:37.351692|2018-06-01 04:31:37.351692
NCT00204022|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-10-13|2005-09-12|2005-09-20|Estimate|||||||2011-10-13|2011-10-14|Estimate|February 2001||2001-02-28|October 2011|2011-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MAINTAIN||Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.|A Randomized Multicenter Trial Comparing Mycophenolate Mofetil and Azathioprine as Remission-maintaining Treatment for Proliferative Lupus Glomerulonephritis. The MAINTAIN Nephritis Trial.|Completed||Phase 3|105|Actual|Université Catholique de Louvain||2|||f||||f||||||||||2018-06-01 04:31:37.417523|2018-06-01 04:31:37.417523
NCT00204009|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-09-04|2005-09-13|2005-09-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 1992||1992-07-31|September 2013|2013-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||Chicago Childhood Diabetes Registry|Population-based Epidemiologic Study of Childhood Diabetes in Chicago: a) Disease Surveillance; b) Family Studies; c) Questionnaire Followup.|Completed|||2400|Actual|University of Chicago|||||f||||||||||||||2018-06-01 04:31:37.492433|2018-06-01 04:31:37.492433
NCT00203996|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-03-05||2013-07-16|2005-09-13|2005-09-20|Estimate|2013-06-11|2013-07-16|Estimate||||2013-07-16|2013-07-22|Estimate|September 2003||2003-09-30|July 2013|2013-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Polycystic Ovary Syndrome (PCOS) and Sleep Apnea|Sleep, Metabolic, and Cardiovascular Dysfunction in Polycystic Ovary Syndrome|Terminated||Phase 4|37|Actual|University of Chicago|No participants were randomized to any of the 3 study arms in Aim 1. Also, the recruitment of control subjects for Aim 2 was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria.|10||Did not meet target patient accrual goals|f||||f||||||||||2018-06-01 04:31:37.585406|2018-06-01 04:31:37.585406
NCT00203970|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-28|2005-09-12|2005-09-20|Estimate|||||||2017-08-28|2017-08-30|Actual|February 2001||2001-02-28|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|March 2001|Actual|2001-03-31||Observational|||Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services|Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services|Active, not recruiting|||645|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 04:31:38.072394|2018-06-01 04:31:38.072394
NCT00203957|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-10|2005-09-13|2005-09-20|Estimate|||||||2013-06-10|2013-06-11|Estimate|March 2005||2005-03-31|June 2013|2013-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa|A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy|Completed||Phase 3|10|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:31:38.126378|2018-06-01 04:31:38.126378
NCT00203944|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-08|2005-09-13|2005-09-20|Estimate|||||||2013-10-08|2013-10-09|Estimate|July 2002||2002-07-31|October 2013|2013-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||International Adoption and Stress Response Study|International Adoption and Stress Response Study|Completed|||39|Actual|University of Chicago|||2||f||||f||||||||||2018-06-01 04:31:38.218481|2018-06-01 04:31:38.218481
NCT00203931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-12-10||2014-02-12|2005-09-12|2005-09-20|Estimate|2014-02-12|2014-03-31|Estimate||||2014-02-12|2014-03-31|Estimate|March 2005||2005-03-31|February 2014|2014-02-28|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional||Includes evaluable patients (those that received at least 3 doses of cetuximab)|Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer|A Randomized Phase II Trial Comparing Cetuximab With Concurrent Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer Refractory to Primary Treatment|Terminated||Phase 2|55|Actual|University of Chicago||2||"Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed~   after first-line therapy"|f||||t||||||||||2018-06-01 04:31:38.284242|2018-06-01 04:31:38.284242
NCT00203918|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-28|2005-09-12|2005-09-20|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2004||2004-01-31|August 2017|2017-08-31|February 2013|Actual|2013-02-28|February 2011|Actual|2011-02-28||Observational|||Prostate Cancer Utilities and Cost-Effectiveness Analysis|Prostate Cancer Utilities and Cost-Effectiveness Analysis|Completed|||481|Actual|University of Chicago|||1||f||||f||||||||||2018-06-01 04:31:38.647661|2018-06-01 04:31:38.647661
NCT00203905|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-01-16|2005-09-12|2005-09-20|Estimate|||||||2014-01-16|2014-01-17|Estimate|January 2004||2004-01-31|January 2014|2014-01-31|November 2008|Actual|2008-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck|A Randomized Phase II Study of Concomitant Chemoradiotherapy With 5-Fluorouracil/Hydroxyurea Compared to FHX Plus Bevacizumab for Intermediate Stage and Selected Stage IV Cancers of the Head and Neck|Completed||Phase 2|23|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:31:38.724418|2018-06-01 04:31:38.724418
NCT00203892|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-01-31||2014-03-21|2005-09-12|2005-09-20|Estimate|2014-01-31|2014-03-14|Estimate||||2014-03-21|2014-04-16|Estimate|April 2003||2003-04-30|March 2014|2014-03-31|May 2012|Actual|2012-05-31|June 2009|Actual|2009-06-30||Interventional||The 19 patients who received at least 1 dose of the CEA vaccine are included in the baseline analysis population|Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma|A Randomized Pilot Phase II Study of Immunization With Modified CEA (CAP1-6D) Peptide In Patients With Locally Advanced Or Surgically Resected Adenocarcinoma of the Pancreas|Completed||Phase 1/Phase 2|23|Actual|University of Chicago||3|||f||||t||||||||||2018-06-01 04:31:38.816086|2018-06-01 04:31:38.816086
NCT00203879|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-04|2005-09-12|2005-09-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2002||2002-02-28|September 2013|2013-09-30|May 2007|Actual|2007-05-31|May 2006|Actual|2006-05-31||Interventional|||Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma|Randomized Phase II Study of Immunization With MAGE-3/Melan-A/gp 100/NA17 Peptide-Pulsed Autologous PBMC and rhIL-12 With or Without Low Dose IL-2 Inpatients With Metastatic Melanoma|Completed||Phase 2|19|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:31:39.120959|2018-06-01 04:31:39.120959
NCT00203866|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-04|2005-09-12|2005-09-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2003||2003-10-31|September 2013|2013-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma|A Randomized Pilot Phase II Trial of Adjuvant Immunization With G250 Peptide andThree Different Dose Levels of IL-2 Following Surgical Resection of Locally Advanced or Metastatic Renal Cell Carcinoma|Terminated||Phase 2|40|Anticipated|University of Chicago||||Study completed|f||||t||||||||||2018-06-01 04:31:39.196809|2018-06-01 04:31:39.196809
NCT00203853|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-04|2005-09-12|2005-09-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2005||2005-01-31|September 2013|2013-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults|Evaluation of an Intervention (Consisting of an Electronic Reminder Device, Pillboxes, and Monthly Telephone Calls) on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults|Terminated||N/A|200||University of Chicago|||||f||||||||||||||2018-06-01 04:31:39.261606|2018-06-01 04:31:39.261606
NCT00203840|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-05-12|2005-09-12|2005-09-20|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 2004||2004-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Pediatric Sleep Questionnaire: Normalization and Validation Study|Pediatric Sleep Questionnaire: Normalization and Validation Study|Completed|||325|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 04:31:39.328879|2018-06-01 04:31:39.328879
NCT00203827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-04|2005-09-12|2005-09-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2004||2004-09-30|September 2013|2013-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Pediatric Sleep Questionnaire: Use for Collection of Clinical Data|Pediatric Sleep Questionnaire: Use for Collection of Clinical Data|Completed|||300|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 04:31:39.390776|2018-06-01 04:31:39.390776
NCT00203814|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-15|2005-09-13|2005-09-20|Estimate|||||||2006-11-15|2006-11-16|Estimate|January 2004||2004-01-31|August 2005|2005-08-31|March 2005||2005-03-31|||||Interventional|||A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria|Open-Label, Randomised, Parallel Group in Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT), Artesunate and Sulfadoxine-Pyrimethamine Versus Sulfadoxine-Pyrimethamine Alone, in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carriage and Prevalence of Molecular Markers Associated With SP Resistance In Uncomplicated Plasmodium Falciparum Infections.|Completed||N/A|280||University of Cape Town|||||f||||||||||||||2018-06-01 04:31:39.461447|2018-06-01 04:31:39.461447
NCT00203801|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2006-09-07|2005-09-13|2005-09-20|Estimate|||||||2006-09-07|2006-09-11|Estimate|January 2002||2002-01-31|August 2005|2005-08-31|July 2005||2005-07-31|||||Interventional|||Combination Antimalarials in Uncomplicated Malaria|An Open Label In Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT),in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carriage and Prevalence of Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections.|Completed||N/A|700||University of Cape Town|||||f||||||||||||||2018-06-01 04:31:39.54652|2018-06-01 04:31:39.54652
NCT00203788|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-07-28|2005-09-14|2005-09-20|Estimate|||||||2013-07-28|2013-07-30|Estimate|May 1999||1999-05-31|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Improving Work Outcome in People With Recent-onset Schizophrenia|Developmental Processes in Schizophrenic Disorders: Improving and Predicting Work Outcome in Recent-Onset Schizophrenia|Completed||Phase 4|87|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 04:31:39.623694|2018-06-01 04:31:39.623694
NCT00203775|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-12|2005-09-12|2005-09-20|Estimate|||||||2006-10-12|2006-10-13|Estimate|July 2002||2002-07-31|May 2005|2005-05-31|April 2004||2004-04-30|||||Interventional|||Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates|Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates|Terminated||N/A|||UConn Health|||||f||||||||||||||2018-06-01 04:31:39.719055|2018-06-01 04:31:39.719055
NCT00203762|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-23|2005-09-12|2005-09-20|Estimate|||||||2007-10-23|2007-10-24|Estimate|May 2003||2003-05-31|March 2004|2004-03-31|December 2006||2006-12-31|||||Interventional|||Effect of Public Sector Antiretroviral Treatment Programme on Tuberculosis and Immunization Care|Effect of the South African Public Sector Antiretroviral Treatment Programme on the Performance of Tuberculosis and Immunization Programmes - A Cluster Controlled (Non-Randomized) Trial|Unknown status|Recruiting|N/A|39|Anticipated|University of Cape Town|||||f||||||||||||||2018-06-01 04:31:39.772853|2018-06-01 04:31:39.772853
NCT00203749|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-11|2005-09-13|2005-09-20|Estimate|||||||2013-12-11|2013-12-12|Estimate|December 2004||2004-12-31|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand|NIMH Project Accept: A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand|Completed||Phase 3|192814|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 04:31:39.846244|2018-06-01 04:31:39.846244
NCT00203736|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-15|2005-09-13|2005-09-20|Estimate|||||||2006-11-15|2006-11-16|Estimate|January 2003||2003-01-31|August 2005|2005-08-31|October 2003||2003-10-31|||||Interventional|||A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria|Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections|Completed||N/A|240||University of Cape Town|||||f||||||||||||||2018-06-01 04:31:39.924425|2018-06-01 04:31:39.924425
NCT00203723|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-05-17|2005-09-13|2005-09-20|Estimate|||||||2006-05-17|2006-05-18|Estimate|March 2005||2005-03-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Use of Risperidone in ECT for Treatment Resistant Depression|A Comparison Study of Combined ECT and Risperidone Versus ECT Alone for Treatment Resistant Depression.|Terminated||Phase 4|45||University of California, Los Angeles|||||f||||||||||||||2018-06-01 04:31:39.989546|2018-06-01 04:31:39.989546
NCT00203710|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-10|2005-09-13|2005-09-20|Estimate|||||||2015-12-10|2015-12-14|Estimate|October 2003||2003-10-31|December 2015|2015-12-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Concentric Retriever Device (CRD) in Acute Ischemic Stroke|A Single-Center Controlled Registry to Evaluate the Concentric Retriever System for the Treatment of Stroke|Completed||N/A|50||University of California, Los Angeles|||||||||||||||||||2018-06-01 04:31:40.057325|2018-06-01 04:31:40.057325
NCT00203697|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-07|2005-09-13|2005-09-20|Estimate|||||||2006-09-07|2006-09-11|Estimate||||September 2006|2006-09-30||||||||Interventional|||Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study|Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study|Unknown status|Active, not recruiting|Phase 3|||University of California, Los Angeles|||||||||||||||||||2018-06-01 04:31:40.120013|2018-06-01 04:31:40.120013
NCT00203684|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-15|2005-09-13|2005-09-20|Estimate|||||||2017-02-15|2017-02-17|Actual||||February 2017|2017-02-28||||||||Interventional|||Mentored Patient-Oriented Research Career Development Award|The Effects of Different Sized Inhaled Corticosteroids on Peripheral Lung Inflammation in Asthma Assessed Through Lung Tissue Samples (SMART Protocol)|Recruiting||Phase 1/Phase 2|||University of California, Los Angeles|||||||||||||||||||2018-06-01 04:31:40.176503|2018-06-01 04:31:40.176503
NCT00203671|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-12|2005-09-12|2005-09-20|Estimate|||||||2010-07-12|2010-07-13|Estimate|April 2006||2006-04-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Observational|||Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation|Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation|Completed|||651|Actual|University of California, Los Angeles|||||f||||||||||||||2018-06-01 04:31:40.24548|2018-06-01 04:31:40.24548
NCT00203658|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-02-08|2005-09-12|2005-09-20|Estimate|||||||2007-02-08|2007-02-09|Estimate|April 1997||1997-04-30|September 2005|2005-09-30|October 2000||2000-10-31|||||Interventional|||Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin|LITE Study, Appendix A (HOME-LITE), Amendment 6|Completed||Phase 4|400||University of Calgary|||||||||||||||||||2018-06-01 04:31:40.29045|2018-06-01 04:31:40.29045
NCT00203645|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-13|2005-09-13|2005-09-20|Estimate|||||||2009-02-13|2009-02-16|Estimate|July 2003||2003-07-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|April 2006|Actual|2006-04-30||Interventional|||Minimal and Brief Treatments for Pathological Gamblers|Minimal and Brief Treatments for Pathological Gamblers: Developing Effective Treatment Systems|Completed||Phase 3|312|Actual|University of Calgary||4|||f||||f||||||||||2018-06-01 04:31:40.35335|2018-06-01 04:31:40.35335
NCT00203632|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-30|2005-09-13|2005-09-20|Estimate|||||||2008-10-30|2008-11-03|Estimate|September 2003||2003-09-30|October 2008|2008-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Glitazones and Endothelial Function (GATE)|A Trial of the Effect of Rosiglitazone as Add on to Metformin Therapy on Endothelial Function in Subjects With Type II DM|Terminated||Phase 3|40|Actual|University of Calgary||||Terminated at 50% enrollment due to recent concerns about rosiglitazone|f||||t||||||||||2018-06-01 04:31:40.433979|2018-06-01 04:31:40.433979
NCT00203619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-12-01|2005-09-13|2005-09-20|Estimate|||||||2017-12-01|2017-12-05|Actual|May 2005||2005-05-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||Capsule Endoscopy in Obscure GI Bleeding|An Economic Evaluation of Capsule Endoscopy for Obscure Gastrointestinal Bleeding|Completed||N/A|40|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 04:31:40.49839|2018-06-01 04:31:40.49839
NCT00203606|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-03|2005-09-13|2005-09-20|Estimate|||||||2011-08-03|2011-08-04|Estimate|January 2004||2004-01-31|August 2011|2011-08-31|August 2011|Actual|2011-08-31|January 2009|Actual|2009-01-31||Interventional|||Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C|Effectiveness of Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C|Completed||Phase 4|66|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 04:31:40.580602|2018-06-01 04:31:40.580602
NCT00203593|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-12|2005-09-13|2005-09-20|Estimate|||||||2007-03-12|2007-03-14|Estimate|March 2006||2006-03-31|March 2007|2007-03-31|June 2007||2007-06-30|||||Interventional|||Exercise and Prevention of Syncope: EXPOSE|EXercise for the Prevention of Syncope Evaluation|Suspended||Phase 1|20||University of Calgary||||No Resources - No Personnel|f||||||||||||||2018-06-01 04:31:40.65199|2018-06-01 04:31:40.65199
NCT00203580|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-02-08|2005-09-12|2005-09-20|Estimate|||||||2007-02-08|2007-02-09|Estimate|December 1994||1994-12-31|September 2005|2005-09-30|March 2002||2002-03-31|||||Interventional|||Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)|A Randomized Trial of the Effect of Low-Molecular-Weight Heparin Versus Warfarin Sodium on the Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (Main LITE Study)|Completed||Phase 4|910||University of Calgary|||||||||||||||||||2018-06-01 04:31:40.719785|2018-06-01 04:31:40.719785
NCT00203567|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-23|2005-09-12|2005-09-20|Estimate|||||||2008-06-23|2008-06-24|Estimate|August 2005||2005-08-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|February 2007|Actual|2007-02-28||Interventional|||Carbamazepine Extended-Release for the Treatment of Bipolar Depression|Carbamazepine Extended-Release for the Treatment of Bipolar Depression|Completed||Phase 4|25|Actual|Tuscaloosa Research & Education Advancement Corporation||1|||f||||f||||||||||2018-06-01 04:31:40.785351|2018-06-01 04:31:40.785351
NCT00203554|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2008-03-26|2005-09-16|2005-09-20|Estimate|||||||2008-03-26|2008-03-27|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Percutaneous Vertebroplasty Versus Conservative Treatment of Pain|Percutaneous Vertebroplasty Versus Conservative Treatment of Pain: A Prospective, Randomized Controlled Study of Osteoporotic Fractures in the Spine|Completed||N/A|27|Actual|University of Aarhus|||||f||||t||||||||||2018-06-01 04:31:40.945503|2018-06-01 04:31:40.945503
NCT00203541|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-16|2005-09-14|2005-09-20|Estimate|||||||2007-11-16|2007-11-19|Estimate|February 2004||2004-02-29|November 2007|2007-11-30|June 2006||2006-06-30|||||Interventional|||Effects of a New Antimicrobial Dressing on Wound Healing and Incidence of Sternal Wound Infections|Effects of a New Antimicrobial Dressing on Wound Healing and Incidence of Sternal Wound Infections in Subjects Who Have Undergone Cardiac Surgical Procedures Requiring Median Sternotomy|Terminated||N/A|1100||Tyco Healthcare Group||||Reallocation of funding.|f||||||||||||||2018-06-01 04:31:41.030153|2018-06-01 04:31:41.030153
NCT00203528|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-16|2005-09-12|2005-09-20|Estimate|||||||2007-03-16|2007-03-19|Estimate|January 2004||2004-01-31|March 2007|2007-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder|Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder|Completed||Phase 4|30||Tuscaloosa Research & Education Advancement Corporation|||||f||||f||||||||||2018-06-01 04:31:41.099022|2018-06-01 04:31:41.099022
NCT00203515|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-04|2005-09-12|2005-09-20|Estimate|||||||2008-01-04|2008-01-14|Estimate|January 2005||2005-01-31|January 2008|2008-01-31||||March 2007|Actual|2007-03-31||Interventional|||Study Comparing the DOVER Silver Foley Catheter to a Standard of Care Catheter and a Marketed Silver Coated Foley Catheter|A Prospective, Randomized, Controlled Study Comparing the DOVER Silver Foley Catheter to a Standard of Care Catheter and a Marketed Silver Coated Foley Catheter|Completed||N/A|1000||Tyco Healthcare Group|||||||||||||||||||2018-06-01 04:31:41.172745|2018-06-01 04:31:41.172745
NCT00203502|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-10-21||2016-05-02|2005-09-12|2005-09-20|Estimate|2015-11-30|2016-01-05|Estimate||||2016-05-02|2016-05-11|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer|Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorubicin in Operable/Locally Advanced Breast Cancer|Completed||Phase 2|40|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 04:31:41.279646|2018-06-01 04:31:41.279646
NCT00203489|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-16|2005-09-12|2005-09-20|Estimate|||||||2007-11-16|2007-11-19|Estimate|June 2005||2005-06-30|November 2007|2007-11-30|August 2007||2007-08-31|||||Interventional|||A Clinical Study of An Antimicrobial Gauze Dressing|A Prospective Randomized Double-Blind Trial of a Polyhexamethylene Biguanide (PHMB) Impregnated Gauze Dressing for the Prevention of Chronic Wound Colonization With Resistant and Prevalent Microorganisms|Terminated||N/A|200|Anticipated|Tyco Healthcare Group||||Reallocation of funding.|f||||||||||||||2018-06-01 04:31:41.537152|2018-06-01 04:31:41.537152
NCT00203476|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-12-05||2014-08-08|2005-09-12|2005-09-20|Estimate|2014-08-08|2014-08-12|Estimate||||2014-08-08|2014-08-12|Estimate|May 2005||2005-05-31|August 2014|2014-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||100% male, age 50 years or greater|A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction|A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction|Completed||Phase 4|30|Actual|Tuscaloosa Research & Education Advancement Corporation|Open label.|3|||f||||f||||||||||2018-06-01 04:31:41.619968|2018-06-01 04:31:41.619968
NCT00203463|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-07-28|2005-09-12|2005-09-20|Estimate|||||||2009-07-28|2009-07-29|Estimate|July 2001||2001-07-31|July 2009|2009-07-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)|Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)|Completed||Phase 4|40||Tuscaloosa Research & Education Advancement Corporation|||||f||||||||||||||2018-06-01 04:31:41.971967|2018-06-01 04:31:41.971967
NCT00203450|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-08-30|2005-09-12|2005-09-20|Estimate|||||||2012-08-30|2012-09-03|Estimate|May 2003||2003-05-31|August 2012|2012-08-31|March 2006|Actual|2006-03-31|March 2005|Actual|2005-03-31||Interventional|Zonegran||Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial|Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial|Completed||Phase 4|20|Actual|Tuscaloosa Research & Education Advancement Corporation||2|||f||||f||||||||||2018-06-01 04:31:42.038404|2018-06-01 04:31:42.038404
NCT00203424|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-04-12||2016-02-26|2005-09-13|2005-09-20|Estimate|2011-04-12|2011-05-09|Estimate||||2016-02-26|2016-03-25|Estimate|January 2006||2006-01-31|February 2016|2016-02-29|June 2010|Actual|2010-06-30|February 2009|Actual|2009-02-28||Interventional|||Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib|A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer|Completed||Phase 2|23|Actual|Translational Oncology Research International|This was a small study with only 22 participants who received study treatment. With such a small sample size the study doesnt have the statistcical power to make categorical assessments or statements.|1|||f||||t||||||||||2018-06-01 04:31:42.133107|2018-06-01 04:31:42.133107
NCT00203411|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-02-10||2017-02-03|2005-09-13|2005-09-20|Estimate|2017-02-03|2017-02-06|Estimate||||2017-02-03|2017-02-06|Estimate|March 2006||2006-03-31|March 2016|2016-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer|A Phase II Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Capecitabine (Xeloda) in Frail Patients With Untreated Metastatic Colorectal Cancer|Completed||Phase 2|45|Actual|Translational Oncology Research International|This was a small study with only 45 participants who received study treatment. With such a small sample size the study does not have the statistical power to make categorical assessments or statements.|1|||f||||t||||||||||2018-06-01 04:31:42.37177|2018-06-01 04:31:42.37177
NCT00203385|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-24|2005-09-12|2005-09-20|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2003|Actual|2003-05-31|April 2017|2017-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder|Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder|Terminated||Phase 4|20|Actual|Tuscaloosa Research & Education Advancement Corporation||1||Funding expired|f||||f||||||||No||2018-06-01 04:31:42.598218|2018-06-01 04:31:42.598218
NCT00203372|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-09|2005-09-12|2005-09-20|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2005||2005-05-31|February 2011|2011-02-28||||June 2012|Actual|2012-06-30||Interventional|||Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)|A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer|Completed||Phase 2|6|Actual|Translational Oncology Research International||4|||f||||t||||||||||2018-06-01 04:31:42.686137|2018-06-01 04:31:42.686137
NCT00203359|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-04-20|2005-09-12|2005-09-20|Estimate|||||||2006-04-20|2006-04-24|Estimate|September 2004||2004-09-30|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||TNF-Alpha Inhibition for Treatment of Alzheimer's Disease|Etanercept for Alzheimer's-Type Memory Loss Pilot Study|Completed||Phase 1|15||Tobinick, Edward Lewis, M.D.|||||f||||||||||||||2018-06-01 04:31:42.771829|2018-06-01 04:31:42.771829
NCT00203346|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-22|2005-09-13|2005-09-20|Estimate|||||||2009-01-22|2009-01-23|Estimate|June 2005||2005-06-30|January 2009|2009-01-31||||||||Observational|||Research Study Examining Nerve Block for Migraine|Greater Occipital Nerve (GON) Block for Migraine|Completed|||30||Thomas Jefferson University|||||f||||||||||||||2018-06-01 04:31:42.815827|2018-06-01 04:31:42.815827
NCT00203333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-17|2005-09-13|2005-09-20|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2002||2002-04-30|October 2016|2016-10-31|January 2010|Actual|2010-01-31|June 2007|Actual|2007-06-30||Observational|||Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death|Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death|Completed|||19|Actual|Thomas Jefferson University|||||f||||t||||||||||2018-06-01 04:31:42.85847|2018-06-01 04:31:42.85847
NCT00203320|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-04-20|2005-09-12|2005-09-20|Estimate|||||||2006-04-20|2006-04-24|Estimate|April 2005||2005-04-30|April 2006|2006-04-30|January 2006||2006-01-31|||||Interventional|||TNF-Alpha Inhibition for Treatment of Alzheimer's Disease|Etanercept for Alzheimer's-Type Memory Loss Pilot Study II|Completed||Phase 1|30||Tobinick, Edward Lewis, M.D.|||||f||||||||||||||2018-06-01 04:31:42.908293|2018-06-01 04:31:42.908293
NCT00203307|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-05-24||2011-08-23|2005-09-13|2005-09-20|Estimate|2011-07-13|2011-08-10|Estimate||||2011-08-23|2011-08-25|Estimate|May 2004||2004-05-31|August 2011|2011-08-31|June 2006|Actual|2006-06-30|March 2006|Actual|2006-03-31||Interventional|||A Research Study Examining the Use of Olanzapine for the Prevention of Migraine|A Single-Site, Double-Blind, Placebo-Controlled Cross-Over Trial Examining the Safety and Efficacy of Olanzapine Taken Daily for the Prevention of Episodic Migraine.|Terminated||N/A|3|Actual|Thomas Jefferson University||2||Study terminated by sponsor|f||||||||||||||2018-06-01 04:31:42.958158|2018-06-01 04:31:42.958158
NCT00203294|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-05-19||2014-04-07|2005-09-13|2005-09-20|Estimate|2014-04-07|2014-05-07|Estimate||||2014-04-07|2014-05-07|Estimate|June 2005||2005-06-30|April 2014|2014-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache|Comparison Of Greater Occipital Nerve Block With Lidocaine And Bupivicaine Alone Or With Steroids In a Chronic Headache Population|Completed||N/A|45|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-06-01 04:31:43.983563|2018-06-01 04:31:43.983563
NCT00203281|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-19|2005-09-13|2005-09-20|Estimate|||||||2016-10-19|2016-10-21|Estimate|February 2003||2003-02-28|October 2016|2016-10-31|September 2009|Anticipated|2009-09-30|September 2009|Anticipated|2009-09-30||Observational|||Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis|Pharmacokinetic Evaluation of Plasmapheresis in Cross Match Positive or ABO Incompatible Kidney Allograft Recipients|Withdrawn|||0|Actual|Thomas Jefferson University||||funding withdrawn|f||||f||||||||||2018-06-01 04:31:44.172365|2018-06-01 04:31:44.172365
NCT00203268|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-10-25||2014-05-08|2005-09-13|2005-09-20|Estimate|2014-05-08|2014-06-09|Estimate||||2014-05-08|2014-06-09|Estimate|December 2003||2003-12-31|May 2014|2014-05-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity|An Open Label Pilot Trial to Collect and Evaluate Data on the Use of Dihydroergotamine Mesylate in the Treatment of Two Migraine Attacks Associated With Cutaneous Allodynia|Completed||N/A|13|Actual|Thomas Jefferson University||1|||f||||f||||||||||2018-06-01 04:31:44.238007|2018-06-01 04:31:44.238007
NCT00203255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-22|2005-09-13|2005-09-20|Estimate|||||||2009-01-22|2009-01-23|Estimate|May 2003||2003-05-31|January 2009|2009-01-31|March 2005||2005-03-31|||||Interventional|||Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache|An Open-Label, Pilot Study Examining the Use of Soy Isoflavones in the Prevention of Menstrually-Associated Migraine|Completed||N/A|25||Thomas Jefferson University|||||f||||||||||||||2018-06-01 04:31:44.38443|2018-06-01 04:31:44.38443
NCT00203242|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-06-07||2011-07-13|2005-09-13|2005-09-20|Estimate|2011-06-07|2011-07-06|Estimate||||2011-07-13|2011-07-15|Estimate|July 2003||2003-07-31|July 2011|2011-07-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.|An Open-label Pilot Study to Collect/Evaluate Data on the Use of Consecutive Daily Intravenous Doses of Depacon in Combination With Daily Dose of Depakote ER During a Cluster Headache Cycle.|Completed||N/A|15|Actual|Thomas Jefferson University||1|||f||||||||||||||2018-06-01 04:31:44.448879|2018-06-01 04:31:44.448879
NCT00203229|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-02-07||2014-05-02|2005-09-13|2005-09-20|Estimate|2014-05-02|2014-06-03|Estimate||||2014-05-02|2014-06-03|Estimate|June 2003||2003-06-30|May 2014|2014-05-31|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia|A Double-Blind Placebo Controlled Add-on Study to Determine the Efficacy and Safety of Lamictal (Lamotrigine) in Patients With Trigeminal Neuralgia (Tic Doloureux)|Completed||N/A|20|Actual|Thomas Jefferson University|Limited enrollment due to fear of placebo and high drop out rate.|2|||f||||f||||||||||2018-06-01 04:31:44.699704|2018-06-01 04:31:44.699704
NCT00203216|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-05-23||2011-07-15|2005-09-13|2005-09-20|Estimate|2011-07-15|2011-08-11|Estimate||||2011-07-15|2011-08-11|Estimate|September 2002||2002-09-30|July 2011|2011-07-31|September 2005|Actual|2005-09-30|January 2005|Actual|2005-01-31||Interventional|||A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches|A Single-Center, Open-Label Trial Examining the Efficacy and Safety of Levetiracetam for the Prophylactic Treatment of Migraine, With or Without Aura|Completed||N/A|31|Actual|Thomas Jefferson University||1|||f||||||||||||||2018-06-01 04:31:44.91632|2018-06-01 04:31:44.91632
NCT00203203|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-07-06||2016-10-17|2005-09-12|2005-09-20|Estimate|2012-12-20|2013-01-30|Estimate||||2016-10-17|2016-11-28|Estimate|April 2004||2004-04-30|October 2016|2016-10-31|November 2009|Actual|2009-11-30|August 2008|Actual|2008-08-31||Interventional|||Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)|Randomized Controlled Single Blind Trial of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Therapeutic Angiogenesis|Completed||Phase 1|30|Actual|Texas Heart Institute|The study is a preliminary study based on a small sample size which limits the statistical rigor of the analysis.|2|||f||||t||||||||No|Data summarized and published. No need to share individual patient data.|2018-06-01 04:31:45.120611|2018-06-01 04:31:45.120611
NCT00203190|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-22|2005-09-12|2005-09-20|Estimate|||||||2009-01-22|2009-01-23|Estimate|September 2004||2004-09-30|January 2009|2009-01-31|June 2006||2006-06-30|||||Interventional|||A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache|A Single-Center, Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache.|Terminated||Phase 4|60||Thomas Jefferson University|||||f||||||||||||||2018-06-01 04:31:45.736216|2018-06-01 04:31:45.736216
NCT00203177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-08|2005-09-13|2005-09-20|Estimate|||||||2010-03-08|2010-03-09|Estimate|October 2001||2001-10-31|March 2010|2010-03-31||||December 2006|Actual|2006-12-31||Interventional|||Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.|A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.|Completed||Phase 3|254|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 04:31:45.793424|2018-06-01 04:31:45.793424
NCT00203164|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-08|2005-09-13|2005-09-20|Estimate|||||||2010-03-08|2010-03-09|Estimate|May 2002||2002-05-31|March 2010|2010-03-31|September 2006|Actual|2006-09-30|July 2005|Actual|2005-07-31||Interventional|||Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients|A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy|Completed||Phase 3|254|Actual|Teva Pharmaceutical Industries||1|||||||f||||||||||2018-06-01 04:31:45.868424|2018-06-01 04:31:45.868424
NCT00203151|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-08|2005-09-13|2005-09-20|Estimate|||||||2011-04-08|2011-04-12|Estimate|July 2005||2005-07-31|April 2011|2011-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|PRELUDE||A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus|A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Edratide for Subcutaneous Injection in Systemic Lupus Erythematosus (SLE)|Terminated||Phase 2|340|Actual|Teva Pharmaceutical Industries||2||TV-4710/201 did not meet its primary endpoints in patients with SLE|t||||||||||||||2018-06-01 04:31:46.035089|2018-06-01 04:31:46.035089
NCT00203138|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-08|2005-09-13|2005-09-20|Estimate|||||||2011-04-08|2011-04-12|Estimate|June 2004||2004-06-30|April 2011|2011-04-30|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease|A Multicenter, Open-Label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline Mesylate in Patients With Parkinson's Disease|Completed||Phase 3|306|Actual|Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:31:46.090987|2018-06-01 04:31:46.090987
NCT00203125|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-08|2005-09-13|2005-09-20|Estimate|||||||2011-04-08|2011-04-12|Estimate|October 2000||2000-10-31|April 2011|2011-04-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.|Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)|Completed||Phase 3|55|Actual|Teva Pharmaceutical Industries|||||f||||t||||||||||2018-06-01 04:31:46.140832|2018-06-01 04:31:46.140832
NCT00203112|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-11|2005-09-13|2005-09-20|Estimate|||||||2011-04-11|2011-04-12|Estimate|June 2004||2004-06-30|April 2011|2011-04-30|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline|A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA).|Completed||Phase 2|44|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 04:31:46.2005|2018-06-01 04:31:46.2005
NCT00203099|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-11|2005-09-13|2005-09-20|Estimate|||||||2012-05-11|2012-05-14|Estimate|December 2004||2004-12-31|May 2012|2012-05-31|June 2008|Actual|2008-06-30|August 2006|Actual|2006-08-31||Interventional|||Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine|A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)|Completed||Phase 2|18|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 04:31:46.274762|2018-06-01 04:31:46.274762
NCT00203086|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-27|2005-09-13|2005-09-20|Estimate|||||||2010-04-27|2010-04-29|Estimate|October 2005||2005-10-31|April 2010|2010-04-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis|A Multi-Centered, Two Arm, Open Label Extension Study (to Protocol NC-100) to Evaluate the Long-Term Safety and Efficacy of Short-Term Induction Treatment With Mitoxantrone (Novantrone®) Preceding Treatment With Glatiramer Acetate (Copaxone®) vs. Chronic Treatment With Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis|Completed|||30|Actual|Teva Pharmaceutical Industries|||||f||||t||||||||||2018-06-01 04:31:46.343146|2018-06-01 04:31:46.343146
NCT00203073|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-13|2005-09-13|2005-09-20|Estimate|||||||2011-04-13|2011-04-14|Estimate|June 2003||2003-06-30|April 2011|2011-04-30|April 2005|Actual|2005-04-30|January 2005|Actual|2005-01-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.|A Multi-Center, Randomized, Open Label Study To Evaluate Safety, Tolerability And Efficacy Of Treatment With Mitoxantrone; Pre-Treatment With Glatiramer Acetate (GA) Versus Treatment With GA Alone In Relapsing Forms Of Multiple Sclerosis.|Completed||Phase 2|40|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:31:46.405562|2018-06-01 04:31:46.405562
NCT00203060|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-08|2005-09-13|2005-09-20|Estimate|||||||2011-04-08|2011-04-12|Estimate|July 1997||1997-07-31|April 2011|2011-04-30|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial For The Efficacy, Tolerability And Safety Of Two Doses Of Rasagiline Mesylate In Early Parkinson's Disease (PD) Patients Not Treated With Levodopa|Completed||Phase 3|404|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-06-01 04:31:46.470264|2018-06-01 04:31:46.470264
NCT00203047|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-08-29||2013-11-15|2005-09-13|2005-09-20|Estimate|2013-11-15|2014-01-06|Estimate||||2013-11-15|2014-01-06|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|ASSERT|Represents database as of January 29, 2009|Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate|A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-on Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated With Glatiramer Acetate (GA)|Terminated||Phase 4|414|Actual|Teva Pharmaceutical Industries||2||Slow enrollment decreased sample size; No unexpected safety issues.|f||||t||||||||||2018-06-01 04:31:46.603876|2018-06-01 04:31:46.603876
NCT00203034|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-08|2005-09-13|2005-09-20|Estimate|||||||2010-03-08|2010-03-09|Estimate|May 2000||2000-05-31|March 2010|2010-03-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations|A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study, for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations|Completed||Phase 3|472|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-06-01 04:31:47.673692|2018-06-01 04:31:47.673692
NCT00203021|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-06|2005-09-12|2005-09-20|Estimate|||||||2017-12-06|2017-12-08|Actual|May 2, 1994|Actual|1994-05-02|December 2017|2017-12-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.|Open Label Study to Evaluate the Safety of Copaxone(R) and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone(R)|Active, not recruiting||Phase 4|208|Actual|Teva Pharmaceutical Industries||1|||f||||f|t|f||||||||2018-06-01 04:31:47.728397|2018-06-01 04:31:47.728397
NCT00203008|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-10-14|2005-09-13|2005-09-20|Estimate|||||||2010-10-14|2010-10-18|Estimate|January 2003||2003-01-31|October 2010|2010-10-31|September 2003|Actual|2003-09-30|||||Observational|||A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma|A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients|Completed|||2106|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-06-01 04:31:47.876458|2018-06-01 04:31:47.876458
NCT00202995|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-10-14|2005-09-13|2005-09-20|Estimate|||||||2010-10-14|2010-10-18|Estimate|July 2004||2004-07-31|October 2010|2010-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS|A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone® to That of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients|Terminated||Phase 4|91|Actual|Teva Pharmaceutical Industries||2||Slow enrollment decreased sample size No unexpected safety issues.|f||||t||||||||||2018-06-01 04:31:47.924339|2018-06-01 04:31:47.924339
NCT00202982|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-12|2005-09-12|2005-09-20|Estimate|||||||2010-01-12|2010-01-14|Estimate|August 2003||2003-08-31|January 2010|2010-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose|A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients|Completed||Phase 2|90|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 04:31:47.989203|2018-06-01 04:31:47.989203
NCT00202969|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-07-06|2005-09-12|2005-09-20|Estimate|||||||2011-07-06|2011-07-07|Estimate|July 2005||2005-07-31|July 2011|2011-07-31|June 2007|Actual|2007-06-30|January 2007|Actual|2007-01-31||Interventional|||Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer|An Open-label, Multicenter, Randomized, 3 Arm Study of S-1 Compared With S-1/CDDP, or S-1/CDDP Compared With 5-FU/CDDP in Patients With Advanced Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease|Completed||Phase 3|180|Anticipated|Taiho Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-06-01 04:31:48.094562|2018-06-01 04:31:48.094562
NCT00202956|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|June 2004||2004-06-30|September 2005|2005-09-30|May 2005||2005-05-31|||||Interventional|||Safety and Efficacy Study of Bugusan (BGS)to Treat Osteoporosis.|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects on Biomarkers and Safety of Bugusan (BGS) in Postmenopausal Patients With Osteoporosis.|Unknown status|Recruiting|Phase 2|||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 04:31:48.16311|2018-06-01 04:31:48.16311
NCT00202943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|March 2004||2004-03-31|||||Interventional|||Randomized Controlled Trial of TCRFVR and LAUP in Snorers|Comparison of Clinical Effect Between Temperature-Controlled Radio-Frequency Uvuloplasty and Laser Assisted Uvulo-Pharyngoplasty in Patients Who Snore|Completed||N/A|40||Taichung Veterans General Hospital|||||f||||||||||||||2018-06-01 04:31:48.236215|2018-06-01 04:31:48.236215
NCT00202930|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-19|2005-09-12|2005-09-20|Estimate|||||||2006-09-19|2006-09-20|Estimate|July 2005||2005-07-31|September 2006|2006-09-30|July 2008||2008-07-31|||||Interventional|||Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma|Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma|Unknown status|Recruiting|Phase 2|10||Tersak, Jean M., M.D.|||||||||||||||||||2018-06-01 04:31:48.285457|2018-06-01 04:31:48.285457
NCT00202917|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-28|2005-09-12|2005-09-20|Estimate|||||||2014-05-28|2014-05-29|Estimate|February 2004||2004-02-29|May 2014|2014-05-31|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Interventional|||Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies|Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies|Completed||Phase 1/Phase 2|61|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:31:48.368806|2018-06-01 04:31:48.368806
NCT00202904|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-28|2005-09-13|2005-09-20|Estimate|||||||2015-04-28|2015-04-29|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)|A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of the Daily Co-Administration of Ezetimibe 10 mg or Ezetimibe Placebo to Ongoing Treatment With Atorvastatin 10 mg in Subjects With Primary Hypercholesterolemia and Coronary Heart Disease|Completed||Phase 4|81|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:31:48.456187|2018-06-01 04:31:48.456187
NCT00202891|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-06-02|2005-09-16|2005-09-20|Estimate|||||||2015-06-02|2015-06-03|Estimate|May 2007||2007-05-31|June 2015|2015-06-30|September 2007|Actual|2007-09-30|||||Interventional|||Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)|Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||||No further local interest in pursuing the study.|f||||||||||||||2018-06-01 04:31:48.525331|2018-06-01 04:31:48.525331
NCT00202878|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2015-08-28||2017-05-10|2005-09-13|2005-09-20|Estimate|2015-08-28|2015-09-30|Estimate||||2017-05-10|2017-06-12|Actual|October 17, 2005|Actual|2005-10-17|May 2017|2017-05-31|September 18, 2014|Actual|2014-09-18|September 18, 2014|Actual|2014-09-18||Interventional|||IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)|A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)|Completed||Phase 3|18144|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:31:48.726115|2018-06-01 04:31:48.726115
NCT00202865|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-03-22|2005-09-16|2005-09-20|Estimate|||||||2017-03-22|2017-03-24|Actual|May 1, 2005|Actual|2005-05-01|March 2017|2017-03-31|May 1, 2007|Actual|2007-05-01|May 1, 2007|Actual|2007-05-01||Interventional|CANDLE||Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)|CANaDian Evaluation of Low DosE Infliximab in Ankylosing Spondylitis|Completed||Phase 3|76|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:31:53.622115|2018-06-01 04:31:53.622115
NCT00202852|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-22|2005-09-13|2005-09-20|Estimate|||||||2017-03-22|2017-03-24|Actual|June 1, 2005|Actual|2005-06-01|March 2017|2017-03-31|March 1, 2006|Actual|2006-03-01|March 1, 2006|Actual|2006-03-01||Interventional|||A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)|A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate|Completed||Phase 3|143|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:31:53.692452|2018-06-01 04:31:53.692452
NCT00201617|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-04-13|2005-09-12|2005-09-20|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2004||2004-07-31|April 2015|2015-04-30|August 2007|Actual|2007-08-31|||||Observational|||Efficacy of the Bone-anchored Hearing Aid for Unilateral Deafness|Short-term and Long-term Efficacy of the BAHA for Single Sided Deafness|Completed|||28|Actual|The New York Eye & Ear Infirmary|||2||f||||||||||||||2018-06-01 04:32:08.355218|2018-06-01 04:32:08.355218
NCT00202839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-08-28||2017-03-08|2005-09-12|2005-09-20|Estimate|2011-02-25|2011-03-24|Estimate||||2017-03-08|2017-04-06|Actual|March 2005||2005-03-31|March 2017|2017-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)|Comparison of the Sustained Response of Peg-Intron/Ribavirin Combination Therapy in Genotype 1-Infected Hepatitis C Patients for Non-extended Versus 24-week Extended Treatment After 24 Weeks Pilot Treatment in Taiwan|Completed||Phase 4|160|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:31:53.784445|2018-06-01 04:31:53.784445
NCT00202826|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-16|2005-09-13|2005-09-20|Estimate|||||||2009-01-16|2009-01-19|Estimate|November 2003||2003-11-30|January 2009|2009-01-31|March 2004||2004-03-31|||||Interventional|||Study of Fluid Collection of the Chest in Children With Pneumonia|Parapneumonic Effusion in Children Study|Completed||Phase 3|30||Spectrum Health Hospitals|||||f||||||||||||||2018-06-01 04:31:54.094106|2018-06-01 04:31:54.094106
NCT00202813|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-12-29|2005-09-13|2005-09-20|Estimate|||||||2009-12-29|2009-12-30|Estimate|July 2003||2003-07-31|December 2009|2009-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study of the Use of Coated Venous Catheters in the Critically Ill Child|The Use of Antibiotic-coated Venous Catheters in the Critically Ill Child: Reducing the Rate of Bloodstream Related Infections|Completed||Phase 4|500||Spectrum Health Hospitals|||||f||||||||||||||2018-06-01 04:31:54.269946|2018-06-01 04:31:54.269946
NCT00202800|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-06-03|2005-09-12|2005-09-20|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2002||2002-03-31|June 2013|2013-06-30|January 2011|Actual|2011-01-31|September 2007|Actual|2007-09-30||Interventional|||Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer|Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|40|Anticipated|Spectrum Health Hospitals|||||f||||||||||||||2018-06-01 04:31:54.412754|2018-06-01 04:31:54.412754
NCT00202787|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-19|2005-09-12|2005-09-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|February 2005||2005-02-28|February 2013|2013-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer|Open-label, Phase II, Randomised, Pilot Study to Evaluate the Safety and Efficacy of Combination Therapy With Cetuximab and FOLFOX4 or FOLFOX4 Alone in Patients Colorectal Cancer and Initially Non-resectable|Completed||Phase 2|136|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-06-01 04:31:54.508072|2018-06-01 04:31:54.508072
NCT00202774|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-19|2005-09-12|2005-09-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|April 2002||2002-04-30|February 2013|2013-02-28|December 2005|Actual|2005-12-31|August 2004|Actual|2004-08-31||Interventional|||Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer|Phase III, Multicenter, Ramdomised, Open-label, Study to Evaluate the Safety and Efficacy of Combination Therapy With XELOX vs. Oxaliplatin and 5-FU CI as First Line Treatment in Advanced or Metastatic Colorectal Cancer|Completed||Phase 3|348||Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)|||||f||||f||||||||||2018-06-01 04:31:54.588789|2018-06-01 04:31:54.588789
NCT00202761|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-07|2005-09-19|2005-09-20|Estimate|||||||2016-12-07|2016-12-08|Estimate|March 2004||2004-03-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Project:Intensive Habilitation (PIH)|Project:Intensive Habilitation (PIH) -a New Norwegian Multidisciplinary Program for Intensive Training for Children With Disabilities|Active, not recruiting||Phase 2/Phase 3|20|Anticipated|Sorlandet Hospital HF||1|||f||||t||||||||||2018-06-01 04:31:54.670838|2018-06-01 04:31:54.670838
NCT00202748|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-22|2005-09-19|2005-09-20|Estimate|||||||2005-12-22|2005-12-23|Estimate|March 2004||2004-03-31|December 2003|2003-12-31|March 2007||2007-03-31|||||Interventional|||Change of Lifestyle by Persons in Risk of Type 2 Diabetes|Phase 3 Study of Changing of Lifestyle by Persons in Risk of Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 3|220||Sorlandet Hospital HF|||||f||||||||||||||2018-06-01 04:31:54.742578|2018-06-01 04:31:54.742578
NCT00202735|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-05-07|2005-09-13|2005-09-20|Estimate|||||||2009-05-07|2009-05-08|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Does Immobilization of the Shoulder in External Rotation Reduce the Recurrence Rate of Shoulder Dislocation?|Does Immobilization of the Shoulder in External Rotation Reduce the Recurrence Rate of Shoulder Dislocation?|Completed||Phase 2/Phase 3|188|Actual|Sorlandet Hospital HF||2|||f||||t||||||||||2018-06-01 04:31:54.835819|2018-06-01 04:31:54.835819
NCT00202722|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-03-16||2014-05-22|2005-09-13|2005-09-20|Estimate|2014-05-22|2014-06-23|Estimate||||2014-05-22|2014-06-23|Estimate|January 2004||2004-01-31|May 2014|2014-05-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||Remifentanil as Intravenous Patient-controlled Analgesia (IVPCA) During Labour|Remifentanil as Analgesia for Labour Pain|Completed||Phase 4|41|Actual|Sorlandet Hospital HF||1|||f||||t||||||||||2018-06-01 04:31:54.922523|2018-06-01 04:31:54.922523
NCT00202709|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-07-27|2005-09-12|2005-09-20|Estimate|||||||2011-07-27|2011-07-28|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?|Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.|Completed||N/A|52|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-06-01 04:31:55.076783|2018-06-01 04:31:55.076783
NCT00202696|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-15|2005-09-12|2005-09-20|Estimate|||||||2008-05-15|2008-05-19|Estimate|September 2005||2005-09-30|May 2008|2008-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Nalmefene Smoking Cessation Study|A Single Center Evaluation of Nalmefene HCl Versus Placebo on Smoking Cessation|Completed||Phase 2|76|Actual|Somaxon Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:31:55.157904|2018-06-01 04:31:55.157904
NCT00202683|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-05-16|2005-09-16|2005-09-20|Estimate|||||||2007-05-16|2007-05-17|Estimate|March 2005||2005-03-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Observational|||Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness|Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Associated With Chemoreflex Failure|Completed|||83|Actual|Société Française de Cardiologie|||||f||||f||||||||||2018-06-01 04:31:55.225571|2018-06-01 04:31:55.225571
NCT00202670|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-10-19|2005-09-13|2005-09-20|Estimate|||||||2010-10-19|2010-10-20|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Diagnosis of Coronary Artery Disease in High Risk Diabetic Patients|Diagnosis of Coronary Artery Disease in High Risk Diabetic Patients :Comparison Between Stress Echocardiography and Stress Scintigraphy in the Detection of Silent Myocardial Ischemia|Terminated|||220|Anticipated|Société Française de Cardiologie|||2|Positive Predictive value not related to follow up duration.|f||||t||||||||||2018-06-01 04:31:55.30318|2018-06-01 04:31:55.30318
NCT00202657|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-12-05|2005-09-12|2005-09-20|Estimate|||||||2011-12-05|2011-12-06|Estimate|April 2005||2005-04-30|December 2011|2011-12-31|February 2007||2007-02-28|||||Observational|||Observational Study of Heart Valve Disease in Patients With Parkinson's Disease Treated With Pergolide|Etude Observationnelle Des Valvulopathies Chez Les Patients Parkinsoniens Traites Par Pergolide Par Rapport a Une Population Temoin|Completed|||149|Actual|Société Française de Cardiologie|||||f||||||||||||||2018-06-01 04:31:55.637012|2018-06-01 04:31:55.637012
NCT00202644|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-10-13||2017-06-16|2005-09-14|2005-09-20|Estimate|2017-06-16|2018-01-24|Actual||||2017-06-16|2018-01-24|Actual|January 2006||2006-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||The safety population was defined as all participants who received at least 1 dose of study medication.|A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients|A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.|Completed||Phase 4|146|Actual|Shire||2|||f||||f||||||||||2018-06-01 04:31:55.743142|2018-06-01 04:31:55.743142
NCT00202631|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-24|2005-09-12|2005-09-20|Estimate|||||||2006-11-24|2006-11-28|Estimate|June 2002||2002-06-30|November 2006|2006-11-30|November 2006||2006-11-30|||||Interventional|||Abdominal Functional Electrical Stimulation in Tetraplegia|Abdominal Functional Electrical Stimulation to Augment Breathing in Tetraplegia|Unknown status|Active, not recruiting|N/A|4||South Glasgow University Hospitals NHS Trust|||||f||||||||||||||2018-06-01 04:31:56.27554|2018-06-01 04:31:56.27554
NCT00202618|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-04-27|2005-09-12|2005-09-20|Estimate|||||||2006-04-27|2006-04-27|Estimate|December 2003||2003-12-31|July 2005|2005-07-31|June 2006||2006-06-30|||||Interventional|||Rationale and Design for Shiga Microalbuminuria Reduction Trial|The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART)|Unknown status|Recruiting|Phase 4|160||Shiga University|||||f||||||||||||||2018-06-01 04:31:56.340638|2018-06-01 04:31:56.340638
NCT00202605|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-02|2005-09-12|2005-09-20|Estimate|||||||2007-11-02|2007-11-06|Estimate|September 2005||2005-09-30|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Safety and Efficacy of SPD465 in Adults With ADHD|A Phase II, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|72||Shire|||||||||||||||||||2018-06-01 04:31:56.458997|2018-06-01 04:31:56.458997
NCT00202592|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-10|2005-09-12|2005-09-20|Estimate|||||||2018-04-10|2018-04-12|Actual|November 2003||2003-11-30|April 2018|2018-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||S90652 in Paediatric Hypertension|Safety and Effects on Blood Pressure of Daily Dose 0.025 to 0.135 Milligram Per Kilogram of S90625 a Paediatric Formulation of Perindopril, in Hypertensive Children - 24 Months|Completed||Phase 2|50|Anticipated|Servier|||||f||||||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies in patients:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-06-01 04:31:56.521958|2018-06-01 04:31:56.521958
NCT00202579|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-03-13|2005-09-13|2005-09-20|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2004||2004-09-30|March 2018|2018-03-31|February 2006|Actual|2006-02-28|||||Interventional|||Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure|Evaluation of the Effects on Peripheral and Central Haemodynamics Parameters, Safety, and Tolerance of Three-hour Intravenous Perfusion (0.1 mg/kg) of Ivabradine Given to Severe Congestive Heart Failure Patients|Completed||Phase 2|12|Anticipated|Servier|||||f||||||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-06-01 04:31:56.587237|2018-06-01 04:31:56.587237
NCT00202566|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-03-13|2005-09-12|2005-09-20|Estimate|||||||2018-03-13|2018-03-15|Actual|June 2005||2005-06-30|March 2018|2018-03-31|October 2007|Actual|2007-10-31|||||Interventional|ASSOCIATE||Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris|Evaluation of the Anti-anginal Efficacy and Safety of Oral Administration of Ivabradine Compared to Placebo on Top of Background Therapy With Atenolol in Patients With Stable Angina Pectoris. A Four-month Randomised Double-blind, Parallel Group International Multicentre Study.|Completed||Phase 3|750|Anticipated|Servier|||||f||||||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-06-01 04:31:56.646872|2018-06-01 04:31:56.646872
NCT00202553|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-10|2005-09-12|2005-09-20|Estimate|||||||2018-04-10|2018-04-11|Actual|July 2003||2003-07-31|April 2018|2018-04-30|December 2006|Actual|2006-12-31|||||Interventional|||S90652 in Paediatric Hypertension|Acceptability, Safety, Pharmacokinetics and Effects on Blood Pressure of a Daily Dose of 0.025 to 0.135 Milligram Per Kilogram of S90652, a Paediatric Formulation of Perindopril, in 2-16 Years Old Hypertensive Children - 3 Month Study|Completed||Phase 2|50|Anticipated|Servier|||||f||||||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies in patients:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-06-01 04:31:56.714824|2018-06-01 04:31:56.714824
NCT00202371|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-01|2005-09-12|2005-09-20|Estimate|||||||2015-06-01|2015-06-02|Estimate|July 2002||2002-07-31|June 2015|2015-06-30|July 2005|Anticipated|2005-07-31|||||Interventional|||Transfusion Effects in Myelodysplastic Patients: Limiting Exposure|Transfusion Effects in Myelodysplastic Patients: Limiting Exposure (Temple)|Withdrawn||Phase 4|0|Actual|Sanquin Research & Blood Bank Divisions||||Too few inclusions|f||||f||||||||||2018-06-01 04:31:58.090329|2018-06-01 04:31:58.090329
NCT00202540|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-03-19|2005-09-12|2005-09-20|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2005||2005-06-30|March 2018|2018-03-31|March 29, 2006|Actual|2006-03-29|March 29, 2006|Actual|2006-03-29||Interventional|||Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients|Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period|Terminated||Phase 2|38|Actual|Servier|||||f||||||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-06-01 04:31:56.775911|2018-06-01 04:31:56.775911
NCT00202527|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-22|2005-09-15|2005-09-20|Estimate|||||||2005-12-22|2005-12-23|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Spanish Cohort for the Study of the Effect of CPAP in Hypertension (CEPECTA)|Efficacy of the Treatment With Nasal Positive Continuous Airway Pressure to Reduce the Arterial Blood Pressure in Patients With Apneas-Hypopneas During the Sleep and Systemic Hypertension|Unknown status|Recruiting|N/A|340||Sociedad Española de Neumología y Cirugía Torácica|||||f||||||||||||||2018-06-01 04:31:56.829706|2018-06-01 04:31:56.829706
NCT00202514|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-10-07|2005-09-12|2005-09-20|Estimate|||||||2009-10-07|2009-10-08|Estimate|September 2004||2004-09-30|October 2009|2009-10-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms|Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and/or Anxiety Symptoms|Completed||Phase 2/Phase 3|40||Seattle Institute for Biomedical and Clinical Research|||||f||||t||||||||||2018-06-01 04:31:56.903942|2018-06-01 04:31:56.903942
NCT00202501|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-20|2005-09-12|2005-09-20|Estimate|||||||2009-05-20|2009-05-21|Estimate|September 2005||2005-09-30|May 2009|2009-05-31|March 2009|Actual|2009-03-31|December 2006|Actual|2006-12-31||Interventional|||Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome|Usefulness of Nasal CPAP Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome|Completed||N/A|80|Actual|Sociedad Española de Neumología y Cirugía Torácica|||||f||||||||||||||2018-06-01 04:31:56.981219|2018-06-01 04:31:56.981219
NCT00202488|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-29|2005-09-13|2005-09-20|Estimate|||||||2008-07-29|2008-07-30|Estimate|November 2002||2002-11-30|July 2008|2008-07-31|September 2007||2007-09-30|||||Interventional|||The Effect of H. Pylori Infection on Iron Metabolism|The Effect of H. Pylori Infection on Iron Metabolism|Completed||Phase 2/Phase 3|39||Seattle Institute for Biomedical and Clinical Research|||||f||||||||||||||2018-06-01 04:31:57.038067|2018-06-01 04:31:57.038067
NCT00202475|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-10-19|2005-09-19|2005-09-20|Estimate|||||||2009-10-19|2009-10-20|Estimate|September 2003||2003-09-30|October 2009|2009-10-31|December 2007|Actual|2007-12-31|September 2006|Actual|2006-09-30||Interventional|||Collection of Autologous Blood Products by Double Erythrocytapheresis|Collection of Autologous Blood Products by Double Erythrocytapheresis - Cost Effectiveness Study|Completed||Phase 3|100|Actual|Sanquin Research & Blood Bank Divisions||2|||f||||f||||||||||2018-06-01 04:31:57.096047|2018-06-01 04:31:57.096047
NCT00202462|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-30|2005-09-12|2005-09-20|Estimate|||||||2008-09-30|2008-10-01|Estimate|November 2002||2002-11-30|September 2008|2008-09-30|November 2006|Actual|2006-11-30|December 2005|Actual|2005-12-31||Interventional|||The Effect of Testosterone on Mood and Quality of Life|The Effect of Testosterone Treatment on Depressive Symptoms and Quality of Life in Older Men With Age-Related Hypogonadism and Subsyndromal Depression.|Completed||N/A|33|Actual|Seattle Institute for Biomedical and Clinical Research|||||f||||f||||||||||2018-06-01 04:31:57.169474|2018-06-01 04:31:57.169474
NCT00202449|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-02-24||2018-04-25|2005-09-12|2005-09-20|Estimate|2012-06-11|2012-07-12|Estimate||||2018-04-25|2018-05-23|Actual|July 2004||2004-07-31|April 2018|2018-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance|A Placebo-Controlled Trial of Prazosin vs. Paroxetine in Combat Stress-Related PTSD Nightmares and Sleep Disturbance|Terminated||N/A|59|Actual|Seattle Institute for Biomedical and Clinical Research|High rate of early termination leading to small number of patients analyzed.|3||recruitment difficulties|f||||t||||||||||2018-06-01 04:31:57.26701|2018-06-01 04:31:57.26701
NCT00202436|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-10-19|2005-09-13|2005-09-20|Estimate|||||||2009-10-19|2009-10-20|Estimate|October 2004||2004-10-31|October 2009|2009-10-31|September 2009|Actual|2009-09-30|December 2008|Actual|2008-12-31||Interventional|||Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy|Therapeutic Erythrocytapheresis as Treatment for Hemochromatosis Patients.|Completed||Phase 3|40|Anticipated|Sanquin Research & Blood Bank Divisions||2|||f||||f||||||||||2018-06-01 04:31:57.56821|2018-06-01 04:31:57.56821
NCT00202423|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-28|2005-09-12|2005-09-20|Estimate|||||||2005-11-28|2005-11-29|Estimate|July 2005||2005-07-31|September 2005|2005-09-30||||||||Interventional|||Use of Cannabinoids in Patients With Multiple Sclerosis|fMRI and Neurophysiological Study Protocol on Cannabinoids in Multiple Sclerosis|Unknown status|Recruiting|Phase 2|20||S. Andrea Hospital|||||f||||||||||||||2018-06-01 04:31:57.633399|2018-06-01 04:31:57.633399
NCT00202410|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-18|2005-09-12|2005-09-20|Estimate|||||||2011-05-18|2011-05-19|Estimate|November 2001||2001-11-30|May 2011|2011-05-31|April 2008|Actual|2008-04-30|September 2007|Actual|2007-09-30||Interventional|||Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis|Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, Randomized, Single Blind Study.|Completed||Phase 2/Phase 3|80|Actual|S. Andrea Hospital||2|||f||||t||||||||||2018-06-01 04:31:57.840213|2018-06-01 04:31:57.840213
NCT00202397|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-02-10|2005-09-12|2005-09-20|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2005||2005-06-30|December 2013|2013-12-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia|Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia|Completed||Phase 2|40|Actual|S. Andrea Hospital||2|||f||||t||||||||||2018-06-01 04:31:57.932416|2018-06-01 04:31:57.932416
NCT00202384|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-17|2005-09-13|2005-09-20|Estimate|||||||2018-04-17|2018-04-19|Actual|November 2004||2004-11-30|April 2018|2018-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Gene Expression in MS Patients Before and During Treatment With Interferon-beta|Gene Expression in MS Patients Before and During Treatment With High-dose Interferon Beta: Prospective Study for the Identification of Predicting Factors of Therapeutic Response.|Terminated|||600|Actual|S. Andrea Hospital||||Few participants enrolled|f||||t||||||||||2018-06-01 04:31:58.026169|2018-06-01 04:31:58.026169
NCT00202358|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-13|2005-09-12|2005-09-20|Estimate|||||||2008-06-13|2008-06-17|Estimate|November 2002||2002-11-30|June 2008|2008-06-30|September 2008|Anticipated|2008-09-30|November 2007|Actual|2007-11-30||Interventional|||Perioperative Effect of Atenolol on Cytokine Profiles|The Effect of Perioperative Atenolol on Post-Operative Cytokines|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Saini Foundation||2|||f||||||||||||||2018-06-01 04:31:58.144594|2018-06-01 04:31:58.144594
NCT00202345|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-05-04|2005-09-15|2005-09-20|Estimate|||||||2015-05-04|2015-05-05|Estimate|August 2004||2004-08-31|May 2015|2015-05-31|February 2007|Actual|2007-02-28|||||Interventional|||Iron Sucrose in Stage 3/4 Kidney Disease|Assessment of the Use of Intravenous Iron Sucrose to Maintain Haemoglobin Levels and Delay the Onset of Use of Erythropoietic Agents and/or Dialysis in Stage 3/4 Chronic Kidney Disease|Completed||Phase 3|120||Melbourne Health|||||f||||||||||||||2018-06-01 04:31:58.206824|2018-06-01 04:31:58.206824
NCT00202332|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-07-15|2005-09-15|2005-09-20|Estimate|||||||2015-07-15|2015-07-16|Estimate|February 2001||2001-02-28|July 2015|2015-07-31|February 2004|Actual|2004-02-29|February 2003|Actual|2003-02-28||Interventional|||CABG Without the Use of CPB|A Prospective Randomised Study od Coronary Artery Bypass Surgery Without the Use of Cardiopulmonary Bypass|Completed||Phase 2|||Melbourne Health|||||f||||||||||||||2018-06-01 04:31:58.277677|2018-06-01 04:31:58.277677
NCT00202319|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-20|Estimate|||||||2005-09-14|2005-09-20|Estimate|November 2001||2001-11-30|September 2005|2005-09-30|September 2002||2002-09-30|||||Interventional|||Effectiveness of Sedation Management in an Australian Intensive Care Unit|Evaluating the Effectiveness of Protocol Directed Sedation Management With Non-Protocol Directed Sedation Management on Mechanically Ventilated Patients in an Australian Intensive Care Unit.|Completed||N/A|316||Melbourne Health|||||f||||||||||||||2018-06-01 04:31:58.390112|2018-06-01 04:31:58.390112
NCT00202306|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-05-28|2005-09-14|2005-09-20|Estimate|||||||2013-05-28|2013-05-30|Estimate|November 2001||2001-11-30|September 2005|2005-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Indicated Prevention of Psychotic Disorders With Low-dose Lithium|An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder|Completed||Phase 4|30|Anticipated|Melbourne Health|||||f||||t||||||||||2018-06-01 04:31:58.460176|2018-06-01 04:31:58.460176
NCT00202293|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-11-18|2005-09-14|2005-09-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|October 2001||2001-10-31|November 2015|2015-11-30||||||||Interventional|||Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features|Comparison of Combination Olanzapine and Lithium and Combination Chlorpromazine and Lithium in the Treatment of a First Manic Episode With Psychotic Features.|Unknown status|Recruiting|Phase 4|75|Anticipated|Melbourne Health|||||f||||||||||||||2018-06-01 04:31:58.538628|2018-06-01 04:31:58.538628
NCT00202280|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-11-18|2005-09-14|2005-09-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2004||2004-09-30|November 2015|2015-11-30|June 2009|Actual|2009-06-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication|VIP (Vitamins In Psychosis) Study. A Randomized Double Blind Placebo Controlled Trial of the Effects of Vitamin B12, B6 and Folic Acid Augmentation on Cognition and Symptoms in Early Psychosis.|Completed||Phase 2/Phase 3|120|Actual|Melbourne Health||2|||f||||t||||||||||2018-06-01 04:31:58.631145|2018-06-01 04:31:58.631145
NCT00202267|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-11-18|2005-09-19|2005-09-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2004||2004-01-31|November 2015|2015-11-30|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|||Community RCT of the Effectiveness of Two Compression Bandaging Technologies|Community Randomised Control Trial of the Effectiveness of Two Compression Bandaging Technologies|Completed||Phase 2|426|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 04:31:58.708286|2018-06-01 04:31:58.708286
NCT00202254|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-01|2005-09-12|2005-09-20|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2004||2004-12-31|June 2015|2015-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Multiple Sclerosis Rehabilitation Study|'Functioning and Disability' and 'Quality of Life' in an Australian Community Cohort With Multiple Sclerosis.|Completed||N/A|100||Melbourne Health|||||f||||||||||||||2018-06-01 04:31:58.812669|2018-06-01 04:31:58.812669
NCT00202241|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-12|2005-09-13|2005-09-20|Estimate|||||||2016-01-12|2016-01-13|Estimate|September 1999||1999-09-30|January 2016|2016-01-31|June 2001||2001-06-30|||||Interventional|||The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS|The Effects of Anabolic Steroids and Protease Inhibitors on Serum Blood Lipids,Muscle Mass, and Total Body Fat in People Living With HIV/AIDS|Completed||N/A|30||Queen's University|||||f||||||||||||||2018-06-01 04:31:58.872296|2018-06-01 04:31:58.872296
NCT00202228|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-12|2005-09-13|2005-09-20|Estimate|||||||2016-01-12|2016-01-13|Estimate|July 2002||2002-07-31|January 2016|2016-01-31|September 2011|Actual|2011-09-30|October 2008|Actual|2008-10-31||Interventional|||Lactate Metabolism Study in HIV Infected Persons|Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation.|Completed||Phase 4|30|Actual|Queen's University||4|||f||||f||||||||||2018-06-01 04:31:58.947616|2018-06-01 04:31:58.947616
NCT00202215|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-10-15|2005-09-13|2005-09-20|Estimate|||||||2007-10-15|2007-10-16|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|June 2007|Actual|2007-06-30|||||Interventional|||Chrysalis Day Program Body Mass Index Study|A Study on the Effects of a Personality Disorder Day Hospital Program on Clients Body Mass Index|Completed||N/A|106|Actual|Queen's University|||||f||||f||||||||||2018-06-01 04:31:59.02529|2018-06-01 04:31:59.02529
NCT00202202|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-03-10|2005-09-13|2005-09-20|Estimate|||||||2015-03-10|2015-03-11|Estimate|November 2002||2002-11-30|March 2015|2015-03-31|April 2004|Actual|2004-04-30|||||Interventional|||User Satisfaction Survey - Personality Disorder Service|Survey of the Consultation Service of the Providence Continuing Care Centre Personality Disorder Service Users Satisfaction With the Change in Service Delivery|Completed||N/A|100|Actual|Queen's University|||||f||||f||||||||||2018-06-01 04:31:59.082978|2018-06-01 04:31:59.082978
NCT00202189|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-08-12|2005-09-13|2005-09-20|Estimate|||||||2008-08-12|2008-08-13|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)|Acute Effects of Inhaled Corticosteroids on Dynamic Airway Function During Rest and Exercise in Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|4|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 04:31:59.142876|2018-06-01 04:31:59.142876
NCT00202176|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-18|2005-09-13|2005-09-20|Estimate|||||||2011-04-18|2011-04-19|Estimate|July 2005||2005-07-31|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Bronchodilators in Mild Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Bronchodilators on Exertional Dyspnea and Exercise Performance in Mild Chronic Obstructive Pulmonary Disease (COPD) Patients and Healthy Elderly Subjects.|Completed||Phase 4|32|Actual|Queen's University||2|||f||||t||||||||||2018-06-01 04:31:59.223826|2018-06-01 04:31:59.223826
NCT00202163|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-12|2005-09-13|2005-09-20|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2006||2006-12-31|January 2016|2016-01-31|September 2007|Actual|2007-09-30|July 2007|Actual|2007-07-31||Interventional|||ANDRO 2002: Dehydroepiandrosterone (DHEA) or Testosterone Versus Placebo in Men With Sexual Dysfunction|A Randomized Double-Blind Placebo-Controlled Study Comparing the Safety and Efficacy of Dehydroepiandrosterone (DHEA) or Testosterone Versus Placebo in Men With Sexual Dysfunction|Completed||Phase 2|120|Anticipated|Queen's University|||||f||||||||||||||2018-06-01 04:31:59.297729|2018-06-01 04:31:59.297729
NCT00202150|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-10|2005-09-13|2005-09-20|Estimate|||||||2015-03-10|2015-03-11|Estimate|September 2004||2004-09-30|March 2015|2015-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Primary Care Management/Action Plans for Advanced Chronic Diseases|Primary Care Management/Action Plans for Advanced Chronic Diseases (The RoadMAP Project)|Completed||Phase 2/Phase 3|139|Actual|Queen's University|||||f||||||||||||||2018-06-01 04:31:59.365031|2018-06-01 04:31:59.365031
NCT00202137|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-13|2005-09-13|2005-09-20|Estimate|||||||2016-01-13|2016-01-14|Estimate|July 2002||2002-07-31|January 2016|2016-01-31|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Home Blood Pressure Monitoring and Blood Pressure Control|A Randomized Controlled Trial of the Effects of Home Blood Pressure Monitoring on Blood Pressure Control|Completed||N/A|597|Actual|Queen's University||2|||f||||f||||||||||2018-06-01 04:31:59.425016|2018-06-01 04:31:59.425016
NCT00202124|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|April 2001||2001-04-30|November 2002|2002-11-30|March 2002||2002-03-31|||||Interventional|||Double Blind Study of Trp01 in Patients With Alzheimer's Disease|Double Blind Medium Term Efficacy Study of Trp01 in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 4|12||Queen's University|||||f||||||||||||||2018-06-01 04:31:59.493384|2018-06-01 04:31:59.493384
NCT00202111|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-16|2005-09-12|2005-09-20|Estimate|||||||2006-10-16|2006-10-17|Estimate|January 1998||1998-01-31|February 2006|2006-02-28|March 2010||2010-03-31|||||Interventional|||Comparative Study of Laparoscopic Versus Open Operations for Colon Cancer|Australasian Multicentered Prospective Randomised Clinical Study Comparing Laparoscopic and Conventional Open Surgical Treatments of Colon Cancer in Adults|Unknown status|Active, not recruiting|N/A|600||The Queen Elizabeth Hospital|||||f||||||||||||||2018-06-01 04:31:59.5498|2018-06-01 04:31:59.5498
NCT00202098|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-18|2005-09-12|2005-09-20|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2005||2005-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of Variable Ventilation on Respiratory System of Acute Respiratory Distress Syndrome (ARDS) Patients|Effects of Variable Ventilation on Respiratory System of ARDS Patients|Completed||N/A|16|Anticipated|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:31:59.633397|2018-06-01 04:31:59.633397
NCT00202072|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Mucin in Sputum of CF During Pulmonary Exacerbation||Unknown status|Recruiting||25||Philipps University Marburg Medical Center|||||f||||||||||||||2018-06-01 04:31:59.722205|2018-06-01 04:31:59.722205
NCT00202059|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-15|2005-09-13|2005-09-20|Estimate|||||||2015-12-15|2015-12-16|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer|The Effects of Zoledronic Acid (Zometa) and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer|Completed||Phase 3|72||HealthPartners Institute|||||f||||||||||||||2018-06-01 04:31:59.792367|2018-06-01 04:31:59.792367
NCT00202046|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-02|2005-09-13|2005-09-20|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2003||2003-01-31|April 2007|2007-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Predictors of Lymphedema Following Breast Cancer Surgery|Predictors of Lymphedema Following Breast Cancer Surgery|Completed|||188|Actual|HealthPartners Institute|||2||f||||t||||||||||2018-06-01 04:31:59.855516|2018-06-01 04:31:59.855516
NCT00202033|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-02|2005-09-12|2005-09-20|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2004||2004-09-30|April 2013|2013-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes|Impact of Self-Monitoring Blood Glucose Frequency on Glycemic Control in Patients With Type 2 Diabetes|Completed||Phase 4|150|Actual|HealthPartners Institute||3|||f||||t||||||||||2018-06-01 04:31:59.919895|2018-06-01 04:31:59.919895
NCT00202020|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-15|2005-09-12|2005-09-20|Estimate|||||||2006-03-15|2006-03-16|Estimate|May 2004||2004-05-31|March 2006|2006-03-31|January 2006||2006-01-31|||||Interventional|||Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke|Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial|Completed||Phase 3|720||Otsuka Beijing Research Institute|||||f||||||||||||||2018-06-01 04:31:59.980604|2018-06-01 04:31:59.980604
NCT00202007|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|February 2005||2005-02-28|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia|A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia|Completed||Phase 2|240||Otsuka Beijing Research Institute|||||f||||||||||||||2018-06-01 04:32:00.180302|2018-06-01 04:32:00.180302
NCT00201994|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-02|2005-09-14|2005-09-20|Estimate|||||||2012-05-02|2012-05-03|Estimate|November 2003||2003-11-30|May 2012|2012-05-31|July 2005|Actual|2005-07-31|||||Interventional|||"SALT-2 Trial Study of Ascending Levels of Tolvaptan in Hyponatremia"|Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia, Study 2|Completed||Phase 3|243|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||f||||||||||2018-06-01 04:32:00.248845|2018-06-01 04:32:00.248845
NCT00201981|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-04|2005-09-12|2005-09-20|Estimate|||||||2008-01-04|2008-01-07|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|February 2007|Actual|2007-02-28|||||Interventional|||Study of Rebamipide Eye Drops to Treat Dry Eye|Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multicenter, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 52 Week Study|Completed||Phase 3|740|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||||||||||||2018-06-01 04:32:00.329158|2018-06-01 04:32:00.329158
NCT00201968|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-25|2005-09-12|2005-09-20|Estimate|||||||2013-02-25|2013-02-27|Estimate|April 2005||2005-04-30|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury|Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury|Unknown status|Active, not recruiting|Phase 4|32|Anticipated|Ontario Neurotrauma Foundation||2|||f||||t||||||||||2018-06-01 04:32:00.520136|2018-06-01 04:32:00.520136
NCT00201955|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-31|2005-09-12|2005-09-20|Estimate|||||||2006-10-31|2006-11-02|Estimate|May 2004||2004-05-31|October 2006|2006-10-31|July 2006||2006-07-31|||||Interventional|||Study of Rebamipide Eye Drops to Treat Dry Eye|Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multicenter, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 26 Week Study|Completed||Phase 3|740||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 04:32:00.691743|2018-06-01 04:32:00.691743
NCT00201942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-17|2005-09-14|2005-09-20|Estimate|||||||2007-10-17|2007-10-18|Estimate|February 2005||2005-02-28|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)|A Prospective Study to Determine the Role of 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)Positron Emission Tomography (PET)in the Assessment of Regional Nodal Spread of Disease in Breast Cancer Patients|Completed||Phase 3|336|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||t||||||||||2018-06-01 04:32:00.860858|2018-06-01 04:32:00.860858
NCT00201929|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-27|2005-09-13|2005-09-20|Estimate|||||||2007-06-27|2007-06-29|Estimate|April 2002||2002-04-30|June 2007|2007-06-30|November 2006|Actual|2006-11-30|||||Interventional|||A Decision Aid for Women With Early Stage Breast Cancer|Development and Evaluation of Different Versions of the Decision Board for Early Breast Cancer|Completed||Phase 3|300||Ontario Clinical Oncology Group (OCOG)|||||f||||||||||||||2018-06-01 04:32:00.952351|2018-06-01 04:32:00.952351
NCT00201916|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-08-16|2005-09-13|2005-09-20|Estimate|||||||2010-08-16|2010-08-17|Estimate|March 1995||1995-03-31|August 2010|2010-08-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Shorter Radiation Schedule for the Treatment of Prostate Cancer|A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer|Completed||Phase 3|936|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||f||||||||||2018-06-01 04:32:01.037389|2018-06-01 04:32:01.037389
NCT00201903|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-05|2005-09-13|2005-09-20|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2004||2004-01-31|May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Observational|||The Roles of Tissue Factor in Malignant Gliomas|The Roles of Tissue Factor in Malignant Gliomas|Completed|||30|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||t||||||||||2018-06-01 04:32:01.13756|2018-06-01 04:32:01.13756
NCT00201890|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-10-09|2005-09-12|2005-09-20|Estimate|||||||2012-10-09|2012-10-10|Estimate|March 2003||2003-03-31|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional|||"Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer DELTA STUDY"|DELTA - A Randomized Trial of Decongestive Lymphatic Therapy for Lymphedema in Women With Breast Cancer|Completed||Phase 3|103|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 04:32:01.205842|2018-06-01 04:32:01.205842
NCT00201877|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-11-12||2018-03-07|2005-09-19|2005-09-20|Estimate|2014-04-17|2014-05-20|Estimate||||2018-03-07|2018-03-12|Actual|December 2004|Actual|2004-12-31|March 2018|2018-03-31|March 2012|Actual|2012-03-31|June 2009|Actual|2009-06-30||Interventional|||Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma|A Phase II Study of Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|25|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:01.315797|2018-06-01 04:32:01.315797
NCT00201864|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-11-10||2016-07-14|2005-09-13|2005-09-20|Estimate|2016-07-14|2016-08-15|Estimate||||2016-07-14|2016-08-15|Estimate|September 2005||2005-09-30|July 2016|2016-07-31|February 2014|Actual|2014-02-28|June 2012|Actual|2012-06-30||Interventional|||Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer|Phase II Trial of Exemestane (Aromasin) in Combination With Fulvestrant (Faslodex) in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer|Completed||Phase 2|40|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:01.525716|2018-06-01 04:32:01.525716
NCT00201851|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-03-31||2015-04-13|2005-09-13|2005-09-20|Estimate|2015-04-13|2015-04-29|Estimate||||2015-04-13|2015-04-29|Estimate|January 2004||2004-01-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|December 2011|Actual|2011-12-31||Interventional||Baseline measures were not available on all participants.|Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer|Phase III Randomized Study of Immediate Versus Luteal Phase Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-positive Breast Cancer|Completed||Phase 3|740|Actual|International Breast Cancer Research Foundation||3|||f||||t||||||||||2018-06-01 04:32:01.759997|2018-06-01 04:32:01.759997
NCT00201838|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-11-04||2017-11-28|2005-09-13|2005-09-20|Estimate|2015-08-13|2015-08-14|Estimate||||2017-11-28|2017-11-30|Actual|July 2001||2001-07-31|November 2017|2017-11-30|May 2007|Actual|2007-05-31|October 2006|Actual|2006-10-31||Interventional|||Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma|A Phase I/II Study of Etanercept and Gemcitabine in Patients With Advanced Stage and Chemotherapy Naive Pancreatic Adenocarcinoma|Completed||Phase 1/Phase 2|38|Actual|Ohio State University Comprehensive Cancer Center|The interpretation of the results for this study is limited by the relatively small patient sample and correlative samples.|2|||f||||t||||||||||2018-06-01 04:32:02.213478|2018-06-01 04:32:02.213478
NCT00201825|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-09-25||2014-10-01|2005-09-12|2005-09-20|Estimate|2014-10-01|2014-10-06|Estimate||||2014-10-01|2014-10-06|Estimate|December 2004||2004-12-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional||Eligible patients had histologically confirmed advanced NSCLC and had not received prior chemotherapy.|A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients|A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients|Completed||Phase 2|29|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:02.534461|2018-06-01 04:32:02.534461
NCT00201812|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-04|2005-09-12|2005-09-20|Estimate|||||||2017-12-04|2017-12-06|Actual|November 2000||2000-11-30|December 2017|2017-12-31|May 2005|Actual|2005-05-31|January 2004|Actual|2004-01-31||Interventional|||Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors|Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|27|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:32:02.752822|2018-06-01 04:32:02.752822
NCT00201799|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-09|2005-09-12|2005-09-20|Estimate|||||||2015-06-09|2015-06-10|Estimate|February 2004||2004-02-29|June 2015|2015-06-30|March 2008|Actual|2008-03-31|August 2006|Actual|2006-08-31||Interventional|||Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation|Phase II Trial of Infliximab for the Prevention of Acute Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|19|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:02.816042|2018-06-01 04:32:02.816042
NCT00201786|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-04-25|2005-09-12|2005-09-20|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2003||2003-07-31|April 2016|2016-04-30|July 2013|Actual|2013-07-31|October 2007|Actual|2007-10-31||Interventional|||Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease|Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease|Completed||Phase 2|8|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:02.893331|2018-06-01 04:32:02.893331
NCT00201773|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-02-17||2015-06-25|2005-09-12|2005-09-20|Estimate|2015-06-25|2015-06-30|Estimate||||2015-06-25|2015-06-30|Estimate|July 2003||2003-07-31|June 2015|2015-06-30|June 2011|Actual|2011-06-30|November 2007|Actual|2007-11-30||Interventional|||Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer|A Phase II Trial of Exemestane (Aromasin) in Combination With Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer|Completed||Phase 2|22|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:02.971857|2018-06-01 04:32:02.971857
NCT00201760|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-06-15||2017-11-30|2005-09-12|2005-09-20|Estimate|2017-10-10|2017-11-09|Actual||||2017-11-30|2017-12-27|Actual|February 25, 2005|Actual|2005-02-25|November 2017|2017-11-30|October 31, 2009|Actual|2009-10-31|October 31, 2009|Actual|2009-10-31||Interventional|||Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer|A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer|Completed||Phase 2|10|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:32:03.294065|2018-06-01 04:32:03.294065
NCT00201747|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-04|2005-09-12|2005-09-20|Estimate|||||||2017-12-04|2017-12-06|Actual|September 2001||2001-09-30|December 2017|2017-12-31|February 2010|Actual|2010-02-28|October 2006|Actual|2006-10-31||Interventional|||Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer|Phase II Randomized Trial of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer|Completed||Phase 2|80|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:32:03.654492|2018-06-01 04:32:03.654492
NCT00201734|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-04-25||2016-08-15|2005-09-12|2005-09-20|Estimate|2016-04-25|2016-06-01|Estimate||||2016-08-15|2016-09-23|Estimate|June 2005||2005-06-30|August 2016|2016-08-31|June 2013|Actual|2013-06-30|November 2007|Actual|2007-11-30||Interventional|||Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary|A Phase I Dose Escalation Study of Capecitabine, Carboplatin and Weekly Paclitaxel and a Phase II Trial of the Same Combination in Patients With Adenocarcinoma of Unknown Primary|Terminated||Phase 1/Phase 2|57|Actual|Ohio State University Comprehensive Cancer Center||1||Due to lack of funding provided for Phase II portion of trial|f||||t||||||||||2018-06-01 04:32:04.785846|2018-06-01 04:32:04.785846
NCT00201721|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-06|2005-09-12|2005-09-20|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2002||2002-07-31|February 2017|2017-02-28|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia|Phase II Trial of Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|28|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:32:05.903547|2018-06-01 04:32:05.903547
NCT00201708|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-09-01|2005-09-12|2005-09-20|Estimate|||||||2016-09-01|2016-09-02|Estimate|October 2004||2004-10-31|September 2016|2016-09-30|February 2014|Actual|2014-02-28|December 2006|Actual|2006-12-31||Interventional|||Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer|Phase II Randomized Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide (AC) in Axillary Node-Positive Breast Cancer|Completed||Phase 2|56|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:32:06.144841|2018-06-01 04:32:06.144841
NCT00201695|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-09|2005-09-12|2005-09-20|Estimate|||||||2015-06-09|2015-06-10|Estimate|July 2004||2004-07-31|June 2015|2015-06-30|August 2008|Actual|2008-08-31|September 2006|Actual|2006-09-30||Interventional|||Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma|Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in Combination With Arsenic Trioxide (Trisenox) in Untreated Patients With Symptomatic Multiple Myeloma|Completed||Phase 2|12|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:32:06.404143|2018-06-01 04:32:06.404143
NCT00201682|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-06|2005-09-12|2005-09-20|Estimate|||||||2017-02-06|2017-02-08|Estimate|October 2002||2002-10-31|February 2017|2017-02-28|August 2009|Actual|2009-08-31|August 2006|Actual|2006-08-31||Interventional|||Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Phase I/II Study of Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Completed||Phase 1/Phase 2|36|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:06.651476|2018-06-01 04:32:06.651476
NCT00201669|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-04|2005-09-12|2005-09-20|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2004||2004-10-31|December 2017|2017-12-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|6|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:32:06.895113|2018-06-01 04:32:06.895113
NCT00201656|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-17|2005-09-13|2005-09-20|Estimate|||||||2014-12-17|2014-12-19|Estimate|November 2004||2004-11-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|PROMCerclage||Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)|Removal Versus Retention of Cervical Cerclage in Preterm Premature Rupture of Membranes-A Multicenter Randomized Clinical Trial|Terminated||Phase 4|58|Actual|Mednax Center for Research, Education, Quality and Safety||2||"This trial was terminated following a futility analysis confirming futility of continuing the~   study"|f||||t||||||||||2018-06-01 04:32:07.043667|2018-06-01 04:32:07.043667
NCT00201643|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-09-07||2014-12-17|2005-09-12|2005-09-20|Estimate|2011-02-25|2011-03-01|Estimate||||2014-12-17|2015-01-07|Estimate|November 2003||2003-11-30|December 2014|2014-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|ACS||A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome|A Randomized Double-Blinded Study Comparing the Impact of One Versus Two Courses of Antenatal Steroids on Neonatal Outcome|Completed||Phase 4|437|Actual|Mednax Center for Research, Education, Quality and Safety||2|||f||||t||||||||||2018-06-01 04:32:07.401133|2018-06-01 04:32:07.401133
NCT00201630|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|September 2005||2005-09-30|August 2005|2005-08-31|September 2005||2005-09-30|||||Interventional|||Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy|Randomized, Open-Labeled Study of Prophylactic Vs. Therapeutic Use of Uroxatrol to Determine Improvements in Urinary Morbidity Following Men Undergoing Prostate Brachytherapy|Unknown status|Not yet recruiting|Phase 3|150||New York Prostate Institute|||||f||||||||||||||2018-06-01 04:32:08.228928|2018-06-01 04:32:08.228928
NCT00201591|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2011-08-25|2005-09-16|2005-09-20|Estimate|||||||2011-08-25|2011-08-26|Estimate|August 2002||2002-08-31|August 2011|2011-08-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Training at Different Intensities in Coronary Artery Disease -Effects on Myocardial Function|Which Training Intensity is Most Effective in Improving Myocardial Function in Patients With Coronary Artery Disease?|Completed||N/A|17|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:32:08.476306|2018-06-01 04:32:08.476306
NCT00201578|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-04-27|2005-09-12|2005-09-20|Estimate|||||||2006-04-27|2006-04-27|Estimate||||January 2005|2005-01-31||||||||Observational|||Case Control Study of Non Viral Hepatitis Relating to Herbal Drug Use in the Emergency Department||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:32:08.571052|2018-06-01 04:32:08.571052
NCT00201565|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-19|2005-09-19|2005-09-20|Estimate|||||||2005-09-19|2005-09-20|Estimate|May 2005||2005-05-31|March 2005|2005-03-31||||||||Observational|||Association Between Peripheral Artery Stiffness and Cardiovascular Disease||Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:32:08.625587|2018-06-01 04:32:08.625587
NCT00201552|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-19|2005-09-19|2005-09-20|Estimate|||||||2005-09-19|2005-09-20|Estimate||||September 2005|2005-09-30||||||||Interventional|||Statin and PAF in Patients With Pacemaker|Atorvastatin Decreases Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation|Unknown status|Recruiting|N/A|||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:32:08.692142|2018-06-01 04:32:08.692142
NCT00201539|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-04-07|2005-09-16|2005-09-20|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2002||2002-04-30|April 2015|2015-04-30|February 2008|Actual|2008-02-29|November 2006|Actual|2006-11-30||Interventional|||Double Bedtime Dosing During Immediate-release Morphine Administration to Cancer Patients|Double Bedtime Dosing During Immediate-release Morphine Administration to Cancer Patients: A Randomized, Double-blind Cross-over Comparison of a Double Bedtime Dose Ver-sus Two Standard Doses at Bedtime and at Night|Completed||Phase 3|19|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:32:08.803061|2018-06-01 04:32:08.803061
NCT00201526|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-12-07|2005-09-16|2005-09-20|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2003|Actual|2003-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Bipolar Research And Innovation Network - BRAIN|Bipolar Research And Innovation Network - BRAIN|Recruiting|||3000|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 04:32:08.999173|2018-06-01 04:32:08.999173
NCT00201513|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-10-08|2005-09-16|2005-09-20|Estimate|||||||2012-10-08|2012-10-10|Estimate|January 2006||2006-01-31|October 2012|2012-10-31|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Anticipatory Muscle Control and Effect of Stabilizing Exercises in Patients With Subacute and Chronic Low Back Pain|Randomized Controlled Trial of Stabilizing Exercises and Effect on Anticipatory Muscle Control in Patients With Subacute and Chronic Low Back Pain|Completed||N/A|99|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-06-01 04:32:09.098997|2018-06-01 04:32:09.098997
NCT00201500|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2016-08-03|2005-09-16|2005-09-20|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2004||2004-10-31|August 2016|2016-08-31|March 2006|Actual|2006-03-31|December 2005|Actual|2005-12-31||Observational|||Left Ventricular and Endothelial Function in Preeclampsia|Left Ventricular and Endothelial Function in Preeclampsia, a Case Control Study|Completed|||39|Actual|Norwegian University of Science and Technology|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 04:32:09.284935|2018-06-01 04:32:09.284935
NCT00201487|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-10-30|2005-09-16|2005-09-20|Estimate|||||||2013-10-30|2013-10-31|Estimate|November 2007||2007-11-30|October 2013|2013-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Choline Quantification in Breast Cancer by MRS|Choline Quantification in Breast Cancer by MRS|Withdrawn|||0|Actual|Norwegian University of Science and Technology||||"We chose to use an exsisting NMR pulse sequence already established and available at the~   hospital."|f||||f||||||||||2018-06-01 04:32:09.401429|2018-06-01 04:32:09.401429
NCT00201474|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2016-08-03|2005-09-16|2005-09-20|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 1998||1998-10-31|August 2016|2016-08-31|June 2010|Actual|2010-06-30|October 2004|Actual|2004-10-31||Observational|||Acute, Affective, Organic Disorders.|Signs of Organic Brain Dysfunction in Psychiatric Patients With Fluctuating Psychiatric Symptoms Including Brief Depressions Compared to Patients With a Major Depressive Episode.|Completed|||32|Actual|Norwegian University of Science and Technology|||2||f||||f||||||Samples Without DNA|"~     Ordinary laboratory tests, medication, substances.~   "|||2018-06-01 04:32:09.50119|2018-06-01 04:32:09.50119
NCT00201461|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-12-29|2005-09-12|2005-09-20|Estimate|||||||2008-12-29|2008-12-30|Estimate|June 2003||2003-06-30|November 2008|2008-11-30|April 2010|Anticipated|2010-04-30|||||Interventional|||Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)|A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale|Unknown status|Active, not recruiting|Phase 2/Phase 3|900|Anticipated|NMT Medical||2|||f||||t||||||||||2018-06-01 04:32:09.657171|2018-06-01 04:32:09.657171
NCT00201448|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-04-03||2016-05-27|2005-09-13|2005-09-20|Estimate|2016-05-27|2016-05-30|Estimate||||2016-05-27|2016-05-30|Estimate|June 2007||2007-06-30|May 2016|2016-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women|Epidemiology of Cytomegalovirus -- Evaluation of the Immunogenicity and Efficacy of the Towne Strain of CMV in Seronegative Women: A Phase II-III Study|Terminated||Phase 2/Phase 3|82|Actual|Virginia Commonwealth University||2||Suspended due to lack of funding|f||||t||||||||||2018-06-01 04:32:09.84551|2018-06-01 04:32:09.84551
NCT00201435|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-19|2005-09-12|2005-09-20|Estimate|||||||2008-05-19|2008-05-20|Estimate|March 2005||2005-03-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|||Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC|Weekly Taxol® Plus Xeloda® Versus Taxotere® Every Three Weeks Plus Xeloda® in the Treatment of Metastatic Breast Cancer A Phase II/III Study|Completed||Phase 2/Phase 3|224|Anticipated|Norwegian Breast Cancer Group|||||f||||f||||||||||2018-06-01 04:32:10.379863|2018-06-01 04:32:10.379863
NCT00201422|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-25|2005-09-13|2005-09-20|Estimate|||||||2016-03-25|2016-03-28|Estimate|June 1996||1996-06-30|March 2016|2016-03-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma|Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach|Completed||N/A|70|Actual|National Health Research Institutes, Taiwan||1|||f||||t||||||||No||2018-06-01 04:32:10.525033|2018-06-01 04:32:10.525033
NCT00201409|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-06-25||2015-11-30|2005-09-16|2005-09-20|Estimate|2015-04-24|2015-04-27|Estimate||||2015-11-30|2015-12-29|Estimate|July 2004||2004-07-31|November 2015|2015-11-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||A Randomized Trial of GM-CSF in Patients With ALI/ARDS|A Randomized Trial of GM-CSF in Patients With ALI/ARDS|Completed||Phase 2|132|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 04:32:10.675589|2018-06-01 04:32:10.675589
NCT00201396|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-02-23|2005-09-14|2005-09-20|Estimate|||||||2015-02-23|2015-02-25|Estimate|August 2003||2003-08-31|May 2006|2006-05-31|December 2011|Actual|2011-12-31|August 2009|Actual|2009-08-31||Interventional|||A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma|A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC)|Completed||Phase 3|480|Actual|National Health Research Institutes, Taiwan||2|||f||||||||||||||2018-06-01 04:32:11.196353|2018-06-01 04:32:11.196353
NCT00201383|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|October 1999||1999-10-31|January 2005|2005-01-31|August 2009||2009-08-31|||||Interventional|||Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients|Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients|Completed||Phase 3|161||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:32:11.306302|2018-06-01 04:32:11.306302
NCT00201370|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-03-23|2005-09-14|2005-09-20|Estimate|||||||2016-03-23|2016-03-25|Estimate|August 1999||1999-08-31|September 2005|2005-09-30|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Observational|||A Multi-center Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal Follow-up of LSIL Cases|A Multi-center Survey of HPV in Cervical Intraepithelial Neoplasia (CIN) With Longitudinal Follow-up of LSIL Cases|Completed|||1000|Actual|National Health Research Institutes, Taiwan|||||f||||t||||||||No||2018-06-01 04:32:11.400153|2018-06-01 04:32:11.400153
NCT00201357|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-23|2005-09-13|2005-09-20|Estimate|||||||2016-03-23|2016-03-25|Estimate|October 2002||2002-10-31|March 2016|2016-03-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer|An Open, Non-Comparative Trial to Assess the Efficacy and Safety of Oral Thalidomide (THADO) in Patientswith Hormone-Refractory Prostate Cancer-A PHASE II CLINICAL TRIAL|Completed||Phase 2|30|Actual|National Health Research Institutes, Taiwan|||||f||||t||||||||No||2018-06-01 04:32:11.487696|2018-06-01 04:32:11.487696
NCT00201344|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-25|2005-09-13|2005-09-20|Estimate|||||||2010-03-25|2010-03-26|Estimate|November 1994||1994-11-30|June 2009|2009-06-30|January 2000||2000-01-31|||||Interventional|||A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients|A Phase III Study of Radiotherapy With or Without Adjuvant Chemotherapy in Advanced Stage Nasopharyngeal Carcinoma Patients|Terminated||Phase 3|320||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:32:11.570115|2018-06-01 04:32:11.570115
NCT00201331|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-15|2005-09-13|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|April 2002||2002-04-30|December 2005|2005-12-31|October 2012||2012-10-31|||||Interventional|||Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer|Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer|Unknown status|Recruiting|Phase 2|162||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:32:11.653918|2018-06-01 04:32:11.653918
NCT00201318|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|October 2005||2005-10-31|||||Interventional|||A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen|A Randomized Study of Lamivudine Prophylaxis or Treatment Against Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen|Completed||Phase 2|50||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:32:11.747672|2018-06-01 04:32:11.747672
NCT00201305|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-30|2005-09-13|2005-09-20|Estimate|||||||2009-03-30|2009-04-01|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|August 2012||2012-08-31|||||Interventional|||Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract|Prospective Phase II Randomized Trial-Weekly Gemcitabine Plus High-Dose 5-Fluorouracil/ Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract|Completed||Phase 2|50||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:32:11.82742|2018-06-01 04:32:11.82742
NCT00201292|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-14|2005-09-12|2005-09-20|Estimate|||||||2007-11-14|2007-11-15|Estimate|March 2005||2005-03-31|May 2007|2007-05-31|October 2008|Anticipated|2008-10-31|||||Observational|||Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)|Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)|Unknown status|Recruiting||1350|Anticipated|National Health Research Institutes, Taiwan|||||f||||t||||||||||2018-06-01 04:32:11.899599|2018-06-01 04:32:11.899599
NCT00201279|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|April 1999||1999-04-30|January 2005|2005-01-31|September 2012||2012-09-30|||||Interventional|||Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma|Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients|Completed||Phase 3|342||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:32:12.080148|2018-06-01 04:32:12.080148
NCT00201266|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-03-11|2005-09-16|2005-09-20|Estimate|||||||2013-03-11|2013-03-13|Estimate|July 2005||2005-07-31|March 2013|2013-03-31||||August 2011|Actual|2011-08-31||Observational|||Histoblood Group Antigens as a Risk Factor of Asthma|Histoblood Group Antigens, Viruses and Asthma|Completed|||126|Actual|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     DNA, plasma, saliva, induced sputum.~   "|||2018-06-01 04:32:12.146303|2018-06-01 04:32:12.146303
NCT00201253|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2015-01-22|2005-09-16|2005-09-20|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2000||2000-09-30|January 2015|2015-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Expression of Tuberculosis in the Lung|Expression of Tuberculosis in the Lung|Completed|||40|Actual|Rutgers, The State University of New Jersey|||||f||||||||||Samples With DNA|"~     Cell culture supernatants and cell lysates from bronchoalveolar cells, as well as peripheral~     blood mononuclear cells.~      Bronchoalveolar lavage fluid~   "|||2018-06-01 04:32:12.228406|2018-06-01 04:32:12.228406
NCT00201006|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-11-02||2014-01-21|2005-09-12|2005-09-20|Estimate|2014-01-21|2014-03-07|Estimate||||2014-01-21|2014-03-07|Estimate|June 2003||2003-06-30|January 2014|2014-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|TOURS||Treatment of Obesity in Underserved Rural Settings (TOURS)|Treatment of Obesity in Underserved Rural Settings (TOURS)|Completed||N/A|234|Actual|University of Florida||3|||f||||t||||||||||2018-06-01 04:32:15.16614|2018-06-01 04:32:15.16614
NCT00200993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-04-13|2005-09-12|2005-09-20|Estimate|||||||2009-04-13|2009-04-14|Estimate|September 1998||1998-09-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:32:15.747042|2018-06-01 04:32:15.747042
NCT00201240|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2012-05-14||2017-08-24|2005-09-16|2005-09-20|Estimate|2014-11-07|2014-11-10|Estimate||||2017-08-24|2017-09-25|Actual|June 2005||2005-06-30|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)|A Single Arm, Multicenter Phase II Trial of Transplants of HLA-Matched, CD34+ Enriched, T Cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With AML in First or Second Morphologic Complete Remission (BMT CTN #0303)|Completed||Phase 2|47|Actual|National Heart, Lung, and Blood Institute (NHLBI)||1|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-06-01 04:32:12.354212|2018-06-01 04:32:12.354212
NCT00201227|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2017-07-07|2005-09-16|2005-09-20|Estimate|||||||2017-07-07|2017-07-11|Actual|September 2002||2002-09-30|October 2015|2015-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|ULTRA||Trial to Enhance Adherence to Multiple Guidelines|Using Learning Teams for Reflective Adaptation|Completed||N/A|60|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-06-01 04:32:12.900781|2018-06-01 04:32:12.900781
NCT00201214|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-09-10|2005-09-16|2005-09-20|Estimate|||||||2013-09-10|2013-09-12|Estimate|December 2003||2003-12-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|January 2006|Actual|2006-01-31||Interventional|||Citrulline for Children Undergoing Cardiopulmonary Bypass Surgery|Phase I/II Clinical Trial to Determine the Pharmacokinetics and Safety Profile of Citrulline in Children Undergoing Cardiopulmonary Bypass|Completed||Phase 1/Phase 2|26|Actual|Vanderbilt University|||||f||||t||||||||||2018-06-01 04:32:12.996707|2018-06-01 04:32:12.996707
NCT00201201|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2013-08-13||2013-12-17|2005-09-16|2005-09-20|Estimate|2013-12-17|2014-02-03|Estimate||||2013-12-17|2014-02-03|Estimate|September 2007||2007-09-30|December 2013|2013-12-31|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|||Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension|Reducing Adverse Self-Medication Behaviors in Older Adults With Hypertension|Completed||N/A|160|Actual|University of Connecticut||2|||f||||t||||||||||2018-06-01 04:32:13.107425|2018-06-01 04:32:13.107425
NCT00201188|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-03-07|2005-09-16|2005-09-20|Estimate|||||||2013-03-07|2013-03-11|Estimate|December 2003||2003-12-31|March 2013|2013-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Enhancing Collaboration Between Doctors and Patients to Improve Asthma|Cueing Patient-Clinician Collaboration to Improve Asthma|Completed||N/A|139|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:32:13.553343|2018-06-01 04:32:13.553343
NCT00201162|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2014-03-19|2005-09-16|2005-09-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Soy and Lipoproteins in Postmenopausal Women||Completed||N/A|||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:32:13.626215|2018-06-01 04:32:13.626215
NCT00201149|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2016-04-06|2005-09-16|2005-09-20|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2004||2004-02-29|April 2016|2016-04-30|December 2015|Actual|2015-12-31|April 2008|Actual|2008-04-30||Interventional|HCTA||Clinician Counseling and Cultural Competency to Improve Hypertension Control and Therapy Adherence|Hypertension Control and Therapy Adherence|Completed||N/A|870|Actual|Boston Medical Center||3|||f||||t||||||||No||2018-06-01 04:32:13.720542|2018-06-01 04:32:13.720542
NCT00201136|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-11|2005-09-16|2005-09-20|Estimate|||||||2015-10-11|2015-10-14|Estimate|February 2004||2004-02-29|February 2012|2012-02-29|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|HIP||Interventions to Improve Hypertension Control and Reduce Cardiovascular Disease Risk|Hypertension Improvement Project (HIP)|Completed||Phase 2|574|Actual|Duke University||4|||f||||t||||||||||2018-06-01 04:32:13.802804|2018-06-01 04:32:13.802804
NCT00201123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2014-01-22||2016-12-14|2005-09-16|2005-09-20|Estimate|2014-06-09|2014-06-10|Estimate||||2016-12-14|2016-12-16|Estimate|April 2005||2005-04-30|December 2016|2016-12-31|August 2007|Actual|2007-08-31|January 2007|Actual|2007-01-31||Interventional||"Demographic information provided for all subjects who were eligible for the study after all screening procedures were performed. 7 subjects who were found to be ineligible after randomization but prior to administration of treatment (listed as did not meet continuation criteria in participant flow section) are not included in baseline analysis."|Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs|Host Response to Tuberculosis and Acquired Immune Deficiency Syndrome|Completed||Phase 2|89|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-06-01 04:32:13.918786|2018-06-01 04:32:13.918786
NCT00201110|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-03-19|2005-09-16|2005-09-20|Estimate|||||||2013-03-19|2013-03-20|Estimate|July 2004||2004-07-31|March 2013|2013-03-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Problem Solving and Cardiovascular Disease Risk Management in Diabetic Blacks|Problem Solving & CVD Risk Management in Diabetic Blacks|Completed||N/A|139|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 04:32:14.388921|2018-06-01 04:32:14.388921
NCT00201084|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2014-07-17|2005-09-16|2005-09-20|Estimate|||||||2014-07-17|2014-07-21|Estimate|September 2004||2004-09-30|July 2014|2014-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Physician Uncertainty Reduction for Hypertension|Physician Uncertainty Reduction for Hypertension|Completed||N/A|670|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 04:32:14.56217|2018-06-01 04:32:14.56217
NCT00201071|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-09-27|2005-09-12|2005-09-20|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Observational|||Asthma Surveillance and Education in Preschool Settings|Asthma Surveillance and Education in Preschool Settings|Completed|||208|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||1||f||||||||||||||2018-06-01 04:32:14.739861|2018-06-01 04:32:14.739861
NCT00201058|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2012-12-18|2005-09-16|2005-09-20|Estimate|||||||2012-12-18|2012-12-20|Estimate|July 2006||2006-07-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|Puff City||Tailored Asthma Management for Urban Teens|Tailored Asthma Management for Urban Teens|Completed||N/A|450|Actual|Henry Ford Health System||2|||f||||t||||||||||2018-06-01 04:32:14.842621|2018-06-01 04:32:14.842621
NCT00201045|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-03-26|2005-09-12|2005-09-20|Estimate|||||||2014-03-26|2014-03-27|Estimate|July 2003||2003-07-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Team Management of High Blood Pressure|Collaborative Management of Hypertension|Completed||N/A|179|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 04:32:14.936007|2018-06-01 04:32:14.936007
NCT00201019|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-11-30|2005-09-12|2005-09-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2003||2003-08-31|November 2015|2015-11-30|July 2009|Actual|2009-07-31|April 2008|Actual|2008-04-30||Interventional|||Improving Adherence to Blood Pressure Guidelines|Improving Adherence to Blood Pressure Guidelines|Completed||N/A|623|Actual|University of Iowa||3|||f||||t||||||||||2018-06-01 04:32:15.058396|2018-06-01 04:32:15.058396
NCT00200980|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-03-06|2005-09-12|2005-09-20|Estimate|||||||2009-03-06|2009-03-09|Estimate|August 2005||2005-08-31|March 2009|2009-03-31||||||||Observational|||Importance of Non-Acid Reflux in Asthma in Children|Importance of Non-Acid Reflux in Moderate and Severe Asthma|Completed|||120|Anticipated|Nemours Children's Clinic|||||f||||||||||||||2018-06-01 04:32:15.851993|2018-06-01 04:32:15.851993
NCT00200967|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-05||2017-12-26|2005-09-12|2005-09-20|Estimate|2009-04-08|2009-06-02|Estimate||||2017-12-26|2018-01-23|Actual|December 2004||2004-12-31|December 2017|2017-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)|Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)|Completed||Phase 3|87|Actual|Milton S. Hershey Medical Center|The study used a moderately high dose of ICS. Genotype-specific effects may be evident at lower doses of ICS often used in combination therapy. Also, short-acting β2-agonists have been shown to have genotype-specific effects on asthma outcomes.|2|||f||||t||||||||||2018-06-01 04:32:15.954461|2018-06-01 04:32:15.954461
NCT00200954|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-08-13|2005-09-12|2005-09-20|Estimate|||||||2008-08-13|2008-08-18|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|August 2008|Actual|2008-08-31|December 2007|Actual|2007-12-31||Interventional|||Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics|Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics.|Completed||N/A|157|Actual|The Netherlands Asthma Foundation||2|||f||||||||||||||2018-06-01 04:32:16.68657|2018-06-01 04:32:16.68657
NCT00200941|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-15|2005-09-12|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|August 2001||2001-08-31|September 2005|2005-09-30|April 2005||2005-04-30|||||Interventional|||Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS)|Completed||Phase 4|44||Neurocare|||||f||||||||||||||2018-06-01 04:32:16.823535|2018-06-01 04:32:16.823535
NCT00200928|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-04-03|2005-09-12|2005-09-20|Estimate|||||||2006-04-03|2006-04-04|Estimate|January 1999||1999-01-31|April 2006|2006-04-30|July 2005||2005-07-31|||||Interventional|||Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood.|Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood.|Completed||N/A|120||The Netherlands Asthma Foundation|||||f||||||||||||||2018-06-01 04:32:16.89661|2018-06-01 04:32:16.89661
NCT00200902|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-11-19|2005-09-14|2005-09-20|Estimate|||||||2009-11-19|2009-11-23|Estimate|August 2005||2005-08-31|November 2009|2009-11-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression|Factors of Treatment Response in Major Depressive Disorder|Suspended||Phase 4|140|Anticipated|University of California, Los Angeles||5|||f||||t||||||||||2018-06-01 04:32:17.02332|2018-06-01 04:32:17.02332
NCT00200889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-24|2005-09-16|2005-09-20|Estimate|||||||2018-05-24|2018-05-28|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Mapping Auricular Vagus Nerve Circuitry|Spatiotemporal Patterns for Neuromodulation Processing in the Brain Using MRI and M/EEG|Recruiting||Early Phase 1|60|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||||2018-06-01 04:32:17.156602|2018-06-01 04:32:17.156602
NCT00200876|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-21|2005-09-13|2005-09-20|Estimate|||||||2017-03-21|2017-03-24|Actual|September 2003||2003-09-30|March 2017|2017-03-31|June 2008|Actual|2008-06-30|February 2008|Actual|2008-02-29||Interventional|||Effects of Anticipation of Pain Relief on Brain Mechanisms|Neurochemical Mediation of Placebo Responses in Humans|Completed||N/A|60|Actual|University of Michigan||2|||f||||t|f|f||||||No||2018-06-01 04:32:17.334388|2018-06-01 04:32:17.334388
NCT00200863|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-08-08|2005-09-13|2005-09-20|Estimate|||||||2014-08-08|2014-08-12|Estimate|April 2005||2005-04-30|August 2014|2014-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effects of Different Colors of Light on Human Physiology|Mechanism Underlying the Effects of Blue Light in Humans|Completed||N/A|47|Actual|Brigham and Women's Hospital||6|||f||||f||||||||||2018-06-01 04:32:17.457695|2018-06-01 04:32:17.457695
NCT00200850|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-12|2005-09-13|2005-09-20|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2006||2006-01-31|May 2016|2016-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy|Sublingual Immunotherapy in Dust Mite Allergy|Completed||N/A|31|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-06-01 04:32:17.615285|2018-06-01 04:32:17.615285
NCT00200837|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-03-27|2005-09-13|2005-09-20|Estimate|||||||2007-03-27|2007-03-28|Estimate|March 2002||2002-03-31|March 2007|2007-03-31|February 2007|Actual|2007-02-28|||||Observational|||Ethnopharmacological Studies in Oral Medicine|Ethnopharmacological Studies in Oral Medicine|Completed|||1000||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:32:17.72567|2018-06-01 04:32:17.72567
NCT00200824|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-10|2005-09-13|2005-09-20|Estimate|||||||2009-03-10|2009-03-12|Estimate|May 2000||2000-05-31|August 2006|2006-08-31|January 2005||2005-01-31|||||Interventional|||Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone Health|Effects of Soy Isoflavones on the Prostate, Breast and Bone|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:32:17.812499|2018-06-01 04:32:17.812499
NCT00200798|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-06|2005-09-13|2005-09-20|Estimate|||||||2018-04-06|2018-04-09|Actual|May 2006||2006-05-31|April 2018|2018-04-30|August 2007||2007-08-31|||||Observational|||An Assessment of Milk Thistle Pharmacokinetics and Drug Interactions|Pharmacokinetics and Drug Interactions With Milk Thistle|Recruiting|||32|Anticipated|Medical University of South Carolina|||||f||||t||||||Samples Without DNA|"~     plasma & urine~   "|||2018-06-01 04:32:17.894136|2018-06-01 04:32:17.894136
NCT00200785|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-04-23||2009-12-04|2005-09-12|2005-09-20|Estimate|2009-12-04|2010-01-11|Estimate||||2009-12-04|2010-01-11|Estimate|March 2006||2006-03-31|December 2009|2009-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Identifying the Anti-Blood-Clotting Compounds in Garlic|Identification of the Antiplatelet Compounds of Garlic Ex Vivo|Completed||N/A|9|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 04:32:17.983779|2018-06-01 04:32:17.983779
NCT00200759|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-05-23|2005-09-12|2005-09-20|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2004||2004-10-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Drug Interactions and Bioavailability of Cranberry|Drug Interactions and Bioavailability of Cranberry|Completed||Phase 1|16|Actual|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 04:32:18.356898|2018-06-01 04:32:18.356898
NCT00200746|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-03-11|2005-09-12|2005-09-20|Estimate|||||||2013-03-11|2013-03-12|Estimate|April 2006||2006-04-30|March 2013|2013-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Treatment of Alcohol-Related Hepatitis With Arginine|Arginine Treatment for Alcoholic Hepatitis|Withdrawn||Phase 2|0|Actual|National Center for Complementary and Integrative Health (NCCIH)||3||lack of enrollment|f||||t||||||||||2018-06-01 04:32:18.44962|2018-06-01 04:32:18.44962
NCT00200733|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-08-17|2005-09-12|2005-09-20|Estimate|||||||2006-08-17|2006-08-18|Estimate|June 2003||2003-06-30|December 2005|2005-12-31|March 2004||2004-03-31|||||Observational|||The Use of Narrative in Public Health Research and Practice: Patient Experience of Wellness Acupuncture|The Use of Narrative in Public Health Research and Practice: Patient Experience of Wellness Acupuncture|Terminated|||30||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:32:18.543617|2018-06-01 04:32:18.543617
NCT00200720|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-04|2005-09-12|2005-09-20|Estimate|||||||2012-12-04|2012-12-06|Estimate|April 2005||2005-04-30|February 2008|2008-02-29|June 2010|Actual|2010-06-30|March 2009|Actual|2009-03-31||Interventional|||Effectiveness of a Low Carbohydrate Diet Versus a High Carbohydrate Diet in Promoting Weight Loss and Improved Health|Metabolic Consequences of High and Low Carbohydrate Diets|Completed||Phase 2|260|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 04:32:18.641553|2018-06-01 04:32:18.641553
NCT00200707|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-04-29|2005-09-13|2005-09-20|Estimate|||||||2014-04-29|2014-04-30|Estimate|December 2004||2004-12-31|April 2014|2014-04-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||BONAMI (BOne Marrow in Acute Myocardial Infarction)|Intracoronary Injection of Autologous Bone Marrow Mononuclear Cells for Severe Myocardial Infarction|Completed||Phase 2|101|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 04:32:18.75626|2018-06-01 04:32:18.75626
NCT00200694|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-03|2005-09-13|2005-09-20|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 2005||2005-03-31|February 2009|2009-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.||Terminated||Phase 4|18||Nantes University Hospital||||difficulty in patients's inclusion|f||||||||||||||2018-06-01 04:32:18.832108|2018-06-01 04:32:18.832108
NCT00200681|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-02-04|2005-09-12|2005-09-20|Estimate|||||||2009-02-04|2009-02-05|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma|Etude Multicentrique Ouverte Randomisée de Phase III Comparant l'Association de VELCADE®-Dexaméthasone à la Chimiothérapie de Type VAD Pour le Traitement Des Patients Porteurs de Myélome Multiple de Novo Jusqu'à l'âge de 65 Ans|Completed||Phase 3|493|Actual|Nantes University Hospital|||||f||||t||||||||||2018-06-01 04:32:18.908819|2018-06-01 04:32:18.908819
NCT00200668|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-05|2005-09-12|2005-09-20|Estimate|||||||2008-06-05|2008-06-09|Estimate|March 2005||2005-03-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|||||Interventional|||Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.||Terminated||N/A|0|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:32:19.001348|2018-06-01 04:32:19.001348
NCT00200655|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-04-27|2005-09-12|2005-09-20|Estimate|||||||2016-04-27|2016-04-28|Estimate|December 2004||2004-12-31|June 2008|2008-06-30|November 2007|Actual|2007-11-30|||||Interventional|||Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis|Safety and Efficacy of Pravastatin in Relapsing-remitting MS: a Double Blind Placebo Controlled Study|Completed||Phase 3|40|Actual|Nantes University Hospital|||||f||||f||||||||||2018-06-01 04:32:19.090612|2018-06-01 04:32:19.090612
NCT00200642|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-20|2005-09-12|2005-09-20|Estimate|||||||2008-05-20|2008-05-22|Estimate|December 2003||2003-12-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease|Evaluation of the Efficiency of Radiofrequency in the Treatment of Gastroesophageal Reflux Disease|Completed||N/A|54|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:32:19.152803|2018-06-01 04:32:19.152803
NCT00200629|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-08-08|2005-09-12|2005-09-20|Estimate|||||||2011-08-08|2011-08-09|Estimate|June 2005||2005-06-30|August 2011|2011-08-31||||||||Interventional|||Both Exercise and Adenosine Stress Testing|A Pilot Study Examining the Value of Combined Exercise and Adenosine Stress Myocardial Perfusion Imaging as Compared With Adenosine Testing Alone for the Evaluation of Women at Intermediate or High Likelihood for Coronary Artery Disease|Terminated||Phase 4|200|Anticipated|Midwest Heart Foundation||||Poor enrollment|f||||||||||||||2018-06-01 04:32:19.323743|2018-06-01 04:32:19.323743
NCT00200616|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-30|2005-09-12|2005-09-20|Estimate|||||||2008-06-30|2008-07-01|Estimate|April 2001||2001-04-30|June 2008|2008-06-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Usefulness of Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux.|Antimicrobial Prophylaxis in Children With Isolated Vesico-Ureteral Reflux. A Randomised Prospective Study of Continuous Low Dose of Trimethoprim-Sulfamethoxazole Versus Surveillance.|Completed||N/A|232||Nantes University Hospital|||||f||||f||||||||||2018-06-01 04:32:19.49306|2018-06-01 04:32:19.49306
NCT00200603|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-15|2005-09-12|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|May 1999||1999-05-31|May 2004|2004-05-31||||||||Interventional|||Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy|Autograft Versus Calcium Phosphate Macroporous Bioceramics as Bone Substitute for Tibial Valgus Osteotomy|Unknown status|Active, not recruiting|N/A|50||Nantes University Hospital|||||f||||||||||||||2018-06-01 04:32:19.627422|2018-06-01 04:32:19.627422
NCT00200590|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-18|2005-09-12|2005-09-20|Estimate|||||||2008-04-18|2008-04-21|Estimate|December 2003||2003-12-31|April 2008|2008-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Analgesic Strategies in Newborns Receiving Prostaglandin Therapy|Analgesic Strategies in Newborns Receiving Prostaglandin Therapy|Terminated||N/A|30|Anticipated|Nantes University Hospital||||More important number of SAE in one arms|f||||||||||||||2018-06-01 04:32:19.737061|2018-06-01 04:32:19.737061
NCT00200577|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-31|2005-09-12|2005-09-20|Estimate|||||||2017-05-31|2017-06-01|Actual|May 2005||2005-05-31|May 2017|2017-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|TIL||Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma|TIL (Tumor Infiltrating Lymphocytes) and IL2 (Interleukin 2) Versus Abstention as Adjuvant Treatment in Melanoma With Only One Invaded Lymphnode After Lymphnodes Excision|Completed||Phase 3|70|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-06-01 04:32:19.883417|2018-06-01 04:32:19.883417
NCT00200564|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-22|2005-09-12|2005-09-20|Estimate|||||||2007-10-22|2007-10-23|Estimate|February 2004||2004-02-29|July 2005|2005-07-31||||||||Interventional|||Ketamine and Postoperative Analgesia in Children|Ketamine and Postoperative Analgesia in Children|Unknown status|Recruiting|Phase 4|74|Anticipated|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:32:20.126112|2018-06-01 04:32:20.126112
NCT00200551|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-04|2005-09-12|2005-09-20|Estimate|||||||2013-02-04|2013-02-05|Estimate|January 2001||2001-01-31|February 2013|2013-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant|A Prospective, Randomized, Open, Multicentric Study Intended to Evaluate the Efficacy and Tolerability of Sequential Treatment Based on Rabbit Anti-T-lymphocyte Serum, of Mycophenolate Mofetil and of Cyclosporin, Without Concomitant Corticosteroids, After a First Cadaveric Renal Transplant|Completed||Phase 4|200||Nantes University Hospital|||||f||||||||||||||2018-06-01 04:32:20.297509|2018-06-01 04:32:20.297509
NCT00200538|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-05-02|2005-09-12|2005-09-20|Estimate|||||||2013-05-02|2013-05-03|Estimate|September 2005||2005-09-30|January 2005|2005-01-31||||||||Interventional|||Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients|Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients|Completed||Phase 2|52|Actual|Nantes University Hospital|||||f||||||||||||||2018-06-01 04:32:20.415962|2018-06-01 04:32:20.415962
NCT00200525|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-15|2005-09-13|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|July 2001||2001-07-31|September 2005|2005-09-30|June 2002||2002-06-30|||||Interventional|||Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease|"A Randomized, Placebo-Controlled Study of the Continued Efficacy and Safety of SC Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing-Off Effects Associated With Late-Stage PD After Apomorphine Use"|Completed||Phase 3|60||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:32:20.514839|2018-06-01 04:32:20.514839
NCT00200512|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-15|2005-09-13|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|September 1999||1999-09-30|March 2000|2000-03-31|November 1999||1999-11-30|||||Interventional|||Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months|"A Prospective, Randomized, Placebo-Controlled, Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of Off Episodes in Patients With On/Off or Wearing Off Effects Associated With Late Stage Parkinson's Disease"|Completed||Phase 2/Phase 3|16||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:32:20.608827|2018-06-01 04:32:20.608827
NCT00200499|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-15|2005-09-13|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|March 2002||2002-03-31|September 2005|2005-09-30|September 2003||2003-09-30|||||Interventional|||A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients|A Multi-Center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients With Mild to Moderate Hypertension|Completed||Phase 3|845||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:32:20.705454|2018-06-01 04:32:20.705454
NCT00200486|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-03-19|2005-09-16|2005-09-20|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2002||2002-05-31|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|May 2020|Anticipated|2020-05-31||Observational|||Molecular and Genomic Profiling of Head and Neck Tumors|Molecular and Genomic Profiling of Head and Neck Tumors to Explore Biomarkers Associated With Prognosis and Response to Therapy|Recruiting|||400|Anticipated|Montefiore Medical Center|||||f||||t||||||Samples With DNA|"~     1. Tumor specimens along with normal mucosa obtained at the time of surgery for biopsy or~          resection of primary or recurrent tumors of the head and neck~        2. blood, urine and sputum from patients participating in the tumor collection described~          above~   "|||2018-06-01 04:32:20.795919|2018-06-01 04:32:20.795919
NCT00200473|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|March 2003||2003-03-31|||||Interventional|||A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients|A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Effects of Nebivolol on Safety and Efficacy in Patients With Mild to Moderate Hypertension|Completed||Phase 3|800||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:32:20.969402|2018-06-01 04:32:20.969402
NCT00200460|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|March 2003||2003-03-31|||||Interventional|||A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients|A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Dosing Study Evaluating the Effects of Nebivolol on Blood Pressure in Patients With Mild to Moderate Hypertension|Completed||Phase 3|825||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:32:21.097997|2018-06-01 04:32:21.097997
NCT00200447|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-17|2005-09-12|2005-09-20|Estimate|||||||2008-01-17|2008-01-21|Estimate|March 2004||2004-03-31|January 2008|2008-01-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)|Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)|Completed||Phase 2|3|Actual|Molecular NeuroImaging|||||f||||||||||||||2018-06-01 04:32:21.20737|2018-06-01 04:32:21.20737
NCT00200434|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|October 2003||2003-10-31|||||Interventional|||A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension|A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Mild to Moderate Hypertension|Completed||Phase 3|600||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:32:21.336744|2018-06-01 04:32:21.336744
NCT00200421|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-15|2005-09-12|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|May 2002||2002-05-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension|A Double-Blind, Randomized, Multi-Center, Active Comparator, Five Treatment Study of the Effects of Nebivolol Compared to Atenolol on Cardiovascular Hemodynamics and Exercise Capacity in Patients With Mild to Moderate Hypertension|Completed||Phase 2|110||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:32:21.44437|2018-06-01 04:32:21.44437
NCT00200408|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-07|2005-09-13|2005-09-20|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2004||2004-03-31|April 2015|2015-04-30||||January 2005|Actual|2005-01-31||Observational|||Assessment of Early Genetic Changes in Smokers|Assessment of Early Genetic Changes in Smokers|Terminated|||10|Actual|Montefiore Medical Center|||2|unable to obtain funding|f||||||||||||||2018-06-01 04:32:21.58058|2018-06-01 04:32:21.58058
NCT00200395|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|June 2003||2003-06-30|September 2005|2005-09-30||||||||Interventional|||Phs. II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients W/Advanced Stage or Inoperable Non-Small Cell Lung Cancer (NSCLC)|Phase II Study of OSI-774 (Erlotinib, Tarceva) in Elderly Patients With Advanced Stage or Inoperable Non Small Cell Lung Cancer (NSCLC)|Suspended||Phase 2|27||Montefiore Medical Center|||||||||||||||||||2018-06-01 04:32:21.66945|2018-06-01 04:32:21.66945
NCT00200382|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-07|2005-09-13|2005-09-20|Estimate|||||||2007-12-07|2007-12-11|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer|Phase II Study to Evaluate the Efficacy and Safety of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer|Terminated||Phase 2|27|Anticipated|Montefiore Medical Center||||The study did not achieve the statistical success to continue.|||||||||||||||2018-06-01 04:32:21.767765|2018-06-01 04:32:21.767765
NCT00200369|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-11-04|2005-09-12|2005-09-20|Estimate|||||||2009-11-04|2009-11-05|Estimate|May 2004||2004-05-31|November 2009|2009-11-30|March 2006|Actual|2006-03-31|||||Observational|||Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen|Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen|Completed|||90|Anticipated|Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:32:21.829836|2018-06-01 04:32:21.829836
NCT00198809|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|November 2002||2002-11-30|April 2004|2004-04-30|February 2004||2004-02-29|||||Interventional|||Use of Herbal Supplements in Weight Loss and Weight Maintenance|Use of Herbal Supplements in Weight Loss and Weight Maintenance|Terminated||N/A|250||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:39.369811|2018-06-01 04:32:39.369811
NCT00200356|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-09-13||2012-12-09|2005-09-12|2005-09-20|Estimate|2012-12-09|2013-01-15|Estimate||||2012-12-09|2013-01-15|Estimate|August 2004||2004-08-31|December 2012|2012-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke|Edaravone-Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) Comparative Post-Marketing Study on Acute Ischemic Stroke|Completed||Phase 4|401|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 04:32:21.918582|2018-06-01 04:32:21.918582
NCT00200343|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-08-17||2012-03-07|2005-09-12|2005-09-20|Estimate|2011-09-29|2011-11-07|Estimate||||2012-03-07|2012-03-12|Estimate|July 2002||2002-07-31|March 2012|2012-03-31|December 2004||2004-12-31|||||Interventional|||Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C|A 24-week Multicenter Double-blind Control Trial With Ursodeoxycholic Acid in Patients With Chronic Hepatitis C|Completed||Phase 3|596|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||||||||||||2018-06-01 04:32:22.599747|2018-06-01 04:32:22.599747
NCT00200330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-17|2005-09-13|2005-09-20|Estimate|||||||2007-04-17|2007-04-18|Estimate|November 2004||2004-11-30|September 2005|2005-09-30|April 2008|Anticipated|2008-04-30|||||Interventional|||Modifying Obesogenic Homes: Impact on Weight Maintenance||Unknown status|Active, not recruiting|N/A|400||The Miriam Hospital|||||f||||||||||||||2018-06-01 04:32:23.193481|2018-06-01 04:32:23.193481
NCT00200317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-27|2005-09-13|2005-09-20|Estimate|||||||2007-04-27|2007-05-01|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|May 2006|Actual|2006-05-31|||||Interventional|||Interactive Technologies to Increase Exercise Behavior|Interactive Technologies to Increase Exercise Behavior|Completed||Phase 1/Phase 2|240|Actual|The Miriam Hospital|||||f||||||||||||||2018-06-01 04:32:23.247503|2018-06-01 04:32:23.247503
NCT00200304|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-04-23|2005-09-14|2005-09-20|Estimate|||||||2013-04-23|2013-04-24|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Evaluation of a SlimFast Internet Behavioral Weight Loss Program|Development and Evaluation of a SlimFast Internet Behavioral Weight Loss Program|Completed||N/A|225||The Miriam Hospital|||||f||||||||||||||2018-06-01 04:32:23.346829|2018-06-01 04:32:23.346829
NCT00200291|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-04-19|2005-09-12|2005-09-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|July 2004||2004-07-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Changes in Food Reinforcement During Obesity Treatment|Changes in Food Reinforcement During Obesity Treatment|Completed||N/A|147|Anticipated|The Miriam Hospital||2|||f||||||||||||||2018-06-01 04:32:24.488377|2018-06-01 04:32:24.488377
NCT00200278|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|August 2000||2000-08-31|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Exercise Instruction Via Phone or Print|Exercise Instruction Via Phone or Print|Completed||Phase 2|228||The Miriam Hospital|||||f||||||||||||||2018-06-01 04:32:24.589373|2018-06-01 04:32:24.589373
NCT00200265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-04-19|2005-09-12|2005-09-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|July 2005||2005-07-31|December 2007|2007-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Changing Eating Behaviors in Young Children: Should Healthy Foods be Increased or Unhealthy Foods Decreased?|Changing Eating Behaviors in Young Children: Should Healthy Foods be Increased or Unhealthy Foods Decreased?|Completed||N/A|101|Actual|The Miriam Hospital||3|||f||||||||||||||2018-06-01 04:32:24.69349|2018-06-01 04:32:24.69349
NCT00200252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-11-08|2005-09-12|2005-09-20|Estimate|||||||2012-11-08|2012-11-09|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|July 2007|Actual|2007-07-31|||||Interventional|||Oxytocin Administration in the Third Stage of Labour - A Study of Appropriate Route and Dose|Intramuscular Versus Intravascular Oxytocin for the Third Stage of Labour|Completed||Phase 4|300|Actual|Memorial University of Newfoundland||3|||f||||||||||||||2018-06-01 04:32:24.783423|2018-06-01 04:32:24.783423
NCT00200239|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-04-19|2005-09-12|2005-09-20|Estimate|||||||2012-04-19|2012-04-20|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Provision of Breakfast Food in Behavioral Weight Loss|Provision of Breakfast Food in Behavioral Weight Loss|Completed||N/A|25|Anticipated|The Miriam Hospital||2|||f||||||||||||||2018-06-01 04:32:24.900491|2018-06-01 04:32:24.900491
NCT00200226|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-20|2005-09-12|2005-09-20|Estimate|||||||2007-09-20|2007-09-21|Estimate|February 2003||2003-02-28|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Oral Misoprostol Before Endometrial Biopsy|Oral Misoprostol Before Endometrial Biopsy|Completed||Phase 3|72|Actual|Memorial University of Newfoundland||2|||f||||f||||||||||2018-06-01 04:32:25.001743|2018-06-01 04:32:25.001743
NCT00200213|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Liking of Snack Foods - Sub-Study 1|The Effect of Portion Size and Quantity of Food Provided on Intake|Completed||N/A|32||The Miriam Hospital|||||f||||||||||||||2018-06-01 04:32:25.134759|2018-06-01 04:32:25.134759
NCT00200200|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-14|2005-09-12|2005-09-20|Estimate|||||||2017-12-14|2017-12-15|Actual|November 19, 2004||2004-11-19|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer|Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo With/Without Bevacizumab (mAB to Vascular Endothelial Growth Factor-A) in Patients With Resected Hepatic Metastases From Colorectal Cancer|Active, not recruiting||Phase 2|73|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:32:25.262293|2018-06-01 04:32:25.262293
NCT00200187|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-25|2005-09-12|2005-09-20|Estimate|||||||2007-01-25|2007-01-26|Estimate|February 2005||2005-02-28|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery|A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Radical Retropubic Prostatectomy|Completed||Phase 2|246||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:32:25.53358|2018-06-01 04:32:25.53358
NCT00200174|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-12-21|2005-09-12|2005-09-20|Estimate|||||||2015-12-21|2015-12-23|Estimate|July 1999||1999-07-31|December 2015|2015-12-31|August 2008|Actual|2008-08-31|July 2003|Actual|2003-07-31||Interventional|||Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease|Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease: A Pilot Chemoprevention Trial|Completed||N/A|11|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:32:25.665358|2018-06-01 04:32:25.665358
NCT00199966|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-03-06|2005-09-13|2005-09-20|Estimate|||||||2008-03-06|2008-03-07|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|November 2005|Actual|2005-11-30|||||Interventional|||Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder|A Pilot Study Of Safety And Effectiveness For Depakote ER In Pediatric Bipolar Disorder|Completed||Phase 4|30||Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 04:32:28.539003|2018-06-01 04:32:28.539003
NCT00200161|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2018-01-10||2018-03-05|2005-09-12|2005-09-20|Estimate|2018-03-05|2018-03-07|Actual||||2018-03-05|2018-03-07|Actual|August 9, 2005||2005-08-09|September 2016|2016-09-30|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma|A Randomized Phase II Trial of Concurrent Temozolomide and Radiotherapy Followed by Dose Dense Versus Metronomic Temozolomide and Maintenance Cis-Retinoic Acid for Patients With Newly Diagnosed Glioblastoma and Other Malignant Gliomas|Completed||Phase 2|127|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:32:25.824225|2018-06-01 04:32:25.824225
NCT00200148|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-04|2005-09-12|2005-09-20|Estimate|||||||2015-03-04|2015-03-06|Estimate|March 2004||2004-03-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy|A Prospective Randomized Trial of Acute Normovolemic Hemodilution Compared to Standard Intraoperative Management in Patients Undergoing Major Hepatic Resection and Pancreaticoduodenectomy|Completed||Phase 3|372|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:32:26.510724|2018-06-01 04:32:26.510724
NCT00200135|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-07-02|2005-09-19|2005-09-20|Estimate|||||||2013-07-02|2013-07-03|Estimate|June 2005||2005-06-30|July 2013|2013-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Financial and Clinical Impact of Repeal of the Pennsylvania Motorcycle Helmet Law|Financial and Clinical Impact of Repeal of the Pennsylvania Helmet Law: A Multi-Center Prospective Study Comparing Helmeted and Non-Helmeted Motorcycle Accident Victims|Completed|||480|Anticipated|Memorial Medical Center|||4||f||||f||||||||||2018-06-01 04:32:26.593189|2018-06-01 04:32:26.593189
NCT00200122|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-20|2005-09-12|2005-09-20|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Restore Claims Characterization Study|Restore Claims Characterization Study|Completed||Phase 4|100||MedtronicNeuro|||||||||||||||||||2018-06-01 04:32:26.670242|2018-06-01 04:32:26.670242
NCT00200109|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-10-07|2005-09-12|2005-09-20|Estimate|||||||2011-10-07|2011-10-12|Estimate|May 2004||2004-05-31|October 2011|2011-10-31|May 2011|Actual|2011-05-31|June 2008|Actual|2008-06-30||Interventional|ONSTIM||Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.|ONSTIM: Occipital Nerve Stimulation for the Treatment of Intractable Migraine.|Completed||Phase 1|110|Actual|MedtronicNeuro||4|||f||||f||||||||||2018-06-01 04:32:26.759845|2018-06-01 04:32:26.759845
NCT00200096|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-02-11|2005-09-12|2005-09-20|Estimate|||||||2011-02-11|2011-02-15|Estimate|July 2004||2004-07-31|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial|Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial|Completed||Phase 3|101|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:32:26.880664|2018-06-01 04:32:26.880664
NCT00200083|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-26|2005-09-12|2005-09-20|Estimate|||||||2015-03-26|2015-03-27|Estimate|May 2004||2004-05-31|March 2015|2015-03-31|January 2008|Actual|2008-01-31|September 2005|Actual|2005-09-30||Interventional|SHAPE||Study of Weight Loss Using Gastric Stimulation in Obese Patients|SHAPE: Screened Health Assessment & Pacer Evaluation|Completed||N/A|190|Actual|MedtronicNeuro||2|||f||||t||||||||||2018-06-01 04:32:26.975715|2018-06-01 04:32:26.975715
NCT00200070|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-26|2005-09-12|2005-09-20|Estimate|||||||2010-08-26|2010-08-30|Estimate|December 2002||2002-12-31|August 2010|2010-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|STARTSTIM||Neurostimulation to Treat Refractory Angina Pectoris Pain|STARTSTIM - Stimulation Therapy for Angina Refractory To Standard Treatments, Interventions and Medications|Terminated||Phase 3|228||MedtronicNeuro|||||f||||||||||||||2018-06-01 04:32:27.180453|2018-06-01 04:32:27.180453
NCT00200057|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-04-13|2010-05-07|2013-01-17|2005-09-12|2005-09-20|Estimate|2011-07-29|2011-08-30|Estimate|2011-03-29|2011-04-04|Estimate|2013-01-17|2013-01-24|Estimate|January 2002||2002-01-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|August 2007|Actual|2007-08-31||Interventional|||Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence|Medtronic InterStim® Sacral Nerve Stimulation Therapy for Bowel Control: Fecal Incontinence Study|Completed||N/A|285|Actual|MedtronicNeuro|||||f||||f||||||||||2018-06-01 04:32:27.339903|2018-06-01 04:32:27.339903
NCT00200044|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-07-10|2005-09-12|2005-09-20|Estimate|||||||2009-07-10|2009-07-13|Estimate|December 2002||2002-12-31|July 2009|2009-07-31|June 2008|Actual|2008-06-30|June 2006|Actual|2006-06-30||Interventional|||An Evaluation of the Medtronic Gatekeeper System in the Treatment of SUBJECTS With Gastroesophageal Reflux Disease (GERD)|Gatekeeper® System Sham-Controlled Study for the Treatment of GERD|Terminated||N/A|143|Actual|MedtronicNeuro||2||Lack of efficacy|f||||t||||||||||2018-06-01 04:32:27.83827|2018-06-01 04:32:27.83827
NCT00200031|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-07-24|2005-09-12|2005-09-20|Estimate|||||||2008-07-24|2008-07-28|Estimate|July 2005||2005-07-31|July 2008|2008-07-31|April 2006|Actual|2006-04-30|||||Observational|||A Cost Analysis of Interstim Therapy|Interstim Therapy Retrospective Cost Analysis and Quality of Life|Completed|||150||MedtronicNeuro|||||f||||||||||||||2018-06-01 04:32:27.987569|2018-06-01 04:32:27.987569
NCT00200018|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-02-03|2005-09-12|2005-09-20|Estimate|||||||2009-02-03|2009-02-05|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|February 2007|Actual|2007-02-28||Interventional|ASSIST||Study of Weight Loss Using Gastric Stimulation in Obese Patients With Type 2 Diabetes|ASSIST: Appetite Suppression Induced by Stimulation Trial|Completed||N/A|46|Actual|MedtronicNeuro|||||f||||t||||||||||2018-06-01 04:32:28.078063|2018-06-01 04:32:28.078063
NCT00200005|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-01-09|2005-09-12|2005-09-20|Estimate|||||||2014-01-09|2014-01-10|Estimate|November 1998||1998-11-30|January 2014|2014-01-31|September 2012|Actual|2012-09-30|December 2006|Actual|2006-12-31||Interventional|MDT-301||Sacral Nerve Stimulation for Anal Incontinence and Bowel Control|Sacral Nerve Stimulation for Anal Incontinence and Bowel Control|Completed||Phase 4|140|Anticipated|MedtronicNeuro||1|||f||||f||||||||||2018-06-01 04:32:28.181117|2018-06-01 04:32:28.181117
NCT00199992|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Platelets in Acute Wounds: A Pilot Study (PAWS)|Platelets in Acute Wounds: A Pilot Study (PAWS)|Completed||N/A|8||Medtronic|||||f||||||||||||||2018-06-01 04:32:28.326638|2018-06-01 04:32:28.326638
NCT00199979|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-15|2005-09-12|2005-09-20|Estimate|||||||2005-12-15|2005-12-16|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|June 2008||2008-06-30|||||Interventional|||Zidovudine / Lamivudine + Nevirapine Twice Daily, Versus Tenofovir + Lamivudine + Nevirapine Once Daily in ARV-Naive Patients|Multicenter, Randomized, Open-Label Trial, Assessing the Efficacy of Zidovudine, Lamivudine and Nevirapine Combination Administered Twice Daily, Versus the Association of Tenofovir, Lamivudine and Nevirapine, Once Daily, in Antiretroviral Naive HIV-1 Infected Patients|Unknown status|Recruiting|Phase 3|250||MEDEX|||||f||||||||||||||2018-06-01 04:32:28.430097|2018-06-01 04:32:28.430097
NCT00199953|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-01-27|2005-09-12|2005-09-20|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2002||2002-06-30|November 2013|2013-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Post-nasal Drainage as an Extraesophageal Manifestation of Reflux|Post-nasal Drainage as an Extraesophageal Manifestation of Reflux|Completed||Phase 2|50||Medical College of Wisconsin|||||||||||||||||||2018-06-01 04:32:28.621385|2018-06-01 04:32:28.621385
NCT00199940|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-03-06|2005-09-13|2005-09-20|Estimate|||||||2008-03-06|2008-03-12|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness|A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness|Completed||Phase 4|20||Medical College of Wisconsin|||||f||||f||||||||||2018-06-01 04:32:28.768311|2018-06-01 04:32:28.768311
NCT00199927|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-04-27|2005-09-12|2005-09-20|Estimate|||||||2010-04-27|2010-04-28|Estimate|March 2003||2003-03-31|April 2010|2010-04-30|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|ESPLANADE||Statins in Proteinuric Nephropathies|A Prospective, Randomized, Multicenter Trial Testing the Antiproteinuric Effect of Statins Added to Combined ACE-inhibitor and Angiotensin Receptor Antagonist Therapy in Proteinuric, Chronic Nephropathies|Completed||Phase 3|217|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-06-01 04:32:28.842982|2018-06-01 04:32:28.842982
NCT00199914|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-05-19||2013-09-06|2005-09-12|2005-09-20|Estimate|2013-09-06|2013-11-08|Estimate||||2013-09-06|2013-11-08|Estimate|January 2004||2004-01-31|September 2013|2013-09-30|June 2004|Actual|2004-06-30|May 2004|Actual|2004-05-31||Interventional|||Efficacy Study of Shortwave Diathermy for the Treatment of Patients With Knee Osteoarthritis|The Effectiveness of Shortwave Diathermy in Knee Osteoarthritis: A Randomized Controlled Trial|Completed||Phase 3|113|Actual|Mahidol University||2|||f||||f||||||||||2018-06-01 04:32:28.982012|2018-06-01 04:32:28.982012
NCT00199901|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2013-02-27|2005-09-16|2005-09-20|Estimate|||||||2013-02-27|2013-02-28|Estimate|September 2005||2005-09-30|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma|Randomized, Double-blind Phase II Trial of NY-ESO-1 ISCOMATRIX® Vaccine and ISCOMATRIX® Adjuvant Alone in Patients With Resected Stage IIc, III or IV Malignant Melanoma|Completed||Phase 2|111|Actual|Ludwig Institute for Cancer Research||2|||f||||||||||||||2018-06-01 04:32:29.433756|2018-06-01 04:32:29.433756
NCT00199888|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-08-29|2005-09-16|2005-09-20|Estimate|||||||2006-08-29|2006-08-30|Estimate|February 2005||2005-02-28|August 2006|2006-08-31|June 2006||2006-06-30|||||Interventional|||Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.|Pilot Study of Iodine-124 Labeled Chimeric G250 (124 I-cG250) in Presurgical Patients With Renal Masses|Completed||Phase 1|54||Ludwig Institute for Cancer Research|||||||||||||||||||2018-06-01 04:32:29.627943|2018-06-01 04:32:29.627943
NCT00199875|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-09|2005-09-13|2005-09-20|Estimate|||||||2011-05-09|2011-05-10|Estimate|July 2005||2005-07-31|May 2011|2011-05-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250|Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer|Unknown status|Recruiting|Phase 1|24|Anticipated|Ludwig Institute for Cancer Research|||||f||||||||||||||2018-06-01 04:32:29.762543|2018-06-01 04:32:29.762543
NCT00199862|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-17|2005-09-13|2005-09-20|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2004|Actual|2004-02-29|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer|A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer|Active, not recruiting||N/A|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 04:32:29.95701|2018-06-01 04:32:29.95701
NCT00199849|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-21|2005-09-12|2005-09-20|Estimate|||||||2007-08-21|2007-08-22|Estimate|May 2004||2004-05-31|August 2007|2007-08-31|May 2007|Actual|2007-05-31|||||Interventional|||NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine|Safety and Immunological Evaluation of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Given by Particle-Mediated Epidermal Delivery (PMED) in Patients With Tumor Type Known to Express NY-ESO-1 or LAGE-1 Antigen.|Completed||Phase 1|15||Ludwig Institute for Cancer Research|||||||||||||||||||2018-06-01 04:32:30.059082|2018-06-01 04:32:30.059082
NCT00199836|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-08-21|2005-09-12|2005-09-20|Estimate|||||||2006-08-21|2006-08-23|Estimate|September 2003||2003-09-30|August 2006|2006-08-31|December 2005||2005-12-31|||||Interventional|||A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.|A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1.|Completed||Phase 1|9||Ludwig Institute for Cancer Research|||||||||||||||||||2018-06-01 04:32:30.207772|2018-06-01 04:32:30.207772
NCT00199823|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-03|2005-09-19|2005-09-20|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2003||2003-09-30|September 2010|2010-09-30|May 2006||2006-05-31|||||Interventional|||Autologous Stem Cell Transplantation in Acute Myocardial Infarction|Autologous Stem Cell Transplantation in Acute Myocardial Infarction|Completed||Phase 2|100||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:32:30.321614|2018-06-01 04:32:30.321614
NCT00199810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-10-14|2005-09-19|2005-09-20|Estimate|||||||2016-10-14|2016-10-17|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Hemodynamic Measurements in Women With Serious Preeclampsia|Hemodynamic Measurements in Women With Serious Preeclampsia|Completed|||68|Actual|Oslo University Hospital|||||f||||f||||||||||2018-06-01 04:32:30.425073|2018-06-01 04:32:30.425073
NCT00199797|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-03-02|2005-09-12|2005-09-20|Estimate|||||||2009-03-02|2009-03-03|Estimate|October 2004||2004-10-31|March 2009|2009-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer|Phase I Trial of huA33 Plus 5-Fluorouracil (5FU), Leucovorin and Oxaliplatin in Patients With Metastatic Colorectal Cancer|Completed||Phase 1|20|Actual|Ludwig Institute for Cancer Research|||||f||||f||||||||||2018-06-01 04:32:30.542577|2018-06-01 04:32:30.542577
NCT00199784|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-03|2005-09-15|2005-09-20|Estimate|||||||2011-07-03|2011-07-06|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|April 2007||2007-04-30|||||Interventional|||Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia|Hemodynamic Measurements During Cesarean Section With Spinal Anesthesia|Completed||Phase 4|80|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:32:30.630419|2018-06-01 04:32:30.630419
NCT00199771|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-30|2005-09-14|2005-09-20|Estimate|||||||2011-06-30|2011-07-01|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|February 2005|Actual|2005-02-28|December 2004|Actual|2004-12-31||Interventional|||Hypertonic Saline Dextran in Pediatric Cardiac Surgery|The Use of Hypertonic Saline Dextran in Cardiac Surgery Utilizing Cardio Pulmonary Bypass in Children Less Than 17 Weeks Old.|Completed||Phase 2|14||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:32:30.722674|2018-06-01 04:32:30.722674
NCT00199758|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-11-09|2005-09-14|2005-09-20|Estimate|||||||2007-11-09|2007-11-12|Estimate|September 2003||2003-09-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer|A Randomized Phase II Trial of Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer.|Completed||Phase 2|227||University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:30.801576|2018-06-01 04:32:30.801576
NCT00199745|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-05-09|2005-09-12|2005-09-20|Estimate|||||||2012-05-09|2012-05-10|Estimate|October 2005||2005-10-31|May 2012|2012-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity|Investigations on Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity|Completed||Phase 4|53|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:32:30.932774|2018-06-01 04:32:30.932774
NCT00199732|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-04-16|2005-09-14|2005-09-20|Estimate|||||||2013-04-16|2013-04-17|Estimate|December 2004||2004-12-31|September 2005|2005-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|DNA-EVAL||Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a|Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a|Completed|||19|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 04:32:31.022258|2018-06-01 04:32:31.022258
NCT00199719|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-10-30|2005-09-14|2005-09-20|Estimate|||||||2007-10-30|2007-10-31|Estimate|June 2003||2003-06-30|June 2007|2007-06-30|September 2006|Actual|2006-09-30|||||Interventional|CINAM||Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM|Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C Non 2 -3 Genotype naïve Patients Treated With a 12 Weeks Bitherapy of Peginterferon Alpha 2a-Ribavirin, and Followed by a Tritherapy of Peginterferon Alpha 2a-Ribavirin-Amantadine for 36 Weeks|Completed||Phase 2|30|Actual|University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:31.094749|2018-06-01 04:32:31.094749
NCT00199706|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-30|2005-09-14|2005-09-20|Estimate|||||||2011-06-30|2011-07-01|Estimate|April 2002||2002-04-30|November 2005|2005-11-30|October 2004||2004-10-31|||||Interventional|||HyperHAES Versus Placebo - Effect on Intracranial Pressure in SAH Patients|7.2% NaCl in 6% Hydroxyethyl Starch Versus Placebo - Effect on Intracranial Pressure and Haemodynamics in Subarachnoidal Haemorrhage (SAH) Patients.|Completed||Phase 2|20||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:32:31.163488|2018-06-01 04:32:31.163488
NCT00199693|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-03|2005-09-13|2005-09-20|Estimate|||||||2011-07-03|2011-07-06|Estimate|April 2007||2007-04-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Hemodynamic and Respiratory Function in Healthy Pregnant Women|Hemodynamic and Respiratory Function in Healthy Pregnant Women - A Longitudinal Study|Completed|||100|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:32:31.221096|2018-06-01 04:32:31.221096
NCT00199680|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-01-31|2005-09-14|2005-09-20|Estimate|||||||2006-01-31|2006-02-01|Estimate|October 2003||2003-10-31|September 2005|2005-09-30||||||||Interventional|||Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer|Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer|Unknown status|Recruiting|Phase 2|42||University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:31.290228|2018-06-01 04:32:31.290228
NCT00199667|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-12-14|2005-09-14|2005-09-20|Estimate|||||||2008-12-14|2008-12-16|Estimate|October 2002||2002-10-31|December 2008|2008-12-31||||||||Interventional|||Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients|APOMYGRE : Multicenter, Randomized, Open-Label Study of MMF Therapeutic Follow-up's Interest in the the 12 First Months in Kidney Transplantation|Unknown status|Active, not recruiting|Phase 4|137||University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:31.392519|2018-06-01 04:32:31.392519
NCT00199654|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-04-08|2005-09-14|2005-09-20|Estimate|||||||2013-04-08|2013-04-09|Estimate|February 2004||2004-02-29|April 2013|2013-04-30|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|||Positron Emission Tomography (PET) Interest in the Follow Up of Colorectal Cancer Stage II and III|PET Interest in the Follow Up of Colorectal Cancer Stage II and III: Phase III Randomised Study|Completed||Phase 3|376|Actual|University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:31.477249|2018-06-01 04:32:31.477249
NCT00199641|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-12-02|2005-09-14|2005-09-20|Estimate|||||||2008-12-02|2008-12-04|Estimate|July 2002||2002-07-31|December 2008|2008-12-31||||||||Interventional|||Evaluation of Two Enteral Nutrition Strategies in Mechanically Ventilated Patients|Evaluation of Two Enteral Nutrition Strategies in Mechanically Ventilated Patients|Completed||N/A|100|Actual|University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:31.58222|2018-06-01 04:32:31.58222
NCT00199628|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-03-10|2005-09-14|2005-09-20|Estimate|||||||2006-03-10|2006-03-13|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Observational|||Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization|Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization|Unknown status|Recruiting||100||University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:31.628794|2018-06-01 04:32:31.628794
NCT00199615|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-10-30|2005-09-14|2005-09-20|Estimate|||||||2007-10-30|2007-10-31|Estimate|April 2001||2001-04-30|September 2005|2005-09-30|December 2006|Actual|2006-12-31|||||Interventional|||Follow-up of Patients With Curative-Intent Surgical Resection for NSCLC|Follow-up of Patients With Curative-Intent Surgical Resection for NSCLC : CT Scanning Versus 18 FDG Imaging.|Completed||N/A|73|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 04:32:31.732121|2018-06-01 04:32:31.732121
NCT00199602|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-12-30|2005-09-14|2005-09-20|Estimate|||||||2008-12-30|2008-12-31|Estimate|August 1999||1999-08-31|December 2008|2008-12-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients|Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study|Unknown status|Recruiting|Phase 3|420|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 04:32:31.827173|2018-06-01 04:32:31.827173
NCT00199589|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-12-29|2005-09-14|2005-09-20|Estimate|||||||2008-12-29|2008-12-30|Estimate|October 2002||2002-10-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Treatment of Spastic Equinovarus Foot After Stroke|Treatment of Spastic Equinovarus Foot After Stroke. Efficacy: Association Between Ankle Foot Orthosis and Botulinum Toxin A (BTA) Injection|Completed||N/A|46|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-06-01 04:32:32.026266|2018-06-01 04:32:32.026266
NCT00199576|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|December 2000||2000-12-31|September 2005|2005-09-30|January 2002||2002-01-31|||||Interventional|||Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids|Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids: a Prospective, Double-Blind, Placebo-Controlled Trial.|Completed||Phase 3|670||University Hospital, Limoges|||||f||||||||||||||2018-06-01 04:32:32.164706|2018-06-01 04:32:32.164706
NCT00199563|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-24|2005-09-13|2005-09-20|Estimate|||||||2013-01-24|2013-01-25|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Use of Sildenafil (Viagra) in Diabetic Men With Erectile Dysfunction: the Impact on Blood Vessels|The Use and Efficacy of Sildenafil in Diabetic Men With Erectile Dysfunction: the Impact on Endothelial Function, a Pilot Feasibility Study|Completed||Phase 4|24|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:32:32.295404|2018-06-01 04:32:32.295404
NCT00199550|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-25|2005-09-13|2005-09-20|Estimate|||||||2008-07-25|2008-07-29|Estimate|May 2004||2004-05-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)|A Prospective Randomized Clinical Trial of Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)|Completed||Phase 4|43|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:32:32.445279|2018-06-01 04:32:32.445279
NCT00199537|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-25|2005-09-13|2005-09-20|Estimate|||||||2008-07-25|2008-07-29|Estimate|February 2005||2005-02-28|July 2008|2008-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer|Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer|Completed|||25|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 04:32:32.610773|2018-06-01 04:32:32.610773
NCT00199524|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-10-13|2005-09-13|2005-09-20|Estimate|||||||2009-10-13|2009-10-14|Estimate|May 2005||2005-05-31|October 2009|2009-10-31|May 2009|Actual|2009-05-31|March 2009|Actual|2009-03-31||Interventional|||Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate|A Prospective Randomized Controlled Clinical Trial of the Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate|Terminated||Phase 4|44|Actual|Lawson Health Research Institute||2||Enrollment was slower than anticipated.|f||||f||||||||||2018-06-01 04:32:32.733072|2018-06-01 04:32:32.733072
NCT00199511|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-21|2005-09-13|2005-09-20|Estimate|||||||2007-06-21|2007-06-25|Estimate|January 2005||2005-01-31|June 2007|2007-06-30|April 2007|Actual|2007-04-30|||||Interventional|||Hypertonic Saline 75% vs Mannitol 20%|Comparison of Equiosmolar Doses of Mannitol 20% Versus Hypertonic Saline 7.5% Infusion in the Reduction of Brain Bulk During Elective Craniotomies for Supratentorial Brain Tumor Resection|Completed||N/A|162||Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:32:32.872488|2018-06-01 04:32:32.872488
NCT00199498|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-04-11|2005-09-13|2005-09-20|Estimate|||||||2016-04-11|2016-04-13|Estimate|April 2005||2005-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|RASP||Right Apical Versus Septal Pacing Trial|Right Apical Versus Septal Pacing Trial|Unknown status|Active, not recruiting|N/A|160|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:32:32.983385|2018-06-01 04:32:32.983385
NCT00199485|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-25|2005-09-13|2005-09-20|Estimate|||||||2008-07-25|2008-07-29|Estimate|October 2002||2002-10-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer|Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer|Completed||Phase 4|44|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:32:33.080477|2018-06-01 04:32:33.080477
NCT00199472|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-24|2005-09-13|2005-09-20|Estimate|||||||2017-08-24|2017-08-25|Actual||||August 2017|2017-08-31|June 2001|Actual|2001-06-30|||||Observational|||Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO|Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of Ureteropelvic Junction Obstruction|Withdrawn|||0|Actual|Lawson Health Research Institute|||||f||||||||||||||2018-06-01 04:32:33.215512|2018-06-01 04:32:33.215512
NCT00199459|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-09-02|2005-09-12|2005-09-20|Estimate|||||||2009-09-02|2009-09-03|Estimate|January 2005||2005-01-31|September 2009|2009-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Proteomic Study of Urinary Stone Disease|Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers|Completed|||20|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-06-01 04:32:33.330756|2018-06-01 04:32:33.330756
NCT00199446|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-07-12|2005-09-13|2005-09-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 2005||2005-07-31|July 2016|2016-07-31|October 2006|Actual|2006-10-31|August 2006|Actual|2006-08-31||Interventional|||Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome|A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) in Subjects With Restless Legs Syndrome|Completed||Phase 2|160||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 04:32:33.398623|2018-06-01 04:32:33.398623
NCT00199433|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-12|2005-09-13|2005-09-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2005||2005-05-31|July 2016|2016-07-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients|A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease|Completed||Phase 2|160||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 04:32:33.46361|2018-06-01 04:32:33.46361
NCT00199420|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-12|2005-09-13|2005-09-20|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 2004||2004-07-31|July 2016|2016-07-31|December 2005|Actual|2005-12-31|November 2005|Actual|2005-11-30||Interventional|||A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa|A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.|Completed||Phase 3|580||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 04:32:33.535964|2018-06-01 04:32:33.535964
NCT00199407|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-12|2005-09-13|2005-09-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|June 2004||2004-06-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|November 2005|Actual|2005-11-30||Interventional|||A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy.|Completed||Phase 3|230||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 04:32:33.623985|2018-06-01 04:32:33.623985
NCT00199225|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-14|2005-09-12|2005-09-20|Estimate|||||||2005-12-14|2005-12-15|Estimate|February 2005||2005-02-28|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers|Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers: A Randomised, Parallel, Placebo and Positive Controlled Study|Completed||Phase 1|160||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:32:35.444451|2018-06-01 04:32:35.444451
NCT00199394|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-12|2005-09-13|2005-09-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|November 2004||2004-11-30|July 2016|2016-07-31|November 2005|Actual|2005-11-30|October 2005|Actual|2005-10-31||Interventional|||A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease|A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.|Completed||Phase 3|405||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 04:32:33.740303|2018-06-01 04:32:33.740303
NCT00199381|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-04-04|2011-04-04|2013-10-29|2005-09-12|2005-09-20|Estimate|2013-07-23|2013-07-30|Estimate|2011-04-20|2011-04-25|Estimate|2013-10-29|2013-11-21|Estimate|October 2005||2005-10-31|October 2013|2013-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||503 subjects took at least 1 dose of study drug|An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001|An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline.|Terminated||Phase 3|504|Actual|Kyowa Kirin Pharmaceutical Development, Inc.|The Sponsor decided to terminate the study early (not for safety reasons); as a result 323 subjects discontinued early. Mean duration of therapy was 18.7 months (0.4 to 31.4 months); median duration was 21.0 months. Total exposure 767 subject years.|1||Additional long-term safety data no longer needed|f||||f||||||||||2018-06-01 04:32:33.911606|2018-06-01 04:32:33.911606
NCT00199368|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-12|2005-09-12|2005-09-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 2004||2004-10-31|July 2016|2016-07-31|May 2007|Actual|2007-05-31|March 2007|Actual|2007-03-31||Interventional|||An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018|A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.|Completed||Phase 3|1100||Kyowa Kirin Pharmaceutical Development, Inc.|||||f||||f||||||||||2018-06-01 04:32:34.348245|2018-06-01 04:32:34.348245
NCT00199355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-21|2005-09-12|2005-09-20|Estimate|||||||2014-05-21|2014-05-23|Estimate|April 2005||2005-04-30|August 2012|2012-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa|Placebo-Controlled , Double-Blind , Exploratory Study of KW-6002(Istradefylline) in the Treatment of Parkinson's Disease. [Adjunctive Therapy to Levodopa]|Completed||Phase 2|75||Kyowa Hakko Kirin Co., Ltd|||||f||||f||||||||||2018-06-01 04:32:34.423372|2018-06-01 04:32:34.423372
NCT00199342|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-02-24|2005-09-12|2005-09-20|Estimate|||||||2015-02-24|2015-02-26|Estimate|November 2004||2004-11-30|February 2007|2007-02-28||||October 2005|Actual|2005-10-31||Interventional|||A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma|An Open-Label Study of KW-2871 Administered With a Premedication Regimen in Patients With Advanced Stage IV Melanoma|Terminated||Phase 1/Phase 2|5|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||||Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I.|f||||f||||||||||2018-06-01 04:32:34.526464|2018-06-01 04:32:34.526464
NCT00199329|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-03-19|2005-09-14|2005-09-20|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2005||2005-01-31|October 2007|2007-10-31||||||||Interventional|||Antiemetic Effect of the Addition of Ondansetron to the Morphine Solution in Patient-Controlled Analgesia (PCA)||Completed||N/A|160|Actual|Khon Kaen University|||||f||||||||||||||2018-06-01 04:32:34.618778|2018-06-01 04:32:34.618778
NCT00199316|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-03-19|2005-09-19|2005-09-20|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2005||2005-01-31|October 2007|2007-10-31|November 2005||2005-11-30|||||Interventional|||Postoperative Pain Control After Kidney Surgery : a Comparison of Intrathecal Morphine Plus PCA and PCA Only||Unknown status|Recruiting|N/A|80|Anticipated|Khon Kaen University|||||f||||||||||||||2018-06-01 04:32:34.681319|2018-06-01 04:32:34.681319
NCT00199303|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|December 2002||2002-12-31|July 2002|2002-07-31|December 2003||2003-12-31|||||Interventional|||Efficacy of Pre- and Post-Operative Oral Dextromethorphan|Efficacy of Pre- and Post-Operative Oral Dextromethorphan for Reduction of Intra- and 24-Hr Post-Operative Morphine Consumption for Transabdominal Hysterectomy|Completed||N/A|100||Khon Kaen University|||||f||||||||||||||2018-06-01 04:32:34.743998|2018-06-01 04:32:34.743998
NCT00199290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-02-01|2005-09-12|2005-09-20|Estimate|||||||2008-02-01|2008-02-05|Estimate|August 2005||2005-08-31|February 2008|2008-02-29|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan|A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan|Completed||Phase 2|267|Actual|Kaken Pharmaceutical||4|||f||||f||||||||||2018-06-01 04:32:34.804186|2018-06-01 04:32:34.804186
NCT00199277|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2005-09-16|2005-09-16|2005-09-20|Estimate|||||||2005-09-16|2005-09-20|Estimate||||September 2005|2005-09-30||||||||Interventional|||Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.|Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia.|Unknown status|Not yet recruiting|Phase 4|150||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:32:34.987074|2018-06-01 04:32:34.987074
NCT00199264|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-02|2005-09-13|2005-09-20|Estimate|||||||2006-10-02|2006-10-03|Estimate|June 2004||2004-06-30|October 2003|2003-10-31|October 2004||2004-10-31|||||Interventional|||Efficacy Vulvovaginitis Candida|A Single-Blind, Randomized, Dose-Finding Study Versus Fluconazole to Assess the Efficacy and Tolerability of Five Single Doses of Albaconazole in the Treatment of Acute Non-Recurrent Candida Spp Vulvovaginitis|Terminated||Phase 2|60||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:32:35.175769|2018-06-01 04:32:35.175769
NCT00199251|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-22|2005-09-13|2005-09-20|Estimate|||||||2005-12-22|2005-12-23|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria|A 6-Week Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Rupatadine 10 and 20 Mg in the Treatment of Chronic Idiopathic Urticaria (CIU): a Phase III Clinical Trial|Terminated||Phase 3|300||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:32:35.276659|2018-06-01 04:32:35.276659
NCT00199238|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|October 2002||2002-10-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Interventional|||Efficacy of Rupatadine 5, 10 and 20 Mg in Chronic Idiopathic Urticaria|A 4-Week Dose-Finding, Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Different Doses of Rupatadine Compared to Placebo in the Treatment of Chronic Idiopathic Urticaria|Terminated||Phase 2|248||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:32:35.360102|2018-06-01 04:32:35.360102
NCT00199212|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-23|2005-09-19|2005-09-20|Estimate|||||||2011-02-23|2011-02-24|Estimate|October 2003||2003-10-31|February 2011|2011-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2|A Phase I, Open Label, Dose-escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2|Completed||Phase 1|19|Actual|Jules Bordet Institute|||||f||||f||||||||||2018-06-01 04:32:35.529529|2018-06-01 04:32:35.529529
NCT00199186|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2007-10-18|2005-09-16|2005-09-20|Estimate|||||||2007-10-18|2007-10-19|Estimate|March 2002||2002-03-31|September 2005|2005-09-30||||||||Interventional|||Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)|A Randomized, Multicenter Open Label Phase II Study to Determine the Safety and Efficacy of Induction Therapy With Imatinib in Comparison With Standard Induction Chemotherapy in Elderly (> 55 Years) Patients With Ph Positive Acute Lymphoblastic Leukemia (ALL)|Unknown status|Recruiting|Phase 2|||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:35.635206|2018-06-01 04:32:35.635206
NCT00199173|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-23|2005-09-13|2005-09-20|Estimate|||||||2011-02-23|2011-02-24|Estimate||||February 2011|2011-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comparing Hepatic Intra-arterial Injection of Yttrium-90 Microspheres Versus Fluorouracil (5FU) in Colorectal Cancer Metastatic to the Liver Only|Comparison Hepatic Intra-arterial Injection of Yttrium-90 Versus 5FU in Colorectal Cancer Metastatic to the Liver Only|Completed||Phase 3|||Jules Bordet Institute|||||f||||||||||||||2018-06-01 04:32:35.778206|2018-06-01 04:32:35.778206
NCT00199160|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-19|2005-09-13|2005-09-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer||Completed||Phase 2|60|Actual|Jules Bordet Institute|||||f||||||||||||||2018-06-01 04:32:35.857728|2018-06-01 04:32:35.857728
NCT00199147|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-10-25|2005-09-14|2005-09-20|Estimate|||||||2005-10-25|2005-10-26|Estimate|January 2000||2000-01-31|September 2005|2005-09-30||||||||Interventional|||Efficacy of G-CSF-Priming in Elderly AML Patients|Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation|Unknown status|Recruiting|Phase 4|250||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.0659|2018-06-01 04:32:36.0659
NCT00199134|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-01-05|2005-09-12|2005-09-20|Estimate|||||||2015-01-05|2015-01-06|Estimate|November 2004||2004-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole|FRAGRANCE Trial(Femara Reanalysed Through Genomics for Response Assessment, Calibration and Empowerment)|Completed||Phase 2|49|Anticipated|Jules Bordet Institute||1|||f||||t||||||||||2018-06-01 04:32:36.155698|2018-06-01 04:32:36.155698
NCT00199121|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-13|2005-09-13|2005-09-20|Estimate|||||||2005-12-13|2005-12-14|Estimate||||July 2005|2005-07-31||||||||Interventional|||A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients|An Open, Single-Arm, Multi-Center, Phase IV Pilot Study of Treatment of Antiretroviral Naive HIV-1 Infected Patients With Tenofovir Disoproxil Fumarate in Combination With Emtricitabine and Zidovudine|Unknown status|Recruiting|Phase 4|||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.231676|2018-06-01 04:32:36.231676
NCT00199108|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-29|2005-09-12|2005-09-20|Estimate|||||||2008-05-29|2008-05-30|Estimate|April 2004||2004-04-30|May 2008|2008-05-31|June 2008|Anticipated|2008-06-30|||||Interventional|||Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt|A Phase-2 Clinical Study to Determine the Efficacy and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of CNS Relapse in Adult Patients With Acute Lymphoblastic Leukemia or Very Aggressive Lymphoma|Unknown status|Active, not recruiting|Phase 2/Phase 3|20|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.288139|2018-06-01 04:32:36.288139
NCT00199095|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-16|2005-09-12|2005-09-20|Estimate|||||||2008-05-16|2008-05-20|Estimate|February 1997||1997-02-28|May 2008|2008-05-31||||||||Interventional|||Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia|Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia|Completed||Phase 4|40||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.354942|2018-06-01 04:32:36.354942
NCT00199082|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-08-04|2005-09-12|2005-09-20|Estimate|||||||2016-08-04|2016-08-05|Estimate|July 2002||2002-07-31|August 2016|2016-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults|Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)|Completed||Phase 4|650|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||No||2018-06-01 04:32:36.433383|2018-06-01 04:32:36.433383
NCT00199069|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-16|2005-09-12|2005-09-20|Estimate|||||||2008-05-16|2008-05-20|Estimate|April 1993||1993-04-30|May 2008|2008-05-31||||||||Interventional|||German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)|Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93)|Completed||Phase 4|720||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.530713|2018-06-01 04:32:36.530713
NCT00199056|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-16|2005-09-12|2005-09-20|Estimate|||||||2008-05-16|2008-05-20|Estimate|October 1999||1999-10-31|May 2008|2008-05-31||||||||Interventional|||German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)|Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99)|Completed||Phase 4|225||Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.610081|2018-06-01 04:32:36.610081
NCT00199043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-20|2005-09-12|2005-09-20|Estimate|||||||2010-08-20|2010-08-23|Estimate|May 2003||2003-05-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma|Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs)|Completed||Phase 3|80|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.725109|2018-06-01 04:32:36.725109
NCT00198822|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-09-01||2012-03-05|2005-09-12|2005-09-20|Estimate|2011-09-01|2011-10-12|Estimate||||2012-03-05|2012-03-07|Estimate|August 2001||2001-08-31|March 2012|2012-03-31|March 2008|Actual|2008-03-31|January 2007|Actual|2007-01-31||Interventional|||Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh|Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh|Completed||Phase 3|59666|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-06-01 04:32:38.83974|2018-06-01 04:32:38.83974
NCT00199030|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-29|2005-09-12|2005-09-20|Estimate|||||||2008-05-29|2008-05-30|Estimate|February 2004||2004-02-29|May 2008|2008-05-31|December 2007||2007-12-31|||||Interventional|||Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath|German Multicenter Phase II Trial to Study Effectivity and Feasibility of Alemtuzumab (MabCampath®) in T-ALL and T-Lymphoblastic Lymphomas With Minimal Residual Disease (MRD), in Refractory Relapse or in Primary Failure|Completed||Phase 2|25|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.825136|2018-06-01 04:32:36.825136
NCT00199017|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-20|2005-09-12|2005-09-20|Estimate|||||||2010-08-20|2010-08-23|Estimate|April 2004||2004-04-30|May 2008|2008-05-31||||March 2009|Actual|2009-03-31||Interventional|||German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults|Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1)|Completed||Phase 4|75|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.891699|2018-06-01 04:32:36.891699
NCT00199004|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-20|2005-09-12|2005-09-20|Estimate|||||||2010-08-20|2010-08-23|Estimate|April 2004||2004-04-30|May 2008|2008-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab|German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2)|Completed||Phase 4|60|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:36.957072|2018-06-01 04:32:36.957072
NCT00198991|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-29|2005-09-12|2005-09-20|Estimate|||||||2008-05-29|2008-05-30|Estimate|April 2003||2003-04-30|May 2008|2008-05-31||||December 2008|Anticipated|2008-12-31||Interventional|||German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)|German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003)|Unknown status|Recruiting|Phase 4|1250|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:37.024323|2018-06-01 04:32:37.024323
NCT00198978|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-04|2005-09-12|2005-09-20|Estimate|||||||2008-06-04|2008-06-05|Estimate|January 2003||2003-01-31|June 2008|2008-06-30||||June 2008|Anticipated|2008-06-30||Interventional|||German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2)|Unknown status|Recruiting|Phase 4|200|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||||||||||||2018-06-01 04:32:37.135797|2018-06-01 04:32:37.135797
NCT00198965|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|March 1999||1999-03-31|April 2004|2004-04-30|December 2003||2003-12-31|||||Interventional|||Olestra Containing Foods and Weight Loss and Weight Maintenance|Benefits of Sensory-Enhanced Products in Weight Loss and Maintenance|Completed||N/A|257||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:37.209956|2018-06-01 04:32:37.209956
NCT00198952|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|February 2000||2000-02-29|April 2002|2002-04-30|March 2001||2001-03-31|||||Interventional|||Effects of Herbal Products on Metabolism and Hunger|Effects of Herbal Products on Metabolism and Hunger|Completed||N/A|30||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:37.263865|2018-06-01 04:32:37.263865
NCT00198939|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-27|2005-09-13|2005-09-20|Estimate|||||||2012-09-27|2012-09-28|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Neurological Influences on Drug Prevention Intervention|Neurological Influences on Drug Prevention Intervention|Completed||Phase 1/Phase 2|330|Actual|University of Florida||4|||f||||f||||||||||2018-06-01 04:32:37.312273|2018-06-01 04:32:37.312273
NCT00198926|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|May 2000||2000-05-31|September 2001|2001-09-30|August 2001||2001-08-31|||||Interventional|||Type 2 Diabetes Controlled Eating Experiment|Use of Modified Foods in the Dietary Treatment of Type II Diabetes Mellitus: Short Term Feeding Study|Completed||N/A|100||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:37.389377|2018-06-01 04:32:37.389377
NCT00198913|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|June 2002||2002-06-30|April 2003|2003-04-30|February 2003||2003-02-28|||||Interventional|||Long Term Free Living Study With Modified Foods and Type 2 Diabetics|Use of Modified Foods in the Dietary Treatment of Type II Diabetes Mellitus: Long Term Free Living Study|Completed||N/A|100||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:37.439658|2018-06-01 04:32:37.439658
NCT00198900|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|January 2000||2000-01-31|April 2000|2000-04-30|March 2000||2000-03-31|||||Observational|||Diabetes Knowledge Assessment|Use of Modified Foods in the Dietary Treatment of Type II Diabetes Mellitus: Knowledge Assessment|Completed|||350||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:37.48806|2018-06-01 04:32:37.48806
NCT00198887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-07-03|2005-09-13|2005-09-20|Estimate|||||||2007-07-03|2007-07-06|Estimate|January 2003||2003-01-31|July 2007|2007-07-31|October 2006|Actual|2006-10-31|||||Interventional|||Operations Research to Improve Newborn Health|Operations Research to Improve Newborn Health and Survival in the (INHP-II) Area of CARE/India|Completed||N/A|59651|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:38.482985|2018-06-01 04:32:38.482985
NCT00198874|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-27|2005-09-13|2005-09-20|Estimate|||||||2012-09-27|2012-09-28|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional|||Youth Drug Abuse Family and Cognitive-Behavioral Therapy|Youth Drug Abuse Family and Cognitive-Behavioral Therapy|Completed||Phase 2|296|Actual|University of Florida||4|||f||||||||||||||2018-06-01 04:32:38.556116|2018-06-01 04:32:38.556116
NCT00198861|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-01|2005-09-13|2005-09-20|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2002||2002-02-28|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Observational|||Neurobehavioral Model of HIV in Injection Drug Users|Neurobehavioral Model of HIV in Injection Drug Users|Completed|||836|Actual|The City College of New York|||1||f||||f||||||||||2018-06-01 04:32:38.629548|2018-06-01 04:32:38.629548
NCT00198848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-18|2005-09-13|2005-09-20|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2005||2005-09-30|January 2006|2006-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Iron Supplementation Among Adolescent Girls in India|Iron Supplementation Among Adolescent Girls in India|Completed||N/A|2800|Anticipated|Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:38.697349|2018-06-01 04:32:38.697349
NCT00198835|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-18|2005-09-13|2005-09-20|Estimate|||||||2018-04-18|2018-04-20|Actual|August 2003|Actual|2003-08-31|July 2005|2005-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Evaluation Research of the Nutrition Interventions in the INHP II Areas of CARE India|Evaluation Research of the Nutrition Interventions in the INHP II Areas of CARE India|Completed||N/A|17000||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:38.76212|2018-06-01 04:32:38.76212
NCT00198796|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-07|2005-09-13|2005-09-20|Estimate|||||||2017-04-07|2017-04-11|Actual|September 2005|Actual|2005-09-30|April 2017|2017-04-30|May 30, 2007|Actual|2007-05-30|February 22, 2007|Actual|2007-02-22||Interventional|||Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge Strains|Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic E. Coli (ETEC) Challenge Strains That Express Colonization Factors CS17 and CFA/I|Completed||Phase 1|5|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||||||||||No||2018-06-01 04:32:39.451191|2018-06-01 04:32:39.451191
NCT00198783|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-03|2005-09-12|2005-09-20|Estimate|||||||2007-04-03|2007-04-04|Estimate|August 2005||2005-08-31|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Observational|||Real-Time Assessment of Food Craving, Use, and Triggers During Outpatient Treatment of Obesity: A Development and Feasibility Study|Real-Time Assessment of Food Craving, Use, and Triggers During Outpatient Treatment of Obesity: A Development and Feasibility Study|Completed|||75||Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||||||2018-06-01 04:32:39.531133|2018-06-01 04:32:39.531133
NCT00198770|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-30|2005-09-13|2005-09-20|Estimate|||||||2018-03-30|2018-04-03|Actual|March 2006||2006-03-31|March 2018|2018-03-31|December 2006|Actual|2006-12-31|||||Interventional|Mush 1||Dietary Compensation With Substitution of Meat Products With White Button Mushrooms.|Does Substitution of Meat Products With White Button Mushrooms Have Potential for Weight Reduction? Studies of the Level of Short and Intermediate-term Caloric Compensation, Satiety, and Dietary Satisfaction Among Lean and Obese Men and Women.|Completed||N/A|55|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||||2018-06-01 04:32:39.590765|2018-06-01 04:32:39.590765
NCT00198757|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|July 2002||2002-07-31|May 2005|2005-05-31|January 2005||2005-01-31|||||Interventional|||Efficacy of 2 Diet Plans Designed for People With Type II Diabetes on Weight and Health Measures|Efficacy of 2 Diet Plans Designed for People With Type II Diabetes on Weight and Health Measures|Completed||N/A|120||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:39.668321|2018-06-01 04:32:39.668321
NCT00198744|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|June 2004||2004-06-30|January 2005|2005-01-31|June 2006||2006-06-30|||||Interventional|||Efficacy of Parent-Child Dieting Plans Incorporating Medifast Meal Replacements for Weight Loss||Completed||N/A|80||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:39.731286|2018-06-01 04:32:39.731286
NCT00198731|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-07-13|2005-09-13|2005-09-20|Estimate|||||||2009-07-13|2009-07-14|Estimate|April 2005||2005-04-30|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Observational|||Evaluation of the Effects of Community-based Interventions|Evaluation of the Effects of Community-based Interventions on Maternal Morbidity in the Early Postpartum Period in Rural Bangladesh|Completed|||1506|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||||||2018-06-01 04:32:39.787532|2018-06-01 04:32:39.787532
NCT00198718|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-06|2005-09-12|2005-09-20|Estimate|||||||2017-03-06|2017-03-07|Actual|November 1997||1997-11-30|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|May 2001|Actual|2001-05-31||Interventional|ZVITAMBO||Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates|Vitamin A Supplementation of Breast Feeding Mothers and Their Neonates at Delivery: Impact on Mother to Child Transmission of HIV During Lactation, HIV Infection Among Women During the Postpartum Year, and Infant Mortality.|Active, not recruiting||Phase 2|28220|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||||2018-06-01 04:32:39.860473|2018-06-01 04:32:39.860473
NCT00198705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-09-12|2005-09-12|2005-09-20|Estimate|||||||2014-09-12|2014-09-16|Estimate|June 2003||2003-06-30|September 2014|2014-09-30|August 2012|Actual|2012-08-31|July 2007|Actual|2007-07-31||Interventional|||Community Based Interventions to Reduce Neonatal Mortality in Bangladesh|Community Based Interventions to Reduce Neonatal Mortality in Bangladesh|Completed||N/A|10670|Anticipated|Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:39.982596|2018-06-01 04:32:39.982596
NCT00198692|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-27|2005-09-12|2005-09-20|Estimate|||||||2008-10-27|2008-10-28|Estimate|August 2003||2003-08-31|September 2005|2005-09-30|March 2006||2006-03-31|||||Interventional|||Self-Management Program for Persons With Limb Loss|Randomized Clinical Trial of Self-Management Educational Program for Persons With Limb Loss.|Completed||N/A|500||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:40.06294|2018-06-01 04:32:40.06294
NCT00198679|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-18|2005-09-12|2005-09-20|Estimate|||||||2018-04-18|2018-04-20|Actual|March 2004||2004-03-31|May 2006|2006-05-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Effect of Chlorhexidine Skin Cleansing on Skin Flora|Effect of Chlorhexidine Skin Cleansing on Skin Flora of Newborn Infants in Bangladesh|Completed||Phase 4|210||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:40.159701|2018-06-01 04:32:40.159701
NCT00198666|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-01-09|2005-09-12|2005-09-20|Estimate|||||||2015-01-09|2015-01-12|Estimate|September 2003||2003-09-30|January 2015|2015-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Efficacy of Zinc in the Treatment of Pneumonia|Efficacy of Zinc in the Treatment of Pneumonia in Hospitalized Children Less Than 2 Years of Age|Completed||N/A|299|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 04:32:40.232377|2018-06-01 04:32:40.232377
NCT00198653|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-03|2005-09-12|2005-09-20|Estimate|||||||2007-05-03|2007-05-07|Estimate|March 2003||2003-03-31|April 2007|2007-04-30|October 2006|Actual|2006-10-31|||||Interventional|||Newborn Thermal Care Practices: A Community Based Program to Prevent Hypothermia|Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia|Terminated||N/A|||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:40.290297|2018-06-01 04:32:40.290297
NCT00198640|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-01|2005-09-12|2005-09-20|Estimate|||||||2005-11-01|2005-11-02|Estimate||||August 2005|2005-08-31||||||||Interventional|||AMR of Streptococcus Pneumoniae Carriage Strains|Antimicrobial Resistance of Streptococcus Pneumoniae Carriage Strains Among Bangladeshi Neonates: Epidemiology, Determinants and Risk Factors|Completed||N/A|||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:40.441468|2018-06-01 04:32:40.441468
NCT00198627|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-18|2005-09-12|2005-09-20|Estimate|||||||2018-04-18|2018-04-20|Actual|December 2003||2003-12-31|April 2018|2018-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Etiology, Prevention and Treatment of Neonatal Infections in the Community|Etiology, Prevention, and Treatment of Neonatal Infections in the Community|Completed||N/A|16359||Johns Hopkins Bloomberg School of Public Health|||||f||||t||||||||||2018-06-01 04:32:40.491618|2018-06-01 04:32:40.491618
NCT00198614|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-02-28|2005-09-13|2005-09-20|Estimate|||||||2007-02-28|2007-03-01|Estimate|January 2005||2005-01-31|February 2007|2007-02-28||||||||Interventional|||Carvedilol Versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery|A Comparison of the Effectiveness of Carvedilol Versus Metoprolol for Atrial Fibrillation Appearing After Off-Pump Coronary Bypass Surgery in the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT)|Completed||N/A|650||Ministry of Health, Labour and Welfare, Japan|||||f||||||||||||||2018-06-01 04:32:40.564555|2018-06-01 04:32:40.564555
NCT00198601|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-18|2005-09-12|2005-09-20|Estimate|||||||2018-04-18|2018-04-20|Actual|August 2003||2003-08-31|September 2005|2005-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Determination of Gentamicin Dosing in Neonatal Patients|Determination of Gentamicin Dosing in Neonatal Patients for Use in the Uniject Pre-filled Syringe [A Three-site Study at: 1) Dhaka Shishu Hospital, Dhaka Bangladesh; 2) Christain Medical Center, Vellore, India; and 3) Aga Khan University Medical Center, Karachi, Pakistan]|Completed||Phase 4|||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:32:40.640864|2018-06-01 04:32:40.640864
NCT00198588|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-11-11|2005-09-12|2005-09-20|Estimate|||||||2008-11-11|2008-11-13|Estimate|June 2005||2005-06-30|November 2008|2008-11-30|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia|Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia|Completed||Phase 3|8|Actual|Ministry of Health, Labour and Welfare, Japan|||||f||||t||||||||||2018-06-01 04:32:40.71845|2018-06-01 04:32:40.71845
NCT00198575|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-02-15|2005-09-12|2005-09-20|Estimate|||||||2006-02-15|2006-02-16|Estimate|November 2004||2004-11-30|February 2006|2006-02-28|March 2006||2006-03-31|||||Observational|||A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients|A Multicenter, Prospective Cohort Study to Determine the Prevalence and Profile of Heparin-Induced Thrombocytopenia in Patients Undergoing Cardiovascular Surgery or Percutaneous Coronary Intervention|Unknown status|Active, not recruiting||1500||Ministry of Health, Labour and Welfare, Japan|||||f||||||||||||||2018-06-01 04:32:40.824228|2018-06-01 04:32:40.824228
NCT00198562|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-18|2005-09-12|2005-09-20|Estimate|||||||2008-04-18|2008-04-22|Estimate|April 2000||2000-04-30|April 2008|2008-04-30|March 2012|Anticipated|2012-03-31|March 2012|Anticipated|2012-03-31||Interventional|||Hypertension Control Based on Home Blood Pressure|Hypertension Control Based on Home Systolic Pressure Study (HOSP Study)|Unknown status|Active, not recruiting|Phase 4|2600|Anticipated|Ministry of Health, Labour and Welfare, Japan||2|||f||||t||||||||||2018-06-01 04:32:40.909738|2018-06-01 04:32:40.909738
NCT00198549|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-15|2005-09-13|2005-09-20|Estimate|||||||2013-03-15|2013-03-19|Estimate|September 2004||2004-09-30|March 2013|2013-03-31|March 2005|Actual|2005-03-31|January 2005|Actual|2005-01-31||Interventional|||Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics|Phase IV Post-Approval Evaluation of Vitrase as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Anesthetics for Ophthalmic Surgical Procedures|Completed||Phase 4|40|Actual|Bausch & Lomb Incorporated|||||f||||f||||||||||2018-06-01 04:32:41.007164|2018-06-01 04:32:41.007164
NCT00198536|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-13|2005-09-13|2005-09-20|Estimate|||||||2013-03-13|2013-03-14|Estimate|April 2005||2005-04-30|March 2013|2013-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome|Efficacy and Safety of Ecabet Ophthalmic Solution (2.83% and 3.70%) for Treatment of Dry Eye Syndrome|Completed||Phase 2/Phase 3|159|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-06-01 04:32:41.093719|2018-06-01 04:32:41.093719
NCT00198523|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-13|2005-09-13|2005-09-20|Estimate|||||||2013-03-13|2013-03-15|Estimate|July 2005||2005-07-31|March 2013|2013-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte|A Multi-Center, Randomized, Double Masked, Bioequivalence Study of Tobramycin and Prednisolone Acetate (0.3/1.0%, ISTA) Ophthalmic Suspension Compared to PredForte (1.0% Prednisolone Acetate, Allergan) Ophthalmic Suspension|Completed||Phase 3|132||Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 04:32:41.16833|2018-06-01 04:32:41.16833
NCT00198510|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-14|2005-09-13|2005-09-20|Estimate|||||||2013-03-14|2013-03-15|Estimate|November 1998||1998-11-30|March 2013|2013-03-31|March 2003|Actual|2003-03-31|September 2001|Actual|2001-09-30||Interventional|||Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage|Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage|Completed||Phase 3|750||Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 04:32:41.272988|2018-06-01 04:32:41.272988
NCT00198497|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-13|2005-09-13|2005-09-20|Estimate|||||||2013-03-13|2013-03-15|Estimate|June 1999||1999-06-30|March 2013|2013-03-31|June 2003|Actual|2003-06-30|September 2001|Actual|2001-09-30||Interventional|||Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage|Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage|Completed||Phase 3|510||Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 04:32:41.444034|2018-06-01 04:32:41.444034
NCT00198484|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-13|2005-09-13|2005-09-20|Estimate|||||||2013-03-13|2013-03-14|Estimate|October 2004||2004-10-31|March 2013|2013-03-31|February 2005|Actual|2005-02-28|December 2004|Actual|2004-12-31||Interventional|||Evaluation of Vitrase as a Spreading Agent|Evaluation of Vitrase (Hyaluronidase for Injection) Ovine, 200 USP Units/mL, as an Adjuvant to Increase the Absorption and Dispersion of Other Injected Drugs Prior to Ocular Surgery|Completed||Phase 3|108|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 04:32:41.57221|2018-06-01 04:32:41.57221
NCT00198471|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-13|2005-09-13|2005-09-20|Estimate|||||||2013-03-13|2013-03-15|Estimate|July 2005||2005-07-31|March 2013|2013-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment|An Open-label Assessment of Intravitreous Injections of Vitrase (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects With Moderate to Severe Non-proliferative Diabetic Retinopathy|Completed||Phase 2|10||Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 04:32:41.757185|2018-06-01 04:32:41.757185
NCT00198458|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-14|2005-09-13|2005-09-20|Estimate|||||||2013-03-14|2013-03-18|Estimate|July 2004||2004-07-31|March 2013|2013-03-31|September 2004|Actual|2004-09-30|July 2004|Actual|2004-07-31||Interventional|||Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)|Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase, 150 USP Units/mL) Open Label, Normal Volunteer Study|Completed||Phase 1|65||Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 04:32:41.859362|2018-06-01 04:32:41.859362
NCT00198445|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-03-13|2005-09-12|2005-09-20|Estimate|||||||2013-03-13|2013-03-14|Estimate|May 2003||2003-05-31|March 2013|2013-03-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery|Efficacy and Safety of Topical Bromfenac Ophthalmic Solution, 0.1% vs. Placebo for Treatment of Ocular Inflammation Following Cataract Surgery|Completed||Phase 3|527|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-06-01 04:32:41.946278|2018-06-01 04:32:41.946278
NCT00198263|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2012-11-09|2017-09-27|2005-09-12|2005-09-20|Estimate||||2012-11-09|2012-11-16|Estimate|2017-09-27|2017-10-03|Actual|January 2004||2004-01-31|September 2017|2017-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer|An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer|Completed||Phase 4|95|Actual|Inovio Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:32:43.150393|2018-06-01 04:32:43.150393
NCT00198432|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-09|2005-09-13|2005-09-20|Estimate|||||||2016-03-09|2016-03-10|Estimate|March 2002||2002-03-31|March 2016|2016-03-31|December 2006||2006-12-31|||||Interventional|||Chemoradiotherapy of NSCLC Stage IIIB|Randomized Phase II Study Evaluating an Induction Chemotherapy Followed by a Concomitant Chemoradiotherapy and a Concomitant Chemoradiotherapy Followed by a Consolidation Chemotherapy Among Patients With NSCLC Stage III Not Resectable|Completed||Phase 2|130||Intergroupe Francophone de Cancerologie Thoracique|||||f||||||||||||||2018-06-01 04:32:42.088809|2018-06-01 04:32:42.088809
NCT00198419|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-13|2005-09-13|2005-09-20|Estimate|||||||2013-03-13|2013-03-14|Estimate|March 2004||2004-03-31|March 2013|2013-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)|Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Open Label, Normal Volunteer Study|Completed||Phase 1|65|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-06-01 04:32:42.160533|2018-06-01 04:32:42.160533
NCT00198406|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-01|2005-09-13|2005-09-20|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2002||2002-09-30|March 2017|2017-03-31|December 2005||2005-12-31|||||Observational|||A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.|A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.|Completed|||1653||Intergroupe Francophone de Cancerologie Thoracique|||||f||||||||||||||2018-06-01 04:32:42.252986|2018-06-01 04:32:42.252986
NCT00198393|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-28|2005-09-13|2005-09-20|Estimate|||||||2010-04-28|2010-04-30|Estimate|November 2004||2004-11-30|April 2010|2010-04-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV|Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV|Completed||Phase 2|126|Actual|Intergroupe Francophone de Cancerologie Thoracique||3|||f||||f||||||||||2018-06-01 04:32:42.317635|2018-06-01 04:32:42.317635
NCT00198380|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-28|2005-09-13|2005-09-20|Estimate|||||||2010-04-28|2010-04-30|Estimate|April 2005||2005-04-30|April 2010|2010-04-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature|Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)|Completed||Phase 2|90|Actual|Intergroupe Francophone de Cancerologie Thoracique||1|||f||||f||||||||||2018-06-01 04:32:42.41481|2018-06-01 04:32:42.41481
NCT00198367|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-10|2005-09-13|2005-09-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2003||2003-01-31|May 2016|2016-05-31|July 2012|Actual|2012-07-31|January 2008|Actual|2008-01-31||Interventional|||Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)|Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) NSCLC. Randomized Phase II Study|Completed||Phase 2|120|Actual|Hospices Civils de Lyon||3|||f||||||||||||||2018-06-01 04:32:42.516927|2018-06-01 04:32:42.516927
NCT00198354|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-09|2005-09-13|2005-09-20|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2001||2001-05-31|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Stage I/II NSCLC Perioperative Chemotherapy|Phase III Trial Comparing 2 Chemotherapy Schedules (Preoperative vs Pre and Postoperative) in Stage I and II NSCLC|Completed||Phase 3|530|Actual|Intergroupe Francophone de Cancerologie Thoracique||4|||f||||t||||||||Undecided||2018-06-01 04:32:42.609228|2018-06-01 04:32:42.609228
NCT00198341|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-24|2005-09-12|2005-09-20|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2005||2005-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Post-Surgical Non-Small Cell Lung Cancer (NSCLC) Follow-up|Multicentric Randomized Phase III Study of Post-Surgical NSCLC Follow-up|Active, not recruiting||N/A|1744|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||||||||||||2018-06-01 04:32:42.695389|2018-06-01 04:32:42.695389
NCT00198328|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-09-27|2005-09-12|2005-09-20|Estimate|||||||2017-09-27|2017-09-29|Actual|November 2004||2004-11-30|September 2017|2017-09-30|June 2007||2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma|A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Base of the Tongue, Posterior Lateral Pharyngeal Wall, Hypopharynx, or Larynx That Have Failed Primary Curative Therapy|Suspended||Phase 3|200|Anticipated|Inovio Pharmaceuticals||2||Enrollment was stopped based on the Data Monitoring Committee's recommendation.|f||||t||||||||||2018-06-01 04:32:42.782183|2018-06-01 04:32:42.782183
NCT00198315|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-09-27|2005-09-12|2005-09-20|Estimate|||||||2017-09-27|2017-09-29|Actual|June 2004||2004-06-30|September 2017|2017-09-30|June 1, 2007|Actual|2007-06-01|June 2007|Actual|2007-06-30||Interventional|||Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma|A Randomized Trial Comparing Preservation of Function Status After Either Medpulser Electroporation With Intratumoral Bleomycin Therapy or Surgery in Patients With Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Anterior Oral Cavity, Soft Palate, or Tonsil That Have Failed Primary Curative Therapy|Withdrawn||Phase 3|0|Actual|Inovio Pharmaceuticals||2||Enrollment was stopped based on the Data Monitoring Committee's recommendation.|f||||t||||||||||2018-06-01 04:32:42.857435|2018-06-01 04:32:42.857435
NCT00198302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-03-28|2005-09-12|2005-09-20|Estimate|||||||2013-03-28|2013-03-29|Estimate||||March 2013|2013-03-31|February 2005||2005-02-28|||||Interventional|||Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)|A Phase II, Randomized, Double-blind, Multi-center Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)|Completed||Phase 2|60||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:32:42.935946|2018-06-01 04:32:42.935946
NCT00198289|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-03-28|2005-09-12|2005-09-20|Estimate|||||||2013-03-28|2013-03-29|Estimate|April 2005||2005-04-30|March 2013|2013-03-31|June 2006||2006-06-30|||||Interventional|||Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs|A Phase IIa Dose Escalation Study to Assess Safety and Pharmacokinetics of Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs|Completed||Phase 2|30||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:32:43.012671|2018-06-01 04:32:43.012671
NCT00198276|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2013-04-24|2017-09-27|2005-09-12|2005-09-20|Estimate||||2013-04-24|2013-05-03|Estimate|2017-09-27|2017-10-03|Actual|February 2004||2004-02-29|September 2017|2017-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer|An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer|Completed||Phase 4|88|Actual|Inovio Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:32:43.084297|2018-06-01 04:32:43.084297
NCT00198250|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-11-13|2005-09-15|2005-09-20|Estimate|||||||2008-11-13|2008-11-14|Estimate|May 2000||2000-05-31|November 2008|2008-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Venlafaxine for Hot Flashes After Breast Cancer|Venlafaxine for Hot Flashes After Breast Cancer|Completed||Phase 2|75|Actual|Indiana University|||||f||||f||||||||||2018-06-01 04:32:43.21637|2018-06-01 04:32:43.21637
NCT00198237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2014-05-30|2005-09-15|2005-09-20|Estimate|||||||2014-05-30|2014-06-03|Estimate|March 2003||2003-03-31|May 2014|2014-05-31|December 2005||2005-12-31|||||Interventional|||Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer|Genomic and Proteomic Analysis of Docetaxel and Capecitabine as Primary Chemotherapy for Stage II-III Breast Cancer|Completed||Phase 2|40||Indiana University|||||f||||||||||||||2018-06-01 04:32:43.280509|2018-06-01 04:32:43.280509
NCT00198224|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|January 2003||2003-01-31|November 2004|2004-11-30|May 2005||2005-05-31|||||Interventional|||Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients|Pilot Study of In Vitro Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients|Completed||N/A|50||Indiana University|||||f||||||||||||||2018-06-01 04:32:43.349415|2018-06-01 04:32:43.349415
NCT00198198|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-04-03|2005-09-14|2005-09-20|Estimate|||||||2007-04-03|2007-04-05|Estimate|August 2005||2005-08-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Aripiprazole Treatment of Bipolar Depression|Open Label Pilot Study of Aripiprazole Treatment of Difficult to Treat Bipolar Depression|Completed||Phase 4|10||Indiana University|||||f||||||||||||||2018-06-01 04:32:43.438792|2018-06-01 04:32:43.438792
NCT00198185|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-01-02|2005-09-15|2005-09-20|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2005||2005-01-31|January 2018|2018-01-31|January 2005||2005-01-31|January 2005||2005-01-31||Interventional|||Cascade PRFM Study: The Evaluation of Cascade Platelet-Rich Fibrin Matrix (PRFM) on Rotator Cuff Healing|The Evaluation of Cascade PRFM on Rotator Cuff Healing|Withdrawn||Phase 3|0|Actual|Hospital for Special Surgery, New York|||||f||||||||||||||2018-06-01 04:32:43.495509|2018-06-01 04:32:43.495509
NCT00198172|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-05-30|2005-09-13|2005-09-20|Estimate|||||||2014-05-30|2014-06-03|Estimate|October 2000||2000-10-31|May 2014|2014-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors|Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors|Terminated||Phase 2|37||Indiana University||||Accrual Goal Met|f||||||||||||||2018-06-01 04:32:43.566204|2018-06-01 04:32:43.566204
NCT00198159|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-09-18|2005-09-13|2005-09-20|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2002||2002-09-30|September 2014|2014-09-30|March 2006|Actual|2006-03-31|February 2006|Actual|2006-02-28||Interventional|IUCRO-0021||A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR|A Phase II Study of ZD1839 (Iressa)in Chemotherapy Refractory Germ Cell Tumors Expressing Epidermal Growth Factor Receptor (EGFR)|Terminated||Phase 2|21||Indiana University|||||||||||||||||||2018-06-01 04:32:43.633345|2018-06-01 04:32:43.633345
NCT00198146|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-10-25|2005-09-12|2005-09-20|Estimate|||||||2005-10-25|2005-10-26|Estimate|July 2000||2000-07-31|September 2005|2005-09-30||||||||Interventional|||Prevention of Diabetes Progression Trial (PDPT)|PD Initiated/Prevention of Diabetes Progression Trial (PDPT) ZEN119|Completed||Phase 2|40||Indiana University|||||||||||||||||||2018-06-01 04:32:43.806823|2018-06-01 04:32:43.806823
NCT00198133|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-12-16||2015-12-16|2005-09-12|2005-09-20|Estimate|2015-12-16|2016-01-25|Estimate||||2015-12-16|2016-01-25|Estimate|January 2005||2005-01-31|December 2015|2015-12-31|May 2012|Actual|2012-05-31|December 2006|Actual|2006-12-31||Interventional|||Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma|Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma|Completed||Phase 2|27|Actual|Indiana University||1|||f||||||||||||||2018-06-01 04:32:43.902718|2018-06-01 04:32:43.902718
NCT00198120|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-04-08|2005-09-12|2005-09-20|Estimate|||||||2016-04-08|2016-04-12|Estimate|February 2004||2004-02-29|April 2016|2016-04-30|August 2010|Actual|2010-08-31|September 2007|Actual|2007-09-30||Interventional|||Safety and Effectiveness of D-Cycloserine in Children With Autism|A Randomized Controlled Trial of D-Cycloserine in Autism|Completed||Phase 3|80|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 04:32:44.661384|2018-06-01 04:32:44.661384
NCT00198107|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2017-04-14|2017-04-14|2005-09-12|2005-09-20|Estimate||||2017-04-14|2017-04-20|Actual|2017-04-14|2017-04-20|Actual|September 2005||2005-09-30|April 2017|2017-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism|Novel Pharmacological Strategies in Autism|Completed||Phase 3|81|Actual|Indiana University||3|||f||||t||||||||||2018-06-01 04:32:44.753872|2018-06-01 04:32:44.753872
NCT00198094|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-19|2005-09-12|2005-09-20|Estimate|||||||2007-10-19|2007-10-22|Estimate|December 2003||2003-12-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients|A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients|Completed||Phase 4|150|Anticipated|Indiana University|||||f||||t||||||||||2018-06-01 04:32:44.852073|2018-06-01 04:32:44.852073
NCT00198081|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-10-21||2016-02-26|2005-09-12|2005-09-20|Estimate|2016-02-26|2016-02-29|Estimate||||2016-02-26|2016-02-29|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)|A Phase II Trial of Celecoxib in Patients With IPMN|Terminated||Phase 2|8|Actual|Indiana University||2||Lack of funding and personnel to conduct study.|f||||t||||||||||2018-06-01 04:32:44.943987|2018-06-01 04:32:44.943987
NCT00198068|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-05-16|2005-09-12|2005-09-20|Estimate|||||||2018-05-16|2018-05-17|Actual|September 2003||2003-09-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|PROMISSE||Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)|Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)|Recruiting|||700|Anticipated|Hospital for Special Surgery, New York|||4||f||||t||||||Samples With DNA|"~     Serum, plasma, whole blood, RNA, urine~   "|No|Because the investigative team is still analyzing the data for biomarkers and genetics, the authors are not willing to make the data public at this time. Published study results can be found under Publications on the ClinicalTrials.gov site for this study.|2018-06-01 04:32:45.581932|2018-06-01 04:32:45.581932
NCT00198055|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-06-03|2005-09-12|2005-09-20|Estimate|||||||2014-06-03|2014-06-04|Estimate|January 2005||2005-01-31|June 2014|2014-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.|An Open-Label Study of Aripiprazole in Children and Adolescents With Autistic Disorder|Completed||Phase 2|25|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 04:32:45.68761|2018-06-01 04:32:45.68761
NCT00198042|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-03-20||2017-05-16|2005-09-13|2005-09-20|Estimate|2017-05-16|2017-05-17|Actual||||2017-05-16|2017-05-17|Actual|June 2004||2004-06-30|May 2017|2017-05-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Bone Tunnel Widening Following ACL Reconstruction|Bone Tunnel Widening Following ACL Reconstruction|Completed||N/A|18|Actual|Hospital for Special Surgery, New York||1|||f||||||||||||||2018-06-01 04:32:45.777681|2018-06-01 04:32:45.777681
NCT00198029|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-01-31||2017-03-20|2005-09-13|2005-09-20|Estimate|2013-05-03|2013-06-10|Estimate||||2017-03-20|2017-04-17|Actual|October 2004||2004-10-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||The average baseline VAS for pain was 62(range 38-100), and DASH was 29.7 (range 1- 68). 53% had ≥ 1 previous corticosteroid injection. All patients had moderate or severe radiographic OA of the CMC joint: 59% were K+L Grade 4, 25% Grade 3, and 16% Grade 2. No patients had clinical evidence of carpal tunnel syndrome or DeQuervain’s tenosynovitis.|An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study|An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study|Completed||N/A|32|Actual|Hospital for Special Surgery, New York||1|||f||||t||||||||||2018-06-01 04:32:45.99607|2018-06-01 04:32:45.99607
NCT00198016|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-16|2005-09-12|2005-09-20|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2004||2004-01-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Coil Embolization of Coronary Artery Fistulas|Coil Embolization of Coronary Artery Fistulas: A Single Centre Experience|Completed|||||HOSPITEN|||||f||||||||||||||2018-06-01 04:32:46.157412|2018-06-01 04:32:46.157412
NCT00198003|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-22|2005-09-12|2005-09-20|Estimate|||||||2011-11-22|2011-11-23|Estimate|November 2001||2001-11-30|November 2011|2011-11-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Addressing Patients' Expectations of Total Hip Arthroplasty in a Randomized Trial|Addressing Patients Expectations of Total Hip Arthroplasty: Developing and Testing an Educational Intervention in a Randomized Trial|Completed||N/A|178|Actual|Hospital for Special Surgery, New York|||||f||||f||||||||||2018-06-01 04:32:46.322154|2018-06-01 04:32:46.322154
NCT00197990|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-22|2005-09-12|2005-09-20|Estimate|||||||2011-11-22|2011-11-23|Estimate|July 2003||2003-07-31|November 2011|2011-11-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Observational|||Expectations, Satisfaction and Quality of Life in Total Hip Arthroplasty|Expectations, Satisfaction and Quality of Life in Total Hip Arthroplasty|Completed|||405|Actual|Hospital for Special Surgery, New York|||||f||||f||||||||||2018-06-01 04:32:46.40406|2018-06-01 04:32:46.40406
NCT00197977|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-22|2005-09-12|2005-09-20|Estimate|||||||2011-11-22|2011-11-23|Estimate|November 2001||2001-11-30|November 2011|2011-11-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Addressing Patients' Expectations of Total Knee Arthroplasty in a Randomized Trial|Addressing Patients' Expectations of Total Knee Arthroplasty: Developing and Testing an Educational Intervention in a Randomized Trial|Completed||N/A|146|Actual|Hospital for Special Surgery, New York|||||f||||f||||||||||2018-06-01 04:32:46.484737|2018-06-01 04:32:46.484737
NCT00197964|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-22|2005-09-12|2005-09-20|Estimate|||||||2011-11-22|2011-11-23|Estimate|August 2001||2001-08-31|November 2011|2011-11-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Randomized Trial to Improve Quality of Life Outcomes in Asthma Patients|A Randomized Trial to Improve Quality of Life Outcomes in Asthma Patients|Completed||N/A|180|Actual|Hospital for Special Surgery, New York|||||f||||f||||||||||2018-06-01 04:32:46.583669|2018-06-01 04:32:46.583669
NCT00197951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-12|2005-09-20|Estimate|||||||2007-04-20|2007-04-23|Estimate|October 2004||2004-10-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism|Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology, Not Being a Severe Mental Disorder, Associated to Alcohol Dependence Disorder.|Completed||Phase 3|60||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t||||||||||2018-06-01 04:32:46.695489|2018-06-01 04:32:46.695489
NCT00197938|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-06-05|2005-09-14|2005-09-20|Estimate|||||||2009-06-05|2009-06-09|Estimate|November 2005||2005-11-30|June 2009|2009-06-30|April 2009|Actual|2009-04-30|||||Observational|||Lactic Acid in the Rectum and Life-Threatening Infection|Does the Concentration of L-Lactate in the Rectum Correlate With Mortality and Morbidity in Patients With Septic Shock?|Completed|||130|Actual|Herlev Hospital|||||f||||||||||||||2018-06-01 04:32:46.818471|2018-06-01 04:32:46.818471
NCT00197925|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-02|2005-09-12|2005-09-20|Estimate|||||||2008-01-02|2008-01-03|Estimate|September 2004||2004-09-30|January 2008|2008-01-31||||||||Interventional|||Dendritic Cell Based Therapy of Metastatic Breast Cancer|Vaccination With Autologous Dendritic Cells Pulsed With Onco-Peptides for Treatment of Patients With Metastatic Breast Cancer.A Phase I/II Study|Terminated||Phase 1/Phase 2|40|Anticipated|Herlev Hospital||||all patients recruited|f||||||||||||||2018-06-01 04:32:46.884858|2018-06-01 04:32:46.884858
NCT00197912|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-04-23|2005-09-12|2005-09-20|Estimate|||||||2010-04-23|2010-04-26|Estimate|September 2004||2004-09-30|July 2009|2009-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Dendritic Cell Based Therapy of Malignant Melanoma|Vaccination With Autologous Dendritic Cells Pulsed With Tumor Antigens for Treatment of Patients With Malignant Melanoma. Phase I/II Study|Completed||Phase 1/Phase 2|25|Actual|Herlev Hospital|||||f||||||||||||||2018-06-01 04:32:46.958986|2018-06-01 04:32:46.958986
NCT00197899|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-12|2005-09-13|2005-09-20|Estimate|||||||2005-12-12|2005-12-13|Estimate|March 2004||2004-03-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Low-Dose Endotoxemia and the Acute Phase Response||Unknown status|Active, not recruiting|N/A|||Herlev Hospital|||||f||||||||||||||2018-06-01 04:32:47.035821|2018-06-01 04:32:47.035821
NCT00197886|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-09-19|2005-09-14|2005-09-20|Estimate|||||||2006-09-19|2006-09-20|Estimate|October 2004||2004-10-31|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||Dose of Norepinephrine and the Concentration of L-Lactate in the Rectum and Stomach in Patients With Septic Shock.||Completed||N/A|10||Herlev Hospital|||||f||||||||||||||2018-06-01 04:32:47.090236|2018-06-01 04:32:47.090236
NCT00197873|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-02-20|2005-09-12|2005-09-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2005||2005-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea|Randomized, Double Blind, Placebo Controlled, Cross-over Phase II Study on the Effects of Lactobacillus Rhamnosus GG Supplementation in Patients on 1st Line XELOXA Treatment for Metastatic Colorectal Cancer|Active, not recruiting||N/A|84|Anticipated|Helsinki University||2|||f||||f||||||||||2018-06-01 04:32:47.154251|2018-06-01 04:32:47.154251
NCT00197860|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-22|2005-09-12|2005-09-20|Estimate|||||||2011-11-22|2011-11-23|Estimate|September 2004||2004-09-30|November 2011|2011-11-30|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Dendritic Cell Based Therapy of Renal Cell Carcinoma|Vaccination With Autologous Dendritic Cells Pulsed With Tumor Antigens for Treatment of Patients With Renal Cell Carcinoma.A Phase I/II Study.|Completed||Phase 1/Phase 2|40|Actual|Herlev Hospital|||||f||||||||||||||2018-06-01 04:32:47.241917|2018-06-01 04:32:47.241917
NCT00197834|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-08-10|2005-09-12|2005-09-20|Estimate|||||||2006-08-10|2006-08-15|Estimate|March 2004||2004-03-31|September 2005|2005-09-30||||||||Interventional|||Study of Depakote for Behavioral and Psychological Symptoms in Dementia|An Open-Label Prospective Study of Depakote for Behavioral and Psychological Symptoms in Dementia (BPSD): Use Alone and in Co-Prescription With Atypical Antipsychotic Medications|Unknown status|Recruiting|Phase 1|20||Hearthstone Alzheimer Care|||||f||||||||||||||2018-06-01 04:32:47.374131|2018-06-01 04:32:47.374131
NCT00197821|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-27|2005-09-12|2005-09-20|Estimate|||||||2012-03-27|2012-03-28|Estimate|January 2004||2004-01-31|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults||Completed||Phase 2|611|Actual|Public Health England|||||f||||||||||||||2018-06-01 04:32:47.609134|2018-06-01 04:32:47.609134
NCT00197808|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-27|2005-09-12|2005-09-20|Estimate|||||||2012-03-27|2012-03-28|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|sched1||Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines|Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines|Completed||Phase 4|392|Actual|Public Health England||6|||f||||||||||||||2018-06-01 04:32:47.703693|2018-06-01 04:32:47.703693
NCT00197795|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-27|2005-09-12|2005-09-20|Estimate|||||||2012-03-27|2012-03-28|Estimate|January 2005||2005-01-31|March 2012|2012-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults||Completed||Phase 2|30||Public Health England|||||f||||||||||||||2018-06-01 04:32:47.805077|2018-06-01 04:32:47.805077
NCT00197782|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-27|2005-09-12|2005-09-20|Estimate|||||||2012-03-27|2012-03-28|Estimate|April 2003||2003-04-30|March 2012|2012-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine||Completed||Phase 4|||Public Health England|||||f||||||||||||||2018-06-01 04:32:47.853715|2018-06-01 04:32:47.853715
NCT00197769|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-30|2005-09-12|2005-09-20|Estimate|||||||2008-04-30|2008-05-01|Estimate|September 2000||2000-09-30|February 2008|2008-02-29|January 2004||2004-01-31|||||Interventional|||Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants||Completed||Phase 2|||Public Health England|||||f||||||||||||||2018-06-01 04:32:47.900823|2018-06-01 04:32:47.900823
NCT00197756|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-08-20|2005-09-13|2005-09-20|Estimate|||||||2009-08-20|2009-08-21|Estimate|September 2004||2004-09-30|August 2009|2009-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Vitamins, Breastmilk HIV Shedding, and Child Health|Vitamins, Breastmilk HIV Shedding, and Child Health|Completed|||771|Actual|Harvard School of Public Health|||4||f||||f||||||Samples Without DNA|"~     Breast milk samples collected from breast at delivery and at 3 month intervals thereafter.~   "|||2018-06-01 04:32:47.961102|2018-06-01 04:32:47.961102
NCT00197743|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-09|2005-09-13|2005-09-20|Estimate|||||||2010-11-09|2010-11-11|Estimate|April 1995||1995-04-30|November 2010|2010-11-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Trial of Vitamins in HIV Progression and Transmission|Trial of Vitamins in HIV Progression and Transmission|Completed||Phase 3|1085|Actual|Harvard School of Public Health||4|||f||||t||||||||||2018-06-01 04:32:48.07298|2018-06-01 04:32:48.07298
NCT00197730|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-08-20|2005-09-13|2005-09-20|Estimate|||||||2009-08-20|2009-08-21|Estimate|June 2004||2004-06-30|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Trial of Vitamins Among Children of HIV-infected Women|Trial of Vitamins Among Children of HIV-infected Women|Completed||Phase 3|2387|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-06-01 04:32:48.152924|2018-06-01 04:32:48.152924
NCT00197704|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-11-09|2005-09-13|2005-09-20|Estimate|||||||2010-11-09|2010-11-11|Estimate|March 2000||2000-03-31|November 2010|2010-11-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Nutrition, Immunology and Epidemiology of Tuberculosis|Nutrition, Immunology and Epidemiology of Tuberculosis|Completed||Phase 3|876|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-06-01 04:32:48.289163|2018-06-01 04:32:48.289163
NCT00197691|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-30|2005-09-13|2005-09-20|Estimate|||||||2012-03-30|2012-04-02|Estimate|March 2001||2001-03-31|March 2012|2012-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|||Botswana Pediatric Respiratory Disease and Bloodstream Infection Study|Botswana Pediatric Respiratory Disease and Bloodstream Infection|Completed|||||Harvard School of Public Health|||||f||||f||||||||||2018-06-01 04:32:48.414439|2018-06-01 04:32:48.414439
NCT00197678|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-09|2005-09-13|2005-09-20|Estimate|||||||2010-11-09|2010-11-11|Estimate|November 2002||2002-11-30|November 2010|2010-11-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women|Comparison of Two Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women From Tanzania|Completed||Phase 3|1141|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-06-01 04:32:48.518027|2018-06-01 04:32:48.518027
NCT00197652|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-10-06|2005-09-12|2005-09-20|Estimate|||||||2011-10-06|2011-10-07|Estimate|March 2001||2001-03-31|October 2011|2011-10-31|March 2008|Actual|2008-03-31|October 2003|Actual|2003-10-31||Observational|||Botswana Diarrheal Diseases Study|Botswana Diarrheal Diseases Study|Completed|||1350|Actual|Harvard School of Public Health|||2||f||||f||||||||||2018-06-01 04:32:48.595136|2018-06-01 04:32:48.595136
NCT00197639|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-10|2005-09-13|2005-09-20|Estimate|||||||2010-11-10|2010-11-15|Estimate|September 2006||2006-09-30|November 2010|2010-11-30|August 2010|Actual|2010-08-31|May 2009|Actual|2009-05-31||Observational|||Pharmacokinetic Study of Indinavir Drug Levels When Boosted With Ritonavir in Thailand|A Pharmacokinetic Study to Assess the Inter-patient Variability of Indinavir Drug Levels When Boosted With Ritonavir in Thai Patients on Highly Active Antiretroviral Therapy|Completed|||19|Actual|Harvard School of Public Health|||||f||||f||||||||||2018-06-01 04:32:48.658216|2018-06-01 04:32:48.658216
NCT00197613|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-09-14|2005-09-12|2005-09-20|Estimate|||||||2012-09-14|2012-09-17|Estimate|December 2002||2002-12-31|September 2012|2012-09-30|December 2007|Actual|2007-12-31|||||Interventional|||The Adult Antiretroviral Treatment and Resistance Study (Tshepo)|The Adult Antiretroviral Treatment and Resistance Study (Tshepo)|Completed||Phase 3|650||Harvard School of Public Health|||||f||||t||||||||||2018-06-01 04:32:48.742875|2018-06-01 04:32:48.742875
NCT00197587|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-05-17|2005-09-12|2005-09-20|Estimate|||||||2013-05-17|2013-05-20|Estimate|August 2002||2002-08-31|May 2013|2013-05-31||||May 2005|Actual|2005-05-31||Interventional|Mashi||Prevention of Milk-Borne Transmission of HIV-1C in Botswana|"Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi)"|Completed||N/A|1200|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-06-01 04:32:48.830815|2018-06-01 04:32:48.830815
NCT00197093|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-15|2005-09-13|2005-09-20|Estimate|||||||2009-05-15|2009-05-18|Estimate|September 2004||2004-09-30|May 2009|2009-05-31||||||||Interventional|||In-Patient Study In Schizophrenic Patients|A Placebo Controlled, Double-Blind, Randomised Study Investigating the Safety, Tolerability and Pharmacokinetics of Ascending Multiple Oral Doses of SB-773812 in Male and Female Schizophrenic Patients for up to 28 Days|Completed||Phase 1|60||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:32:54.841645|2018-06-01 04:32:54.841645
NCT00197561|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-11-09|2005-09-12|2005-09-20|Estimate|||||||2010-11-09|2010-11-11|Estimate|September 2003||2003-09-30|November 2010|2010-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection|Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection|Completed||Phase 3|915|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-06-01 04:32:48.929991|2018-06-01 04:32:48.929991
NCT00197548|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-11-09|2005-09-12|2005-09-20|Estimate|||||||2010-11-09|2010-11-11|Estimate|August 2001||2001-08-31|November 2010|2010-11-30|July 2006|Actual|2006-07-31|December 2004|Actual|2004-12-31||Interventional|||A Trial of Micronutrients and Adverse Pregnancy Outcomes|A Trial of Micronutrients and Adverse Pregnancy Outcomes|Completed||Phase 3|8468|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-06-01 04:32:49.053081|2018-06-01 04:32:49.053081
NCT00197522|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-10-31|2005-09-12|2005-09-20|Estimate|||||||2012-10-31|2012-11-01|Estimate|October 2004||2004-10-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Administration of Autologous Dendritic Cells (DCs) Infected With an Adenovirus Expressing Her-2|A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Vector Expressing Inactivated HER-2/Neu in Patients With Metastatic Breast Cancer|Completed||Phase 1|5|Actual|McMaster University|||||f||||||||||||||2018-06-01 04:32:49.131639|2018-06-01 04:32:49.131639
NCT00197509|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|February 2006||2006-02-28|||||Interventional|||Sit-to-Stand Training for Survivors of Stroke in a Long-Term Care Setting|Task Specific Training for Stroke Patients|Unknown status|Active, not recruiting|Phase 2|120||Hamilton Health Sciences Corporation|||||f||||||||||||||2018-06-01 04:32:49.2054|2018-06-01 04:32:49.2054
NCT00197496|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-12-14||2017-03-29|2005-09-12|2005-09-20|Estimate|2017-03-29|2017-03-30|Actual||||2017-03-29|2017-03-30|Actual|January 2007||2007-01-31|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Body Weight Supported Treadmill Training Following Hip Fracture|Body Weight Supported Treadmill Training Following Hip Fracture|Completed||N/A|21|Actual|McMaster University|It was not possible to blind outcome assessors. We did not randomize participants because we wanted a minimum of 12 to test feasibility of intervention. Control group had a longer average length of stay, and may have received more physiotherapy.|2|||f||||t||||||||No||2018-06-01 04:32:49.284265|2018-06-01 04:32:49.284265
NCT00197483|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate|March 2003||2003-03-31|September 2005|2005-09-30||||||||Observational|||Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia|Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia|Suspended|||20||Hamamatsu University|||||f||||||||||||||2018-06-01 04:32:49.626193|2018-06-01 04:32:49.626193
NCT00197470|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|January 2000||2000-01-31|September 2005|2005-09-30||||||||Interventional|||Cytokine Gene Polymorphisms in Gastric Diseases|Effects of Pro-Inflammatory and Anti-Inflammatory Cytokine Gene Polymorphism on the Development of Gastric Cancer and Peptic Ulcer in Japanese|Unknown status|Recruiting|N/A|||Hamamatsu University|||||f||||||||||||||2018-06-01 04:32:49.679296|2018-06-01 04:32:49.679296
NCT00197457|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-01-31|2005-09-12|2005-09-20|Estimate|||||||2006-01-31|2006-02-01|Estimate|June 2001||2001-06-30|May 2001|2001-05-31||||||||Interventional|||Pepsinogens as the Early Marker of H. Pylori Eradication|Serum Pepsinogens as an Early Diagnostic Marker of H. Pylori Eradication|Completed||Phase 2|||Hamamatsu University|||||f||||||||||||||2018-06-01 04:32:49.745674|2018-06-01 04:32:49.745674
NCT00197444|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-19|2005-09-13|2005-09-20|Estimate|||||||2009-02-19|2009-02-20|Estimate|January 2003||2003-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer|A Phase II Study of Daily Low-Dose of Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum) and Continuous Infusion of 5-FU Combined With Radiation for the Treatment of Esophageal Cancer|Completed||Phase 2|33|Actual|Hamamatsu University||1|||f||||t||||||||||2018-06-01 04:32:49.794299|2018-06-01 04:32:49.794299
NCT00197431|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-21|2005-09-12|2005-09-20|Estimate|||||||2006-03-21|2006-03-22|Estimate|January 2004||2004-01-31|December 2003|2003-12-31||||||||Interventional|||Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer|Pharmacokinetic and Pharmacodynamic Study of S-1 and Its Effects in Patients With the Digestive Organ Cancer With Reference to Genetic Polymorphism and Activity of CYP2A6 and DPD|Unknown status|Recruiting|Phase 2|||Hamamatsu University|||||f||||||||||||||2018-06-01 04:32:49.861785|2018-06-01 04:32:49.861785
NCT00197418|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-20|2005-09-12|2005-09-20|Estimate|||||||2006-03-20|2006-03-21|Estimate|August 2003||2003-08-31|March 2003|2003-03-31||||||||Interventional|||Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection|Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection|Unknown status|Recruiting|Phase 2/Phase 3|||Hamamatsu University|||||f||||||||||||||2018-06-01 04:32:49.92065|2018-06-01 04:32:49.92065
NCT00197405|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-08-03|2005-09-12|2005-09-20|Estimate|||||||2009-08-03|2009-08-04|Estimate|August 1999||1999-08-31|August 2009|2009-08-31|December 2010|Anticipated|2010-12-31|||||Observational|||Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma|Comparative Study of Fecal RNA Test With Immunochemical Fecal Occult Blood Test for Detecting Colorectal Cancer and Adenoma|Unknown status|Recruiting||400|Anticipated|Hamamatsu University|||||f||||t||||||Samples Without DNA|"~     freces, biopsy tissue samples~   "|||2018-06-01 04:32:50.100036|2018-06-01 04:32:50.100036
NCT00197392|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-03-02||2013-10-11|2005-09-13|2005-09-20|Estimate|2013-10-11|2013-11-05|Estimate||||2013-10-11|2013-11-05|Estimate|November 2004||2004-11-30|October 2013|2013-10-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System|Establishment of Baseline and Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System|Completed||Phase 4|434|Actual|Codman & Shurtleff||2|||f||||f||||||||||2018-06-01 04:32:50.198202|2018-06-01 04:32:50.198202
NCT00197379|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-28|2005-09-12|2005-09-20|Estimate|||||||2010-07-28|2010-07-29|Estimate|May 2005||2005-05-31|April 2005|2005-04-30|January 2007|Anticipated|2007-01-31|||||Interventional|||The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia|The Study for New Effect of Roxithromycin on Androgenetic Alopecia.|Unknown status|Active, not recruiting|N/A|20|Anticipated|Hamamatsu University|||||f||||||||||||||2018-06-01 04:32:50.948286|2018-06-01 04:32:50.948286
NCT00196807|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-19|2005-09-12|2005-09-20|Estimate|||||||2010-01-19|2010-01-20|Estimate|August 2004||2004-08-31|January 2010|2010-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Prostate Cancer Screening: Fostering Informed Decisions|Prostate Cancer Screening: Fostering Informed Decisions|Completed||Phase 3|543|Actual|Georgetown University||4|||f||||t||||||||||2018-06-01 04:33:04.405904|2018-06-01 04:33:04.405904
NCT00197366|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-11-26|2005-09-14|2005-09-20|Estimate|||||||2017-11-26|2017-11-28|Actual|March 2005||2005-03-31|September 2005|2005-09-30|December 2007||2007-12-31|||||Observational|||Development of Resistance Mutations in Pregnant HIV-positive (+) Women Following Perinatal Antiretroviral Therapy in Israel|Development of Resistance Mutations in the Human Immunodeficiency Virus (HIV) in Pregnant HIV+ Women Receiving Perinatal Antiretroviral Therapy in Israel|Terminated|||50|Anticipated|Hadassah Medical Organization||||Difficulties in data collection|f||||||||||||||2018-06-01 04:32:51.01519|2018-06-01 04:32:51.01519
NCT00197353|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-05|2005-09-13|2005-09-20|Estimate|||||||2009-03-05|2009-03-06|Estimate|March 1999||1999-03-31|May 2005|2005-05-31|September 1999||1999-09-30|||||Interventional|||Study of Different Concentrations of Epidural Bupivacaine for the Effects on Vasodilatation and Sensory Block|Sympathectomy-Mediated Vasodilatation and Differential Sensory Block After Epidural Bupivacaine: a Randomized Concentration Ranging Study|Completed||Phase 3|60||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:32:51.090707|2018-06-01 04:32:51.090707
NCT00197340|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-14|2005-09-13|2005-09-20|Estimate|||||||2008-07-14|2008-07-15|Estimate|August 2003||2003-08-31|February 2006|2006-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction|Antepartum Chronic Epidural Therapy (ACET) Using Ropivacaine to Improve Uteroplacental Blood Flow in Pre-Eclampsia and Intrauterine Growth Restriction|Completed||Phase 3|20|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:32:51.160796|2018-06-01 04:32:51.160796
NCT00197327|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-03-02|2005-09-13|2005-09-20|Estimate|||||||2006-03-02|2006-03-03|Estimate|February 1998||1998-02-28|March 2003|2003-03-31|March 2000||2000-03-31|||||Interventional|||Dilute Versus Concentrated Epidural Bupivacaine in Labor|Analgesia Requirement and Maternal Satisfaction Following Epidural PCA in Nulliparous Labor: the Effect of a Four-Fold Change in Local Anesthetic Concentration.|Completed||Phase 3|60||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:32:51.231332|2018-06-01 04:32:51.231332
NCT00197314|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-06|2005-09-12|2005-09-20|Estimate|||||||2006-11-06|2006-11-07|Estimate|June 2004||2004-06-30|September 2005|2005-09-30|March 2006||2006-03-31|||||Interventional|||Effectiveness of Circular Muscle Exercise (Paula Method) Versus Kegel Exercise for Urinary Stress Incontinence|A Randomized Controlled Trial of Circular Muscle Exercises (Paula Method) vs. Pelvic Floor Training (Kegel Exercises) for Urinary Stress Incontinence in Women|Completed||Phase 3|200||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:32:51.314712|2018-06-01 04:32:51.314712
NCT00197301|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-06|2005-09-12|2005-09-20|Estimate|||||||2006-11-06|2006-11-07|Estimate|October 2005||2005-10-31|September 2005|2005-09-30|April 2006||2006-04-30|||||Interventional|||Liposomal Based Intranasal Influenza Vaccine:Safety and Efficacy|Phase 1 Study to Examine the Safety and Efficacy of a Novel Liposomal Based Intranasal Influenza Vaccine|Completed||Phase 1/Phase 2|200||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:32:51.388034|2018-06-01 04:32:51.388034
NCT00197288|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2017-01-16|2005-09-19|2005-09-20|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines|A Phase III, Observer-blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix™ (GlaxoSmithKline Biologicals) Compared With Fluzone® (Aventis Pasteur) Administered Intramuscularly in Adults 18 Years and Older in the U.S.|Completed||Phase 3|1847|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:51.451594|2018-06-01 04:32:51.451594
NCT00197275|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-19|||2016-10-06|2005-09-19|2005-09-20|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2006||2006-02-28|October 2016|2016-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants|Demonstrate Lot-to-lot Consistency of Final Production Method of GSK Biologicals' Hib-MenAC Vaccine Mixed Extemporaneously With Tritanrix™-HepB & Demonstrate Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Healthy Infants at 2, 4 and 6 Months|Completed||Phase 3|800||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:51.577174|2018-06-01 04:32:51.577174
NCT00197262|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-01-18|2005-09-15|2005-09-20|Estimate|||||||2017-01-18|2017-01-19|Estimate|August 2005||2005-08-31|January 2017|2017-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)|A Randomized, Single-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100 mcg for 2 Weeks in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|288||GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:51.683599|2018-06-01 04:32:51.683599
NCT00197249|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-09-08|2005-09-15|2005-09-20|Estimate|||||||2016-09-08|2016-09-09|Estimate|May 2002||2002-05-31|September 2016|2016-09-30|November 2005|Actual|2005-11-30|June 2003|Actual|2003-06-30||Interventional|||Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity|A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Biologicals' Combined Vi Polysaccharide Typhoid Vaccine and Inactivated Hepatitis A Vaccine, to That Elicited by GSK Biologicals' Hepatitis A Vaccine, Administered Singly or Concomitantly With GSK Biologicals' Vi Polysaccharide Vaccine|Completed||Phase 3|1034|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:51.80299|2018-06-01 04:32:51.80299
NCT00197236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2008-12-02||2017-01-16|2005-09-15|2005-09-20|Estimate|2009-06-04|2009-07-24|Estimate||||2017-01-16|2017-02-28|Actual|November 2003||2003-11-30|January 2017|2017-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months|Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 Months of Age|Completed||Phase 3|468|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:51.923521|2018-06-01 04:32:51.923521
NCT00197223|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-03-21|2005-09-15|2005-09-20|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2005||2005-09-30|March 2017|2017-03-31|May 2006|Actual|2006-05-31|October 2005|Actual|2005-10-31||Interventional|||Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine|A Randomized, Double-blind, Placebo-controlled, Post-marketing Phase III Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults.|Completed||Phase 3|6213|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:52.491167|2018-06-01 04:32:52.491167
NCT00197210|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-11-03|2005-09-15|2005-09-20|Estimate|||||||2016-11-03|2016-11-04|Estimate|December 2003||2003-12-31|November 2016|2016-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants|A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants|Completed||Phase 3|10708|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:52.558914|2018-06-01 04:32:52.558914
NCT00197197|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-03-28|2005-09-13|2005-09-20|Estimate|||||||2011-03-28|2011-03-29|Estimate|July 2005||2005-07-31|March 2011|2011-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.|Terminated||Phase 3|18|Actual|GlaxoSmithKline||||The study was terminated due to hepatoxicity of compound|||||||||||||||2018-06-01 04:32:52.630721|2018-06-01 04:32:52.630721
NCT00197184|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2009-02-20||2016-10-21|2005-09-15|2005-09-20|Estimate|2009-04-10|2009-06-04|Estimate||||2016-10-21|2016-12-02|Estimate|November 2003||2003-11-30|October 2016|2016-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared|Evaluate the Persistence of Immune Response of GSK Biologicals' Twinrix™ Vaccine, Administered According to a 0,6 Month Schedule and a 0,1,6 Month Schedule, in Healthy Children Aged Between 1-11 Years at the Time of First Vaccine Dose|Completed||Phase 3|276|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:52.723542|2018-06-01 04:32:52.723542
NCT00197171|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-09-06|2005-09-14|2005-09-20|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine|Evaluate the Persistence of Immune Response of GSK Biologicals' TWINRIX™ ADULT, Administered According to 0,6 Month Schedule and 0,12 Month Schedule, in Volunteers Aged 12-15 Years Inclusive at the Time of First Vaccine Dose|Completed||Phase 3|143|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:53.249217|2018-06-01 04:32:53.249217
NCT00197158|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-09-20|2005-09-15|2005-09-20|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response|Demonstrate the Non-inferiority of Immunogenicity Elicited by GSK Biologicals' Hepatitis B Vaccine, Multidose Engerix™-B to That of Monodose Engerix™-B When Administered According to 0,1,6 Mths Schedule in Healthy Adults Aged ≥ 18 Yrs|Completed||Phase 4|280|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:53.343314|2018-06-01 04:32:53.343314
NCT00197145|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-07-25|2005-09-13|2005-09-20|Estimate|||||||2017-07-25|2017-07-28|Actual|July 21, 2005|Actual|2005-07-21|July 2017|2017-07-31|September 11, 2007|Actual|2007-09-11|September 11, 2007|Actual|2007-09-11||Interventional|||Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Compare the Efficacy and Safety of GW873140 400mg BID in Combination With a Ritonavir-containing Optimized Background Therapy (OBT) Regimen Versus Placebo Plus OBT Over 48 Weeks.|Terminated||Phase 3|24|Actual|ViiV Healthcare||1|||f||||||||||||||2018-06-01 04:32:53.435254|2018-06-01 04:32:53.435254
NCT00197132|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-12-02|2005-09-14|2005-09-20|Estimate|||||||2016-12-02|2016-12-05|Estimate|October 2002||2002-10-31|December 2016|2016-12-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Study In Patients With Insulin Resistance|A Single-centre, Randomised, Double-blind, Placebo Controlled, Two 12 Week Period, Cross-over Phase III Study to Investigate the Effect of Rosiglitazone 4mg bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects.|Completed||Phase 3|18|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:53.664827|2018-06-01 04:32:53.664827
NCT00197119|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2009-07-02||2017-03-21|2005-09-14|2005-09-20|Estimate|2009-07-02|2009-08-14|Estimate||||2017-03-21|2017-04-20|Actual|May 2004||2004-05-31|March 2017|2017-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years|Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 Years at Time of First Vaccine Dose|Completed||Phase 3|244|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:53.780648|2018-06-01 04:32:53.780648
NCT00197106|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-09-11||2017-02-01|2005-09-13|2005-09-20|Estimate|2009-11-10|2009-12-14|Estimate||||2017-02-01|2017-03-14|Actual|June 2005||2005-06-30|April 2012|2012-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Treatment Of Symptomatic Asthma In Children|A Multicentre, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Salmeterol/Fluticasone Propionate Combination Product (Seretide®) 50/100 mcg With Fluticasone Propionate (Flixotide® ) 200 mcg, Both Delivered Twice Daily Via the DISKUS Inhaler, in the Treatment of Children Aged 6-12 Years With Symptomatic Asthma|Completed||Phase 4|176|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:32:54.228862|2018-06-01 04:32:54.228862
NCT00197080|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-09-22|2005-09-13|2005-09-20|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|January 2006|Actual|2006-01-31|||||Interventional|||Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome|A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome|Completed||Phase 3|380||GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:54.919715|2018-06-01 04:32:54.919715
NCT00197067|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-01|2005-09-13|2005-09-20|Estimate|||||||2017-06-01|2017-06-02|Actual|March 15, 2004|Actual|2004-03-15|June 2017|2017-06-30|April 26, 2005|Actual|2005-04-26|April 26, 2005|Actual|2005-04-26||Interventional|||A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.|A Bridging Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.|Completed||Phase 1|200|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:32:55.269952|2018-06-01 04:32:55.269952
NCT00197054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-02-01|2005-09-13|2005-09-20|Estimate|||||||2013-02-01|2013-02-04|Estimate|July 2005||2005-07-31|February 2013|2013-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study to Evaluate Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.|A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.|Completed||Phase 2|255|Actual|U.S. Army Medical Research and Materiel Command|||||f||||||||||||||2018-06-01 04:32:55.378956|2018-06-01 04:32:55.378956
NCT00197041|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-09-20|2005-09-13|2005-09-20|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2003||2003-07-31|September 2016|2016-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.|A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule in Toddlers and Children Aged 1 to 4 Years in a Malaria-endemic Region of Mozambique.|Completed||Phase 2|2022|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:55.464243|2018-06-01 04:32:55.464243
NCT00197028|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-12-13|2009-05-29|2017-04-24|2005-09-13|2005-09-20|Estimate|2012-12-13|2013-01-18|Estimate|2009-10-01|2009-10-02|Estimate|2017-04-24|2017-06-05|Actual|August 23, 2005||2005-08-23|April 2017|2017-04-30|December 27, 2007|Actual|2007-12-27|December 27, 2007|Actual|2007-12-27||Interventional|||Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region|A Phase I/IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine in Infants Living in a Malaria-endemic Region|Completed||Phase 2|214|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:55.595856|2018-06-01 04:32:55.595856
NCT00197015|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-03-11||2016-10-11|2005-09-13|2005-09-20|Estimate|2010-03-11|2010-04-01|Estimate||||2016-10-11|2016-11-23|Estimate|October 2003||2003-10-31|October 2016|2016-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children|Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age|Completed||Phase 3|1474|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:56.316333|2018-06-01 04:32:56.316333
NCT00197002|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-12-23||2016-12-23|2005-09-13|2005-09-20|Estimate|2016-12-23|2017-02-20|Actual||||2016-12-23|2017-02-20|Actual|September 2003||2003-09-30|September 2016|2016-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age|A Phase IIIb, Open, Randomized, Controlled, Multicenter Study of the Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine Administered on a 0-6 Mth Schedule Concomitantly With Wyeth Lederle's Pneumococcal Conjugate Vaccine in Healthy Children 15 Months of Age|Completed||Phase 3|521|Actual|GlaxoSmithKline|None reported.||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:57.016803|2018-06-01 04:32:57.016803
NCT00196989|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-21|2005-09-13|2005-09-20|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2005||2005-09-30|March 2017|2017-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study In People With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|448|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:58.839822|2018-06-01 04:32:58.839822
NCT00196976|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-01-11||2017-04-25|2005-09-13|2005-09-20|Estimate|2017-01-11|2017-03-01|Actual||||2017-04-25|2017-06-01|Actual|March 24, 2005||2005-03-24|April 2017|2017-04-30|March 3, 2006|Actual|2006-03-03|March 1, 2006|Actual|2006-03-01||Interventional|||Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old|Evaluate the Immunogenicity, Reactogenicity, Safety of 4 Different Formulations of GSK Biologicals' Conjugate Vaccine (MenACWY) vs 1 Dose of MenC-CRM197 or Mencevax™ ACWY in Children Aged 12-14 Months & 3-5 Years|Completed||Phase 2|461|Actual|GlaxoSmithKline|None reported.|14|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:32:59.336277|2018-06-01 04:32:59.336277
NCT00196261|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-09|2005-09-13|2005-09-20|Estimate|||||||2018-03-09|2018-03-12|Actual|January 1995||1995-01-31|September 2005|2005-09-30||||||||Observational|||Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Long-Term Prediction|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Long-Term Prediction|Completed|||3500||Deutsches Herzzentrum Muenchen|||||f||||||||||||||2018-06-01 04:33:09.787161|2018-06-01 04:33:09.787161
NCT00196963|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-09-20|2005-09-13|2005-09-20|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs|Assess the Immunogenicity, Safety, Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of Mencevax™ ACWY in Healthy Subjects Aged 15-19 Yrs|Completed||Phase 2|125|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:33:02.471276|2018-06-01 04:33:02.471276
NCT00196950|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-09-06|2005-09-13|2005-09-20|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years|Assess the Safety, Reactogenicity, Immunogenicity & Long-term Persistence of One Intramuscular Dose of GSK Biologicals' MenACWY Conjugate Vaccine vs One Subcutaneous Dose of Mencevax™ ACWY in Healthy Adults Aged 18-25 Yrs|Completed||Phase 2|50|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:33:02.632862|2018-06-01 04:33:02.632862
NCT00196937|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-11-12||2016-11-23|2005-09-13|2005-09-20|Estimate|2010-07-08|2010-08-06|Estimate||||2016-11-23|2017-01-11|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18|Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up|Completed||Phase 3|667|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:33:02.729311|2018-06-01 04:33:02.729311
NCT00196924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-21|2005-09-13|2005-09-20|Estimate|||||||2017-03-21|2017-03-23|Actual|June 2004||2004-06-30|March 2017|2017-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.|Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years)|Completed||Phase 3|2067|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:33:03.500744|2018-06-01 04:33:03.500744
NCT00196911|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2006-11-29|2005-09-17|2005-09-20|Estimate|||||||2006-11-29|2006-11-30|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||STN-Stimulation Versus Best Medical Treatment in Advanced PD|Randomized, Multicenter, Prospective, Parallel-Group Study of the Effect of Deep Brain Stimulation (Subthalamic Nucleus) on Quality of Life and Motor Complications in Patients With Advanced Parkinson's Disease Compared With Best Medical Treatment|Completed||Phase 3|156||German Parkinson Study Group (GPS)|||||f||||||||||||||2018-06-01 04:33:03.661509|2018-06-01 04:33:03.661509
NCT00196898|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-16|2005-09-12|2005-09-20|Estimate|||||||2012-03-16|2012-03-19|Estimate|March 2005||2005-03-31|April 2011|2011-04-30|December 2013|Anticipated|2013-12-31|||||Observational|||Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists|A National, Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson´s Disease Treated With Dopamine Agonists|Unknown status|Recruiting||100|Anticipated|German Parkinson Study Group (GPS)|||||f||||||||||||||2018-06-01 04:33:03.730132|2018-06-01 04:33:03.730132
NCT00196885|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-18|2005-09-12|2005-09-20|Estimate|||||||2008-06-18|2008-06-20|Estimate|December 2003||2003-12-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|||||Interventional|||Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training|Effect of N-Acetylcysteine on Skeletal Muscle in Cachectic Cancer Patients Undergoing a Resistance Training Program (Phase 2 Study)|Completed||Phase 2|60||German Cancer Research Center|||||f||||||||||||||2018-06-01 04:33:03.806754|2018-06-01 04:33:03.806754
NCT00196872|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-07-16|2005-09-12|2005-09-20|Estimate|||||||2014-07-16|2014-07-17|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)|A Phase III Trial to Compare ETC vs, EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)|Completed||Phase 3|3000|Anticipated|German Breast Group||4|||f||||||||||||||2018-06-01 04:33:03.873562|2018-06-01 04:33:03.873562
NCT00196859|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-07-16|2005-09-12|2005-09-20|Estimate|||||||2014-07-16|2014-07-17|Estimate|June 2004||2004-06-30|August 2011|2011-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study in Elderly Patients With Early Breast Cancer (ICE)|Ibandronate With or Without Capecitabine in Elderly Patients With Early Breast Cancer|Completed||Phase 3|1500|Anticipated|German Breast Group||2|||f||||t||||||||||2018-06-01 04:33:04.080147|2018-06-01 04:33:04.080147
NCT00196846|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-11|2005-09-12|2005-09-20|Estimate|||||||2010-06-11|2010-06-14|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|March 2010|Actual|2010-03-31|December 2008|Actual|2008-12-31||Interventional|||Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)|Prospective Randomized Multicenter Study to Prevent Chemotherapy Induced Ovarian Failure With the GnRH-Agonist Goserelin in Young Hormone Insensitive Breast Cancer Patients Receiving Anthracycline Containing (Neo-)Adjuvant Chemotherapy|Completed||Phase 2|62|Anticipated|German Breast Group|||||f||||t||||||||||2018-06-01 04:33:04.16985|2018-06-01 04:33:04.16985
NCT00196833|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-01|2005-09-12|2005-09-20|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2003||2003-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|BCP||Breast Cancer in Pregnancy Register Study|Prospective and Retrospective Register Study of the German Breast Group (GBG) for Diagnosis and Treatment of Breast Cancer in Pregnancy|Recruiting|||500|Anticipated|German Breast Group|||||f||||f||||||Samples With DNA|"~     Tumour and placenta specimens are collected~   "|||2018-06-01 04:33:04.265598|2018-06-01 04:33:04.265598
NCT00196820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-10-05|2005-09-12|2005-09-20|Estimate|||||||2011-10-05|2011-10-06|Estimate|July 2005||2005-07-31|May 2008|2008-05-31|December 2008|Actual|2008-12-31|||||Interventional|||Mono Efficacy of Capecitabine (MoniCa)|A Multicenter Phase II Study to Determine the Efficacy of Capecitabine as First Line Monochemotherapy in Patients With HER2 Negative, Medium-risk, Metastatic Breast Cancer|Completed||Phase 2|200|Anticipated|German Breast Group||1|||f||||t||||||||||2018-06-01 04:33:04.331275|2018-06-01 04:33:04.331275
NCT00196794|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-03-17|2005-09-13|2005-09-20|Estimate|||||||2014-03-17|2014-03-19|Estimate|April 2005||2005-04-30|March 2014|2014-03-31|August 2007|Actual|2007-08-31|||||Interventional|||A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea|A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea|Completed||Phase 3|520|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:33:04.495048|2018-06-01 04:33:04.495048
NCT00196781|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-11|2005-09-12|2005-09-20|Estimate|||||||2010-01-11|2010-01-13|Estimate|September 2002||2002-09-30|January 2010|2010-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Treatment Decision Making in Early-Stage Prostate Cancer|Treatment Decision Making in Early-Stage Prostate Cancer: Evaluation of Computer Based Patient Education and an Interactive Decision Aid|Completed||Phase 3|168|Actual|Georgetown University||2|||f||||t||||||||||2018-06-01 04:33:04.796978|2018-06-01 04:33:04.796978
NCT00196768|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-22|2005-09-12|2005-09-20|Estimate|||||||2007-10-22|2007-10-23|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|December 2010||2010-12-31|||||Interventional|||Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic|Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study)|Unknown status|Recruiting|Phase 4|30|Anticipated|German AML Cooperative Group|||||f||||||||||||||2018-06-01 04:33:04.871847|2018-06-01 04:33:04.871847
NCT00196755|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-03-17|2005-09-15|2005-09-20|Estimate|||||||2015-03-17|2015-03-18|Estimate|December 2004||2004-12-31|March 2015|2015-03-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional|||Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis|An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride (Renagel®) Compared With Calcium Acetate in Peritoneal Dialysis Patients|Completed||Phase 3|138|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:33:04.950351|2018-06-01 04:33:04.950351
NCT00196742|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-12-18|2005-09-13|2005-09-20|Estimate|||||||2017-12-18|2017-12-20|Actual|July 31, 2001|Actual|2001-07-31|December 2017|2017-12-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Observational|||Fabry Disease Registry|Fabry Disease Registry|Recruiting|||9000|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 04:33:05.068662|2018-06-01 04:33:05.068662
NCT00196729|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-17|2005-09-19|2005-09-20|Estimate|||||||2015-03-17|2015-03-18|Estimate|December 2001||2001-12-31|March 2015|2015-03-31|September 2003||2003-09-30|||||Interventional|||Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration|A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State|Completed||Phase 3|63||Sanofi|||||||||||||||||||2018-06-01 04:33:05.239802|2018-06-01 04:33:05.239802
NCT00196716|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-12-05||2015-03-17|2005-09-12|2005-09-20|Estimate|2009-03-02|2009-04-02|Estimate||||2015-03-17|2015-04-03|Estimate|June 2003||2003-06-30|March 2015|2015-03-31|March 2007|Actual|2007-03-31|April 2006|Actual|2006-04-30||Interventional|||A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease|A Multicenter, Open-label Study of Low Dose Maintenance Treatment of Fabrazyme (Recombinant Human Alpha-Galactosidase A (R-h Alpha-GAL)) Replacement Therapy in Patients With Fabry Disease|Completed||Phase 2|21|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:33:05.51851|2018-06-01 04:33:05.51851
NCT00196703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|September 2005||2005-09-30|||||Interventional|||Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial|A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.|Unknown status|Recruiting|Phase 4|30||Gabinete Berthier y Martínez|||||f||||||||||||||2018-06-01 04:33:05.914647|2018-06-01 04:33:05.914647
NCT00196690|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial|Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial.|Completed||Phase 4|30||Gabinete Berthier y Martínez|||||f||||||||||||||2018-06-01 04:33:05.985659|2018-06-01 04:33:05.985659
NCT00196677|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-03-10|2005-09-19|2005-09-20|Estimate|||||||2009-03-10|2009-03-11|Estimate|September 2005||2005-09-30|March 2009|2009-03-31|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Study of Glaucoma Treatment With Food Additives|Treatment of Glaucomatous Neuropathy With Food Additives|Terminated||Phase 1/Phase 2|25|Anticipated|Future Products Management||||The trial was terminated due to investigator's decision|f||||||||||||||2018-06-01 04:33:06.043714|2018-06-01 04:33:06.043714
NCT00196664|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-12|2005-09-16|2005-09-20|Estimate|||||||2009-05-12|2009-05-13|Estimate|October 2005||2005-10-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|||||Interventional|||Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin|Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin. Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg|Completed||Phase 3|144|Anticipated|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:33:06.174755|2018-06-01 04:33:06.174755
NCT00196651|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|August 2000||2000-08-31|September 2005|2005-09-30|February 2004||2004-02-29|||||Interventional|||HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection|Randomized Study on HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides (LIPO-6T) in Patients Treated Early With HAART During Primary Infection. ANRS 095 PRIMOVAC|Terminated||Phase 2|60||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:33:06.241212|2018-06-01 04:33:06.241212
NCT00196638|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-08-28|2005-09-12|2005-09-20|Estimate|||||||2006-08-28|2006-08-29|Estimate|May 2002||2002-05-31|August 2006|2006-08-31|March 2006||2006-03-31|||||Interventional|||Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection|Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection.ANRS 112 INTERPRIM|Terminated||Phase 2/Phase 3|90||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:33:06.300116|2018-06-01 04:33:06.300116
NCT00196248|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-20|Estimate|||||||2005-09-13|2005-09-20|Estimate||||September 2005|2005-09-30||||||||Observational|||Out-of Hospital Resuscitation Study||Unknown status|Recruiting||||Deutsches Herzzentrum Muenchen|||||f||||||||||||||2018-06-01 04:33:09.989135|2018-06-01 04:33:09.989135
NCT00196625|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|November 2000||2000-11-30|September 2005|2005-09-30|February 2002||2002-02-28|||||Interventional|||Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.|Study on Safety and Efficacy of Salvage Therapy With Amprenavir, Lopinavir and Ritonavir 200 Mg/d or 400 Mg/d in HIV-Infected Patients in Virological Failure.ANRS 104 PUZZLE 1|Completed||Phase 2|100||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:33:06.366099|2018-06-01 04:33:06.366099
NCT00196612|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|April 2001||2001-04-30|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART|Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE|Completed||Phase 3|350||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:33:06.428701|2018-06-01 04:33:06.428701
NCT00196599|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|February 1999||1999-02-28|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults|Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA|Completed||Phase 2|39||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:33:06.498857|2018-06-01 04:33:06.498857
NCT00196586|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-15|2005-09-12|2005-09-20|Estimate|||||||2007-11-15|2007-11-16|Estimate|April 2003||2003-04-30|November 2007|2007-11-30|November 2006||2006-11-30|||||Interventional|||Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients|Pilot Study of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin for the Treatment of Chronic Hepatitis C in HIV-HCV Coinfected Patients Non Responders to Three Months of Therapy With Pegylated Interferon Alpha 2a and Ribavirin. ANRS HC09 SECOIIA|Completed||Phase 2|75||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:33:06.584931|2018-06-01 04:33:06.584931
NCT00196573|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-04-24|2005-09-12|2005-09-20|Estimate|||||||2014-04-24|2014-04-25|Estimate|November 2003||2003-11-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Subacromial Decompression Versus Subacromial Bursectomy for Patients With Rotator Cuff Tendinosis|A Randomized Clinical Trial Comparing the Effectiveness of Subacromial Decompression (Acromioplasty) Versus Subacromial Bursectomy (no Acromioplasty) in the Arthroscopic Treatment of Patients With Rotator Cuff Tendinosis|Unknown status|Active, not recruiting|Phase 3|114|Anticipated|University of Western Ontario, Canada||1|||f||||||||||||||2018-06-01 04:33:06.744805|2018-06-01 04:33:06.744805
NCT00196560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-11-26|2005-09-12|2005-09-20|Estimate|||||||2015-11-26|2015-11-30|Estimate|September 2003||2003-09-30|November 2015|2015-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Immobilization in External Rotation of Acute Shoulder Dislocations|A Randomized Evaluation of Immobilization in External Rotation in the Management of Acute Anterior Dislocations of the Shoulder|Completed||Phase 3|50|Actual|Fowler Kennedy Sport Medicine Clinic||1|||f||||f||||||||||2018-06-01 04:33:06.898672|2018-06-01 04:33:06.898672
NCT00196547|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-15|2005-09-12|2005-09-20|Estimate|||||||2012-03-15|2012-03-16|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|November 2005||2005-11-30|||||Interventional|||Montelukast in Modulating Exacerbations of Asthma in Children|Randomized Placebo-controlled Trial of Montelukast in Modulating Exacerbations of Asthma in Children, September 2005|Completed||Phase 4|200||Firestone Institute for Respiratory Health|||||f||||||||||||||2018-06-01 04:33:06.986568|2018-06-01 04:33:06.986568
NCT00196534|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-24|2005-09-19|2005-09-20|Estimate|||||||2007-08-24|2007-08-28|Estimate|November 2004||2004-11-30|August 2007|2007-08-31|July 2006||2006-07-31|||||Interventional|||A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery|A Comparative Evaluation of Human Thrombin Versus Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Cardiovascular, Neurologic (Spine) and General Surgery Procedures.|Completed||Phase 3|304||Ethicon, Inc.|||||||||||||||||||2018-06-01 04:33:07.051039|2018-06-01 04:33:07.051039
NCT00196521|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-11|2005-09-13|2005-09-20|Estimate|||||||2007-12-11|2007-12-13|Estimate|January 2005||2005-01-31|March 2007|2007-03-31|March 2007||2007-03-31|||||Interventional|||A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)|A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence|Completed||N/A|300||Ethicon, Inc.|||||f||||f||||||||||2018-06-01 04:33:07.132319|2018-06-01 04:33:07.132319
NCT00196508|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-13|2005-09-13|2005-09-20|Estimate|||||||2007-10-13|2007-10-16|Estimate|April 2005||2005-04-30|June 2006|2006-06-30|January 2006||2006-01-31|||||Interventional|||A Study Comparing Topical Skin Adhesive or Sutures for Closure Due to Episiotomy or Perineal Tears Following Childbirth|A Randomized, Multi Center Study to Evaluate the Clinical Performance of Topical Skin Adhesive in Comparison to Sutures for Perineal Skin Closure Following Childbirth|Completed||Phase 3|118||Ethicon, Inc.|||||||||||||||||||2018-06-01 04:33:07.207466|2018-06-01 04:33:07.207466
NCT00196495|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-12-15|2005-09-12|2005-09-20|Estimate|||||||2006-12-15|2006-12-18|Estimate|June 2004||2004-06-30|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse|Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse|Completed||Phase 4|90||Ethicon, Inc.|||||f||||||||||||||2018-06-01 04:33:07.258007|2018-06-01 04:33:07.258007
NCT00196482|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-11|2005-09-19|2005-09-20|Estimate|||||||2006-09-11|2006-09-12|Estimate|June 2004||2004-06-30|September 2005|2005-09-30|February 2006||2006-02-28|||||Interventional|||Human Milk Fortifiers and Acid-Base Status|Impact of Human Milk Fortifiers on Acid-Base Status in Preterm Infants|Unknown status|Recruiting|N/A|30||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:33:07.302754|2018-06-01 04:33:07.302754
NCT00196469|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-22|2005-09-12|2005-09-20|Estimate|||||||2007-10-22|2007-10-23|Estimate|December 2003||2003-12-31|September 2006|2006-09-30|March 2007||2007-03-31|||||Interventional|||Impact of Heparin on the Need for Mechanical Ventilation in Neonates|Randomized Double Blind Trial Comparing Heparin and Placebo as Additives to Continuous Infusion in Intensive Care Neonates for Prevention of Ventilation|Unknown status|Recruiting|Phase 4|270|Anticipated|University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:33:07.367277|2018-06-01 04:33:07.367277
NCT00196456|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Photodynamic Lasertherapy (PDT) in Periodontal Treatment (in Vivo)|Photodynamic Lasertherapy (PDT) in Periodontal Treatment (in Vivo)|Completed||Phase 2|60||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:33:07.430763|2018-06-01 04:33:07.430763
NCT00196443|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||The Influence of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Disease|Prospective, Randomized and Explorative Controlled Study About Influences of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Insufficiency|Completed||Phase 2/Phase 3|42||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:33:07.629793|2018-06-01 04:33:07.629793
NCT00196430|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|August 2004||2004-08-31|||||Interventional|||Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute Neurodermatitis|Prospective, Controlled Three-Armed Study About Effectiveness and Compatibility of Silver-Containing Textiles for Treatment of Acute Neurodermatitis|Completed||Phase 3|32||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:33:07.733113|2018-06-01 04:33:07.733113
NCT00196417|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|November 2005||2005-11-30|||||Interventional|||The HIT-TRAP Trial|Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial|Unknown status|Active, not recruiting|Phase 4|600||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:33:07.823492|2018-06-01 04:33:07.823492
NCT00196404|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-17|2005-09-14|2005-09-20|Estimate|||||||2012-08-17|2012-08-20|Estimate|October 2004||2004-10-31|August 2012|2012-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder|A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder|Completed||Phase 2|800|Anticipated|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 04:33:07.932345|2018-06-01 04:33:07.932345
NCT00196391|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-07-29|2005-09-14|2005-09-20|Estimate|||||||2014-07-29|2014-07-30|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea|A Multicenter Study to Evaluate Induction of Withdrawal Bleeding After Administration of DR-2021 in Women With Secondary Amenorrhea|Completed||Phase 2|180|Anticipated|Teva Pharmaceutical Industries||6|||f||||f||||||||||2018-06-01 04:33:08.101746|2018-06-01 04:33:08.101746
NCT00196378|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-30|2005-09-14|2005-09-20|Estimate|||||||2013-08-30|2013-09-02|Estimate|November 2004||2004-11-30|January 2010|2010-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy|A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Synthetic Conjugated Estrogens, B (Enjuvia) 0.3 mg Tablets for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women|Completed||Phase 3|300|Anticipated|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:33:08.286404|2018-06-01 04:33:08.286404
NCT00196365|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-09|2005-09-14|2005-09-20|Estimate|||||||2014-05-09|2014-05-12|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain|A Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval Compared to Conventional Oral Contraceptive Therapy for Cyclic Pelvic Pain|Completed||Phase 3|97|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:33:08.43076|2018-06-01 04:33:08.43076
NCT00196352|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-04-07|2005-09-14|2005-09-20|Estimate|||||||2014-04-07|2014-04-08|Estimate|May 2003||2003-05-31|April 2014|2014-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.|A Prospective, Multiple Site Study to Evaluate the Safety of an Extended Cycle Combination Oral Contraceptive, Seasonique, Which Utilizes Ethinyl Estradiol During the Pill-free Interval.|Completed||Phase 3|320|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 04:33:08.544174|2018-06-01 04:33:08.544174
NCT00196339|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2013-08-27|2016-07-20|2005-09-12|2005-09-20|Estimate||||2013-08-27|2013-09-12|Estimate|2016-07-20|2016-07-22|Estimate|June 2005||2005-06-30|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients|A Dose-ranging Clinical Trial to Study the Efficacy and Safety of DR-2031 for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients|Completed||Phase 2|315|Actual|Teva Pharmaceutical Industries||4|||f||||t||||||||||2018-06-01 04:33:08.675077|2018-06-01 04:33:08.675077
NCT00196326|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-11-21||2016-09-28|2005-09-14|2005-09-20|Estimate|2009-03-12|2009-04-15|Estimate||||2016-09-28|2016-11-16|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional||Safety population|Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive|A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose, Combination Oral Contraceptive, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle|Completed||Phase 3|2235|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-06-01 04:33:08.960594|2018-06-01 04:33:08.960594
NCT00196313|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-10-12||2016-08-16|2005-09-12|2005-09-20|Estimate|2012-04-25|2012-05-25|Estimate||||2016-08-16|2016-09-22|Estimate|May 2005||2005-05-31|August 2016|2016-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain|A Multicenter Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval to Placebo for the Treatment of Cyclic Pelvic Pain in Adolescents|Completed||Phase 2|95|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:33:09.289915|2018-06-01 04:33:09.289915
NCT00196300|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-09|2005-09-13|2005-09-20|Estimate|||||||2018-03-09|2018-03-12|Actual|January 1995||1995-01-31|September 2005|2005-09-30||||||||Observational|||Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Eldery|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Eldery|Completed|||500||Deutsches Herzzentrum Muenchen|||||f||||||||||||||2018-06-01 04:33:09.597191|2018-06-01 04:33:09.597191
NCT00196287|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-09|2005-09-13|2005-09-20|Estimate|||||||2018-03-09|2018-03-12|Actual|January 1995||1995-01-31|September 2005|2005-09-30||||||||Observational|||Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Female Patients|Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Female Patients|Completed|||750||Deutsches Herzzentrum Muenchen|||||f||||||||||||||2018-06-01 04:33:09.668116|2018-06-01 04:33:09.668116
NCT00196274|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-09|2005-09-13|2005-09-20|Estimate|||||||2018-03-09|2018-03-12|Actual|May 2000||2000-05-31|September 2005|2005-09-30||||||||Observational|||Autonomic Regulation Trial (ART)|Autonomic Regulation Trial (ART)|Completed|||1000||Deutsches Herzzentrum Muenchen|||||f||||||||||||||2018-06-01 04:33:09.728954|2018-06-01 04:33:09.728954
NCT00196222|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-03|2005-09-19|2005-09-20|Estimate|||||||2013-07-03|2013-07-04|Estimate|March 2003||2003-03-31|July 2013|2013-07-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|||European Multicenter Study Radiofrequency (RF) Versus Cryo in Atrioventricular Nodal Reentry Tachycardia (AVNRT)|European Multicenter Study RF Versus Cryo in AVNRT: A Randomized Study Comparing Cryo-Energy vs. Radiofrequency-Energy Ablation Technique for AV Nodal Reentry Tachycardia (AVNRT)|Completed||Phase 4|509|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:33:10.145512|2018-06-01 04:33:10.145512
NCT00196209|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-18|2005-09-19|2005-09-20|Estimate|||||||2008-03-18|2008-03-19|Estimate|August 2005||2005-08-31|March 2008|2008-03-31|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation|Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation|Unknown status|Recruiting|Phase 4|130|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:33:10.25335|2018-06-01 04:33:10.25335
NCT00196196|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-11-04||2012-05-22|2005-09-12|2005-09-20|Estimate|2008-12-02|2008-12-05|Estimate||||2012-05-22|2012-05-28|Estimate|September 2004||2004-09-30|February 2011|2011-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.|A Precision and Accuracy Study of the Codman Valve Position Verification (VPV) System.|Completed||Phase 3|274|Actual|Codman & Shurtleff|||||f||||f||||||||||2018-06-01 04:33:10.345503|2018-06-01 04:33:10.345503
NCT00196183|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-14|2005-09-19|2005-09-20|Estimate|||||||2008-03-14|2008-03-18|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|June 2006|Actual|2006-06-30|||||Interventional|||Trigger- vs. Substrate-Ablation for Paroxysmal Atrial Fibrillation|Randomized Study Comparing Pulmonary Vein Isolation Alone vs. Pulmonary Vein Isolation Plus Electrogram-Guided Substrate Ablation|Completed||Phase 4|98|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:33:10.507916|2018-06-01 04:33:10.507916
NCT00196170|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-18|2005-09-19|2005-09-20|Estimate|||||||2008-03-18|2008-03-19|Estimate|May 2003||2003-05-31|March 2008|2008-03-31|July 2008|Anticipated|2008-07-31|April 2008|Anticipated|2008-04-30||Interventional|||Randomized Study of Radiofrequency- vs. Cryo-Ablation for Typical Isthmus-Dependent Atrial Flutter|Multicenter Prospective Randomized Clinical Study Comparing Radiofrequency- vs. Cryo-Ablation in Typical Isthmus-Dependent Atrial Flutter|Unknown status|Active, not recruiting|Phase 4|500|Anticipated|Deutsches Herzzentrum Muenchen||4|||f||||t||||||||||2018-06-01 04:33:10.65084|2018-06-01 04:33:10.65084
NCT00196157|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-28|2005-09-19|2005-09-20|Estimate|||||||2009-05-28|2009-05-29|Estimate|August 2004||2004-08-31|May 2009|2009-05-31|November 2008|Anticipated|2008-11-30|May 2008|Anticipated|2008-05-31||Interventional|||Line Versus Spot Ablation in Persistent Atrial Fibrillation|Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation|Unknown status|Recruiting|Phase 4|116|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:33:10.751912|2018-06-01 04:33:10.751912
NCT00196144|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-23|2005-09-12|2005-09-20|Estimate|||||||2007-11-23|2007-11-26|Estimate|July 2002||2002-07-31|November 2007|2007-11-30|April 2004|Actual|2004-04-30|||||Interventional|||FFS - Far Field Sensing Test Study in Cardiac Dual Chamber Pacemakers|Far Field Sensing Test Study in Patients With Implanted Cardiac Dual Chamber Pacemakers|Completed||Phase 4|207|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:33:10.857287|2018-06-01 04:33:10.857287
NCT00196131|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-08|2005-09-12|2005-09-20|Estimate|||||||2008-04-08|2008-04-10|Estimate|January 2005||2005-01-31|September 2006|2006-09-30|April 2008|Anticipated|2008-04-30|||||Interventional|||Problems With Morphine Use in Patients With a Severe Brain Injury|Changes in Morphine Handling and Response in Patients With Brain Trauma|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Actual|Dalhousie University||1|||f||||f||||||||||2018-06-01 04:33:10.950773|2018-06-01 04:33:10.950773
NCT00196118|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-07|2005-09-12|2005-09-20|Estimate|||||||2007-12-07|2007-12-11|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|July 2007||2007-07-31|||||Interventional|||Study of IVC Filter Retrieval With the Günther Tulip Vena Cava Filter|A Non-Randomized Prospective Study of IVC Filter Retrieval|Completed||Phase 4|800||Cook Group Incorporated|||||f||||||||||||||2018-06-01 04:33:11.039115|2018-06-01 04:33:11.039115
NCT00196105|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-09-25||2011-09-28|2005-09-12|2005-09-20|Estimate|2010-01-11|2010-01-12|Estimate||||2011-09-28|2011-10-03|Estimate|September 2003||2003-09-30|September 2011|2011-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)|Multicenter Prospective Randomized Controlled Trial of the Nitinol ZILVER Expandable Endoprosthesis in the Palliation of Extrahepatic Malignant Biliary Obstruction|Completed||N/A|241|Actual|Cook Group Incorporated||3|||f||||||||||||||2018-06-01 04:33:11.141499|2018-06-01 04:33:11.141499
NCT00196092|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-11|2005-09-13|2005-09-20|Estimate|||||||2015-03-11|2015-03-12|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|July 2006|Actual|2006-07-31|||||Interventional|||Zenith® AAA Endovascular Graft Clinical Study|Zenith® AAA Endovascular Graft Clinical Study|Completed||N/A|819|Actual|Cook Group Incorporated||8|||||||||||||||||2018-06-01 04:33:11.640442|2018-06-01 04:33:11.640442
NCT00196079|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-01-30|2005-09-12|2005-09-20|Estimate|||||||2012-01-30|2012-02-01|Estimate|February 2000||2000-02-29|January 2012|2012-01-31|August 2001||2001-08-31|||||Interventional|||The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial|The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial|Completed||N/A|177||Cook Group Incorporated|||||f||||||||||||||2018-06-01 04:33:11.724669|2018-06-01 04:33:11.724669
NCT00196066|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-01-30|2005-09-12|2005-09-20|Estimate|||||||2012-01-30|2012-02-01|Estimate|October 2002||2002-10-31|January 2012|2012-01-31|April 2006||2006-04-30|||||Interventional|||Evaluation of the Zilver Vascular Stent in the Iliac Arteries (ZIPS)||Completed||Phase 2|150||Cook Group Incorporated|||||||||||||||||||2018-06-01 04:33:11.779318|2018-06-01 04:33:11.779318
NCT00196053|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-30|2005-09-13|2005-09-20|Estimate|||||||2012-04-30|2012-05-02|Estimate|March 2005||2005-03-31|April 2012|2012-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||The Effectiveness of Pain Management Using the ARCHIMEDES® Constant-Flow Infusion Pump System for Intrathecal Delivery|Observational Registry: The Effectiveness of Pain Management Using the ARCHIMEDES® Implantable Constant-Flow Infusion Pump System for Intrathecal Delivery|Completed||Phase 4|55|Actual|Codman & Shurtleff|||||f||||f||||||||||2018-06-01 04:33:11.832297|2018-06-01 04:33:11.832297
NCT00196040|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-18|2005-09-12|2005-09-20|Estimate|||||||2007-12-18|2007-12-24|Estimate|October 2005||2005-10-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness|Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness|Completed||N/A|60||Cierra|||||f||||||||||||||2018-06-01 04:33:11.902106|2018-06-01 04:33:11.902106
NCT00194506|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-04-12|2005-09-12|2005-09-19|Estimate|||||||2006-04-12|2006-04-14|Estimate|August 2002||2002-08-31|April 2006|2006-04-30|May 2006||2006-05-31|||||Interventional|||Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home|Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home|Completed||N/A|82||University of Washington|||||f||||||||||||||2018-06-01 04:33:46.575935|2018-06-01 04:33:46.575935
NCT00196027|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-27|2005-09-19|2005-09-20|Estimate|||||||2006-11-27|2006-11-29|Estimate|April 2005||2005-04-30|November 2006|2006-11-30||||||||Interventional|||Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism|Feasibility Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism|Unknown status|Active, not recruiting|N/A|40||Cierra|||||f||||||||||||||2018-06-01 04:33:11.95081|2018-06-01 04:33:11.95081
NCT00196014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-07-31|2005-09-12|2005-09-20|Estimate|||||||2009-07-31|2009-08-04|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|IWPS-R||Individual Workload Perception Scale - Revised (IWPS-R)|Evaluation of a Tool to Measure a Nurse's Individual Perception of Workload|Unknown status|Enrolling by invitation||12000|Anticipated|Children's Mercy Hospital Kansas City|||||f||||t||||||||||2018-06-01 04:33:12.004824|2018-06-01 04:33:12.004824
NCT00196001|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-02-16|2005-09-12|2005-09-20|Estimate|||||||2007-02-16|2007-02-19|Estimate|July 2005||2005-07-31|February 2006|2006-02-28||||||||Observational|||ACTH Stimulation and G Protein|G Protein Expression in Response to ACTH Stimulation Testing|Unknown status|Recruiting||40||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:33:12.06096|2018-06-01 04:33:12.06096
NCT00195988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-16|2005-09-12|2005-09-20|Estimate|||||||2005-11-16|2005-11-17|Estimate|September 2002||2002-09-30|June 2005|2005-06-30|July 2006||2006-07-31|||||Interventional|||Comparison of Immunosuppression Protocols After LTx in Children|Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy|Completed||Phase 4|40||Children's Memorial Health Institute, Poland|||||f||||||||||||||2018-06-01 04:33:12.240094|2018-06-01 04:33:12.240094
NCT00195975|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-06-27|2005-09-14|2005-09-20|Estimate|||||||2011-06-27|2011-06-28|Estimate|June 2005||2005-06-30|June 2011|2011-06-30|March 2009|Actual|2009-03-31|August 2008|Actual|2008-08-31||Observational|||Heart Rate Variability in Children With a Functional Gastrointestinal Disorder|Heart Rate Variability in Children With Abdominal Pain Related to a Functional Gastrointestinal Disorder: Relationship to Anxiety/Stress, Electrogastrography, and Rapid Water Loading|Completed|||44|Actual|Children's Mercy Hospital Kansas City|||2||f||||f||||||||||2018-06-01 04:33:12.30265|2018-06-01 04:33:12.30265
NCT00195962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-17|2005-09-13|2005-09-20|Estimate|||||||2008-12-17|2008-12-18|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Risk Factors of Breastfeeding Study|Identification of Risk Factors Among Breast-Fed Infants|Completed|||1500|Anticipated|Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:33:12.380865|2018-06-01 04:33:12.380865
NCT00195949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-05|2005-09-12|2005-09-20|Estimate|||||||2007-04-05|2007-04-06|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|February 2006|Actual|2006-02-28|||||Interventional|||Laparoscopic Versus Open Pyloromyotomy for Infants With Idiopathic Hypertrophic Pyloric Stenosis|Laparoscopic Versus Open Pyloromyotomy for Infants With Idiopathic Hypertrophic Pyloric Stenosis|Completed||Phase 3|200||Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 04:33:12.439856|2018-06-01 04:33:12.439856
NCT00195936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-22|2005-09-13|2005-09-20|Estimate|||||||2007-10-22|2007-10-23|Estimate|June 2005||2005-06-30|August 2005|2005-08-31||||||||Interventional|||Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets|Effect of Calcimimetic (Cinacalcet) on Phosphate-Induced Hyperparathyroidism in Children With Hypophosphatemic Rickets|Unknown status|Recruiting|Phase 1|||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:33:12.502703|2018-06-01 04:33:12.502703
NCT00195923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-05|2005-09-12|2005-09-20|Estimate|||||||2007-04-05|2007-04-06|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|January 2007|Actual|2007-01-31|||||Observational|||Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis|Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis|Completed|||100||Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 04:33:12.56318|2018-06-01 04:33:12.56318
NCT00195910|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-20|Estimate|||||||2005-09-12|2005-09-20|Estimate|October 2004||2004-10-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Safety and Efficacy Study of Hydromorphone and Morphine|Safety and Efficacy of Hydromorphone as an Analgesic Alternative to Morphine in Acute, Severe Pain: A Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 4|198||Chang, Andrew, M.D.|||||f||||||||||||||2018-06-01 04:33:12.62357|2018-06-01 04:33:12.62357
NCT00195897|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-08-19|2005-09-12|2005-09-20|Estimate|||||||2016-08-19|2016-08-22|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX)|Early Assessment of Anthracycline-induced Cardiotoxicity: Usefulness of Biochemical Markers and Ventricular Function Assessment.|Terminated|||6|Actual|Centre Henri Becquerel||||No patients; only 6 enrolled after 2 years|f||||f||||||||No||2018-06-01 04:33:12.684222|2018-06-01 04:33:12.684222
NCT00195884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-01-22|2005-09-19|2005-09-20|Estimate|||||||2013-01-22|2013-01-23|Estimate|September 1999||1999-09-30|January 2013|2013-01-31|April 2011|Actual|2011-04-30|March 2005|Actual|2005-03-31||Interventional|||Diabetes Aerobic and Resistance Exercise (DARE) Study|Resistance Exercise as an Intervention in Type 2 Diabetes Mellitus|Completed||N/A|251|Actual|Ottawa Hospital Research Institute||4|||f||||f||||||||||2018-06-01 04:33:12.750311|2018-06-01 04:33:12.750311
NCT00195871|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-06|2005-09-12|2005-09-20|Estimate|||||||2013-11-06|2013-11-07|Estimate|February 2004||2004-02-29|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma|A Multicenter, Phase 2 Study, to Evaluate Safety and Efficacy of an Acute Lymphoblastic Leukemia (ALL) Intensive Chemotherapy for Adult Lymphoblastic Lymphoma (LL).|Unknown status|Active, not recruiting|Phase 2|155|Actual|Centre Henri Becquerel|||||f||||f||||||||||2018-06-01 04:33:12.839388|2018-06-01 04:33:12.839388
NCT00195858|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-04-20|2005-09-12|2005-09-20|Estimate|||||||2015-04-20|2015-04-22|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|June 2011|Actual|2011-06-30|November 2010|Actual|2010-11-30||Interventional|||Healthy Eating Aerobic and Resistance Training in Youth (HEARTY) Trial|Healthy Eating, Aerobic and Resistance Training in Youth (HEARTY) Trial|Completed||Phase 2/Phase 3|304|Actual|Ottawa Hospital Research Institute||4|||f||||f||||||||||2018-06-01 04:33:12.932756|2018-06-01 04:33:12.932756
NCT00195845|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-17|2005-09-12|2005-09-20|Estimate|||||||2017-04-17|2017-04-18|Actual|April 2003||2003-04-30|April 2017|2017-04-30|February 2007|Actual|2007-02-28|September 2006|Actual|2006-09-30||Interventional|||A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder|A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder|Completed||Phase 4|30|Anticipated|Cambridge Health Alliance||2|||f||||f||||||||||2018-06-01 04:33:13.0115|2018-06-01 04:33:13.0115
NCT00195819|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|2009-12-17||2011-06-24|2005-09-16|2005-09-20|Estimate|2010-04-07|2010-04-28|Estimate||||2011-06-24|2011-06-28|Estimate|December 2003||2003-12-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|October 2004|Actual|2004-10-31||Interventional|||Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis|A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis|Completed||Phase 3|82|Actual|Abbott|The modified SASSS was pooled with a study (NCT00085644) similar in structure and sharing the same endpoints as this study.|2|||f||||f||||||||||2018-06-01 04:33:13.151854|2018-06-01 04:33:13.151854
NCT00195806|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-08-30|2005-09-14|2005-09-20|Estimate|||||||2007-08-30|2007-09-03|Estimate|February 2005||2005-02-28|August 2007|2007-08-31||||||||Interventional|||Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine|Divalproex Sodium Extended-Release Tablets for Migraine Prophylaxis in Adolescents: An Open-Label, Long-Term Safety Study|Completed||Phase 3|315||Abbott|||||||||||||||||||2018-06-01 04:33:15.556665|2018-06-01 04:33:15.556665
NCT00195793|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-10-02|2005-09-14|2005-09-20|Estimate|||||||2007-10-02|2007-10-04|Estimate|August 2004||2004-08-31|October 2007|2007-10-31||||||||Interventional|||A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin|A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of Fenofibrate or Ezetimibe as Add-On Therapy to Atorvastatin in Subjects With Combined Hyperlipidemia, Typical of the Metabolic Syndrome|Completed||Phase 3|174|Actual|Abbott|||||f||||f||||||||||2018-06-01 04:33:15.651154|2018-06-01 04:33:15.651154
NCT00195780|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-06-29|2005-09-14|2005-09-20|Estimate|||||||2007-06-29|2007-07-02|Estimate|February 2005||2005-02-28|June 2007|2007-06-30||||||||Interventional|||A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents|An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents|Completed||Phase 3|227|Actual|Abbott|||||||||||||||||||2018-06-01 04:33:15.869146|2018-06-01 04:33:15.869146
NCT00195767|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-03-17|2005-09-14|2005-09-20|Estimate|||||||2007-03-17|2007-03-19|Estimate|July 2004||2004-07-31|March 2007|2007-03-31||||||||Interventional|||Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents|An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents|Completed||Phase 3|150||Abbott|||||||||||||||||||2018-06-01 04:33:15.983317|2018-06-01 04:33:15.983317
NCT00195754|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-30|2005-09-13|2005-09-20|Estimate|||||||2007-07-30|2007-07-31|Estimate|July 2004||2004-07-31|July 2007|2007-07-31||||||||Interventional|||A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.|The Safety of Divalproex Sodium Extended Release Tablets in Migraine Prophylaxis: An Open-Label Extension Study in Adolescents|Completed||Phase 3|114|Actual|Abbott|||||f||||||||||||||2018-06-01 04:33:16.052562|2018-06-01 04:33:16.052562
NCT00195741|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-02-07|2005-09-13|2005-09-20|Estimate|||||||2007-02-07|2007-02-08|Estimate|May 2003||2003-05-31|February 2007|2007-02-28||||||||Interventional|||The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents|Phase III, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Center Study Designed to Evaluate the Safety and Efficacy of Prophylactic Depakote ER in the Treatment of Adolescent Migraine|Completed||Phase 3|300||Abbott|||||||||||||||||||2018-06-01 04:33:16.115143|2018-06-01 04:33:16.115143
NCT00195728|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-17|2005-09-13|2005-09-20|Estimate|||||||2011-01-17|2011-01-19|Estimate|June 2005||2005-06-30|January 2011|2011-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain|An Open-Label Study Evaluating the Safety and Tolerability of Long Term Administration of Hydrocodone/Acetaminophen Extended ReleaseTablets (Vicodin® CR) in Subjects With Moderate to Severe Chronic, Non-Malignant Pain|Completed||Phase 3|431|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:33:16.191997|2018-06-01 04:33:16.191997
NCT00195715|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-12-01||2011-07-08|2005-09-13|2005-09-20|Estimate|2009-12-01|2010-01-07|Estimate||||2011-07-08|2011-07-12|Estimate|September 2004||2004-09-30|July 2011|2011-07-31|December 2008|Actual|2008-12-31|March 2006|Actual|2006-03-31||Interventional|||Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease|A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease|Completed||Phase 3|777|Actual|Abbott|This study was stopped by the sponsor in December 2008 when the pre-specified termination criteria were met. Subjects who continued in the study through the termination date were considered as having completed the study.||||f||||||||||||||2018-06-01 04:33:16.430622|2018-06-01 04:33:16.430622
NCT00195702|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-12-08||2011-08-23|2005-09-13|2005-09-20|Estimate|2010-02-02|2010-03-01|Estimate||||2011-08-23|2011-08-26|Estimate|February 2000||2000-02-29|August 2011|2011-08-31|August 2010|Actual|2010-08-31|September 2002|Actual|2002-09-30||Interventional|||Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate|Completed||Phase 3|619|Actual|Abbott||6|||f||||t||||||||||2018-06-01 04:33:17.676028|2018-06-01 04:33:17.676028
NCT00195689|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-28|2005-09-13|2005-09-20|Estimate|||||||2007-08-28|2007-08-29|Estimate|August 2003||2003-08-31|August 2007|2007-08-31||||||||Interventional|||Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis|A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis|Completed||Phase 3|400||Abbott|||||f||||f||||||||||2018-06-01 04:33:20.580334|2018-06-01 04:33:20.580334
NCT00195676|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-10-20||2011-04-11|2005-09-13|2005-09-20|Estimate|2010-10-20|2010-11-19|Estimate||||2011-04-11|2011-04-13|Estimate|May 2004||2004-05-31|April 2011|2011-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab|Completed||Phase 3|1469|Actual|Abbott||1|||f||||||||||||||2018-06-01 04:33:20.744569|2018-06-01 04:33:20.744569
NCT00195481|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-21|2005-09-13|2005-09-19|Estimate|||||||2007-12-21|2007-12-28|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study Evaluating Sirolimus in Kidney Transplant Recipients in India|A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation.|Completed||Phase 4|100||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:30.31809|2018-06-01 04:33:30.31809
NCT00195663|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-12-08||2013-06-07|2005-09-13|2005-09-20|Estimate|2010-02-02|2010-02-25|Estimate||||2013-06-07|2013-07-12|Estimate|December 2000||2000-12-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|April 2004|Actual|2004-04-30||Interventional|PREMIER||Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis|A Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week With Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in Patients With Early Rheumatoid Arthritis (PREMIER).|Completed||Phase 3|799|Actual|AbbVie||3|||f||||f||||||||||2018-06-01 04:33:21.747091|2018-06-01 04:33:21.747091
NCT00195650|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-05-04||2012-08-24|2005-09-13|2005-09-20|Estimate|2012-06-26|2012-07-31|Estimate||||2012-08-24|2012-08-31|Estimate|July 2000||2000-07-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Long Term Open Label Continuation Study|A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis|Completed||Phase 3|846|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:33:25.400136|2018-06-01 04:33:25.400136
NCT00195637|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-18|||2018-05-23|2005-09-17|2005-09-19|Estimate|||||||2018-05-23|2018-05-24|Actual|September 16, 2005||2005-09-16|May 22, 2018|2018-05-22|July 3, 2006|Actual|2006-07-03|July 3, 2006|Actual|2006-07-03||Interventional|||Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy|Pilot Study of the Use of Intravenous Immune Globulin in Hereditary Inclusion Body Myopathy|Completed||Phase 1|4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:33:26.561629|2018-06-01 04:33:26.561629
NCT00195624|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-16|||2018-05-23|2005-09-16|2005-09-19|Estimate|||||||2018-05-23|2018-05-24|Actual|September 15, 2005||2005-09-15|December 19, 2017|2017-12-19|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Alemtuzumab to Treat Severe Aplastic Anemia|A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia|Active, not recruiting||Phase 2|47|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:33:26.631259|2018-06-01 04:33:26.631259
NCT00195611|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-27|2005-09-15|2005-09-19|Estimate|||||||2010-06-27|2010-06-29|Estimate|September 2005||2005-09-30|June 2010|2010-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media|Observational Study of the Rhinopharyngeal Carriage of Streptococcus Pneumoniae (Sp) in Infants With Acute Otitis Media (AOM)|Completed|||3293|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:26.730922|2018-06-01 04:33:26.730922
NCT00195598|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-04-01|2005-09-16|2005-09-19|Estimate|||||||2010-04-01|2010-04-02|Estimate|January 2005||2005-01-31|March 2010|2010-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder|Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.|Completed||Phase 3|70|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:26.898728|2018-06-01 04:33:26.898728
NCT00195585|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-08-12|2005-09-15|2005-09-19|Estimate|||||||2009-08-12|2009-08-13|Estimate|October 2002||2002-10-31|August 2009|2009-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Study Evaluating Isovorin in Colon Cancer|Post-Approved Phase III Study of 1-LV/5FU Therapy|Completed||Phase 3|650||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:27.005475|2018-06-01 04:33:27.005475
NCT00195572|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-08-12|2005-09-15|2005-09-19|Estimate|||||||2009-08-12|2009-08-13|Estimate|May 2002||2002-05-31|August 2009|2009-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer|Post-Approved Phase III Study of 1-LV/5FU Therapy|Completed||Phase 3|200|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:27.085034|2018-06-01 04:33:27.085034
NCT00195559|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-18|2005-09-15|2005-09-19|Estimate|||||||2007-12-18|2007-12-27|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder|Completed||Phase 3|526|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:27.220465|2018-06-01 04:33:27.220465
NCT00195546|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-31|2005-09-13|2005-09-19|Estimate|||||||2007-05-31|2007-06-01|Estimate|April 2005||2005-04-30|May 2007|2007-05-31|January 2006|Actual|2006-01-31|||||Interventional|||Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause|Completed||Phase 3|465|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:33:27.373156|2018-06-01 04:33:27.373156
NCT00195533|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-11-13|2005-09-15|2005-09-19|Estimate|||||||2009-11-13|2009-11-16|Estimate|July 2001||2001-07-31|November 2009|2009-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Observational|||Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients|Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study.|Completed|||801|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||Samples Without DNA|"~     Whole blood~   "|||2018-06-01 04:33:27.480998|2018-06-01 04:33:27.480998
NCT00195520|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-08-01|2005-09-13|2005-09-19|Estimate|||||||2008-08-01|2008-08-05|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Study Evaluating Totelle® in Menopausal Symptoms and Sexual Function|An Open Assessment of the Effect of Low-Dose Totelle® 1 mg on Menopausal Symptoms, Sexual Function and Quality of Life|Completed||Phase 4|100|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:27.556829|2018-06-01 04:33:27.556829
NCT00195507|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-03-31||2013-02-20|2005-09-13|2005-09-19|Estimate|2010-04-07|2010-05-04|Estimate||||2013-02-20|2013-02-25|Estimate|December 2004||2004-12-31|April 2010|2010-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis|A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis|Completed||Phase 4|720|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:27.656835|2018-06-01 04:33:27.656835
NCT00195494|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-03-31||2012-08-01|2005-09-13|2005-09-19|Estimate|2012-08-01|2012-09-05|Estimate||||2012-08-01|2012-09-05|Estimate|November 2004||2004-11-30|August 2012|2012-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis|A 24-Month,Randomized,Double-Blind,Two-Period Study to Evaluate the Efficacy and Safety of the Combination of Etanercept and Methotrexate and Methotrexate Alone in Subjects With Early Rheumatoid Arthritis|Completed||Phase 4|542|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-06-01 04:33:28.82133|2018-06-01 04:33:28.82133
NCT00195468|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-07|2005-09-13|2005-09-19|Estimate|||||||2011-03-07|2011-03-08|Estimate|March 2004||2004-03-31|December 2007|2007-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus|A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune.|Completed||Phase 4|280|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:30.373659|2018-06-01 04:33:30.373659
NCT00195455|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-17|2005-09-13|2005-09-19|Estimate|||||||2007-12-17|2007-12-20|Estimate|February 2005||2005-02-28|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Interventional|||Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.|A Prospective Open Label Study to Evaluate Vasomotor Symptoms Control and Bleeding Patterns With a Continuous Regimen of a New Progestin Trimegestone 0.125 mg and 17 b Estradiol 1 mg (Totelle),as HT on Postmenopausal Women|Completed||Phase 4|133|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:30.436143|2018-06-01 04:33:30.436143
NCT00195442|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-01-12||2011-02-07|2005-09-13|2005-09-19|Estimate|2011-01-12|2011-02-07|Estimate||||2011-02-07|2011-02-11|Estimate|July 1999||1999-07-31|February 2011|2011-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Study Evaluating Refacto For Pharmacovigilance|Pharmacovigilance Evaluation Of Refacto In Usual Care Settings|Completed|||288|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 04:33:30.516549|2018-06-01 04:33:30.516549
NCT00195429|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-12-19||2010-04-22|2005-09-16|2005-09-19|Estimate|2009-04-06|2009-06-02|Estimate||||2010-04-22|2010-04-28|Estimate|August 2005||2005-08-31|April 2010|2010-04-30|October 2007|Actual|2007-10-31|||||Interventional|||A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients|A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients|Completed||Phase 4|47|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 04:33:31.369789|2018-06-01 04:33:31.369789
NCT00195416|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-09-15|2005-09-13|2005-09-19|Estimate|||||||2009-09-15|2009-09-16|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Study Investigating Enbrel Treatment for Ankylosing Spondylitis|A Drug Use Investigation of Enbrel for Post-marketing Surveillance (PMS) for Ankylosing Spondylitis|Completed|||526|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-06-01 04:33:31.568029|2018-06-01 04:33:31.568029
NCT00195403|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-06-11||2013-06-11|2005-09-13|2005-09-19|Estimate|2013-06-11|2013-08-15|Estimate||||2013-06-11|2013-08-15|Estimate|May 2004||2004-05-31|June 2013|2013-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational||Safety population included all participants who received at least (>=) 1 dose of study medication and had the safety assessment through appropriate follow-up.|A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA|A Drug Use Investigation of Enbrel for Post-Marketing Surveillance|Completed|||1014|Actual|Pfizer|||1||f||||f||||||||||2018-06-01 04:33:31.641206|2018-06-01 04:33:31.641206
NCT00195390|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-24|2005-09-13|2005-09-19|Estimate|||||||2008-09-24|2008-09-25|Estimate|July 2004||2004-07-31|September 2008|2008-09-30|July 2008|Actual|2008-07-31|||||Observational|||Study Investigating Administration of Prevenar for Post-Marketing Surveillance|Investigation of Prevenar (Pneumococcal 7-Valent Conjugate Vaccine) Administration for Post-Marketing Surveillance|Completed|||600|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:31.917664|2018-06-01 04:33:31.917664
NCT00195377|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-17|2005-09-13|2005-09-19|Estimate|||||||2009-06-17|2009-06-18|Estimate|April 2003||2003-04-30|June 2009|2009-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain|Evaluating Safety and QoL in Patients Treated With Etanercept: an Open Multicenter Study|Completed|||1000||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:31.976965|2018-06-01 04:33:31.976965
NCT00195364|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-03|2005-09-13|2005-09-19|Estimate|||||||2009-06-03|2009-06-04|Estimate|July 2003||2003-07-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Study Evaluating Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain|Long-Term Safety Study of Etanercept in Patients With Rheumatoid Arthritis Who Completed Trial 0881A1-301-EU in Spain|Completed|||93||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:32.025422|2018-06-01 04:33:32.025422
NCT00195351|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-02-27||2013-02-20|2005-09-16|2005-09-19|Estimate|2009-04-16|2009-06-10|Estimate||||2013-02-20|2013-02-25|Estimate|September 2005||2005-09-30|February 2013|2013-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection|A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection|Completed||Phase 4|467|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||||||||||||2018-06-01 04:33:32.273218|2018-06-01 04:33:32.273218
NCT00195338|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-12-16||2011-12-16|2005-09-13|2005-09-19|Estimate|2011-12-16|2012-01-23|Estimate||||2011-12-16|2012-01-23|Estimate|May 2004||2004-05-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg|A Post-Marketing Surveillance Looking At Safety And Adherence To Treatment Of Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg|Completed|||25|Actual|Pfizer|||1||f||||t||||||||||2018-06-01 04:33:32.852691|2018-06-01 04:33:32.852691
NCT00195325|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-22|2005-09-16|2005-09-19|Estimate|||||||2007-03-22|2007-03-26|Estimate|August 2005||2005-08-31|March 2007|2007-03-31||||||||Interventional|||Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.|A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously (IV) Once Weekly in Subjects With Advanced Malignant Solid Tumors.|Terminated||Phase 1|45||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:33:33.073205|2018-06-01 04:33:33.073205
NCT00195312|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2007-12-03|2005-09-12|2005-09-19|Estimate|||||||2007-12-03|2007-12-05|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Evaluating Vaccine in Adults With HIV|A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine Administered Alone or With Escalating Doses of IL-12 DNA or IL-15 DNA Molecular Adjuvants to HIV-1 Positive Adults Receiving Stable HAART.|Terminated||Phase 1|91|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:33:33.131184|2018-06-01 04:33:33.131184
NCT00194740|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-12-03|2005-09-14|2005-09-19|Estimate|||||||2007-12-03|2007-12-06|Estimate|November 1997||1997-11-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer|Taxotere Plus Weekly Navelbine and G-CSF: A Phase II Study in Stage IV Breast Cancer|Completed||Phase 2|48|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:44.617301|2018-06-01 04:33:44.617301
NCT00195299|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-18|2005-09-12|2005-09-19|Estimate|||||||2007-12-18|2007-12-27|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Observational|||Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck|An Exploratory Biomarker Trail of Temsirolimus in Subjects With Newly Diagnosed Advanced Stage Squamous Cell Carcinoma of the Head & Neck|Completed|||20||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:33.211719|2018-06-01 04:33:33.211719
NCT00195286|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-09-24|2005-09-12|2005-09-19|Estimate|||||||2009-09-24|2009-09-25|Estimate|June 2004||2004-06-30|September 2009|2009-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.|Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.|Completed|||180|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:33.266778|2018-06-01 04:33:33.266778
NCT00195273|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-07-31||2010-04-22|2005-09-12|2005-09-19|Estimate|2009-07-31|2009-09-07|Estimate||||2010-04-22|2010-04-28|Estimate|November 2004||2004-11-30|April 2010|2010-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating Sirolimus in Kidney Transplant Recipients|A Randomized Open-Label Study Comparing the Efficacy and Safety of Sirolimus Combined With Daclizumab, Mycophenolate and Corticosteroids vs Cyclosporine, Mycophenolate and Corticosteroids in Renal Allograft Recipients Receiving Kidneys From Older Donors|Completed||Phase 3|61|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 04:33:33.389798|2018-06-01 04:33:33.389798
NCT00195260|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-10-04||2013-01-03|2005-09-12|2005-09-19|Estimate|2013-01-03|2013-02-11|Estimate||||2013-01-03|2013-02-11|Estimate|October 2004||2004-10-31|January 2013|2013-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors|Phase I Dose-Escalation Study Of Oral SKI-606 In Subjects With Advanced Malignant Solid Tumors|Completed||Phase 1|151|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 04:33:34.133834|2018-06-01 04:33:34.133834
NCT00195247|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-22|2005-09-12|2005-09-19|Estimate|||||||2007-03-22|2007-03-26|Estimate|May 2005||2005-05-31|March 2007|2007-03-31||||||||Interventional|||Study Evaluating TTI-237 in Advanced Malignant Solid Tumors|A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors|Terminated||Phase 1|45||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:33:38.567396|2018-06-01 04:33:38.567396
NCT00195234|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-03|2005-09-12|2005-09-19|Estimate|||||||2007-12-03|2007-12-05|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Study Evaluating Vaccine in Adults With HIV|A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV CTL Multi-Epitope Peptide Vaccine Formulated With RC529-SE and GM-CSF Given to HIV-1 Positive Adults on Stable HAART.|Completed||Phase 1|60||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:33:38.65393|2018-06-01 04:33:38.65393
NCT00195221|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-03|2005-09-12|2005-09-19|Estimate|||||||2007-12-03|2007-12-05|Estimate|February 2005||2005-02-28|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Observational|||Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B|A Retrospective Study to Describe the Incidence of Moderate to Severe Allergic Reactions to Factor IX in Patients With Hemophilia B|Completed|||166||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:38.772173|2018-06-01 04:33:38.772173
NCT00195208|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-07|2005-09-12|2005-09-19|Estimate|||||||2013-02-07|2013-02-08|Estimate|June 2005||2005-06-30|February 2013|2013-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis|A Randomized, 2-Period, Crossover, Pharmacodynamic Comparability Study Comparing A Pantoprazole Spheroid Formulation to the Currently Marketed Tablet Formulation in Subjects With GERD and a History of Erosive Esophagitis.|Completed||Phase 3|97|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:33:39.811595|2018-06-01 04:33:39.811595
NCT00195195|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-01-26|2005-09-12|2005-09-19|Estimate|||||||2012-01-26|2012-01-31|Estimate|January 2005||2005-01-31|January 2012|2012-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries|"A Rapamune Follow-up Registry in Transplant Recipients in the Nordic Countries, Wrap-up"|Completed|||66|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-06-01 04:33:39.890266|2018-06-01 04:33:39.890266
NCT00195182|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-05-15|2005-09-14|2005-09-19|Estimate|||||||2008-05-15|2008-05-21|Estimate|September 2003||2003-09-30|May 2008|2008-05-31|June 2008|Anticipated|2008-06-30|||||Observational|||Psychosocial Determinants of Medication Adherence in Hypertensive African Americans|Psychosocial Determinants of Medication Adherence in Hypertensive African Americans|Unknown status|Active, not recruiting||262|Anticipated|Weill Medical College of Cornell University|||2||f||||t||||||||||2018-06-01 04:33:39.955469|2018-06-01 04:33:39.955469
NCT00195169|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2010-08-10|2005-09-15|2005-09-19|Estimate|||||||2010-08-10|2010-08-12|Estimate|July 2001||2001-07-31|August 2010|2010-08-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|||Quality of Life After Myocardial Infarction|Quality of Life After Myocardial Infarction: The Impact of Social Support|Completed|||213|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:33:40.036308|2018-06-01 04:33:40.036308
NCT00195156|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-09-12|2005-09-16|2005-09-19|Estimate|||||||2006-09-12|2006-09-14|Estimate|July 2003||2003-07-31|September 2006|2006-09-30||||||||Interventional|||Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies|Phase I Trial of ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies|Terminated||Phase 1|||Weill Medical College of Cornell University|||||||||||||||||||2018-06-01 04:33:40.102623|2018-06-01 04:33:40.102623
NCT00195143|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-03-26|2005-09-15|2005-09-19|Estimate|||||||2008-03-26|2008-03-27|Estimate|August 2003||2003-08-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease|Phase I Study of Subthalamic GAD Gene Transfer in Medically Refractory Parkinson's Disease Patients|Completed||Phase 1|12||Neurologix, Inc.|||||||||||||||||||2018-06-01 04:33:40.19625|2018-06-01 04:33:40.19625
NCT00195130|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-03-27|2005-09-15|2005-09-19|Estimate|||||||2008-03-27|2008-03-28|Estimate|January 1998||1998-01-31|March 2008|2008-03-31|January 1999||1999-01-31|||||Observational|||Prognostic Measures in Ambulatory Care Settings|Prognostic Measures in Ambulatory Care Settings|Completed|||2000||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:33:40.292554|2018-06-01 04:33:40.292554
NCT00195117|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-02-17|2005-09-14|2005-09-19|Estimate|||||||2017-02-17|2017-02-23|Actual|October 2004|Actual|2004-10-31|February 2017|2017-02-28|July 2007|Actual|2007-07-31|July 2006|Actual|2006-07-31||Interventional|||A Randomized Trial of Changing Exercise and Physical Activity Behavior in Asthma Patients|A Randomized Trial of Changing Exercise and Physical Activity Behavior in Asthma Patients|Completed||N/A|258|Actual|Weill Medical College of Cornell University||2|||f||||f|f|f||||||No|No Plan to Share IPD|2018-06-01 04:33:40.41525|2018-06-01 04:33:40.41525
NCT00195104|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-03-02|2005-09-14|2005-09-19|Estimate|||||||2017-03-02|2017-03-03|Actual|September 17, 2003|Actual|2003-09-17|March 2017|2017-03-31|June 20, 2006|Actual|2006-06-20|March 17, 2006|Actual|2006-03-17||Interventional|||Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML|Phase I/II Study of Arsenic Trioxide in Combination With Cytosine Arabinoside in Patients With High-risk Myelodysplastic Syndrome and Poor-prognosis Acute Myelogenous Leukemia|Completed||Phase 1/Phase 2|87|Actual|Weill Medical College of Cornell University||1|||f||||t|t|f||||||||2018-06-01 04:33:40.580326|2018-06-01 04:33:40.580326
NCT00195091|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-01-29|2005-09-14|2005-09-19|Estimate|||||||2018-01-29|2018-01-31|Actual|December 2003||2003-12-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer|A Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer at Moderate to High Risk of Recurrence|Active, not recruiting||Phase 2|50|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-06-01 04:33:40.678522|2018-06-01 04:33:40.678522
NCT00195078|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-07-19|2005-09-16|2005-09-19|Estimate|||||||2007-07-19|2007-07-20|Estimate|April 2004||2004-04-30|July 2007|2007-07-31|September 2006|Actual|2006-09-30|||||Interventional|||Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer|Phase I-II Study of ZD1839 (IRESSA®), Cisplatin, and External-Beam Radiation Therapy in Patients With Locally Advanced, Non-Metastatic, Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1/Phase 2|29|Anticipated|Weill Medical College of Cornell University|||||||||||||||||||2018-06-01 04:33:40.765349|2018-06-01 04:33:40.765349
NCT00195065|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-01|2005-09-13|2005-09-19|Estimate|||||||2008-04-01|2008-04-03|Estimate|April 2003||2003-04-30|April 2008|2008-04-30|September 2003||2003-09-30|||||Observational|||Cornell Translational Behavioral Science Research Consortium: Asthma Qualitative Study|Cornell Translational Behavioral Science Research Consortium: Asthma Qualitative Study|Completed|||60||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:33:40.850364|2018-06-01 04:33:40.850364
NCT00195052|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-01-26|2005-09-14|2005-09-19|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2002||2002-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Intrinsic Optical Imaging Study to Map Neocortical Seizure in Human Epilepsy Patients|Intraoperative Optical Mapping of Human Epileptiform and Functional Cortex|Recruiting|||40|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||No||2018-06-01 04:33:40.936895|2018-06-01 04:33:40.936895
NCT00195039|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2017-03-01||2017-09-06|2005-09-14|2005-09-19|Estimate|2017-09-06|2017-10-05|Actual||||2017-09-06|2017-10-05|Actual|August 2004||2004-08-31|September 2017|2017-09-30|October 2013|Actual|2013-10-31|February 2012|Actual|2012-02-29||Interventional|||Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer|A Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Androgen-Independent Prostate Cancer|Completed||Phase 2|47|Actual|Weill Medical College of Cornell University||1|||f||||||||||||No||2018-06-01 04:33:41.050055|2018-06-01 04:33:41.050055
NCT00195026|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-03-13|2005-09-14|2005-09-19|Estimate|||||||2008-03-13|2008-03-18|Estimate|March 2005||2005-03-31|March 2008|2008-03-31||||||||Observational|||Infrared Imaging (Breast Scan IR) for Early Breast Cancer Detection|Infrared Imaging (Breast Scan IR) for Early Breast Cancer Detection|Completed|||200|Anticipated|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:33:41.561583|2018-06-01 04:33:41.561583
NCT00195013|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2017-02-02||2017-07-20|2005-09-14|2005-09-19|Estimate|2017-07-20|2017-08-18|Actual||||2017-07-20|2017-08-18|Actual|December 2003||2003-12-31|July 2017|2017-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Randomized Placebo-Controlled Trial of Glutamine for Breast Cancer Patients With Peripheral Neuropathy|A Randomized Placebo-controlled Trial of Glutamine to Reduce the Signs and Symptoms of Peripheral Neuropathy in Breast Cancer Patients With a Mild Peripheral Neuropathy Receiving Paclitaxel Chemotherapy|Completed||Phase 3|30|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-06-01 04:33:41.627857|2018-06-01 04:33:41.627857
NCT00195000|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|May 2003||2003-05-31|June 2013|2013-06-30|February 2008|Actual|2008-02-29|May 2006|Actual|2006-05-31||Interventional|||Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS|Phase II Evaluation of Gemtuzumab Ozogamicin in Combination With Cytarabine in Untreated Patients Above the Age of 60 Years With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome|Completed||Phase 2|43|Actual|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:33:41.872296|2018-06-01 04:33:41.872296
NCT00194987|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-24|2005-09-13|2005-09-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 2001||2001-04-30|May 2018|2018-05-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia|A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia|Completed||Phase 2/Phase 3|101|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-06-01 04:33:41.989941|2018-06-01 04:33:41.989941
NCT00194974|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-27|2005-09-13|2005-09-19|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 2004||2004-07-31|January 2017|2017-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Treatment Targets for Chronic Hypertension in Pregnancy|Treatment Targets for Chronic Hypertension in Pregnancy|Withdrawn||Phase 1/Phase 2|0|Actual|Weill Medical College of Cornell University||||Lack of funding|f||||f||||||||No|Study terminated|2018-06-01 04:33:42.12073|2018-06-01 04:33:42.12073
NCT00194961|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-24|2005-09-12|2005-09-19|Estimate|||||||2008-03-24|2008-03-25|Estimate||||March 2008|2008-03-31|December 2007||2007-12-31|||||Interventional|||Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease|A Multicenter Study of the Effect of Recombinant Human Growth Hormone on Leptin and Cytokines in Relation to Body Composition in Pediatric Patients With Growth Failure Due to Chronic Kidney Disease (CKD)|Terminated||Phase 4|15|Anticipated|Weill Medical College of Cornell University||||Funding was not approved|f||||||||||||||2018-06-01 04:33:42.223316|2018-06-01 04:33:42.223316
NCT00194948|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-01|2005-09-12|2005-09-19|Estimate|||||||2013-11-01|2013-11-04|Estimate|September 2003||2003-09-30|November 2013|2013-11-30|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|||Treatment Choices for Improving Adherence and Outcome|Patient Preference in Primary Care Depression Treatment|Completed||N/A|60||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:33:42.294019|2018-06-01 04:33:42.294019
NCT00194935|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-12|2005-09-13|2005-09-19|Estimate|||||||2006-09-12|2006-09-13|Estimate|February 2003||2003-02-28|September 2006|2006-09-30|August 2006||2006-08-31|||||Interventional|||Weekly Topotecan Therapy in Patients With Ovarian Cancer|A Phase II Trial of Weekly Topotecan As Consolidation Therapy in Ovarian Cancer Patients After Initial Chemotherapy|Terminated||Phase 2|32||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:33:42.361225|2018-06-01 04:33:42.361225
NCT00194922|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-03|2005-09-12|2005-09-19|Estimate|||||||2008-04-03|2008-04-04|Estimate|August 2004||2004-08-31|April 2008|2008-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Tolerance and Efficacy of the Probiotic E. Coli Strain M17 on Symptoms and Quality of Life in Individuals With Irritable Bowel Syndrome (IBS)|Completed||Phase 2|35|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-06-01 04:33:42.444462|2018-06-01 04:33:42.444462
NCT00194909|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-24|2005-09-12|2005-09-19|Estimate|||||||2008-03-24|2008-03-25|Estimate|August 2004||2004-08-31|March 2008|2008-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)|An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)|Completed||Phase 4|8|Actual|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:33:42.553826|2018-06-01 04:33:42.553826
NCT00194896|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2011-02-22||2018-03-27|2005-09-14|2005-09-19|Estimate|2011-07-13|2011-08-10|Estimate||||2018-03-27|2018-03-29|Actual|February 2000||2000-02-29|March 2018|2018-03-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Preferred Treatment of Type 1.5 Diabetes|Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes|Completed||N/A|64|Actual|University of Washington|Small numbers based on high drop out of participants.|2|||f||||t||||||||||2018-06-01 04:33:42.653667|2018-06-01 04:33:42.653667
NCT00194883|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-11-17|2005-09-12|2005-09-19|Estimate|||||||2017-11-17|2017-11-21|Actual|April 1997||1997-04-30|November 2017|2017-11-30|May 2003||2003-05-31|||||Interventional|||Effect of Cytokines on Growth of Children With Chronic Kidney Failure|Cytokines and Growth in Children With CRI and ESRD|Suspended||Phase 4|50||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:33:43.100162|2018-06-01 04:33:43.100162
NCT00194870|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-01-11|2005-09-12|2005-09-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2003||2003-10-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Electroencephalography (EEG) and Deep Brain Stimulation (DBS) in Epilepsy|Electroencephalography (EEG) and Deep Brain Stimulation (DBS) in Epilepsy|Completed||N/A|5|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-06-01 04:33:43.166906|2018-06-01 04:33:43.166906
NCT00194857|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-14|2005-09-12|2005-09-19|Estimate|||||||2012-12-14|2012-12-17|Estimate|February 2002||2002-02-28|December 2012|2012-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin|A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV.|Terminated||Phase 4|||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:33:43.241478|2018-06-01 04:33:43.241478
NCT00194844|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-15|2005-09-16|2005-09-19|Estimate|||||||2008-02-15|2008-02-18|Estimate|September 2001||2001-09-30|February 2008|2008-02-29|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Couples Miscarriage Healing Project:Randomized Trial|Caring Interventions for Couples Who Have Miscarried|Completed||Phase 1/Phase 2|682|Actual|University of Washington||4|||f||||t||||||||||2018-06-01 04:33:43.325395|2018-06-01 04:33:43.325395
NCT00194831|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-11|2005-09-12|2005-09-19|Estimate|||||||2015-06-11|2015-06-15|Estimate|June 2005||2005-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Correlation of Volumetric Brain Analysis With Development at 18 Months|Volumetric Brain Analysis in the Premature Brain: Correlation With Future Development|Withdrawn|||0|Actual|Weill Medical College of Cornell University||||No data. Study never completed.|f||||||||||||||2018-06-01 04:33:43.417064|2018-06-01 04:33:43.417064
NCT00194818|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-02-13|2005-09-15|2005-09-19|Estimate|||||||2008-02-13|2008-02-15|Estimate|June 2003||2003-06-30|February 2008|2008-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Asacol Dosing Study for Active Ulcerative Colitis|Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis|Completed||Phase 4|7|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:33:43.470662|2018-06-01 04:33:43.470662
NCT00194805|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2007-11-13|2005-09-15|2005-09-19|Estimate|||||||2007-11-13|2007-11-14|Estimate|September 2003||2003-09-30|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Telehealth for Diabetes Self-Management|Telehealth for Diabetes Self-Management|Completed||N/A|62|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 04:33:43.552455|2018-06-01 04:33:43.552455
NCT00194792|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2017-04-14||2017-06-09|2005-09-14|2005-09-19|Estimate|2017-06-05|2017-06-06|Actual||||2017-06-09|2017-07-11|Actual|August 2005||2005-08-31|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer|Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study|Terminated||Phase 2|28|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:43.645196|2018-06-01 04:33:43.645196
NCT00194779|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-04-14||2018-02-12|2005-09-16|2005-09-19|Estimate|2018-02-12|2018-03-12|Actual||||2018-02-12|2018-03-12|Actual|October 2003||2003-10-31|February 2018|2018-02-28|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery|A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study|Completed||Phase 2|50|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:43.941237|2018-06-01 04:33:43.941237
NCT00194766|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-11-13|2005-09-14|2005-09-19|Estimate|||||||2007-11-13|2007-11-14|Estimate|July 2000||2000-07-31|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer|Continuous Temozolomide (SCH 52365) in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer, Phase II|Completed||Phase 2|35|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:44.417675|2018-06-01 04:33:44.417675
NCT00194753|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-09-12|2005-09-14|2005-09-19|Estimate|||||||2012-09-12|2012-09-13|Estimate|December 2001||2001-12-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12|Adjuvant Therapy for High-Risk Localized Breast Cancer With Weekly Adriamycin +/- Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Taxol for 12 Weeks, Phase II|Completed||Phase 2|80|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:44.518213|2018-06-01 04:33:44.518213
NCT00194727|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-12|2005-09-13|2005-09-19|Estimate|||||||2012-09-12|2012-09-13|Estimate|May 2002||2002-05-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer|Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer: A Phase II Trial With Molecular Correlates|Completed||Phase 2|40|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:44.720494|2018-06-01 04:33:44.720494
NCT00194714|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-01-03|2005-09-13|2005-09-19|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2016||2016-05-31|January 2018|2018-01-31||||November 2018|Anticipated|2018-11-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab|Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo|Enrolling by invitation||Phase 1/Phase 2|20|Anticipated|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:44.807216|2018-06-01 04:33:44.807216
NCT00194701|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-01-02|2005-09-13|2005-09-19|Estimate|||||||2008-01-02|2008-01-11|Estimate|April 1998||1998-04-30|January 2008|2008-01-31|March 2002||2002-03-31|||||Interventional|||Exercise to Improve Sleep in Heart Failure|Exercise to Improve Sleep in Heart Failure|Completed||Phase 3|152||University of Washington|||||f||||||||||||||2018-06-01 04:33:44.900531|2018-06-01 04:33:44.900531
NCT00194688|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-01-02|2005-09-13|2005-09-19|Estimate|||||||2008-01-02|2008-01-11|Estimate|March 2003||2003-03-31|January 2008|2008-01-31|June 2005||2005-06-30|||||Interventional|||Breath Ammonia Method for H. Pylori Detection: Phase II|Breath Ammonia Method for H. Pylori Detection: Phase II|Completed||Phase 2|278||University of Washington|||||f||||||||||||||2018-06-01 04:33:44.976|2018-06-01 04:33:44.976
NCT00194675|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-05-02||2017-10-30|2005-09-13|2005-09-19|Estimate|2012-07-16|2012-08-20|Estimate||||2017-10-30|2017-12-05|Actual|March 2005||2005-03-31|October 2017|2017-10-31|December 2010|Actual|2010-12-31|April 2010|Actual|2010-04-30||Interventional|TRADE||TRADE-Testosterone Replacement and Dutasteride Effectiveness|Testosterone Replacement and Dutasteride Effectiveness (TRADE)|Completed||Phase 4|53|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:33:45.052567|2018-06-01 04:33:45.052567
NCT00194649|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-18|2005-09-13|2005-09-19|Estimate|||||||2008-09-18|2008-09-19|Estimate|June 2005||2005-06-30|September 2008|2008-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|MIG-2||Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)|Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study|Completed||Phase 4|8|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:33:45.425756|2018-06-01 04:33:45.425756
NCT00194636|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-05|2005-09-13|2005-09-19|Estimate|||||||2017-04-05|2017-04-07|Actual|November 2003||2003-11-30|October 2007|2007-10-31|November 2006||2006-11-30|||||Interventional|||Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)|Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)|Suspended||Phase 4|20||University of Washington||||PI health issues|f||||||||||||||2018-06-01 04:33:45.533244|2018-06-01 04:33:45.533244
NCT00194623|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-17|2005-09-13|2005-09-19|Estimate|||||||2007-10-17|2007-10-19|Estimate|August 2003||2003-08-31|October 2007|2007-10-31|August 2007||2007-08-31|||||Interventional|||Botox as a Treatment for Chronic Male Pelvic Pain Syndrome|Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial|Terminated||Phase 4|30||University of Washington||||Reorganization of personnel forced termination.|f||||||||||||||2018-06-01 04:33:45.633238|2018-06-01 04:33:45.633238
NCT00194610|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-12-29||2012-09-12|2005-09-13|2005-09-19|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|May 2004||2004-05-31|September 2012|2012-09-30|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional|||Botox as a Treatment for Interstitial Cystitis in Women|Botox (Botulinum Toxin A) as a Treatment for Interstitial Cystitis in Women: A Randomized Placebo Controlled Trial|Completed||Phase 4|20|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:33:45.741669|2018-06-01 04:33:45.741669
NCT00194597|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-21|2005-09-13|2005-09-19|Estimate|||||||2008-10-21|2008-10-22|Estimate|July 2004||2004-07-31|October 2008|2008-10-31|July 2007||2007-07-31|||||Interventional|||Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III|Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III|Terminated||Phase 4|30||University of Washington||||Illness of PI forced termination.|||||||||||||||2018-06-01 04:33:45.96258|2018-06-01 04:33:45.96258
NCT00194584|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-25|2005-09-13|2005-09-19|Estimate|||||||2008-09-25|2008-09-29|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|February 2007|Actual|2007-02-28|||||Interventional|||Childhood Chronic Illness: An Educational Program for Parents of Children With On-Going Health Care Needs|Building on Family Strengths: An Educational Program for Parents of Children With On-Going Health Care Needs|Completed||N/A|129|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:33:46.025584|2018-06-01 04:33:46.025584
NCT00194571|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-19|2005-09-13|2005-09-19|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 1999||1999-06-30|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|EC R01||Enhancing Connections: Helping the Mother With Breast Cancer Support Her Child|Helping the Mother With Breast Cancer Support Her Child|Completed||Phase 3|181|Anticipated|University of Washington|||||f||||f||||||||||2018-06-01 04:33:46.115189|2018-06-01 04:33:46.115189
NCT00194558|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-30|2005-09-16|2005-09-19|Estimate|||||||2008-09-30|2008-10-02|Estimate|February 2005||2005-02-28|September 2008|2008-09-30||||||||Interventional|||Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care|Outcomes and Cost Consequences of Using an Internet Co-Management Module to Improve the Quality of Type 1 Diabetes Care|Completed||N/A|82|Actual|University of Washington|||||f||||||||||||||2018-06-01 04:33:46.174296|2018-06-01 04:33:46.174296
NCT00194545|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-07-05|2005-09-13|2005-09-19|Estimate|||||||2012-07-05|2012-07-09|Estimate|July 2004||2004-07-31|July 2012|2012-07-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Effect of Medication Diaries on Adherence to Highly Active Antiretroviral Drugs Among HIV-1 Infected Kenyan Children|Effect of Medication Diaries on Adherence to Highly Active Antiretroviral Drugs Among HIV-1 Infected Kenyan Children|Completed||Phase 2|100|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:33:46.233423|2018-06-01 04:33:46.233423
NCT00194532|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-03-30||2014-06-03|2005-09-13|2005-09-19|Estimate|2011-03-30|2011-04-28|Estimate||||2014-06-03|2014-06-10|Estimate|June 2005||2005-06-30|June 2014|2014-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Cefpodoxime vs Ciprofloxacin for Acute Cystitis|Cefpodoxime vs Ciprofloxacin for Acute Cystitis|Completed||N/A|300|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:33:46.304201|2018-06-01 04:33:46.304201
NCT00194519|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-16|2005-09-13|2005-09-19|Estimate|||||||2011-03-16|2011-03-17|Estimate|November 2004||2004-11-30|March 2011|2011-03-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Interventional|||Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission|Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples|Completed||Phase 3|3408|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:33:46.490185|2018-06-01 04:33:46.490185
NCT00194493|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-04-30|2005-09-12|2005-09-19|Estimate|||||||2015-04-30|2015-05-04|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|ESRA-C||Computerized Assessment for Patients With Cancer|Computerized Assessment for Patients With Cancer|Completed||Phase 3|1058|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 04:33:46.687083|2018-06-01 04:33:46.687083
NCT00194480|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-01-11|2005-09-12|2005-09-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2003||2003-04-30|October 2008|2008-10-31|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|||Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users|Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks|Completed||Phase 4|21|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||t||||||||||2018-06-01 04:33:46.811572|2018-06-01 04:33:46.811572
NCT00194467|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-29|2005-09-12|2005-09-19|Estimate|||||||2007-12-29|2008-01-10|Estimate|December 2002||2002-12-31|December 2007|2007-12-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Suppression of Oral HHV8 Shedding With Valganciclovir|Suppression of Oral Shedding of Human Herpesvirus 8 (HHV-8) With Valganciclovir|Completed||Phase 2|32|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:33:46.880781|2018-06-01 04:33:46.880781
NCT00194454|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-21|2005-09-12|2005-09-19|Estimate|||||||2008-09-21|2008-09-23|Estimate|March 2002||2002-03-31|September 2008|2008-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Psychosocial/Behavioral Intervention in Post-Stroke Depression|Psychosocial/Behavioral Intervention in PSD|Completed||N/A|101|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:33:46.945399|2018-06-01 04:33:46.945399
NCT00194441|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-29|2005-09-12|2005-09-19|Estimate|||||||2014-05-29|2014-06-02|Estimate|April 1999||1999-04-30|May 2014|2014-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Cerebral Perfusion Pressure (CPP) Management Information Feedback and Nursing|CPP Management Information Feedback and Nursing|Completed||N/A|260|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:33:47.023833|2018-06-01 04:33:47.023833
NCT00194428|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-03-26|2005-09-14|2005-09-19|Estimate|||||||2013-03-26|2013-03-28|Estimate|February 2005||2005-02-28|January 2008|2008-01-31|October 2009|Actual|2009-10-31|October 2007|Actual|2007-10-31||Interventional|||Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons|Weight and Metabolic Effects of an Almond Enriched Hypocaloric, Low Fat Diet on Overweight and Obese Persons|Completed||Phase 1/Phase 2|123|Actual|Temple University||2|||f||||f||||||||||2018-06-01 04:33:47.115171|2018-06-01 04:33:47.115171
NCT00194415|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-29|2005-09-12|2005-09-19|Estimate|||||||2007-12-29|2008-01-10|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study of HSV Testing Among Pregnant Women|A Randomized Clinical Trial of Antenatal vs Delayed (Post Partum) Testing for HSV Type-Specific Antibodies Among Pregnant Women.|Terminated||N/A|173|Actual|University of Washington||2||An interim data analysis found no significant difference between testing groups.|f||||f||||||||||2018-06-01 04:33:47.197402|2018-06-01 04:33:47.197402
NCT00194402|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-08-20|2005-09-12|2005-09-19|Estimate|||||||2008-08-20|2008-08-21|Estimate|August 2003||2003-08-31|August 2008|2008-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia|SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers|Completed||Phase 4|64|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:33:47.269009|2018-06-01 04:33:47.269009
NCT00194376|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-02-16|2005-09-14|2005-09-19|Estimate|||||||2018-02-16|2018-02-19|Actual|June 2005||2005-06-30|February 2018|2018-02-28|June 2007|Actual|2007-06-30|September 2006|Actual|2006-09-30||Interventional|||Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea|Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea|Completed||N/A|10|Anticipated|University of Pennsylvania|||||f||||||||||||||2018-06-01 04:33:47.343246|2018-06-01 04:33:47.343246
NCT00194363|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-07-25|2005-09-13|2005-09-19|Estimate|||||||2017-07-25|2017-07-28|Actual|October 2005||2005-10-31|July 2017|2017-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Strength Training Intervention for Breast Cancer Survivors and the Effects on Lymphedema Status|The PAL Trial (Physical Activity and Lymphedema)|Completed||N/A|295|Actual|Milton S. Hershey Medical Center|||||f||||t||||||||||2018-06-01 04:33:47.399281|2018-06-01 04:33:47.399281
NCT00194350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-08|2005-09-13|2005-09-19|Estimate|||||||2011-08-08|2011-08-09|Estimate|September 2001||2001-09-30|August 2011|2011-08-31|August 2005|Actual|2005-08-31|||||Observational|||Factor V Leiden Mutation and Implantation Failure|Evaluation of the Role of Factor V Leiden Mutation in Implantation Failure|Completed|||399||University of Pennsylvania|||||f||||f||||||||||2018-06-01 04:33:47.464901|2018-06-01 04:33:47.464901
NCT00194337|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-24|2005-09-13|2005-09-19|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 1999||1999-10-31|January 2007|2007-01-31||||July 2012|Actual|2012-07-31||Interventional|||Digital Mammography, Ultrasound, MRI, and PET Scans in Women With Newly Diagnosed Breast Cancer|Evaluation of Multimodality Breast Imaging: Project 3-Lesion Staging|Unknown status|Active, not recruiting|Phase 2/Phase 3|400|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||||||||||||2018-06-01 04:33:47.518177|2018-06-01 04:33:47.518177
NCT00194324|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-08|2005-09-13|2005-09-19|Estimate|||||||2011-08-08|2011-08-09|Estimate|July 2004||2004-07-31|August 2011|2011-08-31|October 2004|Actual|2004-10-31|||||Interventional|||Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina|Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE|Completed||Phase 4|12||University of Pennsylvania|||||f||||f||||||||||2018-06-01 04:33:47.578688|2018-06-01 04:33:47.578688
NCT00194311|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-15|2005-09-13|2005-09-19|Estimate|||||||2016-08-15|2016-08-17|Estimate|April 2005||2005-04-30|August 2016|2016-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Human Papillomavirus (HPV) Infection in Pregnancy||Completed|||620|Anticipated|University of Pennsylvania|||1||f||||||||||||||2018-06-01 04:33:47.640291|2018-06-01 04:33:47.640291
NCT00194298|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-03|2005-09-13|2005-09-19|Estimate|||||||2018-05-03|2018-05-07|Actual|October 2002||2002-10-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||FDG-PET Imaging in Complicated Diabetic Foot|FDG-PET Imaging in Complicated Diabetic Foot (Protocol Version Dated 3/01/2004)|Active, not recruiting|||240|Anticipated|University of Pennsylvania|||||f||||||||||||||2018-06-01 04:33:47.689702|2018-06-01 04:33:47.689702
NCT00194285|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-03|2005-09-13|2005-09-19|Estimate|||||||2018-05-03|2018-05-07|Actual|March 2001||2001-03-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||FDG-PET Imaging in Painful Joint Prosthesis|FDG-PET Imaging in Painful Joint Prosthesis (Protocol Amendment, Version 11, Dated 9/2005)|Active, not recruiting|||530|Anticipated|University of Pennsylvania|||||f||||||||||||||2018-06-01 04:33:47.744611|2018-06-01 04:33:47.744611
NCT00194259|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-03-05|2005-09-13|2005-09-19|Estimate|||||||2014-03-05|2014-03-07|Estimate|August 2001||2001-08-31|January 2008|2008-01-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Sleep Apnea in Look AHEAD (Action for Health in Diabetes)|Sleep Apnea in Look AHEAD (Action for Health in Diabetes)|Unknown status|Active, not recruiting||320|Anticipated|Temple University|||||f||||t||||||Samples Without DNA|"~     Saliva Samples~   "|||2018-06-01 04:33:47.89507|2018-06-01 04:33:47.89507
NCT00194246|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-28|2005-09-13|2005-09-19|Estimate|||||||2013-06-28|2013-07-01|Estimate|August 2003||2003-08-31|August 2007|2007-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Cognitive Function and Cue-Reactivity Study|Cognitive Performance and Food Reactivity During High and Low Carbohydrate Obesity Treatment|Completed|||29|Actual|Temple University|||||f||||f||||||Samples Without DNA|"~     salivary cortisol~   "|||2018-06-01 04:33:47.95917|2018-06-01 04:33:47.95917
NCT00194233|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-15|2005-09-13|2005-09-19|Estimate|||||||2016-08-15|2016-08-16|Estimate|November 2003||2003-11-30|August 2016|2016-08-31|June 2008|Actual|2008-06-30|January 2007|Actual|2007-01-31||Observational|||Serum and Peritoneal Fluid Bank for Endometriosis Markers|Serum and Peritoneal Fluid Bank for Assessment of Markers of Endometriosis|Completed|||300|Anticipated|University of Pennsylvania|||||f||||||||||Samples With DNA|"~     Serum, Plasma, Peritoneal fluid~   "|||2018-06-01 04:33:48.012975|2018-06-01 04:33:48.012975
NCT00194220|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-28|2005-09-13|2005-09-19|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2002||2002-09-30|September 2015|2015-09-30|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Observational|||Infertility Markers in Serum, Urine, and Follicular Fluid|Markers in Women Undergoing Infertility Treatment|Completed|||1235|Actual|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     Blood, Urine, Follicular Fluid~   "|||2018-06-01 04:33:48.123869|2018-06-01 04:33:48.123869
NCT00194207|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-15|2005-09-13|2005-09-19|Estimate|||||||2016-08-15|2016-08-17|Estimate|October 1999||1999-10-31|August 2016|2016-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Risk Factors of Ectopic Pregnancy|Risk Factors as Predictors of Ectopic PRegnancy|Completed|||3000|Anticipated|University of Pennsylvania|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 04:33:48.20258|2018-06-01 04:33:48.20258
NCT00194194|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-03-13|2005-09-12|2005-09-19|Estimate|||||||2009-03-13|2009-03-17|Estimate|August 2004||2004-08-31|October 2008|2008-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Healthetech, Inc. SMART Study|The Effect of Measuring Resting Metabolic Rate (RMR) in the Context of Moderate or Intensive Behavior Modification Treatment on Weight Loss|Completed||Phase 2|56|Actual|Temple University||2|||f||||f||||||||||2018-06-01 04:33:48.266081|2018-06-01 04:33:48.266081
NCT00194181|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-14|2005-09-12|2005-09-19|Estimate|||||||2006-07-14|2006-07-17|Estimate|March 2003||2003-03-31|July 2006|2006-07-31|March 2005||2005-03-31|||||Interventional|||Rt-PA Infusion Versus Catheter Exchange for Dialysis Catheter Malfunction Due to Fibrin Sheath|Randomized Prospective Trial of Rt-PA Infusion Versus Catheter Exchange for Treatment of Dialysis Catheter Malfunction Due to Fibrin Sheath Formation|Terminated||N/A|40||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:33:48.333719|2018-06-01 04:33:48.333719
NCT00194168|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-08-15|2005-09-13|2005-09-19|Estimate|||||||2016-08-15|2016-08-16|Estimate|June 2000||2000-06-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Ectopic Pregnancy Biomarkers|Serum Bank for Assessment of Markers of Ectopic Pregnancy|Completed|||1306|Actual|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     Blood (Plasma, Serum)~   "|||2018-06-01 04:33:48.384306|2018-06-01 04:33:48.384306
NCT00194155|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-08-15|2005-09-12|2005-09-19|Estimate|||||||2016-08-15|2016-08-17|Estimate|May 2003||2003-05-31|August 2016|2016-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Cytomegalovirus (CMV) Infection in Pregnancy|Cytomegalovirus Infection and Pregnancy Outcomes|Completed|||283|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 04:33:48.440511|2018-06-01 04:33:48.440511
NCT00194142|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-08-15|2005-09-12|2005-09-19|Estimate|||||||2016-08-15|2016-08-17|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Cytomegalovirus (CMV) Infection in Amniotic Fluid||Completed|||37|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 04:33:48.493429|2018-06-01 04:33:48.493429
NCT00194129|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-11-04||2018-01-22|2005-09-13|2005-09-19|Estimate|2013-11-04|2013-12-23|Estimate||||2018-01-22|2018-02-20|Actual|November 1997||1997-11-30|January 2018|2018-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder|A Randomized, Double Blind Comparison of Lithium Monotherapy Versus Lithium Plus Divalproex for the Outpatient Management of Hypomania/Mania in Patients With Rapid Cycling Bipolar Disorder Comorbid With Substance Abuse/Dependence|Completed||Phase 3|31|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 04:33:48.554882|2018-06-01 04:33:48.554882
NCT00194116|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-01|2005-09-13|2005-09-19|Estimate|||||||2014-12-01|2014-12-03|Estimate|September 2004||2004-09-30|December 2014|2014-12-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression|Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression|Completed||Phase 3|30|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 04:33:48.83747|2018-06-01 04:33:48.83747
NCT00194103|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-25|2005-09-12|2005-09-19|Estimate|||||||2010-06-25|2010-06-28|Estimate|May 2004||2004-05-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Interventional|ETM||Effectiveness of Extended Telephone Monitoring||Completed||Phase 3|252|Actual|University of Pennsylvania||3|||f||||||||||||||2018-06-01 04:33:48.903818|2018-06-01 04:33:48.903818
NCT00194090|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-19|Estimate|||||||2005-09-13|2005-09-19|Estimate|June 2004||2004-06-30|July 2004|2004-07-31|September 2005||2005-09-30|||||Interventional|||Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk|A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy of Celecoxib 200 Mg Qd in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee|Unknown status|Recruiting|Phase 4|40||University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-06-01 04:33:48.973851|2018-06-01 04:33:48.973851
NCT00194077|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|2013-06-26||2014-12-17|2005-09-16|2005-09-19|Estimate|2013-11-12|2013-12-05|Estimate||||2014-12-17|2015-01-07|Estimate|August 2004||2004-08-31|December 2014|2014-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||No differences.|Study of Aripiprazole (Abilify) in Children With Symptoms of Mania|Aripiprazole in Children With Symptoms of Mania|Completed||Phase 3|60|Actual|University Hospitals Cleveland Medical Center|No deaths occured during this study.|2|||f||||t||||||||||2018-06-01 04:33:49.047659|2018-06-01 04:33:49.047659
NCT00194064|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-03|2005-09-13|2005-09-19|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2002||2002-07-31|October 2016|2016-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine|Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine Monotherapy in Treatment Refractory Bipolar Disorder Mania|Terminated||Phase 3|18|Actual|University Hospitals Cleveland Medical Center||1||Slow enrollment|f||||t||||||||||2018-06-01 04:33:49.228286|2018-06-01 04:33:49.228286
NCT00194051|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-05|2005-09-13|2005-09-19|Estimate|||||||2006-10-05|2006-10-06|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|May 2006||2006-05-31|||||Observational|||Symptomatic, Biomechanical and Radiographic Outcomes in Knee Osteoarthritis Following Gastric Bypass Surgery|Symptomatic, Biomechanical and Radiographic Outcomes in Knee Osteoarthritis Following Gastric Bypass Surgery|Unknown status|Active, not recruiting||35||University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-06-01 04:33:49.33646|2018-06-01 04:33:49.33646
NCT00194038|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-16|2005-09-13|2005-09-19|Estimate|||||||2014-12-16|2014-12-17|Estimate|April 2004||2004-04-30|January 2010|2010-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Aripiprazole in Late Life Bipolar Disorder|Aripiprazole in Late Life Bipolar Disorder|Completed||Phase 4|20|Actual|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-06-01 04:33:49.401725|2018-06-01 04:33:49.401725
NCT00194025|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-01-26||2014-12-16|2005-09-13|2005-09-19|Estimate|2011-02-03|2011-03-01|Estimate||||2014-12-16|2015-01-06|Estimate|November 2004||2004-11-30|February 2011|2011-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Valproate in Late Life Schizophrenia|Add-on Valproate in Late Life Schizophrenia|Completed||Phase 4|20|Actual|University Hospitals Cleveland Medical Center|The findings of this study must be interpreted cautiously given the limitations of small sample size, open-label, add-on design and lack of a control or comparator group. The mean age of 61 years is not representative of the “old-old” populations.|1|||f||||f||||||||||2018-06-01 04:33:49.568743|2018-06-01 04:33:49.568743
NCT00194012|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|2013-06-26||2017-06-02|2005-09-11|2005-09-19|Estimate|2014-04-04|2014-05-05|Estimate||||2017-06-02|2017-06-26|Actual|August 2004||2004-08-31|June 2017|2017-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder|Aripiprazole in At-Risk Children With Symptoms of Bipolar Disorder|Completed||Phase 3|62|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-06-01 04:33:49.962043|2018-06-01 04:33:49.962043
NCT00193999|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-10-26|2005-09-15|2005-09-19|Estimate|||||||2009-10-26|2009-10-27|Estimate|February 2003||2003-02-28|September 2008|2008-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Do Nasogastric Tubes After Cardiac Surgery Reduce Nausea and Vomiting|Do Nasogastric Tubes After Cardiac Surgery Reduce Nausea and Vomiting. A Prospective Randomized Clinical Trial.|Completed||Phase 4|300|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:33:50.693918|2018-06-01 04:33:50.693918
NCT00193986|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-11-13|2005-09-15|2005-09-19|Estimate|||||||2006-11-13|2006-11-14|Estimate|May 2005||2005-05-31|September 2006|2006-09-30|June 2005||2005-06-30|||||Interventional|||Assessment of Prepulse Inhibition for Shock Pain Reduction|Assessment of Prepulse Inhibition for Shock Pain Reduction- Ventricular|Completed||N/A|10||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:33:50.760422|2018-06-01 04:33:50.760422
NCT00193973|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-15|2005-09-13|2005-09-19|Estimate|||||||2017-02-15|2017-02-17|Actual|July 2001||2001-07-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|July 2008|Actual|2008-07-31||Interventional|||Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma|A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma|Completed||Phase 2|20|Actual|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||f||||||||||2018-06-01 04:33:50.827994|2018-06-01 04:33:50.827994
NCT00193960|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-29|2005-09-09|2005-09-19|Estimate|||||||2005-11-29|2005-12-01|Estimate|January 1997||1997-01-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Observational|||The Results of Ahmed Valve Operations|A Comparison Between Superior and Inferior Ahmed Glaucoma Valve Implantation: Surgical Success and Complications|Unknown status|Recruiting||80||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:33:50.938458|2018-06-01 04:33:50.938458
NCT00193947|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-08-02|2005-09-15|2005-09-19|Estimate|||||||2011-08-02|2011-08-03|Estimate|November 2003||2003-11-30|April 2007|2007-04-30|May 2008|Actual|2008-05-31|||||Observational|||An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy|An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy|Terminated|||56|Anticipated|University Health Network, Toronto|||1||f||||f||||||||||2018-06-01 04:33:51.015393|2018-06-01 04:33:51.015393
NCT00193934|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-07-10|2005-09-12|2005-09-19|Estimate|||||||2017-07-10|2017-07-12|Actual|January 2006||2006-01-31|July 2017|2017-07-31|May 15, 2014|Actual|2014-05-15|May 2014|Actual|2014-05-31||Observational|||Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer|Prospective Study to Determine the Relationships Between Survival and FIGO Stage, Tumour Volume and Corpus Invasion in Cervical Cancer|Completed|||109|Actual|Trans-Tasman Radiation Oncology Group (TROG)|||1||f||||f||||||||||2018-06-01 04:33:51.077297|2018-06-01 04:33:51.077297
NCT00193921|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-07-31|2005-09-13|2005-09-19|Estimate|||||||2014-07-31|2014-08-04|Estimate|February 2003||2003-02-28|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2009|Actual|2009-12-31||Interventional|||Chemoradiotherapy in Patients With Localised Lung Cancer|A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer|Completed||Phase 2|82|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||f||||||||||2018-06-01 04:33:51.176134|2018-06-01 04:33:51.176134
NCT00193908|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-13|2005-09-12|2005-09-19|Estimate|||||||2009-05-13|2009-05-14|Estimate|March 2004||2004-03-31|May 2009|2009-05-31|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||"Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine (Sorbolene) Cream"|"A Paired Double Blind Randomised Comparison of Cavilon(TM) Durable Barrier Cream(TM)[CDBC] to 10% Glycerine (Sorbolene) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care"|Completed||Phase 3|333|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||f||||||||||2018-06-01 04:33:51.275992|2018-06-01 04:33:51.275992
NCT00193895|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-04|2005-09-13|2005-09-19|Estimate|||||||2018-04-04|2018-04-06|Actual|April 2005||2005-04-30|April 2018|2018-04-30|March 31, 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck|Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|321|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||f||||||||||2018-06-01 04:33:51.35815|2018-06-01 04:33:51.35815
NCT00193882|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-07-10|2005-09-13|2005-09-19|Estimate|||||||2017-07-10|2017-07-12|Actual|July 7, 2003||2003-07-07|July 2017|2017-07-31|June 18, 2013|Actual|2013-06-18|March 21, 2012|Actual|2012-03-21||Interventional|||Advanced Oesophageal Cancer Study to Compare Quality of Life and Palliation of Dysphagia.|A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients Treated With Radiotherapy vs ChemoRadiotherapy.|Completed||Phase 3|220|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||t||||||||||2018-06-01 04:33:51.576653|2018-06-01 04:33:51.576653
NCT00193869|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-05-08|2005-09-11|2005-09-19|Estimate|||||||2007-05-08|2007-05-10|Estimate|September 2001||2001-09-30|May 2007|2007-05-31|December 2003|Actual|2003-12-31|||||Interventional|||SuperDEX Trial (Comparison of Two Doses of Dexamethasone for Malignant Spinal Cord Compression Treated by Radiotherapy).|A Pilot Randomised Comparison of Dexamethasone 96 mg Versus 16 mg Per Day for Malignant Spinal Cord Compression Treated by Radiotherapy|Completed||Phase 2|20|Actual|Trans-Tasman Radiation Oncology Group (TROG)|||||f||||f||||||||||2018-06-01 04:33:51.764571|2018-06-01 04:33:51.764571
NCT00193856|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-10-10|2005-09-12|2005-09-19|Estimate|||||||2017-10-10|2017-10-12|Actual|October 2003||2003-10-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||RADAR Trial - Randomised Androgen Deprivation and Radiotherapy|A Randomised Trial Investigating the Effect on Biochemical (PSA) Control and Survival of Different Durations of Adjuvant Androgen Deprivation in Association With Definitive Radiation Treatment for Localised Carcinoma of the Prostate.|Completed||Phase 3|1071|Actual|Trans-Tasman Radiation Oncology Group (TROG)||4|||f||||t||||||||||2018-06-01 04:33:51.842878|2018-06-01 04:33:51.842878
NCT00193843|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-23|2005-09-13|2005-09-19|Estimate|||||||2005-12-23|2005-12-26|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|June 2017||2017-06-30|||||Interventional|||Oral Cancer Adjuvant Therapy (OCAT) Trial|Phase III Trial of Surgery Followed by Conventional RT(5fr/Week)Vs.Concurrent Chemo-Radiotherapy Vs.Accelerated RT(6fr/Week)in High Risk, Loco-Regionally Advanced, Stage III&IVA, Resectable, Squamous Cell Carcinomas of Oralcavity|Unknown status|Recruiting|Phase 3|900||Tata Memorial Hospital|||||f||||||||||||||2018-06-01 04:33:51.954846|2018-06-01 04:33:51.954846
NCT00193830|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-05|2005-09-13|2005-09-19|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 1996||1996-05-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix|High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix|Completed||Phase 3|750||Tata Memorial Hospital|||||f||||||||||||||2018-06-01 04:33:52.031847|2018-06-01 04:33:52.031847
NCT00193817|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-02-06|2005-09-14|2005-09-19|Estimate|||||||2006-02-06|2006-02-07|Estimate|January 2005||2005-01-31|July 2005|2005-07-31|December 2015||2015-12-31|||||Interventional|||Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial||Unknown status|Recruiting|Phase 3|700||Tata Memorial Hospital|||||f||||||||||||||2018-06-01 04:33:52.083319|2018-06-01 04:33:52.083319
NCT00193804|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-26|2005-09-13|2005-09-19|Estimate|||||||2017-03-26|2017-03-28|Actual|February 2005||2005-02-28|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix|A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix|Active, not recruiting|||200|Anticipated|Tata Memorial Hospital|||1||f||||t||||||||Undecided||2018-06-01 04:33:53.113803|2018-06-01 04:33:53.113803
NCT00193791|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-26|2005-09-13|2005-09-19|Estimate|||||||2017-03-26|2017-03-28|Actual|July 2003||2003-07-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CRACx||Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix|Concomitant Chemo-radiation in Advanced Stage Carcinoma Cervix: A Phase III Randomized Trial|Active, not recruiting||Phase 3|850|Actual|Tata Memorial Hospital||2|||f||||t||||||||Yes|Individual patient data (IPD) related to patient characteristics, treatment and outcome variables.|2018-06-01 04:33:53.22265|2018-06-01 04:33:53.22265
NCT00193778|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-01-16|2005-09-12|2005-09-19|Estimate|||||||2018-01-16|2018-01-17|Actual|February 2005||2005-02-28|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation|A Randomized Trial To Assess The Impact Of Loco-Regional Treatment On Survival Of Patients With Metastatic Breast Cancer At First Presentation|Active, not recruiting||N/A|350|Actual|Tata Memorial Hospital||2|||f||||t||||||||||2018-06-01 04:33:53.304206|2018-06-01 04:33:53.304206
NCT00193765|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-15|2005-09-13|2005-09-19|Estimate|||||||2017-06-15|2017-06-16|Actual|January 2004||2004-01-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity|Elective Versus Therapeutic Neck Dissection in the Treatment of Early Node Negative Squamous Cell Carcinoma of the Oral Cavity|Active, not recruiting||N/A|710|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||No||2018-06-01 04:33:53.395661|2018-06-01 04:33:53.395661
NCT00193752|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-01-18|2005-09-13|2005-09-19|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2005||2005-09-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2015|Actual|2015-01-31||Observational|||Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix|Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cervical Cancer|Completed|||100|Actual|Tata Memorial Hospital|||||f||||t||||||||Undecided||2018-06-01 04:33:53.49939|2018-06-01 04:33:53.49939
NCT00193739|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2017-10-23|2005-09-11|2005-09-19|Estimate|||||||2017-10-23|2017-10-24|Actual|September 4, 2003|Actual|2003-09-04|October 2017|2017-10-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|NACTcervix||Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix|A Prospective Randomized Trial of Neoadjuvant Chemotherapy and Surgery Versus Concurrent Chemoradiation Therapy in Patients With Stage IB2-IIB Squamous Carcinoma of the Uterine Cervix|Active, not recruiting||Phase 3|635|Actual|Tata Memorial Hospital||2|||f||||t||||||||||2018-06-01 04:33:53.591338|2018-06-01 04:33:53.591338
NCT00193726|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2016-10-25|2005-09-11|2005-09-19|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer|Estrogen Priming to Increase the Efficacy of Standard Adjuvant Chemotherapy in Operable Breast Cancer.|Recruiting||Phase 3|730|Anticipated|Tata Memorial Hospital||2|||f||||f||||||||Undecided||2018-06-01 04:33:53.703362|2018-06-01 04:33:53.703362
NCT00193713|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-01-15|2005-09-11|2005-09-19|Estimate|||||||2015-01-15|2015-01-16|Estimate|May 2005||2005-05-31|January 2007|2007-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Bifeprunox in the Treatment of Schizophrenia|A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)|Completed||Phase 3|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:33:53.944282|2018-06-01 04:33:53.944282
NCT00193700|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2006-12-23|2005-09-11|2005-09-19|Estimate|||||||2006-12-23|2006-12-25|Estimate|August 2002||2002-08-31|November 2006|2006-11-30||||||||Interventional|||Pharmacokinetic Evaluation of Testosterone Gel (1%)|Pharmacokinetic Evaluation of Testosterone Gel (1%) in Prepubertal Boys of Adolescent Age|Completed||Phase 1|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:33:54.10246|2018-06-01 04:33:54.10246
NCT00193687|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2008-03-20|2005-09-11|2005-09-19|Estimate|||||||2008-03-20|2008-03-24|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Bifeprunox in the Treatment of Schizophrenia|An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizpohrenia (Extension of S154.3.001)|Completed||Phase 3|986|Actual|Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:33:54.269059|2018-06-01 04:33:54.269059
NCT00193674|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-08-25|2005-09-11|2005-09-19|Estimate|||||||2011-08-25|2011-08-26|Estimate|September 2003||2003-09-30|August 2011|2011-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage|Oral Dydrogesterone Treatment During the First Trimester of Pregnancy in Women With Recurrent Miscarriage: A Double-Blind, Prospectively Randomized, Placebo-Controlled, Parallel Group Trial|Completed||Phase 3|71|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:33:54.360384|2018-06-01 04:33:54.360384
NCT00193661|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-01-15|2005-09-11|2005-09-19|Estimate|||||||2015-01-15|2015-01-16|Estimate|August 2002||2002-08-31|September 2006|2006-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism|A Multi-Center, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Hypogonadism|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:33:54.487386|2018-06-01 04:33:54.487386
NCT00193648|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-10-19|2005-09-12|2005-09-19|Estimate|||||||2007-10-19|2007-10-22|Estimate|July 2005||2005-07-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)|Novel Therapies for Resistant FSGS|Completed||Phase 1|21|Actual|Northwell Health||2|||f||||t||||||||||2018-06-01 04:33:54.596947|2018-06-01 04:33:54.596947
NCT00193635|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-10-17|2005-09-11|2005-09-19|Estimate|||||||2007-10-17|2007-10-19|Estimate|March 2002||2002-03-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Pilot Study of Mycophenolate Mofetil in Congenital Uropathies|Pilot Study of Mycophenolate Mofetil in Congenital Uropathies|Completed||Phase 1|12|Actual|Northwell Health||1|||f||||t||||||||||2018-06-01 04:33:54.692049|2018-06-01 04:33:54.692049
NCT00193622|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-09-15|2005-09-12|2005-09-19|Estimate|||||||2010-09-15|2010-09-17|Estimate|April 2004||2004-04-30|September 2010|2010-09-30|January 2009|Actual|2009-01-31|September 2005|Actual|2005-09-30||Interventional|||Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site|A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site|Completed||Phase 2|50||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:54.859255|2018-06-01 04:33:54.859255
NCT00193609|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-08-15||2013-10-18|2005-09-12|2005-09-19|Estimate|2013-08-15|2013-10-21|Estimate||||2013-10-18|2013-11-11|Estimate|September 2004||2004-09-30|October 2013|2013-10-31|January 2009|Actual|2009-01-31|April 2008|Actual|2008-04-30||Interventional|||Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site|A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site|Completed||Phase 2|48|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:33:54.967495|2018-06-01 04:33:54.967495
NCT00193596|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-01-14||2013-03-22|2005-09-12|2005-09-19|Estimate|2013-03-22|2013-05-03|Estimate||||2013-03-22|2013-05-03|Estimate|September 2003||2003-09-30|March 2013|2013-03-31|June 2009|Actual|2009-06-30|September 2008|Actual|2008-09-30||Interventional|||Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site|A Randomized, Phase III Comparison of Gemcitabine/Irinotecan Followed by IRESSA Versus Paclitaxel/Carboplatin/Etoposide Followed by IRESSA in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site|Completed||Phase 3|198|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 04:33:55.428116|2018-06-01 04:33:55.428116
NCT00193583|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-03|2005-09-12|2005-09-19|Estimate|||||||2011-05-03|2011-05-04|Estimate|May 2003||2003-05-31|May 2011|2011-05-31|May 2005|Actual|2005-05-31|May 2004|Actual|2004-05-31||Interventional|||Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors|A Phase I Study of Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Patients With Refractory and/or Advanced Solid Tumors|Completed||Phase 1|18||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:56.205712|2018-06-01 04:33:56.205712
NCT00193570|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-22|2005-09-12|2005-09-19|Estimate|||||||2009-01-22|2009-01-23|Estimate|February 2002||2002-02-28|January 2009|2009-01-31|January 2009|Actual|2009-01-31|August 2004|Actual|2004-08-31||Interventional|||Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors|A Phase I Study of Topotecan in Combination With Docetaxel in Patients With Refractory and/or Advanced Solid Tumors|Completed||Phase 1|20||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:56.340174|2018-06-01 04:33:56.340174
NCT00193557|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-28|2005-09-12|2005-09-19|Estimate|||||||2010-06-28|2010-06-29|Estimate|May 2004||2004-05-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|May 2006|Actual|2006-05-31||Interventional|||Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma|Phase I Trial of Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma|Completed||Phase 2|40||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:56.407506|2018-06-01 04:33:56.407506
NCT00193544|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-21|2005-09-12|2005-09-19|Estimate|||||||2009-01-21|2009-01-23|Estimate|March 2002||2002-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|October 2005|Actual|2005-10-31||Interventional|||Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma|Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients With Refractory Multiple Myeloma|Completed||Phase 2|40||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:56.485697|2018-06-01 04:33:56.485697
NCT00193531|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-28|2005-09-12|2005-09-19|Estimate|||||||2010-06-28|2010-06-29|Estimate|December 1998||1998-12-31|October 2008|2008-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma|Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma|Completed||Phase 2|100||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:56.554822|2018-06-01 04:33:56.554822
NCT00193518|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|April 2004||2004-04-30|May 2011|2011-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Completed||Phase 2|41||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:56.630706|2018-06-01 04:33:56.630706
NCT00192582|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-20|2005-09-12|2005-09-19|Estimate|||||||2007-05-20|2007-05-22|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|August 2007|Anticipated|2007-08-31|||||Interventional|||AIMHI NT Relapse Prevention Trial|Relapse Prevention Trial in Top End Aboriginal People With Chronic Mental Illness|Unknown status|Active, not recruiting|N/A|90||Menzies School of Health Research|||||f||||||||||||||2018-06-01 04:34:07.058259|2018-06-01 04:34:07.058259
NCT00193505|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|October 2003||2003-10-31|May 2011|2011-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma|Phase II Trial of Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in the Treatment of Patients With Relapsed/Refractory Intermediate Grade B-Cell Lymphoma|Completed||Phase 2|40||SCRI Development Innovations, LLC|||||f||||f||||||||||2018-06-01 04:33:56.705414|2018-06-01 04:33:56.705414
NCT00193492|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2014-12-05||2014-12-11|2005-09-12|2005-09-19|Estimate|2014-12-05|2014-12-12|Estimate||||2014-12-11|2015-01-05|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma|Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial|Completed||Phase 2|60|Actual|SCRI Development Innovations, LLC||2|||f||||t||||||||||2018-06-01 04:33:56.798118|2018-06-01 04:33:56.798118
NCT00193479|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-01-08||2014-01-08|2005-09-12|2005-09-19|Estimate|2014-01-08|2014-02-21|Estimate||||2014-01-08|2014-02-21|Estimate|April 2003||2003-04-30|January 2014|2014-01-31|February 2010|Actual|2010-02-28|July 2008|Actual|2008-07-31||Interventional|||Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma|A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|51|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:33:57.173185|2018-06-01 04:33:57.173185
NCT00193466|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-12-29|2005-09-12|2005-09-19|Estimate|||||||2010-12-29|2010-12-30|Estimate|January 2002||2002-01-31|December 2010|2010-12-31|April 2008|Actual|2008-04-30|January 2007|Actual|2007-01-31||Interventional|||Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Rituximab/Fludarabine Followed by CAMPATH-1H in the First-Line Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Completed||Phase 2|40||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:57.409632|2018-06-01 04:33:57.409632
NCT00193453|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-10-11||2012-10-11|2005-09-12|2005-09-19|Estimate|2012-10-11|2012-11-13|Estimate||||2012-10-11|2012-11-13|Estimate|July 2005||2005-07-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|||Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer|A Phase II Trial of First-Line Therapy With Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer|Completed||Phase 2|69|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:33:57.512505|2018-06-01 04:33:57.512505
NCT00193440|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-12-29|2005-09-12|2005-09-19|Estimate|||||||2010-12-29|2010-12-30|Estimate|April 2002||2002-04-30|December 2010|2010-12-31|January 2009|Actual|2009-01-31|April 2004|Actual|2004-04-30||Interventional|||Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma|Phase II Trial of Rituximab and Short Duration Chemotherapy Followed by Zevalin as First-Line Treatment for Patients With Low Grade Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|40||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:57.876057|2018-06-01 04:33:57.876057
NCT00193427|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-10-11||2012-10-11|2005-09-12|2005-09-19|Estimate|2012-10-11|2012-11-13|Estimate||||2012-10-11|2012-11-13|Estimate|April 2004||2004-04-30|October 2012|2012-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer|Phase II Trial of Preoperative (Neo-adjuvant) Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer|Completed||Phase 2|76|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:33:57.943148|2018-06-01 04:33:57.943148
NCT00193414|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-10-11||2012-10-11|2005-09-12|2005-09-19|Estimate|2012-10-11|2012-11-13|Estimate||||2012-10-11|2012-11-13|Estimate|May 2005||2005-05-31|October 2012|2012-10-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Interventional|||Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study of First-Line Therapy With Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|74|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:33:58.251153|2018-06-01 04:33:58.251153
NCT00193401|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-27|2005-09-12|2005-09-19|Estimate|||||||2010-07-27|2010-07-28|Estimate|August 2002||2002-08-31|July 2010|2010-07-31|November 2004||2004-11-30|June 2004|Actual|2004-06-30||Interventional|||Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer|Phase II Trial of Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer|Completed||Phase 2|40||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:58.573233|2018-06-01 04:33:58.573233
NCT00193388|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-27|2005-09-12|2005-09-19|Estimate|||||||2010-07-27|2010-07-28|Estimate|September 2002||2002-09-30|July 2010|2010-07-31|February 2007||2007-02-28|December 2004|Actual|2004-12-31||Interventional|||Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer|Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer|Completed||Phase 2|100||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:58.636427|2018-06-01 04:33:58.636427
NCT00193375|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-10-05||2016-06-29|2005-09-12|2005-09-19|Estimate|2012-10-11|2012-11-13|Estimate||||2016-06-29|2016-08-10|Estimate|August 2003||2003-08-31|June 2016|2016-06-30|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer|Phase II Trial of Concurrent Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab (Avastin) in the Treatment of Patients With Limited Stage Small Cell Lung Cancer|Completed||Phase 2|60|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:33:58.709676|2018-06-01 04:33:58.709676
NCT00193362|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-27|2005-09-12|2005-09-19|Estimate|||||||2010-07-27|2010-07-28|Estimate|June 2004||2004-06-30|July 2010|2010-07-31|September 2007|Actual|2007-09-30|June 2005|Actual|2005-06-30||Interventional|||Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer|Phase III Randomized Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine as First-Line Chemotherapy for Stage IIIB and IV Non-Small Cell Lung Cancer|Completed||Phase 3|200||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:58.964031|2018-06-01 04:33:58.964031
NCT00193349|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-24|2005-09-12|2005-09-19|Estimate|||||||2010-06-24|2010-06-28|Estimate|September 2002||2002-09-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer|Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC|Completed||Phase 2|60||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.046451|2018-06-01 04:33:59.046451
NCT00193336|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|March 2003||2003-03-31|May 2011|2011-05-31|September 2005|Actual|2005-09-30|March 2004|Actual|2004-03-31||Interventional|||Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer|Phase II Trial of Single Agent ZD1839 (Iressa) in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|60||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.115101|2018-06-01 04:33:59.115101
NCT00193323|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-24|2005-09-12|2005-09-19|Estimate|||||||2010-06-24|2010-06-28|Estimate|August 2001||2001-08-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|May 2006|Actual|2006-05-31||Interventional|||Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients|A Randomized Phase III Comparison of Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|346||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.178345|2018-06-01 04:33:59.178345
NCT00193310|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-17|2005-09-12|2005-09-19|Estimate|||||||2015-03-17|2015-03-18|Estimate|November 2000||2000-11-30|March 2015|2015-03-31|January 2009|Actual|2009-01-31|November 2003|Actual|2003-11-30||Interventional|||Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer|Preoperative (Neoadjuvant) or Postoperative (Adjuvant) Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer|Completed||Phase 2|250||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.246054|2018-06-01 04:33:59.246054
NCT00193297|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|February 2002||2002-02-28|May 2011|2011-05-31|June 2006|Actual|2006-06-30|June 2005|Actual|2005-06-30||Interventional|||Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma|A Phase II Study of a Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin on Day Three in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma|Completed||Phase 2|50||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.319306|2018-06-01 04:33:59.319306
NCT00193284|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-18|2005-09-12|2005-09-19|Estimate|||||||2010-06-18|2010-06-22|Estimate|October 2003||2003-10-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|February 2006|Actual|2006-02-28||Interventional|||Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer|A Phase I/II Trial of Induction Chemotherapy Plus Gefitinib (Iressa) Followed by Concurrent Chemotherapy, Radiation Therapy, and Gefitinib (Iressa) For Patients With Locally Advanced Squamous Carcinoma of the Head and Neck|Completed||Phase 2|50||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.378705|2018-06-01 04:33:59.378705
NCT00193271|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|August 2004||2004-08-31|May 2011|2011-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer|Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer|Completed||Phase 2|30||SCRI Development Innovations, LLC|||||f||||f||||||||||2018-06-01 04:33:59.440367|2018-06-01 04:33:59.440367
NCT00193258|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-12-07||2013-01-24|2005-09-12|2005-09-19|Estimate|2012-12-07|2013-01-14|Estimate||||2013-01-24|2013-01-31|Estimate|June 2004||2004-06-30|January 2013|2013-01-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma|A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma|Completed||Phase 1/Phase 2|94|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:33:59.507103|2018-06-01 04:33:59.507103
NCT00193245|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-24|2005-09-12|2005-09-19|Estimate|||||||2010-06-24|2010-06-28|Estimate|November 2000||2000-11-30|January 2009|2009-01-31|January 2009|Actual|2009-01-31|October 2005|Actual|2005-10-31||Interventional|||Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer|A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer|Completed||Phase 2|80||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.846083|2018-06-01 04:33:59.846083
NCT00193232|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-27|2005-09-12|2005-09-19|Estimate|||||||2010-07-27|2010-07-28|Estimate|May 2004||2004-05-31|July 2010|2010-07-31|February 2007|Actual|2007-02-28|October 2005|Actual|2005-10-31||Interventional|||Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer|A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer|Completed||Phase 2|50||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:33:59.946358|2018-06-01 04:33:59.946358
NCT00193219|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-12-07||2013-03-06|2005-09-12|2005-09-19|Estimate|2013-02-01|2013-03-07|Estimate||||2013-03-06|2013-03-12|Estimate|July 2005||2005-07-31|March 2013|2013-03-31|July 2010|Actual|2010-07-31|June 2008|Actual|2008-06-30||Interventional|||Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer|A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|36|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:34:00.083432|2018-06-01 04:34:00.083432
NCT00193206|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-08-22||2012-10-31|2005-09-12|2005-09-19|Estimate|2012-10-31|2012-11-30|Estimate||||2012-10-31|2012-11-30|Estimate|September 2005||2005-09-30|October 2012|2012-10-31|May 2009|Actual|2009-05-31|October 2008|Actual|2008-10-31||Interventional|||Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer|Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer|Completed||Phase 2|123|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:34:00.416489|2018-06-01 04:34:00.416489
NCT00193193|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-03|2005-09-12|2005-09-19|Estimate|||||||2010-08-03|2010-08-04|Estimate|August 2000||2000-08-31|July 2010|2010-07-31|February 2007|Actual|2007-02-28|December 2003|Actual|2003-12-31||Interventional|||Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma|A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma|Completed||Phase 2|100||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:34:00.690942|2018-06-01 04:34:00.690942
NCT00193180|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-03-25||2016-04-27|2005-09-12|2005-09-19|Estimate|2013-03-25|2013-05-14|Estimate||||2016-04-27|2016-05-27|Estimate|May 2005||2005-05-31|April 2016|2016-04-30|January 2009|Actual|2009-01-31|May 2008|Actual|2008-05-31||Interventional|||Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer|Phase II Trial of Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer|Completed||Phase 2|37|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:34:00.796202|2018-06-01 04:34:00.796202
NCT00192569|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-04-13|2005-09-11|2005-09-19|Estimate|||||||2011-04-13|2011-04-15|Estimate|July 2004||2004-07-31|October 2009|2009-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Australian Trial in Acute Hepatitis C|Australian Trial in Acute Hepatitis C|Completed||Phase 4|167|Actual|Kirby Institute||2|||f||||t||||||||||2018-06-01 04:34:07.149986|2018-06-01 04:34:07.149986
NCT00193167|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|January 2004||2004-01-31|May 2011|2011-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer|Phase II Study of Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer|Completed||Phase 2|40||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:34:01.090646|2018-06-01 04:34:01.090646
NCT00193154|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-03-31|2005-09-12|2005-09-19|Estimate|||||||2014-03-31|2014-04-01|Estimate|February 2003||2003-02-28|March 2014|2014-03-31|March 2014|Actual|2014-03-31|January 2004|Actual|2004-01-31||Interventional|||OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma|A Phase II Trial of Tarceva (OSI-774) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|63|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:34:01.153339|2018-06-01 04:34:01.153339
NCT00193141|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|October 1999||1999-10-31|May 2011|2011-05-31|July 2007|Actual|2007-07-31|October 2004|Actual|2004-10-31||Interventional|||Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer|Paclitaxel, Carboplatin, Infusional 5-Fluorouracil, and Radiation Therapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer|Completed||Phase 2|200||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:34:01.240955|2018-06-01 04:34:01.240955
NCT00193128|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-03-26||2013-03-26|2005-09-12|2005-09-19|Estimate|2013-03-26|2013-05-13|Estimate||||2013-03-26|2013-05-13|Estimate|April 2004||2004-04-30|March 2013|2013-03-31|January 2009|Actual|2009-01-31|February 2008|Actual|2008-02-29||Interventional|||Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer|A Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction|Completed||Phase 1/Phase 2|59|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 04:34:01.319514|2018-06-01 04:34:01.319514
NCT00193115|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-03|2005-09-12|2005-09-19|Estimate|||||||2010-08-03|2010-08-04|Estimate|March 2004||2004-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|June 2005|Actual|2005-06-30||Interventional|||Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer|Phase II Pilot Trial of Dose-Dense Docetaxel Followed by Doxorubicin Plus Cyclophosphamide (T-AC) Given as Adjuvant or Neoadjuvant Treatment for Women With Node Positive or High-Risk Primary Breast Cancer|Completed||Phase 2|32||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:34:01.650372|2018-06-01 04:34:01.650372
NCT00193102|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|April 2001||2001-04-30|May 2011|2011-05-31|June 2010|Actual|2010-06-30|February 2005|Actual|2005-02-28||Interventional|||Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer|Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer|Terminated||Phase 2|40|Anticipated|SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:34:01.706452|2018-06-01 04:34:01.706452
NCT00193089|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-09|2005-09-12|2005-09-19|Estimate|||||||2015-12-09|2015-12-10|Estimate|April 2001||2001-04-30|December 2015|2015-12-31|September 2009|Actual|2009-09-30|April 2005|Actual|2005-04-30||Interventional|||Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer|Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2|Completed||Phase 2|60|Actual|SCRI Development Innovations, LLC|||||f||||t||||||||||2018-06-01 04:34:01.755026|2018-06-01 04:34:01.755026
NCT00193076|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|November 2003||2003-11-30|May 2011|2011-05-31|October 2008|Actual|2008-10-31|May 2006|Actual|2006-05-31||Interventional|||Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer|A Phase II Trial of Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer|Completed||Phase 2|96|Anticipated|SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:34:01.813268|2018-06-01 04:34:01.813268
NCT00193063|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-08-16||2014-02-10|2005-09-12|2005-09-19|Estimate|2014-02-10|2014-03-12|Estimate||||2014-02-10|2014-03-12|Estimate|July 2001||2001-07-31|February 2014|2014-02-28|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional|||Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer|Phase II Trial of Weekly Gemcitabine and Herceptin in the Treatment of Patients With HER-2 Overexpressing Metastatic Breast Cancer|Completed||Phase 2|41|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:34:01.872296|2018-06-01 04:34:01.872296
NCT00193050|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-08-22||2012-08-22|2005-09-12|2005-09-19|Estimate|2012-08-22|2012-09-21|Estimate||||2012-08-22|2012-09-21|Estimate|November 2001||2001-11-30|August 2012|2012-08-31|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer|Phase II Trial of Induction Chemotherapy With Weekly Gemcitabine, Epirubicin, Docetaxel as Primary Treatment of Locally Advanced or Inflammatory Breast Cancer Patients|Completed||Phase 2|110|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-06-01 04:34:02.054931|2018-06-01 04:34:02.054931
NCT00193037|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-08-22||2013-07-24|2005-09-12|2005-09-19|Estimate|2013-06-17|2013-07-19|Estimate||||2013-07-24|2013-07-31|Estimate|February 2001||2001-02-28|July 2013|2013-07-31|November 2009|Actual|2009-11-30|December 2008|Actual|2008-12-31||Interventional|||Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer|A Phase II Randomized Crossover Study Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer|Completed||Phase 2|102|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-06-01 04:34:02.216404|2018-06-01 04:34:02.216404
NCT00193024|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|September 2001||2001-09-30|May 2011|2011-05-31|October 2004|Actual|2004-10-31|October 2003|Actual|2003-10-31||Interventional|||Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer|A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer|Terminated||Phase 2|90||SCRI Development Innovations, LLC|||||f||||||||||||||2018-06-01 04:34:02.631031|2018-06-01 04:34:02.631031
NCT00193011|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-02|2005-09-12|2005-09-19|Estimate|||||||2011-05-02|2011-05-03|Estimate|March 2002||2002-03-31|May 2011|2011-05-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer|A Randomized Multicenter Trial Comparing Weekly Docetaxel and CMF in the Adjuvant Treatment of Women With High-Risk Breast Cancer Who Are > 65 Years Old or Are Not Candidates for Anthracycline-Based Adjuvant Therapy|Completed||Phase 3|150|Anticipated|SCRI Development Innovations, LLC||2|||f||||||||||||||2018-06-01 04:34:02.730287|2018-06-01 04:34:02.730287
NCT00192998|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-26|2005-09-13|2005-09-19|Estimate|||||||2007-09-26|2007-09-27|Estimate|October 2003||2003-10-31|September 2005|2005-09-30||||||||Observational|||The Serotonergic Transmitter System in Dementia and Affective Disorders||Unknown status|Recruiting||100|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:02.823188|2018-06-01 04:34:02.823188
NCT00192972|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-21|2005-09-12|2005-09-19|Estimate|||||||2005-12-21|2005-12-22|Estimate|November 2002||2002-11-30|November 2003|2003-11-30|June 2005||2005-06-30|||||Interventional|||A Randomized Trial of the Ostial Versus the Extra-Ostial Ablation Strategy for Atrial Fibrillation|A Randomized Trial of the Ostial Versus the Extra-Ostial Ablation Strategy for Atrial Fibrillation (LASso Vs CARto)|Completed||N/A|100||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:02.98686|2018-06-01 04:34:02.98686
NCT00192959|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-16|2005-09-16|2005-09-19|Estimate|||||||2005-09-16|2005-09-19|Estimate|March 2004||2004-03-31|June 2005|2005-06-30|December 2004||2004-12-31|||||Interventional|||Xenon Inhalation During Orthopaedic Surgery in Elderly Subjects.|Xenon Inhalation as Cover Sedation During Orthopaedic Surgery in Elderly Subjects Comparing the Effects of Inhaled Xenon and Intravenous Propofol|Completed||Phase 3|44||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:03.079812|2018-06-01 04:34:03.079812
NCT00192946|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-07-09|2005-09-16|2005-09-19|Estimate|||||||2007-07-09|2007-07-10|Estimate||||February 2006|2006-02-28|September 2008|Anticipated|2008-09-30|||||Interventional|||The CRT-KIR Study (Cardiac Resynchronization Therapy [CRT] in the Early Phase After Heart Surgery)|Cardiac Resynchronization Therapy (CRT) in the Early Phase After Heart Surgery|Withdrawn||N/A|60|Anticipated|Rigshospitalet, Denmark||||The study population is smaller than expected. No subjects were included.|f||||||||||||||2018-06-01 04:34:03.15728|2018-06-01 04:34:03.15728
NCT00192933|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-18|2005-09-13|2005-09-19|Estimate|||||||2006-10-18|2006-10-19|Estimate|January 2000||2000-01-31|September 2005|2005-09-30|December 2010||2010-12-31|||||Observational|||Evaluation of the Quality of the NovoSeven (rFVIIa) Tratment Practice at Rigshospitalet, Copenhagen University Hospital||Unknown status|Recruiting||||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:03.234137|2018-06-01 04:34:03.234137
NCT00192920|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-18|2005-09-13|2005-09-19|Estimate|||||||2006-10-18|2006-10-19|Estimate|January 2000||2000-01-31|September 2005|2005-09-30|December 2010||2010-12-31|||||Observational|||Evaluation of the Quality of the Transfusion Practice at Rigshospitalet, Copenhagen University Hospital||Unknown status|Recruiting||||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:03.297099|2018-06-01 04:34:03.297099
NCT00192907|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-16|2005-09-16|2005-09-19|Estimate|||||||2005-09-16|2005-09-19|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Inflammation and Infection in Trauma, Role in Posttraumatic Complications||Unknown status|Active, not recruiting||380||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:03.362183|2018-06-01 04:34:03.362183
NCT00192894|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-19|Estimate|||||||2005-09-12|2005-09-19|Estimate|May 2004||2004-05-31|September 2005|2005-09-30|March 2005||2005-03-31|||||Observational|||New Methods to Detect a Decrease in Heart Function|Cardiac Output Changes During Onset of Spinal Anesthesia in Elderly Patients|Completed|||32||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:03.415714|2018-06-01 04:34:03.415714
NCT00192881|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-17|2005-09-12|2005-09-19|Estimate|||||||2010-08-17|2010-08-18|Estimate|October 2002||2002-10-31|July 2010|2010-07-31||||||||Interventional|||Stenting With or Without Coating Compared With Angioplasty in Non-benestent Disease|Stenting With or Without Coating Compared With Angioplasty in Non-benestent Disease. A Randomised Comparison of Optimal Balloon Angioplasty and Primary Implantation of Stents With and Without Drug Elution in Complex Coronary Lesions|Unknown status|Not yet recruiting|N/A|||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:03.465731|2018-06-01 04:34:03.465731
NCT00192868|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-09-22|2005-09-12|2005-09-19|Estimate|||||||2009-09-22|2009-09-23|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|November 2011|Anticipated|2011-11-30|November 2009|Anticipated|2009-11-30||Interventional|||Drug Elution and Distal Protection During Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction|Drug Elution and DIstal Protection During Percutaneous CoronAry Intervention in sT Elevation Myocardial InfarctiON. Acronym: Dedication|Unknown status|Active, not recruiting|N/A|600|Anticipated|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:34:03.533028|2018-06-01 04:34:03.533028
NCT00192855|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-08-24|2005-09-14|2005-09-19|Estimate|||||||2010-08-24|2010-08-25|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Entacapone Augmentation for Schizophrenia|Entacapone Augmentation for Schizophrenia- A Randomized Controlled Trial|Completed||N/A|52|Actual|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:03.602862|2018-06-01 04:34:03.602862
NCT00192842|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-09-21|2005-09-16|2005-09-19|Estimate|||||||2010-09-21|2010-09-22|Estimate|July 2004||2004-07-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|November 2007|Actual|2007-11-30||Interventional|||Gemcitabine With Curcumin for Pancreatic Cancer|Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|17|Actual|Rambam Health Care Campus|||||f||||f||||||||||2018-06-01 04:34:03.678553|2018-06-01 04:34:03.678553
NCT00192829|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-10|2005-09-14|2005-09-19|Estimate|||||||2007-04-10|2007-04-11|Estimate|June 2005||2005-06-30|March 2007|2007-03-31||||||||Observational|||Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma|Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma|Unknown status|Recruiting||100||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:03.749921|2018-06-01 04:34:03.749921
NCT00192816|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-19|Estimate|||||||2005-09-13|2005-09-19|Estimate|June 2005||2005-06-30|September 2005|2005-09-30||||||||Observational|||Pain Perception in Alzheimer's Disease|Pain Perception in Alzheimer's Disease|Unknown status|Recruiting||60||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:03.837078|2018-06-01 04:34:03.837078
NCT00192803|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-02-22|2005-09-14|2005-09-19|Estimate|||||||2006-02-22|2006-02-23|Estimate||||September 2005|2005-09-30||||||||Interventional|||Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs|ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs|Unknown status|Not yet recruiting|Phase 4|20||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:03.904526|2018-06-01 04:34:03.904526
NCT00192790|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-10|2005-09-12|2005-09-19|Estimate|||||||2007-04-10|2007-04-11|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|March 2005|Actual|2005-03-31|||||Observational|||Pain Perception is Attenuated in Patients With Painless Myocardial Infarction|Clinical and Experimental Pain Perception is Attenuated in Patients With Painless Myocardial Infarction|Completed|||100||Rambam Health Care Campus|||||f||||t||||||||||2018-06-01 04:34:03.967987|2018-06-01 04:34:03.967987
NCT00192777|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-05|2005-09-13|2005-09-19|Estimate|||||||2007-10-05|2007-10-08|Estimate|November 2004||2004-11-30|September 2005|2005-09-30||||||||Interventional|||Concurrent Xeloda and Radiotherapy for Bone Metastases|Concurrent Xeloda and Radiotherapy for Bone Metastases|Unknown status|Recruiting|Phase 2|20|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:04.024027|2018-06-01 04:34:04.024027
NCT00192764|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-09-21|2005-09-13|2005-09-19|Estimate|||||||2010-09-21|2010-09-22|Estimate|December 1996||1996-12-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|||||Interventional|||High Dose CHOP in Lymphoma|Phase II Study of Short High-dose CHOP Chemotherapy for Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|45||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:04.12908|2018-06-01 04:34:04.12908
NCT00192751|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-10-26|2005-09-12|2005-09-19|Estimate|||||||2005-10-26|2005-10-27|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||From Compliance to Alliance: Engaging Psychiatric Patients in Illness Management|Impact of Psycho-Educational Intervention on Patients With Severe Mental Illness Recently Discharged From Psychiatric Inpatient Services|Unknown status|Recruiting|N/A|150||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:04.192515|2018-06-01 04:34:04.192515
NCT00192738|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-10|2005-09-12|2005-09-19|Estimate|||||||2007-04-10|2007-04-11|Estimate|April 2003||2003-04-30|April 2007|2007-04-30|January 2006|Actual|2006-01-31|||||Observational|||Does Telephone Follow-up Improve Patients Satisfaction|Does Telephone Follow-up After Discharge Improve Patients Satisfaction and Decrease Hospitalization|Completed|||400||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:04.254299|2018-06-01 04:34:04.254299
NCT00192725|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-08-24|2005-09-11|2005-09-19|Estimate|||||||2010-08-24|2010-08-25|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|June 2008|Actual|2008-06-30|October 2007|Actual|2007-10-31||Interventional|||Tryptophan Depletion in Acute Mania|Tryptophan Depletion in Acute Mania - A Randomized Controlled Trial|Completed||N/A|40|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:04.300473|2018-06-01 04:34:04.300473
NCT00192712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-11-09|2005-09-11|2005-09-19|Estimate|||||||2010-11-09|2010-11-10|Estimate|November 2002||2002-11-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|||||Interventional|||Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer|Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer|Completed||Phase 2/Phase 3|20||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:34:04.356649|2018-06-01 04:34:04.356649
NCT00192699|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2014-03-28|2005-09-11|2005-09-19|Estimate|||||||2014-03-28|2014-03-31|Estimate|January 2004||2004-01-31|March 2014|2014-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Bimetric-10: Investigation of Patients Who Have Underwent Total Hip Arthroplasty With a Cemented Bi-Metric Stem|10 Year Follow-up Investigation of Patients Who Have Underwent Total Hip Arthroplasty With a Cemented Bi-metric Stem|Completed|||80|Actual|Northern Orthopaedic Division, Denmark|||1||f||||t||||||||||2018-06-01 04:34:04.407559|2018-06-01 04:34:04.407559
NCT00192686|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2014-03-28|2005-09-11|2005-09-19|Estimate|||||||2014-03-28|2014-03-31|Estimate|January 2004||2004-01-31|March 2014|2014-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Cultures a.m.Kamme-Lindbergh in Suspicion of Infected TKA|Cultures From Total Knee Arthroplasties, Obtained a.m. Kamme-Lindberg in Revision Cases.|Completed|||||Northern Orthopaedic Division, Denmark|||||f||||||||||||||2018-06-01 04:34:04.488249|2018-06-01 04:34:04.488249
NCT00192673|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2009-09-29|2005-09-11|2005-09-19|Estimate|||||||2009-09-29|2009-09-30|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|December 2013|Anticipated|2013-12-31|||||Interventional|||Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses|PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 4|85|Anticipated|Nordic Society for Pediatric Hematology and Oncology|||||f||||||||||||||2018-06-01 04:34:04.541057|2018-06-01 04:34:04.541057
NCT00192660|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-04-11|2005-09-16|2005-09-19|Estimate|||||||2012-04-11|2012-04-12|Estimate|February 2003||2003-02-28|April 2012|2012-04-30|December 2007|Actual|2007-12-31|October 2006|Actual|2006-10-31||Interventional|||HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)|Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time|Completed||Phase 4|80|Actual|Kirby Institute|||||f||||f||||||||||2018-06-01 04:34:04.622373|2018-06-01 04:34:04.622373
NCT00192647|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-05-06||2016-06-23|2005-09-13|2005-09-19|Estimate|2016-05-06|2016-06-14|Estimate||||2016-06-23|2016-08-04|Estimate|August 2004||2004-08-31|June 2016|2016-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||Intent-to-treat (ITT) analysis population included all randomized participants who received at least 1 dose of study drug.|A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection|A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1|Completed||Phase 4|896|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:34:04.795258|2018-06-01 04:34:04.795258
NCT00192634|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-24|2005-09-13|2005-09-19|Estimate|||||||2011-05-24|2011-05-25|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study|A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study.|Completed||Phase 4|357|Actual|Kirby Institute||2|||f||||t||||||||||2018-06-01 04:34:06.524027|2018-06-01 04:34:06.524027
NCT00192621|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-04-11|2005-09-12|2005-09-19|Estimate|||||||2012-04-11|2012-04-12|Estimate|November 2004||2004-11-30|April 2012|2012-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects|A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism|Completed||Phase 4|50|Actual|Kirby Institute|||||f||||f||||||||||2018-06-01 04:34:06.765353|2018-06-01 04:34:06.765353
NCT00192608|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-25|2005-09-13|2005-09-19|Estimate|||||||2009-06-25|2009-06-26|Estimate|November 2004||2004-11-30|June 2009|2009-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|ASK-500||A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study|A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation.|Completed||N/A|40|Actual|Kirby Institute||2|||f||||f||||||||||2018-06-01 04:34:06.882474|2018-06-01 04:34:06.882474
NCT00192595|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-03-30|2005-09-12|2005-09-19|Estimate|||||||2015-03-30|2015-04-01|Estimate|January 2004||2004-01-31|March 2015|2015-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|TICO||Tenofovir in HIV/HBV Coinfection|Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection|Completed||Phase 4|36|Actual|Kirby Institute||3|||f||||t||||||||||2018-06-01 04:34:06.975511|2018-06-01 04:34:06.975511
NCT00192556|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-02-08|2005-09-11|2005-09-19|Estimate|||||||2007-02-08|2007-02-12|Estimate|March 2005||2005-03-31|February 2007|2007-02-28|August 2006||2006-08-31|||||Interventional|||Food Incentives for TB Treatment Compliance in East Timor (FITTCET)|Food Incentives for TB Treatment Compliance in East Timor|Completed||N/A|270||Menzies School of Health Research|||||f||||||||||||||2018-06-01 04:34:07.264604|2018-06-01 04:34:07.264604
NCT00192543|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-08-03|2005-09-11|2005-09-19|Estimate|||||||2011-08-03|2011-08-04|Estimate|May 2004||2004-05-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Fish and Fruit Study: Trial of Fish and Fruit to Improve Survival of Aboriginal People With End Stage Renal Disease|A Clinical Trial of Fish and Fruit to Improve Survival of Aboriginal People With End Stage Renal Disease|Completed||Phase 3|152|Actual|Menzies School of Health Research||2|||f||||f||||||||||2018-06-01 04:34:07.33366|2018-06-01 04:34:07.33366
NCT00192517|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-02|2005-09-13|2005-09-19|Estimate|||||||2009-04-02|2009-04-03|Estimate|December 2003||2003-12-31|April 2009|2009-04-30|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of MEDI-522, a Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults With Plaque Psoriasis|Completed||Phase 2|44|Actual|MedImmune LLC||2|||f||||||||||||||2018-06-01 04:34:07.410403|2018-06-01 04:34:07.410403
NCT00192504|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-23|2005-09-13|2005-09-19|Estimate|||||||2006-10-23|2006-10-25|Estimate|March 2004||2004-03-31|October 2006|2006-10-31|January 2005||2005-01-31|||||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection|A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children Hospitalized With RSV Infection|Completed||Phase 1|31||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:07.51393|2018-06-01 04:34:07.51393
NCT00192491|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-02-07|2005-09-14|2005-09-19|Estimate|||||||2008-02-07|2008-02-08|Estimate|December 2000||2000-12-31|February 2008|2008-02-29|December 2003|Actual|2003-12-31|September 2003|Anticipated|2003-09-30||Interventional|||Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children|A Randomized, Placebo-Controlled, Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, (MMRIIÒ) and Varicella (VARIVAXÒ) Vaccines Administered Concurrently to Healthy Children (AV018)|Completed||Phase 3|1200|Anticipated|MedImmune LLC||3|||f||||f||||||||||2018-06-01 04:34:07.581191|2018-06-01 04:34:07.581191
NCT00192478|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-24|2005-09-13|2005-09-19|Estimate|||||||2008-07-24|2008-07-28|Estimate|February 2004||2004-02-29|July 2008|2008-07-31|August 2006|Actual|2006-08-31|May 2006|Actual|2006-05-31||Interventional|||Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524|A Phase 1/2, Open-Label, Repeat-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children at Risk for Serious RSV Disease|Completed||Phase 1/Phase 2|217|Actual|MedImmune LLC||1|||f||||||||||||||2018-06-01 04:34:07.661358|2018-06-01 04:34:07.661358
NCT00192465|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-28|2005-09-13|2005-09-19|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 2003||2003-11-30|January 2009|2009-01-31|November 2004|Actual|2004-11-30|April 2004|Actual|2004-04-30||Interventional|||Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults|A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 (NUMAX TM), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Healthy Adults|Completed||Phase 1|30|Actual|MedImmune LLC||5|||f||||||||||||||2018-06-01 04:34:07.73726|2018-06-01 04:34:07.73726
NCT00192452|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-23|2005-09-13|2005-09-19|Estimate|||||||2006-10-23|2006-10-25|Estimate|March 2001||2001-03-31|October 2006|2006-10-31|December 2001||2001-12-31|||||Interventional|||Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis|A Phase II Randomized, Double-Blind, Placebo-Controlled Study of MEDI-507, a Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults With Plaque Psoriasis|Completed||Phase 2|120||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:07.815439|2018-06-01 04:34:07.815439
NCT00192439|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-04|2005-09-13|2005-09-19|Estimate|||||||2007-05-04|2007-05-07|Estimate|December 2003||2003-12-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Observational|||Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk|A Study to Describe the Incidence Rate and Clinical Features of Human Meta Pneumovirus (hMPV) Infection of the Lower Respiratory Tract in Hospitalized Children at High Risk for Severe Disease|Completed|||1500|Actual|MedImmune LLC|||||f||||||||||||||2018-06-01 04:34:08.01666|2018-06-01 04:34:08.01666
NCT00192426|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-02|2005-09-13|2005-09-19|Estimate|||||||2006-10-02|2006-10-03|Estimate|September 2001||2001-09-30|October 2006|2006-10-31|December 2001||2001-12-31|||||Interventional|||Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.|A Prospective, Randomized, Partially-Blinded, Placebo-Controlled, Phase III, Multicenter Trial to Assess Safety, Tolerability and Immunogenicity of Liquid CAIV-T Administered Concomitantly With OPV in Healthy Children|Completed||Phase 3|2400||MedImmune LLC|||||f||||||||||||||2018-06-01 04:34:08.126064|2018-06-01 04:34:08.126064
NCT00192413|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-13|2005-09-13|2005-09-19|Estimate|||||||2012-03-13|2012-03-14|Estimate|March 2002||2002-03-31|March 2012|2012-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|FluMist||Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza|A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older|Completed||Phase 3|3009|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 04:34:08.20973|2018-06-01 04:34:08.20973
NCT00192400|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-02|2005-09-13|2005-09-19|Estimate|||||||2006-10-02|2006-10-03|Estimate|March 2002||2002-03-31|October 2006|2006-10-31|November 2002||2002-11-30|||||Interventional|||Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of One Dose and Two Doses of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) Compared With Placebo in Healthy Children|Completed||Phase 3|2160||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:08.328094|2018-06-01 04:34:08.328094
NCT00192387|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-12-27|2005-09-13|2005-09-19|Estimate|||||||2006-12-27|2006-12-28|Estimate|September 2001||2001-09-30|December 2006|2006-12-31|December 2001||2001-12-31|||||Interventional|||Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)|A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate Viral Shedding in Healthy Children (6 Mos and Less Than or Equal to 18 Months of Age) Vaccinated With Two Doses of Liquid Formulation of Influenza Virus Vaccine, Live Cold Adapted (CAIV-T)|Completed||Phase 2|60||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:08.49668|2018-06-01 04:34:08.49668
NCT00192374|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-02|2005-09-12|2005-09-19|Estimate|||||||2006-10-02|2006-10-03|Estimate|February 2002||2002-02-28|October 2006|2006-10-31|November 2002||2002-11-30|||||Interventional|||Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase III, Multicenter Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B,Live, Cold-Adapted (CAIV-T) in Healthy Children|Completed||Phase 3|1920||MedImmune LLC|||||f||||||||||||||2018-06-01 04:34:08.608346|2018-06-01 04:34:08.608346
NCT00192361|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-23|2005-09-12|2005-09-19|Estimate|||||||2006-10-23|2006-10-25|Estimate|November 1999||1999-11-30|October 2006|2006-10-31||||||||Interventional|||Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)|A Randomized, Double-Blind Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)|Completed||Phase 3|200||MedImmune LLC|||||f||||||||||||||2018-06-01 04:34:08.710426|2018-06-01 04:34:08.710426
NCT00192348|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-02|2005-09-12|2005-09-19|Estimate|||||||2006-10-02|2006-10-03|Estimate|May 2002||2002-05-31|October 2006|2006-10-31|December 2002||2002-12-31|||||Interventional|||A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants|A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Infants|Completed||Phase 1|120||MedImmune LLC|||||f||||||||||||||2018-06-01 04:34:08.797998|2018-06-01 04:34:08.797998
NCT00192335|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-26|2005-09-12|2005-09-19|Estimate|||||||2007-11-26|2007-11-27|Estimate|July 2004||2004-07-31|November 2007|2007-11-30|February 2005|Actual|2005-02-28|||||Interventional|||Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants|A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years|Completed||Phase 3|890|Actual|MedImmune LLC||2|||f||||||||||||||2018-06-01 04:34:08.86601|2018-06-01 04:34:08.86601
NCT00192322|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-02-15|2005-09-12|2005-09-19|Estimate|||||||2012-02-15|2012-02-17|Estimate|September 2001||2001-09-30|February 2012|2012-02-29|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|CAIVT||Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children|A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live Cold Adapted (CAIV-T) in Healthy Children Aged 6 to Less Than 36 Months|Completed||Phase 2|173|Actual|MedImmune LLC||4|||f||||f||||||||||2018-06-01 04:34:08.964706|2018-06-01 04:34:08.964706
NCT00192309|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-02-13|2005-09-12|2005-09-19|Estimate|||||||2012-02-13|2012-02-14|Estimate|September 2001||2001-09-30|February 2012|2012-02-29|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.|A Randomized, Open-Label, Placebo-Controlled Trial to Investigate the Kinetics of the Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Adults Aged 18 to <65 Years.|Completed||Phase 2|31|Actual|MedImmune LLC||3|||f||||f||||||||||2018-06-01 04:34:09.067666|2018-06-01 04:34:09.067666
NCT00192296|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-10-17||2014-02-04|2005-09-12|2005-09-19|Estimate|2014-02-04|2014-03-06|Estimate||||2014-02-04|2014-03-06|Estimate|August 2004||2004-08-31|February 2014|2014-02-28|March 2005|Actual|2005-03-31|February 2005|Actual|2005-02-28||Interventional|||Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers|A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|MedImmune LLC||4|||f||||||||||||||2018-06-01 04:34:09.223434|2018-06-01 04:34:09.223434
NCT00192283|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-04-08|2005-09-12|2005-09-19|Estimate|||||||2009-04-08|2009-04-10|Estimate|September 2000||2000-09-30|April 2009|2009-04-30|May 2002|Actual|2002-05-31|April 2002|Actual|2002-04-30||Interventional|||Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in Healthy Children Attending Day Care Centers|Completed||Phase 3|2903|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 04:34:10.011783|2018-06-01 04:34:10.011783
NCT00192270|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-05|2005-09-12|2005-09-19|Estimate|||||||2012-03-05|2012-03-06|Estimate|October 2000||2000-10-31|March 2012|2012-03-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|FluMist||Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children|A Prospective, Open-label, Phase II, Multi-center Study of the Safety, Tolerability and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children, Aged 6 to 17 Years|Completed||Phase 2|498|Actual|MedImmune LLC||1|||f||||f||||||||||2018-06-01 04:34:10.101476|2018-06-01 04:34:10.101476
NCT00192257|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-02|2005-09-12|2005-09-19|Estimate|||||||2006-10-02|2006-10-03|Estimate|October 2002||2002-10-31|October 2006|2006-10-31|May 2003||2003-05-31|||||Interventional|||Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma|A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children With Asthma Aged 6 Years to 17 Years|Completed||Phase 3|2229||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:10.202659|2018-06-01 04:34:10.202659
NCT00192088|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|May 2004||2004-05-31|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||A Study of Pemetrexed Plus Oxaliplatin as First Line Therapy in Advanced Gastric Carcinoma|Open-Label Single-Arm Phase II Study of ALIMTA in Combination With Oxaliplatin as First-Line Therapy in Advanced Gastric Carcinoma|Completed||Phase 2|43||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:11.546401|2018-06-01 04:34:11.546401
NCT00192244|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-02|2005-09-12|2005-09-19|Estimate|||||||2006-10-02|2006-10-03|Estimate|September 2000||2000-09-30|October 2006|2006-10-31|October 2002||2002-10-31|||||Interventional|||Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in Healthy Children|Completed||Phase 3|3000||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:10.268479|2018-06-01 04:34:10.268479
NCT00192231|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-23|2005-09-12|2005-09-19|Estimate|||||||2006-10-23|2006-10-25|Estimate|April 2001||2001-04-30|October 2006|2006-10-31|June 2001||2001-06-30|||||Interventional|||Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)|A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults Aged 18 and Older|Completed||Phase 3|120||MedImmune LLC|||||f||||||||||||||2018-06-01 04:34:10.405699|2018-06-01 04:34:10.405699
NCT00192218|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-19|2005-09-12|2005-09-19|Estimate|||||||2008-09-19|2008-09-22|Estimate|October 2004||2004-10-31|September 2008|2008-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program|A Phase IV Study to Evaluate the Effectiveness of Flumist (Influenza Vaccine, Live Intranasal) Vaccination in a School-Based Intervention Program|Completed||Phase 4|3022|Actual|MedImmune LLC||1|||f||||||||||||||2018-06-01 04:34:10.580797|2018-06-01 04:34:10.580797
NCT00192205|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-02|2005-09-12|2005-09-19|Estimate|||||||2006-10-02|2006-10-03|Estimate|October 2002||2002-10-31|October 2006|2006-10-31|June 2003||2003-06-30|||||Interventional|||Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children|A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, Trivalent, Type A&B, Live, Cold-Adapted (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children With a History of Recurrent Respiratory Tract Infections Aged 6 Months to Less Than 72 Months|Completed||Phase 3|2200||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:10.711128|2018-06-01 04:34:10.711128
NCT00192192|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-23|2005-09-12|2005-09-19|Estimate|||||||2006-10-23|2006-10-25|Estimate|November 2000||2000-11-30|October 2006|2006-10-31|December 2000||2000-12-31|||||Interventional|||Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults|A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults Aged 18 to 64 Years|Completed||Phase 3|20||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:10.804662|2018-06-01 04:34:10.804662
NCT00192179|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-02-29|2005-09-12|2005-09-19|Estimate|||||||2012-02-29|2012-03-02|Estimate|June 2003||2003-06-30|February 2012|2012-02-29|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|FluMist||A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.|A Phase II, Prospective, Randomized, Double-Blind, Placebo, Controlled Trial, to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A & B Live Cold-Adapted Liquid Formulation (CAIV-T) in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.|Completed||Phase 2|240|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 04:34:10.8725|2018-06-01 04:34:10.8725
NCT00192166|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-12-05|2005-09-12|2005-09-19|Estimate|||||||2008-12-05|2008-12-08|Estimate|October 2002||2002-10-31|December 2008|2008-12-31|May 2003|Actual|2003-05-31|March 2003|Actual|2003-03-31||Interventional|||Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months|Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months|Completed||Phase 2|1200||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:11.018351|2018-06-01 04:34:11.018351
NCT00192153|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-23|2005-09-12|2005-09-19|Estimate|||||||2006-10-23|2006-10-25|Estimate|July 2001||2001-07-31|October 2006|2006-10-31|October 2001||2001-10-31|||||Interventional|||Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older|A Randomized, Partially-Blinded, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Adults 18 to 59 Years and Healthy Adults,60 Years/Older|Completed||Phase 2|240||MedImmune LLC|||||||||||||||||||2018-06-01 04:34:11.103515|2018-06-01 04:34:11.103515
NCT00192140|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-27|2005-09-12|2005-09-19|Estimate|||||||2007-12-27|2007-12-28|Estimate|June 2004||2004-06-30|December 2007|2007-12-31|January 2005|Actual|2005-01-31|October 2004|Actual|2004-10-31||Interventional|||Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age|An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age|Completed||Phase 4|345||MedImmune LLC||1|||f||||t||||||||||2018-06-01 04:34:11.1753|2018-06-01 04:34:11.1753
NCT00192127|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-12|2005-09-12|2005-09-19|Estimate|||||||2007-12-12|2007-12-18|Estimate|August 2004||2004-08-31|December 2007|2007-12-31|February 2005|Actual|2005-02-28|||||Interventional|||Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|Completed||Phase 3|300||MedImmune LLC||2|||f||||||||||||||2018-06-01 04:34:11.276678|2018-06-01 04:34:11.276678
NCT00192114|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14||2009-02-17|2009-10-05|2005-09-14|2005-09-19|Estimate||||2009-10-05|2009-10-07|Estimate|2009-10-05|2009-10-07|Estimate|August 2005||2005-08-31|October 2009|2009-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Enzastaurin for Patients With Metastatic Colorectal Cancer|A Phase 2 Study of Oral Enzastaurin HCl in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|30|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 04:34:11.377738|2018-06-01 04:34:11.377738
NCT00192101|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-16|2005-09-13|2005-09-19|Estimate|||||||2007-11-16|2007-11-20|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|July 2005||2005-07-31|||||Interventional|||Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes|Randomized Phase II Study of the Combination of Gemcitabine (Gemzar) Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines an/or Taxanes|Completed||Phase 2|100||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:11.470851|2018-06-01 04:34:11.470851
NCT00192075|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-10-30||2011-02-04|2005-09-13|2005-09-19|Estimate|2009-11-17|2009-12-23|Estimate||||2011-02-04|2011-02-07|Estimate|June 2003||2003-06-30|November 2009|2009-11-30|November 2007|Actual|2007-11-30|||||Interventional|||A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer|A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer|Completed||Phase 2|84|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 04:34:11.715681|2018-06-01 04:34:11.715681
NCT00192062|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-29|2005-09-15|2005-09-19|Estimate|||||||2007-08-29|2007-08-31|Estimate|July 2004||2004-07-31|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer|A Phase II Trial of Gemcitabine (Gemzar) Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer|Completed||Phase 2|80||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:12.90874|2018-06-01 04:34:12.90874
NCT00192049|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-16|2005-09-12|2005-09-19|Estimate|||||||2007-05-16|2007-05-17|Estimate|December 2003||2003-12-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer|A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer|Completed||Phase 2|90||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:12.987738|2018-06-01 04:34:12.987738
NCT00192036|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-02-23||2010-11-22|2005-09-12|2005-09-19|Estimate|2009-02-23|2009-03-25|Estimate||||2010-11-22|2010-12-09|Estimate|August 2004||2004-08-31|November 2010|2010-11-30|November 2009|Actual|2009-11-30|January 2008|Actual|2008-01-31||Interventional|||Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer|Multicenter Phase II Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer|Completed||Phase 2|49|Actual|Eli Lilly and Company|Enrollment was stopped early due to difficulties with patient recruitment. Given the number of missing/unknown tumor assessments, care should be taken when interpreting the primary outcome measure. An identified error was corrected in the results.|1|||f||||f||||||||||2018-06-01 04:34:13.103408|2018-06-01 04:34:13.103408
NCT00192023|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-05-15||2009-12-09|2005-09-12|2005-09-19|Estimate|2009-12-09|2010-01-18|Estimate||||2009-12-09|2010-01-18|Estimate|October 2004||2004-10-31|December 2009|2009-12-31|May 2008|Actual|2008-05-31|August 2006|Actual|2006-08-31||Interventional|||An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).|An Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder|Completed||Phase 3|139|Actual|Eli Lilly and Company|Due to the open-ended timing of the open-label period (up to 1.5 years or until commercial availability) the efficacy data from the open-label extension phase is not included except for adverse event data.|2|||f||||f||||||||||2018-06-01 04:34:13.64144|2018-06-01 04:34:13.64144
NCT00191997|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-21|2005-09-12|2005-09-19|Estimate|||||||2006-07-21|2006-07-25|Estimate|October 2004||2004-10-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode|Optimal Treatment Duration With Olanzapine Following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies.|Completed||Phase 4|180||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:14.577698|2018-06-01 04:34:14.577698
NCT00191984|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-04-27||2011-01-03|2005-09-12|2005-09-19|Estimate|2009-04-27|2009-06-15|Estimate||||2011-01-03|2011-01-05|Estimate|June 2004||2004-06-30|January 2011|2011-01-31|May 2008|Actual|2008-05-31|February 2007|Actual|2007-02-28||Interventional|||A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer|Open Multicenter Phase II Study in Second-Line Metastatic Colorectal Cancer Patients: Combination of ALIMTA and Irinotecan Administered Every Two-Weeks|Completed||Phase 2|46|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:34:14.805268|2018-06-01 04:34:14.805268
NCT00191971|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen|A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|40||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:15.355831|2018-06-01 04:34:15.355831
NCT00191945|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-02-06||2010-01-26|2005-09-12|2005-09-19|Estimate|2009-12-21|2010-01-26|Estimate||||2010-01-26|2010-02-02|Estimate|May 2005||2005-05-31|January 2010|2010-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 Weeks in Newly Diagnosed Children and Adolescents Outpatients With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|151|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:34:15.586033|2018-06-01 04:34:15.586033
NCT00191932|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-21|2005-09-12|2005-09-19|Estimate|||||||2006-07-21|2006-07-25|Estimate|August 2004||2004-08-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Switching to Duloxetine From Other Antidepressants|Switching to Duloxetine From Other Antidepressants: A Regional Multicentre Trial Comparing Two Switching Techniques|Completed||Phase 4|360||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:16.678295|2018-06-01 04:34:16.678295
NCT00191919|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|May 2005||2005-05-31|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain|A Ten-Week, Randomized, Double-Blind Study Evaluating the Efficacy of Duloxetine 60mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain|Completed||Phase 3|310||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:16.993017|2018-06-01 04:34:16.993017
NCT00191906|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-12-11||2010-05-17|2005-09-12|2005-09-19|Estimate|2010-03-19|2010-04-06|Estimate||||2010-05-17|2010-05-25|Estimate|April 2005||2005-04-30|May 2010|2010-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)|A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder.|Completed||Phase 4|121|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 04:34:17.202326|2018-06-01 04:34:17.202326
NCT00191893|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|November 2006||2006-11-30|||||Interventional|||Bone Effects of Teriparatide Following Alendronate|Bone Effects of Subcutaneous Teriparatide Following Discontinuation of Alendronate Treatment in Postmenopausal Women With Osteoporosis|Completed||Phase 3|66||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:19.49079|2018-06-01 04:34:19.49079
NCT00191880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-08-24|2005-09-12|2005-09-19|Estimate|||||||2006-08-24|2006-08-29|Estimate|May 2004||2004-05-31|August 2006|2006-08-31|June 2006||2006-06-30|||||Interventional|||Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder|A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|100||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:19.831433|2018-06-01 04:34:19.831433
NCT00191867|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Clinical Trial of Teriparatide in Japan|Assessment of Dose Response of LY333334 in Japanese Postmenopausal Women With Osteoporosis|Completed||Phase 2|160||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:20.201289|2018-06-01 04:34:20.201289
NCT00191854|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-07-21||2010-02-24|2005-09-12|2005-09-19|Estimate|2009-07-21|2009-08-31|Estimate||||2010-02-24|2010-03-02|Estimate|March 2005||2005-03-31|February 2010|2010-02-28|November 2009|Actual|2009-11-30|August 2008|Actual|2008-08-31||Interventional|||Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line|Randomized Phase II Study of Biweekly Gemcitabine-Paclitaxel, Biweekly Gemcitabine-Carboplatin and Biweekly Gemcitabine-Cisplatin as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure|Completed||Phase 2|147|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-06-01 04:34:20.373911|2018-06-01 04:34:20.373911
NCT00191841|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-21|2005-09-12|2005-09-19|Estimate|||||||2006-07-21|2006-07-24|Estimate|December 2002||2002-12-31|July 2006|2006-07-31|February 2006||2006-02-28|||||Interventional|||Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy|Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy in Operable Non Small Cell Lung Cancer|Completed||Phase 2|50||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:21.71613|2018-06-01 04:34:21.71613
NCT00191828|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|March 2003||2003-03-31|January 2007|2007-01-31|August 2005||2005-08-31|||||Interventional|||A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme|A Prospective/Parallel Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme|Completed||Phase 4|60||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:21.866363|2018-06-01 04:34:21.866363
NCT00191815|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-10-13||2009-11-09|2005-09-12|2005-09-19|Estimate|2009-07-07|2009-08-19|Estimate||||2009-11-09|2009-11-11|Estimate|October 2002||2002-10-31|November 2009|2009-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Combination Chemotherapy for Metastatic Breast Cancer|Phase II Study of Gemcitabine Plus Cisplatin as First-line Treatment of Metastatic Breast Cancer|Completed||Phase 2|70|Actual|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:34:22.060498|2018-06-01 04:34:22.060498
NCT00191802|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|October 2005||2005-10-31|||||Interventional|||Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients|Compliance With and Acceptance of Teriparatide Pen Injection in Severely Osteoporotic Patients [CATS]|Completed||Phase 3|120||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:22.669075|2018-06-01 04:34:22.669075
NCT00191789|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-04-29||2010-07-21|2005-09-12|2005-09-19|Estimate|2010-06-23|2010-07-22|Estimate||||2010-07-21|2010-07-27|Estimate|February 2003||2003-02-28|July 2010|2010-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer|Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study|Completed||Phase 2|65|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:34:22.76202|2018-06-01 04:34:22.76202
NCT00191763|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|November 2002||2002-11-30|November 2007|2007-11-30|December 2005|Actual|2005-12-31|||||Interventional|||Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer|Phase II Trial of Gemcitabine and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Non-Small Cell Lung Cancer|Completed||Phase 2|52||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:24.464078|2018-06-01 04:34:24.464078
NCT00191750|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|July 2004||2004-07-31|January 2007|2007-01-31|September 2006||2006-09-30|||||Interventional|||A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned|Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer|Completed||Phase 2|80||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:24.585275|2018-06-01 04:34:24.585275
NCT00191737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|February 2006||2006-02-28|||||Interventional|||An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder|An Open-Label Study on Effectiveness and Tolerability of Atomoxetine, as Perceived by Patients, Parents, and Physicians in Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany|Completed||Phase 3|147||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:24.747129|2018-06-01 04:34:24.747129
NCT00191724|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-01-14||2009-06-16|2005-09-12|2005-09-19|Estimate|2009-04-28|2009-06-17|Estimate||||2009-06-16|2009-06-24|Estimate|September 2004||2004-09-30|June 2009|2009-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study|Drotrecogin Alfa (Activated) (LY203638)] Exploratory, Safety Study, Multi-Center, Randomized, Placebo-Controlled, Dose Escalating Study Design, Comparing a Standard Therapy (Enoxaparin Sodium) for Submassive Pulmonary Embolism to a Combined Therapy of Drotrecogin Alfa (Activated) Plus Enoxaparin Sodium.|Completed||Phase 2|47|Actual|Eli Lilly and Company|This study was stopped early after 47 patients had been enrolled (planned enrollment was 48 patients). Study was stopped early due to slow enrollment.|5|||f||||t||||||||||2018-06-01 04:34:25.813455|2018-06-01 04:34:25.813455
NCT00191711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|February 2004||2004-02-29|January 2007|2007-01-31|October 2005||2005-10-31|||||Interventional|||Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.|Phase II Study of 6 Weeks Intravesical Gemcitabine Instillation Followed By Transurethral Resection in Patients Affected By Superficial Bladder Cancer at Low Risk|Completed||Phase 2|43||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:29.532902|2018-06-01 04:34:29.532902
NCT00191698|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-29|2005-09-12|2005-09-19|Estimate|||||||2008-10-29|2008-10-31|Estimate|December 2003||2003-12-31|October 2008|2008-10-31|November 2007|Actual|2007-11-30|June 2005|Actual|2005-06-30||Interventional|||Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD|A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride and Placebo in Child and Adolescent Outpatients With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder|Completed||Phase 3|226|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:34:29.603483|2018-06-01 04:34:29.603483
NCT00191685|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-21|2005-09-12|2005-09-19|Estimate|||||||2006-07-21|2006-07-25|Estimate|May 2004||2004-05-31|July 2006|2006-07-31|September 2005||2005-09-30|||||Interventional|||Duloxetine in the Treatment of Melancholic Depression|Duloxetine in the Treatment of Melancholic Depression: An 8-Week Open-Label Dose Study|Completed||Phase 3|200||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:29.854491|2018-06-01 04:34:29.854491
NCT00191672|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|December 2003||2003-12-31|January 2007|2007-01-31|November 2006||2006-11-30|||||Interventional|||A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer|A Phase II Randomized Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Patients With Metastatic Breast Cancer|Completed||Phase 2|120||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:29.979272|2018-06-01 04:34:29.979272
NCT00191659|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-02-28|2005-09-12|2005-09-19|Estimate|||||||2007-02-28|2007-03-02|Estimate|June 2004||2004-06-30|February 2007|2007-02-28|April 2006||2006-04-30|||||Interventional|||Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents|A Randomised, Controlled, Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents|Completed||Phase 3|200||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:30.057055|2018-06-01 04:34:30.057055
NCT00191646|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-08-12||2011-02-28|2005-09-12|2005-09-19|Estimate|2010-08-12|2010-09-09|Estimate||||2011-02-28|2011-03-04|Estimate|October 2002||2002-10-31|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy|Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma|Completed||Phase 3|919|Actual|Eli Lilly and Company|Trial was designed with overall survival as primary endpoint. Enrollment was slower than expected. After 4 years, 919 patients were randomized and in August 2006, protocol was amended: primary endpoint was changed to progression free survival (PFS).|2|||f||||t||||||||||2018-06-01 04:34:30.19899|2018-06-01 04:34:30.19899
NCT00191633|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|April 2005||2005-04-30|January 2007|2007-01-31|June 2006||2006-06-30|||||Interventional|||Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes|A 3 Month Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder; Symptomatic and Functional Outcomes.|Completed||Phase 4|200||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.078939|2018-06-01 04:34:33.078939
NCT00191620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|March 2004||2004-03-31|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.|Randomized Phase II Study of Cisplatin + Gemcitabine Administered Either as Short Infusion or at a Fixed Dose Rate in Non-Small Cell Lung Cancer|Completed||Phase 2|64||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.2083|2018-06-01 04:34:33.2083
NCT00191607|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|July 2002||2002-07-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.|A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy|Completed||Phase 3|162||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.271495|2018-06-01 04:34:33.271495
NCT00191594|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|March 2005||2005-03-31|January 2007|2007-01-31|August 2006||2006-08-31|||||Interventional|||Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine Trials|Open-Label Duloxetine Extension Phase in Patients Who Have Completed the HMDG Clinical Trial|Completed||Phase 3|105||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.334046|2018-06-01 04:34:33.334046
NCT00191581|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-28|2005-09-12|2005-09-19|Estimate|||||||2006-07-28|2006-07-31|Estimate|March 2005||2005-03-31|July 2006|2006-07-31|April 2006||2006-04-30|||||Interventional|||Local Registration Trial in China Humalog Mix 50|Comparison of 2-Hour Postprandial Blood Glucose Excursion in Response to a Standard Test Meal in Insulin-Requiring Diabetic Patients Treated Twice Daily With Either Insulin Lispro Mix 50/50 or Human Insulin Mix 50/50|Completed||Phase 3|120||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.399696|2018-06-01 04:34:33.399696
NCT00191568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-18|2005-09-12|2005-09-19|Estimate|||||||2007-10-18|2007-10-19|Estimate|October 2002||2002-10-31|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer|A Phase II Trial of Adjuvant Treatment With Gemcitabine and Oxaliplatin Followed by Concomitant Gemcitabine and Radiation Therapy in Patients With Resected Pancreatic Adenocarcinoma|Completed||Phase 2|45||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.464756|2018-06-01 04:34:33.464756
NCT00191555|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-06-08|2005-09-12|2005-09-19|Estimate|||||||2012-06-08|2012-06-12|Estimate|August 2003||2003-08-31|July 2006|2006-07-31|May 2006||2006-05-31|||||Interventional|||Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment|Double-Blind Long-term Study Comparing the Efficacy and Safety of Olanzapine Versus Haloperidol in Patients With Schizophrenia Previously Stabilized With Conventional Antipsychotic Treatment|Completed||Phase 4|360||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.654653|2018-06-01 04:34:33.654653
NCT00191542|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-10|2005-09-12|2005-09-19|Estimate|||||||2006-10-10|2006-10-11|Estimate|March 2005||2005-03-31|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents|A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and Adolescents|Completed||Phase 3|100||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.872607|2018-06-01 04:34:33.872607
NCT00187291|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-13|2005-09-13|2005-09-16|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2001||2001-04-30|April 2015|2015-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study to Compare TWA Test and EPS Test for Predicting Patients at Risk for Life-threatening Heart Rhythms (ABCD Study)|Alternans Before Cardioverter Defibrillator (ABCD) Trial|Completed||Phase 3|618||St. Jude Medical|||||f||||t||||||||||2018-06-01 04:35:23.07809|2018-06-01 04:35:23.07809
NCT00191529|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-06-13|2005-09-12|2005-09-19|Estimate|||||||2007-06-13|2007-06-15|Estimate|December 2002||2002-12-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Growth Hormone Treatment in Short Children Born Small for Gestational Age|Optimization of Growth Hormone Treatment in Short Children Born Small for Gestational Age Based on a Growth Prediction Model-The OPTIMA Trial|Completed||Phase 3|200||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:33.955572|2018-06-01 04:34:33.955572
NCT00191516|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|February 2006||2006-02-28|||||Interventional|||An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder|An Open-Label Study on Effectiveness and Tolerability of Atomoxetine as Perceived by Patients, Parents, and Physicians in Children With Attention-Deficit/Hyperactivity Disorder in Germany|Completed||Phase 3|257||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:34.059432|2018-06-01 04:34:34.059432
NCT00191503|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma|Phase II Study of Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma|Completed||Phase 2|30||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:34.111947|2018-06-01 04:34:34.111947
NCT00191490|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|July 2002||2002-07-31|January 2007|2007-01-31|May 2005||2005-05-31|||||Interventional|||A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer|A Multicenter Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel (RP56976, TAXOTERE *) and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non Small Cell Lung Cancer|Completed||Phase 2|162||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:34.172602|2018-06-01 04:34:34.172602
NCT00191477|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-17||2009-09-24|2005-09-12|2005-09-19|Estimate|2009-09-24|2009-10-28|Estimate||||2009-09-24|2009-10-28|Estimate|January 2004||2004-01-31|September 2009|2009-09-30|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Instillation of Gemcitabine in Patients With Superficial Bladder Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder|Terminated||Phase 3|355|Actual|Eli Lilly and Company|The study was stopped early for futility reasons. In addition, due to limitations in this databank, some original outcome measures are not disclosed. Time to Recurrence and Recurrence-Free Survival in Subgroups had data that were un-estimated.|2||The study was stopped early for futility reasons.|f||||t||||||||||2018-06-01 04:34:34.254046|2018-06-01 04:34:34.254046
NCT00191464|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-10-12|2005-09-12|2005-09-19|Estimate|||||||2010-10-12|2010-10-13|Estimate|December 2003||2003-12-31|October 2010|2010-10-31|September 2005||2005-09-30|||||Interventional|||Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes|Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes: A Comparison of Premeal Insulin Lispro Mixtures to Once-Daily Insulin Glargine|Completed||Phase 4|320||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:35.386542|2018-06-01 04:34:35.386542
NCT00191451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-10-12||2009-11-17|2005-09-12|2005-09-19|Estimate|2009-10-12|2009-11-17|Estimate||||2009-11-17|2009-11-20|Estimate|April 2004||2004-04-30|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer|Phase II Trial of Gemzar Plus Paraplatin (Plus Herceptin in HER2+ Patients) in Metastatic Breast Cancer|Completed||Phase 2|150|Actual|Eli Lilly and Company||3|||f||||||||||||||2018-06-01 04:34:35.635386|2018-06-01 04:34:35.635386
NCT00191438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-25|2005-09-12|2005-09-19|Estimate|||||||2007-05-25|2007-05-28|Estimate|October 2002||2002-10-31|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents|Phase III Study of Docetaxel in Combination With Gemcitabine Versus Docetaxel in Combination With Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 3|300||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:36.581631|2018-06-01 04:34:36.581631
NCT00191425|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-07-12|2005-09-12|2005-09-19|Estimate|||||||2007-07-12|2007-07-16|Estimate|August 2002||2002-08-31|July 2007|2007-07-31|November 2005||2005-11-30|||||Interventional|||2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis|Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis|Completed||Phase 4|810||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:36.667528|2018-06-01 04:34:36.667528
NCT00191412|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-19|2005-09-12|2005-09-19|Estimate|||||||2007-11-19|2007-11-20|Estimate|January 2005||2005-01-31|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver|Phase II Study of Single-Agent Alimta in the Treatment of Patients With Advanced and Metastatic Hepatoma|Completed||Phase 2|41||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:36.718718|2018-06-01 04:34:36.718718
NCT00191399|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|May 2004||2004-05-31|January 2007|2007-01-31|March 2006||2006-03-31|||||Interventional|||Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response|Bipolar Depression Assessment Study on Tx Response|Completed||Phase 4|150||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:36.773625|2018-06-01 04:34:36.773625
NCT00191386|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-08-24||2010-12-14|2005-09-12|2005-09-19|Estimate|2010-10-14|2010-11-10|Estimate||||2010-12-14|2010-12-28|Estimate|May 2005||2005-05-31|December 2010|2010-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)|Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|228|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:34:36.846334|2018-06-01 04:34:36.846334
NCT00191373|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-11|2005-09-12|2005-09-19|Estimate|||||||2007-09-11|2007-09-12|Estimate|March 2002||2002-03-31|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease|Phase II Study of Gemcitabine and Trastuzumab Therapy in Patients With HER2 Overexpressing Metastatic Breast Cancer|Completed||Phase 2|66||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:37.446929|2018-06-01 04:34:37.446929
NCT00190801|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|September 2005||2005-09-30|||||Interventional|||Phase 2 Study on Use of a Combination of Pemetrexed in Patients With Advanced Gastric Carcinoma|Open-Label Single-Arm Phase 2 Study of ALIMTA Plus Cisplatin in Korean Patients With Advanced Gastric Carcinoma|Completed||Phase 2|50||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.750991|2018-06-01 04:34:49.750991
NCT00191360|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|January 2003||2003-01-31|November 2007|2007-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency|Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency|Completed||Phase 3|68||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:37.519253|2018-06-01 04:34:37.519253
NCT00191347|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer|A Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer|Completed||Phase 2|30||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:37.648349|2018-06-01 04:34:37.648349
NCT00191334|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-12-17||2009-02-24|2005-09-12|2005-09-19|Estimate|2009-02-24|2009-03-27|Estimate||||2009-02-24|2009-03-27|Estimate|December 2004||2004-12-31|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Gemcitabine in Ovarian Cancer|Phase II Study of Gemcitabine Plus Cisplatin as First-Line Therapy in Patients With Epithelial Ovarian Cancer|Completed||Phase 2|50|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 04:34:37.737458|2018-06-01 04:34:37.737458
NCT00191321|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|July 2004||2004-07-31|January 2007|2007-01-31|December 2005||2005-12-31|||||Interventional|||Teriparatide Use in Hip Replaced Subjects|TUHRS Study - Teriparatide Use in Hip Replaced Subjects A Pilot Study on the Use of Teriparatide in Severe Osteoporotic Women With Hip Fracture and Submitted to Hip Replacement|Completed||Phase 3|60||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:38.171665|2018-06-01 04:34:38.171665
NCT00191308|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-03-16||2011-10-13|2005-09-12|2005-09-19|Estimate|2010-03-16|2010-04-20|Estimate||||2011-10-13|2011-10-21|Estimate|May 2005||2005-05-31|October 2011|2011-10-31|December 2010|Actual|2010-12-31|July 2008|Actual|2008-07-31||Interventional|||Molecular Profiling in Lung Cancer Patients|Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy|Completed||Phase 2|30|Actual|Eli Lilly and Company|Trial enrollment was terminated early due to lack of eligible participants.|1|||f||||f||||||||||2018-06-01 04:34:38.259652|2018-06-01 04:34:38.259652
NCT00191295|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 2/Phase 3|240||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:38.485021|2018-06-01 04:34:38.485021
NCT00191282|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-10-17||2011-01-18|2005-09-12|2005-09-19|Estimate|2009-06-19|2009-08-04|Estimate||||2011-01-18|2011-01-20|Estimate|October 2002||2002-10-31|January 2011|2011-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|IONM||Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes|Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D)|Completed||Phase 4|1116|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 04:34:38.832236|2018-06-01 04:34:38.832236
NCT00191269|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-23||2010-03-10|2005-09-12|2005-09-19|Estimate|2009-03-23|2009-05-14|Estimate||||2010-03-10|2010-03-17|Estimate|June 2005||2005-06-30|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2008|Actual|2008-03-31||Interventional|||Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen|A Multicenter Study of LY188011 in Anthracyclines and Taxanes Pre-treated Metastatic/Recurrent Breast Cancer|Completed||Phase 2|68|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 04:34:40.518192|2018-06-01 04:34:40.518192
NCT00191256|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|June 2001||2001-06-30|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer|Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC|Completed||Phase 2|77||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:41.253266|2018-06-01 04:34:41.253266
NCT00191243|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-21|2005-09-12|2005-09-19|Estimate|||||||2016-11-21|2016-11-22|Estimate|March 2002||2002-03-31|November 2016|2016-11-30|April 2009|Actual|2009-04-30|August 2007|Actual|2007-08-31||Interventional|||Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer|A Randomized Phase II Study Comparing Single-Agent Docetaxel to Alternating Docetaxel-Gemcitabine as Primary Chemotherapy in Patients With Metastatic Breast Cancer|Completed||Phase 2|237|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 04:34:41.326535|2018-06-01 04:34:41.326535
NCT00191230|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2001||2001-09-30|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer|A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC|Completed||Phase 2|70||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:41.410729|2018-06-01 04:34:41.410729
NCT00191204|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2001||2001-09-30|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Open Label Phase III Duloxetine Study for Stress Urinary Incontinence|Long Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence|Completed||Phase 3|363||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:41.462937|2018-06-01 04:34:41.462937
NCT00191191|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-10-23||2009-12-04|2005-09-12|2005-09-19|Estimate|2009-10-23|2009-11-25|Estimate||||2009-12-04|2009-12-09|Estimate|October 2004||2004-10-31|December 2009|2009-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)|LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial|Completed||Phase 2|226|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:34:41.543443|2018-06-01 04:34:41.543443
NCT00191178|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-10-12|2005-09-12|2005-09-19|Estimate|||||||2010-10-12|2010-10-13|Estimate|August 2003||2003-08-31|October 2010|2010-10-31|July 2005||2005-07-31|||||Interventional|||Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes|Pilot Study Investigating the Effects of Insulin Lispro Low Mixture Therapy Compared With Insulin Glargine on Perceived Mood Symptoms in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|60||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:42.242034|2018-06-01 04:34:42.242034
NCT00191165|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-04-07||2009-06-08|2005-09-12|2005-09-19|Estimate|2009-04-07|2009-06-08|Estimate||||2009-06-08|2009-06-10|Estimate|March 2004||2004-03-31|June 2009|2009-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency|Efficacy and Safety of a High Dosage Compared to the Label Dosage of Humatrope in Early Pubertal Stage Children With Growth Hormone Deficiency|Completed||Phase 3|27|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:34:42.320005|2018-06-01 04:34:42.320005
NCT00191152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-11-04||2009-12-21|2005-09-12|2005-09-19|Estimate|2009-11-04|2009-12-08|Estimate||||2009-12-21|2009-12-24|Estimate|February 2002||2002-02-28|December 2009|2009-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Phase III Trial For Patients With Metastatic Breast Cancer|Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd|Completed||Phase 3|475|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 04:34:42.753638|2018-06-01 04:34:42.753638
NCT00191139|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-11-20||2010-02-04|2005-09-12|2005-09-19|Estimate|2009-11-20|2009-12-25|Estimate||||2010-02-04|2010-02-17|Estimate|March 2003||2003-03-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|November 2008|Actual|2008-11-30||Interventional|||Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)|A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC|Completed||Phase 2|64|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:34:43.869492|2018-06-01 04:34:43.869492
NCT00191126|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-21|2005-09-12|2005-09-19|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2000||2000-09-30|November 2016|2016-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC|Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages(T2N0, T1 - 2N1, T3N0 AND T3N1) Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|263|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 04:34:44.59636|2018-06-01 04:34:44.59636
NCT00191113|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-12-01||2009-12-13|2005-09-12|2005-09-19|Estimate|2009-12-13|2010-01-27|Estimate||||2009-12-13|2010-01-27|Estimate|February 1989||1989-02-28|December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|GDCT||Somatropin Treatment to Final Height in Turner Syndrome|Humatrope Treatment to Final Height in Turner's Syndrome|Completed||Phase 3|154|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 04:34:44.810294|2018-06-01 04:34:44.810294
NCT00191100|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-30||2009-08-08|2005-09-12|2005-09-19|Estimate|2009-03-30|2009-05-25|Estimate||||2009-08-08|2009-08-11|Estimate|May 2002||2002-05-31|August 2009|2009-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix|Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA|Completed||Phase 3|515|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 04:34:45.884686|2018-06-01 04:34:45.884686
NCT00191087|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|April 2001||2001-04-30|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Duloxetine in the Treatment of Stress Urinary Incontinence.|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence.|Completed||Phase 3|458||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:34:46.789781|2018-06-01 04:34:46.789781
NCT00191074|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-07|2005-09-12|2005-09-19|Estimate|||||||2007-03-07|2007-03-09|Estimate|February 2001||2001-02-28|March 2007|2007-03-31|January 2006||2006-01-31|||||Interventional|||Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature|Phase III Study of Humatrope in Non-Growth Hormone Deficient Children With Short Stature|Completed||Phase 3|11||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:46.840894|2018-06-01 04:34:46.840894
NCT00191061|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|January 2006||2006-01-31|||||Interventional|||A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder|A Comparison of Duloxetine Dosing Strategies in The Treatment of Patients With Major Depression|Completed||Phase 4|640||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:46.894999|2018-06-01 04:34:46.894999
NCT00191048|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2003||2003-10-31|January 2007|2007-01-31|March 2006||2006-03-31|||||Interventional|||Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD|Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia|Completed||Phase 4|105||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:47.002535|2018-06-01 04:34:47.002535
NCT00191035|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-12-12|2005-09-12|2005-09-19|Estimate|||||||2006-12-12|2006-12-13|Estimate|March 2004||2004-03-31|December 2006|2006-12-31|November 2006||2006-11-30|||||Interventional|||Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD|Maintenance of Benefit After 8-Week and 52-Week Treatment With Atomoxetine Hydrochloride in Adolescents With ADHD|Completed||Phase 4|520||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:47.087213|2018-06-01 04:34:47.087213
NCT00191022|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-02-12|2005-09-12|2005-09-19|Estimate|||||||2007-02-12|2007-02-13|Estimate|December 2004||2004-12-31|February 2007|2007-02-28|January 2007||2007-01-31|||||Interventional|||Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder|A Randomized, Double-Blind Comparison of LY686017, Paroxetine, and Placebo in the Treatment of Social Anxiety Disorder|Completed||Phase 2|185||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:47.172108|2018-06-01 04:34:47.172108
NCT00191009|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|October 2003||2003-10-31|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease|Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer's Disease|Completed||Phase 2/Phase 3|124||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:47.248866|2018-06-01 04:34:47.248866
NCT00190996|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|January 2003||2003-01-31|January 2007|2007-01-31|June 2006||2006-06-30|||||Interventional|||Evaluate Safety and Efficacy of Duloxetine in Predominant Stress Urinary Incontinence|The Safety and Effectiveness of Duloxetine Compared With Placebo and Its Long-Term Safety and Efficacy in the Treatment of Predominant Stress Urinary Incontinence|Completed||Phase 3|2765||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:48.207367|2018-06-01 04:34:48.207367
NCT00190983|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2008-10-21||2009-11-13|2005-09-12|2005-09-19|Estimate|2009-07-13|2009-08-24|Estimate||||2009-11-13|2009-11-20|Estimate|February 2005||2005-02-28|November 2009|2009-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Trial for Patients With Advanced/Recurrent Cervical Cancer|A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix|Completed||Phase 2|29|Actual|Eli Lilly and Company||1|||||||||||||||||2018-06-01 04:34:48.305444|2018-06-01 04:34:48.305444
NCT00190970|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-07-25|2005-09-12|2005-09-19|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2004||2004-10-31|July 2016|2016-07-31|November 2005||2005-11-30|||||Interventional|||The Effect of Ruboxistaurin on Small Fiber Function|The Effect of Ruboxistaurin Mesylate (LY333531) on Small Fiber Function as Measured by Microvascular Skin Blood Flow, C-Fiber Quantitations in Skin and Quantitative Sensory Testing of Cold and Heat.|Completed||Phase 2|52||Chromaderm, Inc.|||||||||||||||||||2018-06-01 04:34:48.535855|2018-06-01 04:34:48.535855
NCT00190957|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|August 2004||2004-08-31|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse|Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial|Completed||Phase 4|140||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:48.589251|2018-06-01 04:34:48.589251
NCT00190944|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-10|2005-09-12|2005-09-19|Estimate|||||||2007-10-10|2007-10-12|Estimate|December 2004||2004-12-31|October 2007|2007-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Effects of Teriparatide on Distal Radius Fracture Healing|Effects of Teriparatide on Distal Radius Fracture Healing|Completed||Phase 2|105||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:48.667118|2018-06-01 04:34:48.667118
NCT00190931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-21|2005-09-12|2005-09-19|Estimate|||||||2006-07-21|2006-07-24|Estimate|November 2003||2003-11-30|July 2006|2006-07-31|July 2005||2005-07-31|||||Interventional|||A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder|A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder|Completed||Phase 4|400||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:48.842449|2018-06-01 04:34:48.842449
NCT00190918|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-07|2005-09-12|2005-09-19|Estimate|||||||2007-08-07|2007-08-09|Estimate|July 2006||2006-07-31|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||A Trial for Patients With Gestational Trophoblastic Disease|A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor|Completed||Phase 2|50|Anticipated|Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:48.902055|2018-06-01 04:34:48.902055
NCT00190905|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-21|2005-09-12|2005-09-19|Estimate|||||||2006-07-21|2006-07-25|Estimate|February 2004||2004-02-29|July 2006|2006-07-31|July 2005||2005-07-31|||||Interventional|||Safety and Effectiveness Study of Duloxetine HCl in Women of Different Backgrounds With Stress Urinary Incontinence Who May Also Have Other Various Medical Conditions.|Study of Duloxetine HCl in Women of Different Demographic Characteristics and Co-Morbidities With Stress Urinary Incontinence: Evaluation of Efficacy and Safety|Completed||Phase 4|4000||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:48.971385|2018-06-01 04:34:48.971385
NCT00190892|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2004||2004-09-30|January 2007|2007-01-31|June 2006||2006-06-30|||||Interventional|||Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania|Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder|Completed||Phase 4|120||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.028126|2018-06-01 04:34:49.028126
NCT00190879|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-06-06|2005-09-12|2005-09-19|Estimate|||||||2007-06-06|2007-06-08|Estimate|June 2005||2005-06-30|June 2007|2007-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder|Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder|Completed||Phase 4|440||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.118384|2018-06-01 04:34:49.118384
NCT00190866|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|June 2005||2005-06-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome|Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome|Completed||Phase 3|210||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.234494|2018-06-01 04:34:49.234494
NCT00190853|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|September 2006||2006-09-30|||||Interventional|||Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence|Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women With Stress Urinary Incontinence|Completed||Phase 3|93||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.342409|2018-06-01 04:34:49.342409
NCT00190840|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|October 2005||2005-10-31|||||Interventional|||A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer|Open-Label Single-Arm Phase 2 Study of ALIMTA in Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy|Completed||Phase 2|186||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.416522|2018-06-01 04:34:49.416522
NCT00190827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)|The Effectiveness of Duloxetine Compared With Placebo in the Treatment of Predominant Stress Urinary Incontinence|Completed||Phase 3|500||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.48987|2018-06-01 04:34:49.48987
NCT00190814|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.|Efficacy and Safety of Duloxetine Compared With Placebo in Women With Symptoms of Mixed Urinary Incontinence.|Completed||Phase 3|600||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.641409|2018-06-01 04:34:49.641409
NCT00190788|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-10|2005-09-12|2005-09-19|Estimate|||||||2007-10-10|2007-10-12|Estimate|June 2004||2004-06-30|October 2007|2007-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion|A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96 Hour Infusion With Commercial Drotrecogin Alfa (Activated)|Completed||Phase 3|200|Anticipated|Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:49.829339|2018-06-01 04:34:49.829339
NCT00190775|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-07-14||2011-08-18|2005-09-12|2005-09-19|Estimate|2010-10-04|2010-10-21|Estimate||||2011-08-18|2011-08-22|Estimate|September 2004||2004-09-30|October 2010|2010-10-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder: With a Secondary Examination of Impact of Treatment on Family Functioning|Completed||Phase 4|502|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:34:50.054669|2018-06-01 04:34:50.054669
NCT00190762|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2001||2001-10-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma|A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma|Completed||Phase 3|240||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:52.677937|2018-06-01 04:34:52.677937
NCT00190749|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-06-03||2010-04-26|2005-09-12|2005-09-19|Estimate|2009-06-03|2009-07-23|Estimate||||2010-04-26|2010-05-04|Estimate|October 2003||2003-10-31|April 2010|2010-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder|Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone|Completed||Phase 4|130|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:34:52.790057|2018-06-01 04:34:52.790057
NCT00190736|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-05|2005-09-12|2005-09-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)|Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months); With a Brief Evaluation of Executive Cognition|Completed||Phase 4|440||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:54.198951|2018-06-01 04:34:54.198951
NCT00190723|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2002||2002-10-31|January 2007|2007-01-31|December 2006||2006-12-31|||||Interventional|||A Study of LY317615 in Patients With Brain Tumors|A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas|Completed||Phase 2|120||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:54.320573|2018-06-01 04:34:54.320573
NCT00190710|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-10|2005-09-12|2005-09-19|Estimate|||||||2007-11-10|2007-11-14|Estimate|March 2004||2004-03-31|November 2007|2007-11-30|August 2007|Actual|2007-08-31|||||Interventional|||A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer|A Randomized Phase III Trial of Paraplatin (Carboplatin) + Gemzar Versus Gemzar Alone in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|242||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:54.463541|2018-06-01 04:34:54.463541
NCT00190697|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-23|2005-09-12|2005-09-19|Estimate|||||||2007-05-23|2007-05-25|Estimate|January 2001||2001-01-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment|Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer|Completed||Phase 4|70||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:54.537468|2018-06-01 04:34:54.537468
NCT00190684|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-10-01||2010-12-15|2005-09-12|2005-09-19|Estimate|2010-12-15|2011-01-17|Estimate||||2010-12-15|2011-01-17|Estimate|August 2000||2000-08-31|December 2010|2010-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Long-Term, Open Label Atomoxetine Study|Long-Term, Open Label Safety Study of Atomoxetine Hydrochloride in Patients, 6 Years and Older With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|1553|Actual|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:34:54.646137|2018-06-01 04:34:54.646137
NCT00190671|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-17||2009-11-17|2005-09-12|2005-09-19|Estimate|2009-05-28|2009-07-16|Estimate||||2009-11-17|2009-11-20|Estimate|June 2005||2005-06-30|November 2009|2009-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients|A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|103|Actual|Eli Lilly and Company|600 mg/m2 arm discontinued at end of Phase 1 because of lack of efficacy. Enrollment in 1800 mg/m2 arm continued to Phase 2. (Phase 1 outcomes were tumor response and pharmacokinetics). Secondary efficacy endpoints analyzed for 1800 mg/m2 arm only.|2|||f||||f||||||||||2018-06-01 04:34:55.976964|2018-06-01 04:34:55.976964
NCT00190658|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-12-17|2005-09-12|2005-09-19|Estimate|||||||2010-12-17|2010-12-20|Estimate|February 2000||2000-02-29|December 2010|2010-12-31|September 2010|Actual|2010-09-30|July 2004|Actual|2004-07-31||Interventional|||Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome|Safety and Efficacy of Humatrope in Pediatric Patients With Genetic Short Stature (SHOX Gene Defect)|Completed||Phase 3|75||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:56.57834|2018-06-01 04:34:56.57834
NCT00190645|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|February 2001||2001-02-28|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence|Completed||Phase 3|600||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:56.631991|2018-06-01 04:34:56.631991
NCT00190632|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|March 2001||2001-03-31|January 2007|2007-01-31|April 2006||2006-04-30|||||Interventional|||To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence|Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence|Completed||Phase 3|600||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:56.749291|2018-06-01 04:34:56.749291
NCT00190619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|May 2001||2001-05-31|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Efficacy and Safety of Duloxetine|Efficacy and Safety of Duloxetine Compared With Placebo in Subjects Electing Surgery for Severe Pure Genuine Stress Incontinence|Completed||Phase 3|100||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:56.80293|2018-06-01 04:34:56.80293
NCT00190606|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|January 2002||2002-01-31|January 2007|2007-01-31|April 2006||2006-04-30|||||Interventional|||Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence|Efficacy and Safety of Duloxetine Compared With Placebo,Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects With Moderate to Sever Stress Urinary Incontinence|Completed||Phase 2|200||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:56.862367|2018-06-01 04:34:56.862367
NCT00190593|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|June 1998||1998-06-30|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Raloxifene Use for The Heart|Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events|Completed||Phase 3|10000||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:56.919268|2018-06-01 04:34:56.919268
NCT00190580|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-03-30|2005-09-11|2005-09-19|Estimate|||||||2015-03-30|2015-03-31|Estimate|February 2003||2003-02-28|March 2009|2009-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease|Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT)|Completed||Phase 4|312|Actual|KVT-Study Group||2|||f||||t||||||||||2018-06-01 04:34:56.978056|2018-06-01 04:34:56.978056
NCT00190567|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-24|2005-09-12|2005-09-19|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2001||2001-10-31|January 2007|2007-01-31|April 2006||2006-04-30|||||Interventional|||Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence|Biomechanical Effects of Duloxetine on Bladder Function and Sphincter Resistance During the Emptying Phase and on Urethral Function During the Filling Phase of the Micturition Cycle in Women With Pure Genuine Stress Incontinence|Completed||Phase 2|50||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:34:57.050425|2018-06-01 04:34:57.050425
NCT00190554|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-09-20|2005-09-13|2005-09-19|Estimate|||||||2016-09-20|2016-09-22|Estimate|May 2000||2000-05-31|September 2016|2016-09-30|May 2009|Actual|2009-05-31|May 2004|Actual|2004-05-31||Interventional|||A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma|A Randomized Controlled Trial of Chemotherapy With 5FU and Cisplatin Before and After Surgery for Stage II,III Squamous Cell Carcinoma of the Thoracic Esophagus:JCOG9907|Terminated||Phase 3|330||Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:34:57.123287|2018-06-01 04:34:57.123287
NCT00190541|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-09-20|2005-09-13|2005-09-19|Estimate|||||||2016-09-20|2016-09-22|Estimate|June 2003||2003-06-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Mesorectal Excision (ME) Versus ME With Lateral Node Dissection for Stage II, III Lower Rectal Cancer (JCOG0212)|Mesorectal Excision With Lateral Lymph Node Dissection Versus Without Lateral Lymph Node Dissection for Clinical Stage II, III Lower Rectal Cancer (JCOG0212)|Completed||Phase 3|700|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:34:57.212292|2018-06-01 04:34:57.212292
NCT00190528|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-09-20|2005-09-13|2005-09-19|Estimate|||||||2016-09-20|2016-09-22|Estimate|February 2002||2002-02-28|September 2016|2016-09-30|February 2009|Actual|2009-02-28|December 2004|Actual|2004-12-31||Interventional|||A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer|Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Bulky Stage I/II Cervical Cancer: Japan Clinical Oncology Group Trial (JCOG0102)|Terminated||Phase 3|200|Actual|Japan Clinical Oncology Group||2|||f||||||||||||||2018-06-01 04:34:58.321644|2018-06-01 04:34:58.321644
NCT00190515|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-09-20|2005-09-12|2005-09-19|Estimate|||||||2016-09-20|2016-09-22|Estimate|February 2003||2003-02-28|September 2016|2016-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)|Randomized Phase III Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)|Completed||Phase 3|1101|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:34:58.408018|2018-06-01 04:34:58.408018
NCT00190502|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-01-08|2005-09-11|2005-09-19|Estimate|||||||2007-01-08|2007-01-09|Estimate|November 2000||2000-11-30|February 2004|2004-02-29|December 2007||2007-12-31|||||Interventional|||Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes|The Use of Polyclonal Anti-T-Lymphocyte Globulin to Prevent Progression of Autoimmune Beta-Cell Destruction in Recent Type 1 Diabetes|Unknown status|Recruiting|N/A|28||Institute for Clinical and Experimental Medicine|||||f||||||||||||||2018-06-01 04:34:58.546104|2018-06-01 04:34:58.546104
NCT00190489|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-08-31|2005-09-12|2005-09-19|Estimate|||||||2016-08-31|2016-09-02|Estimate|January 1999||1999-01-31|August 2016|2016-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer|Phase III Trial of Doxorubicin /Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D (AC-D) as Front-line Chemotherapy for Metastatic Breast Cancer: Japan Clinical Oncology Group Trial (JCOG9802)|Completed||Phase 3|450||Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:34:58.724145|2018-06-01 04:34:58.724145
NCT00190476|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2016-09-08|2005-09-11|2005-09-19|Estimate|||||||2016-09-08|2016-09-12|Estimate|April 2003||2003-04-30|September 2016|2016-09-30|April 2007||2007-04-30|||||Interventional|||Elderly NSCLC/D vs DP (JCOG0207)|Randomized Controlled Trial Comparing Docetaxel-cisplatin Combination With Docetaxel Alone in Elderly Patients With Advanced Non-small-cell Lung Cancer(JCOG0207)|Terminated||Phase 3|230||Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:34:58.812421|2018-06-01 04:34:58.812421
NCT00190463|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2006-09-20|2005-09-16|2005-09-19|Estimate|||||||2006-09-20|2006-09-21|Estimate|April 2003||2003-04-30|September 2006|2006-09-30|July 2006||2006-07-31|||||Interventional|||Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia|"The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias . Study PREVERT"|Terminated||Phase 4|300||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:34:58.951058|2018-06-01 04:34:58.951058
NCT00190450|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-10-12|2005-09-15|2005-09-19|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2002||2002-01-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MIG-HD||MIG-HD: Multicentric Intracerebral Grafting in Huntington's Disease|Multicentric Intracerebral Grafting in Huntington's Disease|Completed||Phase 2|54|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||||2018-06-01 04:34:59.037403|2018-06-01 04:34:59.037403
NCT00190437|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-04-29|2005-09-15|2005-09-19|Estimate|||||||2011-04-29|2011-05-02|Estimate|August 2003||2003-08-31|March 2007|2007-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||ANTEAB: a Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD|ANTEAB: a Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD|Completed||Phase 4|520|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:34:59.122039|2018-06-01 04:34:59.122039
NCT00190424|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-12-12|2005-09-14|2005-09-19|Estimate|||||||2012-12-12|2012-12-13|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|October 2010|Actual|2010-10-31|October 2008|Actual|2008-10-31||Interventional|||Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma|Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma|Completed||Phase 2|80|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||||||||||||2018-06-01 04:34:59.210738|2018-06-01 04:34:59.210738
NCT00190411|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-15|2005-09-16|2005-09-19|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2003||2003-10-31|March 2007|2007-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type|Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome|Completed||Phase 4|54|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:34:59.282793|2018-06-01 04:34:59.282793
NCT00190398|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-04-29|2005-09-14|2005-09-19|Estimate|||||||2011-04-29|2011-05-02|Estimate|November 2000||2000-11-30|February 2007|2007-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||EVA3S: Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis|Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis|Completed||Phase 3|900|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:34:59.363244|2018-06-01 04:34:59.363244
NCT00190385|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-02-24|2005-09-14|2005-09-19|Estimate|||||||2011-02-24|2011-02-25|Estimate|July 2000||2000-07-31|March 2007|2007-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis|Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis. A Randomized Trial Comparing Two Periodicities of Ultrasonographic Surveillance: 3-month vs 6-month|Completed||Phase 3|1200|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:34:59.437762|2018-06-01 04:34:59.437762
NCT00190372|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-02-16|2005-09-14|2005-09-19|Estimate|||||||2011-02-16|2011-02-17|Estimate|October 2004||2004-10-31|March 2007|2007-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||AIDMA: A Psycho-educational Program Designed to Support and Train Carers of Alzheimer's Disease (AD) Patients|Contribution of a Psycho-Educational Program of Help to Help in the Pharmacological Assumption of Responsibility of the Disease of Alzheimer|Completed||N/A|240|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:34:59.505333|2018-06-01 04:34:59.505333
NCT00190359|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-19|Estimate|||||||2005-09-14|2005-09-19|Estimate|September 2000||2000-09-30|April 2002|2002-04-30|February 2003||2003-02-28|||||Observational|||Growth Hormone and Heart Failure|Modifications of the Growth Hormone/IGF1 Axis in Heart Failure Patients|Terminated|||180||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:34:59.578566|2018-06-01 04:34:59.578566
NCT00190346|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-10-25|2005-09-13|2005-09-19|Estimate|||||||2011-10-25|2011-10-26|Estimate|December 2001||2001-12-31|August 2005|2005-08-31|April 2003||2003-04-30|||||Interventional|||Comparison of Humidification Devices During Non Invasive Ventilation, in Acute Respiratory Failure|Randomized RCT Comparing HH and HME During NIV in Acute Respiratory Failure|Terminated||N/A|250||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:34:59.626791|2018-06-01 04:34:59.626791
NCT00190333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-17|2005-09-13|2005-09-19|Estimate|||||||2011-02-17|2011-02-18|Estimate|June 2005||2005-06-30|March 2007|2007-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension|Evaluation of the Therapeutic Effects of Escitalopram in Pulmonary Hypertension, Either Primary or Associated|Completed||Phase 3|30|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:34:59.803134|2018-06-01 04:34:59.803134
NCT00190320|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-16|2005-09-13|2005-09-19|Estimate|||||||2011-02-16|2011-02-17|Estimate|February 2005||2005-02-28|March 2007|2007-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||DAME: Induction of Labor or Waiting for Suspicion Fetal Macrosomia|Induction of Labor or Waiting for Suspicion Fetal Macrosomia (DAME)|Completed||Phase 4|1000|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-06-01 04:34:59.893247|2018-06-01 04:34:59.893247
NCT00190307|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-09-20|2005-09-13|2005-09-19|Estimate|||||||2011-09-20|2011-09-21|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|STRATAGEM||STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery|Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery|Completed||Phase 4|293|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:34:59.968372|2018-06-01 04:34:59.968372
NCT00190294|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-29|2005-09-13|2005-09-19|Estimate|||||||2011-04-29|2011-05-02|Estimate|April 2003||2003-04-30|March 2007|2007-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Expectant Versus Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW|Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW|Completed||Phase 4|200|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:35:00.075059|2018-06-01 04:35:00.075059
NCT00190281|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-12|2005-09-13|2005-09-19|Estimate|||||||2005-12-12|2005-12-13|Estimate|August 2005||2005-08-31|March 2005|2005-03-31||||||||Observational|||Contrast-Enhanced US of Spleen, Liver and Kidney|Contrast-Enhanced US of Spleen, Liver and Kidney in Patients With Acute Infection (Malaria and Other Infectious Diseases: a Functional Study|Unknown status|Recruiting||53||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:35:00.149963|2018-06-01 04:35:00.149963
NCT00190268|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-18|2005-09-13|2005-09-19|Estimate|||||||2011-02-18|2011-02-21|Estimate|February 2005||2005-02-28|March 2007|2007-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis|Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis|Completed||Phase 3|126|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:35:00.223181|2018-06-01 04:35:00.223181
NCT00190255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-09|2005-09-13|2005-09-19|Estimate|||||||2011-05-09|2011-05-10|Estimate|April 2004||2004-04-30|March 2007|2007-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Pharmacogenetics of Gastrointestinal Bleeding|Pharmacogenetics of Gastrointestinal Bleeding Under Nonsteroidal Anti-inflammatory Drugs : the Role of Cytochrome P450 2C9|Completed|||200|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the~     use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for~     the elimination of several NSAIDs. This protein is inactive in 12% of the subjects because of~     genetic mutations. We hypothesized that individuals carrying such mutations should be at~     higher risk of gastrointestinal bleeding since they display decreased NSAIDs elimination.~   "|||2018-06-01 04:35:00.308461|2018-06-01 04:35:00.308461
NCT00190242|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-12-15|2005-09-13|2005-09-19|Estimate|||||||2011-12-15|2011-12-16|Estimate|June 2003||2003-06-30|June 2005|2005-06-30|October 2009|Actual|2009-10-31|October 2006|Actual|2006-10-31||Interventional|HEPAVAC||Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients|Study of Immunogenicity of Anti-HAV Immunisation in HIV-1 Infected Patients, Co-infected or Not With HBV and/or HCV. HEP.A.VAC Study.|Completed||Phase 3|99|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 04:35:00.384396|2018-06-01 04:35:00.384396
NCT00190229|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-03|2005-09-13|2005-09-19|Estimate|||||||2011-05-03|2011-05-04|Estimate|September 2002||2002-09-30|March 2007|2007-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura|CESAR (Randomized Therapeutic Study of Steroid vs. Steroid Plus Cyclosphosphamide for Severe Viscera Henoch-Schoenlein Purpura)|Completed||N/A|200|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:35:00.46874|2018-06-01 04:35:00.46874
NCT00190216|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-06|2005-09-13|2005-09-19|Estimate|||||||2007-11-06|2007-11-08|Estimate|December 2001||2001-12-31|July 2005|2005-07-31|October 2007|Actual|2007-10-31|||||Interventional|||Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS)|Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression|Terminated||Phase 3|60|Actual|Assistance Publique - Hôpitaux de Paris||1||terminated|f||||f||||||||||2018-06-01 04:35:00.543649|2018-06-01 04:35:00.543649
NCT00190203|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-01-16|2005-09-13|2005-09-19|Estimate|||||||2008-01-16|2008-01-17|Estimate|December 2001||2001-12-31|September 2007|2007-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|DECIMAL||Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts|Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts : A Sequential Design, Multicenter, Randomized, Controlled Trial|Terminated||Phase 3|60|Actual|Assistance Publique - Hôpitaux de Paris||1||the study is publiched|f||||t||||||||||2018-06-01 04:35:00.611273|2018-06-01 04:35:00.611273
NCT00190190|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-16|2005-09-13|2005-09-19|Estimate|||||||2008-07-16|2008-07-18|Estimate|January 2005||2005-01-31|July 2007|2007-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Internal Limiting Membrane Peeling for Large Macular Holes|Comparison of the Success Rate of a Procedure With Peeling of Limiting the Intern of the Retina Versus a Traditional Procedure Without Peeling of Limiting, at Patients Presenting a Macular Hole.|Completed||N/A|80|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 04:35:00.690468|2018-06-01 04:35:00.690468
NCT00190177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-10-17|2005-09-12|2005-09-19|Estimate|||||||2013-10-17|2013-10-18|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||ECLAXIR:Search for an Association Between CX3CR1 V249I Polymorphism, Preeclampsia and Endothelial Injury||Completed|||370|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 04:35:00.765671|2018-06-01 04:35:00.765671
NCT00190164|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-07-17|2005-09-12|2005-09-19|Estimate|||||||2008-07-17|2008-07-18|Estimate|August 2005||2005-08-31|July 2007|2007-07-31|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Alleviated Positioning for Small Macular Holes|Evaluation of the Success Rate of a Procedure Without Strict Positioning Post Surgical Versus With Positioning Face Towards the Strict Ground, at Patients Presenting a Macular Hole. Study of Non-Inferiority.|Completed||N/A|69|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:35:00.814561|2018-06-01 04:35:00.814561
NCT00190151|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-09-17|2005-09-12|2005-09-19|Estimate|||||||2012-09-17|2012-09-18|Estimate|September 2004||2004-09-30|September 2005|2005-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora|Pharmacokinetic/Pharmacodynamic Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora|Terminated||N/A|48|Actual|Assistance Publique - Hôpitaux de Paris||||terminated|f||||f||||||||||2018-06-01 04:35:00.878471|2018-06-01 04:35:00.878471
NCT00190138|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-10-05|2005-09-12|2005-09-19|Estimate|||||||2010-10-05|2010-10-07|Estimate||||December 2004|2004-12-31||||||||Interventional|||Effect of Bi-ventricular Pacing on Autonomous Nervous System|Effect of Bi-ventricular Pacing on Autonomous Nervous System|Unknown status|Not yet recruiting|N/A|||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:35:00.93474|2018-06-01 04:35:00.93474
NCT00190125|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2009-02-06|2005-09-11|2005-09-19|Estimate|||||||2009-02-06|2009-02-09|Estimate||||August 2005|2005-08-31|August 2007|Anticipated|2007-08-31|||||Observational|||The Influences of Malnutrition and Inflammation Complex Syndrome in Hemodialysis Patients|The Influences of Malnutrition and Inflammation Complex Syndrome in Hemodialysis Patients|Unknown status|Not yet recruiting||300|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:35:00.985542|2018-06-01 04:35:00.985542
NCT00190112|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-10-05|2005-09-12|2005-09-19|Estimate|||||||2010-10-05|2010-10-07|Estimate||||December 2004|2004-12-31||||||||Interventional|||Change of Heart Rate Variability and Baroreflex Sensitivity After Ventral Cardiac Denervation||Unknown status|Not yet recruiting|N/A|30|Anticipated|Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:35:01.062291|2018-06-01 04:35:01.062291
NCT00190099|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-11-17|2005-09-11|2005-09-19|Estimate|||||||2005-11-17|2005-11-18|Estimate|January 2003||2003-01-31|December 2004|2004-12-31|December 2003||2003-12-31|||||Interventional|||Dexamethasone-Eluting Stent in Acute Coronary Syndrome to Prevent Restenosis||Completed||Phase 4|40||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:35:01.104543|2018-06-01 04:35:01.104543
NCT00190086|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-11|2005-09-11|2005-09-19|Estimate|||||||2005-09-11|2005-09-19|Estimate|January 2001||2001-01-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Observational|||Syndrome X and Endothelial Dysfunction||Terminated|||28||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:35:01.149284|2018-06-01 04:35:01.149284
NCT00190073|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-11|2005-09-11|2005-09-19|Estimate|||||||2005-09-11|2005-09-19|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|December 2005||2005-12-31|||||Observational|||Cutaneous Denervation in Alcoholic Neuropathy|Cutaneous Denervation in Alcoholic Neuropathy|Unknown status|Recruiting||30||Far Eastern Memorial Hospital|||||f||||||||||||||2018-06-01 04:35:01.189652|2018-06-01 04:35:01.189652
NCT00190060|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-11-29|2005-09-11|2005-09-19|Estimate|||||||2007-11-29|2007-11-30|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|March 2007|Actual|2007-03-31|||||Interventional|||Study of The Effects of Testosterone in Frail Elderly Men|Study of The Effects of Testosterone on Muscle Function, Physical Performance, Body Composition and Quality of Life in Frail Elderly Men|Completed||Phase 4|262|Actual|Manchester University NHS Foundation Trust||2|||f||||t||||||||||2018-06-01 04:35:01.33477|2018-06-01 04:35:01.33477
NCT00190047|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-11-22|2005-09-11|2005-09-19|Estimate|||||||2007-11-22|2007-11-26|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|October 2006||2006-10-31|||||Interventional|||Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Study To Evaluate The Effects Of DP-b99 On Neurologic Function And Disability In Subjects With Acute Ischemic Hemispheric Stroke|Completed||Phase 2|150||D-Pharm Ltd.|||||f||||||||||||||2018-06-01 04:35:01.437833|2018-06-01 04:35:01.437833
NCT00190034|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2009-02-06|2005-09-11|2005-09-19|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2005||2005-01-31|June 2006|2006-06-30|June 2007|Anticipated|2007-06-30|||||Interventional|||Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.|N-Acetylcysteine Protects Against Acute Renal Insult in Patients With Abnormal Renal Function Undergoing Cardiopulmonary Bypass.|Suspended||Phase 4|60|Anticipated|Far Eastern Memorial Hospital||||opposite result|f||||||||||||||2018-06-01 04:35:01.574516|2018-06-01 04:35:01.574516
NCT00190021|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-09-05|2005-09-11|2005-09-19|Estimate|||||||2010-09-05|2010-09-08|Estimate||||October 2005|2005-10-31||||||||Interventional|||Donepezil Treatment of Psychotic Symptoms in Dementia Patients|Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Beersheva Mental Health Center|||||f||||||||||||||2018-06-01 04:35:01.646539|2018-06-01 04:35:01.646539
NCT00190008|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2009-11-23|2005-09-11|2005-09-19|Estimate|||||||2009-11-23|2009-11-25|Estimate|August 2003||2003-08-31|November 2009|2009-11-30||||||||Interventional|||Piracetam for Treatment Tardive Dyskinesia|Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study|Completed||Phase 3|40||Beersheva Mental Health Center|||||f||||||||||||||2018-06-01 04:35:01.77776|2018-06-01 04:35:01.77776
NCT00189995|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-07-23|2005-09-11|2005-09-19|Estimate|||||||2013-07-23|2013-07-24|Estimate||||October 2005|2005-10-31||||||||Interventional|||Clozapine IM and Aggression in Schizophrenic Patients|Intramuscular Clozapine in the Management of Aggression in Schizophrenic Patients|Withdrawn||Phase 3|0|Actual|Beersheva Mental Health Center|||||f||||||||||||||2018-06-01 04:35:01.895639|2018-06-01 04:35:01.895639
NCT00189982|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-13|2005-09-19|Estimate|||||||2017-10-19|2017-10-23|Actual|December 2004||2004-12-31|July 2013|2013-07-31|November 2006|Actual|2006-11-30|||||Interventional|||Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101|Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (ADVATE rAHF-PFM): Safety Monitoring in Pediatric Patients Diagnosed With Severe to Moderately Severe Hemophilia A - A Continuation of Baxter Clinical Study 060101|Completed||Phase 2/Phase 3|4|Actual|Shire|||||f||||||||||||||2018-06-01 04:35:01.965769|2018-06-01 04:35:01.965769
NCT00189969|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-04-20|2005-09-13|2005-09-19|Estimate|||||||2006-04-20|2006-04-21|Estimate|September 2003||2003-09-30|April 2006|2006-04-30|February 2006||2006-02-28|||||Interventional|||Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects|Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic’s Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years|Completed||Phase 1|50||Bavarian Nordic|||||f||||||||||||||2018-06-01 04:35:02.027758|2018-06-01 04:35:02.027758
NCT00189956|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-02-03|2005-09-11|2005-09-19|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2003||2003-04-30|February 2015|2015-02-28|November 2003|Actual|2003-11-30|||||Interventional|||Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.|Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects|Completed||Phase 2|165|Actual|Bavarian Nordic||3|||f||||||||||||||2018-06-01 04:35:02.082181|2018-06-01 04:35:02.082181
NCT00189943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-19|Estimate|||||||2005-09-12|2005-09-19|Estimate|April 2001||2001-04-30|September 2005|2005-09-30|July 2003||2003-07-31|||||Interventional|||Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects|Phase I Study on Safety, Tolerability and Immunogenicity of the MVA-BN Vaccine Administered to Healthy Subjects|Completed||Phase 1|90||Bavarian Nordic|||||f||||||||||||||2018-06-01 04:35:02.151211|2018-06-01 04:35:02.151211
NCT00189930|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-09-28|2005-09-12|2005-09-19|Estimate|||||||2012-09-28|2012-10-01|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|December 2006|Actual|2006-12-31|||||Interventional|||An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients|A Single-blind, Randomized, Controlled, Phase II Study to Evaluate Immunogenicity and Safety of Two Doses of the MVA-nef HIV Vaccine in HIV-1 Infected Patients With CD4 > 250/µl|Completed||Phase 2|77|Actual|Bavarian Nordic||3|||f||||f||||||||||2018-06-01 04:35:02.215742|2018-06-01 04:35:02.215742
NCT00189917|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-06-02|2005-09-11|2005-09-19|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 2004||2004-04-30|June 2015|2015-06-30|April 2006||2006-04-30|||||Interventional|||Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders|An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders|Completed||Phase 1|60||Bavarian Nordic|||||||||||||||||||2018-06-01 04:35:02.285128|2018-06-01 04:35:02.285128
NCT00189904|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2012-09-27|2005-09-11|2005-09-19|Estimate|||||||2012-09-27|2012-09-28|Estimate|July 2005||2005-07-31|December 2007|2007-12-31||||||||Interventional|||Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients|A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination|Completed||Phase 1/Phase 2|151|Actual|Bavarian Nordic|||||||||||||||||||2018-06-01 04:35:02.354302|2018-06-01 04:35:02.354302
NCT00189878|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2016-02-18|2005-09-11|2005-09-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|August 2003||2003-08-31|February 2016|2016-02-29|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria|Multi-centre Prospective Randomised Double-blind Placebo-controlled Study of Methotrexate in the Treatment of Chronic Idiopathic Urticaria|Terminated||Phase 2|3|Actual|Barnsley Hospital||2||unable to recruit|f||||t||||||||||2018-06-01 04:35:02.440182|2018-06-01 04:35:02.440182
NCT00189852|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-02-18|2005-09-13|2005-09-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|February 2009|Actual|2009-02-28|September 2007|Actual|2007-09-30||Interventional|||Supporting Care and Independence at Home|Supporting Care and Independence at Home|Completed||N/A|62|Actual|Barnsley Hospital||2|||f||||f||||||||||2018-06-01 04:35:02.506057|2018-06-01 04:35:02.506057
NCT00189839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-07-07|2005-09-13|2005-09-19|Estimate|||||||2014-07-07|2014-07-09|Estimate|August 2004||2004-08-31|July 2014|2014-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation|A Multicentre, Randomised, Double Blind, Two Arm Parallel Group Study to Evaluate and Compare the Efficacy and Safety of Modified Release Tacrolimus FK506E (MR4) Versus Tacrolimus FK506 in Combination With MMF (Cellcept®) and Steroids in Patients Undergoing Kidney Transplantation|Completed||Phase 3|699|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:35:02.58536|2018-06-01 04:35:02.58536
NCT00189826|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-07-07|2005-09-13|2005-09-19|Estimate|||||||2014-07-07|2014-07-09|Estimate|August 2004||2004-08-31|July 2014|2014-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Liver Transplantation.|A Multicentre, Randomised, Double Blind, Two Arm Parallel Group Study to Evaluate and Compare the Efficacy and Safety of Modified Release Tacrolimus FK506E (MR4) Versus Tacrolimus FK506 in Combination With Steroids in Patients Undergoing Primary Liver Transplantation|Completed||Phase 3|475|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:35:02.754259|2018-06-01 04:35:02.754259
NCT00189813|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-08-27|2005-09-13|2005-09-19|Estimate|||||||2014-08-27|2014-08-28|Estimate|March 2005||2005-03-31|August 2014|2014-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Potential Efficacy, Safety and Tolerability of Different Oral Doses of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome|Completed||Phase 2|691|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:02.899676|2018-06-01 04:35:02.899676
NCT00189800|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-15|2005-09-13|2005-09-19|Estimate|||||||2011-11-15|2011-11-17|Estimate||||October 2006|2006-10-31||||||||Interventional|||A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder||Completed||Phase 3|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:02.999363|2018-06-01 04:35:02.999363
NCT00189787|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-15|2005-09-12|2005-09-19|Estimate|||||||2008-04-15|2008-04-17|Estimate||||April 2008|2008-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma||Completed||Phase 2|370|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:03.187577|2018-06-01 04:35:03.187577
NCT00189774|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-03-11|2005-09-13|2005-09-19|Estimate|||||||2008-03-11|2008-03-13|Estimate||||March 2008|2008-03-31||||||||Interventional|||Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients||Completed||Phase 2/Phase 3|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:03.34235|2018-06-01 04:35:03.34235
NCT00189761|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-19|2005-09-13|2005-09-19|Estimate|||||||2006-09-19|2006-09-20|Estimate||||September 2006|2006-09-30||||||||Interventional|||A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients|A Phase 2, Open-Label, Multi-Center Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in De Novo Bone Marrow Transplant Recipients|Completed||Phase 2|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:03.413682|2018-06-01 04:35:03.413682
NCT00189748|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-19|2005-09-13|2005-09-19|Estimate|||||||2006-09-19|2006-09-20|Estimate|August 2004||2004-08-31|September 2006|2006-09-30||||||||Interventional|||A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-|An Extension Study of the Patients Enrolled in Acute Graft Versus Host Disease (GVHD) Prophylaxis Study (Protocol No. FJ-506E-BT01) to Assess Safety and Efficacy of GVHD Prophylaxis of a Tacrolimus New Oral Formulation (MR4).|Completed||Phase 2|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:03.502066|2018-06-01 04:35:03.502066
NCT00189735|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-15|2005-09-12|2005-09-19|Estimate|||||||2008-04-15|2008-04-17|Estimate|September 2003||2003-09-30|April 2008|2008-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study to Evaluate FK778 in Kidney Transplant Patients|A Multicentre, Randomised, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Different Concentrations of FK778 With Tacrolimus (FK506) and Steroids Versus a Standard Regimen of Tacrolimus, MMF and Steroids in Renal Transplant Patients|Completed||Phase 2|364|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:03.577846|2018-06-01 04:35:03.577846
NCT00189722|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-15|2005-09-12|2005-09-19|Estimate|||||||2008-04-15|2008-04-17|Estimate||||April 2008|2008-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma||Completed||Phase 2|160|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:03.713209|2018-06-01 04:35:03.713209
NCT00189709|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-26|2005-09-12|2005-09-19|Estimate|||||||2007-12-26|2008-01-02|Estimate|August 2004||2004-08-31|December 2007|2007-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia|A Single Center, Open, Parallel, Comparative, Randomized Study of Micafungin (FK463) vs Fluconazole (Diflucan) in the Treatment of Invasive Candidiasis and Candidaemia (Protocol No: MCFGCAN-0301F-TW)|Completed||Phase 3|24|Actual|Astellas Pharma Inc||2|||f||||||||||||||2018-06-01 04:35:03.819872|2018-06-01 04:35:03.819872
NCT00189696|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-09|2005-09-12|2005-09-19|Estimate|||||||2015-10-09|2015-10-12|Estimate||||October 2015|2015-10-31||||||||Interventional|||Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)||Completed||Phase 3|||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:35:03.901159|2018-06-01 04:35:03.901159
NCT00189683|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-19|Estimate|||||||2005-09-12|2005-09-19|Estimate||||September 2005|2005-09-30||||||||Interventional|||Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy||Unknown status|Recruiting|Phase 3|||Association Européenne de Recherche en Oncologie|||||f||||||||||||||2018-06-01 04:35:03.969912|2018-06-01 04:35:03.969912
NCT00189670|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-19|Estimate|||||||2005-09-12|2005-09-19|Estimate||||September 2005|2005-09-30||||||||Interventional|||Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer|A Phase II Randomized Trial of 6 TEC Every 3 Weeks, Versus 4 EC Followed by 4 Taxotere Every 2 Weeks, Versus 4 Taxotere Followed by 4 EC Every 2 Weeks in Node Positive Breast Cancer|Completed||Phase 2|||Association Européenne de Recherche en Oncologie|||||f||||||||||||||2018-06-01 04:35:04.042073|2018-06-01 04:35:04.042073
NCT00189657|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-19|Estimate|||||||2005-09-12|2005-09-19|Estimate||||September 2005|2005-09-30||||||||Interventional|||5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer||Unknown status|Recruiting|Phase 3|||Association Européenne de Recherche en Oncologie|||||f||||||||||||||2018-06-01 04:35:04.105721|2018-06-01 04:35:04.105721
NCT00189644|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-19|Estimate|||||||2005-09-12|2005-09-19|Estimate||||September 2005|2005-09-30||||||||Interventional|||6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer||Unknown status|Active, not recruiting|Phase 3|||Association Européenne de Recherche en Oncologie|||||f||||||||||||||2018-06-01 04:35:04.175354|2018-06-01 04:35:04.175354
NCT00189631|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-07|2005-09-12|2005-09-19|Estimate|||||||2005-12-07|2005-12-08|Estimate||||September 2005|2005-09-30||||||||Interventional|||UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy||Unknown status|Recruiting|Phase 3|||Association Européenne de Recherche en Oncologie|||||f||||||||||||||2018-06-01 04:35:04.229266|2018-06-01 04:35:04.229266
NCT00189449|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-30|2005-09-12|2005-09-19|Estimate|||||||2008-04-30|2008-05-01|Estimate||||April 2008|2008-04-30|June 2007||2007-06-30|||||Observational|||Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis|Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis|Completed|||||West Penn Allegheny Health System|||||f||||||||||||||2018-06-01 04:35:07.195028|2018-06-01 04:35:07.195028
NCT00189618|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-03|2005-09-12|2005-09-19|Estimate|||||||2008-10-03|2008-10-06|Estimate|May 2005||2005-05-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD)|The Effects of Physical Training, Aspirin, and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease|Completed||Phase 4|250|Anticipated|Arteriogenesis Competence Network||2|||f||||t||||||||||2018-06-01 04:35:04.294375|2018-06-01 04:35:04.294375
NCT00189605|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-08-25|2005-09-13|2005-09-19|Estimate|||||||2015-08-25|2015-08-26|Estimate|September 2004||2004-09-30|August 2015|2015-08-31|April 2009|Actual|2009-04-30|December 2007|Actual|2007-12-31||Interventional|SPINE||Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression|Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression Efficacy|Completed||Phase 4|90|Actual|ArthroCare Corporation||2|||f||||f||||||||||2018-06-01 04:35:04.38876|2018-06-01 04:35:04.38876
NCT00189592|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-08-25|2005-09-12|2005-09-19|Estimate|||||||2015-08-25|2015-08-26|Estimate|August 2005||2005-08-31|August 2015|2015-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Plantar Fasciosis Treatment Using Coblation|Plantar Fasciosis Treatment Using Coblation® Prospective, Double-Blind, Randomized Controlled Study|Completed||Phase 4|45|Actual|ArthroCare Corporation||2|||f||||f||||||||||2018-06-01 04:35:04.474607|2018-06-01 04:35:04.474607
NCT00189579|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-16|2005-09-12|2005-09-19|Estimate|||||||2007-08-16|2007-08-17|Estimate||||August 2007|2007-08-31|January 2007|Actual|2007-01-31|||||Interventional|||Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer|A Phase II Study Designed to Evaluate the Safety and Efficacy of the Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Early Relapse Patients (< 6 Months) With Ovarian Cancer, Overexpressing HER2, Previously Treated With Carboplatin-Paclitaxel|Terminated||Phase 2|45|Anticipated|ARCAGY/ GINECO GROUP|||||f||||||||||||||2018-06-01 04:35:04.542396|2018-06-01 04:35:04.542396
NCT00189566|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-24|2005-09-12|2005-09-19|Estimate|||||||2011-02-24|2011-02-25|Estimate|April 2004||2004-04-30|February 2011|2011-02-28|April 2009|Actual|2009-04-30|||||Interventional|||Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse|National, Randomized, Phase II Study Comparing Efficacy of Weekly Administration of Paclitaxel in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse|Completed||Phase 2|165|Anticipated|ARCAGY/ GINECO GROUP|||||f||||||||||||||2018-06-01 04:35:04.595789|2018-06-01 04:35:04.595789
NCT00189553|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-01-09|2005-09-12|2005-09-19|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2005||2005-04-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|January 2009|Actual|2009-01-31||Interventional|CALYPSO||Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse|A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months)|Completed||Phase 3|976|Actual|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-06-01 04:35:04.660709|2018-06-01 04:35:04.660709
NCT00189540|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-06-21||2017-09-14|2005-09-12|2005-09-19|Estimate|2011-07-25|2011-08-19|Estimate||||2017-09-14|2017-10-16|Actual|August 2005||2005-08-31|September 2017|2017-09-30|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers|A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers|Completed||Phase 2|27|Actual|AnGes USA, Inc.||2|||f||||f|t|||||||||2018-06-01 04:35:04.765291|2018-06-01 04:35:04.765291
NCT00189527|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-16|2005-09-12|2005-09-19|Estimate|||||||2011-02-16|2011-02-17|Estimate|January 2006||2006-01-31|February 2011|2011-02-28|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Assist Control Versus Pressure Support Modes for Domiciliary Noninvasive Ventilation in Chronic Respiratory Failure|Assist Control Versus Pressure Support Modes for Domiciliary Noninvasive Ventilation|Completed||N/A|100|Actual|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||2|||f||||f||||||||||2018-06-01 04:35:05.192194|2018-06-01 04:35:05.192194
NCT00189514|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-10|2005-09-12|2005-09-19|Estimate|||||||2015-06-10|2015-06-11|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects|Extension Study of Protocol 137OB-201 to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects|Completed||Phase 2|210|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 04:35:05.254346|2018-06-01 04:35:05.254346
NCT00189501|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-20|2005-09-12|2005-09-19|Estimate|||||||2007-12-20|2007-12-28|Estimate|December 2004||2004-12-31|December 2007|2007-12-31||||||||Observational|||A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)|A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)|Completed|||1000||Amgen|||||f||||||||||||||2018-06-01 04:35:05.426497|2018-06-01 04:35:05.426497
NCT00189488|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2009-11-25||2014-09-12|2005-09-15|2005-09-19|Estimate|2014-09-12|2014-09-15|Estimate||||2014-09-12|2014-09-15|Estimate|December 2005||2005-12-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|November 2008|Actual|2008-11-30||Interventional|||Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation|A Randomized, Double-blind, Placebo-controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation|Completed||Phase 2|155|Actual|Swedish Orphan Biovitrum||2|||f||||||||||||||2018-06-01 04:35:05.548906|2018-06-01 04:35:05.548906
NCT00189475|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-09-23||2014-10-13|2005-09-13|2005-09-19|Estimate|2014-10-13|2014-10-17|Estimate||||2014-10-13|2014-10-17|Estimate|October 2003||2003-10-31|October 2014|2014-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds|A Pilot Study to Evaluate the Potential of Montelukast to Prevent the Development of Nasal Symptomatology During Natural Viral Upper Respiratory Infections|Completed||Phase 4|84|Actual|West Penn Allegheny Health System||2|||f||||f||||||||||2018-06-01 04:35:06.793957|2018-06-01 04:35:06.793957
NCT00189462|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-09-23||2014-10-13|2005-09-13|2005-09-19|Estimate|2014-10-06|2014-10-08|Estimate||||2014-10-13|2014-10-22|Estimate|March 2004||2004-03-31|October 2014|2014-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children|A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children|Completed||Phase 4|99|Actual|West Penn Allegheny Health System||2|||f||||f||||||||||2018-06-01 04:35:06.996419|2018-06-01 04:35:06.996419
NCT00189436|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-07-08||2014-07-08|2005-09-12|2005-09-19|Estimate|2014-07-08|2014-08-04|Estimate||||2014-07-08|2014-08-04|Estimate|March 2003||2003-03-31|July 2014|2014-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|BudER|61 subjects were enrolled and 31 were randomized to nebulized budesonide and 30 to standard of care. 74% of subjects enrolled in the nebulized budesonide and 83% enrolled in the standard care group completed the study.|Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children|A Pilot Study to Evaluate the Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Pediatric Patients Following Discharge From the Emergency Department/Outpatient Care Facility|Completed||Phase 4|61|Actual|West Penn Allegheny Health System||2|||f||||||||||||||2018-06-01 04:35:07.251878|2018-06-01 04:35:07.251878
NCT00189423|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-03-01||2017-12-06|2005-09-12|2005-09-19|Estimate|2012-07-18|2012-08-22|Estimate||||2017-12-06|2017-12-08|Actual|October 2005||2005-10-31|December 2017|2017-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|ResQ||ResQ Trial: Impact of an ITD and Active Compression Decompression CPR on Survival From Out-of-Hospital Cardiac Arrest|ResQ Trial: Comparison of Standard CPR Alone Versus Active Compression Decompression CPR Plus an ITD on Survival From Out-of-Hospital Cardiac Arrest|Terminated||N/A|1653|Actual|Advanced Circulatory Systems||2||Terminated due to lack of funding. Follow-up completed for all enrolled subjects.|f||||t||||||||||2018-06-01 04:35:07.513441|2018-06-01 04:35:07.513441
NCT00189410|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-19|2005-09-12|2005-09-19|Estimate|||||||2010-07-19|2010-07-20|Estimate|June 2003||2003-06-30|July 2010|2010-07-31|September 2006|Actual|2006-09-30|September 2005|Actual|2005-09-30||Interventional|||Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours|Phase II Trial With Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin (PLD) and Carboplatin in Malignant Gynecologic Tumour's|Completed||Phase 2|140|Actual|AGO Study Group|||||f||||||||||||||2018-06-01 04:35:07.925956|2018-06-01 04:35:07.925956
NCT00189397|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-06|2005-09-12|2005-09-19|Estimate|||||||2008-05-06|2008-05-08|Estimate|February 2003||2003-02-28|May 2008|2008-05-31|January 2006|Actual|2006-01-31|October 2005|Actual|2005-10-31||Interventional|||Azathioprine Versus Corticosteroids in Parthenium Dermatitis|Azathioprine Versus Corticosteroids for the Treatment of Parthenium Dermatitis|Completed||N/A|||All India Institute of Medical Sciences, New Delhi|||||f||||t||||||||||2018-06-01 04:35:08.008186|2018-06-01 04:35:08.008186
NCT00189384|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-07|2005-09-12|2005-09-19|Estimate|||||||2006-09-07|2006-09-11|Estimate|November 2003||2003-11-30|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||Efficacy Study of Community-Based Treatment of Serious Bacterial Infections in Young Infants|Randomized Controlled Trial of Intramuscular Ceftriaxone Versus Procaine Penicillin Versus Cotrimoxazole and Gentamicin for Management of Serious Bacterial Infections in Young Infants in Community Settings|Unknown status|Active, not recruiting|Phase 3|426||Aga Khan University|||||f||||||||||||||2018-06-01 04:35:08.075425|2018-06-01 04:35:08.075425
NCT00189371|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-16|2005-09-16|2005-09-19|Estimate|||||||2005-09-16|2005-09-19|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|December 2005||2005-12-31|||||Interventional|||Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum|Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum|Terminated||Phase 3|300||AGO Study Group|||||f||||||||||||||2018-06-01 04:35:09.122132|2018-06-01 04:35:09.122132
NCT00189358|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-19|2005-09-12|2005-09-19|Estimate|||||||2010-07-19|2010-07-20|Estimate||||July 2010|2010-07-31||||||||Interventional|||A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy|A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy|Completed||Phase 2|||AGO Study Group|||||f||||||||||||||2018-06-01 04:35:09.196289|2018-06-01 04:35:09.196289
NCT00189345|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-07|2005-09-12|2005-09-19|Estimate|||||||2006-11-07|2006-11-08|Estimate|May 2004||2004-05-31|December 2003|2003-12-31|October 2005||2005-10-31|||||Interventional|||Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients|Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients|Completed||Phase 2|44||AGO Study Group|||||f||||||||||||||2018-06-01 04:35:09.260618|2018-06-01 04:35:09.260618
NCT00189332|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-24|2005-09-13|2005-09-19|Estimate|||||||2008-10-24|2008-10-27|Estimate|February 2005||2005-02-28|October 2008|2008-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Use of 852A in Metastatic Cutaneous Melanoma.|Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects With Unresectable Metastatic Cutaneous Melanoma.|Completed||Phase 2|28||Pfizer|||||f||||||||||||||2018-06-01 04:35:09.326803|2018-06-01 04:35:09.326803
NCT00189319|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-02-20|2005-09-13|2005-09-19|Estimate|||||||2007-02-20|2007-02-21|Estimate|September 2003||2003-09-30|September 2006|2006-09-30||||||||Interventional|||To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation|Impact of Oral Controlled Release Flecainide Acetate Capsules on Health-Related QoL in Patients With Paroxysmal Atrial Fibrillation|Completed||Phase 4|200||MEDA Pharma GmbH & Co. KG|||||f||||||||||||||2018-06-01 04:35:09.394705|2018-06-01 04:35:09.394705
NCT00189306|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2008-10-30||2010-08-05|2005-09-13|2005-09-19|Estimate|2008-11-25|2008-11-26|Estimate||||2010-08-05|2010-08-10|Estimate|March 2001||2001-03-31|August 2010|2010-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream|An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma|Completed||Phase 3|169|Actual|Graceway Pharmaceuticals, LLC||1|||f||||f||||||||||2018-06-01 04:35:09.477174|2018-06-01 04:35:09.477174
NCT00189293|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-01-05|2005-09-12|2005-09-19|Estimate|||||||2011-01-05|2011-01-06|Estimate|June 2005||2005-06-30|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts|Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts|Completed||Phase 4|128|Actual|MEDA Pharma GmbH & Co. KG||2|||f||||||||||||||2018-06-01 04:35:09.844107|2018-06-01 04:35:09.844107
NCT00189280|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-24|2005-09-12|2005-09-19|Estimate|||||||2008-09-24|2008-09-26|Estimate|May 2003||2003-05-31|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Aldara for the Treatment of Large and/or Multiple sBCC|Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma.|Completed||Phase 3|111|Actual|MEDA Pharma GmbH & Co. KG||1|||f||||||||||||||2018-06-01 04:35:09.950316|2018-06-01 04:35:09.950316
NCT00189267|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-11-19|2005-09-12|2005-09-19|Estimate|||||||2010-11-19|2010-11-22|Estimate|November 2002||2002-11-30|August 2006|2006-08-31|September 2005|Actual|2005-09-30|||||Interventional|||A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients|Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily 3 Days Per Week for the Treatment of Actinic Keratoses in Immunosuppressed Organ Transplant Recipients.|Completed||Phase 2|45||MEDA Pharma GmbH & Co. KG|||||||||||||||||||2018-06-01 04:35:10.030742|2018-06-01 04:35:10.030742
NCT00189254|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-28|2005-09-12|2005-09-19|Estimate|||||||2016-11-28|2016-11-29|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ|A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study|Completed|||72||MEDA Pharma GmbH & Co. KG|||1||||||||||||||||2018-06-01 04:35:10.109238|2018-06-01 04:35:10.109238
NCT00189241|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-25|2005-09-12|2005-09-19|Estimate|||||||2010-08-25|2010-08-26|Estimate|February 2001||2001-02-28|August 2010|2010-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma|An Open-Label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 5 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma|Completed||Phase 3|160||MEDA Pharma GmbH & Co. KG|||||||||||||||||||2018-06-01 04:35:10.179825|2018-06-01 04:35:10.179825
NCT00189228|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2013-01-18|2005-09-10|2005-09-16|Estimate|||||||2013-01-18|2013-01-23|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Immune Dysfunction in Allergic Asthma|Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma|Completed||N/A|18|Actual|University of New Mexico||1|||f||||t||||||||||2018-06-01 04:35:10.240148|2018-06-01 04:35:10.240148
NCT00189215|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-03|2005-09-13|2005-09-16|Estimate|||||||2007-12-03|2007-12-04|Estimate|March 1998||1998-03-31|March 2005|2005-03-31|December 2005||2005-12-31|||||Interventional|||Long-Term Cognitive Decline After Coronary Artery Bypass Grafting: is Off-Pump Surgery Beneficial?|Long-Term Cognitive Decline After Coronary Artery Bypass Grafting: is Off-Pump Surgery Beneficial?|Completed||Phase 4|280||UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:10.315175|2018-06-01 04:35:10.315175
NCT00189202|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-02-20||2018-02-27|2005-09-13|2005-09-16|Estimate|2017-02-20|2017-04-05|Actual||||2018-02-27|2018-03-27|Actual|August 2004||2004-08-31|February 2018|2018-02-28|July 1, 2008|Actual|2008-07-01|July 1, 2008|Actual|2008-07-01||Interventional||From the 49 consented, 5 were not begun on treatment or removed very early on for clinical reasons, so they are not included in baseline data.|Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans|Efficacy of Sirolimus-Based, Steroid Avoidance Maintenance Immunosuppression in Black de Novo Kidney Transplant Recipients|Completed||Phase 2/Phase 3|49|Actual|University of Michigan||1|||f||||||||||||||2018-06-01 04:35:10.388441|2018-06-01 04:35:10.388441
NCT00189189|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-01|2005-09-13|2005-09-16|Estimate|||||||2007-10-01|2007-10-02|Estimate|July 2003||2003-07-31|July 2005|2005-07-31|November 2008|Anticipated|2008-11-30|||||Interventional|||Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children|Parent Management Training to Prevent Oppositional Defiant and Conduct Disorders in Preschool Children|Unknown status|Recruiting|N/A|160|Anticipated|UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:10.569808|2018-06-01 04:35:10.569808
NCT00189176|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2013-02-05|2005-09-10|2005-09-16|Estimate|||||||2013-02-05|2013-02-06|Estimate|March 2003||2003-03-31|February 2013|2013-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis|Phase I/II Trial of Tetrathiomolybdate (TM) in Patients With Usual Interstitial Pneumonia Refractory to Previous Therapy|Completed||Phase 1/Phase 2|23|Actual|University of Michigan||1|||f||||||||||||||2018-06-01 04:35:10.634318|2018-06-01 04:35:10.634318
NCT00189163|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-12-15|2005-09-15|2005-09-16|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2005||2005-01-31|December 2016|2016-12-31||||December 2007|Actual|2007-12-31||Interventional|||Pioglitazone in Hepatitis C|Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study|Completed||Phase 4|40|Actual|University of Michigan||2|||f||||||||||||||2018-06-01 04:35:10.695507|2018-06-01 04:35:10.695507
NCT00189150|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-05-23|2005-09-12|2005-09-16|Estimate|||||||2016-05-23|2016-05-25|Estimate|April 2005||2005-04-30|May 2016|2016-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Pharmacokinetics of Mmf and Valganciclovir|Pharmacokinetics of Mycophenolate Mofetil Alone and in Combination With Valganciclovir in Renal and Heart Transplant Recipients|Completed||Phase 4|16|Actual|University of Michigan|||||f||||||||||||||2018-06-01 04:35:10.845249|2018-06-01 04:35:10.845249
NCT00189137|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-11-17||2015-11-06|2005-09-13|2005-09-16|Estimate|2014-11-17|2014-11-24|Estimate||||2015-11-06|2015-12-07|Estimate|August 2004||2004-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma|Phase II Evaluation of Ifosfamide Plus Doxorubicin & Filgrastim Versus Gemcitabine Plus Docetaxel & Filgrastim in the Treatment of Localized Poor Prognosis Soft Tissue Sarcoma|Completed||Phase 2|84|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-06-01 04:35:10.926105|2018-06-01 04:35:10.926105
NCT00189124|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-17|2005-09-13|2005-09-16|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2003||2003-09-30|May 2016|2016-05-31|July 2006|Actual|2006-07-31|December 2005|Actual|2005-12-31||Interventional|||Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention|Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?|Completed||Phase 2/Phase 3|13|Actual|University of Michigan|||||||||||||||||||2018-06-01 04:35:11.229405|2018-06-01 04:35:11.229405
NCT00189111|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-02-14|2005-09-12|2005-09-16|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2005||2005-01-31|November 2016|2016-11-30|April 2012|Actual|2012-04-30|||||Interventional|||Non-invasive Cardiac Screening in High Risk Patients -The GROUND Study|Non-invasive Cardiac Screening in High Risk Patients -The GROUND Study|Completed||Phase 3|1200|Actual|UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:11.294739|2018-06-01 04:35:11.294739
NCT00188110|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-08|2005-09-12|2005-09-16|Estimate|||||||2007-01-08|2007-01-09|Estimate|March 2003||2003-03-31|September 2005|2005-09-30||||||||Interventional|||Performance of the Water-Enema Computed Tomography (WE-CT)|Evaluation of the Water-Enema Computed Tomography for the Diagnosis of Colon Tumor|Unknown status|Recruiting|N/A|200||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:16.805789|2018-06-01 04:35:16.805789
NCT00189098|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-04-12||2012-06-08|2005-09-12|2005-09-16|Estimate|2012-06-08|2012-07-13|Estimate||||2012-06-08|2012-07-13|Estimate|February 2003||2003-02-28|April 2012|2012-04-30|November 2006|Actual|2006-11-30|June 2006|Actual|2006-06-30||Interventional|||Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media|Effectiveness of Sulfamethoxazole-trimethoprim in the Treatment of Chronic Otitis Media|Completed||N/A|101|Actual|UMC Utrecht||2|||f||||||||||||||2018-06-01 04:35:11.385045|2018-06-01 04:35:11.385045
NCT00189085|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-09|2005-09-15|2005-09-16|Estimate|||||||2010-06-09|2010-06-10|Estimate|December 2004||2004-12-31|August 2004|2004-08-31|July 2005||2005-07-31|||||Interventional|||Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function|The Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Dysfunction in Patients With the Metabolic Syndrome.|Completed||Phase 4|20||UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:11.671827|2018-06-01 04:35:11.671827
NCT00189072|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|April 2003||2003-04-30|May 2005|2005-05-31||||||||Interventional|||Effects of Gabapentin in the Treatment of Neuropathic Pain on Driving Performance and Cognition|Effects of Pain and the Treatment of Pain With Gabapentin (900-3600 Mg) on Driving Ability, Attentional Capacity and Psychomotor Performance in Chronic Neuropathic Pain Patients|Terminated||Phase 4|24||UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:11.733902|2018-06-01 04:35:11.733902
NCT00189059|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|October 2002||2002-10-31|April 2005|2005-04-30|May 2005||2005-05-31|||||Interventional|||Effects of Amitriptyline for the Treatment of Pain on Driving Performance and Cognition.|Effects of Pain and the Treatment of Pain With Amitriptyline on Driving Performance, Attentional Capacity and Psychomotor Performance in Chronic Neuropathic Pain Patients|Terminated||Phase 4|24||UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:11.792585|2018-06-01 04:35:11.792585
NCT00189046|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|January 2004||2004-01-31|December 2004|2004-12-31|April 2005||2005-04-30|||||Observational|||Effects of Pain on Driving Performance and Cognition.|Effects of Pain on Driving Performance, Attentional Capacity and Psychomotor Performances: a Comparative Study Between Healthy Controls and Chronic Pain Patients.|Terminated|||30||UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:11.846983|2018-06-01 04:35:11.846983
NCT00189033|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-19|2005-09-09|2005-09-16|Estimate|||||||2007-04-19|2007-04-20|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?|Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre? A Randomized Controlled Trial in Primary Care.|Completed||N/A|285||UMC Utrecht|||||f||||||||||||||2018-06-01 04:35:11.896651|2018-06-01 04:35:11.896651
NCT00189020|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-19|2005-09-09|2005-09-16|Estimate|||||||2011-08-19|2011-08-22|Estimate|June 2005||2005-06-30|August 2011|2011-08-31||||February 2008|Actual|2008-02-29||Interventional|MNOES||Effect of Two Versus Three Pneumococcal Conjugate Vaccinations|Effect of 2 Versus 3 Pneumococcal Conjugate Vaccinations Prevnar on Nasopharyngeal Carriage, Transmission and Herd-immunity;a Randomized, Controlled Study|Completed||Phase 3|1005|Actual|UMC Utrecht||3|||f||||t||||||||||2018-06-01 04:35:11.956258|2018-06-01 04:35:11.956258
NCT00189007|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2012-03-28|2005-09-11|2005-09-16|Estimate|||||||2012-03-28|2012-03-29|Estimate|October 2009||2009-10-31|March 2012|2012-03-31|December 2016|Anticipated|2016-12-31|December 2011|Actual|2011-12-31||Interventional|||Antenatal Allopurinol During Fetal Hypoxia|Does Antenatal Allopurinol Administration Reduce Post-hypoxic-ischemic Reperfusion Damage During Fetal Hypoxia in the Newborn?|Unknown status|Active, not recruiting|Phase 3|222|Actual|UMC Utrecht||2|||f||||t||||||||||2018-06-01 04:35:12.025119|2018-06-01 04:35:12.025119
NCT00188994|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-28|2005-09-13|2005-09-16|Estimate|||||||2005-12-28|2005-12-29|Estimate|August 1999||1999-08-31|July 2005|2005-07-31||||||||Interventional|||Insulin Cardioplegia for Poor Left Ventricular Function|Insulin Cardioplegia Trial for Poor Left Ventricular Function|Unknown status|Recruiting|N/A|800||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:12.105764|2018-06-01 04:35:12.105764
NCT00188981|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-19|2005-09-09|2005-09-16|Estimate|||||||2007-04-19|2007-04-20|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|June 2008|Anticipated|2008-06-30|||||Observational|||Dutch Prediction of Psychosis Study|Dutch Prediction of Psychosis Study|Unknown status|Active, not recruiting||120||UMC Utrecht|||||f||||f||||||||||2018-06-01 04:35:12.250151|2018-06-01 04:35:12.250151
NCT00188968|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-30|2005-09-13|2005-09-16|Estimate|||||||2007-04-30|2007-05-02|Estimate|November 2004||2004-11-30|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Randomized Trial of Nasal Continuous Positive Airway Pressure or Synchronized Nasal Ventilation in Premature Infants.|A Randomized, Controlled Trial of Synchronized Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure Using the Infant Flow Advance to Facilitate Successful Extubation in Premature Infants.|Completed||Phase 3|48|Actual|University of Manitoba|||||f||||t||||||||||2018-06-01 04:35:12.312266|2018-06-01 04:35:12.312266
NCT00188955|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2010-02-19|2005-09-10|2005-09-16|Estimate|||||||2010-02-19|2010-02-22|Estimate|March 2004||2004-03-31|February 2010|2010-02-28|October 2008|Actual|2008-10-31|||||Interventional|||Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant|Phase 4 Randomized, Controlled Study Comparing Sirolimus and Mycophenolate Mofetil to Prevent or Reverse Progression in Pediatric Renal Transplants With Chronic Allograft Nephropathy|Completed||Phase 4|40||University of Manitoba|||||f||||||||||||||2018-06-01 04:35:12.383057|2018-06-01 04:35:12.383057
NCT00188942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-06|2005-09-12|2005-09-16|Estimate|||||||2013-02-06|2013-02-08|Estimate|February 2005||2005-02-28|February 2013|2013-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder|Neural Correlates of Emotional Processing in Depressed and Remitted Bipolar and Unipolar Depressed Subjects: An fMRI Investigation|Completed||Phase 4|42|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:35:12.449328|2018-06-01 04:35:12.449328
NCT00188929|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-12|2005-09-12|2005-09-16|Estimate|||||||2010-08-12|2010-08-13|Estimate|August 2005||2005-08-31|August 2010|2010-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma|Spatio-temporal Response of Non-Hodgkin's Lymphoma to External Beam Radiation Therapy Measuring 18F-Fluorodeoxyglucose (FDG) Uptake Using a Combined PET/CT Scanner: A Pilot Study|Completed||Phase 2|10|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:12.534932|2018-06-01 04:35:12.534932
NCT00188916|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-11|2005-09-13|2005-09-16|Estimate|||||||2007-06-11|2007-06-12|Estimate||||September 2006|2006-09-30||||||||Observational|||A Clinical Comparison of Three Bronchial Blockers for One-Lung Ventilation in Thoracic Surgery||Unknown status|Recruiting||120|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:12.608063|2018-06-01 04:35:12.608063
NCT00188097|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-01-18|2005-09-12|2005-09-16|Estimate|||||||2006-01-18|2006-01-19|Estimate|November 1999||1999-11-30|August 2005|2005-08-31|June 2002||2002-06-30|||||Interventional|||Diagnosis of Variceal Bleeding and Its Control in Cirrhosis|Diagnosis of Variceal Bleeding and Its Control in Cirrhosis|Terminated||N/A|400||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:16.900811|2018-06-01 04:35:16.900811
NCT00188903|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-08-03|2005-09-13|2005-09-16|Estimate|||||||2010-08-03|2010-08-05|Estimate|March 2004||2004-03-31|April 2008|2008-04-30|March 2010|Actual|2010-03-31|November 2007|Actual|2007-11-30||Observational|||Diastolic Dysfunction and Atrial Fibrillation in CABG Surgery|Diastolic Dysfunction and Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery|Completed|||250|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:12.689958|2018-06-01 04:35:12.689958
NCT00188890|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-03-22|2005-09-15|2005-09-16|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 2005|Actual|2005-03-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers|Early Diagnosis of Mesothelioma and Lung Cancer Following Asbestos Exposure Using Low-dose Computed Tomography|Recruiting|||2000|Anticipated|University Health Network, Toronto|||1||f||||f||||||||Undecided||2018-06-01 04:35:12.749495|2018-06-01 04:35:12.749495
NCT00188877|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-09-21|2005-09-12|2005-09-16|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2003||2003-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2008|Actual|2008-06-30||Interventional|||Intensity Modulated Radiation Therapy for Head and Neck Cancer|A Phase II Study of Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer|Active, not recruiting||Phase 2|44|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:12.820708|2018-06-01 04:35:12.820708
NCT00188864|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-28|2005-09-12|2005-09-16|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2003||2003-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Dexamethasone for Palliation - Brain Metastases|Dexamethasone as Palliative Treatment in Addition to Radiation Therapy for Patients With Brain Metastases: A Prospective Study|Active, not recruiting||Phase 2|50|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:12.894495|2018-06-01 04:35:12.894495
NCT00188851|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|November 2005||2005-11-30|||||Interventional|||Structured Treatment Interruption for HIV Patients With Virologic Failure|A Prospective Randomized Trial of Structured Treatment Interruption(STI) Followed by Initiation of a New Antiretroviral Regimen(ARV) Versus Immediate Switching to a New ARV in HIV-Infected Patients Experiencing Virologic Failure on HAART|Completed||N/A|196||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:12.960081|2018-06-01 04:35:12.960081
NCT00188838|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|July 2002||2002-07-31|July 2005|2005-07-31|August 2006||2006-08-31|||||Interventional|||Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder|Psychoeducation Versus Cognitive-Behavioral Therapy in Bipolar Disorder|Unknown status|Active, not recruiting|N/A|210||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:13.035163|2018-06-01 04:35:13.035163
NCT00188825|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-03|2005-09-12|2005-09-16|Estimate|||||||2017-05-03|2017-05-04|Actual|May 2004||2004-05-31|May 2017|2017-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant|A Randomized, Double Blind, Placebo Controlled Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans Syndrome in Bilateral Lung and Single Lung Transplant Patients|Completed||Phase 3|22|Actual|University Health Network, Toronto||2|||f||||||||||||||2018-06-01 04:35:13.112461|2018-06-01 04:35:13.112461
NCT00188812|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-09|2005-09-12|2005-09-16|Estimate|||||||2009-01-09|2009-01-12|Estimate|May 2004||2004-05-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease|Open-Label, Multicentre, One Year Extension of the Evaluation of the Safety of Donepezil Hcl in Patients With Dementia Associated With Cerebrovascular Disease|Completed||Phase 3|||University Health Network, Toronto|||||||||||||||||||2018-06-01 04:35:13.18514|2018-06-01 04:35:13.18514
NCT00188799|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-07-15|2005-09-12|2005-09-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|November 2003||2003-11-30|July 2015|2015-07-31|November 2004||2004-11-30|||||Interventional|||Xray Volume Imaging (Cone Beam CT) - Prostate Cancer|A Clinical Study of X-ray Volume Imaging to Evaluate the Daily Set-up Accuracy of Conformal Prostate Radiotherapy|Completed||Phase 2|30||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:13.246201|2018-06-01 04:35:13.246201
NCT00188786|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-11|2005-09-12|2005-09-16|Estimate|||||||2011-02-11|2011-02-15|Estimate|April 2005||2005-04-30|February 2011|2011-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Cone Beam CT for Daily Image Guidance - Prostate Cancer|A Phase II Feasibility Study of Cone Beam Computed Tomography for Daily Image Guidance in Patients Receiving Dose Escalated Conformal Radiation Therapy for Prostate Cancer|Completed||Phase 2|30|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:13.302382|2018-06-01 04:35:13.302382
NCT00188773|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-04|2005-09-12|2005-09-16|Estimate|||||||2008-06-04|2008-06-05|Estimate|January 2004||2004-01-31|June 2007|2007-06-30|January 2008|Actual|2008-01-31|August 2007|Actual|2007-08-31||Interventional|||Mechanism of Fatty Acid-Induced Impairment of Glucose-Stimulated Insulin Secretion||Completed||Phase 4|15|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:35:13.360696|2018-06-01 04:35:13.360696
NCT00188760|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-10-06|2005-09-12|2005-09-16|Estimate|||||||2011-10-06|2011-10-07|Estimate|May 2004||2004-05-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|||||Observational|||Breast Study Investigating a New Light Technique to Monitor Changes in Breast Tissue Density|Optical Quantification of Breast Density Changes Due to Hormone Treatment, Pregnancy and Breast-feeding.|Completed|||300|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:35:13.423211|2018-06-01 04:35:13.423211
NCT00188747|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-10|2005-09-12|2005-09-16|Estimate|||||||2006-10-10|2006-10-11|Estimate|June 2005||2005-06-30|April 2006|2006-04-30||||||||Interventional|||Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding|Comparison of Three Management Strategies for Post Cardiac Surgery Coagulopathy.|Completed||Phase 4|150||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:13.478662|2018-06-01 04:35:13.478662
NCT00188734|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-08-09|2005-09-12|2005-09-16|Estimate|||||||2016-08-09|2016-08-10|Estimate|September 2003||2003-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Early Lung Cancer Detection Using Computed Tomography|Lung Cancer Screening in High-risk Smokers Using Low-dose Computed Tomography|Completed|||5000|Actual|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:13.533801|2018-06-01 04:35:13.533801
NCT00188721|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-11|2005-09-12|2005-09-16|Estimate|||||||2011-08-11|2011-08-12|Estimate|July 2006||2006-07-31|August 2011|2011-08-31|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Observational|||Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.|Transillumination for Breast Cancer Risk Assessment|Completed|||500|Anticipated|University Health Network, Toronto|||2||f||||f||||||||||2018-06-01 04:35:13.593933|2018-06-01 04:35:13.593933
NCT00188708|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-05-22|2005-09-12|2005-09-16|Estimate|||||||2018-05-22|2018-05-23|Actual|April 2001||2001-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Casodex on Tumour Hypoxia - Prostate Cancer|A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer|Active, not recruiting||Phase 2|30|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:35:13.650347|2018-06-01 04:35:13.650347
NCT00188695|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-05|2005-09-12|2005-09-16|Estimate|||||||2008-05-05|2008-05-07|Estimate|April 2004||2004-04-30|April 2008|2008-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Combidex USPIO - Ultra-Small Superparamagnetic Iron Oxide|A Pilot Study of MR Imaging With Ultra-Small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition|Completed||Phase 1/Phase 2|61|Actual|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 04:35:13.720598|2018-06-01 04:35:13.720598
NCT00188682|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-11-13|2005-09-12|2005-09-16|Estimate|||||||2007-11-13|2007-11-15|Estimate|March 2000||2000-03-31|November 2007|2007-11-30|September 2003|Actual|2003-09-30|||||Observational|||Breast Study to Determine the Ability of Non-Invasive Optical Transillumination Spectroscopy to Predict Breast Density.|Optical Transillumination Spectroscopy of Breast Tissue in Pre- and Post-Menopausal Women.|Completed|||300|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:35:13.774494|2018-06-01 04:35:13.774494
NCT00188669|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-10|2005-09-12|2005-09-16|Estimate|||||||2010-08-10|2010-08-11|Estimate|July 2002||2002-07-31|August 2010|2010-08-31||||||||Interventional|||The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain|A Phase II Study of the Use of Pentoxifylline and a-Tocopherol in the Treatment of Chronic Breast Pain Associated With Breast Radiotherapy|Terminated||Phase 2|48|Anticipated|University Health Network, Toronto||||date: August 2006. No annual renewal|f||||||||||||||2018-06-01 04:35:13.819552|2018-06-01 04:35:13.819552
NCT00188656|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-12-14|2005-09-12|2005-09-16|Estimate|||||||2010-12-14|2010-12-15|Estimate|August 2003||2003-08-31|December 2010|2010-12-31|September 2006||2006-09-30|||||Interventional|||Computed Tomography (CT) in Head and Neck Patients|Minimum Dose CT in the Detection of Lung Nodules in Patients With Head and Neck Cancer|Terminated||Phase 1|100||University Health Network, Toronto||||insufficient recruitment|f||||||||||||||2018-06-01 04:35:13.869812|2018-06-01 04:35:13.869812
NCT00188643|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-08|2005-09-12|2005-09-16|Estimate|||||||2011-02-08|2011-02-09|Estimate|January 2002||2002-01-31|February 2005|2005-02-28|January 2007||2007-01-31|||||Interventional|||Venlafaxine Versus Lamotrigine in the Treatment of Bipolar I/II Depression|Double-Blind, Acute Depression Study Comparing Venlafaxine XR and Lamotrigine When Added to Mood Stabilizer in the Treatment of Bipolar Depression|Completed||Phase 4|40||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:14.00058|2018-06-01 04:35:14.00058
NCT00188630|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-19|2005-09-12|2005-09-16|Estimate|||||||2011-04-19|2011-04-20|Estimate|July 2003||2003-07-31|April 2011|2011-04-30|July 2007|Actual|2007-07-31|February 2007|Actual|2007-02-28||Interventional|||N-Acetylcysteine for Preventing Renal Injury After Cardiac Surgery|The PRIME (Perioperative Renal Insufficiency Management) Study: A Randomized, Double-blinded, Placebo-controlled Trial of N-acetylcysteine for Preventing Renal Injury After Cardiac Surgery.|Completed||Phase 3|176|Actual|University Health Network, Toronto||2|||f||||||||||||||2018-06-01 04:35:14.070093|2018-06-01 04:35:14.070093
NCT00188617|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-10|2005-09-12|2005-09-16|Estimate|||||||2017-03-10|2017-03-14|Actual|January 2005||2005-01-31|March 2017|2017-03-31|November 2009|Actual|2009-11-30|June 2007|Actual|2007-06-30||Interventional|||Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC|Phase II Study Of Single Agent Gefitinib (Iressa) In Patients With Clinical Stage I Non-Small Cell Lung Cancer (NSCLC) Proceeding To Mediastinoscopy And Surgery|Completed||Phase 2|35|Actual|University Health Network, Toronto|||||f||||t||||||||||2018-06-01 04:35:14.149129|2018-06-01 04:35:14.149129
NCT00188604|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-12|2005-09-12|2005-09-16|Estimate|||||||2010-08-12|2010-08-13|Estimate|January 2004||2004-01-31|August 2010|2010-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||The Use of Selenium to Treat Secondary Lymphedema - Breast Cancer|A Randomized Phase II Placebo-controlled Double Blind Study of Using Selenium in the Treatment of Secondary Lymphedema in Breast Cancer Patients|Completed||Phase 2|34|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:14.219099|2018-06-01 04:35:14.219099
NCT00188591|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-11-21|2005-09-12|2005-09-16|Estimate|||||||2008-11-21|2008-11-25|Estimate|April 2005||2005-04-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|||||Observational|||Light Based Analysis of Developing Breast Tissue in Adolescent Girls: a Feasibility Study|Pilot Study to Investigate the Feasibility of Optical Spectroscopy to Quantify Bulk Breast Tissue Properties in Girls Age 10 - 14 Years|Completed|||20|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:35:14.281144|2018-06-01 04:35:14.281144
NCT00188578|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-02-08|2005-09-12|2005-09-16|Estimate|||||||2016-02-08|2016-02-09|Estimate|June 2003||2003-06-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Intensity Modulated Radiation Therapy - Gyne Cancer (GY03.2)|A Pilot Study of Conformal Intensity Modulated Radiation Therapy (IMRT) for Gynaecological Cancer Patients Not Suitable for Intracavitary Brachytherapy Boost (GY03.2)|Completed||Phase 1/Phase 2|12|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:35:14.338044|2018-06-01 04:35:14.338044
NCT00188565|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-12|2005-09-12|2005-09-16|Estimate|||||||2010-08-12|2010-08-13|Estimate|March 2004||2004-03-31|August 2010|2010-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Celebrex With Preoperative Chemoradiation - Rectal Cancer|A Phase I/II Trial of Celecoxib With Preoperative Chemoradiation for Resectable Rectal Cancer With In Vivo Analysis of Celecoxib Effector Pathways|Completed||Phase 1/Phase 2|39|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:14.396244|2018-06-01 04:35:14.396244
NCT00188552|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-12|2005-09-12|2005-09-16|Estimate|||||||2010-08-12|2010-08-13|Estimate|July 2002||2002-07-31|August 2010|2010-08-31||||||||Interventional|||The Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries|A Phase II Study of the Use of Pentoxifylline and Vitamin E in the Treatment of Late Radiation Related Injuries|Terminated||Phase 2|50|Anticipated|University Health Network, Toronto||||May 2007: No annual renewal|f||||||||||||||2018-06-01 04:35:14.451556|2018-06-01 04:35:14.451556
NCT00188539|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-09-21|2005-09-12|2005-09-16|Estimate|||||||2017-09-21|2017-09-25|Actual|December 1995||1995-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cervix:Hypoxia, Interstitial Fluid Pressure and GSH Levels|Predictive Assays in Cervix Cancer: Assessment of Hypoxia, Interstitial Fluid Pressure, and GSH Levels|Active, not recruiting||Phase 2|300|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 04:35:14.510025|2018-06-01 04:35:14.510025
NCT00188526|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-09-19|2005-09-12|2005-09-16|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2005||2005-09-30|September 2017|2017-09-30|September 2006||2006-09-30|||||Interventional|||Computed Tomography (CT) Guided Lung Biopsy: Core or Fine Needle Aspiration|CT Guided Lung Biopsy: Core or Fine Needle Aspiration|Withdrawn||N/A|0|Actual|University Health Network, Toronto||||Unknown Reason|f||||f||||||||||2018-06-01 04:35:14.578368|2018-06-01 04:35:14.578368
NCT00188513|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-09-20|2005-09-12|2005-09-16|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2001||2001-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|April 2006|Actual|2006-04-30||Interventional|||Intensity Modulated Radiation Therapy - Prostate Cancer|A Phase I-II Prospective Trial of Conformal Hypofractionated Intensity Modulated Radiotherapy (IMRT) for Localized Adenocarcinoma of the Prostate|Active, not recruiting||Phase 1/Phase 2|267|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:35:14.719245|2018-06-01 04:35:14.719245
NCT00188500|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-28|2005-09-12|2005-09-16|Estimate|||||||2005-12-28|2005-12-29|Estimate|August 2005||2005-08-31|March 2004|2004-03-31|September 2005||2005-09-30|||||Interventional|||Efficacy of Modified Ketogenic Diet (Atkins) in Management of Epilepsy|Efficacy, Tolerability and Long-Term Adherence of a Modified Ketogenic Diet (Atkins) in the Management of Pharmacoresistant Epilepsy|Unknown status|Recruiting|N/A|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:14.781076|2018-06-01 04:35:14.781076
NCT00188487|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-12|2005-09-16|Estimate|||||||2007-04-20|2007-04-23|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|December 2005||2005-12-31|||||Interventional|||Magnetic Resonance (MR) in Asthmatic Patients|MR Perfusion Imaging in Asthmatic Patients|Suspended||Phase 1|80||University Health Network, Toronto||||no funding|f||||||||||||||2018-06-01 04:35:14.849333|2018-06-01 04:35:14.849333
NCT00188474|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-03|2005-09-12|2005-09-16|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2004||2004-08-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A Quality of Life Study re Management of Malignant Pleural Effusions|A Prospective Study of Patient Centered Outcomes in the Management of Malignant Pleural Effusions|Completed|||149|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:35:14.900926|2018-06-01 04:35:14.900926
NCT00188461|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-12|2005-09-16|Estimate|||||||2007-04-20|2007-04-23|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Dose Reduction in Thoracic CT|Dose Reduction in Thoracic CT: A Comparison of on Line Automatic Dose Reduction and a 50% Reduction in Dose|Completed||Phase 1|100||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:14.972664|2018-06-01 04:35:14.972664
NCT00188448|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-12|2005-09-16|Estimate|||||||2007-04-20|2007-04-23|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|April 2004||2004-04-30|||||Interventional|||MRI Superficial Temporal Artery|MRI of the Superficial Temporal Artery|Completed||Phase 1|5||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.023147|2018-06-01 04:35:15.023147
NCT00188435|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-23|2005-09-12|2005-09-16|Estimate|||||||2007-04-23|2007-04-24|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Comparison of CXR and MnDCT|A Comparison of Chest Radiography and Minimum Dose Chest CT|Completed||Phase 1|100||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.07932|2018-06-01 04:35:15.07932
NCT00188422|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-12|2005-09-16|Estimate|||||||2007-04-20|2007-04-23|Estimate|August 2003||2003-08-31|April 2007|2007-04-30|January 2006||2006-01-31|||||Interventional|||Study of Low Dose CT in Sarcoma Patients|Surveillance Low Dose Computed Tomography of the Thorax in Patients With High Grade Extremity Soft Tissue Sarcoma|Completed||Phase 1|70||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.128735|2018-06-01 04:35:15.128735
NCT00188409|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-12|2005-09-16|Estimate|||||||2007-04-20|2007-04-23|Estimate|February 2002||2002-02-28|September 2005|2005-09-30|February 2004||2004-02-29|||||Interventional|||Pneumothorax Post CT Lung Biopsy|Pneumothorax Following CT-Guided Lung Biopsy: Is There a Role for the Post Biopsy CT in Patient Management|Completed||N/A|200||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.182364|2018-06-01 04:35:15.182364
NCT00188396|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-03-12|2005-09-09|2005-09-16|Estimate|||||||2009-03-12|2009-03-13|Estimate|April 2004||2004-04-30|January 2007|2007-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response|The Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response: A Comparison of Premenopausal, Perimenopausal and Postmenopausal Women|Completed||N/A|44|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:35:15.233734|2018-06-01 04:35:15.233734
NCT00188383|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-03-13|2005-09-09|2005-09-16|Estimate|||||||2006-03-13|2006-03-14|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy|Effects of NMDA-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy in Young and Elderly Patients|Unknown status|Recruiting|Phase 1/Phase 2|132||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.29966|2018-06-01 04:35:15.29966
NCT00188370|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-16|Estimate|||||||2005-09-09|2005-09-16|Estimate|April 1999||1999-04-30|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Ultrasound Biomicroscopy - Apoptosis|Ultrasound Biomicroscopy for Monitoring Apoptosis in Lymphoma, Melanoma and Basal Cell Carcinoma Patients During Chemotherapy or Radiation Therapy|Completed||Phase 2|50||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.368256|2018-06-01 04:35:15.368256
NCT00188357|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-02-13|2005-09-09|2005-09-16|Estimate|||||||2007-02-13|2007-02-14|Estimate|August 2003||2003-08-31|September 2005|2005-09-30||||||||Interventional|||HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus|HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus|Unknown status|Recruiting|N/A|360||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.42267|2018-06-01 04:35:15.42267
NCT00188344|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2005||2005-09-30|May 2014|2014-05-31|March 2015|Anticipated|2015-03-31|March 2011|Actual|2011-03-31||Interventional|||A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia|A Randomized Comparison of Laparoscopic Myotomy and Pneumatic Dilatation for Achalasia|Unknown status|Active, not recruiting|N/A|56|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 04:35:15.491327|2018-06-01 04:35:15.491327
NCT00188331|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-03-21|2005-09-09|2005-09-16|Estimate|||||||2016-03-21|2016-03-22|Estimate|November 2003||2003-11-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy|Cognitive Function and Fatigue in Cancer Patients After Chemotherapy: A Longitudinal Controlled Study in Patients With Colorectal Cancer|Completed|||441|Actual|University Health Network, Toronto|||3||f||||f||||||Samples With DNA|"~     cytokines, genotyping apoE, EUC, LFTs, sex hormones, coagulation factors~   "|||2018-06-01 04:35:15.566373|2018-06-01 04:35:15.566373
NCT00188318|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-02-08|2005-09-09|2005-09-16|Estimate|||||||2016-02-08|2016-02-09|Estimate|June 1998||1998-06-30|February 2016|2016-02-29|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Hardwins - Squamous Cell Carcinoma Head & Neck (Surgery/RT)|A Phase II Study of Hyperfractionated Accelerated Radiotherapy Delivered With Integrated Neck Surgery for Node-positive Cases in Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|169|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:35:15.641433|2018-06-01 04:35:15.641433
NCT00188305|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-08-14|2005-09-09|2005-09-16|Estimate|||||||2015-08-14|2015-08-17|Estimate|January 2005||2005-01-31|August 2015|2015-08-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients|A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients|Completed||Phase 3|252|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-06-01 04:35:15.69665|2018-06-01 04:35:15.69665
NCT00188292|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-03-04|2005-09-09|2005-09-16|Estimate|||||||2016-03-04|2016-03-08|Estimate|August 2002||2002-08-31|March 2016|2016-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|TRACE||Screening for HIV-Associated Anal Cancer|Screening for HIV-Associated Anal Cancer|Completed|||401|Actual|University Health Network, Toronto|||2||f||||t||||||||||2018-06-01 04:35:15.755841|2018-06-01 04:35:15.755841
NCT00188279|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-05-03|2005-09-09|2005-09-16|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2005||2005-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma|Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma|Active, not recruiting||Phase 2|250|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 04:35:15.806208|2018-06-01 04:35:15.806208
NCT00188266|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-09-19|2005-09-09|2005-09-16|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2002|Actual|2002-08-31|September 2017|2017-09-30|August 18, 2017|Actual|2017-08-18|December 19, 2013|Actual|2013-12-19||Interventional|||Study of Adjuvant Radiochemotherapy for Gastric Cancer|Prospective Phase I/II Study of Adjuvant Radiochemotherapy for Gastric Cancer|Completed||Phase 1/Phase 2|65|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 04:35:15.864204|2018-06-01 04:35:15.864204
NCT00188253|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-05-22|2005-09-09|2005-09-16|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2005||2005-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2017|Actual|2017-02-28||Observational|||Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma.|Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma.|Active, not recruiting|||30|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.916298|2018-06-01 04:35:15.916298
NCT00188240|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-28|2005-09-09|2005-09-16|Estimate|||||||2005-11-28|2005-11-29|Estimate|August 2003||2003-08-31|September 2005|2005-09-30||||||||Interventional|||Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy|Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Anti-Viral Therapy|Unknown status|Recruiting|N/A|200||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:15.966243|2018-06-01 04:35:15.966243
NCT00188227|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-04-19|2005-09-10|2005-09-16|Estimate|||||||2007-04-19|2007-04-20|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|November 2003||2003-11-30|||||Interventional|||Comparison of Three Different Pain and Anxiety Reducing Methods in Adult Patients Undergoing Bone Marrow Puncture|Comparison of Three Different Pain and Anxiety Reducing Methods in Adult Patients Undergoing Bone Marrow Puncture|Completed||Phase 4|748||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:35:16.026471|2018-06-01 04:35:16.026471
NCT00188214|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-05-03|2005-09-09|2005-09-16|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2003||2003-10-31|May 2017|2017-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||CT Perfusion Scans for Assessment of Lung Cancer Before and After Chemo +/- Radiotherapy|Dynamic CT Perfusion for Assessment of Lung Cancer Before and After Neoadjuvant Chemo-/ Radiotherapy|Completed||Phase 2|38|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-06-01 04:35:16.088561|2018-06-01 04:35:16.088561
NCT00188201|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-28|2005-09-09|2005-09-16|Estimate|||||||2005-11-28|2005-11-29|Estimate|January 2002||2002-01-31|September 2005|2005-09-30||||||||Observational|||Neurocognitive Functioning in Patients With Hepatitis C Pre- and Post-Treatment With Antiviral Medication|An Investigation of Cognitive Functioning and Brain Metabolites in Patients With Non-Cirrhotic Hepatitis-C Both Pre- and Post-Treatment With Antiviral Medication|Unknown status|Recruiting||150||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:16.239635|2018-06-01 04:35:16.239635
NCT00188188|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-28|2005-09-09|2005-09-16|Estimate|||||||2005-12-28|2005-12-29|Estimate|March 2002||2002-03-31|March 2005|2005-03-31||||||||Interventional|||Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease|Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion.|Unknown status|Recruiting|Phase 4|50||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:16.314249|2018-06-01 04:35:16.314249
NCT00188175|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-06-02|2005-09-09|2005-09-16|Estimate|||||||2014-06-02|2014-06-03|Estimate|May 2003||2003-05-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||IMRT Lower Limb Soft Tissue Sarcoma|A Phase II Study of Preoperative Intensity-Modulated Radiation Therapy For Lower Limb Soft Tissue Sarcoma|Completed||Phase 2|59|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 04:35:16.388381|2018-06-01 04:35:16.388381
NCT00188162|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-20|2005-09-12|2005-09-16|Estimate|||||||2007-04-20|2007-04-23|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|September 2005|Actual|2005-09-30|||||Interventional|||Minimum Dose CT Post Lung Biopsy|Can Minimum Dose CT Post Lung Biopsy Predict Patient Outcome?|Completed||Phase 1|100||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:35:16.458229|2018-06-01 04:35:16.458229
NCT00188149|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-12-28|2005-09-10|2005-09-16|Estimate|||||||2005-12-28|2005-12-29|Estimate|May 2000||2000-05-31|September 2005|2005-09-30|December 2007||2007-12-31|||||Interventional|||Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET|Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy|Unknown status|Recruiting|Phase 4|300||University Hospital Carl Gustav Carus|||||f||||||||||||||2018-06-01 04:35:16.543157|2018-06-01 04:35:16.543157
NCT00188136|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-07|2005-09-12|2005-09-16|Estimate|||||||2015-12-07|2015-12-08|Estimate|August 2002||2002-08-31|December 2015|2015-12-31|December 2010|Actual|2010-12-31|July 2010|Actual|2010-07-31||Interventional|||Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)|Phase II Study of Early Allogeneic Blood Stem Cell Transplantation During Induction-chemotherapy Induced Aplasia in High-risk Acute Myeloid Leukemia|Completed||Phase 2|32|Actual|University Hospital Carl Gustav Carus|||||f||||||||||||||2018-06-01 04:35:16.648516|2018-06-01 04:35:16.648516
NCT00188123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-07-14|2005-09-15|2005-09-16|Estimate|||||||2009-07-14|2009-07-15|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|April 2009|Actual|2009-04-30|September 2005|Actual|2005-09-30||Observational|||Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With Magnetic Resonance Imaging (MRI)|Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With MRI|Completed|||20|Actual|University Hospital, Linkoeping|||||f||||f||||||||||2018-06-01 04:35:16.734179|2018-06-01 04:35:16.734179
NCT00188084|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-10-27|2005-09-12|2005-09-16|Estimate|||||||2005-10-27|2005-10-28|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Description and Prognostic Evaluation of Four Biological Parameters of Blast Cells in Adult Acute Lymphoblastic Leukemia|Analysis of Four Biological Parameters at Diagnosis of Adult Acute Lymphoblastic Leukaemia: DNA Index, Percentage of Cells in S-Phase, CD45 Fluorescence Index, and Protein P16: Prognostic Study in Patients Enrolled in a Multicentric Trial|Unknown status|Recruiting||400||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:16.961973|2018-06-01 04:35:16.961973
NCT00188071|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-10-30|2005-09-12|2005-09-16|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2002||2002-09-30|September 2005|2005-09-30|August 2003||2003-08-31|||||Interventional|||Postoperative Pain After Medical Abortion Under Local Anesthesia : Comparison of Several Analgesic Regimen|Postoperative Pain After Medical Abortion Under Local Anesthesia : a Prospective and Randomized Trial Comparing Several Analgesic Regimen|Completed||N/A|240||University Hospital, Angers|||||f|||||f|f||||||||2018-06-01 04:35:17.02813|2018-06-01 04:35:17.02813
NCT00188058|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|September 2002||2002-09-30|September 2005|2005-09-30||||||||Interventional|||Comparison of 2 Strategies of Adjustment of Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome|Comparison of Two Strategies for Setting Positive End-Expiratory Pressure in Acute Lung Injury/ Acute Respiratory Distress Syndrome (ExPress Study).|Unknown status|Recruiting|N/A|800||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.12034|2018-06-01 04:35:17.12034
NCT00188045|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-10-30|2005-09-12|2005-09-16|Estimate|||||||2017-10-30|2017-11-01|Actual|April 1995||1995-04-30|December 2001|2001-12-31|December 2003||2003-12-31|||||Interventional|||Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients|Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients|Terminated||Phase 4|54||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.357409|2018-06-01 04:35:17.357409
NCT00188032|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-02-04|2005-09-12|2005-09-16|Estimate|||||||2009-02-04|2009-02-05|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|September 2006|Actual|2006-09-30|||||Interventional|||Strategies for Suspected Pulmonary Embolism in Emergency Departments|Strategies for Suspected Pulmonary Embolism in Emergency Departments - SPEED Study|Completed||N/A|1331|Anticipated|University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.406945|2018-06-01 04:35:17.406945
NCT00188019|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-07-22|2005-09-12|2005-09-16|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2005||2005-11-30|July 2015|2015-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers|Evaluation Des méthodes de dépistage du Paragangliome héréditaire Chez Les Sujets prédisposés génétiquement|Completed||N/A|248|Actual|University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.481925|2018-06-01 04:35:17.481925
NCT00188006|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-16|Estimate|||||||2005-09-09|2005-09-16|Estimate||||September 2005|2005-09-30||||||||Interventional|||Complement Activation and Central Nervous System Injury After Coronary Artery Surgery|Biocompatible Cardiopulmonary Bypass and Neuropsychological Outcome After Coronary Artery Bypass Surgery|Completed||N/A|||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.525813|2018-06-01 04:35:17.525813
NCT00187993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|May 2005||2005-05-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Observational|||Growth Hormone Treatment of Young Growth Hormone-Deficient Adults|Growth Hormone Treatment of Young Adults Deficient in Growth Hormone Since Childhood : Study of Body Composition Modifications.|Unknown status|Recruiting||30||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.58077|2018-06-01 04:35:17.58077
NCT00187980|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-16|Estimate|||||||2005-09-09|2005-09-16|Estimate|June 2005||2005-06-30|September 2005|2005-09-30||||||||Observational|||Sleep Disturbance in Lung Cancer Patients.||Unknown status|Recruiting||50||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.642951|2018-06-01 04:35:17.642951
NCT00187967|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-09-24|2005-09-09|2005-09-16|Estimate|||||||2007-09-24|2007-09-26|Estimate|January 2005||2005-01-31|September 2005|2005-09-30||||||||Interventional|||Cardiopulmonary Bypass (CPB) Pumps and Blood Activation|Blood Activation During Cardiopulmonary Bypass Using Roller or Centrifugal Pumps|Unknown status|Recruiting|N/A|||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:35:17.692991|2018-06-01 04:35:17.692991
NCT00187954|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-10-02|2005-09-14|2005-09-16|Estimate|||||||2015-10-02|2015-10-05|Estimate|June 2003||2003-06-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||WISE ARIC: Retinal Photography in Women With Chest Pain|Retinal Photography in Women With Chest Pain: A WISE/ARIC Collaboration|Completed|||160|Actual|University of Florida|||||f||||t||||||||||2018-06-01 04:35:17.782948|2018-06-01 04:35:17.782948
NCT00187941|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-19|2005-09-13|2005-09-16|Estimate|||||||2012-06-19|2012-06-20|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression|Pilot Trial for Implementation of a Medroxyprogesterone(MPA)Pharmacokinetic(PK) Monitoring Strategy in Patients on Mycophenolate Mofetil(MMF)/FK Based Immunosuppression.|Completed||Early Phase 1|22|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 04:35:17.839867|2018-06-01 04:35:17.839867
NCT00187928|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-10-04|2005-09-15|2005-09-16|Estimate|||||||2011-10-04|2011-10-05|Estimate|January 2003||2003-01-31|October 2011|2011-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder|Completed||Phase 3|96||University of Florida|||||f||||t||||||||||2018-06-01 04:35:17.904231|2018-06-01 04:35:17.904231
NCT00187915|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-10-19|2005-09-14|2005-09-16|Estimate|||||||2011-10-19|2011-10-20|Estimate|July 2003||2003-07-31|October 2011|2011-10-31|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|MPA||Pilot Trial for Implementation of a MPA PK Monitoring Strategy|Pilot Trial for Implementation of a MPA PK Monitoring Strategy|Completed||N/A|24|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 04:35:17.958679|2018-06-01 04:35:17.958679
NCT00187902|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-04-13|2005-09-15|2005-09-16|Estimate|||||||2011-04-13|2011-04-14|Estimate|October 2005||2005-10-31|April 2011|2011-04-30|December 2008|Actual|2008-12-31|May 2007|Actual|2007-05-31||Observational|||Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM|Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM|Completed|||907|Actual|University of California, San Francisco|||||f||||f||||||Samples With DNA|"~     self-collected glans swab; clinician-collected rectal and pharyngeal swabs~   "|||2018-06-01 04:35:18.04439|2018-06-01 04:35:18.04439
NCT00187889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|2013-04-25|2012-02-23|2013-08-07|2005-09-10|2005-09-16|Estimate|2013-08-07|2013-10-14|Estimate|2012-02-23|2012-02-24|Estimate|2013-08-07|2013-10-14|Estimate|August 2004||2004-08-31|October 2011|2011-10-31|December 2011|Actual|2011-12-31|February 2009|Actual|2009-02-28||Interventional|||EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia|A Double-Blind, Multicenter, Placebo Controlled Study of Aldosterone Blockade (Eplerenone) in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease|Completed||Phase 4|70|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 04:35:18.106429|2018-06-01 04:35:18.106429
NCT00187876|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-12-04||2014-01-30|2005-09-12|2005-09-16|Estimate|2014-01-30|2014-03-04|Estimate||||2014-01-30|2014-03-04|Estimate|February 2004||2004-02-29|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of Biocleanse Allografts For ACL Reconstruction|Evaluation of Biocleanse Patellar Tendon Allografts For The Reconstruction of Anterior Cruciate Ligaments: A Prospective, Randomized Investigation|Completed||Phase 4|67|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 04:35:19.232722|2018-06-01 04:35:19.232722
NCT00187863|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-20|2005-09-12|2005-09-16|Estimate|||||||2015-03-20|2015-03-24|Estimate|May 2005||2005-05-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Biopsychosocial Factors' Influence on Shoulder Pain|Biopsychosocial Factors' Influence on Shoulder Pain|Completed|||340|Actual|University of Florida|||2||f||||||||||||||2018-06-01 04:35:19.386782|2018-06-01 04:35:19.386782
NCT00187850|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-14|2005-09-13|2005-09-16|Estimate|||||||2016-10-14|2016-10-18|Estimate|February 2005||2005-02-28|October 2016|2016-10-31|June 2013|Actual|2013-06-30|March 2007|Actual|2007-03-31||Interventional|||The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy|The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy on CAP-1 Patients: A Randomised, Patient - and Observer-Blinded Multicenter Trial|Completed||N/A|120|Anticipated|University of Copenhagen||2|||f||||t||||||||||2018-06-01 04:35:19.44804|2018-06-01 04:35:19.44804
NCT00187837|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-10-14|2005-09-15|2005-09-16|Estimate|||||||2016-10-14|2016-10-18|Estimate|February 2005||2005-02-28|October 2016|2016-10-31|June 2013|Actual|2013-06-30|March 2007|Actual|2007-03-31||Interventional|||The CAP-1 Trial: Stepwise Excavation Versus One Completed Excavation in Deep Caries|The CAP-1 Trial: Effect of Stepwise Versus One Completed Excavation in Deep Caries in Permanent Teeth: A Randomised, Patient - and Observer-blinded Multicenter Trial|Completed||N/A|314|Actual|University of Copenhagen||2|||f||||t||||||||Yes|1½ yr results published in European Journal of Oral Sciences 2010; 118: 290-297.|2018-06-01 04:35:19.517216|2018-06-01 04:35:19.517216
NCT00187824|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-11|2005-09-11|2005-09-16|Estimate|||||||2005-09-11|2005-09-16|Estimate|July 2004||2004-07-31|March 2004|2004-03-31|August 2007||2007-08-31|||||Observational|||Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis|Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis|Unknown status|Recruiting||30||University College London Hospitals|||||f||||||||||||||2018-06-01 04:35:19.593625|2018-06-01 04:35:19.593625
NCT00187811|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-28|2005-09-09|2005-09-16|Estimate|||||||2005-12-28|2005-12-29|Estimate|February 2001||2001-02-28|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||The Safety and Efficacy of Photodynamic Therapy for Femoral Artery Stenosis|Randomised Controlled Trial of Adjuvant Photodynamic Therapy to Reduce Restenosis After Percutaneous Transluminal Angioplasty to the Superficial Femoral Angioplasty|Unknown status|Active, not recruiting|Phase 2/Phase 3|120||University College London Hospitals|||||f||||||||||||||2018-06-01 04:35:19.657229|2018-06-01 04:35:19.657229
NCT00187798|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-24|2005-09-15|2005-09-16|Estimate|||||||2012-09-24|2012-09-25|Estimate|August 2001||2001-08-31|September 2012|2012-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Impact of Genetics on Metformin Pharmacokinetics|Impact of Genetics on Metformin Pharmacokinetics|Completed||N/A|24|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:35:19.71263|2018-06-01 04:35:19.71263
NCT00187785|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-01-13|2005-09-15|2005-09-16|Estimate|||||||2006-01-13|2006-01-18|Estimate|September 2005||2005-09-30|August 2005|2005-08-31|December 2006||2006-12-31|||||Interventional|||Doctor-Patient Communication in Spanish|Doctor-Patient Communication in Spanish|Terminated||N/A|100||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:19.871719|2018-06-01 04:35:19.871719
NCT00187772|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-09-17|2005-09-14|2005-09-16|Estimate|||||||2013-09-17|2013-09-19|Estimate|December 1996||1996-12-31|September 2013|2013-09-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Child-Parent Psychotherapy for Preschooler Witnesses of Domestic Violence Program|Preschooler Witnesses of Domestic Violence: A Preventive Intervention Program|Completed||Phase 3|60||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:19.936225|2018-06-01 04:35:19.936225
NCT00187759|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-05-06|2005-09-15|2005-09-16|Estimate|||||||2015-05-06|2015-05-07|Estimate|November 2004||2004-11-30|May 2015|2015-05-31|March 2005||2005-03-31|||||Interventional|||Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection|A Placebo Controlled, Randomized, and Blinded Study of Antibiotic Treatment of Patients With Uncomplicated Soft Tissue Infection|Completed||N/A|500||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:19.999768|2018-06-01 04:35:19.999768
NCT00187746|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-11-20|2005-09-14|2005-09-16|Estimate|||||||2012-11-20|2012-11-21|Estimate|August 2005||2005-08-31|November 2012|2012-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effect of Age on the Renal Clearance of Adefovir|Effect of Age on the Renal Clearance of Adefovir|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||2||Budget exceeded for project.|f||||t||||||||||2018-06-01 04:35:20.067489|2018-06-01 04:35:20.067489
NCT00187733|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-09-11|2005-09-14|2005-09-16|Estimate|||||||2012-09-11|2012-09-13|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides|Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides|Completed|||16|Actual|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Blood Draw (10cc) to determine eligibility (CBC, blood chemistries). Blood draw (20cc) at t=0~     in fasting state for baseline measurement of biochemical markers (including carnitine,~     acylcarnitines, creatinine, and total lipid panel) Urine collection at t=0 Blood draw (20cc)~     at t=2 hours for measurement of biochemical markers (including carnitine, acylcarnitines,~     creatinine, and total lipid panel) Urine collection at t=2 hours Transformation of blood to~     establish lymphoblastoid cell lines (from blood samples collected at t=0 and t=2 hours)~   "|||2018-06-01 04:35:20.150784|2018-06-01 04:35:20.150784
NCT00187720|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-03-31||2012-12-06|2005-09-15|2005-09-16|Estimate|2012-12-06|2013-01-10|Estimate||||2012-12-06|2013-01-10|Estimate|May 2002||2002-05-31|December 2012|2012-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Genetic Basis for Variation in the Renal Elimination of Metformin|Genetic Basis for Variation in the Renal Elimination of Metformin|Completed||Phase 4|23|Actual|University of California, San Francisco|Recruitment of subjects with interested genotypes was our limitation.|2|||f||||t||||||||||2018-06-01 04:35:20.262008|2018-06-01 04:35:20.262008
NCT00187707|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-08-07|2005-09-14|2005-09-16|Estimate|||||||2012-08-07|2012-08-09|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|August 2008|Actual|2008-08-31|January 2007|Actual|2007-01-31||Interventional|||Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin|Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin|Completed||N/A|30|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:35:20.516225|2018-06-01 04:35:20.516225
NCT00187681|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-05-20||2012-12-06|2005-09-13|2005-09-16|Estimate|2012-12-06|2013-01-08|Estimate||||2012-12-06|2013-01-08|Estimate|July 2003||2003-07-31|December 2012|2012-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects|Effect of Genetic Variants in the Xenobiotic Transporter, OCT1, on Response to Metformin in Healthy Subjects|Completed||Phase 4|20|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:35:20.589861|2018-06-01 04:35:20.589861
NCT00187668|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-05-07|2005-09-13|2005-09-16|Estimate|||||||2018-05-07|2018-05-14|Actual|February 2004||2004-02-29|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|SOPHIE||Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)|Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)|Active, not recruiting|||500|Anticipated|University of California, San Francisco|||4||f||||t||||||Samples With DNA|"~     40 mL of blood for DNA extraction~   "|||2018-06-01 04:35:20.798854|2018-06-01 04:35:20.798854
NCT00187655|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-05-21||2014-10-21|2005-09-13|2005-09-16|Estimate|2014-04-10|2014-05-12|Estimate||||2014-10-21|2014-10-29|Estimate|January 2004||2004-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of, OAT3, on the Renal Secretion of Cefotaxime|Effect of Genetic Variation in the Transporter, OAT3, on the Renal Secretion of Cefotaxime|Completed||Phase 1|24|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:35:20.87108|2018-06-01 04:35:20.87108
NCT00187629|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-08|2005-09-13|2005-09-16|Estimate|||||||2013-10-08|2013-10-09|Estimate|March 2004||2004-03-31|October 2013|2013-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Phosphate Intake's Effect on the Skeletal System - Pilot|Phosphate Intake's Effect on the Skeletal System Calcitropic Hormones and FGF23 - Pilot Study|Completed||N/A|27|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:35:21.00501|2018-06-01 04:35:21.00501
NCT00187616|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|April 2002||2002-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Questioning Patients About Adverse Medical Events: A Randomized Controlled Trial|Questioning Patients About Adverse Medical Events: A Randomized Controlled Trial|Completed|||214||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:21.058728|2018-06-01 04:35:21.058728
NCT00187603|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-05|2005-09-13|2005-09-16|Estimate|||||||2008-05-05|2008-05-08|Estimate|July 2003||2003-07-31|August 2005|2005-08-31|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Interventional|||Protecting the 'Hood Against Tobacco|Protecting the 'Hood Against Tobacco: Cessation Project|Completed||N/A|270|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:21.186581|2018-06-01 04:35:21.186581
NCT00187590|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-01-21|2005-09-13|2005-09-16|Estimate|||||||2014-01-21|2014-01-23|Estimate|April 2004||2004-04-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Case Management Intervention to Prevent ER Visits in HIV-infected Persons||Terminated||N/A|612|Actual|University of California, San Francisco||2||Intervention was taken up as a standard of care.|f||||||||||||||2018-06-01 04:35:21.245954|2018-06-01 04:35:21.245954
NCT00187577|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-07|2005-09-13|2005-09-16|Estimate|||||||2011-06-07|2011-06-09|Estimate|June 2005||2005-06-30|June 2011|2011-06-30|March 2006|Actual|2006-03-31|February 2006|Actual|2006-02-28||Interventional|||Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata|Efficacy and Safety of Latanoprost (Xalatan) and Bimatoprost (Lumigan) Ophthalmic Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata|Completed||N/A|14|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:35:21.309919|2018-06-01 04:35:21.309919
NCT00187564|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-02|2005-09-13|2005-09-16|Estimate|||||||2008-05-02|2008-05-06|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|October 2005|Actual|2005-10-31|||||Interventional|||Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus|Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus|Completed||N/A|40||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:21.395416|2018-06-01 04:35:21.395416
NCT00187551|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-08|2005-09-13|2005-09-16|Estimate|||||||2011-02-08|2011-02-10|Estimate|May 2000||2000-05-31|June 2006|2006-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance|Partial Treatment Interruptions in HIV-1 Patients With Multi-Drug Resistant Virus|Completed||Phase 4|25|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-06-01 04:35:21.464258|2018-06-01 04:35:21.464258
NCT00187538|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-08-20|2005-09-13|2005-09-16|Estimate|||||||2014-08-20|2014-08-21|Estimate|February 2002||2002-02-28|August 2014|2014-08-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Dietary Protein Source on Calcium Metabolism|Effect of Dietary Protein Source on Calcium Metabolism|Completed||N/A|183|Actual|University of California, San Francisco||4|||f||||f||||||||||2018-06-01 04:35:21.539483|2018-06-01 04:35:21.539483
NCT00187525|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-11-08|2005-09-13|2005-09-16|Estimate|||||||2012-11-08|2012-11-12|Estimate|May 2004||2004-05-31|November 2012|2012-11-30|October 2006|Actual|2006-10-31|October 2005|Actual|2005-10-31||Interventional|||A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration||Completed||Phase 4|||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:21.608764|2018-06-01 04:35:21.608764
NCT00187512|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-28|2005-09-13|2005-09-16|Estimate|||||||2017-03-28|2017-03-29|Actual|March 2000||2000-03-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31||Observational|SCOPE||SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era|SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era|Recruiting|||2500|Anticipated|University of California, San Francisco|||||f||||f||||||Samples With DNA|"~     Plasma, serum, PMBCs, saliva~   "|||2018-06-01 04:35:21.660573|2018-06-01 04:35:21.660573
NCT00187499|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-02|2005-09-13|2005-09-16|Estimate|||||||2008-04-02|2008-04-03|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|February 2005||2005-02-28|||||Interventional|||Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma|Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma|Completed||N/A|||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:21.743124|2018-06-01 04:35:21.743124
NCT00187304|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-06-04|2005-09-15|2005-09-16|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2005||2005-09-30|June 2013|2013-06-30||||||||Interventional|||ACTION - Anticoagulation Treatment Influence on Post-operative Patients|Anticoagulation Treatment Influence on Post-operative Patients -Action SJM EPIC Trial|Withdrawn||Phase 4|0|Actual|St. Jude Medical||||Study replaced by an observational study|f||||||||||||||2018-06-01 04:35:23.029907|2018-06-01 04:35:23.029907
NCT00187486|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-04-25||2017-08-04|2005-09-13|2005-09-16|Estimate|2012-09-26|2012-09-27|Estimate||||2017-08-04|2017-09-05|Actual|August 2004||2004-08-31|August 2017|2017-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors|Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma|Completed||Phase 2|66|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-06-01 04:35:21.825165|2018-06-01 04:35:21.825165
NCT00187473|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-07-18|2005-09-13|2005-09-16|Estimate|||||||2014-07-18|2014-07-22|Estimate|June 2000||2000-06-30|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31||Observational|||Natural History of Hepatitis C in Patients With Normal Liver Tests|Determinants of Disease Severity in Patients With Chronic Hepatitis C and Normal Serum Aminotransferases (Normal Liver Tests)|Unknown status|Active, not recruiting||92|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 04:35:21.987907|2018-06-01 04:35:21.987907
NCT00187460|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-11-30|2005-09-13|2005-09-16|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2001||2001-11-30|May 2005|2005-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|EFFECT||Study of the Effectiveness of Report Cards on the Quality of Care for Heart Attack and Heart Failure Patients|Enhanced Feedback for Effective Cardiac Treatment (EFFECT)|Completed||N/A|46000|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 04:35:22.042173|2018-06-01 04:35:22.042173
NCT00187447|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-06-02|2005-09-10|2005-09-16|Estimate|||||||2008-06-02|2008-06-04|Estimate|August 2003||2003-08-31|September 2005|2005-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus|Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus|Completed||Phase 2|100|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 04:35:22.127552|2018-06-01 04:35:22.127552
NCT00187434|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-01-22|2005-09-14|2005-09-16|Estimate|||||||2007-01-22|2007-01-23|Estimate|September 2003||2003-09-30|September 2005|2005-09-30||||||||Interventional|||Comparison of Two Methods of Continuous Positive Airway Pressure (CPAP) to Support Successful Extubation of Infants of Birth Weights ≤ 1500 Grams (C2CPAP)|A Randomized Control Trial Comparing Two Methods of Delivering Continuous Positive Airway Pressure (CPAP), Infant Flow System CPAP and Bubble CPAP, in Supporting Successful Extubation of Infants of Birth Weights Less Than or Equal to 1500 Grams at Birth (C2CPAP)|Unknown status|Recruiting|N/A|76||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:35:22.194406|2018-06-01 04:35:22.194406
NCT00187421|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-12-11|2005-09-14|2005-09-16|Estimate|||||||2012-12-11|2012-12-12|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|GRIIP||Using Intraoperative Coronary Bypass Graft Imaging to Improve Graft Patency|Graft Imaging to Improve Patency (GRIIP)|Completed||Phase 3|156|Actual|Sunnybrook Health Sciences Centre||2|||f||||||||||||||2018-06-01 04:35:22.299993|2018-06-01 04:35:22.299993
NCT00187408|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-02-26|2005-09-13|2005-09-16|Estimate|||||||2007-02-26|2007-02-27|Estimate|August 2002||2002-08-31|February 2006|2006-02-28|January 2007||2007-01-31|||||Interventional|||The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial|Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention|Completed||Phase 4|700||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:35:22.378535|2018-06-01 04:35:22.378535
NCT00187395|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-09|2005-09-13|2005-09-16|Estimate|||||||2009-03-09|2009-03-12|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|December 2005||2005-12-31|||||Interventional|||CHIPS (Control of Hypertension in Pregnancy Study): A Pilot Trial|Control of Hypertension in Pregnancy Study: A Pilot Trial|Completed||N/A|132||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:35:22.450754|2018-06-01 04:35:22.450754
NCT00187382|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-14|2005-09-13|2005-09-16|Estimate|||||||2010-06-14|2010-06-15|Estimate|April 2001||2001-04-30|June 2010|2010-06-30|December 2011||2011-12-31|June 2007|Actual|2007-06-30||Interventional|||Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS)|Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS)|Completed||Phase 4|1858|Actual|Sunnybrook Health Sciences Centre|||||f||||t||||||||||2018-06-01 04:35:22.506475|2018-06-01 04:35:22.506475
NCT00187369|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-10-08|2005-09-12|2005-09-16|Estimate|||||||2013-10-08|2013-10-09|Estimate|December 2003||2003-12-31|October 2013|2013-10-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||The Twin Birth Study: A Trial Comparing Planned Vaginal Birth to Elective Caesarean Section of Twins|The Twin Birth Study: A Multicentre Randomised Controlled Trial Comparing Planned Vaginal Birth to Elective Caesarean Section of Twins More Than or Equal to 32 Weeks Gestation|Completed||N/A|2804|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-06-01 04:35:22.561762|2018-06-01 04:35:22.561762
NCT00187356|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2013-06-04|2005-09-10|2005-09-16|Estimate|||||||2013-06-04|2013-06-05|Estimate|July 2002||2002-07-31|June 2013|2013-06-30|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|RAPS - 5 years||Multicentre Radial Artery Patency Study: Results of Patency Beyond 5 Years After Coronary Artery Bypass Surgery|Multicentre Radial Artery Patency Study: Results of Patency Beyond 5 Years After Coronary Artery Bypass Surgery|Completed||Phase 3|269|Actual|Sunnybrook Health Sciences Centre||1|||f||||||||||||||2018-06-01 04:35:22.633474|2018-06-01 04:35:22.633474
NCT00187343|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-05|2005-09-12|2005-09-16|Estimate|||||||2008-09-05|2008-09-08|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||A Clinical Trial to Reduce Skin Burn Induced by Breast Radiotherapy Using Intensity Modulated Radiation Therapy (IMRT)|A Phase III Study of Adjuvant Radiation Therapy in Early Breast Cancer Comparing the Use of Breast Intensity Modulated Radiation Therapy (IMRT) to Conventional Wedge Technique|Completed||Phase 3|340||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:35:22.81054|2018-06-01 04:35:22.81054
NCT00187330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-16|Estimate|||||||2005-09-09|2005-09-16|Estimate|March 2004||2004-03-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||A Study of The Effectiveness of N-Acetylcysteine in Kidney Protection Following Cardiopulmonary Bypass|A Randomized Placebo Controlled Trial of Intravenous N-Acetylcysteine (NAC) As A Renal Protective Agent for Prevention of Renal Dysfunction Following Cardiopulmonary Bypass (CPB)|Completed||Phase 2|104||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:35:22.881512|2018-06-01 04:35:22.881512
NCT00187317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-04-01|2005-09-09|2005-09-16|Estimate|||||||2010-04-01|2010-04-02|Estimate|November 2005||2005-11-30|April 2010|2010-04-30|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Evaluation of a Balance-recovery Specific Falls Prevention Exercise Program|Development and Evaluation of a Perturbation-based Balance-training Program for Older Adults|Completed||Phase 1|37|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-06-01 04:35:22.94343|2018-06-01 04:35:22.94343
NCT00187278|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-08-06|2005-09-13|2005-09-16|Estimate|||||||2015-08-06|2015-08-07|Estimate|May 2003||2003-05-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization|Biventricular Pacing for Atrioventricular Block in Left Ventricular Dysfunction to Prevent Cardiac Desynchronization|Completed||N/A|1833|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 04:35:23.136738|2018-06-01 04:35:23.136738
NCT00187265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-05|2005-09-13|2005-09-16|Estimate|||||||2006-10-05|2006-10-06|Estimate|April 2003||2003-04-30|April 2006|2006-04-30|October 2005||2005-10-31|||||Interventional|||Trip HF Study: Triple Resynchronization in Paced Heeart Failure Patients|Triple Resynchronization in Paced Heart Failure Patients|Completed||N/A|||St. Jude Medical|||||f||||||||||||||2018-06-01 04:35:23.219882|2018-06-01 04:35:23.219882
NCT00187252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-11|2005-09-13|2005-09-16|Estimate|||||||2009-02-11|2009-02-12|Estimate|September 2003||2003-09-30|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|MASCOT||Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity Therapy|Management of Atrial Fibrillation Suppression in AF-HF COmorbidity Therapy|Completed||N/A|380|Anticipated|St. Jude Medical||2|||f||||f||||||||||2018-06-01 04:35:23.270256|2018-06-01 04:35:23.270256
NCT00187239|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2015-04-20|2005-09-10|2005-09-16|Estimate|||||||2015-04-20|2015-04-22|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study|Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search (REDUCE Study)|Completed||Phase 4|157|Actual|St. Jude Medical||2|||f||||||||||||||2018-06-01 04:35:23.337468|2018-06-01 04:35:23.337468
NCT00187226|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-05-04||2012-08-17|2005-09-13|2005-09-16|Estimate|2012-08-17|2012-08-20|Estimate||||2012-08-17|2012-08-20|Estimate|June 1997||1997-06-30|August 2012|2012-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects|A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects|Completed||Phase 2|202|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 04:35:23.41328|2018-06-01 04:35:23.41328
NCT00187213|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-21|2005-09-13|2005-09-16|Estimate|||||||2008-02-21|2008-02-22|Estimate|December 2004||2004-12-31|February 2008|2008-02-29|January 2008|Actual|2008-01-31|July 2007|Actual|2007-07-31||Interventional|||B-Left HF: Biventricular Versus Left Univentricular Pacing With Implantable Cardiac Defibrillator (ICD) Back-Up in Heart Failure Patients|Biventricular Versus Left Univentricular Pacing With ICD Back-up in Heart Failure Patients|Completed||N/A|||St. Jude Medical|||||f||||t||||||||||2018-06-01 04:35:23.751685|2018-06-01 04:35:23.751685
NCT00187200|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|2014-08-27||2015-08-25|2005-09-10|2005-09-16|Estimate|2015-08-25|2015-09-25|Estimate||||2015-08-25|2015-09-25|Estimate|January 2005||2005-01-31|August 2015|2015-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Response of Cardiac Resynchronization Therapy Optimization With Ventricle to Ventricle Timing in Heart Failure Patients|RESPONSE HF - Response of Cardiac Resynchronization Therapy Optimization With Interventricular (VV) Timing in Heart Failure Patients|Completed||Phase 4|816|Actual|St. Jude Medical|Due to the lower than expected non-responder rate at 3 months, the study did not reach the target randomized sample size.|2|||f||||f||||||||||2018-06-01 04:35:23.83087|2018-06-01 04:35:23.83087
NCT00187187|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2010-10-20|2005-09-10|2005-09-16|Estimate|||||||2010-10-20|2010-10-22|Estimate|June 2003||2003-06-30|October 2010|2010-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|DAVIDII||DAVID II (Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial II)|DAVID II (Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial II)|Completed||N/A|600|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 04:35:24.186964|2018-06-01 04:35:24.186964
NCT00187174|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-03|2005-09-13|2005-09-16|Estimate|||||||2015-03-03|2015-03-04|Estimate|October 2004||2004-10-31|December 2009|2009-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors|Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors|Completed||Phase 1|41|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:24.276133|2018-06-01 04:35:24.276133
NCT00187161|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-06-03|2005-09-13|2005-09-16|Estimate|||||||2008-06-03|2008-06-04|Estimate|November 1994||1994-11-30|June 2008|2008-06-30|January 2007|Actual|2007-01-31|||||Interventional|||Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL|Small Noncleaved Cell (SNCC), Non-Hodgkin Lymphoma (NHL), Large Cell NHL (B-Cell) and B-Cell Acute Lymphoblastic Leukemia (B-ALL) Study II|Completed||Phase 2|68|Actual|St. Jude Children's Research Hospital||3|||f||||f||||||||||2018-06-01 04:35:24.339517|2018-06-01 04:35:24.339517
NCT00187148|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-24|2005-09-12|2005-09-16|Estimate|||||||2017-04-24|2017-04-26|Actual|February 2005||2005-02-28|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults|Evaluation of the Tolerability and Safety of a Recombinant HIV-1 Multi-Envelope DNA Plasmid Vaccine (EnvDNA) in Healthy Adults|Completed||Phase 1|6|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:24.404059|2018-06-01 04:35:24.404059
NCT00187135|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-10-13||2017-04-03|2005-09-12|2005-09-16|Estimate|2010-03-04|2010-03-19|Estimate||||2017-04-03|2017-04-04|Actual|March 2002||2002-03-31|March 2010|2010-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration|Fentanyl-Propofol-EMLA or L.M.X4™ Technique for Bone Marrow Aspiration in Pediatric Patients - A Phase III Study|Terminated||Phase 3|168|Actual|St. Jude Children's Research Hospital|All 162 participants were expected to receive three treatments. Not all participants received all three treatments. Therefore, analysis required the identification of subsets of treated participants. The trial terminated early due to slow accrual.|3||The study was terminated due to slow accrual.|f||||f||||||||||2018-06-01 04:35:24.478184|2018-06-01 04:35:24.478184
NCT00187122|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-21|2005-09-13|2005-09-16|Estimate|||||||2008-04-21|2008-04-23|Estimate|March 1993||1993-03-31|April 2008|2008-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma|Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study)|Completed||N/A|42|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:24.932312|2018-06-01 04:35:24.932312
NCT00187109|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-08|2005-09-13|2005-09-16|Estimate|||||||2008-04-08|2008-04-10|Estimate|June 2000||2000-06-30|May 2007|2007-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy|A Phase I/II Trial of Recombinant Human Thrombopoietin in Children With Malignant Solid Tumors and Lymphoma Receiving Ifosfamide, Carboplatin and Etoposide|Completed||Phase 1/Phase 2|40||St. Jude Children's Research Hospital|||||f||||||||||||||2018-06-01 04:35:25.034006|2018-06-01 04:35:25.034006
NCT00187096|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-10-10||2014-06-18|2005-09-12|2005-09-16|Estimate|2012-10-10|2012-11-09|Estimate||||2014-06-18|2014-06-19|Estimate|September 2005||2005-09-30|October 2013|2013-10-31|March 2013|Actual|2013-03-31|February 2012|Actual|2012-02-29||Interventional|||Natural Killer (NK) Cell Transplantation for AML|Pilot Study Of Haplo-Identical Natural Killer Cell Transplantation For Acute Myeloid Leukemia|Completed||N/A|49|Actual|St. Jude Children's Research Hospital||2|||f||||t||||||||||2018-06-01 04:35:25.119565|2018-06-01 04:35:25.119565
NCT00187083|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-03|2005-09-12|2005-09-16|Estimate|||||||2008-06-03|2008-06-04|Estimate|February 1997||1997-02-28|June 2008|2008-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||A Study of Children With Refractory or Relapsed ALL|A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16)|Completed||Phase 3|40|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 04:35:25.554828|2018-06-01 04:35:25.554828
NCT00187070|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-06|2005-09-12|2005-09-16|Estimate|||||||2008-05-06|2008-05-07|Estimate|December 1997||1997-12-31|May 2008|2008-05-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Large Cell Lymphoma Pilot Study III|Large Cell Lymphoma, Pilot Study III|Completed||N/A|8|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:25.639426|2018-06-01 04:35:25.639426
NCT00187057|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-08-26|2005-09-12|2005-09-16|Estimate|||||||2015-08-26|2015-08-27|Estimate|September 2002||2002-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|August 2006|Actual|2006-08-31||Interventional|||Study for Treatment of Cancer in Children With Ataxia-telangiectasia|Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia|Completed||N/A|6|Actual|St. Jude Children's Research Hospital||5|||f||||f||||||||||2018-06-01 04:35:25.708041|2018-06-01 04:35:25.708041
NCT00187044|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-09-28|2005-09-12|2005-09-16|Estimate|||||||2011-09-28|2011-09-29|Estimate|October 1997||1997-10-31|June 2011|2011-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Evaluation of the Safety of a Polyvalent Virus in Healthy Adults|Evaluation of the Safety of a Polyvalent Vaccinia Virus-HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults|Completed||Phase 1|18|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:25.791971|2018-06-01 04:35:25.791971
NCT00187031|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-03|2005-09-12|2005-09-16|Estimate|||||||2008-06-03|2008-06-04|Estimate|November 2002||2002-11-30|June 2008|2008-06-30|October 2007|Actual|2007-10-31|||||Interventional|||A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor|A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor|Completed||Phase 2|37|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:35:25.856519|2018-06-01 04:35:25.856519
NCT00187018|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-03|2005-09-12|2005-09-16|Estimate|||||||2015-03-03|2015-03-04|Estimate|March 2004||2004-03-31|May 2007|2007-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study|Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study|Completed||N/A|9|Actual|St. Jude Children's Research Hospital|||||f||||f||||||||||2018-06-01 04:35:25.944182|2018-06-01 04:35:25.944182
NCT00187005|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-03-29|2005-09-12|2005-09-16|Estimate|||||||2011-03-29|2011-03-30|Estimate|July 1998||1998-07-31|June 2008|2008-06-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Terminated||Phase 3|53|Actual|St. Jude Children's Research Hospital||1||Toxicity|f||||t||||||||||2018-06-01 04:35:26.002795|2018-06-01 04:35:26.002795
NCT00186992|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-11-13|2005-09-12|2005-09-16|Estimate|||||||2017-11-13|2017-11-17|Actual|January 10, 2003|Actual|2003-01-10|November 2017|2017-11-30|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|||Radiation Therapy to Treat Musculoskeletal Tumors|Image Guided Radiotherapy for the Treatment of Musculoskeletal Tumors: A Phase II Prospective Evaluation of Radiation-related Treatment Effects|Active, not recruiting||Phase 2|202|Actual|St. Jude Children's Research Hospital||1|||f||||f|f|t|f|f||||||2018-06-01 04:35:26.079594|2018-06-01 04:35:26.079594
NCT00186979|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-24|2005-09-12|2005-09-16|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2003||2003-05-31|October 2011|2011-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors|A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors|Completed||Phase 1|34|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:26.15457|2018-06-01 04:35:26.15457
NCT00186966|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-05|2005-09-12|2005-09-16|Estimate|||||||2011-04-05|2011-04-06|Estimate|March 2002||2002-03-31|April 2011|2011-04-30|September 2010|Actual|2010-09-30|April 2009|Actual|2009-04-30||Interventional|||Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia|A Randomized Phase III Study of the Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia|Completed||Phase 3|394|Actual|Dutch Childhood Oncology Group||2|||f||||t||||||||||2018-06-01 04:35:26.214493|2018-06-01 04:35:26.214493
NCT00186953|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-09-19|2005-09-12|2005-09-16|Estimate|||||||2011-09-19|2011-09-20|Estimate|June 2002||2002-06-30|September 2011|2011-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors|Determination of Optimal Dose and Safety Profile of Optison Ultrasound Contrast Agent in Pediatric Solid Tumor Patients|Completed||Phase 1|14|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:26.283015|2018-06-01 04:35:26.283015
NCT00186940|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-24|2005-09-12|2005-09-16|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2005||2005-03-31|October 2011|2011-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients|A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies|Completed|||16|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-06-01 04:35:26.344622|2018-06-01 04:35:26.344622
NCT00186927|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-11-13|2005-09-12|2005-09-16|Estimate|||||||2017-11-13|2017-11-17|Actual|May 5, 2005|Actual|2005-05-05|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers|A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity|Recruiting||Phase 1|54|Anticipated|St. Jude Children's Research Hospital||1|||f||||t|t|f||||||||2018-06-01 04:35:26.416251|2018-06-01 04:35:26.416251
NCT00186914|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-03-03|2005-09-09|2005-09-16|Estimate|||||||2015-03-03|2015-03-04|Estimate|July 1999||1999-07-31|February 2008|2008-02-29|January 2008|Actual|2008-01-31|November 2001|Actual|2001-11-30||Interventional|||Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation|Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation: A Phase I Study|Completed||Phase 1|8|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:26.480537|2018-06-01 04:35:26.480537
NCT00186901|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-12-20||2017-04-03|2005-09-12|2005-09-16|Estimate|2012-02-27|2012-03-27|Estimate||||2017-04-03|2017-05-10|Actual|July 2000||2000-07-31|December 2011|2011-12-31|September 2011|Actual|2011-09-30|June 2009|Actual|2009-06-30||Interventional|||A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors|Diminished Bone Mineral Density in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial|Completed||Phase 3|429|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 04:35:26.551769|2018-06-01 04:35:26.551769
NCT00186888|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-06-29||2018-01-05|2005-09-12|2005-09-16|Estimate|2011-07-28|2011-08-30|Estimate||||2018-01-05|2018-01-08|Actual|April 7, 2005|Actual|2005-04-07|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|November 2013|Actual|2013-11-30||Interventional|||Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma|Protocol for the Study and Treatment of Patients With Intraocular Retinoblastoma|Active, not recruiting||Phase 3|107|Actual|St. Jude Children's Research Hospital||3|||f||||t||||||||||2018-06-01 04:35:27.05643|2018-06-01 04:35:27.05643
NCT00186875|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2013-10-25||2017-07-26|2005-09-12|2005-09-16|Estimate|2013-10-25|2013-12-16|Estimate||||2017-07-26|2017-07-28|Actual|November 2003||2003-11-30|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||One patient who was >21 years at diagnosis was enrolled because early versions of the protocol had no upper age limit for participants previously treated on St Jude frontline protocols. The protocol was subsequently amended to change the age criteria to ≤21 years of age at diagnosis for all patients.|Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia|A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia|Completed||Phase 2|47|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-06-01 04:35:27.951601|2018-06-01 04:35:27.951601
NCT00186862|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-02|2005-09-12|2005-09-16|Estimate|||||||2008-06-02|2008-06-03|Estimate|August 1998||1998-08-31|June 2008|2008-06-30|October 2007|Actual|2007-10-31|April 2000|Actual|2000-04-30||Interventional|||Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma|Phase I Study of Chemokine and Cytokine Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma Using a Retroviral Vector|Completed||Phase 1|24|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:28.350043|2018-06-01 04:35:28.350043
NCT00186849|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-19|2005-09-12|2005-09-16|Estimate|||||||2009-05-19|2009-05-20|Estimate|October 1997||1997-10-31|May 2009|2009-05-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Therapy for Children With Advanced Stage High Risk Neuroblastoma|Therapy for Children With Advanced Stage High Risk Neuroblastoma|Completed||Phase 2|30|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:35:28.41892|2018-06-01 04:35:28.41892
NCT00186836|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-19|2005-09-13|2005-09-16|Estimate|||||||2007-04-19|2007-04-20|Estimate|November 2004||2004-11-30|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Efficacy Study of Combined Hepatitis A and Hepatitis B Vaccine to Protect Against Hepatitis B in Hemodialysis Patients|Efficacy of Combined Hepatitis A and Hepatitis B (Twinrix) Vaccine Compared With Hepatitis B Vaccine Alone in Providing Seroprotection Against Hepatitis B in Hemodialysis Patients|Completed||Phase 4|200||St. Joseph's Healthcare Hamilton|||||f||||||||||||||2018-06-01 04:35:28.489817|2018-06-01 04:35:28.489817
NCT00186823|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-28|2005-09-09|2005-09-16|Estimate|||||||2009-01-28|2009-01-29|Estimate|March 2002||2002-03-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|September 2005|Actual|2005-09-30||Interventional|||Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies|Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies|Completed||Phase 3|57|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:35:28.549342|2018-06-01 04:35:28.549342
NCT00186810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-05-28|2005-09-09|2005-09-16|Estimate|||||||2009-05-28|2009-05-29|Estimate|December 1992||1992-12-31|May 2009|2009-05-31|October 2007|Actual|2007-10-31|February 2006|Actual|2006-02-28||Interventional|||Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease|Allogeneic Stem Cell Transplantation From HLA/MLC Genotype Identical Donors for Patients With High Risk Sickle Cell Disease|Completed||Phase 2|15|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:35:28.614583|2018-06-01 04:35:28.614583
NCT00186797|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-04-07|2005-09-09|2005-09-16|Estimate|||||||2010-04-07|2010-04-09|Estimate|December 2002||2002-12-31|April 2010|2010-04-30|May 2007|Actual|2007-05-31|September 2005|Actual|2005-09-30||Interventional|AACD34||Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia||Completed||N/A|28||St. Jude Children's Research Hospital|||||||||||||||||||2018-06-01 04:35:28.690216|2018-06-01 04:35:28.690216
NCT00186784|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-02|2005-09-13|2005-09-16|Estimate|||||||2011-08-02|2011-08-03|Estimate|December 2000||2000-12-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Transcranial Magnetic Treatment (TMS) in Unipolar Depression|Repetitive Transcranial Magnetic Stimulation (rTMS) in Unipolar Depression|Completed||Early Phase 1|21|Actual|St. Joseph's Healthcare Hamilton|||||f||||f||||||||||2018-06-01 04:35:28.746331|2018-06-01 04:35:28.746331
NCT00186771|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-27|2005-09-13|2005-09-16|Estimate|||||||2011-07-27|2011-07-28|Estimate|November 2004||2004-11-30|July 2011|2011-07-31|January 2015|Anticipated|2015-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia|Transcranial Magnetic Stimulation Used to Treat Auditory Hallucinations in Schizophrenia|Unknown status|Recruiting|Phase 4|10|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-06-01 04:35:28.802928|2018-06-01 04:35:28.802928
NCT00186758|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-02|2005-09-13|2005-09-16|Estimate|||||||2011-08-02|2011-08-03|Estimate|July 2002||2002-07-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|TMS||Transcranial Magnetic Stimulation in Bipolar Depression|A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression|Completed||Phase 4|40|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-06-01 04:35:29.015336|2018-06-01 04:35:29.015336
NCT00186745|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-04-18|2005-09-13|2005-09-16|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2005||2005-03-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure|Tinzaparin for Treatment of Venous Thromboembolism in Renal Insufficiency: A Pilot Study|Terminated||N/A|148|Actual|St. Joseph's Healthcare Hamilton||1||Funding ceased|f||||f||||||||Undecided||2018-06-01 04:35:29.085252|2018-06-01 04:35:29.085252
NCT00186732|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-08-10|2005-09-12|2005-09-16|Estimate|||||||2011-08-10|2011-08-11|Estimate|July 2005||2005-07-31|August 2011|2011-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Comparison of Subcuticular Suture Versus Surgical Staples for Closure of Pfannenstiel Skin Incisions|Pfannenstiel Incision Closure: Subcuticular Suture Versus Surgical Staples|Completed||N/A|288|Anticipated|St. Joseph's Healthcare Hamilton|||||f||||||||||||||2018-06-01 04:35:29.15701|2018-06-01 04:35:29.15701
NCT00186719|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-25|2005-09-13|2005-09-16|Estimate|||||||2011-07-25|2011-07-26|Estimate|May 2005||2005-05-31|July 2011|2011-07-31|April 2012|Anticipated|2012-04-30|||||Observational|||How Smoking Causes COPD: Examination of Immune System Changes|How Smoking Causes COPD: Examination of Immune System Changes|Unknown status|Recruiting||100|Anticipated|St. Joseph's Healthcare Hamilton|||||f||||||||||||||2018-06-01 04:35:29.213896|2018-06-01 04:35:29.213896
NCT00186706|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-05-21|2005-09-10|2005-09-16|Estimate|||||||2008-05-21|2008-05-22|Estimate|September 2005||2005-09-30|May 2008|2008-05-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Selenium Supplementation in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effect of Selenium Supplementation on Anti-Oxidant Levels in COPD Patients: A 12-Week, Randomized, Placebo-Controlled Trial|Completed||Phase 4|60|Actual|St. Joseph's Healthcare Hamilton|||||f||||||||||||||2018-06-01 04:35:29.285237|2018-06-01 04:35:29.285237
NCT00186693|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-07-25|2005-09-10|2005-09-16|Estimate|||||||2011-07-25|2011-07-26|Estimate|September 2006||2006-09-30|July 2006|2006-07-31|June 2009|Anticipated|2009-06-30|||||Observational|||How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction in Asthma|How Airway Remodeling and Hyperresponsiveness Contribute to Airflow Obstruction in Asthma|Withdrawn|||12|Anticipated|St. Joseph's Healthcare Hamilton||||never received funding|f||||||||||||||2018-06-01 04:35:29.350878|2018-06-01 04:35:29.350878
NCT00186680|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-02-26|2005-09-14|2005-09-16|Estimate|||||||2010-02-26|2010-03-02|Estimate|September 1996||1996-09-30|February 2010|2010-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant|Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment|Completed||Phase 1/Phase 2|99|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:29.39693|2018-06-01 04:35:29.39693
NCT00186667|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-07-23|2005-09-14|2005-09-16|Estimate|||||||2010-07-23|2010-07-27|Estimate|January 1999||1999-01-31|July 2010|2010-07-31|September 2005|Actual|2005-09-30|January 2000|Actual|2000-01-31||Interventional|||Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease|An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant|Completed||Phase 2|30|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:35:29.543314|2018-06-01 04:35:29.543314
NCT00186654|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-09-22|2005-09-14|2005-09-16|Estimate|||||||2008-09-22|2008-09-25|Estimate||||August 2008|2008-08-31||||||||Interventional|||Acupuncture and Massage for Depression During Pregnancy|Acupuncture and Massage for Depression During Pregnancy|Completed||Phase 2|180||Stanford University|||||f||||||||||||||2018-06-01 04:35:29.600671|2018-06-01 04:35:29.600671
NCT00186641|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-07-10|2005-09-14|2005-09-16|Estimate|||||||2007-07-10|2007-07-11|Estimate||||July 2007|2007-07-31|March 2005||2005-03-31|||||Interventional|||High Dose Chemotherapy and Autologous Transplant for Breast Cancer|High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||Stanford University|||||f||||||||||||||2018-06-01 04:35:29.657252|2018-06-01 04:35:29.657252
NCT00186628|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2016-12-12||2017-10-20|2005-09-14|2005-09-16|Estimate|2017-10-20|2017-11-28|Actual||||2017-10-20|2017-11-28|Actual|June 2005||2005-06-30|October 2017|2017-10-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD|An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation|Completed||Phase 2|36|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 04:35:29.713421|2018-06-01 04:35:29.713421
NCT00186602|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-10-04|2005-09-14|2005-09-16|Estimate|||||||2006-10-04|2006-10-05|Estimate||||September 2005|2005-09-30||||||||Interventional|||Does a Peer Navigator Improve Quality of Life at Diagnosis for Women With Breast Cancer?|Does a Peer Navigator Improve Quality of Life at Diagnosis?|Unknown status|Active, not recruiting|Phase 2|||Stanford University|||||f||||||||||||||2018-06-01 04:35:29.974049|2018-06-01 04:35:29.974049
NCT00186589|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-06-05|2005-09-14|2005-09-16|Estimate|||||||2012-06-05|2012-06-06|Estimate|May 2004||2004-05-31|October 2010|2010-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL|90Y-Ibritumomab Tiuxetan and Autologous Hematopoietic Cell Infusion Followed by High Dose Chemotherapy and Autologous Transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma|Completed||Phase 1|30|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:30.037802|2018-06-01 04:35:30.037802
NCT00186576|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-10-13|2005-09-14|2005-09-16|Estimate|||||||2010-10-13|2010-10-14|Estimate|December 2001||2001-12-31|October 2010|2010-10-31|July 2010|Actual|2010-07-31|March 2004|Actual|2004-03-31||Interventional|||Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders|Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)|Completed||N/A|40|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:30.25623|2018-06-01 04:35:30.25623
NCT00186563|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-06-18|2005-09-14|2005-09-16|Estimate|||||||2013-06-18|2013-06-19|Estimate||||June 2013|2013-06-30||||||||Interventional|||A Human In-vivo Model for the Detection of Inflammatory and Nociceptive Biomarkers|Proof-of-concept Study for Bio-marker Assay Validation in Humans|Completed||N/A|13||Stanford University|||||f||||||||||||||2018-06-01 04:35:30.315778|2018-06-01 04:35:30.315778
NCT00186550|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-03|2005-09-13|2005-09-16|Estimate|||||||2013-12-03|2013-12-04|Estimate||||December 2013|2013-12-31|November 2000|Actual|2000-11-30|||||Interventional|||Group Psychotherapy for People With HIV|An Evaluation of Group Psychotherapy for People With HIV|Completed||N/A|186|Actual|Stanford University|||||f||||f||||||||||2018-06-01 04:35:30.363306|2018-06-01 04:35:30.363306
NCT00186537|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2016-04-01||2016-11-21|2005-09-14|2005-09-16|Estimate|2016-04-01|2016-05-05|Estimate||||2016-11-21|2017-01-12|Estimate|September 2003||2003-09-30|November 2016|2016-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||Baseline analysis was done on those who completed the study|Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.|Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.|Completed||N/A|47|Actual|Stanford University||3|||f||||f||||||||No||2018-06-01 04:35:30.426592|2018-06-01 04:35:30.426592
NCT00186524|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-03-11|2005-09-14|2005-09-16|Estimate|||||||2011-03-11|2011-03-15|Estimate||||March 2011|2011-03-31||||||||Interventional|||Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?||Completed||Phase 2|||Stanford University|||||f||||||||||||||2018-06-01 04:35:30.693197|2018-06-01 04:35:30.693197
NCT00186511|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-12-04|2005-09-13|2005-09-16|Estimate|||||||2006-12-04|2006-12-05|Estimate|November 2004||2004-11-30|December 2006|2006-12-31|June 2006||2006-06-30|||||Interventional|||Expanding Rural Access: Distance Delivery of Support|Expanding Rural Access: Distance Delivery of Support|Completed||Phase 2|40||Stanford University|||||f||||||||||||||2018-06-01 04:35:30.760495|2018-06-01 04:35:30.760495
NCT00186498|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-11-06|2005-09-14|2005-09-16|Estimate|||||||2008-11-06|2008-11-10|Estimate|February 2004||2004-02-29|October 2008|2008-10-31||||||||Interventional|||Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode|Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode|Unknown status|Active, not recruiting|N/A|20||Stanford University|||||f||||||||||||||2018-06-01 04:35:30.817825|2018-06-01 04:35:30.817825
NCT00186485|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2016-10-10||2017-10-04|2005-09-14|2005-09-16|Estimate|2017-05-10|2017-06-08|Actual||||2017-10-04|2017-10-06|Actual|May 2003||2003-05-31|August 2017|2017-08-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression|Safety and Efficacy of Open Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression|Completed||N/A|28|Actual|Stanford University||1|||f||||f||||||||No||2018-06-01 04:35:30.91057|2018-06-01 04:35:30.91057
NCT00186472|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-31|2005-09-13|2005-09-16|Estimate|||||||2011-05-31|2011-06-02|Estimate||||December 2006|2006-12-31||||||||Interventional|||Intervention to Decrease Anxiety in Parents of Infants in the Neonatal Intensive Care Unit (NICU)||Completed||N/A|||Stanford University|||||f||||||||||||||2018-06-01 04:35:31.099204|2018-06-01 04:35:31.099204
NCT00186459|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-12|2005-09-13|2005-09-16|Estimate|||||||2013-03-12|2013-03-13|Estimate|October 2000||2000-10-31|March 2013|2013-03-31||||||||Interventional|||Obesity, Weight Loss, and Cardiovascular Disease Risk|GCRC-CAP-Tracey McLaughlin, MD|Unknown status|Enrolling by invitation|N/A|550|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:31.281191|2018-06-01 04:35:31.281191
NCT00186446|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-10-18||2017-02-15|2005-09-13|2005-09-16|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|June 2004||2004-06-30|February 2017|2017-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Treatment of Nicotine Dependence and Acute Depression|Treatment of Nicotine Dependence and Acute Depression|Completed||Phase 4|20|Actual|Stanford University||1|||f||||||||||||||2018-06-01 04:35:31.349787|2018-06-01 04:35:31.349787
NCT00186433|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-22|2005-09-13|2005-09-16|Estimate|||||||2015-05-22|2015-05-27|Estimate|November 2001||2001-11-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations|A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations|Completed|||49|Actual|Stanford University|||||f||||t||||||Samples With DNA|"~     blood~   "|||2018-06-01 04:35:31.760049|2018-06-01 04:35:31.760049
NCT00186420|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-12|2005-09-13|2005-09-16|Estimate|||||||2012-06-12|2012-06-13|Estimate|July 2003||2003-07-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|January 2006|Actual|2006-01-31||Interventional|||Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation|Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation|Completed||Phase 2|13|Actual|Stanford University|||||f||||t||||||||||2018-06-01 04:35:31.827375|2018-06-01 04:35:31.827375
NCT00186407|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-09-10|2005-09-13|2005-09-16|Estimate|||||||2010-09-10|2010-09-14|Estimate|April 1998||1998-04-30|September 2010|2010-09-30|February 2010|Actual|2010-02-28|February 2008|Actual|2008-02-29||Interventional|||Autologous Stem Cell Rescue for Primary Amyloidosis|High Dose Chemotherapy and Autologous Stem Cell Rescue for Primary Amyloidosis|Completed||Phase 2|50|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:31.890046|2018-06-01 04:35:31.890046
NCT00186394|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-07-23|2005-09-13|2005-09-16|Estimate|||||||2010-07-23|2010-07-27|Estimate|April 2000||2000-04-30|July 2010|2010-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma|High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma|Completed||Phase 2|35|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:31.944411|2018-06-01 04:35:31.944411
NCT00186381|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-07-23|2005-09-13|2005-09-16|Estimate|||||||2010-07-23|2010-07-27|Estimate|November 1995||1995-11-30|July 2010|2010-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission|Autologous Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission|Completed||Phase 2|200|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:32.023277|2018-06-01 04:35:32.023277
NCT00186368|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-12|2005-09-13|2005-09-16|Estimate|||||||2017-01-12|2017-01-13|Estimate|April 1999||1999-04-30|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Microarray Analysis of Gene Expression in Prostate Tissues|Microarray Analysis of Gene Expression in Prostate Tissues (Translating Prostate Cancer Gene Expression Sub-types)|Active, not recruiting|||2000|Anticipated|Stanford University|||||f||||t||||||||||2018-06-01 04:35:32.14226|2018-06-01 04:35:32.14226
NCT00186355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-10|2005-09-13|2005-09-16|Estimate|||||||2012-05-10|2012-05-14|Estimate|October 2003||2003-10-31|May 2012|2012-05-31|February 2010|Actual|2010-02-28|March 2007|Actual|2007-03-31||Interventional|||Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma|Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma|Completed||N/A|97|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:35:32.20339|2018-06-01 04:35:32.20339
NCT00186342|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-12-13|2005-09-13|2005-09-16|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 1992||1992-09-30|December 2012|2012-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies|Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide|Completed||N/A|120|Anticipated|Stanford University||1|||f||||||||||||||2018-06-01 04:35:32.267443|2018-06-01 04:35:32.267443
NCT00186329|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-24|2005-09-13|2005-09-16|Estimate|||||||2015-04-24|2015-04-28|Estimate|March 2004||2004-03-31|April 2015|2015-04-30|October 2006||2006-10-31|||||Interventional|||BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)|B-type Natriuretic Peptide for Cardio-Renal Decompensation Syndrome|Completed||Phase 4|100||Stanford University|||||f||||||||||||||2018-06-01 04:35:32.335675|2018-06-01 04:35:32.335675
NCT00186316|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-08-21|2005-09-13|2005-09-16|Estimate|||||||2009-08-21|2009-08-25|Estimate|April 2003||2003-04-30|August 2009|2009-08-31|December 2008|Actual|2008-12-31|April 2006|Actual|2006-04-30||Interventional|||Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells|A Phase I/II Study of Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells|Completed||Phase 1/Phase 2|30|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:32.398233|2018-06-01 04:35:32.398233
NCT00186303|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-12-13|2005-09-13|2005-09-16|Estimate|||||||2012-12-13|2012-12-17|Estimate|November 1996||1996-11-30|December 2012|2012-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Transplantation for Patients With Chronic Lymphocytic Leukemia|Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia|Completed||N/A|28|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:32.452157|2018-06-01 04:35:32.452157
NCT00186290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-10-07|2005-09-13|2005-09-16|Estimate|||||||2010-10-07|2010-10-11|Estimate|December 1989||1989-12-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Allo BMT in Advanced Leukemia or High Grade Lymphoma|Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma|Completed||N/A|145|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:32.508702|2018-06-01 04:35:32.508702
NCT00186277|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-28|2005-09-13|2005-09-16|Estimate|||||||2011-03-28|2011-03-30|Estimate|December 2003||2003-12-31|March 2011|2011-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer|Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer|Completed||Phase 2|10|Actual|Stanford University|||||f||||t||||||||||2018-06-01 04:35:32.562367|2018-06-01 04:35:32.562367
NCT00186264|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-14|2005-09-13|2005-09-16|Estimate|||||||2007-12-14|2007-12-20|Estimate|August 2002||2002-08-31|December 2007|2007-12-31|April 2006||2006-04-30|||||Interventional|||Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?|Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?|Unknown status|Active, not recruiting|N/A|20||Stanford University|||||f||||||||||||||2018-06-01 04:35:32.647575|2018-06-01 04:35:32.647575
NCT00186251|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-11-09|2005-09-13|2005-09-16|Estimate|||||||2012-11-09|2012-11-12|Estimate|March 1998||1998-03-31|July 2012|2012-07-31|July 2005||2005-07-31|||||Interventional|||High Dose Chemotherapy Followed By PBSC Rescue for HD|Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease|Completed||N/A|200||Stanford University|||||f||||||||||||||2018-06-01 04:35:32.70979|2018-06-01 04:35:32.70979
NCT00186238|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-09-10|2005-09-13|2005-09-16|Estimate|||||||2010-09-10|2010-09-14|Estimate|September 1994||1994-09-30|September 2010|2010-09-30|April 2010|Actual|2010-04-30|September 2006|Actual|2006-09-30||Interventional|||High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma|High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma|Completed||Phase 2|300|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:32.762245|2018-06-01 04:35:32.762245
NCT00186225|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-07-23|2005-09-13|2005-09-16|Estimate|||||||2010-07-23|2010-07-27|Estimate|November 1989||1989-11-30|July 2010|2010-07-31|May 2010|Actual|2010-05-31|June 2007|Actual|2007-06-30||Interventional|||Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors|Stem Cell Transplantation From Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY)|Completed||N/A|250|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:32.823045|2018-06-01 04:35:32.823045
NCT00186212|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-29|2005-09-13|2005-09-16|Estimate|||||||2011-06-29|2011-07-01|Estimate|September 2000||2000-09-30|June 2011|2011-06-30|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Alternative Support for Rural and Isolated Women in an HMO|Alternative Support for Rural and Isolated Women in an HMO|Completed||Phase 3|150|Actual|Stanford University|||||f||||f||||||||||2018-06-01 04:35:32.903054|2018-06-01 04:35:32.903054
NCT00186199|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-17|2005-09-13|2005-09-16|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2005||2005-06-30|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31|12 Months|Observational [Patient Registry]|||Determination of Voiding Patterns of Children With Vesicoureteral Reflux|Determination of Voiding Patterns of Children With Vesicoureteral Reflux|Unknown status|Enrolling by invitation||250|Anticipated|Stanford University|||||f||||f||||||||||2018-06-01 04:35:32.95825|2018-06-01 04:35:32.95825
NCT00186186|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-05-12||2017-03-01|2005-09-13|2005-09-16|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|January 2004||2004-01-31|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Depakote ER in Bipolar Depression|Depakote ER in Bipolar Depression|Completed||Phase 4|28|Actual|Stanford University|This trial is limited by small sample size, as well as an open-label study design with no placebo control.|1|||f||||f||||||||No||2018-06-01 04:35:33.016323|2018-06-01 04:35:33.016323
NCT00186173|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-07-11|2005-09-13|2005-09-16|Estimate|||||||2012-07-11|2012-07-13|Estimate|November 2004||2004-11-30|July 2012|2012-07-31||||February 2006|Actual|2006-02-28||Interventional|||Sports to Prevent Obesity: Feasibility and Pilot RCT|Sports to Prevent Obesity: Feasibility and Pilot RCT|Completed||Phase 1/Phase 2|21|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 04:35:33.185861|2018-06-01 04:35:33.185861
NCT00186147|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-08|2005-09-13|2005-09-16|Estimate|||||||2016-11-08|2016-11-09|Estimate|March 1988||1988-03-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Bone Marrow Grafting for Leukemia and Lymphoma|Bone Marrow Grafting for Leukemia and Lymphoma|Recruiting|||9999|Anticipated|Stanford University|||1||f||||||||||Samples With DNA|"~     Tissue samples will be obtained from subjects undergoing transplantation or donors providing~     the graft.~   "|||2018-06-01 04:35:33.249848|2018-06-01 04:35:33.249848
NCT00186134|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|October 2004||2004-10-31|September 2005|2005-09-30|May 2005||2005-05-31|||||Interventional|||Walk to School and Physical Activity|Walk to School and Physical Activity|Completed||Phase 2|30||Stanford University|||||f||||||||||||||2018-06-01 04:35:33.324008|2018-06-01 04:35:33.324008
NCT00186121|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-02-01||2018-04-03|2005-09-13|2005-09-16|Estimate|2018-04-03|2018-04-05|Actual||||2018-04-03|2018-04-05|Actual|October 2000||2000-10-31|April 2018|2018-04-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women|A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women|Completed||Phase 2|35|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 04:35:33.40768|2018-06-01 04:35:33.40768
NCT00186108|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-24|2005-09-13|2005-09-16|Estimate|||||||2007-07-24|2007-07-25|Estimate|October 2002||2002-10-31|July 2007|2007-07-31|September 2005|Actual|2005-09-30|||||Interventional|||A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer|A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer|Completed||Phase 1|23|Actual|Stanford University|||||f||||t||||||||||2018-06-01 04:35:33.735984|2018-06-01 04:35:33.735984
NCT00186095|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-05|2005-09-13|2005-09-16|Estimate|||||||2007-10-05|2007-10-10|Estimate|December 2000||2000-12-31|October 2007|2007-10-31|September 2006||2006-09-30|||||Interventional|||Mixed Chimeric Transplantation for Primary Amyloidosis|Mixed Chimeric Transplantation for Primary Amyloidosis|Withdrawn||N/A|45|Anticipated|Stanford University||||Closed, never started.|f||||t||||||||||2018-06-01 04:35:33.897339|2018-06-01 04:35:33.897339
NCT00186082|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-13|2005-09-13|2005-09-16|Estimate|||||||2011-06-13|2011-06-15|Estimate|September 2003||2003-09-30|June 2011|2011-06-30|June 2008|Actual|2008-06-30|June 2006|Actual|2006-06-30||Interventional|||Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs|A Randomized Controlled Trial of the Effect of Prophylactic Antibiotics on the Infection Rate in Postpartum Third and Fourth Degree Perineal Tear Repairs|Completed||N/A|147|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 04:35:33.957725|2018-06-01 04:35:33.957725
NCT00186069|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-10-12||2017-12-01|2005-09-13|2005-09-16|Estimate|2017-03-09|2017-04-20|Actual||||2017-12-01|2018-01-02|Actual|March 2004||2004-03-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|June 2014|Actual|2014-06-30||Interventional|||Magnesium Sulfate vs Placebo for Placental Abruption|Randomized, Double Blind Trial of Magnesium Sulfate Tocolysis Versus Intravenous Saline for Suspected Placental Abruption|Completed||N/A|30|Actual|Stanford University||2|||f||||f||||||||Undecided||2018-06-01 04:35:34.038914|2018-06-01 04:35:34.038914
NCT00186056|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-10-13||2017-02-17|2005-09-13|2005-09-16|Estimate|2017-02-17|2017-04-05|Actual||||2017-02-17|2017-04-05|Actual|January 2003||2003-01-31|February 2017|2017-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Mifepristone in Refractory Depression|Mifepristone in Refractory Depression|Completed||N/A|31|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 04:35:34.615983|2018-06-01 04:35:34.615983
NCT00186043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-01-11||2017-09-26|2005-09-12|2005-09-16|Estimate|2017-09-26|2017-09-27|Actual||||2017-09-26|2017-09-27|Actual|August 2008||2008-08-31|September 2017|2017-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II|A Double-Blind, Placebo-Controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients|Completed||Phase 4|55|Actual|Stanford University|Results are limited in their generalizability due to the small sample drawn from two specialty clinics for mood disorders clinical research. Suspected assignment to active quetiapine or placebo possibly influencing ratings on outcome variables|2|||f||||f||||||||No||2018-06-01 04:35:35.190735|2018-06-01 04:35:35.190735
NCT00186030|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-05|2005-09-13|2005-09-16|Estimate|||||||2006-10-05|2006-10-06|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|March 2004||2004-03-31|||||Interventional|||Reducing Risk and Trauma-Related Stress in Persons Living With HIV|Reducing Risk and Trauma-Related Stress in Persons Living With HIV|Terminated||Phase 1/Phase 2|102||Stanford University|||||f||||||||||||||2018-06-01 04:35:35.682254|2018-06-01 04:35:35.682254
NCT00186017|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-12-21||2017-04-12|2005-09-12|2005-09-16|Estimate|2017-04-12|2017-05-16|Actual||||2017-04-12|2017-05-16|Actual|July 2005||2005-07-31|April 2017|2017-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Short Term Rescue Study of Olanzapine|Double-Blind Placebo-Controlled Olanzapine Add-on Therapy in the Treatment of Acute Syndromal and Subsyndromal Exacerbations in Bipolar Disorders|Completed||Phase 4|50|Actual|Stanford University|Small Sample Size.|2|||f||||f||||||||No||2018-06-01 04:35:35.792547|2018-06-01 04:35:35.792547
NCT00186004|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-06-13|2005-09-13|2005-09-16|Estimate|||||||2011-06-13|2011-06-15|Estimate|December 2002||2002-12-31|June 2011|2011-06-30|May 2008|Actual|2008-05-31|September 2006|Actual|2006-09-30||Observational|||Correlation Between Continuous Glucose Monitoring and Intermittent Glucose Monitoring Values and Pregnancy Outcomes|Correlation Between Continuous Glucose Monitoring and Intermittent Glucose Monitoring Values and Pregnancy Outcomes|Completed|||21|Actual|Stanford University|||||f||||f||||||||||2018-06-01 04:35:36.285157|2018-06-01 04:35:36.285157
NCT00185991|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-06-13|2005-09-12|2005-09-16|Estimate|||||||2011-06-13|2011-06-15|Estimate|June 2004||2004-06-30|June 2011|2011-06-30|February 2010|Actual|2010-02-28|October 2006|Actual|2006-10-31||Interventional|||Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis|Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis|Completed||N/A|126|Anticipated|Stanford University||2|||f||||||||||||||2018-06-01 04:35:36.379352|2018-06-01 04:35:36.379352
NCT00185978|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|April 1998||1998-04-30|September 2005|2005-09-30|March 2001||2001-03-31|||||Interventional|||Obesity Prevention for Pre-Adolescents|School- and Family-Based Obesity Prevention for Children|Completed||Phase 2|900||Stanford University|||||f||||||||||||||2018-06-01 04:35:36.513796|2018-06-01 04:35:36.513796
NCT00185965|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-07-07||2014-07-07|2005-09-12|2005-09-16|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|July 2004||2004-07-31|July 2014|2014-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas|Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas|Completed||Phase 1/Phase 2|30|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 04:35:36.696856|2018-06-01 04:35:36.696856
NCT00185952|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-06-10|2005-09-12|2005-09-16|Estimate|||||||2011-06-10|2011-06-13|Estimate|November 2001||2001-11-30|June 2011|2011-06-30|August 2008|Actual|2008-08-31|January 2007|Actual|2007-01-31||Interventional|||Nifedipine vs Placebo for Maintenance Tocolysis of Preterm Labor.|Nifedipine for the Maintenance Tocolysis of Preterm Labor: Comparison to Placebo in a Prospective, Randomized Double Blind Trial|Completed||N/A|70|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 04:35:37.150087|2018-06-01 04:35:37.150087
NCT00185939|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-12-01|2005-09-12|2005-09-16|Estimate|||||||2006-12-01|2006-12-05|Estimate|August 2003||2003-08-31|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||The Use of Prophylactic Antibiotics In the Management of Dog Bites||Completed||Phase 2/Phase 3|125||Stanford University|||||f||||||||||||||2018-06-01 04:35:37.568964|2018-06-01 04:35:37.568964
NCT00185913|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-04-20|2005-09-12|2005-09-16|Estimate|||||||2010-04-20|2010-04-22|Estimate|September 2000||2000-09-30|April 2010|2010-04-30|May 2008|Actual|2008-05-31|October 2003|Actual|2003-10-31||Observational|||Identification of Serum Markers For Tumor Hypoxia in Non-Small Cell Lung Cancers|Identification of Serum Markers For Tumor Hypoxia in Non-Small Cell Lung Cancers|Completed|||50|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     blood~   "|||2018-06-01 04:35:37.675137|2018-06-01 04:35:37.675137
NCT00185900|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-05-25|2005-09-12|2005-09-16|Estimate|||||||2016-05-25|2016-05-27|Estimate|April 1999||1999-04-30|May 2016|2016-05-31|July 2007|Actual|2007-07-31|July 2005|Actual|2005-07-31||Interventional|||Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial|Magnesium Sulfate Versus Nifedipine for the Acute Tocolysis of Preterm Labor: A Prospective, Randomized Trial|Completed||N/A|192|Actual|Stanford University||2|||f||||||||||||No||2018-06-01 04:35:37.83506|2018-06-01 04:35:37.83506
NCT00185887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-03-04|2005-09-12|2005-09-16|Estimate|||||||2011-03-04|2011-03-08|Estimate|October 2003||2003-10-31|March 2011|2011-03-31|October 2007|Actual|2007-10-31|July 2006|Actual|2006-07-31||Interventional|||Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation|Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation|Completed||N/A|110|Actual|Stanford University||2|||f||||||||||||||2018-06-01 04:35:38.117343|2018-06-01 04:35:38.117343
NCT00185874|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-11|2005-09-12|2005-09-16|Estimate|||||||2010-01-11|2010-01-13|Estimate|January 2004||2004-01-31|January 2010|2010-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases|A Phase I Trial of Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases|Terminated||Phase 1|22|Anticipated|Stanford University||||Study closed due to lack of funding|f||||||||||||||2018-06-01 04:35:38.314774|2018-06-01 04:35:38.314774
NCT00184899|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-02-28|2005-09-12|2005-09-16|Estimate|||||||2007-02-28|2007-03-01|Estimate|August 2005||2005-08-31|February 2007|2007-02-28|August 2006||2006-08-31|||||Interventional|||The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids|The Potential Role for Adenosine in the Haemodynamic Effects of Free Fatty Acids|Completed||N/A|20||Radboud University|||||f||||||||||||||2018-06-01 04:35:55.844637|2018-06-01 04:35:55.844637
NCT00185861|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-04-08|2005-09-12|2005-09-16|Estimate|||||||2009-04-08|2009-04-09|Estimate|December 2003||2003-12-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|January 2008|Actual|2008-01-31||Interventional|||Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma|Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma|Completed||Phase 1|12|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:35:38.817086|2018-06-01 04:35:38.817086
NCT00185848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-12|2005-09-12|2005-09-16|Estimate|||||||2017-03-12|2017-03-14|Actual|April 2005||2005-04-30|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis|Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.|Completed||Phase 1|10|Actual|Stanford University||1|||f||||t||||||||||2018-06-01 04:35:38.905664|2018-06-01 04:35:38.905664
NCT00185835|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-03-25|2005-09-12|2005-09-16|Estimate|||||||2010-03-25|2010-03-29|Estimate|June 2002||2002-06-30|March 2010|2010-03-31||||July 2006|Actual|2006-07-31||Interventional|||Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck|Phase I Study of Cisplatin And ZD1839 (IRESSA®) in Combination With Concomitant Re-Irradiation in Patients With Loco-Regional Recurrent Squamous Cell Cancer of the Head and Neck|Completed||Phase 1|10|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:35:39.104819|2018-06-01 04:35:39.104819
NCT00185809|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-16|2005-09-12|2005-09-16|Estimate|||||||2010-07-16|2010-07-20|Estimate|November 2000||2000-11-30|July 2010|2010-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study|Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study|Completed|||25|Anticipated|Stanford University|||||f||||||||||Samples Without DNA|"~     Archival tissue blocks and blood~   "|||2018-06-01 04:35:39.209376|2018-06-01 04:35:39.209376
NCT00185796|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-03-16|2005-09-12|2005-09-16|Estimate|||||||2015-03-16|2015-03-18|Estimate|July 2004||2004-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|||TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD|Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)|Completed||Phase 2|77|Actual|Stanford University||1|||f||||||||||||||2018-06-01 04:35:39.364497|2018-06-01 04:35:39.364497
NCT00185783|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-07|2005-09-12|2005-09-16|Estimate|||||||2011-04-07|2011-04-11|Estimate|March 2005||2005-03-31|April 2011|2011-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis|Pilot Study of White Blood Cell Gene Expression in Critically Ill Patients With Severe Sepsis and Relative Adrenal Insufficiency After Hydrocortisone Administration|Completed|||10|Actual|Stanford University|||||f||||t||||||||||2018-06-01 04:35:39.599448|2018-06-01 04:35:39.599448
NCT00185770|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|April 1999||1999-04-30|September 2005|2005-09-30||||||||Interventional|||Reducing Television Viewing to Prevent Childhood Obesity|Reducing Television Viewing to Prevent Childhood Obesity|Completed||Phase 2/Phase 3|900||Stanford University|||||f||||||||||||||2018-06-01 04:35:39.744516|2018-06-01 04:35:39.744516
NCT00185757|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-13|2005-09-12|2005-09-16|Estimate|||||||2012-12-13|2012-12-17|Estimate|June 2004||2004-06-30|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation|Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Stanford University||1|||f||||||||||||||2018-06-01 04:35:39.859715|2018-06-01 04:35:39.859715
NCT00185744|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-08|2005-09-12|2005-09-16|Estimate|||||||2016-12-08|2016-12-12|Estimate|September 2002||2002-09-30|December 2016|2016-12-31|March 2029|Anticipated|2029-03-31|March 2029|Anticipated|2029-03-31||Interventional|||Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer|Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer|Active, not recruiting||N/A|400|Anticipated|Stanford University||2|||f||||t||||||||No||2018-06-01 04:35:39.96984|2018-06-01 04:35:39.96984
NCT00185731|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-01-24||2017-10-25|2005-09-12|2005-09-16|Estimate|2017-10-25|2017-12-02|Actual||||2017-10-25|2017-12-02|Actual|April 2005||2005-04-30|October 2017|2017-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma|A Phase II Study of Atorvastatin in Patients With Low Grade or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|25|Actual|Stanford University||1|||f||||t|t|f|||f|||No||2018-06-01 04:35:40.07429|2018-06-01 04:35:40.07429
NCT00185718|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-12|2005-09-12|2005-09-16|Estimate|||||||2012-12-12|2012-12-17|Estimate|November 2003||2003-11-30|December 2012|2012-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Impact of Treatment Induced Premature Menopause on Quality of Life|Impact of Treatment Induced Premature Menopause on Quality of Life Following Blood and Marrow Transplantation|Completed|||97|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:35:40.867758|2018-06-01 04:35:40.867758
NCT00185705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-02-12|2005-09-09|2005-09-16|Estimate|||||||2007-02-12|2007-02-14|Estimate|October 2006||2006-10-31|February 2007|2007-02-28|June 2007||2007-06-30|||||Interventional|||Treatment of Insulin Resistance in Hypertensive, Obese Adolescents|Randomized, Placebo Controlled, Double Blind Trial of Telmisartan in Hypertensive, Obese Adolescents|Unknown status|Recruiting|N/A|30||Stanford University|||||f||||||||||||||2018-06-01 04:35:40.954704|2018-06-01 04:35:40.954704
NCT00185692|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-12-01||2016-12-01|2005-09-12|2005-09-16|Estimate|2016-12-01|2017-01-26|Estimate||||2016-12-01|2017-01-26|Estimate|August 2000||2000-08-31|January 2015|2015-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Allogeneic Transplantation From Related Haploidentical Donors|Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies|Completed||Phase 2|16|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 04:35:41.332624|2018-06-01 04:35:41.332624
NCT00185679|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-02-26||2015-02-26|2005-09-12|2005-09-16|Estimate|2015-02-26|2015-03-09|Estimate||||2015-02-26|2015-03-09|Estimate|November 2001||2001-11-30|February 2015|2015-02-28|February 2010|Actual|2010-02-28|October 2009|Actual|2009-10-31||Interventional|||Haploid Allogeneic Transplant Using the CliniMACS System|A Feasibility Study Evaluating Haploidentical Allogeneic Transplantation Using the CliniMACS System in Patients With Advanced Hematologic Malignancies|Terminated||Phase 2|13|Actual|Stanford University||1||This study was superseded by the subsequent study IRB-15919 (NCT01050764)|f||||t||||||||||2018-06-01 04:35:41.591179|2018-06-01 04:35:41.591179
NCT00185666|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-12|2005-09-12|2005-09-16|Estimate|||||||2010-07-12|2010-07-14|Estimate|May 2002||2002-05-31|July 2010|2010-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Cyberknife Precision Radiation Delivery System for Tumors of the Spine|Cyberknife Precision Radiation Delivery System for Tumors of the Spine|Completed||Phase 1/Phase 2|200|Actual|Stanford University|||||f||||||||||||||2018-06-01 04:35:41.744648|2018-06-01 04:35:41.744648
NCT00185653|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-10|2005-09-12|2005-09-16|Estimate|||||||2011-02-10|2011-02-14|Estimate|October 2000||2000-10-31|February 2011|2011-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma|Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors for the Treatment of Multiple Myeloma|Completed||N/A|40|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:41.899078|2018-06-01 04:35:41.899078
NCT00185640|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-12-01||2017-09-04|2005-09-12|2005-09-16|Estimate|2017-09-04|2017-10-03|Actual||||2017-09-04|2017-10-03|Actual|March 2003||2003-03-31|February 2015|2015-02-28|January 2016|Actual|2016-01-31|April 2014|Actual|2014-04-30||Interventional|||Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies|Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies|Completed||Phase 2|303|Actual|Stanford University||1|||f||||t||||||||No||2018-06-01 04:35:42.988048|2018-06-01 04:35:42.988048
NCT00185614|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-10-31||2018-01-16|2005-09-12|2005-09-16|Estimate|2018-01-16|2018-01-18|Actual||||2018-01-16|2018-01-18|Actual|August 2000||2000-08-31|January 2018|2018-01-31|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|||Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma|Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma|Completed||Phase 2|63|Actual|Stanford University||1|||f||||t||f||||||No||2018-06-01 04:35:43.562359|2018-06-01 04:35:43.562359
NCT00185601|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-04-18|2005-09-09|2005-09-16|Estimate|||||||2013-04-18|2013-04-19|Estimate|February 2006||2006-02-28|April 2013|2013-04-30|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Internet Diabetes Self-Management Workshop|Internet Diabetes Self-Management Evaluation|Completed||N/A|761|Actual|Stanford University||3|||f||||f||||||||||2018-06-01 04:35:44.18223|2018-06-01 04:35:44.18223
NCT00185588|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-07-30||2014-09-10|2005-09-12|2005-09-16|Estimate|2014-09-10|2014-09-15|Estimate||||2014-09-10|2014-09-15|Estimate|October 2004||2004-10-31|September 2014|2014-09-30|December 2009|Actual|2009-12-31|January 2009|Actual|2009-01-31||Interventional||33 adult patients with advanced pancreatic cancer|Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer|A Phase 1-2 Study of the VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 <Vatalanib> and Gemcitabine in Patients With Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|33|Actual|Stanford University||4|||f||||t||||||||||2018-06-01 04:35:44.351854|2018-06-01 04:35:44.351854
NCT00185575|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-04-07|2005-09-09|2005-09-16|Estimate|||||||2009-04-07|2009-04-09|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Duloxetine for the Treatment of Dysthymia|Duloxetine for the Treatment of Dysthymia|Completed||N/A|24|Anticipated|Stanford University|||||f||||||||||||||2018-06-01 04:35:45.52562|2018-06-01 04:35:45.52562
NCT00185562|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-03-23|2005-09-09|2005-09-16|Estimate|||||||2006-03-23|2006-03-24|Estimate|June 2005||2005-06-30|March 2006|2006-03-31|January 2006||2006-01-31|||||Interventional|||A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis|A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis|Completed||Phase 2|12||Stanford University|||||f||||||||||||||2018-06-01 04:35:45.713182|2018-06-01 04:35:45.713182
NCT00185549|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-04|2005-09-12|2005-09-16|Estimate|||||||2006-10-04|2006-10-05|Estimate|March 2004||2004-03-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||An Interactive Program to Improve Care for Children With CF|An Interactive Program to Improve Care for Children With Cystic Fibrosis|Completed||N/A|60||Stanford University|||||f||||||||||||||2018-06-01 04:35:45.807927|2018-06-01 04:35:45.807927
NCT00185536|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|April 2002||2002-04-30|September 2005|2005-09-30||||||||Observational|||Effects of Advertising on Young Children's Perception of Taste|Effects of Advertising on Young Children's Perception of Taste|Completed|||100||Stanford University|||||f||||||||||||||2018-06-01 04:35:45.95961|2018-06-01 04:35:45.95961
NCT00185523|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-06-14|2005-09-12|2005-09-16|Estimate|||||||2016-06-14|2016-06-16|Estimate|May 2002||2002-05-31|June 2016|2016-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)|Allogeneic Peripheral Blood Stem Cell Transplantation for Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia in First or Second Remission or Chronic Myelogenous Leukemia in First and Second Chronic Phase or Accelerated Phase|Terminated|||88|Actual|Stanford University|||2||f||||||||||||||2018-06-01 04:35:46.069508|2018-06-01 04:35:46.069508
NCT00185510|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2014-02-23|2005-09-15|2005-09-16|Estimate|||||||2014-02-23|2014-02-25|Estimate|March 2005||2005-03-31|February 2014|2014-02-28|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis|Double-Blind, Placebo Controlled, Randomized, Multicenter, Parallel-Group Study to Compare the Efficacy and Safety of Advantan Cream Twice Weekly With Advabase Cream During a Maintenance Phase of 16 Weeks After Successful Treatment of Atopic Dermatitis With Advantan Cream|Completed||Phase 4|250|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:46.287909|2018-06-01 04:35:46.287909
NCT00185484|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-12-30|2005-09-13|2005-09-16|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2004||2004-03-31|December 2014|2014-12-31|January 2006|Actual|2006-01-31|||||Interventional|||Efficacy and Safety Oral Contraceptive Study|Multi-center, Open, Uncontrolled Study to Investigate the Efficacy and Safety of the Oral Contraceptive SH T 186 D Containing 0.02 mg Ethinylestradiol-b-cyclodextrin Clathrate and 3 mg Drospirenone in a 24-day Regimen for 13 Cycles in 1010 Healthy Female Volunteers|Completed||Phase 3|1113|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:35:46.448368|2018-06-01 04:35:46.448368
NCT00185458|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-07-23||2013-11-05|2005-09-13|2005-09-16|Estimate|2009-10-12|2009-11-19|Estimate||||2013-11-05|2013-11-27|Estimate|May 2000||2000-05-31|November 2013|2013-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).|A 60-month Non-comparative Study on Bleeding Profiles With Levonorgestrel Intrauterine System in Transition From Reproductive Age Contraception to Menopause Age Endometrial Protection During Estrogen Replacement Therapy.|Completed||Phase 3|394|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:35:46.57998|2018-06-01 04:35:46.57998
NCT00185445|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-02|2005-09-13|2005-09-16|Estimate|||||||2013-12-02|2013-12-04|Estimate|June 2004||2004-06-30|December 2013|2013-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL|A Phase II Study to Evaluate the Efficacy and Safety of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL|Completed||Phase 2|62|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 04:35:47.48008|2018-06-01 04:35:47.48008
NCT00185419|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-01-13|2005-09-13|2005-09-16|Estimate|||||||2009-01-13|2009-01-14|Estimate|November 2003||2003-11-30|January 2009|2009-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception|An Open-Label, Randomised, Parallel-Group Comparison to Investigate the Efficacy of Yasmin® (30 µg Ethinylestradiol, 3mg Drospirenone) and Marvelon® (30 µg Ethinylestradiol, 150 µg Desogestrel) on Cycle Control in Healthy Chinese Women Over 13 Cycles|Completed||Phase 3|842|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:47.727146|2018-06-01 04:35:47.727146
NCT00185393|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-11-26|2005-09-12|2005-09-16|Estimate|||||||2008-11-26|2008-12-01|Estimate|August 2001||2001-08-31|November 2008|2008-11-30|February 2007|Actual|2007-02-28|||||Interventional|||Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy|Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial|Completed||Phase 3|414|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:47.878436|2018-06-01 04:35:47.878436
NCT00185380|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-12-10||2015-05-15|2005-09-13|2005-09-16|Estimate|2010-02-22|2010-03-10|Estimate||||2015-05-15|2015-06-10|Estimate|April 2005||2005-04-30|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)|Multi-center, Open, Randomized, Dose Finding Phase II Study to Investigate Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) Releasing Different Amounts of Levonorgestrel Compared to MIRENA in Nulliparous and Parous Women in Need of Contraception.|Completed||Phase 2|742|Actual|Bayer||3|||f||||f||||||||||2018-06-01 04:35:48.274026|2018-06-01 04:35:48.274026
NCT00185367|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-14|2005-09-13|2005-09-16|Estimate|||||||2011-07-14|2011-07-15|Estimate|March 2005||2005-03-31|July 2011|2011-07-31|September 2006|Actual|2006-09-30|||||Interventional|||Comparative Cycle Control Europe|A Multi-center, Double-blind, Double-dummy, Controlled, Randomized Study to Evaluate Cycle Control and Safety of a Four Phasic Oral Contraceptive (SH T00658ID) in Comparison to an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D 593 B) in Healthy Female Volunteers Aged Between 18 and 50 Years.|Completed||Phase 3|798|Actual|Bayer||2|||f||||||||||||||2018-06-01 04:35:49.098795|2018-06-01 04:35:49.098795
NCT00185354|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-30|2005-09-13|2005-09-16|Estimate|||||||2015-12-30|2015-12-31|Estimate|November 2004||2004-11-30|December 2015|2015-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||FC Patch Comparator Study|Multi-center, Open, Randomized, Parallel Group Comparison of Cycle Control for Seven Cycles and Endometrial Safety in a Subgroup for Thirteen Cycles of Contraceptive Patch SH P00331F (0.9 mg Ethinylestradiol/1.9 mg Gestodene) vs. a Contraceptive Comparator Patch (0.6 mg Ethinylestradiol/6 mg Norelgestromin) in 400 Healthy Female Volunteers|Completed||Phase 3|422|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:49.272032|2018-06-01 04:35:49.272032
NCT00185341|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-04-29|2005-09-12|2005-09-16|Estimate|||||||2016-04-29|2016-05-02|Estimate|February 2005||2005-02-28|April 2016|2016-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability and Efficacy of the CCR1 Antagonist ZK 811752, Given Orally in a Dose of 600 mg Three Times Daily, for the Treatment of Endometriosis Over 12 Weeks|Completed||Phase 2|110|Actual|Bayer||2|||f||||||||||||||2018-06-01 04:35:49.427778|2018-06-01 04:35:49.427778
NCT00185328|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-12-11|2005-09-12|2005-09-16|Estimate|||||||2008-12-11|2008-12-12|Estimate|September 2005||2005-09-30|December 2008|2008-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Efficacy and Tolerability of Angeliq in Thai Women|A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of Angeliq® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles|Completed||Phase 4|55|Actual|Bayer||1|||f||||f||||||||||2018-06-01 04:35:49.567111|2018-06-01 04:35:49.567111
NCT00185315|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-19|2005-09-13|2005-09-16|Estimate|||||||2010-04-19|2010-04-20|Estimate|February 2000||2000-02-29|April 2010|2010-04-30|August 2005|Actual|2005-08-31|||||Interventional|||Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension|Open-label, Uncontrolled, Long-term Surveillance Study of Iloprost Aerosol Inhalation Therapy in the Treatment of Patients With Primary or Secondary Pulmonary Hypertension. Follow-up Program for Patients Who Completed 12 Weeks in Study ME97218/300180.|Completed||Phase 3|71|Actual|Bayer||1|||f||||||||||||||2018-06-01 04:35:49.62837|2018-06-01 04:35:49.62837
NCT00185302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-10|2005-09-12|2005-09-16|Estimate|||||||2015-12-10|2015-12-14|Estimate|December 2004||2004-12-31|December 2015|2015-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma|Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma|Completed||Phase 2|28|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:49.715125|2018-06-01 04:35:49.715125
NCT00185289|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-07-14|2005-09-10|2005-09-16|Estimate|||||||2011-07-14|2011-07-15|Estimate|April 2004||2004-04-30|July 2011|2011-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Study to Investigate Efficacy and Safety of a New Oral Contraceptive|Multi-center , Open, Uncontrolled Study to Investigate the Efficacy and Safety of a 4 Phasic Oral Contraceptive SH T00658 in a 28-day Regimen for 20 Cycles in Healthy Female Volunteers|Completed||Phase 3|1392|Actual|Bayer||1|||f||||||||||||||2018-06-01 04:35:49.809621|2018-06-01 04:35:49.809621
NCT00185276|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2014-12-29|2005-09-10|2005-09-16|Estimate|||||||2014-12-29|2014-12-30|Estimate|March 2003||2003-03-31|December 2014|2014-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries|Randomized, Multi-center Open Label Study of the Safety (Open-label) and Efficacy (Open-label & Blinded Reader) of Magnevist® Injection-enhanced Magnetic Resonance Arteriography (MRA) at Two Dose Levels and 2-dimensional-time-of-flight (2D-TOF) MRA in Patients Undergoing MRA of the Infrarenal Aorta and Peripheral Arteries With Intra-arterial Digital Subtraction Arteriography (i.a. DSA) as Standard of Reference|Completed||Phase 3|365|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:50.038131|2018-06-01 04:35:50.038131
NCT00185263|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-11-04|2005-09-10|2005-09-16|Estimate|||||||2008-11-04|2008-11-06|Estimate|March 2002||2002-03-31|November 2008|2008-11-30|November 2008|Anticipated|2008-11-30|January 2005|Actual|2005-01-31||Interventional|AGENT-4||Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina|A Multinational Multicenter, Randomized , Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients With Stable Angina|Unknown status|Active, not recruiting|Phase 2/Phase 3|116|Actual|Cardium Therapeutics||3|||f||||t||||||||||2018-06-01 04:35:50.150977|2018-06-01 04:35:50.150977
NCT00185250|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-12-18|2005-09-10|2005-09-16|Estimate|||||||2008-12-18|2008-12-19|Estimate|December 2002||2002-12-31|December 2008|2008-12-31|November 2005|Actual|2005-11-30|||||Interventional|||Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy|Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study to Evaluate Efficacy and Safety of 4 and 8 Million Units Betaferon®/Betaseron® (Interferon Beta-1b) Given Subcutaneously Every Other Day Over 24 Weeks in Patients With Chronic Viral Cardiomyopathy|Completed||Phase 2|138|Actual|Bayer||4|||f||||t||||||||||2018-06-01 04:35:50.227355|2018-06-01 04:35:50.227355
NCT00185237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-12-22|2005-09-09|2005-09-16|Estimate|||||||2014-12-22|2014-12-23|Estimate|July 2005||2005-07-31|December 2014|2014-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Treatment of Hot Flushes in Asian Women With Ultra-low Dose Estradiol Patch|A Multicenter, Double-blind, Randomized, Placebo Controlled Study on the Effect of Ultra-low Dose Transdermal Estradiol (Menostar®) on the Incidence and Severity of Hot Flushes, Other Menopausal Symptoms and on Well-being in Postmenopausal Asian Women Over 12 Weeks.|Completed||Phase 3|165|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:50.484303|2018-06-01 04:35:50.484303
NCT00185224|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-07-14|2005-09-10|2005-09-16|Estimate|||||||2011-07-14|2011-07-15|Estimate|March 2005||2005-03-31|July 2011|2011-07-31|March 2006|Actual|2006-03-31|||||Interventional|||Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive|A Single-center, Open-label, Controlled, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive (SH T00658ID) as Compared to a Sequential Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D00264A) on Plasma Lipids, Hemostatic Variables, and Carbohydrate Metabolism in Healthy Female Volunteers Aged 18-50 Years Over 7 Treatment Cycles, Including the Pharmacokinetics|Completed||Phase 2|58|Actual|Bayer||2|||f||||||||||||||2018-06-01 04:35:50.557148|2018-06-01 04:35:50.557148
NCT00185211|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-07-23||2013-12-04|2005-09-09|2005-09-16|Estimate|2010-10-29|2010-11-30|Estimate||||2013-12-04|2013-12-30|Estimate|August 2002||2002-08-31|December 2013|2013-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study|Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.|Completed||Phase 3|468|Actual|Bayer|"Participant Flow: Subject with Other as reason for not completing a study period are presented according to the NIH pre-specified categories as far as possible."|2|||f||||t||||||||||2018-06-01 04:35:50.704482|2018-06-01 04:35:50.704482
NCT00185198|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-04-01|2005-09-09|2005-09-16|Estimate|||||||2014-04-01|2014-04-02|Estimate|September 2004||2004-09-30|April 2014|2014-04-30|October 2007|Actual|2007-10-31|September 2006|Actual|2006-09-30||Interventional|||Efficacy and Safety of Testogel® in Men With Partial Androgen Deficiency of Aging Males (PADAM)|Multicenter, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone 50-100mg) to Evaluate Its Efficacy and Safety in Men Presenting With Typical Symptoms of Partial Androgen Deficiency of Aging Males (PADAM) Over a Period of 6 Months With 12 Months Open Label Follow-up|Completed||Phase 3|363|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:35:51.746348|2018-06-01 04:35:51.746348
NCT00185185|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-12|2005-09-12|2005-09-16|Estimate|||||||2007-12-12|2007-12-14|Estimate|November 2001||2001-11-30|December 2007|2007-12-31|February 2006|Actual|2006-02-28|||||Interventional|||Olmesartan Medoxomil in Atherosclerosis|Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)|Completed||Phase 3|165|Actual|Daiichi Sankyo, Inc.||2|||f||||||||||||||2018-06-01 04:35:52.031707|2018-06-01 04:35:52.031707
NCT00185172|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-28|2005-09-12|2005-09-16|Estimate|||||||2008-04-28|2008-04-29|Estimate|January 2002||2002-01-31|April 2008|2008-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Olmesartan in Essential Hypertension|Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension|Completed||Phase 3|2333|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-06-01 04:35:52.176536|2018-06-01 04:35:52.176536
NCT00185159|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-19|2005-09-12|2005-09-16|Estimate|||||||2010-01-19|2010-01-20|Estimate|October 2004||2004-10-31|January 2010|2010-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Olmesartan Medoxomil in Diabetes Mellitus|Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)|Completed||Phase 3|4449|Actual|Daiichi Sankyo, Inc.||2|||f||||||||||||||2018-06-01 04:35:52.363678|2018-06-01 04:35:52.363678
NCT00185146|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-27|2005-09-12|2005-09-16|Estimate|||||||2007-03-27|2007-03-28|Estimate|September 2002||2002-09-30|March 2007|2007-03-31|August 2005||2005-08-31|||||Interventional|||Efficacy and Safety of Pactimibe in Patients With Atherosclerosis|Effect of Pactimibe on the Progression of Atherosclerosis as Measured by 2-D and 3-D Carotid Ultrasound|Completed||Phase 2|200||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:35:52.544434|2018-06-01 04:35:52.544434
NCT00185133|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-12|2005-09-09|2005-09-16|Estimate|||||||2007-12-12|2007-12-14|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|January 2007||2007-01-31|||||Interventional|||Study of co-Administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension|A Randomized, Double-Blind, Placebo-Controlled Factorial Study Evaluating the Efficacy and Safety of co-Administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension|Completed||Phase 3|1900||Daiichi Sankyo, Inc.|||||f||||f||||||||||2018-06-01 04:35:52.643081|2018-06-01 04:35:52.643081
NCT00185120|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-01-16|2005-09-09|2005-09-16|Estimate|||||||2012-01-16|2012-01-18|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker|A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension|Completed||Phase 4|152||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:35:53.099477|2018-06-01 04:35:53.099477
NCT00185107|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-09-10|2005-09-09|2005-09-16|Estimate|||||||2007-09-10|2007-09-11|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|October 2005||2005-10-31|||||Interventional|||Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Combination With Zetia® Compared to Zetia® Alone in Patients With Primary Hypercholesterolemia|Completed||Phase 4|45||Daiichi Sankyo, Inc.|||||f||||f||||||||||2018-06-01 04:35:53.318331|2018-06-01 04:35:53.318331
NCT00184886|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-02-13|2005-09-12|2005-09-16|Estimate|||||||2006-02-13|2006-02-14|Estimate|November 2003||2003-11-30|February 2006|2006-02-28|January 2005||2005-01-31|||||Interventional|||The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans|The Influence of Methotrexate on the Metabolism and Vascular Effects of Adenosine in Humans|Completed||N/A|10||Radboud University|||||f||||||||||||||2018-06-01 04:35:55.960012|2018-06-01 04:35:55.960012
NCT00185094|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-22|2005-09-09|2005-09-16|Estimate|||||||2005-12-22|2005-12-23|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin|The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension|Completed||Phase 4|60||Daiichi Sankyo, Inc.|||||||||||||||||||2018-06-01 04:35:53.497199|2018-06-01 04:35:53.497199
NCT00185081|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-04-06|2005-09-15|2005-09-16|Estimate|||||||2016-04-06|2016-04-07|Estimate|July 2005||2005-07-31|April 2016|2016-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging|Radioimmunodetection of CEA-Producing Tumors Using a Bispecific Antibody Pre-targeting Method and an In-Labeled Peptide|Completed||Phase 1|42|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:35:53.612334|2018-06-01 04:35:53.612334
NCT00185068|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-16|Estimate|||||||2005-09-09|2005-09-16|Estimate|March 2004||2004-03-31|September 2005|2005-09-30|October 2004||2004-10-31|||||Interventional|||An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension|A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension|Completed||Phase 4|110||Daiichi Sankyo, Inc.|||||||||||||||||||2018-06-01 04:35:53.859752|2018-06-01 04:35:53.859752
NCT00185055|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-15|2005-09-15|2005-09-16|Estimate|||||||2005-09-15|2005-09-16|Estimate|November 2004||2004-11-30|September 2005|2005-09-30|February 2005||2005-02-28|||||Interventional|||The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects|The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects|Completed||Phase 4|20||Daiichi Sankyo, Inc.|||||||||||||||||||2018-06-01 04:35:54.065789|2018-06-01 04:35:54.065789
NCT00185042|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-09-10|2005-09-09|2005-09-16|Estimate|||||||2007-09-10|2007-09-11|Estimate|November 2002||2002-11-30|September 2007|2007-09-30|July 2005||2005-07-31|||||Interventional|||Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Coronary Artery Disease Using Intravascular Ultrasound (IVUS)|Completed||Phase 2|534|Actual|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:35:54.202711|2018-06-01 04:35:54.202711
NCT00185029|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-14|2005-09-14|2005-09-16|Estimate|||||||2005-09-14|2005-09-16|Estimate|April 2002||2002-04-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||MR-Lymphography and Lymph Node Staging in Prostate Cancer|MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer?|Unknown status|Active, not recruiting|Phase 4|396||Radboud University|||||f||||||||||||||2018-06-01 04:35:54.541993|2018-06-01 04:35:54.541993
NCT00185016|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2005-09-15|2005-09-15|2005-09-16|Estimate|||||||2005-09-15|2005-09-16|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|November 2004||2004-11-30|||||Interventional|||Women Abuse and the Role of the Family Doctor.|Women Abuse and the Role of the Family Doctor. Testing an Intervention in a Randomised Controlled Trial.|Terminated||N/A|||Radboud University|||||f||||||||||||||2018-06-01 04:35:54.711131|2018-06-01 04:35:54.711131
NCT00185003|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-16|2005-09-13|2005-09-16|Estimate|||||||2008-10-16|2008-10-17|Estimate|January 2003||2003-01-31|April 2008|2008-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Blockade of Vascular Potassium Channels During Human Endotoxemia|Blockade of Vascular Potassium Channels During Human Endotoxemia|Completed||Phase 1|36|Actual|Radboud University|||||f||||f||||||||||2018-06-01 04:35:54.847859|2018-06-01 04:35:54.847859
NCT00184990|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-14|2005-09-12|2005-09-16|Estimate|||||||2008-04-14|2008-04-15|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Effect of Selective iNOS Inhibition During Human Endotoxemia|Effect of Selective iNOS Inhibition During Human Endotoxemia|Completed||Phase 1|7|Actual|Radboud University|||||f||||f||||||||||2018-06-01 04:35:54.986459|2018-06-01 04:35:54.986459
NCT00184977|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-03-11|2005-09-12|2005-09-16|Estimate|||||||2010-03-11|2010-03-12|Estimate|December 1998||1998-12-31|August 2006|2006-08-31|January 2003||2003-01-31|||||Interventional|||COPD on Primary Care Treatment (COOPT)|A Double-blind Placebo-controlled Trial Comparing the Efficacy and Cost-effectiveness of Inhaled Fluticason Propionate Versus Oral N-acetylcysteine in the Treatment of Patients With COPD in General Practice|Completed||Phase 4|270||Radboud University|||||f||||||||||||||2018-06-01 04:35:55.120773|2018-06-01 04:35:55.120773
NCT00184964|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-03|2005-09-12|2005-09-16|Estimate|||||||2008-06-03|2008-06-04|Estimate|June 2004||2004-06-30|June 2008|2008-06-30||||||||Interventional|||Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis|The Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis With Histological Examination of the Resected Specimen|Unknown status|Recruiting|N/A|15|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:35:55.275743|2018-06-01 04:35:55.275743
NCT00184951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-21|2005-09-12|2005-09-16|Estimate|||||||2008-10-21|2008-10-22|Estimate|April 2004||2004-04-30|October 2008|2008-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients|Pharmacodynamics and Pharmacokinetics of Combined Use of Rosuvastatin (Crestor) and Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients With Hyperlipidemia (ROSALKA)|Completed||Phase 2|30||Radboud University|||||f||||||||||||||2018-06-01 04:35:55.417398|2018-06-01 04:35:55.417398
NCT00184938|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-27|2005-09-12|2005-09-16|Estimate|||||||2008-03-27|2008-03-28|Estimate|January 2005||2005-01-31|March 2008|2008-03-31||||||||Interventional|||Opioid Receptors Influence Ischemia-Reperfusion Injury|Opioid Induced Acute Preconditioning|Suspended||N/A|40|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:35:55.526933|2018-06-01 04:35:55.526933
NCT00184925|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-11-05|2005-09-12|2005-09-16|Estimate|||||||2014-11-05|2014-11-06|Estimate|October 2003||2003-10-31|November 2014|2014-11-30|August 2005|Actual|2005-08-31|April 2005|Actual|2005-04-30||Interventional|||Ventilator Associated Pneumonia and Late Complications of Percutaneous Tracheostomy|The Development of Ventilator Associated Pneumonia and Late Complications of Two Different Percutaneous Tracheostomy Techniques|Terminated||N/A|120|Actual|Radboud University||1||Analysis was frustrated by inadequate PhD's....|f||||t||||||||||2018-06-01 04:35:55.61258|2018-06-01 04:35:55.61258
NCT00184912|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-28|2005-09-12|2005-09-16|Estimate|||||||2006-11-28|2006-11-29|Estimate|September 2003||2003-09-30|February 2006|2006-02-28|January 2006||2006-01-31|||||Interventional|||The Effect of Caffeine on Ischemic Preconditioning|Caffeine Reduces Acute Ischemic Preconditioning|Completed||N/A|24||Radboud University|||||f||||||||||||||2018-06-01 04:35:55.758707|2018-06-01 04:35:55.758707
NCT00184873|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-02-08|2005-09-12|2005-09-16|Estimate|||||||2010-02-08|2010-02-09|Estimate|January 2005||2005-01-31|August 2007|2007-08-31|December 2008|Actual|2008-12-31|May 2008|Actual|2008-05-31||Interventional|||Legtest Multi Centre Testing of the Lively Legs Program for Promoting Compliance in Leg Ulcer Patients|Legtest Multi Centre Testing of the Lively Legs Program for Promoting Compliance With Compression Therapy and Prescribed Exercise in Leg Ulcer Patients|Completed||N/A|180|Actual|Radboud University||2|||f||||f||||||||||2018-06-01 04:35:56.049252|2018-06-01 04:35:56.049252
NCT00184860|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-26|2005-09-12|2005-09-16|Estimate|||||||2007-04-26|2007-04-27|Estimate|June 2003||2003-06-30|April 2007|2007-04-30||||||||Interventional|||The Role of CT-PET-MRI Image Fusion in Determining Radiation Treatment Volumes of Head-and-Neck Cancer Patients|The Value of CT-PET-MRI Image Fusion in Determining Radiation Treatment Volumes in Patients With a Squamous Cell Carcinoma of the Head-and-Neck Region, Who Are to be Treated With Definitive Radiotherapy|Completed||N/A|80||Radboud University|||||f||||||||||||||2018-06-01 04:35:56.263879|2018-06-01 04:35:56.263879
NCT00184847|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-27|2005-09-12|2005-09-16|Estimate|||||||2008-03-27|2008-03-28|Estimate|March 2005||2005-03-31|March 2008|2008-03-31||||||||Interventional|||Adenosine Receptors Influence Ischemia-Reperfusion Injury|Adenosine Receptor Involvement in Acute Ischemic Preconditioning of the Vascular Endothelium|Suspended||N/A|8|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:35:56.35371|2018-06-01 04:35:56.35371
NCT00184834|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|June 1999||1999-06-30|September 2005|2005-09-30|November 2002||2002-11-30|||||Observational|||Quality of Life and Liver Metastases|Quality of Life After Surgical Treatment of Colorectal Liver Metastases|Completed|||100||Radboud University|||||f||||||||||||||2018-06-01 04:35:56.450836|2018-06-01 04:35:56.450836
NCT00184821|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-04|2005-09-09|2005-09-16|Estimate|||||||2007-04-04|2007-04-05|Estimate|June 2004||2004-06-30|April 2007|2007-04-30|May 2005|Actual|2005-05-31|||||Observational|||Ischemic Injury and Ischemic Preconditioning in Diabetes|Acute Local Ischemic Preconditioning in Patients With Type 1 Diabetes in Vivo|Completed|||20||Radboud University|||||f||||f||||||||||2018-06-01 04:35:56.520826|2018-06-01 04:35:56.520826
NCT00184808|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate||||September 2005|2005-09-30||||||||Observational|||Ambulatory Assessment of Motor State in Patients With Parkinson's Disease in Real Daily Life||Unknown status|Recruiting||15||Radboud University|||||f||||||||||||||2018-06-01 04:35:56.637689|2018-06-01 04:35:56.637689
NCT00184795|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-22|2005-09-15|2005-09-16|Estimate|||||||2017-02-22|2017-02-23|Actual|May 28, 2004|Actual|2004-05-28|February 2017|2017-02-28|May 4, 2005|Actual|2005-05-04|May 4, 2005|Actual|2005-05-04||Interventional|CHOICE||Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations|A Six Month Double-blind, Randomised, Parallel-group, Placebo-controlled, Multi-centre Trial to Investigate the Efficacy and Safety of Two Ultra-low Dose Combinations With 0.5 mg Estradiol and 0.1 mg or 0.25 mg Norethisterone Acetate (Activelle Low Dose 0.1/Activelle Low Dose 0.25) for Treatment of Menopausal Symptoms|Completed||Phase 3|576|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 04:35:56.74092|2018-06-01 04:35:56.74092
NCT00184782|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-20|2005-09-12|2005-09-16|Estimate|||||||2007-09-20|2007-09-21|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning|Exploratory Study on FDG-PET Scanning in Evaluating the Metabolic Activity of Liver Metastases Before and After Resection of the Primary Tumor in Patients With a Colorectal Malignancy|Unknown status|Recruiting|N/A|30|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:35:56.955569|2018-06-01 04:35:56.955569
NCT00184769|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-23|2005-09-13|2005-09-16|Estimate|||||||2017-02-23|2017-02-27|Actual|January 29, 1998|Actual|1998-01-29|February 2017|2017-02-28|December 21, 2005|Actual|2005-12-21|December 21, 2005|Actual|2005-12-21||Interventional|||Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.|Open Randomized Trial Examining the Growth and Safety Effects of Treatment With Recombinant Growth Hormone on Infants Aged 1 to 2 Years With Growth Retardation Secondary to Chronic Renal Insufficiency|Completed||Phase 4|16|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:35:58.078726|2018-06-01 04:35:58.078726
NCT00184756|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-12|2005-09-13|2005-09-16|Estimate|||||||2017-01-12|2017-01-13|Estimate|November 2002||2002-11-30|January 2017|2017-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy on Height in SGA Children Treated With Growth Hormone|Effect of Two Years Treatment With Growth Hormone on Height in SGA Children.|Completed||Phase 3|151|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:35:58.258927|2018-06-01 04:35:58.258927
NCT00184743|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-27|2005-09-13|2005-09-16|Estimate|||||||2017-02-27|2017-02-28|Actual|December 6, 2003|Actual|2003-12-06|February 2017|2017-02-28|December 28, 2005|Actual|2005-12-28|December 28, 2005|Actual|2005-12-28||Interventional|||Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)|Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency|Completed||Phase 3|112|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:35:58.408979|2018-06-01 04:35:58.408979
NCT00184730|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-16|2005-09-13|2005-09-16|Estimate|||||||2016-11-16|2016-11-17|Estimate|November 2004||2004-11-30|November 2016|2016-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)|Investigation of the Efficacy and Safety of hGH in Long Term (More Than 48 Weeks) in GHDA.|Completed||Phase 3|86|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:35:58.487684|2018-06-01 04:35:58.487684
NCT00184717|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-12-22||2017-06-06|2005-09-13|2005-09-16|Estimate|2011-06-29|2011-07-07|Estimate||||2017-06-06|2017-07-07|Actual|August 18, 2004|Actual|2004-08-18|June 2017|2017-06-30|December 28, 2009|Actual|2009-12-28|March 29, 2006|Actual|2006-03-29||Interventional|||Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)|GHLIQUID-1516: A 104-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Subjects With Short Stature Born Small for Gestational Age / GHLIQUID-1517: A Long-term, Multi-centre, Randomised, Controlled, Double-blind, Parallel-group Trial, Investigating the Efficacy and Safety of Two Doses of NN-220 in Subjects With Short Stature Born Small for Gestational Age|Completed||Phase 3|98|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-06-01 04:35:58.660061|2018-06-01 04:35:58.660061
NCT00184691|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-17|2005-09-13|2005-09-16|Estimate|||||||2017-01-17|2017-01-18|Estimate|April 1999||1999-04-30|January 2017|2017-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years|Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone Which Will be Started Randomly at the Ages of 2 to 5, in Children Diagnosed of IUGR|Completed||Phase 3|78|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:35:59.892465|2018-06-01 04:35:59.892465
NCT00183599|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-17|2005-09-13|2005-09-16|Estimate|||||||2011-11-17|2011-11-21|Estimate|April 1999||1999-04-30|November 2011|2011-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Gambling and Brief Interventions|Effect of Type and Duration of Therapy on Treatment for Gambling|Completed||Phase 1|500||UConn Health||3|||f||||t||||||||||2018-06-01 04:36:14.939378|2018-06-01 04:36:14.939378
NCT00184678|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-12|2005-09-13|2005-09-16|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2002||2002-02-28|January 2017|2017-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency|Effect of Two Years of Treatment With Norditropin® SimpleXx® on Bone Mineral Density in Young Adults With Childhood-Onset Growth Hormone Deficiency|Completed||Phase 3|161|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:35:59.970543|2018-06-01 04:35:59.970543
NCT00184665|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-26|2005-09-13|2005-09-16|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2004||2004-06-30|January 2017|2017-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes|2 Year Efficiency and Safety Comparison of Insulin Detemir and NPH Insulin in Type 1 Diabetes.|Completed||Phase 3|501|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:36:00.172047|2018-06-01 04:36:00.172047
NCT00184652|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-23|2005-09-13|2005-09-16|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2003||2003-04-30|January 2017|2017-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease|The Effect of Norditropin® on Nutritional Status in Adult Patients in Chronic Haemodialysis|Completed||Phase 2|140|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:36:00.269097|2018-06-01 04:36:00.269097
NCT00184639|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-22|2005-09-13|2005-09-16|Estimate|||||||2017-02-22|2017-02-24|Actual|August 16, 2004|Actual|2004-08-16|February 2017|2017-02-28|November 22, 2005|Actual|2005-11-22|November 22, 2005|Actual|2005-11-22||Interventional|||Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir and Insulin Semilente®MC in Children, Adolescents and Young Adults With Type 1 Diabetes on Basal-Bolus Regimen.|Completed||Phase 3|71|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:36:00.355817|2018-06-01 04:36:00.355817
NCT00184626|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-22|2005-09-12|2005-09-16|Estimate|||||||2017-02-22|2017-02-24|Actual|September 10, 2004|Actual|2004-09-10|February 2017|2017-02-28|October 24, 2005|Actual|2005-10-24|October 24, 2005|Actual|2005-10-24||Interventional|||Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.|Safety and Efficacy of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.|Completed||Phase 4|97|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:36:00.41236|2018-06-01 04:36:00.41236
NCT00184613|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-10-14|2005-09-12|2005-09-16|Estimate|||||||2016-10-14|2016-10-17|Estimate|May 2005||2005-05-31|October 2016|2016-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes|An Open-label, Randomised, In-patient, Cross Over PK/PD Trial Investigating the Pharmackinectic and Pharmacodynamic Profiles Following Continuous Subcutaneous Infusion of Insulin Aspart or Injection of Insulin Glargine in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|22|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:36:00.51915|2018-06-01 04:36:00.51915
NCT00184600|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-05-10||2017-01-26|2005-09-13|2005-09-16|Estimate|2011-06-23|2011-07-25|Estimate||||2017-01-26|2017-03-09|Actual|November 2004||2004-11-30|January 2017|2017-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|4T||Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes|A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin Versus a Twice Daily Insulin Mixture Versus a Meal-time Rapid-Acting Insulin in Subjects With Type 2 Diabetes Inadequately Controlled on Therapy With Oral Agents, and Assessing the Requirement for More Complex Insulin Regimens to Achieve and Maintain Glycaemic Control, Their Efficacy and Durability|Completed||Phase 3|708|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-06-01 04:36:00.655085|2018-06-01 04:36:00.655085
NCT00184587|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-04-22|2005-09-13|2005-09-16|Estimate|||||||2013-04-22|2013-04-23|Estimate|March 2005||2005-03-31|September 2010|2010-09-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Prophylactic Treatment of Episodic Cluster Headache|Prophylactic Treatment of Episodic Cluster Headache With an Angiotensin II Receptor Blocker (Candesartan Cilexetil); a Randomized, Placebo Controlled Parallel Study|Completed||Phase 2|40|Actual|Norwegian University of Science and Technology||2|||f||||||||||||||2018-06-01 04:36:02.856997|2018-06-01 04:36:02.856997
NCT00184574|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-01-04|2005-09-12|2005-09-16|Estimate|||||||2017-01-04|2017-01-05|Estimate|April 2005||2005-04-30|January 2017|2017-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes|Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 70/30, Biphasic Insulin Aspart 50/50, and Biphasic Insulin Aspart 30/70 All in Combination With Metformin in Subjects With Type 2 Diabetes (the INTENSIMIX Trial).|Completed||Phase 3|603|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:36:03.002458|2018-06-01 04:36:03.002458
NCT00184561|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2017-01-05|2005-09-12|2005-09-16|Estimate|||||||2017-01-05|2017-01-06|Estimate|July 2005||2005-07-31|January 2017|2017-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes|Change in HbA1c With Biphasic Insulin Aspart 70/30 in Two Different Treatment Regiments in Subjects With Type 2 Diabetes Inadequately Controlled With Oral Anti-diabetic Drug Therapy.|Completed||Phase 4|321|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:36:03.280605|2018-06-01 04:36:03.280605
NCT00184548|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-09-04||2014-06-13|2005-09-09|2005-09-16|Estimate|2009-10-16|2009-11-26|Estimate||||2014-06-13|2014-06-25|Estimate|October 2005||2005-10-31|June 2014|2014-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|CONTROL||Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding|A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/NiaStase®) in Severely Injured Trauma Patients With Bleeding Refractory to Standard Treatment|Terminated||Phase 3|554|Actual|Novo Nordisk A/S|Trial was terminated after planned interim analysis for futility showed a lower than expected conditional power for showing superiority (11.2% [actual] vs. 50% [required]). 554 of 1502 planned patients were included in the intent-to-treat population.|4||See termination reason in detailed description|f||||f||||||||||2018-06-01 04:36:03.400631|2018-06-01 04:36:03.400631
NCT00184535|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-09-20|2005-09-15|2005-09-16|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2005|Actual|2005-07-31|September 2017|2017-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|||"Recording Methods of Muscle Activity Onset."|"Muscle Activity Onset in the Transversus Abdominis - Simultaneous Recordings by Intramuscular Electromyography and High Frame Rate Ultrasound Imaging."|Completed|||10|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-06-01 04:36:05.013118|2018-06-01 04:36:05.013118
NCT00184522|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-08-08|2005-09-15|2005-09-16|Estimate|||||||2011-08-08|2011-08-09|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||On Demand Treatment of Reflux Disease|Aflurax Versus Nexium Given on Demand to Patients With Gastro-esophageal Reflux Disease.|Completed||Phase 4|82|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:36:05.154313|2018-06-01 04:36:05.154313
NCT00184509|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-01-25|2005-09-15|2005-09-16|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 1993||1993-02-28|January 2017|2017-01-31|May 1998||1998-05-31|||||Interventional|||Continued Early Intervention for Recent-onset Schizophrenia|Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.|Terminated||Phase 3|50||Norwegian University of Science and Technology|||||f||||||||||||||2018-06-01 04:36:05.241429|2018-06-01 04:36:05.241429
NCT00184496|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2014-02-27|2005-09-15|2005-09-16|Estimate|||||||2014-02-27|2014-02-28|Estimate|August 2004||2004-08-31|February 2014|2014-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study|Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study|Completed||Phase 3|42|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:36:05.298982|2018-06-01 04:36:05.298982
NCT00184483|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-02-04|2005-09-15|2005-09-16|Estimate|||||||2016-02-04|2016-02-05|Estimate|October 2001||2001-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Multi-site Trial Comparing Lichtensteins Operation and Prolene Hernia System in Inguinal HErnia Repair|Randomized Multi Site Trial Comparing Lichtensteins Operation and Prolene Hernia System in Inguinal HErnia Repair.|Completed||N/A|405|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:36:05.374532|2018-06-01 04:36:05.374532
NCT00184470|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-04-18|2005-09-15|2005-09-16|Estimate|||||||2008-04-18|2008-04-21|Estimate|December 2004||2004-12-31|April 2008|2008-04-30|January 2007||2007-01-31|June 2006|Actual|2006-06-30||Observational|||Trauma Registration at St. Olavs Hospital 2000-2003|Mapping of Traumatized Patients Referred to St. Olavs Hospital in the Period 2000-2003-Norwegian University of Science and Technology|Terminated|||1000||Norwegian University of Science and Technology|||||f||||||||||||||2018-06-01 04:36:05.449348|2018-06-01 04:36:05.449348
NCT00184457|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-01-16|2005-09-15|2005-09-16|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2005||2005-09-30|November 2011|2011-11-30|September 2007|Actual|2007-09-30|April 2007|Actual|2007-04-30||Interventional|||Maximal Leg Press Strength Training Study for Coronary Artery Disease Patients|Maximal Leg Press Strength Training for Coronary Artery Disease Patients. Training Effect on Serum Testosterone and Work Economy|Completed||N/A|12|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:36:05.497369|2018-06-01 04:36:05.497369
NCT00184444|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-07-19|2005-09-15|2005-09-16|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 2004||2004-09-30|July 2016|2016-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients|Effect of Increased Oxygenation in the Air During Endurance Training in Stable Angina Pectoris Patients|Completed||N/A|25|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:36:05.633015|2018-06-01 04:36:05.633015
NCT00184431|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2011-10-17|2005-09-15|2005-09-16|Estimate|||||||2011-10-17|2011-10-18|Estimate|April 2004||2004-04-30|October 2011|2011-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Does Intensive Task Specific Training Improve Balance After Acute Stroke?|A Randomized Controlled Trial Comparing Intensive Task Specific Training With Traditional Follow up Care After Discharge From a Stroke Unit.|Completed||N/A|62|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:36:05.714979|2018-06-01 04:36:05.714979
NCT00184418|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-03-09|2005-09-15|2005-09-16|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2005|Actual|2005-01-31|March 2017|2017-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||The Immune System and Psychiatric Disorders|The Immune System and Psychiatric Disorders|Completed|||1400|Actual|Norwegian University of Science and Technology|||1||f||||f|f|f||||Samples Without DNA|"~     Serum, frozen~   "|No||2018-06-01 04:36:05.821352|2018-06-01 04:36:05.821352
NCT00184405|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-01-05|2005-09-15|2005-09-16|Estimate|||||||2009-01-05|2009-01-06|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Child Results Following Preventive Children of Parents With Psychiatric and Addictive Problems (COPP) Groups|Preventive Peer Groups for Children of Parents With Psychiatric and Addictive Problems (COPP). Child Experiences and Observed Child Changes Following the Intervention|Terminated|||6|Actual|Norwegian University of Science and Technology||||Terminated to financial cut|f||||t||||||||||2018-06-01 04:36:06.077758|2018-06-01 04:36:06.077758
NCT00184392|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2014-02-27|2005-09-15|2005-09-16|Estimate|||||||2014-02-27|2014-02-28|Estimate|January 2005||2005-01-31|February 2014|2014-02-28|September 2007|Actual|2007-09-30|December 2005|Actual|2005-12-31||Interventional|||Cleaning of the Nose After Sinus Surgery: Necessary or Only Bothersome?|Debridement After Functional Endoscopic Sinus Surgery|Completed||N/A|60|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-06-01 04:36:06.165461|2018-06-01 04:36:06.165461
NCT00184379|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-24|2005-09-15|2005-09-16|Estimate|||||||2017-08-24|2017-08-28|Actual|April 2005||2005-04-30|August 2017|2017-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects of Psychoeducation of Relatives to Patients With Serious Mental Illness|Effects of Psychoeducation of Relatives to Patients With Serious Mental Illness|Completed||N/A|50|Actual|Norwegian University of Science and Technology||4|||f||||f|f|f||||||||2018-06-01 04:36:06.243497|2018-06-01 04:36:06.243497
NCT00184366|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-18|2005-09-13|2005-09-16|Estimate|||||||2012-01-18|2012-01-19|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Observational|||Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis|Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab|Terminated|||96|Actual|Norwegian University of Science and Technology||||efalizumab was withdrawn from market; full 2 years follow-up only 14 patients|f||||f||||||||||2018-06-01 04:36:06.343039|2018-06-01 04:36:06.343039
NCT00184353|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-10-20|2005-09-15|2005-09-16|Estimate|||||||2011-10-20|2011-10-21|Estimate|November 2003||2003-11-30|October 2011|2011-10-31|June 2005|Actual|2005-06-30|December 2004|Actual|2004-12-31||Observational|||Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.|In Vivo Proton MR Spectroscopy of Brain Metastases Obtained at 1,5T and 3T.|Completed|||19|Actual|Norwegian University of Science and Technology|||2||f||||f||||||||||2018-06-01 04:36:06.447451|2018-06-01 04:36:06.447451
NCT00184340|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-08|2005-09-13|2005-09-16|Estimate|||||||2017-02-08|2017-02-09|Estimate|January 2004|Actual|2004-01-31|February 2017|2017-02-28|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Secured Internet-mediated Psychotherapy With Psychiatry Patients|Secured Internet-mediated Psychotherapy With Psychiatry Patients. Software Improvement, Clinical Trials and Development of Clinical Precautions|Completed|||6|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:36:06.585491|2018-06-01 04:36:06.585491
NCT00184327|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-16|2005-09-13|2005-09-16|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2002||2002-01-31|January 2017|2017-01-31|June 2008|Actual|2008-06-30|December 2006|Actual|2006-12-31||Observational|||Changes Following Inpatient Child-oriented Family Treatment|Change Across Intensive Inpatient Family Treatment in Child and Adolescent Psychiatry. A Multi-site Study of Parents and Children in Inpatient Family Treatment|Completed|||150|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:36:06.79888|2018-06-01 04:36:06.79888
NCT00184314|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-08|2005-09-13|2005-09-16|Estimate|||||||2017-02-08|2017-02-09|Estimate|March 2004|Actual|2004-03-31|February 2017|2017-02-28|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Observational|||Follow-up of Eating Disorder Patients From a 15-year Period.|Follow-up Eating Disorder Patients and Their Parents Leaving Treatment From 1988 to 2002 at Child and Adolescent Department at Levanger Hospital.|Completed|||40|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-06-01 04:36:07.104033|2018-06-01 04:36:07.104033
NCT00184301|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-28|2005-09-15|2005-09-16|Estimate|||||||2017-03-28|2017-03-29|Actual|September 2005|Actual|2005-09-30|March 2017|2017-03-31|October 2013|Actual|2013-10-31|December 2011|Actual|2011-12-31||Interventional|||A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.|Treatment of Patients With Concurrent Eating Disorder and Personality Disorder: A Controlled Randomized Comparison Study, of Treatments Given to In-patients and Out-patients.|Completed||N/A|43|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-06-01 04:36:07.18661|2018-06-01 04:36:07.18661
NCT00184288|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-01|2005-09-13|2005-09-16|Estimate|||||||2011-11-01|2011-11-02|Estimate|November 2004||2004-11-30|October 2011|2011-10-31|December 2010|Actual|2010-12-31|June 2006|Actual|2006-06-30||Observational|||Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.|Single Volume 1H MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response.|Withdrawn|||0|Actual|Norwegian University of Science and Technology||||no patients recruited|f||||f||||||||||2018-06-01 04:36:07.279731|2018-06-01 04:36:07.279731
NCT00184275|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-03-06|2005-09-13|2005-09-16|Estimate|||||||2014-03-06|2014-03-07|Estimate|May 2005||2005-05-31|March 2014|2014-03-31|December 2010|Actual|2010-12-31|May 2007|Actual|2007-05-31||Observational|||Characterization of Brain Metastases|Brain Metastases Tissue Characterized by High-resolution Magic Angle Spinning MR and Micro Array|Completed|||26|Actual|Norwegian University of Science and Technology|||||f||||f||||||Samples With DNA|"~     frozen tumor tissue samples~   "|||2018-06-01 04:36:07.339907|2018-06-01 04:36:07.339907
NCT00184262|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-20|2005-09-15|2005-09-16|Estimate|||||||2012-03-20|2012-03-21|Estimate|January 2003||2003-01-31|March 2012|2012-03-31|December 2006|Actual|2006-12-31|||||Interventional|||Exposure and Response Prevention With Behavioral- Versus Cognitive Therapy Rationale in Obsessive Compulsive Disorder|Exposure and Response Prevention (ERP) With Behavioral- Versus Cognitive Therapy Rationale in the Treatment of OCD|Completed||N/A|35|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:36:07.425326|2018-06-01 04:36:07.425326
NCT00184249|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-03-18|2005-09-13|2005-09-16|Estimate|||||||2015-03-18|2015-03-20|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|June 2012|Actual|2012-06-30|June 2010|Actual|2010-06-30||Interventional|||A Prospective Multi Centre Trial on Bipolar Radiofrequency Ablation of Atrial Fibrillation|A Prospective Multi Centre Trial on Bipolar Radiofrequency Ablation of Atrial Fibrillation|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||1||Collaborators did not enter patients into the study|f||||f||||||||||2018-06-01 04:36:07.76112|2018-06-01 04:36:07.76112
NCT00184236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-29|2005-09-13|2005-09-16|Estimate|||||||2017-03-29|2017-03-30|Actual|February 2005|Actual|2005-02-28|March 2017|2017-03-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Cardiovascular Risk Factors in Overweight Adolescents|Aerobic Interval Training Reduces Cardiovascular Risk Factors More Than a Multitreatment Approach in Overweight Adolescents|Completed||N/A|54|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-06-01 04:36:08.262684|2018-06-01 04:36:08.262684
NCT00184223|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-06-03|2005-09-15|2005-09-16|Estimate|||||||2016-06-03|2016-06-06|Estimate|October 2004||2004-10-31|May 2016|2016-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Motivational Interviewing to Acutely Admitted Psychiatric Patients With Comorbid Substance Use|Motivational Interviewing to Acutely Admitted Psychiatric Patients With Comorbid Substance Use|Completed||N/A|135|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||No||2018-06-01 04:36:08.559308|2018-06-01 04:36:08.559308
NCT00184210|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-17|2005-09-12|2005-09-16|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2000|Actual|2000-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue|HR MAS MR Spectroscopy of Breast Cancer Tissue|Recruiting|||1000|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     tissue~   "|||2018-06-01 04:36:08.733784|2018-06-01 04:36:08.733784
NCT00184197|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-10|2005-09-12|2005-09-16|Estimate|||||||2017-03-10|2017-03-13|Actual|May 2005|Actual|2005-05-31|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Botulinum Toxin Injection in Neck Muscles in Cervicogenic Headache|Botulinum Toxin Injection in Neck Muscles in Cervicogenic Headache: A Prospective, Randomized, Double-blind, Cross-over Study|Completed||Phase 2|28|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 04:36:08.818025|2018-06-01 04:36:08.818025
NCT00184184|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-10|2005-09-15|2005-09-16|Estimate|||||||2017-03-10|2017-03-14|Actual|October 2004|Actual|2004-10-31|March 2017|2017-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Observational|||Registration of Tobacco, Coffee and Substance Use Among Acutely Admitted Psychiatric Patients|Registration of Tobacco, Coffee and Substance Use Among Acutely Admitted Psychiatric Patients|Completed|||262|Actual|Norwegian University of Science and Technology|||||f||||||||||||||2018-06-01 04:36:08.932925|2018-06-01 04:36:08.932925
NCT00184171|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2015-01-20|2005-09-15|2005-09-16|Estimate|||||||2015-01-20|2015-01-21|Estimate|November 2001||2001-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|September 2010|Actual|2010-09-30||Interventional|||Treatment of Microscopic Colitis|Treatment of Microscopic Colitis (Collagenous Colitis and Lymphocytic Colitis) With Budesonide, Bismuth or Fiber|Terminated||N/A|105|Actual|Norwegian University of Science and Technology||3||insufficient data quality|f||||f||||||||||2018-06-01 04:36:09.002205|2018-06-01 04:36:09.002205
NCT00184158|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-08-17|2005-09-12|2005-09-16|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2005|Actual|2005-01-31|August 2017|2017-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Treatment for Cubital Tunnel Syndrome|Cubital Tunnel Treatment, Evaluation of Conservative and Operative Alternatives|Completed||N/A|81|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-06-01 04:36:09.155926|2018-06-01 04:36:09.155926
NCT00183586|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-06-16|2005-09-13|2005-09-16|Estimate|||||||2016-06-16|2016-06-20|Estimate|April 2004||2004-04-30|June 2016|2016-06-30||||March 2009|Actual|2009-03-31||Interventional|||Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents|Treatment for Adolescent Anorexia Nervosa|Completed||Phase 2|121|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:36:15.014597|2018-06-01 04:36:15.014597
NCT00184145|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-02-24|2005-09-10|2005-09-16|Estimate|||||||2017-02-24|2017-02-28|Actual|June 2004|Actual|2004-06-30|February 2017|2017-02-28|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||EMDR in the Treatment of Specific Phobia.|EMDR (Eye Movement Desensitization and Reprocessing) in the Treatment of Specific Phobia. A Randomised Controlled Trial.|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||1||approval of ethical committee was denied|f||||t|f|f||||||||2018-06-01 04:36:09.312506|2018-06-01 04:36:09.312506
NCT00184132|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-03-10|2005-09-15|2005-09-16|Estimate|||||||2017-03-10|2017-03-13|Actual|November 2000|Actual|2000-11-30|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||The Effects of Different Interior Decorations in a Psychiatric Intensive Care Unit.|The Effects of Different Interior Decorations in a Psychiatric Intensive Care Unit.|Completed||N/A|54|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-06-01 04:36:09.456707|2018-06-01 04:36:09.456707
NCT00184119|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-03-10|2005-09-15|2005-09-16|Estimate|||||||2017-03-10|2017-03-13|Actual|October 2001||2001-10-31|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects of a Psychiatric Intensive Care Unit|Effects of a Psychiatric Intensive Care Unit in an Acute Psychiatric Department.|Completed||N/A|118|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-06-01 04:36:09.629034|2018-06-01 04:36:09.629034
NCT00184106|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-02-23|2005-09-15|2005-09-16|Estimate|||||||2017-02-23|2017-02-24|Actual|October 2004|Actual|2004-10-31|February 2017|2017-02-28|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo|A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia|Completed||Phase 4|86|Actual|Norwegian University of Science and Technology||4|||f||||f|f|f||||||||2018-06-01 04:36:09.763054|2018-06-01 04:36:09.763054
NCT00184093|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-07-14||2017-07-14|2005-09-12|2005-09-16|Estimate|2017-07-14|2017-08-15|Actual||||2017-07-14|2017-08-15|Actual|June 1999||1999-06-30|July 2017|2017-07-31|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma|Phase I/II Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma: Analysis of Prognostic Factors and Determinants of Response: A Pilot Study|Completed||Phase 1/Phase 2|35|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 04:36:09.939129|2018-06-01 04:36:09.939129
NCT00184080|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-20|2005-09-13|2005-09-16|Estimate|||||||2014-05-20|2014-05-21|Estimate|May 2004||2004-05-31|May 2014|2014-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multicenter Open-Label Non-Randomized Phase II Study of Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|7|Actual|University of Southern California|||||f||||||||||||||2018-06-01 04:36:10.309419|2018-06-01 04:36:10.309419
NCT00184067|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-20|2005-09-12|2005-09-16|Estimate|||||||2014-05-20|2014-05-21|Estimate|May 2004||2004-05-31|January 2014|2014-01-31|September 2009|Actual|2009-09-30|April 2007|Actual|2007-04-30||Interventional|||Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma|A Randomized Phase II Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Resected Stages IIB/C, III, and IV Melanoma|Terminated||Phase 2|23|Actual|University of Southern California||2||Primary PI left institution|f||||||||||||||2018-06-01 04:36:10.368503|2018-06-01 04:36:10.368503
NCT00184054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-06-13||2014-07-16|2005-09-12|2005-09-16|Estimate|2014-06-13|2014-07-17|Estimate||||2014-07-16|2014-07-25|Estimate|April 2002||2002-04-30|July 2014|2014-07-31|August 2011|Actual|2011-08-31|June 2009|Actual|2009-06-30||Interventional||All participants were included in the analysis.|Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia|Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia|Terminated||Phase 2|11|Actual|University of Southern California||1||Competing studies|f||||||||||||||2018-06-01 04:36:10.441462|2018-06-01 04:36:10.441462
NCT00184041|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-20|2005-09-12|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|July 2004||2004-07-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Intensified Post Remission Therapy Containing PEG-Asparaginase|Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase.|Completed||Phase 2|47|Actual|University of Southern California||1|||f||||t||||||||||2018-06-01 04:36:10.624257|2018-06-01 04:36:10.624257
NCT00184028|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-03-21||2014-05-20|2005-09-12|2005-09-16|Estimate|2013-03-21|2013-05-06|Estimate||||2014-05-20|2014-05-22|Estimate|September 2004||2004-09-30|May 2014|2014-05-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck|Phase II Trial of Taxotere and Oxaliplatin Combination Chemotherapy in Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|12|Actual|University of Southern California||1||Insufficient Accrual|f||||||||||||||2018-06-01 04:36:10.701374|2018-06-01 04:36:10.701374
NCT00184015|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-08|2005-09-12|2005-09-16|Estimate|||||||2017-04-08|2017-04-11|Actual|August 18, 2005|Actual|2005-08-18|April 2017|2017-04-30|August 21, 2018|Anticipated|2018-08-21|August 21, 2016|Actual|2016-08-21||Interventional|||"Bortezomib and Bevacizumab (BB-mib-mab) in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)"||Active, not recruiting||Phase 1/Phase 2|50|Actual|University of Southern California||2|||f||||||||||||||2018-06-01 04:36:10.95118|2018-06-01 04:36:10.95118
NCT00184002|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-07-13||2017-07-13|2005-09-12|2005-09-16|Estimate|2017-07-13|2017-08-10|Actual||||2017-07-13|2017-08-10|Actual|January 10, 2003|Actual|2003-01-10|July 2017|2017-07-31|May 7, 2013|Actual|2013-05-07|December 19, 2012|Actual|2012-12-19||Interventional|||Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas|A Phase II Study Of Pegylated Liposomal Doxorubicin (Doxil) In Combination With Rituxan, Cyclophosphamide, Vincristine and Prednisone (DR-COP) In Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas|Completed||Phase 2|68|Actual|University of Southern California||1|||f||||t|t|f|||f|||||2018-06-01 04:36:11.034229|2018-06-01 04:36:11.034229
NCT00183989|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-20|2005-09-12|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|August 2000||2000-08-31|May 2014|2014-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma|A Pilot Phase II Trial of Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma|Terminated||Phase 2|30|Anticipated|University of Southern California||||Insufficient accrual|f||||||||||||||2018-06-01 04:36:11.475356|2018-06-01 04:36:11.475356
NCT00183976|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-20|2005-09-12|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|April 2005||2005-04-30|May 2006|2006-05-31|January 2006|Actual|2006-01-31|September 2005|Actual|2005-09-30||Interventional|||Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas|A Pilot Phase II Study of Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas|Terminated||Phase 2|15||University of Southern California||||Insufficient Accrual|f||||t||||||||||2018-06-01 04:36:11.544717|2018-06-01 04:36:11.544717
NCT00183963|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-11-09||2014-05-20|2005-09-12|2005-09-16|Estimate|2012-11-09|2012-12-06|Estimate||||2014-05-20|2014-05-22|Estimate|August 2006||2006-08-31|May 2014|2014-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)|A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)|Terminated||Phase 2|4|Actual|University of Southern California|Due to insufficient accrual, analysis was not conducted.|4||Insufficient accrual|f||||||||||||||2018-06-01 04:36:11.627298|2018-06-01 04:36:11.627298
NCT00183950|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|March 2000||2000-03-31|May 2014|2014-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy|Phase I/II Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy|Terminated||Phase 1/Phase 2|12|Actual|University of Southern California||||No funding|||||t||||||||||2018-06-01 04:36:12.086115|2018-06-01 04:36:12.086115
NCT00183937|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-05-10|2005-09-09|2005-09-16|Estimate|||||||2018-05-10|2018-05-14|Actual|April 30, 2005|Actual|2005-04-30|May 2018|2018-05-31|June 11, 2012|Actual|2012-06-11|October 23, 2010|Actual|2010-10-23||Interventional|||Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer|A Phase II Study of Bortezomib (Velcade®, PS-341) and Docetaxel for Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|15|Actual|University of Southern California||1|||f||||t||||||||||2018-06-01 04:36:12.138846|2018-06-01 04:36:12.138846
NCT00183924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|March 2001||2001-03-31|May 2014|2014-05-31|December 2008|Actual|2008-12-31|July 2006|Actual|2006-07-31||Interventional|||Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.|A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.|Completed||Phase 2|20|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 04:36:12.208878|2018-06-01 04:36:12.208878
NCT00183911|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|November 2003||2003-11-30|May 2014|2014-05-31|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma|Phase II Study of Adjuvant Intraperitoneal FUDR Treatment Added to Chemoradiation (5-Fluorouracil/Leucovorin Plus Total Dose 4500 cGy of External Beam Radiotherapy) in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma|Completed||Phase 2|25|Anticipated|University of Southern California|||||f||||t||||||||||2018-06-01 04:36:12.320464|2018-06-01 04:36:12.320464
NCT00183898|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-03-28|2005-09-09|2005-09-16|Estimate|||||||2018-03-28|2018-03-30|Actual|December 28, 2004|Actual|2004-12-28|March 2018|2018-03-31|June 28, 2019|Anticipated|2019-06-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer|Phase II Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer|Active, not recruiting||Phase 2|75|Actual|University of Southern California||1|||f||||t|t|f|||f|||||2018-06-01 04:36:12.390288|2018-06-01 04:36:12.390288
NCT00183885|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-05-10|2005-09-09|2005-09-16|Estimate|||||||2018-05-10|2018-05-16|Actual|October 18, 2004|Actual|2004-10-18|May 2018|2018-05-31|May 28, 2019|Anticipated|2019-05-28|May 28, 2013|Actual|2013-05-28||Interventional|||A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma|A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C|Active, not recruiting||Phase 2|76|Actual|University of Southern California||1|||f||||t|t|f|||f|||||2018-06-01 04:36:12.468145|2018-06-01 04:36:12.468145
NCT00183872|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2018-01-21||2018-01-21|2005-09-09|2005-09-16|Estimate|2018-01-21|2018-02-16|Estimate||||2018-01-21|2018-02-16|Estimate|April 14, 2005|Actual|2005-04-14|December 2017|2017-12-31|October 20, 2015|Actual|2015-10-20|October 20, 2014|Actual|2014-10-20||Interventional|||Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma|Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma|Completed||Phase 2|40|Actual|University of Southern California||1|||f||||t|t|f|||f|||||2018-06-01 04:36:12.558101|2018-06-01 04:36:12.558101
NCT00183859|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|September 1999||1999-09-30|May 2014|2014-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan|Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan|Completed||Phase 1|42|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 04:36:12.905568|2018-06-01 04:36:12.905568
NCT00183846|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|December 2000||2000-12-31|May 2014|2014-05-31|July 2009|Actual|2009-07-31|October 2007|Actual|2007-10-31||Interventional|||Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers|Phase I Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers|Completed||Phase 1|22|Actual|University of Southern California|||||f||||||||||||||2018-06-01 04:36:12.986152|2018-06-01 04:36:12.986152
NCT00183833|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|December 2002||2002-12-31|May 2014|2014-05-31|August 2010|Actual|2010-08-31|July 2009|Actual|2009-07-31||Interventional|||Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors|Phase I/II Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors|Completed||Phase 1|40|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 04:36:13.061093|2018-06-01 04:36:13.061093
NCT00183820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-07-05|2005-09-09|2005-09-16|Estimate|||||||2017-07-05|2017-07-07|Actual|November 2004||2004-11-30|July 2017|2017-07-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|||Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma|A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma|Completed||Phase 2|30|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 04:36:13.123859|2018-06-01 04:36:13.123859
NCT00183807|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|October 2003||2003-10-31|May 2014|2014-05-31|March 2008|Actual|2008-03-31|February 2006|Actual|2006-02-28||Interventional|||A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer|A Phase II Study of Irinotecan (Camptosar), Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer|Terminated||Phase 2|6|Actual|University of Southern California||||Insufficient Accrual|f||||t||||||||||2018-06-01 04:36:13.190534|2018-06-01 04:36:13.190534
NCT00183794|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-10-06||2014-05-20|2005-09-09|2005-09-16|Estimate|2012-12-14|2013-01-25|Estimate||||2014-05-20|2014-05-22|Estimate|November 2002||2002-11-30|December 2012|2012-12-31|May 2010|Actual|2010-05-31|May 2009|Actual|2009-05-31||Interventional|||Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma|Phase II Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma|Completed||Phase 2|20|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 04:36:13.261956|2018-06-01 04:36:13.261956
NCT00183781|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-08-20|2005-09-14|2005-09-16|Estimate|||||||2013-08-20|2013-08-22|Estimate|September 2000||2000-09-30|August 2013|2013-08-31|June 2004|Actual|2004-06-30|||||Interventional|||Effectiveness of a Telephone Intervention Program in Improving Depression, Coping, and Family Functioning in HIV-Infected Individuals and Caregivers|Adapting to HIV Disease - A Family Intervention|Completed||Phase 3|270||Butler Hospital|||||f||||||||||||||2018-06-01 04:36:13.474823|2018-06-01 04:36:13.474823
NCT00183768|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-08-20|2005-09-14|2005-09-16|Estimate|||||||2013-08-20|2013-08-22|Estimate|September 1999||1999-09-30|August 2013|2013-08-31|February 2003|Actual|2003-02-28|||||Interventional|||Cognitive Behavioral Therapy Combined With Antidepressants to Reduce HIV Risk and Drug Relapse Among Depressed Intravenous Drug Users|Antidepressant Treatment to Reduce HIV Risk Among IDUs|Completed||Phase 3|175||Butler Hospital|||||f||||||||||||||2018-06-01 04:36:13.530629|2018-06-01 04:36:13.530629
NCT00183755|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2014-04-16|2005-09-14|2005-09-16|Estimate|||||||2014-04-16|2014-04-21|Estimate|April 2005||2005-04-30|April 2014|2014-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Understanding Brain Reward Responses in Individuals With Major Depressive Disorder|Neuroimaging Studies of Reward Processing in Depression|Completed|||87|Actual|Mclean Hospital|||2||f||||t||||||||||2018-06-01 04:36:13.587986|2018-06-01 04:36:13.587986
NCT00183742|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-09|2005-09-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|December 2000||2000-12-31|May 2014|2014-05-31|May 2006|Actual|2006-05-31|October 2005|Actual|2005-10-31||Interventional|||Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)|Phase I Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)|Completed||Phase 1|35||University of Southern California|||||f||||||||||||||2018-06-01 04:36:13.651534|2018-06-01 04:36:13.651534
NCT00183729|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2016-07-01||2017-12-18|2005-09-14|2005-09-16|Estimate|2016-10-20|2016-12-15|Estimate||||2017-12-18|2018-01-17|Actual|August 2005||2005-08-31|December 2017|2017-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults|Memantine for Enhancement of Rehabilitation Efficacy and Prevention of Major Depressive Disorder in Older Adults|Completed||Phase 4|35|Actual|University of Pittsburgh||2|||f||||f||||||||Yes|study has small sample size and is unlikely to be useful for data sharing efforts; however, interested researchers can contact the first author via email.|2018-06-01 04:36:13.843418|2018-06-01 04:36:13.843418
NCT00183716|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-07-20|2005-09-14|2005-09-16|Estimate|||||||2012-07-20|2012-07-23|Estimate|April 2004||2004-04-30|July 2012|2012-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|TREM||The Trauma Recovery and Empowerment Model for Treating Post-Traumatic Stress Disorder in Women|An Randomized Controlled Trial (RCT) of the Trauma Recovery and Empowerment Model|Completed||Phase 3|300|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 04:36:14.087939|2018-06-01 04:36:14.087939
NCT00183703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-03-21|2005-09-14|2005-09-16|Estimate|||||||2018-03-21|2018-03-23|Actual|July 2004||2004-07-31|March 2018|2018-03-31|August 2007|Actual|2007-08-31|November 2006|Actual|2006-11-30||Observational|||Understanding Treatment Adherence Among Individuals With Rapid Cycling Bipolar Disorder|Rapid Cycling Bipolar Disorder (RCBPD), Subjective Illness Experience and Gender|Completed|||40|Actual|Case Western Reserve University|||1||f||||f||||||||||2018-06-01 04:36:14.16175|2018-06-01 04:36:14.16175
NCT00183690|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-11|2005-09-13|2005-09-16|Estimate|||||||2008-12-11|2008-12-12|Estimate|September 2004||2004-09-30|December 2008|2008-12-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents|Treating Terror-Related PTSD in Adolescents|Completed||Phase 1|60|Actual|National Institute of Mental Health (NIMH)||2|||f||||t||||||||||2018-06-01 04:36:14.233879|2018-06-01 04:36:14.233879
NCT00183677|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-09-22||2016-11-04|2005-09-13|2005-09-16|Estimate|2016-11-04|2017-01-04|Estimate||||2016-11-04|2017-01-04|Estimate|July 2003||2003-07-31|November 2016|2016-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram|Biochemical Brain Changes Correlated With the Antidepressant Effect of Escitalopram: A Magnetic Resonance Spectroscopic Imaging Study|Completed||Phase 4|97|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:36:14.315381|2018-06-01 04:36:14.315381
NCT00183651|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-31|2005-09-13|2005-09-16|Estimate|||||||2012-01-31|2012-02-02|Estimate|April 2004||2004-04-30|January 2012|2012-01-31|June 2010|Actual|2010-06-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Suicidal Women With Borderline Personality Disorder|Assessment and Treatment of Parasuicidal Patients|Completed||Phase 2|99|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 04:36:14.478933|2018-06-01 04:36:14.478933
NCT00183638|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-26|2005-09-13|2005-09-16|Estimate|||||||2013-11-26|2013-11-27|Estimate|June 2003||2003-06-30|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|Youthnet||A Tailored Interactive Website for Promoting Condom Use Among Young Adults|Randomized Controlled Trial to Establish Efficacy of a Website to Promote Condom Use for Adults Aged 18-25|Completed||Phase 2|1870|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-06-01 04:36:14.56578|2018-06-01 04:36:14.56578
NCT00183625|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-05-21||2015-05-20|2005-09-13|2005-09-16|Estimate|2015-05-20|2015-06-10|Estimate||||2015-05-20|2015-06-10|Estimate|June 2000||2000-06-30|November 2005|2005-11-30|September 2006|Actual|2006-09-30|June 2005|Actual|2005-06-30||Interventional|||Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients|The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training|Completed||Phase 4|107|Actual|University of California, Los Angeles||4|||f||||t||||||||||2018-06-01 04:36:14.654502|2018-06-01 04:36:14.654502
NCT00183612|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-01-07|2005-09-13|2005-09-16|Estimate|||||||2014-01-07|2014-01-08|Estimate|May 2000||2000-05-31|January 2014|2014-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents|Developmental Pharmacokinetics of Psychotropic Drugs: Olanzapine|Terminated||N/A|68||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:14.880113|2018-06-01 04:36:14.880113
NCT00183573|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-06|2005-09-13|2005-09-16|Estimate|||||||2013-06-06|2013-06-07|Estimate|March 2004||2004-03-31|June 2013|2013-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||HIV Prevention Program for Patients Receiving Care at a Sexually Transmitted Diseases Clinic|HIV Prevention for STD Clinic Patients|Completed||Phase 2/Phase 3|1554|Actual|The Miriam Hospital||6|||f||||f||||||||||2018-06-01 04:36:16.068073|2018-06-01 04:36:16.068073
NCT00183560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-06-30|2005-09-13|2005-09-16|Estimate|||||||2015-06-30|2015-07-01|Estimate|July 2004||2004-07-31|June 2015|2015-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy|Prevention of Relapse in Recurrent Depression With MBCT|Completed||Phase 4|184|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-06-01 04:36:16.158313|2018-06-01 04:36:16.158313
NCT00183547|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-05-28|2005-09-13|2005-09-16|Estimate|||||||2013-05-28|2013-05-29|Estimate|January 2005||2005-01-31|December 2008|2008-12-31|September 2007||2007-09-30|March 2007|Actual|2007-03-31||Interventional|||Depression Prevention Program for American Indian Adolescents During and After Pregnancy|Depression Prevention in Pregnant American Indian Teens Using CBT|Completed||N/A|45||Johns Hopkins University||2|||f||||||||||||||2018-06-01 04:36:16.245089|2018-06-01 04:36:16.245089
NCT00183521|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-30|2005-09-13|2005-09-16|Estimate|||||||2011-11-30|2011-12-02|Estimate|March 2005||2005-03-31|November 2011|2011-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Breathing Regulation Training for Individuals With Panic Disorder|Respiratory Therapeutic Procedures in Panic Disorder|Completed||N/A|136|Actual|Stanford University||3|||f||||f||||||||||2018-06-01 04:36:16.317464|2018-06-01 04:36:16.317464
NCT00183508|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-11|2005-09-13|2005-09-16|Estimate|||||||2015-12-11|2015-12-14|Estimate||||December 2015|2015-12-31|May 2009|Actual|2009-05-31|December 2005|Actual|2005-12-31||Interventional|||Behavioral Treatments for Acute Stress Disorder In Firefighters|Developing Group Treatments for Acute Stress Disorder|Completed||N/A|169|Actual|Boston University||2|||f||||||||||||||2018-06-01 04:36:16.388945|2018-06-01 04:36:16.388945
NCT00183495|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-01|2005-09-13|2005-09-16|Estimate|||||||2013-07-01|2013-07-02|Estimate|March 2004||2004-03-31|June 2013|2013-06-30|August 2007|Actual|2007-08-31|March 2007|Actual|2007-03-31||Observational|||Understanding Treatment Adherence Among Individuals With Bipolar Disorder|Determinants and Manifestation of Illness Behavior in Promoting Treatment Adherence Among Individuals With Bipolar Depression|Completed|||140|Actual|Case Western Reserve University|||||f||||f||||||||||2018-06-01 04:36:16.461962|2018-06-01 04:36:16.461962
NCT00183482|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-11|2005-09-13|2005-09-16|Estimate|||||||2017-04-11|2017-04-12|Actual|August 1, 2010|Actual|2010-08-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Family Cognitive Behavioral Therapy for Preventing Depression in Children|Family Cognitive Behavioral Prevention of Depression in Children of Parents With a History of Major Depressive Disorder|Recruiting||N/A|750|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-06-01 04:36:16.521135|2018-06-01 04:36:16.521135
NCT00183469|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-04-10||2017-04-19|2005-09-13|2005-09-16|Estimate|2015-04-15|2015-04-20|Estimate||||2017-04-19|2017-05-17|Actual|December 2004||2004-12-31|April 2017|2017-04-30|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Maintenance Treatment of Bipolar Depression|Eight-Month Maintenance Treatment of Bipolar Depression With Lamotrigine or Lamotrigine Plus Divalproex Combination|Completed||Phase 4|86|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-06-01 04:36:16.644644|2018-06-01 04:36:16.644644
NCT00183456|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-09-14||2013-06-24|2005-09-13|2005-09-16|Estimate|2012-09-14|2012-10-18|Estimate||||2013-06-24|2013-06-28|Estimate|September 2005||2005-09-30|June 2013|2013-06-30|December 2009|Actual|2009-12-31|July 2007|Actual|2007-07-31||Interventional|||A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs|Network HIV Prevention Intervention for Drug Users|Completed||Phase 2|746|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||||||||||||2018-06-01 04:36:16.960232|2018-06-01 04:36:16.960232
NCT00183443|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-08|2005-09-13|2005-09-16|Estimate|||||||2013-10-08|2013-10-09|Estimate|February 2005||2005-02-28|October 2013|2013-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Treatment of Mania Symptoms With Drug Therapy|Divalproex Extended Release and Placebo, Lithium, or Quetiapine for Mania|Completed||Phase 3|75|Actual|Palo Alto Veterans Institute for Research||3|||f||||t||||||||||2018-06-01 04:36:17.492939|2018-06-01 04:36:17.492939
NCT00183430|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-10-22||2018-04-25|2005-09-13|2005-09-16|Estimate|2012-11-26|2012-11-27|Estimate||||2018-04-25|2018-05-23|Actual|October 2003||2003-10-31|April 2018|2018-04-30|December 2010|Actual|2010-12-31|May 2009|Actual|2009-05-31||Interventional|||Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder|Prazosin for Noncombat Trauma PTSD|Terminated||N/A|20|Actual|Seattle Institute for Biomedical and Clinical Research||2||Insufficient Enrollment|f||||t||||||||||2018-06-01 04:36:17.610497|2018-06-01 04:36:17.610497
NCT00183417|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-23|2005-09-13|2005-09-16|Estimate|||||||2012-04-23|2012-04-25|Estimate|September 2004||2004-09-30|April 2012|2012-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Depression Prevention Program for Adolescents|Depression Prevention Program for High-Risk Adolescents|Completed||N/A|350|Actual|University of Texas at Austin||4|||f||||||||||||||2018-06-01 04:36:17.929023|2018-06-01 04:36:17.929023
NCT00183404|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-08-14|2005-09-13|2005-09-16|Estimate|||||||2014-08-14|2014-08-15|Estimate|September 2004||2004-09-30|August 2014|2014-08-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Long-Term Olanzapine Treatment in Children With Autism|Long-Term Olanzapine Treatment in Children With Autism|Completed||Phase 2/Phase 3|32|Actual|Drexel University||1|||f||||t||||||||||2018-06-01 04:36:17.996848|2018-06-01 04:36:17.996848
NCT00183391|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-06|2005-09-13|2005-09-16|Estimate|||||||2009-04-06|2009-04-07|Estimate|July 2005||2005-07-31|April 2009|2009-04-30|November 2010|Anticipated|2010-11-30|November 2010|Anticipated|2010-11-30||Interventional|||Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children|Measuring and Predicting Response to Atomoxetine and Methylphenidate|Unknown status|Recruiting|Phase 3|160|Anticipated|National Institute of Mental Health (NIMH)||2|||f||||||||||||||2018-06-01 04:36:18.188215|2018-06-01 04:36:18.188215
NCT00183378|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-12|2005-09-13|2005-09-16|Estimate|||||||2012-01-12|2012-01-13|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|September 2009|Actual|2009-09-30||Interventional|||Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease|Behavioral Treatment of Nocturnal Disturbances in Alzheimer's Disease|Completed||N/A|132|Actual|University of Washington||4|||f||||t||||||||||2018-06-01 04:36:18.310165|2018-06-01 04:36:18.310165
NCT00183365|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-02-06|2005-09-12|2005-09-16|Estimate|||||||2014-02-06|2014-02-07|Estimate|October 2005||2005-10-31|February 2014|2014-02-28|November 2009|Actual|2009-11-30|July 2008|Actual|2008-07-31||Interventional|||Effect of Family-Based Prevention on Children of Depressed Parents|Children of Depressed Parents: Family-Based Prevention|Completed||Phase 1|42|Actual|Children's Hospital of Philadelphia||2|||f||||||||||||||2018-06-01 04:36:18.398777|2018-06-01 04:36:18.398777
NCT00183352|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-14|2005-09-12|2005-09-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|January 2004||2004-01-31|April 2009|2009-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Reproductive Function and Mood in Women With Bipolar Disorder|Reproductive Endocrine Function and Mood Over the Menstrual Cycle of Women Treated for Bipolar Disorder|Completed|||90|Anticipated|Stanford University|||2||f||||f||||||||||2018-06-01 04:36:18.470654|2018-06-01 04:36:18.470654
NCT00183339|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2013-09-10||2014-02-07|2005-09-12|2005-09-16|Estimate|2014-02-07|2014-03-26|Estimate||||2014-02-07|2014-03-26|Estimate|July 2005||2005-07-31|February 2014|2014-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Early Intervention With Fluoxetine in Autism|A Randomized, Placebo-controlled Trial of Fluoxetine in Preschool Children|Completed||Phase 2|18|Actual|University of North Carolina, Chapel Hill|It took twice as long to recruit subjects for a study in children 30-58 months than it generally takes to recruit older children. It is possible to maintain subjects in double-blind trails for extended periods.|2|||f||||t||||||||||2018-06-01 04:36:18.58355|2018-06-01 04:36:18.58355
NCT00183326|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-07-20|2005-09-12|2005-09-16|Estimate|||||||2015-07-20|2015-07-22|Estimate|May 2004||2004-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Treating Post Traumatic Stress Disorder in Children Exposed to Domestic Violence|Treating PTSD in Children Exposed to Domestic Violence|Completed||N/A|124|Actual|Allegheny Singer Research Institute||2|||f||||t||||||||||2018-06-01 04:36:19.000309|2018-06-01 04:36:19.000309
NCT00183313|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-18|2005-09-12|2005-09-16|Estimate|||||||2013-11-18|2013-11-19|Estimate|July 2004||2004-07-31|November 2013|2013-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Improving Primary Care in Patients With Mental Disorders|Improving Primary Care in Patients With Mental Disorders|Completed||Phase 3|407|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:36:19.082052|2018-06-01 04:36:19.082052
NCT00183300|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-02|2005-09-12|2005-09-16|Estimate|||||||2015-10-02|2015-10-06|Estimate|September 2001||2001-09-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Relationship Between the Biological and Psychological Correlates of PTSD|Effectiveness of Prolonged Exposure Therapy on Reducing Neuroendocrine-Related Symptoms of Post-Traumatic Stress Disorder in Women|Completed||Phase 2|120||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:36:19.161342|2018-06-01 04:36:19.161342
NCT00183287|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-25|2005-09-13|2005-09-16|Estimate|||||||2012-04-25|2012-04-26|Estimate||||April 2012|2012-04-30|March 2003|Actual|2003-03-31|||||Observational|||Long Term Follow-Up of HIV Infected Patients Who Have Previously Participated in HIV Clinical Trials|Clinical, Virologic, and Immunologic Evaluation and Monitoring of Patients With Known or Suspected HIV Infection|Completed|||150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||Samples With DNA|"~     Blood collection~   "|||2018-06-01 04:36:19.221483|2018-06-01 04:36:19.221483
NCT00183274|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-12-14||2016-11-29|2005-09-12|2005-09-16|Estimate|2016-10-06|2016-11-30|Estimate||||2016-11-29|2017-01-16|Estimate|January 2004||2004-01-31|November 2016|2016-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||334 participants were consented, but 64 withdrew consent and 2 deviated from protocol, resulting in 268 participants who entered the initial Phase 1.|Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR|Short-term Versus Long-term Treatment in Generalized Anxiety Disorder|Completed||Phase 4|268|Actual|University of Pennsylvania|Increased attrition occurring as a function of trial length|6|||f||||t||||||||No||2018-06-01 04:36:19.282024|2018-06-01 04:36:19.282024
NCT00183261|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-07|2005-09-13|2005-09-16|Estimate|||||||2013-06-07|2013-06-11|Estimate|March 2006||2006-03-31|June 2013|2013-06-30|October 2010|Actual|2010-10-31|August 2007|Actual|2007-08-31||Interventional|||Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection|A Randomized Phase II Study of Therapeutic Immunization and Treatment Interruption Among Subjects Who Began Potent Antiretroviral Therapy Within 30 Days of Diagnosis of Acute or Recent HIV Infection|Completed||Phase 2|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:36:19.557154|2018-06-01 04:36:19.557154
NCT00183248|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|2012-04-05||2012-09-17|2005-09-11|2005-09-16|Estimate|2012-05-18|2012-06-21|Estimate||||2012-09-17|2012-10-02|Estimate|September 2004||2004-09-30|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients|Pilot Study Using Donor Stem Cells and Campath-1H to Induce Renal Transplant Tolerance (ITN022ST)|Completed||Phase 1/Phase 2|9|Actual|University of Miami|In July 2007 after the trial had been enrolling for approximately 42 months, enrollment was stopped at the current number of nine subjects due to time and resource constraints.|2|||f||||t||||||||||2018-06-01 04:36:19.678537|2018-06-01 04:36:19.678537
NCT00183235|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-04|2005-09-13|2005-09-16|Estimate|||||||2010-05-04|2010-05-05|Estimate|June 2005||2005-06-30|May 2010|2010-05-31|February 2006|Actual|2006-02-28|||||Interventional|||Aripiprazole Effects on Alcohol Reactivity and Consumption|Effectiveness of Aripiprazole to Reduce Craving for Alcohol and Drinking Under Natural Observation, During Cue Induced Brain Imaging, and During a Motivated Free Choice Drinking Procedure Compared to Placebo|Completed||Phase 2|30||Medical University of South Carolina|||||f||||||||||||||2018-06-01 04:36:20.256082|2018-06-01 04:36:20.256082
NCT00183222|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-04|2005-09-13|2005-09-16|Estimate|||||||2010-05-04|2010-05-05|Estimate|May 2005||2005-05-31|May 2010|2010-05-31|December 2005|Actual|2005-12-31|||||Interventional|||Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking|Alcohol Research Center Grant. Component #1. COMBINING MEDICATIONS: ALCOHOL REACTIVITY AND CONSUMPTION|Completed||Phase 2|160||Medical University of South Carolina|||||f||||||||||||||2018-06-01 04:36:20.329625|2018-06-01 04:36:20.329625
NCT00183209|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-01-31|2005-09-13|2005-09-16|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2001||2001-12-31|January 2018|2018-01-31|January 2008|Actual|2008-01-31|July 2006|Actual|2006-07-31||Interventional|||Interventions for HIV+ Mothers With Problem Drinking|Interventions for HIV+ Mothers With Problem Drinking|Completed||N/A|118|Actual|New York University||2|||f||||f||||||||||2018-06-01 04:36:20.39394|2018-06-01 04:36:20.39394
NCT00183196|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-11-20||2016-03-17|2005-09-13|2005-09-16|Estimate|2013-04-23|2013-05-30|Estimate||||2016-03-17|2016-04-15|Estimate|January 2003||2003-01-31|March 2016|2016-03-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone|Gabapentin as an Adjunct to Naltrexone for Alcoholism|Completed||Phase 3|150|Actual|Medical University of South Carolina||3|||f||||f||||||||||2018-06-01 04:36:20.484169|2018-06-01 04:36:20.484169
NCT00183183|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-05-21|2005-09-12|2005-09-16|Estimate|||||||2010-05-21|2010-05-24|Estimate|April 2004||2004-04-30|May 2010|2010-05-31|December 2005|Actual|2005-12-31|||||Interventional|||Impact of a Brief Motivational Interview on Drinking Behaviors of At Risk Drinkers Screened in the Emergency Room|Alcohol Screening and Brief Intervention in the Emergency Department|Completed||Phase 3|1137|Actual|UConn Health|||||f||||||||||||||2018-06-01 04:36:20.793585|2018-06-01 04:36:20.793585
NCT00183170|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-14|2005-09-13|2005-09-16|Estimate|||||||2007-06-14|2007-06-18|Estimate|February 2004||2004-02-29|June 2007|2007-06-30|January 2009|Anticipated|2009-01-31|||||Interventional|||Residual Effects of Intoxication on Student Performance|Residual Effects of Intoxication on Student Performance|Unknown status|Recruiting|Phase 2|200|Anticipated|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 04:36:20.886967|2018-06-01 04:36:20.886967
NCT00183157|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-02-12|2005-09-12|2005-09-16|Estimate|||||||2009-02-12|2009-02-13|Estimate|October 2004||2004-10-31|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Project RAP: Reaching Adolescents for Prevention|RAP: Reaching Adolescents for Prevention - A Randomized Trial of a Brief Negotiated Interview and Active Referral to Reduce Alcohol Related Morbidity Among Youth and Young Adults in the Pediatric Emergency Department|Unknown status|Recruiting|Phase 2|1400|Anticipated|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||3|||f||||||||||||||2018-06-01 04:36:20.973654|2018-06-01 04:36:20.973654
NCT00183144|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-18|2005-09-13|2005-09-16|Estimate|||||||2010-05-18|2010-05-19|Estimate|November 2001||2001-11-30|October 2007|2007-10-31|April 2006|Actual|2006-04-30|||||Interventional|||A Therapeutic Workplace for Alcohol Dependence|A Therapeutic Workplace for Alcohol Dependence|Completed||Phase 2|156||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:21.085102|2018-06-01 04:36:21.085102
NCT00183131|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-05-05|2005-09-09|2005-09-16|Estimate|||||||2010-05-05|2010-05-06|Estimate|October 2004||2004-10-31|December 2007|2007-12-31|November 2004|Actual|2004-11-30|||||Interventional|||The iHealth Study in College Students|Internet Screening and Brief Intervention for Hazardous Drinking in College Students: A Pilot Study|Completed||Phase 2|4300||Boston Medical Center|||||f||||||||||||||2018-06-01 04:36:21.157465|2018-06-01 04:36:21.157465
NCT00183118|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-07-19|2005-09-09|2005-09-16|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2004||2004-10-31|July 2017|2017-07-31|December 2005|Actual|2005-12-31|||||Interventional|||Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)|HIV Prevention Partnership in Russian Alcohol Treatment|Completed||Phase 1/Phase 2|180|Actual|Boston Medical Center|||||f||||f|f|f||||||||2018-06-01 04:36:21.24097|2018-06-01 04:36:21.24097
NCT00183105|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-05-05|2005-09-09|2005-09-16|Estimate|||||||2010-05-05|2010-05-06|Estimate|February 2001||2001-02-28|December 2007|2007-12-31|April 2006|Actual|2006-04-30|||||Interventional|||ASAP Study - Hospital-Based Brief Intervention for Alcohol Problems|Hospital-based Brief Intervention for Alcohol Problems|Completed||Phase 3|350||Boston Medical Center|||||f||||||||||||||2018-06-01 04:36:21.310313|2018-06-01 04:36:21.310313
NCT00183092|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2014-01-21||2014-05-28|2005-09-14|2005-09-16|Estimate|2014-04-29|2014-05-29|Estimate||||2014-05-28|2014-06-09|Estimate|April 2005||2005-04-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||CJD (Creutzfeldt-Jakob Disease) Quinacrine Study|Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease|Completed||Phase 2|69|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:36:21.401689|2018-06-01 04:36:21.401689
NCT00183079|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-11-05|2005-09-09|2005-09-16|Estimate|||||||2014-11-05|2014-11-07|Estimate|March 2004||2004-03-31|October 2008|2008-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Reducing Alcohol Use in Depressed Patients|Brief Alcohol Intervention With Depressed Patients|Completed||Phase 2|200|Actual|Rhode Island Hospital||1|||f||||||||||||||2018-06-01 04:36:21.822272|2018-06-01 04:36:21.822272
NCT00183066|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-03|2005-09-14|2005-09-16|Estimate|||||||2012-08-03|2012-08-06|Estimate|July 2002||2002-07-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Collection of Bone Marrow Aspirate From Volunteer Donors|Collection of Bone Marrow Aspirate From Volunteer Donors for In Vitro Hematopoietic Research|Completed|||63|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||Samples With DNA|"~     Bone marrow aspirates Whole blood~   "|||2018-06-01 04:36:21.886188|2018-06-01 04:36:21.886188
NCT00183053|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-10-29|2005-09-13|2005-09-16|Estimate|||||||2009-10-29|2009-11-02|Estimate|May 2006||2006-05-31|October 2009|2009-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Proximity Alarms to Reduce Patient Falls|Trial of Proximity Alarms to Reduce Patient Falls|Completed||N/A|10000|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:21.942123|2018-06-01 04:36:21.942123
NCT00183040|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-28|2005-09-13|2005-09-16|Estimate|||||||2009-05-28|2009-06-02|Estimate|September 2002||2002-09-30|May 2009|2009-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||HORMA: Hormonal Regulators of Muscle and Metabolism in Aging|Hormonal Regulators of Muscle and Metabolism in Aging|Completed||Phase 2|108|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.077544|2018-06-01 04:36:22.077544
NCT00183027|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-08|2005-09-13|2005-09-16|Estimate|||||||2006-11-08|2006-11-09|Estimate|November 2002||2002-11-30|November 2006|2006-11-30|December 2004||2004-12-31|||||Interventional|||Dietary Energy Restriction and Metabolic Aging in Humans|Dietary Energy Restriction and Metabolic Aging in Humans|Completed||N/A|44||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.141496|2018-06-01 04:36:22.141496
NCT00183014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-16|2005-09-13|2005-09-16|Estimate|||||||2012-05-16|2012-05-18|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Caminemos! Trial to Increase Walking Among Sedentary Older Latinos|Trial to Increase Walking Among Sedentary Older Latinos|Completed||N/A|600|Anticipated|National Institute on Aging (NIA)||2|||f||||||||||||||2018-06-01 04:36:22.199084|2018-06-01 04:36:22.199084
NCT00183001|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-02-13|2005-09-13|2005-09-16|Estimate|||||||2009-02-13|2009-02-16|Estimate|October 2001||2001-10-31|February 2009|2009-02-28|October 2006||2006-10-31|||||Interventional|||Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification|Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification|Completed||Phase 3|452||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.267706|2018-06-01 04:36:22.267706
NCT00182988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-11-24|2005-09-13|2005-09-16|Estimate|||||||2009-11-24|2009-11-25|Estimate|October 2004||2004-10-31|November 2009|2009-11-30|December 2007|Actual|2007-12-31|||||Observational|||Alzheimer's Caregiver Communication Study|Alzheimer's Caregiver Ratings of Communication & Coping Behavior|Completed|||140|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.388668|2018-06-01 04:36:22.388668
NCT00182975|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-08-21|2005-09-13|2005-09-16|Estimate|||||||2008-08-21|2008-08-25|Estimate|September 2002||2002-09-30|August 2008|2008-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effects of Dehydroepiandrosterone (DHEA) in Humans|Is DHEA Replacement Beneficial?|Completed||Phase 3|142|Actual|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.446015|2018-06-01 04:36:22.446015
NCT00182962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-16|2005-09-13|2005-09-16|Estimate|||||||2006-11-16|2006-11-20|Estimate|March 2002||2002-03-31|November 2006|2006-11-30|October 2006||2006-10-31|||||Interventional|||GRACE: Geriatric Resources for Assessment and Care of Elders|Geriatric Resources for Assessment and Care of Elders|Completed||N/A|1270||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.510421|2018-06-01 04:36:22.510421
NCT00182949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-04|2005-09-13|2005-09-16|Estimate|||||||2018-04-04|2018-04-05|Actual|November 19, 2003||2003-11-19|January 2, 2015|2015-01-02|January 2, 2015||2015-01-02|||||Observational|||Genetics and Epidemiology of Aging Associated Conditions in the Sardinian Population|Genetics and Epidemiology of Aging Associated Conditions in the Sardinian Population (SARDINIA)|Completed|||6926|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:36:22.579494|2018-06-01 04:36:22.579494
NCT00182936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-16|2005-09-13|2005-09-16|Estimate|||||||2006-11-16|2006-11-20|Estimate|May 2000||2000-05-31|November 2006|2006-11-30|June 2004||2004-06-30|||||Interventional|||A Trial to Reduce Delirium in Aged Post Acute Patients|A Trial to Reduce Delirium in Aged Post Acute Patients|Completed||Phase 3|500||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.642909|2018-06-01 04:36:22.642909
NCT00182923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-08-28|2005-09-12|2005-09-16|Estimate|||||||2008-08-28|2008-08-29|Estimate|May 2003||2003-05-31|August 2008|2008-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Forearm Vascular Relaxation|Determinants of Forearm Vascular Relaxation: Role of Genetic Polymorphisms|Completed|||400||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.718258|2018-06-01 04:36:22.718258
NCT00182897|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-09|2005-09-12|2005-09-16|Estimate|||||||2006-11-09|2006-11-14|Estimate|October 2000||2000-10-31|November 2006|2006-11-30|November 2005||2005-11-30|||||Interventional|||PACT: Providers and Alzheimer's Caregivers Together|Providers and Alzheimer's Caregivers Together|Completed||N/A|120||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.776747|2018-06-01 04:36:22.776747
NCT00182884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-02-28|2005-09-09|2005-09-16|Estimate|||||||2008-02-28|2008-03-03|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Donepezil in Preventing Delirium in Hospitalized Elderly|Preventing Delirium in Hospitalized Elderly|Completed||Phase 4|30||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.837326|2018-06-01 04:36:22.837326
NCT00182871|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-10-29|2005-09-12|2005-09-16|Estimate|||||||2009-10-29|2009-10-30|Estimate|November 2001||2001-11-30|October 2009|2009-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Testosterone Effects on Bone and Frailty|Testosterone Effects on Bone and Frailty in Men With Osteoporosis|Completed||Phase 4|140||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:22.90604|2018-06-01 04:36:22.90604
NCT00182858|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-03-01|2005-09-12|2005-09-16|Estimate|||||||2018-03-01|2018-03-02|Actual|February 10, 2003||2003-02-10|February 28, 2018|2018-02-28|December 31, 2022||2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Gerontology Research Center Tissue Procurement for Biomedical Research|Tissue Procurement for Biomedical Research|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:36:22.976722|2018-06-01 04:36:22.976722
NCT00182845|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-02-28|2005-09-09|2005-09-16|Estimate|||||||2008-02-28|2008-03-03|Estimate|February 2005||2005-02-28|February 2008|2008-02-29|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Donepezil in the Prevention of Post-Operative Cognitive Decline|Preventing Post-Operative Cognitive Decline|Completed||Phase 4|30||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:36:23.061382|2018-06-01 04:36:23.061382
NCT00182832|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-04-11|2005-09-09|2005-09-16|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2006||2006-06-30|April 2016|2016-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems|Enhancing Care for Hospitalized Older Adults With Cognitive Impairment|Completed||N/A|424|Actual|Indiana University||2|||f||||f||||||||||2018-06-01 04:36:23.147397|2018-06-01 04:36:23.147397
NCT00182819|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-10-11|2005-09-15|2005-09-16|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|||Radiation Therapy or Temozolomide in Treating Patients With Gliomas|Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study|Completed||Phase 3|709|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 04:36:23.248043|2018-06-01 04:36:23.248043
NCT00182806|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2012-03-05|2005-09-15|2005-09-16|Estimate|||||||2012-03-05|2012-03-06|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|||Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Irinotecan Followed by Gemcitabine in NSCLC Following Failure of Platinum Based Therapy|Completed||Phase 2|38|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 04:36:23.454485|2018-06-01 04:36:23.454485
NCT00182793|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2017-01-31||2017-01-31|2005-09-15|2005-09-16|Estimate|2017-01-31|2017-02-23|Actual||||2017-01-31|2017-02-23|Actual|July 2005||2005-07-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer|Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) ± Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer|Completed||Phase 2|32|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-06-01 04:36:23.546321|2018-06-01 04:36:23.546321
NCT00182780|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-10-27|2005-09-15|2005-09-16|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2005||2005-10-31|October 2017|2017-10-31|April 2010|Actual|2010-04-30|September 5, 2006|Actual|2006-09-05||Interventional|||American Ginseng in Treating Patients With Cancer-Related Fatigue|The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Dose-Finding, Placebo-Controlled Study|Completed||N/A|290|Actual|Alliance for Clinical Trials in Oncology||4|||f||||f||||||||||2018-06-01 04:36:23.865289|2018-06-01 04:36:23.865289
NCT00182767|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2015-06-17||2016-02-11|2005-09-15|2005-09-16|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|January 2006||2006-01-31|February 2014|2014-02-28|May 2014|Actual|2014-05-31|April 2012|Actual|2012-04-30||Interventional|||Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer|A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients With Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated With a Platinum and a Taxane|Completed||Phase 1/Phase 2|45|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:36:23.959534|2018-06-01 04:36:23.959534
NCT00182754|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2017-02-28||2017-02-28|2005-09-15|2005-09-16|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|October 2005||2005-10-31|February 2017|2017-02-28|March 2013|Actual|2013-03-31|September 2009|Actual|2009-09-30||Interventional|||Octreotide in Treating Patients With Cancer-Related Malignant Ascites|An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LARDepot) for Symptomatic Ascites in Cancer Patients|Completed||Phase 3|33|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 04:36:24.959163|2018-06-01 04:36:24.959163
NCT00182741|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-05-01|2005-09-15|2005-09-16|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2004||2004-09-30|May 2017|2017-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer|Phase II Study of DN-101 (High Dose Pulse Calcitriol), Mitoxantrone, Prednisone in Androgen-Independent Prostate Cancer (AIPC)|Completed||Phase 2|19|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 04:36:25.46663|2018-06-01 04:36:25.46663
NCT00182728|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2017-03-20||2017-06-14|2005-09-15|2005-09-16|Estimate|2017-05-18|2017-06-14|Actual||||2017-06-14|2017-07-11|Actual|March 18, 2003|Actual|2003-03-18|June 2017|2017-06-30|July 2, 2027|Anticipated|2027-07-02|September 2011|Actual|2011-09-30||Interventional|NRR||Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer|Partial Breast Treatment Using Single Dose Intraoperative Radiotherapy for Patients With Early Stage Breast Cancer - A Feasibility Study With Molecular Analysis of Tumors and Normal Breast Epithelial Tissue|Active, not recruiting||N/A|89|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 04:36:25.556296|2018-06-01 04:36:25.556296
NCT00182715|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-09-16|2005-09-15|2005-09-16|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2005||2005-03-31|December 2007|2007-12-31||||May 2009|Anticipated|2009-05-31||Interventional|||Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Metastatic Colorectal Cancer (COIN)|Unknown status|Active, not recruiting|Phase 3|2421|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:36:25.798456|2018-06-01 04:36:25.798456
NCT00182702|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-03-22|2005-09-15|2005-09-16|Estimate|||||||2013-03-22|2013-03-25|Estimate|July 2005||2005-07-31|January 2013|2013-01-31||||September 2007|Actual|2007-09-30||Interventional|||Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer|A Phase II Trial of BMS 247550 (Ixabepilone) in Advanced Renal Cell Carcinoma|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:36:26.867496|2018-06-01 04:36:26.867496
NCT00182689|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2012-08-20||2014-05-06|2005-09-15|2005-09-16|Estimate|2012-08-20|2012-09-19|Estimate||||2014-05-06|2014-05-21|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer|A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|89|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:36:26.970355|2018-06-01 04:36:26.970355
NCT00182663|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-06-22|2005-09-15|2005-09-16|Estimate|||||||2017-06-22|2017-06-26|Actual|June 2003||2003-06-30|April 2017|2017-04-30||||April 2007|Actual|2007-04-30||Interventional|||Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant|Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma|Completed||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 04:36:27.677129|2018-06-01 04:36:27.677129
NCT00182650|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-12-23|2005-09-15|2005-09-16|Estimate|||||||2009-12-23|2009-12-29|Estimate|June 2004||2004-06-30|December 2009|2009-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma|Pilot/Feasibility Study To Evaluate The Safety Of Cellular Immunotherapy For CD19+ Follicular Lymphoma Using Autologous Cytolytic T Cells Genetically-Modified To Be CD19-Specific And Co-Express HyTK|Completed||Phase 1|5|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 04:36:27.767346|2018-06-01 04:36:27.767346
NCT00182637|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2016-01-19||2016-01-19|2005-09-15|2005-09-16|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|July 2004||2004-07-31|January 2016|2016-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma|A Phase II Study of Bortezomib (VELCADE®) in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)|Completed||Phase 2|5|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:36:27.841128|2018-06-01 04:36:27.841128
NCT00182624|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2017-06-30|2005-09-15|2005-09-16|Estimate|||||||2017-06-30|2017-07-02|Actual|February 2, 2004||2004-02-02|September 6, 2007|2007-09-06|September 6, 2007||2007-09-06|||||Observational|||Magnetic Resonance Imaging to Evaluate Prostate Cancer|Comprehensive Prostate MRI for the Evaluation of Prostate Cancer at 3.0T: A Pilot Study|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:36:28.04074|2018-06-01 04:36:28.04074
NCT00182611|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-06-25|2005-09-15|2005-09-16|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2004||2004-04-30|November 2008|2008-11-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer|Phase III Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Potentially Resectable Stage III Advanced Gastric Cancer|Completed||Phase 3|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:36:28.097797|2018-06-01 04:36:28.097797
NCT00182598|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-08-11|2005-09-10|2005-09-16|Estimate|||||||2008-08-11|2008-08-13|Estimate|December 2004||2004-12-31|August 2008|2008-08-31||||||||Interventional|||Applying Web Technology to Buprenorphine Treatment|Applying Web Technology to Buprenorphine Treatment|Unknown status|Recruiting|N/A|90|Anticipated|National Development and Research Institutes, Inc.|||||f||||||||||||||2018-06-01 04:36:28.170319|2018-06-01 04:36:28.170319
NCT00182585|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-08-11|2005-09-10|2005-09-16|Estimate|||||||2008-08-11|2008-08-13|Estimate|August 2004||2004-08-31|August 2008|2008-08-31||||||||Interventional|||Computer-Assisted HIV Prevention for Young Drug Users|Computer-Assisted HIV Prevention for Young Drug Users|Unknown status|Active, not recruiting|N/A|56|Anticipated|National Development and Research Institutes, Inc.|||||f||||||||||||||2018-06-01 04:36:28.246683|2018-06-01 04:36:28.246683
NCT00182572|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-08-11|2005-09-10|2005-09-16|Estimate|||||||2008-08-11|2008-08-12|Estimate|July 2005||2005-07-31|August 2008|2008-08-31||||||||Interventional|||Science-Based Treatment for Opioid-Dependent Adolescents|Science-Based Treatment for Opioid-Dependent Adolescents|Unknown status|Recruiting|Phase 2|80|Anticipated|National Development and Research Institutes, Inc.|||||||||||||||||||2018-06-01 04:36:28.31012|2018-06-01 04:36:28.31012
NCT00182559|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2014-02-04|2005-09-10|2005-09-16|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2004||2004-04-30|February 2014|2014-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Vienna Prograf and Endothelial Progenitor Cell Study|The Vienna Prograf and Endothelial Progenitor Cell Study|Completed||Phase 4|148|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-06-01 04:36:28.410192|2018-06-01 04:36:28.410192
NCT00182546|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-04-27|2005-09-15|2005-09-16|Estimate|||||||2006-04-27|2006-05-03|Estimate|August 1998||1998-08-31|August 2005|2005-08-31|January 2001||2001-01-31|||||Interventional|||Canadian Pulmonary Embolism Diagnosis Study (CANPEDS)|Canadian Pulmonary Embolism Diagnosis Study|Terminated||Phase 3|1126||McMaster University|||||f||||||||||||||2018-06-01 04:36:28.487298|2018-06-01 04:36:28.487298
NCT00182533|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-03-20|2005-09-14|2005-09-16|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2002||2002-07-31|March 2017|2017-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders|Sertraline in the Treatment of Generalized Social Phobia With Comorbidity|Terminated||Phase 4|170|Anticipated|McMaster University||2||Study drug could not be re-supplied|f||||f||||||||||2018-06-01 04:36:28.558391|2018-06-01 04:36:28.558391
NCT00182520|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-04-09|2005-09-14|2005-09-16|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2002||2002-01-31|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)|A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder|Recruiting||Phase 4|48|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 04:36:28.740808|2018-06-01 04:36:28.740808
NCT00182507|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-09-08|2005-09-14|2005-09-16|Estimate|||||||2006-09-08|2006-09-11|Estimate|June 2000||2000-06-30|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Olanzapine in the Treatment of Hair Pulling (Trichotillomania)|A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania|Completed||Phase 4|34||McMaster University|||||f||||||||||||||2018-06-01 04:36:28.820962|2018-06-01 04:36:28.820962
NCT00182494|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-16|Estimate|||||||2005-09-14|2005-09-16|Estimate|February 2005||2005-02-28|July 2005|2005-07-31|January 2009||2009-01-31|||||Interventional|||Diabetes Prevention Program in Schizophrenia [DPPS]|A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus.|Unknown status|Recruiting|Phase 4|200||McMaster University|||||f||||||||||||||2018-06-01 04:36:28.886161|2018-06-01 04:36:28.886161
NCT00182481|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-15|2005-09-12|2005-09-16|Estimate|||||||2005-12-15|2005-12-16|Estimate|September 1999||1999-09-30|October 2003|2003-10-31|September 2001||2001-09-30|||||Interventional|||LOMA: Long-Term Management of Asthma|Long Term Management of Asthma (LOMA) Study- How Useful is the Sputum Count Compared With the Usual Clincal Variables?|Completed||N/A|112||McMaster University|||||f||||||||||||||2018-06-01 04:36:28.961344|2018-06-01 04:36:28.961344
NCT00182468|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-09-08|2005-09-13|2005-09-16|Estimate|||||||2009-09-08|2009-09-09|Estimate|April 2005||2005-04-30|September 2009|2009-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Does Routine Screening for Intimate Partner Violence Against Women in Health Care Settings do More Good Than Harm?|If, When and How to Ask the Question(s): Assessing Screening Approaches to Identifying Woman Abuse in Health Care Settings|Completed||N/A|5681|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 04:36:29.051985|2018-06-01 04:36:29.051985
NCT00182455|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2018-04-09|2005-09-14|2005-09-16|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2004||2004-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)|Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial.|Recruiting||Phase 4|48|Anticipated|McMaster University||2|||f||||f||||||||||2018-06-01 04:36:29.160438|2018-06-01 04:36:29.160438
NCT00182442|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2006-10-10|2005-09-14|2005-09-16|Estimate|||||||2006-10-10|2006-10-11|Estimate|October 2003||2003-10-31|March 2005|2005-03-31|March 2006||2006-03-31|||||Interventional|||Cognition, Functioning and Quality of Life|A One-Year Multi-Centre Randomized, Double Blind, Controlled Effectiveness Study of Quetiapine and Olanzapine, Comparing Their Relative Potential in Improving Neuro-Cognitive Deficits, Functional Outcomes and Quality of Life in Schizophrenia|Completed||Phase 4|80||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.250397|2018-06-01 04:36:29.250397
NCT00182429|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-04-12|2005-09-13|2005-09-16|Estimate|||||||2016-04-12|2016-04-14|Estimate|February 2004||2004-02-29|April 2016|2016-04-30|April 2005||2005-04-30|||||Interventional|||Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment|Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD)|Completed||Phase 3|100||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.314738|2018-06-01 04:36:29.314738
NCT00182416|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-10-18|2005-09-13|2005-09-16|Estimate|||||||2007-10-18|2007-10-19|Estimate|May 2004||2004-05-31|October 2007|2007-10-31|January 2006|Actual|2006-01-31|||||Interventional|||Second Canadian Trial of Physiologic Pacing (CTOPP II): Pilot Trial|Second Canadian Trial of Physiologic Pacing (CTOPP II): Pilot Trial|Completed||Phase 3|300||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.389046|2018-06-01 04:36:29.389046
NCT00182403|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-06|2005-09-13|2005-09-16|Estimate|||||||2017-06-06|2017-06-07|Actual|September 1998||1998-09-30|June 2017|2017-06-30|May 2004||2004-05-31|||||Interventional|||Fixed Dose Heparin Study|Fixed Dose Unfractionated Heparin for Initial Treatment of Venous Thromboembolism|Completed||Phase 3|866||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.459656|2018-06-01 04:36:29.459656
NCT00182390|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-22|2005-09-13|2005-09-16|Estimate|||||||2015-09-22|2015-09-24|Estimate|February 2001||2001-02-28|September 2015|2015-09-30|November 2005|Actual|2005-11-30|February 2003|Actual|2003-02-28||Interventional|||Premature Infants in Need of Transfusion (PINT)|A Randomized Controlled Trial of Two Hemoglobin Thresholds for Transfusion in Newborns <1000g Birth Weight|Completed||Phase 3|424||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.551817|2018-06-01 04:36:29.551817
NCT00182377|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-19|2005-09-13|2005-09-16|Estimate|||||||2007-09-19|2007-09-20|Estimate||||September 2004|2004-09-30||||||||Interventional|||Pentastarch Use in Cardiac Surgery|A Randomized, Prospective, Blinded Clinical Trial to Evaluate the Efficacy and Safety of Pentastarch Use in Patients Undergoing Coronary Artery Bypass Surgery or Valve Replacement Surgery Using Cardiopulmonary Bypass Circuits|Unknown status|Recruiting|N/A|||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.646935|2018-06-01 04:36:29.646935
NCT00182364|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2006-11-16|2005-09-10|2005-09-16|Estimate|||||||2006-11-16|2006-11-17|Estimate|February 2003||2003-02-28|November 2006|2006-11-30|February 2004||2004-02-29|||||Interventional|||PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)|PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)|Completed||Phase 3|120||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.713676|2018-06-01 04:36:29.713676
NCT00182351|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-07|2005-09-13|2005-09-16|Estimate|||||||2006-09-07|2006-09-08|Estimate|April 1996||1996-04-30|September 2006|2006-09-30|July 1999||1999-07-31|||||Interventional|||D-Dimer Vs Serial Compression Ultrasound Study|Evaluation of the Safety, Efficacy and Cost-Effectiveness of Two Strategies for the Diagnosis of Deep Vein Thrombosis|Completed||Phase 3|810||McMaster University|||||f||||||||||||||2018-06-01 04:36:29.791367|2018-06-01 04:36:29.791367
NCT00182338|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-19|2005-09-13|2005-09-16|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2005||2005-01-31|July 2011|2011-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Evaluation of Volume Status in Peritoneal Dialysis Patients|Evaluation of Volume Status in Peritoneal Dialysis Patients|Completed|||22|Actual|McMaster University|||1||f||||f||||||||||2018-06-01 04:36:29.856225|2018-06-01 04:36:29.856225
NCT00182325|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-18|2005-09-13|2005-09-16|Estimate|||||||2007-04-18|2007-04-19|Estimate|February 2004||2004-02-29|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Effects of a Personalized Web-Based Antenatal Care Planner|Women's Web Access to Their Own Antenatal Health Record and Personalized Health Information: Effect on Pregnancy Health Outcomes and Patient Satisfaction|Completed||Phase 3|210||McMaster University|||||f||||f||||||||||2018-06-01 04:36:29.913638|2018-06-01 04:36:29.913638
NCT00182312|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-03-20|2005-09-13|2005-09-16|Estimate|||||||2018-03-20|2018-03-22|Actual|October 1999||1999-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|March 2007|Actual|2007-03-31||Interventional|||Caffeine for Apnea of Prematurity (CAP)|Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants|Completed||Phase 3|2000|Anticipated|McMaster University|||||f||||t||||||||||2018-06-01 04:36:30.015536|2018-06-01 04:36:30.015536
NCT00182299|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-19|2005-09-13|2005-09-16|Estimate|||||||2007-04-19|2007-04-20|Estimate|September 2003||2003-09-30|April 2007|2007-04-30|April 2008|Anticipated|2008-04-30|||||Interventional|||An RCT to Compare the Outcomes of Patients With Large Rotator Cuff Repair That Undergo Repair With or Without SIS|A Randomized Clinical Trial Comparing the Effectiveness of Rotator Cuff Repair With or Without Augmentation With Porcine Small Intestine Submucosa (SIS) for Large Rotator Cuff Tears: Pilot Study Phase|Unknown status|Active, not recruiting|Phase 4|60||McMaster University|||||f||||t||||||||||2018-06-01 04:36:30.205252|2018-06-01 04:36:30.205252
NCT00182286|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|September 1999||1999-09-30|August 2005|2005-08-31|July 2001||2001-07-31|||||Observational|||Evaluation of Continuity of Care at a Health Service Organization|The Evaluation of the Continuity of Care at the Group Health Centre, A Unique Multi-Specialty, Multi-Disciplinary Health Service Organization|Completed|||342||McMaster University|||||f||||||||||||||2018-06-01 04:36:30.270051|2018-06-01 04:36:30.270051
NCT00182273|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|January 2002||2002-01-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Canalith Repositioning Procedure for BPPV in Primary Care|Treatment of Benign Paroxysmal Positional Vertigo With the Canalith Repositioning Procedure in Family Practice: A Randomized Controlled Trial|Completed||Phase 3|56||McMaster University|||||f||||||||||||||2018-06-01 04:36:30.348944|2018-06-01 04:36:30.348944
NCT00182260|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-11-14|2005-09-12|2005-09-16|Estimate|||||||2012-11-14|2012-11-15|Estimate|January 2000||2000-01-31|November 2012|2012-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication Treatment of Patients With Chronic GERD|ELVIS (Esophagitis-Laparoscopy Versus Inhibitors of Secretion) A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication (LNF) Versus Omeprazole for Treatment of Patients With Chronic Gastro-Esophageal Reflux Disease (GERD)|Completed||N/A|216|Actual|McMaster University||2|||f||||||||||||||2018-06-01 04:36:30.418543|2018-06-01 04:36:30.418543
NCT00182247|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|December 1998||1998-12-31|September 2005|2005-09-30|January 2001||2001-01-31|||||Interventional|||D-Dimer and IPG for Recurrent Thrombosis (DIRECT)|D-Dimer and IPG for Recurrent Thrombosis (DIRECT) Study|Terminated||Phase 3|600||McMaster University|||||f||||||||||||||2018-06-01 04:36:30.503058|2018-06-01 04:36:30.503058
NCT00182234|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-17|2005-09-13|2005-09-16|Estimate|||||||2009-06-17|2009-06-18|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||SONICS - Effectiveness of Specialist Oncology Nursing|A Study of the Effectiveness of Specialist Oncology Nursing Case Management in Improving Continuity of Supportive Cancer Care in the Community (SONICS)|Completed||Phase 3|183|Actual|McMaster University|||||f||||f||||||||||2018-06-01 04:36:30.58163|2018-06-01 04:36:30.58163
NCT00182221|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-28|2005-09-13|2005-09-16|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2003||2003-08-31|March 2017|2017-03-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Safety of a Diagnostic Strategy With D-Dimer Testing for PE|A Cohort Study Evaluating the Safety of a Diagnostic Strategy Involving D-Dimer Testing in Patients With Suspected Pulmonary Embolism|Completed||Phase 3|1000|Anticipated|McMaster University|||||f||||t||||||||||2018-06-01 04:36:30.65328|2018-06-01 04:36:30.65328
NCT00182208|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-07-21|2005-09-12|2005-09-16|Estimate|||||||2008-07-21|2008-07-22|Estimate|May 2004||2004-05-31|July 2008|2008-07-31|December 2005|Actual|2005-12-31|June 2005|Actual|2005-06-30||Interventional|||Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial|Evaluation of a Venous-Return Assist Device (Venowave) to Treat Post-Thrombotic Syndrome: A Randomized Controlled Trial|Completed||Phase 3|32||McMaster University|||||f||||t||||||||||2018-06-01 04:36:30.727779|2018-06-01 04:36:30.727779
NCT00182195|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-19|2005-09-12|2005-09-16|Estimate|||||||2007-04-19|2007-04-23|Estimate|August 2000||2000-08-31|April 2007|2007-04-30|March 2006|Actual|2006-03-31|||||Interventional|LOVS||Lung Open Ventilation to Decrease Mortality in the Acute Respiratory Distress Syndrome|A Randomized Trial of a Lung-Open Ventilation Strategy in Acute Lung Injury|Completed||Phase 3|980||McMaster University|||||f||||t||||||||||2018-06-01 04:36:30.788664|2018-06-01 04:36:30.788664
NCT00182182|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-08|2005-09-12|2005-09-16|Estimate|||||||2006-09-08|2006-09-11|Estimate|July 2003||2003-07-31|September 2006|2006-09-30|October 2006||2006-10-31|||||Interventional|||Evaluation of a Primary Care Based Heart Failure Management Program|Congestive Heart Failure Assessment and Management in Primary Care: CHAMP|Unknown status|Active, not recruiting|Phase 2/Phase 3|170||McMaster University|||||f||||||||||||||2018-06-01 04:36:30.846235|2018-06-01 04:36:30.846235
NCT00182169|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|July 1997||1997-07-31|March 2003|2003-03-31|June 2005||2005-06-30|||||Interventional|||Evaluation of the Effect of Human Recombinant Growth Hormone in Patients With Advanced Heart Failure|Randomized, Placebo Control, Clinical Trial Evaluating the Effect of Human Recombinant Growth Hormone in Patients With Severe Congestive Heart Failure. The Growth Hormone In Heart Failure Trial (GIFT)|Completed||Phase 2|80||McMaster University|||||f||||||||||||||2018-06-01 04:36:30.917162|2018-06-01 04:36:30.917162
NCT00182156|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-06-16|2005-09-10|2005-09-16|Estimate|||||||2008-06-16|2008-06-17|Estimate|October 2004||2004-10-31|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Observational|||Cohort Study Comparing Short Daily Hemodialysis (HD) With Conventional HD|Cohort Study Examining the Effects of Short Daily Hemodialysis As Compared to Conventional Hemodialysis in Outpatients Treated at St Joseph's Healthcare, Hamilton|Unknown status|Active, not recruiting||40|Anticipated|McMaster University|||3||f||||f||||||||||2018-06-01 04:36:30.984115|2018-06-01 04:36:30.984115
NCT00182143|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-01-07|2005-09-10|2005-09-16|Estimate|||||||2011-01-07|2011-01-10|Estimate|May 2006||2006-05-31|October 2007|2007-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)|PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)|Completed||Phase 3|3659|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 04:36:31.064576|2018-06-01 04:36:31.064576
NCT00182104|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-19|2005-09-09|2005-09-16|Estimate|||||||2007-04-19|2007-04-20|Estimate|August 1998||1998-08-31|April 2007|2007-04-30|July 2005|Actual|2005-07-31|||||Interventional|||International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures|An International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures|Completed||Phase 4|111||McMaster University|||||f||||||||||||||2018-06-01 04:36:31.369678|2018-06-01 04:36:31.369678
NCT00182091|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-02-07||2012-04-26|2005-09-14|2005-09-16|Estimate|2012-04-26|2012-05-28|Estimate||||2012-04-26|2012-05-28|Estimate|August 2004||2004-08-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency|Effects of Physiologic Growth Hormone Administration on Cardiovascular Risk in Subjects With Growth Hormone Deficiency Following Cure of Acromegaly|Completed||N/A|75|Actual|Massachusetts General Hospital||4|||f||||t||||||||||2018-06-01 04:36:31.436307|2018-06-01 04:36:31.436307
NCT00182078|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2012-06-12||2014-07-08|2005-09-14|2005-09-16|Estimate|2014-07-08|2014-08-05|Estimate||||2014-07-08|2014-08-05|Estimate|November 2002||2002-11-30|July 2014|2014-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional||Analysis was conducted with participants using available data. The different number participants who completed measures at the final time point is as follows: DICA-Parent (6 placebo, 15 sertraline); DICA-Child (6 placebo, 16 sertraline); and CDI (4 placebo, 16 sertraline).|A Study of Sertraline to Prevent PTSD|A Study of Sertraline to Prevent PTSD|Completed||Phase 4|26|Actual|Massachusetts General Hospital|One limitation of this study was the small sample size, due to the challenge of recruiting traumatized children and their parents for participation in a randomized controlled trial of a medication.|2|||f||||t||||||||||2018-06-01 04:36:31.693589|2018-06-01 04:36:31.693589
NCT00182065|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-07|2005-09-09|2005-09-16|Estimate|||||||2006-09-07|2006-09-11|Estimate|March 2004||2004-03-31|August 2005|2005-08-31|October 2006||2006-10-31|||||Observational|||Heart Failure, Functional and Cognitive Decline, and Psychiatric Symptoms in Nursing Home Patients|The Effect of Congestive Heart Failure on Functional and Cognitive Decline and Neuropsychiatric Symptoms in Residents of Long-Term Care Facilities|Unknown status|Active, not recruiting||586||McMaster University|||||f||||||||||||||2018-06-01 04:36:31.91905|2018-06-01 04:36:31.91905
NCT00182052|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-05-22|2005-09-14|2005-09-16|Estimate|||||||2013-05-22|2013-05-23|Estimate|September 2000||2000-09-30|May 2013|2013-05-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer|Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer: A Randomized Double-Blind, Placebo Controlled Phase III Study|Completed||Phase 3|100|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:36:31.968333|2018-06-01 04:36:31.968333
NCT00182039|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-04-10|2005-09-09|2005-09-16|Estimate|||||||2008-04-10|2008-04-11|Estimate|October 2002||2002-10-31|January 2008|2008-01-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|POISE||POISE Trial: Perioperative Ischemic Evaluation Study|Perioperative Ischemic Evaluation Study (POISE) Trial|Terminated||Phase 3|8351|Actual|McMaster University||2||Please see detailed description for reason why study was terminated.|f||||t||||||||||2018-06-01 04:36:32.131219|2018-06-01 04:36:32.131219
NCT00182026|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-10-07|2005-09-09|2005-09-16|Estimate|||||||2010-10-07|2010-10-08|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|||Diabetes IN-CHARGE: Trial of Diabetes Intervention in the Community to Help Achieve Reduced Glucose Elevation|A Randomized Trial of Diabetes Intervention in the Community to Help Achieve Reduced Glucose Elevation: Diabetes IN-CHARGE|Unknown status|Active, not recruiting|N/A|500|Anticipated|McMaster University|||||f||||f||||||||||2018-06-01 04:36:32.20511|2018-06-01 04:36:32.20511
NCT00182013|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-06-12|2005-09-14|2005-09-16|Estimate|||||||2013-06-12|2013-06-13|Estimate|June 2001||2001-06-30|June 2013|2013-06-30||||February 2004|Actual|2004-02-29||Interventional|||Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder||Completed||Phase 4|106|Actual|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:32.267347|2018-06-01 04:36:32.267347
NCT00182000|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-05-01||2012-07-10|2005-09-13|2005-09-16|Estimate|2012-06-05|2012-07-06|Estimate||||2012-07-10|2012-07-16|Estimate|November 2003||2003-11-30|July 2012|2012-07-31||||January 2008|Actual|2008-01-31||Interventional|||Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy|A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy|Completed||Phase 3|33|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 04:36:32.326443|2018-06-01 04:36:32.326443
NCT00181987|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-21|2005-09-13|2005-09-16|Estimate|||||||2013-10-21|2013-10-22|Estimate|August 2002||2002-08-31|October 2013|2013-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder|Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder|Completed||Phase 4|29|Actual|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:32.538949|2018-06-01 04:36:32.538949
NCT00181974|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-10-22|2005-09-14|2005-09-16|Estimate|||||||2012-10-22|2012-10-24|Estimate|March 2000||2000-03-31|October 2012|2012-10-31|November 2007|Actual|2007-11-30|February 2007|Actual|2007-02-28||Interventional|||Efficacy of a Fibrin Sealant in Burn Surgery|Efficacy of a Fibrin Sealant in Burn Surgery|Completed||N/A|25|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:32.605475|2018-06-01 04:36:32.605475
NCT00181961|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-02-09|2005-09-13|2005-09-16|Estimate|||||||2006-02-09|2006-02-13|Estimate|April 2005||2005-04-30|February 2006|2006-02-28||||||||Interventional|||Safety and Effectiveness Study of Maca Root to Treat Antidepressant-Induced Sexual Dysfunction|A Dose-Finding Study of the Tolerability and Efficacy of Maca Root in Patients With Antidepressant-Induced Sexual Dysfunction|Unknown status|Active, not recruiting|Phase 3|20||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:32.701716|2018-06-01 04:36:32.701716
NCT00181948|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-18|2005-09-13|2005-09-16|Estimate|||||||2010-06-18|2010-06-22|Estimate|September 2004||2004-09-30|June 2010|2010-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy|A Pilot Study of Strattera Treatment in Children With Attention-Deficit/Hyperactivity Disorder Who Have Poor Response to Stimulant Therapy|Completed||Phase 4|30|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:36:32.763047|2018-06-01 04:36:32.763047
NCT00181935|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-05-03|2005-09-13|2005-09-16|Estimate|||||||2013-05-03|2013-05-06|Estimate|March 2001||2001-03-31|May 2013|2013-05-31|July 2004|Actual|2004-07-31|||||Interventional|||Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder|Open-Label Comparative Study of Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Spectrum Disorder|Completed||Phase 4|40||Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:36:32.828642|2018-06-01 04:36:32.828642
NCT00181922|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-21|2005-09-13|2005-09-16|Estimate|||||||2013-10-21|2013-10-22|Estimate|March 2002||2002-03-31|October 2013|2013-10-31|December 2004|Actual|2004-12-31|||||Interventional|||Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder|Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder|Completed||Phase 4|20||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:32.89944|2018-06-01 04:36:32.89944
NCT00181909|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-27|2005-09-13|2005-09-16|Estimate|||||||2006-11-27|2006-11-28|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Efficacy of Proactive Telephone Counseling for Pregnant Smokers Enrolled in a Managed Care Organization||Completed||Phase 3|434||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:32.968807|2018-06-01 04:36:32.968807
NCT00181896|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-07-14|2005-09-13|2005-09-16|Estimate|||||||2011-07-14|2011-07-15|Estimate|January 2005||2005-01-31|July 2011|2011-07-31||||February 2007|Actual|2007-02-28||Interventional|||Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder|Open-Label Study of Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar and Bipolar Spectrum Disorder|Terminated||Phase 4|1|Actual|Massachusetts General Hospital||||Study was terminated due to lack of recruitment|f||||t||||||||||2018-06-01 04:36:33.039303|2018-06-01 04:36:33.039303
NCT00181883|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-07-19||2012-03-09|2005-09-13|2005-09-16|Estimate|2012-03-09|2012-04-06|Estimate||||2012-03-09|2012-04-06|Estimate|February 2005||2005-02-28|March 2012|2012-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder|Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder|Completed||Phase 4|30|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:36:33.113882|2018-06-01 04:36:33.113882
NCT00181870|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-06-18|2005-09-13|2005-09-16|Estimate|||||||2010-06-18|2010-06-22|Estimate|July 2005||2005-07-31|June 2010|2010-06-30||||August 2007|Actual|2007-08-31||Interventional|||Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder|Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder|Completed||Phase 4|33|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:36:33.275441|2018-06-01 04:36:33.275441
NCT00181857|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-30|2005-09-13|2005-09-16|Estimate|||||||2013-10-30|2013-10-31|Estimate|February 2005||2005-02-28|October 2013|2013-10-31|February 2008|Actual|2008-02-29|February 2006|Actual|2006-02-28||Observational|||Risk of Attention Deficit Hyperactivity Disorder (ADHD) in the Children of Adults With ADHD Not Otherwise Specified (NOS)|Risk of Attention Deficit Hyperactivity Disorder in the Children of Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified: A Pilot Study|Completed|||58|Actual|Massachusetts General Hospital|||1||f||||t||||||||||2018-06-01 04:36:33.334349|2018-06-01 04:36:33.334349
NCT00181844|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-07-27||2012-03-09|2005-09-13|2005-09-16|Estimate|2012-03-09|2012-04-06|Estimate||||2012-03-09|2012-04-06|Estimate|January 2005||2005-01-31|March 2012|2012-03-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder|A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders|Completed||Phase 4|51|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:36:33.399497|2018-06-01 04:36:33.399497
NCT00181831|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-12|2005-09-13|2005-09-16|Estimate|||||||2013-06-12|2013-06-13|Estimate|December 2002||2002-12-31|June 2013|2013-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Spectroscopy in Children and Adolescents With Bipolar Disorder|Proton Magnetic Resonance Spectroscopy in Children and Adolescents With Bipolar Disorder|Completed|||80||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:33.569138|2018-06-01 04:36:33.569138
NCT00181818|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|October 1999||1999-10-31|September 2005|2005-09-30|December 2003||2003-12-31|||||Interventional|||Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease|Safety and Efficacy of Sustained-Release (SR) Bupropion for Smokers Hospitalized Smokers With Acute Coronary Heart Disease|Completed||Phase 4|248||Massachusetts General Hospital|||||||||||||||||||2018-06-01 04:36:33.626809|2018-06-01 04:36:33.626809
NCT00181805|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-23|2005-09-13|2005-09-16|Estimate|||||||2013-10-23|2013-10-24|Estimate|September 2004||2004-09-30|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|June 2010|Actual|2010-06-30||Observational|||Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents|The Natural History of Children With Persistent Gastroesophageal Reflux Disease (Ages 12 to 17 Years)|Unknown status|Active, not recruiting||25|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-06-01 04:36:33.68926|2018-06-01 04:36:33.68926
NCT00181792|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-05-02|2005-09-13|2005-09-16|Estimate|||||||2012-05-02|2012-05-04|Estimate|May 2005||2005-05-31|May 2012|2012-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta|Family Risk Analysis of Substance Use in ADHD Youth Treated With Concerta|Completed|||70|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:36:33.73724|2018-06-01 04:36:33.73724
NCT00181779|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-21|2005-09-13|2005-09-16|Estimate|||||||2013-10-21|2013-10-22|Estimate|February 2003||2003-02-28|October 2013|2013-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder|Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder|Completed||Phase 4|20||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:33.783176|2018-06-01 04:36:33.783176
NCT00181766|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2010-02-26||2013-12-02|2005-09-13|2005-09-16|Estimate|2010-05-27|2010-06-23|Estimate||||2013-12-02|2013-12-27|Estimate|December 2003||2003-12-31|December 2013|2013-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)|A Pilot Study of Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified|Completed||Phase 4|45|Actual|Massachusetts General Hospital|"small, open label study~short exposure to medication"|1|||f||||t||||||||||2018-06-01 04:36:33.856341|2018-06-01 04:36:33.856341
NCT00181753|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-12|2005-09-13|2005-09-16|Estimate|||||||2017-01-12|2017-01-13|Estimate|November 2009||2009-11-30|January 2017|2017-01-31|October 2010|Anticipated|2010-10-31|October 2010|Anticipated|2010-10-31||Interventional|||Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition|Study of Glutamate and Glutamine Metabolism in Burn Patients Receiving Enteral or Parenteral Nutrition|Withdrawn||N/A|0|Actual|National Institute of General Medical Sciences (NIGMS)||4||"State of Mass. tightened regulations for making intravenous solutions for research subjects.~   Study was withdrawn and no participants were enrolled."|f||||t||||||||||2018-06-01 04:36:34.013143|2018-06-01 04:36:34.013143
NCT00181740|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-07-22|2005-09-13|2005-09-16|Estimate|||||||2010-07-22|2010-07-23|Estimate|December 2003||2003-12-31|July 2010|2010-07-31|July 2005|Actual|2005-07-31|||||Interventional|||Concerta Treatment in Adults With ADHD NOS|A Pilot Study of Concerta Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified|Completed||Phase 4|30||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:34.090012|2018-06-01 04:36:34.090012
NCT00181727|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-10-21|2005-09-13|2005-09-16|Estimate|||||||2013-10-21|2013-10-22|Estimate|January 2004||2004-01-31|October 2013|2013-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder|Open-Label Study of Divalproex Sodium Extended Release for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder|Completed||Phase 4|14||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:34.165555|2018-06-01 04:36:34.165555
NCT00181714|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-01-05||2013-05-02|2005-09-13|2005-09-16|Estimate|2012-01-05|2012-02-07|Estimate||||2013-05-02|2013-05-07|Estimate|November 2003||2003-11-30|May 2013|2013-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta|Prevention of Cigarette Smoking in ADHD Youth With Concerta|Completed||Phase 4|203|Actual|Massachusetts General Hospital|The main limitation of this report stems from its uncontrolled, open-label design. Thus, we cannot assert a causal relationship between lower smoking rates and OROS MPH prescription.|1|||f||||t||||||||||2018-06-01 04:36:34.220427|2018-06-01 04:36:34.220427
NCT00181701|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-04|2005-09-12|2005-09-16|Estimate|||||||2012-12-04|2012-12-05|Estimate|October 2004||2004-10-31|December 2012|2012-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin|A Phase II Trial of Intraperitoneal Paclitaxel and Carboplatin Therapy in the Treatment of Women With Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin|Completed||Phase 2|46|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:36:34.487942|2018-06-01 04:36:34.487942
NCT00181688|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-04|2005-09-12|2005-09-16|Estimate|||||||2012-12-04|2012-12-05|Estimate|October 2003||2003-10-31|December 2012|2012-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer|A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer|Completed||Phase 2|35||Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:36:34.56557|2018-06-01 04:36:34.56557
NCT00181675|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-22|2005-09-12|2005-09-16|Estimate|||||||2010-07-22|2010-07-23|Estimate|December 2002||2002-12-31|July 2010|2010-07-31|September 2003||2003-09-30|||||Interventional|||A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder|A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder|Completed||Phase 4|40||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:34.641005|2018-06-01 04:36:34.641005
NCT00181662|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-02|2005-09-12|2005-09-16|Estimate|||||||2007-04-02|2007-04-04|Estimate|August 2005||2005-08-31|April 2007|2007-04-30||||||||Interventional|||Pharmacokinetics of Curcumin in Healthy Volunteers|Evaluation of Naturally Occurring Inhibitors of UDP-Glucuronyltransferase on the Oral Bioavailability of Curcumin in Normal Healthy Volunteers|Completed||N/A|6||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:34.727645|2018-06-01 04:36:34.727645
NCT00181649|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-05-08|2005-09-09|2005-09-16|Estimate|||||||2013-05-08|2013-05-09|Estimate|September 2006||2006-09-30|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Recombinant Human Prolactin for Lactation Induction|Recombinant Human Prolactin for Lactation Induction in Adoptive Mothers|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||1||Not able to recruit any subjects.|f||||||||||||||2018-06-01 04:36:34.811989|2018-06-01 04:36:34.811989
NCT00181636|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-23|2005-09-12|2005-09-16|Estimate|||||||2007-04-23|2007-04-24|Estimate||||April 2007|2007-04-30|October 2006|Actual|2006-10-31|||||Interventional|||Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder||Completed||N/A|25||Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:36:34.897628|2018-06-01 04:36:34.897628
NCT00181623|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-02-05||2017-12-08|2005-09-09|2005-09-16|Estimate|2013-05-07|2013-05-09|Estimate||||2017-12-08|2017-12-11|Actual|January 2005||2005-01-31|December 2017|2017-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Recombinant Human Prolactin for Lactation Induction|Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers|Completed||Phase 2|6|Actual|Massachusetts General Hospital|Small numbers as this was an orphan disease trial.|1|||f||||||||||||||2018-06-01 04:36:34.969481|2018-06-01 04:36:34.969481
NCT00181610|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-02-05||2017-12-31|2005-09-09|2005-09-16|Estimate|2013-05-08|2013-05-10|Estimate||||2017-12-31|2018-01-03|Actual|September 2004||2004-09-30|December 2017|2017-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||One subject did not complete the study and data was not analyzed for that subject.|Recombinant Human Prolactin for Lactation Induction|Recombinant Human Prolactin for Lactation Induction in Mothers of Premature Infants|Completed||Phase 2|11|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 04:36:35.135051|2018-06-01 04:36:35.135051
NCT00181597|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-12-02|2005-09-09|2005-09-16|Estimate|||||||2013-12-02|2013-12-03|Estimate|March 2004||2004-03-31|December 2013|2013-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Trilostane for Androgen-Independent Prostate Cancer|A Phase II Study of Trilostane for Androgen-Independent Prostate Cancer|Completed||Phase 2|24|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:36:35.435404|2018-06-01 04:36:35.435404
NCT00181584|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-07-09|2005-09-09|2005-09-16|Estimate|||||||2013-07-09|2013-07-11|Estimate|September 2003||2003-09-30|July 2013|2013-07-31||||February 2006|Actual|2006-02-28||Interventional|||Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer|Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer|Completed||Phase 2|60|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-06-01 04:36:35.503311|2018-06-01 04:36:35.503311
NCT00181571|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-26|2005-09-13|2005-09-16|Estimate|||||||2013-06-26|2013-06-27|Estimate|June 2003||2003-06-30|June 2013|2013-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder|A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder|Completed||Phase 4|297|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:36:35.589537|2018-06-01 04:36:35.589537
NCT00181558|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-05-07|2005-09-09|2005-09-16|Estimate|||||||2010-05-07|2010-05-10|Estimate|December 2001||2001-12-31|May 2010|2010-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone|Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study|Completed||Phase 2|44||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:36:35.68091|2018-06-01 04:36:35.68091
NCT00181545|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-29|2005-09-13|2005-09-16|Estimate|||||||2009-06-29|2009-06-30|Estimate|December 2004||2004-12-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.|Individualised Radiation Dose Determination on Basis of Normal Tissue Dose Constraints in Patients With Non-Small-Cell Lung Cancer: A Phase I Study|Completed||Phase 1|30|Anticipated|Maastricht Radiation Oncology|||||f||||t||||||||||2018-06-01 04:36:35.754315|2018-06-01 04:36:35.754315
NCT00181532|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-29|2005-09-13|2005-09-16|Estimate|||||||2009-06-29|2009-06-30|Estimate|May 2003||2003-05-31|June 2009|2009-06-30|January 2008|Actual|2008-01-31|||||Interventional|||Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC|A Multicentre Randomised Double Blind Placebo-Controlled Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC. An Evaluation of Both Tumor Radiosensitization and Normal Tissue Protection|Completed||Phase 2|102||Maastricht Radiation Oncology|||||f||||t||||||||||2018-06-01 04:36:35.813458|2018-06-01 04:36:35.813458
NCT00181506|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-06-29|2005-09-13|2005-09-16|Estimate|||||||2009-06-29|2009-06-30|Estimate|December 2001||2001-12-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy|HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Accelerated Conformal Radiotherapy in Patients With Inoperable Non-Small Cell Lung Cancer.|Completed||Phase 1/Phase 2|180||Maastricht Radiation Oncology|||||f||||||||||||||2018-06-01 04:36:35.876153|2018-06-01 04:36:35.876153
NCT00181363|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-25|2005-09-09|2005-09-16|Estimate|||||||2007-04-25|2007-04-27|Estimate|December 2003||2003-12-31|April 2007|2007-04-30|January 2010|Anticipated|2010-01-31|||||Interventional|||Prone Breast Irradiation for Pendulous Breasts|Mamma Board Project: Prone Breast Irradiation for Pendulous Breasts|Unknown status|Active, not recruiting|N/A|10||Maastricht Radiation Oncology|||||f||||t||||||||||2018-06-01 04:36:35.936204|2018-06-01 04:36:35.936204
NCT00181350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-06-29|2005-09-09|2005-09-16|Estimate|||||||2009-06-29|2009-06-30|Estimate|November 2003||2003-11-30|June 2009|2009-06-30|July 2007|Actual|2007-07-31|||||Interventional|||Serial CT Scans in Fractionated Stereotactic Radiotherapy|Serial CT Scans for the Evaluation of Two Different Relocatable Fixation Systems in Fractionated Stereotactic Radiotherapy|Completed||Phase 3|20||Maastricht Radiation Oncology|||||f||||t||||||||||2018-06-01 04:36:36.023694|2018-06-01 04:36:36.023694
NCT00181311|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2006-10-25|2005-09-10|2005-09-16|Estimate|||||||2006-10-25|2006-10-26|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|October 2006||2006-10-31|||||Observational|||Investigation of the Incidence of Complications After Vaginal and Abdominal Hysterectomy|Prospective Investigation of the Incidence of Complications After Vaginal and Abdominal Hysterectomy|Unknown status|Recruiting||200||Maasland Hospital|||||f||||||||||||||2018-06-01 04:36:36.074664|2018-06-01 04:36:36.074664
NCT00181298|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-03-05|2005-09-13|2005-09-16|Estimate|||||||2008-03-05|2008-03-07|Estimate|March 2006||2006-03-31|March 2008|2008-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Memantine in Systemic Lupus Erythematosus|Memantine in Systemic Lupus Erythematosus|Completed||N/A|61|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-06-01 04:36:36.130785|2018-06-01 04:36:36.130785
NCT00181285|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-05-09|2005-09-15|2005-09-16|Estimate|||||||2013-05-09|2013-05-13|Estimate|October 2003||2003-10-31|May 2013|2013-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT)|Chest Wall Oscillation for Asthma and COPD Exacerbations Trial (COAT)|Completed||Phase 2|6|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 04:36:36.191408|2018-06-01 04:36:36.191408
NCT00181272|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2013-05-09|2005-09-15|2005-09-16|Estimate|||||||2013-05-09|2013-05-13|Estimate|September 2005||2005-09-30|May 2013|2013-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease|Macrolides to Prevent Exacerbations of Asthma and Chronic Obstructive Pulmonary Disease|Terminated||Phase 2|18||Johns Hopkins University||||Principal Investigator moved institutions|f||||||||||||||2018-06-01 04:36:36.277313|2018-06-01 04:36:36.277313
NCT00181259|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-28|2005-09-13|2005-09-16|Estimate|||||||2017-04-28|2017-05-02|Actual|January 1988||1988-01-31|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|||Magnetic Resonance Spectroscopy Studies of Cardiac Muscle Metabolism|In Vivo Cardiac Metabolism in Normal, Ischemic, and Cardiomyopathic Patients During Rest and Stress|Recruiting|||500|Anticipated|Johns Hopkins University|||||f||||f||||||||No||2018-06-01 04:36:36.340733|2018-06-01 04:36:36.340733
NCT00181246|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2017-08-23|2005-09-14|2005-09-16|Estimate|||||||2017-08-23|2017-08-24|Actual|October 2003||2003-10-31|August 2017|2017-08-31|September 2005||2005-09-30|||||Interventional|||Efficacy of Transdermal Fentanyl for Chronic Neuropathic Pain||Completed||N/A|53||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:36.397593|2018-06-01 04:36:36.397593
NCT00181233|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-27|2005-09-13|2005-09-16|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2003||2003-10-31|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|June 2019|Anticipated|2019-06-30||Observational|||Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk|Functional Energetics and Imaging for Phenotypic Characterization of Patients at Risk for Sudden Cardiac Death|Recruiting|||400|Anticipated|Johns Hopkins University|||||f||||f||||||||No||2018-06-01 04:36:36.446673|2018-06-01 04:36:36.446673
NCT00181220|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-08-21|2005-09-13|2005-09-16|Estimate|||||||2006-08-21|2006-08-22|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|September 2006||2006-09-30|||||Interventional|||Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma|Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 1|20||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:36.503466|2018-06-01 04:36:36.503466
NCT00181207|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-03-29|2005-09-13|2005-09-16|Estimate|||||||2012-03-29|2012-03-30|Estimate|May 2004||2004-05-31|June 2011|2011-06-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Airway Clearance for Prevention of COPD Exacerbation|A Randomized, Sham-controlled, Double-blinded Pilot Study to Assess the Effects of High Frequency Chest Wall Oscillation (HFCWO) Therapy in Patients With Chronic Bronchitis|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:36.56195|2018-06-01 04:36:36.56195
NCT00181194|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|May 2005||2005-05-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||Reducing Asthma Disparities by Improving Provider-Patient Communication|Reducing Asthma Disparities by Improving Provider-Patient Communication About Asthma Severity and Adherence With Therapy|Unknown status|Recruiting|N/A|350||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:36.634362|2018-06-01 04:36:36.634362
NCT00181181|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-27|2005-09-13|2005-09-16|Estimate|||||||2010-05-27|2010-05-28|Estimate|May 2003||2003-05-31|September 2006|2006-09-30|April 2007|Actual|2007-04-30|June 2006|Actual|2006-06-30||Interventional|||The Effect of Statin Use on Vascular Function in Hypertensive Subjects|The Effect of Statin Use on Vascular Function in Hypertensive Subjects|Terminated||Phase 4|24|Actual|Johns Hopkins University||2||"Coronary flow by echo Doppler was obtainable in about 50% of subjects. The study was stopped~   early because of insufficient sample size to achieve adequate power"|f||||||||||||||2018-06-01 04:36:36.697663|2018-06-01 04:36:36.697663
NCT00181168|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-24|2005-09-12|2005-09-16|Estimate|||||||2007-09-24|2007-09-26|Estimate|March 2005||2005-03-31|September 2007|2007-09-30||||||||Interventional|||Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer|Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-Differentiated Epithelial Thyroid Cancer|Unknown status|Recruiting|Phase 2|70|Anticipated|Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:37.671689|2018-06-01 04:36:37.671689
NCT00181155|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-11-11||2017-04-28|2005-09-12|2005-09-16|Estimate|2016-01-06|2016-02-09|Estimate||||2017-04-28|2017-05-30|Actual|November 2004||2004-11-30|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Intravenous Allopurinol in Heart Failure|Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure|Completed||Phase 2|18|Actual|Johns Hopkins University|The limitations of the current study include the small placebo group sample size and the etiologic heterogeneity of the nonischemic cardiomyopathy group.|2|||f||||f||||||||No||2018-06-01 04:36:37.777112|2018-06-01 04:36:37.777112
NCT00181142|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-12-21|2005-09-10|2005-09-16|Estimate|||||||2017-12-21|2017-12-26|Actual|October 1999|Actual|1999-10-31|December 2017|2017-12-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation|A Phase 3 Study Comparing the Use of Daclizumab vs Thymoglobulin as Induction Therapy in Lung Transplantation|Completed||Phase 2/Phase 3|60||Johns Hopkins University|||||||||||||||||||2018-06-01 04:36:37.963699|2018-06-01 04:36:37.963699
NCT00181129|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-29|2005-09-12|2005-09-16|Estimate|||||||2008-09-29|2008-09-30|Estimate|September 2002||2002-09-30|September 2008|2008-09-30||||||||Interventional|||Fatigue and Cancer Treatment(FACT)- an Exercise Intervention|Mitigating Cancer Treatment-Related Fatigue by Exercise|Completed||N/A|140|Anticipated|Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:38.035981|2018-06-01 04:36:38.035981
NCT00181116|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2009-03-26|2005-09-10|2005-09-16|Estimate|||||||2009-03-26|2009-03-27|Estimate|March 2005||2005-03-31|March 2009|2009-03-31|September 2006|Actual|2006-09-30|||||Interventional|||Levetiracetam for Benign Rolandic Epilepsy|Efficacy of Levetiracetam for Language Dysfunction Associated With Benign Epilepsy With Centrotemporal Spikes|Completed||Phase 4|6||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:38.086138|2018-06-01 04:36:38.086138
NCT00181090|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2009-03-26|2005-09-10|2005-09-16|Estimate|||||||2009-03-26|2009-03-27|Estimate|February 2005||2005-02-28|March 2009|2009-03-31|September 2006|Actual|2006-09-30|||||Interventional|||Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits||Completed||Phase 1|30||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:36:38.144286|2018-06-01 04:36:38.144286
NCT00181077|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2012-09-21|2005-09-10|2005-09-16|Estimate|||||||2012-09-21|2012-09-25|Estimate|June 2003||2003-06-30|September 2012|2012-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Hypertonic Saline Use in Preeclampsia|Hypertonic Saline Use for Volume Expansion in Postpartum Preeclampsia|Completed||Phase 1|20||Johns Hopkins University|||||f||||f||||||||||2018-06-01 04:36:38.30155|2018-06-01 04:36:38.30155
NCT00181064|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-07-01|2005-09-09|2005-09-16|Estimate|||||||2009-07-01|2009-07-02|Estimate|September 2005||2005-09-30|June 2009|2009-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Atkins Diet for Difficult-to-Control Headaches in Teenagers|Use of the Atkins Diet for Adolescents With Chronic Daily Headache.|Completed||Phase 1|10|Anticipated|Johns Hopkins University|||||f||||t||||||||||2018-06-01 04:36:38.377878|2018-06-01 04:36:38.377878
NCT00181051|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|February 2003||2003-02-28|September 2005|2005-09-30||||||||Interventional|||Clinical Utility of the Alaris MidLatencyAuditoryEvoked Potentials Monitor to Titrate the Anesthetic-Hypnotic Component of Anesthesia|Clinical Utility of the Alaris MidLatencyAuditoryEvoked Potentials Monitor to Titrate the Anesthetic-Hypnotic Component of Anesthesia|Suspended||Phase 3|128||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.448723|2018-06-01 04:36:38.448723
NCT00181038|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-27|2005-09-13|2005-09-16|Estimate|||||||2007-08-27|2007-08-28|Estimate|June 2004||2004-06-30|September 2006|2006-09-30||||||||Interventional|||Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery|Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery: Comparing Continuous Infusion of Local Anesthetic With Systemic Multimodal Analgesia|Unknown status|Recruiting|Phase 3|40|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.50559|2018-06-01 04:36:38.50559
NCT00181025|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-11|2005-09-13|2005-09-16|Estimate|||||||2007-06-11|2007-06-12|Estimate|May 2004||2004-05-31|September 2006|2006-09-30||||||||Interventional|||Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs’ Girdle|Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs’ Girdle|Unknown status|Recruiting|Phase 2|33|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.57076|2018-06-01 04:36:38.57076
NCT00181012|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-18|2005-09-13|2005-09-16|Estimate|||||||2007-09-18|2007-09-19|Estimate|May 2005||2005-05-31|September 2006|2006-09-30||||||||Interventional|||Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics|Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics: Efficacy Study in Adults and Children. Randomized Prospective Study With Direct Individual Benefit|Unknown status|Recruiting|Phase 3|100|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.64006|2018-06-01 04:36:38.64006
NCT00180999|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-07|2005-09-13|2005-09-16|Estimate|||||||2006-09-07|2006-09-11|Estimate|February 2002||2002-02-28|September 2006|2006-09-30||||||||Interventional|||Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course|Randomised Study to Compare the Effect of r-Hu-EPO Administration With Transfusion of Red Blood Cell Concentrates and Also With the Administration of Polyvitamins in Anemic and Tired Patients Presenting a Bad Prognostic in Middle Course|Terminated||Phase 3|420||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.716597|2018-06-01 04:36:38.716597
NCT00180986|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-13|2005-09-13|2005-09-16|Estimate|||||||2005-12-13|2005-12-14|Estimate|October 1995||1995-10-31|September 2005|2005-09-30||||||||Interventional|||Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child|Randomized Trial Of Platelet Transfusion Policies After Blood Stem Cells Transplantation In Young Children: Reduction Of Number Of Single Platelet Concentrate Donors Per Child|Unknown status|Active, not recruiting|Phase 3|120||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.770608|2018-06-01 04:36:38.770608
NCT00180596|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2016-01-05|2005-09-15|2005-09-16|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2000||2000-01-31|June 2005|2005-06-30|September 2005||2005-09-30|||||Interventional|||PACMAN - PAcing for CardioMyopathies, a EuropeAN Study|Pacing for Cardiomyopathies, a European Study- A Therapy Acceptance Study|Completed||Phase 4|262||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:36:41.292234|2018-06-01 04:36:41.292234
NCT00180973|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|February 1995||1995-02-28|September 2005|2005-09-30||||||||Interventional|||PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.|MULTICENTRIC INTERNATIONAL RANDOMIZED PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.|Unknown status|Active, not recruiting|Phase 3|520||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.831248|2018-06-01 04:36:38.831248
NCT00180960|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-07|2005-09-13|2005-09-16|Estimate|||||||2006-09-07|2006-09-11|Estimate|June 2003||2003-06-30|September 2006|2006-09-30||||||||Interventional|||Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia|Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan|Terminated||Phase 2|100||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.894816|2018-06-01 04:36:38.894816
NCT00180947|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-07|2005-09-13|2005-09-16|Estimate|||||||2006-09-07|2006-09-08|Estimate|June 2003||2003-06-30|September 2006|2006-09-30||||||||Interventional|||Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse|Phase II Study of Vinorelbine + Cyclofosfamide Association Among Patients Reached of Refractory Tumours or in Relapse|Unknown status|Recruiting|Phase 2|210||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:38.945295|2018-06-01 04:36:38.945295
NCT00180934|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-22|2005-09-13|2005-09-16|Estimate|||||||2005-12-22|2005-12-23|Estimate|July 1999||1999-07-31|September 2005|2005-09-30||||||||Interventional|||Reirradiation With Concomitant Chemotherapy After Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area|Interest of a Reirradiation With Concomitant Chemotherapy After Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area: a Multicentric Phase III Randomized Trial|Unknown status|Active, not recruiting|Phase 3|280||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.008726|2018-06-01 04:36:39.008726
NCT00180921|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-24|2005-09-13|2005-09-16|Estimate|||||||2007-09-24|2007-09-26|Estimate|July 2004||2004-07-31|September 2006|2006-09-30||||||||Interventional|||Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck|Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT|Unknown status|Recruiting|Phase 2|30|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.058534|2018-06-01 04:36:39.058534
NCT00180908|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|June 1994||1994-06-30|September 2005|2005-09-30||||||||Interventional|||Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children|SFOP-OS94: Multicentric Randomised Phase III Trial Comparing Efficacy of Preoperative High-Dose Methotrexate Plus Doxorubicin to Efficacy of High-Dose Methotrexate Plus Etoposide and Ifosfamide, in Children and Adolescents Osteosarcoma|Completed||Phase 3|226||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.118486|2018-06-01 04:36:39.118486
NCT00180895|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-07|2005-09-12|2005-09-16|Estimate|||||||2006-09-07|2006-09-11|Estimate|June 2004||2004-06-30|September 2006|2006-09-30||||||||Interventional|||Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL|A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL|Terminated||Phase 2|40||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.178081|2018-06-01 04:36:39.178081
NCT00180882|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-07|2005-09-12|2005-09-16|Estimate|||||||2006-09-07|2006-09-11|Estimate|October 2004||2004-10-31|September 2006|2006-09-30||||||||Interventional|||LMBA02 Protocol for Patients With a Burkitt Lymphoma||Unknown status|Recruiting|Phase 3|260||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.25129|2018-06-01 04:36:39.25129
NCT00180869|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-16|Estimate|||||||2005-09-12|2005-09-16|Estimate|September 1997||1997-09-30|September 2005|2005-09-30||||||||Interventional|||Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients|A Randomized Study of Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion During Surgery in Cancer Patients|Completed||Phase 3|150||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.412728|2018-06-01 04:36:39.412728
NCT00180856|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-11|2005-09-11|2005-09-16|Estimate|||||||2005-09-11|2005-09-16|Estimate|January 2002||2002-01-31|September 2005|2005-09-30||||||||Interventional|||Radiofrequency Ablation of Lung Tumors|A Phase II Study of Radiofrequency Ablation of Lung Tumors|Completed||Phase 2|60||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.480757|2018-06-01 04:36:39.480757
NCT00180843|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-09-21|2005-09-13|2005-09-16|Estimate|||||||2013-09-21|2013-09-24|Estimate|September 2005||2005-09-30|September 2013|2013-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease|Assessment of Ventilation-perfusion Abnormalities in Patients With Smoking-related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy|Terminated||N/A|2|Actual|Imperial College London||2||lack of resources research fellow left|f||||f||||||||||2018-06-01 04:36:39.546057|2018-06-01 04:36:39.546057
NCT00180830|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-07|2005-09-09|2005-09-16|Estimate|||||||2006-09-07|2006-09-11|Estimate|December 2003||2003-12-31|September 2006|2006-09-30||||||||Interventional|||Glivec Phase II Pediatric Study|Open Label, Pilot Phase II Study of Glivec in Children and Adolescents With Life Threatening Diseases Known to Be Associated With One or More Glivec-Sensitive Tyrosine Kinases|Terminated||Phase 2|36||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.629795|2018-06-01 04:36:39.629795
NCT00180817|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|September 1998||1998-09-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Observational|||Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.|Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies in Women Presenting as Recurrent Miscarriages.|Unknown status|Recruiting||250||Imperial College London|||||f||||||||||||||2018-06-01 04:36:39.727053|2018-06-01 04:36:39.727053
NCT00180804|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-13|2005-09-13|2005-09-16|Estimate|||||||2005-12-13|2005-12-14|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Observational|||Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages|Combination of Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages|Unknown status|Recruiting||400||Imperial College London|||||f||||||||||||||2018-06-01 04:36:39.816262|2018-06-01 04:36:39.816262
NCT00180791|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-09-17|2005-09-09|2005-09-16|Estimate|||||||2007-09-17|2007-09-18|Estimate|July 2002||2002-07-31|September 2006|2006-09-30||||||||Interventional|||High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood|Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy|Unknown status|Recruiting|Phase 2|71|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:36:39.891177|2018-06-01 04:36:39.891177
NCT00180778|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-16|Estimate|||||||2005-09-13|2005-09-16|Estimate|October 2005||2005-10-31|September 2005|2005-09-30||||||||Interventional|||Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss|Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS|Unknown status|Not yet recruiting|Phase 1/Phase 2|90||Imperial College London|||||f||||||||||||||2018-06-01 04:36:39.975306|2018-06-01 04:36:39.975306
NCT00180765|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-08-24|2005-09-13|2005-09-16|Estimate|||||||2015-08-24|2015-08-25|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Observational|||Regulation of the Release of Inflammatory Mediators From Blood Leukocytes|Regulation of the Release of Inflammatory Mediators From Blood Leukocytes: A Comparison of Healthy Subjects, Healthy Smokers and Patients With COPD.|Completed|||30||Imperial College London|||||f||||||||||||||2018-06-01 04:36:40.072303|2018-06-01 04:36:40.072303
NCT00180752|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-02-17|2005-09-13|2005-09-16|Estimate|||||||2016-02-17|2016-02-19|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||HDAC Activity in Peripheral Skeletal Muscle in COPD|The Investigation of HDAC and NF Kappa B Activity in Peripheral Skeletal Muscle in COPD|Completed|||31|Actual|Imperial College London|||||f||||f||||||Samples With DNA|"~     Plasma and serum samples, quadriceps muscle specimens~   "|No||2018-06-01 04:36:40.147683|2018-06-01 04:36:40.147683
NCT00180739|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-08-12|2005-09-13|2005-09-16|Estimate|||||||2008-08-12|2008-08-13|Estimate|April 2004||2004-04-30|August 2008|2008-08-31||||||||Interventional|||Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future|Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies|Completed||Phase 4|60|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:36:40.208187|2018-06-01 04:36:40.208187
NCT00180726|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-08-12|2005-09-13|2005-09-16|Estimate|||||||2008-08-12|2008-08-13|Estimate|December 2003||2003-12-31|August 2008|2008-08-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Molecular Mechanism of Asthma|Regulation of Inflammatory Mediators in Asthma|Withdrawn||N/A|30|Anticipated|Imperial College London|||||f||||t||||||||||2018-06-01 04:36:40.289004|2018-06-01 04:36:40.289004
NCT00180713|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-03|2005-09-12|2005-09-16|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2005||2005-10-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|October 2008|Actual|2008-10-31||Interventional|||Simvastatin as a Treatment for Pulmonary Hypertension|Simvastatin as a Treatment for Pulmonary Hypertension|Completed||Phase 1/Phase 2|42|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 04:36:40.360719|2018-06-01 04:36:40.360719
NCT00180700|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-02-11|2005-09-13|2005-09-16|Estimate|||||||2016-02-11|2016-02-12|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||The Influence of Psychological Interventions Upon Disease Progression in HIV-infected Patients Receiving no Medication|The Effects of Two Psychological Intervention Techniques, Self-hypnosis and Johrei Healing Method, on Quality of Life, Psychological Well-being, EEG Measures and Various Immunological Measures Including CD4+ Counts in Early HIV: a Randomly Controlled Pilot Study|Completed||N/A|100||Imperial College London|||||f||||||||||||||2018-06-01 04:36:40.451911|2018-06-01 04:36:40.451911
NCT00180687|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-06-09||2015-08-12|2005-09-12|2005-09-16|Estimate|2015-08-12|2015-09-15|Estimate||||2015-08-12|2015-09-15|Estimate|October 2004||2004-10-31|August 2015|2015-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Clinical Trial of the Use of Intraperitoneal Local Anaesthetic|Prospective Double Blind Randomized Controlled Trial of the Use of Intraperitoneal Nebulised Local Anaesthetic|Completed||Phase 3|80|Actual|Imperial College London||4|||f||||t||||||||||2018-06-01 04:36:40.53578|2018-06-01 04:36:40.53578
NCT00180674|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-10|2005-09-13|2005-09-16|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||Anticoagulation in Liver Fibrosis|Anticoagulation for Liver Fibrosis in Patients With Hepatitis C Virus Infection: Pilot Study|Completed||Phase 2|12|Actual|Imperial College London|||||f||||||||||||||2018-06-01 04:36:40.871121|2018-06-01 04:36:40.871121
NCT00180661|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-27|2005-09-12|2005-09-16|Estimate|||||||2015-10-27|2015-10-29|Estimate|August 2003||2003-08-31|October 2015|2015-10-31|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Observational|SARP||Inflammation and Corticosteroid Responsiveness in Severe Asthma|Inflammation and Corticosteroid Responsiveness in Severe Asthma|Completed|||95|Actual|Imperial College London|||3||f||||t||||||Samples With DNA|"~     endobronchial biopsies and blood specimens.~   "|||2018-06-01 04:36:40.938165|2018-06-01 04:36:40.938165
NCT00180648|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-02-19|2005-09-12|2005-09-16|Estimate|||||||2016-02-19|2016-02-22|Estimate|February 2005||2005-02-28|May 2008|2008-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure|Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure|Completed|||30|Actual|Imperial College London|||||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-06-01 04:36:41.000315|2018-06-01 04:36:41.000315
NCT00180635|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-06-03|2005-09-09|2005-09-16|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2003||2003-10-31|April 2008|2008-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD|A Double Blind, Crossover Placebo-controlled Study to Evaluate the Effect of L-arginine and Aminoguanidine on Bronchial and Alveolar Nitric Oxide and Nitric Oxide Metabolites in Exhaled Air, Breath Condensate, Nasal Lavage, Mouth Wash Fluid, and Induced Sputum in 7 Healthy Non-smokers, 10 Smokers and 12 COPD Patients|Completed||N/A|29|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:36:41.062397|2018-06-01 04:36:41.062397
NCT00180622|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-16|Estimate|||||||2005-09-09|2005-09-16|Estimate|July 2001||2001-07-31|September 2005|2005-09-30||||||||Observational|||Markers for COPD|Non-Invasive Markers for COPD|Completed|||52||Imperial College London|||||f||||||||||||||2018-06-01 04:36:41.115065|2018-06-01 04:36:41.115065
NCT00180609|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2009-04-22|2005-09-15|2005-09-16|Estimate|||||||2009-04-22|2009-04-23|Estimate|December 2003||2003-12-31|April 2009|2009-04-30|July 2006||2006-07-31|||||Observational|||SCANCAP Scandinavian Automatic Capture Study|Scandinavian Automatic Capture Study|Completed|||203||Guidant Corporation|||||f||||||||||||||2018-06-01 04:36:41.163513|2018-06-01 04:36:41.163513
NCT00180583|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2008-07-31|2005-09-15|2005-09-16|Estimate|||||||2008-07-31|2008-08-01|Estimate|February 2002||2002-02-28|July 2008|2008-07-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Vision II: Evaluation of GALILEO Intravascular Radiotherapy System|Vision II: Non Randomized French Evaluation of GALILEO Intravascular Radiotherapy System in Patients With de Novo Coronary Arteries Lesions by Restenosis on Angioplasty or Restenosis on Endoprosthesis|Completed||Phase 4|268|Actual|Abbott Vascular||1|||f||||||||||||||2018-06-01 04:36:41.354407|2018-06-01 04:36:41.354407
NCT00180570|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-03-10|2005-09-15|2005-09-16|Estimate|||||||2015-03-10|2015-03-11|Estimate|January 1997||1997-01-31|September 2005|2005-09-30|January 2006||2006-01-31|||||Interventional|SALT||SALT - Success of Active Versus Passive Lead Fixation of Atrial Pacing/Sensing Electrodes|Scandinavian Atrial Lead Trial|Suspended||Phase 4|385||Guidant Corporation|||||f||||||||||||||2018-06-01 04:36:41.41863|2018-06-01 04:36:41.41863
NCT00180557|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2015-03-10|2005-09-15|2005-09-16|Estimate|||||||2015-03-10|2015-03-17|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Austria Study - Analysis of Difference Between Active and Passive Fixation Leads|Analyse Der Unterschiede Zwischen Aktiv-fixierenden Und Passiv-fixierenden Stimulations-Elektroden Hinsichtlich Implantationsdauer Und Elektrischer Parameter|Completed||Phase 4|120|Actual|Guidant Corporation||2|||f||||f||||||||||2018-06-01 04:36:41.477968|2018-06-01 04:36:41.477968
NCT00180544|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-07-24|2005-09-13|2005-09-16|Estimate|||||||2008-07-24|2008-07-28|Estimate|July 2000||2000-07-31|July 2008|2008-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|HERCULINK 14||Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease|A Prospective, Non-Randomized, Multicenter, Single-Arm, Clinical Trial to Assess the Safety and Efficacy of the RX HERCULINK 14 Peripheral Stent System for Treatment in de Novo or Restenotic Renal Artery Stenosis|Terminated||Phase 3|167|Actual|Abbott Vascular||1||"Device superceded by next generation device. Enrollment stopped, long term follow up was~   completed in August of 2004."|f||||t||||||||||2018-06-01 04:36:41.545835|2018-06-01 04:36:41.545835
NCT00180531|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-12-12|2005-09-14|2005-09-16|Estimate|||||||2007-12-12|2007-12-13|Estimate|February 2004||2004-02-29|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Monitoring of Arrhythmias and HRV in Patients With Heart Failure Treated With the CRT Pacemaker Renewal TR2|Monitoring of Arrhythmias and Heart Rate Variability in Patients With Congestive Heart Failure Treated With the Cardiac Resynchronisation Pacemaker Renewal TR2|Completed||Phase 4|500||Guidant Corporation|||||f||||||||||||||2018-06-01 04:36:41.624939|2018-06-01 04:36:41.624939
NCT00180518|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-10|2005-09-13|2005-09-16|Estimate|||||||2008-09-10|2008-09-12|Estimate|May 2000||2000-05-31|September 2008|2008-09-30|November 2003|Actual|2003-11-30|October 2003|Actual|2003-10-31||Interventional|||"ACCULINK for Revascularization of Carotids in High Risk Patients The ARCHeR Trial"|Prospective, Non-Randomized, Multi-Center, Single-Arm Trial to Assess Safety & Efficacy of the Acculink Carotid Stent System With the Accunet Embolic Protection System in High-Risk Patients With Carotid Artery Lesions.|Completed||Phase 2/Phase 3|581||Abbott Vascular||1|||f||||t||||||||||2018-06-01 04:36:41.716224|2018-06-01 04:36:41.716224
NCT00180505|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-23|2005-09-13|2005-09-16|Estimate|||||||2010-02-23|2010-02-24|Estimate|March 2005||2005-03-31|February 2010|2010-02-28|October 2009|Actual|2009-10-31|March 2006|Actual|2006-03-31||Interventional|||ASSESS Study: Evaluation of ABSOLUTE™ Stent System for Occluded Arteries|Non-Randomized, Prospective, Multi-center Evaluation of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System for Occluded or Stenotic Superficial Femoral or Proximal Popliteal Arteries|Completed||Phase 4|120|Anticipated|Abbott Vascular||1|||f||||f||||||||||2018-06-01 04:36:41.800244|2018-06-01 04:36:41.800244
NCT00180492|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-27|2005-09-13|2005-09-16|Estimate|||||||2008-10-27|2008-10-29|Estimate|October 2004||2004-10-31|October 2008|2008-10-31|August 2007|Actual|2007-08-31|December 2006|Actual|2006-12-31||Interventional|||Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE|Carotid RX ACCULINK(TM)/ACCUNET(TM) Post-Approval Trial to Uncover Unanticipated or Rare Events - CAPTURE|Completed||N/A|1500||Abbott Vascular|||||f||||||||||||||2018-06-01 04:36:41.896686|2018-06-01 04:36:41.896686
NCT00180479|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2008-10-15||2011-11-16|2005-09-13|2005-09-16|Estimate|2008-12-11|2008-12-15|Estimate||||2011-11-16|2011-11-23|Estimate|June 2005||2005-06-30|November 2011|2011-11-30|November 2011|Actual|2011-11-30|December 2006|Actual|2006-12-31||Interventional|||SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions|Completed||Phase 3|1002|Actual|Abbott Vascular||2|||f||||t||||||||||2018-06-01 04:36:42.015624|2018-06-01 04:36:42.015624
NCT00180466|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-24|2005-09-13|2005-09-16|Estimate|||||||2010-05-24|2010-05-25|Estimate|October 2004||2004-10-31|May 2010|2010-05-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Observational|||PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions|Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) An Imaging Study in Patients With Unstable Atherosclerotic Lesions|Completed|||697|Actual|Abbott Vascular|||||f||||t||||||Samples With DNA|"~     Aproximately 1 ML blood~   "|||2018-06-01 04:36:43.207165|2018-06-01 04:36:43.207165
NCT00180453|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-01-05|2005-09-13|2005-09-16|Estimate|||||||2010-01-05|2010-01-06|Estimate|December 2003||2003-12-31|June 2009|2009-06-30|June 2009|Actual|2009-06-30|April 2005|Actual|2005-04-30||Interventional|||SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System|SPIRIT First: A Clinical Evaluation of an Investigational Device. The Abbott XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions|Completed||Phase 3|60|Actual|Abbott Vascular||2|||f||||t||||||||||2018-06-01 04:36:43.418579|2018-06-01 04:36:43.418579
NCT00180440|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-03-25|2005-09-12|2005-09-16|Estimate|||||||2009-03-25|2009-03-26|Estimate|July 2002||2002-07-31|March 2009|2009-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||INSURE: INcidence Free SUrvival Before and After Implantable Cardioverter Defibrillator (ICD) Replacement|INcidence Free SUrvival Before and After ICD Replacement|Completed|||528|Anticipated|Guidant Corporation|||||f||||||||||||||2018-06-01 04:36:43.531404|2018-06-01 04:36:43.531404
NCT00180427|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-22|2005-09-12|2005-09-16|Estimate|||||||2008-04-22|2008-04-24|Estimate|June 2001||2001-06-30|April 2008|2008-04-30|November 2004|Actual|2004-11-30|||||Interventional|||"VERRARI - Are Ventricular Arrhythmic Episodes Reduced by Rate Response in ICDs?"|"VERRARI - Are Ventricular Arrhythmic Episodes Reduced by Rate Response in ICDs?"|Completed||Phase 4|75||Guidant Corporation|||||f||||||||||||||2018-06-01 04:36:43.590876|2018-06-01 04:36:43.590876
NCT00180232|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2012-02-02|2005-09-14|2005-09-16|Estimate|||||||2012-02-02|2012-02-03|Estimate|April 2006||2006-04-30|February 2012|2012-02-29|June 2006|Actual|2006-06-30|||||Observational|||An Open Clinical Trial to Assess the Influence of Newly Prescribed Aminobiphosphonates on Arterial Stiffness|An Open Clinical Trial to Assess the Influence of Newly Prescribed Aminobiphosphonates on Arterial Stiffness (Changes of the Aortal Elasticity Due to a Newly Established Aminobiphosphinate Therapy for the Treatment of Osteoporosis)|Withdrawn|||0|Actual|Technische Universität Dresden|||1|Clinical partner left University,|f||||f||||||||||2018-06-01 04:36:45.282675|2018-06-01 04:36:45.282675
NCT00180414|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-17|2005-09-12|2005-09-16|Estimate|||||||2017-02-17|2017-02-23|Actual|August 2003||2003-08-31|February 2017|2017-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||MODULA Modul 7 VRR: Correlation Between Ventricular Rate Regulation (VRR) and the Percentage of Biventricular Pacing in Cardiac Resynchronization Therapy (CRT) Patients With Atrial Fibrillation|MODULA-Study: Modul 7 VRR: Correlation Between Ventricular Rate Regulation (VRR) and the Percentage of Biventricular Pacing as Well as Subjective Quality of Life and Level of Physical Ability in CRT Patients With Atrial Fibrillation|Terminated||Phase 4|40|Anticipated|Boston Scientific Corporation||||low enrolment rate|f||||||||||||||2018-06-01 04:36:43.65483|2018-06-01 04:36:43.65483
NCT00180401|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-17|2005-09-12|2005-09-16|Estimate|||||||2017-02-17|2017-02-23|Actual|June 2002||2002-06-30|February 2017|2017-02-28|October 2007|Actual|2007-10-31|||||Observational|||MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms|MODULA-Study: Modul 10: Benefit of CRT-therapy in CRT-Patients With QRS-complex of 120 - 150 ms|Terminated|||100|Anticipated|Boston Scientific Corporation|||2|no longer interest from medical community|f||||||||||||||2018-06-01 04:36:43.727873|2018-06-01 04:36:43.727873
NCT00180388|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-08-31|2005-09-12|2005-09-16|Estimate|||||||2016-08-31|2016-09-01|Estimate|May 2004||2004-05-31|March 2007|2007-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||VENEK: Healing in Different Vein Harvesting Methods During Aortocoronary Coronary Artery Bypass Graft Surgery (CABG)|Comparison of Clinical and Economical Parameters of Healing in Different Vein Harvesting Methods During Aortocoronary CABG|Terminated||Phase 4|300|Anticipated|Boston Scientific Corporation||2||terminated for logistical reasons|f||||||||||||||2018-06-01 04:36:43.798227|2018-06-01 04:36:43.798227
NCT00180375|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-17|2005-09-12|2005-09-16|Estimate|||||||2017-02-17|2017-02-23|Actual|May 2002||2002-05-31|February 2017|2017-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator|OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator|Completed|||636|Actual|Boston Scientific Corporation|||||f||||f||||||||No||2018-06-01 04:36:43.886114|2018-06-01 04:36:43.886114
NCT00180362|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-17|2005-09-12|2005-09-16|Estimate|||||||2017-02-17|2017-02-23|Actual|May 2004||2004-05-31|February 2017|2017-02-28|September 2004||2004-09-30|||||Interventional|Quick ICD||Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ?|Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary in Patients After Survived Cardiac Arrest? A Prospective Randomised Multi-centre Trial.|Completed||Phase 4|200||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:36:44.014058|2018-06-01 04:36:44.014058
NCT00180349|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-12|2005-09-12|2005-09-16|Estimate|||||||2017-04-12|2017-04-14|Actual|December 2004||2004-12-31|April 2017|2017-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Leader - Evaluation of Endotak Reliance|Short and Long Term Evaluation of Electrical Measurements and Defibrillation Energies, Results of ATP and Diagnostic Functions of Devices Connected to Endotak RELIANCE® Defibrillation Leads|Completed|||904|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-06-01 04:36:44.075835|2018-06-01 04:36:44.075835
NCT00180336|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-06-22|2005-09-12|2005-09-16|Estimate|||||||2007-06-22|2007-06-25|Estimate|July 2004||2004-07-31|June 2007|2007-06-30||||||||Interventional|||Safety and Efficacy Study of RENEWAL 4 AVT|CONTAK RENEWAL 4 AVT Field Following|Completed||Phase 2/Phase 3|170||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:36:44.168718|2018-06-01 04:36:44.168718
NCT00180323|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-03-09||2016-01-05|2005-09-12|2005-09-16|Estimate|2012-10-11|2012-11-12|Estimate||||2016-01-05|2016-02-03|Estimate|November 2004||2004-11-30|October 2012|2012-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||ACC - Atrial Contribution to CRT|ACC - Atrial Contribution to CRT|Completed||Phase 4|43|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-06-01 04:36:44.252737|2018-06-01 04:36:44.252737
NCT00180310|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-07-18|2005-09-11|2005-09-16|Estimate|||||||2011-07-18|2011-07-20|Estimate|July 2005||2005-07-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|July 2007|Actual|2007-07-31||Interventional|SPIRIT II||SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System|A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions|Completed||Phase 3|300|Actual|Abbott Vascular||2|||f||||t||||||||||2018-06-01 04:36:44.457297|2018-06-01 04:36:44.457297
NCT00180297|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-24|2005-09-12|2005-09-16|Estimate|||||||2017-02-24|2017-02-28|Actual|April 2005||2005-04-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead|Evaluation of the Success Rate and the Clinical Evolution of a Ventricular Lead Implanted in the Septum Versus the Right Ventricular Apex.|Completed||N/A|208|Actual|Boston Scientific Corporation||2|||f||||||||||||||2018-06-01 04:36:44.588724|2018-06-01 04:36:44.588724
NCT00180284|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-09-28|2005-09-09|2005-09-16|Estimate|||||||2011-09-28|2011-09-29|Estimate|November 2004||2004-11-30|September 2011|2011-09-30|February 2008|Actual|2008-02-29|May 2005|Actual|2005-05-31||Interventional|||SITELINE 2 Polyurethane|SITELINE 2 Polyurethane Clinical Investigation|Completed||Phase 3|200|Actual|Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:36:44.716195|2018-06-01 04:36:44.716195
NCT00180271|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2011-02-23|2010-07-09|2012-01-24|2005-09-09|2005-09-16|Estimate|2011-05-31|2011-06-02|Estimate|2010-07-12|2010-07-14|Estimate|2012-01-24|2012-01-30|Estimate|December 2004||2004-12-31|January 2012|2012-01-31|September 2010|Actual|2010-09-30|June 2009|Actual|2009-06-30||Interventional|MADIT-CRT||MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy|Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy|Completed||Phase 2/Phase 3|1820|Actual|Boston Scientific Corporation|The FDA Circulatory Devices advisory panel recommended approval for the patient subpopulation with left bundle branch block (LBBB) only. Consequently, FDA has restricted indications for use to LBBB.|2|||f||||t||||||||||2018-06-01 04:36:44.788842|2018-06-01 04:36:44.788842
NCT00180258|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-01-23|2005-09-09|2005-09-16|Estimate|||||||2007-01-23|2007-01-25|Estimate|January 2000||2000-01-31|January 2007|2007-01-31|December 2002||2002-12-31|||||Interventional|||Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure|Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure|Completed||Phase 2/Phase 3|2200||Boston Scientific Corporation|||||||||||||||||||2018-06-01 04:36:45.182055|2018-06-01 04:36:45.182055
NCT00180245|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-15|2005-09-13|2005-09-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2005||2005-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Tumor Metabolism of Head and Neck Cancer in Patients Who Underwent Radiation Therapy Measured With F-18-FDG-PET||Completed|||44|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 04:36:45.235341|2018-06-01 04:36:45.235341
NCT00180024|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-16|Estimate|||||||2005-09-09|2005-09-16|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.||Completed||N/A|||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:46.449942|2018-06-01 04:36:46.449942
NCT00180219|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2016-08-24|2005-09-15|2005-09-16|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|June 2006|Actual|2006-06-30|||||Observational|||Clinical Trial to Assess the Influence of Gestational Stage and Maternal Age on Arterial Stiffness of the Mother|An Open Clinical Trial to Assess the Influence of Gestational Stage and Maternal Age on Arterial Stiffness of the Mother (Hormonal and Age Related Changes of the Aortal Elasticity)|Withdrawn|||0|Actual|Technische Universität Dresden|||3|recruitment failure|f||||f||||||||||2018-06-01 04:36:45.329928|2018-06-01 04:36:45.329928
NCT00180206|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-01-13|2005-09-13|2005-09-16|Estimate|||||||2006-01-13|2006-01-16|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|December 2008||2008-12-31|||||Interventional|||Birmingham Hip Resurfacing (BHR) Study: Implantation of a Hip Resurfacing Endoprosthesis|Prospective, Non-Randomised, Non-Comparative Multicentric Investigation of the Functional and Radiological Result and Subjective Patient Outcome After Implantation of a Hip Resurfacing Endoprosthesis (Birmingham Hip Resurfacing)|Unknown status|Recruiting|Phase 4|300||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:45.378416|2018-06-01 04:36:45.378416
NCT00180193|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-08-25|2005-09-13|2005-09-16|Estimate|||||||2009-08-25|2009-08-26|Estimate|December 2003||2003-12-31|August 2009|2009-08-31||||||||Observational|||F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response|F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response|Terminated|||40|Anticipated|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 04:36:45.438916|2018-06-01 04:36:45.438916
NCT00180180|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-03-15|2005-09-13|2005-09-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Tumor Hypoxia of Head-and-neck Cancer Underwent Radiation Therapy Measured With F-18-FMISO|Tumor Hypoxia of Head-and-neck Cancer Underwent Radiation Therapy Measured With F-18-FMISO|Active, not recruiting|||60|Actual|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 04:36:45.479343|2018-06-01 04:36:45.479343
NCT00180167|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-08-19|2005-09-13|2005-09-16|Estimate|||||||2010-08-19|2010-08-20|Estimate|January 2005||2005-01-31|August 2010|2010-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC|Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC|Completed||Phase 4|492|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 04:36:45.525417|2018-06-01 04:36:45.525417
NCT00180154|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-23|2005-09-13|2005-09-16|Estimate|||||||2011-08-23|2011-08-24|Estimate|July 2005||2005-07-31|August 2011|2011-08-31||||||||Observational|||Tumor Metabolism of Lung Cancer in Patients Who Underwent Percutaneous Radiation Measured With F-18-FDG-PET|Tumor Metabolism of Lung Cancer Underwent Percutaneous Radiation Measured With F-18-FDG-PET|Completed|||50|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:45.623621|2018-06-01 04:36:45.623621
NCT00180141|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-06|2005-09-12|2005-09-16|Estimate|||||||2008-05-06|2008-05-09|Estimate|April 2005||2005-04-30|May 2008|2008-05-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Elidel-Study: Elidel in Patients With Atopic Dermatitis|Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods|Completed||Phase 4|24|Anticipated|Technische Universität Dresden|||||f||||f||||||||||2018-06-01 04:36:45.669588|2018-06-01 04:36:45.669588
NCT00180128|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-07-08|2005-09-12|2005-09-16|Estimate|||||||2011-07-08|2011-07-11|Estimate|January 2000||2000-01-31|July 2011|2011-07-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia|AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL)|Unknown status|Recruiting|Phase 4|80|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:45.781615|2018-06-01 04:36:45.781615
NCT00180115|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-07-16|2005-09-12|2005-09-16|Estimate|||||||2007-07-16|2007-07-17|Estimate|February 1996||1996-02-29|July 2007|2007-07-31|November 2008||2008-11-30|||||Interventional|||AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients|AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients. A Cooperative AML-Study of the German SHG-Study Group.|Completed||Phase 4|400||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:45.87647|2018-06-01 04:36:45.87647
NCT00180102|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-12-23|2005-09-12|2005-09-16|Estimate|||||||2009-12-23|2009-12-24|Estimate|December 2003||2003-12-31|December 2009|2009-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years|AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.|Completed||Phase 4|600|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:45.959204|2018-06-01 04:36:45.959204
NCT00180089|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-29|2005-09-09|2005-09-16|Estimate|||||||2010-03-29|2010-03-30|Estimate|January 2004||2004-01-31|March 2010|2010-03-31|January 2010||2010-01-31|March 2009|Actual|2009-03-31||Interventional|||Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation|Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation|Completed||Phase 3|242|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:46.050146|2018-06-01 04:36:46.050146
NCT00180076|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-29|2005-09-09|2005-09-16|Estimate|||||||2010-03-29|2010-03-30|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|March 2008||2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Budesonide for Maintenance Treatment of Collagenous Colitis|Efficacy and Safety of Budesonide in Maintenance Treatment of Collagenous Colitis|Completed||Phase 3|75|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:46.129851|2018-06-01 04:36:46.129851
NCT00180063|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-01|2005-09-09|2005-09-16|Estimate|||||||2005-11-01|2005-11-02|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Characterization of Local Vascular Effects of LNMMA||Completed||N/A|||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:46.198632|2018-06-01 04:36:46.198632
NCT00180050|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-29|2005-09-09|2005-09-16|Estimate|||||||2010-03-29|2010-03-30|Estimate|January 2002||2002-01-31|March 2010|2010-03-31|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Interventional|||Budesonide Treatment for Lymphocytic Colitis|Efficacy and Safety of Budesonide for Treatment of Lymphocytic Colitis|Completed||Phase 3|40|Anticipated|Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:36:46.25739|2018-06-01 04:36:46.25739
NCT00180037|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-16|2005-09-09|2005-09-16|Estimate|||||||2009-01-16|2009-01-19|Estimate|September 2003||2003-09-30|January 2009|2009-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease|Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease|Completed||Phase 3|132||Technische Universität Dresden|||||f||||t||||||||||2018-06-01 04:36:46.344699|2018-06-01 04:36:46.344699
NCT00180011|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2012-02-27|2005-09-10|2005-09-16|Estimate|||||||2012-02-27|2012-02-28|Estimate|September 2005||2005-09-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma|Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma|Completed||Phase 2/Phase 3|18|Actual|DiMango, Emily, M.D.||1|||f||||f||||||||||2018-06-01 04:36:46.510985|2018-06-01 04:36:46.510985
NCT00179998|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2013-08-19|2005-09-10|2005-09-16|Estimate|||||||2013-08-19|2013-08-20|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|July 2015|Anticipated|2015-07-31|October 2008|Actual|2008-10-31||Interventional|||Effectiveness of Pulmozyme in Infants With Cystic Fibrosis|Efficacy of Pulmozyme in Infants and Young Children With Cystic Fibrosis|Unknown status|Active, not recruiting|Phase 2|24|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-06-01 04:36:46.589835|2018-06-01 04:36:46.589835
NCT00179985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2011-07-28|2005-09-14|2005-09-16|Estimate|||||||2011-07-28|2011-07-29|Estimate|December 2004||2004-12-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|May 2006|Actual|2006-05-31||Observational|||The Impact of Implementing NIDCAP on the Developmental Sensitivity of Nurses Caring for Preterm Infants|The Impact of Implementing The Newborn Individualized Developmental Care & Assessment Program on the Developmental Sensitivity of Nurses Caring for Preterm Infants|Completed|||32|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||t||||||||||2018-06-01 04:36:46.695615|2018-06-01 04:36:46.695615
NCT00179972|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2015-07-29|2005-09-14|2005-09-16|Estimate|||||||2015-07-29|2015-07-31|Estimate|September 2005||2005-09-30|July 2015|2015-07-31|May 2010|Actual|2010-05-31|||||Observational|||Evaluation of Pulse Oximetry Sensors in Neonates|Evaluation of Pulse Oximetry Sensors in Neonates|Terminated|||32|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||||"Lack of resources and loss of personnel precluded study progress. No adverse events or~   unanticipated problems involving risks to subjects."|f||||||||||||||2018-06-01 04:36:46.758263|2018-06-01 04:36:46.758263
NCT00179959|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-04-04||2014-11-20|2005-09-13|2005-09-16|Estimate|2011-04-04|2011-04-29|Estimate||||2014-11-20|2014-12-08|Estimate|September 2005||2005-09-30|November 2014|2014-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis|The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis|Completed||Phase 4|31|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 04:36:46.823308|2018-06-01 04:36:46.823308
NCT00179946|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-14|2005-09-12|2005-09-16|Estimate|||||||2008-01-14|2008-01-15|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||HLA Matching - Unrelated Umbilical Cord Blood Transplantation|Impact of HLA Matching on Outcome in Pediatric Patients Undergoing Unrelated Umbilical Cord Blood Transplantation.|Completed|||30|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||||||||||||2018-06-01 04:36:47.037941|2018-06-01 04:36:47.037941
NCT00179933|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-10-07|2005-09-14|2005-09-16|Estimate|||||||2010-10-07|2010-10-11|Estimate|September 2005||2005-09-30|October 2010|2010-10-31|February 2007|Actual|2007-02-28|||||Interventional|||The Impact of Implementing NIDCAP on Preterm Infants in the NICU|The Impact of Implementing the Newborn Individualized Developmental Care and Assessment Program on Neurobehavioral Organization of Preterm Infants in the NICU|Terminated||N/A|40||Ann & Robert H Lurie Children's Hospital of Chicago||||Unable to fulfill intention of study, lost investigators.|f||||f||||||||||2018-06-01 04:36:47.089525|2018-06-01 04:36:47.089525
NCT00179920|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-09-25|2005-09-12|2005-09-16|Estimate|||||||2012-09-25|2012-09-27|Estimate|April 1996||1996-04-30|June 2011|2011-06-30|September 2006||2006-09-30|||||Interventional|||Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma|Chemotherapy Plus Local Surgical Treatment in Children With Intraocular Germ-Line Retinoblastoma|Unknown status|Active, not recruiting|Phase 2|30||Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||||||||||||2018-06-01 04:36:47.142259|2018-06-01 04:36:47.142259
NCT00179907|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-02-27|2005-09-12|2005-09-16|Estimate|||||||2015-02-27|2015-03-02|Estimate|May 2001||2001-05-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase I/II Study of the Photon Radiosurgery System|A Phase I/II Study of Reirradiation for Recurrent Pediatric Brain and Spinal Cord Tumors and Primary Glioblastoma Multiforme Using the Photon Radiosurgery System|Completed||Phase 1/Phase 2|35|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||||||||||||2018-06-01 04:36:47.20413|2018-06-01 04:36:47.20413
NCT00179894|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-08-14|2005-09-12|2005-09-16|Estimate|||||||2015-08-14|2015-08-17|Estimate|June 2003||2003-06-30|August 2015|2015-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Improving Attention Deficit Hyperactivity Disorder Treatment Adherence and Outcome in Primary Care Settings|Improving Medication Use for ADHD in Primary Care|Completed||N/A|270|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-06-01 04:36:47.258364|2018-06-01 04:36:47.258364
NCT00179881|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-06-22|2005-09-12|2005-09-16|Estimate|||||||2011-06-22|2011-06-27|Estimate|December 1999||1999-12-31|June 2011|2011-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma|Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma|Completed||Phase 2|47|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||||||||||||2018-06-01 04:36:47.317919|2018-06-01 04:36:47.317919
NCT00179868|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-08-26|2005-09-10|2005-09-16|Estimate|||||||2008-08-26|2008-08-27|Estimate|January 2003||2003-01-31|August 2008|2008-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||C-Reactive Protein as a Predictor of Stem Cell Transplant Complications|C-Reactive Protein As a Predictor of Major Transplant Complications in Pediatric Stem Cell Transplant Patients|Completed|||44|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 04:36:47.380956|2018-06-01 04:36:47.380956
NCT00179855|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2010-10-07|2005-09-10|2005-09-16|Estimate|||||||2010-10-07|2010-10-11|Estimate|July 2003||2003-07-31|October 2010|2010-10-31|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Extracorporeal Photopheresis for Acute Graft Versus Host Disease|Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study.|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 04:36:47.435867|2018-06-01 04:36:47.435867
NCT00179842|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2015-09-21|2005-09-10|2005-09-16|Estimate|||||||2015-09-21|2015-09-23|Estimate||||January 2009|2009-01-31|December 2008||2008-12-31|||||Interventional|||Immune Ablation and Stem Cell Support for Crohn's Disease|Immune Ablation and Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease|Withdrawn||Phase 2|0|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 04:36:47.497508|2018-06-01 04:36:47.497508
NCT00179075|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-12|2005-09-13|2005-09-15|Estimate|||||||2008-12-12|2008-12-15|Estimate|April 2003||2003-04-30|December 2008|2008-12-31|April 2008|Actual|2008-04-30|||||Observational|||Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant|Repository for Study: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)|Completed|||100|Anticipated|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:36:58.110852|2018-06-01 04:36:58.110852
NCT00179829|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-01-14|2005-09-10|2005-09-16|Estimate|||||||2008-01-14|2008-01-15|Estimate|February 1999||1999-02-28|January 2008|2008-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||WT1 for the Detection of Minimal Residual Disease|Detection of Minimal Residual Disease in Newly Diagnosed Patients With Leukemia and Those Who Undergo a Bone Marrow Transplant Using the Wilms Tumor Suppressor Gene (WT1) as a Marker By RT-PCR|Completed||Phase 2/Phase 3|50|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||||||||||||2018-06-01 04:36:47.588327|2018-06-01 04:36:47.588327
NCT00179816|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2010-10-07|2005-09-10|2005-09-16|Estimate|||||||2010-10-07|2010-10-11|Estimate|April 1999||1999-04-30|October 2010|2010-10-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors|High-Dose Chemotherapy With Tandem Peripheral Blood Stem Cell (PBSC) Rescue for the Treatment of High-Risk Pediatric Solid Tumors.|Unknown status|Recruiting|Phase 1/Phase 2|12|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 04:36:47.649955|2018-06-01 04:36:47.649955
NCT00179803|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-03-10|2005-09-10|2005-09-16|Estimate|||||||2011-03-10|2011-03-14|Estimate|March 1998||1998-03-31|March 2011|2011-03-31||||January 2008|Actual|2008-01-31||Interventional|||Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors|Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors|Unknown status|Active, not recruiting|Phase 2/Phase 3|50|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 04:36:47.729797|2018-06-01 04:36:47.729797
NCT00179790|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-03-02|2005-09-09|2005-09-16|Estimate|||||||2017-03-02|2017-03-06|Actual|July 2005||2005-07-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|June 2010|Actual|2010-06-30||Interventional|||Reduced Intensity Transplant Using Extracorporeal Photopheresis|Reduced Intensity Stem Cell Transplant in Children and Young Adults Utilizing Photopheresis, Fludarabine, and Busulfan|Completed||Phase 1/Phase 2|22|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||||||||||||2018-06-01 04:36:47.784955|2018-06-01 04:36:47.784955
NCT00179777|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-07-12|2005-09-10|2005-09-16|Estimate|||||||2017-07-12|2017-07-14|Actual|March 2002|Actual|2002-03-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|March 2017|Actual|2017-03-31||Interventional|||TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk|TRIGR - Trial to Reduce IDDM in the Genetically at Risk|Active, not recruiting||N/A|2032|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||Undecided||2018-06-01 04:36:47.898688|2018-06-01 04:36:47.898688
NCT00179764|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2016-07-25|2005-09-10|2005-09-16|Estimate|||||||2016-07-25|2016-07-27|Estimate|March 2000||2000-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])|Immunoablative Protocol for Allogeneic Related and Unrelated Hematopoietic Peripheral Blood Stem Cell Transplant (HPBSC)|Recruiting||Phase 2|100|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-06-01 04:36:48.032101|2018-06-01 04:36:48.032101
NCT00179751|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-11-02|2005-09-13|2005-09-16|Estimate|||||||2005-11-02|2005-11-07|Estimate|April 2005||2005-04-30|November 2005|2005-11-30|August 2006||2006-08-31|||||Interventional|||A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas|A Phase I/II Study Of Lenalidomide (Revlimid ) In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas|Terminated||Phase 1/Phase 2|50||Celgene|||||||||||||||||||2018-06-01 04:36:48.101676|2018-06-01 04:36:48.101676
NCT00179738|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-11-22|2005-09-13|2005-09-16|Estimate|||||||2005-11-22|2005-11-23|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|April 2007||2007-04-30|||||Interventional|||A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.|A Multicenter, Single-Arm, Open-Label, Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®) In Subjects With Androgen Independent Prostate Cancer|Terminated||Phase 2|40||Celgene|||||||||||||||||||2018-06-01 04:36:48.160076|2018-06-01 04:36:48.160076
NCT00179725|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2006-04-10|2005-09-13|2005-09-16|Estimate|||||||2006-04-10|2006-04-12|Estimate|November 2005||2005-11-30|April 2006|2006-04-30|June 2007||2007-06-30|||||Interventional|||Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma|Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma|Terminated||Phase 1/Phase 2|60||Celgene|||||||||||||||||||2018-06-01 04:36:49.166138|2018-06-01 04:36:49.166138
NCT00179712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2016-11-30|2005-09-13|2005-09-16|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2005||2005-04-30|November 2016|2016-11-30|November 2006||2006-11-30|||||Interventional|||Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma|Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma|Completed||Phase 1/Phase 2|60||Celgene Corporation|||||||||||||||||||2018-06-01 04:36:49.234548|2018-06-01 04:36:49.234548
NCT00179699|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-11-02|2005-09-13|2005-09-16|Estimate|||||||2005-11-02|2005-11-07|Estimate|September 2005||2005-09-30|October 2005|2005-10-31|November 2006||2006-11-30|||||Interventional|||Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer|Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1|40||Celgene|||||||||||||||||||2018-06-01 04:36:49.301575|2018-06-01 04:36:49.301575
NCT00179686|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2006-12-19|2005-09-13|2005-09-16|Estimate|||||||2006-12-19|2006-12-20|Estimate|March 2005||2005-03-31|December 2006|2006-12-31|July 2006||2006-07-31|||||Interventional|||A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer|A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer|Completed||Phase 2|40||Celgene|||||||||||||||||||2018-06-01 04:36:49.363574|2018-06-01 04:36:49.363574
NCT00179673|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|2013-08-09||2013-11-06|2005-09-13|2005-09-16|Estimate|2013-08-09|2013-10-14|Estimate||||2013-11-06|2013-11-28|Estimate|August 2005||2005-08-31|November 2013|2013-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|Completed||Phase 2|43|Actual|Celgene||1|||f||||f||||||||||2018-06-01 04:36:49.455532|2018-06-01 04:36:49.455532
NCT00179660|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-06-25||2015-12-17|2005-09-13|2005-09-16|Estimate|2013-06-25|2013-09-02|Estimate||||2015-12-17|2016-01-21|Estimate|August 2005||2005-08-31|December 2015|2015-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional||Intent to treat population includes all participants who received at least 1 dose of study drug.|Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)|A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|50|Actual|Celgene||1|||f||||||||||||||2018-06-01 04:36:49.942129|2018-06-01 04:36:49.942129
NCT00179647|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-12-21||2010-03-10|2005-09-13|2005-09-16|Estimate|2010-02-02|2010-03-03|Estimate||||2010-03-10|2010-03-16|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|April 2009|Actual|2009-04-30|December 2008|Actual|2008-12-31||Interventional|||Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma|A Multicenter, Single-Arm, Open-Label, Expanded Access Program for Lenalidomide With or Without Dexamethasone in Previously Treated Subjects With Multiple Myeloma|Completed||Phase 3|1913|Actual|Celgene||1|||t||||f||||||||||2018-06-01 04:36:50.389776|2018-06-01 04:36:50.389776
NCT00179634|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-22|2005-09-13|2005-09-16|Estimate|||||||2017-03-22|2017-03-24|Actual|March 2005||2005-03-31|March 2017|2017-03-31|March 27, 2008|Actual|2008-03-27|March 27, 2008|Actual|2008-03-27||Interventional|||Study of Fine Art Photographs and Visualization Tapes to Improve Surgical Recovery in Breast Cancer|Using Visual Milieu Enrichment and Guided Visualization to Augment Patient Well-being and Post-surgical Recovery|Terminated||N/A|24|Actual|Beth Israel Deaconess Medical Center||3||Expired for lack of continuing review|f||||f||||||||||2018-06-01 04:36:51.36344|2018-06-01 04:36:51.36344
NCT00179621|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|2011-02-09||2011-04-12|2005-09-10|2005-09-16|Estimate|2011-02-09|2011-03-17|Estimate||||2011-04-12|2011-04-14|Estimate|July 2005||2005-07-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2008|Actual|2008-06-30||Interventional|||Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of the Efficacy and Safety of 2 Doses of Lenalidomide Versus Placebo in Red Blood Cell (RBC) Transfusion-Dependent Subjects With Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated With a Deletion (Del) 5q[31] Cytogenetic Abnormality|Completed||Phase 3|205|Actual|Celgene||3|||f||||t||||||||||2018-06-01 04:36:51.520317|2018-06-01 04:36:51.520317
NCT00179608|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-30|2005-09-13|2005-09-16|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2005||2005-09-30|November 2016|2016-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy|Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy|Completed||Phase 1|28||Celgene Corporation|||||||||||||||||||2018-06-01 04:36:53.392624|2018-06-01 04:36:53.392624
NCT00179595|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-14|2005-09-13|2005-09-16|Estimate|||||||2017-02-14|2017-02-16|Actual|May 2002||2002-05-31|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Does the Relaxation Response Inhibit Acute Stress?|Does the Relaxation Response Inhibit Acute Stress?|Completed||Phase 2|140|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||||No||2018-06-01 04:36:53.452548|2018-06-01 04:36:53.452548
NCT00179582|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-02|2005-09-13|2005-09-16|Estimate|||||||2017-03-02|2017-03-06|Actual|January 2005|Actual|2005-01-31|March 2017|2017-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS|A Randomized, Multi-center, Double-blind, Placebo Controlled, Dose Ranging Study With VSL#3 in Diarrhea Predominant IBS Patients|Terminated||N/A|180|Anticipated|Beth Israel Deaconess Medical Center||||Lack of enrollment|f||||||||||||||2018-06-01 04:36:53.50465|2018-06-01 04:36:53.50465
NCT00179569|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-02|2005-09-15|2005-09-16|Estimate|||||||2007-11-02|2007-11-05|Estimate|August 2005||2005-08-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||Molecular Processes of the Relaxation Response in Older Adults|Molecular Processes of the Relaxation Response in Older Adults|Completed||Phase 2|40|Anticipated|Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:36:53.562295|2018-06-01 04:36:53.562295
NCT00179556|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-12|2005-09-13|2005-09-16|Estimate|||||||2017-03-12|2017-03-14|Actual|June 2003||2003-06-30|March 2017|2017-03-31|September 2005|Actual|2005-09-30|July 2005|Actual|2005-07-31||Interventional|||Effects of Soy Isoflavones on Menopausal Hot Flashes|Daidzein-rich Isoflavone-aglycones for Menopausal Symptoms|Completed||Phase 2/Phase 3|210||Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:36:53.612064|2018-06-01 04:36:53.612064
NCT00179543|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-09-18|2005-09-13|2005-09-16|Estimate|||||||2006-09-18|2006-09-19|Estimate|August 2001||2001-08-31|September 2006|2006-09-30||||||||Interventional|||Mechanisms and Therapeutic Effects of the Relaxation Response in Elderly Hypertensive Patients|Mechanisms and Therapeutic Effects of the Relaxation Response in Elderly Hypertensive Patients|Completed||Phase 2|122||Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:36:53.663937|2018-06-01 04:36:53.663937
NCT00179530|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-02|2005-09-13|2005-09-16|Estimate|||||||2007-11-02|2007-11-05|Estimate|May 1999||1999-05-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||The Effect of Relaxation Response Training on Declarative Memory and Salivary Cortisol in Older Adults|The Effect of Relaxation Response Training on Declarative Memory and Salivary Cortisol in Older Adults|Completed||Phase 2|16|Actual|Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:36:53.71331|2018-06-01 04:36:53.71331
NCT00179517|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2017-03-16||2017-08-31|2005-09-13|2005-09-16|Estimate|2017-07-07|2017-08-08|Actual||||2017-08-31|2017-10-03|Actual|June 2001||2001-06-30|August 2017|2017-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo|Comparison of Anastrozole and Testosterone Versus Placebo and Testosterone Treatment of Reproductive and Sexual Dysfunction in Men With Epilepsy and Hypogonadism|Completed||Phase 2|40|Actual|Beth Israel Deaconess Medical Center||2|||f||||||||||||No||2018-06-01 04:36:53.849358|2018-06-01 04:36:53.849358
NCT00179504|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-02|2005-09-13|2005-09-16|Estimate|||||||2007-11-02|2007-11-05|Estimate|July 2000||2000-07-31|November 2007|2007-11-30|September 2007|Actual|2007-09-30|||||Interventional|||The Effect of Relaxation Response Training on Declarative Memory and Learning in High School Students|The Effect of Relaxation Response Training on Declarative Memory and Learning in High School Students|Completed||Phase 2|90|Actual|Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:36:54.224847|2018-06-01 04:36:54.224847
NCT00179491|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-02|2005-09-13|2005-09-16|Estimate|||||||2007-11-02|2007-11-05|Estimate|April 1998||1998-04-30|November 2007|2007-11-30|November 2001|Actual|2001-11-30|||||Interventional|||Study of the Therapeutic Effects of Intercessory Prayer (STEP)|Study of the Therapeutic Effects of Intercessory Prayer (STEP)|Completed||Phase 3|1802|Actual|Beth Israel Deaconess Medical Center||3|||f||||||||||||||2018-06-01 04:36:54.279148|2018-06-01 04:36:54.279148
NCT00179478|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-04-14||2017-08-06|2005-09-12|2005-09-16|Estimate|2017-08-06|2017-09-06|Actual||||2017-08-06|2017-09-06|Actual|February 2001||2001-02-28|August 2017|2017-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|CHAMPIONS10||Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis|Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10)|Completed||Phase 4|155|Actual|Beth Israel Deaconess Medical Center|selective attrition of patients with greater levels of disease activity may have occurred in this long term extension study|2|||f||||t||||||||No||2018-06-01 04:36:54.44893|2018-06-01 04:36:54.44893
NCT00179465|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-10|2005-09-12|2005-09-16|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2003||2003-11-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Treating Schizophrenia by Correcting Abnormal Brain Development|Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex|Active, not recruiting||Phase 3|36|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 04:36:54.893759|2018-06-01 04:36:54.893759
NCT00179452|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-09|2005-09-13|2005-09-16|Estimate|||||||2017-03-09|2017-03-13|Actual|October 2003||2003-10-31|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Yoga for Patients With Epilepsy|Is Yoga Safe for Patients With Epilepsy?|Completed||N/A|20|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||No|No plan to share as was not included in original protocol as approved by the IRB, so subject consent was not obtained.|2018-06-01 04:36:54.978602|2018-06-01 04:36:54.978602
NCT00179439|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-11|2005-09-12|2005-09-16|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2004|Actual|2004-01-31|December 2017|2017-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|NPD||NPDT Evaluation in Children With CFTR and (PSC)|Nasal Potential Difference Testing: Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Children With Primary Sclerosing Cholangitis (PSC)|Completed|||50|Anticipated|Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:36:55.038186|2018-06-01 04:36:55.038186
NCT00179426|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-09|2005-09-12|2005-09-16|Estimate|||||||2017-03-09|2017-03-13|Actual|October 1999||1999-10-31|March 2017|2017-03-31|June 2006||2006-06-30|||||Observational|||Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy|Antiseizure Medication-Induced Elevation of Serum Estradiol and Reproductive Dysfunction in Men With Epilepsy|Completed|||175||Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:36:55.11113|2018-06-01 04:36:55.11113
NCT00179413|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|2017-04-13||2017-06-11|2005-09-10|2005-09-16|Estimate|2017-06-11|2017-07-11|Actual||||2017-06-11|2017-07-11|Actual|January 15, 2000|Actual|2000-01-15|June 2017|2017-06-30|March 3, 2010|Actual|2010-03-03|December 31, 2009|Actual|2009-12-31||Interventional|COPILOT||Study of Long-term Peg Intron vs. Colchicine in Non-responders.|Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial|Completed||Phase 4|549|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||No||2018-06-01 04:36:55.177236|2018-06-01 04:36:55.177236
NCT00179400|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-30|2005-09-13|2005-09-16|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2000|Actual|2000-12-31|June 2017|2017-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone|The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans|Completed||N/A|18|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-06-01 04:36:55.613247|2018-06-01 04:36:55.613247
NCT00179387|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-23|2005-09-13|2005-09-16|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 1, 2004|Actual|2004-12-01|January 2017|2017-01-31|February 25, 2016|Actual|2016-02-25|February 25, 2016|Actual|2016-02-25||Interventional|||Mind-Body Program for Cancer Patients|Evaluation of Mind-Body Groups on the Quality of Life of Cancer Patients|Completed||N/A|166|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-06-01 04:36:55.669951|2018-06-01 04:36:55.669951
NCT00179374|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-04-24|2005-09-13|2005-09-16|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2003||2003-07-31|April 2018|2018-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Improving Diabetes Outcomes With Activity, Nutrition and Medication|Improving Diabetes Medication Adherence and Outcomes|Completed||N/A|556|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-06-01 04:36:55.739643|2018-06-01 04:36:55.739643
NCT00179361|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-02-28|2005-09-13|2005-09-16|Estimate|||||||2018-02-28|2018-03-02|Actual|November 2004||2004-11-30|February 2018|2018-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Natural History of Oro-pharyngeal Cancer Precursors|Natural History of Oral Cancer Precursors|Completed|||374|Actual|Albert Einstein College of Medicine, Inc.|||||f||||f||||||Samples With DNA|"~     Oral brush samples.~   "|||2018-06-01 04:36:55.801068|2018-06-01 04:36:55.801068
NCT00179348|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-23|2005-09-13|2005-09-16|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 8, 2001|Actual|2001-02-08|January 2017|2017-01-31|July 20, 2016|Actual|2016-07-20|July 20, 2016|Actual|2016-07-20||Interventional|||Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer|Evaluation of a Yoga-Based Cancer Rehabilitation Program|Completed||N/A|399|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-06-01 04:36:55.914935|2018-06-01 04:36:55.914935
NCT00179335|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2009-08-05|2005-09-10|2005-09-16|Estimate|||||||2009-08-05|2009-08-06|Estimate|August 2003||2003-08-31|August 2009|2009-08-31|September 2006|Actual|2006-09-30|January 2006|Actual|2006-01-31||Observational|||Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults|Cross Sectional Case-Sectional Control Pharmacokinetic Study of Efavirenz or Lopinavir/Ritonavir as Part of an Antiretroviral Regimen With Two Nucleosides in HIV-Infected Adults 55 Years of Age or Older Compared With Adults Aged 18-35 Years|Completed|||45|Actual|Albert Einstein College of Medicine, Inc.|||||f||||||||||Samples Without DNA|"~     Residual plasma left from measurement of drug levels.~   "|||2018-06-01 04:36:56.018182|2018-06-01 04:36:56.018182
NCT00179322|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|||2018-05-19|2005-09-14|2005-09-15|Estimate|||||||2018-05-19|2018-05-22|Actual|September 10, 2005||2005-09-10|September 30, 2016|2016-09-30|September 30, 2016||2016-09-30|||||Observational|||Effects of Sleep Deprivation and Recovery on Cognitive Functions|Effects of Sleep Deprivation and Recovery Sleep on Speech, Language and Other Higher Cognitive Functions: A Combined EEG-fMRI Study|Completed|||29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:36:56.077052|2018-06-01 04:36:56.077052
NCT00179062|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-08-25|2005-09-13|2005-09-15|Estimate|||||||2008-08-25|2008-08-26|Estimate|February 2000||2000-02-29|August 2008|2008-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder|Effects of Risperidone and Olanzapine on Weight Gain, Physical Health, and Outcome in a Community Sample of Severity and Persistently Ill Patients|Completed||N/A|300|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:36:58.17819|2018-06-01 04:36:58.17819
NCT00179309|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-15|2013-04-29||2014-06-30|2005-09-14|2005-09-15|Estimate|2013-06-25|2013-06-27|Estimate||||2014-06-30|2014-07-15|Estimate|September 2005||2005-09-30|June 2014|2014-06-30|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Interventional|||Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer|A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer|Completed||Phase 2|48|Actual|National Institutes of Health Clinical Center (CC)|The goal of this study was to get preliminary evidence of improved progression free survival with the combination compared with docetaxel alone and obtain data on which to plan a larger more definitive study in a more uniform patient population.|2|||f||||t||||||||||2018-06-01 04:36:56.172642|2018-06-01 04:36:56.172642
NCT00179283|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-06-01|2005-09-13|2005-09-15|Estimate|||||||2015-06-01|2015-06-02|Estimate|April 2002||2002-04-30|June 2015|2015-06-30|April 2003||2003-04-30|||||Interventional|||Sertraline vs. Venlafaxine XR|A Multi-center, Randomized, Double-blind, Parallel-group Study of Sertraline vs. Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder|Completed||Phase 3|20||Vanderbilt University|||||f||||||||||||||2018-06-01 04:36:56.865559|2018-06-01 04:36:56.865559
NCT00179257|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-06-01|2005-09-13|2005-09-15|Estimate|||||||2015-06-01|2015-06-02|Estimate|June 2004||2004-06-30|June 2015|2015-06-30|March 2005||2005-03-31|||||Interventional|||The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to Escitalopram|The Effectiveness of Sertraline in Patients Who Have Had Inadequate Response to|Completed||Phase 3|20||Vanderbilt University|||||f||||||||||||||2018-06-01 04:36:56.930993|2018-06-01 04:36:56.930993
NCT00179244|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-06-01|2005-09-13|2005-09-15|Estimate|||||||2015-06-01|2015-06-02|Estimate|July 2004||2004-07-31|June 2015|2015-06-30|April 2005|Actual|2005-04-30|||||Interventional|||Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression|Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression|Completed||Phase 3|30||Vanderbilt University|||||f||||||||||||||2018-06-01 04:36:56.983014|2018-06-01 04:36:56.983014
NCT00179231|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|May 2000||2000-05-31|September 2005|2005-09-30|February 2004||2004-02-29|||||Interventional|||Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia||Completed||N/A|80||Vanderbilt University|||||f||||||||||||||2018-06-01 04:36:57.040487|2018-06-01 04:36:57.040487
NCT00179218|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-07-08|2005-09-13|2005-09-15|Estimate|||||||2009-07-08|2009-07-09|Estimate|April 2005||2005-04-30|July 2009|2009-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients|The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients|Completed||Phase 2|19|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:36:57.137677|2018-06-01 04:36:57.137677
NCT00179205|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-08-05|2005-09-13|2005-09-15|Estimate|||||||2008-08-05|2008-08-06|Estimate|May 2005||2005-05-31|August 2008|2008-08-31|December 2007|Actual|2007-12-31|November 2006|Actual|2006-11-30||Interventional|||Complementary Intradialytic Nutritional Supplementation in Dialysis Patients|Complementary Intradialytic Nutritional Supplementation in Dialysis Patients|Terminated||Phase 2|27|Actual|Vanderbilt University||2||funding exhausted|f||||f||||||||||2018-06-01 04:36:57.219047|2018-06-01 04:36:57.219047
NCT00179192|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-21|2005-09-13|2005-09-15|Estimate|||||||2015-05-21|2015-05-25|Estimate|May 1998||1998-05-31|May 2015|2015-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Prevention and Treatment of Hemodialysis Vascular Access Malfunction|Prevention and Treatment of Hemodialysis Vascular Access Malfunction|Withdrawn||Phase 2|0|Actual|Vanderbilt University||3||non-enrollment|f||||f||||||||||2018-06-01 04:36:57.292812|2018-06-01 04:36:57.292812
NCT00179179|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-07-08|2005-09-13|2005-09-15|Estimate|||||||2009-07-08|2009-07-09|Estimate|April 2005||2005-04-30|July 2009|2009-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis|The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis|Completed||Phase 2|11|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:36:57.359537|2018-06-01 04:36:57.359537
NCT00179166|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-09-23|2005-09-13|2005-09-15|Estimate|||||||2010-09-23|2010-09-27|Estimate|June 2004||2004-06-30|September 2010|2010-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Assessment of Metabolic Response in Critically Ill Patients With Acute Renal Failure|Assessment of Metabolic Response in Critically Ill Patients With Acute Renal Failure|Terminated||Phase 2|3|Actual|Vanderbilt University||2||lack of enrollment|f||||f||||||||||2018-06-01 04:36:57.42194|2018-06-01 04:36:57.42194
NCT00179153|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-27|2005-09-13|2005-09-15|Estimate|||||||2014-05-27|2014-05-29|Estimate|February 2005||2005-02-28|May 2014|2014-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Improving The Nutritional Status Of The Malnourished Chronic Hemodialysis Patients In The State Of Tennessee|Improving The Nutritional Status Of The Malnourished Chronic Hemodialysis Patients In The State Of Tennessee|Completed||Phase 2|352|Actual|Vanderbilt University||1|||f||||f||||||||||2018-06-01 04:36:57.607732|2018-06-01 04:36:57.607732
NCT00179140|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-21|2005-09-13|2005-09-15|Estimate|||||||2015-05-21|2015-05-25|Estimate|November 2002||2002-11-30|May 2015|2015-05-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients|The Effects of Protein Supplementation and Resistance Exercise in Hemodialysis Patients|Completed||Phase 2|26|Actual|Vanderbilt University||3|||f||||f||||||||||2018-06-01 04:36:57.687967|2018-06-01 04:36:57.687967
NCT00179127|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-20|2005-09-13|2005-09-15|Estimate|||||||2012-06-20|2012-06-21|Estimate|August 2004||2004-08-31|June 2012|2012-06-30|September 2012|Anticipated|2012-09-30|July 2009|Actual|2009-07-31||Interventional|||Use of Insulin Glargine to Treat Diabetic Ketoacidosis|Early Use of Insulin Glargine in Diabetic Ketoacidosis|Unknown status|Active, not recruiting|N/A|75|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:36:57.7551|2018-06-01 04:36:57.7551
NCT00179114|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-17|2005-09-13|2005-09-15|Estimate|||||||2007-08-17|2007-08-20|Estimate|August 2002||2002-08-31|August 2007|2007-08-31|February 2006||2006-02-28|||||Interventional|||Vanderbilt University Spasticity Management Program Evaluation Plan|Vanderbilt University Spasticity Management Program Evaluation Plan|Completed||Phase 4|20||Vanderbilt University|||||f||||f||||||||||2018-06-01 04:36:57.844686|2018-06-01 04:36:57.844686
NCT00179101|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-08-11|2005-09-13|2005-09-15|Estimate|||||||2006-08-11|2006-08-15|Estimate|April 2004||2004-04-30|August 2006|2006-08-31|November 2005||2005-11-30|||||Observational|||Effect of Deep Brain Stimulation on Depression and Quality of Life in Parkinson’s Patients|Effect of Deep Brain Stimulation on Depression and Quality of Life in Parkinson’s Patients|Completed|||42||Vanderbilt University|||||f||||||||||||||2018-06-01 04:36:57.930703|2018-06-01 04:36:57.930703
NCT00179088|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-29|2005-09-13|2005-09-15|Estimate|||||||2017-03-29|2017-03-31|Actual|May 2003||2003-05-31|March 2017|2017-03-31|November 2007|Actual|2007-11-30|||||Interventional|||Safety of Non-delayed Weight Bearing After Total Hip Replacement With Non-Cemented Fiber Metal Taper Stem|Fiber Metal Taper Prospective Randomized Weight Bearing Investigation|Completed||N/A|33||Vanderbilt University Medical Center|||||f||||||||||||||2018-06-01 04:36:58.048591|2018-06-01 04:36:58.048591
NCT00179049|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-12|2005-09-13|2005-09-15|Estimate|||||||2008-12-12|2008-12-15|Estimate|April 2003||2003-04-30|December 2008|2008-12-31|April 2008|Actual|2008-04-30|||||Observational|||Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant|Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT)|Completed|||100|Anticipated|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:36:58.306599|2018-06-01 04:36:58.306599
NCT00179036|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-05|2005-09-13|2005-09-15|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2000||2000-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|SQUID||Biomagnetic Signals of Intestinal Ischemia II|Biomagnetic Signals of Intestinal Ischemia II|Completed|||17|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-06-01 04:36:58.378187|2018-06-01 04:36:58.378187
NCT00179023|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-02-27|2005-09-13|2005-09-15|Estimate|||||||2018-02-27|2018-03-01|Actual|April 2003||2003-04-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Autonomic Nervous System and Obesity|The Autonomic Nervous System and Obesity|Completed||Phase 1|128|Actual|Vanderbilt University Medical Center||5|||f||||f||||||||No||2018-06-01 04:36:58.472438|2018-06-01 04:36:58.472438
NCT00179010|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-02-02|2005-09-13|2005-09-15|Estimate|||||||2015-02-02|2015-02-04|Estimate|October 2003||2003-10-31|February 2015|2015-02-28|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||AMP as a Better Delivery System of Adenosine|Use of AMP to Improve Tissue Delivery of Adenosine|Suspended||N/A|64|Anticipated|Vanderbilt University||2||In process of renewing IND for AMP|f||||f||||||||||2018-06-01 04:36:58.585734|2018-06-01 04:36:58.585734
NCT00178997|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-05|2005-09-13|2005-09-15|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2004||2004-02-29|April 2017|2017-04-30|September 1, 2010|Actual|2010-09-01|September 1, 2010|Actual|2010-09-01||Observational|SQUID||Realistic Models of Gastrointestinal Bioelectromagnetism|Realistic Models of Gastrointestinal Bioelectromagnetism|Completed|||20|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-06-01 04:36:58.77654|2018-06-01 04:36:58.77654
NCT00178984|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-05|2005-09-13|2005-09-15|Estimate|||||||2017-04-05|2017-04-07|Actual|June 2000||2000-06-30|April 2017|2017-04-30|August 10, 2012|Actual|2012-08-10|August 10, 2012|Actual|2012-08-10||Observational|SQUID||Biomagnetic Characterization of Gastric Dysrhythmias:Study 2|Biomagnetic Characterization of Gastric Dysrhythmias:Study 2|Completed|||78|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-06-01 04:36:58.865252|2018-06-01 04:36:58.865252
NCT00178971|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-06-05|2005-09-12|2005-09-15|Estimate|||||||2017-06-05|2017-06-07|Actual|January 2003||2003-01-31|June 2017|2017-06-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Serotonin 1A Agonists and Cognition in Schizophrenia|Serotonin 1A Agonists and Cognition in Schizophrenia|Completed||Phase 3|60|Actual|Northwestern University||2|||f||||f||||||||||2018-06-01 04:36:58.958532|2018-06-01 04:36:58.958532
NCT00178958|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-06-05|2005-09-12|2005-09-15|Estimate|||||||2017-06-05|2017-06-07|Actual|August 2003||2003-08-31|June 2017|2017-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Evaluation of QTc Interval by Continuous Holter ECG Recording in Antipsychotic Drug-treated Patients With Schizophrenia||Completed||N/A|70||Northwestern University|||||f||||f||||||||||2018-06-01 04:36:59.061368|2018-06-01 04:36:59.061368
NCT00178945|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-05-27|2005-09-12|2005-09-15|Estimate|||||||2016-05-27|2016-06-01|Estimate|March 2004||2004-03-31|August 2007|2007-08-31|March 2006||2006-03-31|||||Interventional|||Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain|Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Botulinum Toxin Type A (Botox) for the Treatment of Pain Associated With Cervical Dystonia and Refractory Cervicothoracic Myofascial Pain Syndrome|Completed||Phase 1/Phase 2|20||Vanderbilt University|||||f||||||||||||||2018-06-01 04:36:59.16715|2018-06-01 04:36:59.16715
NCT00178932|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-11-01|2005-09-12|2005-09-15|Estimate|||||||2010-11-01|2010-11-03|Estimate|November 1998||1998-11-30|November 2010|2010-11-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Interventional|||Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors|Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors|Unknown status|Recruiting|N/A|1000|Anticipated|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:36:59.367129|2018-06-01 04:36:59.367129
NCT00178919|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-04-10||2013-05-24|2005-09-12|2005-09-15|Estimate|2010-04-09|2010-05-03|Estimate||||2013-05-24|2013-06-04|Estimate|August 2002||2002-08-31|May 2013|2013-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Nitric Oxide and the Autonomic Nervous System|Cardiovascular Regulation: Autonomic/Metabolic Mechanisms PO1 HL56693, Project 4: Cardiovascular Regulation: Autonomic/Metabolic Mechanisms|Completed||N/A|112|Actual|Vanderbilt University||2|||f||||f||||||||||2018-06-01 04:36:59.499187|2018-06-01 04:36:59.499187
NCT00178906|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-21|2005-09-12|2005-09-15|Estimate|||||||2016-11-21|2016-11-23|Estimate|December 1999||1999-12-31|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Acoustical Properties of Speech as Indicators of Suicidal Risk|Acoustical Properties of Speech as Indicators of Suicidal Risk|Completed|||124|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:36:59.722442|2018-06-01 04:36:59.722442
NCT00178893|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-06-10|2005-09-12|2005-09-15|Estimate|||||||2017-06-10|2017-06-14|Actual|April 2004|Actual|2004-04-30|February 2017|2017-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||Hepatocellular Research Registry|CellzDirect: Hepatocellular Research Registry|Recruiting|||200|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||Samples Without DNA|"~     Hepatocytes~   "|||2018-06-01 04:36:59.771822|2018-06-01 04:36:59.771822
NCT00178880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-30|2005-09-12|2005-09-15|Estimate|||||||2017-03-30|2017-04-04|Actual|November 2008|Actual|2008-11-30|March 2017|2017-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||MRI Imaging of Chronobiologic Abnormalities in Depression|MRI Imaging of Chronobiologic Abnormalities in Depression|Completed|||7|Actual|Vanderbilt University Medical Center|||2||f||||||||||||||2018-06-01 04:36:59.827857|2018-06-01 04:36:59.827857
NCT00178867|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-09|2005-09-12|2005-09-15|Estimate|||||||2008-10-09|2008-10-10|Estimate|January 2002||2002-01-31|October 2008|2008-10-31|August 2008|Actual|2008-08-31|||||Observational|||A National Registry of Patients With Hepatocellular Carcinoma|A National Registry of Patients With Hepatocellular Carcinoma|Completed|||150|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:36:59.884701|2018-06-01 04:36:59.884701
NCT00178854|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-30|2005-09-12|2005-09-15|Estimate|||||||2017-03-30|2017-04-04|Actual|May 2004||2004-05-31|March 2017|2017-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment|Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment|Withdrawn||Phase 4|0|Actual|Vanderbilt University Medical Center||||failed recruitment efforts|f||||||||||||||2018-06-01 04:36:59.940081|2018-06-01 04:36:59.940081
NCT00178490|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-06-02|2005-09-13|2005-09-15|Estimate|||||||2014-06-02|2014-06-04|Estimate|January 2005||2005-01-31|June 2014|2014-06-30|January 2010|Actual|2010-01-31|June 2009|Actual|2009-06-30||Interventional|||Effect of High Blood Pressure and Antihypertensive Treatment on Brain Functioning in Children|Neurocognitive Function in Children With Hypertension|Completed||Phase 1|100|Anticipated|University of Rochester||2|||f||||f||||||||||2018-06-01 04:37:03.712597|2018-06-01 04:37:03.712597
NCT00178841|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-05-27||2016-01-20|2005-09-12|2005-09-15|Estimate|2016-01-20|2016-02-17|Estimate||||2016-01-20|2016-02-17|Estimate|June 2005||2005-06-30|January 2016|2016-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL|Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma|Completed||Phase 2|4|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:37:00.016573|2018-06-01 04:37:00.016573
NCT00178828|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-04-07|2005-09-12|2005-09-15|Estimate|||||||2017-04-07|2017-04-11|Actual|October 2002||2002-10-31|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Dynamic Measures of Neurochemistry in Mood Disorders|Dynamic Measures of Neurochemistry in Mood Disorders|Completed||Phase 4|42|Actual|Vanderbilt University Medical Center|||||f|||||f|f||||||||2018-06-01 04:37:00.177774|2018-06-01 04:37:00.177774
NCT00178802|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-22|2005-09-13|2005-09-15|Estimate|||||||2010-04-22|2010-04-23|Estimate|June 1996||1996-06-30|April 2010|2010-04-30|December 2010|Anticipated|2010-12-31|June 2010|Anticipated|2010-06-30||Interventional|||Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers|Phase II Study of Mild Whole Body Hyperthermia Combined With 5-Fluorouracil/Interferon-a/Liposomal Doxorubicin in Patients With Advanced Malignancy|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-06-01 04:37:00.241587|2018-06-01 04:37:00.241587
NCT00178789|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-05-22|2005-09-13|2005-09-15|Estimate|||||||2007-05-22|2007-05-23|Estimate|September 2005||2005-09-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Observational|||Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis|Prospective Observational Trial of Point-of-Care, Limited Ultrasonography (PLUS) for Lower Extremity Deep Venous Thrombosis in the Emergency Department: The Sonography Outcomes Assessment Program (SOAP-4 Trial)|Completed|||51|Anticipated|The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:37:00.307691|2018-06-01 04:37:00.307691
NCT00178776|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-10|2005-09-13|2005-09-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2003||2003-10-31|September 2014|2014-09-30|June 2007|Actual|2007-06-30|November 2006|Actual|2006-11-30||Interventional|||A Transtheoretical Model Group Therapy for Cocaine|A Transtheoretical Model Group Therapy for Cocaine|Completed||Phase 1|138|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:37:00.35331|2018-06-01 04:37:00.35331
NCT00178763|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-02|2005-09-13|2005-09-15|Estimate|||||||2011-03-02|2011-03-03|Estimate|September 2003||2003-09-30|March 2011|2011-03-31|June 2013|Anticipated|2013-06-30|June 2012|Anticipated|2012-06-30||Interventional|FR-WB-TT||Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer|Phase II Clinical Trial of Cisplatin + Gemcitabine in Combination With Mild, Fever-Range Whole-Body Hyperthermia to Treat Patients With Advanced, Inoperable Pancreatic Cancer|Unknown status|Recruiting|Phase 2|36|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-06-01 04:37:00.427603|2018-06-01 04:37:00.427603
NCT00178750|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-27|2005-09-13|2005-09-15|Estimate|||||||2007-12-27|2008-01-08|Estimate||||December 2007|2007-12-31||||||||Interventional|||"Loss of Resistance Versus CompuFlo® for Epidural Placement"|"A Randomized Clinical Comparison of the Loss of Resistance Technique Versus the CompuFlo® Computerized Syringe Pump for Proper Epidural Placement"|Withdrawn||Phase 1/Phase 2|100|Anticipated|The University of Texas Health Science Center, Houston||||Study did not start due to investigator time constraints|f||||||||||||||2018-06-01 04:37:00.619759|2018-06-01 04:37:00.619759
NCT00178737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-18|2005-09-13|2005-09-15|Estimate|||||||2010-02-18|2010-02-19|Estimate||||February 2010|2010-02-28|December 2006||2006-12-31|||||Interventional|||Does the Message Matter? Enhancing Adherence in Healthcare Through Persuasive Messages|Does the Message Matter? Enhancing Adherence in Healthcare Through Persuasive Messages|Completed||N/A|1200|Anticipated|The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:37:00.697615|2018-06-01 04:37:00.697615
NCT00178724|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-09-12|2005-09-13|2005-09-15|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2005||2005-07-31|September 2017|2017-09-30|July 2023|Anticipated|2023-07-31|July 2020|Anticipated|2020-07-31||Observational|NACTN||Spinal Cord Injury Registry - NACTN|Spinal Cord Injury Registry - North American Clinical Trials Network for Spinal Cord Injury|Recruiting|||1500|Anticipated|The Methodist Hospital System|||1||f||||f|f|f||||||No||2018-06-01 04:37:00.757014|2018-06-01 04:37:00.757014
NCT00178711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2014-07-31||2014-09-13|2005-09-13|2005-09-15|Estimate|2014-08-08|2014-08-11|Estimate||||2014-09-13|2014-09-17|Estimate|November 2005||2005-11-30|September 2014|2014-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|NABIS:HIIR|hypothermia group-- 26 ± 9 years of age, 40 males/12 females normothermia group--31 ± 11 year of age, 41 males/4 females|Effects of Hypothermia Upon Outcomes After Acute Traumatic Brain Injury|National Acute Brain Injury Study: Hypothermia IIR|Terminated||Phase 3|232|Actual|The University of Texas Health Science Center, Houston|Early termination for futility.|2||Futility|f||||t||||||||||2018-06-01 04:37:00.902385|2018-06-01 04:37:00.902385
NCT00178698|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-02|2005-09-13|2005-09-15|Estimate|||||||2011-03-02|2011-03-03|Estimate|July 2002||2002-07-31|March 2011|2011-03-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|FR-WB-TT/che||Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors|A Phase II Clinical Trial of Cisplatin + Gemcitabine HCl (GEM) + Low-Dose Metronomic Interferon-a (IFN-a) Combined With Fever-Range Whole-Body Thermal Therapy (FR-WB-TT) in Patients With Metastatic/or Locally Advanced Malignancies (Small-Cell Lung Cancer, Neuroendocrine Cancer, Gastric Cancer)|Unknown status|Recruiting|Phase 2|36|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-06-01 04:37:01.214726|2018-06-01 04:37:01.214726
NCT00178685|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-01-15||2013-01-15|2005-09-13|2005-09-15|Estimate|2013-01-15|2013-02-15|Estimate||||2013-01-15|2013-02-15|Estimate|August 2004||2004-08-31|July 2009|2009-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|SHP||Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence|Self-determination and Maintaining Tobacco Abstinence|Completed||Phase 4|837|Actual|University of Rochester|A limitation of this study is the low completion rate of smokers enrolling in the study. This increases the chance of accepting the null hypothesis when there may be differences between groups if all smokers had provided their outcomes.||||f||||||||||||||2018-06-01 04:37:01.377198|2018-06-01 04:37:01.377198
NCT00178672|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-11|2005-09-13|2005-09-15|Estimate|||||||2007-12-11|2007-12-14|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||A Single Center of Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease|A Single Center IDE Study on Carotid Stenting With Distal Protection for the Treatment of Obstructive Carotid Artery Disease|Completed||Phase 4|69|Actual|The University of Texas Health Science Center, Houston|||||f||||t||||||||||2018-06-01 04:37:01.687252|2018-06-01 04:37:01.687252
NCT00178659|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-02-06|2005-09-12|2005-09-15|Estimate|||||||2018-02-06|2018-02-08|Actual|July 2004||2004-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|Proteomics||Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)|Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP)|Active, not recruiting|||260|Anticipated|The University of Texas Health Science Center, Houston|||4||f||||f||||||Samples Without DNA|"~     Plasma and serum samples for use in identifying proteins related to head trauma~   "|No|There is no plan to make individual participant data available|2018-06-01 04:37:01.773437|2018-06-01 04:37:01.773437
NCT00178646|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2013-12-09|2013-12-09|2005-09-12|2005-09-15|Estimate||||2013-12-09|2014-01-09|Estimate|2013-12-09|2014-01-09|Estimate|January 2002||2002-01-31|December 2013|2013-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity|Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity|Completed||Phase 4|33|Actual|The University of Texas Health Science Center, Houston||3|||f||||f||||||||||2018-06-01 04:37:01.867941|2018-06-01 04:37:01.867941
NCT00178633|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-08-01||2014-09-03|2005-09-12|2005-09-15|Estimate|2014-09-03|2014-09-11|Estimate||||2014-09-03|2014-09-11|Estimate|May 2004||2004-05-31|September 2014|2014-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational||43 patients were originally enrolled, and 37 participated through 9 months; 15 female participants returned for an additional 2 year analysis.|Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery|Dramatic Reversal of Derangements in Muscle Metabolism and Left Ventricular Function After Bariatric Surgery|Completed|||43|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||Samples Without DNA|"~     Skeletal muscle biopsies, plasma~   "|||2018-06-01 04:37:02.042675|2018-06-01 04:37:02.042675
NCT00178620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-12-06|2005-09-12|2005-09-15|Estimate|||||||2014-12-06|2014-12-09|Estimate|November 2003||2003-11-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PATCAR||Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization|PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization|Completed||Phase 4|254|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-06-01 04:37:02.544744|2018-06-01 04:37:02.544744
NCT00178607|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-05-10|2005-09-12|2005-09-15|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2002||2002-08-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia|Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia|Completed|||99|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||Samples With DNA|"~     Serum and Plasma~   "|Yes|The data will be analyzed and published|2018-06-01 04:37:02.673222|2018-06-01 04:37:02.673222
NCT00178594|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-05-10|2005-09-12|2005-09-15|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2002||2002-10-31|May 2016|2016-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Evaluation of Hemostasis in Bleeding and Thrombotic Disorders|Evaluation of Hemostasis in Bleeding and Thrombotic Disorders Using the Roteg Analyzer and the Thrombin Generation Assay|Recruiting|||100|Anticipated|The University of Texas Health Science Center, Houston|||||f||||f||||||||Undecided|Undecided at this time|2018-06-01 04:37:02.759393|2018-06-01 04:37:02.759393
NCT00178581|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-04-22|2005-09-12|2005-09-15|Estimate|||||||2010-04-22|2010-04-23|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|September 2006||2006-09-30|||||Interventional|||Enteral Glutamine Supplementation for the Patient With Major Torso Trauma|Early Enteral Glutamine Supplement to Enteral Nutrition Support of the Major Torso Trauma Patient: Proposal for a Prospective Randomized Clinical Trial|Terminated||Phase 1|20||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:37:02.842719|2018-06-01 04:37:02.842719
NCT00178568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-26|2005-09-13|2005-09-15|Estimate|||||||2015-05-26|2015-05-28|Estimate|February 2003||2003-02-28|May 2015|2015-05-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Observational|||Reducing Caregiver Stress and Sleep Disturbances in Patients With Progressive Dementia|AgeWise Project 2: Reducing Stress and Sleep Disturbances in Caregivers of Patients With Progressive Dementia|Completed|||60|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     Saliva collected on cotton rolls and frozen by participant. Kept frozen until shipped for~     assay.~   "|||2018-06-01 04:37:02.932391|2018-06-01 04:37:02.932391
NCT00178555|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-03-22|2005-09-12|2005-09-15|Estimate|||||||2016-03-22|2016-03-23|Estimate|August 2003||2003-08-31|March 2016|2016-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Comparison of the Video and Macintosh Laryngoscope in Patients Who May be Difficult to Intubate|A Comparison of Laryngoscopy Techniques Using the Video Laryngoscope and the Traditional Macintosh Laryngoscope in Patients Who May be Difficult to Intubate|Completed||Phase 4|200||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:37:03.034451|2018-06-01 04:37:03.034451
NCT00178542|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-05-03|2005-09-12|2005-09-15|Estimate|||||||2013-05-03|2013-05-06|Estimate|September 2005||2005-09-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle|Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle|Terminated|||20|Actual|The University of Texas Health Science Center, Houston||||Insufficient enrollment|f||||f||||||||||2018-06-01 04:37:03.087853|2018-06-01 04:37:03.087853
NCT00178529|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-02|2005-09-12|2005-09-15|Estimate|||||||2007-03-02|2007-03-05|Estimate|July 2001||2001-07-31|March 2007|2007-03-31|September 2005||2005-09-30|||||Interventional|||Intervention for Stroke Survivors and Their Spousal Caregivers|Intervention for Stroke Survivors and Their Spousal Caregivers|Completed||N/A|160||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:37:03.145339|2018-06-01 04:37:03.145339
NCT00178516|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-07-29|2005-09-13|2005-09-15|Estimate|||||||2009-07-29|2009-07-30|Estimate|June 2004||2004-06-30|July 2009|2009-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Vitamin E and Male Infertility|Vitamin E and Male Infertility|Completed|||58|Actual|University of Rochester|||||f||||f||||||Samples With DNA|"~     whole blood, serum, semen~   "|||2018-06-01 04:37:03.209116|2018-06-01 04:37:03.209116
NCT00178503|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-01-14||2013-05-06|2005-09-12|2005-09-15|Estimate|2013-03-22|2013-05-07|Estimate||||2013-05-06|2013-05-09|Estimate|September 2005||2005-09-30|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children|ADHD Symptoms in Autism: Cognition, Behavior, Treatment|Completed||Phase 2/Phase 3|24|Actual|The University of Texas Health Science Center, Houston|We did not have teacher behavioral data for all of the children because some of them were seen during the summer, when teacher input was not available.|4|||f||||t||||||||||2018-06-01 04:37:03.393138|2018-06-01 04:37:03.393138
NCT00178477|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-08-12||2013-04-18|2005-09-13|2005-09-15|Estimate|2013-04-18|2013-04-19|Estimate||||2013-04-18|2013-04-19|Estimate|January 2002||2002-01-31|April 2013|2013-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study of Breath-holding as a Means to Reduce Tumor Motion From Breathing|Feasibility Study for Gated External-Beam Radiotherapy for Patients With Internal, Extra-cranial Tumors|Terminated||N/A|10|Actual|University of Rochester||1||Drs Okunieff and ODell have left the University of Rochester|f||||f||||||||||2018-06-01 04:37:03.813374|2018-06-01 04:37:03.813374
NCT00178464|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-08-09||2017-10-04|2005-09-13|2005-09-15|Estimate|2011-11-29|2012-01-04|Estimate||||2017-10-04|2017-11-06|Actual|March 2005||2005-03-31|October 2017|2017-10-31|November 2009|Actual|2009-11-30|April 2009|Actual|2009-04-30||Interventional|START||Aspirin Prophylaxis in Sickle Cell Disease|Aspirin Prophylaxis in Sickle Cell Disease|Completed||Phase 1|11|Actual|University of Rochester||1|||f||||t|t|f||||||||2018-06-01 04:37:03.950272|2018-06-01 04:37:03.950272
NCT00178451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-17|2005-09-12|2005-09-15|Estimate|||||||2015-12-17|2015-12-18|Estimate||||December 2015|2015-12-31||||||||Interventional|||Stroke Prevention With Abciximab in Carotid Endarterectomy|Stroke Prevention With Abciximab in Carotid Endarterectomy|Withdrawn||Phase 1/Phase 2|0|Actual|University of Rochester|||||||||||||||||||2018-06-01 04:37:04.124552|2018-06-01 04:37:04.124552
NCT00178438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-09-16|2005-09-13|2005-09-15|Estimate|||||||2015-09-16|2015-09-18|Estimate|June 2005||2005-06-30|September 2015|2015-09-30|June 2006||2006-06-30|||||Interventional|||Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease|A Prospective Trial of Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease|Withdrawn||Phase 1/Phase 2|0|Actual|University of Rochester|||||f||||||||||||||2018-06-01 04:37:04.191523|2018-06-01 04:37:04.191523
NCT00178425|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-18|2005-09-12|2005-09-15|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Interventional|||PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients|Pharmacokinetics of Intravenous / Oral MMF and Oral Tacrolimus in Live Donor and Deceased Donor Liver Transplant Patients|Completed||Phase 4|24||University of Rochester|||||f||||f||||||||||2018-06-01 04:37:04.261339|2018-06-01 04:37:04.261339
NCT00178412|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-06-13|2005-09-12|2005-09-15|Estimate|||||||2012-06-13|2012-06-14|Estimate|April 2003||2003-04-30|June 2012|2012-06-30|March 2009|Actual|2009-03-31|April 2006|Actual|2006-04-30||Interventional|||Improving Outcomes of Hospitalized Elders and Caregivers|Improving Outcomes of Hospitalized Elders and Caregivers|Completed||Phase 2|421|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 04:37:04.316649|2018-06-01 04:37:04.316649
NCT00178399|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-01|2005-09-12|2005-09-15|Estimate|||||||2017-05-01|2017-05-04|Actual|April 2001||2001-04-30|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study For Using Radiosurgery On Limited Metastases|A Pilot Study For Using Radiosurgery On Limited Metastases|Suspended||N/A|138|Actual|University of Rochester||1||to analyze data of subjects already enrolled.|f||||t||||||||||2018-06-01 04:37:04.390495|2018-06-01 04:37:04.390495
NCT00178386|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-11|2005-09-12|2005-09-15|Estimate|||||||2015-06-11|2015-06-15|Estimate|September 2004||2004-09-30|June 2015|2015-06-30|April 2008|Actual|2008-04-30|September 2005|Actual|2005-09-30||Observational|||Comparison of Educational Services and Outcomes for Patients Treated for Childhood Cancer|Comparison of Educational Services and Outcomes for Patients Treated for Childhood Cancer and Brain Tumor in Facilities With and Without Educational Liaison Services.|Completed|||220|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 04:37:04.464269|2018-06-01 04:37:04.464269
NCT00178373|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-21|2005-09-12|2005-09-15|Estimate|||||||2015-12-21|2015-12-23|Estimate|May 2004||2004-05-31|December 2015|2015-12-31|March 2006|Actual|2006-03-31|December 2005|Actual|2005-12-31||Interventional|||Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer|Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer|Completed||Phase 2|96|Anticipated|University of Rochester||2|||f||||t||||||||||2018-06-01 04:37:04.518183|2018-06-01 04:37:04.518183
NCT00178360|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-08-19|2005-09-12|2005-09-15|Estimate|||||||2011-08-19|2011-08-22|Estimate|July 2004||2004-07-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|December 2008|Actual|2008-12-31||Interventional|||Effects of Music Therapy on Huntington's Disease|The Effects of Music Therapy on Depression, Chorea and Other Symptoms of Huntington's Disease|Completed||Phase 1|11|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 04:37:05.654298|2018-06-01 04:37:05.654298
NCT00178347|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-15|2005-09-12|2005-09-15|Estimate|||||||2009-05-15|2009-05-19|Estimate|December 2004||2004-12-31|May 2009|2009-05-31||||||||Observational|||Radiation Dosimetry in Teeth|Radiation Dosimetry in Teeth|Terminated|||10|Anticipated|University of Rochester|||||f||||f||||||||||2018-06-01 04:37:05.731641|2018-06-01 04:37:05.731641
NCT00178334|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-01-28|2005-09-12|2005-09-15|Estimate|||||||2013-01-28|2013-01-29|Estimate|March 2006||2006-03-31|January 2013|2013-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Screening for Urinary Incontinence by Primary Care Providers|Screening for Urinary Incontinence by Primary Care Providers|Completed|||554|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 04:37:05.790541|2018-06-01 04:37:05.790541
NCT00178321|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-04-29|2005-09-12|2005-09-15|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|August 2006||2006-08-31|||||Interventional|||Improving Sleep in the Pediatric Intensive Care Unit|Improving Sleep and Outcomes in Critically Ill Children|Withdrawn||N/A|0|Actual|University of Rochester|||||f||||||||||||||2018-06-01 04:37:05.852624|2018-06-01 04:37:05.852624
NCT00178308|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-06|2005-09-12|2005-09-15|Estimate|||||||2006-09-06|2006-09-11|Estimate||||September 2006|2006-09-30||||||||Observational|||Measuring Alterations of DNA in Human Blood||Completed|||24||University of Rochester|||||f||||||||||||||2018-06-01 04:37:05.920511|2018-06-01 04:37:05.920511
NCT00178295|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-08-03|2005-09-12|2005-09-15|Estimate|||||||2015-08-03|2015-08-05|Estimate|November 1999||1999-11-30|August 2015|2015-08-31||||December 2013|Actual|2013-12-31||Observational|||Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury|Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury|Completed|||44|Actual|University of Rochester|||||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|||2018-06-01 04:37:05.980575|2018-06-01 04:37:05.980575
NCT00178282|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-02|2005-09-12|2005-09-15|Estimate|||||||2011-11-02|2011-11-03|Estimate|June 2005||2005-06-30|November 2011|2011-11-30|October 2007|Actual|2007-10-31|January 2007|Actual|2007-01-31||Interventional|||Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence|Pilot Study: Low Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence|Terminated||N/A|23|Actual|University of Rochester||||The study was terminated early due to poor subject enrollment.|f||||f||||||||||2018-06-01 04:37:06.056982|2018-06-01 04:37:06.056982
NCT00178269|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-15|2005-09-12|2005-09-15|Estimate|||||||2009-05-15|2009-05-19|Estimate|January 2005||2005-01-31|May 2009|2009-05-31||||June 2006|Actual|2006-06-30||Interventional|||Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix|A Phase Ii Clinical Study Using Weekly Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix|Completed||Phase 2|||University of Rochester|||||f||||||||||||||2018-06-01 04:37:06.119952|2018-06-01 04:37:06.119952
NCT00178256|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-12-11||2015-08-03|2005-09-12|2005-09-15|Estimate|2013-12-11|2014-01-30|Estimate||||2015-08-03|2015-08-21|Estimate|June 1998||1998-06-30|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer|A Phase I/II Clinical Trial Of Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable (Stage III) Lung Cancers|Completed||Phase 1/Phase 2|41|Actual|University of Rochester||4|||f||||||||||||||2018-06-01 04:37:06.285032|2018-06-01 04:37:06.285032
NCT00178243|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-06|2005-09-12|2005-09-15|Estimate|||||||2006-09-06|2006-09-08|Estimate||||September 2006|2006-09-30||||||||Interventional|||Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation|A Phase I/II Trial Of the Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation Delivered by 3D Conformal Radiation Therapy and Radiosurgery|Completed||Phase 1/Phase 2|||University of Rochester|||||f||||||||||||||2018-06-01 04:37:06.485939|2018-06-01 04:37:06.485939
NCT00178230|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-06-09|2005-09-12|2005-09-15|Estimate|||||||2017-06-09|2017-06-14|Actual|March 15, 1996|Actual|1996-03-15|June 2017|2017-06-30|November 25, 2013|Actual|2013-11-25|November 25, 2013|Actual|2013-11-25||Observational|||Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity|Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity in Thoracic Malignancies|Completed|||82|Actual|University of Rochester|||||f|||||f|f||||||||2018-06-01 04:37:06.543045|2018-06-01 04:37:06.543045
NCT00178217|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-12-22|2005-09-12|2005-09-15|Estimate|||||||2015-12-22|2015-12-23|Estimate|July 2002||2002-07-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Interventional|||Music Therapy During Botulinum Injections|Music Therapy as Procedural Support During Botulinum Injections for Pediatric Patients|Completed||Phase 1/Phase 2|101|Actual|University of Rochester||2|||f||||f||||||||||2018-06-01 04:37:06.607067|2018-06-01 04:37:06.607067
NCT00178204|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-12-03|2005-09-12|2005-09-15|Estimate|||||||2014-12-03|2014-12-05|Estimate|November 2004||2004-11-30|December 2014|2014-12-31|December 2011|Actual|2011-12-31|May 2009|Actual|2009-05-31||Observational|||Sleep Architecture and Chemotherapy-Related Fatigue|Sleep Architecture and Chemotherapy-Related Fatigue|Completed|||26|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 04:37:06.696225|2018-06-01 04:37:06.696225
NCT00178191|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-06-12||2011-09-27|2005-09-12|2005-09-15|Estimate|2009-07-31|2009-08-03|Estimate||||2011-09-27|2011-10-03|Estimate|June 2005||2005-06-30|September 2011|2011-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Randomized Trial for Botox Urinary Incontinence|A Randomized Trial of Botox for Severe Urge Incontinence|Completed||N/A|28|Actual|University of Rochester|Please see published manuscripts for additional details|3|||f||||t||||||||||2018-06-01 04:37:06.79521|2018-06-01 04:37:06.79521
NCT00178178|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-04-09||2015-08-27|2005-09-12|2005-09-15|Estimate|2015-04-30|2015-05-18|Estimate||||2015-08-27|2015-09-11|Estimate|March 2005||2005-03-31|August 2015|2015-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions|A Placebo Controlled, Prospective, Randomized Clinical Investigation of the Efficacy of Continuous Infusion Regional Anesthetic on Postoperative Pain Following Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions|Completed||N/A|96|Actual|University of Rochester||4|||f||||f||||||||||2018-06-01 04:37:07.041201|2018-06-01 04:37:07.041201
NCT00178165|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|September 1996||1996-09-30|September 2005|2005-09-30|November 2001||2001-11-30|||||Interventional|||Coordinating Center for Enhancing ADRD Caregiving|Coordinating Center for Enhancing Alzheimer Disease and Related Disorder Caregiving|Completed||N/A|1200||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:07.426142|2018-06-01 04:37:07.426142
NCT00178152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-11|2005-09-12|2005-09-15|Estimate|||||||2011-05-11|2011-05-12|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Erythema Toxicum Neonatorum in Newborns and the Development of Asthma|The Implication of Erythema Toxicum Neonatorum in Newborns on the Development of Future Asthma|Completed|||334|Actual|University of Rochester|||||f||||||||||||||2018-06-01 04:37:07.510584|2018-06-01 04:37:07.510584
NCT00178139|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-08-26|2005-09-12|2005-09-15|Estimate|||||||2015-08-26|2015-08-28|Estimate|April 2004||2004-04-30|August 2015|2015-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Music Therapy for Patients Being Weaned From Mechanical Ventilation|Music Therapy as an Adjunctive Treatment in the Management of Stress for Patients Being Weaned From Mechanical Ventilation|Completed||Phase 1|77|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 04:37:07.561096|2018-06-01 04:37:07.561096
NCT00178126|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-10-11||2017-04-28|2005-09-13|2005-09-15|Estimate|2017-04-28|2017-06-02|Actual||||2017-04-28|2017-06-02|Actual|March 2004||2004-03-31|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||An RCT on Preventing Pressure Ulcers With Wheelchair Seat Cushions|An RCT on Preventing Pressure Ulcers With Seat Cushions|Completed||N/A|232|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-06-01 04:37:07.723622|2018-06-01 04:37:07.723622
NCT00178113|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-26|2005-09-13|2005-09-15|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2003||2003-07-31|May 2015|2015-05-31|July 2004||2004-07-31|||||Interventional|||A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia|Phase I Clinical Trial: Randomized Lycopene Supplementation in Tobago Men With High-Grade Prostatic-Intraepithelial Neoplasia|Completed||Phase 1|80||University of Pittsburgh|||||||||||||||||||2018-06-01 04:37:07.985483|2018-06-01 04:37:07.985483
NCT00178100|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-31|2005-09-13|2005-09-15|Estimate|||||||2013-07-31|2013-08-02|Estimate|March 1999||1999-03-31|July 2013|2013-07-31|August 2005||2005-08-31|||||Interventional|||Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression|Maintenance Therapies in Late-Life Depression 2 (MTLD-2)|Completed||Phase 4|225||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:08.070953|2018-06-01 04:37:08.070953
NCT00178087|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-06|2005-09-13|2005-09-15|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2005||2005-08-31|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Determining Changes in Brain Structure Associated With Symptoms of Late-life Depression|Pathways Linking Late-Life Depression to MCI & Dementia|Completed|||331|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:08.154958|2018-06-01 04:37:08.154958
NCT00178074|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-31|2005-09-13|2005-09-15|Estimate|||||||2013-07-31|2013-08-02|Estimate|February 1999||1999-02-28|July 2013|2013-07-31|April 2003||2003-04-30|||||Interventional|||The Effects of Sleep Deprivation on Antidepressant Response|The Effects of Sleep Deprivation on Antidepressant Response in Geriatric Depression: Neurometabolic Substrates Studied With PET|Completed||Phase 4|80||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:08.234647|2018-06-01 04:37:08.234647
NCT00178061|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-21|2005-09-13|2005-09-15|Estimate|||||||2013-06-21|2013-06-25|Estimate|August 1997||1997-08-31|June 2013|2013-06-30|August 2002||2002-08-31|||||Interventional|||Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder|Treatment of Primary Mood Disorders in the Comorbidly Ill|Completed||Phase 4|13||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:08.315248|2018-06-01 04:37:08.315248
NCT00178048|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|September 1998||1998-09-30|September 2005|2005-09-30|December 2003||2003-12-31|||||Interventional|||Paroxetine in the Treatment of Chronic Primary Insomnia|Paroxetine in the Treatment of Chronic Primary Insomnia: A Double-Blind, Randomized, Placebo-Controlled Study of Efficacy Over Six Weeks|Completed||Phase 4|66||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:08.378449|2018-06-01 04:37:08.378449
NCT00178035|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-07-31|2005-09-13|2005-09-15|Estimate|||||||2013-07-31|2013-08-02|Estimate|December 1999||1999-12-31|July 2013|2013-07-31|August 2003||2003-08-31|||||Interventional|||Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals|Geriatric Depression: Neurobiology of Treatment|Completed||Phase 4|158||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:08.448489|2018-06-01 04:37:08.448489
NCT00178022|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-27|2005-09-13|2005-09-15|Estimate|||||||2008-05-27|2008-05-29|Estimate|February 2005||2005-02-28|May 2008|2008-05-31|September 2006|Actual|2006-09-30|||||Interventional|||A Trial of Two On-Line Interventions for Child Brain Injury|A Trial of Two On-Line Interventions for Child Brain Injury|Completed||N/A|120||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:08.523109|2018-06-01 04:37:08.523109
NCT00178009|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-18|2005-09-13|2005-09-15|Estimate|||||||2011-02-18|2011-02-21|Estimate|January 2006||2006-01-31|February 2011|2011-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Developing and Assessing Competencies for Caregivers and Patients With Ventricular Assist Devices|Developing and Assessing Competencies for Patients, Caregivers and Health Professionals for the Care of Patients Implanted With Ventricular Assist Devices|Completed|||8|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 04:37:08.617608|2018-06-01 04:37:08.617608
NCT00177996|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-14|2005-09-13|2005-09-15|Estimate|||||||2016-01-14|2016-01-15|Estimate|October 2001||2001-10-31|January 2016|2016-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Pharmacotherapy in Depression With Panic Spectrum|Pharmacotherapy in Depression With Panic Spectrum|Completed||Phase 4|30|Actual|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-06-01 04:37:08.77968|2018-06-01 04:37:08.77968
NCT00177983|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-06-26|2005-09-13|2005-09-15|Estimate|||||||2014-06-26|2014-06-30|Estimate|January 2003||2003-01-31|June 2014|2014-06-30|January 2005||2005-01-31|||||Interventional|||Web-based Support for People With Schizophrenia and Their Families|Support to Patients and Families|Completed||N/A|80||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:08.920437|2018-06-01 04:37:08.920437
NCT00177970|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-06-15||2016-09-14|2005-09-13|2005-09-15|Estimate|2016-06-15|2016-07-15|Estimate||||2016-09-14|2016-10-25|Estimate|October 2003||2003-10-31|September 2016|2016-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||No results available record destroyed due to age of study. no publications|IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff|Intravenous Immunoglobulin G Versus Placebo for the Treatment of Patients With Severe Clostridium Difficile-Associated Diarrhea and Colitis|Terminated||Phase 4|14|Actual|University of Pittsburgh||2||We were unable to receive IVIG free from phamaceutical company.|f||||t||||||||No|records not available|2018-06-01 04:37:09.037266|2018-06-01 04:37:09.037266
NCT00177957|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-08|2005-09-13|2005-09-15|Estimate|||||||2017-06-08|2017-06-09|Actual|April 2005||2005-04-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Gram Negative Bacteremia, Risk Factors for Failure of Therapy|Gram Negative Bacteremia, Risk Factors for Failure of Therapy|Completed|||600|Anticipated|University of Pittsburgh|||||f||||t|f|f||||||No|not sharing|2018-06-01 04:37:09.439842|2018-06-01 04:37:09.439842
NCT00177944|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-15|2005-09-13|2005-09-15|Estimate|||||||2013-01-15|2013-01-17|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Invasive Fungal Infections Surveillance Initiative|Invasive Fungal Infections Surveillance Initiative|Completed|||172|Actual|University of Pittsburgh|||1||f||||t||||||||||2018-06-01 04:37:09.538673|2018-06-01 04:37:09.538673
NCT00177931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-12-16|2005-09-13|2005-09-15|Estimate|||||||2015-12-16|2015-12-17|Estimate|March 2005||2005-03-31|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit|Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit|Completed|||25|Actual|University of Pittsburgh|||1||f||||||||||Samples Without DNA|"~     All biologic samples will be under the control of the principal investigator of this research~     project. To protect confidentiality, all personal identifiers will be removed and replaced~     with a specific code number. The information linking these code numbers to the corresponding~     subjects' identities will be kept in a separate, secure location. The investigators on this~     study will keep the samples indefinitely. All samples will be provided to investigators not~     associated with the study without any identifiers and only contain a code number. If a~     subject withdraws samples collected and not already processed will be destroyed.~   "|||2018-06-01 04:37:09.620149|2018-06-01 04:37:09.620149
NCT00177918|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-08|2005-09-13|2005-09-15|Estimate|||||||2017-06-08|2017-06-12|Actual|August 2006||2006-08-31|June 2017|2017-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Prospective Evaluations of Infectious Complication in Lung Transplant Recipients|Prospective Evaluations of Infectious Complications in Lung Transplant Recipients|Recruiting|||600|Anticipated|University of Pittsburgh|||1||f||||t||||||Samples Without DNA|"~     All biologic samples will be under the control of the principal investigator of this research~     project. To protect confidentiality, all personal identifiers will be removed and replaced~     with a specific code number. The information linking these code numbers to the corresponding~     subjects' identities will be kept in a separate, secure location. The investigators on this~     study will keep the samples indefinitely. All samples that are provided to outside facilities~     will be sent with a code number. Samples may be sent to other investigators not associated~     with this study to perform diagnostic testing (e.g., viral, fungal, bacterial and~     immunological). All samples will be provided to investigators not associated with the study~     without any identifiers and only contain a code number. If a subject withdraws and provides~     the request in writing, samples collected and not already processed will be destroyed.~   "|||2018-06-01 04:37:09.729444|2018-06-01 04:37:09.729444
NCT00177892|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-02-28|2005-09-13|2005-09-15|Estimate|||||||2008-02-28|2008-03-03|Estimate|September 2003||2003-09-30|February 2008|2008-02-29|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Interventional|||Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress|OSA and Metabolic Syndrome: Role of Oxidative Stress|Unknown status|Recruiting|N/A|76|Anticipated|National Institute on Aging (NIA)||5|||f||||t||||||||||2018-06-01 04:37:09.868817|2018-06-01 04:37:09.868817
NCT00177879|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-06|2005-09-13|2005-09-15|Estimate|||||||2015-05-06|2015-05-07|Estimate|August 2005||2005-08-31|August 2008|2008-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Usability of a Website for People With Schizophrenia|Schizophrenia Website Usability|Withdrawn||N/A|0|Actual|National Institute of Mental Health (NIMH)||||Funding was never granted for this study. No participants were ever enrolled.|f||||||||||||||2018-06-01 04:37:10.078007|2018-06-01 04:37:10.078007
NCT00177866|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2016-06-15||2016-07-28|2005-09-13|2005-09-15|Estimate|2016-06-15|2016-07-15|Estimate||||2016-07-28|2016-08-29|Estimate|December 2003||2003-12-31|June 2016|2016-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||No results or publication, data destroyed due to age of study.|Safety of Celecoxib in Patients With Crohn's Disease|The Safety of Celecoxib (Celebrex) in Patients With Crohn's Disease|Terminated||Phase 4|28|Actual|University of Pittsburgh||2||We were unable to get additional funding to complete study.|f||||t||||||||||2018-06-01 04:37:10.143106|2018-06-01 04:37:10.143106
NCT00177853|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-07-01|2005-09-13|2005-09-15|Estimate|||||||2010-07-01|2010-07-02|Estimate|December 2006||2006-12-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|December 2006|Actual|2006-12-31||Interventional|||Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer|A Phase I Study of Celecoxib, Irinotecan and Concurrent Radiotherapy in the Preoperative Treatment of Pancreatic Cancer|Terminated||Phase 1|23|Anticipated|University of Pittsburgh||1||terminated|f||||t||||||||||2018-06-01 04:37:10.473634|2018-06-01 04:37:10.473634
NCT00177840|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-03-27|2005-09-13|2005-09-15|Estimate|||||||2008-03-27|2008-03-28|Estimate|September 2005||2005-09-30|March 2008|2008-03-31|September 2007|Actual|2007-09-30|July 2007|Actual|2007-07-31||Interventional|||Acupuncture to Treat Cancer-Related Fatigue in Breast Cancer Patients|Acupuncture for Cancer-Related Fatigue in Breast Cancer Patients|Completed||Phase 1|54|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:37:10.616192|2018-06-01 04:37:10.616192
NCT00177827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-12-02|2005-09-13|2005-09-15|Estimate|||||||2009-12-02|2009-12-03|Estimate|March 2004||2004-03-31|December 2009|2009-12-31|March 2006|Actual|2006-03-31|||||Observational|||Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients|Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients: Pharmacokinetics and Correlation Between Plasma and Lung Concentrations With Toxicity/Efficacy|Completed|||104||University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:10.819944|2018-06-01 04:37:10.819944
NCT00177814|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-23|2005-09-13|2005-09-15|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2005|Actual|2005-09-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit|Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit|Completed|||1000|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:11.001414|2018-06-01 04:37:11.001414
NCT00177801|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-14|2005-09-13|2005-09-15|Estimate|||||||2012-08-14|2012-08-16|Estimate|May 2006||2006-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Organ Transplant Infection Prevention and Detection Project|"Organ Transplant Infection Prevention and Detection Project 1.0; Cohort Study of Transplant Recipients at Ultra-High Risk for Invasive Fungal Infections"|Completed|||200|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     No genetic testing will be performed on any of the samples being obtained. The biologic~     samples will be under the control of the principal investigator of this research project. To~     protect confidentiality, all personal identifiers (i.e., name, social security number, and~     birth date) will be removed (de-identified) and replaced with a specific code number. The~     information linking these code numbers to the corresponding subjects' identities will be kept~     in a separate, secure location. The investigators on this study will keep the samples~     indefinitely. The biologic samples may be given to the Centers for Disease Control and~     Prevention. If a subject withdraws and provides the request in writing, samples collected and~     not already processed will be destroyed. All samples will be kept in the investigator's~     laboratory located in Scaife Hall, Room 812, 3550 Terrace Street.~   "|||2018-06-01 04:37:11.141111|2018-06-01 04:37:11.141111
NCT00177788|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-14|2005-09-13|2005-09-15|Estimate|||||||2012-08-14|2012-08-16|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Voriconazole as Prophylaxis for Liver Transplant Recipients|Voriconazole as Prophylaxis for Liver Transplant Recipients|Completed|||800|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:11.377348|2018-06-01 04:37:11.377348
NCT00177775|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-16|2005-09-13|2005-09-15|Estimate|||||||2008-12-16|2008-12-17|Estimate|April 2005||2005-04-30|December 2008|2008-12-31|August 2005||2005-08-31|||||Interventional|||Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea|Whey Protein Concentrate 40% (WPC-40) Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea: A Prospective, Randomized, Controlled Phase II Study - Version 5.1.B|Terminated||Phase 2/Phase 3|60||University of Pittsburgh||||Study is completed and analysis completed|f||||||||||||||2018-06-01 04:37:11.565961|2018-06-01 04:37:11.565961
NCT00177762|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|September 1999||1999-09-30|September 2005|2005-09-30|December 2002||2002-12-31|||||Interventional|||Dose-Response of Exercise on Long-Term Weight Loss|Dose-Response of Exercise on Long-Term Weight Loss|Completed||Phase 1/Phase 2|200||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:11.728511|2018-06-01 04:37:11.728511
NCT00177749|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-16|2005-09-13|2005-09-15|Estimate|||||||2008-12-16|2008-12-17|Estimate|August 2004||2004-08-31|December 2008|2008-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095|Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095|Terminated||Phase 4|10||University of Pittsburgh||||Study is complete Analysis is complete|||||||||||||||2018-06-01 04:37:11.931488|2018-06-01 04:37:11.931488
NCT00177736|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-11|2005-09-13|2005-09-15|Estimate|||||||2007-12-11|2007-12-13|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Observational|||Pharmacodynamic Parameters of Two Different Doses of Cefepime|Pharmacodynamic Parameters of Two Different Doses of Cefepime|Completed|||180|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:12.09382|2018-06-01 04:37:12.09382
NCT00177723|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-16|2005-09-13|2005-09-15|Estimate|||||||2008-12-16|2008-12-17|Estimate|August 2005||2005-08-31|December 2008|2008-12-31|February 2007|Actual|2007-02-28|||||Observational|||Towards Reducing Resistance and Hematological Toxicity of Linezolid|Towards Reducing Resistance and Hematological Toxicity of Linezolid|Completed|||50||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:12.188095|2018-06-01 04:37:12.188095
NCT00177710|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-16|2005-09-13|2005-09-15|Estimate|||||||2008-12-16|2008-12-17|Estimate|January 2006||2006-01-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study|Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study|Completed||Phase 3|48|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:12.354002|2018-06-01 04:37:12.354002
NCT00177697|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|September 1999||1999-09-30|September 2005|2005-09-30|July 2002||2002-07-31|||||Interventional|||A Mentor-Based Approach to Long-Term Weight Loss|A Mentor-Based Approach to Long-Term Weight Loss|Completed||Phase 1/Phase 2|174||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:12.548462|2018-06-01 04:37:12.548462
NCT00177684|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-16|2005-09-13|2005-09-15|Estimate|||||||2008-12-16|2008-12-17|Estimate|September 2004||2004-09-30|December 2008|2008-12-31|September 2005|Actual|2005-09-30|||||Interventional|||Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)|Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)|Completed||Phase 3|48||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:12.84017|2018-06-01 04:37:12.84017
NCT00177671|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-02-18||2013-01-31|2005-09-13|2005-09-15|Estimate|2011-05-06|2011-06-08|Estimate||||2013-01-31|2013-02-06|Estimate|December 2003||2003-12-31|January 2013|2013-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Antidepressant Medication Plus Donepezil for Treating Late-life Depression|Maintenance Therapies in Late-Life Depression: MTLD III|Completed||Phase 4|220|Actual|University of Pittsburgh|Observations about dementia conversion rates were obtained from post hoc subgroup analyses of participants with mild cognitive impairment (N=57) and participants with normal cognition at time of randomization (N=63).|2|||f||||t||||||||||2018-06-01 04:37:12.955167|2018-06-01 04:37:12.955167
NCT00177658|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-23|2005-09-13|2005-09-15|Estimate|||||||2017-06-23|2017-06-26|Actual|March 2006|Actual|2006-03-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||NCCLS Interpretive Criteria for Salmonella|NCCLS Interpretive Criteria for Salmonella|Completed|||50|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:13.554714|2018-06-01 04:37:13.554714
NCT00177645|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-02-12|2005-09-13|2005-09-15|Estimate|||||||2016-02-12|2016-02-17|Estimate|March 2002||2002-03-31|January 2016|2016-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Inhaled Bicarbonate Therapy in Cystic Fibrosis|Inhaled Bicarbonate Therapy in Cystic Fibrosis|Completed||Phase 1|16|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-06-01 04:37:13.662724|2018-06-01 04:37:13.662724
NCT00177632|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|July 2003||2003-07-31|September 2005|2005-09-30|July 2004||2004-07-31|||||Interventional|||Evaluation of Alternative Exercise Treatments on Weight Loss in Overweight Women.|Evaluation of Alternative Exercise Treatments on Weight Loss in Overweight Women.|Completed||Phase 1/Phase 2|66||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:13.781617|2018-06-01 04:37:13.781617
NCT00177619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-02-10|2005-09-13|2005-09-15|Estimate|||||||2014-02-10|2014-02-11|Estimate|May 2002||2002-05-31|February 2014|2014-02-28|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)|Prevention of Osteoporosis in Men With Prostate Cancer|Completed||Phase 3|120||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:13.876076|2018-06-01 04:37:13.876076
NCT00177606|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-05-26|2005-09-13|2005-09-15|Estimate|||||||2017-05-26|2017-05-31|Actual|July 2003||2003-07-31|March 2008|2008-03-31|December 2007|Actual|2007-12-31|||||Observational|||Donors After Cardiac Death: Validating Identification Criteria|Donors After Cardiac Death: Validating Identification Criteria|Completed|||600||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:13.937556|2018-06-01 04:37:13.937556
NCT00177593|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||The Effect of HealthWear on Short-Term Weight Loss|The Effect of HealthWear on Short-Term Weight Loss|Completed||Phase 1/Phase 2|75||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:14.008333|2018-06-01 04:37:14.008333
NCT00177580|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-01-08|2005-09-13|2005-09-15|Estimate|||||||2008-01-08|2008-01-15|Estimate|July 2003||2003-07-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|January 2007|Actual|2007-01-31||Interventional|||Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin|A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Adjunctive Treatment With Pravastatin in Partially Remitted Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|72|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:14.124496|2018-06-01 04:37:14.124496
NCT00177567|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|July 2001||2001-07-31|September 2005|2005-09-30|January 2004||2004-01-31|||||Interventional|||Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study|Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study|Completed||Phase 4|60||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:14.197406|2018-06-01 04:37:14.197406
NCT00177554|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-27|2005-09-13|2005-09-15|Estimate|||||||2008-05-27|2008-05-29|Estimate|November 2003||2003-11-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma|Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma|Completed||Phase 2|60|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:14.283142|2018-06-01 04:37:14.283142
NCT00177541|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-08-04|2005-09-13|2005-09-15|Estimate|||||||2017-08-04|2017-08-08|Actual|February 2004||2004-02-29|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Further Enhancing Non-pharmacologic Therapy for Incontinence|Further Enhancing Non-pharmacologic Therapy for Incontinence|Completed||N/A|123|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:37:14.468103|2018-06-01 04:37:14.468103
NCT00177528|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-08|2005-09-13|2005-09-15|Estimate|||||||2008-10-08|2008-10-09|Estimate|October 2000||2000-10-31|October 2008|2008-10-31||||November 2004|Actual|2004-11-30||Interventional|||Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression|Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression|Completed||Phase 4|70||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:14.682234|2018-06-01 04:37:14.682234
NCT00177515|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-04|2005-09-13|2005-09-15|Estimate|||||||2010-05-04|2010-05-05|Estimate|March 2005||2005-03-31|May 2010|2010-05-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Computer-assisted Preventive Health Education for Women of Reproductive Age in Urgent Care Settings|Preventive Health Education for Women of Reproductive Age|Completed||Phase 3|446|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:37:14.760502|2018-06-01 04:37:14.760502
NCT00177502|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||Effect of Exercise on Prevention of Weight Gain|Effect of Exercise on Prevention of Weight Gain|Completed||Phase 1/Phase 2|294||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:14.89056|2018-06-01 04:37:14.89056
NCT00177489|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-04|2005-09-12|2005-09-15|Estimate|||||||2016-01-04|2016-01-05|Estimate|June 2002||2002-06-30|January 2016|2016-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|REACH||Coordinating Center for Caregiver Intervention Trial|Coordinating Center for Multisite Intervention Trial for Diverse Caregivers|Completed||N/A|613|Actual|University of Pittsburgh||2|||f||||t||||||||Yes|There is no plan to make individual participant data available.|2018-06-01 04:37:15.001525|2018-06-01 04:37:15.001525
NCT00177476|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|May 2006||2006-05-31|||||Interventional|||Enhancing Exercise Participation in Overweight Adults|Enhancing Exercise Participation in Overweight Adults|Completed||Phase 1/Phase 2|225||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:15.1764|2018-06-01 04:37:15.1764
NCT00177463|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-07|2005-09-12|2005-09-15|Estimate|||||||2016-01-07|2016-01-11|Estimate|September 2004||2004-09-30|January 2016|2016-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||L-Carnosine for Bipolar I Disorder|A Pilot Add-on Randomized, Placebo Controlled Intervention Trial of Cognitive Enhancement in Persons With Bipolar Disorder Using an Antioxidant and Advanced Glycation End (AGE) Product Inhibitor: L-Carnosine|Completed||N/A|47|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:37:15.265331|2018-06-01 04:37:15.265331
NCT00177437|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-12|2005-09-12|2005-09-15|Estimate|||||||2007-12-12|2007-12-13|Estimate|June 1999||1999-06-30|December 2007|2007-12-31|September 2005|Actual|2005-09-30|||||Interventional|||Home Screening for Chlamydia Surveillance|Home Screening for Chlamydia Surveillance|Completed||Phase 3|403||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:15.397521|2018-06-01 04:37:15.397521
NCT00177424|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-06-26|2005-09-12|2005-09-15|Estimate|||||||2014-06-26|2014-06-27|Estimate|July 2004||2004-07-31|February 2009|2009-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes|Intervention to Prevent Post-Stroke Major Depression.|Terminated||Phase 4|154|Anticipated|University of Pittsburgh||2||Recruitment goals could not be met.|f||||||||||||||2018-06-01 04:37:15.464672|2018-06-01 04:37:15.464672
NCT00177411|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-09-03|2005-09-12|2005-09-15|Estimate|||||||2014-09-03|2014-09-05|Estimate|July 2005||2005-07-31|September 2014|2014-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||"PTHrP(1-36) IV Dose Escalation Study"|"Determining the Maximum Tolerable Dose and Pharmacokinetic Parameters of Intravenous PTHrP(1-36)"|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||1||Protocol design was changed so it no longer fit the description of this study.|f||||t||||||||||2018-06-01 04:37:15.66595|2018-06-01 04:37:15.66595
NCT00177398|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-13|2005-09-12|2005-09-15|Estimate|||||||2007-12-13|2007-12-19|Estimate|February 2005||2005-02-28|December 2007|2007-12-31|August 2006|Actual|2006-08-31|||||Interventional|||Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings|The Effect of Insulin Glargine on Glycemic Control, Morbidity, and Length of Stay in Hospitalized Subjects With Diabetes Receiving Enteral Nutrition|Completed||Phase 4|50||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:15.792723|2018-06-01 04:37:15.792723
NCT00177385|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-05-27|2005-09-12|2005-09-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2003||2003-06-30|May 2015|2015-05-31|September 2011|Actual|2011-09-30|June 2009|Actual|2009-06-30||Interventional|AgeWise||Aging Well, Sleeping Efficiently: Protecting Health In Later Life|AGEWISE Project 4: PROTECTING HEALTH IN LATER LIFE|Completed||N/A|66||University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:15.982406|2018-06-01 04:37:15.982406
NCT00177372|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-28|2005-09-12|2005-09-15|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2005||2005-01-31|January 2016|2016-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|MIMID||Mifepristone and Misoprostol for Fetal Demise|Mifepristone and Misoprostol for the Treatment of Early Pregnancy Failure: a Pilot Clinical Trial|Completed||Phase 4|30|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-06-01 04:37:16.122006|2018-06-01 04:37:16.122006
NCT00177359|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-12|2005-09-12|2005-09-15|Estimate|||||||2007-12-12|2007-12-13|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Restoring Skill in Walking|Restoring Skill in Walking|Completed||Phase 2|48|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:16.242008|2018-06-01 04:37:16.242008
NCT00177346|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-05|2005-09-12|2005-09-15|Estimate|||||||2016-01-05|2016-01-07|Estimate|October 2003||2003-10-31|January 2016|2016-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection|A Randomized Trial of Carotid Artery Stenting With and Without Cerebral Protection|Completed||N/A|52|Actual|University of Pittsburgh||2|||f||||||||||||||2018-06-01 04:37:16.314783|2018-06-01 04:37:16.314783
NCT00177333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-28|2005-09-12|2005-09-15|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2005||2005-09-30|January 2016|2016-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens|Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens|Completed||Phase 4|40|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 04:37:16.471356|2018-06-01 04:37:16.471356
NCT00177320|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-21|2005-09-12|2005-09-15|Estimate|||||||2016-01-21|2016-01-25|Estimate|March 2005||2005-03-31|January 2016|2016-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Observational|||Rheumatic Diseases and Computer Use|Rheumatic Diseases and Computer Use: A Needs Assessment|Completed|||359|Actual|University of Pittsburgh|||||f||||f||||||||||2018-06-01 04:37:16.589878|2018-06-01 04:37:16.589878
NCT00177307|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-01-12||2016-06-01|2005-09-12|2005-09-15|Estimate|2016-06-01|2016-07-12|Estimate||||2016-06-01|2016-07-12|Estimate|January 2005||2005-01-31|June 2016|2016-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer|Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated Advanced Colorectal Cancer|Completed||Phase 2|40|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:37:16.696612|2018-06-01 04:37:16.696612
NCT00177294|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-12-22||2012-01-10|2005-09-12|2005-09-15|Estimate|2011-02-18|2011-03-15|Estimate||||2012-01-10|2012-01-12|Estimate|April 2004||2004-04-30|November 2010|2010-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression|Geriatric Depression: Getting Better, Getting Well|Completed||Phase 4|319|Actual|University of Pittsburgh|The study design does not allow an inference about which specific intervention led to further improvement. Was it simply a dose increase of escitalopram from 10mg to 20mg? Is this intensive contact necessary for improvement?|2|||f||||t||||||||||2018-06-01 04:37:17.040358|2018-06-01 04:37:17.040358
NCT00177281|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-18|2005-09-12|2005-09-15|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2003||2003-09-30|December 2013|2013-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety Study of S-CKD602 in Patients With Advanced Malignancies|A Phase I Study to Evaluate the Safety and Pharmacokinetics of S-CKD602 in Patients With Advanced Malignancies|Completed||Phase 1|45|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:37:17.730431|2018-06-01 04:37:17.730431
NCT00177268|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-01|2005-09-12|2005-09-15|Estimate|||||||2017-12-01|2017-12-05|Actual|October 2004||2004-10-31|December 2017|2017-12-31|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Observational|||Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research|Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research|Recruiting|||200|Anticipated|University of Pittsburgh|||1||f||||f||||||Samples Without DNA|"~     White blood cells and/or skin biopsy tissue are retained.~   "|Undecided||2018-06-01 04:37:17.835488|2018-06-01 04:37:17.835488
NCT00177255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-01-10||2016-01-10|2005-09-12|2005-09-15|Estimate|2016-01-10|2016-02-08|Estimate||||2016-01-10|2016-02-08|Estimate|April 2005||2005-04-30|January 2016|2016-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers|A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas.|Terminated||Phase 2|40|Actual|University of Pittsburgh||1||Roche has withdrawn support|f||||t||||||||||2018-06-01 04:37:18.005675|2018-06-01 04:37:18.005675
NCT00177242|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-15|2005-09-12|2005-09-15|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2004||2004-09-30|January 2016|2016-01-31|December 2006|Actual|2006-12-31|||||Interventional|||Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma|Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma|Completed||Phase 2|45||University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:18.345832|2018-06-01 04:37:18.345832
NCT00177229|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-02-15|2005-09-12|2005-09-15|Estimate|||||||2008-02-15|2008-02-18|Estimate|July 2001||2001-07-31|February 2008|2008-02-29|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||KidQuest Family-Based Weight Control|Family-Based Treatment of Severe Pediatric Obesity|Completed||N/A|192|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:37:18.408944|2018-06-01 04:37:18.408944
NCT00177216|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-05-26||2016-02-29|2005-09-12|2005-09-15|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|February 2002||2002-02-28|February 2016|2016-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Characteristics of Sleep Patterns in Young Adults With and Without Insomnia|Psychobiology and Treatment Response in Primary Insomnia|Completed||Phase 4|69|Actual|University of Pittsburgh||3|||f||||t||||||||Yes|To gain access to data, researchers must submit a description of their project to the Principal Investigator, including the investigator's personal identification and institutional affiliation, a current CV, qualifications, duration of the proposed research, source of funding, and a conflict of interest statement. The protocol must include study aims, background and significance, methods and types of analysis, and a description of the data requested. Once approved, the investigator must complete a University of Pittsburgh IRB exempt research application form and document completion of a responsible conduct of research program. Data will be prepared by an 'honest broker' from the data management staff of the project. This person will complete the honest broker certification form required by our IRB. Data will be provided as a SAS data set, and will not include information that could identify individual research participants or that the original consent form expressly forbade.|2018-06-01 04:37:18.519631|2018-06-01 04:37:18.519631
NCT00177203|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-05-27|2005-09-12|2005-09-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2003||2003-06-30|May 2015|2015-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|AW3||Agewise Project 3: Brief Behavioral Treatment of Insomnia in Primary Care|Agewise Project 3: Brief Behavioral Treatment of Insomnia in Primary Care|Completed||N/A|140|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:37:18.828095|2018-06-01 04:37:18.828095
NCT00177190|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-27|2005-09-12|2005-09-15|Estimate|||||||2014-05-27|2014-05-28|Estimate|June 2002||2002-06-30|June 2013|2013-06-30|January 2006|Actual|2006-01-31|January 2005|Actual|2005-01-31||Observational|||In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)|In Vitro Evaluation of Immune Responses in CTCL|Completed|||8|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     White cells~   "|||2018-06-01 04:37:19.00672|2018-06-01 04:37:19.00672
NCT00177177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-01-15|2005-09-12|2005-09-15|Estimate|||||||2013-01-15|2013-01-16|Estimate|March 2004||2004-03-31|January 2013|2013-01-31|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||L-carnosine for Schizophrenia|L-Carnosine, an Antioxidant and AGE Inhibitor (Advanced Glycation End Products) for Cognitive Enhancement Among Persons With Schizophrenia: A Randomized, Add-on Double-Blind, Placebo Controlled, Clinical Trial|Completed||N/A|84|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:37:19.109059|2018-06-01 04:37:19.109059
NCT00177164|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-01-07||2016-03-17|2005-09-12|2005-09-15|Estimate|2016-01-07|2016-02-08|Estimate||||2016-03-17|2016-04-19|Estimate|November 2003||2003-11-30|March 2016|2016-03-31|December 2009|Actual|2009-12-31|March 2008|Actual|2008-03-31||Interventional||Two patients in the Risperidone LAI group were not included in the analysis as they did not receive any assessment after the baseline assessment|Risperdal Consta for Bipolar Disorder|A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study|Completed||Phase 3|50|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:37:19.235422|2018-06-01 04:37:19.235422
NCT00177138|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-02-05|2005-09-13|2005-09-15|Estimate|||||||2013-02-05|2013-02-07|Estimate|July 2004||2004-07-31|February 2013|2013-02-28|November 2006|Actual|2006-11-30|||||Interventional|||Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation|Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation|Terminated||Phase 4|9|Actual|University of Minnesota - Clinical and Translational Science Institute||2||The clinical use of Campath for transplant patients was temporarily suspended.|f||||f||||||||||2018-06-01 04:37:19.741828|2018-06-01 04:37:19.741828
NCT00177125|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-03|2005-09-13|2005-09-15|Estimate|||||||2012-02-03|2012-02-06|Estimate|January 2004||2004-01-31|February 2012|2012-02-29|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Evaluating the Effect of the VCD on Erectile Function and Penile Length Post RRP|Evaluating the Effect of the Vacuum Constriction Device on Erectile Function and Penile Length Post Radical Retropubic Prostatectomy|Completed||Phase 3|220||University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 04:37:19.86249|2018-06-01 04:37:19.86249
NCT00177112|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-01-31|2005-09-13|2005-09-15|Estimate|||||||2008-01-31|2008-02-04|Estimate|June 2005||2005-06-30|January 2008|2008-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy|Impact of Sterilization Technique on Incidence of Urinary Tract Infection After Cystoscopy|Completed||Phase 3|275|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:37:19.953096|2018-06-01 04:37:19.953096
NCT00177099|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-11-08|2005-09-13|2005-09-15|Estimate|||||||2006-11-08|2006-11-13|Estimate|July 2003||2003-07-31|November 2006|2006-11-30|September 2004||2004-09-30|||||Interventional|||Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice|Neurotrophic Effects of Immunophilin Ligands on Human Hair Follicles Grafted Onto Service Combined Immunodeficient (SCID) Mice|Completed||Phase 1|35||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:37:20.048458|2018-06-01 04:37:20.048458
NCT00175812|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-06-23|2005-09-09|2005-09-15|Estimate|||||||2015-06-23|2015-06-24|Estimate|November 2004||2004-11-30|June 2015|2015-06-30|November 2009|Actual|2009-11-30|May 2008|Actual|2008-05-31||Interventional|||Differentiation Induction in Acute Myelogenous Leukemia|Differentiation Induction Therapy for Acute Myelogenous Leukemia|Completed||Phase 1/Phase 2|24|Actual|University of Bergen||1|||f||||f||||||||||2018-06-01 04:37:43.984979|2018-06-01 04:37:43.984979
NCT00177086|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-03-15|2005-09-13|2005-09-15|Estimate|||||||2013-03-15|2013-03-18|Estimate|September 2005||2005-09-30|March 2013|2013-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi|Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi|Completed||Phase 3|76|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 04:37:20.120403|2018-06-01 04:37:20.120403
NCT00177060|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-26|2005-09-13|2005-09-15|Estimate|||||||2010-02-26|2010-03-01|Estimate|October 2003||2003-10-31|February 2010|2010-02-28|May 2007|Actual|2007-05-31|||||Interventional|||Topical Hydromorphone for Wound Healing|Topical Hydromorphone for Wound Healing|Terminated||Phase 1/Phase 2|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||||No funding available.|f||||f||||||||||2018-06-01 04:37:20.232862|2018-06-01 04:37:20.232862
NCT00177047|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-02-12|2005-09-13|2005-09-15|Estimate|||||||2018-02-12|2018-02-13|Actual|April 20, 2004|Actual|2004-04-20|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Autologous Transplant for Multiple Myeloma|Autologous Transplantation for Multiple Myeloma|Active, not recruiting||Phase 2/Phase 3|363|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-06-01 04:37:20.318852|2018-06-01 04:37:20.318852
NCT00177034|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-07-09|2005-09-12|2005-09-15|Estimate|||||||2012-07-09|2012-07-10|Estimate|November 2004||2004-11-30|July 2012|2012-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Examination Of Vitiligo Skin Samples Before and After UVB Treatment|Characterization of Keratinocyte Populations From Normal, Perilesional and Lesional Skin in Vitiligo Patients by Laser Capture Microdissection and Gene Array Analysis Before and After Narrow Band UVB Treatment|Terminated||N/A|12||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:37:20.42912|2018-06-01 04:37:20.42912
NCT00177021|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-11-08|2005-09-12|2005-09-15|Estimate|||||||2006-11-08|2006-11-13|Estimate|October 2000||2000-10-31|November 2006|2006-11-30|August 2002||2002-08-31|||||Interventional|||Aldara for the Treatment of Extensive Alopecia Areata|Aldara for the Treatment of Extensive Alopecia Areata|Completed||Phase 4|20||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:37:20.526706|2018-06-01 04:37:20.526706
NCT00177008|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-01-25|2005-09-13|2005-09-15|Estimate|||||||2007-01-25|2007-01-29|Estimate|March 2004||2004-03-31|January 2007|2007-01-31|January 2007||2007-01-31|||||Interventional|||Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety|Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety|Completed||Phase 4|18||Rutgers, The State University of New Jersey|||||||||||||||||||2018-06-01 04:37:20.616721|2018-06-01 04:37:20.616721
NCT00176995|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-08|2005-09-12|2005-09-15|Estimate|||||||2006-11-08|2006-11-13|Estimate|March 1999||1999-03-31|November 2006|2006-11-30|October 2000||2000-10-31|||||Interventional|||Effect of 15% Eflornithine Hydrochloride Cream on African-American Males With Pseudofolliculitis Barbae|Phase II, Open-Label Study of the Effect of 15% Eflornithine Hydrochloride Cream on Facial Hair of Men of African-American Descent With Pseudofolliculitis Barbae: A Laser Scanning Confocal Microscopy and Video Imaging Study|Completed||Phase 2|15||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:37:20.735841|2018-06-01 04:37:20.735841
NCT00176982|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-08-12|2005-09-12|2005-09-15|Estimate|||||||2009-08-12|2009-08-13|Estimate|April 2002||2002-04-30|August 2009|2009-08-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Plaquenil for Alopecia Areata, Alopecia Totalis|Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis|Completed||Phase 4|16||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 04:37:20.849999|2018-06-01 04:37:20.849999
NCT00176969|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-05-30|2005-09-12|2005-09-15|Estimate|||||||2014-05-30|2014-06-02|Estimate|August 1997||1997-08-31|May 2014|2014-05-31|June 2000||2000-06-30|||||Interventional|||Response of Topical Capsaicin in Alopecia Areata|Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin|Completed||Phase 4|24||University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 04:37:20.980579|2018-06-01 04:37:20.980579
NCT00176956|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-02-01|2005-09-12|2005-09-15|Estimate|||||||2013-02-01|2013-02-05|Estimate|November 2002||2002-11-30|February 2013|2013-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients|Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients|Terminated||Phase 3|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||||IRB approval has lapsed.|f||||f||||||||||2018-06-01 04:37:21.074637|2018-06-01 04:37:21.074637
NCT00176943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-02-13|2005-09-12|2005-09-15|Estimate|||||||2014-02-13|2014-02-14|Estimate|October 2000||2000-10-31|February 2014|2014-02-28|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%|Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry|Completed||Phase 4|20||University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 04:37:21.192279|2018-06-01 04:37:21.192279
NCT00176930|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-05|2005-09-12|2005-09-15|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2001|Actual|2001-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stem Cell Transplant for Hematological Malignancy|Allogeneic Transplant for Hematological Malignancy|Suspended||N/A|350|Anticipated|Masonic Cancer Center, University of Minnesota||1||Trial re-written as MT2015-29|f||||t||||||||||2018-06-01 04:37:21.310897|2018-06-01 04:37:21.310897
NCT00176917|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-07-28||2017-12-03|2005-09-12|2005-09-15|Estimate|2009-07-28|2009-09-04|Estimate||||2017-12-03|2017-12-28|Actual|May 1999||1999-05-31|December 2017|2017-12-31|May 2010|Actual|2010-05-31|May 2008|Actual|2008-05-31||Interventional|||Stem Cell Transplantation for Hurler|Hematopoietic Stem Cell Transplantation for Hurler Syndrome, Maroteaux Lamy Syndrome (MPS VI), and Alpha Mannosidase Deficiency (Mannosidosis)|Completed||Phase 2|41|Actual|Masonic Cancer Center, University of Minnesota|"Based on variability in age, diagnosis and condition of these patients, the data on enzyme levels and neuropsych testing is extremely difficult to report.~See Secondary Outcome Measures #3 and #4; no other adverse events were collected."|1|||f||||f||||||||||2018-06-01 04:37:21.430345|2018-06-01 04:37:21.430345
NCT00176904|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-05-17||2017-12-03|2005-09-12|2005-09-15|Estimate|2011-05-17|2011-06-10|Estimate||||2017-12-03|2017-12-28|Actual|January 1995||1995-01-31|December 2017|2017-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Stem Cell Transplant for Inborn Errors of Metabolism|Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation|Completed||Phase 2/Phase 3|135|Actual|Masonic Cancer Center, University of Minnesota|Change in Neuropsychometric function data is not available. Data would have been noted as descriptive and patient specific, as well as disease specific; not table format. No formal analysis was intended.|1|||f||||f||||||||||2018-06-01 04:37:21.764365|2018-06-01 04:37:21.764365
NCT00176891|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-07-08|2005-09-12|2005-09-15|Estimate|||||||2014-07-08|2014-07-09|Estimate|March 2004||2004-03-31|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Stem Cell Transplant w/Laronidase for Hurler|Phase II Study of Combined Laronidase (AldurazymeTM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)|Completed||Phase 2|25|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-06-01 04:37:22.045813|2018-06-01 04:37:22.045813
NCT00176878|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-06-18||2017-12-03|2005-09-12|2005-09-15|Estimate|2009-06-18|2009-08-06|Estimate||||2017-12-03|2017-12-28|Actual|June 2000||2000-06-30|December 2017|2017-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Stem Cell Transplant for Bone Marrow Failure Syndromes|Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders|Completed||Phase 2/Phase 3|10|Actual|Masonic Cancer Center, University of Minnesota|Pharmacokinetic parameters in patients receiving 2 mg/kg/dose of busulfan twice daily was not performed. No data is available.|1|||f||||t||||||||||2018-06-01 04:37:22.149172|2018-06-01 04:37:22.149172
NCT00176865|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-05-06||2017-12-03|2005-09-12|2005-09-15|Estimate|2017-03-03|2017-04-14|Actual||||2017-12-03|2017-12-28|Actual|August 2002||2002-08-31|December 2017|2017-12-31|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Interventional|||Stem Cell Transplant for Immunologic or Histiocytic Disorders|Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism|Completed||Phase 2|19|Actual|Masonic Cancer Center, University of Minnesota||3|||f||||t||||||||||2018-06-01 04:37:22.470714|2018-06-01 04:37:22.470714
NCT00176852|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-03-28||2017-12-03|2005-09-12|2005-09-15|Estimate|2017-03-28|2017-05-09|Actual||||2017-12-03|2017-12-05|Actual|June 2002||2002-06-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|March 2014|Actual|2014-03-31||Interventional|||Stem Cell Transplant for Hemoglobinopathy|Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathy Using a Preparative Regimen to Achieve Stable Mixed Chimerism|Active, not recruiting||Phase 2/Phase 3|22|Actual|Masonic Cancer Center, University of Minnesota||3|||f||||t||||||||||2018-06-01 04:37:28.195739|2018-06-01 04:37:28.195739
NCT00176839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-01-11||2017-12-03|2005-09-12|2005-09-15|Estimate|2013-01-11|2013-02-13|Estimate||||2017-12-03|2017-12-05|Actual|June 7, 2000|Actual|2000-06-07|December 2017|2017-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Stem Cell Transplantation for Hematological Malignancies|Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies|Terminated||Phase 2/Phase 3|11|Actual|Masonic Cancer Center, University of Minnesota||1||Replaced by a different study|f||||t||||||||||2018-06-01 04:37:30.131234|2018-06-01 04:37:30.131234
NCT00176826|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-03-27||2017-12-29|2005-09-12|2005-09-15|Estimate|2014-03-27|2014-04-28|Estimate||||2017-12-29|2018-01-23|Actual|September 2000||2000-09-30|May 2015|2015-05-31|August 2015|Actual|2015-08-31|August 2012|Actual|2012-08-31||Interventional|||T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders|In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders|Terminated||Phase 2/Phase 3|22|Actual|Masonic Cancer Center, University of Minnesota||1||Replaced by another protocol|f||||t||||||||||2018-06-01 04:37:30.514984|2018-06-01 04:37:30.514984
NCT00176813|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-04-29|2005-09-09|2005-09-15|Estimate|||||||2008-04-29|2008-05-06|Estimate|March 2003||2003-03-31|April 2008|2008-04-30|November 2006|Actual|2006-11-30|November 2003|Actual|2003-11-30||Interventional|||Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer|Phase II Study of Gemcitabine, Cisplatin, and Celecoxib in the Treatment of Metastatic Pancreatic Cancer|Completed||Phase 2|5|Actual|University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:37:30.94607|2018-06-01 04:37:30.94607
NCT00176800|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2016-04-14||2016-07-12|2005-09-12|2005-09-15|Estimate|2016-07-12|2016-08-22|Estimate||||2016-07-12|2016-08-22|Estimate|November 2001||2001-11-30|July 2016|2016-07-31|May 2013|Actual|2013-05-31|February 2006|Actual|2006-02-28||Interventional|||Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma|Pre-Operative Chemoradiation Followed by Post-Operative Tetrathiomolybdate (TM) in Patients With Loco-Regional Esophageal Carcinoma (UMCC 2001-007)|Completed||Phase 2|69|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:37:31.0544|2018-06-01 04:37:31.0544
NCT00176787|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-12-28|2005-09-12|2005-09-15|Estimate|||||||2007-12-28|2008-01-10|Estimate|October 2000||2000-10-31|December 2007|2007-12-31|June 2007|Actual|2007-06-30|May 2005|Actual|2005-05-31||Interventional|||Radiation Therapy With Capecitabine in Rectal Cancer|Phase II Trial of Preoperative Radiation Therapy With Capecitabine in Rectal Cancer (UMCC 0046)|Terminated||Phase 2|30||University of Michigan Cancer Center||||recruitment goals met|f||||||||||||||2018-06-01 04:37:31.39119|2018-06-01 04:37:31.39119
NCT00176774|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-02-05|2005-09-12|2005-09-15|Estimate|||||||2012-02-05|2012-02-07|Estimate|February 2001||2001-02-28|February 2012|2012-02-29|April 2004|Actual|2004-04-30|February 2004|Actual|2004-02-29||Interventional|||Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma|A Pilot Trial of Irinotecan, 5-Fluorouracil, and Leucovorin Combined With the Anti-Angiogenesis Agent Tetrathiomolybdate in Metastatic Colorectal Carcinoma (UMCC 0075)|Completed||Phase 2|24|Actual|University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:37:31.497675|2018-06-01 04:37:31.497675
NCT00176761|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-06|2005-09-09|2005-09-15|Estimate|||||||2006-09-06|2006-09-11|Estimate|March 2000||2000-03-31|September 2006|2006-09-30|May 2006||2006-05-31|||||Interventional|||Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine|A Phase II Trial Assessing Autologous, Tumor-Pulsed Dendritic Cells as a Tumor Vaccine Administered With IL-2 in Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|27||University of Michigan Cancer Center|||||||||||||||||||2018-06-01 04:37:31.584862|2018-06-01 04:37:31.584862
NCT00176748|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-01-14|2005-09-09|2005-09-15|Estimate|||||||2010-01-14|2010-01-15|Estimate|July 2005||2005-07-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|August 2006|Actual|2006-08-31||Interventional|||Treatment for Patients With Metastatic Thyroid Cancer|Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment|Completed||Phase 2|3|Actual|University of Michigan Cancer Center||1|||f||||||||||||||2018-06-01 04:37:31.702554|2018-06-01 04:37:31.702554
NCT00176735|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-05-18|2005-09-09|2005-09-15|Estimate|||||||2015-05-18|2015-05-20|Estimate|December 2001||2001-12-31|May 2015|2015-05-31|August 2005||2005-08-31|||||Interventional|||Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer|Pilot Trial of Capecitabine and Radiation Therapy With Pre and Post Combination Chemotherapy in Advanced Pancreatic Cancer|Terminated||N/A|||University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:37:31.820156|2018-06-01 04:37:31.820156
NCT00176722|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-23|2005-09-13|2005-09-15|Estimate|||||||2015-04-23|2015-04-24|Estimate|June 2006||2006-06-30|April 2015|2015-04-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Observational|||Intraocular Pressure During Prone Spinal Surgery|The Effect of Table Position on Intraocular Pressure (IOP) and Ocular Perfusion Pressure (OPP) During Prone Spine Surgery|Terminated|||7|Actual|Rutgers, The State University of New Jersey|||1|Principal Investigator is leaving the UMDNJ|f||||f||||||||||2018-06-01 04:37:31.982147|2018-06-01 04:37:31.982147
NCT00176696|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-04|2005-09-13|2005-09-15|Estimate|||||||2016-10-04|2016-10-06|Estimate|August 2005||2005-08-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Biobehavioral Recovery From Surgery and Anesthesia|"Detection of Nociception (Pain) During General Anesthesia"|Terminated|||20|Actual|Rutgers, The State University of New Jersey||||Principal Investigator has left the UMDNJ|f||||f||||||||No||2018-06-01 04:37:32.045136|2018-06-01 04:37:32.045136
NCT00176683|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-26|2005-09-13|2005-09-15|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2005||2005-07-31|January 2017|2017-01-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Observational|||The Use of Capnography as a Guide for Oral Intubation|Assessing the Use of Capnography as a Guide for Endotracheal Intubation|Terminated|||20|Actual|Rutgers, The State University of New Jersey|||1|study was suspended because of difficluty maintaining equipment|f||||f||||||||||2018-06-01 04:37:32.169476|2018-06-01 04:37:32.169476
NCT00176670|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-10-04|2005-09-13|2005-09-15|Estimate|||||||2016-10-04|2016-10-06|Estimate|January 2004||2004-01-31|June 2008|2008-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A GameBoy as a Distraction Before Surgery in Children|Is Preoperative Distraction With a Hand Held Game Boy as Effective as Midazolam in Reducing Preoperative Anxiety Levels in Children?|Completed||Phase 2|158||Rutgers, The State University of New Jersey|||||f||||f||||||||No||2018-06-01 04:37:32.256061|2018-06-01 04:37:32.256061
NCT00176657|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-27|2005-09-13|2005-09-15|Estimate|||||||2007-04-27|2007-05-01|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||The Use of HEMOBAG to Salvage Blood After Cardiac Surgery|Comparison of Whole Blood Return and Normal Practice Red Blood Cell Salvage Return Following Cardiopulmonary Bypass|Terminated||Phase 2|50||Rutgers, The State University of New Jersey||||Inability to attain sufficient numbers of subjects|f||||||||||||||2018-06-01 04:37:32.371268|2018-06-01 04:37:32.371268
NCT00176644|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-11-05||2013-11-05|2005-09-13|2005-09-15|Estimate|2013-11-05|2013-12-24|Estimate||||2013-11-05|2013-12-24|Estimate|May 2005||2005-05-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer|Phase II Trial of Transdermal Estradiol in Patients With Hormone Refractory Prostate Cancer|Terminated||Phase 2|23|Actual|Rutgers, The State University of New Jersey||1||Treatment ineffective|f||||f||||||||||2018-06-01 04:37:32.504194|2018-06-01 04:37:32.504194
NCT00176631|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-11-15||2013-11-15|2005-09-13|2005-09-15|Estimate|2013-11-15|2014-01-07|Estimate||||2013-11-15|2014-01-07|Estimate|September 2007||2007-09-30|November 2013|2013-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of Licorice Root and Docetaxel in Patients With Hormone Refractory Prostate Cancer|Terminated||Phase 2|10|Actual|Rutgers, The State University of New Jersey||1||slow accrual|f||||f||||||||||2018-06-01 04:37:32.903133|2018-06-01 04:37:32.903133
NCT00176618|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-12-10|2005-09-13|2005-09-15|Estimate|||||||2009-12-10|2009-12-11|Estimate|April 2004||2004-04-30|December 2009|2009-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon|The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon|Terminated||N/A|60|Anticipated|Rutgers, The State University of New Jersey||||principal Investigator left institution|f||||||||||||||2018-06-01 04:37:33.14698|2018-06-01 04:37:33.14698
NCT00176605|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-09-17||2014-04-18|2005-09-13|2005-09-15|Estimate|2014-04-18|2014-05-20|Estimate||||2014-04-18|2014-05-20|Estimate|May 2005||2005-05-31|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer|A Phase II Trial of Metronomic Dosing of Etoposide and Cyclophosphamide in Patients With Stage D0 Prostate Cancer.|Completed||Phase 2|15|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 04:37:33.255271|2018-06-01 04:37:33.255271
NCT00176592|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-11-07|2005-09-13|2005-09-15|Estimate|||||||2014-11-07|2014-11-10|Estimate|January 2003||2003-01-31|November 2014|2014-11-30|January 2016|Anticipated|2016-01-31|January 2007|Actual|2007-01-31||Interventional|BECOME||Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI|Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium|Unknown status|Active, not recruiting|Phase 4|93|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-06-01 04:37:33.515679|2018-06-01 04:37:33.515679
NCT00176579|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-08-11|2005-09-13|2005-09-15|Estimate|||||||2011-08-11|2011-08-12|Estimate|June 2003||2003-06-30|August 2011|2011-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer|Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer|Completed|||27|Actual|Rutgers, The State University of New Jersey|||||f||||t||||||||||2018-06-01 04:37:33.64261|2018-06-01 04:37:33.64261
NCT00176566|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-12-10|2005-09-12|2005-09-15|Estimate|||||||2009-12-10|2009-12-11|Estimate|September 2003||2003-09-30|December 2009|2009-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia|A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia|Terminated||Phase 2|8|Actual|Rutgers, The State University of New Jersey||||Transitioned into a national study through ECOG|f||||||||||||||2018-06-01 04:37:33.748696|2018-06-01 04:37:33.748696
NCT00176553|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-12-10|2005-09-12|2005-09-15|Estimate|||||||2009-12-10|2009-12-11|Estimate|March 2003||2003-03-31|December 2009|2009-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity|A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity|Terminated||N/A|20|Anticipated|Rutgers, The State University of New Jersey||||slow accrual|f||||t||||||||||2018-06-01 04:37:33.828749|2018-06-01 04:37:33.828749
NCT00176540|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-16|2005-09-12|2005-09-15|Estimate|||||||2011-05-16|2011-05-17|Estimate|October 2003||2003-10-31|May 2011|2011-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Dextromethorphan in Treating Patients With Fatigue Caused by Cancer|A Pilot Trial to Evaluate the Effects of Dextromethorphan in Patients Suffering From Cancer-Related Fatigue|Terminated||N/A|30|Anticipated|Rutgers, The State University of New Jersey||||slow accrual|f||||t||||||||||2018-06-01 04:37:34.020324|2018-06-01 04:37:34.020324
NCT00176527|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-12-10|2005-09-12|2005-09-15|Estimate|||||||2009-12-10|2009-12-11|Estimate|November 2002||2002-11-30|December 2009|2009-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy|A Phase II Trial of 13-Cis Retinoic Acid, Alpha Interferon, Taxotere, and Estramustine (R.I.T.E.) for the Treatment of Hormone Refractory Prostate Cancer|Terminated||Phase 2|40|Anticipated|Rutgers, The State University of New Jersey||||accrual goal met|f||||t||||||||||2018-06-01 04:37:34.117612|2018-06-01 04:37:34.117612
NCT00176514|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-12-10|2005-09-12|2005-09-15|Estimate|||||||2009-12-10|2009-12-11|Estimate|July 2000||2000-07-31|December 2009|2009-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Pilot Trial to Assess the Effects of Green Tea in the Prevention of Therapy-Induced Mucositis|A Pilot Trial to Assess the Effects of Green Tea in the Prevention of Therapy-Induced Mucositis|Terminated||N/A|37||Rutgers, The State University of New Jersey||||slow accrual|f||||f||||||||||2018-06-01 04:37:34.271406|2018-06-01 04:37:34.271406
NCT00176501|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-11-18||2013-11-18|2005-09-12|2005-09-15|Estimate|2013-11-18|2014-01-06|Estimate||||2013-11-18|2014-01-06|Estimate|August 2004||2004-08-31|November 2013|2013-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer|Immunotherapy for Patients With Renal Cell Carcinoma|Terminated||Phase 2|3|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||f||||||||||2018-06-01 04:37:34.377151|2018-06-01 04:37:34.377151
NCT00176488|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-09-18||2017-02-20|2005-09-12|2005-09-15|Estimate|2013-09-18|2013-11-25|Estimate||||2017-02-20|2017-03-23|Actual|June 2003||2003-06-30|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer|A Phase II Trial of Sequential Epirubicin/Vinorelbine in Patients With Advanced Breast Cancer|Terminated||Phase 2|31|Actual|Rutgers, The State University of New Jersey||1||Competing studies|f||||f||||||||||2018-06-01 04:37:34.820296|2018-06-01 04:37:34.820296
NCT00176475|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-13|2005-09-12|2005-09-15|Estimate|||||||2013-09-13|2013-09-17|Estimate|January 2005||2005-01-31|September 2013|2013-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease|A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes in Conjunction With Rituximab for Selected Patients With CD20 + Malignancies|Terminated||Phase 1|2|Actual|Rutgers, The State University of New Jersey||1||slow accrual|f||||t||||||||||2018-06-01 04:37:35.156903|2018-06-01 04:37:35.156903
NCT00176462|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-11-15||2014-05-12|2005-09-12|2005-09-15|Estimate|2014-05-12|2014-06-09|Estimate||||2014-05-12|2014-06-09|Estimate|February 2001||2001-02-28|May 2014|2014-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||CINJALL: Treatment for Children With Acute Lymphocytic Leukemia|CINJALL: Treatment for Children With Acute Lymphocytic Leukemia|Completed||Phase 2|60|Actual|Rutgers, The State University of New Jersey|Antifolate therapy was non-randomly assigned, therefore, we do not have a statistical basis to compare the toxicity observed among patients on the standard risk and high risk treatment arms.|2|||f||||f||||||||||2018-06-01 04:37:35.453403|2018-06-01 04:37:35.453403
NCT00176449|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-30|2005-09-13|2005-09-15|Estimate|||||||2017-03-30|2017-04-04|Actual|April 2001||2001-04-30|March 2017|2017-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Comparison of Bupropion SR and Placebo for Smoking Cessation|A Comparison of Bupropion SR and Placebo for Smoking Cessation|Completed||Phase 4|52|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 04:37:36.15244|2018-06-01 04:37:36.15244
NCT00176436|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-01-18||2013-05-07|2005-09-12|2005-09-15|Estimate|2013-05-07|2013-06-17|Estimate||||2013-05-07|2013-06-17|Estimate|February 2004||2004-02-29|May 2013|2013-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients|Double-Blind Study of Atomoxetine for Weight Management in Patients Taking Olanzapine or Clozapine|Completed||Phase 4|40|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 04:37:36.326586|2018-06-01 04:37:36.326586
NCT00176423|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-06-26|2005-09-09|2005-09-15|Estimate|||||||2007-06-26|2007-06-27|Estimate|May 2002||2002-05-31|June 2007|2007-06-30|December 2006|Actual|2006-12-31|||||Interventional|||Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia|Adjunctive Galantamine for Treatment of Cognitive Impairments in Patients With Schizophrenia|Completed||Phase 4|120||University of Maryland|||||f||||t||||||||||2018-06-01 04:37:36.838082|2018-06-01 04:37:36.838082
NCT00176410|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-01-13|2005-09-13|2005-09-15|Estimate|||||||2010-01-13|2010-01-14|Estimate|January 2003||2003-01-31|September 2006|2006-09-30|December 2009|Anticipated|2009-12-31|September 2009|Anticipated|2009-09-30||Interventional|||Statin Therapy in Asymptomatic Aortic Stenosis||Unknown status|Recruiting|Phase 2|100|Anticipated|University of Leipzig|||||f||||||||||||||2018-06-01 04:37:36.936715|2018-06-01 04:37:36.936715
NCT00176397|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-06|2005-09-13|2005-09-15|Estimate|||||||2007-09-06|2007-09-10|Estimate|August 2003||2003-08-31|September 2005|2005-09-30||||||||Interventional|||Percutaneous Coronary Intervention (PCI) With Drug-Eluting Stents (DES) Versus Coronary Artery Bypass Graft (CABG) for Patients With Significant Left Main Stenosis|PCI With DES Versus CABG for Patients With Significant Left Main Stenosis|Unknown status|Recruiting|Phase 2|200|Anticipated|University of Leipzig|||||f||||||||||||||2018-06-01 04:37:37.0672|2018-06-01 04:37:37.0672
NCT00176384|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-07-31|2005-09-10|2005-09-15|Estimate|||||||2007-07-31|2007-08-01|Estimate|March 2003||2003-03-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Impact of Exercise Training on Exercise Capacity in Patients With Severe Chronic Heart Failure|Impact of Three Months of Aerobic Exercise Training on Exercise Capacity and Peripheral Maladaptations in Patients With Severe Chronic Heart Failure (NYHA III b)|Completed||Phase 2|36||University of Leipzig|||||f||||||||||||||2018-06-01 04:37:37.192017|2018-06-01 04:37:37.192017
NCT00176371|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-09-07|2005-09-13|2005-09-15|Estimate|||||||2007-09-07|2007-09-10|Estimate|July 2005||2005-07-31|September 2006|2006-09-30|December 2006||2006-12-31|||||Interventional|||Improvement of Physical Activity and Correction of Body Mass Index in School Children||Unknown status|Recruiting|N/A|500|Anticipated|University of Leipzig|||||f||||||||||||||2018-06-01 04:37:37.318514|2018-06-01 04:37:37.318514
NCT00176358|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-09-07|2005-09-09|2005-09-15|Estimate|||||||2007-09-07|2007-09-10|Estimate||||September 2005|2005-09-30||||||||Interventional|||Percutaneous Coronary Angioplasty Compared With Exercise Training in Symptomatic Coronary Artery Disease||Unknown status|Recruiting|Phase 2/Phase 3|400|Anticipated|University of Leipzig|||||f||||||||||||||2018-06-01 04:37:37.37444|2018-06-01 04:37:37.37444
NCT00176345|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-11|2005-09-11|2005-09-15|Estimate|||||||2005-09-11|2005-09-15|Estimate|January 2001||2001-01-31|September 2005|2005-09-30||||||||Interventional|||Impact of Exercise Training on Endothelial Function in CAD|Impact of Exercise Training on Bradykinin-Mediated Endothelial Function in Patients With Coronary Artery Disease|Unknown status|Recruiting|Phase 2|20||University of Leipzig|||||f||||||||||||||2018-06-01 04:37:37.425841|2018-06-01 04:37:37.425841
NCT00176332|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-07-31|2005-09-10|2005-09-15|Estimate|||||||2007-07-31|2007-08-01|Estimate|March 2004||2004-03-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Impact of Rosuvastatin on Endothelial Function and Inflammation in Patients With Chronic Heart Failure|Impact of Three Months of Rosuvastatin Treatment on Peripheral Endothelial Function, Inflammatory Markers in the Blood and the Skeletal Muscle and on Postnatal Vasculogenesis in Patients With Severe Chronic Heart Failure|Completed||Phase 2|40||University of Leipzig|||||f||||||||||||||2018-06-01 04:37:37.535781|2018-06-01 04:37:37.535781
NCT00176319|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-07-14|2005-09-09|2005-09-15|Estimate|||||||2009-07-14|2009-07-15|Estimate|May 2005||2005-05-31|July 2009|2009-07-31||||December 2008|Actual|2008-12-31||Interventional|LEICA||Leipzig Exercise Intervention in Chronic Heart Failure and Aging|Age-related Functional and Molecular Effects of Short-term Aerobic Endurance Training in Patients With Stable Chronic Heart Failure and Age-matched Healthy Controls.|Completed||Phase 2|120|Actual|University of Leipzig|||||f||||||||||||||2018-06-01 04:37:37.594849|2018-06-01 04:37:37.594849
NCT00176306|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-08-02||2012-09-12|2005-09-12|2005-09-15|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Levofloxacin Pharmacokinetics (PK) in the Severely Obese|Levofloxacin Pharmacokinetics in the Severely Obese|Completed||Phase 4|15|Actual|University of Kentucky|The number of ambulatory volunteers was low The acutely ill cohort was a heterogeneous population We remain unable to predict the precise effect of all of these different physiologic processes on drug pharmacokinetics|1|||f||||f||||||||||2018-06-01 04:37:37.819428|2018-06-01 04:37:37.819428
NCT00176293|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-20|2005-09-13|2005-09-15|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer|A Randomized Phase II Trial of Doxil With or Without Dexamethasone in Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer|Terminated||Phase 2|2|Actual|University of Kentucky||2||Slow accrual|f||||||||||||||2018-06-01 04:37:38.011423|2018-06-01 04:37:38.011423
NCT00176280|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-06-16|2005-09-09|2005-09-15|Estimate|||||||2015-06-16|2015-06-18|Estimate|September 2005||2005-09-30|June 2015|2015-06-30||||||||Interventional|||Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma|A Randomized Phase II Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemcitabine and 5-Fluorouracil (5-FU) in Patients With Metastatic Renal Cell Carcinoma (RCC)|Withdrawn||Phase 2|0|Actual|University of Kentucky||||Slow accrual|f||||||||||||||2018-06-01 04:37:38.156786|2018-06-01 04:37:38.156786
NCT00176267|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-04-18|2005-09-09|2005-09-15|Estimate|||||||2017-04-18|2017-04-19|Actual|September 2002||2002-09-30|April 2017|2017-04-30|January 31, 2017|Actual|2017-01-31|January 2005|Actual|2005-01-31||Interventional|||Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer|Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer|Completed||Phase 2|26|Actual|University of Kentucky||1|||f||||f||||||||||2018-06-01 04:37:38.283692|2018-06-01 04:37:38.283692
NCT00176254|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-12-08||2014-01-24|2005-09-09|2005-09-15|Estimate|2013-12-08|2014-01-23|Estimate||||2014-01-24|2014-02-27|Estimate|May 2000||2000-05-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer|Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer|Completed||Phase 2|40|Actual|University of Kentucky|Heterogeneity of post-induction treatment given. While definitive therapy did differ, it was stratified by response to induction therapy, an accepted practice. Conclusions remain exploratory, because of the small sample size and heterogeneity.|1|||f||||f||||||||||2018-06-01 04:37:38.383362|2018-06-01 04:37:38.383362
NCT00176241|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-06-03|2005-09-12|2005-09-15|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2005||2005-12-31|June 2015|2015-06-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer|A Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent Head & Neck Cancer|Terminated||Phase 1|7|Actual|University of Kentucky||1||Slow accrual|f||||f||||||||||2018-06-01 04:37:38.638925|2018-06-01 04:37:38.638925
NCT00176228|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-06-20||2015-07-28|2005-09-13|2005-09-15|Estimate|2015-07-28|2015-07-30|Estimate||||2015-07-28|2015-07-30|Estimate|February 2004||2004-02-29|June 2015|2015-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Lamotrigine Monotherapy in Pediatric Bipolar Disorder|Open Trial of Lamotrigine Monotherapy in Pediatric Bipolar Disorder|Completed||Phase 2|48|Actual|University of Illinois at Chicago||1|||f||||t||||||||||2018-06-01 04:37:38.760435|2018-06-01 04:37:38.760435
NCT00176215|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|May 2003||2003-05-31|July 2005|2005-07-31||||||||Interventional|||Clinical Comparison of RPDs Retained by Conical and Galvanoformed Double Crowns.||Unknown status|Active, not recruiting|Phase 4|||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:39.066278|2018-06-01 04:37:39.066278
NCT00176202|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2015-06-02||2015-11-04|2005-09-09|2005-09-15|Estimate|2015-11-04|2015-11-05|Estimate||||2015-11-04|2015-11-05|Estimate|April 2003||2003-04-30|November 2015|2015-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||AGE 10 TO 20 YRS GENDER :BOTH|Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar|Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar|Completed||Phase 3|65|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-06-01 04:37:39.135137|2018-06-01 04:37:39.135137
NCT00176189|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-25|2005-09-14|2005-09-15|Estimate|||||||2006-09-25|2006-09-26|Estimate|February 2005||2005-02-28|September 2006|2006-09-30|December 2006||2006-12-31|||||Interventional|||Clinical Performance of Extended All-Ceramic Fixed Partial Dentures Based on Zircon-Oxide Ceramics.|Clinical Performance of Extended All-Ceramic Fixed Partial Dentures Based on Zircon-Oxide Ceramics|Completed||N/A|30||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:39.41538|2018-06-01 04:37:39.41538
NCT00176176|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-11|2005-09-13|2005-09-15|Estimate|||||||2006-10-11|2006-10-12|Estimate||||November 2004|2004-11-30||||||||Interventional|||Investigation of Cognitive Function Before and After Induced Ventricular Fibrillation in Electrophysiological (EP) Study|Change of EEG Activity and Cerebral Circulation During Induced Ventricular Fibrillation and Investigation of Cognitive Function Before and After Induced Ventricular Fibrillation in EP Study|Unknown status|Recruiting|N/A|30||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:39.48774|2018-06-01 04:37:39.48774
NCT00176163|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-01|2005-09-13|2005-09-15|Estimate|||||||2010-02-01|2010-02-02|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|May 2009||2009-05-31|||||Interventional|||Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain|Supporting Effect of Dronabinol on Behavioral Therapy in Fibromyalgia and Chronic Back Pain|Completed||Phase 2|240|Anticipated|Heidelberg University|||||f||||||||||||||2018-06-01 04:37:39.635762|2018-06-01 04:37:39.635762
NCT00176150|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate||||April 2003|2003-04-30||||||||Observational|||Drug Transport in Patients With Anorexia Nervosa|Influence of Cholesterol Plasma Levels on Drug Transport in Patients With Anorexia Nervosa|Unknown status|Recruiting||||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:39.701764|2018-06-01 04:37:39.701764
NCT00176137|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-21|2005-09-13|2005-09-15|Estimate|||||||2008-04-21|2008-04-22|Estimate|October 1995||1995-10-31|April 2008|2008-04-30|September 2005||2005-09-30|||||Interventional|||Preoperative Twice Daily Chemoradiation in Addition to Chemotherapy Prior to Surgery in Stage III Non-Small Cell Lung Cancer (NSCLC)|Cisplatin/Etoposide Followed by Twice-Daily Chemoradiation (hfRT/CT) Versus Cisplatin/Etoposide Alone Before Surgery in Stage III Non-Small Cell Lung Cancer. A Phase III Trial of the German Lung Cancer Cooperative Group (GLCCG)|Completed||Phase 3|500||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:39.787711|2018-06-01 04:37:39.787711
NCT00176124|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2008-06-09|2005-09-12|2005-09-15|Estimate|||||||2008-06-09|2008-06-10|Estimate|April 2001||2001-04-30|June 2008|2008-06-30|September 2005|Actual|2005-09-30|April 2005|Actual|2005-04-30||Interventional|LDAWB-2001||Leukocyte Depletion of Autologous Whole Blood|Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients|Completed||Phase 4|1089|Actual|Heidelberg University||2|||f||||t||||||||||2018-06-01 04:37:39.861858|2018-06-01 04:37:39.861858
NCT00176111|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-15|2005-09-12|2005-09-15|Estimate|||||||2005-11-15|2005-11-17|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|January 2005||2005-01-31|||||Interventional|||Effects of Local Anesthetic or Saline Solution on Peripheral Nerve Stimulation – a Randomised Study|Effects of Local Anesthetic or Saline Solution on Peripheral Nerve Stimulation – a Randomised, Double-Blind, Multicenter Study About the Stimulability of Anesthetized Nerves|Terminated||Phase 4|40||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:39.941601|2018-06-01 04:37:39.941601
NCT00176098|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-02-06|2005-09-12|2005-09-15|Estimate|||||||2006-02-06|2006-02-07|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Interventional|||Hypnosis for Eye Surgery|Correlation of Stress, Patient Comfort and Safety to Bispectral Index in Patients Under Hypnosis for Cataract Surgery|Unknown status|Recruiting|Phase 1/Phase 2|70||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.002119|2018-06-01 04:37:40.002119
NCT00176085|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-05-27|2005-09-12|2005-09-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2004||2004-10-31|May 2015|2015-05-31|March 2005|Actual|2005-03-31|||||Observational|||Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH|Pharmacokinetics of 11-Nor-9-carboxy-D9-tetrahydrocannabinol (THCCOOH) and Its Acyl-glucuronide (THCCOOH-GLu) After Intravenous Administration of THCCOOH in Healthy Human Subjects|Completed|||10||Heidelberg University|||1||f||||||||||||||2018-06-01 04:37:40.100803|2018-06-01 04:37:40.100803
NCT00176072|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2004||2004-08-31|July 2004|2004-07-31|November 2004||2004-11-30|||||Observational|||BlueCQ Bioavailability|B l u e C Q - P r o j e c t: Bioavailability of Methylene Blue (MB) - Comparison of an Intravenous and Two Oral Formulations - and Influence of Sustained Release MB on Chloroquine (CQ) Concentrations|Completed|||18||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.170721|2018-06-01 04:37:40.170721
NCT00176059|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-05-08|2005-09-09|2005-09-15|Estimate|||||||2007-05-08|2007-05-10|Estimate|October 2001||2001-10-31|May 2007|2007-05-31|May 2006|Actual|2006-05-31|||||Interventional|||Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients|Immunoglobulin Induction Therapy in Renal Transplant Recipients on Tacrolimus/Azathioprine or Tacrolimus/MMF: Effects on Th1, Th2, B Cell-/Monokine Responses and Immunoregulatory Autoantibody Levels|Completed||Early Phase 1|50|Actual|University of Giessen|||||f||||f||||||||||2018-06-01 04:37:40.220102|2018-06-01 04:37:40.220102
NCT00176046|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-05-03|2005-09-10|2005-09-15|Estimate|||||||2017-05-03|2017-05-08|Actual|May 1999|Actual|1999-05-31|June 2009|2009-06-30|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study|Prospective Controlled Randomized Feasibility Study on a Treatment With Viscum Album in Patients With Breast Cancer to Identify Appropriate Surrogate Parameters for a Randomized Study of the Efficacy of Treatment With Mistletoe Extracts|Completed||Phase 4|114|Actual|Heidelberg University||2|||f||||f||||||||||2018-06-01 04:37:40.297162|2018-06-01 04:37:40.297162
NCT00176033|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-02-12|2005-09-12|2005-09-15|Estimate|||||||2009-02-12|2009-02-13|Estimate|January 2005||2005-01-31|February 2009|2009-02-28||||||||Observational|||Influence of Drug Transporter Expression on the Pharmacokinetics of the HIV Protease Inhibitor Kaletra|Influence of Drug Transporter Expression on the Pharmacokinetics of the HIV Protease Inhibitor Kaletra (Lopinavir/Ritonavir) and on the Concentration Relations Between Plasma, Blood Cells, Saliva and Urine|Completed|||12|Anticipated|Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.42473|2018-06-01 04:37:40.42473
NCT00176020|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-14|2005-09-12|2005-09-15|Estimate|||||||2006-03-14|2006-03-15|Estimate||||August 2005|2005-08-31||||||||Interventional|||Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression|Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects|Unknown status|Not yet recruiting|Phase 1|18||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.523604|2018-06-01 04:37:40.523604
NCT00176007|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-09-10|2005-09-10|2005-09-15|Estimate|||||||2005-09-10|2005-09-15|Estimate||||June 2005|2005-06-30||||||||Interventional|||Hypoxia Impairs Endothelial Function in HAPEs|Hypoxia Impairs Systemic Endothelial Function in Individuals Prone to High-Altitude Pulmonary Edema.|Completed||Phase 1|||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.577732|2018-06-01 04:37:40.577732
NCT00175994|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-04-16|2005-09-12|2005-09-15|Estimate|||||||2007-04-16|2007-04-17|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Observational|||Bioavailability and Metabolism of Voriconazole in Relation to Its Modulation by the CYP2C19 Genetic Polymorphism|Bioavailability and Metabolism of Voriconazole as a Function of the CYP2C19 Genotype|Completed|||24||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.627022|2018-06-01 04:37:40.627022
NCT00175981|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-15|Estimate|||||||2005-09-09|2005-09-15|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|November 2004||2004-11-30|||||Interventional|||Interaction Between Fluvoxamine and Sildenafil|Pharmacokinetic and Pharmacodynamic Evaluation of the Interaction Between Fluvoxamine and Sildenafil in Healthy Males|Completed||Phase 1|12||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.775023|2018-06-01 04:37:40.775023
NCT00175968|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-15|Estimate|||||||2005-09-09|2005-09-15|Estimate|March 2001||2001-03-31|September 2005|2005-09-30|April 2003||2003-04-30|||||Interventional|||Influence of Bedrest and Hypocaloric Nutrition on Endothelium-Dependent Vasoreactivity|Influence of Bed-Rest and Hypocaloric Nutrition on Endothelium-Dependent Vasoreactivity|Completed||Phase 1|10||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.836671|2018-06-01 04:37:40.836671
NCT00175799|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-05|2005-09-13|2005-09-15|Estimate|||||||2015-05-05|2015-05-06|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|July 2013|Actual|2013-07-31|September 2011|Actual|2011-09-30||Observational|||Validation of Severity of Illness Scoring Systems in Paediatric Intensive Care Units in Canada|Validation of Severity of Illness Scoring Systems in Paediatric Intensive Care Units in Canada Outcome: Validation and Comparison of 2 Severity of Illness Scores in Canadian PICU Population|Completed|||10000|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:44.05885|2018-06-01 04:37:44.05885
NCT00175955|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-12-05|2005-09-09|2005-09-15|Estimate|||||||2013-12-05|2013-12-06|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia|An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years.|Completed||Phase 2|70||UCB Pharma|||||f||||||||||||||2018-06-01 04:37:40.885055|2018-06-01 04:37:40.885055
NCT00175942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-09-10|2005-09-10|2005-09-15|Estimate|||||||2005-09-10|2005-09-15|Estimate|February 2003||2003-02-28|May 2005|2005-05-31||||||||Observational|||Risk Indicators in Patients With Ventricular Fibrillation During Acute Myocardial Infarction|Indicators of Coagulation Activation and Inflammation Contributing to Ventricular Fibrillation Complicating Acute Myocardial Infarction|Unknown status|Recruiting||300||Heidelberg University|||||f||||||||||||||2018-06-01 04:37:40.963714|2018-06-01 04:37:40.963714
NCT00175929|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-04-10|2005-09-09|2005-09-15|Estimate|||||||2015-04-10|2015-04-13|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study of Brivaracetam in Subjects With Partial Onset Seizures|A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized|Completed||Phase 2|157|Actual|UCB Pharma||3|||f||||t||||||||||2018-06-01 04:37:41.059185|2018-06-01 04:37:41.059185
NCT00175916|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-04-26|2005-09-09|2005-09-15|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2005||2005-09-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy|An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy|Active, not recruiting||Phase 3|853|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:37:41.250497|2018-06-01 04:37:41.250497
NCT00175903|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-03-12|2005-09-09|2005-09-15|Estimate|||||||2015-03-12|2015-03-17|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy|A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/Day Oral ER Tablets 300-500 mg b.i.d.) and Carbamazepine (600 to 1600 mg/Day Oral CR Tablets 200-400 mg b.i.d.) as Monotherapy in Subjects With Newly Diagnosed Epilepsy.|Completed||Phase 3|1701|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 04:37:41.560656|2018-06-01 04:37:41.560656
NCT00175890|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-07-06|2005-09-09|2005-09-15|Estimate|||||||2015-07-06|2015-07-08|Estimate|October 2004||2004-10-31|July 2015|2015-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.|A Double-Blind, Randomized, Multicenter, Placebo-controlled, In-Patient, Maximum 34 Day Study of Levetiracetam Oral Solution (20-50 mg/kg/Day) as Adjunctive Treatment of Refractory Partial Onset Seizures in Pediatric Epileptic Subjects Ranging in Age From 1 Month to Less Than 4 Years of Age. N01009|Completed||Phase 3|116|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 04:37:42.011219|2018-06-01 04:37:42.011219
NCT00175877|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-02-04||2013-03-22|2005-09-09|2005-09-15|Estimate|2013-02-04|2013-03-08|Estimate||||2013-03-22|2013-04-01|Estimate|June 2005||2005-06-30|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Baseline Characteristics refer to the Safety Set (SS). SS consists of all enrolled subjects who received at least 1 dose of study medication.|A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis|A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|857|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:37:42.361312|2018-06-01 04:37:42.361312
NCT00175864|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-03-19|2005-09-09|2005-09-15|Estimate|||||||2012-03-19|2012-03-20|Estimate|February 2006||2006-02-28|March 2012|2012-03-31||||||||Interventional|||Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.|Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (Ucb 44212) at Individualized Doses up to a Maximum of 160mg/Day in Refractory Epileptic Patients.|Withdrawn||Phase 3|0|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:37:43.653699|2018-06-01 04:37:43.653699
NCT00175851|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-05-25|2005-09-09|2005-09-15|Estimate|||||||2012-05-25|2012-05-28|Estimate|May 2008||2008-05-31|May 2012|2012-05-31||||||||Interventional|||Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy|An Open-label, Multicenter, Follow-up Trial to Evaluate the Long-term Safety and Efficacy of Seletracetam Used as Adjunctive Treatment Using a Flexible Dosing Scheme of 4 to 80 mg b.i.d. in Subjects Aged 16 Years or Older Suffering From Epilepsy|Withdrawn||Phase 3|0|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:37:43.70863|2018-06-01 04:37:43.70863
NCT00175838|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-17|2005-09-09|2005-09-15|Estimate|||||||2017-01-17|2017-01-18|Estimate|July 1997||1997-07-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|PT-1||Primary Thrombocythaemia 1 Trial|A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia|Completed||N/A|1398|Actual|University of Cambridge||2|||f||||t||||||||||2018-06-01 04:37:43.757154|2018-06-01 04:37:43.757154
NCT00175825|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-08-28|2005-09-09|2005-09-15|Estimate|||||||2012-08-28|2012-08-29|Estimate|November 2005||2005-11-30|August 2012|2012-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.|A Double-blind, Randomized, Placebo-controlled, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.|Completed||Phase 2|210|Actual|UCB Pharma||4|||f||||f||||||||||2018-06-01 04:37:43.860628|2018-06-01 04:37:43.860628
NCT00175773|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-07-10|2005-09-13|2005-09-15|Estimate|||||||2012-07-10|2012-07-12|Estimate|November 2004||2004-11-30|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Mechanisms of Orthostatic Intolerance in Spinal Cord Injured Individuals and Following Bed Rest|Mechanisms of Orthostatic Intolerance in Spinal Cord Injured Individuals and Following Bed Rest|Completed|||51|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:44.153399|2018-06-01 04:37:44.153399
NCT00175760|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-11|2005-09-13|2005-09-15|Estimate|||||||2011-04-11|2011-04-12|Estimate|December 2004||2004-12-31|April 2011|2011-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Can a Very High Result From a Screening Test for Celiac Disease be Used to Diagnose Celiac Disease?|Prospective Assessment of High Titre TTG to Diagnose Celiac Disease in Select Paediatric Patients.|Completed|||100|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:44.202308|2018-06-01 04:37:44.202308
NCT00175747|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|January 2000||2000-01-31|September 2005|2005-09-30|December 2002||2002-12-31|||||Interventional|||A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)|A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People With Dysplasia of the Bronchial Epithelium|Completed||Phase 2/Phase 3|120||University of British Columbia|||||f||||||||||||||2018-06-01 04:37:44.253317|2018-06-01 04:37:44.253317
NCT00175734|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-01-30|2005-09-13|2005-09-15|Estimate|||||||2013-01-30|2013-02-01|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2007|Actual|2007-12-31||Interventional|||Interactive Studies of Endstage Diabetic Dialysis Patients|Integrated Studies in Vascular Reactivity and Anemia Correction Therapy in Endstage Kidney Disease Patients|Unknown status|Active, not recruiting|N/A|80|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:45.349467|2018-06-01 04:37:45.349467
NCT00175721|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-03-14|2005-09-13|2005-09-15|Estimate|||||||2014-03-14|2014-03-17|Estimate|December 2005||2005-12-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Trial Comparing Care in Multiple Clinics Versus Care in a Cardiac, Diabetes and Kidney Care Clinic|Randomized Controlled Trial Comparing Current Care in Multiple Clinics Vs Care in a Novel Cardiac, Diabetes & Kidney Care Clinic|Completed||N/A|150|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:45.43087|2018-06-01 04:37:45.43087
NCT00175708|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-30|2005-09-13|2005-09-15|Estimate|||||||2016-05-30|2016-06-01|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Pedobarographic Assessments of Clubfoot Treated Patients|Pedobarographic Assessments of Clubfoot Treated Patients|Unknown status|Recruiting||100|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:45.497415|2018-06-01 04:37:45.497415
NCT00175695|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-02-03|2005-09-13|2005-09-15|Estimate|||||||2011-02-03|2011-02-04|Estimate|December 2004||2004-12-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Disease Modification in Toxaemia of Pregnancy|A Safety and Efficacy Trial of Recombinant Human Activated Protein C in Both Early-onset Pre-eclampsia and Severe Postpartum Pre-eclampsia.|Completed|||30|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:45.571452|2018-06-01 04:37:45.571452
NCT00175682|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-01|2005-09-13|2005-09-15|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2004||2004-12-31|March 2017|2017-03-31|July 28, 2011|Actual|2011-07-28|July 28, 2011|Actual|2011-07-28||Interventional|||Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study|Prophylactic Value of Prazosin in Reducing the Objective and Subjective Measures of Autonomic Dysreflexia Provoked by Ejaculation in Men With Spinal Cord Injury|Completed||N/A|7|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:45.637776|2018-06-01 04:37:45.637776
NCT00175669|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-11|2005-09-13|2005-09-15|Estimate|||||||2011-04-11|2011-04-12|Estimate|August 2007||2007-08-31|April 2011|2011-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking|Randomized Controlled Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking|Completed||Phase 2|32|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:45.711007|2018-06-01 04:37:45.711007
NCT00175656|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-04-12|2005-09-13|2005-09-15|Estimate|||||||2011-04-12|2011-04-14|Estimate|January 2007||2007-01-31|April 2011|2011-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Titanium Elastic Nails in the Treatment of Pediatric Femur Fractures|Titanium Elastic Nails in the Treatment of Paediatric Femoral Fractures: A Prospective Randomized Clinical Trial of Eliminating Nail Protrusion to Decrease Soft Tissue Complications|Completed||Phase 1|80|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:45.773187|2018-06-01 04:37:45.773187
NCT00175643|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2006-05-08|2005-09-11|2005-09-15|Estimate|||||||2006-05-08|2006-05-09|Estimate|February 2005||2005-02-28|May 2006|2006-05-31|November 2005||2005-11-30|||||Interventional|||Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses|Open-Label Study to Assess Safety and Efficacy of Imiquimod 5% Cream Applied 3 Days Per Week in 1 or 2 Cycles for Treatment of Actinic Keratoses on the Head|Completed||Phase 3|20||University of British Columbia|||||f||||||||||||||2018-06-01 04:37:45.850969|2018-06-01 04:37:45.850969
NCT00175630|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-05-30|2005-09-13|2005-09-15|Estimate|||||||2016-05-30|2016-06-01|Estimate|December 2010||2010-12-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2011|Actual|2011-09-30||Interventional|||The Effect of Femoral Nerve Block on Postoperative Opioid Use After Anterior Cruciate Ligament (ACL) Reconstruction|Effect of Femoral Nerve Block on Opioid Requirements Following Anterior Cruciate Ligament Reconstruction: A Double Blind, Prospective Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 1|30|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.006942|2018-06-01 04:37:46.006942
NCT00175617|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-01|2005-09-13|2005-09-15|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2005||2005-09-30|March 2017|2017-03-31|March 9, 2009|Actual|2009-03-09|March 9, 2009|Actual|2009-03-09||Interventional|||Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss|Efficacy of Therapy With the Anti-androgen Spironolactone Compared to Topical Minoxidil in Female Pattern Hair Loss|Completed||Phase 2|40|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.086553|2018-06-01 04:37:46.086553
NCT00175604|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-05-05|2005-09-13|2005-09-15|Estimate|||||||2015-05-05|2015-05-06|Estimate|August 2004||2004-08-31|February 2011|2011-02-28|February 2008|Anticipated|2008-02-29|February 2008|Anticipated|2008-02-29||Interventional|||Comparative Trial of Botox in the Management of Children With Congenital Muscular Torticollis|Comparative Trial of Botox Versus Conventional Treatment Used in the Management of Children With Congenital Muscular Torticollis (CMT)|Withdrawn||Phase 1|0|Actual|University of British Columbia||||Not able to recruit any subjects for the study and was closed in February 2008|f||||f||||||||||2018-06-01 04:37:46.151843|2018-06-01 04:37:46.151843
NCT00175591|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2018-01-08|2005-09-13|2005-09-15|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2007||2007-08-31|January 2018|2018-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||The Effect of Femoral Nerve Block on Opioid Requirements After Surgery for a Femur Fracture in Children|The Effect of Femoral Nerve Block on Opioid Requirements Following Femoral Fracture Fixation With Flexible Nails in the Paediatric Population: A Double Blind, Prospective Randomized Clinical Trial|Completed||Phase 1|25|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.238097|2018-06-01 04:37:46.238097
NCT00175578|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-15|2005-09-13|2005-09-15|Estimate|||||||2011-11-15|2011-11-16|Estimate|May 2005||2005-05-31|November 2011|2011-11-30|December 2011|Anticipated|2011-12-31|||||Observational|||Detection of Early Lung Cancer by Serum Protein Expression Profiling|Differences in SELDI Produced Serum Protein Profiles of Non-small Cell Lung Cancer Patients Compared to Healthy Heavy Smoking Adults|Unknown status|Recruiting||220|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.319463|2018-06-01 04:37:46.319463
NCT00175565|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-07-26|2005-09-11|2005-09-15|Estimate|||||||2010-07-26|2010-07-28|Estimate|January 2002||2002-01-31|July 2010|2010-07-31|July 2003||2003-07-31|||||Interventional|||Inhaled Steroid Reduces Systemic Inflammation in COPD|Effects of Fluticasone On Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease|Completed||Phase 4|50||University of British Columbia|||||f||||||||||||||2018-06-01 04:37:46.390953|2018-06-01 04:37:46.390953
NCT00175552|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-16|2005-09-13|2005-09-15|Estimate|||||||2007-07-16|2007-07-18|Estimate||||July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Ministry of Child and Family Development (MCFD) Interpersonal Psychotherapy for Adolescents (IPT-A) Training Project|Evaluating the Effectiveness of Different Interpersonal Psychotherapy for Adolescents (IPT-A) Therapist Training Models|Completed||N/A|24|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:37:46.464386|2018-06-01 04:37:46.464386
NCT00175539|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-30|2005-09-12|2005-09-15|Estimate|||||||2017-05-30|2017-06-01|Actual|November 2005||2005-11-30|May 2017|2017-05-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties|Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties|Completed||N/A|25|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.523846|2018-06-01 04:37:46.523846
NCT00175526|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-05-30|2005-09-12|2005-09-15|Estimate|||||||2016-05-30|2016-06-01|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Predicting Complications in Women With Toxaemia|PIERS (Pre-eclampsia Integrated Estimate of RiSk) Model: Predicting Adverse Maternal Outcomes in Pre-eclampsia|Completed|||650|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.583933|2018-06-01 04:37:46.583933
NCT00175513|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-04-12|2005-09-11|2005-09-15|Estimate|||||||2011-04-12|2011-04-14|Estimate|September 2005||2005-09-30|April 2011|2011-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis|V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis|Completed||Phase 2|100|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.655078|2018-06-01 04:37:46.655078
NCT00175500|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-09-20|2005-09-11|2005-09-15|Estimate|||||||2011-09-20|2011-09-22|Estimate|September 2007||2007-09-30|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|April 2009|Actual|2009-04-30||Interventional|||Comparison of Conventional and Large Diameter Femoral Heads for the Prevention of Hip Dislocation|A Randomized Multi-Centre Controlled Trial of Large Diameter (36/40 mm) Versus Conventional Diameter (32 mm) Femoral Heads for the Prevention of Post Revision Arthroplasty Dislocation|Unknown status|Active, not recruiting|N/A|400|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.717366|2018-06-01 04:37:46.717366
NCT00175487|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2014-03-17|2005-09-11|2005-09-15|Estimate|||||||2014-03-17|2014-03-18|Estimate|September 2007||2007-09-30|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of Hip Resurfacing to Large Femoral Head Total Hip Arthroplasty|Femoral Head Resurfacing Versus a Large Femoral Head (Durom®) Total Hip System: A Prospective Randomized Trial|Unknown status|Active, not recruiting|N/A|56|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.769306|2018-06-01 04:37:46.769306
NCT00175474|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-10-12|2005-09-11|2005-09-15|Estimate|||||||2011-10-12|2011-10-14|Estimate|September 2005||2005-09-30|October 2011|2011-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Comparison of a Minimally Invasive Technique for Total Knee Replacement to a Standard Technique|Minimally Invasive Total Knee Arthroplasty Versus a Standard Surgical Technique: a Single-blinded Single-centre Randomized Controlled Trial|Completed||Phase 1|102|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.827923|2018-06-01 04:37:46.827923
NCT00175461|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2017-03-01|2005-09-11|2005-09-15|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2005||2005-09-30|March 2017|2017-03-31|August 31, 2011|Actual|2011-08-31|April 2009|Actual|2009-04-30||Interventional|||Comparison of Two Minimally Invasive Surgical Techniques for Hip Replacement|Comparison of the Clinical Effectiveness and Cost-effectiveness of the MIS Anterolateral Approach (MIS Watson Jones, G3) Versus Anterolateral Mini or Posterolateral Mini Approaches in Primary Total Hip Arthroplasty|Completed||Phase 1|156|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:46.882236|2018-06-01 04:37:46.882236
NCT00175448|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2008-09-24|2005-09-11|2005-09-15|Estimate|||||||2008-09-24|2008-09-25|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Comparison of Physiotherapy Versus Home Exercise Following Hip Replacement Surgery|A Randomized Controlled Trial of Outpatient Physiotherapy Versus a Self-Administered Home Exercise Program Following Discharge Home From Total Hip Arthroplasty|Completed||N/A|144|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:37:46.930403|2018-06-01 04:37:46.930403
NCT00175435|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-10-29|2005-09-11|2005-09-15|Estimate|||||||2010-10-29|2010-11-02|Estimate|August 2005||2005-08-31|October 2010|2010-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator|Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator|Completed||Phase 1/Phase 2|39|Actual|University of British Columbia||3|||f||||f||||||||||2018-06-01 04:37:47.071679|2018-06-01 04:37:47.071679
NCT00175422|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-12-15|2005-09-11|2005-09-15|Estimate|||||||2010-12-15|2010-12-17|Estimate|May 2005||2005-05-31|December 2010|2010-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Parents Helping Infants Study: Educational Intervention to Change the Knowledge, Attitudes and Behaviour of New Parents About Early Infant Crying|The Period of PURPLE Crying: An Educational Intervention to Change the Knowledge, Attitudes and Behaviour of New Parents About Early Infant Crying|Completed||Phase 1/Phase 2|1833|Actual|University of British Columbia|||||f||||||||||||||2018-06-01 04:37:47.166937|2018-06-01 04:37:47.166937
NCT00175409|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-04-11|2005-09-11|2005-09-15|Estimate|||||||2011-04-11|2011-04-12|Estimate|January 2008||2008-01-31|April 2011|2011-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Breast Feeding Analgesia in Preterm Infants|Breast Feeding Analgesia in Preterm Infants|Completed||Phase 1|50|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 04:37:47.235308|2018-06-01 04:37:47.235308
NCT00175396|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2014-03-14|2005-09-11|2005-09-15|Estimate|||||||2014-03-14|2014-03-17|Estimate|May 2004||2004-05-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|December 2011|Actual|2011-12-31||Interventional|||Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy|A Randomized Phase III Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by High Dose 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by 125-Iodine Brachytherapy Implant Boost for Patients With Intermediate and High Risk Localized Prostate Cancer|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 04:37:47.326229|2018-06-01 04:37:47.326229
NCT00175383|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-04-09|2005-09-11|2005-09-15|Estimate|||||||2013-04-09|2013-04-11|Estimate|June 2004||2004-06-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer|A Randomized Trial of Short Versus Long Acting LHRH Agonist Preparation Prior to Transperineal Implantation of the Prostate|Unknown status|Recruiting|Phase 3|100|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-06-01 04:37:47.417646|2018-06-01 04:37:47.417646
NCT00175370|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-06-18|2005-09-09|2005-09-15|Estimate|||||||2008-06-18|2008-06-20|Estimate|September 2000||2000-09-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus|Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus; Removal of Catheter Followed by 2 Days Compared With 7 Days Intravenous Vancomycin|Completed||N/A|60|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:37:47.527535|2018-06-01 04:37:47.527535
NCT00175357|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-09-25|2005-09-09|2005-09-15|Estimate|||||||2014-09-25|2014-09-29|Estimate|March 2005||2005-03-31|September 2014|2014-09-30|April 2009|Actual|2009-04-30|April 2007|Actual|2007-04-30||Interventional|||NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction|North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users|Completed||Phase 3|192|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 04:37:47.601363|2018-06-01 04:37:47.601363
NCT00175344|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2014-02-18|2005-09-11|2005-09-15|Estimate|||||||2014-02-18|2014-02-19|Estimate|February 2004||2004-02-29|February 2014|2014-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Does Scar Massage Improve Postoperative Pain and Function in Women With Breast Cancer?|Does Scar Tissue Massage Improve Postoperative Pain and Function in Women With Breast Cancer? A Randomized Controlled Study.|Completed||Phase 3|96|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 04:37:47.68626|2018-06-01 04:37:47.68626
NCT00175318|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-02-09|2005-09-09|2005-09-15|Estimate|||||||2011-02-09|2011-02-11|Estimate|April 2005||2005-04-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Testing a Tooth Decay Prevention Program With Cree Mothers and Infants|A Clinical Trial of the Effectiveness of Motivational Interviewing as a Preventive Strategy for Dental Caries in Cree Infants|Completed||N/A|309|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:37:47.760541|2018-06-01 04:37:47.760541
NCT00175305|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-10-29|2005-09-09|2005-09-15|Estimate|||||||2007-10-29|2007-10-31|Estimate|August 2004||2004-08-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Prader-Willi Syndrome and Appetite|Effect of Somatostatin on Ghrelin Concentrations, Food Seeking Behaviour and Weight in Patients With Prader-Willi Syndrome|Terminated||Phase 3|10|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:37:47.836149|2018-06-01 04:37:47.836149
NCT00175292|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-12|2005-09-13|2005-09-15|Estimate|||||||2008-05-12|2008-05-14|Estimate|December 2003||2003-12-31|May 2008|2008-05-31||||||||Interventional|||A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.|A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.|Completed||Phase 3|120|Anticipated|University of Alberta|||||f||||||||||||||2018-06-01 04:37:47.910527|2018-06-01 04:37:47.910527
NCT00175279|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-05-09|2005-09-10|2005-09-15|Estimate|||||||2011-05-09|2011-05-10|Estimate|January 2002||2002-01-31|May 2011|2011-05-31|April 2005||2005-04-30|||||Interventional|||A Cluster Randomized Trial to Assess the Impact of Opinion Leader Endorsed Evidence Summaries on Improving Quality of Prescribing for Patients With Chronic Cardiovascular Disease|A Cluster Randomized Trial to Assess the Impact of Opinion Leader Endorsed Evidence Summaries on Improving Quality of Prescribing for Patients With Chronic Cardiovascular Disease|Completed||N/A|160||University of Alberta|||||f||||||||||||||2018-06-01 04:37:47.995063|2018-06-01 04:37:47.995063
NCT00175266|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-10-01|2005-09-12|2005-09-15|Estimate|||||||2009-10-01|2009-10-02|Estimate||||October 2009|2009-10-31||||||||Interventional|||Islet Transplantation Using Campath-1H and Infliximab Induction|Islet Transplantation in Type 1 Diabetic Patients Using Campath-1H and Infliximab Induction|Completed||Phase 2|12||University of Alberta|||||f||||||||||||||2018-06-01 04:37:48.0743|2018-06-01 04:37:48.0743
NCT00175253|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-07-11|2005-09-13|2005-09-15|Estimate|||||||2012-07-11|2012-07-12|Estimate|November 2005||2005-11-30|July 2012|2012-07-31|April 2012|Actual|2012-04-30|||||Interventional|||Alemtuzumab Induction in Islet Transplantation|Alemtuzumab Induction With Tacrolimus and MMF Maintenance Immunosuppression in Islet Transplantation|Completed||Phase 2|12|Anticipated|University of Alberta|||||f||||||||||||||2018-06-01 04:37:48.132858|2018-06-01 04:37:48.132858
NCT00175240|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-07-25|2005-09-12|2005-09-15|Estimate|||||||2015-07-25|2015-07-28|Estimate|March 2005||2005-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|August 2011|Actual|2011-08-31||Interventional|||Enhancing the Secondary Prevention of Coronary Artery Disease|Enhancing the Use of Secondary Prevention Strategies in Patients With Coronary Artery Disease (The ESP-CAD Study)|Completed||Phase 4|480|Anticipated|University of Alberta|||||f||||||||||||||2018-06-01 04:37:48.184777|2018-06-01 04:37:48.184777
NCT00175227|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-05-09|2005-09-10|2005-09-15|Estimate|||||||2011-05-09|2011-05-10|Estimate|May 1996||1996-05-31|May 2011|2011-05-31||||October 2000|Actual|2000-10-31||Interventional|||Prevention of Contrast-Induced Nephropathy|Prevention of Contrast-Induced Nephropathy: a Randomized Controlled Trial of Saline + Furosemide + Mannitol in High Risk Patients Undergoing Cardiac Angiography|Completed||N/A|200|Anticipated|University of Alberta||2|||f||||f||||||||||2018-06-01 04:37:48.242059|2018-06-01 04:37:48.242059
NCT00175214|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-09-10|2005-09-10|2005-09-15|Estimate|||||||2005-09-10|2005-09-15|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Controlled Trial to Increase Detection and Treatment of Osteoporosis in Older Patients With a Wrist Fracture|Controlled Trial to Increase Detection and Treatment of Osteoporosis in Older Patients With a Wrist Fracture|Completed||N/A|160||University of Alberta|||||f||||||||||||||2018-06-01 04:37:48.310604|2018-06-01 04:37:48.310604
NCT00175201|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2006-05-04|2005-09-10|2005-09-15|Estimate|||||||2006-05-04|2006-05-05|Estimate|May 2005||2005-05-31|May 2006|2006-05-31|March 2008||2008-03-31|||||Interventional|||Cost Efficacy of a Clinical Pathway to Patients Undergoing Hip and Knee Replacement Surgery|From Efficacy to Effectiveness of a Proactive Perioperative Care and Rehabilitation in Patients Undergoing Primary Total Hip or Knee Replacement|Unknown status|Recruiting|N/A|80||University of Aarhus|||||f||||||||||||||2018-06-01 04:37:48.385488|2018-06-01 04:37:48.385488
NCT00175188|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2010-10-12|2005-09-10|2005-09-15|Estimate|||||||2010-10-12|2010-10-13|Estimate|June 2004||2004-06-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||An RSA and DEXA Study on Migration of Proximal Interphalangeal (PIP) Joint Prostheses of the Hand|A Roentgen Stereophotogrammetric Analysis and DEXA Study on Migration of Proximal Interphalangeal Joint Prostheses of the Hand. A Randomised Prospective Study of Cemented Versus Non-cemented Implants|Completed||N/A|30|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 04:37:48.45099|2018-06-01 04:37:48.45099
NCT00175175|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-13|2005-09-09|2005-09-15|Estimate|||||||2006-09-13|2006-09-15|Estimate|March 2002||2002-03-31|September 2006|2006-09-30||||||||Interventional|||Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|Completed||N/A|220||University of Alberta|||||f||||||||||||||2018-06-01 04:37:48.522276|2018-06-01 04:37:48.522276
NCT00175162|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2010-10-13|2005-09-10|2005-09-15|Estimate|||||||2010-10-13|2010-10-14|Estimate|June 2007||2007-06-30|October 2010|2010-10-31|December 2010||2010-12-31|||||Interventional|||A Comparison of Fixation Method in Total Knee Arthroplasty - Low Viscosity Versus High Viscosity Bone Cement|A Comparison of Fixation Method in Total Knee Arthroplasty - Low Viscosity Versus High Viscosity Bone Cement. A Prospective Randomized Migration- and Bone Density Study on Primary Cemented Knee Implants.|Withdrawn||N/A|50|Anticipated|University of Aarhus||2||No financing possible|f||||f||||||||||2018-06-01 04:37:48.694693|2018-06-01 04:37:48.694693
NCT00175149|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-12-06|2005-09-11|2005-09-15|Estimate|||||||2015-12-06|2015-12-08|Estimate|January 2002||2002-01-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Active Vitamin D Effect on Left Ventricular Hypertrophy|The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction|Terminated||Phase 4|24|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 04:37:48.784735|2018-06-01 04:37:48.784735
NCT00175136|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2018-03-20|2005-09-10|2005-09-15|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2005||2005-01-31|October 2010|2010-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Comparison of the Design of Tibia Stems in Cemented Total Knee Arthroplasty - Wedge Stem Versus I-beam Stem.|A Comparison of the Design of Tibia Stems - Wedge Stem Versus I-beam Stem. A Prospective Randomized Migration- and Bone Density Study on Primary Cemented Knee Implants.|Completed||N/A|54|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 04:37:48.895181|2018-06-01 04:37:48.895181
NCT00175123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-02-19|2005-09-09|2005-09-15|Estimate|||||||2009-02-19|2009-02-20|Estimate|May 2005||2005-05-31|February 2009|2009-02-28|June 2008|Anticipated|2008-06-30|March 2008|Anticipated|2008-03-31||Interventional|||Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele|Phase 4 Study of the Effect of Botulinum-A Toxin Injected in Neurogenic Overactive Bladders of Children Born With Myelomeningocele|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 04:37:48.983279|2018-06-01 04:37:48.983279
NCT00175110|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-12-02|2005-09-12|2005-09-15|Estimate|||||||2009-12-02|2009-12-03|Estimate||||December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effect of Hibiscus Sabdariffa L. Tea on Blood Pressure|The Effect of Hibiscus Sabdariffa L. Tisane on Blood Pressure in Prehypertensive and Mildly Hypertensive Men and Women|Completed||Phase 1/Phase 2|66|Actual|Tufts University|||||f||||f||||||||||2018-06-01 04:37:49.062552|2018-06-01 04:37:49.062552
NCT00175097|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-11-26|2005-09-13|2005-09-15|Estimate|||||||2014-11-26|2014-12-02|Estimate|June 2001||2001-06-30|November 2014|2014-11-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Soybean Based Diets and CVD Risk Factors|Impact of Different Forms of Soybean Based Foods on Cardiovascular Disease Risk Factors in Hypercholesterolemic Subjects.|Completed||N/A|30|Actual|Tufts University||4|||f||||f||||||||||2018-06-01 04:37:49.136279|2018-06-01 04:37:49.136279
NCT00175084|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-05-21|2005-09-09|2005-09-15|Estimate|||||||2014-05-21|2014-05-23|Estimate|October 2004||2004-10-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|June 2007|Actual|2007-06-30||Interventional|||Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers|Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers|Completed||N/A|30|Anticipated|Tufts University|||||f||||f||||||||||2018-06-01 04:37:49.227904|2018-06-01 04:37:49.227904
NCT00175071|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-04-24|2005-09-09|2005-09-15|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2004||2004-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|April 2007|Actual|2007-04-30||Interventional|||Effect of Vegetable Oils for Use by the Snack Food Industry on Plasma Lipid Levels and Inflammatory Markers|Effect of Conventional and Reformulated Vegetable Oils for Use by the Snack Food Industry on Plasma Lipid Levels and Inflammatory Markers|Active, not recruiting||N/A|30|Anticipated|Tufts University||1|||f||||f||||||||||2018-06-01 04:37:49.29024|2018-06-01 04:37:49.29024
NCT00175058|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-06-15|2005-09-09|2005-09-15|Estimate|||||||2012-06-15|2012-06-18|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|May 2008|Actual|2008-05-31|June 2007|Actual|2007-06-30||Interventional|AMIHOT II||Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)|Acute Myocardial Infarction With HyperOxemic Therapy II|Completed||Phase 3|317|Actual|TherOx||2|||f||||t||||||||||2018-06-01 04:37:49.362025|2018-06-01 04:37:49.362025
NCT00175045|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-20|2005-09-12|2005-09-15|Estimate|||||||2010-07-20|2010-07-21|Estimate|June 2003||2003-06-30|July 2010|2010-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis|A Phase 2, Open-Label Multicenter Study to Evaluate the Pharmacodynamics of Intravenous Lansoprazole to That of Oral Lansoprazole in Subjects With Erosive Esophagitis|Completed||Phase 2|68|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:37:49.45547|2018-06-01 04:37:49.45547
NCT00174863|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-12-22|2005-09-13|2005-09-15|Estimate|||||||2008-12-22|2008-12-23|Estimate|October 2003||2003-10-31|December 2008|2008-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|ODYSSEY||Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer|Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study|Completed||Phase 2|232|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:37:55.967582|2018-06-01 04:37:55.967582
NCT00175032|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-20|2005-09-12|2005-09-15|Estimate|||||||2010-07-20|2010-07-22|Estimate|July 2003||2003-07-31|July 2010|2010-07-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin|A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin|Completed||Phase 3|1045|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:37:49.558916|2018-06-01 04:37:49.558916
NCT00175019|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-12||2010-07-22|2005-09-12|2005-09-15|Estimate|2009-07-31|2009-09-07|Estimate||||2010-07-22|2010-07-27|Estimate|July 2003||2003-07-31|July 2010|2010-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|EXCEL||Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010|A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout|Completed||Phase 3|1086|Actual|Takeda|Subjects may receive >1 treatment. Adverse events are summarized by treatment at time of observation and subjects who receive >1 treatment are summarized for each treatment they receive, so subjects at risk will not match number of participants.|3|||f||||f||||||||||2018-06-01 04:37:49.688303|2018-06-01 04:37:49.688303
NCT00175006|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-12||2010-07-22|2005-09-12|2005-09-15|Estimate|2009-05-26|2009-07-16|Estimate||||2010-07-22|2010-07-27|Estimate|November 2002||2002-11-30|July 2010|2010-07-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Observational|||Validation Study of Physical Measurement of Tophi|A Study to Assess a Direct Physical Measurement Method for Evaluation of Tophus Nodules in Subjects With Gout.|Completed|||13|Actual|Takeda|||1||f||||f||||||None Retained|"~     None taken or retained~   "|||2018-06-01 04:37:50.643507|2018-06-01 04:37:50.643507
NCT00174993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-02-27|2005-09-09|2005-09-15|Estimate|||||||2012-02-27|2012-02-28|Estimate|May 2001||2001-05-31|February 2012|2012-02-29|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|PROactive||Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes|PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy|Completed||Phase 3|4373|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:37:50.779535|2018-06-01 04:37:50.779535
NCT00174980|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-06-09|2005-09-09|2005-09-15|Estimate|||||||2011-06-09|2011-06-10|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|July 2008|Actual|2008-07-31|January 2008|Actual|2008-01-31||Interventional|||Study of Oxycyte in Severe Closed Head Injury|An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL-II-002|Completed||Phase 2|9|Actual|Tenax Therapeutics, Inc.|||||f||||||||||||||2018-06-01 04:37:50.977723|2018-06-01 04:37:50.977723
NCT00174967|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-03-12||2011-07-27|2005-09-09|2005-09-15|Estimate|2009-05-26|2009-07-16|Estimate||||2011-07-27|2011-07-29|Estimate|January 2001||2001-01-31|July 2011|2011-07-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout|Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.|Completed||Phase 2|153|Actual|Takeda||4|||f||||f||||||||||2018-06-01 04:37:51.072129|2018-06-01 04:37:51.072129
NCT00174954|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-12||2010-07-22|2005-09-12|2005-09-15|Estimate|2009-05-26|2009-07-16|Estimate||||2010-07-22|2010-07-27|Estimate|March 2002||2002-03-31|July 2010|2010-07-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Observational|||Magnetic Resonance Imaging in Subjects With Gouty Tophi|A Study to Validate Magnetic Resonance Imaging (MRI) in the Quantitative Assessment of Gouty Tophi.|Completed|||32|Actual|Takeda|||1||f||||f||||||None Retained|"~     None taken or retained.~   "|||2018-06-01 04:37:51.972565|2018-06-01 04:37:51.972565
NCT00174941|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-12||2011-01-25|2005-09-12|2005-09-15|Estimate|2009-05-26|2009-07-16|Estimate||||2011-01-25|2011-01-27|Estimate|March 2001||2001-03-31|January 2011|2011-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|FOCUS||Long-Term Safety of Febuxostat in Subjects With Gout.|Phase II, Open-Label Study, to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout|Completed||Phase 2|116|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:37:52.679018|2018-06-01 04:37:52.679018
NCT00174928|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-07-20|2005-09-09|2005-09-15|Estimate|||||||2010-07-20|2010-07-22|Estimate|May 2005||2005-05-31|July 2010|2010-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease|A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multi-center Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Neonates With Clinically-Evident Gastroesophageal Reflux Disease.|Completed||Phase 1|24|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:37:53.618568|2018-06-01 04:37:53.618568
NCT00174915|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-03-12||2012-01-31|2005-09-09|2005-09-15|Estimate|2009-05-26|2009-07-16|Estimate||||2012-01-31|2012-02-02|Estimate|February 2003||2003-02-28|January 2012|2012-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|APEX||Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.|A Phase 3, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout.|Completed||Phase 3|1072|Actual|Takeda||5|||f||||f||||||||||2018-06-01 04:37:53.740185|2018-06-01 04:37:53.740185
NCT00174902|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-10-24|2005-09-09|2005-09-15|Estimate|||||||2006-10-24|2006-10-25|Estimate|October 2003||2003-10-31|October 2003|2003-10-31|August 2004||2004-08-31|||||Interventional|||The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress|The Effect of Beta-Blockers, Aspirin, and Natural Habituation on Procoagulant Activity, Expression of Cellular Adhesion Molecules, and Endothelial Activation in Response to Acute Mental Stress: a Randomized Controlled Trial.|Unknown status|Active, not recruiting|Phase 1/Phase 2|80||Swiss Federal Institute of Technology|||||f||||||||||||||2018-06-01 04:37:55.688867|2018-06-01 04:37:55.688867
NCT00174889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-05-20|2005-09-09|2005-09-15|Estimate|||||||2008-05-20|2008-05-21|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Pregnenolone in the Management of Schizophrenia Patients|Efficacy and Safety of Pregnenolone Augmentation in the Management of Schizophrenia Patients: a Randomised Double-Blind Placebo-Controlled Trial|Completed||Phase 1|60||Sha’ar Menashe Mental Health Center|||||f||||||||||||||2018-06-01 04:37:55.813025|2018-06-01 04:37:55.813025
NCT00174876|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-09-17|2005-09-09|2005-09-15|Estimate|||||||2008-09-17|2008-09-18|Estimate|July 2004||2004-07-31|September 2008|2008-09-30|May 2005||2005-05-31|||||Interventional|||Aripiprazole as Augmentation for TRD|An Open-Label Study of Aripiprazole (Abilify) as an Augmentation Agent in Patients With Treatment-Resistant Depression|Completed||Phase 2|20||State University of New York - Upstate Medical University|||||f||||||||||||||2018-06-01 04:37:55.905603|2018-06-01 04:37:55.905603
NCT00173992|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|September 2005||2005-09-30|June 2005|2005-06-30|December 2007||2007-12-31|||||Interventional|||Balance Recovery and Training on Fall Prevention in Stroke|Balance Recovery and Training on Fall Prevention in Stroke|Unknown status|Not yet recruiting|N/A|100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.331974|2018-06-01 04:38:08.331974
NCT00174850|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2008-09-17|2005-09-14|2005-09-15|Estimate|||||||2008-09-17|2008-09-18|Estimate|July 2004||2004-07-31|September 2008|2008-09-30|May 2005||2005-05-31|||||Interventional|||Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction|A 14 Week Open-Label Study to Evaluate the Tolerability of Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction in Generalized Anxiety Disorder Patients|Completed||Phase 4|30||State University of New York - Upstate Medical University|||||f||||||||||||||2018-06-01 04:37:56.054079|2018-06-01 04:37:56.054079
NCT00174837|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13||2016-04-27|2016-04-27|2005-09-13|2005-09-15|Estimate||||2016-04-27|2016-05-26|Estimate|2016-04-27|2016-05-26|Estimate|April 2005||2005-04-30|April 2016|2016-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|TRACE||TRACE: Tirapazamine-Radiation And Cisplatin Evaluation|Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer|Completed||Phase 3|317|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:37:56.115573|2018-06-01 04:37:56.115573
NCT00174824|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-03-26|2005-09-13|2005-09-15|Estimate|||||||2009-03-26|2009-03-27|Estimate|June 2001||2001-06-30|March 2009|2009-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients|Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin|Completed||Phase 4|1024|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:37:56.216197|2018-06-01 04:37:56.216197
NCT00174811|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-02|2005-09-13|2005-09-15|Estimate|||||||2009-04-02|2009-04-03|Estimate|June 2005||2005-06-30|April 2009|2009-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections|Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of Telithromycin 25 mg/kg Given Once Daily for 5 or 10 Days Depending on Age and Previous Treatment History Versus Cefuroxime Axetil 15 mg/kg, Given Twice Daily for 10 Days, in Children With Acute Otitis Media|Terminated||Phase 3|639|Actual|Sanofi||||Pediatric development program terminated by sponsor|f||||||||||||||2018-06-01 04:37:56.283722|2018-06-01 04:37:56.283722
NCT00174798|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-02-01|2005-09-13|2005-09-15|Estimate|||||||2012-02-01|2012-02-02|Estimate|May 2005||2005-05-31|February 2012|2012-02-29|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.|A Randomized, Double-blind, Placebo and Active-controlled Efficacy and Safety Study of SSR240600C in Patients With Overactive Bladder (OAB) or Urge Urinary Incontinence (UUI)|Completed||Phase 2|118|Actual|Sanofi||3|||f||||||||||||||2018-06-01 04:37:56.354242|2018-06-01 04:37:56.354242
NCT00174785|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-07-24||2010-01-05|2005-09-13|2005-09-15|Estimate|2009-11-17|2009-12-23|Estimate||||2010-01-05|2010-01-12|Estimate|June 2005||2005-06-30|January 2010|2010-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|ATHENA||A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation|A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)|Completed||Phase 3|4628|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 04:37:56.519399|2018-06-01 04:37:56.519399
NCT00174772|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-02-15|2005-09-12|2005-09-15|Estimate|||||||2010-02-15|2010-02-17|Estimate|March 2004||2004-03-31|February 2010|2010-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)|A Two Arm Phase II Study Comparing Docetaxel/Cisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-Multiple cN2 or IIIB)|Completed||Phase 2|72|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:37:58.497667|2018-06-01 04:37:58.497667
NCT00174759|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-01-10|2005-09-09|2005-09-15|Estimate|||||||2011-01-10|2011-01-11|Estimate|September 2004||2004-09-30|January 2011|2011-01-31||||||||Interventional|||CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease|A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.|Completed||Phase 3|1460|Anticipated|Sanofi|||||f||||||||||||||2018-06-01 04:37:58.57459|2018-06-01 04:37:58.57459
NCT00174746|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-07|2005-09-13|2005-09-15|Estimate|||||||2009-04-07|2009-04-08|Estimate|March 2005||2005-03-31|April 2009|2009-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Dose Response Study of Inhaled Ciclesonide (Glucocorticosteroid) to Patients With Persistent Asthma|A Placebo- and Active-Controlled (Ciclesonide Metered-Dose Inhaler), Randomized, Parallel-Group, Dose-Range Finding Study of Ciclesonide Administered by Dry Powder Inhaler (Ultrahaler) in Adult and Adolescent Patients With Persistent Asthma|Completed||Phase 2|1145|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:37:58.637658|2018-06-01 04:37:58.637658
NCT00174733|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-07|2005-09-13|2005-09-15|Estimate|||||||2009-04-07|2009-04-08|Estimate|July 2005||2005-07-31|April 2009|2009-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered for Twelve Weeks Either in a Once-Daily Regimen in the Morning (160 μg qd AM) or in a Twice Daily Regimen (80 μg Bid) in Adults and Adolescents With Mild to Moderate Persistent Asthma Treated Previously With Inhaled Corticosteroids|Completed||Phase 3|456|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:37:58.693384|2018-06-01 04:37:58.693384
NCT00174720|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-04-07|2005-09-13|2005-09-15|Estimate|||||||2009-04-07|2009-04-08|Estimate|September 2005||2005-09-30|April 2009|2009-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.|A Multinational,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Parallel-Group Study to Assess the Efficacy of Ciclesonide Metered-Dose Inhaler at a Daily Dose of 160 μg Administered Either in a Once-Daily in the Morning Regimen (160 μg qd AM) for 16 Weeks or in a 160 μg qd AM Regimen for 12 Weeks Preceded by a Twice-Daily Regimen (80 μg Bid) for 4 Weeks,or in an 80 μg Bid Regimen for 16 Weeks,in Adults and Adolescents With Mild to Moderate Persistent Asthma Not Treated With Steroids|Completed||Phase 3|708|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:37:58.74876|2018-06-01 04:37:58.74876
NCT00173979|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-05|2005-09-13|2005-09-15|Estimate|||||||2007-06-05|2007-06-06|Estimate|June 2005||2005-06-30|June 2005|2005-06-30||||||||Observational|||Tendon Mechanical Properties and Morphological Characteristics of Human Bicep and Tricep Muscles: An In Vivo Ultrasonographical Study|Tendon Mechanical Properties and Morphological Characteristics of Human Muscle|Unknown status|Recruiting||15|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.412379|2018-06-01 04:38:08.412379
NCT00174707|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-12-04|2005-09-12|2005-09-15|Estimate|||||||2009-12-04|2009-12-07|Estimate|December 1997||1997-12-31|December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Docetaxel in Breast Cancer Patients|A Phase III Randomized Study of Sequential Epidoxorubicin Followed By CMF: Cyclophosphamide+Methotrexate+Fluorouracil (Arm A) Versus Sequential Epidoxorubicin Followed By Docetaxel Followed By CMF (Arm B) Versus Sequential Intensified Epidoxorubicin Followed By Docetaxel Followed By High-Dose Cyclophosphamide (Arm C) in Early Breast Cancer Patients With Positive Axillary Lymph Nodes|Completed||Phase 3|998|Actual|Sanofi||3|||f||||||||||||||2018-06-01 04:37:58.891205|2018-06-01 04:37:58.891205
NCT00174694|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-09-24|2005-09-09|2005-09-15|Estimate|||||||2009-09-24|2009-09-25|Estimate|November 2004||2004-11-30|September 2009|2009-09-30||||December 2005|Actual|2005-12-31||Interventional|||CHOOSE : Telithromycin, Acute Bacterial Sinusitis|A Prospective, Randomized, Open-label, Active-controlled Study in Adult Subjects With Acute Bacterial Sinusitis Comparing the Clinical Efficacy of Telithromycin (KETEK®) 800 mg Once a Day for 5 Days Versus Amoxicillin-clavulanic Acid (AUGMENTIN®) 875/125 mg Twice a Day for 10 Days|Completed||Phase 4|298|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:37:58.958301|2018-06-01 04:37:58.958301
NCT00174681|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-01-10|2005-09-09|2005-09-15|Estimate|||||||2011-01-10|2011-01-11|Estimate|April 2003||2003-04-30|January 2011|2011-01-31||||||||Interventional|||Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes|Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes|Completed||Phase 4|390||Sanofi|||||f||||||||||||||2018-06-01 04:37:59.015765|2018-06-01 04:37:59.015765
NCT00174668|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-09-14|2005-09-09|2005-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|November 2004||2004-11-30|September 2009|2009-09-30||||November 2007|Actual|2007-11-30||Interventional|GINGER||Insulin Glulisine in Diabetes Mellitus, Type 2|52-week, Open, Randomized, Multinational, Multicenter Clinical Trial Comparing Insulin Glulisine in Combination With Insulin Glargine in an Intensified Insulin Regimen to a Two-injection Conventional Insulin Regimen in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control Pretreated With a Two-injection Conventional Insulin Therapy|Completed||Phase 3|311|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:37:59.08105|2018-06-01 04:37:59.08105
NCT00174655|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-11-09|2005-09-09|2005-09-15|Estimate|||||||2011-11-09|2011-11-10|Estimate|June 1998||1998-06-30|November 2011|2011-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||BIG 02/98 Docetaxel - Breast Cancer|An Intergroup Phase III Trial to Evaluate the Activity of Docetaxel, Given Either Sequentially or in Combination With Doxorubicin, Followed by CMF, in Comparison to Doxorubicin Alone or in Combination With Cyclophosphamide, Followed by CMF, in the Adjuvant Treatment of Node-positive Breast Cancer Patients.|Completed||Phase 3|2887|Actual|Sanofi||4|||f||||||||||||||2018-06-01 04:37:59.165004|2018-06-01 04:37:59.165004
NCT00174642|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-09-14|2005-09-09|2005-09-15|Estimate|||||||2009-09-14|2009-09-15|Estimate|December 2004||2004-12-31|September 2009|2009-09-30||||December 2008|Actual|2008-12-31||Interventional|OSIRIS||Opposing Step-by-step Insulin Reinforcement to Intensified Strategy|Comparison of Three Therapeutic Strategies for Treating Type 2 Diabetes Mellitus Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs|Completed||Phase 3|811|Actual|Sanofi||3|||f||||||||||||||2018-06-01 04:37:59.259176|2018-06-01 04:37:59.259176
NCT00174629|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-12-04|2005-09-09|2005-09-15|Estimate|||||||2009-12-04|2009-12-07|Estimate|June 2001||2001-06-30|December 2009|2009-12-31||||January 2007|Actual|2007-01-31||Interventional|||GILT Docetaxel - Non-Small Cell Lung Cancer|Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients|Completed||Phase 3|449|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:37:59.343209|2018-06-01 04:37:59.343209
NCT00174616|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-12-04|2005-09-09|2005-09-15|Estimate|||||||2009-12-04|2009-12-07|Estimate|July 2003||2003-07-31|December 2009|2009-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision|Phase 2 Study of Weekly Oxaliplatin and Capecitabine (XELOX) in Combination With Preoperative Radiotherapy in Patients With MRI Defined Locally Advanced Rectal Cancer|Completed||Phase 2|87|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:37:59.400241|2018-06-01 04:37:59.400241
NCT00174603|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-28|2005-09-09|2005-09-15|Estimate|||||||2007-12-28|2008-01-10|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Treatment of Depression With Quetiapine|Treatment of Major Depressive Disorder With Psychotic Features With Quetiapine Monotherapy; Quetiapine and Citalopram; or Haloperidol and Citalopram|Terminated||Phase 3|60||Rush University Medical Center||||Unable to recruit subjects|f||||f||||||||||2018-06-01 04:37:59.457629|2018-06-01 04:37:59.457629
NCT00174590|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-28|2005-09-09|2005-09-15|Estimate|||||||2007-12-28|2008-01-10|Estimate|September 2001||2001-09-30|December 2007|2007-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Treatment of Major Depressive Disorder With Psychotic Features.|Treatment of Major Depressive Disorder With Psychotic Features With Risperidone Monotherapy; Risperidone and Sertraline; or Haloperidol and Sertraline|Terminated||Phase 3|30||Rush University Medical Center|||||f||||||||||||||2018-06-01 04:37:59.513697|2018-06-01 04:37:59.513697
NCT00174577|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-15|Estimate|||||||2005-09-09|2005-09-15|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|February 2005||2005-02-28|||||Interventional|||Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant|Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to an Adequate Trial of Antidepressant|Unknown status|Active, not recruiting|Phase 3|84||Rhode Island Hospital|||||f||||||||||||||2018-06-01 04:37:59.567864|2018-06-01 04:37:59.567864
NCT00174564|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-02-15|2005-09-09|2005-09-15|Estimate|||||||2012-02-15|2012-02-17|Estimate|April 2003||2003-04-30|February 2012|2012-02-29|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||EXIBIT: Oxaliplatin in Biliary Tract Cancer|A Multicentre Phase II Trial of Gemcitabine and Oxaliplatin (GEMOX) in Patients With Biliary Tract Cancer|Completed||Phase 2|67|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:38:00.689393|2018-06-01 04:38:00.689393
NCT00174551|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-07|2005-09-09|2005-09-15|Estimate|||||||2006-09-07|2006-09-11|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|November 2005||2005-11-30|||||Interventional|||Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD|The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD|Unknown status|Active, not recruiting|N/A|20||Rainier Associates|||||f||||||||||||||2018-06-01 04:38:00.738649|2018-06-01 04:38:00.738649
NCT00174538|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-06-29|2005-09-09|2005-09-15|Estimate|||||||2011-06-29|2011-06-30|Estimate|March 2005||2005-03-31|July 2005|2005-07-31|December 2005||2005-12-31|||||Interventional|||Codeine in Sickle Cell Disease|The Effects of Cytochrome P450 2D6 Genotype on Pain Management With Codeine in Sickle Cell Disease|Completed||Phase 1/Phase 2|60|Anticipated|PriCara, Unit of Ortho-McNeil, Inc.|||||f||||||||||||||2018-06-01 04:38:00.798136|2018-06-01 04:38:00.798136
NCT00174525|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-05-08|2005-09-09|2005-09-15|Estimate|||||||2012-05-08|2012-05-09|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|April 2008||2008-04-30|||||Interventional|||Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease|A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD|Unknown status|Active, not recruiting|Phase 2|||Pharmacology Research Institute|||||||||||||||||||2018-06-01 04:38:00.855174|2018-06-01 04:38:00.855174
NCT00174512|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-11-07|2005-09-12|2005-09-15|Estimate|||||||2006-11-07|2006-11-08|Estimate|March 2005||2005-03-31|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade|A Methodological Open-Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarisation and QT Interval At Fixed Heart Rate Under Autonomic Blockade|Completed||Phase 1|36||Pfizer|||||f||||||||||||||2018-06-01 04:38:00.9126|2018-06-01 04:38:00.9126
NCT00174499|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-07-06|2005-09-14|2005-09-15|Estimate|||||||2012-07-06|2012-07-10|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Interventional|||A Pilot Drug Trial That Evaluates the Whitening Potential of Nicotine Gum|An Open-label Study on Nicorette Freshmint Gum, 2 MG AND 4 MG in Smokers With Visible Teeth Staining Motivated to Quit|Completed||Phase 4|78|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-06-01 04:38:00.973921|2018-06-01 04:38:00.973921
NCT00174486|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-07-23|2005-09-12|2005-09-15|Estimate|||||||2006-07-23|2006-07-25|Estimate|February 2005||2005-02-28|November 2005|2005-11-30|June 2005||2005-06-30|||||Interventional|||Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction|A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Duration Of Action, Safety And Toleration Of Differing Doses and Combinations Of Immediate and Modified Release Formulations Of UK-369,003 and Cialis Compared To Placebo In Adult Male Subjects With Erectile Dysfunction|Completed||Phase 2|300||Pfizer|||||f||||||||||||||2018-06-01 04:38:01.037388|2018-06-01 04:38:01.037388
NCT00174473|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-09|2005-09-12|2005-09-15|Estimate|||||||2011-05-09|2011-05-10|Estimate|June 2003||2003-06-30|May 2011|2011-05-31|August 2005|Actual|2005-08-31|||||Interventional|||A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children|An Open-label, Intravenous to Oral Switch, Multiple Dose Multi-Centre Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Hospitalized Children Aged 2 to 12 Years Who Require Treatment for the Prevention of Systemic Fungal Infections.|Completed||Phase 1/Phase 2|49|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:38:01.086858|2018-06-01 04:38:01.086858
NCT00174460|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-03-16||2017-03-07|2005-09-12|2005-09-15|Estimate|2009-03-24|2009-05-12|Estimate||||2017-03-07|2017-04-05|Actual|August 2005||2005-08-31|March 2017|2017-03-31|March 2010|Actual|2010-03-31|March 2008|Actual|2008-03-31||Interventional|AGA||Somatropin Therapy In Children Born Preterm But Appropriate For Gestational Age|Somatropin Therapy For Short Children Born Of Premature Gestation, A Controlled, Prospective Randomized, Multicenter Study With An Untreated Control Group.|Completed||Phase 2|33|Actual|Pfizer|Result values for the primary outcome measures were revised at the final analysis due to programmatic corrections: age rounded up if >6 months past last birthday. Height and height SDS not rounded for final analysis; rounded only for the reports.|2|||f||||f||||||||||2018-06-01 04:38:01.306051|2018-06-01 04:38:01.306051
NCT00174447|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-10-15||2009-11-20|2005-09-12|2005-09-15|Estimate|2009-10-15|2009-11-17|Estimate||||2009-11-20|2009-11-25|Estimate|October 2001||2001-10-31|November 2009|2009-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031|Open Extension Study Evaluating The Long Term Efficacy , Safety And Tolerability Of Oral Ziprasidone In The Treatment Of Patients Who Have Successfully Completed The Previous Ziprasidone Study A1281031|Completed||Phase 3|43|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:38:02.116851|2018-06-01 04:38:02.116851
NCT00174434|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-26|2005-09-12|2005-09-15|Estimate|||||||2009-01-26|2009-01-27|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer|A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting|Completed||Phase 1|22|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:38:02.581723|2018-06-01 04:38:02.581723
NCT00174421|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-01|2005-09-12|2005-09-15|Estimate|||||||2007-05-01|2007-05-03|Estimate|April 2001||2001-04-30|May 2007|2007-05-31|August 2005||2005-08-31|||||Interventional|||Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height|Genotropin in Short Children Born Small for Gestational Ag - A Long-Term Study in Belgium|Completed||Phase 3|36||Pfizer|||||f||||||||||||||2018-06-01 04:38:02.663948|2018-06-01 04:38:02.663948
NCT00174408|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-05-01|2005-09-12|2005-09-15|Estimate|||||||2007-05-01|2007-05-03|Estimate|March 1990||1990-03-31|May 2007|2007-05-31|February 2005||2005-02-28|||||Interventional|||Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age|Growth Hormone Treatment in Short Children Born Small for Date (Genotonorm)|Completed||Phase 3|110||Pfizer|||||f||||||||||||||2018-06-01 04:38:02.71528|2018-06-01 04:38:02.71528
NCT00174395|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-10-31|2005-09-09|2005-09-15|Estimate|||||||2007-10-31|2007-11-02|Estimate|March 2005||2005-03-31|October 2007|2007-10-31|October 2006|Actual|2006-10-31|||||Interventional|||A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine|A Multi-Center, Open-Label, Randomized, Parallel-Group Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine in Early Intervention.|Completed||Phase 4|220||Pfizer|||||f||||||||||||||2018-06-01 04:38:02.77817|2018-06-01 04:38:02.77817
NCT00174382|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2009-04-24||2015-03-04|2005-09-09|2005-09-15|Estimate|2009-04-24|2009-06-12|Estimate||||2015-03-04|2015-03-24|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia|An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia|Terminated||Phase 3|149|Actual|Pfizer||1||See Detailed Description|f||||f||||||||||2018-06-01 04:38:02.951259|2018-06-01 04:38:02.951259
NCT00174369|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-03-16|2005-09-09|2005-09-15|Estimate|||||||2009-03-16|2009-03-17|Estimate|November 2005||2005-11-30|February 2009|2009-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer|Phase 2 Study Of The MEK Inhibitor PD-0325901 In Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|34|Actual|Pfizer||1||Terminated [See Detailed Description for Termination Reason.]|f||||f||||||||||2018-06-01 04:38:03.491421|2018-06-01 04:38:03.491421
NCT00172965|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|June 2005||2005-06-30|||||Observational|||Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography|Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography|Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.358969|2018-06-01 04:38:14.358969
NCT00174356|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-11-06|2005-09-09|2005-09-15|Estimate|||||||2006-11-06|2006-11-08|Estimate|December 2002||2002-12-31|January 2006|2006-01-31|October 2005||2005-10-31|||||Interventional|||PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients|A Phase 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel And Carboplatin As First-Line Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|39||Pfizer|||||f||||||||||||||2018-06-01 04:38:03.575564|2018-06-01 04:38:03.575564
NCT00174343|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-21|2005-09-09|2005-09-15|Estimate|||||||2011-04-21|2011-04-22|Estimate|November 2001||2001-11-30|April 2011|2011-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients|Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.|Completed||Phase 2|46||Pfizer|||||f||||||||||||||2018-06-01 04:38:03.728936|2018-06-01 04:38:03.728936
NCT00174330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-02-20|2005-09-09|2005-09-15|Estimate|||||||2007-02-20|2007-02-21|Estimate|May 2005||2005-05-31|February 2007|2007-02-28|February 2006||2006-02-28|||||Interventional|||Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia|A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And Safety Of Dual Therapy With Atorvastatin Plus Amlodipine When Compared Amlodipine Therapy Alone In The Treatment Of Subjects With Concurrent Hyperlipidemia And Hypertension.|Completed||Phase 4|330||Pfizer|||||f||||||||||||||2018-06-01 04:38:03.804207|2018-06-01 04:38:03.804207
NCT00174317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-11-30|2005-09-09|2005-09-15|Estimate|||||||2006-11-30|2006-12-05|Estimate|August 2003||2003-08-31|December 2005|2005-12-31|February 2005||2005-02-28|||||Interventional|||Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip|Clinical Protocol For A Multicentre, Double-Blind, Randomised, Parallel Group Study To Compare The Efficacy and Tolerability Of Celecoxib Vs. Diclofenac In The Treatment Of Subjects With Osteoarthritis Of The Hip Requiring Joint Replacement Therapy|Completed||Phase 4|250||Pfizer|||||f||||||||||||||2018-06-01 04:38:03.908511|2018-06-01 04:38:03.908511
NCT00174304|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-01-06|2005-09-09|2005-09-15|Estimate|||||||2010-01-06|2010-01-08|Estimate|October 2004||2004-10-31|April 2007|2007-04-30|September 2006||2006-09-30|||||Interventional|JEWEL II||Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.|An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)|Completed||Phase 4|1120||Pfizer|||||f||||||||||||||2018-06-01 04:38:04.041017|2018-06-01 04:38:04.041017
NCT00174291|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-10-26||2012-10-26|2005-09-09|2005-09-15|Estimate|2012-10-26|2012-12-04|Estimate||||2012-10-26|2012-12-04|Estimate|March 2002||2002-03-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy|Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years|Terminated||Phase 3|21|Actual|Pfizer|Data for bone mineral density (BMD), bone mineral content (BMC) and IGFBP3 were not analyzed because of change in planned analysis after the study was prematurely terminated due to Good Clinical Practice (GCP) non-compliance issues.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:38:04.327507|2018-06-01 04:38:04.327507
NCT00174278|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-08-04|2005-09-09|2005-09-15|Estimate|||||||2008-08-04|2008-08-05|Estimate|February 1997||1997-02-28|August 2008|2008-08-31|October 2006|Actual|2006-10-31|||||Interventional|||Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) In Children With Short Stature Secondary|Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.|Completed||Phase 3|14||Pfizer|||||f||||||||||||||2018-06-01 04:38:05.003211|2018-06-01 04:38:05.003211
NCT00174265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2010-05-27|2009-06-09|2015-06-08|2005-09-09|2005-09-15|Estimate|2010-05-27|2010-07-05|Estimate|2009-10-02|2009-10-06|Estimate|2015-06-08|2015-07-03|Estimate|July 2005||2005-07-31|June 2015|2015-06-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)|A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed Protocol A7501013|Completed||Phase 3|196|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:38:05.068315|2018-06-01 04:38:05.068315
NCT00174252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2010-04-02||2010-06-10|2005-09-09|2005-09-15|Estimate|2010-05-04|2010-06-04|Estimate||||2010-06-10|2010-06-15|Estimate|February 2005||2005-02-28|June 2009|2009-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age|Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation, Treated by Genotonorm Especially Evolution After Dose Adaptation.|Completed||Phase 3|57|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:38:05.31195|2018-06-01 04:38:05.31195
NCT00174239|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-05-24|2005-09-09|2005-09-15|Estimate|||||||2007-05-24|2007-05-25|Estimate|July 2004||2004-07-31|May 2007|2007-05-31|September 2005|Actual|2005-09-30|||||Interventional|||Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.|A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.|Terminated||Phase 4|220||Pfizer||||See Detailed Description for termination reason.|f||||f||||||||||2018-06-01 04:38:05.926168|2018-06-01 04:38:05.926168
NCT00174226|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-07-10|2005-09-09|2005-09-15|Estimate|||||||2008-07-10|2008-07-15|Estimate|November 2004||2004-11-30|July 2008|2008-07-31|January 2006|Actual|2006-01-31|||||Interventional|||Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar|Eight-Week, Double-Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy And Safety Trial Of Atomoxetine, Atomoxetine Plus Buspirone, And Placebo In Adults With Attention Deficit Hyperactivity Disorder|Completed||Phase 2|241|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:38:06.023807|2018-06-01 04:38:06.023807
NCT00174213|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-08-29|2005-09-14|2005-09-15|Estimate|||||||2007-08-29|2007-08-30|Estimate|September 1994||1994-09-30|August 1994|1994-08-31||||||||Observational|||Validity and Reliability in Measuring Iliotibial Tract by Using Ultrasound|Validity and Reliability in Measuring Iliotibial Tract by Using Ultrasound|Unknown status|Recruiting||40|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:06.105408|2018-06-01 04:38:06.105408
NCT00173966|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|January 2005||2005-01-31|December 2004|2004-12-31||||||||Observational|||A Case Control Study to Investigate the Possible Association Between Atrial Fibrillation and Endothelium Dysfunction by Using Flow-Mediated Vasodilation Method||Unknown status|Recruiting||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.469067|2018-06-01 04:38:08.469067
NCT00174200|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-07-11|2005-09-09|2005-09-15|Estimate|||||||2008-07-11|2008-07-15|Estimate|December 2004||2004-12-31|July 2008|2008-07-31|May 2006|Actual|2006-05-31|||||Interventional|||Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone|A Randomized, Double-Blind, Crossover Add-On Study To Assess The Differential Sensitivity Of 2 Spatial Working Memory Tests (The Groton Maze Learning Test [GMLT] And The Motor Delayed Response Test [MDR]) In Non-Agitated, Antipsychotic Drug-Naive First-Episode Schizophrenic Or Schizophreniform Patients Treated With Risperidone 2 Mg Daily Or Placebo|Completed||N/A|20||Pfizer|||||f||||||||||||||2018-06-01 04:38:06.170614|2018-06-01 04:38:06.170614
NCT00174187|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-09-11||2012-11-05|2005-09-09|2005-09-15|Estimate|2012-11-05|2012-12-04|Estimate||||2012-11-05|2012-12-04|Estimate|September 2000||2000-09-30|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy|Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety.|Terminated||Phase 3|30|Actual|Pfizer|Results for secondary and other pre-specified endpoints (except IGF-1) are reported for only up to 3 years because data beyond Year 3 was not summarized as the study was terminated due to Good Clinical Practice (GCP) non-compliance issues.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:38:06.321471|2018-06-01 04:38:06.321471
NCT00174174|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2005-09-14|2005-09-14|2005-09-15|Estimate|||||||2005-09-14|2005-09-15|Estimate|September 2003||2003-09-30|October 2004|2004-10-31||||||||Interventional|||Provigil (Modafinil) Study by Taiwan Biotech Co.|A Placebo Control, Double Blind, Cross Over Study of Modafinil in Patients With Narcolepsy|Completed||N/A|30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.418522|2018-06-01 04:38:07.418522
NCT00174161|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2005||2005-08-31|July 2005|2005-07-31|December 2005||2005-12-31|||||Observational|||The Symptom Experience of Women With Perimenstrual Syndrome;Women's Health Related Quality of Life.||Unknown status|Recruiting||1000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.465566|2018-06-01 04:38:07.465566
NCT00174148|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-20|2005-09-13|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|July 2005||2005-07-31|December 2004|2004-12-31|July 2006||2006-07-31|||||Observational|||Sensorimotor Dysfunction of Individuals With Neck Pain|Sensorimotor Dysfunction of Individuals With Neck Pain|Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.514589|2018-06-01 04:38:07.514589
NCT00174135|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-08-29|2005-09-13|2005-09-15|Estimate|||||||2007-08-29|2007-08-30|Estimate|August 2005||2005-08-31|December 2004|2004-12-31||||||||Observational|||Sarcopenia Studies for the Elderly Population in Taiwan|Sarcopenia Studies for the Elderly Population in Taiwan|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.560174|2018-06-01 04:38:07.560174
NCT00174122|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-02-28|2005-09-13|2005-09-15|Estimate|||||||2006-02-28|2006-03-01|Estimate|July 2005||2005-07-31|September 2004|2004-09-30|June 2006||2006-06-30|||||Observational|||Procalcitonin in Diagnosing Bacteremia in the Emergency Department||Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.607382|2018-06-01 04:38:07.607382
NCT00174109|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2005||2005-08-31|June 2005|2005-06-30|July 2006||2006-07-31|||||Observational|||The Relation of Microtubule-Associated Protein 2 and Cell Migration||Unknown status|Recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.655808|2018-06-01 04:38:07.655808
NCT00174096|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-03-30|2005-09-13|2005-09-15|Estimate|||||||2006-03-30|2006-03-31|Estimate|August 2005||2005-08-31|June 2005|2005-06-30|July 2006||2006-07-31|||||Observational|||The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.717336|2018-06-01 04:38:07.717336
NCT00174083|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2005||2005-08-31|July 2005|2005-07-31|December 2006||2006-12-31|||||Observational|||Diagnosis of Active Tuberculosis by ELISPOT|Diagnosis of Active Tuberculosis in Endemic Area by Using Enzyme-Linked Immunospot Assay for Gamma-Interferon|Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.859157|2018-06-01 04:38:07.859157
NCT00174070|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-11-02|2005-09-14|2005-09-15|Estimate|||||||2005-11-02|2005-11-03|Estimate|August 2005||2005-08-31|July 2005|2005-07-31|February 2006||2006-02-28|||||Observational|||Etiologies and Outcomes of Acute Respiratory Failure in Community|Etiologies and Outcomes Analysis of Acute Respiratory Failure in Community|Unknown status|Recruiting||150||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.932434|2018-06-01 04:38:07.932434
NCT00174057|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2005||2005-08-31|June 2005|2005-06-30|July 2006||2006-07-31|||||Observational|||The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves’Ophthalmopathy||Unknown status|Recruiting||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:07.999521|2018-06-01 04:38:07.999521
NCT00174044|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-20|2005-09-13|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|July 2006||2006-07-31|||||Observational|||Control Strategies of the Locomotor System During Obstacle-Crossing in Stroke Patients|Control Strategies of the Locomotor System During Obstacle-Crossing in Stroke Patients|Unknown status|Recruiting||120||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.122497|2018-06-01 04:38:08.122497
NCT00174031|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-11-25|2005-09-13|2005-09-15|Estimate|||||||2005-11-25|2005-11-28|Estimate|December 1993||1993-12-31|September 1993|1993-09-30||||||||Observational|||Prevalence and Profiles of Sports Injury in Taiwanese Adolescent Baseball Players|Prevalence and Profiles of Sports Injury in Taiwanese Adolescent Baseball Players|Unknown status|Recruiting||800||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.169839|2018-06-01 04:38:08.169839
NCT00174018|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-06|2005-09-13|2005-09-15|Estimate|||||||2005-12-06|2005-12-07|Estimate|September 1993||1993-09-30|August 1993|1993-08-31||||||||Observational|||Validity and Reliability in Measuring the Subacromial Space by Using Ultrasound|Validity and Reliability in Measuring the Subacromial Space by Using Ultrasound|Completed|||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.220456|2018-06-01 04:38:08.220456
NCT00174005|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-06-05|2005-09-13|2005-09-15|Estimate|||||||2007-06-05|2007-06-06|Estimate|December 1994||1994-12-31|December 1994|1994-12-31||||||||Observational|||Validity and Reliability in Measuring Biceps and Triceps by Using Ultrasound|Validity and Reliability in Measuring Tendon and Muscular Morphologic Characteristics of Biceps and Triceps by Using Ultrasound|Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.280126|2018-06-01 04:38:08.280126
NCT00173953|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|January 2001||2001-01-31|December 2000|2000-12-31|October 2001||2001-10-31|||||Interventional|||Lymphocytic Subsets and Cytokine Production With H. Pylori Infection|Lymphocytic Subsets and Cytokine Production in the Gastric Samples of Patients With Helicobacter Pylori Infection|Completed||N/A|50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.526498|2018-06-01 04:38:08.526498
NCT00173940|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-27|2005-09-13|2005-09-15|Estimate|||||||2007-11-27|2007-11-28|Estimate||||July 2002|2002-07-31||||||||Observational|||Collection of Blood and Urine Specimens From Volunteers Utilizing Health Examination Services||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.595752|2018-06-01 04:38:08.595752
NCT00173927|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-29|2005-09-13|2005-09-15|Estimate|||||||2007-10-29|2007-10-30|Estimate|March 2004||2004-03-31|September 2005|2005-09-30||||||||Observational|||Images in Extracranial Artery Stenosis|The Differences in Images of Vertebral Artery Stenosis and Carotid Artery Stenosis Pre- and Post-Percutaneous Transluminal Angioplasty and the Gene Expression Patterns in Peripheral White Blood Cells|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.652901|2018-06-01 04:38:08.652901
NCT00173914|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|March 2003||2003-03-31|September 2005|2005-09-30||||||||Observational|||The Association of Endothelial Dysfunction and Cardiac Allograft Vasculopathy||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.720763|2018-06-01 04:38:08.720763
NCT00173901|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|March 2001||2001-03-31|January 2001|2001-01-31|April 2002||2002-04-30|||||Interventional|||Adverse Drug Reactions of Different Brands of Ceftazidime Injection|Adverse Drug Reactions of Different Brands of Ceftazidime Injection|Unknown status|Active, not recruiting|Phase 4|536||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:08.769616|2018-06-01 04:38:08.769616
NCT00173888|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-12-04|2005-09-13|2005-09-15|Estimate|||||||2012-12-04|2012-12-06|Estimate|July 2003||2003-07-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer|Completed||Phase 2|15|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 04:38:08.830558|2018-06-01 04:38:08.830558
NCT00173875|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-27|2005-09-13|2005-09-15|Estimate|||||||2007-07-27|2007-07-30|Estimate|March 2005||2005-03-31|July 2005|2005-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer|A Phase II Study to Evaluate the Efficacy and Safety of Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|108|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:38:08.898518|2018-06-01 04:38:08.898518
NCT00173862|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-07-23|2005-09-13|2005-09-15|Estimate|||||||2007-07-23|2007-07-25|Estimate|May 2000||2000-05-31|June 2005|2005-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC|A Phase II Study of Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced Transitional Cell Carcinoma|Completed||Phase 2|18|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:38:08.958895|2018-06-01 04:38:08.958895
NCT00173849|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|January 2006||2006-01-31|June 2005|2005-06-30|July 2006||2006-07-31|||||Observational|||The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma||Unknown status|Not yet recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.027387|2018-06-01 04:38:09.027387
NCT00173836|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-09-04|2005-09-13|2005-09-15|Estimate|||||||2009-09-04|2009-09-09|Estimate|August 2003||2003-08-31|August 2009|2009-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount|Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount|Completed|||122|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 04:38:09.078875|2018-06-01 04:38:09.078875
NCT00173823|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-03-10|2005-09-13|2005-09-15|Estimate|||||||2006-03-10|2006-03-13|Estimate|June 2004||2004-06-30|August 2005|2005-08-31||||||||Observational|||Malnutrition and Inflammation in Dialysis Patients in Taiwan|Malnutrition and Inflammation in Taiwan: Prospective Outcome Evaluation Method (MIT-POEM) in Dialysis Patients|Unknown status|Recruiting||1500||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.12998|2018-06-01 04:38:09.12998
NCT00173810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2005||2005-08-31|July 2005|2005-07-31|April 2007||2007-04-30|||||Observational|||Development of a Refined Version of the Stroke Rehabilitation Assessment of Movement Scale for Stroke Patients|Development of a Refined Version of the Stroke Rehabilitation Assessment of Movement Scale for Stroke Patients|Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.180353|2018-06-01 04:38:09.180353
NCT00173797|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2005||2005-08-31|July 2005|2005-07-31|April 2008||2008-04-30|||||Observational|||Comparison of Psychometric Properties of Three Depression Measures in Patients With Stroke|Comparison of Psychometric Properties of Three Depression Measures in Patients With Stroke|Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.258629|2018-06-01 04:38:09.258629
NCT00173784|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2005||2005-08-31|July 2005|2005-07-31|April 2008||2008-04-30|||||Observational|||Development of an Instrumental Activities of Daily Living Scale|Development of an Instrumental Activities of Daily Living Scale for Patients|Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.317101|2018-06-01 04:38:09.317101
NCT00173771|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|August 2004||2004-08-31|August 2005|2005-08-31|May 2007||2007-05-31|||||Observational|||Development of a Comprehensive ADL Scale for Stroke Patients|Development of a Comprehensive ADL Scale for Stroke Patients|Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.372973|2018-06-01 04:38:09.372973
NCT00173758|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-12-20|2005-09-13|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|September 2005||2005-09-30|June 2005|2005-06-30||||||||Interventional|||The Expression of IL-15 and Its Receptor in Decidua|The Expression of IL-15 and Its Receptor in Uterine NK Cells and Clinical Applications|Unknown status|Recruiting|N/A|30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.428109|2018-06-01 04:38:09.428109
NCT00173745|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|June 2003||2003-06-30|July 2002|2002-07-31|September 2005||2005-09-30|||||Interventional|||Treatment of Drooling With Type A Botulinum Toxin in Children With Cerebral Palsy|Treatment of Drooling With Type A Botulinum Toxin A in Children With Cerebral Palsy|Unknown status|Recruiting|N/A|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.486945|2018-06-01 04:38:09.486945
NCT00173732|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|September 2005||2005-09-30|June 2005|2005-06-30||||||||Observational|||Establishment of Comprehensive Genetic Analysis From a Single Cell|Establishment of Comprehensive Genetic Analysis From a Single Cell|Unknown status|Not yet recruiting||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.54808|2018-06-01 04:38:09.54808
NCT00173719|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-08-26|2005-09-12|2005-09-15|Estimate|||||||2013-08-26|2013-08-28|Estimate|September 2003||2003-09-30|January 2013|2013-01-31|July 2004|Actual|2004-07-31|January 2004|Actual|2004-01-31||Interventional|||Influence of Assistive Device Use While Performing Dual Task in Patients With Stroke|Influence of Assistive Device Use on Dynamic Balance and the Associated Attentional Demands During Standing and Walking in Patients With Stroke|Completed||N/A|40|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.679504|2018-06-01 04:38:09.679504
NCT00173706|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-02-28|2005-09-12|2005-09-15|Estimate|||||||2006-02-28|2006-03-01|Estimate|October 2004||2004-10-31|August 2005|2005-08-31||||||||Interventional|||Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis|Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis|Unknown status|Recruiting|Phase 4|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.741092|2018-06-01 04:38:09.741092
NCT00173693|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-06|2005-09-12|2005-09-15|Estimate|||||||2012-12-06|2012-12-10|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|December 2010|Anticipated|2010-12-31|||||Interventional|||What is the Best Policy to Prevent Osteoporotic Fracture?||Withdrawn||N/A|0|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.798724|2018-06-01 04:38:09.798724
NCT00173680|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|August 2005||2005-08-31|August 2005|2005-08-31||||||||Observational|||Methylation Status of CD44 Promoter Region in Primary Lung Cancer||Unknown status|Recruiting||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.852451|2018-06-01 04:38:09.852451
NCT00173667|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate||||July 2005|2005-07-31||||||||Interventional|||A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension|A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension|Unknown status|Not yet recruiting|Phase 4|60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.90541|2018-06-01 04:38:09.90541
NCT00173654|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|August 2006||2006-08-31|||||Observational|||Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency||Unknown status|Recruiting||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:09.954554|2018-06-01 04:38:09.954554
NCT00173641|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|August 2006||2006-08-31|||||Observational|||The Role of Regulatory T Cell in Patients With Type 1 Diabetes Mellitus||Unknown status|Recruiting||150||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.007851|2018-06-01 04:38:10.007851
NCT00173628|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|January 1990||1990-01-31|August 2005|2005-08-31|December 2006||2006-12-31|||||Observational|||Autoantibodies in Patients With Type 1 Diabetes Mellitus||Unknown status|Recruiting||150||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.061689|2018-06-01 04:38:10.061689
NCT00173615|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-16|2005-09-12|2005-09-15|Estimate|||||||2009-01-16|2009-01-19|Estimate|April 1996||1996-04-30|January 2009|2009-01-31|December 2006|Actual|2006-12-31|||||Observational|||Extracorporeal Membrane Oxygenation Effect in Prolonged Cardiopulmonary Resuscitation||Completed|||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.171555|2018-06-01 04:38:10.171555
NCT00173602|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-30|2005-09-12|2005-09-15|Estimate|||||||2007-11-30|2007-12-03|Estimate|September 2005||2005-09-30|August 2005|2005-08-31|August 2007|Anticipated|2007-08-31|||||Observational|||The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients|The Burden of Peripheral Artery Occlusion Disease and Associated Factors in Peritoneal Dialysis Patients|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.23251|2018-06-01 04:38:10.23251
NCT00173589|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||August 2005|2005-08-31||||||||Observational|||Inflammatory and Fibrotic Markers and Atrial Fibrillation||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.307802|2018-06-01 04:38:10.307802
NCT00173576|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-10-26|2005-09-12|2005-09-15|Estimate|||||||2005-10-26|2005-10-27|Estimate|April 2003||2003-04-30|August 2005|2005-08-31|March 2005||2005-03-31|||||Observational|||Clinical Study of SARS in Children|Clinical Study of SARS in Children|Completed|||800||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.361933|2018-06-01 04:38:10.361933
NCT00173563|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-30|2005-09-12|2005-09-15|Estimate|||||||2007-11-30|2007-12-03|Estimate|January 2005||2005-01-31|August 2005|2005-08-31|September 2005|Anticipated|2005-09-30|||||Observational|||Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children|Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children|Unknown status|Recruiting||10|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.414084|2018-06-01 04:38:10.414084
NCT00173550|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-01-22|2005-09-12|2005-09-15|Estimate|||||||2007-01-22|2007-01-23|Estimate|August 2004||2004-08-31|July 2005|2005-07-31||||||||Observational|||Perception and Attitude Toward Estrogen Therapy Among Surgically Menopausal Women|Perception and Attitude Toward Estrogen Therapy Among Operated Women With Premature or Immature Menopause|Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.482512|2018-06-01 04:38:10.482512
NCT00173537|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-26|2005-09-12|2005-09-15|Estimate|||||||2012-12-26|2012-12-27|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|November 2009|Actual|2009-11-30||Interventional|||Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension|Genetic Research of Bone Morphogenetic Protein Receptor-II Gene in Taiwanese Patient With Primary Pulmonary Hypertension|Unknown status|Recruiting|N/A|1|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-06-01 04:38:10.567771|2018-06-01 04:38:10.567771
NCT00173524|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-05-18|2005-09-12|2005-09-15|Estimate|||||||2009-05-18|2009-05-19|Estimate|September 2005||2005-09-30|April 2009|2009-04-30|September 2005|Anticipated|2005-09-30|||||Observational|||PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)|PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) : A Cost-Effectiveness Analysis and Cost-Utility Analysis|Unknown status|Active, not recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.654516|2018-06-01 04:38:10.654516
NCT00173472|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|July 2002||2002-07-31|July 2002|2002-07-31|July 2005||2005-07-31|||||Observational|||Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer|Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer|Unknown status|Active, not recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:10.984007|2018-06-01 04:38:10.984007
NCT00173459|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||July 2004|2004-07-31||||||||Observational|||Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.048296|2018-06-01 04:38:11.048296
NCT00173446|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-06-07|2005-09-12|2005-09-15|Estimate|||||||2007-06-07|2007-06-08|Estimate|January 2002||2002-01-31|August 2005|2005-08-31||||||||Observational|||D2 Dopamine Receptor on Human Aldosterone-Producing Adenoma and Its Role in Aldosterone Secretion and Cell Proliferation|Expression of D2-Like Dopamine Receptor of Human Aldosterone-Producing Adenoma and Its Role in Regulation of Aldosterone Secretion and Cell Proliferation|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.094979|2018-06-01 04:38:11.094979
NCT00173433|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-12-08|2005-09-12|2005-09-15|Estimate|||||||2014-12-08|2014-12-09|Estimate|August 2005||2005-08-31|December 2014|2014-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Exogenous Reinfection of Tuberculosis in Taiwan|The Importance of Exogenous Reinfection in the Tuberculosis Endemic of Taiwan|Completed|||150|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-06-01 04:38:11.162101|2018-06-01 04:38:11.162101
NCT00173420|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-22|2005-09-12|2005-09-15|Estimate|||||||2007-10-22|2007-10-23|Estimate|June 2005||2005-06-30|June 2005|2005-06-30||||||||Observational|||Mechanisms of Neuropathic Pain: Investigation by Contact Heat Evoked Potential|Mechanisms of Neuropathic Pain: Investigation by Contact Heat Evoked Potential|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.227989|2018-06-01 04:38:11.227989
NCT00173407|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-26|2005-09-12|2005-09-15|Estimate|||||||2012-12-26|2012-12-27|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion|Correlation of PTEN and IGFBP-3 in the Invasion of Ovarian Endometrioid Carcinoma|Withdrawn||N/A|0|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 04:38:11.27909|2018-06-01 04:38:11.27909
NCT00173394|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-12-18|2005-09-12|2005-09-15|Estimate|||||||2006-12-18|2006-12-19|Estimate|August 2005||2005-08-31|July 2005|2005-07-31|December 2008||2008-12-31|||||Observational|||The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients||Unknown status|Recruiting||250||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.341957|2018-06-01 04:38:11.341957
NCT00173381|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-29|2005-09-12|2005-09-15|Estimate|||||||2006-03-29|2006-03-30|Estimate|August 2004||2004-08-31|June 2005|2005-06-30||||||||Observational|||The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.396988|2018-06-01 04:38:11.396988
NCT00173368|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2003||2003-01-31|August 2005|2005-08-31|March 2005||2005-03-31|||||Observational|||Study of Endoscopic Sphincterotomy With Needle Knife Papillotome in Patients of Ampullary Impacted Stone||Completed|||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.450845|2018-06-01 04:38:11.450845
NCT00173355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|June 2005||2005-06-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Clinical Outcome of Pediatric Dermatofibrosarcoma Protuberans|Retrospective Clinical Outcome Study of Pediatric Dermatofibrosarcoma Protuberans: Single Institutional Experience of Twelve Cases From 1977-2002|Unknown status|Recruiting||12||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.504632|2018-06-01 04:38:11.504632
NCT00173342|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2005||2005-06-30|June 2005|2005-06-30||||||||Observational|||Congenital or Idiopathic Complete Right Bundle Branch Block: Physiological Significance and Molecular Characterization|Congenital or Idiopathic Complete Right Bundle Branch Block: Physiological Significance and Molecular Characterization|Unknown status|Recruiting||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.575208|2018-06-01 04:38:11.575208
NCT00173329|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-10-20|2005-09-12|2005-09-15|Estimate|||||||2005-10-20|2005-10-21|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|July 2006||2006-07-31|||||Observational|||The Quality of Life of Patients With Severe Illnesses||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.636215|2018-06-01 04:38:11.636215
NCT00173316|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|June 2005||2005-06-30|||||Observational|||Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions|The Role of Vascular Endothelial Growth Factor-C (VEGF-C) and Its Receptors Induced Lymphangiogenesis on the Carcinogenesis of Oral Cancers and Premalignant Lesions|Unknown status|Recruiting||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.77467|2018-06-01 04:38:11.77467
NCT00173303|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2006||2006-01-31|June 2005|2005-06-30|January 2008||2008-01-31|||||Observational|||The Diagnostic Efficacy of Computer-Aided Detection (CAD) in Full-Field Digital Mammography (FFDM)- A Prospective Study||Unknown status|Not yet recruiting||3000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.839818|2018-06-01 04:38:11.839818
NCT00173290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-02|2005-09-12|2005-09-15|Estimate|||||||2008-06-02|2008-06-03|Estimate|July 2004||2004-07-31|June 2005|2005-06-30|December 2006|Anticipated|2006-12-31|||||Observational|||Cytokine Regulation of Natural Killer Receptors in Inhibiting Activated T Cell Function||Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.899235|2018-06-01 04:38:11.899235
NCT00173277|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2003||2003-06-30|June 2005|2005-06-30|July 2004||2004-07-31|||||Observational|||Screening for CRC Using a Mixed Strategy of Sigmoidoscopy and Colonoscopy in Average-Risk Population According to Age|Screening for CRC Using a Mixed Strategy of Sigmoidoscopy and Colonoscopy in Average-Risk Population According to Age|Unknown status|Recruiting||2500||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:11.954858|2018-06-01 04:38:11.954858
NCT00173264|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2005||2005-06-30|May 2005|2005-05-31|June 2005||2005-06-30|||||Observational|||Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis||Unknown status|Recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.010286|2018-06-01 04:38:12.010286
NCT00173251|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2006||2006-01-31|June 2005|2005-06-30|August 2006||2006-08-31|||||Interventional|||The Difference in Presentation Level of Variant Receptors in Female Breast Tissue in Macromastia and Micromastia||Unknown status|Not yet recruiting|Phase 1|60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.057873|2018-06-01 04:38:12.057873
NCT00173225|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Sputum and Plasma Levels of Nociceptin and Substance P in Patients With Asthma, COPD and Chronic Cough|Association Between Sputum and Plasma Levels of Nociceptin and Substance P With Cough Severity and Airway Hyperreactivity in Patients With Asthma, COPD and Chronic Cough|Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.152617|2018-06-01 04:38:12.152617
NCT00173212|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|September 2005||2005-09-30|May 2005|2005-05-31|March 2006||2006-03-31|||||Observational|||Proliferation of Endometrial Stromal Cells in Adenomyosis||Unknown status|Active, not recruiting||45||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.212594|2018-06-01 04:38:12.212594
NCT00173199|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-29|2005-09-12|2005-09-15|Estimate|||||||2005-11-29|2005-12-01|Estimate|June 2005||2005-06-30|June 2005|2005-06-30||||||||Observational|||The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation|The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation|Unknown status|Recruiting||150||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.259706|2018-06-01 04:38:12.259706
NCT00173186|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 1987||1987-01-31|June 2005|2005-06-30|February 2005||2005-02-28|||||Observational|||Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect|Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect|Unknown status|Recruiting||411||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.308002|2018-06-01 04:38:12.308002
NCT00173173|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2003||2003-08-31|August 2003|2003-08-31|July 2004||2004-07-31|||||Observational|||Epidemiological Studies of Eating Disorders in Gifted Dance Students(1st Year)|Epidemiological Studies of Eating Disorders in Gifted Dance Students and Ordinary High School Students:Prevalence Rate, Risk Factors and 1-Year Outcome (1st Year).|Completed|||2200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.364924|2018-06-01 04:38:12.364924
NCT00173160|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|July 2005||2005-07-31|||||Observational|||Epidemiological Studies of Eating Disorders in Gifted Dance Students (2nd Year).|Epidemiological Studies of Eating Disorders in Gifted Dance Students: Prevalence Rate, Risk Factors and 1-Year Outcome (2nd Year).|Completed|||700||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.431863|2018-06-01 04:38:12.431863
NCT00173147|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-24|2005-09-12|2005-09-15|Estimate|||||||2008-10-24|2008-10-27|Estimate|May 2005||2005-05-31|April 2005|2005-04-30||||||||Observational|||Morphology of the VMO in Patients With PFPS and Healthy Young Adults--A Sonographic Study|Morphology of the Vastus Medialis Obliquus in Patients With Patellofemoral Pain Syndrome and Healthy Young Adults --A Sonographic Study|Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.495024|2018-06-01 04:38:12.495024
NCT00173134|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|May 2005||2005-05-31|June 2005|2005-06-30|March 2006||2006-03-31|||||Observational|||The Prevalence of Erectile Dysfunction (ED) and ED Related Quality of Life of Diabetic Men|Investigating the Prevalence of Erectile Dysfunction and Erectile Dysfunction Related Quality of Life of Diabetic Men in Taiwan|Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.53512|2018-06-01 04:38:12.53512
NCT00173121|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|May 2005||2005-05-31|April 2005|2005-04-30|June 2005||2005-06-30|||||Observational|||Environmental Enterovirus Monitoring|Environmental Enterovirus Monitoring|Unknown status|Recruiting||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:12.582556|2018-06-01 04:38:12.582556
NCT00173108|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-21|2005-09-12|2005-09-15|Estimate|||||||2011-04-21|2011-04-22|Estimate|January 2006||2006-01-31|March 2011|2011-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Early Intervention for Preterm Infants|Early Intervention for Preterm Infants|Completed||N/A|240|Actual|National Taiwan University Hospital||4|||f||||f||||||||||2018-06-01 04:38:12.65581|2018-06-01 04:38:12.65581
NCT00173095|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|January 2008||2008-01-31|||||Observational|||The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients|The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients|Unknown status|Recruiting||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:13.68957|2018-06-01 04:38:13.68957
NCT00173082|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-28|2005-09-12|2005-09-15|Estimate|||||||2007-11-28|2007-11-29|Estimate|June 2005||2005-06-30|November 2007|2007-11-30|July 2008|Anticipated|2008-07-31|||||Observational|||Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism|Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:13.741069|2018-06-01 04:38:13.741069
NCT00173069|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|January 2006||2006-01-31|July 2005|2005-07-31|December 2010||2010-12-31|||||Observational|||A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)|A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)|Unknown status|Not yet recruiting||324||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:13.807278|2018-06-01 04:38:13.807278
NCT00173056|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-11-23|2005-09-12|2005-09-15|Estimate|||||||2007-11-23|2007-11-26|Estimate||||December 2004|2004-12-31||||||||Observational|||The Factors Predicting Change of Peritoneal Transport Characters in Peritoneal Dialysate||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:13.864168|2018-06-01 04:38:13.864168
NCT00173043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|October 2004||2004-10-31|October 2004|2004-10-31|August 2005||2005-08-31|||||Observational|||The Role of Insulin Resistance in PCOS|The Role of Insulin Resistance and Adiponectin in the Pathogenesis of Polycystic Ovary Syndrome|Unknown status|Recruiting||500||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:13.918735|2018-06-01 04:38:13.918735
NCT00173030|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||April 2004|2004-04-30||||||||Observational|||Genetic Study of Atrial Fibrillation: Focusing on Renin-Angiotensin System and C-Reactive Protein Genes||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:13.983146|2018-06-01 04:38:13.983146
NCT00173017|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2003||2003-08-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||The Physiological Impact of N95 Masks on Medical Staff|The Physiological Impact of N95 Masks on Medical Staff|Completed||N/A|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.040976|2018-06-01 04:38:14.040976
NCT00173004|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||February 2003|2003-02-28||||||||Observational|||Angiotensinogen Gene and Hypertension||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.098325|2018-06-01 04:38:14.098325
NCT00172939|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-14|2005-09-14|2005-09-15|Estimate|||||||2005-09-14|2005-09-15|Estimate|June 2005||2005-06-30|March 2005|2005-03-31|January 2008||2008-01-31|||||Interventional|||Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model|Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model|Unknown status|Recruiting|Phase 1|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.485074|2018-06-01 04:38:14.485074
NCT00172926|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|May 2005||2005-05-31|June 2005|2005-06-30|April 2007||2007-04-30|||||Observational|||Study on the Relationship Between Physical Constitution and Diseases|Cross Sectional Study on Relationship Between Physical Constitution and Diseases in the Integrative Chinese Medicine and Western Medicine|Unknown status|Recruiting||1000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.557382|2018-06-01 04:38:14.557382
NCT00172913|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|July 2008||2008-07-31|||||Observational|||Aberration-Free Refraction Correction|National Taiwan University Hospital|Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.685602|2018-06-01 04:38:14.685602
NCT00172900|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|June 2005||2005-06-30|June 2005|2005-06-30||||||||Observational|||MRS and DTI of White Matter in Alzheimer's Disease|MR Spectroscopy and Diffusion Tensor Imaging of White Matter in Alzheimer's Disease|Unknown status|Recruiting||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.748572|2018-06-01 04:38:14.748572
NCT00172887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-22|2005-09-12|2005-09-15|Estimate|||||||2007-10-22|2007-10-23|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|July 2005||2005-07-31|||||Observational|||Needs Assessment of Long-Term Care for Psychiatric Patients||Unknown status|Recruiting||1150|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.805806|2018-06-01 04:38:14.805806
NCT00172874|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-12-29|2005-09-12|2005-09-15|Estimate|||||||2008-12-29|2008-12-31|Estimate|January 1998||1998-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Observational|||Cross-Cultural Validity of EDI-1 Among Clinical and Non-Clinical Taiwanese Population|Cross-Cultural Validity of EDI-1 Among Clinical and Non-Clinical Taiwanese Population|Completed|||1500|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 04:38:14.864744|2018-06-01 04:38:14.864744
NCT00172861|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2005||2005-01-31|March 2005|2005-03-31||||||||Observational|||Cyclooxygenase-2-Associated Factors and Gastric Carcinogenesis Mechanisms-Clinical Association and Genomic Investigation||Unknown status|Recruiting||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.913862|2018-06-01 04:38:14.913862
NCT00172848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|October 2004||2004-10-31|July 2005|2005-07-31|April 2005||2005-04-30|||||Observational|||Mastery, Social Support and Depression of Patients With Major Depression||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:14.964703|2018-06-01 04:38:14.964703
NCT00172835|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|March 2005||2005-03-31|March 2005|2005-03-31||||||||Observational|||Use of Procalcitonin in the Diagnosis of Pleural Effusion|Evaluation of Procalcitonin as a Diagnostic Tool for Patients With Pleural Effusion|Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.004932|2018-06-01 04:38:15.004932
NCT00172822|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2003||2003-01-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Appendicitis With Medical Treatment||Unknown status|Recruiting||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.054631|2018-06-01 04:38:15.054631
NCT00172809|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-05|2005-09-12|2005-09-15|Estimate|||||||2008-03-05|2008-03-06|Estimate|July 2005||2005-07-31|June 2007|2007-06-30|January 2007|Actual|2007-01-31|June 2006|Actual|2006-06-30||Interventional|||Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease|A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C|Completed||Phase 4|50|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 04:38:15.106762|2018-06-01 04:38:15.106762
NCT00172796|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-29|2005-09-12|2005-09-15|Estimate|||||||2006-03-29|2006-03-30|Estimate|April 2005||2005-04-30|April 2005|2005-04-30||||||||Observational|||Pancreatic Islet Function, Insulin Sensitivity, and Chronic Complications in Pre-Diabetes||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.182678|2018-06-01 04:38:15.182678
NCT00172783|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|December 2005||2005-12-31|||||Observational|||PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period|PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period|Unknown status|Recruiting||460||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.323383|2018-06-01 04:38:15.323383
NCT00172770|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|July 2006||2006-07-31|||||Observational|||The Establishment of the Early Intervention Program for Patients With Schizophrenia||Unknown status|Recruiting||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.389952|2018-06-01 04:38:15.389952
NCT00172757|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-25|2005-09-12|2005-09-15|Estimate|||||||2005-11-25|2005-11-28|Estimate|January 2002||2002-01-31|January 2003|2003-01-31|June 2005||2005-06-30|||||Observational|||Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan|Risk Factors of Colorectal Cancer in Taiwan-With Special Reference to the Association With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations|Unknown status|Recruiting||1000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.452797|2018-06-01 04:38:15.452797
NCT00172744|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-10|2005-09-12|2005-09-15|Estimate|||||||2007-10-10|2007-10-11|Estimate|April 2005||2005-04-30|March 2005|2005-03-31|July 2006||2006-07-31|||||Observational|||Effect of Cyclic Tensional Force on Osteogenic Differentiation of Human Periodontal Ligament Stem Cells||Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.519393|2018-06-01 04:38:15.519393
NCT00172731|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate|March 2005||2005-03-31|February 2005|2005-02-28|June 2005||2005-06-30|||||Observational|||Measurement of Activity Participation for Persons With Schizophrenia Living in the Community||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.581446|2018-06-01 04:38:15.581446
NCT00172718|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-05|2005-09-12|2005-09-15|Estimate|||||||2008-06-05|2008-06-06|Estimate|March 2005||2005-03-31|February 2005|2005-02-28||||||||Observational|||Using 3.3mm Screw Tap and Cutting Resistance to Evaluate Bone Quality Around Dental Implant|Using 3.3mm Screw Tap to Modify the Standard Implantation Procedure and to Measure the Cutting Resistance for Establishing a More Objective Method to Evaluate the Peri-Implant Bone Quality|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.633626|2018-06-01 04:38:15.633626
NCT00172705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|September 2004||2004-09-30|February 2005|2005-02-28|February 2005||2005-02-28|||||Observational|||Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique|Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique|Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.696101|2018-06-01 04:38:15.696101
NCT00172692|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-12-14|2005-09-12|2005-09-15|Estimate|||||||2006-12-14|2006-12-15|Estimate|July 2004||2004-07-31|June 2005|2005-06-30|August 2004||2004-08-31|||||Observational|||Observation and Evaluation of Chewing Velocity Changes on Soft Food Chewing Efficiency||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.752842|2018-06-01 04:38:15.752842
NCT00172679|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-26|2005-09-12|2005-09-15|Estimate|||||||2007-09-26|2007-09-27|Estimate|July 2005||2005-07-31|December 2004|2004-12-31|June 2006||2006-06-30|||||Observational|||Effects of Tai Chi Exercise on Innate and Adaptive Immune Function||Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.806714|2018-06-01 04:38:15.806714
NCT00172666|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-29|2005-09-12|2005-09-15|Estimate|||||||2006-03-29|2006-03-30|Estimate|August 2005||2005-08-31|December 2004|2004-12-31|July 2006||2006-07-31|||||Observational|||Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)|Investigating Genetic Polymorphism of Decoy Receptor 3 (DcR3) Gene in Rheumatoid Arthritis and Systemic Lupus Erythematosus|Unknown status|Recruiting||450||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.86685|2018-06-01 04:38:15.86685
NCT00172653|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-15|2005-09-12|2005-09-15|Estimate|||||||2007-10-15|2007-10-16|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|July 2006||2006-07-31|||||Observational|||Function-Related Tests for Subjects With Stiff Shoulders: Reliability and Validity|Assessment of Function-Related Tests for Subjects With Stiff Shoulders: Reliability, Validity, Clinical Usefulness, and Biomechanical Analysis|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.928245|2018-06-01 04:38:15.928245
NCT00172640|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2005||2005-01-31|December 2004|2004-12-31||||||||Observational|||Genetic Studies in Liver Cancer Patients|Identification of Differentially Expressed Genes in Hepatocellular Carcinoma With DNA Microarrays|Unknown status|Recruiting||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:15.992223|2018-06-01 04:38:15.992223
NCT00172627|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|January 2005||2005-01-31|December 2004|2004-12-31||||||||Observational|||Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer|Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer|Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.044817|2018-06-01 04:38:16.044817
NCT00172614|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-28|2005-09-12|2005-09-15|Estimate|||||||2006-03-28|2006-03-29|Estimate|December 2004||2004-12-31|December 2004|2004-12-31||||||||Observational|||The Roles of Cytokines in the Mechanism of Insulin Resistance and Energy Balance||Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.104932|2018-06-01 04:38:16.104932
NCT00172601|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|August 2005||2005-08-31|December 2004|2004-12-31||||||||Interventional|||Mobilization Techniques in Patients With Frozen Shoulder: a Randomized Multiple-Treatment Trial||Unknown status|Recruiting|N/A|30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.163739|2018-06-01 04:38:16.163739
NCT00172588|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-25|2005-09-12|2005-09-15|Estimate|||||||2005-11-25|2005-11-28|Estimate|January 2005||2005-01-31|December 2004|2004-12-31|October 2005||2005-10-31|||||Observational|||Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis||Unknown status|Recruiting||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.223521|2018-06-01 04:38:16.223521
NCT00172575|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|December 2004||2004-12-31|December 2004|2004-12-31|December 2006||2006-12-31|||||Observational|||Differentiation of Malig. & Ben. Solitary Pulm. Nodules & Prediction of Clin. Outcome Using Perfus. Analysis of DCEMRI||Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.275516|2018-06-01 04:38:16.275516
NCT00172562|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-02-28|2005-09-12|2005-09-15|Estimate|||||||2006-02-28|2006-03-01|Estimate||||August 2005|2005-08-31||||||||Observational|||Bone Marrow Angiogenesis in Acute Myeloid Leukemia - Evaluated by Dynamic Contrast Enhanced Magnetic Resonance (MR) Image||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.330467|2018-06-01 04:38:16.330467
NCT00172549|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|March 2004||2004-03-31|July 2005|2005-07-31|October 2004||2004-10-31|||||Observational|||Quality of Life and Its Related Factors of Patients With Major Depressive Disorder||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.376509|2018-06-01 04:38:16.376509
NCT00172536|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-21|2005-09-12|2005-09-15|Estimate|||||||2011-04-21|2011-04-22|Estimate|October 2004||2004-10-31|March 2011|2011-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft|Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft|Completed||N/A|65|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 04:38:16.415576|2018-06-01 04:38:16.415576
NCT00172523|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|October 2004||2004-10-31|October 2004|2004-10-31|August 2005||2005-08-31|||||Observational|||Metabolic Disorders in Polycystic Ovarian Syndrome||Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.486112|2018-06-01 04:38:16.486112
NCT00172510|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|August 2005||2005-08-31|||||Observational|||Mutation Analysis of 17α-Hydroxylase||Unknown status|Recruiting||25||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.557004|2018-06-01 04:38:16.557004
NCT00172497|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2001||2001-08-31|August 2001|2001-08-31|October 2005||2005-10-31|||||Observational|||Aggressive Acts Among Patients With Schizophrenia|A Study of the Aggressive Acts Among Patients With Schizophrenia|Suspended|||450||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.608485|2018-06-01 04:38:16.608485
NCT00172484|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-11-15|2005-09-12|2005-09-15|Estimate|||||||2012-11-15|2012-11-16|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||North Taiwan Stroke Center for Prevention and Treatment|North Taiwan Stroke Center for Prevention and Treatment|Completed||Phase 3|250|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.657097|2018-06-01 04:38:16.657097
NCT00172471|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-15|Estimate|||||||2005-12-20|2005-12-21|Estimate||||December 2004|2004-12-31||||||||Observational|||The Relationship Between Sleep Disorders and Cytokine Levels Among Hemodialysis and Peritoneal Dialysis Patients||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.804597|2018-06-01 04:38:16.804597
NCT00172458|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-14|2005-09-14|2005-09-15|Estimate|||||||2005-09-14|2005-09-15|Estimate||||August 2005|2005-08-31||||||||Observational|||Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents|Clinical Results and Restenosis Analysis of Symptomatic Ostial Vertebral Artery Stenosis Treated With Tubular Coronary Stents|Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.864198|2018-06-01 04:38:16.864198
NCT00172445|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-06|2005-09-14|2005-09-15|Estimate|||||||2012-12-06|2012-12-10|Estimate||||June 2004|2004-06-30||||||||Interventional|||Clinical Studies of Kikuchi's Disease||Withdrawn||N/A|0|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.920149|2018-06-01 04:38:16.920149
NCT00172432|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||August 2005|2005-08-31||||||||Observational|||Aminoterminal Propeptide of Type III Procollagen and Severity of Coronary Artery Disease in Patients Without Myocardial Infarction||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:16.970841|2018-06-01 04:38:16.970841
NCT00172419|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-01-02|2005-09-12|2005-09-15|Estimate|||||||2009-01-02|2009-01-05|Estimate|March 2007||2007-03-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.|Statin-Induced Vulnerable Plaque Regression After Atorvastatin Treatment: Serial Evaluation by 18F-Fluorodeoxyglucose Positron Emission Tomography Study|Completed||N/A|43|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:38:17.162196|2018-06-01 04:38:17.162196
NCT00172406|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||August 2005|2005-08-31||||||||Observational|||The Relation Between Serum Level of Amioterminal Propeptide of Type I Procollagen and Diastolic Dysfunction in Hypertensive Patients Without Diabetes Mellitus||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.240032|2018-06-01 04:38:17.240032
NCT00172393|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-03|2005-09-14|2005-09-15|Estimate|||||||2006-10-03|2006-10-04|Estimate|January 2003||2003-01-31|June 2005|2005-06-30|May 2005||2005-05-31|||||Observational|||Long Term Outcomes of EV71 CNS Infection|Long Term Outcomes of EV71 Central Nervous System Infection|Unknown status|Recruiting||150||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.287871|2018-06-01 04:38:17.287871
NCT00172380|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-19|2005-09-12|2005-09-15|Estimate|||||||2012-12-19|2012-12-20|Estimate|February 2005||2005-02-28|December 2012|2012-12-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III|Phase II Study Evaluating Docetaxel and CDDP as Neoadjuvant Chemotherapy Prior to Surgery, Followed by Adjuvant Docetaxel Plus CDDP in Chemonaive Patients With NSCLC Stage III|Completed||Phase 2|41|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:38:17.355058|2018-06-01 04:38:17.355058
NCT00172367|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-25|2005-09-12|2005-09-15|Estimate|||||||2008-09-25|2008-09-26|Estimate|January 2006||2006-01-31|November 2004|2004-11-30||||||||Interventional|||Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma||Withdrawn||Phase 2|80|Anticipated|National Taiwan University Hospital||||"This study was for National Science Council project. The study was not funded, so the study was~   withdrawn."|f||||||||||||||2018-06-01 04:38:17.419641|2018-06-01 04:38:17.419641
NCT00172354|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-11-30|2005-09-12|2005-09-15|Estimate|||||||2012-11-30|2012-12-03|Estimate|October 2004||2004-10-31|November 2012|2012-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Hydrocortisone in Patients of Out-of-hospital Cardiac Arrest|Hydrocortisone in Patients of Out-of-hospital Cardiac Arrest|Completed||N/A|100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.485662|2018-06-01 04:38:17.485662
NCT00172341|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-02|2005-09-12|2005-09-15|Estimate|||||||2005-11-02|2005-11-03|Estimate||||July 2004|2004-07-31||||||||Interventional|||Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children|Efficacy and Safety of Sublingual Immunotherapy With House Dust Mite Extract in Asthmatic Children: A Double-Blind, Randomized, and Placebo-Controlled Study|Unknown status|Not yet recruiting|Phase 4|100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.538156|2018-06-01 04:38:17.538156
NCT00172328|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||September 2004|2004-09-30||||||||Interventional|||Antibody Response and Immune Memory 15-18 Years After HBV Vaccination||Unknown status|Recruiting|N/A|||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.583812|2018-06-01 04:38:17.583812
NCT00172315|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-03-28|2005-09-12|2005-09-15|Estimate|||||||2006-03-28|2006-03-29|Estimate|December 2003||2003-12-31|August 2005|2005-08-31||||||||Observational|||Proton Magnetic Resonance Spectroscopy (1H MRS) in Evaluating the Bone Marrow, Muscle and Adipose Tissue on Normal and Human Immunodeficiency Virus Infected Subjects|Proton Magnetic Resonance Spectroscopy (1H MRS) in Evaluating the Bone Marrow, Muscle and Adipose Tissue on Normal and Human Immunodeficiency Virus Infected Subjects, With Serial Follow-Up|Unknown status|Recruiting||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.64834|2018-06-01 04:38:17.64834
NCT00172302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|November 2005||2005-11-30|May 2005|2005-05-31||||||||Interventional|||Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?|Can Intravenous Vitamin C Improve Skin Hyperpigmentation in Long-Term Hemodialysis Patients?|Unknown status|Not yet recruiting|N/A|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.700839|2018-06-01 04:38:17.700839
NCT00172289|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-01-06|2005-09-12|2005-09-15|Estimate|||||||2006-01-06|2006-01-09|Estimate|August 2004||2004-08-31|December 2004|2004-12-31|December 2006||2006-12-31|||||Observational|||Measurement of Pulse Wave Velocity in Spinal Cord Injury and Stroke Patients|Measurement of Pulse Wave Velocity in Spinal Cord Injury and Stroke Patients|Unknown status|Recruiting||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.76707|2018-06-01 04:38:17.76707
NCT00172276|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-14|2005-09-14|2005-09-15|Estimate|||||||2005-09-14|2005-09-15|Estimate||||June 2005|2005-06-30||||||||Observational|||Angiotensin Converting Enzyme Gene Polymorphism in Children With Idiopathic Nephrotic Syndrome||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.83986|2018-06-01 04:38:17.83986
NCT00172263|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-06|2005-09-14|2005-09-15|Estimate|||||||2012-12-06|2012-12-10|Estimate||||December 2012|2012-12-31||||||||Interventional|||The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes||Withdrawn||N/A|0|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.877509|2018-06-01 04:38:17.877509
NCT00172250|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-15|Estimate|||||||2005-11-23|2005-11-24|Estimate|September 2003||2003-09-30|August 2005|2005-08-31||||||||Observational|||The Study of Relationship of Plasma Concentrations of Folic Acid, Vitamin B and Homocysteine With Carotid Atherosclerosis and Endothelium-Dependent Vasodilatation of Geriatric and Young Patients in the Ambulatory Care Department of NTUH||Completed|||||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:17.92309|2018-06-01 04:38:17.92309
NCT00172237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-28|2005-09-14|2005-09-15|Estimate|||||||2010-01-28|2010-01-29|Estimate|December 2009||2009-12-31|January 2010|2010-01-31|July 2010|Anticipated|2010-07-31|||||Observational|||Proprioception and Eye-head Coordination for the Cervical Spine|Proprioception and Eye-head Coordination for the Cervical Spine|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 04:38:17.964306|2018-06-01 04:38:17.964306
NCT00172224|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-11-13|2005-09-12|2005-09-15|Estimate|||||||2012-11-13|2012-11-14|Estimate|August 2002||2002-08-31|November 2012|2012-11-30||||||||Observational|||Dynamic Magnetic Resonance (MR) Study in Evaluating the Vertebral Bone Marrow Perfusion and Its Related Research|Dynamic MR Study in Evaluating the Vertebral Bone Marrow Perfusion and Its Related Research|Completed|||100|Actual|National Taiwan University Hospital|||1||f||||t||||||||||2018-06-01 04:38:18.032782|2018-06-01 04:38:18.032782
NCT00172211|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-04|2005-09-12|2005-09-15|Estimate|||||||2008-05-04|2008-05-07|Estimate|September 2005||2005-09-30|January 2007|2007-01-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Comparison of Oxidative Stress and Insulin Resistance Before and After Using Physioneal in Peritoneal Dialysis Patients|Comparison of Oxidative Stress and Insulin Resistance Before and After Using Physioneal in Peritoneal Dialysis Patients|Completed||N/A|30|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:18.08636|2018-06-01 04:38:18.08636
NCT00172198|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|March 2005||2005-03-31|January 2005|2005-01-31|March 2007||2007-03-31|||||Interventional|||Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.|A Prospective, Controlled, Randomized, Study Evaluating the Clinical Efficacy, Including Nutritional Status, Immune Function and Safety of Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.|Unknown status|Recruiting|Phase 4|30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:18.144805|2018-06-01 04:38:18.144805
NCT00172185|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-03-12||2015-11-10|2005-09-13|2005-09-15|Estimate|2013-03-12|2013-04-23|Estimate||||2015-11-10|2015-12-08|Estimate|January 2005||2005-01-31|September 2014|2014-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)|A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)|Completed||Phase 3|65|Actual|Shire||2|||f||||t||||||||||2018-06-01 04:38:18.231039|2018-06-01 04:38:18.231039
NCT00172172|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-11-11|2005-09-13|2005-09-15|Estimate|||||||2015-11-11|2015-11-13|Estimate|February 2004||2004-02-29|August 2008|2008-08-31|April 2005|Actual|2005-04-30|March 2005|Actual|2005-03-31||Interventional|CAP||Calcium Supplementation in Postmenopausal Women|A Study to Evaluate the Effects of Calcium Supplementation on the Efficacy and Safety of Recombinant Human Parathyroid Hormone (ALX1-11) in Postmenopausal Women With Osteoporosis (CAP Study)|Completed||Phase 3|374|Actual|Shire||3|||t||||f||||||||||2018-06-01 04:38:18.921538|2018-06-01 04:38:18.921538
NCT00172159|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-06-22|2005-09-12|2005-09-15|Estimate|||||||2010-06-22|2010-06-23|Estimate|January 2000||2000-01-31|January 2000|2000-01-31|June 2005|Anticipated|2005-06-30|||||Interventional|||Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers|Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers|Unknown status|Recruiting|Phase 2|100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:19.0601|2018-06-01 04:38:19.0601
NCT00172146|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|July 2003||2003-07-31|||||Observational|||Influences of Cane Use on Voluntary Forward Stepping Movement and Associated Attentional Demands in Hemiplegic Patients|Influences of Cane Use on Voluntary Forward Stepping Movement and Associated Attentional Demands in Hemiplegic Patients|Unknown status|Active, not recruiting||22||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:38:19.138721|2018-06-01 04:38:19.138721
NCT00172133|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-11-11|2005-09-12|2005-09-15|Estimate|||||||2015-11-11|2015-11-13|Estimate|October 2001||2001-10-31|August 2008|2008-08-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|OLES||Open Label Extension Study of PREOS|An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)|Completed||Phase 3|1683|Actual|Shire||1|||t||||t||||||||||2018-06-01 04:38:19.229517|2018-06-01 04:38:19.229517
NCT00172120|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-11-11|2005-09-12|2005-09-15|Estimate|||||||2015-11-11|2015-11-13|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|TRES||Open Label Extension|An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)|Completed||Phase 3|91|Actual|Shire|||||f||||f||||||||||2018-06-01 04:38:19.506126|2018-06-01 04:38:19.506126
NCT00172107|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-11-11|2005-09-12|2005-09-15|Estimate|||||||2015-11-11|2015-11-13|Estimate|May 1995||1995-05-31|September 2005|2005-09-30|March 1997|Actual|1997-03-31|March 1997|Actual|1997-03-31||Interventional|||A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis|A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis|Completed||Phase 2|217|Actual|Shire||4|||f||||f||||||||||2018-06-01 04:38:19.587315|2018-06-01 04:38:19.587315
NCT00172094|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-11-11|2005-09-09|2005-09-15|Estimate|||||||2015-11-11|2015-11-13|Estimate|December 2003||2003-12-31|September 2005|2005-09-30|July 2004|Actual|2004-07-31|June 2004|Actual|2004-06-30||Interventional|||Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches|A Phase 2 Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches|Completed||Phase 2|189|Actual|Shire||3|||f||||f||||||||||2018-06-01 04:38:19.698053|2018-06-01 04:38:19.698053
NCT00172081|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-11-10|2005-09-09|2005-09-15|Estimate|||||||2015-11-10|2015-11-13|Estimate|April 2000||2000-04-30|September 2005|2005-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis|An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis|Completed||Phase 3|2532|Actual|Shire||2|||f||||t||||||||||2018-06-01 04:38:19.855092|2018-06-01 04:38:19.855092
NCT00172068|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-12-21|2005-09-13|2005-09-15|Estimate|||||||2009-12-21|2009-12-23|Estimate|January 2002||2002-01-31|December 2009|2009-12-31||||November 2008|Actual|2008-11-30||Interventional|MRD-1||Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow|Efficacy and Tolerability of Intravenous Zometa® (Zoledronic Acid) 4 mg in Primary Breast Cancer Patients With Disseminated Tumor Cells in Bone Marrow. A Prospective, Randomized, Parallel Group, Open-label, Clinical Pilot Study.|Terminated||Phase 2|96|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:38:20.11551|2018-06-01 04:38:20.11551
NCT00172055|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-03-02|2005-09-13|2005-09-15|Estimate|||||||2017-03-02|2017-03-06|Actual|December 2004||2004-12-31|March 2017|2017-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy|Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy|Completed||Phase 3|218|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:20.286171|2018-06-01 04:38:20.286171
NCT00172042|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-06-16||2015-04-13|2005-09-13|2005-09-15|Estimate|2011-06-16|2011-07-19|Estimate||||2015-04-13|2015-05-04|Estimate|March 2005||2005-03-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)|A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer|Completed||Phase 3|437|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:38:20.427789|2018-06-01 04:38:20.427789
NCT00172029|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-26|2005-09-13|2005-09-15|Estimate|||||||2010-03-26|2010-03-29|Estimate|April 2003||2003-04-30|March 2010|2010-03-31||||September 2005|Actual|2005-09-30||Interventional|||Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid|Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid|Completed||Phase 4|116|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:38:21.303219|2018-06-01 04:38:21.303219
NCT00172016|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-27|2005-09-13|2005-09-15|Estimate|||||||2012-04-27|2012-04-30|Estimate|January 2004||2004-01-31|April 2012|2012-04-30||||April 2005|Actual|2005-04-30||Interventional|||A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates|A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates|Completed||Phase 4|43|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:21.368386|2018-06-01 04:38:21.368386
NCT00172003|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-16|2005-09-13|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2004||2004-09-30|November 2016|2016-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis|Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis|Completed||Phase 4|50|Actual|Novartis||1|||f||||t||||||||||2018-06-01 04:38:21.422365|2018-06-01 04:38:21.422365
NCT00171990|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-08-14|2005-09-14|2005-09-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|January 2003||2003-01-31|August 2013|2013-08-31|February 2006|Actual|2006-02-28|||||Interventional|||Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes|Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes|Completed||Phase 3|1461|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:21.486514|2018-06-01 04:38:21.486514
NCT00171977|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-08-06|2005-09-14|2005-09-15|Estimate|||||||2012-08-06|2012-08-07|Estimate|July 2004||2004-07-31|August 2012|2012-08-31||||April 2009|Actual|2009-04-30||Interventional|||Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)|Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)|Completed||Phase 4|64|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:21.536757|2018-06-01 04:38:21.536757
NCT00171964|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-05-31|2005-09-13|2005-09-15|Estimate|||||||2017-05-31|2017-06-01|Actual|May 2002||2002-05-31|April 2012|2012-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions|Evaluation of the Efficacy and Tolerability of Zoledronic Acid in Combination With Radiotherapy in Patients With Advanced Osteolytic Bone Lesions|Completed||Phase 4|75|Actual|Novartis||1|||f||||t||||||||||2018-06-01 04:38:21.595206|2018-06-01 04:38:21.595206
NCT00171951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-15|2005-09-13|2005-09-15|Estimate|||||||2016-11-15|2016-11-16|Estimate|August 2004||2004-08-31|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease|Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease|Completed||Phase 2|19|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:21.691853|2018-06-01 04:38:21.691853
NCT00171938|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-23|2005-09-13|2005-09-15|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2004|Actual|2004-04-30|November 2009|2009-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)|Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)|Terminated||Phase 2|30|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:21.767281|2018-06-01 04:38:21.767281
NCT00171925|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-01-20||2012-04-05|2005-09-13|2005-09-15|Estimate|2011-03-25|2011-04-20|Estimate||||2012-04-05|2012-04-11|Estimate|August 2000||2000-08-31|April 2012|2012-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I|Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I|Terminated||Phase 3|143|Actual|Novartis|Only exploratory analyses were performed as the trial was terminated early due to lack of obtaining the required sample size. Secondary Outcomes for Quality of Life and Bone Markers not posted due to sparse data.|2||Recruitment in study could not be reached after 8 yrs of recruiting|f||||||||||||||2018-06-01 04:38:21.837808|2018-06-01 04:38:21.837808
NCT00171912|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-21|2005-09-13|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2004||2004-09-30|February 2017|2017-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes|Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes|Completed||Phase 2|38|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:23.166619|2018-06-01 04:38:23.166619
NCT00171899|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-21|2005-09-13|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2005||2005-04-30|February 2017|2017-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)|Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML|Completed||Phase 4|80|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:23.251786|2018-06-01 04:38:23.251786
NCT00171886|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-23|2005-09-13|2005-09-15|Estimate|||||||2017-02-23|2017-02-24|Actual|July 2002||2002-07-31|March 2011|2011-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Octreotide Efficacy and Safety in First-line Acromegalic Patients|Octreotide Efficacy and Safety in First-line Acromegalic Patients|Completed||Phase 4|20|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:23.324135|2018-06-01 04:38:23.324135
NCT00171873|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-02-28||2012-05-08|2005-09-13|2005-09-15|Estimate|2011-02-28|2011-03-28|Estimate||||2012-05-08|2012-05-10|Estimate|September 2001||2001-09-30|May 2012|2012-05-31|December 2013|Anticipated|2013-12-31|June 2008|Actual|2008-06-30||Interventional|||Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut|Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut|Unknown status|Active, not recruiting|Phase 3|85|Actual|Philipps University Marburg Medical Center||2|||f||||||||||||||2018-06-01 04:38:23.415478|2018-06-01 04:38:23.415478
NCT00171860|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-29|2005-09-13|2005-09-15|Estimate|||||||2012-04-29|2012-05-01|Estimate|September 2002||2002-09-30|April 2012|2012-04-30||||July 2007|Actual|2007-07-31||Interventional|||A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome|A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome|Terminated||Phase 2|24|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:23.598212|2018-06-01 04:38:23.598212
NCT00171847|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-03-30|2005-09-13|2005-09-15|Estimate|||||||2010-03-30|2010-03-31|Estimate|March 2003||2003-03-31|March 2010|2010-03-31||||October 2008|Actual|2008-10-31||Interventional|eLEcTRA||Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer|An Open Label, Randomized Comparison of Femara® 2.5mg Once Daily With or Without Weekly Herceptin® Until Disease Progression as First-line Treatment in Postmenopausal Women With Advanced Breast Cancer.|Terminated||Phase 4|93|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:38:23.66109|2018-06-01 04:38:23.66109
NCT00171834|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2011-01-11||2014-01-06|2005-09-13|2005-09-15|Estimate|2011-06-09|2011-07-07|Estimate||||2014-01-06|2014-02-05|Estimate|August 2003||2003-08-31|January 2014|2014-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer|An Open Label, Phase I/II Dose Escalating Study Evaluating the Safety and Efficacy of EPO906, qw3, in Patients With Non-small Cell Lung Cancer.|Completed||Phase 1/Phase 2|89|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:23.884385|2018-06-01 04:38:23.884385
NCT00171821|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-06-05|2005-09-13|2005-09-15|Estimate|||||||2013-06-05|2013-06-06|Estimate|April 2005||2005-04-30|June 2013|2013-06-30|July 2010|Actual|2010-07-31|May 2009|Actual|2009-05-31||Interventional|||A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload|A One Year, Open-label, Single-arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 (20 mg/kg/Day) in Patients Diagnosed With Transfusion-dependent Iron Overload|Completed||Phase 3|1784|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:25.165596|2018-06-01 04:38:25.165596
NCT00171808|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-16|2005-09-13|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2005||2005-04-30|November 2016|2016-11-30||||May 2010|Actual|2010-05-31||Interventional|deFEND||Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer|Phase II Study on Letrozole in Patients With Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer|Completed||Phase 2|26|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:25.442118|2018-06-01 04:38:25.442118
NCT00171795|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-22|2005-09-13|2005-09-15|Estimate|||||||2011-11-22|2011-11-23|Estimate|November 2002||2002-11-30|November 2011|2011-11-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment|Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment|Completed||Phase 3|67|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:25.529734|2018-06-01 04:38:25.529734
NCT00171782|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-11-07|2005-09-13|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|February 2004||2004-02-29|June 2006|2006-06-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Hypertension and Cardiovascular Risk Factors|Valsartan Plus Hydrochlorothiazide in Patients With Hypertension and Cardiovascular Risk Factors|Completed||Phase 4|76|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:25.586354|2018-06-01 04:38:25.586354
NCT00171769|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-21|2005-09-13|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2005||2005-04-30|February 2017|2017-02-28||||August 2006|Actual|2006-08-31||Interventional|||Atrial Fibrillation Feasibility Certoparin Trial - AFFECT|An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation|Completed||Phase 3|200||Novartis|||||f||||||||||||||2018-06-01 04:38:25.63883|2018-06-01 04:38:25.63883
NCT00171756|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-20|2005-09-13|2005-09-15|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2004||2004-06-30|February 2017|2017-02-28|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.|A Double-blind, Double-dummy, Multi-centre, Randomized, Active Controlled, Parallel Group Pilot Trial to Compare the Effects of Valsartan and Atenolol on the Pro-thrombotic State in Patients With Mild to Moderate Hypertension.|Completed||Phase 4|92|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:25.721495|2018-06-01 04:38:25.721495
NCT00171743|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-06-05|2005-09-13|2005-09-15|Estimate|||||||2017-06-05|2017-06-07|Actual|April 2004||2004-04-30|June 2017|2017-06-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients|Switch From Tacrolimus to Cyclosporine Microemulsion: Immunosuppressive Agents and Diabetes Management in Liver Transplant Recipients in Maintenance (DIALIVER)|Completed||Phase 4|47|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:25.78849|2018-06-01 04:38:25.78849
NCT00171730|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-11-15|2005-09-13|2005-09-15|Estimate|||||||2016-11-15|2016-11-16|Estimate|August 2004||2004-08-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly|Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients|Completed||Phase 2|30|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:38:25.842793|2018-06-01 04:38:25.842793
NCT00171717|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-01-31|2005-09-13|2005-09-15|Estimate|||||||2011-01-31|2011-02-01|Estimate|February 2004||2004-02-29|January 2011|2011-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant|Pilot Study of the Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients Presenting With New Onset Diabetes After the 3rd Month Post-transplant.|Completed||Phase 4|39|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:25.921239|2018-06-01 04:38:25.921239
NCT00171704|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2012-02-27||2017-03-01|2005-09-13|2005-09-15|Estimate|2012-05-01|2012-06-04|Estimate||||2017-03-01|2017-03-03|Actual|April 2005||2005-04-30|May 2012|2012-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer|A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer|Completed||Phase 3|263|Actual|Novartis|The study was designed to investigate the effects of letrozole compared with tamoxifen for 2 years on BMD spine (L2-L4). The study was too small to investigate the comparative efficacy of treatments on disease-free survival or on overall survival.|2|||f||||||||||||||2018-06-01 04:38:25.997872|2018-06-01 04:38:25.997872
NCT00171691|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-20|2005-09-13|2005-09-15|Estimate|||||||2012-04-20|2012-04-23|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Completed||Phase 3|450||Novartis|||||f||||||||||||||2018-06-01 04:38:26.679176|2018-06-01 04:38:26.679176
NCT00171678|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-20|2005-09-13|2005-09-15|Estimate|||||||2012-04-20|2012-04-23|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Completed||Phase 3|480||Novartis|||||f||||||||||||||2018-06-01 04:38:26.881396|2018-06-01 04:38:26.881396
NCT00171665|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-04-13|2005-09-13|2005-09-15|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|December 2005||2005-12-31|||||Interventional|||Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis|Completed||Phase 3|360||Novartis|||||||||||||||||||2018-06-01 04:38:26.96543|2018-06-01 04:38:26.96543
NCT00171652|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-09|2005-09-13|2005-09-15|Estimate|||||||2006-10-09|2006-10-11|Estimate|May 2005||2005-05-31|October 2006|2006-10-31|October 2005||2005-10-31|||||Interventional|||Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis|Completed||Phase 3|360||Novartis|||||||||||||||||||2018-06-01 04:38:27.147072|2018-06-01 04:38:27.147072
NCT00171639|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-21|2005-09-12|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2004||2004-06-30|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis|The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis|Completed||Phase 3|28|Actual|Novartis|||||f||||f||||||||||2018-06-01 04:38:27.408897|2018-06-01 04:38:27.408897
NCT00171626|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-20|2005-09-13|2005-09-15|Estimate|||||||2012-04-20|2012-04-23|Estimate|August 2004||2004-08-31|April 2012|2012-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis|Completed||Phase 3|480||Novartis|||||f||||||||||||||2018-06-01 04:38:27.563997|2018-06-01 04:38:27.563997
NCT00171613|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-04-27|2005-09-13|2005-09-15|Estimate|||||||2012-04-27|2012-04-30|Estimate|February 2005||2005-02-28|April 2012|2012-04-30||||October 2005|Actual|2005-10-31||Interventional|||A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients|A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients|Completed||Phase 4|32||Novartis|||||f||||||||||||||2018-06-01 04:38:27.717356|2018-06-01 04:38:27.717356
NCT00171600|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|July 2005||2005-07-31|November 2011|2011-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Antialbuminuric Effects of Valsartan and Lisinopril|Comparative, Open Multicenter Trial Assessing the Effect on Albumin Excretion Rate of 320mg Valsartan (With or Without HCTZ) vs 40mg Lisinopril (With or Without HCTZ) on Hypertensive Patients With Diabetic and Non-diabetic Nephropathy and Albuminuria|Terminated||Phase 4|54|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:27.799098|2018-06-01 04:38:27.799098
NCT00171587|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-11-18|2005-09-12|2005-09-15|Estimate|||||||2009-11-18|2009-11-19|Estimate|May 2002||2002-05-31|November 2009|2009-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer|A Phase IB, Open-label, Dose-escalating Study of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer|Completed||Phase 1/Phase 2|22|Anticipated|Novartis|||||f||||||||||||||2018-06-01 04:38:27.869741|2018-06-01 04:38:27.869741
NCT00171574|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-22|2005-09-12|2005-09-15|Estimate|||||||2017-02-22|2017-02-24|Actual|November 2004||2004-11-30|February 2017|2017-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Antiproteinuric Effect of Valsartan and Lisinopril|Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up|Completed||Phase 4|124|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:27.930947|2018-06-01 04:38:27.930947
NCT00171561|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|March 2003||2003-03-31|November 2011|2011-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.|A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria|Completed||Phase 4|144|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:27.988384|2018-06-01 04:38:27.988384
NCT00171548|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-19|2005-09-12|2005-09-15|Estimate|||||||2008-09-19|2008-09-22|Estimate|October 2004||2004-10-31|September 2008|2008-09-30||||July 2007|Actual|2007-07-31||Observational|||Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients|Project to Promote the Evaluation of Cardiovascular Risk in Clinical Practice, and Assess Its Evolution After the Implementation of Multifactorial Preventive Strategy Aimed at Reducing the Level of Global Risk (SCORE Algorithm) in Subjects With Metabolic Syndrome and a Risk Level of 5%|Completed|||600|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:28.050399|2018-06-01 04:38:28.050399
NCT00171535|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|October 2004||2004-10-31|June 2006|2006-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension|A Study to Evaluate the Safety and Efficacy of Valsartan/Amlodipine Compared to Lisinopril/Hydrochlorothiazide Given Once Daily for 6 Weeks is Patients With Severe Hypertension|Completed||Phase 3|130|Actual|Novartis|||||||||||||||||||2018-06-01 04:38:28.092006|2018-06-01 04:38:28.092006
NCT00171522|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-03-02|2005-09-12|2005-09-15|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|September 2005|Actual|2005-09-30|||||Interventional|||Preference of Tegaserod vs. PEG 3350 in Patients With Constipation|A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation|Completed||Phase 4|52||Novartis|||||||||||||||||||2018-06-01 04:38:28.141297|2018-06-01 04:38:28.141297
NCT00171509|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-01-31|2005-09-12|2005-09-15|Estimate|||||||2011-01-31|2011-02-01|Estimate|May 2004||2004-05-31|January 2011|2011-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients|A Multicenter, Randomized Open-label Pilot Study to Explore the Benefit of a Conversion From a Twice a Day Administration of Cyclosporine Microemulsion to a Once a Day Administration and to Identify the C2 Ranges to Target After Conversion in Stable Liver Transplant Recipients|Completed||Phase 4|61|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:38:28.199823|2018-06-01 04:38:28.199823
NCT00171496|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-16|2005-09-12|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2003||2003-10-31|November 2016|2016-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients|A Six-month Open Label, Multicenter, Randomized Study to Evaluate the Incidence of New Onset Diabetes Mellitus and Glucose Metabolism in Patients Receiving Cyclosporine Microemulsion With C-2 Monitoring Versus Tacrolimus After de Novo Kidney Transplantation|Completed||Phase 4|693|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:38:28.360829|2018-06-01 04:38:28.360829
NCT00171483|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-24|2005-09-12|2005-09-15|Estimate|||||||2008-01-24|2008-01-28|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|April 2005|Actual|2005-04-30|||||Interventional|||Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).|Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).|Completed||Phase 3|30||Novartis|||||||||||||||||||2018-06-01 04:38:28.428323|2018-06-01 04:38:28.428323
NCT00171470|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-31|2005-09-12|2005-09-15|Estimate|||||||2008-01-31|2008-02-01|Estimate|April 2005||2005-04-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|||||Interventional|||The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.|The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.|Completed||Phase 3|60||Novartis|||||||||||||||||||2018-06-01 04:38:28.490537|2018-06-01 04:38:28.490537
NCT00171457|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-10-09|2005-09-12|2005-09-15|Estimate|||||||2007-10-09|2007-10-10|Estimate|April 2005||2005-04-30|October 2007|2007-10-31|September 2006|Actual|2006-09-30|||||Interventional|||The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.|The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.|Completed||Phase 3|24||Novartis|||||||||||||||||||2018-06-01 04:38:28.547187|2018-06-01 04:38:28.547187
NCT00171444|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|June 2004||2004-06-30|September 2005|2005-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Comparison of Two Treatment Strategies in Hypertensive Patients|A 8-week Comparison, in a General Practice Setting, Between Two Treatment Strategies With Valsartan and Valsartan/HCTZ Aiming at Normalizing de Novo Hypertensive Patients Who Are Not Adequately Controlled With Their Monotherapy or Biotherapy Treatment or Experiencing Unacceptable Side-effects, According to Their Baseline Blood Pressure|Completed||Phase 4|4445|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:28.604169|2018-06-01 04:38:28.604169
NCT00171431|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-04-19|2005-09-12|2005-09-15|Estimate|||||||2012-04-19|2012-04-20|Estimate|November 2004||2004-11-30|April 2012|2012-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)|The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)|Terminated||Phase 3|20||Novartis||||This study was terminated early in May 2006 due to low patient enrollment|f||||||||||||||2018-06-01 04:38:28.654363|2018-06-01 04:38:28.654363
NCT00171418|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-24|2005-09-12|2005-09-15|Estimate|||||||2008-01-24|2008-01-28|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|February 2005|Actual|2005-02-28|||||Interventional|||Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).|Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).|Completed||Phase 3|54||Novartis|||||||||||||||||||2018-06-01 04:38:28.799235|2018-06-01 04:38:28.799235
NCT00171405|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2016-11-16|2005-09-12|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2005||2005-06-30|November 2016|2016-11-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg|A 4 Month Extension to a 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long-term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension|Completed||Phase 3|250||Novartis|||||||||||||||||||2018-06-01 04:38:28.87022|2018-06-01 04:38:28.87022
NCT00171392|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-01|2005-09-12|2005-09-15|Estimate|||||||2011-02-01|2011-02-02|Estimate|March 2004||2004-03-31|February 2011|2011-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus|Open-label Study to Evaluate the Tolerability, Safety and Efficacy of the Equimolar Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium in Patients With Stable Renal Transplant Receiving Tacrolimus|Completed||Phase 3|132|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:29.142148|2018-06-01 04:38:29.142148
NCT00171379|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-01|2005-09-12|2005-09-15|Estimate|||||||2011-02-01|2011-02-02|Estimate|March 2004||2004-03-31|February 2011|2011-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant|Open-label Study to Evaluate the Tolerability, Safety and Efficacy of the Equimolar Conversion From Mycophenolate Mofetil (MMF) to Enteric-Coated Mycophenolate Sodium (EC-MPS) in Patients With Renal Transplant|Completed||Phase 3|162|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:29.625399|2018-06-01 04:38:29.625399
NCT00171366|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-04-05|2005-09-12|2005-09-15|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2004||2004-07-31|April 2016|2016-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.|A Multicenter, Group Study to Evaluate the Safety and Efficacy of Amlodipine and Benazepril Administered in Combination Compared to Amlodipine Monotherapy in Hypertensive Patients Not Adequately Controlled With Amlodipine Alone|Completed||Phase 3|1422|Actual|Novartis|||||||||||||||||||2018-06-01 04:38:30.020109|2018-06-01 04:38:30.020109
NCT00171353|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|July 2004||2004-07-31|November 2011|2011-11-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure|A Study to Describe Vascular and Renal Effects and Safety of Valsartan 80 and 160 mg in Arterial Hypertension Patients|Completed||Phase 4|109|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:30.693386|2018-06-01 04:38:30.693386
NCT00171340|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-03-22||2012-04-10|2005-09-12|2005-09-15|Estimate|2011-04-27|2011-05-26|Estimate||||2012-04-10|2012-04-16|Estimate|May 2003||2003-05-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.|An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy|Completed||Phase 3|1065|Actual|Novartis||2|||f||||t||||||||||2018-06-01 04:38:30.92176|2018-06-01 04:38:30.92176
NCT00171327|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|July 2004||2004-07-31|November 2011|2011-11-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction|Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction|Completed||Phase 4|213|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:32.30488|2018-06-01 04:38:32.30488
NCT00171314|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-12-15||2012-03-19|2005-09-12|2005-09-15|Estimate|2012-03-19|2012-04-11|Estimate||||2012-03-19|2012-04-11|Estimate|March 2004||2004-03-31|March 2012|2012-03-31||||November 2010|Actual|2010-11-30||Interventional|||The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer|The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer|Completed||Phase 3|527|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:38:32.626381|2018-06-01 04:38:32.626381
NCT00171301|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-01-12||2011-08-28|2005-09-14|2005-09-15|Estimate|2011-06-30|2011-07-29|Estimate||||2011-08-28|2011-08-31|Estimate|June 2005||2005-06-30|August 2011|2011-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|ESCALATOR||Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)|1-year Extension to CICL670A2402 an Open-label, Multi-center Trial of the Efficacy and Safety of Long-term Treatment With Deferasirox (10 to 20 mg/kg/Day) in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2- Year Duration)|Completed||Phase 4|233|Actual|Novartis|An internal review revealed major Good Clinical Practice violations at 2 sites in Saudi Arabia: 602 for core + extension, 601 for 2-yr extension. Therefore data was excluded (completely for 602 + partly for 601) from analyses.|1|||f||||t||||||||||2018-06-01 04:38:33.711113|2018-06-01 04:38:33.711113
NCT00171288|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|August 2003||2003-08-31|November 2011|2011-11-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone|Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone|Completed||Phase 3|83|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:34.699982|2018-06-01 04:38:34.699982
NCT00171275|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-07-15|2005-09-12|2005-09-15|Estimate|||||||2010-07-15|2010-07-16|Estimate|November 2003||2003-11-30|July 2010|2010-07-31||||February 2007|Actual|2007-02-28||Interventional|||Fluvastatin in the Therapy of Acute Coronary Syndrome|Fluvastatin in the Therapy of Acute Coronary Syndrome|Completed||Phase 4|1000||Novartis|||||f||||||||||||||2018-06-01 04:38:34.836639|2018-06-01 04:38:34.836639
NCT00171262|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-20|2005-09-12|2005-09-15|Estimate|||||||2017-02-20|2017-02-23|Actual|August 2004||2004-08-31|February 2017|2017-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers|Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers|Completed||Phase 4|120|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:34.94944|2018-06-01 04:38:34.94944
NCT00171249|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-21|2005-09-12|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2004||2004-08-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia|Completed||Phase 2|57|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:35.089571|2018-06-01 04:38:35.089571
NCT00171236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-07|2005-09-12|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia|Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|84|Actual|Novartis|||||||||||||||||||2018-06-01 04:38:35.200167|2018-06-01 04:38:35.200167
NCT00171223|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-21|2005-09-12|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2004||2004-08-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Adult Patients With Ph + Leukemia|Completed||Phase 2|356|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:35.375851|2018-06-01 04:38:35.375851
NCT00171210|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-12-14||2011-05-24|2005-09-12|2005-09-15|Estimate|2011-03-31|2011-05-02|Estimate||||2011-05-24|2011-05-30|Estimate|October 2004||2004-10-31|May 2011|2011-05-31||||April 2008|Actual|2008-04-30||Interventional|||An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload|An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670)in β-thalassemia Patients With Transfusional Iron Overload|Completed||Phase 3|506|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:38:35.613243|2018-06-01 04:38:35.613243
NCT00171184|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-16|2005-09-12|2005-09-15|Estimate|||||||2017-05-16|2017-05-18|Actual|April 2005||2005-04-30|May 2017|2017-05-31|June 2006|Actual|2006-06-30|||||Interventional|||Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder|Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder|Completed||Phase 4|400|Actual|Novartis||2|||||||||||||||||2018-06-01 04:38:36.999673|2018-06-01 04:38:36.999673
NCT00171171|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-28|2005-09-14|2005-09-15|Estimate|||||||2017-02-28|2017-03-01|Actual|May 2004||2004-05-31|November 2016|2016-11-30||||November 2006|Actual|2006-11-30||Interventional|||A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis|A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis|Completed||Phase 3|252|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:37.168045|2018-06-01 04:38:37.168045
NCT00171158|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-02-21|2005-09-12|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2004||2004-08-31|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis|An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis|Completed||Phase 2|20|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:38:37.294328|2018-06-01 04:38:37.294328
NCT00171145|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-01-18|2005-09-12|2005-09-15|Estimate|||||||2008-01-18|2008-01-23|Estimate|April 2004||2004-04-30|January 2008|2008-01-31|December 2004|Actual|2004-12-31|||||Interventional|||A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.|A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.|Completed||Phase 3|445|Actual|Novartis||2|||||||||||||||||2018-06-01 04:38:37.447203|2018-06-01 04:38:37.447203
NCT00171132|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-02-21|2005-09-10|2005-09-15|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2004||2004-08-31|February 2017|2017-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women|A 26-week Double-blind, Randomized, Multicenter Parallel-group Trial to Compare the Effects of Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women With Impaired Exercise Tolerance|Completed||Phase 4|64|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:37.618906|2018-06-01 04:38:37.618906
NCT00171119|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-12-16|2005-09-10|2005-09-15|Estimate|||||||2008-12-16|2008-12-17|Estimate|January 2004||2004-01-31|December 2008|2008-12-31||||March 2005|Actual|2005-03-31||Interventional|||A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril|A 24-Week Study to Assess Blood Pressure Independent Effects of Valsartan Treatment, Benazepril Treatment and Combination of Both Valsartan and Benazepril Treatment on Urinary Albumin Excretion Rate With Type II Diabetes Mellitus and Microalbuminuria|Terminated||Phase 4|81|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:37.821578|2018-06-01 04:38:37.821578
NCT00171106|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2016-11-16|2005-09-10|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2002||2002-12-31|November 2016|2016-11-30|February 2008|Actual|2008-02-29|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure|A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure|Completed||Phase 4|150||Novartis|||||f||||||||||||||2018-06-01 04:38:37.969119|2018-06-01 04:38:37.969119
NCT00171093|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-02-20|2005-09-10|2005-09-15|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2004||2004-09-30|February 2017|2017-02-28||||January 2006|Actual|2006-01-31||Interventional|||A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia|A 10-12 Week Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of the Combination of Valsartan (320 mg) and Simvastatin (80 mg) Compared to Valsartan (320 mg) and Simvastatin (80 mg) Monotherapies in Essential Hypertension and Hypercholesterolemia|Completed||Phase 3|369||Novartis|||||||||||||||||||2018-06-01 04:38:38.129919|2018-06-01 04:38:38.129919
NCT00171080|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-05-16|2005-09-10|2005-09-15|Estimate|||||||2017-05-16|2017-05-18|Actual|April 2004||2004-04-30|May 2017|2017-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis|A 2 x 5-week Multicenter, Cross-over Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan 80 mg Compared to Irbesartan 150 mg in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis|Completed||Phase 3|86|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:38.228434|2018-06-01 04:38:38.228434
NCT00171067|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-05-15|2005-09-10|2005-09-15|Estimate|||||||2017-05-15|2017-05-17|Actual|July 2004||2004-07-31|May 2017|2017-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria|A Study to Evaluate the Effectiveness of Valsartan 320 mg in Combination With Lisinopril 20 mg Versus Monotherapy With Lisinopril 40 mg or Valsartan 320 mg in Hypertensive Patients With Microalbuminuria on the Reduction of Urinary Albumin Creatinine Ratio|Completed||Phase 3|134|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:38.399054|2018-06-01 04:38:38.399054
NCT00171054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|2010-12-21||2011-06-02|2005-09-10|2005-09-15|Estimate|2011-03-31|2011-05-03|Estimate||||2011-06-02|2011-06-06|Estimate|September 2003||2003-09-30|June 2011|2011-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension|A Randomized, Double-blind, Parallel Group, Active-controlled, 38-week Study to Evaluate the Efficacy of Valsartan Versus Amlodipine on the Arterial Properties of Postmenopausal Women With Mild to Moderate Hypertension|Completed||Phase 4|125|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:38:38.538547|2018-06-01 04:38:38.538547
NCT00171041|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2016-11-16|2005-09-10|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2002||2002-12-31|November 2016|2016-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age|A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertensive Patients|Completed||Phase 3|265|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:39.087335|2018-06-01 04:38:39.087335
NCT00171028|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-11-07|2005-09-10|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2003||2003-12-31|June 2006|2006-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension|A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertension Patients 1 - 5 Years Of Age|Completed||Phase 3|90|Actual|Novartis|||||||||||||||||||2018-06-01 04:38:39.168851|2018-06-01 04:38:39.168851
NCT00171015|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-11-07|2005-09-10|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2004||2004-12-31|November 2011|2011-11-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil|An Open,Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Valsartan/Hydrochlorothiazide 160/25 (Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg) in Patients Not Adequately Responding to a 4 Week Monotherapy With Olmesartan Medoxomil 40 mg or Combination Therapy With Olmesartan Medoxomil 20 mg Plus HCTZ 12.5 mg|Completed||Phase 3|212|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:39.253165|2018-06-01 04:38:39.253165
NCT00171002|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-05-15|2005-09-10|2005-09-15|Estimate|||||||2017-05-15|2017-05-17|Actual|November 2004||2004-11-30|May 2017|2017-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone|A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy|Completed||Phase 3|936|Actual|Novartis|||||||||||||||||||2018-06-01 04:38:39.33552|2018-06-01 04:38:39.33552
NCT00170989|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-11-07|2005-09-10|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|September 2004||2004-09-30|June 2006|2006-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone|Comparison of the Combination of Valsartan 320 mg Plus Hydrochlorothiazide 12.5 mg and Valsartan 320 mg Plus Hydrochlorothiazide 25 mg to Valsartan 320 mg in Mild to Moderate Hypertensive Patients Not Adequately Controlled With Valsartan 320 mg|Completed||Phase 3|2714|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:39.416857|2018-06-01 04:38:39.416857
NCT00170976|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-11-07|2005-09-10|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|April 2004||2004-04-30|November 2011|2011-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension|A 54 Week, Extension to the Double-blind, Multicenter, Multifactorial, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients|Completed||Phase 3|403|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:39.498669|2018-06-01 04:38:39.498669
NCT00170963|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2017-05-15|2005-09-10|2005-09-15|Estimate|||||||2017-05-15|2017-05-17|Actual|October 2004||2004-10-31|May 2017|2017-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone|Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy|Completed||Phase 3|1018|Actual|Novartis|||||||||||||||||||2018-06-01 04:38:39.573914|2018-06-01 04:38:39.573914
NCT00170950|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|2011-01-13||2011-04-19|2005-09-10|2005-09-15|Estimate|2011-04-19|2011-05-17|Estimate||||2011-04-19|2011-05-17|Estimate|October 2003||2003-10-31|April 2011|2011-04-30|May 2008|Actual|2008-05-31|January 2008|Actual|2008-01-31||Interventional|ACCOMPLISH||Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension|A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension|Terminated||Phase 3|11506|Actual|Novartis|Study was stopped early, as recommended by the Data Monitoring Committee, due to positive efficacy results.|2||"The study was terminated early because of significant efficacy results for the primary endpoint~   in favor of benazepril/amlodipine treatment."|f||||||||||||||2018-06-01 04:38:39.747457|2018-06-01 04:38:39.747457
NCT00170937|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2016-11-16|2005-09-10|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2004||2004-11-30|November 2016|2016-11-30||||March 2006|Actual|2006-03-31||Interventional|||A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome|A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome|Completed||Phase 4|507||Novartis|||||f||||||||||||||2018-06-01 04:38:42.943206|2018-06-01 04:38:42.943206
NCT00170924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-11-07|2005-09-10|2005-09-15|Estimate|||||||2011-11-07|2011-11-08|Estimate|August 2004||2004-08-31|November 2011|2011-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.|A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction|Completed||Phase 4|317|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:43.068202|2018-06-01 04:38:43.068202
NCT00170911|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-11-01|2005-09-09|2005-09-15|Estimate|||||||2011-11-01|2011-11-02|Estimate|March 2005||2005-03-31|November 2011|2011-11-30||||December 2005|Actual|2005-12-31||Interventional|||Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.|Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.|Completed||Phase 2|160||Novartis|||||f||||||||||||||2018-06-01 04:38:43.286692|2018-06-01 04:38:43.286692
NCT00170898|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-10-12|2005-09-09|2005-09-15|Estimate|||||||2006-10-12|2006-10-13|Estimate|November 2004||2004-11-30|June 2006|2006-06-30||||||||Interventional|||Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain|A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Acute Musculoskeletal Pain Due to Uncomplicated Soft Tissue Injury|Completed||Phase 4|419||Novartis|||||f||||||||||||||2018-06-01 04:38:43.362666|2018-06-01 04:38:43.362666
NCT00170885|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-11-15|2005-09-09|2005-09-15|Estimate|||||||2016-11-15|2016-11-16|Estimate|May 2005||2005-05-31|November 2016|2016-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients|Multicenter, Randomized, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de Novo Renal Transplant Recipients|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 04:38:43.453844|2018-06-01 04:38:43.453844
NCT00170872|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-05-18|2005-09-09|2005-09-15|Estimate|||||||2012-05-18|2012-05-21|Estimate|November 2004||2004-11-30|May 2012|2012-05-31||||July 2005|Actual|2005-07-31||Interventional|||6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis|A 6 Week, Multicenter, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Lumiracoxib 200mg o.d. in Patients With Primary Knee Osteoarthritis or Rheumatoid Arthritis|Completed||Phase 3|135||Novartis|||||f||||||||||||||2018-06-01 04:38:43.52505|2018-06-01 04:38:43.52505
NCT00170859|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-11-16|2005-09-09|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|August 2004||2004-08-31|November 2016|2016-11-30|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients|A One-year Multicenter, Randomized, Open-label Study of the Safety and Efficacy of Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 04:38:43.607906|2018-06-01 04:38:43.607906
NCT00170846|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2010-12-17||2015-01-15|2005-09-09|2005-09-15|Estimate|2011-03-31|2011-05-02|Estimate||||2015-01-15|2015-01-27|Estimate|February 2005||2005-02-28|March 2011|2011-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients|Assessment of Everolimus in Addition to Calcineurin Inhibitors Reduction in Maintenance Renal Transplant Recipients|Completed||Phase 4|394|Actual|Novartis||3|||f||||t||||||||||2018-06-01 04:38:43.741835|2018-06-01 04:38:43.741835
NCT00170833|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-11-01|2005-09-09|2005-09-15|Estimate|||||||2011-11-01|2011-11-02|Estimate|November 2003||2003-11-30|November 2011|2011-11-30||||November 2005|Actual|2005-11-30||Interventional|||Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients|A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Recipients|Completed||Phase 3|80||Novartis|||||||||||||||||||2018-06-01 04:38:46.314151|2018-06-01 04:38:46.314151
NCT00170820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-02-23|2005-09-09|2005-09-15|Estimate|||||||2017-02-23|2017-02-27|Actual|February 2005||2005-02-28|February 2017|2017-02-28||||March 2006|Actual|2006-03-31||Interventional|||Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen|A Single Arm, Prospective, Open-label, Pilot Study to Assess Effects of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen|Completed||Phase 4|20||Novartis|||||f||||||||||||||2018-06-01 04:38:46.47507|2018-06-01 04:38:46.47507
NCT00170794|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-11-16|2005-09-09|2005-09-15|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2004||2004-09-30|November 2016|2016-11-30||||July 2006|Actual|2006-07-31||Interventional|||Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.|A One Year, Multicenter, Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.|Completed||Phase 3|||Novartis|||||f||||||||||||||2018-06-01 04:38:47.2501|2018-06-01 04:38:47.2501
NCT00170781|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-11-29|2005-09-09|2005-09-15|Estimate|||||||2006-11-29|2006-11-30|Estimate|June 2005||2005-06-30|June 2006|2006-06-30||||||||Interventional|||Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout|A 1-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Parallel Trial Comparing Lumiracoxib (400 mg Once Daily) in Patients With Acute Flares of Gout, Using Indomethacin (50 mg Three Times a Day)|Completed||Phase 4|234||Novartis|||||f||||||||||||||2018-06-01 04:38:47.364881|2018-06-01 04:38:47.364881
NCT00170768|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-01-18|2005-09-09|2005-09-15|Estimate|||||||2008-01-18|2008-01-23|Estimate|February 2005||2005-02-28|January 2008|2008-01-31|May 2005|Actual|2005-05-31|||||Interventional|||Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over|Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over|Completed||Phase 2|150|Actual|Novartis||3|||||||||||||||||2018-06-01 04:38:47.513786|2018-06-01 04:38:47.513786
NCT00170755|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-01-15|2005-09-09|2005-09-15|Estimate|||||||2008-01-15|2008-01-17|Estimate|April 2002||2002-04-30|January 2008|2008-01-31|January 2005|Actual|2005-01-31|||||Interventional|||A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder|A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder|Completed||Phase 3|718|Actual|Novartis||1|||||||||||||||||2018-06-01 04:38:47.644212|2018-06-01 04:38:47.644212
NCT00170742|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-08-08|2005-09-09|2005-09-15|Estimate|||||||2008-08-08|2008-08-12|Estimate|December 2003||2003-12-31|August 2008|2008-08-31||||May 2006|Actual|2006-05-31||Interventional|||Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.|A Randomized, Open Label, Controlled Study on the Efficacy and Safety of Octreotide i.m. in Patients With Proliferative Diabetic Retinopathy (PDR) After Start of Laser Coagulation|Terminated||Phase 3|17||Novartis||||trial stopped on Sept 24, 2007|f||||||||||||||2018-06-01 04:38:47.815682|2018-06-01 04:38:47.815682
NCT00170729|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-02-28|2005-09-09|2005-09-15|Estimate|||||||2017-02-28|2017-03-01|Actual|August 17, 2004|Actual|2004-08-17|February 2017|2017-02-28|February 28, 2005|Actual|2005-02-28|February 28, 2005|Actual|2005-02-28||Interventional|||A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery|Multi-center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular Inflammation After Cataract Surgery, Followed by an Open Label Observational Period of 12 Days|Completed||Phase 4|62|Actual|Novartis|||||f||||||||||||||2018-06-01 04:38:47.958552|2018-06-01 04:38:47.958552
NCT00170716|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-18|2005-09-09|2005-09-15|Estimate|||||||2007-12-18|2007-12-28|Estimate|September 2004||2004-09-30|December 2007|2007-12-31|March 2008|Anticipated|2008-03-31|||||Interventional|EVEREST||Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis|Safety and Effectiveness of Targeted Sub-Threshold Epidural Cortical Stimulation Delivered Concurrent With Rehabilitation Activities to Enhance Motor Recovery in Patients Suffering From Upper Extremity Hemiparesis Following a Stroke|Unknown status|Active, not recruiting|Phase 3|174|Anticipated|Northstar Neuroscience||2|||f||||t||||||||||2018-06-01 04:38:48.546561|2018-06-01 04:38:48.546561
NCT00170703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-19|2005-09-12|2005-09-15|Estimate|||||||2007-09-19|2007-09-21|Estimate|December 2004||2004-12-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Assessment of Cortical Stimulation Combined With Rehabilitation to Enhance Recovery in Broca's Aphasia.|Assessment of the Safety and Effectiveness of Targeted Sub-Threshold Epidural Cortical Stimulation Delivered Concurrent With Speech-Language Rehabilitation to Enhance Recovery in Patients Suffering From Broca's Aphasia, Following a Stroke.|Completed||Phase 1|8||Northstar Neuroscience|||||f||||f||||||||||2018-06-01 04:38:48.884556|2018-06-01 04:38:48.884556
NCT00170690|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-05-31|2005-09-12|2005-09-15|Estimate|||||||2013-05-31|2013-06-03|Estimate|August 2004||2004-08-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Preference Study With Elderly Patients Recurrent Ovarian Cancer|Präferenz-Studie Bei älteren Patientinnen Mit Ovarialkarzinomrezidiv: Treosulfan Oral vs. intravenös|Completed||Phase 3|123|Actual|North Eastern Germany Society of Gynaecologic Oncology||2|||f||||f||||||||||2018-06-01 04:38:48.947549|2018-06-01 04:38:48.947549
NCT00170677|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-05-13|2005-09-13|2005-09-15|Estimate|||||||2014-05-13|2014-05-14|Estimate|September 2005||2005-09-30|July 2010|2010-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer|Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer|Completed||Phase 2|194|Actual|North Eastern Germany Society of Gynaecologic Oncology||2|||f||||f||||||||||2018-06-01 04:38:49.297055|2018-06-01 04:38:49.297055
NCT00170664|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-03-24|2005-09-12|2005-09-15|Estimate|||||||2016-03-24|2016-03-25|Estimate|January 1999||1999-01-31|March 2016|2016-03-31|September 2004|Actual|2004-09-30|March 2003|Actual|2003-03-31||Interventional|||Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer||Completed||Phase 2|129|Actual|North Eastern Germany Society of Gynaecologic Oncology||1|||f||||||||||||||2018-06-01 04:38:49.723908|2018-06-01 04:38:49.723908
NCT00170638|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-04-24|2005-09-13|2005-09-15|Estimate|||||||2008-04-24|2008-04-25|Estimate|April 2005||2005-04-30|January 2008|2008-01-31|April 2010||2010-04-30|||||Observational|||Tuberculosis Immunity in Children|Tuberculosis Immunity in Children|Completed|||260||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:49.815434|2018-06-01 04:38:49.815434
NCT00170625|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2016-10-04||2016-12-13|2005-09-09|2005-09-15|Estimate|2016-12-13|2017-02-06|Estimate||||2016-12-13|2017-02-06|Estimate|June 2004||2004-06-30|December 2016|2016-12-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer|Multicenter, Prospective Phase-I/II-study: Topotecan and Carboplatin in the Therapy of Patients With Relapsed Ovarian Cancer|Completed||Phase 1/Phase 2|28|Actual|North Eastern Germany Society of Gynaecologic Oncology||1|||f||||f||||||||No||2018-06-01 04:38:50.041491|2018-06-01 04:38:50.041491
NCT00170612|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-10-20|2005-09-13|2005-09-15|Estimate|||||||2008-10-20|2008-10-21|Estimate|November 2005||2005-11-30|October 2008|2008-10-31|August 2008|Actual|2008-08-31|January 2008|Actual|2008-01-31||Interventional|||Pneumococcal Vaccination of Fiji Infants|A Single-Blind Open-Label Randomized Phase II Study of the Safety, Immunogenicity and Impact on Pneumococcus (Pnc) Carriage of the Pnc Vaccination Regimens Combining 1, 2, or 3 Doses of 7-Valent Pneumococcal Conjugate Vaccine (PCV) in the First 4 Months of Life Followed by a Single Dose of 23-Valent Pneumococcal Polysaccharide Vaccine (PPS) at 12 Months of Age|Completed||Phase 2|552|Actual|University of Melbourne||8|||f||||t||||||||||2018-06-01 04:38:50.326775|2018-06-01 04:38:50.326775
NCT00170586|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-08-26|2005-09-13|2005-09-15|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2003||2003-09-30|March 2007|2007-03-31|August 2005||2005-08-31|||||Interventional|||Novel Protective Underglove|Novel Protective Underglove|Completed||Phase 2|325||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:50.463795|2018-06-01 04:38:50.463795
NCT00170573|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-03-24|2005-09-09|2005-09-15|Estimate|||||||2016-03-24|2016-03-25|Estimate|October 2001||2001-10-31|March 2016|2016-03-31|August 2010|Actual|2010-08-31|April 2009|Actual|2009-04-30||Interventional|||Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer||Completed||Phase 2|82|Actual|North Eastern Germany Society of Gynaecologic Oncology||1|||f||||f||||||||||2018-06-01 04:38:50.540246|2018-06-01 04:38:50.540246
NCT00170560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-08-26|2005-09-13|2005-09-15|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2001||2001-10-31|October 2007|2007-10-31|February 2007||2007-02-28|||||Observational|||Impact of Gender on Patients|Impact of Gender on Infected Hospitalized Patients|Unknown status|Recruiting||570||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:50.670705|2018-06-01 04:38:50.670705
NCT00170547|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-12-04|2005-09-09|2005-09-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2005||2005-09-30|July 2006|2006-07-31|February 2006||2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Comparison of Delivery Routes of Flu Vaccine in Adults|Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone(R) in Healthy Adults|Completed||Phase 2|1597|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:38:50.73432|2018-06-01 04:38:50.73432
NCT00170534|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-26|2005-09-12|2005-09-15|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2004||2004-10-31|April 2009|2009-04-30|April 2007||2007-04-30|||||Interventional|||Intervention for Male STDs in India|An Intervention for Male STD Patients in India|Terminated||N/A|1892||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:50.881062|2018-06-01 04:38:50.881062
NCT00170521|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-26|2005-09-12|2005-09-15|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2006||2006-08-31|December 2006|2006-12-31|August 2008||2008-08-31|||||Observational|||Mol Epi GrAS in Nicaragua|The Molecular Epidemiology of Streptococcus Pyogenes Among Children in Leon, Nicaragua|Terminated|||13000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:51.048163|2018-06-01 04:38:51.048163
NCT00170508|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-08-22|2005-09-09|2005-09-15|Estimate|||||||2013-08-22|2013-08-23|Estimate|June 2005||2005-06-30|July 2011|2011-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Young Adult Influenza Vaccine Immunogenicity Substudy|In Depth Immunologic Studies in Healthy Young Adults Who Receive The Standard Dose Fluzone® (15mcgHA/Virus Strain) Trivalent Inactivated Influenza Virus Vaccine|Completed||N/A|15|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:38:51.11114|2018-06-01 04:38:51.11114
NCT00170495|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-08-26|2005-09-12|2005-09-15|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2004||2004-09-30|September 2008|2008-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Acute Viral Respiratory Infections in Elderly|Etiology and Impact of Acute Viral Respiratory Infections in Ambulatory Elderly Populations|Terminated|||3000|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples Without DNA|"~     blood, sputum, nasal and throat swabs~   "|||2018-06-01 04:38:51.210462|2018-06-01 04:38:51.210462
NCT00170482|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-11|2005-09-09|2005-09-15|Estimate|||||||2011-08-11|2011-08-12|Estimate|April 2005||2005-04-30|April 2011|2011-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Observational|||Elderly Influenza Vaccine Immunogenicity Substudy|In Depth Immunologic Studies in Elderly Subjects Receiving Either Standard-Dose Fluzone (15mcg HA/Virus Strain) or High-Dose (60 Mcg HA/Virus Strain) Trivalent Inactivated Influenza Virus Vaccine|Completed|||60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:51.313935|2018-06-01 04:38:51.313935
NCT00170469|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-09-12|2005-09-09|2005-09-15|Estimate|||||||2008-09-12|2008-09-15|Estimate|March 2005||2005-03-31|September 2008|2008-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed|A Phase II, Dose Ranging Multi-Centre, Single Blind, Parallel-Group, Controlled Study of the Safety, Tolerability and Immunogenicity of Recombinant (rPA Based) Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed in a Healthy Population|Completed||Phase 2|226|Actual|PharmAthene UK Limited||3|||f||||t||||||||||2018-06-01 04:38:51.42959|2018-06-01 04:38:51.42959
NCT00170456|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-09-12|2005-09-09|2005-09-15|Estimate|||||||2008-09-12|2008-09-15|Estimate|March 2005||2005-03-31|September 2008|2008-09-30|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||Phase II Study of Range and Schedule of rPA Doses|A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects|Completed||Phase 2|415|Actual|PharmAthene UK Limited||4|||f||||t||||||||||2018-06-01 04:38:51.560878|2018-06-01 04:38:51.560878
NCT00170443|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-11|2005-09-09|2005-09-15|Estimate|||||||2011-08-11|2011-08-12|Estimate||||April 2006|2006-04-30|June 2004||2004-06-30|||||Interventional|||Trivalent rHA Dose Escalation Study in Elderly Subjects|A Phase II Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Intramuscular Trivalent Baculovirus-expressed Influenza HA Vaccine in Healthy Elderly Adults|Completed||Phase 2|399|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:51.658338|2018-06-01 04:38:51.658338
NCT00170430|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-16|2005-09-09|2005-09-15|Estimate|||||||2010-03-16|2010-03-18|Estimate|May 2003||2003-05-31|March 2010|2010-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Reducing Vaginal Infections in Women|Reducing Vaginal Infections in Women at Risk for HIV-1|Completed||Phase 3|400||University of Washington|||||f||||||||||||||2018-06-01 04:38:51.772014|2018-06-01 04:38:51.772014
NCT00170417|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-15|Estimate|||||||2005-09-09|2005-09-15|Estimate|December 2000||2000-12-31|December 2000|2000-12-31|May 2003||2003-05-31|||||Interventional|||Clinical Benefit of CBT for Insomnia in Primary Care|Clinical and Health Economic Benefit of Non-Pharmacological Treatment of Chronic Insomnia in Primary Care|Completed||N/A|||NHS Greater Clyde and Glasgow|||||f||||||||||||||2018-06-01 04:38:51.832404|2018-06-01 04:38:51.832404
NCT00170404|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-08-26|2005-09-09|2005-09-15|Estimate|||||||2010-08-26|2010-08-27|Estimate|June 2000||2000-06-30|February 2007|2007-02-28|October 2005||2005-10-31|||||Interventional|||TB Nutrition, Immunology and Epidemiology|Nutrition, Immunology, and Epidemiology of Tuberculosis|Completed||Phase 3|887||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:38:51.918467|2018-06-01 04:38:51.918467
NCT00170391|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-09-10|2005-09-10|2005-09-15|Estimate|||||||2005-09-10|2005-09-15|Estimate|October 2002||2002-10-31|October 2002|2002-10-31|December 2005||2005-12-31|||||Interventional|||Do People With Insomnia Sleep Better After Psychological Treatment?|Does CBT for Insomnia Improve the PSG Sleep of Patients Treated in Primary Care?|Unknown status|Active, not recruiting|N/A|||NHS Greater Clyde and Glasgow|||||f||||||||||||||2018-06-01 04:38:52.041579|2018-06-01 04:38:52.041579
NCT00170378|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-06-26|2005-09-12|2005-09-15|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2002||2002-12-31|October 2012|2012-10-31|August 2005|Actual|2005-08-31|||||Interventional|||The Use of Low Molecular Weight Heparin in Traumatic Brain Injury|The Use of Low Molecular Weight Heparin in Traumatic Brain Injury|Completed||Phase 4|300||Minneapolis Medical Research Foundation|||||f||||||||||||No||2018-06-01 04:38:52.0878|2018-06-01 04:38:52.0878
NCT00170365|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-09-12|2005-09-09|2005-09-15|Estimate|||||||2016-09-12|2016-09-14|Estimate|July 2004||2004-07-31|September 2016|2016-09-30|March 2005||2005-03-31|||||Interventional|||Restorative Yoga for Stress Management|Restorative Yoga for Stress Management|Completed||N/A|30||Minneapolis Medical Research Foundation|||||f||||||||||||||2018-06-01 04:38:52.252658|2018-06-01 04:38:52.252658
NCT00170352|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-08-27|2005-09-12|2005-09-15|Estimate|||||||2015-08-27|2015-08-28|Estimate|November 2002||2002-11-30|August 2015|2015-08-31|November 2008|Actual|2008-11-30|November 2007|Actual|2007-11-30||Interventional|||Comparison Between Different Types of Oxygen Treatment Following Traumatic Brain Injury|Hyperbaric and Normobaric Oxygen in Severe Brain Injury|Completed||Phase 2|80|Actual|Minneapolis Medical Research Foundation|||||f||||t||||||||||2018-06-01 04:38:52.310104|2018-06-01 04:38:52.310104
NCT00170339|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-09-12|2005-09-09|2005-09-15|Estimate|||||||2016-09-12|2016-09-14|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|April 2007|Actual|2007-04-30|||||Observational|||Bone Density and Serum Testosterone in Male Methadone Maintained Patients|Bone Density and Serum Testosterone in Male Methadone Maintained Patients|Completed|||60||Minneapolis Medical Research Foundation|||||f||||||||||||||2018-06-01 04:38:52.458029|2018-06-01 04:38:52.458029
NCT00170326|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-04-18|2005-09-13|2005-09-15|Estimate|||||||2017-04-18|2017-04-19|Actual|January 2002||2002-01-31|April 2017|2017-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|Prevent-HF||Progressive Ventricular Dysfunction Prevention in Pacemaker Patients|Progressive Ventricular Dysfunction Prevention in Pacemaker Patients|Completed||N/A|108|Actual|Medtronic Bakken Research Center||2|||f||||t||||||||No||2018-06-01 04:38:52.677681|2018-06-01 04:38:52.677681
NCT00170313|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-02-14|2005-09-13|2005-09-15|Estimate|||||||2017-02-14|2017-02-15|Actual|December 2003||2003-12-31|January 2017|2017-01-31|January 2007|Actual|2007-01-31|||||Interventional|||CORE: Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation|Conducted AF-Response Study (Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation Treated With InSync III Marquis)|Terminated||Phase 4|100|Anticipated|Medtronic Bakken Research Center||2||Ventricular rate during AF in CRT-patients much lower than expected|f||||f||||||||No||2018-06-01 04:38:52.798663|2018-06-01 04:38:52.798663
NCT00170300|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-01-29|2005-09-13|2005-09-15|Estimate|||||||2018-01-29|2018-01-30|Actual|January 2001||2001-01-31|January 2018|2018-01-31|May 2005||2005-05-31|||||Interventional|||Care-HF CArdiac Resynchronization in Heart Failure|Outcome Trial (Long Term)to Evaluate the Effects of Cardiac Resynchronization Therapy on the Mortality and Morbidity of Patients With Heart Failure|Completed||N/A|813||Medtronic Bakken Research Center|||||f||||||||||||||2018-06-01 04:38:52.949974|2018-06-01 04:38:52.949974
NCT00170287|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-09-05|2005-09-09|2005-09-15|Estimate|||||||2017-09-05|2017-09-06|Actual|May 2002||2002-05-31|September 2017|2017-09-30|August 2011|Actual|2011-08-31|April 2010|Actual|2010-04-30||Interventional|SMS||SMS: Substrate Modification Study in Patients Getting an Implantable Cardioverter Defibrillator (ICD)|Substrate Modification Study in Patients Getting an ICD|Completed||Phase 4|116|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||No||2018-06-01 04:38:53.027919|2018-06-01 04:38:53.027919
NCT00170274|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-01-29|2005-09-12|2005-09-15|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2000||2000-08-31|January 2018|2018-01-31|October 2014|Actual|2014-10-31|June 2011|Actual|2011-06-30||Interventional|||APART: Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias|Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias Who Need Cardiac Pacing|Completed||N/A|156|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||No||2018-06-01 04:38:53.145433|2018-06-01 04:38:53.145433
NCT00170261|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-04-04|2005-09-12|2005-09-15|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2002||2002-04-30|April 2018|2018-04-30|September 2006|Actual|2006-09-30|September 2005|Actual|2005-09-30||Interventional|||ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope|Early Loop-Recorder in Suspected Arrhythmogenic Syncope|Completed||Phase 4|100|Anticipated|Medtronic Bakken Research Center|||||f||||||||||||||2018-06-01 04:38:53.238347|2018-06-01 04:38:53.238347
NCT00170248|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-04-07|2005-09-13|2005-09-15|Estimate|||||||2014-04-07|2014-04-08|Estimate|October 2006||2006-10-31|April 2014|2014-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Computer-Based Decision Support in Managing Asthma in Primary Care|Evaluating the Impact of Computer-Based Decision Support for the Management of Asthma in Primary Care|Completed||N/A|4447|Actual|McGill University||2|||f||||||||||||||2018-06-01 04:38:53.382663|2018-06-01 04:38:53.382663
NCT00170235|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-09-03|2005-09-09|2005-09-15|Estimate|||||||2010-09-03|2010-09-06|Estimate|August 2004||2004-08-31|May 2008|2008-05-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Reducing Arm Morbidity in Pre- and Post-breast Cancer Surgery|Reducing Arm Morbidity Through Physical Therapy Provided Pre- and Post-breast Cancer Surgery|Completed||N/A|50|Actual|McGill University||2|||f||||f||||||||||2018-06-01 04:38:53.53232|2018-06-01 04:38:53.53232
NCT00170222|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-09-26|2005-09-09|2005-09-15|Estimate|||||||2008-09-26|2008-09-29|Estimate|July 2002||2002-07-31|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|The Value of Antibiotic Treatment of Exacerbations of Hospitalised COPD Patients|Completed||Phase 4|258|Anticipated|Medical Center Alkmaar|||||f||||||||||||||2018-06-01 04:38:53.674077|2018-06-01 04:38:53.674077
NCT00170209|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-15|2005-09-12|2005-09-15|Estimate|||||||2017-12-15|2017-12-19|Actual|August 2011||2011-08-31|December 2017|2017-12-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)|A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial|Completed||Phase 3|844|Actual|McGill University||2|||f||||t||||||||Undecided||2018-06-01 04:38:53.830016|2018-06-01 04:38:53.830016
NCT00170196|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-09-26|2005-09-12|2005-09-15|Estimate|||||||2008-09-26|2008-09-29|Estimate|August 2005||2005-08-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Efficacy Studies of Corticosteroid Therapy in Community-Acquired Pneumonia|The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids|Completed||Phase 3|216|Actual|Medical Center Alkmaar|||||f||||||||||||||2018-06-01 04:38:54.046006|2018-06-01 04:38:54.046006
NCT00170183|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-11-13|2005-09-13|2005-09-15|Estimate|||||||2009-11-13|2009-11-16|Estimate|March 2003||2003-03-31|November 2009|2009-11-30|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Interventional|||Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure|BNP as Adjuvant Therapy to Preserve Renal Function and Facilitate Diuresis in Hospitalized Patients With Heart Failure|Completed||Phase 3|104|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 04:38:54.2363|2018-06-01 04:38:54.2363
NCT00170170|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-01|2005-09-13|2005-09-15|Estimate|||||||2010-02-01|2010-02-02|Estimate|November 2004||2004-11-30|February 2010|2010-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation|Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis|Completed|||500|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:38:54.327116|2018-06-01 04:38:54.327116
NCT00170157|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-05-03||2017-04-06|2005-09-13|2005-09-15|Estimate|2013-12-20|2014-01-31|Estimate||||2017-04-06|2017-05-15|Actual|June 2004||2004-06-30|January 2017|2017-01-31|June 2013|Actual|2013-06-30|April 2011|Actual|2011-04-30||Interventional|||Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer|A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer|Completed||Phase 2|112|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 04:38:54.494734|2018-06-01 04:38:54.494734
NCT00170144|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-03-14|2005-09-13|2005-09-15|Estimate|||||||2011-03-14|2011-03-15|Estimate|September 2005||2005-09-30|March 2011|2011-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Branched Chain Amino Acids on Muscle|Branched Chain Amino Acids as Stimulant of Muscle Mitochondrial Function in Elderly People|Completed||N/A|40|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 04:38:54.913108|2018-06-01 04:38:54.913108
NCT00170131|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-20|2005-09-13|2005-09-15|Estimate|||||||2011-05-20|2011-05-23|Estimate|September 2002||2002-09-30|May 2011|2011-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||MMF Influence on HCV Viral Evolution After Liver Transplantation|The Influence MMF on 5UTR HCV Quasispecies Variation: A Potential Factor in the Natural History of Post-OLT x HCV Infection|Completed|||17|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:38:55.028634|2018-06-01 04:38:55.028634
NCT00170118|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-01-27|2005-09-13|2005-09-15|Estimate|||||||2010-01-27|2010-01-28|Estimate|June 2005||2005-06-30|January 2010|2010-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||"Effects of Motivational Interviewing on Self-Efficacy and Standardized Low Back Pain Outcomes in Patients With Chronic Back Pain"|Effects of Motivational Interviewing on Self-Efficacy and Standardized Low Back Pain Outcomes in Patients With Chronic Back Pain|Completed||N/A|6|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:38:55.141917|2018-06-01 04:38:55.141917
NCT00170105|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-02-01|2005-09-13|2005-09-15|Estimate|||||||2010-02-01|2010-02-02|Estimate|August 2005||2005-08-31|February 2010|2010-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Posturing Effects on Perception of Time and Perceptions of the Provider-Patient Interaction in the Emergency Department|Posturing Effects on Perception of Time and Perceptions of the Provider-Patient Interaction in the Emergency Department|Completed|||244|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 04:38:55.259024|2018-06-01 04:38:55.259024
NCT00170079|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-12-01|2005-09-12|2005-09-15|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2005||2005-04-30|December 2014|2014-12-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Prolonged Smoking Cessation Using Prescription Step Care|Prolonged Smoking Cessation Using Prescription Step Care|Completed||N/A|270|Actual|University of Tennessee||1|||f||||t||||||||||2018-06-01 04:38:55.313197|2018-06-01 04:38:55.313197
NCT00170053|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-07-27|2005-09-12|2005-09-15|Estimate|||||||2012-07-27|2012-07-31|Estimate|June 2005||2005-06-30|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids|Randomized Trial of Thymoglobulin Induction, Initial Tacrolimus, and Mycophenolate Mofetil Therapy With Steroid Avoidance in Primary Kidney Transplant Recipients Followed by Continued Tacrolimus/Mycophenolate Mofetil Therapy vs. Sirolimus/ Mycophenolate Mofetil Therapy|Completed||Phase 1|177|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:38:55.445487|2018-06-01 04:38:55.445487
NCT00170027|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-14|2005-09-12|2005-09-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|July 2003||2003-07-31|February 2011|2011-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Efficacy of MCG for Diagnosing Coronary Heart Disease|Safety and Efficacy of the CMI Magnetocardiograph Model 2409 for Diagnosing Coronary Heart Disease|Completed||Phase 3|250|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 04:38:55.544614|2018-06-01 04:38:55.544614
NCT00170014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-14|2005-09-12|2005-09-15|Estimate|||||||2011-02-14|2011-02-15|Estimate|October 2004||2004-10-31|February 2011|2011-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Precision of the Magnetocardiographer for Data Aquision and Analysis.|Reproducibility of Magnetocardiography Measurements Using the Cardiomag Magnetocardiograph System Model 2409 and Its Software for Data Acquisition and Analysis|Completed||Phase 3|12|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:38:55.668765|2018-06-01 04:38:55.668765
NCT00170001|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-12-13|2005-09-12|2005-09-15|Estimate|||||||2011-12-13|2011-12-15|Estimate|April 2005||2005-04-30|December 2011|2011-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy|Which Supraesophageal Reflux Symptoms Reliably Respond to PPI Therapy: A Large Simple Trial|Completed||N/A|500|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 04:38:55.748845|2018-06-01 04:38:55.748845
NCT00169988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-12-16|2005-09-09|2005-09-15|Estimate|||||||2009-12-16|2009-12-17|Estimate|March 2004||2004-03-31|October 2007|2007-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms|Sertraline Alone vs. in Combination With Risperidone in the Treatment of Attenuated Positive and Negative Symptoms|Completed||N/A|8|Actual|Northwell Health|||||f||||t||||||||||2018-06-01 04:38:55.986307|2018-06-01 04:38:55.986307
NCT00169975|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-07-15|2005-09-12|2005-09-15|Estimate|||||||2011-07-15|2011-07-18|Estimate|August 2004||2004-08-31|July 2011|2011-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Efficacy of the CMI Magnetocardiograph in Diagnosing Acute Coronary Syndromes in Patients Presenting With High Risk Unstable Angina.|Efficacy of the CMI Magnetocardiograph in Diagnosing Acute Coronary Syndromes in Patients Presenting With High Risk Unstable Angina as Defined by ACC/AHA Guidelines|Completed|||137|Actual|Mayo Clinic|||||f||||f||||||||||2018-06-01 04:38:56.086077|2018-06-01 04:38:56.086077
NCT00169962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-10-09|2005-09-12|2005-09-15|Estimate|||||||2015-10-09|2015-10-12|Estimate|January 2004||2004-01-31|October 2015|2015-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study of Pulmozyme to Treat Severe Asthma Episodes|Use of Aerosolized rhDNase (Pulmozyme®) in Emergency Department Adults With Refractory Acute Asthma: A Pilot Study|Completed||Phase 2|51|Anticipated|Northwell Health|||||f||||||||||||||2018-06-01 04:38:56.21277|2018-06-01 04:38:56.21277
NCT00169949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-09-24|2005-09-09|2005-09-15|Estimate|||||||2009-09-24|2009-09-25|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|May 2006|Actual|2006-05-31|||||Interventional|||Aripiprazole Treatment of the Prodrome|Open-Label Study of Aripiprazole in Individuals at Risk for Chronic Mental Illness|Terminated||N/A|30||Northwell Health||||The study was terminated due to low enrollment.|f||||t||||||||||2018-06-01 04:38:56.381505|2018-06-01 04:38:56.381505
NCT00169936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-26|2005-09-12|2005-09-15|Estimate|||||||2010-01-26|2010-01-28|Estimate|December 2004||2004-12-31|January 2010|2010-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Magnetocardiography as a Non-Invasive Tool for Detecting Tissue Rejection in Heart Transplant Patients|Evaluation of Magnetocardiography as a Tool for Non-invasive Detection of Tissue Rejection in Cardiac Transplant Recipients|Completed||Phase 3|6|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 04:38:56.473413|2018-06-01 04:38:56.473413
NCT00169923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-30|2005-09-14|2005-09-15|Estimate|||||||2008-09-30|2008-10-01|Estimate|April 2007||2007-04-30|September 2008|2008-09-30|May 2009|Anticipated|2009-05-31|||||Interventional|Hercules||Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease|Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease|Withdrawn||Phase 2/Phase 3|200|Anticipated|Leiden University Medical Center||||it was not possible to recruit any patient in the study|f||||t||||||||||2018-06-01 04:38:56.586097|2018-06-01 04:38:56.586097
NCT00169910|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-12-13|2005-09-09|2005-09-15|Estimate|||||||2012-12-13|2012-12-17|Estimate|December 2005||2005-12-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients|VIP: Vascular Imaging Project. Prospective Randomized Study on the Effect of AUC-monitored Treatment With Steroids Combined With Either a Calcineurin Inhibitor or Mycophenolate Mofetil on the Progression of Subclinical Cardiovascular Disease in Renal Transplant Recipients.|Completed||Phase 4|119|Actual|Leiden University Medical Center||2|||f||||||||||||||2018-06-01 04:38:56.687786|2018-06-01 04:38:56.687786
NCT00169897|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-11-11|2005-09-13|2005-09-15|Estimate|||||||2010-11-11|2010-11-15|Estimate|January 2004||2004-01-31|August 2005|2005-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Pulmonary Rehabilitation at Home Versus at the Gymnasium|Effects of a Home-based Versus a Hospital-based Outpatient Pulmonary Rehabilitation Program in Patients With COPD: a Multicenter, Randomized Trial|Completed||N/A|252|Actual|Laval University||2|||f||||f||||||||||2018-06-01 04:38:56.891371|2018-06-01 04:38:56.891371
NCT00169884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-01-31|2005-09-13|2005-09-15|Estimate|||||||2006-01-31|2006-02-01|Estimate|March 2002||2002-03-31|January 2005|2005-01-31|March 2007||2007-03-31|||||Interventional|||The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients|The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients: A Randomized Controlled Trial Among Adolescents and Young Adults|Unknown status|Recruiting|Phase 2|120||Leiden University Medical Center|||||f||||||||||||||2018-06-01 04:38:57.008422|2018-06-01 04:38:57.008422
NCT00169871|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-20|2005-09-13|2005-09-15|Estimate|||||||2007-04-20|2007-04-23|Estimate|March 2005||2005-03-31|May 2006|2006-05-31|December 2006|Actual|2006-12-31|||||Observational|||Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia|Hs-CRP as Clinical Marker of Inflammatory Atherogenic Dyslipidemia|Completed|||1000||CHU de Quebec-Universite Laval|||||f||||||||||||||2018-06-01 04:38:57.20114|2018-06-01 04:38:57.20114
NCT00169858|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-05-24|2005-09-13|2005-09-15|Estimate|||||||2013-05-24|2013-05-29|Estimate|September 1995||1995-09-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||Long Term Immunogenicity Study of Engerix-B Vaccine in 10 Year Old Children and the Effect of Booster Injections|Open Randomised Clinical Study of the Long Term Immunogenicity of Engerix-B in 10 Year Old Children and of the Effect of Booster Injections Given 5, 10 or 15 Years After Primary Vaccination|Completed||Phase 4|1129|Actual|Laval University|||||f||||f||||||||||2018-06-01 04:38:57.280906|2018-06-01 04:38:57.280906
NCT00169845|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-03-12|2005-09-09|2005-09-15|Estimate|||||||2018-03-12|2018-03-14|Actual|October 1994||1994-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|June 2003|Actual|2003-06-30||Interventional|||Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients|Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients|Completed||Phase 3|540|Actual|Laval University||2|||f||||t||||||||Yes|A letter was sent to each participant.|2018-06-01 04:38:57.39922|2018-06-01 04:38:57.39922
NCT00169832|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-09|2005-09-12|2005-09-15|Estimate|||||||2008-10-09|2008-10-10|Estimate|June 2003||2003-06-30|October 2008|2008-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|VICTORY||Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial|A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression After Coronary Bypass Surgery in Diabetic Patients|Completed||Phase 3|193|Actual|Laval University||2|||f||||t||||||||||2018-06-01 04:38:57.526258|2018-06-01 04:38:57.526258
NCT00169819|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-02-23|2005-09-12|2005-09-15|Estimate|||||||2007-02-23|2007-02-26|Estimate|October 2003||2003-10-31|February 2007|2007-02-28|April 2006||2006-04-30|||||Interventional|||EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study|A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting|Completed||Phase 4|1000||Laval University|||||f||||t||||||||||2018-06-01 04:38:57.698673|2018-06-01 04:38:57.698673
NCT00169806|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-02-14|2005-09-12|2005-09-15|Estimate|||||||2018-02-14|2018-02-15|Actual|November 1998||1998-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis|Randall's Plaques: Pathogenesis and Relationship to Nephrolithiasis|Recruiting||N/A|400|Anticipated|Indiana Kidney Stone Institute||1|||f||||t||||||||||2018-06-01 04:38:57.804476|2018-06-01 04:38:57.804476
NCT00169793|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-03-04|2005-09-09|2005-09-15|Estimate|||||||2014-03-04|2014-03-05|Estimate|August 2005||2005-08-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2009|Actual|2009-12-31||Interventional|||Nephrolithiasis and Bariatric Surgery|Nephrolithiasis and Bariatric Surgery|Completed||N/A|89|Actual|Indiana Kidney Stone Institute||1|||f||||f||||||||||2018-06-01 04:38:57.941281|2018-06-01 04:38:57.941281
NCT00169780|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-12-05|2005-09-09|2005-09-15|Estimate|||||||2011-12-05|2011-12-07|Estimate|July 2002||2002-07-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Kidney Stone Structural Analysis By Helical Computed Tomography (CT)|Kidney Stone Structural Analysis by Helical Computed Tomography (A Pilot Study)|Completed|||7|Actual|Indiana Kidney Stone Institute|||1||f||||f||||||||||2018-06-01 04:38:58.076305|2018-06-01 04:38:58.076305
NCT00169767|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-04-23|2005-09-09|2005-09-15|Estimate|||||||2008-04-23|2008-04-25|Estimate|May 2005||2005-05-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate|Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate: A Randomized Comparison Study|Terminated|||18|Actual|Indiana Kidney Stone Institute|||1|Poor enrollment|f||||f||||||||||2018-06-01 04:38:58.19242|2018-06-01 04:38:58.19242
NCT00169754|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-09-16|2005-09-09|2005-09-15|Estimate|||||||2008-09-16|2008-09-17|Estimate|April 2005||2005-04-30|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Attached Stone Project: Do Calcium Oxalate Renal Calculi Originate From Randall's Plaque?|Do Calcium Oxalate Renal Calculi Originate From Randall's Plaque?|Completed||N/A|32|Actual|Indiana Kidney Stone Institute||1|||f||||f||||||||||2018-06-01 04:38:58.306984|2018-06-01 04:38:58.306984
NCT00169741|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-02-22|2005-09-09|2005-09-15|Estimate|||||||2016-02-22|2016-02-23|Estimate|May 2005||2005-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC|Alterations in Renal Blood Flow as a Consequence of Percutaneous Nephrolithotomy (PERC)|Completed||N/A|4|Actual|Indiana Kidney Stone Institute||1|||f||||f||||||||||2018-06-01 04:38:58.378324|2018-06-01 04:38:58.378324
NCT00169728|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-06-06|2005-09-13|2005-09-15|Estimate|||||||2012-06-06|2012-06-07|Estimate|September 2003||2003-09-30|June 2012|2012-06-30|October 2006|Actual|2006-10-31|June 2006|Actual|2006-06-30||Interventional|||Vaccination of Children Following Allogeneic Stem Cell Transplantation|Immunogenicity of the DTaP-IPV-HBV/Hib Combination Vaccine Infanrix Hexa and the Heptavalent Pneumococcal Conjugate Vaccine Prevenar in Pediatric Recipients of Allogeneic Haematopoietic Stem Cell Transplantation|Completed||Phase 3|53|Actual|Heinrich-Heine University, Duesseldorf|||||f||||||||||||||2018-06-01 04:38:58.464839|2018-06-01 04:38:58.464839
NCT00169715|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-09-16|2005-09-09|2005-09-15|Estimate|||||||2008-09-16|2008-09-18|Estimate|February 2003||2003-02-28|September 2008|2008-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Database and Registry for Renal Diverticulum|Percutaneous Surgical Outcomes and Metabolic Findings in Patients With Stone-Bearing Calicial Diverticula|Completed||N/A|86|Actual|Indiana Kidney Stone Institute||1|||f||||f||||||||||2018-06-01 04:38:58.567425|2018-06-01 04:38:58.567425
NCT00169702|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-01-28|2005-09-09|2005-09-15|Estimate|||||||2008-01-28|2008-01-30|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|July 2007|Actual|2007-07-31|||||Interventional|||The Effect of a Weight Management Program During Treatment With Olanzapine|The Effect of a Weight Management Program to Prevent Weight Gain and Metabolic Abnormalities During Treatment With the Atypical Neuroleptic Olanzapine: A Randomised Study|Completed||N/A|100|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-06-01 04:38:58.665493|2018-06-01 04:38:58.665493
NCT00169689|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-01-28|2005-09-09|2005-09-15|Estimate|||||||2008-01-28|2008-01-30|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|||||Interventional|||Repetitive Transcranial Magnetic Stimulation|Therapeutic and Biological Effects of High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia|Completed||N/A|40|Actual|Heinrich-Heine University, Duesseldorf||1|||f||||f||||||||||2018-06-01 04:38:58.780248|2018-06-01 04:38:58.780248
NCT00169676|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-06-28|2005-09-09|2005-09-15|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2003||2003-06-30|September 2008|2008-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Registry and Database Lap Prostatectomy|Laparoscopic Radical Prostatectomy: A Registry and Database|Completed|||9|Actual|Indiana Kidney Stone Institute|||1||f||||f||||||||||2018-06-01 04:38:58.919432|2018-06-01 04:38:58.919432
NCT00169663|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-04-23|2005-09-09|2005-09-15|Estimate|||||||2012-04-23|2012-04-24|Estimate|July 2003||2003-07-31|April 2012|2012-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Brushite Kidney Stones: A Registry and Database of Clinical and Laboratory Findings|Brushite Stones: A Registry and Database of Clinical and Laboratory Findings|Completed|||90|Actual|Indiana Kidney Stone Institute|||||f||||f||||||||||2018-06-01 04:38:59.078127|2018-06-01 04:38:59.078127
NCT00169650|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-02-14|2005-09-09|2005-09-15|Estimate|||||||2017-02-14|2017-02-16|Actual|July 2003||2003-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Laparoscopic Pyeloplasty Registry and Database|Laparoscopic Pyeloplasty: A Registry and Database|Completed|||64|Actual|Indiana Kidney Stone Institute|||1||f||||f||||||||||2018-06-01 04:38:59.186026|2018-06-01 04:38:59.186026
NCT00169637|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-30|2005-09-13|2005-09-15|Estimate|||||||2008-10-30|2008-10-31|Estimate|June 2006||2006-06-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|||||Interventional|||Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome|Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome|Completed||Phase 3|14|Actual|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:38:59.358955|2018-06-01 04:38:59.358955
NCT00169468|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-05-26|2005-09-13|2005-09-15|Estimate|||||||2009-05-26|2009-05-27|Estimate|January 2005||2005-01-31|May 2009|2009-05-31|August 2011|Anticipated|2011-08-31|||||Interventional|||Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma|Phase II Study of the Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma|Unknown status|Active, not recruiting|Phase 2|48||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:39:01.751965|2018-06-01 04:39:01.751965
NCT00169624|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-10-04|2005-09-09|2005-09-15|Estimate|||||||2007-10-04|2007-10-05|Estimate|October 2005||2005-10-31|October 2007|2007-10-31||||||||Interventional|||Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin|The DIAMET Study: Peripheral and Coronary Endothelial Dysfunction in Type 2diabetic Patients- Evaluation of Reversibility Following 3 Months of Metformin Treatment|Terminated||Phase 3|30||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:38:59.469155|2018-06-01 04:38:59.469155
NCT00169611|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-01-26|2005-09-09|2005-09-15|Estimate|||||||2011-01-26|2011-01-27|Estimate|January 2004||2004-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate|Comportemental and Neuropsychologic Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate. A Double-blind Randomised Study Methylphenidate Versus Placebo|Completed||Phase 4|80|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:38:59.613203|2018-06-01 04:38:59.613203
NCT00169598|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-26|2005-09-13|2005-09-15|Estimate|||||||2007-04-26|2007-04-27|Estimate|February 2002||2002-02-28|April 2007|2007-04-30||||||||Interventional|TEPELY||Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study|Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study|Unknown status|Active, not recruiting|N/A|80||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:38:59.793564|2018-06-01 04:38:59.793564
NCT00169585|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-24|2005-09-12|2005-09-15|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2005||2005-03-31|May 2017|2017-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)|A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA.|Completed||Phase 3|240|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:38:59.875676|2018-06-01 04:38:59.875676
NCT00169572|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-05-06|2005-09-12|2005-09-15|Estimate|||||||2010-05-06|2010-05-10|Estimate|February 2005||2005-02-28|May 2010|2010-05-31||||||||Interventional|||Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy|See Detailed Description|Completed||Phase 2|492||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:39:00.172344|2018-06-01 04:39:00.172344
NCT00169559|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-10-18|2005-09-12|2005-09-15|Estimate|||||||2012-10-18|2012-10-22|Estimate|November 2003||2003-11-30|October 2012|2012-10-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||"Dyslipidemia Study Investigating The Increase In Good Cholesterol"|A Multi-center, Three-staged, Randomized, Parallel Group, Sequential, Double-blind, fenofibrate-and Placebo-controlled Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma HDLc and TG of Eight Weeks Treatment With 1µg to 20µg Daily Doses of GW590735 in Otherwise Healthy Subjects With Low HDLc, Mildly to Moderately Elevated TG, and Normal LDLc|Completed||Phase 2|250|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 04:39:00.424315|2018-06-01 04:39:00.424315
NCT00169546|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-09-13|2005-09-12|2005-09-15|Estimate|||||||2016-09-13|2016-09-15|Estimate|January 2003||2003-01-31|September 2016|2016-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.|Randomised, Double-blind Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS ® Inhlaer 50/100mcg Twice Daily vs. FLIXOTIDE® Inhaler 200mcg Twice Daily.|Completed||Phase 4|64|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:39:00.670717|2018-06-01 04:39:00.670717
NCT00169533|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-11-13|2005-09-12|2005-09-15|Estimate|||||||2017-11-13|2017-11-17|Actual|August 19, 2004|Actual|2004-08-19|November 2017|2017-11-30|May 5, 2009|Actual|2009-05-05|May 5, 2009|Actual|2009-05-05||Interventional|||Rollover Study Of Lapatinib In Cancer Patients|An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.|Completed||Phase 1|31|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:39:00.895597|2018-06-01 04:39:00.895597
NCT00169520|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-10-15|2005-09-12|2005-09-15|Estimate|||||||2008-10-15|2008-10-16|Estimate|June 2004||2004-06-30|October 2008|2008-10-31||||||||Interventional|||SB-715992 In Combination With Docetaxel In Patients With Solid Tumors|A Phase I, Open-Label Study of SB-715992 in Combination With Docetaxel in Patients With Advanced Solid Tumors.|Completed||Phase 1|30|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:39:01.029968|2018-06-01 04:39:01.029968
NCT00169507|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-05-24|2005-09-12|2005-09-15|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2005||2005-03-31|May 2017|2017-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)|Phase III Multicentric Open Study to Evaluate Immunological Memory Induced by 3-dose Primary Vaccination Followed by Booster Dose of GSK Biologicals' 11-valent Conjugate Pneumococcal Vaccine Compared to Unprimed Subjects by Giving 1 Dose of Aventis Pasteur's Pneumo 23|Completed||Phase 3|100||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:39:01.141098|2018-06-01 04:39:01.141098
NCT00169494|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-09-09|2005-09-12|2005-09-15|Estimate|||||||2016-09-09|2016-09-12|Estimate|September 2004||2004-09-30|September 2016|2016-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18|Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process|Completed||Phase 3|770|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:39:01.246611|2018-06-01 04:39:01.246611
NCT00169481|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-01-09|2005-09-12|2005-09-15|Estimate|||||||2017-01-09|2017-01-10|Estimate|October 2004||2004-10-31|January 2017|2017-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine|A Randomized, Controlled, Phase II Study to Evaluate the Safety and Immunogenicity of Different Formulations of GlaxoSmithKline Biologicals' 11-valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly as a 3-dose Primary Immunization (2-3-4 Month Schedule) Before 6 Months of Age|Completed||Phase 2|689|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:39:01.509424|2018-06-01 04:39:01.509424
NCT00169455|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-13|2005-09-09|2005-09-15|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2005||2005-03-31|January 2017|2017-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants|A Phase IIIb, Partially Blind, Randomized, Placebo-controlled Study to Asses the Effect on Immunogenicity of Administration of Vaccine Without Buffering Agent and to Assess Heat Stability in Terms of Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Following a 0, 2 Month Schedule, in Healthy Infants Previously Uninfected With Human Rotavirus|Completed||Phase 3|450|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:39:01.881346|2018-06-01 04:39:01.881346
NCT00169442|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2017-01-10||2017-05-08|2005-09-12|2005-09-15|Estimate|2017-01-10|2017-02-28|Actual||||2017-05-08|2017-06-12|Actual|February 10, 2005|Actual|2005-02-10|May 2017|2017-05-31|March 10, 2006|Actual|2006-03-10|March 1, 2006|Actual|2006-03-01||Interventional|||Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants|Immune Memory of GSK's DTPw-HBV/Hib Vaccine by Giving Plain PRP Polysaccharide at 10 Mths. Immuno & Reacto of a Booster Dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 Mths in Infants Previously Primed With DTPw-HBV/Hib|Completed||Phase 3|745|Actual|GlaxoSmithKline|None reported.|6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:39:02.070763|2018-06-01 04:39:02.070763
NCT00169416|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-04-14|2005-09-09|2005-09-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2005||2005-03-31|April 2015|2015-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Evaluation Of Valaciclovir In Patients With Chickenpox|Clinical Evaluation of Valaciclovir Hydrochloride: 256U87 in Patients With Chickenpox - Open Uncontrolled Study.|Completed||Phase 3|43|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:39:03.590939|2018-06-01 04:39:03.590939
NCT00169403|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-28|2005-09-12|2005-09-15|Estimate|||||||2007-08-28|2007-08-29|Estimate||||September 2005|2005-09-30||||||||Interventional|||Pallidal Stimulation in Patients With Idiopathic Generalised Dystonia||Unknown status|Recruiting|Phase 3|||Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:39:03.686686|2018-06-01 04:39:03.686686
NCT00169390|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-03-17|2005-09-09|2005-09-15|Estimate|||||||2015-03-17|2015-03-19|Estimate|March 2004||2004-03-31|August 2009|2009-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Monoamine Oxidases in Smoking Pregnant Women and Newborns|Comparison of Monoamines Oxidases A and B Activities and the Metabolism of Nicotine in Smoking and Nonsmoking Pregnant Women and in Their Newborns. Evaluation of Their Effects on the Newborns' Behavior|Completed|||59|Actual|Groupe Hospitalier Pitie-Salpetriere|||2||f||||f||||||Samples Without DNA|"~     plasma DHPG, HVA, 5HIAA, 5HT, cotinine~   "|||2018-06-01 04:39:03.779201|2018-06-01 04:39:03.779201
NCT00169377|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2018-03-20|2005-09-12|2005-09-15|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2005||2005-10-31|March 2018|2018-03-31|May 2007|Actual|2007-05-31|||||Interventional|||Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)|Study of the Effects of High Frequency Stimulation of the Subthalamic Stimulation in the Treatment of Severe Obsessive-compulsive Disorders|Completed||Phase 1/Phase 2|16|Actual|Groupe Hospitalier Pitie-Salpetriere||2|||f||||t||||||||||2018-06-01 04:39:03.922308|2018-06-01 04:39:03.922308
NCT00169364|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-28|2005-09-12|2005-09-15|Estimate|||||||2007-08-28|2007-08-29|Estimate|May 2002||2002-05-31|September 2005|2005-09-30||||||||Interventional|||Clinical, Molecular and Metabolic Characteristics of Parkinson's Disease (PD) Patients With Parkin Mutation|Comparison of Clinical, Molecular and Metabolic Characteristics of PD Patients With and Without Parkin Mutation|Unknown status|Recruiting|N/A|50|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:39:04.036743|2018-06-01 04:39:04.036743
NCT00169351|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate||||September 2005|2005-09-30||||||||Observational|||National Gilles De La Tourette Study Group||Unknown status|Recruiting||||Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:39:04.124809|2018-06-01 04:39:04.124809
NCT00169338|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-09-14|2005-09-13|2005-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2005||2005-09-30|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia||Completed||Phase 2|13|Actual|Groupe Hospitalier Pitie-Salpetriere||2|||f||||||||||||||2018-06-01 04:39:04.192943|2018-06-01 04:39:04.192943
NCT00169325|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-09-11|2005-09-12|2005-09-15|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2005||2005-09-30|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Clinical, Neurophysiological and Radiological Evaluation of Patients With Basal Ganglia Lesions||Completed|||11|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:39:04.251648|2018-06-01 04:39:04.251648
NCT00169312|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-09-19|2005-09-13|2005-09-15|Estimate|||||||2013-09-19|2013-09-20|Estimate|August 2005||2005-08-31|September 2009|2009-09-30|June 2007||2007-06-30|||||Interventional|||Internet-Based Nutrition Education Program in Preventing Cancer in Participants of Health Maintenance Organizations|The HMO Cancer Research Network (CRN) - Making Effective Nutritional Choices for Cancer Prevention: The MENU Study|Unknown status|Active, not recruiting|N/A|2619|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:39:04.301118|2018-06-01 04:39:04.301118
NCT00169299|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|June 2001||2001-06-30|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||Herbal Alternatives for Menopause Symptoms (HALT Study)|Herbal Alternatives for Menopause Symptoms: A Randomized Trial|Unknown status|Active, not recruiting|Phase 4|351||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:39:04.372307|2018-06-01 04:39:04.372307
NCT00169286|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-10-11|2005-09-12|2005-09-15|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2003||2003-07-31|October 2017|2017-10-31|June 2005||2005-06-30|||||Interventional|||Organized Self-management Support for Chronic Depression|Organized Self-management Support for Chronic Depression|Completed||N/A|104||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:39:04.431041|2018-06-01 04:39:04.431041
NCT00169273|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-10-11|2005-09-12|2005-09-15|Estimate|||||||2017-10-11|2017-10-13|Actual|April 2004||2004-04-30|October 2017|2017-10-31|April 2007|Actual|2007-04-30|February 2007|Actual|2007-02-28||Interventional|||Epidemiology and Care of Comorbid Obesity and Depression|Epidemiology and Care of Comorbid Obesity and Depression|Completed||N/A|192|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 04:39:04.514389|2018-06-01 04:39:04.514389
NCT00169260|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-12-27|2005-09-12|2005-09-15|Estimate|||||||2010-12-27|2010-12-29|Estimate|February 2005||2005-02-28|December 2010|2010-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Proactive Health Intervention for Tobacco Users (Get PHIT)|Proactive Cessation Intervention With Biomarker Feedback|Completed||Phase 2/Phase 3|536|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-06-01 04:39:04.583316|2018-06-01 04:39:04.583316
NCT00169247|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-06-23|2005-09-12|2005-09-15|Estimate|||||||2011-06-23|2011-06-27|Estimate|October 2005||2005-10-31|June 2011|2011-06-30||||April 2011|Actual|2011-04-30||Interventional|||Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation|Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study|Completed||Phase 2|156|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou|||||f||||||||||||||2018-06-01 04:39:04.672995|2018-06-01 04:39:04.672995
NCT00169234|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-10-11|2005-09-09|2005-09-15|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2003||2003-05-31|October 2017|2017-10-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Pneumococcal Adult-dose Ranging Immunization Study|Immunogenicity and Safety of Varying Doses of a 7-valent Conjugate Pneumococcal Vaccine in Adults 70-79 Years of Age Who Were Previously Vaccinated With the 23-valent Pneumococcal Polysaccharide Vaccine|Completed||Phase 1/Phase 2|220|Actual|Kaiser Permanente||5|||f||||t||||||||||2018-06-01 04:39:05.766504|2018-06-01 04:39:05.766504
NCT00169221|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-11-14|2005-09-12|2005-09-15|Estimate|||||||2011-11-14|2011-11-15|Estimate|September 2005||2005-09-30|November 2011|2011-11-30|July 2011|Actual|2011-07-31|July 2009|Actual|2009-07-31||Interventional|||Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas|CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) in Upper Aerodigestive Tract Carcinomas|Terminated||Phase 2|54|Actual|Groupe Oncologie Radiotherapie Tete et Cou||2||"Toxicity in an independent study IMEX. The trial was subsequently terminated (54 pts instead of~   140) despite safety analyses showing no excess of toxicity"|f||||||||||||||2018-06-01 04:39:05.850401|2018-06-01 04:39:05.850401
NCT00169208|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-09|2005-09-09|2005-09-15|Estimate|||||||2005-12-09|2005-12-13|Estimate|April 2001||2001-04-30|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma|An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-Tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma.|Completed||Phase 2|50||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:39:05.919218|2018-06-01 04:39:05.919218
NCT00169195|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2015-09-01|2005-09-12|2005-09-15|Estimate|||||||2015-09-01|2015-09-02|Estimate|April 2003||2003-04-30|September 2015|2015-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma|Gemcitabine-oxaliplatin Plus Rituximab (R-GEMOX) in Refractory/Relapsed Patients With CD 20 Positive Diffuse Large B-cell Lymphoma, Non Eligible for High-dose Chemotherapy Followed by Autotransplantation|Completed||Phase 2|49|Actual|Lymphoma Study Association||1|||f||||||||||||||2018-06-01 04:39:06.028135|2018-06-01 04:39:06.028135
NCT00169182|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-15|Estimate|||||||2005-09-09|2005-09-15|Estimate|December 2000||2000-12-31|September 2005|2005-09-30||||||||Interventional|||Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma|Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma|Completed||Phase 3|220||Groupe Oncologie Radiotherapie Tete et Cou|||||f||||||||||||||2018-06-01 04:39:06.133242|2018-06-01 04:39:06.133242
NCT00169169|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|October 1999||1999-10-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma|Randomised Phase 3 Study of Rituximab in High-Risk Patients With Diffuse Large B-Cell Lymphoma Who Received a First-Line Consolidative Chemotherapy With Autologous Stem Cell Transplant (ASCT).|Terminated||Phase 3|430||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:39:06.199801|2018-06-01 04:39:06.199801
NCT00169156|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-09|2005-09-12|2005-09-15|Estimate|||||||2017-03-09|2017-03-13|Actual|December 2005|Actual|2005-12-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|December 2008|Actual|2008-12-31||Interventional|||A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma|Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).|Completed||Phase 2|27|Actual|Lymphoma Study Association||1|||f||||t||||||||No||2018-06-01 04:39:06.370202|2018-06-01 04:39:06.370202
NCT00169143|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-09-06|2005-09-12|2005-09-15|Estimate|||||||2006-09-06|2006-09-08|Estimate|May 2004||2004-05-31|September 2006|2006-09-30|January 2007||2007-01-31|||||Interventional|||Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma|Study of R-ACVBP Regimen Supported by Pegfilgrastim in Previously Untreated Patients Aged From 18 to 60 Years With High-Risk Diffuse Large B-Cell Lymphoma (Age-Adjusted Ipi >or= 2)|Completed||Phase 2|60||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:39:06.476084|2018-06-01 04:39:06.476084
NCT00169130|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-07-12|2005-09-12|2005-09-15|Estimate|||||||2007-07-12|2007-07-13|Estimate|October 1999||1999-10-31|July 2007|2007-07-31||||||||Interventional|||ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma|Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma|Completed||Phase 2/Phase 3|300||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:39:06.582596|2018-06-01 04:39:06.582596
NCT00169117|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2017-01-11|2005-09-13|2005-09-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2002||2002-06-30|January 2017|2017-01-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Stitch in Time May Save Lives: Turning Poor Bednets Into Good Ones|A Stitch in Time May Save Lives: Turning Poor Bednets Into Good Ones|Completed||N/A|772|Actual|London School of Hygiene and Tropical Medicine||1|||f||||f||||||||||2018-06-01 04:39:06.697836|2018-06-01 04:39:06.697836
NCT00169104|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-10-19|2005-09-10|2005-09-15|Estimate|||||||2011-10-19|2011-10-21|Estimate|July 2002||2002-07-31|October 2011|2011-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function|A Phase II Trial of Trastuzumab, Neupogen, and Vinorelbine Investigating the Effects on Immune Function and Clinical Outcomes in Patients With Metastatic Breast Cancer Overexpressing Her-2/Neu|Terminated||Phase 2/Phase 3|23|Actual|Dartmouth-Hitchcock Medical Center||2||Closed due to achievement of primary study endpoint|f||||t||||||||||2018-06-01 04:39:06.802859|2018-06-01 04:39:06.802859
NCT00169091|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2015-04-06|2005-09-10|2005-09-15|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 1996||1996-03-31|April 2015|2015-04-30|October 2003||2003-10-31|September 2003|Actual|2003-09-30||Interventional|||Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia|Clozapine or Haloperidol in First Episode Schizophrenia|Terminated||Phase 4|32|Actual|Harvard Medical School||2|||f||||||||||||||2018-06-01 04:39:06.936997|2018-06-01 04:39:06.936997
NCT00169078|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-11|2005-09-09|2005-09-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2002||2002-07-31|January 2017|2017-01-31|December 2002||2002-12-31|||||Interventional|||Impact of Insecticide-treated Curtains on Antimalarial Drug Resistance|A Study of the Impact of Insecticide-treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso|Completed||N/A|1035||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:39:07.022814|2018-06-01 04:39:07.022814
NCT00169065|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2015-04-06|2005-09-10|2005-09-15|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 1998||1998-08-31|April 2015|2015-04-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|COES||Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia|Clozapine vs. Olanzapine: An Effectiveness Study|Completed||Phase 4|38|Actual|Harvard Medical School||2|||f||||t||||||||||2018-06-01 04:39:07.089652|2018-06-01 04:39:07.089652
NCT00169052|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-09-06|2005-09-11|2005-09-15|Estimate|||||||2013-09-06|2013-09-10|Estimate|September 2001||2001-09-30|September 2001|2001-09-30|August 2006||2006-08-31|||||Interventional|||Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in Older People|Rehabilitation and Health Care for Elderly With SMI|Completed||N/A|180||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 04:39:07.156387|2018-06-01 04:39:07.156387
NCT00169039|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2015-04-06|2005-09-10|2005-09-15|Estimate|||||||2015-04-06|2015-04-07|Estimate|December 1994||1994-12-31|April 2015|2015-04-30|February 2002||2002-02-28|||||Interventional|||Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia|Clozapine Response and Biogenic Amines in Schizophrenia|Terminated||Phase 4|66||Harvard Medical School|||||f||||||||||||||2018-06-01 04:39:07.225822|2018-06-01 04:39:07.225822
NCT00169026|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2018-03-12|2005-09-10|2005-09-15|Estimate|||||||2018-03-12|2018-03-14|Actual|May 1999||1999-05-31|March 2018|2018-03-31|January 2004||2004-01-31|||||Interventional|||Alcoholism and Schizophrenia: Effects of Clozapine|Alcoholism and Schizophrenia: Effects of Clozapine|Terminated||Phase 4|64||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 04:39:07.302035|2018-06-01 04:39:07.302035
NCT00169013|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-11|2005-09-09|2005-09-15|Estimate|||||||2007-04-11|2007-04-12|Estimate|May 2002||2002-05-31|April 2007|2007-04-30|June 2006||2006-06-30|||||Interventional|||Gabapentin in Phantom and Stump Pain|Gabapentin in the Prevention of Phantom Limb Pain|Completed||Phase 4|||Danish Pain Research Center|||||f||||t||||||||||2018-06-01 04:39:07.36248|2018-06-01 04:39:07.36248
NCT00169000|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-08-04|2005-09-09|2005-09-15|Estimate|||||||2009-08-04|2009-08-06|Estimate|January 2003||2003-01-31|August 2009|2009-08-31|March 2006|Actual|2006-03-31|September 2005|Actual|2005-09-30||Interventional|||Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers|Phase I Study of a Novel Schedule of Capecitabine and Docetaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 04:39:07.414979|2018-06-01 04:39:07.414979
NCT00168987|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-05-05|2005-09-14|2005-09-15|Estimate|||||||2008-05-05|2008-05-09|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|June 2007|Actual|2007-06-30|November 2006|Actual|2006-11-30||Interventional|||Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors|Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors|Completed||Phase 4|30|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:07.584378|2018-06-01 04:39:07.584378
NCT00168974|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-11-15|2005-09-13|2005-09-15|Estimate|||||||2007-11-15|2007-11-16|Estimate|January 2004||2004-01-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Observational|||Neuropathic Pain and Fabry Disease|Somatosensoric and Autonomic Disturbances in Female Patients With Fabry Disease|Completed|||25||Danish Pain Research Center|||||f||||||||||||||2018-06-01 04:39:07.659246|2018-06-01 04:39:07.659246
NCT00168961|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-06|2005-09-13|2005-09-15|Estimate|||||||2010-05-06|2010-05-07|Estimate|December 2003||2003-12-31|September 2005|2005-09-30|June 2007|Actual|2007-06-30|December 2006|Actual|2006-12-31||Interventional|||Enteral Nutrition in Liver Cirrhosis||Completed||Phase 4|||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:07.710883|2018-06-01 04:39:07.710883
NCT00168948|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-11-01|2005-09-13|2005-09-15|Estimate|||||||2005-11-01|2005-11-02|Estimate|March 2003||2003-03-31|February 2003|2003-02-28|August 2005||2005-08-31|||||Interventional|||Intermittent Antimalaria Treatment With SP in African Children|Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial|Unknown status|Active, not recruiting|Phase 4|1200||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:07.76515|2018-06-01 04:39:07.76515
NCT00168935|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-05-06|2005-09-13|2005-09-15|Estimate|||||||2010-05-06|2010-05-07|Estimate|March 2004||2004-03-31|September 2005|2005-09-30|December 2008|Actual|2008-12-31|August 2007|Actual|2007-08-31||Interventional|||Malnutrition in Gastroenterology Patients||Completed||Phase 4|||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:07.842671|2018-06-01 04:39:07.842671
NCT00168922|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-04-27|2005-09-09|2005-09-15|Estimate|||||||2006-04-27|2006-04-27|Estimate|February 2001||2001-02-28|January 2001|2001-01-31|December 2006||2006-12-31|||||Interventional|||Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)|Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy|Unknown status|Recruiting|Phase 2|50||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:07.906972|2018-06-01 04:39:07.906972
NCT00168909|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-05-08|2005-09-11|2005-09-15|Estimate|||||||2008-05-08|2008-05-09|Estimate|June 2003||2003-06-30|May 2008|2008-05-31|May 2008|Actual|2008-05-31|July 2007|Actual|2007-07-31||Interventional|||Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)|Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls|Completed||Phase 4|282|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 04:39:07.986403|2018-06-01 04:39:07.986403
NCT00168896|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-02-13|2005-09-09|2005-09-15|Estimate|||||||2006-02-13|2006-02-14|Estimate|October 2001||2001-10-31|September 2001|2001-09-30|December 2006||2006-12-31|||||Interventional|||A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage|A Randomised Phase II/III Study to Compare the Combination of Carboplatin Plus Irinotecan Vs. the Combination of Carboplatin Plus Etoposide for SCLC in Extensive Disease Stage|Unknown status|Recruiting|Phase 2/Phase 3|286||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:08.101535|2018-06-01 04:39:08.101535
NCT00168883|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-10-31|2005-09-09|2005-09-15|Estimate|||||||2006-10-31|2006-11-01|Estimate|October 2002||2002-10-31|September 2006|2006-09-30|December 2006||2006-12-31|||||Interventional|||Study for Patients With Non Small Cell Lung Cancer (NSCLC)|Randomized Phase II Study to Determine the Efficacy of a Three Weekly vs. Weekly Therapy With Paclitaxel Plus Carboplatin vs. Paclitaxel Plus Vinorelbine for Patients With Non Small Cell Lung Cancer According to UICC Stage IIIB and IV|Unknown status|Recruiting|Phase 2|80||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:08.202735|2018-06-01 04:39:08.202735
NCT00168870|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-08-30|2005-09-09|2005-09-15|Estimate|||||||2007-08-30|2007-08-31|Estimate|February 2003||2003-02-28|September 2006|2006-09-30||||||||Interventional|||Study of Metastatic Ocular Melanoma|Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma|Unknown status|Recruiting|Phase 2|48|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:39:08.320432|2018-06-01 04:39:08.320432
NCT00168857|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-04|2005-09-14|2005-09-15|Estimate|||||||2013-11-04|2013-11-05|Estimate|July 2003||2003-07-31|November 2013|2013-11-30||||June 2006|Actual|2006-06-30||Interventional|||A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)|A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)|Completed||Phase 4|860|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:39:08.420432|2018-06-01 04:39:08.420432
NCT00168844|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-01-30||2014-05-15|2005-09-12|2005-09-15|Estimate|2009-09-04|2009-10-07|Estimate||||2014-05-15|2014-05-20|Estimate|January 2003||2003-01-31|September 2013|2013-09-30||||June 2005|Actual|2005-06-30||Interventional|||Tiotropium / Respimat One-Year Study|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|983|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 04:39:08.754872|2018-06-01 04:39:08.754872
NCT00168831|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-01-30||2014-05-15|2005-09-12|2005-09-15|Estimate|2009-09-04|2009-10-07|Estimate||||2014-05-15|2014-05-20|Estimate|February 2003||2003-02-28|September 2013|2013-09-30||||June 2005|Actual|2005-06-30||Interventional|||Tiotropium / Respimat One-Year Study|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1007|Actual|Boehringer Ingelheim||3|||||||||||||||||2018-06-01 04:39:10.972936|2018-06-01 04:39:10.972936
NCT00168818|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-11-18||2014-05-08|2005-09-12|2005-09-15|Estimate|2010-11-18|2010-12-20|Estimate||||2014-05-08|2014-05-19|Estimate|November 2004||2004-11-30|February 2014|2014-02-28||||July 2006|Actual|2006-07-31||Interventional|||Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery|A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Replacement Surgery. RE-NOVATE (Extended Thromboembolism Prevention After Hip Surgery)|Completed||Phase 3|3494|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 04:39:13.234227|2018-06-01 04:39:13.234227
NCT00168805|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-11-18||2014-05-08|2005-09-12|2005-09-15|Estimate|2010-11-18|2010-12-17|Estimate||||2014-05-08|2014-05-19|Estimate|November 2004||2004-11-30|February 2014|2014-02-28||||May 2006|Actual|2006-05-31||Interventional|||RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery|RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days|Completed||Phase 3|2101|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 04:39:14.645085|2018-06-01 04:39:14.645085
NCT00168792|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-10-28|2005-09-09|2005-09-15|Estimate|||||||2013-10-28|2013-10-29|Estimate|November 2003||2003-11-30|October 2013|2013-10-31||||July 2006||2006-07-31||Interventional|||A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)|A Phase IIIb - IV, Randomised, Open Label Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early PCI as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction. ASSENT 4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction.)|Terminated||Phase 4|1671||Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:39:15.606825|2018-06-01 04:39:15.606825
NCT00168779|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-12-27|2005-09-12|2005-09-15|Estimate|||||||2017-12-27|2017-12-28|Actual|September 2005||2005-09-30|December 2017|2017-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension|A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 Hypertension.|Completed||Phase 4|1185||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:39:16.052918|2018-06-01 04:39:16.052918
NCT00168766|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-09-12|2005-09-13|2005-09-15|Estimate|||||||2013-09-12|2013-09-16|Estimate|January 2003||2003-01-31|April 2011|2011-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS|A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 4|345|Actual|Biogen||2|||f||||f||||||||||2018-06-01 04:39:16.30127|2018-06-01 04:39:16.30127
NCT00168753|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-09-05|2005-09-13|2005-09-15|Estimate|||||||2014-09-05|2014-09-08|Estimate|July 2004||2004-07-31|September 2014|2014-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Community Based Trial for AMEVIVE®|An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of Alefacept, Following a Standard 12-Week Course of Amevive®, With Commonly Used Clinical Assessment Tools|Completed||Phase 4|114|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 04:39:16.423238|2018-06-01 04:39:16.423238
NCT00168740|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-15|Estimate|||||||2005-09-13|2005-09-15|Estimate|April 1995||1995-04-30|September 2005|2005-09-30||||||||Interventional|||Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)|Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma|Completed||Phase 3|150||Biogen|||||||||||||||||||2018-06-01 04:39:16.576616|2018-06-01 04:39:16.576616
NCT00168727|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-18|2005-09-13|2005-09-15|Estimate|||||||2006-10-18|2006-10-19|Estimate|June 2003||2003-06-30|October 2006|2006-10-31|October 2005||2005-10-31|||||Interventional|||Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma|Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma|Completed||Phase 4|12||Biogen|||||f||||||||||||||2018-06-01 04:39:16.691355|2018-06-01 04:39:16.691355
NCT00168714|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-06-06|2005-09-09|2005-09-15|Estimate|||||||2014-06-06|2014-06-09|Estimate|February 2004||2004-02-29|June 2014|2014-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)|Avonex Pregnancy Exposure Registry|Completed|||329|Actual|Biogen|||1||f||||t||||||||||2018-06-01 04:39:16.76732|2018-06-01 04:39:16.76732
NCT00168701|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-11-14|2005-09-09|2005-09-15|Estimate|||||||2007-11-14|2007-11-15|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Efficacy and Safety of BG00012 in MS|Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|260||Biogen|||||f||||||||||||||2018-06-01 04:39:16.859211|2018-06-01 04:39:16.859211
NCT00168688|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-15|2005-09-13|2005-09-15|Estimate|||||||2013-11-15|2013-11-18|Estimate|January 2001||2001-01-31|November 2013|2013-11-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Prenatal Multi-micronutrient Supplementation and Pregnancy Outcome|The Effects of Prenatal Multi-micronutrient Supplements on Pregnancy Outcome, Peri- and Neonatal Mortality on Maternal and Infant Nutritional Status: A Randomised, Controlled Trial Among Women in Guinea-Bissau|Completed||Phase 1|2100|Actual|Bandim Health Project||3|||f||||||||||||||2018-06-01 04:39:16.978498|2018-06-01 04:39:16.978498
NCT00168662|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-02-25|2005-09-09|2005-09-15|Estimate|||||||2008-02-25|2008-02-26|Estimate|March 1995||1995-03-31|February 2008|2008-02-29|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Non-Specific Effects of Standard Titre Measles Vaccination|Trial of Two-Dose Standard Measles Vaccination Schedule: Long-Term Impact on Morbidity and Mortality of a Two-Dose Vaccination Schedule at 6 and 9 Months of Age Compared With a Standard Regimen of One Dose at 9 Months of Age|Completed||Phase 4|7800||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.051591|2018-06-01 04:39:17.051591
NCT00168649|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-14|2005-09-12|2005-09-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|June 2005||2005-06-30|November 2013|2013-11-30|June 2014||2014-06-30|||||Interventional|||Vitamin A and Response to Endotoxin|The Effect of Vitamin A on the Response to Endotoxin|Unknown status|Active, not recruiting|N/A|40||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.139804|2018-06-01 04:39:17.139804
NCT00168636|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-14|2005-09-12|2005-09-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2004||2004-11-30|November 2013|2013-11-30||||November 2013|Actual|2013-11-30||Interventional|||Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality|The Impact of Different Doses of Vitamin A Supplementation on Male and Female Childhood Morbidity and Mortality|Completed||Phase 4|11000||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.194546|2018-06-01 04:39:17.194546
NCT00168623|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-14|2005-09-12|2005-09-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2003||2003-11-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|||||Interventional|||Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity|Randomised Trial of Vitamin A Supplementation Given With Routine Childhood Vaccines at National Immunisation Days|Unknown status|Active, not recruiting|Phase 4|6200||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.253417|2018-06-01 04:39:17.253417
NCT00168610|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-14|2005-09-09|2005-09-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2004||2004-11-30|November 2013|2013-11-30||||||||Interventional|||Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine|Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau|Unknown status|Active, not recruiting|Phase 4|7600|Actual|Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.310364|2018-06-01 04:39:17.310364
NCT00168597|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-14|2005-09-09|2005-09-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|August 2002||2002-08-31|November 2013|2013-11-30||||November 2013|Actual|2013-11-30||Interventional|||Vitamin A With BCG Vaccine|Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries?|Completed||Phase 4|4800||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.384806|2018-06-01 04:39:17.384806
NCT00168584|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-15|Estimate|||||||2005-09-12|2005-09-15|Estimate|November 2002||2002-11-30|September 2005|2005-09-30|August 2003||2003-08-31|||||Interventional|||Different Doses of Vitamin A and Childhood Morbidity and Mortality|Randomised Study of the Impact of Different Doses of Vitamin A on Childhood Morbidity and Mortality|Completed||Phase 4|5400||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.440085|2018-06-01 04:39:17.440085
NCT00168571|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-09-21|2005-09-09|2005-09-15|Estimate|||||||2011-09-21|2011-09-22|Estimate|March 2002||2002-03-31|September 2006|2006-09-30|January 2007|Actual|2007-01-31|||||Interventional|||Long-term Follow-up of Measles Antibodies|Long-term Follow-up of Protective Measles Antibodies in the Two-dose Study of Standard-titre Measles Vaccine in Guinea-Bissau|Completed||Phase 4|1960||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.490786|2018-06-01 04:39:17.490786
NCT00168558|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-03-04|2005-09-09|2005-09-15|Estimate|||||||2012-03-04|2012-03-06|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Early Two-dose Measles Vaccination Trial|Measles Vaccination in Guinea-Bissau. Strategies to Reduce Disease Burden and Improve Child Survival|Completed||Phase 4|5879|Actual|Bandim Health Project||3|||f||||t||||||||||2018-06-01 04:39:17.544986|2018-06-01 04:39:17.544986
NCT00168545|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-09-21|2005-09-09|2005-09-15|Estimate|||||||2011-09-21|2011-09-22|Estimate|January 2006||2006-01-31|September 2006|2006-09-30|January 2007|Actual|2007-01-31|||||Interventional|||Immunology of Non-specific Effects of Vaccine|Non-specific Effects of Vaccines - In Search of the Immunological Background|Completed||Phase 4|400||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.639321|2018-06-01 04:39:17.639321
NCT00168532|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-02-25|2005-09-09|2005-09-15|Estimate|||||||2008-02-25|2008-02-26|Estimate|January 1998||1998-01-31|February 2008|2008-02-29|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Prophylactic Antibiotics in Measles|Prophylactic Antibiotics in Measles Infection. A Community-Based Randomised Double-Blind Placebo-Controlled Trial in Guinea-Bissau|Completed||Phase 3|218||Bandim Health Project|||||f||||||||||||||2018-06-01 04:39:17.724489|2018-06-01 04:39:17.724489
NCT00168519|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2009-12-14|2005-09-14|2005-09-15|Estimate|||||||2009-12-14|2009-12-15|Estimate|October 2002||2002-10-31|December 2009|2009-12-31|April 2009|Actual|2009-04-30|||||Interventional|||Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes|Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes|Completed||N/A|40|Anticipated|Baker Heart Research Institute||1|||f||||||||||||||2018-06-01 04:39:17.783193|2018-06-01 04:39:17.783193
NCT00168506|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-04-04|2005-09-10|2005-09-15|Estimate|||||||2007-04-04|2007-04-05|Estimate|June 2002||2002-06-30|April 2007|2007-04-30|December 2008|Anticipated|2008-12-31|||||Interventional|||Panic Disorder and Cardiac Risk|Panic Disorder and Cardiac Risk: Evaluation of a Psychological Treatment Which Addresses Biology, Psychology and Behaviour|Unknown status|Recruiting|N/A|50||Baker Heart Research Institute|||||f||||||||||||||2018-06-01 04:39:17.842879|2018-06-01 04:39:17.842879
NCT00168493|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-05-19|2005-09-10|2005-09-15|Estimate|||||||2008-05-19|2008-05-20|Estimate|June 2000||2000-06-30|May 2008|2008-05-31|December 2009|Anticipated|2009-12-31|December 2008|Anticipated|2008-12-31||Interventional|||The Neurobiology of Depressive Illness|The Neurobiology of Depressive Illness: Causes and Consequences of Altered Brain Monoaminergic Function|Unknown status|Recruiting|N/A|40|Anticipated|Baker Heart Research Institute||1|||f||||f||||||||||2018-06-01 04:39:17.897784|2018-06-01 04:39:17.897784
NCT00168480|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-26|2005-09-13|2005-09-15|Estimate|||||||2008-09-26|2008-09-29|Estimate|November 2003||2003-11-30|September 2008|2008-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis||Completed||Phase 4|424|Actual|Allergan||1|||f||||||||||||||2018-06-01 04:39:17.960193|2018-06-01 04:39:17.960193
NCT00168467|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-28|2005-09-09|2005-09-15|Estimate|||||||2009-01-28|2009-01-29|Estimate||||January 2009|2009-01-31||||||||Interventional|||The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease|The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease|Completed||Phase 4|40||Baker Heart Research Institute|||||f||||||||||||||2018-06-01 04:39:18.029193|2018-06-01 04:39:18.029193
NCT00168454|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-09-02||2013-10-11|2005-09-12|2005-09-15|Estimate|2010-01-15|2010-02-11|Estimate||||2013-10-11|2013-11-06|Estimate|July 2005||2005-07-31|October 2013|2013-10-31|June 2008|Actual|2008-06-30|January 2008|Actual|2008-01-31||Interventional|||A Research Study for Patients With Overactive Bladder||Completed||Phase 2|313|Actual|Allergan||6|||f||||t||||||||||2018-06-01 04:39:19.010794|2018-06-01 04:39:19.010794
NCT00168441|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-27|2005-09-12|2005-09-15|Estimate|||||||2011-05-27|2011-05-30|Estimate|June 2004||2004-06-30|May 2011|2011-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia||Completed||Phase 2|117|Actual|Allergan|||||f||||||||||||||2018-06-01 04:39:19.923615|2018-06-01 04:39:19.923615
NCT00168428|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-11-05|2009-06-17|2013-10-24|2005-09-12|2005-09-15|Estimate|2010-11-05|2010-12-07|Estimate|2009-09-25|2009-09-28|Estimate|2013-10-24|2013-11-18|Estimate|March 2006||2006-03-31|October 2013|2013-10-31|August 2008|Actual|2008-08-31|December 2007|Actual|2007-12-31||Interventional|||A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches||Completed||Phase 3|705|Actual|Allergan||2|||f||||||||||||||2018-06-01 04:39:20.816963|2018-06-01 04:39:20.816963
NCT00168415|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2008-09-26|2005-09-13|2005-09-15|Estimate|||||||2008-09-26|2008-09-29|Estimate|August 2005||2005-08-31|September 2008|2008-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis||Completed||Phase 4|144|Actual|Allergan||1|||f||||||||||||||2018-06-01 04:39:21.172482|2018-06-01 04:39:21.172482
NCT00168402|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2011-05-27|2005-09-13|2005-09-15|Estimate|||||||2011-05-27|2011-05-30|Estimate|February 2002||2002-02-28|May 2011|2011-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis||Completed||Phase 3|193|Actual|Allergan|||||f||||||||||||||2018-06-01 04:39:21.233309|2018-06-01 04:39:21.233309
NCT00168389|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-07-10|2013-06-21|2014-07-10|2005-09-12|2005-09-15|Estimate|2014-07-10|2014-08-04|Estimate|2013-06-21|2013-07-01|Estimate|2014-07-10|2014-08-04|Estimate|February 2005||2005-02-28|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema||Completed||Phase 3|494|Actual|Allergan||3|||f||||f||||||||||2018-06-01 04:39:21.420793|2018-06-01 04:39:21.420793
NCT00168376|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-04-13|2005-09-14|2005-09-15|Estimate|||||||2007-04-13|2007-04-16|Estimate|July 2004||2004-07-31|April 2007|2007-04-30|April 2006|Actual|2006-04-30|||||Interventional|||A Randomised Double-Blind Trial of Targeted Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder|A Randomised Double-Blind Trial of Targeted Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder|Completed||N/A|60||The Alfred|||||f||||||||||||||2018-06-01 04:39:22.440379|2018-06-01 04:39:22.440379
NCT00168363|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-27|2005-09-12|2005-09-15|Estimate|||||||2011-05-27|2011-05-30|Estimate|January 2005||2005-01-31|May 2011|2011-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|207|Actual|Allergan|||||f||||||||||||||2018-06-01 04:39:22.491219|2018-06-01 04:39:22.491219
NCT00168350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-11-03|2005-09-09|2005-09-15|Estimate|||||||2010-11-03|2010-11-04|Estimate|March 2000||2000-03-31|November 2010|2010-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Memantine in Patients With Chronic Glaucoma||Completed||Phase 3|1179|Actual|Allergan|||||f||||f||||||||||2018-06-01 04:39:22.537809|2018-06-01 04:39:22.537809
NCT00168337|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-07-10|2013-05-30|2014-07-10|2005-09-12|2005-09-15|Estimate|2014-07-10|2014-08-04|Estimate|2013-05-30|2013-06-07|Estimate|2014-07-10|2014-08-04|Estimate|May 2005||2005-05-31|July 2014|2014-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema||Completed||Phase 3|554|Actual|Allergan||3|||f||||f||||||||||2018-06-01 04:39:22.723918|2018-06-01 04:39:22.723918
NCT00168324|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-07-15||2013-07-15|2005-09-12|2005-09-15|Estimate|2009-07-15|2009-08-26|Estimate||||2013-07-15|2013-09-18|Estimate|October 2004||2004-10-31|July 2013|2013-07-31|October 2008|Actual|2008-10-31|March 2008|Actual|2008-03-31||Interventional|||A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion||Completed||Phase 3|599|Actual|Allergan||3|||f||||f||||||||||2018-06-01 04:39:23.94302|2018-06-01 04:39:23.94302
NCT00168311|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|2010-06-15||2012-04-15|2005-09-14|2005-09-15|Estimate|2012-04-15|2012-05-14|Estimate||||2012-04-15|2012-05-14|Estimate|August 2002||2002-08-31|April 2012|2012-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|rTMS||A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia|A Double-Blind Placebo Controlled Trial of Repetitive Transcranial Magentic Stimulation (rTMS) in the Treatment of Negative Symptoms in Schizophrenia and Related Disorders|Completed||N/A|22|Actual|The Alfred|Insufficient time period used to be able to establish a substantive therapeutic effect of rTMS; standard dosing method may be inadequate due to volumetric changes in brain regions in schizophrenia; concurrent antipsychotic medication.|2|||f||||f||||||||||2018-06-01 04:39:24.42486|2018-06-01 04:39:24.42486
NCT00168298|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2009-07-15||2013-07-15|2005-09-12|2005-09-15|Estimate|2009-07-15|2009-08-26|Estimate||||2013-07-15|2013-09-18|Estimate|November 2004||2004-11-30|July 2013|2013-07-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|||A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion||Completed||Phase 3|668|Actual|Allergan||3|||f||||f||||||||||2018-06-01 04:39:24.667698|2018-06-01 04:39:24.667698
NCT00168285|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-04-04|2005-09-13|2005-09-15|Estimate|||||||2007-04-04|2007-04-05|Estimate|March 2005||2005-03-31|April 2007|2007-04-30|May 2007|Anticipated|2007-05-31|||||Interventional|||Pulmonary Rehabilitation in Interstitial Lung Disease|Pulmonary Rehabilitation in Interstitial Lung Disease - a Multi-Centre, Single-Blinded Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|56||The Alfred|||||f||||f||||||||||2018-06-01 04:39:25.164425|2018-06-01 04:39:25.164425
NCT00168272|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2007-04-13|2005-09-14|2005-09-15|Estimate|||||||2007-04-13|2007-04-16|Estimate|June 2004||2004-06-30|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Priming rTMS In Major Depression|A Randomised Double-Blind Trial of Low and High Frequency Stimulation rTMS (Repetitive Transcranial Magnetic Stimulation) In Major Depression|Completed||N/A|100||The Alfred|||||f||||||||||||||2018-06-01 04:39:25.270633|2018-06-01 04:39:25.270633
NCT00168259|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-19|2005-09-13|2005-09-15|Estimate|||||||2012-01-19|2012-01-20|Estimate|December 2004||2004-12-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|||||Observational|||Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals|Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals|Completed|||20|Actual|The Alfred|||||f||||f||||||Samples With DNA|"~     Plasma, and DNA~   "|||2018-06-01 04:39:25.477189|2018-06-01 04:39:25.477189
NCT00168246|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-02-26|2005-09-13|2005-09-15|Estimate|||||||2007-02-26|2007-02-27|Estimate|June 2005||2005-06-30|February 2007|2007-02-28||||||||Observational|||Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific|A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region|Unknown status|Active, not recruiting||600||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 04:39:25.612537|2018-06-01 04:39:25.612537
NCT00168233|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-01-19|2005-09-09|2005-09-15|Estimate|||||||2012-01-19|2012-01-20|Estimate|June 2005||2005-06-30|January 2012|2012-01-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Observational|||Impact of HIV and Its Treatment on Reverse Cholesterol Transport|Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport|Completed|||44|Actual|The Alfred|||3||f||||f||||||||||2018-06-01 04:39:25.773445|2018-06-01 04:39:25.773445
NCT00168220|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-19|2005-09-13|2005-09-15|Estimate|||||||2012-01-19|2012-01-20|Estimate|August 2005||2005-08-31|January 2012|2012-01-31||||||||Observational|||Predictors of Drug Hypersensitivity in HIV Infected Subjects|Predictors of Drug Hypersensitivity in HIV Infected Subjects|Withdrawn|||0|Actual|The Alfred|||2|Insufficient recruitment|f||||f||||||Samples With DNA|"~     plasma, DNA~   "|||2018-06-01 04:39:25.961444|2018-06-01 04:39:25.961444
NCT00168207|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-01-19|2005-09-09|2005-09-15|Estimate|||||||2012-01-19|2012-01-20|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|May 2009|Actual|2009-05-31|||||Observational|||IL-7 Receptor Polymorphisms and Immune Recovery With HAART|The Relationship of Single Nucleotide Polymorphisms in the Interleukin-7 Receptor-α Gene to CD4+ Immune Recovery in HIV Infected Patients Who Begin Antiretroviral Treatment With HAART|Completed|||106|Actual|The Alfred|||||f||||f||||||Samples With DNA|"~     Plasma, PBMC and DNA~   "|||2018-06-01 04:39:26.101703|2018-06-01 04:39:26.101703
NCT00168194|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-01-19|2005-09-09|2005-09-15|Estimate|||||||2012-01-19|2012-01-20|Estimate|December 2004||2004-12-31|January 2012|2012-01-31|December 2009|Actual|2009-12-31|||||Observational|||Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History|Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History|Completed|||104|Actual|The Alfred|||||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-06-01 04:39:26.223485|2018-06-01 04:39:26.223485
NCT00168181|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-15|2005-09-14|2005-09-15|Estimate|||||||2011-04-15|2011-04-18|Estimate|April 2002||2002-04-30|April 2011|2011-04-30|April 2008||2008-04-30|||||Interventional|||Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients|A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients|Completed||Phase 3|220|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:39:26.293099|2018-06-01 04:39:26.293099
NCT00168168|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2010-02-08|2005-09-14|2005-09-15|Estimate|||||||2010-02-08|2010-02-09|Estimate|July 2003||2003-07-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159|ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159|Completed||N/A|60||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:39:26.436376|2018-06-01 04:39:26.436376
NCT00168155|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-01-18|2005-09-13|2005-09-15|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2002||2002-01-31|September 2011|2011-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma|Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma|Completed||Phase 2|70||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:39:26.55252|2018-06-01 04:39:26.55252
NCT00168142|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-02-23|2005-09-14|2005-09-15|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2003||2003-10-31|December 2011|2011-12-31|August 2009|Actual|2009-08-31|July 2008|Actual|2008-07-31||Observational|||MVCT Imaging Pilot Study Using Helical Tomotherapy|MVCT Imaging Pilot Study Using Helical Tomotherapy|Completed|||16|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:39:26.665364|2018-06-01 04:39:26.665364
NCT00168129|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-12-08|2005-09-09|2005-09-15|Estimate|||||||2011-12-08|2011-12-09|Estimate|June 2001||2001-06-30|December 2011|2011-12-31|July 2005||2005-07-31|||||Interventional|||Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases|Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases|Completed||Phase 1|10||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:39:26.831461|2018-06-01 04:39:26.831461
NCT00168116|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-02-23|2005-09-12|2005-09-15|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2000||2000-07-31|October 2011|2011-10-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure|To Evaluate the Effects of Transfer of Submandibular Salivary Gland to the Submental Region (Outside the Radiation Field) on Xerostomia in Head and Neck Cancer Patients Receiving Radiation as the Primary Treatment Versus Patients Who Will Not Have Such a Procedure|Completed||Phase 2|42|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:39:26.930217|2018-06-01 04:39:26.930217
NCT00167934|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-03-10|2005-09-12|2005-09-14|Estimate|||||||2009-03-10|2009-03-12|Estimate|December 2004||2004-12-31|March 2009|2009-03-31|December 2008|Anticipated|2008-12-31|December 2008|Anticipated|2008-12-31||Interventional|||Determining Metabolic Effects of Valproate and Antipsychotic Therapy|Metabolic Effects of Valproate and Antipsychotic Therapy|Unknown status|Recruiting|N/A|88|Anticipated|National Institute of Mental Health (NIMH)||2|||f||||f||||||||||2018-06-01 04:39:28.969408|2018-06-01 04:39:28.969408
NCT00168103|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-04-21||2015-03-11|2005-09-12|2005-09-14|Estimate|2010-07-26|2010-08-24|Estimate||||2015-03-11|2015-03-31|Estimate|June 2005||2005-06-30|February 2011|2011-02-28|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks|Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency and Acute Abdominal or Facial HAE Attacks|Completed||Phase 2/Phase 3|126|Actual|CSL Behring|A test for futility of the C1-INH 10 U/kg bw group conducted during a planned interim analysis led to ceasing recruitment for the C1-INH 10 U/kg bw group.|3|||f||||t||||||||||2018-06-01 04:39:27.028803|2018-06-01 04:39:27.028803
NCT00168090|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-10|2005-09-12|2005-09-14|Estimate|||||||2011-02-10|2011-02-11|Estimate|October 2001||2001-10-31|February 2011|2011-02-28|May 2006||2006-05-31|||||Interventional|||Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)|Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von Willebrand's Disease.|Completed||Phase 4|30||CSL Behring|||||f||||||||||||||2018-06-01 04:39:27.547801|2018-06-01 04:39:27.547801
NCT00168077|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-10|2005-09-12|2005-09-14|Estimate|||||||2011-02-10|2011-02-11|Estimate|September 2005||2005-09-30|February 2011|2011-02-28|November 2006|Actual|2006-11-30|||||Interventional|||Prothrombin Complex Concentrate for Anticoagulant Reversal|Efficacy and Tolerance of BERIPLEX® P/N in Subjects With Acquired Deficiency of Coagulation Factors II, VII, IX and X Due to Oral Anticoagulation|Completed||Phase 3|40||CSL Behring|||||f||||||||||||||2018-06-01 04:39:27.671507|2018-06-01 04:39:27.671507
NCT00168064|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2011-07-12||2012-10-02|2005-09-07|2005-09-14|Estimate|2012-10-02|2012-10-31|Estimate||||2012-10-02|2012-10-31|Estimate|May 2006||2006-05-31|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides|A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)|Completed||Phase 2|260|Actual|Yaupon Therapeutics||2|||f||||f||||||||||2018-06-01 04:39:27.761317|2018-06-01 04:39:27.761317
NCT00168051|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-02-07|2005-09-12|2005-09-14|Estimate|||||||2013-02-07|2013-02-08|Estimate|April 2005||2005-04-30|February 2013|2013-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A|A Single Dose, Randomized, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of ReFacto (B-domain Deleted Recombinant Human Factor VIII (BDDrFVIII) and Advante (a Full-length Recombinant Factor VIII (FLrFVIII)|Completed||Phase 4|21|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:39:28.083545|2018-06-01 04:39:28.083545
NCT00168038|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-08-22||2011-10-18|2005-09-12|2005-09-14|Estimate|2011-10-18|2011-11-23|Estimate||||2011-10-18|2011-11-23|Estimate|December 2004||2004-12-31|October 2011|2011-10-31|February 2006|Actual|2006-02-28|||||Interventional|||Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10|An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)|Completed||Phase 3|58|Actual|CSL Behring||1|||f||||||||||||||2018-06-01 04:39:28.172252|2018-06-01 04:39:28.172252
NCT00168025|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-06-05|2005-09-12|2005-09-14|Estimate|||||||2012-06-05|2012-06-06|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|March 2006|Actual|2006-03-31|||||Interventional|||Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)|A Multicenter Study on the Efficacy, Safety and Pharmacokinetics of IgPro10 in Patients With Primary Immunodeficiency (PID)|Completed||Phase 3|89|Actual|CSL Behring||1|||f||||||||||||||2018-06-01 04:39:28.420544|2018-06-01 04:39:28.420544
NCT00168012|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-02-10|2005-09-12|2005-09-14|Estimate|||||||2011-02-10|2011-02-11|Estimate|September 2004||2004-09-30|February 2011|2011-02-28|September 2005|Actual|2005-09-30|||||Interventional|||Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)|An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID)|Completed||Phase 3|42||CSL Behring|||||||||||||||||||2018-06-01 04:39:28.486847|2018-06-01 04:39:28.486847
NCT00167999|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-03-14|2005-09-11|2005-09-14|Estimate|||||||2007-03-14|2007-03-15|Estimate|February 2005||2005-02-28|March 2007|2007-03-31||||||||Observational|||Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units|Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.|Completed|||200||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:39:28.544876|2018-06-01 04:39:28.544876
NCT00167986|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-03-14|2005-09-11|2005-09-14|Estimate|||||||2007-03-14|2007-03-15|Estimate|January 2005||2005-01-31|March 2007|2007-03-31||||||||Observational|||Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care|Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae.|Completed|||480||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:39:28.598241|2018-06-01 04:39:28.598241
NCT00167973|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-05-25|2005-09-11|2005-09-14|Estimate|||||||2010-05-25|2010-05-26|Estimate|January 2002||2002-01-31|May 2010|2010-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use|A Prospective Registry of European Hemophilia B Patients Receiving BeneFIX®(Nonacog Alfa, Recombinant Human Factor IX) for Usual Use|Completed|||218|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:39:28.671618|2018-06-01 04:39:28.671618
NCT00167960|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-03-14|2005-09-11|2005-09-14|Estimate|||||||2007-03-14|2007-03-15|Estimate|January 2005||2005-01-31|March 2007|2007-03-31||||||||Observational|||Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit|Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.|Completed|||1500||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:39:28.839468|2018-06-01 04:39:28.839468
NCT00167947|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-13|2005-09-09|2005-09-14|Estimate|||||||2008-03-13|2008-03-14|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study Evaluating Sirolimus in Kidney Transplant Recipients.|A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Renal Transplant Patients.|Completed||Phase 3|150|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 04:39:28.894085|2018-06-01 04:39:28.894085
NCT00167323|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-05-16|2005-09-09|2005-09-14|Estimate|||||||2008-05-16|2008-05-19|Estimate|July 2003||2003-07-31|May 2008|2008-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Early Recovery Adherence Therapy for Bipolar Alcoholics|Early Recovery Adherence Therapy for Bipolar Alcoholics|Completed||N/A|48||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:39:34.603002|2018-06-01 04:39:34.603002
NCT00167921|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-05-25|2005-09-09|2005-09-14|Estimate|||||||2007-05-25|2007-05-28|Estimate|October 2005||2005-10-31|May 2007|2007-05-31||||||||Interventional|||Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis|A Multiple-Dose, Comparative Bioavailability Study of Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Postmenopausal Women With Atrophic Vaginitis.|Completed||Phase 1|24||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:39:29.155841|2018-06-01 04:39:29.155841
NCT00167908|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-02-03|2005-09-09|2005-09-14|Estimate|||||||2009-02-03|2009-02-04|Estimate|October 2001||2001-10-31|February 2009|2009-02-28|May 2007|Actual|2007-05-31|||||Interventional|||Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer|Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT|Completed||Phase 2|27||Washington University School of Medicine|||||f||||||||||||||2018-06-01 04:39:29.209607|2018-06-01 04:39:29.209607
NCT00167895|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-04-24|2005-09-10|2005-09-14|Estimate|||||||2007-04-24|2007-04-25|Estimate|October 2004||2004-10-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||The Use of Platelet Derived Growth Factors in Total Knee Arthroplasty, a Randomized Trial|The Use of Platelet Derived Growth Factors in Total Knee Arthroplasty, a Randomized Trial|Completed||Phase 3|100||Westfries Hospital|||||f||||t||||||||||2018-06-01 04:39:29.261646|2018-06-01 04:39:29.261646
NCT00167882|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-08|2005-09-09|2005-09-14|Estimate|||||||2006-09-08|2006-09-11|Estimate|July 2005||2005-07-31|August 2006|2006-08-31|August 2006||2006-08-31|||||Interventional|||The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels||Completed||Phase 4|24||VU University Medical Center|||||f||||||||||||||2018-06-01 04:39:29.321763|2018-06-01 04:39:29.321763
NCT00167869|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-23|2005-09-12|2005-09-14|Estimate|||||||2008-05-23|2008-05-29|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.|LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.|Completed||Phase 2|135||Wageningen University|||||f||||||||||||||2018-06-01 04:39:29.381141|2018-06-01 04:39:29.381141
NCT00167856|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-03-26|2005-09-09|2005-09-14|Estimate|||||||2014-03-26|2014-03-27|Estimate|June 2005||2005-06-30|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2007|Actual|2007-08-31||Interventional|||Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury|Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury|Completed||N/A|16|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:39:29.437181|2018-06-01 04:39:29.437181
NCT00167843|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-01-23|2005-09-11|2005-09-14|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 2002||2002-12-31|January 2013|2013-01-31|March 2007||2007-03-31|||||Interventional|||Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses|A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health|Completed||Phase 4|1189||Albert Schweitzer Hospital|||||f||||||||||||||2018-06-01 04:39:29.510627|2018-06-01 04:39:29.510627
NCT00167830|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-01-16|2005-09-12|2005-09-14|Estimate|||||||2014-01-16|2014-01-20|Estimate|November 2003||2003-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Barriers to Treatment in Obese Adolescents|Understanding The Barriers in Treatment of Obesity in Adolescents 11-18 in Central Virginia|Completed||Phase 1/Phase 2|292|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 04:39:29.580596|2018-06-01 04:39:29.580596
NCT00167817|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2007-04-18|2005-09-12|2005-09-14|Estimate|||||||2007-04-18|2007-04-19|Estimate|July 2003||2003-07-31|April 2007|2007-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study|Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study|Completed||Phase 4|15||Veterans Medical Research Foundation|||||f||||f||||||||||2018-06-01 04:39:29.744925|2018-06-01 04:39:29.744925
NCT00167804|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-12-02|2005-09-12|2005-09-14|Estimate|||||||2011-12-02|2011-12-06|Estimate|September 2004||2004-09-30|December 2011|2011-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Comparing Virtual Reality Therapy to Usual Treatment for PTSD|Comparing Virtual Reality Therapy to Usual Treatment for PTSD|Completed||N/A|20|Actual|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:39:29.823133|2018-06-01 04:39:29.823133
NCT00167791|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-10-13|2005-09-13|2005-09-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|July 2005||2005-07-31|April 2014|2014-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant|Multicenter Trial Using Multi-dose Rituximab as Induction and Desensitization Therapy for Patients on the Waiting List for Kidney Transplant With a Positive Donor Specific Crossmatch to a Living Donor|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||||lack of enrollment|f||||t||||||||||2018-06-01 04:39:29.908146|2018-06-01 04:39:29.908146
NCT00167778|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2013-10-25||2014-07-28|2005-09-09|2005-09-14|Estimate|2014-07-28|2014-08-15|Estimate||||2014-07-28|2014-08-15|Estimate|January 2005||2005-01-31|July 2014|2014-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Prosthetic Components and Stability in Amputee Gait|Turning Corners: Prosthetic Components and Stability in Amputee Gait|Completed||N/A|12|Actual|VA Office of Research and Development|Our sample population consisted of community ambulators whose results may not generalize to all lower limb amputees.|2|||f||||f||||||||||2018-06-01 04:39:30.020393|2018-06-01 04:39:30.020393
NCT00167765|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-05-01|2005-09-09|2005-09-14|Estimate|||||||2007-05-01|2007-05-03|Estimate|March 2005||2005-03-31|May 2007|2007-05-31|May 2005|Actual|2005-05-31|||||Interventional|||Abciximab in Wake-up Stroke|Does Abciximab Save Hypoperfused Ischemic Brain Tissue in Wake-Up Stroke: A Placebo-Controlled, Randomized, MR Imaging Study|Terminated||Phase 3|50||University of Zurich||||Higher hemorrhage rates of Abciximab in ABESST II trial|f||||t||||||||||2018-06-01 04:39:30.674223|2018-06-01 04:39:30.674223
NCT00167752|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2016-10-24|2005-09-13|2005-09-14|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2002||2002-12-31|October 2016|2016-10-31||||February 2006|Actual|2006-02-28||Observational|||Psychiatric Problems in Chronic Skin Diseases|Quality of Life, Emotional and Sleep Problems in Chronic Skin Diseases|Completed|||||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 04:39:30.731084|2018-06-01 04:39:30.731084
NCT00167739|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-19|2005-09-11|2005-09-14|Estimate|||||||2005-09-19|2005-09-21|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|February 2004||2004-02-29|||||Interventional|||Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine|Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria|Completed||Phase 4|50||Albert Schweitzer Hospital|||||f||||||||||||||2018-06-01 04:39:30.776364|2018-06-01 04:39:30.776364
NCT00167726|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-12-05|2005-09-13|2005-09-14|Estimate|||||||2014-12-05|2014-12-09|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Neuraxial and Neurolytic Analgesia for Intractable Pain|Neuraxial and Neurolytic Analgesia for Intractable Pain|Completed|||19|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 04:39:30.843856|2018-06-01 04:39:30.843856
NCT00167713|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-19|2005-09-11|2005-09-14|Estimate|||||||2005-09-19|2005-09-21|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|January 2004||2004-01-31|||||Interventional|||Treatment of Fever Due to Malaria With Ibuprofen|Randomised, Double-Blind, Placebo Controlled Study of the Antipyretic Effect of Ibuprofen in Children With Uncomplicated Malaria|Completed||Phase 4|50||Albert Schweitzer Hospital|||||f||||||||||||||2018-06-01 04:39:30.896348|2018-06-01 04:39:30.896348
NCT00167700|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2012-10-03|2005-09-11|2005-09-14|Estimate|||||||2012-10-03|2012-10-04|Estimate|February 1997||1997-02-28|September 2012|2012-09-30|December 2015|Anticipated|2015-12-31|||||Interventional|NAMI||Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight|Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI): Pre-, Peri- and Postnatal Programming and Origins of Disease: Early Targeting the Epidemics of Allergy and Overweight|Unknown status|Recruiting|N/A|800|Anticipated|University of Turku||6|||f||||f||||||||||2018-06-01 04:39:30.961033|2018-06-01 04:39:30.961033
NCT00167687|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-02-13|2005-09-09|2005-09-14|Estimate|||||||2008-02-13|2008-02-15|Estimate|September 2005||2005-09-30|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Prazosin Alcohol Dependence IVR Study|A Double-Blind Placebo-Controlled Trial of Prazosin for the Treatment of Alcohol Dependence|Completed||Phase 4|23|Actual|University of Washington||1|||f||||t||||||||||2018-06-01 04:39:31.1388|2018-06-01 04:39:31.1388
NCT00167674|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-06-14|2005-09-12|2005-09-14|Estimate|||||||2012-06-14|2012-06-18|Estimate|May 2003||2003-05-31|June 2012|2012-06-30|April 2006|Actual|2006-04-30|March 2005|Actual|2005-03-31||Interventional|||ARVs to Prevent Breastmilk HIV:Viral and Immune Responses|ARVs to Prevent Breastmilk HIV:Viral and Immune Responses|Completed||Phase 2|58|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:39:31.21361|2018-06-01 04:39:31.21361
NCT00167661|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2015-10-09|2005-09-13|2005-09-14|Estimate|||||||2015-10-09|2015-10-12|Estimate|June 2004||2004-06-30|October 2015|2015-10-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation|Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation|Terminated||Phase 1/Phase 2|50|Anticipated|University of Wisconsin, Madison||1||Enrollment suspended pending protocol revision to change study to observational|f||||t||||||||||2018-06-01 04:39:31.288394|2018-06-01 04:39:31.288394
NCT00167648|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-15|2005-09-09|2005-09-14|Estimate|||||||2009-01-15|2009-01-19|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|NE2||Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer|Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer|Completed||Phase 2|17|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:39:31.352546|2018-06-01 04:39:31.352546
NCT00167635|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-05-21|2005-09-09|2005-09-14|Estimate|||||||2009-05-21|2009-05-25|Estimate|January 2003||2003-01-31|May 2009|2009-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Nursing Management of Irritable Bowel Syndrome:Improving Outcomes|Nursing Management of Irritable Bowel Syndrome: Improving Outcomes|Completed||Phase 2/Phase 3|188|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 04:39:31.420047|2018-06-01 04:39:31.420047
NCT00167622|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2016-07-19|2005-09-10|2005-09-14|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2005||2005-04-30|July 2016|2016-07-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Early Mechanical Ventilation for Guillain Barré Syndrome|Efficacy and Safety of Preventive Mechanical Ventilation in Adults With Guillain Barré Syndrome|Completed||Phase 2|50|Actual|University of Versailles||2|||f||||f||||||||||2018-06-01 04:39:31.513067|2018-06-01 04:39:31.513067
NCT00167609|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2010-04-05|2005-09-10|2005-09-14|Estimate|||||||2010-04-05|2010-04-06|Estimate|November 2004||2004-11-30|April 2010|2010-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Efficacy and Safety of DHEA for Myotonic Dystrophy|Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy|Completed||Phase 2/Phase 3|75|Actual|University of Versailles|||||f||||t||||||||||2018-06-01 04:39:31.591518|2018-06-01 04:39:31.591518
NCT00167596|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-07-19|2005-09-09|2005-09-14|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2005||2005-07-31|July 2016|2016-07-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|OTO-STS||Near Infrared Spectroscopy (NIRS) in Severe Sepsis|Phase III Study of Usefulness of Near Infrared Spectroscopy to Optimize Tissues Perfusion and Oxygenation in Severe Sepsis|Terminated||Phase 2/Phase 3|103|Actual|University of Versailles||2||recruitment was stopped as consequence of cessation of funding (economic crisis)|f||||t||||||||||2018-06-01 04:39:31.664464|2018-06-01 04:39:31.664464
NCT00167583|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-05-14|2005-09-09|2005-09-14|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2004||2004-11-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|INCYTOB||Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB)|Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)|Completed||Phase 3|37|Actual|University Hospital Tuebingen||2|||f||||t||||||||Undecided||2018-06-01 04:39:31.738346|2018-06-01 04:39:31.738346
NCT00167570|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-04-24|2005-09-09|2005-09-14|Estimate|||||||2017-04-24|2017-04-26|Actual|April 2003||2003-04-30|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Long Term Clinical Evaluation of SLS Transtibial Sockets|Long Term Clinical Evaluation of SLS Transtibial Sockets|Completed|||11|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-06-01 04:39:31.818189|2018-06-01 04:39:31.818189
NCT00167557|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-18|2005-09-09|2005-09-14|Estimate|||||||2013-11-18|2013-11-19|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment|Tacrolimus Monotherapy in OLT Recipients With HCV Under Preemptive Treatment With Interferon and Ribavirin|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center, Houston||1||The PI left the institution.|f||||f||||||||||2018-06-01 04:39:31.872852|2018-06-01 04:39:31.872852
NCT00167544|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-03-25||2013-07-29|2005-09-12|2005-09-14|Estimate|2013-07-29|2013-08-30|Estimate||||2013-07-29|2013-08-30|Estimate|November 2005||2005-11-30|July 2013|2013-07-31|November 2012|Actual|2012-11-30|January 2009|Actual|2009-01-31||Interventional|||Randomized Trial of Hydrocortisone in Very Preterm High-Risk Infants|A Randomized Trial of Hydrocortisone in Very Preterm Infants at High Risk for Neurologic and Pulmonary Impairments|Completed||Phase 2|64|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-06-01 04:39:31.949217|2018-06-01 04:39:31.949217
NCT00167531|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-10-01|2005-09-12|2005-09-14|Estimate|||||||2009-10-01|2009-10-02|Estimate|August 2002||2002-08-31|September 2006|2006-09-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||The Efficacy of Treadmill Training in Establishing Walking After Stroke|The Efficacy of Treadmill Training in Establishing Walking After Stroke|Completed||Phase 2|126|Actual|University of Sydney||2|||f||||f||||||||||2018-06-01 04:39:32.192048|2018-06-01 04:39:32.192048
NCT00167518|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2005-09-11|2005-09-11|2005-09-14|Estimate|||||||2005-09-11|2005-09-14|Estimate|March 2002||2002-03-31|January 2005|2005-01-31|April 2005||2005-04-30|||||Interventional|||Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)|Phase II/III Intravitreal Triamcinolone for Treatment of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment|Completed||Phase 2/Phase 3|70||University of Sydney|||||f||||||||||||||2018-06-01 04:39:33.204822|2018-06-01 04:39:33.204822
NCT00167505|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-10-25|2005-09-09|2005-09-14|Estimate|||||||2010-10-25|2010-10-26|Estimate|September 2006||2006-09-30|October 2010|2010-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||All About Youth: Evaluation of Sexual Risk Avoidance and Risk Reduction Programs for Middle School Students|SIP 4-04 Evaluation of Abstinence-Only and Abstinence-Plus Program to Prevent HIV, STD, and Pregnancy Among Middle School Students|Completed||N/A|1742|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 04:39:33.266545|2018-06-01 04:39:33.266545
NCT00167492|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-12-05|2005-09-12|2005-09-14|Estimate|||||||2013-12-05|2013-12-09|Estimate|September 2005||2005-09-30|December 2013|2013-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Enteric Coated Myfortic for Liver Transplant Recipients|Enteric Coated Mycophenolic Acid (Myfortic) in Liver Transplant Recipients- Effect on Compliance and Calcineurin Inhibitor and Corticosteroid Sparing|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:39:33.3353|2018-06-01 04:39:33.3353
NCT00167479|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2006-09-08|2005-09-12|2005-09-14|Estimate|||||||2006-09-08|2006-09-11|Estimate|September 2003||2003-09-30|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||A Study of Risperidone Monotherapy in Bipolar Anxiety|A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder|Completed||Phase 4|60||University of South Florida|||||f||||||||||||||2018-06-01 04:39:33.392743|2018-06-01 04:39:33.392743
NCT00167466|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-10-26|2005-09-13|2005-09-14|Estimate|||||||2010-10-26|2010-10-28|Estimate|October 2005||2005-10-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Placebo Controlled Trial of a Titanium Dioxide Semiconductor Toothbrush on Mild-to-moderate Gum Disease|Randomized, Double-blind, Placebo-controlled Crossover Trial of the Soladey-3 Toothbrush on Periodontal Disease Indices in Patients With Mild-to-moderate Periodontal Disease|Completed||N/A|120|Anticipated|University of Saskatchewan||2|||f||||t||||||||||2018-06-01 04:39:33.483701|2018-06-01 04:39:33.483701
NCT00167453|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-10-04|2005-09-09|2005-09-14|Estimate|||||||2007-10-04|2007-10-10|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Benefits of Exercise and Education for Individuals With Parkinson's Disease (BEEP)|Evaluation of the Benefits of a Group Exercise Program and a Group Exercise and Education Program for Individuals With Parkinson's Disease (BEEP)|Completed||Phase 1|45|Anticipated|University of Saskatchewan|||||f||||||||||||||2018-06-01 04:39:33.548857|2018-06-01 04:39:33.548857
NCT00167440|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-11-25|2005-09-09|2005-09-14|Estimate|||||||2015-11-25|2015-11-26|Estimate|August 2004||2004-08-31|November 2015|2015-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Pediatric Patients|Comparison of Techniques for Assessing Cardiac Output and Preload in Critically Ill Patients|Withdrawn|||0|Actual|University of Rochester||||Personelle changes mandated suspension.|f||||f||||||||||2018-06-01 04:39:33.607477|2018-06-01 04:39:33.607477
NCT00167427|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-01-10|2005-09-12|2005-09-14|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2006||2006-04-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Genotoxicity Assessment for Patients Undergoing Radiation Treatment|Genotoxicity Assessment for Patients Receiving Large Field Irradiation|Recruiting|||120|Anticipated|University of Rochester|||||f||||f||||||||||2018-06-01 04:39:33.752554|2018-06-01 04:39:33.752554
NCT00167414|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2017-10-10||2017-12-08|2005-09-12|2005-09-14|Estimate|2017-12-08|2018-01-05|Actual||||2017-12-08|2018-01-05|Actual|December 2000|Actual|2000-12-31|December 2017|2017-12-31|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Study for Using Radiosurgery on Limited Metastases of Breast Cancer|A Phase II Study for Using Radiosurgery on Limited Metastases of Breast Cancer|Completed||N/A|49|Actual|University of Rochester||1|||f||||f||||||||No||2018-06-01 04:39:33.829149|2018-06-01 04:39:33.829149
NCT00167401|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-05-15|2005-09-09|2005-09-14|Estimate|||||||2009-05-15|2009-05-19|Estimate|February 2002||2002-02-28|May 2009|2009-05-31||||June 2007|Actual|2007-06-30||Interventional|||Trial of Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer|A Phase II Trial of One-Cycle Induction Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer|Completed||Phase 2|||University of Rochester|||||f||||t||||||||||2018-06-01 04:39:34.010706|2018-06-01 04:39:34.010706
NCT00167388|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2016-01-06||2017-04-19|2005-09-12|2005-09-14|Estimate|2017-04-19|2017-07-21|Actual||||2017-04-19|2017-07-21|Actual|September 2005||2005-09-30|April 2017|2017-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||The Effect of Blood Transfusion on Blood Flow to the Intestines of Premature Infants|The Effect of Packed Red Blood Cell Transfusion on Superior Mesenteric Artery Blood Flow Velocity in Premature Infants After Feeding|Completed||Phase 1|22|Actual|University of Pittsburgh||4|||f||||t||||||||No||2018-06-01 04:39:34.091052|2018-06-01 04:39:34.091052
NCT00167375|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-02-13|2005-09-12|2005-09-14|Estimate|||||||2008-02-13|2008-02-15|Estimate|January 2005||2005-01-31|February 2008|2008-02-29|June 2007|Actual|2007-06-30|||||Observational|||Testing the Nocturnal Sleep Latency Profile in Primary Insomnia|Testing the Nocturnal Sleep Latency Profile in Primary Insomnia|Completed|||24|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:39:34.388428|2018-06-01 04:39:34.388428
NCT00167362|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-06|2005-09-12|2005-09-14|Estimate|||||||2017-01-06|2017-01-10|Estimate|August 2001||2001-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2009|Actual|2009-08-31||Interventional|||Cognitive Enhancement Therapy for Early-Stage Schizophrenia|Rehabilitation, Brain Function and Early Schizophrenia|Completed||Phase 3|67|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-06-01 04:39:34.443105|2018-06-01 04:39:34.443105
NCT00167349|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-14|2005-09-09|2005-09-14|Estimate|||||||2011-04-14|2011-04-15|Estimate|December 2003||2003-12-31|April 2011|2011-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Observational|CPB-I||Cardiopulmonary Bypass and Inflammatory Response|Cardiopulmonary Bypass and Inflammatory Response|Completed|||37|Actual|University of Pittsburgh|||||f||||f||||||Samples Without DNA|"~     plasma and serum~   "|||2018-06-01 04:39:34.508773|2018-06-01 04:39:34.508773
NCT00167336|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-12-15|2005-09-09|2005-09-14|Estimate|||||||2015-12-15|2015-12-16|Estimate|May 2004||2004-05-31|June 2006|2006-06-30|March 2005||2005-03-31|||||Observational|||Developing an Instrument to Measure Personal Keyboarding Style|Developing an Instrument to Measure Personal Keyboarding Style|Completed|||40||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:39:34.555874|2018-06-01 04:39:34.555874
NCT00167310|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2017-01-06||2017-02-24|2005-09-09|2005-09-14|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|September 2005||2005-09-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CAD|The participants withdraw voluntarily after signing the consent form.|Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation|CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation|Completed||Phase 2|57|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:39:34.667828|2018-06-01 04:39:34.667828
NCT00167297|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-10|2005-09-12|2005-09-14|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2004||2004-11-30|June 2010|2010-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Atomoxetine for the Treatment of Cannabis Dependence|A Pilot Trial of Atomoxetine to Enhance Motivational Interviewing Therapy for the Treatment of Cannabis Dependence|Completed||Phase 2|16|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||f||||||||||2018-06-01 04:39:35.025867|2018-06-01 04:39:35.025867
NCT00167284|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-14|Estimate|||||||2005-09-09|2005-09-14|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|February 2005||2005-02-28|||||Interventional|||Patient Provider Partnership: Improving Diabetes Care in the Community|Patient Provider Partnership: Improving Diabetes Care in the Community|Completed||N/A|270||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:39:35.094534|2018-06-01 04:39:35.094534
NCT00167271|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-02-18|2005-09-09|2005-09-14|Estimate|||||||2011-02-18|2011-02-21|Estimate|October 2002||2002-10-31|February 2011|2011-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Promoting Health in People With Fibromyalgia|Efficacy of Computer and SenseWear Technologies for Promoting Health in People With Fibromyalgia: A Randomized Clinical Trial|Completed||N/A|72|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:39:35.150861|2018-06-01 04:39:35.150861
NCT00167258|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-12-14|2005-09-12|2005-09-14|Estimate|||||||2009-12-14|2009-12-15|Estimate||||December 2009|2009-12-31|February 2007||2007-02-28|||||Interventional|||Effectiveness and Costs of Enhanced Cocaine Treatments||Completed||Phase 2|||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:39:35.229745|2018-06-01 04:39:35.229745
NCT00167245|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-04-24||2014-08-21|2005-09-09|2005-09-14|Estimate|2014-08-21|2014-09-01|Estimate||||2014-08-21|2014-09-01|Estimate|September 2004||2004-09-30|June 2014|2014-06-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|TOP2||Topiramate for Alcohol and Cocaine Dependence|A Phase II, Randomized, Double-blind, Placebo-Controlled, Pilot Trial of Topiramate for Alcohol and Comorbid Cocaine Dependence|Completed||Phase 2|170|Actual|University of Pennsylvania|The total number of subjects was relatively small and thus the results should be considered preliminary. The study drop-out rate was formidable, though it was comparable with most trials involving cocaine-dependent patients.|2|||f||||t||||||||||2018-06-01 04:39:35.296768|2018-06-01 04:39:35.296768
NCT00167232|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-02-26|2005-09-09|2005-09-14|Estimate|||||||2018-02-26|2018-02-28|Actual|January 1998||1998-01-31|September 2013|2013-09-30|July 2003|Actual|2003-07-31|February 2003|Actual|2003-02-28||Interventional|||Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence|Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence|Completed||Phase 3|164|Actual|University of Pennsylvania||2|||f||||||||||||||2018-06-01 04:39:35.561697|2018-06-01 04:39:35.561697
NCT00167219|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-12-03|2005-09-09|2005-09-14|Estimate|||||||2017-12-03|2017-12-05|Actual|November 18, 1999|Actual|1999-11-18|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)|Hematopoietic Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia|Recruiting||Phase 1/Phase 2|20|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f|||f|||||2018-06-01 04:39:35.631066|2018-06-01 04:39:35.631066
NCT00167206|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-07-07||2018-02-23|2005-09-09|2005-09-14|Estimate|2009-10-21|2009-11-26|Estimate||||2018-02-23|2018-03-20|Actual|March 2004||2004-03-31|February 2018|2018-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Stem Cell Transplantation for Fanconi Anemia|A Study of Thymic Shielding in Recipients of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Stem Cell Transplantation in Patients With Fanconi Anemia|Terminated||Phase 1/Phase 2|16|Actual|Masonic Cancer Center, University of Minnesota|Study ended early as thymic shielding was found to be safe. Therefore, a new study was designed using thymic shielding.|1||Treatment with thymic shielding found safe, another study started.|f||||t||||||||||2018-06-01 04:39:35.738352|2018-06-01 04:39:35.738352
NCT00167180|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2017-04-28||2017-12-03|2005-09-09|2005-09-14|Estimate|2017-06-09|2017-07-11|Actual||||2017-12-03|2017-12-05|Actual|January 2004||2004-01-31|December 2017|2017-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Post Transplant Donor Lymphocyte Infusion|Use of Cyclophosphamide/Fludarabine to Promote in Vivo Expansion of Donor Lymphocyte Infusions (DLI) to Enhance Efficacy After Allogeneic Transplant|Completed||Phase 2|57|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-06-01 04:39:35.966154|2018-06-01 04:39:35.966154
NCT00167167|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-11-27|2005-09-09|2005-09-14|Estimate|||||||2017-11-27|2017-11-29|Actual|December 1995||1995-12-31|November 2017|2017-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia|Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-derived Lymphocytes|Completed||N/A|40|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-06-01 04:39:36.282465|2018-06-01 04:39:36.282465
NCT00167154|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2012-03-15|2005-09-10|2005-09-14|Estimate|||||||2012-03-15|2012-03-16|Estimate|June 2004||2004-06-30|March 2012|2012-03-31|August 2008|Actual|2008-08-31|April 2007|Actual|2007-04-30||Interventional|||Risperidone and Suicidality in Major Depressive Disorder|Efficacy of Risperidone in the Management of Suicidality in Major Depressive Disorder|Completed||Phase 3|30|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-06-01 04:39:36.34908|2018-06-01 04:39:36.34908
NCT00167141|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-02-01|2005-09-09|2005-09-14|Estimate|||||||2010-02-01|2010-02-02|Estimate|February 2005||2005-02-28|March 2007|2007-03-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Contraception in Normal and Subnormal Men|Hormonal Male Contraception in Men With Normal and Subnormal Semen Parameters|Terminated||Phase 2|41|Actual|University Hospital Muenster||1|||f||||||||||||||2018-06-01 04:39:36.414333|2018-06-01 04:39:36.414333
NCT00167128|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-14|2005-09-12|2005-09-14|Estimate|||||||2007-08-14|2007-08-15|Estimate|March 2005||2005-03-31|May 2006|2006-05-31||||||||Interventional|||The Phonak EduLink-System in Students With Specific Performance Deficits in Speech-in-Noise Intelligibility|The Phonak EduLink-System in Students With Specific Performance Deficits in Speech-in-Noise Intelligibility|Unknown status|Recruiting|N/A|30|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:39:36.474079|2018-06-01 04:39:36.474079
NCT00167115|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-07-09|2005-09-09|2005-09-14|Estimate|||||||2012-07-09|2012-07-10|Estimate|December 2004||2004-12-31|July 2012|2012-07-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Metabolic Effects of Alcohol|Metabolic Effects of Alcohol in the Form of Wine in Persons With Type 2 Diabetes Mellitus|Completed||N/A|20||University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 04:39:36.619143|2018-06-01 04:39:36.619143
NCT00167102|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-02-27||2017-11-22|2005-09-12|2005-09-14|Estimate|2013-02-27|2013-04-09|Estimate||||2017-11-22|2017-11-24|Actual|July 2005||2005-07-31|November 2017|2017-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||23 participants were allocated to alefacept 22 participants were allocated to placebo|Alefacept in Patients With Severe Scalp Alopecia Areata|A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Evaluate The Safety and Therapeutic Efficacy of Intramuscular Administration of Alefacept in Patients With Chronic, Severe Scalp Alopecia Areata|Completed||N/A|45|Actual|University of Minnesota - Clinical and Translational Science Institute|This study was limited by the number of patients randomized to receive treatment.|2|||f||||f||||||||||2018-06-01 04:39:36.685062|2018-06-01 04:39:36.685062
NCT00167089|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-10-05|2005-09-12|2005-09-14|Estimate|||||||2009-10-05|2009-10-06|Estimate|August 1998||1998-08-31|September 2009|2009-09-30|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Effects of Early Treadmill Training on Ambulatory Ability in Stroke Patients: Electromyographic and Kinematic Analyses|Effects of Early Treadmill Training on Ambulatory Ability in Stroke Patients: Electromyographic and Kinematic Analyses|Completed||N/A|40|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 04:39:36.955274|2018-06-01 04:39:36.955274
NCT00167076|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|August 1999||1999-08-31|September 2005|2005-09-30|July 2002||2002-07-31|||||Observational|||Clinical Applications and Evaluations of A Portable In-Shoe Plantar Pressure Monitoring and Biofeedback Gait System for Ambulation Training in Stroke Rehabilitation|Clinical Applications and Evaluations of A Portable In-Shoe Plantar Pressure Monitoring and Biofeedback Gait System for Ambulation Training in Stroke Rehabilitation|Unknown status|Active, not recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.028439|2018-06-01 04:39:37.028439
NCT00167063|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|August 1999||1999-08-31|September 2005|2005-09-30|December 2000||2000-12-31|||||Observational|||Falls in Stroke Patients After Hospital Discharge: Prevalence and Risk Factors|Falls in Stroke Patients After Hospital Discharge: Prevalence and Risk Factors|Unknown status|Active, not recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.084609|2018-06-01 04:39:37.084609
NCT00167050|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-25|2005-09-13|2005-09-14|Estimate|||||||2005-11-25|2005-11-28|Estimate|July 2005||2005-07-31|June 2005|2005-06-30|June 2006||2006-06-30|||||Observational|||The Pathogenesis of Superior Limbic Keratoconjunctivitis||Unknown status|Recruiting||10||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.138743|2018-06-01 04:39:37.138743
NCT00167037|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|August 1999||1999-08-31|September 2005|2005-09-30|July 2002||2002-07-31|||||Observational|||Fast Stepping in Stroke Patients for Fall Prediction and Prevention:Control Mechanisms and Clinical Implications|Fast Stepping in Stroke Patients for Fall Prediction and Prevention:Control Mechanisms and Clinical Implications|Unknown status|Active, not recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.203736|2018-06-01 04:39:37.203736
NCT00167024|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-25|2005-09-12|2005-09-14|Estimate|||||||2005-11-25|2005-11-28|Estimate|March 2005||2005-03-31|March 2005|2005-03-31||||||||Observational|||Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.252036|2018-06-01 04:39:37.252036
NCT00167011|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-12-05|2005-09-12|2005-09-14|Estimate|||||||2012-12-05|2012-12-06|Estimate|July 1995||1995-07-31|November 2012|2012-11-30|January 2002|Actual|2002-01-31|||||Interventional|||Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography|Patterns of Coronary Artery Anatomy in Children With Congenital Heart Disease by Computed Tomography|Completed||N/A|200|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.324567|2018-06-01 04:39:37.324567
NCT00166998|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|March 2005||2005-03-31|February 2005|2005-02-28|July 2006||2006-07-31|||||Observational|||The Study of Infrared Imaging on Breast Cancer||Unknown status|Recruiting||600||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.386443|2018-06-01 04:39:37.386443
NCT00166985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-12-26|2005-09-12|2005-09-14|Estimate|||||||2006-12-26|2006-12-27|Estimate|September 2004||2004-09-30|August 2004|2004-08-31|December 2008||2008-12-31|||||Observational|||The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients|The Role of Functional MRI and Doppler Sonography in Assessing Intratumoral Angiogenesis of Endometrial Cancer Patients|Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.444592|2018-06-01 04:39:37.444592
NCT00166972|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|January 2005||2005-01-31|July 2005|2005-07-31|April 2005||2005-04-30|||||Observational|||Molecular Mechanism of Trophinin in Cancer Invasion and Metastasis|Molecular Mechanism of Trophinin in Cancer Invasion and Metastasis|Completed|||150||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.502614|2018-06-01 04:39:37.502614
NCT00166959|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|January 2005||2005-01-31|June 2005|2005-06-30|December 2005||2005-12-31|||||Observational|||Reliability and Validity of Modified Postural Assessment Scale for Stroke Patients and the Application of This Scale on Early Detection of Patients With Stroke at High Risk of Falls|Reliability and Validity of Modified Postural Assessment Scale for Stroke Patients and the Application of This Scale on Early Detection of Patients With Stroke at High Risk of Falls|Unknown status|Recruiting||90||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.546228|2018-06-01 04:39:37.546228
NCT00166946|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-14|Estimate|||||||2005-12-20|2005-12-21|Estimate|June 2005||2005-06-30|November 2004|2004-11-30|January 2008||2008-01-31|||||Interventional|||Effects of Arsenic on Keratinocytes in a Skin Equivalent Model|Effects of Arsenic on Keratinocytes in a Skin Equivalent Model|Unknown status|Recruiting|N/A|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.599637|2018-06-01 04:39:37.599637
NCT00166933|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-20|2005-09-12|2005-09-14|Estimate|||||||2005-12-20|2005-12-21|Estimate|June 2005||2005-06-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Minimal Erythema Dose of UV-B in Normal Population of Taiwan|Minimal Erythema Dose of UV-B in Normal Population of Taiwan|Completed|||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.655439|2018-06-01 04:39:37.655439
NCT00166920|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|July 2004||2004-07-31|February 2005|2005-02-28|July 2004||2004-07-31|||||Observational|||Measurement of Cerebral Oxygen Extraction Fraction Using MRI Technique||Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.709307|2018-06-01 04:39:37.709307
NCT00166907|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-13|2005-09-13|2005-09-14|Estimate|||||||2005-09-13|2005-09-14|Estimate|January 2002||2002-01-31|June 2005|2005-06-30|December 2007||2007-12-31|||||Interventional|||Balance Recovery and Training on Fall Prevention in Stroke|Balance Recovery and Training on Fall Prevention in Stroke|Unknown status|Recruiting|N/A|100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.756898|2018-06-01 04:39:37.756898
NCT00166894|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-14|Estimate|||||||2005-11-23|2005-11-24|Estimate|May 2005||2005-05-31|May 2005|2005-05-31||||||||Observational|||Use of the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in the Diagnosis of Pleural Effusion|Evaluation of the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a Diagnostic Tool for Patients With Pleural Effusion|Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:37.820321|2018-06-01 04:39:37.820321
NCT00166881|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-07-04|2005-09-12|2005-09-14|Estimate|||||||2013-07-04|2013-07-08|Estimate|June 2000||2000-06-30|November 2012|2012-11-30|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|P-HDFL-DI||Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin|Phase II Trial of Consolidation or Salvage Chemotherapy by Using Weekly Docetaxel/Irinotecan After Cisplatin Plus Weekly 24-Hour Infusion of High-dose 5-Fluorouracil/Leucovorin for Non-resectable Gastric Cancers|Completed||Phase 2|29|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 04:39:37.877019|2018-06-01 04:39:37.877019
NCT00166868|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-08-19|2005-09-12|2005-09-14|Estimate|||||||2013-08-19|2013-08-21|Estimate|December 2003||2003-12-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy|Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia|Completed||N/A|30|Actual|National Taiwan University Hospital||3|||f||||||||||||||2018-06-01 04:39:37.94923|2018-06-01 04:39:37.94923
NCT00166855|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-23|2005-09-12|2005-09-14|Estimate|||||||2005-11-23|2005-11-24|Estimate|July 2005||2005-07-31|May 2005|2005-05-31|July 2009||2009-07-31|||||Interventional|||Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma||Unknown status|Recruiting|N/A|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.0394|2018-06-01 04:39:38.0394
NCT00166842|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|September 2002||2002-09-30|July 2002|2002-07-31||||||||Interventional|||Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets|Effects of Conversion From Sirolimus Oral Solution to Tablets in Renal Transplant Recipients.|Unknown status|Active, not recruiting|Phase 4|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.111872|2018-06-01 04:39:38.111872
NCT00166829|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-07|2005-09-12|2005-09-14|Estimate|||||||2007-03-07|2007-03-08|Estimate|May 2004||2004-05-31|August 2003|2003-08-31||||||||Interventional|||The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus|The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus|Unknown status|Recruiting|Phase 4|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.180842|2018-06-01 04:39:38.180842
NCT00166816|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|March 2002||2002-03-31|July 2001|2001-07-31|June 2003||2003-06-30|||||Interventional|||The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients|The Pharmacokinetics and Dosage Regimen of Sirolimus in a Cyclosporine or Tacrolimus-Based Immunosuppression in Renal Transplant Patients|Unknown status|Active, not recruiting|Phase 4|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.245702|2018-06-01 04:39:38.245702
NCT00166803|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2009-01-02|2005-09-11|2005-09-14|Estimate|||||||2009-01-02|2009-01-05|Estimate|June 2005||2005-06-30|December 2008|2008-12-31||||November 2008|Anticipated|2008-11-30||Interventional|||The Impact of Rosiglitazone on Regression of Atherosclerosis|The Impact of Rosiglitazone on Regression of Atherosclerosis: A Serial 18F-Fluorodeoxyglucose Positron Emission Tomography Study|Suspended||N/A|60|Anticipated|National Taiwan University Hospital||||no fund|f||||||||||||||2018-06-01 04:39:38.308237|2018-06-01 04:39:38.308237
NCT00166790|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2014-12-05|2005-09-11|2005-09-14|Estimate|||||||2014-12-05|2014-12-08|Estimate|September 2005||2005-09-30|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Detection of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease|Detection of Minimal Amount of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.374246|2018-06-01 04:39:38.374246
NCT00166777|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2006-09-07|2005-09-11|2005-09-14|Estimate|||||||2006-09-07|2006-09-11|Estimate|September 2005||2005-09-30|August 2005|2005-08-31|June 2006||2006-06-30|||||Interventional|||Effect of Hip Adduction Combination With Knee Extension Exercise on Morphology of Quadriceps Muscles, Pain and Functional Outcomes in Patients With PFPS||Unknown status|Recruiting|Phase 1|90||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.484352|2018-06-01 04:39:38.484352
NCT00166764|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-10-26|2005-09-11|2005-09-14|Estimate|||||||2005-10-26|2005-10-28|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|July 2006||2006-07-31|||||Observational|||A Study on Evaluation of Mental Health Index of Patients With Psychiatric Disorders|A Study on Evaluation of Mental Health Index of Patients With Psychiatric Disorders|Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.620985|2018-06-01 04:39:38.620985
NCT00166751|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-10-26|2005-09-11|2005-09-14|Estimate|||||||2005-10-26|2005-10-28|Estimate|September 2005||2005-09-30|December 2004|2004-12-31|November 2006||2006-11-30|||||Observational|||Sonographic Assessment of Laryngeal Elevation|Sonographic Assessment of Laryngeal Elevation in Cerebrovascular Accident Patients With Dysphagia|Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.68107|2018-06-01 04:39:38.68107
NCT00166738|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-08-23|2005-09-11|2005-09-14|Estimate|||||||2007-08-23|2007-08-24|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|December 2005||2005-12-31|||||Observational|||Analysis of Genomic DNA Alterations in Familial Schizophrenia|Analysis of Genomic DNA Alterations in Familial Schizophrenia|Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:39:38.746606|2018-06-01 04:39:38.746606
NCT00166725|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-11-18|2005-09-13|2005-09-14|Estimate|||||||2009-11-18|2009-11-19|Estimate|February 2004||2004-02-29|November 2009|2009-11-30||||||||Interventional|||Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients|A Randomized, Open Label, Multicenter Study Evaluating the Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients|Completed||Phase 2|40|Anticipated|Novartis|||||f||||||||||||||2018-06-01 04:39:38.824895|2018-06-01 04:39:38.824895
NCT00166712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-11-29||2015-10-20|2005-09-09|2005-09-14|Estimate|2015-01-09|2015-01-15|Estimate||||2015-10-20|2015-10-26|Estimate|April 2005||2005-04-30|October 2015|2015-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|Cell220||A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression|A Phase IV, Single Center Pilot Study Using Alemtuzumab (Campath-1H) Induction Combined With Prednisone-Free, Calcineurin-Inhibitor-Free Immunosuppression in Kidney Transplantation|Terminated||Phase 4|40|Actual|Northwestern University||2||Study stopped due to lack of efficacy & funding.|f||||t||||||||||2018-06-01 04:39:38.892006|2018-06-01 04:39:38.892006
NCT00166699|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-06-10|2005-09-09|2005-09-14|Estimate|||||||2008-06-10|2008-06-11|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Trial of the Use of Ultrasound to Aid the Insertion of Combined Spinal Epidural Anaesthesia|The Clinical Evaluation of a Novel Ultrasound Probe to Guide the Insertion of Central Regional Anaesthesia Using a Regional Anaesthetic Needle Modified to Aid Insertion Under Ultrasound Guidance in Morbidly Obese Women Undergoing Elective Caesarean Section|Completed||Phase 3|42|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-06-01 04:39:39.299939|2018-06-01 04:39:39.299939
NCT00166686|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-01-10|2005-09-09|2005-09-14|Estimate|||||||2013-01-10|2013-01-11|Estimate||||January 2013|2013-01-31||||||||Interventional|||Clonidine for Neurocognitive Sequelae|Clonidine for the Treatment of Neurocognitive Sequelae Following Cancer Treatment in Children|Withdrawn||Phase 1/Phase 2|0|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||||Study was never initiated|f||||||||||||||2018-06-01 04:39:39.387241|2018-06-01 04:39:39.387241
NCT00166673|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-09-02|2005-09-09|2005-09-14|Estimate|||||||2016-09-02|2016-09-05|Estimate|August 2005||2005-08-31|September 2016|2016-09-30|August 2007|Actual|2007-08-31|||||Interventional|||Pilot Study of the Navigator Continuous Glucose Monitor|A Pilot Study to Evaluate the Navigator Continuous Glucose Sensor in the Management of Type 1 Diabetes in Children|Completed||Phase 2/Phase 3|60||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 04:39:39.451018|2018-06-01 04:39:39.451018
NCT00166660|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-04-01|2005-09-09|2005-09-14|Estimate|||||||2009-04-01|2009-04-03|Estimate|July 2004||2004-07-31|March 2009|2009-03-31|June 2009|Anticipated|2009-06-30|December 2008|Anticipated|2008-12-31||Interventional|||Preterm Fetal Growth Restriction and Developmental Care|Preterm Fetal Growth Restriction and Developmental Care|Unknown status|Recruiting|Phase 2|30|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 04:39:39.53365|2018-06-01 04:39:39.53365
NCT00166647|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-01-10|2005-09-09|2005-09-14|Estimate|||||||2013-01-10|2013-01-11|Estimate|February 2004||2004-02-29|January 2013|2013-01-31||||||||Observational|||Thiopurine Methyltransferase Polymorphisms Evaluation|Evaluation of Thiopurine Methyltransferase Polymorphisms in the Hispanic Population|Withdrawn|||0|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||||Observational Study should not be in CT.gov|f||||||||||||||2018-06-01 04:39:39.618406|2018-06-01 04:39:39.618406
NCT00166634|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-01-10|2005-09-09|2005-09-14|Estimate|||||||2011-01-10|2011-01-11|Estimate|July 2003||2003-07-31|January 2011|2011-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Ambulatory Blood Pressure Monitoring in Hypertension|The Role of Ambulatory Blood Pressure Monitoring (ABPM) in Interventional Trials Conducted in Children With Hypertension|Completed||N/A|126|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:39:39.673083|2018-06-01 04:39:39.673083
NCT00166621|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-07-19|2005-09-09|2005-09-14|Estimate|||||||2011-07-19|2011-07-20|Estimate|March 2004||2004-03-31|July 2011|2011-07-31|August 2005|Actual|2005-08-31|||||Interventional|||Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy|Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy|Completed||Phase 1/Phase 2|20||Chugani, Diane C.|||||f||||t||||||||||2018-06-01 04:39:39.742656|2018-06-01 04:39:39.742656
NCT00166608|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-04-10|2005-09-09|2005-09-14|Estimate|||||||2012-04-10|2012-04-12|Estimate|December 2002||2002-12-31|April 2012|2012-04-30|September 2007|Actual|2007-09-30|May 2007|Actual|2007-05-31||Observational|||Cytokines Polymorphisms and Acetaminophen Toxicity|Measurement of Nitrotyrosine Adducts and Cytokines in Acetaminophen Overdose Patients|Completed|||111|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-06-01 04:39:39.819429|2018-06-01 04:39:39.819429
NCT00166595|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-01-27|2005-09-09|2005-09-14|Estimate|||||||2014-01-27|2014-01-28|Estimate|February 2003||2003-02-28|July 2012|2012-07-31|March 2005|Actual|2005-03-31|||||Interventional|||Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)|Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)|Completed||Phase 1/Phase 2|100||Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 04:39:39.919304|2018-06-01 04:39:39.919304
NCT00166582|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-06-28|2005-09-09|2005-09-14|Estimate|||||||2007-06-28|2007-07-02|Estimate|April 2002||2002-04-30|November 2005|2005-11-30|September 2005||2005-09-30|||||Interventional|||Parent-Youth Teamwork in Pediatric Asthma Management|Parent-Youth Teamwork in Pediatric Asthma Management|Completed||Phase 2|60||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:39:39.977319|2018-06-01 04:39:39.977319
NCT00166569|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-03-27|2005-09-09|2005-09-14|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2003||2003-01-31|March 2017|2017-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||The Genetics of Polycystic Ovarian Syndrome|The Genetics of Polycystic Ovarian Syndrome|Recruiting|||2700|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 04:39:40.036623|2018-06-01 04:39:40.036623
NCT00166556|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-20|2005-09-12|2005-09-14|Estimate|||||||2011-05-20|2011-05-23|Estimate|January 2005||2005-01-31|May 2011|2011-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation|Thistlethwaite Protocol # ITN025ST - Immunosuppression With Campath-1H and Tacrolimus in Liver Transplantation|Completed||Phase 2|10|Anticipated|Mayo Clinic|||||||||||||||||||2018-06-01 04:39:40.108164|2018-06-01 04:39:40.108164
NCT00166543|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12||2015-06-26|2015-07-28|2005-09-12|2005-09-14|Estimate||||2015-07-28|2015-08-18|Estimate|2015-07-28|2015-08-18|Estimate|May 2004||2004-05-31|June 2015|2015-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer|A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy|Completed||Phase 2|146|Actual|SRI International||3|||f||||||||||||||2018-06-01 04:39:40.191014|2018-06-01 04:39:40.191014
NCT00166530|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-03-13|2005-09-09|2005-09-14|Estimate|||||||2017-03-13|2017-03-14|Actual|November 2005||2005-11-30|March 2017|2017-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)|A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used.|Completed||Phase 4|367|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:39:40.261423|2018-06-01 04:39:40.261423
NCT00166517|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-07-06||2015-03-12|2005-09-09|2005-09-14|Estimate|2009-08-13|2009-09-23|Estimate||||2015-03-12|2015-04-01|Estimate|August 2005||2005-08-31|March 2015|2015-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||V260 Registration Study (V260-013)(COMPLETED)|Immunogenicity and Safety of V260 in Healthy Infants in Korea|Completed||Phase 3|178|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:39:40.369789|2018-06-01 04:39:40.369789
NCT00166504|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2008-10-13||2017-03-13|2005-09-09|2005-09-14|Estimate|2008-11-04|2008-11-05|Estimate||||2017-03-13|2017-04-11|Actual|October 2005||2005-10-31|March 2017|2017-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)|A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Patients With Primary Hypercholesterolemia|Completed||Phase 4|203|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:39:40.692757|2018-06-01 04:39:40.692757
NCT00166491|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-04-15|2005-09-12|2005-09-14|Estimate|||||||2011-04-15|2011-04-18|Estimate|July 2005||2005-07-31|April 2011|2011-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Comparing Two Ways of Controlling Blood Sugar With Insulin in Patients Admitted to the Intensive Care Unit|Comparison of Two Approved Insulin Infusion Protocols for Glycemic Control in Critically Ill Patients|Completed||N/A|238|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:39:40.922438|2018-06-01 04:39:40.922438
NCT00166478|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-26|2005-09-12|2005-09-14|Estimate|||||||2010-01-26|2010-01-28|Estimate|April 2002||2002-04-30|January 2010|2010-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Exisulind Prior to Radical Prostatectomy|A Prospective Controlled Phase II Study of Preoperative Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis|Completed||Phase 2|130|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 04:39:40.976373|2018-06-01 04:39:40.976373
NCT00166465|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-03-11|2005-09-12|2005-09-14|Estimate|||||||2011-03-11|2011-03-14|Estimate|August 2003||2003-08-31|March 2011|2011-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Stage IV Colorectal CA ALIMTA|A Phase I Dose-Finding Study and a Randomized Phase II Study of ALIMTA Plus Oxaliplatin Versus Oxaliplatin Plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) in the First-Line Treatment of Patients With Locally Advanced Unresectable or Stage IV Colorectal Cancer|Completed||Phase 1/Phase 2|200||Mayo Clinic|||||f||||t||||||||||2018-06-01 04:39:41.024261|2018-06-01 04:39:41.024261
NCT00166452|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-03-22|2005-09-12|2005-09-14|Estimate|||||||2011-03-22|2011-03-23|Estimate|July 2005||2005-07-31|March 2011|2011-03-31|February 2009|Actual|2009-02-28|April 2007|Actual|2007-04-30||Interventional|||A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1|Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1|Completed||Phase 3|7|Actual|Mayo Clinic|||||||||||||||||||2018-06-01 04:39:41.084574|2018-06-01 04:39:41.084574
NCT00166439|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2017-03-21|2005-09-12|2005-09-14|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2005|Actual|2005-03-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma|A Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma|Completed||Phase 2|50|Actual|Mayo Clinic|||||f||||t||||||||||2018-06-01 04:39:41.221038|2018-06-01 04:39:41.221038
NCT00166426|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-11-13|2005-09-12|2005-09-14|Estimate|||||||2009-11-13|2009-11-16|Estimate|February 2003||2003-02-28|November 2009|2009-11-30|May 2008|Actual|2008-05-31|May 2007|Actual|2007-05-31||Interventional|||Exisulind Versus Placebo After Surgical Removal of the Prostate|Prospective, Randomized, Double-Blind Trial of Adjuvant Exisulind Versus Placebo for Patients at Risk for Prostate Cancer Recurrence After Radical Prostatectomy|Completed||Phase 2|240|Anticipated|Mayo Clinic|||||||||||||||||||2018-06-01 04:39:41.304657|2018-06-01 04:39:41.304657
NCT00166413|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-05-05|2005-09-12|2005-09-14|Estimate|||||||2011-05-05|2011-05-06|Estimate|April 2005||2005-04-30|May 2011|2011-05-31||||December 2006|Actual|2006-12-31||Interventional|||Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis|A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis|Completed||Phase 2|38|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-06-01 04:39:41.377011|2018-06-01 04:39:41.377011
NCT00166400|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-07-23|2005-09-12|2005-09-14|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2004||2004-07-31|July 2008|2008-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Randomized Clinical Trial of Metoprolol in Participants With Mitral Regurgitation.|Beta Blockade in Mitral Regurgitation|Completed||Phase 4|60|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 04:39:41.456682|2018-06-01 04:39:41.456682
NCT00166387|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-03-24|2005-09-09|2005-09-14|Estimate|||||||2014-03-24|2014-03-26|Estimate|April 2003||2003-04-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Hemophilia Inhibitor Genetics Study (HIGS)|Hemophilia Inhibitor Genetics Study (HIGS)|Completed|||1137|Actual|Skane University Hospital|||1||f||||t||||||Samples With DNA|"~     Plasma, cells, DNA~   "|||2018-06-01 04:39:41.528987|2018-06-01 04:39:41.528987
NCT00166374|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-19|2005-09-12|2005-09-14|Estimate|||||||2010-01-19|2010-01-20|Estimate||||January 2010|2010-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||To Evaluate Success of Cement Treatment of Spinal Compression Fractures|Outcomes Following Balloon Kyphoplasty for Vertebral Compression Fracture|Completed||N/A|200|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:39:41.612725|2018-06-01 04:39:41.612725
NCT00166361|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-06-19||2014-06-19|2005-09-12|2005-09-14|Estimate|2014-06-19|2014-07-18|Estimate||||2014-06-19|2014-07-18|Estimate|February 2004||2004-02-29|June 2014|2014-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent|Long-Term Temporary Drainage of Malignant Extrinsic Ureteral Obstruction Secondary to Inoperable Pelvic or Abdominal Malignancies Using the Memokath 051 Ureteral Stent|Completed||N/A|29|Actual|Mayo Clinic|Low number of subjects in each cohort.|2|||f||||t||||||||||2018-06-01 04:39:41.722032|2018-06-01 04:39:41.722032
NCT00166348|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-19|2005-09-12|2005-09-14|Estimate|||||||2010-01-19|2010-01-20|Estimate|March 2003||2003-03-31|January 2010|2010-01-31|March 2008|Actual|2008-03-31|February 2007|Actual|2007-02-28||Interventional|||Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?|Efficacy of Group Based Cognitive Rehabilitation Following Acquired Brain Injury|Completed||N/A|20|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 04:39:42.136577|2018-06-01 04:39:42.136577
NCT00166322|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-05-06|2005-09-09|2005-09-14|Estimate|||||||2008-05-06|2008-05-07|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects||Completed||N/A|35|Actual|Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 04:39:42.202726|2018-06-01 04:39:42.202726
NCT00166309|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-18|2005-09-09|2005-09-14|Estimate|||||||2007-04-18|2007-04-19|Estimate|July 2000||2000-07-31|April 2007|2007-04-30|June 2005|Actual|2005-06-30|||||Interventional|||The FEIBA NovoSeven Comparative Study|FENOC: The FEIBA NovoSeven Comparative Study|Completed||N/A|60||Skane University Hospital|||||f||||t||||||||||2018-06-01 04:39:42.276761|2018-06-01 04:39:42.276761
NCT00166296|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2011-02-08||2011-03-04|2005-09-09|2005-09-14|Estimate|2011-03-04|2011-03-30|Estimate||||2011-03-04|2011-03-30|Estimate|March 2005||2005-03-31|March 2011|2011-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients|Study of the Efficacy and Safety of Escitalopram for the Prevention of Depressive Episodes Induced by Peg-Interferon Alpha2a and Ribavirin in Chronic Hepatitis C Patients. Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 2|133|Actual|Germans Trias i Pujol Hospital|The low depression rate found may have underpowered the study. Selection of a much less depressive sample than in other studies. Limitation to the first 12 weeks of antiviral treatment.|2|||f||||f||||||||||2018-06-01 04:39:42.361514|2018-06-01 04:39:42.361514
NCT00166283|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-06-08|2005-09-09|2005-09-14|Estimate|||||||2013-06-08|2013-06-11|Estimate|February 2005||2005-02-28|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Improving New Learning and Memory in Multiple Sclerosis|Improving New Learning in Multiple Sclerosis: A Randomized Clinical Trial|Completed||N/A|88|Actual|Kessler Foundation||2|||f||||t||||||||||2018-06-01 04:39:42.656943|2018-06-01 04:39:42.656943
NCT00166270|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-03-26|2005-09-09|2005-09-14|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2005||2005-01-31|March 2018|2018-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids|Post Approval Study: MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids|Completed||N/A|70|Actual|InSightec||1|||f||||||||||||||2018-06-01 04:39:42.723687|2018-06-01 04:39:42.723687
NCT00166257|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-05-26|2005-09-09|2005-09-14|Estimate|||||||2009-05-26|2009-05-27|Estimate|February 2000||2000-02-29|May 2009|2009-05-31|May 2011|Anticipated|2011-05-31|February 2011|Anticipated|2011-02-28||Interventional|||PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism|Randomized Clinical Trial Comparing the Efficacy of Percutaneous Closure of Patent Foramen Ovale (PFO) With Medical Treatment in Patients With Cryptogenic Embolism|Unknown status|Active, not recruiting|Phase 4|414|Actual|Foundation for Cardiovascular Research, Zurich||2|||f||||t||||||||||2018-06-01 04:39:42.798139|2018-06-01 04:39:42.798139
NCT00166244|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-02-11|2005-09-09|2005-09-14|Estimate|||||||2009-02-11|2009-02-12|Estimate|May 2003||2003-05-31|February 2009|2009-02-28|April 2006|Actual|2006-04-30|March 2005|Actual|2005-03-31||Interventional|||Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation|An Open, Prospective, Randomised, Controlled, Multi-Center Study Comparing Fixed Dose vs Concentration Controlled Mycophenolate Mofetil Regimens for de Novo Patients Following Transplantation|Completed||Phase 4|901|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-06-01 04:39:42.881076|2018-06-01 04:39:42.881076
NCT00166231|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2015-02-24|2005-09-13|2005-09-14|Estimate|||||||2015-02-24|2015-02-25|Estimate|March 2004||2004-03-31|February 2015|2015-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Understanding Pediatric Chest Pain and Other Symptoms|Understanding Pediatric Symptoms and Other Symptoms|Completed|||156|Actual|Emory University|||2||f||||f||||||||||2018-06-01 04:39:43.048714|2018-06-01 04:39:43.048714
NCT00166218|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-26|2005-09-13|2005-09-14|Estimate|||||||2013-11-26|2013-11-27|Estimate|February 2004||2004-02-29|November 2013|2013-11-30|February 2005||2005-02-28|||||Observational|||NIRS Monitoring in the Ambulatory Single Ventricle Patient|Evaluation of Near-infrared Spectroscopy for Non-invasive Monitoring of the Ambulatory Single Ventricle Patient|Terminated|||30||Emory University|||||f||||||||||||||2018-06-01 04:39:43.115047|2018-06-01 04:39:43.115047
NCT00166205|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2008-10-21||2015-08-03|2005-09-09|2005-09-14|Estimate|2008-12-10|2008-12-11|Estimate||||2015-08-03|2015-09-01|Estimate|June 2003||2003-06-30|August 2015|2015-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Safety and Effectiveness Study of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity|A Single-Arm, Multi-Center Study of the Safety and Effectiveness of The Swedish Adjustable Gastric Band (SAGB) in the Treatment of Morbid Obesity|Completed||Phase 3|276|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||||2018-06-01 04:39:43.182721|2018-06-01 04:39:43.182721
NCT00166192|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-12|2005-09-13|2005-09-14|Estimate|||||||2013-11-12|2013-11-14|Estimate|January 2008||2008-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|January 2010|Actual|2010-01-31||Interventional|||Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid|Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid: A Comparison of Clinical Efficacy|Completed||Phase 4|19|Actual|Emory University||1|||f||||t||||||||||2018-06-01 04:39:44.495803|2018-06-01 04:39:44.495803
NCT00166179|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-09-25|2005-09-13|2005-09-14|Estimate|||||||2014-09-25|2014-09-26|Estimate|November 2003||2003-11-30|September 2014|2014-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Observational|||Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI|Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI|Completed|||57|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:39:44.564579|2018-06-01 04:39:44.564579
NCT00166166|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2015-05-08||2015-05-12|2005-09-13|2005-09-14|Estimate|2015-05-12|2015-05-13|Estimate||||2015-05-12|2015-05-13|Estimate|July 2002||2002-07-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Baseline characteristics represent subjects that completed the study.|Endothelial Hyperpolarization in Humans|Physiology and Pathologic Role of Endothelium-Derived Hyperpolarizing Factor in Humans|Terminated||Phase 2|174|Actual|Emory University|Findings are limited to the forearm microcirculations, thus other vascular beds including conductance arteries warrant further investigation. Nevertheless, it is known that the contribution of EDHF is less in conductance vessels than in microvessels.|2||Limited clinical staff|f||||f||||||||||2018-06-01 04:39:44.639804|2018-06-01 04:39:44.639804
NCT00166153|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-19|2005-09-12|2005-09-14|Estimate|||||||2013-11-19|2013-11-21|Estimate|January 2003||2003-01-31|November 2013|2013-11-30|May 2005||2005-05-31|||||Interventional|||Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept|The Relationships Between Mycophenolic Acid Levels, T-Cell Subsets and Outcomes in Pediatric Heat Transplant Recipients Receiving Mycophenolate Mofetil (Cellcept)|Terminated||N/A|30||Emory University|||||f||||||||||||||2018-06-01 04:39:45.003524|2018-06-01 04:39:45.003524
NCT00166140|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-19|2005-09-12|2005-09-14|Estimate|||||||2013-11-19|2013-11-20|Estimate|December 2002||2002-12-31|November 2013|2013-11-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.|Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.|Completed|||125||Emory University|||||f||||||||||||||2018-06-01 04:39:45.076873|2018-06-01 04:39:45.076873
NCT00166127|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-13|2005-09-12|2005-09-14|Estimate|||||||2013-11-13|2013-11-15|Estimate|May 2005||2005-05-31|November 2013|2013-11-30|January 2007|Actual|2007-01-31|||||Interventional|||Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery|Pharmacokinetics and Pharmacodynamics of Levosimendan During Cardiac Surgery|Terminated||Phase 3|1|Actual|Emory University||||Unable to renegotiate an expired contract w/sponsor providing study med|f||||f||||||||||2018-06-01 04:39:45.140162|2018-06-01 04:39:45.140162
NCT00166114|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2013-12-09||2015-07-15|2005-09-13|2005-09-14|Estimate|2015-07-15|2015-07-23|Estimate||||2015-07-15|2015-07-23|Estimate|February 2002||2002-02-28|July 2015|2015-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Depression, Epinephrine, and Platelet Function|Do Antidepressants Reverse the Effects of Early Life Stress on the Brain and Thrombovascular System and Improve Psychological, Neuroendocrine, and Platelet Function: A Study of Men and Women With Childhood Abuse.|Completed||Phase 4|40|Actual|Emory University||2|||f||||t||||||||||2018-06-01 04:39:45.212635|2018-06-01 04:39:45.212635
NCT00166101|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-11-09|2005-09-12|2005-09-14|Estimate|||||||2012-11-09|2012-11-14|Estimate|August 2002||2002-08-31|November 2012|2012-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||NIRS in Neonatal Cardiac Surgery|Near Infrared Spectroscopy Monitoring of Cerebral Oxygen Saturation in Neonatal Cardiac Surgery - Comparison With Common Methods of Estimating Adequate Systemic Perfusion|Completed|||25|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:39:45.493658|2018-06-01 04:39:45.493658
NCT00166088|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-15|2005-09-12|2005-09-14|Estimate|||||||2013-11-15|2013-11-18|Estimate|December 2004||2004-12-31|November 2013|2013-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Effect of a Mediterranean Diet and Omega-3 Fatty Acids on Oxidative Stress and Endothelial Progenitor Cells (EPC's)|Effects of Mediterranean Diet and Omega-3 Fatty Acids on Oxidative Stress and EPC's|Completed||Phase 2|30|Actual|Emory University||3|||f||||f||||||||||2018-06-01 04:39:45.568145|2018-06-01 04:39:45.568145
NCT00166075|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-12|2005-09-12|2005-09-14|Estimate|||||||2013-12-12|2013-12-13|Estimate|January 2004||2004-01-31|December 2013|2013-12-31|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Observational|||Mental Health Symptoms and Intimate Partner Violence|Mental Health Symptoms and Intimate Partner Violence|Completed|||569|Actual|Emory University|||1||f||||f||||||||||2018-06-01 04:39:45.639332|2018-06-01 04:39:45.639332
NCT00166062|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-09-19|2005-09-12|2005-09-14|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2004||2004-01-31|September 2013|2013-09-30|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Effectiveness of Computer Screening for Intimate Partner Violence||Completed||N/A|||Emory University|||||f||||||||||||||2018-06-01 04:39:45.734198|2018-06-01 04:39:45.734198
NCT00166049|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-11-09|2005-09-12|2005-09-14|Estimate|||||||2015-11-09|2015-11-11|Estimate|April 2005||2005-04-30|September 2013|2013-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Education and Supportive Partners Improving Self-Care (ENSPIRE)|A Family Partnership Intervention in Heart Failure|Completed||N/A|170|Actual|Emory University||3|||f||||t||||||||||2018-06-01 04:39:45.807572|2018-06-01 04:39:45.807572
NCT00166036|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2012-06-08||2014-08-28|2005-09-12|2005-09-14|Estimate|2014-08-28|2014-09-08|Estimate||||2014-08-28|2014-09-08|Estimate|September 2004||2004-09-30|August 2014|2014-08-31|April 2009|Actual|2009-04-30|March 2008|Actual|2008-03-31||Interventional|STOPCAP||Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells|Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells: Comparison of Atorvastatin With Pravastatin|Completed||Phase 2|36|Actual|Emory University|Detection of changes in Oxidative stress with significance requires a much larger cohort study.|2|||f||||f||||||||||2018-06-01 04:39:45.899898|2018-06-01 04:39:45.899898
NCT00166023|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-25|2005-09-12|2005-09-14|Estimate|||||||2013-11-25|2013-11-26|Estimate|August 2005||2005-08-31|November 2013|2013-11-30|December 2006||2006-12-31|||||Observational|||Outcomes Following Medical or Surgical Management of Endocarditis|A Review of Outcomes Following Medical or Surgical Management of Endocarditis|Completed|||100||Emory University|||||f||||||||||||||2018-06-01 04:39:46.096949|2018-06-01 04:39:46.096949
NCT00166010|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-06-03|2005-09-12|2005-09-14|Estimate|||||||2014-06-03|2014-06-05|Estimate|October 2004||2004-10-31|June 2014|2014-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects of Nesiritide in Pediatric Patients With Heart Failure|A Single-center, Pharmacokinetic Evaluation of Nesiritide in the Pediatric Population With Heart Failure|Withdrawn||N/A|0|Actual|Emory University||1||"Observational study that DSMB placed on hold (withdrew 4 subjects). Protocol revised and~   received IND to become interventional PK study (no subjects enrolled)."|f||||t||||||||||2018-06-01 04:39:46.144286|2018-06-01 04:39:46.144286
NCT00165997|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-09|2005-09-12|2005-09-14|Estimate|||||||2013-12-09|2013-12-10|Estimate|February 2004||2004-02-29|December 2013|2013-12-31|October 2007|Actual|2007-10-31|||||Observational|||Quality of Life in Patients Post Radiofrequency Ablation|The Effects of Radiofrequency Ablation Procedures on Quality of Life in the Pediatric Cohort|Terminated|||50|Anticipated|Emory University||||sufficient data collected for significant conclusive results|f||||||||||||||2018-06-01 04:39:46.209212|2018-06-01 04:39:46.209212
NCT00165984|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2011-11-11||2012-04-04|2005-09-09|2005-09-14|Estimate|2012-04-04|2012-05-02|Estimate||||2012-04-04|2012-05-02|Estimate|January 2004||2004-01-31|April 2012|2012-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy|Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy|Completed|||224|Actual|Emory University|Relatively small number of patients given the low incidence of this mutation||||f||||f||||||Samples With DNA|"~     Whole blood and serum.~   "|||2018-06-01 04:39:46.353761|2018-06-01 04:39:46.353761
NCT00165971|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-16|2005-09-09|2005-09-14|Estimate|||||||2007-04-16|2007-04-17|Estimate|December 2003||2003-12-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Recovery From General Anesthesia|Recovery From General Anesthesia|Completed||N/A|100||Emory University|||||f||||||||||||||2018-06-01 04:39:46.525046|2018-06-01 04:39:46.525046
NCT00165958|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-07-17||2014-07-11|2005-09-12|2005-09-14|Estimate|2014-07-11|2014-08-04|Estimate||||2014-07-11|2014-08-04|Estimate|January 2005||2005-01-31|July 2014|2014-07-31|July 2011|Actual|2011-07-31|July 2008|Actual|2008-07-31||Interventional|||Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts|Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts|Completed||Phase 4|40|Actual|Emory University|The limitations of this study include the small, predominately male patient population, lack of complete follow-up of secondary endpoint measurements at every time point.|2|||f||||f||||||||||2018-06-01 04:39:46.596776|2018-06-01 04:39:46.596776
NCT00165945|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-03-30|2005-09-12|2005-09-14|Estimate|||||||2012-03-30|2012-04-02|Estimate|June 2004||2004-06-30|March 2012|2012-03-31|March 2010|Actual|2010-03-31|March 2009|Actual|2009-03-31||Observational|||4-D Visualization Using Magnetic Resonance Imaging (MRI) in the Congenital Heart Disease Population|Using 4-D Visualization Software With Magnetic Resonance Images in the Congenital Heart Disease Population|Completed|||500|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:39:46.789917|2018-06-01 04:39:46.789917
NCT00165932|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-05-30|2005-09-09|2005-09-14|Estimate|||||||2012-05-30|2012-06-01|Estimate|June 2004||2004-06-30|May 2012|2012-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Ventricular Synchrony in Pediatric Patients|A Single Center Prospective, Pilot Study Examining the Non-invasive Evaluation of Ventricular Synchrony in Pediatric Patients|Completed|||145|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:39:46.85543|2018-06-01 04:39:46.85543
NCT00165919|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-12|2005-09-09|2005-09-14|Estimate|||||||2013-11-12|2013-11-13|Estimate|September 2005||2005-09-30|November 2013|2013-11-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||Immune Response to Hepatitis C Virus|Immunologic Determinants of Hepatitis C Virus Infection Resolution or Persistence|Withdrawn|||0|Actual|Emory University|||1|Not a clinical trial; human specimens from treatment site for basic research.|f||||f||||||||||2018-06-01 04:39:46.921725|2018-06-01 04:39:46.921725
NCT00165906|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-19|2005-09-09|2005-09-14|Estimate|||||||2013-11-19|2013-11-21|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Thrombin Generation in Neonates|A Pilot Study Examining Thrombin Generation in the Neonatal Population|Completed|||20|Actual|Emory University|||||f||||f||||||Samples With DNA|"~     A blood sample is obtained to measure the thrombin level.~   "|||2018-06-01 04:39:47.005296|2018-06-01 04:39:47.005296
NCT00165893|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-12-23|2005-09-09|2005-09-14|Estimate|||||||2013-12-23|2013-12-24|Estimate|September 2004||2004-09-30|December 2013|2013-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Comparison of IDD Therapy and Non-surgical Treatment for Low Back Pain Caused by Degenerative Disc Disease|Comparison of Internal Disc Decompression (IDD) vs. a Standardized Non-surgical Treatment Program for Chronic Low Back Pain Secondary to Mild to Moderate Degenerative Disc Disease (DDD)|Completed||Phase 4|50||Emory University|||||f||||||||||||||2018-06-01 04:39:47.085184|2018-06-01 04:39:47.085184
NCT00165880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-06-30|2005-09-13|2005-09-14|Estimate|||||||2014-06-30|2014-07-01|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|September 2007|Actual|2007-09-30|||||Interventional|||An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine|An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Metastatic Breast Cancer Patients Following Prior Anthracycline and Taxane Therapy|Terminated||Phase 2|62|Actual|Eisai Inc.||||This study was stopped prematurely due to lack of efficacy.|f||||||||||||||2018-06-01 04:39:47.158006|2018-06-01 04:39:47.158006
NCT00165867|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-06|2005-09-13|2005-09-14|Estimate|||||||2006-10-06|2006-10-09|Estimate|April 2005||2005-04-30|October 2006|2006-10-31||||||||Interventional|||An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin||Completed||Phase 2|40||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:47.264517|2018-06-01 04:39:47.264517
NCT00165854|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-06-26|2005-09-13|2005-09-14|Estimate|||||||2014-06-26|2014-06-27|Estimate|March 2003||2003-03-31|October 2006|2006-10-31||||||||Interventional|||Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer||Completed||Phase 2|46||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:47.327722|2018-06-01 04:39:47.327722
NCT00165841|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|2009-08-18||2013-05-13|2005-09-13|2005-09-14|Estimate|2009-11-02|2009-12-03|Estimate||||2013-05-13|2013-05-20|Estimate|October 2004||2004-10-31|December 2009|2009-12-31|June 2008|Actual|2008-06-30|December 2005|Actual|2005-12-31||Interventional|||Maintenance Intermittent Therapy for Symptomatic GERD Patients|A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease|Completed||Phase 2|200|Actual|Eisai Inc.||2|||f||||f||||||||||2018-06-01 04:39:47.4056|2018-06-01 04:39:47.4056
NCT00165828|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2014-06-26|2005-09-13|2005-09-14|Estimate|||||||2014-06-26|2014-06-27|Estimate|May 2005||2005-05-31|November 2013|2013-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization|Randomized Trial to Assess Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization|Terminated||Phase 4|157|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:39:47.671656|2018-06-01 04:39:47.671656
NCT00165815|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-05-08|2005-09-13|2005-09-14|Estimate|||||||2013-05-08|2013-05-10|Estimate|August 2002||2002-08-31|November 2005|2005-11-30|July 2005||2005-07-31|||||Interventional|||The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia||Completed||Phase 3|||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:47.755961|2018-06-01 04:39:47.755961
NCT00165802|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-05-20|2005-09-12|2005-09-14|Estimate|||||||2013-05-20|2013-05-22|Estimate|May 2006||2006-05-31|August 2009|2009-08-31|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|||A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors|A Phase I Open Label Study of E7974 Administered on Day 1 of a 21-Day Cycle In Patients With Advanced Solid Tumors|Completed||Phase 1|40|Anticipated|Eisai Inc.||1|||f||||||||||||||2018-06-01 04:39:47.808317|2018-06-01 04:39:47.808317
NCT00165789|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2015-04-15||2015-05-28|2005-09-12|2005-09-14|Estimate|2015-05-28|2015-06-02|Estimate||||2015-05-28|2015-06-02|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|September 2006|Actual|2006-09-30|February 2006|Actual|2006-02-28||Interventional|||A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations|A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations|Completed||Phase 2|75|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:47.994517|2018-06-01 04:39:47.994517
NCT00165776|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2013-07-12||2014-02-06|2005-09-12|2005-09-14|Estimate|2013-11-12|2014-01-08|Estimate||||2014-02-06|2014-03-10|Estimate|June 2004||2004-06-30|February 2014|2014-02-28|November 2006|Actual|2006-11-30|May 2006|Actual|2006-05-31||Interventional||After randomized to the treatment groups, 3 patients (2 of the placebo group and 1 of the 5000U group) had no treatment. The reason was that 2 of them requested withdrawal from the study and 1 ceased to return for visits.|Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis|Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis|Completed||Phase 2|133|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:48.996787|2018-06-01 04:39:48.996787
NCT00165763|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-05-02|2005-09-12|2005-09-14|Estimate|||||||2012-05-02|2012-05-04|Estimate|September 2005||2005-09-30|September 2009|2009-09-30||||September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia|An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia|Completed||Phase 4|36|Actual|Eisai Inc.||1|||f||||t||||||||||2018-06-01 04:39:49.441903|2018-06-01 04:39:49.441903
NCT00165750|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-19|2005-09-12|2005-09-14|Estimate|||||||2013-11-19|2013-11-20|Estimate|March 2005||2005-03-31|November 2013|2013-11-30|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients|Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients|Terminated||Phase 4|40|Actual|Eisai Inc.||1||Lack of patients to enroll.|f||||||||||||||2018-06-01 04:39:49.504873|2018-06-01 04:39:49.504873
NCT00165737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-03-31|2005-09-12|2005-09-14|Estimate|||||||2011-03-31|2011-04-01|Estimate|March 2003||2003-03-31|March 2011|2011-03-31|June 2006|Actual|2006-06-30|August 2005|Actual|2005-08-31||Interventional|||Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease|A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease|Completed||Phase 3|974|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:49.562938|2018-06-01 04:39:49.562938
NCT00165724|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-05-02|2005-09-12|2005-09-14|Estimate|||||||2012-05-02|2012-05-04|Estimate|June 2004||2004-06-30|July 2010|2010-07-31|December 2006|Actual|2006-12-31|July 2006|Actual|2006-07-31||Interventional|||Alzheimer's Disease Long-term Follow-up Study (ALF Study)|Alzheimer's Disease Long-term Follow-up Study (ALF Study)|Completed||Phase 4|114|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:49.62613|2018-06-01 04:39:49.62613
NCT00165711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-08|2005-09-12|2005-09-14|Estimate|||||||2005-12-08|2005-12-12|Estimate|March 2003||2003-03-31|December 2005|2005-12-31||||||||Interventional|||The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.||Completed||Phase 4|||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:49.703542|2018-06-01 04:39:49.703542
NCT00165698|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-12-02||2014-07-11|2005-09-12|2005-09-14|Estimate|2011-07-18|2011-08-11|Estimate||||2014-07-11|2014-07-22|Estimate|May 2005||2005-05-31|July 2014|2014-07-31|July 2007|Actual|2007-07-31|January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women|Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women|Completed||Phase 3|240|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:39:49.85848|2018-06-01 04:39:49.85848
NCT00165685|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-28|2005-09-12|2005-09-14|Estimate|||||||2010-01-28|2010-01-29|Estimate|July 2004||2004-07-31|January 2010|2010-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Comparative Study of KES524 in Patients With Obesity Disease|A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease|Completed||Phase 3|||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:50.298033|2018-06-01 04:39:50.298033
NCT00165672|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-07-19||2011-09-06|2005-09-12|2005-09-14|Estimate|2011-09-06|2011-10-05|Estimate||||2011-09-06|2011-10-05|Estimate|May 2005||2005-05-31|August 2010|2010-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease|A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease|Completed||Phase 3|26|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:39:50.38608|2018-06-01 04:39:50.38608
NCT00165659|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-28|2005-09-12|2005-09-14|Estimate|||||||2010-01-28|2010-01-29|Estimate|November 2002||2002-11-30|January 2010|2010-01-31||||May 2005|Actual|2005-05-31||Interventional|||A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020||Completed||Phase 2|||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:50.630003|2018-06-01 04:39:50.630003
NCT00165646|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2011-05-23||2011-07-14|2005-09-12|2005-09-14|Estimate|2011-05-23|2011-06-17|Estimate||||2011-07-14|2011-07-18|Estimate|September 2004||2004-09-30|August 2010|2010-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease|A Double-Blind, Placebo-Controlled, Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease|Completed||Phase 3|288|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 04:39:50.777532|2018-06-01 04:39:50.777532
NCT00165633|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-12-05|2005-09-12|2005-09-14|Estimate|||||||2008-12-05|2008-12-09|Estimate|March 2004||2004-03-31|December 2008|2008-12-31|March 2007|Actual|2007-03-31|||||Interventional|||A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma|A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma|Terminated||Phase 2/Phase 3|540|Anticipated|Eisai Inc.||3|||f||||||||||||||2018-06-01 04:39:51.358051|2018-06-01 04:39:51.358051
NCT00165620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-28|2005-09-12|2005-09-14|Estimate|||||||2010-01-28|2010-01-29|Estimate|November 2004||2004-11-30|January 2010|2010-01-31||||April 2005|Actual|2005-04-30||Interventional|||A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease||Completed||Phase 2|||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:51.455622|2018-06-01 04:39:51.455622
NCT00165607|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-28|2005-09-12|2005-09-14|Estimate|||||||2010-01-28|2010-01-29|Estimate|April 1996||1996-04-30|January 2010|2010-01-31||||June 2005|Actual|2005-06-30||Interventional|||Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)||Completed||Phase 4|||Eisai Inc.|||||f||||||||||||||2018-06-01 04:39:51.56588|2018-06-01 04:39:51.56588
NCT00165594|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-01-22|2005-09-12|2005-09-14|Estimate|||||||2014-01-22|2014-01-23|Estimate|February 2005||2005-02-28|January 2014|2014-01-31|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||A Study of E7070 in Patients With Gastric Cancer|Non-Randomized, Open, Uncontrolled, Dose Comparison Study of E7070 in Patients With Gastric Cancer|Terminated||Phase 1/Phase 2|50||Eisai Inc.||||Study was completed.|f||||||||||||||2018-06-01 04:39:51.619795|2018-06-01 04:39:51.619795
NCT00165581|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-12-20|2005-09-13|2005-09-14|Estimate|||||||2007-12-20|2007-12-21|Estimate|December 2002||2002-12-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma|A Pilot Clinical Trial to Evaluate High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Favorable Stage I and II Breast Cancer|Terminated||N/A|15||Dana-Farber Cancer Institute||||Due to continuing review|f||||||||||||||2018-06-01 04:39:51.690271|2018-06-01 04:39:51.690271
NCT00165568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-10-30|2005-09-12|2005-09-14|Estimate|||||||2009-10-30|2009-11-02|Estimate|July 2005||2005-07-31|October 2009|2009-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer|Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer|Completed||Phase 2|20||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:51.748229|2018-06-01 04:39:51.748229
NCT00165555|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-03-26|2005-09-12|2005-09-14|Estimate|||||||2014-03-26|2014-03-27|Estimate|August 1999||1999-08-31|March 2014|2014-03-31|November 2009|Actual|2009-11-30|April 2002|Actual|2002-04-30||Interventional|||Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma|Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin and Intravenous Sodium Thiosulfate in the Multimodality Treatment of Malignant Pleural Mesothelioma|Completed||Phase 1|70|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:51.808798|2018-06-01 04:39:51.808798
NCT00165542|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-21|2005-09-12|2005-09-14|Estimate|||||||2016-11-21|2016-11-23|Estimate|June 1998||1998-06-30|November 2016|2016-11-30|August 2009|Actual|2009-08-31|February 2004|Actual|2004-02-29||Observational|||A-protein Levels in Adult and Pediatric Brain Tumor Patients|Determination of A-Protein Levels in Adult and Pediatric Brain Tumor Patients|Completed|||54|Actual|Dana-Farber Cancer Institute|||1||f||||f||||||Samples With DNA|"~     whole blood cerebrospinal fluid~   "|No||2018-06-01 04:39:51.871327|2018-06-01 04:39:51.871327
NCT00165516|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2014-03-26|2005-09-12|2005-09-14|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2004||2004-01-31|March 2014|2014-03-31|December 2009|Actual|2009-12-31|July 2006|Actual|2006-07-31||Interventional|||Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate|A Phase II Feasibility Study of Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate|Completed||Phase 2|85|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:51.939303|2018-06-01 04:39:51.939303
NCT00165503|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2014-04-23||2016-07-25|2005-09-12|2005-09-14|Estimate|2016-07-25|2016-09-09|Estimate||||2016-07-25|2016-09-09|Estimate|April 2004||2004-04-30|July 2016|2016-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate|A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin|Terminated||Phase 2|16|Actual|Dana-Farber Cancer Institute|This trial was terminated due to low accrual and feasibility.|1||lack of acurral|f||||t||||||||No||2018-06-01 04:39:52.008498|2018-06-01 04:39:52.008498
NCT00165490|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-11-07|2005-09-09|2005-09-14|Estimate|||||||2014-11-07|2014-11-10|Estimate|August 2004||2004-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2007|Actual|2007-11-30||Interventional|||Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer|Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer|Completed||Phase 2|19|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:52.202723|2018-06-01 04:39:52.202723
NCT00165477|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-08|2005-09-09|2005-09-14|Estimate|||||||2010-03-08|2010-03-10|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|July 2009|Actual|2009-07-31|November 2007|Actual|2007-11-30||Interventional|||Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study of Lenalidomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme.|Completed||Phase 2|23|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:52.271911|2018-06-01 04:39:52.271911
NCT00165464|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-04-24|2005-09-09|2005-09-14|Estimate|||||||2009-04-24|2009-04-28|Estimate|August 2001||2001-08-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|March 2005|Actual|2005-03-31||Interventional|||Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer|A Phase II Trial of Taxotere, Cisplatin, and Irinotecan in Advanced Esophageal and Gastric Cancer|Completed||Phase 2|54|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:52.343182|2018-06-01 04:39:52.343182
NCT00165451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-07-06|2005-09-09|2005-09-14|Estimate|||||||2011-07-06|2011-07-07|Estimate|June 2001||2001-06-30|July 2011|2011-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer|Anti-Angiogenic Chemotherapy: A Phase II Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer|Completed||Phase 2|20|Actual|Dana-Farber Cancer Institute|||||f||||f||||||||||2018-06-01 04:39:52.41324|2018-06-01 04:39:52.41324
NCT00165438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-12-19|2005-09-09|2005-09-14|Estimate|||||||2012-12-19|2012-12-20|Estimate|October 2001||2001-10-31|December 2012|2012-12-31|January 2010|Actual|2010-01-31|November 2005|Actual|2005-11-30||Observational|||Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy|A Prospective Study of Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy With or Without Mediastinal Irradiation|Completed|||60|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:52.479948|2018-06-01 04:39:52.479948
NCT00165425|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-07-26|2005-09-09|2005-09-14|Estimate|||||||2017-07-26|2017-07-28|Actual|February 2004||2004-02-29|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|October 2007|Actual|2007-10-31||Interventional|||Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation|Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation|Active, not recruiting||N/A|210|Actual|Dana-Farber Cancer Institute||1|||f||||f||||||||No||2018-06-01 04:39:52.548109|2018-06-01 04:39:52.548109
NCT00165412|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-08-13|2005-09-09|2005-09-14|Estimate|||||||2012-08-13|2012-08-14|Estimate|July 2005||2005-07-31|August 2012|2012-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease|Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease|Completed|||168|Anticipated|Dana-Farber Cancer Institute|||||f||||f||||||||||2018-06-01 04:39:52.612578|2018-06-01 04:39:52.612578
NCT00165399|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-07-02|2005-09-09|2005-09-14|Estimate|||||||2013-07-02|2013-07-04|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|April 2005|Actual|2005-04-30||Interventional|||Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment|Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment|Completed||Phase 2|61|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:52.671315|2018-06-01 04:39:52.671315
NCT00165386|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-12-07|2005-09-09|2005-09-14|Estimate|||||||2009-12-07|2009-12-09|Estimate|July 2001||2001-07-31|December 2009|2009-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||MRI-guided Bone Marrow Biopsies of Prostate Cancer Patients|MRI-guided Bone Marrow Biopsies of Advanced CaP Patients|Completed||N/A|20||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:52.725054|2018-06-01 04:39:52.725054
NCT00165373|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-21|2005-09-09|2005-09-14|Estimate|||||||2007-12-21|2007-12-28|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||rhEndostatin Protein Involving Pediatric Patients With Cancer|A Phase I, Safety, Pharmacokinetic and Pharmacodynamic Study of rhEndostatin Protein Administered by Continuous Intravenous Infusion to Pediatric Patients With Cancer|Terminated||Phase 1|21|Actual|Dana-Farber Cancer Institute||||Lack of drug supply|f||||f||||||||||2018-06-01 04:39:52.773547|2018-06-01 04:39:52.773547
NCT00165360|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-10-30|2005-09-09|2005-09-14|Estimate|||||||2009-10-30|2009-11-02|Estimate|September 2001||2001-09-30|October 2009|2009-10-31|September 2009|Actual|2009-09-30|December 2006|Actual|2006-12-31||Interventional|||Prolonged Daily Temozolomide for Low-Grade Glioma|A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma|Completed||Phase 2|46|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:52.844029|2018-06-01 04:39:52.844029
NCT00165347|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-20|2005-09-09|2005-09-14|Estimate|||||||2007-12-20|2007-12-21|Estimate|December 2003||2003-12-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Protein Tyrosine Kinases (PTK) in Multiple Myeloma|Phase II Study of PTK787/ZK222584 in Multiple Myeloma|Completed||Phase 2|10||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.024|2018-06-01 04:39:53.024
NCT00165334|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-07-21|2005-09-09|2005-09-14|Estimate|||||||2009-07-21|2009-07-22|Estimate|June 2005||2005-06-30|July 2009|2009-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer|Phase II Trial of Cetuximab Plus Vinorelbine in Previously Untreated Patients > 70 With Advanced NSCLC|Completed||Phase 2|53||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.107451|2018-06-01 04:39:53.107451
NCT00165308|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-07-08|2005-09-09|2005-09-14|Estimate|||||||2014-07-08|2014-07-09|Estimate|April 2001||2001-04-30|July 2014|2014-07-31|June 2009|Actual|2009-06-30|March 2004|Actual|2004-03-31||Interventional|||Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors|A Feasibility Study of Tamoxifen Prevention of Breast Cancer in Hodgkin's Disease Survivors|Completed||N/A|29|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:39:53.179771|2018-06-01 04:39:53.179771
NCT00165295|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-06-23|2005-09-09|2005-09-14|Estimate|||||||2011-06-23|2011-06-27|Estimate|September 2005||2005-09-30|June 2011|2011-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Sildenafil Citrate in Waldenstrom's Macroglobulinemia|Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia|Completed||Phase 2|30||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.271273|2018-06-01 04:39:53.271273
NCT00165282|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-26|2005-09-09|2005-09-14|Estimate|||||||2013-11-26|2013-11-28|Estimate|April 2005||2005-04-30|November 2013|2013-11-30|June 2011|Actual|2011-06-30|January 2010|Actual|2010-01-31||Interventional|||Mindfulness Meditation in Bone Marrow Transplantation|Mindfulness Meditation in Bone Marrow Transplantation|Completed||Phase 2/Phase 3|241|Actual|Emory University||3|||f||||t||||||||||2018-06-01 04:39:53.335075|2018-06-01 04:39:53.335075
NCT00165269|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-10-30|2005-09-09|2005-09-14|Estimate|||||||2009-10-30|2009-11-02|Estimate|May 1992||1992-05-31|October 2009|2009-10-31|February 2008|Actual|2008-02-29|June 2000|Actual|2000-06-30||Interventional|||Mantle Irradiation for Hodgkin's Disease|Mantle Irradiation for Selected Hodgkin's Disease Patients With Stage IA-IIA Disease|Completed||Phase 2|100|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.417537|2018-06-01 04:39:53.417537
NCT00165256|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-07-05|2005-09-09|2005-09-14|Estimate|||||||2016-07-05|2016-07-06|Estimate|May 1995||1995-05-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|July 2002|Actual|2002-07-31||Observational|||Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast|Wide Excision Alone for DCIS-Grades 1 and 2|Terminated|||158|Actual|Dana-Farber Cancer Institute|||1|The pre-specified stopping boundary was reached.|f||||f||||||||No||2018-06-01 04:39:53.474671|2018-06-01 04:39:53.474671
NCT00165243|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-06-06|2005-09-09|2005-09-14|Estimate|||||||2017-06-06|2017-06-07|Actual|September 1998||1998-09-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|January 2004|Actual|2004-01-31||Interventional|||Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer|Tangential Radiation Therapy Without Axillary Dissection in Early-Stage Breast Cancer|Completed||Phase 2|100|Actual|Dana-Farber Cancer Institute|||||f||||f||||||||||2018-06-01 04:39:53.547539|2018-06-01 04:39:53.547539
NCT00165230|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-04-27|2005-09-09|2005-09-14|Estimate|||||||2009-04-27|2009-04-28|Estimate|May 2002||2002-05-31|April 2009|2009-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors|A Phase II Study of Thalidomide in Combination With Temodar in Patients With Metastatic Neuroendocrine Tumors|Completed||Phase 2|32||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.676787|2018-06-01 04:39:53.676787
NCT00165217|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-20|2005-09-09|2005-09-14|Estimate|||||||2007-12-20|2007-12-21|Estimate|November 2001||2001-11-30|December 2007|2007-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma|A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma|Completed||Phase 2|37||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.748769|2018-06-01 04:39:53.748769
NCT00165204|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-20|2005-09-09|2005-09-14|Estimate|||||||2007-12-20|2007-12-21|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy|A Randomized Study of the Effects of Tibolone on Bone Density, Menopause Symptoms and Breast Density in High Risk Women After Prophylactic Oophorectomy|Completed||Phase 2|50||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.813791|2018-06-01 04:39:53.813791
NCT00165191|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-04-27|2005-09-09|2005-09-14|Estimate|||||||2009-04-27|2009-04-28|Estimate|August 1998||1998-08-31|April 2009|2009-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus|A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus|Completed||Phase 2|32||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:53.889072|2018-06-01 04:39:53.889072
NCT00165178|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-04-23|2005-09-09|2005-09-14|Estimate|||||||2013-04-23|2013-04-25|Estimate|September 2000||2000-09-30|April 2013|2013-04-30|May 2011|Actual|2011-05-31|December 2004|Actual|2004-12-31||Interventional|||Treatment of Acute Lymphoblastic Leukemia in Children|Treatment of Acute Lymphoblastic Leukemia in Children|Completed||Phase 3|498|Actual|Dana-Farber Cancer Institute||4|||f||||t||||||||||2018-06-01 04:39:53.990283|2018-06-01 04:39:53.990283
NCT00165152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-08-07|2005-09-09|2005-09-14|Estimate|||||||2012-08-07|2012-08-09|Estimate|July 1998||1998-07-31|August 2012|2012-08-31|June 2005|Actual|2005-06-30|September 2001|Actual|2001-09-30||Interventional|||Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing|A Randomized Study of Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing|Completed||N/A|150|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 04:39:54.100076|2018-06-01 04:39:54.100076
NCT00165139|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-10-30|2005-09-09|2005-09-14|Estimate|||||||2009-10-30|2009-11-02|Estimate|January 1996||1996-01-31|October 2009|2009-10-31|February 2009|Actual|2009-02-28|November 2000|Actual|2000-11-30||Interventional|||Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas|Double Dose Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Stage Neuroblastoma and Sarcomas|Completed||Phase 2|20|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:54.225984|2018-06-01 04:39:54.225984
NCT00165126|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-10-30|2005-09-09|2005-09-14|Estimate|||||||2009-10-30|2009-11-02|Estimate|January 2004||2004-01-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|January 2006|Actual|2006-01-31||Observational|||Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma|Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial Carcinoma|Completed|||40|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:39:54.418392|2018-06-01 04:39:54.418392
NCT00165100|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-20|2005-09-09|2005-09-14|Estimate|||||||2007-12-20|2007-12-28|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer|Dynamic Area Telethermometry (DAT) as an Auxiliary Imaging Modality in Assessment of Patients With Cancer|Completed||N/A|50||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:39:54.479666|2018-06-01 04:39:54.479666
NCT00165087|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-12-20|2005-09-09|2005-09-14|Estimate|||||||2007-12-20|2007-12-28|Estimate|January 1996||1996-01-31|December 2007|2007-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Treatment of Childhood Acute Lymphoblastic Leukemia|Treatment of Childhood Acute Lymphoblastic Leukemia|Terminated||Phase 3|491||Dana-Farber Cancer Institute||||Terminated by IRB for continuing review|||||||||||||||2018-06-01 04:39:54.538341|2018-06-01 04:39:54.538341
NCT00165074|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-11-19|2005-09-09|2005-09-14|Estimate|||||||2007-11-19|2007-11-22|Estimate|June 2003||2003-06-30|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory Decompensation|Pilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With|Completed||N/A|11|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-06-01 04:39:54.629456|2018-06-01 04:39:54.629456
NCT00165061|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2005-09-13|2005-09-13|2005-09-14|Estimate|||||||2005-09-13|2005-09-14|Estimate|July 2000||2000-07-31|September 2005|2005-09-30||||||||Interventional|||Multi-Center Prospective Randomized Trial Comparing Standard Esophagectomy Against Chemo-Radiotherapy for Treatment of Squamous Esophageal Cancer – Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)|Phase 3 Multicenter Randomized Study Comparing Esophagectomy Against Definitive Chemoradiation for Treatment of Squamous Esophageal Cancer|Completed||Phase 3|80||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:54.693009|2018-06-01 04:39:54.693009
NCT00165048|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-08|2005-09-13|2005-09-14|Estimate|||||||2005-12-08|2005-12-09|Estimate|October 2004||2004-10-31|September 2005|2005-09-30||||||||Interventional|||Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial|Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 3|206||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:54.764807|2018-06-01 04:39:54.764807
NCT00165035|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-03|2005-09-09|2005-09-14|Estimate|||||||2011-08-03|2011-08-04|Estimate|May 2005||2005-05-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|January 2007|Actual|2007-01-31||Interventional|||Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)|Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries|Completed||Phase 3|1701|Actual|Cordis Corporation||2|||f||||t||||||||||2018-06-01 04:39:54.834174|2018-06-01 04:39:54.834174
NCT00165022|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-03-27|2005-09-12|2005-09-14|Estimate|||||||2008-03-27|2008-03-31|Estimate|September 2003||2003-09-30|March 2008|2008-03-31|October 2006|Actual|2006-10-31|||||Observational|||Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population|Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population|Completed|||330|Actual|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:54.931354|2018-06-01 04:39:54.931354
NCT00165009|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-05-10|2005-09-12|2005-09-14|Estimate|||||||2013-05-10|2013-05-13|Estimate|June 2005||2005-06-30|May 2013|2013-05-31|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|||Resolution Endoclips Vs Epinephrine Injection and Heater Probe|A Prospective Randomized Comparison of a Novel Hemostatic Clip (Resolution Clip™) to Combined Epinephrine Injection and Heater Probe Thermocoagulation in the Endoscopic Control of Ulcer Bleeding|Terminated||Phase 3|103|Actual|Chinese University of Hong Kong||2||Slow recruitment|f||||f||||||||||2018-06-01 04:39:54.983233|2018-06-01 04:39:54.983233
NCT00164996|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2012-02-16|2005-09-13|2005-09-14|Estimate|||||||2012-02-16|2012-02-17|Estimate|September 2004||2004-09-30|September 2005|2005-09-30||||September 2010|Actual|2010-09-30||Interventional|||Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia|Comparison of Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patients With or Without Local Pharyngeal Anaesthesia: A Randomized Controlled Trial|Completed||Phase 3|400|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.075983|2018-06-01 04:39:55.075983
NCT00164970|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-02-02|2005-09-12|2005-09-14|Estimate|||||||2009-02-02|2009-02-03|Estimate|October 2004||2004-10-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia?|Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia?|Completed||Phase 4|166|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.134465|2018-06-01 04:39:55.134465
NCT00164957|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-02-02|2005-09-12|2005-09-14|Estimate|||||||2009-02-02|2009-02-03|Estimate|September 2002||2002-09-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effect of Continuous Versus Enteral Pump Feeding in Aspiration in Tube Fed Patients|The Effect of Continuous vs Enteral Pump Feeding in Aspiration in Tube Fed Patients|Completed||N/A|222|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.197184|2018-06-01 04:39:55.197184
NCT00164944|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-04-20|2005-09-12|2005-09-14|Estimate|||||||2017-04-20|2017-04-21|Actual|April 2004||2004-04-30|April 2017|2017-04-30|April 6, 2017|Actual|2017-04-06|August 2016|Actual|2016-08-31||Observational|||Screening for Colorectal Neoplasm in First Degree Relatives of the Affected|Colonoscopic Screening in First-degree Relatives of Hong Kong Chinese Patients With Sporadic Colorectal Cancer: a Cohort Study With Case Control Analysis|Completed|||748|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-06-01 04:39:55.256233|2018-06-01 04:39:55.256233
NCT00164931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-06-09|2005-09-11|2005-09-14|Estimate|||||||2011-06-09|2011-06-10|Estimate|October 2003||2003-10-31|September 2005|2005-09-30||||||||Interventional|||A Study Comparing High Dose Omeprazole Infusion Against Scheduled Second Endoscopy for Bleeding Peptic Ulcer|Phase 3 Study of Prospective Randomized Trial Comparing Adjunctive High Dose Omeprazole Infusion Against Scheduled Second Endoscopy in the Prevention of Peptic Ulcer Rebleeding After Therapeutic Endoscopy|Completed||Phase 3|240|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.330728|2018-06-01 04:39:55.330728
NCT00164918|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|September 2004||2004-09-30|September 2005|2005-09-30||||||||Interventional|||Role of Routine Nasogastric Decompression After Subtotal Gastrectomy|Role of Routine Nasogastric Decompression After Subtotal Gastrectomy|Unknown status|Recruiting|Phase 3|90||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.415644|2018-06-01 04:39:55.415644
NCT00164905|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-08-27|2005-09-12|2005-09-14|Estimate|||||||2012-08-27|2012-08-28|Estimate|September 2004||2004-09-30|August 2012|2012-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage|Role of Doppler Ultrasound in Severe Peptic Ulcer Hemorrhage: Can it Guide the Use of and Predict Failure of Endoscopic Treatment? A Prospective, Multicenter, Randomized, Controlled Study|Terminated||N/A|121|Actual|Chinese University of Hong Kong||2||Slow recruitment|f||||f||||||||||2018-06-01 04:39:55.472827|2018-06-01 04:39:55.472827
NCT00164892|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-16|2005-09-12|2005-09-14|Estimate|||||||2005-11-16|2005-11-17|Estimate|October 2004||2004-10-31|September 2005|2005-09-30||||||||Interventional|||Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial|Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial|Unknown status|Active, not recruiting|Phase 3|214||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.546841|2018-06-01 04:39:55.546841
NCT00164879|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-08-06|2005-09-12|2005-09-14|Estimate|||||||2007-08-06|2007-08-07|Estimate|January 2000||2000-01-31|September 2005|2005-09-30||||||||Interventional|||Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers|Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial|Unknown status|Recruiting|Phase 3|70|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.593266|2018-06-01 04:39:55.593266
NCT00164866|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-06-05|2005-09-12|2005-09-14|Estimate|||||||2007-06-05|2007-06-06|Estimate|February 2004||2004-02-29|June 2007|2007-06-30|September 2005||2005-09-30|||||Interventional|||Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy|Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study.|Completed||Phase 4|638||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.648494|2018-06-01 04:39:55.648494
NCT00164853|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2012-02-16|2005-09-11|2005-09-14|Estimate|||||||2012-02-16|2012-02-17|Estimate|September 2005||2005-09-30|September 2010|2010-09-30||||September 2011|Actual|2011-09-30||Interventional|||Compare Combined Sphincterotomy and Balloon Dilation (ESBD) Versus Standard Sphincterotomy (ES) in Removing Biliary Stones|Combined Sphincterotomy and Balloon Dilation (ESBD) Versus Standard Sphincterotomy (ES) in Removing Biliary Stones—a Randomized Controlled Trial|Completed||Phase 3|180|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 04:39:55.700626|2018-06-01 04:39:55.700626
NCT00164840|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-29|2005-09-09|2005-09-14|Estimate|||||||2010-03-29|2010-03-30|Estimate|May 2003||2003-05-31|March 2010|2010-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy|Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy|Completed||Phase 3|244|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.862714|2018-06-01 04:39:55.862714
NCT00164827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2005-09-11|2005-09-11|2005-09-14|Estimate|||||||2005-09-11|2005-09-14|Estimate|January 2003||2003-01-31|September 2005|2005-09-30||||||||Observational|||Surveillance of Bleeding Peptic Ulcer Using Wireless Capsule Endoscopy|Phase 3 Study on the Use of Capsule Endoscope for Surveillance and Detection of Peptic Ulcer Rebleeding After Therapeutic Endoscopy|Unknown status|Recruiting||50||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:39:55.944344|2018-06-01 04:39:55.944344
NCT00164814|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-25|2005-09-09|2005-09-14|Estimate|||||||2008-03-25|2008-03-26|Estimate||||March 2008|2008-03-31||||||||Observational|||The Role of Visceral Hyperalgesia, Gastroesophageal Reflux Disease (GERD) and Esophageal Motility Disorder (EMD) in NCCP Patients|Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pian in Chinese? Part I: The Role of Visceral Hyperalgesia, Gastroesophageal Reflux Disease (GERD) and Esophageal Motility Disorder (EMD) in NCCP Patients|Terminated|||100|Actual|Chinese University of Hong Kong||||Funding ended|f||||||||||||||2018-06-01 04:39:56.008957|2018-06-01 04:39:56.008957
NCT00164801|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-25|2005-09-09|2005-09-14|Estimate|||||||2008-03-25|2008-03-26|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|January 2007|Actual|2007-01-31|||||Interventional|||Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese?|Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese? Part 2: Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients|Terminated||N/A|60|Actual|Chinese University of Hong Kong||||Funding ended|f||||||||||||||2018-06-01 04:39:56.054809|2018-06-01 04:39:56.054809
NCT00164788|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-08-27|2005-09-09|2005-09-14|Estimate|||||||2012-08-27|2012-08-28|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole|A Randomized Comparison of High Dose Oral to Intravenous Esomeprazole in Patients After Endoscopic Control to Their Bleeding Peptic Ulcers: an Intra-gastric pH Study.|Terminated||Phase 2|7|Actual|Chinese University of Hong Kong||2||No suitable patients and many patients refused the study|f||||f||||||||||2018-06-01 04:39:56.109545|2018-06-01 04:39:56.109545
NCT00164775|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-09-14|2005-09-09|2005-09-14|Estimate|||||||2016-09-14|2016-09-16|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia|The Efficacy of Imipramine in Treatment of Functional Dyspepsia: A Double Blind Randomized Placebo Controlled Trial|Completed||Phase 3|107|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-06-01 04:39:56.176302|2018-06-01 04:39:56.176302
NCT00164762|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-27|2005-09-13|2005-09-14|Estimate|||||||2007-09-27|2007-10-01|Estimate|June 2005||2005-06-30|September 2007|2007-09-30|November 2006|Actual|2006-11-30|||||Observational|||Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers|Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi|Completed|||126|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:56.252113|2018-06-01 04:39:56.252113
NCT00164749|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-04-25|2005-09-09|2005-09-14|Estimate|||||||2008-04-25|2008-04-30|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease|A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease|Completed||Phase 1/Phase 2|36|Actual|Chinese University of Hong Kong||3|||f||||||||||||||2018-06-01 04:39:56.306778|2018-06-01 04:39:56.306778
NCT00164736|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2010-04-22|2005-09-13|2005-09-14|Estimate|||||||2010-04-22|2010-04-23|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Breastfeeding, Antiretroviral, and Nutrition Study|HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health|Completed||Phase 3|2369|Actual|Centers for Disease Control and Prevention||6|||f||||t||||||||||2018-06-01 04:39:56.461244|2018-06-01 04:39:56.461244
NCT00164723|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-08-10|2005-09-09|2005-09-14|Estimate|||||||2015-08-10|2015-08-13|Estimate|February 2005||2005-02-28|January 2011|2011-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Endoscopic Evaluation of Lower Gastrointestinal Bleeding (GIB) in Patients Presenting With Melena|Endoscopic Evaluation of the Incidence and Etiology of Lower Gastrointestinal Bleeding in Patients Presenting With Melena|Completed||N/A|165|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 04:39:56.583004|2018-06-01 04:39:56.583004
NCT00164710|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2012-09-26|2005-09-13|2005-09-14|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi|An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi|Completed||Phase 4|365||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:56.667471|2018-06-01 04:39:56.667471
NCT00164697|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-02-02|2005-09-13|2005-09-14|Estimate|||||||2016-02-02|2016-02-03|Estimate|October 1999||1999-10-31|September 2012|2012-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|Legacy||Legacy for Children, an Early Intervention Study to Promote Optimal Child Development in Low-income Families|Legacy for Children, The CDC Parenting Research Projects|Completed||N/A|547|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||No||2018-06-01 04:39:56.771259|2018-06-01 04:39:56.771259
NCT00164684|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-02-08|2005-09-12|2005-09-14|Estimate|||||||2012-02-08|2012-02-09|Estimate|September 2001||2001-09-30|February 2012|2012-02-29|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Men of Color Fatherhood Education and Violence Prevention Project|Men of Color Fatherhood Education and Violence Prevention Project|Completed||Phase 1|||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:56.889926|2018-06-01 04:39:56.889926
NCT00164671|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Testing the POWER Project: A Neighborhood Intervention Trial|Testing the POWER Project: A Neighborhood Intervention Trial|Completed||N/A|5000||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:56.96502|2018-06-01 04:39:56.96502
NCT00164658|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-01-06|2005-09-12|2005-09-14|Estimate|||||||2010-01-06|2010-01-07|Estimate|September 2005||2005-09-30|January 2010|2010-01-31|October 2007|Actual|2007-10-31|||||Interventional|||Evaluating Tools for Health Promotion and Disease Prevention|Evaluating Tools for Health Promotion and Disease Prevention|Completed||Phase 1|8400|Anticipated|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:57.040471|2018-06-01 04:39:57.040471
NCT00164645|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-04-26|2005-09-12|2005-09-14|Estimate|||||||2006-04-26|2006-04-27|Estimate||||September 2005|2005-09-30||||||||Interventional|||Problem Solving for Caregivers of Persons With Brain Injury|Problem Solving for Caregivers of Patients With Traumatic Brain Injury|Unknown status|Recruiting|Phase 3|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.124021|2018-06-01 04:39:57.124021
NCT00164632|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|October 2001||2001-10-31|September 2005|2005-09-30||||||||Interventional|||No More Falls Injury Prevention Study|California No More Falls! Senior Injury Prevention Program|Completed||N/A|552||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.197142|2018-06-01 04:39:57.197142
NCT00164619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-06-04|2005-09-12|2005-09-14|Estimate|||||||2008-06-04|2008-06-05|Estimate|July 2001||2001-07-31|June 2008|2008-06-30|March 2008|Actual|2008-03-31|November 2006|Actual|2006-11-30||Interventional|||Testing the Effectiveness of VOICES as Implemented by STD & HIV Prevention Agencies in the US and PR|Testing the Effectiveness of the VOICES/VOCES Intervention Package as Implemented by STD and HIV Prevention Agencies That Target Hispanics and African Americans in the U.S. and Puerto Rico|Completed||Phase 2/Phase 3|3660|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 04:39:57.250257|2018-06-01 04:39:57.250257
NCT00164606|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-20|2005-09-12|2005-09-14|Estimate|||||||2007-09-20|2007-09-21|Estimate|May 2003||2003-05-31|September 2007|2007-09-30|September 2007|Actual|2007-09-30|||||Interventional|||A Dissemination Trial of the Positive Parenting Program to Reduce Child Maltreatment in South Carolina|A Dissemination Trial of the Positive Parenting Program to Reduce Child Maltreatment in South Carolina|Completed||Phase 2|14690|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.333951|2018-06-01 04:39:57.333951
NCT00164593|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-04-04|2005-09-12|2005-09-14|Estimate|||||||2012-04-04|2012-04-05|Estimate|April 2005||2005-04-30|April 2012|2012-04-30|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|||Youth Empowerment Solutions for Peaceful Communities|Youth Empowerment Solutions for Peaceful Communities|Completed||Phase 1|1142|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:57.389607|2018-06-01 04:39:57.389607
NCT00164580|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-26|2005-09-09|2005-09-14|Estimate|||||||2012-09-26|2012-09-27|Estimate|October 1996||1996-10-31|September 2012|2012-09-30|August 2004|Actual|2004-08-31|August 2002|Actual|2002-08-31||Interventional|||Community Intervention Trial for Youth (CITY) Study|Prevention of HIV Infection in Youth at Risk: Developing Community-Level Intervention Strategies That Work (Community Intervention Trial for Youth (CITY) Study)|Completed||Phase 2/Phase 3|12000||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:57.464712|2018-06-01 04:39:57.464712
NCT00164567|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2009-10-22|2005-09-12|2005-09-14|Estimate|||||||2009-10-22|2009-10-23|Estimate||||October 2009|2009-10-31||||||||Interventional|||Intimate Partner Violence (IPV)Screening in Health Care Clinics in Rural South Carolina|IPV Screening in Health Care Clinics in Rural South Carolina|Completed||Phase 2|1200||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.545066|2018-06-01 04:39:57.545066
NCT00164554|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-04-25|2005-09-12|2005-09-14|Estimate|||||||2008-04-25|2008-04-28|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Fetal Alcohol Syndrome/ARND Research Consortion|Fetal Alcohol Syndrome/ARND Research Consortion-Oklahoma|Completed||Phase 1/Phase 2|100||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.595824|2018-06-01 04:39:57.595824
NCT00164541|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-09-20|2005-09-12|2005-09-14|Estimate|||||||2007-09-20|2007-09-21|Estimate|September 2004||2004-09-30|September 2007|2007-09-30|September 2006|Actual|2006-09-30|||||Interventional|||An Arts-Based Initiative for the Prevention of Violence Against Women and Girls|An Arts-Based Initiative for the Prevention of Violence Against Women and Girls|Completed||Phase 1|1440|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:57.647562|2018-06-01 04:39:57.647562
NCT00164528|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Intervening With Children/Adolescents With FAS/ARND|Intervening With Children/Adolescents With FAS/ARND|Completed||Phase 1/Phase 2|52||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.704689|2018-06-01 04:39:57.704689
NCT00164515|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2011-07-27|2005-09-12|2005-09-14|Estimate|||||||2011-07-27|2011-07-28|Estimate|October 2004||2004-10-31|July 2011|2011-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|PEP||Increasing Physical Activity Among Overweight Women With Mobility Disabilities.|Personalized Exercise Programme (PEP) I: Physician Referral Approach to Increasing Awareness and Sustainability of Physical Activity for Overweight Adults With Mobility Limitations.|Completed||Phase 2|96|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-06-01 04:39:57.750432|2018-06-01 04:39:57.750432
NCT00164502|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Limb Loss Self-Management Program|"Limb Loss Self-Management Program: Promoting Amputee Life Skills"|Completed||Phase 2|500||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.821224|2018-06-01 04:39:57.821224
NCT00164489|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Health Promotion of People With Disabilities|Intervention Research Grants to Promote the Health of People With Disabilities|Completed||Phase 2/Phase 3|400||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.879718|2018-06-01 04:39:57.879718
NCT00164476|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Promoting Clinical Preventive Services Among Adults With Disabilities|Promoting Prevention Among Adults With Disabilities|Completed||Phase 1|200||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:57.928684|2018-06-01 04:39:57.928684
NCT00164463|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2011-06-07|2005-09-10|2005-09-14|Estimate|||||||2011-06-07|2011-06-08|Estimate|July 2004||2004-07-31|June 2011|2011-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment|TBTC Study 27/28 PK: Pharmacokinetic Issues in the Use of Moxifloxacin for Treatment of Tuberculosis|Completed||Phase 2|72|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 04:39:58.108758|2018-06-01 04:39:58.108758
NCT00164450|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-08-22|2005-09-10|2005-09-14|Estimate|||||||2008-08-22|2008-08-25|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection|TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children Receiving Once Weekly Rifapentine and Isoniazid for the Treatment of Latent Tuberculosis Infection|Completed||N/A|230|Anticipated|Centers for Disease Control and Prevention|||||f||||t||||||||||2018-06-01 04:39:58.195796|2018-06-01 04:39:58.195796
NCT00164437|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|September 2002||2002-09-30|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||CD-ROM Intervention for Prostate Cancer Screening|CD-ROM Intervention for Prostate Cancer Screening|Completed||Phase 2/Phase 3|554||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:58.279842|2018-06-01 04:39:58.279842
NCT00164424|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-10|2005-09-10|2005-09-14|Estimate|||||||2012-09-10|2012-09-11|Estimate|March 2005||2005-03-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|March 2009|Actual|2009-03-31||Interventional|||Episodic Acyclovir Therapy for Genital Ulcers|Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa|Completed||Phase 2/Phase 3|613|Actual|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:58.335044|2018-06-01 04:39:58.335044
NCT00164411|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-03-13|2005-09-09|2005-09-14|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2004||2004-01-31|March 2012|2012-03-31|March 2005||2005-03-31|||||Interventional|||Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine|Pneumococcal Conjugate Vaccine (Prevnar; Wyeth) With Pneumococcal Polysaccharide Vaccine (23-valent) and Tetanus/Diphtheria Vaccine|Completed||Phase 1|30||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 04:39:58.393807|2018-06-01 04:39:58.393807
NCT00164398|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-10|2005-09-09|2005-09-14|Estimate|||||||2012-09-10|2012-09-11|Estimate|June 2004||2004-06-30|September 2012|2012-09-30|September 2008|Actual|2008-09-30|October 2006|Actual|2006-10-31||Interventional|||HIP: HIV Intervention for Providers|HIP: HIV Intervention for Providers|Completed||Phase 2|50|Anticipated|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:58.453801|2018-06-01 04:39:58.453801
NCT00164385|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-10-20|2005-09-09|2005-09-14|Estimate|||||||2005-10-20|2005-10-21|Estimate||||September 2005|2005-09-30||||||||Interventional|||Adolescent Impact: A Behavioral Intervention for Adolescents Living With HIV/AIDS|Adolescent Impact: A Behavioral Intervention for Adolescents Living With HIV/AIDS|Completed||N/A|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:58.501786|2018-06-01 04:39:58.501786
NCT00164372|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-26|2005-09-09|2005-09-14|Estimate|||||||2012-09-26|2012-09-27|Estimate|May 2002||2002-05-31|September 2012|2012-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users|Collaborative Injection Drug Users Study III/Drug Users Intervention Trial (CIDUS III/DUIT)|Completed||Phase 2/Phase 3|1400||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:58.547571|2018-06-01 04:39:58.547571
NCT00164359|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-26|2005-09-09|2005-09-14|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi|A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi|Completed||Phase 4|212||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:58.60688|2018-06-01 04:39:58.60688
NCT00164346|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-03-23|2005-09-09|2005-09-14|Estimate|||||||2011-03-23|2011-03-24|Estimate|January 2002||2002-01-31|March 2011|2011-03-31|December 2009|Actual|2009-12-31|September 2008|Actual|2008-09-30||Interventional|||Neurocognitive Habilitation for Children With Fetal Alcohol Syndrome (FAS)/Alcohol-Related Neurodevelopmental Disorder (ARND)|Neurocognitive Habilitation for Children With FAS/ARND|Completed||Phase 1/Phase 2|100|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:58.667247|2018-06-01 04:39:58.667247
NCT00164333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-26|2005-09-09|2005-09-14|Estimate|||||||2012-09-26|2012-09-27|Estimate|September 2004||2004-09-30|September 2012|2012-09-30|April 2008|Actual|2008-04-30|May 2007|Actual|2007-05-31||Interventional|||The Treatment Advocacy Program|The Treatment Advocacy Program|Completed||Phase 2|300||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:58.728621|2018-06-01 04:39:58.728621
NCT00164320|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-14|Estimate|||||||2005-09-09|2005-09-14|Estimate|May 2004||2004-05-31|September 2005|2005-09-30|May 2006||2006-05-31|||||Interventional|||Project TEAM: Teaching HIV Prevention in the HIV Clinic|Project TEAM: Teaching HIV Prevention in the HIV Clinic|Completed||Phase 2|600||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:58.775432|2018-06-01 04:39:58.775432
NCT00164307|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-07|2005-09-09|2005-09-14|Estimate|||||||2005-11-07|2005-11-08|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships|Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships|Completed||Phase 1/Phase 2|100||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:58.824094|2018-06-01 04:39:58.824094
NCT00164294|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-14|Estimate|||||||2005-09-09|2005-09-14|Estimate||||September 2005|2005-09-30||||||||Interventional|||ED Intervention to Reduce Risky Behaviors in Drivers|ED Intervention to Reduce Risky Behaviors in Drivers|Completed||Phase 2|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:39:59.774311|2018-06-01 04:39:59.774311
NCT00164281|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-02-05|2005-09-09|2005-09-14|Estimate|||||||2014-02-05|2014-02-06|Estimate|November 2004||2004-11-30|February 2014|2014-02-28|May 2011|Actual|2011-05-31|July 2009|Actual|2009-07-31||Interventional|||Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana|A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana|Completed||Phase 4|2000|Actual|Centers for Disease Control and Prevention||1|||f||||t||||||||||2018-06-01 04:39:59.85723|2018-06-01 04:39:59.85723
NCT00164268|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-09-06|2005-09-09|2005-09-14|Estimate|||||||2007-09-06|2007-09-10|Estimate|October 2002||2002-10-31|September 2007|2007-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Ke Ala Lokahi Demonstration Project for Sexual and Domestic Violence Prevention|Ke Ala Lokahi Demonstration Project for the Early Intervention and Prevention of Sexual and Domestic Violence Among Racial and Ethnic Populations|Completed||Phase 1|300||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:59.934434|2018-06-01 04:39:59.934434
NCT00164255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-10|2005-09-09|2005-09-14|Estimate|||||||2012-09-10|2012-09-11|Estimate|January 2003||2003-01-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy|Efficacy of Intermittent Sulfadoxine-Pyrimethamine and Sulfadoxine-Pyrimethamine + Artesunate Treatment in the Prevention of Malaria in Pregnancy in an Area With Chloroquine-Resistant Plasmodium Falciparum|Completed||Phase 4|1614|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:39:59.98877|2018-06-01 04:39:59.98877
NCT00164242|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-14|Estimate|||||||2005-09-09|2005-09-14|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|October 2004||2004-10-31|||||Interventional|||Treatment of Tardive Dyskinesia With Galantamine|Treatment of Tardive Dyskinesia With Galantamine|Completed||Phase 4|36||Caroff, Stanley N., M.D.|||||f||||||||||||||2018-06-01 04:40:00.059918|2018-06-01 04:40:00.059918
NCT00164229|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-04-25|2005-09-09|2005-09-14|Estimate|||||||2008-04-25|2008-04-28|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Fetal Alcohol Syndrome: Socio-Cognitive Habilitation|Study to Investigate the Effectiveness of a Math Intervention for Children With Fetal Alcohol Syndrome or Related Condition|Completed||Phase 1/Phase 2|100||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:40:00.12748|2018-06-01 04:40:00.12748
NCT00164216|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-09-10|2005-09-09|2005-09-14|Estimate|||||||2012-09-10|2012-09-11|Estimate|March 2005||2005-03-31|September 2012|2012-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru|Evaluation of the Efficacy and Effectiveness of Combined Therapy With Mefloquine and Artesunate for Uncomplicated Malaria Treatment in the Loreto Region (Amazon Basin), Peru|Completed|||208|Actual|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:40:00.188622|2018-06-01 04:40:00.188622
NCT00164203|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-04|2005-09-09|2005-09-14|Estimate|||||||2011-08-04|2011-08-05|Estimate|April 2005||2005-04-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|December 2007|Actual|2007-12-31||Interventional|||The Feelings Club: Evaluating a School-based Intervention for Children at Risk for Depression and Anxiety Disorders|The Feelings Club: Evaluating a School-based Intervention for Children at Risk for Depression and Anxiety Disorders|Completed||N/A|150|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 04:40:00.250805|2018-06-01 04:40:00.250805
NCT00164190|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-10-14|2005-09-09|2005-09-14|Estimate|||||||2010-10-14|2010-10-18|Estimate|July 2004||2004-07-31|October 2010|2010-10-31|January 2009|Actual|2009-01-31|December 2007|Actual|2007-12-31||Interventional|||Routine Angioplasty and Stenting After Fibrinolysis for Acute Myocardial Infarction|Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction- The TRANSFER-AMI Trial|Completed||N/A|1200|Anticipated|Canadian Heart Research Centre|||||f||||t||||||||||2018-06-01 04:40:00.4046|2018-06-01 04:40:00.4046
NCT00164177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-02-06|2005-09-09|2005-09-14|Estimate|||||||2013-02-06|2013-02-07|Estimate|October 2004||2004-10-31|February 2013|2013-02-28||||December 2004|Actual|2004-12-31||Interventional|||Evaluation Of The Efficacy Of HalfLYTELY For Bowel Cleansing Before Virtual Colonoscopy and Conventional Colonoscopy.|A Preliminary Evaluation Of The Efficacy Of HalfLYTELY® For Bowel Cleansing Before Virtual Colonoscopy (VC) and Conventional Colonoscopy (CC).|Completed||Phase 4|20||Braintree Laboratories|||||||||||||||||||2018-06-01 04:40:00.478796|2018-06-01 04:40:00.478796
NCT00164164|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-02-06|2005-09-09|2005-09-14|Estimate|||||||2013-02-06|2013-02-07|Estimate|August 1999||1999-08-31|February 2013|2013-02-28||||June 2000|Actual|2000-06-30||Interventional|||HalfLytely Bowel Prep System for Colonoscopy|HalfLytely Bowel Prep System for Colonoscopy|Completed||Phase 3|200||Braintree Laboratories|||||||||||||||||||2018-06-01 04:40:00.536671|2018-06-01 04:40:00.536671
NCT00164151|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-02-06|2005-09-09|2005-09-14|Estimate|||||||2013-02-06|2013-02-07|Estimate|June 2001||2001-06-30|February 2013|2013-02-28||||May 2002|Actual|2002-05-31||Interventional|||A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy.|A Comparison of the Efficacy and Safety of Two Bowel Preparations: HalfLytely® (2L NuLYTELY and 20 mg Bisacodyl), and Visicol™ Prior To Colonoscopy.|Completed||Phase 3|60||Braintree Laboratories|||||||||||||||||||2018-06-01 04:40:00.595375|2018-06-01 04:40:00.595375
NCT00164138|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-11-26|2005-09-13|2005-09-14|Estimate|||||||2013-11-26|2013-11-28|Estimate|December 2001||2001-12-31|September 2005|2005-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Prevalence and Treatment of Urinary Incontinence in Women With Cystic Fibrosis and Chronic Obstructive Pulmonary Disease|Development of an Intervention and and Education Program for Adult Women With Urinary Incontinence and Chronic Lung Disease Including Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|99|Actual|Bayside Health||1|||f||||f||||||||||2018-06-01 04:40:00.661087|2018-06-01 04:40:00.661087
NCT00164125|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-02-06|2005-09-09|2005-09-14|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2003||2003-07-31|February 2013|2013-02-28||||November 2004|Actual|2004-11-30||Interventional|||An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients|An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients|Completed||Phase 4|300||Braintree Laboratories|||||||||||||||||||2018-06-01 04:40:00.756198|2018-06-01 04:40:00.756198
NCT00164112|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-13|2005-09-13|2005-09-14|Estimate|||||||2005-09-13|2005-09-14|Estimate|November 2004||2004-11-30|March 2005|2005-03-31|June 2005||2005-06-30|||||Interventional|||Comparative Effects of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes|Comparison of the Effect of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes Using the Validated Cooperstown 5+1 Cocktail|Completed||Phase 4|16||Bassett Healthcare|||||f||||||||||||||2018-06-01 04:40:00.887435|2018-06-01 04:40:00.887435
NCT00164099|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-10-30|2005-09-09|2005-09-14|Estimate|||||||2007-10-30|2007-11-01|Estimate|November 2005||2005-11-30|September 2006|2006-09-30|June 2007|Actual|2007-06-30|||||Interventional|||The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study|The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study|Terminated||Phase 4|40|Actual|Beth Israel Medical Center||||Patients would not take product|f||||f||||||||||2018-06-01 04:40:00.93756|2018-06-01 04:40:00.93756
NCT00164086|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2006-10-10|2005-09-13|2005-09-14|Estimate|||||||2006-10-10|2006-10-11|Estimate||||September 2005|2005-09-30||||||||Interventional|||Atorvastatin in Myeloma||Unknown status|Not yet recruiting|Phase 1|||Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.001161|2018-06-01 04:40:01.001161
NCT00164073|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-31|2005-09-13|2005-09-14|Estimate|||||||2007-07-31|2007-08-01|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|February 2007||2007-02-28|||||Observational|||Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection|Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection|Unknown status|Recruiting||60|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.047916|2018-06-01 04:40:01.047916
NCT00164060|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-03|2005-09-13|2005-09-14|Estimate|||||||2013-12-03|2013-12-05|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection|Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection|Terminated|||158|Actual|Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.107158|2018-06-01 04:40:01.107158
NCT00164047|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2009-07-29|2005-09-13|2005-09-14|Estimate|||||||2009-07-29|2009-07-31|Estimate|April 2003||2003-04-30|July 2009|2009-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||ENIGMA - Evaluation of Nitrous Oxide In the Gas Mixture for Anaesthesia: a Randomised Controlled Trial|Evaluation of Nitrous Oxide In the Gas Mixture for Anaesthesia: a Randomised Controlled Trial|Completed||Phase 4|2070|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.160851|2018-06-01 04:40:01.160851
NCT00164034|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-02-10|2005-09-13|2005-09-14|Estimate|||||||2013-02-10|2013-02-12|Estimate|November 2005||2005-11-30|September 2005|2005-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Trauma Reception and Resuscitation Project|Trauma Reception and Resuscitation Project - 'Time for a New Approach'|Completed||N/A|1171|Actual|Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.221686|2018-06-01 04:40:01.221686
NCT00164021|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2016-01-13|2005-09-13|2005-09-14|Estimate|||||||2016-01-13|2016-01-15|Estimate|February 2001||2001-02-28|January 2016|2016-01-31||||December 2016|Anticipated|2016-12-31||Observational|||The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation|The Prevalence and Significance of Gastro-oesophageal Reflux in Adults With Cystic Fibrosis Before and After Lung Transplantation, Together With the Effects of Physiotherapy Airway Clearance Techniques on Gastro-oesophageal Function|Unknown status|Recruiting||180|Anticipated|Bayside Health|||2||f||||f||||||||||2018-06-01 04:40:01.37183|2018-06-01 04:40:01.37183
NCT00164008|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2013-12-03|2005-09-13|2005-09-14|Estimate|||||||2013-12-03|2013-12-05|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention|Comparison Between Pamidronate and Zoledronic Acid for the Treatment of Heart and Lung Transplant Related Osteopaenia and Osteoporosis|Completed||Phase 4|56|Actual|Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.454702|2018-06-01 04:40:01.454702
NCT00163995|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-25|2005-09-13|2005-09-14|Estimate|||||||2007-07-25|2007-07-26|Estimate||||September 2005|2005-09-30||||||||Observational|||Urotensin II and Vascular Tone in Cirrhosis||Unknown status|Recruiting||40|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.529929|2018-06-01 04:40:01.529929
NCT00163982|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-25|2005-09-13|2005-09-14|Estimate|||||||2007-07-25|2007-07-26|Estimate||||September 2005|2005-09-30||||||||Interventional|||Vasoactive Peptides in Portal Pressure||Unknown status|Recruiting|N/A|||Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.645966|2018-06-01 04:40:01.645966
NCT00163969|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-13|2005-09-12|2005-09-14|Estimate|||||||2016-01-13|2016-01-15|Estimate|April 2002||2002-04-30|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||The Use of Ketamine as Rescue Analgesia in the Recovery Room Following Opioid Administration. A Double-blind Randomised Trial in Postoperative Patients|The Use of Ketamine as Rescue Analgesia in the Recovery Room Following Opioid Administration. A Double-blind Randomised Trial in Postoperative Patients.|Completed||Phase 4|40||Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.710737|2018-06-01 04:40:01.710737
NCT00163956|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-03|2005-09-12|2005-09-14|Estimate|||||||2006-10-03|2006-10-04|Estimate|August 2005||2005-08-31|September 2005|2005-09-30|December 2010||2010-12-31|||||Observational|||Failed Retrieval of Inferior Vena Cava (IVC) Filters: Long-Term Outcomes|Failed Retrieval of Inferior Vena Cava (IVC) Filters: Long-Term Outcomes|Unknown status|Recruiting||20||Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.782148|2018-06-01 04:40:01.782148
NCT00163943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-07-31|2005-09-12|2005-09-14|Estimate|||||||2007-07-31|2007-08-01|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|December 2007|Anticipated|2007-12-31|||||Interventional|||Sympathetic Activity in Individuals With the Metabolic Syndrome: Benefits of Lifestyle Interventions|Neural Mechanisms Predisposing to Cardiovascular Risk in Individuals With the Metabolic Syndrome: Benefits of Dietary Weight Loss, Weight Loss Maintenance and Aerobic Exercise|Unknown status|Recruiting|N/A|66|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:01.922142|2018-06-01 04:40:01.922142
NCT00163930|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-02|2005-09-12|2005-09-14|Estimate|||||||2006-10-02|2006-10-03|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|December 2007||2007-12-31|||||Observational|||Post-Operative Pain Management in Patients Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata|Post-Operative Pain Management in Patients Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata|Unknown status|Recruiting||||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.050256|2018-06-01 04:40:02.050256
NCT00163917|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-03-14|2005-09-12|2005-09-14|Estimate|||||||2007-03-14|2007-03-15|Estimate|September 2004||2004-09-30|September 2005|2005-09-30||||||||Interventional|||A Study of the Effectiveness of Virtual Reality Relaxation Combined With Patient-Controlled Analgesia (PCA) Morphine for Those Undergoing Burn Dressing Changes|Predicting the Effectiveness of Virtual Reality Relaxation on Pain and Anxiety When Added to PCA Morphine in a Population of Burn Patients Having Dressing Changes|Unknown status|Recruiting|N/A|90||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.110204|2018-06-01 04:40:02.110204
NCT00163904|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-13|||2007-07-31|2005-09-13|2005-09-14|Estimate|||||||2007-07-31|2007-08-01|Estimate|January 2005||2005-01-31|September 2005|2005-09-30||||||||Interventional|||Can a Modified Fat Diet With Low Glycaemic Load Improve Insulin Sensitivity and Inflammatory Mediators in Overweight People With Chronic Heart Failure?|Can a Modified Fat Diet With Low Glycaemic Load Improve Insulin Sensitivity and Inflammatory Mediators in Overweight People With Chronic Heart Failure?|Unknown status|Recruiting|Phase 1|50|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.183917|2018-06-01 04:40:02.183917
NCT00163891|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-03|2005-09-12|2005-09-14|Estimate|||||||2006-10-03|2006-10-04|Estimate|September 2003||2003-09-30|September 2005|2005-09-30||||||||Interventional|||Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients|A Prospective Randomised Two Month Trial Comparing Twho Chest Physiotherapy Protocols in Lung Transplant Recipients|Completed||N/A|40||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.263547|2018-06-01 04:40:02.263547
NCT00163878|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2006-10-03|2005-09-12|2005-09-14|Estimate|||||||2006-10-03|2006-10-04|Estimate|November 2004||2004-11-30|August 2005|2005-08-31|December 2006||2006-12-31|||||Interventional|||Is Sensory Stimulation Effective in Reducing Time Spent in a Coma or Vegetative State|A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment|Unknown status|Recruiting|Phase 4|||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.330189|2018-06-01 04:40:02.330189
NCT00163865|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-25|2005-09-12|2005-09-14|Estimate|||||||2013-11-25|2013-11-27|Estimate|May 2005||2005-05-31|September 2005|2005-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents|A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents|Completed|||71|Actual|Bayside Health|||2||f||||f||||||||||2018-06-01 04:40:02.397994|2018-06-01 04:40:02.397994
NCT00163852|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-09-12|2005-09-12|2005-09-14|Estimate|||||||2005-09-12|2005-09-14|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|February 2006||2006-02-28|||||Interventional|||Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis|Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis|Unknown status|Recruiting|Phase 2/Phase 3|40||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.462431|2018-06-01 04:40:02.462431
NCT00163839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-02-14|2005-09-12|2005-09-14|Estimate|||||||2012-02-14|2012-02-16|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Interventional|||The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema|The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria or Angioedema: A Randomised Controlled Study|Unknown status|Not yet recruiting|N/A|50|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.553674|2018-06-01 04:40:02.553674
NCT00163826|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-06|2005-09-12|2005-09-14|Estimate|||||||2016-01-06|2016-01-08|Estimate|March 2004||2004-03-31|January 2016|2016-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Spinal Clearance Study: Expediting the Spinal Clearance Process in the Major Trauma Patient|Optimisation of Patient Management Through Expediting the Spinal Clearance Process in the Major Trauma Patient|Completed|||299|Actual|Bayside Health|||1||f||||f||||||||||2018-06-01 04:40:02.610354|2018-06-01 04:40:02.610354
NCT00163813|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2007-02-23|2005-09-12|2005-09-14|Estimate|||||||2007-02-23|2007-02-26|Estimate||||August 2005|2005-08-31||||||||Interventional|ENTERIC||The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care (ENTERIC) Study|The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care Study|Unknown status|Not yet recruiting|N/A|180||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.663071|2018-06-01 04:40:02.663071
NCT00163800|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-12-07|2005-09-12|2005-09-14|Estimate|||||||2005-12-07|2005-12-08|Estimate|July 2003||2003-07-31|September 2005|2005-09-30|July 2005||2005-07-31|||||Observational|||Outcome Predictors in Acute Brain Injury|Outcome Predictors in Acute Brain Injury, A Pilot Study|Completed|||60||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.731539|2018-06-01 04:40:02.731539
NCT00163787|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-10-24|2005-09-12|2005-09-14|Estimate|||||||2005-10-24|2005-10-25|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Observational|||Clinical Identification of Fall Risk Early After Unilateral Transtibial Amputation|Clinical Identification of Increased Fall Risk Early After Unilateral Transtibial Amputation|Completed|||50||Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.772854|2018-06-01 04:40:02.772854
NCT00163774|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-05-16|2005-09-12|2005-09-14|Estimate|||||||2008-05-16|2008-05-19|Estimate|November 2002||2002-11-30|September 2005|2005-09-30|December 2005||2005-12-31|||||Interventional|||Intensive Monitoring of Brain Injured Patients|Intensive Monitoring of Brain Injured Patients; Icp Monitoring, Transcranial Doppler, Jugular Bulb Oximetry, Brain Oxygenation, Brain Temperature and Microdialysis.|Completed||N/A|20|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:02.819088|2018-06-01 04:40:02.819088
NCT00163761|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2016-01-06|2005-09-11|2005-09-14|Estimate|||||||2016-01-06|2016-01-08|Estimate|December 2002||2002-12-31|January 2016|2016-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Efficacy Study of Outpatient Therapy for Lymphoma|A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma|Completed||Phase 2|90|Actual|Bayside Health||2|||f||||f||||||||||2018-06-01 04:40:02.871774|2018-06-01 04:40:02.871774
NCT00163748|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-01-06|2005-09-12|2005-09-14|Estimate|||||||2016-01-06|2016-01-08|Estimate|February 2001||2001-02-28|January 2016|2016-01-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma|A Pilot Study of Outpatient Vinorelbine and Gemcitabine With Filgrastim Support for Patients With Relapsed or Refractory Lymphoma.|Completed||Phase 2|40||Bayside Health|||||f||||||||||||||2018-06-01 04:40:03.06415|2018-06-01 04:40:03.06415
NCT00163735|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-12-03|2005-09-12|2005-09-14|Estimate|||||||2013-12-03|2013-12-05|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Potential Allergens in Wine: Double-blind Placebo-controlled Trial|Potential Allergens in Wine: Double Blind Placebo-controlled Trial and Basophil Activation Analysis|Completed||N/A|48|Actual|Bayside Health|||||f||||||||||||||2018-06-01 04:40:03.130691|2018-06-01 04:40:03.130691
NCT00163722|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-02-17|2005-09-12|2005-09-14|Estimate|||||||2013-02-17|2013-02-20|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients|A Multicentre Randomised Controlled Trial Comparing the Current Standard Diagnostic Strategy for Invasive Aspergillosis to the New Diagnostic Strategy for Invasive Aspergillosis in High-Risk Haematology Patients in Order to Determine Which Strategy Results in the Lower Rates of Use of Empiric Antifungal Therapy|Completed||Phase 3|240|Actual|Bayside Health||2|||f||||t||||||||||2018-06-01 04:40:03.203073|2018-06-01 04:40:03.203073
NCT00163709|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2006-10-03|2005-09-11|2005-09-14|Estimate|||||||2006-10-03|2006-10-04|Estimate|August 2005||2005-08-31|May 2005|2005-05-31||||||||Interventional|||BNP Testing in Patients With SOB on Presentation to ED|A Randomised Trial of BNP Testing in Patients With Shortness of Breath in the Emergency Department to Improve Patient Outcome|Unknown status|Recruiting|Phase 1|600||Bayside Health|||||f||||||||||||||2018-06-01 04:40:03.289355|2018-06-01 04:40:03.289355
NCT00163696|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2007-07-25|2005-09-12|2005-09-14|Estimate|||||||2007-07-25|2007-07-26|Estimate|September 2004||2004-09-30|September 2005|2005-09-30||||||||Observational|||Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease|Measurements of Inhomogeneity of the Small Airway With Patients With Cystic Fibrosis, Asthma and Bronchiolitis Obliterans Syndrome (Post Transplant) Using the Multi Breath Nitrogen Washout Technique|Unknown status|Recruiting||90|Anticipated|Bayside Health|||||f||||||||||||||2018-06-01 04:40:03.363711|2018-06-01 04:40:03.363711
NCT00163683|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-12-03|2005-09-11|2005-09-14|Estimate|||||||2013-12-03|2013-12-05|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effects of a Mediterranean Style Diet on Vascular Health in Type 2 Diabetes|The Effect of a Mediterranean Style Diet Versus a Conventional High Carbohydrate, Low Fat Diet on Glycaemic and Lipid Control and on Vascular Inflammatory Markers in People With Newly Diagnosed Type 2 Diabetes|Completed||N/A|24|Actual|Bayside Health|||||f||||f||||||||||2018-06-01 04:40:03.42558|2018-06-01 04:40:03.42558
NCT00163670|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2013-12-04|2005-09-11|2005-09-14|Estimate|||||||2013-12-04|2013-12-05|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||The Impact of Sleep Disorders on Motor Vehicle Accidents|The Impact of Sleep Disorders on Motor Vehicle Accidents|Completed|||40|Actual|Bayside Health|||2||f||||f||||||||||2018-06-01 04:40:03.492808|2018-06-01 04:40:03.492808
NCT00163657|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-02-23||2016-11-15|2005-09-09|2005-09-14|Estimate|2016-11-15|2017-01-12|Estimate||||2016-11-15|2017-01-12|Estimate|July 2002||2002-07-31|November 2016|2016-11-30|January 2007|Actual|2007-01-31|April 2006|Actual|2006-04-30||Interventional|||Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection|An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among 3 Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For ESLD Caused By Chronic Hepatitis C|Completed||Phase 4|312|Actual|Baylor Research Institute||3|||f||||t||||||||No|No their is not a plan to make individual Participant data available|2018-06-01 04:40:03.56362|2018-06-01 04:40:03.56362
NCT00163644|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2016-01-06|2005-09-11|2005-09-14|Estimate|||||||2016-01-06|2016-01-08|Estimate|November 2003||2003-11-30|January 2016|2016-01-31||||December 2009|Actual|2009-12-31||Interventional|||RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT|Randomised Controlled Trial to Investigate the Effects of an Exercise Programme on Physical Performance and Quality of Life After a Bone Marrow Transplant|Unknown status|Active, not recruiting|N/A|66|Anticipated|Bayside Health||3|||f||||||||||||||2018-06-01 04:40:03.879012|2018-06-01 04:40:03.879012
NCT00163631|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2006-10-03|2005-09-11|2005-09-14|Estimate|||||||2006-10-03|2006-10-04|Estimate||||September 2005|2005-09-30||||||||Observational|||Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis|Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis|Completed|||||Bayside Health|||||f||||||||||||||2018-06-01 04:40:03.954055|2018-06-01 04:40:03.954055
NCT00163618|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-13|2005-09-14|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2005||2005-06-30|May 2015|2015-05-31|July 2006|Actual|2006-07-31|||||Observational|||Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children|Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children|Completed|||||Pfizer|||||f||||f||||||||||2018-06-01 04:40:04.00278|2018-06-01 04:40:04.00278
NCT00163605|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-11-14|2005-09-13|2005-09-14|Estimate|||||||2007-11-14|2007-11-15|Estimate|September 2004||2004-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Performance and Safety of Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures|A Prospective Clinical Study to Evaluate the Performance and Safety of the Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures|Completed||Phase 2/Phase 3|86||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 04:40:04.081169|2018-06-01 04:40:04.081169
NCT00163592|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-20|2005-09-13|2005-09-14|Estimate|||||||2006-10-20|2006-10-23|Estimate|September 2003||2003-09-30|October 2006|2006-10-31|February 2004||2004-02-29|||||Observational|||Post-Marketing Surveillance of TISSUCOL for Hemostasis in Subjects Undergoing Vascular Reconstruction With Polytetrafluoroethylene (PTFE) Prosthesis|Non- Interventional Study of Tissucol® for Hemostasis in Subjects With Femoral Vascular Anastomosis Undergoing Vascular Reconstruction With PTFE Prosthesis|Completed|||60||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 04:40:04.158332|2018-06-01 04:40:04.158332
NCT00163579|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-04-14|2005-09-09|2005-09-14|Estimate|||||||2009-04-14|2009-04-16|Estimate|July 2004||2004-07-31|September 2005|2005-09-30|March 2007|Anticipated|2007-03-31|||||Interventional|||The Impact of Bryophyllum on Preterm Delivery|The Impact of the Prophylactic or Therapeutic Application of Bryophyllum on Preterm Delivery - a Prospective Study|Unknown status|Recruiting|Phase 4|180|Anticipated|Basel Women’s University Hospital|||||f||||f||||||||||2018-06-01 04:40:04.236003|2018-06-01 04:40:04.236003
NCT00163566|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-07-10|2005-09-09|2005-09-14|Estimate|||||||2012-07-10|2012-07-12|Estimate|October 2004||2004-10-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|October 2006|Actual|2006-10-31||Interventional|||Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80|A Phase II, Placebo-Controlled, Double-Blind, Dose-Ranging (35mg/Day or 70 mg/Day), Randomized, Study of Cutaneous Dihydrotestosterone (DHT)-Gel (0.7% Hydroalcoholic Gel) in Older Hypogonadal Males Ages 55-80 Years: Effect on Body Composition, Libido, and Physical and Sexual Functioning|Unknown status|Active, not recruiting|Phase 2|128|Actual|ASCEND Therapeutics||3|||f||||||||||||||2018-06-01 04:40:04.316014|2018-06-01 04:40:04.316014
NCT00163553|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-29|2005-09-09|2005-09-14|Estimate|||||||2009-01-29|2009-01-30|Estimate|December 2004||2004-12-31|January 2009|2009-01-31||||||||Interventional|||Neuraxial Pethidine After Lumbar Surgery Trial|Neuraxial Pethidine After Lumbar Surgery Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|Austin Health||2|||f||||||||||||||2018-06-01 04:40:04.420652|2018-06-01 04:40:04.420652
NCT00163540|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-13|2005-09-14|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|June 2005||2005-06-30|||||Interventional|||Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)|Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225)|Completed||Phase 4|||Pfizer|||||f||||||||||||||2018-06-01 04:40:04.504572|2018-06-01 04:40:04.504572
NCT00163527|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-01|2005-09-12|2005-09-14|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2003||2003-04-30|September 2016|2016-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)|A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Chronic Asthma|Completed||Phase 3|2054||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:04.556608|2018-06-01 04:40:04.556608
NCT00163514|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-01|2005-09-12|2005-09-14|Estimate|||||||2016-12-01|2016-12-02|Estimate|May 2004||2004-05-31|October 2016|2016-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied as a Nasal Spray at Three Dose Levels (200 Mcg, 100 Mcg, or 25 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age|Completed||Phase 3|636||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:04.654842|2018-06-01 04:40:04.654842
NCT00163501|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-29|2005-09-12|2005-09-14|Estimate|||||||2016-11-29|2016-11-30|Estimate|December 2003||2003-12-31|October 2016|2016-10-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older|Completed||Phase 3|600||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:04.878353|2018-06-01 04:40:04.878353
NCT00163488|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-02|2005-09-12|2005-09-14|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)|Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Fluticasone Propionate/Salmeterol (FP/SAL) in Patients (18-60 Years) With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|106||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:05.00763|2018-06-01 04:40:05.00763
NCT00163475|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-10-24|2005-09-12|2005-09-14|Estimate|||||||2016-10-24|2016-10-25|Estimate|May 2004||2004-05-31|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)|The MOVE-study: Morning Versus Evening Administration of 500 mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma|Completed||Phase 3|511||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:05.10939|2018-06-01 04:40:05.10939
NCT00163462|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-02|2005-09-12|2005-09-14|Estimate|||||||2016-12-02|2016-12-05|Estimate|October 2004||2004-10-31|October 2016|2016-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)|Comparison of Ciclesonide (80 mcg or 160 mcg Once Daily in the Evening) and Fluticasone Propionate (100 mcg Twice Daily in the Morning and Evening) in Pediatric Asthma Patients|Completed||Phase 3|750||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:05.200343|2018-06-01 04:40:05.200343
NCT00163449|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-07|2005-09-12|2005-09-14|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2005||2005-11-30|December 2016|2016-12-31|May 2007|Actual|2007-05-31|November 2006|Actual|2006-11-30||Interventional|||Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)|BALLOON: Efficacy and Safety - Study by ALTANA on Ciclesonide in Pre-school Asthma Patients|Completed||Phase 3|1000|Anticipated|AstraZeneca||4|||f||||||||||||||2018-06-01 04:40:05.378788|2018-06-01 04:40:05.378788
NCT00163436|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-29|2005-09-12|2005-09-14|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)|Comparison of the Efficacy and Safety of 160 mcg Ciclesonide Administered Once Daily in the Evening With or Without Different Spacer Types in Patients With Asthma|Completed||Phase 3|450||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:05.584914|2018-06-01 04:40:05.584914
NCT00163423|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-07|2005-09-12|2005-09-14|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2004||2004-11-30|December 2016|2016-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)|Comparison of Ciclesonide (80 mcg Once Daily in the Evening) and Fluticasone Propionate (100 mcg Twice Daily) in Patients With Mild to Moderate Asthma|Completed||Phase 3|480||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:05.762549|2018-06-01 04:40:05.762549
NCT00163410|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-01|2005-09-12|2005-09-14|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2003||2003-04-30|December 2016|2016-12-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)|A Comparative Study of Inhaled Ciclesonide 200 mcg/Day vs Fluticasone Propionate 200 mcg/Day in Children With Asthma|Completed||Phase 3|500||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:05.901335|2018-06-01 04:40:05.901335
NCT00163397|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-29|2005-09-12|2005-09-14|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2004||2004-01-31|October 2016|2016-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)|A Comparative Study of Inhaled Ciclesonide 160 mcg/Day vs Budesonide 400 mcg/Day in Patients With Asthma|Completed||Phase 3|120||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:06.005878|2018-06-01 04:40:06.005878
NCT00163384|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-29|2005-09-12|2005-09-14|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2004||2004-01-31|October 2016|2016-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)|A Comparative Study of Inhaled Ciclesonide 160 mcg/Day vs Budesonide 400 mcg/Day in Patients With Asthma|Completed||Phase 3|240||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:06.089971|2018-06-01 04:40:06.089971
NCT00163371|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-30|2005-09-12|2005-09-14|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)|Effect of Ciclesonide (320 mcg/Day) vs Fluticasone Propionate (375 mcg/Day) vs. Placebo on Short-term Linear Growth Rate and HPA-axis Function in Prepubertal Children With Mild Asthma|Completed||Phase 3|28||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:06.183243|2018-06-01 04:40:06.183243
NCT00163358|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-11-29|2005-09-12|2005-09-14|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2003||2003-09-30|October 2016|2016-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)|Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-term Asthma Control|Completed||Phase 3|630||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:06.259622|2018-06-01 04:40:06.259622
NCT00163345|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-07|2005-09-12|2005-09-14|Estimate|||||||2016-12-07|2016-12-08|Estimate|September 2003||2003-09-30|December 2016|2016-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)|Evaluation of Parameters of the Small Airways and Their Changes Under Treatment With Ciclesonide (320 mcg Once Daily) Versus Placebo in Patients With Asthma|Completed||Phase 3|20||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:06.581935|2018-06-01 04:40:06.581935
NCT00163332|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-02|2005-09-12|2005-09-14|Estimate|||||||2016-12-02|2016-12-06|Estimate|March 2003||2003-03-31|September 2016|2016-09-30||||||||Interventional|||Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)|Comparison of Inhaled Ciclesonide (160 mcg b.i.d. or 320 mcg b.i.d.) and Fluticasone Propionate (250 mcg b.i.d. or 500 mcg b.i.d.) in Pretreated Patients With Mild to Moderate Asthma|Completed||Phase 3|30||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:06.671505|2018-06-01 04:40:06.671505
NCT00163319|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2016-12-01|2005-09-12|2005-09-14|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|November 2005|Actual|2005-11-30|||||Interventional|||Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)|Comparison of Inhaled Ciclesonide (640 mcg/Day) and Fluticasone Propionate (1000 mcg/Day) in Patients With Moderate and Severe Persistent Asthma|Completed||Phase 3|500||AstraZeneca|||||f||||||||||||||2018-06-01 04:40:06.78824|2018-06-01 04:40:06.78824
NCT00163306|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-05-04|2005-09-12|2005-09-14|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2005||2005-05-31|May 2007|2007-05-31||||||||Interventional|||Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)|Complete Remission: Evaluation of the Complete Remission Rates in Patients With Symptomatic Non-erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (GERD) Treated With Pantoprazole 40 Milligram o.d. Over 4 or 8 or 12 Weeks|Completed||Phase 3|1200||Takeda|||||f||||||||||||||2018-06-01 04:40:07.064155|2018-06-01 04:40:07.064155
NCT00163293|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|2010-12-01|2010-07-01|2017-03-27|2005-09-12|2005-09-14|Estimate|2010-12-01|2010-12-22|Estimate|2010-07-01|2010-07-07|Estimate|2017-03-27|2017-04-26|Actual|January 1, 2005|Actual|2005-01-01|March 2017|2017-03-31|April 1, 2010|Actual|2010-04-01|June 1, 2009|Actual|2009-06-01||Interventional|POPCICLE|Safety analysis set included all randomized participants who received at least 1 dose of trial medication.|Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)|Effect of Low Dose Continuous Treatment With Ciclesonide Over One Year on the Time to First Exacerbation in Children With Mild Asthma Versus Intermittent Treatment for Exacerbations|Completed||Phase 3|240|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 04:40:07.315655|2018-06-01 04:40:07.315655
NCT00163280|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-02-11|2005-09-09|2005-09-14|Estimate|||||||2008-02-11|2008-02-12|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis|Randomised Double-Blind Placebo-Controlled Study of Orally Administered ATL-104 to Assess Safety, Tolerance and Effect on Oral Mucositis in Patients Following Treatment With Chemotherapy and Peripheral Blood Stem Cell Transplant (PBSCT)|Completed||Phase 2|63|Actual|Alizyme||4|||f||||t||||||||||2018-06-01 04:40:08.430845|2018-06-01 04:40:08.430845
NCT00163267|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-08-05|2005-09-12|2005-09-13|Estimate|||||||2011-08-05|2011-08-09|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|April 2011|Actual|2011-04-30|December 2009|Actual|2009-12-31||Interventional|||Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel|Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study|Completed||Phase 2/Phase 3|80|Actual|University Hospital Tuebingen||2|||f||||||||||||||2018-06-01 04:40:08.498327|2018-06-01 04:40:08.498327
NCT00163254|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-11|2005-09-12|2005-09-13|Estimate|||||||2006-09-11|2006-09-12|Estimate|September 2003||2003-09-30|September 2006|2006-09-30|November 2006||2006-11-30|||||Interventional|||Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee|Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee|Unknown status|Active, not recruiting|Phase 2|||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:40:08.581714|2018-06-01 04:40:08.581714
NCT00163241|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-07-17|2005-09-09|2005-09-13|Estimate|||||||2007-07-17|2007-07-18|Estimate|June 2004||2004-06-30|July 2007|2007-07-31|January 2006||2006-01-31|||||Interventional|||Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression|A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE|Terminated||Phase 3|666||Pfizer||||Please see detailed description for termination reason.|f||||||||||||||2018-06-01 04:40:08.647007|2018-06-01 04:40:08.647007
NCT00163228|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-10-15|2005-09-12|2005-09-13|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2001||2001-01-31|October 2008|2008-10-31|May 2007|Anticipated|2007-05-31|||||Observational|||Functional Evaluation of the Total Knee Prostheses:Rising From a Chair|Functional Evaluation of Total Knee Arthroplasties,Protocol for Rising From a Chair.|Withdrawn|||100|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:40:09.835632|2018-06-01 04:40:09.835632
NCT00163215|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-10-02||2012-11-19|2005-09-09|2005-09-13|Estimate|2012-11-19|2012-12-19|Estimate||||2012-11-19|2012-12-19|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Growth Retardation In Children With Special Pathological Conditions Or Disease|Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study.|Completed||Phase 3|46|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 04:40:09.935923|2018-06-01 04:40:09.935923
NCT00163202|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-14|2005-09-09|2005-09-13|Estimate|||||||2008-03-14|2008-03-18|Estimate|June 2002||2002-06-30|April 2007|2007-04-30|August 2005|Actual|2005-08-31|||||Interventional|CAP||Comparative Atorvastatin Pleiotropic Effects|A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis|Completed||Phase 4|330||Pfizer|||||f||||||||||||||2018-06-01 04:40:10.467985|2018-06-01 04:40:10.467985
NCT00163007|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-05-08|2005-09-09|2005-09-13|Estimate|||||||2009-05-08|2009-05-11|Estimate|May 2005||2005-05-31|May 2009|2009-05-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Nutritional Therapy for Stroke Patients|Nutritional Therapy for Patients With Acute Stroke and With Poor Nutritional Status or at Risk of Poor Nutritional Status|Completed||Phase 2/Phase 3|125|Anticipated|Ostfold Hospital Trust|||||f||||||||||||||2018-06-01 04:40:16.603971|2018-06-01 04:40:16.603971
NCT00163189|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2015-06-01||2015-06-22|2005-09-09|2005-09-13|Estimate|2015-06-22|2015-06-25|Estimate||||2015-06-22|2015-06-25|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Safety analysis set included all participants (including a site with GCP issues) who had received at least 1 study dose of growth hormone (GH).|Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm|Evolution Of Growth Rate In Children With Growth Retardation Related To Long-term Corticotherapy And Treated By Genotonorm|Completed||Phase 3|98|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:40:10.70207|2018-06-01 04:40:10.70207
NCT00163176|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-12-15|2005-09-12|2005-09-13|Estimate|||||||2011-12-15|2011-12-16|Estimate|July 2005||2005-07-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Observational|||Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors|Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors|Completed|||50|Actual|Radboud University|||||f||||f||||||||||2018-06-01 04:40:11.637897|2018-06-01 04:40:11.637897
NCT00163163|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-17|2005-09-09|2005-09-13|Estimate|||||||2008-03-17|2008-03-18|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women|Carotid Atorvastatin Study In Hyperlipidemic Post-Menopausal Women: A Randomized Evaluation of Atorvastatin, Versus Placebo (CASHMERE)|Completed||Phase 3|400||Pfizer|||||f||||||||||||||2018-06-01 04:40:11.71212|2018-06-01 04:40:11.71212
NCT00163150|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-13|2005-09-09|2005-09-13|Estimate|||||||2008-03-13|2008-03-14|Estimate|June 2003||2003-06-30|April 2007|2007-04-30|February 2006|Actual|2006-02-28|||||Interventional|LA BICHAT||Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke|Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.|Completed||Phase 4|128||Pfizer|||||f||||||||||||||2018-06-01 04:40:11.84262|2018-06-01 04:40:11.84262
NCT00163137|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-10|2005-09-09|2005-09-13|Estimate|||||||2011-08-10|2011-08-12|Estimate|May 2003||2003-05-31|August 2011|2011-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|CORAL||Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss|Double-Blind Placebo-Controlled Trial Of The Safety, Toleration and Efficacy Of Lasofoxifene 0.25 Mg/D and Raloxifene 60Mg/D For The Prevention Of Bone Loss In Postmenopausal Women|Completed||Phase 3|540|Actual|Ligand Pharmaceuticals||3|||f||||||||||||||2018-06-01 04:40:11.907011|2018-06-01 04:40:11.907011
NCT00163124|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-12|2005-09-12|2005-09-13|Estimate|||||||2005-09-12|2005-09-13|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||A Randomized Controlled Trial of Best Approach to Care Compared to Diversified Chiropractic Adjustive Technique|A Randomized Controlled Trial of Best Approach to Care Compared to Diversified Adjustive Technique|Completed||N/A|155||Parker College of Chiropractic|||||f||||||||||||||2018-06-01 04:40:12.151655|2018-06-01 04:40:12.151655
NCT00163111|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-25|2005-09-09|2005-09-13|Estimate|||||||2011-04-25|2011-04-26|Estimate|September 1998||1998-09-30|April 2011|2011-04-30|May 2003|Actual|2003-05-31|||||Interventional|||A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.|A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non Neutropenic Subjects.|Completed||Phase 3|412|Actual|Pfizer|||||||||||||||||||2018-06-01 04:40:12.20452|2018-06-01 04:40:12.20452
NCT00163098|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-12|2005-09-11|2005-09-13|Estimate|||||||2006-10-12|2006-10-13|Estimate|December 2004||2004-12-31|October 2006|2006-10-31|December 2005||2005-12-31|||||Interventional|||A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD|A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 1/Phase 2|136||Pfizer|||||f||||||||||||||2018-06-01 04:40:12.254999|2018-06-01 04:40:12.254999
NCT00163085|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-21|2005-09-09|2005-09-13|Estimate|||||||2006-09-21|2006-09-22|Estimate|May 2005||2005-05-31|September 2006|2006-09-30|January 2006||2006-01-31|||||Interventional|||The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease|Completed||Phase 2|12||Pfizer|||||||||||||||||||2018-06-01 04:40:12.352987|2018-06-01 04:40:12.352987
NCT00163072|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-10-24|2005-09-12|2005-09-13|Estimate|||||||2013-10-24|2013-10-25|Estimate|October 2005||2005-10-31|April 2007|2007-04-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Pharmacokinetics and Safety of Transdermal Megestrol Acetate|Pharmacokinetics and Safety of Transdermal Megestrol Acetate|Withdrawn||Phase 4|0|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-06-01 04:40:12.410505|2018-06-01 04:40:12.410505
NCT00163059|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-21|2005-09-09|2005-09-13|Estimate|||||||2006-09-21|2006-09-22|Estimate|May 2004||2004-05-31|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD|A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder|Completed||Phase 2|30||Pfizer|||||||||||||||||||2018-06-01 04:40:12.478405|2018-06-01 04:40:12.478405
NCT00163046|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-04-23|2005-09-12|2005-09-13|Estimate|||||||2008-04-23|2008-04-24|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|April 2006|Actual|2006-04-30|||||Interventional|||A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-Day, Polysomnographic Study of Gabapentin 250 mg in Transient Insomnia Induced by a Sleep Phase Advance|Completed||Phase 3|256|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:40:12.541184|2018-06-01 04:40:12.541184
NCT00163033|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2012-05-18|2005-09-12|2005-09-13|Estimate|||||||2012-05-18|2012-05-21|Estimate|June 2005||2005-06-30|May 2012|2012-05-31|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||Study to Evaluate 3 Dosages of Estetrol After 28 Days Administration in Healthy Postmenopausal Women|Phase I Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics of 3 Dosages of Estetrol, the Lowest Dose of 2 mg Estetrol Compared With 2 mg of E2, After Daily Oral Administration for 28 Days in Healthy Postmenopausal Women|Completed||Phase 1|49|Actual|Pantarhei Bioscience|||||f||||f||||||||||2018-06-01 04:40:12.632945|2018-06-01 04:40:12.632945
NCT00163020|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-06-05||2016-03-11|2005-09-09|2005-09-13|Estimate|2012-10-09|2012-11-07|Estimate||||2016-03-11|2016-04-11|Estimate|November 2004||2004-11-30|March 2016|2016-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|170HP||17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies|17-Alpha-Hydroxyprogesterone Caproate for Reduction of Neonatal Morbidity Due to Preterm Birth in Twin and Triplet Pregnancies - A Concurrent Randomized Double-blinded Clinical Trial|Completed||Phase 2/Phase 3|321|Actual|Mednax Center for Research, Education, Quality and Safety||2|||f||||t||||||||Undecided||2018-06-01 04:40:12.782693|2018-06-01 04:40:12.782693
NCT00162994|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-12-20|2005-09-10|2005-09-13|Estimate|||||||2005-12-20|2005-12-21|Estimate|February 2002||2002-02-28|February 2002|2002-02-28|August 2005||2005-08-31|||||Interventional|||Prevention Recurrent Otitis Media in the Young Children|Effect of Adenotomy and Tympanostomy on Preventing Recurrent Otitis Media in the Young Children|Unknown status|Active, not recruiting|N/A|300||Oulu University Hospital|||||f||||||||||||||2018-06-01 04:40:16.72482|2018-06-01 04:40:16.72482
NCT00162981|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2011-11-07||2012-01-06|2005-09-09|2005-09-13|Estimate|2012-01-06|2012-02-09|Estimate||||2012-01-06|2012-02-09|Estimate|October 2005||2005-10-31|January 2012|2012-01-31|October 2006|Actual|2006-10-31|August 2006|Actual|2006-08-31||Interventional|||Clobazam in Subjects With Lennox-Gastaut Syndrome|Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome|Completed||Phase 2|68|Actual|Lundbeck LLC||2|||f||||t||||||||||2018-06-01 04:40:16.798595|2018-06-01 04:40:16.798595
NCT00162968|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-23|2005-09-09|2005-09-13|Estimate|||||||2007-04-23|2007-04-24|Estimate|December 2004||2004-12-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Escitalopram as a Treatment for Pain in Polyneuropathy|Escitalopram as a Treatment for Pain in Polyneuropathy. A Double-Blind, Randomized, Placebo Controlled Trial.|Completed||Phase 4|50||Odense University Hospital|||||f||||||||||||||2018-06-01 04:40:17.633805|2018-06-01 04:40:17.633805
NCT00162955|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-05-07|2005-09-09|2005-09-13|Estimate|||||||2012-05-07|2012-05-08|Estimate|May 2004||2004-05-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Prevention of CHOP-induced Chronic Cardiotoxicity|The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP|Completed||Phase 4|150|Actual|Osaka City University||2|||f||||t||||||||||2018-06-01 04:40:17.713784|2018-06-01 04:40:17.713784
NCT00162942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-01-15||2009-03-05|2005-09-09|2005-09-13|Estimate|2009-03-05|2009-04-07|Estimate||||2009-03-05|2009-04-07|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study for the Treatment of Crohn's Disease With Adacolumn|A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Crohn's Disease|Completed||Phase 3|235|Actual|Otsuka America Pharmaceutical||2|||f||||||||||||||2018-06-01 04:40:17.83045|2018-06-01 04:40:17.83045
NCT00162929|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2012-05-31|2005-09-10|2005-09-13|Estimate|||||||2012-05-31|2012-06-04|Estimate|January 2005||2005-01-31|May 2012|2012-05-31|May 2012|Actual|2012-05-31|July 2009|Actual|2009-07-31||Interventional|AdHERe||Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)|A Phase I Study Investigating Multiple Injections of Autologous CD34+ Derived Dendritic Cells Transduced With an Adenovirus Expressing Rat Her-2/Neu in Patients With Metastatic or Locally Recurrent Breast Cancer|Completed||Phase 1|5|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||t||||||||||2018-06-01 04:40:19.109015|2018-06-01 04:40:19.109015
NCT00162916|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2008-06-03|2005-09-10|2005-09-13|Estimate|||||||2008-06-03|2008-06-04|Estimate|May 2005||2005-05-31|June 2008|2008-06-30|October 2008|Anticipated|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||Antidepressant Maintenance in Traumatic Brain Injury|A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury|Unknown status|Active, not recruiting|Phase 4|21|Actual|Ontario Neurotrauma Foundation||2|||f||||f||||||||||2018-06-01 04:40:19.227278|2018-06-01 04:40:19.227278
NCT00162903|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-22|2005-09-12|2005-09-13|Estimate|||||||2005-11-22|2005-11-23|Estimate|January 2002||2002-01-31|October 2001|2001-10-31|December 2002||2002-12-31|||||Observational|||Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants|The Role of Nitric Oxide, Endothelin-1, and Inflammatory Mediators in the Patency of Ductus Arteriosus in Preterm Infants|Completed|||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:40:19.322663|2018-06-01 04:40:19.322663
NCT00162890|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2010-03-15|2005-09-12|2005-09-13|Estimate|||||||2010-03-15|2010-03-16|Estimate|February 2002||2002-02-28|December 2009|2009-12-31|July 2003|Actual|2003-07-31|July 2002|Actual|2002-07-31||Observational|||Evaluation and Physical Therapy for Patients With Degenerated Cervical Spine|Evaluation and Physical Therapy for Patients With Degenerated Cervical Spine|Completed|||100|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-06-01 04:40:19.368714|2018-06-01 04:40:19.368714
NCT00162877|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-22|2005-09-12|2005-09-13|Estimate|||||||2005-11-22|2005-11-23|Estimate|June 2004||2004-06-30|January 2004|2004-01-31|April 2005||2005-04-30|||||Interventional|||The Role of CYP2C19 on the Eradication of H. Pylori Infection:Implication of PK/PD Relationships|The Role of CYP2C19 Poor Metabolizers and Extensive Metabolizers of PPI in Short-Term Triple Therapy on the Eradication of H. Pylori Infection: Implication of PK/PD Relationships|Unknown status|Active, not recruiting|N/A|80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:40:19.436377|2018-06-01 04:40:19.436377
NCT00162864|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-03-23|2005-09-11|2005-09-13|Estimate|||||||2006-03-23|2006-03-24|Estimate|December 1999||1999-12-31|September 2005|2005-09-30|April 2002||2002-04-30|||||Interventional|||A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease|A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease|Completed||Phase 3|200||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:40:19.504606|2018-06-01 04:40:19.504606
NCT00162851|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-23|2005-09-08|2005-09-13|Estimate|||||||2007-07-23|2007-07-25|Estimate|April 2003||2003-04-30|August 2005|2005-08-31|July 2006|Actual|2006-07-31|||||Interventional|||Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia|A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|20|Anticipated|Karolinska University Hospital|||||f||||||||||||||2018-06-01 04:40:19.609201|2018-06-01 04:40:19.609201
NCT00162838|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2005-11-22|2005-09-12|2005-09-13|Estimate|||||||2005-11-22|2005-11-23|Estimate|October 2003||2003-10-31|May 2003|2003-05-31||||||||Observational|||Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells|Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells.|Unknown status|Recruiting||20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:40:19.684341|2018-06-01 04:40:19.684341
NCT00162825|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2008-07-09|2005-09-12|2005-09-13|Estimate|||||||2008-07-09|2008-07-11|Estimate|January 2004||2004-01-31|June 2003|2003-06-30|December 2006|Actual|2006-12-31|||||Observational|||Role of CD7 in Skin Inflammation and Psoriasis||Completed|||30|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:40:19.751781|2018-06-01 04:40:19.751781
NCT00162812|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-07-16|2005-09-09|2005-09-13|Estimate|||||||2008-07-16|2008-07-18|Estimate|January 2003||2003-01-31|July 2008|2008-07-31|April 2009|Anticipated|2009-04-30|December 2008|Anticipated|2008-12-31||Interventional|TOP||Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin|Prospective Evaluation of Topoisomerase II Alpha Gene Amplification and Protein Overexpression as Markers Predicting the Efficacy of Epirubicin in the Primary Treatment of Breast Cancer Patients|Terminated||Phase 2|338|Anticipated|Jules Bordet Institute||||Low accrual rate|f||||f||||||||||2018-06-01 04:40:19.831114|2018-06-01 04:40:19.831114
NCT00162799|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-06-22|2005-09-12|2005-09-13|Estimate|||||||2006-06-22|2006-06-23|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity|Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity|Completed||Phase 2|30||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:40:20.006043|2018-06-01 04:40:20.006043
NCT00162786|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-10-19|2005-09-11|2005-09-13|Estimate|||||||2006-10-19|2006-10-20|Estimate|May 2005||2005-05-31|December 2005|2005-12-31|November 2005||2005-11-30|||||Interventional|||Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance|Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance|Terminated||Phase 4|20||J. Uriach and Company|||||f||||||||||||||2018-06-01 04:40:20.118262|2018-06-01 04:40:20.118262
NCT00162773|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2017-06-29||2017-07-27|2005-09-08|2005-09-13|Estimate|2017-07-27|2017-08-28|Actual||||2017-07-27|2017-08-28|Actual|April 2005|Actual|2005-04-30|July 2017|2017-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effect of Anti-IgE in Non-Allergic Asthma|Effect of Anti-IgE in Non-Allergic Asthma|Terminated||Phase 2|29|Actual|Johns Hopkins University||2||PI left institution|f||||f||||||||||2018-06-01 04:40:20.237806|2018-06-01 04:40:20.237806
NCT00162760|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-06-18|2005-09-11|2005-09-13|Estimate|||||||2010-06-18|2010-06-22|Estimate|October 2003||2003-10-31|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|||Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide|Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide|Completed||Phase 2|19||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:40:20.436047|2018-06-01 04:40:20.436047
NCT00162747|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-11|2005-09-11|2005-09-13|Estimate|||||||2005-09-11|2005-09-13|Estimate|December 2001||2001-12-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Topical Therapy for Prevention of Infections in Preterm Infants|Topical Emollient Therapy for Prevention of Infections in Preterm Infants|Completed||Phase 4|600||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:40:20.519365|2018-06-01 04:40:20.519365
NCT00162734|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-06-21|2005-09-08|2005-09-13|Estimate|||||||2012-06-21|2012-06-22|Estimate|February 2005||2005-02-28|June 2012|2012-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy|A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa Plus Ribavirin Therapy and During at Least 24 Weeks of No Treatment in IRHC-001|Completed||Phase 3|144|Actual|Valeant Pharmaceuticals International, Inc.|||||f||||||||||||||2018-06-01 04:40:20.571785|2018-06-01 04:40:20.571785
NCT00162721|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-08-09|2005-09-09|2005-09-13|Estimate|||||||2007-08-09|2007-08-10|Estimate|September 2001||2001-09-30|August 2007|2007-08-31||||||||Interventional|||The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas|Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas|Unknown status|Recruiting|Phase 3|270|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||f||||||||||2018-06-01 04:40:20.641869|2018-06-01 04:40:20.641869
NCT00162708|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-13|Estimate|||||||2005-09-09|2005-09-13|Estimate|July 1996||1996-07-31|September 2005|2005-09-30||||||||Interventional|||Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC|A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma|Completed||Phase 2/Phase 3|120||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:40:20.740459|2018-06-01 04:40:20.740459
NCT00162695|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-13|Estimate|||||||2005-09-09|2005-09-13|Estimate|July 1995||1995-07-31|September 2005|2005-09-30||||||||Interventional|||Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood||Terminated||Phase 3|400||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:40:20.825044|2018-06-01 04:40:20.825044
NCT00162682|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-01-04|2005-09-07|2005-09-13|Estimate|||||||2012-01-04|2012-01-06|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|April 2010|Actual|2010-04-30||Interventional|||Monitoring Highly Active Antiretroviral Therapy in HIV-infected Parents in Thailand|A Phase III, Randomized, Non-inferiority Trial Comparing the Standard Viral Load Based Antiretroviral Monitoring Strategy With a CD4 Based Monitoring Strategy Among Antiretroviral Naive Immunocompromised Adults in Thailand|Completed||Phase 3|716|Actual|Institut de Recherche pour le Developpement||2|||f||||t||||||||||2018-06-01 04:40:20.90693|2018-06-01 04:40:20.90693
NCT00162669|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-07|2005-09-08|2005-09-13|Estimate|||||||2006-09-07|2006-09-08|Estimate|May 2005||2005-05-31|September 2006|2006-09-30||||||||Interventional|||Bevacizumab in Advanced Hepatocellular Carcinoma|Phase II Study Evaluating the Efficacy of Bevacizumab (Avastin@) in Hepatocellular Carcinoma Not Amenable to Curative Treatment|Unknown status|Recruiting|Phase 2|50||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:40:21.108074|2018-06-01 04:40:21.108074
NCT00162656|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-03-27|2005-09-08|2005-09-13|Estimate|||||||2012-03-27|2012-03-28|Estimate|May 1996||1996-05-31|March 2012|2012-03-31|May 2011|Actual|2011-05-31|May 2004|Actual|2004-05-31||Interventional|||Treatment of Mature B-cell Lymphoma/Leukaemia|Treatment of Mature B-cell Lymphoma/Leukaemia A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study|Completed||Phase 3|848|Actual|Gustave Roussy, Cancer Campus, Grand Paris||6|||f||||t||||||||||2018-06-01 04:40:21.188219|2018-06-01 04:40:21.188219
NCT00162643|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-09-13|2005-09-07|2005-09-13|Estimate|||||||2006-09-13|2006-09-14|Estimate|December 2004||2004-12-31|September 2006|2006-09-30|December 2007||2007-12-31|||||Interventional|||PI Vs. NNRTI Based Therapy for HIV Advanced Disease|Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease|Unknown status|Recruiting|Phase 4|300||Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||||||||||||2018-06-01 04:40:21.295255|2018-06-01 04:40:21.295255
NCT00162630|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-13|2005-09-11|2005-09-13|Estimate|||||||2006-09-13|2006-09-15|Estimate|May 2003||2003-05-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||Fascia Iliaca Compartment Blockade as Analgesia for Hip Fractures in the Acute Phase|Fascia Iliaca Compartment Blockade as Analgesia for Hip Fractures in the Acute Phase|Completed||Phase 4|48||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:40:21.491221|2018-06-01 04:40:21.491221
NCT00162617|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-08-29|2005-09-11|2005-09-13|Estimate|||||||2011-08-29|2011-08-30|Estimate|January 2004||2004-01-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||The Effect of Liberal vs. Restrictive Transfusion Strategies on Rehabilitation After Hip Fracture Surgery|The Effect of Liberal vs. Restrictive Transfusion Strategies on Rehabilitation After Hip Fracture Surgery|Unknown status|Active, not recruiting|Phase 4|120||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:40:21.611095|2018-06-01 04:40:21.611095
NCT00162604|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-09-08|2005-09-12|2005-09-13|Estimate|||||||2006-09-08|2006-09-11|Estimate|May 2005||2005-05-31|February 2005|2005-02-28||||||||Interventional|||Prophylactic Antibiotic Treatment During Vaginal Repair|Antibiotikaprofylakse Ved Vaginalplastik|Unknown status|Recruiting|N/A|200||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:40:21.686415|2018-06-01 04:40:21.686415
NCT00162591|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2005-11-21|2005-09-10|2005-09-13|Estimate|||||||2005-11-21|2005-11-22|Estimate|October 2004||2004-10-31|October 2004|2004-10-31||||||||Interventional|||Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl|Bispectral Index as an Analgesia Monitoring in Severely Ill Patient: Effect of Remifentanyl|Unknown status|Recruiting|N/A|40||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:40:21.816048|2018-06-01 04:40:21.816048
NCT00162578|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-07-20|2005-09-09|2005-09-13|Estimate|||||||2007-07-20|2007-07-23|Estimate|December 2002||2002-12-31|July 2007|2007-07-31|November 2005|Actual|2005-11-30|||||Observational|||Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis|Vancomycin Concentration in Cerebrospinal Fluid During Pneumococcal Meningitis Treated With Dexamethasone|Completed|||14|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 04:40:21.920903|2018-06-01 04:40:21.920903
NCT00162565|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-05-22|2005-09-09|2005-09-13|Estimate|||||||2009-05-22|2009-05-25|Estimate|November 2004||2004-11-30|August 2005|2005-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|BConvinced||Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening|Beta-Blocker Continuation Versus Interruption in Patients With Congestive Heart Failure Hospitalized for Heart Failure Worsening (B-CONVINCED)|Completed||Phase 4|180|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-06-01 04:40:22.014819|2018-06-01 04:40:22.014819
NCT00162552|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-01-16|2005-09-09|2005-09-13|Estimate|||||||2008-01-16|2008-01-17|Estimate|August 2004||2004-08-31|August 2005|2005-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|PENTOCIR||Clinical Trial of Pentoxifylline in Patient With Cirrhosis|Clinical Trial of Pentoxifylline Administration Versus Placebo on Survival in Patients With Cirrhosis and Severe Liver Failure|Completed||Phase 3|342|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 04:40:22.157164|2018-06-01 04:40:22.157164
NCT00162539|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-10|||2012-07-25|2005-09-10|2005-09-13|Estimate|||||||2012-07-25|2012-07-26|Estimate|October 2005||2005-10-31|May 2005|2005-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Relation Between Maternal Iodine Status and Prenatal Foetal Thyroid Dimension|Relation Between Maternal Iodine Status and Prenatal Foetal Thyroid Dimension|Completed||N/A|130|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 04:40:22.352553|2018-06-01 04:40:22.352553
NCT00162526|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-04-07|2005-09-11|2005-09-13|Estimate|||||||2011-04-07|2011-04-08|Estimate|December 2005||2005-12-31|September 2005|2005-09-30||||||||Interventional|||Tocopherol is a Novel Treatment for Cancer Related Mucositis|A Randomized Double Blind Placebo Controlled Clinical Trial Aim to Assess the Efficacy of Vitamin E Formulation (Tocopherol) in the Treatment of Chemotherapy Induced Stomatitis in Patients Undergoing Stem Cell Transplantation|Withdrawn||Phase 2|30|Anticipated|Hadassah Medical Organization||||the PI is no longer work at Hadassah|f||||||||||||||2018-06-01 04:40:22.410383|2018-06-01 04:40:22.410383
NCT00162513|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2011-04-27|2005-09-11|2005-09-13|Estimate|||||||2011-04-27|2011-04-28|Estimate|December 2006||2006-12-31|September 2006|2006-09-30||||||||Interventional|||Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia|Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia|Withdrawn||Phase 1/Phase 2|||Hadassah Medical Organization||||PI is no longer work at Hadassah|f||||||||||||||2018-06-01 04:40:22.50534|2018-06-01 04:40:22.50534
NCT00162500|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2010-11-09|2005-09-11|2005-09-13|Estimate|||||||2010-11-09|2010-11-10|Estimate||||September 2005|2005-09-30||||||||Interventional|||A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies|A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies|Withdrawn||Phase 2|15|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:40:22.571948|2018-06-01 04:40:22.571948
NCT00162487|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2008-10-28|2005-09-11|2005-09-13|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 2002||2002-08-31|October 2008|2008-10-31||||||||Interventional|||Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation|Evaluation of β2 Genetic Polymorphisms and the Effect of Albuterol Inhalation on Potassium and Glucose Plasma Concentration|Unknown status|Recruiting|N/A|150|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:40:22.659413|2018-06-01 04:40:22.659413
NCT00162474|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2017-03-03|2005-09-11|2005-09-13|Estimate|||||||2017-03-03|2017-03-06|Actual|September 2003||2003-09-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Determinants of Warfarin Metabolism|Correlation Between Phenotypic Activity of CYP2C9 and Genetic Polymorphism in CYP2C9 and Warfarin Metabolism.|Recruiting||N/A|600|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-06-01 04:40:22.77759|2018-06-01 04:40:22.77759
NCT00162461|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2017-03-03|2005-09-11|2005-09-13|Estimate|||||||2017-03-03|2017-03-06|Actual|August 1998||1998-08-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluation of CYP2C9 Activity|The Use of Phenytoin Metabolic Ratio as a Putative Marker of CYP2C9 Activity In-vivo|Recruiting||N/A|1200|Anticipated|Hadassah Medical Organization||1|||f||||||||||||Undecided||2018-06-01 04:40:22.873667|2018-06-01 04:40:22.873667
NCT00162448|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-08-18|2005-09-11|2005-09-13|Estimate|||||||2008-08-18|2008-08-20|Estimate|January 2005||2005-01-31|August 2008|2008-08-31||||||||Interventional|||A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators|Double-Blind, Randomized, Single-Dose Study to Evaluate the Atrial Selectivity and Safety of BMS-394136 in Patients With Implanted Dual-Chamber Pacemakers or Defibrillators|Completed||Phase 1|36||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 04:40:22.976986|2018-06-01 04:40:22.976986
NCT00162435|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2017-03-03|2005-09-11|2005-09-13|Estimate|||||||2017-03-03|2017-03-06|Actual|August 2002||2002-08-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Genetic Determinants of Warfarin Anticoagulation Effect|Warfarin Induction Regimen Based Upon CYP2C9, VKORC1 Factor VII Genotyping, PMR and INR Monitoring, as Compared to the Conventional Regimen: a Prospective Controlled Study|Recruiting||N/A|500|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 04:40:23.157956|2018-06-01 04:40:23.157956
NCT00162422|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2008-10-28|2005-09-11|2005-09-13|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 2003||2003-08-31|October 2008|2008-10-31||||||||Interventional|||Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo|The Effect of β2 Genetic Polymorphisms on the Brochodilatation Effect of Albuterol ex-Vivo|Unknown status|Recruiting|N/A|150|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:40:23.259767|2018-06-01 04:40:23.259767
NCT00162409|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2008-10-28|2005-09-11|2005-09-13|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 2001||2001-08-31|October 2008|2008-10-31||||||||Interventional|||Relationship Between Folic Acid and Warfarin Metabolism and Effect|The Effect of Folic Acid Concentration and Folic Acid Supplementation on Warfarin Pharmacokinetic and Warfarin Dose Requirement at Steady State.|Unknown status|Recruiting|N/A|400|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:40:23.343866|2018-06-01 04:40:23.343866
NCT00162396|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2008-10-28|2005-09-11|2005-09-13|Estimate|||||||2008-10-28|2008-10-29|Estimate|August 1999||1999-08-31|October 2008|2008-10-31||||||||Interventional|||Genetic Determinants of the Response to Salbutamol Among Asthma Patients|Evaluation of Genetic Factors That May Account for Variability in the Response to Salbutamol Among Patients Suffering From Asthma|Unknown status|Recruiting|N/A|150|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:40:23.440451|2018-06-01 04:40:23.440451
NCT00162383|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-11|||2017-03-03|2005-09-11|2005-09-13|Estimate|||||||2017-03-03|2017-03-06|Actual|July 1995||1995-07-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Metabolic Capacity of Israeli Populations|Phenotypic and Genotypic Evaluation of Cytochrome P450 Isoforms in Populations of Different Ethnic Composition|Recruiting||N/A|1200|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-06-01 04:40:23.546283|2018-06-01 04:40:23.546283
NCT00162370|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2016-04-17||2016-10-14|2005-09-11|2005-09-13|Estimate|2016-10-14|2016-12-08|Estimate||||2016-10-14|2016-12-08|Estimate|April 2004||2004-04-30|September 2014|2014-09-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional||Peri- or post-menopausal female subjects between 40 and 65 years of age with an intermediate likelihood of CAD who are scheduled to undergo stress echocardiography|A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease|SMART: Stress Echocardiography in Menopausal Women at Risk for Coronary Artery Disease Trial|Completed||Phase 4|400|Actual|Lantheus Medical Imaging||1|||f||||f||||||||No||2018-06-01 04:40:23.663639|2018-06-01 04:40:23.663639
NCT00162357|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-14|2005-09-11|2005-09-13|Estimate|||||||2011-04-14|2011-04-15|Estimate|April 2004||2004-04-30|April 2011|2011-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty|Cardiolite-406; A Phase IV Open-Label, Randomized, Multi-Center Trial To Evaluate The Ability of Cardiolite Stress MPI to Detect Asymptomatic Restenosis in Diabetic Patients Who Have Undergone Percutaneous Coronary Intervention|Completed||Phase 4|106|Actual|Lantheus Medical Imaging|||||f||||f||||||||||2018-06-01 04:40:23.944292|2018-06-01 04:40:23.944292
NCT00162344|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-14|2005-09-11|2005-09-13|Estimate|||||||2011-04-14|2011-04-15|Estimate|December 2003||2003-12-31|April 2011|2011-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease.|AceP-D: Non-invasive Assessment of Atypical Chest Pain in Patients With Diabetes|Completed||Phase 4|205|Actual|Lantheus Medical Imaging|||||f||||||||||||||2018-06-01 04:40:24.098642|2018-06-01 04:40:24.098642
NCT00162331|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-14|2005-09-11|2005-09-13|Estimate|||||||2011-04-14|2011-04-15|Estimate|January 2005||2005-01-31|April 2011|2011-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI|AIR-MI: Assessment of Ischemia and Remodeling Following Acute Myocardial Infarction|Completed||Phase 4|74|Actual|Lantheus Medical Imaging|||||f||||f||||||||||2018-06-01 04:40:24.208314|2018-06-01 04:40:24.208314
NCT00162318|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-10-26|2005-09-11|2005-09-13|Estimate|||||||2015-10-26|2015-10-28|Estimate|March 2005||2005-03-31|October 2015|2015-10-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|Completed||Phase 1|30||Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:40:24.286381|2018-06-01 04:40:24.286381
NCT00162305|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-10-26|2005-09-09|2005-09-13|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2005||2005-04-30|October 2016|2016-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects|A Double-blind, Placebo-controlled, Randomized, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Bms-512148 in Diabetic Subjects|Completed||Phase 2|47|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 04:40:24.364371|2018-06-01 04:40:24.364371
NCT00162292|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09||2010-02-27|2010-02-27|2005-09-09|2005-09-13|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|November 2005||2005-11-30|August 2008|2008-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background|Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background|Completed||Phase 1|33|Anticipated|Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:40:24.452531|2018-06-01 04:40:24.452531
NCT00162279|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09||2010-09-10|2010-12-02|2005-09-09|2005-09-13|Estimate||||2010-09-10|2010-09-14|Estimate|2010-12-02|2010-12-06|Estimate|October 2000||2000-10-31|December 2010|2010-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||The Study of Abatacept in Combination With Etanercept|A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|141||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:40:24.531848|2018-06-01 04:40:24.531848
NCT00162266|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-02-21||2012-05-30|2005-09-09|2005-09-13|Estimate|2012-05-30|2012-06-01|Estimate||||2012-05-30|2012-06-01|Estimate|October 2000||2000-10-31|May 2012|2012-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Abatacept With Methotrexate- Phase IIB|A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate|Completed||Phase 2|524|Actual|Bristol-Myers Squibb||4|||f||||||||||||||2018-06-01 04:40:24.845483|2018-06-01 04:40:24.845483
NCT00162253|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09||2010-02-27|2010-02-27|2005-09-09|2005-09-13|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|April 2005||2005-04-30|September 2007|2007-09-30||||June 2006|Actual|2006-06-30||Interventional|||Study of BMS-587101 in Patients With Moderate to Severe Psoriasis|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of BMS-587101 in Patients With Moderate to Severe Psoriasis|Terminated||Phase 2|120||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:40:31.486037|2018-06-01 04:40:31.486037
NCT00162240|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-04-26|2005-09-09|2005-09-13|Estimate|||||||2012-04-26|2012-04-27|Estimate|June 2003||2003-06-30|April 2012|2012-04-30|May 2004|Actual|2004-05-31|||||Interventional|||PPAR - Combination With Metformin|A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Metformin Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone|Completed||Phase 3|534||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:40:31.616232|2018-06-01 04:40:31.616232
NCT00162058|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-17|2005-09-09|2005-09-13|Estimate|||||||2011-08-17|2011-08-18|Estimate|March 2004||2004-03-31|August 2011|2011-08-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Phase II Study of DMP 115 to Assess Focal Liver Lesions|An Open-Label, Non-Randomized, Phase II Trial To Assess Focal Liver Lesion Detection Using Definity-Enhanced Ultrasound Imaging|Completed||Phase 2|80||Lantheus Medical Imaging|||||f||||||||||||||2018-06-01 04:40:39.292504|2018-06-01 04:40:39.292504
NCT00162227|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-01-08|2005-09-09|2005-09-13|Estimate|||||||2014-01-08|2014-01-09|Estimate|September 2000||2000-09-30|January 2014|2014-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Expanded Access|||An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection|US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)|No longer available|||||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:40:32.065909|2018-06-01 04:40:32.065909
NCT00162214|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-13|2005-09-09|2005-09-13|Estimate|||||||2011-04-13|2011-04-14|Estimate|August 2005||2005-08-31|April 2011|2011-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of Dasatinib in Patients With Advanced Solid Tumors|Phase I Study to Evaluate the Effect of Ketoconazole on the Pharmacokinetics of Dasatinib and the Effect of Dasatinib on Pharmacodynamic Markers in Patients With Advanced Solid Tumors|Terminated||Phase 1|60||Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 04:40:32.210246|2018-06-01 04:40:32.210246
NCT00162201|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-11|2005-09-09|2005-09-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2003||2003-10-31|April 2011|2011-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy|An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy|Completed||Phase 1|16|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 04:40:32.291683|2018-06-01 04:40:32.291683
NCT00162188|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-01-08|2005-09-09|2005-09-13|Estimate|||||||2014-01-08|2014-01-09|Estimate|May 2001||2001-05-31|January 2014|2014-01-31|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Expanded Access|||An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada|Canadian Sustiva Oral Liquid Expanded Access Program: An Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP266)|No longer available|||||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:40:32.383636|2018-06-01 04:40:32.383636
NCT00162175|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09||2010-09-10|2010-09-10|2005-09-09|2005-09-13|Estimate||||2010-09-10|2010-09-14|Estimate|2010-09-10|2010-09-14|Estimate|July 2003||2003-07-31|September 2007|2007-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||PPAR-COMBO With Sulfonylurea|A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination With Glyburide Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone|Completed||Phase 3|534||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:40:32.525215|2018-06-01 04:40:32.525215
NCT00162149|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-07|2005-09-09|2005-09-13|Estimate|||||||2011-04-07|2011-04-08|Estimate|October 2005||2005-10-31|June 2008|2008-06-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||ATV/Ritonavir Nevirapine Interaction (USPAC)|Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Nevirapine on the Pharmacokinetics of Atazanavir in HIV-Infected Individuals|Completed||Phase 1|46||Bristol-Myers Squibb||4|||f||||||||||||||2018-06-01 04:40:32.968361|2018-06-01 04:40:32.968361
NCT00162136|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-07-03||2016-02-09|2005-09-09|2005-09-13|Estimate|2009-12-22|2010-01-27|Estimate||||2016-02-09|2016-03-10|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.|Phase I Study of Ixabepilone Administered as a 24-Hour Infusion in Patients With Advanced Solid Malignancies|Completed||Phase 1|35|Actual|R-Pharm||1|||f||||f||||||||||2018-06-01 04:40:33.14143|2018-06-01 04:40:33.14143
NCT00162123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-12-31|2011-01-29|2016-06-28|2005-09-09|2005-09-13|Estimate|2014-03-19|2014-04-15|Estimate|2011-08-30|2011-09-02|Estimate|2016-06-28|2016-07-27|Estimate|May 2006||2006-05-31|June 2016|2016-06-30|April 2014|Actual|2014-04-30|September 2012|Actual|2012-09-30||Interventional||All patients who were enrolled and passed screening in the current study|A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies|A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.|Completed||Phase 2|248|Actual|Bristol-Myers Squibb|Significant heterogeneity existed between patients, who rolled over from 6 studies assessing ipilimumab in different doses and combinations. Since not all eligible patients from parent studies were enrolled, some selection bias existed.|7|||f||||t||||||||||2018-06-01 04:40:34.910733|2018-06-01 04:40:34.910733
NCT00162110|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-10-26|2005-09-09|2005-09-13|Estimate|||||||2015-10-26|2015-10-28|Estimate|November 2004||2004-11-30|October 2015|2015-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces|A Phase II Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces|Completed||Phase 2|40||Eli Lilly and Company||1|||f||||||||||||||2018-06-01 04:40:37.729665|2018-06-01 04:40:37.729665
NCT00162097|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2010-07-28||2010-09-07|2005-09-09|2005-09-13|Estimate|2010-07-28|2010-08-25|Estimate||||2010-09-07|2010-09-14|Estimate|November 2004||2004-11-30|September 2010|2010-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment|Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects With Hepatic Impairment.|Completed||Phase 1|21|Actual|Bristol-Myers Squibb|The study was terminated early leading to a small number of participants treated and analyzed. Due to the small sample size, no conclusion could be made for participants with Child-Pugh scores B and C (moderate and severe hepatic impairment).|4|||f||||f||||||||||2018-06-01 04:40:37.862284|2018-06-01 04:40:37.862284
NCT00162084|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-31|2005-09-09|2005-09-13|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2005||2005-04-30|January 2017|2017-01-31||||March 2006|Actual|2006-03-31||Interventional|||A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography|A Phase 3, Parallel, Double Blind, Multicenter Trial to Examine Inducible Myocardial Perfusion Abnormality Detection With BMS068645 and Adenosine Stress SPECT Compared to Coronary Angiography|Terminated||Phase 3|2000||Forest Laboratories||||Business decision to stop the program|f||||||||||||||2018-06-01 04:40:38.908527|2018-06-01 04:40:38.908527
NCT00162071|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-31|2005-09-09|2005-09-13|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2005||2005-07-31|January 2017|2017-01-31||||March 2006|Actual|2006-03-31||Interventional|||A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging|"A Phase II Open-Label, Non-Randomized, Single-Center Trial to Determine the Optimal Myocardial Perfusion Image Acquisition Time Following BMS068645 Administration"|Terminated||Phase 2|20||Forest Laboratories||||Sponsor decided not to continue with the development program|f||||||||||||||2018-06-01 04:40:39.204308|2018-06-01 04:40:39.204308
NCT00162045|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-06-01|2005-09-09|2005-09-13|Estimate|||||||2011-06-01|2011-06-02|Estimate|January 2005||2005-01-31|June 2011|2011-06-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects|A Phase I-II, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of Technetium Tc99m Sestamibi in Pediatric Subjects|Completed||Phase 1/Phase 2|79|Actual|Lantheus Medical Imaging|||||f||||f||||||||||2018-06-01 04:40:39.379207|2018-06-01 04:40:39.379207
NCT00162032|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2013-04-30||2013-10-08|2005-09-09|2005-09-13|Estimate|2013-10-08|2013-12-06|Estimate||||2013-10-08|2013-12-06|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|December 2010|Actual|2010-12-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease|A Phase III, Open-Label, Non-Randomized, International, Multicenter Trial to Evaluate the Efficacy and Safety of CARDIOLITE® Myocardial Perfusion Imaging in Pediatric Subjects With Kawasaki Disease|Completed||Phase 3|445|Actual|Lantheus Medical Imaging||2|||f||||f||||||||||2018-06-01 04:40:39.569149|2018-06-01 04:40:39.569149
NCT00162019|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-12|2005-09-13|Estimate|||||||2017-10-19|2017-10-23|Actual|March 2003||2003-03-31|April 2008|2008-04-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients|Phase 3, Prospective, Multicenter Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Efficacy of IMMUNATE Solvent Detergent (IMMUNATE SD) in Previously Treated Patients With Severe or Moderately Severe Hemophilia A|Completed||Phase 3|56|Actual|Shire|||||f||||t||||||||||2018-06-01 04:40:40.242382|2018-06-01 04:40:40.242382
NCT00162006|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-01-16|2005-09-12|2005-09-13|Estimate|||||||2018-01-16|2018-01-18|Actual|January 1, 2003||2003-01-01|January 2018|2018-01-31|December 1, 2003|Actual|2003-12-01|December 1, 2003|Actual|2003-12-01||Interventional|||Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura|Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura|Completed||Phase 2|28|Actual|Shire|||||f||||||||||||||2018-06-01 04:40:40.350824|2018-06-01 04:40:40.350824
NCT00161993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-01-04|2005-09-12|2005-09-13|Estimate|||||||2018-01-04|2018-01-08|Actual|June 1, 2002||2002-06-01|January 2018|2018-01-31||||||||Interventional|||Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)|Prospective Open-Label Study of Pharmacokinetics, Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Patients With Hypo- or Agammaglobulinemia|Completed||Phase 2|||Shire|||||f||||||||||||||2018-06-01 04:40:40.451777|2018-06-01 04:40:40.451777
NCT00161980|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-20|2005-09-12|2005-09-13|Estimate|||||||2006-10-20|2006-10-23|Estimate|June 2001||2001-06-30|October 2006|2006-10-31|December 2002||2002-12-31|||||Interventional|||Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites|A Randomized and Controlled Clinical Study to Evaluate the Efficacy and Safety of Fibrin Sealant VH S/D (FS VH S/D) in Reduction of Lymphatic Leakage by Sealing Axillary Lymph Node Dissection Sites|Completed||Phase 3|||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 04:40:40.551521|2018-06-01 04:40:40.551521
NCT00161967|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|||TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)|Open-label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-borne Encephalitis Vaccine in Children and Adolescents Aged 3 - 18 Years|Completed||Phase 4|375|Anticipated|Pfizer|||||f||||t||||||||||2018-06-01 04:40:40.627234|2018-06-01 04:40:40.627234
NCT00161954|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|March 2004||2004-03-31|May 2015|2015-05-31|May 2004||2004-05-31|||||Interventional|||Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years|Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years|Completed||Phase 4|||Pfizer|||||f||||||||||||||2018-06-01 04:40:40.984473|2018-06-01 04:40:40.984473
NCT00161941|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2003||2003-06-30|May 2015|2015-05-31|December 2003||2003-12-31|||||Observational|||Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216|Open-label Multicenter Phase 3B Follow-up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens One Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in the NeisVac-C Non-interference Study 216|Completed|||321||Pfizer|||||f||||||||||||||2018-06-01 04:40:41.076188|2018-06-01 04:40:41.076188
NCT00161928|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|April 2002||2002-04-30|May 2015|2015-05-31|January 2003||2003-01-31|||||Interventional|||Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants|A Randomized, Open-Label Trial of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants|Completed||Phase 3|330||Pfizer|||||f||||||||||||||2018-06-01 04:40:41.190869|2018-06-01 04:40:41.190869
NCT00161915|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-20|2005-09-12|2005-09-13|Estimate|||||||2006-10-20|2006-10-23|Estimate|December 2000||2000-12-31|October 2006|2006-10-31|January 2004||2004-01-31|||||Interventional|||Efficacy and Safety of Endoscopic Injection of Fibrin Sealant Versus Endoscopic Ligature for Bleeding Esophageal Varices|Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices|Completed||Phase 3|||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 04:40:41.271771|2018-06-01 04:40:41.271771
NCT00161902|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-20|2005-09-12|2005-09-13|Estimate|||||||2006-10-20|2006-10-23|Estimate|August 2001||2001-08-31|October 2006|2006-10-31|March 2003||2003-03-31|||||Interventional|||Efficacy and Safety of Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D) for Hemostasis in Subjects Undergoing Total Hip Replacement|A Randomized, Controlled, Multicenter Study to Evaluate Efficacy and Safety of Fibrin Sealant VH S/D for Hemostasis in Subjects Undergoing Total Hip Replacement|Completed||Phase 3|||Baxter Healthcare Corporation|||||f||||||||||||||2018-06-01 04:40:41.360208|2018-06-01 04:40:41.360208
NCT00159393|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-02-14|2005-09-08|2005-09-12|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2003||2003-10-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Percutaneous Nephrolithotomy: A Registry and Database|Percutaneous Nephrolithotomy: A Registry and Database|Recruiting|||3000|Anticipated|Indiana Kidney Stone Institute|||||f||||f||||||||||2018-06-01 04:41:22.114297|2018-06-01 04:41:22.114297
NCT00161889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2002||2002-02-28|May 2015|2015-05-31|August 2002||2002-08-31|||||Interventional|||FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years|Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years|Completed||Phase 2|615||Pfizer|||||f||||||||||||||2018-06-01 04:40:41.491857|2018-06-01 04:40:41.491857
NCT00161876|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 2002||2002-05-31|May 2015|2015-05-31|August 2002||2002-08-31|||||Interventional|||FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years|Open-label, Multicenter, Follow-up Phase III Study to Investigate the Safety of the Third Vaccination of FSME-IMMUN NEW in Volunteers Aged 16 to 66 Years|Completed||Phase 3|3973||Pfizer|||||f||||||||||||||2018-06-01 04:40:41.653259|2018-06-01 04:40:41.653259
NCT00161863|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|September 2002||2002-09-30|May 2015|2015-05-31|January 2003||2003-01-31|||||Interventional|||Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years|Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 04:40:41.755842|2018-06-01 04:40:41.755842
NCT00161850|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2002||2002-02-28|May 2015|2015-05-31|August 2002||2002-08-31|||||Interventional|||FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years|Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 1 to 6 Years|Completed||Phase 2|615||Pfizer|||||f||||||||||||||2018-06-01 04:40:41.858444|2018-06-01 04:40:41.858444
NCT00161837|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-10-07|2005-09-12|2005-09-13|Estimate|||||||2015-10-07|2015-10-09|Estimate|December 2003||2003-12-31|October 2006|2006-10-31|July 2004||2004-07-31|||||Interventional|||Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004|Single-blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived) in Comparison to a Licensed Egg-derived Influenza Vaccine for Season 2003/2004|Completed||Phase 2/Phase 3|||Ology Bioservices|||||f||||||||||||||2018-06-01 04:40:41.991973|2018-06-01 04:40:41.991973
NCT00161824|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|October 2001||2001-10-31|May 2015|2015-05-31|January 2002||2002-01-31|||||Interventional|||Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR|Single-blind, Randomized, Multicenter Comparison of FSME IMMUN NEW and ENCEPUR: Safety and Tolerability of Two Vaccinations in Healthy Volunteers Aged 16 to 65 Years.|Completed||Phase 3|3800||Pfizer|||||f||||||||||||||2018-06-01 04:40:42.283618|2018-06-01 04:40:42.283618
NCT00161811|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-10-07|2005-09-12|2005-09-13|Estimate|||||||2015-10-07|2015-10-09|Estimate|November 2004||2004-11-30|October 2006|2006-10-31|July 2005||2005-07-31|||||Interventional|||Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005|Single-blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety After a Single Vaccination With Three Different Lots of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell-derived) in Comparison to a Licensed Egg Derived Influenza Vaccine for Season 2004/2005.|Completed||Phase 2/Phase 3|1400||Ology Bioservices|||||f||||||||||||||2018-06-01 04:40:42.58536|2018-06-01 04:40:42.58536
NCT00161798|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|September 2001||2001-09-30|May 2015|2015-05-31|March 2002||2002-03-31|||||Interventional|||Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.|Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.|Completed||Phase 2|||Pfizer|||||f||||||||||||||2018-06-01 04:40:44.495821|2018-06-01 04:40:44.495821
NCT00161785|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2004||2004-06-30|May 2015|2015-05-31|July 2005||2005-07-31|||||Interventional|||Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years||Completed||Phase 4|340||Pfizer|||||f||||||||||||||2018-06-01 04:40:44.826116|2018-06-01 04:40:44.826116
NCT00161772|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|March 2002||2002-03-31|May 2015|2015-05-31|August 2002||2002-08-31|||||Interventional|||Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.|Double-blind, Randomized, Multicenter Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.|Completed||Phase 2|||Pfizer|||||f||||||||||||||2018-06-01 04:40:45.402994|2018-06-01 04:40:45.402994
NCT00161759|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-19|2005-09-08|2005-09-13|Estimate|||||||2006-10-19|2006-10-20|Estimate|March 2002||2002-03-31|October 2006|2006-10-31|January 2004||2004-01-31|||||Interventional|||Safety and Efficacy Study of Fibrin Sealant (FS 4IU) for Skin Graft Fixation and Wound Healing in Subjects With Burn Wounds|A Study to Assess the Safety and Efficacy of Fibrin Sealant (FS 4IU) for Wound Healing in Subjects With Burn Wounds Requiring Skin Grafting Procedures|Completed||Phase 1/Phase 2|40||Baxter Healthcare Corporation|||||||||||||||||||2018-06-01 04:40:45.962285|2018-06-01 04:40:45.962285
NCT00161746|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-20|2005-09-12|2005-09-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|April 1998||1998-04-30|May 2015|2015-05-31|June 1999||1999-06-30|||||Interventional|||Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years|Multicentre Randomized Double-Blind Phase II/III Study on the Safety and Immunogenicity of Three Vaccinations With TICOVAC in Two Dosages in Healthy Children Aged Between Six Months and Three Years|Completed||Phase 2/Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 04:40:46.141904|2018-06-01 04:40:46.141904
NCT00161733|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-04-04|2005-09-10|2005-09-13|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2002||2002-09-30|April 2017|2017-04-30|November 2004||2004-11-30|||||Interventional|||Safety and Hemostatic Efficacy of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated (FS VH S/D) Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery|Evaluation of the Topical Hemostatic Efficacy and Safety of Fibrin Sealant Vapor Heated, Solvent/Detergent Treated Compared With Currently Licensed TISSEEL VH Fibrin Sealant in Subjects Undergoing Cardiac Surgery|Completed||Phase 3|||Baxter Healthcare Corporation|||||||||||||||||||2018-06-01 04:40:46.287581|2018-06-01 04:40:46.287581
NCT00161538|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-10-19|2005-09-09|2005-09-12|Estimate|||||||2006-10-19|2006-10-20|Estimate|July 2000||2000-07-31|October 2006|2006-10-31|June 2006||2006-06-30|||||Interventional|||Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation|A Randomized, Prospective Multicenter Study to Examine the Optimal Position of the Atrial Leads for Therapy of the Sinus Node Syndrome|Completed||Phase 4|456||Medtronic BRC|||||f||||||||||||||2018-06-01 04:40:49.460407|2018-06-01 04:40:49.460407
NCT00161720|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-08|2005-09-13|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2005||2005-06-30|October 2006|2006-10-31|December 2005||2005-12-31|||||Observational|||Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND|A Retrospective Study to Capture Dosing and Treatment Outcome Data in Subjects With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND|Completed|||||Shire|||||||||||||||||||2018-06-01 04:40:46.471526|2018-06-01 04:40:46.471526
NCT00161707|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-08|2005-09-13|Estimate|||||||2017-10-19|2017-10-23|Actual|January 2003||2003-01-31|October 2006|2006-10-31|October 2003||2003-10-31|||||Interventional|||Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency|Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency|Completed||Phase 1/Phase 2|||Shire|||||||||||||||||||2018-06-01 04:40:46.732922|2018-06-01 04:40:46.732922
NCT00161694|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-06-02|2005-09-11|2005-09-12|Estimate|||||||2008-06-02|2008-06-04|Estimate|July 2005||2005-07-31|June 2008|2008-06-30||||||||Interventional|||Use of Sucrose to Relieve Pain During Eye Exams in Infants|Effectiveness of an Oral Sucrose Solution in Reducing Pain and Anxiety Associated With Neonatal Ophthalmologic Examination|Terminated||N/A|300|Anticipated|Weill Medical College of Cornell University||||results did not show intervention was beneficial|f||||||||||||||2018-06-01 04:40:46.880142|2018-06-01 04:40:46.880142
NCT00161681|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-02-07|2005-09-07|2005-09-12|Estimate|||||||2013-02-07|2013-02-08|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Levonorgestrel 90 Mcg and Ethinyl Estradiol 20 Mcg in a Continuous Daily Regimen on Menstrual Cycle-Related Symptoms|Completed||Phase 3|200||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:40:46.980846|2018-06-01 04:40:46.980846
NCT00161668|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-03-14|2005-09-11|2005-09-12|Estimate|||||||2007-03-14|2007-03-15|Estimate|October 2001||2001-10-31|March 2007|2007-03-31||||||||Observational|||Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care|Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care|Completed|||500||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:40:47.450292|2018-06-01 04:40:47.450292
NCT00161655|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-09-25|2005-09-08|2005-09-12|Estimate|||||||2009-09-25|2009-09-28|Estimate|April 2005||2005-04-30|September 2009|2009-09-30|December 2006|Actual|2006-12-31|August 2006|Actual|2006-08-31||Interventional|||Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis|A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy|Completed||Phase 4|60||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:40:47.706685|2018-06-01 04:40:47.706685
NCT00161642|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-09-09|2005-09-07|2005-09-12|Estimate|||||||2009-09-09|2009-09-10|Estimate|November 2004||2004-11-30|September 2009|2009-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study Evaluating CMD-193 in Advanced Malignant Solid Tumors|A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.|Completed||Phase 1|54|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:40:47.878768|2018-06-01 04:40:47.878768
NCT00161629|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-12-03|2005-09-07|2005-09-12|Estimate|||||||2007-12-03|2007-12-05|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures|A Phase 1 Dose-Escalating, Double-Blind, Placebo-Controlled, Multicenter, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy for Closed Distal Radius Fractures|Completed||Phase 1|40|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:40:48.171581|2018-06-01 04:40:48.171581
NCT00161616|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2009-07-31||2009-07-31|2005-09-07|2005-09-12|Estimate|2009-07-31|2009-09-07|Estimate||||2009-07-31|2009-09-07|Estimate|September 2003||2003-09-30|July 2009|2009-07-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating InductOs in Diaphyseal Tibia Fractures|A Prospective, Randomized, Controlled, Stratified Study of InductOs in Subjects With Open Diaphyseal Tibia Fractures Treated With Reamed Locked Intramedullary Nail Fixation|Completed||Phase 4|277|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||f||||||||||2018-06-01 04:40:48.267663|2018-06-01 04:40:48.267663
NCT00161603|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-04-01|2005-09-11|2005-09-12|Estimate|||||||2008-04-01|2008-04-03|Estimate|April 2003||2003-04-30|April 2008|2008-04-30|September 2003||2003-09-30|||||Observational|||Cornell Translational Behavioral Science Research Consortium: Angioplasty Qualitative Study|Cornell Translational Behavioral Science Research Consortium: Angioplasty Qualitative Study|Completed|||18||Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:40:48.943089|2018-06-01 04:40:48.943089
NCT00161590|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-10-21|2005-09-11|2005-09-12|Estimate|||||||2008-10-21|2008-10-22|Estimate|July 2004||2004-07-31|October 2008|2008-10-31||||||||Interventional|||Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma|Phase I Study of CHOP Plus Campath (C-CHOP) for the Treatment of T-Cell, Null-Cell, and NK-Cell Lymphomas|Completed||Phase 1|||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:40:49.022424|2018-06-01 04:40:49.022424
NCT00161577|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-05-12|2005-09-11|2005-09-12|Estimate|||||||2009-05-12|2009-05-13|Estimate|January 2004||2004-01-31|May 2009|2009-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Use of Ketorolac in Management of Post-Operative Pain After Heart Surgery|Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Ketorolac in the Management of Post-Operative Pain After Heart Surgery|Completed||Phase 4|25|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 04:40:49.114741|2018-06-01 04:40:49.114741
NCT00161564|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-15|2005-09-08|2005-09-12|Estimate|||||||2008-05-15|2008-05-19|Estimate|February 2004||2004-02-29|May 2008|2008-05-31||||||||Interventional|||A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone|A Randomized Trial Comparing Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine,and Prednisone) in Subjects With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment|Withdrawn||Phase 2|||Weill Medical College of Cornell University|||||||||||||||||||2018-06-01 04:40:49.248108|2018-06-01 04:40:49.248108
NCT00161551|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-08-01|2005-09-09|2005-09-12|Estimate|||||||2011-08-01|2011-08-02|Estimate|November 2004||2004-11-30|October 2006|2006-10-31|December 2010||2010-12-31|||||Interventional|||Mode Evaluation in Sick Sinus Syndrome Trial (MODEST)|A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers|Unknown status|Recruiting|Phase 4|402|Anticipated|Medtronic BRC|||||f||||||||||||||2018-06-01 04:40:49.357435|2018-06-01 04:40:49.357435
NCT00161525|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-01-03|2005-09-08|2005-09-12|Estimate|||||||2011-01-03|2011-01-04|Estimate|October 2003||2003-10-31|January 2011|2011-01-31|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Pneumatic Displacement of Subretinal Hemorrhage With Perfluorocarbon Gases|Perfluorocarbon Gases for the Repair of Retinal Detachments.|Unknown status|Recruiting|Phase 2|25|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 04:40:49.528341|2018-06-01 04:40:49.528341
NCT00161486|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-09-18|2005-09-08|2005-09-12|Estimate|||||||2008-09-18|2008-09-19|Estimate|July 2004||2004-07-31|September 2008|2008-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|ACYP-1||The Effects of Testosterone on Prostate Tissue (ACYP-1)|The Effects of Testosterone on Prostate Tissue in Normal Men (ACYP-1)|Completed||Phase 1|13|Actual|University of Washington||3|||f||||f||||||||||2018-06-01 04:40:49.6525|2018-06-01 04:40:49.6525
NCT00161473|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2012-02-24||2012-06-26|2005-09-08|2005-09-12|Estimate|2012-06-26|2012-08-02|Estimate||||2012-06-26|2012-08-02|Estimate|January 2001||2001-01-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Alzheimer's in Long-Term Care--Treatment for Agitation|Alzheimer's in Long-Term Care--Treatment for Agitation|Completed||N/A|24|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:40:49.749147|2018-06-01 04:40:49.749147
NCT00161460|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-05-11|2005-09-08|2005-09-12|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2005||2005-06-30|May 2016|2016-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Colorectal Cancer Screening Intervention in UWPN Clinics|Colorectal Cancer Screening Intervention in UWPN Clinics|Completed||N/A|80|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:40:50.143552|2018-06-01 04:40:50.143552
NCT00161447|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-09-18|2005-09-08|2005-09-12|Estimate|||||||2008-09-18|2008-09-19|Estimate|May 2004||2004-05-31|September 2008|2008-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|ACY-5||Male Hormonal Contraceptive Development-ACY-5|Male Hormonal Contraceptive Development: Suppression of Spermatogenesis With the Addition of a Potent Antagonist (Acyline) to Testosterone and DMPA (ACY-5)|Completed||Phase 1/Phase 2|43|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:40:50.210272|2018-06-01 04:40:50.210272
NCT00161434|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-12-29|2005-09-08|2005-09-12|Estimate|||||||2007-12-29|2008-01-10|Estimate|March 2003||2003-03-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons|A Randomized, Double-Blind, Placebo Controlled Crossover Trial Using Valacyclovir to Suppress HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons|Completed||Phase 4|60|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:40:50.319423|2018-06-01 04:40:50.319423
NCT00161421|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-09-18|2005-09-08|2005-09-12|Estimate|||||||2008-09-18|2008-09-19|Estimate|March 2005||2005-03-31|September 2008|2008-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone|Oral Androgens in Man-3: Pharmacokinetics of Oral Testosterone With Concomitant Inhibition of 5α-Reductase by Dutasteride Short Title: ORAL T-3|Completed||Phase 2|18|Actual|University of Washington||1|||f||||f||||||||||2018-06-01 04:40:50.39061|2018-06-01 04:40:50.39061
NCT00161408|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|December 2000||2000-12-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Psychological Intervention for Relapse Prevention in First Episode Schizophrenia|Psychological Intervention for Relapse Prevention in First Episode Schizophrenia|Unknown status|Active, not recruiting|N/A|106||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:40:50.476312|2018-06-01 04:40:50.476312
NCT00161395|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-14|2005-09-08|2005-09-12|Estimate|||||||2008-05-14|2008-05-16|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|March 2007|Actual|2007-03-31|August 2006|Actual|2006-08-31||Interventional|||Study of Time to Pregnancy in Normal Fertility|Randomized Trial of Fertility Awareness and Time to Pregnancy in Couples of Normal Fertility|Completed||Phase 2|143|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 04:40:50.540701|2018-06-01 04:40:50.540701
NCT00161382|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2014-05-21||2014-06-23|2005-09-08|2005-09-12|Estimate|2014-05-21|2014-06-24|Estimate||||2014-06-23|2014-07-08|Estimate|September 2002||2002-09-30|June 2014|2014-06-30|July 2008|Actual|2008-07-31|March 2007|Actual|2007-03-31||Interventional|||Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students|HIV Prevention Programs for Middle School Students|Completed||N/A|3007|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 04:40:50.703724|2018-06-01 04:40:50.703724
NCT00161369|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-10-19|2005-09-09|2005-09-12|Estimate|||||||2005-10-19|2005-10-21|Estimate|April 2000||2000-04-30|October 2005|2005-10-31|March 2005||2005-03-31|||||Observational|||Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients|Contribution of Homocysteine and Asymmetric Dimethylarginine to Atherosclerosis and Cardiovascular Events in Maintenance Hemodialysis Patients|Completed|||200||University of Shizuoka|||||f||||||||||||||2018-06-01 04:40:50.909317|2018-06-01 04:40:50.909317
NCT00161356|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-06-20|2005-09-08|2005-09-12|Estimate|||||||2008-06-20|2008-06-23|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|||||Interventional|||Ambisome in Liver Transplant Patients|Blood, Bile and Tissue Pharmacokinetics of Single Dose Liposomal Amphotericin B (AmBisome ®) in Liver Transplant Patients.|Terminated||Phase 4|10|Actual|The University of Texas Health Science Center, Houston||||Budget issues|f||||f||||||||||2018-06-01 04:40:50.9753|2018-06-01 04:40:50.9753
NCT00161343|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-09-04|2005-09-08|2005-09-12|Estimate|||||||2012-09-04|2012-09-06|Estimate|December 2004||2004-12-31|April 2009|2009-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Maintaining HIV Prevention Gains in Female Adolescents|Randomized Controlled Trial of an Group Intervention to Maintain HIV Prevention Gains in Female Adolescents|Completed||Phase 2|640|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 04:40:51.046077|2018-06-01 04:40:51.046077
NCT00161330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|June 2000||2000-06-30|July 2004|2004-07-31|July 2005||2005-07-31|||||Interventional|||Oral Vs Initial Intravenous Antibiotic Treatment of Urinary Tract Infections in Children: a RCT|A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid Vs Initial Iv Ceftriaxone.|Terminated||Phase 3|440||University of Padova|||||f||||||||||||||2018-06-01 04:40:51.135499|2018-06-01 04:40:51.135499
NCT00161317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-01-05|2005-09-11|2005-09-12|Estimate|||||||2016-01-05|2016-01-06|Estimate|December 2003||2003-12-31|January 2016|2016-01-31|February 2006||2006-02-28|||||Interventional|||Evaluation of a Living With Hope Program|Development, Implementation and Evaluation of a Psychosocial Supportive Hope Focused Program for Patients With Advanced Cancer|Completed||N/A|60||University of Saskatchewan|||||f||||||||||||||2018-06-01 04:40:51.208527|2018-06-01 04:40:51.208527
NCT00161304|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-11|2005-09-11|2005-09-12|Estimate|||||||2005-09-11|2005-09-12|Estimate|April 2003||2003-04-30|November 2004|2004-11-30|November 2004||2004-11-30|||||Interventional|||Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency|Effects of Testosterone Administration on Tissues of Men With A.D.A.M. (Androgen Deficiency of Aging Men)|Completed||Phase 2/Phase 3|44||Urological Sciences Research Foundation|||||f||||||||||||||2018-06-01 04:40:51.258604|2018-06-01 04:40:51.258604
NCT00161291|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-12-30|2005-09-11|2005-09-12|Estimate|||||||2010-12-30|2011-01-04|Estimate|June 2005||2005-06-30|December 2010|2010-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer|A Phase II Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer|Completed||Phase 2|28|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 04:40:51.314735|2018-06-01 04:40:51.314735
NCT00161278|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-07-28|2005-09-11|2005-09-12|Estimate|||||||2008-07-28|2008-07-30|Estimate|December 2004||2004-12-31|July 2008|2008-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling|Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer Through Gene Expression Profiling.|Terminated||Phase 2|1|Actual|University of Michigan Cancer Center||||recruitment has ended|f||||t||||||||||2018-06-01 04:40:51.384825|2018-06-01 04:40:51.384825
NCT00161265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-07-28|2005-09-11|2005-09-12|Estimate|||||||2016-07-28|2016-07-29|Estimate|May 2005||2005-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|August 2012|Actual|2012-08-31||Observational|||Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer|UMCC 2004.064: Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer|Completed|||68|Actual|University of Michigan Cancer Center|||1||f||||t||||||Samples Without DNA|"~     tissue~   "|Undecided||2018-06-01 04:40:51.443304|2018-06-01 04:40:51.443304
NCT00161252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-27|2005-09-11|2005-09-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2005||2005-03-31|May 2011|2011-05-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Observational|||Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly|Assessment of Primary Androgen Deprivation Therapy for Non-metastatic Prostate Cancer Among Elderly Men|Withdrawn|||0|Actual|Rutgers, The State University of New Jersey|||||f||||||||||||||2018-06-01 04:40:51.511489|2018-06-01 04:40:51.511489
NCT00161239|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-12-10|2005-09-11|2005-09-12|Estimate|||||||2009-12-10|2009-12-11|Estimate|February 2005||2005-02-28|December 2009|2009-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma|LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma|Terminated||N/A|64|Anticipated|Rutgers, The State University of New Jersey||||toxicity|f||||||||||||||2018-06-01 04:40:51.564313|2018-06-01 04:40:51.564313
NCT00161226|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-12-10|2005-09-11|2005-09-12|Estimate|||||||2009-12-10|2009-12-11|Estimate|February 2004||2004-02-29|December 2009|2009-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35|A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35|Terminated|||44|Anticipated|Rutgers, The State University of New Jersey||||Principal investigator left institution|f||||||||||||||2018-06-01 04:40:51.616985|2018-06-01 04:40:51.616985
NCT00161213|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2012-11-21||2012-11-21|2005-09-11|2005-09-12|Estimate|2012-11-21|2012-12-27|Estimate||||2012-11-21|2012-12-27|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer|Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer|Completed||Phase 2|44|Actual|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-06-01 04:40:51.675334|2018-06-01 04:40:51.675334
NCT00161200|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-12-10|2005-09-08|2005-09-12|Estimate|||||||2009-12-10|2009-12-11|Estimate|December 2002||2002-12-31|December 2009|2009-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor|Studies of Esophageal Metaplasia Using a Novel Antibody: Reversibility of Columnar Metaplasia by Proton Pump Inhibitor|Terminated||Phase 3|60||Rutgers, The State University of New Jersey||||slow accrual|||||||||||||||2018-06-01 04:40:51.865165|2018-06-01 04:40:51.865165
NCT00161187|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-11-05|2005-09-08|2005-09-12|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2001||2001-05-31|September 2013|2013-09-30|October 2011|Actual|2011-10-31|October 2010|Actual|2010-10-31||Interventional|||Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor|A Pilot Study of Irradiated HLA-Partially Matched Allogeneic Related Donor Lymphocytes for Patients With Selected Malignancies|Completed||Phase 1|37|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-06-01 04:40:51.936504|2018-06-01 04:40:51.936504
NCT00161174|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-04-28|2005-09-08|2005-09-12|Estimate|||||||2015-04-28|2015-04-29|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity|Cardiovascular Morbidity in Testicular Cancer Survivors: Study of Risk Factors and Assessment of Pharmacogenomic Determinants of Toxicity. (KWF RUG 2004-3157)|Completed|||173|Actual|University Medical Center Groningen|||||f||||||||||Samples With DNA|"~     For cured patients with complete data on cardiovascular risk factors and presence of~     subclinical cardiovascular damage only DNA will be collected.~   "|||2018-06-01 04:40:52.156909|2018-06-01 04:40:52.156909
NCT00161161|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-29|2005-09-08|2005-09-12|Estimate|||||||2005-12-29|2005-12-30|Estimate|October 1999||1999-10-31|September 2005|2005-09-30|December 2002||2002-12-31|||||Observational|||Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder|Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder|Completed|||90||UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.22779|2018-06-01 04:40:52.22779
NCT00161148|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-01-08|2005-09-08|2005-09-12|Estimate|||||||2007-01-08|2007-01-09|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Probiotics in Patients With Primary Sclerosing Cholangitis|Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial|Unknown status|Recruiting|Phase 3|12||UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.277954|2018-06-01 04:40:52.277954
NCT00161135|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-04-19|2005-09-08|2005-09-12|Estimate|||||||2007-04-19|2007-04-20|Estimate|January 1999||1999-01-31|April 2007|2007-04-30||||||||Observational|||Magnetic Resonance Imaging in Children and Adolescents With Autism and Multiple Complex Developmental Disorders|Magnetic Resonance Imaging in Children and Adolescents With Autism and Multiple Complex Developmental Disorders|Completed|||150||UMC Utrecht|||||f||||f||||||||||2018-06-01 04:40:52.353444|2018-06-01 04:40:52.353444
NCT00161122|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-02-13|2005-09-08|2005-09-12|Estimate|||||||2008-02-13|2008-02-18|Estimate|September 2003||2003-09-30|July 2005|2005-07-31|June 2006||2006-06-30|||||Interventional|||Prevention of Respiratory Infections and MAnagement Among Children (PRIMAKid)|Effectiveness and Costs of Combined Influenza and Pneumococcal Vaccination in Pre-School Children With Recurrent Respiratory Tract Infections (RTI): a General Practice-Based Randomized Controlled Trial|Completed||Phase 4|660||UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.411996|2018-06-01 04:40:52.411996
NCT00161096|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-02-01|2005-09-08|2005-09-12|Estimate|||||||2006-02-01|2006-02-02|Estimate|March 2004||2004-03-31|November 2004|2004-11-30|September 2005||2005-09-30|||||Interventional|||On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication|Comparison of the Percentage Chronic on-Demand Users Treated With 20 Mg Pantoprazole on-Demand and Placebo o.d Versus Placebo on-Demand and 20 Mg Pantoprazole o.d. After Symptom Relief With 20 Mg Pantoprazole o.d.|Unknown status|Active, not recruiting|Phase 3|276||UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.558646|2018-06-01 04:40:52.558646
NCT00161083|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-07-26|2005-09-08|2005-09-12|Estimate|||||||2006-07-26|2006-07-27|Estimate|November 2001||2001-11-30|September 2005|2005-09-30|November 2004||2004-11-30|||||Interventional|||UDCA for Symptomatic Gallstone Disease|Studie Naar De Effectiviteit Van Ursodeoxycholzuur Ter Preventie Van Galsteen-Gerelateerde Klachten Bij patiënten in Afwachting Van Een Cholecystectomie|Completed||Phase 4|180||UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.610875|2018-06-01 04:40:52.610875
NCT00161070|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-03-21|2005-09-08|2005-09-12|Estimate|||||||2007-03-21|2007-03-22|Estimate|July 1997||1997-07-31|March 2007|2007-03-31|December 2006|Actual|2006-12-31|||||Interventional|||ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial|ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial|Completed||Phase 4|4500||UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.688965|2018-06-01 04:40:52.688965
NCT00161057|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-04-22|2005-09-08|2005-09-12|Estimate|||||||2009-04-22|2009-04-23|Estimate|December 2001||2001-12-31|April 2009|2009-04-30|September 2008|Actual|2008-09-30|||||Observational|||Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment|Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment|Completed|||78|Actual|UMC Utrecht|||||f||||||||||||||2018-06-01 04:40:52.748436|2018-06-01 04:40:52.748436
NCT00161044|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-03-04|2005-09-11|2005-09-12|Estimate|||||||2015-03-04|2015-03-05|Estimate|September 2004||2004-09-30|March 2015|2015-03-31|September 2005||2005-09-30|||||Interventional|||An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms|An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms|Completed||N/A|20||University of Maryland|||||f||||||||||||||2018-06-01 04:40:52.800118|2018-06-01 04:40:52.800118
NCT00161031|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-03-04|2005-09-11|2005-09-12|Estimate|||||||2015-03-04|2015-03-05|Estimate|April 2004||2004-04-30|March 2015|2015-03-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia|Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia|Completed||N/A|30|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 04:40:52.858324|2018-06-01 04:40:52.858324
NCT00161018|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-03-04|2005-09-11|2005-09-12|Estimate|||||||2015-03-04|2015-03-05|Estimate|November 2003||2003-11-30|March 2015|2015-03-31|November 2004|Actual|2004-11-30|||||Interventional|||New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia||Completed||Phase 3|150||University of Maryland|||||f||||||||||||||2018-06-01 04:40:52.918288|2018-06-01 04:40:52.918288
NCT00161005|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-04-16|2005-09-09|2005-09-12|Estimate|||||||2009-04-16|2009-04-17|Estimate|February 2005||2005-02-28|April 2009|2009-04-30|December 2009|Anticipated|2009-12-31|June 2009|Anticipated|2009-06-30||Interventional|||Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction|Benefits and Costs in Two Different Strategies for Treating Acute Myocardial Infarction With ST-Elevation.|Unknown status|Active, not recruiting|N/A|266|Anticipated|Ullevaal University Hospital|||||f||||t||||||||||2018-06-01 04:40:52.96925|2018-06-01 04:40:52.96925
NCT00160992|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|July 2004||2004-07-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients|Phase I Study of in Vivo Expansion of Melan-A/MART-1 Antigen-Specific CD8 T Lymphocytes Following Transient Immunosuppression in Patients With Advanced Melanoma|Suspended||Phase 1|6||University of Lausanne Hospitals|||||f||||||||||||||2018-06-01 04:40:53.057015|2018-06-01 04:40:53.057015
NCT00160979|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-09-21|2005-09-08|2005-09-12|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2001||2001-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Transrectal Tumour Oxygen - US Army|A Study of Transrectal Tumour Oxygen Measurements in Patients With Clinically Localized Prostate Cancer|Active, not recruiting||Phase 2|195|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:40:54.209936|2018-06-01 04:40:54.209936
NCT00160966|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-03-27|2005-09-08|2005-09-12|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2004||2004-09-30|January 2017|2017-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy|Prospective Randomized Study to Characterize Risk Factors of Polyomavirus-related Transplant Nephropathy and the Impact of Three Immunosuppressive Regimens on Nephropathy Incidence|Completed||Phase 4|108|Actual|University of Giessen||3|||f||||t||||||||Yes|De-identified data of all participants will be made available within 1 year of study completion.|2018-06-01 04:40:54.293648|2018-06-01 04:40:54.293648
NCT00160953|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-08-10|2005-09-08|2005-09-12|Estimate|||||||2010-08-10|2010-08-11|Estimate|February 2005||2005-02-28|August 2010|2010-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Endorectal Coil Magnetic Resonance Images (ERC-MRI)|Development of a Prostate Deformation Model to Enable Accurate Registration of Endorectal Coil Magnetic Resonance Images (ERC-MRI) to Reference Treatment Planning CT Images|Completed||Phase 2|20||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:40:54.379325|2018-06-01 04:40:54.379325
NCT00160940|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-29|2005-09-08|2005-09-12|Estimate|||||||2005-11-29|2005-12-01|Estimate|February 2002||2002-02-28|September 2005|2005-09-30||||||||Observational|||Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis|Differential Gene Expression in Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis With or Without a Complicating Hepatoma or Autoimmune Liver Disease|Unknown status|Recruiting||200||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:40:54.507572|2018-06-01 04:40:54.507572
NCT00160927|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-03-16|2005-09-11|2005-09-12|Estimate|||||||2007-03-16|2007-03-19|Estimate|January 2003||2003-01-31|March 2007|2007-03-31|January 2008|Anticipated|2008-01-31|||||Observational|||Microvascular Response in Diabetes Mellitus|Microcirculation cutanée et Vasodilatation Induite Par la Pression Non-Nociceptive Chez Les diabètiques|Unknown status|Recruiting||90||University Hospital, Angers|||||f||||f||||||||||2018-06-01 04:40:54.641026|2018-06-01 04:40:54.641026
NCT00160914|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-04-06|2005-09-11|2005-09-12|Estimate|||||||2016-04-06|2016-04-07|Estimate|December 2001||2001-12-31|April 2016|2016-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Childhood Obesity: Variations in Management|Childhood Obesity: Variations in Management|Completed|||500|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 04:40:54.742287|2018-06-01 04:40:54.742287
NCT00160901|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-04-18|2005-09-08|2005-09-12|Estimate|||||||2007-04-18|2007-04-19|Estimate|August 2003||2003-08-31|March 2007|2007-03-31|December 2005|Actual|2005-12-31|||||Interventional|||Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer|Prospective Randomized Trial With Complementary Therapies During Chemotherapy at the Women's Hospital of the University of Heidelberg|Completed||Phase 4|150||Heidelberg University|||||f||||f||||||||||2018-06-01 04:40:54.805241|2018-06-01 04:40:54.805241
NCT00160888|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|November 1999||1999-11-30|September 2005|2005-09-30|December 2006||2006-12-31|||||Interventional|||Vasoreactivity in Carriers of Genetic Polymorphisms|Endothelium-Dependent Vasoreactivity in Nitric Oxide Synthase Gene (Glu298Asp) Polymorphism: Studies in Healthy Volunteers|Unknown status|Recruiting|Phase 1|100||Heidelberg University|||||f||||||||||||||2018-06-01 04:40:54.864588|2018-06-01 04:40:54.864588
NCT00160875|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-05-03|2005-09-08|2005-09-12|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2009||2009-04-30|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer|A Phase II Study to Assess the Efficacy of Combined Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy (External Beam, Brachytherapy), Plus Surgery for Potentially Resectable Thoracic Esophageal Cancer|Completed||Phase 2/Phase 3|54|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 04:40:55.027043|2018-06-01 04:40:55.027043
NCT00160862|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|May 2003||2003-05-31|September 2005|2005-09-30|November 2003||2003-11-30|||||Interventional|||NK-1 Antagonism of SLV317 in Humans|A Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Effect of a Single Oral Dose of SLV 317 on Substance P-Induced Venodilation in the Hand Vein of Healthy Male Volunteers|Completed||Phase 1|18||Heidelberg University|||||f||||||||||||||2018-06-01 04:40:55.117792|2018-06-01 04:40:55.117792
NCT00160849|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-10-19|2005-09-08|2005-09-12|Estimate|||||||2005-10-19|2005-10-21|Estimate|August 2004||2004-08-31|July 2005|2005-07-31|March 2007||2007-03-31|||||Interventional|||Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression|Study on the Feasibility of Antiretroviral Therapy With a Single Agent - Lopinavir/r - in Patients Treated With HAART and With Viral Load Below 80 Copies/Ml|Completed||Phase 4|60||Universidade Federal do Rio de Janeiro|||||f||||||||||||||2018-06-01 04:40:55.187741|2018-06-01 04:40:55.187741
NCT00160836|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-04-18|2005-09-08|2005-09-12|Estimate|||||||2007-04-18|2007-04-19|Estimate|October 2004||2004-10-31|April 2007|2007-04-30||||||||Interventional|||Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter|Biliary Tissue Sampling Using a Cytology Brush or the G.I.U.M. Catheter: a Prospective Randomized Controlled Study.|Unknown status|Recruiting|Phase 1|68||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:40:55.260025|2018-06-01 04:40:55.260025
NCT00160823|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-11|2005-09-08|2005-09-12|Estimate|||||||2006-09-11|2006-09-13|Estimate|September 2005||2005-09-30|September 2006|2006-09-30||||||||Interventional|||Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients|Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital|Unknown status|Recruiting|Phase 3|102||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:40:55.343284|2018-06-01 04:40:55.343284
NCT00160810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-05-17|2005-09-11|2005-09-12|Estimate|||||||2013-05-17|2013-05-20|Estimate|April 2001||2001-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|October 2010|Actual|2010-10-31||Observational|||Outcome Study of Complex Distal Radius Fractures|Outcome Study of Complex Distal Radius Fractures: Open Reduction Internal Fixation (ORIF) With A Volar Fixed Angled Plate Versus A Distal Radius Volar (DRV) Plate Versus External Fixation|Completed|||74|Actual|University of Florida|||||f||||f||||||||||2018-06-01 04:40:55.429253|2018-06-01 04:40:55.429253
NCT00160797|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-04-30|2005-09-11|2005-09-12|Estimate|||||||2012-04-30|2012-05-02|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Total Knee Arthroplasty Outcome Study|MIS™ Minimally Invasive Solutions™ Total Knee Arthroplasty Outcome Study #02-800|Withdrawn||Phase 4|0|Actual|University of Florida||||10/2005 PI assigned duties as trauma physician in addition other duties|f||||||||||||||2018-06-01 04:40:55.499397|2018-06-01 04:40:55.499397
NCT00160784|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-12-04|2005-09-11|2005-09-12|Estimate|||||||2012-12-04|2012-12-05|Estimate|March 1997||1997-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Arthroscopy and Manipulation vs a Home Therapy Program in the Treatment of Adhesive Capsulitis|Arthroscopy and Manipulation vs a Home Therapy Program in the Treatment of Adhesive Capsulitis of the Shoulder - A Prospective Randomized Study|Completed||Phase 4|58|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 04:40:55.554728|2018-06-01 04:40:55.554728
NCT00160771|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-08-15|2005-09-11|2005-09-12|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2005||2005-01-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Biomechanics/Motion Analysis Laboratory Data Bank|University of Florida Biomechanics/Motion Analysis Laboratory Data Bank|Recruiting|||10000|Anticipated|University of Florida|||1||f||||f||||||||||2018-06-01 04:40:55.622748|2018-06-01 04:40:55.622748
NCT00160758|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-10-26|2005-09-11|2005-09-12|Estimate|||||||2012-10-26|2012-10-30|Estimate|December 1999||1999-12-31|October 2012|2012-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Physical Characteristics of Retrieved Massive Allografts|Physical Characteristics of Retrieved Massive Allografts|Completed|||18|Actual|University of Florida|||||f||||f||||||||||2018-06-01 04:40:55.702343|2018-06-01 04:40:55.702343
NCT00160745|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2018-02-22|2005-09-08|2005-09-12|Estimate|||||||2018-02-22|2018-02-26|Actual||||February 2018|2018-02-28|September 2006||2006-09-30|||||Interventional|||Rosuvastatin and Renal Endothelial Function|A Randomised, Double-blind, Placebo-controlled, Mono-centre, Explorative Phase II Trial to Study the Effects of Rosuvastatin on Basal Production and Release of Nitric Oxide From the Renal Vasculature in Patients With Hypercholesterolemia.|Completed||Phase 2|46||University of Erlangen-Nürnberg Medical School|||||f||||||||||||||2018-06-01 04:40:55.754661|2018-06-01 04:40:55.754661
NCT00160732|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-11-16|2005-09-08|2005-09-12|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2003||2003-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Allogenic Islet Cell Transplantation|Allogenic Islet Cells (Human, U. of Chicago) Administered Via Intraportal Infusion; and Immunosuppressive Therapy|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|University of Chicago||1|||f||||f||||||||||2018-06-01 04:40:55.814859|2018-06-01 04:40:55.814859
NCT00160719|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-10-26|2005-09-11|2005-09-12|Estimate|||||||2012-10-26|2012-10-30|Estimate|September 1999||1999-09-30|October 2012|2012-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||HLA Sensitization Following Major Cortical Allograft Bone Procedures|HLA Sensitization Following Major Cortical Allograft Bone Procedures|Completed|||10|Actual|University of Florida|||||f||||f||||||||||2018-06-01 04:40:55.877078|2018-06-01 04:40:55.877078
NCT00160706|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-05-16||2013-05-16|2005-09-09|2005-09-12|Estimate|2013-05-16|2013-07-04|Estimate||||2013-05-16|2013-07-04|Estimate|February 2004||2004-02-29|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|PRECiSE 4|Baseline Characteristics refer to the Safety Population, including all enrolled subjects who received at least one injection of study treatment in feeder study C87031 [NCT00152490] or C87032 [NCT00152425].|A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease|A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease.|Completed||Phase 3|310|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:40:56.002093|2018-06-01 04:40:56.002093
NCT00160693|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2012-02-15||2018-03-08|2005-09-08|2005-09-12|Estimate|2012-06-04|2012-07-09|Estimate||||2018-03-08|2018-04-04|Actual|March 2003||2003-03-31|March 2018|2018-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis|A Phase III, Multicenter, Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks, in Subjects With Rheumatoid Arthritis|Completed||Phase 3|402|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:40:56.918316|2018-06-01 04:40:56.918316
NCT00160680|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-12-13|2005-09-08|2005-09-12|Estimate|||||||2013-12-13|2013-12-16|Estimate|March 2005||2005-03-31|September 2009|2009-09-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)|A Pilot, Open, Monocenter Randomized Two Parallel Groups, Clinical Efficacy Trial: Comparison Continuous Versus on Demand Regimen of Treatment With Levocetirizine 5 mg Oral Tablets, Once a Day, in Adults Suffering From Persistent Allergic Rhinitis (PER) Over 6 Months|Completed||Phase 4|100||UCB Pharma|||||f||||||||||||||2018-06-01 04:40:57.835978|2018-06-01 04:40:57.835978
NCT00160667|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-10-15|2005-09-08|2005-09-12|Estimate|||||||2010-10-15|2010-10-18|Estimate|October 2004||2004-10-31|October 2010|2010-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)|A Double Blind, Randomized, Placebo-controlled, Parallel Group Study, for the Assessment of Efficacy, Safety and Tolerability of Brivaracetam at the Doses of 200 mg/Day and 400 mg/Day, in Subjects (at Least 18 Years Old) Suffering From Post-herpetic Neuralgia (PHN)|Completed||Phase 2|152|Actual|UCB Pharma||3|||f||||f||||||||||2018-06-01 04:40:57.912481|2018-06-01 04:40:57.912481
NCT00160654|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-11-14|2005-09-08|2005-09-12|Estimate|||||||2013-11-14|2013-11-15|Estimate|November 2003||2003-11-30|July 2010|2010-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy|A Phase IV, Open-label, Multi-center, Community-based Trial Studying the Safety and Efficacy of Keppra™ as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy.|Completed||Phase 4|345||UCB Pharma|||||f||||||||||||||2018-06-01 04:40:58.085415|2018-06-01 04:40:58.085415
NCT00160641|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-01-31||2013-04-10|2005-09-08|2005-09-12|Estimate|2013-01-31|2013-03-07|Estimate||||2013-04-10|2013-04-19|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||Baseline Characteristics refer to the Safety Set (SS). SS consists of all enrolled subjects who received at least 1 dose of study medication.|A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis|A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and in the Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Participated in Study CDP870-050|Completed||Phase 3|567|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:40:58.246662|2018-06-01 04:40:58.246662
NCT00160628|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-11-25|2005-09-08|2005-09-12|Estimate|||||||2013-11-25|2013-11-26|Estimate|March 2004||2004-03-31|February 2010|2010-02-28|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy|A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Levetiracetam as Adjunctive Therapy in Adult Subjects With Uncontrolled Partial Epilepsy for Bridging Purpose With a Similar Study on Caucasian Epileptic Subjects|Completed||Phase 3|100||UCB Pharma|||||f||||||||||||||2018-06-01 04:40:59.103527|2018-06-01 04:40:59.103527
NCT00160615|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-03-03|2005-09-08|2005-09-12|Estimate|||||||2015-03-03|2015-03-04|Estimate|September 2001||2001-09-30|September 2009|2009-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method|Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method|Completed||Phase 3|97||UCB Pharma|||||f||||||||||||||2018-06-01 04:40:59.162049|2018-06-01 04:40:59.162049
NCT00160602|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-09-06|2005-09-08|2005-09-12|Estimate|||||||2013-09-06|2013-09-09|Estimate|June 2005||2005-06-30|February 2010|2010-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis|A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.|Completed||Phase 3|590||UCB Pharma|||||f||||||||||||||2018-06-01 04:40:59.237042|2018-06-01 04:40:59.237042
NCT00160589|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-12-13|2005-09-08|2005-09-12|Estimate|||||||2013-12-13|2013-12-16|Estimate|April 2005||2005-04-30|September 2009|2009-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)|A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)|Completed||Phase 4|729||UCB Pharma|||||f||||||||||||||2018-06-01 04:40:59.398487|2018-06-01 04:40:59.398487
NCT00159198|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-09-05|2005-09-07|2005-09-12|Estimate|||||||2008-09-05|2008-09-08|Estimate|September 2002||2002-09-30|September 2008|2008-09-30|June 2007|Actual|2007-06-30|||||Observational|||Amyotrophic Lateral Sclerosis and Frontotemporal Dementia|Genetic Linkage in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia|Terminated|||400|Actual|Assistance Publique - Hôpitaux de Paris|||2|Completed|f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 04:41:23.135801|2018-06-01 04:41:23.135801
NCT00160576|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-12-05|2005-09-08|2005-09-12|Estimate|||||||2013-12-05|2013-12-06|Estimate|July 2003||2003-07-31|September 2009|2009-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias|A Therapeutic Exploratory, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of Levetiracetam up to 4000 mg/Day (500mg Oral Tablets) on Levodopa Induced Dyskinesias in Adults With Idiopathic Parkinson's Disease|Completed||Phase 2|30||UCB Pharma|||||f||||||||||||||2018-06-01 04:40:59.458541|2018-06-01 04:40:59.458541
NCT00160563|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2009-06-17||2015-02-12|2005-09-08|2005-09-12|Estimate|2009-06-17|2009-08-04|Estimate||||2015-02-12|2015-03-03|Estimate|June 2004||2004-06-30|May 2011|2011-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)|The Prolongation of the EPAAC™ Trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). A Multi-country, Double Blind, Placebo (PLC) Controlled, Follow-up Trial With 3 Parallel Groups (LCTZ-LCTZ, LCTZ-PLC and PLC-PLC) : Evaluation of the Long Term Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for an Additional 18 Months Period in Preventing the Onset of Asthma in Children Coming From the EPAAC Trial.|Terminated||Phase 3|207|Actual|UCB Pharma||3||"The predecessor study A00309 (NCT00152464) did not show statistical significance in time to~   onset of asthma between the levocetirizine and placebo groups."|f||||f||||||||||2018-06-01 04:40:59.54665|2018-06-01 04:40:59.54665
NCT00160550|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-11-25|2005-09-08|2005-09-12|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 2001||2001-09-30|September 2009|2009-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures|A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With 3000 mg/Day (Pediatric Target Dose of 60 mg/kg/Day) Oral Levetiracetam (LEV) (166, 250, and 500mg Tablets), in Adult and Pediatric Subjects (4-65 Years) Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic (PGTC) Seizures.|Completed||Phase 3|154||UCB Pharma|||||f||||||||||||||2018-06-01 04:41:00.072316|2018-06-01 04:41:00.072316
NCT00160537|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-12-13|2005-09-08|2005-09-12|Estimate|||||||2013-12-13|2013-12-16|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)|A Monocenter, Double-blind, Randomized Trial, With Two Parallel Groups Comparing the Clinical Efficacy of Levocetirizine 5 mg Capsules and Desloratadine 5 mg Capsules Taken Once a Day Over 3 Weeks of Treatment in Adult Subjects Suffering From Seasonal Allergic Rhinitis (SAR) Due to Grass Pollen|Completed||Phase 4|200||UCB Pharma|||||f||||||||||||||2018-06-01 04:41:00.126914|2018-06-01 04:41:00.126914
NCT00160524|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-08-02||2013-08-02|2005-09-08|2005-09-12|Estimate|2013-08-02|2013-10-10|Estimate||||2013-08-02|2013-10-10|Estimate|July 2004||2004-07-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PRECiSE 3|Baseline Characteristics refer to the Safety Population, including all enrolled subjects who received at least one injection of study treatment in feeder study C87031 [NCT00152490] or C87032 [NCT00152425].|A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]|A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032|Completed||Phase 3|596|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:41:00.240531|2018-06-01 04:41:00.240531
NCT00160511|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-11-25|2005-09-08|2005-09-12|Estimate|||||||2013-11-25|2013-11-26|Estimate|April 2004||2004-04-30|September 2009|2009-09-30|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Interventional|||A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)|A Double-blind, Randomized, Placebo-controlled, Parallel-group, 16 Week, Multicenter Trial Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (≥ 18 Years of Age) Suffering From Postherpetic Neuralgia|Completed||Phase 2|170||UCB Pharma|||||f||||||||||||||2018-06-01 04:41:01.182768|2018-06-01 04:41:01.182768
NCT00160498|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-03-07|2005-09-08|2005-09-12|Estimate|||||||2008-03-07|2008-03-10|Estimate|May 2004||2004-05-31|March 2008|2008-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Dose-Titration Study to Assess the Efficacy of Lercanidipine 10 mg and 20 mg Once Daily p. o. in Hypertensive Subjects (I or II WHO) With Elevated Body Weight.|Completed||N/A|180||UCB Pharma|||||f||||||||||||||2018-06-01 04:41:01.240099|2018-06-01 04:41:01.240099
NCT00160485|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-02-10|2005-09-08|2005-09-12|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2004||2004-06-30|July 2011|2011-07-31|June 2010|Anticipated|2010-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes|Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes|Withdrawn||Phase 4|0|Actual|Tripler Army Medical Center||2||Active Duty principle investigator currently deployed|f||||t||||||||||2018-06-01 04:41:01.293255|2018-06-01 04:41:01.293255
NCT00160472|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-02-25|2005-09-08|2005-09-12|Estimate|||||||2010-02-25|2010-02-26|Estimate|March 2004||2004-03-31|March 2004|2004-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms|Evaluation of Vasopressin and Vasopressin Receptor Expression in the Arteries and Veins of Ovarian Neoplasms|Completed||N/A|110|Anticipated|Tripler Army Medical Center|||||f||||||||||||||2018-06-01 04:41:01.369529|2018-06-01 04:41:01.369529
NCT00160459|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-27|2005-09-08|2005-09-12|Estimate|||||||2008-05-27|2008-05-29|Estimate|May 2000||2000-05-31|May 2008|2008-05-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids|A Phase 2, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Asoprisnil (J867) in Patients With Uterine Leiomyomata.|Completed||Phase 2|129|Actual|Abbott||4|||f||||f||||||||||2018-06-01 04:41:01.430903|2018-06-01 04:41:01.430903
NCT00160446|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-27|2005-09-08|2005-09-12|Estimate|||||||2008-05-27|2008-05-29|Estimate|May 2000||2000-05-31|May 2008|2008-05-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis|A Phase II Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of J867 Administered in Patients With Endometriosis|Completed||Phase 2|130|Actual|Abbott||4|||f||||f||||||||||2018-06-01 04:41:01.503051|2018-06-01 04:41:01.503051
NCT00160433|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-27|2005-09-08|2005-09-12|Estimate|||||||2008-05-27|2008-05-29|Estimate|August 2002||2002-08-31|May 2008|2008-05-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Women With Endometriosis.|A Phase II, 3-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Three Doses of J867 (0.5, 1.5 and 5 mg QD) Versus Placebo in Subjects With Endometriosis|Completed||Phase 2|131|Actual|Abbott||4|||f||||f||||||||||2018-06-01 04:41:01.567641|2018-06-01 04:41:01.567641
NCT00160420|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-27|2005-09-08|2005-09-12|Estimate|||||||2008-05-27|2008-05-29|Estimate|December 2002||2002-12-31|May 2008|2008-05-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A Long-Term Study to Evaluate the Safety of Asoprisnil in the Treatment of Women With Endometriosis From Study M01-398|A Phase 2, 12-Month, Open Label Extension Study to Evaluate the Safety of J867(5 mg QD) in Subjects With Endometriosis|Completed||Phase 2|73|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:41:01.636343|2018-06-01 04:41:01.636343
NCT00160407|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-11-19|2005-09-08|2005-09-12|Estimate|||||||2007-11-19|2007-11-20|Estimate|October 2003||2003-10-31|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)|Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 4|50||St. Louis University|||||f||||||||||||||2018-06-01 04:41:01.703629|2018-06-01 04:41:01.703629
NCT00160394|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-05-24|2005-09-09|2005-09-12|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2004||2004-12-31|May 2017|2017-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris|Multi-Centre, Single-Blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Duac® Gel And Differin® Gel in the Topical Treatment of Mild to Moderate Acne Vulgaris|Completed||Phase 4|130|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:41:01.766204|2018-06-01 04:41:01.766204
NCT00160381|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-27|2005-09-08|2005-09-12|Estimate|||||||2008-05-27|2008-05-29|Estimate|September 2002||2002-09-30|May 2008|2008-05-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids|A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of J867 Versus Placebo in Subjects With Uterine Leiomyomata.|Completed||Phase 3|432|Actual|Abbott||3|||f||||t||||||||||2018-06-01 04:41:01.831499|2018-06-01 04:41:01.831499
NCT00160368|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-04-24|2005-09-08|2005-09-12|Estimate|||||||2007-04-24|2007-04-25|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Effects of Potassium Salts on Blood Pressure and Target Organ Damage|Effect of Potassium Bicarbonate and Potassium Chloride on Blood Pressure and Markers of Target Organ Damage in Hypertensives|Unknown status|Recruiting|Phase 3|45||St George's, University of London|||||f||||||||||||||2018-06-01 04:41:01.907719|2018-06-01 04:41:01.907719
NCT00160355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-04-24|2005-09-08|2005-09-12|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2005||2005-05-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional|||Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome|Haploidentical Hematopoietic Stem Cell Transplantation for Pediatric Patients With Wiskott-Aldrich Syndrome: A Pilot Study|Completed||Phase 1|4|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:41:01.975423|2018-06-01 04:41:01.975423
NCT00160342|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-08-14|2005-09-09|2005-09-12|Estimate|||||||2008-08-14|2008-08-15|Estimate|June 2005||2005-06-30|August 2008|2008-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes|A Multi-Center, Double-Blind, Placebo-Controlled Comparison of Multiple Doses of Esterified Estrogens and Methyltestosterone, in Combination and Alone, in Relieving Vasomotor Symptoms in Postmenopausal Women|Completed||Phase 2|1251|Anticipated|Solvay Pharmaceuticals||9|||f||||f||||||||||2018-06-01 04:41:02.062614|2018-06-01 04:41:02.062614
NCT00160329|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-07-19|2005-09-10|2005-09-12|Estimate|||||||2011-07-19|2011-07-21|Estimate|January 2004||2004-01-31|July 2011|2011-07-31|March 2009|Actual|2009-03-31|April 2007|Actual|2007-04-30||Interventional|||Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia|The De-Escalate Trial: Atazanavir or Atazanavir/Ritonavir Substitution for Ritonavir Boosted PI Therapy in HIV-Infected Individuals Experiencing Ongoing HIV Viremia and Hyperlipidemia: A Randomized Controlled Pilot Study|Completed||Phase 3|60|Actual|Stanford University|||||f||||t||||||||||2018-06-01 04:41:02.26226|2018-06-01 04:41:02.26226
NCT00160316|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-11|2005-09-09|2005-09-12|Estimate|||||||2008-03-11|2008-03-12|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination|Endometrial Safety of a Low Dose Continuous Combined 17 -Estradiol/Dydrogesterone Hormone Replacement Regimen (E2 0.5 mg/ D 2.5 mg) in Postmenopausal Women - A One-Year, Open Label, Multi-Center Study|Completed||Phase 3|454|Actual|Solvay Pharmaceuticals||1|||f||||f||||||||||2018-06-01 04:41:02.418225|2018-06-01 04:41:02.418225
NCT00160303|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-07-22|2005-09-10|2005-09-12|Estimate|||||||2011-07-22|2011-07-25|Estimate|January 2005||2005-01-31|July 2011|2011-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Efficacy Study of Prolotherapy vs Corticosteroid for Tennis Elbow|Prolotherapy vs. Corticosteroid Therapy for the Treatment of Lateral Epicondylitis of the Elbow, A Randomized Controlled Trial.|Completed||Phase 3|56|Anticipated|Spaulding Rehabilitation Hospital|||||f||||||||||||||2018-06-01 04:41:02.514559|2018-06-01 04:41:02.514559
NCT00160290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-04-29|2005-09-09|2005-09-12|Estimate|||||||2008-04-29|2008-05-06|Estimate|March 2002||2002-03-31|April 2008|2008-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Trial to Evaluate Effect of Lactulose on Hard Stools in Patients With Hemorrhoids or Anal Fissures|An Open, Randomized, Parallel Group, Single Center Study to Investigate the Effect of Lactulose Versus Plantago Ovate on the Quality of Life of Patients With Hard Stools and Hemorrhoids or Anal Fissure|Terminated||Phase 4|97|Actual|Solvay Pharmaceuticals||2||This trial discontinued on 30 JUN 2006 due to a lack of enrolment|f||||f||||||||||2018-06-01 04:41:02.583842|2018-06-01 04:41:02.583842
NCT00160277|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-29|2005-09-09|2005-09-12|Estimate|||||||2009-01-29|2009-01-30|Estimate|July 2005||2005-07-31|January 2009|2009-01-31||||||||Interventional|||Efficacy and Safety of Moxonidine in Indian Patients|Open Label, Multi-Center, Force-Titration Study to Evaluate the Efficacy and Safety of Moxonidine in Ambulatory Subjects With Essential Hypertension|Completed||Phase 3|100||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:41:02.691273|2018-06-01 04:41:02.691273
NCT00160121|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-09-03|2005-09-10|2005-09-12|Estimate|||||||2014-09-03|2014-09-05|Estimate|January 2005||2005-01-31|December 2013|2013-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease|A Phase IV, Open-Label, Multi-Center Trial Evaluating the Efficacy of Fosrenol Compared to Existing Therapy in Adults With End Stage Renal Disease Treated for Hyperphosphatemia|Completed||Phase 4|2500||Shire|||||f||||||||||||||2018-06-01 04:41:07.107409|2018-06-01 04:41:07.107409
NCT00160264|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-29|2005-09-09|2005-09-12|Estimate|||||||2009-01-29|2009-01-30|Estimate|January 2003||2003-01-31|January 2009|2009-01-31||||||||Interventional|||Study to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal Women|A Randomized, Double-Blind, Multicenter, Parallel Pilot Clinical Trial to Study the Efficay of a Treatment of Lactulose + Vitamin D + Calcium 0.5 g Concurrently Controlled With a Standard Treatment (Vit D + Calcium) in Bone Mass Preservation Among Postmenopausal Women|Completed||Phase 4|40||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:41:02.760217|2018-06-01 04:41:02.760217
NCT00160251|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2011-05-13||2015-10-13|2005-09-08|2005-09-12|Estimate|2011-11-23|2011-12-29|Estimate||||2015-10-13|2015-10-14|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)|PEG-Intron/REBETOL vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 (HCV-1) Peginterferon Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding Phase 2 Study|Completed||Phase 2|357|Actual|Merck Sharp & Dohme Corp.|The implementation of amendment 2 led to changes in boceprevir dose in all treatment arms and different overall lengths of therapy within the same treatment arm, making the SVR endpoint uninterpretable.|9|||f||||t||||||||||2018-06-01 04:41:02.901647|2018-06-01 04:41:02.901647
NCT00160238|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-12-21|2005-09-09|2005-09-12|Estimate|||||||2006-12-21|2006-12-22|Estimate|January 2003||2003-01-31|December 2006|2006-12-31||||||||Interventional|||Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy|A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease|Completed||Phase 4|20||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:41:04.756724|2018-06-01 04:41:04.756724
NCT00160225|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-11-09|2005-09-09|2005-09-12|Estimate|||||||2007-11-09|2007-11-14|Estimate|July 2005||2005-07-31|November 2007|2007-11-30||||||||Interventional|||Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension|A Randomized, Double-Blind, Placebo Controlled, Two-Treatment and Two-Period Cross-Over, Mono-Center Study to Evaluate the Efficacy and Safety of Daglutril 300 mg Once Daily Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:41:04.807195|2018-06-01 04:41:04.807195
NCT00160212|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-01-29|2005-09-09|2005-09-12|Estimate|||||||2009-01-29|2009-01-30|Estimate|December 2004||2004-12-31|January 2009|2009-01-31||||||||Interventional|||Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension|A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:41:04.861025|2018-06-01 04:41:04.861025
NCT00160199|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-02-11||2010-06-30|2005-09-08|2005-09-12|Estimate|2010-05-03|2010-06-02|Estimate||||2010-06-30|2010-07-07|Estimate|November 2004||2004-11-30|June 2010|2010-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion|Evaluation of Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding in Subjects With Secondary Amenorrhea|Completed||Phase 4|240|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:41:05.989577|2018-06-01 04:41:05.989577
NCT00160186|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-03-28|2005-09-09|2005-09-12|Estimate|||||||2008-03-28|2008-03-31|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Gastrectomy Study: Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy|Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy|Completed||Phase 4|40||Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:41:06.32543|2018-06-01 04:41:06.32543
NCT00160173|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-07-11|2005-09-08|2005-09-12|Estimate|||||||2013-07-11|2013-07-15|Estimate||||July 2013|2013-07-31||||||||Interventional|||Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy|Efficacy Study Comparing 0.9 g and 1.25 g EstroGelÂ® 0.03% Doses With Placebo in the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated With Menopause|Completed||Phase 4|||ASCEND Therapeutics|||||f||||||||||||||2018-06-01 04:41:06.519738|2018-06-01 04:41:06.519738
NCT00160160|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-01-29|2005-09-08|2005-09-12|Estimate|||||||2009-01-29|2009-01-30|Estimate|October 2004||2004-10-31|January 2009|2009-01-31||||||||Interventional|||Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes|A Multi-Center, Double-Blind, Randomized Study Comparing the Efficacy of Combination Therapy of Eprosartan Respectively Ramipril With Low-Dose Hydrochlorothiazide and Moxonidine on Blood Pressure Levels in Patients With Hypertension and Associated Diabetes Mellitus Type 2|Completed||N/A|440||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:41:06.746997|2018-06-01 04:41:06.746997
NCT00160147|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08||2015-01-29|2015-01-29|2005-09-08|2005-09-12|Estimate||||2015-01-29|2015-02-09|Estimate|2015-01-29|2015-02-09|Estimate|December 2005||2005-12-31|June 2009|2009-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type|A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type|Terminated||Phase 3|60|Actual|Solvay Pharmaceuticals||2||The study was discontinued prematurely on 25 February 2008 due to slow enrollment|f||||||||||||||2018-06-01 04:41:06.907589|2018-06-01 04:41:06.907589
NCT00160134|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-01-29|2005-09-08|2005-09-12|Estimate|||||||2009-01-29|2009-01-30|Estimate|January 2005||2005-01-31|January 2009|2009-01-31||||||||Interventional|||Study to Evaluate Cardiac Hemodynamics and Safety of SLV320 in Subjects With Congestive Heart Failure|A Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Parallel Group, Single Dose Study to Evaluate Cardiac Hemodynamics and Safety During Right Heart Catheterization of Three IV Doses of SLV320 in Subjects With Congestive Heart Failure Requiring Diuretic Treatment|Completed||Phase 2|||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:41:07.031621|2018-06-01 04:41:07.031621
NCT00160108|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-03-19|2005-09-10|2005-09-12|Estimate|||||||2018-03-19|2018-03-20|Actual|July 2005|Actual|2005-07-31|September 2006|2006-09-30|July 2007|Actual|2007-07-31|||||Interventional|||A Dietary Intervention- Randomized Controlled Trial (DIRECT) Study; BGU-Harvard-Robarts Collaboration||Completed||Phase 1|300||The S. Daniel Abraham International Center for Health and Nutrition|||||f||||||||||||||2018-06-01 04:41:07.257974|2018-06-01 04:41:07.257974
NCT00160095|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-05-06|2005-09-09|2005-09-12|Estimate|||||||2015-05-06|2015-05-07|Estimate|July 2001||2001-07-31|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2010|Actual|2010-03-31||Observational|||Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas|Patient Selection for Hypoxia Modifying Treatments Based on Functional Microregional Imaging of Tumor Vasculature, Oxygenation and Proliferation in Squamous Cell Carcinoma of the Larynx|Completed|||79|Actual|Radboud University|||||f||||||||||Samples With DNA|"~     Tumor biopsies~   "|||2018-06-01 04:41:07.34121|2018-06-01 04:41:07.34121
NCT00160082|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-04-02|2005-09-09|2005-09-12|Estimate|||||||2007-04-02|2007-04-03|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|May 2003||2003-05-31|||||Interventional|||Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)|Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS): A Randomized, Two-Arm, Parallel, Double-Blind, Multi-Centre, Placebo Controlled Study|Completed||N/A|124||Calliditas Therapeutics AB|||||f||||||||||||||2018-06-01 04:41:07.412739|2018-06-01 04:41:07.412739
NCT00160069|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-12-02|2005-09-08|2005-09-12|Estimate|||||||2014-12-02|2014-12-04|Estimate|August 2005||2005-08-31|December 2014|2014-12-31|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer|Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|128|Actual|Bayer||3|||f||||f||||||||||2018-06-01 04:41:07.498868|2018-06-01 04:41:07.498868
NCT00160056|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-05-08|2005-09-09|2005-09-12|Estimate|||||||2015-05-08|2015-05-12|Estimate|April 2005||2005-04-30|May 2015|2015-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity|The Effect of Antecedent Hypoglycaemia on β2-adrenergic Sensitivity in Subjects With Homozygous Arg16 and gly16 Polymorphism of the β2-adrenergic Receptor|Completed||N/A|16|Actual|Radboud University||1|||f||||||||||||||2018-06-01 04:41:07.599031|2018-06-01 04:41:07.599031
NCT00160043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-12-14|2005-09-09|2005-09-12|Estimate|||||||2014-12-14|2014-12-16|Estimate|March 2005||2005-03-31|December 2014|2014-12-31|November 2008|Actual|2008-11-30|August 2007|Actual|2007-08-31||Interventional|||Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.|Phase II Open-label Study to Investigate the Efficacy and Safety of PTK787/ZK 222584 Orally Administered Once Daily or Twice Daily at 1250 mg as Second-line Monotherapy in Patients With Stage IIIB or Stage IV Non-small-cell Lung Cancer (NSCLC)|Completed||Phase 2|112|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:41:07.683848|2018-06-01 04:41:07.683848
NCT00160030|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-12-04|2005-09-09|2005-09-12|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 2004||2004-09-30|December 2009|2009-12-31||||October 2007|Actual|2007-10-31||Interventional|||Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer|Phase II Study Comparing Radiochemotherapy With the Folfox 4 Regimen Versus Radiochemotherapy With 5FU-Cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Esophageal Cancer|Completed||Phase 2|97|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:41:07.765677|2018-06-01 04:41:07.765677
NCT00160017|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-11-27|2005-09-09|2005-09-12|Estimate|||||||2015-11-27|2015-11-30|Estimate|January 2005||2005-01-31|November 2015|2015-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative|Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative to Improve Diabetes Care, Its Health Outcomes and Economic Costs|Completed|||1861|Actual|Radboud University|||2||f||||||||||||||2018-06-01 04:41:07.851481|2018-06-01 04:41:07.851481
NCT00160004|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-06-05|2005-09-09|2005-09-12|Estimate|||||||2009-06-05|2009-06-08|Estimate|March 2006||2006-03-31|June 2009|2009-06-30|December 2008|Actual|2008-12-31|||||Interventional|||The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis|The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis|Terminated||Phase 1/Phase 2|20|Anticipated|Radboud University||||problems with including patients and a large multicenter Trial is now starting as follow-up|f||||||||||||||2018-06-01 04:41:07.991403|2018-06-01 04:41:07.991403
NCT00159991|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-02-12|2005-09-08|2005-09-12|Estimate|||||||2008-02-12|2008-02-15|Estimate|February 2002||2002-02-28|January 2008|2008-01-31|February 2015|Anticipated|2015-02-28|February 2011|Anticipated|2011-02-28||Interventional|CARRPO||Copenhagen Arterial Revascularization Randomized Patency and Outcome Trial|Arterial Revascularization for Coronary Bypass Surgery: A Randomized Trial Comparing the Outcome After Using LIMA + Vein Grafts Versus Total Arterial Revascularization With LIMA + RIMA + Radial Artery Grafts|Unknown status|Active, not recruiting|Phase 3|331|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-06-01 04:41:08.057769|2018-06-01 04:41:08.057769
NCT00159978|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-05-06|2005-09-09|2005-09-12|Estimate|||||||2015-05-06|2015-05-07|Estimate|July 2005||2005-07-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Validation of 18F-MISO-PET and 18F-FLT-PET|Validation of 18F-MISO-PET and 18F-FLT-PET by Immunohistochemical Assessment of Head and Neck Cancer Resection Specimen|Terminated|||21|Actual|Radboud University||||Problems with FMISO supply|f||||f||||||Samples With DNA|"~     Tumor resection specimen~   "|||2018-06-01 04:41:08.123109|2018-06-01 04:41:08.123109
NCT00159965|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-08-11||2014-11-07|2005-09-10|2005-09-12|Estimate|2011-01-04|2011-01-25|Estimate||||2014-11-07|2014-11-20|Estimate|December 2003||2003-12-31|November 2014|2014-11-30|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|NES||Treatments for Psychogenic Nonepileptic Seizures (NES)|Treatment for Psychogenic Nonepileptic Seizures: A Pilot, 12 Week, Prospective, Randomized, Placebo-controlled, Double-blind, Clinical Trial of Sertraline in the Treatment of Comorbid Psychiatric Disorders in NES|Completed||Phase 4|38|Actual|Rhode Island Hospital|pilot sample size; drop-outs because of some patient’s concern that they would receive the placebo, despite the equipoise that exists for NES treatment(s). Excluding patients who did not have vEEG may present a potential sampling bias.|2|||f||||t||||||||||2018-06-01 04:41:08.216808|2018-06-01 04:41:08.216808
NCT00159952|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-11-26|2005-09-08|2005-09-12|Estimate|||||||2013-11-26|2013-11-27|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|November 2007|Actual|2007-11-30|March 2007|Actual|2007-03-31||Interventional|||Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock|Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock|Completed||Phase 2/Phase 3|90|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:41:08.767|2018-06-01 04:41:08.767
NCT00159939|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-06-09|2005-09-08|2005-09-12|Estimate|||||||2008-06-09|2008-06-11|Estimate|February 2004||2004-02-29|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Prone-Supine Study II: The Effect of Prone Positioning for Patients Affected by Acute Respiratory Distress Syndrome|Prone-Supine Study II: The Effect of Prone Positioning for Patients Affected by Acute Respiratory Distress Syndrome|Completed||Phase 3|344|Actual|Policlinico Hospital||2|||f||||t||||||||||2018-06-01 04:41:08.85548|2018-06-01 04:41:08.85548
NCT00159926|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-01-04|2005-09-08|2005-09-12|Estimate|||||||2008-01-04|2008-01-14|Estimate|January 2003||2003-01-31|November 2007|2007-11-30|February 2004|Actual|2004-02-29|||||Interventional|||Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response|Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ?|Terminated||Phase 3|30|Actual|Rigshospitalet, Denmark||2||For financial and logistical reasons|f||||f||||||||||2018-06-01 04:41:08.958271|2018-06-01 04:41:08.958271
NCT00159913|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2009-06-02||2014-01-23|2005-09-08|2005-09-12|Estimate|2009-06-02|2009-07-21|Estimate||||2014-01-23|2014-02-21|Estimate|August 2003||2003-08-31|January 2014|2014-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.|A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension.|Completed||Phase 3|235|Actual|Pfizer||4|||f||||t||||||||||2018-06-01 04:41:09.083124|2018-06-01 04:41:09.083124
NCT00159900|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-04-04|2005-09-08|2005-09-12|Estimate|||||||2008-04-04|2008-04-08|Estimate|May 2005||2005-05-31|April 2008|2008-04-30|January 2006||2006-01-31|||||Interventional|||Quality of Erection Study|A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate|Completed||Phase 4|300||Pfizer|||||f||||||||||||||2018-06-01 04:41:10.081696|2018-06-01 04:41:10.081696
NCT00159887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-06-07|2005-09-11|2005-09-12|Estimate|||||||2011-06-07|2011-06-08|Estimate|December 2002||2002-12-31|June 2011|2011-06-30|February 2007|Actual|2007-02-28|||||Interventional|||Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension|A Multi-Centre, Multinational, Long-Term Extension Study, to Assess the Safety and Toleration of Subject Optimised Treatment Regimens of Oral Sildenafil Citrate for Pulmonary Arterial Hypertension in Subjects Who Have Completed Study A1481140.|Completed||Phase 3|260|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:41:10.155217|2018-06-01 04:41:10.155217
NCT00159874|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-12-19||2014-07-17|2005-09-08|2005-09-12|Estimate|2014-07-17|2014-08-11|Estimate||||2014-07-17|2014-08-11|Estimate|January 2004||2004-01-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children|A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil Citrate In The Treatment Of Subjects Who Have Completed Study A1481131|Completed||Phase 3|234|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 04:41:10.414702|2018-06-01 04:41:10.414702
NCT00159861|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-04-02||2013-12-20|2005-09-11|2005-09-12|Estimate|2010-12-13|2011-01-12|Estimate||||2013-12-20|2014-01-28|Estimate|July 2003||2003-07-31|December 2013|2013-12-31|January 2006|Actual|2006-01-31|||||Interventional|||The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH|A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination With Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension.|Completed||Phase 3|267|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:41:12.51724|2018-06-01 04:41:12.51724
NCT00159848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-05-02|2005-09-08|2005-09-12|Estimate|||||||2013-05-02|2013-05-03|Estimate|September 2003||2003-09-30|May 2013|2013-05-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra|Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil|Completed||Phase 4|8000||Pfizer|||||f||||||||||||||2018-06-01 04:41:16.749778|2018-06-01 04:41:16.749778
NCT00159835|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-04-21|2005-09-08|2005-09-12|Estimate|||||||2015-04-21|2015-04-22|Estimate|February 1999||1999-02-28|April 2015|2015-04-30|March 2005||2005-03-31|||||Interventional|IDEAL||Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD|Atorvastatin Compared With Simvastatin In The Prevention of CHD Morbidity And Mortality In Patients With CHD|Completed||Phase 4|8600||Pfizer|||||f||||||||||||||2018-06-01 04:41:16.846919|2018-06-01 04:41:16.846919
NCT00159822|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2009-12-02||2010-01-13|2005-09-08|2005-09-12|Estimate|2009-12-02|2010-01-07|Estimate||||2010-01-13|2010-01-20|Estimate|July 2005||2005-07-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Voriconazole For Chronic Bronchopulmonary Aspergillosis|Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts|Completed||Phase 2/Phase 3|48|Actual|Pfizer|Study treatment duration is at least 6 months for subjects with best achievable response after 3 months of treatment, of 9 months for subjects with best achievable response after 6 months of treatment and of 12 months in other cases.|1|||f||||f||||||||||2018-06-01 04:41:18.196084|2018-06-01 04:41:18.196084
NCT00159809|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-01-18|2005-09-08|2005-09-12|Estimate|||||||2008-01-18|2008-01-23|Estimate|March 2004||2004-03-31|January 2008|2008-01-31|August 2004||2004-08-31|||||Interventional|||Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction|A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED)|Completed||Phase 4|140||Pfizer|||||f||||||||||||||2018-06-01 04:41:18.584508|2018-06-01 04:41:18.584508
NCT00159796|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-05-29|2005-09-10|2005-09-12|Estimate|||||||2017-05-29|2017-05-31|Actual|December 14, 2004|Actual|2004-12-14|May 2017|2017-05-31|April 28, 2006|Actual|2006-04-28|March 28, 2006|Actual|2006-03-28||Interventional|||3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)|A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501005 (Secondary Title: ARES)|Completed||Phase 3|489|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:41:18.71815|2018-06-01 04:41:18.71815
NCT00159783|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-04-15||2015-02-06|2005-09-11|2005-09-12|Estimate|2010-06-17|2010-07-16|Estimate||||2015-02-06|2015-02-25|Estimate|July 2005||2005-07-31|February 2015|2015-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)|A Double-Blind, 40-Week Continuation Study Evaluating the Safety of Asenapine and Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501007 (Secondary Title: ARES)|Completed||Phase 3|218|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:41:18.826281|2018-06-01 04:41:18.826281
NCT00159406|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-02-14|2005-09-08|2005-09-12|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2003||2003-10-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Laser Prostatectomy Database and Registry|Laser Prostatectomy for Benign Prostatic Hyperplasia: A Registry and Database|Recruiting|||3000|Anticipated|Indiana Kidney Stone Institute|||1||f||||f||||||||||2018-06-01 04:41:22.050655|2018-06-01 04:41:22.050655
NCT00159770|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-12-28|2005-09-11|2005-09-12|Estimate|||||||2006-12-28|2007-01-01|Estimate|November 2001||2001-11-30|December 2006|2006-12-31|September 2004||2004-09-30|||||Interventional|||Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients|Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.|Completed||Phase 3|290||Pfizer|||||f||||||||||||||2018-06-01 04:41:19.310456|2018-06-01 04:41:19.310456
NCT00159757|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-08-01|2005-09-11|2005-09-12|Estimate|||||||2007-08-01|2007-08-02|Estimate|November 2003||2003-11-30|August 2007|2007-08-31|February 2005||2005-02-28|||||Interventional|||12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients|12 Week Open Label, Multicenter, Non-Comparative Switch Study Evaluating Efficacy, Tolerability And Safety Of Oral Ziprasidone In Treatment Of Patients Suffering From Schizophrenia Who Have Already Been Treated With An Other Antipsychotic.|Terminated||Phase 4|150||Pfizer||||See Detailed Description for Termination Reason|f||||||||||||||2018-06-01 04:41:19.413785|2018-06-01 04:41:19.413785
NCT00159744|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-05-29|2005-09-10|2005-09-12|Estimate|||||||2017-05-29|2017-05-31|Actual|November 30, 2004|Actual|2004-11-30|May 2017|2017-05-31|April 29, 2006|Actual|2006-04-29|April 29, 2006|Actual|2006-04-29||Interventional|||3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)|A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in In-Patients With an Acute Manic Episode Clinical Trial Protocol 7501004 (Secondary Title: ARES)|Completed||Phase 3|488|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:41:19.46982|2018-06-01 04:41:19.46982
NCT00159731|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-03-14|2005-09-10|2005-09-12|Estimate|||||||2008-03-14|2008-03-18|Estimate|January 2005||2005-01-31|July 2006|2006-07-31|May 2006||2006-05-31|||||Interventional|||Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy|An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy|Completed||Phase 4|160||Pfizer|||||||||||||||||||2018-06-01 04:41:19.541772|2018-06-01 04:41:19.541772
NCT00159718|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-01-29|2005-09-08|2005-09-12|Estimate|||||||2008-01-29|2008-01-31|Estimate|July 2001||2001-07-31|January 2008|2008-01-31|January 2007||2007-01-31|||||Interventional|DUAAL||Double Blind Atorvastatin Amlodipine Study|Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease.|Completed||Phase 4|360||Pfizer|||||f||||||||||||||2018-06-01 04:41:19.719773|2018-06-01 04:41:19.719773
NCT00159705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-10-09|2005-09-08|2005-09-12|Estimate|||||||2008-10-09|2008-10-10|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy|A Randomized Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy|Completed||Phase 3|276|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:41:19.834826|2018-06-01 04:41:19.834826
NCT00159692|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-02-06|2005-09-08|2005-09-12|Estimate|||||||2009-02-06|2009-02-10|Estimate|March 2003||2003-03-31|February 2009|2009-02-28|August 2005|Actual|2005-08-31|||||Interventional|ADHERE||Amlodipine Diabetic Hypertension Efficacy Response Trial|A Multi-Center, Randomized, Double-Blind, Double-Dummy Study Evaluating The Safety and Efficacy Of The Addition Of Amlodipine To Quinapril Or Losartan In The Treatment Of Diabetic Hypertensive Subjects|Completed||Phase 4|739|Actual|Pfizer|||||||||||||||||||2018-06-01 04:41:19.977187|2018-06-01 04:41:19.977187
NCT00159679|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-04-28|2005-09-08|2005-09-12|Estimate|||||||2009-04-28|2009-04-29|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|October 2005|Actual|2005-10-31|||||Interventional|||Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy|A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy|Completed||Phase 4|167|Actual|Pfizer|||||||||||||||||||2018-06-01 04:41:20.04338|2018-06-01 04:41:20.04338
NCT00159666|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-03-07|2005-09-08|2005-09-12|Estimate|||||||2008-03-07|2008-03-11|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|June 2006||2006-06-30|||||Interventional|||Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia|A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Pain Relief in Subjects With Post Therapeutic Neuralgia (PHN) Treated With Pregabalin (150 - 600 Mg/Day Flexible Optimized Dose or 300 Mg/Day Fixed Dose) or Placebo|Completed||Phase 4|255||Pfizer|||||||||||||||||||2018-06-01 04:41:20.151112|2018-06-01 04:41:20.151112
NCT00159653|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-10-08|2005-09-08|2005-09-12|Estimate|||||||2012-10-08|2012-10-10|Estimate|July 2005||2005-07-31|October 2012|2012-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma|A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Xalacom Given In The Evening, Xalatan Given In The Evening, And Timolol Given In The Morning In Patients With Open Angle Glaucoma Or Ocular Hypertension.|Completed||Phase 3|500|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:41:20.282901|2018-06-01 04:41:20.282901
NCT00159640|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-03-27|2005-09-07|2005-09-12|Estimate|||||||2007-03-27|2007-03-28|Estimate|February 2004||2004-02-29|March 2007|2007-03-31||||||||Interventional|||Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia|A Multi-Center, Randomized, Double Blind, Dose-Response, Placebo And Gabapentin Controlled Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia|Terminated||Phase 2|315||Pfizer|||||f||||||||||||||2018-06-01 04:41:20.428652|2018-06-01 04:41:20.428652
NCT00159627|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-01-28|2005-09-07|2005-09-12|Estimate|||||||2008-01-28|2008-01-29|Estimate|August 2004||2004-08-31|January 2008|2008-01-31||||||||Interventional|||Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).|A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Effects of KW-3902 on Diuresis in Patients With Congestive Heart Failure (CHF) Refractory to High Dose Diuretic Therapy|Completed||Phase 2|52||NovaCardia, Inc.|||||f||||||||||||||2018-06-01 04:41:20.523003|2018-06-01 04:41:20.523003
NCT00159614|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-01-28|2005-09-07|2005-09-12|Estimate|||||||2008-01-28|2008-01-29|Estimate|September 2005||2005-09-30|January 2008|2008-01-31||||||||Interventional|||Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment|Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment|Completed||Phase 2|30||NovaCardia, Inc.|||||f||||||||||||||2018-06-01 04:41:20.580209|2018-06-01 04:41:20.580209
NCT00159601|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-03-31|2005-09-09|2005-09-12|Estimate|||||||2017-03-31|2017-04-04|Actual|June 2003|Actual|2003-06-30|March 2017|2017-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Quality of Life and Mental Health in Children and Adolescents|Quality of Life and Mental Health in Children and Adolescents in a Child and Adolescent Psychiatric Outpatient Clinic and in the Normal Population|Completed|||2342|Actual|Norwegian University of Science and Technology|||2||f||||f|f|f||||||No||2018-06-01 04:41:20.723937|2018-06-01 04:41:20.723937
NCT00159588|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-07-18|2005-09-09|2005-09-12|Estimate|||||||2016-07-18|2016-07-19|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|December 2007|Actual|2007-12-31|November 2006|Actual|2006-11-30||Interventional|||Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly?|Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly? A Randomized Multi-centre Follow-up.|Completed||N/A|64|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-06-01 04:41:20.789261|2018-06-01 04:41:20.789261
NCT00159575|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-01-02|2005-09-09|2005-09-12|Estimate|||||||2012-01-02|2012-01-05|Estimate|March 2005||2005-03-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|August 2009|Actual|2009-08-31||Interventional|||Metformin in Assisted Reproduction-MET-AR-study|Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome|Terminated||Phase 4|150|Actual|Norwegian University of Science and Technology||1||Slow patient recruitment and expiry of study medication(aug2009)|f||||f||||||||||2018-06-01 04:41:20.858033|2018-06-01 04:41:20.858033
NCT00159562|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-06-04|2005-09-09|2005-09-12|Estimate|||||||2016-06-04|2016-06-07|Estimate|September 2005||2005-09-30|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Psycho-education of Patients With Bipolar Disorder|Effects of Psycho-education of Patients With Bipolar Disorder|Completed||N/A|85|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:41:20.932813|2018-06-01 04:41:20.932813
NCT00159549|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-16|2005-09-08|2005-09-12|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2000||2000-01-31|January 2017|2017-01-31|December 2005||2005-12-31|||||Interventional|||Long Term Effect of an Education and Training Program for Patients With Chronic Obstructive Pulmonary Disease|Long Term Effect of an Education and Training Program for Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|60|Actual|Norwegian University of Science and Technology|||||f||||||||||||||2018-06-01 04:41:21.002601|2018-06-01 04:41:21.002601
NCT00159536|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-04-17|2005-09-08|2005-09-12|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2005||2005-02-28|April 2018|2018-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|PregMet||Metformin in Pregnant PCOS Women|Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)|Completed||Phase 3|257|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-06-01 04:41:21.060481|2018-06-01 04:41:21.060481
NCT00159523|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-02-04|2005-09-08|2005-09-12|Estimate|||||||2016-02-04|2016-02-05|Estimate|December 2003||2003-12-31|August 2015|2015-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Impact in Off-spring of Mothers After Perinatal Daily Intake of a Probiotic|The Impact of Perinatal Daily Supplement of a Probiotic (Lactobacillus Rhamnosus GG), Given to Mothers, on Immunological Development, Atopic Sensitisation and Allergic Disease in Their Off-spring|Completed||N/A|416|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-06-01 04:41:21.155782|2018-06-01 04:41:21.155782
NCT00159510|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-10-05|2005-09-08|2005-09-12|Estimate|||||||2015-10-05|2015-10-06|Estimate|April 2004||2004-04-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MB-NO||Studies of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome|A Controlled Prospective Randomized Open-Label Study of Methylene Blue and Inhaled Nitric Oxide in Patients With Septic Shock and Acute Lung Injury|Terminated||Phase 1|28|Actual|Northern State Medical University||4||Inability to recruit the patients due to the short supply and changed local hospital protocol|f||||f||||||||||2018-06-01 04:41:21.232205|2018-06-01 04:41:21.232205
NCT00159497|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-03-28|2005-09-09|2005-09-12|Estimate|||||||2014-03-28|2014-03-31|Estimate|October 1998||1998-10-31|March 2014|2014-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bone Remodeling Around HA-coated Acetabular Cups.|Bone Remodeling Around HA-coated Acetabular Cups.|Completed||Phase 4|100|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-06-01 04:41:21.308694|2018-06-01 04:41:21.308694
NCT00159484|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-06-23|2005-09-08|2005-09-12|Estimate|||||||2017-06-23|2017-06-27|Actual|October 2004||2004-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer|Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer (CEPO906AUS10)|Active, not recruiting||Phase 1/Phase 2|75|Actual|University of Southern California||1|||f||||t||||||||||2018-06-01 04:41:21.3753|2018-06-01 04:41:21.3753
NCT00159471|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-05-20|2005-09-10|2005-09-12|Estimate|||||||2014-05-20|2014-05-22|Estimate|February 2005||2005-02-28|May 2014|2014-05-31|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.|A Pilot Trial of Germline Polymorphisms as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.|Terminated||N/A|1|Actual|University of Southern California||||Insufficient Accrual|f||||t||||||||||2018-06-01 04:41:21.447179|2018-06-01 04:41:21.447179
NCT00159458|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-05-20|2005-09-08|2005-09-12|Estimate|||||||2014-05-20|2014-05-22|Estimate|July 2003||2003-07-31|May 2014|2014-05-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer|Phase II Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer|Terminated||Phase 2|7|Actual|University of Southern California||||Insufficient Accrual|||||||||||||||2018-06-01 04:41:21.504577|2018-06-01 04:41:21.504577
NCT00159445|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-05-20|2005-09-07|2005-09-12|Estimate|||||||2014-05-20|2014-05-22|Estimate|March 2004||2004-03-31|May 2014|2014-05-31|November 2007|Actual|2007-11-30|March 2007|Actual|2007-03-31||Interventional|||Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer|Phase II Study of Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|53|Anticipated|University of Southern California|||||f||||||||||||||2018-06-01 04:41:21.556804|2018-06-01 04:41:21.556804
NCT00159432|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2013-11-27||2014-07-22|2005-09-07|2005-09-12|Estimate|2013-11-27|2014-01-15|Estimate||||2014-07-22|2014-07-29|Estimate|February 2005||2005-02-28|July 2014|2014-07-31|March 2013|Actual|2013-03-31|June 2009|Actual|2009-06-30||Interventional||All the participants who were enrolled are included in the analysis as per protocol.|Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer|Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer|Completed||Phase 2|63|Actual|University of Southern California||1|||f||||||||||||||2018-06-01 04:41:21.629971|2018-06-01 04:41:21.629971
NCT00159419|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2013-11-12||2017-05-17|2005-09-07|2005-09-12|Estimate|2016-02-29|2016-03-31|Estimate||||2017-05-17|2017-06-14|Actual|August 1999||1999-08-31|May 2017|2017-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Bisphosphonate Therapy for Osteogenesis Imperfecta|Bisphosphonate Therapy for Osteogenesis Imperfecta|Completed||Phase 4|18|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 04:41:21.889166|2018-06-01 04:41:21.889166
NCT00159380|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-06-03|2005-09-09|2005-09-12|Estimate|||||||2015-06-03|2015-06-04|Estimate|September 2003||2003-09-30|April 2008|2008-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects|A Double Blind, Crossover Placebo-controlled Study to Evaluate the Effect of L-arginine and Aminoguanidine on Bronchial, Alveolar and Nasal NO and NO Metabolites in Exhaled Air, Breath Condensate, Saliva, Nasal Lavage Fluid and Induced Sputum in 10 Normal and 15 Asthmatic Subjects|Completed||N/A|25|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.169378|2018-06-01 04:41:22.169378
NCT00159367|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-02-16|2005-09-09|2005-09-12|Estimate|||||||2016-02-16|2016-02-17|Estimate|January 2005||2005-01-31|August 2008|2008-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle|The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|20|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.215243|2018-06-01 04:41:22.215243
NCT00159354|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-05-28|2005-09-09|2005-09-12|Estimate|||||||2015-05-28|2015-05-29|Estimate|June 2005||2005-06-30|November 2007|2007-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Measurement of Smoking−Induced Neutrophil Activation|Evaluation of Smoking−Induced Neutrophil Activation as a Potential Biomarker of Response to Therapeutic Interventions in COPD: Proof of Concept Study|Completed||N/A|16|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.294037|2018-06-01 04:41:22.294037
NCT00159341|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-08-12|2005-09-08|2005-09-12|Estimate|||||||2008-08-12|2008-08-15|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Cigarette Smoke Nasal and Whole Blood Challenge in Patients With COPD|Completed||Phase 1|16|Actual|Imperial College London|||||f||||f||||||||||2018-06-01 04:41:22.415323|2018-06-01 04:41:22.415323
NCT00159328|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-08-12|2005-09-09|2005-09-12|Estimate|||||||2008-08-12|2008-08-13|Estimate|March 2003||2003-03-31|August 2008|2008-08-31|December 2006||2006-12-31|||||Interventional|||Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids|Phase 4 Study of Magnetic Resonance Guided Focused Ultrasound Surgery Following Gonadotrophin Releasing Hormone Agonist Treatment for Symptomatic Uterine Fibroids|Completed||Phase 4|50||Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.485362|2018-06-01 04:41:22.485362
NCT00159315|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-06-03|2005-09-08|2005-09-12|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2002||2002-10-31|August 2008|2008-08-31||||||||Interventional|||ATP/AMP Challenge in Healthy Non-smokers, Smokers, Patients With Asthma, and Patients With Chronic Obstructive Pulmonary Disease (COPD)|Adenosine 5`-Triphosphate (ATP) Challenge in Healthy Non-smokers, Current Smokers and Patients With Mild Asthma and Chronic Obstructive Pulmonary Disease (COPD)|Withdrawn||N/A|0|Actual|Imperial College London||||no resources available|f||||||||||||||2018-06-01 04:41:22.541182|2018-06-01 04:41:22.541182
NCT00159302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|September 2003||2003-09-30|September 2005|2005-09-30||||||||Observational|||Biomarkers of iNOS Activity in COPD, Asthma, Healthy Control|A Pilot Study to Evaluate and Develop Biomarkers of iNOS Activity in Patients With COPD or Asthma and Healthy Volunteers|Completed|||36||Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.611354|2018-06-01 04:41:22.611354
NCT00159289|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-06-03|2005-09-08|2005-09-12|Estimate|||||||2015-06-03|2015-06-04|Estimate|June 2003||2003-06-30|August 2008|2008-08-31||||||||Interventional|||Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Endotoxin on Inflammatory Markers in Exhaled Breath, Sputum, Saliva and Nasal Lavage in Healthy Non-Smokers and Current Smokers Including Patients With COPD|Withdrawn||N/A|0|Actual|Imperial College London||2||No resources available|f||||||||||||||2018-06-01 04:41:22.668216|2018-06-01 04:41:22.668216
NCT00159276|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-08-12|2005-09-08|2005-09-12|Estimate|||||||2008-08-12|2008-08-13|Estimate|December 2005||2005-12-31|August 2008|2008-08-31|December 2008||2008-12-31|||||Observational|||GR Defect in Sputum Cells in COPD|GR Defect in Sputum Cells in COPD|Completed|||30|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.726623|2018-06-01 04:41:22.726623
NCT00159263|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|November 2004||2004-11-30|September 2005|2005-09-30||||||||Interventional|||Effect of Symbicort on GR Localisation in Asthma|Effect of Symbicort on GR (Glucocorticoid Receptor) Translocation in Induced Sputum in Comparison With Budesonide, Formoterol and Placebo. A Single Dose Exploratory Study in Patients With Mild Asthma|Completed||N/A|10||Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.773415|2018-06-01 04:41:22.773415
NCT00159250|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-02-22|2005-09-08|2005-09-12|Estimate|||||||2010-02-22|2010-02-23|Estimate|October 2007||2007-10-31|February 2010|2010-02-28|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy|Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658|Completed||Phase 1/Phase 2|7|Actual|Imperial College London|||||f||||t||||||||||2018-06-01 04:41:22.828516|2018-06-01 04:41:22.828516
NCT00159237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-08-12|2005-09-08|2005-09-12|Estimate|||||||2008-08-12|2008-08-13|Estimate|February 2005||2005-02-28|August 2008|2008-08-31|December 2008||2008-12-31|||||Observational|||GR Defect in Peripheral Blood Mononuclear Cells in COPD|GR Defect in Peripheral Blood Mononuclear Cells in COPD|Completed|||30|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:41:22.905108|2018-06-01 04:41:22.905108
NCT00159224|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-09-04|2005-09-07|2005-09-12|Estimate|||||||2015-09-04|2015-09-07|Estimate|April 2005||2005-04-30|September 2015|2015-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Induction-maintenance of Lopinavir/r in HIV-infected Subjects|"Study ACA-ARGE-04-001 A Pilot, Open-Label Study Assessing Safety, Tolerability, Efficacy of a Simplified Lopinavir/Ritonavir Induction/Maintenance Therapy in HIV-Infected Subjects on Their First Protease Inhibitor-Based Regimen."|Completed||Phase 4|100|Actual|The Huesped Foundation||2|||f||||f||||||||||2018-06-01 04:41:22.958681|2018-06-01 04:41:22.958681
NCT00159211|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-11-06|2005-09-07|2005-09-12|Estimate|||||||2007-11-06|2007-11-08|Estimate|May 2005||2005-05-31|April 2007|2007-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin|Evolution of Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin, in Association With Metformin or Sulfonylurea.|Terminated||N/A|28|Actual|Assistance Publique - Hôpitaux de Paris||2||inclusion was finished|f||||f||||||||||2018-06-01 04:41:23.044238|2018-06-01 04:41:23.044238
NCT00159185|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-07-20|2005-09-09|2005-09-12|Estimate|||||||2006-07-20|2006-07-21|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|May 2006||2006-05-31|||||Observational|||Epidemiology Study in Major Orthopaedic Surgery|Epidemiology Study in Major Orthopaedic Surgery|Completed|||500||Hoersholm Hospital|||||f||||||||||||||2018-06-01 04:41:23.227591|2018-06-01 04:41:23.227591
NCT00159172|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-03-05|2005-09-07|2005-09-12|Estimate|||||||2007-03-05|2007-03-06|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|May 2008||2008-05-31|||||Interventional|||Safety and Efficacy of Motor Cortex Stimulation in the Treatment of Advanced Parkinson Disease|Phase 1 Study of Motor Cortex Stimulation in the Treatment of Advanced Parkinson Disease|Unknown status|Recruiting|Phase 1/Phase 2|10||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:41:23.397818|2018-06-01 04:41:23.397818
NCT00159159|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-04-26|2005-09-08|2005-09-12|Estimate|||||||2007-04-26|2007-04-27|Estimate|March 2004||2004-03-31|April 2007|2007-04-30||||||||Interventional|||LOW CYCLO: Study Evaluating the Benefit of Two Doses of Ciclosporine in de Novo Cardiac Transplant|LOW CYCLO: A Multicenter, Prospective, Randomized Study Evaluating the Benefit, on Renal Function, of Two Doses of Ciclosporine: Low Dose Versus Usual Dose, in Association With Mycophenolate and Corticoïds, in de Novo Cardiac Transplant|Unknown status|Active, not recruiting|Phase 4|106||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:41:23.474929|2018-06-01 04:41:23.474929
NCT00159146|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-12-20|2005-09-07|2005-09-12|Estimate|||||||2007-12-20|2007-12-27|Estimate|August 2002||2002-08-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression|A Short Term Double Blind Randomised Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression|Terminated||N/A|31|Actual|Hillerod Hospital, Denmark||2||lack of participants fulfilling inclusion criteria|f||||f||||||||||2018-06-01 04:41:23.539374|2018-06-01 04:41:23.539374
NCT00159133|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-01-28|2005-09-07|2005-09-12|Estimate|||||||2008-01-28|2008-01-30|Estimate|November 2001||2001-11-30|January 2008|2008-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia|Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepine in Patients With First-Episode Schizophrenia After One Year Maintenance Treatment Under Further Maintenance Treatment vs. Stepwise Discontinued Drugs|Completed||Phase 4|71|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||||2018-06-01 04:41:23.613947|2018-06-01 04:41:23.613947
NCT00159120|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-01-28|2005-09-07|2005-09-12|Estimate|||||||2008-01-28|2008-01-30|Estimate|November 2001||2001-11-30|January 2008|2008-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia|Maintenance Treatment vs. Stepwise Drug Discontinuation After One Year of Maintenance Treatment in First-Episode Schizophrenia|Completed||Phase 4|71|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||||2018-06-01 04:41:23.692499|2018-06-01 04:41:23.692499
NCT00159107|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-01-29|2005-09-08|2005-09-12|Estimate|||||||2008-01-29|2008-01-30|Estimate|May 2003||2003-05-31|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Integrative Therapy in Alcoholism|Acamprosate and Integrative Behavior Therapy in the Outpatient Treatment of Alcohol Dependents|Completed||Phase 4|371|Actual|Heinrich-Heine University, Duesseldorf||3|||f||||t||||||||||2018-06-01 04:41:23.77188|2018-06-01 04:41:23.77188
NCT00159094|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-30|2005-09-11|2005-09-12|Estimate|||||||2008-05-30|2008-06-02|Estimate|October 2003||2003-10-31|September 2005|2005-09-30||||||||Interventional|||A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer|A Phase II Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|Hematology Oncology Consultants|||||f||||||||||||||2018-06-01 04:41:23.841018|2018-06-01 04:41:23.841018
NCT00159081|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-02-06|2005-09-07|2005-09-12|Estimate|||||||2008-02-06|2008-02-07|Estimate|November 2000||2000-11-30|January 2008|2008-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||One Year Drug Treatment in First-Episode Schizophrenia|One Year Maintenance Treatment With Low Dose Haloperidol vs. Risperidone in First-Episode Schizophrenia|Completed||Phase 4|159|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||||2018-06-01 04:41:23.909098|2018-06-01 04:41:23.909098
NCT00159068|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-08-09|2005-09-09|2005-09-12|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2004||2004-02-29|August 2017|2017-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Analysis of Genetic Factors Which May Influence the Course of HIV Infection|Genetic Influences on the Course and Response to Treatment of HIV: Contribution of Polymorphisms in Drug Metabolism and Disposition Genes and Haptoglobin Polymorphisms|Completed|||100|Actual|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     DNA isolated from peripheral blood.~   "|||2018-06-01 04:41:23.97816|2018-06-01 04:41:23.97816
NCT00159055|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-04-07|2005-09-09|2005-09-12|Estimate|||||||2011-04-07|2011-04-08|Estimate|February 2004||2004-02-29|September 2005|2005-09-30||||||||Interventional|||Adoptive Immunotherapy for CMV Disease|Prevention and Treatment of CMV Disease by Adoptive Immunotherapy With Immune Donor Lymphocytes in Conjunction With Non-myeloablative Stem Cell Transplantation (NST)|Withdrawn||Phase 1/Phase 2|20|Anticipated|Hadassah Medical Organization||||the PI is no longer work at Hadassah|f||||||||||||||2018-06-01 04:41:24.0533|2018-06-01 04:41:24.0533
NCT00159042|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-08-09|2005-09-09|2005-09-12|Estimate|||||||2017-08-09|2017-08-10|Actual|July 2004|Actual|2004-07-31|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Genetic Factors Affecting the Severity of Beta Thalassemia|Identification of Novel Genetic Modifiers in Beta-thalassemia|Completed|||50|Actual|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     DNA isolated from peripheral blood~   "|||2018-06-01 04:41:24.098385|2018-06-01 04:41:24.098385
NCT00159029|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-08-09|2005-09-09|2005-09-12|Estimate|||||||2017-08-09|2017-08-10|Actual|April 1, 2004|Actual|2004-04-01|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Genetics of Alpha Thalassemia in Israeli Ethnic Groups|Haplotype Analysis of Alpha Globin Genes in Israeli Ethnic Groups|Completed|||100|Actual|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     DNA isolated from peripheral blood.~   "|||2018-06-01 04:41:24.150202|2018-06-01 04:41:24.150202
NCT00159016|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-04-27|2005-09-08|2005-09-12|Estimate|||||||2011-04-27|2011-04-28|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.|The Possible Role of Glivec in Patients With Tumor Cells Positive for C-kit or Platelet Derived Growth Factor Receptor (PDGFR); a Multi Center Study.|Withdrawn||Phase 2|100||Hadassah Medical Organization||||the PI is no longer work at Hadassah|f||||||||||||||2018-06-01 04:41:24.298393|2018-06-01 04:41:24.298393
NCT00159003|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-08-09|2005-09-08|2005-09-12|Estimate|||||||2017-08-09|2017-08-10|Actual|January 1, 1998|Actual|1998-01-01|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel|Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel|Completed|||100|Actual|Hadassah Medical Organization|||||f||||f||||||Samples With DNA|"~     DNA only~   "|||2018-06-01 04:41:24.362917|2018-06-01 04:41:24.362917
NCT00158990|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-01-02|2005-09-08|2005-09-12|Estimate|||||||2007-01-02|2007-01-04|Estimate|October 2002||2002-10-31|August 2005|2005-08-31|July 2007||2007-07-31|||||Interventional|||Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.|Triiodothyronine (T3) Supplementation in Bipolar and Unipolar Depression: A Random Assignment, Double Blind, Placebo-Controlled Study.|Completed||Phase 3|220||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:41:24.434532|2018-06-01 04:41:24.434532
NCT00158977|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-09-28|2005-09-08|2005-09-12|Estimate|||||||2011-09-28|2011-09-29|Estimate|November 2003||2003-11-30|September 2011|2011-09-30|February 2008|Actual|2008-02-29|October 2004|Actual|2004-10-31||Interventional|||CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT Study|Completed||Phase 3|73|Actual|Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:41:24.513055|2018-06-01 04:41:24.513055
NCT00158964|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-06-22|2005-09-08|2005-09-12|Estimate|||||||2007-06-22|2007-06-25|Estimate|March 2005||2005-03-31|June 2007|2007-06-30|April 2007|Actual|2007-04-30|||||Interventional|||EASYTRAK 4 Steerable LV Lead|EASYTRAK® 4 STEERABLE LV Lead Clinical Investigation|Completed||Phase 2/Phase 3|110||Boston Scientific Corporation|||||||||||||||||||2018-06-01 04:41:24.589503|2018-06-01 04:41:24.589503
NCT00158951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-06-22|2005-09-08|2005-09-12|Estimate|||||||2007-06-22|2007-06-25|Estimate|March 2003||2003-03-31|June 2007|2007-06-30|October 2004||2004-10-31|||||Interventional|||Device Evaluation of Contak Renewal 2and Easytrak 2 - DECREASE-HF|Device Evaluation of CONTAK(R) RENEWAL 2/4/4HE and EASYTRAK(R) 2: Assessment of Safety and Effectiveness in Heart Failure (DECREASE-HF)|Completed||Phase 2/Phase 3|360||Boston Scientific Corporation|||||||||||||||||||2018-06-01 04:41:24.671398|2018-06-01 04:41:24.671398
NCT00158938|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-06-22|2005-09-08|2005-09-12|Estimate|||||||2007-06-22|2007-06-25|Estimate|May 2003||2003-05-31|June 2007|2007-06-30|November 2004|Actual|2004-11-30|||||Interventional|||Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense Lead|Clinical Study of the EASYTRAK 3 Spiral Fixation Coronary Venous Bipolar Pace/Sense Lead|Completed||Phase 2/Phase 3|115||Boston Scientific Corporation|||||||||||||||||||2018-06-01 04:41:24.750621|2018-06-01 04:41:24.750621
NCT00158925|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2017-03-17||2017-05-02|2005-09-08|2005-09-12|Estimate|2017-03-17|2017-04-28|Actual||||2017-05-02|2017-05-31|Actual|September 2004||2004-09-30|May 2017|2017-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|EASYTRAK EPI||The EASYTRAK EPI Clinical Investigation|The EASYTRAK EPI Clinical Investigation|Completed||N/A|100|Actual|Boston Scientific Corporation||1|||f||||||||||||No||2018-06-01 04:41:24.832811|2018-06-01 04:41:24.832811
NCT00158912|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-11-20|2005-09-11|2005-09-12|Estimate|||||||2006-11-20|2006-11-22|Estimate|August 2003||2003-08-31|November 2006|2006-11-30|May 2005||2005-05-31|||||Interventional|||VAST - Ventricular Arrhythmia Suppression Trial|Ventricular Arrhythmia Suppression Trial|Completed||Phase 4|550||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:41:25.190608|2018-06-01 04:41:25.190608
NCT00158899|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-05-24|2005-09-08|2005-09-12|Estimate|||||||2017-05-24|2017-05-30|Actual|August 2004||2004-08-31|May 2017|2017-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol|A Multi-center, Three-staged With Interim Analyses, Parallel, Randomized, Double-blind, fenofibrate-and Placebo-controlled Proof of Concept and Dose-response Evaluation of the Safety, Tolerability, and Effects on Plasma High-density Lipoprotein Cholesterol (HDLc) and Triglycerides of Eight Weeks Treatment With GW501516 in Otherwise Healthy Patients With Low HDLc, Mildly to Moderately Elevated Triglycerides, and Normal Low-density Lipoprotein Cholesterol (LDLc)|Completed||Phase 2|424|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:41:25.271391|2018-06-01 04:41:25.271391
NCT00158886|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-11-10|2005-09-08|2005-09-12|Estimate|||||||2017-11-10|2017-11-14|Actual|November 8, 2001|Actual|2001-11-08|November 2017|2017-11-30|August 11, 2006|Actual|2006-08-11|August 11, 2006|Actual|2006-08-11||Interventional|||Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer|A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer|Terminated||Phase 1|26|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:41:25.442358|2018-06-01 04:41:25.442358
NCT00158873|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-10-15|2005-09-08|2005-09-12|Estimate|||||||2008-10-15|2008-10-16|Estimate|September 2004||2004-09-30|October 2008|2008-10-31||||||||Interventional|||Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects|A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation|Completed||Phase 4|224||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:41:25.532066|2018-06-01 04:41:25.532066
NCT00158860|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-04-12|2005-09-08|2005-09-12|Estimate|||||||2017-04-12|2017-04-14|Actual|June 21, 2004|Actual|2004-06-21|April 2017|2017-04-30|July 26, 2006|Actual|2006-07-26|July 26, 2006|Actual|2006-07-26||Interventional|||A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.|An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients|Completed||Phase 4|384|Actual|GlaxoSmithKline||1|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:41:25.636456|2018-06-01 04:41:25.636456
NCT00158847|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-01-10|2005-09-08|2005-09-12|Estimate|||||||2006-01-10|2006-01-20|Estimate|April 2000||2000-04-30|January 2005|2005-01-31|May 2005||2005-05-31|||||Interventional|||Modification Of Disease Outcome In COPD|Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.|Terminated||Phase 4|200||Leiden University Medical Center|||||f||||||||||||||2018-06-01 04:41:25.832127|2018-06-01 04:41:25.832127
NCT00158834|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-10-09|2005-09-11|2005-09-12|Estimate|||||||2008-10-09|2008-10-13|Estimate|November 1999||1999-11-30|October 2008|2008-10-31||||||||Interventional|||Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications|Comparison of Stepwise Treatment of Asthmatic Children With Salmeterol/Fluticasone Propionate Combination Product (Seretide®) and/or Fluticasone Propionate (Flixotide®) Based on PD20 Methacholine and Symptoms or Based on Symptoms Only (Children Asthma Therapy Optimal)|Completed||Phase 3|200||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:41:25.892246|2018-06-01 04:41:25.892246
NCT00158821|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-06-21|2005-09-07|2005-09-12|Estimate|||||||2013-06-21|2013-06-25|Estimate|March 2000||2000-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|December 2001|Actual|2001-12-31||Interventional|||Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.|A Phase 3, Randomized, Double-Blind, Multicenter Study of the Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.(Extension)|Completed||Phase 3|180|Anticipated|Gilead Sciences|||||f||||||||||||||2018-06-01 04:41:25.959834|2018-06-01 04:41:25.959834
NCT00158808|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-05-24|2005-09-08|2005-09-12|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2005||2005-01-31|May 2017|2017-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths|Assess the Immunogenicity &d Reactogenicity of a Booster Dose of a Formulation of GSK Biologicals' DTPw-HBV/Hib Vaccine at 15-18 Mths of Age in Infants Previously Primed With the Same Vaccine|Completed||Phase 2|175|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:41:26.01502|2018-06-01 04:41:26.01502
NCT00158795|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-05-24|2005-09-08|2005-09-12|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2005||2005-01-31|May 2017|2017-05-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine|Assess the Safety & Reactogenicity of GSK Biologicals Hib Vaccine Co-administered With Chinese Local DTPw Vaccine When Compared to Chinese Local DTPw Vaccine Administered Alone, in Healthy Infants at 3,4 & 5 Mths of Age|Completed||Phase 4|454|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:41:26.900491|2018-06-01 04:41:26.900491
NCT00158782|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-11-13|2005-09-08|2005-09-12|Estimate|||||||2017-11-13|2017-11-17|Actual|September 28, 2004|Actual|2004-09-28|November 2017|2017-11-30|August 21, 2007|Actual|2007-08-21|August 21, 2007|Actual|2007-08-21||Interventional|||Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients|An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients|Completed||Phase 1|75|Actual|GlaxoSmithKline||10|||f||||f||||||||||2018-06-01 04:41:26.95883|2018-06-01 04:41:26.95883
NCT00158769|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-09-20|2005-09-11|2005-09-12|Estimate|||||||2017-09-20|2017-09-25|Actual|March 31, 2005|Actual|2005-03-31|September 2017|2017-09-30|October 26, 2005|Actual|2005-10-26|October 26, 2005|Actual|2005-10-26||Interventional|||A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers|An Open-Label, Non-Randomised, Pharmacokinetic, Metabolic Disposition and Safety Study of a 3 Day Continuous Infusion of GR270773 in Healthy Subjects and Subjects With Hepatic Impairment.|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:41:27.035597|2018-06-01 04:41:27.035597
NCT00158756|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2016-12-20||2017-04-14|2005-09-08|2005-09-12|Estimate|2017-04-14|2017-07-12|Actual||||2017-04-14|2017-07-12|Actual|September 12, 2005|Actual|2005-09-12|April 2017|2017-04-30|November 23, 2006|Actual|2006-11-23|November 1, 2006|Actual|2006-11-01||Interventional|||Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants|A Phase III, Partially Blind, Randomized Study to Evaluate the Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Tritanrix™-HepB and GSK Biologicals Kft's DTPw-HBV Vaccines as Compared to Concomitant Administration of Commonwealth Serum Laboratory's (CSL's) DTPw (Triple Antigen™) and GSK Biologicals' HBV (Engerix™-B), When Co-administered With GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, to Healthy Infants at 3, 4½ and 6 Months of Age, After a Birth Dose of Hepatitis B Vaccine.|Completed||Phase 3|308|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:41:27.166397|2018-06-01 04:41:27.166397
NCT00158743|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2014-07-17||2014-07-17|2005-09-08|2005-09-12|Estimate|2014-07-17|2014-08-08|Estimate||||2014-07-17|2014-08-08|Estimate|February 2004||2004-02-29|July 2014|2014-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy Study of Digibind for Treatment of Severe Preeclampsia|A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia|Completed||Phase 2|51|Actual|BTG International Inc.||2|||f||||t||||||||||2018-06-01 04:41:28.543804|2018-06-01 04:41:28.543804
NCT00158730|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-11-17|2005-09-07|2005-09-12|Estimate|||||||2005-11-17|2005-11-18|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment|Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients|Completed||Phase 3|800||Gilead Sciences|||||||||||||||||||2018-06-01 04:41:28.7721|2018-06-01 04:41:28.7721
NCT00158717|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-01-06|2005-09-07|2005-09-12|Estimate|||||||2014-01-06|2014-01-07|Estimate|April 2003||2003-04-30|January 2014|2014-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.|A Phase 3b, Long-Term, Observational Study of the Durability of Seroconversion in Patients With Chronic Hepatitis B Virus Infection Who Have Seroconverted While Participating in a Previous Gilead-Sponsored Study of Adefovir Dipivoxil.|Completed|||107|Actual|Gilead Sciences|||||||||||||||||||2018-06-01 04:41:28.816585|2018-06-01 04:41:28.816585
NCT00158704|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-03-07|2005-09-07|2005-09-12|Estimate|||||||2007-03-07|2007-03-08|Estimate|January 2002||2002-01-31|April 2006|2006-04-30|January 2005||2005-01-31|||||Interventional|||Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.|An Open-Label, Continued Access Study of Adefovir Dipivoxil for Patients With Chronic HBV Infection Who Have Completed a Gilead-Sponsored Study of Adefovir Dipivoxil.|Terminated||N/A|400||Gilead Sciences||||The study stopped due to marketing approval by the FDA.|||||||||||||||2018-06-01 04:41:28.948434|2018-06-01 04:41:28.948434
NCT00158691|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|March 2001||2001-03-31|September 2005|2005-09-30||||||||Interventional|||Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas|A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas|Completed||Phase 3|296||Groupe Oncologie Radiotherapie Tete et Cou|||||f||||||||||||||2018-06-01 04:41:28.99812|2018-06-01 04:41:28.99812
NCT00158678|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-02-15|2005-09-09|2005-09-12|Estimate|||||||2018-02-15|2018-02-16|Estimate|September 2005||2005-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC|Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 3|310|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||||||||||||2018-06-01 04:41:29.065109|2018-06-01 04:41:29.065109
NCT00158665|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-11|2005-09-11|2005-09-12|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2004||2004-08-31|October 2017|2017-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age|A Comparison of One Versus Two Doses of Influenza Vaccine in Children Aged 5-8 Years of Age Receiving Influenza Vaccine for the First Time|Completed||N/A|280|Actual|Kaiser Permanente||1|||f||||f||||||||||2018-06-01 04:41:29.144934|2018-06-01 04:41:29.144934
NCT00158652|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2011-11-07|2005-09-09|2005-09-12|Estimate|||||||2011-11-07|2011-11-08|Estimate|March 2000||2000-03-31|November 2011|2011-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC|Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma|Completed||Phase 3|840|Actual|Groupe Oncologie Radiotherapie Tete et Cou||3|||f||||||||||||||2018-06-01 04:41:29.218855|2018-06-01 04:41:29.218855
NCT00158639|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-11|2005-09-11|2005-09-12|Estimate|||||||2017-10-11|2017-10-13|Actual|June 2005||2005-06-30|October 2017|2017-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Electronic Communications and Home Blood Pressure Monitoring|Electronic Communications and Home Blood Pressure Monitoring|Completed||Phase 3|778|Actual|Kaiser Permanente|||||f||||t||||||||||2018-06-01 04:41:29.302733|2018-06-01 04:41:29.302733
NCT00158626|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-03-18|2005-09-08|2005-09-12|Estimate|||||||2015-03-18|2015-03-19|Estimate|September 2003||2003-09-30|March 2015|2015-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Does Doing Pelvic Floor Exercise Ease Symptoms for Women Living With Prolapse?|A Feasibility Study for an RCT of a Pelvic Floor Muscle Training Intervention for Pelvic Organ Prolapse|Completed||Phase 1/Phase 2|50||Glasgow Caledonian University|||||f||||||||||||||2018-06-01 04:41:29.361665|2018-06-01 04:41:29.361665
NCT00158613|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-06-01|2005-09-11|2005-09-12|Estimate|||||||2017-06-01|2017-06-02|Actual|March 2000||2000-03-31|June 2017|2017-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study of the Treatment of Articular Repair (STAR)|A Prospective, Longitudinal Within-Patient Evaluation of the Effectiveness (Durability) of Carticel® (Autologous Cultured Chondrocytes) Compared to Non-Carticel Surgical Treatment for Articular Cartilage Defects of the Knee.|Completed||Phase 4|126|Actual|Vericel Corporation|||||f||||f||||||||||2018-06-01 04:41:29.426289|2018-06-01 04:41:29.426289
NCT00158600|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-06-24||2015-04-06|2005-09-08|2005-09-12|Estimate|2010-06-24|2010-07-23|Estimate||||2015-04-06|2015-04-28|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease|Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.|Completed||Phase 3|90|Actual|Sanofi||2|||t||||t||||||||||2018-06-01 04:41:29.567232|2018-06-01 04:41:29.567232
NCT00158587|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-11|2005-09-09|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2004||2004-04-30|January 2017|2017-01-31|March 2007|Actual|2007-03-31|||||Interventional|||Eight Week Primaquine Regimen for the Treatment of Vivax Malaria|A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.|Completed||Phase 3|150|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:41:30.970793|2018-06-01 04:41:30.970793
NCT00158574|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-11|2005-09-08|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Kilimanjaro IPTi Drug Options Trial|Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs|Completed||Phase 2/Phase 3|2419|Actual|London School of Hygiene and Tropical Medicine||4|||f||||t||||||||||2018-06-01 04:41:31.043573|2018-06-01 04:41:31.043573
NCT00158561|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-11|2005-09-09|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2004||2004-02-29|January 2017|2017-01-31|March 2006|Actual|2006-03-31|||||Interventional|||Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria|An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan|Completed||Phase 3|750||London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:41:31.143618|2018-06-01 04:41:31.143618
NCT00158548|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-11|2005-09-08|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2001||2001-06-30|January 2017|2017-01-31|December 2004|Actual|2004-12-31|||||Interventional|||ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan|Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan|Completed||Phase 3|650|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:41:31.211796|2018-06-01 04:41:31.211796
NCT00158535|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|June 2002||2002-06-30|September 2005|2005-09-30||||||||Interventional|||Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection|Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection ANRS HC08 Thevic|Terminated||Phase 2|15||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:41:31.279902|2018-06-01 04:41:31.279902
NCT00158522|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-02-06|2005-09-08|2005-09-12|Estimate|||||||2008-02-06|2008-02-08|Estimate|February 2003||2003-02-28|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)|Clinical Trial of the Efficacy of Pegylated Interferon (PEG-IFNα-2a) Alone in Egyptian Patients With Acute Hepatitis C|Completed||Phase 3|31|Actual|French National Agency for Research on AIDS and Viral Hepatitis||1|||f||||t||||||||||2018-06-01 04:41:31.343438|2018-06-01 04:41:31.343438
NCT00158509|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-06-06|2005-09-09|2005-09-12|Estimate|||||||2006-06-06|2006-06-07|Estimate|August 2004||2004-08-31|June 2006|2006-06-30|July 2005||2005-07-31|||||Interventional|||Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding|Efficacy of an HSV2 Genital Herpes Suppressive Treatment on HIV and HSV2 Genital Shedding Among Co-Infected Patients Receiving or Not Antiretroviral Drugs|Completed||Phase 2|215||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:41:31.417581|2018-06-01 04:41:31.417581
NCT00158496|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-04-23|2005-09-08|2005-09-12|Estimate|||||||2007-04-23|2007-04-24|Estimate|August 2002||2002-08-31|April 2007|2007-04-30|January 2005|Actual|2005-01-31|||||Interventional|||Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)|Clinical Trial of the Efficacy of the Combination of Pegylated Interferon (PEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C|Completed||Phase 3|100||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:41:31.475091|2018-06-01 04:41:31.475091
NCT00158483|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-12-29|2005-09-08|2005-09-12|Estimate|||||||2008-12-29|2008-12-30|Estimate|May 2003||2003-05-31|December 2008|2008-12-31|October 2005|Actual|2005-10-31|||||Interventional|||Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)|Anti-Herpetic Treatment Associated With Syndromic Management of Genital Ulcer in Africa: Clinical and Biological Evaluation on HIV-1 and HSV-2 Shedding (ANRS 1212)|Completed||Phase 2|449|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||f||||||||||2018-06-01 04:41:31.662782|2018-06-01 04:41:31.662782
NCT00158470|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-07-02|2005-09-07|2005-09-12|Estimate|||||||2007-07-02|2007-07-03|Estimate|September 2003||2003-09-30|July 2007|2007-07-31|May 2007|Actual|2007-05-31|||||Interventional|||Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)|Feasibility Study of a Once Daily Antiretroviral Regimen for HIV-Infected Patients With CD4 Below 200/mm3, in Hô Chi Minh City, Vietnam|Completed||Phase 3|100|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||f||||||||||2018-06-01 04:41:31.733946|2018-06-01 04:41:31.733946
NCT00158457|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-02|2005-09-08|2005-09-12|Estimate|||||||2007-07-02|2007-07-03|Estimate|June 2004||2004-06-30|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)|Pilot Trial to Evaluate the Efficacy and Tolerance of a Simple Once Daily Combined Regimen Including Tenofovir (TDF), Emtricitabine (FTC) and Efavirenz (EFV) in HIV-1 Infected Patients Naive to Prior Antiretroviral Treatment in Senegal|Completed||Phase 3|40|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:41:31.798109|2018-06-01 04:41:31.798109
NCT00158431|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-11-26|2005-09-07|2005-09-12|Estimate|||||||2015-11-26|2015-11-30|Estimate|January 1999||1999-01-31|November 2015|2015-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Surgery Versus no Surgery for OA of the Knee|Arthroscopic Surgery Versus Non-surgical Treatment of Osteoarthritis of the Knee|Completed||Phase 3|186|Actual|Fowler Kennedy Sport Medicine Clinic||2|||f||||t||||||||||2018-06-01 04:41:31.862658|2018-06-01 04:41:31.862658
NCT00158418|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-01-28|2005-09-07|2005-09-12|Estimate|||||||2009-01-28|2009-01-29|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Cemented vs. Non-Cemented TSA for OA of the Shoulder|Cemented Versus Uncemented Fixation of Humeral Components in Total Shoulder Arthroplasty for Osteoarthritis of the Shoulder|Completed||Phase 3|160||Fowler Kennedy Sport Medicine Clinic|||||f||||||||||||||2018-06-01 04:41:31.950917|2018-06-01 04:41:31.950917
NCT00158405|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-12-29|2005-09-07|2005-09-12|Estimate|||||||2008-12-29|2008-12-30|Estimate|December 2002||2002-12-31|December 2008|2008-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)|Multicentric Randomised Controlled Trial Assessing the Efficacy of Two Strategies of Structured Treatment Interruption of Highly Active Antiretroviral Therapy (HAART) Compared With a Continuous HAART in HIV- Infected Adults in Abidjan|Completed||Phase 3|840|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:41:32.080698|2018-06-01 04:41:32.080698
NCT00158379|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2016-10-04||2016-12-12|2005-09-10|2005-09-12|Estimate|2016-10-04|2016-11-25|Estimate||||2016-12-12|2017-02-06|Estimate|July 2003||2003-07-31|December 2016|2016-12-31|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Taxol Carboplatin and Erythropoetin|Carboplatin With Following Taxol® Therapy Under Additional Application of Epoetin Alfa (ERYPO ®) With Female Patients With Advanced Ovarian Cancer FIGO IA/G3 - IV|Completed||Phase 2|105|Actual|North Eastern Germany Society of Gynaecologic Oncology||1|||f||||f||||||||No||2018-06-01 04:41:32.157815|2018-06-01 04:41:32.157815
NCT00158366|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-07-19|2005-09-07|2005-09-12|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2004||2004-05-31|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|May 2010|Actual|2010-05-31||Interventional|||Reducing the Weight of Overweight Schizophrenia Patients|A Clinical Trial Of Weight Reduction in Schizophrenia|Active, not recruiting||N/A|300|Anticipated|University of Pittsburgh||4|||f||||t||||||||||2018-06-01 04:41:32.277349|2018-06-01 04:41:32.277349
NCT00158353|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-06-18|2005-09-07|2005-09-12|Estimate|||||||2013-06-18|2013-06-19|Estimate|May 2005||2005-05-31|June 2013|2013-06-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Evaluation of a Youth Mentoring Program|Development and Evaluation of a Youth Mentoring Program|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-06-01 04:41:32.350311|2018-06-01 04:41:32.350311
NCT00158340|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-11-04|2005-09-07|2005-09-12|Estimate|||||||2011-11-04|2011-11-07|Estimate|August 2004||2004-08-31|November 2011|2011-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|BEST||Guided Self-Help Treatment for Binge Eating Disorder|Binge Eating Self-Guided Treatment (BEST)|Completed||N/A|284|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-06-01 04:41:32.425825|2018-06-01 04:41:32.425825
NCT00158327|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-01-21|2005-09-07|2005-09-12|Estimate|||||||2014-01-21|2014-01-22|Estimate|March 2004||2004-03-31|January 2014|2014-01-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Telephone-Based Care Management Program for Individuals With Anxiety Disorders|The RELAX Trial: Reducing Limitations From Anxiety in Primary Care|Completed||Phase 3|360|Anticipated|University of Pittsburgh||2|||f||||||||||||||2018-06-01 04:41:32.484077|2018-06-01 04:41:32.484077
NCT00158314|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-06-28|2005-09-07|2005-09-12|Estimate|||||||2013-06-28|2013-07-01|Estimate|March 1998||1998-03-31|June 2013|2013-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Cognitive Behavioral Therapy for Treatment of Pathological Gambling|Cognitive Behavioral Treatment for Pathological Gambling|Completed||Phase 1|231||UConn Health|||||f||||t||||||||||2018-06-01 04:41:32.546319|2018-06-01 04:41:32.546319
NCT00158301|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-11-07|2005-09-07|2005-09-12|Estimate|||||||2013-11-07|2013-11-08|Estimate|September 2004||2004-09-30|November 2013|2013-11-30|February 2008|Actual|2008-02-29|November 2007|Actual|2007-11-30||Interventional|||Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents|Continuation Phase CBT for Youth With MDD|Completed||N/A|72|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 04:41:32.819457|2018-06-01 04:41:32.819457
NCT00158288|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-11|2005-09-08|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 1997||1997-03-31|September 2005|2005-09-30|August 2001||2001-08-31|||||Interventional|||The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1|LAAM With Behavioral Treatment for Opioid/Cocaine Abuse|Completed||Phase 2|140||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:41:32.892692|2018-06-01 04:41:32.892692
NCT00158275|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-10-11|2005-09-07|2005-09-12|Estimate|||||||2017-10-11|2017-10-13|Actual|October 2004||2004-10-31|October 2017|2017-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Combined Interventions for Treating Depression and Chronic Back Pain|Integrated Care for Depression and Chronic Back Pain|Completed||N/A|71|Actual|Kaiser Permanente||2|||f||||||||||||||2018-06-01 04:41:32.959569|2018-06-01 04:41:32.959569
NCT00158262|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2013-05-07||2017-04-06|2005-09-07|2005-09-12|Estimate|2017-04-06|2017-04-10|Actual||||2017-04-06|2017-04-10|Actual|September 2004|Actual|2004-09-30|April 2017|2017-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||All randomized participants with data available for analysis. 1 participant in each arm dropped out prior to analysis and are excluded.|Effect of Propranolol on Preventing Posttraumatic Stress Disorder|Prophylaxis of Posttraumatic Stress Disorder With Post-Trauma Propranolol|Completed||Phase 4|43|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:41:33.049143|2018-06-01 04:41:33.049143
NCT00158249|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2014-10-15||2014-10-15|2005-09-08|2005-09-12|Estimate|2014-10-15|2014-10-22|Estimate||||2014-10-15|2014-10-22|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals|Cannabis Dependence: Imaging and Medication Development - 1|Completed||Phase 2|21|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 04:41:33.293652|2018-06-01 04:41:33.293652
NCT00158236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-11|2005-09-08|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 1997||1997-01-31|January 2006|2006-01-31|March 1998||1998-03-31|||||Interventional|||Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users|Effects of Buprenorphine/Naloxone in Non-Dependent Opioid Abusers|Completed||N/A|7||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 04:41:33.611184|2018-06-01 04:41:33.611184
NCT00158223|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2013-09-03||2015-04-07|2005-09-07|2005-09-12|Estimate|2015-04-07|2015-04-09|Estimate||||2015-04-07|2015-04-09|Estimate|October 2004||2004-10-31|April 2015|2015-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia|Pimozide Augmentation of Clozapine in Schizophrenia|Completed||Phase 4|76|Actual|Icahn School of Medicine at Mount Sinai|Neither baseline nor follow-up clozapine plasma concentrations were reported. Possible that one or both groups did not have therapeutic baseline clozapine levels and/or had pharmacokinetic interactions with the study drug changing concentrations.|2|||f||||t||||||||||2018-06-01 04:41:33.683413|2018-06-01 04:41:33.683413
NCT00158210|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-11|2005-09-08|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2006||2006-05-31|September 2009|2009-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Rivastigmine For Methamphetamine Dependent Individuals|Double-Blind Randomized Placebo Controlled Trial of Rivastigmine (Excelon) as a Potential Medication for Methamphetamine Abuse|Completed||Phase 1|18|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:41:33.886122|2018-06-01 04:41:33.886122
NCT00158197|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-05-30||2015-08-11|2005-09-08|2005-09-12|Estimate|2014-06-30|2014-07-02|Estimate||||2015-08-11|2015-08-25|Estimate|December 2004||2004-12-31|August 2015|2015-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Long-term Behavior Change - 1|Behavior Change: Reinforcement Schedule Effects|Completed||N/A|119|Actual|Friends Research Institute, Inc.||4|||f||||t||||||||||2018-06-01 04:41:33.964187|2018-06-01 04:41:33.964187
NCT00158184|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-04-10||2017-06-08|2005-09-08|2005-09-12|Estimate|2017-06-08|2017-07-07|Actual||||2017-06-08|2017-07-07|Actual|June 2004||2004-06-30|June 2017|2017-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Prescription Opioid Effects in Abusers Versus Non-Abusers|Prescription Opioid Effects in Drug and Non-drug Abusers - 1|Completed||Phase 2|27|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-06-01 04:41:34.36416|2018-06-01 04:41:34.36416
NCT00158171|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-09|2005-09-08|2005-09-12|Estimate|||||||2017-01-09|2017-01-10|Estimate|April 2002||2002-04-30|October 2016|2016-10-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1|Interventions for Tobacco Dependent Adolescents|Completed||Phase 2|128|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 04:41:34.544289|2018-06-01 04:41:34.544289
NCT00158158|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-09|2005-09-08|2005-09-12|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2|Interventions for Tobacco Dependent Adolescents|Completed||Phase 2/Phase 3|200|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 04:41:34.611244|2018-06-01 04:41:34.611244
NCT00158145|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-09|2005-09-08|2005-09-12|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2005||2005-09-30|June 2008|2008-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2|Longitudinal Study of Prostate, Lung, Colon, and Ovarian Cancer (PLCO) Screen Trial|Completed|||72|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||Samples Without DNA|"~     Urine and blood samples.~   "|||2018-06-01 04:41:34.671569|2018-06-01 04:41:34.671569
NCT00158132|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-11|2005-09-08|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 1999||1999-09-30|October 2016|2016-10-31|February 2006|Actual|2006-02-28|March 2005|Actual|2005-03-31||Interventional|||Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2|A Double-Blind, Placebo Controlled Trial of Propranolol and Amantadine for the Treatment of Cocaine Dependent Subjects With Severe Cocaine Withdrawal Symptoms|Completed||Phase 2|199|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||f||||||||||2018-06-01 04:41:34.844742|2018-06-01 04:41:34.844742
NCT00158119|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-07-23|2005-09-07|2005-09-12|Estimate|||||||2010-07-23|2010-07-26|Estimate|July 2001||2001-07-31|July 2010|2010-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Comparison of Weighted Vest Exercise and Strength Training|Ameliorating Disability Through Power Training|Completed||Phase 3|160||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:41:34.92032|2018-06-01 04:41:34.92032
NCT00158106|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate|February 2005||2005-02-28|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Assessing the Effectiveness of Communication Therapy in the North West (The ACT NoW Pilot Study)|Assessing the Effectiveness of Communication Therapy in the North West (The ACT NoW Pilot Study)|Completed||N/A|60||NHS Health Technology Assessment Programme|||||f||||||||||||||2018-06-01 04:41:34.982766|2018-06-01 04:41:34.982766
NCT00158093|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|July 2003||2003-07-31|||||Interventional|||A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo|A Randomized, Parallel Group Safety Evaluation of Electrocardiographic Intervals and Blood Pressure in Normal Healthy Volunteers After Nebivolol, Atenolol, Moxifloxacin, or Placebo Administration After Single and Repeated Doses|Completed||Phase 1|260||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:41:35.033838|2018-06-01 04:41:35.033838
NCT00158080|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate||||September 2005|2005-09-30||||||||Interventional|||Hemofiltration for Contrast-Induced Nephropathy|Prevention of Contrast-Induced Nephropathy by Real-Time Hemofiltration|Unknown status|Recruiting|N/A|100||Nara Medical University|||||f||||||||||||||2018-06-01 04:41:35.084743|2018-06-01 04:41:35.084743
NCT00158067|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-08-24|2005-09-08|2005-09-12|Estimate|||||||2010-08-24|2010-08-26|Estimate|March 2002||2002-03-31|August 2010|2010-08-31|March 2008|Actual|2008-03-31|April 2007|Actual|2007-04-30||Interventional|||Study of an External Responsive Neurostimulator System on Epileptiform Activity|Automated Response to Spontaneous Epileptiform Activity Using the External Responsive Neurostimulator (eRNS) System Clinical Investigation|Completed||Phase 2|150|Anticipated|NeuroPace|||||||||||||||||||2018-06-01 04:41:35.140505|2018-06-01 04:41:35.140505
NCT00158054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2015-03-04||2017-08-15|2005-09-08|2005-09-12|Estimate|2016-02-04|2016-03-03|Estimate||||2017-08-15|2017-08-23|Actual|January 2005||2005-01-31|August 2017|2017-08-31|April 2015|Actual|2015-04-30|February 2008|Actual|2008-02-29||Interventional|||COPES Phase I Randomized Controlled Trial of Treatment For Distress in Heart Disease Patients|Consortium for Translation of Psychosocial Depression Theories to Interventions and Dissemination - Project 2: Phase I Randomized Controlled Trial of Patient Preference, Stepped-Care Treatment For Distress in Heart Disease Patients|Completed||N/A|157|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 04:41:35.239379|2018-06-01 04:41:35.239379
NCT00158041|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|January 2005||2005-01-31|||||Interventional|||Subcutaneous Amifostine Safety Study|Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities|Completed||Phase 4|452||Mt. Sinai Medical Center, Miami|||||f||||||||||||||2018-06-01 04:41:35.757586|2018-06-01 04:41:35.757586
NCT00158028|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-08-02|2005-09-10|2005-09-12|Estimate|||||||2016-08-02|2016-08-04|Estimate|November 1995||1995-11-30|August 2016|2016-08-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder|Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder|Completed||N/A|25|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-06-01 04:41:35.828016|2018-06-01 04:41:35.828016
NCT00158015|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-10-03|2005-09-08|2005-09-12|Estimate|||||||2012-10-03|2012-10-04|Estimate|October 2004||2004-10-31|October 2012|2012-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Prospective Minnesota Study of ECHO Tissue Doppler Imaging in Cardiac Resynchronization Therapy|Prospective Minnesota Study of ECHO Tissue Doppler Imaging in Cardiac Resynchronization Therapy|Completed|||70|Actual|Minneapolis Medical Research Foundation|||||f||||f||||||||||2018-06-01 04:41:35.918376|2018-06-01 04:41:35.918376
NCT00158002|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-04-04|2005-09-10|2005-09-12|Estimate|||||||2007-04-04|2007-04-05|Estimate|February 2004||2004-02-29|April 2007|2007-04-30|August 2006||2006-08-31|||||Interventional|||A Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine|An Open-Label Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine|Completed||Phase 2|40||Monarch Medical Research|||||f||||||||||||||2018-06-01 04:41:35.986178|2018-06-01 04:41:35.986178
NCT00157989|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-08|2005-09-08|2005-09-12|Estimate|||||||2006-09-08|2006-09-11|Estimate|October 2004||2004-10-31|September 2006|2006-09-30|August 2006||2006-08-31|||||Interventional|||Pilot Study to Assess Safety and Feasibility of Resuscitation of Preterm Infants With Controlled Volume of Air/Oxygen|Safety and Feasibility of Controlled Tidal Volume Resuscitation of Preterm Infants ≤ 28 Weeks’ Gestation: A Randomized Controlled Pilot Study|Terminated||Phase 3|40||Mount Sinai Hospital, Canada|||||f||||||||||||||2018-06-01 04:41:36.052512|2018-06-01 04:41:36.052512
NCT00157976|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-29|2005-09-08|2005-09-12|Estimate|||||||2005-11-29|2005-12-01|Estimate|September 2005||2005-09-30|November 2005|2005-11-30||||||||Interventional|||Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration|A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD|Unknown status|Recruiting|Phase 3|660||Miravant Pharmaceuticals|||||||||||||||||||2018-06-01 04:41:36.114389|2018-06-01 04:41:36.114389
NCT00157963|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-04-12|2005-09-07|2005-09-12|Estimate|||||||2017-04-12|2017-04-13|Actual|February 5, 2005|Actual|2005-02-05|April 2017|2017-04-30|February 8, 2006|Actual|2006-02-08|February 8, 2006|Actual|2006-02-08||Interventional|||Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)|A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients.|Completed||Phase 4|174|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:41:36.18317|2018-06-01 04:41:36.18317
NCT00157950|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-08-17||2016-01-07|2005-09-07|2005-09-12|Estimate|2010-08-17|2010-09-14|Estimate||||2016-01-07|2016-02-04|Estimate|October 2005||2005-10-31|January 2016|2016-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)|An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea|Completed||Phase 3|176|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:41:36.252996|2018-06-01 04:41:36.252996
NCT00157937|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-03-03|2005-09-07|2005-09-12|Estimate|||||||2017-03-03|2017-03-06|Actual|February 2003||2003-02-28|March 2017|2017-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)|A Randomized, Open Label, Cross-Over Study Comparing Effectiveness for the Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics|Completed||Phase 4|31|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:41:36.502405|2018-06-01 04:41:36.502405
NCT00157924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-03-14|2005-09-07|2005-09-12|Estimate|||||||2017-03-14|2017-03-15|Actual|November 2005||2005-11-30|March 2017|2017-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)|A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Hypercholesterolemic Patients With Diabetes Mellitus or Metabolic Syndrome|Completed||Phase 4|190|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:41:36.555022|2018-06-01 04:41:36.555022
NCT00157911|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-03-07|2005-09-07|2005-09-12|Estimate|||||||2017-03-07|2017-03-10|Actual|December 2002||2002-12-31|March 2017|2017-03-31|December 2003|Actual|2003-12-31|October 2003|Actual|2003-10-31||Interventional|||A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)|A Double-Blind, Randomized, Multicenter, Active-Comparative, 12-Week Study to Assess the Efficacy and Safety of the Drug in Conjunction With Another Drug in Korean Patients With Primary Hypercholesterolemia|Completed||Phase 3|136|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:41:36.626191|2018-06-01 04:41:36.626191
NCT00157898|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-02-17|2005-09-07|2005-09-12|Estimate|||||||2017-02-17|2017-02-20|Actual|January 2004||2004-01-31|February 2017|2017-02-28|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)|A Prospective, Multicenter, Open, Randomized, Comparative Study to Evaluate the Safety and Efficacy of Ertapenem Versus it's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults|Completed||Phase 4|134|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:41:36.688279|2018-06-01 04:41:36.688279
NCT00157885|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-06-23|2005-09-08|2005-09-12|Estimate|||||||2006-06-23|2006-06-26|Estimate|July 2005||2005-07-31|June 2006|2006-06-30|December 2005||2005-12-31|||||Interventional|||A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.|A Randomized Trial to Compare the Efficacy of Artekin and Amodiaquine Plus Artesunate for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua|Completed||N/A|400||Menzies School of Health Research|||||f||||||||||||||2018-06-01 04:41:36.739716|2018-06-01 04:41:36.739716
NCT00157872|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-05-23|2005-09-07|2005-09-12|Estimate|||||||2017-05-23|2017-05-25|Actual|January 7, 2004|Actual|2004-01-07|May 2017|2017-05-31|September 19, 2004|Actual|2004-09-19|July 5, 2004|Actual|2004-07-05||Interventional|||A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)|A Multicenter, Randomized, Parallel-Group, 8-Week, Double-Blind, and Active Comparator-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Rofecoxib Tablet 25 mg Once Daily Versus Naproxen Table 500 mg Twice Daily in the Treatment of Chinese Patient With Rheumatoid Arthritis|Completed||Phase 4|150||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:41:36.796611|2018-06-01 04:41:36.796611
NCT00157859|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|September 2004||2004-09-30|||||Interventional|||To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia|To Evaluate the Efficacy of Chloroquine and SP for Acute Uncomplicated P. Falciparum and the Efficacy of Chloroquine for Acute Uncomplicated P. Vivax in the Timika Region of Papua, Indonesia.|Completed||N/A|150||Menzies School of Health Research|||||f||||||||||||||2018-06-01 04:41:36.848985|2018-06-01 04:41:36.848985
NCT00157846|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-02-14|2005-09-10|2005-09-12|Estimate|||||||2017-02-14|2017-02-15|Actual|October 2003||2003-10-31|February 2017|2017-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure|Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure to Investigate the Effect of Preventive Stimulation|Terminated||Phase 4|36|Actual|Medtronic Bakken Research Center||2||Due to existing evidence eligible patients receive CRT treatment in first place|f||||f||||||||No||2018-06-01 04:41:36.927786|2018-06-01 04:41:36.927786
NCT00157833|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-06-23|2005-09-07|2005-09-12|Estimate|||||||2006-06-23|2006-06-26|Estimate|July 2004||2004-07-31|June 2006|2006-06-30|August 2005||2005-08-31|||||Interventional|||A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.|A Randomized Trial to Determine the Efficacy and Safety of Coartemether and Artekin for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua|Completed||N/A|750||Menzies School of Health Research|||||f||||||||||||||2018-06-01 04:41:37.151703|2018-06-01 04:41:37.151703
NCT00157820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2011-03-10||2017-03-09|2005-09-08|2005-09-12|Estimate|2012-07-17|2012-08-21|Estimate||||2017-03-09|2017-04-06|Actual|November 2000||2000-11-30|March 2017|2017-03-31|October 2005|Actual|2005-10-31|May 2005|Actual|2005-05-31||Interventional|DATAS||DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study|DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study|Completed||N/A|354|Actual|Medtronic Bakken Research Center|"The follow-up might have been too short to reveal differences in heart failure-related hospitalizations and related mortality.~Premature crossovers are a limitation of RCT. However, our scoring system severely penalized this cross-overs."|3|||f||||t||||||||No||2018-06-01 04:41:37.25812|2018-06-01 04:41:37.25812
NCT00157807|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-02-14|2005-09-10|2005-09-12|Estimate|||||||2017-02-14|2017-02-15|Actual|September 2005||2005-09-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|June 2008|Actual|2008-06-30||Interventional|||Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery|Clinical and Economic Consequences of Left Atrial Bipolar Radiofrequency Ablation of Persistent and Permanent Atrial Fibrillation During Cardiac Surgery. A Prospective Randomized Multi Center Trial|Terminated||N/A|24|Actual|Medtronic Bakken Research Center||2||no eligible patients can be found|f||||||||||||||2018-06-01 04:41:38.00122|2018-06-01 04:41:38.00122
NCT00157794|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-02-14|2005-09-10|2005-09-12|Estimate|||||||2017-02-14|2017-02-15|Actual|February 2004||2004-02-29|February 2017|2017-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||EnTRINSIC - EnPulse Trial on Search AV+ Influence|EnPulse Trial on Search AV+ Influence|Terminated||Phase 4|135|Actual|Medtronic Bakken Research Center||||"Protocol pre-specified interim analysis showed that difference between groups was too small to~   reach significance."|f||||f||||||||||2018-06-01 04:41:38.150095|2018-06-01 04:41:38.150095
NCT00157781|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-01-29|2005-09-08|2005-09-12|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2000||2000-08-31|January 2018|2018-01-31|November 2003||2003-11-30|||||Interventional|||LEAF - Low Energy In Atrial Fibrillation|Low Energy in Atrial Fibrillation AF Phase IV Study in AT/AF Population Atrial Arrhythmias Prevention and Reduction With Low Energy Atrial Antitachycardia Pacemaker|Completed||Phase 4|237||Medtronic Bakken Research Center|||||f||||||||||||||2018-06-01 04:41:38.34259|2018-06-01 04:41:38.34259
NCT00157768|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-08-04|2005-09-08|2005-09-12|Estimate|||||||2008-08-04|2008-08-05|Estimate|June 1999||1999-06-30|August 2008|2008-08-31|April 2008|Anticipated|2008-04-30|||||Interventional|||IRIS : Use of Implantable Defibrillator in High-Risk Patients Early After Acute Myocardial Infarction|IRIS - Immediate Risk-Stratification Improves Survival - Joint Study of the German University Hospitals and German Society of Leading Cardiological Hospital Physicians (ALKK)|Unknown status|Active, not recruiting|Phase 4|900|Anticipated|Medtronic Bakken Research Center|||||f||||||||||||||2018-06-01 04:41:38.466011|2018-06-01 04:41:38.466011
NCT00157755|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2009-12-18||2010-02-23|2005-09-08|2005-09-12|Estimate|2010-02-23|2010-03-10|Estimate||||2010-02-23|2010-03-10|Estimate|June 2002||2002-06-30|December 2009|2009-12-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)|Gastric Stimulation for Vomiting, Nausea and Related Symptoms Associated With Gastroparesis Using Enterra® Gastric Stimulation System|Terminated||N/A|87|Actual|MedtronicNeuro|Early termination of the study impacted the ability to analyze the primary endpoint and secondary endpoint 1 for the idiopathic arm of the study. The minimum sample size for analysis of these endpoints was 32 subjects.||||f||||||||||||||2018-06-01 04:41:38.573351|2018-06-01 04:41:38.573351
NCT00157742|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-15|2005-09-09|2005-09-12|Estimate|||||||2005-12-15|2005-12-16|Estimate|September 2000||2000-09-30|September 2005|2005-09-30|January 2007||2007-01-31|||||Interventional|||Comparison of SCS and PMR in Patients With Refractory Angina Pectoris|An Open Single-Centre Parallel Randomised Trial of Spinal Cord Stimulation (SCS) and Percutaneous Myocardial Revascularisation (PMR) in Patients With Refractory Angina Pectoris|Terminated||Phase 4|66||Medtronic|||||f||||||||||||||2018-06-01 04:41:39.383701|2018-06-01 04:41:39.383701
NCT00157729|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-30|2005-09-08|2005-09-12|Estimate|||||||2006-10-30|2006-10-31|Estimate|August 2004||2004-08-31|October 2006|2006-10-31|July 2005||2005-07-31|||||Interventional|||MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)|Evaluation of the Effects of MC-1 Alone and in Combination With an ACE Inhibitor on Ambulatory Blood Pressure and Metabolic Function in Hypertensive Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|160||Medicure|||||f||||||||||||||2018-06-01 04:41:39.494783|2018-06-01 04:41:39.494783
NCT00157716|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-30|2005-09-08|2005-09-12|Estimate|||||||2006-10-30|2006-10-31|Estimate|April 2004||2004-04-30|October 2006|2006-10-31|October 2005||2005-10-31|||||Interventional|||MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Cardiovascular and Cerebrovascular Effects of MC-1 in Patients Undergoing High-Risk Coronary Artery Bypass Graft (CABG) Surgery|Completed||Phase 2|900||Medicure|||||f||||||||||||||2018-06-01 04:41:39.681947|2018-06-01 04:41:39.681947
NCT00157703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-12-12|2005-09-08|2005-09-12|Estimate|||||||2008-12-12|2008-12-16|Estimate|May 2005||2005-05-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||G207 Followed by Radiation Therapy in Malignant Glioma|A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy|Completed||Phase 1|9|Actual|MediGene|||||f||||t||||||||||2018-06-01 04:41:39.84343|2018-06-01 04:41:39.84343
NCT00157690|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-10-22|2005-09-08|2005-09-12|Estimate|||||||2008-10-22|2008-10-23|Estimate|December 2003||2003-12-31|October 2008|2008-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients|A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients|Completed||Phase 4|56|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 04:41:40.042317|2018-06-01 04:41:40.042317
NCT00157677|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-10-25|2005-09-08|2005-09-12|Estimate|||||||2011-10-25|2011-10-27|Estimate|October 2004||2004-10-31|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|SELECT||Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis (SELECT)|Selective D-Dimer Testing Compared With Uniform D-Dimer Testing in the Diagnosis of Deep Vein Thrombosis: A Randomized Trial|Completed||Phase 3|1727|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 04:41:40.257098|2018-06-01 04:41:40.257098
NCT00157664|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-06-16|2005-09-10|2005-09-12|Estimate|||||||2008-06-16|2008-06-17|Estimate|July 2004||2004-07-31|June 2008|2008-06-30|December 2008|Anticipated|2008-12-31|May 2008|Anticipated|2008-05-31||Observational|||Long Study - Longitudinal Thrombosis in End Stage Renal Disease|Canadian Longitudinal Thrombosis in End Stage Renal Disease Pilot Study|Unknown status|Active, not recruiting||400|Anticipated|McMaster University|||||f||||t||||||Samples Without DNA|"~     serum and plasma~   "|||2018-06-01 04:41:40.4266|2018-06-01 04:41:40.4266
NCT00157651|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-06-16|2005-09-10|2005-09-12|Estimate|||||||2008-06-16|2008-06-17|Estimate|February 1999||1999-02-28|June 2008|2008-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters|A Double-Blind, Placebo Controlled, Randomized Trial of Low-Intensity Adjusted-Dose Warfarin for the Prevention of Mechanical Malfunction of Double-Lumen Haemodialysis Catheters|Completed||Phase 3|170|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 04:41:40.550647|2018-06-01 04:41:40.550647
NCT00157638|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-08|2005-09-08|2005-09-12|Estimate|||||||2006-09-08|2006-09-11|Estimate|February 2004||2004-02-29|September 2006|2006-09-30|July 2006||2006-07-31|||||Interventional|||Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics|Optimizing Drug Therapy in Primary Care: Integrating Pharmacists With Ontario Family Physician Group Practices.|Completed||Phase 4|1400||McMaster University|||||f||||||||||||||2018-06-01 04:41:40.707389|2018-06-01 04:41:40.707389
NCT00157625|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-09-11|2005-09-07|2005-09-12|Estimate|||||||2006-09-11|2006-09-12|Estimate|April 2003||2003-04-30|September 2006|2006-09-30|July 2006||2006-07-31|||||Interventional|||Automatic Stop Orders for Urinary Catheters|A Randomized Controlled Trial of Automatic Stop Orders for Urinary Catheterization in Hospitalized Patients|Completed||N/A|630||McMaster University|||||f||||||||||||||2018-06-01 04:41:40.81483|2018-06-01 04:41:40.81483
NCT00157612|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-07-19|2005-09-07|2005-09-12|Estimate|||||||2006-07-19|2006-07-21|Estimate|January 2001||2001-01-31|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||A Clinical Pathway for Nursing Home Acquired Pneumonia|A Randomized Control Trial of a Clinical Pathway for Nursing Home Pneumonia.|Completed||N/A|680||McMaster University|||||f||||||||||||||2018-06-01 04:41:40.955615|2018-06-01 04:41:40.955615
NCT00157599|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-07-25|2005-09-07|2005-09-12|Estimate|||||||2011-07-25|2011-07-26|Estimate|January 2002||2002-01-31|October 2007|2007-10-31|March 2007||2007-03-31|||||Interventional|||MDA D-Dimer / Recurrent DVT Study|A Cohort Study Evaluating the Safety of a Diagnostic Strategy Involving D-Dimer and Compression Ultrasonography in Patients With Suspected Recurrent Deep Vein Thrombosis|Completed||N/A|500||McMaster University|||||f||||||||||||||2018-06-01 04:41:41.070247|2018-06-01 04:41:41.070247
NCT00157586|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-04-08|2005-09-08|2005-09-12|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2002||2002-02-28|March 2006|2006-03-31|June 2008||2008-06-30|||||Interventional|||Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)|A Multicenter, Randomized, Prospective, Double-blind Study to Evaluate the Nephroprotective Effect of Delapril Alone or Combined With Manidipine in Patients With Type 2 Diabetes|Completed||Phase 3|342||Mario Negri Institute for Pharmacological Research|||||f||||||||||||||2018-06-01 04:41:41.209702|2018-06-01 04:41:41.209702
NCT00157573|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-04-23||2017-03-27|2005-09-08|2005-09-12|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|December 2004||2004-12-31|March 2017|2017-03-31|April 2010|Actual|2010-04-30|October 2008|Actual|2008-10-31||Interventional||72 ovarian cancer patients with evaluable or measurable disease.|GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer|Phase II Trial of GM-CSF in Women With Asymptomatic Ovarian, Primary Peritoneal, or Tubal Carcinoma|Completed||Phase 2|72|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:41:41.341717|2018-06-01 04:41:41.341717
NCT00157560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-12-28|2005-09-07|2005-09-12|Estimate|||||||2007-12-28|2008-01-03|Estimate|December 2000||2000-12-31|December 2007|2007-12-31|July 2005|Actual|2005-07-31|November 2006|Actual|2006-11-30||Interventional|||Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma|A Phase II Trial of ModifiedTriple Doublet Therapy in the Treatment of Women With Newly Diagnosed Carcinoma of Müllerian Origin|Completed||Phase 2|83||Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:41:42.361416|2018-06-01 04:41:42.361416
NCT00157547|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-23|2005-09-10|2005-09-12|Estimate|||||||2008-05-23|2008-05-28|Estimate|April 2003||2003-04-30|May 2008|2008-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression|The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder|Completed||Phase 4|95|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:41:42.546688|2018-06-01 04:41:42.546688
NCT00157534|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate|October 2004||2004-10-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection|A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection|Completed||Phase 2|43||BioWest Therapeutics Inc|||||f||||||||||||||2018-06-01 04:41:42.628414|2018-06-01 04:41:42.628414
NCT00157521|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-12-21|2005-09-08|2005-09-12|Estimate|||||||2006-12-21|2006-12-22|Estimate|September 2002||2002-09-30|December 2006|2006-12-31|May 2006||2006-05-31|||||Interventional|||L-Arginine in Pre-Eclampsia|A Double-Blind, Randomized, Pilot Study to Explore Whether Enhancing L-Arginine Bioavailability by Oral Supplementation Increases NO Production and Prevents Peroxynitrite Generation in the Pre-Eclamptic Placenta|Completed||Phase 3|30||Mario Negri Institute for Pharmacological Research|||||f||||||||||||||2018-06-01 04:41:42.927256|2018-06-01 04:41:42.927256
NCT00157508|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-04-08|2005-09-08|2005-09-12|Estimate|||||||2015-04-08|2015-04-09|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|August 2004||2004-08-31|||||Interventional|||Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy|A Pilot, Randomised, Double-blind, Cross-over Study to Assess the Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy|Terminated||Phase 2|13||Mario Negri Institute for Pharmacological Research|||||f||||||||||||||2018-06-01 04:41:43.19562|2018-06-01 04:41:43.19562
NCT00157482|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-02-12|2005-09-08|2005-09-12|Estimate|||||||2007-02-12|2007-02-13|Estimate|January 2005||2005-01-31|December 2006|2006-12-31|December 2006||2006-12-31|||||Interventional|||Ezetimibe and Simvastatin in Dyslipidemia of Diabetes|A Randomized, Prospective, Double-Blind Study to Evaluate the Effects on Lipid Profile of Combined Ezetimibe and Simvastatin Therapy as Compared to Simvastatin Alone in People With Type 2 Diabetes|Completed||Phase 2|108||Mario Negri Institute for Pharmacological Research|||||f||||||||||||||2018-06-01 04:41:43.387033|2018-06-01 04:41:43.387033
NCT00157378|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|November 2000||2000-11-30|January 2000|2000-01-31|December 2004||2004-12-31|||||Interventional|||Optimization of Acute Treatment in First Episode Schizophrenia|Optimization of Acute Treatment in First Episode Schizophrenic Patients by New Pharmacological Treatments|Unknown status|Active, not recruiting|Phase 4|300||Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 04:41:43.932458|2018-06-01 04:41:43.932458
NCT00157339|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07||2018-03-07|2018-03-07|2005-09-07|2005-09-12|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|August 2005||2005-08-31|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD|A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma|Completed||Phase 3|299|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 04:41:44.531911|2018-06-01 04:41:44.531911
NCT00157326|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-10-23|2005-09-08|2005-09-12|Estimate|||||||2007-10-23|2007-10-25|Estimate|September 2005||2005-09-30|October 2007|2007-10-31|June 2006|Actual|2006-06-30|||||Interventional|||Tadalafil in Subjects With Mild to Moderate Hypertension|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension|Completed||Phase 2|180|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 04:41:45.000134|2018-06-01 04:41:45.000134
NCT00157313|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-01-27|2005-09-08|2005-09-12|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 1998||1998-01-31|September 2005|2005-09-30|December 2022|Anticipated|2022-12-31|||||Interventional|||Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis|Randomised Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis|Active, not recruiting||N/A|600||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:41:45.073053|2018-06-01 04:41:45.073053
NCT00157300|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-07-30|2005-09-07|2005-09-12|Estimate|||||||2010-07-30|2010-08-02|Estimate|July 2005||2005-07-31|July 2010|2010-07-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|||PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation|PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation|Completed||Phase 4|92|Actual|Leiden University Medical Center||1|||f||||t||||||||||2018-06-01 04:41:45.226569|2018-06-01 04:41:45.226569
NCT00157287|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-08-24|2005-09-08|2005-09-12|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2003||2003-06-30|August 2017|2017-08-31|April 2006|Actual|2006-04-30|June 2005|Actual|2005-06-30||Interventional|||A Cluster Randomized Trial to Improve Weaning and Extubation From Mechanical Ventilation in Community Hospitals|A Cluster Randomized Trial to Improve Weaning and Extubation From Mechanical Ventilation in Community Hospitals|Completed||Phase 3|||Lawson Health Research Institute|||||f||||f|f|f||||||||2018-06-01 04:41:45.315113|2018-06-01 04:41:45.315113
NCT00157274|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-04-02|2005-09-08|2005-09-12|Estimate|||||||2007-04-02|2007-04-03|Estimate|July 2005||2005-07-31|September 2005|2005-09-30|July 2008|Anticipated|2008-07-31|||||Interventional|||Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome|Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome|Unknown status|Recruiting|Phase 2|20||Latin American Cooperative Onco-Haematology Group - Peru|||||f||||||||||||||2018-06-01 04:41:45.397922|2018-06-01 04:41:45.397922
NCT00157261|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-10-28|2005-09-08|2005-09-12|Estimate|||||||2013-10-28|2013-10-29|Estimate|January 2004||2004-01-31|October 2013|2013-10-31|June 2006||2006-06-30|June 2006||2006-06-30||Interventional|||Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial|A Prospective, Randomised, Double-blind, Placebo-controlled, International, Multicentre, Parallel-group Comparison Trial Evaluating the Efficacy and Safety of Tenecteplase During Cardiopulmonary Resuscitation as Compared With Standard Treatment in Patients Suffering From Out-of-hospital Cardiac Arrest of Presumed Cardiac Origin Thrombolysis in Cardiac Arrest (TROICA) Trial|Terminated||Phase 3|1050||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:41:45.533453|2018-06-01 04:41:45.533453
NCT00157248|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-11-18||2014-05-08|2005-09-08|2005-09-12|Estimate|2011-01-11|2011-02-03|Estimate||||2014-05-08|2014-05-19|Estimate|December 2003||2003-12-31|February 2014|2014-02-28||||January 2009|Actual|2009-01-31||Interventional||All patients in follow-up study.|Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048|Long-term, Open-label Follow-up Treatment of Patients With Atrial Fibrillation Who Have Been Previously Treated With BIBR 1048 in the PETRO Trial (Trial 1160.20 - NCT01227629). (PETRO Extension Trial: PETRO-Ex)|Terminated||Phase 2|361|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-06-01 04:41:45.823224|2018-06-01 04:41:45.823224
NCT00157235|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-12-27|2005-09-07|2005-09-12|Estimate|||||||2017-12-27|2017-12-28|Actual|September 2002||2002-09-30|December 2017|2017-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients|A Randomized, Double Blind , Placebo Controlled Trial to Compare the Effect of Tiotropium Inhalation Capsules on Exercise Tolerance in Patients With COPD Participating in 8 Weeks of Pulmonary Rehabilitation|Completed||Phase 3|234||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:41:49.483724|2018-06-01 04:41:49.483724
NCT00157222|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-07|2005-09-08|2005-09-12|Estimate|||||||2005-12-07|2005-12-08|Estimate|May 2005||2005-05-31|September 2005|2005-09-30|April 2008||2008-04-30|||||Observational|||Characterizing and Diagnosis’s of the Charcot Foot (Charcot Osteoarthropathy) in Diabetic Patients|Characterizing and Diagnosis’s of the Charcot Foot (Charcot Osteoarthropathy) in Diabetic Patients|Unknown status|Recruiting||50||Bispebjerg Hospital|||||f||||||||||||||2018-06-01 04:41:50.398781|2018-06-01 04:41:50.398781
NCT00157209|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2015-07-23||2015-10-19|2005-09-09|2005-09-12|Estimate|2015-10-19|2015-11-18|Estimate||||2015-10-19|2015-11-18|Estimate|August 2000||2000-08-31|October 2015|2015-10-31|July 2012|Actual|2012-07-31|March 2006|Actual|2006-03-31||Interventional||Baseline analysis population included all randomized participants.|Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)|A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer|Completed||Phase 2|171|Actual|Merck KGaA||2|||f||||||||||||||2018-06-01 04:41:50.583956|2018-06-01 04:41:50.583956
NCT00157196|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2015-07-23||2015-07-23|2005-09-09|2005-09-12|Estimate|2015-07-23|2015-08-18|Estimate||||2015-07-23|2015-08-18|Estimate|April 2005||2005-04-30|July 2015|2015-07-31|April 2012|Actual|2012-04-30|September 2007|Actual|2007-09-30||Interventional||The intention-to-treat (ITT) analysis set included all the enrolled participants who received at least 1 dose of trial treatment.|Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease|A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease|Completed||Phase 2|22|Actual|Merck KGaA||1|||f||||||||||||||2018-06-01 04:41:51.218016|2018-06-01 04:41:51.218016
NCT00157183|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-12-04|2005-09-10|2005-09-12|Estimate|||||||2013-12-04|2013-12-05|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation|Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation|Completed||Phase 1/Phase 2|59|Actual|Bayside Health|||||f||||||||||||||2018-06-01 04:41:52.529986|2018-06-01 04:41:52.529986
NCT00157170|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-10-19|2005-09-09|2005-09-12|Estimate|||||||2005-10-19|2005-10-21|Estimate|September 2002||2002-09-30|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||The Effects of a Supervised Exercise Program on Self Efficacy of People Living With HIV/AIDS.|The Effects of a Supervised Exercise Program on Self Efficacy, Quality of Life Status, Cardiovascular Fitness and Hospital Readmission Rates of People Living With HIV/AIDS.|Completed||N/A|40||Bayside Health|||||f||||||||||||||2018-06-01 04:41:52.887389|2018-06-01 04:41:52.887389
NCT00157157|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2011-02-15||2017-10-19|2005-09-09|2005-09-12|Estimate|2011-06-18|2011-07-15|Estimate||||2017-10-19|2017-11-22|Actual|April 2004||2004-04-30|June 2014|2014-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients|Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Patients With Hemophilia A|Completed||Phase 3|66|Actual|Shire||1|||f||||t||||||||||2018-06-01 04:41:53.32773|2018-06-01 04:41:53.32773
NCT00157144|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-03-06|2005-09-09|2005-09-12|Estimate|||||||2014-03-06|2014-03-10|Estimate|October 2004||2004-10-31|March 2014|2014-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005||Completed|||||Bayside Health|||||f||||||||||||||2018-06-01 04:41:54.849839|2018-06-01 04:41:54.849839
NCT00157131|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-04-19|2005-09-08|2005-09-12|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2004||2004-06-30|April 2017|2017-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients|A Study To Evaluate the Safety and Efficacy of Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated (FS 4IU VH S/D) to Adhere Tissues and Improve Wound Healing|Completed||Phase 3|150|Actual|Baxter Healthcare Corporation||2|||||||||||||||||2018-06-01 04:41:55.028761|2018-06-01 04:41:55.028761
NCT00157118|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-08|2005-09-12|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2003||2003-08-31|July 2013|2013-07-31|March 2005|Actual|2005-03-31|||||Interventional|||Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency|A Phase II/III Clinical Study for the Determination of the Efficacy and Safety of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency|Completed||Phase 2/Phase 3|18|Actual|Shire|||||||||||||||||||2018-06-01 04:41:55.254034|2018-06-01 04:41:55.254034
NCT00157105|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-08|2005-09-12|Estimate|||||||2017-10-19|2017-10-23|Actual|February 2001||2001-02-28|October 2006|2006-10-31|August 2004||2004-08-31|||||Interventional|||Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery|Recombinant Antihemophilic Factor (rAHF PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Safety and Efficacy in Hemophilia A Patients Undergoing Surgical or Invasive Procedures|Completed||N/A|||Shire|||||||||||||||||||2018-06-01 04:41:55.383042|2018-06-01 04:41:55.383042
NCT00157092|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-08|2005-09-12|Estimate|||||||2017-10-19|2017-10-23|Actual|March 2004||2004-03-31|October 2006|2006-10-31|October 2004||2004-10-31|||||Interventional|||Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency|A Phase 1B/2A Study to Evaluate the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency|Completed||Phase 1/Phase 2|15||Shire|||||||||||||||||||2018-06-01 04:41:55.46308|2018-06-01 04:41:55.46308
NCT00157079|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-01-16|2005-09-10|2005-09-12|Estimate|||||||2018-01-16|2018-01-18|Actual|June 25, 2002|Actual|2002-06-25|January 2018|2018-01-31|December 16, 2003|Actual|2003-12-16|December 16, 2003|Actual|2003-12-16||Interventional|||Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders|A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders|Completed||Phase 3|||Shire|||||f|||||t|||||||||2018-06-01 04:41:55.580108|2018-06-01 04:41:55.580108
NCT00157066|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-01-05|2005-09-08|2005-09-12|Estimate|||||||2007-01-05|2007-01-08|Estimate|December 2002||2002-12-31|January 2007|2007-01-31|September 2006||2006-09-30|||||Interventional|||Effects of Vitamin D Supplementation on Antimycobacterial Immunity|Effects of Vitamin D Supplementation on Antimycobacterial Immunity: A Randomised Trial|Completed||N/A|230||Barts & The London NHS Trust|||||f||||||||||||||2018-06-01 04:41:55.695117|2018-06-01 04:41:55.695117
NCT00156455|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-04-29|2005-09-08|2005-09-12|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2004||2004-09-30|April 2015|2015-04-30||||March 2008|Actual|2008-03-31||Observational|||Sleep Disordered Breathing in Children With Single Ventricle Physiology|Sleep Disordered Breathing in Children With Single Ventricle Physiology|Withdrawn|||0|Actual|University of Rochester||||lack of study personel|f||||f||||||||||2018-06-01 04:42:04.408567|2018-06-01 04:42:04.408567
NCT00157053|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-08|2005-09-12|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2001||2001-11-30|February 2011|2011-02-28|August 2004|Actual|2004-08-31|||||Interventional|||Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901|Evaluation of Pharmacokinetics, Safety, Efficacy and Immunogenicity of rAHF-PFM in Previously Treated Hemophilia A Patients - A Continuation Study|Completed||Phase 2/Phase 3|||Shire|||||||||||||||||||2018-06-01 04:41:55.780778|2018-06-01 04:41:55.780778
NCT00157040|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-19|2005-09-08|2005-09-12|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2002||2002-06-30|September 2011|2011-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A|Recombinant Antihemophilic Factor (rAHF-PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Pharmacokinetics, Immunogenicity, Efficacy and Safety in Previously Treated Pediatric Patients With Hemophilia A|Completed||Phase 2/Phase 3|50||Shire|||||f||||||||||||||2018-06-01 04:41:56.023554|2018-06-01 04:41:56.023554
NCT00157027|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-01-15|2005-09-10|2005-09-12|Estimate|||||||2014-01-15|2014-01-16|Estimate|December 2003||2003-12-31|January 2014|2014-01-31|April 2010|Anticipated|2010-04-30|||||Interventional|HIV-HAART||RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)|The Use of Extracorporeal Photochemotherapy With UVADEX in Patients With HIV Who Are Refractory or Intolerant to HAART|Withdrawn||Phase 1|0|Actual|Atlantic Health System||1|||f||||t||||||||||2018-06-01 04:41:56.172512|2018-06-01 04:41:56.172512
NCT00157014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-10-28|2009-07-15|2017-05-04|2005-09-08|2005-09-12|Estimate|2011-01-24|2011-02-21|Estimate|2010-02-25|2010-02-26|Estimate|2017-05-04|2017-06-05|Actual|May 10, 2004|Actual|2004-05-10|April 2017|2017-04-30|July 18, 2008|Actual|2008-07-18|July 18, 2008|Actual|2008-07-18||Interventional|||Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens|Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens With MPA TDM|Completed||Phase 3|111|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|4|||f||||t||||||||||2018-06-01 04:41:56.456408|2018-06-01 04:41:56.456408
NCT00157001|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-01-15|2005-09-10|2005-09-12|Estimate|||||||2014-01-15|2014-01-16|Estimate|August 2000||2000-08-31|January 2014|2014-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Feasibility Study of Photopheresis Post Angioplasty|Feasibility Study of Photopheresis Post Angioplasty|Terminated||Phase 2|120||Atlantic Health System|||||f||||t||||||||||2018-06-01 04:41:58.908013|2018-06-01 04:41:58.908013
NCT00156988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-08-07|2005-09-08|2005-09-12|Estimate|||||||2009-08-07|2009-08-10|Estimate|March 2004||2004-03-31|August 2009|2009-08-31|December 2005||2005-12-31|||||Interventional|||The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns|The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns|Completed||Phase 4|||Association of Dutch Burn Centres|||||f||||||||||||||2018-06-01 04:41:59.033578|2018-06-01 04:41:59.033578
NCT00156975|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-12-24|2005-09-09|2005-09-12|Estimate|||||||2009-12-24|2009-12-25|Estimate|November 2004||2004-11-30|April 2007|2007-04-30||||||||Interventional|||Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases|Adjuvant Chemotherapy With Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases- Randomized Phase III Study|Unknown status|Active, not recruiting|Phase 3|384||Arbeitsgruppe Lebermetastasen und Tumoren|||||f||||||||||||||2018-06-01 04:41:59.144336|2018-06-01 04:41:59.144336
NCT00156962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-07-17|2005-09-08|2005-09-12|Estimate|||||||2008-07-17|2008-07-21|Estimate|April 2005||2005-04-30|July 2008|2008-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)|A Randomized, Open-Label Study to Assess the Safety of Epoetin Alfa Manufactured by Deep Tank Technology and Epoetin Alfa Manufactured by Roller Bottle Technology in Subjects With Chronic Kidney Disease Not on Dialysis|Terminated||Phase 3|850|Anticipated|Amgen||2||Regulatory decision not to proceed|f||||||||||||||2018-06-01 04:41:59.258874|2018-06-01 04:41:59.258874
NCT00156949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-02-18|2005-09-08|2005-09-12|Estimate|||||||2010-02-18|2010-02-19|Estimate|April 2005||2005-04-30|February 2010|2010-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||EPO Deep Tank in Dialysis Subjects|An Open-Label, Single-Arm Study to Assess the Safety of Epoetin Alfa Manufactured by a Deep Tank Technology in Subjects With Chronic Kidney Disease Receiving Dialysis|Completed||Phase 3|580|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:41:59.36516|2018-06-01 04:41:59.36516
NCT00156936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-10-08||2010-11-05|2005-09-07|2005-09-12|Estimate|2010-10-08|2010-11-03|Estimate||||2010-11-05|2010-11-17|Estimate|August 2004||2004-08-31|November 2010|2010-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])|An Open-Label, Multi-Center Study to Evaluate the Long-Term Safety of Medisorb® Naltrexone|Terminated||Phase 3|108|Actual|Alkermes, Inc.||2||Business decision|f||||f||||||||||2018-06-01 04:41:59.531575|2018-06-01 04:41:59.531575
NCT00156923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-10-08||2017-06-08|2005-09-07|2005-09-12|Estimate|2010-11-05|2010-12-03|Estimate||||2017-06-08|2017-07-11|Actual|October 2003||2003-10-31|June 2017|2017-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults|A Multi-Center Extension of Alkermes' Study ALK21-003-EXT (NCT01218971) to Evaluate the Long-Term Safety of Medisorb® Naltrexone|Completed||Phase 3|108|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-06-01 04:42:00.064316|2018-06-01 04:42:00.064316
NCT00156910|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-11-05|2009-06-17|2013-10-24|2005-09-07|2005-09-12|Estimate|2010-11-05|2010-12-07|Estimate|2009-09-25|2009-09-28|Estimate|2013-10-24|2013-11-18|Estimate|February 2006||2006-02-28|October 2013|2013-10-31|July 2008|Actual|2008-07-31|November 2007|Actual|2007-11-30||Interventional|||A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches||Completed||Phase 3|679|Actual|Allergan||2|||f||||||||||||||2018-06-01 04:42:00.368668|2018-06-01 04:42:00.368668
NCT00156897|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-08-25|2005-09-08|2005-09-12|Estimate|||||||2006-08-25|2006-08-29|Estimate|December 2004||2004-12-31|August 2006|2006-08-31|October 2005||2005-10-31|||||Interventional|||Efficacy and Safety of ATL-962 in Obese Diabetics|Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat|Completed||Phase 2|600||Alizyme|||||f||||||||||||||2018-06-01 04:42:00.85962|2018-06-01 04:42:00.85962
NCT00156676|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-09-18|2005-09-08|2005-09-12|Estimate|||||||2013-09-18|2013-09-20|Estimate|September 2004||2004-09-30|September 2013|2013-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Restoration of Walking in Multiple Sclerosis Using Treadmill Training.|Pilot Study on Gait & Motor Function in MS Using BWS Treadmill Training|Completed||N/A|30|Anticipated|VA Office of Research and Development||2|||f||||||||||||||2018-06-01 04:42:02.725618|2018-06-01 04:42:02.725618
NCT00156884|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-01-18|2005-09-08|2005-09-12|Estimate|||||||2012-01-18|2012-01-19|Estimate|August 2003||2003-08-31|August 2008|2008-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer|A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer|Completed||Phase 2|58|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:42:00.963484|2018-06-01 04:42:00.963484
NCT00156871|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-01-18|2005-09-08|2005-09-12|Estimate|||||||2012-01-18|2012-01-19|Estimate|April 2003||2003-04-30|August 2011|2011-08-31|December 2005|Actual|2005-12-31|||||Interventional|||Individualized Exercise Program for Treatment of Fatigue in Patients After Hematologic Stem Cell Transplant (HSCT)|Individualized Exercise Program for Treatment of Fatigue in Patients After Hematologic Stem Cell Transplant|Completed||N/A|24|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:42:01.019937|2018-06-01 04:42:01.019937
NCT00156858|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-01-18|2005-09-08|2005-09-12|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 1998||1998-01-31|September 2011|2011-09-30|December 2010||2010-12-31|||||Interventional|||Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study|Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell|Unknown status|Recruiting|N/A|200|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:42:01.101634|2018-06-01 04:42:01.101634
NCT00156845|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-07-13|2005-09-08|2005-09-12|Estimate|||||||2006-07-13|2006-07-14|Estimate|December 2003||2003-12-31|July 2006|2006-07-31|June 2006||2006-06-30|||||Interventional|||Phase 3 Safety and Imaging Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing Coronary Angiography|A Phase 3, International, Multicenter, Open-Label, Dual-Injection, Echocardiographic Imaging and Safety Study in Patients With Suspected Ischemic Heart Disease Undergoing Diagnostic Coronary Angiography (Real-Time Assessment of Myocardial Perfusion With Echocardiography: RAMP 2)|Completed||Phase 3|450||Acusphere|||||||||||||||||||2018-06-01 04:42:01.153269|2018-06-01 04:42:01.153269
NCT00156819|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2015-11-04||2015-11-04|2005-09-08|2005-09-12|Estimate|2015-11-04|2015-12-09|Estimate||||2015-11-04|2015-12-09|Estimate|June 2003||2003-06-30|November 2015|2015-11-30|August 2006|Actual|2006-08-31|August 2005|Actual|2005-08-31||Interventional|||The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial|The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial|Completed||Phase 4|500|Actual|JHSPH Center for Clinical Trials||3|||f||||||||||||||2018-06-01 04:42:01.208099|2018-06-01 04:42:01.208099
NCT00156806|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-01-23|2005-09-07|2005-09-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2002||2002-03-31|January 2017|2017-01-31|May 2006|Actual|2006-05-31|May 2005|Actual|2005-05-31||Interventional|||Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.|Investigating the Therapeutic Effectiveness of Aloe Barbadensis in Reducing Cutaneous Side-Effects of Radiation Treatment for Breast Cancer.|Completed||Phase 3|231||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:42:01.6929|2018-06-01 04:42:01.6929
NCT00156793|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-07-13|2005-09-08|2005-09-12|Estimate|||||||2006-07-13|2006-07-14|Estimate|December 2003||2003-12-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging|A Phase 3, International, Multicenter, Open Label, Dual-Injection, Echocardiographic Imaging and Safety Study of AI-700 in Patients With Suspected Ischemic Heart Disease Undergoing Single-Photon Emission Computed Tomography (Real-Time Assessment of Myocardial Perfusion With Echocardiography: RAMP 1)|Completed||Phase 3|400||Acusphere|||||||||||||||||||2018-06-01 04:42:01.756204|2018-06-01 04:42:01.756204
NCT00156780|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-19|2005-09-08|2005-09-12|Estimate|||||||2006-10-19|2006-10-23|Estimate|August 2004||2004-08-31|July 2006|2006-07-31|July 2005||2005-07-31|||||Interventional|||Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF|A Phase 1, Double Blind, Crossover, Placebo-Controlled, Dual-Injection, Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and Chronic Obstructive Pulmonary Disease (COPD) and/or Congestive Heart Failure (CHF)|Completed||Phase 1|||Acusphere|||||||||||||||||||2018-06-01 04:42:01.828314|2018-06-01 04:42:01.828314
NCT00156767|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2018-03-27|2005-09-09|2005-09-12|Estimate|||||||2018-03-27|2018-03-29|Actual|October 21, 2004||2004-10-21|January 17, 2018|2018-01-17||||||||Observational|||Adrenal Function in Critical Illness|Adrenal Function in Critical Illness|Completed|||225|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:42:01.888907|2018-06-01 04:42:01.888907
NCT00156741|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-08-01|2005-09-07|2005-09-12|Estimate|||||||2011-08-01|2011-08-02|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|April 2006||2006-04-30|||||Interventional|||Efficacy of a Pacemaker Algorithm in Promotion of the Intrinsic Heart Activity.|IntAct, Study on Promotion of Intrinsic Activity.|Unknown status|Active, not recruiting|Phase 4|150||Medtronic BRC|||||f||||||||||||||2018-06-01 04:42:01.967924|2018-06-01 04:42:01.967924
NCT00156728|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-11-03|2005-09-08|2005-09-12|Estimate|||||||2008-11-03|2008-11-04|Estimate|October 2003||2003-10-31|November 2008|2008-11-30|December 2005|Actual|2005-12-31|||||Interventional|||Study to Characterize Atrial Fibrillation in CHF Patients Indicated for CRT|Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)|Completed||Phase 4|172||Medtronic BRC|||||f||||||||||||||2018-06-01 04:42:02.20275|2018-06-01 04:42:02.20275
NCT00156715|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2010-11-19||2018-03-12|2005-09-07|2005-09-12|Estimate|2010-11-19|2010-12-21|Estimate||||2018-03-12|2018-03-14|Actual|March 2004||2004-03-31|March 2018|2018-03-31|October 2008|Actual|2008-10-31|September 2006|Actual|2006-09-30||Interventional|||Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder|Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia|Completed||Phase 4|23|Actual|Dartmouth-Hitchcock Medical Center|Lack of a control group; Small study group size, and the consequent lack of power to detect a significant change; Differences between the populations at the two sites.|1|||f||||t||||||||||2018-06-01 04:42:02.381318|2018-06-01 04:42:02.381318
NCT00156702|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-01-07|2005-09-08|2005-09-12|Estimate|||||||2013-01-07|2013-01-08|Estimate|January 2001||2001-01-31|January 2013|2013-01-31|October 2006|Actual|2006-10-31|||||Interventional|||Researching the Youth Smoking Experience|Researching the Youth Smoking Experience|Completed||Phase 1|40|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-06-01 04:42:02.590527|2018-06-01 04:42:02.590527
NCT00156689|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-01-02|2005-09-08|2005-09-12|Estimate|||||||2008-01-02|2008-01-11|Estimate|August 2005||2005-08-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|||||Interventional|||A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.|A Pilot Study in a Double Blind, Randomized, Placebo-Controlled, Parallel-Group, 16 Week, Trial Design Evaluating the Efficacy and Safety of Levetiracetam 500 mg Tablets in Bid Administration (Daily Dose Ranging From 1000 mg to 3000 mg), in Adults (>18 Years of Ages) Suffering From Chronic Idiopathic Axonal Polyneuropathy|Completed||Phase 2|30|Actual|Vanderbilt University|||||f||||f||||||||||2018-06-01 04:42:02.656112|2018-06-01 04:42:02.656112
NCT00156663|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2015-04-06|2005-09-07|2005-09-12|Estimate|||||||2015-04-06|2015-04-07|Estimate|May 2004||2004-05-31|February 2007|2007-02-28|September 2005|Actual|2005-09-30|||||Interventional|||Toward Gender Aware VA Healthcare: Development and Evaluation of an Intervention|Toward Gender Aware VA Health Care: Development and Evaluation of an Intervention|Completed||N/A|250|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:42:02.817143|2018-06-01 04:42:02.817143
NCT00156650|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-09-18|2005-09-08|2005-09-12|Estimate|||||||2008-09-18|2008-09-19|Estimate|December 2004||2004-12-31|September 2008|2008-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|IHOP-5||Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (HOP 5) Testicular Aspiration Addendum|Male Hormonal Contraception Development: Suppression of Spermatogenesis With the Addition of a Potent GnRH Antagonist (Acyline) to Testosterone and DMPA (ACY-5) -Sub-Study (HOP 5)|Completed||Phase 1/Phase 2|23|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:42:02.904083|2018-06-01 04:42:02.904083
NCT00156637|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-04-06|2005-09-07|2005-09-12|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2005||2005-06-30|April 2008|2008-04-30|March 2008|Actual|2008-03-31|January 2007|Actual|2007-01-31||Interventional|||A Study of Strategies to Improve Schizophrenia Treatment|A Study of Strategies to Improve Schizophrenia Treatment|Completed||N/A|106|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:42:02.993352|2018-06-01 04:42:02.993352
NCT00156624|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-04-24|2005-09-08|2005-09-12|Estimate|||||||2006-04-24|2006-04-25|Estimate|July 2004||2004-07-31|September 2005|2005-09-30|October 2007||2007-10-31|||||Interventional|||Thunder Trial - Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries|Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries (Thunder – Trial)|Unknown status|Active, not recruiting|Phase 2/Phase 3|135||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:42:03.072395|2018-06-01 04:42:03.072395
NCT00156611|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-09-11|2005-09-08|2005-09-12|Estimate|||||||2006-09-11|2006-09-12|Estimate|January 2002||2002-01-31|September 2006|2006-09-30|December 2009||2009-12-31|||||Interventional|||Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease|ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease – A Randomized Prospective Trial (RIO-Trial)|Unknown status|Active, not recruiting|Phase 2/Phase 3|420||University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:42:03.132913|2018-06-01 04:42:03.132913
NCT00156598|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-06-28|2005-09-07|2005-09-12|Estimate|||||||2012-06-28|2012-07-02|Estimate|August 2004||2004-08-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Metal Ion Serum Concentrations in Patients With Total Hip Replacements|Cobalt, Chromium and Titanium Serum Concentrations in Patients With Metal-on-Metal vs. Metal on Polyethylene Total Hip Replacements|Terminated|||5|Actual|The University of Texas Health Science Center at San Antonio||||Resident graduated; faculty mentor retired|f||||||||||||||2018-06-01 04:42:03.191519|2018-06-01 04:42:03.191519
NCT00156585|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-01-13|2005-09-07|2005-09-12|Estimate|||||||2015-01-13|2015-01-15|Estimate|August 2005||2005-08-31|January 2015|2015-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Predictive Value of Dynamic Contrast Enhancement MRI on a Cerebral Tumor Response to Gamma Knife Treatment|Prospective Study of Predictive Value of Dynamic Contrast Enhancement Magnetic Resonance Imaging With Gadolinium on the Response of a Cerebral Tumor to a Treatment With Gamma Knife|Completed|||31|Actual|Université de Sherbrooke|||||f||||f||||||||||2018-06-01 04:42:03.236427|2018-06-01 04:42:03.236427
NCT00156572|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-12-26|2005-09-07|2005-09-12|Estimate|||||||2007-12-26|2007-12-27|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Management of Hyponatremia in Preterm Infants on Diuretics|Management of Hyponatremia in Preterm Infants on Diuretics|Terminated||Phase 3|58|Anticipated|The University of Texas Health Science Center, Houston||||decreasing rate of enrollment|f||||||||||||||2018-06-01 04:42:03.288286|2018-06-01 04:42:03.288286
NCT00156559|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-09-15|2005-09-08|2005-09-12|Estimate|||||||2015-09-15|2015-09-17|Estimate|January 2004||2004-01-31|September 2015|2015-09-30|May 2005|Actual|2005-05-31|||||Observational|||MMR and Varicella Vaccine in Premature Infants|MMR and Varicella Vaccine Responses in Extremely Premature Infants|Completed|||32||University of Rochester|||||f||||||||||||||2018-06-01 04:42:03.341244|2018-06-01 04:42:03.341244
NCT00156546|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-11-30|2005-09-07|2005-09-12|Estimate|||||||2005-11-30|2005-12-01|Estimate|May 2000||2000-05-31|September 2005|2005-09-30|July 2006||2006-07-31|||||Interventional|||Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection|Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a History of Upper Urinary Tract Infections:a Multicentre Randomised Study|Unknown status|Active, not recruiting|Phase 4|660||University of Padova|||||f||||||||||||||2018-06-01 04:42:03.533917|2018-06-01 04:42:03.533917
NCT00156533|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2011-10-10||2015-10-21|2005-09-08|2005-09-12|Estimate|2013-04-04|2013-05-16|Estimate||||2015-10-21|2015-11-20|Estimate|March 2005||2005-03-31|October 2015|2015-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing|Long Term Treatment With Zolpidem: The Relative Efficacy of Nightly (Quaque Hora Somni [QHS]) & Intermittent Dosing and the Potential for Long Term Clinical Gains After Treatment Discontinuation.|Completed||Phase 4|20|Actual|University of Rochester|About 25% of the target sample was obtained. As a result our capacity to detect trends and to calculate effect sizes was greatly diminished. Accordingly, our observations must be very limited in scope.|4|||f||||t||||||||||2018-06-01 04:42:03.668864|2018-06-01 04:42:03.668864
NCT00156520|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-04-09|2005-09-08|2005-09-12|Estimate|||||||2010-04-09|2010-04-12|Estimate|March 2005||2005-03-31|April 2010|2010-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Platelet Function And Aggregometry In Patients With Aortic Valve Stenosis|Jeanne Grace; Head Research Subjects Review Board|Completed||Phase 4|40|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:42:03.969134|2018-06-01 04:42:03.969134
NCT00156507|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-05-11|2005-09-08|2005-09-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Improving Asthma Care for Very Low Birth Weight Infants|Improving Asthma Care for Very Low Birth Weight Infants|Completed||N/A|192|Actual|University of Rochester||1|||f||||f||||||||||2018-06-01 04:42:04.039734|2018-06-01 04:42:04.039734
NCT00156494|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-05-11|2005-09-08|2005-09-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|June 2004||2004-06-30|May 2011|2011-05-31||||||||Observational|||Attitudes About Smoking: A Telephone Survey|"Attitudes About Smoking A Telephone Survey of Parents of Young Urban Children"|Completed|||371|Actual|University of Rochester|||||f||||f||||||||||2018-06-01 04:42:04.174705|2018-06-01 04:42:04.174705
NCT00156481|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-05-11|2005-09-08|2005-09-12|Estimate|||||||2011-05-11|2011-05-12|Estimate|December 2004||2004-12-31|May 2011|2011-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||A Qualitative Study About Smoking Practices|Smoking Practices Among Parents of Urban Children With Asthma: A Qualitative Study|Completed|||35|Actual|University of Rochester|||||f||||||||||||||2018-06-01 04:42:04.221231|2018-06-01 04:42:04.221231
NCT00156442|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-01-11|2005-09-08|2005-09-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||A Study to Examine the Relationship Between Sleep Apnea and Cleft Lip/Palate|OSAS in Children With Cleft Lip/Palate|Completed|||100|Anticipated|University of Rochester|||||f||||f||||||||||2018-06-01 04:42:04.464605|2018-06-01 04:42:04.464605
NCT00156429|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2018-01-02|2005-09-08|2005-09-12|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2005||2005-07-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Genetic Predictors of Outcome in HCM Patients|Genetic Predictors of Outcome in HCM Patients|Active, not recruiting|||540|Anticipated|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     Blood sample for DNA analysis~   "|||2018-06-01 04:42:04.547992|2018-06-01 04:42:04.547992
NCT00156416|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-12-02|2005-09-08|2005-09-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2005||2005-02-28|December 2014|2014-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Menopause and Meditation for Breast Cancer Survivors|Menopause and Meditation for Breast Cancer Survivors|Completed||Phase 1/Phase 2|51|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:42:04.607195|2018-06-01 04:42:04.607195
NCT00156403|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-12-13|2005-09-08|2005-09-12|Estimate|||||||2007-12-13|2007-12-17|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|December 2005|Actual|2005-12-31|||||Interventional|||A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis|Hereditary Pancreatitis Amlodipine Trial(H-PAT): A Pilot Study|Completed||Phase 1/Phase 2|8||University of Pittsburgh|||||||||||||||||||2018-06-01 04:42:04.802922|2018-06-01 04:42:04.802922
NCT00156390|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2014-05-21||2017-12-06|2005-09-08|2005-09-12|Estimate|2014-11-21|2014-11-24|Estimate||||2017-12-06|2018-01-05|Actual|June 2005||2005-06-30|December 2017|2017-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Predictors of Response to Biventricular Pacing in Heart Failure|Predictors of Response to Biventricular Pacing in Heart Failure|Completed||N/A|187|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 04:42:04.890655|2018-06-01 04:42:04.890655
NCT00156377|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-05-24|2005-09-08|2005-09-12|Estimate|||||||2010-05-24|2010-05-25|Estimate|November 2002||2002-11-30|September 2005|2005-09-30||||||||Interventional|||Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections|Investigation of the Influence of Intranasal Mupirocin on the Prevalence of S. Aureus Nosocomial Infections by Eradication of Intranasal S. Aureus|Completed||Phase 4|1200||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:42:05.111764|2018-06-01 04:42:05.111764
NCT00156364|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-12-10|2005-09-08|2005-09-12|Estimate|||||||2014-12-10|2014-12-11|Estimate|January 1981||1981-01-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Studies of Organ Transplantation in Animals and Man|"Ii-Pancreas Transplantation in Man, Long Term Effects of Cyclosporine (CSA) and Tacrolimus (FK506) on Renal Structure and Function, Studies of the Renal Interstitium Type I Diabetic Patients,"|Completed|||655|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||Samples With DNA|"~     Skin Fibroblasts, Plasma and Serum samples, Urine samples, kidney biopsy culture samples.~   "|||2018-06-01 04:42:05.178257|2018-06-01 04:42:05.178257
NCT00156351|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-03-26|2005-09-08|2005-09-12|Estimate|||||||2008-03-26|2008-03-28|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Walking For Wellness Program Evaluation|Evaluation of the National Black Women's Health Project Walking for Wellness Program|Completed||N/A|186||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:42:05.276229|2018-06-01 04:42:05.276229
NCT00156338|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-01-16|2005-09-08|2005-09-12|Estimate|||||||2012-01-16|2012-01-18|Estimate|July 2005||2005-07-31|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Intraoperative Fluid Management on Morbidity|Effect of Intraoperative Fluid Management on Morbidity in Patients Undergoing Colorectal Surgery|Completed||N/A|108|Actual|University Hospital Muenster||3|||f||||f||||||||||2018-06-01 04:42:05.338936|2018-06-01 04:42:05.338936
NCT00156325|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-30|2005-09-08|2005-09-12|Estimate|||||||2005-12-30|2006-01-02|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|February 2005||2005-02-28|||||Interventional|||Escitalopram as a Mood Stabilizer for Bipolar II Disorder|A Double-Blind, Placebo-Controlled Trial of Escitalopram as a Mood Stabilizer for Bipolar II Disorder|Completed||Phase 2|10||The University of New South Wales|||||f||||||||||||||2018-06-01 04:42:05.403392|2018-06-01 04:42:05.403392
NCT00156312|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-02-05|2005-09-08|2005-09-12|Estimate|||||||2012-02-05|2012-02-07|Estimate|July 2003||2003-07-31|February 2012|2012-02-29|February 2007|Actual|2007-02-28|May 2005|Actual|2005-05-31||Interventional|||Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine|Evaluation of Thymidine Phosphorylase and Other Predictive/Prognostic Factors in Primary Breast Cancer Treated With Docetaxel and Capecitabine (DC)|Completed||N/A|25|Anticipated|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:42:05.468815|2018-06-01 04:42:05.468815
NCT00156299|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-11-18|2005-09-08|2005-09-12|Estimate|||||||2013-11-18|2013-11-19|Estimate|March 2003||2003-03-31|November 2013|2013-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate|A Pilot Study of Nuclear Factor-kappa B (NFkB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia (AML)|Terminated||Phase 1|15|Actual|Rutgers, The State University of New Jersey||2||Replaced by another study|f||||f||||||||||2018-06-01 04:42:05.528323|2018-06-01 04:42:05.528323
NCT00156286|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-11-12|2005-09-08|2005-09-12|Estimate|||||||2010-11-12|2010-11-16|Estimate|March 2002||2002-03-31|November 2010|2010-11-30|April 2006|Actual|2006-04-30|January 2006|Actual|2006-01-31||Interventional|||Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC|Phase II Trial of Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive, Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|20||University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:42:05.607975|2018-06-01 04:42:05.607975
NCT00156273|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-07-03|2005-09-08|2005-09-12|Estimate|||||||2017-07-03|2017-07-05|Actual|April 2005||2005-04-30|July 2017|2017-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer|A Pilot Study to Determine the Feasibility of Quantifying Apoptosis and Bcl-2 Expression in Circulating Tumor Cells (CTCs) in Women Undergoing Treatment for Metastatic Breast Cancer|Completed|||69|Actual|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:42:05.663114|2018-06-01 04:42:05.663114
NCT00156260|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-10-04|2005-09-08|2005-09-12|Estimate|||||||2008-10-04|2008-10-08|Estimate|January 2003||2003-01-31|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage|UMCC 2-48 Feasibility Study of Evaluating Breast Cancer Patients With Ductal Lavage|Terminated|||88|Anticipated|University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:42:05.716203|2018-06-01 04:42:05.716203
NCT00156247|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2011-07-11||2015-02-13|2005-09-08|2005-09-12|Estimate|2015-02-13|2015-02-16|Estimate||||2015-02-13|2015-02-16|Estimate|September 2005||2005-09-30|February 2015|2015-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Acitretin and Etanercept in Psoriasis|Pilot, Single-Arm Study of the Effect of Adding Acitretin to Etanercept Therapy in Patients With Moderate to Severe Psoriasis Who Fail to Respond to Etanercept Monotherapy|Completed||Phase 2|10|Actual|Rutgers, The State University of New Jersey|small sample size; lack of control group|1|||f||||f||||||||||2018-06-01 04:42:05.764286|2018-06-01 04:42:05.764286
NCT00156234|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|March 2005||2005-03-31|September 2005|2005-09-30||||||||Interventional|||Skeletal Muscle Dysfunction in Heart Failure|Training and Congestive Heart Failure|Unknown status|Recruiting|N/A|45||Ullevaal University Hospital|||||f||||||||||||||2018-06-01 04:42:05.902922|2018-06-01 04:42:05.902922
NCT00156221|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|September 2000||2000-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||MR Scanning of Very Young Children With Severe Developmental Disorders|MR Scanning of Very Young Children With Severe Developmental Disorders (Autistic Spectrum Disorders and/or Mental Retardation and/or Language Disorders)|Completed|||||UMC Utrecht|||||f||||||||||||||2018-06-01 04:42:05.964533|2018-06-01 04:42:05.964533
NCT00156208|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-27|2005-09-07|2005-09-12|Estimate|||||||2008-05-27|2008-05-29|Estimate|April 2004||2004-04-30|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety of Treatment of Uterine Fibroids With Asoprisnil|A Phase III, 18-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata|Completed||Phase 3|166|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:42:06.007369|2018-06-01 04:42:06.007369
NCT00156195|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-27|2005-09-07|2005-09-12|Estimate|||||||2008-05-27|2008-05-29|Estimate|September 2003||2003-09-30|May 2008|2008-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids|A Phase 3, 12-Month, Extension Study to Evaluate the Safety of Asoprisnil in Subjects With Uterine Leiomyomata|Completed||Phase 3|523|Actual|Abbott||2|||f||||t||||||||||2018-06-01 04:42:06.068928|2018-06-01 04:42:06.068928
NCT00156182|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-03-03|2005-09-07|2005-09-12|Estimate|||||||2009-03-03|2009-03-04|Estimate|April 2001||2001-04-30|May 2008|2008-05-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.|A Phase 2, Long-Term, Open-Label, Safety Extension Study of Asoprisnil (J867) in Patients With Uterine Leiomyomata|Completed||Phase 2|38|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:42:06.25325|2018-06-01 04:42:06.25325
NCT00156169|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-08-10|2005-09-09|2005-09-12|Estimate|||||||2009-08-10|2009-08-12|Estimate|May 2001||2001-05-31|August 2009|2009-08-31|December 2006|Actual|2006-12-31|||||Interventional|||The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid on Lipid Profile in Fibrate Treated Patients.|The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid|Completed||Phase 3|50|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-06-01 04:42:06.329337|2018-06-01 04:42:06.329337
NCT00156156|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-27|2005-09-07|2005-09-12|Estimate|||||||2008-05-27|2008-05-28|Estimate|November 2004||2004-11-30|May 2008|2008-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of Asoprisnil in the Treatment of Uterine Fibroids.|A Phase 3, Continuation Study to Evaluate the Long-Term Safety of Asoprisnil in Subjects With Uterine Leiomyomata|Completed||Phase 3|149|Actual|Abbott||2|||f||||f||||||||||2018-06-01 04:42:06.379986|2018-06-01 04:42:06.379986
NCT00156143|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-07-27|2005-09-09|2005-09-12|Estimate|||||||2007-07-27|2007-07-30|Estimate|April 2002||2002-04-30|July 2007|2007-07-31|April 2005||2005-04-30|||||Interventional|TAUBER||Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents|GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.|Completed||Phase 3|90||Pfizer|||||f||||||||||||||2018-06-01 04:42:06.463535|2018-06-01 04:42:06.463535
NCT00156130|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-05-06|2005-09-09|2005-09-12|Estimate|||||||2016-05-06|2016-05-09|Estimate|October 2003||2003-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Accelerated Radiotherapy Outcomes in Women|Accelerated Radiotherapy Outcomes in Women (Long Term Outcomes of a Randomized Trial of Breast Irradiation Schedules After Lumpectomy in Women With Node-Negative Breast Cancer)(AROW)|Completed|||1234|Actual|Ontario Clinical Oncology Group (OCOG)|||2||f||||f||||||||||2018-06-01 04:42:06.519591|2018-06-01 04:42:06.519591
NCT00156117|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-08-18|2005-09-09|2005-09-12|Estimate|||||||2017-08-18|2017-08-22|Actual|May 12, 2005|Actual|2005-05-12|August 2017|2017-08-31|May 30, 2006|Actual|2006-05-30|April 28, 2006|Actual|2006-04-28||Interventional|||Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)|A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia|Completed||Phase 3|417|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:42:06.602324|2018-06-01 04:42:06.602324
NCT00156104|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-08-18|2005-09-09|2005-09-12|Estimate|||||||2017-08-18|2017-08-22|Actual|July 1, 2005|Actual|2005-07-01|August 2017|2017-08-31|September 16, 2006|Actual|2006-09-16|August 18, 2006|Actual|2006-08-18||Interventional|||Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia|Completed||Phase 3|460|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 04:42:06.694089|2018-06-01 04:42:06.694089
NCT00156091|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-08-10|2005-09-09|2005-09-12|Estimate|||||||2015-08-10|2015-08-11|Estimate|April 2005||2005-04-30|August 2015|2015-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)|A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Olanzapine Positive Control in Subjects Who Complete Protocols 041021 or 041022.|Completed||Phase 3|260|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:42:06.855009|2018-06-01 04:42:06.855009
NCT00156078|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-03-28|2005-09-07|2005-09-12|Estimate|||||||2008-03-28|2008-04-01|Estimate|January 2005||2005-01-31|March 2008|2008-03-31|May 2007||2007-05-31|||||Interventional|||A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)|A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).|Completed||Phase 4|450||Pfizer|||||f||||||||||||||2018-06-01 04:42:06.945684|2018-06-01 04:42:06.945684
NCT00155649|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|April 2002||2002-04-30|October 2001|2001-10-31|April 2005||2005-04-30|||||Observational|||A Positional Cloning Study on Schizophrenia||Completed|||320||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.786525|2018-06-01 04:42:10.786525
NCT00156065|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-02-24||2015-10-12|2005-09-09|2005-09-12|Estimate|2010-02-24|2010-04-07|Estimate||||2015-10-12|2015-10-14|Estimate|September 2005||2005-09-30|October 2015|2015-10-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)|A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Haloperidol Positive Control in Subjects Who Complete Protocol 041023 [NCT00156104]|Completed||Phase 3|187|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:42:07.094834|2018-06-01 04:42:07.094834
NCT00156052|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-06-03|2005-09-08|2005-09-12|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 1993||1993-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer|A Randomized Trial of Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer|Completed||N/A|1234|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||f||||||||||2018-06-01 04:42:07.502913|2018-06-01 04:42:07.502913
NCT00156039|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-07-24|2005-09-08|2005-09-12|Estimate|||||||2009-07-24|2009-07-28|Estimate|January 1997||1997-01-31|July 2009|2009-07-31|June 2003|Actual|2003-06-30|||||Interventional|||Randomized Trial of Follow-up Strategies in Breast Cancer|A Randomized Trial of Follow-up Strategies in Breast Cancer|Completed||Phase 4|968|Actual|Ontario Clinical Oncology Group (OCOG)|||||f||||f||||||||||2018-06-01 04:42:07.585316|2018-06-01 04:42:07.585316
NCT00156026|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-01-28|2005-09-08|2005-09-12|Estimate|||||||2009-01-28|2009-01-29|Estimate|November 2000||2000-11-30|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1|Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1|Completed||Phase 3|415|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||f||||||||||2018-06-01 04:42:07.651928|2018-06-01 04:42:07.651928
NCT00156013|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2011-10-06||2017-10-24|2005-09-09|2005-09-12|Estimate|2012-06-04|2012-07-09|Estimate||||2017-10-24|2017-11-29|Actual|September 2005||2005-09-30|October 2017|2017-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)|A Phase I/II Open-label Study of Clofarabine in Patients With Relapsed or Refractory Diffuse Large Cell B-Cell NHL|Completed||Phase 1/Phase 2|33|Actual|Oncology Specialists, S.C.||1|||f||||f||||||||||2018-06-01 04:42:07.757555|2018-06-01 04:42:07.757555
NCT00156000|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-12-17|2005-09-09|2005-09-12|Estimate|||||||2014-12-17|2014-12-19|Estimate|August 2005||2005-08-31|December 2014|2014-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||fFN & E3 in the Prediction of PTB in Women With Twin Pregnancies Receiving 17OHP or Placebo|Fetal Fibronectin (fFN) and Salivary Estriol (E3) in the Prediction of Preterm Birth in Women With Twin Pregnancies Receiving 17-Alpha-Hydroxyprogesterone Caproate or Placebo|Withdrawn|||0|Actual|Mednax Center for Research, Education, Quality and Safety||||This study was stopped because of insufficient enrollment.|f||||f||||||||||2018-06-01 04:42:08.008122|2018-06-01 04:42:08.008122
NCT00155987|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-07-22|2005-09-07|2005-09-12|Estimate|||||||2010-07-22|2010-07-23|Estimate|August 2003||2003-08-31|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|November 2010|Anticipated|2010-11-30||Interventional|||The DECRA Trial: Early Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury|Multi-centre Prospective Randomised Trial of Early Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury|Unknown status|Active, not recruiting|Phase 3|165|Anticipated|National Trauma Research Institute|||||f||||t||||||||||2018-06-01 04:42:08.217356|2018-06-01 04:42:08.217356
NCT00155974|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-21|2005-09-09|2005-09-12|Estimate|||||||2006-09-21|2006-09-22|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|October 2005||2005-10-31|||||Interventional|||Rapid Vaccination of Hard-To-Reach Populations|Rapid Vaccination of Hard-to-Reach Populations|Unknown status|Recruiting|N/A|4000||The New York Academy of Medicine|||||f||||||||||||||2018-06-01 04:42:08.280081|2018-06-01 04:42:08.280081
NCT00155961|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-02-02|2005-09-06|2005-09-12|Estimate|||||||2006-02-02|2006-02-03|Estimate|March 2002||2002-03-31|September 2005|2005-09-30||||||||Observational|||Odense Androgen Study in the Elderly|Odense Androgen Study in the Elderly|Completed|||600||Odense University Hospital|||||f||||||||||||||2018-06-01 04:42:08.358257|2018-06-01 04:42:08.358257
NCT00155948|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|September 2003||2003-09-30|April 2004|2004-04-30|May 2004||2004-05-31|||||Observational|||Estimation of Muscle Area and Thickness of Deep Cervical Muscle Contraction During Cervical and Limb Movements|Estimation of Muscle Area and Thickness of Deep Cervical Muscle Contraction During Cervical and Limb Movements|Completed|||40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.412239|2018-06-01 04:42:08.412239
NCT00155935|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-08-10|2005-09-09|2005-09-12|Estimate|||||||2007-08-10|2007-08-13|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|December 2008||2008-12-31|||||Interventional|||The Development of Human Immunologic Assays Specific to Folate Receptor Antigen|The Development of Human Immunologic Assays Specific to Folate Receptor Antigen|Unknown status|Recruiting|N/A|50|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.462309|2018-06-01 04:42:08.462309
NCT00155922|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-12-13|2005-09-09|2005-09-12|Estimate|||||||2006-12-13|2006-12-14|Estimate|November 2003||2003-11-30|September 2005|2005-09-30||||||||Observational|||The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients|The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients, Special Relevance to Atherosclerosis|Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.52406|2018-06-01 04:42:08.52406
NCT00155909|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-22|2005-09-09|2005-09-12|Estimate|||||||2005-11-22|2005-11-23|Estimate|July 2003||2003-07-31|June 2005|2005-06-30|June 2006||2006-06-30|||||Observational|||Risk Factors of Radiation Pneumonitis|To Investigate Risk Factors of Radiation Pneumonitis, Fibrosis, and Impairment of Quality of Life by Radiotherapeutic Dosimetric and Biological Parameters for Lung Cancer Patients Receiving Thoracic Radiotherapy|Unknown status|Recruiting||53||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.608655|2018-06-01 04:42:08.608655
NCT00155896|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|January 2003||2003-01-31|September 2002|2002-09-30|December 2008||2008-12-31|||||Observational|||Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.701996|2018-06-01 04:42:08.701996
NCT00155883|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-08-14|2005-09-09|2005-09-12|Estimate|||||||2008-08-14|2008-08-18|Estimate|June 2004||2004-06-30|July 2005|2005-07-31|July 2005|Anticipated|2005-07-31|||||Interventional|||Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer|Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer|Terminated||Phase 2|54|Anticipated|National Taiwan University Hospital||||slow a accrul due to many competitive trials.|f||||||||||||||2018-06-01 04:42:08.756184|2018-06-01 04:42:08.756184
NCT00155870|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Health-Related QoL Among Women Receiving Hysterectomy in NTUH|Health-Related Quality of Life Among Women Receiving Hysterectomy in National Taiwan University Hospital|Unknown status|Recruiting||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.806163|2018-06-01 04:42:08.806163
NCT00155857|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-22|2005-09-09|2005-09-12|Estimate|||||||2005-11-22|2005-11-23|Estimate|July 2003||2003-07-31|June 2005|2005-06-30|July 2007||2007-07-31|||||Observational|||The Genetic Study of Primary Angle-Closure Glaucoma|National Taiwan University Hospital|Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.880265|2018-06-01 04:42:08.880265
NCT00155844|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|February 2003||2003-02-28|January 2003|2003-01-31|July 2004||2004-07-31|||||Observational|||"Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing ThroughMarrow-Blood Barrier"||Unknown status|Recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:08.93265|2018-06-01 04:42:08.93265
NCT00155831|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-29|2005-09-09|2005-09-12|Estimate|||||||2010-03-29|2010-03-31|Estimate|August 2003||2003-08-31|March 2010|2010-03-31|March 2007|Actual|2007-03-31|March 2005|Actual|2005-03-31||Observational|||Neural Development and Its Influencing Factors in Premature Infants With Chronic Lung Disease||Completed|||120|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-06-01 04:42:08.982941|2018-06-01 04:42:08.982941
NCT00155818|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|August 2003||2003-08-31|August 2003|2003-08-31|July 2004||2004-07-31|||||Observational|||Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia|Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia|Completed|||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:09.030314|2018-06-01 04:42:09.030314
NCT00155805|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|February 2004||2004-02-29|February 2004|2004-02-29|December 2006||2006-12-31|||||Observational|||Immunologic Factors in Reflux Esophagitis and Barrett’s Esophagus|Immunologic Factors Correlating With Cyclooxygenase and Nitric Oxide Synthase in Reflux Esophagitis and Barrett’s Esophagus|Unknown status|Recruiting||90||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:09.074127|2018-06-01 04:42:09.074127
NCT00155792|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|January 2002||2002-01-31|December 2001|2001-12-31|December 2006||2006-12-31|||||Observational|||The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being||Unknown status|Recruiting||300||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:09.12735|2018-06-01 04:42:09.12735
NCT00155779|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|December 2003||2003-12-31|December 2003|2003-12-31|December 2004||2004-12-31|||||Observational|||ACE Gene Polymorphism and ARDS Outcome|Polymorphism of the Angiotensin-Converting Enzyme Gene and the Outcome of Acute Respiratory Distress Syndrome|Completed|||250||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.084282|2018-06-01 04:42:10.084282
NCT00155766|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|January 2003||2003-01-31|June 2002|2002-06-30|March 2006||2006-03-31|||||Interventional|||Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs)|A Pilot Study for the Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs) Pulsed With Human Papillomavirus Type 16 E7 Antigen|Unknown status|Recruiting|Phase 1|12||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.135844|2018-06-01 04:42:10.135844
NCT00155753|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-06-08|2005-09-09|2005-09-12|Estimate|||||||2010-06-08|2010-06-09|Estimate|August 2002||2002-08-31|April 2010|2010-04-30|August 2010|Anticipated|2010-08-31|August 2010|Anticipated|2010-08-31||Observational|||Genomewide Screening of Pathological Myopia|Genomewide Screening of Pathological Myopia|Unknown status|Recruiting||600|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     DNA extracted from blood~   "|||2018-06-01 04:42:10.194649|2018-06-01 04:42:10.194649
NCT00155740|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|January 2002||2002-01-31|October 2001|2001-10-31|December 2006||2006-12-31|||||Observational|||Mesothelin as a New Tumor Marker for Ovarian Cancer||Unknown status|Recruiting||250||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.263158|2018-06-01 04:42:10.263158
NCT00155727|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|January 2000||2000-01-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Observational|||Comparison of Laparoscopic Colectomy Versus Open Colectomy for Colorectal Cancer: … A Prospective Randomized Trial|Comparison of Treatment Outcome for Laparoscopic Colectomy Versus Traditional Open Colectomy for the Treatment of Colorectal Cancer: … A Prospective Randomized Clinical Trial|Unknown status|Recruiting||600||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.318791|2018-06-01 04:42:10.318791
NCT00155714|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-03-15|2005-09-09|2005-09-12|Estimate|||||||2010-03-15|2010-03-16|Estimate|November 2002||2002-11-30|January 2010|2010-01-31|May 2005|Anticipated|2005-05-31|||||Interventional|||Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary Hypertension|Clinical Efficacy of Type-5 Phosphodiesterase Inhibitors (Sildenafil and Vadenafil) in Primary and Secondary Pulmonary Hypertension|Withdrawn||N/A|20|Anticipated|National Taiwan University Hospital||||"We can't obtained the test drug (Vadenafil) from Bayer. They decided not to carry out this~   trail in Taiwan. Therefore this trail has never been started."|f||||||||||||||2018-06-01 04:42:10.380755|2018-06-01 04:42:10.380755
NCT00155701|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|August 2002||2002-08-31|August 2002|2002-08-31|July 2003||2003-07-31|||||Observational|||Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia|Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia|Completed|||500||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.442069|2018-06-01 04:42:10.442069
NCT00155688|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|December 1998||1998-12-31|December 1998|1998-12-31|December 2002||2002-12-31|||||Observational|||A Genetic Linkage Study of Schizophrenia|A Genetic Linkage Study of Schizophrenia|Completed|||2400||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.488152|2018-06-01 04:42:10.488152
NCT00155675|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-01-11|2005-09-09|2005-09-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|January 2000||2000-01-31|December 2009|2009-12-31|January 2001|Actual|2001-01-31|||||Interventional|||Pseudodrynaria Coronana (Wall) Ching|"Clinical Effect of Traditional Chinese Medicine - Gusuibu"|Completed||Phase 1|120|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.533929|2018-06-01 04:42:10.533929
NCT00155662|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-12-05|2005-09-09|2005-09-12|Estimate|||||||2012-12-05|2012-12-06|Estimate|August 2002||2002-08-31|December 2012|2012-12-31|September 2007|Actual|2007-09-30|December 2004|Actual|2004-12-31||Interventional|||The Effect of a Work-hardening Program for Return-to-work for Workers With Low Back Pain||Completed||N/A|60|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.693408|2018-06-01 04:42:10.693408
NCT00155623|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-10-19|2005-09-09|2005-09-12|Estimate|||||||2005-10-19|2005-10-20|Estimate|February 2001||2001-02-28|January 2001|2001-01-31|July 2003||2003-07-31|||||Observational|||Establish Epidemiologic Data of H. Pylori Infection in Children and Adolescents-Using C13-UBT|Establish the Precise Epidemiologic Data of Helicobacter Pylori Infection in Children and Adolescents – Using the 13C-Urea Breath Test|Completed|||3000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:10.95056|2018-06-01 04:42:10.95056
NCT00155610|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-01-28|2005-09-09|2005-09-12|Estimate|||||||2008-01-28|2008-01-30|Estimate||||September 2005|2005-09-30|December 2006||2006-12-31|||||Observational|||The Relationship Between Voiding Dysfunction and Intravesical Sensory Threshold in Diabetes Women|A Cross-Sectional Study of the Relationship Between Voiding Dysfunction and Intravesical Sensory Threshold in Diabetes Women|Terminated|||120|Anticipated|National Taiwan University Hospital||||No clinical significant|f||||||||||||||2018-06-01 04:42:11.009756|2018-06-01 04:42:11.009756
NCT00155597|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2010-01-11|2005-09-09|2005-09-12|Estimate|||||||2010-01-11|2010-01-12|Estimate|August 1999||1999-08-31|December 2009|2009-12-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||The Outcome and Cost Analysis of Home-care Physical Therapy for Postoperative Hip Fracture Patients||Completed||N/A|40|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.068137|2018-06-01 04:42:11.068137
NCT00155584|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|December 1994||1994-12-31|December 1994|1994-12-31|December 1996||1996-12-31|||||Observational|||Topical 5-ALA Photodynamic Therapy for the Treatment of Verruca Vulgaris|Topical 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of Verruca Vulgaris: Comparison of Red and Green Light-Emitting Diode Array|Unknown status|Recruiting||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.147581|2018-06-01 04:42:11.147581
NCT00155571|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|August 2001||2001-08-31|January 2001|2001-01-31||||||||Observational|||The Occurrence of Periopathogens in Betel-Nut Chewers and the Effects of Areca-Nut on Periopathogens|The Occurrence of Periopathogens in Betel-Nut Chewers and the Effects of Areca-Nut on Periopathogens|Completed|||186||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.209486|2018-06-01 04:42:11.209486
NCT00155558|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-07-23|2005-09-09|2005-09-12|Estimate|||||||2007-07-23|2007-07-25|Estimate|March 2001||2001-03-31|November 2000|2000-11-30|December 2005|Actual|2005-12-31|||||Interventional|||A Phase I Trial of HDFL48 in Recurrent or Metastatic Colorectal Cancers|A Phase I Trial of HDFL48(Weekly 48-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) in Recurrent or Metastatic Colorectal Cancers|Completed||Phase 1|16|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:42:11.262959|2018-06-01 04:42:11.262959
NCT00155545|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-12-06|2005-09-09|2005-09-12|Estimate|||||||2012-12-06|2012-12-10|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Influence of Leg Length Discrepancy on the Spinal Shape and Biomechanics in Functional and Idiopathic Scoliosis Patients|Influence of Leg Length Discrepancy on the Spinal Shape and Biomechanics During Static and Dynamic Activities in Functional and Idiopathic Scoliosis Patients|Completed||Phase 1|30|Actual|National Taiwan University Hospital||1|||f||||||||||||||2018-06-01 04:42:11.32127|2018-06-01 04:42:11.32127
NCT00155532|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|April 2002||2002-04-30|June 2005|2005-06-30|March 2004||2004-03-31|||||Interventional|||Skin Denervation in Systemic Lupus Erythematosus||Completed||Phase 1|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.404115|2018-06-01 04:42:11.404115
NCT00155519|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|July 2002||2002-07-31|August 2000|2000-08-31|July 2002||2002-07-31|||||Observational|||A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions|A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions|Completed|||130||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.455492|2018-06-01 04:42:11.455492
NCT00155506|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|November 2002||2002-11-30|November 2002|2002-11-30|December 2004||2004-12-31|||||Observational|||Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios|Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios|Completed|||600||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.497133|2018-06-01 04:42:11.497133
NCT00155493|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|January 2006||2006-01-31|June 2005|2005-06-30|August 2006||2006-08-31|||||Interventional|||Age-Related Changes in Proliferation and Differentiation Capacity of Human Preadipocytes From Periorbital Fat.||Unknown status|Not yet recruiting|Phase 1|60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.564639|2018-06-01 04:42:11.564639
NCT00155480|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-12-05|2005-09-08|2005-09-12|Estimate|||||||2012-12-05|2012-12-06|Estimate|January 2000||2000-01-31|November 2012|2012-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Establish Finite Element Mesh of the Numerical Models of the Thoracic Aorta|Establish Finite Element Mesh of the Numerical Models of the Thoracic Aorta|Completed||N/A|80|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.610579|2018-06-01 04:42:11.610579
NCT00155467|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-10-19|2005-09-08|2005-09-12|Estimate|||||||2005-10-19|2005-10-20|Estimate|January 1995||1995-01-31|January 1995|1995-01-31|December 2010||2010-12-31|||||Interventional|||Establish a CT Images Database of Patients With Congenital Heart Disease|Establish a CT Images Database of Patients With Congenital Heart Disease|Unknown status|Recruiting|N/A|5000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.668492|2018-06-01 04:42:11.668492
NCT00155454|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-12-26|2005-09-08|2005-09-12|Estimate|||||||2012-12-26|2012-12-27|Estimate|September 2004||2004-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy|Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy|Completed||N/A|61|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-06-01 04:42:11.811849|2018-06-01 04:42:11.811849
NCT00155441|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-01-08|2005-09-08|2005-09-12|Estimate|||||||2007-01-08|2007-01-09|Estimate|June 2005||2005-06-30|May 2005|2005-05-31||||||||Interventional|||Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients|Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients|Unknown status|Recruiting|Phase 3|30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.8934|2018-06-01 04:42:11.8934
NCT00155428|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-19|2005-09-08|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|December 2008||2008-12-31|||||Interventional|||Biomodel in Tetralogy of Fallot|Application of Biocardiac Model in Total Correction of Tetralogy of Fallot|Unknown status|Recruiting|N/A|50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:11.991904|2018-06-01 04:42:11.991904
NCT00155415|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-12-01|2005-09-08|2005-09-12|Estimate|||||||2008-12-01|2008-12-02|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Prospective Single-Blinded Randomized Trial Comparing Colonoscopic Preparation at Different Time||Completed||N/A|120||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.069992|2018-06-01 04:42:12.069992
NCT00155402|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-28|2005-09-08|2005-09-12|Estimate|||||||2008-05-28|2008-05-29|Estimate|April 2005||2005-04-30|March 2005|2005-03-31|March 2008||2008-03-31|||||Interventional|||The Application of Fibrin Glue in Ocular Surface Diseases|Phase 1 Study of Applying Fibrin Glue in Patients With Corneal Ulcer or Patients Requiring Wound Closure by Suture|Withdrawn||Phase 1|30|Anticipated|National Taiwan University Hospital||1||Short of supply of fibrin glue|f||||f||||||||||2018-06-01 04:42:12.133283|2018-06-01 04:42:12.133283
NCT00155389|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-11-12|2005-09-08|2005-09-12|Estimate|||||||2012-11-12|2012-11-14|Estimate|January 2004||2004-01-31|July 2012|2012-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Community-based Helicobacter Pylori Eradication|Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer|Unknown status|Recruiting|Phase 4|5000|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 04:42:12.212287|2018-06-01 04:42:12.212287
NCT00155376|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-25|2005-09-08|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|September 2005||2005-09-30|April 2005|2005-04-30|September 2005||2005-09-30|||||Interventional|||Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography||Unknown status|Recruiting|Phase 4|100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.306462|2018-06-01 04:42:12.306462
NCT00155363|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-19|2005-09-08|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|September 2004||2004-09-30|June 2005|2005-06-30||||||||Interventional|||Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis|The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis|Unknown status|Recruiting|Phase 4|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.386728|2018-06-01 04:42:12.386728
NCT00155350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-02-24|2005-09-08|2005-09-12|Estimate|||||||2006-02-24|2006-02-27|Estimate|November 2004||2004-11-30|August 2005|2005-08-31|December 2007||2007-12-31|||||Interventional|||Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients|Treatment of Coronary Atherosclerosis and Calcification by Insulin Sensitizers in Insulin-Resistant Patients: Evaluated by EBCT, 16-Slice MDCT Coronary Angiography/Scanning, and Intravascular Ultrasound|Unknown status|Recruiting|Phase 4|120||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.459855|2018-06-01 04:42:12.459855
NCT00155337|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-12-20|2005-09-09|2005-09-12|Estimate|||||||2012-12-20|2012-12-21|Estimate|August 2004||2004-08-31|December 2012|2012-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia|Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia|Completed||Phase 4|40|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.533873|2018-06-01 04:42:12.533873
NCT00155324|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-11-30|2005-09-08|2005-09-12|Estimate|||||||2012-11-30|2012-12-03|Estimate|October 2004||2004-10-31|November 2012|2012-11-30|July 2006|Actual|2006-07-31|||||Interventional|||Change and Clinical Significance of Plantar Fascia Thickness After ESWT|Change and Clinical Significance of Plantar Fascia Thickness After Extracorporeal Shock Wave Therapy|Completed||N/A|60|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.599959|2018-06-01 04:42:12.599959
NCT00155311|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-03-14|2005-09-08|2005-09-12|Estimate|||||||2013-03-14|2013-03-15|Estimate|January 2005||2005-01-31|March 2013|2013-03-31||||December 2008|Actual|2008-12-31||Interventional|||The Regulation of Osteoprotegerin by Mechanical Stimulation||Completed||Phase 1|10|Actual|National Taiwan University Hospital||1|||f||||||||||||||2018-06-01 04:42:12.663162|2018-06-01 04:42:12.663162
NCT00155285|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-10-19|2005-09-08|2005-09-12|Estimate|||||||2005-10-19|2005-10-20|Estimate|January 2000||2000-01-31|April 2003|2003-04-30|December 2006||2006-12-31|||||Interventional|||Evaluating the Infant Complex Congenital Heart Disease by Multidetector Computed Tomography|Integrated Evaluating the Infant Complex Congenital Heart Disease by Multidetector(16)Spiral Computed Tomography|Unknown status|Recruiting|N/A|200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.726132|2018-06-01 04:42:12.726132
NCT00155272|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|March 2005||2005-03-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma|A Pilot Clinical and Mechanistic Study of Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|19||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:12.812343|2018-06-01 04:42:12.812343
NCT00155259|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-23|2005-09-08|2005-09-12|Estimate|||||||2007-07-23|2007-07-25|Estimate|October 2004||2004-10-31|July 2005|2005-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer|Docetaxel by 1 Hour Infusion Followed by 24 Hour Infusion of Cisplatin Plus Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer|Completed||Phase 2|47|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:42:12.89417|2018-06-01 04:42:12.89417
NCT00155246|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-01-27|2005-09-08|2005-09-12|Estimate|||||||2010-01-27|2010-01-29|Estimate|July 2004||2004-07-31|January 2010|2010-01-31|January 2007|Actual|2007-01-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy of Pentoxifylline on Chronic Kidney Disease|Phase 4 Study of the Efficacy of Pentoxifylline in Patients With Chronic Kidney Disease Receiving Angiotensin Receptor Blockade|Completed||Phase 4|60|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 04:42:12.998142|2018-06-01 04:42:12.998142
NCT00155233|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-22|2005-09-08|2005-09-12|Estimate|||||||2005-11-22|2005-11-23|Estimate|January 2005||2005-01-31|June 2005|2005-06-30||||||||Interventional|||Interaction Between Nalbuphine and Morphine in PCA|Interaction Between Nalbuphine and Morphine in Postoperative PCA for Gynecologic Patients|Unknown status|Recruiting|Phase 4|200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.067267|2018-06-01 04:42:13.067267
NCT00155220|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-01-25|2005-09-08|2005-09-12|Estimate|||||||2006-01-25|2006-01-27|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|March 2006||2006-03-31|||||Interventional|||Treatment of Lymphedema: Application of the Kinesio Taping|Treatment of Lymphedema- Application of the Kinesio Taping|Unknown status|Recruiting|Phase 2|60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.134327|2018-06-01 04:42:13.134327
NCT00155207|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|April 2008||2008-04-30|||||Observational|||A Study on Risk Mutations of Vulnerability Genes of Schizophrenia|A Study on Risk Mutations of Vulnerability Genes of Schizophrenia|Unknown status|Recruiting||1065||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.20015|2018-06-01 04:42:13.20015
NCT00155194|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|April 2004||2004-04-30|June 2005|2005-06-30||||||||Observational|||Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice|Impaired T-Lymphocyte Proliferative Function in Biliary Atresia Children With Prolonged Jaundice|Unknown status|Recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.253087|2018-06-01 04:42:13.253087
NCT00155181|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|August 2005||2005-08-31|||||Observational|||Molecular Mechanism of Nasopharyngeal Carcinoma|the Garduate Institute of Microbiology in National Taiwan University|Unknown status|Recruiting||25||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.309087|2018-06-01 04:42:13.309087
NCT00155168|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|April 2004||2004-04-30|April 2004|2004-04-30||||||||Observational|||Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System|Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System: Establishing a Novel Highly Efficient and Reliable SMA Carrier Screening Test|Unknown status|Recruiting||500||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.363864|2018-06-01 04:42:13.363864
NCT00155155|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2008-12-01|2005-09-09|2005-09-12|Estimate|||||||2008-12-01|2008-12-02|Estimate|May 2005||2005-05-31|November 2008|2008-11-30||||April 2008|Actual|2008-04-30||Observational|||Studies of Immune Responses in Patients With Chronic Hepatitis B|Analysis of HBV-Specific T Cell Responses and Regulatory T Cells in Patients With Chronic Hepatitis B Virus Infection|Completed|||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-06-01 04:42:13.499165|2018-06-01 04:42:13.499165
NCT00155142|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|September 2004||2004-09-30|September 2004|2004-09-30||||||||Observational|||Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.|Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.|Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.55518|2018-06-01 04:42:13.55518
NCT00155129|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|January 2005||2005-01-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||The Role of CGRPand Nociceptin in Migraine|The Role of Calcitonin Gene-Related Peptide(CGRP)and Nociceptin in the Pathogenesis of Migraine|Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.618817|2018-06-01 04:42:13.618817
NCT00155116|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-22|2005-09-09|2005-09-12|Estimate|||||||2005-11-22|2005-11-23|Estimate|October 2004||2004-10-31|October 2004|2004-10-31|December 2006||2006-12-31|||||Observational|||SERPIN D1 and Its Role in Lung Cancer Invasion and Metastasis||Unknown status|Recruiting||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.697622|2018-06-01 04:42:13.697622
NCT00155103|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2007-03-20|2005-09-09|2005-09-12|Estimate|||||||2007-03-20|2007-03-21|Estimate|August 2004||2004-08-31|July 2005|2005-07-31||||||||Observational|||Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma|Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma|Unknown status|Recruiting||1600||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.755667|2018-06-01 04:42:13.755667
NCT00155090|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|January 2005||2005-01-31|January 2005|2005-01-31|December 2005||2005-12-31|||||Observational|||Proton Magnetic Resonance Spectroscopy of Normal Breast Tissues in Women Volunteers||Unknown status|Recruiting||80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.821219|2018-06-01 04:42:13.821219
NCT00155077|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-10-19|2005-09-09|2005-09-12|Estimate|||||||2005-10-19|2005-10-20|Estimate|June 2004||2004-06-30|June 2004|2004-06-30|June 2009||2009-06-30|||||Observational|||The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients|The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients|Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.886549|2018-06-01 04:42:13.886549
NCT00155064|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2014-12-15|2005-09-09|2005-09-12|Estimate|||||||2014-12-15|2014-12-17|Estimate|July 2002||2002-07-31|December 2014|2014-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism||Completed||Phase 4|100|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:13.948159|2018-06-01 04:42:13.948159
NCT00155051|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|July 2004||2004-07-31|June 2004|2004-06-30|April 2005||2005-04-30|||||Observational|||Progestin Treatment for Endometrial Stromal Cells in Adenomyosis||Unknown status|Recruiting||45||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.015087|2018-06-01 04:42:14.015087
NCT00155038|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|January 1998||1998-01-31|May 2004|2004-05-31|December 2005||2005-12-31|||||Observational|||Imaging Characteristics of Breast Cancer in Women Under 40 Years of Age||Unknown status|Recruiting||75||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.075928|2018-06-01 04:42:14.075928
NCT00155025|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|May 2004||2004-05-31|April 2004|2004-04-30||||||||Observational|||Family History in Prostate Cancer Patients in Taiwan||Unknown status|Recruiting||1500||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.141422|2018-06-01 04:42:14.141422
NCT00155012|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|August 2004||2004-08-31|April 2004|2004-04-30|August 2006||2006-08-31|||||Observational|||Clinical Application of MDCT in Coronary Artery Disease|Clinical Application of 16-Detector Row Computed Tomography in Coronary Artery Disease|Unknown status|Recruiting||200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.199232|2018-06-01 04:42:14.199232
NCT00154999|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-28|2005-09-09|2005-09-12|Estimate|||||||2005-11-28|2005-11-29|Estimate|April 2005||2005-04-30|March 2004|2004-03-31|June 2005||2005-06-30|||||Observational|||The Predictors of the Neonatal Hyperbilirubinemia|The Predictors of the Neonatal Hyperbilirubinemia|Completed|||100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.252652|2018-06-01 04:42:14.252652
NCT00154986|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|August 2004||2004-08-31|April 2004|2004-04-30|July 2005||2005-07-31|||||Interventional|||IGFBP-3 in Ovarian Cancer Invasion|Study of IGFBP-3 in the Ovarian Carcinoma Cell Invasion|Unknown status|Recruiting|N/A|30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.299132|2018-06-01 04:42:14.299132
NCT00154973|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|June 2005||2005-06-30|||||Observational|||Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers||Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.374841|2018-06-01 04:42:14.374841
NCT00154960|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-25|2005-09-09|2005-09-12|Estimate|||||||2005-11-25|2005-11-28|Estimate|June 2004||2004-06-30|June 2004|2004-06-30||||||||Observational|||Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.|Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.|Unknown status|Recruiting||1000||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.447738|2018-06-01 04:42:14.447738
NCT00154947|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-07-18|2005-09-09|2005-09-12|Estimate|||||||2006-07-18|2006-07-20|Estimate|May 2004||2004-05-31|July 2006|2006-07-31|May 2006||2006-05-31|||||Observational|||Develop Biomarkers for Assessing RA Joint Erosion|Develop Biomarkers for Assessing RA Joint Erosion|Unknown status|Active, not recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.50733|2018-06-01 04:42:14.50733
NCT00154934|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2009-02-02|2005-09-09|2005-09-12|Estimate|||||||2009-02-02|2009-02-03|Estimate|January 2004||2004-01-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|||||Observational|||the Implications of Pathogenesis of Pre-Eclampsia|The Impact of Interleukin-10 in the Invasion Capacity and Immunoregulation During Pregnancy: the Implications of Pathogenesis of Pre-Eclampsia.|Terminated|||0|Actual|National Taiwan University Hospital||||difficult to enroll subjects|f||||t||||||Samples Without DNA|"~     placenta biopsy~   "|||2018-06-01 04:42:14.557294|2018-06-01 04:42:14.557294
NCT00154921|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-22|2005-09-09|2005-09-12|Estimate|||||||2005-11-22|2005-11-23|Estimate|January 2004||2004-01-31|January 2004|2004-01-31|December 2007||2007-12-31|||||Observational|||Clinical Usefulness of Optical Skin Biopsy|Clinical Usefulness of Optical Skin Biopsy|Unknown status|Recruiting||30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.711619|2018-06-01 04:42:14.711619
NCT00154895|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-10-19|2005-09-08|2005-09-12|Estimate|||||||2005-10-19|2005-10-20|Estimate|June 2001||2001-06-30|June 2001|2001-06-30|March 2005||2005-03-31|||||Interventional|||Additional Minocycline Pleurodesis After Thoracoscopic Procedures for Primary Spontaneous Pneumothorax|Phase III Study of Additional Minocycline Pleurodesis After Video-Assisted Thoracoscopic Surgery for Primary Spontaneous Pneumothorax|Unknown status|Recruiting|Phase 3|200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.768953|2018-06-01 04:42:14.768953
NCT00154882|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-01-20|2005-09-08|2005-09-12|Estimate|||||||2010-01-20|2010-01-21|Estimate|September 2003||2003-09-30|July 2005|2005-07-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Paclitaxel (Phyxol) and Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer|Weekly Low-dose Paclitaxel (Phyxol) Plus 24-Hour Infusion of Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|43|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:42:14.857925|2018-06-01 04:42:14.857925
NCT00154869|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-08-10|2005-09-08|2005-09-12|Estimate|||||||2007-08-10|2007-08-13|Estimate|June 2004||2004-06-30|August 2005|2005-08-31|August 2007||2007-08-31|||||Interventional|||Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C|An Open Label, Comparative, Multi-Center Study, to Evaluate the Efficacy and Safety of Peginterferon Alfa-2a Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C|Unknown status|Recruiting|Phase 3|320|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:14.947643|2018-06-01 04:42:14.947643
NCT00154856|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|August 2004||2004-08-31|February 2003|2003-02-28|July 2005||2005-07-31|||||Interventional|||Influence of Mechanical Stimulus on Distraction Osteogenesis|Influence of Mechanical Stimulus on Distraction Osteogenesis|Completed||Phase 4|10||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.041984|2018-06-01 04:42:15.041984
NCT00154843|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-01-08|2005-09-08|2005-09-12|Estimate|||||||2008-01-08|2008-01-14|Estimate|March 2004||2004-03-31|August 2006|2006-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation|A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation|Completed||Phase 2|74|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-06-01 04:42:15.131549|2018-06-01 04:42:15.131549
NCT00154830|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-22|2005-09-08|2005-09-12|Estimate|||||||2005-11-22|2005-11-23|Estimate|August 2004||2004-08-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children|Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children|Completed||Phase 4|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.223148|2018-06-01 04:42:15.223148
NCT00154817|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-21|2005-09-09|2005-09-12|Estimate|||||||2005-11-21|2005-11-22|Estimate|January 2002||2002-01-31|January 2002|2002-01-31|May 2005||2005-05-31|||||Interventional|||A Phase II Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma (HCC)|A Phase II Clinical and Mechanistic Study of Radiotherapy for Locally Advanced Hepatocellular Carcinoma|Completed||Phase 2|12||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.298799|2018-06-01 04:42:15.298799
NCT00154804|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-08-22|2005-09-08|2005-09-12|Estimate|||||||2007-08-22|2007-08-23|Estimate|August 2001||2001-08-31|April 2004|2004-04-30|April 2004|Actual|2004-04-30|||||Interventional|||CCRT With Twice Weekly Paclitaxel and Cisplatin Followed by Surgery for Locally Advanced Esophageal Cancer|A Phase II Study of Concurrent Chemoradiotherapy With Twice Weekly Paclitaxel and Cisplatin (Twice Weekly TP) Followed by Surgery for Locally Advanced Esophageal Cancer|Completed||Phase 2|40|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:42:15.350759|2018-06-01 04:42:15.350759
NCT00154791|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|March 2003||2003-03-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma|Phase I/II Trial of Biweekly Gemcitabine, Oxaliplatin, and 48-Hour Infusion of High-Dose 5-FU/Leucovorin (GOFL) in Advanced Pancreatic Adenocarcinoma|Completed||Phase 1/Phase 2|45||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.41686|2018-06-01 04:42:15.41686
NCT00154778|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-30|2005-09-08|2005-09-12|Estimate|||||||2007-07-30|2007-07-31|Estimate|March 2003||2003-03-31|July 2005|2005-07-31|June 2005|Actual|2005-06-30|||||Interventional|||Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer|An Open,Multi-Center,Phase II Clinical Trial tO Evaluate Efficacy and Safety oF TAXOL(PACLITAXEL),UFT,and LEUCOVORIN in Patients With Advanced Gastric Cancer|Completed||Phase 2|55|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-06-01 04:42:15.481813|2018-06-01 04:42:15.481813
NCT00154765|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-21|2005-09-08|2005-09-12|Estimate|||||||2005-11-21|2005-11-22|Estimate|March 2003||2003-03-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Interventional|||Effect of Sling Suspension Exercises in Proprioception of Patients With Knee Osteoarthritis|Graduate School of Physical Therapy, College of Medicine, NTU, Taiwan|Completed||N/A|30||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.550036|2018-06-01 04:42:15.550036
NCT00154752|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-21|2005-09-08|2005-09-12|Estimate|||||||2005-11-21|2005-11-22|Estimate|January 1999||1999-01-31|January 1999|1999-01-31|June 2005||2005-06-30|||||Interventional|||Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer|A Randomized Trial Comparing Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer|Unknown status|Recruiting|Phase 3|200||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.688616|2018-06-01 04:42:15.688616
NCT00154739|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-08-01|2005-09-08|2005-09-12|Estimate|||||||2008-08-01|2008-08-04|Estimate|October 1998||1998-10-31|July 2005|2005-07-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)|A Phase II Randomized Trial of Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin in Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 2|86|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.755342|2018-06-01 04:42:15.755342
NCT00154726|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-21|2005-09-08|2005-09-12|Estimate|||||||2005-11-21|2005-11-22|Estimate|April 1997||1997-04-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers|A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers|Completed||Phase 2|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.828066|2018-06-01 04:42:15.828066
NCT00154713|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|July 2005||2005-07-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment|A Phase I/II Clinical Study of Immunotherapy for Advanced Colorectal Cancers Using CEA-Pulsed Dendritic Cells Mixed With Tetanus Toxoid and Subsequent IL-2 Treatment|Unknown status|Recruiting|Phase 1/Phase 2|37||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.895013|2018-06-01 04:42:15.895013
NCT00154700|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-19|2005-09-08|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|January 2001||2001-01-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer|A Phase II Study of Twice Weekly Paclitaxel, Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Folinic Acid in the Treatment of Recurrent or Metastatic Esophageal Cancer|Completed||Phase 2|40||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:15.975091|2018-06-01 04:42:15.975091
NCT00154687|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-30|2005-09-08|2005-09-12|Estimate|||||||2007-07-30|2007-07-31|Estimate|October 2000||2000-10-31|July 2005|2005-07-31|December 2004|Actual|2004-12-31|||||Interventional|||Weekly TP-HDFL in the Treatment of Advanced TCC|A Phase II Study of Weekly Paclitaxel, Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin(Weekly TP-HDFL) in the Treatment of Advanced Transitional Cell Carcinoma(TCC)|Completed||Phase 2|40|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-06-01 04:42:16.043434|2018-06-01 04:42:16.043434
NCT00154674|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-21|2005-09-08|2005-09-12|Estimate|||||||2005-11-21|2005-11-22|Estimate|April 2005||2005-04-30|January 2004|2004-01-31|October 2005||2005-10-31|||||Interventional|||Safety and Feasibility of Endovascular Cooling Device in Patients With Hypothermic Cardiopulmonary Resuscitation||Unknown status|Recruiting|N/A|15||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.115221|2018-06-01 04:42:16.115221
NCT00154661|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|January 2000||2000-01-31|June 2001|2001-06-30|June 2001||2001-06-30|||||Interventional|||Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis|Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis|Completed||N/A|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.179769|2018-06-01 04:42:16.179769
NCT00154648|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-06-04|2005-09-08|2005-09-12|Estimate|||||||2007-06-04|2007-06-05|Estimate|June 2005||2005-06-30|June 2005|2005-06-30||||||||Interventional|||CE-MRA Using Gadovist in Comparison to IA DSA Using Ultravist|An Open, Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) Study of Arteries Using Gadovist 1.0 in Comparison to Intra-Arterial Digital Subtraction Angiography (IA DSA) Using Ultravist|Unknown status|Recruiting|Phase 4|40|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.270612|2018-06-01 04:42:16.270612
NCT00154635|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|September 2005||2005-09-30|September 2005|2005-09-30||||||||Interventional|||Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease|A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease|Unknown status|Not yet recruiting|Phase 2|80||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.33803|2018-06-01 04:42:16.33803
NCT00154622|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2012-12-05|2005-09-09|2005-09-12|Estimate|||||||2012-12-05|2012-12-06|Estimate|January 2004||2004-01-31|December 2012|2012-12-31|December 2008|Actual|2008-12-31|December 2006|Actual|2006-12-31||Interventional|||Management and Outcome of Work-Related Musculoskeletal Disorders|National Taiwan University Hospital|Completed||N/A|160|Actual|National Taiwan University Hospital||1|||f||||||||||||||2018-06-01 04:42:16.410456|2018-06-01 04:42:16.410456
NCT00154609|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-01-20|2005-09-09|2005-09-12|Estimate|||||||2006-01-20|2006-01-23|Estimate|January 2002||2002-01-31|January 2002|2002-01-31||||||||Interventional|||Davallia Divaricata BL: The Use of Traditional Chinese Native Medicine for Osteoporosis|The Use Tradition Chinese Native Medicine Treats the Osteoporosis Research|Unknown status|Recruiting|Phase 1|100||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.47507|2018-06-01 04:42:16.47507
NCT00154596|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2015-03-15|2005-09-09|2005-09-12|Estimate|||||||2015-03-15|2015-03-17|Estimate|February 2004||2004-02-29|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Etiology Study of Kawasaki Disease|Etiology Study of Kawasaki Disease--A Prospective Household and Case Control Study|Recruiting|||700|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Blood, throat swab, nasopharyngeal aspiration, and rectal swab will be obtained during acute~     illness and at convalescence (about 2 weeks after discharge). These specimens will be~     processed for viral isolation, bacterial culture and toxin detection, PCR, subtractive~     cloning, VIDISCA, gene chips, peptide library, cytokine/chemokine measurement, antibody~     detection for specific pathogens, etc. Questionnaire for contact history and clinical~     symptoms will be performed.~   "|||2018-06-01 04:42:16.535474|2018-06-01 04:42:16.535474
NCT00154583|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-12-20|2005-09-09|2005-09-12|Estimate|||||||2006-12-20|2006-12-21|Estimate|January 2003||2003-01-31|January 2003|2003-01-31|December 2008||2008-12-31|||||Observational|||Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions||Unknown status|Recruiting||500||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.601031|2018-06-01 04:42:16.601031
NCT00154570|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-11-21|2005-09-09|2005-09-12|Estimate|||||||2005-11-21|2005-11-22|Estimate|February 2004||2004-02-29|February 2004|2004-02-29|August 2005||2005-08-31|||||Observational|||24 Hour Esophageal and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis|Integrating Simultaneous Recording of 24 Hour Esophageal pH and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis|Unknown status|Recruiting||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.66282|2018-06-01 04:42:16.66282
NCT00154557|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|August 2004||2004-08-31|August 2004|2004-08-31|July 2006||2006-07-31|||||Observational|||Influence of the Psychophysiological Status of Elite Judo Athletes on Their Performance and Injury||Unknown status|Recruiting||60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.731155|2018-06-01 04:42:16.731155
NCT00154544|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|August 2004||2004-08-31|December 2003|2003-12-31||||||||Observational|||Searching for the Liver Cancer-Related Biomarkers|Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by PROTEOMEX|Unknown status|Recruiting||50||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.815403|2018-06-01 04:42:16.815403
NCT00154531|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-12-19|2005-09-09|2005-09-12|Estimate|||||||2005-12-19|2005-12-20|Estimate|August 2004||2004-08-31|December 2003|2003-12-31|May 2005||2005-05-31|||||Observational|||Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI|Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by Surface-Enhanced Laser Desorption/Ionization (SELDI)|Unknown status|Recruiting||230||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:16.900681|2018-06-01 04:42:16.900681
NCT00154518|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-02-20|2005-09-09|2005-09-12|Estimate|||||||2013-02-20|2013-02-22|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|December 2005||2005-12-31|||||Interventional|||The Role of Matrix Metalloproteinases (MMPs) in Orthodontic Tooth Movement|The Role of Matrix Metalloproteinases in Orthodontic Treatment|Completed||Phase 1|12|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:17.051095|2018-06-01 04:42:17.051095
NCT00154505|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|September 2002||2002-09-30|August 2002|2002-08-31|November 2004||2004-11-30|||||Interventional|||Effects of Lateral Trunk Support on Spinal Alignment in Spinal Cord Injured Persons|Effects of Lateral Trunk Support on Spinal Alignment in Spinal Cord Injured Persons|Completed||Phase 1|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:17.109704|2018-06-01 04:42:17.109704
NCT00154492|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-12|2005-09-09|2005-09-12|Estimate|||||||2017-01-12|2017-01-13|Estimate|April 2004||2004-04-30|January 2017|2017-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Use of NovoSeven® in Active Variceal Bleeding|Effectiveness and Safety of Use of NovoSeven® in the Treatment of Active Variceal Bleeding in Patients With Advanced Cirrhosis|Completed||Phase 2|265|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:42:17.179881|2018-06-01 04:42:17.179881
NCT00154479|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2006-12-13|2005-09-09|2005-09-12|Estimate|||||||2006-12-13|2006-12-14|Estimate|October 2003||2003-10-31|October 2003|2003-10-31|December 2008||2008-12-31|||||Observational|||The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus||Unknown status|Recruiting||700||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:17.299111|2018-06-01 04:42:17.299111
NCT00154466|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2012-12-06||2014-05-25|2005-09-09|2005-09-12|Estimate|2014-05-25|2014-06-26|Estimate||||2014-05-25|2014-06-26|Estimate|July 2004||2004-07-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|July 2010|Actual|2010-07-31||Interventional|||Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement|An Association Study Between Cardiac Rehabilitation and Stem Cell Mobilization in Patients With Myocardial Infarction|Completed||N/A|58|Actual|National Taiwan University Hospital|First, our trial is small size. Second, these results are applicable only for male patients less than 65 years old with ST-segment elevation MI after successful PCI. Third, the source of angiogenic cytokines cannot be elucidated.|3|||f||||t||||||||||2018-06-01 04:42:17.372822|2018-06-01 04:42:17.372822
NCT00154453|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2005-09-09|2005-09-09|2005-09-12|Estimate|||||||2005-09-09|2005-09-12|Estimate|January 2004||2004-01-31|October 2003|2003-10-31|August 2004||2004-08-31|||||Interventional|||Age-Related Changes in Myosin Heavy Chain Composition in Human Orbicularis Oculi Muscle||Completed||Phase 1|60||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:42:17.620179|2018-06-01 04:42:17.620179
NCT00154440|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-03-23|2005-09-08|2005-09-12|Estimate|||||||2007-03-23|2007-03-26|Estimate|November 2001||2001-11-30|March 2007|2007-03-31|October 2013|Anticipated|2013-10-31|||||Interventional|||Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation|Treatment of Low-Grade Gastric Non-Hodgkin‘s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study)|Unknown status|Recruiting|Phase 3|200||Technische Universität Dresden|||||f||||t||||||||||2018-06-01 04:42:17.668776|2018-06-01 04:42:17.668776
NCT00154427|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-01-11|2005-09-09|2005-09-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2004||2004-08-31|January 2017|2017-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Use of Activated Recombinant Human Factor VII in Cardiac Surgery|A Multi-centre, Randomised, Double-blind, Placebocontrolled, Dose Escalation Trial on Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in the Treatment of Post-operative Bleeding in Patients Following Cardiac Surgery Requiring Cardiopulmonary Bypass|Terminated||Phase 2|172|Actual|Novo Nordisk A/S||||"Trial terminated after recruiting 172 patients but without proceeding to the highest dosing~   cohort as this no longer reflects common clinical practice"|f||||f||||||||||2018-06-01 04:42:17.755766|2018-06-01 04:42:17.755766
NCT00154414|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-24|2005-09-08|2005-09-12|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes|Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes.|Completed||Phase 2|226|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:42:17.873907|2018-06-01 04:42:17.873907
NCT00154401|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-01-24|2005-09-08|2005-09-12|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes|Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.|Completed||Phase 2|177|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:42:17.933776|2018-06-01 04:42:17.933776
NCT00154388|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2016-11-16|2005-09-09|2005-09-12|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2001||2001-02-28|November 2016|2016-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases|Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases|Completed||Phase 2|185|Actual|Novartis|||||f||||||||||||||2018-06-01 04:42:18.189085|2018-06-01 04:42:18.189085
NCT00154375|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2011-01-13||2011-04-19|2005-09-09|2005-09-12|Estimate|2011-01-13|2011-02-02|Estimate||||2011-04-19|2011-04-26|Estimate|October 2004||2004-10-31|April 2011|2011-04-30||||August 2008|Actual|2008-08-31||Interventional|||Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma|Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma|Completed||Phase 3|240|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:42:18.317528|2018-06-01 04:42:18.317528
NCT00154362|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-11-22|2005-09-09|2005-09-12|Estimate|||||||2011-11-22|2011-11-24|Estimate|April 2003||2003-04-30|November 2011|2011-11-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.|A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents|Completed||Phase 4|50|Actual|Novartis|||||f||||||||||||||2018-06-01 04:42:19.147933|2018-06-01 04:42:19.147933
NCT00154349|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2017-02-21|2005-09-09|2005-09-12|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2003||2003-10-31|February 2017|2017-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia|Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia|Completed||Phase 2|8|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:42:19.19883|2018-06-01 04:42:19.19883
NCT00154336|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-04-24|2005-09-08|2005-09-12|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2004|Actual|2004-07-31|April 2017|2017-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.|3-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety & Tolerability of Imatinib 400 mg Daily in Combination With Methotrexate (MTX)Compared to MTX Alone in the Treatment of Rheumatoid Arthritis (RA).|Completed||Phase 2|50|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:42:19.262697|2018-06-01 04:42:19.262697
NCT00154323|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-02-21|2005-09-09|2005-09-12|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2003||2003-01-31|February 2017|2017-02-28|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.|A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment|Completed||Phase 4|55|Actual|Novartis|||||f||||||||||||||2018-06-01 04:42:19.367286|2018-06-01 04:42:19.367286
NCT00154310|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2011-01-11||2013-10-21|2005-09-08|2005-09-12|Estimate|2011-04-19|2011-05-24|Estimate||||2013-10-21|2013-11-13|Estimate|June 2005||2005-06-30|October 2013|2013-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Everolimus in Comparison to Standard Therapy With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Cyclosporine Microemulsion in de Novo Renal Transplant Patients|Completed||Phase 4|300|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:42:19.474741|2018-06-01 04:42:19.474741
NCT00154297|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2011-01-04||2011-03-30|2005-09-08|2005-09-12|Estimate|2011-01-04|2011-01-26|Estimate||||2011-03-30|2011-04-04|Estimate|June 2005||2005-06-30|March 2011|2011-03-31||||June 2008|Actual|2008-06-30||Interventional|||Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients|A National Multicentre Randomized Study Comparing the Early Versus Delayed Administration of Everolimus in de Novo Kidney Transplant Recipients at Risk of Delayed Graft Function|Completed||Phase 4|139|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:42:21.260212|2018-06-01 04:42:21.260212
NCT00154284|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2011-01-04||2017-02-28|2005-09-08|2005-09-12|Estimate|2011-03-09|2011-03-11|Estimate||||2017-02-28|2017-03-30|Actual|July 2005||2005-07-31|February 2017|2017-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|CERTES02||Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients|A 12 Month, Multicenter, Randomized, Parallel, Open-label Study, to Evaluate Renal Function and Efficacy of Everolimus With Basiliximab and Cyclosporine Microemulsion Discontinuation at 3 Month Post-transplant Versus Minimization, in de Novo Kidney Transplant Recipients|Completed||Phase 3|114|Actual|Novartis|This is a combined analysis using 81 patients randomized and treated in CRAD001A2419 with 33 randomized and treated in CRAD001A2423. This approach is reflected in the protocol amendments for each study, and the one clinical study report for both.|2|||f||||||||||||||2018-06-01 04:42:22.028224|2018-06-01 04:42:22.028224
NCT00154271|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-11-07|2005-09-08|2005-09-12|Estimate|||||||2011-11-07|2011-11-08|Estimate|January 2004||2004-01-31|August 2006|2006-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)|Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)|Completed||Phase 4|1677|Actual|Novartis|||||||||||||||||||2018-06-01 04:42:22.404825|2018-06-01 04:42:22.404825
NCT00154258|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-03-17|2005-09-08|2005-09-12|Estimate|||||||2017-03-17|2017-03-21|Actual|April 2001||2001-04-30|March 2017|2017-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia|An Open Extension Study to Phase IIb Study of Clozapine in Patients With Treatment-resistant Schizophrenia|Completed||Phase 2|19|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:42:22.465388|2018-06-01 04:42:22.465388
NCT00154245|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-02-21|2005-09-08|2005-09-12|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2004||2004-01-31|February 2017|2017-02-28|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.||Completed||Phase 4|20||Novartis|||||f||||||||||||||2018-06-01 04:42:22.533622|2018-06-01 04:42:22.533622
NCT00154063|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2015-05-21||2015-05-21|2005-09-06|2005-09-12|Estimate|2015-05-21|2015-06-08|Estimate||||2015-05-21|2015-06-08|Estimate|January 2005||2005-01-31|August 2009|2009-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Efficacy and Safety Study of E2007 in Migraine Prophylaxis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis|Completed||Phase 2|206|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:42:25.399546|2018-06-01 04:42:25.399546
NCT00154232|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-11-01|2005-09-07|2005-09-12|Estimate|||||||2011-11-01|2011-11-02|Estimate|June 2004||2004-06-30|November 2011|2011-11-30||||March 2005|Actual|2005-03-31||Interventional|||Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)|A 3 Month, Multicenter, Open-label Study to Evaluate the Impact of the Immunosuppressive Combination of Enteric-Coated Mycophenolate Sodium (EC- MPS), Basiliximab and Cyclosporine for Microemulsion With C2 Monitoring, on Efficacy and Safety Outcomes in de Novo Kidney Transplant Recipients at Potential High Risk of DGF.|Completed||Phase 4|46||Novartis|||||f||||||||||||||2018-06-01 04:42:22.613137|2018-06-01 04:42:22.613137
NCT00154219|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-05-18|2005-09-07|2005-09-12|Estimate|||||||2012-05-18|2012-05-21|Estimate|November 2004||2004-11-30|May 2012|2012-05-31||||October 2006|Actual|2006-10-31||Interventional|||Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis|A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control|Completed||Phase 3|1200||Novartis|||||||||||||||||||2018-06-01 04:42:22.670283|2018-06-01 04:42:22.670283
NCT00154206|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-02-22|2005-09-08|2005-09-12|Estimate|||||||2017-02-22|2017-02-24|Actual|September 2004||2004-09-30|February 2017|2017-02-28||||January 2007|Actual|2007-01-31||Interventional|||Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients|A Multicenter, Open, Single Arm, Pilot Study to Evaluate Efficacy, Tolerability and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients|Completed||Phase 4|15||Novartis|||||f||||||||||||||2018-06-01 04:42:22.731504|2018-06-01 04:42:22.731504
NCT00154193|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-04-20|2005-09-06|2005-09-12|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2004||2004-06-30|April 2016|2016-04-30||||November 2007|Actual|2007-11-30||Interventional|||Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels|A 12-month Study to Investigate the Correlations Between Cyclosporine Microemulsion C2 Levels (High, Medium and Low) and AUC0-4 With Regard to Outcome in de Novo Heart and Lung Transplantation - Identification of Target Cyclosporine Microemulsion C2 Levels.|Completed||Phase 4|190|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:42:22.796699|2018-06-01 04:42:22.796699
NCT00154180|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-09-10|2005-09-09|2005-09-12|Estimate|||||||2009-09-10|2009-09-14|Estimate|September 2005||2005-09-30|September 2009|2009-09-30|July 2012|Anticipated|2012-07-31|May 2012|Anticipated|2012-05-31||Interventional|||Kronos Early Estrogen Prevention Study (KEEPS)|Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women|Unknown status|Active, not recruiting|Phase 4|728|Anticipated|Kronos Longevity Research Institute||2|||f||||t||||||||||2018-06-01 04:42:22.867413|2018-06-01 04:42:22.867413
NCT00154167|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-12|2005-09-08|2005-09-12|Estimate|||||||2005-09-12|2005-09-14|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|June 2003||2003-06-30|||||Interventional|||Safety and Efficacy Study of NV-101 in Dental Patients|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of NV-101 in Dental Patients|Completed||Phase 2|122||Novalar Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:42:22.967185|2018-06-01 04:42:22.967185
NCT00154154|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-12-11|2005-09-07|2005-09-12|Estimate|||||||2012-12-11|2012-12-12|Estimate|October 2002||2002-10-31|December 2012|2012-12-31|April 2009|Actual|2009-04-30|June 2007|Actual|2007-06-30||Interventional|||Hope for the Chronically Suicidal Patient|Hope for the Chronically Suicidal Patient: Evaluating the Clinical and Health Services Impact of Dialectical Behaviour Therapy in Individuals With Borderline Personality Disorder|Completed||N/A|180|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-06-01 04:42:23.114579|2018-06-01 04:42:23.114579
NCT00154141|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-07-11|2005-09-07|2005-09-12|Estimate|||||||2006-07-11|2006-07-13|Estimate|June 2005||2005-06-30|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Evaluation of Fibrin Sealant 2 in Vascular Surgical Procedures|A Prospective, Randomized Controlled Study to Compare the Effects of a Fibrin Sealant (FS2) Versus Manual Compression on Haemostatic Efficacy During Vascular Surgical Procedures Utilising Polytetrafluorethylene Graft Material on an End-to-Side Femoral or Upper Extremity Vascular Access Arterial Anastomosis|Completed||Phase 3|150||Ethicon, Inc.|||||||||||||||||||2018-06-01 04:42:23.25554|2018-06-01 04:42:23.25554
NCT00154128|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-17|2005-09-08|2005-09-12|Estimate|||||||2005-11-17|2005-11-18|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||The Influence of a Stabilization Splint on the Body Posture|The Influence of of a Stabilization Splint on the Body Posture in TMD Cases and Controls|Completed||Phase 1|40||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:42:23.365144|2018-06-01 04:42:23.365144
NCT00154115|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-01-20|2005-09-08|2005-09-12|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Levosimendan in High Risk Heart Valve Surgery|Efficacy of Levosimendan in Cardiac Failure After Heart Valve Surgery|Completed||Phase 4|200|Anticipated|Kuopio University Hospital||2|||f||||t||||||||||2018-06-01 04:42:23.425107|2018-06-01 04:42:23.425107
NCT00154102|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-11-30||2017-01-12|2005-09-08|2005-09-12|Estimate|2011-01-27|2011-02-23|Estimate||||2017-01-12|2017-01-30|Estimate|May 2004||2004-05-31|January 2017|2017-01-31|March 2011|Actual|2011-03-31|December 2006|Actual|2006-12-31||Interventional|CRYSTAL||Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)|Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer|Completed||Phase 3|1221|Actual|Merck KGaA|A non-specific outcome measure 'Safety' was deleted from the entry in error. A replacement outcome was created. The outcome refers to adverse events.|2|||f||||t||||||||||2018-06-01 04:42:23.578971|2018-06-01 04:42:23.578971
NCT00154089|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-02-20|2005-09-08|2005-09-12|Estimate|||||||2016-02-20|2016-02-23|Estimate|November 2004||2004-11-30|August 2006|2006-08-31|December 2006|Actual|2006-12-31|April 2006|Actual|2006-04-30||Interventional|||A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia|A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus|Completed||Phase 1/Phase 2|8|Actual|Erimos Pharmaceuticals||1|||f||||f||||||||No||2018-06-01 04:42:25.193753|2018-06-01 04:42:25.193753
NCT00154076|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-09-01|2005-09-08|2005-09-12|Estimate|||||||2009-09-01|2009-09-02|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies||Completed||Phase 4|140|Anticipated|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:42:25.26033|2018-06-01 04:42:25.26033
NCT00154037|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-12|2005-09-09|2005-09-12|Estimate|||||||2006-09-12|2006-09-13|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.|Characterization of Vascular Effects of Candesartan and Pioglitazone.|Completed||N/A|40||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:42:26.233958|2018-06-01 04:42:26.233958
NCT00154024|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-27|2005-09-08|2005-09-12|Estimate|||||||2006-09-27|2006-09-28|Estimate|March 2003||2003-03-31|July 2006|2006-07-31|October 2006||2006-10-31|||||Interventional|||Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.|Characterization of Local Vascular Effects of Angiotensin II and Histamine After Treatment With Irbesartan and Atorvastatin.|Completed||N/A|||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:42:26.283204|2018-06-01 04:42:26.283204
NCT00154011|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-11|2005-09-08|2005-09-12|Estimate|||||||2006-09-11|2006-09-12|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|June 2006||2006-06-30|||||Interventional|||Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.|Characterization of Vascular Effects of Rosiglitazone.|Completed||N/A|24||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:42:26.336771|2018-06-01 04:42:26.336771
NCT00153998|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-02-26|2005-09-08|2005-09-12|Estimate|||||||2009-02-26|2009-02-27|Estimate|November 2004||2004-11-30|April 2007|2007-04-30||||March 2008|Actual|2008-03-31||Interventional|||Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)|Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases|Completed||Phase 2|135|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-06-01 04:42:26.392804|2018-06-01 04:42:26.392804
NCT00153985|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2012-12-05||2013-07-24|2005-09-08|2005-09-12|Estimate|2013-02-06|2013-03-12|Estimate||||2013-07-24|2013-07-30|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|July 2009|Actual|2009-07-31|March 2008|Actual|2008-03-31||Interventional|||Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies|Multi-Center Study Using Allogeneic Stem Cell Transplantation Following Reduced Intensity Chemotherapy in Patients With Hemoglobinopathies|Completed||Phase 2|2|Actual|Dana-Farber Cancer Institute|Early termination leading to small numbers of subjects analyzed.||||f||||t||||||||||2018-06-01 04:42:26.598085|2018-06-01 04:42:26.598085
NCT00153972|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-12-17|2005-09-07|2005-09-12|Estimate|||||||2012-12-17|2012-12-18|Estimate|February 2005||2005-02-28|December 2012|2012-12-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease|Dopamine Turnover Rate Measured With F-Dopa-PET as Surrogate Parameter for Diagnosis and Progression Analysis of Early Parkinson's Disease|Completed||Phase 4|39|Actual|Technische Universität Dresden||2|||f||||t||||||||||2018-06-01 04:42:26.750288|2018-06-01 04:42:26.750288
NCT00153959|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate||||September 2005|2005-09-30||||||||Interventional|||Psychiatric Day Hospital Treatment||Completed||N/A|||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:42:26.827331|2018-06-01 04:42:26.827331
NCT00153946|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-12|2005-09-08|2005-09-12|Estimate|||||||2008-05-12|2008-05-14|Estimate|August 2004||2004-08-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|EAST||Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke|Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy|Completed||Phase 4|814|Actual|Combination Therapy for Acute Ischemic Stroke Study Group||2|||f||||t||||||||||2018-06-01 04:42:26.881977|2018-06-01 04:42:26.881977
NCT00153933|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-01-21|2005-09-08|2005-09-12|Estimate|||||||2016-01-21|2016-01-25|Estimate|August 2004||2004-08-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma|An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma|Completed||Phase 1|58|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 04:42:26.950031|2018-06-01 04:42:26.950031
NCT00153920|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2016-01-21||2016-01-21|2005-09-08|2005-09-12|Estimate|2016-01-21|2016-02-18|Estimate||||2016-01-21|2016-02-18|Estimate|December 2003||2003-12-31|January 2016|2016-01-31|September 2008|Actual|2008-09-30|July 2007|Actual|2007-07-31||Interventional||The analysis population is comprised of eligible and treated participants.|Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma|Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma|Completed||Phase 2|66|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 04:42:27.032443|2018-06-01 04:42:27.032443
NCT00153907|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-02-05|2005-09-08|2005-09-12|Estimate|||||||2013-02-05|2013-02-07|Estimate|March 2002||2002-03-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer|A Phase I Study of Oral Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer|Completed||Phase 1|40|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:42:27.38674|2018-06-01 04:42:27.38674
NCT00153894|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-06-24|2005-09-08|2005-09-12|Estimate|||||||2016-06-24|2016-06-27|Estimate|December 2003||2003-12-31|June 2016|2016-06-30|February 2008|Actual|2008-02-29|June 2006|Actual|2006-06-30||Interventional|||Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors|Pilot Study of the Effects of an Exercise Intervention on Insulin Levels in Breast Cancer Survivors|Completed||N/A|100|Actual|Dana-Farber Cancer Institute||2|||f||||f||||||||No||2018-06-01 04:42:27.472166|2018-06-01 04:42:27.472166
NCT00153881|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-11-11|2005-09-09|2005-09-12|Estimate|||||||2014-11-11|2014-11-13|Estimate|February 2000||2000-02-29|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer|Docetaxel and Carboplatin Followed by a Dose-Ranging Study of Oral Capecitabine, Weekly Docetaxel, and Concomitant External Beam Radiotherapy for the Treatment of Patients With Stage II-III Carcinoma of the Esophagus and Gastro-Esophageal Junction|Completed||Phase 1|44|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 04:42:27.561068|2018-06-01 04:42:27.561068
NCT00153868|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-06-27|2005-09-08|2005-09-12|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2003||2003-10-31|June 2016|2016-06-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer|Pilot Web-based Study of Functional Status, Symptom Palliation and Quality of Life Benefits Associated With Darbepoetin Alfa (Aranesp®) Administration in Anemic Patients With Cancer.|Active, not recruiting||N/A|43|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 04:42:27.645623|2018-06-01 04:42:27.645623
NCT00153855|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-09-06|2005-09-08|2005-09-12|Estimate|||||||2006-09-06|2006-09-08|Estimate|January 2005||2005-01-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Observational|||Structural Brain Abnormalities in Children Born Prematurely: New Detection Methods and Clinical-Pathological Correlates|Structural Brain Abnormalities in Children Born Prematurely: New Detection Methods and Clinical-Pathological Correlates|Terminated|||50||Children's Hospital of Philadelphia|||||f||||||||||||||2018-06-01 04:42:27.826979|2018-06-01 04:42:27.826979
NCT00153842|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-10-19|2005-09-08|2005-09-12|Estimate|||||||2011-10-19|2011-10-20|Estimate|August 2001||2001-08-31|October 2011|2011-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer|Phase I and II Clinical Studies of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules for the Treatment of Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|33|Actual|Dartmouth-Hitchcock Medical Center||1||"study closed to enrollment 04/07/2005 due to two large phase III trials showing no survival~   benefit of combining bexarotene with platinum-based chemotherapy"|f||||t||||||||||2018-06-01 04:42:27.89255|2018-06-01 04:42:27.89255
NCT00153829|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-02-20|2005-09-09|2005-09-12|Estimate|||||||2015-02-20|2015-02-23|Estimate|December 2004||2004-12-31|February 2015|2015-02-28|February 2006||2006-02-28|||||Interventional|||Chronic Illness Care Management (CICM) Study In Primary Care||Completed||Phase 1|200||Bruyere Research Institute|||||f||||||||||||||2018-06-01 04:42:28.09613|2018-06-01 04:42:28.09613
NCT00153816|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2015-09-21|2015-08-04|2017-02-06|2005-09-07|2005-09-12|Estimate|2015-09-21|2015-10-20|Estimate|2015-08-04|2015-08-06|Estimate|2017-02-06|2017-03-15|Actual|July 2004|Actual|2004-07-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|October 2013|Actual|2013-10-31||Interventional|||Vitamin D/Calcium Polyp Prevention Study|Vitamin D/Calcium Polyp Prevention Study|Completed||Phase 2/Phase 3|2813|Actual|Dartmouth-Hitchcock Medical Center||6|||f||||t||||||||||2018-06-01 04:42:28.235167|2018-06-01 04:42:28.235167
NCT00153803|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-11-11|2005-09-07|2005-09-12|Estimate|||||||2014-11-11|2014-11-13|Estimate|May 2005||2005-05-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)|A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410).|Completed||Phase 3|30|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 04:42:30.276516|2018-06-01 04:42:30.276516
NCT00153790|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-03-12|2005-09-07|2005-09-12|Estimate|||||||2014-03-12|2014-03-13|Estimate|April 2005||2005-04-30|March 2014|2014-03-31|May 2006||2006-05-31|||||Interventional|||LEAN Project: Weight Loss and Appetite Suppression|The Effect of Soy Lecithin-derived N-oleoyl-phosphatidyl-ethanolamine (NOPE) and Green Tea-derived Epigallocatechin Gallate (EGCG) on Indices of Weight Loss and Appetite Suppression|Completed||Phase 1|60||The Cooper Institute|||||f||||||||||||||2018-06-01 04:42:30.427073|2018-06-01 04:42:30.427073
NCT00153777|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-08-27|2005-09-08|2005-09-12|Estimate|||||||2015-08-27|2015-08-28|Estimate|July 2005||2005-07-31|August 2015|2015-08-31|March 2007|Actual|2007-03-31|||||Interventional|||Cellulose Sulfate and HIV Transmission Among Women|Randomized Controlled Trial of 6% Cellulose Sulfate Gel and the Effect on Vaginal HIV Transmission|Terminated||Phase 3|1428|Actual|CONRAD||||IDMC recommendation|f||||t||||||||||2018-06-01 04:42:30.480006|2018-06-01 04:42:30.480006
NCT00153764|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-08-01|2005-09-07|2005-09-12|Estimate|||||||2012-08-01|2012-08-02|Estimate|September 2004||2004-09-30|August 2012|2012-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|Omega-3||Effectiveness of a Vitamin Mineral Supplement|Effectiveness of a One-a-Day Cooper Complete Vitamin / Mineral Supplement With or Without Omega-3 Fatty Acid Ingestion|Completed||Phase 1|75|Actual|The Cooper Institute||1|||f||||f||||||||||2018-06-01 04:42:30.646783|2018-06-01 04:42:30.646783
NCT00153751|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-09|2005-09-08|2005-09-12|Estimate|||||||2008-05-09|2008-05-13|Estimate|September 2005||2005-09-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||The Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With Irritable Bowel Syndrome (IBS)|Clinical Study to Test the Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With IBS|Completed||Phase 2|84|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-06-01 04:42:30.718693|2018-06-01 04:42:30.718693
NCT00153738|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-03-12|2005-09-07|2005-09-12|Estimate|||||||2014-03-12|2014-03-13|Estimate|March 2004||2004-03-31|March 2014|2014-03-31|August 2005||2005-08-31|||||Interventional|||Phytosterol Supplementation and Cardiovascular Risk|Effectiveness of Phytosterol Supplementation on Select Indices of Cardiovascular Risk|Completed||N/A|72||The Cooper Institute|||||f||||||||||||||2018-06-01 04:42:30.791562|2018-06-01 04:42:30.791562
NCT00153725|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-10-26|2005-09-08|2005-09-12|Estimate|||||||2006-10-26|2006-10-27|Estimate|February 2003||2003-02-28|October 2006|2006-10-31|September 2006||2006-09-30|||||Interventional|||Intravenous Pantoloc In Aspirin-Induced Ulcer Bleeding||Completed||N/A|156||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:42:30.851441|2018-06-01 04:42:30.851441
NCT00153712|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-08-15|2005-09-08|2005-09-12|Estimate|||||||2017-08-15|2017-08-17|Actual|August 2002||2002-08-31|August 2017|2017-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Natural History of Non-steroidal Anti-inflammatory Drug and Non-Helicobacter Pylori in Bleeding Peptic Ulcers|A Prospective Cohort Study to Study the Natural History and Ulcer Recurrence Without Acid Suppression of Non-NSAID, Non-HP Bleeding Peptic Ulcer Patients|Completed|||391|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-06-01 04:42:30.908052|2018-06-01 04:42:30.908052
NCT00153699|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-10-30|2005-09-08|2005-09-12|Estimate|||||||2007-10-30|2007-10-31|Estimate|September 2004||2004-09-30|October 2007|2007-10-31|July 2007|Anticipated|2007-07-31|||||Interventional|||Relationship Between Topiramate Use and Ocular Angle Status|Relationship Between Topiramate Use and Ocular Angle Status: A Prospective Pilot Study|Unknown status|Active, not recruiting|Phase 4|15|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:42:30.966713|2018-06-01 04:42:30.966713
NCT00153686|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-09|2005-09-08|2005-09-12|Estimate|||||||2008-05-09|2008-05-13|Estimate|June 2005||2005-06-30|May 2008|2008-05-31|March 2008|Actual|2008-03-31|November 2007|Actual|2007-11-30||Interventional|||Capsule Endoscopy or Mesenteric Angiogram in Patients With Overt Gastrointestinal Bleeding (GIB) of Obscure Origin|Capsule Endoscopy or Mesenteric Angiogram in Patients With Overt Gastrointestinal Bleeding of Obscure Origin: A Randomized Study|Completed||N/A|58|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 04:42:31.027017|2018-06-01 04:42:31.027017
NCT00153673|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-04-20|2005-09-08|2005-09-12|Estimate|||||||2017-04-20|2017-04-21|Actual|February 2001||2001-02-28|April 2017|2017-04-30|April 12, 2017|Actual|2017-04-12|December 28, 2016|Actual|2016-12-28||Interventional|||Effect of Selective COX-2 Inhibition on Ulcer Healing|Phase III Study of a Double-Blind Randomized Comparison of Famotidine Plus Celecoxib Versus Dologesics for Gastric Ulcer Healing in Arthritis Patients (NSAID#5A Study)|Completed||Phase 3|200|Actual|Chinese University of Hong Kong||2|||f||||||||||||||2018-06-01 04:42:31.155837|2018-06-01 04:42:31.155837
NCT00153660|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2016-12-30|2005-09-08|2005-09-12|Estimate|||||||2016-12-30|2017-01-02|Estimate|June 2005||2005-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2014|Actual|2014-11-30||Interventional|||Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients|A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)|Completed||Phase 3|514|Actual|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-06-01 04:42:31.22378|2018-06-01 04:42:31.22378
NCT00153647|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-03-14|2005-09-08|2005-09-12|Estimate|||||||2008-03-14|2008-03-18|Estimate|May 2005||2005-05-31|August 2007|2007-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|CAC||A Study to Assess Cap-Assisted Colonoscopy Versus Regular Colonoscopy for the First or Repeated Colonoscopy|A Study to Assess the Success Rate of Cap-Assisted Colonoscopy Versus Regular Colonoscopy for the First or Repeated Colonoscopy (CAC Study)|Completed||N/A|1000|Actual|Chinese University of Hong Kong||2|||f||||||||||||||2018-06-01 04:42:31.30491|2018-06-01 04:42:31.30491
NCT00153634|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-03-12|2005-09-09|2005-09-12|Estimate|||||||2008-03-12|2008-03-13|Estimate|March 2004||2004-03-31|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)|Standard vs. Biofilm Susceptibility Testing in CF|Completed||N/A|75|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-06-01 04:42:31.381134|2018-06-01 04:42:31.381134
NCT00153621|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-02|2005-09-09|2005-09-12|Estimate|||||||2008-05-02|2008-05-05|Estimate|September 2004||2004-09-30|September 2005|2005-09-30|September 2007|Actual|2007-09-30|||||Observational|||Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric HIV-Infected Patients|Prevalence of Proteinuria and Chronic Kidney Disease in Pediatric Patients in the Special Immunology, Burgess, and Nephrology Clinics|Completed|||320|Anticipated|Children's Research Institute|||||f||||||||||||||2018-06-01 04:42:31.474355|2018-06-01 04:42:31.474355
NCT00153608|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-02-13|2005-09-08|2005-09-12|Estimate|||||||2006-02-13|2006-02-14|Estimate|April 2004||2004-04-30|September 2005|2005-09-30||||||||Interventional|||WT1 Peptid Vaccination in Carcinomas|Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas|Unknown status|Recruiting|Phase 2|25||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:42:31.532225|2018-06-01 04:42:31.532225
NCT00153595|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-23|2005-09-08|2005-09-12|Estimate|||||||2007-07-23|2007-07-25|Estimate|November 2004||2004-11-30|September 2005|2005-09-30||||||||Interventional|||EWO1 in Persistent Allergic Rhinitis Patients|A Double-Blind, Randomized Parallel Group, Placebo-Control Study of EW01 in Persistent Allergic Rhinitis (PAR) Patients|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|China Medical University Hospital|||||f||||||||||||||2018-06-01 04:42:31.590123|2018-06-01 04:42:31.590123
NCT00153582|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-02-21|2005-09-08|2005-09-12|Estimate|||||||2006-02-21|2006-02-22|Estimate|April 2002||2002-04-30|September 2005|2005-09-30||||||||Interventional|||WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)|Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML|Unknown status|Recruiting|Phase 2|25||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:42:31.671295|2018-06-01 04:42:31.671295
NCT00153569|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-05-25|2005-09-08|2005-09-12|Estimate|||||||2010-05-25|2010-05-26|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Multiepitope Peptide Vaccination in Melanoma|Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma|Unknown status|Active, not recruiting|Phase 2|25||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:42:31.749572|2018-06-01 04:42:31.749572
NCT00153556|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|September 2001||2001-09-30|September 2005|2005-09-30|November 2003||2003-11-30|||||Interventional|||Study to Eliminate Hib Carriage in Rural Alaska Native Villages|A Demonstration Project for the Elimination of Haemophilus Influenzae Type B in Three Rural Alaska Native Villages|Completed||Phase 4|3200||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 04:42:31.802273|2018-06-01 04:42:31.802273
NCT00153543|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-03-19|2005-09-08|2005-09-12|Estimate|||||||2007-03-19|2007-03-20|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|June 2003||2003-06-30|||||Interventional|||Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders|Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders|Completed||Phase 1|90||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 04:42:32.081915|2018-06-01 04:42:32.081915
NCT00153530|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-12-23|2005-09-08|2005-09-12|Estimate|||||||2009-12-23|2009-12-24|Estimate|May 2000||2000-05-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|||||Interventional|||Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)|Phase IV Study on the Role of Whole Brain Irradiation in Primary CNS Lymphoma (PCNSL) After High-dose Methotrexate|Completed||Phase 4|604|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-06-01 04:42:32.136342|2018-06-01 04:42:32.136342
NCT00153517|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|October 1999||1999-10-31|September 2005|2005-09-30|March 2005||2005-03-31|||||Interventional|||Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy|Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy (Randomized Trial of BV Treatment in Pregnancy)|Completed||Phase 2|126||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.20913|2018-06-01 04:42:32.20913
NCT00153504|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-04-04|2005-09-08|2005-09-12|Estimate|||||||2012-04-04|2012-04-05|Estimate|July 2004||2004-07-31|April 2012|2012-04-30|January 2007|Actual|2007-01-31|||||Interventional|H&H||Housing and Health Study|Housing and Health Study|Completed||N/A|630|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 04:42:32.271203|2018-06-01 04:42:32.271203
NCT00153491|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|August 2006||2006-08-31|||||Observational|||Adherence to Lumefantrine-Artemether|Assessment of Adherence to a 6-Dose Regimen of Coartem for Treatment of Uncomplicated Malaria in Children Under 5 Years in Tanzania|Completed|||300||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.33781|2018-06-01 04:42:32.33781
NCT00153478|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|July 2002||2002-07-31|September 2005|2005-09-30|August 2004||2004-08-31|||||Interventional|||Project CHOICES Efficacy Study|Project CHOICES Efficacy Study for Preventing Alcohol-Exposed Pregnancies|Completed||Phase 2|1200||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.402501|2018-06-01 04:42:32.402501
NCT00153465|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-09-06|2005-09-08|2005-09-12|Estimate|||||||2007-09-06|2007-09-10|Estimate|January 2004||2004-01-31|September 2007|2007-09-30|September 2006|Actual|2006-09-30|||||Interventional|||University of Oklahoma Parenting Program Attrition|University of Oklahoma Health Sciences Center Parenting Program Attrition and Compliance Efficacy Trial|Completed||Phase 1|450||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:42:32.476257|2018-06-01 04:42:32.476257
NCT00153452|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|November 2004||2004-11-30|September 2005|2005-09-30|July 2005||2005-07-31|||||Observational|||Workplace Productivity of Persons Who Use Controlling Behavior With Intimate Partners|Workplace Productivity of Persons Who Use Controlling Behavior With Intimate Partners|Completed|||630||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.544124|2018-06-01 04:42:32.544124
NCT00153439|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-09-06|2005-09-08|2005-09-12|Estimate|||||||2007-09-06|2007-09-10|Estimate|July 2003||2003-07-31|September 2007|2007-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Purdue University Parenting Program Attrition|Purdue University Parenting Program Attrition and Compliance Efficacy Trial|Completed||Phase 1|560||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:42:32.661417|2018-06-01 04:42:32.661417
NCT00153426|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-06-27|2005-09-08|2005-09-12|Estimate|||||||2012-06-27|2012-06-28|Estimate|July 2003||2003-07-31|June 2012|2012-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||West Virginia WISEWOMAN Project|West Virginia WISEWOMAN Project|Completed||N/A|733|Actual|West Virginia University||1|||f||||f||||||||||2018-06-01 04:42:32.735972|2018-06-01 04:42:32.735972
NCT00153413|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate||||September 2005|2005-09-30||||||||Interventional|||West Virginia WISEWOMAN Focus Groups|West Virginia WISEWOMAN Focus Groups|Unknown status|Active, not recruiting|N/A|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.795122|2018-06-01 04:42:32.795122
NCT00153400|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-02-10|2005-09-08|2005-09-12|Estimate|||||||2006-02-10|2006-02-13|Estimate||||September 2005|2005-09-30||||||||Interventional|||California WISEWOMAN Project|California WISEWOMAN Project|Unknown status|Not yet recruiting|N/A|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.845543|2018-06-01 04:42:32.845543
NCT00153387|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate||||September 2005|2005-09-30||||||||Interventional|||Illinois WISEWOMAN Project|Illinois WISEWOMAN Project|Completed||N/A|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.903346|2018-06-01 04:42:32.903346
NCT00153374|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-03-13|2005-09-08|2005-09-12|Estimate|||||||2012-03-13|2012-03-14|Estimate||||March 2012|2012-03-31||||||||Interventional|||Iowa WISEWOMAN Project|Iowa WISEWOMAN Project|Completed||N/A|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:32.949468|2018-06-01 04:42:32.949468
NCT00153361|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-01-06|2005-09-07|2005-09-12|Estimate|||||||2010-01-06|2010-01-07|Estimate|October 2002||2002-10-31|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Project MIX: Behavioral Intervention to Reduce Risk Among Substance-Using MSM|Project Mix: Behavioral Intervention to Reduce Sexual Risk Behavior of Substance-Using (Non-Injection) Men Who Have Sex With Men|Completed||N/A|1750|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:33.003186|2018-06-01 04:42:33.003186
NCT00153348|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-03-13|2005-09-08|2005-09-12|Estimate|||||||2012-03-13|2012-03-14|Estimate|January 2001||2001-01-31|March 2012|2012-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||South Central Foundation - WISEWOMAN Project|South Central Foundation - WISEWOMAN Project|Completed||N/A|||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:33.0929|2018-06-01 04:42:33.0929
NCT00153335|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-02-24|2005-09-07|2005-09-12|Estimate|||||||2010-02-24|2010-02-26|Estimate|June 2005||2005-06-30|February 2010|2010-02-28|September 2007|Actual|2007-09-30|||||Interventional|||Computerized Risk Assessment in an Employee Population|Computerized Risk Assessment in an Employee Population|Completed||N/A|300|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:33.145522|2018-06-01 04:42:33.145522
NCT00153322|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-12|Estimate|||||||2005-09-07|2005-09-12|Estimate|November 2002||2002-11-30|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Shape Up Somerville: Eat Smart Play Hard|Shape Up Somerville: Eat Smart Play Hard|Completed||N/A|3000||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:33.216704|2018-06-01 04:42:33.216704
NCT00153309|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-11-16|2005-09-07|2005-09-12|Estimate|||||||2005-11-16|2005-11-17|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Program Evaluation of People With Arthritis Can Exercise|Evaluation of the Health Benefits of the People With Arthritis Can Exercise Program|Completed||Phase 2/Phase 3|320||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:42:33.290376|2018-06-01 04:42:33.290376
NCT00153296|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-02-18|2005-09-08|2005-09-12|Estimate|||||||2009-02-18|2009-02-19|Estimate|August 2004||2004-08-31|February 2009|2009-02-28|April 2005||2005-04-30|||||Interventional|||Study of Efficacy of Carbamazepine in Therapy of Patients With Moderate Persistent and Severe Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Carbamazepine Efficacy in Moderate Persistent and Severe Asthma Therapy|Completed||Phase 4|68||Centre of Chinese Medicine, Georgia|||||f||||||||||||||2018-06-01 04:42:33.352818|2018-06-01 04:42:33.352818
NCT00153283|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-02-18|2005-09-08|2005-09-12|Estimate|||||||2009-02-18|2009-02-19|Estimate|September 2003||2003-09-30|February 2009|2009-02-28|April 2004||2004-04-30|||||Interventional|||Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Gabapentin Efficacy in Asthma Therapy|Completed||Phase 4|68||Centre of Chinese Medicine, Georgia|||||f||||||||||||||2018-06-01 04:42:33.407062|2018-06-01 04:42:33.407062
NCT00153270|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-02-18|2005-09-08|2005-09-12|Estimate|||||||2009-02-18|2009-02-19|Estimate|September 2000||2000-09-30|February 2009|2009-02-28|April 2001||2001-04-30|||||Interventional|||Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Sodium Valproate Efficacy in Asthma Therapy|Completed||Phase 4|46||Centre of Chinese Medicine, Georgia|||||f||||||||||||||2018-06-01 04:42:33.457813|2018-06-01 04:42:33.457813
NCT00153257|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-12|Estimate|||||||2005-09-08|2005-09-12|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|June 2011||2011-06-30|||||Interventional|||Comparative Study of Mesh Versus No Mesh in Prolapse Surgery|Comparison of the Prosthesis Ugytex by the Trans-Obturator Approach and Anterior Colporrhaphy for the Surgical Treatment of Anterior Vaginal Wall Prolapse.|Unknown status|Recruiting|Phase 4|194||Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-06-01 04:42:33.510343|2018-06-01 04:42:33.510343
NCT00153244|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-02-18|2005-09-08|2005-09-12|Estimate|||||||2009-02-18|2009-02-19|Estimate|August 2002||2002-08-31|February 2009|2009-02-28|May 2003||2003-05-31|||||Interventional|||Study of Efficacy of Lamotrigine in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Lamotrigine Efficacy in Asthma Therapy|Completed||Phase 4|76||Centre of Chinese Medicine, Georgia|||||f||||||||||||||2018-06-01 04:42:33.566568|2018-06-01 04:42:33.566568
NCT00153231|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-03-26|2005-09-08|2005-09-12|Estimate|||||||2015-03-26|2015-03-27|Estimate|March 2003||2003-03-31|March 2015|2015-03-31|May 2007|Actual|2007-05-31|December 2005|Actual|2005-12-31||Interventional|||Posterior IVS Versus Sacrospinous Suspension in Vaginal Vault Prolapse Repair|Clinical Evaluation of Morbidity and Efficacy of Posterior IVS (Infracoccygeal Sacropexy), in Comparison to the Standard Sacrospinous Suspension in the Surgical Treatment of Vaginal Vault Prolapse by the Vaginal Route.|Completed||Phase 4|49|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-06-01 04:42:33.617471|2018-06-01 04:42:33.617471
NCT00153218|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-02-13|2005-09-09|2005-09-12|Estimate|||||||2012-02-13|2012-02-14|Estimate|June 2004||2004-06-30|February 2012|2012-02-29||||||||Observational|||An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu|An Observational Study of Current Practice Pattern on the Treatment of Women With Metastatic Breast Cancer Whose Tumors Overexpress Her2neu|Completed|||94|Actual|Cancer Research Network|||||f||||||||||||||2018-06-01 04:42:33.67452|2018-06-01 04:42:33.67452
NCT00153205|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-02-14|2005-09-08|2005-09-12|Estimate|||||||2017-02-14|2017-02-16|Actual|February 2000||2000-02-29|February 2017|2017-02-28|May 2007|Actual|2007-05-31|May 2006|Actual|2006-05-31||Interventional|||Serious Medication Errors in Pediatrics: Evaluation of Prevention Strategies|Serious Medication Errors in Pediatrics: Evaluation of Prevention Strategies|Withdrawn||N/A|0|Actual|Brigham and Women's Hospital||2|||f||||||||||||||2018-06-01 04:42:33.726348|2018-06-01 04:42:33.726348
NCT00153192|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-04-25|2005-09-07|2005-09-12|Estimate|||||||2013-04-25|2013-04-26|Estimate|April 2001||2001-04-30|April 2013|2013-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study to Evaluate the Efficacy of Dronabinol (Marinol) as Add-On Therapy for Patients on Opioids for Chronic Pain|A Randomized Controlled Clinical Trial of Dronabinol (Marinol) vs Placebo as Add-on Therapy For Patients on Opioids for Chronic Pain|Completed||Phase 2/Phase 3|30||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:42:33.91864|2018-06-01 04:42:33.91864
NCT00153179|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-03-19||2013-05-30|2005-09-08|2005-09-12|Estimate|2013-05-30|2013-07-08|Estimate||||2013-05-30|2013-07-08|Estimate|September 2005||2005-09-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|December 2011|Actual|2011-12-31||Interventional|||Free Fatty Acids and Vascular Function in Subjects With Diabetes|The Impact of Free Fatty Acid Reduction on Vascular Function and Skeletal Muscle Glucose Utilization in Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|110|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 04:42:33.999053|2018-06-01 04:42:33.999053
NCT00153166|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2013-04-24||2014-09-22|2005-09-08|2005-09-12|Estimate|2014-09-22|2014-09-30|Estimate||||2014-09-22|2014-09-30|Estimate|January 2004||2004-01-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|November 2010|Actual|2010-11-30||Interventional||Baseline Characteristics were collected according to the clinical diagnosis of the patients and not according to randomization. Participants are grouped at Baseline regardless of randomization because we are measuring baseline characteristics that do not depend on which intervention they received.|ARREST PAD (Peripheral Arterial Disease)|The Contribution of Inflammation and Insulin Resistance to Intermittent Claudication|Completed||Phase 2/Phase 3|76|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-06-01 04:42:34.248456|2018-06-01 04:42:34.248456
NCT00153153|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-02-06|2005-09-07|2005-09-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|August 2003||2003-08-31|February 2013|2013-02-28||||December 2004|Actual|2004-12-31||Interventional|||Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients|Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients|Completed||Phase 4|300||Braintree Laboratories|||||||||||||||||||2018-06-01 04:42:34.517414|2018-06-01 04:42:34.517414
NCT00153140|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-02-06|2005-09-07|2005-09-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2004||2004-07-31|February 2013|2013-02-28||||October 2004|Actual|2004-10-31||Interventional|||Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation|Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation|Completed||Phase 4|239||Braintree Laboratories|||||||||||||||||||2018-06-01 04:42:34.688138|2018-06-01 04:42:34.688138
NCT00153127|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-02-06|2005-09-07|2005-09-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|November 2001||2001-11-30|February 2013|2013-02-28||||September 2004|Actual|2004-09-30||Interventional|||Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications|Comparison of Braintree PolyethyleneGlycol(PEG) Laxative and Placebo for Relief of Constipation From Constipating Medications|Completed||Phase 4|100||Braintree Laboratories|||||||||||||||||||2018-06-01 04:42:34.774285|2018-06-01 04:42:34.774285
NCT00153114|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-02-06|2005-09-07|2005-09-12|Estimate|||||||2013-02-06|2013-02-07|Estimate|January 2003||2003-01-31|February 2013|2013-02-28||||September 2004|Actual|2004-09-30||Interventional|||PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children|PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children|Completed||Phase 4|100||Braintree Laboratories|||||||||||||||||||2018-06-01 04:42:34.839254|2018-06-01 04:42:34.839254
NCT00153101|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-06-15||2014-05-13|2005-09-09|2005-09-12|Estimate|2009-07-13|2009-08-25|Estimate||||2014-05-13|2014-05-20|Estimate|November 2001||2001-11-30|May 2014|2014-05-31||||June 2008|Actual|2008-06-30||Interventional||The Full Analysis Set (FAS) followed the intent-to-treat principle; it included all patients who were randomised and had any follow-up information available (i.e. 'date last seen' was available for these patients).|Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.|ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.|Completed||Phase 4|31546|Actual|Boehringer Ingelheim|Only non-serious Adverse Events (AE) which lead to discontinuation of study medication were assessed and collected; the frequency was under 5%. Non-serious AEs per se were not assessed or collected.||||f||||||||||||||2018-06-01 04:42:35.623719|2018-06-01 04:42:35.623719
NCT00153088|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-10-31|2005-09-09|2005-09-12|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2003||2003-01-31|October 2013|2013-10-31|November 2005||2005-11-30|November 2005|Actual|2005-11-30||Interventional|||INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy|A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study -|Completed||Phase 4|527|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:42:54.841155|2018-06-01 04:42:54.841155
NCT00153075|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-10-28|2005-09-09|2005-09-12|Estimate|||||||2013-10-28|2013-10-29|Estimate|September 2005||2005-09-30|October 2013|2013-10-31|December 2005||2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat Inhaler vs. a Metered Dose Inhaler (HFA-MDI) Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 4|19||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:42:55.470038|2018-06-01 04:42:55.470038
NCT00153062|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|2009-02-06||2014-04-22|2005-09-09|2005-09-12|Estimate|2009-07-22|2009-09-02|Estimate||||2014-04-22|2014-05-13|Estimate|August 2003||2003-08-31|April 2014|2014-04-30||||April 2008|Actual|2008-04-30||Interventional|||PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes|PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis|Completed||Phase 4|20332|Actual|Boehringer Ingelheim|All SAEs and AEs that led to temporary or permanent trial drug discontinuation were reported, except in Japan, where all AEs were collected. Protocol-defined outcome events were not reported as AEs, but were recorded on the appropriate form|4|||f||||||||||||||2018-06-01 04:42:56.112697|2018-06-01 04:42:56.112697
NCT00153049|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-07|2005-09-09|2005-09-12|Estimate|||||||2013-11-07|2013-11-08|Estimate|June 2004||2004-06-30|November 2013|2013-11-30|June 2005||2005-06-30|June 2005|Actual|2005-06-30||Interventional|||3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension|A Randomised, Double-Blind, Placebo-Controlled, 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension|Completed||Phase 2|583|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:43:05.631609|2018-06-01 04:43:05.631609
NCT00153036|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09||2014-04-30|2014-04-30|2005-09-09|2005-09-12|Estimate||||2014-04-30|2014-05-16|Estimate|2014-04-30|2014-05-16|Estimate|April 2003||2003-04-30|April 2014|2014-04-30||||February 2008|Actual|2008-02-29||Interventional|||Rt-PA in the Treatment of Acute Ischemic Stroke|ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset|Completed||Phase 3|821|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:43:05.747654|2018-06-01 04:43:05.747654
NCT00153023|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-12|2005-09-09|2005-09-12|Estimate|||||||2013-11-12|2013-11-13|Estimate|April 2003||2003-04-30|November 2013|2013-11-30|December 2005||2005-12-31|December 2005|Actual|2005-12-31||Interventional|||1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy|A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study|Completed||Phase 4|885||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:43:06.434918|2018-06-01 04:43:06.434918
NCT00153010|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-10-28|2005-09-09|2005-09-12|Estimate|||||||2013-10-28|2013-10-29|Estimate|February 2003||2003-02-28|October 2013|2013-10-31||||March 2005|Actual|2005-03-31||Interventional|||An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type|A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type|Completed||Phase 2|430|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:43:06.738844|2018-06-01 04:43:06.738844
NCT00152997|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-10-30|2005-09-09|2005-09-12|Estimate|||||||2013-10-30|2013-10-31|Estimate|August 2004||2004-08-31|October 2013|2013-10-31||||December 2005|Actual|2005-12-31||Interventional|||Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pramipexole With the Dose Range From 0.125 mg to 0.75 mg Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome.|Completed||Phase 2|41|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:43:07.153972|2018-06-01 04:43:07.153972
NCT00152984|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-12-27|2005-09-08|2005-09-12|Estimate|||||||2017-12-27|2017-12-28|Actual|December 2004||2004-12-31|December 2017|2017-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma|A 12-week Randomised, Double Blind, Placebo Controlled, Parallel Group Trial Evaluating the Efficacy and Safety of Inhaled Tiotropium 18μg q.d. in Patients With COPD and a Concomitant Diagnosis of Asthma|Completed||Phase 4|472||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:43:07.242837|2018-06-01 04:43:07.242837
NCT00152971|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-11-18||2014-04-22|2005-09-08|2005-09-12|Estimate|2010-11-18|2010-12-17|Estimate||||2014-04-22|2014-05-05|Estimate|November 2004||2004-11-30|April 2014|2014-04-30||||June 2006|Actual|2006-06-30||Interventional|||Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement|A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery|Completed||Phase 3|2615|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 04:43:07.461881|2018-06-01 04:43:07.461881
NCT00152958|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-11-18|2005-09-08|2005-09-12|Estimate|||||||2013-11-18|2013-11-19|Estimate|January 2004||2004-01-31|November 2013|2013-11-30||||February 2005|Actual|2005-02-28||Interventional|||A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)|A Double-blind, Placebo-controlled, Randomised Withdrawal Study of 3 Month Duration in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)|Completed||Phase 3|224||Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:43:08.563054|2018-06-01 04:43:08.563054
NCT00152945|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-09-28|2005-09-08|2005-09-09|Estimate|||||||2012-09-28|2012-10-02|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|October 2008|Actual|2008-10-31|July 2008|Actual|2008-07-31||Interventional|||Determining the Responsiveness of Intestinal Lipoprotein Production to an Elevation of Plasma Free Fatty Acids||Completed||N/A|10|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:43:08.78244|2018-06-01 04:43:08.78244
NCT00152932|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-23|2005-09-08|2005-09-09|Estimate|||||||2007-07-23|2007-07-25|Estimate|May 2005||2005-05-31|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide|Ocular Blood Flow Measured by HRF and CLBF in Newly Diagnosed and Early Glaucoma Patients Before and After Instillation of Dorzolamide 2%|Unknown status|Recruiting|N/A|17|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:43:08.84881|2018-06-01 04:43:08.84881
NCT00152919|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-08-12|2005-09-08|2005-09-09|Estimate|||||||2010-08-12|2010-08-13|Estimate|February 2004||2004-02-29|August 2010|2010-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy|A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial|Completed||Phase 3|100|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:43:08.914033|2018-06-01 04:43:08.914033
NCT00152906|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-09-19|2005-09-08|2005-09-09|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2003||2003-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Stereotactic Radiotherapy (SRT) Liver (COLD 1)|Phase I/II Trial of Highly Conformal Radiotherapy for Unresectable Liver Metastases and Hepatobiliary Carcinoma|Active, not recruiting||Phase 1/Phase 2|140|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:43:08.965562|2018-06-01 04:43:08.965562
NCT00152893|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-07-17|2005-09-08|2005-09-09|Estimate|||||||2013-07-17|2013-07-19|Estimate|August 2002||2002-08-31|July 2013|2013-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities|The Effects of Chromium Supplementation on Glucose and Lipid Metabolism in Patients With HIV Infection|Completed||Phase 2|52|Actual|University Health Network, Toronto||2|||f||||||||||||||2018-06-01 04:43:09.036342|2018-06-01 04:43:09.036342
NCT00152880|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-11-29|2005-09-08|2005-09-09|Estimate|||||||2005-11-29|2005-12-01|Estimate|July 2005||2005-07-31|September 2005|2005-09-30||||||||Observational|||Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative|Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative, Have Normal ALT, and HBV DNA ≥10,000 Copies/mL|Unknown status|Recruiting||30||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:43:09.110947|2018-06-01 04:43:09.110947
NCT00152867|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-06-26|2005-09-08|2005-09-09|Estimate|||||||2012-06-26|2012-06-28|Estimate|January 2005||2005-01-31|June 2012|2012-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy|A Randomised Double-Blind Placebo Controlled Cross Over Trial of the Impact on Quality of Life of Continuing Dexamethasone Beyond 24 Hours Following Moderately Emetogenic Chemotherapy|Completed||Phase 3|86|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-06-01 04:43:09.232857|2018-06-01 04:43:09.232857
NCT00152854|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-03-04|2005-09-08|2005-09-09|Estimate|||||||2016-03-04|2016-03-08|Estimate|July 2005||2005-07-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Acetaminophen for Cancer Pain|A Randomised, Placebo-controlled, Crossover Trial of Acetaminophen in Cancer Patients on Strong Opioids|Completed||Phase 3|12|Actual|University Health Network, Toronto||2|||f||||||||||||||2018-06-01 04:43:09.320762|2018-06-01 04:43:09.320762
NCT00152841|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-03-16|2005-09-07|2005-09-09|Estimate|||||||2009-03-16|2009-03-17|Estimate|June 2002||2002-06-30|March 2009|2009-03-31||||February 2009|Actual|2009-02-28||Interventional|||Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis|Effect of Iron and Antioxidant Vitamins on Disease Activity and Oxidative Stress in Inflammatory Bowel Disease (IBD)|Terminated||Phase 2|30|Anticipated|University Health Network, Toronto||||Lack of patients|f||||f||||||||||2018-06-01 04:43:09.42011|2018-06-01 04:43:09.42011
NCT00152828|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2016-02-08|2005-09-07|2005-09-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|February 2001||2001-02-28|February 2016|2016-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix|A Phase I/II Trial of the Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix|Completed||Phase 1/Phase 2|31|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-06-01 04:43:09.487572|2018-06-01 04:43:09.487572
NCT00152815|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-07-17|2005-09-07|2005-09-09|Estimate|||||||2013-07-17|2013-07-19|Estimate|October 2003||2003-10-31|July 2013|2013-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions|Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions|Terminated||Phase 2|30|Actual|University Health Network, Toronto||1||Not enough eligible patients available|f||||f||||||||||2018-06-01 04:43:09.551011|2018-06-01 04:43:09.551011
NCT00152802|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-02-16|2005-09-07|2005-09-09|Estimate|||||||2007-02-16|2007-02-19|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|January 2009||2009-01-31|||||Interventional|||Pneumonia Vaccine in Liver Transplant Recipients: a Booster Strategy Using a Conjugate Vaccine|Immunogenicity of Pneumococcal Vaccine in Liver Transplant Recipients Using a Conjugate-Polysaccharide Priming-Booster Strategy|Unknown status|Active, not recruiting|Phase 4|130||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:43:09.622144|2018-06-01 04:43:09.622144
NCT00152789|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-08-07|2005-09-07|2005-09-09|Estimate|||||||2009-08-07|2009-08-10|Estimate|April 2001||2001-04-30|January 2008|2008-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Normal Prostate: Oxygenation of the Prostate Gland in Men Undergoing Prostate Biopsy|Oxygenation of the Prostate Gland: a Polarographic Electrode Study in Men Undergoing Prostate Biopsy.|Completed||Phase 2|40|Anticipated|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:43:09.680297|2018-06-01 04:43:09.680297
NCT00152776|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-04-18|2005-09-08|2005-09-09|Estimate|||||||2007-04-18|2007-04-19|Estimate|February 2005||2005-02-28|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Treating Climacteric Symptoms With a Complex Homeopathic Remedy|Treatment of Climacteric Symptoms With Ovaria Comp - A Prospective Randomized Placebo Controlled Doubleblind Study|Completed||Phase 4|102||Heidelberg University|||||f||||f||||||||||2018-06-01 04:43:09.734208|2018-06-01 04:43:09.734208
NCT00152763|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-10-27||2011-01-05|2005-09-07|2005-09-09|Estimate|2011-01-05|2011-01-28|Estimate||||2011-01-05|2011-01-28|Estimate|October 2003||2003-10-31|January 2011|2011-01-31|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Psychological Support for Patients With an Implantable Cardioverter Defibrillator|Psychological Support for Patients With an Implantable Cardioverter Defibrillator|Completed||Phase 3|193|Actual|University Health Network, Toronto||4|||f||||||||||||||2018-06-01 04:43:09.834991|2018-06-01 04:43:09.834991
NCT00152750|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-02-27|2005-09-07|2005-09-09|Estimate|||||||2007-02-27|2007-02-28|Estimate|September 2006||2006-09-30|October 2006|2006-10-31|October 2008||2008-10-31|||||Interventional|||Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD|Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)|Unknown status|Recruiting|Phase 4|32||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:43:10.565599|2018-06-01 04:43:10.565599
NCT00152737|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-07-16|2005-09-08|2005-09-09|Estimate|||||||2015-07-16|2015-07-17|Estimate|March 2004||2004-03-31|July 2015|2015-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Objective Evaluation of Proximal Ischemia|Effet Des Gestes de Revascularisation à l'étage Proximal|Completed|||165|Actual|University Hospital, Angers|||||f||||t||||||||||2018-06-01 04:43:10.641209|2018-06-01 04:43:10.641209
NCT00152724|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-10-30|2005-09-08|2005-09-09|Estimate|||||||2017-10-30|2017-11-01|Actual|January 1996||1996-01-31|March 2007|2007-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers|Etude de la Reserve Vasomotrice Microcirculatoire cutanée|Completed|||85|Actual|University Hospital, Angers|||||f||||f||||||||||2018-06-01 04:43:10.716872|2018-06-01 04:43:10.716872
NCT00152711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-02-12|2005-09-08|2005-09-09|Estimate|||||||2007-02-12|2007-02-13|Estimate|September 2004||2004-09-30|September 2005|2005-09-30||||||||Interventional|||Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis|Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis: A Prospective Cross Over Trial|Unknown status|Recruiting|N/A|40||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:43:10.787215|2018-06-01 04:43:10.787215
NCT00152698|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-01-18|2005-09-08|2005-09-09|Estimate|||||||2013-01-18|2013-01-21|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia|A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Study the Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia|Completed||Phase 3|80||University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-06-01 04:43:10.991417|2018-06-01 04:43:10.991417
NCT00152685|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-11-29|2005-09-07|2005-09-09|Estimate|||||||2005-11-29|2005-12-01|Estimate||||September 2005|2005-09-30||||||||Interventional|||High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury||Unknown status|Recruiting|Phase 2/Phase 3|40||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:43:11.055074|2018-06-01 04:43:11.055074
NCT00152672|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-10-27|2005-09-08|2005-09-09|Estimate|||||||2005-10-27|2005-10-28|Estimate|June 2005||2005-06-30|February 2005|2005-02-28||||||||Interventional|||Treatment of Sleep Apnea Syndrome With nCPAP Versus Oral Appliance|Treatment of Sleep Apnea Syndrome With nCPAP Versus Oral Appliance: a Multicentre Prospective Randomized Crossover Trial|Unknown status|Recruiting|N/A|60||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:43:11.127669|2018-06-01 04:43:11.127669
NCT00152659|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2016-05-16|2005-09-08|2005-09-09|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 1998||1998-09-30|May 2016|2016-05-31||||December 2030|Anticipated|2030-12-31||Observational|||Developing Criteria for Cortical Resections|Developing Functional and Structural Criteria for Cortical Resections|Recruiting|||1000|Anticipated|University of Chicago|||||f||||f||||||||||2018-06-01 04:43:11.182873|2018-06-01 04:43:11.182873
NCT00152646|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-02-03|2005-09-07|2005-09-09|Estimate|||||||2010-02-03|2010-02-04|Estimate|March 2005||2005-03-31|September 2005|2005-09-30|January 2008|Anticipated|2008-01-31|||||Interventional|||Platelets Induced Vasodilation, in Vitro and in Vivo Study|Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects.|Unknown status|Recruiting|Phase 4|36|Anticipated|University Hospital, Angers|||||f||||t||||||||||2018-06-01 04:43:11.251097|2018-06-01 04:43:11.251097
NCT00152633|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-07-04|2005-09-08|2005-09-09|Estimate|||||||2012-07-04|2012-07-06|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension|Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension|Withdrawn||Phase 2/Phase 3|0|Actual|University of Erlangen-Nürnberg Medical School||2||No patient could be recruited.|f||||f||||||||||2018-06-01 04:43:11.311156|2018-06-01 04:43:11.311156
NCT00152620|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-09-04|2005-09-08|2005-09-09|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2004||2004-06-30|September 2013|2013-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease|Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease|Terminated||N/A|40||University of Chicago||||study completed|f||||||||||||||2018-06-01 04:43:11.380646|2018-06-01 04:43:11.380646
NCT00152607|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-09-26|2005-09-08|2005-09-09|Estimate|||||||2013-09-26|2013-09-27|Estimate|April 2000||2000-04-30|September 2013|2013-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Orthotopic Liver Transplantation Using a Living Donor|Orthotopic Liver Transplantation Using a Living Donor Into An Adult Recipient|Terminated||Phase 4|20|Actual|University of Chicago||||Poor accrual|f||||||||||||||2018-06-01 04:43:11.513121|2018-06-01 04:43:11.513121
NCT00152594|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-11-13|2005-09-07|2005-09-09|Estimate|||||||2006-11-13|2006-11-14|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|January 2006||2006-01-31|||||Interventional|||Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia|Phase III Study of Safety, Tolerance, Efficacy, Pharmacokinetics, and Costs of Therapy With Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia|Terminated||Phase 3|150||University of Cologne|||||f||||||||||||||2018-06-01 04:43:11.574201|2018-06-01 04:43:11.574201
NCT00152581|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-11-29|2005-09-07|2005-09-09|Estimate|||||||2005-11-29|2005-12-01|Estimate|April 2002||2002-04-30|September 2005|2005-09-30||||||||Interventional|||Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication|Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication|Completed||Phase 4|40||University College London Hospitals|||||f||||||||||||||2018-06-01 04:43:11.647848|2018-06-01 04:43:11.647848
NCT00152568|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-09-04|2005-09-08|2005-09-09|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2001||2001-06-30|September 2013|2013-09-30|December 2003|Actual|2003-12-31|September 2003|Actual|2003-09-30||Interventional|||The Effectiveness of Car Seat Checks at Routine Pediatric Visits|The Effectiveness of Car Seat Checks at Routine Pediatric Visits|Completed||N/A|364|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 04:43:11.713378|2018-06-01 04:43:11.713378
NCT00152555|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-06-11|2005-09-08|2005-09-09|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 2003||2003-03-31|April 2007|2007-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Physical Therapy for Systemic Lupus Erythematosus (SLE)|Physical Therapy for Improvement of Quality of Life in Patients With Systemic Lupus Erythematosus (SLE)|Terminated||N/A|100||University of Chicago||||study completed|f||||||||||||||2018-06-01 04:43:11.781854|2018-06-01 04:43:11.781854
NCT00152542|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-06-11|2005-09-08|2005-09-09|Estimate|||||||2013-06-11|2013-06-12|Estimate|May 2005||2005-05-31|March 2009|2009-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants|Follow up at School-age of Children Participating in the Nitric Oxide Ventilatory Approach (NOVA) Study|Completed||Phase 3|160|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:43:11.854481|2018-06-01 04:43:11.854481
NCT00152529|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-09-04|2005-09-07|2005-09-09|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2003||2003-10-31|September 2013|2013-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Observational|||C.A.T.C.H.-I.T.Competent Adulthood Transition With Cognitive, Humanistic and Interpersonal Teaching|"C.A.T.C.H.-I.T. Competent Adulthood Transition With Cognitive, Humanistic and Interpersonal Teaching"|Terminated|||8||University of Chicago||||Study completed|f||||||||||||||2018-06-01 04:43:11.940621|2018-06-01 04:43:11.940621
NCT00149838|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-04-26|2005-09-06|2005-09-08|Estimate|||||||2012-04-26|2012-04-30|Estimate|February 2005||2005-02-28|April 2012|2012-04-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Magnetic Brain Stimulation for the Treatment of Adult Depression|Optimization of TMS for Depression|Completed||Phase 2/Phase 3|199|Actual|National Institute of Mental Health (NIMH)||4|||f||||t||||||||||2018-06-01 04:43:49.183668|2018-06-01 04:43:49.183668
NCT00152516|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2009-08-27||2013-02-08|2005-09-07|2005-09-09|Estimate|2009-12-09|2010-01-13|Estimate||||2013-02-08|2013-02-12|Estimate|October 2004||2004-10-31|April 2010|2010-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures|A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures.|Completed||Phase 3|255|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:43:12.055062|2018-06-01 04:43:12.055062
NCT00152503|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-09-30|2005-09-07|2005-09-09|Estimate|||||||2008-09-30|2008-10-01|Estimate|August 2005||2005-08-31|September 2008|2008-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam|An Open Label, Exploratory, Dose-Escalation, Multicenter Study Examining the Safety, Tolerability and Efficacy of Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures Who Are Currently Receiving Levetiracetam (LEV) But Still Experiencing Seizures|Completed||Phase 2|60||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:12.660086|2018-06-01 04:43:12.660086
NCT00152490|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-09-06|2005-09-08|2005-09-09|Estimate|||||||2013-09-06|2013-09-09|Estimate|December 2003||2003-12-31|February 2010|2010-02-28|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)|A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease|Completed||Phase 3|604||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:12.730921|2018-06-01 04:43:12.730921
NCT00152477|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-02-22|2005-09-08|2005-09-09|Estimate|||||||2017-02-22|2017-02-23|Actual|August 2005||2005-08-31|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer|A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjects With Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer|Completed||Phase 2|165|Actual|UCB Pharma||3|||f||||||||||||||2018-06-01 04:43:12.786475|2018-06-01 04:43:12.786475
NCT00152464|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-04-09|2005-09-08|2005-09-09|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2002||2002-03-31|September 2009|2009-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)|The Early Prevention of Asthma in Atopic Children (EPAAC™) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for 18 Months in Preventing the Onset of Asthma in 12 to 24 Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens.|Completed||Phase 3|2500||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:12.885275|2018-06-01 04:43:12.885275
NCT00152451|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-02-09|2005-09-08|2005-09-09|Estimate|||||||2017-02-09|2017-02-10|Actual|May 2005||2005-05-31|February 2017|2017-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures|An Open-label, Exploratory, Multicenter, Dose-escalation Study Examining the Efficacy, Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg, 20 mg, 40 mg and 80 mg b.i.d. (Total Daily Dose of 20 to 160 mg) in Adult Subjects (18-65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures (Whether or Not Secondarily Generalized) and Treated With 1, 2 or 3 Approved Antiepileptic Drugs|Completed||Phase 2|30||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:12.93795|2018-06-01 04:43:12.93795
NCT00152438|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-09-20|2005-09-08|2005-09-09|Estimate|||||||2011-09-20|2011-09-22|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|December 2012|Anticipated|2012-12-31|October 2009|Actual|2009-10-31||Interventional|||Vasomotor Symptoms (VMS) Progesterone Study: Vasomotor Symptoms and Endothelial Function - Trial of Oral Micronized Progesterone|Vasomotor Symptoms and Endothelial Function—A Randomized Placebo-controlled Trial of Oral Micronized Progesterone (Prometrium®)|Unknown status|Active, not recruiting|Phase 2|125|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 04:43:13.007125|2018-06-01 04:43:13.007125
NCT00152425|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-09-06|2005-09-07|2005-09-09|Estimate|||||||2013-09-06|2013-09-09|Estimate|February 2004||2004-02-29|July 2010|2010-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).|A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870|Completed||Phase 3|392||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:13.212293|2018-06-01 04:43:13.212293
NCT00152412|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-08-25|2005-09-08|2005-09-09|Estimate|||||||2014-08-25|2014-08-26|Estimate|June 2004||2004-06-30|September 2009|2009-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis|A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis.|Completed||Phase 2|30||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:13.266945|2018-06-01 04:43:13.266945
NCT00152399|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-09-17|2005-09-07|2005-09-09|Estimate|||||||2012-09-17|2012-09-18|Estimate|September 2000||2000-09-30|September 2012|2012-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding|A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial To Study The Efficacy And The Safety Of The Early Administration Of Somatostatin (Ucb) 12 Mg/24 H IV Infusion And Two IV Boluses Of 250 Mcg During 72 Hours In The Treatment Of Subjects With Acute Severe Upper Gastrointestinal Bleeding (UGIB) With Suspicion Of Peptic Ulcer Bleeding [The PUB Study]|Completed||Phase 2|370||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:13.323396|2018-06-01 04:43:13.323396
NCT00152022|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-01-12|2005-09-07|2005-09-09|Estimate|||||||2017-01-12|2017-01-16|Estimate|April 2005||2005-04-30|January 2017|2017-01-31|April 2006|Actual|2006-04-30|||||Interventional|||Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.|A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).|Completed||Phase 3|412||Shire|||||||||||||||||||2018-06-01 04:43:15.502015|2018-06-01 04:43:15.502015
NCT00152386|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-08-26|2005-09-07|2005-09-09|Estimate|||||||2014-08-26|2014-08-27|Estimate|February 2005||2005-02-28|July 2010|2010-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis|A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate|Completed||Phase 3|950||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:13.42354|2018-06-01 04:43:13.42354
NCT00152373|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-12-02|2005-09-07|2005-09-09|Estimate|||||||2013-12-02|2013-12-03|Estimate|July 2004||2004-07-31|September 2009|2009-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS|A Double-blind, Placebo-controlled, Randomized Study: 16-week Evaluation of the Efficacy and Safety of Levetiracetam (LEV) as add-on Therapy in Adults and Adolescents Older Than 16 Years Suffering From Partial Seizures.|Completed||Phase 3|192||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:13.672848|2018-06-01 04:43:13.672848
NCT00152360|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-03-28|2005-09-07|2005-09-09|Estimate|||||||2013-03-28|2013-04-01|Estimate|June 2005||2005-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effect of Xenical on Weight and Risk Factors|The Effect of Xenical on Weight, Risk Factors and Burden of Medication|Completed||Phase 4|25|Actual|University of British Columbia||1|||f||||f||||||||||2018-06-01 04:43:13.728183|2018-06-01 04:43:13.728183
NCT00152347|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2018-05-14|2005-09-07|2005-09-09|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2005||2005-09-30|May 2018|2018-05-31|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Interventional|||A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot|A Double-Blind, Randomized Control Trial Comparing Botulinum Toxin Type A (Botox) and Placebo in the Treatment of Idiopathic Clubfoot|Completed||N/A|36|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:43:13.795344|2018-06-01 04:43:13.795344
NCT00152334|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2016-05-30|2005-09-07|2005-09-09|Estimate|||||||2016-05-30|2016-06-01|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy of Botox in Patients With Idiopathic Clubfoot|Treatment of Idiopathic Clubfoot Utilizing Botulinum Toxin A: A New Treatment for Correction|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:43:13.856167|2018-06-01 04:43:13.856167
NCT00152321|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-07-25|2005-09-07|2005-09-09|Estimate|||||||2015-07-25|2015-07-28|Estimate|September 2003||2003-09-30|July 2015|2015-07-31|March 2010|Actual|2010-03-31|March 2006|Actual|2006-03-31||Interventional|||Strategies Targeting Osteoporosis to Prevent Recurrent Fractures|Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP# Study)|Completed||N/A|242|Actual|University of Alberta||2|||f||||f||||||||||2018-06-01 04:43:13.922563|2018-06-01 04:43:13.922563
NCT00152308|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-09|Estimate|||||||2005-09-08|2005-09-09|Estimate|December 2004||2004-12-31|September 2005|2005-09-30|February 2007||2007-02-28|||||Interventional|||Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis|A Prospective, Placebo-Controlled, Double-Blind, Randomized Study Evaluating the Efficacy of Non-Polymer-Based Coating With Two Different Rapamycin-Dosages for the Prevention of Restenosis After Percutaneous Coronary Interventions|Unknown status|Recruiting|Phase 4|333||Translumina GmbH|||||f||||||||||||||2018-06-01 04:43:14.008968|2018-06-01 04:43:14.008968
NCT00152295|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-27|2005-09-07|2005-09-09|Estimate|||||||2008-05-27|2008-05-29|Estimate|April 2001||2001-04-30|May 2008|2008-05-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women|A Phase II Long-Term Extension Safety Study of J867 Administered With Estrogen to Postmenopausal Women|Completed||Phase 2|18|Actual|Abbott||1|||f||||f||||||||||2018-06-01 04:43:14.111908|2018-06-01 04:43:14.111908
NCT00152282|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-27|2005-09-07|2005-09-09|Estimate|||||||2008-05-27|2008-05-29|Estimate|September 2000||2000-09-30|May 2008|2008-05-31|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of Asoprisnil and Estrogen Administration to Postmenopausal Women|A Phase II Pilot Study to Evaluate the Safety and Efficacy of J867 Administered With Estrogen to Postmenopausal Women|Completed||Phase 2|105|Actual|Abbott||4|||f||||f||||||||||2018-06-01 04:43:14.180707|2018-06-01 04:43:14.180707
NCT00152269|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-27|2005-09-07|2005-09-09|Estimate|||||||2008-05-27|2008-05-29|Estimate|July 2002||2002-07-31|May 2008|2008-05-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Treatment of Uterine Fibroids With Asoprisnil(J867)|A Phase III, 12-Month, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety (Including Bone Density Assessment) of Two Doses of J867 Versus Placebo in Subjects With Uterine Leiomyomata|Completed||Phase 3|475|Actual|Abbott||3|||f||||t||||||||||2018-06-01 04:43:14.254414|2018-06-01 04:43:14.254414
NCT00152256|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-27|2005-09-07|2005-09-09|Estimate|||||||2008-05-27|2008-05-29|Estimate|September 2003||2003-09-30|May 2008|2008-05-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids|A Phase 3,6-Month, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Two Doses of Asoprisnil Versus Placebo in Subjects With Uterine Leiomyomata|Completed||Phase 3|239|Actual|Abbott||3|||f||||t||||||||||2018-06-01 04:43:14.32107|2018-06-01 04:43:14.32107
NCT00152243|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-07-06|2005-09-08|2005-09-09|Estimate|||||||2011-07-06|2011-07-07|Estimate|June 1997||1997-06-30|July 2011|2011-07-31|August 2007|Actual|2007-08-31|March 2006|Actual|2006-03-31||Interventional|||A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)|A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone for Serosa-negative Advanced Gastric Cancer (NSAS-GC)|Completed||Phase 3|500|Anticipated|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 04:43:14.403547|2018-06-01 04:43:14.403547
NCT00152230|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-07-06|2005-09-08|2005-09-09|Estimate|||||||2011-07-06|2011-07-07|Estimate|October 1996||1996-10-31|July 2011|2011-07-31|February 2008|Actual|2008-02-29|March 2006|Actual|2006-03-31||Interventional|||A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)|A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone in Patients With Dukes C Colorectal Cancer (NSAS-CC)|Completed||Phase 3|900|Anticipated|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 04:43:14.466822|2018-06-01 04:43:14.466822
NCT00152217|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-07-06|2005-09-08|2005-09-09|Estimate|||||||2011-07-06|2011-07-07|Estimate|September 2001||2001-09-30|July 2011|2011-07-31|December 2010|Actual|2010-12-31|May 2007|Actual|2007-05-31||Interventional|||Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)|Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)|Completed||Phase 3|1000|Anticipated|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 04:43:14.541731|2018-06-01 04:43:14.541731
NCT00152204|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-05-21|2005-09-07|2005-09-09|Estimate|||||||2008-05-21|2008-05-22|Estimate|March 2005||2005-03-31|May 2008|2008-05-31|December 2008|Anticipated|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||The Community Effectiveness of IPTi in Southern Tanzania|Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants|Unknown status|Active, not recruiting|Phase 3|13000|Anticipated|Swiss Tropical & Public Health Institute||2|||f||||t||||||||||2018-06-01 04:43:14.604262|2018-06-01 04:43:14.604262
NCT00152191|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-07-06|2005-09-07|2005-09-09|Estimate|||||||2011-07-06|2011-07-07|Estimate|October 1996||1996-10-31|July 2011|2011-07-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)|A Randomized Controlled Study of Postoperative Adjuvant Therapy of UFT Compared With CMF in High-risk Women With Axillary Node-negative Breast Cancer (NSAS-BC)|Completed||Phase 3|1300|Anticipated|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 04:43:14.717292|2018-06-01 04:43:14.717292
NCT00152178|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-07-06|2005-09-08|2005-09-09|Estimate|||||||2011-07-06|2011-07-07|Estimate|July 1996||1996-07-31|July 2011|2011-07-31|August 2008|Actual|2008-08-31|April 2008|Actual|2008-04-30||Interventional|||The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)|The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)|Completed||Phase 3|680|Anticipated|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 04:43:14.78186|2018-06-01 04:43:14.78186
NCT00152165|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-12-01|2005-09-08|2005-09-09|Estimate|||||||2008-12-01|2008-12-02|Estimate|November 2003||2003-11-30|December 2008|2008-12-31||||||||Observational|||Use of Radiostereometric Analysis (RSA) Following Spinal Fusion Versus the DYNESYS Stabilization System|A Biomechanical Assessment of the DYNESYS Stabilization System Using Radiostereometric Analysis|Completed|||12||State University of New York - Upstate Medical University|||||f||||||||||||||2018-06-01 04:43:14.84777|2018-06-01 04:43:14.84777
NCT00152152|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-05-22|2005-09-08|2005-09-09|Estimate|||||||2008-05-22|2008-05-23|Estimate|October 2002||2002-10-31|May 2008|2008-05-31||||September 2007|Actual|2007-09-30||Observational|||Use of Radiostereometric Analysis Beads (RSA) to Measure Motion in the Spine, Following Lumbar Spinal Surgery|Use of Radiostereometric Analysis (RSA) for Measuring Spinal Motion Following Lumbar Spinal Surgery|Completed|||75|Anticipated|State University of New York - Upstate Medical University|||||f||||||||||||||2018-06-01 04:43:14.899007|2018-06-01 04:43:14.899007
NCT00152139|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2009-01-28|2005-09-08|2005-09-09|Estimate|||||||2009-01-28|2009-01-29|Estimate|May 2002||2002-05-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|June 2005|Actual|2005-06-30||Interventional|||Stem Cell Transplantation for Patients With Hematologic Malignancies|Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies|Completed||Phase 3|33|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:43:14.948627|2018-06-01 04:43:14.948627
NCT00152126|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-02-12|2005-09-07|2005-09-09|Estimate|||||||2009-02-12|2009-02-13|Estimate|August 2003||2003-08-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|August 2005|Actual|2005-08-31||Interventional|||Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas|Busulfan and Melphalan With Autologous Hematopoietic Stem Cell Support With Positively-Selected CD133+ Hematopoietic Cells for Children With High Risk Solid Tumors and Lymphomas|Completed||N/A|26|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:43:15.031296|2018-06-01 04:43:15.031296
NCT00152113|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-04-24|2005-09-07|2005-09-09|Estimate|||||||2017-04-24|2017-04-26|Actual|April 2005||2005-04-30|February 2009|2009-02-28|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound|Hematopoietic Stem Cell Transplantation for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Doppler Ultrasound Using Reduced-Intensity Conditioning and T-Cell Depleted HSC From Partially Matched Family Donors|Completed||Phase 1|5|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:43:15.104696|2018-06-01 04:43:15.104696
NCT00152100|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-05-19|2005-09-07|2005-09-09|Estimate|||||||2009-05-19|2009-05-20|Estimate|February 2004||2004-02-29|May 2009|2009-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome|Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome|Completed||Phase 1|4|Actual|St. Jude Children's Research Hospital|||||f||||f||||||||||2018-06-01 04:43:15.172039|2018-06-01 04:43:15.172039
NCT00152087|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-09|Estimate|||||||2005-09-07|2005-09-09|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.|Treatment of Unresectable Hepatocellular Carcinoma With Therasphere. A Human Device Evaluation Protocol.|Unknown status|Recruiting|Phase 2|25||St. Joseph's Hospital, Florida|||||||||||||||||||2018-06-01 04:43:15.229734|2018-06-01 04:43:15.229734
NCT00152074|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2015-06-08|2005-09-08|2005-09-09|Estimate|||||||2015-06-08|2015-06-09|Estimate|April 2004||2004-04-30|September 2006|2006-09-30|December 2007|Actual|2007-12-31|||||Interventional|||Salt Reduction on Blood Pressure and Cardiovascular Organ Damage|Effects of Modest Salt Reduction on Blood Pressure and Markers of Target Organ Damage in Patients With Untreated Essential Hypertension or Prehypertension|Completed||Phase 3|210|Anticipated|St George's, University of London|||||f||||||||||||||2018-06-01 04:43:15.292474|2018-06-01 04:43:15.292474
NCT00152061|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2013-06-18|2005-09-08|2005-09-09|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2005||2005-01-31|June 2013|2013-06-30|August 2005|Actual|2005-08-31|||||Interventional|||The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens|The Role of 3TC/FTC in Partially Suppressive Antiretroviral Regimens: The Switch Study|Completed||N/A|40||Stanford University|||||f||||f||||||||||2018-06-01 04:43:15.34274|2018-06-01 04:43:15.34274
NCT00152048|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2014-06-06|2005-09-08|2005-09-09|Estimate|||||||2014-06-06|2014-06-09|Estimate|November 2004||2004-11-30|September 2007|2007-09-30|October 2005|Actual|2005-10-31|||||Interventional|||Evaluation of Eflornithine on Facial and Forearm Skin|A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women With Excessive Facial Hair|Completed||Phase 4|78||Shire|||||f||||||||||||||2018-06-01 04:43:15.409349|2018-06-01 04:43:15.409349
NCT00152035|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-01-12|2005-09-07|2005-09-09|Estimate|||||||2017-01-12|2017-01-16|Estimate|March 2005||2005-03-31|January 2017|2017-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Safety of SPD465 in Treating Adults With ADHD.|A Phase III, Multi-center, 12-month, Open-label Safety Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).|Completed||Phase 3|1040||Shire|||||f||||||||||||||2018-06-01 04:43:15.455081|2018-06-01 04:43:15.455081
NCT00152009|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2009-09-10||2009-11-25|2005-09-07|2005-09-09|Estimate|2009-10-22|2009-11-26|Estimate||||2009-11-25|2009-12-01|Estimate|January 2003||2003-01-31|November 2009|2009-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17|A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|345|Actual|Shire||4|||||||||||||||||2018-06-01 04:43:15.563119|2018-06-01 04:43:15.563119
NCT00151996|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2009-09-10||2009-11-25|2005-09-07|2005-09-09|Estimate|2009-10-15|2009-11-26|Estimate||||2009-11-25|2009-12-01|Estimate|August 2004||2004-08-31|November 2009|2009-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|75|Actual|Shire||2|||||||||||||||||2018-06-01 04:43:16.176233|2018-06-01 04:43:16.176233
NCT00151983|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-07-08|2005-09-07|2005-09-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|June 2005||2005-06-30|July 2015|2015-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy|A Prospective, Open-Label, Multi-Center Study Evaluating the Safety and Tolerability of Methylphenidate Transdermal System (MTS) in Children Aged 6-12 Previously Treated With Extended-Release Methylphenidate Product.|Completed||Phase 3|175|Actual|Noven Therapeutics||2|||f||||f||||||||||2018-06-01 04:43:16.474486|2018-06-01 04:43:16.474486
NCT00151970|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-07-08|2005-09-07|2005-09-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|June 2005||2005-06-30|July 2015|2015-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD|A Phase IIB, Randomized, Double-blind, Multi-Center, Placebo-Controlled, Dose-Optimization, 3-way Cross-Over, Analog Classroom Study to Assess the Efficacy, Duration of Effect, Tolerability and Safety of 4- and 6- Hour Wear Times of Methylphenidate Transdermal System (MTS) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|128|Actual|Noven Therapeutics||3|||f||||f||||||||||2018-06-01 04:43:16.654443|2018-06-01 04:43:16.654443
NCT00151957|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-03-27|2005-09-07|2005-09-09|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2004||2004-10-31|March 2017|2017-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials|A Phase III, Multi-center, Open-label Study of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 3|450|Actual|Noven Therapeutics||1|||f||||f||||||||No||2018-06-01 04:43:16.747819|2018-06-01 04:43:16.747819
NCT00151944|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-06-06|2005-09-07|2005-09-09|Estimate|||||||2014-06-06|2014-06-09|Estimate|November 2003||2003-11-30|December 2008|2008-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.|A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.|Completed||Phase 3|400||Shire|||||f||||||||||||||2018-06-01 04:43:16.829921|2018-06-01 04:43:16.829921
NCT00151931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-08-31|2005-09-07|2005-09-09|Estimate|||||||2011-08-31|2011-09-02|Estimate|May 2004||2004-05-31|August 2011|2011-08-31|January 2006|Actual|2006-01-31|||||Interventional|||Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis|A Multi-Centre, Open-Label Study Assessing the Efficacy and Tolerability of Lanthanum Carbonate in the Reduction of Serum Phosphate Levels in End Stage Renal Disease Patients Receiving Dialysis|Completed||Phase 3|456||Shire|||||f||||||||||||||2018-06-01 04:43:16.897321|2018-06-01 04:43:16.897321
NCT00151918|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-06-06|2005-09-07|2005-09-09|Estimate|||||||2014-06-06|2014-06-09|Estimate|January 2005||2005-01-31|September 2007|2007-09-30|August 2006|Actual|2006-08-31|||||Interventional|||Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease|A Multi-Centre, Open Label, Randomized, Parallel Group Pilot Study to Assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease|Completed||Phase 3|48||Shire|||||||||||||||||||2018-06-01 04:43:16.95873|2018-06-01 04:43:16.95873
NCT00151905|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-05-04|2005-09-07|2005-09-09|Estimate|||||||2007-05-04|2007-05-07|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|September 2006||2006-09-30|||||Interventional|||The Use of an Inhaled Salt Solution to Treat Viral Lung Infections in Infants.|Nebulized Hypertonic Saline in the Treatment of Bronchiolitis in Infants|Completed||Phase 2/Phase 3|||Sheikh Khalifa Medical City|||||f||||||||||||||2018-06-01 04:43:17.031678|2018-06-01 04:43:17.031678
NCT00151892|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-08-26||2017-02-13|2005-09-07|2005-09-09|Estimate|2010-08-26|2010-09-21|Estimate||||2017-02-13|2017-03-20|Actual|April 2005||2005-04-30|February 2017|2017-02-28|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis|A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis|Completed||Phase 3|829|Actual|Shire||2|||f||||||||||||||2018-06-01 04:43:17.175237|2018-06-01 04:43:17.175237
NCT00151879|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2014-09-19|2005-09-07|2005-09-09|Estimate|||||||2014-09-19|2014-09-22|Estimate|February 2005||2005-02-28|July 2010|2010-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures|A Multicenter, Open-label Trial to Investigate the Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures With or Without Secondary Generalization.|Completed||Phase 2/Phase 3|160|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:43:17.95827|2018-06-01 04:43:17.95827
NCT00151866|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-02-26|2005-09-07|2005-09-09|Estimate|||||||2007-02-26|2007-02-27|Estimate|October 2003||2003-10-31|September 2005|2005-09-30|May 2005||2005-05-31|||||Interventional|||Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma|A Multicentre Randomised Study of the Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma|Completed||Phase 3|180||Sanquin Research & Blood Bank Divisions|||||f||||||||||||||2018-06-01 04:43:18.023903|2018-06-01 04:43:18.023903
NCT00151853|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-01-30|2005-09-08|2005-09-09|Estimate|||||||2006-01-30|2006-01-31|Estimate|March 2002||2002-03-31|January 2006|2006-01-31|September 2004||2004-09-30|||||Interventional|||Study Use of PPSB-SD and VP-VI in Patients With Anticoagulant Therapy and Undergoing Acute CPB Surgery|Phase IV Study on the Efficacy of PPSB-SD and VP-VI in Patients Using Oral Anticoagulant Therapy and Undergoing Acute Cardiac Surgery With a Cardiopulmonary Bypass|Completed||Phase 4|40||Sanquin|||||f||||||||||||||2018-06-01 04:43:18.073922|2018-06-01 04:43:18.073922
NCT00151840|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-01-30|2005-09-08|2005-09-09|Estimate|||||||2006-01-30|2006-01-31|Estimate|October 2001||2001-10-31|January 2006|2006-01-31|March 2002||2002-03-31|||||Interventional|||Efficacy and Safety of IVIG-L in ITP Patients|Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients|Completed||Phase 3|20||Sanquin|||||f||||||||||||||2018-06-01 04:43:18.128313|2018-06-01 04:43:18.128313
NCT00151827|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2010-10-13|2005-09-08|2005-09-09|Estimate|||||||2010-10-13|2010-10-14|Estimate|August 2003||2003-08-31|October 2010|2010-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Olmesartan Medoxomil in Hypertension and Renal Impairment|Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment|Completed||Phase 3|393|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-06-01 04:43:18.19345|2018-06-01 04:43:18.19345
NCT00151814|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2010-03-19|2008-12-05|2010-04-12|2005-09-08|2005-09-09|Estimate|2010-03-19|2010-04-09|Estimate|2009-10-05|2009-10-07|Estimate|2010-04-12|2010-04-15|Estimate|September 2005||2005-09-30|April 2010|2010-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Olmesartan Pediatric Pharmacokinetic (PK) Study|An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension|Completed||Phase 1|24|Actual|Daiichi Sankyo, Inc.||1|||f||||||||||||||2018-06-01 04:43:18.413752|2018-06-01 04:43:18.413752
NCT00151801|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-08|2005-09-08|2005-09-09|Estimate|||||||2005-09-08|2005-09-09|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|December 2008||2008-12-31|||||Interventional|||Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients|Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis|Unknown status|Recruiting|Phase 2|200||S. Andrea Hospital|||||f||||||||||||||2018-06-01 04:43:18.725063|2018-06-01 04:43:18.725063
NCT00151788|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-01-16|2005-09-07|2005-09-09|Estimate|||||||2012-01-16|2012-01-18|Estimate|February 2004||2004-02-29|January 2012|2012-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.|A Randomized, Double-blind, Stratified, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of the ACAT Inhibitor CS-505 for Reducing the Progression of Atherosclerosis in Subjects With Heterozygous Familial Hypercholesterolemia and Carotid Atherosclerosis Using Carotid Ultrasound (CUS)|Terminated||Phase 2/Phase 3|796||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:43:18.81024|2018-06-01 04:43:18.81024
NCT00151775|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2010-03-08|2009-08-19|2016-05-26|2005-09-07|2005-09-09|Estimate|2010-03-08|2010-04-02|Estimate|2009-08-19|2009-08-21|Estimate|2016-05-26|2016-06-30|Estimate|May 2005||2005-05-31|May 2016|2016-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure|Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension|Completed||Phase 2/Phase 3|362|Actual|Daiichi Sankyo, Inc.||3|||f||||||||||||||2018-06-01 04:43:19.013011|2018-06-01 04:43:19.013011
NCT00151762|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-12-26|2005-09-07|2005-09-09|Estimate|||||||2007-12-26|2008-01-09|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes|A Multi-Center, 52-Week, Open-Label Extension Study (From Studies WEL-301, WEL-302, and WEL-303) to Evaluate the Long-Term Safety and Tolerability of WelChol® in Type 2 Diabetic Patients|Completed||Phase 3|780||Daiichi Sankyo, Inc.|||||f||||f||||||||||2018-06-01 04:43:21.999881|2018-06-01 04:43:21.999881
NCT00151749|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-01-16|2005-09-07|2005-09-09|Estimate|||||||2012-01-16|2012-01-18|Estimate|June 2004||2004-06-30|January 2012|2012-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||WelChol® and Insulin in Treating Patients With Type 2 Diabetes|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetes With Inadequate Glycemic Control on Insulin Therapy Alone or Insulin Therapy Combination With Other Oral Anti-diabetic Agents|Completed||Phase 3|260||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:43:22.177754|2018-06-01 04:43:22.177754
NCT00151736|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-06-08|2005-09-07|2005-09-09|Estimate|||||||2012-06-08|2012-06-11|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|February 2008|Actual|2008-02-29|February 2006|Actual|2006-02-28||Interventional|||Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)|A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 2|88|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 04:43:22.297188|2018-06-01 04:43:22.297188
NCT00151723|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-07-17|2005-09-08|2005-09-09|Estimate|||||||2007-07-17|2007-07-18|Estimate|April 2004||2004-04-30|September 2005|2005-09-30||||||||Interventional|||Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?|Subclinical Hyperthyroidism ”To Treat or Not to Treat?” A Dutch Multicenter Trial|Unknown status|Recruiting|N/A|200|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:43:22.395044|2018-06-01 04:43:22.395044
NCT00151710|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-02-28|2005-09-08|2005-09-09|Estimate|||||||2007-02-28|2007-03-01|Estimate||||February 2007|2007-02-28||||||||Interventional|||Effects of Pioglitazone in Congenital Adrenal Hyperplasia|Effects of Pioglitazone in Glucocorticoid-Induced Insulin Resistance. Studies in Congenital Adrenal Hyperplasia.|Completed||N/A|||Radboud University|||||f||||||||||||||2018-06-01 04:43:22.592402|2018-06-01 04:43:22.592402
NCT00151697|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2011-08-08|2005-09-08|2005-09-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|May 2005||2005-05-31|August 2011|2011-08-31||||||||Interventional|||LANN-study: Lantus, Amaryl, Novorapid, Novomix Study|New Approach to Treat Type II Diabetes Failing on Maximal Oral Treatment|Completed||Phase 3|150|Anticipated|Rijnstate Hospital|||||f||||||||||||||2018-06-01 04:43:22.645151|2018-06-01 04:43:22.645151
NCT00151684|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2008-02-27|2005-09-08|2005-09-09|Estimate|||||||2008-02-27|2008-02-29|Estimate|November 2004||2004-11-30|February 2008|2008-02-29||||||||Interventional|||Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men|Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men: a Dose Response Study, Part II|Completed||Phase 2|25|Anticipated|Rijnstate Hospital|||||f||||||||||||||2018-06-01 04:43:22.723493|2018-06-01 04:43:22.723493
NCT00151671|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-02-24|2005-09-08|2005-09-09|Estimate|||||||2012-02-24|2012-02-27|Estimate|April 2003||2003-04-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|April 2008|Actual|2008-04-30||Interventional|IMPACT||Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer|Prospective, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Oral Immune-Enhancing Nutritional Supplement on Hepatic Function After Liver Resection for Primary or Secondary Cancer on Cirrhosis or Liver Fibrosis|Terminated||Phase 2/Phase 3|35|Actual|Rennes University Hospital||2||insufficient enrollment rate|f||||f||||||||||2018-06-01 04:43:22.787036|2018-06-01 04:43:22.787036
NCT00151658|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-09-12|2005-09-08|2005-09-09|Estimate|||||||2005-09-12|2005-09-14|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|June 2006||2006-06-30|||||Interventional|||Sirolimus Eluting Stents in Complex Coronary Lesions (SCANDSTENT)|Randomized Multicenter Comparison of Sirolimus Versus Bare Metal Stent Implantation in Complex Coronary Lesions. Acronym: Scand Stent|Completed||N/A|322||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:43:22.860276|2018-06-01 04:43:22.860276
NCT00151645|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-30|2005-09-08|2005-09-09|Estimate|||||||2005-12-30|2006-01-02|Estimate|December 2003||2003-12-31|December 2005|2005-12-31|July 2005||2005-07-31|||||Interventional|||Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.|Renal Cell Carcinoma Treatment With Activated Tumor- Infiltrated Lymphocytes. A Non-Randomized Phase II Trial.|Terminated||Phase 2|36||Rennes University Hospital|||||f||||||||||||||2018-06-01 04:43:23.0016|2018-06-01 04:43:23.0016
NCT00151632|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-07-03|2005-09-08|2005-09-09|Estimate|||||||2012-07-03|2012-07-04|Estimate|May 2003||2003-05-31|July 2012|2012-07-31|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|MMF-FK||Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation|Evaluation of the Benefit/Risk Ratio of a Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil on the Prevention of Complications in Adult Liver Transplantation|Terminated||Phase 3|195|Actual|Rennes University Hospital||2||insufficient enrollment|f||||t||||||||||2018-06-01 04:43:23.092741|2018-06-01 04:43:23.092741
NCT00151619|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2005-12-30|2005-09-08|2005-09-09|Estimate|||||||2005-12-30|2006-01-02|Estimate|February 1999||1999-02-28|December 2005|2005-12-31||||||||Interventional|||Effects of Amlodipine in the Management of Chronic Heart Failure|Regional and Systemic Hemodynamic Effects of a Long-Term Administration of Amlodipine in Patients With Chronic Heart Failure Treated With a Combination of Enalapril, Furosemide and Digoxin|Suspended||Phase 2|24||Rennes University Hospital|||||f||||||||||||||2018-06-01 04:43:23.19103|2018-06-01 04:43:23.19103
NCT00151606|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2006-01-09|2005-09-08|2005-09-09|Estimate|||||||2006-01-09|2006-01-10|Estimate|December 2002||2002-12-31|January 2006|2006-01-31|February 2004||2004-02-29|||||Interventional|||Comparison of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus.|Evaluation of Two Protocols to Prevent the Acquisition of Methicillin-Resistant Staphylococcus Aureus in Intensive Care Units.|Completed||N/A|500||Rennes University Hospital|||||f||||||||||||||2018-06-01 04:43:23.275171|2018-06-01 04:43:23.275171
NCT00151593|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2007-11-22|2005-09-08|2005-09-09|Estimate|||||||2007-11-22|2007-11-26|Estimate|February 2002||2002-02-28|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Evaluation of Celsior® in Liver Transplant Preservation.|Celsior®: Evaluation of an Organ Preservation Solution in Liver Transplantation.|Completed||Phase 2|140|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-06-01 04:43:23.356176|2018-06-01 04:43:23.356176
NCT00151580|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-05-18|2005-09-08|2005-09-09|Estimate|||||||2012-05-18|2012-05-21|Estimate|February 2002||2002-02-28|November 2007|2007-11-30|July 2006|Actual|2006-07-31|||||Interventional|TRANSPEG||Treatment of Recurrent Hepatitis C After Liver Transplantation|Comparison of Maintenance Treatment by Ribavirin to a Placebo, After an Initial One-year Treatment With Pegylated Interferon-α2a - Ribavirin Association in Hepatitis C Viral Recurrence After Liver Transplantation|Completed||Phase 3|200|Actual|Rennes University Hospital||2|||f||||||||||||||2018-06-01 04:43:23.498042|2018-06-01 04:43:23.498042
NCT00151567|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2012-12-03|2005-09-08|2005-09-09|Estimate|||||||2012-12-03|2012-12-04|Estimate|February 2002||2002-02-28|September 2008|2008-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|TAMSULOSINE||Evaluation of Tamsulosin in the Treatment of Ureteral Stones|Interest of a Treatment With the alpha1-blocker Tamsulosin in the Elimination of Pelvis Ureteral Stones|Completed||Phase 3|129|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 04:43:23.605196|2018-06-01 04:43:23.605196
NCT00151554|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-07-28|2005-09-07|2005-09-09|Estimate|||||||2010-07-28|2010-07-29|Estimate|February 2005||2005-02-28|July 2010|2010-07-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Reducing Intensive Care Unit (ICU) Related Anxiety Through a Structured Information Program|Reducing ICU Related Anxiety Through a Structured Information Program. A Randomized Controlled Clinical Trial|Completed||N/A|140|Actual|Philipps University Marburg Medical Center||2|||f||||||||||||||2018-06-01 04:43:23.696583|2018-06-01 04:43:23.696583
NCT00151541|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-05-27|2005-09-07|2005-09-09|Estimate|||||||2011-05-27|2011-05-30|Estimate|February 2005||2005-02-28|May 2011|2011-05-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%|A Phase 3, Randomized, Double-blind, Multi-dose Study to Evaluate the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG 5%) When Co-administered With Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% in the Treatment of Acne Vulgaris.|Completed||Phase 3|301|Actual|Allergan|||||||||||||||||||2018-06-01 04:43:23.780462|2018-06-01 04:43:23.780462
NCT00151528|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-03-07|2005-09-08|2005-09-09|Estimate|||||||2008-03-07|2008-03-11|Estimate|January 2005||2005-01-31|July 2006|2006-07-31|June 2006||2006-06-30|||||Interventional|||An Open-Label Trial of Pregabalin in Patients With Fibromyalgia|A Long-Term, Open-Label, Safety Trial of Pregabalin in Patients With Fibromyalgia|Completed||Phase 3|428||Pfizer|||||||||||||||||||2018-06-01 04:43:23.937507|2018-06-01 04:43:23.937507
NCT00151515|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2016-09-28|2005-09-08|2005-09-09|Estimate|||||||2016-09-28|2016-09-30|Estimate|October 2003||2003-10-31|September 2016|2016-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss|A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males|Completed||Phase 3|352|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f||||||||||2018-06-01 04:43:24.21343|2018-06-01 04:43:24.21343
NCT00151502|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-07-09|2005-09-08|2005-09-09|Estimate|||||||2008-07-09|2008-07-11|Estimate|November 2002||2002-11-30|July 2008|2008-07-31|July 2007|Actual|2007-07-31|||||Interventional|||To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.|An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.|Completed||Phase 3|600||Pfizer|||||||||||||||||||2018-06-01 04:43:24.359504|2018-06-01 04:43:24.359504
NCT00151489|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-03-14|2005-09-07|2005-09-09|Estimate|||||||2008-03-14|2008-03-17|Estimate|April 2005||2005-04-30|September 2006|2006-09-30|June 2006|Actual|2006-06-30|||||Interventional|||Safety and Efficacy Study of Pregabalin in Fibromyalgia|A Six-Month, Double-Blind, Placebo Controlled, Durability of Effect Study of Pregabalin for Pain Associated With Fibromyalgia|Completed||Phase 3|1020||Pfizer|||||||||||||||||||2018-06-01 04:43:24.63346|2018-06-01 04:43:24.63346
NCT00149045|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-11-06|2005-09-07|2005-09-08|Estimate|||||||2006-11-06|2006-11-07|Estimate|November 2001||2001-11-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Follow up and Observation of Charcot Marie Tooth Disease in Families|Clinical and Genetic Features of Familial Neuropathy|Completed|||||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:43:59.639071|2018-06-01 04:43:59.639071
NCT00151476|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2009-11-19||2010-03-04|2005-09-08|2005-09-09|Estimate|2010-02-12|2010-03-04|Estimate||||2010-03-04|2010-03-09|Estimate|November 2004||2004-11-30|March 2010|2010-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients|A Registry-Based Observational Study Assessing Clinical Outcomes In Familial Adenomatous Polyposis In Patients Receiving Celecoxib (Celebrex(Registered), Onsenal(Registered)) Compared With Control Patients|Terminated|||68|Actual|Pfizer|Study prematurely discontinued May 2008 prior to reaching enrollment target; due to limited number of matched pairs, results do not provide sufficient data to evaluate effectiveness of celecoxib. Last subject last visit was November 2008.||2|See Detailed Description|f||||f||||||||||2018-06-01 04:43:24.889454|2018-06-01 04:43:24.889454
NCT00151463|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-08-15|2005-09-07|2005-09-09|Estimate|||||||2007-08-15|2007-08-16|Estimate|January 2005||2005-01-31|August 2007|2007-08-31||||||||Interventional|||QEQ Treatment Responsiveness Evaluation Study|An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)|Completed||Phase 4|100||Pfizer|||||f||||||||||||||2018-06-01 04:43:25.664229|2018-06-01 04:43:25.664229
NCT00151450|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-03-19|2005-09-07|2005-09-09|Estimate|||||||2008-03-19|2008-03-21|Estimate|March 2005||2005-03-31|March 2008|2008-03-31|November 2006|Actual|2006-11-30|||||Interventional|||Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder|An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients|Completed||Phase 3|390||Pfizer|||||f||||||||||||||2018-06-01 04:43:25.723926|2018-06-01 04:43:25.723926
NCT00151437|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-04-22|2005-09-07|2005-09-09|Estimate|||||||2008-04-22|2008-04-24|Estimate|November 2004||2004-11-30|April 2008|2008-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Canadian Pegvisomant Compassionate Study In Acromegalic Patients|A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program.|Completed||Phase 4|30||Pfizer|||||f||||||||||||||2018-06-01 04:43:25.914256|2018-06-01 04:43:25.914256
NCT00151424|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|||2017-08-18|2005-09-08|2005-09-09|Estimate|||||||2017-08-18|2017-08-22|Actual|February 15, 2005|Actual|2005-02-15|August 2017|2017-08-31|February 6, 2006|Actual|2006-02-06|January 6, 2006|Actual|2006-01-06||Interventional|||Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)|A Multicenter, Randomized, Double-Blind, Flexible-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine Positive Control in Subjects With an Acute Exacerbation of Schizophrenia|Completed||Phase 3|277|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-06-01 04:43:25.978911|2018-06-01 04:43:25.978911
NCT00151411|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-08|2011-06-07||2018-03-19|2005-09-08|2005-09-09|Estimate|2011-10-03|2011-11-08|Estimate||||2018-03-19|2018-03-21|Actual|October 2004||2004-10-31|March 2018|2018-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)|The Effect of Combination Therapy With Lifestyle Intervention and Metformin in Females With Polycystic Ovary Syndrome|Completed||Phase 2|114|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 04:43:26.069247|2018-06-01 04:43:26.069247
NCT00151398|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06||2013-02-07|2013-02-07|2005-09-07|2005-09-08|Estimate||||2013-02-07|2013-02-11|Estimate|2013-02-07|2013-02-11|Estimate|September 2005||2005-09-30|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)|A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.|Completed||Phase 2|229|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||4|||f||||t||||||||||2018-06-01 04:43:26.569089|2018-06-01 04:43:26.569089
NCT00151385|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-06-26|2005-09-07|2005-09-08|Estimate|||||||2012-06-26|2012-06-28|Estimate|November 2005||2005-11-30|June 2012|2012-06-30|October 2007|Actual|2007-10-31|||||Interventional|||Study Evaluating Inhibitor Specificity in Hemophilia A|A Multicenter Study to Describe the Immunogenic Epitope(s) of Factor VIII in Previously Treated Patients With Congenital Hemophilia A Who Develop De Novo Factor VIII Inhibitors While Receiving Factor VIII Infusion Therapy.|Withdrawn||Phase 4|0|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:43:26.739185|2018-06-01 04:43:26.739185
NCT00151372|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2009-07-07||2009-12-07|2005-09-07|2005-09-08|Estimate|2009-12-07|2010-01-11|Estimate||||2009-12-07|2010-01-11|Estimate|March 2002||2002-03-31|December 2009|2009-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients|Treatment Effectiveness in Depressed Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|141|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 04:43:26.858048|2018-06-01 04:43:26.858048
NCT00151359|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|February 2002||2002-02-28|September 2005|2005-09-30||||||||Observational|||Clinical Trials Stage of 'SoleSensor': A Balance-Enhancing Shoe Insert.|Clinical Trials Stage of 'SoleSensor': A Balance-Enhancing Shoe Insert.|Completed|||||Wilfrid Laurier University|||||f||||||||||||||2018-06-01 04:43:27.140581|2018-06-01 04:43:27.140581
NCT00151346|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-03-17|2005-09-07|2005-09-08|Estimate|||||||2008-03-17|2008-03-18|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Combined Spinal-Epidural Versus Traditional Labor Epidural|Combined Spinal-Epidural Versus Traditional Labor Epidural: A Randomized, Controlled Trial Comparing Maternal and Fetal Effects|Completed||Phase 4|127|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 04:43:27.197005|2018-06-01 04:43:27.197005
NCT00151333|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-09-03|2005-09-06|2005-09-08|Estimate|||||||2009-09-03|2009-09-04|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)|A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending Fixed Doses of SRA-333 in Subjects With Mild to Moderate Alzheimer's Disease.|Completed||Phase 2|16||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:43:27.289949|2018-06-01 04:43:27.289949
NCT00151320|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2017-02-23||2017-02-23|2005-09-07|2005-09-08|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|January 2004|Actual|2004-01-31|February 2017|2017-02-28|April 24, 2013|Actual|2013-04-24|April 2010|Actual|2010-04-30||Interventional|||Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL|Phase I/II Trial of VELCADE+ CHOP-Rituximab in Patients With Previously Untreated Diffuse Large B Cell or Mantle Cell Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|76|Actual|Weill Medical College of Cornell University||1|||f|||||t|f||||||Undecided||2018-06-01 04:43:27.358389|2018-06-01 04:43:27.358389
NCT00151307|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-06-05|2005-09-07|2005-09-08|Estimate|||||||2008-06-05|2008-06-06|Estimate|February 2001||2001-02-28|June 2008|2008-06-30|April 2007||2007-04-30|||||Interventional|||Effects of Cerebral Oxygen Saturation on Neuropsychological Outcomes|The Effects of Monitoring and Maintaining Cerebral Oxygen Saturation on Neuropsychological Outcomes in Patients Undergoing Cardiac Surgery|Terminated||Phase 2/Phase 3|200|Anticipated|Weill Medical College of Cornell University||||Could not recruit any more people.|f||||||||||||||2018-06-01 04:43:27.530291|2018-06-01 04:43:27.530291
NCT00151294|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-09-12|2005-09-07|2005-09-08|Estimate|||||||2006-09-12|2006-09-14|Estimate|November 2004||2004-11-30|September 2006|2006-09-30|October 2006||2006-10-31|||||Interventional|||The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis|A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis|Terminated||Phase 4|20||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:43:27.588976|2018-06-01 04:43:27.588976
NCT00151281|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2017-02-23||2017-08-10|2005-09-07|2005-09-08|Estimate|2017-08-10|2017-09-12|Actual||||2017-08-10|2017-09-12|Actual|November 2004||2004-11-30|August 2017|2017-08-31|April 7, 2011|Actual|2011-04-07|December 2009|Actual|2009-12-31||Interventional|||Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma|Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma|Completed||Phase 2|25|Actual|Weill Medical College of Cornell University||1|||f||||||||||||||2018-06-01 04:43:27.651129|2018-06-01 04:43:27.651129
NCT00151268|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-07-28|2005-09-06|2005-09-08|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2004||2004-03-31|July 2016|2016-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Genotype - Phenotype Correlations of LINCL|Genotype - Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis|Completed|||18|Actual|Weill Medical College of Cornell University|||||f||||t||||||Samples With DNA|"~     whole blood, serum~   "|No||2018-06-01 04:43:27.823728|2018-06-01 04:43:27.823728
NCT00151255|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-04-18|2005-09-06|2005-09-08|Estimate|||||||2017-04-18|2017-04-19|Actual|June 2004||2004-06-30|April 2017|2017-04-30|January 2011|Actual|2011-01-31|June 2009|Actual|2009-06-30||Interventional|||All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 3|500|Anticipated|University of Ulm|||||f||||||||||||||2018-06-01 04:43:27.875711|2018-06-01 04:43:27.875711
NCT00151242|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-09-19|2005-09-06|2005-09-08|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2004||2004-07-31|September 2017|2017-09-30|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|||Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia|Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 2/Phase 3|920|Actual|University of Ulm||2|||f||||||||||||||2018-06-01 04:43:27.965455|2018-06-01 04:43:27.965455
NCT00151229|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-06-03|2005-09-07|2005-09-08|Estimate|||||||2015-06-03|2015-06-04|Estimate|October 2003||2003-10-31|June 2015|2015-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|VALISH||Valsartan in Elderly Isolated Systolic Hypertension Study|Valsartan in Elderly Isolated Systolic Hypertension|Completed||Phase 4|3079|Actual|VALISH study||2|||f||||t||||||||||2018-06-01 04:43:28.193306|2018-06-01 04:43:28.193306
NCT00151216|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2018-04-30|2005-09-06|2005-09-08|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2004||2004-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis|Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children With Late Infantile Neuronal Ceroid Lipofuscinosis|Active, not recruiting||Phase 1|10|Actual|Weill Medical College of Cornell University||2|||f||||t|t|f||||||Undecided||2018-06-01 04:43:28.265484|2018-06-01 04:43:28.265484
NCT00151203|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2018-02-27|2005-09-06|2005-09-08|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2004|Actual|2004-12-31|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|April 2007|Actual|2007-04-30||Interventional|||Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma|A Phase II Study of Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) for Newly Diagnosed Subjects With Multiple Myeloma|Active, not recruiting||Phase 2|50|Anticipated|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 04:43:28.388853|2018-06-01 04:43:28.388853
NCT00151190|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-01-07|2005-09-06|2005-09-08|Estimate|||||||2010-01-07|2010-01-11|Estimate|April 2005||2005-04-30|January 2010|2010-01-31|August 2006||2006-08-31|||||Interventional|||"Community Diabetes Education Program Evaluation Code Evaluation"|Community Diabetes Education Program Evaluation|Completed||Phase 3|180||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 04:43:28.442928|2018-06-01 04:43:28.442928
NCT00151177|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-11-23|2005-09-07|2005-09-08|Estimate|||||||2010-11-23|2010-11-24|Estimate|April 2005||2005-04-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Continuous Positive Airway Pressure Ventilation After Acute Ischemic Stroke|Feasibility and Efficacy Study of Early Continuous Positive Airway Pressure Ventilation in Patients With Acute Ischemic Stroke|Completed||Phase 1/Phase 2|100|Anticipated|University Hospital Muenster||2|||f||||f||||||||||2018-06-01 04:43:28.500245|2018-06-01 04:43:28.500245
NCT00151164|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-07-11|2005-09-07|2005-09-08|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2004||2004-04-30|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Thymic Tolerance in Pediatric Heart Transplantation|Thymic Tolerance in Pediatric Heart Transplantation|Terminated||Phase 2|48|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||||"Due to failure to control sufficient patients in the active arm, this study has now been~   closed."|f||||||||||||||2018-06-01 04:43:28.564364|2018-06-01 04:43:28.564364
NCT00151151|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-09-12|2005-09-07|2005-09-08|Estimate|||||||2011-09-12|2011-09-13|Estimate|February 2003||2003-02-28|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The S.A.F.E. Study : Computer-Aided Counseling to Prevent Teen Pregnancy/Sexually Transmitted Diseases (STDs)|The S.A.F.E. Study: Computer-Aided Counseling to Prevent Teen Pregnancy/STDs - Validity and Reliability Testing of Computer Measures, Pilot-testing of Timeline Followback Calendar Protocol, and Randomized Efficacy Study|Completed||N/A|660|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-06-01 04:43:28.614973|2018-06-01 04:43:28.614973
NCT00151138|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-12-13|2005-09-06|2005-09-08|Estimate|||||||2007-12-13|2007-12-17|Estimate|September 2002||2002-09-30|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Cognitive/Cerebrovascular Consequences of HTN Treatment|Cognitive and Cerebrovascular Sequelae of Hypertension|Completed||N/A|50||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:43:28.675754|2018-06-01 04:43:28.675754
NCT00151125|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-05-16|2005-09-06|2005-09-08|Estimate|||||||2016-05-16|2016-05-17|Estimate|July 2004||2004-07-31|May 2016|2016-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Phase II Study of IL-11 (Neumega) in Von Willebrand Disease|Phase II Comparison Study of Hemostatic Efficacy of Escalating Doses of Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease|Completed||Phase 2|12|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 04:43:28.736454|2018-06-01 04:43:28.736454
NCT00151112|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-09-10|2005-09-07|2005-09-08|Estimate|||||||2008-09-10|2008-09-11|Estimate|September 2005||2005-09-30|September 2008|2008-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of Two Different Procedures for Plexus Anesthesia|Comparison of Two Different Procedures for Plexus Anesthesia: Standard Position Versus Combination of Lateral Position and 20° Trendelenburg Position|Completed||N/A|100|Actual|University Hospital Muenster||2|||f||||f||||||||||2018-06-01 04:43:28.826968|2018-06-01 04:43:28.826968
NCT00151099|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-12-17|2005-09-07|2005-09-08|Estimate|||||||2015-12-17|2015-12-18|Estimate|September 2005||2005-09-30|August 2007|2007-08-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Safety of Preoperative Oral Administration of a High Caloric Drink With Protein|Safety of Preoperative Oral Administration of a High Caloric Drink With Protein in Patients With Dysgnathia|Withdrawn||Phase 4|0|Actual|University Hospital Muenster||||There is no possibility to reach the target patient number within the set time frame|f||||||||||||||2018-06-01 04:43:28.901511|2018-06-01 04:43:28.901511
NCT00151086|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-01-20|2005-09-06|2005-09-08|Estimate|||||||2015-01-20|2015-01-22|Estimate|December 2001||2001-12-31|January 2015|2015-01-31|August 2006|Actual|2006-08-31|March 2004|Actual|2004-03-31||Interventional|||Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer|Phase I/II Evaluation of Oral Estramustine and Oral Vinorelbine on an Intermittent Schedule in Patients With Hormone-Refractory Adenocarcinoma of the Prostate|Completed||Phase 1/Phase 2|33|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:43:28.961847|2018-06-01 04:43:28.961847
NCT00151073|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-01-21|2005-09-06|2005-09-08|Estimate|||||||2015-01-21|2015-01-22|Estimate|April 2002||2002-04-30|January 2015|2015-01-31|September 2007|Actual|2007-09-30|September 2005|Actual|2005-09-30||Interventional|||Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate|An Evaluation of Estramustine, Docetaxel and Zoledronate in Patients With Hormone-Refractory Adenocarcinoma of the Prostate|Completed||Phase 2|28|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-06-01 04:43:29.050252|2018-06-01 04:43:29.050252
NCT00151060|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-01-19|2005-09-06|2005-09-08|Estimate|||||||2015-01-19|2015-01-21|Estimate|December 1998||1998-12-31|January 2015|2015-01-31|June 2006|Actual|2006-06-30|November 2004|Actual|2004-11-30||Interventional|||Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate|Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Patients With Hormonally Responsive Adenocarcinoma of the Prostate|Completed||Phase 2|28|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:43:29.127348|2018-06-01 04:43:29.127348
NCT00151047|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-01-19|2005-09-07|2005-09-08|Estimate|||||||2015-01-19|2015-01-21|Estimate|March 2003||2003-03-31|January 2015|2015-01-31|October 2007|Actual|2007-10-31|January 2005|Actual|2005-01-31||Interventional|||Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer|Evaluation of Primary Chemotherapy With Docetaxel Plus Capecitabine in Selected Patients With Newly Diagnosed Localized or Locally Advanced Prostate Cancer|Completed||Phase 2|15|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:43:29.186159|2018-06-01 04:43:29.186159
NCT00151034|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-01-20|2005-09-06|2005-09-08|Estimate|||||||2015-01-20|2015-01-21|Estimate|September 2000||2000-09-30|January 2015|2015-01-31|October 2007|Actual|2007-10-31|August 2004|Actual|2004-08-31||Interventional|||Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer|Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer|Completed||Phase 2|33|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:43:29.243415|2018-06-01 04:43:29.243415
NCT00151021|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-12-08|2005-09-06|2005-09-08|Estimate|||||||2009-12-08|2009-12-09|Estimate|June 2005||2005-06-30|December 2009|2009-12-31|January 2006||2006-01-31|||||Interventional|||Stepping Up to Health: Feedback to Promote Physical Activity in Diabetes|Automated Step-count Feedback to Promote Physical Activity in Diabetes|Completed||N/A|40|Anticipated|University of Michigan|||||f||||||||||||||2018-06-01 04:43:29.317906|2018-06-01 04:43:29.317906
NCT00151008|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-08-06|2005-09-07|2005-09-08|Estimate|||||||2008-08-06|2008-08-07|Estimate|November 2003||2003-11-30|August 2008|2008-08-31|August 2005||2005-08-31|||||Interventional|||Bexarotene With Narrow-Band UVB for Psoriasis|Investigator-Initiated, Double Blind, Vehicle-Controlled, Bilateral Comparison Trial of Bexarotene (Targretin) Gel 1% vs. Vehicle Gel in Combination With Narrow Band UVB Phototherapy for Moderate to Severe Psoriasis Vulgaris|Completed||Phase 2|35||Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:43:29.370681|2018-06-01 04:43:29.370681
NCT00150995|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-01-20|2005-09-06|2005-09-08|Estimate|||||||2015-01-20|2015-01-21|Estimate|May 2001||2001-05-31|January 2015|2015-01-31|April 2006|Actual|2006-04-30|October 2003|Actual|2003-10-31||Interventional|||Tetrathiomolybdate in Hormone Refractory Prostate Cancer|A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|19|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:43:29.421193|2018-06-01 04:43:29.421193
NCT00150982|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-08-06|2005-09-07|2005-09-08|Estimate|||||||2008-08-06|2008-08-07|Estimate|September 2003||2003-09-30|August 2008|2008-08-31|February 2005||2005-02-28|||||Interventional|||Alefacept Mechanism of Action in Psoriasis|In Vivo Induction of T Cell Apoptosis by Alefacept (LFA-3/IgG1 Fusion Protein, Amevive) in Patients With Psoriasis: An Investigator-Initiated, Open-Label, Mechanism of Action Study|Completed||Phase 2|9||Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:43:29.479661|2018-06-01 04:43:29.479661
NCT00150969|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2012-01-10||2012-11-19|2005-09-06|2005-09-08|Estimate|2012-02-23|2012-03-26|Estimate||||2012-11-19|2012-11-22|Estimate|January 2002||2002-01-31|November 2012|2012-11-30|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Interventional|||Vitamin K Supplementation in Post-Menopausal Osteopenia|Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia (ECKO Trial)|Completed||Phase 3|440|Actual|University Health Network, Toronto|Originally designed as a 2-year study with BMD as primary outcome. Thus, the number of women followed to 3 and 4 years was small, and the study was not powered to examine fracture outcomes.|2|||f||||t||||||||||2018-06-01 04:43:29.55312|2018-06-01 04:43:29.55312
NCT00150956|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|April 1999||1999-04-30|October 2000|2000-10-31|January 2002||2002-01-31|||||Interventional|||Effects of Daily Home Hemodialysis on Circulation, Mental Functions, and Quality of Life|Study Into the Effects of Daily Home Hemodialysis on Hemodynamics, Neurocognitive Functions, and Quality of Life|Completed||Phase 3|12||UMC Utrecht|||||f||||||||||||||2018-06-01 04:43:29.890682|2018-06-01 04:43:29.890682
NCT00150943|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-04-26|2005-09-06|2005-09-08|Estimate|||||||2006-04-26|2006-04-27|Estimate|June 2000||2000-06-30|April 2006|2006-04-30||||||||Interventional|||Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis|The Benefit of STent Placement and Blood Pressure and Lipid-Lowering for the Prevention of Progression of Renal Dysfunction Caused by Atherosclerotic Ostial Stenosis of the Renal Artery (STAR)|Completed||Phase 3|140||UMC Utrecht|||||f||||||||||||||2018-06-01 04:43:29.950794|2018-06-01 04:43:29.950794
NCT00150930|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-11-27|2005-09-06|2005-09-08|Estimate|||||||2006-11-27|2006-11-28|Estimate|October 2002||2002-10-31|August 2005|2005-08-31|March 2005||2005-03-31|||||Interventional|||Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness|Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness|Unknown status|Active, not recruiting|Phase 4|200||UMC Utrecht|||||f||||||||||||||2018-06-01 04:43:30.01109|2018-06-01 04:43:30.01109
NCT00150917|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-06-12|2005-09-06|2005-09-08|Estimate|||||||2008-06-12|2008-06-17|Estimate|July 2001||2001-07-31|December 2006|2006-12-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||RCT of a Group Intervention for Women With a Family History of Breast Cancer|A Randomized Controlled Trial of a Group Intervention for Women With a Family History of Breast Cancer|Completed||Phase 3|150|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:43:30.069412|2018-06-01 04:43:30.069412
NCT00150904|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-02-13|2005-09-06|2005-09-08|Estimate|||||||2009-02-13|2009-02-16|Estimate|August 2005||2005-08-31|February 2009|2009-02-28|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Observational|||Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)|Request for Blood Samples to Examine the Effect of Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Patients With Hepatitis C and in Patients Coinfected With Hepatitis C and HIV|Completed|||28|Actual|UMC Utrecht|||||f||||||||||||||2018-06-01 04:43:30.124705|2018-06-01 04:43:30.124705
NCT00150891|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-05-08|2005-09-06|2005-09-08|Estimate|||||||2007-05-08|2007-05-10|Estimate|January 1998||1998-01-31|May 2007|2007-05-31|January 2006|Actual|2006-01-31|||||Observational|||Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection|Role of Th1, Th2 and Monokine Responses as Risk Factors of Acute and Chronic Renal Transplant Rejection – Impact of Different Immunosuppressive Protocols|Completed|||84|Actual|University of Giessen|||||f||||f||||||||||2018-06-01 04:43:30.173868|2018-06-01 04:43:30.173868
NCT00150878|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-06-19|2005-09-06|2005-09-08|Estimate|||||||2013-06-19|2013-06-20|Estimate|December 2003||2003-12-31|June 2013|2013-06-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission|Randomized Phase III Comparison of 12 Gy TBI and Cyclophosphamide 120 mg/kg With Fludarabine 120 mg/Sqm and 8 Gy TBI Before Allogeneic Transplantation in Patients With Acute Myeloid Leukemia in First Remission|Terminated||Phase 3|198|Actual|University Hospital Carl Gustav Carus||2||Insurance coverage reached|f||||t||||||||||2018-06-01 04:43:30.22938|2018-06-01 04:43:30.22938
NCT00150865|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-10-30|2005-09-07|2005-09-08|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2001||2001-09-30|September 2005|2005-09-30|March 2002||2002-03-31|||||Interventional|||Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery|Study of Posterior Lumbar Plexus Block for Pain Relief After Hip Surgery|Completed||N/A|60||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:43:30.294589|2018-06-01 04:43:30.294589
NCT00150852|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-12-28|2005-09-06|2005-09-08|Estimate|||||||2005-12-28|2005-12-29|Estimate|September 2004||2004-09-30|September 2005|2005-09-30||||||||Interventional|||Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus.|Vancomycin for Prophylaxis of PEG-Related Wound Infection in MRSA-Positive Patients: a Double-Blind, Randomized, Placebo-Controlled Study|Unknown status|Recruiting|Phase 2|96||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:43:30.33805|2018-06-01 04:43:30.33805
NCT00150839|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-11-20|2005-09-06|2005-09-08|Estimate|||||||2008-11-20|2008-11-21|Estimate|March 2006||2006-03-31|July 2008|2008-07-31|December 2009|Anticipated|2009-12-31|December 2009|Anticipated|2009-12-31||Interventional|COATS||Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy|Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-Blind, Placebo-Controlled Trial|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-06-01 04:43:30.39995|2018-06-01 04:43:30.39995
NCT00150826|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-04-12|2005-09-07|2005-09-08|Estimate|||||||2012-04-12|2012-04-13|Estimate|May 2000||2000-05-31|April 2012|2012-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia|A Double-Blind, Multicenter, Placebo Controlled Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease.|Completed||Phase 4|78|Actual|University of Florida||2|||f||||t||||||||||2018-06-01 04:43:30.558815|2018-06-01 04:43:30.558815
NCT00150813|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-12-05|2005-09-06|2005-09-08|Estimate|||||||2013-12-05|2013-12-06|Estimate|August 2005||2005-08-31|September 2009|2009-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.|A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials.|Completed||Phase 3|70||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:30.635405|2018-06-01 04:43:30.635405
NCT00150800|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-09-29|2005-09-06|2005-09-08|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2006|Actual|2006-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment|An Open-label, Multi-center, Follow-up Trial to Evaluate Long Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy|Completed||Phase 3|668|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:43:30.728684|2018-06-01 04:43:30.728684
NCT00150787|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-11-25|2005-09-06|2005-09-08|Estimate|||||||2013-11-25|2013-11-26|Estimate|July 2003||2003-07-31|September 2009|2009-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.|A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Coming From the N01061 Trial.|Completed||Phase 3|250||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:31.024268|2018-06-01 04:43:31.024268
NCT00150774|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-09-16|2005-09-06|2005-09-08|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 2001||2001-11-30|February 2010|2010-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults|A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (≥ 12 Years) and Adults (≤ 65 Years) Suffering From Idiopathic Generalized Epilepsy With Myoclonic Seizures.|Completed||Phase 3|116||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:31.090968|2018-06-01 04:43:31.090968
NCT00150761|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-08-25|2005-09-06|2005-09-08|Estimate|||||||2014-08-25|2014-08-26|Estimate|July 2004||2004-07-31|September 2009|2009-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Facial Thermography Study of Levocetirizine Versus Cetirizine|A Randomized, Double-blind, Double Dummy, Placebo Controlled, Cross-over Exploratory Trial in Healthy Male Adult Subjects: Comparison by Means of Infrared Thermography of the Anti-H1 Potency of Levocetirizine 5 mg and Cetirizine 10 mg Tablet Single Oral Dose After Nasal Histamine Provocation.|Completed||Phase 4|60||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:31.159582|2018-06-01 04:43:31.159582
NCT00150748|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-03-24|2005-09-06|2005-09-08|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2001||2001-11-30|March 2015|2015-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy|An Open-label, Multicenter, Follow-up Study to Evaluate the Safety and Efficacy of Levetiracetam (LEV) (Oral Tablets of 166, 250 or 500 mg b.i.d.), at Individualized Doses up to a Maximum of 4000 mg/Day (or 80 mg/kg/Day for Children and Adolescents Less Than 50 kg), in Children (≥ 4 Years Old), Adolescents and Adults Suffering From Primary Generalized Seizures|Completed||Phase 3|217|Actual|UCB Pharma||1|||f||||f||||||||||2018-06-01 04:43:31.226645|2018-06-01 04:43:31.226645
NCT00150735|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-11-25|2005-09-06|2005-09-08|Estimate|||||||2013-11-25|2013-11-26|Estimate|June 2002||2002-06-30|July 2010|2010-07-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy|A Multicenter, Double-blind, Randomized, Parallel Group, Positive-controlled Trial Comparing the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) to Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy for up to a Maximum of 121 Weeks in Subjects (≥ 16 Years) Newly or Recently Diagnosed as Suffering From Epilepsy, and Experiencing Partial or Generalized Tonic-clonic Seizures|Completed||Phase 3|580||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:31.313879|2018-06-01 04:43:31.313879
NCT00150722|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-11-07|2005-09-06|2005-09-08|Estimate|||||||2008-11-07|2008-11-10|Estimate|September 2005||2005-09-30|November 2008|2008-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||High-Density Lipoprotein (HDL) Modulation and Endothelial Function|HDL Modulation and Endothelial Function|Completed||Phase 3|75|Actual|University of Calgary|||||f||||||||||||||2018-06-01 04:43:31.379486|2018-06-01 04:43:31.379486
NCT00150709|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-02-14|2005-09-06|2005-09-08|Estimate|||||||2017-02-14|2017-02-15|Actual|February 1998||1998-02-28|February 2017|2017-02-28|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy|A Multi-Center, Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of Levetiracetam (Ucb L059) In Children With Epilepsy|Completed||Phase 3|238||UCB Pharma|||||f||||||||||||||2018-06-01 04:43:31.446311|2018-06-01 04:43:31.446311
NCT00150696|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-11-20|2005-09-06|2005-09-08|Estimate|||||||2007-11-20|2007-11-21|Estimate|February 2000||2000-02-29|November 2007|2007-11-30|November 2005||2005-11-30|||||Interventional|||Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.|Risedronate for Prevention of Osteoporosis After Spinal Cord Injury|Completed||Phase 3|38||Toronto Rehabilitation Institute|||||f||||||||||||||2018-06-01 04:43:31.505255|2018-06-01 04:43:31.505255
NCT00150683|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|March 1999||1999-03-31|September 2005|2005-09-30|July 2001||2001-07-31|||||Interventional|||Effectiveness of Vibration and Standing Versus Standing Alone for the Treatment of Osteoporosis for People With Spinal Cord Injury.|Evaluation of Conventional and Innovative Standing Frame for the Treatment of Osteoporosis After Spinal Cord Injury|Completed||N/A|60||Toronto Rehabilitation Institute|||||f||||||||||||||2018-06-01 04:43:31.567545|2018-06-01 04:43:31.567545
NCT00150670|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-07-06|2005-09-07|2005-09-08|Estimate|||||||2011-07-06|2011-07-07|Estimate|March 2002||2002-03-31|July 2011|2011-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer|Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer|Completed||Phase 3|300||Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-06-01 04:43:31.627632|2018-06-01 04:43:31.627632
NCT00150657|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-11-28|2005-09-06|2005-09-08|Estimate|||||||2005-11-28|2005-11-29|Estimate|November 2004||2004-11-30|September 2005|2005-09-30||||||||Interventional|||Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer|Phase II Trial of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|45||St. John Providence Health System|||||||||||||||||||2018-06-01 04:43:31.70296|2018-06-01 04:43:31.70296
NCT00150644|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-05-27|2005-09-06|2005-09-08|Estimate|||||||2008-05-27|2008-05-29|Estimate|July 2003||2003-07-31|May 2008|2008-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy|A Phase 2, 12-Week, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of J867 on Uterine Artery Blood Flow and the Morphology of the Endometrium, Myometrium, and Uterine Leiomyomata in Subjects With Uterine Leiomyomata Scheduled for Hysterectomy.|Completed||Phase 2|33|Actual|Abbott||3|||f||||f||||||||||2018-06-01 04:43:31.778766|2018-06-01 04:43:31.778766
NCT00150631|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-11-25|2005-09-06|2005-09-08|Estimate|||||||2014-11-25|2014-11-26|Estimate|November 2000||2000-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|January 2004|Actual|2004-01-31||Interventional|||Danish Hypertension Prevention Project - DHYPP|Danish Hypertension Prevention Project|Unknown status|Active, not recruiting|Phase 3|100|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-06-01 04:43:31.854312|2018-06-01 04:43:31.854312
NCT00150618|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2009-09-10||2009-11-25|2005-09-06|2005-09-08|Estimate|2009-09-11|2009-10-15|Estimate||||2009-11-25|2009-12-01|Estimate|April 2004||2004-04-30|November 2009|2009-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17|A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|324|Actual|Shire||5|||||||||||||||||2018-06-01 04:43:31.945961|2018-06-01 04:43:31.945961
NCT00150605|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-11-01|2005-09-06|2005-09-08|Estimate|||||||2007-11-01|2007-11-02|Estimate|February 2005||2005-02-28|June 2006|2006-06-30|October 2005||2005-10-31|||||Interventional|||Safety of SPD417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder|A Phase IIIb, Open Label Observational Study of SPD417 Used in Combination With Other Psychotropic Medications for the Treatment of Bipolar I Disorder|Completed||Phase 3|50||Validus Pharmaceuticals|||||||||||||||||||2018-06-01 04:43:32.489785|2018-06-01 04:43:32.489785
NCT00150592|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2009-09-10||2011-05-06|2005-09-06|2005-09-08|Estimate|2009-09-11|2009-10-14|Estimate||||2011-05-06|2011-05-10|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|April 2006|Actual|2006-04-30|||||Interventional|||Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17|A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2|182|Actual|Shire||2|||||||||||||||||2018-06-01 04:43:32.552217|2018-06-01 04:43:32.552217
NCT00150579|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-11-02|2005-09-06|2005-09-08|Estimate|||||||2007-11-02|2007-11-06|Estimate|January 2005||2005-01-31|November 2007|2007-11-30|December 2005|Actual|2005-12-31|||||Interventional|||Efficacy and Safety of SPD465 in Adults With ADHD|A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).|Completed||Phase 3|240||Shire|||||||||||||||||||2018-06-01 04:43:32.971356|2018-06-01 04:43:32.971356
NCT00150566|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-04-29|2005-09-06|2005-09-08|Estimate|||||||2010-04-29|2010-04-30|Estimate|February 2004||2004-02-29|April 2010|2010-04-30|August 2006|Actual|2006-08-31|||||Interventional|||Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood|A Phase IIIb, Multi-center, Two-Cohort, Randomized Study, With an Open-Label Run-In and a Long-Term Extensions Phase, Assessing an Extended Dose Range of Lanthanum Carbonate in End Stage Renal Disease Subjects Receiving Hemodialysis|Completed||Phase 3|460||Shire|||||f||||||||||||||2018-06-01 04:43:33.03269|2018-06-01 04:43:33.03269
NCT00150553|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-11-01|2005-09-06|2005-09-08|Estimate|||||||2007-11-01|2007-11-02|Estimate|January 2005||2005-01-31|May 2006|2006-05-31|October 2005||2005-10-31|||||Interventional|||Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder|A Phase IIIb, Randomized, Double-Blind, Parallel Group Study in Bipolar I Patients to Assess the Efficacy and Safety of SPD417 Administered Once Daily vs Twice Daily in the Treatment of Manic Symptoms|Completed||Phase 3|102||Validus Pharmaceuticals|||||||||||||||||||2018-06-01 04:43:33.077806|2018-06-01 04:43:33.077806
NCT00150540|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-09-13|2005-09-06|2005-09-08|Estimate|||||||2007-09-13|2007-09-17|Estimate|October 2002||2002-10-31|September 2007|2007-09-30|January 2006|Actual|2006-01-31|||||Interventional|||A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.|A Long Term, Open Label Extension Study of Protocols LAM-IV-301, LAM-IV 303, LAM-IV 307 AND LAM-IV 308.|Completed||Phase 3|93||Shire|||||||||||||||||||2018-06-01 04:43:33.117551|2018-06-01 04:43:33.117551
NCT00150527|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-02-04|2005-09-06|2005-09-08|Estimate|||||||2009-02-04|2009-02-05|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Observational|||Specific Effects of Escitalopram on Neuroendocrine Response|Specific Effects of Escitalopram on Neuroendocrine Response|Completed|||8|Actual|Queen's University|||||f||||f||||||||||2018-06-01 04:43:33.162999|2018-06-01 04:43:33.162999
NCT00150514|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-08|Estimate|||||||2005-09-07|2005-09-08|Estimate|January 2002||2002-01-31|November 2003|2003-11-30|December 2006||2006-12-31|||||Interventional|||Effects of Sublingual Immunotherapy on Grasspollen Allergy|A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose.|Completed||Phase 4|38||Radboud University|||||f||||||||||||||2018-06-01 04:43:33.229854|2018-06-01 04:43:33.229854
NCT00150488|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-09-17|2005-09-06|2005-09-08|Estimate|||||||2008-09-17|2008-09-18|Estimate|September 2005||2005-09-30|September 2008|2008-09-30|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||URACYST® For the Treatment of GAG Deficient Interstitial Cystitis|URACYST® For the Treatment of GAG Deficient Interstitial Cystitis|Completed||Phase 2/Phase 3|53|Actual|Queen's University||1|||f||||f||||||||||2018-06-01 04:43:33.28413|2018-06-01 04:43:33.28413
NCT00150475|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|May 2005||2005-05-31|||||Interventional|||Contamination During Removal of Two Different Personal Protective Systems|Contamination During Removal of Two Different Personal Protective Systems When Working Under Conditions Requiring Enhanced Respiratory and Contact Precautions|Completed||N/A|50||Queen's University|||||f||||||||||||||2018-06-01 04:43:33.381609|2018-06-01 04:43:33.381609
NCT00150462|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2015-10-29||2017-04-28|2005-09-06|2005-09-08|Estimate|2015-10-29|2015-12-03|Estimate||||2017-04-28|2017-05-02|Actual|September 2005||2005-09-30|April 2017|2017-04-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies|A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies|Completed||Phase 1|48|Actual|Amgen||11|||f||||f||||||||||2018-06-01 04:43:34.452204|2018-06-01 04:43:34.452204
NCT00150449|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-07-13|2005-09-06|2005-09-08|Estimate|||||||2006-07-13|2006-07-14|Estimate|January 2001||2001-01-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.|A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders|Completed||Phase 3|511||Pfizer|||||f||||||||||||||2018-06-01 04:43:41.304653|2018-06-01 04:43:41.304653
NCT00150436|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-12-20|2005-09-06|2005-09-08|Estimate|||||||2006-12-20|2006-12-22|Estimate|February 2002||2002-02-28|December 2006|2006-12-31|July 2005||2005-07-31|||||Interventional|||To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.|An Open-Label Extension Safety and Efficacy Study of Pregabalin in Patients With Postherpetic Neuralgia|Completed||Phase 3|276||Pfizer|||||f||||||||||||||2018-06-01 04:43:41.603283|2018-06-01 04:43:41.603283
NCT00150423|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-12-28|2005-09-06|2005-09-08|Estimate|||||||2006-12-28|2007-01-01|Estimate|January 2001||2001-01-31|December 2006|2006-12-31|July 2005||2005-07-31|||||Interventional|||To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.|An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.|Completed||Phase 3|384||Pfizer|||||f||||||||||||||2018-06-01 04:43:41.647866|2018-06-01 04:43:41.647866
NCT00150241|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-10-16|2005-09-06|2005-09-08|Estimate|||||||2015-10-16|2015-10-19|Estimate|February 2000||2000-02-29|October 2015|2015-10-31|January 2002|Actual|2002-01-31|||||Interventional|||A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation|A Seven-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Three Doses of CP-526,555 ( 0.3 mg QD, 1 mg QD, and 1 mg BID ) in Comparison With Zyban in Smoking Cessation|Completed||Phase 2|625||Pfizer|||||||||||||||||||2018-06-01 04:43:44.556684|2018-06-01 04:43:44.556684
NCT00150410|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-10-28|2005-09-06|2005-09-08|Estimate|||||||2008-10-28|2008-10-31|Estimate|January 2003||2003-01-31|October 2008|2008-10-31|June 2007|Actual|2007-06-30|||||Interventional|||Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose|A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera® (Insulin Dry Powder Pulmonary Inhaler) vs. Avandia® (Rosiglitazone Maleate) as Add-On Therapy vs. Exubera® Substitution of Sulfonylurea in Patients With Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment|Completed||Phase 3|626|Actual|Pfizer|||||||||||||||||||2018-06-01 04:43:41.702107|2018-06-01 04:43:41.702107
NCT00150397|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-06-07|2005-09-06|2005-09-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|March 2005||2005-03-31|June 2012|2012-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six-Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults With Persistent Asthma|Completed||Phase 2|112||Pfizer|||||f||||||||||||||2018-06-01 04:43:42.121174|2018-06-01 04:43:42.121174
NCT00150384|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-04-21|2005-09-06|2005-09-08|Estimate|||||||2015-04-21|2015-04-22|Estimate|July 2004||2004-07-31|April 2015|2015-04-30|August 2005|Actual|2005-08-31|||||Interventional|CAPABLE||Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population|Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE)|Completed||Phase 4|500||Pfizer|||||||||||||||||||2018-06-01 04:43:42.234854|2018-06-01 04:43:42.234854
NCT00150371|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-07-01|2005-09-06|2005-09-08|Estimate|||||||2009-07-01|2009-07-03|Estimate|June 2004||2004-06-30|April 2007|2007-04-30|May 2005|Actual|2005-05-31|||||Interventional|CANACTFAST||Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration|A Multicenter, 12 Week Treatment Single Step Titration Open-Label Study Assessing The % Of Patients Achieving Ldl-C Target With Atorvastatin Starting Doses Of 10mg, 20mg, 40mg and 80mg.|Completed||Phase 3|1100||Pfizer|||||f||||||||||||||2018-06-01 04:43:42.53404|2018-06-01 04:43:42.53404
NCT00150358|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-12-07|2005-09-06|2005-09-08|Estimate|||||||2006-12-07|2006-12-11|Estimate|March 2005||2005-03-31|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .|Open Label, Multicenter, Non Comparative Study, To Confirm The Efficacy And Tolerability Of Viagra In Subjects With Erectile Dysfunction And Arterial Hypertension Who Are Taking Antihypertensive Treatment.|Completed||Phase 4|253||Pfizer|||||f||||||||||||||2018-06-01 04:43:42.700505|2018-06-01 04:43:42.700505
NCT00150345|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2010-04-05||2012-01-17|2005-09-06|2005-09-08|Estimate|2010-07-22|2010-08-18|Estimate||||2012-01-17|2012-01-19|Estimate|January 2005||2005-01-31|January 2012|2012-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|IDEA||Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients|Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In High-Risk Neutropenic Patients With Fever And A Positive Panfungal Polymerase Chain Reaction Assay (IDEA Study)|Completed||Phase 3|147|Actual|Pfizer|One participant in the Immediate Voriconazole treatment group was incorrectly included in the original Primary efficacy analysis and has now been excluded; IFI was identified on the day study treatment started (not prior to study treatment).|2|||f||||f||||||||||2018-06-01 04:43:42.831917|2018-06-01 04:43:42.831917
NCT00150332|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-05-09|2005-09-06|2005-09-08|Estimate|||||||2011-05-09|2011-05-10|Estimate|January 2003||2003-01-31|May 2011|2011-05-31|January 2006|Actual|2006-01-31|||||Interventional|||Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan|Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial|Completed||Phase 3|24|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:43:43.767366|2018-06-01 04:43:43.767366
NCT00150319|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-09-25|2005-09-06|2005-09-08|Estimate|||||||2008-09-25|2008-09-29|Estimate|June 2005||2005-06-30|September 2008|2008-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend|An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Iv Containing Sbecd As An Excipient Following Multiple Dosing With Vfend®; I.V. In Subjects With Moderately Impaired Renal Function|Terminated||Phase 1/Phase 2|1|Actual|Pfizer||||See Detailed Description|f||||||||||||||2018-06-01 04:43:43.837298|2018-06-01 04:43:43.837298
NCT00150306|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-08-16|2005-09-06|2005-09-08|Estimate|||||||2007-08-16|2007-08-17|Estimate|November 2002||2002-11-30|August 2007|2007-08-31|July 2007|Actual|2007-07-31|||||Interventional|||A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD|A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD)|Terminated||Phase 3|160||Pfizer||||Please see Detailed Description below for termination reason.|||||f||||||||||2018-06-01 04:43:43.969399|2018-06-01 04:43:43.969399
NCT00150293|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-03-04|2005-09-06|2005-09-08|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2002||2002-03-31|March 2015|2015-03-31|November 2005||2005-11-30|||||Interventional|||Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.|Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.|Completed||Phase 3|337||Pfizer|||||f||||||||||||||2018-06-01 04:43:44.089965|2018-06-01 04:43:44.089965
NCT00150280|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-07-23|2005-09-06|2005-09-08|Estimate|||||||2006-07-23|2006-07-25|Estimate|October 2004||2004-10-31|November 2005|2005-11-30|July 2005||2005-07-31|||||Interventional|||Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery|A Prospective, Randomized, Double-Blind, Double-Dummy, Multi-Center Study Comparing Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery|Completed||Phase 3|132||Pfizer|||||f||||||||||||||2018-06-01 04:43:44.254912|2018-06-01 04:43:44.254912
NCT00150267|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-11-04|2005-09-06|2005-09-08|Estimate|||||||2008-11-04|2008-11-05|Estimate|February 2002||2002-02-28|November 2008|2008-11-30||||||||Interventional|||A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension|A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension|Completed||Phase 3|976|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:43:44.333687|2018-06-01 04:43:44.333687
NCT00150254|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-06-01|2005-09-06|2005-09-08|Estimate|||||||2007-06-01|2007-06-04|Estimate|September 2001||2001-09-30|June 2007|2007-06-30|October 2002|Actual|2002-10-31|||||Interventional|||12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 ( 0.5 mg BID Titrated, 0.5 mg BID, 1 mg BID, and Titrated 1 mg BID ) in Smoking Cessation|Completed||Phase 2|625||Pfizer|||||||||||||||||||2018-06-01 04:43:44.48503|2018-06-01 04:43:44.48503
NCT00150228|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-05-31|2005-09-06|2005-09-08|Estimate|||||||2007-05-31|2007-06-04|Estimate|December 2001||2001-12-31|May 2007|2007-05-31|September 2002|Actual|2002-09-30|||||Interventional|||12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation|A Twelve-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of a Flexible-Dosing Strategy for CP-526,555 ( 0.5 mg to 2.0 mg Total Daily Dose ) in Smoking Cessation|Completed||Phase 2|300||Pfizer|||||||||||||||||||2018-06-01 04:43:44.621032|2018-06-01 04:43:44.621032
NCT00150215|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-07-24|2005-09-06|2005-09-08|Estimate|||||||2006-07-24|2006-07-25|Estimate|July 2005||2005-07-31|April 2006|2006-04-30|October 2005||2005-10-31|||||Interventional|||A First In Human Study Of PF-00184562 In Healthy Volunteers|An Oral, Rising Single-Dose Tolerance, Pharmacokinetic, and Pharmacodynamic Study of Pf-00184562 Capsules In Healthy Volunteers|Completed||Phase 1|18||Pfizer|||||||||||||||||||2018-06-01 04:43:44.682998|2018-06-01 04:43:44.682998
NCT00150202|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-05-04|2005-09-06|2005-09-08|Estimate|||||||2007-05-04|2007-05-07|Estimate|July 2004||2004-07-31|November 2006|2006-11-30|October 2006|Actual|2006-10-31|||||Interventional|||Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)|Clinical Study Of EYE001 In Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration|Completed||Phase 3|90||Pfizer|||||f||||||||||||||2018-06-01 04:43:44.73358|2018-06-01 04:43:44.73358
NCT00150189|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2018-05-23|2005-09-06|2005-09-08|Estimate|||||||2018-05-23|2018-05-25|Actual|November 1, 2003|Actual|2003-11-01|December 2006|2006-12-31|October 11, 2006|Actual|2006-10-11|October 11, 2006|Actual|2006-10-11||Interventional|||Utilization of Oral Sucrose to Decrease Pain in Infants During Immunizations|Efficacy of Oral Sucrose Analgesia During Routine Immunizations at 6 Weeks and 4 Months of Age|Completed||N/A|140||Milton S. Hershey Medical Center|||||f||||||||||||||2018-06-01 04:43:44.794159|2018-06-01 04:43:44.794159
NCT00150176|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2010-04-28|2009-04-29|2015-10-29|2005-09-07|2005-09-08|Estimate|2010-04-28|2010-05-28|Estimate|2009-10-02|2009-10-06|Estimate|2015-10-29|2015-10-30|Estimate|April 2005||2005-04-30|October 2015|2015-10-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)|A Randomized, Placebo-Controlled, Double-Blind Trial of Asenapine in the Prevention of Relapse After Long-Term Treatment of Schizophrenia|Completed||Phase 3|831|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:43:44.877767|2018-06-01 04:43:44.877767
NCT00150163|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-03-28|2005-09-06|2005-09-08|Estimate|||||||2007-03-28|2007-03-29|Estimate|March 2002||2002-03-31|September 2005|2005-09-30|December 2008||2008-12-31|||||Observational|||Odense Androgen Study: Study of Androgens, Body Composition, and Muscle Function in Danish Men|Odense Androgen Study – A Population-Based Study of Androgens, Body Composition, and Muscle Function in 20-29 Year-Old Danish Men|Unknown status|Active, not recruiting||800||Odense University Hospital|||||f||||||||||||||2018-06-01 04:43:45.516688|2018-06-01 04:43:45.516688
NCT00150150|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-03-26|2005-09-06|2005-09-08|Estimate|||||||2007-03-26|2007-03-27|Estimate|January 2001||2001-01-31|March 2007|2007-03-31|March 2006||2006-03-31|||||Interventional|||Laser Therapy of Benign Thyroid Nodules|Ultrasound Guided Interstitial Laser Photocoagulation on Benign Thyroid Nodules|Unknown status|Active, not recruiting|Phase 3|70||Odense University Hospital|||||f||||||||||||||2018-06-01 04:43:45.567462|2018-06-01 04:43:45.567462
NCT00150137|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-02-02|2005-09-06|2005-09-08|Estimate|||||||2006-02-02|2006-02-03|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Antithyroid Drugs During Radioiodine Therapy|The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism|Completed||Phase 4|80||Odense University Hospital|||||f||||||||||||||2018-06-01 04:43:45.624437|2018-06-01 04:43:45.624437
NCT00150124|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-12-03|2005-09-06|2005-09-08|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 2003||2003-01-31|December 2013|2013-12-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Block-replacement Therapy During Radioiodine Therapy|The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism|Completed||Phase 4|100|Actual|Odense University Hospital||2|||f||||f||||||||||2018-06-01 04:43:45.677767|2018-06-01 04:43:45.677767
NCT00150111|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-10-05|2005-09-06|2005-09-08|Estimate|||||||2006-10-05|2006-10-06|Estimate|June 2003||2003-06-30|October 2006|2006-10-31|October 2006||2006-10-31|||||Interventional|||Rituximab in the Treatment of Graves' Disease|B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease|Completed||Phase 1/Phase 2|20||Odense University Hospital|||||f||||||||||||||2018-06-01 04:43:45.797824|2018-06-01 04:43:45.797824
NCT00150098|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-04-07|2005-09-06|2005-09-08|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2005||2005-02-28|April 2014|2014-04-30|October 2010|Actual|2010-10-31|November 2009|Actual|2009-11-30||Interventional|||Project UNITY - HIV Risk Reduction and Vaccine Education Interventions|Project UNITY - A Randomized Trial of Enhanced HIV Risk Reduction and Vaccine Education Interventions in Reducing Sexual Risk and Increasing Vaccine Trial Knowledge Among HIV-negative, High-risk Women Who Use Non-injection Drugs|Completed||N/A|400|Actual|New York Blood Center||1|||f||||f||||||||||2018-06-01 04:43:45.875845|2018-06-01 04:43:45.875845
NCT00150085|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-02-17|2005-09-07|2005-09-08|Estimate|||||||2011-02-17|2011-02-18|Estimate|February 2004||2004-02-29|February 2011|2011-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion|A Prospective, Randomized, Open-label, Twenty-six Week Study of the Efficacy and Safety of Converting Kidney and Liver Transplant Recipients With Tacrolimus-associated Abnormal Glucose Metabolism to Cyclosporine Micro-emulsion With C2 Monitoring|Terminated||Phase 4|50|Actual|Novartis|||||f||||||||||||||2018-06-01 04:43:45.952682|2018-06-01 04:43:45.952682
NCT00150072|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-02-21|2005-09-07|2005-09-08|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2004||2004-10-31|February 2017|2017-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Efficacy and Safety of Imatinib in Chordoma|Phase II Study of Imatinib Mesylate in Chordoma|Completed||Phase 2|55|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:43:46.040617|2018-06-01 04:43:46.040617
NCT00150059|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-02-14|2005-09-07|2005-09-08|Estimate|||||||2008-02-14|2008-02-15|Estimate|December 2004||2004-12-31|February 2008|2008-02-29|December 2005|Actual|2005-12-31|||||Interventional|||Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis||Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 04:43:46.132881|2018-06-01 04:43:46.132881
NCT00150046|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2011-11-01|2005-09-07|2005-09-08|Estimate|||||||2011-11-01|2011-11-02|Estimate|December 2004||2004-12-31|November 2011|2011-11-30||||May 2007|Actual|2007-05-31||Interventional|||Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients|A 12-month, Multicenter, Randomized, Open-label Non-inferiority Study of Renal Function and Efficacy Comparing Concentration-controlled Certican (1.5 mg/Day Starting Dose) With Reduced Neoral Dose Versus MMF With Standard Neoral Dose in de Novo Heart Transplant Recipients|Completed||Phase 3|176|Anticipated|Novartis|||||f||||||||||||||2018-06-01 04:43:46.199362|2018-06-01 04:43:46.199362
NCT00150020|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-01-21|2005-09-06|2005-09-08|Estimate|||||||2008-01-21|2008-01-24|Estimate|October 2004||2004-10-31|January 2008|2008-01-31||||February 2006|Actual|2006-02-28||Interventional|||Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance|Safety and Tolerability of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients With GI Intolerance|Completed||Phase 4|728|Anticipated|Novartis|||||||||||||||||||2018-06-01 04:43:46.318733|2018-06-01 04:43:46.318733
NCT00150007|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2017-09-12|2005-09-06|2005-09-08|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2004||2004-06-30|November 2011|2011-11-30||||June 2005|Actual|2005-06-30||Interventional|||Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)|Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)|Completed||Phase 4|335||Novartis|||||f||||||||||||||2018-06-01 04:43:46.377468|2018-06-01 04:43:46.377468
NCT00149994|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2011-01-25||2011-04-07|2005-09-06|2005-09-08|Estimate|2011-01-25|2011-02-14|Estimate||||2011-04-07|2011-04-12|Estimate|December 2002||2002-12-31|April 2011|2011-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients|DELTA Study Dutch Evaluation in Liver Transplantation To Assess the Efficacy of Cyclosporine A Microemulsion With C-2h Monitoring Versus Tacrolimus With Trough Monitoring in de Novo Liver Transplant Recipients|Completed||Phase 4|171|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:43:46.458239|2018-06-01 04:43:46.458239
NCT00149981|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-12-10|2005-09-06|2005-09-08|Estimate|||||||2014-12-10|2014-12-11|Estimate|August 2003||2003-08-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|Umbrella||A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation|A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation|Completed||Phase 4|1025|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:43:47.003706|2018-06-01 04:43:47.003706
NCT00149968|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-10-14|2005-09-06|2005-09-08|Estimate|||||||2009-10-14|2009-10-15|Estimate|April 2005||2005-04-30|October 2009|2009-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)|Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)|Completed||Phase 4|196|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:43:47.445521|2018-06-01 04:43:47.445521
NCT00149942|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-11-16|2005-09-06|2005-09-08|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy|Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-Coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From GI Adverse Events While on Mycophenolate Mofetil Therapy|Completed||Phase 4|23|Actual|Novartis|||||f||||||||||||||2018-06-01 04:43:47.54594|2018-06-01 04:43:47.54594
NCT00149929|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-02-01|2005-09-06|2005-09-08|Estimate|||||||2011-02-01|2011-02-02|Estimate|December 1999||1999-12-31|February 2011|2011-02-28|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301|Multicenter, Open-label Follow-up Study on the Safety of Enteric-coated Mycophenolate Sodium in de Novo Renal Transplant Patients|Completed||Phase 3|246|Actual|Novartis|||||||||||||||||||2018-06-01 04:43:47.63058|2018-06-01 04:43:47.63058
NCT00149916|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-11-01|2005-09-06|2005-09-08|Estimate|||||||2011-11-01|2011-11-02|Estimate|April 2000||2000-04-30|November 2011|2011-11-30||||April 2004|Actual|2004-04-30||Interventional|||Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107|Multicenter, Open-label Follow-up Study on the Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Patients.|Completed||Phase 3|139|Actual|Novartis||1|||||||||||||||||2018-06-01 04:43:47.724551|2018-06-01 04:43:47.724551
NCT00149903|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-11-16|2005-09-06|2005-09-08|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2005||2005-01-31|November 2016|2016-11-30||||June 2006|Actual|2006-06-30||Interventional|||Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients|Multicenter, Double-blind, Randomized, Parallel Group Study on Efficacy and Safety of Enteric-coated Mycophenolate Sodium vs. Mycophenolate Mofetil in de Novo Chinese Renal Transplant Recipients|Completed||Phase 3|300||Novartis|||||f||||||||||||||2018-06-01 04:43:47.819811|2018-06-01 04:43:47.819811
NCT00149890|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2011-01-20||2011-08-17|2005-09-06|2005-09-08|Estimate|2011-08-17|2011-09-22|Estimate||||2011-08-17|2011-09-22|Estimate|March 2004||2004-03-31|August 2011|2011-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids|A Multicenter, Open-label, Randomized, Two Arm Study to Investigate the Efficacy and Safety of a Therapy Avoiding Intraoperative Steroids in Combination With Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients|Completed||Phase 3|77|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:43:47.93884|2018-06-01 04:43:47.93884
NCT00149877|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-01-31|2005-09-06|2005-09-08|Estimate|||||||2008-01-31|2008-02-01|Estimate|April 2004||2004-04-30|January 2008|2008-01-31|February 2006|Actual|2006-02-28|||||Interventional|||Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation|Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation|Completed||Phase 4|250||Novartis|||||f||||||||||||||2018-06-01 04:43:48.920923|2018-06-01 04:43:48.920923
NCT00149864|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-02-01|2005-09-06|2005-09-08|Estimate|||||||2011-02-01|2011-02-02|Estimate|February 2000||2000-02-29|February 2011|2011-02-28|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302|Multicenter, Open-label Follow-up Study on the Safety of Enteric-coated Mycophenolate Sodium in Maintenance Renal Transplant Patients|Completed||Phase 3|264|Actual|Novartis|||||||||||||||||||2018-06-01 04:43:49.007145|2018-06-01 04:43:49.007145
NCT00149851|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-08-31|2005-09-06|2005-09-08|Estimate|||||||2010-08-31|2010-09-01|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)|A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)|Completed||Phase 2|832||Novartis|||||||||||||||||||2018-06-01 04:43:49.083817|2018-06-01 04:43:49.083817
NCT00149825|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2009-07-30||2014-05-12|2005-09-07|2005-09-08|Estimate|2009-09-11|2009-10-14|Estimate||||2014-05-12|2014-05-20|Estimate|June 2004||2004-06-30|May 2014|2014-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome||Completed||Phase 2|30|Actual|Stanford University|Limitations of the current pilot study include a small sample size, relative racial homogeneity, and exclusion of patients with comorbidity.|2|||f||||||||||||||2018-06-01 04:43:49.314087|2018-06-01 04:43:49.314087
NCT00149812|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-08-03|2005-09-06|2005-09-08|Estimate|||||||2016-08-03|2016-08-05|Estimate|January 2005||2005-01-31|August 2016|2016-08-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||A Clinic-based Prevention Program for Families of Depressed Mothers|A Clinic-based Program for Families of Depressed Mothers|Completed||Phase 1|26|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||No||2018-06-01 04:43:49.669208|2018-06-01 04:43:49.669208
NCT00149799|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2014-10-17||2017-11-30|2005-09-06|2005-09-08|Estimate|2014-11-14|2014-11-21|Estimate||||2017-11-30|2017-12-05|Actual|May 2005||2005-05-31|November 2017|2017-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||As the primary endpoint is based on participants randomized to Phase II (i.e. those who completed Phase I, met criteria for response, and were willing to continue on in the study), baseline characteristics are provided for the 58 Phase II participants.|Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder|Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder|Completed||Phase 3|100|Actual|Massachusetts General Hospital|Our findings may not be fully generalizable - for example, we excluded those with a co-occurring substance use disorder, higher levels of suicidality, and more severely ill patients who required concomitant therapy or a higher level of care.|2|||f||||t||||||||||2018-06-01 04:43:49.784019|2018-06-01 04:43:49.784019
NCT00149786|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-04-09|2005-09-06|2005-09-08|Estimate|||||||2012-04-09|2012-04-10|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|March 2009|Actual|2009-03-31|March 2008|Actual|2008-03-31||Interventional|||Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa|Treatment of Adolescents With Anorexia Nervosa|Completed||Phase 1|120|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 04:43:50.410948|2018-06-01 04:43:50.410948
NCT00149773|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-04-06|2005-09-06|2005-09-08|Estimate|||||||2015-04-06|2015-04-08|Estimate|May 2005||2005-05-31|June 2006|2006-06-30|February 2011|Actual|2011-02-28|December 2008|Actual|2008-12-31||Interventional|||Cognitive Therapy for Suicidal Older Men in Primary Care Settings|Cognitive Therapy for Suicidal Older Men in Primary Care Settings|Completed||Phase 1|34|Actual|University of Pennsylvania||2|||f||||||||||||||2018-06-01 04:43:50.505541|2018-06-01 04:43:50.505541
NCT00149760|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-02-19|2005-09-06|2005-09-08|Estimate|||||||2014-02-19|2014-02-20|Estimate|August 2003||2003-08-31|February 2014|2014-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effectiveness of Cognitive-Affective Behavior Therapy for the Treatment of Somatization Disorder|Cognitive Affective Behavior Therapy for Somatization|Completed||Phase 2|88|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 04:43:50.685825|2018-06-01 04:43:50.685825
NCT00149747|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2013-06-18||2016-04-25|2005-09-06|2005-09-08|Estimate|2014-04-01|2014-05-01|Estimate||||2016-04-25|2016-05-24|Estimate|August 1999||1999-08-31|April 2016|2016-04-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|RTC||The Effectiveness of Regular Exercise on Improving Sleep in Older Adults|Promoting Exercise, Sleep and Well-Being in Older Adults|Completed||Phase 2/Phase 3|66|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 04:43:50.81871|2018-06-01 04:43:50.81871
NCT00149734|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-05-12|2005-09-06|2005-09-08|Estimate|||||||2017-05-12|2017-05-16|Actual|January 2005||2005-01-31|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia|Atypical Antipsychotics and P50 Sensory Gating|Completed||N/A|85|Actual|University of Colorado, Denver||2|||f||||f|t|f|||f|||No||2018-06-01 04:43:51.272155|2018-06-01 04:43:51.272155
NCT00149721|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2010-03-01|2005-09-07|2005-09-08|Estimate|||||||2010-03-01|2010-03-02|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|December 2007||2007-12-31|||||Interventional|||Anterior Pituitary Function in Patients With Hydrocephalus|Anterior Pituitary Function in Patients With Hydrocephalus|Terminated||N/A|30||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:43:51.395616|2018-06-01 04:43:51.395616
NCT00149708|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-06-13|2005-09-07|2005-09-08|Estimate|||||||2010-06-13|2010-06-15|Estimate|September 2005||2005-09-30|June 2010|2010-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Consequence of Lifetime Isolated Growth Hormone Deficiency|Consequence of Lifetime Isolated Growth Hormone Deficiency|Completed||N/A|400|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:43:51.515248|2018-06-01 04:43:51.515248
NCT00149695|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2010-08-20|2005-09-06|2005-09-08|Estimate|||||||2010-08-20|2010-08-24|Estimate|July 2004||2004-07-31|August 2010|2010-08-31|December 2005|Actual|2005-12-31|||||Interventional|||Soft Drink, Milk and Obesity in Chilean Children|Soft Drink, Milk and Obesity in Chilean Children|Completed||N/A|96||Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:43:51.63839|2018-06-01 04:43:51.63839
NCT00149682|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-01-12|2005-09-06|2005-09-08|Estimate|||||||2010-01-12|2010-01-13|Estimate|July 2005||2005-07-31|January 2010|2010-01-31|December 2007||2007-12-31|||||Interventional|||Obesity Assessment and Education Through the Internet|Obesity Assessment and Education Through the Internet|Completed||Phase 2|100||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:43:51.759443|2018-06-01 04:43:51.759443
NCT00149669|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2016-09-02||2017-08-15|2005-09-06|2005-09-08|Estimate|2017-08-14|2017-08-16|Actual||||2017-08-15|2017-09-14|Actual|December 2005||2005-12-31|August 2017|2017-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Employment-based Reinforcement of Naltrexone Ingestion and Abstinence|Employment-Based Addiction Pharmacotherapy|Completed||N/A|67|Actual|Johns Hopkins University||2|||f||||f|f|f|||f|||No||2018-06-01 04:43:51.852924|2018-06-01 04:43:51.852924
NCT00149656|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-04-26|2005-09-06|2005-09-08|Estimate|||||||2013-04-26|2013-04-29|Estimate|June 2003||2003-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|July 2010|Actual|2010-07-31||Interventional|||The Effects of Nutritional Supplementation and Drug Abuse on HIV|HIV Disease, Drug Abuse, and Nutrient Therapy in Botswana|Completed||N/A|878|Actual|Florida International University||4|||f||||t||||||||||2018-06-01 04:43:52.400842|2018-06-01 04:43:52.400842
NCT00149643|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2012-02-08||2013-06-17|2005-09-06|2005-09-08|Estimate|2012-08-01|2012-09-03|Estimate||||2013-06-17|2013-06-24|Estimate|September 2004||2004-09-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|August 2009|Actual|2009-08-31||Interventional|CADY||Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence|Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People|Completed||Phase 2|70|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 04:43:52.529416|2018-06-01 04:43:52.529416
NCT00149630|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2012-10-22||2017-02-04|2005-09-06|2005-09-08|Estimate|2012-11-27|2012-12-28|Estimate||||2017-02-04|2017-03-15|Actual|January 2005||2005-01-31|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|Disulfiram||Pharmacogenetics of Disulfiram for Cocaine|Effectiveness of Disulfiram for Treating Cocaine Dependence in Individuals With Different Dopamine Beta Hydroxylase (DBH) Genes|Completed||Phase 2|93|Actual|Baylor College of Medicine|The sample size is small for this genetic association study, and larger replications of this preliminary study are needed. Most cocaine abusers are not also opioid dependent, which limits generalization of findings.|2|||f||||t||||||||No||2018-06-01 04:43:52.9273|2018-06-01 04:43:52.9273
NCT00149617|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-10-08|2005-09-06|2005-09-08|Estimate|||||||2015-10-08|2015-10-09|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1|Career Training in Marijuana Dependence|Completed||Phase 2|81|Actual|Medical University of South Carolina|||||f||||||||||||||2018-06-01 04:43:53.24466|2018-06-01 04:43:53.24466
NCT00149604|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-12-01|2005-09-06|2005-09-08|Estimate|||||||2009-12-01|2009-12-02|Estimate|March 2000||2000-03-31|December 2009|2009-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||AFTER: Altering Fat Through Estrogen and Raloxifene|Modulation of Visceral Fat by Estrogens After Menopause|Completed||Phase 2|108||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:43:53.32233|2018-06-01 04:43:53.32233
NCT00149591|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-09-04|2005-09-06|2005-09-08|Estimate|||||||2008-09-04|2008-09-05|Estimate|April 2001||2001-04-30|September 2006|2006-09-30|January 2007||2007-01-31|||||Interventional|||The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial)|Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.|Unknown status|Active, not recruiting|N/A|300||Netherlands Heart Foundation|||||f||||||||||||||2018-06-01 04:43:53.399623|2018-06-01 04:43:53.399623
NCT00149578|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-05-16|2005-09-07|2005-09-08|Estimate|||||||2007-05-16|2007-05-17|Estimate|October 2004||2004-10-31|May 2007|2007-05-31|October 2008|Anticipated|2008-10-31|||||Interventional|||A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer|A Phase II Study of Induction Chemotherapy Followed by Concurrent Chemotherapy With Radiotherapy in Locally Advanced Pancreatic Cancer|Unknown status|Recruiting|Phase 2|45|Anticipated|National Health Research Institutes, Taiwan|||||f||||t||||||||||2018-06-01 04:43:53.54826|2018-06-01 04:43:53.54826
NCT00149565|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-12-15|2005-09-07|2005-09-08|Estimate|||||||2005-12-15|2005-12-16|Estimate|October 1997||1997-10-31|December 2004|2004-12-31|July 2005||2005-07-31|||||Interventional|||Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma|Hepatocellular Carcinoma Postoperative Adjuvant Therapy Disease Committee of Taiwan Cooperative Oncology Group|Completed||Phase 3|268||National Health Research Institutes, Taiwan|||||f||||||||||||||2018-06-01 04:43:53.656208|2018-06-01 04:43:53.656208
NCT00149552|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-03-01|2005-09-06|2005-09-08|Estimate|||||||2012-03-01|2012-03-05|Estimate|June 2001||2001-06-30|March 2012|2012-03-31|January 2007|Actual|2007-01-31|||||Interventional|||Zinc Therapy in HIV Infected Individuals Who Abuse Drugs|Zinc Therapy in Zinc Deficient HIV Positive Drug Users|Completed||N/A|231|Actual|Florida International University||2|||f||||t||||||||||2018-06-01 04:43:53.727957|2018-06-01 04:43:53.727957
NCT00149539|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-01-11|2005-09-06|2005-09-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2004||2004-06-30|July 2007|2007-07-31|January 2006|Actual|2006-01-31|||||Interventional|||Abuse Potential of Buprenorphine/Naloxone|Abuse Potential of Buprenorphine/Naloxone as a Function of Maintenance Dose of Buprenorphine/Naloxone|Terminated||Phase 2|12|Actual|National Institute on Drug Abuse (NIDA)||||Funding ended for the study|f||||f||||||||||2018-06-01 04:43:53.828116|2018-06-01 04:43:53.828116
NCT00149526|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-02-17|2005-09-06|2005-09-08|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 2001||2001-06-30|January 2008|2008-01-31|May 2006|Actual|2006-05-31|||||Interventional|||Does Shared Decision-Making Improve Asthma Outcomes?||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:43:53.886855|2018-06-01 04:43:53.886855
NCT00149513|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-12-21|2005-09-06|2005-09-08|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2003||2003-09-30|December 2017|2017-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Post-Hospital Case Management to Improve Clinical Outcomes in Individuals Requiring Mechanical Ventilation|King County Lung Injury Project: Survivor Outcome Study (KCLIP:SOS)|Completed||N/A|600|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:43:53.954515|2018-06-01 04:43:53.954515
NCT00149500|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2018-05-02|2005-09-06|2005-09-08|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2003||2003-09-30|May 2018|2018-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|SSEA||Social Support and Education in Asthma Follow-up (SSEA)|Social Support and Education in Asthma Follow-up (SSEA)|Completed||N/A|241|Actual|Washington University School of Medicine||2|||f||||t||||||||No||2018-06-01 04:43:54.07311|2018-06-01 04:43:54.07311
NCT00149487|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-11-06|2005-09-06|2005-09-08|Estimate|||||||2006-11-06|2006-11-08|Estimate|January 2001||2001-01-31|November 2006|2006-11-30||||||||Interventional|||Enhancing Treatment Adherence in Pediatric Asthma With a Problem Solving Intervention|Randomized Controlled Trial of Problem Solving Intervention to Enhance Treatment Adherence in Pediatric Asthma|Unknown status|Active, not recruiting|N/A|120||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:43:54.161946|2018-06-01 04:43:54.161946
NCT00149474|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-02-17|2005-09-06|2005-09-08|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1994||1994-08-31|September 2005|2005-09-30|July 1999|Actual|1999-07-31|||||Interventional|||Peak Flow Monitoring in Older Adults With Asthma||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:43:54.369502|2018-06-01 04:43:54.369502
NCT00149461|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-01-16|2005-09-06|2005-09-08|Estimate|||||||2014-01-16|2014-01-17|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|July 2009|Actual|2009-07-31|April 2008|Actual|2008-04-30||Interventional|||Written Asthma Actions Plans Versus No Written Instructions In Specialty Care|The Efficacy of Written Treatment Plans in Asthma|Completed||N/A|407|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 04:43:54.449212|2018-06-01 04:43:54.449212
NCT00149448|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-04-13|2005-09-06|2005-09-08|Estimate|||||||2009-04-13|2009-04-14|Estimate|May 2004||2004-05-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Effectiveness of the TB Contact Priority Model||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:43:54.564335|2018-06-01 04:43:54.564335
NCT00149435|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2018-05-01|2005-09-06|2005-09-08|Estimate|||||||2018-05-01|2018-05-07|Actual|September 2005||2005-09-30|May 2018|2018-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Cardiovascular Health Study (CHS) Events Follow-up Study||Completed|||5888|Actual|University of Washington|||||f||||||||||||||2018-06-01 04:43:54.641125|2018-06-01 04:43:54.641125
NCT00149422|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-02-08|2005-09-06|2005-09-08|Estimate|||||||2010-02-08|2010-02-09|Estimate|June 2004||2004-06-30|August 2008|2008-08-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Effect of NT-proBNP Guided Treatment of Chronic Heart Failure|Can Pro-brain-natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?|Completed||N/A|||Netherlands Heart Foundation||2|||f||||t||||||||||2018-06-01 04:43:54.92229|2018-06-01 04:43:54.92229
NCT00149409|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-07-12|2005-09-06|2005-09-08|Estimate|||||||2010-07-12|2010-07-13|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure|Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure:Effects On Endothelial Function, Left Ventricular Remodelling, Natriuretic Peptide Levels, And Exercise Capacity|Completed||Phase 2/Phase 3|||Medical University of Vienna||3|||f||||||||||||||2018-06-01 04:43:55.031827|2018-06-01 04:43:55.031827
NCT00149396|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2015-12-29||2018-03-21|2005-09-06|2005-09-08|Estimate|2018-03-21|2018-04-24|Actual||||2018-03-21|2018-04-24|Actual|July 2004||2004-07-31|March 2018|2018-03-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver|A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver|Completed||Phase 1/Phase 2|32|Actual|MediGene||1|||f||||t||||||||No||2018-06-01 04:43:55.194823|2018-06-01 04:43:55.194823
NCT00149383|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-04-10|2005-09-06|2005-09-08|Estimate|||||||2015-04-10|2015-04-13|Estimate|December 2004||2004-12-31|April 2015|2015-04-30|January 2006|Actual|2006-01-31|November 2005|Actual|2005-11-30||Interventional|||Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria|A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection|Completed||Phase 1/Phase 2|140|Actual|Mahidol University||2|||f||||||||||||||2018-06-01 04:43:56.2868|2018-06-01 04:43:56.2868
NCT00149370|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|January 2001||2001-01-31|August 2005|2005-08-31|August 2003||2003-08-31|||||Observational|||Quality of Life Among Breast Reduction Patients|A Prospective Study of Patients Undergoing Breast Reduction Surgery: Health-Related Quality of Life and Clinical Outcomes|Completed|||52||McMaster University|||||f||||||||||||||2018-06-01 04:43:56.438536|2018-06-01 04:43:56.438536
NCT00149357|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-03-21|2005-09-06|2005-09-08|Estimate|||||||2017-03-21|2017-03-23|Actual|July 2005||2005-07-31|March 2017|2017-03-31|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Observational|||Fetal Loss in Women With Unprovoked Thromboembolism (FLUTE)|Determining the Risk of Fetal Loss in Women With Unprovoked Venous Thromboembolism (VTE) Who Do NOT Have Identifiable Inherited Thrombophilia Compared With Women Who Have the Diagnosis of VTE Excluded|Terminated|||239|Actual|McMaster University|||1|Funding withdrawn due to low enrollment|f||||t||||||||||2018-06-01 04:43:56.549401|2018-06-01 04:43:56.549401
NCT00149344|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-07-27|2005-09-06|2005-09-08|Estimate|||||||2011-07-27|2011-07-28|Estimate|September 2005||2005-09-30|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Vertical Scar Versus Inferior Pedicle Reduction Mammoplasty|Vertical Scar Versus Inferior Pedicle Reduction Mammoplasty: A Randomized Controlled Trial and Cost-Utility Analysis|Completed||N/A|254|Actual|McMaster University|||||f||||f||||||||||2018-06-01 04:43:56.649617|2018-06-01 04:43:56.649617
NCT00149331|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-09-07|2005-09-06|2005-09-08|Estimate|||||||2006-09-07|2006-09-11|Estimate|July 2005||2005-07-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||The Effects of Two Education Strategies About Insulin on Patient Preferences and Perceptions About Insulin Therapy|A Randomized Controlled Trial Comparing the Effects of Two Education Strategies About Insulin on Preferences and Perceptions About Insulin Therapy|Completed||Phase 4|86||McMaster University|||||f||||||||||||||2018-06-01 04:43:56.737306|2018-06-01 04:43:56.737306
NCT00149318|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-11-07|2005-09-06|2005-09-08|Estimate|||||||2014-11-07|2014-11-10|Estimate|December 2002||2002-12-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2008|Actual|2008-10-31||Observational|||Enzyme Replacement Therapy in Fabry Disease|Evaluation of the Long Term Efficacy of Enzyme Replacement Therapy in Fabry Disease|Terminated|||2|Actual|Mario Negri Institute for Pharmacological Research|||1|Difficulties in the patient's enrolment|f||||f||||||Samples With DNA|"~     Whole blood on EDTA. Serum. Urine samples.~   "|||2018-06-01 04:43:56.816668|2018-06-01 04:43:56.816668
NCT00149305|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-04-08|2005-09-07|2005-09-08|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2005||2005-05-31|October 2009|2009-10-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Observational|||Genetic Study of Nephrolithiasis in Gouty Diathesis|Genetic Study of Nephrolithiasis in Gouty Diathesis|Terminated|||37|Actual|Mario Negri Institute for Pharmacological Research|||2|Non significative preliminary data|f||||f||||||Samples With DNA|"~     Whole blood on EDTA~   "|||2018-06-01 04:43:56.926915|2018-06-01 04:43:56.926915
NCT00149292|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-07-31|2005-09-06|2005-09-08|Estimate|||||||2006-07-31|2006-08-01|Estimate|August 2005||2005-08-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||Study of LY2140023 in Schizophrenia|A Randomized, Double-Blind Comparison of LY2140023, Olanzapine, and Placebo in the Treatment of Patients With Schizophrenia|Completed||Phase 2|250||Eli Lilly and Company|||||f||||||||||||||2018-06-01 04:43:57.016223|2018-06-01 04:43:57.016223
NCT00149279|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2016-09-20|2005-09-07|2005-09-08|Estimate|||||||2016-09-20|2016-09-22|Estimate|July 1995||1995-07-31|September 2016|2016-09-30|April 2006||2006-04-30|||||Interventional|||A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer|Randomized Controlled Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer (JCOG9501)|Completed||Phase 3|520||Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:43:57.099278|2018-06-01 04:43:57.099278
NCT00149266|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-02-02|2005-09-07|2005-09-08|Estimate|||||||2009-02-02|2009-02-03|Estimate|July 1995||1995-07-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)|Randomized Controlled Trial to Evaluate Surgical Approaches to Gastric Cancer Invading the Esophagus (JCOG9502)|Terminated||Phase 3|167|Actual|Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:43:57.180841|2018-06-01 04:43:57.180841
NCT00149253|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|December 2004||2004-12-31|October 2004|2004-10-31|May 2005||2005-05-31|||||Interventional|||Pre-Emptive Analgesia Efficacy of Etoricoxib for Postoperative Pain|A Randomized, Double-Blind, Controlled Trial of Etoricoxib as a Pre-Emptive Analgesic for Abdominal Hysterectomy|Completed||Phase 3|50||Khon Kaen University|||||f||||||||||||||2018-06-01 04:43:57.261797|2018-06-01 04:43:57.261797
NCT00149240|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-09-29|2005-09-07|2005-09-08|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2005||2005-01-31|July 2007|2007-07-31|September 2005||2005-09-30|||||Interventional|||Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome|A Phase II, Multicentre, Randomised, Double-blind, Parallel and Controlled With Placebo Pilot Study to Evaluate the Efficacy and Safety of a Single Dose of Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment, in Patients With Primary Myofascial Syndrome of Cervical and Dorsal Localisation|Completed||Phase 2|24||Ipsen|||||f||||||||||||||2018-06-01 04:43:57.338589|2018-06-01 04:43:57.338589
NCT00149227|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2011-07-05||2012-12-09|2005-09-06|2005-09-08|Estimate|2012-12-09|2012-12-12|Estimate||||2012-12-09|2012-12-12|Estimate|January 2004||2004-01-31|December 2012|2012-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)|Add-on Effects of Valsartan on Morbi- Mortality in High Risk Hypertension|Completed||Phase 4|3031|Actual|Kyoto Prefectural University of Medicine|The study was performed using PROBE design, which does not exclude possible bias for softer endpoints such as angina and TIA. However, all softer endpoints were diagnosed by CAG and CT/MRI. We believe that under reporting would be unlikely.|2|||f||||t||||||||||2018-06-01 04:43:57.422672|2018-06-01 04:43:57.422672
NCT00149214|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2009-02-11||2012-03-15|2005-09-02|2005-09-08|Estimate|2009-03-26|2009-05-13|Estimate||||2012-03-15|2012-03-21|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|March 2011|Actual|2011-03-31|February 2008|Actual|2008-02-29||Interventional|||Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens|A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer|Completed||Phase 2|257|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:43:57.867693|2018-06-01 04:43:57.867693
NCT00149201|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-02-02|2005-09-07|2005-09-08|Estimate|||||||2009-02-02|2009-02-03|Estimate|November 2002||2002-11-30|February 2009|2009-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis|Randomized Phase III Study of 5-FU Continuous Infusion (5FUci) Versus MTX+5-FU Sequential Therapy (MF) in Gastric Cancer With Peritoneal Metastasis (JCOG0106-MF, MF/5FU)|Completed||Phase 3|160||Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:43:58.567023|2018-06-01 04:43:58.567023
NCT00149188|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2012-06-18|2005-09-07|2005-09-08|Estimate|||||||2012-06-18|2012-06-19|Estimate|February 2004||2004-02-29|June 2012|2012-06-30||||||||Interventional|||Somatuline Autogel: Acromegaly Self/Partner Injection Study|A Phase IV, Multicentre, Open Label, Controlled Study to Assess the Ability of Patients With Acromegaly, or Their Partners, to Administer Somatuline Autogel.|Completed||Phase 4|30||Ipsen|||||f||||||||||||||2018-06-01 04:43:58.672688|2018-06-01 04:43:58.672688
NCT00149175|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-03-12|2005-09-06|2005-09-08|Estimate|||||||2010-03-12|2010-03-15|Estimate|December 2002||2002-12-31|March 2010|2010-03-31|October 2007|Anticipated|2007-10-31|||||Observational|||Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment|Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment|Unknown status|Recruiting||4000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||||||||||||2018-06-01 04:43:58.749839|2018-06-01 04:43:58.749839
NCT00149162|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-02-11|2005-09-06|2005-09-08|Estimate|||||||2009-02-11|2009-02-12|Estimate|March 2005||2005-03-31|February 2009|2009-02-28|March 2012|Anticipated|2012-03-31|December 2010|Anticipated|2010-12-31||Interventional|Elam02||Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2|Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2|Unknown status|Recruiting|Phase 3|580|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:43:58.857779|2018-06-01 04:43:58.857779
NCT00149149|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-07-16|2005-09-07|2005-09-08|Estimate|||||||2007-07-16|2007-07-17|Estimate|May 2005||2005-05-31|September 2005|2005-09-30||||||||Interventional|||Effect of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers|Use of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers Taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)|Unknown status|Recruiting|Phase 1|12|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:43:59.011872|2018-06-01 04:43:59.011872
NCT00149136|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-04-26|2005-09-06|2005-09-08|Estimate|||||||2007-04-26|2007-04-27|Estimate|August 2002||2002-08-31|April 2007|2007-04-30||||||||Interventional|||Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.|Evaluation of Imatinib (GLIVEC) After Induction Therapy in Patients Aged More Than 55 Years With Philadelphia Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) : a Non Randomised, Controlled, Open, Multicentric, International Phase II Clinical Study (CSTI 571 AFR09 Trial)|Unknown status|Active, not recruiting|Phase 2|30||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:43:59.094905|2018-06-01 04:43:59.094905
NCT00149123|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-02-11|2005-09-06|2005-09-08|Estimate|||||||2015-02-11|2015-02-12|Estimate|April 2005||2005-04-30|October 2007|2007-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Low-dose Hydrocortisone in Acutely Burned Patients|Low-dose Hydrocortisone in the Treatment of the Shock of Burned Patients|Completed||Phase 4|40|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:43:59.157406|2018-06-01 04:43:59.157406
NCT00149110|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-08-04|2005-09-06|2005-09-08|Estimate|||||||2009-08-04|2009-08-06|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Chronos: the Use of Chronobiological Treatment in Depression|"The CHRONOS Study: Can the Sleep-deprivation Induced Antidepressive Effect in Patients With Major Depression be Sustained by Correction of Diurnal Rhythms, Long Term Light Treatment and Duloxetine Treatment?"|Completed||N/A|75|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-06-01 04:43:59.213997|2018-06-01 04:43:59.213997
NCT00149097|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-05-06|2005-09-06|2005-09-08|Estimate|||||||2008-05-06|2008-05-12|Estimate|March 2005||2005-03-31|May 2008|2008-05-31|January 2007|Actual|2007-01-31|||||Observational|||Role of the Autonomic Nervous System in HIV-Lipodystrophy|Autonomic Nervous System Activity in the Pathogenesis of the Lipodystrophy Syndrome in HIV-Infected Patients.|Completed|||54|Actual|Hannover Medical School|||||f||||f||||||Samples Without DNA|"~     Serum and Plasma~   "|||2018-06-01 04:43:59.301098|2018-06-01 04:43:59.301098
NCT00149084|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-09-08|2005-09-06|2005-09-08|Estimate|||||||2006-09-08|2006-09-11|Estimate|April 2003||2003-04-30|September 2005|2005-09-30||||||||Interventional|||Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori|Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori|Unknown status|Recruiting|Phase 3|296||Hamamatsu University|||||f||||||||||||||2018-06-01 04:43:59.375995|2018-06-01 04:43:59.375995
NCT00149071|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-11-02|2005-09-06|2005-09-08|Estimate|||||||2007-11-02|2007-11-05|Estimate|March 2004||2004-03-31|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression|Treatment of Therapy-Resistant Major Depression With Transcranial Stimulation rTMS in Combination With Escitalopram|Completed||N/A|61|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-06-01 04:43:59.473663|2018-06-01 04:43:59.473663
NCT00149058|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|October 2005||2005-10-31|September 2005|2005-09-30|January 2008||2008-01-31|||||Interventional|||Erythropoietin in Acute Myocardial Infarction|A Phase II Randomised Trial to Investigate the Safety and Efficacy of Recombinant Human Erythropoietin on Infarct Size in Patients Undergoing Primary Percutaneous Coronary Angioplasty for ST-Segment Elevation Myocardial Infarction|Unknown status|Not yet recruiting|Phase 2|124||Hammersmith Hospitals NHS Trust|||||f||||||||||||||2018-06-01 04:43:59.554854|2018-06-01 04:43:59.554854
NCT00149032|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-04-07|2005-09-07|2005-09-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|August 2001||2001-08-31|September 2005|2005-09-30||||||||Interventional|||Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host|Treatment of Patients With Resistant Cancer/ Post Allogeneic Stem Cell Transplantation With Donor Lymphocytes Sensitized by Antigens Expressed by the Host|Withdrawn||Phase 2|50|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:43:59.693861|2018-06-01 04:43:59.693861
NCT00149019|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-04-07|2005-09-07|2005-09-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|May 2002||2002-05-31|September 2005|2005-09-30|September 2005|Anticipated|2005-09-30|||||Interventional|||Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.|Innovative Approaches for Targeted Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.|Withdrawn||Phase 2|12|Anticipated|Hadassah Medical Organization||||the PI is no longer work at Hadassah|f||||||||||||||2018-06-01 04:43:59.752051|2018-06-01 04:43:59.752051
NCT00149006|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-03-13|2005-09-07|2005-09-08|Estimate|||||||2007-03-13|2007-03-14|Estimate|December 1996||1996-12-31|September 2005|2005-09-30||||||||Interventional|||Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors|Tumor-Selective and Systemic Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With rIL-2 and Non-Myeloablative Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|100|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:43:59.808293|2018-06-01 04:43:59.808293
NCT00148993|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-04-07|2005-09-07|2005-09-08|Estimate|||||||2011-04-07|2011-04-08|Estimate|July 1998||1998-07-31|July 2005|2005-07-31|July 2005|Anticipated|2005-07-31|||||Interventional|||Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors|Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors|Withdrawn||Phase 1/Phase 2|100|Anticipated|Hadassah Medical Organization||||PI (Prof. Slavin) not longer work at Hadassah|f||||||||||||||2018-06-01 04:43:59.867267|2018-06-01 04:43:59.867267
NCT00148980|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-04-27|2005-09-07|2005-09-08|Estimate|||||||2011-04-27|2011-04-28|Estimate|April 2003||2003-04-30|February 2006|2006-02-28||||||||Interventional|||Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation|Creation of Bone Marrow Microenvironment for Treatment of MDS in Conjunction With Allogeneic Stem Cell Transplantation|Withdrawn||Phase 2|24|Anticipated|Hadassah Medical Organization||||the PI is no longer work at Hadassah|f||||||||||||||2018-06-01 04:43:59.92641|2018-06-01 04:43:59.92641
NCT00148967|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2006-11-20|2005-09-07|2005-09-08|Estimate|||||||2006-11-20|2006-11-22|Estimate|July 2003||2003-07-31|November 2006|2006-11-30|October 2005||2005-10-31|||||Interventional|||INTRINSIC RV - Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs|Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs|Completed||Phase 4|1535||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:43:59.985397|2018-06-01 04:43:59.985397
NCT00148954|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2011-10-07||2012-01-10|2005-09-07|2005-09-08|Estimate|2011-11-21|2011-12-26|Estimate||||2012-01-10|2012-01-12|Estimate|July 2005||2005-07-31|January 2012|2012-01-31|July 2010|Actual|2010-07-31|March 2009|Actual|2009-03-31||Interventional|||RIGHT: Rhythm ID Going Head-to-Head Trial|Rhythm ID Going Head-to-head Trial|Completed||Phase 4|1962|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 04:44:00.050951|2018-06-01 04:44:00.050951
NCT00148941|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2016-10-06|2005-09-07|2005-09-08|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Immune Response & Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccine.|Safety, Immunogenicity&Consistency of 3 Manufacturing Lots of DTaP-IPV Vaccine vs Separate Injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV Admd as Booster Doses to Healthy Children 4-6 Yrs, Each Co-admd With Merck's MMR Vaccine|Completed||Phase 3|4087|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:44:00.292198|2018-06-01 04:44:00.292198
NCT00148928|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-06-01|2005-09-07|2005-09-08|Estimate|||||||2017-06-01|2017-06-02|Actual|March 1, 2005|Actual|2005-03-01|June 2017|2017-06-30|November 7, 2006|Actual|2006-11-07|November 7, 2006|Actual|2006-11-07||Interventional|||Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA|A Multicenter, Open-label Phase I/II Trial to Evaluate the Safety and Activity of CPC-P501 Protein Formulated With the Adjuvant AS15 as First-line Treatment in Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA|Completed||Phase 1|25|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:44:00.406323|2018-06-01 04:44:00.406323
NCT00148915|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-11-04|2005-09-06|2005-09-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|August 2005||2005-08-31|November 2016|2016-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo|A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150 mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis|Completed||Phase 4|98|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-06-01 04:44:00.47157|2018-06-01 04:44:00.47157
NCT00148902|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-12-04|2005-09-06|2005-09-08|Estimate|||||||2017-12-04|2017-12-06|Actual|April 28, 2003|Actual|2003-04-28|December 2017|2017-12-31|January 21, 2006|Actual|2006-01-21|January 21, 2006|Actual|2006-01-21||Interventional|||Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)|A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (Taxotere)|Completed||Phase 1|52|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 04:44:00.549984|2018-06-01 04:44:00.549984
NCT00148889|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2018-02-15|2005-09-07|2005-09-08|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2005||2005-07-31|February 2018|2018-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia|Prospective,Randomised, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Bilateral Globus Pallidus Internus - in Patients With Medically Refractory Primary Cervical Dystonia|Completed||Phase 3|63|Actual|German Parkinson Study Group (GPS)||2|||f||||f||||||||||2018-06-01 04:44:00.622238|2018-06-01 04:44:00.622238
NCT00148876|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2011-02-22|2005-09-07|2005-09-08|Estimate|||||||2011-02-22|2011-02-23|Estimate|September 2003||2003-09-30|February 2011|2011-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||TBP Study With Capecitabine Plus Minus Trastuzumab|A Multicenter Randomized Phase III Study to Compare Capecitabine Alone or in Combination With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer and Progression After Previous Treatment With Trastuzumab|Completed||Phase 3|482|Anticipated|German Breast Group||2|||f||||t||||||||||2018-06-01 04:44:00.698413|2018-06-01 04:44:00.698413
NCT00148863|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-08-29|2005-09-07|2005-09-08|Estimate|||||||2007-08-29|2007-08-30|Estimate|June 2004||2004-06-30|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C|Pilot Study on Interferon Gamma in Association With Peg-Interferon Alpha 2a and Ribavirin Among Patients With a Chronic Hepatitis C and Non Responders to the Association of Peg-Interferon Alpha 2b or 2a and Ribavirin ANRS HC16 Gammatri|Completed||Phase 2|65||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:44:00.88428|2018-06-01 04:44:00.88428
NCT00148850|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-10-19|2005-09-07|2005-09-08|Estimate|||||||2005-10-19|2005-10-20|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|October 2004||2004-10-31|||||Interventional|||Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients|A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study|Terminated||Phase 3|130||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:44:00.95311|2018-06-01 04:44:00.95311
NCT00148837|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-02-06|2005-09-07|2005-09-08|Estimate|||||||2008-02-06|2008-02-08|Estimate|September 2004||2004-09-30|February 2008|2008-02-29||||||||Interventional|||Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis|Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis|Unknown status|Active, not recruiting|Phase 2|112|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||f||||||||||2018-06-01 04:44:01.018256|2018-06-01 04:44:01.018256
NCT00148824|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-03-20|2005-09-07|2005-09-08|Estimate|||||||2008-03-20|2008-03-21|Estimate|February 2003||2003-02-28|March 2008|2008-03-31|January 2006|Actual|2006-01-31|||||Interventional|||Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.|Immunological Efficacy of a Prime-Boost Strategy Combining a 7-Valent Pneumococcal Conjugate Vaccine (PCV) Followed by a 23-Valent Pneumococcal Polysaccharide Vaccine (PPV) Versus PPV Alone in HIV-Infected Adults. ANRS 114 PNEUMOVAC.|Completed||Phase 2|212||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:44:01.085772|2018-06-01 04:44:01.085772
NCT00148798|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2011-08-24||2014-06-13|2005-09-07|2005-09-08|Estimate|2011-08-24|2011-10-04|Estimate||||2014-06-13|2014-06-25|Estimate|October 2004||2004-10-31|June 2014|2014-06-30|May 2012|Actual|2012-05-31|July 2007|Actual|2007-07-31||Interventional|FLEX||Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)|Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC.|Completed||Phase 3|1861|Actual|Merck KGaA||2|||f||||t||||||||||2018-06-01 04:44:01.193562|2018-06-01 04:44:01.193562
NCT00148785|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-11-08|2005-09-07|2005-09-08|Estimate|||||||2013-11-08|2013-11-11|Estimate|July 2005||2005-07-31|November 2013|2013-11-30|January 2007|Actual|2007-01-31|||||Interventional|||A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir|Pharmacokinetics of an Indinavir, Ritonavir and Amprenavir Regimen in HIV-Infected Individuals: A Pilot Study|Completed||Phase 4|15|Anticipated|Emory University|||||f||||||||||||||2018-06-01 04:44:04.314507|2018-06-01 04:44:04.314507
NCT00148772|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-06-24|2005-09-06|2005-09-08|Estimate|||||||2011-06-24|2011-06-28|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy|Phase II Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising PSA on Hormone Therapy|Completed||Phase 2|29|Anticipated|NorthShore University HealthSystem Research Institute|||||f||||||||||||||2018-06-01 04:44:04.383512|2018-06-01 04:44:04.383512
NCT00148759|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2009-11-24||2013-11-08|2005-09-07|2005-09-08|Estimate|2013-08-15|2013-10-22|Estimate||||2013-11-08|2013-12-03|Estimate|June 2005||2005-06-30|November 2013|2013-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|LPVGenderPK||Kaletra Sex/Gender Pharmacokinetics (PK) Study|A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir: A 24-hour Pharmacokinetic Profile to Evaluate Sex Differences|Completed||Phase 4|23|Actual|Emory University||2|||f||||f||||||||||2018-06-01 04:44:04.461781|2018-06-01 04:44:04.461781
NCT00148746|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-06-08|2005-09-06|2005-09-08|Estimate|||||||2010-06-08|2010-06-09|Estimate|May 2004||2004-05-31|June 2010|2010-06-30|March 2008|Actual|2008-03-31|September 2006|Actual|2006-09-30||Interventional|||Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis|Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis|Completed||N/A|||Technische Universität Dresden|||||f||||||||||||||2018-06-01 04:44:04.691782|2018-06-01 04:44:04.691782
NCT00148733|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2015-02-02||2017-01-30|2005-09-06|2005-09-08|Estimate|2015-02-02|2015-02-16|Estimate||||2017-01-30|2017-03-10|Actual|January 2004||2004-01-31|January 2017|2017-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia|Community- and Health Facility-based Intervention With Zinc as Adjuvant Therapy for Pneumonia to Enhance Child Health and Nutrition|Completed||Phase 2/Phase 3|2628|Actual|Centre For International Health||2|||f||||t||||||||No||2018-06-01 04:44:04.766359|2018-06-01 04:44:04.766359
NCT00148720|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2015-11-09|2005-09-07|2005-09-08|Estimate|||||||2015-11-09|2015-11-11|Estimate|September 2004||2004-09-30|November 2015|2015-11-30||||September 2007|Actual|2007-09-30||Interventional|||Capecitabine in Women With Operable Breast Cancer|A Phase II Study of Preoperative Capecitabine in Women With Operable Breast Cancer|Terminated||Phase 2|80|Anticipated|Dana-Farber Cancer Institute||||Slow accrual|f||||||||||||||2018-06-01 04:44:05.014304|2018-06-01 04:44:05.014304
NCT00148707|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-12-19|2005-09-07|2005-09-08|Estimate|||||||2007-12-19|2007-12-21|Estimate|October 2004||2004-10-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer|Phase II Study of CT-2103 in Patients With Metastatic Breast Cancer|Completed||Phase 2|45||Dana-Farber Cancer Institute|||||||||||||||||||2018-06-01 04:44:05.149826|2018-06-01 04:44:05.149826
NCT00148694|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2016-08-29|2005-09-07|2005-09-08|Estimate|||||||2016-08-29|2016-08-31|Estimate|July 2004||2004-07-31|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2006|Actual|2006-05-31||Interventional|||Preoperative Cisplatin in Early Stage Breast Cancer|A Phase II Trial of Cisplatin in Early Stage ER-, PR-, HER-2 Negative Breast Cancer|Completed||Phase 2|27|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 04:44:05.227966|2018-06-01 04:44:05.227966
NCT00148681|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2009-10-30|2005-09-07|2005-09-08|Estimate|||||||2009-10-30|2009-11-02|Estimate|May 2001||2001-05-31|October 2009|2009-10-31|April 2010|Anticipated|2010-04-30|May 2003|Actual|2003-05-31||Interventional|||Preoperative Herceptin and Navelbine for Breast Cancer|Preoperative Herceptin and Navelbine in Early Stage, HER-2 Positive Breast Cancer|Unknown status|Active, not recruiting|Phase 2|49|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 04:44:05.315049|2018-06-01 04:44:05.315049
NCT00148668|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|2012-12-19||2013-03-29|2005-09-07|2005-09-08|Estimate|2012-12-19|2013-01-25|Estimate||||2013-03-29|2013-04-09|Estimate|December 2003||2003-12-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|January 2009|Actual|2009-01-31||Interventional|||Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer|A Randomized Phase II Study of Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Early Stage, HER-2 Positive Breast Cancer|Completed||Phase 2|81|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 04:44:05.416775|2018-06-01 04:44:05.416775
NCT00148655|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-12-22|2005-09-07|2005-09-08|Estimate|||||||2007-12-22|2007-12-28|Estimate|May 2003||2003-05-31|December 2007|2007-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Educational Interventions for Patients With DCIS|A Randomized Trial for Educational Interventions for Patients With DCIS Actually Making Treatment Decisions|Completed||N/A|120|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:44:05.646294|2018-06-01 04:44:05.646294
NCT00148642|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-01-14|2005-09-06|2005-09-08|Estimate|||||||2017-01-14|2017-01-18|Estimate|November 2002||2002-11-30|January 2017|2017-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|NASCENT||Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)|Multi-center Clinical Trial of the Bard Silver-coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)|Completed||Phase 3|2003|Actual|C. R. Bard||2|||f||||t||||||||||2018-06-01 04:44:05.726111|2018-06-01 04:44:05.726111
NCT00148629|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-11-16|2005-09-06|2005-09-08|Estimate|||||||2005-11-16|2005-11-18|Estimate|April 2004||2004-04-30|September 2005|2005-09-30||||||||Interventional|||Treatment and Prevention of Severe Anemia in Pregnant Zanzibari Women|Preventing Unnecessary Blood Transfusions in Pregnant Women in Africa Through Effective Primary Health Care|Unknown status|Active, not recruiting|Phase 3|2500||Cornell University|||||f||||||||||||||2018-06-01 04:44:05.810106|2018-06-01 04:44:05.810106
NCT00148616|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-10-17|2005-09-07|2005-09-08|Estimate|||||||2013-10-17|2013-10-18|Estimate|April 2004||2004-04-30|October 2013|2013-10-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Memantine for the Treatment of Negative Symptomatology|Memantine for the Treatment of Negative Symptomatology and Cognitive Impairment in Schizophrenia|Terminated||Phase 3|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 04:44:05.871929|2018-06-01 04:44:05.871929
NCT00148603|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-12-26|2005-09-06|2005-09-08|Estimate|||||||2011-12-26|2011-12-29|Estimate|September 2005||2005-09-30|December 2011|2011-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Montelukast in the Treatment of Duodenal Eosinophilia|Montelukast in the Treatment of Duodenal Eosinophilia in Children With Dyspepsia: Effect on Eosinophil Density and Activation in Relation to Pharmacokinetics|Completed||N/A|24|Anticipated|Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:44:05.934808|2018-06-01 04:44:05.934808
NCT00148590|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-10-17|2005-09-07|2005-09-08|Estimate|||||||2013-10-17|2013-10-18|Estimate|November 2005||2005-11-30|October 2013|2013-10-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Memantine for the Prevention of Negative Symptomatology|Memantine for the Prevention of Negative Symptomatology and Cognitive Impairment in Schizophrenia|Terminated||Phase 3|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 04:44:05.992676|2018-06-01 04:44:05.992676
NCT00148577|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-07|2005-09-07|2005-09-08|Estimate|||||||2005-09-07|2005-09-08|Estimate|August 2002||2002-08-31|September 2005|2005-09-30|December 2003||2003-12-31|||||Observational|||Pain Relief by Applying TENS on Acupuncture Points During the First Stage of Labour|Pain Relief by Applying Transcutaneous Electrical Nerve Stimulation (TENS) on Acupuncture Points During the First Stage of Labour: a Randomised Controlled Trial|Unknown status|Active, not recruiting||100||Chang Gung Memorial Hospital|||||f||||||||||||||2018-06-01 04:44:06.059222|2018-06-01 04:44:06.059222
NCT00148564|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-09-26|2005-09-07|2005-09-08|Estimate|||||||2008-09-26|2008-09-29|Estimate|March 2004||2004-03-31|September 2008|2008-09-30|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Energy Homeostasis Under Treatment With Atypical Antipsychotics|Energy Homeostasis and Metabolism in Patients With Schizophrenic Disorders Under Treatment With Atypical Antipsychotics|Completed||Phase 4|40|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 04:44:06.1089|2018-06-01 04:44:06.1089
NCT00148551|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-07-26|2005-09-06|2005-09-08|Estimate|||||||2007-07-26|2007-07-30|Estimate|January 2004||2004-01-31|July 2007|2007-07-31|March 2008|Anticipated|2008-03-31|||||Interventional|||Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.|Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.|Unknown status|Active, not recruiting|Phase 2/Phase 3|120|Anticipated|Canadian Retinal Trials Group|||||f||||||||||||||2018-06-01 04:44:06.171455|2018-06-01 04:44:06.171455
NCT00148538|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2013-02-25|2005-09-06|2005-09-08|Estimate|||||||2013-02-25|2013-02-27|Estimate|July 2005||2005-07-31|February 2013|2013-02-28|April 2012|Actual|2012-04-30|December 2010|Actual|2010-12-31||Interventional|||Type 1 Diabetes Aerobic and Resistance Exercise (T1-DARE)|Type 1 Diabetes Aerobic and Resistance Exercise (T1-DARE)|Completed||Phase 2/Phase 3|66|Actual|Ottawa Hospital Research Institute||1|||f||||||||||||||2018-06-01 04:44:06.265066|2018-06-01 04:44:06.265066
NCT00148525|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-07-01|2005-09-06|2005-09-08|Estimate|||||||2015-07-01|2015-07-02|Estimate|July 2006||2006-07-31|June 2011|2011-06-30|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|||The Study of Automated Telephone Programs for the Maintenance of Dietary Change|Trial of 2 TeleComputer Diet Change Maintenance Programs|Completed||Phase 1|1049|Actual|Boston Medical Center||3|||f||||t||||||||||2018-06-01 04:44:06.401079|2018-06-01 04:44:06.401079
NCT00148512|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-10-28|2005-09-07|2005-09-08|Estimate|||||||2013-10-28|2013-10-29|Estimate|March 2003||2003-03-31|October 2013|2013-10-31|February 2005||2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations|A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)|Completed||Phase 2|254|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:44:06.492976|2018-06-01 04:44:06.492976
NCT00148499|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2017-12-27|2005-09-07|2005-09-08|Estimate|||||||2017-12-27|2017-12-28|Actual|October 2005||2005-10-31|December 2017|2017-12-31|June 2006||2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis|Efficacy and Tolerability of Ambroxol Lozenge 20 mg in Relieving Pain of Sore Throat in Patients With Acute Viral Pharyngitis-A Randomised, Double-blind,Placebo- and Active-controlled Parallel Group Study|Completed||Phase 3|751||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:44:06.635682|2018-06-01 04:44:06.635682
NCT00148486|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-10-28|2005-09-07|2005-09-08|Estimate|||||||2013-10-28|2013-10-29|Estimate|June 2003||2003-06-30|October 2013|2013-10-31||||March 2005|Actual|2005-03-31||Interventional|||A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)|A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)|Completed||Phase 2|261||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:44:06.730446|2018-06-01 04:44:06.730446
NCT00148473|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-08|Estimate|||||||2005-09-06|2005-09-08|Estimate|March 2000||2000-03-31|September 2005|2005-09-30|October 2001||2001-10-31|||||Interventional|||Oral Versus Vaginal Misoprostol for Induction of Labor|A Single Dose of Oral Versus Vaginal Misoprostol for Induction of Labor: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|180||Bangkok Metropolitan Administration Medical College and Vajira Hospital|||||f||||||||||||||2018-06-01 04:44:06.880949|2018-06-01 04:44:06.880949
NCT00148460|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2013-10-28|2005-09-07|2005-09-08|Estimate|||||||2013-10-28|2013-10-29|Estimate|March 2001||2001-03-31|October 2013|2013-10-31|February 2006||2006-02-28|||||Interventional|||Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction|A Randomised, Open-label, Multi-center, Angiographic Trial to Compare the Efficacy and Safety of Single Bolus of Tenecteplase (Metalyse®) With Accelerated Infusion of Alteplase in Asian Patients With Acute Myocardial Infarction|Completed||Phase 3|270||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:44:06.951265|2018-06-01 04:44:06.951265
NCT00148447|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-05-02|2005-09-06|2005-09-08|Estimate|||||||2007-05-02|2007-05-03|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|September 2005||2005-09-30|||||Interventional|||The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia|Placebo-Controlled Trial of Cipralex in the Treatment of Negative Symptoms in Schizophrenia|Completed||Phase 3|40||BeerYaakov Mental Health Center|||||f||||f||||||||||2018-06-01 04:44:07.036264|2018-06-01 04:44:07.036264
NCT00148434|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2005-09-26|2005-09-07|2005-09-08|Estimate|||||||2005-09-26|2005-09-27|Estimate|January 2002||2002-01-31|September 2005|2005-09-30|March 2003||2003-03-31|||||Interventional|||Study on Impact of Patient-Held Guidelines on Blood Pressure|A Pilot Randomised Controlled Trial to Assess the Impact on Blood Pressure Control of Empowering Patients to Become Involved in Their Own Blood Pressure Management.|Completed||Phase 2|300||Ashgrove Research Practice|||||f||||||||||||||2018-06-01 04:44:07.102623|2018-06-01 04:44:07.102623
NCT00148421|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-05-13|2005-09-06|2005-09-08|Estimate|||||||2013-05-13|2013-05-15|Estimate||||May 2013|2013-05-31||||||||Interventional|||Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.|A Study of Darbepoetin Alfa Administered Once Every 2 Weeks (Q2W) Compared With Epoetin Alfa Administered Once Every Week (QW) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.|Completed||Phase 3|||Amgen|||||f||||||||||||||2018-06-01 04:44:07.161063|2018-06-01 04:44:07.161063
NCT00148408|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-04-28|2005-09-07|2005-09-08|Estimate|||||||2010-04-28|2010-04-30|Estimate|December 2003||2003-12-31|September 2006|2006-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Trial of Asthma Patient Education (TAPE)|Trial of Asthma Patient Education (TAPE)|Completed||Phase 4|600||American Lung Association Asthma Clinical Research Centers|||||f||||||||||||||2018-06-01 04:44:07.232091|2018-06-01 04:44:07.232091
NCT00148395|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2008-04-21|2005-09-07|2005-09-08|Estimate|||||||2008-04-21|2008-04-22|Estimate|June 2002||2002-06-30|April 2008|2008-04-30|April 2008|Actual|2008-04-30|||||Interventional|||Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.|Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.|Completed||Phase 3|280||Aktion Bronchialkarzinom e.V.|||||f||||||||||||||2018-06-01 04:44:07.317081|2018-06-01 04:44:07.317081
NCT00148382|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-07|||2007-04-10|2005-09-07|2005-09-08|Estimate|||||||2007-04-10|2007-04-11|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|July 2005||2005-07-31|||||Interventional|||Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects|Randomized, Double Blind, Parallel Group, Repeat Dose Pharmacokinetic and Pharmacodynamic Study of Four Doses of ATL-962 (40mg, 80mg, 120mg 240mg) in Otherwise-Healthy Obese Volunteers|Completed||Phase 1|80||Alizyme|||||f||||||||||||||2018-06-01 04:44:07.368652|2018-06-01 04:44:07.368652
NCT00148369|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-02-18|2005-09-06|2005-09-08|Estimate|||||||2010-02-18|2010-02-19|Estimate|June 2005||2005-06-30|February 2010|2010-02-28|September 2007|Actual|2007-09-30|November 2006|Actual|2006-11-30||Observational|||A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin|A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin|Completed|||31|Actual|Amgen|||1||f||||||||||None Retained|"~     none collected.~   "|||2018-06-01 04:44:07.418165|2018-06-01 04:44:07.418165
NCT00148356|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-03-31|2005-09-06|2005-09-08|Estimate|||||||2011-03-31|2011-04-01|Estimate|September 2004||2004-09-30|March 2011|2011-03-31|October 2010|Actual|2010-10-31|May 2006|Actual|2006-05-31||Interventional|ZoMaxx™ I||Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries|A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System Compared to the TAXUS™ Express2 Paclitaxel-Eluting Coronary Stent System in de Novo Coronary Artery Lesions|Completed||Phase 2/Phase 3|401|Actual|Abbott Vascular||2|||f||||t||||||||||2018-06-01 04:44:07.473649|2018-06-01 04:44:07.473649
NCT00148343|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2011-12-22|2005-09-02|2005-09-07|Estimate|||||||2011-12-22|2011-12-23|Estimate|July 2005||2005-07-31|December 2011|2011-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Functional Electrical Stimulation for Footdrop in Hemiparesis|Functional Electrical Stimulation for Footdrop in Hemiparesis|Completed||Phase 2|110|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-06-01 04:44:07.68296|2018-06-01 04:44:07.68296
NCT00148330|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-06-29|2005-09-06|2005-09-07|Estimate|||||||2010-06-29|2010-06-30|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study|An Open Label Extension of the Phase II/III Clinical Trial of Intravitreal Triamcinolone on the Effects and Safety of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment|Completed||Phase 2/Phase 3|64|Actual|University of Sydney|||||f||||t||||||||||2018-06-01 04:44:07.789527|2018-06-01 04:44:07.789527
NCT00147953|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2010-01-26|2005-09-02|2005-09-07|Estimate|||||||2010-01-26|2010-01-27|Estimate|June 2004||2004-06-30|January 2010|2010-01-31||||||||Interventional|||Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma|A Phase II Study of Rituximab Plus Low-Dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma|Completed||Phase 2|30|Anticipated|University of Cologne|||||f||||||||||||||2018-06-01 04:44:10.853046|2018-06-01 04:44:10.853046
NCT00148317|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2017-02-24||2017-06-19|2005-09-06|2005-09-07|Estimate|2017-06-19|2017-07-18|Actual||||2017-06-19|2017-07-18|Actual|June 2005||2005-06-30|June 2017|2017-06-30|November 2012|Actual|2012-11-30|February 2011|Actual|2011-02-28||Interventional|||Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma|A Sequential Phase II Trial of the Combination of Bortezomib (VELCADE), Dexamethasone (DECADRON) and Pegylated Liposomal Doxorubicin (DOXIL) Followed by High Dose Cyclophosphamide in Multiple Myeloma Patients|Completed||Phase 2|38|Actual|Weill Medical College of Cornell University||1|||f||||||||||||||2018-06-01 04:44:07.892734|2018-06-01 04:44:07.892734
NCT00148304|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2016-06-03|2005-09-02|2005-09-07|Estimate|||||||2016-06-03|2016-06-06|Estimate|September 2005||2005-09-30|June 2016|2016-06-30|June 2008|Actual|2008-06-30|August 2007|Actual|2007-08-31||Observational|||Insulin Treatment Variation in Southwestern Diabetics|Insulin Treatment Variation in Southwestern Diabetics - Therapeutic Decision-making|Completed|||1248|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:44:08.301567|2018-06-01 04:44:08.301567
NCT00148291|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-01-05|2005-09-06|2005-09-07|Estimate|||||||2006-01-05|2006-01-06|Estimate|June 1999||1999-06-30|September 2005|2005-09-30||||||||Interventional|||Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer|Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|180||West Japan Thoracic Oncology Group|||||f||||||||||||||2018-06-01 04:44:08.379494|2018-06-01 04:44:08.379494
NCT00148278|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2010-07-21|2005-09-02|2005-09-07|Estimate|||||||2010-07-21|2010-07-22|Estimate|October 1999||1999-10-31|July 2010|2010-07-31|December 2005|Actual|2005-12-31|December 2004|Actual|2004-12-31||Interventional|CATS||Norepinephrine Plus Dobutamine Versus Epinephrine Alone for the Management of Septic Shock|Prospective, Multicenter, Randomized, Double-Blind Study Comparing Safety and Efficacy of Norepinephrine Plus Dobutamine Versus Epinephrine Alone in Septic Shock.|Completed||Phase 2/Phase 3|330|Actual|University of Versailles||2|||f||||t||||||||||2018-06-01 04:44:08.431084|2018-06-01 04:44:08.431084
NCT00148265|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-06-21|2005-09-06|2005-09-07|Estimate|||||||2010-06-21|2010-06-23|Estimate|April 2005||2005-04-30|November 2005|2005-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema|Phase II/III Multicentre Randomised Clinical Trial of Laser Treatment Plus 4 mg Intravitreal Triamcinolone Injection to Reduce Diabetic Macular Oedema|Completed||Phase 2/Phase 3|54|Actual|University of Sydney|||||f||||t||||||||||2018-06-01 04:44:08.528793|2018-06-01 04:44:08.528793
NCT00148252|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-06-06|2005-09-06|2005-09-07|Estimate|||||||2012-06-06|2012-06-07|Estimate|February 2003||2003-02-28|June 2012|2012-06-30|February 2007|Actual|2007-02-28|November 2005|Actual|2005-11-30||Interventional|||Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant|Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant - Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)|Terminated||Phase 4|298||University of Oslo School of Pharmacy||||To high rejection rate in CsA withdrawal arm|f||||||||||||||2018-06-01 04:44:08.603874|2018-06-01 04:44:08.603874
NCT00148239|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-11-30|2005-09-06|2005-09-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2002||2002-09-30|November 2015|2015-11-30|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Interventional|SCI||Health Interventions for Survivors and Primary Support Persons of Spinal Cord Injury|Caregiver Intervention for Caregivers of SCI Patients|Completed||Phase 2/Phase 3|380|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 04:44:08.680382|2018-06-01 04:44:08.680382
NCT00148226|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2006-01-03|2005-09-05|2005-09-07|Estimate|||||||2006-01-03|2006-01-04|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||ICIBS Trial - Improving Patient Information About Bowel Cancer Screening - a Decision Aid Trial|Randomized Controlled Trial of Patient Decision Aids for Faecal Occult Blood Test Screening|Completed||Phase 2|||University of Sydney|||||f||||||||||||||2018-06-01 04:44:08.752421|2018-06-01 04:44:08.752421
NCT00148213|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-07|Estimate|||||||2005-09-06|2005-09-07|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|June 2005||2005-06-30|||||Observational|||Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma|Clinical Evaluation of a New Highly Sensitive Thyroglobulin Assay in Differentiated Thyroid Carcinoma|Completed|||100||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:44:08.801518|2018-06-01 04:44:08.801518
NCT00148200|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-02-17|2005-09-02|2005-09-07|Estimate|||||||2009-02-17|2009-02-18|Estimate|February 2005||2005-02-28|February 2009|2009-02-28|February 2007|Actual|2007-02-28|November 2006|Actual|2006-11-30||Observational|||Female Sexual Dysfunction: Prevalence Among Italian Healthy Women|Prevalence of Female Sexual Dysfunctions Among Healthy Women Coming to the University of Bologna Gynecology Clinic as Outpatients.|Completed|||500|Actual|Unita Complessa di Ostetricia e Ginecologia|||||f||||||||||||||2018-06-01 04:44:08.858421|2018-06-01 04:44:08.858421
NCT00148187|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-05-28|2005-09-02|2005-09-07|Estimate|||||||2015-05-28|2015-06-01|Estimate|January 2003||2003-01-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Prediction of Medication Compliance Following Renal Transplantation|Prediction of Medication Compliance Following Renal Transplantation|Completed|||30|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 04:44:08.917999|2018-06-01 04:44:08.917999
NCT00148174|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-05-28|2005-09-02|2005-09-07|Estimate|||||||2015-05-28|2015-06-01|Estimate|August 1998||1998-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Predictors and Intervention for Noncompliance|Predictors and Intervention for Noncompliance|Completed||N/A|273|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-06-01 04:44:08.977029|2018-06-01 04:44:08.977029
NCT00148161|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-04-26|2005-09-06|2005-09-07|Estimate|||||||2007-04-26|2007-04-27|Estimate|November 2004||2004-11-30|September 2006|2006-09-30||||||||Observational|||Activity of the Auditory Cortex During Speech Perception and Speech Production in Stuttering|Evoked and Induced Auditory Cortical Activity During Speech Perception and Speech Production in Stuttering|Unknown status|Recruiting||20|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:44:09.038821|2018-06-01 04:44:09.038821
NCT00148148|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-01-09|2005-09-06|2005-09-07|Estimate|||||||2008-01-09|2008-01-16|Estimate|May 2004||2004-05-31|January 2007|2007-01-31|December 2007||2007-12-31|||||Interventional|||A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation|Phase II Randomised Study of the Safety, Efficacy and Pharmacokinetics of Caspofungin (CAS), Liposomal Amphotericin B (LAMB) or the Combination of Caspofungin With Liposomal Amphotericin B for Patients After Stem-Cell Transplantation|Completed||Phase 2|75|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:44:09.095993|2018-06-01 04:44:09.095993
NCT00148135|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-12-28|2005-09-06|2005-09-07|Estimate|||||||2007-12-28|2008-01-10|Estimate|May 2001||2001-05-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|April 2006|Actual|2006-04-30||Interventional|||Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site|A Phase II Trial Evaluating the Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site|Terminated||Phase 2|||University of Michigan Cancer Center||||recruitment goals met|f||||||||||||||2018-06-01 04:44:09.149033|2018-06-01 04:44:09.149033
NCT00148122|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2014-02-13||2014-03-28|2005-09-06|2005-09-07|Estimate|2014-02-13|2014-03-28|Estimate||||2014-03-28|2014-04-17|Estimate|November 2002||2002-11-30|March 2014|2014-03-31|July 2010|Actual|2010-07-31|August 2008|Actual|2008-08-31||Interventional||Although 40 patients were enrolled, 2 patients withdrew consent after treatment started, therefore only 38 were included in baseline analysis.|A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer|A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients With Metastatic or Advanced, Locally, Recurrent Head and Neck Cancer|Completed||Phase 2|40|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:44:09.215558|2018-06-01 04:44:09.215558
NCT00148109|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2011-04-12||2013-01-15|2005-09-06|2005-09-07|Estimate|2011-08-08|2011-09-12|Estimate||||2013-01-15|2013-01-24|Estimate|June 2005||2005-06-30|January 2013|2013-01-31|December 2009|Actual|2009-12-31|July 2008|Actual|2008-07-31||Interventional|||Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas|Phase II Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas|Completed||Phase 2|36|Actual|University of Michigan Cancer Center|accrual to EGFR + cohort suspended after first step for lack of efficacy of cetuximab.|2|||f||||t||||||||||2018-06-01 04:44:09.667668|2018-06-01 04:44:09.667668
NCT00148096|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-12-23|2005-09-02|2005-09-07|Estimate|||||||2009-12-23|2009-12-24|Estimate|February 2003||2003-02-28|November 2007|2007-11-30|April 2007|Actual|2007-04-30|||||Interventional|||Mechanical Heat Recovery Ventilation on House Dust Mite Sensitive Asthma|Randomised Controlled Trial of Mechanical Heat Recovery Ventilation on Asthma Control of Patients Allergic to the House Dust Mite|Completed||Phase 2|119|Actual|University of Glasgow||2|||f||||f||||||||||2018-06-01 04:44:09.980866|2018-06-01 04:44:09.980866
NCT00148083|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-02-27|2005-09-02|2005-09-07|Estimate|||||||2006-02-27|2006-03-01|Estimate|September 2005||2005-09-30|August 2005|2005-08-31|August 2007||2007-08-31|||||Interventional|||Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia|Efficacy of Risperidone Consta for Improving Ability to Benefit From Skills Training in Schizophrenia|Unknown status|Recruiting|Phase 3|60||University of Illinois at Chicago|||||f||||||||||||||2018-06-01 04:44:10.066988|2018-06-01 04:44:10.066988
NCT00148070|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-10-03|2005-09-02|2005-09-07|Estimate|||||||2012-10-03|2012-10-05|Estimate|March 1999||1999-03-31|October 2012|2012-10-31|February 2006|Actual|2006-02-28|September 2004|Actual|2004-09-30||Interventional|||Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer|Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer|Completed||Phase 2|45|Actual|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:44:10.152914|2018-06-01 04:44:10.152914
NCT00148057|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-07|Estimate|||||||2005-09-02|2005-09-07|Estimate|January 1988||1988-01-31|August 2005|2005-08-31|December 2005||2005-12-31|||||Interventional|||Diet and Breast Cancer Prevention Trial|An Explanatory Clinical Trial of Breast Cancer Prevention|Completed||Phase 3|4695||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:44:10.218814|2018-06-01 04:44:10.218814
NCT00148044|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-12-19|2005-09-06|2005-09-07|Estimate|||||||2007-12-19|2007-12-28|Estimate|October 2003||2003-10-31|December 2007|2007-12-31|February 2004|Actual|2004-02-29|||||Observational|||Uremic Toxins of Patients With Acute Kidney Failure|Uremic Toxins of Patients With Acute Kidney Failure|Completed|||30||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:44:10.27987|2018-06-01 04:44:10.27987
NCT00148031|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-04-23|2005-09-06|2005-09-07|Estimate|||||||2013-04-23|2013-04-24|Estimate|September 2003||2003-09-30|April 2013|2013-04-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Improving Hepatitis C Treatment in Injection Drug Users|Improving Hepatitis C Treatment in Injection Drug Users|Completed||Phase 4|111|Actual|State University of New York - Upstate Medical University||2|||f||||t||||||||||2018-06-01 04:44:10.337342|2018-06-01 04:44:10.337342
NCT00148018|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-07-09|2005-09-02|2005-09-07|Estimate|||||||2008-07-09|2008-07-10|Estimate|March 2005||2005-03-31|September 2006|2006-09-30||||||||Interventional|||Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma|A Phase II Study of Bortezomib in Combination With Dexamethasone in Patients With Relapsed Hodgkin's Lymphoma|Terminated||Phase 2|37||University of Cologne|||||f||||||||||||||2018-06-01 04:44:10.418482|2018-06-01 04:44:10.418482
NCT00148005|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-12-19|2005-09-06|2005-09-07|Estimate|||||||2007-12-19|2007-12-28|Estimate|September 2004||2004-09-30|December 2007|2007-12-31||||||||Interventional|||Prevalence, Etiology and Therapy of Micturition Disorders of Children With a Mental and/or Motoric Disability|Prevalence, Etiology and Therapy of Micturition Disorders of Children With a Mental and/or Motoric Disability|Completed||N/A|250||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:44:10.485324|2018-06-01 04:44:10.485324
NCT00147992|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-06-02|2005-09-06|2005-09-07|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2005||2005-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction|Immediate Loading of Implants in Totally Edentate Upper and Lower Jaw. A Retrospective Trial to Evaluate Survival of the Implants and Bridges, Quality of Prosthetic Work and Patient Satisfaction|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:44:10.547172|2018-06-01 04:44:10.547172
NCT00147979|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-12-04|2005-09-06|2005-09-07|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2004||2004-04-30|December 2014|2014-12-31|August 2013|Actual|2013-08-31|January 2009|Actual|2009-01-31||Interventional|||Multicentric, Prospective, Randomized, Comparing Trial Between Bypass of the Femoropoplitea by PTFE and Heparin Bounded PTFE|Multicentric, Prospective, Randomized, Comparing Trial Between Bypass of the Femoropoplitea by PTFE and Heparin Bounded PTFE|Completed||N/A|596|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-06-01 04:44:10.613176|2018-06-01 04:44:10.613176
NCT00147966|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2010-03-19||2010-03-22|2005-09-02|2005-09-07|Estimate|2010-03-22|2010-03-23|Estimate||||2010-03-22|2010-03-23|Estimate|June 2008||2008-06-30|June 2008|2008-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)|Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies|Completed||Phase 2|24|Actual|University of California, San Diego||1|||f||||f||||||||||2018-06-01 04:44:10.696697|2018-06-01 04:44:10.696697
NCT00145860|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-09-04|2005-09-02|2005-09-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|April 2002||2002-04-30|September 2013|2013-09-30|August 2005||2005-08-31|||||Observational|||Do Patients With Colorectal Cancer Understand That Their Family is at Risk?|Do Patients With Colorectal Cancer Understand That Their Family is at Increased Risk?|Terminated|||650||University of Chicago|||||f||||||||||||||2018-06-01 04:44:55.872638|2018-06-01 04:44:55.872638
NCT00147940|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-06-11|2005-09-06|2005-09-07|Estimate|||||||2013-06-11|2013-06-12|Estimate|April 2004||2004-04-30|June 2013|2013-06-30|August 2005||2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Correlation of Nasal Volume, Cross-Sectional Area With Nasalance Scores Measured by Acoustic Rhinometry and Nasometry|Correlation of Nasal Volume and Cross-Sectional Area With Nasalance Scores as Measured by Acoustic Rhinometry and Nasometry|Terminated||Phase 4|20||University of Chicago|||||f||||||||||||||2018-06-01 04:44:10.913457|2018-06-01 04:44:10.913457
NCT00147927|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-07-31|2005-09-02|2005-09-07|Estimate|||||||2007-07-31|2007-08-01|Estimate|December 2003||2003-12-31|July 2007|2007-07-31|December 2005||2005-12-31|||||Interventional|||Using Tailored Emails to Motivate Healthy Behavior Among Employees|Using Tailored Emails to Motivate Healthy Behavior, Improve Health Status, & Reduce Health Care Costs in Employee Populations: A Randomized Trial|Completed||N/A|2000||Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:44:10.972781|2018-06-01 04:44:10.972781
NCT00147914|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2017-05-01|2005-09-06|2005-09-07|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2005||2005-02-28|May 2017|2017-05-31|February 18, 2017|Actual|2017-02-18|February 2007|Actual|2007-02-28||Interventional|||Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life|A Comparison Study Between Cefdinir and Amoxicilline/Clavulanate in Patients With Acute Sinusitis and Assessment of Quality of Life (QOL)|Completed||Phase 4|100|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:44:11.032859|2018-06-01 04:44:11.032859
NCT00147901|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2016-09-30|2005-09-02|2005-09-07|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|November 2011|Actual|2011-11-30|November 2008|Actual|2008-11-30||Interventional|||Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)|Multicenter Phase II Trial of Fludarabine and Cyclophosphamide in Combination With Alemtuzumab (FC-Cam) for Patients With Relapsed Chronic Lymphocytic Leukemia - CLL-2L Protocol of the German CLL-Study Group (GCLLSG)|Completed||Phase 2|61|Actual|German CLL Study Group||1|||f||||f||||||||No||2018-06-01 04:44:11.106498|2018-06-01 04:44:11.106498
NCT00147888|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-09-04|2005-09-06|2005-09-07|Estimate|||||||2013-09-04|2013-09-05|Estimate|March 2004||2004-03-31|September 2013|2013-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Changes in Nasal Patency With Changes in Posture, Temperature, Humidity and Nasal Patency Seen by Acoustic Rhinometry|Physiological Changes in Nasal Patency in Response to Changes in Posture, Temperature, Humidity and Nasal Patency Measured by Acoustic Rhinometry|Completed||Phase 4|15|Actual|University of Chicago|||||f||||t||||||||||2018-06-01 04:44:11.185687|2018-06-01 04:44:11.185687
NCT00147875|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-09-04|2005-09-02|2005-09-07|Estimate|||||||2009-09-04|2009-09-07|Estimate|March 2004||2004-03-31|September 2009|2009-09-30||||July 2007|Actual|2007-07-31||Interventional|||Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma|PVAG - Phase I/II Dose Finding Trial in Elderly Patients (> 60 Years) With Advanced Stages Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|60|Actual|University of Cologne|||||f||||||||||||||2018-06-01 04:44:11.247114|2018-06-01 04:44:11.247114
NCT00147862|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-02-06|2005-09-02|2005-09-07|Estimate|||||||2007-02-06|2007-02-07|Estimate|May 2005||2005-05-31|February 2007|2007-02-28|January 2007||2007-01-31|||||Interventional|||Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?|Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?|Completed||Phase 3|240||Tata Memorial Hospital|||||f||||||||||||||2018-06-01 04:44:11.305267|2018-06-01 04:44:11.305267
NCT00147849|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-11-28|2005-09-02|2005-09-07|Estimate|||||||2005-11-28|2005-11-29|Estimate|September 2000||2000-09-30|September 2005|2005-09-30|March 2006||2006-03-31|||||Interventional|||A Cluster Controlled Trial Comparing Three Methods of Disseminating Practice Guidelines for Children With Croup|A Cluster Controlled Trial Comparing Three Methods of Disseminating Practice|Terminated||N/A|||University of Calgary|||||f||||||||||||||2018-06-01 04:44:11.3605|2018-06-01 04:44:11.3605
NCT00147836|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2008-03-31|2005-09-04|2005-09-07|Estimate|||||||2008-03-31|2008-04-01|Estimate|September 2004||2004-09-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients|Evaluation of the Effects of Oral Anti-Hyperglycemic Agents, Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion on Glycemic Control, B-Cell Function and the Remission Rate in Newly-Diagnosed Type 2 Diabetic Patients|Completed||N/A|436|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-06-01 04:44:11.408702|2018-06-01 04:44:11.408702
NCT00147823|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2013-12-17||2015-06-04|2005-09-06|2005-09-07|Estimate|2015-06-04|2015-06-08|Estimate||||2015-06-04|2015-06-08|Estimate|December 2004||2004-12-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Subjects were randomized|Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions|A Prospective Randomized Study Comparing Vitoss Alone Versus Vitoss With Bone Marrow Aspirate in Benign Bone Lesions|Completed||N/A|63|Actual|State University of New York - Upstate Medical University|Limitation due to incomplete follow up by subjects or unavailability of radiographs. Also difficulties in assessing the outcomes of resorption if lesions were small or there was artifact from hardware in the area.|2|||f||||t||||||||||2018-06-01 04:44:11.487132|2018-06-01 04:44:11.487132
NCT00147810|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-03-23|2005-09-06|2005-09-07|Estimate|||||||2006-03-23|2006-03-24|Estimate|November 2001||2001-11-30|September 2005|2005-09-30|July 2004||2004-07-31|||||Interventional|||Adult Asthma Surveillance and Intervention in a Managed Care Setting|Adult Asthma Surveillance and Intervention in a Managed Care Setting|Completed||N/A|6948||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:44:11.895989|2018-06-01 04:44:11.895989
NCT00147797|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2016-10-24|2005-09-02|2005-09-07|Estimate|||||||2016-10-24|2016-10-25|Estimate|May 2003||2003-05-31|April 2007|2007-04-30|June 2005||2005-06-30|||||Observational|||Influence of Pravastatin on Carotid Artery Structure and Function in HIV-infected Patients Under Antiretroviral Therapy|Influence of Pravastatin on Carotid Artery Structure and Function in HIV-infected Patients Under Antiretroviral Therapy|Completed|||84||Saint Antoine University Hospital|||2||f||||||||||||||2018-06-01 04:44:11.974112|2018-06-01 04:44:11.974112
NCT00147784|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-03-26|2005-09-06|2005-09-07|Estimate|||||||2008-03-26|2008-03-28|Estimate|March 2006||2006-03-31|March 2008|2008-03-31|January 2008|Actual|2008-01-31|June 2007|Actual|2007-06-30||Interventional|||HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.|HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a Methadone Maintenance Treated (MMT) Opioid Addicted Group.|Completed||Phase 3|10|Anticipated|Sorlandet Hospital HF|||||f||||||||||||||2018-06-01 04:44:12.036659|2018-06-01 04:44:12.036659
NCT00147771|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-08-01|2005-09-02|2005-09-07|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2005||2005-09-30|August 2013|2013-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Imiquimod in Children With Plaque Morphea|Evaluation of the Efficacy and Safety of the Imiquimod 5% Topical Cream in Plaque Morphea: A Prospective, Multiple Baseline, Open Label Pilot Study|Completed||Phase 3|10|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||||2018-06-01 04:44:12.113553|2018-06-01 04:44:12.113553
NCT00147758|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-01-16|2005-09-02|2005-09-07|Estimate|||||||2012-01-16|2012-01-18|Estimate|June 2004||2004-06-30|January 2012|2012-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents|Completed||Phase 3|400||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:44:12.201857|2018-06-01 04:44:12.201857
NCT00147745|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2009-07-15||2014-03-05|2005-09-02|2005-09-07|Estimate|2009-11-03|2009-12-04|Estimate||||2014-03-05|2014-04-02|Estimate|June 2005||2005-06-30|March 2014|2014-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes|Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus|Completed||Phase 2|36|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-06-01 04:44:12.385333|2018-06-01 04:44:12.385333
NCT00147732|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-05-06|2005-09-06|2005-09-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|April 2001||2001-04-30|May 2015|2015-05-31|April 2013|Actual|2013-04-30|February 2008|Actual|2008-02-29||Interventional|||Randomized Trial of ARCON in Larynx Cancer|A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma.|Completed||Phase 3|345|Actual|Radboud University||2|||f||||||||||||||2018-06-01 04:44:12.912154|2018-06-01 04:44:12.912154
NCT00147719|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-01-16|2005-09-02|2005-09-07|Estimate|||||||2012-01-16|2012-01-18|Estimate|June 2004||2004-06-30|January 2012|2012-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||WelChol® With Metformin in Treating Patients With Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents|Completed||Phase 3|300||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:44:12.998154|2018-06-01 04:44:12.998154
NCT00147706|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2011-07-25|2005-09-02|2005-09-07|Estimate|||||||2011-07-25|2011-07-26|Estimate|September 2004||2004-09-30|July 2011|2011-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Does Access to an EHR Patient Portal Influence Chronic Disease Outcomes?|Does Access to an EHR Patient Portal Influence Chronic Disease Outcomes? A Randomised Trial Assessing Clinical and Behavioural Change Outcomes in Patients With CHF, Diabetes, or Secondary CVD|Completed||N/A|6000|Anticipated|Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:44:13.111651|2018-06-01 04:44:13.111651
NCT00147693|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-09-30|2005-09-06|2005-09-07|Estimate|||||||2008-09-30|2008-10-01|Estimate|June 2005||2005-06-30|September 2008|2008-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?|Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?|Completed||N/A|304|Actual|Radboud University|||||f||||||||||||||2018-06-01 04:44:13.16841|2018-06-01 04:44:13.16841
NCT00147680|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-02-01|2005-09-06|2005-09-07|Estimate|||||||2012-02-01|2012-02-02|Estimate|September 2004||2004-09-30|February 2012|2012-02-29|October 2009|Actual|2009-10-31|June 2008|Actual|2008-06-30||Interventional|||Uterine Papillary Serous Cancer (UPSC) Trial|Prospective, Non-randomised Phase 2 Clinical Trial of Carboplatin Plus Paclitaxel With Sequential Radical Pelvic Radiotherapy for Uterine Serous Papillary Cancer|Completed||Phase 2|30|Anticipated|Queensland Centre for Gynaecological Cancer|||||f||||f||||||||||2018-06-01 04:44:13.237422|2018-06-01 04:44:13.237422
NCT00147667|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-07|Estimate|||||||2005-09-02|2005-09-07|Estimate|April 2004||2004-04-30|March 2004|2004-03-31|March 2006||2006-03-31|||||Interventional|||Effects of Long Term Macrolide Antibiotic Therapy in Patients With COPD|Randomised Double Blind Placebo Controlled Trial of Effects of Long Term Low Dose Oral Erythromycin Therapy in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Active, not recruiting|Phase 2/Phase 3|120||Royal Free and University College Medical School|||||f||||||||||||||2018-06-01 04:44:13.295715|2018-06-01 04:44:13.295715
NCT00147654|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2011-06-07|2005-09-02|2005-09-07|Estimate|||||||2011-06-07|2011-06-08|Estimate|November 2004||2004-11-30|June 2011|2011-06-30|May 2006|Actual|2006-05-31|||||Interventional|||Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction|A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction|Completed||Phase 4|830||Pfizer|||||f||||||||||||||2018-06-01 04:44:13.37017|2018-06-01 04:44:13.37017
NCT00147628|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2011-06-07|2005-09-04|2005-09-07|Estimate|||||||2011-06-07|2011-06-08|Estimate|November 2005||2005-11-30|June 2011|2011-06-30|September 2006|Actual|2006-09-30|||||Interventional|||Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire|A Multi-Center, Double-Blind Placebo Controlled, Flexible-Dose Study With An Open-Label Phase To Assess The Efficacy Of Sildenafil Citrate On Erectile Function And Intercourse Satisfaction As Well As To Validate The Sexual Experience Questionnaire And Its Treatment Responsiveness In Men With Erectile Dysfunction|Completed||Phase 4|209|Actual|Pfizer|||||||||||||||||||2018-06-01 04:44:13.568023|2018-06-01 04:44:13.568023
NCT00147615|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-06-04|2005-09-02|2005-09-07|Estimate|||||||2007-06-04|2007-06-05|Estimate|October 2004||2004-10-31|June 2007|2007-06-30|June 2006||2006-06-30|||||Interventional|||The Long-Term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years|Peds II (Pediatric Eplerenone Development Study II)--An Open Label, Long-Term Study To Evaluate The Safety Of Eplerenone In The Treatment Of Hypertension In Children|Completed||Phase 3|140||Pfizer|||||||||||||||||||2018-06-01 04:44:13.63862|2018-06-01 04:44:13.63862
NCT00147602|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-04-21|2005-09-06|2005-09-07|Estimate|||||||2015-04-21|2015-04-22|Estimate|November 1998||1998-11-30|April 2015|2015-04-30|November 2005||2005-11-30|||||Interventional|SPARCL||Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke|A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke|Completed||Phase 4|4732||Pfizer|||||||||||||||||||2018-06-01 04:44:14.651761|2018-06-01 04:44:14.651761
NCT00147589|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-01-23|2005-09-02|2005-09-07|Estimate|||||||2008-01-23|2008-01-25|Estimate|September 2004||2004-09-30|March 2007|2007-03-31|January 2007|Actual|2007-01-31|||||Interventional|||A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.|Peds I (Pediatric Eplerenone Development Study I): A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of Eplerenone In The Treatment Of Hypertension In Children|Completed||Phase 3|320||Pfizer|||||||||||||||||||2018-06-01 04:44:14.907833|2018-06-01 04:44:14.907833
NCT00147576|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-10-01|2005-09-02|2005-09-07|Estimate|||||||2012-10-01|2012-10-02|Estimate|December 2003||2003-12-31|October 2012|2012-10-31|December 2004|Actual|2004-12-31|||||Interventional|||Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.|Randomized, Placebo-Controlled Parallel Group Study Comparing Effect Of Three Doses Of CP-866,087 And Naltrexone On Acute Alcohol Consumption And Craving After Seven Days Of Treatment In Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking Treatment|Completed||Phase 2|88|Actual|Pfizer|||||||||||||||||||2018-06-01 04:44:15.157221|2018-06-01 04:44:15.157221
NCT00147563|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-04-14|2005-09-02|2005-09-07|Estimate|||||||2008-04-14|2008-04-15|Estimate|October 2003||2003-10-31|May 2007|2007-05-31||||May 2006|Actual|2006-05-31||Interventional|||Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT|A Double-Blind, Parallel Design Study to Compare the Effectiveness of Eplerenone Versus Atenolol in Reversing the Remodeling of Resistance Arteries in Subjects With Mild to Moderate Primary Hypertension|Completed||Phase 4|34||Pfizer|||||||||||||||||||2018-06-01 04:44:15.247955|2018-06-01 04:44:15.247955
NCT00147550|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-09-11|2005-09-02|2005-09-07|Estimate|||||||2013-09-11|2013-09-13|Estimate|February 2004||2004-02-29|September 2013|2013-09-30|July 2013|Actual|2013-07-31|May 2007|Actual|2007-05-31||Interventional|||MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.|A Multicenter, Open-Label, Noncomparative Phase 1-2 Clinical And Pharmacokinetic Study Of Oral PD 0325901 In Patients With Advanced Cancer|Terminated||Phase 1/Phase 2|79|Actual|Pfizer||1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:44:15.322027|2018-06-01 04:44:15.322027
NCT00147537|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2013-01-18|2012-05-08|2013-10-01|2005-09-02|2005-09-07|Estimate|2013-03-06|2013-04-24|Estimate|2012-05-08|2012-05-10|Estimate|2013-10-01|2013-10-30|Estimate|February 2005||2005-02-28|October 2013|2013-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer|A Phase 1b Dose Escalation/Phase 2 Randomized, Non-Comparative, Multiple Center, Open Label Study Of CP 751,871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|282|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:44:15.731753|2018-06-01 04:44:15.731753
NCT00147524|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-04-26|2005-09-02|2005-09-07|Estimate|||||||2007-04-26|2007-04-30|Estimate|October 2003||2003-10-31|April 2007|2007-04-30|May 2005|Actual|2005-05-31|||||Interventional|||Non-Comparative Study To Evaluate Changes In FMD After Quinapril Therapy In Hypertensive Women|Multicenter, Open-Label (Non-Comparative) Study To Evaluate Changes In Flow Mediated Dilatation During And After A 6 Months Treatment Period With Step By Step Increased Doses With Quinapril Therapy In Post-Menopausal Women With Mild Or Moderate Hypertension|Completed||Phase 4|70||Pfizer|||||f||||||||||||||2018-06-01 04:44:22.929543|2018-06-01 04:44:22.929543
NCT00147511|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2011-05-09|2005-09-02|2005-09-07|Estimate|||||||2011-05-09|2011-05-10|Estimate|June 2003||2003-06-30|May 2011|2011-05-31|June 2005|Actual|2005-06-30|||||Interventional|||Time To Efficacy and Onset Of Action Of Linezolid|Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections|Completed||Phase 4|118|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:44:22.98083|2018-06-01 04:44:22.98083
NCT00147498|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2012-11-19|2012-11-07|2012-12-20|2005-09-02|2005-09-07|Estimate|2012-12-20|2013-01-30|Estimate|2012-11-07|2012-11-12|Estimate|2012-12-20|2013-01-30|Estimate|January 2005||2005-01-31|December 2012|2012-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|264|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 04:44:23.205852|2018-06-01 04:44:23.205852
NCT00147485|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-08-14|2005-09-02|2005-09-07|Estimate|||||||2008-08-14|2008-08-18|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer|A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of AG-024322, An Inhibitor Of Cyclin-Dependent Kinase 1, 2 And 4, Administered Intravenously Daily For 5 Days Every 3 Weeks To Patients With Advanced Cancer|Terminated||Phase 1|37|Actual|Pfizer||1||See Detailed Description|f||||||||||||||2018-06-01 04:44:25.021023|2018-06-01 04:44:25.021023
NCT00147472|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-06-20|2005-09-06|2005-09-07|Estimate|||||||2012-06-20|2012-06-22|Estimate|May 2004||2004-05-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|August 2009|Actual|2009-08-31||Interventional|||Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial)|A Prospective Cohort Study to Determine the Sensitivity of Positron Emission Tomography (PET) in Detecting Metastatic Cancer in Neck Lymph Nodes in Patients With Squamous Cell Head & Neck Cancer Managed With Primary Radiation Therapy|Completed||Phase 3|400|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||t||||||||||2018-06-01 04:44:25.086153|2018-06-01 04:44:25.086153
NCT00147459|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2012-12-04|2005-09-05|2005-09-07|Estimate|||||||2012-12-04|2012-12-06|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2006|Actual|2006-12-31||Interventional|||Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation|Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation|Unknown status|Recruiting|N/A|31|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-06-01 04:44:25.155365|2018-06-01 04:44:25.155365
NCT00147446|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2012-10-26||2013-09-06|2005-09-02|2005-09-07|Estimate|2013-09-06|2013-09-10|Estimate||||2013-09-06|2013-09-10|Estimate|May 2005||2005-05-31|September 2013|2013-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Stress Management for Patients With Multiple Sclerosis|Phase II Study of the Effects of Stress Management on Neuroimaging, Clinical, Immune and Psychosocial Outcomes|Completed||Phase 2|121|Actual|Northwestern University|we caution that it is premature to make specific clinical recommendations regarding the use of SMT-MS to manage MS disease-related activity. Future work should identify, refine, and optimize the active ingredients in this behavioral intervention.|2|||f||||t||||||||||2018-06-01 04:44:25.319053|2018-06-01 04:44:25.319053
NCT00147433|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-03-30|2005-09-02|2005-09-07|Estimate|||||||2006-03-30|2006-03-31|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|November 2008||2008-11-30|||||Observational|||The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children|Are IQs Low in Offspring of Euthyroid Women With Low T4?|Unknown status|Recruiting||5000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:44:25.600384|2018-06-01 04:44:25.600384
NCT00147420|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-12-16|2005-09-02|2005-09-07|Estimate|||||||2013-12-16|2013-12-17|Estimate|September 2005||2005-09-30|December 2013|2013-12-31|March 2007|Actual|2007-03-31|||||Interventional|||RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet|RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet|Completed||N/A|848||NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 04:44:25.666194|2018-06-01 04:44:25.666194
NCT00147394|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-10-25|2005-09-02|2005-09-07|Estimate|||||||2012-10-25|2012-10-29|Estimate|December 2001||2001-12-31|October 2012|2012-10-31|June 2004|Actual|2004-06-30|||||Interventional|||Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)|Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder|Completed||Phase 1|100||Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 04:44:25.739541|2018-06-01 04:44:25.739541
NCT00147381|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-06-18|2005-09-06|2005-09-07|Estimate|||||||2012-06-18|2012-06-19|Estimate|January 2004||2004-01-31|June 2012|2012-06-30|July 2011|Actual|2011-07-31|August 2008|Actual|2008-08-31||Interventional|||Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection|Effectiveness and Safety of Campath-1H as an Induction Agent in Combination With Tacrolimus Monotherapy for Prevention of Graft Rejection Compared to Tacrolimus in Combination With MMF and Steroids in Cadaveric Kidney Transplantation|Completed||Phase 3|197|Actual|Medical University Innsbruck||3|||f||||f||||||||||2018-06-01 04:44:25.808502|2018-06-01 04:44:25.808502
NCT00147368|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-05-30|2005-09-06|2005-09-07|Estimate|||||||2008-05-30|2008-06-02|Estimate|February 2005||2005-02-28|May 2008|2008-05-31|December 2007|Actual|2007-12-31|April 2006|Actual|2006-04-30||Interventional|||Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria|Pharmacokinetic-Pharmacodynamic Study of Adjunctive Arginine in Falciparum Malaria|Completed||Phase 1/Phase 2|50|Anticipated|Menzies School of Health Research|||||f||||t||||||||||2018-06-01 04:44:25.953006|2018-06-01 04:44:25.953006
NCT00147355|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2012-04-11|2005-09-05|2005-09-07|Estimate|||||||2012-04-11|2012-04-12|Estimate|November 2005||2005-11-30|April 2012|2012-04-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy|An Open-label, Randomised Study Comparing the Uptake of rIL-2 in HIV-1 Infected Individuals Receiving Different Combinations of Antiemetics and Analgesic Agents During rIL-2 Dosing in ESPRIT: Toxicity Substudy of ESPRIT: TOXIL-2 Substudy|Terminated||Phase 3|28|Actual|Kirby Institute||4||28 of 168 patients only were enrolled, numbers too low to be conclusive|f||||t||||||||||2018-06-01 04:44:26.028322|2018-06-01 04:44:26.028322
NCT00147342|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2016-09-02|2005-09-02|2005-09-07|Estimate|||||||2016-09-02|2016-09-05|Estimate|May 2005||2005-05-31|September 2016|2016-09-30|December 2005||2005-12-31|||||Observational|||The Effect of Insulin During Exercise on the Development of Low Blood Sugar in Individuals With Type I Diabetes|The Effect of Basal Insulin During Exercise on the Development of Hypoglycemia in Children With Type 1 Diabetes|Completed|||55||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 04:44:26.137521|2018-06-01 04:44:26.137521
NCT00147329|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-02-21|2005-09-06|2005-09-07|Estimate|||||||2007-02-21|2007-02-23|Estimate|September 2005||2005-09-30|February 2007|2007-02-28|July 2006||2006-07-31|||||Interventional|||Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis|A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of MM-093 in Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|30||Merrimack Pharmaceuticals|||||f||||||||||||||2018-06-01 04:44:26.202427|2018-06-01 04:44:26.202427
NCT00147316|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|2012-01-19||2012-02-29|2005-09-05|2005-09-07|Estimate|2012-01-19|2012-02-24|Estimate||||2012-02-29|2012-03-01|Estimate|April 2002||2002-04-30|February 2012|2012-02-29|September 2003||2003-09-30|||||Interventional|||Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke|Japan Alteplase Clinical Trial (J-ACT): Phase 3 Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Acute Ischemic Stroke Within 3 Hours of Onset|Completed||Phase 3|103|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||||||||||||2018-06-01 04:44:26.264954|2018-06-01 04:44:26.264954
NCT00147303|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2015-04-08|2005-09-04|2005-09-07|Estimate|||||||2015-04-08|2015-04-10|Estimate|April 2004||2004-04-30|April 2015|2015-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study|Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Clinical-pharmacological Dose-response Study.|Completed||Phase 3|46|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-06-01 04:44:26.44281|2018-06-01 04:44:26.44281
NCT00147290|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2008-11-20||2015-08-12|2005-09-06|2005-09-07|Estimate|2009-04-21|2009-06-10|Estimate||||2015-08-12|2015-08-13|Estimate|February 2004||2004-02-29|August 2015|2015-08-31|January 2008|Actual|2008-01-31|April 2007|Actual|2007-04-30||Interventional|ADVANCE-CRTD||ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy|ADVANCE CRT - D: ATP Delivery for Painless ICD Therapy|Completed||Phase 4|526|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||||2018-06-01 04:44:26.676481|2018-06-01 04:44:26.676481
NCT00147277|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2008-11-20||2015-08-12|2005-09-06|2005-09-07|Estimate|2009-03-25|2009-05-12|Estimate||||2015-08-12|2015-08-13|Estimate|March 2004||2004-03-31|August 2015|2015-08-31|January 2008|Actual|2008-01-31|January 2006|Actual|2006-01-31||Interventional|ADVANCE_D||ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy|ADVANCE-D: ATP Delivery for Painless ICD Therapy|Completed||Phase 4|925|Actual|Medtronic Bakken Research Center||2|||f||||f||||||||||2018-06-01 04:44:27.019163|2018-06-01 04:44:27.019163
NCT00147264|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2016-12-13|2005-09-02|2005-09-07|Estimate|||||||2016-12-13|2016-12-14|Estimate|April 2004||2004-04-30|December 2016|2016-12-31|November 2006|Actual|2006-11-30|January 2006|Actual|2006-01-31||Interventional|||Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial|A Randomized, Double Blind, 2X2 Factorial Design Study to Evaluate the Effects of Telmisartan vs Placebo, and of a Low-Glycemic Diet vs Control Diet, in Reducing Intra-Myocellular Lipids In Individuals With Abdominal Obesity|Completed||Phase 3|120||McMaster University|||||f||||||||||||||2018-06-01 04:44:27.694799|2018-06-01 04:44:27.694799
NCT00147251|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-10-31|2005-09-02|2005-09-07|Estimate|||||||2006-10-31|2006-11-01|Estimate|May 2003||2003-05-31|September 2005|2005-09-30|May 2007||2007-05-31|||||Interventional|||Stop Atherosclerosis in Native Diabetics Study|Stop Atherosclerosis in Native Diabetics Study|Completed||Phase 4|548||Medstar Health Research Institute|||||f||||||||||||||2018-06-01 04:44:27.938134|2018-06-01 04:44:27.938134
NCT00147238|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2009-04-24||2012-07-31|2005-09-06|2005-09-07|Estimate|2009-12-23|2010-01-27|Estimate||||2012-07-31|2012-08-07|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast|A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast|Terminated||N/A|10|Actual|M.D. Anderson Cancer Center||2||Terminated at request of sponsor.|f||||f||||||||||2018-06-01 04:44:28.067245|2018-06-01 04:44:28.067245
NCT00146809|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2018-02-15|2005-09-03|2005-09-07|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2003||2003-12-31|February 2018|2018-02-28|December 2005||2005-12-31|||||Interventional|||Study About Efficacy and Safety to Treat Multi-System-Atrophy|Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment|Completed||Phase 3|60||German Parkinson Study Group (GPS)|||||f||||||||||||||2018-06-01 04:44:35.643063|2018-06-01 04:44:35.643063
NCT00147225|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2014-04-07||2014-04-07|2005-09-06|2005-09-07|Estimate|2014-04-07|2014-05-08|Estimate||||2014-04-07|2014-05-08|Estimate|August 2005||2005-08-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by AMG 531 subcutaneously of 21-28 day treatment cycle. There were 51 participants who received at least one dose of the study drug.|AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin|Phase I/II Study of AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin|Completed||Phase 1/Phase 2|55|Actual|M.D. Anderson Cancer Center||6|||f||||f||||||||||2018-06-01 04:44:28.472493|2018-06-01 04:44:28.472493
NCT00147212|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2012-03-16||2012-12-11|2005-09-02|2005-09-07|Estimate|2012-12-11|2013-01-18|Estimate||||2012-12-11|2013-01-18|Estimate|June 2002||2002-06-30|December 2012|2012-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||ET 743 (Yondelis) in Men With Advanced Prostate Cancer|A Phase II Study of Three Hour, Weekly Infusion of ET 743 (Yondelis) in Men With Advanced Prostate Cancer|Completed||Phase 2|50|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 04:44:29.701768|2018-06-01 04:44:29.701768
NCT00147199|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2012-12-03||2013-07-11|2005-09-02|2005-09-07|Estimate|2013-07-11|2013-08-12|Estimate||||2013-07-11|2013-08-12|Estimate|June 2005||2005-06-30|July 2013|2013-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|TRIUMPH||Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)|TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension|Completed||Phase 3|235|Actual|United Therapeutics||2|||f||||f||||||||||2018-06-01 04:44:29.959115|2018-06-01 04:44:29.959115
NCT00147186|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-01-12|2005-09-06|2005-09-07|Estimate|||||||2007-01-12|2007-01-15|Estimate|January 2000||2000-01-31|June 2005|2005-06-30|May 2005||2005-05-31|||||Interventional|||The Effectiveness of Hylan GF-20 on Joint Reaction Forces and Kinematic Patterns During Gait in Patients With Knee Osteoarthritis||Unknown status|Active, not recruiting|N/A|||Kessler Foundation|||||f||||||||||||||2018-06-01 04:44:30.644561|2018-06-01 04:44:30.644561
NCT00147160|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-04-10|2005-09-06|2005-09-07|Estimate|||||||2012-04-10|2012-04-11|Estimate|October 2003||2003-10-31|September 2006|2006-09-30|December 2007|Actual|2007-12-31|July 2006|Actual|2006-07-31||Interventional|||Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents|Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse|Completed||Phase 2|87|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:44:30.714825|2018-06-01 04:44:30.714825
NCT00147147|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2016-09-20|2005-09-05|2005-09-07|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 1993||1993-01-31|September 2016|2016-09-30|March 2004||2004-03-31|||||Interventional|||Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)|Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-positive Gastric Cancer (JCOG9206-2)|Completed||Phase 3|280||Japan Clinical Oncology Group|||||f||||||||||||||2018-06-01 04:44:30.881549|2018-06-01 04:44:30.881549
NCT00147134|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2016-09-20|2005-09-05|2005-09-07|Estimate|||||||2016-09-20|2016-09-22|Estimate|November 2004||2004-11-30|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer|Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery for Colorectal Cancer（JCOG 0404,CRC Surg-LAP/OPEN)|Completed||Phase 3|1050|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:44:31.011566|2018-06-01 04:44:31.011566
NCT00147121|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2016-09-20|2005-09-05|2005-09-07|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2002||2002-09-30|September 2016|2016-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)|Rituximab + Standard CHOP (R･S-CHOP) vs Rituximab+ Bi-weekly CHOP (R･Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203)|Completed||Phase 2/Phase 3|300|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:44:31.430494|2018-06-01 04:44:31.430494
NCT00147108|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-09-13|2005-09-02|2005-09-07|Estimate|||||||2012-09-13|2012-09-17|Estimate|January 2003||2003-01-31|September 2012|2012-09-30|October 2005|Actual|2005-10-31|August 2005|Actual|2005-08-31||Interventional|||MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas|Phase 3 Study of MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas|Terminated||Phase 3|102|Actual|InSightec|||||f||||||||||||||2018-06-01 04:44:31.689439|2018-06-01 04:44:31.689439
NCT00147095|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-05-27|2005-09-06|2005-09-07|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Observational|||Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease|Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease|Completed|||80|Actual|Imperial College London|||||f||||||||||Samples Without DNA|"~     RNA was isolated and sent to GeneLogic~   "|||2018-06-01 04:44:31.797659|2018-06-01 04:44:31.797659
NCT00147082|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-08-24|2005-09-06|2005-09-07|Estimate|||||||2015-08-24|2015-08-25|Estimate|February 2001||2001-02-28|September 2006|2006-09-30|April 2007|Actual|2007-04-30|December 2004|Actual|2004-12-31||Observational|||Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD)|Leukocyte Migration and Differentiation in COPD Patients Compared to Healthy Smokers and Healthy Non-smoking Subjects.|Completed|||90|Anticipated|Imperial College London|||3||f||||||||||||||2018-06-01 04:44:32.020875|2018-06-01 04:44:32.020875
NCT00147069|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-05-27|2005-09-06|2005-09-07|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2004||2004-04-30|September 2005|2005-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Leukocyte Function in Asthma and COPD|Investigation Into Inflammatory Mechanisms in Airway Cells in Smokers and Non-smokers With Inflammatory Lung Disease.|Completed|||90|Actual|Imperial College London|||||f||||f||||||||||2018-06-01 04:44:32.139075|2018-06-01 04:44:32.139075
NCT00147056|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2018-03-26|2005-09-02|2005-09-07|Estimate|||||||2018-03-26|2018-03-29|Actual|August 2012||2012-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors|A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors|Recruiting||N/A|10|Anticipated|InSightec||1|||f||||t||||||||||2018-06-01 04:44:32.24491|2018-06-01 04:44:32.24491
NCT00147043|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2016-02-11|2005-09-05|2005-09-07|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||Adult Stem Cell Therapy in Liver Insufficiency|Adult Stem Therapy for Patients With Liver Insufficiency|Completed||Phase 1|5||Imperial College London|||||f||||||||||||||2018-06-01 04:44:32.437395|2018-06-01 04:44:32.437395
NCT00147030|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|2016-03-08||2016-04-06|2005-09-05|2005-09-07|Estimate|2016-04-06|2016-05-11|Estimate||||2016-04-06|2016-05-11|Estimate|December 2002||2002-12-31|November 2013|2013-11-30|August 2008|Actual|2008-08-31|November 2006|Actual|2006-11-30||Interventional||Infants who were less than 6 hours of age who had a gestational age of at least 36 weeks and perinatal asphyxial encephalopathy confirmed by 30 minutes’ amplitude-integrated electro-encephalography that showed abnormal background activity or seizures.|TOBY (TOtal Body hYpothermia): a Study of Treatment for Perinatal Asphyxia|Whole Body Hypothermia for the Treatment of Perinatal Asphyxial Encephalopathy|Completed||N/A|325|Actual|Imperial College London||2|||f||||t||||||||No||2018-06-01 04:44:32.710526|2018-06-01 04:44:32.710526
NCT00147017|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2015-03-23|2005-09-05|2005-09-07|Estimate|||||||2015-03-23|2015-03-24|Estimate|June 2001||2001-06-30|September 2005|2005-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Regulation of the Release of Inflammatory Mediators From Lung Macrophages.|Regulation of the Release of Inflammatory Mediators From Lung Macrophages.|Completed|||60|Actual|Imperial College London|||||f||||||||||Samples Without DNA|"~     protein samples have been retained~   "|||2018-06-01 04:44:33.765409|2018-06-01 04:44:33.765409
NCT00147004|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-04-23|2005-09-06|2005-09-07|Estimate|||||||2008-04-23|2008-04-24|Estimate|March 2002||2002-03-31|April 2008|2008-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|Corticus||Corticosteroid Therapy of Septic Shock - Corticus|Corticosteroid Therapy of Septic Shock - Corticus. A Multi-National, Prospective, Double-Blind, Randomized, Placebo-Controlled Study|Completed||Phase 3|500|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-06-01 04:44:33.873131|2018-06-01 04:44:33.873131
NCT00146978|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2006-11-06|2005-09-04|2005-09-07|Estimate|||||||2006-11-06|2006-11-07|Estimate|December 2000||2000-12-31|March 2006|2006-03-31|August 2005||2005-08-31|||||Interventional|||Intra-Arterial Catheter Directed Therapy for Severe Graft vs. Host Disease (GVHD)|A Phase 1/2 Study to Evaluate Intra-Arterial Catheter Directed Therapy for Severe Gastro-Intestinal and/or Hepatic Graft vs. Host Disease (GVHD)|Completed||Phase 1/Phase 2|50||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:44:34.114808|2018-06-01 04:44:34.114808
NCT00146952|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2016-11-10|2005-09-05|2005-09-07|Estimate|||||||2016-11-10|2016-11-11|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|December 2007||2007-12-31|||||Interventional|||Use of a Vibrotactile Sensory Prosthesis in Patients With Postural Imbalance and Spatial Disorientation|Evaluation of a Vibrotactile Sensory Aid Developed by the US Navy to Combat Pilot Disorientation as a Prosthesis in Patients With Postural Imbalance and Spatial Disorientation|Unknown status|Recruiting|Phase 1|30|Anticipated|Imperial College London|||||f||||||||||||||2018-06-01 04:44:34.234192|2018-06-01 04:44:34.234192
NCT00146926|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2007-04-26|2005-09-05|2005-09-07|Estimate|||||||2007-04-26|2007-04-27|Estimate|September 2005||2005-09-30|April 2007|2007-04-30||||||||Interventional|||Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion|Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion|Unknown status|Active, not recruiting|Phase 3|200||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:44:34.356719|2018-06-01 04:44:34.356719
NCT00146913|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2007-04-26|2005-09-06|2005-09-07|Estimate|||||||2007-04-26|2007-04-27|Estimate|March 2004||2004-03-31|April 2007|2007-04-30||||||||Interventional|||AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year|A Phase II Study Evaluating the Efficacy and Tolerance of Combination Therapy of Imatinib Mesylate (IM) +-2A Interféron for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year|Unknown status|Active, not recruiting|Phase 2|30||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:44:34.446385|2018-06-01 04:44:34.446385
NCT00146900|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2016-02-17|2005-09-04|2005-09-07|Estimate|||||||2016-02-17|2016-02-19|Estimate|August 2004||2004-08-31|February 2016|2016-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Prevention of Post Traumatic Stress Disorder by Early Treatment|Prevention of Post Traumatic Stress Disorder by Early Treatment|Completed||N/A|298|Actual|Hadassah Medical Organization||5|||f||||f||||||||||2018-06-01 04:44:34.558301|2018-06-01 04:44:34.558301
NCT00146887|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2006-11-06|2005-09-04|2005-09-07|Estimate|||||||2006-11-06|2006-11-07|Estimate|January 2005||2005-01-31|August 2005|2005-08-31|August 2005|Anticipated|2005-08-31|||||Interventional|||Comparison of Coronary CT Angiography to Invasive Coronary Angiography|A Trial Comparing the Sensitivity and Specificity of Coronary Angiography With Coronary CT Angiography|Unknown status|Recruiting|N/A|40|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:44:34.714823|2018-06-01 04:44:34.714823
NCT00146874|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2010-08-17|2005-09-06|2005-09-07|Estimate|||||||2010-08-17|2010-08-18|Estimate|May 2004||2004-05-31|November 2006|2006-11-30||||March 2007|Actual|2007-03-31||Observational|||CRT RENEWAL Registry|Cardiac Resynchronization Therapy Registry Evaluating Patient Response With RENEWAL Family Devices|Completed|||1000||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:44:34.819601|2018-06-01 04:44:34.819601
NCT00146861|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2017-05-17|2005-09-06|2005-09-07|Estimate|||||||2017-05-17|2017-05-18|Actual|July 2003|Actual|2003-07-31|May 2017|2017-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||LIFE Study - Limiting Chronotropic Incompetence for Pacemaker Recipients|Limiting Chronotropic Incompetence for Pacemaker Recipients|Completed||Phase 4|1500||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:44:34.910341|2018-06-01 04:44:34.910341
NCT00146848|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2010-02-28||2011-12-20|2005-09-06|2005-09-07|Estimate|2010-09-21|2010-09-23|Estimate||||2011-12-20|2011-12-28|Estimate|December 2004||2004-12-31|December 2011|2011-12-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|PEGASUS CRT||PEGASUS CRT Study: Atrial Support Study in Cardiac Resynchronization Therapy|Pacing Evaluation - Atrial Support Study in Cardiac Resynchronization Therapy|Completed||Phase 4|1742|Actual|Boston Scientific Corporation|Lack of longer-term follow-up. Single blind design where investigator could be aware of treatment assignment. Two conservative atrial support pacing modes; results should not be extended to substantially more atrial pacing and higher heart rates.|3|||f||||t||||||||||2018-06-01 04:44:34.984951|2018-06-01 04:44:34.984951
NCT00146835|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2014-01-09|2005-09-06|2005-09-07|Estimate|||||||2014-01-09|2014-01-13|Estimate|April 2003||2003-04-30|January 2014|2014-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine|Phase IV, Prospective Study of the Safety of GSK Bios' Pediarix Administered to a Cohort of Infants in a US Health Maintenance Organization (HMO). (Post-Marketing PEDIARIX Safety Study)|Completed|||120794|Actual|GlaxoSmithKline|||3||f||||||||||||||2018-06-01 04:44:35.435265|2018-06-01 04:44:35.435265
NCT00146822|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2017-02-02|2005-09-06|2005-09-07|Estimate|||||||2017-02-02|2017-02-06|Estimate|February 2004||2004-02-29|February 2017|2017-02-28|March 2006||2006-03-31|||||Interventional|||REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance|ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance Study|Completed||Phase 4|1500||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:44:35.600582|2018-06-01 04:44:35.600582
NCT00146796|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2017-01-11|2005-09-05|2005-09-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|November 2005|Actual|2005-11-30|||||Interventional|||A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Malaria in Tanzania|A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Non-Severe Malaria at Different Transmission Intensities of Plasmodium Falciparum in Tanzania|Completed||Phase 4|2400|Actual|London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-06-01 04:44:35.908574|2018-06-01 04:44:35.908574
NCT00146783|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2017-01-11|2005-09-05|2005-09-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2004||2004-06-30|January 2017|2017-01-31|February 2007|Actual|2007-02-28|||||Interventional|||Navrongo Drug Options for IPT in Pregnancy Trial|Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|3642|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:44:36.026003|2018-06-01 04:44:36.026003
NCT00146770|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2009-01-07||2015-03-17|2005-09-02|2005-09-07|Estimate|2009-04-28|2009-06-16|Estimate||||2015-03-17|2015-04-03|Estimate|May 2001||2001-05-31|March 2015|2015-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients|A Multicenter, Multinational, Open-Label Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I|Completed||Phase 3|45|Actual|Sanofi|Rare disease with limited sample size, lack of control group.FVC calculations less reliable for patients whose height is below the 3rdpercent of general population.Height term used to calculate FVC may be influenced by joint contractures and posture.|2|||f||||||||||||||2018-06-01 04:44:36.266765|2018-06-01 04:44:36.266765
NCT00146757|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2008-11-20||2015-03-17|2005-09-02|2005-09-07|Estimate|2009-04-27|2009-06-16|Estimate||||2015-03-17|2015-04-03|Estimate|October 2002||2002-10-31|March 2015|2015-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old|A Phase II Open-Label Clinical Trial of Recombinant Human Alpha-L-iduronidase (Aldurazyme®) to Evaluate the Safety and Pharmacokinetics in Mucopolysaccharidosis I (MPS I) Patients Less Than 5 Years Old|Completed||Phase 2|20|Actual|Sanofi|Due to the rarity of the disease, this study is limited by its small sample size and lack of a control group.|2|||f||||||||||||||2018-06-01 04:44:38.020033|2018-06-01 04:44:38.020033
NCT00146744|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2017-05-24|2005-09-06|2005-09-07|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2005||2005-07-31|May 2017|2017-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02A in Healthy PPD-positive Adults|Double-blind (Observer-blind), Randomised, Controlled, Phase I/II Study, to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Candidate Tuberculosis Vaccine, Mtb72F/AS02A Administered Intramuscularly at 0, 1, 2 Months to Healthy PPD-positive Volunteers Aged 18 to 50 Years|Completed||Phase 2|38||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:44:38.700992|2018-06-01 04:44:38.700992
NCT00146731|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2017-01-11|2005-09-05|2005-09-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|January 2017|2017-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania|Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania|Completed||Phase 3|310|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:44:38.801412|2018-06-01 04:44:38.801412
NCT00146718|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2017-01-11|2005-09-05|2005-09-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2003||2003-08-31|January 2017|2017-01-31|May 2005||2005-05-31|||||Interventional|||Anti-Malarial Drug Resistance in Cameroon|Anti-malarial Drug Resistance in Cameroon: Therapeutic Efficacy and Biological Markers of Resistance|Completed||Phase 2/Phase 3|755||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:44:38.91543|2018-06-01 04:44:38.91543
NCT00146705|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2007-07-31|2005-09-05|2005-09-07|Estimate|||||||2007-07-31|2007-08-01|Estimate|May 2005||2005-05-31|July 2007|2007-07-31|September 2006|Actual|2006-09-30|||||Observational|||Long Term Follow-up of Pegylated-Interferon Alpha-2b|Long Term Follow-up of Pegylated-Interferon Alpha-2b and Lamivudine Combination Therapy in Patients With Chronic HBV Infection|Completed|||266|Actual|Foundation for Liver Research|||||f||||f||||||||||2018-06-01 04:44:38.975156|2018-06-01 04:44:38.975156
NCT00146692|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2017-01-11|2005-09-05|2005-09-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2004||2004-04-30|January 2017|2017-01-31|February 2005|Actual|2005-02-28|||||Interventional|||A Trial of Improved Financial Access to Healthcare in Ghana|Impact of Improved Financial Access to Health Care on Morbidity Due to Severe Malaria and Healthcare Utilization Among Children 6 Months to Five Years of Age in a Hyper Endemic Area in Ghana: a Randomized Controlled Trial|Completed||Phase 4|2000||London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-06-01 04:44:39.083155|2018-06-01 04:44:39.083155
NCT00146679|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-09-06|2005-09-06|2005-09-07|Estimate|||||||2013-09-06|2013-09-10|Estimate|March 2001||2001-03-31|September 2013|2013-09-30|February 2006|Actual|2006-02-28|June 2005|Actual|2005-06-30||Interventional|||Psychoeducational Intervention for ICD Patients (PEACE)|Psychoeducational Intervention for ICD Patients (PEACE)|Completed||N/A|246|Actual|Emory University||3|||f||||t||||||||||2018-06-01 04:44:39.185255|2018-06-01 04:44:39.185255
NCT00146666|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-03|||2009-12-16|2005-09-06|2005-09-07|Estimate|||||||2009-12-16|2009-12-17|Estimate|September 2005||2005-09-30|August 2009|2009-08-31|September 2006|Anticipated|2006-09-30|||||Interventional|||Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)|Evaluation of FM220 in Patients With Peripheral Arterial Disease (PAD)|Unknown status|Recruiting|Phase 2|90|Anticipated|FlowMedic|||||f||||||||||||||2018-06-01 04:44:39.34643|2018-06-01 04:44:39.34643
NCT00146653|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-11-19|2005-09-06|2005-09-07|Estimate|||||||2013-11-19|2013-11-20|Estimate|December 2005||2005-12-31|November 2013|2013-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Heparin Management During Cardiopulmonary Bypass in Children|A Comparison of Heparin Management Strategies in Children Undergoing Cardiopulmonary Bypass.|Completed|||20|Actual|Emory University|||1||f||||f||||||Samples With DNA|"~     Blood is being collected to obtain Xa results.~   "|||2018-06-01 04:44:39.459879|2018-06-01 04:44:39.459879
NCT00146640|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|2017-09-06||2017-09-06|2005-09-06|2005-09-07|Estimate|2017-09-06|2018-05-28|Estimate||||2017-09-06|2018-05-28|Estimate|August 31, 2004|Actual|2004-08-31|September 2017|2017-09-30|January 31, 2007|Actual|2007-01-31|January 31, 2007|Actual|2007-01-31||Interventional||Intent-to-Treat (ITT) population included all randomized participants.|Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis|A New Timed-Release Tablet Formulation of Prednisone Compared to Standard Prednisone in Patients With Rheumatoid Arthritis- A Randomized, Multi-Centre, Double-Blind, Active Controlled Study With Open Extension on the New Drug Only|Completed||Phase 3|288|Actual|Merck KGaA|For SAEs, due diligence was done and all potential information sources have been exhausted, no further information could be retrieved apart from what is currently reported.|2|||f||||||||||||||2018-06-01 04:44:39.5873|2018-06-01 04:44:39.5873
NCT00146627|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2016-09-28|2005-09-06|2005-09-07|Estimate|||||||2016-09-28|2016-09-29|Estimate||||September 2009|2009-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis|Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase|Completed||Phase 3|280|Anticipated|Drugs for Neglected Diseases|||||f||||||||||||||2018-06-01 04:44:40.183025|2018-06-01 04:44:40.183025
NCT00146614|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2012-03-06|2005-09-06|2005-09-07|Estimate|||||||2012-03-06|2012-03-08|Estimate|July 2002||2002-07-31|March 2012|2012-03-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation|Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Allogeneic Non-Myeloablative Peripheral Blood Stem Cell Transplantation|Completed||Phase 2|105||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:44:41.47935|2018-06-01 04:44:41.47935
NCT00146601|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2007-12-20|2005-09-06|2005-09-07|Estimate|||||||2007-12-20|2007-12-21|Estimate|June 2004||2004-06-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer|A Phase II Study of Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer|Completed||Phase 2|35|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:44:41.641572|2018-06-01 04:44:41.641572
NCT00146588|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2015-03-23|2005-09-06|2005-09-07|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2002||2002-04-30|October 2014|2014-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer|A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer|Completed||N/A|55|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:44:41.869429|2018-06-01 04:44:41.869429
NCT00146575|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2008-01-10|2005-09-06|2005-09-07|Estimate|||||||2008-01-10|2008-01-11|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|February 2005|Actual|2005-02-28|||||Interventional|||Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)|Randomized Trial of Paclitaxel-Eluting Stent and Sirolimus-Eluting Stent for Restenosis Reduction in Small Coronary Vessels (ISAR-SMART-3)|Completed||Phase 4|360|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:44:42.209588|2018-06-01 04:44:42.209588
NCT00146562|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-02-15|2005-09-02|2005-09-07|Estimate|||||||2013-02-15|2013-02-18|Estimate|July 2003||2003-07-31|February 2013|2013-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer|A Phase II Study of Pegfilgrastim (Neulasta) and Darbepoetin Alfa (Aranesp) in Support of Dose-Dense Adjuvant Chemotherapy for Breast Cancer|Completed||Phase 2|109|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:44:42.53458|2018-06-01 04:44:42.53458
NCT00146549|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-10-30|2005-09-02|2005-09-07|Estimate|||||||2009-10-30|2009-11-02|Estimate|August 2001||2001-08-31|October 2009|2009-10-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer|A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-based Chemotherapy in Patients With HER2 Overexpressing Metastatic Breast Cancer|Completed||Phase 3|250||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:44:42.71204|2018-06-01 04:44:42.71204
NCT00146536|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2017-03-30|2005-09-02|2005-09-07|Estimate|||||||2017-03-30|2017-03-31|Actual|November 2004||2004-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy|The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma, DCIS, or Atypical Ductal Hyperplasia (ADH) in Patients Diagnosed With Lobular Neoplasia of the Breast by Core Needle Biopsy|Completed|||78|Anticipated|Dana-Farber Cancer Institute|||||f||||f||||||Samples With DNA|"~     Option of keeping tissue sample for further research~   "|||2018-06-01 04:44:42.952494|2018-06-01 04:44:42.952494
NCT00146523|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-02-14|2005-09-02|2005-09-07|Estimate|||||||2012-02-14|2012-02-15|Estimate|May 2005||2005-05-31|February 2012|2012-02-29|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression|An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD)|Completed||Phase 3|247|Actual|Corcept Therapeutics||2|||f||||f||||||||||2018-06-01 04:44:43.111337|2018-06-01 04:44:43.111337
NCT00146510|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2014-03-12|2005-09-02|2005-09-07|Estimate|||||||2014-03-12|2014-03-13|Estimate|March 2004||2004-03-31|March 2014|2014-03-31|February 2006||2006-02-28|||||Interventional|||HealtheTech Lifestyle Program|HealtheLifestyle Behavioral Intervention Clinical Trial|Completed||Phase 1|130||The Cooper Institute|||||f||||||||||||||2018-06-01 04:44:43.250066|2018-06-01 04:44:43.250066
NCT00146497|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2006-06-26|2005-09-04|2005-09-07|Estimate|||||||2006-06-26|2006-06-27|Estimate|August 2004||2004-08-31|June 2006|2006-06-30||||||||Interventional|||Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants||Terminated||Phase 4|30||China Medical University Hospital|||||f||||||||||||||2018-06-01 04:44:43.37049|2018-06-01 04:44:43.37049
NCT00146484|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2005-09-06|2005-09-06|2005-09-07|Estimate|||||||2005-09-06|2005-09-07|Estimate|April 1996||1996-04-30|September 2005|2005-09-30|January 2001||2001-01-31|||||Interventional|||A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes|A Randomized Controlled Trial of Two Versus Three Daily Insulin Injections in Children and Adolescents With New Onset Type 1 Diabetes Mellitus|Completed||Phase 2|100||Children's Hospital of Eastern Ontario|||||f||||||||||||||2018-06-01 04:44:43.498417|2018-06-01 04:44:43.498417
NCT00146471|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-12-29|2005-09-06|2005-09-07|Estimate|||||||2009-12-29|2009-12-30|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|September 2007|Actual|2007-09-30|July 2007|Actual|2007-07-31||Interventional|||Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome|Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome [Sicherheit Und Wirksamkeit Von Levetiracetam (Keppra) für Die Behandlung Des stationären Alkoholentzugsyndroms]|Completed||Phase 3|120|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 04:44:43.594179|2018-06-01 04:44:43.594179
NCT00146458|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2006-09-19|2005-09-06|2005-09-07|Estimate|||||||2006-09-19|2006-09-20|Estimate|January 2002||2002-01-31|September 2006|2006-09-30|December 2007||2007-12-31|||||Interventional|||Usefulness of FDG-PET for Advanced Cervical Cancer|A Phase III Randomized Trial of FDG-PET in the Management of Advanced Cervical Cancer With Enlarged Pelvic Lymph Node on MRI Image|Unknown status|Active, not recruiting|Phase 3|200||Chang Gung Memorial Hospital|||||f||||||||||||||2018-06-01 04:44:43.739605|2018-06-01 04:44:43.739605
NCT00146445|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-09-26|2005-09-02|2005-09-07|Estimate|||||||2012-09-26|2012-09-27|Estimate|August 2001||2001-08-31|September 2012|2012-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Behavioral Intervention Trial for HIV-infected Injection Drug Users|Intervention for Seropositive Injection Drug Users - Research and Evaluation (INSPIRE)|Completed||Phase 2/Phase 3|1000||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:44:43.876751|2018-06-01 04:44:43.876751
NCT00146432|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-08-21|2005-09-06|2005-09-07|Estimate|||||||2009-08-21|2009-08-25|Estimate||||August 2009|2009-08-31||||||||Interventional|||Immunoadsorption of LPS, C5a and IL-6 in Severe Sepsis and Septic Shock (ISASS-1)|Prospective, Controlled Pilot Trial: Treatment of Patients in Severe Sepsis and Septic Shock With Immunoadsorption of LPS, IL-6, C5a|Completed||Phase 2/Phase 3|||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:44:44.000822|2018-06-01 04:44:44.000822
NCT00146419|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-07-28|2005-09-02|2005-09-07|Estimate|||||||2015-07-28|2015-07-30|Estimate|March 2004||2004-03-31|September 2012|2012-09-30|June 2013|Actual|2013-06-30|August 2006|Actual|2006-08-31||Observational|||Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)|Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)|Completed|||699|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:44:44.107462|2018-06-01 04:44:44.107462
NCT00146406|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-09-10|2005-09-02|2005-09-07|Estimate|||||||2012-09-10|2012-09-11|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Multi-level Interventions for STD Prevention Among Adolescents|Integrated Multi-level Interventions to Improve Adolescent Health Through the Prevention of STD, Including HIV, and Teen Pregnancy|Terminated||N/A|36502|Actual|Centers for Disease Control and Prevention||||IRB terminated due to no continuation request.|f||||||||||||||2018-06-01 04:44:44.330065|2018-06-01 04:44:44.330065
NCT00146393|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-12-08|2005-09-02|2005-09-07|Estimate|||||||2005-12-08|2005-12-09|Estimate|July 2003||2003-07-31|September 2005|2005-09-30|June 2004||2004-06-30|||||Interventional|||Health Benefits of an Exercise Program for Adults With Arthritis|Evaluation of People With Arthritis Can Exercise|Completed||Phase 2/Phase 3|347||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:44:44.444192|2018-06-01 04:44:44.444192
NCT00146380|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-09-26|2005-09-02|2005-09-07|Estimate|||||||2012-09-26|2012-09-27|Estimate|July 2003||2003-07-31|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|January 2009|Actual|2009-01-31||Interventional|KiBS||A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding|A Phase II Open Label Clinical Trial of Maternal Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Maximal Reduction of Mother-to-child HIV Transmission in Resource-limited Settings Among Breastfeeding Populations|Unknown status|Active, not recruiting|Phase 2|520|Anticipated|Centers for Disease Control and Prevention|||||f||||t||||||||||2018-06-01 04:44:44.57513|2018-06-01 04:44:44.57513
NCT00146367|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-12|2005-09-02|2005-09-07|Estimate|||||||2005-09-12|2005-09-14|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|October 2005||2005-10-31|||||Interventional|||Evaluation of the Active Living Every Day Exercise Program for People With Arthritis|Evaluation of the Health Benefits of the Active Living Every Day Physical Activity Program Among Persons With Arthritis|Completed||Phase 2/Phase 3|355||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:44:44.698526|2018-06-01 04:44:44.698526
NCT00146354|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-03-01|2005-09-02|2005-09-07|Estimate|||||||2007-03-01|2007-03-02|Estimate||||August 2005|2005-08-31||||||||Interventional|||The Effects of a Results Management System on Physician Awareness of Post-Discharge Test Results|The Effects of a Results Management System on Physician Awareness of Post-Discharge Laboratory and Radiology Results|Completed||Phase 3|||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:44:44.90509|2018-06-01 04:44:44.90509
NCT00146341|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2017-12-27|2005-09-05|2005-09-07|Estimate|||||||2017-12-27|2017-12-28|Actual|April 2005||2005-04-30|December 2017|2017-12-31|September 2006||2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg|An Eight Week Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg to Telmisartan 80mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80mg.|Completed||Phase 3|345|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:44:45.037713|2018-06-01 04:44:45.037713
NCT00146328|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|2009-05-26||2014-01-31|2005-09-05|2005-09-07|Estimate|2009-05-26|2009-07-16|Estimate||||2014-01-31|2014-03-06|Estimate|April 2001||2001-04-30|January 2014|2014-01-31||||May 2008|Actual|2008-05-31||Interventional|||Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects|A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects|Completed||Phase 2/Phase 3|997|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-06-01 04:44:45.327779|2018-06-01 04:44:45.327779
NCT00146315|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2011-05-31|2005-09-06|2005-09-07|Estimate|||||||2011-05-31|2011-06-01|Estimate|January 2005||2005-01-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||ESCAP: Supervised Exercise for Patients With Coronary Heart Disease in the Primary Care Setting|Effectiveness of the Supervised Exercise for Patients With Coronary Heart Disease in the Primary Care Setting (ESCAP): a Randomized Clinical Trial|Completed||Phase 3|97|Actual|Basque Health Service||2|||f||||f||||||||||2018-06-01 04:44:48.697409|2018-06-01 04:44:48.697409
NCT00146302|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-05|||2012-03-16|2005-09-05|2005-09-07|Estimate|||||||2012-03-16|2012-03-19|Estimate|November 2002||2002-11-30|March 2012|2012-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth in Developing Countries?|BCG Vaccination and Childhood Morbidity and Mortality: Interventions With Possible Implications for the Immunisation Policy in Developing Countries. Should Low Birth Weight Infants Be Vaccinated With BCG Vaccine at Birth?|Completed||Phase 4|2320|Actual|Bandim Health Project|||||f||||||||||||||2018-06-01 04:44:48.905804|2018-06-01 04:44:48.905804
NCT00146289|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-10-31|2005-09-02|2005-09-07|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 2005||2005-02-28|October 2013|2013-10-31||||October 2005|Actual|2005-10-31||Interventional|||The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects|A Randomised, DB, Placebo-controlled, Parallel Group, 16-wk MICARDIS (160mg) Tab, Proof-of-concept, Evaluating Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive, Using the OGTT, With a Clamp Sub-group|Completed||Phase 2|138||Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:44:49.069132|2018-06-01 04:44:49.069132
NCT00146276|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-09-26|2005-09-02|2005-09-07|Estimate|||||||2006-09-26|2006-09-27|Estimate|July 2000||2000-07-31|September 2005|2005-09-30||||||||Interventional|||Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer|Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study|Unknown status|Recruiting|Phase 3|178||Association of Urologic Oncology (AUO)|||||f||||||||||||||2018-06-01 04:44:49.287436|2018-06-01 04:44:49.287436
NCT00146263|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2010-09-05|2005-09-04|2005-09-07|Estimate|||||||2010-09-05|2010-09-08|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|June 2007||2007-06-30|||||Interventional|||Cognitive Training in the Elderly|The Effect of Computerized Cognitive Training on Neuropsychological Measures of Cognitive Function in the Elderly|Unknown status|Recruiting|N/A|300|Anticipated|Beersheva Mental Health Center|||||f||||||||||||||2018-06-01 04:44:49.552117|2018-06-01 04:44:49.552117
NCT00146250|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2018-01-09|2005-09-06|2005-09-07|Estimate|||||||2018-01-09|2018-01-11|Actual|March 1, 2005|Actual|2005-03-01|January 2018|2018-01-31|September 30, 2005|Actual|2005-09-30|July 20, 2005|Actual|2005-07-20||Interventional|||The Effect of N2O Administration on Arterial Oxygenation|Relationship of Oxygenation During Anaesthesia in the Presence of N2O or N2 to Mode of Ventilation|Completed||Phase 4|20|Actual|Austin Health||2|||f||||f|t|f|||f|||||2018-06-01 04:44:49.79874|2018-06-01 04:44:49.79874
NCT00146237|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2009-11-23|2005-09-06|2005-09-07|Estimate|||||||2009-11-23|2009-11-25|Estimate|November 2003||2003-11-30|November 2009|2009-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Phenytoin as an Augmentation for SSRI Failures|Phenytoin as an Augmentation for SSRI Failures: A Controlled Study|Completed||Phase 4|40|Anticipated|Beersheva Mental Health Center|||||f||||||||||||||2018-06-01 04:44:50.004712|2018-06-01 04:44:50.004712
NCT00146224|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-06|||2010-02-25|2005-09-06|2005-09-07|Estimate|||||||2010-02-25|2010-02-26|Estimate|September 2005||2005-09-30|February 2010|2010-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis|A Randomized, Double-Blind, Equivalence Study of the Efficacy of Epoetin Alfa Manufactured by Deep Tank Bioreactor Technology and Epoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) Receiving Hemodialysis|Completed||Phase 3|420|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 04:44:50.119315|2018-06-01 04:44:50.119315
NCT00146211|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-12-24|2005-09-02|2005-09-07|Estimate|||||||2007-12-24|2007-12-27|Estimate|September 2005||2005-09-30|December 2007|2007-12-31|July 2007|Actual|2007-07-31|August 2007|Actual|2007-08-31||Interventional|||TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease|A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease|Completed||Phase 3|300|Actual|Amarin Neuroscience Ltd|||||f||||||||||||||2018-06-01 04:44:50.27136|2018-06-01 04:44:50.27136
NCT00146198|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2006-12-18|2005-09-04|2005-09-07|Estimate|||||||2006-12-18|2006-12-20|Estimate|September 2005||2005-09-30|December 2006|2006-12-31|February 2006||2006-02-28|||||Interventional|||Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects After Inguinal Hernia Repair|Completed||Phase 2|40||AlgoRx Pharmaceuticals|||||f||||||||||||||2018-06-01 04:44:50.501849|2018-06-01 04:44:50.501849
NCT00146185|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-04|||2005-11-15|2005-09-04|2005-09-07|Estimate|||||||2005-11-15|2005-11-16|Estimate|February 2005||2005-02-28|April 2005|2005-04-30|July 2005||2005-07-31|||||Interventional|||Efficacy and Safety of ALGRX 3268 in Children Undergoing Minor Needle-Stick Procedures.|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Effectiveness and Safety of ALGRX 3268 in Pediatric Subjects.|Completed||Phase 3|504||AlgoRx Pharmaceuticals|||||||||||||||||||2018-06-01 04:44:50.67443|2018-06-01 04:44:50.67443
NCT00146172|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2017-08-10||2017-08-10|2005-09-02|2005-09-05|Estimate|2017-08-10|2018-02-13|Actual||||2017-08-10|2018-02-13|Actual|November 2003|Actual|2003-11-30|August 2017|2017-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study Evaluating HKI-272 in Tumors|An Ascending Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Subjects With HER-2/NEU or HER-1/EGFR-Positive Tumors|Completed||Phase 1|72|Actual|Puma Biotechnology, Inc.||1|||||||||||||||||2018-06-01 04:44:51.179295|2018-06-01 04:44:51.179295
NCT00146159|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-12-21|2005-09-01|2005-09-05|Estimate|||||||2007-12-21|2007-12-28|Estimate|March 2005||2005-03-31|December 2007|2007-12-31||||September 2007|Actual|2007-09-30||Interventional|||Study Evaluating Mitoxantrone in Multiple Sclerosis|A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis|Terminated||Phase 3|336|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer||3|||f||||||||||||||2018-06-01 04:44:53.58705|2018-06-01 04:44:53.58705
NCT00146146|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2018-03-19|2005-09-01|2005-09-05|Estimate|||||||2018-03-19|2018-03-21|Actual|May 2005||2005-05-31|February 2009|2009-02-28|January 2008|Actual|2008-01-31|May 2006|Actual|2006-05-31||Interventional|||Testosterone and Its Metabolites in GID|Role of Testosterone and Its Metabolites Regarding Different Physiological Functions in Subjects Affected by Gender Identity Disorder (FtM Transsexuals)|Completed||Phase 3|15|Actual|Unita Complessa di Ostetricia e Ginecologia|||||f||||f||||||||||2018-06-01 04:44:53.669198|2018-06-01 04:44:53.669198
NCT00146133|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-05-02|2005-09-02|2005-09-05|Estimate|||||||2006-05-02|2006-05-03|Estimate|January 2003||2003-01-31|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Weight Loss and Exercise in Physically Limited Obese Elderly Subjects|Effect of Weight Loss and Physical Training on Musculoskeletal Status, Physical Function, and Quality-of-Life in Physically Limited, Obese, Elderly Subjects|Completed||Phase 3|28||Washington University School of Medicine|||||f||||||||||||||2018-06-01 04:44:53.739826|2018-06-01 04:44:53.739826
NCT00146120|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2009-02-05|2005-09-01|2005-09-05|Estimate|||||||2009-02-05|2009-02-09|Estimate|May 1998||1998-05-31|December 2008|2008-12-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result|Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result|Completed||Phase 3|400||University of Ulm|||||f||||||||||||||2018-06-01 04:44:53.794792|2018-06-01 04:44:53.794792
NCT00146107|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-04-22|2005-09-02|2005-09-05|Estimate|||||||2013-04-22|2013-04-23|Estimate|January 2005||2005-01-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Weight Loss and Exercise in Obese, Physically Limited, Older Women and Men|Weight Loss and Exercise in Frail Obese Elderly Subjects|Completed||Phase 3|107|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-06-01 04:44:53.899457|2018-06-01 04:44:53.899457
NCT00146094|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2011-08-29|2005-09-02|2005-09-05|Estimate|||||||2011-08-29|2011-08-30|Estimate|March 2003||2003-03-31|August 2011|2011-08-31||||||||Interventional|||Bone Mineral Density (BMD) in HIV Infection|Osteopenia and Osteoporosis in HIV Infection. Prospective BMD Measurement in Antiretroviral (ARV) Treated and Untreated HIV-1 Infected Patients|Completed||N/A|||University Hospital, Strasbourg, France|||||f||||||||||||||2018-06-01 04:44:54.271469|2018-06-01 04:44:54.271469
NCT00146081|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-03-26|2005-09-01|2005-09-05|Estimate|||||||2008-03-26|2008-03-31|Estimate|August 2002||2002-08-31|March 2008|2008-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|SHARE||Weight Management Skills in African American Outpatients|Weight Management Skills in African American Outpatients|Completed||N/A|344||University of Pennsylvania||4|||f||||||||||||||2018-06-01 04:44:54.380472|2018-06-01 04:44:54.380472
NCT00146068|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-02-28|2005-09-01|2005-09-05|Estimate|||||||2008-02-28|2008-03-05|Estimate|September 2004||2004-09-30|February 2008|2008-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis|Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period|Completed||Phase 4|30||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 04:44:54.450799|2018-06-01 04:44:54.450799
NCT00146055|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-08-07|2005-09-02|2005-09-05|Estimate|||||||2012-08-07|2012-08-09|Estimate|March 2000||2000-03-31|August 2012|2012-08-31|October 2007|Actual|2007-10-31|November 2004|Actual|2004-11-30||Interventional|||Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood|Low-Intensity Preparative Regimen and Allogeneic Peripheral Blood Stem Cell Transplantation From Unrelated Donor in Patients With Hematologic Malignancy|Completed||Phase 2|60||University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:44:54.533356|2018-06-01 04:44:54.533356
NCT00146042|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-10-03|2005-09-01|2005-09-05|Estimate|||||||2012-10-03|2012-10-05|Estimate|March 1999||1999-03-31|October 2012|2012-10-31|March 2005|Actual|2005-03-31|March 2004|Actual|2004-03-31||Interventional|||UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer|Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer|Completed||Phase 2|22|Actual|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:44:54.603357|2018-06-01 04:44:54.603357
NCT00146029|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-03-24|2005-09-02|2005-09-05|Estimate|||||||2008-03-24|2008-03-26|Estimate||||March 2008|2008-03-31||||||||Observational|||Companion Pharmacogenetic Study to UMCC 9900/9901||Terminated|||||University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:44:54.694733|2018-06-01 04:44:54.694733
NCT00146016|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-09-01|2005-09-01|2005-09-05|Estimate|||||||2005-09-01|2005-09-05|Estimate|February 2000||2000-02-29|September 2005|2005-09-30|January 2007||2007-01-31|||||Interventional|||Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients|Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients|Completed||Phase 3|390||UMC Utrecht|||||f||||||||||||||2018-06-01 04:44:54.815943|2018-06-01 04:44:54.815943
NCT00146003|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-08-06|2005-09-02|2005-09-05|Estimate|||||||2008-08-06|2008-08-07|Estimate|March 2005||2005-03-31|August 2008|2008-08-31|December 2007||2007-12-31|||||Interventional|||Efalizumab for Eczema|Investigator-Initiated Trial of Efalizumab for Atopic Dermatitis: A Proof of Concept Study in Adults|Completed||Phase 2|10||Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:44:54.895557|2018-06-01 04:44:54.895557
NCT00145990|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-03-01|2005-09-02|2005-09-05|Estimate|||||||2012-03-01|2012-03-05|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||The Impact of Dosimeter on Measurement of Airway Responsiveness to Methacholine||Completed||N/A|12||University of Florida|||||f||||||||||||||2018-06-01 04:44:54.959878|2018-06-01 04:44:54.959878
NCT00145977|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-04-14|2005-09-02|2005-09-05|Estimate|||||||2016-04-14|2016-04-18|Estimate|July 2001||2001-07-31|April 2016|2016-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Texture Analysis for Postmenopausal Osteoporosis|Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis|Completed||N/A|36|Actual|University of Chicago||2|||f||||f||||||||No||2018-06-01 04:44:55.048124|2018-06-01 04:44:55.048124
NCT00145964|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-11-28|2005-09-02|2005-09-05|Estimate|||||||2005-11-28|2005-11-29|Estimate|August 2004||2004-08-31|August 2005|2005-08-31||||||||Observational|||Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)|Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)|Unknown status|Recruiting||500||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:44:55.140767|2018-06-01 04:44:55.140767
NCT00145951|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2014-03-27|2005-09-02|2005-09-05|Estimate|||||||2014-03-27|2014-03-28|Estimate|May 2006||2006-05-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|September 2007|Actual|2007-09-30||Observational|||Reducing the Risk of Developing Major Depression in Adolescents/Young Adults With Minor Depression/Depression Symptoms|Randomized Trial of a Motivational Interview Versus Brief Advice in Primary Care to Engage Mid-Late Adolescents With a Web-based Depression Prevention Intervention|Terminated|||93|Actual|University of Chicago|||3|Lost funding|f||||||||||||||2018-06-01 04:44:55.209456|2018-06-01 04:44:55.209456
NCT00145938|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-10-07|2005-09-01|2005-09-05|Estimate|||||||2013-10-07|2013-10-08|Estimate|September 2003||2003-09-30|September 2006|2006-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Sildenafil and Pulmonary Artery Pressure|A Pilot Study of the Effect of Chronic Administration of Sildenafil on Pulmonary Artery Pressure in Patients With Portopulmonary Hypertension|Terminated||Phase 2|10||University of Chicago||||Unable to complete study|f||||||||||||||2018-06-01 04:44:55.288648|2018-06-01 04:44:55.288648
NCT00145925|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-09-16|2005-09-02|2005-09-05|Estimate|||||||2008-09-16|2008-09-17|Estimate|June 2001||2001-06-30|September 2008|2008-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes|ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation|Completed||Phase 3|11140|Actual|The George Institute||2|||f||||t||||||||||2018-06-01 04:44:55.366426|2018-06-01 04:44:55.366426
NCT00145912|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-09-04|2005-09-02|2005-09-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2007||2007-02-28|September 2013|2013-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|CATCH-IT||Primary Care Based Depression Prevention for Adolescents/Young Adults/Young Adults and Young Adults|Primary Care Based Depression Prevention for Adolescents/Young Adults/Young Adults and Young Adults|Completed||N/A|49|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 04:44:55.449615|2018-06-01 04:44:55.449615
NCT00145886|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-01-08|2005-09-02|2005-09-05|Estimate|||||||2016-01-08|2016-01-12|Estimate|February 2003||2003-02-28|January 2016|2016-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||rhPTH Therapy for Low Turnover Bone Fragility|Effect of 12 Months Treatment With rhPTH on Calcium Balance, Bone Turnover, Bone Mineral Density, and Bone Micro-architecture in Patients With Fractures Associated With Low Bone Turnover and Sclerosing Bone Disorders|Terminated||Phase 1|2|Actual|University of Chicago||1||Slow enrollment|f||||f||||||||||2018-06-01 04:44:55.525412|2018-06-01 04:44:55.525412
NCT00145873|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-10-07|2005-09-01|2005-09-05|Estimate|||||||2013-10-07|2013-10-08|Estimate|August 2003||2003-08-31|September 2006|2006-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Nesiritide in Chronic Heart Failure|Continuous Infusion Nesiritide in Chronic Heart Failure-University of Chicago (CINCH-UC)|Terminated||Phase 2|20||University of Chicago||||Unable to complete study|f||||||||||||||2018-06-01 04:44:55.808281|2018-06-01 04:44:55.808281
NCT00145847|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-01-07|2005-09-02|2005-09-05|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2003||2003-04-30|January 2013|2013-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Naltrexone Treatment of Alcohol Abuse in Schizophrenia|Naltrexone Treatment of Alcohol Abuse in Schizophrenia|Completed||Phase 4|90|Actual|State University of New York - Upstate Medical University||2|||f||||t||||||||||2018-06-01 04:44:55.937593|2018-06-01 04:44:55.937593
NCT00145834|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-09-01|2005-09-01|2005-09-05|Estimate|||||||2005-09-01|2005-09-05|Estimate|February 2004||2004-02-29|September 2005|2005-09-30|April 2005||2005-04-30|||||Interventional|||Early Breastfeeding Cessation - is It Possible to Prevent?|A Randomised Community Based Experimental Trial in the Health Visitor's Practice Field|Completed||Phase 1|1456||University of Aarhus|||||f||||||||||||||2018-06-01 04:44:56.229626|2018-06-01 04:44:56.229626
NCT00145808|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-09-04|2005-09-02|2005-09-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2005||2005-06-30|September 2013|2013-09-30|November 2008|Actual|2008-11-30|June 2007|Actual|2007-06-30||Interventional|||Wireless Capsule Endoscopy in Ulcerative Colitis|Prospective Controlled Assessment of Wireless Capsule Endoscopy (WCE) in Ulcerative Colitis (UC)|Completed||Phase 3|116|Anticipated|University of Chicago|||||f||||||||||||||2018-06-01 04:44:56.296809|2018-06-01 04:44:56.296809
NCT00145795|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2012-10-24||2013-08-23|2005-09-02|2005-09-05|Estimate|2013-08-23|2013-08-27|Estimate||||2013-08-23|2013-08-27|Estimate|April 2004||2004-04-30|August 2013|2013-08-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment|Randomized Trial of a Switch to a Kaletra + Current Dual Nucleoside Reverse Transcriptase Inhibitor (NRTI) Backbone Versus Continuation of the Current Regimen in Patients With Poor Immune Responses to Highly Active Antiretroviral Therapy (HAART) in Patients With Complete Viral Suppression: A Pilot Study|Completed||Phase 4|20|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:44:56.396233|2018-06-01 04:44:56.396233
NCT00145782|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-09-01|2005-09-01|2005-09-05|Estimate|||||||2005-09-01|2005-09-05|Estimate|September 1991||1991-09-30|September 2005|2005-09-30|December 1999||1999-12-31|||||Interventional|||The Ebeltoft Health Promotion Project|The Ebeltoft Health Promotion Project - A Randomized Controlled Trial With Multiphasic Preventive Health Screenings and Discussions in General Practice.|Completed||Phase 3|||University of Aarhus|||||f||||||||||||||2018-06-01 04:44:56.819368|2018-06-01 04:44:56.819368
NCT00145769|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-08-07|2005-09-02|2005-09-05|Estimate|||||||2013-08-07|2013-08-09|Estimate|July 2001||2001-07-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|June 2009|Actual|2009-06-30||Interventional|||A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum|A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum|Completed||Phase 3|326|Actual|Trans-Tasman Radiation Oncology Group (TROG)||3|||f||||t||||||||||2018-06-01 04:44:56.888283|2018-06-01 04:44:56.888283
NCT00145756|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-05|Estimate|||||||2005-09-02|2005-09-05|Estimate|May 2004||2004-05-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||China Salt Substitute Study|China Salt Substitute Study-A Randomised Trial to Determine the Long-Term Effects of a Low Sodium, High Potassium Salt Substitute on Blood Pressure Among High-Risk Individuals in Northern China|Completed||N/A|600||The George Institute|||||f||||||||||||||2018-06-01 04:44:57.002844|2018-06-01 04:44:57.002844
NCT00145743|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-11-26|2005-09-01|2005-09-05|Estimate|||||||2007-11-26|2007-11-27|Estimate|November 2004||2004-11-30|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer|Diagnostics and Therapy of Disease-Related Quality of Life of Patients With Breast Cancer: Protocol of a Randomized Clinical Trial at the Tumor Center Regensburg|Completed||Phase 1/Phase 2|200|Actual|Tumorzentrum Regensburg e.V.||2|||f||||t||||||||||2018-06-01 04:44:57.062148|2018-06-01 04:44:57.062148
NCT00145730|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-11-28|2005-09-02|2005-09-05|Estimate|||||||2006-11-28|2006-11-29|Estimate|February 2002||2002-02-28|September 2005|2005-09-30|May 2004||2004-05-31|||||Interventional|||Prevention of Ectopic Bone Related Pain and Disability After Hip Replacement Surgery With Peri-Operative Ibuprofen|A Multicentre Randomised Placebo-Controlled Trail of Ibuprofen for the Prevention of Ectopic Bone-Related Pain and Disability After Elective Hip Replacement Surgery (HIPAID)|Completed||Phase 4|1000||The George Institute|||||f||||||||||||||2018-06-01 04:44:57.123503|2018-06-01 04:44:57.123503
NCT00145717|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-05|Estimate|||||||2005-09-02|2005-09-05|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||China Plant Sterol Trial|China Plant Sterol Trial – A Randomised Trial to Determine the Effects on Blood Cholesterol Levels of a Milk Tea Product Enriched With Plant Sterol Among 300 Chinese Living in Beijing|Completed||Phase 3|300||The George Institute|||||f||||||||||||||2018-06-01 04:44:57.182084|2018-06-01 04:44:57.182084
NCT00145704|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2010-10-26||2013-03-01|2005-09-02|2005-09-05|Estimate|2013-03-01|2013-04-08|Estimate||||2013-03-01|2013-04-08|Estimate|June 2002||2002-06-30|March 2013|2013-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density|Treatment of Childhood Cancer Therapy-induced Osteopenia in Growth Hormone Deficient Adult Survivors: Does Bisphosphonate Treatment Improve Bone Mineral Density?|Terminated||N/A|6|Actual|State University of New York - Upstate Medical University|Early termination due to low enrollment, and lost to follow up of three subjects. Data was limited and therefore not reviewed/analyzed|2||due to low enrollment, participants are no longer being examined or treated|f||||f||||||||||2018-06-01 04:44:57.331183|2018-06-01 04:44:57.331183
NCT00145691|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-03-20|2005-09-01|2005-09-05|Estimate|||||||2007-03-20|2007-03-21|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|October 2006|Actual|2006-10-31|||||Interventional|||The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD)|The Effect of Oxcarbazepine in the Treatment of Agitation / Aggression in Dementia (OBAD) - An Eight Week Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi Center Trial. A Phase III Study|Completed||Phase 3|100||Sykehuset Innlandet HF|||||f||||t||||||||||2018-06-01 04:44:57.494266|2018-06-01 04:44:57.494266
NCT00145678|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-01-05|2005-09-01|2005-09-05|Estimate|||||||2015-01-05|2015-01-06|Estimate|June 2004||2004-06-30|January 2015|2015-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder|Psychodynamic Therapy for Patients With Borderline Personality Disorder and Alcohol Abuse|Completed||Phase 2|30|Actual|State University of New York - Upstate Medical University||2|||f||||f||||||||||2018-06-01 04:44:57.634157|2018-06-01 04:44:57.634157
NCT00145665|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-09-02|2005-09-01|2005-09-05|Estimate|||||||2011-09-02|2011-09-05|Estimate|January 2005||2005-01-31|February 2007|2007-02-28|December 2012|Anticipated|2012-12-31|December 2011|Anticipated|2011-12-31||Interventional|||The Role of Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases|The Role of 3-Deoxy-3[18]Fluorothymidine Positron Emission Tomography (FLT-PET) in Proliferation of Colorectal Liver Metastases|Terminated||Phase 1/Phase 2|80|Anticipated|Radboud University||||no accrual achieved|f||||||||||||||2018-06-01 04:44:57.726248|2018-06-01 04:44:57.726248
NCT00145652|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-07-27|2005-09-01|2005-09-05|Estimate|||||||2007-07-27|2007-07-30|Estimate|December 2003||2003-12-31|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.|Phase 3 Study of Recombinant Erythropoetin and Adjuvant I.V. Iron Therapy of Anemic Patients With Lymphoproliferative Disorders|Completed||Phase 3|66||Sundsvall Hospital|||||f||||||||||||||2018-06-01 04:44:57.804536|2018-06-01 04:44:57.804536
NCT00145639|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-06-08|2005-09-02|2005-09-05|Estimate|||||||2011-06-08|2011-06-10|Estimate|May 1999||1999-05-31|June 2011|2011-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma|Osteosarcoma 1999-A Study Of Intensive Chemotherapy Utilizing Ifosfamide, Carboplatin, and Doxorubicin for Adjuvant Chemotherapy for Treatment of Osteosarcoma|Completed||Phase 2|80|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:44:57.882583|2018-06-01 04:44:57.882583
NCT00145626|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2015-06-08||2017-05-25|2005-09-01|2005-09-05|Estimate|2015-11-05|2015-12-14|Estimate||||2017-05-25|2017-06-19|Actual|May 2004||2004-05-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|March 2015|Actual|2015-03-31||Interventional||All evaluable participants are included.|HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies|HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies|Completed||Phase 2|40|Actual|St. Jude Children's Research Hospital|The study was limited due to the unavailability of the study drug OKT3 beginning in June 2011. The study was temporarily closed to accrual. Because OKT3 is still unavailable, the study was formally closed to accrual in March 2015.|1|||f||||f|f|t|f|||||||2018-06-01 04:44:58.009144|2018-06-01 04:44:58.009144
NCT00145613|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2009-02-12|2005-09-01|2005-09-05|Estimate|||||||2009-02-12|2009-02-13|Estimate|June 2003||2003-06-30|February 2009|2009-02-28|February 2009|Actual|2009-02-28|July 2006|Actual|2006-07-31||Interventional|||Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies|Haploidentical Stem Cell Transplantation Utilizing T-Cell Depletion as Therapy for Patients With Refractory Hematological Malignancies|Completed||Phase 2|25|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:44:58.739302|2018-06-01 04:44:58.739302
NCT00145600|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2013-02-12||2018-01-30|2005-09-02|2005-09-05|Estimate|2013-03-25|2013-05-07|Estimate||||2018-01-30|2018-02-27|Actual|March 2, 2000|Actual|2000-03-02|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|May 31, 2012|Actual|2012-05-31||Interventional|||Therapy for Pediatric Hodgkin Lymphoma|Risk-Adapted Therapy for Pediatric Hodgkin's Disease|Active, not recruiting||Phase 2|296|Actual|St. Jude Children's Research Hospital||4|||f||||t|t|f||||||||2018-06-01 04:44:58.85494|2018-06-01 04:44:58.85494
NCT00145587|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2011-06-22||2017-04-24|2005-09-02|2005-09-05|Estimate|2011-07-25|2011-08-22|Estimate||||2017-04-24|2017-05-30|Actual|July 2004||2004-07-31|January 2011|2011-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Stem Cell Transplantation for Children Affected With Osteopetrosis|Allogeneic Hematopoietic Stem Cell Transplantation for Children Affected With Malignant Osteopetrosis: A Pilot Study|Terminated||N/A|15|Actual|St. Jude Children's Research Hospital|This study closed prior to completion of enrollment due to the principal investigator having left the institution.|1||Due to the principal investigator having left the institution.|f||||f||||||||||2018-06-01 04:45:00.26724|2018-06-01 04:45:00.26724
NCT00145574|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2009-11-06|2009-10-17|2010-04-08|2005-09-01|2005-09-05|Estimate|2009-12-18|2010-01-26|Estimate|2009-10-05|2009-10-07|Estimate|2010-04-08|2010-04-15|Estimate|November 2005||2005-11-30|April 2010|2010-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol|Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients With Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins or Treatment Naive to Lipid-lowering Therapy|Completed||Phase 4|194|Actual|Daiichi Sankyo, Inc.||3|||f||||||||||||||2018-06-01 04:45:00.679618|2018-06-01 04:45:00.679618
NCT00145561|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-10-21|2005-09-02|2005-09-05|Estimate|||||||2008-10-21|2008-10-22|Estimate|August 2005||2005-08-31|October 2008|2008-10-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-Infected Pregnant Women.|The Pharmacokinetics of SAquinavir (Invirase New Tablet Formulation) 1,000mg + Ritonavir (Norvir) 100mg q12h in HIV-Infected Pregnant Women (SARA)|Completed||Phase 1/Phase 2|40|Actual|Radboud University|||||f||||f||||||||||2018-06-01 04:45:01.96428|2018-06-01 04:45:01.96428
NCT00145548|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-06-14|2005-09-01|2005-09-05|Estimate|||||||2011-06-14|2011-06-16|Estimate|December 2003||2003-12-31|May 2007|2007-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Pilot Study of the Spiration IBV™ System|Pilot Study of the Spiration IBV™ System|Completed||Phase 2|91|Actual|Spiration, Inc.|||||f||||t||||||||||2018-06-01 04:45:02.322161|2018-06-01 04:45:02.322161
NCT00145535|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2010-01-28|2005-09-01|2005-09-05|Estimate|||||||2010-01-28|2010-01-29|Estimate|May 2004||2004-05-31|July 2009|2009-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||SOLX Titanium Sapphire Laser for Trabeculoplasty|SOLX Titanium Sapphire Laser for Trabeculoplasty|Completed||Phase 3|120|Anticipated|SOLX, Inc.||2|||f||||f||||||||||2018-06-01 04:45:02.557274|2018-06-01 04:45:02.557274
NCT00145522|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-03-31|2005-09-02|2005-09-05|Estimate|||||||2009-03-31|2009-04-01|Estimate|November 2005||2005-11-30|March 2009|2009-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women|A Twelve 28-Day Cycles, Multicenter, Prospective, Randomized, Open, Blinded Endpoint, Parallel Group Study Comparing the Effect on Breast and Cardiovascular Metabolic Markers of Continuously Combined 17β-Estradiol/Dydrogesterone and Tibolone in Postmenopausal Women.|Completed||Phase 4|135|Actual|Solvay Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:45:02.870898|2018-06-01 04:45:02.870898
NCT00145509|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2010-03-26|2009-04-23|2015-01-07|2005-09-02|2005-09-05|Estimate|2010-03-26|2010-04-16|Estimate|2009-10-02|2009-10-06|Estimate|2015-01-07|2015-01-16|Estimate|August 2005||2005-08-31|January 2015|2015-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||40 Week Trial to Study the Safety of Asenapine When Added to Lithium or Valproate in the Treatment of Bipolar Disorder (A7501009)(P05786)|A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode|Completed||Phase 3|77|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:45:03.091902|2018-06-01 04:45:03.091902
NCT00144651|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-08-06|2005-09-02|2005-09-05|Estimate|||||||2013-08-06|2013-08-09|Estimate|August 2001||2001-08-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Study of MRA in Patients With Rheumatoid Arthritis (RA)|An Open-label, Extension, Phase II Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Were Participated in Study MRA009JP|Completed||Phase 2|135|Actual|Chugai Pharmaceutical||1|||f||||f||||||||||2018-06-01 04:45:16.508018|2018-06-01 04:45:16.508018
NCT00145496|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2010-03-05|2009-04-17|2015-09-24|2005-09-02|2005-09-05|Estimate|2010-03-05|2010-03-25|Estimate|2009-10-02|2009-10-06|Estimate|2015-09-24|2015-09-25|Estimate|December 2004||2004-12-31|September 2015|2015-09-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)|A Multicenter, Double-Blind, Flexible -Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia.|Completed||Phase 3|468|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:45:03.483812|2018-06-01 04:45:03.483812
NCT00145483|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-01-30|2005-09-01|2005-09-05|Estimate|||||||2008-01-30|2008-01-31|Estimate|June 2002||2002-06-30|January 2008|2008-01-31||||||||Interventional|||Sildenafil For Meniere's Disease|A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Of The Efficacy and Safety Of Sildenafil Given For The Acute Treatment Of Meniere's Disease|Completed||Phase 2|180||Pfizer|||||f||||||||||||||2018-06-01 04:45:03.999758|2018-06-01 04:45:03.999758
NCT00145470|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-04-21|2005-09-01|2005-09-05|Estimate|||||||2015-04-21|2015-04-22|Estimate|June 2005||2005-06-30|April 2015|2015-04-30|March 2007|Actual|2007-03-31|February 2007|Actual|2007-02-28||Interventional|||12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008)(COMPLETED)(P05844)|A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode|Completed||Phase 3|324|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:45:04.123264|2018-06-01 04:45:04.123264
NCT00145457|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-06-05|2005-09-01|2005-09-05|Estimate|||||||2007-06-05|2007-06-06|Estimate|April 2001||2001-04-30|May 2007|2007-05-31|January 2005||2005-01-31|||||Interventional|CAREL||IGF1 Generation Test|A Multicentre Study on the Capacity of the IGF-1 Stimulation Test to Predict the Growth Promoting Effect of Standard and High Doses of Genotonorm® in Prepubertal Children With Growth Hormone Deficiency.|Completed||Phase 4|82||Pfizer|||||f||||||||||||||2018-06-01 04:45:04.257176|2018-06-01 04:45:04.257176
NCT00145444|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-12-28|2005-09-01|2005-09-05|Estimate|||||||2006-12-28|2007-01-01|Estimate|March 2003||2003-03-31|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study|A Multicenter, Double-Blind, Randomized Trial Of Ziprasidone (80 - 160 Mg) Versus Olanzapine (10 - 20 Mg) In Patients With Recent-Onset Schizophrenia, Schizoaffective And Schizophreniform Disorder.|Completed||Phase 3|100||Pfizer|||||f||||||||||||||2018-06-01 04:45:04.457789|2018-06-01 04:45:04.457789
NCT00145431|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31||2012-02-15|2012-02-15|2005-08-31|2005-09-05|Estimate||||2012-02-15|2012-02-17|Estimate|2012-02-15|2012-02-17|Estimate|March 2005||2005-03-31|February 2012|2012-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.|Phase 3, Multi-Center, Double-Blind, Randomized, Crossover Study Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (Cp-529,414)/Atorvastatin, Compared With Atorvastatin Therapy Alone, And Fenofibrate Alone, In Subjects With Fredrickson Type III Hyperlipoproteinemia (Familial Dysbetalipoproteinemia).|Terminated||Phase 3|41|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:45:04.636176|2018-06-01 04:45:04.636176
NCT00145418|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2011-07-20||2014-06-19|2005-09-02|2005-09-05|Estimate|2013-01-30|2013-01-31|Estimate||||2014-06-19|2014-06-30|Estimate|February 2005||2005-02-28|June 2014|2014-06-30|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer|Phase 2 Study Evaluating the Safety and Efficacy of Eloxatin (Oxaliplatin) and Docetaxel as First-line Therapy of Stage IV or IIIB Unresectable Non-Small Cell Lung Cancer|Terminated||Phase 2|15|Actual|Oncology Specialists, S.C.|Due to lack of recruitment, the study was closed early and conclusions should not necessarily be drawn from the data presented for duration of response|1||low enrollment|f||||f||||||||||2018-06-01 04:45:04.754004|2018-06-01 04:45:04.754004
NCT00145405|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-09-06|2005-09-02|2005-09-05|Estimate|||||||2006-09-06|2006-09-08|Estimate|September 2002||2002-09-30|September 2005|2005-09-30|December 2004||2004-12-31|||||Interventional|||Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction|Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction - A Twelve Month Randomized Cross-Over Study in Patients With Acromegaly|Completed||Phase 4|12||Odense University Hospital|||||f||||||||||||||2018-06-01 04:45:04.973662|2018-06-01 04:45:04.973662
NCT00145392|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-06-23|2005-09-02|2005-09-05|Estimate|||||||2008-06-23|2008-06-24|Estimate|September 2002||2002-09-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|January 2007|Actual|2007-01-31||Observational|||Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women|Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women|Completed|||10||Odense University Hospital|||||f||||f||||||||||2018-06-01 04:45:05.031831|2018-06-01 04:45:05.031831
NCT00145379|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-05-17|2005-09-02|2005-09-05|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 2003||2003-03-31|May 2013|2013-05-31|June 2006|Actual|2006-06-30|||||Interventional|||The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus|The Effect of Metformin in Overweight Patients With Dysregulated Type 1 Diabetes Mellitus|Completed||Phase 4|42|Actual|Odense University Hospital||2|||f||||||||||||||2018-06-01 04:45:05.084808|2018-06-01 04:45:05.084808
NCT00145366|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2010-12-27|2005-09-02|2005-09-05|Estimate|||||||2010-12-27|2010-12-28|Estimate|April 2002||2002-04-30|April 2009|2009-04-30|July 2005|Actual|2005-07-31|||||Interventional|||rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter|Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.|Completed||Phase 2|110||Odense University Hospital|||||f||||||||||||||2018-06-01 04:45:05.210566|2018-06-01 04:45:05.210566
NCT00145353|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2006-10-10|2005-09-02|2005-09-05|Estimate|||||||2006-10-10|2006-10-11|Estimate|November 2004||2004-11-30|October 2006|2006-10-31|June 2006||2006-06-30|||||Interventional|||Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose|Is Insulin NovoRapid Better Than Actrapid for Treating Type 1 Diabetic Patients When Simultaneously, Daily Adjusting the Insulin Dose?|Unknown status|Active, not recruiting|Phase 4|16||Odense University Hospital|||||f||||||||||||||2018-06-01 04:45:05.290001|2018-06-01 04:45:05.290001
NCT00145340|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-09-25|2005-09-02|2005-09-05|Estimate|||||||2008-09-25|2008-09-26|Estimate|September 2002||2002-09-30|September 2008|2008-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Pioglitazone Treatment in Polycystic Ovary Syndrome|The Effect of PPARgamma Stimulation on Glucose Metabolism, Insulin Resistance, Growth Hormone and Cortisol on Women Suffering From Polycystic Ovary Syndrome|Completed||Phase 4|30||Odense University Hospital|||||f||||t||||||||||2018-06-01 04:45:05.346317|2018-06-01 04:45:05.346317
NCT00145327|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2011-01-21||2011-06-24|2005-09-01|2005-09-05|Estimate|2011-03-23|2011-04-20|Estimate||||2011-06-24|2011-06-28|Estimate|May 2005||2005-05-31|June 2011|2011-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)|A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D|Completed||Phase 3|2456|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:45:05.585903|2018-06-01 04:45:05.585903
NCT00145314|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2011-01-13|2005-09-02|2005-09-05|Estimate|||||||2011-01-13|2011-01-14|Estimate|May 2005||2005-05-31|January 2011|2011-01-31|August 2010|Actual|2010-08-31|May 2009|Actual|2009-05-31||Interventional|||FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer|5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.|Completed||Phase 3|571|Actual|The Nordic Colorectal Cancer Biomodulation Group||3|||f||||||||||||||2018-06-01 04:45:09.88276|2018-06-01 04:45:09.88276
NCT00145301|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-05-18|2005-09-01|2005-09-05|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2004||2004-09-30|May 2012|2012-05-31||||November 2005|Actual|2005-11-30||Interventional|||52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine|A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in Patients With Primary Osteoarthritis of Hip, Knee, Hand or Spine|Completed||Phase 3|3036||Novartis|||||||||||||||||||2018-06-01 04:45:10.076855|2018-06-01 04:45:10.076855
NCT00145288|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-03-23|2005-09-02|2005-09-05|Estimate|||||||2007-03-23|2007-03-26|Estimate|October 2003||2003-10-31|March 2007|2007-03-31|March 2005||2005-03-31|||||Observational|||Prospective Study of Patients With Hirsutism|Prospective Study of Patients Med Hirsutism as Primary Work Diagnose|Unknown status|Active, not recruiting||340||Odense University Hospital|||||f||||f||||||||||2018-06-01 04:45:10.140056|2018-06-01 04:45:10.140056
NCT00145275|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-04-26|2005-09-01|2005-09-05|Estimate|||||||2012-04-26|2012-04-27|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women|To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women|Completed||Phase 3|455||Novartis|||||||||||||||||||2018-06-01 04:45:10.196321|2018-06-01 04:45:10.196321
NCT00145262|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-12-29|2005-09-02|2005-09-05|Estimate|||||||2005-12-29|2005-12-30|Estimate|August 2003||2003-08-31|August 2003|2003-08-31||||||||Observational|||TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation|Therapeutic Angiogenesis Using Cell Transplantation (TACT) Study at Nagoya|Unknown status|Recruiting||||Nagoya University|||||f||||||||||||||2018-06-01 04:45:10.263658|2018-06-01 04:45:10.263658
NCT00145249|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2010-03-18||2012-05-10|2005-09-02|2005-09-05|Estimate|2010-05-27|2010-06-23|Estimate||||2012-05-10|2012-05-16|Estimate|May 2005||2005-05-31|October 2009|2009-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis|A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis|Completed||Phase 2|143|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 04:45:10.375322|2018-06-01 04:45:10.375322
NCT00145236|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-09-12|2005-09-01|2005-09-05|Estimate|||||||2005-09-12|2005-09-14|Estimate|November 2001||2001-11-30|September 2005|2005-09-30|August 2003||2003-08-31|||||Interventional|||Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension|A Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension.|Completed||Phase 3|300||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:45:11.267801|2018-06-01 04:45:11.267801
NCT00145223|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2010-08-26|2005-09-02|2005-09-05|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2003||2003-08-31|March 2007|2007-03-31|July 2005||2005-07-31|||||Observational|||Research for Elim of Filariasis|Research for Elimination of Human Filariasis|Completed|||||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:45:11.383548|2018-06-01 04:45:11.383548
NCT00145210|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-03-06|2005-09-01|2005-09-05|Estimate|||||||2008-03-06|2008-03-07|Estimate|April 2005||2005-04-30|September 2005|2005-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans|A Double-Blind, Randomized, Placebo- and Active-Controlled, Forced Titration Study Evaluating the Effects of Nebivolol on Blood Pressure and Heart Rate in African American Patients With Hypertension|Completed||Phase 3|630|Anticipated|Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:45:11.489052|2018-06-01 04:45:11.489052
NCT00145197|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-12-02|2005-09-02|2005-09-05|Estimate|||||||2013-12-02|2013-12-03|Estimate|January 2004||2004-01-31|December 2013|2013-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Reducing Underuse of Early-Stage Breast Cancer Treatment in Minority Communities|Improving the Delivery of Effective Care to Minorities|Completed||N/A|1164|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-06-01 04:45:11.555091|2018-06-01 04:45:11.555091
NCT00145184|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-03-28|2005-09-02|2005-09-05|Estimate|||||||2015-03-28|2015-03-31|Estimate|May 2005||2005-05-31|March 2015|2015-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effect of Multivitamin Supplements on Clinical and Immunological Response in Childhood Tuberculosis|Effect of Multivitamin Supplements on Clinical and Immunological Response in Childhood Tuberculosis|Terminated||Phase 3|40|Actual|Harvard School of Public Health||2||Slow recruitment|f||||t||||||||||2018-06-01 04:45:11.636461|2018-06-01 04:45:11.636461
NCT00145171|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-05|Estimate|||||||2005-09-02|2005-09-05|Estimate|February 2001||2001-02-28|November 2002|2002-11-30|August 2002||2002-08-31|||||Interventional|||A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.|Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.|Completed||Phase 3|56||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:45:11.720827|2018-06-01 04:45:11.720827
NCT00144638|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-09-01|2005-09-01|2005-09-05|Estimate|||||||2005-09-01|2005-09-05|Estimate|January 2002||2002-01-31|February 2005|2005-02-28|January 2003||2003-01-31|||||Observational|||Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality|Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality|Completed|||450||Danish Procalcitonin Study Group|||||f||||||||||||||2018-06-01 04:45:16.568945|2018-06-01 04:45:16.568945
NCT00145158|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2009-06-19|2005-09-01|2005-09-05|Estimate|||||||2009-06-19|2009-06-22|Estimate|January 2005||2005-01-31|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|March 2009|Anticipated|2009-03-31||Interventional|||Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma|Phase I/II Study of Immunization With Multiple Peptides Mixed With the Immunological Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma|Suspended||Phase 1/Phase 2|28|Anticipated|Ludwig Institute for Cancer Research||||Availability of Investigational agent|f||||||||||||||2018-06-01 04:45:11.778453|2018-06-01 04:45:11.778453
NCT00145145|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-08-21|2005-09-01|2005-09-05|Estimate|||||||2007-08-21|2007-08-22|Estimate|January 2005||2005-01-31|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma|Phase I/II Study of Immunization With the MAGE-3.A1 Peptide Mixed With the Immunological Adjuvant CpG 7909 in Patients With Metastatic Melanoma|Terminated||Phase 1/Phase 2|14|Anticipated|Ludwig Institute for Cancer Research||||Poor Accrual|f||||||||||||||2018-06-01 04:45:11.845175|2018-06-01 04:45:11.845175
NCT00145132|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2010-06-01|2005-09-01|2005-09-05|Estimate|||||||2010-06-01|2010-06-02|Estimate|June 2005||2005-06-30|May 2010|2010-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Beta-CIT-SPECT and Neurophysiology in Depression|Serotonin and Dopamine Transporter (SERT, DAT) Availabilities as Assessed by b-CIT and SPECT, and Neurophysiological Measures of Central Serotonergic Activity in Patients With Depression Under Treatment With Escitalopram|Completed||Phase 4|30|Actual|Ludwig-Maximilians - University of Munich|||||f||||||||||||||2018-06-01 04:45:11.919814|2018-06-01 04:45:11.919814
NCT00145119|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2013-12-02||2015-11-04|2005-09-02|2005-09-05|Estimate|2013-12-02|2014-01-17|Estimate||||2015-11-04|2015-12-01|Estimate|August 2001||2001-08-31|January 2014|2014-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational||Survivors of an acute Myocardial Infarction (AMI) with impaired left ventricular ejection fraction|CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction|Incidence and Prediction of Life-threatening Cardiac Arrhythmias in Patients With Depressed Left Ventricular Function After Acute Myocardial Infarction|Completed|||312|Actual|Medtronic Bakken Research Center|||||f||||||||||||||2018-06-01 04:45:11.988726|2018-06-01 04:45:11.988726
NCT00145106|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-12-14|2005-09-01|2005-09-05|Estimate|||||||2005-12-14|2005-12-15|Estimate|March 2002||2002-03-31|September 2005|2005-09-30|August 2002||2002-08-31|||||Interventional|||Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris|Regimen of Tazorac .1% Gel & Minocycline Cap in Tx of Individuals w/Acne Vulgaris: Effects of Maintenance Therapy on Duration of Improvement of Tazorac .1% Gel Used in Conjunction w/Placebo Cap Compared w/Minocycline Cap Used in Conjunction w/Either Tazorac .1% Gel or Vehicle Gel|Completed||Phase 4|189||KGL, Inc.|||||f||||||||||||||2018-06-01 04:45:12.126142|2018-06-01 04:45:12.126142
NCT00145093|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-11-21|2005-09-02|2005-09-05|Estimate|||||||2005-11-21|2005-11-22|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|February 2005||2005-02-28|||||Interventional|||Effects of Chromium Supplementation on Parameters of the Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus|The Effects of Organic Chromium Supplementation on Clinical Parameters of the Metabolic Syndrome, in Patients With Type 2 Diabetes Mellitus. A Randomised, Double-Blind, Placebo-Controlled Trial|Completed||Phase 3|60||Medical Research Foundation, The Netherlands|||||f||||||||||||||2018-06-01 04:45:12.187231|2018-06-01 04:45:12.187231
NCT00145080|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-10-30|2005-09-02|2005-09-05|Estimate|||||||2015-10-30|2015-11-02|Estimate|July 2004||2004-07-31|October 2015|2015-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Comparison of Osteoporosis Disease Management Strategies (0000-039)|Evaluation of Strategies for Increasing Osteoporosis Screening and Treatment in a Managed Care Organization|Completed||N/A|4685|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:45:12.246768|2018-06-01 04:45:12.246768
NCT00145067|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-11-02|2005-09-02|2005-09-05|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2003||2003-11-30|November 2015|2015-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Osteoporosis Disease Management Demonstration Project (0000-040)|Three Methods of Delivering Health Care for Secondary Prevention of Osteoporosis|Completed||N/A|230|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:45:12.294377|2018-06-01 04:45:12.294377
NCT00145054|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-03-23|2005-09-01|2005-09-05|Estimate|||||||2006-03-23|2006-03-24|Estimate||||September 2005|2005-09-30||||||||Interventional|||Study of a Self-Help Depression Skills Program for College-Aged Youth|Randomized, Controlled Pilot Study of a Self-Help Depression Skills Program for College-Aged Youth|Completed||Phase 2/Phase 3|150||Kaiser Permanente|||||f||||||||||||||2018-06-01 04:45:12.34219|2018-06-01 04:45:12.34219
NCT00145041|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2011-11-29||2014-03-27|2005-09-01|2005-09-05|Estimate|2011-11-29|2012-01-05|Estimate||||2014-03-27|2014-04-17|Estimate|February 2005||2005-02-28|March 2014|2014-03-31|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction|An Evaluation of the Pharmacokinetic Profile of VSLI (Vincristine Sulfate Liposome Injection, 0.16 mg/mL) in Patients With Malignant Melanoma and Hepatic Dysfunction Secondary to Metastases|Completed||Phase 1|7|Actual|Spectrum Pharmaceuticals, Inc|The dose administered to subjects with impaired liver function was ~1 mg/m2 which is lower than is administered to subjects with normal liver function (2 mg/m2). The impact of liver impairment on that higher dose remains unknown.|1|||f||||f||||||||||2018-06-01 04:45:12.404277|2018-06-01 04:45:12.404277
NCT00145028|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-03-17|2005-09-02|2005-09-05|Estimate|||||||2009-03-17|2009-03-18|Estimate|May 2005||2005-05-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|December 2007|Actual|2007-12-31||Interventional|||Determination of Carboplatin's Optimal Plasmatic Exposure|Determination of Carboplatin's Optimal Plasmatic Exposure|Completed||N/A|400|Anticipated|Institut Claudius Regaud|||||f||||f||||||||||2018-06-01 04:45:12.607294|2018-06-01 04:45:12.607294
NCT00145015|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-07-29|2005-09-01|2005-09-05|Estimate|||||||2008-07-29|2008-07-30|Estimate|December 2004||2004-12-31|July 2008|2008-07-31|April 2008|Actual|2008-04-30|||||Interventional|||FishGastro Study: Fish Consumption and Gastro-Intestinal Health|Fish Consumption and Gastro-Intestinal Health With Special Emphasis on Reduction of Risk of Colon Cancer and Inflammatory Bowel Disease|Completed||N/A|270|Anticipated|Quadram Institute|||||f||||||||||||||2018-06-01 04:45:12.758373|2018-06-01 04:45:12.758373
NCT00145002|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-09-20|2005-09-01|2005-09-05|Estimate|||||||2016-09-20|2016-09-22|Estimate|August 1998||1998-08-31|September 2016|2016-09-30|December 2004||2004-12-31|||||Interventional|||A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)|Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.|Completed||Phase 3|130||Japan Clinical Oncology Group|||||f||||||||||||||2018-06-01 04:45:12.830362|2018-06-01 04:45:12.830362
NCT00143923|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2018-05-03|2005-09-01|2005-09-02|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2003||2003-03-31|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|HeartSCORE||Novel Strategies for Reducing Heart Disease Risk Disparities|Heart Strategies Concentrating On Risk Evaluation (Heart SCORE) Study|Active, not recruiting||N/A|2000|Actual|University of Pittsburgh||3|||f||||f|f|f||||||No||2018-06-01 04:45:36.523313|2018-06-01 04:45:36.523313
NCT00144989|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-09-20|2005-09-01|2005-09-05|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2002||2002-09-30|September 2016|2016-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC|A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF|Completed||Phase 3|281|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:45:12.960719|2018-06-01 04:45:12.960719
NCT00144976|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-03-26|2005-09-02|2005-09-05|Estimate|||||||2015-03-26|2015-03-27|Estimate|October 2003||2003-10-31|May 2008|2008-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma|Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up.|Completed||N/A|43|Actual|Institut Claudius Regaud|||||f||||t||||||||||2018-06-01 04:45:13.109099|2018-06-01 04:45:13.109099
NCT00144963|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2012-05-11||2014-03-27|2005-09-01|2005-09-05|Estimate|2011-12-07|2012-01-18|Estimate||||2014-03-27|2014-04-17|Estimate|July 2002||2002-07-31|March 2014|2014-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Phase I-II Study of Liposomal Vincristine (VSLI) and Dexamethasone in Relapsed or Refractory Acute Lymphoblastic Leukemia|Completed||Phase 1/Phase 2|36|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-06-01 04:45:13.214963|2018-06-01 04:45:13.214963
NCT00144950|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-05|Estimate|||||||2005-09-02|2005-09-05|Estimate||||September 2005|2005-09-30||||||||Interventional|||Urokinase Versus Primary Video-Assisted Thorascopic Surgery for Empyema||Completed||Phase 1|60||Institute of Child Health|||||f||||||||||||||2018-06-01 04:45:13.526315|2018-06-01 04:45:13.526315
NCT00144937|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-09-01|2005-09-01|2005-09-05|Estimate|||||||2005-09-01|2005-09-05|Estimate|March 2003||2003-03-31|September 2005|2005-09-30|August 2005||2005-08-31|||||Interventional|||Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease|A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP).|Unknown status|Active, not recruiting|Phase 4|120||Hospital de Sabadell|||||f||||||||||||||2018-06-01 04:45:13.583626|2018-06-01 04:45:13.583626
NCT00144924|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-06-12|2005-09-02|2005-09-05|Estimate|||||||2008-06-12|2008-06-13|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|August 2008|Anticipated|2008-08-31|August 2008|Anticipated|2008-08-31||Interventional|||Open vs Laparoscopic Pyloromyotomy for Pyloric Stenosis||Unknown status|Recruiting|N/A|200|Anticipated|Institute of Child Health|||||f||||||||||||||2018-06-01 04:45:13.65177|2018-06-01 04:45:13.65177
NCT00144911|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-10-26|2005-09-01|2005-09-05|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2004||2004-10-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.|A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS® Inhaler Combination Product 250/50mcg Twice Daily With Salmeterol DISKUS® Inhaler 50mcg Twice Daily on the Annual Rate of Moderate/Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|740|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:45:13.747508|2018-06-01 04:45:13.747508
NCT00144898|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-07-26|2005-09-02|2005-09-05|Estimate|||||||2013-07-26|2013-07-29|Estimate|July 2003||2003-07-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||GF-GS 01: Comparing Conventional Axillary Dissection Versus Sentinel Node Resection in Clinically Node-negative Operable Breast Cancer|A Randomized, Phase III Clinical Trial GF-GS 01 to Compare Conventional Axillary Dissection Versus Sentinel Node Resection (GS) in Clinically Node-negative Operable Breast Cancer Unifocal N0 Patients|Completed||Phase 3|1627|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-06-01 04:45:13.95771|2018-06-01 04:45:13.95771
NCT00144885|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-02-11|2005-09-02|2005-09-05|Estimate|||||||2009-02-11|2009-02-12|Estimate|June 2005||2005-06-30|September 2005|2005-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|IMAGE||IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis|Resonance Magnetic Imaging at the Acute Phase of Endocarditis: Diagnostic and Therapeutic Impact|Completed||N/A|150|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-06-01 04:45:14.019123|2018-06-01 04:45:14.019123
NCT00144872|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-09-27|2005-09-01|2005-09-05|Estimate|||||||2017-09-27|2017-09-29|Actual|November 1, 2004|Actual|2004-11-01|September 2017|2017-09-30|April 22, 2006|Actual|2006-04-22|April 22, 2006|Actual|2006-04-22||Interventional|||LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures|Evaluation of Lamotrigine in Subjects With Absence Seizures|Completed||Phase 1|54|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:45:14.09639|2018-06-01 04:45:14.09639
NCT00144859|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-05-31|2005-09-01|2005-09-05|Estimate|||||||2012-05-31|2012-06-04|Estimate|July 2005||2005-07-31|March 2011|2011-03-31||||||||Interventional|||Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)|A 28-day, Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Anti-inflammatory Effect and Steady-state Pharmacokinetics of SB-681323 7.5 mg Per Day in Patients With Chronic Obstructive Pulmonary Disease.|Completed||Phase 2|82||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:45:14.201991|2018-06-01 04:45:14.201991
NCT00144846|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-09-22|2005-09-01|2005-09-05|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2004||2004-09-30|September 2016|2016-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children|A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively With a Valved Holding Chamber and an Attached Facemask in Subjects Between Birth to 23 Months of Age With Acute Wheezing Due to Obstructive Airways Disease|Completed||Phase 3|80|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:45:14.278333|2018-06-01 04:45:14.278333
NCT00144833|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-11-09|2005-09-01|2005-09-05|Estimate|||||||2007-11-09|2007-11-12|Estimate|March 2005||2005-03-31|November 2007|2007-11-30||||||||Interventional|||Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects|A Phase III, Randomized, Controlled, Open-Label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-Boosted HIV-1 Protease Inhibitor Regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-Infected Adults Experiencing Virological Failure|Terminated||Phase 3|150|Anticipated|GlaxoSmithKline||||Incomplete data|f||||t||||||||||2018-06-01 04:45:14.454733|2018-06-01 04:45:14.454733
NCT00144820|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-05|Estimate|||||||2005-09-02|2005-09-05|Estimate|May 1999||1999-05-31|August 2005|2005-08-31|November 2001||2001-11-30|||||Interventional|||Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis|Intra-Articular Injections of Hyaluronan Versus 20 Ml NaCl Versus Placebo in Treatment of Knee Osteoarthritis: a Randomised, Double-Blind, Placebo Controlled Single Centre Trial.|Unknown status|Active, not recruiting|Phase 4|251||Glostrup University Hospital, Copenhagen|||||f||||||||||||||2018-06-01 04:45:14.630988|2018-06-01 04:45:14.630988
NCT00144807|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-09-01|2005-09-02|2005-09-05|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2003||2003-12-31|September 2015|2015-09-30|April 2012|Actual|2012-04-30|September 2008|Actual|2008-09-30||Interventional|||ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma|Study of ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 59 Years With High Risk Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 2-3)|Completed||Phase 2|128|Actual|Lymphoma Study Association||1|||f||||t||||||||||2018-06-01 04:45:14.711421|2018-06-01 04:45:14.711421
NCT00144794|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2018-05-14|2005-09-02|2005-09-05|Estimate|||||||2018-05-14|2018-05-15|Actual|November 20, 2003||2003-11-20|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Mucopolysaccharidosis I (MPS I) Registry|Mucopolysaccharidosis I (MPS I) Registry|Recruiting|||1500|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 04:45:14.836057|2018-06-01 04:45:14.836057
NCT00144781|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2009-03-27||2015-03-17|2005-09-02|2005-09-05|Estimate|2009-04-27|2009-06-16|Estimate||||2015-03-17|2015-04-03|Estimate|December 2004||2004-12-31|March 2015|2015-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease|A Multicenter, Multinational, Randomized, Dose-Optimization Study of the Safety and Pharmacodynamic Response of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I|Completed||Phase 4|34|Actual|Sanofi|This study is limited by its small sample size and ability to detect small differences in urinary GAG levels between groups.|4|||f||||||||||||||2018-06-01 04:45:15.066334|2018-06-01 04:45:15.066334
NCT00144768|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2014-05-02|2005-09-02|2005-09-05|Estimate|||||||2014-05-02|2014-05-05|Estimate|July 2004||2004-07-31|April 2013|2013-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients|A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients With Mucopolysaccharidosis I (MPS I) Being Treated With Aldurazyme® (Laronidase).|Completed||Phase 4|25|Anticipated|Sanofi|||||f||||f||||||||||2018-06-01 04:45:15.899758|2018-06-01 04:45:15.899758
NCT00144755|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2015-09-01|2005-09-02|2005-09-05|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2003||2003-12-31|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma|Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma.|Completed||Phase 3|600|Actual|Lymphoma Study Association||4|||f||||t||||||||||2018-06-01 04:45:15.961576|2018-06-01 04:45:15.961576
NCT00144729|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-04-28|2005-09-01|2005-09-05|Estimate|||||||2008-04-28|2008-04-30|Estimate|May 1993||1993-05-31|April 2008|2008-04-30|July 2007|Actual|2007-07-31|||||Interventional|||Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor|Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor|Completed||Phase 1/Phase 2|85||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:45:16.047574|2018-06-01 04:45:16.047574
NCT00144716|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2017-01-11|2005-09-02|2005-09-05|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2003||2003-06-30|January 2017|2017-01-31|October 2003||2003-10-31|||||Interventional|||Evaluation of Combined Use of ITN's and Insect Repellents Against Malaria|Clinical Evaluation of Combined Use of ITN's and Plant-based Insect Repellent Against Malaria in the Amazon|Completed||Phase 3|4250||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:45:16.096635|2018-06-01 04:45:16.096635
NCT00144703|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-01-24|2005-09-01|2005-09-05|Estimate|||||||2012-01-24|2012-01-26|Estimate|July 2002||2002-07-31|January 2009|2009-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation|Open Label Phase II Trial of Sirolimus in Combination With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|55||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:45:16.161899|2018-06-01 04:45:16.161899
NCT00144690|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-11-02|2005-09-01|2005-09-05|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2005||2005-03-31|November 2015|2015-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures|Completed||Phase 2|||Eisai Inc.|||||f||||||||||||||2018-06-01 04:45:16.222487|2018-06-01 04:45:16.222487
NCT00144677|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-01-24|2005-09-01|2005-09-05|Estimate|||||||2012-01-24|2012-01-26|Estimate|November 2003||2003-11-30|March 2009|2009-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation|Open Label Phase II Trial of Sirolimus in Combination With Tacrolimus for Graft-vs-Host Disease Prophylaxis After HLA-Matched, Unrelated, Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|30||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:45:16.323683|2018-06-01 04:45:16.323683
NCT00144664|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-07-29|2005-09-02|2005-09-05|Estimate|||||||2008-07-29|2008-07-30|Estimate|November 2004||2004-11-30|July 2008|2008-07-31|October 2005|Actual|2005-10-31|April 2005|Actual|2005-04-30||Interventional|||Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)|An Open-Label, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With pJIA|Completed||Phase 3|19|Actual|Chugai Pharmaceutical||1|||f||||f||||||||||2018-06-01 04:45:16.393521|2018-06-01 04:45:16.393521
NCT00144625|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-12-21|2005-09-02|2005-09-05|Estimate|||||||2009-12-21|2009-12-23|Estimate|February 2005||2005-02-28|December 2009|2009-12-31|June 2009|Actual|2009-06-30|July 2005|Actual|2005-07-31||Interventional|||Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP|Completed||Phase 3|19|Actual|Chugai Pharmaceutical||1|||f||||||||||||||2018-06-01 04:45:16.627017|2018-06-01 04:45:16.627017
NCT00144612|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-12-21|2005-09-02|2005-09-05|Estimate|||||||2009-12-21|2009-12-23|Estimate|July 2004||2004-07-31|December 2009|2009-12-31|June 2009|Actual|2009-06-30|June 2005|Actual|2005-06-30||Interventional|||Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP|Completed||Phase 3|60|Actual|Chugai Pharmaceutical||1|||f||||||||||||||2018-06-01 04:45:16.698238|2018-06-01 04:45:16.698238
NCT00144599|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-07-29|2005-09-02|2005-09-05|Estimate|||||||2008-07-29|2008-07-30|Estimate|May 2004||2004-05-31|July 2008|2008-07-31|October 2005|Actual|2005-10-31|||||Interventional|||Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)|A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA|Completed||Phase 3|56|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 04:45:16.762067|2018-06-01 04:45:16.762067
NCT00144586|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-08-06|2005-09-02|2005-09-05|Estimate|||||||2013-08-06|2013-08-09|Estimate|March 2005||2005-03-31|August 2013|2013-08-31|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA220JP or MRA221JP|Completed||Phase 3|42|Actual|Chugai Pharmaceutical||1|||f||||||||||||||2018-06-01 04:45:16.828017|2018-06-01 04:45:16.828017
NCT00144573|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-12-11|2005-09-02|2005-09-05|Estimate|||||||2008-12-11|2008-12-15|Estimate|January 2005||2005-01-31|December 2008|2008-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment|An Open-Label, Clinical Pharmacology Study to Evaluate the Safety and PK of MRA in Patients With RA With Renal Impairment|Completed||N/A|14|Actual|Chugai Pharmaceutical|||||f||||||||||||||2018-06-01 04:45:16.899369|2018-06-01 04:45:16.899369
NCT00144560|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2008-12-11|2005-09-02|2005-09-05|Estimate|||||||2008-12-11|2008-12-15|Estimate|February 2005||2005-02-28|December 2008|2008-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)|An Open-Label, Clinical Pharmacology Study to Investigate Drug-Drug Interaction in Patients With RA|Completed||N/A|31|Actual|Chugai Pharmaceutical|||||f||||||||||||||2018-06-01 04:45:16.967499|2018-06-01 04:45:16.967499
NCT00144547|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-08-06|2005-09-02|2005-09-05|Estimate|||||||2013-08-06|2013-08-09|Estimate|April 2004||2004-04-30|August 2013|2013-08-31|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP|Completed||Phase 3|241|Actual|Chugai Pharmaceutical||1|||f||||f||||||||||2018-06-01 04:45:17.025031|2018-06-01 04:45:17.025031
NCT00144534|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-12-21|2005-09-02|2005-09-05|Estimate|||||||2009-12-21|2009-12-23|Estimate|June 2004||2004-06-30|December 2009|2009-12-31|June 2009|Actual|2009-06-30|August 2005|Actual|2005-08-31||Interventional|||Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP|An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP|Completed||Phase 3|115|Actual|Chugai Pharmaceutical||1|||f||||||||||||||2018-06-01 04:45:17.084042|2018-06-01 04:45:17.084042
NCT00144521|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-01-30|2005-09-02|2005-09-05|Estimate|||||||2009-01-30|2009-02-02|Estimate|February 2004||2004-02-29|January 2009|2009-01-31|April 2006|Actual|2006-04-30|August 2004|Actual|2004-08-31||Interventional|||Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)|A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA|Completed||Phase 3|127|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 04:45:17.136669|2018-06-01 04:45:17.136669
NCT00144508|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-01-30|2005-09-02|2005-09-05|Estimate|||||||2009-01-30|2009-02-02|Estimate|March 2003||2003-03-31|January 2009|2009-01-31|February 2006|Actual|2006-02-28|May 2004|Actual|2004-05-31||Interventional|||Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)|An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA|Completed||Phase 3|306|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 04:45:17.205499|2018-06-01 04:45:17.205499
NCT00144495|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-01-29|2005-09-02|2005-09-05|Estimate|||||||2009-01-29|2009-02-02|Estimate|February 2004||2004-02-29|January 2009|2009-01-31|May 2005|Actual|2005-05-31|November 2004|Actual|2004-11-30||Interventional|||A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy|A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy|Completed||Phase 3|104|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 04:45:17.267553|2018-06-01 04:45:17.267553
NCT00144482|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-01-29|2005-09-02|2005-09-05|Estimate|||||||2009-01-29|2009-02-02|Estimate|December 2003||2003-12-31|January 2009|2009-01-31|August 2005|Actual|2005-08-31|March 2005|Actual|2005-03-31||Interventional|||A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy|A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy|Completed||Phase 3|122|Actual|Chugai Pharmaceutical||2|||f||||f||||||||||2018-06-01 04:45:17.325691|2018-06-01 04:45:17.325691
NCT00144469|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2009-01-29|2005-09-02|2005-09-05|Estimate|||||||2009-01-29|2009-02-02|Estimate|May 2002||2002-05-31|January 2009|2009-01-31|March 2005|Actual|2005-03-31|||||Interventional|||A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C|A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C|Completed||Phase 3|300|Actual|Chugai Pharmaceutical|||||f||||f||||||||||2018-06-01 04:45:17.378408|2018-06-01 04:45:17.378408
NCT00144456|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-08-06|2005-09-02|2005-09-05|Estimate|||||||2013-08-06|2013-08-09|Estimate|September 2004||2004-09-30|August 2013|2013-08-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||A New Active Vitamin D, ED-71 for Osteoporosis|A Prospective, Randomized, Double-blind Study to Compare the Effect of ED-71 With That of Alfacalcidol on Fracture Incidence in Osteoporotic Patients|Completed||Phase 3|1056|Actual|Chugai Pharmaceutical||2|||f||||||||||||||2018-06-01 04:45:17.441414|2018-06-01 04:45:17.441414
NCT00144443|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-12-08|2005-09-02|2005-09-05|Estimate|||||||2005-12-08|2005-12-09|Estimate|March 2003||2003-03-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Kansas City Community Environmental Remediation And Training (KC CERT)|Kansas City Community Environmental Remediation And Training (KC CERT)|Unknown status|Active, not recruiting|N/A|200||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:45:17.501507|2018-06-01 04:45:17.501507
NCT00144430|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-02-02|2005-09-01|2005-09-05|Estimate|||||||2009-02-02|2009-02-03|Estimate|January 2004||2004-01-31|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children|A Phase II Study of Pentostatin For the Treatment of High Risk or Refractory Chronic GVHD in Children|Completed||Phase 2|60|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||t||||||||||2018-06-01 04:45:17.564624|2018-06-01 04:45:17.564624
NCT00144417|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-08-02|2005-09-01|2005-09-05|Estimate|||||||2011-08-02|2011-08-03|Estimate|February 2006||2006-02-28|June 2011|2011-06-30|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment|TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment|Completed||Phase 2|433|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 04:45:17.682513|2018-06-01 04:45:17.682513
NCT00144404|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-04-15|2005-09-02|2005-09-05|Estimate|||||||2017-04-15|2017-04-18|Actual|August 2002||2002-08-31|April 2017|2017-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Observational|||Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism|Baseline Sexual Function, Cognitive Function, Body Composition and Muscle Parameters and Pharmacokinetics of Transdermal Testosterone Gel in Women With Hypopituitarism|Withdrawn|||0|Actual|Charles Drew University of Medicine and Science||||this was not a clinical trial|f||||t||||||||||2018-06-01 04:45:17.777493|2018-06-01 04:45:17.777493
NCT00144391|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2017-04-14||2017-05-25|2005-09-02|2005-09-05|Estimate|2017-05-25|2017-06-27|Actual||||2017-05-25|2017-06-27|Actual|July 2003||2003-07-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Testosterone Gel Applied to Women With Pituitary Gland Problems|Physiologic Testosterone Replacement in Women With Hypopituitarism|Completed||Phase 4|20|Actual|Charles Drew University of Medicine and Science|Small number of patients recruited.|2|||f||||t||||||||||2018-06-01 04:45:17.948115|2018-06-01 04:45:17.948115
NCT00144378|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-04-17|2005-09-02|2005-09-05|Estimate|||||||2007-04-17|2007-04-18|Estimate|October 2002||2002-10-31|April 2007|2007-04-30||||||||Interventional|||Irinotecan Versus Only Best Supportive Care for Gastric Cancer|Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer|Completed||Phase 3|44||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:45:18.143123|2018-06-01 04:45:18.143123
NCT00144365|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2012-09-10|2005-09-02|2005-09-05|Estimate|||||||2012-09-10|2012-09-11|Estimate|February 2005||2005-02-28|September 2012|2012-09-30|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|||Comparison of Facility and Home-based ART Delivery Systems in Uganda|Comparison of Facility and Home-based ART Delivery Systems in Uganda|Completed||Phase 3|1453|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:45:18.200505|2018-06-01 04:45:18.200505
NCT00144352|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-05|Estimate|||||||2005-09-02|2005-09-05|Estimate|September 2002||2002-09-30|September 2005|2005-09-30|July 2004||2004-07-31|||||Interventional|||In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults|The in-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Individuals-a 28 Day Efficacy Trial Involving HIV+ and HIV- Adults.|Completed||Phase 4|540||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:45:18.25609|2018-06-01 04:45:18.25609
NCT00144339|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2009-02-21||2014-05-15|2005-09-02|2005-09-05|Estimate|2009-07-03|2009-08-17|Estimate||||2014-05-15|2014-05-20|Estimate|December 2002||2002-12-31|April 2014|2014-04-30||||February 2008|Actual|2008-02-29||Interventional|||Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients|A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|5993|Actual|Boehringer Ingelheim|Tio patients had significantly longer drug exposure,thus had increased chance of AE.Simple frequencies are biased for AE comparisons;exposure-adjusted incidence rates (IR) should be used. IR for serious AE(>1% patients) are in Outcome Measures.||||f||||||||||||||2018-06-01 04:45:18.611442|2018-06-01 04:45:18.611442
NCT00144326|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-10-31|2005-09-02|2005-09-05|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2003||2003-07-31|October 2013|2013-10-31|October 2005||2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect, of Tiotropium Inhalation Capsules on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|250|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:25.409314|2018-06-01 04:45:25.409314
NCT00144313|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2007-09-20|2005-09-02|2005-09-05|Estimate|||||||2007-09-20|2007-09-21|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|January 2006|Actual|2006-01-31|||||Interventional|||VaxTeen Hepatitis B Vaccine Booster Study|Persistence of Antibody and Response to Booster of a Recombinant Hepatitis B Vaccine in Children Who Responded to a Primary Course of 2.5µg Recombinant Hepatitis B Vaccine as Infants|Completed||Phase 4|60|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:45:25.581535|2018-06-01 04:45:25.581535
NCT00144300|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2011-09-16||2014-02-17|2005-09-02|2005-09-05|Estimate|2011-11-02|2011-11-04|Estimate||||2014-02-17|2014-03-14|Estimate|January 2005||2005-01-31|February 2014|2014-02-28||||September 2010|Actual|2010-09-30||Interventional|||Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients|A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients|Completed||Phase 4|246|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 04:45:25.881417|2018-06-01 04:45:25.881417
NCT00144287|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-11-04|2005-09-02|2005-09-05|Estimate|||||||2013-11-04|2013-11-05|Estimate|May 2004||2004-05-31|November 2013|2013-11-30|April 2006||2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options|An Open Label Safety Study of Tipranavir Co-Administered With Low-Dose Ritonavir (TVP/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options|Completed||Phase 3|255|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:27.609981|2018-06-01 04:45:27.609981
NCT00144274|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-10-28|2005-09-02|2005-09-05|Estimate|||||||2013-10-28|2013-10-29|Estimate|April 2005||2005-04-30|October 2013|2013-10-31|November 2005||2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis|Efficacy and Tolerability of Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis - A Randomised, Double-blind, Placebo-controlled Parallel Group Study. AMBROSIA: Ambroxol Lozenges In Sore Throat In Adolescents|Completed||Phase 3|220||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:27.768289|2018-06-01 04:45:27.768289
NCT00144261|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2017-12-27|2005-09-02|2005-09-05|Estimate|||||||2017-12-27|2017-12-28|Actual|November 2003||2003-11-30|December 2017|2017-12-31||||December 2006|Actual|2006-12-31||Interventional|||An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects|An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets|Completed||Phase 4|15|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:27.975712|2018-06-01 04:45:27.975712
NCT00144248|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2017-12-27|2005-09-02|2005-09-05|Estimate|||||||2017-12-27|2017-12-28|Actual|May 2004||2004-05-31|December 2017|2017-12-31||||June 2006|Actual|2006-06-30||Interventional|||A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions|A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic Function|Completed||Phase 4|51|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:45:28.089141|2018-06-01 04:45:28.089141
NCT00144235|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-10-30|2005-09-02|2005-09-05|Estimate|||||||2013-10-30|2013-10-31|Estimate|March 2005||2005-03-31|October 2013|2013-10-31|July 2005||2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Pharmaton Upgrade in Improving Mental Performance and Decreasing Fatigue|A 28 Day, Randomised, Double-blind, Placebo-controlled, Single-centre Trial to Evaluate the Efficacy and Safety of Pharmaton® PHL 00749 Film Coated Tablets (G115 40 mg, Multivitamin, Multimineral + Guarana 75 mg) 1/Day p.o. in Improving Mental Performance and to Decrease Fatigue in Healthy Male and Female Subjects in Regular Employment.|Completed||Phase 3|412||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:28.253552|2018-06-01 04:45:28.253552
NCT00144222|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-11-04|2005-09-02|2005-09-05|Estimate|||||||2013-11-04|2013-11-05|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|August 2005||2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy|A Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg|Completed||Phase 3|218|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:28.325934|2018-06-01 04:45:28.325934
NCT00144209|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-10-31|2005-09-02|2005-09-05|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 2003||2003-02-28|October 2013|2013-10-31|February 2005||2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome|Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome|Completed||Phase 3|58|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:28.512301|2018-06-01 04:45:28.512301
NCT00144196|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2014-07-22|2005-09-02|2005-09-05|Estimate|||||||2014-07-22|2014-07-23|Estimate|March 2004||2004-03-31|July 2014|2014-07-31|July 2005||2005-07-31|July 2005|Actual|2005-07-31||Interventional|||12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)|A 12-week Double-blind, Randomised, Parallel-group, Multi-centre Study Evaluating the Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD, According to Swedish Guidelines (SPIRIMILD)|Completed||Phase 4|224||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:28.682341|2018-06-01 04:45:28.682341
NCT00144183|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-11-01|2005-09-02|2005-09-05|Estimate|||||||2013-11-01|2013-11-04|Estimate|January 2003||2003-01-31|November 2013|2013-11-30|January 2007||2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)|An Open-label Study Evaluating the Resistance Profile of Single Dose Nevirapine(NVP) When Combined With a 4 or 7 Day Course of Combivir® (ZDV/3TC) Compared to Single Dose Nevirapine for the Prevention of Mother to Child Transmission (pMTCT) of HIV - Treatment Options Preservation Study (T.O.P.S.)|Completed||Phase 3|407||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:28.905784|2018-06-01 04:45:28.905784
NCT00144170|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|2009-09-11||2014-06-23|2005-09-02|2005-09-05|Estimate|2009-11-17|2009-12-23|Estimate||||2014-06-23|2014-07-02|Estimate|February 2003||2003-02-28|April 2014|2014-04-30||||October 2008|Actual|2008-10-31||Interventional|||Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)|Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)|Completed||Phase 3|882|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 04:45:29.167786|2018-06-01 04:45:29.167786
NCT00144157|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-11-13|2005-09-02|2005-09-05|Estimate|||||||2013-11-13|2013-11-14|Estimate|June 2003||2003-06-30|November 2013|2013-11-30|July 2006||2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV|An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1.|Completed||Phase 4|53|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:45:34.058476|2018-06-01 04:45:34.058476
NCT00144144|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-07-13|2005-09-01|2005-09-05|Estimate|||||||2006-07-13|2006-07-14|Estimate|September 2004||2004-09-30|July 2006|2006-07-31|September 2008||2008-09-30|||||Interventional|||A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes|A Randomized, Controlled Study on Calcium Channel Blocker Versus Angiotensin II Antagonists in the Hypertensive Patients With Type 2 Diabetes Mellitus Under the Inadequately Controlled Blood Pressure With Angiotension II Antagonists|Unknown status|Active, not recruiting|Phase 4|300||Advanced-J|||||f||||||||||||||2018-06-01 04:45:34.154674|2018-06-01 04:45:34.154674
NCT00144131|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-05-22|2005-09-01|2005-09-05|Estimate|||||||2013-05-22|2013-05-24|Estimate|August 2005||2005-08-31|May 2013|2013-05-31||||||||Interventional|||Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy|Flexibility: A Study to Assess the Impact of Once Per Cycle Correction and Maintenance Dosing of Darbepoetin Alfa in Subjects With Non-Myeloid Malignancies With Anemia Due to Chemotherapy|Completed||Phase 2|750||Amgen|||||||||||||||||||2018-06-01 04:45:34.234429|2018-06-01 04:45:34.234429
NCT00144118|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2005-09-02|2005-09-02|2005-09-05|Estimate|||||||2005-09-02|2005-09-05|Estimate|January 2002||2002-01-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||The Effect of Isoflurane or Sevoflurane on Kidney Function|Post-Operative Creatinine Changes In Patients With Pre-Existing Renal Impairment After Low-Flow Isoflurane Or Sevoflurane: A Randomised Clinical Trial|Terminated||Phase 4|270||Austin Health|||||f||||||||||||||2018-06-01 04:45:34.302009|2018-06-01 04:45:34.302009
NCT00144105|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-02|||2013-10-31|2005-09-02|2005-09-05|Estimate|||||||2013-10-31|2013-11-01|Estimate|February 2004||2004-02-29|October 2013|2013-10-31||||November 2006|Actual|2006-11-30||Interventional|||A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.|A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks|Terminated||Phase 2|562|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:45:34.387514|2018-06-01 04:45:34.387514
NCT00144092|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-11-18|2005-09-01|2005-09-05|Estimate|||||||2011-11-18|2011-11-21|Estimate|May 2001||2001-05-31|August 2011|2011-08-31|June 2010|Actual|2010-06-30|||||Interventional|||HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma|High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma|Completed||Phase 2|60|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:45:34.619067|2018-06-01 04:45:34.619067
NCT00144079|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-05-08|2005-09-01|2005-09-02|Estimate|||||||2006-05-08|2006-05-09|Estimate|January 2000||2000-01-31|September 2005|2005-09-30|January 2010||2010-01-31|||||Interventional|||Multicenter Study Differentiated Thyroid Carcinoma|Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma|Completed||Phase 3|500||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:45:34.762826|2018-06-01 04:45:34.762826
NCT00144066|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-09-01|2005-09-01|2005-09-02|Estimate|||||||2005-09-01|2005-09-02|Estimate|January 2003||2003-01-31|September 2005|2005-09-30||||||||Interventional|||A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer|A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 3|600||West Japan Thoracic Oncology Group|||||f||||||||||||||2018-06-01 04:45:34.902252|2018-06-01 04:45:34.902252
NCT00144053|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2006-01-05|2005-08-31|2005-09-02|Estimate|||||||2006-01-05|2006-01-06|Estimate|April 2001||2001-04-30|August 2005|2005-08-31||||||||Interventional|||A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer|A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer|Completed||Phase 3|450||West Japan Thoracic Oncology Group|||||f||||||||||||||2018-06-01 04:45:34.973532|2018-06-01 04:45:34.973532
NCT00144040|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-04-06|2005-08-31|2005-09-02|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2004||2004-02-29|April 2015|2015-04-30|July 2007|Actual|2007-07-31|||||Interventional|IMPAACT||Improving Antibiotic Use in Acute Care Treatment|Improving Antibiotic Use in Acute Care Setting|Completed||N/A|1000|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:45:35.071745|2018-06-01 04:45:35.071745
NCT00144027|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2014-10-28||2015-04-06|2005-09-01|2005-09-02|Estimate|2014-12-12|2014-12-23|Estimate||||2015-04-06|2015-04-24|Estimate|December 2004||2004-12-31|July 2014|2014-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|AMAIS||Patient-Centered Medication Adherence Intervention for Schizophrenia|Patient-Centered Medication Adherence Intervention for Schizophrenia|Completed||N/A|75|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:45:35.200528|2018-06-01 04:45:35.200528
NCT00144014|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01||2016-05-04|2016-05-04|2005-09-01|2005-09-02|Estimate||||2016-05-04|2016-06-03|Estimate|2016-05-04|2016-06-03|Estimate|August 2005||2005-08-31|May 2016|2016-05-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|VASST||Safety and Efficacy Study in Acute Ischaemic Stroke|A Phase II, Multi-centre, Two-part Study to Evaluate the Safety and Efficacy of Study Drug in Acute Ischaemic Stroke.|Completed||Phase 2|49|Actual|Vernalis (R&D) Ltd||5|||f||||t||||||||Undecided||2018-06-01 04:45:35.570512|2018-06-01 04:45:35.570512
NCT00144001|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-04-06|2005-08-31|2005-09-02|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2000||2000-10-31|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2004|Actual|2004-09-30||Observational|TIGER||Factors Associated With in Suboptimal Prescribing for Older Patients With Epilepsy|Appropriateness of Antiepileptic Drug Use for Older Veterans|Completed|||9682|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:45:35.709831|2018-06-01 04:45:35.709831
NCT00143988|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2009-08-06|2005-09-01|2005-09-02|Estimate|||||||2009-08-06|2009-08-24|Estimate|May 2004||2004-05-31|August 2009|2009-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|SEXERRCISE||Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers|Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers|Completed|||36|Actual|Rutgers, The State University of New Jersey|||4||f||||f||||||||||2018-06-01 04:45:35.824692|2018-06-01 04:45:35.824692
NCT00143975|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2010-08-11|2005-08-31|2005-09-02|Estimate|||||||2010-08-11|2010-08-12|Estimate|June 2004||2004-06-30|August 2010|2010-08-31|June 2009|Actual|2009-06-30|July 2007|Actual|2007-07-31||Interventional|||Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)|Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia|Completed||Phase 2|95|Actual|University of Ulm|||||f||||||||||||||2018-06-01 04:45:35.921194|2018-06-01 04:45:35.921194
NCT00143962|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-08-15|2005-09-01|2005-09-02|Estimate|||||||2016-08-15|2016-08-17|Estimate|July 2004||2004-07-31|August 2016|2016-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Comparison of Two Approaches to Weight Loss Follow-Up Study|Comparison of Two Approaches to Weight Loss Follow-Up Study|Completed||Phase 4|6|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 04:45:36.231148|2018-06-01 04:45:36.231148
NCT00143949|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-11-05|2005-09-01|2005-09-02|Estimate|||||||2008-11-05|2008-11-06|Estimate|March 1997||1997-03-31|November 2008|2008-11-30|May 2008|Actual|2008-05-31|March 2007|Actual|2007-03-31||Interventional|||Renin Angiotensin System Study (RASS/B-RASS)|Renin Angiotensin System Blockage-DN (RASS)|Completed||Phase 2|285|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 04:45:36.333041|2018-06-01 04:45:36.333041
NCT00143936|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2010-01-14|2005-09-01|2005-09-02|Estimate|||||||2010-01-14|2010-01-15|Estimate|April 2003||2003-04-30|January 2008|2008-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||The Safety and Efficacy of Low and High Carbohydrate Diets|The Safety and Efficacy of Low and High Carbohydrate Diets|Completed||Phase 4|360|Actual|Temple University||2|||f||||t||||||||||2018-06-01 04:45:36.430268|2018-06-01 04:45:36.430268
NCT00143910|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-12-05|2005-09-01|2005-09-02|Estimate|||||||2013-12-05|2013-12-06|Estimate|April 1993||1993-04-30|December 2013|2013-12-31|October 1999|Actual|1999-10-31|October 1999|Actual|1999-10-31||Observational|||Natural History Study of Azathioprine Adherence|Measurement of Compliance in Renal Transplant Recipients|Completed|||180||University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||||2018-06-01 04:45:36.683535|2018-06-01 04:45:36.683535
NCT00143884|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-04-20|2005-09-01|2005-09-02|Estimate|||||||2007-04-20|2007-04-23|Estimate|March 2000||2000-03-31|January 2007|2007-01-31||||||||Interventional|||Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood|Adjuvant Cellular Immunotherapy for High-Risk Hematologic Malignancy After Allogeneic Stem Cell Transplantation Using Low Intensity Conditioning|Terminated||Phase 2|30||University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:45:36.750803|2018-06-01 04:45:36.750803
NCT00143871|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2012-01-30|2005-09-01|2005-09-02|Estimate|||||||2012-01-30|2012-02-01|Estimate|April 2001||2001-04-30|January 2012|2012-01-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma|Rituximab Plus High-dose Chemotherapy With Autologous Stem Cell Support for Non-Hodgkin's Lymphoma|Completed||Phase 2|35||University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:45:36.907469|2018-06-01 04:45:36.907469
NCT00143858|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-08-06|2005-09-01|2005-09-02|Estimate|||||||2009-08-06|2009-08-11|Estimate|September 2004||2004-09-30|August 2009|2009-08-31|October 2007|Actual|2007-10-31|||||Observational|||Assessment of the Clinical Utility of Non Invasive Peripheral Signal Averaged Pulse Volume|Assessment of the Clinical Utility of Non Invasive Peripheral Signal Averaged Pulse Volume|Completed|||16|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:45:37.004037|2018-06-01 04:45:37.004037
NCT00143845|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2014-05-19||2017-01-18|2005-09-01|2005-09-02|Estimate|2014-05-19|2014-06-20|Estimate||||2017-01-18|2017-03-08|Actual|April 2003||2003-04-30|January 2017|2017-01-31|February 2013|Actual|2013-02-28|November 2010|Actual|2010-11-30||Interventional||54 patients were enrolled however 9 patients did not receive planned donor lymphocyte infusion. 45 patients were analyzed.|Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant|Phase II Trial of Adjuvant Cellular Immunotherapy for High-Risk Hematologic Malignancy After Reduced Intensity Allogeneic Stem Cell Transplantation|Completed||Phase 2|54|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:45:37.104423|2018-06-01 04:45:37.104423
NCT00143832|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-03-18|2005-08-31|2005-09-02|Estimate|||||||2007-03-18|2007-03-20|Estimate|September 2004||2004-09-30|March 2007|2007-03-31||||||||Observational|||Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning|Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning|Unknown status|Recruiting||90||UMC Utrecht|||||f||||||||||||||2018-06-01 04:45:37.382112|2018-06-01 04:45:37.382112
NCT00143819|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2017-01-04||2017-04-07|2005-09-01|2005-09-02|Estimate|2017-04-07|2017-04-25|Actual||||2017-04-07|2017-04-25|Actual|September 2005||2005-09-30|April 2017|2017-04-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis|Double-Blind, Bilateral, Vehicle-Controlled, Randomized Trial of Neuroskin Forte to Relieve Symptoms of Dry Skin|Terminated||Phase 2|13|Actual|Rutgers, The State University of New Jersey|small sample size|2||Low enrollment|f||||f||||||||||2018-06-01 04:45:37.487507|2018-06-01 04:45:37.487507
NCT00143806|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-12-31|2005-09-01|2005-09-02|Estimate|||||||2008-12-31|2009-01-05|Estimate|October 2003||2003-10-31|December 2008|2008-12-31|May 2007||2007-05-31|||||Interventional|||Transitioning From Cyclosporine to Alefacept in Psoriasis|Investigator-Initiated, Use Study of Alefacept (Amevive) in Combination With Tapering Doses of Cyclosporine in Patients With Moderate to Severe Psoriasis|Completed||Phase 2|13||Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:45:37.885622|2018-06-01 04:45:37.885622
NCT00143793|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2016-11-22|2005-08-31|2005-09-02|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2005||2005-06-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|||||Observational|MANPRO||NT-proBNP and New Biomarkers in Patients With Dyspnea and/or Peripheral Edema|Mannheim NT-proBNP Study (MANPRO) Evaluating NT-proBNP and New Biomarkers in Patients Suffering From Dyspnea and/or Peripheral Edema for the Differential Diagnosis of Congestive Heart Failure|Active, not recruiting|||400|Anticipated|Universitätsmedizin Mannheim|||||f||||f||||||Samples Without DNA|"~     Peripheral blood samples~   "|||2018-06-01 04:45:37.97816|2018-06-01 04:45:37.97816
NCT00143780|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-04-15|2005-08-31|2005-09-02|Estimate|||||||2008-04-15|2008-04-16|Estimate|May 2002||2002-05-31|August 2005|2005-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Pneumonia Vaccine in Bone Marrow Transplant Recipients: Usefulness of Donor Vaccination|Immunogenicity of Pneumococcal Conjugate Vaccine in Adult Allogeneic Bone Marrow Transplant Recipients - Randomized Controlled Trial of Pre-Transplant Donor Immunization|Completed||Phase 4|70||University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:45:38.100844|2018-06-01 04:45:38.100844
NCT00143767|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-03-18|2005-08-31|2005-09-02|Estimate|||||||2007-03-18|2007-03-20|Estimate|August 2005||2005-08-31|March 2007|2007-03-31||||||||Observational|||Magnetic Resonance Imaging of Brain Development in Attention Deficit Hyperactivity Disorder|Magnetic Resonance Imaging of Brain Development in Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting||400||UMC Utrecht|||||f||||||||||||||2018-06-01 04:45:38.206204|2018-06-01 04:45:38.206204
NCT00143754|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-08-31|2005-08-31|2005-09-02|Estimate|||||||2005-08-31|2005-09-02|Estimate||||August 2005|2005-08-31||||||||Interventional|||Effect of Chronic Oral Hydration in Patients With Recurrent Unexplained Syncope|Benefit of Controlled Rehydration in Unexplained Syncope|Terminated||Phase 3|||University Hospital, Angers|||||f||||||||||||||2018-06-01 04:45:38.323851|2018-06-01 04:45:38.323851
NCT00143741|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-01-09|2005-09-01|2005-09-02|Estimate|||||||2013-01-09|2013-01-10|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers|Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers|Completed||Phase 1|20|Actual|University of Chicago||1|||f||||||||||||||2018-06-01 04:45:38.378386|2018-06-01 04:45:38.378386
NCT00143728|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-09-24|2005-08-31|2005-09-02|Estimate|||||||2008-09-24|2008-09-25|Estimate|January 2004||2004-01-31|September 2008|2008-09-30|May 2010|Anticipated|2010-05-31|May 2010|Anticipated|2010-05-31||Interventional|||3TC or No 3TC for HIV With 3TC Resistance|A Randomized Study to Evaluate Virologic Response Following Discontinuation vs. no Discontinuation of 3TC in Patients Who Are Infected With HIV With Previously Documented Reduced Susceptibility to 3TC and Who Have Adequate Virologic Suppression on Combination Antiretroviral Therapy|Suspended||Phase 4|152|Anticipated|University of British Columbia||||Enrollment.|f||||||||||||||2018-06-01 04:45:38.470093|2018-06-01 04:45:38.470093
NCT00143715|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2011-07-19|2005-08-31|2005-09-02|Estimate|||||||2011-07-19|2011-07-20|Estimate|September 2004||2004-09-30|July 2011|2011-07-31|January 2007|Actual|2007-01-31|October 2006|Actual|2006-10-31||Interventional|||Oral Vitamin K for Warfarin Associated Coagulopathy|A Multicentre, Multinational Study of Oral Vitamin K for the Treatment of Warfarin Associated Coagulopathy|Completed||Phase 3|690|Actual|St. Joseph's Healthcare Hamilton||2|||f||||t||||||||||2018-06-01 04:45:38.626492|2018-06-01 04:45:38.626492
NCT00143702|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-09-24|2005-08-31|2005-09-02|Estimate|||||||2008-09-24|2008-09-25|Estimate|August 2001||2001-08-31|September 2005|2005-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE)|Randomized, Open-Label Study of Continued Stavudine Versus Abacavir Substitution With or Without Riboflavin and Thiamine Supplementation in HIV-Infected Patients Who Have Elevated Venous Lactic Acid While on Stavudine-Based Therapy (DAVE)|Completed||Phase 2/Phase 3|80|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:45:38.808664|2018-06-01 04:45:38.808664
NCT00143689|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2014-09-25|2005-08-31|2005-09-02|Estimate|||||||2014-09-25|2014-09-26|Estimate|April 2002||2002-04-30|September 2014|2014-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||NRTI-Sparing Pilot Study|A Pilot Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor Sparing Regimen in Antiretroviral-Naïve, HIV-infected Patients|Completed||Phase 4|13|Actual|University of British Columbia||1|||f||||||||||||||2018-06-01 04:45:38.889087|2018-06-01 04:45:38.889087
NCT00143676|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2012-05-23|2005-08-31|2005-09-02|Estimate|||||||2012-05-23|2012-05-24|Estimate|August 2005||2005-08-31|May 2012|2012-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia|A Double-blind, Randomized Placebo-controlled Study to Evaluate the Efficacy and Safety of TAK-475 50 mg, 100 mg, or Placebo When Co-administered With Atorvastatin (10 mg to 40 mg) in Subjects With Primary Hypercholesterolemia|Completed||Phase 3|448|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:45:38.983799|2018-06-01 04:45:38.983799
NCT00143663|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2012-05-23|2005-08-31|2005-09-02|Estimate|||||||2012-05-23|2012-05-24|Estimate|September 2005||2005-09-30|May 2012|2012-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol|A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg Versus Placebo in Subjects With Primary Hypercholesterolemia|Completed||Phase 3|361|Actual|Takeda||2|||f||||f||||||||||2018-06-01 04:45:39.268402|2018-06-01 04:45:39.268402
NCT00143650|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-01-16|2005-09-01|2005-09-02|Estimate|||||||2007-01-16|2007-01-17|Estimate|January 2001||2001-01-31|January 2005|2005-01-31|September 2002||2002-09-30|||||Interventional|||SENOC-I Det Sunda Huset II - Sensitization of Occupants of Water Damaged Buildings.|Does House Dust From Water Damaged Buildings Cause Stronger Responses Among Occupants Than Dust From Buildings Without Water Damage? Can Occupants’ Sensitivity be Predicted by Biomarkers?|Completed||Phase 1/Phase 2|27||University of Aarhus|||||f||||||||||||||2018-06-01 04:45:39.44238|2018-06-01 04:45:39.44238
NCT00143637|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-03-26|2005-09-01|2005-09-02|Estimate|||||||2008-03-26|2008-03-27|Estimate|May 2005||2005-05-31|March 2008|2008-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Dose Response Relations for Health Effects Caused by Office Dust|Dose Response Relations for Health Effects Caused by Office Dust.|Completed||Phase 1/Phase 2|24|Actual|University of Aarhus||2|||f||||f||||||||||2018-06-01 04:45:39.496352|2018-06-01 04:45:39.496352
NCT00143624|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-12-08|2005-08-31|2005-09-02|Estimate|||||||2009-12-08|2009-12-09|Estimate|June 2003||2003-06-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels|Effect of Rosiglitazone Maleate (Avandia®) on Carotid Intima Media Thickness, Brachial Artery Reactivity, Glucose Metabolism, Blood Lipid Concentrations, Body Fat Distribution, and Biochemical Markers of Cardiovascular Risk in Patients With the HIV Metabolic Syndrome|Completed||N/A|50|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-06-01 04:45:39.671224|2018-06-01 04:45:39.671224
NCT00143611|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2012-01-31|2005-08-31|2005-09-02|Estimate|||||||2012-01-31|2012-02-02|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Efficacy & Safety of Resatorvid in Adults With Severe Sepsis|A Pivotal, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety of TAK-242 in Adults With Severe Sepsis|Completed||Phase 3|277|Actual|Takeda||3|||f||||t||||||||||2018-06-01 04:45:39.856556|2018-06-01 04:45:39.856556
NCT00143598|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2014-06-03||2014-08-15|2005-09-01|2005-09-02|Estimate|2014-08-15|2014-08-18|Estimate||||2014-08-15|2014-08-18|Estimate|June 2004||2004-06-30|August 2014|2014-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||806 patients were randomly assigned to an intervention. Three patients were identified as ineligible soon after randomization and were excluded from further analysis (ie, modified intention-to-treat). In the active ECS group, one patient had no DVT and in the placebo ECS group one patient had a previous DVT and another patient was moribund.|The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome|The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome After Symptomatic Proximal Deep Venous Thrombosis|Completed||Phase 3|806|Actual|Sir Mortimer B. Davis - Jewish General Hospital|While 14% withdrew or were lost to follow-up (F/U), the total rate of withdrawal, loss to F/U and death was less than what was projected. Adherence to study stockings tended to diminish over F/U; this occurred to a similar degree in both groups.|2|||f||||t||||||||||2018-06-01 04:45:40.328243|2018-06-01 04:45:40.328243
NCT00143585|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-07-24|2005-09-01|2005-09-02|Estimate|||||||2008-07-24|2008-07-25|Estimate|June 2002||2002-06-30|July 2008|2008-07-31|June 2007|Anticipated|2007-06-30|||||Interventional|||NOGA Angiogenesis Revascularization Therapy: Evaluation by RadioNuclide Imaging - The Northern Trial|Multicentre, Randomized,Double Blind,Placebo Controlled Trial of Myocardial Angiogenesis Using VEGF165, Intramyocardial Gene Delivery in Patients With Severe Angina|Unknown status|Active, not recruiting|Phase 2/Phase 3|120||St. Michael's Hospital, Toronto|||||f||||||||||||||2018-06-01 04:45:40.884197|2018-06-01 04:45:40.884197
NCT00143572|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-04-24|2005-09-01|2005-09-02|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2004||2004-11-30|February 2010|2010-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease|Phase I Study of Combination Treatment With Hydroxyurea and Magnesium Pidolate in Patients With Sickle Cell Disease|Completed||Phase 1|16|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:45:40.958194|2018-06-01 04:45:40.958194
NCT00143559|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2009-01-28|2005-09-01|2005-09-02|Estimate|||||||2009-01-28|2009-01-29|Estimate|August 2005||2005-08-31|January 2009|2009-01-31|January 2009|Actual|2009-01-31|July 2006|Actual|2006-07-31||Interventional|||Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies|Haploidentical Hematopoietic Stem Cell Transplantation Utilizing Partial T-Cell Depletion as Immunotherapy for Hematologic Malignancies|Completed||Phase 2|17|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:45:41.018777|2018-06-01 04:45:41.018777
NCT00143546|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-04-24|2005-09-01|2005-09-02|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2003||2003-11-30|April 2017|2017-04-30||||||||Expanded Access|||Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver|Compassionate Use of Defibrotide for Patients With Veno-Occlusive Disease|No longer available|||||St. Jude Children's Research Hospital|||||||||||||||||||2018-06-01 04:45:41.103136|2018-06-01 04:45:41.103136
NCT00143533|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-04-24|2005-09-01|2005-09-02|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2003||2003-09-30|September 2011|2011-09-30|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|||Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors|Phase I Study of Intravenous Irinotecan Using Selective Gastrointestinal Decontamination for Prevention of Diarrhea in Relapsed or Refractory Pediatric Solid Tumors|Completed||Phase 1|20|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:45:41.173513|2018-06-01 04:45:41.173513
NCT00143520|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-04-08|2005-09-01|2005-09-02|Estimate|||||||2011-04-08|2011-04-11|Estimate|December 2004||2004-12-31|April 2011|2011-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes|A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects With Type 2 Diabetes|Completed||Phase 2/Phase 3|441|Actual|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 04:45:41.347291|2018-06-01 04:45:41.347291
NCT00143507|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2015-05-13||2018-03-13|2005-08-31|2005-09-02|Estimate|2015-06-22|2015-06-25|Estimate||||2018-03-13|2018-04-12|Actual|December 2004||2004-12-31|March 2018|2018-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction|Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-year Randomised Double-blind Placebo-controlled International Multicentre Study.|Completed||Phase 3|10917|Actual|Servier|The section Other Adverse Events (Not including serious) has been completed by the sponsor to include only the Non Serious Adverse Events emergent on treatment during the study.|2|||f||||||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-06-01 04:45:41.589507|2018-06-01 04:45:41.589507
NCT00143494|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-09-24|2005-09-01|2005-09-02|Estimate|||||||2008-09-24|2008-09-25|Estimate|July 2005||2005-07-31|September 2008|2008-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||The Estimation of Abdominal Pressure by the Bladder and Gastric Pressure|The Estimation of Abdominal Pressure by the Bladder and Gastric Pressure|Completed||N/A|13|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:45:44.914935|2018-06-01 04:45:44.914935
NCT00143481|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-04-09|2005-09-01|2005-09-02|Estimate|||||||2013-04-09|2013-04-10|Estimate|March 2005||2005-03-31|April 2013|2013-04-30||||June 2006|Actual|2006-06-30||Interventional|||Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women|A Multi-Center, Double-Phase, Randomized, Double-Blind, Placebo Controlled (12-Week Double-Blind Followed by 12-Week Open-Label) Study Evaluating the Effect of Tolterodine ER on Urgency Urinary Incontinence (UUI), Urgency, Frequency, Sexual Quality of Life and Sexual Function in Women With Overactive Bladder|Completed||Phase 4|400||Pfizer|||||||||||||||||||2018-06-01 04:45:44.994283|2018-06-01 04:45:44.994283
NCT00143468|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2011-11-30|2005-08-31|2005-09-02|Estimate|||||||2011-11-30|2011-12-01|Estimate|March 2005||2005-03-31|November 2011|2011-11-30|May 2008|Actual|2008-05-31|March 2007|Actual|2007-03-31||Interventional|||The Specific Elastance in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients|The Specific Elastance in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients: Barotrauma and Volutrauma|Completed||N/A|100|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:45:45.131342|2018-06-01 04:45:45.131342
NCT00143455|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2009-12-11||2010-02-10|2005-09-01|2005-09-02|Estimate|2009-12-11|2010-01-21|Estimate||||2010-02-10|2010-02-18|Estimate|June 2002||2002-06-30|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer|Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer|Completed||Phase 3|485|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:45:45.373598|2018-06-01 04:45:45.373598
NCT00143442|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-08-04|2005-09-01|2005-09-02|Estimate|||||||2006-08-04|2006-08-08|Estimate|December 2003||2003-12-31|August 2006|2006-08-31|October 2004||2004-10-31|||||Interventional|||Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures|A 5-Week, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN), Who Are Gabapentin Treatment Failures.|Completed||Phase 2|184||Pfizer|||||||||||||||||||2018-06-01 04:45:46.826452|2018-06-01 04:45:46.826452
NCT00143429|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-03-04|2005-09-01|2005-09-02|Estimate|||||||2015-03-04|2015-03-05|Estimate||||March 2015|2015-03-31||||||||Interventional|||Corneal Versus Conjunctival Delivery Using a Delivery Device|Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device|Withdrawn||Phase 2|0|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:45:46.885054|2018-06-01 04:45:46.885054
NCT00143416|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-07-24|2005-09-01|2005-09-02|Estimate|||||||2008-07-24|2008-07-29|Estimate|April 2004||2004-04-30|July 2008|2008-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Long Term Study With B2036-PEG|Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -|Completed||Phase 3|16||Pfizer|||||f||||||||||||||2018-06-01 04:45:47.052043|2018-06-01 04:45:47.052043
NCT00143403|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2009-02-26||2010-09-24|2005-09-01|2005-09-02|Estimate|2009-04-11|2009-06-01|Estimate||||2010-09-24|2010-09-28|Estimate|December 2001||2001-12-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|February 2008|Actual|2008-02-29||Interventional|||Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer|Multi-Centre Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone, As Adjuvant Treatment After Resection Of Liver Metastases For Colorectal Cancer.|Completed||Phase 3|321|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:45:47.151427|2018-06-01 04:45:47.151427
NCT00143390|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2011-10-12||2011-12-19|2005-09-01|2005-09-02|Estimate|2011-12-19|2012-01-25|Estimate||||2011-12-19|2012-01-25|Estimate|April 2005||2005-04-30|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer|A Randomized, Double-Blind, Controlled Study Of Exemestane (Aromasin) Vs Anastrozole (Arimidex) As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer|Completed||Phase 3|298|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:45:47.755911|2018-06-01 04:45:47.755911
NCT00143377|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-11-17|2005-09-01|2005-09-02|Estimate|||||||2008-11-17|2008-11-18|Estimate|September 2004||2004-09-30|December 2006|2006-12-31|October 2005||2005-10-31|||||Interventional|||Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB|A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).|Completed||Phase 4|600||Pfizer|||||f||||||||||||||2018-06-01 04:45:48.716765|2018-06-01 04:45:48.716765
NCT00143364|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-06-01|2005-08-31|2005-09-02|Estimate|||||||2007-06-01|2007-06-04|Estimate|June 2003||2003-06-30|June 2007|2007-06-30|March 2005|Actual|2005-03-31|||||Interventional|||A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation|Completed||Phase 3|1005||Pfizer|||||||||||||||||||2018-06-01 04:45:48.765411|2018-06-01 04:45:48.765411
NCT00143351|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2006-12-28|2005-08-31|2005-09-02|Estimate|||||||2006-12-28|2007-01-01|Estimate|June 2003||2003-06-30|December 2006|2006-12-31|September 2005||2005-09-30|||||Interventional|||Mozart Relapse Study|Open Extension Study Evaluating the Long-Term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study|Completed||Phase 3|75||Pfizer|||||f||||||||||||||2018-06-01 04:45:48.845121|2018-06-01 04:45:48.845121
NCT00143338|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-02-11|2005-08-31|2005-09-02|Estimate|||||||2008-02-11|2008-02-12|Estimate|November 2004||2004-11-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|||||Interventional|||To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.|A Phase 2, Exploratory Study to Examine the Effects of Inhaled Insulin, Compared With Subcutaneously Administered Insulin, on Airway Lining Fluid Composition in Subjects With Type 2 Diabetes Mellitus.|Completed||Phase 2|20||Pfizer|||||||||||||||||||2018-06-01 04:45:48.918799|2018-06-01 04:45:48.918799
NCT00143325|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-06-01|2005-08-31|2005-09-02|Estimate|||||||2007-06-01|2007-06-04|Estimate|January 2005||2005-01-31|June 2007|2007-06-30|June 2006|Actual|2006-06-30|||||Interventional|||An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation|An Open-Label, Multicenter Study With Follow-Up Evaluating the Safety and Efficacy of Varenicline Tartrate in Comparison to Transdermal Nicotine Patch for Smoking Cessation|Completed||Phase 3|730||Pfizer|||||||||||||||||||2018-06-01 04:45:49.059973|2018-06-01 04:45:49.059973
NCT00143312|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2009-04-02||2009-09-23|2005-09-01|2005-09-02|Estimate|2009-04-02|2009-06-01|Estimate||||2009-09-23|2009-10-06|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|VOSIFI||Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants|Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).|Completed||Phase 4|45|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 04:45:49.188547|2018-06-01 04:45:49.188547
NCT00143299|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-06-01|2005-08-31|2005-09-02|Estimate|||||||2007-06-01|2007-06-04|Estimate|October 2003||2003-10-31|June 2007|2007-06-30|March 2005||2005-03-31|||||Interventional|||A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline|A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety of Varenicline Tartrate ( CP-526,555) for Smoking Cessation|Completed||Phase 3|375||Pfizer|||||||||||||||||||2018-06-01 04:45:49.582509|2018-06-01 04:45:49.582509
NCT00143286|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-06-01|2005-08-31|2005-09-02|Estimate|||||||2007-06-01|2007-06-04|Estimate|April 2003||2003-04-30|June 2007|2007-06-30|March 2005|Actual|2005-03-31|||||Interventional|||A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation|A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline ( CP-526,555) for the Maintenance of Smoking Cessation|Completed||Phase 3|2000||Pfizer|||||||||||||||||||2018-06-01 04:45:49.650264|2018-06-01 04:45:49.650264
NCT00143273|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2011-08-08|2005-08-31|2005-09-02|Estimate|||||||2011-08-08|2011-08-10|Estimate|June 2004||2004-06-30|August 2011|2011-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|JADE||Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation|Dose Response Study Of Lasofoxifene In Postmenopausal Women With Osteoporosis (Placebo-Controlled, Multicenter, Double-Blind, Comparative Study) - Japanese Asian Dose Evaluation: JADE|Completed||Phase 2|497|Actual|Ligand Pharmaceuticals||4|||f||||||||||||||2018-06-01 04:45:49.743879|2018-06-01 04:45:49.743879
NCT00143260|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2012-06-07|2005-08-31|2005-09-02|Estimate|||||||2012-06-07|2012-06-08|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose|Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II|Completed||Phase 4|250||Pfizer|||||||||||||||||||2018-06-01 04:45:49.840144|2018-06-01 04:45:49.840144
NCT00143247|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2009-01-16||2010-04-10|2005-08-31|2005-09-02|Estimate|2009-11-03|2009-11-09|Estimate||||2010-04-10|2010-04-15|Estimate|March 2003||2003-03-31|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus|An Open-Label, Phase 2, Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus Participating in Extension Protocols 217-102, 103, or 104|Terminated||Phase 2|173|Actual|Pfizer|Study terminated early due to business and operational issues. All subjects who were treated with inhaled insulin in parent protocols(217-102,-103,or-104) or in extension protocols (217-102E,-103E,-104E,or A2171036)are included in safety evaluation.|1||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:45:49.988698|2018-06-01 04:45:49.988698
NCT00143234|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-04-21|2005-08-31|2005-09-02|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2004||2004-05-31|April 2015|2015-04-30|July 2005||2005-07-31|||||Interventional|GEMINI-AALA||Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels|Clinical Utility of Amlodipine/Atorvastatin to Improve Concomitant Cardiovascular Risk Factors of Hypertension and Dyslipidemia|Completed||Phase 3|1825||Pfizer|||||f||||||||||||||2018-06-01 04:45:51.305716|2018-06-01 04:45:51.305716
NCT00143221|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2006-12-07|2005-08-31|2005-09-02|Estimate|||||||2006-12-07|2006-12-11|Estimate|March 2004||2004-03-31|December 2006|2006-12-31|May 2005||2005-05-31|||||Interventional|||Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)|A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Flexible Dose Study With and Open-Label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States|Completed||Phase 4|350||Pfizer|||||||||||||||||||2018-06-01 04:45:51.622529|2018-06-01 04:45:51.622529
NCT00143208|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-01-18|2005-08-31|2005-09-02|Estimate|||||||2008-01-18|2008-01-23|Estimate|May 2003||2003-05-31|January 2008|2008-01-31|April 2006|Actual|2006-04-30|||||Interventional|||Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.|Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy|Completed||Phase 4|250||Pfizer|||||f||||||||||||||2018-06-01 04:45:51.712718|2018-06-01 04:45:51.712718
NCT00143195|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-04-17|2005-08-31|2005-09-02|Estimate|||||||2007-04-17|2007-04-18|Estimate|April 2001||2001-04-30|April 2007|2007-04-30|January 2005||2005-01-31|||||Interventional|ANISSA||Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina|Open Label Study Comparing Amlodipine vs Long-Acting Nitrates in Patients With Chronic Stable Angina.|Completed||Phase 4|200||Pfizer|||||f||||||||||||||2018-06-01 04:45:51.829854|2018-06-01 04:45:51.829854
NCT00143182|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-05-29|2005-08-31|2005-09-02|Estimate|||||||2017-05-29|2017-05-31|Actual|January 7, 2005|Actual|2005-01-07|May 2017|2017-05-31|June 28, 2006|Actual|2006-06-28|June 28, 2006|Actual|2006-06-28||Interventional|||9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)|A Double-Blind, 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Asenapine vs. Olanzapine in the Treatment of Subjects With Acute Mania Clinical Trial Protocol A7501006 (Secondary Title: ARES)|Completed||Phase 3|504|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:45:51.914572|2018-06-01 04:45:51.914572
NCT00143169|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-04-14|2005-08-31|2005-09-02|Estimate|||||||2008-04-14|2008-04-15|Estimate|September 2004||2004-09-30|November 2005|2005-11-30|June 2005||2005-06-30|||||Interventional|||Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Of Morphine-Sparing Effect And Safety Of Parecoxib Administered Intravenously For The Treatment Of Postoperative Pain Following Orthopedic Or Gynecological Surgery|Completed||Phase 3|220||Pfizer|||||f||||||||||||||2018-06-01 04:45:51.99265|2018-06-01 04:45:51.99265
NCT00143156|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-04-09|2005-08-31|2005-09-02|Estimate|||||||2008-04-09|2008-04-14|Estimate|March 2005||2005-03-31|April 2008|2008-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|Completed||Phase 3|450||Pfizer|||||||||||||||||||2018-06-01 04:45:52.078099|2018-06-01 04:45:52.078099
NCT00143143|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-07-21|2005-09-01|2005-09-02|Estimate|||||||2006-07-21|2006-07-24|Estimate|September 2001||2001-09-30|March 2006|2006-03-31|February 2006||2006-02-28|||||Interventional|||Pregabalin Open-Label Extension Trial in Patients With Partial Seizures|Pregabalin BID Open-Label Add-On Trial: A Follow-Up Study To Determine Long-Term Safety and Efficacy in Patients With Partial Seizures|Completed||Phase 3|300||Pfizer|||||f||||||||||||||2018-06-01 04:45:52.238436|2018-06-01 04:45:52.238436
NCT00143130|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-03-04|2005-09-01|2005-09-02|Estimate|||||||2015-03-04|2015-03-05|Estimate|April 2005||2005-04-30|March 2015|2015-03-31|September 2007|Actual|2007-09-30|||||Interventional|PREPS EXT||Pregabalin In Partial Seizures Extension Study|Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-month Follow-on Open-label, International, Multicenter Add-on Therapy Trial|Completed||Phase 3|227|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:45:52.35248|2018-06-01 04:45:52.35248
NCT00143117|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2012-11-05|2005-08-30|2005-09-02|Estimate|||||||2012-11-05|2012-11-07|Estimate|August 2004||2004-08-31|November 2012|2012-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation|A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation|Completed||Phase 2/Phase 3|460||Pfizer|||||||||||||||||||2018-06-01 04:45:52.464277|2018-06-01 04:45:52.464277
NCT00143104|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-03-09|2005-08-31|2005-09-02|Estimate|||||||2008-03-09|2008-03-11|Estimate|December 2004||2004-12-31|February 2007|2007-02-28|October 2006|Actual|2006-10-31|||||Interventional|||To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.|A Phase 2, Exploratory Study to Examine the Effects of Inhaled Insulin, Compared With Subcutaneously Administered Insulin, on Airway Lining Fluid Composition in Subjects With Type 1 Diabetes Mellitus.|Completed||Phase 2|20||Pfizer|||||||||||||||||||2018-06-01 04:45:52.652565|2018-06-01 04:45:52.652565
NCT00143091|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-03-19|2005-08-31|2005-09-02|Estimate|||||||2008-03-19|2008-03-24|Estimate|April 2005||2005-04-30|March 2008|2008-03-31|April 2006|Actual|2006-04-30|||||Interventional|||Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder|A Six-Week, Fixed Dose, Double-Blind, Double-Dummy, Placebo and Sertraline Controlled, Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Outpatients With Major Depressive Disorder|Terminated||Phase 2|200||Pfizer||||See Detailed Description for termination reason.|||||t||||||||||2018-06-01 04:45:52.707337|2018-06-01 04:45:52.707337
NCT00143078|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-11-13|2005-09-01|2005-09-02|Estimate|||||||2015-11-13|2015-11-16|Estimate|June 2005||2005-06-30|November 2015|2015-11-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|||Obesity and Weight Loss on Reproductive Function|The Effects of Morbid Obesity and Weight Loss on Reproductive Function: The Bariatric Surgery Model|Terminated|||35|Actual|Milton S. Hershey Medical Center||||Close-out of the grant - study ceased on 1/1/2010|f||||f||||||Samples With DNA|"~     whole blood & urine~   "|||2018-06-01 04:45:52.785755|2018-06-01 04:45:52.785755
NCT00143065|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-02-06|2005-09-01|2005-09-02|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 2005||2005-08-31|February 2017|2017-02-28|July 2009|Actual|2009-07-31|February 2007|Actual|2007-02-28||Interventional|||Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Feasibility/Phase II Trial of Fludarabine, Rituximab, and Alemtuzumab for Previously Treated B-Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Completed||Phase 2|8|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:45:52.836378|2018-06-01 04:45:52.836378
NCT00143052|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-06-23|2005-09-01|2005-09-02|Estimate|||||||2008-06-23|2008-06-24|Estimate|January 2002||2002-01-31|June 2008|2008-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Bone Status and Insulin Resistance in Hirsutism|Body Composition, Insulin Concentration, Androgens and Bone Status in Women Referred With Hirsutism|Completed|||50|Actual|Odense University Hospital|||||f||||||||||||||2018-06-01 04:45:52.895996|2018-06-01 04:45:52.895996
NCT00143039|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2014-12-17|2005-09-01|2005-09-02|Estimate|||||||2014-12-17|2014-12-19|Estimate|March 2006||2006-03-31|December 2014|2014-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|TandemMS||Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR|Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by Nonimmune Hydrops and Severe Symmetrical Intrauterine Growth Restriction-A Multicenter Prospective Pilot Cohort Study|Terminated|||48|Actual|Mednax Center for Research, Education, Quality and Safety|||2|No metabolic disordered ID'd by TMS in either control/test group at >50%enrolled|f||||t||||||||||2018-06-01 04:45:52.946802|2018-06-01 04:45:52.946802
NCT00143026|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-03-27|2005-08-31|2005-09-02|Estimate|||||||2017-03-27|2017-03-29|Actual|July 2005||2005-07-31|March 2017|2017-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States|Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.|Completed||Phase 4|184|Actual|Novartis|||||f||||||||||||||2018-06-01 04:45:53.030425|2018-06-01 04:45:53.030425
NCT00143013|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-06-11|2005-09-01|2005-09-02|Estimate|||||||2008-06-11|2008-06-12|Estimate|October 2004||2004-10-31|June 2008|2008-06-30|April 2007||2007-04-30|||||Observational|||Gene Expression Profiling and Bioinformatic Analysis Identifying Genes and Biochemical Pathways in Type 2 Diabetes|Gene Expression Profiling by DNA Chips and Subsequent Bioinformatic Analysis for Identification of Genes and Biochemical Pathways Associated With Type 2 Diabetes|Unknown status|Recruiting||100|Anticipated|Odense University Hospital|||||f||||||||||||||2018-06-01 04:45:53.099365|2018-06-01 04:45:53.099365
NCT00143000|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-04-04|2005-09-01|2005-09-02|Estimate|||||||2008-04-04|2008-04-07|Estimate|April 2004||2004-04-30|April 2008|2008-04-30|October 2006|Actual|2006-10-31|||||Interventional|||Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3|A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection|Completed||Phase 4|392|Actual|NORDynamIC Study Group|||||f||||t||||||||||2018-06-01 04:45:53.143978|2018-06-01 04:45:53.143978
NCT00142987|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-01-24|2005-08-31|2005-09-02|Estimate|||||||2008-01-24|2008-01-28|Estimate|April 2004||2004-04-30|January 2008|2008-01-31|June 2005|Actual|2005-06-30|||||Interventional|||Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS|Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS|Completed||Phase 4|664||Novartis|||||||||||||||||||2018-06-01 04:45:53.206298|2018-06-01 04:45:53.206298
NCT00142974|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2012-04-19|2005-08-31|2005-09-02|Estimate|||||||2012-04-19|2012-04-20|Estimate|May 2004||2004-05-31|April 2012|2012-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy|Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy|Terminated||Phase 2|120||Novartis||||This study was terminated early in April 2005 due to low patient enrollment|||||||||||||||2018-06-01 04:45:53.249247|2018-06-01 04:45:53.249247
NCT00142961|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2018-05-10|2005-09-01|2005-09-02|Estimate|||||||2018-05-10|2018-05-16|Actual|October 2005||2005-10-31|May 2018|2018-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder|Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment|Completed||Phase 2|2|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 04:45:53.301291|2018-06-01 04:45:53.301291
NCT00142948|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-10-22|2005-09-01|2005-09-02|Estimate|||||||2012-10-22|2012-10-24|Estimate|February 2006||2006-02-28|October 2012|2012-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts|Heroin Addiction Treatment: Naltrexone and Adrenergic Agents|Completed||Phase 2|301|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 04:45:54.332597|2018-06-01 04:45:54.332597
NCT00142935|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2013-12-05||2014-05-08|2005-09-01|2005-09-02|Estimate|2014-05-08|2014-06-06|Estimate||||2014-05-08|2014-06-06|Estimate|September 2006||2006-09-30|May 2009|2009-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1|Opiate Replacement Therapy at Release From Incarceration|Completed||N/A|87|Actual|The Miriam Hospital||3|||f||||t||||||||||2018-06-01 04:45:54.586199|2018-06-01 04:45:54.586199
NCT00142922|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2010-03-01|2005-08-31|2005-09-02|Estimate|||||||2010-03-01|2010-03-02|Estimate|October 2002||2002-10-31|March 2010|2010-03-31|October 2007||2007-10-31|||||Interventional|||Breaking Down Barriers to Diabetes Self-Care|Breaking Down Barriers to Diabetes Self-Care|Completed||N/A|222||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 04:45:54.980697|2018-06-01 04:45:54.980697
NCT00142909|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2012-11-01||2015-07-28|2005-09-01|2005-09-02|Estimate|2013-10-27|2013-11-20|Estimate||||2015-07-28|2015-07-30|Estimate|February 2005||2005-02-28|July 2015|2015-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1|Lofexidine: Enhancing Naltrexone Treatment for Opiate Addiction|Completed||Phase 2|86|Actual|Yale University||2|||f||||t||||||||||2018-06-01 04:45:55.076269|2018-06-01 04:45:55.076269
NCT00142896|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-01-11|2005-09-01|2005-09-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2005||2005-02-28|August 2008|2008-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Tramadol to Reduce Opioid Withdrawal Symptoms|Withdrawal Suppression Efficacy of Tramadol|Completed||Phase 2|16|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:45:56.1948|2018-06-01 04:45:56.1948
NCT00142883|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-07-07|2005-09-01|2005-09-02|Estimate|||||||2015-07-07|2015-07-08|Estimate|September 2004||2004-09-30|July 2015|2015-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3|The Effects of GABA Medications on Cocaine Responses in Humans|Terminated||N/A|72|Actual|Yale University||2||Study has been completed|f||||t||||||||||2018-06-01 04:45:56.254387|2018-06-01 04:45:56.254387
NCT00142870|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-01-11|2005-09-01|2005-09-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2005||2005-03-31|October 2016|2016-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effectiveness of Bupropion in Treating Marijuana Dependent Individuals|Effects of Bupropion on Marijuana Withdrawal Symptoms|Completed||Phase 2|30|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||f||||||||||2018-06-01 04:45:56.331284|2018-06-01 04:45:56.331284
NCT00142844|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-01-11|2005-09-01|2005-09-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 1999||1999-09-30|October 2016|2016-10-31|January 2008|Actual|2008-01-31|March 2005|Actual|2005-03-31||Interventional|||Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1|Two Medications, Disulfiram and Naltrexone, in the Treatment of Patients With Both Cocaine and Alcohol Dependence|Completed||Phase 2|208|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||f||||||||||2018-06-01 04:45:56.399927|2018-06-01 04:45:56.399927
NCT00142831|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-01-11|2005-09-01|2005-09-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 1999||1999-04-30|August 2008|2008-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Bupropion as an Adjunct to the Nicotine Patch Plus CBT|Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1|Completed||Phase 4|293|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:45:56.494572|2018-06-01 04:45:56.494572
NCT00142818|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2014-08-12||2018-02-07|2005-09-01|2005-09-02|Estimate|2014-08-27|2014-08-29|Estimate||||2018-02-07|2018-03-09|Actual|February 2006||2006-02-28|February 2018|2018-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|Mod-Nal||Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence|A Phase II, Double-blind, Placebo-Controlled, Pilot Trial of the Combination of Modafinil and Naltrexone for the Treatment of Cocaine and Alcohol Dependence|Completed||Phase 2|164|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 04:45:56.575702|2018-06-01 04:45:56.575702
NCT00142805|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-12-30|2005-09-01|2005-09-02|Estimate|||||||2008-12-30|2008-12-31|Estimate|October 2004||2004-10-31|September 2006|2006-09-30|March 2006||2006-03-31|||||Interventional|||Ketasyn in Mild to Moderate Alzheimer's Disease|Safety, Tolerability and Efficacy Study of Ketasyn™ (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity|Completed||Phase 2|100||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:45:56.983822|2018-06-01 04:45:56.983822
NCT00142792|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2017-09-15||2018-03-02|2005-08-31|2005-09-02|Estimate|2018-03-02|2018-03-29|Actual||||2018-03-02|2018-03-29|Actual|December 2005||2005-12-31|March 2018|2018-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Non-hospitalized adults within 6 months of stroke aged 21-89 years.|Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke|Electrical Stimulation for Upper Limb Recovery in Stroke|Completed||N/A|122|Actual|MetroHealth Medical Center|the estimated sample size needed to reach 90% power to detect clinically meaningful differences within the groups was not met due to slow recruitment. The lower power creates the possibility that a type II error was made.|3|||f||||f|f|||||||No||2018-06-01 04:45:57.12416|2018-06-01 04:45:57.12416
NCT00142779|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-01-11|2005-09-01|2005-09-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|May 2009|2009-05-31|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||Fluoxetine to Reduce Cocaine Use in Cocaine and Opioid Addicts|Serotonin Treatment of Cocaine Dependence|Completed||N/A|220||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:45:57.641051|2018-06-01 04:45:57.641051
NCT00142766|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-10-05|2005-08-31|2005-09-02|Estimate|||||||2015-10-05|2015-10-07|Estimate|February 2004||2004-02-29|October 2015|2015-10-31|March 2007|Actual|2007-03-31|July 2006|Actual|2006-07-31||Interventional|||Sedation Management in Pediatric Patients Supported on Mechanical Ventilation|Sedation Management in Pediatric Patients Supported on Mechanical Ventilation|Completed||Phase 2|245|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||||||2018-06-01 04:45:57.708673|2018-06-01 04:45:57.708673
NCT00142753|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-02-27|2005-08-31|2005-09-02|Estimate|||||||2017-02-27|2017-02-28|Actual|August 2005||2005-08-31|February 2016|2016-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Immunologic Memory (Supp. of ATN 024)|Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents: A Substudy of ATN 024 and ATN 025|Completed||Phase 4|95|Actual|University of North Carolina, Chapel Hill||5|||f||||||||||||||2018-06-01 04:45:57.782314|2018-06-01 04:45:57.782314
NCT00142740|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-02-27|2005-08-31|2005-09-02|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2005||2005-10-31|February 2016|2016-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025|Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025|Completed|||337|Actual|University of North Carolina, Chapel Hill|||2||f||||t||||||Samples With DNA|"~     Approximately 5 ml whole blood or 5 x 106 peripheral blood mononuclear cells.~   "|||2018-06-01 04:45:57.888856|2018-06-01 04:45:57.888856
NCT00142727|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2017-01-11|2005-09-01|2005-09-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|July 2007|2007-07-31|February 2006||2006-02-28|||||Interventional|||Opioid Agonist and Antagonist Effects on Opioid Dependence|The Variability of Agonist and Antagonist Effects as a Function of Level of Physical Dependence|Terminated||Phase 2|16|Anticipated|National Institute on Drug Abuse (NIDA)||||Study terminated due to halt in funding; may resume recruiting in future|f||||f||||||||||2018-06-01 04:45:57.982908|2018-06-01 04:45:57.982908
NCT00142714|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-10-13|2005-09-01|2005-09-02|Estimate|||||||2006-10-13|2006-10-16|Estimate|August 2003||2003-08-31|October 2006|2006-10-31|June 2005||2005-06-30|||||Interventional|||Effects of Spinal Cord Injury on Female Sexual Response|Effects of SCI on Female Sexual Response|Unknown status|Recruiting|N/A|70||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:45:58.13473|2018-06-01 04:45:58.13473
NCT00142701|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-02-04|2005-09-01|2005-09-02|Estimate|||||||2016-02-04|2016-02-08|Estimate|April 1999||1999-04-30|February 2016|2016-02-29|March 2005|Actual|2005-03-31|September 2004|Actual|2004-09-30||Interventional|||Enhancing Support for Women at Risk for Heart Disease||Completed||N/A|||Oregon Research Institute|||||f||||f||||||||Undecided||2018-06-01 04:45:58.249244|2018-06-01 04:45:58.249244
NCT00142688|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2015-10-28|2005-09-01|2005-09-02|Estimate|||||||2015-10-28|2015-10-29|Estimate|August 2004||2004-08-31|October 2015|2015-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Examining Psychosocial Mediators of Exercise Behavior|Examining Psychosocial Mediators of Exercise Behavior|Completed||Phase 1|448|Actual|HealthPartners Institute||2|||f||||||||||||||2018-06-01 04:45:58.55147|2018-06-01 04:45:58.55147
NCT00142675|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2014-03-04|2005-09-01|2005-09-02|Estimate|||||||2014-03-04|2014-03-05|Estimate|February 2003||2003-02-28|March 2014|2014-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Using Peers to Promote Exercise in Older Adults||Completed||N/A|||Stanford University|||||f||||||||||||||2018-06-01 04:45:58.692002|2018-06-01 04:45:58.692002
NCT00142662|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2014-03-26|2005-09-01|2005-09-02|Estimate|||||||2014-03-26|2014-03-27|Estimate|September 2002||2002-09-30|January 2008|2008-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Cafeteria-Based Study of Weight Gain Prevention||Completed||N/A|||Drexel University|||||f||||||||||||||2018-06-01 04:45:58.838995|2018-06-01 04:45:58.838995
NCT00142649|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-01-18|2005-09-01|2005-09-02|Estimate|||||||2008-01-18|2008-01-21|Estimate|September 2002||2002-09-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Adherence to Weight Loss for Hypertension in African American Women||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:45:59.058917|2018-06-01 04:45:59.058917
NCT00142636|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-11-21|2005-09-01|2005-09-02|Estimate|||||||2005-11-21|2005-11-22|Estimate|February 2004||2004-02-29|August 2005|2005-08-31|September 2005||2005-09-30|||||Observational|||CRICKET Study, Coronary Calcium Scores in Patients With Chronic Kidney Disease|Coronary Artery Calcification in Chronic Kidney Disease Using Multidetector Row Spiral Computed Tomography|Unknown status|Active, not recruiting||200||United States Naval Medical Center, San Diego|||||f||||||||||||||2018-06-01 04:45:59.246812|2018-06-01 04:45:59.246812
NCT00142623|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-07-29|2005-09-01|2005-09-02|Estimate|||||||2008-07-29|2008-07-30|Estimate|February 2006||2006-02-28|July 2008|2008-07-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Interventional|ETS||Tailored Videos to Reduce Tobacco Smoke Exposure Among Pregnant Women and Newborns|Reducing ETS Exposure of Pregnant Women and Newborns|Unknown status|Recruiting|N/A|650|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 04:45:59.350782|2018-06-01 04:45:59.350782
NCT00142610|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-03-01|2005-09-01|2005-09-02|Estimate|||||||2013-03-01|2013-03-04|Estimate|August 2005||2005-08-31|February 2013|2013-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|VITAS||The Role of Vitamins E and C in Maintaining Lung Health in People With Asthma|Effect of Alpha Tocopherol and Ascorbate Supplementation on Airway Antioxidant Levels in Allergic Asthmatics|Completed||Phase 1|16|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 04:45:59.562917|2018-06-01 04:45:59.562917
NCT00142597|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2014-12-04||2015-04-09|2005-09-01|2005-09-02|Estimate|2015-04-09|2015-04-13|Estimate||||2015-04-09|2015-04-13|Estimate|May 2005||2005-05-31|December 2014|2014-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Effectiveness of Acupuncture in Relieving Pain Due to Fibromyalgia|Mechanisms of Acupuncture Analgesia|Completed||Phase 1/Phase 2|46|Actual|University of Michigan||2|||f||||||||||||||2018-06-01 04:45:59.685061|2018-06-01 04:45:59.685061
NCT00142584|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-03-06|2005-08-31|2005-09-02|Estimate|||||||2008-03-06|2008-03-12|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|March 2008|Actual|2008-03-31|March 2008|Anticipated|2008-03-31||Interventional|||Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension|An Open-Label, Randomized Study Evaluating the Long-Term Effects of Metoprolol Versus Nebivolol as Monotherapy or in Combination With Amlodipine or Hydrochlorothiazide for the Treatment of Patients With Hypertension|Completed||Phase 3|1000|Anticipated|Mylan Bertek Pharmaceuticals||2|||f||||||||||||||2018-06-01 04:46:00.603574|2018-06-01 04:46:00.603574
NCT00142571|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-10-01|2005-09-01|2005-09-02|Estimate|||||||2007-10-01|2007-10-02|Estimate|January 2003||2003-01-31|October 2007|2007-10-31|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma|Ph III Random Trial of 120-Min Infusion Gemcitabine v. 90-Min Infusion Gemcitabine + Docetaxel in Unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North Amer. Sarcoma Study Group of the Connective Tissue Oncology Society|Completed||Phase 3|120||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:46:01.029486|2018-06-01 04:46:01.029486
NCT00142558|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-04-07|2005-08-31|2005-09-02|Estimate|||||||2017-04-07|2017-04-11|Actual|January 1, 2005|Actual|2005-01-01|April 2017|2017-04-30|May 1, 2005|Actual|2005-05-01|May 1, 2005|Actual|2005-05-01||Interventional|||A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)|A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 mg Versus Indomethacin 150 mg in the Treatment of Acute Gout|Completed||Phase 4|180|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:46:01.301751|2018-06-01 04:46:01.301751
NCT00142545|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-08-31|2005-08-31|2005-09-02|Estimate|||||||2005-08-31|2005-09-02|Estimate|July 1999||1999-07-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||"Long Term Safety and Efficacy of SC Apomorphine in Treatment of Off Episodes in Late-Stage Parkinson's Disease"|Long-Term Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of “Off” Episodes in Patients With “On-Off” or “Wearing-Off” Effects Associated With Late-Stage Parkinson’s Disease|Completed||Phase 3|800||Mylan Bertek Pharmaceuticals|||||||||||||||||||2018-06-01 04:46:01.585996|2018-06-01 04:46:01.585996
NCT00142532|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-01-13|2005-09-01|2005-09-02|Estimate|||||||2009-01-13|2009-01-14|Estimate|June 2005||2005-06-30|January 2009|2009-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Acupuncture for Post-Thoracotomy Pain|Acupuncture for Post-Thoracotomy Pain: A Randomized Controlled Trial|Completed||Phase 3|162|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:46:05.411145|2018-06-01 04:46:05.411145
NCT00142519|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2018-04-03|2005-09-01|2005-09-02|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2005|Actual|2005-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain|Translational Studies in Analgesic Pharmacology: Analgesic Synergy in Clinical Pain. A Phase 2 Study Comparing a Single Dose of a 1:1 Combination of Methadone and Morphine With Morphine Alone in Patients With Post-operative Pain.|Active, not recruiting||Phase 2|70|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:46:06.339996|2018-06-01 04:46:06.339996
NCT00142506|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2015-12-17||2017-09-19|2005-09-01|2005-09-02|Estimate|2017-09-19|2017-10-20|Actual||||2017-09-19|2017-10-20|Actual|February 2005||2005-02-28|September 2017|2017-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer|This Protocol is a Randomized Prospective Study Comparing Prophylactic and on Demand Sildenafil Citrate Usage Administered During and After Radiotherapy With or Without Hormone Therapy Versus Radiotherapy With or Without Hormone Therapy Alone for the Preservation of Erectile Function After Therapy for Potent Patients With Clinically Localized Prostate Cancer|Completed||Phase 3|290|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:46:07.220169|2018-06-01 04:46:07.220169
NCT00142493|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-12-23|2005-09-01|2005-09-02|Estimate|||||||2015-12-23|2015-12-24|Estimate|September 2004||2004-09-30|December 2015|2015-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Effect of Affective Content on Drug Induced Amnesia of Episodic Memory|Effect of Affective Content on Drug Induced Amnesia of Episodic Memory|Completed||Phase 1|79|Actual|Memorial Sloan Kettering Cancer Center||5|||f||||||||||||||2018-06-01 04:46:08.335372|2018-06-01 04:46:08.335372
NCT00142480|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2018-04-23|2005-08-31|2005-09-02|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2004||2004-12-31|April 2018|2018-04-30|April 2011|Actual|2011-04-30|July 2007|Actual|2007-07-31||Interventional|||Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer|Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer|Completed||Phase 2|8|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:46:09.098007|2018-06-01 04:46:09.098007
NCT00142467|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2014-03-15|2005-08-31|2005-09-02|Estimate|||||||2014-03-15|2014-03-18|Estimate|April 2004||2004-04-30|March 2014|2014-03-31|June 2011|Actual|2011-06-30|August 2006|Actual|2006-08-31||Interventional|||Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma|Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Patients With Hepatocellular Carcinoma|Completed||Phase 2|33|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:46:09.877641|2018-06-01 04:46:09.877641
NCT00142454|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-09-20|2005-09-01|2005-09-02|Estimate|||||||2007-09-20|2007-09-21|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|||NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)|NY-ESO-1 Protein Vaccination in Malignant Melanoma Administered With Imiquimod as Adjuvant|Completed||Phase 1|9||Ludwig Institute for Cancer Research|||||||||||||||||||2018-06-01 04:46:10.889914|2018-06-01 04:46:10.889914
NCT00142441|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-06-01|2005-09-01|2005-09-02|Estimate|||||||2016-06-01|2016-06-03|Estimate|June 2003||2003-06-30|June 2016|2016-06-30|December 2004||2004-12-31|||||Interventional|||Effect of Pulse Width on Scar Treatment Using a 595-nm Pulsed Dye Laser|Effect of Pulse Width of a 595-nm Flashlamp-pumped Pulsed-dye Laser on the Treatment Response of Keloidal and Hypertrophic Sternotomy Scars|Completed||N/A|19||Mahidol University|||||f||||||||||||||2018-06-01 04:46:11.241056|2018-06-01 04:46:11.241056
NCT00142428|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2014-03-16|2005-08-31|2005-09-02|Estimate|||||||2014-03-16|2014-03-18|Estimate|January 2005||2005-01-31|March 2014|2014-03-31|October 2008|Actual|2008-10-31|October 2005|Actual|2005-10-31||Interventional|||Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma|A Phase II Study of Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|30|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:46:12.819705|2018-06-01 04:46:12.819705
NCT00142415|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2016-11-30||2017-02-01|2005-08-31|2005-09-02|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|February 2005||2005-02-28|February 2017|2017-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||The Safety Analysis Set comprises all subjects who received at least 1 dose of 111-In-DOTA-cG250 or 177-Lu-DOTA-cG250.|Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer|Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer|Completed||Phase 1/Phase 2|26|Actual|Ludwig Institute for Cancer Research||6|||f||||f||||||||Yes|Data have been published|2018-06-01 04:46:13.019635|2018-06-01 04:46:13.019635
NCT00142402|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-09-25|2005-09-01|2005-09-02|Estimate|||||||2013-09-25|2013-09-26|Estimate|June 2003||2003-06-30|September 2013|2013-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Modafinil in Multiple Sclerosis|Modafinil for Improving New Learning and Memory in Multiple Sclerosis|Completed||N/A|20||Kessler Foundation|||||f||||||||||||||2018-06-01 04:46:16.485781|2018-06-01 04:46:16.485781
NCT00142389|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-06-21|2005-09-01|2005-09-02|Estimate|||||||2011-06-21|2011-06-23|Estimate|August 2004||2004-08-31|August 2005|2005-08-31|December 2006||2006-12-31|||||Interventional|||Mother's Gift Project|Comparison of Maternal and Infant Immunization Strategies to Prevent Pneumococcal Disease|Completed||Phase 1/Phase 2|680||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:46:16.646199|2018-06-01 04:46:16.646199
NCT00142376|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-09-01|2005-09-01|2005-09-02|Estimate|||||||2005-09-01|2005-09-02|Estimate|September 2004||2004-09-30|September 2004|2004-09-30|August 2005||2005-08-31|||||Observational|||Short Term Outcomes of Children With Acute Respiratory Distress Syndrome||Completed|||||Nationwide Children's Hospital|||||f||||||||||||||2018-06-01 04:46:16.784487|2018-06-01 04:46:16.784487
NCT00142363|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-02-28|2005-09-01|2005-09-02|Estimate|||||||2006-02-28|2006-03-01|Estimate|May 2004||2004-05-31|February 2006|2006-02-28|December 2006||2006-12-31|||||Observational|||Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and Epilepsies|The DNA and Cell Bank of IFR of Neurosciences: Clinical and Genetic Study of Parkinson's Disease and Epilepsies|Terminated|||1700||Institut National de la Santé Et de la Recherche Médicale, France|||||f||||||||||||||2018-06-01 04:46:16.916355|2018-06-01 04:46:16.916355
NCT00142350|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2016-09-08|2005-09-01|2005-09-02|Estimate|||||||2016-09-08|2016-09-12|Estimate|November 2000||2000-11-30|September 2016|2016-09-30|January 2007||2007-01-31|||||Interventional|||A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer|Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)|Completed||Phase 3|690||Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:46:17.020603|2018-06-01 04:46:17.020603
NCT00142337|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-01-04|2005-09-01|2005-09-02|Estimate|||||||2012-01-04|2012-01-06|Estimate|December 2004||2004-12-31|January 2012|2012-01-31|February 2009|Actual|2009-02-28|May 2006|Actual|2006-05-31||Interventional|||One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine|A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV|Completed||Phase 2|244|Actual|Institut de Recherche pour le Developpement|||||f||||||||||||||2018-06-01 04:46:17.244279|2018-06-01 04:46:17.244279
NCT00142324|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-12-13|2005-09-01|2005-09-02|Estimate|||||||2005-12-13|2005-12-14|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|December 2005||2005-12-31|||||Interventional|||CALM-AD|A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention|Unknown status|Active, not recruiting|Phase 4|190||Institute of Psychiatry, London|||||f||||||||||||||2018-06-01 04:46:17.490491|2018-06-01 04:46:17.490491
NCT00142311|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-04-18|2005-09-01|2005-09-02|Estimate|||||||2007-04-18|2007-04-19|Estimate|November 2003||2003-11-30|April 2007|2007-04-30|September 2006||2006-09-30|||||Observational|||Functional Characterization of Parkin + Patients|Clinical, Molecular and Metabolic Comparison Between Early Onset Parkinsonian, With or Without Parkin Mutation: Physiopathological Perspectives|Terminated|||97||Institut National de la Santé Et de la Recherche Médicale, France|||||f||||||||||||||2018-06-01 04:46:17.606763|2018-06-01 04:46:17.606763
NCT00142298|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2011-01-12||2015-03-24|2005-08-31|2005-09-02|Estimate|2011-06-24|2011-07-25|Estimate||||2015-03-24|2015-04-14|Estimate|March 2005||2005-03-31|March 2015|2015-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies|An Open Label Trial of Telbivudine (LdT) in Adults With Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies|Completed||Phase 3|1869|Actual|Novartis|||||f||||||||||||||2018-06-01 04:46:17.801638|2018-06-01 04:46:17.801638
NCT00142285|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-01-06|2005-09-01|2005-09-02|Estimate|||||||2013-01-06|2013-01-08|Estimate|November 2004||2004-11-30|July 2006|2006-07-31|May 2008|Actual|2008-05-31|May 2006|Actual|2006-05-31||Interventional|||Zinc Pneumonia Outpatient Trial in Children < 2 Years|Efficacy of Zinc in the Treatment of Outpatient Pneumonia in an Urban Slum Among Children Less Than 2 Years Old|Completed||Phase 3|2260|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:46:20.668636|2018-06-01 04:46:20.668636
NCT00142272|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2005-11-18|2005-09-01|2005-09-02|Estimate|||||||2005-11-18|2005-11-21|Estimate|May 2001||2001-05-31|September 2005|2005-09-30|July 2002||2002-07-31|||||Interventional|||Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial|Randomised, Open, Parallel Group Clinical Trial to Compare the Efficacy and Safety of a Single Dose of Ciprofloxacin Oral Suspension 20 Mg/Kg With a 3-Day Course of Erythromycin Oral Suspension Administered in a Dose of 12.5 Mg/Kg Every 6 Hours (12 Doses) in the Treatment of Children,With Clinically Severe Cholera Due to V. Cholerae O1 or O139.|Completed||Phase 3|180||International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||||||||||||2018-06-01 04:46:20.80538|2018-06-01 04:46:20.80538
NCT00141687|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-09-14|2005-08-30|2005-09-01|Estimate|||||||2016-09-14|2016-09-15|Estimate|December 2004||2004-12-31|September 2016|2016-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Early External Cephalic Version (ECV) 2 Trial|Early External Cephalic Version 2 Trial|Completed||N/A|1543|Actual|McMaster University||2|||f||||f||||||||||2018-06-01 04:46:29.500129|2018-06-01 04:46:29.500129
NCT00142259|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2006-12-05|2005-09-01|2005-09-02|Estimate|||||||2006-12-05|2006-12-06|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|August 2009||2009-08-31|||||Interventional|||Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia|Randomisierte, Doppelblinde Langzeitstudie Zur Klinischen Wirksamkeit Der Bilateralen Globus Pallidus Internus-Stimulation Bei Idiopathischer Generalisierter Oder Segmentaler Dystonie|Unknown status|Active, not recruiting|Phase 4|40||German Parkinson Study Group (GPS)|||||f||||||||||||||2018-06-01 04:46:20.931775|2018-06-01 04:46:20.931775
NCT00142246|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-01-25|2005-08-31|2005-09-02|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education.|Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya|Completed||Phase 3|6758|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-06-01 04:46:21.042509|2018-06-01 04:46:21.042509
NCT00142233|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-09-11|2005-08-31|2005-09-02|Estimate|||||||2007-09-11|2007-09-12|Estimate|June 2004||2004-06-30|August 2005|2005-08-31|December 2008|Anticipated|2008-12-31|||||Interventional|||EUROPAC-2 - Pain Treatment of Hereditary and Idiopathic Pancreatitis|Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis|Unknown status|Recruiting|Phase 2/Phase 3|240|Anticipated|University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:46:21.238404|2018-06-01 04:46:21.238404
NCT00142220|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2006-09-08|2005-09-01|2005-09-02|Estimate|||||||2006-09-08|2006-09-11|Estimate|January 2004||2004-01-31|September 2006|2006-09-30||||||||Interventional|||The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients|Comparison Between Two Different Proportions of Omega-3- and Omega-6-Fatty Acids in the Parenteral Nutrition of Critically Ill Patients|Completed||Phase 4|160||University Medicine Greifswald|||||f||||||||||||||2018-06-01 04:46:21.382541|2018-06-01 04:46:21.382541
NCT00142207|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-01-11|2005-08-31|2005-09-02|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|January 2017|2017-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Preventing Malaria During Pregnancy in Epidemic-prone Areas.|The Efficacy and Cost-effectiveness of Malaria Prevention in Pregnancy in an Area of Low and Unstable Transmission in Kabale, Uganda: Use of Intermittent Preventive Treatment and Insecticide-treated Nets.|Completed||Phase 3|4775|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-06-01 04:46:21.444627|2018-06-01 04:46:21.444627
NCT00142194|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2013-09-26|2005-09-01|2005-09-02|Estimate|||||||2013-09-26|2013-09-27|Estimate|June 2005||2005-06-30|September 2013|2013-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Markers of Oxidative Stress Present in Blood in Patients With Atrial Fibrillation|Markers of Oxidative Stress Present in Blood in Patients With Atrial Fibrillation|Completed|||47|Actual|Emory University|||||f||||f||||||||||2018-06-01 04:46:21.553501|2018-06-01 04:46:21.553501
NCT00142181|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-12-19|2005-09-01|2005-09-02|Estimate|||||||2012-12-19|2012-12-21|Estimate|March 2003||2003-03-31|December 2012|2012-12-31|June 2008|Actual|2008-06-30|October 2005|Actual|2005-10-31||Interventional|||Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia|Phase II Study of Campath-1H in Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)|Completed||Phase 2|27|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 04:46:21.679138|2018-06-01 04:46:21.679138
NCT00142168|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2012-12-19||2016-03-23|2005-09-01|2005-09-02|Estimate|2015-11-11|2015-12-16|Estimate||||2016-03-23|2016-04-21|Estimate|September 2004||2004-09-30|March 2016|2016-03-31|April 2008|Actual|2008-04-30|May 2006|Actual|2006-05-31||Interventional|||CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia|Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia|Terminated||Phase 2|16|Actual|Dana-Farber Cancer Institute|Due to toxicity, study was terminated.|1||Toxicity|f||||t||||||||||2018-06-01 04:46:21.85309|2018-06-01 04:46:21.85309
NCT00142155|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-06-23|2005-09-01|2005-09-02|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2002||2002-01-31|June 2011|2011-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia|Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia|Completed||N/A|300|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:46:22.160354|2018-06-01 04:46:22.160354
NCT00142129|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-06-23|2005-09-01|2005-09-02|Estimate|||||||2011-06-23|2011-06-27|Estimate|December 2003||2003-12-31|June 2011|2011-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia|Phase II Study of Velcade in Waldenstrom's Macroglobulinemia|Completed||Phase 2|27||Dana-Farber Cancer Institute|||||||||||||||||||2018-06-01 04:46:22.275461|2018-06-01 04:46:22.275461
NCT00142116|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|2013-06-13||2014-05-08|2005-09-01|2005-09-02|Estimate|2014-05-08|2014-06-02|Estimate||||2014-05-08|2014-06-02|Estimate|May 2003||2003-05-31|May 2014|2014-05-31|February 2008|Actual|2008-02-29|February 2004|Actual|2004-02-29||Interventional|||Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia|Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia|Completed||Phase 2|25|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:46:22.403229|2018-06-01 04:46:22.403229
NCT00142103|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2011-05-13|2005-09-01|2005-09-02|Estimate|||||||2011-05-13|2011-05-16|Estimate|September 2005||2005-09-30|May 2011|2011-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects|CPG10101 Combination Therapy For The Treatment Of Hepatitis C: A Phase 1b Open Label Randomized Trial Of CPG10101 Alone, With Interferon, Ribavirin, Or Interferon And Ribavirin In The Treatment Of Relapsed Hepatitis C Virus (HCV) Subjects|Completed||Phase 1|91|Actual|Pfizer||6|||f||||t||||||||||2018-06-01 04:46:22.698047|2018-06-01 04:46:22.698047
NCT00142090|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2009-02-02|2005-09-01|2005-09-02|Estimate|||||||2009-02-02|2009-02-03|Estimate|November 2004||2004-11-30|January 2009|2009-01-31|July 2007|Actual|2007-07-31|December 2005|Actual|2005-12-31||Interventional|||Use of Salt-Water Solution to Improve Symptoms in Concussion|Use of 3% Hypertonic Saline to Improve Clinical Symptoms in Concussed Patients|Completed||N/A|8|Actual|Rady Children's Hospital, San Diego||2|||f||||f||||||||||2018-06-01 04:46:22.82103|2018-06-01 04:46:22.82103
NCT00142077|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-04-04|2005-08-31|2005-09-02|Estimate|||||||2007-04-04|2007-04-05|Estimate|October 2005||2005-10-31|January 2006|2006-01-31|May 2006|Actual|2006-05-31|||||Interventional|||Electronic Health Records for Health Promotion|Health Promotion in the Workplace Using Personally Controlled Health Records|Completed||N/A|700||Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:46:23.186797|2018-06-01 04:46:23.186797
NCT00140634|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-06-01|2005-08-31|2005-09-01|Estimate|||||||2017-06-01|2017-06-02|Actual|March 1995||1995-03-31|June 2017|2017-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients|Cartilage Repair Registry|Completed|||2233|Actual|Vericel Corporation|||||f||||f||||||||||2018-06-01 04:46:57.668202|2018-06-01 04:46:57.668202
NCT00142064|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-04-16|2005-09-01|2005-09-02|Estimate|||||||2007-04-16|2007-04-18|Estimate|August 2005||2005-08-31|September 2006|2006-09-30|April 2007|Actual|2007-04-30|||||Interventional|||A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures|A Randomized Control Trial Comparing Single to Multiple Application Lidocaine Analgesia Prior to Urethral Catheterization Procedures|Completed||Phase 2|200||Children's Mercy Hospital Kansas City|||||f||||t||||||||||2018-06-01 04:46:23.273751|2018-06-01 04:46:23.273751
NCT00142051|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-07-15|2005-08-31|2005-09-02|Estimate|||||||2017-07-15|2017-07-19|Actual|April 2005||2005-04-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis|Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis|Terminated||Phase 2|18|Actual|Boston Children’s Hospital||2||18 or 20 enrolled, stopped due to paucity of available participants|f||||t||||||||||2018-06-01 04:46:23.348947|2018-06-01 04:46:23.348947
NCT00142038|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2007-04-17|2005-09-01|2005-09-02|Estimate|||||||2007-04-17|2007-04-18|Estimate|March 2004||2004-03-31|April 2007|2007-04-30|December 2007||2007-12-31|||||Interventional|||Docetaxel and Capecitabine in Advanced Gastric Cancer|Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer|Completed||Phase 2|80||Charite University, Berlin, Germany|||||f||||||||||||||2018-06-01 04:46:23.438831|2018-06-01 04:46:23.438831
NCT00142025|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2009-02-18|2005-09-01|2005-09-02|Estimate|||||||2009-02-18|2009-02-19|Estimate|September 2001||2001-09-30|February 2009|2009-02-28|March 2002||2002-03-31|||||Interventional|||Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma|Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Oxcarbazepine Efficacy in Asthma Therapy|Completed||Phase 4|55||Centre of Chinese Medicine, Georgia|||||f||||||||||||||2018-06-01 04:46:23.531284|2018-06-01 04:46:23.531284
NCT00142012|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-11-16|2005-09-01|2005-09-02|Estimate|||||||2005-11-16|2005-11-17|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|June 2005||2005-06-30|||||Interventional|||School-Based Obesity Prevention Program|School-Based Obesity Prevention Program|Completed||N/A|1500||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:46:23.595546|2018-06-01 04:46:23.595546
NCT00141999|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2012-09-26|2005-09-01|2005-09-02|Estimate|||||||2012-09-26|2012-09-27|Estimate|May 2001||2001-05-31|September 2012|2012-09-30|March 2008|Actual|2008-03-31|March 2005|Actual|2005-03-31||Observational|||Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents|An Evaluation of Long-Term Protection Against Hepatitis B Virus Infection: Response of Alaska Native Children and Adolescents Who Received the Primary Recombinant Hepatitis B Vaccine Series Beginning at Birth to an Additional Dose of Vaccine|Completed|||400||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:46:23.680482|2018-06-01 04:46:23.680482
NCT00141986|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-04-25|2005-09-01|2005-09-02|Estimate|||||||2011-04-25|2011-04-26|Estimate|November 2003||2003-11-30|September 2005|2005-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Feasibility Study of 2000 IU Per Day of Vitamin D for the Primary Prevention of Type 1 Diabetes|Pilot Trial of Vitamin D for the Prevention of Type 1 Diabetes|Completed||Phase 1|9|Actual|Canadian Diabetes Association||2|||f||||f||||||||||2018-06-01 04:46:23.857487|2018-06-01 04:46:23.857487
NCT00141973|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2008-05-13|2005-09-01|2005-09-02|Estimate|||||||2008-05-13|2008-05-14|Estimate|November 2004||2004-11-30|May 2008|2008-05-31|December 2005||2005-12-31|||||Observational|||Time Course of Procalcitonin and C Reactive Protein in Septic Patients Under Treatment With Corticosteroids||Completed|||||Ospedale Regionale Bellinzona e Valli|||||f||||||||||||||2018-06-01 04:46:23.991142|2018-06-01 04:46:23.991142
NCT00141960|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2011-11-18|2005-09-01|2005-09-02|Estimate|||||||2011-11-18|2011-11-21|Estimate|September 2005||2005-09-30|June 2010|2010-06-30||||||||Interventional|||Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease|YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease|Completed||Phase 2/Phase 3|480||Astellas Pharma Inc|||||f||||||||||||||2018-06-01 04:46:24.258244|2018-06-01 04:46:24.258244
NCT00141947|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-07-23|2005-09-01|2005-09-02|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2005||2005-09-30|October 2005|2005-10-31|September 2006||2006-09-30|||||Interventional|||Bexarotene Treatment in Schizophrenia|Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial|Unknown status|Recruiting|Phase 3|15|Anticipated|Beersheva Mental Health Center|||||f||||t||||||||||2018-06-01 04:46:24.393543|2018-06-01 04:46:24.393543
NCT00141934|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-04-04|2005-08-31|2005-09-02|Estimate|||||||2007-04-04|2007-04-05|Estimate|August 2005||2005-08-31|April 2007|2007-04-30||||||||Interventional|||A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.|Phase II Randomised, Double-Blind, Multicentre, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of 3 Strengths of AD 452 in Adults With Active RA Who Are Currently Taking Methotrexate.|Completed||Phase 2|232||Sosei|||||||||||||||||||2018-06-01 04:46:24.518486|2018-06-01 04:46:24.518486
NCT00141921|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2016-11-29||2017-09-07|2005-08-31|2005-09-02|Estimate|2016-12-15|2017-02-10|Actual||||2017-09-07|2017-10-05|Actual|August 11, 2005|Actual|2005-08-11|September 2017|2017-09-30|August 16, 2017|Actual|2017-08-16|December 19, 2011|Actual|2011-12-19||Interventional|||Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis|An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis|Completed||Phase 3|182|Actual|Amgen||1|||f||||t||||||||||2018-06-01 04:46:24.655113|2018-06-01 04:46:24.655113
NCT00141908|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-07-18|2005-09-01|2005-09-02|Estimate|||||||2013-07-18|2013-07-19|Estimate|October 2006||2006-10-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate|Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate|Completed||Phase 2|290|Anticipated|American University of Beirut Medical Center||2|||f||||f||||||||||2018-06-01 04:46:25.386918|2018-06-01 04:46:25.386918
NCT00141895|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-01|||2013-07-18|2005-09-01|2005-09-02|Estimate|||||||2013-07-18|2013-07-19|Estimate|September 2004||2004-09-30|July 2013|2013-07-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death|A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Intrauterine Fetal Death|Terminated||Phase 3|73|Actual|American University of Beirut Medical Center||2||Difficulty recruiting|f||||f||||||||||2018-06-01 04:46:25.494576|2018-06-01 04:46:25.494576
NCT00141882|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2010-11-03|2005-08-31|2005-09-02|Estimate|||||||2010-11-03|2010-11-04|Estimate|March 1999||1999-03-31|November 2010|2010-11-30|August 2006|Actual|2006-08-31|January 2006|Actual|2006-01-31||Interventional|||Memantine in Patients With Chronic Glaucoma||Completed||Phase 3|1119|Actual|Allergan|||||f||||f||||||||||2018-06-01 04:46:25.632012|2018-06-01 04:46:25.632012
NCT00141869|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-06-30|2005-08-31|2005-09-01|Estimate|||||||2017-06-30|2017-07-02|Actual|August 30, 2005||2005-08-30|September 6, 2007|2007-09-06|September 6, 2007||2007-09-06|||||Observational|||Brain Activity Associated With Tics in Patients With Tourette Syndrome|MEG Study of Altered Sensory Processing in Tourette Syndrome: An Exploration of Sensory Tics|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:46:25.671968|2018-06-01 04:46:25.671968
NCT00141856|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-06-19|2005-08-30|2005-09-01|Estimate|||||||2008-06-19|2008-06-23|Estimate|June 2005||2005-06-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Health E Heart Study (South Texas Veterans Health Care System Heart Failure Disease Management Program/Study)|Health E Heart Study (South Texas Veterans Health Care System Heart Failure Disease Management Program/Study)|Completed||Phase 4|420|Actual|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:46:25.77091|2018-06-01 04:46:25.77091
NCT00141843|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-04-21|2005-08-30|2005-09-01|Estimate|||||||2008-04-21|2008-04-22|Estimate|July 2005||2005-07-31|April 2008|2008-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A|A Randomized Two-Way Blinded Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII,Refacto AF) With a Full Length Recombinant Factor VIII Preparation (FLrFVIII,Advate), Followed by an Open-Label Trial of the Safety and Efficacy of ReFacto AF in Previously Treated Patients With Hemophilia A.|Completed||Phase 3|100||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:46:25.833406|2018-06-01 04:46:25.833406
NCT00141830|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-09-15|2005-08-30|2005-09-01|Estimate|||||||2009-09-15|2009-09-17|Estimate|August 2005||2005-08-31|September 2009|2009-09-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis|A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy|Completed||Phase 2|159|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:46:26.02206|2018-06-01 04:46:26.02206
NCT00141817|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2011-11-23||2011-11-23|2005-08-30|2005-09-01|Estimate|2011-11-23|2011-12-28|Estimate||||2011-11-23|2011-12-28|Estimate|August 2005||2005-08-31|November 2011|2011-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study Evaluating Pantoprazole in Children With GERD|A Multicenter, Randomized, Open Label, Single, and Multiple Dose Study of the Safety and Pharmacokinetics of 2 Dose Levels of Pantoprazole Sodium in Children Aged 1 Through 11 Years With Endoscopically Proven GERD|Completed||Phase 3|41|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:46:26.273702|2018-06-01 04:46:26.273702
NCT00141804|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-11-30|2005-08-31|2005-09-01|Estimate|||||||2005-11-30|2005-12-01|Estimate|January 2002||2002-01-31|August 2005|2005-08-31|June 2005||2005-06-30|||||Interventional|||Efficacy and Safety of Sirolimus in Combination With Tacrolimus|A Randomized Multicenter Study to Compare Tacrolimus and MMF With Tacrolimus and Rapamycin in Patients After Renal Transplantation|Unknown status|Active, not recruiting|Phase 3|190||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:46:26.95451|2018-06-01 04:46:26.95451
NCT00141791|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-08-06|2005-08-30|2005-09-01|Estimate|||||||2009-08-06|2009-08-07|Estimate|May 2005||2005-05-31|August 2009|2009-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study Evaluating Etanercept in Moderate to Severe Asthma|A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25mg Twice Weekly in Subjects With Moderate to Severe Persistent Asthma|Completed||Phase 2|120||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:46:27.06462|2018-06-01 04:46:27.06462
NCT00141778|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2012-08-03||2013-02-19|2005-08-31|2005-09-01|Estimate|2013-02-19|2013-03-22|Estimate||||2013-02-19|2013-03-22|Estimate|April 2005||2005-04-30|February 2013|2013-02-28|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)|RAAS, Inflammation, and Post-operative AF|Completed||Phase 2/Phase 3|455|Actual|Vanderbilt University|We excluded patients with an ejection fraction less than 30% or a creatinine above 1.6 and therefore the results are not applicable to patients with left ventricular dysfunction or more severe chronic kidney disease.|3|||f||||t||||||||||2018-06-01 04:46:27.190693|2018-06-01 04:46:27.190693
NCT00141765|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2014-05-19||2014-05-19|2005-08-31|2005-09-01|Estimate|2014-05-19|2014-06-20|Estimate||||2014-05-19|2014-06-20|Estimate|January 1997||1997-01-31|May 2014|2014-05-31|February 2010|Actual|2010-02-28|December 2008|Actual|2008-12-31||Interventional|||Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers|Myeloablative Chemotherapy With Stem Cell Rescue for Rare Poor-Prognosis Cancers|Completed||Phase 2|25|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:46:28.120017|2018-06-01 04:46:28.120017
NCT00141752|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-10-31|2005-08-30|2005-09-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2002||2002-10-31|January 2012|2012-01-31||||December 2006|Actual|2006-12-31||Observational|||Toronto Bedside Swallowing Screening Test (TOR-BSST) - A Bedside Swallowing Screening for Stroke Patients|Toronto Bedside Swallowing Screening Test (TOR-BSST) - A Bedside Swallowing Screening for Stroke Patients|Completed|||311|Actual|University Health Network, Toronto|||||f||||||||||||||2018-06-01 04:46:28.346648|2018-06-01 04:46:28.346648
NCT00141739|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2014-01-21||2016-12-01|2005-08-31|2005-09-01|Estimate|2014-05-20|2014-06-04|Estimate||||2016-12-01|2017-01-30|Estimate|August 2004||2004-08-31|December 2016|2016-12-31|September 2012|Actual|2012-09-30|August 2011|Actual|2011-08-31||Interventional|||Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)|The Addition of Etanercept to Standard GVHD Prophylaxis in Patients Undergoing a Full Intensity Allogeneic Hematopoietic Stem Cell Transplant for the Prevention of Transplant Related Complications|Completed||Phase 2|100|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:46:28.440293|2018-06-01 04:46:28.440293
NCT00141726|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2014-03-12||2015-11-04|2005-08-30|2005-09-01|Estimate|2014-06-18|2014-06-19|Estimate||||2015-11-04|2015-12-03|Estimate|October 2003||2003-10-31|November 2015|2015-11-30|February 2009|Actual|2009-02-28|July 2008|Actual|2008-07-31||Interventional||All patients enrolled that received at least one scheduled dose.|Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant|Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study|Completed||Phase 2|34|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:46:28.832261|2018-06-01 04:46:28.832261
NCT00141713|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2013-03-12|2005-08-30|2005-09-01|Estimate|||||||2013-03-12|2013-03-13|Estimate|October 2003||2003-10-31|March 2013|2013-03-31|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease|The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease|Completed||Phase 2|40|Actual|University of Michigan Cancer Center||1|||f||||||||||||||2018-06-01 04:46:29.262353|2018-06-01 04:46:29.262353
NCT00141700|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-12-28|2005-08-31|2005-09-01|Estimate|||||||2007-12-28|2008-01-10|Estimate|March 2003||2003-03-31|December 2007|2007-12-31|December 2005|Actual|2005-12-31|March 2005|Actual|2005-03-31||Interventional|||Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma|Rituximab Plus High-Dose Chemotherapy With Autologous Stem Cell Support for Poor-Prognosis Non-Hodgkin's Lymphoma|Terminated||Phase 2|30||University of Michigan Cancer Center||||enrollment completed|f||||||||||||||2018-06-01 04:46:29.363989|2018-06-01 04:46:29.363989
NCT00141674|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-09-02|2005-08-30|2005-09-01|Estimate|||||||2008-09-02|2008-09-04|Estimate|March 2005||2005-03-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Age of Blood in Brain Injury|A Prospective Randomized Controlled Trial Comparing the Effects of Fresh vs. Old Blood on Cerebral Oxygen Extraction in Patients With Traumatic Brain Injuries|Completed||N/A|60|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:46:29.649501|2018-06-01 04:46:29.649501
NCT00141661|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-08-19|2005-08-30|2005-09-01|Estimate|||||||2009-08-19|2009-08-20|Estimate|October 2005||2005-10-31|August 2009|2009-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients|A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700|Completed||Phase 2|67|Actual|Pfizer||3|||f||||f||||||||||2018-06-01 04:46:29.724621|2018-06-01 04:46:29.724621
NCT00141648|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-09-29|2005-08-30|2005-09-01|Estimate|||||||2009-09-29|2009-10-01|Estimate|September 2000||2000-09-30|September 2009|2009-09-30|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Interventional|||Chemotherapy and Radiotherapy for Osteolymphoma|A Prospective Non-randomised Trial of Chemotherapy and Radiotherapy for Osteolymphoma|Completed||N/A|70|Actual|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||f||||||||||2018-06-01 04:46:29.835724|2018-06-01 04:46:29.835724
NCT00141635|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-08-31|2005-08-31|2005-09-01|Estimate|||||||2005-08-31|2005-09-01|Estimate|December 2002||2002-12-31|August 2005|2005-08-31|June 2004||2004-06-30|||||Observational|||Implementation of Quality of Life Diagnostics and Therapy|Enhancing the Status of Quality of Life Diagnostics in Caring for Breast Cancer Patients: Results From a Multilevel Implementation Study in a Regional Tumor Centre|Completed|||190||Tumorzentrum Regensburg e.V.|||||f||||||||||||||2018-06-01 04:46:29.988549|2018-06-01 04:46:29.988549
NCT00141622|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-05-14|2005-08-31|2005-09-01|Estimate|||||||2007-05-14|2007-05-15|Estimate|April 2005||2005-04-30|August 2005|2005-08-31|October 2006||2006-10-31|||||Interventional|||Sodium-Endothelial Function-CKD Study|Does Sodium Affect Endothelial Function in Individuals With Chronic Kidney Disease?|Completed||N/A|50|Anticipated|St George's, University of London|||||f||||||||||||||2018-06-01 04:46:30.049318|2018-06-01 04:46:30.049318
NCT00141609|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-05-10|2005-08-31|2005-09-01|Estimate|||||||2007-05-10|2007-05-14|Estimate|April 2004||2004-04-30|May 2007|2007-05-31|October 2006||2006-10-31|||||Interventional|||Haemodialysis Salt Reduction Study|A Study Looking at the Effects of a Modest Reduction in Dietary Salt Intake on Blood Pressure Control in Haemodialysis Patients|Completed||N/A|20|Anticipated|St George's, University of London|||||f||||||||||||||2018-06-01 04:46:30.113047|2018-06-01 04:46:30.113047
NCT00141596|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-06-05|2005-08-31|2005-09-01|Estimate|||||||2015-06-05|2015-06-09|Estimate|July 2003||2003-07-31|May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Interventional|||Extracellular Fluid in Resistant Hypertension|A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension|Terminated||N/A|32|Anticipated|St George's, University of London||||Insufficient accrual rate|f||||||||||||||2018-06-01 04:46:30.18437|2018-06-01 04:46:30.18437
NCT00141583|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-06-05|2005-08-31|2005-09-01|Estimate|||||||2015-06-05|2015-06-09|Estimate|April 2004||2004-04-30|May 2007|2007-05-31|October 2006|Actual|2006-10-31|||||Interventional|||The Renin-Angiotensin System in Essential Hypertension|The Renin-Angiotensin System in Essential Hypertension|Terminated||N/A|11|Anticipated|St George's, University of London||||Insufficient accrual rate|f||||||||||||||2018-06-01 04:46:30.242279|2018-06-01 04:46:30.242279
NCT00141570|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-01-15|2005-08-30|2005-09-01|Estimate|||||||2015-01-15|2015-01-16|Estimate|June 2004||2004-06-30|January 2009|2009-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women|A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women|Completed||Phase 2|350||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:46:30.299083|2018-06-01 04:46:30.299083
NCT00141557|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-04-10|2005-08-30|2005-09-01|Estimate|||||||2008-04-10|2008-04-11|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|April 2007|Actual|2007-04-30||Interventional|||The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women|A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women|Terminated||Phase 2|133|Actual|Solvay Pharmaceuticals||2||Lack of enrollment|f||||f||||||||||2018-06-01 04:46:31.429594|2018-06-01 04:46:31.429594
NCT00141544|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-04-10|2005-08-30|2005-09-01|Estimate|||||||2008-04-10|2008-04-11|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|April 2007|Actual|2007-04-30||Interventional|||The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women|A Multi-Center, Double-Blind Study to Determine the Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women|Terminated||Phase 2|28|Actual|Solvay Pharmaceuticals||2||Lack of enrollment|f||||f||||||||||2018-06-01 04:46:31.768438|2018-06-01 04:46:31.768438
NCT00141531|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2012-06-13|2005-08-30|2005-09-01|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Phase II Trial of EOquin in High-risk Superficial Bladder Cancer|Phase II Study of Intravesical Instillation of EOQUIN™ in High Risk Superficial Bladder Cancer|Completed||Phase 2|53|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-06-01 04:46:32.061078|2018-06-01 04:46:32.061078
NCT00141518|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2016-04-11||2016-06-06|2005-08-30|2005-09-01|Estimate|2016-06-06|2016-07-18|Estimate||||2016-06-06|2016-07-18|Estimate|March 2006||2006-03-31|June 2016|2016-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|DAPHNE||Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact|A Long-term Health Economics Study of Intraduodenal Levodopa (Duodopa®) in Routine Care for Patients With Advanced Idiopathic Parkinson's Disease With Severe Motor Fluctuations and Hyper-/Dyskinesia|Completed||Phase 4|77|Actual|AbbVie||3|||f||||||||||||||2018-06-01 04:46:32.436365|2018-06-01 04:46:32.436365
NCT00141505|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-01-15|2005-08-30|2005-09-01|Estimate|||||||2015-01-15|2015-01-16|Estimate|February 2005||2005-02-28|September 2007|2007-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||PK Effects of Bifeprunox & Valproate in Bipolar I|Placebo-controlled Study on the Pharmacokinetics,Pharmacodynamics, Safety and Tolerability of Concurrent Valproate and Bifeprunox Administration in Subjects With Bipolar I Disorder|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:46:37.77633|2018-06-01 04:46:37.77633
NCT00133055|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2018-04-11|2005-08-18|2005-08-22|Estimate|||||||2018-04-11|2018-04-13|Actual|July 2005||2005-07-31|August 2011|2011-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Parenting Matters: Helping Parents With Young Children|Parenting Matters: Helping Parents With Young Children|Completed||Phase 2|548|Actual|Western University, Canada||2|||f||||||||||||||2018-06-01 04:48:59.59766|2018-06-01 04:48:59.59766
NCT00141492|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-01-19|2005-08-30|2005-09-01|Estimate|||||||2015-01-19|2015-01-21|Estimate|October 2004||2004-10-31|January 2009|2009-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes|A Double Blind, Randomized, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Androgel, as an Adjunct to Hypoglycemic Therapy, in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:46:37.869156|2018-06-01 04:46:37.869156
NCT00141479|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-01-15|2005-08-30|2005-09-01|Estimate|||||||2015-01-15|2015-01-16|Estimate|May 2005||2005-05-31|May 2006|2006-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox|A Single-center Safety and Tolerability Study to Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:46:38.056649|2018-06-01 04:46:38.056649
NCT00141466|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-04-22|2005-08-31|2005-09-01|Estimate|||||||2008-04-22|2008-04-23|Estimate|September 2005||2005-09-30|February 2007|2007-02-28|July 2007|Anticipated|2007-07-31|||||Interventional|||Implementation of a New Strategy to Identify HNPCC Patients|Cost Effectiveness of Two Different Implementation Procedures to Change Clinicians Practice Roles in the Detection of Hereditary Colorectal Cancer|Unknown status|Recruiting|N/A|360|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:46:38.136996|2018-06-01 04:46:38.136996
NCT00141453|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2009-08-31||2011-05-09|2005-08-31|2005-09-01|Estimate|2011-05-09|2011-05-10|Estimate||||2011-05-09|2011-05-10|Estimate|April 2003||2003-04-30|May 2011|2011-05-31|January 2009|Actual|2009-01-31|August 2008|Actual|2008-08-31||Interventional|||ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial|CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus|Completed||Phase 3|577|Actual|Daiichi Sankyo, Inc.||2|||f||||||||||||||2018-06-01 04:46:38.43214|2018-06-01 04:46:38.43214
NCT00141440|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-12-29|2005-08-31|2005-09-01|Estimate|||||||2009-12-29|2009-12-30|Estimate|July 2005||2005-07-31|September 2008|2008-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The Effect of Cycling Off Criteria During Pressure Support Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients|The Effect of Cycling Off Criteria During Pressure Support Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||N/A|13|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:46:39.486898|2018-06-01 04:46:39.486898
NCT00141427|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-03-21|2005-08-31|2005-09-01|Estimate|||||||2008-03-21|2008-03-25|Estimate|November 2004||2004-11-30|June 2006|2006-06-30|May 2006|Actual|2006-05-31|||||Interventional|||Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.|Pregabalin In Partial Seizures (Preps) : An Open-Label, International, Multicenter Add-On Therapy Trial|Completed||Phase 4|540||Pfizer|||||f||||||||||||||2018-06-01 04:46:39.566996|2018-06-01 04:46:39.566996
NCT00141414|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-12-28|2005-08-30|2005-09-01|Estimate|||||||2006-12-28|2007-01-01|Estimate|November 1997||1997-11-30|December 2006|2006-12-31|October 2005||2005-10-31|||||Interventional|||To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.|Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.|Completed||Phase 2|82||Pfizer|||||||||||||||||||2018-06-01 04:46:39.685356|2018-06-01 04:46:39.685356
NCT00141401|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-08-15|2005-08-31|2005-09-01|Estimate|||||||2007-08-15|2007-08-17|Estimate|September 1999||1999-09-30|August 2007|2007-08-31|July 2005|Actual|2005-07-31|||||Interventional|||Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.|An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.|Completed||Phase 3|240||Pfizer|||||f||||||||||||||2018-06-01 04:46:39.860856|2018-06-01 04:46:39.860856
NCT00141388|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-11-05|2005-08-30|2005-09-01|Estimate|||||||2009-11-05|2009-11-06|Estimate|July 1998||1998-07-31|November 2009|2009-11-30|October 2005|Actual|2005-10-31|||||Interventional|||To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures|Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.|Completed||Phase 3|455|Actual|Pfizer|||||||||||||||||||2018-06-01 04:46:39.92537|2018-06-01 04:46:39.92537
NCT00141375|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-01-09|2005-08-31|2005-09-01|Estimate|||||||2008-01-09|2008-01-15|Estimate|August 2002||2002-08-31|January 2008|2008-01-31|January 2006|Actual|2006-01-31|||||Interventional|||To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.|An Open-Label Extension to Evaluate the Safety and Efficacy of Pregabalin for Treatment of Chronic Central Neuropathic Pain After Spinal Cord Injury.|Completed||Phase 3|132||Pfizer|||||f||||||||||||||2018-06-01 04:46:40.038716|2018-06-01 04:46:40.038716
NCT00141362|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-12-29|2005-08-31|2005-09-01|Estimate|||||||2006-12-29|2007-01-01|Estimate|October 2001||2001-10-31|December 2006|2006-12-31|August 2005||2005-08-31|||||Interventional|||Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.|An Open-Label, Extension Safety and Efficacy Study of Pregabalin in Patients With Chronic Neuropathic Pain.|Completed||Phase 3|325||Pfizer|||||f||||||||||||||2018-06-01 04:46:40.0926|2018-06-01 04:46:40.0926
NCT00141349|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-07-23|2005-08-30|2005-09-01|Estimate|||||||2006-07-23|2006-07-25|Estimate|February 2005||2005-02-28|January 2006|2006-01-31|August 2005||2005-08-31|||||Interventional|||Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction|A Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Assess the Time to Onset, Safety, and Toleration of Differing Doses and Combinations of Immediate Release and Modified Release Formulations of UK369,003 in Adult Male Subject With Erectile Dysfunction|Completed||Phase 2|300||Pfizer|||||||||||||||||||2018-06-01 04:46:40.137473|2018-06-01 04:46:40.137473
NCT00141336|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-12-28|2005-08-30|2005-09-01|Estimate|||||||2006-12-28|2007-01-01|Estimate|November 1999||1999-11-30|December 2006|2006-12-31|July 2005||2005-07-31|||||Interventional|||To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.|Pregabalin BID Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.|Completed||Phase 3|750||Pfizer|||||||||||||||||||2018-06-01 04:46:40.304791|2018-06-01 04:46:40.304791
NCT00141323|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30||2009-03-26|2011-08-08|2005-08-30|2005-09-01|Estimate||||2009-09-24|2009-09-28|Estimate|2011-08-08|2011-08-15|Estimate|November 2001||2001-11-30|August 2011|2011-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|PEARL||Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)|PEARL: Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene|Completed||Phase 3|8556|Anticipated|Ligand Pharmaceuticals||3|||f||||t||||||||||2018-06-01 04:46:40.477464|2018-06-01 04:46:40.477464
NCT00140439|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2015-08-21|2005-08-31|2005-09-01|Estimate|||||||2015-08-21|2015-08-25|Estimate|April 2002||2002-04-30|August 2015|2015-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Improving Asthma Outcomes in an Urban Pediatric Population|Improving Asthma Outcomes in a High Morbidity Urban Pediatric Population: an Emergency Department-based Randomized Clinical Trial|Completed||N/A|488|Actual|Children's Research Institute|||||f||||f||||||||||2018-06-01 04:46:59.279264|2018-06-01 04:46:59.279264
NCT00141310|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-07-23|2005-08-30|2005-09-01|Estimate|||||||2007-07-23|2007-07-25|Estimate|September 2004||2004-09-30|July 2007|2007-07-31|April 2006|Actual|2006-04-30|||||Interventional|||Sildenafil Citrate for the Treatment of Established Pre-Eclampsia|A Randomised, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety and Toleration of Oral Sildenafil Citrate Administered in the Dose Range of 20 - 80 Mg TID for the Treatment of Pre-Eclampsia. (PET)|Terminated||Phase 2|76||Pfizer||||"Study prematurely discont’d 20-Apr-2006 after interim analysis suggested sample size could be~   reduced without losing power. No safety concerns led to decision."|f||||||||||||||2018-06-01 04:46:40.995188|2018-06-01 04:46:40.995188
NCT00141297|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2015-03-04||2015-12-03|2005-08-30|2005-09-01|Estimate|2015-09-29|2015-10-28|Estimate||||2015-12-03|2016-01-05|Estimate|September 2004||2004-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|July 2008|Actual|2008-07-31||Interventional||Full Analysis Set (FAS) included all enrolled participants who received at least one dose of study medication.|A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer|A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer|Completed||Phase 1|74|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:46:41.274564|2018-06-01 04:46:41.274564
NCT00141284|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30||2011-01-03|2011-05-09|2005-08-30|2005-09-01|Estimate||||2011-01-03|2011-01-05|Estimate|2011-05-09|2011-05-16|Estimate|October 2005||2005-10-31|May 2011|2011-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C|A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction.|Completed||Phase 4|12|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:46:44.850394|2018-06-01 04:46:44.850394
NCT00141271|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2009-02-24||2009-04-03|2005-08-30|2005-09-01|Estimate|2009-02-24|2009-03-24|Estimate||||2009-04-03|2009-05-04|Estimate|July 2005||2005-07-31|April 2009|2009-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression|A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients With Bipolar I Depression|Completed||Phase 3|536|Actual|Pfizer||3|||f||||t||||||||||2018-06-01 04:46:45.035733|2018-06-01 04:46:45.035733
NCT00141258|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-04-28|2005-08-30|2005-09-01|Estimate|||||||2009-04-28|2009-04-29|Estimate|October 2005||2005-10-31|April 2009|2009-04-30|August 2006|Actual|2006-08-31|||||Interventional|||Pregabalin Epilepsy Add-On Trial|Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures|Completed||Phase 3|178|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:46:47.699713|2018-06-01 04:46:47.699713
NCT00141245|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-12-28|2005-08-30|2005-09-01|Estimate|||||||2006-12-28|2007-01-01|Estimate|October 1998||1998-10-31|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.|Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.|Completed||Phase 3|325||Pfizer|||||f||||||||||||||2018-06-01 04:46:47.792079|2018-06-01 04:46:47.792079
NCT00141232|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-11-21|2005-08-30|2005-09-01|Estimate|||||||2008-11-21|2008-11-24|Estimate|November 2004||2004-11-30|November 2008|2008-11-30|July 2006|Actual|2006-07-31|||||Interventional|AFORRD||Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes|A Multicentre, Randomised, Double Blind Placebo Controlled Trial Evaluating Atorvastatin in Factorial With Omega-3 Fatty Acids Cardiovascular Risk Reduction in Patients With Type 2 Diabetes|Completed||Phase 4|810|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:46:47.926829|2018-06-01 04:46:47.926829
NCT00141219|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2008-12-19||2009-09-23|2005-08-30|2005-09-01|Estimate|2009-02-10|2009-03-13|Estimate||||2009-09-23|2009-09-30|Estimate|December 2005||2005-12-31|September 2009|2009-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pregabalin Peripheral Neuropathic Pain Study|A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Peripheral Neuropathic Pain|Completed||Phase 3|241|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:46:48.255771|2018-06-01 04:46:48.255771
NCT00141206|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-06-01|2005-08-30|2005-09-01|Estimate|||||||2007-06-01|2007-06-04|Estimate|May 2003||2003-05-31|June 2007|2007-06-30|April 2005|Actual|2005-04-30|||||Interventional|||A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation|Completed||Phase 3|1005||Pfizer|||||||||||||||||||2018-06-01 04:46:49.216246|2018-06-01 04:46:49.216246
NCT00141193|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-08-05|2005-08-30|2005-09-01|Estimate|||||||2008-08-05|2008-08-06|Estimate|February 2001||2001-02-28|August 2008|2008-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|PRESAP||Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)|Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)|Completed||Phase 3|1561|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 04:46:49.336443|2018-06-01 04:46:49.336443
NCT00141180|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-07-23|2005-08-30|2005-09-01|Estimate|||||||2006-07-23|2006-07-25|Estimate|September 2003||2003-09-30|November 2005|2005-11-30|October 2005||2005-10-31|||||Interventional|||CP-481,715 Nickel Allergy Study.|Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.|Completed||Phase 1|48||Pfizer|||||||||||||||||||2018-06-01 04:46:49.567531|2018-06-01 04:46:49.567531
NCT00141167|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2010-09-03|2005-08-30|2005-09-01|Estimate|||||||2010-09-03|2010-09-06|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|January 2006|Actual|2006-01-31|||||Interventional|||A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation|A Twelve-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 MG BID for Smoking Cessation|Completed||Phase 3|250|Actual|Pfizer|||||||||||||||||||2018-06-01 04:46:49.640465|2018-06-01 04:46:49.640465
NCT00141154|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2011-05-27|2005-08-30|2005-09-01|Estimate|||||||2011-05-27|2011-05-30|Estimate|October 2004||2004-10-31|May 2011|2011-05-31||||||||Interventional|||Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan|A Randomized, Multicenter, Active And Placebo Controlled Parallel Group Study To Evaluate The Efficacy And Safety Of Celecoxib (Ym177) 200 Bid Compared To Loxoprofen 60 Mg Tid In Patients With Low Back Pain|Completed||Phase 3|1234|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:46:49.709058|2018-06-01 04:46:49.709058
NCT00141141|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-10-28|2005-08-30|2005-09-01|Estimate|||||||2008-10-28|2008-10-31|Estimate|January 2004||2004-01-31|October 2008|2008-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia|A Phase IV, Multicenter, Randomized, Open Label Study To Evaluate The Efficacy And Safety Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia|Completed||Phase 4|383|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:46:49.843037|2018-06-01 04:46:49.843037
NCT00141128|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2011-05-31|2005-08-31|2005-09-01|Estimate|||||||2011-05-31|2011-06-01|Estimate|December 2005||2005-12-31|May 2011|2011-05-31|June 2006|Actual|2006-06-30|||||Interventional|||Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.|Measurement Of Urethral Function In Women With Stress Urinary Incontinence - Evaluation Of The Sensitivity Of Urethral Reflectometry Compared To Urethral Pressure Profilometry, Using [S,S]-Reboxetine To Detect Pharmacological Augmentation Of Urethral Pressure.|Completed||Phase 2|18|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:46:50.090255|2018-06-01 04:46:50.090255
NCT00141115|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2012-11-26||2017-08-17|2005-08-31|2005-09-01|Estimate|2017-08-17|2017-09-15|Actual||||2017-08-17|2017-09-15|Actual|March 2004||2004-03-31|August 2017|2017-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Levetiracetam for the Treatment of Alcohol Dependence and Anxiety|Pilot Trial of Levetiracetam in the Treatment of Alcohol Dependence With Comorbid Anxiety|Completed||Phase 2|3|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 04:46:50.168149|2018-06-01 04:46:50.168149
NCT00141102|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2010-05-11||2011-04-18|2005-08-31|2005-09-01|Estimate|2010-05-11|2010-06-11|Estimate||||2011-04-18|2011-04-21|Estimate|October 2005||2005-10-31|April 2011|2011-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|CONDOR||Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis|Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events|Completed||Phase 4|4484|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:46:50.434049|2018-06-01 04:46:50.434049
NCT00141089|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-01-31|2005-08-31|2005-09-01|Estimate|||||||2008-01-31|2008-02-01|Estimate|March 2004||2004-03-31|January 2008|2008-01-31|February 2005|Actual|2005-02-28|||||Interventional|||Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.|Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.|Completed||Phase 3|1026||Novartis|||||f||||||||||||||2018-06-01 04:46:51.802692|2018-06-01 04:46:51.802692
NCT00141076|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2010-08-27|2005-08-31|2005-09-01|Estimate|||||||2010-08-27|2010-08-30|Estimate|October 2003||2003-10-31|August 2010|2010-08-31|July 2006|Actual|2006-07-31|||||Interventional|||Glycemic Index and CVD: a Crossover Feeding Study|Glycemic Index, Obesity, Insulin Resistance and CVD Risk, Part 2|Completed||N/A|24||Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:46:51.845841|2018-06-01 04:46:51.845841
NCT00141063|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-12-17|2005-08-30|2005-09-01|Estimate|||||||2007-12-17|2007-12-21|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|August 2005|Actual|2005-08-31|||||Interventional|||Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD|Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD|Completed||Phase 3|90||Novartis|||||||||||||||||||2018-06-01 04:46:52.027852|2018-06-01 04:46:52.027852
NCT00141050|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-12-17|2005-08-30|2005-09-01|Estimate|||||||2007-12-17|2007-12-21|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|July 2005|Actual|2005-07-31|||||Interventional|||Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD|Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD|Completed||Phase 3|90||Novartis|||||||||||||||||||2018-06-01 04:46:52.079195|2018-06-01 04:46:52.079195
NCT00141037|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|2013-05-21||2016-10-19|2005-08-30|2005-09-01|Estimate|2013-05-21|2013-07-11|Estimate||||2016-10-19|2016-11-29|Estimate|March 2004||2004-03-31|October 2016|2016-10-31|November 2010|Actual|2010-11-30|September 2006|Actual|2006-09-30||Interventional|||Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation|Randomized, Multi-Center Comparative Trial of Tacrolimus w/Steroids and Standard Daclizumab Induction vs a Novel Steroid-Free Tacrolimus Based Immunosuppression Protocol w/ Extended Daclizumab Induction in Pediatric Renal Transplantation|Completed||Phase 1/Phase 2|130|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|"The results cannot be generalized and daclizumab has since been withdrawn from the United States market (business-related, not due to any safety issues).~The study was not powered to definitively evaluate small differences in rejection rate."|2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 04:46:52.165608|2018-06-01 04:46:52.165608
NCT00141024|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-06-28|2005-08-30|2005-09-01|Estimate|||||||2016-06-28|2016-06-29|Estimate|January 2006||2006-01-31|June 2016|2016-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Protein Vaccine EP-1043 and the DNA Vaccine EP HIV-1090 Given Alone or in Combination in Healthy, HIV-1-Uninfected Adult Participants|Completed||Phase 1|84|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 04:46:52.766499|2018-06-01 04:46:52.766499
NCT00141011|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-12-21|2005-08-31|2005-09-01|Estimate|||||||2009-12-21|2009-12-23|Estimate|September 2005||2005-09-30|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke|ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment Within 6 Hours of the Onset of Acute, Ischemic Stroke|Terminated||Phase 3|277|Actual|Neurobiological Technologies||2||Futility|f||||t||||||||||2018-06-01 04:46:52.856512|2018-06-01 04:46:52.856512
NCT00140998|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2017-11-28|2005-08-31|2005-09-01|Estimate|||||||2017-11-28|2017-11-30|Actual|January 2001||2001-01-31|August 2017|2017-08-31|June 2004||2004-06-30|||||Interventional|||Estrogen Treatment (Oral vs. Patches) in Turner Syndrome|Estrogen Replacement in Hypogonadal Girls Treated With GH: Differential Effects of Mode of Estrogen Delivery|Completed||Phase 3|16||Nemours Children's Clinic|||||f||||||||||||||2018-06-01 04:46:54.077819|2018-06-01 04:46:54.077819
NCT00140985|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-01-09|2005-08-30|2005-09-01|Estimate|||||||2015-01-09|2015-01-12|Estimate|February 2000||2000-02-29|January 2015|2015-01-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)|A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors (TGFß and VEGF)|Completed||Phase 4|97|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:46:54.155423|2018-06-01 04:46:54.155423
NCT00140972|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2017-04-06|2005-08-30|2005-09-01|Estimate|||||||2017-04-06|2017-04-10|Actual|December 3, 2004|Actual|2004-12-03|April 2017|2017-04-30|June 27, 2005|Actual|2005-06-27|June 27, 2005|Actual|2005-06-27||Interventional|||A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)|A Multicenter, Randomized, Parallel-group, 4-Week, Double-Blind and Active Comparator-Controlled Study to Assess Efficacy, Safety, and Tolerability of Etoricoxib 60 mg Once Daily Versus Diclofenac Sodium 75 mg Twice Daily in the Treatment of Chinese Patients With Osteoarthritis of the Knee or Hip|Completed||Phase 4|160|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:46:54.222596|2018-06-01 04:46:54.222596
NCT00140959|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-04-12|2005-08-31|2005-09-01|Estimate|||||||2017-04-12|2017-04-13|Actual|February 1, 2003|Actual|2003-02-01|April 2017|2017-04-30|June 30, 2004|Actual|2004-06-30|June 30, 2004|Actual|2004-06-30||Interventional|||Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)|Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.|Completed||Phase 4|120||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:46:54.393304|2018-06-01 04:46:54.393304
NCT00140946|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-01-21|2005-08-30|2005-09-01|Estimate|||||||2016-01-21|2016-01-22|Estimate|March 1998||1998-03-31|January 2016|2016-01-31|October 2000|Actual|2000-10-31|October 2000|Actual|2000-10-31||Interventional|||A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Two-Period, Parallel-group Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients.|Completed||Phase 4|546|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:46:54.480026|2018-06-01 04:46:54.480026
NCT00140933|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-12-01|2005-08-30|2005-09-01|Estimate|||||||2006-12-01|2006-12-05|Estimate|April 2003||2003-04-30|December 2006|2006-12-31||||||||Interventional|||A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome|A Randomized, Double-Blind, 7-Day Study of the Efficacy and Safety of Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome|Terminated||Phase 3|274||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:46:54.55598|2018-06-01 04:46:54.55598
NCT00140920|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2017-05-05|2005-08-30|2005-09-01|Estimate|||||||2017-05-05|2017-05-09|Actual|May 25, 2004|Actual|2004-05-25|May 2017|2017-05-31|September 27, 2004|Actual|2004-09-27|September 27, 2004|Actual|2004-09-27||Interventional|||A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259)|A Study to Compare Pre-Operative Administration of Rofecoxib Vs Post-Operative Administration of Diclofenac or Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement in Patients With Osteoarthritis of the Knee.|Terminated||Phase 4|11|Actual|Merck Sharp & Dohme Corp.||||Recruitment/study discontinued after withdrawal of marketing authorisation. No data entered.|f||||||||||||||2018-06-01 04:46:55.34962|2018-06-01 04:46:55.34962
NCT00140907|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2017-09-15|2005-08-30|2005-09-01|Estimate|||||||2017-09-15|2017-09-18|Actual|March 14, 2000|Actual|2000-03-14|September 2017|2017-09-30|January 1, 2005|Actual|2005-01-01|January 1, 2005|Actual|2005-01-01||Interventional|||ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)|A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplant|Completed||Phase 4|367|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:46:55.403299|2018-06-01 04:46:55.403299
NCT00140894|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2017-09-27|2005-08-30|2005-09-01|Estimate|||||||2017-09-27|2017-09-29|Actual|March 1, 2003|Actual|2003-03-01|September 2017|2017-09-30||||||||Interventional|||A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Rofecoxib in Familial Adenomatous Polyposis (FAP)|Terminated||Phase 4|62||Merck Sharp & Dohme Corp.|||||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:46:55.464232|2018-06-01 04:46:55.464232
NCT00140881|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2017-03-24|2005-08-30|2005-09-01|Estimate|||||||2017-03-24|2017-03-28|Actual|June 1, 2000|Actual|2000-06-01|March 2017|2017-03-31|February 14, 2003|Actual|2003-02-14|February 14, 2003|Actual|2003-02-14||Interventional|||A Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children (0476-165)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Effect of Montelukast Sodium as an Episode Modifier in the Treatment of Infrequent Episodic Asthma in Children|Completed||Phase 4|220|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:46:55.535114|2018-06-01 04:46:55.535114
NCT00140868|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-12-06|2005-08-31|2005-09-01|Estimate|||||||2007-12-06|2007-12-10|Estimate|December 2002||2002-12-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Outcome of Palliative Management of Malignant Large Bowel Obstruction w/Colorectal Stents or Surgery|Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery|Completed||Phase 3|180||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:46:55.596949|2018-06-01 04:46:55.596949
NCT00140855|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2018-03-07|2005-08-30|2005-09-01|Estimate|||||||2018-03-07|2018-03-09|Actual|July 2005||2005-07-31|March 2018|2018-03-31|April 2007|Actual|2007-04-30|||||Interventional|||A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma|A Phase II Study of Anti-CTLA4 Antibody in Advanced Synovial Sarcoma Patients|Terminated||Phase 2|17||Ludwig Institute for Cancer Research||||Study discontinued due to poor accrual.|f||||t||||||||||2018-06-01 04:46:55.654379|2018-06-01 04:46:55.654379
NCT00140842|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2011-03-03||2011-10-03|2005-08-30|2005-09-01|Estimate|2011-08-02|2011-09-02|Estimate||||2011-10-03|2011-10-07|Estimate|May 2005||2005-05-31|September 2011|2011-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents|Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents|Completed|||47|Actual|Massachusetts General Hospital|Limited number of participants-pilot study||2||f||||f||||||Samples Without DNA|"~     Serum and urine collected~   "|||2018-06-01 04:46:55.727724|2018-06-01 04:46:55.727724
NCT00140829|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2012-03-26|2005-08-30|2005-09-01|Estimate|||||||2012-03-26|2012-03-27|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|December 2012|Anticipated|2012-12-31|||||Observational|Spatax||SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias|Clinical and Genetic Analysis of Autosomal Recessive Forms of Cerebellar Ataxias and Spastic Paraplegias|Unknown status|Recruiting||6000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-06-01 04:46:56.114476|2018-06-01 04:46:56.114476
NCT00140816|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2011-07-03|2005-08-31|2005-09-01|Estimate|||||||2011-07-03|2011-07-06|Estimate|September 2005||2005-09-30|February 2009|2009-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Dairy Products and Metabolic Effects (Norwegian Part)|Dairy Products and Metabolic Effects - A Multicentre Nordic Study|Completed||N/A|40|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:46:56.327103|2018-06-01 04:46:56.327103
NCT00140803|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-07-11|2005-08-30|2005-09-01|Estimate|||||||2007-07-11|2007-07-12|Estimate|October 2003||2003-10-31|July 2007|2007-07-31|January 2007|Actual|2007-01-31|||||Interventional|||Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration|A Randomized, Single-Masked, Multi-Center, Phase 2 Evaluation Of The Effect Of PDT Using Visudyne In Combination With Intravitreal Injection Of Either 0 mg, 1mg or 4mg of Kenalog In Subfoveal Occult & Minimally Classic CNV Secondary To ARMD|Completed||Phase 2|106|Actual|Manhattan Eye, Ear & Throat Hospital|||||t||||t||||||||||2018-06-01 04:46:56.399741|2018-06-01 04:46:56.399741
NCT00140790|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2016-02-25|2005-08-31|2005-09-01|Estimate|||||||2016-02-25|2016-02-26|Estimate|August 2006||2006-08-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study|Effects of Valsartan on Cardiovascular Events in Patients With Renal Dysfunction|Terminated||Phase 4|1000|Actual|Kumamoto University||2||"The number of actual events was extremely low. We extended the study period, but it was still~   not enough. Also, many patients were loss of follow up."|f||||t||||||||||2018-06-01 04:46:56.473103|2018-06-01 04:46:56.473103
NCT00140764|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2011-08-09|2005-08-30|2005-09-01|Estimate|||||||2011-08-09|2011-08-10|Estimate|January 2003||2003-01-31|August 2011|2011-08-31|March 2005||2005-03-31|||||Interventional|||Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi||Completed||Phase 3|||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:46:56.545006|2018-06-01 04:46:56.545006
NCT00140751|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2013-09-18|2005-08-30|2005-09-01|Estimate|||||||2013-09-18|2013-09-19|Estimate|October 2005||2005-10-31|September 2013|2013-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|KALESOLO||Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients|A 48-Weeks National Multicenter Randomized Open Clinical Trial Evaluating Tolerance and Efficacy of a Treatment Simplification by Lopinavir/Ritonavir Versus Continuation of Current Treatment in HIV-Infected Patients With a Viral Load Inferior to 50 Copies/mL Since 6 Months At Least|Completed||Phase 3|186|Actual|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba||2|||f||||||||||||||2018-06-01 04:46:56.6016|2018-06-01 04:46:56.6016
NCT00140738|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-10-23|2005-08-31|2005-09-01|Estimate|||||||2017-10-23|2017-10-24|Actual|March 10, 2005|Actual|2005-03-10|October 2017|2017-10-31|September 29, 2009|Actual|2009-09-29|September 29, 2008|Actual|2008-09-29||Interventional|||Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer|A Multicenter, Open-label Phase I/II Trial of the Safety and Efficacy of the dHER2 Recombinant Protein Combined With Immunological Adjuvant AS15 in Patients With Metastatic Breast Cancer Overexpressing HER2/Neu|Completed||Phase 1|3|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:46:56.706516|2018-06-01 04:46:56.706516
NCT00140725|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-10-15|2005-08-31|2005-09-01|Estimate|||||||2008-10-15|2008-10-16|Estimate|April 2000||2000-04-30|October 2008|2008-10-31||||||||Interventional|||Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)|A Randomised Trial of Lamivudine Plus Interferon Versus Lamivudine for the Treatment of HBeAg Positive Chronic Hepatitis B Virus (HBV)|Completed||Phase 3|160||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:46:56.817701|2018-06-01 04:46:56.817701
NCT00140712|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-09-08|2005-08-31|2005-09-01|Estimate|||||||2017-09-08|2017-09-11|Actual|June 10, 2005|Actual|2005-06-10|September 2017|2017-09-30|February 28, 2008|Actual|2008-02-28|February 28, 2008|Actual|2008-02-28||Interventional|||Ropinirole Tablets In Young Patients With Restless Legs Syndrome|A Study to Determine the Tolerability and Pharmacokinetics for Ropinirole in Paediatric / Adolescent Patients With RLS (Type 2)|Completed||Phase 1|9|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:46:56.965838|2018-06-01 04:46:56.965838
NCT00140699|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-04-26|2005-08-31|2005-09-01|Estimate|||||||2007-04-26|2007-04-27|Estimate||||April 2007|2007-04-30||||||||Observational|||Balance Control and Maturation in Normal and Deaf Children Aged From 6 to 14 Years Old|Balance Control and Maturation in Normal and Deaf Children Aged From 6 to 14 Years Old|Unknown status|Active, not recruiting||240||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:46:57.076189|2018-06-01 04:46:57.076189
NCT00140686|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-03-21|2005-08-31|2005-09-01|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2004||2004-09-30|March 2017|2017-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines|A Multi-country & Multi-center Study to Assess the Efficacy, Safety & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines|Completed||Phase 3|3994|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:46:57.160171|2018-06-01 04:46:57.160171
NCT00140673|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2016-09-20|2005-08-31|2005-09-01|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2003||2003-08-31|September 2016|2016-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.|A Placebo-controlled, Multi-country & Multi-center Study to Assess the Efficacy, Safety & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants|Completed||Phase 3|63227|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:46:57.409579|2018-06-01 04:46:57.409579
NCT00140660|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-03-09|2005-08-31|2005-09-01|Estimate|||||||2017-03-09|2017-03-13|Actual|December 2003|Actual|2003-12-31|March 2017|2017-03-31|April 2012|Actual|2012-04-30|July 2008|Actual|2008-07-31||Interventional|||ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma|Randomized Study of ACVBP Versus ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 65 Years With Low-risk Localized Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 0)|Terminated||Phase 3|223|Actual|Lymphoma Study Association||2||Low acrual|f||||t|f|f||||||No||2018-06-01 04:46:57.526807|2018-06-01 04:46:57.526807
NCT00140647|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-08-21|2005-08-30|2005-09-01|Estimate|||||||2008-08-21|2008-08-25|Estimate|July 2001||2001-07-31|August 2008|2008-08-31|July 2006|Actual|2006-07-31|||||Interventional|||The Study of Atherosclerosis With Ramipril and Rosiglitazone|The Study of Atherosclerosis With Ramipril and Rosiglitazone|Completed||Phase 3|1200||Gerstein, Hertzel, MD|||||||||||||||||||2018-06-01 04:46:57.613983|2018-06-01 04:46:57.613983
NCT00140621|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2015-04-01||2015-04-16|2005-08-30|2005-09-01|Estimate|2015-04-01|2015-04-15|Estimate||||2015-04-16|2015-05-12|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Efficacy evaluable population (EEP) included all registered participants except those who had serious deviations from protocol compliance requirements, did not receive study drug, had no data available at baseline or after study drug administration, and who were found to have no condition in cardiac Fabry disease.|A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease|A Multicenter Open-label Study of the Safety and Efficacy of α-galactosidase A (R-h α-GAL) Replacement Therapy in Patients With Cardiac Fabry Disease|Completed||Phase 4|6|Actual|Sanofi||1|||f||||f||||||||||2018-06-01 04:46:57.751152|2018-06-01 04:46:57.751152
NCT00140608|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2015-03-17|2005-08-31|2005-09-01|Estimate|||||||2015-03-17|2015-03-18|Estimate|June 2003||2003-06-30|March 2015|2015-03-31|May 2005||2005-05-31|||||Interventional|||Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery||Terminated||N/A|||Sanofi|||||f||||||||||||||2018-06-01 04:46:57.989601|2018-06-01 04:46:57.989601
NCT00140595|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2011-03-03|2005-08-31|2005-09-01|Estimate|||||||2011-03-03|2011-03-04|Estimate|December 2003||2003-12-31|March 2011|2011-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1|Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1.|Completed||Phase 3|380|Anticipated|Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:46:58.05202|2018-06-01 04:46:58.05202
NCT00140582|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2017-03-09|2005-08-31|2005-09-01|Estimate|||||||2017-03-09|2017-03-13|Actual|December 2004|Actual|2004-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|May 2007|Actual|2007-05-31||Interventional|||Primary Rituximab and Maintenance|Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy|Completed||Phase 3|1217|Actual|Lymphoma Study Association||2|||f||||t||||||||No||2018-06-01 04:46:58.11685|2018-06-01 04:46:58.11685
NCT00140569|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-08-31|2005-08-31|2005-09-01|Estimate|||||||2005-08-31|2005-09-01|Estimate|January 1994||1994-01-31|August 2005|2005-08-31|January 2004||2004-01-31|||||Interventional|||Randomized Study for Patients With Follicular Lymphoma Needing Treatment|Randomized Study for Patients With Follicular Lymphoma Needing Treatment|Completed||Phase 3|400||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:46:58.312573|2018-06-01 04:46:58.312573
NCT00140556|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2010-08-19||2013-01-14|2005-08-29|2005-09-01|Estimate|2011-08-01|2011-08-31|Estimate||||2013-01-14|2013-01-18|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|April 2010|Actual|2010-04-30|May 2009|Actual|2009-05-31||Interventional|||Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer|Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer|Completed||Early Phase 1|28|Actual|Duke University||1|||f||||f||||||||||2018-06-01 04:46:58.418637|2018-06-01 04:46:58.418637
NCT00140543|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-11-17|2005-08-31|2005-09-01|Estimate|||||||2005-11-17|2005-11-18|Estimate|February 2002||2002-02-28|August 2005|2005-08-31|April 2008||2008-04-30|||||Interventional|||European Trial of Immunosuppression in SPK Tx|A European Multicenter Open-Label Randomised Trial to Evaluate the Efficacy and Safety of Sirolimus and Tacrolimus Compared to MMF and Tacrolimus With Short-Course Induction Therapy, Short-Term Steroids Application in De Novo SPK Transplanted Diabetic Patients|Unknown status|Active, not recruiting|Phase 3|228||EUROSPK Study Group|||||f||||||||||||||2018-06-01 04:46:58.653065|2018-06-01 04:46:58.653065
NCT00140530|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2008-01-10|2005-08-31|2005-09-01|Estimate|||||||2008-01-10|2008-01-11|Estimate|March 2004||2004-03-31|January 2008|2008-01-31|June 2005|Actual|2005-06-30|||||Interventional|||Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)|A Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Prevention of Restenosis (ISAR-TEST-1)|Completed||Phase 4|450|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:46:58.750301|2018-06-01 04:46:58.750301
NCT00140517|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2017-01-11|2005-08-31|2005-09-01|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2002||2002-10-31|January 2017|2017-01-31|March 2008|Actual|2008-03-31|June 2007|Actual|2007-06-30||Interventional|||Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance|Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance|Completed||N/A|700||London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:46:58.836373|2018-06-01 04:46:58.836373
NCT00140504|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2013-02-24|2005-08-31|2005-09-01|Estimate|||||||2013-02-24|2013-02-26|Estimate|April 2003||2003-04-30|February 2013|2013-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Preventing Adverse Drug Events With PatientSite|Preventing Adverse Drug Events With PatientSite|Completed||N/A|800|Anticipated|Dana-Farber Cancer Institute||2|||f||||f||||||||||2018-06-01 04:46:58.910815|2018-06-01 04:46:58.910815
NCT00140491|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2013-10-22|2005-08-31|2005-09-01|Estimate|||||||2013-10-22|2013-10-23|Estimate|August 2005||2005-08-31|October 2013|2013-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Vision Restoration Therapy (VRT) to Treat Non-Arteritic Anterior Ischemic Optic Neuropathy|Visual Field Defects in Non-Arteritic Anterior Ischemic Optic Neuropathy: Effect of Vision Restoration Therapy (VRT)|Completed||N/A|20||Emory University|||||f||||||||||||||2018-06-01 04:46:59.014092|2018-06-01 04:46:59.014092
NCT00140478|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2009-12-07|2005-08-30|2005-09-01|Estimate|||||||2009-12-07|2009-12-09|Estimate|February 2005||2005-02-28|December 2009|2009-12-31|January 2008|Actual|2008-01-31|June 2006|Actual|2006-06-30||Interventional|||Mifepristone (RU-486) in Androgen Independent Prostate Cancer|A Phase II Study of Mifepristone (RU-486) in Androgen Independent Prostate Cancer With Correlative Assessment of Androgen Receptor Co-Repressor Proteins|Completed||Phase 2|48|Anticipated|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:46:59.077501|2018-06-01 04:46:59.077501
NCT00140465|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-11-13|2005-08-31|2005-09-01|Estimate|||||||2007-11-13|2007-11-14|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|July 2005|Actual|2005-07-31|||||Interventional|||75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)|A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)|Completed||Phase 4|60|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:46:59.148829|2018-06-01 04:46:59.148829
NCT00140452|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2007-11-20|2005-08-31|2005-09-01|Estimate|||||||2007-11-20|2007-11-21|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Phase II Study Using Thalidomide for the Treatment of ALS|Phase II Study Using Thalidomide for the Treatment of Amyotrophic Lateral Sclerosis|Completed||Phase 2|24|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||f||||||||||2018-06-01 04:46:59.218528|2018-06-01 04:46:59.218528
NCT00140426|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2015-06-08||2015-12-29|2005-08-31|2005-09-01|Estimate|2015-12-29|2016-02-02|Estimate||||2015-12-29|2016-02-02|Estimate|August 2004||2004-08-31|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||Females age 12 - 21|A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa|A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa|Completed||Phase 4|41|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 04:46:59.370202|2018-06-01 04:46:59.370202
NCT00140413|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|2015-02-17||2015-03-27|2005-08-31|2005-09-01|Estimate|2015-03-27|2015-04-01|Estimate||||2015-03-27|2015-04-01|Estimate|December 2004||2004-12-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Please note, 3 children were unenrolled from the study and were therefore excluded from our analysis of results. Therefore, while the participant flow section lists 20 participants, the baseline analysis and results are based on 17 participants.|Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia|Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia|Completed||Phase 4|20|Actual|Children's Hospital Los Angeles||2|||f||||f||||||||||2018-06-01 04:46:59.748628|2018-06-01 04:46:59.748628
NCT00140400|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-08-30|2005-08-30|2005-09-01|Estimate|||||||2005-08-30|2005-09-01|Estimate|May 1999||1999-05-31|August 2005|2005-08-31|January 2001||2001-01-31|||||Interventional|||Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer|Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Hormone-Refractory Prostate Cancer|Completed||Phase 1/Phase 2|50||Cell Genesys|||||||||||||||||||2018-06-01 04:47:00.012452|2018-06-01 04:47:00.012452
NCT00140387|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-08-30|2005-08-30|2005-09-01|Estimate|||||||2005-08-30|2005-09-01|Estimate|May 1999||1999-05-31|August 2005|2005-08-31|March 2001||2001-03-31|||||Interventional|||Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)|Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) in Hormone-naïve Prostate Cancer Patients|Completed||Phase 1/Phase 2|20||Cell Genesys|||||||||||||||||||2018-06-01 04:47:00.055003|2018-06-01 04:47:00.055003
NCT00140374|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-08-30|2005-08-30|2005-09-01|Estimate|||||||2005-08-30|2005-09-01|Estimate|December 1998||1998-12-31|August 2005|2005-08-31|February 2001||2001-02-28|||||Interventional|||Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)|Phase I/II Study of Vaccination Priming and Vaccine Boosting With Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines in Patients With Prostate Cancer|Completed||Phase 1/Phase 2|36||Cell Genesys|||||||||||||||||||2018-06-01 04:47:00.099011|2018-06-01 04:47:00.099011
NCT00140361|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2012-09-10|2005-08-30|2005-09-01|Estimate|||||||2012-09-10|2012-09-11|Estimate|January 2000||2000-01-31|September 2012|2012-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria|Assessing and Monitoring the Efficacy of Sulfadoxine/ Pyrimethamine (SP) and the Combination of SP Plus Artesunate for Uncomplicated Malaria Infections Among Children|Completed||Phase 4|390|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:47:00.140899|2018-06-01 04:47:00.140899
NCT00140348|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-12-18|2005-08-30|2005-09-01|Estimate|||||||2007-12-18|2007-12-24|Estimate|December 2001||2001-12-31|December 2007|2007-12-31|April 2005|Actual|2005-04-30|||||Interventional|||Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine|A Phase I/II Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine in Patients With Metastatic Hormone-Refractory Prostate Cancer|Completed||Phase 1/Phase 2|80||Cell Genesys|||||||||||||||||||2018-06-01 04:47:00.292735|2018-06-01 04:47:00.292735
NCT00140335|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2010-03-08|2005-08-30|2005-09-01|Estimate|||||||2010-03-08|2010-03-09|Estimate|December 2004||2004-12-31|March 2010|2010-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Evaluation of a Handwashing Promotion Program in Chinese Elementary Schools|Evaluation of a Handwashing Promotion Program in Chinese Elementary Schools|Completed||Phase 4|5000||Centers for Disease Control and Prevention|||||f||||t||||||||||2018-06-01 04:47:00.368395|2018-06-01 04:47:00.368395
NCT00140322|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-02-02|2005-08-30|2005-09-01|Estimate|||||||2016-02-02|2016-02-03|Estimate|October 2002||2002-10-31|February 2016|2016-02-29|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Dane County Safety Assessment (SAFE) Research Study|Dane County Safety Assessment for Elders (SAFE) Research Study|Completed||N/A|455||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:47:00.439174|2018-06-01 04:47:00.439174
NCT00140309|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-03-16|2005-08-30|2005-09-01|Estimate|||||||2007-03-16|2007-03-19|Estimate|July 2003||2003-07-31|March 2007|2007-03-31|December 2005|Actual|2005-12-31|||||Interventional|||TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment|TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium|Completed||Phase 2|350||Centers for Disease Control and Prevention|||||f||||t||||||||||2018-06-01 04:47:00.512673|2018-06-01 04:47:00.512673
NCT00140296|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-08-30|2005-08-30|2005-09-01|Estimate|||||||2005-08-30|2005-09-01|Estimate|March 2003||2003-03-31|August 2005|2005-08-31|September 2005||2005-09-30|||||Interventional|||Using the Healthcare Visit to Improve Contraceptive Use|Using the Healthcare Visit to Improve Contraceptive Use|Completed||N/A|747||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:00.613008|2018-06-01 04:47:00.613008
NCT00140283|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-08-31|2005-08-31|2005-09-01|Estimate|||||||2005-08-31|2005-09-01|Estimate|July 2004||2004-07-31|August 2005|2005-08-31|May 2005||2005-05-31|||||Interventional|||Effectiveness of a Educational Intervention to Improve the Resolution Capacity of Primary Health Care Teams.|Phase IV Cluster Randomised Controlled Trial With 2 Parallel Groups, to Evaluate the Effectiveness of a Educational Intervention to Improve the Resolution Capacity.|Unknown status|Active, not recruiting|Phase 4|48||Catalan Institute of Health|||||f||||||||||||||2018-06-01 04:47:00.677115|2018-06-01 04:47:00.677115
NCT00140270|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-08-30|2005-08-30|2005-09-01|Estimate|||||||2005-08-30|2005-09-01|Estimate|August 2002||2002-08-31|August 2005|2005-08-31|December 2002||2002-12-31|||||Interventional|||RCT of PEP Program to Reduce ACL Injuries in Female Collegiate Soccer Players|Evaluating the Effectiveness of a Neuromuscular and Proprioceptive Training Program to Reduce Ligamentous Knee Injuries Among Female Collegiate Soccer Players.|Completed||Phase 2|4000||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:00.743219|2018-06-01 04:47:00.743219
NCT00140257|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-12-30|2005-08-30|2005-09-01|Estimate|||||||2008-12-30|2008-12-31|Estimate|November 2004||2004-11-30|December 2008|2008-12-31||||December 2008|Anticipated|2008-12-31||Interventional|||DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome|A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome|Unknown status|Active, not recruiting|Phase 4|240|Actual|Bispebjerg Hospital|||||f||||f||||||||||2018-06-01 04:47:00.799305|2018-06-01 04:47:00.799305
NCT00140244|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2015-12-22||2017-04-06|2005-08-30|2005-09-01|Estimate|2017-02-22|2017-04-06|Actual||||2017-04-06|2017-05-11|Actual|December 2001||2001-12-31|April 2017|2017-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome|Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients|Completed||Phase 2|7|Actual|Beth Israel Deaconess Medical Center||2|||f||||||||||||||2018-06-01 04:47:00.894804|2018-06-01 04:47:00.894804
NCT00140231|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2015-12-29||2017-05-05|2005-08-30|2005-09-01|Estimate|2017-05-05|2017-06-07|Actual||||2017-05-05|2017-06-07|Actual|October 2002||2002-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|March 2011|Actual|2011-03-31||Interventional|||Role of Leptin in the Neuroendocrine and Immune Response to Fasting|Role of Leptin in the Neuroendocrine and Immune Response to Fasting in Humans|Completed||Phase 1/Phase 2|13|Actual|Beth Israel Deaconess Medical Center|Our study is confined to lean, healthy female subjects; therefore, our results should not be generalized to male, obese,or diabetic subjects|2|||f||||f||||||||Undecided||2018-06-01 04:47:01.456438|2018-06-01 04:47:01.456438
NCT00140218|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-01-05|2005-08-30|2005-09-01|Estimate|||||||2008-01-05|2008-01-08|Estimate|August 2005||2005-08-31|January 2008|2008-01-31|December 2006|Actual|2006-12-31|January 2007|Actual|2007-01-31||Interventional|||R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis|Futility Study of R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis|Completed||Phase 1/Phase 2|30|Actual|Bennett, James P., Jr., M.D., Ph.D.|||||t||||t||||||||||2018-06-01 04:47:01.920542|2018-06-01 04:47:01.920542
NCT00140205|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-01-15|2005-08-30|2005-09-01|Estimate|||||||2016-01-15|2016-01-18|Estimate|February 2001||2001-02-28|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|June 2004|Actual|2004-06-30||Interventional|||Pharmacokinetics of Leptin Administration During Fasting|Pharmacokinetics of Leptin Administration During Fasting|Active, not recruiting||Phase 1|28|Actual|Beth Israel Deaconess Medical Center|||||||||f||||||||||2018-06-01 04:47:02.033656|2018-06-01 04:47:02.033656
NCT00140192|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-07-28|2005-08-31|2005-09-01|Estimate|||||||2009-07-28|2009-07-29|Estimate|September 2004||2004-09-30|October 2005|2005-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Creatine Treatment in Psychiatric Disorders|Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial|Completed||Phase 3|12|Actual|Beersheva Mental Health Center|||||f||||||||||||||2018-06-01 04:47:02.114798|2018-06-01 04:47:02.114798
NCT00140179|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-11-23|2005-08-31|2005-09-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|September 2004||2004-09-30|November 2009|2009-11-30|May 2008|Actual|2008-05-31|||||Interventional|||Valnoctamide in Mania|Valnoctamide as a Valproate Substitute With Low Teratogenic Potential: Double-Blind Controlled Clinical Trial|Completed||Phase 3|80|Anticipated|Beersheva Mental Health Center|||||f||||t||||||||||2018-06-01 04:47:02.1988|2018-06-01 04:47:02.1988
NCT00140166|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-11-23|2005-08-31|2005-09-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|July 2005||2005-07-31|November 2009|2009-11-30|May 2008|Actual|2008-05-31|||||Interventional|||Treatment of Acute Schizophrenia With Vitamin Therapy|The Treatment of Acute Schizophrenia With High Dose Niacinmide Plus Ascorbate Plus Pyridoxine Plus Centrum Forte vs. Centrum Forte Only as an Add-On to Risperidone and Dietary Counseling|Completed||Phase 4|55|Anticipated|Beersheva Mental Health Center|||||f||||t||||||||||2018-06-01 04:47:02.310994|2018-06-01 04:47:02.310994
NCT00140153|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2009-11-23|2005-08-31|2005-09-01|Estimate|||||||2009-11-23|2009-11-25|Estimate|April 2005||2005-04-30|November 2009|2009-11-30|April 2006||2006-04-30|||||Interventional|||Testosterone in Female Hypoactive Sexual Desire Disorder|Transdermal Testosterone Gel Prn Application for Hypoactive Sexual Desire Disorder in Women: A Controlled Study|Completed||Phase 3|20||Beersheva Mental Health Center|||||f||||||||||||||2018-06-01 04:47:02.411929|2018-06-01 04:47:02.411929
NCT00140140|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|2013-08-20||2013-08-20|2005-08-30|2005-09-01|Estimate|2013-08-20|2013-10-24|Estimate||||2013-08-20|2013-10-24|Estimate|August 2005||2005-08-31|August 2013|2013-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer|An Open-Label Phase I/II Study of Weekly ABI-007 and Vinorelbine With or Without G-CSF in Patients With Stage IV (Metastatic) Breast Cancer|Terminated||Phase 1/Phase 2|16|Actual|Celgene||3||Unable to determine the optimum tolerated dose|f||||f||||||||||2018-06-01 04:47:02.539385|2018-06-01 04:47:02.539385
NCT00140114|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2012-07-12|2005-08-31|2005-09-01|Estimate|||||||2012-07-12|2012-07-13|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|September 2006|Actual|2006-09-30|||||Interventional|||Sublingual Versus Vaginal Misoprostol for Labor Induction at Term||Completed||Phase 3|170|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-06-01 04:47:03.721643|2018-06-01 04:47:03.721643
NCT00140101|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2012-01-06|2005-08-30|2005-09-01|Estimate|||||||2012-01-06|2012-01-10|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|September 2007|Actual|2007-09-30||Interventional|ZoMaxx™ II||Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries|A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx Drug Eluting Coronary Stent System as Compared to the TAXUS™ Express2™ Paclitaxel-Eluting Stent in de Novo Coronary Artery Lesions|Completed||Phase 2|1099|Actual|Abbott Vascular||2|||f||||t||||||||||2018-06-01 04:47:03.933683|2018-06-01 04:47:03.933683
NCT00140088|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-31|||2005-08-31|2005-08-31|2005-09-01|Estimate|||||||2005-08-31|2005-09-01|Estimate|December 2004||2004-12-31|August 2005|2005-08-31|April 2005||2005-04-30|||||Interventional|||Efficacy and Safety of ALGRX 3268 in Management of Needlestick Pain in Children.|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Effectiveness and Safety of ALGRX 3268 in Pediatric Subjects.|Completed||Phase 3|504||AlgoRx Pharmaceuticals|||||||||||||||||||2018-06-01 04:47:04.338302|2018-06-01 04:47:04.338302
NCT00140075|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2011-05-24|2005-08-30|2005-08-31|Estimate|||||||2011-05-24|2011-05-26|Estimate|November 2000||2000-11-30|May 2011|2011-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer|Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer|Completed||Phase 3|606|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 04:47:04.827265|2018-06-01 04:47:04.827265
NCT00140062|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-04-04|2005-08-30|2005-08-31|Estimate|||||||2008-04-04|2008-04-07|Estimate|February 2002||2002-02-28|April 2008|2008-04-30|April 2006||2006-04-30|||||Interventional|||Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.|"A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With Usual Care Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension"|Completed||Phase 4|329||Pfizer|||||f||||||||||||||2018-06-01 04:47:05.126743|2018-06-01 04:47:05.126743
NCT00137085|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-06-13|2005-08-26|2005-08-29|Estimate|||||||2007-06-13|2007-06-14|Estimate|September 2004||2004-09-30|April 2006|2006-04-30|August 2006|Actual|2006-08-31|||||Interventional|||Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation|Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation|Completed||N/A|124||Queen's University|||||f||||||||||||||2018-06-01 04:47:54.331156|2018-06-01 04:47:54.331156
NCT00140049|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-11-29|2005-08-30|2005-08-31|Estimate|||||||2007-11-29|2007-11-30|Estimate|July 2005||2005-07-31|November 2007|2007-11-30|July 2006|Actual|2006-07-31|||||Interventional|||A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma|A 12-Week Randomized, Evaluator-Masked, Parallel-Group, Multinational, Multi-Center Study Comparing The Efficacy And Safety Of The Fixed Combination Of Latanoprost And Timolol (Xalacom) With The Fixed Combination Of Dorzolamide And Timolol (Cosopt) In Patients With Open-Angle Glaucoma Or Ocular Hypertension.|Completed||Phase 4|238||Pfizer|||||f||||||||||||||2018-06-01 04:47:05.285021|2018-06-01 04:47:05.285021
NCT00140036|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-02-28|2005-08-30|2005-08-31|Estimate|||||||2008-02-28|2008-03-03|Estimate|September 2002||2002-09-30|February 2008|2008-02-29|August 2005||2005-08-31|||||Interventional|||Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).|Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).|Completed||Phase 4|137||Pfizer|||||f||||||||||||||2018-06-01 04:47:05.411203|2018-06-01 04:47:05.411203
NCT00140023|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2011-05-09|2005-08-30|2005-08-31|Estimate|||||||2011-05-09|2011-05-10|Estimate|September 2005||2005-09-30|May 2011|2011-05-31|June 2006|Actual|2006-06-30|||||Interventional|||Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia|A Multi-center, Open Label Study to Evaluate the Efficacy and Safety of Azithromycin Microspheres in Subjects Identified as Having Low Risk Community Acquired Pneumonia (CAP)|Completed||Phase 3|47|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:47:05.624366|2018-06-01 04:47:05.624366
NCT00140010|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2009-05-19|2005-08-29|2005-08-31|Estimate|||||||2009-05-19|2009-05-20|Estimate|April 2005||2005-04-30|May 2009|2009-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Erythropoietin Therapy for Subarachnoid Hemorrhage|Effects of Systemic Erythropoietin Therapy on Cerebral Autoregulation and Incidence of Delayed Ischemic Deficits in Patients With Aneurysmal Subarachnoid Hemorrhage|Completed||Phase 2|80|Actual|University of Cambridge||1|||f||||t||||||||||2018-06-01 04:47:05.789123|2018-06-01 04:47:05.789123
NCT00139997|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2012-09-07||2013-01-29|2005-08-29|2005-08-31|Estimate|2013-01-29|2013-03-06|Estimate||||2013-01-29|2013-03-06|Estimate|January 2002||2002-01-31|January 2013|2013-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Environmental Treatment for Seasonal Affective Disorder (SAD)|A Multicenter, Randomized Controlled Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy For Seasonal Affective Disorder|Completed||N/A|26|Actual|Yale University||2|||f||||f||||||||||2018-06-01 04:47:05.998146|2018-06-01 04:47:05.998146
NCT00139984|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2017-02-01|2005-08-29|2005-08-31|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2003||2003-10-31|February 2017|2017-02-28|May 2007|Actual|2007-05-31|||||Interventional|||Ambulatory Blood Pressure Monitoring for Antihypertensive Treatment Guidance|Impact of Ambulatory Blood Pressure Monitoring for Antihypertensive Treatment Guidance in Medical Outpatients: The Hyper-ABC Study|Completed||Phase 4|170|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 04:47:06.629331|2018-06-01 04:47:06.629331
NCT00139971|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2006-01-05|2005-08-30|2005-08-31|Estimate|||||||2006-01-05|2006-01-06|Estimate|December 2001||2001-12-31|August 2005|2005-08-31||||||||Interventional|||Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer||Unknown status|Recruiting|Phase 3|600||West Japan Thoracic Oncology Group|||||f||||||||||||||2018-06-01 04:47:06.705714|2018-06-01 04:47:06.705714
NCT00139958|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2010-07-26|2005-08-29|2005-08-31|Estimate|||||||2010-07-26|2010-07-28|Estimate|November 2003||2003-11-30|May 2010|2010-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Prognosis of Acute Coronary Syndrome in HIV-infected Patients|Prognosis After Acute Coronary Syndrome in HIV-infected Patients|Completed|||300|Actual|Saint Antoine University Hospital|||2||f||||t||||||Samples Without DNA|"~     Lipids, CRP, glycemia, insulinemia~   "|||2018-06-01 04:47:06.782225|2018-06-01 04:47:06.782225
NCT00139945|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2010-01-19|2005-08-30|2005-08-31|Estimate|||||||2010-01-19|2010-01-20|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients|Effects of Acute Ghrelin Infusion to Growth Hormone Deficient Adults: Growth Hormone and Cortisol Interaction|Completed||N/A|8|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 04:47:06.878923|2018-06-01 04:47:06.878923
NCT00139932|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2017-03-22|2005-08-30|2005-08-31|Estimate|||||||2017-03-22|2017-03-24|Actual|September 1, 2005|Actual|2005-09-01|March 2017|2017-03-31|November 21, 2006|Actual|2006-11-21|November 21, 2006|Actual|2006-11-21||Interventional|||Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)|A Double-Blind Randomized, Parallel-Group, Multicenter Clinical Study to Compare the Efficacy and Tolerability of Tiotropium Bromide Alone vs. the Co-Administration of Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD|Completed||Phase 4|255|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:47:06.976355|2018-06-01 04:47:06.976355
NCT00139919|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-01-15|2005-08-30|2005-08-31|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2006||2006-01-31|November 2007|2007-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder|A Randomized, Double-Blind, Placebo-Controlled, Sequential Panel Study of the Safety and Tolerability of Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Either Schizophrenia or Bipolar Disorder With an Optional Open-Label 26-Week Extension Study|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:47:07.090249|2018-06-01 04:47:07.090249
NCT00139906|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-01-15|2005-08-30|2005-08-31|Estimate|||||||2015-01-15|2015-01-16|Estimate|August 2005||2005-08-31|March 2006|2006-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:47:07.167447|2018-06-01 04:47:07.167447
NCT00139893|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-03-25|2005-08-30|2005-08-31|Estimate|||||||2013-03-25|2013-03-26|Estimate|June 2005||2005-06-30|May 2008|2008-05-31||||October 2005|Actual|2005-10-31||Interventional|||A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis|A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis|Completed||N/A|||UCB Pharma|||||f||||||||||||||2018-06-01 04:47:07.219019|2018-06-01 04:47:07.219019
NCT00139880|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-09-03|2005-08-30|2005-08-31|Estimate|||||||2013-09-03|2013-09-04|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease|A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease|Completed||Phase 3|||UCB Pharma|||||f||||||||||||||2018-06-01 04:47:07.274078|2018-06-01 04:47:07.274078
NCT00139867|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2014-10-17|2005-08-30|2005-08-31|Estimate|||||||2014-10-17|2014-10-20|Estimate|January 2004||2004-01-31|September 2009|2009-09-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease|A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease|Completed||Phase 3|||UCB Pharma|||||f||||||||||||||2018-06-01 04:47:07.42759|2018-06-01 04:47:07.42759
NCT00139854|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-08-29|2005-08-30|2005-08-31|Estimate|||||||2013-08-29|2013-08-30|Estimate|August 2004||2004-08-31|September 2009|2009-09-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety|A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety|Completed||Phase 3|||UCB Pharma|||||f||||||||||||||2018-06-01 04:47:07.55673|2018-06-01 04:47:07.55673
NCT00139841|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2014-05-08|2005-08-29|2005-08-31|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2005||2005-10-31|May 2014|2014-05-31|October 2009|Actual|2009-10-31|July 2007|Actual|2007-07-31||Interventional|||Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab|A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab|Completed||Phase 3|103|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 04:47:07.646949|2018-06-01 04:47:07.646949
NCT00139828|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-08-29|2005-08-30|2005-08-31|Estimate|||||||2007-08-29|2007-08-30|Estimate|May 2003||2003-05-31|August 2007|2007-08-31|February 2007|Actual|2007-02-28|||||Interventional|||Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)|Post Marketing Study in Haemophilia B Patients Using Nonafact® 100 IU/ml Powder and Solvent for Solution for Injection(Human Coagulation Factor IX)(Human Plasma Derived Factor IX Product, Freeze Dried)|Completed||Phase 4|12|Actual|Sanquin||1|||f||||f||||||||||2018-06-01 04:47:07.75432|2018-06-01 04:47:07.75432
NCT00139815|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-09-13|2005-08-29|2005-08-31|Estimate|||||||2016-09-13|2016-09-15|Estimate|April 2003||2003-04-30|September 2016|2016-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Michelangelo - Oasis 5|An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes|Completed||Phase 3|20078|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:47:07.934906|2018-06-01 04:47:07.934906
NCT00139802|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-08-30|2005-08-30|2005-08-31|Estimate|||||||2005-08-30|2005-08-31|Estimate|April 1997||1997-04-30|January 1997|1997-01-31|June 2001||2001-06-30|||||Interventional|||DANish Multicenter STENT Trial|Low Restenosis Rate of the NIR Coronary Stent: Results of the Danish Multicenter Stent Study (DANSTENT) – a Randomized Study Comparing a First-Generation With a Second-Generation Stent.|Completed||Phase 4|400||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:47:08.214989|2018-06-01 04:47:08.214989
NCT00139789|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-08-29|2005-08-30|2005-08-31|Estimate|||||||2013-08-29|2013-08-30|Estimate|January 2005||2005-01-31|September 2009|2009-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis|A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis|Completed||Phase 3|60|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:47:08.29571|2018-06-01 04:47:08.29571
NCT00139776|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2009-02-20||2009-06-24|2005-08-30|2005-08-31|Estimate|2009-03-27|2009-05-19|Estimate||||2009-06-24|2009-07-09|Estimate|July 2005||2005-07-31|June 2009|2009-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||"Study Of Continuous Use Of Celecoxib Vs. Usual or Intermittent Use"|"Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of Continuous Use Of Celecoxib Vs. The Usual Use Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-Inflammatory Medication for Control Of Their Pain"|Completed||Phase 4|875|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 04:47:09.386549|2018-06-01 04:47:09.386549
NCT00139763|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-03-15|2005-08-30|2005-08-31|Estimate|||||||2007-03-15|2007-03-19|Estimate|July 2005||2005-07-31|March 2007|2007-03-31|March 2006||2006-03-31|||||Interventional|||US Inhaled Insulin Therapeutic Choice Questionnaire Study|A US Randomized Questionnaire-Based Trial Assessing The Impact Of The Availability Of Inhaled Insulin On Therapeutic Choice In Patients With Suboptimally Controlled Type 2 Diabetes|Completed||Phase 3|740||Pfizer|||||f||||||||||||||2018-06-01 04:47:12.080678|2018-06-01 04:47:12.080678
NCT00139750|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-06-01|2005-08-30|2005-08-31|Estimate|||||||2007-06-01|2007-06-04|Estimate|December 2004||2004-12-31|June 2007|2007-06-30|February 2006|Actual|2006-02-28|||||Interventional|||12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation|A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking|Completed||Phase 2|600||Pfizer|||||f||||||||||||||2018-06-01 04:47:12.305911|2018-06-01 04:47:12.305911
NCT00139737|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2010-06-15||2010-08-02|2005-08-29|2005-08-31|Estimate|2010-06-15|2010-07-14|Estimate||||2010-08-02|2010-08-10|Estimate|March 2002||2002-03-31|August 2010|2010-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia|Open Extension Study Evaluating the Safety and Tolerability of Oral Ziprasidone in the Treatment of Subjects Who Have Successfully Completed a Previous Ziprasidone Study|Completed||Phase 3|344|Actual|Pfizer|||||f||||f||||||||||2018-06-01 04:47:12.488658|2018-06-01 04:47:12.488658
NCT00139724|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2009-12-18|2005-08-29|2005-08-31|Estimate|||||||2009-12-18|2009-12-21|Estimate|May 2005||2005-05-31|December 2009|2009-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet|A Phase III Randomized, Double-Blind, Double Dummy, Multi-Center Study To Compare The Efficacy, Safety And Tolerability Of Tolterodine Extended Release Capsule With Tolterodine Immediate Release Tablet In Subjects With Symptoms Of Overactive Bladder|Completed||Phase 3|260|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:47:12.946832|2018-06-01 04:47:12.946832
NCT00136344|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-02-11|2005-08-26|2005-08-29|Estimate|||||||2016-02-11|2016-02-12|Estimate|September 2003||2003-09-30|June 2007|2007-06-30|May 2006||2006-05-31|||||Interventional|||Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery|Antibiotic Prophylaxis for Cataract Surgery Version 7e January 22 2003|Completed||N/A|35000||City, University of London|||||f||||||||||||||2018-06-01 04:48:08.46286|2018-06-01 04:48:08.46286
NCT00139711|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-03-27|2005-08-29|2005-08-31|Estimate|||||||2008-03-27|2008-04-01|Estimate|March 2003||2003-03-31|October 2006|2006-10-31|June 2006||2006-06-30|||||Interventional|||Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer|A Multicenter Randomized Phase II Study Evaluating The Activity And Tolerability Of Three Different Combinations Of Docetaxel (Taxotere) And Irinotecan (Campto) As Second Line Therapy For Recurrent Or Metastatic Non Small Cell Lung Cancer (NSCLS)|Completed||Phase 2|138||Pfizer|||||f||||||||||||||2018-06-01 04:47:13.079762|2018-06-01 04:47:13.079762
NCT00139698|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-07-30|2005-08-29|2005-08-31|Estimate|||||||2007-07-30|2007-07-31|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|July 2006||2006-07-31|||||Interventional|OSCAR||Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension|A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension|Completed||Phase 3|410||Pfizer|||||f||||||||||||||2018-06-01 04:47:13.211359|2018-06-01 04:47:13.211359
NCT00139685|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-09-23|2005-08-30|2005-08-31|Estimate|||||||2008-09-23|2008-09-25|Estimate|April 1998||1998-04-30|September 2008|2008-09-30|July 2007|Actual|2007-07-31|August 2006|Actual|2006-08-31||Interventional|||Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception|Depo-Provera: Evaluation of Bone Mineral Density and Total Body Calcium in Adolescent DP 150 CI Users and Matched Controls|Completed||Phase 4|350||Pfizer|||||f||||||||||||||2018-06-01 04:47:13.445205|2018-06-01 04:47:13.445205
NCT00139672|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-06-12|2005-08-30|2005-08-31|Estimate|||||||2008-06-12|2008-06-17|Estimate|January 2004||2004-01-31|June 2008|2008-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Investigate The Effect Of Pd-217,014 In Patients With Irritable Bowel Syndrome (IBS)|Completed||Phase 2|330||Pfizer|||||f||||||||||||||2018-06-01 04:47:13.567116|2018-06-01 04:47:13.567116
NCT00139659|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2009-10-21||2010-05-26|2005-08-29|2005-08-31|Estimate|2010-04-10|2010-05-12|Estimate||||2010-05-26|2010-06-02|Estimate|January 2003||2003-01-31|October 2009|2009-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma|Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial|Completed||Phase 3|288|Actual|Pfizer|Data for some secondary endpoints were not tabulated or analyzed for this study and some concomitant medication data were not accurately recorded and tabulated due to lack of resources resulting from scaling down of Exubera® development.|2|||f||||f||||||||||2018-06-01 04:47:13.894523|2018-06-01 04:47:13.894523
NCT00139646|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-05-02|2005-08-29|2005-08-31|Estimate|||||||2008-05-02|2008-05-06|Estimate|April 2002||2002-04-30|May 2008|2008-05-31|April 2004||2004-04-30|||||Interventional|||Parecoxib in Renal Colic|A Multicenter Single-Blind, Single Dose Efficacy and Safety Pilot Study Comparing Intramuscular Parecoxib and Diclofenac in Renal Colic|Terminated||Phase 3|50||Pfizer||||See Detailed Description|f||||||||||||||2018-06-01 04:47:16.656491|2018-06-01 04:47:16.656491
NCT00139633|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-08-29|2005-08-29|2005-08-31|Estimate|||||||2005-08-29|2005-08-31|Estimate|July 2000||2000-07-31|August 2005|2005-08-31|June 2005||2005-06-30|||||Interventional|||Selective Dose Escalation for Esophageal Cancer|Phase II Selective Dose Escalation of Chemoradiotherapy for Esophageal Cancer|Unknown status|Active, not recruiting|Phase 2|25||The Oregon Clinic|||||f||||||||||||||2018-06-01 04:47:16.781767|2018-06-01 04:47:16.781767
NCT00139620|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2018-02-06|2005-08-29|2005-08-31|Estimate|||||||2018-02-06|2018-02-08|Actual|August 22, 2005|Actual|2005-08-22|June 2015|2015-06-30|June 25, 2007|Actual|2007-06-25|June 25, 2007|Actual|2007-06-25||Interventional|||A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function|An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function|Completed||Phase 1|39|Actual|Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:47:16.87658|2018-06-01 04:47:16.87658
NCT00139607|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2009-08-13|2005-08-29|2005-08-31|Estimate|||||||2009-08-13|2009-08-14|Estimate|September 2002||2002-09-30|August 2009|2009-08-31|January 2005||2005-01-31|||||Interventional|||Parecoxib In Post Surgery (Hemicolectomy) Pain|A Multicenter, Open Label, Pilot Study To Evaluate Analgesic Activity And Safety Of Parecoxib 40 Mg IV In Patients Undergoing Hemicolectomy, In The Optimal Management Of Acute Post-Operative Pain Of Surgical Patients|Terminated||Phase 3|60||Pfizer||||Please see detailed description for termination reason.|f||||||||||||||2018-06-01 04:47:16.958911|2018-06-01 04:47:16.958911
NCT00139594|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2017-03-24|2005-08-29|2005-08-31|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2004||2004-12-31|March 2017|2017-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder|A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder|Completed||Phase 4|181|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:47:17.056381|2018-06-01 04:47:17.056381
NCT00139581|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-04-22|2005-08-30|2005-08-31|Estimate|||||||2008-04-22|2008-04-23|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects|Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects|Completed||Phase 4|||Novartis||2|||f||||||||||||||2018-06-01 04:47:17.295091|2018-06-01 04:47:17.295091
NCT00139568|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2008-01-31|2005-08-30|2005-08-31|Estimate|||||||2008-01-31|2008-02-01|Estimate|February 2005||2005-02-28|January 2008|2008-01-31|October 2005|Actual|2005-10-31|||||Interventional|||An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation|An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation|Completed||Phase 3|600||Novartis|||||f||||||||||||||2018-06-01 04:47:17.434005|2018-06-01 04:47:17.434005
NCT00139555|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2017-02-21|2005-08-29|2005-08-31|Estimate|||||||2017-02-21|2017-02-23|Actual|July 2004||2004-07-31|February 2017|2017-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension|Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension|Completed||Phase 4|125|Actual|Novartis|||||||||||||||||||2018-06-01 04:47:17.497731|2018-06-01 04:47:17.497731
NCT00136331|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-07-17|2005-08-26|2005-08-29|Estimate|||||||2016-07-17|2016-07-19|Estimate|October 2005||2005-10-31|November 2008|2008-11-30|November 2006||2006-11-30|||||Interventional|||Study of a Pandemic Influenza Vaccine|Phase Ia Study of a Pandemic Influenza Vaccine|Completed||Phase 1|400||Seqirus|||||f||||||||||||||2018-06-01 04:48:08.655773|2018-06-01 04:48:08.655773
NCT00139542|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2009-05-08|2005-08-29|2005-08-31|Estimate|||||||2009-05-08|2009-05-11|Estimate|September 2005||2005-09-30|May 2009|2009-05-31|June 2008|Actual|2008-06-30|March 2007|Actual|2007-03-31||Interventional|DEFI2005||"AED Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named One Shock Per Minute"|"Automated External Defibrillator (AED) Use in Out-of-Hospital Cardiac Arrest: A New Algorithm Named One Shock Per Minute"|Completed||Phase 3|5107|Actual|Fire Brigade Of Paris Emergency Medicine Dept||2|||f||||t||||||||||2018-06-01 04:47:17.613852|2018-06-01 04:47:17.613852
NCT00139529|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2015-12-21|2005-08-29|2005-08-31|Estimate|||||||2015-12-21|2015-12-23|Estimate|March 2006||2006-03-31|December 2015|2015-12-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Education and Counseling for Abstinence From Tobacco After Pregnancy|Postpartum Maintenance of Abstinence From Tobacco|Completed||N/A|757|Actual|Brown University||2|||f||||f||||||||||2018-06-01 04:47:17.77878|2018-06-01 04:47:17.77878
NCT00139516|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2014-03-11|2005-08-29|2005-08-31|Estimate|||||||2014-03-11|2014-03-13|Estimate|September 2001||2001-09-30|March 2014|2014-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Chinese Community Smoking Cessation Project||Completed||N/A|||University of California, San Francisco|||||f||||||||||||||2018-06-01 04:47:17.892158|2018-06-01 04:47:17.892158
NCT00139490|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2012-12-19|2005-08-29|2005-08-31|Estimate|||||||2012-12-19|2012-12-21|Estimate|February 2006||2006-02-28|December 2012|2012-12-31|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|||Home-Based Program to Treat High Blood Pressure in African Americans|Home-Based Blood Pressure Interventions for African Americans|Completed||N/A|846|Actual|Visiting Nurse Service of New York||3|||f||||t||||||||||2018-06-01 04:47:17.949023|2018-06-01 04:47:17.949023
NCT00139477|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2012-06-25||2012-10-21|2005-08-30|2005-08-31|Estimate|2012-09-09|2012-10-11|Estimate||||2012-10-21|2012-10-26|Estimate|November 2003||2003-11-30|October 2012|2012-10-31|September 2011|Actual|2011-09-30|May 2009|Actual|2009-05-31||Interventional|||Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention|Understanding the Effects of Therapeutic Intervention on Cardiovascular Risk Markers, Insulin Resistance, and Intra-Hepatic Fat Contents in Obese Children at High Risk for the Metabolic Syndrome.|Completed||N/A|66|Actual|Nemours Children's Clinic|Protocol #2 attrition was high, such that, we could not derive conclusions beyond the 6 month time period. Therefore, conclusions were based on participants after completing the first intervention without crossover to the second intervention.|2|||f||||t||||||||||2018-06-01 04:47:18.090877|2018-06-01 04:47:18.090877
NCT00139451|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2011-10-11|2005-08-30|2005-08-31|Estimate|||||||2011-10-11|2011-10-12|Estimate|May 2004||2004-05-31|October 2011|2011-10-31|September 2010|Actual|2010-09-30|December 2007|Actual|2007-12-31||Interventional|||Nutrients and Hormones: Effects in Boys With Disordered Growth|Nutrients and Hormones: Effects in Boys With Disordered Growth|Completed||Phase 2|20|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-06-01 04:47:18.484068|2018-06-01 04:47:18.484068
NCT00139438|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-04-21|2005-08-30|2005-08-31|Estimate|||||||2016-04-21|2016-04-22|Estimate|September 2004||2004-09-30|April 2016|2016-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)|Improving Management of Patients at High Risk for Osteoporotic Fractures|Completed||N/A|4266||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:47:18.587586|2018-06-01 04:47:18.587586
NCT00139425|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-04-21|2005-08-30|2005-08-31|Estimate|||||||2016-04-21|2016-04-22|Estimate|May 2003||2003-05-31|April 2016|2016-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Osteoporosis Disease Management Demonstration Project (0000-037)|Osteoporosis Prevention and Treatment Program: A Disease Management Demonstration Project|Completed||N/A|10000||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:47:18.659436|2018-06-01 04:47:18.659436
NCT00139399|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2011-10-19|2005-08-30|2005-08-31|Estimate|||||||2011-10-19|2011-10-20|Estimate|May 1998||1998-05-31|October 2011|2011-10-31|November 2006|Actual|2006-11-30|July 2006|Actual|2006-07-31||Interventional|RSVP||Radial Artery Versus Saphenous Vein Patency (RSVP) Study|A Randomised Controlled Trial to Compare Angiographic Patency of Radial Artery Versus Saphenous Vein Used as Free Aorto-coronary Grafts in Coronary Revascularisation|Completed||Phase 3|142|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 04:47:18.727427|2018-06-01 04:47:18.727427
NCT00139386|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-04-17|2005-08-29|2005-08-31|Estimate|||||||2013-04-17|2013-04-18|Estimate|October 2005||2005-10-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2009|Actual|2009-04-30||Interventional|||Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial|Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation|Completed||Phase 4|1119|Actual|Kumamoto University||2|||f||||t||||||||||2018-06-01 04:47:19.007759|2018-06-01 04:47:19.007759
NCT00139373|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2007-09-12|2005-08-30|2005-08-31|Estimate|||||||2007-09-12|2007-09-14|Estimate||||July 2005|2005-07-31||||||||Interventional|||Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy|Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy|Unknown status|Recruiting|Phase 2|16|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:47:19.146351|2018-06-01 04:47:19.146351
NCT00139360|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2015-08-26|2005-08-30|2005-08-31|Estimate|||||||2015-08-26|2015-08-27|Estimate|May 2005||2005-05-31|August 2015|2015-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma|Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma and Predictive Value of Angiogenic Markers|Completed||Phase 2|35|Actual|Haukeland University Hospital||1|||f||||||||||||||2018-06-01 04:47:19.222452|2018-06-01 04:47:19.222452
NCT00139347|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-10-27|2005-08-30|2005-08-31|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2003||2003-12-31|October 2016|2016-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants|A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants|Completed||Phase 3|6360||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:47:19.330717|2018-06-01 04:47:19.330717
NCT00139334|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2016-09-20|2005-08-30|2005-08-31|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2005||2005-06-30|September 2016|2016-09-30|January 2006|Actual|2006-01-31|||||Interventional|||A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh|Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV Versus Given Alone (HRV Vaccine Dose Given 15 Days After the OPV Dose) in Healthy Infants in Bangladesh|Completed||Phase 2|300||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:47:19.498941|2018-06-01 04:47:19.498941
NCT00139321|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2013-01-07|2005-08-30|2005-08-31|Estimate|||||||2013-01-07|2013-01-08|Estimate|June 2004||2004-06-30|January 2013|2013-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes|Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes|Terminated||N/A|110|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:47:19.653593|2018-06-01 04:47:19.653593
NCT00139308|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-08-30|2005-08-30|2005-08-31|Estimate|||||||2005-08-30|2005-08-31|Estimate||||August 2005|2005-08-31||||||||Interventional|||High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome|Pilot Study of Internal Globus Pallidus or Median Centre of the Thalamus High Frequency Stimulation for the Treatment of Patients With Severe Tourette's Syndrome|Completed||Phase 1|||Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:47:19.811405|2018-06-01 04:47:19.811405
NCT00139295|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2014-02-04|2005-08-29|2005-08-31|Estimate|||||||2014-02-04|2014-02-05|Estimate|October 2004||2004-10-31|February 2014|2014-02-28|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee|Comparison of the Efficacy and Safety of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee|Completed||Phase 3|||Sanofi|||||||||||||||||||2018-06-01 04:47:20.090617|2018-06-01 04:47:20.090617
NCT00139282|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-11-27|2005-08-29|2005-08-31|Estimate|||||||2007-11-27|2007-11-28|Estimate|June 2005||2005-06-30|November 2007|2007-11-30||||||||Interventional|||"A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for Wet Age-Related Macular Degeneration"|A Phase 3, Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration|Terminated||Phase 3|||Genaera Corporation|||||||||||||||||||2018-06-01 04:47:20.428855|2018-06-01 04:47:20.428855
NCT00139269|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-06-02|2005-08-29|2005-08-31|Estimate|||||||2008-06-02|2008-06-04|Estimate|February 1998||1998-02-28|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Phase I/II Pilot Study of Induction Chemotherapy With Docetaxel in Combination With Cisplatin and 5-Fluorouracil (5-FU) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 1/Phase 2|38||Dana-Farber Cancer Institute|||||||||||||||||||2018-06-01 04:47:20.598789|2018-06-01 04:47:20.598789
NCT00139256|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-11-25|2005-08-30|2005-08-31|Estimate|||||||2013-11-25|2013-11-27|Estimate|August 2005||2005-08-31|November 2013|2013-11-30|September 2007|Actual|2007-09-30|April 2007|Actual|2007-04-30||Interventional|||Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section|Randomized Controlled Trial of Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section|Terminated||Phase 2/Phase 3|67|Actual|Emory University||2||Slow enrollment and lack of funds.|f||||f||||||||||2018-06-01 04:47:20.732422|2018-06-01 04:47:20.732422
NCT00139243|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-06-02|2005-08-29|2005-08-31|Estimate|||||||2008-06-02|2008-06-04|Estimate|October 1997||1997-10-31|June 2008|2008-06-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Study of Taxotere, Cisplatin, 5-Fluorouracil and Leucovorin for Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1/Phase 2|30||Dana-Farber Cancer Institute|||||||||||||||||||2018-06-01 04:47:21.009165|2018-06-01 04:47:21.009165
NCT00139230|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-06-02|2005-08-30|2005-08-31|Estimate|||||||2008-06-02|2008-06-03|Estimate|January 1997||1997-01-31|June 2008|2008-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma|Completed||Phase 2|30||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:47:21.248047|2018-06-01 04:47:21.248047
NCT00139217|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2014-05-27|2005-08-30|2005-08-31|Estimate|||||||2014-05-27|2014-05-29|Estimate|August 2005||2005-08-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn|NO Need to Ventilate: A Trial of Non-invasive iNO in Persistent Pulmonary Hypertension of the Newborn|Completed||N/A|400|Anticipated|Emory University|||||f||||t||||||||||2018-06-01 04:47:21.407357|2018-06-01 04:47:21.407357
NCT00139204|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2009-10-30|2005-08-29|2005-08-31|Estimate|||||||2009-10-30|2009-11-02|Estimate|April 2005||2005-04-30|October 2009|2009-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine in Prostate Cancer Patients|An Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine (C11 MET) in Prostate Cancer, as Assessed by Positron Emission Tomography (PET)|Completed||N/A|20||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:47:21.521362|2018-06-01 04:47:21.521362
NCT00139191|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2009-10-30|2005-08-29|2005-08-31|Estimate|||||||2009-10-30|2009-11-02|Estimate|July 2005||2005-07-31|October 2009|2009-10-31|May 2006|Actual|2006-05-31|||||Interventional|||Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer|A Pilot Study Evaluating the Correlation Between Carbon 11 Acetate (C-11 Acetate) Uptake and Retention as Measured by Positron Emission Tomography (PET) and Fatty Acid Synthase (FAS) Expression in Prostate Cancer|Completed||N/A|20||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:47:21.602278|2018-06-01 04:47:21.602278
NCT00139178|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-30|||2005-09-02|2005-08-30|2005-08-31|Estimate|||||||2005-09-02|2005-09-05|Estimate|March 2004||2004-03-31|August 2005|2005-08-31|April 2007||2007-04-30|||||Interventional|||Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.|Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities|Completed||Phase 4|100||Danish HIV Research Group|||||f||||||||||||||2018-06-01 04:47:21.68237|2018-06-01 04:47:21.68237
NCT00139165|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-03-03|2005-08-29|2005-08-31|Estimate|||||||2008-03-03|2008-03-06|Estimate|September 2004||2004-09-30|August 2005|2005-08-31|March 2006||2006-03-31|||||Interventional|||Long-Term Treatment of Collagenous Colitis With Budesonide|Long-Term Treatment of Collagenous Colitis With Budesonide. Prospective, Doubleblind Placebo-Controlled Trial.|Unknown status|Active, not recruiting|Phase 3|36||Bonderup, Ole K., M.D.|||||f||||t||||||||||2018-06-01 04:47:21.749133|2018-06-01 04:47:21.749133
NCT00139152|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2014-01-06|2005-08-29|2005-08-31|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2005||2005-09-30|January 2014|2014-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair|Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair|Completed||Phase 4|65|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 04:47:21.816166|2018-06-01 04:47:21.816166
NCT00139139|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-08-29|2005-08-29|2005-08-31|Estimate|||||||2005-08-29|2005-08-31|Estimate|September 2003||2003-09-30|August 2005|2005-08-31|May 2005||2005-05-31|||||Interventional|||A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A|A Blinded Randomized Comparative Study of Hepatitis A Vaccine and Immune Globulin for Postexposure Prophylaxis for Hepatitis A Disease|Completed||N/A|1500||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:21.892505|2018-06-01 04:47:21.892505
NCT00139126|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2012-03-13|2005-08-29|2005-08-31|Estimate|||||||2012-03-13|2012-03-14|Estimate|August 2005||2005-08-31|March 2012|2012-03-31||||May 2008|Actual|2008-05-31||Interventional|||Research to Improve Smoke Alarm Functioning and Maintenance|Research to Improve Smoke Alarm Functioning and Maintenance|Completed||N/A|4500|Actual|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:22.002595|2018-06-01 04:47:22.002595
NCT00139113|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2012-08-29|2005-08-29|2005-08-31|Estimate|||||||2012-08-29|2012-08-30|Estimate|September 1996||1996-09-30|August 2012|2012-08-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children|Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children|Completed||Phase 4|248|Actual|Centers for Disease Control and Prevention||6|||f||||t||||||||||2018-06-01 04:47:22.141524|2018-06-01 04:47:22.141524
NCT00139100|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-10-23|2005-08-29|2005-08-31|Estimate|||||||2008-10-23|2008-10-24|Estimate|February 2001||2001-02-28|August 2005|2005-08-31|March 2002||2002-03-31|||||Interventional|||Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area|Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis|Completed||N/A|200||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:22.356449|2018-06-01 04:47:22.356449
NCT00139087|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-08-29|2005-08-29|2005-08-31|Estimate|||||||2005-08-29|2005-08-31|Estimate|January 2002||2002-01-31|August 2005|2005-08-31|March 2005||2005-03-31|||||Interventional|||Mother-Infant Rapid Intervention at Delivery Telephone Outreach for Neonatal Therapy (TOT) Trial.|Mother-Infant Rapid Intervention at Delivery Telephone Outreach for Neonatal Therapy (TOT) Trial.|Completed||N/A|300||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:22.476582|2018-06-01 04:47:22.476582
NCT00139074|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-01-25|2005-08-29|2005-08-31|Estimate|||||||2013-01-25|2013-01-28|Estimate|July 2005||2005-07-31|January 2013|2013-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients|Phase IV Study to Investigate if Valproate Add-on Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients|Terminated||Phase 4|17|Actual|AstraZeneca||2||terminated due to very low recruitment rate (27 June 2006)|f||||f||||||||||2018-06-01 04:47:22.688937|2018-06-01 04:47:22.688937
NCT00139061|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-10-30|2005-08-26|2005-08-30|Estimate|||||||2007-10-30|2007-10-31|Estimate|March 2005||2005-03-31|December 2006|2006-12-31|May 2006||2006-05-31|||||Interventional|||Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate|Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Forced Titration Study Of The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Compared To Fenofibrate In Subjects With Fredrickson Type IIB Dyslipidemia (Mixed Hyperlipidemia|Completed||Phase 3|128||Pfizer|||||||||||||||||||2018-06-01 04:47:22.841488|2018-06-01 04:47:22.841488
NCT00139048|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-28|||2017-05-02|2005-08-28|2005-08-30|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2005||2005-09-30|May 2017|2017-05-31|February 2007|Actual|2007-02-28|||||Interventional|||Australian Screening Mammography Decision Aid Trial: A Decision Aid for Women Aged 40 Thinking About Starting Mammography Screening|A Randomised Controlled Trial of an On-line Decision Aid for Women Aged 40 Considering Whether to Have Screening Mammograms to Evaluate the Change in Knowledge Regarding Mammography Screening.|Completed||N/A|200||University of Sydney|||||f||||||||||||||2018-06-01 04:47:22.97108|2018-06-01 04:47:22.97108
NCT00139035|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2012-10-31|2005-08-29|2005-08-30|Estimate|||||||2012-10-31|2012-11-02|Estimate|April 2005||2005-04-30|October 2012|2012-10-31||||January 2006|Actual|2006-01-31||Interventional|||Effects of Cyclosporine A on Pancreatic Insulin Secretion|Effects of Cyclosporine A on Pancreatic Insulin Secretion|Completed||Phase 4|16||University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:47:23.091256|2018-06-01 04:47:23.091256
NCT00139022|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-10-04|2005-08-26|2005-08-30|Estimate|||||||2007-10-04|2007-10-10|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|June 2007|Actual|2007-06-30|||||Interventional|||Home Diagnosis and Treatment of Obstructive Sleep Apnea|Can Obstructive Sleep Apnea be Diagnosed at Home? A Randomised Trial of Home vs.in-Lab Diagnosis and Treatment of OSA.|Completed||N/A|50|Anticipated|University of Saskatchewan|||||f||||||||||||||2018-06-01 04:47:23.24408|2018-06-01 04:47:23.24408
NCT00139009|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-06-14|2005-08-29|2005-08-30|Estimate|||||||2007-06-14|2007-06-15|Estimate|June 2005||2005-06-30|September 2006|2006-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation||Completed||Phase 4|30||University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:47:23.37944|2018-06-01 04:47:23.37944
NCT00138996|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-08-24|2005-08-29|2005-08-30|Estimate|||||||2007-08-24|2007-08-27|Estimate|March 2002||2002-03-31|August 2007|2007-08-31|June 2006|Actual|2006-06-30|||||Interventional|||Quality of Cardiopulmonary Resuscitation Without and With Defibrillator Feedback|Can the Quality of Cardiopulmonary Resuscitation Improve With Direct Online Feedback From the Defibrillator to the Rescuers on Their Resuscitation Efforts|Completed||Phase 2|300||University of Oslo|||||f||||f||||||||||2018-06-01 04:47:23.543563|2018-06-01 04:47:23.543563
NCT00138983|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2006-11-28|2005-08-29|2005-08-30|Estimate|||||||2006-11-28|2006-11-29|Estimate|May 2000||2000-05-31|March 2000|2000-03-31|November 2003||2003-11-30|||||Interventional|||Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.|Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.|Completed||Phase 3|200||UMC Utrecht|||||f||||||||||||||2018-06-01 04:47:23.759979|2018-06-01 04:47:23.759979
NCT00138970|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-11-30|2005-08-29|2005-08-30|Estimate|||||||2005-11-30|2005-12-01|Estimate|January 2002||2002-01-31|August 2005|2005-08-31|February 2005||2005-02-28|||||Interventional|||Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk|Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of Renal Function and Acute Rejection in 0 DR Mis-Matched Renal Allograft Recipients|Completed||Phase 4|70||University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:47:23.941357|2018-06-01 04:47:23.941357
NCT00138957|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-07-09|2005-08-29|2005-08-30|Estimate|||||||2008-07-09|2008-07-11|Estimate|September 2005||2005-09-30|July 2008|2008-07-31|December 2007|Anticipated|2007-12-31|||||Interventional|||Study of a New Laparoscopic Technique for Parastomal Hernia Repair With Mesh|Laparoscopic Parastomal Hernia Repair Using an Innovative Composite Polypropylene Mesh - A Prospective Study|Withdrawn||N/A|20|Anticipated|University Hospital, Gentofte, Copenhagen||||too few patients included|f||||||||||||||2018-06-01 04:47:24.203005|2018-06-01 04:47:24.203005
NCT00138944|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-04-16|2005-08-29|2005-08-30|Estimate|||||||2013-04-16|2013-04-17|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension|Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension|Completed||Phase 3|85|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-06-01 04:47:24.377236|2018-06-01 04:47:24.377236
NCT00138931|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-08-23|2005-08-29|2005-08-30|Estimate|||||||2016-08-23|2016-08-24|Estimate|September 1996||1996-09-30|August 2016|2016-08-31||||January 2025|Anticipated|2025-01-31||Observational|||Genetics of Cardiovascular and Neuromuscular Disease|Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.|Recruiting|||2000|Anticipated|University of Chicago|||||f||||f||||||||||2018-06-01 04:47:24.55444|2018-06-01 04:47:24.55444
NCT00138918|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2017-03-01|2005-08-26|2005-08-30|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2005||2005-06-30|March 2017|2017-03-31|May 13, 2008|Actual|2008-05-13|May 13, 2008|Actual|2008-05-13||Interventional|||Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer|A Phase II Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer|Completed||Phase 2|20|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:47:24.769115|2018-06-01 04:47:24.769115
NCT00138905|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-09-06|2005-08-29|2005-08-30|Estimate|||||||2007-09-06|2007-09-10|Estimate|February 2005||2005-02-28|September 2007|2007-09-30|April 2006|Actual|2006-04-30|||||Interventional|||Experimental Study of Mobile Base Station Related Radio-Frequency Electromagnetic Radiation|Experimental Study of Mobile Base Station Related Radio-Frequency Electromagnetic Radiation in Healthy Adults and Adolescents|Completed||Phase 4|80||University of Aarhus|||||f||||||||||||||2018-06-01 04:47:24.950946|2018-06-01 04:47:24.950946
NCT00138892|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2011-10-12|2005-08-26|2005-08-30|Estimate|||||||2011-10-12|2011-10-14|Estimate|August 2002||2002-08-31|October 2011|2011-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty|A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty|Unknown status|Active, not recruiting|Phase 4|236|Anticipated|University of British Columbia|||||f||||f||||||||||2018-06-01 04:47:25.096538|2018-06-01 04:47:25.096538
NCT00138879|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-12-14|2005-08-29|2005-08-30|Estimate|||||||2005-12-14|2005-12-15|Estimate|May 2003||2003-05-31|August 2005|2005-08-31|June 2005||2005-06-30|||||Observational|||Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients|Plasma Citrulline Level: A Simple, Sensitive Method to Assess and Monitor Small Bowel Absorptive Function in Patients With Crohn's Disease?|Completed|||54||St Mark's Hospital Foundation|||||f||||||||||||||2018-06-01 04:47:25.165853|2018-06-01 04:47:25.165853
NCT00138866|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2010-10-12|2005-08-29|2005-08-30|Estimate|||||||2010-10-12|2010-10-13|Estimate|November 2004||2004-11-30|July 2008|2008-07-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Interventional|||Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury|Risedronate for Treatment of Sublesional Osteoporosis After Spinal Cord Injury|Completed||Phase 3|46|Anticipated|Toronto Rehabilitation Institute|||||f||||t||||||||||2018-06-01 04:47:25.288456|2018-06-01 04:47:25.288456
NCT00138853|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2010-10-12|2005-08-29|2005-08-30|Estimate|||||||2010-10-12|2010-10-13|Estimate|November 2003||2003-11-30|October 2010|2010-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|Ti-Tan||A Roentgen Stereophotogrammetric Analysis on Migration of Knee Prostheses.|A Roentgen Stereophotogrammetric Analysis on Migration of Knee Prostheses. A Randomised Prospective Study of Tantalum Versus Titanium Implants.|Completed||N/A|50|Actual|University of Aarhus||2|||f||||t||||||||||2018-06-01 04:47:25.423342|2018-06-01 04:47:25.423342
NCT00138840|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2008-12-03|2005-08-26|2005-08-30|Estimate|||||||2008-12-03|2008-12-04|Estimate|August 2005||2005-08-31|December 2008|2008-12-31||||||||Interventional|||Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease|Completed||Phase 2|282||Synta Pharmaceuticals Corp.|||||||||||||||||||2018-06-01 04:47:25.520863|2018-06-01 04:47:25.520863
NCT00138827|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-12-14|2005-08-29|2005-08-30|Estimate|||||||2005-12-14|2005-12-15|Estimate|November 1999||1999-11-30|May 1998|1998-05-31|March 2003||2003-03-31|||||Interventional|||Mouth Care Regimes During Radiotherapy|A Pilot Randomised Comparison of Bicarbonate Based Mouth Care Versus Biotene Based Mouth Care During Radiotherapy|Completed||Phase 4|50||St George Hospital, Australia|||||f||||||||||||||2018-06-01 04:47:25.652851|2018-06-01 04:47:25.652851
NCT00138814|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-12-14|2005-08-29|2005-08-30|Estimate|||||||2005-12-14|2005-12-15|Estimate|January 1997||1997-01-31|September 2005|2005-09-30|December 2015||2015-12-31|||||Interventional|||Boost Use in Breast Conservation Radiotherapy|A Randomised Comparison of Breast Conservation With or Without Lumpectomy Radiotherapy Boost|Unknown status|Recruiting|Phase 3|680||St George Hospital, Australia|||||f||||||||||||||2018-06-01 04:47:25.756689|2018-06-01 04:47:25.756689
NCT00138801|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2010-02-04|2005-08-29|2005-08-30|Estimate|||||||2010-02-04|2010-02-05|Estimate|March 2004||2004-03-31|March 2005|2005-03-31|December 2008|Actual|2008-12-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis|Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison|Completed||Phase 3|||Sorlandet Hospital HF|||||f||||f||||||||||2018-06-01 04:47:25.84686|2018-06-01 04:47:25.84686
NCT00138788|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-11-19|2005-08-29|2005-08-30|Estimate|||||||2008-11-19|2008-11-20|Estimate|February 1996||1996-02-29|November 2008|2008-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Brain Metastases Study: Radiotherapy Fractionation Schemes in the Treatment of Brain Metastases|To Determine Which of Two Radiotherapy Brain Fractionation Schemes is Superior in the Treatment of Brain Metastases|Completed||Phase 3|112|Anticipated|St George Hospital, Australia|||||f||||||||||||||2018-06-01 04:47:25.897189|2018-06-01 04:47:25.897189
NCT00138775|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-28|||2006-12-24|2005-08-28|2005-08-30|Estimate|||||||2006-12-24|2006-12-27|Estimate|October 2004||2004-10-31|October 2006|2006-10-31|October 2007||2007-10-31|||||Interventional|||Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia|D-Serine Adjuvant Pharmacotherapy for the Treatment of Schizophrenia|Unknown status|Recruiting|Phase 2|200||Sheba Medical Center|||||f||||||||||||||2018-06-01 04:47:25.975433|2018-06-01 04:47:25.975433
NCT00138762|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26||2012-02-15|2012-02-15|2005-08-26|2005-08-30|Estimate||||2012-02-15|2012-02-17|Estimate|2012-02-15|2012-02-17|Estimate|July 2004||2004-07-31|February 2012|2012-02-29|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol|A Phase 3, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally Once Daily for 6 Months, Compared to Atorvastatin Alone or Placebo in Subjects With Mixed Dyslipidemia (Fredrickson Types IIa and IIb).|Completed||Phase 3|3800||Pfizer|||||f||||||||||||||2018-06-01 04:47:26.143374|2018-06-01 04:47:26.143374
NCT00138749|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2011-04-06|2005-08-26|2005-08-30|Estimate|||||||2011-04-06|2011-04-07|Estimate|November 2004||2004-11-30|April 2011|2011-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.|An 8-Week, Multi-Centre,Randomised Double-Blind, Placebo Controlled, Parallel Group Study To Evaluate The Efficacy,Toleration And Safety Of (+)- [S,S]- Reboxetine In The Treatment Of Stress Urinary Incontinence (SUI) In Women.|Completed||Phase 2|402||Pfizer|||||f||||||||||||||2018-06-01 04:47:26.552063|2018-06-01 04:47:26.552063
NCT00138736|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-08-29|2005-08-29|2005-08-30|Estimate|||||||2007-08-29|2007-08-30|Estimate|April 2004||2004-04-30|August 2007|2007-08-31|October 2006|Actual|2006-10-31|||||Interventional|||Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia|Phase II Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia|Completed||Phase 2|12|Actual|Sanquin||1|||f||||f||||||||||2018-06-01 04:47:26.885406|2018-06-01 04:47:26.885406
NCT00138723|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2008-04-09|2005-08-29|2005-08-30|Estimate|||||||2008-04-09|2008-04-10|Estimate|October 2003||2003-10-31|March 2008|2008-03-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome|A Phase 3, Parallel Group, Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome|Completed||Phase 3|||Pfizer|||||||||||||||||||2018-06-01 04:47:27.086738|2018-06-01 04:47:27.086738
NCT00138710|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2010-10-21|2005-08-29|2005-08-30|Estimate|||||||2010-10-21|2010-10-22|Estimate|August 2005||2005-08-31|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Short-term Effects of Aromatase Inhibition in Obese Men|Short-term Effects of Aromatase Inhibition in Obese Men|Completed||Phase 3|50|Anticipated|Rijnstate Hospital|||||f||||||||||||||2018-06-01 04:47:27.24692|2018-06-01 04:47:27.24692
NCT00138697|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-04-18|2005-08-29|2005-08-30|Estimate|||||||2007-04-18|2007-04-19|Estimate|May 2001||2001-05-31|April 2007|2007-04-30|December 2004|Actual|2004-12-31|||||Interventional|||Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients|Kinetics, Efficacy and Safety of IVIG-L (Human Normal Intravenous Immunoglobulin for Intravenous Use) in Hypogammaglobulinemia Patients|Completed||Phase 2/Phase 3|15||Sanquin|||||f||||||||||||||2018-06-01 04:47:27.403656|2018-06-01 04:47:27.403656
NCT00138684|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2012-05-18|2005-08-29|2005-08-30|Estimate|||||||2012-05-18|2012-05-21|Estimate|September 2003||2003-09-30|May 2012|2012-05-31|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||Cytochrome P450 2E1 and Iron Overload|Cytochrome P450 2E1 and Iron Overload|Completed||Phase 2|50|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-06-01 04:47:27.532178|2018-06-01 04:47:27.532178
NCT00138671|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2009-09-02||2010-01-25|2005-08-26|2005-08-30|Estimate|2009-10-06|2009-11-13|Estimate||||2010-01-25|2010-02-02|Estimate|January 2003||2003-01-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD|Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial|Terminated||Phase 3|105|Actual|Pfizer|This study was terminated due to Pfizer's decision to stop marketing Exubera®. Due to inconsistency in concomitant medication data entry, interpretation of the event rates for non-severe exacerbations may be of limited clinical value.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:47:27.698011|2018-06-01 04:47:27.698011
NCT00138658|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2011-10-06||2012-02-02|2005-08-26|2005-08-30|Estimate|2011-12-01|2012-01-10|Estimate||||2012-02-02|2012-02-06|Estimate|November 2004||2004-11-30|February 2012|2012-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Phase 1-2 Study of Weekly OGX-011 Plus a Gemcitabine/Platinum-Based Regimen in Patients With Stage IIIB or IV Non Small Cell Lung Cancer|Completed||Phase 1/Phase 2|85|Actual|Achieve Life Sciences|||||f||||f||||||||||2018-06-01 04:47:29.490101|2018-06-01 04:47:29.490101
NCT00138645|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2009-04-21||2016-01-15|2005-08-29|2005-08-30|Estimate|2009-04-21|2009-06-10|Estimate||||2016-01-15|2016-02-08|Estimate|April 2005||2005-04-30|January 2016|2016-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|FORMULA||The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet|The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet|Completed||Phase 4|60|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-06-01 04:47:29.995529|2018-06-01 04:47:29.995529
NCT00138632|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2008-11-12|2005-08-29|2005-08-30|Estimate|||||||2008-11-12|2008-11-14|Estimate|September 2005||2005-09-30|November 2008|2008-11-30||||November 2007|Actual|2007-11-30||Interventional|ADVANCE||Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)|A Randomized, Double-Masked, Multicenter, Phase I/II Study of the Safety of PTK787 Administered to Patients With Predominantly Classic , Minimally Classic or Occult With no Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|Completed||Phase 1/Phase 2|50|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:47:31.216533|2018-06-01 04:47:31.216533
NCT00138619|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2012-05-04|2005-08-27|2005-08-30|Estimate|||||||2012-05-04|2012-05-07|Estimate|November 2004||2004-11-30|May 2012|2012-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|478|Actual|Novartis|||||f||||||||||||||2018-06-01 04:47:31.362775|2018-06-01 04:47:31.362775
NCT00138606|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2016-11-16|2005-08-27|2005-08-30|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes|Completed||Phase 3|179|Actual|Novartis|||||f||||||||||||||2018-06-01 04:47:31.455863|2018-06-01 04:47:31.455863
NCT00138593|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2017-02-28|2005-08-27|2005-08-30|Estimate|||||||2017-02-28|2017-03-01|Actual|July 2004||2004-07-31|February 2017|2017-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%|Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%|Completed||Phase 3|180||Novartis|||||f||||||||||||||2018-06-01 04:47:31.584031|2018-06-01 04:47:31.584031
NCT00138580|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2017-02-28|2005-08-27|2005-08-30|Estimate|||||||2017-02-28|2017-03-01|Actual|November 2004||2004-11-30|February 2017|2017-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes|Completed||Phase 3|345||Novartis|||||f||||||||||||||2018-06-01 04:47:31.706155|2018-06-01 04:47:31.706155
NCT00138567|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2016-11-16|2005-08-27|2005-08-30|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|530||Novartis|||||f||||||||||||||2018-06-01 04:47:31.868374|2018-06-01 04:47:31.868374
NCT00138554|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2017-02-21|2005-08-27|2005-08-30|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2004||2004-11-30|February 2017|2017-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes|Completed||Phase 3|318|Actual|Novartis||2|||||||||||||||||2018-06-01 04:47:32.00519|2018-06-01 04:47:32.00519
NCT00138541|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2017-02-28|2005-08-27|2005-08-30|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2004||2004-10-31|February 2017|2017-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes|Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes|Completed||Phase 3|440|Actual|Novartis|||||f||||||||||||||2018-06-01 04:47:32.253061|2018-06-01 04:47:32.253061
NCT00138528|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2017-02-20|2005-08-25|2005-08-30|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2004||2004-10-31|February 2017|2017-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome|Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome|Completed||Phase 4|55|Actual|Novartis|||||f||||||||||||||2018-06-01 04:47:32.424847|2018-06-01 04:47:32.424847
NCT00138515|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2017-02-28|2005-08-27|2005-08-30|Estimate|||||||2017-02-28|2017-03-01|Actual|November 2004||2004-11-30|February 2017|2017-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes|Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes|Completed||Phase 3|418|Actual|Novartis|||||f||||||||||||||2018-06-01 04:47:32.557211|2018-06-01 04:47:32.557211
NCT00138502|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2001||2001-09-30|October 2007|2007-10-31|April 2005||2005-04-30|||||Observational|||Funguria in Hospitalized Patients|The Significance of Funguria In Hospitalized Patients|Unknown status|Active, not recruiting||926||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:32.702265|2018-06-01 04:47:32.702265
NCT00138489|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|January 2004||2004-01-31|October 2007|2007-10-31||||||||Observational|||Papua New Guinean Duffy Negativity And Vivax Malar|Protocol 3B Susceptibility to Plasmodium Vivax Infection and Malaria During Early Childhood|Suspended|||266||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:32.820378|2018-06-01 04:47:32.820378
NCT00138476|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2014-05-08|2005-08-26|2005-08-30|Estimate|||||||2014-05-08|2014-05-09|Estimate|August 2004||2004-08-31|April 2012|2012-04-30|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|||New Challenge Pool of Norwalk Virus Inoculum|Evaluation of a New Challenge Pool of Norwalk Virus Inoculum (Lot 42399) in Human Subjects|Completed||Phase 1|57|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 04:47:33.005565|2018-06-01 04:47:33.005565
NCT00138463|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2011-11-03|2005-08-26|2005-08-30|Estimate|||||||2011-11-03|2011-11-07|Estimate|September 2003||2003-09-30|February 2010|2010-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||West Nile Virus Natural History|Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease|Completed|||30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Cerebrospinal fluid, urine, serum.~   "|||2018-06-01 04:47:33.182284|2018-06-01 04:47:33.182284
NCT00138450|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2007|2007-03-31|November 2004||2004-11-30|||||Observational|||Urinary Schistosomiasis Infection|Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease|Completed|||4400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:33.318959|2018-06-01 04:47:33.318959
NCT00138437|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2014-11-05|2005-08-26|2005-08-30|Estimate|||||||2014-11-05|2014-11-07|Estimate|April 2006||2006-04-30|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses|Molecular Epidemiology of Leprosy in Colombia|Completed|||1554|Actual|Colorado State University|||3||f||||f||||||Samples With DNA|"~     Blood, Nasal Swabs, Skin Biopsies and scrapings~   "|||2018-06-01 04:47:33.387261|2018-06-01 04:47:33.387261
NCT00138424|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2012-06-14|2011-09-22|2013-02-28|2005-08-26|2005-08-30|Estimate|2012-11-29|2013-01-07|Estimate|2011-09-22|2011-10-05|Estimate|2013-02-28|2013-03-08|Estimate|May 2006||2006-05-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|June 2010|Actual|2010-06-30||Interventional|||Cidofovir in Renal Transplant Recipients With BKVN|A Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Effect of Cidofovir in Renal Transplant Recipients With BK Virus Nephropathy|Terminated||Phase 1/Phase 2|22|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study closed early due to failure to enroll in a timely manner.|2|||f||||||||||||||2018-06-01 04:47:33.554954|2018-06-01 04:47:33.554954
NCT00138411|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2005||2005-10-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Monoclonal Antibody for Treatment of Inhalation Anthrax|Randomized, Placebo-Controlled, Double Blind, Dose-Escalation Phase I Study of the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 [Anthim(TM)] and Its Potential Interaction With Ciprofloxacin|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:47:35.15041|2018-06-01 04:47:35.15041
NCT00138398|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|October 2005||2005-10-31|October 2007|2007-10-31|October 2007||2007-10-31|||||Interventional|||T-cell Response-Flu Risk in Older Adults|T-cell Responses Predict Influenza Risk in Older Adults|Unknown status|Recruiting|N/A|850||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:35.227417|2018-06-01 04:47:35.227417
NCT00138385|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2005||2005-08-31|November 2007|2007-11-30|June 2007||2007-06-30|||||Interventional|||Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment|A Randomized Comparison of the Immune Response to Either Inactivated or Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age|Completed||Phase 4|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:35.305066|2018-06-01 04:47:35.305066
NCT00138372|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2008-09-30|2005-08-26|2005-08-30|Estimate|||||||2008-09-30|2008-10-02|Estimate||||September 2008|2008-09-30||||||||Observational|||Human Immunity to MSP-1 in Western Kenya|Human Immunity to MSP-1 in Western Kenya|Unknown status|Not yet recruiting||445||Case Western Reserve University|||||f||||f||||||||||2018-06-01 04:47:35.397391|2018-06-01 04:47:35.397391
NCT00138359|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|December 2004||2004-12-31|December 2006|2006-12-31|January 2005||2005-01-31|||||Interventional|||Mass Treatment T Solium Community Study|The Effect of a Single Control Intervention in the T Solium Life Cycle|Terminated||N/A|4200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:35.490054|2018-06-01 04:47:35.490054
NCT00138346|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2004||2004-08-31|December 2006|2006-12-31|April 2007||2007-04-30|||||Observational|||Epi Cystic Hydatid Disease Peru|Epidemiology of Human Cystic Hydatid Disease|Completed|||840||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:35.584226|2018-06-01 04:47:35.584226
NCT00138333|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2011-11-10|2005-08-29|2005-08-30|Estimate|||||||2011-11-10|2011-11-11|Estimate|December 2005||2005-12-31|October 2007|2007-10-31|November 2006||2006-11-30|||||Observational|||Mercury Levels in Premature and LBW Infants Receiving Thimerosal-containing Vaccines|Assessment of Mercury Levels and Metabolism in Premature and Low Birth Weight (LBW) Infants Receiving Vaccines Containing Thimerosal|Completed|||71|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:35.659432|2018-06-01 04:47:35.659432
NCT00138320|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2013-09-12|2005-08-26|2005-08-30|Estimate|||||||2013-09-12|2013-09-13|Estimate|August 2005||2005-08-31|August 2013|2013-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Herpevac Neonatal Substudy|Transfer of Herpes Simplex Virus Type 2 gD Subunit Vaccine-Induced Antibodies From Mothers to Neonates|Terminated|||6|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||Samples Without DNA|"~     Sera obtained from collected blood samples will be used. Ten mL of blood will be collected at~     the maternal blood draw and from the umbilical vein. Three to 5 mL of blood will be collected~     at each infant blood draw~   "|||2018-06-01 04:47:35.735264|2018-06-01 04:47:35.735264
NCT00138307|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2007|2007-03-31|March 2006||2006-03-31|||||Observational|||Correlates of Protection in Ghana|Immunological Correlates of Protection Against Clinical Malaria in a Cohort of Young Children in the Kassena Nankana District of Ghana|Completed|||300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:35.826752|2018-06-01 04:47:35.826752
NCT00138294|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2016-02-01||2017-05-16|2005-08-26|2005-08-30|Estimate|2017-05-16|2017-05-19|Actual||||2017-05-16|2017-05-19|Actual|October 1998|Actual|1998-10-31|May 2017|2017-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|CEI||Control of Epidemic Influenza Through a School-based Influenza Vaccination Program|Phase 4, School-based, Open-labeled Research Trial for Control of Epidemic Influenza Through a School-based Influenza Vaccination Program in Central Texas.|Completed||Phase 4|29255|Actual|Baylor College of Medicine||2|||f||||t|t|f|||f|||No||2018-06-01 04:47:36.013554|2018-06-01 04:47:36.013554
NCT00138281|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2010|2010-03-31|January 2006|Actual|2006-01-31|November 2005|Actual|2005-11-30||Interventional|||Influenza Immunity Against Pandemic Respiratory Virus|Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus|Completed||Phase 4|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:36.41352|2018-06-01 04:47:36.41352
NCT00138268|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate||||October 2007|2007-10-31|February 2005||2005-02-28|||||Observational|||Pilot Study Freeze and Transport Immune Cells|Pilot Study to Optimize and Standardize Umbilical Cord Blood Collection and the Isolation, Freezing and Transportation of Cells for Studies of Cellular Immune Responses to Immunization|Completed|||12||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:47:36.534069|2018-06-01 04:47:36.534069
NCT00138255|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-08-26|2005-08-26|2005-08-30|Estimate|||||||2010-08-26|2010-08-27|Estimate|June 2004||2004-06-30|May 2005|2005-05-31|June 2005||2005-06-30|||||Observational|||Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines|MMR and Varicella Vaccine Responses in Extremely Premature Infants|Terminated|||32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:47:36.658898|2018-06-01 04:47:36.658898
NCT00138242|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-06-25|2005-08-29|2005-08-30|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 2004||2004-12-31|October 2006|2006-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer|Phase II Trial of Weekly Docetaxel (Taxotere®) and Carboplatin as Initial Chemotherapy for Women With Ovarian Cancer and Similar Malignancies|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:47:36.714064|2018-06-01 04:47:36.714064
NCT00138229|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2012-03-28|2005-08-29|2005-08-30|Estimate|||||||2012-03-28|2012-03-29|Estimate|July 2005||2005-07-31|March 2012|2012-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma|Phase II Trial Using Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy and Reinfusion of Autologous Lymphocytes Depleted of T Regulatory Lymphocytes in Metastatic Melanoma|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 04:47:36.853969|2018-06-01 04:47:36.853969
NCT00138216|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2014-02-18|2005-08-29|2005-08-30|Estimate|||||||2014-02-18|2014-02-20|Estimate|October 2005||2005-10-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|June 2009|Actual|2009-06-30||Interventional|||Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors|A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid Tumors|Completed||Phase 1|42|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 04:47:36.968843|2018-06-01 04:47:36.968843
NCT00138203|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2013-02-13||2018-01-03|2005-08-29|2005-08-30|Estimate|2014-04-25|2014-05-21|Estimate||||2018-01-03|2018-01-30|Actual|June 2005||2005-06-30|January 2018|2018-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:47:37.145463|2018-06-01 04:47:37.145463
NCT00138177|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-09-27|2005-08-29|2005-08-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|July 2005||2005-07-31|September 2013|2013-09-30||||August 2011|Actual|2011-08-31||Interventional|||Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors|Completed||Phase 1|54|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:47:37.570341|2018-06-01 04:47:37.570341
NCT00138164|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-05-29|2005-08-29|2005-08-30|Estimate|||||||2013-05-29|2013-05-30|Estimate|December 2004||2004-12-31|November 2008|2008-11-30|November 2008|Actual|2008-11-30|February 2006|Actual|2006-02-28||Interventional|||Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Multicenter Study of Ontak® (Denileukin Diftitox) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:47:37.716882|2018-06-01 04:47:37.716882
NCT00138151|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2013-09-17||2013-09-17|2005-08-29|2005-08-30|Estimate|2013-09-17|2013-11-20|Estimate||||2013-09-17|2013-11-20|Estimate|March 2001||2001-03-31|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer|A Phase II Trial of Chemosensitization With Paclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma|Terminated||Phase 2|33|Actual|Rutgers, The State University of New Jersey||1||Slow accrual and lack of study drug|f||||f||||||||||2018-06-01 04:47:37.876992|2018-06-01 04:47:37.876992
NCT00138138|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-12-06|2005-08-29|2005-08-30|Estimate|||||||2007-12-06|2007-12-10|Estimate|October 2002||2002-10-31|December 2007|2007-12-31|August 2006|Actual|2006-08-31|||||Interventional|||Psychostimulants for Fatigue in Prostate Cancer|Psychostimulants for Fatigue in Advanced Prostate Cancer|Completed||Phase 2|120||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:47:38.277768|2018-06-01 04:47:38.277768
NCT00138125|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2013-01-08||2018-01-05|2005-08-29|2005-08-30|Estimate|2013-01-08|2013-02-11|Estimate||||2018-01-05|2018-01-30|Actual|April 2005||2005-04-30|January 2013|2013-01-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer|Phase II Randomized Trial of Faslodex and Herceptin, Alone and Combined, in the First - Line Treatment of Hormone Receptor-Positive, HER-2/Neu-Overexpressing Metastatic Breast Cancer|Terminated||Phase 2|2|Actual|Translational Oncology Research International|Trial terminated due to slow patient accrual.Study closed with two subjects enrolled to treatment phase.Slow accrual was due to specific requirements of study population limiting enrollment and possibly due to availability of study drugs in clinic.|1||Due to low accrual|f||||t||||||||||2018-06-01 04:47:38.420105|2018-06-01 04:47:38.420105
NCT00138112|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2006-09-07|2005-08-29|2005-08-30|Estimate|||||||2006-09-07|2006-09-08|Estimate|November 2003||2003-11-30|September 2006|2006-09-30|November 2005||2005-11-30|||||Interventional|||Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation|Randomized Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Early Viridans Streptococcal Sepsis After Hematopoietic Cell Transplantation|Completed||Phase 3|126||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:47:38.679719|2018-06-01 04:47:38.679719
NCT00138099|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-05-30|2005-08-29|2005-08-30|Estimate|||||||2007-05-30|2007-06-01|Estimate|July 2004||2004-07-31|November 2006|2006-11-30|June 2006|Actual|2006-06-30|||||Observational|||Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)|Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)|Completed|||140|Actual|McMaster University|||||f||||t||||||||||2018-06-01 04:47:38.77431|2018-06-01 04:47:38.77431
NCT00138086|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2006-09-06|2005-08-29|2005-08-30|Estimate|||||||2006-09-06|2006-09-08|Estimate|March 2005||2005-03-31|September 2006|2006-09-30|March 2009||2009-03-31|||||Interventional|||Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma|Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Transplantation (ASCT)|Completed||Phase 2|75||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:47:38.894224|2018-06-01 04:47:38.894224
NCT00138073|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2014-03-24||2014-05-29|2005-08-29|2005-08-30|Estimate|2014-05-29|2014-06-30|Estimate||||2014-05-29|2014-06-30|Estimate|December 2005||2005-12-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effectiveness of a Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation|Effectiveness of a Web-Based Computer Application in Improving Pulmonary Artery Catheter Waveform Interpretation Among Nurses and Physicians|Terminated||N/A|55|Actual|Massachusetts General Hospital|Study not completed.|1||The study was terminated because of lack of resources to complete it.|f||||t||||||||||2018-06-01 04:47:39.022738|2018-06-01 04:47:39.022738
NCT00138060|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-07-19|2005-08-26|2005-08-30|Estimate|||||||2010-07-19|2010-07-20|Estimate|June 2005||2005-06-30|July 2010|2010-07-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants|Protocole Evaluant Chez Des Patients Porteurs de Cancers Colorectaux Metastatiques l'Interet Des Determinants Genotypiques Pour l'Optimisation de l'Efficacite et de la Tolerance de la Chimiotherapie Par Irinotecan et 5-fluorouracile|Completed||Phase 4|71|Actual|Institut de Recherche Clinique sur les Cancers et le Sang|||||f||||f||||||||||2018-06-01 04:47:39.227559|2018-06-01 04:47:39.227559
NCT00138047|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2005-12-02|2005-08-26|2005-08-30|Estimate|||||||2005-12-02|2005-12-05|Estimate|March 2003||2003-03-31|August 2005|2005-08-31|September 2004||2004-09-30|||||Interventional|||Safety and Efficacy of Zinc Supplementation in HIV-1-Infected Children in South Africa|Randomized, Double-Blind, Placebo-Controlled Trial of Zinc Supplementation in HIV-1-Infected Children|Completed||Phase 2|100||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:47:39.369024|2018-06-01 04:47:39.369024
NCT00138034|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|2012-02-20||2012-04-25|2005-08-29|2005-08-30|Estimate|2012-03-29|2012-04-19|Estimate||||2012-04-25|2012-04-30|Estimate|January 2005||2005-01-31|April 2012|2012-04-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3|A Multicenter Randomized Trial in the Prevention of Reocclusion Following Successful Thrombolysis for Suspected Acute Myocardial Infarction: An Invasive Versus a Conservative Strategy|Completed||Phase 4|49|Actual|Heartcenter, University Medical Center St. Radboud||2|||f||||f||||||||||2018-06-01 04:47:39.476063|2018-06-01 04:47:39.476063
NCT00138021|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-10-31|2005-08-29|2005-08-30|Estimate|||||||2007-10-31|2007-11-02|Estimate|July 2005||2005-07-31|October 2007|2007-10-31|May 2008|Anticipated|2008-05-31|||||Interventional|CT+SE||Cognitive Remediation in Supported Employment at Human Service Center (HSC)|Cognitive Remediation in Supported Employment at HSC|Unknown status|Active, not recruiting|N/A|50|Anticipated|Human Service Center, Illinois|||||f||||f||||||||||2018-06-01 04:47:39.824163|2018-06-01 04:47:39.824163
NCT00138008|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-09-20|2005-08-29|2005-08-30|Estimate|||||||2016-09-20|2016-09-22|Estimate|May 2004||2004-05-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy|Randomized Controlled Trial to Evaluate Radiotherapy Followed by Endocrine Therapy vs. Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy (JCOG0401)|Completed||Phase 3|200|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:47:39.930661|2018-06-01 04:47:39.930661
NCT00137995|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2017-03-09|2005-08-29|2005-08-30|Estimate|||||||2017-03-09|2017-03-13|Actual|June 2003||2003-06-30|March 2017|2017-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma|Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab|Completed||Phase 3|481|Actual|Lymphoma Study Association||2|||f||||t|f|f||||||No||2018-06-01 04:47:40.09943|2018-06-01 04:47:40.09943
NCT00137982|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2006-09-07|2005-08-29|2005-08-30|Estimate|||||||2006-09-07|2006-09-08|Estimate|August 2004||2004-08-31|August 2005|2005-08-31|July 2008||2008-07-31|||||Interventional|||Evaluation of Therapeutic Strategies for Treatment of Ectopic Pregnancies (EP) and Evaluation of Subsequent Fertility|Prospective Study, Randomized Controlled Trial Between Medical Treatment by Methotrexate Versus Conservative Surgical Treatment (Group 1) and Conservative Versus Radical Surgical Treatment (Group 2) to Evaluate Subsequent Fertility|Unknown status|Recruiting|Phase 4|600||Hopital Antoine Beclere|||||f||||||||||||||2018-06-01 04:47:40.242492|2018-06-01 04:47:40.242492
NCT00137969|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2009-06-05||2015-04-30|2005-08-26|2005-08-30|Estimate|2010-11-11|2010-12-10|Estimate||||2015-04-30|2015-05-19|Estimate|May 2005||2005-05-31|April 2015|2015-04-30||||August 2008|Actual|2008-08-31||Interventional|EXPLORER|Intent-to-treat population: All randomized participants who received any amount of study drug.|A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With Moderate to Severe Systemic Lupus Erythematosus|Completed||Phase 2/Phase 3|262|Actual|Genentech, Inc.||2|||f||||f||||||||||2018-06-01 04:47:40.584389|2018-06-01 04:47:40.584389
NCT00137956|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2009-08-14|2005-08-26|2005-08-30|Estimate|||||||2009-08-14|2009-08-18|Estimate|December 2004||2004-12-31|August 2009|2009-08-31||||||||Interventional|||Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study|Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study|Terminated||Phase 3|270||Emphasys Medical|||||||||||||||||||2018-06-01 04:47:41.503272|2018-06-01 04:47:41.503272
NCT00137943|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2012-09-26|2005-08-26|2005-08-30|Estimate|||||||2012-09-26|2012-09-27|Estimate|September 1999||1999-09-30|September 2012|2012-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Parents Matter!: Interventions to Promote Effective Parent-Child Communication|Parents Matter!: Interventions to Promote Effective Parent-Child Communication About Sex and Sexual Risk Among African American Families|Completed||Phase 1|2210||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:47:41.605638|2018-06-01 04:47:41.605638
NCT00137930|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-09-20|2005-08-29|2005-08-30|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2005||2005-08-31|September 2016|2016-09-30|November 2005|Actual|2005-11-30|||||Interventional|||Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis|Compare the Immunogenicity, Reactogenicity & Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV|Completed||Phase 2|250||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:47:41.707062|2018-06-01 04:47:41.707062
NCT00137917|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-09-15|2005-08-26|2005-08-30|Estimate|||||||2016-09-15|2016-09-16|Estimate|July 2002||2002-07-31|September 2016|2016-09-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs|A Primary Vaccination Study to Evaluate Immunogenicity, Safety and Reactogenicity of 3 Doses of GSK Biologicals/Finlay's Meningococcal B Candidate Vaccine Given Intramuscularly Using Either 0-2-4 Month or 0-1-6 Month Schedule to Healthy Subjects Aged 12-18 Years|Completed||Phase 2|478|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:47:41.871778|2018-06-01 04:47:41.871778
NCT00137904|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2006-02-08|2005-08-29|2005-08-30|Estimate|||||||2006-02-08|2006-02-09|Estimate||||August 2005|2005-08-31||||||||Observational|||Sleep Disorders in Patients With Multiple Sclerosis|Study of Sleep Disorders and Fatigue in Patients With Multiple Sclerosis|Unknown status|Recruiting||51||Groupe Hospitalier Pitie-Salpetriere|||||f||||||||||||||2018-06-01 04:47:41.96945|2018-06-01 04:47:41.96945
NCT00137891|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2015-03-17|2005-08-26|2005-08-30|Estimate|||||||2015-03-17|2015-03-18|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|August 2005||2005-08-31|||||Interventional|||Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone|Phase I Study Comparing Pharmacokinetics and Safety Profile of Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone|Completed||Phase 1|46||Sanofi|||||||||||||||||||2018-06-01 04:47:42.033151|2018-06-01 04:47:42.033151
NCT00137878|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2012-02-22|2005-08-26|2005-08-30|Estimate|||||||2012-02-22|2012-02-23|Estimate||||May 2011|2011-05-31||||||||Interventional|||TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer|A Phase II Randomized Trial Comparing TNFerade™ Biologic With Capecitabine and Radiation Therapy Followed by Surgical Resection Versus Capecitabine and Radiation Therapy Followed by Surgical Resection for the Treatment of Rectal Cancer|Completed||Phase 2|||GenVec|||||||||||||||||||2018-06-01 04:47:42.116331|2018-06-01 04:47:42.116331
NCT00137865|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2013-02-27|2005-08-29|2005-08-30|Estimate|||||||2013-02-27|2013-02-28|Estimate|August 2005||2005-08-31|February 2013|2013-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer|A Phase 1, Open Label, Dose Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intraperitoneal EGEN-001 in Patients With Recurrent Epithelial Ovarian Cancer|Terminated||Phase 1|18|Actual|EGEN, Inc.||1||"Sponsor decided to terminate the study early so they could begin a second dose-escalation study~   of EGEN-001 in combination with standard chemotherapy."|f||||||||||||||2018-06-01 04:47:42.180187|2018-06-01 04:47:42.180187
NCT00137852|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2017-09-18|2005-08-29|2005-08-30|Estimate|||||||2017-09-18|2017-09-20|Actual|January 2002||2002-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2004|Actual|2004-08-31||Interventional|||Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer|Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer|Completed||Phase 2|35|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 04:47:42.251215|2018-06-01 04:47:42.251215
NCT00137839|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-08-02|2005-08-29|2005-08-30|Estimate|||||||2016-08-02|2016-08-03|Estimate|October 2004||2004-10-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung|A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung|Active, not recruiting||Phase 2|75|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:47:42.361124|2018-06-01 04:47:42.361124
NCT00137826|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2011-12-23|2005-08-29|2005-08-30|Estimate|||||||2011-12-23|2011-12-26|Estimate|February 2004||2004-02-29|December 2011|2011-12-31|July 2009|Actual|2009-07-31|March 2007|Actual|2007-03-31||Interventional|||Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma|Phase II Study of Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Malignant Mesothelioma|Completed||Phase 2|37|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:47:42.431026|2018-06-01 04:47:42.431026
NCT00137813|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-05-09|2005-08-29|2005-08-30|Estimate|||||||2016-05-09|2016-05-10|Estimate|August 2004||2004-08-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|September 2006|Actual|2006-09-30||Interventional|||Avastin and Taxotere for Esophagogastric Cancer|Phase II Study of Bevacizumab and Docetaxel (AvaTax) in Metastatic Esophagogastric Cancer|Unknown status|Active, not recruiting|Phase 2|42|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:47:42.502152|2018-06-01 04:47:42.502152
NCT00137800|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2016-08-02|2005-08-29|2005-08-30|Estimate|||||||2016-08-02|2016-08-03|Estimate|February 2003||2003-02-28|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|May 2005|Actual|2005-05-31||Interventional|||Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients|A Phase II Study of OSI-774 (Tarceva) in Elderly Subjects With Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|80|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:47:42.566249|2018-06-01 04:47:42.566249
NCT00137787|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-28|||2008-11-11|2005-08-28|2005-08-30|Estimate|||||||2008-11-11|2008-11-13|Estimate|April 2005||2005-04-30|November 2008|2008-11-30|March 2010|Anticipated|2010-03-31|December 2009|Anticipated|2009-12-31||Interventional|||Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases|Randomized Controlled Trial Comparing Ciprofloxacin With Cefepime in Febrile Neutropenic Patients With Hematologic Diseases|Unknown status|Recruiting|Phase 3|200|Anticipated|Center for Supporting Hematology-Oncology Trials||2|||f||||t||||||||||2018-06-01 04:47:42.632246|2018-06-01 04:47:42.632246
NCT00137774|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2013-04-07|2005-08-26|2005-08-30|Estimate|||||||2013-04-07|2013-04-09|Estimate|November 2004||2004-11-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|July 2005|Actual|2005-07-31||Interventional|||Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors|A Phase II Study of Bevacizumab in Combination With Temozolomide in Patients With Advanced Neuroendocrine Tumors|Completed||Phase 2|34|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:47:42.757559|2018-06-01 04:47:42.757559
NCT00137761|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2009-10-30|2005-08-26|2005-08-30|Estimate|||||||2009-10-30|2009-11-02|Estimate|October 2004||2004-10-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|June 2007|Actual|2007-06-30||Interventional|||Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer|A Phase II Study of Docetaxel in Combination With ZD 1839 (IRESSA) in Previously Treated Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|32|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:47:42.830054|2018-06-01 04:47:42.830054
NCT00137748|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2010-06-08|2005-08-29|2005-08-30|Estimate|||||||2010-06-08|2010-06-10|Estimate|January 2001||2001-01-31|June 2010|2010-06-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients|Does Replacement With CMVIG in Hypogammaglobulinemic Patients Decrease the Rate of Opportunistic Infections and Chronic Rejection?|Completed||Phase 2/Phase 3|50|Anticipated|The Cleveland Clinic|||||f||||||||||||||2018-06-01 04:47:42.924542|2018-06-01 04:47:42.924542
NCT00137735|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-10-30|2005-08-29|2005-08-30|Estimate|||||||2007-10-30|2007-10-31|Estimate|October 2003||2003-10-31|October 2007|2007-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Gabapentin for Carpal Tunnel Syndrome|Gabapentin for Carpal Tunnel Syndrome: A Randomised Controlled Trial|Completed||Phase 3|150|Actual|Chinese University of Hong Kong||2|||f||||||||||||||2018-06-01 04:47:43.078654|2018-06-01 04:47:43.078654
NCT00137722|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2015-02-02|2005-08-29|2005-08-30|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2000||2000-01-31|December 2008|2008-12-31|August 2005||2005-08-31|||||Observational|||Outcomes From an Asthma Disease Management Program|Identification of Outcomes From an Asthma Disease Management Program|Completed|||||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:47:43.155137|2018-06-01 04:47:43.155137
NCT00137709|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2007-10-30|2005-08-29|2005-08-30|Estimate|||||||2007-10-30|2007-10-31|Estimate|November 2004||2004-11-30|October 2007|2007-10-31|July 2008|Anticipated|2008-07-31|||||Interventional|||Hormone Profiles in Adults With Newly Diagnosed Epilepsy|Hormone Profiles in Adults Treated With Valproate vs. Lamotrigine Monotherapy for Newly Diagnosed Epilepsy: A Prospective Randomised Study|Unknown status|Recruiting|Phase 4|80|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:47:43.260632|2018-06-01 04:47:43.260632
NCT00137696|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2005-12-12|2005-08-27|2005-08-30|Estimate|||||||2005-12-12|2005-12-13|Estimate|September 2002||2002-09-30|August 2005|2005-08-31|March 2005||2005-03-31|||||Interventional|||Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine|Immunogenicity of Inactivated Polio Vaccine in Puerto Rico; A Comparative Cohort Study of Two Vaccination Schedules|Completed||N/A|500||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:43.477753|2018-06-01 04:47:43.477753
NCT00137683|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2012-03-13|2005-08-27|2005-08-30|Estimate|||||||2012-03-13|2012-03-14|Estimate|September 2001||2001-09-30|March 2012|2012-03-31|March 2005||2005-03-31|||||Interventional|||Colorectal Cancer Control in Appalachian Churches|Colorectal Cancer Control in Appalachian Churches|Withdrawn||Phase 2/Phase 3|0|Actual|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:43.575363|2018-06-01 04:47:43.575363
NCT00137670|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-27|||2012-09-26|2005-08-27|2005-08-30|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2002||2002-04-30|September 2012|2012-09-30|March 2009|Actual|2009-03-31|March 2006|Actual|2006-03-31||Interventional|||Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients|Effectiveness of a Video-based Educational Intervention to Prevent Human Immunodeficiency Virus (HIV) and Sexually Transmitted Diseases (STDs) Among Patients Attending STD Clinics|Completed||N/A|45000||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:47:43.691741|2018-06-01 04:47:43.691741
NCT00137657|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-12-12|2005-08-29|2005-08-30|Estimate|||||||2005-12-12|2005-12-13|Estimate|February 2002||2002-02-28|August 2005|2005-08-31|November 2003||2003-11-30|||||Interventional|||Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance|An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum, Streptococcus Pneumoniae, and Escherichia Coli|Completed||Phase 4|1478||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:43.785648|2018-06-01 04:47:43.785648
NCT00137644|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-01-06|2005-08-26|2005-08-30|Estimate|||||||2010-01-06|2010-01-07|Estimate|March 2005||2005-03-31|January 2010|2010-01-31|January 2007|Actual|2007-01-31|||||Interventional|||Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents|Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Innovative HIV Prevention Intervention for Minority Adolescents by the Philadelphia Health Management Corporation in Philadelphia, PA|Completed||Phase 1/Phase 2|264|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:47:43.891718|2018-06-01 04:47:43.891718
NCT00137631|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2010-03-10||2010-06-23|2005-08-26|2005-08-30|Estimate|2010-04-27|2010-05-14|Estimate||||2010-06-23|2010-06-24|Estimate|August 2005||2005-08-31|April 2010|2010-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|3MV||Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM|Evaluation of Many Men, Many Voices, A Group Intervention for STD/HIV Prevention for Black Men Who Have Sex With Men (MSM) in the New York Metropolitan Area by People of Color in Crisis, Brooklyn, NY|Completed||Phase 1/Phase 2|341|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-06-01 04:47:43.997138|2018-06-01 04:47:43.997138
NCT00137618|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-03-16|2005-08-26|2005-08-30|Estimate|||||||2010-03-16|2010-03-18|Estimate|November 2004||2004-11-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening|Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Univ of Texas - SIP 21-04|Completed||N/A|264|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:47:44.423326|2018-06-01 04:47:44.423326
NCT00137605|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2014-02-11|2005-08-29|2005-08-30|Estimate|||||||2014-02-11|2014-02-13|Estimate|September 2004||2004-09-30|February 2014|2014-02-28|October 2007|Actual|2007-10-31|||||Interventional|||Early Versus Delayed Pneumococcal Vaccination in HIV|A Pilot Study Assessing the Efficacy of Pneumococcal Vaccine in HIV Patients: Delayed Versus Immediate Immunization|Completed||Phase 1/Phase 2|79|Actual|CIHR Canadian HIV Trials Network||4|||f||||||||||||||2018-06-01 04:47:44.533957|2018-06-01 04:47:44.533957
NCT00137592|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2012-09-06|2005-08-26|2005-08-30|Estimate|||||||2012-09-06|2012-09-07|Estimate|October 2005||2005-10-31|September 2012|2012-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Promoting Colorectal Cancer Screening in Rural Colorado|Promoting Colorectal Cancer Screening in Rural Colorado|Completed||N/A|480|Actual|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-06-01 04:47:44.723831|2018-06-01 04:47:44.723831
NCT00137579|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2005-12-12|2005-08-29|2005-08-30|Estimate|||||||2005-12-12|2005-12-13|Estimate|September 2003||2003-09-30|January 2003|2003-01-31|May 2004||2004-05-31|||||Interventional|||Safety of the Intramuscular Route of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation Therapy|Phase IV, Simple Blind, 2-Parallel Groups Randomized Trial to Evaluate the Safety and Effectiveness of the Intramuscular Vs Subcutaneous Route for the Administration of the Anti-Flu Vaccine in Patients Receiving Oral Anticoagulation|Completed||Phase 4|216||Catalan Institute of Health|||||f||||||||||||||2018-06-01 04:47:44.866755|2018-06-01 04:47:44.866755
NCT00137566|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-28|||2010-07-06|2005-08-28|2005-08-30|Estimate|||||||2010-07-06|2010-07-07|Estimate|May 2004||2004-05-31|July 2010|2010-07-31|January 2010|Anticipated|2010-01-31|November 2006|Actual|2006-11-30||Interventional|||The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau|The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau|Unknown status|Active, not recruiting|Phase 4|||Bandim Health Project||2|||f||||||||||||||2018-06-01 04:47:45.00093|2018-06-01 04:47:45.00093
NCT00137553|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-28|||2010-03-15|2005-08-28|2005-08-30|Estimate|||||||2010-03-15|2010-03-16|Estimate|May 2001||2001-05-31|March 2010|2010-03-31|March 2004||2004-03-31|||||Interventional|||The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children|The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children With Recrudescent Malaria in Guinea-Bissau|Completed||Phase 4|60||Bandim Health Project|||||f||||f||||||||||2018-06-01 04:47:45.148493|2018-06-01 04:47:45.148493
NCT00137540|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2014-11-03|2005-08-29|2005-08-30|Estimate|||||||2014-11-03|2014-11-04|Estimate|September 2005||2005-09-30|November 2014|2014-11-30|July 2008|Actual|2008-07-31|April 2007|Actual|2007-04-30||Interventional|||FLAT Study: First Line Ablation Therapy for Treatment of Paroxysmal Atrial Fibrillation (RAAFT)|First Line Radiofrequency Ablation vs. Antiarrhythmic Drugs for Atrial Fibrillation Treatment|Completed||Phase 3|40|Actual|Biosense Webster, Inc.|||||f||||||||||||||2018-06-01 04:47:45.267685|2018-06-01 04:47:45.267685
NCT00137527|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2014-01-16|2005-08-29|2005-08-30|Estimate|||||||2014-01-16|2014-01-17|Estimate|February 2004||2004-02-29|January 2014|2014-01-31|February 2009|Actual|2009-02-28|||||Interventional|||Brain Oxygenation Monitoring in Patients Undergoing Coronary Artery Bypass Surgery|Prospective, Randomized Trial of Cerebral Oximetry Monitoring in Patients Undergoing Coronary Artery Bypass Surgery|Terminated||N/A|250||Atlantic Health System|||||f||||||||||||||2018-06-01 04:47:45.404868|2018-06-01 04:47:45.404868
NCT00137514|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-28|||2008-04-06|2005-08-28|2005-08-30|Estimate|||||||2008-04-06|2008-04-08|Estimate|March 2001||2001-03-31|April 2008|2008-04-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Chloroquine and Amodiaquine for Treatment of Malaria in Children|Chloroquine and Amodiaquine for Treatment of Symptomatic Children With Plasmodium Malaria in Guinea-Bissau|Completed||Phase 4|720||Bandim Health Project|||||f||||||||||||||2018-06-01 04:47:45.527621|2018-06-01 04:47:45.527621
NCT00137501|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-29|||2013-07-18|2005-08-29|2005-08-30|Estimate|||||||2013-07-18|2013-07-19|Estimate|May 2003||2003-05-31|July 2013|2013-07-31|June 2009|Actual|2009-06-30|January 2009|Actual|2009-01-31||Interventional|||Two Dose Regimens of Nifedipine for the Management of Preterm Labor|Study of Different Doses of Nifedipine to Treat Preterm Labor|Terminated||Phase 3|102|Actual|American University of Beirut Medical Center||2||The trial was terminated because of difficulties in recruitement.|f||||f||||||||||2018-06-01 04:47:45.632043|2018-06-01 04:47:45.632043
NCT00137488|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-02-24|2005-08-29|2005-08-30|Estimate|||||||2016-02-24|2016-02-26|Estimate|November 2005||2005-11-30|April 2012|2012-04-30||||December 2007|Actual|2007-12-31||Observational|||Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG)|Angiogenic Profile and Non-invasive Imaging May Predict Tumor Progression of High Risk Group Low Grade Glioma (LGG)|Completed|||10|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:47:45.729351|2018-06-01 04:47:45.729351
NCT00137475|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-02-24|2005-08-26|2005-08-30|Estimate|||||||2016-02-24|2016-02-26|Estimate|February 2002||2002-02-28|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Using Intensity-Modulated Radiation Therapy to Permit Sparing of Parotid Gland Function|A Phase I/II Feasibility/Efficacy Study Using Intensity-Modulated Radiation Therapy in Head and Neck (H&N) Cancer Patients to Permit Sparing of Parotid Gland Function|Completed||Phase 1/Phase 2|130|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:47:45.820197|2018-06-01 04:47:45.820197
NCT00137462|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-11-15|2005-08-26|2005-08-29|Estimate|||||||2007-11-15|2007-11-16|Estimate|November 2004||2004-11-30|December 2006|2006-12-31|September 2006||2006-09-30|||||Interventional|||Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.|A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias|Completed||Phase 3|900||Pfizer|||||||||||||||||||2018-06-01 04:47:45.928716|2018-06-01 04:47:45.928716
NCT00137449|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2009-04-10||2009-09-09|2005-08-26|2005-08-29|Estimate|2009-07-29|2009-09-04|Estimate||||2009-09-09|2009-09-15|Estimate|September 2005||2005-09-30|September 2009|2009-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor|A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Advanced Gastrointestinal Stromal Tumor|Completed||Phase 2|60|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:47:46.101707|2018-06-01 04:47:46.101707
NCT00137436|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2009-05-28||2011-08-25|2005-08-26|2005-08-29|Estimate|2010-02-05|2010-02-23|Estimate||||2011-08-25|2011-08-29|Estimate|October 2005||2005-10-31|August 2011|2011-08-31|March 2010|Actual|2010-03-31|May 2008|Actual|2008-05-31||Interventional|||Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer|A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC)|Completed||Phase 1/Phase 2|93|Actual|Pfizer|Per FDAAA, only the Phase 2 study results are posted.|1|||f||||f||||||||||2018-06-01 04:47:47.234797|2018-06-01 04:47:47.234797
NCT00137423|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2009-05-14||2009-09-24|2005-08-26|2005-08-29|Estimate|2009-05-14|2009-07-08|Estimate||||2009-09-24|2009-09-30|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|May 2008|Actual|2008-05-31|September 2007|Actual|2007-09-30||Interventional|||Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer|A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma|Completed||Phase 2|107|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:47:48.978382|2018-06-01 04:47:48.978382
NCT00137410|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2008-06-09|2005-08-26|2005-08-29|Estimate|||||||2008-06-09|2008-06-10|Estimate|November 2002||2002-11-30|July 2006|2006-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee|Protocol For A Multicentre, Double Blind, Parallel Group Pilot Study To Compare Celecoxib Long Term Vs Celecoxib Short Term Therapy In Treatment And Prevention Of New Flare In Patients With Osteoarthritis Of The Knee|Completed||Phase 3|200||Pfizer|||||f||||||||||||||2018-06-01 04:47:49.912637|2018-06-01 04:47:49.912637
NCT00137397|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2006-10-05|2005-08-25|2005-08-29|Estimate|||||||2006-10-05|2006-10-06|Estimate|November 2004||2004-11-30|October 2006|2006-10-31|August 2006||2006-08-31|||||Interventional|||A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder|A Multi-Centre, Randomised, Placebo Controlled, Double Blind, Parallel Group Study in Female Patients to Evaluate Whether Tolterodine ER Can Reverse the Increased Bladder Wall Thickness in Patients With Overactive Bladder.|Completed||Phase 4|80||Pfizer|||||f||||||||||||||2018-06-01 04:47:50.014667|2018-06-01 04:47:50.014667
NCT00137384|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2018-04-28|2005-08-26|2005-08-29|Estimate|||||||2018-04-28|2018-05-01|Actual|August 25, 2005||2005-08-25|April 27, 2018|2018-04-27|April 27, 2018||2018-04-27|||||Observational|||Movement-Related Brain Networks Involved in Hand Dystonia|The Role of Cortical Coherence in Focal Hand Dystonia|Completed|||60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:47:50.104148|2018-06-01 04:47:50.104148
NCT00137371|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-12-07|2005-08-25|2005-08-29|Estimate|||||||2007-12-07|2007-12-10|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis|Efficacy and Safety of 2 Low-Dose Regimens of Conjugated Estrogen Cream Administered Vaginally in Postmenopausal Women With Atrophic Vaginitis|Completed||Phase 3|480||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:47:50.198028|2018-06-01 04:47:50.198028
NCT00137358|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2013-01-23|2005-08-26|2005-08-29|Estimate|||||||2013-01-23|2013-01-24|Estimate||||January 2013|2013-01-31||||||||Interventional|||Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer|Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer|Withdrawn||Phase 1|0|Actual|University of Alabama at Birmingham||||unable to obtain funding to conduct study|f||||||||||||||2018-06-01 04:47:50.325805|2018-06-01 04:47:50.325805
NCT00137345|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2013-02-07|2005-08-25|2005-08-29|Estimate|||||||2013-02-07|2013-02-08|Estimate|June 2005||2005-06-30|September 2006|2006-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients|A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus Versus Cyclosporine When Combined in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticosteroids in Primary De Novo Renal Allograft Recipients|Terminated||Phase 3|500||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:47:50.421148|2018-06-01 04:47:50.421148
NCT00137332|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-12-06|2005-08-25|2005-08-29|Estimate|||||||2007-12-06|2007-12-10|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease|A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction|Terminated||Phase 2|90||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:47:50.718845|2018-06-01 04:47:50.718845
NCT00137319|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2015-07-20|2005-08-25|2005-08-29|Estimate|||||||2015-07-20|2015-07-22|Estimate|October 2004||2004-10-31|July 2015|2015-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Impedance Threshold Device Tilt Study|An Evaluation of an Impedance Threshold Device (ITD) to Improve Hemodynamic Function During Orthostatic Challenge in Burn Patients|Terminated||N/A|2|Actual|United States Army Institute of Surgical Research||||Aims of the study re-evaluated, did not justify allocation of resources.|f||||f||||||||||2018-06-01 04:47:50.847322|2018-06-01 04:47:50.847322
NCT00137306|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2015-04-06|2005-08-25|2005-08-29|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2004||2004-01-31|February 2007|2007-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Facilitating the Adoption of Evidence-Based Depression Management in Substance Use Treatment Programs|Translating Depression Guidelines Into Substance Abuse Treatment|Completed||Phase 4|300|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:47:50.933592|2018-06-01 04:47:50.933592
NCT00137293|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-12-06|2005-08-25|2005-08-29|Estimate|||||||2007-12-06|2007-12-10|Estimate|November 2005||2005-11-30|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Study Evaluating GAP-486 in Heart Rhythm|A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486|Terminated||Phase 2|30||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:47:51.053794|2018-06-01 04:47:51.053794
NCT00137280|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2014-10-03||2018-01-24|2005-08-25|2005-08-29|Estimate|2014-10-08|2014-10-15|Estimate||||2018-01-24|2018-02-22|Actual|June 13, 2007|Actual|2007-06-13|January 2018|2018-01-31|May 31, 2011|Actual|2011-05-31|March 5, 2010|Actual|2010-03-05||Interventional|EQUIP-2|People with schizophrenia|Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)|Implementing Effective, Collaborative Care for Schizophrenia|Completed||N/A|1067|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-06-01 04:47:51.170427|2018-06-01 04:47:51.170427
NCT00137267|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2014-08-25||2015-04-29|2005-08-25|2005-08-29|Estimate|2015-04-08|2015-04-29|Estimate||||2015-04-29|2015-05-15|Estimate|June 2005||2005-06-30|April 2015|2015-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|TLC||A Brief Community Linkage Intervention for Dually Diagnosed Individuals|A Brief Community Linkage Intervention for Dually Diagnosed Individuals|Completed||N/A|102|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:47:51.92077|2018-06-01 04:47:51.92077
NCT00137254|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2012-04-10|2005-08-25|2005-08-29|Estimate|||||||2012-04-10|2012-04-12|Estimate|December 2005||2005-12-31|April 2012|2012-04-30|August 2008|Actual|2008-08-31|February 2007|Actual|2007-02-28||Interventional|||Insulin on Post Burn Hypermetabolism|Effects of Insulin on Post Burn Hypermetabolism|Completed||N/A|14|Actual|United States Army Institute of Surgical Research||1|||f||||f||||||||||2018-06-01 04:47:52.255593|2018-06-01 04:47:52.255593
NCT00137241|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2015-04-06|2005-08-25|2005-08-29|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2004||2004-07-31|October 2006|2006-10-31|November 2005|Actual|2005-11-30|||||Observational|||Veterans as Leaders in Understanding and Education (VALUE)|Determining the Prevalence of Health Literacy Among Veterans|Completed|||1850|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:47:52.354897|2018-06-01 04:47:52.354897
NCT00137228|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-12-24|2005-08-25|2005-08-29|Estimate|||||||2007-12-24|2008-01-08|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Measuring Hand Edema in Burn Patients|The Reliability and Concurrent Validity of the Figure-of-Eight Method of Measuring Hand Edema in Patients With Burn Injuries|Completed||N/A|20|Actual|United States Army Institute of Surgical Research|||||f||||f||||||||||2018-06-01 04:47:52.423535|2018-06-01 04:47:52.423535
NCT00137215|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2008-07-24|2005-08-25|2005-08-29|Estimate|||||||2008-07-24|2008-07-28|Estimate|January 2006||2006-01-31|July 2008|2008-07-31|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Evaluation of Silverlon Dressing for Autogenous Skin Donor Sites|Evaluation of Silverlon Dressing for Autogenous Skin Donor Sites|Completed||N/A|17|Actual|United States Army Institute of Surgical Research||1|||f||||f||||||||||2018-06-01 04:47:52.493373|2018-06-01 04:47:52.493373
NCT00137202|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2008-07-24|2005-08-25|2005-08-29|Estimate|||||||2008-07-24|2008-07-28|Estimate|June 2005||2005-06-30|July 2008|2008-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Post Burn Pruritus Study in Patients Undergoing Wound Healing|A Pilot Study to Determine the Pruritic Benefits of Ondansetron Versus Diphenhydramine in Burn Patients Undergoing Wound Healing|Completed||N/A|36|Actual|United States Army Institute of Surgical Research||1|||f||||f||||||||||2018-06-01 04:47:52.627674|2018-06-01 04:47:52.627674
NCT00137189|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2017-05-12|2005-08-26|2005-08-29|Estimate|||||||2017-05-12|2017-05-15|Actual|April 2005||2005-04-30|May 2017|2017-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation|Resource-oriented Music Therapy for Psychiatric Patients With Low Therapy Motivation: A Randomised Controlled Trial|Completed||N/A|144|Actual|Uni Research||2|||f||||f||||||||No||2018-06-01 04:47:52.726214|2018-06-01 04:47:52.726214
NCT00137176|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2009-06-22|2005-08-26|2005-08-29|Estimate|||||||2009-06-22|2009-06-23|Estimate|October 2004||2004-10-31|June 2009|2009-06-30|October 2008|Actual|2008-10-31|October 2007|Actual|2007-10-31||Interventional|||EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis|EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis|Completed||N/A|30|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 04:47:52.955992|2018-06-01 04:47:52.955992
NCT00137163|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2008-07-24|2005-08-25|2005-08-29|Estimate|||||||2008-07-24|2008-07-28|Estimate|March 2005||2005-03-31|July 2008|2008-07-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Evaluation of Dermafill Dressing for Donor Sites|Evaluation of Dermafill Dressing for Autogenous Skin Donor Sites|Completed||N/A|17||United States Army Institute of Surgical Research|||||f||||f||||||||||2018-06-01 04:47:53.092204|2018-06-01 04:47:53.092204
NCT00137150|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-12-19|2005-08-26|2005-08-29|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Comparison of Outcome and Complications Encountered in Flapless Surgery and Immediate Loading Versus the Classical Surgical Approach and Loading After 6-8 Weeks in the Posterior Maxilla|Comparison of Outcome and Complications Encountered in Flapless Surgery and Immediate Loading Versus the Classical Surgical Approach and Loading After 6-8 Weeks in the Posterior Maxilla|Completed||N/A|15||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:47:53.168486|2018-06-01 04:47:53.168486
NCT00137137|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-12-19|2005-08-26|2005-08-29|Estimate|||||||2007-12-19|2007-12-28|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|November 2006|Actual|2006-11-30|||||Interventional|||The Mini-Screw as Orthodontic Anchoring: Survival, Clinical Efficiency and Experience of the Patient|The Mini-Screw as Orthodontic Anchoring: A Clinical Trial to Study Survival, Clinical Efficiency and Experience of the Patient|Completed||N/A|20||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:47:53.259234|2018-06-01 04:47:53.259234
NCT00137124|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2012-07-06|2005-08-26|2005-08-29|Estimate|||||||2012-07-06|2012-07-10|Estimate|May 2006||2006-05-31|July 2012|2012-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||L-Arginine Metabolism in Essential Hypertension|Transport and Metabolism of L-arginine: Role for Endothelial Dysfunction in Essential Hypertension|Completed||Phase 2/Phase 3|120|Actual|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-06-01 04:47:53.344469|2018-06-01 04:47:53.344469
NCT00137111|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2011-02-28||2017-07-31|2005-08-26|2005-08-29|Estimate|2011-04-22|2011-04-26|Estimate||||2017-07-31|2017-08-29|Actual|July 8, 2000|Actual|2000-07-08|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|November 2010|Actual|2010-11-30||Interventional|||Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 3|501|Actual|St. Jude Children's Research Hospital||2|||f||||t|t|f||||||||2018-06-01 04:47:53.487584|2018-06-01 04:47:53.487584
NCT00137098|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2009-10-02|2005-08-26|2005-08-29|Estimate|||||||2009-10-02|2009-10-05|Estimate|September 2003||2003-09-30|October 2009|2009-10-31|January 2006|Actual|2006-01-31|||||Observational|||Coronary Care Caffeine: Influence of Coffee on Heart Rate Post Myocardial Infarction|Influence of Coffee on Heart Rate Variability Post Myocardial Infarction|Completed|||100|Actual|The Royal Bournemouth Hospital|||||f||||t||||||||||2018-06-01 04:47:54.186976|2018-06-01 04:47:54.186976
NCT00137072|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2011-09-03|2005-08-26|2005-08-29|Estimate|||||||2011-09-03|2011-09-07|Estimate|April 2005||2005-04-30|September 2011|2011-09-30|February 2006|Actual|2006-02-28|||||Interventional|||Mild To Moderate Erectile Dysfunction Study|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study of Men With Mild to Moderate Erectile Dysfunction to Evaluate the Efficacy of Viagra 8 Hours Post-Dose|Completed||Phase 4|355|Actual|Pfizer|||||||||||||||||||2018-06-01 04:47:54.466931|2018-06-01 04:47:54.466931
NCT00137059|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2005-12-12|2005-08-26|2005-08-29|Estimate|||||||2005-12-12|2005-12-13|Estimate|November 2002||2002-11-30|August 2005|2005-08-31|May 2005||2005-05-31|||||Interventional|||Acetaminophen-Induced Hepatotoxicity in Chronic Alcohol Abusers||Completed||N/A|40||Queen's University|||||f||||||||||||||2018-06-01 04:47:54.654439|2018-06-01 04:47:54.654439
NCT00137046|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2009-12-07||2010-02-03|2005-08-26|2005-08-29|Estimate|2009-12-07|2010-01-26|Estimate||||2010-02-03|2010-02-18|Estimate|May 2002||2002-05-31|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes|Efficacy and Safety of Exubera (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 1 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial|Terminated||Phase 3|582|Actual|Pfizer|Due to early termination of study, none of the subjects completed the study as planned. Subjects active at the time of study termination completed an end-of-study assessment and a 3-month follow-up visit.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:47:54.867444|2018-06-01 04:47:54.867444
NCT00137033|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2008-07-14|2005-08-26|2005-08-29|Estimate|||||||2008-07-14|2008-07-16|Estimate|September 2004||2004-09-30|September 2007|2007-09-30|July 2005|Actual|2005-07-31|||||Interventional|||Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population|A Multicenter, Randomized, Active-Controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated With Celecoxib and Low Dose ASA Versus Naproxen and Low Dose ASA in Healthy Subjects (50-75 Years of Age)|Completed||Phase 4|605||Pfizer|||||||||||||||||||2018-06-01 04:47:57.683725|2018-06-01 04:47:57.683725
NCT00137020|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2006-08-11|2005-08-26|2005-08-29|Estimate|||||||2006-08-11|2006-08-15|Estimate|November 2004||2004-11-30|August 2006|2006-08-31|April 2006||2006-04-30|||||Interventional|||Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder|A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|294||Pfizer|||||f||||||||||||||2018-06-01 04:47:57.847186|2018-06-01 04:47:57.847186
NCT00137007|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-04-20|2005-08-25|2005-08-29|Estimate|||||||2011-04-20|2011-04-22|Estimate|November 2003||2003-11-30|April 2011|2011-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Zithromax EV in Community-Acquired Pneumonia (CAP)|A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP)|Completed||Phase 4|151|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:47:57.948705|2018-06-01 04:47:57.948705
NCT00136994|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-07-28|2005-08-25|2005-08-29|Estimate|||||||2011-07-28|2011-07-29|Estimate|March 2003||2003-03-31|July 2011|2011-07-31|November 2005|Actual|2005-11-30|||||Interventional|||IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)|An Open Trial to Evaluate the Efficacy and Tolerability of Ziprasidone IM and Oral in Patients With Psychosis and Acute Agitation.|Completed||Phase 3|160||Pfizer|||||f||||||||||||||2018-06-01 04:47:58.029644|2018-06-01 04:47:58.029644
NCT00136981|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2015-04-21|2005-08-25|2005-08-29|Estimate|||||||2015-04-21|2015-04-22|Estimate|December 2003||2003-12-31|April 2015|2015-04-30|November 2006|Actual|2006-11-30|||||Interventional|RADIANCE 1||Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.|Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.|Completed||Phase 3|800||Pfizer|||||||||||||||||||2018-06-01 04:47:58.145464|2018-06-01 04:47:58.145464
NCT00136968|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2009-03-10|2005-08-25|2005-08-29|Estimate|||||||2009-03-10|2009-03-12|Estimate|April 2005||2005-04-30|March 2009|2009-03-31|May 2005|Actual|2005-05-31|||||Interventional|||Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy|Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy|Completed||Phase 1|12|Actual|Pfizer|||||||||||||||||||2018-06-01 04:47:58.280041|2018-06-01 04:47:58.280041
NCT00136955|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2009-05-07||2015-05-22|2005-08-25|2005-08-29|Estimate|2009-05-07|2009-06-25|Estimate||||2015-05-22|2015-06-19|Estimate|June 2004||2004-06-30|May 2015|2015-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Irinotecan Study For Cervical Cancer|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix|Completed||Phase 2|41|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:47:58.364091|2018-06-01 04:47:58.364091
NCT00136942|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2008-02-28|2005-08-25|2005-08-29|Estimate|||||||2008-02-28|2008-03-03|Estimate|April 2005||2005-04-30|April 2007|2007-04-30||||||||Interventional|ACTFAST SWISS||A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol|A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin|Completed||Phase 3|370||Pfizer|||||f||||||||||||||2018-06-01 04:47:58.696985|2018-06-01 04:47:58.696985
NCT00136929|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2005-12-12|2005-08-26|2005-08-29|Estimate|||||||2005-12-12|2005-12-13|Estimate||||August 2005|2005-08-31||||||||Interventional|||Senior PAMI: Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly|"A Prospective Randomized Trial of Primary Angioplasty Versus Thrombolytic Therapy for Acute Myocardial Infarction in the Elderly Senior PAMI"|Unknown status|Active, not recruiting|N/A|530||PAMI Coordinating Center|||||f||||||||||||||2018-06-01 04:47:58.81624|2018-06-01 04:47:58.81624
NCT00136916|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2009-12-10||2010-02-12|2005-08-25|2005-08-29|Estimate|2009-12-10|2010-01-18|Estimate||||2010-02-12|2010-02-18|Estimate|June 2002||2002-06-30|December 2009|2009-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes|Efficacy and Safety of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 2 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial|Terminated||Phase 3|635|Actual|Pfizer|Due to early termination of study, none of the subjects completed the study as planned. Subjects active at the time of study termination completed an end-of-study assessment and a 3-month follow-up visit.|2||See termination reason in detailed description.|f||||f||||||||||2018-06-01 04:47:58.986639|2018-06-01 04:47:58.986639
NCT00136903|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2009-09-03|2005-08-25|2005-08-29|Estimate|||||||2009-09-03|2009-09-04|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute GVHD.|A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of aGVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|33|Actual|Osiris Therapeutics||2|||f||||f||||||||||2018-06-01 04:48:01.875006|2018-06-01 04:48:01.875006
NCT00136890|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2013-01-14|2005-08-25|2005-08-29|Estimate|||||||2013-01-14|2013-01-15|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|November 2008|Actual|2008-11-30||Interventional|ELPET||PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers|The Impact of Positron Emission Tomography (PET) Imaging in Staging Potentially Surgically Resectable Non-small Cell Lung Cancers: A Prospective Multicentre Randomized Clinical Trial|Completed||Phase 3|337|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 04:48:02.047178|2018-06-01 04:48:02.047178
NCT00136877|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2006-12-27|2005-08-26|2005-08-29|Estimate|||||||2006-12-27|2006-12-29|Estimate|October 2001||2001-10-31|December 2006|2006-12-31|December 2005||2005-12-31|||||Interventional|||Tonsillectomy in Recurrent Tonsillitis|Effect of Tonsillectomy on Preventing Recurrent Streptococcal Throat Infections: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|70||Oulu University Hospital|||||f||||||||||||||2018-06-01 04:48:02.130247|2018-06-01 04:48:02.130247
NCT00136864|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-11-17|2005-08-25|2005-08-29|Estimate|||||||2011-11-17|2011-11-18|Estimate|August 2004||2004-08-31|November 2011|2011-11-30|September 2011|Actual|2011-09-30|November 2009|Actual|2009-11-30||Interventional|||Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)|The Impact of Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer: A Prospective Randomized Clinical Trial (PET START Trial)|Completed||Phase 3|310|Actual|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-06-01 04:48:02.20693|2018-06-01 04:48:02.20693
NCT00136851|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2011-11-07|2005-08-26|2005-08-29|Estimate|||||||2011-11-07|2011-11-08|Estimate|December 2004||2004-12-31|June 2006|2006-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension|A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension|Completed||Phase 4|259|Actual|Novartis|||||||||||||||||||2018-06-01 04:48:02.303434|2018-06-01 04:48:02.303434
NCT00136838|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2015-04-14||2016-04-06|2005-08-25|2005-08-29|Estimate|2016-04-06|2016-05-11|Estimate||||2016-04-06|2016-05-11|Estimate|October 2001||2001-10-31|December 2015|2015-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2|Effect of Smoking Exposure on Tobacco Self-Administration Following Brief Abstinence|Completed||N/A|12|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 04:48:02.36147|2018-06-01 04:48:02.36147
NCT00136825|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2017-01-11|2005-08-25|2005-08-29|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2003||2003-03-31|August 2007|2007-08-31|September 2005|Actual|2005-09-30|||||Interventional|||Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1|N-acetylcysteine as Treatment in Cocaine Addiction|Completed||Phase 1|17|Actual|National Institute on Drug Abuse (NIDA)||2|||||||t||||||||||2018-06-01 04:48:02.593744|2018-06-01 04:48:02.593744
NCT00136812|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2016-02-22||2016-04-23|2005-08-25|2005-08-29|Estimate|2016-02-22|2016-03-23|Estimate||||2016-04-23|2016-05-25|Estimate|July 2006||2006-07-31|April 2016|2016-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Treating Tobacco Dependence in Inpatient Psychiatry - 1|Treating Tobacco Dependence in Inpatient Psychiatry|Completed||Phase 2|224|Actual|Stanford University||2|||f||||t||||||||No|no plan to make individual participant data available|2018-06-01 04:48:02.701614|2018-06-01 04:48:02.701614
NCT00136799|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2017-02-20|2005-08-25|2005-08-29|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2005||2005-06-30|February 2017|2017-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia|Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia|Completed||Phase 3|325|Actual|Novartis|||||f||||||||||||||2018-06-01 04:48:03.992794|2018-06-01 04:48:03.992794
NCT00136786|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2018-05-17|2005-08-25|2005-08-29|Estimate|||||||2018-05-17|2018-05-21|Actual|December 2006||2006-12-31|May 2018|2018-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3|Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals|Completed||Phase 1|25|Actual|New York State Psychiatric Institute||3|||f||||||||||||||2018-06-01 04:48:04.135652|2018-06-01 04:48:04.135652
NCT00136773|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-03-08|2005-08-25|2005-08-29|Estimate|||||||2011-03-08|2011-03-09|Estimate|April 2003||2003-04-30|March 2008|2008-03-31|November 2005|Actual|2005-11-30|October 2005|Actual|2005-10-31||Interventional|||Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus|Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|332|Actual|Novartis|||||||||||||||||||2018-06-01 04:48:04.230546|2018-06-01 04:48:04.230546
NCT00136760|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2012-11-16||2015-10-05|2005-08-25|2005-08-29|Estimate|2012-11-19|2012-12-17|Estimate||||2015-10-05|2015-10-07|Estimate|September 2003||2003-09-30|April 2013|2013-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia|Incentives Plus Bupropion for Smoking in Schizophrenics|Completed||Phase 2|57|Actual|Brown University||4|||f||||t||||||||||2018-06-01 04:48:04.307232|2018-06-01 04:48:04.307232
NCT00136747|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2018-05-17|2005-08-25|2005-08-29|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2004||2004-01-31|May 2018|2018-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1|Developing Medication For Tobacco Addiction: NMDA Agents|Completed||Phase 1|45|Actual|New York State Psychiatric Institute||3|||f||||||||||||||2018-06-01 04:48:04.838224|2018-06-01 04:48:04.838224
NCT00136734|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2018-05-10|2005-08-25|2005-08-29|Estimate|||||||2018-05-10|2018-05-16|Actual|April 1998||1998-04-30|May 2018|2018-05-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Methylphenidate Treatment for Cocaine Abuse and ADHD - 1|Methylphenidate Treatment for Cocaine Abuse and ADHD|Completed||Phase 1|124|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 04:48:04.973058|2018-06-01 04:48:04.973058
NCT00136721|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-12-03|2005-08-26|2005-08-29|Estimate|||||||2007-12-03|2007-12-04|Estimate|June 2002||2002-06-30|December 2007|2007-12-31|May 2006||2006-05-31|||||Observational|||Parkin Mutations and Their Functional Consequences|Parkin Mutations and Their Functional Consequences|Unknown status|Active, not recruiting||2500||Institut National de la Santé Et de la Recherche Médicale, France|||||f||||||||||||||2018-06-01 04:48:05.175951|2018-06-01 04:48:05.175951
NCT00136708|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2014-07-29|2005-08-25|2005-08-29|Estimate|||||||2014-07-29|2014-07-31|Estimate|March 2005||2005-03-31|July 2014|2014-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||First Breath: Neonatal Resuscitation in Developing Countries|FIRST BREATH: Neonatal Resuscitation in Developing Countries|Completed||N/A|120009|Actual|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-06-01 04:48:05.307411|2018-06-01 04:48:05.307411
NCT00136695|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2016-11-30||2016-11-30|2005-08-25|2005-08-29|Estimate|2016-11-30|2017-01-27|Estimate||||2016-11-30|2017-01-27|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|October 2009|Actual|2009-10-31|October 2008|Actual|2008-10-31||Interventional|||Anastrozole Administration in Elderly Hypogonadal Men|Anastrozole Administration in Elderly Hypogonadal Men|Completed||Phase 2|100|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:48:05.444172|2018-06-01 04:48:05.444172
NCT00136682|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2008-11-06|2005-08-26|2005-08-29|Estimate|||||||2008-11-06|2008-11-10|Estimate|August 2004||2004-08-31|November 2008|2008-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Patient-Controlled Epidural Analgesia (PCEA) for Patients Who Have Had Major Open Gynecologic Surgery|Postoperative Recovery in Patients Receiving Patient-Controlled Epidural Analgesia (PCEA) Compared to Patient-Controlled Intravenous Analgesia (PCA) After Major Open Gynecologic Surgery: A Randomized Controlled Trial|Completed||Phase 3|240|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:48:05.773373|2018-06-01 04:48:05.773373
NCT00136669|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2006-09-07|2005-08-26|2005-08-29|Estimate|||||||2006-09-07|2006-09-08|Estimate|September 2003||2003-09-30|September 2006|2006-09-30|September 2005||2005-09-30|||||Interventional|||Acupuncture For Pancreatic Cancer Pain|Acupuncture For Pancreatic Cancer Pain: A Randomized Phase III Study|Completed||Phase 3|60||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:48:05.886137|2018-06-01 04:48:05.886137
NCT00136656|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2009-02-11|2005-08-26|2005-08-29|Estimate|||||||2009-02-11|2009-02-12|Estimate|July 2005||2005-07-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|June 2008|Actual|2008-06-30||Interventional|||Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old|Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence.|Completed||Phase 4|700|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:48:05.983395|2018-06-01 04:48:05.983395
NCT00136643|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-10-09|2005-08-26|2005-08-29|Estimate|||||||2007-10-09|2007-10-10|Estimate|June 2005||2005-06-30|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|||Safety, Tolerance and Acceptability Trial of the Invisible Condom® in Healthy Women|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance and Acceptability of a Vaginal Gel Containing Sodium Lauryl Sulfate (Invisible Condom®) in Healthy Female Subjects|Completed||Phase 1/Phase 2|452||Laval University|||||||||||||||||||2018-06-01 04:48:06.142697|2018-06-01 04:48:06.142697
NCT00136630|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2012-01-27|2005-08-26|2005-08-29|Estimate|||||||2012-01-27|2012-01-31|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|December 2012|Anticipated|2012-12-31|||||Observational|||Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations|Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations|Unknown status|Active, not recruiting||225|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||||||||||||2018-06-01 04:48:06.263598|2018-06-01 04:48:06.263598
NCT00136617|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2009-02-27|2005-08-26|2005-08-29|Estimate|||||||2009-02-27|2009-03-02|Estimate|August 2003||2003-08-31|February 2009|2009-02-28|September 2008|Actual|2008-09-30|July 2006|Actual|2006-07-31||Interventional|||Outpatient Treatment of Alcohol Withdrawal Syndrome|Comparison of a Fixed-Schedule Therapy Versus a Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome in Medical Out-Patients|Completed||Phase 3|165|Actual|Hvidovre University Hospital|||||f||||t||||||||||2018-06-01 04:48:06.39698|2018-06-01 04:48:06.39698
NCT00136604|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2016-09-22|2005-08-26|2005-08-29|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2006||2006-01-31|September 2016|2016-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m|Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax™ ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix™-HepB/Hib-MenAC|Completed||Phase 3|617|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:48:06.507806|2018-06-01 04:48:06.507806
NCT00136591|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2010-10-22|2005-08-26|2005-08-29|Estimate|||||||2010-10-22|2010-10-26|Estimate|September 2005||2005-09-30|October 2010|2010-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma|A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma|Terminated||Phase 2|87|Actual|Lymphoma Study Association||2||An arm closed due to lack of efficacy|f||||t||||||||||2018-06-01 04:48:06.650219|2018-06-01 04:48:06.650219
NCT00136578|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2017-09-22|2005-08-25|2005-08-29|Estimate|||||||2017-09-22|2017-09-25|Actual|October 20, 2004|Actual|2004-10-20|September 2017|2017-09-30|October 25, 2006|Actual|2006-10-25|October 25, 2006|Actual|2006-10-25||Interventional|||Ispinesib In Combination With Carboplatin In Patients With Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Carboplatin on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors.|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:48:06.72494|2018-06-01 04:48:06.72494
NCT00136565|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2007-11-06|2005-08-26|2005-08-29|Estimate|||||||2007-11-06|2007-11-08|Estimate|November 2005||2005-11-30|November 2007|2007-11-30|November 2008|Anticipated|2008-11-30|||||Interventional|||Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma|A Phase II Study Evaluating the Efficacy and Safety of Bortezomib (Velcade™) Combined With ACVBP Regimen in Patients With Previously Untreated Peripheral T-Cell Lymphoma|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:48:06.890166|2018-06-01 04:48:06.890166
NCT00136552|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-07-02|2005-08-25|2005-08-29|Estimate|||||||2007-07-02|2007-07-03|Estimate|May 2000||2000-05-31|July 2007|2007-07-31|December 2004||2004-12-31|||||Interventional|||Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden|FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden|Completed||Phase 3|360||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:48:06.99545|2018-06-01 04:48:06.99545
NCT00136539|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2013-02-15|2005-08-26|2005-08-29|Estimate|||||||2013-02-15|2013-02-18|Estimate|March 1999||1999-03-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|November 2006|Actual|2006-11-30||Interventional|||Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer|Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer|Completed||Phase 2|41|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:48:07.073731|2018-06-01 04:48:07.073731
NCT00136526|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2013-05-07|2005-08-26|2005-08-29|Estimate|||||||2013-05-07|2013-05-09|Estimate|December 2002||2002-12-31|May 2013|2013-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer|Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer: A Phase II Study|Completed||Phase 2|30|Actual|University of Washington|||||f||||t||||||||||2018-06-01 04:48:07.156296|2018-06-01 04:48:07.156296
NCT00136513|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2008-10-15|2005-08-25|2005-08-29|Estimate|||||||2008-10-15|2008-10-16|Estimate|April 2004||2004-04-30|October 2008|2008-10-31||||||||Interventional|||SB-743921 In Patients With Solid Tumors|A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB743921 on a Once Every 3 Week Schedule in Patients With Solid Tumors|Completed||Phase 1|30|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:48:07.216536|2018-06-01 04:48:07.216536
NCT00136500|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2018-03-15|2005-08-26|2005-08-29|Estimate|||||||2018-03-15|2018-03-16|Actual|February 2005||2005-02-28|March 2018|2018-03-31|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Observational|CRiALS||Clinical Research in ALS Study|Clinical Research in Amyotrophic Lateral Sclerosis|Recruiting|||10000|Anticipated|University of Miami|||||f||||f||||||Samples With DNA|"~     DNA, blood, urine, CSF, skin biopsies~   "|||2018-06-01 04:48:07.284502|2018-06-01 04:48:07.284502
NCT00136487|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2009-12-07|2005-08-26|2005-08-29|Estimate|||||||2009-12-07|2009-12-09|Estimate|October 2002||2002-10-31|December 2009|2009-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer|A Randomized, Double Blind, Placebo-Controlled Trial of Celecoxib Versus Placebo in Men With Prostate Cancer With Rising PSA Following Prostatectomy or Radiation Therapy|Completed||Phase 2/Phase 3|85||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:48:07.361981|2018-06-01 04:48:07.361981
NCT00136474|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2009-10-30|2005-08-25|2005-08-29|Estimate|||||||2009-10-30|2009-11-02|Estimate|May 2003||2003-05-31|October 2009|2009-10-31|March 2009|Actual|2009-03-31|May 2005|Actual|2005-05-31||Interventional|||Amifostine for Head and Neck Irradiation in Lymphoma|A Randomized Phase II Trial of Amifostine for Head and Neck Irradiation in Lymphoma|Completed||Phase 2|75|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 04:48:07.455284|2018-06-01 04:48:07.455284
NCT00136461|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-03-09|2005-08-25|2005-08-29|Estimate|||||||2011-03-09|2011-03-10|Estimate|May 1997||1997-05-31|March 2011|2011-03-31|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|A Randomized Phase II Trial of All-Trans Retinoic Acid and One of Two Schedules of Bryostatin 1 in Patients With Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)|Completed||Phase 2|40||Dana-Farber Cancer Institute|||||||||||||||||||2018-06-01 04:48:07.537479|2018-06-01 04:48:07.537479
NCT00136448|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-03-09|2005-08-25|2005-08-29|Estimate|||||||2011-03-09|2011-03-10|Estimate|February 1993||1993-02-28|March 2011|2011-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)|High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission|Completed||Phase 2|30||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:48:07.610508|2018-06-01 04:48:07.610508
NCT00136435|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2018-02-08|2005-08-25|2005-08-29|Estimate|||||||2018-02-08|2018-02-09|Actual|June 2002||2002-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study in Adults With Untreated Acute Lymphoblastic Leukemia|A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol|Active, not recruiting||Phase 2|100|Anticipated|Dana-Farber Cancer Institute||1|||f|||||t|f||||||||2018-06-01 04:48:07.685217|2018-06-01 04:48:07.685217
NCT00136422|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-03-09|2005-08-25|2005-08-29|Estimate|||||||2011-03-09|2011-03-10|Estimate|January 2000||2000-01-31|March 2011|2011-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia|A Phase I Study of Vaccination With Lethally Irradiated, Autologous Acute Myeloblastic Leukemia Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia|Completed||Phase 1|30||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:48:07.823243|2018-06-01 04:48:07.823243
NCT00136409|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2016-12-22|2005-08-25|2005-08-29|Estimate|||||||2016-12-22|2016-12-23|Estimate|May 2002||2002-05-31|December 2016|2016-12-31|December 2008|Actual|2008-12-31|August 2005|Actual|2005-08-31||Interventional|||A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)|A Phase II Study of Gleevec (Imatinib Mesylate) In Patients With BCR-Negative Myeloproliferative Disorders Including Patients With Idiopathic Myelofibrosis With Myeloid Dysplasia or Chronic Myelomonocytic Leukemia|Completed||Phase 2|34|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:48:07.917372|2018-06-01 04:48:07.917372
NCT00136396|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2013-06-10|2005-08-26|2005-08-29|Estimate|||||||2013-06-10|2013-06-12|Estimate|January 2004||2004-01-31|June 2013|2013-06-30|November 2010|Actual|2010-11-30|November 2006|Actual|2006-11-30||Interventional|||Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease|An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease|Completed||Phase 1/Phase 2|30|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:48:07.989709|2018-06-01 04:48:07.989709
NCT00136383|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2014-07-18|2005-08-25|2005-08-29|Estimate|||||||2014-07-18|2014-07-21|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|||Comparing Paroxetine and Duloxetine on Cardiovascular Measures|A Study of the Effects of Paroxetine vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control|Completed||Phase 2/Phase 3|40|Anticipated|Duke University|||||||||||||||||||2018-06-01 04:48:08.083227|2018-06-01 04:48:08.083227
NCT00136370|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-09-21|2005-08-25|2005-08-29|Estimate|||||||2007-09-21|2007-09-24|Estimate|April 2004||2004-04-30|September 2007|2007-09-30|November 2007|Anticipated|2007-11-30|||||Interventional|||Prevention of Perinatal Sepsis (PoPS): Evaluation of Chlorhexidine Wipes of Birth Canal and Newborn|Preventing Serious Neonatal and Maternal Peripartum Infections in Developing Country Settings With a High Prevalence of HIV Infection: Assessment of the Disease Burden and Evaluation of an Affordable Intervention in Soweto, South Africa|Unknown status|Recruiting|Phase 3|8000|Anticipated|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 04:48:08.14824|2018-06-01 04:48:08.14824
NCT00136357|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2014-01-27||2015-02-02|2005-08-26|2005-08-29|Estimate|2015-02-02|2015-02-16|Estimate||||2015-02-02|2015-02-16|Estimate|August 2004||2004-08-31|February 2015|2015-02-28|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Treatment of Posttraumatic Stress Disorder in Kosovar High School Students Using Mind-Body Skills Groups|Treatment of Posttraumatic Stress Disorder in Kosovar High School Students Using Mind-Body Skills Groups: A Randomized Controlled Trial|Completed||N/A|82|Actual|The Center for Mind-Body Medicine||2|||f||||f||||||||||2018-06-01 04:48:08.233818|2018-06-01 04:48:08.233818
NCT00136318|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|2012-10-25||2013-03-20|2005-08-26|2005-08-29|Estimate|2013-03-20|2013-03-21|Estimate||||2013-03-20|2013-03-21|Estimate|January 2004||2004-01-31|March 2013|2013-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|CIPPAD||Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients|Efficacy and Tolerability of Escitalopram for the Prevention of Pegylated Interferon Alfa Associated Depression in Patients With Chronic Hepatitis C Infection: a Randomized Controlled Trial.|Completed||Phase 3|208|Actual|Charite University, Berlin, Germany|Random assignment of patients before the preobservation period followed by patient withdrawal from the trial independent of antidepressant treatment weakens the strength of the randomization.|2|||f||||t||||||||||2018-06-01 04:48:08.727079|2018-06-01 04:48:08.727079
NCT00136305|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-26|||2015-02-03|2005-08-26|2005-08-29|Estimate|||||||2015-02-03|2015-02-04|Estimate|August 2005||2005-08-31|February 2015|2015-02-28||||May 2006|Actual|2006-05-31||Interventional|||Comparing Asthma Action Plans for Pediatric Asthma|Relative Effectiveness of Pictorial and Written Asthma Action Plans for Pediatric Asthma|Terminated||Phase 2|4|Actual|Children's Mercy Hospital Kansas City||2||PI moved to a different institution|f||||f||||||||||2018-06-01 04:48:09.068648|2018-06-01 04:48:09.068648
NCT00136292|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2017-12-19|2005-08-25|2005-08-29|Estimate|||||||2017-12-19|2017-12-20|Actual|August 24, 2005|Actual|2005-08-24|December 2017|2017-12-31|August 9, 2006|Actual|2006-08-09|August 1, 2006|Actual|2006-08-01||Interventional|||Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics|An Evaluation of the Pharmacokinetics of a Single Dose of Daptomycin (4 mg/kg) in Pediatric Patients Aged Two to Seventeen Years Who Are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection|Completed||Phase 1|33|Actual|Cubist Pharmaceuticals LLC|||||||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:48:09.166549|2018-06-01 04:48:09.166549
NCT00136279|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2009-01-30|2005-08-26|2005-08-29|Estimate|||||||2009-01-30|2009-02-03|Estimate|January 2004||2004-01-31|January 2009|2009-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Linking Lives: Building Quality Parent Components for School-Based Health Programs in Middle Schools|RCT of Tobacco Use Prevention and Sexual Risk Reduction Interventions for Parents of African American and Latino Youth in Middle School|Completed||N/A|9510|Anticipated|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-06-01 04:48:09.274178|2018-06-01 04:48:09.274178
NCT00136266|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2016-02-02|2005-08-25|2005-08-29|Estimate|||||||2016-02-02|2016-02-03|Estimate|March 2005||2005-03-31|September 2007|2007-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Adherence With Iron Sprinkles Among High-Risk Infants|Adherence With Iron Sprinkles Among High-Risk Infants|Completed||Phase 3|128|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:48:09.362691|2018-06-01 04:48:09.362691
NCT00136253|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2005-12-12|2005-08-25|2005-08-29|Estimate|||||||2005-12-12|2005-12-13|Estimate|February 2002||2002-02-28|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||Overcoming Nutritional Barriers in Hemodialysis Patients||Completed||N/A|||Case Western Reserve University|||||f||||||||||||||2018-06-01 04:48:09.446458|2018-06-01 04:48:09.446458
NCT00136240|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2013-07-24|2005-08-25|2005-08-29|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2003||2003-04-30|August 2008|2008-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Automated Telephone System to Improve Treatment Adherence in People With Depression|Telecom System to Improve Adherence to Antidepressants|Completed||N/A|144||Boston Medical Center|||||f||||||||||||||2018-06-01 04:48:09.502713|2018-06-01 04:48:09.502713
NCT00136227|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2012-09-06|2005-08-25|2005-08-29|Estimate|||||||2012-09-06|2012-09-07|Estimate|October 2005||2005-10-31|September 2012|2012-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Use and Decision-making About Colorectal Cancer Screening Among Hispanic Men and Women|Trial of Interventions to Increase Utilization of Colorectal Cancer Screening and Promote Informed Decision Making About Colorectal Cancer Screening Among Hispanic Men and Women|Completed||N/A|521|Actual|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-06-01 04:48:09.576072|2018-06-01 04:48:09.576072
NCT00136214|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-12-19|2005-08-26|2005-08-29|Estimate|||||||2007-12-19|2007-12-24|Estimate|March 2004||2004-03-31|August 2005|2005-08-31|December 2006||2006-12-31|||||Observational|||Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects|A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects|Unknown status|Recruiting||26|Anticipated|Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:48:09.664903|2018-06-01 04:48:09.664903
NCT00136201|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2009-07-06|2005-08-25|2005-08-26|Estimate|||||||2009-07-06|2009-07-07|Estimate|November 2005||2005-11-30|July 2009|2009-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections|A Multicenter, Randomized, Open-Label Comparison of the Safety and Efficacy of Tigecycline> vs Imipenem/Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Chinese Subjects|Completed||Phase 3|200||Wyeth is now a wholly owned subsidiary of Pfizer||1|||f||||||||||||||2018-06-01 04:48:09.74153|2018-06-01 04:48:09.74153
NCT00136188|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2012-06-18|2005-08-25|2005-08-26|Estimate|||||||2012-06-18|2012-06-19|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Nitric Oxide (NO) Activity and Diabetic Nephropathy|Role of NO Activity for the Development of Diabetic Nephropathy|Completed||Phase 2/Phase 3|100|Actual|University of Erlangen-Nürnberg Medical School|||||f||||||||||||||2018-06-01 04:48:09.832918|2018-06-01 04:48:09.832918
NCT00136175|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2015-01-20|2005-08-25|2005-08-26|Estimate|||||||2015-01-20|2015-01-21|Estimate|November 1999||1999-11-30|January 2015|2015-01-31|October 2007|Actual|2007-10-31|December 2005|Actual|2005-12-31||Interventional|||Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder|Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder|Completed||Phase 2|68|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-06-01 04:48:09.924698|2018-06-01 04:48:09.924698
NCT00136149|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2014-12-04|2005-08-25|2005-08-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Study on Immediate Placement to Evaluate Astra Tech Osseospeed Implants in an Immediate Loading Protocol in Extraction Sockets and Healed Ridges|An Open, Prospective, Controlled Study on Immediate Placement to Evaluate Clinical Outcome of Astra Tech Implants, Fixture Microthread Osseospeed in an Immediate Loading Protocol in Extraction Sockets and Healed Ridges|Unknown status|Active, not recruiting|N/A|51|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:48:10.010255|2018-06-01 04:48:10.010255
NCT00136136|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2014-12-04|2005-08-25|2005-08-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2003||2003-08-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Validation of Bispectral Index (BIS)-Monitor in 3 Groups of Newborn Children|Validation of BIS-monitor in 3 Groups of Newborn Children|Unknown status|Recruiting||60|Anticipated|University Hospital, Ghent|||3||f||||f||||||||||2018-06-01 04:48:10.078329|2018-06-01 04:48:10.078329
NCT00136123|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2014-12-04|2005-08-25|2005-08-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2005||2005-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Immediate Load of Dental Implants, Placed in Atrophic Upper and/or Lower Jaw of Partial or Complete Edentate Patients, According to Flapless Technique|Immediate Load of Dental Implants, Placed in Atrophic Upper and/or Lower Jaw of Partial or Complete Edentate Patients, According to Flapless Technique|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:48:10.146934|2018-06-01 04:48:10.146934
NCT00136110|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-04-30|2005-08-24|2005-08-26|Estimate|||||||2007-04-30|2007-05-01|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis|A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS|Completed||Phase 3|165|Actual|UMC Utrecht|||||f||||||||||||||2018-06-01 04:48:10.211653|2018-06-01 04:48:10.211653
NCT00136097|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-12-19|2005-08-25|2005-08-26|Estimate|||||||2007-12-19|2007-12-28|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Study on the Infection Risk of Long Dwell Period Catheters in High Risk Intensive Care Unit (ICU) Patients|Study on the Infection Risk of Long Dwell Period Catheters in High Risk ICU Patients|Terminated||N/A|142||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:48:10.272285|2018-06-01 04:48:10.272285
NCT00136084|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|2010-03-05||2012-11-02|2005-08-25|2005-08-26|Estimate|2010-03-05|2010-03-26|Estimate||||2012-11-02|2012-12-05|Estimate|August 2002||2002-08-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|July 2008|Actual|2008-07-31||Interventional|||Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia|A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia|Completed||Phase 3|238|Actual|St. Jude Children's Research Hospital||2|||f||||t||||||||||2018-06-01 04:48:10.363376|2018-06-01 04:48:10.363376
NCT00136071|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2005-12-19|2005-08-25|2005-08-26|Estimate|||||||2005-12-19|2005-12-20|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|May 2010||2010-05-31|||||Interventional|||Transvaginal Tension Free Vaginal Tape-Obturator (TVT-O) Versus Transobturator Tape-Mentor (TOT) in the Management of Urodynamic Stress Urinary Incontinence|Randomised Prospective Blinded Trial Comparing Transvaginal Tension Free Vaginal Tape-Obturator (Outside-In) With Transobturator Tape-Mentor (Inside-Out) in Surgical Management of Urodynamic Stress Urinary Incontinence|Unknown status|Recruiting|N/A|230||South Glasgow University Hospitals NHS Trust|||||f||||||||||||||2018-06-01 04:48:10.764032|2018-06-01 04:48:10.764032
NCT00136058|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-12-15|2005-08-25|2005-08-26|Estimate|||||||2011-12-15|2011-12-16|Estimate|January 2002||2002-01-31|December 2011|2011-12-31|April 2006||2006-04-30|||||Interventional|||Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients|Completed||Phase 3|250||University of Alberta|||||f||||||||||||||2018-06-01 04:48:10.926642|2018-06-01 04:48:10.926642
NCT00136045|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2014-09-24|2005-08-24|2005-08-26|Estimate|||||||2014-09-24|2014-09-25|Estimate|May 2005||2005-05-31|February 2010|2010-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome|A Multi-center, Randomized, Double-blind, Placebo-controlled, Four-arm Parallel-group Trial to Investigate the Efficacy and Safety of Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome|Completed||Phase 3|549|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:48:11.00593|2018-06-01 04:48:11.00593
NCT00136032|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2008-02-12|2005-08-25|2005-08-26|Estimate|||||||2008-02-12|2008-02-18|Estimate|January 2002||2002-01-31|February 2008|2008-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women|Gender-Specific Effects of Physiologic GH Administration on Cardiovascular Risk Factors in Women With Growth Hormone Deficiency|Completed||N/A|63|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:48:11.074063|2018-06-01 04:48:11.074063
NCT00136019|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2014-09-19|2005-08-24|2005-08-26|Estimate|||||||2014-09-19|2014-09-22|Estimate|March 2004||2004-03-31|July 2010|2010-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization|Completed||Phase 3|400|Anticipated|UCB Pharma|||||f||||||||||||||2018-06-01 04:48:11.163834|2018-06-01 04:48:11.163834
NCT00136006|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2013-01-30|2005-08-25|2005-08-26|Estimate|||||||2013-01-30|2013-02-01|Estimate|August 2005||2005-08-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Vancouver-BOLD Study: The Burden of Chronic Obstructive Lung Disease|The Burden of Chronic Obstructive Lung Disease (BOLD) Study|Unknown status|Active, not recruiting||1000|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:48:11.228435|2018-06-01 04:48:11.228435
NCT00135993|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2014-09-24|2005-08-24|2005-08-26|Estimate|||||||2014-09-24|2014-09-25|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome|Completed||Phase 3|811|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:48:11.295822|2018-06-01 04:48:11.295822
NCT00135980|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-02-28|2005-08-25|2005-08-26|Estimate|||||||2007-02-28|2007-03-01|Estimate|August 2004||2004-08-31|February 2007|2007-02-28|July 2007||2007-07-31|||||Interventional|||Integrated Care for Cancer Patients; Developing, Implementing and Testing a Programme to Improve Integrated Care|Integrated Care for Cancer Patients|Unknown status|Recruiting|N/A|300||Radboud University|||||f||||||||||||||2018-06-01 04:48:11.376176|2018-06-01 04:48:11.376176
NCT00135967|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2005-12-05|2005-08-25|2005-08-26|Estimate|||||||2005-12-05|2005-12-06|Estimate|May 2002||2002-05-31|August 2005|2005-08-31||||||||Interventional|||Mycophenolate Mofetil in Membranous Nephropathy|Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study|Completed||Phase 2/Phase 3|30||Radboud University|||||f||||||||||||||2018-06-01 04:48:11.474759|2018-06-01 04:48:11.474759
NCT00135954|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2014-01-27|2005-08-25|2005-08-26|Estimate|||||||2014-01-27|2014-01-28|Estimate|July 1997||1997-07-31|February 2007|2007-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Treatment of Patients With Idiopathic Membranous Nephropathy|Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy|Completed||Phase 3|29|Actual|Radboud University||2|||f||||||||||||||2018-06-01 04:48:11.546636|2018-06-01 04:48:11.546636
NCT00135941|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2009-06-02|2005-08-25|2005-08-26|Estimate|||||||2009-06-02|2009-06-04|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|||||Interventional|||Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)|Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes|Completed||Phase 3|582|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:48:11.624478|2018-06-01 04:48:11.624478
NCT00135928|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-08-04|2005-08-25|2005-08-26|Estimate|||||||2011-08-04|2011-08-08|Estimate|May 2003||2003-05-31|February 2005|2005-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Stem Cells in Myocardial Infarction|Bone Marrow Stimulation With G-CSF in Acute Myocardial Infarction,|Completed||Phase 2|78||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:48:11.696808|2018-06-01 04:48:11.696808
NCT00135915|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2009-10-30|2005-08-24|2005-08-26|Estimate|||||||2009-10-30|2009-11-02|Estimate|August 2005||2005-08-31|October 2009|2009-10-31|February 2007|Actual|2007-02-28|||||Observational|||Influence of Binge Drinking on Glucose Metabolism in Patients With Type 1 Diabetes - A Pilot Study|Influence of Binge Drinking on Glucose Metabolism in Patients With Type 1 Diabetes - A Pilot Study|Completed|||10|Actual|The Royal Bournemouth Hospital|||||f||||t||||||||||2018-06-01 04:48:11.768214|2018-06-01 04:48:11.768214
NCT00135902|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2016-09-29|2005-08-25|2005-08-26|Estimate|||||||2016-09-29|2016-10-03|Estimate|February 2005||2005-02-28|September 2016|2016-09-30|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies|A Randomized Trial of Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in Pregnancies at High Risk|Completed||Phase 3|800|Actual|The George Washington University Biostatistics Center|||||f||||t||||||||Yes|The data will be shared after completion and publication of the main analyses in accordance with NIH policy. The contact to obtain datasets is mfmudatasets@bsc.gwu.edu.|2018-06-01 04:48:11.830484|2018-06-01 04:48:11.830484
NCT00135889|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2009-10-07|2005-08-24|2005-08-26|Estimate|||||||2009-10-07|2009-10-08|Estimate|January 2005||2005-01-31|October 2009|2009-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Continuous Femoral Nerve Block Following Total Knee Replacement|Improving Postoperative Rehabilitation Following Total Knee Arthroplasty With Perineural Local Anesthetic Infusion|Completed||N/A|50||National Institute of General Medical Sciences (NIGMS)|||||f||||t||||||||||2018-06-01 04:48:11.952313|2018-06-01 04:48:11.952313
NCT00135876|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-04-25|2005-08-24|2005-08-26|Estimate|||||||2007-04-25|2007-04-27|Estimate|October 2002||2002-10-31|April 2007|2007-04-30|November 2006|Actual|2006-11-30|||||Interventional|||Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients|A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)|Completed||Phase 3|512||Ontario Clinical Oncology Group (OCOG)|||||f||||f||||||||||2018-06-01 04:48:12.021057|2018-06-01 04:48:12.021057
NCT00135863|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2015-05-20|2005-08-25|2005-08-26|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 2004||2004-05-31|January 2004|2004-01-31|May 2005||2005-05-31|||||Interventional|||MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis|Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis|Terminated||N/A|36||Ribe County Hospital|||||f||||||||||||||2018-06-01 04:48:12.10545|2018-06-01 04:48:12.10545
NCT00135850|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-08-04|2005-08-25|2005-08-26|Estimate|||||||2011-08-04|2011-08-05|Estimate|March 2003||2003-03-31|October 2002|2002-10-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris|The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris|Completed||Phase 1/Phase 2|48||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:48:12.169206|2018-06-01 04:48:12.169206
NCT00135837|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2006-06-20|2005-08-24|2005-08-26|Estimate|||||||2006-06-20|2006-06-21|Estimate|June 2003||2003-06-30|June 2006|2006-06-30||||||||Interventional|||Photodynamic Therapy in Occult-Only Lesions (POOL)|An Open-Label, Multicenter, Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration|Completed||Phase 4|202||Novartis|||||f||||||||||||||2018-06-01 04:48:12.225231|2018-06-01 04:48:12.225231
NCT00135824|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-11-16|2005-08-25|2005-08-26|Estimate|||||||2011-11-16|2011-11-17|Estimate|March 2004||2004-03-31|November 2011|2011-11-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Local Tolerability and Safety of Povidone K25 Eye Drops (Artificial Tears Containing Povidone) Versus Placebo in Healthy Volunteers|Local Tolerability and Safety of Povidone K25 (Artificial Tears Containing Povidone) vs. Placebo in Healthy Volunteers|Completed||Phase 4|30|Actual|Novartis|||||f||||||||||||||2018-06-01 04:48:12.304345|2018-06-01 04:48:12.304345
NCT00135811|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2012-05-21|2005-08-24|2005-08-26|Estimate|||||||2012-05-21|2012-05-22|Estimate|November 2004||2004-11-30|May 2012|2012-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)|Focal Segmental Glomerulosclerosis Clinical Trial|Completed||Phase 3|207|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 04:48:12.375505|2018-06-01 04:48:12.375505
NCT00135798|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|2012-06-13||2013-04-11|2005-08-25|2005-08-26|Estimate|2013-02-22|2013-04-04|Estimate||||2013-04-11|2013-04-23|Estimate|September 2005||2005-09-30|April 2013|2013-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|LADR||Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation|The Adult-to-adult Living Donor Liver Transplantation Cohort Study (A2ALL) Low Accelerated Dosing Regimen (LADR) Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C Virus (HCV) After Liver Transplantation|Completed||Phase 2|79|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Failure to reach target of 84 transplanted patients (47 achieved); Inability to complete planned 12 weeks of treatment for some; Incomplete HCV RNA follow up; Inconsistent limits of detection of HCV RNA; Noncompliance with assigned treatment.|3|||f||||t||||||||||2018-06-01 04:48:12.467109|2018-06-01 04:48:12.467109
NCT00135785|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-11|2005-08-23|2005-08-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Bupropion vs Placebo for the Treatment of Methamphetamine Dependence|Completed||Phase 2|73|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 04:48:12.826644|2018-06-01 04:48:12.826644
NCT00135772|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-11|2005-08-23|2005-08-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2003||2003-10-31|August 2008|2008-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Observational|||Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2|Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder|Completed|||100||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:48:12.898021|2018-06-01 04:48:12.898021
NCT00135759|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-11|2005-08-25|2005-08-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2005||2005-04-30|August 2008|2008-08-31|July 2006|Actual|2006-07-31|||||Interventional|||Addition of Naltrexone to Methadone Taper|Place of Low-Dose Naltrexone in Opiate Detoxification|Completed||Phase 2|174|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 04:48:12.981492|2018-06-01 04:48:12.981492
NCT00135746|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-11|2005-08-23|2005-08-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2004||2004-05-31|October 2015|2015-10-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2|Effects of Transdermal Nicotine on Tobacco Withdrawal and the Effects of Smoking in Men and Women|Completed||N/A|128|Anticipated|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:48:13.096422|2018-06-01 04:48:13.096422
NCT00135733|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2009-02-10|2005-08-24|2005-08-26|Estimate|||||||2009-02-10|2009-02-12|Estimate|April 2004||2004-04-30|February 2009|2009-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Efficacy and Safety of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus|Terminated||Phase 2|13|Actual|Massachusetts General Hospital||2||Pharmaceutical sponsor withdrew financial support.|f||||f||||||||||2018-06-01 04:48:13.163952|2018-06-01 04:48:13.163952
NCT00135720|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2015-06-02|2005-08-24|2005-08-26|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|November 2007|Actual|2007-11-30|||||Interventional|||Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris|A Double-Blinded, Placebo-Controlled Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris|Completed||Phase 2|12|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:48:13.255618|2018-06-01 04:48:13.255618
NCT00135707|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2010-05-12|2005-08-24|2005-08-26|Estimate|||||||2010-05-12|2010-05-13|Estimate|June 2003||2003-06-30|May 2010|2010-05-31|January 2009|Actual|2009-01-31|February 2008|Actual|2008-02-29||Interventional|CAPPS||Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)|A Randomized Clinical Trial of Antioxidants to Prevent Preeclampsia and An Observational Cohort Study to Predict Preeclampsia|Completed||Phase 3|10154|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 04:48:13.325742|2018-06-01 04:48:13.325742
NCT00135694|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2016-10-13||2016-12-08|2005-08-25|2005-08-26|Estimate|2016-10-13|2016-12-08|Estimate||||2016-12-08|2017-02-02|Estimate|October 2005||2005-10-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|A-WISH|Enrolled sample (subjects transplanted in the study)|Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant|A Phase II Trial to Assess the Safety of Immunosuppression Withdrawal in Liver Transplant Recipients|Completed||Phase 2|275|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 04:48:13.571633|2018-06-01 04:48:13.571633
NCT00135681|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2016-01-14|2005-08-23|2005-08-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|December 1996||1996-12-31|January 2016|2016-01-31|November 2001||2001-11-30|||||Interventional|||Immune Dysregulation in Children and Adults With Asthma||Completed||N/A|||University of New Mexico|||||f||||||||||||||2018-06-01 04:48:15.208485|2018-06-01 04:48:15.208485
NCT00135668|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2009-05-26|2005-08-25|2005-08-26|Estimate|||||||2009-05-26|2009-05-27|Estimate|August 2005||2005-08-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|March 2008|Actual|2008-03-31||Interventional|||Dose-Response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room|A Phase 2 Multicenter, Randomized, Double-Blind, Parallel Group, Dose-Ranging, Effect-Controlled Study to Determine the Pharmacokinetics and Pharmacodynamics of Sodium Nitroprusside in Pediatric Subjects|Completed||Phase 2|203|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||4|||f||||t||||||||||2018-06-01 04:48:15.269566|2018-06-01 04:48:15.269566
NCT00135655|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2013-05-20|2005-08-24|2005-08-26|Estimate|||||||2013-05-20|2013-05-21|Estimate|August 2005||2005-08-31|May 2013|2013-05-31||||||||Interventional|||A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema|A Randomized, Double-Masked, Parallel, Group, Multi-Center, Dose Ranging Pilot Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:48:15.407383|2018-06-01 04:48:15.407383
NCT00135642|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2016-02-11|2005-08-25|2005-08-26|Estimate|||||||2016-02-11|2016-02-12|Estimate|February 1996||1996-02-29|August 2005|2005-08-31|October 1998||1998-10-31|||||Interventional|||Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and Asthma|Randomized Double Blind Placebo Controlled Trial of Grass Pollen Immunotherapy Using a Cluster Regime|Completed||Phase 3|44||Imperial College London|||||f||||||||||||||2018-06-01 04:48:15.464411|2018-06-01 04:48:15.464411
NCT00135629|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2010-11-22|2005-08-25|2005-08-26|Estimate|||||||2010-11-22|2010-11-23|Estimate|October 2002||2002-10-31|November 2010|2010-11-30|February 2004||2004-02-29|||||Interventional|||Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever|Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever: A Pilot Study. (Up-dosing Study)|Unknown status|Active, not recruiting|Phase 3|18||Imperial College London|||||f||||||||||||||2018-06-01 04:48:15.559175|2018-06-01 04:48:15.559175
NCT00135616|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-04-27|2005-08-25|2005-08-26|Estimate|||||||2007-04-27|2007-04-30|Estimate|March 2005||2005-03-31|April 2007|2007-04-30|March 2008|Anticipated|2008-03-31|||||Interventional|||Treatment of Female Stress Urinary Incontinence: Study Comparing Two Suburethral Slings, Retropubic Approach (TVT) and Trans-Obturator (TVT-O) Approach|Randomized Controlled Study Comparing Two Types of Suburethral Slings for the Surgical Treatment of Female Stress Incontinence : TVT and TVT-O.|Unknown status|Active, not recruiting|Phase 4|180|Anticipated|Hopital Antoine Beclere|||||f||||||||||||||2018-06-01 04:48:15.639201|2018-06-01 04:48:15.639201
NCT00135603|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2009-02-11|2005-08-24|2005-08-26|Estimate|||||||2009-02-11|2009-02-12|Estimate|February 2004||2004-02-29|January 2009|2009-01-31|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|||Antibiotic Therapy Versus Appendectomy for Acute Appendicitis|A Prospective Randomized Multicentric Trial Comparing Amoxicillin/Clavulanate Potassium Therapy to Appendectomy for Acute Non Complicated Appendicitis|Completed||N/A|243|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:48:15.706346|2018-06-01 04:48:15.706346
NCT00135590|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-11-20|2005-08-24|2005-08-26|Estimate|||||||2007-11-20|2007-11-22|Estimate|November 2004||2004-11-30|November 2004|2004-11-30|October 2007|Actual|2007-10-31|||||Interventional|PRO-PULSé||Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients|Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients|Completed||N/A|68|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:48:15.774081|2018-06-01 04:48:15.774081
NCT00135577|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2015-09-01|2005-08-24|2005-08-26|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects|A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects|Completed||Phase 2|67|Actual|Cubist Pharmaceuticals LLC||4|||f||||||||||||||2018-06-01 04:48:15.84157|2018-06-01 04:48:15.84157
NCT00135564|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2016-09-15|2005-08-25|2005-08-26|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2003||2003-01-31|September 2016|2016-09-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers|Evaluate the Persistence and Immune Memory Induced by a Primary Vaccination Course With GSK Biologicals' MenC-TT (1 Formulation) & GSK Biologicals' Hib-MenC-TT (2 Formulations) or Meningitec™ in Healthy Toddlers Aged 12-15 Months Primed in Study 711202/001|Completed||Phase 2|500|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:48:16.901305|2018-06-01 04:48:16.901305
NCT00135551|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2012-02-19|2005-08-24|2005-08-26|Estimate|||||||2012-02-19|2012-02-22|Estimate|May 2003||2003-05-31|February 2012|2012-02-29|November 2010|Actual|2010-11-30|May 2010|Actual|2010-05-31||Interventional|COPE||Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients|The Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial|Completed||Phase 4|3501|Actual|COPE Trial Group||3|||f||||t||||||||||2018-06-01 04:48:16.982795|2018-06-01 04:48:16.982795
NCT00135538|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2007-04-04|2005-08-25|2005-08-26|Estimate|||||||2007-04-04|2007-04-05|Estimate|November 2004||2004-11-30|April 2007|2007-04-30|April 2009|Anticipated|2009-04-30|||||Interventional|||The Additional Value of Noninvasive Ventilation Next to Rehabilitation in Hypercapnic COPD Patients|Does Chronic Ventilatory Support Improve the Outcomes of Rehabilitation in Hypercapnic COPD Patients?|Unknown status|Active, not recruiting|Phase 3|100||Groningen Research Institute for Asthma and COPD|||||f||||f||||||||||2018-06-01 04:48:17.078577|2018-06-01 04:48:17.078577
NCT00135525|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2011-01-27|2005-08-24|2005-08-26|Estimate|||||||2011-01-27|2011-01-31|Estimate|May 2003||2003-05-31|January 2011|2011-01-31|May 2006|Actual|2006-05-31|October 2005|Actual|2005-10-31||Interventional|||Study Of Generalized Anxiety Disorder|Clinical Evaluation of BRL29060 A in Generalized Anxiety Disorder|Completed||Phase 2|||GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 04:48:17.141948|2018-06-01 04:48:17.141948
NCT00135512|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2017-06-21|2005-08-24|2005-08-26|Estimate|||||||2017-06-21|2017-06-22|Actual|December 1, 2004||2004-12-01|June 2017|2017-06-30|May 28, 2007|Actual|2007-05-28|May 1, 2007|Actual|2007-05-01||Interventional|||Study Of 323U66 SR In Major Depressive Disorder|An Open-Label, Multi-Cetre, Phase II Study Evaluating the Safety and Efficacy of 323U66 SR in Patients With Depression|Completed||Phase 2|100|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:48:17.212731|2018-06-01 04:48:17.212731
NCT00135499|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2006-09-07|2005-08-25|2005-08-26|Estimate|||||||2006-09-07|2006-09-08|Estimate|January 2002||2002-01-31|September 2006|2006-09-30|January 2011||2011-01-31|||||Interventional|||R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-Cell Lymphoma|Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Non Previously Treated Patients Aged From 60 to 65 Years With Diffuse Large B-Cell Lymphoma|Terminated||Phase 3|560||Lymphoma Study Association|||||f||||||||||||||2018-06-01 04:48:17.292859|2018-06-01 04:48:17.292859
NCT00135486|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2016-09-15|2005-08-25|2005-08-26|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2002||2002-03-31|September 2016|2016-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants|Evaluate Immunogenicity, Reactogenicity, Safety of GSK Biologicals' MenC-TT Vaccine (2 Formulations) Given With Infanrix Hexa® + GSK Biologicals' Hib MenC-TT Vaccine (2 Formulations) Given With Infanrix Penta® to Infants in Mths 3,4,5 of Life|Completed||Phase 2|500|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:48:17.494463|2018-06-01 04:48:17.494463
NCT00135473|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2016-02-10|2005-08-24|2005-08-26|Estimate|||||||2016-02-10|2016-02-11|Estimate|April 2003||2003-04-30|February 2016|2016-02-29|September 2005||2005-09-30|||||Interventional|||Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)|Prospective Randomized Multicenter Study on the Influence of Colloid vs Crystalloid Volume Resuscitation and of Intensive vs Conventional Insulin Therapy on Outcome in Patients With Severe Sepsis and Septic Shock|Completed||Phase 3|600||German Competence Network Sepsis|||||f||||||||||||||2018-06-01 04:48:17.608123|2018-06-01 04:48:17.608123
NCT00135460|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2006-03-13|2005-08-25|2005-08-26|Estimate|||||||2006-03-13|2006-03-14|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|November 2007||2007-11-30|||||Interventional|||Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients|Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial.|Unknown status|Active, not recruiting|Phase 4|100||Danish HIV Research Group|||||f||||||||||||||2018-06-01 04:48:17.713369|2018-06-01 04:48:17.713369
NCT00135447|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-04-13|2005-08-25|2005-08-26|Estimate|||||||2011-04-13|2011-04-14|Estimate|September 2004||2004-09-30|April 2011|2011-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen|A Phase IV, Multicenter, Cross-sectional Study to Evaluate the I50L Substitution Among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)|Completed|||5000|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-06-01 04:48:17.81944|2018-06-01 04:48:17.81944
NCT00135434|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2011-04-07|2005-08-25|2005-08-26|Estimate|||||||2011-04-07|2011-04-08|Estimate|September 2004||2004-09-30|November 2009|2009-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism|Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism|Completed||Phase 1|25||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:48:18.003601|2018-06-01 04:48:18.003601
NCT00135421|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25||2010-02-27|2010-02-27|2005-08-25|2005-08-26|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|November 2005||2005-11-30|September 2008|2008-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder|Completed||Phase 1/Phase 2|271|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 04:48:18.089691|2018-06-01 04:48:18.089691
NCT00135408|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|||2016-09-26|2005-08-25|2005-08-26|Estimate|||||||2016-09-26|2016-09-28|Estimate|December 2005||2005-12-31|September 2016|2016-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide|Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients With Previously Treated Unresectable Stage III or IV Malignant Melanoma|Completed||Phase 2|115|Actual|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 04:48:18.208572|2018-06-01 04:48:18.208572
NCT00135395|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25||2010-02-03|2010-02-03|2005-08-25|2005-08-26|Estimate||||2010-02-03|2010-02-05|Estimate|2010-02-03|2010-02-05|Estimate|May 2004||2004-05-31|July 2008|2008-07-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen|A Phase IIIb, Open -Label, Randomized Multi-center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, in Combination With Two Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in HIV-1 Infected Subjects Experiencing Their First Virologic Failure While Receiving a NNRTI-containing HAART Regimen.|Completed||Phase 3|200|Anticipated|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 04:48:18.400594|2018-06-01 04:48:18.400594
NCT00135382|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25||2010-01-27|2010-01-27|2005-08-25|2005-08-26|Estimate||||2010-01-27|2010-02-17|Estimate|2010-01-27|2010-02-17|Estimate|June 2002||2002-06-30|January 2010|2010-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen|A Phase 3 Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen|Completed||Phase 3|254||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:48:18.603019|2018-06-01 04:48:18.603019
NCT00135369|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25||2010-01-28|2011-04-08|2005-08-25|2005-08-26|Estimate||||2010-01-28|2010-02-01|Estimate|2011-04-08|2011-04-25|Estimate|September 2002||2002-09-30|April 2011|2011-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen|A Phase 3 Study Switching HIV-1 Infected Subjects With an Undetectable Viral Load From a HAART Regimen Dosed Twice Daily or More Frequently to a Once-Daily HAART Regimen|Completed||Phase 3|300||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:48:18.761288|2018-06-01 04:48:18.761288
NCT00135356|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25|2009-12-15||2010-04-20|2005-08-25|2005-08-26|Estimate|2010-04-20|2010-05-07|Estimate||||2010-04-20|2010-05-07|Estimate|July 2005||2005-07-31|April 2010|2010-04-30|June 2008|Actual|2008-06-30|July 2007|Actual|2007-07-31||Interventional|||Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome|A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study)|Completed||Phase 4|219|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 04:48:18.966775|2018-06-01 04:48:18.966775
NCT00135343|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-25||2010-01-27|2011-04-07|2005-08-25|2005-08-26|Estimate||||2010-01-27|2010-02-15|Estimate|2011-04-07|2011-04-14|Estimate|April 2004||2004-04-30|July 2008|2008-07-31|October 2005||2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen|A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen|Completed||Phase 3|60||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 04:48:20.26603|2018-06-01 04:48:20.26603
NCT00135330|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|2009-07-21||2015-03-19|2005-08-24|2005-08-26|Estimate|2009-07-21|2009-08-28|Estimate||||2015-03-19|2015-04-07|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus|An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin|Completed||Phase 3|137|Actual|AstraZeneca||3|||f||||f||||||||||2018-06-01 04:48:20.44881|2018-06-01 04:48:20.44881
NCT00135317|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2013-05-21|2005-08-24|2005-08-26|Estimate|||||||2013-05-21|2013-05-23|Estimate|November 2004||2004-11-30|May 2013|2013-05-31||||||||Interventional|||AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies|A Randomized Open-Label Study of Darbepoetin Alfa Administered Every Three Weeks With or Without Parenteral Iron in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy|Completed||Phase 3|||Amgen|||||f||||||||||||||2018-06-01 04:48:21.655527|2018-06-01 04:48:21.655527
NCT00135304|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2014-02-07|2005-08-25|2005-08-26|Estimate|||||||2014-02-07|2014-02-11|Estimate|August 2005||2005-08-31|February 2014|2014-02-28|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism|ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone|Completed||Phase 4|170|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:48:21.715472|2018-06-01 04:48:21.715472
NCT00135291|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2008-01-02|2005-08-23|2005-08-25|Estimate|||||||2008-01-02|2008-01-11|Estimate|February 2003||2003-02-28|January 2008|2008-01-31|September 2004|Actual|2004-09-30|||||Interventional|||Effect of Leukoreduced Blood Transfusions on Infection Following Trauma|Effect of Leukoreduction in Infection Risk in Trauma|Completed||Phase 2/Phase 3|300||University of Washington|||||f||||||||||||||2018-06-01 04:48:21.782858|2018-06-01 04:48:21.782858
NCT00135278|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-10-24|2005-08-23|2005-08-25|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2008||2008-03-31|October 2017|2017-10-31|January 14, 2010|Actual|2010-01-14|January 27, 2009|Actual|2009-01-27||Interventional|||Cerebrospinal Fluid (CSF) Drainage and Cytokine Profiling in the Treatment of Acute Spinal Cord Injury (SCI)|Cerebrospinal Fluid (CSF) Drainage and Cytokine Profiling in the Treatment of Acute Spinal Cord Injury (SCI) - A Pilot Study|Completed||N/A|31|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 04:48:21.841407|2018-06-01 04:48:21.841407
NCT00135265|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2010-06-24|2005-08-23|2005-08-25|Estimate|||||||2010-06-24|2010-06-28|Estimate|October 2006||2006-10-31|June 2010|2010-06-30|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||PROS Smokebusters: Adolescent Smoking Cessation in Pediatric Primary Care|Adolescent Smoking Cessation in Pediatric Primary Care|Completed||Phase 1|4100|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:48:21.906977|2018-06-01 04:48:21.906977
NCT00135252|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-12-23|2005-08-23|2005-08-25|Estimate|||||||2007-12-23|2008-01-08|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Method of Oxygen Delivery and the Effect on Transcutaneous PaCO2|Method of Oxygen Delivery (Comparison Nasal Cannula vs Oxygen Hood) and the Effect on Transcutaneous PaCO2|Terminated||Phase 2/Phase 3|44|Anticipated|The University of Texas Health Science Center, Houston||||Investigator left institution|f||||||||||||||2018-06-01 04:48:21.95436|2018-06-01 04:48:21.95436
NCT00135239|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2008-06-16|2005-08-23|2005-08-25|Estimate|||||||2008-06-16|2008-06-17|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Care Versus Usual Care for Acute Mechanical Lower Back Pain|Study Care Versus Usual Care for Acute Mechanical Lower Back Pain|Completed||N/A|88|Anticipated|University of British Columbia|||||f||||||||||||||2018-06-01 04:48:22.100868|2018-06-01 04:48:22.100868
NCT00135226|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2015-12-02|2005-08-24|2005-08-25|Estimate|||||||2015-12-02|2015-12-03|Estimate|March 2005||2005-03-31|December 2015|2015-12-31||||September 2017|Anticipated|2017-09-30||Interventional|||ASCEND: A Study of Cardiovascular Events iN Diabetes|A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes|Unknown status|Active, not recruiting|Phase 4|15480|Actual|University of Oxford||4|||f||||||||||||||2018-06-01 04:48:22.167072|2018-06-01 04:48:22.167072
NCT00135213|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-12-20|2005-08-23|2005-08-25|Estimate|||||||2007-12-20|2008-01-03|Estimate|October 2005||2005-10-31|September 2006|2006-09-30|July 2007|Actual|2007-07-31|||||Interventional|||PROS Brief Smoking Cessation Counseling in Pediatric Practice to Reduce Secondhand Smoke Exposure of Young Children|PROS Brief Smoking Cessation Counseling in Pediatric Practice to Reduce Secondhand Smoke Exposure of Young Children|Completed||Phase 1|1200|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:48:22.315325|2018-06-01 04:48:22.315325
NCT00135200|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|2014-11-13||2017-05-03|2005-08-24|2005-08-25|Estimate|2014-11-13|2014-11-20|Estimate||||2017-05-03|2017-06-05|Actual|August 2005||2005-08-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|August 2013|Actual|2013-08-31||Interventional|||Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma|A Phase II Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma|Active, not recruiting||Phase 2|16|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:48:22.386015|2018-06-01 04:48:22.386015
NCT00135187|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2012-02-05|2005-08-23|2005-08-25|Estimate|||||||2012-02-05|2012-02-07|Estimate|July 2004||2004-07-31|February 2012|2012-02-29|December 2007|Actual|2007-12-31|August 2006|Actual|2006-08-31||Interventional|||Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma|A Pilot Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma|Completed||N/A|30|Actual|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 04:48:22.661456|2018-06-01 04:48:22.661456
NCT00135174|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2008-06-12|2005-08-23|2005-08-25|Estimate|||||||2008-06-12|2008-06-17|Estimate|September 2003||2003-09-30|June 2008|2008-06-30|January 2012|Anticipated|2012-01-31|January 2012|Anticipated|2012-01-31||Observational|||Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study|Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The FOLLOWPACE Study|Unknown status|Active, not recruiting||1526|Actual|UMC Utrecht|||||f||||t||||||||||2018-06-01 04:48:22.797487|2018-06-01 04:48:22.797487
NCT00135161|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2014-12-04|2005-08-24|2005-08-25|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2003||2003-09-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer|Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:48:22.898423|2018-06-01 04:48:22.898423
NCT00135148|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-12-19|2005-08-24|2005-08-25|Estimate|||||||2007-12-19|2007-12-28|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|August 2005|Actual|2005-08-31|||||Observational|||Decrease of Libido of Post-Operative Male-Female Transsexuals and a Healthy Female Control Group|Decrease of Libido of Post-Operative Male-Female Transsexuals and a Healthy Female Control Group|Completed|||150||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:48:23.001826|2018-06-01 04:48:23.001826
NCT00135135|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2008-06-02|2005-08-24|2005-08-25|Estimate|||||||2008-06-02|2008-06-03|Estimate|August 2005||2005-08-31|June 2008|2008-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Therapy for Children With Neuroblastoma|Neuroblastoma Protocol 2005: Therapy for Children With Advanced Stage High-Risk Neuroblastoma|Completed||Phase 2|23|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:48:23.146067|2018-06-01 04:48:23.146067
NCT00135122|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2008-09-11|2005-08-24|2005-08-25|Estimate|||||||2008-09-11|2008-09-12|Estimate|September 2003||2003-09-30|September 2008|2008-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache|Medication Overuse Headache: A Randomised Double Blind Study of Prednisolone or Placebo in Withdrawal Therapy (Phase 3), and a Randomised 1 Year Follow up by Neurologist or General Physician After Successful Withdrawal Therapy|Completed||Phase 3|100|Actual|Sorlandet Hospital HF||1|||f||||f||||||||||2018-06-01 04:48:23.298321|2018-06-01 04:48:23.298321
NCT00135109|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2014-09-19|2005-08-23|2005-08-25|Estimate|||||||2014-09-19|2014-09-22|Estimate|October 2004||2004-10-31|February 2010|2010-02-28|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy|Completed||Phase 3|654|Actual|UCB Pharma|||||f||||||||||||||2018-06-01 04:48:23.423112|2018-06-01 04:48:23.423112
NCT00135096|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-01-10|2005-08-24|2005-08-25|Estimate|||||||2011-01-10|2011-01-11|Estimate|August 2004||2004-08-31|January 2011|2011-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin|APIDRA® (Insulin Glulisine) Administered Premeal vs Postmeal in Adult Subjects With Type 2 Diabetes Mellitus Receiving LANTUS® (Insulin Glargine) as Basal Insulin: a Multicenter, Randomized, Parallel, Open Label Clinical Study|Completed||Phase 3|345|Actual|Sanofi||2|||||||||||||||||2018-06-01 04:48:23.48612|2018-06-01 04:48:23.48612
NCT00135083|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-01-10|2005-08-24|2005-08-25|Estimate|||||||2011-01-10|2011-01-11|Estimate|August 2004||2004-08-31|January 2011|2011-01-31|November 2007|Actual|2007-11-30|||||Interventional|||Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus|One Versus Two Versus Three Daily Rapid-acting Insulin Injections of APIDRA (Insulin Glulisine) as add-on to Lantus® and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-label Clinical Study|Completed||Phase 3|347|Actual|Sanofi||3|||||||f||||||||||2018-06-01 04:48:23.646813|2018-06-01 04:48:23.646813
NCT00135070|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-04-27|2005-08-23|2005-08-25|Estimate|||||||2007-04-27|2007-05-01|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Interventional|||Hospital In-Patient Insulin Study|A Randomised Study Comparing Continuous Intravenous Insulin Infusion With Subcutaneous Insulin Analogues in Hospitalised Patients With Type II Diabetes and Hyperglycaemia|Terminated||Phase 4|41|Actual|The Royal Bournemouth Hospital||||No documentation with MHRA to support clinical trial of a medicinal product.|f||||t||||||||||2018-06-01 04:48:23.744317|2018-06-01 04:48:23.744317
NCT00135057|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-01-10|2005-08-24|2005-08-25|Estimate|||||||2011-01-10|2011-01-11|Estimate|April 2004||2004-04-30|January 2011|2011-01-31|August 2005||2005-08-31|||||Interventional|||Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin|Insulin Glulisine Administered in a Fixed Bolus Regimen Versus Variable Bolus Regimen Based on Carbohydrate Counting in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin|Completed||Phase 3|281||Sanofi|||||||||||||||||||2018-06-01 04:48:23.82103|2018-06-01 04:48:23.82103
NCT00135044|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-09-21|2005-08-24|2005-08-25|Estimate|||||||2007-09-21|2007-09-24|Estimate|June 2005||2005-06-30|September 2007|2007-09-30||||||||Interventional|||A Trial of Taurine Supplementation in Parenteral Nutrition 1|A Randomised Double Blind Controlled Crossover Trial of Intravenous Taurine Supplementation in Parenteral Nutrition as an Effective Treatment for Reducing Hepatobiliary Complications in Chronic Intestinal Failure|Unknown status|Recruiting|N/A|24|Anticipated|London North West Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:48:24.100562|2018-06-01 04:48:24.100562
NCT00135031|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-06-14|2005-08-23|2005-08-25|Estimate|||||||2011-06-14|2011-06-15|Estimate|January 2004||2004-01-31|June 2011|2011-06-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Safety and Efficacy Evaluation of Bifidobacterium Infantis 35624 in Female Subjects With Irritable Bowel Syndrome|Completed||Phase 3|362||Procter and Gamble|||||f||||f||||||||||2018-06-01 04:48:24.339001|2018-06-01 04:48:24.339001
NCT00135018|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2012-05-22|2005-08-24|2005-08-25|Estimate|||||||2012-05-22|2012-05-24|Estimate|February 2006||2006-02-28|May 2012|2012-05-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer|Phase II Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer|Completed||Phase 2|||Organisation for Oncology and Translational Research|||||f||||t||||||||||2018-06-01 04:48:24.427538|2018-06-01 04:48:24.427538
NCT00135005|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2013-05-09|2005-08-23|2005-08-25|Estimate|||||||2013-05-09|2013-05-13|Estimate|August 2005||2005-08-31|May 2013|2013-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)|A Phase I Multicenter, Dose Escalation Study of AMN107 in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant Gastrointestinal Stromal Tumors (GIST)|Completed||Phase 1|59|Actual|Novartis||1|||f||||||||||||||2018-06-01 04:48:24.489899|2018-06-01 04:48:24.489899
NCT00134992|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2006-06-07|2005-08-24|2005-08-25|Estimate|||||||2006-06-07|2006-06-09|Estimate|August 2004||2004-08-31|June 2006|2006-06-30||||||||Interventional|||A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers|Single-Center, Randomized, Double Masked, Two-Period Cross-Over, Three Days Per Period, Phase IV Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers|Completed||Phase 4|30||Novartis|||||f||||||||||||||2018-06-01 04:48:24.668527|2018-06-01 04:48:24.668527
NCT00134979|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2011-10-24|2005-08-24|2005-08-25|Estimate|||||||2011-10-24|2011-10-25|Estimate|October 2004||2004-10-31|October 2011|2011-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease|Efficacy and Safety of Formoterol Certihaler, Tiotropium HandiHaler and Tiotropium HandiHaler in Combination With Formoterol Certihaler in Patients With Stable Chronic Obstructive Pulmonary Disease|Completed||Phase 4|847|Actual|Novartis|||||f||||||||||||||2018-06-01 04:48:24.735452|2018-06-01 04:48:24.735452
NCT00134966|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-05-15|2005-08-23|2005-08-25|Estimate|||||||2017-05-15|2017-05-17|Actual|August 2005||2005-08-31|May 2017|2017-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa|A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa|Completed||Phase 3|493|Actual|Novartis||2|||||||||||||||||2018-06-01 04:48:24.808472|2018-06-01 04:48:24.808472
NCT00134953|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-12-14|2005-08-23|2005-08-25|Estimate|||||||2007-12-14|2007-12-17|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|May 2004|Actual|2004-05-31|||||Interventional|||Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment|Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment|Terminated||Phase 3|24||Novartis||||The Principal Investigator left the clinic and there was no one who could take over this study.|f||||||||||||||2018-06-01 04:48:24.95639|2018-06-01 04:48:24.95639
NCT00134940|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-06-15|2005-08-23|2005-08-25|Estimate|||||||2011-06-15|2011-06-16|Estimate|January 2005||2005-01-31|June 2011|2011-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Post-marketing Study to Collect Safety Data in Heart Transplant Patients Receiving Everolimus|A Non-interventional Protocol to Collect Prospective and Retrospective Data in Patients Receiving Everolimus to Prevent Acute Rejection Following Cardiac Transplantation|Completed|||100|Actual|Novartis|||||f||||||||||||||2018-06-01 04:48:25.052078|2018-06-01 04:48:25.052078
NCT00134927|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-09|2005-08-23|2005-08-25|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2005||2005-09-30|October 2008|2008-10-31|November 2006|Actual|2006-11-30|May 2006|Actual|2006-05-31||Observational|||A Survey on Consumer Use of Over-the-Counter (OTC) Nicotine Patches|Usage Patterns of OTC Nicotine Patches: Consumer Survey|Completed|||600|Actual|National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 04:48:25.161961|2018-06-01 04:48:25.161961
NCT00134914|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-11|2005-08-23|2005-08-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1996||1996-08-31|July 2008|2008-07-31|May 1998|Actual|1998-05-31|April 1998|Actual|1998-04-30||Interventional|||Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence|Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals|Completed||N/A|10|Actual|National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 04:48:25.22397|2018-06-01 04:48:25.22397
NCT00133835|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2005-10-24|2005-08-23|2005-08-24|Estimate|||||||2005-10-24|2005-10-25|Estimate|March 1998||1998-03-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Comparison of Extracorporeal Shock Wave Lithotripsy (ESWL) Alone and ESWL Plus Endoscopy for Painful Chronic Pancreatitis|Comparison of ESWL Alone and ESWL Combined With Endoscopic Drainage of the Main Pancreatic Duct for Painful Chronic Pancreatitis|Completed||Phase 1/Phase 2|50||Erasme University Hospital|||||f||||||||||||||2018-06-01 04:48:47.731727|2018-06-01 04:48:47.731727
NCT00134901|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|2014-08-25||2018-05-10|2005-08-23|2005-08-25|Estimate|2014-08-25|2014-09-05|Estimate||||2018-05-10|2018-05-15|Actual|March 2003||2003-03-31|May 2018|2018-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2|A Double-Blind, Placebo-Controlled Trial of the Effectiveness of Memantine in Treating Cocaine Dependence|Completed||Phase 2|81|Actual|New York State Psychiatric Institute|participants who had achieved abstinence during the lead-in remained abstinent throughout the trial and there was little relapse-like behavior for a medication to address.|2|||f||||t||||||||||2018-06-01 04:48:25.308273|2018-06-01 04:48:25.308273
NCT00134888|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-11|2005-08-23|2005-08-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2000||2000-12-31|July 2007|2007-07-31|November 2002|Actual|2002-11-30|||||Interventional|||Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence|The Acute and Protracted Blockade Efficacy of Buprenorphine/Naloxone|Completed||N/A|8|Actual|National Institute on Drug Abuse (NIDA)|||||||||f||||||||||2018-06-01 04:48:25.580143|2018-06-01 04:48:25.580143
NCT00134875|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-11|2005-08-23|2005-08-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2000||2000-12-31|October 2008|2008-10-31|December 2017|Anticipated|2017-12-31|December 2002|Actual|2002-12-31||Interventional|||Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers|Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers|Terminated||N/A|9|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:48:25.660812|2018-06-01 04:48:25.660812
NCT00134849|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-09-21|2005-08-24|2005-08-25|Estimate|||||||2007-09-21|2007-09-24|Estimate|September 2005||2005-09-30|September 2007|2007-09-30|March 2006|Actual|2006-03-31|||||Observational|||Hypertension in Management of Military Medicine|Hypertension in Management of Military Medicine|Terminated|||1000|Anticipated|United States Naval Medical Center, San Diego||||Inadequate number of records screened; primary investigator left institution.|f||||f||||||||||2018-06-01 04:48:25.747741|2018-06-01 04:48:25.747741
NCT00134836|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2008-12-11|2005-08-23|2005-08-25|Estimate|||||||2008-12-11|2008-12-16|Estimate|April 2004||2004-04-30|December 2008|2008-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|PPCO||Preventive Primary Care Outreach for High Risk Older Persons|Preventive Primary Care Outreach for High Risk Older Persons|Completed||Phase 1|719|Actual|McMaster University|||||f||||f||||||||||2018-06-01 04:48:25.808531|2018-06-01 04:48:25.808531
NCT00134823|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-07-20|2005-08-24|2005-08-25|Estimate|||||||2011-07-20|2011-07-21|Estimate|March 2005||2005-03-31|July 2011|2011-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Improving Pediatric Safety and Quality With Health Care Information Technology|Improving Pediatric Safety and Quality With Health Care IT|Completed||N/A|5420|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:48:25.882686|2018-06-01 04:48:25.882686
NCT00134810|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-01-09|2005-08-23|2005-08-25|Estimate|||||||2007-01-09|2007-01-11|Estimate|March 2005||2005-03-31|January 2007|2007-01-31|May 2006||2006-05-31|||||Interventional|||Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome|A Phase II Multicentre Multinational Prospective Randomised Double-Blind Placebo-Controlled Study Assessing the Efficacy and Safety of a Single Application of Three Doses of Dysport® in Patients With Upper Back Myofascial Pain Syndrome|Completed||Phase 2|340||Ipsen|||||f||||||||||||||2018-06-01 04:48:25.954061|2018-06-01 04:48:25.954061
NCT00134797|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2005-11-04|2005-08-24|2005-08-25|Estimate|||||||2005-11-04|2005-11-07|Estimate|February 2005||2005-02-28|August 2005|2005-08-31|February 2006||2006-02-28|||||Observational|||Glomerular Filtration Rate (GFR) Reporting on Nephrology Referral Patterns by Internists|The Effect of MDRD GFR Reporting on Nephrology Referral Patterns by Internists|Unknown status|Recruiting||1500||United States Naval Medical Center, San Diego|||||f||||||||||||||2018-06-01 04:48:26.054763|2018-06-01 04:48:26.054763
NCT00134784|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|2010-10-07||2014-07-15|2005-08-23|2005-08-25|Estimate|2014-07-15|2014-08-08|Estimate||||2014-07-15|2014-08-08|Estimate|April 2000||2000-04-30|July 2014|2014-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|ELLDOPA||Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression|[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease|Completed||Phase 2|142|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 04:48:26.133876|2018-06-01 04:48:26.133876
NCT00134771|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2005-11-04|2005-08-24|2005-08-25|Estimate|||||||2005-11-04|2005-11-07|Estimate|February 2001||2001-02-28|August 2005|2005-08-31|June 2003||2003-06-30|||||Interventional|||Trial of Nutritional Supplementation in Infants Born Small for Gestational Age||Completed||N/A|||Institute of Child Health|||||f||||||||||||||2018-06-01 04:48:26.359746|2018-06-01 04:48:26.359746
NCT00134758|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2009-07-28|2005-08-23|2005-08-25|Estimate|||||||2009-07-28|2009-07-29|Estimate|October 2004||2004-10-31|July 2009|2009-07-31|October 2009|Anticipated|2009-10-31|June 2009|Actual|2009-06-30||Interventional|||Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients|Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF|Unknown status|Active, not recruiting|Phase 2/Phase 3|90|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:48:26.426092|2018-06-01 04:48:26.426092
NCT00134745|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2013-06-13|2005-08-24|2005-08-25|Estimate|||||||2013-06-13|2013-06-14|Estimate|June 2005||2005-06-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome|The Growth of Genitalia Interna and the Bone Mineralization Under Hormonal Replacement Therapy and the Presence of Aortic Root Dilatation in Girls With Turner Syndrome|Completed||Phase 4|43|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-06-01 04:48:26.532807|2018-06-01 04:48:26.532807
NCT00134732|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2016-09-22|2005-08-24|2005-08-25|Estimate|||||||2016-09-22|2016-09-23|Estimate|July 2005||2005-07-31|September 2016|2016-09-30|May 2006|Actual|2006-05-31|||||Interventional|||Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis|Assess the Immunogenicity, Safety & Reactogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants (6-12 Weeks of Age at First Dose) Previously Uninfected With Human Rotavirus|Completed||Phase 3|150||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:48:26.61155|2018-06-01 04:48:26.61155
NCT00134719|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2012-06-15||2016-09-23|2005-08-24|2005-08-25|Estimate|2012-06-15|2012-07-20|Estimate||||2016-09-23|2016-10-20|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines|A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months|Completed||Phase 2|1104|Actual|GlaxoSmithKline||3|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:48:26.779993|2018-06-01 04:48:26.779993
NCT00134706|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2009-12-07|2005-08-24|2005-08-25|Estimate|||||||2009-12-07|2009-12-09|Estimate|January 2004||2004-01-31|December 2009|2009-12-31|September 2009|Actual|2009-09-30|April 2006|Actual|2006-04-30||Interventional|||A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer|A Phase II Study of Docetaxel Plus Carboplatin in Hormone Refractory Prostate Cancer Patients Refractory to Prior Docetaxel-based Chemotherapy|Completed||Phase 2|30|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:48:28.838542|2018-06-01 04:48:28.838542
NCT00134693|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2017-07-27|2005-08-24|2005-08-25|Estimate|||||||2017-07-27|2017-07-31|Actual|June 21, 2005|Actual|2005-06-21|July 2017|2017-07-31|August 3, 2006|Actual|2006-08-03|August 3, 2006|Actual|2006-08-03||Interventional|||A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis|A Randomised, Placebo-controlled, Parallel Group Single Dose Study of SB681323 in Patients With Active RA to Investigate the CRP Dose Response Relationship|Completed||Phase 2|77|Actual|GlaxoSmithKline|||||f||||t||||||||||2018-06-01 04:48:28.954635|2018-06-01 04:48:28.954635
NCT00134680|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2014-09-12|2005-08-24|2005-08-25|Estimate|||||||2014-09-12|2014-09-16|Estimate|January 2000||2000-01-31|October 2012|2012-10-31|July 2005|Actual|2005-07-31|January 2005|Actual|2005-01-31||Interventional|||Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC|Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 2 mg/kg Weekly in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer|Completed||Phase 2|33|Actual|Duke University||1|||f||||f||||||||||2018-06-01 04:48:29.101003|2018-06-01 04:48:29.101003
NCT00134667|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-01-12|2005-08-24|2005-08-25|Estimate|||||||2007-01-12|2007-01-15|Estimate|March 2005||2005-03-31|January 2007|2007-01-31|October 2008||2008-10-31|||||Interventional|||Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)|A Phase IIIb/IV Randomized, Double-Masked, Active Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 102 Weeks, to Pegaptanib Sodium Plus Photodynamic Therapy (PDT) With Visudyne, in Patients With Exudative Age-Related Macular Degeneration (AMD)|Terminated||Phase 4|360||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 04:48:29.217134|2018-06-01 04:48:29.217134
NCT00134654|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2011-06-14|2005-08-24|2005-08-25|Estimate|||||||2011-06-14|2011-06-16|Estimate|March 2003||2003-03-31|June 2011|2011-06-30|June 2011|Actual|2011-06-30|July 2005|Actual|2005-07-31||Interventional|||Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer|A Phase II Trial of Two Doses of Conjugated Estrogens (Premarin) in Patients With Androgen-Independent Prostate Cancer|Completed||Phase 2|48|Actual|Dana-Farber Cancer Institute||2|||f||||||||||||||2018-06-01 04:48:29.279794|2018-06-01 04:48:29.279794
NCT00134641|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2007-12-20|2005-08-24|2005-08-25|Estimate|||||||2007-12-20|2007-12-21|Estimate|February 2003||2003-02-28|December 2007|2007-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas|A Phase II Study Evaluating Efficacy of the Combination of Gemcitabine and Vinorelbine in Advanced Soft Tissue Sarcoma|Completed||Phase 2|40||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:48:29.387251|2018-06-01 04:48:29.387251
NCT00134628|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2016-01-11|2005-08-24|2005-08-25|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2001||2001-01-31|February 2012|2012-02-29|December 2015|Actual|2015-12-31|August 2011|Actual|2011-08-31||Interventional|||Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries|Hyperbaric Oxygen Radiation Tissue Injury Study - Project HORTIS|Terminated||Phase 3|248|Actual|Baromedical Research Foundation||2||"Discontinued cystitis study due to poor recruitment. To continue the trial under these~   circumstances is considered non-viable."|f||||t||||||||||2018-06-01 04:48:29.488551|2018-06-01 04:48:29.488551
NCT00134615|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2016-06-02|2005-08-24|2005-08-25|Estimate|||||||2016-06-02|2016-06-03|Estimate|August 2004||2004-08-31|June 2016|2016-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|RQP||Testing the Right Question Project (RQP) Health Education Strategy in a Mental Health Setting|Testing the Right Question Project Health Education Strategy in a Mental Health Setting|Completed||N/A|231|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-06-01 04:48:29.655082|2018-06-01 04:48:29.655082
NCT00134602|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-24|||2012-09-26|2005-08-24|2005-08-25|Estimate|||||||2012-09-26|2012-09-27|Estimate|April 2003||2003-04-30|September 2012|2012-09-30|October 2008|Actual|2008-10-31|January 2007|Actual|2007-01-31||Interventional|||Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children|An Intervention to Promote Adherence to Antiretroviral Medications Among HIV-infected Children 5-12 Years of Age|Completed||N/A|180||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:48:29.749715|2018-06-01 04:48:29.749715
NCT00134589|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2009-08-03|2005-08-23|2005-08-25|Estimate|||||||2009-08-03|2009-08-04|Estimate|April 2005||2005-04-30|July 2007|2007-07-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||CHOICE: Communicating Health Options Through Information and Cancer Education|Increasing CRC Screening in Health Plan Members|Completed||Phase 4|450|Actual|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:48:29.828149|2018-06-01 04:48:29.828149
NCT00134576|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2010-06-01|2005-08-24|2005-08-25|Estimate|||||||2010-06-01|2010-06-03|Estimate|May 2007||2007-05-31|May 2010|2010-05-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Automated Assessment of Mental Health in the Workplace|Automated Assessment of Mental Health in the Workplace|Completed||N/A|150|Anticipated|Boston Medical Center|||||f||||f||||||||||2018-06-01 04:48:29.904634|2018-06-01 04:48:29.904634
NCT00134563|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|2012-10-03|2011-08-08|2013-01-02|2005-08-23|2005-08-25|Estimate|2012-10-03|2012-11-06|Estimate|2011-08-08|2011-08-15|Estimate|2013-01-02|2013-01-04|Estimate|September 2004||2004-09-30|January 2013|2013-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|TEMSO||Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses|Completed||Phase 3|1088|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 04:48:30.03797|2018-06-01 04:48:30.03797
NCT00134550|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2009-09-22|2005-08-23|2005-08-25|Estimate|||||||2009-09-22|2009-09-23|Estimate|February 2005||2005-02-28|September 2009|2009-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Improving Diabetic Foot Ulcers With Atorvastatin|Improving Diabetic Foot Ulcers With Atorvastatin|Completed||Phase 2|13|Actual|Asker & Baerum Hospital|||||f||||f||||||||||2018-06-01 04:48:31.427608|2018-06-01 04:48:31.427608
NCT00134537|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-10-03|2005-08-23|2005-08-25|Estimate|||||||2011-10-03|2011-10-04|Estimate|November 2004||2004-11-30|October 2011|2011-10-31|April 2012|Anticipated|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Wallis Mechanical Normalization System for Low Back Pain||Unknown status|Active, not recruiting|Phase 3|300|Anticipated|Zimmer Spine||2|||f||||t||||||||||2018-06-01 04:48:31.59999|2018-06-01 04:48:31.59999
NCT00134524|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-07-08|2005-08-24|2005-08-25|Estimate|||||||2007-07-08|2007-07-10|Estimate|July 2005||2005-07-31|July 2007|2007-07-31|January 2008|Anticipated|2008-01-31|||||Interventional|||The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy|A Randomized, Sham-Controlled Clinical Study to Evaluate The Effect of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Advanced Magnetic Research Institute International|||||f||||f||||||||||2018-06-01 04:48:31.72961|2018-06-01 04:48:31.72961
NCT00134511|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-11-05|2005-08-22|2005-08-24|Estimate|||||||2007-11-05|2007-11-07|Estimate|March 2005||2005-03-31|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder|Phase 3 Multi-Center, Open Label, Forced Titration Study To Evaluate The Efficacy, Safety, And Tolerability Of Torcetrapib/Atorvastatin Combination Administered Orally, Once Daily (Qd) In Patients With Homozygous Familial Hypercholesterolaemia|Completed||Phase 3|30||Pfizer|||||||||||||||||||2018-06-01 04:48:31.827677|2018-06-01 04:48:31.827677
NCT00134498|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-11-15|2005-08-22|2005-08-24|Estimate|||||||2007-11-15|2007-11-16|Estimate|February 2005||2005-02-28|March 2007|2007-03-31|November 2006||2006-11-30|||||Interventional|||A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides|Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia|Completed||Phase 3|160||Pfizer|||||||||||||||||||2018-06-01 04:48:31.911115|2018-06-01 04:48:31.911115
NCT00134485|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-10-28|2005-08-22|2005-08-24|Estimate|||||||2007-10-28|2007-10-30|Estimate|March 2005||2005-03-31|December 2006|2006-12-31|March 2006||2006-03-31|||||Interventional|||Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia|Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|400||Pfizer|||||||||||||||||||2018-06-01 04:48:32.070307|2018-06-01 04:48:32.070307
NCT00134472|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2012-05-10|2005-08-23|2005-08-24|Estimate|||||||2012-05-10|2012-05-11|Estimate|December 2002||2002-12-31|May 2012|2012-05-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Therapeutic Hypothermia for Severe Traumatic Brain Injury in Japan|Therapeutic Strategy for Severe Head Trauma Patients With Mild Hypothermia and Estimation of Medical Expenses in Japan|Completed||Phase 3|150|Actual|Yamaguchi University Hospital|||||f||||||||||||||2018-06-01 04:48:33.510381|2018-06-01 04:48:33.510381
NCT00134459|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2013-02-12|2005-08-22|2005-08-24|Estimate|||||||2013-02-12|2013-02-15|Estimate|June 2005||2005-06-30|July 2009|2009-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Study Evaluating Bifeprunox in Bipolar Depression|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients With Bipolar Disorder|Completed||Phase 3|434|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 04:48:33.751614|2018-06-01 04:48:33.751614
NCT00134446|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2005-10-28|2005-08-23|2005-08-24|Estimate|||||||2005-10-28|2005-10-31|Estimate|March 2004||2004-03-31|March 2005|2005-03-31||||||||Interventional|||Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder|A Prospective Double Blind Randomized Placebo Controlled Trial of Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder|Unknown status|Recruiting|Phase 4|40||White River Junction Veterans Affairs Medical Center|||||f||||||||||||||2018-06-01 04:48:33.959107|2018-06-01 04:48:33.959107
NCT00134433|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2012-06-20|2005-08-22|2005-08-24|Estimate|||||||2012-06-20|2012-06-21|Estimate|November 2004||2004-11-30|June 2012|2012-06-30|October 2007|Actual|2007-10-31|March 2007|Actual|2007-03-31||Interventional|||Endothelial Modulation for Angiogenic Therapy|Endothelial Modulation With L-Arginine in Patients Undergoing Angiogenic Therapy (EMAT): A 2x2 Factorial Trial|Completed||Phase 1/Phase 2|20|Actual|Ottawa Heart Institute Research Corporation|||||f||||t||||||||||2018-06-01 04:48:34.294166|2018-06-01 04:48:34.294166
NCT00134420|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2016-08-04|2005-08-23|2005-08-24|Estimate|||||||2016-08-04|2016-08-08|Estimate|February 2001||2001-02-28|August 2016|2016-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Growth Hormone and Chromosome 18q- and Abnormal Growth|Growth Hormone Trial for Children With 18q- and Abnormal Growth|Completed||Phase 3|20|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-06-01 04:48:34.449052|2018-06-01 04:48:34.449052
NCT00134407|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2011-09-02|2005-08-22|2005-08-24|Estimate|||||||2011-09-02|2011-09-05|Estimate|February 2001||2001-02-28|September 2011|2011-09-30|June 2006||2006-06-30|||||Interventional|||Postoperative Oral Intake Trial|Postoperative Enteral Feeding or Early Oral Intake at Will. Effects on Clinical Outcome|Completed||Phase 1|450||University Hospital of North Norway|||||f||||||||||||||2018-06-01 04:48:34.623905|2018-06-01 04:48:34.623905
NCT00134394|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2008-08-06|2005-08-23|2005-08-24|Estimate|||||||2008-08-06|2008-08-07|Estimate|February 2005||2005-02-28|August 2008|2008-08-31|December 2007||2007-12-31|||||Interventional|||Etanercept With Tacrolimus for Psoriasis|Double-Blind, Placebo-Controlled, Bilateral Comparison of Topical Tacrolimus 0.1% vs. Placebo Ointment as Adjunctive Therapy for Patients With Moderate to Severe Psoriasis Who Are Candidates for or Poor Responders to Etanercept Therapy|Completed||Phase 2|20||Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 04:48:34.721866|2018-06-01 04:48:34.721866
NCT00134381|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2017-04-11||2017-08-03|2005-08-23|2005-08-24|Estimate|2017-08-03|2017-09-06|Actual||||2017-08-03|2017-09-06|Actual|May 2003||2003-05-31|August 2017|2017-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Green Tea and Ultraviolet Light-induced Skin Damage|The Effects of Topically Applied Constituents of Green Tea on UV Induced Increase in p53 and Apoptotic Markers in the Skin of Human Volunteers|Terminated||Phase 2|68|Actual|Rutgers, The State University of New Jersey|Early termination leading to small numbers of subjects analyzed|2||Principal Investigator left institution before study could complete.|f||||f||||||||||2018-06-01 04:48:34.892302|2018-06-01 04:48:34.892302
NCT00134368|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2008-08-06|2005-08-23|2005-08-24|Estimate|||||||2008-08-06|2008-08-07|Estimate|November 2003||2003-11-30|August 2008|2008-08-31|December 2007||2007-12-31|||||Interventional|||Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo|Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo|Completed||Phase 2|40||Rutgers, The State University of New Jersey|||||||||||||||||||2018-06-01 04:48:35.485379|2018-06-01 04:48:35.485379
NCT00134355|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2015-01-15|2005-08-23|2005-08-24|Estimate|||||||2015-01-15|2015-01-19|Estimate|July 2005||2005-07-31|January 2015|2015-01-31|March 2007|Actual|2007-03-31|November 2006|Actual|2006-11-30||Interventional|||Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer|Phase II Evaluation of PTK787, an Oral Vascular Endothelial Growth Factor Inhibitor, in Patients With Non-Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|5|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-06-01 04:48:35.548932|2018-06-01 04:48:35.548932
NCT00134342|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2010-12-22|2005-08-23|2005-08-24|Estimate|||||||2010-12-22|2010-12-23|Estimate|January 2005||2005-01-31|July 2005|2005-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Observational|||Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations|A Comparison of Traditional Tuberculosis Screening Methods With the T-SPOT TB Test for the Diagnosis of Latent Tuberculosis Infection in Immunocompromised Populations|Completed|||203|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-06-01 04:48:35.681967|2018-06-01 04:48:35.681967
NCT00134329|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-12-19|2005-08-23|2005-08-24|Estimate|||||||2007-12-19|2007-12-28|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|||||Observational|||Erectile Dysfunction and Diabetes Mellitus|Erectile Dysfunction and Diabetes Mellitus|Completed|||300||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:48:35.748604|2018-06-01 04:48:35.748604
NCT00134316|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2011-02-28|2005-08-22|2005-08-24|Estimate|||||||2011-02-28|2011-03-02|Estimate|August 2005||2005-08-31|February 2011|2011-02-28|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Cervical or Endometrial Cancer and Sexual Health Study|Cervical or Endometrial Cancer and Sexual Health Study|Completed||N/A|31|Actual|University of British Columbia|||||f||||f||||||||||2018-06-01 04:48:35.83196|2018-06-01 04:48:35.83196
NCT00134303|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2014-12-04|2005-08-23|2005-08-24|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2005||2005-06-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity|Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity|Unknown status|Recruiting|Phase 4|200|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-06-01 04:48:36.009787|2018-06-01 04:48:36.009787
NCT00134290|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-12-19|2005-08-23|2005-08-24|Estimate|||||||2007-12-19|2007-12-28|Estimate|January 2002||2002-01-31|December 2007|2007-12-31|May 2004|Actual|2004-05-31|||||Interventional|||The Effects of Calorie Restriction With or Without Metformin on Weight and Insulin Resistance|The Effects of Calorie Restriction - Whether or Not Calculated Based on BMR (Basic Metabolic Rate) - With or Without Metformin on Weight and Insulin Resistance of Obese Insulin Resistant Patients|Completed||Phase 4|48||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:48:36.335029|2018-06-01 04:48:36.335029
NCT00134277|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-09-08|2005-08-23|2005-08-24|Estimate|||||||2011-09-08|2011-09-09|Estimate|September 2004||2004-09-30|September 2011|2011-09-30|April 2010|Actual|2010-04-30|January 2009|Actual|2009-01-31||Interventional|||Trial Comparing Different Medical Devices for Infragenual Dilatation|Prospective Randomised Comparing Trial Between an Infragenual Dilatation (ID), an ID With Stenting, an ID With Cutting Balloon and Laser Therapy|Completed||N/A|35|Actual|University Hospital, Ghent||4|||f||||f||||||||||2018-06-01 04:48:36.489448|2018-06-01 04:48:36.489448
NCT00134264|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22||2012-01-30|2012-01-30|2005-08-22|2005-08-24|Estimate||||2012-01-30|2012-02-03|Estimate|2012-01-30|2012-02-03|Estimate|July 2004||2004-07-31|January 2012|2012-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|ILLUMINATE||A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease|Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents|Terminated||Phase 3|15067|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:48:36.659952|2018-06-01 04:48:36.659952
NCT00134251|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2009-01-29|2005-08-22|2005-08-24|Estimate|||||||2009-01-29|2009-01-30|Estimate|October 2005||2005-10-31|January 2009|2009-01-31||||||||Interventional|||Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease|Completed||Phase 3|||Solvay Pharmaceuticals|||||f||||||||||||||2018-06-01 04:48:37.211211|2018-06-01 04:48:37.211211
NCT00134238|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22||2012-02-15|2012-02-15|2005-08-22|2005-08-24|Estimate||||2012-02-15|2012-02-17|Estimate|2012-02-15|2012-02-17|Estimate|November 2003||2003-11-30|February 2012|2012-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|RADIANCE 2||Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.|Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia|Terminated||Phase 3|755|Actual|Pfizer|||||f||||||||||||||2018-06-01 04:48:37.349351|2018-06-01 04:48:37.349351
NCT00134225|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2005-10-25|2005-08-23|2005-08-24|Estimate|||||||2005-10-25|2005-10-26|Estimate|April 2005||2005-04-30|August 2005|2005-08-31|December 2006||2006-12-31|||||Interventional|||Study to Demonstrate That Muscle Pattern Recognition (MPR) is an Effective Evaluation Tool for Musculoskeletal Neck or Back Pain|Multi-Center, Multi-National Study to Demonstrate That Muscle Pattern Recognition is a Reliable and Valid Evaluation Tool for Patients Who Present With Acute, Sub-Acute, or Chronic Symptoms of Neck or Back Pain of a Musculoskeletal Origin|Unknown status|Recruiting|N/A|480||iTech Medical, Inc.|||||f||||||||||||||2018-06-01 04:48:37.541419|2018-06-01 04:48:37.541419
NCT00134212|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2005-12-30|2005-08-22|2005-08-24|Estimate|||||||2005-12-30|2006-01-02|Estimate|March 2002||2002-03-31|December 2005|2005-12-31|June 2004||2004-06-30|||||Interventional|||Dopexamine and Norepinephrine Compared With Epinephrine Alone in Septic Shock|Prospective, Randomized Study on Two Parallel Groups Comparing Dopexamine and Norepinephrine in Combination to Epinephrine Alone on Systemic and Pulmonary Hemodynamics, Gastric Mucosal Perfusion, and Oxidative Stress in Septic Shock|Completed||Phase 2|20||Rennes University Hospital|||||f||||||||||||||2018-06-01 04:48:37.642836|2018-06-01 04:48:37.642836
NCT00134199|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2009-08-11|2005-08-22|2005-08-24|Estimate|||||||2009-08-11|2009-08-12|Estimate|March 2005||2005-03-31|April 2006|2006-04-30|November 2005|Actual|2005-11-30|||||Interventional|||A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects|A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects|Completed||Phase 2/Phase 3|282|Actual|Pfizer|||||||||||||||||||2018-06-01 04:48:38.010557|2018-06-01 04:48:38.010557
NCT00134186|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-03-02|2005-08-22|2005-08-24|Estimate|||||||2007-03-02|2007-03-05|Estimate||||March 2007|2007-03-31||||||||Interventional|||Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer|Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma|Completed||Phase 2|43||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 04:48:38.201478|2018-06-01 04:48:38.201478
NCT00133822|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2015-08-18|2005-08-23|2005-08-24|Estimate|||||||2015-08-18|2015-08-19|Estimate|April 2004||2004-04-30|August 2015|2015-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial|Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD|Completed||Phase 1/Phase 2|65||Emory University|||||f||||||||||||||2018-06-01 04:48:47.835044|2018-06-01 04:48:47.835044
NCT00134173|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-12-06|2005-08-22|2005-08-24|Estimate|||||||2007-12-06|2007-12-10|Estimate|October 2003||2003-10-31|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|ILLUSTRATE||A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease|Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.|Completed||Phase 3|1100||Pfizer|||||||||||||||||||2018-06-01 04:48:38.307803|2018-06-01 04:48:38.307803
NCT00134160|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2010-10-03|2005-08-22|2005-08-24|Estimate|||||||2010-10-03|2010-10-05|Estimate|August 2005||2005-08-31|October 2010|2010-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study|The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk|Completed||Phase 4|1000|Anticipated|OSCAR Study||2|||f||||t||||||||||2018-06-01 04:48:38.634113|2018-06-01 04:48:38.634113
NCT00134147|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2008-04-16|2005-08-22|2005-08-24|Estimate|||||||2008-04-16|2008-04-17|Estimate|April 2005||2005-04-30|April 2008|2008-04-30|May 2007|Actual|2007-05-31|||||Interventional|||A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control|A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents|Completed||Phase 3|1100||Pfizer|||||f||||||||||||||2018-06-01 04:48:38.772826|2018-06-01 04:48:38.772826
NCT00134134|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2006-09-07|2005-08-23|2005-08-24|Estimate|||||||2006-09-07|2006-09-11|Estimate|February 2005||2005-02-28|September 2006|2006-09-30|August 2006||2006-08-31|||||Interventional|||Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa|An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa|Completed||Phase 1|5||New York University School of Medicine|||||||||||||||||||2018-06-01 04:48:39.012174|2018-06-01 04:48:39.012174
NCT00134108|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2005-10-25|2005-08-23|2005-08-24|Estimate|||||||2005-10-25|2005-10-26|Estimate|January 2003||2003-01-31|January 2003|2003-01-31|December 2005||2005-12-31|||||Interventional|||Clinical Benefit of Cognitive Behaviour Therapy (CBT) for Insomnia in Cancer Patients|Randomised Controlled Clinical Effectiveness Trial of Cognitive Behaviour Therapy (CBT) Versus Treatment as Usual (TAU) for Insomnia in Cancer Patients|Unknown status|Active, not recruiting|N/A|||NHS Greater Clyde and Glasgow|||||f||||||||||||||2018-06-01 04:48:39.093099|2018-06-01 04:48:39.093099
NCT00134095|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2013-09-16|2005-08-22|2005-08-24|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2004||2004-09-30|January 2010|2010-01-31||||August 2008|Actual|2008-08-31||Interventional|||S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer|Phase II Clinical Study of Preoperative S-1/CPT-11 Combination Chemotherapy in Patients With Locally Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|70|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:48:39.166394|2018-06-01 04:48:39.166394
NCT00134082|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2017-11-01|2005-08-22|2005-08-24|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2005||2005-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma|Pilot Study of Rituximab, High Dose Cyclophosphamide, and GM-CSF Based Immunotherapy for Relapsed Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:48:39.283394|2018-06-01 04:48:39.283394
NCT00134069|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2014-04-15|2005-08-22|2005-08-24|Estimate|||||||2014-04-15|2014-04-16|Estimate|June 2005||2005-06-30|April 2014|2014-04-30|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer|Phase I/II Clinical, Pharmacological, and Biological Study of BAY 43-9006 in Combination With Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer|Completed||Phase 1|48|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:48:39.47662|2018-06-01 04:48:39.47662
NCT00134056|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2017-01-04||2017-05-04|2005-08-22|2005-08-24|Estimate|2017-03-21|2017-05-02|Actual||||2017-05-04|2017-06-02|Actual|August 2006||2006-08-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||A total of 1038 patients were randomized to this study, 42 of which were ineligible. Baseline analysis population includes 994 patients (excluding the 42 ineligible patients and 2 additional patients who withdrew all consent prior to receiving protocol treatment).|S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy|Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer|Completed||Phase 3|1038|Actual|Southwest Oncology Group||2|||f||||t||||||||Yes|http://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-06-01 04:48:39.810731|2018-06-01 04:48:39.810731
NCT00134043|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2014-04-18||2014-07-23|2005-08-22|2005-08-24|Estimate|2014-07-23|2014-08-11|Estimate||||2014-07-23|2014-08-11|Estimate|December 2005||2005-12-31|July 2014|2014-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer|Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:48:42.693521|2018-06-01 04:48:42.693521
NCT00134030|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2017-05-02|2005-08-22|2005-08-24|Estimate|||||||2017-05-02|2017-05-04|Actual|November 2005||2005-11-30|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma|A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND# 12697)|Active, not recruiting||Phase 3|1164|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 04:48:43.463493|2018-06-01 04:48:43.463493
NCT00134017|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2016-10-17|2005-08-22|2005-08-24|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2004||2004-05-31|October 2016|2016-10-31||||April 2017|Anticipated|2017-04-30||Interventional|||Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer|HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies|Active, not recruiting||Phase 2|92|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:48:43.894107|2018-06-01 04:48:43.894107
NCT00134004|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2015-06-26||2015-09-02|2005-08-22|2005-08-24|Estimate|2015-07-27|2015-08-24|Estimate||||2015-09-02|2015-10-06|Estimate|October 2004||2004-10-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer|A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients With Hematologic Malignancies|Completed||Phase 2|210|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 04:48:44.057598|2018-06-01 04:48:44.057598
NCT00133991|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2014-04-16|2005-08-22|2005-08-24|Estimate|||||||2014-04-16|2014-04-17|Estimate|March 2005||2005-03-31|April 2014|2014-04-30|July 2012|Actual|2012-07-31|July 2010|Actual|2010-07-31||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia|Phase II Study of Intensified CVP, Rituximab, and High Dose Cyclophosphamide for Adult Burkitt or Burkitt-Like Lymphoma|Completed||Phase 2|21|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 04:48:44.393523|2018-06-01 04:48:44.393523
NCT00133978|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2013-04-29||2014-08-26|2005-08-22|2005-08-24|Estimate|2014-08-26|2014-09-09|Estimate||||2014-08-26|2014-09-09|Estimate|April 2005||2005-04-30|August 2014|2014-08-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|REDOXS|Five randomized patients were not evaluable because we could not ascertain their 28-day vital status leaving 1218 patients in the final intention-to-treat analysis.|Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients|REducing Deaths Due to OXidative Stress The REDOXS© Study|Completed||Phase 3|1223|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||4|||f||||t||||||||||2018-06-01 04:48:44.551704|2018-06-01 04:48:44.551704
NCT00133965|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2011-04-19|2005-08-23|2005-08-24|Estimate|||||||2011-04-19|2011-04-20|Estimate|May 2005||2005-05-31|April 2011|2011-04-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Psychosocial Support for Cancer Patients|Psychosocial Support for Cancer Patients|Completed|||281|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-06-01 04:48:45.246857|2018-06-01 04:48:45.246857
NCT00133952|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2015-12-22|2011-09-20|2016-08-25|2005-08-22|2005-08-24|Estimate|2015-12-22|2016-01-28|Estimate|2011-09-20|2011-09-26|Estimate|2016-08-25|2016-10-06|Estimate|August 2005||2005-08-31|August 2016|2016-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Ruboxistaurin on Clinically Significant Macular Edema|The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema|Completed||Phase 3|309|Actual|Chromaderm, Inc.||2|||f||||||||||||||2018-06-01 04:48:45.392662|2018-06-01 04:48:45.392662
NCT00133939|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-04-26|2005-08-23|2005-08-24|Estimate|||||||2007-04-26|2007-04-27|Estimate||||April 2007|2007-04-30||||||||Interventional|||Proportional Ventilation and Ventilatory Synchronism|Proportional Ventilation and Ventilatory Synchronism|Unknown status|Recruiting|N/A|10||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:48:46.62226|2018-06-01 04:48:46.62226
NCT00133926|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2007-04-04|2005-08-23|2005-08-24|Estimate|||||||2007-04-04|2007-04-05|Estimate|March 2005||2005-03-31|April 2007|2007-04-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Prevention of Pre-Term Birth by Treatment of Periodontal Disease|Prevention of Pre-Term Birth by Treatment of Periodontal Disease During Pregnancy - The Smile Study|Unknown status|Recruiting|Phase 2|1094||King Edward Memorial Hospital|||||f||||t||||||||||2018-06-01 04:48:46.717559|2018-06-01 04:48:46.717559
NCT00133913|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2008-03-17|2005-08-23|2005-08-24|Estimate|||||||2008-03-17|2008-03-19|Estimate|March 2004||2004-03-31|March 2008|2008-03-31|January 2009|Anticipated|2009-01-31|January 2007|Actual|2007-01-31||Observational|IMMC-06||Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer|Longitudinal Enumeration of Circulating Tumor Cells in Patients With Metastatic Colorectal Carcinomas|Unknown status|Active, not recruiting||486|Actual|Immunicon|||1||f||||f||||||||||2018-06-01 04:48:46.831072|2018-06-01 04:48:46.831072
NCT00133900|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2009-07-27|2005-08-23|2005-08-24|Estimate|||||||2009-07-27|2009-07-28|Estimate|December 2004||2004-12-31|March 2008|2008-03-31|February 2009|Anticipated|2009-02-28|February 2009|Anticipated|2009-02-28||Observational|IMMC-38||Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy|Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy|Unknown status|Active, not recruiting||276|Actual|Immunicon|||1||f||||f||||||Samples With DNA|"~     Serum Samples and RNA samples have been retained.~   "|||2018-06-01 04:48:46.915924|2018-06-01 04:48:46.915924
NCT00133887|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2014-07-01|2005-08-23|2005-08-24|Estimate|||||||2014-07-01|2014-07-02|Estimate|April 2004||2004-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|March 2011|Actual|2011-03-31||Interventional|||TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients|Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors|Completed||Phase 3|77|Actual|Hospices Civils de Lyon||2|||f||||||||||||||2018-06-01 04:48:47.017321|2018-06-01 04:48:47.017321
NCT00133874|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2017-01-20|2005-08-23|2005-08-24|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2005||2005-04-30|January 2017|2017-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo|An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo|Completed||Phase 3|520|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:48:47.216672|2018-06-01 04:48:47.216672
NCT00133861|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2008-06-30|2005-08-23|2005-08-24|Estimate|||||||2008-06-30|2008-07-04|Estimate|April 2005||2005-04-30|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles|Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles. Assessment of Efficiency of Botulinum Toxin on Spasticity in Agonist and Antagonist Muscles Using Clinical Assessment and Gait Analysis in Cerebral Palsy Children: Rectus Femoris and Semitendinosus|Completed||Phase 2/Phase 3|23|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:48:47.456379|2018-06-01 04:48:47.456379
NCT00133848|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2016-09-22|2005-08-23|2005-08-24|Estimate|||||||2016-09-22|2016-09-23|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|January 2006|Actual|2006-01-31|||||Interventional|||Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment|A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adults and Paediatric Subjects With Impetigo.|Completed||Phase 3|210||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:48:47.581052|2018-06-01 04:48:47.581052
NCT00133809|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2016-04-25||2016-06-16|2005-08-22|2005-08-24|Estimate|2016-04-25|2016-06-01|Estimate||||2016-06-16|2016-07-18|Estimate|July 2002||2002-07-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Eligible participants who received islet transplantation|Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression|Islet Transplantation in Type 1 Diabetes Using the Edmonton Protocol of Steroid Free Immunosuppression|Completed||Phase 2|8|Actual|Emory University||1|||f||||t||||||||||2018-06-01 04:48:47.943942|2018-06-01 04:48:47.943942
NCT00133796|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2017-02-03|2005-08-23|2005-08-24|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2001||2001-10-31|February 2017|2017-02-28|April 2007|Actual|2007-04-30|September 2005|Actual|2005-09-30||Interventional|||Neoadjuvant Herceptin in Patients With Breast Cancer|A Phase II Study of the Effects of Herceptin in Patients With Locally Advanced HER-2/NEU Overexpressing Breast Cancer|Terminated||Phase 2|40|Actual|Baylor Breast Care Center||1||Closed to accrual 4/19/2006 / Study doesn't qualify for reporting.|f||||t||||||||No||2018-06-01 04:48:48.351863|2018-06-01 04:48:48.351863
NCT00133783|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2005-10-25|2005-08-23|2005-08-24|Estimate|||||||2005-10-25|2005-10-26|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|May 2007||2007-05-31|||||Observational|||Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure|Intermedin is an Estrogen- Modulated Factor for Reducing Blood Pressure|Unknown status|Recruiting||500||Chang Gung Memorial Hospital|||||f||||||||||||||2018-06-01 04:48:48.504095|2018-06-01 04:48:48.504095
NCT00133770|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2013-07-29|2005-08-22|2005-08-24|Estimate|||||||2013-07-29|2013-07-31|Estimate|July 2004||2004-07-31|July 2013|2013-07-31|March 2007|Actual|2007-03-31|July 2006|Actual|2006-07-31||Interventional|||Intravenous (IV) Pantoprazole in Erosive Esophagitis|A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis|Completed||Phase 4|20|Actual|Emory University||1|||f||||f||||||||||2018-06-01 04:48:48.654034|2018-06-01 04:48:48.654034
NCT00133757|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2013-02-13|2005-08-23|2005-08-24|Estimate|||||||2013-02-13|2013-02-15|Estimate|June 2005||2005-06-30|February 2013|2013-02-28|May 2006||2006-05-31|||||Interventional|||Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers|Pharmacotherapy-assisted Extinction (Pharmacoextinction): A Novel Approach to the Treatment of Nicotine Dependence in Humans|Completed||Phase 1|50||Centre for Addiction and Mental Health|||||f||||||||||||||2018-06-01 04:48:48.771917|2018-06-01 04:48:48.771917
NCT00133744|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2011-03-18|2005-08-22|2005-08-24|Estimate|||||||2011-03-18|2011-03-21|Estimate|May 2006||2006-05-31|March 2011|2011-03-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Impact of Prenatal Vitamin/Mineral Supplements on Perinatal Mortality|Impact of Iron/Folic Acid Versus Multimicronutrient Versus Folic Acid Supplements During Pregnancy on Mortality, Morbidity, and Complications During Pregnancy, Labor, and Delivery: A Randomized Controlled Trial in China|Completed||Phase 3|18962|Actual|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-06-01 04:48:49.00118|2018-06-01 04:48:49.00118
NCT00133731|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2008-07-01|2005-08-23|2005-08-24|Estimate|||||||2008-07-01|2008-07-02|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|October 2005|Actual|2005-10-31|||||Interventional|SEPIA-PCI||The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention|A Multinational, Randomized, Double-Blind, Double-Dummy, Exploratory, Parallel Group, Dose-Ranging Phase II Study to Evaluate Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Several Intravenous Regimens of Factor Xa Inhibitor Otamixaban (XRP0673), in Comparison to Intravenous Unfractionated Heparin, in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention|Completed||Phase 2|947|Actual|Sanofi|||||||||||||||||||2018-06-01 04:48:49.167206|2018-06-01 04:48:49.167206
NCT00133718|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-23|||2017-01-23|2005-08-23|2005-08-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2002||2002-01-31|January 2017|2017-01-31|May 29, 2012|Actual|2012-05-29|April 2006|Actual|2006-04-30||Interventional|||A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control|Asker and Baerum Cardiovascular Diabetes Study|Completed||Phase 4|120|Actual|Asker & Baerum Hospital||2|||f||||t|t|f|||f|||No||2018-06-01 04:48:49.350662|2018-06-01 04:48:49.350662
NCT00133705|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|2012-11-01||2014-02-13|2005-08-22|2005-08-23|Estimate|2012-11-01|2012-11-30|Estimate||||2014-02-13|2014-03-14|Estimate|July 2003||2003-07-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Trial of Mifepristone for Fibroids|Randomized Control Trial Of Mifepristone for Fibroids|Completed||Phase 3|70|Actual|University of Rochester|There were no adverse events in this clinical trial.|2|||f||||t||||||||||2018-06-01 04:48:49.567755|2018-06-01 04:48:49.567755
NCT00133692|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2011-09-16|2005-08-22|2005-08-23|Estimate|||||||2011-09-16|2011-09-20|Estimate|September 1997||1997-09-30|August 2010|2010-08-31|February 2003||2003-02-28|||||Interventional|||INVEST: INternational VErapamil SR Trandolapril STudy|INternational VErapamil SR Trandolapril STudy|Completed||Phase 4|22000||University of Florida|||||f||||||||||||||2018-06-01 04:48:49.970957|2018-06-01 04:48:49.970957
NCT00133679|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2014-08-11|2005-08-22|2005-08-23|Estimate|||||||2014-08-11|2014-08-13|Estimate|February 2006||2006-02-28|August 2014|2014-08-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Chronic Sildenafil for Severe Diaphragmatic Hernia|Chronic Sildenafil for Severe Diaphragmatic Hernia|Terminated||Phase 4|9|Actual|University of California, San Francisco||2||"Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with~   possibility of placebo beyond 6 weeks of age on study protocol"|f||||t||||||||||2018-06-01 04:48:50.182189|2018-06-01 04:48:50.182189
NCT00133666|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2008-07-16|2005-08-19|2005-08-23|Estimate|||||||2008-07-16|2008-07-17|Estimate|September 2004||2004-09-30|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Improving Asthma Communication in Minority Families|Improving Asthma Communication in Minority Families|Completed||Phase 2|231|Actual|National Institute of Nursing Research (NINR)||2|||f||||||||||||||2018-06-01 04:48:50.340241|2018-06-01 04:48:50.340241
NCT00133653|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2005-10-28|2005-08-22|2005-08-23|Estimate|||||||2005-10-28|2005-10-31|Estimate|August 2001||2001-08-31|August 2004|2004-08-31|July 2004||2004-07-31|||||Observational|||The Double Exposure Study: The Impact of Job Strain and Marital Cohesion on Blood Pressure|The Impact of Job Strain and Marital Cohesion on Ambulatory Blood Pressure Over One Year: The Double Exposure Study|Completed|||250||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:48:50.525179|2018-06-01 04:48:50.525179
NCT00133640|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2006-09-07|2005-08-22|2005-08-23|Estimate|||||||2006-09-07|2006-09-11|Estimate|January 2005||2005-01-31|August 2006|2006-08-31|December 2008||2008-12-31|||||Interventional|||Early Rehabilitation After Hip Fracture|Early Rehabilitation After Hip Fracture: A Randomized Controlled Trial Comparing Different Vitamin D and Rehabilitation Programs|Unknown status|Recruiting|Phase 3|204||Swiss National Science Foundation|||||f||||||||||||||2018-06-01 04:48:50.622021|2018-06-01 04:48:50.622021
NCT00133627|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2011-11-16|2005-08-22|2005-08-23|Estimate|||||||2011-11-16|2011-11-17|Estimate|April 2005||2005-04-30|November 2011|2011-11-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis|Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis|Completed||Phase 4|229|Actual|Novartis|||||f||||||||||||||2018-06-01 04:48:50.789311|2018-06-01 04:48:50.789311
NCT00133601|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2009-01-15|2005-08-19|2005-08-23|Estimate|||||||2009-01-15|2009-01-16|Estimate|October 2004||2004-10-31|January 2009|2009-01-31|October 2008|Actual|2008-10-31|July 2007|Actual|2007-07-31||Interventional|||Cognitive Behavioral Therapy for Insomnia in Chronic Pain Patients|Cognitive Behavioral Therapy for Insomnia in Chronic Pain Patients|Completed||Phase 1|28|Actual|National Institute of Nursing Research (NINR)||2|||f||||t||||||||||2018-06-01 04:48:51.016241|2018-06-01 04:48:51.016241
NCT00133588|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate|November 2006||2006-11-30|May 2007|2007-05-31|January 2007||2007-01-31|||||Interventional|||Proteomic Profiling for Influenza|Proteomic Profiling for Influenza Vaccination|Completed||Phase 4|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:48:51.102427|2018-06-01 04:48:51.102427
NCT00133575|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|2009-03-26||2014-12-11|2005-08-19|2005-08-23|Estimate|2009-05-18|2009-07-08|Estimate||||2014-12-11|2015-01-05|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||ACAM 3000 MVA at Harvard Medical School|ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes|Completed||Phase 1/Phase 2|72|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The Dryvax challenge was optional and administered to only a subset of participants before being discontinued prior to being offered to the subjects in the last cohort.|6|||f||||||||||||||2018-06-01 04:48:51.299087|2018-06-01 04:48:51.299087
NCT00133562|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2008-10-27|2005-08-19|2005-08-23|Estimate|||||||2008-10-27|2008-10-28|Estimate|August 2004||2004-08-31|October 2008|2008-10-31|May 2006||2006-05-31|||||Interventional|||HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition|Prospective Double Blind Randomized Clinical Trial of Alanyl-Glutamine or Glycine in Hospitalized Children With Persistent Diarrhea or Malnutrition.|Withdrawn||Phase 3|108||University of Virginia|||||f||||f||||||||||2018-06-01 04:48:53.247102|2018-06-01 04:48:53.247102
NCT00133549|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2014-10-16|2005-08-19|2005-08-23|Estimate|||||||2014-10-16|2014-10-17|Estimate|November 2000||2000-11-30|May 2011|2011-05-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||9-valent CRM 197 Pneumococcal|Evaluation of a 9-valent CRM 197- Conjugated Pneumococcal Polysaccharide Vaccine in Elderly Adults|Completed||Phase 2|180|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 04:48:53.366308|2018-06-01 04:48:53.366308
NCT00133536|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate|January 2006||2006-01-31|June 2008|2008-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A/H5N1 Vaccine in Healthy Children Aged 2-9 Years|A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Children Aged 2 Years Through 9 Years|Completed||Phase 1/Phase 2|157|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:48:53.548894|2018-06-01 04:48:53.548894
NCT00133523|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2014-12-04|2005-08-19|2005-08-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2004||2004-10-31|October 2009|2009-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||FLU-VACS Comparative Study in Adults|Comparative Study of Influenza Vaccines in Adults - FLU-VACS|Completed||Phase 4|2349|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:48:53.655477|2018-06-01 04:48:53.655477
NCT00133510|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|September 2006||2006-09-30|||||Interventional|||Influenza Vaccine in Pediatric Transplant Subjects|Prospective Comparative Study of the Humoral and Cell-Mediated Immune Responses to the Trivalent Subviron Influenza Vaccine in Pediatric Liver Transplant Recipients as an Indicator for Response of Immunocompromised Subjects to Vaccination Against Agents of Bioterrorism|Completed||Phase 4|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:48:53.763534|2018-06-01 04:48:53.763534
NCT00133497|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19||2017-07-03|2017-07-03|2005-08-19|2005-08-23|Estimate||||2017-07-03|2017-07-06|Actual|2017-07-03|2017-07-06|Actual|June 2006||2006-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Safety and Efficacy of the Cytomegalovirus gB/MF59 Vaccine in Preventing Systemic Cytomegalovirus Infection in Healthy Adolescent Females|Completed||Phase 2|409|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:48:53.880454|2018-06-01 04:48:53.880454
NCT00133484|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate||||December 2005|2005-12-31|May 2007||2007-05-31|||||Interventional|||UMD rPA Regimen Trial in Adults|A Phase II Study to Assess the Safety, Tolerability, Immunogenicity, and Optimal Primary Schedule of 3 Recombinant Protective Antigen (rPA) Anthrax Vaccines Administered in Two Intramuscular Doses to Healthy Adults|Terminated||Phase 2|270||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:48:54.060924|2018-06-01 04:48:54.060924
NCT00133471|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults|Evaluation of the Reactogenicity and Immunogenicity of Four Dosage Levels of Intramuscular Monovalent Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults|Completed||Phase 1/Phase 2|96|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||||||||||||2018-06-01 04:48:54.121758|2018-06-01 04:48:54.121758
NCT00133458|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate||||October 2005|2005-10-31|June 2007||2007-06-30|||||Interventional|||RCT ALB for SA Cysticercosis|Randomized, Double Blind Comparison of Two Lenghts of Albendazole Therapy for Subarachnoid Cysticercosis|Withdrawn||Phase 3|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:48:54.381118|2018-06-01 04:48:54.381118
NCT00133445|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2011-11-03|2005-08-22|2005-08-23|Estimate|||||||2011-11-03|2011-11-07|Estimate|December 2005||2005-12-31|October 2009|2009-10-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Pentavalent DTaP-Hep B-IPV|Randomized, Single Blinded Study of the Safety and Immunogenicity of Pentavalent DTaP-Hep B-IPV Combination Vaccine (Pediarix™; GlaxoSmithKline (GSK) Biologicals) Administered to Healthy Neonates and Infants at Birth, 2, and 6 Months of Age Compared to a Routine Infant Schedule at 2, 4, and 6 Months of Age|Completed||Phase 2|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:48:55.463097|2018-06-01 04:48:55.463097
NCT00133432|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2005||2005-09-30|March 2010|2010-03-31|July 2007|Anticipated|2007-07-31|July 2007|Anticipated|2007-07-31||Interventional|||Zinc and Pneumonia Protocol|The Effect of Zinc Supplementation on Duration of Hospitalization in Tanzanian Children Presenting With Acute Pneumonia|Terminated||Phase 3|600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:48:55.59007|2018-06-01 04:48:55.59007
NCT00133419|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2007|2007-03-31|January 2006||2006-01-31|||||Interventional|||Micronutrients and Enteric Infections in African Children|The Effect of Prophylactic Micronutrient Supplementation of Morbidity and Growth in HIV-infected and HIV-uninfected Children in South Africa|Completed||Phase 2|516||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:48:55.675561|2018-06-01 04:48:55.675561
NCT00133406|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2011-03-04|2005-08-19|2005-08-23|Estimate|||||||2011-03-04|2011-03-08|Estimate|June 2006||2006-06-30|March 2011|2011-03-31|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Long-term Impact and Intervention for Diarrhea in Brazil|Long-term Impact and Intervention for Diarrhea in Brazil|Unknown status|Recruiting|Phase 3|321|Anticipated|University of Virginia||6|||f||||f||||||||||2018-06-01 04:48:55.776685|2018-06-01 04:48:55.776685
NCT00133393|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2010-08-26|2005-08-19|2005-08-23|Estimate|||||||2010-08-26|2010-08-27|Estimate|January 2002||2002-01-31|October 2005|2005-10-31|July 2005||2005-07-31|||||Interventional|||Pentoxifylline in Children With Malaria|Dose Finding Study of Pentoxifylline in Children With Cerebral Malaria|Terminated||Phase 2|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:48:55.935779|2018-06-01 04:48:55.935779
NCT00133380|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2007-04-04|2005-08-19|2005-08-23|Estimate|||||||2007-04-04|2007-04-06|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|September 2006||2006-09-30|||||Interventional|||A Study in People With High Cholesterol|PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia|Completed||Phase 2|300||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:48:56.041313|2018-06-01 04:48:56.041313
NCT00133367|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2016-07-22|2005-08-22|2005-08-23|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2005||2005-08-31|July 2016|2016-07-31|November 2011|Actual|2011-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus|Phase II Study of Sequential Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis|Completed||Phase 2|32|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:48:56.303571|2018-06-01 04:48:56.303571
NCT00133354|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2011-10-11|2005-08-19|2005-08-23|Estimate|||||||2011-10-11|2011-10-12|Estimate|November 2001||2001-11-30|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2006|Actual|2006-08-31||Interventional|||Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys|Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency|Completed||Phase 2/Phase 3|53|Actual|Nemours Children's Clinic||2|||f||||t||||||||||2018-06-01 04:48:56.446101|2018-06-01 04:48:56.446101
NCT00133341|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2006-02-24|2005-08-22|2005-08-23|Estimate|||||||2006-02-24|2006-02-27|Estimate|April 2005||2005-04-30|February 2006|2006-02-28|December 2005||2005-12-31|||||Interventional|||Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate|Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study.|Completed||Phase 2|60||Mekos Laboratories AS|||||f||||||||||||||2018-06-01 04:48:56.561779|2018-06-01 04:48:56.561779
NCT00133328|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2005-10-27|2005-08-22|2005-08-23|Estimate|||||||2005-10-27|2005-10-28|Estimate|January 2002||2002-01-31|January 2002|2002-01-31|November 2005||2005-11-30|||||Interventional|||A Morbidity-Mortality and Remodeling Study With Valsartan|A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease|Unknown status|Active, not recruiting|Phase 4|3000||Jikei University School of Medicine|||||f||||||||||||||2018-06-01 04:48:56.694169|2018-06-01 04:48:56.694169
NCT00133315|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-04-09|2005-08-22|2005-08-23|Estimate|||||||2007-04-09|2007-04-10|Estimate|September 2004||2004-09-30|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||TNFalfa Blocking Treatment of Spondylarthropathies|TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies|Completed||Phase 4|50||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:48:56.853306|2018-06-01 04:48:56.853306
NCT00133302|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2007-01-17|2005-08-22|2005-08-23|Estimate|||||||2007-01-17|2007-01-18|Estimate|February 1999||1999-02-28|August 2006|2006-08-31|February 2005||2005-02-28|||||Interventional|||Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)|Randomized Phase III Study of Standard CHOP (S-CHOP) Versus Biweekly CHOP (Bi-CHOP) in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)|Terminated||Phase 3|450||Japan Clinical Oncology Group|||||f||||||||||||||2018-06-01 04:48:56.947334|2018-06-01 04:48:56.947334
NCT00133289|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2007-07-09|2005-08-22|2005-08-23|Estimate|||||||2007-07-09|2007-07-10|Estimate|July 2005||2005-07-31|July 2007|2007-07-31|June 2007|Actual|2007-06-30|||||Interventional|||ULTRA Study for Pacemaker Patients|Ventricular Automatic Capture Assessment Study|Completed||Phase 4|950||Boston Scientific Corporation|||||f||||||||||||||2018-06-01 04:48:57.062133|2018-06-01 04:48:57.062133
NCT00133276|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2010-02-18|2005-08-22|2005-08-23|Estimate|||||||2010-02-18|2010-02-19|Estimate|August 2005||2005-08-31|February 2010|2010-02-28|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Prophylaxis of Psychiatric Symptoms During Anti-HCV Treatment|Prophylactic Treatment of Peginterferon-associated Psychopathology. A Double-blind Placebo-controlled Trial on the Effects of Escitalopram (Lexapro®) in Patients Treated With Peginterferon and Ribavirin (POPS Study)|Completed||Phase 2/Phase 3|80|Anticipated|Foundation for Liver Research||2|||f||||f||||||||||2018-06-01 04:48:57.146771|2018-06-01 04:48:57.146771
NCT00133263|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2014-07-09|2005-08-22|2005-08-23|Estimate|||||||2014-07-09|2014-07-10|Estimate|January 2001||2001-01-31|March 2008|2008-03-31|December 2006|Actual|2006-12-31|April 2005|Actual|2005-04-30||Interventional|||Effectiveness of a Standardized Bereavement Intervention in Primary Care|"Effectiveness of Primary Bereavement Care (PBC) in Widows: A Cluster Randomized Controlled Trial"|Completed||Phase 3|87|Actual|Carlos III Health Institute||2|||f||||f||||||||||2018-06-01 04:48:57.270859|2018-06-01 04:48:57.270859
NCT00133250|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-20|||2010-03-15|2005-08-20|2005-08-23|Estimate|||||||2010-03-15|2010-03-16|Estimate|June 2003||2003-06-30|March 2010|2010-03-31|March 2008|Actual|2008-03-31|February 2008|Actual|2008-02-29||Interventional|||Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)|Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)|Completed||Phase 4|800|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:48:57.451211|2018-06-01 04:48:57.451211
NCT00133237|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2010-03-12|2005-08-22|2005-08-23|Estimate|||||||2010-03-12|2010-03-15|Estimate|July 2005||2005-07-31|October 2008|2008-10-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)|Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)|Completed||Phase 4|607|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:48:57.584386|2018-06-01 04:48:57.584386
NCT00133224|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2008-09-19|2005-08-19|2005-08-23|Estimate|||||||2008-09-19|2008-09-23|Estimate|July 2005||2005-07-31|September 2008|2008-09-30|June 2009|Anticipated|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients|A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain|Terminated||Phase 3|408|Actual|Cell Genesys||2||Accrual and treatment with CG1940/CG8711 stopped due to IDMC recommendation.|f||||||||||||||2018-06-01 04:48:57.768735|2018-06-01 04:48:57.768735
NCT00133211|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2015-03-05|2005-08-22|2005-08-23|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2005||2005-09-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MANTRA-PAF||Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation|Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective Multicentre Study (MANTRA-PAF)|Completed||Phase 3|294|Actual|Danish Heart Foundation||2|||f||||t||||||||||2018-06-01 04:48:58.20936|2018-06-01 04:48:58.20936
NCT00133198|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2013-11-07|2005-08-22|2005-08-23|Estimate|||||||2013-11-07|2013-11-08|Estimate|April 2004||2004-04-30|November 2013|2013-11-30|February 2005||2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks|Completed||Phase 3|345|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:48:58.348304|2018-06-01 04:48:58.348304
NCT00133185|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2013-11-18|2005-08-22|2005-08-23|Estimate|||||||2013-11-18|2013-11-19|Estimate|March 2004||2004-03-31|November 2013|2013-11-30|March 2005||2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension|A Randomized, Double-Blind, Parallel-Group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5 mg in Comparison With Losartan 50 mg Plus Hydrochlorothiazide 12.5 mg in Taiwanese Patients With Mild to Moderate Hypertension|Completed||Phase 3|31||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:48:58.512962|2018-06-01 04:48:58.512962
NCT00133172|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2014-09-05|2005-08-22|2005-08-23|Estimate|||||||2014-09-05|2014-09-08|Estimate|July 2005||2005-07-31|September 2014|2014-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection|Evaluation of the Long-term Safety and Efficacy of a Tacrolimus-based 5-day Steroid Rapid Withdrawal Immunoprophylactic Regimen in de Novo Renal Transplantation|Terminated||Phase 4|85|Actual|Astellas Pharma Inc||2||Varience of supply chain from that required by protocol|f||||t||||||||||2018-06-01 04:48:58.621489|2018-06-01 04:48:58.621489
NCT00133159|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2010-06-16|2005-08-22|2005-08-23|Estimate|||||||2010-06-16|2010-06-17|Estimate|September 2005||2005-09-30|June 2010|2010-06-30||||||||Interventional|||Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen|A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Grass/Rye Pollen Allergoid With MPL in Patients Sensitized to Grass and Rye Pollen|Completed||Phase 2|68||Allergy Therapeutics|||||||||||||||||||2018-06-01 04:48:58.788|2018-06-01 04:48:58.788
NCT00133146|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-22|||2010-06-16|2005-08-22|2005-08-23|Estimate|||||||2010-06-16|2010-06-17|Estimate|September 2005||2005-09-30|September 2009|2009-09-30||||||||Interventional|||Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine|A Double-Blind Phase IIa Study to Demonstrate the Contribution of MPL to Tyrosine Adsorbed Grass/Rye Pollen Allergoid (Grass MATA) With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Volunteers Allergic to Grass and Rye Pollen|Completed||Phase 2|40||Allergy Therapeutics|||||||||||||||||||2018-06-01 04:48:58.935691|2018-06-01 04:48:58.935691
NCT00133133|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2006-12-18|2005-08-18|2005-08-22|Estimate|||||||2006-12-18|2006-12-20|Estimate|July 2005||2005-07-31|February 2006|2006-02-28|December 2005||2005-12-31|||||Interventional|||Efficacy and Safety of ALGRX 4975 in the Treatment of Postoperative Pain After Gall Bladder Removal|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects After Open Cholecystectomy|Completed||Phase 2|40||AlgoRx Pharmaceuticals|||||f||||||||||||||2018-06-01 04:48:59.055626|2018-06-01 04:48:59.055626
NCT00133107|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2011-08-18|2005-08-19|2005-08-22|Estimate|||||||2011-08-18|2011-08-19|Estimate|January 2005||2005-01-31|August 2011|2011-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus|A Single Center, Open-label, Pilot Study Evaluating the Safety and Effectiveness of Subcutaneous Efalizumab in the Treatment of Oral Lichen Planus|Completed||N/A|4|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 04:48:59.151648|2018-06-01 04:48:59.151648
NCT00133094|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2015-04-06|2005-08-18|2005-08-22|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2006||2006-06-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Systematic Management of High Cholesterol Utilizing Computer Monitoring|Management of Hypercholesterolemia Utilizing a Case Management System, Incorporating Computer-Based Decision Support Technology|Completed||N/A|220|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:48:59.250949|2018-06-01 04:48:59.250949
NCT00133081|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2005-10-20|2005-08-17|2005-08-22|Estimate|||||||2005-10-20|2005-10-21|Estimate|October 2002||2002-10-31|March 2004|2004-03-31|August 2006||2006-08-31|||||Interventional|||Study to Improve the Treatment of Epilepsy (SITE)|Study to Improve the Treatment of Epilepsy (SITE). A Randomized Study Comparing Adjustment of Treatment to Reduce Side Effects of Antiepileptic Drugs With Continuing Treatment Unchanged|Unknown status|Active, not recruiting|Phase 4|255||UMC Utrecht|||||f||||||||||||||2018-06-01 04:48:59.376975|2018-06-01 04:48:59.376975
NCT00133068|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2016-05-10|2005-08-19|2005-08-22|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2005||2005-03-31|May 2016|2016-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Collaboration to Reduce Disparities in Hypertension|Collaboration to Reduce Disparities in Hypertension|Completed||Phase 4|802|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 04:48:59.479202|2018-06-01 04:48:59.479202
NCT00133042|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2011-09-16|2005-08-19|2005-08-22|Estimate|||||||2011-09-16|2011-09-20|Estimate|December 2004||2004-12-31|February 2009|2009-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma||Completed||Phase 4|16||University of Florida|||||||||||||||||||2018-06-01 04:48:59.75264|2018-06-01 04:48:59.75264
NCT00133029|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2016-08-12|2005-08-19|2005-08-22|Estimate|||||||2016-08-12|2016-08-15|Estimate|July 2004||2004-07-31|August 2016|2016-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||The Timing of Prophylactic Antibiotics in Cesarean Section and the Risk of Post-operative Febrile Morbidity||Terminated||Phase 4|||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:48:59.861955|2018-06-01 04:48:59.861955
NCT00133016|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2015-12-01|2005-08-19|2005-08-22|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2006||2006-08-31|December 2015|2015-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||The Efficacy of Early Amniotomy for Induction of Labor|The Efficacy of Early Amniotomy for Induction of Labor|Withdrawn||N/A|0|Actual|University of Pennsylvania||||no funding|f||||||||||||||2018-06-01 04:49:00.043627|2018-06-01 04:49:00.043627
NCT00133003|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2008-04-12|2005-08-18|2005-08-22|Estimate|||||||2008-04-12|2008-04-15|Estimate|March 2003||2003-03-31|April 2008|2008-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)|Completed||Phase 4|2022|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:49:00.189318|2018-06-01 04:49:00.189318
NCT00132990|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2007-01-11|2005-08-18|2005-08-22|Estimate|||||||2007-01-11|2007-01-12|Estimate|February 2003||2003-02-28|January 2007|2007-01-31|September 2005||2005-09-30|||||Interventional|||A Multicenter Pilot Study of Pallidal Deep Brain Stimulation for Cervical Dystonia|A Multicenter Pilot Study of Pallidal Deep Brain Stimulation of Cervical Dystonia|Unknown status|Active, not recruiting|N/A|10||University of Calgary|||||f||||||||||||||2018-06-01 04:49:00.353737|2018-06-01 04:49:00.353737
NCT00132977|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2015-04-13|2005-08-18|2005-08-22|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|RethinQ||RethinQ Study - Evaluating Pacing in Heart Failure Patients|Resynchronization Therapy in Normal QRS (RethinQ) Clinical Investigation|Completed||Phase 3|250|Actual|St. Jude Medical|||||f||||t||||||||||2018-06-01 04:49:00.482377|2018-06-01 04:49:00.482377
NCT00132964|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2017-10-06|2005-08-19|2005-08-22|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2003||2003-07-31|October 2017|2017-10-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Brace Versus Casting in Pediatric Low Risk Ankle Fractures|Randomized Control Trial of Casting Versus Ankle Bracing in Children With Low-risk Ankle Fractures|Completed||Phase 4|112|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-06-01 04:49:00.716765|2018-06-01 04:49:00.716765
NCT00132951|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2009-08-26|2005-08-19|2005-08-22|Estimate|||||||2009-08-26|2009-08-27|Estimate|October 2004||2004-10-31|August 2009|2009-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|KEYS||KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections|A Randomized, Investigator Blinded, Multi-Center Clinical Study To Compare Patient Outcomes and Clinical Effectiveness of Telithromycin Versus Azithromycin in Outpatients With Lower Respiratory Tract Infections|Terminated||Phase 4|2051|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:49:00.837663|2018-06-01 04:49:00.837663
NCT00132938|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2011-06-07|2005-08-19|2005-08-22|Estimate|||||||2011-06-07|2011-06-08|Estimate|January 2004||2004-01-31|June 2011|2011-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis|An Open-label, Randomized, Multicenter, Clinical Study to Compare the Effects of Telithromycin, Azithromycin and Cefuroxime Axetil on the Penicillin or Macrolide Resistance of Streptococcus Pneumoniae in Patients With Acute Exacerbation of Chronic Bronchitis|Completed||Phase 4|5660||Sanofi|||||f||||||||||||||2018-06-01 04:49:00.951738|2018-06-01 04:49:00.951738
NCT00132925|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2011-01-10|2005-08-19|2005-08-22|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2003||2003-11-30|January 2011|2011-01-31|February 2006||2006-02-28|||||Interventional|||An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis|An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis|Completed||Phase 3|460||Sanofi|||||f||||||||||||||2018-06-01 04:49:01.113155|2018-06-01 04:49:01.113155
NCT00132912|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2017-05-23|2005-08-19|2005-08-22|Estimate|||||||2017-05-23|2017-05-25|Actual|August 30, 2005|Actual|2005-08-30|May 2017|2017-05-31|January 28, 2007|Actual|2007-01-28|January 28, 2007|Actual|2007-01-28||Interventional|||Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention|Completed||Phase 2|1030|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:49:01.217966|2018-06-01 04:49:01.217966
NCT00132899|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2013-12-10|2005-08-19|2005-08-22|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2005||2005-12-31|December 2005|2005-12-31|July 2008|Actual|2008-07-31|February 2008|Actual|2008-02-29||Interventional|||COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)|A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Infliximab in Combination With Methotrexate for the Long-term Treatment of Crohn's Disease (CD)|Completed||Phase 3|128|Actual|University of Western Ontario, Canada||2|||f||||t||||||||||2018-06-01 04:49:01.322918|2018-06-01 04:49:01.322918
NCT00132886|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2012-05-02|2005-08-18|2005-08-22|Estimate|||||||2012-05-02|2012-05-03|Estimate|December 2004||2004-12-31|May 2012|2012-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure|Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Single Oral Tolvaptan Tablets on Hemodynamic Parameters in Subjects With Heart Failure|Completed||Phase 2|140|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 04:49:01.440275|2018-06-01 04:49:01.440275
NCT00132873|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|2013-09-18||2013-09-18|2005-08-18|2005-08-22|Estimate|2013-09-18|2013-11-25|Estimate||||2013-09-18|2013-11-25|Estimate|October 2004||2004-10-31|September 2013|2013-09-30|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy|Long-Term, Open-Label, Multi-Center Extension Trial of Xyrem® (Sodium Oxybate) Oral Solution for the Treatment of Narcolepsy|Completed||Phase 3|59|Actual|Jazz Pharmaceuticals|||||f||||||||||||||2018-06-01 04:49:01.590013|2018-06-01 04:49:01.590013
NCT00130481|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2012-03-06|2005-08-12|2005-08-15|Estimate|||||||2012-03-06|2012-03-07|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)|Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)|Completed||N/A|100||University of Florida|||||f||||||||||||||2018-06-01 04:49:38.034797|2018-06-01 04:49:38.034797
NCT00132860|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2005-10-18|2005-08-19|2005-08-22|Estimate|||||||2005-10-18|2005-10-19|Estimate|May 2001||2001-05-31|August 2005|2005-08-31|December 2007||2007-12-31|||||Interventional|||Prophylactic ﻿Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)|﻿Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease: A Prospective, Randomized, Double-Blind Placebo-Controlled Study of Intermittent, Prophylactic Antibiotic Treatment With Azithromycin|Unknown status|Active, not recruiting|Phase 4|800||Odense University Hospital|||||f||||||||||||||2018-06-01 04:49:01.846704|2018-06-01 04:49:01.846704
NCT00132847|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2013-01-18|2005-08-18|2005-08-22|Estimate|||||||2013-01-18|2013-01-23|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|October 2004||2004-10-31|||||Observational|||Comparing Allergenic Effects of 3 German Cockroach Extracts in Adults|German Cockroach Allergen Standardization Evaluation (CASE)|Terminated|||4|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||||||2018-06-01 04:49:01.931052|2018-06-01 04:49:01.931052
NCT00132834|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2013-01-24|2005-08-18|2005-08-22|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2003||2003-11-30|January 2013|2013-01-31|March 2004|Actual|2004-03-31|||||Observational|||Methods of Determining Asthma Severity in Children|"Exhaled Breath Condensates (EBC) Study: Research Plan NIH/NIAID: Inner City Asthma Consortium (ICAC)"|Completed|||80|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||||||||||||2018-06-01 04:49:02.003741|2018-06-01 04:49:02.003741
NCT00132821|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2017-01-11|2005-08-18|2005-08-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Impact of Smoking Cessation on Sleep - 5|Impact of Smoking Cessation on Sleep|Completed||Phase 4|59|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||t||||||||||2018-06-01 04:49:02.105913|2018-06-01 04:49:02.105913
NCT00132808|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|2010-12-10||2016-08-01|2005-08-18|2005-08-22|Estimate|2010-12-10|2011-01-10|Estimate||||2016-08-01|2016-09-12|Estimate|July 2004||2004-07-31|August 2016|2016-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older|A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia|Completed||Phase 3|581|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:49:02.24901|2018-06-01 04:49:02.24901
NCT00132795|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2012-06-20|2005-08-19|2005-08-22|Estimate|||||||2012-06-20|2012-06-21|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|ATIVR||Using Telephone Technology to Prevent Relapse After Alcoholism Treatment|Therapeutic IVR to Augment CBT in Alcohol Dependence|Completed||Phase 2|158|Actual|University of Vermont||2|||f||||f||||||||||2018-06-01 04:49:03.23592|2018-06-01 04:49:03.23592
NCT00132782|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2014-03-03|2005-08-19|2005-08-22|Estimate|||||||2014-03-03|2014-03-04|Estimate|March 2003||2003-03-31|February 2009|2009-02-28|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Observational|||Relationship Between Functional Health Status and Ventricular Performance After Fontan--Pediatric Heart Network|Relationship Between Functional Health Status and Ventricular Performance After Fontan (A Trial Conducted by the Pediatric Heart Network)|Completed|||546|Actual|New England Research Institutes|||||f||||t||||||||||2018-06-01 04:49:03.373461|2018-06-01 04:49:03.373461
NCT00132769|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2013-10-07||2015-07-29|2005-08-19|2005-08-22|Estimate|2013-12-17|2014-02-03|Estimate||||2015-07-29|2015-07-30|Estimate|January 2005||2005-01-31|July 2015|2015-07-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study of a Novel Investigational Drug in Rheumatoid Arthritis Patients (MK-0873-012)(COMPLETED)|A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK-0873 in Rheumatoid Arthritis|Completed||Phase 2|106|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:49:03.481343|2018-06-01 04:49:03.481343
NCT00132756|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2006-11-06|2005-08-19|2005-08-22|Estimate|||||||2006-11-06|2006-11-08|Estimate|December 2003||2003-12-31|November 2006|2006-11-30||||||||Interventional|||Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer|Liposomal Doxorubicin and Estramustine Phosphate: A Phase II Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer|Terminated||Phase 1/Phase 2|30||Morton Plant Mease Health Care|||||f||||||||||||||2018-06-01 04:49:03.973105|2018-06-01 04:49:03.973105
NCT00132743|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2013-04-24|2005-08-19|2005-08-22|Estimate|||||||2013-04-24|2013-04-25|Estimate|February 2007||2007-02-28|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|CLEVER||Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)|Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)|Unknown status|Active, not recruiting|Phase 3|119|Actual|Rhode Island Hospital||3|||f||||t||||||||||2018-06-01 04:49:04.103946|2018-06-01 04:49:04.103946
NCT00132730|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2014-03-17||2017-03-24|2005-08-19|2005-08-22|Estimate|2014-04-25|2014-05-26|Estimate||||2017-03-24|2017-04-24|Actual|June 1, 2004|Actual|2004-06-01|March 2017|2017-03-31|August 17, 2005|Actual|2005-08-17|August 17, 2005|Actual|2005-08-17||Interventional|||An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of MK-0873 in Patients With COPD|Terminated||Phase 2|604|Actual|Merck Sharp & Dohme Corp.|The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.|6|||f||||f||||||||||2018-06-01 04:49:04.376446|2018-06-01 04:49:04.376446
NCT00132717|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2017-04-05|2005-08-19|2005-08-22|Estimate|||||||2017-04-05|2017-04-07|Actual|January 1, 2005|Actual|2005-01-01|April 2017|2017-04-30|June 1, 2007|Actual|2007-06-01|June 1, 2007|Actual|2007-06-01||Interventional|||A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)|An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination Tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary Event|Completed||Phase 3|450|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:49:05.445055|2018-06-01 04:49:05.445055
NCT00132704|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2014-07-23|2005-08-19|2005-08-22|Estimate|||||||2014-07-23|2014-07-24|Estimate|August 2004||2004-08-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation|An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation|Completed|||149|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     tissue~   "|||2018-06-01 04:49:05.529342|2018-06-01 04:49:05.529342
NCT00132691|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|2012-05-14||2016-10-13|2005-08-19|2005-08-22|Estimate|2012-06-22|2012-07-30|Estimate||||2016-10-13|2016-11-25|Estimate|September 2005||2005-09-30|October 2016|2016-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|MUST||Multicenter Uveitis Steroid Treatment (MUST) Trial|Multicenter Uveitis Steroid Treatment (MUST) Trial|Completed||Phase 4|255|Actual|JHSPH Center for Clinical Trials||2|||f||||t||||||||||2018-06-01 04:49:05.657364|2018-06-01 04:49:05.657364
NCT00132678|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2008-10-24||2013-07-23|2005-08-18|2005-08-22|Estimate|2009-01-26|2009-02-27|Estimate||||2013-07-23|2013-07-29|Estimate|February 2005||2005-02-28|July 2013|2013-07-31|December 2007|Actual|2007-12-31|October 2007|Actual|2007-10-31||Interventional|||A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes|A Randomized, Double-blind, Placebo-controlled Study to Explore the Efficacy and Safety of Risperidone Long-acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar 1 Disorder, With Open-label Extension|Completed||Phase 3|559|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 04:49:06.942715|2018-06-01 04:49:06.942715
NCT00132665|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2012-12-06|2005-08-18|2005-08-22|Estimate|||||||2012-12-06|2012-12-07|Estimate|July 2003||2003-07-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301)|Randomized Controlled Trial to Evaluate Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatine in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer (JCOG0301, NCSLC-Elderly-CBDCA-RT Phase III)|Completed||Phase 3|200|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:49:07.702954|2018-06-01 04:49:07.702954
NCT00132652|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2017-02-21|2005-08-18|2005-08-22|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2005||2005-02-28|February 2017|2017-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B|A Randomized Trial of Switching Antiviral Therapy From Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults With Chronic Hepatitis B|Completed||Phase 3|240||Novartis|||||||||||||||||||2018-06-01 04:49:07.860683|2018-06-01 04:49:07.860683
NCT00132639|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2016-09-20|2005-08-19|2005-08-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|October 2002||2002-10-31|September 2016|2016-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)|Randomized Phase II Study of the Induction Chemotherapy With Docetaxel Alone vs CDDP + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (JCOG 0204-MF)|Completed||Phase 2|80|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:49:08.193918|2018-06-01 04:49:08.193918
NCT00132626|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2007-02-20|2005-08-18|2005-08-22|Estimate|||||||2007-02-20|2007-02-21|Estimate|September 1992||1992-09-30|February 2007|2007-02-28|August 2005||2005-08-31|||||Interventional|||Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome|Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism|Completed||Phase 2|500||Institute for Neurodegenerative Disorders|||||f||||||||||||||2018-06-01 04:49:08.286851|2018-06-01 04:49:08.286851
NCT00132613|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2016-09-20|2005-08-19|2005-08-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|August 1999||1999-08-31|September 2016|2016-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion|A Randomized Controlled Trial to Evaluate the Efficacy of Intra-pericardial Instillation of a Sclerosing Agent After Pericardial Drainage in Patients With Malignant Pericardial Effusion Associated With Lung Cancer (JCOG9811)|Completed||Phase 3|80|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:49:08.342906|2018-06-01 04:49:08.342906
NCT00132600|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2005-10-18|2005-08-19|2005-08-22|Estimate|||||||2005-10-18|2005-10-19|Estimate|April 2005||2005-04-30|August 2005|2005-08-31|July 2005||2005-07-31|||||Interventional|||Clinical Evaluation of Bacitracin|Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study|Completed||Phase 2|20||Mekos Laboratories AS|||||||||||||||||||2018-06-01 04:49:08.493394|2018-06-01 04:49:08.493394
NCT00132587|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2008-06-30|2005-08-19|2005-08-22|Estimate|||||||2008-06-30|2008-07-04|Estimate|March 2004||2004-03-31|June 2008|2008-06-30|March 2007|Actual|2007-03-31|December 2006|Actual|2006-12-31||Interventional|||Total Knee Arthroplasty (TKA) Cemented Versus Cementless|Prospective Randomized Study of 130 Total Knee Arthroplasty With Cemented Femoral Implant Versus Cementless|Completed||N/A|130||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:49:08.60194|2018-06-01 04:49:08.60194
NCT00132574|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2006-09-20|2005-08-19|2005-08-22|Estimate|||||||2006-09-20|2006-09-21|Estimate|August 2005||2005-08-31|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||Pilot Study of a Dietary Intervention to Prevent Acne Recurrence|Milk Minimization and Acne Recurrence Trial (MMART)|Terminated||Phase 2|30||Harvard School of Public Health|||||f||||||||||||||2018-06-01 04:49:08.694706|2018-06-01 04:49:08.694706
NCT00132561|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2017-01-11|2005-08-18|2005-08-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2002||2002-06-30|January 2017|2017-01-31|December 2003||2003-12-31|||||Interventional|||A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children|A Double-blind, Randomised, Placebo-controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa|Completed||Phase 2/Phase 3|1200||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:49:08.885079|2018-06-01 04:49:08.885079
NCT00132548|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2017-01-11|2005-08-18|2005-08-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2004||2004-06-30|January 2017|2017-01-31|December 2004||2004-12-31|||||Interventional|||A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children|A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children|Completed||Phase 3|2200||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:49:09.010836|2018-06-01 04:49:09.010836
NCT00132535|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2017-01-11|2005-08-19|2005-08-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2003||2003-08-31|January 2017|2017-01-31|June 2007|Actual|2007-06-30|||||Interventional|||Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda|Influence of HIV Infection on the Effectiveness of Malaria Prevention During Pregnancy, With Emphasis on the Effect of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda|Completed||N/A|2548||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:49:09.141381|2018-06-01 04:49:09.141381
NCT00132522|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2013-10-23|2005-08-19|2005-08-22|Estimate|||||||2013-10-23|2013-10-25|Estimate|May 2005||2005-05-31|October 2013|2013-10-31|April 2009|Actual|2009-04-30|June 2008|Actual|2008-06-30||Interventional|||EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide|A Study to Find the Highest Dose of Biological Study Drug (EMD 273066) That Can Be Given Safely to Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given a Low Dose of Cyclophosphamide|Completed||Phase 1|45|Actual|EMD Serono||1|||f||||f||||||||||2018-06-01 04:49:09.261059|2018-06-01 04:49:09.261059
NCT00132301|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2016-06-22|2005-08-18|2005-08-19|Estimate|||||||2016-06-22|2016-06-24|Estimate|June 2006||2006-06-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|October 2015|Actual|2015-10-31||Interventional|CAP||Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma|CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment (CAP)|Active, not recruiting||Phase 3|298|Actual|VA Office of Research and Development||2|||f||||t||||||||Undecided||2018-06-01 04:49:12.201272|2018-06-01 04:49:12.201272
NCT00132509|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2011-07-21|2005-08-19|2005-08-22|Estimate|||||||2011-07-21|2011-07-22|Estimate|September 2001||2001-09-30|February 2009|2009-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke|Comparison of the Classical Rt-PA Procedure (0.9mg/kg Over 60 Minutes) With a Longer Procedure With Lower Dose (0.8mg/kg Over 90 Minutes) in Acute Ischemic Stroke|Terminated||Phase 2|500|Anticipated|Hospices Civils de Lyon||2||End of promotion by the sponsor|f||||||||||||||2018-06-01 04:49:09.372684|2018-06-01 04:49:09.372684
NCT00132496|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|2009-08-25||2009-11-02|2005-08-19|2005-08-22|Estimate|2009-11-02|2009-12-03|Estimate||||2009-11-02|2009-12-03|Estimate|August 2005||2005-08-31|November 2009|2009-11-30|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole|Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients|Completed||Phase 2|111|Actual|Eisai Inc.|||||f||||f||||||||||2018-06-01 04:49:09.566679|2018-06-01 04:49:09.566679
NCT00132483|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2007-10-19|2005-08-19|2005-08-22|Estimate|||||||2007-10-19|2007-10-22|Estimate|September 2003||2003-09-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||ExStroke Pilot Trial: Physical Exercise After Acute Ischaemic Stroke||Completed||Phase 3|314|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-06-01 04:49:10.040752|2018-06-01 04:49:10.040752
NCT00132470|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2007-07-23|2005-08-18|2005-08-22|Estimate|||||||2007-07-23|2007-07-25|Estimate|December 2004||2004-12-31|July 2007|2007-07-31|March 2007||2007-03-31|||||Interventional|||Treatment With AX200 for Acute Ischemic Stroke|AXIS IIa - Treatment With AX200 for Acute Ischemic Stroke|Completed||Phase 2|42||Axaron Bioscience AG|||||f||||||||||||||2018-06-01 04:49:10.176555|2018-06-01 04:49:10.176555
NCT00132457|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2010-01-06|2005-08-18|2005-08-22|Estimate|||||||2010-01-06|2010-01-07|Estimate|October 2003||2003-10-31|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection|Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection|Completed||N/A|1830|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:49:10.296377|2018-06-01 04:49:10.296377
NCT00132444|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2010-01-06|2005-08-18|2005-08-22|Estimate|||||||2010-01-06|2010-01-07|Estimate|October 2005||2005-10-31|January 2010|2010-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of UC-781 Vaginal Microbicide|Phase I Study of the Safety and Acceptability of UC-781 Topical Vaginal Microbicide in Heterosexual Women and Their Male Partners|Completed||Phase 1|90|Anticipated|Centers for Disease Control and Prevention||3|||f||||||||||||||2018-06-01 04:49:10.384446|2018-06-01 04:49:10.384446
NCT00132431|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2009-02-12|2005-08-19|2005-08-22|Estimate|||||||2009-02-12|2009-02-13|Estimate|July 2004||2004-07-31|February 2009|2009-02-28|July 2005||2005-07-31|||||Interventional|||START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism|Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism|Completed||Phase 4|300||Amgen|||||f||||||||||||||2018-06-01 04:49:10.493965|2018-06-01 04:49:10.493965
NCT00132418|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2011-01-20|2005-08-19|2005-08-22|Estimate|||||||2011-01-20|2011-01-21|Estimate|April 2000||2000-04-30|January 2011|2011-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders|Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders|Completed||Phase 4|564|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:49:10.634933|2018-06-01 04:49:10.634933
NCT00132405|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2005-10-07|2005-08-18|2005-08-22|Estimate|||||||2005-10-07|2005-10-10|Estimate|May 2004||2004-05-31|August 2005|2005-08-31|September 2004||2004-09-30|||||Interventional|||Study of ALGRX 3268 for Needlestick Pain in Children|Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effectiveness and Safety of ALGRX 3268 0.5 Mg/20 Bar at the Back of the Hand in Pediatric Subjects|Completed||Phase 2|260||AlgoRx Pharmaceuticals|||||||||||||||||||2018-06-01 04:49:10.737564|2018-06-01 04:49:10.737564
NCT00132392|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2006-12-18|2005-08-18|2005-08-22|Estimate|||||||2006-12-18|2006-12-20|Estimate|July 2005||2005-07-31|August 2005|2005-08-31|December 2005||2005-12-31|||||Interventional|||ALGRX 4975 After Total Knee Replacement|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects After Total Knee Arthroplasty|Completed||Phase 2|40||AlgoRx Pharmaceuticals|||||||||||||||||||2018-06-01 04:49:10.844446|2018-06-01 04:49:10.844446
NCT00132379|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-19|||2014-08-26|2005-08-19|2005-08-22|Estimate|||||||2014-08-26|2014-08-27|Estimate|November 2005||2005-11-30|August 2014|2014-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer|An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|13|Actual|Active Biotech AB||1|||f||||f||||||||||2018-06-01 04:49:10.938592|2018-06-01 04:49:10.938592
NCT00132366|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2017-06-30|2005-08-18|2005-08-19|Estimate|||||||2017-06-30|2017-07-02|Actual|August 16, 2005||2005-08-16|June 25, 2009|2009-06-25|June 30, 2008|Actual|2008-06-30|June 30, 2008|Actual|2008-06-30||Observational|||Brain Excitability in Patients With Succinic Semialdehyde Dehydrogenase Deficiency|Cortical Excitability in Succinic Semialdehyde Dehydrogenase Deficiency|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:49:11.190994|2018-06-01 04:49:11.190994
NCT00132353|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2018-05-18|2005-08-18|2005-08-19|Estimate|||||||2018-05-18|2018-05-21|Actual|September 1, 2005||2005-09-01|February 23, 2018|2018-02-23||||||||Observational|||Training for Diagnosing Neurological Disorders|Clinical Neurophysiology: Training and Normative Values|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:49:11.301392|2018-06-01 04:49:11.301392
NCT00132340|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2006-07-04|2005-08-18|2005-08-19|Estimate|||||||2006-07-04|2006-07-06|Estimate|August 2005||2005-08-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||Deep Brain Stimulation to Treat Cervical Dystonia|Deep Brain Stimulation of the Globus Pallidus Interna or the Subthalamic Nucleus for Treatment of Primary Cervical Dystonia|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:49:11.41933|2018-06-01 04:49:11.41933
NCT00132327|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2018-03-27|2005-08-18|2005-08-19|Estimate|||||||2018-03-27|2018-03-29|Actual|August 17, 2005||2005-08-17|November 30, 2017|2017-11-30||||||||Observational|||Analysis of Lyme Disease Lesions|Analysis of Erythema Migrans Lesions|Recruiting|||60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:49:11.501005|2018-06-01 04:49:11.501005
NCT00132314|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2013-05-29||2013-10-30|2005-08-17|2005-08-19|Estimate|2013-10-30|2013-12-20|Estimate||||2013-10-30|2013-12-20|Estimate|September 2006||2006-09-30|October 2013|2013-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional||We used the intention to treat (ITT) population as defined in Milestone 2.|Long-Acting Injectable Risperidone in the Treatment of Schizophrenia|CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia|Completed||Phase 3|382|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:49:11.60837|2018-06-01 04:49:11.60837
NCT00132288|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2007-12-13|2005-08-17|2005-08-19|Estimate|||||||2007-12-13|2007-12-19|Estimate|May 2005||2005-05-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||MY PALS: A Community-Based Physical Activity Support Program for Older Adults|A Randomized Controlled Trial Linking Clinical Quality Improvement Programs for Older Diabetics to a Community Based Activity Support Center|Completed||N/A|305|Actual|University of Washington|||||f||||t||||||||||2018-06-01 04:49:12.381104|2018-06-01 04:49:12.381104
NCT00132275|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2008-05-19|2005-08-18|2005-08-19|Estimate|||||||2008-05-19|2008-05-20|Estimate|November 2003||2003-11-30|May 2008|2008-05-31|August 2006|Actual|2006-08-31|||||Interventional|||Guidelines for Acute Sinusitis|Evaluation of National Guidelines for Acute Sinusitis|Completed||N/A|240|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:49:12.519089|2018-06-01 04:49:12.519089
NCT00132262|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2013-01-29|2005-08-17|2005-08-19|Estimate|||||||2013-01-29|2013-01-30|Estimate|May 2003||2003-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2006|Actual|2006-08-31||Interventional|||Brief Intervention to Reduce Injury in Minorities|Brief Intervention to Reduce Injury in Minorities|Completed||N/A|1493|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 04:49:12.593306|2018-06-01 04:49:12.593306
NCT00132249|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2015-06-08|2005-08-17|2005-08-19|Estimate|||||||2015-06-08|2015-06-09|Estimate|April 2004||2004-04-30|June 2015|2015-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Vietnam Head Injury Study - Phase III|A 40+ Year Post-Injury Follow-Up Study of Vietnam Veterans Who Sustained Traumatic Brain Injury While in Combat.|Completed|||254|Actual|U.S. Army Medical Research and Materiel Command|||2||f||||f||||||||||2018-06-01 04:49:12.698028|2018-06-01 04:49:12.698028
NCT00132236|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2005-10-20|2005-08-17|2005-08-19|Estimate|||||||2005-10-20|2005-10-21|Estimate|February 2002||2002-02-28|July 2005|2005-07-31|June 2004||2004-06-30|||||Interventional|||Nurse Smoking Cessation of Patients With Chronic Obstructive Pulmonary Disease (COPD) With Nicotine Replacement Therapy (NRT) and Behavioral Support|Smoking Cessation of Patients With COPD: A Multi-Center, Randomized, Placebo Controlled Nurse Conducted Smoking Cessation Trial|Terminated||Phase 3|300||University Hospital, Gentofte, Copenhagen|||||f||||||||||||||2018-06-01 04:49:12.780098|2018-06-01 04:49:12.780098
NCT00132223|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2006-04-11|2005-08-18|2005-08-19|Estimate|||||||2006-04-11|2006-04-12|Estimate|April 2005||2005-04-30|April 2006|2006-04-30|December 2005||2005-12-31|||||Interventional|||Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients|Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging|Unknown status|Recruiting|Phase 4|10||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:49:12.850977|2018-06-01 04:49:12.850977
NCT00132210|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2010-10-20|2005-08-17|2005-08-19|Estimate|||||||2010-10-20|2010-10-21|Estimate|September 2002||2002-09-30|November 2009|2009-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients|Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients|Completed||Phase 4|200|Anticipated|University Hospital, Bonn|||||f||||f||||||||||2018-06-01 04:49:12.931095|2018-06-01 04:49:12.931095
NCT00132197|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2011-11-11|2005-08-17|2005-08-19|Estimate|||||||2011-11-11|2011-11-16|Estimate|April 2005||2005-04-30|November 2011|2011-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Treatment of Patients With Longstanding Unexplained Health Complaints|Treatment of Patients With Chronic Functional Disorders. A Randomized Controlled Trial of Specialized Treatment Compared to Usual Care.|Completed||Phase 2/Phase 3|120|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 04:49:13.056905|2018-06-01 04:49:13.056905
NCT00132184|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2007-04-12|2005-08-18|2005-08-19|Estimate|||||||2007-04-12|2007-04-13|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|February 2008|Anticipated|2008-02-29|||||Interventional|||Vitamin D Treatment for Crohn´s Disease|Remission Keeping and Remission Inducing Effect by Vitamin-D in Crohns Disease, and in Vitro Vitamin-D Mediated T-Cell Immunomodulation|Unknown status|Active, not recruiting|Phase 2/Phase 3|110||University of Aarhus|||||f||||||||||||||2018-06-01 04:49:13.158506|2018-06-01 04:49:13.158506
NCT00132171|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2005-10-19|2005-08-18|2005-08-19|Estimate|||||||2005-10-19|2005-10-20|Estimate|January 2001||2001-01-31|March 2002|2002-03-31|December 2001||2001-12-31|||||Interventional|||Helicobacter Pylori Eradication With a New Sequential Treatment|High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment|Completed||Phase 3|1000||St. Orsola Hospital|||||f||||||||||||||2018-06-01 04:49:13.221959|2018-06-01 04:49:13.221959
NCT00132158|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2012-04-16|2005-08-17|2005-08-19|Estimate|||||||2012-04-16|2012-04-17|Estimate|September 2005||2005-09-30|April 2012|2012-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors|A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and an Oral Formulation of Irinotecan (Camptosar™) in Children With Refractory Solid Tumors|Completed||Phase 1|19|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-06-01 04:49:13.399636|2018-06-01 04:49:13.399636
NCT00132145|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2016-10-18|2005-08-17|2005-08-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|April 2003||2003-04-30|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III)|A Randomized Trial of Electronic Integration of Care for Better Vascular Outcomes: The Compete III Study Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III)|Completed||N/A|1000|Actual|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||No||2018-06-01 04:49:13.486531|2018-06-01 04:49:13.486531
NCT00132132|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2012-06-22||2015-05-04|2005-08-18|2005-08-19|Estimate|2012-06-22|2012-06-27|Estimate||||2015-05-04|2015-05-21|Estimate|August 2005||2005-08-31|May 2015|2015-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Impact of Behavioral Intervention- Exercise, Nutrition, Education- on Body Mass Index (BMI)|Type 2 Diabetes and Obesity Pediatric Prevention Project|Completed||N/A|30|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.|A limitation of the study is the lost to follow up. However, our rate of lost to follow up is comparable to rates seen in similar studies in this field|2|||f||||t||||||||||2018-06-01 04:49:13.621432|2018-06-01 04:49:13.621432
NCT00132119|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2008-05-15|2005-08-17|2005-08-19|Estimate|||||||2008-05-15|2008-05-19|Estimate|August 2005||2005-08-31|May 2008|2008-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling|Completed||Phase 2/Phase 3|233|Actual|Somaxon Pharmaceuticals||3|||f||||f||||||||||2018-06-01 04:49:14.062066|2018-06-01 04:49:14.062066
NCT00129584|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2009-08-14|2005-08-10|2005-08-12|Estimate|||||||2009-08-14|2009-08-18|Estimate|January 2004||2004-01-31|August 2009|2009-08-31||||||||Interventional|||Endobronchial Valve for Emphysema Palliation Trial (VENT)|Endobronchial Valve for Emphysema Palliation Trial (VENT)|Completed||Phase 3|270||Emphasys Medical|||||||||||||||||||2018-06-01 04:49:49.835981|2018-06-01 04:49:49.835981
NCT00132106|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2007-08-30|2005-08-18|2005-08-19|Estimate|||||||2007-08-30|2007-08-31|Estimate|August 2005||2005-08-31|August 2007|2007-08-31||||||||Interventional|||The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure|The Effect of a-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure|Unknown status|Recruiting|N/A|||Radboud University|||||f||||||||||||||2018-06-01 04:49:14.143429|2018-06-01 04:49:14.143429
NCT00132093|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2006-04-07|2005-08-18|2005-08-19|Estimate|||||||2006-04-07|2006-04-10|Estimate|April 2005||2005-04-30|November 2004|2004-11-30||||||||Interventional|||Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack|The Effects of Eplerenone on Left Ventricular Remodelling Post-Acute Myocardial Infarction: a Double-Blind Placebo-Controlled Cardiac MR-Based Study|Completed||Phase 4|100||NHS Greater Glasgow and Clyde|||||f||||||||||||||2018-06-01 04:49:14.206437|2018-06-01 04:49:14.206437
NCT00132080|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2014-03-03|2005-08-17|2005-08-19|Estimate|||||||2014-03-03|2014-03-04|Estimate|December 2002||2002-12-31|April 2012|2012-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network|Trial of Pulse Steroid Therapy in Kawasaki Disease (A Trial Conducted by the Pediatric Heart Network)|Completed||Phase 3|199|Actual|New England Research Institutes||1|||f||||t||||||||||2018-06-01 04:49:14.314968|2018-06-01 04:49:14.314968
NCT00132067|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2014-06-11|2005-08-16|2005-08-19|Estimate|||||||2014-06-11|2014-06-12|Estimate|October 2005||2005-10-31|January 2013|2013-01-31|July 2008|Actual|2008-07-31|August 2006|Actual|2006-08-31||Interventional|||Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer|A Phase II Evaluation of Vorinostat, (SAHA, NCI-Supplied Agent [NSC #701852]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:49:14.409195|2018-06-01 04:49:14.409195
NCT00132054|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2013-05-29|2005-08-16|2005-08-19|Estimate|||||||2013-05-29|2013-05-30|Estimate|May 2004||2004-05-31|December 2006|2006-12-31|November 2008|Actual|2008-11-30|December 2006|Actual|2006-12-31||Interventional|||Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer|Phase I Study of Weekly Irinotecan Combined With Amrubicin in Previously Treated Small-Cell Lung Cancer|Completed||Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:49:14.526025|2018-06-01 04:49:14.526025
NCT00132041|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2009-02-06|2005-08-16|2005-08-19|Estimate|||||||2009-02-06|2009-02-09|Estimate|December 2005||2005-12-31|November 2007|2007-11-30||||||||Interventional|||Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis|Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:49:14.624986|2018-06-01 04:49:14.624986
NCT00132028|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|2012-02-28||2014-05-07|2005-08-16|2005-08-19|Estimate|2012-08-20|2012-09-19|Estimate||||2014-05-07|2014-05-23|Estimate|September 2005||2005-09-30|January 2013|2013-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma|A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma|Completed||Phase 2|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:49:14.748281|2018-06-01 04:49:14.748281
NCT00132015|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2012-03-14|2005-08-16|2005-08-19|Estimate|||||||2012-03-14|2012-03-15|Estimate|May 2006||2006-05-31|March 2012|2012-03-31|June 2008|Actual|2008-06-30|December 2007|Actual|2007-12-31||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis|A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis|Completed||Phase 2|37|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 04:49:15.953166|2018-06-01 04:49:15.953166
NCT00132002|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|2015-03-06||2015-03-06|2005-08-16|2005-08-19|Estimate|2015-03-06|2015-03-19|Estimate||||2015-03-06|2015-03-19|Estimate|June 2005||2005-06-30|February 2013|2013-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer|Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) as Salvage Therapy in Metastatic Breast Cancer|Terminated||Phase 2|14|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results|1||Early termination for discouraging results|f||||||||||||||2018-06-01 04:49:16.130295|2018-06-01 04:49:16.130295
NCT00131989|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2013-01-08|2005-08-16|2005-08-19|Estimate|||||||2013-01-08|2013-01-09|Estimate|June 2005||2005-06-30|January 2013|2013-01-31||||April 2007|Actual|2007-04-30||Interventional|||Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia|Phase I Dose Escalation Trial of the Raf Kinase Inhibitor BAY 43-9006 (NSC #724772) as Single Agent for Adults With Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis|Completed||Phase 1|48|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:49:16.449102|2018-06-01 04:49:16.449102
NCT00131963|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2016-07-22|2005-08-16|2005-08-19|Estimate|||||||2016-07-22|2016-07-25|Estimate|October 2003||2003-10-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel|A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel|Completed|||94|Actual|Duke University|||2||f||||f||||||Samples With DNA|"~     DNA will be extracted from blood samples taken at the first cycle of Doxorubicin and/or~     Paclitaxel to analyze certain genes that may predict the severity of side-effects that may be~     experienced with chemotherapy.~   "|||2018-06-01 04:49:16.574819|2018-06-01 04:49:16.574819
NCT00131950|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2013-07-09|2005-08-16|2005-08-19|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 2003||2003-08-31|October 2005|2005-10-31|November 2005|Actual|2005-11-30|||||Interventional|||Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer Screening|Chicago Breast Health Project, Phase II|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:49:16.734838|2018-06-01 04:49:16.734838
NCT00131937|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|2015-06-10||2015-08-05|2005-08-16|2005-08-19|Estimate|2015-08-05|2015-09-03|Estimate||||2015-08-05|2015-09-03|Estimate|October 2005||2005-10-31|July 2015|2015-07-31|August 2012|Actual|2012-08-31|September 2011|Actual|2011-09-30||Interventional|||Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|14|Actual|National Cancer Institute (NCI)|The study did not meet pre-specified criteria for continuing to second stage accrual (at least one response among the first 12 eligible patients), and was therefore closed per protocol without full accrual.|1|||f||||f||||||||||2018-06-01 04:49:16.904822|2018-06-01 04:49:16.904822
NCT00131924|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16||2011-02-18|2012-06-07|2005-08-16|2005-08-19|Estimate||||2011-02-18|2011-02-25|Estimate|2012-06-07|2012-06-11|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy|Phase II Study of High-Dose Estrogen in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapies|Terminated||Phase 2|1|Actual|Northwestern University||||Data Monitoring Committee recommended closure due to poor accrual.|f||||||||||||||2018-06-01 04:49:17.21699|2018-06-01 04:49:17.21699
NCT00131911|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|2014-06-19||2014-11-14|2005-08-16|2005-08-19|Estimate|2014-11-14|2014-11-17|Estimate||||2014-11-14|2014-11-17|Estimate|June 2005||2005-06-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|October 2010|Actual|2010-10-31||Interventional|||Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors|A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors|Completed||Phase 2|93|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:49:17.349264|2018-06-01 04:49:17.349264
NCT00131898|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2008-12-22|2005-08-18|2005-08-19|Estimate|||||||2008-12-22|2008-12-23|Estimate|May 2003||2003-05-31|December 2008|2008-12-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma|Phase III Prospective Randomized Trial of Pre-Operative Intensity Modulated Radiation Therapy (IMRT) Plus Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma|Completed||Phase 3|150||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:49:18.104405|2018-06-01 04:49:18.104405
NCT00131885|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2010-03-21||2015-07-15|2005-08-17|2005-08-19|Estimate|2010-05-17|2010-06-09|Estimate||||2015-07-15|2015-08-11|Estimate|August 2005||2005-08-31|July 2015|2015-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel|Effects of St. John's Wort on Levonorgestrel|Completed||Phase 4|36|Actual|University of Utah||4|||f||||t||||||||||2018-06-01 04:49:18.222768|2018-06-01 04:49:18.222768
NCT00131872|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2008-01-24|2005-08-18|2005-08-19|Estimate|||||||2008-01-24|2008-01-29|Estimate|March 2004||2004-03-31|November 2006|2006-11-30|November 2006|Actual|2006-11-30|||||Interventional|||Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts|Clinical Study Comparing Expedial and ePTFE Vascular Access Grafts|Terminated||Phase 2|172||LeMaitre Vascular|||||||||||||||||||2018-06-01 04:49:19.128092|2018-06-01 04:49:19.128092
NCT00131859|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2009-08-12|2005-08-18|2005-08-19|Estimate|||||||2009-08-12|2009-08-13|Estimate|October 2004||2004-10-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Diffusion-Tensor Magnetic Resonance Imaging (MRI) and the Evaluation of Perinatal Brain Injury|Diffusion-Tensor Magnetic Resonance Imaging and the Evaluation of Perinatal Brain Injury|Completed|||5|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 04:49:19.24522|2018-06-01 04:49:19.24522
NCT00131846|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2017-03-14|2005-08-17|2005-08-19|Estimate|||||||2017-03-14|2017-03-15|Actual|April 2004|Actual|2004-04-30|March 2017|2017-03-31|November 2013|Actual|2013-11-30|August 2012|Actual|2012-08-31||Interventional|||Diuretics In the Management of Essential Hypertension (DIME) Study|Effect of Low Dose Thiazide Diuretics on New Onset Type 2 Diabetes in Patients With Essential Hypertension|Completed||Phase 4|1130|Actual|Kyoto University||2|||f||||t||||||||||2018-06-01 04:49:19.352124|2018-06-01 04:49:19.352124
NCT00131833|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2008-03-10|2005-08-18|2005-08-19|Estimate|||||||2008-03-10|2008-03-13|Estimate|October 2001||2001-10-31|March 2008|2008-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China|Typhoid Vi Vaccine Effectiveness in a Population Older Than 5 Years of Age Living in an Endemic Area in Hechi, Guangxi, P.R. China: A Group-Randomized Controlled Demonstration Project|Completed||Phase 4|96468||International Vaccine Institute|||||f||||||||||||||2018-06-01 04:49:19.509433|2018-06-01 04:49:19.509433
NCT00131820|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2008-03-10|2005-08-18|2005-08-19|Estimate|||||||2008-03-10|2008-03-13|Estimate|December 2001||2001-12-31|March 2008|2008-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam|Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam. An Evaluation of Feasibility, Public Acceptability, Effectiveness and Cost-Effectiveness in Students|Completed||Phase 4|100742||International Vaccine Institute|||||f||||||||||||||2018-06-01 04:49:19.662373|2018-06-01 04:49:19.662373
NCT00131807|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2015-05-27|2005-08-18|2005-08-19|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Observational|||A Study to Explore the Association Between Blood Pressure, HIV and Antiretroviral Therapy|A Study to Explore the Association Between Blood Pressure, HIV and Antiretroviral Therapy|Completed|||3000||Imperial College London|||||f||||||||||||||2018-06-01 04:49:19.786762|2018-06-01 04:49:19.786762
NCT00131794|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2016-09-01|2005-08-18|2005-08-19|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2003||2003-01-31|August 2005|2005-08-31|December 2003||2003-12-31|||||Interventional|||Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria|The Effect of BCG Vaccine on Morbidity From Malaria|Completed||Phase 3|1200||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:49:19.892735|2018-06-01 04:49:19.892735
NCT00131781|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2007-04-26|2005-08-18|2005-08-19|Estimate|||||||2007-04-26|2007-04-27|Estimate|March 2001||2001-03-31|April 2007|2007-04-30||||||||Interventional|||Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder|Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder|Unknown status|Active, not recruiting|N/A|70||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:49:20.017933|2018-06-01 04:49:20.017933
NCT00131768|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2015-03-17|2005-08-17|2005-08-19|Estimate|||||||2015-03-17|2015-03-18|Estimate|November 2003||2003-11-30|March 2015|2015-03-31|February 2006||2006-02-28|||||Interventional|||A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Ankle Osteoarthritis||Completed||Phase 3|||Sanofi|||||f||||||||||||||2018-06-01 04:49:20.148914|2018-06-01 04:49:20.148914
NCT00131755|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2011-07-15|2005-08-17|2005-08-19|Estimate|||||||2011-07-15|2011-07-18|Estimate|February 2005||2005-02-28|July 2011|2011-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Efficacy of Diazoxide in Type 1 Diabetes|Efficacy of 6 Months Treatment With Diazoxide at Bedtime in Preventing Beta-cell Demise in Newly Diagnosed Type 1 Diabetes|Completed||Phase 4|40|Actual|Grill, Valdemar, M.D.|||||f||||f||||||||||2018-06-01 04:49:20.24825|2018-06-01 04:49:20.24825
NCT00131742|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2015-05-08|2005-08-18|2005-08-19|Estimate|||||||2015-05-08|2015-05-12|Estimate|July 2004||2004-07-31|May 2015|2015-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B|A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B|Completed||Phase 3|||Novartis|||||||||||||||||||2018-06-01 04:49:20.36763|2018-06-01 04:49:20.36763
NCT00131729|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2006-03-17|2005-08-18|2005-08-19|Estimate|||||||2006-03-17|2006-03-20|Estimate|July 2001||2001-07-31|March 2006|2006-03-31|December 2005||2005-12-31|||||Interventional|||Electronic Recording of Compliance With Occlusion Therapy for Amblyopia|Electronic Recording of Compliance With Occlusion Therapy for Amblyopia: 1 Effects of Patient Education on Compliance 2 Predictors for Non-Compliance|Completed||Phase 3|200||Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:49:20.479237|2018-06-01 04:49:20.479237
NCT00131716|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2017-01-11|2005-08-18|2005-08-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2003||2003-05-31|January 2017|2017-01-31|May 2005||2005-05-31|||||Interventional|||Prevention of Severe Anaemia in Gambian Children|Chemoprophylaxis With Sulfadoxine-pyrimethamine to Prevent Recurrence of Severe Anaemia in Gambian Children Aged 3 Months to 9 Years|Completed||Phase 3|1200|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:49:20.533859|2018-06-01 04:49:20.533859
NCT00131703|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2017-01-11|2005-08-18|2005-08-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2003||2003-03-31|January 2017|2017-01-31|March 2005||2005-03-31|||||Interventional|||Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women|A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy|Completed||Phase 3|900||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:49:20.64502|2018-06-01 04:49:20.64502
NCT00131690|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2005-10-07|2005-08-17|2005-08-19|Estimate|||||||2005-10-07|2005-10-10|Estimate|April 1996||1996-04-30|August 2005|2005-08-31|August 2002||2002-08-31|||||Interventional|||Effect of Caffeine on Fetal Growth|The Importance of Caffeine in Fetal Growth|Completed||Phase 4|1200||The Danish Epdiemiology Science Centre|||||f||||||||||||||2018-06-01 04:49:20.742542|2018-06-01 04:49:20.742542
NCT00131677|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2013-08-08||2014-01-22|2005-08-17|2005-08-19|Estimate|2014-01-22|2014-03-10|Estimate||||2014-01-22|2014-03-10|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||400 participants enrolled (200 in San Francisco, 121 in Atlanta, and 79 in Boston). 201 were randomized to TDF and 199 to placebo. Participants were distributed similarly in terms of age, ethnicity, education, no. male partners in previous 3 mo., and no. of unprotected anal sexual contacts within the previous 3 mo.|Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men|Phase II Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men|Completed||Phase 2|400|Actual|Centers for Disease Control and Prevention||4|||f||||t||||||||||2018-06-01 04:49:20.828831|2018-06-01 04:49:20.828831
NCT00131664|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2012-01-28||2013-04-15|2005-08-17|2005-08-19|Estimate|2013-04-15|2013-04-17|Estimate||||2013-04-15|2013-04-17|Estimate|September 2005||2005-09-30|April 2013|2013-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|AVALANCHE||Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)|Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin: A 48-week Randomized, Open-label, Multicentre Phase IIIB Study to Compare the Effectiveness of Combination Therapy to Monotherapy in Type 2 Diabetes Mellitus Patients|Completed||Phase 3|391|Actual|Canadian Heart Research Centre|The LOCF used in the ITT population for withdrawn subjects or missing values was analyzed as per protocol. The 3 treatment groups used throughout the results section were the numbers where the patients were originally randomized to.|3|||f||||t||||||||||2018-06-01 04:49:21.435006|2018-06-01 04:49:21.435006
NCT00131651|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2007-12-04|2005-08-17|2005-08-19|Estimate|||||||2007-12-04|2007-12-06|Estimate|August 2005||2005-08-31|December 2007|2007-12-31||||||||Interventional|||ATN-161 in Advanced Renal Cell Cancer|A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer|Terminated||Phase 2|36||Attenuon|||||||||||||||||||2018-06-01 04:49:22.19653|2018-06-01 04:49:22.19653
NCT00131638|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2016-12-14|2005-08-17|2005-08-19|Estimate|||||||2016-12-14|2016-12-16|Estimate|January 2005||2005-01-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|November 2007|Actual|2007-11-30||Interventional|||A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer|Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy(RT/CT)|Completed||Phase 3|241|Actual|Amgen||2|||f||||f||||||||||2018-06-01 04:49:22.329942|2018-06-01 04:49:22.329942
NCT00131625|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-18|||2005-10-07|2005-08-18|2005-08-19|Estimate|||||||2005-10-07|2005-10-10|Estimate|March 2000||2000-03-31|August 2005|2005-08-31|February 2002||2002-02-28|||||Interventional|||Impact of Exclusive Breast-Feeding in Guinea Bissau|Aspects of Exclusive Breast-Feeding in Guinea Bissau. Intervention Study to Clarify Recommendations for Breast-Feeding Policy in Developing Countries|Completed||Phase 4|1500||Bandim Health Project|||||f||||||||||||||2018-06-01 04:49:22.449624|2018-06-01 04:49:22.449624
NCT00131612|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2016-02-24|2005-08-17|2005-08-19|Estimate|||||||2016-02-24|2016-02-26|Estimate|January 2002||2002-01-31|June 2012|2012-06-30|January 2013|Actual|2013-01-31|December 2005|Actual|2005-12-31||Observational|||An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment|An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 Using Epirubicin Clearance and the Ratios of Epirubicin and Epirubicinol Glucuronide to Epirubicin|Terminated|||120|Actual|AHS Cancer Control Alberta||||did not apply for ethics renewal|f||||t||||||||||2018-06-01 04:49:22.52806|2018-06-01 04:49:22.52806
NCT00131599|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2017-01-13|2005-08-17|2005-08-19|Estimate|||||||2017-01-13|2017-01-16|Estimate|August 2002||2002-08-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer|Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer|Active, not recruiting|||104|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:49:22.687434|2018-06-01 04:49:22.687434
NCT00131586|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2016-02-24|2005-08-17|2005-08-19|Estimate|||||||2016-02-24|2016-02-26|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins|Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins|Terminated|||100|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:49:22.762803|2018-06-01 04:49:22.762803
NCT00131573|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2013-04-11||2013-10-25|2005-08-17|2005-08-19|Estimate|2013-10-25|2013-11-19|Estimate||||2013-10-25|2013-11-19|Estimate|May 2004||2004-05-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|March 2008|Actual|2008-03-31||Interventional|||An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome|Battery Powered Bion Clinical Investigation: Bion - An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urgency-Frequency Syndrome|Completed||Phase 3|118|Actual|Boston Scientific Corporation|This study was limited by poor adherence to the clinical protocol and by incomplete data recovery. Analysis of efficacy-related endpoints was not possible.|2|||f||||f||||||||||2018-06-01 04:49:22.844681|2018-06-01 04:49:22.844681
NCT00131560|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2011-06-07|2005-08-16|2005-08-18|Estimate|||||||2011-06-07|2011-06-08|Estimate|July 2005||2005-07-31|June 2011|2011-06-30|June 2023|Anticipated|2023-06-30|November 2008|Actual|2008-11-30||Interventional|||Safety and Efficacy of T Cell Genetic Immunotherapy for HIV|A Phase II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Single and Repeated Doses of Autologous T Cells Transduced With VRX496 in HIV-Positive Subjects|Active, not recruiting||Phase 2|60|Anticipated|VIRxSYS Corporation||1|||f||||t||||||||||2018-06-01 04:49:23.188563|2018-06-01 04:49:23.188563
NCT00131547|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2008-10-15|2005-08-17|2005-08-18|Estimate|||||||2008-10-15|2008-10-16|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Randomized Study of a Simple Weight Loss Program for Obese Patients With Obstructive Sleep Apnea|A Randomized Controlled Pilot Study of a Simple Weight Loss Program for Obese Patients With Mild to Moderate Obstructive Sleep Apnea|Completed||N/A|56|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-06-01 04:49:23.304663|2018-06-01 04:49:23.304663
NCT00131534|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2017-04-17|2005-08-17|2005-08-18|Estimate|||||||2017-04-17|2017-04-18|Actual|August 1991||1991-08-31|April 2017|2017-04-30|January 2012|Actual|2012-01-31|February 2009|Actual|2009-02-28||Observational|||The Trauma Recovery and Resiliency Research Project|The Trauma Recovery and Resiliency Research Project|Completed|||969|Actual|Cambridge Health Alliance|||||f||||||||||||||2018-06-01 04:49:23.485418|2018-06-01 04:49:23.485418
NCT00131521|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2009-06-20|2005-08-17|2005-08-18|Estimate|||||||2009-06-20|2009-06-23|Estimate|January 2005||2005-01-31|June 2009|2009-06-30|December 2007|Actual|2007-12-31|||||Interventional|||Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit|Comparison of Different Mucoactive Agents for the Care of the Intubated Patient in a Surgical Trauma Intensive Care Unit: A Randomized, Double Blind, Controlled Trial|Completed||N/A|260|Anticipated|The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 04:49:23.563334|2018-06-01 04:49:23.563334
NCT00131508|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2010-02-19||2017-04-24|2005-08-17|2005-08-18|Estimate|2010-04-22|2010-05-12|Estimate||||2017-04-24|2017-04-26|Actual|May 2004||2004-05-31|March 2010|2010-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Trial of Oral Glutamine in Patients With Sickle Cell Anemia|A Randomized Controlled Trial of Oral Glutamine Supplementation Versus a Placebo Supplement in Children With Sickle Cell Anemia|Terminated||Phase 2|27|Actual|St. Jude Children's Research Hospital|The study was designed to enroll 46 participants (23 per arm). Due to slow accrual the study was terminated after enrolling 27 participants. Of the 27 participants enrolled, 2 dropped out of the study prior to randomization.|2||Due to slow participant accrual|f||||t||||||||||2018-06-01 04:49:23.686833|2018-06-01 04:49:23.686833
NCT00131495|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2013-04-15|2005-08-16|2005-08-18|Estimate|||||||2013-04-15|2013-04-17|Estimate|July 2004||2004-07-31|April 2013|2013-04-30|February 2007|Actual|2007-02-28|February 2006|Actual|2006-02-28||Interventional|||Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido|A Randomized, Double-Blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy/Safety of Transdermal Patches Delivering Testosterone in Menopausal Women With Low Libido Not Receiving Estrogen Therapy|Completed||Phase 3|814|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 04:49:24.387863|2018-06-01 04:49:24.387863
NCT00131482|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2010-08-23|2005-08-16|2005-08-18|Estimate|||||||2010-08-23|2010-08-24|Estimate|November 2004||2004-11-30|August 2010|2010-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of Different Doses of Chrysalin in Adults Who Have a Broken Wrist|A Double-blind, Randomized, Placebo-controlled Phase 2b Study to Establish the Effective Dose Range and to Evaluate the Safety of Chrysalin in Adult Subjects With a Fractured Distal Radius|Terminated||Phase 2|274|Actual|Capstone Therapeutics||5||Treatment with Chrysalin did not demonstrate benefit compared to placebo.|f||||f||||||||||2018-06-01 04:49:24.499607|2018-06-01 04:49:24.499607
NCT00131469|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2013-10-30|2005-08-16|2005-08-18|Estimate|||||||2013-10-30|2013-11-01|Estimate|June 2005||2005-06-30|October 2013|2013-10-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|OI||Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta|A Study to Assess the Effectiveness of Teriparatide (FORTEO) for Increasing Bone Mass and Improving Bone Strength in Adults Affected With Osteogenesis Imperfecta (OI)|Completed||Phase 4|79|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 04:49:24.608783|2018-06-01 04:49:24.608783
NCT00131456|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|2013-04-18||2018-05-10|2005-08-16|2005-08-18|Estimate|2013-04-18|2013-06-04|Estimate||||2018-05-10|2018-05-15|Actual|March 2004||2004-03-31|May 2018|2018-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|VEN||Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1|Marijuana Addiction and Depression: Venlafaxine Treatment|Completed||Phase 2|123|Actual|New York State Psychiatric Institute|This was an outpatient study and excluded patients with very severe depression. Thus we cannot generalize the findings to individuals with more severe depressive symptoms. The study length was relatively brief.|2|||f||||t||||||||||2018-06-01 04:49:24.799788|2018-06-01 04:49:24.799788
NCT00131443|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2012-11-09|2005-08-17|2005-08-18|Estimate|||||||2012-11-09|2012-11-12|Estimate|February 2004||2004-02-29|November 2006|2006-11-30|August 2006||2006-08-31|||||Interventional|||Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine|A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine|Completed||Phase 2/Phase 3|40||Monarch Medical Research|||||f||||||||||||||2018-06-01 04:49:25.220226|2018-06-01 04:49:25.220226
NCT00131430|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2016-06-06|2005-08-17|2005-08-18|Estimate|||||||2016-06-06|2016-06-07|Estimate|August 2005||2005-08-31|March 2016|2016-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED)|An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients|Completed||Phase 2/Phase 3|500|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:49:25.309612|2018-06-01 04:49:25.309612
NCT00131417|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2005-10-04|2005-08-17|2005-08-18|Estimate|||||||2005-10-04|2005-10-05|Estimate|October 2004||2004-10-31|August 2005|2005-08-31|February 2005||2005-02-28|||||Interventional|||Ready to Use Therapeutic Food in the Rehabilitation of Severely Malnourished Children|Comparison of the Efficacy of a Ready-to-Use Therapeutic Food With a Milk-Based Diet in the Rehabilitation of Severely Malnourished Ugandan Children|Unknown status|Active, not recruiting|Phase 3|128||Makerere University|||||f||||||||||||||2018-06-01 04:49:25.453358|2018-06-01 04:49:25.453358
NCT00131404|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2015-02-04|2005-08-17|2005-08-18|Estimate|||||||2015-02-04|2015-02-05|Estimate|September 2005||2005-09-30|February 2015|2015-02-28|December 2008|Actual|2008-12-31|February 2007|Actual|2007-02-28||Interventional|||A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)|A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension|Terminated||Phase 3|2400|Actual|Merck Sharp & Dohme Corp.||5||The overall profile does not support development for obesity|f||||||||||||||2018-06-01 04:49:25.599325|2018-06-01 04:49:25.599325
NCT00131391|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2015-04-02|2005-08-17|2005-08-18|Estimate|||||||2015-04-02|2015-04-03|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|||A Study of MK0364 in Obese Patients (0364-014)|A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK0364) in Obese Patients Followed by a 1-Year Extension|Terminated||Phase 3|2400|Actual|Merck Sharp & Dohme Corp.||6||The overall profile does not support development for obesity|f||||||||||||||2018-06-01 04:49:25.741755|2018-06-01 04:49:25.741755
NCT00131378|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|2013-08-19||2016-03-09|2005-08-16|2005-08-18|Estimate|2014-02-04|2014-03-06|Estimate||||2016-03-09|2016-03-11|Estimate|November 2004||2004-11-30|March 2016|2016-03-31|June 2013|Actual|2013-06-30|November 2012|Actual|2012-11-30||Interventional|||Growth Hormone, Cardiovascular Risk, and Visceral Adiposity|Growth Hormone, Cardiovascular Risk, and Visceral Adiposity|Completed||N/A|142|Actual|Massachusetts General Hospital||4|||f||||t||||||||||2018-06-01 04:49:25.87757|2018-06-01 04:49:25.87757
NCT00131365|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2018-03-26|2005-08-17|2005-08-18|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2006||2006-01-31|March 2018|2018-03-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids|Post Approval Study: MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids|Completed||N/A|20|Actual|InSightec||1|||f||||||||||||||2018-06-01 04:49:26.550698|2018-06-01 04:49:26.550698
NCT00131352|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|2009-08-03||2015-03-17|2005-08-17|2005-08-18|Estimate|2011-12-15|2012-01-19|Estimate||||2015-03-17|2015-04-03|Estimate|May 2005||2005-05-31|March 2015|2015-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee|A Multi-Centre, Parallel, Double-Blind, Blinded Evaluator, Randomised, Placebo-Controlled Evaluation of the Efficacy and Safety of a Single Dose of 6 mL of Synvisc in Patients With Symptomatic Osteoarthritis of the Knee|Completed||Phase 3|253|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:49:26.702594|2018-06-01 04:49:26.702594
NCT00131339|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2009-08-25|2005-08-16|2005-08-18|Estimate|||||||2009-08-25|2009-08-26|Estimate|November 2004||2004-11-30|August 2009|2009-08-31|March 2007|Actual|2007-03-31|||||Interventional|||Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder|Placebo-Controlled Evaluation of the Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Panic Disorder|Completed||N/A|40||Hartford Hospital|||||f||||||||||||||2018-06-01 04:49:27.679868|2018-06-01 04:49:27.679868
NCT00131326|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2017-07-27|2005-08-17|2005-08-18|Estimate|||||||2017-07-27|2017-07-31|Actual|November 2003||2003-11-30|July 2017|2017-07-31|April 2006||2006-04-30|||||Interventional|||A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip||Completed||Phase 3|||Sanofi|||||||||||||||||||2018-06-01 04:49:27.811392|2018-06-01 04:49:27.811392
NCT00131313|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2005-08-17|2005-08-17|2005-08-18|Estimate|||||||2005-08-17|2005-08-18|Estimate|January 2003||2003-01-31|August 2005|2005-08-31|April 2009||2009-04-30|||||Interventional|||Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.|A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia.|Unknown status|Recruiting|Phase 4|180||East Valley Hematology and Oncology Medical Group|||||f||||||||||||||2018-06-01 04:49:27.955606|2018-06-01 04:49:27.955606
NCT00131300|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2015-03-17|2005-08-17|2005-08-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2004||2004-04-30|March 2015|2015-03-31|February 2006||2006-02-28|||||Interventional|||A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis||Completed||Phase 3|||Sanofi|||||f||||||||||||||2018-06-01 04:49:28.269948|2018-06-01 04:49:28.269948
NCT00131287|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2010-01-04|2005-08-16|2005-08-18|Estimate|||||||2010-01-04|2010-01-05|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)||Completed||Phase 3|108||ECbiotech Taiwan|||||f||||||||||||||2018-06-01 04:49:28.37627|2018-06-01 04:49:28.37627
NCT00131274|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2005-10-04|2005-08-17|2005-08-18|Estimate|||||||2005-10-04|2005-10-05|Estimate|April 2003||2003-04-30|August 2005|2005-08-31|August 2007||2007-08-31|||||Interventional|||Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study|A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2/Phase 3|120||Daniels, Craig E., M.D.|||||||||||||||||||2018-06-01 04:49:28.45225|2018-06-01 04:49:28.45225
NCT00131261|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-17|||2015-07-07|2005-08-17|2005-08-18|Estimate|||||||2015-07-07|2015-07-08|Estimate|January 2005||2005-01-31|July 2015|2015-07-31|June 2007|Actual|2007-06-30|January 2007|Actual|2007-01-31||Interventional|||Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma|A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma|Completed||Phase 2|25|Actual|Onxeo|||||||||||||||||||2018-06-01 04:49:28.523968|2018-06-01 04:49:28.523968
NCT00131248|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|2009-11-23||2013-12-12|2005-08-15|2005-08-17|Estimate|2013-12-12|2014-01-15|Estimate||||2013-12-12|2014-01-15|Estimate|April 2004||2004-04-30|December 2013|2013-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||18 participants initially enrolled; 1 withdrew, leaving 17 participants analyzed.|Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants|Cross-over Trial of Medical Treatment for GERD in Preterm Infants|Completed||Phase 3|18|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-06-01 04:49:28.632858|2018-06-01 04:49:28.632858
NCT00131235|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2014-01-21|2005-08-16|2005-08-17|Estimate|||||||2014-01-21|2014-01-22|Estimate|December 2003||2003-12-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|May 2007|Actual|2007-05-31||Interventional|||Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth|Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin|Completed||Phase 3|1320|Actual|University of Tampere||3|||f||||t||||||||||2018-06-01 04:49:28.898962|2018-06-01 04:49:28.898962
NCT00131222|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2014-05-19|2005-08-16|2005-08-17|Estimate|||||||2014-05-19|2014-05-20|Estimate|February 2005||2005-02-28|April 2007|2007-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Trial to Alleviate Malnutrition With Fortified Spread Given as a Food Supplement to Underweight Infants|Lungwena Child Nutrition Intervention Study-4, LCNI-4. A Single-centre Intervention Trial in Rural Malawi, Testing the Potency of RUTF Supplementation to Alleviate Moderate Malnutrition Among 6-17 Month Old Infants|Completed||Phase 3|176||University of Tampere|||||f||||t||||||||||2018-06-01 04:49:29.033539|2018-06-01 04:49:29.033539
NCT00131209|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2008-07-03|2005-08-16|2005-08-17|Estimate|||||||2008-07-03|2008-07-08|Estimate|October 2004||2004-10-31|July 2008|2008-07-31|January 2008|Actual|2008-01-31|January 2006|Actual|2006-01-31||Interventional|||Trial to Test the Growth-Promoting Effect of Fortified Spreads When Used as Complementary Food for Infants|Lungwena Child Nutrition Intervention Study 3, LCNI-3. A Single-Centre Intervention Trial in Rural Malawi, Testing the Anthropometric and Health Benefits of Provision of Ready to - Use - Therapeutic Food RUTF as a Complementary Food|Completed||Phase 3|180||University of Tampere|||||f||||t||||||||||2018-06-01 04:49:29.153599|2018-06-01 04:49:29.153599
NCT00131196|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2016-05-13|2005-08-15|2005-08-17|Estimate|||||||2016-05-13|2016-05-16|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|GAinS||Functional Genomic Influences on Disease Progression and Outcome in Sepsis|Functional Genomic Influences on Disease Progression and Outcome in Sepsis Due to Pneumonia or Peritonitis|Unknown status|Recruiting||4000|Anticipated|University of Oxford|||||f||||t||||||Samples With DNA|"~     whole blood, plasma and extracted DNA~   "|||2018-06-01 04:49:29.281964|2018-06-01 04:49:29.281964
NCT00131183|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2006-09-11|2005-08-15|2005-08-17|Estimate|||||||2006-09-11|2006-09-12|Estimate|September 2005||2005-09-30|September 2006|2006-09-30||||||||Interventional|||Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina|The Effect of Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina|Unknown status|Recruiting|Phase 4|80||Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:49:29.46318|2018-06-01 04:49:29.46318
NCT00131170|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2007-07-04|2005-08-15|2005-08-17|Estimate|||||||2007-07-04|2007-07-06|Estimate|September 2005||2005-09-30|July 2007|2007-07-31|September 2006|Actual|2006-09-30|||||Interventional|||Paravertebral Block for Breast Surgery||Completed||Phase 4|90|Actual|University of Aarhus|||||f||||f||||||||||2018-06-01 04:49:29.55928|2018-06-01 04:49:29.55928
NCT00131157|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2007-02-28|2005-08-16|2005-08-17|Estimate|||||||2007-02-28|2007-03-01|Estimate|January 2003||2003-01-31|February 2007|2007-02-28|August 2006||2006-08-31|||||Interventional|||Evaluation of Spirometry Expert Support in General Practice|A Randomized-Controlled Evaluation of Spirometry Expert Support in General Practice|Unknown status|Active, not recruiting|N/A|39||Radboud University|||||f||||||||||||||2018-06-01 04:49:29.65698|2018-06-01 04:49:29.65698
NCT00131144|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2011-11-16|2005-08-16|2005-08-17|Estimate|||||||2011-11-16|2011-11-17|Estimate|November 1999||1999-11-30|November 2011|2011-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy|A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)|Completed||Phase 3|583|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:49:29.764632|2018-06-01 04:49:29.764632
NCT00131131|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2017-10-05|2005-08-16|2005-08-17|Estimate|||||||2017-10-05|2017-10-06|Actual|May 2003||2003-05-31|October 2017|2017-10-31|December 2009|Actual|2009-12-31|November 2008|Actual|2008-11-30||Interventional|||Epidemiology of Gallbladder Sludge and Stones in Pregnancy|Epidemiology of Gallbladder Sludge & Stones in Pregnancy|Completed||N/A|1196|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f|f|f||||||||2018-06-01 04:49:29.88123|2018-06-01 04:49:29.88123
NCT00131118|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2017-05-31|2005-08-15|2005-08-17|Estimate|||||||2017-05-31|2017-06-01|Actual|July 2004||2004-07-31|November 2016|2016-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta|Efficacy and Safety of Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta|Completed||Phase 2|127||Novartis|||||||||||||||||||2018-06-01 04:49:30.018502|2018-06-01 04:49:30.018502
NCT00131105|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2008-12-22|2005-08-15|2005-08-17|Estimate|||||||2008-12-22|2008-12-23|Estimate|July 2003||2003-07-31|December 2008|2008-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The TLC2 (Teaching Healthy Lifestyles to Caregivers 2)/CALM (Counseling Advice for Lifestyle Management) Study|Combining Exercise and Diet in Older Adults|Completed||Phase 2|200|Actual|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:49:30.123717|2018-06-01 04:49:30.123717
NCT00131092|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2009-12-09|2005-08-15|2005-08-17|Estimate|||||||2009-12-09|2009-12-11|Estimate|June 1999||1999-06-30|December 2008|2008-12-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||The CHAT (Community Health Advice by Telephone) Study|Exercise Advice by Human or Computer: Testing 2 Theories|Completed||Phase 2|225||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:49:30.217257|2018-06-01 04:49:30.217257
NCT00131079|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2018-03-19|2005-08-16|2005-08-17|Estimate|||||||2018-03-19|2018-03-21|Actual|October 2003||2003-10-31|October 2007|2007-10-31|March 2006|Actual|2006-03-31|||||Interventional|||PEPAF: Evaluation of Family Physician's Effectiveness for Physical Activity Promotion|Multi-center Evaluation of the Experimental Program for Physical Activity Promotion (PEPAF), Carried Out by Family Physicians|Completed||Phase 3|4317|Actual|Basque Health Service||2|||f||||f||||||||||2018-06-01 04:49:30.287853|2018-06-01 04:49:30.287853
NCT00131066|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2008-09-18|2005-08-15|2005-08-17|Estimate|||||||2008-09-18|2008-09-22|Estimate|August 2002||2002-08-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|October 2003|Actual|2003-10-31||Observational|||Long-Term Follow-Up Study of Psoriasis Patients|Long-Term Safety Follow-Up Study of Psoriasis Patients Who Have Received MEDI-507|Completed|||200|Actual|MedImmune LLC|||||f||||||||||||||2018-06-01 04:49:30.37645|2018-06-01 04:49:30.37645
NCT00131053|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2008-11-13|2005-08-15|2005-08-17|Estimate|||||||2008-11-13|2008-11-14|Estimate|September 2002||2002-09-30|November 2008|2008-11-30|September 2011|Anticipated|2011-09-30|May 2011|Anticipated|2011-05-31||Interventional|||Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)|Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 2|120|Anticipated|Japan Adult Leukemia Study Group||1|||f||||t||||||||||2018-06-01 04:49:30.566456|2018-06-01 04:49:30.566456
NCT00131040|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2015-05-27|2005-08-15|2005-08-17|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2003||2003-01-31|August 2005|2005-08-31|June 2005||2005-06-30|||||Interventional|||Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass|Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass|Completed||N/A|24||Imperial College London|||||f||||||||||||||2018-06-01 04:49:30.673842|2018-06-01 04:49:30.673842
NCT00131027|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2008-11-13|2005-08-15|2005-08-17|Estimate|||||||2008-11-13|2008-11-14|Estimate|September 2002||2002-09-30|November 2008|2008-11-30|September 2011|Anticipated|2011-09-30|March 2011|Anticipated|2011-03-31||Interventional|||High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)|Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults|Unknown status|Recruiting|Phase 3|240|Anticipated|Japan Adult Leukemia Study Group||2|||f||||t||||||||||2018-06-01 04:49:30.744529|2018-06-01 04:49:30.744529
NCT00131014|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2018-03-30|2005-08-16|2005-08-17|Estimate|||||||2018-03-30|2018-04-03|Actual|August 2004||2004-08-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies|Establishing a Tumor Bank and Initial Analysis of Germline and Tumor-Related Genetic Alterations in Families With Multiple Lymphoproliferative Malignancies|Recruiting|||1500|Anticipated|Dana-Farber Cancer Institute|||3||f||||||||||Samples With DNA|"~     Whole blood Cheek cells Paraffin blocks of tumor tissue~   "|||2018-06-01 04:49:30.856861|2018-06-01 04:49:30.856861
NCT00131001|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2008-10-17|2005-08-16|2005-08-17|Estimate|||||||2008-10-17|2008-10-20|Estimate|April 2001||2001-04-30|April 2007|2007-04-30||||||||Interventional|||CARMEDAS: Cost-Effectiveness Analysis of Imaging Strategies in Symptomatic Carotid Stenosis|Cost-Effectiveness Analysis of Imaging Strategies in Symptomatic Carotid Stenosis|Unknown status|Active, not recruiting|N/A|300||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:49:30.950423|2018-06-01 04:49:30.950423
NCT00130988|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2008-07-11|2005-08-16|2005-08-17|Estimate|||||||2008-07-11|2008-07-15|Estimate|January 2001||2001-01-31|July 2008|2008-07-31|March 2003|Actual|2003-03-31|February 2002|Actual|2002-02-28||Interventional|||DEPENAS: A Psychosocial Intervention for Patients With Medically Unexplained Symptoms|Efficacy of a Biopsychosocial Treatment for Somatizing Patients Carried Out by the General Practitioner|Completed||Phase 3|156||Basque Health Service|||||f||||f||||||||||2018-06-01 04:49:31.037016|2018-06-01 04:49:31.037016
NCT00130975|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-16|||2007-01-03|2005-08-16|2005-08-17|Estimate|||||||2007-01-03|2007-01-04|Estimate|April 2001||2001-04-30|January 2007|2007-01-31|September 2005||2005-09-30|||||Interventional|||Candesartan in the Prevention of Relapsing Atrial Fibrillation||Completed||Phase 3|200||Asker & Baerum Hospital|||||f||||||||||||||2018-06-01 04:49:31.118724|2018-06-01 04:49:31.118724
NCT00130962|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2005-09-30|2005-08-15|2005-08-17|Estimate|||||||2005-09-30|2005-10-03|Estimate|September 2004||2004-09-30|August 2005|2005-08-31|February 2006||2006-02-28|||||Interventional|||ALGRX 4975 in the Treatment of Patients With Morton's Neuroma|A Randomized, Double-Blind, Placebo-Controlled Trial of ALGRX 4975 in Subjects With Painful Intermetatarsal Neuroma|Completed||Phase 2|60||AlgoRx Pharmaceuticals|||||||||||||||||||2018-06-01 04:49:31.264261|2018-06-01 04:49:31.264261
NCT00130949|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2006-12-18|2005-08-15|2005-08-17|Estimate|||||||2006-12-18|2006-12-20|Estimate|November 2004||2004-11-30|August 2005|2005-08-31|November 2005||2005-11-30|||||Interventional|||ALGRX 4975 in the Treatment of Tennis Elbow|A Randomized, Double-Blind, Placebo-Controlled, Phase II, Exploratory Evaluation of ALGRX 4975 in Subjects With Acute Lateral Epicondylitis|Completed||Phase 2|45||AlgoRx Pharmaceuticals|||||f||||||||||||||2018-06-01 04:49:31.358164|2018-06-01 04:49:31.358164
NCT00130936|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2016-02-12|2005-08-15|2005-08-17|Estimate|||||||2016-02-12|2016-02-15|Estimate|October 2005||2005-10-31|September 2009|2009-09-30|November 2007|Actual|2007-11-30|||||Interventional|||Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates|Combined Phase I/II Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates|Terminated||Phase 1/Phase 2|50|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:49:31.479969|2018-06-01 04:49:31.479969
NCT00130923|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|2012-07-23||2018-03-21|2005-08-15|2005-08-16|Estimate|2012-09-23|2012-10-24|Estimate||||2018-03-21|2018-03-23|Actual|September 2005||2005-09-30|March 2018|2018-03-31|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Interventional|||Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder|Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)|Completed||Phase 4|95|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 04:49:31.595516|2018-06-01 04:49:31.595516
NCT00130910|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2007-11-13|2005-08-15|2005-08-16|Estimate|||||||2007-11-13|2007-11-15|Estimate|March 2006||2006-03-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation|Randomized, Double Blind, Placebo Controlled Trial of Albendazole in Soil-Transmitted Helminth and HIV-1 co-Infected Kenyan Individuals to Determine the Effect of Such Treatment on HIV-1 Disease Progression and Genital Shedding.|Completed||N/A|234|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:49:32.055946|2018-06-01 04:49:32.055946
NCT00130897|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-14|||2012-03-08|2005-08-15|2005-08-16|Estimate|||||||2012-03-08|2012-03-09|Estimate|July 2005||2005-07-31|March 2012|2012-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Expanded Access|||Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma|A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248|Approved for marketing|||||Pfizer|||||||||f||||||||||2018-06-01 04:49:32.253451|2018-06-01 04:49:32.253451
NCT00130884|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2007-02-19|2005-08-15|2005-08-16|Estimate|||||||2007-02-19|2007-02-21|Estimate|March 2005||2005-03-31|February 2007|2007-02-28|March 2006||2006-03-31|||||Interventional|||Peroral Levosimendan in Chronic Heart Failure|Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study|Completed||Phase 2|300||Orion Corporation, Orion Pharma|||||f||||||||||||||2018-06-01 04:49:32.737404|2018-06-01 04:49:32.737404
NCT00130871|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2007-02-19|2005-08-15|2005-08-16|Estimate|||||||2007-02-19|2007-02-21|Estimate|January 2004||2004-01-31|February 2007|2007-02-28|January 2006||2006-01-31|||||Interventional|||Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass|Impact of Levosimendan Pretreatment on Weaning From Cardiopulmonary Bypass (CPB) in Patients With Diminished Left Ventricular Function Before Coronary Artery Bypass Grafting (CABG)|Completed||Phase 2|60||Orion Corporation, Orion Pharma|||||f||||||||||||||2018-06-01 04:49:32.789594|2018-06-01 04:49:32.789594
NCT00130858|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2009-04-01|2005-08-15|2005-08-16|Estimate|||||||2009-04-01|2009-04-02|Estimate|January 2005||2005-01-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|December 2007|Actual|2007-12-31||Interventional|||a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4|a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4|Completed||Phase 2|90|Anticipated|Cooperative Weichteilsarkom Study Group|||||f||||||||||||||2018-06-01 04:49:32.881826|2018-06-01 04:49:32.881826
NCT00130845|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2011-11-16|2005-08-15|2005-08-16|Estimate|||||||2011-11-16|2011-11-17|Estimate|February 2000||2000-02-29|November 2011|2011-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy|A Randomized, Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR)|Completed||Phase 3|312|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:49:32.979967|2018-06-01 04:49:32.979967
NCT00130832|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|2009-08-07||2015-03-12|2005-08-12|2005-08-16|Estimate|2010-08-17|2010-09-09|Estimate||||2015-03-12|2015-04-01|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)|Safety and Immunogenicity of Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants|Completed||Phase 3|735|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:49:33.07419|2018-06-01 04:49:33.07419
NCT00130819|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2015-04-14|2005-08-15|2005-08-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2005||2005-11-30|April 2009|2009-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants|Buprenorphine Effectiveness Evaluation in HIV Enhancement (BEEHIVE): A Randomized Trial of HIV Clinic-based Buprenorphine/Naloxone vs. Case Management and Referral in Opioid-dependent Individuals|Completed||Phase 2|120|Anticipated|Johns Hopkins University||2|||f||||||||||||||2018-06-01 04:49:33.408099|2018-06-01 04:49:33.408099
NCT00130806|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2016-09-06|2005-08-12|2005-08-16|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2005||2005-09-30|September 2016|2016-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)|A Study to Assess the Efficacy and Tolerability of MK0478 (Muraglitazar, Also, BMS 298585) Coadministered With Insulin in Patients With Type 2 Diabetes|Terminated||Phase 3|600||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:49:33.47779|2018-06-01 04:49:33.47779
NCT00130793|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|2009-05-11||2015-01-14|2005-08-12|2005-08-16|Estimate|2009-05-11|2009-07-03|Estimate||||2015-01-14|2015-01-26|Estimate|August 2005||2005-08-31|January 2015|2015-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)|A Double-Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of a Refrigerator-Stable Formulation of Zoster Vaccine Live (Oka/Merck)|Completed||Phase 3|368|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:49:33.52887|2018-06-01 04:49:33.52887
NCT00130780|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|2015-12-18||2015-12-18|2005-08-12|2005-08-16|Estimate|2015-12-18|2016-01-25|Estimate||||2015-12-18|2016-01-25|Estimate|August 2005||2005-08-31|December 2015|2015-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC|Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) (BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC)|Completed||Phase 2|71|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:49:33.777649|2018-06-01 04:49:33.777649
NCT00130767|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2007-04-26|2005-08-12|2005-08-16|Estimate|||||||2007-04-26|2007-04-27|Estimate|December 2004||2004-12-31|April 2007|2007-04-30||||||||Interventional|||Kinetics of the Finasteride Prostate Induced Apoptosis|Kinetics of the Finasteride Prostate Induced Apoptosis|Unknown status|Active, not recruiting|Phase 4|90||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:49:34.917691|2018-06-01 04:49:34.917691
NCT00130754|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2011-02-22|2005-08-15|2005-08-16|Estimate|||||||2011-02-22|2011-02-23|Estimate|February 2005||2005-02-28|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation|A Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Thymoglobuline in Non-myeloablative Allogeneic Hemapoietic Stem-cell Transplantation (NST)|Completed||Phase 3|30|Actual|Hadassah Medical Organization||2|||f||||||||||||||2018-06-01 04:49:34.96783|2018-06-01 04:49:34.96783
NCT00130741|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2007-04-10|2005-08-15|2005-08-16|Estimate|||||||2007-04-10|2007-04-11|Estimate|July 2005||2005-07-31|April 2007|2007-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Combination Herbal Therapy (CHT) Versus Placebo in Patients With Irritable Bowel Syndrome (IBS)|A Phase I, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of a Combination Herbal Therapy (CHT), Versus Placebo in Improving the Overall Quality of Life and Symptoms in Patients With Irritable Bowel Syndrome (IBS)|Completed||Phase 1|100||Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:49:35.032303|2018-06-01 04:49:35.032303
NCT00130728|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|2009-11-16||2018-04-24|2005-08-12|2005-08-16|Estimate|2011-09-26|2011-11-03|Estimate||||2018-04-24|2018-04-25|Actual|June 8, 2005|Actual|2005-06-08|April 2018|2018-04-30|December 27, 2018|Anticipated|2018-12-27|July 15, 2008|Actual|2008-07-15||Interventional|||A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer|A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy|Active, not recruiting||Phase 3|636|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 04:49:35.125951|2018-06-01 04:49:35.125951
NCT00130715|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2015-03-11|2005-08-15|2005-08-16|Estimate|||||||2015-03-11|2015-03-12|Estimate|June 1998||1998-06-30|March 2015|2015-03-31|August 2003||2003-08-31|||||Interventional|||Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery|A Prospective, Randomized, Multicenter, Controlled Evaluation of the Efficacy and Safety of Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery|Completed||N/A|||Sanofi|||||||||||||||||||2018-06-01 04:49:35.978242|2018-06-01 04:49:35.978242
NCT00130702|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2014-04-29|2005-08-15|2005-08-16|Estimate|||||||2014-04-29|2014-05-01|Estimate|August 2005||2005-08-31|April 2014|2014-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia|A Phase II Study of Iressa (Gefitinib), in Patients With Relapsed or Refractory Acute Myelogenous Leukemia and in Older Patients With Newly Diagnosed Acute Myelogenous Leukemia|Completed||Phase 2|18|Actual|Dana-Farber Cancer Institute||1|||f||||f||||||||||2018-06-01 04:49:36.055505|2018-06-01 04:49:36.055505
NCT00130689|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|2014-05-28||2015-05-12|2005-08-15|2005-08-16|Estimate|2015-05-12|2015-05-14|Estimate||||2015-05-12|2015-05-14|Estimate|July 2005||2005-07-31|May 2015|2015-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional||The analysis dataset is comprised of eligible and treated patients.|Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer|A Phase II Trial of Cetuximab in Unresectable or Metastatic Esophageal and Gastric Carcinoma|Completed||Phase 2|43|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:49:36.133386|2018-06-01 04:49:36.133386
NCT00130676|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2012-02-14|2005-08-12|2005-08-16|Estimate|||||||2012-02-14|2012-02-15|Estimate|September 2004||2004-09-30|February 2012|2012-02-29|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression|A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features|Completed||Phase 3|257|Actual|Corcept Therapeutics||2|||f||||f||||||||||2018-06-01 04:49:36.307368|2018-06-01 04:49:36.307368
NCT00130663|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2007-10-19|2005-08-15|2005-08-16|Estimate|||||||2007-10-19|2007-10-22|Estimate|January 2006||2006-01-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Recognition of Abnormal Pediatric Blood Pressures in Primary Care|Recognition of Abnormal Pediatric Blood Pressures in Primary Care|Completed||N/A|||Nationwide Children's Hospital|||||f||||||||||||||2018-06-01 04:49:36.480815|2018-06-01 04:49:36.480815
NCT00130650|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-15|||2008-01-24|2005-08-15|2005-08-16|Estimate|||||||2008-01-24|2008-01-25|Estimate|May 2006||2006-05-31|January 2008|2008-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Pain Ease Spray in Reducing Needle Pain Associated With Intravenous Insertion in Children|Efficacy of Pain Ease Spray in Reducing Needle Pain Associated With Intravenous Insertion in Children|Completed||Phase 4|80|Actual|Children's Hospital of Eastern Ontario|||||f||||t||||||||||2018-06-01 04:49:36.522835|2018-06-01 04:49:36.522835
NCT00130637|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|2010-08-12||2017-01-27|2005-08-12|2005-08-15|Estimate|2010-09-13|2010-09-29|Estimate||||2017-01-27|2017-01-30|Estimate|August 2005||2005-08-31|January 2017|2017-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis|Treatment of Active Anterior Uveitis Associated With JIA, Using Humanized Anti-Tac (HAT, Daclizumab)|Completed||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)|The results of this trial need to be interpreted cautiously because of the small number of patients, the heterogeneity of the patient population (such as one participant with systemic JIA), and the nonrandomized and unmasked nature of the trial.|1|||f||||t||||||||No||2018-06-01 04:49:36.600328|2018-06-01 04:49:36.600328
NCT00130624|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2005-10-04|2005-08-12|2005-08-15|Estimate|||||||2005-10-04|2005-10-05|Estimate|June 2001||2001-06-30|February 2005|2005-02-28|February 2005||2005-02-28|||||Interventional|||The Winchester Falls Project|The Winchester Falls Project: A Cluster Randomised Community Intervention Trial of Secondary Prevention of Falls in Community-Dwelling Older People|Completed||Phase 3|516||Winchester and Eastleigh Healthcare NHS Trust|||||f||||||||||||||2018-06-01 04:49:36.824053|2018-06-01 04:49:36.824053
NCT00130611|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2013-05-28|2005-08-12|2005-08-15|Estimate|||||||2013-05-28|2013-05-29|Estimate|January 2004||2004-01-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||B-type Natriuretic Peptide for Acute Shortness of Breath EvaLuation (BASEL) Study - Private Practice|B-type Natriuretic Peptide for Acute Shortness of Breath EvaLuation (BASEL) Study - Private Practice|Completed||Phase 4|250|Actual|University Hospital, Basel, Switzerland||2|||f||||||||||||||2018-06-01 04:49:36.887466|2018-06-01 04:49:36.887466
NCT00130598|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2010-03-04|2005-08-12|2005-08-15|Estimate|||||||2010-03-04|2010-03-05|Estimate|June 2005||2005-06-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION|PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION|Completed||Phase 2/Phase 3|258|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-06-01 04:49:36.984868|2018-06-01 04:49:36.984868
NCT00130585|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2005-10-03|2005-08-12|2005-08-15|Estimate|||||||2005-10-03|2005-10-04|Estimate|May 2005||2005-05-31|August 2005|2005-08-31|June 2005||2005-06-30|||||Interventional|||Bioavailability of Folate From a Mixed Diet Using a Stable Isotope Method|The Relative Bioavailability of Folate From a Mixed Diet Compared to Synthetic Folic Acid Using a Stable Isotope Method|Completed||N/A|75||Wageningen University|||||f||||||||||||||2018-06-01 04:49:37.075162|2018-06-01 04:49:37.075162
NCT00130572|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2008-05-21|2005-08-12|2005-08-15|Estimate|||||||2008-05-21|2008-05-23|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Elidel Cream on Erosive Oral Lichen Planus|Randomized Placebo-Controlled Clinical Pilot Trial Regarding the Efficacy of Elidel Cream on Erosive Oral Lichen Planus|Completed||Phase 3|20|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-06-01 04:49:37.131164|2018-06-01 04:49:37.131164
NCT00130559|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2011-10-18|2005-08-12|2005-08-15|Estimate|||||||2011-10-18|2011-10-19|Estimate|December 2003||2003-12-31|October 2011|2011-10-31|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||B-type Natriuretic Peptide (BNP)-Guided Diagnostic Strategy in Intensive Care Unit (ICU) Patients With Respiratory Failure|Does a Diagnostic Strategy Reduce Duration and Cost of Hospitalization in Patients With Acute Dyspnea? BASEL II Intensive Care Unit|Completed||Phase 4|286|Actual|University Hospital, Basel, Switzerland|||||f||||||||||||||2018-06-01 04:49:37.187754|2018-06-01 04:49:37.187754
NCT00130546|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2009-05-14|2005-08-11|2005-08-15|Estimate|||||||2009-05-14|2009-05-15|Estimate|November 2004||2004-11-30|May 2009|2009-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study)|A Prospective, Randomized Intra-Individual Study With the Sirolimus Coated Cypher Select(TM) and the Paclitaxel(TM) Coated Express Balloon Expandable Stents for the Treatment of Patients With Two de Novo Native Coronary Artery Lesions.|Completed||Phase 3|112|Actual|University Hospital Freiburg||2|||f||||t||||||||||2018-06-01 04:49:37.272795|2018-06-01 04:49:37.272795
NCT00130533|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2018-02-14|2005-08-12|2005-08-15|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 2006|Actual|2006-01-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients|Multicenter, Open-label, Randomized Phase III Trial, to Evaluate Efficacy of Maintenance Treatment With Capecitabine (X) Following Standard Adjuvant Chemotherapy, in Operable Breast Cancer Patients With Negative Hormone Receptor, Negative HER2 Tumours|Completed||Phase 3|876|Actual|Spanish Breast Cancer Research Group||2|||f||||||||||||||2018-06-01 04:49:37.376736|2018-06-01 04:49:37.376736
NCT00130520|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|2010-12-13||2012-05-22|2005-08-12|2005-08-15|Estimate|2010-12-13|2010-12-14|Estimate||||2012-05-22|2012-05-28|Estimate|June 2005||2005-06-30|December 2010|2010-12-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer|Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab in Women With Advanced Ovarian Cancer|Completed||Phase 2|40|Actual|University of Arizona||1|||f||||t||||||||||2018-06-01 04:49:37.570972|2018-06-01 04:49:37.570972
NCT00130507|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2011-10-25|2005-08-12|2005-08-15|Estimate|||||||2011-10-25|2011-10-26|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab|Randomized Clinical Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line Treatment for HER2 Positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Progressing to a Previous Therapy Line With Trastuzumab and Taxanes|Terminated||Phase 2|14|Actual|Spanish Breast Cancer Research Group||2||"A new alternative treatment caused the decrease in the rhythm of recruitment and finally~   termination of the trial."|f||||||||||||||2018-06-01 04:49:37.88462|2018-06-01 04:49:37.88462
NCT00130494|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2007-02-06|2005-08-12|2005-08-15|Estimate|||||||2007-02-06|2007-02-07|Estimate|August 2002||2002-08-31|February 2007|2007-02-28|December 2006||2006-12-31|||||Interventional|||Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-Symptomatic Bone Lesions|Multicenter, Open-Label, Randomized Phase III Trial for Administration of Zoledronate to Breast Cancer Metastatic Patients With Non-Symptomatic Bone Lesions|Terminated||Phase 3|224||Spanish Breast Cancer Research Group|||||f||||||||||||||2018-06-01 04:49:37.960519|2018-06-01 04:49:37.960519
NCT00130468|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2008-04-01|2005-08-12|2005-08-15|Estimate|||||||2008-04-01|2008-04-03|Estimate|November 2004||2004-11-30|April 2008|2008-04-30|May 2006||2006-05-31|||||Interventional|||TREAD-20: Trial of Hyalgan Three Injection-Regimen for the Treatment of Knee Pain Due to Osteoarthritis|A Double Blind, Randomized Trial of Intra-Articular Injections of 20 mg of Hyalgan® for the Treatment of Knee Pain Due to Osteoarthritis (Three Injection-Regimen for Efficacy And Duration-20 mg/2mL Dose: Tread-20)|Completed||Phase 4|150||Sanofi|||||f||||||||||||||2018-06-01 04:49:38.204874|2018-06-01 04:49:38.204874
NCT00130455|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2007-02-05|2005-08-12|2005-08-15|Estimate|||||||2007-02-05|2007-02-06|Estimate|April 2006||2006-04-30|February 2007|2007-02-28|January 2008||2008-01-31|||||Interventional|||Treatment of Depression in the Elderly|A 12 Week Multi-Centre, Randomized, Double-Blind, Placebo Controlled Evaluation of the Most Efficacious and Tolerable Dose of Escitalopram in the Treatment of Elderly Patients|Terminated||Phase 4|189||Psychiatric Hospital, Hillerod|||||f||||||||||||||2018-06-01 04:49:38.255234|2018-06-01 04:49:38.255234
NCT00130442|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2016-03-30|2005-08-12|2005-08-15|Estimate|||||||2016-03-30|2016-03-31|Estimate|June 2005||2005-06-30|March 2016|2016-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma|A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma|Completed||Phase 2|131|Actual|Medigen Biotechnology Corporation||2|||f||||t||||||||||2018-06-01 04:49:38.315921|2018-06-01 04:49:38.315921
NCT00130429|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2009-08-20|2005-08-12|2005-08-15|Estimate|||||||2009-08-20|2009-08-21|Estimate|January 2004||2004-01-31|August 2009|2009-08-31|September 2005|Actual|2005-09-30|||||Interventional|||Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease|Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type|Completed||Phase 2|250||Phytopharm|||||f||||||||||||||2018-06-01 04:49:38.407809|2018-06-01 04:49:38.407809
NCT00130416|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2008-07-03|2005-08-12|2005-08-15|Estimate|||||||2008-07-03|2008-07-08|Estimate|September 2004||2004-09-30|July 2008|2008-07-31|December 2007|Actual|2007-12-31|||||Interventional|||Improving Chronic Disease Care With PatientSite|Improving Chronic Disease Care With PatientSite|Completed||N/A|750||Robert Wood Johnson Foundation|||||f||||f||||||||||2018-06-01 04:49:38.469162|2018-06-01 04:49:38.469162
NCT00130403|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2011-01-10|2005-08-12|2005-08-15|Estimate|||||||2011-01-10|2011-01-11|Estimate|March 2004||2004-03-31|January 2011|2011-01-31|March 2007|Actual|2007-03-31|||||Interventional|||OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women|Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide|Completed||Phase 4|290|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:49:38.530483|2018-06-01 04:49:38.530483
NCT00130390|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2012-05-30|2005-08-12|2005-08-15|Estimate|||||||2012-05-30|2012-05-31|Estimate|August 2005||2005-08-31|May 2012|2012-05-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease|Multi-center, Randomized, Double-Blind, Placebo-Controlled Trial of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease in Adults|Terminated||Phase 2|98|Actual|Romark Laboratories L.C.||2||terminated due to slow recruitment|f||||f||||||||||2018-06-01 04:49:38.595686|2018-06-01 04:49:38.595686
NCT00130377|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2018-01-17|2005-08-12|2005-08-15|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2002||2002-08-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluation of the Treatment of Thoracic & Cardiovascular Disease With Biological Therapy: ClinicalCellRegistry.Com|Biological Cell Therapy for the Treatment of Patients With Thoracic & Cardiovascular Disease|Recruiting||Phase 2/Phase 3|1000|Anticipated|Amit, Patel N, M.D.||2|||f||||t||||||||||2018-06-01 04:49:38.684814|2018-06-01 04:49:38.684814
NCT00130364|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2008-01-10|2005-08-12|2005-08-15|Estimate|||||||2008-01-10|2008-01-15|Estimate|August 2005||2005-08-31|January 2008|2008-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis|Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis|Completed||Phase 4|200||Novartis||2|||f||||||||||||||2018-06-01 04:49:38.76375|2018-06-01 04:49:38.76375
NCT00130351|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2011-10-24|2005-08-12|2005-08-15|Estimate|||||||2011-10-24|2011-10-25|Estimate|July 2005||2005-07-31|October 2011|2011-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma|A 3-week Multicenter Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma|Completed||Phase 3|155|Actual|Novartis|||||||||||||||||||2018-06-01 04:49:38.844762|2018-06-01 04:49:38.844762
NCT00130338|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2017-03-24|2005-08-11|2005-08-15|Estimate|||||||2017-03-24|2017-03-28|Actual|February 2002||2002-02-28|March 2017|2017-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Rivastigmine Capsules in Patients With Probable Vascular Dementia|An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia|Completed||Phase 3|521|Actual|Novartis|||||f||||||||||||||2018-06-01 04:49:38.923282|2018-06-01 04:49:38.923282
NCT00130325|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2010-01-12|2005-08-11|2005-08-15|Estimate|||||||2010-01-12|2010-01-13|Estimate|October 2004||2004-10-31|January 2010|2010-01-31|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Interventional|IRS||A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts|A Double Blind Placebo-controlled Randomized Trial of Isoniazid for the Reversion of a Positive IFNg ELISPOT in TB Case Contacts|Completed||N/A|214|Actual|Medical Research Council Unit, The Gambia||2|||f||||f||||||||||2018-06-01 04:49:39.004636|2018-06-01 04:49:39.004636
NCT00130312|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11||2015-04-13|2015-04-13|2005-08-11|2005-08-15|Estimate||||2015-04-13|2015-05-05|Estimate|2015-04-13|2015-05-05|Estimate|August 2005||2005-08-31|April 2015|2015-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of Sulodexide in Overt Diabetic Nephropathy|The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy|Terminated||Phase 4|1248|Actual|Keryx Biopharmaceuticals||2||No difference in protein excretion at 6&12 months. No safety issues.|f||||t||||||||||2018-06-01 04:49:39.081649|2018-06-01 04:49:39.081649
NCT00130299|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2010-08-27|2005-08-12|2005-08-15|Estimate|||||||2010-08-27|2010-08-30|Estimate|July 2004||2004-07-31|August 2010|2010-08-31|December 2006|Actual|2006-12-31|||||Interventional|||An 18-month Trial of a Low Glycemic Load Diet|An 18-month Randomized Controlled Trial of a Low Glycemic Load Diet|Completed||N/A|||Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:49:39.147514|2018-06-01 04:49:39.147514
NCT00129571|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2008-06-02|2005-08-10|2005-08-12|Estimate|||||||2008-06-02|2008-06-04|Estimate|August 2005||2005-08-31|June 2008|2008-06-30||||||||Interventional|||Study of XL820 in Adults With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of XL820 Administered Orally to Subjects With Solid Tumors|Completed||Phase 1|||Exelixis|||||||||||||||||||2018-06-01 04:49:49.921142|2018-06-01 04:49:49.921142
NCT00130286|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|2013-12-16||2014-02-10|2005-08-12|2005-08-15|Estimate|2014-02-10|2014-02-13|Estimate||||2014-02-10|2014-02-13|Estimate|March 2005||2005-03-31|February 2014|2014-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance|Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance|Completed||Phase 1/Phase 2|77|Actual|Weill Medical College of Cornell University||4|||f||||t||||||||||2018-06-01 04:49:39.209397|2018-06-01 04:49:39.209397
NCT00130273|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2012-07-12|2005-08-11|2005-08-15|Estimate|||||||2012-07-12|2012-07-13|Estimate|July 2005||2005-07-31|July 2012|2012-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|MAPS||Managed Problem Solving to Increase Treatment Adherence in Individuals With HIV|Managed Problem Solving: An HIV Adherence Trial|Completed||N/A|180|Actual|University of Pennsylvania||2|||f||||||||||||||2018-06-01 04:49:39.697703|2018-06-01 04:49:39.697703
NCT00130260|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2007-12-26|2005-08-12|2005-08-15|Estimate|||||||2007-12-26|2008-01-04|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|April 2006|Actual|2006-04-30|December 2005|Actual|2005-12-31||Interventional|SHIELD-2||Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease|Phase 3b Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating Immunogenicity and Safety of a 3rd and 4th Dose of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults With End-Stage Renal Disease|Terminated||Phase 3|99|Actual|Nabi Biopharmaceuticals||4||unsatisfactory efficacy data from preceding trial|f||||f||||||||||2018-06-01 04:49:39.764343|2018-06-01 04:49:39.764343
NCT00130247|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|2009-08-20||2013-01-31|2005-08-12|2005-08-15|Estimate|2009-12-23|2010-01-27|Estimate||||2013-01-31|2013-02-04|Estimate|April 2002||2002-04-30|April 2010|2010-04-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||Tuberculosis Treatment Shortening Trial|A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment|Completed||Phase 3|394|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Enrollment was stopped early and the number of patients enrolled was 1/2 of the original sample size. The study was completed.|2|||f||||||||||||||2018-06-01 04:49:39.852584|2018-06-01 04:49:39.852584
NCT00130234|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2008-05-06|2005-08-12|2005-08-15|Estimate|||||||2008-05-06|2008-05-07|Estimate|November 2004||2004-11-30|May 2008|2008-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Effect of Anti-IgE in Chronic Urticaria|Effect of Anti-IgE in Chronic Urticaria|Completed||Phase 2|20||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:49:40.434181|2018-06-01 04:49:40.434181
NCT00130221|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2007-04-03|2005-08-12|2005-08-15|Estimate|||||||2007-04-03|2007-04-04|Estimate|June 2005||2005-06-30|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Interventional|||Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections|Skin Cleansing With Chlorhexidine to Improve Nosocomial Infection Risks. (SCCIN Project)|Completed||Phase 1|208||John H. Stroger Hospital|||||f||||f||||||||||2018-06-01 04:49:40.500379|2018-06-01 04:49:40.500379
NCT00130208|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|2018-01-23|2015-04-13|2018-02-22|2005-08-11|2005-08-15|Estimate|2018-02-22|2018-03-23|Actual|2015-04-13|2015-05-05|Estimate|2018-02-22|2018-03-23|Actual|August 2005||2005-08-31|February 2018|2018-02-28|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Effect of Sulodexide in Early Diabetic Nephropathy|The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria|Completed||Phase 3|1056|Actual|Keryx Biopharmaceuticals||2|||f||||t||||||||No||2018-06-01 04:49:40.598831|2018-06-01 04:49:40.598831
NCT00130195|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2008-11-13|2005-08-12|2005-08-15|Estimate|||||||2008-11-13|2008-11-14|Estimate|September 2002||2002-09-30|November 2008|2008-11-30|May 2008|Actual|2008-05-31|February 2008|Actual|2008-02-29||Interventional|||Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)|Phase 2 Study of Imatinib-Combined Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia|Completed||Phase 2|100|Actual|Japan Adult Leukemia Study Group||1|||f||||t||||||||||2018-06-01 04:49:41.106617|2018-06-01 04:49:41.106617
NCT00130182|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2013-05-21|2005-08-11|2005-08-15|Estimate|||||||2013-05-21|2013-05-22|Estimate|August 2005||2005-08-31|May 2013|2013-05-31||||September 2006|Actual|2006-09-30||Interventional|||A Study in Pediatric Patients With Cystic Fibrosis Lung Disease|A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Pediatric Patients With Cystic Fibrosis Lung Disease|Completed||Phase 2|13|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:49:41.20284|2018-06-01 04:49:41.20284
NCT00130169|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2015-06-29|2005-08-12|2005-08-15|Estimate|||||||2015-06-29|2015-07-01|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies|A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies|Completed||Phase 1|30|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 04:49:41.254361|2018-06-01 04:49:41.254361
NCT00130156|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2013-05-13|2005-08-12|2005-08-15|Estimate|||||||2013-05-13|2013-05-14|Estimate|October 2005||2005-10-31|February 2011|2011-02-28|March 2009|Actual|2009-03-31|September 2008|Actual|2008-09-30||Interventional|||Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension|Effects of Combination Therapy With an α1-blocker (Sustained-release Preparation of Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in the Treatment of Patients With Mild to Moderate Essential Hypertension|Completed||Phase 4|93|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:49:41.320277|2018-06-01 04:49:41.320277
NCT00130143|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2005-09-26|2005-08-12|2005-08-15|Estimate|||||||2005-09-26|2005-09-27|Estimate|June 2003||2003-06-30|August 2005|2005-08-31|September 2004||2004-09-30|||||Interventional|||Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities|Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities|Completed||N/A|20||The Dale & Frances Hughes Cancer Center|||||f||||||||||||||2018-06-01 04:49:41.418747|2018-06-01 04:49:41.418747
NCT00130130|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2012-01-30|2005-08-12|2005-08-15|Estimate|||||||2012-01-30|2012-02-01|Estimate|August 2005||2005-08-31|January 2012|2012-01-31|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Observational|||Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes|Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes|Completed|||20|Actual|Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 04:49:41.475026|2018-06-01 04:49:41.475026
NCT00124098|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-06-13|2005-07-25|2005-07-27|Estimate|||||||2008-06-13|2008-06-16|Estimate||||June 2008|2008-06-30||||||||Interventional|||An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)|An Open-Label Study of Aranesp® (Darbepoetin Alfa) Administration Once Every Four Weeks in Anaemic Chronic Kidney Disease (CKD) Subjects|Completed||Phase 3|||Amgen|||||f||||||||||||||2018-06-01 04:51:29.423719|2018-06-01 04:51:29.423719
NCT00130117|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|2015-12-24||2017-04-13|2005-08-11|2005-08-15|Estimate|2017-04-13|2017-05-17|Actual||||2017-04-13|2017-05-17|Actual|April 2010||2010-04-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|August 2011|Actual|2011-08-31||Interventional|||Study of Leptin for the Treatment of Hypothalamic Amenorrhea|Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea|Completed||Phase 2|20|Actual|Beth Israel Deaconess Medical Center|Number of participants was small and, therefore, our observations need to be validated in studies with larger sample sizes.|2|||f||||f||||||||No||2018-06-01 04:49:41.541292|2018-06-01 04:49:41.541292
NCT00130104|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2007-10-03|2005-08-12|2005-08-15|Estimate|||||||2007-10-03|2007-10-05|Estimate|July 2005||2005-07-31|August 2005|2005-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Transthecal Metacarpal Block Versus Traditional Digital Block for Painful Finger Procedures in Children|Transthecal Metacarpal Block vs Traditional Digital Block for Painful Finger Procedures in Children|Completed||Phase 4|92|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-06-01 04:49:41.828233|2018-06-01 04:49:41.828233
NCT00130091|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2015-02-18|2005-08-11|2005-08-15|Estimate|||||||2015-02-18|2015-02-20|Estimate|September 2009||2009-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children|The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children|Completed||Phase 2|120|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||||2018-06-01 04:49:41.937368|2018-06-01 04:49:41.937368
NCT00130078|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2005-09-22|2005-08-11|2005-08-15|Estimate|||||||2005-09-22|2005-09-26|Estimate|September 2004||2004-09-30|August 2005|2005-08-31||||||||Interventional|||Trial of SAVVY Vaginal Gel and HIV in Nigeria|Randomized Controlled Trial of SAVVY and HIV in Nigeria|Unknown status|Recruiting|Phase 3|2142||Biosyn|||||||||||||||||||2018-06-01 04:49:42.010077|2018-06-01 04:49:42.010077
NCT00130065|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2012-09-26|2005-08-12|2005-08-15|Estimate|||||||2012-09-26|2012-09-27|Estimate|November 2003||2003-11-30|September 2012|2012-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya|The Effect of Folic Acid Supplementation on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya|Completed||Phase 4|600||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:49:42.081963|2018-06-01 04:49:42.081963
NCT00130039|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|2009-10-23||2010-01-04|2005-08-12|2005-08-15|Estimate|2009-11-27|2010-01-01|Estimate||||2010-01-04|2010-01-12|Estimate|August 2005||2005-08-31|November 2009|2009-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|TOSS-2||Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II|Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel|Completed||Phase 4|457|Actual|Asan Medical Center||2|||f||||t||||||||||2018-06-01 04:49:42.225322|2018-06-01 04:49:42.225322
NCT00130026|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2017-02-03|2005-08-12|2005-08-15|Estimate|||||||2017-02-03|2017-02-07|Estimate|March 2005||2005-03-31|February 2017|2017-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Caffeine in the Prevention of Post-operative Nausea and Vomiting|A Prospective, Randomized, Double-blind, Placebo-controlled Study of Caffeine in the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Ambulatory Surgery Under General Anesthesia|Completed||N/A|135|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-06-01 04:49:42.631416|2018-06-01 04:49:42.631416
NCT00130013|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-12|||2005-09-22|2005-08-12|2005-08-15|Estimate|||||||2005-09-22|2005-09-23|Estimate|September 2003||2003-09-30|July 2004|2004-07-31|June 2004||2004-06-30|||||Interventional|||Efficacy of Single Versus Double Dose of Oral Amoxicillin for Non-Severe Pneumonia in Children|Comparison of Standard Versus Double Dose of Amoxicillin in the Treatment of Non-Severe Pneumonia in Children Aged 2-59 Months: A Multi-Centre Randomized Double Blind Controlled Trial in Pakistan|Completed||Phase 1/Phase 2|900||ARI Research Cell|||||f||||||||||||||2018-06-01 04:49:42.719287|2018-06-01 04:49:42.719287
NCT00130000|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2017-06-30|2005-08-11|2005-08-12|Estimate|||||||2017-06-30|2017-07-02|Actual|August 9, 2005||2005-08-09|June 25, 2007|2007-06-25|June 25, 2007||2007-06-25|||||Interventional|||Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria|SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design|Completed||Phase 3|87||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:49:42.778328|2018-06-01 04:49:42.778328
NCT00129987|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2015-06-03|2005-08-11|2005-08-12|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 2003||2003-11-30|May 2008|2008-05-31|August 2006||2006-08-31|||||Interventional|||Trial of Lay-led Individualised Self-management Education for Adults With Asthma|A Multi-centre Randomised Trial of Lay-led Individualised Self-management Education for Adults With Asthma|Completed||N/A|640||Imperial College London|||||f||||||||||||||2018-06-01 04:49:42.838778|2018-06-01 04:49:42.838778
NCT00129974|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2017-02-01||2017-03-29|2005-08-11|2005-08-12|Estimate|2017-03-29|2017-06-16|Actual||||2017-03-29|2017-06-16|Actual|August 2005||2005-08-31|March 2017|2017-03-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer|A Phase II Trial of Pemetrexed in Combination With Gemcitabine as First Line Treatment in Extensive-Stage Small Cell Lung Carcinoma|Terminated||Phase 2|1|Actual|Tufts Medical Center||||failure to accrue|f||||||||||||||2018-06-01 04:49:42.916344|2018-06-01 04:49:42.916344
NCT00129961|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|2010-01-29||2012-04-09|2005-08-11|2005-08-12|Estimate|2012-02-17|2012-03-23|Estimate||||2012-04-09|2012-04-11|Estimate|August 2005||2005-08-31|April 2012|2012-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients|A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen|Completed||Phase 4|86|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|A blinded review of data in May 2007 determined there was minimal added power in follow-up through 2 years vs. 1 year. The study was then amended to require at least 1 year of follow-up instead of 2 years.|2|||f||||f||||||||||2018-06-01 04:49:43.096374|2018-06-01 04:49:43.096374
NCT00129948|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2006-11-01|2005-08-10|2005-08-12|Estimate|||||||2006-11-01|2006-11-03|Estimate|July 2005||2005-07-31|November 2006|2006-11-30|October 2007||2007-10-31|||||Interventional|||Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage|Terminated||Phase 2|211||SGX Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:49:43.901317|2018-06-01 04:49:43.901317
NCT00129558|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2013-12-02|2005-08-11|2005-08-12|Estimate|||||||2013-12-02|2013-12-04|Estimate|July 2005||2005-07-31|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate PT-523 in Patients With Refractory Leukemia|A Phase I/II Study of PT-523 in Patients With Refractory Leukemia|Withdrawn||Phase 1/Phase 2|0|Actual|Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 04:49:49.969703|2018-06-01 04:49:49.969703
NCT00129935|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2018-03-15|2005-08-11|2005-08-12|Estimate|||||||2018-03-15|2018-03-19|Actual|February 2004|Actual|2004-02-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2013|Actual|2013-01-31||Interventional|||EC Followed Docetaxel VS ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer|Phase III Trial to Compare Epirubicin and Cyclophosphamide (EC) Followed by Docetaxel (T) to Epirubicin and Docetaxel (ET) Followed by Capecitabine (X) as Adjuvant Treatment, Node Positive Breast Cancer Patients|Active, not recruiting||Phase 3|1384|Actual|Spanish Breast Cancer Research Group||2|||f||||f||||||||||2018-06-01 04:49:43.994035|2018-06-01 04:49:43.994035
NCT00129922|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2018-03-15|2005-08-11|2005-08-12|Estimate|||||||2018-03-15|2018-03-19|Actual|November 1999|Actual|1999-11-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2005|Actual|2005-12-31||Interventional|||Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer|Phase III Study to Compare 6 Courses of FEC (Fluorouracil, Epirubicin and Cyclophosphamide) vs. 4 Courses of FEC Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Positive Operable BC Patients|Active, not recruiting||Phase 3|1289|Actual|Spanish Breast Cancer Research Group||2|||f||||||||||||||2018-06-01 04:49:44.123971|2018-06-01 04:49:44.123971
NCT00129909|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2012-06-13|2005-08-10|2005-08-12|Estimate|||||||2012-06-13|2012-06-14|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|January 2007|Actual|2007-01-31|September 2006|Actual|2006-09-30||Interventional|||STITCH (Simplified Therapeutic Intervention To Control Hypertension)|Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Hypertension - Control and Intervention Arms|Completed||Phase 4|2081|Actual|University of Western Ontario, Canada|||||f||||f||||||||||2018-06-01 04:49:44.398099|2018-06-01 04:49:44.398099
NCT00129896|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2018-03-12|2005-08-11|2005-08-12|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2004|Actual|2004-01-31|February 2018|2018-02-28|February 2010|Actual|2010-02-28|December 2008|Actual|2008-12-31||Interventional|||Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients|Open-label Phase I-II Clinical Trial to Evaluate Treatment With Myocet/Taxotere/Herceptin as Primary Chemotherapy Treatment for HER2neu Positive Breast Cancer Patients|Completed||Phase 1/Phase 2|73|Actual|Spanish Breast Cancer Research Group||1|||f||||f||||||||||2018-06-01 04:49:44.478756|2018-06-01 04:49:44.478756
NCT00129883|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2005-09-26|2005-08-11|2005-08-12|Estimate|||||||2005-09-26|2005-09-27|Estimate|September 2002||2002-09-30|August 2002|2002-08-31|April 2005||2005-04-30|||||Interventional|||Adherence to Guidelines for Antibiotic Use in Respiratory Infections at Hospitals|Prevention of Antimicrobial Resistance in Hospitals: Promoting Appropriate Use of Antibiotics in Hospital Departments of Internal and Pulmonary Medicine|Completed||N/A|2000||Radboud University|||||f||||||||||||||2018-06-01 04:49:44.621704|2018-06-01 04:49:44.621704
NCT00129870|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2009-02-12|2005-08-11|2005-08-12|Estimate|||||||2009-02-12|2009-02-13|Estimate|February 2005||2005-02-28|February 2009|2009-02-28|December 2007|Actual|2007-12-31|||||Interventional|||CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer|CONCEPT - Phase IV, Randomized, Prospective, Multicenter Comparison of Intermittent Schedule of Oxaliplatin Combined With FOLFOX/Bevacizumab vs Conventional Mode of Administration of FOLFOX/Bevacizumab + Neuroprophylaxis With Calcium/Magnesium for Optimization of First-Line Therapy of Metastatic Colorectal Cancer|Terminated||Phase 4|180|Actual|Sanofi||||"Unplanned interim analysis by DSMB indicated possible reduced response rate with the addition~   of Ca/Mg in pooled population. Further analysis pending."|f||||t||||||||||2018-06-01 04:49:44.757274|2018-06-01 04:49:44.757274
NCT00129857|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2006-05-04|2005-08-11|2005-08-12|Estimate|||||||2006-05-04|2006-05-05|Estimate|January 2001||2001-01-31|November 2004|2004-11-30|September 2004||2004-09-30|||||Interventional|||Dexanabinol in Severe Traumatic Brain Injury|Efficacy and Safety Evaluation of a Single Intravenous Dose of Dexanabinol in Patients Suffering From Severe Traumatic Brain Injury|Completed||Phase 3|860||Pharmos|||||||||||||||||||2018-06-01 04:49:44.837242|2018-06-01 04:49:44.837242
NCT00129844|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2008-08-19|2005-08-10|2005-08-12|Estimate|||||||2008-08-19|2008-08-20|Estimate|September 2005||2005-09-30|August 2008|2008-08-31|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer|Randomized Phase II Trial of Single Agent Motexafin Gadolinium for Second Line Treatment of Non-Small-Cell Lung Cancer|Completed||Phase 2|108|Anticipated|Pharmacyclics LLC.|||||||||||||||||||2018-06-01 04:49:44.911811|2018-06-01 04:49:44.911811
NCT00129831|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2011-10-24|2005-08-11|2005-08-12|Estimate|||||||2011-10-24|2011-10-25|Estimate|September 2004||2004-09-30|October 2011|2011-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)|Dose Escalation Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|6|Actual|Novartis|||||||||||||||||||2018-06-01 04:49:45.00819|2018-06-01 04:49:45.00819
NCT00129818|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2012-04-26|2005-08-11|2005-08-12|Estimate|||||||2012-04-26|2012-04-27|Estimate|July 2004||2004-07-31|April 2012|2012-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding|A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding|Completed||Phase 4|||Novartis|||||||||||||||||||2018-06-01 04:49:45.072354|2018-06-01 04:49:45.072354
NCT00129805|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2008-08-18|2005-08-11|2005-08-12|Estimate|||||||2008-08-18|2008-08-19|Estimate|January 2001||2001-01-31|August 2008|2008-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)|Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial|Completed||Phase 3|1510|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-06-01 04:49:45.147448|2018-06-01 04:49:45.147448
NCT00129792|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2014-10-27|2005-08-10|2005-08-12|Estimate|||||||2014-10-27|2014-10-29|Estimate|January 2005||2005-01-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|June 2007|Actual|2007-06-30||Interventional|||Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome|Expectancy, Self-Efficacy and Outcomes in Metabolic Syndrome|Completed||N/A|79|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-06-01 04:49:45.2198|2018-06-01 04:49:45.2198
NCT00129779|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2015-06-04|2005-08-11|2005-08-12|Estimate|||||||2015-06-04|2015-06-08|Estimate|December 2003||2003-12-31|May 2008|2008-05-31|August 2006||2006-08-31|||||Interventional|||Assessment of the Effects of an Intermediate Care Package in Preventing Hospitalisation of Patients With COPD|A Randomised Control Trial Assessing the Effects of an Intermediate Care Package in Preventing Hospitalisation of Elderly Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|122||Imperial College London|||||f||||||||||||||2018-06-01 04:49:45.296168|2018-06-01 04:49:45.296168
NCT00129766|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2013-06-21||2013-06-21|2005-08-10|2005-08-12|Estimate|2013-06-21|2013-08-28|Estimate||||2013-06-21|2013-08-28|Estimate|November 2004||2004-11-30|June 2013|2013-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children|A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children|Completed||Phase 3|6635|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 04:49:45.509982|2018-06-01 04:49:45.509982
NCT00129753|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2016-04-06|2005-08-11|2005-08-12|Estimate|||||||2016-04-06|2016-04-07|Estimate|June 2005||2005-06-30|October 2010|2010-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease|Phase II Study of Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Terminated due to slow accrual.|f||||f||||||||||2018-06-01 04:49:48.378757|2018-06-01 04:49:48.378757
NCT00129740|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2018-03-16|2005-08-11|2005-08-12|Estimate|||||||2018-03-16|2018-03-20|Actual|June 27, 2005|Actual|2005-06-27|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib|Active, not recruiting||Phase 2|149|Actual|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-06-01 04:49:48.459074|2018-06-01 04:49:48.459074
NCT00129727|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2011-07-20||2016-04-24|2005-08-10|2005-08-12|Estimate|2016-04-24|2016-06-01|Estimate||||2016-04-24|2016-06-01|Estimate|June 2005||2005-06-30|April 2016|2016-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)|Phase II Evaluation of Carboplatin, Paclitaxel and Bevacizumab as First Line Chemotherapy and Consolidation for Advanced Ovarian Cancer|Completed||Phase 2|62|Actual|Massachusetts General Hospital|Phase II uncontrolled trial|1|||f||||t||||||||Yes|Manuscript was published in JCO|2018-06-01 04:49:48.543417|2018-06-01 04:49:48.543417
NCT00129714|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2012-04-23|2005-08-11|2005-08-12|Estimate|||||||2012-04-23|2012-04-24|Estimate|August 2003||2003-08-31|April 2012|2012-04-30|July 2007|Actual|2007-07-31|April 2007|Actual|2007-04-30||Interventional|WEB||Westeinde Brachialgia Study|A Randomized Controlled Trial of Conservative Therapy in Cervical Radiculopathy|Completed||N/A|240||Medical Center Haaglanden||3|||f||||||||||||||2018-06-01 04:49:48.716565|2018-06-01 04:49:48.716565
NCT00129701|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2015-05-27|2005-08-11|2005-08-12|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2003||2003-11-30|August 2005|2005-08-31|January 2006||2006-01-31|||||Interventional|||Can we Reduce Hospital Attendance Without Compromising Care by the Use of Telephone Consultation|Proposal to Study Whether we Can Reduce Hospital Attendance by Those With Respiratory Conditions Without Compromising Care by the Use of Telephone Consultation|Completed||N/A|500||Imperial College London|||||f||||||||||||||2018-06-01 04:49:48.785841|2018-06-01 04:49:48.785841
NCT00129688|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2005-09-22|2005-08-10|2005-08-12|Estimate|||||||2005-09-22|2005-09-23|Estimate|April 2002||2002-04-30|February 2005|2005-02-28|June 2004||2004-06-30|||||Interventional|||Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children|Comparison of Efficacy, Safety and Economic Outcomes Between Once-Daily Versus Twice-Daily Amikacin in Combination With Cloxacillin in Febrile Neutropenic Children|Completed||N/A|166||Khon Kaen University|||||f||||||||||||||2018-06-01 04:49:48.848719|2018-06-01 04:49:48.848719
NCT00129675|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11||2014-07-14|2014-07-14|2005-08-11|2005-08-12|Estimate||||2014-07-14|2014-07-16|Estimate|2014-07-14|2014-07-16|Estimate|February 2003||2003-02-28|July 2014|2014-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty|Development of a Imaging Marker for Parkinson's Disease Through Use of Dynamic SPECT Imaging With [123I] Beta-CIT in Individuals With Parkinson's Symptoms|Completed||Phase 2|169|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 04:49:48.907268|2018-06-01 04:49:48.907268
NCT00129662|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2017-03-08|2005-08-11|2005-08-12|Estimate|||||||2017-03-08|2017-03-10|Actual|January 2005||2005-01-31|May 2010|2010-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Comprehension and Evaluation of a Pictorial Action Plan for Those With Asthma or COPD|Comprehension and Evaluation of a Pictorial Action Plan for Those With Asthma or Chronic Obstructive Pulmonary Disease|Completed||N/A|69|Actual|Imperial College London||1|||f||||||||||||||2018-06-01 04:49:48.972868|2018-06-01 04:49:48.972868
NCT00129649|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2015-10-21|2005-08-11|2005-08-12|Estimate|||||||2015-10-21|2015-10-22|Estimate|May 2005||2005-05-31|August 2005|2005-08-31|May 2005||2005-05-31|||||Interventional|||Service Development: Assessing Non-attendance Rates in Outpatient Clinics|Service Development: Assessing Non-attendance Rates in Outpatient Clinics|Completed||N/A|500||Imperial College London|||||f||||||||||||||2018-06-01 04:49:49.054422|2018-06-01 04:49:49.054422
NCT00129636|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2015-10-21|2005-08-11|2005-08-12|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2004||2004-03-31|August 2005|2005-08-31|July 2005||2005-07-31|||||Interventional|||The Usefulness of Patients Receiving Their Own Letter After an Outpatient Attendance|A Study to Determine the Usefulness of Patients Receiving Their Own Letter After an Outpatient Attendance Compared to Receiving a Copy of the Letter Being Sent to Their General Practitioner|Completed||N/A|150||Imperial College London|||||f||||||||||||||2018-06-01 04:49:49.108589|2018-06-01 04:49:49.108589
NCT00129623|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|2015-12-05||2015-12-05|2005-08-11|2005-08-12|Estimate|2015-12-05|2016-01-11|Estimate||||2015-12-05|2016-01-11|Estimate|December 2005||2005-12-31|December 2015|2015-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional||Baseline characteristics are presented for the safety population which included participants who had at least one dose of the trial medication documented in the case report form (CRF) whether withdrawn prematurely or not.|A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia|Double-blind, Placebo-controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of Oral Ibandronate Once Monthly in Postmenopausal Women With Osteopenia|Completed||Phase 4|160|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:49:49.190566|2018-06-01 04:49:49.190566
NCT00129610|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2007-04-26|2005-08-11|2005-08-12|Estimate|||||||2007-04-26|2007-04-27|Estimate|January 2004||2004-01-31|April 2007|2007-04-30||||||||Interventional|||Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia|A Comparative Controlled Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia|Unknown status|Active, not recruiting|N/A|90||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:49:49.70224|2018-06-01 04:49:49.70224
NCT00129597|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2007-03-09|2005-08-10|2005-08-12|Estimate|||||||2007-03-09|2007-03-12|Estimate|December 2004||2004-12-31|March 2007|2007-03-31||||||||Interventional|||Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy|Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy|Unknown status|Active, not recruiting|Phase 4|40||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:49:49.770948|2018-06-01 04:49:49.770948
NCT00129545|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2014-10-03||2015-04-29|2005-08-10|2005-08-12|Estimate|2015-04-29|2015-05-15|Estimate||||2015-04-29|2015-05-15|Estimate|February 2005||2005-02-28|April 2015|2015-04-30|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional||2:1 randomazation, outcome analysis excludes the 93 subjects in the Roll-in arm|WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation|WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)|Completed||Phase 2/Phase 3|800|Actual|Boston Scientific Corporation||3|||f||||t||||||||||2018-06-01 04:49:50.062681|2018-06-01 04:49:50.062681
NCT00129532|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2005-09-07|2005-08-11|2005-08-12|Estimate|||||||2005-09-07|2005-09-08|Estimate|January 2004||2004-01-31|August 2005|2005-08-31||||||||Interventional|||Trial of SAVVY and HIV in Ghana|Randomized Controlled Trial of SAVVY and HIV in Ghana|Unknown status|Active, not recruiting|Phase 3|2142||Biosyn|||||||||||||||||||2018-06-01 04:49:50.610875|2018-06-01 04:49:50.610875
NCT00129519|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-11|||2010-07-14|2005-08-11|2005-08-12|Estimate|||||||2010-07-14|2010-07-16|Estimate|January 2004||2004-01-31|July 2010|2010-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence|Open-label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage|Completed||Phase 3|63|Actual|Graceway Pharmaceuticals, LLC||1|||f||||f||||||||||2018-06-01 04:49:50.662614|2018-06-01 04:49:50.662614
NCT00129506|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-04-18|2005-08-09|2005-08-11|Estimate|||||||2007-04-18|2007-04-19|Estimate|May 2005||2005-05-31|April 2007|2007-04-30|October 2005||2005-10-31|||||Interventional|||Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion|Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion|Completed||Phase 4|300||Wiebe, Ellen, M.D.|||||f||||||||||||||2018-06-01 04:49:50.717581|2018-06-01 04:49:50.717581
NCT00129493|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2015-04-06|2005-08-09|2005-08-11|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2004||2004-02-29|May 2009|2009-05-31|August 2007|Actual|2007-08-31|March 2006|Actual|2006-03-31||Interventional|||Group Visits to Improve Hypertension Management|Group Visits to Improve Hypertension Management|Completed||N/A|300|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:49:50.765705|2018-06-01 04:49:50.765705
NCT00129480|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|2014-06-10||2015-04-06|2005-08-09|2005-08-11|Estimate|2015-02-06|2015-02-24|Estimate||||2015-04-06|2015-04-28|Estimate|January 2006||2006-01-31|May 2014|2014-05-31|July 2010|Actual|2010-07-31|January 2009|Actual|2009-01-31||Interventional|SEACAP|Veterans receiving healthcare in VA primary care|Improving Chronic Pain Treatment in Primary Care|Improving the Treatment of Chronic Pain in Primary Care|Completed||N/A|401|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:49:50.827739|2018-06-01 04:49:50.827739
NCT00129467|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|2013-10-16||2015-04-06|2005-08-09|2005-08-11|Estimate|2013-12-20|2014-02-12|Estimate||||2015-04-06|2015-04-24|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|December 2010|Actual|2010-12-31|September 2009|Actual|2009-09-30||Interventional||The number of baseline participants is the number of subjects who received the intervention|Methylphenidate for Depressed Cancer Patients Receiving Palliative Care|Methylphenidate for Depressed Cancer Patients in Hospice|Completed||N/A|47|Actual|VA Office of Research and Development|Frequency threshold for reporting nonserious adverse events was not determined at the start of the study, but a % was required to be entered in order to complete the adverse event module|2|||f||||t||||||||||2018-06-01 04:49:51.1258|2018-06-01 04:49:51.1258
NCT00129454|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2017-06-02|2005-08-09|2005-08-11|Estimate|||||||2017-06-02|2017-06-06|Actual|September 1, 2005|Actual|2005-09-01|June 2017|2017-06-30|March 1, 2008|Actual|2008-03-01|February 22, 2008|Actual|2008-02-22||Interventional|||Telemedicine Treatment for Veterans With Gulf War Illness|Telemedicine Treatment for Veterans With Gulf War Illness|Completed||N/A|128|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:49:51.588985|2018-06-01 04:49:51.588985
NCT00129441|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2011-05-25||2011-10-14|2005-08-10|2005-08-11|Estimate|2011-10-14|2011-10-17|Estimate||||2011-10-14|2011-10-17|Estimate|August 2005||2005-08-31|October 2011|2011-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study|Treatment of Cognitive Disability in Schizophrenia With a GABA-A Alpha2/3 Receptor Agonist|Completed||Phase 2|16|Actual|University of Pittsburgh|Small sample size; RBANS may lack appropriate sensitivity for short-term study; between-group differences in baseline clinical symptoms & neuropsychological function; excluding those with more modest cognitive impairments (RBANS standard score >90).|2|||f||||f||||||||||2018-06-01 04:49:51.694381|2018-06-01 04:49:51.694381
NCT00129428|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2015-04-30|2005-08-09|2005-08-11|Estimate|||||||2015-04-30|2015-05-01|Estimate|August 2002||2002-08-31|April 2015|2015-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix|The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study|Completed||Phase 1/Phase 2|33|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 04:49:52.113692|2018-06-01 04:49:52.113692
NCT00129415|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2015-05-21|2005-08-09|2005-08-11|Estimate|||||||2015-05-21|2015-05-22|Estimate|August 2000||2000-08-31|May 2015|2015-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions|The Effectiveness of UVA1 and UVB Irradiation in the Treatment of Inflammatory Dermatoses: An Open Pilot Study|Terminated||Phase 1/Phase 2|28|Actual|University of Michigan||2||Slow enrollment|f||||f||||||||||2018-06-01 04:49:52.181087|2018-06-01 04:49:52.181087
NCT00129402|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|2010-01-14||2015-09-02|2005-08-09|2005-08-11|Estimate|2010-01-14|2010-02-11|Estimate||||2015-09-02|2015-09-21|Estimate|August 2005||2005-08-31|September 2015|2015-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)|Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|248|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:49:52.275743|2018-06-01 04:49:52.275743
NCT00129389|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2012-11-21|2005-08-10|2005-08-11|Estimate|||||||2012-11-21|2012-11-22|Estimate|September 2003||2003-09-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients|Multicenter Randomized Phase III Clinical Trial to Compare 6 FAC Cycles(Fluorouracil, Doxorubicin, Cyclophosphamide) vs. 4 FAC Cycles Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Negative Operable Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 3|1929|Actual|Spanish Breast Cancer Research Group||2|||f||||f||||||||||2018-06-01 04:49:52.777874|2018-06-01 04:49:52.777874
NCT00129207|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2008-02-07|2005-08-10|2005-08-11|Estimate|||||||2008-02-07|2008-02-11|Estimate||||February 2008|2008-02-29||||September 2006|Actual|2006-09-30||Interventional|||Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade|Effect of Ketoconazole Administration on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors|Completed||Phase 1|||Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 04:49:56.094835|2018-06-01 04:49:56.094835
NCT00129376|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2018-03-15|2005-08-10|2005-08-11|Estimate|||||||2018-03-15|2018-03-19|Actual|February 2003|Actual|2003-02-28|March 2018|2018-03-31|February 2010|Actual|2010-02-28|July 2005|Actual|2005-07-31||Interventional|||Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients|Multicenter Phase II Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel (T) as Neoadjuvant Treatment for Operable Stage II and IIIA Breast Cancer Patients|Completed||Phase 2|63|Actual|Spanish Breast Cancer Research Group||1|||f||||||||||||||2018-06-01 04:49:52.848351|2018-06-01 04:49:52.848351
NCT00129363|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2008-12-24|2005-08-08|2005-08-11|Estimate|||||||2008-12-24|2008-12-25|Estimate|January 2002||2002-01-31|December 2008|2008-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study to Evaluate the Safety of Twice Daily Oral Carvedilol|A Multicenter, Open Label Extension Study to Evaluate the Safety of Twice Daily Oral Carvedilol in Pediatric Patients With Chronic Heart Failure|Completed||Phase 3|75|Actual|Shaddy, Robert, M.D.|||||f||||||||||||||2018-06-01 04:49:52.923405|2018-06-01 04:49:52.923405
NCT00129350|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2005-09-06|2005-08-10|2005-08-11|Estimate|||||||2005-09-06|2005-09-07|Estimate|September 2004||2004-09-30|August 2005|2005-08-31|February 2008||2008-02-29|||||Interventional|||Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation|An Assessment of Patient Outcomes Following a Rehabilitation Programme for Patients Who Have Received Lung or Heart-Lung Transplant - a Randomised Controlled Trial|Unknown status|Recruiting|Phase 1|60||Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:49:52.999498|2018-06-01 04:49:52.999498
NCT00129337|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2011-02-28|2005-08-10|2005-08-11|Estimate|||||||2011-02-28|2011-03-01|Estimate|June 2005||2005-06-30|February 2011|2011-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies|A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients With Refractory Advanced Solid Tumor Malignancies|Completed||Phase 1|28|Anticipated|Peregrine Pharmaceuticals||4|||t||||f||||||||||2018-06-01 04:49:53.062215|2018-06-01 04:49:53.062215
NCT00129324|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2018-03-29|2005-08-10|2005-08-11|Estimate|||||||2018-03-29|2018-04-02|Actual|March 2003|Actual|2003-03-31|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||HOME Study (Health Outcomes and Measures of the Environment Study)|Neurobehavioral Effects of Prevalent Neurotoxicants in Children: A Cohort Study of the Cincinnati Center for Children's Environmental Health|Enrolling by invitation||N/A|468|Actual|National Institute of Environmental Health Sciences (NIEHS)||2|||f||||f||||||||||2018-06-01 04:49:53.138051|2018-06-01 04:49:53.138051
NCT00129311|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|2014-06-16||2015-03-11|2005-08-09|2005-08-11|Estimate|2014-06-16|2014-07-16|Estimate||||2015-03-11|2015-03-31|Estimate|July 2004||2004-07-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Usefulness of Selegiline as an Aid to Quit Smoking - 1|Usefulness of Selegiline for Smoking Cessation|Completed||Phase 2|101|Actual|Yale University||2|||f||||t||||||||||2018-06-01 04:49:53.317063|2018-06-01 04:49:53.317063
NCT00129298|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2017-01-11|2005-08-04|2005-08-11|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1|Tiagabine for the Treatment of Cocaine Dependence in Methadone-Maintained Individuals|Completed||Phase 2|80|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 04:49:53.546928|2018-06-01 04:49:53.546928
NCT00129285|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|2017-03-27||2018-04-05|2005-08-04|2005-08-11|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|July 2004||2004-07-31|April 2018|2018-04-30|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Modafinil Treatment for Cocaine-Dependent Individuals|A Double-Blind, Placebo-Controlled Study of Modafinil for Cocaine Dependence|Completed||Phase 2|210|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 04:49:53.618212|2018-06-01 04:49:53.618212
NCT00129272|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|2017-01-16||2017-04-17|2005-08-04|2005-08-11|Estimate|2017-03-06|2017-04-18|Actual||||2017-04-17|2017-05-22|Actual|May 2004||2004-05-31|April 2017|2017-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effectiveness of Bupropion for Treating Nicotine Dependence in Young People|Stress Response and Smoking Cessation in Depressed Youth|Completed||Phase 2|172|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||No||2018-06-01 04:49:53.98412|2018-06-01 04:49:53.98412
NCT00129259|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|2013-06-21||2017-04-11|2005-08-09|2005-08-11|Estimate|2013-09-11|2013-09-16|Estimate||||2017-04-11|2017-05-22|Actual|September 2005||2005-09-30|April 2017|2017-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|AbATE|Intent-to-treat|Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes|Phase II Multiple-Dose Treatment of New Onset Type 1 Diabetes Mellitus With Anti-CD3 mAb|Completed||Phase 2|83|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from Division of Allergy, Immunology, and Transplantation (DAIT)-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.|2018-06-01 04:49:54.464433|2018-06-01 04:49:54.464433
NCT00129246|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|2013-01-02||2013-01-02|2005-08-09|2005-08-11|Estimate|2013-01-02|2013-02-05|Estimate||||2013-01-02|2013-02-05|Estimate|December 2004||2004-12-31|January 2013|2013-01-31|December 2005|Actual|2005-12-31|||||Interventional|||Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain|Naltrexone & Bupropion to Stop Smoking With Less Weight Gain|Completed||Phase 1/Phase 2|40|Actual|Yale University||2|||f||||||||||||||2018-06-01 04:49:54.986783|2018-06-01 04:49:54.986783
NCT00129233|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2013-04-29|2005-08-10|2005-08-11|Estimate|||||||2013-04-29|2013-05-01|Estimate|October 2004||2004-10-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|July 2010|Actual|2010-07-31||Interventional|||Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance|The Novel Antihypertensive Goal Of hYpertension With diAbetes ― Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study|Completed||Phase 4|1150|Actual|Nagoya University||2|||f||||t||||||||||2018-06-01 04:49:55.238558|2018-06-01 04:49:55.238558
NCT00129220|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2010-01-21||2010-12-10|2005-08-08|2005-08-11|Estimate|2010-01-21|2010-02-15|Estimate||||2010-12-10|2010-12-28|Estimate|July 2005||2005-07-31|December 2010|2010-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder|Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder|Completed||Phase 3|224|Actual|Eli Lilly and Company|Identified errors were corrected.|3|||f||||||||||||||2018-06-01 04:49:55.36025|2018-06-01 04:49:55.36025
NCT00128687|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2014-02-07|2005-08-08|2005-08-10|Estimate|||||||2014-02-07|2014-02-11|Estimate|April 2003||2003-04-30|February 2014|2014-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Improving Coronary Prevention in a County Health System|Improving Coronary Prevention in a County Health System|Completed||N/A|419|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 04:50:06.936642|2018-06-01 04:50:06.936642
NCT00129194|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-12-30|2005-08-09|2005-08-11|Estimate|||||||2007-12-30|2008-01-04|Estimate|August 2005||2005-08-31|December 2007|2007-12-31||||June 2007|Actual|2007-06-30||Interventional|||Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens|A Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults Who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART)|Completed||Phase 1|40|Anticipated|Koronis Pharmaceuticals.|||||f||||||||||||||2018-06-01 04:49:56.137416|2018-06-01 04:49:56.137416
NCT00129181|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2009-08-27|2005-08-09|2005-08-11|Estimate|||||||2009-08-27|2009-08-28|Estimate|January 2005||2005-01-31|August 2009|2009-08-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease|A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease|Completed||N/A|30|Actual|Institute for Neurodegenerative Disorders|||||f||||f||||||||||2018-06-01 04:49:56.281979|2018-06-01 04:49:56.281979
NCT00129168|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2008-03-28|2005-08-09|2005-08-11|Estimate|||||||2008-03-28|2008-04-01|Estimate|August 2005||2005-08-31|March 2008|2008-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)|An Open-Label, Phase I/II, Multicenter Dose Escalation Study of Zosuquidar, Daunorubicin, and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|100|Anticipated|Kanisa Pharmaceuticals|||||||||||||||||||2018-06-01 04:49:56.361033|2018-06-01 04:49:56.361033
NCT00129155|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-10-03|2005-08-10|2005-08-11|Estimate|||||||2007-10-03|2007-10-04|Estimate|February 2005||2005-02-28|October 2007|2007-10-31||||||||Interventional|||MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies|Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies|Unknown status|Recruiting|Phase 2|30|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:49:56.413926|2018-06-01 04:49:56.413926
NCT00129142|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2013-11-13|2005-08-09|2005-08-11|Estimate|||||||2013-11-13|2013-11-15|Estimate|October 2003||2003-10-31|November 2013|2013-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy|A Randomized, Double Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy|Completed||Phase 3|1200||GTx|||||f||||||||||||||2018-06-01 04:49:56.499204|2018-06-01 04:49:56.499204
NCT00129129|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2012-06-15||2016-09-22|2005-08-10|2005-08-11|Estimate|2013-12-05|2013-12-30|Estimate||||2016-09-22|2016-10-20|Estimate|August 2004||2004-08-31|September 2016|2016-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine|Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 Years|Completed||Phase 2|756|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:49:56.829792|2018-06-01 04:49:56.829792
NCT00129116|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|2012-06-15||2016-10-21|2005-08-10|2005-08-11|Estimate|2012-06-15|2012-07-23|Estimate||||2016-10-21|2016-12-02|Estimate|March 2003||2003-03-31|October 2016|2016-10-31|October 2004|Actual|2004-10-31|December 2003|Actual|2003-12-31||Interventional|||3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age|A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Three Different Formulations of GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups C and Y- Conjugate Vaccine and One Formulation of GSK Biologicals' Haemophilus Influenzae Type B-meningococcal Serogroup C Conjugate Vaccine Each Given Concomitantly With InfanrixTM Penta, Versus MeningitecTM, Given Concomitantly With InfanrixTM Hexa in Infants According to a 2-3-4 Month Schedule|Completed||Phase 2|388|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:49:59.60533|2018-06-01 04:49:59.60533
NCT00129090|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2015-09-08|2005-08-10|2005-08-11|Estimate|||||||2015-09-08|2015-09-09|Estimate|March 2003||2003-03-31|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|October 2014|Actual|2014-10-31||Interventional|||Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma|A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL|Unknown status|Active, not recruiting|Phase 3|450|Actual|German High-Grade Non-Hodgkin's Lymphoma Study Group||1|||f||||t||||||||||2018-06-01 04:50:01.792213|2018-06-01 04:50:01.792213
NCT00129077|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-07-09|2005-08-09|2005-08-11|Estimate|||||||2007-07-09|2007-07-10|Estimate|March 2004||2004-03-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?|Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?|Completed||N/A|207|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||t||||||||||2018-06-01 04:50:01.853838|2018-06-01 04:50:01.853838
NCT00129064|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-04-23|2005-08-09|2005-08-11|Estimate|||||||2007-04-23|2007-04-24|Estimate|November 2005||2005-11-30|April 2007|2007-04-30|March 2007||2007-03-31|||||Interventional|||Improving the Outpatient Referral Process With Electronic Communications|Improving the Outpatient Referral Process With Electronic Communications|Completed||N/A|200||Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 04:50:01.912819|2018-06-01 04:50:01.912819
NCT00129051|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2010-02-08|2005-08-09|2005-08-11|Estimate|||||||2010-02-08|2010-02-09|Estimate|August 2001||2001-08-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Helical Tomotherapy as a Radiotherapy Technique for Treating Pelvic and Abdominal Metastases|Helical Tomotherapy as a Radiotherapy Technique for Treating Pelvic and Abdominal Metastases|Completed||Phase 1|20||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:50:01.969659|2018-06-01 04:50:01.969659
NCT00128297|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2009-09-25|2005-08-08|2005-08-09|Estimate|||||||2009-09-25|2009-09-28|Estimate|January 2001||2001-01-31|September 2009|2009-09-30|December 2002||2002-12-31|||||Interventional|||Pamidronate Administration in Breast Cancer Patients With Bone Metastases|Randomized, Multicentric Phase IV Clinical Trial for the Administration of Pamidronate in Breast Cancer Patients With Bone Metastases|Completed||Phase 4|120||Spanish Breast Cancer Research Group|||||f||||f||||||||||2018-06-01 04:50:15.168984|2018-06-01 04:50:15.168984
NCT00129038|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-10|||2013-10-28|2005-08-10|2005-08-11|Estimate|||||||2013-10-28|2013-10-29|Estimate|April 2004||2004-04-30|October 2013|2013-10-31||||January 2007|Actual|2007-01-31||Interventional|||Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients|A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation.|Completed||Phase 4|11|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 04:50:02.02272|2018-06-01 04:50:02.02272
NCT00129025|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2011-10-06|2005-08-09|2005-08-11|Estimate|||||||2011-10-06|2011-10-10|Estimate|October 2004||2004-10-31|October 2011|2011-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer|A Phase I/II Study of Escalated-Dose Short-Course Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer|Completed||Phase 1/Phase 2|35|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:50:02.10357|2018-06-01 04:50:02.10357
NCT00129012|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2016-02-24|2005-08-09|2005-08-11|Estimate|||||||2016-02-24|2016-02-25|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer|Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer: A Feasibility Study|Completed||Phase 1|30|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:50:02.161912|2018-06-01 04:50:02.161912
NCT00128999|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2010-02-08|2005-08-10|2005-08-11|Estimate|||||||2010-02-08|2010-02-09|Estimate|September 2003||2003-09-30|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Study Using Induction Chemotherapy and Intensity-Modulated Radiation Therapy Guided by Combined CT and PET Imaging for Patients With Non-Small Cell Lung Cancer|A Phase I/II Dose Escalation Study Using Induction Chemotherapy and Intensity-Modulated Radiation Therapy Guided by Combined CT and PET Imaging for Patients With Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|5||AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:50:02.215791|2018-06-01 04:50:02.215791
NCT00128986|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2016-04-05|2005-08-09|2005-08-11|Estimate|||||||2016-04-05|2016-04-06|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of Tomotherapy in Patients With Benign Brain Tumour|A Phase I Study of Tomotherapy in Patients With Benign Brain Tumour|Completed||Phase 1|49|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:50:02.264349|2018-06-01 04:50:02.264349
NCT00128973|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2018-04-24|2005-08-09|2005-08-10|Estimate|||||||2018-04-24|2018-04-25|Actual|August 8, 2005||2005-08-08|April 5, 2018|2018-04-05||||||||Observational|||Evaluation of Patients With Immune Function Abnormalities|Screening and Baseline Assessment of Patients With Abnormalities of Immune Function|Recruiting|||2400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:50:02.314084|2018-06-01 04:50:02.314084
NCT00128960|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2018-05-17|2005-08-09|2005-08-10|Estimate|||||||2018-05-17|2018-05-18|Actual|August 8, 2005||2005-08-08|November 27, 2017|2017-11-27||||||||Observational|||Quality of Life in Patients Who Have Undergone Stem Cell Transplant|Prospective Assessment of Functional Status, Psychosocial Adjustment, Health Related Quality of Life and the Symptom Experience in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation|Completed|||173|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:50:02.517149|2018-06-01 04:50:02.517149
NCT00128947|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2008-03-03|2005-08-09|2005-08-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2005||2005-07-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Pharmacokinetics of Mycophenolate Mofetil in Healthy Volunteers|Pharmacokinetics of Mycophenolic Acid and Mycophenolate 7-O-Phenolic Glucuronide in Healthy Subjects With or Without Two Common Genetic Polymorphisms in the Promoter Region of Uridine Diphosphate Glucuronosyltransferase 1A9|Completed||Phase 1|130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:50:02.572522|2018-06-01 04:50:02.572522
NCT00128934|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2007-12-18|2005-08-08|2005-08-10|Estimate|||||||2007-12-18|2007-12-27|Estimate|August 2005||2005-08-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of a Combination of Levonorgestrel and Ethinyl Estradiol in a Continuous Daily Regimen in Subjects With Premenstrual Dysphoric Disorder|Completed||Phase 3|744|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:50:02.661034|2018-06-01 04:50:02.661034
NCT00128921|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2011-04-15||2012-04-25|2005-08-09|2005-08-10|Estimate|2012-04-25|2012-04-26|Estimate||||2012-04-25|2012-04-26|Estimate|April 2006||2006-04-30|April 2012|2012-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma|A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 2|18|Actual|University of Arkansas|Early termination due to difficulty in accruing participants.|3||study terminated due to low accrual|f||||t||||||||||2018-06-01 04:50:02.882124|2018-06-01 04:50:02.882124
NCT00128908|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2009-09-14|2005-08-08|2005-08-10|Estimate|||||||2009-09-14|2009-09-15|Estimate|September 2005||2005-09-30|September 2009|2009-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients|Sequential HAART in Treatment Resistant HIV-1 Infected Patients|Terminated||Phase 4|3|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||Did not recruit|f||||f||||||||||2018-06-01 04:50:03.238727|2018-06-01 04:50:03.238727
NCT00128895|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2014-12-31|2005-08-09|2005-08-10|Estimate|||||||2014-12-31|2015-01-01|Estimate|June 2003||2003-06-30|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis|Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach|Unknown status|Active, not recruiting|Phase 4|180|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 04:50:03.33392|2018-06-01 04:50:03.33392
NCT00128882|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2009-02-02|2005-08-08|2005-08-10|Estimate|||||||2009-02-02|2009-02-03|Estimate|November 2004||2004-11-30|February 2009|2009-02-28|December 2008|Actual|2008-12-31|January 2008|Actual|2008-01-31||Interventional|||Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D|Treatment of Idiopathic Thrombocytopenic Purpura in Children With Subcutaneously Administered Anti-D|Completed||Phase 2|45|Actual|University of Aarhus|||||f||||t||||||||||2018-06-01 04:50:03.453041|2018-06-01 04:50:03.453041
NCT00128869|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2008-05-08|2005-08-09|2005-08-10|Estimate|||||||2008-05-08|2008-05-13|Estimate|May 2005||2005-05-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Comparison of the Effectiveness of Mobilization and Manipulation of the Thoracic Spine in Patients With Mechanical Neck Pain|Comparison of the Effectiveness of Mobilization and Manipulation of the Thoracic Spine in Patients With Mechanical Neck Pain: A Randomized Clinical Trial|Completed||Phase 1|96|Anticipated|Newton-Wellesley Hospital|||||f||||||||||||||2018-06-01 04:50:03.550875|2018-06-01 04:50:03.550875
NCT00128856|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2018-03-15|2005-08-09|2005-08-10|Estimate|||||||2018-03-15|2018-03-19|Actual|March 2003|Actual|2003-03-31|March 2018|2018-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients|Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer|Completed||Phase 2|46|Actual|Spanish Breast Cancer Research Group||1|||f||||||||||||||2018-06-01 04:50:03.629323|2018-06-01 04:50:03.629323
NCT00128843|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2018-03-15|2005-08-09|2005-08-10|Estimate|||||||2018-03-15|2018-03-19|Actual|August 2001|Actual|2001-08-31|March 2018|2018-03-31|October 2014|Actual|2014-10-31|July 2005|Actual|2005-07-31||Interventional|||Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients|Phase II Randomized, Multicenter, Crossover Clinical Trial for Administration of Exemestane vs. Anastrozole as First Line Treatment for Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer|Completed||Phase 2|103|Actual|Spanish Breast Cancer Research Group||2|||f||||f||||||||||2018-06-01 04:50:03.721757|2018-06-01 04:50:03.721757
NCT00128830|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2013-02-27||2013-06-10|2005-08-08|2005-08-10|Estimate|2013-02-27|2013-04-09|Estimate||||2013-06-10|2013-06-20|Estimate|June 2005||2005-06-30|June 2013|2013-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study|An Open-Label Trial With TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks|Completed||Phase 2|211|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||f||||||||||2018-06-01 04:50:03.839373|2018-06-01 04:50:03.839373
NCT00128817|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2013-01-21|2005-08-09|2005-08-10|Estimate|||||||2013-01-21|2013-01-23|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers|Phase III Randomized Clinical Trial to Compare Results of Concurrent Chemo-radiation With Surgery and Postoperative Radiotherapy/Chemoradiotherapy in Advanced Laryngeal and Hypopharyngeal Cancers|Terminated||Phase 3|900|Anticipated|Tata Memorial Hospital||2||Slow Accrual|f||||t||||||||||2018-06-01 04:50:04.362284|2018-06-01 04:50:04.362284
NCT00128804|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2005-08-26|2005-08-09|2005-08-10|Estimate|||||||2005-08-26|2005-08-29|Estimate|July 2004||2004-07-31|August 2005|2005-08-31|October 2004||2004-10-31|||||Interventional|||The STOVITA Study - Bioefficacy of Beta-Carotene in Oil and in a Mixed Diet in Ileostomy Patients|Bioefficacy and Bioavailability of Beta-Carotene in Oil and in a Mixed Diet in Ileostomy Patients Measuring Using Specifically 13C-Labelled Beta-Carotene and Retinol|Completed||N/A|18||Radboud University|||||f||||||||||||||2018-06-01 04:50:04.470059|2018-06-01 04:50:04.470059
NCT00128791|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-05-24|2005-08-09|2005-08-10|Estimate|||||||2007-05-24|2007-05-25|Estimate|January 2003||2003-01-31|May 2007|2007-05-31|April 2005||2005-04-30|||||Interventional|||Nitroprusside for Prevention of no-Reflow in Primary Angioplasty|Intracoronary Nitroprusside for the Prevention of the No-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. A Randomized, Double Blind, Placebo-Controlled Clinical Trial|Terminated||Phase 4|100||Soroka University Medical Center|||||f||||||||||||||2018-06-01 04:50:04.534154|2018-06-01 04:50:04.534154
NCT00128778|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-09-04|2005-08-09|2005-08-10|Estimate|||||||2007-09-04|2007-09-05|Estimate|October 2002||2002-10-31|September 2007|2007-09-30|December 2006||2006-12-31|||||Interventional|||Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients|Phase IV.III Clinical Trial to Evaluate Maintenance Treatment With Caelyx vs. Observation After Administration of Induction Chemotherapy in Metastatic Breast Cancer Patients|Completed||Phase 4|154|Anticipated|Spanish Breast Cancer Research Group|||||f||||||||||||||2018-06-01 04:50:04.667717|2018-06-01 04:50:04.667717
NCT00128765|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2011-11-21|2005-08-09|2005-08-10|Estimate|||||||2011-11-21|2011-11-22|Estimate|January 2005||2005-01-31|November 2011|2011-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Costs and Effects of Three Modes for Disease Management of Chronic Obstructive Pulmonary Disease in General Practice|Costs and Effects of Three Modes for Disease Management of Chronic Obstructive Pulmonary Disease (COPD) in General Practice. A Randomized Controlled Trial Comparing Regular Practice Nurse Review, Self-management Education and Usual Care|Completed||N/A|165|Actual|Radboud University||3|||f||||t||||||||||2018-06-01 04:50:04.821809|2018-06-01 04:50:04.821809
NCT00128752|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2005-08-26|2005-08-09|2005-08-10|Estimate|||||||2005-08-26|2005-08-29|Estimate|March 2003||2003-03-31|August 2005|2005-08-31|October 2003||2003-10-31|||||Interventional|||The CARO Study - Bioefficacy of Beta-Carotene in Oil and in a Mixed Diet in Healthy Subjects|Bioefficacy and Bioavailability of Beta-Carotene in Oil and in a Mixed Diet in Healthy Subjects Measured Using Specifically 13C-Labelled Beta-Carotene and Retinol|Completed||N/A|24||Radboud University|||||f||||||||||||||2018-06-01 04:50:04.903931|2018-06-01 04:50:04.903931
NCT00128739|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2005-08-26|2005-08-09|2005-08-10|Estimate|||||||2005-08-26|2005-08-29|Estimate|January 2001||2001-01-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Treatment of Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide in Patients Following Peripheral Blood Stem Cell Transplantation|A Phase 3 Study to Evaluate the Place of Budesonide in the Treatment of GVHD|Completed||Phase 3|24||Rafa Laboratories|||||f||||||||||||||2018-06-01 04:50:05.016346|2018-06-01 04:50:05.016346
NCT00128726|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-12-20|2005-08-09|2005-08-10|Estimate|||||||2012-12-20|2012-12-21|Estimate|June 2001||2001-06-30|December 2012|2012-12-31|August 2006|Actual|2006-08-31|||||Observational|||The Effects of Continuous Administration of a Monophasic Oral Contraceptive on Bleeding Days and Endometrial and Ovarian Function|The Effects of Continuous Administration of a Monophasic Oral Contraceptive on Bleeding Days and Endometrial and Ovarian Function|Completed|||62|Actual|Milton S. Hershey Medical Center|||||f||||f||||||Samples With DNA|"~     whole blood, urines, tissue~   "|||2018-06-01 04:50:05.178522|2018-06-01 04:50:05.178522
NCT00128713|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2009-01-30||2015-10-05|2005-08-08|2005-08-10|Estimate|2009-05-29|2009-07-16|Estimate||||2015-10-05|2015-10-28|Estimate|July 2004||2004-07-31|August 2013|2013-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|PLADO||Optimal Platelet Dose Strategy for Management of Thrombocytopenia|Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)|Completed||Phase 3|1351|Actual|New England Research Institutes||3|||f||||t||||||||||2018-06-01 04:50:05.335576|2018-06-01 04:50:05.335576
NCT00128700|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-09-20|2005-08-08|2005-08-10|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2005||2005-06-30|September 2012|2012-09-30||||November 2007|Actual|2007-11-30||Interventional|||Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Study on Concomitant and Adjuvant Temozolomide and Radiotherapy With or Without PTK787/ZK222584 in Newly Diagnosed GBM|Completed||Phase 1/Phase 2|20|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:50:06.841209|2018-06-01 04:50:06.841209
NCT00128661|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2011-12-15||2012-05-24|2005-08-08|2005-08-10|Estimate|2012-04-05|2012-05-02|Estimate||||2012-05-24|2012-06-01|Estimate|June 2004||2004-06-30|May 2012|2012-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants|A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.|Completed||Phase 3|7466|Actual|GlaxoSmithKline|"The following analysis occurence of histopathologically confirmed CIN2+ cases associated with HPV16 or HPV18 infection was not performed, in accordance with the Statistical Analysis Plan submitted to the FDA."|2|||f||||||||||||||2018-06-01 04:50:07.030552|2018-06-01 04:50:07.030552
NCT00128635|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2016-02-17|2005-08-08|2005-08-10|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2005||2005-10-31|May 2007|2007-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse|Completed||Phase 1|22|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||||||||||||2018-06-01 04:50:10.191379|2018-06-01 04:50:10.191379
NCT00128622|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-11-08|2005-08-08|2005-08-10|Estimate|||||||2012-11-08|2012-11-12|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|May 2009|Actual|2009-05-31|March 2007|Actual|2007-03-31||Interventional|||Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer|A Phase I Study of Regulatory T Cell Depletion With Denileukin Diftitox Followed by Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox-Tricom in Patients With Advanced or Metastatic Malignancies Expressing CEA|Completed||Phase 1|24|Actual|Duke University||1|||f||||||||||||||2018-06-01 04:50:10.255845|2018-06-01 04:50:10.255845
NCT00128596|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2017-04-25|2005-08-08|2005-08-10|Estimate|||||||2017-04-25|2017-04-27|Actual|June 2004||2004-06-30|January 2006|2006-01-31||||December 2005|Actual|2005-12-31||Interventional|||Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery|A Phase II Study of Trisenox (Arsenic Trioxide) in the Treatment of Unresectable Liver Cancer|Completed||Phase 2|25|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 04:50:10.422203|2018-06-01 04:50:10.422203
NCT00128583|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2013-12-18|2005-08-08|2005-08-10|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2005||2005-07-31|September 2005|2005-09-30||||||||Interventional|||Vaccine Therapy in Treating Patients With Malignant Melanoma|Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:50:10.490589|2018-06-01 04:50:10.490589
NCT00128570|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2013-09-16|2005-08-08|2005-08-10|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2006||2006-04-30|June 2009|2009-06-30|March 2011|Actual|2011-03-31|February 2010|Actual|2010-02-28||Interventional|||An Individualized Internet-Based Health Behavior Program or a Standard Internet-Based Health Behavior Program in Preventing Cancer and Improving Physical Activity and Nutrition in Participants Who Are Physically Inactive With a Higher Body Mass Index|Cancer Prevention Mastery Model Internet Intervention|Completed||N/A|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:50:10.570681|2018-06-01 04:50:10.570681
NCT00128557|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2007-04-09|2005-08-09|2005-08-10|Estimate|||||||2007-04-09|2007-04-10|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh|A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh|Terminated||Phase 3|25000||Johns Hopkins Bloomberg School of Public Health||||Study terminated based on DSMB recommendation in December 2006|f||||t||||||||||2018-06-01 04:50:10.630252|2018-06-01 04:50:10.630252
NCT00128544|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2017-06-15|2005-08-08|2005-08-10|Estimate|||||||2017-06-15|2017-06-16|Actual|May 2005||2005-05-31|June 2017|2017-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B|A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B|Completed||Phase 2|130||Novartis|||||||||||||||||||2018-06-01 04:50:10.699788|2018-06-01 04:50:10.699788
NCT00128531|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2007-11-12|2005-08-08|2005-08-10|Estimate|||||||2007-11-12|2007-11-14|Estimate|September 2005||2005-09-30|November 2007|2007-11-30|November 2007|Actual|2007-11-30|||||Interventional|||Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer|Efficacy and Safety of a New Leuprolide Acetate 3.75 mg Depot Formulation, GP-Pharm S.A., When Given as Palliative Treatment to Prostate Cancer Patients|Completed||Phase 3|120||GP-Pharm|||||f||||||||||||||2018-06-01 04:50:10.765779|2018-06-01 04:50:10.765779
NCT00128518|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2011-12-29|2005-08-09|2005-08-10|Estimate|||||||2011-12-29|2012-01-02|Estimate|October 2004||2004-10-31|December 2011|2011-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs|IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs|Completed||Phase 4|139|Actual|Hospices Civils de Lyon||4|||f||||||||||||||2018-06-01 04:50:10.864104|2018-06-01 04:50:10.864104
NCT00128505|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-02-14|2005-08-08|2005-08-10|Estimate|||||||2012-02-14|2012-02-15|Estimate|August 2005||2005-08-31|February 2012|2012-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression|An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features|Completed||Phase 3|104|Actual|Corcept Therapeutics||1|||f||||f||||||||||2018-06-01 04:50:10.9644|2018-06-01 04:50:10.9644
NCT00128492|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2010-06-03||2011-05-17|2005-08-08|2005-08-10|Estimate|2011-02-16|2011-03-11|Estimate||||2011-05-17|2011-05-19|Estimate|August 2005||2005-08-31|May 2011|2011-05-31|January 2009|Actual|2009-01-31|November 2008|Actual|2008-11-30||Interventional|AIR-CF3||Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)|A Phase 3, Open-label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3)|Completed||Phase 3|274|Actual|Gilead Sciences|Descriptive statistics for all participants receiving 1 or more doses of AZLI were summarized for the safety, microbiology, and efficacy endpoints. No formal hypothesis tests were planned. Rates of AEs and SAEs are not adjusted for time on study.||||f||||t||||||||||2018-06-01 04:50:11.159139|2018-06-01 04:50:11.159139
NCT00123357|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2015-04-06|2005-07-18|2005-07-22|Estimate|||||||2015-04-06|2015-04-07|Estimate||||January 2005|2005-01-31|March 2003|Actual|2003-03-31|||||Observational|||Measuring Health Related Quality of Life in Veterans With Stroke|Measuring Health Related Quality of Life in Veterans With Stroke|Completed|||800|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:51:46.857059|2018-06-01 04:51:46.857059
NCT00128479|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-02-14|2005-08-08|2005-08-10|Estimate|||||||2012-02-14|2012-02-15|Estimate|September 2004||2004-09-30|February 2012|2012-02-29|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of CORLUX™ (Mifepristone) Plus an Antidepressant vs. Placebo Plus an Antidepressant in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features (PMD)|Completed||Phase 3|443|Actual|Corcept Therapeutics||4|||f||||f||||||||||2018-06-01 04:50:12.7751|2018-06-01 04:50:12.7751
NCT00128466|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2009-02-24|2005-08-09|2005-08-10|Estimate|||||||2009-02-24|2009-02-26|Estimate|August 2004||2004-08-31|February 2009|2009-02-28|February 2007|Actual|2007-02-28|||||Interventional|||Treatment and Diagnosis of Plague|Safety and Efficacy of Gentamicin Versus Streptomycin for the Treatment of Naturally Occurring Human Plague and Evaluation of Rapid Diagnostic Test Kits for Yersinia Pestis|Completed||Phase 2/Phase 3|114|Actual|Centers for Disease Control and Prevention|||||||||t||||||||||2018-06-01 04:50:13.044725|2018-06-01 04:50:13.044725
NCT00128453|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-06-06|2005-08-08|2005-08-10|Estimate|||||||2012-06-06|2012-06-07|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The ICAP Trial: Investigation on Colchicine for Acute Pericarditis|Completed||Phase 3|240|Actual|Azienda Sanitaria Locale 3, Torino||2|||f||||||||||||||2018-06-01 04:50:13.192604|2018-06-01 04:50:13.192604
NCT00128440|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-09|||2013-10-28|2005-08-09|2005-08-10|Estimate|||||||2013-10-28|2013-10-29|Estimate|August 2005||2005-08-31|October 2013|2013-10-31||||September 2006|Actual|2006-09-30||Interventional|||High Dose Trial in COPD|A Randomized, Multiple-dose, Double-Blind, Crossover Study to Compare the Efficacy and Safety of 200 μg and 400 μg of BEA 2180 BR to Tiotropium 5 μg and Placebo When Each is Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|78|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:50:13.2934|2018-06-01 04:50:13.2934
NCT00128427|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2010-06-13|2005-08-08|2005-08-10|Estimate|||||||2010-06-13|2010-06-15|Estimate|June 2005||2005-06-30|June 2010|2010-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study of Colchicine to Prevent the Postpericardiotomy Syndrome|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The COPPS Trial: COlchicine for the Prevention of Postpericardiotomy Syndrome|Completed||Phase 3|360|Anticipated|Azienda Sanitaria Locale 3, Torino|||||f||||t||||||||||2018-06-01 04:50:13.389113|2018-06-01 04:50:13.389113
NCT00128414|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2011-02-14|2005-08-08|2005-08-10|Estimate|||||||2011-02-14|2011-02-16|Estimate|August 2005||2005-08-31|February 2011|2011-02-28|October 2010|Actual|2010-10-31|April 2009|Actual|2009-04-30||Interventional|CORP||Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)|Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP Trial: COlchicine for Recurrent Pericarditis|Completed||Phase 3|120|Anticipated|Azienda Sanitaria Locale 3, Torino||2|||f||||t||||||||||2018-06-01 04:50:13.475123|2018-06-01 04:50:13.475123
NCT00128401|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2013-07-01||2014-04-17|2005-08-08|2005-08-09|Estimate|2014-04-17|2014-05-20|Estimate||||2014-04-17|2014-05-20|Estimate|August 2005||2005-08-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional||The baseline mean and SD for CGI outcome measure was captured for 42 subjects only. The baseline mean and SD for LSAS outcome measure was captured for 40 subjects. Only 39 subjects were randomized.|Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia|Effect of D-Cycloserine on Treatment of Social Phobia|Completed||Phase 2|48|Actual|National Institutes of Health Clinical Center (CC)|The baseline mean and SD for CGI outcome measure was captured for 42 subjects only. The baseline mean and SD for LSAS outcome measure was captured for 40 subjects.|2|||f||||||||||||||2018-06-01 04:50:13.620319|2018-06-01 04:50:13.620319
NCT00128388|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2013-06-26|2005-08-05|2005-08-09|Estimate|||||||2013-06-26|2013-06-27|Estimate|February 2000||2000-02-29|June 2013|2013-06-30|July 2005|Actual|2005-07-31|January 2005|Actual|2005-01-31||Interventional|||Psychodynamic Therapy for Treating Panic Disorder|Randomized Controlled Trial of Psychodynamic Psychotherapy vs. Applied Relaxation for Panic Disorder|Completed||Phase 2/Phase 3|49|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-06-01 04:50:14.247588|2018-06-01 04:50:14.247588
NCT00128375|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2007-12-12|2005-08-08|2005-08-09|Estimate|||||||2007-12-12|2007-12-17|Estimate|March 2005||2005-03-31|December 2007|2007-12-31|April 2008||2008-04-30|||||Interventional|||Financial Incentives for Smoking Cessation|Financial Incentives for Smoking Cessation|Completed||N/A|878||University of Pennsylvania|||||f||||||||||||||2018-06-01 04:50:14.459492|2018-06-01 04:50:14.459492
NCT00128362|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2014-06-23|2005-08-08|2005-08-09|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2005||2005-09-30|June 2014|2014-06-30||||December 2011|Actual|2011-12-31||Interventional|||Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer|Clinical Trial of Sentinel Node Biopsy Versus Axillary Sampling in Women With Clinically Node Negative Operable Breast Cancer|Terminated||Phase 2|478|Actual|Tata Memorial Hospital||1||"After initiation of study many studies reported an equivalence of SNB and ALND which led to~   widespread adoption of the former as standard procedure."|f||||||||||||||2018-06-01 04:50:14.563158|2018-06-01 04:50:14.563158
NCT00128336|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2016-05-12|2005-08-08|2005-08-09|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2004||2004-05-31|May 2016|2016-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||The Heat Study: 2 Year Lifestyle Intervention in Overweight Women to Encourage Weight Management|The Heat Study: A 2-year Lifestyle Intervention in Overweight Women to Determine Optimal Approaches for Successful Maintenance of Weight Loss|Completed||Phase 3|200|Actual|University of Otago||4|||f||||f||||||||||2018-06-01 04:50:14.73332|2018-06-01 04:50:14.73332
NCT00128323|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-07|||2008-02-07|2005-08-07|2005-08-09|Estimate|||||||2008-02-07|2008-02-11|Estimate|November 2002||2002-11-30|February 2008|2008-02-29|April 2005|Actual|2005-04-30|||||Interventional|||A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis|A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis|Completed||Phase 3|558||University of Malawi College of Medicine|||||f||||||||||||||2018-06-01 04:50:14.93475|2018-06-01 04:50:14.93475
NCT00128310|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2007-02-06|2005-08-08|2005-08-09|Estimate|||||||2007-02-06|2007-02-07|Estimate|January 2001||2001-01-31|February 2007|2007-02-28|October 2005||2005-10-31|||||Interventional|||Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients|Randomized Phase III Trial Comparing Vinorelbine vs. Gemcitabine Plus Vinorelbine in Patients With Advanced Breast Cancer, Previously Treated With Anthracyclines and Taxanes|Completed||Phase 3|252||Spanish Breast Cancer Research Group|||||f||||||||||||||2018-06-01 04:50:15.059086|2018-06-01 04:50:15.059086
NCT00128284|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2008-05-21|2005-08-08|2005-08-09|Estimate|||||||2008-05-21|2008-05-22|Estimate|February 2005||2005-02-28|May 2008|2008-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|||A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time|A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time|Completed|||148|Actual|The SmartPill Corporation|||2||f||||f||||||||||2018-06-01 04:50:15.293669|2018-06-01 04:50:15.293669
NCT00128271|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2008-04-28|2005-08-08|2005-08-09|Estimate|||||||2008-04-28|2008-05-07|Estimate|August 2005||2005-08-31|August 2006|2006-08-31||||August 2006|Actual|2006-08-31||Interventional|||Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection|A Phase 1 Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients Chronically Infected With Hepatitis C Virus (HCV) Who Are Non-Responders or Relapsers After Treatment With Pegylated Interferon Plus Ribavirin|Completed||Phase 1|32||Peregrine Pharmaceuticals|||||f||||||||||||||2018-06-01 04:50:15.403237|2018-06-01 04:50:15.403237
NCT00128258|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2018-01-17|2005-08-08|2005-08-09|Estimate|||||||2018-01-17|2018-01-19|Actual|May 1, 2005|Actual|2005-05-01|January 2018|2018-01-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Autologous/Allogeneic Progenitor Stem Cell Therapy for Congestive Heart Failure|Phase 1 Study: Autologous/Allogeneic Bone Marrow Progenitor Cell Treatment for Heart Failure|Terminated||Phase 1|10|Actual|Amit, Patel N, M.D.||1||study no longer at pittsburgh|f||||t||||||||||2018-06-01 04:50:15.473453|2018-06-01 04:50:15.473453
NCT00128245|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2007-12-19|2005-08-05|2005-08-09|Estimate|||||||2007-12-19|2007-12-28|Estimate|September 2004||2004-09-30|December 2007|2007-12-31||||||||Interventional|||Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca|A 24-Week Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Evaluation of the Safety and Efficacy of 0.3% and 1% Pimecrolimus Ophthalmic Suspensions Used Twice Daily in Patients With Moderate to Severe Keratoconjunctivitis Sicca|Completed||N/A|440||Novartis|||||||||||||||||||2018-06-01 04:50:15.558454|2018-06-01 04:50:15.558454
NCT00128232|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-04-27|2005-08-08|2005-08-09|Estimate|||||||2012-04-27|2012-04-30|Estimate|December 2002||2002-12-31|April 2012|2012-04-30||||August 2004|Actual|2004-08-31||Interventional|||Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients|Safety and Efficacy of Octreotide LAR in Treatment Naïve Acromegalic Patients|Completed||Phase 3|100||Novartis|||||f||||||||||||||2018-06-01 04:50:15.742062|2018-06-01 04:50:15.742062
NCT00128219|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|2009-08-03||2015-01-15|2005-08-05|2005-08-09|Estimate|2010-07-01|2010-07-05|Estimate||||2015-01-15|2015-01-27|Estimate|July 2003||2003-07-31|August 2009|2009-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Prevention of GBS Colonization Via Immunity|A Phase II Randomized, Double-Blinded, Comparative Clinical Trial for a Group B Streptococcus Serotype III-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Acquisition of GBS Type III|Completed||Phase 2|667|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:50:15.912448|2018-06-01 04:50:15.912448
NCT00128206|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|2010-09-21||2013-05-09|2005-08-05|2005-08-09|Estimate|2010-11-05|2010-12-06|Estimate||||2013-05-09|2013-05-14|Estimate|November 2004||2004-11-30|May 2013|2013-05-31|September 2009|Actual|2009-09-30|October 2008|Actual|2008-10-31||Interventional|||Treatment of Latent TB Infection for Jailed Persons|Clinical Trial of Short Course Rifampin Versus INH for LTBI in Jail|Completed||Phase 3|364|Actual|University of California, San Francisco|Initial enrollment estimates were not met, from lower TB rates, increased deportation rates and fewer Jail personnel for LTBI testing. The complexity of treatment in the jail led to technical problems in the analytic plan.|2|||f||||t||||||||||2018-06-01 04:50:17.575543|2018-06-01 04:50:17.575543
NCT00128193|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|2010-09-30||2014-12-04|2005-08-05|2005-08-09|Estimate|2010-09-30|2010-11-01|Estimate||||2014-12-04|2014-12-24|Estimate|April 2002||2002-04-30|August 2010|2010-08-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Leprosy Skin Test Antigens Trial|Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region|Completed||Phase 2|260|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 04:50:18.120584|2018-06-01 04:50:18.120584
NCT00128180|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|2011-12-05||2014-12-05|2005-08-05|2005-08-09|Estimate|2012-07-09|2012-07-10|Estimate||||2014-12-05|2014-12-24|Estimate|January 2003||2003-01-31|December 2014|2014-12-31|October 2011|Actual|2011-10-31|December 2010|Actual|2010-12-31||Interventional|||Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Methylprednisolone as a Treatment for Presumed Hantavirus Cardiopulmonary Syndrome|Completed||Phase 2|66|Actual|University of New Mexico|While the study reached the target accrual of 60 confirmed cases, it was not powered to detect a difference in mortality. Higher disease severity in the placebo group at entry complicated both the efficacy and safety analyses.|2|||f||||t||||||||||2018-06-01 04:50:21.387119|2018-06-01 04:50:21.387119
NCT00128167|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2006-07-05|2005-08-05|2005-08-09|Estimate|||||||2006-07-05|2006-07-07|Estimate|October 2004||2004-10-31|July 2006|2006-07-31|December 2005||2005-12-31|||||Interventional|||Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6–59 Months of Age|A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6–59 Months of Age|Completed||Phase 3|8500||MedImmune LLC|||||||||||||||||||2018-06-01 04:50:22.401554|2018-06-01 04:50:22.401554
NCT00128154|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2006-08-17|2005-08-05|2005-08-09|Estimate|||||||2006-08-17|2006-08-18|Estimate|January 2004||2004-01-31|August 2006|2006-08-31|December 2005||2005-12-31|||||Interventional|||Chromium Picolinate for the Treatment of Metabolic Syndrome|A Double-Blind Randomized Controlled Clinical Trial of Chromium Picolinate on Clinical and Biochemical Features of the Metabolic Syndrome|Completed||N/A|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:50:22.767217|2018-06-01 04:50:22.767217
NCT00128141|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2008-02-04|2005-08-08|2005-08-09|Estimate|||||||2008-02-04|2008-02-05|Estimate|August 2003||2003-08-31|February 2008|2008-02-29|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effect of Tactile and Kinesthetic Stimulation on Very Low Birth Weight Preterm Infants|Effect of Maternal Tactile and Kinesthetic Stimulation on Length of Hospital Stay of Very Low Birth Weight Infants|Completed||N/A|104|Actual|National Bioethics Commission of Brazil||2|||f||||f||||||||||2018-06-01 04:50:22.843203|2018-06-01 04:50:22.843203
NCT00128128|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05||2015-04-27|2015-05-14|2005-08-05|2005-08-09|Estimate||||2015-04-27|2015-05-15|Estimate|2015-05-14|2015-06-04|Estimate|August 2005||2005-08-31|May 2015|2015-05-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Cranberry Juice for the Prevention of Recurrent Urinary Tract Infections|Cranberry and Prevention of UTI A Comprehensive Approach|Completed||Phase 2|176|Actual|National Center for Complementary and Integrative Health (NCCIH)||4|||f||||f||||||||||2018-06-01 04:50:22.922444|2018-06-01 04:50:22.922444
NCT00122057|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2011-05-31|2005-07-14|2005-07-21|Estimate|||||||2011-05-31|2011-06-01|Estimate|June 2005||2005-06-30|September 2006|2006-09-30|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Impact of Antibiotic Treatment on Outcome in Patients With Ventilator-Associated Tracheobronchitis||Completed||N/A|58|Actual|University Hospital, Lille|||||f||||||||||||||2018-06-01 04:52:11.568153|2018-06-01 04:52:11.568153
NCT00128115|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2016-01-19|2005-08-08|2005-08-09|Estimate|||||||2016-01-19|2016-01-20|Estimate|September 2005||2005-09-30|January 2016|2016-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)|Proprietary Information - Exploratory (Non-Confirmatory) Trial|Terminated||Phase 2|83|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:50:23.068852|2018-06-01 04:50:23.068852
NCT00128102|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2015-04-17|2005-08-05|2005-08-09|Estimate|||||||2015-04-17|2015-04-20|Estimate|June 2005||2005-06-30|April 2015|2015-04-30|November 2011|Actual|2011-11-30|July 2011|Actual|2011-07-31||Interventional|||Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy|Completed||Phase 3|662|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:50:23.170868|2018-06-01 04:50:23.170868
NCT00128089|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2005-12-20|2005-08-08|2005-08-09|Estimate|||||||2005-12-20|2005-12-21|Estimate|August 2005||2005-08-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Trial of New Dietary Treatment of Diabetes|Phase 1 Trial of A New Dietary Treatment of Obesity Related Type 2 Diabetes|Terminated||Phase 1|10||Manassas Internal Medicine|||||f||||||||||||||2018-06-01 04:50:23.289128|2018-06-01 04:50:23.289128
NCT00128076|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2016-05-26|2005-08-05|2005-08-09|Estimate|||||||2016-05-26|2016-05-27|Estimate|August 2006||2006-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|August 2014|Actual|2014-08-31||Interventional|||All-Arthroscopic Versus Mini-Open Repair of Small or Moderate Rotator Cuff Tears|All-Arthroscopic Versus Mini-Open Repair of Small or Moderate Rotator Cuff Tears|Completed||Phase 3|275|Actual|McMaster University||2|||f||||t||||||||||2018-06-01 04:50:23.44801|2018-06-01 04:50:23.44801
NCT00128063|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2007-04-23|2005-08-08|2005-08-09|Estimate|||||||2007-04-23|2007-04-24|Estimate|August 2005||2005-08-31|April 2007|2007-04-30|June 2006|Actual|2006-06-30|||||Interventional|||Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection|A Phase 1 & 2, Randomized Open-Label Study to Evaluate the Pharmacokinetics, Safety and Antiretroviral Activity of Succinylated Human Serum Albumin (Suc-HSA) in Treatment Naïve HIV-1 Infected Subjects|Completed||Phase 1/Phase 2|6||International Antiviral Therapy Evaluation Center|||||f||||t||||||||||2018-06-01 04:50:23.581101|2018-06-01 04:50:23.581101
NCT00128050|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2009-02-03|2005-08-08|2005-08-09|Estimate|||||||2009-02-03|2009-02-04|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PRE-SICH||Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH)|Efficacy and Safety of Factor VIIa (Eptacog Alfa) on Rebleeding After Surgery for Spontaneous Supratentorial Intracerebral Hemorrhage. A Randomized, Controlled, Open-Label, Investigator-Blinded Pilot Study|Completed||Phase 2|30|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-06-01 04:50:23.638116|2018-06-01 04:50:23.638116
NCT00128037|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2016-09-20|2005-08-08|2005-08-09|Estimate|||||||2016-09-20|2016-09-22|Estimate|May 1999||1999-05-31|September 2016|2016-09-30|February 2006||2006-02-28|||||Interventional|||Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806)|A Phase II Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors: Initial Report of Japan Clinical Oncology Group Trial (JCOG 9806)|Completed||Phase 2|75||Japan Clinical Oncology Group|||||f||||||||||||||2018-06-01 04:50:23.72936|2018-06-01 04:50:23.72936
NCT00128024|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2013-04-17|2005-08-08|2005-08-09|Estimate|||||||2013-04-17|2013-04-18|Estimate|February 2002||2002-02-28|April 2013|2013-04-30|February 2006|Actual|2006-02-28|February 2004|Actual|2004-02-29||Interventional|||Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients|Effects of Early Statin Treatment on Symptomatic Heart Failure and Ischemic Events After Acute Myocardial Infarction. The MUSASHI-AMI: A Multicenter Randomized Controlled Trial|Completed||Phase 4|460|Actual|Kumamoto University||2|||f||||||||||||||2018-06-01 04:50:23.93097|2018-06-01 04:50:23.93097
NCT00128011|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2006-11-08|2005-08-08|2005-08-09|Estimate|||||||2006-11-08|2006-11-10|Estimate|May 2005||2005-05-31|November 2006|2006-11-30|June 2005||2005-06-30|||||Interventional|||Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine|A Safety and Immunogenicity Study of a New Formulation of the Locally-Produced Bivalent Killed, Whole-Cell Oral Cholera Vaccine in Vietnamese Subjects|Completed||Phase 2|150||International Vaccine Institute|||||f||||||||||||||2018-06-01 04:50:24.085673|2018-06-01 04:50:24.085673
NCT00127998|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2006-08-15|2005-08-08|2005-08-09|Estimate|||||||2006-08-15|2006-08-16|Estimate|July 2005||2005-07-31|August 2006|2006-08-31||||||||Interventional|||Antimalarial Drug Resistance in Mali|Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali|Completed||N/A|1011||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:50:24.289054|2018-06-01 04:50:24.289054
NCT00127985|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2008-05-12|2005-08-08|2005-08-09|Estimate|||||||2008-05-12|2008-05-13|Estimate|August 2005||2005-08-31|May 2008|2008-05-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|NAIF||6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome|The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome|Unknown status|Recruiting|Phase 4|240|Anticipated|Hospital Universitario Principe de Asturias||2|||f||||t||||||||||2018-06-01 04:50:24.414513|2018-06-01 04:50:24.414513
NCT00127972|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2007-04-27|2005-08-08|2005-08-09|Estimate|||||||2007-04-27|2007-04-30|Estimate|February 2004||2004-02-29|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||2NN & CHARM Long-Term Follow-up Study|A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients|Completed||Phase 4|763|Actual|International Antiviral Therapy Evaluation Center|||||f||||f||||||||||2018-06-01 04:50:24.543367|2018-06-01 04:50:24.543367
NCT00127959|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2007-04-23|2005-08-08|2005-08-09|Estimate|||||||2007-04-23|2007-04-24|Estimate|March 2004||2004-03-31|April 2007|2007-04-30|August 2006|Actual|2006-08-31|||||Interventional|||Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection|Virological and Clinical Anti-HBV Efficacy of Tenofovir and Emtricitabine in Antiretroviral Naïve Patients With HIV/HBV co-Infection|Completed||Phase 4|24||International Antiviral Therapy Evaluation Center|||||f||||f||||||||||2018-06-01 04:50:24.989422|2018-06-01 04:50:24.989422
NCT00127946|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2011-08-08|2005-08-08|2005-08-09|Estimate|||||||2011-08-08|2011-08-09|Estimate|November 2005||2005-11-30|August 2005|2005-08-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|AMNIOECHANGE||Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses|Randomized Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses|Unknown status|Active, not recruiting|Phase 3|140|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-06-01 04:50:25.200464|2018-06-01 04:50:25.200464
NCT00127933|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|2011-03-30||2011-07-13|2005-08-05|2005-08-09|Estimate|2011-07-13|2011-08-10|Estimate||||2011-07-13|2011-08-10|Estimate|August 2005||2005-08-31|July 2011|2011-07-31|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer|An Open-label Study of Xeloda Plus Taxotere on Treatment Response in Patients With HER2-neu-negative, and the Addition of Herceptin for HER2-neu-positive Breast Cancer|Completed||Phase 4|157|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:50:25.336778|2018-06-01 04:50:25.336778
NCT00127920|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2015-03-09|2005-08-05|2005-08-09|Estimate|||||||2015-03-09|2015-03-10|Estimate|August 2004||2004-08-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|August 2006|Actual|2006-08-31||Interventional|||Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients|A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer|Completed||Phase 2|20|Actual|Gynecologic Oncology Associates||1|||f||||f||||||||||2018-06-01 04:50:26.240028|2018-06-01 04:50:26.240028
NCT00127907|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2007-10-16|2005-08-05|2005-08-09|Estimate|||||||2007-10-16|2007-10-17|Estimate|May 2004||2004-05-31|October 2007|2007-10-31||||||||Interventional|||Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest|Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests|Completed||Phase 4|2416||Hospices Civils de Lyon|||||f||||||||||||||2018-06-01 04:50:26.440148|2018-06-01 04:50:26.440148
NCT00127881|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|||2012-07-24|2005-08-08|2005-08-09|Estimate|||||||2012-07-24|2012-07-26|Estimate|July 2005||2005-07-31|July 2012|2012-07-31||||February 2014|Anticipated|2014-02-28||Interventional|||Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome|Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy|Terminated||Phase 3|76|Actual|Emergent Product Development Seattle LLC||1||New sponsor, other treatments available|f||||t||||||||||2018-06-01 04:50:26.529038|2018-06-01 04:50:26.529038
NCT00127868|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2008-07-07|2005-08-08|2005-08-09|Estimate|||||||2008-07-07|2008-07-09|Estimate|March 2005||2005-03-31|May 2006|2006-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm)|A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capitis in Children|Completed||N/A|47|Actual|Chen, Catherine, M.D.||4|||f||||||||||||||2018-06-01 04:50:26.640199|2018-06-01 04:50:26.640199
NCT00127855|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-08|2012-06-15||2016-10-21|2005-08-08|2005-08-09|Estimate|2012-06-15|2012-07-23|Estimate||||2016-10-21|2016-12-02|Estimate|March 2003||2003-03-31|October 2016|2016-10-31|August 2004|Actual|2004-08-31|February 2004|Actual|2004-02-29||Interventional|||Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine|A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity (Including Immune Memory), Reactogenicity and Safety of Three Different Formulations of the GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups CY Conjugate Vaccine Given Concomitantly With Infanrix® Penta and Prevenar®, Versus ActHIB® and Meningitec® Given Concomitantly With Infanrix® Penta and Versus ActHIB® Given Concomitantly With Infanrix® Penta and Prevenar® in Infants According to a 2-4-6 Month Schedule.|Completed||Phase 2|409|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:50:26.809034|2018-06-01 04:50:26.809034
NCT00127842|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|2010-11-04||2014-03-24|2005-08-05|2005-08-09|Estimate|2014-03-24|2014-04-24|Estimate||||2014-03-24|2014-04-24|Estimate|August 2005||2005-08-31|March 2014|2014-03-31|September 2009|Actual|2009-09-30|August 2005|Actual|2005-08-31||Interventional|||REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)|Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel®|Completed||Phase 4|110|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:50:29.590834|2018-06-01 04:50:29.590834
NCT00127829|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2009-04-22|2005-08-05|2005-08-09|Estimate|||||||2009-04-22|2009-04-23|Estimate|July 2005||2005-07-31|April 2009|2009-04-30|January 2008|Actual|2008-01-31|||||Interventional|AGUS||Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic|A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA®) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic|Completed||Phase 1|66|Anticipated|AstraZeneca||1|||f||||||||||||||2018-06-01 04:50:30.028176|2018-06-01 04:50:30.028176
NCT00127816|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2016-03-14|2005-08-05|2005-08-09|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2005||2005-04-30|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy|Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy|Completed||N/A|40|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:50:30.115178|2018-06-01 04:50:30.115178
NCT00127803|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|2012-03-13||2012-09-07|2005-08-05|2005-08-09|Estimate|2012-04-19|2012-05-21|Estimate||||2012-09-07|2012-09-14|Estimate|July 2005||2005-07-31|September 2012|2012-09-30|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers|A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study of the Safety, Tolerability and Immunogenicity of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18-55 Years)|Completed||Phase 1|50|Actual|Sanofi||4|||f||||f||||||||||2018-06-01 04:50:30.232428|2018-06-01 04:50:30.232428
NCT00127790|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2012-06-12||2012-09-14|2005-08-04|2005-08-08|Estimate|2012-09-14|2012-10-17|Estimate||||2012-09-14|2012-10-17|Estimate|June 2005||2005-06-30|September 2012|2012-09-30|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Treatment of Insomnia Secondary to Chronic Pain|CBT for Co-Morbid Insomnia and Chronic Pain: Sleep, Pain and Immune Function Outcomes|Completed||N/A|28|Actual|University of Rochester|The foremost limitation of this pilot study is its small sample size, particularly for a four-arm design. Accordingly, a cautious approach to the interpretation of the findings is warranted.|4|||f||||f||||||||||2018-06-01 04:50:30.980145|2018-06-01 04:50:30.980145
NCT00127777|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2005-08-24|2005-08-04|2005-08-08|Estimate|||||||2005-08-24|2005-08-25|Estimate|July 2002||2002-07-31|August 2005|2005-08-31|December 2006||2006-12-31|||||Interventional|||Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)|Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection|Unknown status|Active, not recruiting|Phase 4|700||University Hospital, Saarland|||||f||||||||||||||2018-06-01 04:50:31.645257|2018-06-01 04:50:31.645257
NCT00127764|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2007-08-29|2005-08-04|2005-08-08|Estimate|||||||2007-08-29|2007-08-30|Estimate|January 2001||2001-01-31|August 2004|2004-08-31|April 2005||2005-04-30|||||Interventional|||European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus|European Randomised Placebo-Controlled Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus (Pempuls Trial)|Completed||Phase 2/Phase 3|60||University Medical Center Groningen|||||f||||||||||||||2018-06-01 04:50:31.720559|2018-06-01 04:50:31.720559
NCT00127751|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2005-08-24|2005-08-05|2005-08-08|Estimate|||||||2005-08-24|2005-08-25|Estimate|May 2000||2000-05-31|August 2005|2005-08-31|May 2003||2003-05-31|||||Interventional|||Heart Disease on the Mend|A Cardiovascular Disease Multifactor Risk Reduction Program for Medically Underserved High-Risk Patients|Completed||Phase 2|150||Stanford University|||||f||||||||||||||2018-06-01 04:50:31.813118|2018-06-01 04:50:31.813118
NCT00127738|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2007-01-08|2005-08-04|2005-08-08|Estimate|||||||2007-01-08|2007-01-11|Estimate|January 2005||2005-01-31|February 2006|2006-02-28|December 2006||2006-12-31|||||Interventional|||Renal Atherosclerotic Revascularization Evaluation: RAVE Study||Completed||N/A|240||Sunnybrook Health Sciences Centre|||||f||||||||||||||2018-06-01 04:50:31.933393|2018-06-01 04:50:31.933393
NCT00127725|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2005-11-14|2005-08-05|2005-08-08|Estimate|||||||2005-11-14|2005-11-15|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|August 2009||2009-08-31|||||Interventional|||Pulsed Electromagnetic Field (PEMF) Stimulation for Tibia Fractures|A Double Blind Randomised Controlled Trial of Pulsed Electromagnetic Field (PEMF) Stimulation in Acute Tibial Shaft Fractures|Unknown status|Recruiting|Phase 2|340||Sydney South West Area Health Service|||||f||||||||||||||2018-06-01 04:50:32.197556|2018-06-01 04:50:32.197556
NCT00127712|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|2010-03-02||2013-09-06|2005-08-04|2005-08-08|Estimate|2010-03-02|2010-03-24|Estimate||||2013-09-06|2013-09-18|Estimate|September 2004||2004-09-30|September 2013|2013-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery|Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery|Completed||Phase 4|130|Actual|Indiana University||2|||f||||t||||||||||2018-06-01 04:50:32.364596|2018-06-01 04:50:32.364596
NCT00127699|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2017-11-21|2005-08-05|2005-08-08|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2005||2005-08-31|November 2017|2017-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Triple Dye Plus Alcohol Versus Triple Dye Alone for Newborn Umbilical Cord Care|Triple Dye Plus Alcohol Versus Triple Dye Alone for Newborn Umbilical Cord Care|Completed||Phase 1|400||Penn State University|||||f||||||||||||||2018-06-01 04:50:32.745602|2018-06-01 04:50:32.745602
NCT00127686|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2017-11-21|2005-08-04|2005-08-08|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2005||2005-09-30|November 2017|2017-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep|Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Quality for Coughing Children and Their Parents|Completed||Phase 1|105|Actual|Penn State University|||||f||||||||||||||2018-06-01 04:50:32.83066|2018-06-01 04:50:32.83066
NCT00127673|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2014-01-31|2005-08-05|2005-08-08|Estimate|||||||2014-01-31|2014-02-03|Estimate|September 2004||2004-09-30|January 2014|2014-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of Two Treatments for Post-Traumatic Stress Disorder|Effectiveness of PTSD Treatment: CBT Versus Sertraline|Completed||Phase 3|200|Actual|Case Western Reserve University||4|||f||||t||||||||||2018-06-01 04:50:32.928734|2018-06-01 04:50:32.928734
NCT00127660|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|2014-12-01||2017-08-30|2005-08-05|2005-08-08|Estimate|2017-08-25|2017-08-28|Actual||||2017-08-30|2017-09-01|Actual|September 2005||2005-09-30|August 2017|2017-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Effect of Nutrition Labeling on Fast Food Choices|Effect of Nutrition Labeling on Fast Food Choices|Completed||N/A|605|Actual|University of Minnesota - Clinical and Translational Science Institute|Meal choices were tested on just one occasion.|4|||f||||f||||||||||2018-06-01 04:50:33.131333|2018-06-01 04:50:33.131333
NCT00127647|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2017-03-17|2005-08-05|2005-08-08|Estimate|||||||2017-03-17|2017-03-21|Actual|November 2004||2004-11-30|March 2017|2017-03-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)|MK0476 Phase III Double-Blind Comparative Study - Allergic Rhinitis|Completed||Phase 3|1375|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 04:50:33.483316|2018-06-01 04:50:33.483316
NCT00127634|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04||2018-03-07|2018-03-07|2005-08-04|2005-08-08|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|July 2005||2005-07-31|March 2018|2018-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes|A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|385|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 04:50:33.621097|2018-06-01 04:50:33.621097
NCT00127621|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2005-08-24|2005-08-05|2005-08-08|Estimate|||||||2005-08-24|2005-08-25|Estimate|April 2002||2002-04-30|August 2005|2005-08-31|April 2005||2005-04-30|||||Interventional|||Early Tracheotomy Versus Prolonged Endotracheal Intubation in Intensive Care Unit (ICU) Patients|Early Tracheotomy Versus Prolonged Endotracheal Intubation in Intensive Care Unit Patients|Terminated||Phase 3|468||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:50:33.791191|2018-06-01 04:50:33.791191
NCT00127608|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2017-06-08|2005-08-04|2005-08-08|Estimate|||||||2017-06-08|2017-06-09|Actual|June 2005||2005-06-30|September 2011|2011-09-30||||July 2006|Actual|2006-07-31||Interventional|||Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients|An Open, Prospective, Non-prophylactic, Non Therapeutic Study for the Detection and Characterisation of Varicella Zoster Virus Collected From Dermal Lesions of Patients Who Are Diagnosed of Having Varicella|Completed||Phase 3|||GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:50:33.889056|2018-06-01 04:50:33.889056
NCT00127595|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2005-08-23|2005-08-05|2005-08-08|Estimate|||||||2005-08-23|2005-08-24|Estimate|January 2002||2002-01-31|August 2005|2005-08-31|April 2005||2005-04-30|||||Interventional|||Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract|A Phase II Monocentric Study of Oxaliplatin in Combination With Gemcitabine in Patients With Advanced/Metastatic Transitional Cell Carcinoma of the Urothelial Tract|Terminated||Phase 2|28||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:50:33.979416|2018-06-01 04:50:33.979416
NCT00127582|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2005-08-24|2005-08-04|2005-08-08|Estimate|||||||2005-08-24|2005-08-25|Estimate|January 2003||2003-01-31|May 2005|2005-05-31||||||||Interventional|||RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy|Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1)|Unknown status|Recruiting|Phase 3|537||Catholic University of the Sacred Heart|||||f||||||||||||||2018-06-01 04:50:34.081008|2018-06-01 04:50:34.081008
NCT00127569|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2007-01-11|2005-08-04|2005-08-08|Estimate|||||||2007-01-11|2007-01-12|Estimate|May 2003||2003-05-31|January 2007|2007-01-31|January 2006||2006-01-31|||||Interventional|||Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy|Multicenter, Phase II Trial Assessing the Efficacy of Rituximab in HIV Infected Patients With Multicentric Castleman Disease Dependent on Chemotherapy (ANRS 117 Study, CastlemaB)|Terminated||Phase 2|25||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:50:34.175158|2018-06-01 04:50:34.175158
NCT00127556|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2008-05-06|2005-08-04|2005-08-08|Estimate|||||||2008-05-06|2008-05-09|Estimate|April 2005||2005-04-30|May 2008|2008-05-31|December 2005|Actual|2005-12-31|||||Interventional|||Transfusion Medicine - Prevention of Bedside Errors|Cluster-Randomised Controlled Trial of a Simple Intervention to Prevent Bedside Checking Errors in Blood Transfusion|Completed||N/A|300||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 04:50:34.242272|2018-06-01 04:50:34.242272
NCT00127543|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2006-02-06|2005-08-05|2005-08-08|Estimate|||||||2006-02-06|2006-02-07|Estimate|August 2005||2005-08-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Kid Cards: Teaching Kids About Medicines|Kid Cards: Teaching Kids About Medicines|Unknown status|Active, not recruiting|N/A|50||Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:50:34.326037|2018-06-01 04:50:34.326037
NCT00127530|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|2011-04-12||2016-01-04|2005-08-04|2005-08-08|Estimate|2011-04-12|2011-05-06|Estimate||||2016-01-04|2016-02-04|Estimate|May 2005||2005-05-31|January 2016|2016-01-31|September 2006|Actual|2006-09-30|June 2006|Actual|2006-06-30||Interventional||Safety Population = Placebo (72), Fampridine-SR (228) Intent to Treat (ITT) Population = Placebo (72), Fampridine-SR (224). Four (4) randomized patients discontinued from the study prior to completing any of the scheduled double-blind assessments and therefore were excluded from the ITT population, which consisted of 296 patients.|Study of Oral Fampridine-SR in Multiple Sclerosis|Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis|Completed||Phase 3|301|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-06-01 04:50:34.400099|2018-06-01 04:50:34.400099
NCT00127517|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-05|||2011-06-06|2005-08-05|2005-08-08|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2005||2005-03-31|June 2011|2011-06-30|August 2006|Actual|2006-08-31|||||Interventional|||Palliative Care Study in Patients With Advanced Cancer|A Phase II Double Blind, Placebo Controlled, Randomized, > Multicenter Study With AVR118 Solution in Patients With Advanced > Malignancies Who Are Not Candidates for Curative Chemotherapy.|Terminated||Phase 2|||Advanced Viral Research Corp||||Company shifted focus|||||||||||||||2018-06-01 04:50:34.861689|2018-06-01 04:50:34.861689
NCT00127504|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2005-08-23|2005-08-04|2005-08-08|Estimate|||||||2005-08-23|2005-08-24|Estimate|July 2003||2003-07-31|August 2005|2005-08-31|May 2004||2004-05-31|||||Interventional|||Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness|Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala|Completed||Phase 2|80||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:50:35.097724|2018-06-01 04:50:35.097724
NCT00127491|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2017-02-24|2005-08-04|2005-08-08|Estimate|||||||2017-02-24|2017-02-27|Actual|May 2004||2004-05-31|February 2017|2017-02-28|May 2010|Actual|2010-05-31|August 2007|Actual|2007-08-31||Interventional|||Mechanical Ventilation, Directed by Esophageal Pressure Measurements, in Patients With Acute Lung Injury|A RCT of Mechanical Ventilation, Directed by Esophageal Pressure Measurements, in Patients With Acute Lung Injury|Completed||N/A|63|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||No||2018-06-01 04:50:35.200993|2018-06-01 04:50:35.200993
NCT00127478|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2007-11-28|2005-08-04|2005-08-08|Estimate|||||||2007-11-28|2007-11-29|Estimate|July 2001||2001-07-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||A Long Term Safety Study With Atrasentan|A Phase II/III Extension Study to Evaluate the Safety and Tolerability of Atrasentan|Completed||Phase 2/Phase 3|166|Actual|Abbott|||||f||||||||||||||2018-06-01 04:50:35.378958|2018-06-01 04:50:35.378958
NCT00127465|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2008-12-10|2005-08-04|2005-08-05|Estimate|||||||2008-12-10|2008-12-11|Estimate|November 2001||2001-11-30|August 2005|2005-08-31|July 2003||2003-07-31|||||Interventional|||Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants|Investigating the Impact of Tailored Reports on Anxiety|Completed||Phase 1/Phase 2|400||University of Plymouth|||||f||||||||||||||2018-06-01 04:50:35.499367|2018-06-01 04:50:35.499367
NCT00127452|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2010-07-06|2005-08-03|2005-08-05|Estimate|||||||2010-07-06|2010-07-07|Estimate|April 2002||2002-04-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|November 2009|Actual|2009-11-30||Interventional|||Alpha Omega Trial: Study of Omega-3 Fatty Acids and Coronary Mortality|Alpha Omega Trial: A Randomised, Placebo Controlled, Double Blind Intervention Study of the Effect of Low Doses of Omega-3 Fatty Acids on Cardiovascular Diseases in Patients With a History of Myocardial Infarction|Completed||N/A|4837|Actual|Wageningen University||4|||f||||t||||||||||2018-06-01 04:50:35.60398|2018-06-01 04:50:35.60398
NCT00127439|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2016-08-15||2018-01-23|2005-08-03|2005-08-05|Estimate|2018-01-23|2018-01-24|Actual||||2018-01-23|2018-01-24|Actual|June 2005||2005-06-30|January 2018|2018-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|DE|19 subjects were enrolled; 2 subjects (1:Manual; 1: Robotic) did not complete as intervening medical issues would not permit them to meet the study protocol's requirement for training intensity; and 2 subjects' (Manual) data was insufficient for data analysis and thus eliminated from analysis.|Effects of Robotic Versus Manually-Assisted Locomotor Training for Individuals With Incomplete Spinal Cord Injury|Differential Effects of Robotic vs. Manually-Assisted Locomotor Training|Completed||N/A|19|Actual|VA Office of Research and Development|"Data for two subjects was incomplete during outcome measures acquisition, interpretable and removed from data analysis.Two subjects did not complete.~An n=24 was anticipated; an original N=19 enrolled, the group sizes decreased to 8 and 7."|2|||f||||t||||||||Undecided||2018-06-01 04:50:35.861429|2018-06-01 04:50:35.861429
NCT00127413|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2014-11-17||2015-03-23|2005-08-03|2005-08-05|Estimate|2015-03-23|2015-03-27|Estimate||||2015-03-23|2015-03-27|Estimate|September 2004||2004-09-30|March 2015|2015-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Integrated Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD)|Integrated Treatment for Chronic Pain and PTSD|Completed||N/A|42|Actual|VA Office of Research and Development|Failure to engage in treatment, failure to complete treatment in a timely manner due to missed treatment sessions, and difficulty with compliance with treatment session recommendations led to lower completion rates|4|||f||||f||||||||||2018-06-01 04:50:36.627088|2018-06-01 04:50:36.627088
NCT00127400|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2013-09-04|2005-08-04|2005-08-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2002||2002-02-28|September 2013|2013-09-30|July 2006||2006-07-31|||||Interventional|||A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED|A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With Intermittent Explosive Disorder|Completed||Phase 2|72||University of Chicago|||||f||||||||||||||2018-06-01 04:50:37.787337|2018-06-01 04:50:37.787337
NCT00127387|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2012-06-22|2005-08-04|2005-08-05|Estimate|||||||2012-06-22|2012-06-26|Estimate|May 2001||2001-05-31|June 2012|2012-06-30|November 2005|Actual|2005-11-30|September 2005|Actual|2005-09-30||Interventional|||Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia|A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia|Terminated||Phase 2/Phase 3|54|Anticipated|The University of Texas Health Science Center at San Antonio||||PI moved to Oregon|f||||||||||||||2018-06-01 04:50:37.98547|2018-06-01 04:50:37.98547
NCT00127374|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2016-11-07|2005-08-04|2005-08-05|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||Mood and Behavior Changes Among Overweight Adolescent Females|Mood and Behavior Changes Among Overweight Adolescent Females|Withdrawn|||0|Actual|University of Kentucky||||withdrawn due to non-response. PI left university|f||||||||||||||2018-06-01 04:50:38.089302|2018-06-01 04:50:38.089302
NCT00127361|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2005-08-22|2005-08-04|2005-08-05|Estimate|||||||2005-08-22|2005-08-23|Estimate|January 1998||1998-01-31|April 2005|2005-04-30|February 2003||2003-02-28|||||Interventional|||Study of Having a Female Friend as Labor Support|Evaluation of Continuous Support in Labor|Completed||N/A|600||Saint Peters University Hospital|||||f||||||||||||||2018-06-01 04:50:38.175657|2018-06-01 04:50:38.175657
NCT00127348|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2007-04-02|2005-08-04|2005-08-05|Estimate|||||||2007-04-02|2007-04-04|Estimate|May 2004||2004-05-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness|Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness|Completed||Phase 4|700||Sociedad Española de Neumología y Cirugía Torácica|||||f||||||||||||||2018-06-01 04:50:38.242703|2018-06-01 04:50:38.242703
NCT00127335|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2011-07-26|2005-08-04|2005-08-05|Estimate|||||||2011-07-26|2011-07-28|Estimate|August 2005||2005-08-31|July 2011|2011-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Is Myopathy Part of Statin Therapy (IMPOSTER-16)|Double Blind, Prospective Randomized, Crossover Study of Patients With Muscle Complaints on Statin Therapy|Terminated||Phase 4|60|Anticipated|Scripps Health||2||Lack of funding|f||||f||||||||||2018-06-01 04:50:38.316574|2018-06-01 04:50:38.316574
NCT00127322|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2006-02-09|2005-08-03|2005-08-05|Estimate|||||||2006-02-09|2006-02-13|Estimate|January 2004||2004-01-31|February 2006|2006-02-28|January 2006||2006-01-31|||||Observational|||The Early High Risk Period for Patients With Heart Failure|The Early High Risk Period for Patients With Incident Heart Failure: A Population Based Study|Unknown status|Active, not recruiting||450||Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:50:38.446784|2018-06-01 04:50:38.446784
NCT00127309|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2005-08-23|2005-08-04|2005-08-05|Estimate|||||||2005-08-23|2005-08-24|Estimate|June 2005||2005-06-30|July 2005|2005-07-31|August 2005||2005-08-31|||||Interventional|||Effect of Glutathione on Blood Alcohol and Hangover Symptoms||Completed||N/A|100||Piyavate Hospital|||||f||||||||||||||2018-06-01 04:50:38.61151|2018-06-01 04:50:38.61151
NCT00127296|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2017-01-05|2005-08-03|2005-08-05|Estimate|||||||2017-01-05|2017-01-06|Estimate|July 2005||2005-07-31|January 2017|2017-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe|Comparison of the Accuracy and Precision of NovoLog® Mix 70/30 FlexPen® to Vial and Syringe in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|60|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:50:38.71278|2018-06-01 04:50:38.71278
NCT00127283|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2017-01-11|2005-08-03|2005-08-05|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2005||2005-05-31|January 2017|2017-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|FAST||Recombinant Factor VIIa in Acute Intracerebral Haemorrhage|Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage|Completed||Phase 3|829|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:50:38.830807|2018-06-01 04:50:38.830807
NCT00127270|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-01-23|2005-08-04|2005-08-05|Estimate|||||||2008-01-23|2008-01-24|Estimate|May 2005||2005-05-31|January 2008|2008-01-31|February 2006|Actual|2006-02-28|||||Interventional|||Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder|Using Behavioral Therapy in Combination With Drug-Darifenacin for Symptoms of Overactive Bladder|Completed||Phase 4|395|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:50:39.272343|2018-06-01 04:50:39.272343
NCT00127257|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2010-01-12|2005-08-04|2005-08-05|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 1999||1999-09-30|January 2010|2010-01-31|June 2006||2006-06-30|||||Interventional|||Biofeedback for Dyssynergic Constipation|Biofeedback for Fecal Incontinence and Constipation|Completed||N/A|117||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:50:39.537526|2018-06-01 04:50:39.537526
NCT00127244|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2010-11-30|2005-08-04|2005-08-05|Estimate|||||||2010-11-30|2010-12-02|Estimate|June 2000||2000-06-30|November 2010|2010-11-30|October 2004||2004-10-31|||||Interventional|||Study Comparing Two Different Methods of Treating Periodontal Disease|Outcomes of Traditional and Medical Models of Periodontal Therapy|Completed||Phase 2|400||The Forsyth Institute|||||f||||||||||||||2018-06-01 04:50:39.664235|2018-06-01 04:50:39.664235
NCT00127231|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2017-08-29||2017-11-02|2005-08-03|2005-08-05|Estimate|2017-11-02|2017-12-06|Actual||||2017-11-02|2017-12-06|Actual|September 2007||2007-09-30|November 2017|2017-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women|Brief Alcohol Intervention in HIV+ Women|Completed||N/A|148|Actual|Johns Hopkins University||2|||f||||t||||||||Undecided||2018-06-01 04:50:39.781484|2018-06-01 04:50:39.781484
NCT00127218|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2015-09-01||2017-10-04|2005-08-03|2005-08-05|Estimate|2015-10-12|2015-11-09|Estimate||||2017-10-04|2017-11-06|Actual|September 2003||2003-09-30|October 2017|2017-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|NIA-Plaque||High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly|HDL Increased Plaque Stabilization in the Elderly|Completed||Phase 3|145|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 04:50:40.680548|2018-06-01 04:50:40.680548
NCT00127205|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2017-12-13|2005-08-03|2005-08-05|Estimate|||||||2017-12-13|2017-12-15|Actual|July 2005||2005-07-31|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|December 2017|Actual|2017-12-31||Interventional|||S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.|Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer|Active, not recruiting||Phase 3|5400|Anticipated|Southwest Oncology Group||3|||f||||t||||||||||2018-06-01 04:50:40.988626|2018-06-01 04:50:40.988626
NCT00127192|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2009-08-18||2015-05-20|2005-08-04|2005-08-05|Estimate|2009-09-24|2009-09-25|Estimate||||2015-05-20|2015-06-15|Estimate|July 2005||2005-07-31|May 2015|2015-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)|Sitagliptin (MK0431) Late Phase II Double-Blind Dose-Response Study - Type 2 Diabetes Mellitus|Completed||Phase 2|363|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-06-01 04:50:41.130367|2018-06-01 04:50:41.130367
NCT00127179|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2017-04-05|2005-08-04|2005-08-05|Estimate|||||||2017-04-05|2017-04-07|Actual|January 1, 2004|Actual|2004-01-01|April 2017|2017-04-30|July 25, 2005|Actual|2005-07-25|July 1, 2005|Actual|2005-07-01||Interventional|||A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)|MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia|Completed||Phase 3|600|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:50:41.748718|2018-06-01 04:50:41.748718
NCT00127166|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-06-16||2017-03-10|2005-08-04|2005-08-05|Estimate|2009-10-29|2009-12-03|Estimate||||2017-03-10|2017-04-10|Actual|December 2005||2005-12-31|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)|A Multicenter, Double-Blind, Randomized, Crossover Design Study to Evaluate the Effect of Montelukast Vs. Salmeterol on the Inhibition of Exercise-Induced Bronchoconstriction in Asthmatic Patients Aged 6-14 Years|Completed||Phase 3|154|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:50:41.847664|2018-06-01 04:50:41.847664
NCT00127153|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2015-01-28|2005-08-04|2005-08-05|Estimate|||||||2015-01-28|2015-01-29|Estimate|March 2005||2005-03-31|January 2015|2015-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)|A Comparative Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of V110 Formulated With Either All New Process Polysaccharides or All Current Process Polysaccharides|Completed||Phase 3|130||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:50:42.556205|2018-06-01 04:50:42.556205
NCT00127140|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2015-09-25|2005-08-04|2005-08-05|Estimate|||||||2015-09-25|2015-09-28|Estimate|June 2005||2005-06-30|September 2015|2015-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)|A Phase I Clinical Study of MK0683 in Patients With Malignant Lymphoma|Completed||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 04:50:42.680794|2018-06-01 04:50:42.680794
NCT00127127|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2015-02-02|2005-08-04|2005-08-05|Estimate|||||||2015-02-02|2015-02-03|Estimate|June 2005||2005-06-30|February 2015|2015-02-28|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Solid Tumors (0683-029)(COMPLETED)|A Phase I Clinical Study of MK0683 in Patients With Solid Tumors.|Completed||Phase 1|21|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 04:50:42.860131|2018-06-01 04:50:42.860131
NCT00127114|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2017-08-10|2005-08-04|2005-08-05|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2005|Actual|2005-09-30|August 2017|2017-08-31|July 26, 2007|Actual|2007-07-26|July 26, 2007|Actual|2007-07-26||Interventional|||Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)|Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||2||No funding and exclusion criteria were to stringent.|f||||||||||||||2018-06-01 04:50:42.964737|2018-06-01 04:50:42.964737
NCT00127101|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2009-07-06||2015-04-02|2005-08-04|2005-08-05|Estimate|2009-07-06|2009-08-14|Estimate||||2015-04-02|2015-04-21|Estimate|September 2005||2005-09-30|April 2015|2015-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)|A Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat; Zolinza) in Combination With Bexarotene in Patients With Advanced Cutaneous T-Cell Lymphoma|Terminated||Phase 1|23|Actual|Merck Sharp & Dohme Corp.|Study was discontinued due to low enrollment|6||The study was stopped due to low enrollment.|f||||||||||||||2018-06-01 04:50:43.094083|2018-06-01 04:50:43.094083
NCT00127088|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2006-09-07|2005-08-03|2005-08-05|Estimate|||||||2006-09-07|2006-09-11|Estimate|October 2004||2004-10-31|September 2006|2006-09-30||||||||Interventional|||Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients|A Prospective Phase II of Peri-Operative Docetaxel + Laparoscopic Radical Prostatectomy in Patients With Localized Gleason 7 pT2a-pT2b Adenocarcinoma and a Risk of Relapse After Radical Prostatectomy|Suspended||Phase 2|37||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:50:44.367506|2018-06-01 04:50:44.367506
NCT00127075|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2011-12-28|2005-08-04|2005-08-05|Estimate|||||||2011-12-28|2011-12-30|Estimate|June 2005||2005-06-30|December 2011|2011-12-31|April 2012|Anticipated|2012-04-30|April 2012|Anticipated|2012-04-30||Interventional|||POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis|POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-06-01 04:50:45.502529|2018-06-01 04:50:45.502529
NCT00127062|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2015-03-25|2005-08-04|2005-08-05|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2003||2003-05-31|August 2005|2005-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street|Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street|Completed|||60||Imperial College London|||2||f||||t||||||Samples Without DNA|"~     Exhaled breath condensate~   "|||2018-06-01 04:50:45.685543|2018-06-01 04:50:45.685543
NCT00127049|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2006-09-07|2005-08-03|2005-08-05|Estimate|||||||2006-09-07|2006-09-08|Estimate|December 2004||2004-12-31|September 2006|2006-09-30||||||||Interventional|||Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors|A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis|Unknown status|Recruiting|Phase 2|37||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:50:45.784739|2018-06-01 04:50:45.784739
NCT00127036|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2012-01-05||2017-02-20|2005-08-03|2005-08-05|Estimate|2012-03-09|2012-04-05|Estimate||||2017-02-20|2017-03-23|Actual|October 2003||2003-10-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)|A Multicenter Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)|Terminated||Phase 2|65|Actual|H. Lee Moffitt Cancer Center and Research Institute|Study was Terminated early, not Completed. Study Drug now on the market. Due to slow accrual, too few patients who had both clinical and microarray data to perform the proposed analysis. 65 of 92 patients consented were assigned to treatment arms.|2||drug now on market|f||||t||||||||||2018-06-01 04:50:45.890838|2018-06-01 04:50:45.890838
NCT00127023|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2016-09-20|2005-08-04|2005-08-05|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 2005||2005-05-31|September 2016|2016-09-30|November 2005|Actual|2005-11-30|||||Interventional|||Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases|Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life|Completed||Phase 3|944||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:50:46.34532|2018-06-01 04:50:46.34532
NCT00127010|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2016-09-23|2005-08-04|2005-08-05|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2005||2005-11-30|September 2016|2016-09-30|June 2006|Actual|2006-06-30|||||Interventional|||Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases|Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life|Completed||Phase 3|||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:50:46.727585|2018-06-01 04:50:46.727585
NCT00126997|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2016-09-20|2005-08-04|2005-08-05|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 2005||2005-05-31|September 2016|2016-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases|Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life|Completed||Phase 4|1439|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:50:47.057296|2018-06-01 04:50:47.057296
NCT00126984|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04||2009-09-03|2016-10-06|2005-08-04|2005-08-05|Estimate||||2009-09-03|2009-09-04|Estimate|2016-10-06|2016-10-07|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine|A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC™ or MENCEVAX™ ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old|Completed||Phase 2|508|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:50:47.30371|2018-06-01 04:50:47.30371
NCT00126971|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2006-08-14|2005-08-03|2005-08-05|Estimate|||||||2006-08-14|2006-08-15|Estimate|July 2005||2005-07-31|August 2006|2006-08-31||||||||Interventional|||Chlorproguanil-Dapsone in Pregnant Women|Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment|Suspended||Phase 1|132||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:50:47.781697|2018-06-01 04:50:47.781697
NCT00126958|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2009-02-18|2005-08-04|2005-08-05|Estimate|||||||2009-02-18|2009-02-19|Estimate|July 2002||2002-07-31|August 2005|2005-08-31|July 2005||2005-07-31|||||Observational|||Cost-Effectiveness in Bladder Cancer|Cost-Effectiveness of Follow-up of Patients With Superficial Bladder Cancer|Unknown status|Active, not recruiting||500||Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:50:47.897396|2018-06-01 04:50:47.897396
NCT00126945|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-04|||2016-09-20|2005-08-04|2005-08-05|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2005||2005-08-31|September 2016|2016-09-30|October 2005|Actual|2005-10-31|||||Interventional|||Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs|A Primary Vaccination Study to Assess the Immunogenicity, Safety & Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of MENCEVAX™ ACWY in Healthy Subjects Aged 15-19 Years|Completed||Phase 2|125|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:50:48.051643|2018-06-01 04:50:48.051643
NCT00126932|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2007-12-20|2005-08-03|2005-08-05|Estimate|||||||2007-12-20|2007-12-27|Estimate|October 2004||2004-10-31|December 2007|2007-12-31|December 2004||2004-12-31|||||Interventional|||Reduction of Topical Anesthetic Onset Time Using Ultrasound|Reduction of Topical Anesthetic Onset Time Using Ultrasound: A Randomized Controlled Trial Prior to Venipuncture in Young Children|Completed||Phase 4|70||Connecticut Children's Medical Center|||||f||||||||||||||2018-06-01 04:50:48.199692|2018-06-01 04:50:48.199692
NCT00126919|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2012-02-08|2005-08-03|2005-08-05|Estimate|||||||2012-02-08|2012-02-09|Estimate|October 2004||2004-10-31|February 2012|2012-02-29|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Reduction of Topical Anesthetic Time for Subcutaneous Port Access Using Ultrasound|Randomized Crossover Trial of Sonication Followed by 5 Minute LMX4 Application Compared With 30 Minute LMX4 Application for Topical Anesthesia Prior to Subcutaneous Port Access in Children|Completed||Phase 4|40|Anticipated|Connecticut Children's Medical Center|||||f||||||||||||||2018-06-01 04:50:48.270828|2018-06-01 04:50:48.270828
NCT00126906|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2005-08-22|2005-08-03|2005-08-05|Estimate|||||||2005-08-22|2005-08-23|Estimate|October 2002||2002-10-31|August 2005|2005-08-31|March 2005||2005-03-31|||||Interventional|||Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi|Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly – Malawi|Completed||N/A|700||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:50:48.391646|2018-06-01 04:50:48.391646
NCT00126893|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2007-05-14|2005-08-03|2005-08-05|Estimate|||||||2007-05-14|2007-05-15|Estimate|October 2005||2005-10-31|December 2006|2006-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia|Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia|Terminated||Phase 1|36||Celgene|||||||||||||||||||2018-06-01 04:50:48.523005|2018-06-01 04:50:48.523005
NCT00126880|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2011-06-22|2005-08-03|2005-08-05|Estimate|||||||2011-06-22|2011-06-23|Estimate|July 2005||2005-07-31|June 2011|2011-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV|A Phase II, Randomised, Double-blind, Dose-ranging Study of AVX754 Versus Lamivudine in Treatment-experienced HIV-1 Infected Patients With the M184V Mutation in Reverse Transcriptase|Completed||Phase 2|52|Actual|Avexa||3|||f||||t||||||||||2018-06-01 04:50:48.650471|2018-06-01 04:50:48.650471
NCT00126867|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2017-01-12|2005-08-03|2005-08-05|Estimate|||||||2017-01-12|2017-01-16|Estimate|May 2005||2005-05-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment|Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment|Recruiting|||104|Anticipated|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:50:48.824519|2018-06-01 04:50:48.824519
NCT00111254|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-18|||2015-05-20|2005-05-18|2005-05-19|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2002||2002-06-30|June 2011|2011-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Effects of Microdermabrasion on Skin Remodeling|The Effects of Microdermabrasion on Collagen and Elastin Biosynthesis|Completed||N/A|257|Actual|University of Michigan||2|||f||||f||||||||||2018-06-01 04:56:00.435305|2018-06-01 04:56:00.435305
NCT00126854|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2016-02-24|2005-08-03|2005-08-05|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2005||2005-10-31|March 2012|2012-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation|High Field (3 Tesla) Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Permanent Iodine 125 Brachytherapy Implantation|Completed||N/A|10|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:50:48.926942|2018-06-01 04:50:48.926942
NCT00126841|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2011-12-08|2005-08-03|2005-08-05|Estimate|||||||2011-12-08|2011-12-09|Estimate|November 2004||2004-11-30|December 2011|2011-12-31|November 2005||2005-11-30|||||Observational|||Computed Tomotherapy (CT) and Magnetic Resonance Imaging (MRI) Fusion on Radiation Treatment Planning for Patients With Cancer of the Cervix|To Assess the Feasibility and Impact of Computed Tomotherapy (CT) and Magnetic Resonance Imaging (MRI) Fusion on Radiation Treatment Planning for Ten Patients With Cancer of the Cervix|Completed|||10||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:50:49.002367|2018-06-01 04:50:49.002367
NCT00126828|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2016-02-23|2005-08-03|2005-08-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2003||2003-01-31|October 2011|2011-10-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer|A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer|Completed||Phase 1/Phase 2|18||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:50:49.082787|2018-06-01 04:50:49.082787
NCT00126815|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2016-02-23|2005-08-03|2005-08-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|February 2004||2004-02-29|December 2011|2011-12-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Observational|||Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy|Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy|Completed|||1000|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:50:49.150274|2018-06-01 04:50:49.150274
NCT00126802|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2016-07-04|2005-08-03|2005-08-05|Estimate|||||||2016-07-04|2016-07-06|Estimate|April 2005||2005-04-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer|The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|60|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:50:49.204718|2018-06-01 04:50:49.204718
NCT00126789|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2012-06-04|2005-08-02|2005-08-04|Estimate|||||||2012-06-04|2012-06-05|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain|An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Cancer Pain|Terminated||Phase 3|24|Actual|ZARS Pharma Inc.||1||Based on PK data, product did not meet requirement for further development.|f||||f||||||||||2018-06-01 04:50:49.266877|2018-06-01 04:50:49.266877
NCT00126776|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2009-07-14||2009-07-14|2005-08-03|2005-08-04|Estimate|2009-07-14|2009-08-25|Estimate||||2009-07-14|2009-08-25|Estimate|July 2004||2004-07-31|July 2009|2009-07-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Veterans Integrated Service Network (VISN) 23 Lung Disease Self Management/Case Management Program|VISN 23 Lung Disease Self Management/Case Management Program|Completed||N/A|743|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:50:49.350391|2018-06-01 04:50:49.350391
NCT00126763|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2012-06-04|2005-08-02|2005-08-04|Estimate|||||||2012-06-04|2012-06-05|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain|An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Non-Malignant Chronic Pain|Terminated||Phase 3|105|Actual|ZARS Pharma Inc.||1||PK results suggested product did not meet requirement for further development.|f||||f||||||||||2018-06-01 04:50:49.570432|2018-06-01 04:50:49.570432
NCT00126750|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2015-01-27||2015-06-24|2005-08-02|2005-08-04|Estimate|2015-06-24|2015-07-23|Estimate||||2015-06-24|2015-07-23|Estimate|September 2003||2003-09-30|June 2015|2015-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|VA MI Plus||Web-Enhanced Guideline Implementation for Post MI CBOC Patients|MI-Plus: Web-enhanced Guideline Implementation for Post MI CBOC Patients|Completed||N/A|847|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:50:49.647881|2018-06-01 04:50:49.647881
NCT00126737|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2014-12-02||2014-12-30|2005-08-02|2005-08-04|Estimate|2014-12-30|2015-01-01|Estimate||||2014-12-30|2015-01-01|Estimate|October 2002||2002-10-31|December 2014|2014-12-31|December 2008|Actual|2008-12-31|February 2008|Actual|2008-02-29||Interventional|||Home-Based Exercise and Weight Control Program for Pain Control in Overweight Elderly With Osteoarthritis of the Knee|Home-Based Exercise and Weight Control Program for Pain Control in Overweight Elderly With Osteoarthritis of the Knee|Completed||N/A|110|Actual|VA Office of Research and Development|Due to the small number of females, the results may not be generalizable to females. Limitations include requirement of having good upper body strength, shoulder range, hand eye coordination, and an investment of purchasing poles of $30 per pair.|4|||f||||f||||||||||2018-06-01 04:50:50.017148|2018-06-01 04:50:50.017148
NCT00126724|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2009-07-27|2005-08-02|2005-08-04|Estimate|||||||2009-07-27|2009-07-29|Estimate|August 2005||2005-08-31|July 2009|2009-07-31|May 2009|Actual|2009-05-31|October 2008|Actual|2008-10-31||Interventional|||Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects|A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists|Completed||Phase 1/Phase 2|120|Anticipated|Targeted Genetics Corporation||4|||f||||t||||||||||2018-06-01 04:50:50.650674|2018-06-01 04:50:50.650674
NCT00126698|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2007-04-18|2005-08-03|2005-08-04|Estimate|||||||2007-04-18|2007-04-19|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Interventional|||Prophylactic Antibiotics on Urethral Catheter Withdrawal|Use of Antibiotic Prophylaxis on Urethral Catheter Withdrawal: A Randomized Double-Blind Placebo-Controlled Trial|Completed||Phase 4|100||St. Antonius Hospital|||||f||||||||||||||2018-06-01 04:50:50.77709|2018-06-01 04:50:50.77709
NCT00126685|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2013-09-16|2005-08-03|2005-08-04|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2005||2005-04-30|June 2007|2007-06-30||||||||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Melanoma|Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With Unselected Autologous Amplified Tumor-RNA|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:50:50.837827|2018-06-01 04:50:50.837827
NCT00126672|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2010-02-01|2005-08-02|2005-08-04|Estimate|||||||2010-02-01|2010-02-02|Estimate|June 2005||2005-06-30|October 2008|2008-10-31||||April 2010|Anticipated|2010-04-30||Interventional|||Sirolimus in Treating Patients With Angiomyolipoma of the Kidney|A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas in TSC or LAM Patients|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:50:50.901139|2018-06-01 04:50:50.901139
NCT00126659|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2012-09-28||2014-04-21|2005-08-02|2005-08-04|Estimate|2012-11-28|2012-12-31|Estimate||||2014-04-21|2014-05-09|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer|A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 04:50:50.986309|2018-06-01 04:50:50.986309
NCT00126646|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2010-06-17|2005-08-02|2005-08-04|Estimate|||||||2010-06-17|2010-06-22|Estimate|June 2005||2005-06-30|June 2010|2010-06-30|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|||BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma|Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas|Completed||Phase 1|24|Anticipated|MedImmune LLC|||||f||||f||||||||||2018-06-01 04:50:51.254043|2018-06-01 04:50:51.254043
NCT00126633|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2012-09-13|2005-08-02|2005-08-04|Estimate|||||||2012-09-13|2012-09-17|Estimate|April 2004||2004-04-30|September 2012|2012-09-30|October 2008|Actual|2008-10-31|September 2006|Actual|2006-09-30||Interventional|||Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer|A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|53|Actual|University of California, San Francisco|||||f||||t||||||||||2018-06-01 04:50:51.317606|2018-06-01 04:50:51.317606
NCT00126620|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2015-07-22|2005-08-02|2005-08-04|Estimate|||||||2015-07-22|2015-07-23|Estimate|September 2005||2005-09-30|July 2015|2015-07-31||||May 2011|Actual|2011-05-31||Interventional|||Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors|Completed||Phase 1|17|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:50:51.382204|2018-06-01 04:50:51.382204
NCT00126607|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2013-02-27|2005-08-02|2005-08-04|Estimate|||||||2013-02-27|2013-02-28|Estimate|July 2005||2005-07-31|February 2013|2013-02-28||||May 2007|Actual|2007-05-31||Interventional|||Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer|Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma|Terminated||Phase 2|35|Actual|National Cancer Institute (NCI)||1||Poor accrual.|f||||||||||||||2018-06-01 04:50:51.453394|2018-06-01 04:50:51.453394
NCT00126594|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2016-02-09||2016-07-28|2005-08-02|2005-08-04|Estimate|2016-07-28|2016-09-16|Estimate||||2016-07-28|2016-09-16|Estimate|June 2005||2005-06-30|July 2016|2016-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer|A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:50:51.544722|2018-06-01 04:50:51.544722
NCT00126581|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2013-10-07||2018-04-26|2005-08-02|2005-08-04|Estimate|2014-03-19|2014-04-23|Estimate||||2018-04-26|2018-04-27|Actual|August 15, 2005|Actual|2005-08-15|April 2018|2018-04-30||||June 30, 2010|Actual|2010-06-30||Interventional|||Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer|A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers|Active, not recruiting||Phase 2|188|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 04:50:52.393724|2018-06-01 04:50:52.393724
NCT00126568|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2012-05-23||2017-12-20|2005-08-02|2005-08-04|Estimate|2012-07-02|2012-08-10|Estimate||||2017-12-20|2018-01-19|Actual|June 2005||2005-06-30|December 2017|2017-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer|Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid|Terminated||Phase 2|20|Actual|National Cancer Institute (NCI)|The study met the pre-specified criteria for enrollment of all planned 32 patients. However due to poor accrual the study was halted.|1|||f||||||||||||||2018-06-01 04:50:53.586588|2018-06-01 04:50:53.586588
NCT00126555|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2014-12-16||2014-12-16|2005-08-02|2005-08-04|Estimate|2014-12-16|2014-12-24|Estimate||||2014-12-16|2014-12-24|Estimate|March 2005||2005-03-31|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Of the 23 participants enrolled, one participant who was not evaulable for response withdrew before beginning treatment.|Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer|A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 04:50:53.884159|2018-06-01 04:50:53.884159
NCT00126542|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2014-05-13|2005-08-02|2005-08-04|Estimate|||||||2014-05-13|2014-05-14|Estimate|April 2005||2005-04-30|December 2012|2012-12-31|April 2010|Actual|2010-04-30|January 2007|Actual|2007-01-31||Interventional|||Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase II Trial of Bevacizumab (NSC# 704865) and OSI-774 (NSC# 718781) In Recurrent Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:50:54.529856|2018-06-01 04:50:54.529856
NCT00126516|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|||2013-10-28|2005-08-03|2005-08-04|Estimate|||||||2013-10-28|2013-10-30|Estimate|May 2004||2004-05-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline|Effects of Angiotensin II Receptor Blockers (ARB) and Angiotensin Converting Enzyme Inhibitors (ACEI) on Progression of Silent Brain Infarction and Cognitive Decline in Japanese Patients With Essential Hypertension in the Elderly|Completed||Phase 4|395|Actual|Nara Medical University||2|||f||||t||||||||||2018-06-01 04:50:54.725416|2018-06-01 04:50:54.725416
NCT00126503|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2012-11-16||2015-01-06|2005-08-02|2005-08-04|Estimate|2013-05-23|2013-06-28|Estimate||||2015-01-06|2015-01-15|Estimate|May 2005||2005-05-31|September 2014|2014-09-30|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|||Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer|A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer|Completed||Phase 1/Phase 2|73|Actual|National Cancer Institute (NCI)|To depict results of this Phases I/II study accurately, each phase was entered as an ARM to enable separation of the data by phase. Events reported in the Adverse Event and Serious Adverse Event sections include AEs and SAEs from Phase I and Phase II|1|||f||||||||||||||2018-06-01 04:50:54.840941|2018-06-01 04:50:54.840941
NCT00126490|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2013-05-29||2015-06-03|2005-08-02|2005-08-04|Estimate|2013-07-25|2013-07-30|Estimate||||2015-06-03|2015-06-30|Estimate|March 2005||2005-03-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|June 2012|Actual|2012-06-30||Interventional||18 of the 19 who started treatment were evaluable. One participant had to withdraw after only one infusion because they fell and broke both wrists.|Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|Phase 2 Trial of Sequential Bevacizumab Then Subcutaneous Interleukin-2 in Metastatic Renal Cancer|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)|"Investigators planned to have 38 participants treated on this study. 0 had to be entered for Other (not including Serious) Adverse Events, because they were not tabulated for treatment 3/30/05 through 1/24/07."|1|||f||||||||||||||2018-06-01 04:50:55.545625|2018-06-01 04:50:55.545625
NCT00126477|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2013-04-29|2005-08-02|2005-08-04|Estimate|||||||2013-04-29|2013-05-01|Estimate|March 1996||1996-03-31|April 2013|2013-04-30|March 2010|Actual|2010-03-31|April 2007|Actual|2007-04-30||Observational|||Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer|The Quality of Life of Adult Survivors Who Received a Marrow Transplant as a Child|Completed|||750|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:50:55.767468|2018-06-01 04:50:55.767468
NCT00126464|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2013-11-05|2005-08-02|2005-08-04|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 2004||2004-11-30|July 2006|2006-07-31||||||||Interventional|||Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast|A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant (Faslodex) in Breast Ductal Carcinoma (DCIS)|Unknown status|Active, not recruiting|N/A|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:50:55.835583|2018-06-01 04:50:55.835583
NCT00126451|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2017-04-06|2005-08-03|2005-08-04|Estimate|||||||2017-04-06|2017-04-10|Actual|December 1, 2004|Actual|2004-12-01|April 2017|2017-04-30|October 11, 2005|Actual|2005-10-11|October 11, 2005|Actual|2005-10-11||Interventional|||A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)|A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer.|Terminated||Phase 2|16|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:50:55.897634|2018-06-01 04:50:55.897634
NCT00126438|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-03|2015-06-30||2018-02-15|2005-08-03|2005-08-04|Estimate|2017-03-24|2017-05-05|Actual||||2018-02-15|2018-03-14|Actual|July 2005||2005-07-31|February 2018|2018-02-28|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional||All participants who received IMP manufactured by the sponsor.|Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease|An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event|Completed||Phase 3|515|Actual|GE Healthcare||1|||f||||t||||||||||2018-06-01 04:50:55.968427|2018-06-01 04:50:55.968427
NCT00126425|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2015-06-30||2016-10-19|2005-08-03|2005-08-04|Estimate|2016-10-19|2016-12-13|Estimate||||2016-10-19|2016-12-13|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional||All participants who received IMP manufactured by the sponsor.|Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease|An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event|Completed||Phase 3|587|Actual|GE Healthcare||1|||f||||t||||||||||2018-06-01 04:50:56.17372|2018-06-01 04:50:56.17372
NCT00126412|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2007-05-15|2005-08-03|2005-08-04|Estimate|||||||2007-05-15|2007-05-16|Estimate|July 2005||2005-07-31|May 2007|2007-05-31||||||||Interventional|||Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma||Completed||Phase 3|185||GE Healthcare|||||||||||||||||||2018-06-01 04:50:56.390417|2018-06-01 04:50:56.390417
NCT00126399|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2005-08-18|2005-08-02|2005-08-04|Estimate|||||||2005-08-18|2005-08-19|Estimate|June 2004||2004-06-30|August 2005|2005-08-31|April 2005||2005-04-30|||||Interventional|||A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea||Completed||Phase 3|528||CollaGenex Pharmaceuticals|||||||||||||||||||2018-06-01 04:50:56.44337|2018-06-01 04:50:56.44337
NCT00126386|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2011-11-18|2005-08-02|2005-08-04|Estimate|||||||2011-11-18|2011-11-21|Estimate|January 2004||2004-01-31|August 2011|2011-08-31|September 2006|Actual|2006-09-30|||||Interventional|||Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community|Zoledronic Acid (Zometa) for the Management of Tumor-induced Hypercalcemia (TIH) and Malignant Bone Pain (MBP) in the Community: A Feasibility Study|Completed||N/A|11|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:50:56.488111|2018-06-01 04:50:56.488111
NCT00126373|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2012-01-19|2005-08-02|2005-08-04|Estimate|||||||2012-01-19|2012-01-20|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Trial of Wellbutrin for Crohn's Disease|A Randomized Controlled Trial of Wellbutrin for Crohn's Disease|Completed||Phase 2/Phase 3|1|Actual|Altschuler, Eric, M.D.||2|||f||||||||||||||2018-06-01 04:50:56.546388|2018-06-01 04:50:56.546388
NCT00126360|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2005-11-07|2005-08-02|2005-08-03|Estimate|||||||2005-11-07|2005-11-10|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|May 2016||2016-05-31|||||Interventional|||STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)|Pilot for a Randomised Comparison of Anastrozole Commenced Before and Continued During Adjuvant Radiotherapy for Breast Cancer Versus Anastrozole and Subsequent Ant-Oestrogen Therapy Delayed Until After Radiotherapy|Unknown status|Recruiting|Phase 4|100||St George Hospital, Australia|||||f||||||||||||||2018-06-01 04:50:56.615382|2018-06-01 04:50:56.615382
NCT00126347|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2005-08-17|2005-08-02|2005-08-03|Estimate|||||||2005-08-17|2005-08-18|Estimate|August 2002||2002-08-31|August 2005|2005-08-31|July 2003||2003-07-31|||||Interventional|||Effect of Betaine, Serine and Folic Acid on Vascular Function in Healthy Volunteers|Effect of Lowering of Plasma Homocysteine Concentrations After an Oral Methionine Load on Vascular Function in Healthy Volunteers|Completed||N/A|40||Wageningen Centre for Food Sciences|||||f||||||||||||||2018-06-01 04:50:56.717041|2018-06-01 04:50:56.717041
NCT00126334|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2011-07-20|2005-08-02|2005-08-03|Estimate|||||||2011-07-20|2011-07-21|Estimate|April 2003||2003-04-30|July 2011|2011-07-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|CRIT||Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot||Completed||Phase 4|45|Actual|Medstar Health Research Institute||2|||f||||t||||||||||2018-06-01 04:50:56.776831|2018-06-01 04:50:56.776831
NCT00126321|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2010-02-01|2005-08-02|2005-08-03|Estimate|||||||2010-02-01|2010-02-02|Estimate|November 2004||2004-11-30|February 2010|2010-02-28|March 2011|Anticipated|2011-03-31|November 2010|Anticipated|2010-11-30||Interventional|||Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)|Phase II Study of Cladribine, High-dose Cytarabine and Idarubicin in Patients With Relapsed Acute Myeloid Leukemia|Unknown status|Recruiting|Phase 2|50|Anticipated|University Hospital, Bonn|||||f||||f||||||||||2018-06-01 04:50:56.920084|2018-06-01 04:50:56.920084
NCT00126308|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2009-03-31|2005-08-01|2005-08-03|Estimate|||||||2009-03-31|2009-04-02|Estimate|November 2005||2005-11-30|March 2009|2009-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy|A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH)|Terminated||Phase 4|100|Actual|Kirby Institute||2||no change in primary endpoint at week 48|f||||f||||||||||2018-06-01 04:50:57.011393|2018-06-01 04:50:57.011393
NCT00126295|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2005-08-18|2005-08-02|2005-08-03|Estimate|||||||2005-08-18|2005-08-19|Estimate|June 2003||2003-06-30|August 2005|2005-08-31|May 2005||2005-05-31|||||Interventional|||Evaluation of an Individualised Written Education Package for Stroke Patients|Evaluation of a Computer-Generated Individualised Written Education Package for Patients Following Stroke and Their Carers|Completed||Phase 2|130||Medical Benefits Fund of Australia|||||f||||||||||||||2018-06-01 04:50:57.13142|2018-06-01 04:50:57.13142
NCT00126282|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2009-07-27|2005-08-02|2005-08-03|Estimate|||||||2009-07-27|2009-07-29|Estimate|December 2003||2003-12-31|May 2008|2008-05-31|December 2007|Actual|2007-12-31|||||Interventional|||A Medication Trial Combined With Behavior Therapy for Individuals With Obsessive-compulsive Disorder|A Randomized, Double-blind, Placebo-controlled Medication Trial With D-Cycloserine for Individuals With Obsessive-compulsive Disorder Currently Receiving Behavior Therapy|Completed||N/A|50|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-06-01 04:50:57.196373|2018-06-01 04:50:57.196373
NCT00126269|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2006-09-07|2005-08-02|2005-08-03|Estimate|||||||2006-09-07|2006-09-08|Estimate|May 2003||2003-05-31|September 2006|2006-09-30||||||||Interventional|||Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary|A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis|Unknown status|Recruiting|Phase 3|192||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:50:57.279001|2018-06-01 04:50:57.279001
NCT00126256|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2015-08-11|2005-08-02|2005-08-03|Estimate|||||||2015-08-11|2015-08-13|Estimate|February 2002||2002-02-28|August 2015|2015-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer|Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05|Completed||Phase 3|570|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:50:57.360312|2018-06-01 04:50:57.360312
NCT00126243|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2005-08-16|2005-08-02|2005-08-03|Estimate|||||||2005-08-16|2005-08-17|Estimate|January 1999||1999-01-31|August 2005|2005-08-31|October 2003||2003-10-31|||||Interventional|||Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma|Multicenter, Open Label, Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab + CHOP Regimen in Patients With HIV Related Non-Hodgkin’s Lymphomas. ANRS 085 Rituximab|Terminated||Phase 2|60||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:50:57.454709|2018-06-01 04:50:57.454709
NCT00126230|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2006-09-07|2005-08-02|2005-08-03|Estimate|||||||2006-09-07|2006-09-11|Estimate|January 2004||2004-01-31|September 2006|2006-09-30||||||||Interventional|||Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer|A Prospective Phase II Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer Who Achieve a Response or a Stabilization to Docetaxel-Estramustine|Terminated||Phase 2|55||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 04:50:57.522138|2018-06-01 04:50:57.522138
NCT00126217|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2008-10-20|2005-08-02|2005-08-03|Estimate|||||||2008-10-20|2008-10-21|Estimate|July 2002||2002-07-31|October 2008|2008-10-31|September 2006|Actual|2006-09-30|May 2006|Actual|2006-05-31||Interventional|||Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine|BCG Vaccination and Childhood Morbidity and Mortality: Interventions With Possible Implications for the Immunisation Policy in Developing Countries. Revaccination of Young Children With BCG Vaccine.|Terminated||Phase 4|2871|Actual|Bandim Health Project||2||A cluster of deaths in the BCG-arm compared with controls|f||||||||||||||2018-06-01 04:50:57.585401|2018-06-01 04:50:57.585401
NCT00126204|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2010-03-03|2005-08-02|2005-08-03|Estimate|||||||2010-03-03|2010-03-04|Estimate|March 2004||2004-03-31|September 2006|2006-09-30|July 2006||2006-07-31|||||Interventional|||Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair|Adjunctive Treatment With Doxycycline in Endovascular Aneurysm Repair|Completed||N/A|75||Barnes-Jewish Hospital|||||f||||||||||||||2018-06-01 04:50:57.663083|2018-06-01 04:50:57.663083
NCT00126191|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|2012-11-30||2013-04-17|2005-08-02|2005-08-03|Estimate|2013-04-17|2013-05-23|Estimate||||2013-04-17|2013-05-23|Estimate|July 2005||2005-07-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|||Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma|Phase II Study of Intensive Chemotherapy and Rituximab in Burkitt Lymphoma|Terminated||Phase 2|10|Actual|Dana-Farber Cancer Institute|Early termination leading to small numbers of subjects analyzed.|2||closed due to slow accrual|f||||t||||||||||2018-06-01 04:50:57.743826|2018-06-01 04:50:57.743826
NCT00126178|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2012-09-06|2005-08-02|2005-08-03|Estimate|||||||2012-09-06|2012-09-07|Estimate|May 2005||2005-05-31|September 2012|2012-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer|A Multi-Center, Randomized, Phase 3 Study of Adjuvant Oncophage® Versus Observation in Patients With High Risk After Surgical Treatment for Renal Cell Carcinoma|Terminated||Phase 3|600||Agenus Inc.|||||||||||||||||||2018-06-01 04:50:58.061596|2018-06-01 04:50:58.061596
NCT00126165|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-02|||2012-01-18|2005-08-02|2005-08-03|Estimate|||||||2012-01-18|2012-01-19|Estimate|September 2004||2004-09-30|January 2012|2012-01-31|August 2011|Actual|2011-08-31|||||Interventional|||Short-course Hypofractionated Radiotherapy for Localized Prostate Cancer|A Phase I/II Study of Escalated-dose Short-course Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer|Completed||Phase 1/Phase 2|72|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:50:58.125251|2018-06-01 04:50:58.125251
NCT00126152|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2005-07-29|2005-07-29|2005-08-02|Estimate|||||||2005-07-29|2005-08-02|Estimate|September 2003||2003-09-30|July 2005|2005-07-31|May 2005||2005-05-31|||||Interventional|||Senior Falls Prevention Study|Targeted Injury Prevention Program: Preventing Falls Among Older Adults|Completed||N/A|453||Washington State, Department of Health|||||f||||||||||||||2018-06-01 04:50:58.186042|2018-06-01 04:50:58.186042
NCT00126139|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2007-05-01|2005-07-29|2005-08-02|Estimate|||||||2007-05-01|2007-05-03|Estimate|April 2004||2004-04-30|May 2007|2007-05-31|May 2005|Actual|2005-05-31|||||Interventional|||Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis|Abciximab Versus Aspirin for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic >50% Carotid Stenosis: A Pilot Study (ASTERICS)|Terminated||Phase 3|100||University of Zurich||||Higher hemorrhage rates of Abciximab in ABESST II trial|f||||t||||||||||2018-06-01 04:50:58.246923|2018-06-01 04:50:58.246923
NCT00126126|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|2014-11-24||2015-09-21|2005-08-01|2005-08-02|Estimate|2015-09-21|2015-10-20|Estimate||||2015-09-21|2015-10-20|Estimate|January 2005||2005-01-31|September 2015|2015-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|EBAR||Evidence Based Amputee Rehabilitation (EBAR) Program|Evidence Based Amputee Rehabilitation (EBAR) Program|Completed||N/A|20|Actual|VA Office of Research and Development|Recruitment was challenging. We screened over 350 veterans and non-veterans with lower limb loss and we were only able to enroll 20.|2|||f||||t||||||||||2018-06-01 04:50:58.340491|2018-06-01 04:50:58.340491
NCT00126113|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|2014-09-26||2014-10-06|2005-08-01|2005-08-02|Estimate|2014-10-01|2014-10-06|Estimate||||2014-10-06|2014-10-16|Estimate|August 2005||2005-08-31|October 2014|2014-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|PPT||The Performance-Perceptual Test as a Counseling Tool|The Performance-Perceptual Test as a Counseling Tool|Completed||N/A|74|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:50:58.566271|2018-06-01 04:50:58.566271
NCT00126100|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2007-11-23|2005-08-01|2005-08-02|Estimate|||||||2007-11-23|2007-11-26|Estimate|February 2004||2004-02-29|November 2007|2007-11-30|July 2005|Actual|2005-07-31|||||Interventional|||Bone Marrow Stem Cell Mobilisation Therapy for Acute Myocardial Infarction (AMI)(REVIVAL-2)|A Randomized Clinical Trial of Stem Cell Mobilization by Granulocyte-Colony-Stimulating Factor in Patients With Acute Myocardial Infarction. Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Trial|Completed||Phase 4|114|Actual|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-06-01 04:50:58.806485|2018-06-01 04:50:58.806485
NCT00126087|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-31|||2013-01-18|2005-07-31|2005-08-02|Estimate|||||||2013-01-18|2013-01-21|Estimate|July 2005||2005-07-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2007|Actual|2007-12-31||Interventional|||Potentiation of Procedural Motor Learning in Health and Disease|Potentiation of Procedural Motor Learning by Pharmacological Neuromodulation and Transcranial Direct Current Stimulation in Health and Disease|Terminated||Phase 4|18|Actual|University Hospital Muenster||||no further funding available for recruiting and testing participants|f||||||||||||||2018-06-01 04:50:58.878637|2018-06-01 04:50:58.878637
NCT00126074|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2015-01-15|2005-08-01|2005-08-02|Estimate|||||||2015-01-15|2015-01-16|Estimate|October 2004||2004-10-31|March 2006|2006-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation or Flutter|Completed||Phase 3|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:50:58.934054|2018-06-01 04:50:58.934054
NCT00126061|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2015-01-15|2005-08-01|2005-08-02|Estimate|||||||2015-01-15|2015-01-16|Estimate|October 2004||2004-10-31|March 2006|2006-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Male Subjects With Recent Onset Atrial Fibrillation or Flutter|Completed||Phase 3|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:50:59.040481|2018-06-01 04:50:59.040481
NCT00126048|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2010-03-17|2005-08-01|2005-08-02|Estimate|||||||2010-03-17|2010-03-18|Estimate|July 2005||2005-07-31|September 2008|2008-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma|Randomised Controlled Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma|Completed||Phase 2/Phase 3|54|Actual|University of Glasgow||2|||f||||t||||||||||2018-06-01 04:50:59.136875|2018-06-01 04:50:59.136875
NCT00126035|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2005-08-16|2005-07-29|2005-08-02|Estimate|||||||2005-08-16|2005-08-17|Estimate|February 2004||2004-02-29|July 2005|2005-07-31|December 2004||2004-12-31|||||Interventional|||Study With Migraid Device in Acute, Early Treatment of Migraine With Typical Aura|Open, Randomised, Multi-Centre, Cross-Over Study to Investigate the Efficacy of the Migraid Device Compared With No Device Treatment in the Acute, Early Treatment of Migraine With Typical Aura|Completed||N/A|134||Profess Medical Consultancy|||||f||||||||||||||2018-06-01 04:50:59.206429|2018-06-01 04:50:59.206429
NCT00126022|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2015-01-15|2005-08-01|2005-08-02|Estimate|||||||2015-01-15|2015-01-16|Estimate|December 2004||2004-12-31|March 2006|2006-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation|Completed||Phase 3|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:50:59.263978|2018-06-01 04:50:59.263978
NCT00126009|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2008-04-08|2005-08-01|2005-08-02|Estimate|||||||2008-04-08|2008-04-10|Estimate|May 2004||2004-05-31|April 2008|2008-04-30||||||||Interventional|||SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients|A 3-Month, Open, Randomised Trial Comparing the Efficacy and Safety of the Association Valproate-Amisulpride to the Association Valproate-Haloperidol in Bipolar I Patients Suffering From a Manic Episode|Completed||Phase 2|120||Sanofi|||||f||||||||||||||2018-06-01 04:51:00.353283|2018-06-01 04:51:00.353283
NCT00125996|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2005-08-16|2005-08-01|2005-08-02|Estimate|||||||2005-08-16|2005-08-17|Estimate|July 2004||2004-07-31|January 2005|2005-01-31|February 2006||2006-02-28|||||Interventional|||Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure|A Randomised Controlled Study to Assess the Acute and Chronic Effects of Intravenous Iron Supplementation in Anaemic and Non-Anaemic Iron Deficient Patients With Chronic Heart Failure|Unknown status|Recruiting|Phase 1/Phase 2|42||National Heart and Lung Institute|||||f||||||||||||||2018-06-01 04:51:00.413229|2018-06-01 04:51:00.413229
NCT00125983|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2012-05-17|2005-08-01|2005-08-02|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|January 2007|Actual|2007-01-31|||||Interventional|||Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women|A Phase II Pharmacokinetic Study of the Transdermal Contraceptive System and Oral Contraceptive in HIV-1 Infected Women on Lopinavir/Ritonavir|Completed||Phase 2|32|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:51:00.492149|2018-06-01 04:51:00.492149
NCT00125970|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30||2010-01-30|2012-11-07|2005-08-01|2005-08-02|Estimate||||2010-01-30|2010-02-02|Estimate|2012-11-07|2012-11-12|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|January 2010|Actual|2010-01-31|February 2008|Actual|2008-02-29||Interventional|||Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults|A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed By a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRC-HIVADV014-00-VP, in HIV-1 Uninfected Adult Participants|Completed||Phase 2|480|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:51:00.582127|2018-06-01 04:51:00.582127
NCT00125957|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|2014-06-11||2014-08-05|2005-08-01|2005-08-02|Estimate|2014-08-05|2014-08-06|Estimate||||2014-08-05|2014-08-06|Estimate|August 2005||2005-08-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|||The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression|The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression|Completed||Phase 3|32|Actual|Mclean Hospital||2|||f||||f||||||||||2018-06-01 04:51:00.701303|2018-06-01 04:51:00.701303
NCT00125944|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2007-05-08|2005-08-01|2005-08-02|Estimate|||||||2007-05-08|2007-05-09|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|January 2006||2006-01-31|||||Interventional|||Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults|Completed||Phase 3|300||MedImmune LLC|||||||||||||||||||2018-06-01 04:51:01.03499|2018-06-01 04:51:01.03499
NCT00125931|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|2012-10-22||2014-08-25|2005-08-01|2005-08-02|Estimate|2014-08-25|2014-09-04|Estimate||||2014-08-25|2014-09-04|Estimate|September 2005||2005-09-30|August 2014|2014-08-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional||Inpatients with manic symptoms.|Effects of Pentazocine on Manic Symptoms|Inpatient Clinical Trial Examining the Effects of Pentazocine on Manic Symptoms|Completed||Phase 2|10|Actual|Mclean Hospital|Small number of participants in open-label trial.|1|||f||||f||||||||||2018-06-01 04:51:01.117557|2018-06-01 04:51:01.117557
NCT00125918|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2008-02-13|2005-08-01|2005-08-02|Estimate|||||||2008-02-13|2008-02-21|Estimate|August 2005||2005-08-31|February 2008|2008-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension|PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension|Completed||Phase 3|406|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-06-01 04:51:01.346495|2018-06-01 04:51:01.346495
NCT00125905|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2009-09-29|2005-08-01|2005-08-02|Estimate|||||||2009-09-29|2009-09-30|Estimate|October 2003||2003-10-31|November 2003|2003-11-30|July 2006||2006-07-31|||||Interventional|||ISTAPS: A Stepped Primary Care Smoking Cessation Intervention|Effectiveness of a Stepped Primary Care Smoking Cessation Intervention Based on an Evidence Based Clinical Practice Guideline (ISTAPS Project)|Unknown status|Active, not recruiting|N/A|3012||Jordi Gol i Gurina Foundation|||||f||||||||||||||2018-06-01 04:51:01.469168|2018-06-01 04:51:01.469168
NCT00125892|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2007-05-16|2005-07-29|2005-08-02|Estimate|||||||2007-05-16|2007-05-17|Estimate|July 2005||2005-07-31|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||A Study of Duloxetine in the Treatment of Fibromyalgia|A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome|Completed||Phase 3|320||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:51:01.558206|2018-06-01 04:51:01.558206
NCT00125879|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2014-02-04|2005-08-01|2005-08-02|Estimate|||||||2014-02-04|2014-02-06|Estimate|June 2005||2005-06-30|February 2014|2014-02-28|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Interventional|||Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602|A Long-Term Continuation Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602|Completed||Phase 2/Phase 3|16|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:51:01.662852|2018-06-01 04:51:01.662852
NCT00125866|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2015-05-27|2005-07-29|2005-08-02|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2005||2005-09-30|April 2007|2007-04-30|January 2006|Actual|2006-01-31|||||Interventional|||The Effect of Cocoa Flavonoids on Blood Pressure|The Effect of Cocoa Polyphenols on Various Cardiovascular Measurements Including Blood Pressure|Completed||N/A|50||Imperial College London|||||f||||||||||||||2018-06-01 04:51:01.747905|2018-06-01 04:51:01.747905
NCT00125853|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2014-04-07|2005-07-29|2005-08-02|Estimate|||||||2014-04-07|2014-04-08|Estimate|July 2006||2006-07-31|April 2014|2014-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Nebivolol on Insulin Sensitivity|A Trial to Compare the Effects of Nebivolol Versus Atenolol on Various Cardiovascular Measurements Including Insulin Sensitivity|Completed||N/A|54|Actual|Imperial College London||2|||f||||f||||||||||2018-06-01 04:51:01.823134|2018-06-01 04:51:01.823134
NCT00125840|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2014-02-04|2005-07-29|2005-08-02|Estimate|||||||2014-02-04|2014-02-05|Estimate|August 2002||2002-08-31|February 2014|2014-02-28|August 2007|Actual|2007-08-31|||||Interventional|||Clofarabine in Adult Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetic Study of Clofarabine in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|||Sanofi|||||||||||||||||||2018-06-01 04:51:01.890433|2018-06-01 04:51:01.890433
NCT00125827|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2014-03-17|2005-07-29|2005-08-02|Estimate|||||||2014-03-17|2014-03-19|Estimate|October 2003||2003-10-31|March 2014|2014-03-31|February 2006|Actual|2006-02-28|October 2004|Actual|2004-10-31||Interventional|||Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors|A Phase I Dose Escalation and Pharmacokinetic Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors|Completed||Phase 1|24|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:51:01.949537|2018-06-01 04:51:01.949537
NCT00125814|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2005-08-15|2005-08-01|2005-08-02|Estimate|||||||2005-08-15|2005-08-16|Estimate|December 2001||2001-12-31|August 2005|2005-08-31|January 2005||2005-01-31|||||Interventional|||Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression|Multi-Center Trial to Evaluate the Efficacy and Safety of Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression (ANRS 105 INTERVAC)|Terminated||Phase 3|200||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:51:02.029281|2018-06-01 04:51:02.029281
NCT00125801|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2008-10-13|2005-08-01|2005-08-02|Estimate|||||||2008-10-13|2008-10-15|Estimate|August 2005||2005-08-31|October 2008|2008-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Pain Pen for Breakthrough Cancer Pain|Breakthrough Cancer Pain: A Randomized Trial Comparing Oral Morphine Immediate Release and Self-Administration of Subcutaneous Hydromorphone Using an Injection Pen|Terminated||Phase 3|50|Anticipated|Erasmus Medical Center||||Lack of patients|f||||t||||||||||2018-06-01 04:51:02.185186|2018-06-01 04:51:02.185186
NCT00125788|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01||2011-11-17|2017-08-07|2005-08-01|2005-08-02|Estimate||||2011-11-17|2011-11-21|Estimate|2017-08-07|2017-08-09|Actual|March 2004||2004-03-31|August 2017|2017-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia|A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia|Completed||Phase 2|81|Actual|Emmaus Medical, Inc.||2|||f||||f||||||||Undecided||2018-06-01 04:51:02.259953|2018-06-01 04:51:02.259953
NCT00125775|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2010-01-06|2005-08-01|2005-08-02|Estimate|||||||2010-01-06|2010-01-07|Estimate|May 2005||2005-05-31|July 2009|2009-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?|Phase 4 Study of Recombinant Hepatitis B Vaccine in Peritoneal Dialysis Subjects|Completed||Phase 4|130|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-06-01 04:51:02.348731|2018-06-01 04:51:02.348731
NCT00125762|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|2017-03-22||2017-09-28|2005-08-01|2005-08-02|Estimate|2017-09-28|2017-10-27|Actual||||2017-09-28|2017-10-27|Actual|March 2005|Actual|2005-03-31|September 2017|2017-09-30|October 1, 2008|Actual|2008-10-01|May 1, 2008|Actual|2008-05-01||Interventional|||FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy|Comparison of FibroScan With Histological Evaluations of Liver Fibrosis in Patients With Hepatitis B and C Presenting for Liver Biopsy|Completed||N/A|907|Actual|Beth Israel Deaconess Medical Center||1|||f||||f|f|t||||||No||2018-06-01 04:51:02.422766|2018-06-01 04:51:02.422766
NCT00125749|ClinicalTrials.gov processed this data on May 31, 2018|2005-08-01|||2017-06-09|2005-08-01|2005-08-02|Estimate|||||||2017-06-09|2017-06-12|Actual|July 2005||2005-07-31|June 2017|2017-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Vaccination of Patients With Stage IV Melanoma With Dendritic Cells|Vaccination of Patients With Stage IV Melanoma With Dendritic Cells Generated Ex Vivo From Monocytes and Loaded With Heat Treated Killed Allogeneic Melanoma Cells|Completed||Phase 1/Phase 2|30|Actual|Baylor Research Institute|||||f||||f||||||||||2018-06-01 04:51:02.605679|2018-06-01 04:51:02.605679
NCT00125736|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2010-01-28|2005-07-29|2005-08-02|Estimate|||||||2010-01-28|2010-01-29|Estimate|August 2005||2005-08-31|January 2010|2010-01-31||||September 2008|Actual|2008-09-30||Interventional|||A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium|A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium|Completed||Phase 4|520||Eisai Inc.|||||f||||||||||||||2018-06-01 04:51:02.684596|2018-06-01 04:51:02.684596
NCT00125723|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2010-12-22|2005-08-01|2005-08-02|Estimate|||||||2010-12-22|2010-12-23|Estimate|May 2004||2004-05-31|December 2010|2010-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy|A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy|Completed||Phase 4|2252|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:51:02.831199|2018-06-01 04:51:02.831199
NCT00125710|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2016-07-14|2005-07-29|2005-08-02|Estimate|||||||2016-07-14|2016-07-18|Estimate|June 1998||1998-06-30|June 2014|2014-06-30||||August 2012|Actual|2012-08-31||Observational|||Comparative 2-D Tumor Analysis in Familial Gliomas|Comparative 2-D Tumor Analysis in Familial Gliomas|Completed|||5|Anticipated|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:51:02.89948|2018-06-01 04:51:02.89948
NCT00125697|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2016-07-14|2005-07-29|2005-08-02|Estimate|||||||2016-07-14|2016-07-18|Estimate|May 2005||2005-05-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy|Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy|Completed|||49|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:51:02.953564|2018-06-01 04:51:02.953564
NCT00125684|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2012-01-18|2005-08-01|2005-08-02|Estimate|||||||2012-01-18|2012-01-19|Estimate|July 2003||2003-07-31|August 2011|2011-08-31|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Interventional|||Bioavailability and Effectiveness of Transdermally Administered Morphine|Bioavailability and Effectiveness of Transdermally Administered Morphine|Completed||Phase 1|6|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:51:03.019256|2018-06-01 04:51:03.019256
NCT00125671|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2009-09-27|2005-07-29|2005-08-01|Estimate|||||||2009-09-27|2009-09-29|Estimate|January 2000||2000-01-31|September 2009|2009-09-30|April 2006||2006-04-30|||||Interventional|||Warfarin and Antiplatelet Vascular Evaluation|A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease|Unknown status|Active, not recruiting|Phase 3|2400||Warfarin and Antiplatelet Vascular Evaluation|||||f||||||||||||||2018-06-01 04:51:03.093555|2018-06-01 04:51:03.093555
NCT00125658|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|2015-04-20||2017-06-21|2005-07-28|2005-08-01|Estimate|2017-06-21|2017-06-23|Actual||||2017-06-21|2017-06-23|Actual|February 2008||2008-02-29|June 2017|2017-06-30|September 2011|Actual|2011-09-30|June 2009|Actual|2009-06-30||Interventional|||Mechanisms of Upper-Extremity Motor Recovery in Post-stroke Hemiparesis|Mechanisms of Upper-Extremity Motor Recovery in Post-stroke Hemiparesis|Completed||N/A|14|Actual|VA Office of Research and Development|This was a small clinical trial (total n = 14).|2|||f||||f||||||||Undecided||2018-06-01 04:51:03.186361|2018-06-01 04:51:03.186361
NCT00125645|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2018-05-02|2005-07-29|2005-08-01|Estimate|||||||2018-05-02|2018-05-08|Actual|March 1, 2005|Actual|2005-03-01|April 2007|2007-04-30|September 1, 2011|Actual|2011-09-01|September 1, 2011|Actual|2011-09-01||Interventional|||Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)|Global Left Ventricular Function After Acute Myocardial Infarction. Treatment With the Angiotensin 2-Receptor Blocker Irbesartan|Completed||Phase 4|200|Actual|University of Southern Denmark||1|||f||||||||||||||2018-06-01 04:51:03.490687|2018-06-01 04:51:03.490687
NCT00125632|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2009-02-03|2005-07-28|2005-08-01|Estimate|||||||2009-02-03|2009-02-05|Estimate|August 2005||2005-08-31|December 2006|2006-12-31|May 2008|Actual|2008-05-31|||||Interventional|||Measuring Reading Rehabilitation Outcomes|Measuring Reading Rehabilitation Outcomes|Completed||N/A|90|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:51:03.551033|2018-06-01 04:51:03.551033
NCT00125619|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|2015-04-17||2016-12-23|2005-07-28|2005-08-01|Estimate|2016-12-23|2017-02-17|Actual||||2016-12-23|2017-02-17|Actual|September 2005||2005-09-30|December 2016|2016-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Internally Versus Externally Guided Body Weight-Supported Treadmill Training (BWSTT) for Locomotor Recovery Post-stroke|Internally v. Externally Guided BWSTT for Locomotor Recovery Post-stroke|Completed||N/A|16|Actual|VA Office of Research and Development|Small sample size, but consistent with intent of pilot study Inclusion criterion was >6 months post-event, allowing for large heterogeneity in chronicity Intervention was limited (12 sessions distributed over 4 weeks)|2|||f||||f||||||||||2018-06-01 04:51:03.616239|2018-06-01 04:51:03.616239
NCT00125606|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2012-12-17|2005-07-29|2005-08-01|Estimate|||||||2012-12-17|2012-12-18|Estimate|October 2004||2004-10-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide|Randomized Phase 3 Trial for Patients With AML in CR2 Comparing Total Body Irradiation (TBI) With 8Gy/Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide|Terminated||Phase 3|30|Actual|University Hospital Muenster||2||insufficient patient recruitement|f||||t||||||||||2018-06-01 04:51:04.281964|2018-06-01 04:51:04.281964
NCT00125593|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|2011-08-19||2012-01-31|2005-07-29|2005-08-01|Estimate|2012-01-31|2012-02-01|Estimate||||2012-01-31|2012-02-01|Estimate|June 2003||2003-06-30|January 2012|2012-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|SHARP||Study of Heart and Renal Protection|Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial|Completed||Phase 4|9438|Actual|University of Oxford||3|||f||||t||||||||||2018-06-01 04:51:04.403693|2018-06-01 04:51:04.403693
NCT00125580|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2017-11-21|2005-07-29|2005-08-01|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2005||2005-08-31|November 2017|2017-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Healthy Sleeping and Feeding During Infancy|Healthy Sleeping and Feeding During Infancy: Pilot Study for the Primary Prevention of Obesity in Primary Care|Completed||Phase 1|40|Actual|Penn State University|||||f||||||||||||||2018-06-01 04:51:04.990977|2018-06-01 04:51:04.990977
NCT00125567|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2009-06-19|2005-07-29|2005-08-01|Estimate|||||||2009-06-19|2009-06-22|Estimate|August 2005||2005-08-31|June 2009|2009-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|SEWOP||Stalevo in Early Wearing-Off Patients|Multicentre, Randomised, Double-Blind Study to Compare Stalevo to Levodopa/Carbidopa in Patients With Parkinson's Disease Experiencing Symptoms of Early Wearing-Off|Completed||Phase 4|223|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-06-01 04:51:05.12633|2018-06-01 04:51:05.12633
NCT00125554|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2005-08-11|2005-07-29|2005-08-01|Estimate|||||||2005-08-11|2005-08-12|Estimate|May 1998||1998-05-31|July 2005|2005-07-31|July 2001||2001-07-31|||||Interventional|||Metyrapone as Additive Treatment in Major Depression|Double-Blind, Placebo Controlled Trial of Metyrapone as Augmenting Agent in the Treatment of Major Depression|Completed||Phase 2|63||Universitätsklinikum Hamburg-Eppendorf|||||f||||||||||||||2018-06-01 04:51:05.327313|2018-06-01 04:51:05.327313
NCT00125541|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2009-05-01|2005-07-29|2005-08-01|Estimate|||||||2009-05-01|2009-05-04|Estimate|November 2006||2006-11-30|May 2009|2009-05-31|May 2008|Actual|2008-05-31|April 2008|Actual|2008-04-30||Interventional|||C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema|Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema|Completed||Phase 2/Phase 3|6|Anticipated|Sanquin|||||f||||||||||||||2018-06-01 04:51:05.439483|2018-06-01 04:51:05.439483
NCT00125528|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|2015-02-03||2016-12-16|2005-07-29|2005-08-01|Estimate|2015-02-19|2015-02-23|Estimate||||2016-12-16|2017-02-09|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||D-cycloserine in the Management of Chronic Low Back Pain|D-Cycloserine in the Management of Chronic Low Back Pain: A Double-Blind, Randomized, Placebo-Controlled Pilot Study|Completed||Phase 2|41|Actual|Northwestern University|It is not clear whether observed effects are due to escalating dose or duration of D-cycloserine use. A larger population and longer duration of treatment would be needed to determine this.|2|||f||||f||||||||||2018-06-01 04:51:05.625465|2018-06-01 04:51:05.625465
NCT00125515|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|2012-12-18||2013-01-28|2005-07-28|2005-08-01|Estimate|2012-12-18|2013-01-24|Estimate||||2013-01-28|2013-01-31|Estimate|June 2005||2005-06-30|January 2013|2013-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|NAMHS-1||Memantine and Naltrexone Treatment for Opioid Dependence|Evaluation of NMDA Antagonist for Opiate Dependence|Completed||Phase 2|81|Actual|New York State Psychiatric Institute|It is possible that concomitant naltrexone might have exacerbated protracted withdrawal, thus masking the potential ameliorative effects of memantine that have been previously observed in other trials.|3|||f||||t||||||||||2018-06-01 04:51:05.941387|2018-06-01 04:51:05.941387
NCT00125502|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2011-09-16|2005-07-29|2005-08-01|Estimate|||||||2011-09-16|2011-09-20|Estimate|August 1999||1999-08-31|September 2011|2011-09-30|January 2010|Actual|2010-01-31|June 2007|Actual|2007-06-30||Interventional|||Recombinant CMV gB Vaccine in Postpartum Women|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Recombinant CMV gB Vaccine in Postpartum Women|Completed||Phase 2|464|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 04:51:06.357574|2018-06-01 04:51:06.357574
NCT00125489|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2010-08-26|2005-07-29|2005-08-01|Estimate|||||||2010-08-26|2010-08-27|Estimate|May 2005||2005-05-31|March 2007|2007-03-31|December 2005||2005-12-31|||||Interventional|||CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi|Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi|Completed||Phase 4|210||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:51:06.425659|2018-06-01 04:51:06.425659
NCT00125476|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2006-10-10|2005-07-29|2005-08-01|Estimate|||||||2006-10-10|2006-10-11|Estimate|July 2004||2004-07-31|October 2006|2006-10-31||||||||Interventional|||Effects of Exercise Training on Diastolic Heart Function in Postmenopausal Women|Training and Diastolic Function in Postmenopausal Women|Completed||N/A|215||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:51:06.490214|2018-06-01 04:51:06.490214
NCT00125463|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2005-08-08|2005-07-29|2005-08-01|Estimate|||||||2005-08-08|2005-08-10|Estimate|September 2001||2001-09-30|April 2005|2005-04-30|December 2005||2005-12-31|||||Interventional|||Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients|Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients|Unknown status|Active, not recruiting|Phase 3|3200||The Japanese Society of Hypertension|||||f||||||||||||||2018-06-01 04:51:06.554817|2018-06-01 04:51:06.554817
NCT00125450|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2008-05-26|2005-07-29|2005-08-01|Estimate|||||||2008-05-26|2008-05-28|Estimate|September 2004||2004-09-30|October 2006|2006-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|BRONKINOU||Evaluation of Chest Physiotherapy for Acute Bronchiolitis in Toddlers (BRONKINOU)|Efficacy and Safety of Chest Physiotherapy With Forced Expiratory Technique for Acute Bronchiolitis in Toddlers|Completed||N/A|500|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-06-01 04:51:06.61235|2018-06-01 04:51:06.61235
NCT00125437|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2009-07-13|2005-07-29|2005-08-01|Estimate|||||||2009-07-13|2009-07-15|Estimate|September 2005||2005-09-30|December 2008|2008-12-31|September 2009|Anticipated|2009-09-30|||||Interventional|||Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy|Safety and Efficacy of Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy|Terminated||N/A|200|Anticipated|Hebei Medical University||||Poor compliance with the therapy and lot of patients were lost to follow up.|f||||||||||||||2018-06-01 04:51:06.705871|2018-06-01 04:51:06.705871
NCT00125424|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2008-11-06|2005-07-29|2005-08-01|Estimate|||||||2008-11-06|2008-11-07|Estimate|July 2005||2005-07-31|November 2008|2008-11-30|September 2005|Actual|2005-09-30|||||Interventional|||Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy|A Randomized, Double-Blind, Dose-Response Study to Assess the Efficacy and Safety of AQUAVAN® Injection for Procedural Sedation in Patients Undergoing Colonoscopy|Completed||Phase 2/Phase 3|125||Eisai Inc.|||||||||||||||||||2018-06-01 04:51:06.768076|2018-06-01 04:51:06.768076
NCT00125411|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2012-03-22|2005-07-28|2005-08-01|Estimate|||||||2012-03-22|2012-03-26|Estimate|March 2007||2007-03-31|March 2012|2012-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Study of Satraplatin (JM-216) in Combination With Docetaxel|Phase I Study of the Oral Platinum Agent Satraplatin (JM-216) in Combination With Docetaxel in Treatment of Advanced Malignancies|Terminated||Phase 1|28|Actual|Agennix||||Sponsor decided to discontinue study drug development.|f||||||||||||||2018-06-01 04:51:06.953475|2018-06-01 04:51:06.953475
NCT00125398|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2008-11-06|2005-07-28|2005-08-01|Estimate|||||||2008-11-06|2008-11-07|Estimate|July 2005||2005-07-31|November 2008|2008-11-30|May 2007|Actual|2007-05-31|||||Interventional|||GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting|A Phase II, Randomized, Open-Label Study to Examine the Safety and Efficacy of GPI 15715 for Sedation of Patients Requiring Intubation and Mechanical Ventilation in the Intensive Care Unit Setting|Completed||Phase 2|60||Eisai Inc.|||||f||||||||||||||2018-06-01 04:51:07.012014|2018-06-01 04:51:07.012014
NCT00125385|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2015-04-09|2005-07-29|2005-08-01|Estimate|||||||2015-04-09|2015-04-13|Estimate|July 2005||2005-07-31|April 2015|2015-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 1|25|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 04:51:07.148776|2018-06-01 04:51:07.148776
NCT00125372|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2014-07-14|2005-07-29|2005-08-01|Estimate|||||||2014-07-14|2014-07-15|Estimate|December 2005||2005-12-31|July 2014|2014-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Study of Tarceva and Targretin in Stage I-II Lung Cancer|A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer|Completed||N/A|15|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 04:51:07.227363|2018-06-01 04:51:07.227363
NCT00125359|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2014-11-11|2005-07-29|2005-08-01|Estimate|||||||2014-11-11|2014-11-13|Estimate|August 2005||2005-08-31|July 2013|2013-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer|A Phase II Clinical Study of Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|42|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 04:51:07.312004|2018-06-01 04:51:07.312004
NCT00125346|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2011-10-10|2005-07-28|2005-08-01|Estimate|||||||2011-10-10|2011-10-12|Estimate|September 2005||2005-09-30|October 2011|2011-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|EVOLVE||Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects|Terminated||Phase 3|98|Actual|Novartis||||per Data Monitoring Committee recommendation|||||||||||||||2018-06-01 04:51:07.398605|2018-06-01 04:51:07.398605
NCT00125333|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2008-11-18|2005-07-28|2005-08-01|Estimate|||||||2008-11-18|2008-11-19|Estimate|March 2005||2005-03-31|November 2008|2008-11-30|November 2005||2005-11-30|||||Interventional|||Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis|A Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety of Repeated Topical Application of Three Concentrations of NF-kappaB Decoy in Adults With Mild-to-Moderate Atopic Dermatitis|Completed||Phase 1/Phase 2|75||Anesiva, Inc.|||||||||||||||||||2018-06-01 04:51:07.513053|2018-06-01 04:51:07.513053
NCT00125320|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2007-12-19|2005-07-28|2005-08-01|Estimate|||||||2007-12-19|2007-12-24|Estimate|June 2004||2004-06-30|December 2007|2007-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery|A Phase III Study of the Conversion Efficacy and Safety of Repeated Intravenous Doses of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter Following Valvular and/or Coronary Artery Bypass Graft Surgery|Completed||Phase 3|190|Actual|Astellas Pharma Inc|||||f||||t||||||||||2018-06-01 04:51:07.582316|2018-06-01 04:51:07.582316
NCT00125307|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2015-07-31|2005-07-29|2005-08-01|Estimate|||||||2015-07-31|2015-08-03|Estimate|January 2004||2004-01-31|May 2008|2008-05-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis|Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis|Completed||Phase 4|20||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:51:07.675295|2018-06-01 04:51:07.675295
NCT00125294|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2017-09-21|2005-07-29|2005-08-01|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2003||2003-09-30|August 2011|2011-08-31|January 2007|Actual|2007-01-31|June 2006|Actual|2006-06-30||Interventional|||Sublingual Methadone for the Management of Cancer Breakthrough Pain|Evaluation of a Dose Titration Protocol for Sublingual Methadone Hydrochloride for the Management of Cancer-related Breakthrough Pain|Completed||Phase 1|10|Actual|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:51:07.745515|2018-06-01 04:51:07.745515
NCT00125281|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-29|||2017-06-30|2005-07-28|2005-07-29|Estimate|||||||2017-06-30|2017-07-02|Actual|July 25, 2005||2005-07-25|July 2, 2008|2008-07-02|July 2, 2008|Actual|2008-07-02|July 31, 2007|Actual|2007-07-31||Interventional|||SAMe to Treat Biliary Cirrhosis Symptoms|S-Adenosyl Methionine for Symptomatic Treatment of Primary Biliary Cirrhosis|Terminated||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:51:07.810205|2018-06-01 04:51:07.810205
NCT00125268|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|2012-08-02||2012-08-02|2005-07-28|2005-07-29|Estimate|2012-08-02|2012-09-05|Estimate||||2012-08-02|2012-09-05|Estimate|July 2005||2005-07-31|August 2012|2012-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Near Infrared Light for the Treatment of Painful Peripheral Neuropathy|A Phase III, Double Blind, Randomized, Placebo-controlled Study to Assess the Efficacy of Adjunct Monochromatic Near-infrared Photoenergy (MIRE) in Patients With Painful Axonal Peripheral Neuropathy|Terminated||Phase 3|30|Actual|Mayo Clinic|This study was terminated early because the study was unable to enroll enough patients.|2||Unable to enroll enough patients|f||||t||||||||||2018-06-01 04:51:07.885479|2018-06-01 04:51:07.885479
NCT00125255|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2012-06-04|2005-07-27|2005-07-29|Estimate|||||||2012-06-04|2012-06-06|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children|A Randomized, Double-blind, Placebo Controlled, Parallel Study Evaluating the Efficacy of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) for Induction of Local Dermal Anesthesia Before Vascular Access Procedures in Children|Completed||Phase 3|81|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 04:51:08.120421|2018-06-01 04:51:08.120421
NCT00125242|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|2014-11-21||2014-12-22|2005-07-27|2005-07-29|Estimate|2014-12-22|2014-12-24|Estimate||||2014-12-22|2014-12-24|Estimate|July 2005||2005-07-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|February 2009|Actual|2009-02-28||Interventional||SFA Treatment Participants = Stroke survivors with chronic aphasia. Non Treatment Stimuli Development Participants = non-brain-damaged persons who were enrolled for purposes of stimuli development.|Word-Retrieval Treatment for Aphasia: Semantic Feature Analysis|Word-Retrieval for Aphasia: Facilitation of Generalization|Completed||N/A|110|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:51:08.198649|2018-06-01 04:51:08.198649
NCT00123370|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2007-04-29|2005-07-21|2005-07-22|Estimate|||||||2007-04-29|2007-05-01|Estimate|July 2006||2006-07-31|July 2006|2006-07-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Trial of Modafinil for Methamphetamine Dependence|Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence|Unknown status|Active, not recruiting|Phase 2|87|Anticipated|The University of New South Wales|||||f||||f||||||||||2018-06-01 04:51:46.779382|2018-06-01 04:51:46.779382
NCT00125229|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2012-06-22|2005-07-28|2005-07-29|Estimate|||||||2012-06-22|2012-06-26|Estimate|August 2005||2005-08-31|June 2012|2012-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients|Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients|Terminated|||10|Anticipated|The University of Texas Health Science Center at San Antonio||||Dr. Hladky died Sept 2006 prior to study completion|f||||||||||||||2018-06-01 04:51:08.370538|2018-06-01 04:51:08.370538
NCT00125216|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2014-04-04|2005-07-27|2005-07-29|Estimate|||||||2014-04-04|2014-04-07|Estimate|December 2004||2004-12-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of the Effects of Response Elaboration Training for Aphasia|Evaluation of the Effects of Response Elaboration Training for Aphasia|Completed||N/A|47|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:51:08.44796|2018-06-01 04:51:08.44796
NCT00125203|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2012-03-13|2005-07-27|2005-07-29|Estimate|||||||2012-03-13|2012-03-14|Estimate|July 2003||2003-07-31|March 2012|2012-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis|Completed||Phase 2/Phase 3|20||The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 04:51:08.514558|2018-06-01 04:51:08.514558
NCT00125190|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|2010-03-23||2012-06-14|2005-07-27|2005-07-29|Estimate|2010-03-23|2010-04-15|Estimate||||2012-06-14|2012-06-21|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency|Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study|Completed||Phase 2/Phase 3|45|Actual|Ipsen|||||f||||t||||||||||2018-06-01 04:51:08.596471|2018-06-01 04:51:08.596471
NCT00125177|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2010-11-09|2005-07-28|2005-07-29|Estimate|||||||2010-11-09|2010-11-10|Estimate|January 2003||2003-01-31|July 2005|2005-07-31|April 2008|Actual|2008-04-30|||||Interventional|||IRIS: Incontinence Research Intervention Study|Office for Research on Women's Health (ORWH): Specialized Centers of Research (SCOR) on Sex and Gender Factors Affecting Women's Health. Project 3: Selection Criteria For Muscle Therapy in SUI|Completed||Phase 1/Phase 2|320|Anticipated|University of Michigan|||||f||||||||||||||2018-06-01 04:51:08.846487|2018-06-01 04:51:08.846487
NCT00125164|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|2009-07-08||2012-06-14|2005-07-27|2005-07-29|Estimate|2010-04-28|2010-04-30|Estimate||||2012-06-14|2012-06-21|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency|Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial|Completed||Phase 3|137|Actual|Ipsen||4|||f||||t||||||||||2018-06-01 04:51:08.93464|2018-06-01 04:51:08.93464
NCT00125151|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2009-05-01|2005-07-28|2005-07-29|Estimate|||||||2009-05-01|2009-05-04|Estimate|February 2006||2006-02-28|May 2009|2009-05-31|April 2007|Actual|2007-04-30|||||Interventional|||C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema|Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema|Completed||Phase 3|15|Anticipated|Sanquin|||||f||||||||||||||2018-06-01 04:51:09.902965|2018-06-01 04:51:09.902965
NCT00125138|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|2011-04-11||2011-05-17|2005-07-27|2005-07-29|Estimate|2011-05-17|2011-06-17|Estimate||||2011-05-17|2011-06-17|Estimate|July 2005||2005-07-31|May 2011|2011-05-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease|Safety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's Disease|Completed||Phase 2|90|Actual|Lundbeck LLC||4|||f||||t||||||||||2018-06-01 04:51:10.008294|2018-06-01 04:51:10.008294
NCT00125125|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2017-05-15|2005-07-28|2005-07-29|Estimate|||||||2017-05-15|2017-05-17|Actual|May 2005||2005-05-31|May 2017|2017-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Fluvastatin in Adults With Dislipidemia With History of Muscle Problems|Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake|Completed||Phase 4|218|Actual|Novartis|||||||||||||||||||2018-06-01 04:51:10.389025|2018-06-01 04:51:10.389025
NCT00125112|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2010-01-15|2005-07-28|2005-07-29|Estimate|||||||2010-01-15|2010-01-18|Estimate|February 2005||2005-02-28|January 2010|2010-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Internet Weight Control for Bingeing Adolescents|Internet Weight Control for Bingeing Adolescents|Completed||Phase 1|120|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:51:10.448719|2018-06-01 04:51:10.448719
NCT00125099|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2012-05-16|2005-07-28|2005-07-29|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection|Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (GAG-POL-NEF-MULTICLADE ENV) in HIV-1 Infected Subjects Treated During Acute HIV Infection|Completed||Phase 1/Phase 2|21|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:51:10.503561|2018-06-01 04:51:10.503561
NCT00125086|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2005-09-12|2005-07-28|2005-07-29|Estimate|||||||2005-09-12|2005-09-14|Estimate|July 2005||2005-07-31|September 2005|2005-09-30|February 2006||2006-02-28|||||Interventional|||Platelets for Acute Wound Healing|Platelets in Acute Wounds: A Punch Biopsy Study (PAWS II)|Completed||N/A|4||Medtronic|||||f||||||||||||||2018-06-01 04:51:10.570177|2018-06-01 04:51:10.570177
NCT00125073|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2010-06-25|2005-07-28|2005-07-29|Estimate|||||||2010-06-25|2010-06-28|Estimate|July 2005||2005-07-31|June 2010|2010-06-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Postoperative Dietary Counseling After Bariatric Surgery|Postoperative Dietary Counseling After Bariatric Surgery|Completed||N/A|100|Anticipated|University of Pennsylvania|||||f||||||||||||||2018-06-01 04:51:10.621741|2018-06-01 04:51:10.621741
NCT00125060|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2017-08-23|2005-07-28|2005-07-29|Estimate|||||||2017-08-23|2017-08-24|Actual|August 2000||2000-08-31|August 2017|2017-08-31|April 2004||2004-04-30|||||Interventional|||Transesophageal Magnetic Resonance Imaging (MRI) in Conjunction With Lipid Lowering Measures|Transesophageal MRI in Conjunction With Lipid Lowering Measures|Completed||N/A|72||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:51:10.678275|2018-06-01 04:51:10.678275
NCT00125047|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2008-08-25|2005-07-28|2005-07-29|Estimate|||||||2008-08-25|2008-08-26|Estimate|October 2001||2001-10-31|August 2008|2008-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood|Effectiveness of a Combined Vi Vaccination and Health Education Program on Reducing the Burden of Typhoid During Childhood: A Demonstration Project in Karachi|Completed||Phase 4|27231|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-06-01 04:51:10.756789|2018-06-01 04:51:10.756789
NCT00125034|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|2011-08-23||2014-08-05|2005-07-28|2005-07-29|Estimate|2011-08-23|2011-10-04|Estimate||||2014-08-05|2014-08-07|Estimate|July 2005||2005-07-31|August 2011|2011-08-31|November 2010|Actual|2010-11-30|March 2007|Actual|2007-03-31||Interventional|OPUS||Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)|Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer|Completed||Phase 2|344|Actual|Merck KGaA|A non-specific outcome measure 'Safety' was deleted from this entry in error. A replacement outcome has been created. The 'Safety' outcome refers to adverse events and these are shown in the 'Adverse Events' section.|2|||f||||f||||||||||2018-06-01 04:51:10.894544|2018-06-01 04:51:10.894544
NCT00125021|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2009-10-30|2005-07-27|2005-07-29|Estimate|||||||2009-10-30|2009-11-02|Estimate|October 2003||2003-10-31|October 2009|2009-10-31|September 2008|Actual|2008-09-30|June 2004|Actual|2004-06-30||Interventional|||Tarceva and Capecitabine for Pancreatic Cancer|A Phase II Study of OSI-774 (Tarceva) in Combination With Capecitabine in Previously Treated Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|32|Actual|Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:51:12.697302|2018-06-01 04:51:12.697302
NCT00125008|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-28|||2008-08-25|2005-07-28|2005-07-29|Estimate|||||||2008-08-25|2008-08-26|Estimate|May 2003||2003-05-31|August 2008|2008-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever|Randomized Controlled Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever in Eastern Kolkata, West Bengal, India|Completed||Phase 4|37673|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-06-01 04:51:12.773246|2018-06-01 04:51:12.773246
NCT00124995|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2013-02-12|2005-07-27|2005-07-29|Estimate|||||||2013-02-12|2013-02-15|Estimate|October 2003||2003-10-31|February 2013|2013-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Trial of Terbutaline for the Treatment of Status Asthmaticus in Children|Double-blinded Randomized Trial of Terbutaline to Shorten ICU Length of Stay in the Treatment of Status Asthmaticus in Children|Completed||Phase 4|40||Connecticut Children's Medical Center|||||f||||||||||||||2018-06-01 04:51:12.852747|2018-06-01 04:51:12.852747
NCT00124982|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2011-02-18||2012-02-23|2005-07-28|2005-07-29|Estimate|2011-04-29|2011-06-02|Estimate||||2012-02-23|2012-02-27|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy|A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options|Completed||Phase 3|1286|Actual|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 04:51:13.291234|2018-06-01 04:51:13.291234
NCT00124969|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-05-07|2005-07-27|2005-07-29|Estimate|||||||2008-05-07|2008-05-09|Estimate|January 2002||2002-01-31|October 2006|2006-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure|Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])|Completed||Phase 4|356|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-06-01 04:51:16.63179|2018-06-01 04:51:16.63179
NCT00124956|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2017-09-07|2005-07-28|2005-07-29|Estimate|||||||2017-09-07|2017-09-11|Actual|June 2003||2003-06-30|September 2017|2017-09-30||||||||Interventional|||Doxorubicin Pharmacokinetic (PK) Study|Impact of Body Composition on Pharmacokinetics of Doxorubicin in Pediatric Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:51:16.698151|2018-06-01 04:51:16.698151
NCT00124943|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|2012-02-21||2012-03-28|2005-07-27|2005-07-29|Estimate|2012-02-21|2012-03-08|Estimate||||2012-03-28|2012-04-02|Estimate|July 2005||2005-07-31|March 2012|2012-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|SNAPIST-III||Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis|A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis|Completed||Phase 1/Phase 2|112|Actual|Celgene||4|||f||||f||||||||||2018-06-01 04:51:16.812|2018-06-01 04:51:16.812
NCT00124930|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2012-01-18|2005-07-28|2005-07-29|Estimate|||||||2012-01-18|2012-01-19|Estimate|May 2005||2005-05-31|January 2012|2012-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer|A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer|Terminated||Phase 3|80|Anticipated|AHS Cancer Control Alberta||||Study suspended due to low enrollment|f||||||||||||||2018-06-01 04:51:17.726142|2018-06-01 04:51:17.726142
NCT00124917|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2017-10-05|2005-07-27|2005-07-28|Estimate|||||||2017-10-05|2017-10-06|Actual|July 21, 2005||2005-07-21|May 9, 2017|2017-05-09|May 9, 2017|Actual|2017-05-09|March 6, 2011|Actual|2011-03-06||Interventional|||Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer|A Phase I Study of Image Guided Dose Escalation With Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer|Completed||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 04:51:17.807355|2018-06-01 04:51:17.807355
NCT00124904|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2010-01-12|2005-07-27|2005-07-28|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 1999||1999-09-30|January 2010|2010-01-31|December 2006||2006-12-31|||||Interventional|||Biofeedback for Fecal Incontinence|Biofeedback for Fecal Incontinence and Constipation|Completed||N/A|165||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:51:17.867921|2018-06-01 04:51:17.867921
NCT00124891|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2007-12-06|2005-07-26|2005-07-28|Estimate|||||||2007-12-06|2007-12-10|Estimate|June 2005||2005-06-30|December 2007|2007-12-31|November 2006|Actual|2006-11-30|||||Interventional|||Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia|Study Evaluating Subjects With Non-Sustained Ventricular Tachycardia|Terminated||Phase 2|500||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:51:17.934508|2018-06-01 04:51:17.934508
NCT00124878|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2007-08-09|2005-07-26|2005-07-28|Estimate|||||||2007-08-09|2007-08-10|Estimate|August 2003||2003-08-31|July 2005|2005-07-31|September 2009|Anticipated|2009-09-30|||||Interventional|||Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community|Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community|Unknown status|Active, not recruiting|Phase 3|5200|Actual|Wawer, Maria J., M.D.||2|||f||||t||||||||||2018-06-01 04:51:18.20904|2018-06-01 04:51:18.20904
NCT00124475|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2010-07-16|2005-07-27|2005-07-28|Estimate|||||||2010-07-16|2010-07-19|Estimate|December 2004||2004-12-31|July 2010|2010-07-31|September 2007|Actual|2007-09-30|October 2006|Actual|2006-10-31||Interventional|||Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis|Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis|Completed||Phase 3|1035||Basilea Pharmaceutica|||||f||||||||||||||2018-06-01 04:51:24.544264|2018-06-01 04:51:24.544264
NCT00124865|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2017-09-25|2005-07-26|2005-07-28|Estimate|||||||2017-09-25|2017-09-26|Actual|July 2005||2005-07-31|September 2017|2017-09-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) Dose-Ranging Study|Safety and Immunogenicity Evaluation of an Intranasal Recombinant Flagellin Subunit Campylobacter Vaccine (rFla-MBP) in Volunteers|Withdrawn||Phase 1|0|Actual|U.S. Army Medical Research and Materiel Command||||Sponsor|f||||||||||||||2018-06-01 04:51:18.280471|2018-06-01 04:51:18.280471
NCT00124852|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2011-01-11|2005-07-26|2005-07-28|Estimate|||||||2011-01-11|2011-01-12|Estimate|October 2005||2005-10-31|January 2011|2011-01-31|July 2007|Actual|2007-07-31|December 2006|Actual|2006-12-31||Interventional|||The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People|The Efficacy of Omega-3 Fatty Acids in Maintaining Optimal Mental Health in Elderly People: a Double-blind Placebo-controlled Trial|Completed||N/A|302|Actual|Wageningen University||3|||f||||f||||||||||2018-06-01 04:51:18.340539|2018-06-01 04:51:18.340539
NCT00124839|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2008-04-14|2005-07-27|2005-07-28|Estimate|||||||2008-04-14|2008-04-15|Estimate|October 2005||2005-10-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Naltrexone in Borderline Personality Disorder|Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder|Terminated||Phase 3|48|Anticipated|Central Institute of Mental Health, Mannheim||4||Difficulties in recruiting enough subjects|f||||f||||||||||2018-06-01 04:51:18.409344|2018-06-01 04:51:18.409344
NCT00124826|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2006-01-31|2005-07-27|2005-07-28|Estimate|||||||2006-01-31|2006-02-01|Estimate|May 2004||2004-05-31|July 2005|2005-07-31||||||||Interventional|||SELESTIAL: Trial of Insulin to Control Blood Sugar After Acute Stroke Using Magnetic Resonance Imaging (MRI) End-Points|Spectroscopic Evaluation of Lesion Evolution in Stroke: Trial of Insulin for Acute Lactic Acidosis (SELESTIAL)|Completed||Phase 2|45||University of Glasgow|||||f||||||||||||||2018-06-01 04:51:18.480522|2018-06-01 04:51:18.480522
NCT00124813|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2010-02-01|2005-07-27|2005-07-28|Estimate|||||||2010-02-01|2010-02-02|Estimate|August 2002||2002-08-31|February 2010|2010-02-28|November 2010|Anticipated|2010-11-30|May 2010|Anticipated|2010-05-31||Interventional|||Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma|Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma|Unknown status|Recruiting|Phase 2|80|Anticipated|University Hospital, Bonn|||||f||||||||||||||2018-06-01 04:51:18.543484|2018-06-01 04:51:18.543484
NCT00124800|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2009-09-23|2005-07-27|2005-07-28|Estimate|||||||2009-09-23|2009-09-24|Estimate|November 2005||2005-11-30|September 2009|2009-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||The Effect of Tinnitus Retraining Therapy on Subjective and Objective Measures of Chronic Tinnitus|The Effect of Tinnitus Retraining Therapy on Subjective and Objective Measures of Chronic Tinnitus|Completed||Phase 1|41|Actual|Tinnitus Research Consortium|||||f||||||||||||||2018-06-01 04:51:18.610355|2018-06-01 04:51:18.610355
NCT00124787|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2012-02-29|2005-07-26|2005-07-28|Estimate|||||||2012-02-29|2012-03-01|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|GAG||A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis|A Randomized Double-blind Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Moderate Vomiting Due to Acute Gastroenteritis|Completed||Phase 4|150|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-06-01 04:51:18.733271|2018-06-01 04:51:18.733271
NCT00124774|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2008-03-28|2005-07-27|2005-07-28|Estimate|||||||2008-03-28|2008-04-01|Estimate|November 2004||2004-11-30|March 2008|2008-03-31|April 2006|Actual|2006-04-30|||||Interventional|||Nucleoplasty for Contained Herniated Lumbar Discs|Nucleoplasty for Contained Herniated Lumbar Discs: A Randomised, Double Blind, Prospective Comparison With Sham Treatment|Completed||Phase 3|50|Anticipated|Rijnstate Hospital|||||f||||||||||||||2018-06-01 04:51:18.797004|2018-06-01 04:51:18.797004
NCT00124761|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2010-09-02|2005-07-27|2005-07-28|Estimate|||||||2010-09-02|2010-09-06|Estimate|December 2002||2002-12-31|September 2010|2010-09-30|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||A Trial Comparing Radiosurgery With Surgery for Solitary Brain Metastases|A Randomised Trial of Surgery Plus Whole Brain Radiotherapy (WBRT) Versus Radiosurgery Plus WBRT for Solitary Brain Metastases|Completed||Phase 3|22|Actual|Royal Adelaide Hospital||2|||f||||f||||||||||2018-06-01 04:51:18.856364|2018-06-01 04:51:18.856364
NCT00124748|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|2011-11-02||2012-01-05|2005-07-27|2005-07-28|Estimate|2012-01-05|2012-02-03|Estimate||||2012-01-05|2012-02-03|Estimate|June 2005||2005-06-30|January 2012|2012-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TOPS||Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)|A Randomized Open-label Study of 400 mg Versus 800 mg of Imatinib Mesylate in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints.|Terminated||Phase 3|476|Actual|Novartis||2||"This study was prematurely discontinued because no improvement was observed in the 800mg dose~   compared to 400mg dose"|f||||||||||||||2018-06-01 04:51:18.975789|2018-06-01 04:51:18.975789
NCT00124735|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|2008-12-05||2016-07-14|2005-07-26|2005-07-28|Estimate|2009-03-12|2009-04-15|Estimate||||2016-07-14|2016-08-24|Estimate|October 2004||2004-10-31|June 2016|2016-06-30|September 2007|Actual|2007-09-30|August 2007|Actual|2007-08-31||Interventional|||A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)|An Open-label, Randomized, Phase IIIB, Multicenter Trial to Evaluate the Pharmacodynamic Parameters of Intubation Bolus, and Bolus and Infusion Maintenance Doses of Zemuron® in Pediatric and Adolescent Subjects|Completed||Phase 3|149|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:51:20.227676|2018-06-01 04:51:20.227676
NCT00124722|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2015-05-29|2005-07-26|2005-07-28|Estimate|||||||2015-05-29|2015-06-01|Estimate|December 2004||2004-12-31|May 2015|2015-05-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia|A Randomized, Assessor-blind, Dose-ranging, Phase IIIB, Multicenter Trial Comparing the Intubating Conditions and Time Course of Block of Three Different Intubating Doses (0.45 mg/kg, 0.6 mg/kg, and 1.0 mg/kg) of Zemuron® in Pediatric and Adolescent Subjects Under General Anesthesia|Completed||Phase 3|207|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 04:51:20.721704|2018-06-01 04:51:20.721704
NCT00124488|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2011-12-08|2005-07-26|2005-07-28|Estimate|||||||2011-12-08|2011-12-09|Estimate|June 2005||2005-06-30|December 2011|2011-12-31|November 2005||2005-11-30|||||Observational|||Comparison of Tomotherapy Versus Intensity-modulated Step-and-shoot and Conventional Radiation Treatment Plans for Patients With Locally-advanced Squamous Cell Carcinoma of the Cervix|Comparison of Tomotherapy Versus Intensity-modulated Step-and-shoot and Conventional Radiation Treatment Plans for Patients With Locally-advanced Squamous Cell Carcinoma of the Cervix|Completed|||10||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:51:24.488258|2018-06-01 04:51:24.488258
NCT00124709|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|2010-12-08||2011-02-25|2005-07-26|2005-07-28|Estimate|2011-02-25|2011-03-23|Estimate||||2011-02-25|2011-03-23|Estimate|October 2003||2003-10-31|February 2011|2011-02-28|November 2008|Actual|2008-11-30|January 2008|Actual|2008-01-31||Interventional|||Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification|An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Double-blind Vehicle Controlled Phase to Evaluate Effects on Atopic Dermatitis in Infants, and a 2-3 Year Open-label Phase to Evaluate the Effect of Early Intervention Versus Delayed Intervention With Elidel® on the Incidence of Asthma in Children|Terminated||Phase 4|1091|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:51:20.796215|2018-06-01 04:51:20.796215
NCT00124696|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2017-01-11|2005-07-26|2005-07-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2002||2002-12-31|August 2005|2005-08-31|March 2005||2005-03-31|||||Interventional|||Cocaethylene as a Treatment for Cocaine Dependence - 1|Cocaethylene Substitution Therapy and Tolerance Induction in Treating Cocaine Dependence|Completed||Phase 1|8||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 04:51:21.402767|2018-06-01 04:51:21.402767
NCT00124683|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2017-01-11|2005-07-26|2005-07-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2001||2001-09-30|August 2007|2007-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1|Optimizing Treatment for Schizophrenic Smokers|Completed||Phase 2|59|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-06-01 04:51:21.463988|2018-06-01 04:51:21.463988
NCT00124657|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|2013-09-10||2015-10-29|2005-07-26|2005-07-28|Estimate|2014-03-27|2014-04-29|Estimate||||2015-10-29|2015-12-04|Estimate|March 2005||2005-03-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|July 2012|Actual|2012-07-31||Interventional|||Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma|A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) During and After Radiotherapy in the Treatment of Patients With Newly Diagnosed High Grade Glioma and Unfavorable Low-Grade Glioma|Completed||Phase 1/Phase 2|62|Actual|St. Jude Children's Research Hospital||1|||f||||t||||||||||2018-06-01 04:51:21.590575|2018-06-01 04:51:21.590575
NCT00124644|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2013-05-01|2005-07-26|2005-07-28|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2006||2006-03-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Study of R115777 (Zarnestra) in Combination With Induction Chemotherapy in Patients With Newly Diagnosed, High Risk Acute Myeloid Leukemia|Terminated||Phase 1|30||National Cancer Institute (NCI)||||"Withdrawn due to toxicity problems"|f||||||||||||||2018-06-01 04:51:22.733567|2018-06-01 04:51:22.733567
NCT00124618|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|2015-03-09||2016-07-01|2005-07-26|2005-07-28|Estimate|2015-03-09|2015-03-17|Estimate||||2016-07-01|2016-07-06|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|February 2008|Actual|2008-02-29||Interventional|||Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|Cetuximab (C225) and Radiation in Elderly and /or Poor Performance Status Patients With Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity|Completed||Phase 2|58|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:51:22.802269|2018-06-01 04:51:22.802269
NCT00124605|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2013-01-04|2005-07-26|2005-07-28|Estimate|||||||2013-01-04|2013-01-07|Estimate|April 2005||2005-04-30|January 2013|2013-01-31||||June 2009|Actual|2009-06-30||Interventional|||Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma|Phase I Trial of Arsenic Trioxide in Combination With Pamidronate Disodium|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:51:23.374448|2018-06-01 04:51:23.374448
NCT00124579|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|2013-01-02||2015-03-05|2005-07-26|2005-07-28|Estimate|2013-03-08|2013-04-19|Estimate||||2015-03-05|2015-03-25|Estimate|August 2005||2005-08-31|March 2015|2015-03-31|June 2010|Actual|2010-06-30|June 2008|Actual|2008-06-30||Interventional|||S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma|Terminated||Phase 2|7|Actual|Southwest Oncology Group||1||poor accrual|f||||t||||||||||2018-06-01 04:51:23.501875|2018-06-01 04:51:23.501875
NCT00124566|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2016-01-15|2005-07-26|2005-07-28|Estimate|||||||2016-01-15|2016-01-18|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|December 2009|Actual|2009-12-31|January 2006|Actual|2006-01-31||Interventional|||Study of Irofulven in Patients With Hormone-refractory Prostate Cancer|Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients|Completed||Phase 2|135|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 04:51:23.958091|2018-06-01 04:51:23.958091
NCT00124553|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-27|||2007-03-27|2005-07-27|2005-07-28|Estimate|||||||2007-03-27|2007-03-28|Estimate|August 2006||2006-08-31|March 2007|2007-03-31|June 2008|Anticipated|2008-06-30|||||Interventional|||LOADD (Lifestyle Over and Above Drugs in Diabetes) Study|The Potential for Diet Modification to Improve Glycaemic Control and Cardiovascular Risk Factors Over and Above Drug Therapy in Type 2 Diabetes at High Risk of Cardiovascular Disease|Unknown status|Recruiting|N/A|220||Edgar National Centre for Diabetes Research|||||f||||||||||||||2018-06-01 04:51:24.129132|2018-06-01 04:51:24.129132
NCT00124540|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2008-05-26|2005-07-26|2005-07-28|Estimate|||||||2008-05-26|2008-05-28|Estimate|August 2005||2005-08-31|May 2008|2008-05-31|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Misoprostol for Preventing Postpartum Hemorrhage|Misoprostol for Preventing Postpartum Hemorrhage|Completed||N/A|1200|Actual|Gynuity Health Projects||2|||f||||||||||||||2018-06-01 04:51:24.205073|2018-06-01 04:51:24.205073
NCT00124527|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2008-11-06|2005-07-26|2005-07-28|Estimate|||||||2008-11-06|2008-11-07|Estimate|March 2005||2005-03-31|November 2008|2008-11-30||||||||Interventional|||Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer|Phase 2 Clinical Trial of Bi-Weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer|Completed||Phase 2|35||Eisai Inc.|||||||||||||||||||2018-06-01 04:51:24.28279|2018-06-01 04:51:24.28279
NCT00124514|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2014-07-25|2005-07-26|2005-07-28|Estimate|||||||2014-07-25|2014-07-28|Estimate|June 2003||2003-06-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Triptorelin for Ovary Protection in Childhood Onset Lupus||Completed||Phase 2|30|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-06-01 04:51:24.3465|2018-06-01 04:51:24.3465
NCT00124501|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2008-05-29|2005-07-26|2005-07-28|Estimate|||||||2008-05-29|2008-05-30|Estimate|October 2004||2004-10-31|May 2008|2008-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effectiveness of Biofeedback-Assisted Relaxation Training in Children With Eosinophilic Duodenitis|The Impact of Biofeedback-Assisted Relaxation Training on Pain and Functional Disability in Children Diagnosed With Eosinophilic Duodenitis: Pilot Study|Completed||N/A|20|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-06-01 04:51:24.422448|2018-06-01 04:51:24.422448
NCT00124462|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|2017-04-18||2017-05-30|2005-07-27|2005-07-28|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|March 2008||2008-03-31|May 2017|2017-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Trial of Realignment Therapy for Treatment of Medial Knee Osteoarthritis|A Randomized Trial of Realignment Therapy for Treatment of Medial Knee Osteoarthritis|Completed||N/A|80|Actual|Boston University||2|||f||||f|f|t|f|f|f|||No||2018-06-01 04:51:24.603117|2018-06-01 04:51:24.603117
NCT00124449|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-05-21||2015-03-18|2005-07-27|2005-07-28|Estimate|2009-11-16|2009-11-19|Estimate||||2015-03-18|2015-04-07|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|April 2008|Actual|2008-04-30|May 2007|Actual|2007-05-31||Interventional|||Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients|A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA|Completed||Phase 2|56|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 04:51:24.807989|2018-06-01 04:51:24.807989
NCT00124436|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2010-07-16|2005-07-27|2005-07-28|Estimate|||||||2010-07-16|2010-07-19|Estimate|March 2005||2005-03-31|July 2010|2010-07-31|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis|Follow up Efficacy and Safety Study of BAL4979 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Treatment|Completed||Phase 3|300||Basilea Pharmaceutica|||||f||||||||||||||2018-06-01 04:51:25.543392|2018-06-01 04:51:25.543392
NCT00124423|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2016-02-24|2005-07-26|2005-07-28|Estimate|||||||2016-02-24|2016-02-26|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer|Megavoltage CT (MVCT) Imaging for Intracavitary Radiation Treatment in Cervix Cancer|Completed|||5|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:51:25.594126|2018-06-01 04:51:25.594126
NCT00124410|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2016-02-24|2005-07-26|2005-07-28|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2000||2000-01-31|December 2011|2011-12-31||||December 2008|Actual|2008-12-31||Observational|||Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation|A Pilot Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation|Completed|||100|Actual|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:51:25.6469|2018-06-01 04:51:25.6469
NCT00124397|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2005-08-04|2005-07-26|2005-07-27|Estimate|||||||2005-08-04|2005-08-05|Estimate|July 2001||2001-07-31|July 2005|2005-07-31|December 2004||2004-12-31|||||Interventional|||Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)|Effect of High Dose Statin Therapy on Endothelial Function in Patients With Type 2 Diabetes Mellitus Without CAD|Completed||Phase 4|186||University of Southern Denmark|||||f||||||||||||||2018-06-01 04:51:25.696031|2018-06-01 04:51:25.696031
NCT00124384|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2008-04-22|2005-07-26|2005-07-27|Estimate|||||||2008-04-22|2008-04-23|Estimate|January 2005||2005-01-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia|Phase 4 Study of the Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia|Completed||Phase 4|40|Anticipated|University of Rochester|||||f||||t||||||||||2018-06-01 04:51:25.746005|2018-06-01 04:51:25.746005
NCT00124371|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2005-08-04|2005-07-25|2005-07-27|Estimate|||||||2005-08-04|2005-08-05|Estimate|January 2003||2003-01-31|July 2005|2005-07-31|October 2005||2005-10-31|||||Interventional|||Programme to Optimise Risk Factors in Patients Waiting for Coronary Artery Bypass Surgery|Fit For Surgery Study: A Randomised Controlled Trial of a Nurse-Led Programme to Optimise Mental and Physical Fitness for Surgery and Coronary Risk Factor Control in Patients Waiting for Coronary Artery Bypass Surgery|Completed||Phase 2/Phase 3|200||Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:51:25.801019|2018-06-01 04:51:25.801019
NCT00124358|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2007-03-23|2005-07-26|2005-07-27|Estimate|||||||2007-03-23|2007-03-27|Estimate|August 2005||2005-08-31|March 2007|2007-03-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Buprenorphine and Integrated HIV Care Evaluation|An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings|Unknown status|Recruiting|Phase 4|1350||The New York Academy of Medicine|||||f||||||||||||||2018-06-01 04:51:25.861876|2018-06-01 04:51:25.861876
NCT00124345|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2008-09-24|2005-07-26|2005-07-27|Estimate|||||||2008-09-24|2008-09-25|Estimate|June 2005||2005-06-30|September 2008|2008-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Medical Gas Humidification During Noninvasive Mechanical Ventilation|The Humidification During Noninvasive Mechanical Ventilation Delivered by Helmet|Completed||N/A|19|Actual|Policlinico Hospital||1|||f||||f||||||||||2018-06-01 04:51:26.983057|2018-06-01 04:51:26.983057
NCT00124332|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2009-04-17|2005-07-26|2005-07-27|Estimate|||||||2009-04-17|2009-04-20|Estimate|January 2005||2005-01-31|April 2009|2009-04-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)|Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors|Completed||Phase 3|839|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:51:27.047086|2018-06-01 04:51:27.047086
NCT00124319|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2011-10-03|2005-07-25|2005-07-27|Estimate|||||||2011-10-03|2011-10-05|Estimate|June 2005||2005-06-30|May 2009|2009-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Risk Factors for Anterior Cruciate Ligament (ACL) Injury|Epidemiology of Jump-Landing Movements and ACL Injury|Completed|||4800|Anticipated|University of North Carolina, Chapel Hill|||1||f||||||||||||||2018-06-01 04:51:27.119609|2018-06-01 04:51:27.119609
NCT00124306|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2013-10-28|2005-07-26|2005-07-27|Estimate|||||||2013-10-28|2013-10-30|Estimate|February 2005||2005-02-28|October 2013|2013-10-31|December 2008|Actual|2008-12-31|April 2008|Actual|2008-04-30||Interventional|IC01||Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)|A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients|Completed||Phase 3|271|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||||||||||||2018-06-01 04:51:27.192621|2018-06-01 04:51:27.192621
NCT00124293|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-02-23|2005-07-26|2005-07-27|Estimate|||||||2017-02-23|2017-02-27|Actual|October 6, 2004|Actual|2004-10-06|February 2017|2017-02-28|November 23, 2005|Actual|2005-11-23|November 23, 2005|Actual|2005-11-23||Observational|||Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury|A Multi Centre Observational Study to Evaluate the Incidence and Magnitude of Haemorrhagic Progression of Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury|Completed|||63|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-06-01 04:51:27.28334|2018-06-01 04:51:27.28334
NCT00124280|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2016-11-16|2005-07-26|2005-07-27|Estimate|||||||2016-11-16|2016-11-18|Estimate|July 2005||2005-07-31|November 2016|2016-11-30||||October 2007|Actual|2007-10-31||Interventional|||Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Open Label, Non-randomized, Phase 2 Study Investigating the Effect of RAD001 Monotherapy in Patients With Advanced NSCLC Previously Treated With Either Chemotherapy Only or With Chemotherapy and EGFR Inhibitor(s)|Completed||Phase 2|85|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:51:27.351147|2018-06-01 04:51:27.351147
NCT00124267|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2005-08-03|2005-07-26|2005-07-27|Estimate|||||||2005-08-03|2005-08-04|Estimate|September 2003||2003-09-30|July 2005|2005-07-31|January 2004||2004-01-31|||||Interventional|||Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria|Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 3|108||Makerere University|||||f||||||||||||||2018-06-01 04:51:27.424028|2018-06-01 04:51:27.424028
NCT00124254|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2017-08-21|2005-07-25|2005-07-27|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2003||2003-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Study of People With Rheumatoid Arthritis Who Require Joint Surgery in the Hand|An Outcome Study of Rheumatoid Hand Arthroplasty|Completed||N/A|170|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 04:51:28.247218|2018-06-01 04:51:28.247218
NCT00124241|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2015-05-08|2005-07-25|2005-07-27|Estimate|||||||2015-05-08|2015-05-12|Estimate||||May 2015|2015-05-31|November 2005|Actual|2005-11-30|February 2003|Actual|2003-02-28||Interventional|||An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B|A Phase IIb Extension Study of LdT (Telbivudine), Lamivudine or LdT Plus Lamivudine in Patients With Chronic Hepatitis B Who Have Completed Study NV-02B-003|Completed||Phase 2|||Novartis|||||||||||||||||||2018-06-01 04:51:28.325904|2018-06-01 04:51:28.325904
NCT00124228|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2010-05-26|2005-07-26|2005-07-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|November 2004||2004-11-30|August 2009|2009-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|Infecir||Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis|Effects of Intravenous Albumin Administration on Renal Function and Survival in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. A Prospective, Stratified, Randomized and Controlled Study.|Completed||Phase 3|110|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-06-01 04:51:28.386013|2018-06-01 04:51:28.386013
NCT00124215|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2010-05-03|2005-07-25|2005-07-27|Estimate|||||||2010-05-03|2010-05-05|Estimate|June 2005||2005-06-30|May 2010|2010-05-31|February 2010|Actual|2010-02-28|June 2007|Actual|2007-06-30||Interventional|||Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection|A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C Infection|Completed||Phase 1|48|Anticipated|GlobeImmune|||||f||||||||||||||2018-06-01 04:51:28.457381|2018-06-01 04:51:28.457381
NCT00124202|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2013-07-29|2005-07-25|2005-07-27|Estimate|||||||2013-07-29|2013-07-31|Estimate|May 2003||2003-05-31|July 2013|2013-07-31|May 2007|Actual|2007-05-31|December 2004|Actual|2004-12-31||Interventional|||Effect of a Fatty Meal on Endoscopic Retrograde Cholangiopancreatography (ERCP)|Effect of a Fatty Meal on Cannulation at Endoscopic Retrograde Cholangiopancreatography|Completed||Phase 1/Phase 2|80|Actual|Emory University||1|||f||||f||||||||||2018-06-01 04:51:28.519328|2018-06-01 04:51:28.519328
NCT00124189|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2015-12-22|2005-07-25|2005-07-27|Estimate|||||||2015-12-22|2015-12-24|Estimate|July 2005||2005-07-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease|Completed||Phase 1|48|Anticipated|Geron Corporation||1|||f||||f||||||||||2018-06-01 04:51:28.588083|2018-06-01 04:51:28.588083
NCT00124176|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|2010-07-14||2013-02-12|2005-07-26|2005-07-27|Estimate|2013-02-12|2013-03-14|Estimate||||2013-02-12|2013-03-14|Estimate|April 2004||2004-04-30|December 2012|2012-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Continuous Levalbuterol for Treatment of Status Asthmaticus in Children|Continuous Levalbuterol for Treatment of Status Asthmaticus in Children|Completed||Phase 4|81|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-06-01 04:51:28.775934|2018-06-01 04:51:28.775934
NCT00124163|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2006-01-31|2005-07-26|2005-07-27|Estimate|||||||2006-01-31|2006-02-02|Estimate|July 2005||2005-07-31|January 2006|2006-01-31||||||||Observational|||Evaluation of Stool Tagging for Improved Patient Compliance|CT Colonography Ph. I CDI Trial: Evaluation of Stool Tagging for Improved Patient Compliance|Unknown status|Recruiting||60||Center for Diagnostic Imaging|||||f||||||||||||||2018-06-01 04:51:29.056941|2018-06-01 04:51:29.056941
NCT00124150|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-26|||2009-12-21|2005-07-26|2005-07-27|Estimate|||||||2009-12-21|2009-12-23|Estimate|June 2002||2002-06-30|July 2009|2009-07-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Intravenous Magnesium Sulfate in Aneurysmal Subarachnoid Haemorrhage (IMASH)|Phase 3 Study (Multi-center, Randomized Controlled Clinical Trial) of Intravenous Magnesium Sulfate to Improve Outcome After Aneurysmal Subarachnoid Haemorrhage|Completed||Phase 3|327|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-06-01 04:51:29.133238|2018-06-01 04:51:29.133238
NCT00124137|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2007-03-14|2005-07-26|2005-07-27|Estimate|||||||2007-03-14|2007-03-15|Estimate|April 2004||2004-04-30|December 2005|2005-12-31|October 2005||2005-10-31|||||Interventional|||Ultrafiltration Versus Intravenous (IV) Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: (UNLOAD)|Ultrafiltration Versus IV Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Clinical Trial|Completed||N/A|200||CHF Solutions|||||f||||||||||||||2018-06-01 04:51:29.218307|2018-06-01 04:51:29.218307
NCT00124124|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2015-02-11|2005-07-25|2005-07-27|Estimate|||||||2015-02-11|2015-02-13|Estimate|July 2005||2005-07-31|February 2015|2015-02-28|April 2009|Actual|2009-04-30|July 2008|Actual|2008-07-31||Interventional|||Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine|A Randomized, Controlled Trial of Melanoma Treatment: Comparison of Dendritic Cells Versus Montanide as Adjuvants to Stimulate Anti-tumor Immunity|Completed||Phase 1|50|Actual|Bhardwaj, Nina, M.D.||2|||f||||t||||||||||2018-06-01 04:51:29.287723|2018-06-01 04:51:29.287723
NCT00124111|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2010-02-25|2005-07-25|2005-07-27|Estimate|||||||2010-02-25|2010-02-26|Estimate||||February 2010|2010-02-28||||||||Interventional|||A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer|A Single-arm Study Evaluating the Relative Dose Intensity of IV CMF Given on Day 1 and Day 8 With Pegfilgrastim Support in Subjects With Stage I-III Breast Cancer|Completed||Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:51:29.362193|2018-06-01 04:51:29.362193
NCT00124085|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2012-08-07|2005-07-22|2005-07-26|Estimate|||||||2012-08-07|2012-08-09|Estimate|October 2003||2003-10-31|August 2012|2012-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Asthma in a Decentralized Patient Population: Is Traditional Disease Management Enough?|Asthma in a Decentralized Patient Population: Is Traditional Disease Management Enough? A Randomized, Controlled Trial Comparing Traditional Care to Two Systems of Disease Management for a Decentralized Population of Patients in South Texas|Completed||N/A|1053||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 04:51:29.485541|2018-06-01 04:51:29.485541
NCT00124072|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|2010-03-29||2012-01-31|2005-07-22|2005-07-26|Estimate|2010-05-06|2010-06-09|Estimate||||2012-01-31|2012-02-01|Estimate|July 1998||1998-07-31|January 2012|2012-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|SEARCH||Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine|SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine|Completed||Phase 3|12064|Actual|University of Oxford||4|||f||||t||||||||||2018-06-01 04:51:29.579642|2018-06-01 04:51:29.579642
NCT00124059|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2015-10-02|2005-07-25|2005-07-26|Estimate|||||||2015-10-02|2015-10-06|Estimate|March 2003||2003-03-31|September 2013|2013-09-30|October 2005|Actual|2005-10-31|September 2005|Actual|2005-09-30||Interventional|||Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.|A Double-Blind Study of Quetiapine Fumarate (Seroquel) for the Treatment of Type A vs.Type B Alcoholics.|Completed||Phase 3|61|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 04:51:29.835452|2018-06-01 04:51:29.835452
NCT00124046|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-05-30|2005-07-22|2005-07-26|Estimate|||||||2016-05-30|2016-06-01|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Treatment of Persistent Urinary Incontinence in Children|Treatment of Persistent Urinary Incontinence in Children|Completed||N/A|14|Actual|University of British Columbia||2|||f||||f||||||||||2018-06-01 04:51:29.996624|2018-06-01 04:51:29.996624
NCT00124033|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2006-09-07|2005-07-25|2005-07-26|Estimate|||||||2006-09-07|2006-09-11|Estimate|March 2004||2004-03-31|June 2005|2005-06-30|December 2015||2015-12-31|||||Interventional|||Management of Common Bile Duct (CBD) Stones at Laparoscopic Cholecystectomy|Management of CBD Stones at Laparoscopic Cholecystectomy: A NSW Collaborative Prospective Randomised Trial to Assess the Value of Transcystically Inserted CBD Stents to Facilitate Post-Operative ERCP|Terminated||N/A|340||South West Sydney Local Health District|||||f||||||||||||||2018-06-01 04:51:30.077727|2018-06-01 04:51:30.077727
NCT00124020|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|2009-11-03||2010-05-14|2005-07-22|2005-07-26|Estimate|2010-01-08|2010-02-01|Estimate||||2010-05-14|2010-05-18|Estimate|January 2005||2005-01-31|May 2010|2010-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|ATTAIN2||Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus|Completed||Phase 3|771|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||f||||||||||2018-06-01 04:51:30.221836|2018-06-01 04:51:30.221836
NCT00124007|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2014-07-07|2005-07-22|2005-07-26|Estimate|||||||2014-07-07|2014-07-08|Estimate|November 2005||2005-11-30|July 2014|2014-07-31|April 2007|Actual|2007-04-30|||||Interventional|||Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults|A Phase I, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine Followed by Recombinant, Multiclade HIV-1 Adenoviral Vector Vaccine or the Multiclade HIV-1 Adenoviral Vector Vaccine Alone in Healthy Adult Volunteers Not Infected With HIV|Completed||Phase 1|114|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:51:31.194804|2018-06-01 04:51:31.194804
NCT00123994|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2005-11-02|2005-07-22|2005-07-26|Estimate|||||||2005-11-02|2005-11-03|Estimate|February 2004||2004-02-29|July 2005|2005-07-31|October 2005||2005-10-31|||||Interventional|||Tai Chi or Hydrotherapy for People With Osteoarthritis of the Hip(s) or Knee(s)|Tai Chi or Hydrotherapy for People With Osteoarthritis of the Hip(s) or Knee(s)|Unknown status|Active, not recruiting|N/A|150||St George Hospital, Australia|||||f||||||||||||||2018-06-01 04:51:31.258384|2018-06-01 04:51:31.258384
NCT00123981|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2013-11-05|2005-07-25|2005-07-26|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|January 2011|Actual|2011-01-31|November 2008|Actual|2008-11-30||Interventional|||The Danish On-pump, Off-pump Randomization Study (DOORS)|The Impact of Avoiding Cardiopulmonary By-pass During Coronary Artery Bypass Surgery for Ischemic Heart Disease in Elderly Patients: The Danish On-pump, Off-pump Randomization Study (DOORS)|Completed||N/A|900|Actual|Odense University Hospital||2|||f||||t||||||||||2018-06-01 04:51:31.319728|2018-06-01 04:51:31.319728
NCT00123968|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22||2013-07-18|2014-07-21|2005-07-22|2005-07-26|Estimate||||2013-07-18|2013-07-22|Estimate|2014-07-21|2014-07-24|Estimate|May 2006||2006-05-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults|A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Boosted by a Multiclade HIV-1 Recombinant Adenovirus-5 Vector Vaccine, VRC-HIVADV014-00-VP, in HIV Uninfected Adult Volunteers in East Africa|Completed||Phase 1/Phase 2|326|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 04:51:31.394459|2018-06-01 04:51:31.394459
NCT00123955|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|2015-02-06||2018-01-23|2005-07-22|2005-07-26|Estimate|2015-02-06|2015-02-23|Estimate||||2018-01-23|2018-02-21|Estimate|April 2005||2005-04-30|November 2017|2017-11-30|December 2012|Actual|2012-12-31|June 2009|Actual|2009-06-30||Interventional|||PIE II: Pharmacological Intervention in the Elderly II|Exercise Intolerance in Elderly Diastolic Heart Failure|Completed||Phase 3|80|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-06-01 04:51:31.501763|2018-06-01 04:51:31.501763
NCT00123942|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2007-06-12|2005-07-22|2005-07-26|Estimate|||||||2007-06-12|2007-06-14|Estimate|April 2004||2004-04-30|June 2007|2007-06-30||||||||Interventional|||Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease|Phase I Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease|Terminated||Phase 1|31|Anticipated|MedImmune LLC||||"After review of safety events and have decided that further dose escalation of MEDI-507 as a~   single agent is not feasible."|||||||||||||||2018-06-01 04:51:31.861094|2018-06-01 04:51:31.861094
NCT00123929|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2009-08-03|2005-07-25|2005-07-26|Estimate|||||||2009-08-03|2009-08-06|Estimate|January 2005||2005-01-31|August 2009|2009-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer|Patterns of Genetic Expression Associated to Sensibility to Doxorubicin Versus Docetaxel as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer|Completed||Phase 2|250|Anticipated|Hospital San Carlos, Madrid||2|||f||||f||||||||||2018-06-01 04:51:31.93192|2018-06-01 04:51:31.93192
NCT00123916|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2011-08-01|2005-07-22|2005-07-26|Estimate|||||||2011-08-01|2011-08-03|Estimate|November 2004||2004-11-30|June 2005|2005-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|BENEFIT||BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease|Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial|Unknown status|Recruiting|Phase 3|1000|Anticipated|Population Health Research Institute||2|||f||||t||||||||||2018-06-01 04:51:32.026144|2018-06-01 04:51:32.026144
NCT00123903|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2017-01-16|2005-07-25|2005-07-26|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2005||2005-07-31|January 2017|2017-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria|A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria|Terminated||Phase 3|1220||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:51:32.198748|2018-06-01 04:51:32.198748
NCT00123890|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2011-03-28|2005-07-25|2005-07-26|Estimate|||||||2011-03-28|2011-03-29|Estimate|June 2005||2005-06-30|March 2011|2011-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140|A Screening Protocol to Determine Eligibility for One of Three Phase III Treatment Studies Evaluating the Efficacy and Safety of GW873140 in R5-tropic and R5/X4-tropic HIV-1 Infected, Treatment-experienced Subjects With Drug-resistant Virus or an Observational Study.|Terminated||Phase 3|0|Actual|GlaxoSmithKline||||The study was terminated due to hepatoxicity of compound|||||||||||||||2018-06-01 04:51:32.547839|2018-06-01 04:51:32.547839
NCT00123877|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-23|||2007-01-05|2005-07-23|2005-07-26|Estimate|||||||2007-01-05|2007-01-09|Estimate|March 2005||2005-03-31|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Study of GPX-100 in the Treatment of Metastatic Breast Cancer|Phase II, Open Label, Non-Randomized, Efficacy and Safety Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer|Terminated||Phase 2|40||Gem Pharmaceuticals|||||f||||||||||||||2018-06-01 04:51:32.679804|2018-06-01 04:51:32.679804
NCT00123864|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2010-02-08|2005-07-25|2005-07-26|Estimate|||||||2010-02-08|2010-02-09|Estimate|January 2000||2000-01-31|July 2005|2005-07-31||||||||Interventional|||Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function|A Phase I/II Feasibility Study Using Intensity-modulated Radiation Therapy in Patients With Nasopharynx Cancer to Permit Sparing of Contralateral Parotid Gland Function|Completed||Phase 1/Phase 2|25||AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:51:32.758124|2018-06-01 04:51:32.758124
NCT00123851|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2009-04-27|2005-07-25|2005-07-26|Estimate|||||||2009-04-27|2009-04-28|Estimate|March 2003||2003-03-31|April 2009|2009-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer|A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer|Completed||Phase 2|32||Dana-Farber Cancer Institute|||||||||||||||||||2018-06-01 04:51:32.833364|2018-06-01 04:51:32.833364
NCT00123838|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-04-26|2005-07-22|2005-07-26|Estimate|||||||2016-04-26|2016-04-28|Estimate|July 2005||2005-07-31|April 2016|2016-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Positioning and Tracking the Prostate During External Beam Radiation|Beacon® Transponder Implantation and Localization in the Prostate|Completed||N/A|43|Actual|Varian Medical||1|||f||||f||||||||No||2018-06-01 04:51:32.915693|2018-06-01 04:51:32.915693
NCT00123825|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-25|||2007-12-20|2005-07-25|2005-07-26|Estimate|||||||2007-12-20|2007-12-21|Estimate|July 2002||2002-07-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer|A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer|Completed||Phase 2|30||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:51:33.054739|2018-06-01 04:51:33.054739
NCT00123812|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-02-23|2005-07-25|2005-07-26|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2004||2004-03-31|December 2011|2011-12-31|July 2006||2006-07-31|||||Observational|||Frequency of Portal Images Required to Enhance Quality Assurance for Breast Cancer Patients Treated With Radiotherapy|Frequency of Portal Images Required to Enhance Quality Assurance for Breast Cancer Patients Treated With Radiotherapy|Withdrawn|||0|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:51:33.122795|2018-06-01 04:51:33.122795
NCT00123799|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2014-06-10|2005-07-25|2005-07-26|Estimate|||||||2014-06-10|2014-06-12|Estimate|June 2004||2004-06-30|March 2012|2012-03-31|April 2007|Actual|2007-04-30|||||Interventional|||Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection|A Phase II Study of Fluorodeoxyglucose (FluGlucoScan) in Patients With Breast Cancer: Correlation With Histologic Findings of Sentinel Node Biopsies and Axillary Dissection|Terminated||Phase 2|199|Actual|AHS Cancer Control Alberta||||sufficient enrollment reached|f||||f||||||||||2018-06-01 04:51:33.173199|2018-06-01 04:51:33.173199
NCT00123786|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-02-24|2005-07-25|2005-07-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|August 2005||2005-08-31|March 2012|2012-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma|A Phase II Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Soft Tissue Sarcoma|Terminated||Phase 2|4|Actual|AHS Cancer Control Alberta||||Lack of Enrollment|f||||f||||||||||2018-06-01 04:51:33.243655|2018-06-01 04:51:33.243655
NCT00123773|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-02-24|2005-07-25|2005-07-26|Estimate|||||||2016-02-24|2016-02-26|Estimate|April 2004||2004-04-30|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence|A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence|Completed||Phase 2|1075|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:51:33.323929|2018-06-01 04:51:33.323929
NCT00123760|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-02-24|2005-07-25|2005-07-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2004||2004-02-29|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer|A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer|Completed||Phase 2/Phase 3|10838|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:51:33.393283|2018-06-01 04:51:33.393283
NCT00123747|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-02-24|2005-07-22|2005-07-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|August 2005||2005-08-31|March 2012|2012-03-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer|A Phase II Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer|Completed||Phase 2|23|Actual|AHS Cancer Control Alberta|||||f||||f||||||||||2018-06-01 04:51:33.45812|2018-06-01 04:51:33.45812
NCT00123734|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-24|2009-07-09||2009-07-09|2005-07-24|2005-07-26|Estimate|2009-07-09|2009-08-24|Estimate||||2009-07-09|2009-08-24|Estimate|March 2005||2005-03-31|July 2009|2009-07-31|May 2006||2006-05-31|||||Interventional|||Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis|Phase II Clinical Trial to Evaluate the Accuracy of Anti-Fibrin Humanized Monoclonal Antibody (DI-DD3B6/22-80B3) Fab' Protein Fragment (ThromboView) Conjugated With Technetium-99m in the Detection of Deep Vein Thrombosis|Completed||Phase 2|94|Actual|Agen Biomedical|||||||||||||||||||2018-06-01 04:51:33.537038|2018-06-01 04:51:33.537038
NCT00123708|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-23|||2017-06-30|2005-07-23|2005-07-25|Estimate|||||||2017-06-30|2017-07-02|Actual|July 19, 2005||2005-07-19|November 13, 2009|2009-11-13||||November 13, 2009|Actual|2009-11-13||Observational|||Hypertonia in Patients With Cerebral Palsy|Hypertonia in Patients With Cerebral Palsy|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:51:33.818185|2018-06-01 04:51:33.818185
NCT00123695|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2008-03-26|2005-07-21|2005-07-25|Estimate|||||||2008-03-26|2008-03-27|Estimate|May 2005||2005-05-31|March 2008|2008-03-31|June 2008|Anticipated|2008-06-30|June 2008|Anticipated|2008-06-30||Observational|SEAS||Serial Echocardiography After Subarachnoid Hemorrhage|Serial Echocardiography After Subarachnoid Hemorrhage (S.E.A.S.)|Unknown status|Active, not recruiting||350|Anticipated|VU University Medical Center|||||f||||t||||||||||2018-06-01 04:51:33.866546|2018-06-01 04:51:33.866546
NCT00123682|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2015-01-08||2015-02-26|2005-07-21|2005-07-25|Estimate|2015-02-04|2015-02-26|Estimate||||2015-02-26|2015-03-17|Estimate|May 2005||2005-05-31|February 2015|2015-02-28|September 2009|Actual|2009-09-30|March 2009|Actual|2009-03-31||Interventional|||TeleQuit Smoking Cessation Program|Telephone Care Coordination to Improve Smoking Cessation Counseling|Completed||N/A|3120|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 04:51:33.938364|2018-06-01 04:51:33.938364
NCT00123669|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2018-01-16|2005-07-21|2005-07-25|Estimate|||||||2018-01-16|2018-01-17|Actual|October 1997||1997-10-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2009|Actual|2009-12-31||Interventional|||Primary Progesterone Therapy for Operable Breast Cancer|The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial|Active, not recruiting||Phase 2/Phase 3|1000|Actual|Tata Memorial Hospital||2|||f||||f||||||||||2018-06-01 04:51:34.308157|2018-06-01 04:51:34.308157
NCT00123656|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2008-01-10|2005-07-21|2005-07-25|Estimate|||||||2008-01-10|2008-01-16|Estimate|August 2004||2004-08-31|January 2008|2008-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis|Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis|Completed||Phase 2|30|Actual|University of Utah||2|||f||||f||||||||||2018-06-01 04:51:34.38801|2018-06-01 04:51:34.38801
NCT00123643|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2012-07-02||2013-06-26|2005-07-21|2005-07-25|Estimate|2012-07-02|2012-08-09|Estimate||||2013-06-26|2013-07-15|Estimate|May 2003||2003-05-31|June 2013|2013-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients|Comparison of Rosiglitazone Versus Glyburide on Vascular Structure and Function in Type 2 Diabetic Patients|Completed||Phase 4|36|Actual|St. Paul Heart Clinic|Small sample size; unbalanced sex distribution between groups|2|||f||||f||||||||||2018-06-01 04:51:34.452409|2018-06-01 04:51:34.452409
NCT00123630|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2012-09-05||2016-05-18|2005-07-21|2005-07-25|Estimate|2013-08-09|2013-10-21|Estimate||||2016-05-18|2016-05-20|Estimate|November 2005||2005-11-30|March 2016|2016-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab|A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab|Completed||Phase 2|30|Actual|University of Utah|small numbers enrolled|2|||f||||f||||||||||2018-06-01 04:51:34.781252|2018-06-01 04:51:34.781252
NCT00123617|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2015-04-21|2005-07-21|2005-07-25|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2003||2003-01-31|April 2015|2015-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||The Impact of Cardiac Rehabilitation Participation on Cardiac Syndrome X|The Impact of Cardiac Rehabilitation on Angina Frequency, Psychological Morbidity and Quality of Life in Women With Syndrome X|Completed||Phase 2|64|Actual|National Heart and Lung Institute||2|||f||||f||||||||||2018-06-01 04:51:35.116631|2018-06-01 04:51:35.116631
NCT00123604|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2012-06-29||2014-11-17|2005-07-21|2005-07-25|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-17|2014-11-18|Estimate|June 2004||2004-06-30|November 2014|2014-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes|Effects of Carvedilol and Metoprolol on Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|36|Actual|St. Paul Heart Clinic|The sample size was relatively small|2|||f||||f||||||||||2018-06-01 04:51:35.327317|2018-06-01 04:51:35.327317
NCT00123591|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-01-11|2005-07-13|2005-07-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury|A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/NiaStase®) in Subjects With Brain Contusions|Completed||Phase 2|96|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:51:35.668561|2018-06-01 04:51:35.668561
NCT00123578|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2016-05-10|2005-07-22|2005-07-25|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2004||2004-08-31|May 2016|2016-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1|GHB: Effects, Withdrawal and Treatment|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, Los Angeles||2||Unable to recruit adaquate number of GHB dependent subjects|f||||t||||||||||2018-06-01 04:51:35.851334|2018-06-01 04:51:35.851334
NCT00123565|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2008-08-20|2005-07-22|2005-07-25|Estimate|||||||2008-08-20|2008-08-21|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|SHINE||Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction|A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE)|Completed||Phase 2|1257|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:51:35.971611|2018-06-01 04:51:35.971611
NCT00123552|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-22|||2011-11-28|2005-07-22|2005-07-25|Estimate|||||||2011-11-28|2011-11-30|Estimate|November 2004||2004-11-30|November 2011|2011-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Longitudinal Antimalarial Combinations in Uganda|Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy|Completed||Phase 3|690|Actual|University of California, San Francisco||3|||f||||||||||||||2018-06-01 04:51:36.116377|2018-06-01 04:51:36.116377
NCT00123539|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2016-07-28|2005-07-21|2005-07-25|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2001||2001-06-30|December 2007|2007-12-31|August 2005|Actual|2005-08-31|||||Interventional|||Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery|Estradiol for Neurocognitive Dysfunction After CABG|Terminated||N/A|334||National Heart, Lung, and Blood Institute (NHLBI)||||"DSMB stopped the study based on conclusion of likely futility of treatment on the primary~   outcome."|f||||||||||||||2018-06-01 04:51:36.27008|2018-06-01 04:51:36.27008
NCT00123526|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2013-09-23|2005-07-21|2005-07-25|Estimate|||||||2013-09-23|2013-09-24|Estimate|September 2004||2004-09-30|September 2013|2013-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Workplace-Sponsored Diet and Exercise Program to Reduce Obesity|Active Living and Healthy Diet at the Workplace|Completed||Phase 3|899|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 04:51:36.387719|2018-06-01 04:51:36.387719
NCT00123513|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2012-06-12|2005-07-21|2005-07-25|Estimate|||||||2012-06-12|2012-06-13|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Workplace-Sponsored Program to Reduce Obesity|Images of a Healthy Worksite-Preventing Weight Gain in the Workplace|Completed||N/A|3938|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 04:51:36.480543|2018-06-01 04:51:36.480543
NCT00123500|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2017-03-24|2005-07-21|2005-07-25|Estimate|||||||2017-03-24|2017-03-28|Actual|September 2004||2004-09-30|March 2017|2017-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Wellness Program for Elementary School Personnel|ACTION! Wellness Program for Elementary School Personnel|Completed||N/A|1202|Actual|Tulane University||2|||f||||t||||||||||2018-06-01 04:51:36.60193|2018-06-01 04:51:36.60193
NCT00123487|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2014-10-16||2014-10-30|2005-07-21|2005-07-25|Estimate|2014-10-16|2014-10-22|Estimate||||2014-10-30|2014-11-03|Estimate|June 2005||2005-06-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|November 2006|Actual|2006-11-30||Interventional||Randomized Population analyzed. Baseline data are based on what participants were randomized to receive and not what they actually received.|Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML|A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects With Chronic Myeloid Leukemia in Accelerated Phase or in Myeloid or Lymphoid Blast Phase or With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)|Completed||Phase 3|638|Actual|Bristol-Myers Squibb|Amendment 3 (7 March 2007) allowed participants to switch from BID to QD dosing. Therefore, results for BID summarized by treatment group after Year 2 may not be a complete reflection of the BID experience and should be interpreted with this in mind.|2|||f||||f||||||||||2018-06-01 04:51:36.800094|2018-06-01 04:51:36.800094
NCT00123474|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2015-06-29||2016-07-25|2005-07-21|2005-07-25|Estimate|2015-07-29|2015-08-26|Estimate||||2016-07-25|2016-08-25|Estimate|July 2005||2005-07-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|September 2006|Actual|2006-09-30||Interventional||All participants randomized to a treatment arm are summarized.|Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML|A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)|Completed||Phase 3|724|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-06-01 04:51:38.97514|2018-06-01 04:51:38.97514
NCT00123461|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2015-05-04|2005-07-21|2005-07-25|Estimate|||||||2015-05-04|2015-05-05|Estimate|July 2005||2005-07-31|May 2015|2015-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism|A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT).|Completed||Phase 4|70|Anticipated|Sanofi|||||||||||||||||||2018-06-01 04:51:43.658032|2018-06-01 04:51:43.658032
NCT00123448|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2017-06-30|2005-07-21|2005-07-22|Estimate|||||||2017-06-30|2017-07-02|Actual|July 20, 2005||2005-07-20|July 2, 2008|2008-07-02|July 2, 2008||2008-07-02|||||Observational|||Mirroring a Movement|Mirroring a Movement|Completed|||36||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:51:43.900449|2018-06-01 04:51:43.900449
NCT00123435|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2015-08-19|2005-07-20|2005-07-22|Estimate|||||||2015-08-19|2015-08-21|Estimate|July 2005||2005-07-31|August 2015|2015-08-31|June 2009|Actual|2009-06-30|November 2007|Actual|2007-11-30||Interventional|VWH||Veterans Walk for Health Study|Does Step Count Feedback Enhance Counseling for Weight Loss?|Completed||N/A|254|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:51:44.016326|2018-06-01 04:51:44.016326
NCT00123422|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2014-10-02||2014-10-06|2005-07-20|2005-07-22|Estimate|2014-10-02|2014-10-07|Estimate||||2014-10-06|2014-10-16|Estimate|October 2005||2005-10-31|October 2014|2014-10-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Innovation in Pulmonary Rehabilitation|Innovation Methods to Augment Pulmonary Rehabilitation|Completed||N/A|103|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:51:44.213267|2018-06-01 04:51:44.213267
NCT00123409|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2014-09-26||2015-04-06|2005-07-20|2005-07-22|Estimate|2014-10-28|2014-11-04|Estimate||||2015-04-06|2015-04-24|Estimate|January 2004||2004-01-31|June 2014|2014-06-30|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||Telephone Disease Management At-Risk Drinking (TDM II)|Telephone Disease Management At-Risk Drinking (TDM 11)|Completed||N/A|146|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:51:45.039999|2018-06-01 04:51:45.039999
NCT00123396|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2015-04-06|2005-07-20|2005-07-22|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2004||2004-08-31|April 2015|2015-04-30|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Interventional|||VHA Clinicians and Bioterror Events: Interactive Web-based Learning|VHA Clinicians and Bioterror Events: Interactive Web-based Learning|Completed||N/A|15|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:51:46.558365|2018-06-01 04:51:46.558365
NCT00123383|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2007-04-29|2005-07-21|2005-07-22|Estimate|||||||2007-04-29|2007-05-01|Estimate|July 2005||2005-07-31|July 2006|2006-07-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence|Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|The University of New South Wales|||||f||||f||||||||||2018-06-01 04:51:46.658001|2018-06-01 04:51:46.658001
NCT00123344|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2008-12-10|2005-07-20|2005-07-22|Estimate|||||||2008-12-10|2008-12-11|Estimate|December 1999||1999-12-31|December 2008|2008-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Atrial Pacing for Termination and Prevention of Atrial Fibrillation|Atrial Pacing for Termination and Prevention of Atrial Fibrillation|Completed||N/A|120|Actual|University of Calgary|||||f||||||||||||||2018-06-01 04:51:46.943275|2018-06-01 04:51:46.943275
NCT00123331|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2005-08-01|2005-07-19|2005-07-22|Estimate|||||||2005-08-01|2005-08-02|Estimate|October 2003||2003-10-31|June 2005|2005-06-30|April 2005||2005-04-30|||||Interventional|||Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation|Rapamycin Use in CNI-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation|Completed||Phase 4|40||Heidelberg University|||||f||||||||||||||2018-06-01 04:51:47.003502|2018-06-01 04:51:47.003502
NCT00123318|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2013-06-17|2005-07-19|2005-07-22|Estimate|||||||2013-06-17|2013-06-18|Estimate|February 2003||2003-02-28|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer|A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer|Completed||Phase 3|52|Actual|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||f||||||||||2018-06-01 04:51:47.267866|2018-06-01 04:51:47.267866
NCT00123305|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2014-11-06|2005-07-21|2005-07-22|Estimate|||||||2014-11-06|2014-11-07|Estimate|October 2005||2005-10-31|November 2014|2014-11-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke|A Multicentre, Double-Blind, Placebo-Controlled, Ascending-dose, Clinical Trial of Intravenous Microplasmin Administration in Patients With Acute Ischemic Stroke|Completed||Phase 2|40|Actual|ThromboGenics||4|||f||||t||||||||||2018-06-01 04:51:47.512709|2018-06-01 04:51:47.512709
NCT00123292|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2014-04-04|2005-07-21|2005-07-22|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2005||2005-03-31|April 2014|2014-04-30|November 2009|Actual|2009-11-30|June 2007|Actual|2007-06-30||Interventional|||Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion|An Open-label, Ascending-dose, Clinical Trial of Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion|Terminated||Phase 2|19|Actual|ThromboGenics||5||Sponsor's decision not to pursue development of uPLi for vascular conditions|f||||t||||||||||2018-06-01 04:51:47.765249|2018-06-01 04:51:47.765249
NCT00123279|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2014-04-04|2005-07-21|2005-07-22|Estimate|||||||2014-04-04|2014-04-07|Estimate|December 2004||2004-12-31|April 2014|2014-04-30|November 2008|Actual|2008-11-30|February 2007|Actual|2007-02-28||Interventional|||Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy|A Dose-escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy|Completed||Phase 2|60|Actual|ThromboGenics||6|||f||||t||||||||||2018-06-01 04:51:47.940588|2018-06-01 04:51:47.940588
NCT00123266|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2014-04-04|2005-07-21|2005-07-22|Estimate|||||||2014-04-04|2014-04-07|Estimate|December 2006||2006-12-31|April 2014|2014-04-30|August 2008|Actual|2008-08-31|July 2007|Actual|2007-07-31||Interventional|MITI-IA||Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion|An Open-label, Clinical Trial of Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion|Terminated||Phase 2|2|Actual|ThromboGenics||1||Sponsor's decision not to pursue development of uPLi for vascular conditions.|f||||t||||||||||2018-06-01 04:51:48.164741|2018-06-01 04:51:48.164741
NCT00123253|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2013-11-26|2005-07-20|2005-07-22|Estimate|||||||2013-11-26|2013-11-27|Estimate|June 2005||2005-06-30|November 2013|2013-11-30|April 2007|Actual|2007-04-30|November 2006|Actual|2006-11-30||Interventional|||TH9507 in Patients With HIV-Associated Lipodystrophy|A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation|Completed||Phase 3|412|Actual|Theratechnologies|||||||||||||||||||2018-06-01 04:51:48.262306|2018-06-01 04:51:48.262306
NCT00123240|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2012-01-10|2005-07-21|2005-07-22|Estimate|||||||2012-01-10|2012-01-11|Estimate|July 2004||2004-07-31|January 2012|2012-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||High Carbohydrate vs. High Fat Diets in the Treatment of Obesity (JBR 0512)|High Carbohydrate vs. High Fat Diets in the Treatment of Obesity (JBR 0512)|Completed||N/A|40|Anticipated|Rockefeller University||2|||f||||t||||||||||2018-06-01 04:51:48.382338|2018-06-01 04:51:48.382338
NCT00123227|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2005-07-29|2005-07-19|2005-07-22|Estimate|||||||2005-07-29|2005-08-01|Estimate|October 2002||2002-10-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Rosiglitazone Plaque Study|A Randomised, Double-Blind, Placebo-Controlled, Cardiovascular Magnetic Resonance (CMR) Study to Evaluate the Effect of Rosiglitazone on Carotid Atherosclerotic Plaques in Type 2 Diabetics With Vascular Disease or Hypertension|Unknown status|Active, not recruiting|Phase 3|60||Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:51:48.480744|2018-06-01 04:51:48.480744
NCT00123214|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2006-06-26|2005-07-19|2005-07-22|Estimate|||||||2006-06-26|2006-06-27|Estimate|September 2004||2004-09-30|July 2005|2005-07-31|April 2005||2005-04-30|||||Interventional|||A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation|Pilot Study: A Dietary Intervention May Decrease the Negative Metabolic and Cognitive Consequences of Chronic Sleep Deprivation|Completed||N/A|18||St. Vincent's Medical Center|||||f||||||||||||||2018-06-01 04:51:48.571351|2018-06-01 04:51:48.571351
NCT00123201|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2015-01-15|2005-07-21|2005-07-22|Estimate|||||||2015-01-15|2015-01-16|Estimate|September 2005||2005-09-30|September 2006|2006-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache|Completed||Phase 2|||Solvay Pharmaceuticals|||||||||||||||||||2018-06-01 04:51:48.647853|2018-06-01 04:51:48.647853
NCT00123188|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2015-01-16|2005-07-21|2005-07-22|Estimate|||||||2015-01-16|2015-01-19|Estimate|April 2005||2005-04-30|January 2015|2015-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Ultrasound and Endometrial Hyperplasia|Development of a Screening Test for Endometrial Hyperplasia in an At Risk Cohort|Terminated||N/A|36|Actual|Milton S. Hershey Medical Center||1||enrollment of participants has halted prematurely; difficulty with recruitment|f||||f||||||||||2018-06-01 04:51:48.873153|2018-06-01 04:51:48.873153
NCT00123175|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2013-01-07|2005-07-20|2005-07-22|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|September 2011|Anticipated|2011-09-30|September 2011|Anticipated|2011-09-30||Interventional|||Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD)|Levonorgestrel Containing Intrauterine Device in the Treatment of Endometrial Hyperplasia Without Atypia|Withdrawn||Phase 1/Phase 2|0|Actual|Milton S. Hershey Medical Center||||Study has never received funding and has never been initiated|f||||f||||||||||2018-06-01 04:51:48.950082|2018-06-01 04:51:48.950082
NCT00123162|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2015-01-16||2015-11-18|2005-07-20|2005-07-22|Estimate|2015-11-18|2015-12-23|Estimate||||2015-11-18|2015-12-23|Estimate|May 2007||2007-05-31|November 2015|2015-11-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Viagra in the Treatment of Primary Dysmenorrhea|Sildenafil Citrate in the Treatment of Primary Dysmenorrhea|Completed||Phase 1/Phase 2|25|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-06-01 04:51:49.073487|2018-06-01 04:51:49.073487
NCT00123149|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2016-09-19|2005-07-19|2005-07-22|Estimate|||||||2016-09-19|2016-09-20|Estimate||||July 2011|2011-07-31|October 2007|Anticipated|2007-10-31|||||Interventional|||Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis|An Open-Label (OL) Extension Study to Assess Safety of PROCRIT (Epoetin Alfa) in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis (RA)|Withdrawn||Phase 2|0|Actual|Ortho Biotech Products, L.P.|||||||||||||||||||2018-06-01 04:51:49.640812|2018-06-01 04:51:49.640812
NCT00123136|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2006-06-28|2005-07-20|2005-07-22|Estimate|||||||2006-06-28|2006-07-04|Estimate|August 2005||2005-08-31|June 2006|2006-06-30|December 2006||2006-12-31|||||Interventional|||Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy|Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial|Unknown status|Recruiting|Phase 4|250||Weintraub, Michael I., MD, FACP, FAAN|||||f||||||||||||||2018-06-01 04:51:49.818398|2018-06-01 04:51:49.818398
NCT00123123|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2010-08-12||2010-08-12|2005-07-21|2005-07-22|Estimate|2010-08-12|2010-09-09|Estimate||||2010-08-12|2010-09-09|Estimate|March 2004||2004-03-31|August 2010|2010-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients|Oral Health and Ventilator-associated Pneumonia|Completed||Phase 2|175|Actual|State University of New York at Buffalo||3|||f||||||||||||||2018-06-01 04:51:50.013592|2018-06-01 04:51:50.013592
NCT00123110|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2010-03-09|2005-07-19|2005-07-22|Estimate|||||||2010-03-09|2010-03-11|Estimate|July 2005||2005-07-31|March 2010|2010-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Insulin Resistance and Testosterone in Women|Insulin Resistance and Testosterone in Non-Diabetic Postmenopausal Women|Completed||Phase 2|36|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-06-01 04:51:50.37466|2018-06-01 04:51:50.37466
NCT00123097|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2017-04-05|2005-07-21|2005-07-22|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2005||2005-02-28|April 2017|2017-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Clinical Trial of New Elastomer for Maxillofacial Prosthetics|Multicenter Trial of CPE for Maxillofacial Prosthetics|Completed||Phase 3|42|Actual|University of Louisville||2|||f||||||||||||||2018-06-01 04:51:50.516993|2018-06-01 04:51:50.516993
NCT00123084|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2011-05-06|2005-07-20|2005-07-22|Estimate|||||||2011-05-06|2011-05-09|Estimate|March 2002||2002-03-31|May 2011|2011-05-31|December 2012|Anticipated|2012-12-31|May 2011|Anticipated|2011-05-31||Interventional|||Efficacy of Voice Treatment for Parkinson's Disease|Efficacy of Voice Treatment for Parkinson's Disease|Unknown status|Recruiting|Phase 2|620|Anticipated|University of Colorado, Boulder||4|||f||||||||||||||2018-06-01 04:51:50.650933|2018-06-01 04:51:50.650933
NCT00123071|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2013-01-24|2005-07-20|2005-07-22|Estimate|||||||2013-01-24|2013-01-25|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Observational|VVV||Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network|Variability of Ventricular Mass, Volume, and Ejection Fraction in Pediatric Cardiomyopathy Patients (A Study Conducted by the Pediatric Heart Network)|Completed|||131|Actual|New England Research Institutes|||||f||||t||||||||||2018-06-01 04:51:50.854102|2018-06-01 04:51:50.854102
NCT00123058|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2014-09-05|2005-07-20|2005-07-22|Estimate|||||||2014-09-05|2014-09-08|Estimate|June 2003||2003-06-30|September 2014|2014-09-30|June 2007|Actual|2007-06-30|December 2005|Actual|2005-12-31||Interventional|||Comparison of Two Programs to Improve Blood Pressure Treatment Adherence|Take Control of Your Blood Pressure (TCYB)|Completed||N/A|777|Actual|Duke University||4|||f||||t||||||||||2018-06-01 04:51:50.957368|2018-06-01 04:51:50.957368
NCT00123045|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2016-07-28|2005-07-20|2005-07-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2001||2001-09-30|July 2011|2011-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Patient-Physician Partnership to Improve High Blood Pressure Adherence|Patient-Physician Partnership to Improve High Blood Pressure Adherence|Completed||Phase 4|279|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t||||||||||2018-06-01 04:51:51.109958|2018-06-01 04:51:51.109958
NCT00123032|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2017-07-20|2005-07-20|2005-07-22|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2005||2005-01-31|July 2017|2017-07-31|December 2011|Anticipated|2011-12-31|August 2008|Actual|2008-08-31||Interventional|||School- and Home-Based Program to Prevent Obesity in American Indian Children|Bright Start: Obesity Prevention in American Indian Children|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 04:51:51.169682|2018-06-01 04:51:51.169682
NCT00123019|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2016-07-11|2005-07-20|2005-07-22|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Work, Weight, and Wellness Program: The 3W Program|Overweight and Obesity Control in Worksites|Completed||N/A|6100|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||||||||||||2018-06-01 04:51:51.343031|2018-06-01 04:51:51.343031
NCT00123006|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2016-01-12|2005-07-20|2005-07-22|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|June 2009|Actual|2009-06-30||Interventional|||Effectiveness of the DASH Diet at Reducing High Blood Pressure|Cardiovascular and Renal Hemodynamics and the DASH Diet|Completed||N/A|44|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 04:51:51.456471|2018-06-01 04:51:51.456471
NCT00122993|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2015-01-23|2005-07-21|2005-07-22|Estimate|||||||2015-01-23|2015-01-27|Estimate|September 2004||2004-09-30|January 2015|2015-01-31|April 2008|Actual|2008-04-30|December 2007|Actual|2007-12-31||Interventional|||Worksite Program to Prevent Weight Gain Among Bus Drivers|Worksite Environmental Interventions for Weight Control|Completed||N/A|1200|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 04:51:51.584788|2018-06-01 04:51:51.584788
NCT00122980|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2011-12-28||2013-01-14|2005-07-21|2005-07-22|Estimate|2012-08-15|2012-08-17|Estimate||||2013-01-14|2013-01-18|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Stroke With Transfusions Changing to Hydroxyurea|Stroke With Transfusions Changing to Hydroxyurea|Terminated||Phase 3|134|Actual|St. Jude Children's Research Hospital|The trial was stopped early due to a projected futility of the liver iron component of the primary endpoint in conjunction with the significantly higher number of strokes in the Hydroxyurea/Phlebotomy arm as compared to the Transfusion/Chelation arm.|2||The study has been stopped due to safety and futility concerns.|f||||t||||||||||2018-06-01 04:51:51.736198|2018-06-01 04:51:51.736198
NCT00122954|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2013-11-25||2017-05-11|2005-07-21|2005-07-22|Estimate|2013-11-25|2014-01-14|Estimate||||2017-05-11|2017-06-08|Actual|July 2005||2005-07-31|May 2017|2017-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis|Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis|Completed||Phase 1/Phase 2|39|Actual|Oregon Health and Science University||2|||f||||t||||||||Undecided||2018-06-01 04:51:52.861676|2018-06-01 04:51:52.861676
NCT00122941|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2008-06-13|2005-07-21|2005-07-22|Estimate|||||||2008-06-13|2008-06-16|Estimate|June 2005||2005-06-30|June 2008|2008-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|MMS||Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda|Effect of Multiple Micronutrient Supplementation on Growth, Morbidity, and Mortality of HIV Infected Children in Uganda: a Randomised Double Blind Placebo-Controlled Trial|Completed||Phase 3|860|Actual|Makerere University|||||f||||t||||||||||2018-06-01 04:51:53.537904|2018-06-01 04:51:53.537904
NCT00122928|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2013-11-12|2005-07-21|2005-07-22|Estimate|||||||2013-11-12|2013-11-14|Estimate|October 2004||2004-10-31|November 2013|2013-11-30|September 2009|Actual|2009-09-30|March 2008|Actual|2008-03-31||Interventional|||Comparison of Workplace Obesity Management Programs|Environmental Approaches for Obesity Management at Dow|Completed||N/A|5124|Actual|Emory University||3|||f||||t||||||||||2018-06-01 04:51:53.648926|2018-06-01 04:51:53.648926
NCT00122915|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2018-02-21|2005-07-21|2005-07-22|Estimate|||||||2018-02-21|2018-02-23|Actual|June 2005||2005-06-30|February 2018|2018-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain|A Prospective, Randomized, Double Blind, Crossover, Multi-center Study to Evaluate the Safety and the Efficacy of Motor Cortex Stimulation With the Cortical Stimulation Lead Model 2976 in Patients With Neuropathic Pain|Terminated||Phase 3|104|Anticipated|MedtronicNeuro||||"Based on a consistently low enrolment rate and procedural challenges that were unknown at study~   start. It was not based on safety or efficacy concerns."|f||||||||||||||2018-06-01 04:51:53.727199|2018-06-01 04:51:53.727199
NCT00122902|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2006-08-17|2005-07-19|2005-07-22|Estimate|||||||2006-08-17|2006-08-18|Estimate|February 2002||2002-02-28|August 2006|2006-08-31|February 2004||2004-02-29|||||Observational|||Spirituality and Will to Live in Patients With HIV/AIDS|Spirituality and Will to Live in Patients With HIV/AIDS|Completed|||350||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:51:53.799693|2018-06-01 04:51:53.799693
NCT00122889|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2009-12-30|2005-07-20|2005-07-22|Estimate|||||||2009-12-30|2010-01-01|Estimate|July 2005||2005-07-31|December 2009|2009-12-31|March 2009|Actual|2009-03-31|||||Observational|||Effects of Garlic Supplements on Drug Metabolism|Garlic Metabolism and Cytochrome P450 Modulation|Completed|||80|Actual|Fred Hutchinson Cancer Research Center|||||f||||f||||||Samples With DNA|"~     Whole blood, urine~   "|||2018-06-01 04:51:53.894377|2018-06-01 04:51:53.894377
NCT00122876|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2007-12-05|2005-07-19|2005-07-22|Estimate|||||||2007-12-05|2007-12-07|Estimate|April 2005||2005-04-30|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)|A Phase 1/2 Open-Label Study to Evaluate Safety and Preliminary Evidence of Effectiveness of Tumor Ablation With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LEDs) in the Treatment of Subjects With Inoperable Hepatocellular Carcinoma (HCC)|Completed||Phase 1/Phase 2|25||Light Sciences LLC|||||||||||||||||||2018-06-01 04:51:53.980372|2018-06-01 04:51:53.980372
NCT00122863|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2007-08-29|2005-07-20|2005-07-22|Estimate|||||||2007-08-29|2007-08-31|Estimate|January 2005||2005-01-31|August 2007|2007-08-31|March 2007|Actual|2007-03-31|||||Interventional|||Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder|Duloxetine 60 to 120 mg Once Daily Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder|Completed||Phase 3|380||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:51:54.297022|2018-06-01 04:51:54.297022
NCT00122850|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2007-11-05|2005-07-20|2005-07-22|Estimate|||||||2007-11-05|2007-11-06|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|November 2005|Actual|2005-11-30|||||Interventional|||A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder|A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder.|Completed||Phase 3|480||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:51:54.501175|2018-06-01 04:51:54.501175
NCT00122837|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2007-10-17|2005-07-20|2005-07-22|Estimate|||||||2007-10-17|2007-10-18|Estimate|April 2005||2005-04-30|October 2007|2007-10-31|January 2007|Actual|2007-01-31|||||Interventional|||A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder|A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder|Completed||Phase 3|560||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:51:54.625231|2018-06-01 04:51:54.625231
NCT00122824|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2007-11-05|2005-07-20|2005-07-22|Estimate|||||||2007-11-05|2007-11-06|Estimate|June 2004||2004-06-30|November 2007|2007-11-30|September 2005|Actual|2005-09-30|||||Interventional|||Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder|Duloxetine Hydrochloride 60 mg or 120 mg Once Daily Compared With Placebo in Patients With Generalized Anxiety Disorder.|Completed||Phase 3|480||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:51:54.720482|2018-06-01 04:51:54.720482
NCT00122811|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2007-08-20|2005-07-19|2005-07-22|Estimate|||||||2007-08-20|2007-08-21|Estimate|November 2000||2000-11-30|August 2007|2007-08-31|October 2008|Anticipated|2008-10-31|||||Interventional|||The Hypertension in the Very Elderly Trial (HYVET)|The Hypertension in the Very Elderly Trial (HYVET)|Unknown status|Active, not recruiting|Phase 4|4000|Anticipated|Imperial College London|||||f||||t||||||||||2018-06-01 04:51:54.806353|2018-06-01 04:51:54.806353
NCT00122798|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2006-06-23|2005-07-21|2005-07-22|Estimate|||||||2006-06-23|2006-06-27|Estimate|January 2002||2002-01-31|December 2004|2004-12-31|January 2005||2005-01-31|||||Observational|||Improved Stroke Outcome at 6 Months|Improved Stroke Outcome at 6 Months Attained by a Chain of Structured Acute Treatment With Integrated Rehabilitation and Supported Discharge|Completed|||200||Kantonsspital Baden|||||f||||||||||||||2018-06-01 04:51:54.946234|2018-06-01 04:51:54.946234
NCT00122785|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2005-07-28|2005-07-18|2005-07-22|Estimate|||||||2005-07-28|2005-07-29|Estimate|April 2002||2002-04-30|February 2005|2005-02-28|September 2004||2004-09-30|||||Interventional|||Single Injection of Dexamethasone for Acute Bronchiolitis in Young Children|Efficacy of Single Injection of Dexamethasone for Acute Bronchiolitis in Children Younger Than 2 Years Old: A Randomized, Double-Blind, Placebo Controlled Trial|Completed||N/A|170||Khon Kaen University|||||f||||||||||||||2018-06-01 04:51:55.022666|2018-06-01 04:51:55.022666
NCT00122772|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2011-10-13|2005-07-19|2005-07-22|Estimate|||||||2011-10-13|2011-10-14|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy|CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment|Completed||Phase 3|601|Actual|International Atomic Energy Agency||4|||f||||t||||||||||2018-06-01 04:51:55.151912|2018-06-01 04:51:55.151912
NCT00122759|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2007-07-20|2005-07-19|2005-07-22|Estimate|||||||2007-07-20|2007-07-23|Estimate|December 2005||2005-12-31|July 2007|2007-07-31|September 2007|Anticipated|2007-09-30|||||Interventional|||Ketamine Sedation in Mechanically Ventilated Patients|Prospective Study on the Cost-Effectiveness of Adding Ketamine to Midazolam-Sufentanil Sedation Regimen in Mechanically Ventilated Patients|Unknown status|Recruiting|N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 04:51:55.295087|2018-06-01 04:51:55.295087
NCT00122746|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2011-10-12|2005-07-21|2005-07-22|Estimate|||||||2011-10-12|2011-10-13|Estimate|December 2004||2004-12-31|October 2011|2011-10-31||||June 2012|Anticipated|2012-06-30||Interventional|||Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients|Doctoral CRP on Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients|Unknown status|Recruiting|Phase 3|322|Anticipated|International Atomic Energy Agency||2|||f||||t||||||||||2018-06-01 04:51:55.387865|2018-06-01 04:51:55.387865
NCT00122733|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2007-07-20|2005-07-19|2005-07-22|Estimate|||||||2007-07-20|2007-07-23|Estimate|December 2005||2005-12-31|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Loxapine and Weaning From Ventilator|Facilitation of Weaning From Ventilator by Loxapine|Completed||N/A|9|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-06-01 04:51:55.556253|2018-06-01 04:51:55.556253
NCT00122720|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2006-07-03|2005-07-20|2005-07-22|Estimate|||||||2006-07-03|2006-07-07|Estimate|June 2003||2003-06-30|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery|The Effect of Darbepoetin Alfa Treatment Upon the Rehabilitation Following Planned Surgery for Colorectal Cancer|Completed||Phase 4|200||Herning Hospital|||||f||||||||||||||2018-06-01 04:51:55.665667|2018-06-01 04:51:55.665667
NCT00122707|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2006-03-21|2005-07-19|2005-07-22|Estimate|||||||2006-03-21|2006-03-22|Estimate|April 2004||2004-04-30|June 2005|2005-06-30|October 2005||2005-10-31|||||Interventional|||Comparison of Central and Peripheral Venous Catheters|Randomized Controlled Trial of Mechanical and Infectious Complications of Central Versus Peripheral Venous Catheters in ICU Patients|Completed||N/A|300||Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-06-01 04:51:56.003945|2018-06-01 04:51:56.003945
NCT00122694|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2006-09-11|2005-07-21|2005-07-22|Estimate|||||||2006-09-11|2006-09-12|Estimate|January 2005||2005-01-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)|Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable COPD|Completed||Phase 2|20||Groningen Research Institute for Asthma and COPD|||||f||||||||||||||2018-06-01 04:51:56.134461|2018-06-01 04:51:56.134461
NCT00122681|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2009-11-30||2017-08-07|2005-07-20|2005-07-22|Estimate|2009-12-16|2010-01-20|Estimate||||2017-08-07|2017-08-14|Actual|May 6, 2004|Actual|2004-05-06|April 2017|2017-04-30|November 26, 2009|Actual|2009-11-26|November 3, 2006|Actual|2006-11-03||Interventional|||Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18|A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.|Completed||Phase 3|18729|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:51:56.47619|2018-06-01 04:51:56.47619
NCT00122668|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2005-11-14|2005-07-21|2005-07-22|Estimate|||||||2005-11-14|2005-11-15|Estimate|November 2003||2003-11-30|November 2005|2005-11-30|July 2005||2005-07-31|||||Interventional|||Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients|Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121)|Terminated||Phase 4|112||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:51:59.892391|2018-06-01 04:51:59.892391
NCT00122655|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2005-11-14|2005-07-21|2005-07-22|Estimate|||||||2005-11-14|2005-11-15|Estimate|January 2001||2001-01-31|November 2005|2005-11-30|June 2005||2005-06-30|||||Interventional|||Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy|A Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE Study|Terminated||Phase 4|100||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:51:59.970788|2018-06-01 04:51:59.970788
NCT00122642|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2009-09-24|2005-07-19|2005-07-22|Estimate|||||||2009-09-24|2009-09-25|Estimate|August 2005||2005-08-31|September 2009|2009-09-30|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|||Alcohol Locks for the Prevention of Tunneled Catheter-related Infections|Short Daily Alcohol Locks for the Prevention of Tunneled Catheter Infection in Patients With Haematological Disease. Randomised Placebo Controlled Trial|Completed||Phase 2/Phase 3|440|Anticipated|Erasmus Medical Center||2|||f||||||||||||||2018-06-01 04:52:00.055701|2018-06-01 04:52:00.055701
NCT00122629|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2005-07-28|2005-07-20|2005-07-22|Estimate|||||||2005-07-28|2005-07-29|Estimate|October 2000||2000-10-31|July 2005|2005-07-31|May 2003||2003-05-31|||||Interventional|||Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders|Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI|Terminated||Phase 3|405||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:00.152425|2018-06-01 04:52:00.152425
NCT00122616|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2012-02-21|2005-07-19|2005-07-22|Estimate|||||||2012-02-21|2012-02-22|Estimate|November 2003||2003-11-30|February 2012|2012-02-29|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C|Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and C Hepatitis Who Failed to Active Treatment for HCV. ANRSHC12 Fibrostop|Completed||Phase 3|52|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||t||||||||||2018-06-01 04:52:00.24621|2018-06-01 04:52:00.24621
NCT00122603|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2011-12-21|2005-07-20|2005-07-22|Estimate|||||||2011-12-21|2011-12-22|Estimate|December 2005||2005-12-31|December 2011|2011-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)|Efficacy and Safety of Regimens Restricted to a Combination of Two Boosted Protease Inhibitors as Potent Antiretroviral Therapy in HIV-1 Infected Patients. ANRS 127 2IP|Completed||Phase 2|61|Actual|French National Agency for Research on AIDS and Viral Hepatitis||2|||f||||t||||||||||2018-06-01 04:52:00.364415|2018-06-01 04:52:00.364415
NCT00122590|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2005-07-29|2005-07-20|2005-07-22|Estimate|||||||2005-07-29|2005-08-01|Estimate|July 2002||2002-07-31|July 2005|2005-07-31|March 2005||2005-03-31|||||Interventional|||Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)|Prospective Trial to Evaluate How Therapeutic Drug Monitoring of Protease Inhibitors Increases Virologic Success and Tolerance of HAART (ANRS 111 COPHAR2)|Terminated||N/A|115||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:00.48857|2018-06-01 04:52:00.48857
NCT00122577|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2005-07-27|2005-07-19|2005-07-22|Estimate|||||||2005-07-27|2005-07-28|Estimate|March 2002||2002-03-31|July 2005|2005-07-31|July 2004||2004-07-31|||||Interventional|||Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients|Randomized Open Label Study Assessing the Antiviral Activity, Toxicity and Pharmacologic Interaction of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir as Part of a Salvage Regimen in HIV Infected Patients With Multiple Treatment Failures (ANRS 107 Trial PUZZLE 2)|Terminated||Phase 2|50||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:00.644286|2018-06-01 04:52:00.644286
NCT00122564|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2005-11-10|2005-07-19|2005-07-22|Estimate|||||||2005-11-10|2005-11-11|Estimate|June 2003||2003-06-30|November 2005|2005-11-30|April 2005||2005-04-30|||||Interventional|||Study of HIV-1 Rgp-160 Administered by Mucosal Routes in Healthy Volunteers|Phase I Study Evaluating the Systemic and Mucosal Safety and Immunogenicity of a Recombinant HIV-1 Gp 160 (MN/LAI) Administered by Transmucosal (Nasal or Vaginal) Routes, Alone or Formulated With DC-Chol, in HIV Negative Volunteers (ANRS VAC14)|Terminated||Phase 1|36||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:00.749653|2018-06-01 04:52:00.749653
NCT00122551|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2005-07-28|2005-07-19|2005-07-22|Estimate|||||||2005-07-28|2005-08-01|Estimate|December 2001||2001-12-31|July 2005|2005-07-31|April 2005||2005-04-30|||||Interventional|||Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)|A Prospective, Randomized, Multicenter Trial of Intermittent Therapy in HIV-Infected Patients With Successful Viral Suppression Under HAART (ANRS 106 Window Trial)|Terminated||Phase 3|400||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:00.824976|2018-06-01 04:52:00.824976
NCT00122538|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2011-12-02|2005-07-19|2005-07-22|Estimate|||||||2011-12-02|2011-12-05|Estimate|February 2006||2006-02-28|December 2011|2011-12-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|||Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)|HAART Regimen Comprising 3TC + ddI + EFV in Once-daily Administration in HIV-1 Infected Children in Burkina Faso|Completed||Phase 2|52|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:52:00.9084|2018-06-01 04:52:00.9084
NCT00122525|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2009-04-29|2005-07-19|2005-07-22|Estimate|||||||2009-04-29|2009-04-30|Estimate|July 2002||2002-07-31|April 2009|2009-04-30|July 2005|Actual|2005-07-31|||||Interventional|||Effect of Male Circumcision on HIV Incidence (ANRS 1265)|Effect of Safe Male Circumcision on Incidence of Infection by HIV, HSV-2 and of Genital Ulceration|Terminated||Phase 3|3274|Actual|French National Agency for Research on AIDS and Viral Hepatitis||||following DSMB recommandation.|f||||t||||||||||2018-06-01 04:52:01.126571|2018-06-01 04:52:01.126571
NCT00122512|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2006-02-09|2005-07-21|2005-07-22|Estimate|||||||2006-02-09|2006-02-10|Estimate||||February 2006|2006-02-28||||||||Interventional|||Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV|Phase 2a Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV – An Extended Safety Evaluation|Terminated||Phase 2|500||FHI 360|||||f||||||||||||||2018-06-01 04:52:01.224811|2018-06-01 04:52:01.224811
NCT00122499|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2005-07-26|2005-07-19|2005-07-22|Estimate|||||||2005-07-26|2005-07-27|Estimate|February 2003||2003-02-28|July 2005|2005-07-31|February 2005||2005-02-28|||||Interventional|||A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer|A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer|Completed||Phase 3|||Erasmus Medical Center|||||f||||||||||||||2018-06-01 04:52:01.358819|2018-06-01 04:52:01.358819
NCT00122486|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2006-07-28|2005-07-20|2005-07-22|Estimate|||||||2006-07-28|2006-08-01|Estimate|July 2004||2004-07-31|July 2006|2006-07-31|March 2006||2006-03-31|||||Interventional|||Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV|Phase 2 Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV|Completed||Phase 2|1200||FHI 360|||||f||||||||||||||2018-06-01 04:52:01.465087|2018-06-01 04:52:01.465087
NCT00122473|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2011-07-28|2005-07-21|2005-07-22|Estimate|||||||2011-07-28|2011-07-29|Estimate|January 2004||2004-01-31|July 2011|2011-07-31|January 2007||2007-01-31|||||Interventional|||Imatinib in Dermatofibrosarcoma Protuberans (DFSP)|Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans|Completed||Phase 1/Phase 2|30||Dermatologic Cooperative Oncology Group|||||f||||||||||||||2018-06-01 04:52:01.546325|2018-06-01 04:52:01.546325
NCT00122460|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|2011-08-25||2014-07-11|2005-07-19|2005-07-22|Estimate|2011-08-25|2011-09-30|Estimate||||2014-07-11|2014-07-23|Estimate|December 2004||2004-12-31|July 2014|2014-07-31|January 2011|Actual|2011-01-31|March 2007|Actual|2007-03-31||Interventional|||Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)|Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|442|Actual|Merck KGaA|Non-specific outcome measures 'Safety' & 'QOL assessments' were deleted from this entry in error.Replacement outcomes have been created. The 'Safety' outcome refers to adverse events.|2|||f||||t||||||||||2018-06-01 04:52:01.719256|2018-06-01 04:52:01.719256
NCT00122447|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|2012-05-18||2013-11-12|2005-07-21|2005-07-22|Estimate|2012-05-18|2012-06-20|Estimate||||2013-11-12|2013-12-05|Estimate|May 2005||2005-05-31|November 2013|2013-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance|CVD Risk and Prevention in Early Glucose Intolerance|Completed||N/A|84|Actual|Emory University|Not fully powered due to under-enrollment and high drop-out rate. Higher than anticipated precision error of FMD measures. Possible Hawthorne effect with lifestyle changes. Short treatment period relative to long-term CVD risk in prediabetes.|4|||f||||f||||||||||2018-06-01 04:52:03.193473|2018-06-01 04:52:03.193473
NCT00122434|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2017-12-27|2005-07-21|2005-07-22|Estimate|||||||2017-12-27|2017-12-28|Actual|July 2005||2005-07-31|December 2017|2017-12-31||||May 2006|Actual|2006-05-31||Interventional|||Dose Finding Study in COPD|A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|389|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:52:03.603293|2018-06-01 04:52:03.603293
NCT00122421|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2012-02-17|2005-07-19|2005-07-22|Estimate|||||||2012-02-17|2012-02-20|Estimate|June 2003||2003-06-30|February 2012|2012-02-29|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||The Impact of Pharmacist Recommendations on Quality of Care in Diabetic Patients|The Impact of Pharmacist Recommendations on Quality of Care in Diabetic Patients|Completed||N/A|300|Actual|Brigham and Women's Hospital||2|||f||||||||||||||2018-06-01 04:52:03.749973|2018-06-01 04:52:03.749973
NCT00122408|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2010-09-23|2005-07-19|2005-07-22|Estimate|||||||2010-09-23|2010-09-24|Estimate|January 2006||2006-01-31|September 2010|2010-09-30|December 2009|Anticipated|2009-12-31|August 2009|Anticipated|2009-08-31||Interventional|||Probiotic Enteral Administration in Mechanically Ventilated Patients|Effect of Enterally Administered Probiotics in Mechanically Ventilated Patients: Double-Blind, Prospective Randomized Study Versus Placebo|Terminated||Phase 1|740|Anticipated|Central Hospital, Nancy, France||2|||f||||||||||||||2018-06-01 04:52:03.823777|2018-06-01 04:52:03.823777
NCT00122395|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2006-05-03|2005-07-21|2005-07-22|Estimate|||||||2006-05-03|2006-05-04|Estimate|January 2005||2005-01-31|July 2005|2005-07-31|March 2005||2005-03-31|||||Interventional|||Trial Regarding the Acceptability of Audiotape Intimate Partner Violence (IPV) Screening|A Randomized Clinical Trial Regarding the Acceptability of an Audiotape Questionnaire for Intimate Partner Violence Screening in a Pediatric ED|Completed||N/A|500||Children's Hospital of Philadelphia|||||f||||||||||||||2018-06-01 04:52:03.934809|2018-06-01 04:52:03.934809
NCT00122382|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|2010-05-03||2010-11-03|2005-07-19|2005-07-22|Estimate|2010-06-16|2010-07-13|Estimate||||2010-11-03|2010-11-16|Estimate|July 2005||2005-07-31|November 2010|2010-11-30|February 2009|Actual|2009-02-28|February 2008|Actual|2008-02-29||Interventional|||Remission and Joint Damage Progression in Early Rheumatoid Arthritis|A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate|Completed||Phase 3|1052|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 04:52:04.084094|2018-06-01 04:52:04.084094
NCT00122369|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2012-02-03||2013-02-23|2005-07-20|2005-07-22|Estimate|2012-12-31|2013-02-07|Estimate||||2013-02-23|2013-02-28|Estimate|March 2002||2002-03-31|February 2013|2013-02-28|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy|Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy|Completed||Phase 2|240|Actual|Beth Israel Deaconess Medical Center|For the assessment of the Secondary Outcome parameter we were able to recruit only 19 women whom we could contact early enough on the day of their breast cancer surgery to fill out the IES. This limits the power of the statistical analysis.|3|||f||||t||||||||||2018-06-01 04:52:05.748518|2018-06-01 04:52:05.748518
NCT00122356|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2013-03-11|2005-07-20|2005-07-22|Estimate|||||||2013-03-11|2013-03-13|Estimate|September 2005||2005-09-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|BATMAN||Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment|Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm|Completed||Phase 3|303|Actual|Barwon Health||1|||f||||||||||||||2018-06-01 04:52:06.975219|2018-06-01 04:52:06.975219
NCT00122343|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-21|||2015-02-18|2005-07-21|2005-07-22|Estimate|||||||2015-02-18|2015-02-19|Estimate|August 2005||2005-08-31|February 2015|2015-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)|A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer|Completed||Phase 2|45|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 04:52:07.0806|2018-06-01 04:52:07.0806
NCT00122330|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2006-11-30|2005-07-19|2005-07-22|Estimate|||||||2006-11-30|2006-12-04|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|January 2006||2006-01-31|||||Interventional|||Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients|Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients|Completed||Phase 3|75||Alexion Pharmaceuticals|||||||||||||||||||2018-06-01 04:52:07.143718|2018-06-01 04:52:07.143718
NCT00122317|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|2017-04-24||2018-02-11|2005-07-20|2005-07-22|Estimate|2017-04-24|2017-06-05|Actual||||2018-02-11|2018-03-13|Actual|May 2005|Actual|2005-05-31|February 2018|2018-02-28|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)|Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH|Completed||Phase 3|187|Actual|Alexion Pharmaceuticals||1|||f||||f||||||||No||2018-06-01 04:52:07.367867|2018-06-01 04:52:07.367867
NCT00122304|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2007-02-20|2005-07-19|2005-07-22|Estimate|||||||2007-02-20|2007-02-21|Estimate|December 2004||2004-12-31|February 2007|2007-02-28|November 2006||2006-11-30|||||Interventional|||Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab|Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study|Completed||Phase 3|85||Alexion Pharmaceuticals|||||f||||||||||||||2018-06-01 04:52:07.788504|2018-06-01 04:52:07.788504
NCT00122291|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2012-01-18|2005-07-20|2005-07-22|Estimate|||||||2012-01-18|2012-01-19|Estimate|January 2002||2002-01-31|August 2011|2011-08-31||||||||Interventional|||A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer|A Phase 2 Study of Preoperative Radiation Therapy and Capecitabine (an Oral Fluoropyrimidine Carbamate) in Locally Advanced Rectal Cancer|Unknown status|Active, not recruiting|Phase 2|66|Anticipated|AHS Cancer Control Alberta|||||f||||||||||||||2018-06-01 04:52:07.914342|2018-06-01 04:52:07.914342
NCT00122278|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2008-02-15|2005-07-20|2005-07-22|Estimate|||||||2008-02-15|2008-02-18|Estimate|July 2005||2005-07-31|February 2008|2008-02-29|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines|Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches|Completed||Phase 3|205|Actual|Montefiore Medical Center|||||f||||||||||||||2018-06-01 04:52:07.994597|2018-06-01 04:52:07.994597
NCT00122265|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2016-02-24|2005-07-20|2005-07-22|Estimate|||||||2016-02-24|2016-02-26|Estimate|April 2003||2003-04-30|April 2012|2012-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer|Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal RT for Prostate Cancer|Terminated|||83|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:52:08.075746|2018-06-01 04:52:08.075746
NCT00122044|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2014-05-21|2005-07-20|2005-07-21|Estimate|||||||2014-05-21|2014-05-23|Estimate|January 2003||2003-01-31|May 2014|2014-05-31|December 2004||2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects|Childhood Hypertonia of Central Origin: An Open Label Trial of Anticholinergic Treatment Effects|Completed||Phase 2|35||University of Southern California|||||f||||||||||||||2018-06-01 04:52:11.651539|2018-06-01 04:52:11.651539
NCT00122252|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2011-12-08|2005-07-20|2005-07-22|Estimate|||||||2011-12-08|2011-12-09|Estimate|May 2004||2004-05-31|December 2011|2011-12-31|February 2007|Actual|2007-02-28|||||Observational|||Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) Contouring in Prostate Cancer to Improve the Possibilities for Intensity Modulated RadioTherapy (IMRT) Dose Escalation|Biological Imaging for Optimising CTV and GTV Contouring in Prostate Cancer to Improve the Possibilities for IMRT Dose Escalation|Terminated|||20||AHS Cancer Control Alberta||||Study abandoned.|f||||||||||||||2018-06-01 04:52:08.158136|2018-06-01 04:52:08.158136
NCT00122239|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2016-03-14|2005-07-20|2005-07-22|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2005||2005-01-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers|A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers|Unknown status|Active, not recruiting||13|Actual|AHS Cancer Control Alberta|||||f||||t||||||||||2018-06-01 04:52:08.253484|2018-06-01 04:52:08.253484
NCT00122226|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2006-04-24|2005-07-14|2005-07-21|Estimate|||||||2006-04-24|2006-04-25|Estimate|January 2003||2003-01-31|July 2005|2005-07-31|July 2008||2008-07-31|||||Interventional|||MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)|MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)|Unknown status|Active, not recruiting|Phase 4|50||VU University Medical Center|||||f||||||||||||||2018-06-01 04:52:08.348036|2018-06-01 04:52:08.348036
NCT00122213|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2010-04-20|2005-07-15|2005-07-21|Estimate|||||||2010-04-20|2010-04-21|Estimate|September 2003||2003-09-30|April 2010|2010-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Physical Activity and Diet Program to Prevent Accumulation of Abdominal Fat Mass in Recently Retired Men and Women|An Individual-based Diet and Physical Activity Intervention Program to Prevent Accumulation of Abdominal Fat Mass in Recently Retired Men and Women|Completed||Phase 2|400||Wageningen University|||||f||||||||||||||2018-06-01 04:52:09.500201|2018-06-01 04:52:09.500201
NCT00122187|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|2013-12-05||2015-04-06|2005-07-18|2005-07-21|Estimate|2013-12-05|2014-01-27|Estimate||||2015-04-06|2015-04-24|Estimate|August 2005||2005-08-31|September 2013|2013-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||The population is the number of VAMCs that enrolled in the study.|Translation of Colorectal Cancer Screening Guidelines to Practice: A System Intervention|Translation of Colorectal Cancer Screening Guidelines: A System Intervention|Completed||N/A|8|Actual|VA Office of Research and Development|Half of the sites randomized did not complete the study. GI referral rates should have been nearly 100%, yet were not. Because of programming limitations, we were unable to evaluate the type of diagnostic interventions the patients received.|2|||f||||f||||||||||2018-06-01 04:52:09.570943|2018-06-01 04:52:09.570943
NCT00122174|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2015-04-06|2005-07-18|2005-07-21|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2004||2004-07-31|January 2007|2007-01-31|June 2006|Actual|2006-06-30|||||Interventional|||Stress-Busting Program for Caregivers of Patients With Neruological Diseases|Stress-Busting Program for Caregivers of Patients With Neurological Diseases|Completed||N/A|50|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:52:09.95247|2018-06-01 04:52:09.95247
NCT00122161|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2015-04-06|2005-07-18|2005-07-21|Estimate|||||||2015-04-06|2015-04-07|Estimate||||October 2007|2007-10-31|September 2005|Actual|2005-09-30|||||Interventional|||Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation|Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation|Completed||Phase 3|190|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:52:10.092854|2018-06-01 04:52:10.092854
NCT00122148|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2010-02-04|2005-07-18|2005-07-21|Estimate|||||||2010-02-04|2010-02-08|Estimate|September 2005||2005-09-30|August 2006|2006-08-31|June 2006|Actual|2006-06-30|||||Interventional|||Can Vignettes Be Used to Improve Practice & Outcome|Can Vignettes be Used to Improve Practice and Outcomes?|Terminated||N/A|||VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:52:10.221653|2018-06-01 04:52:10.221653
NCT00122135|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|2015-07-10||2015-11-16|2005-07-18|2005-07-21|Estimate|2015-10-06|2015-11-10|Estimate||||2015-11-16|2015-12-14|Estimate|December 2004||2004-12-31|November 2015|2015-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|Aim3||A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making|A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making|Completed||N/A|120|Actual|VA Office of Research and Development|Difficulties in recruiting enough surrogates led to abandoning having a surrogate arm.|2|||f||||f||||||||||2018-06-01 04:52:10.402809|2018-06-01 04:52:10.402809
NCT00122122|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2015-04-06|2005-07-18|2005-07-21|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2004|Actual|2004-03-31|||||Interventional|||Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients|Randomized Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients|Completed||Phase 3|600|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:52:10.768669|2018-06-01 04:52:10.768669
NCT00122109|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|2014-08-22||2015-04-06|2005-07-18|2005-07-21|Estimate|2014-10-15|2014-10-16|Estimate||||2015-04-06|2015-04-28|Estimate|August 2005||2005-08-31|August 2014|2014-08-31|December 2009|Actual|2009-12-31|October 2008|Actual|2008-10-31||Interventional|||Telemedicine and Anger Management Groups With PTSD Veterans in the Hawaiian Islands|Telemedicine and Anger Management Groups for PTSD Veterans in the Hawaiian Islands|Completed||N/A|125|Actual|VA Office of Research and Development|We conservatively excluced participants with acute safety concerns (homicidal or suicidal) and current substance dependence. However other literature suugests that both issues can be safely addressed via telemedicine.|2|||f||||f||||||||||2018-06-01 04:52:10.852594|2018-06-01 04:52:10.852594
NCT00122096|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2008-09-25|2005-07-18|2005-07-21|Estimate|||||||2008-09-25|2008-09-26|Estimate|November 2002||2002-11-30|September 2008|2008-09-30|January 2006||2006-01-31|||||Interventional|||Perioperative Inflammation and Cyclooxygenase 2 (COX-2)|Preoperative Valdecoxib: CNS Penetration and Effects on Biochemical Markers of Pain and Sensitization|Completed||Phase 4|30||University of Washington|||||f||||||||||||||2018-06-01 04:52:11.291528|2018-06-01 04:52:11.291528
NCT00122083|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2005-07-25|2005-07-18|2005-07-21|Estimate|||||||2005-07-25|2005-07-26|Estimate|April 2004||2004-04-30|March 2004|2004-03-31|June 2004||2004-06-30|||||Interventional|||An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression|A Cluster Randomised Controlled Trial to Assess the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression|Completed||N/A|1680||University of Oxford|||||f||||||||||||||2018-06-01 04:52:11.409441|2018-06-01 04:52:11.409441
NCT00122070|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2008-06-09|2005-07-15|2005-07-21|Estimate|||||||2008-06-09|2008-06-10|Estimate|May 2005||2005-05-31|June 2008|2008-06-30|May 2008|Actual|2008-05-31|September 2007|Actual|2007-09-30||Interventional|||Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder|Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder|Completed||Phase 3|15|Actual|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-06-01 04:52:11.482109|2018-06-01 04:52:11.482109
NCT00122031|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2012-06-13|2005-07-15|2005-07-21|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|April 2009|Actual|2009-04-30||Interventional|||Deep Brain Stimulation for Treatment-Refractory Major Depression|Deep Brain Stimulation for Treatment-Refractory Major Depression|Completed||Phase 1|13|Actual|University Hospital, Bonn||1|||f||||f||||||||||2018-06-01 04:52:11.759936|2018-06-01 04:52:11.759936
NCT00122018|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2014-11-06|2005-07-20|2005-07-21|Estimate|||||||2014-11-06|2014-11-07|Estimate|May 2002||2002-05-31|November 2014|2014-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery|N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery.|Completed||Phase 2|80||Pulmonary Critical Care Associates of Baltimore||4|||f||||f||||||||||2018-06-01 04:52:11.839313|2018-06-01 04:52:11.839313
NCT00122005|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2009-02-23|2005-07-18|2005-07-21|Estimate|||||||2009-02-23|2009-02-24|Estimate|July 2005||2005-07-31|February 2009|2009-02-28|July 2005|Anticipated|2005-07-31|||||Interventional|||GVAX in Advanced Prostate Cancer Patients Made Lymphopenic|Phase I/II Study of Human GM-CSF Gene-Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (GVAX®) in Advanced Prostate Cancer Patients Made Lymphopenic and Infused With Autologous Peripheral Blood Mononuclear Cells|Unknown status|Active, not recruiting|Phase 1/Phase 2|18|Anticipated|Providence Health & Services|||||||||||||||||||2018-06-01 04:52:12.024409|2018-06-01 04:52:12.024409
NCT00121992|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2005-08-08|2005-07-18|2005-07-21|Estimate|||||||2005-08-08|2005-08-10|Estimate|June 1999||1999-06-30|August 2005|2005-08-31|June 2005||2005-06-30|||||Interventional|||Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (5 FAC) as Adjuvant Treatment of Breast Cancer Patients|A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes|Completed||Phase 3|1054||Spanish Breast Cancer Research Group|||||f||||||||||||||2018-06-01 04:52:12.124216|2018-06-01 04:52:12.124216
NCT00121979|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2007-07-02|2005-07-18|2005-07-21|Estimate|||||||2007-07-02|2007-07-03|Estimate|September 2004||2004-09-30|July 2005|2005-07-31|March 2006||2006-03-31|||||Interventional|||Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects|Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir for 3TC in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART Regimen Containing Lamivudine|Completed||Phase 2|60||Pharmasset|||||||||||||||||||2018-06-01 04:52:12.247055|2018-06-01 04:52:12.247055
NCT00121966|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2008-06-18|2005-07-14|2005-07-21|Estimate|||||||2008-06-18|2008-06-19|Estimate|January 2003||2003-01-31|June 2008|2008-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|SDDS||South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus|South Danish Diabetes Study: A Prospective Randomised Multi-Centre Study for the Evaluation of the Optimal Pharmacological Antidiabetic Treatment of Type 2 Diabetes Mellitus|Completed||Phase 4|400||Odense University Hospital|||||f||||||||||||||2018-06-01 04:52:12.349746|2018-06-01 04:52:12.349746
NCT00121953|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2012-10-16|2005-07-18|2005-07-21|Estimate|||||||2012-10-16|2012-10-17|Estimate|July 2005||2005-07-31|October 2012|2012-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis|Endometriosis: Immunomodulation|Withdrawn||Phase 2/Phase 3|0|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||||Due to the recent meta-analysis about CV adverse effects.|f||||||||||||||2018-06-01 04:52:12.455128|2018-06-01 04:52:12.455128
NCT00121940|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2012-04-18|2005-07-18|2005-07-21|Estimate|||||||2012-04-18|2012-04-20|Estimate|February 2006||2006-02-28|April 2012|2012-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Guided Care: Integrating High Tech and High Touch|Guided Care: Integrating High Tech and High Touch|Completed||N/A|904|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-06-01 04:52:12.56151|2018-06-01 04:52:12.56151
NCT00121927|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2010-01-26|2005-07-15|2005-07-21|Estimate|||||||2010-01-26|2010-01-27|Estimate|June 2004||2004-06-30|February 2007|2007-02-28|June 2007||2007-06-30|||||Interventional|||Use of the Atkins Diet for Adults With Intractable Epilepsy|Use of the Atkins Diet for Adults With Intractable Epilepsy|Completed||N/A|30||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:52:12.654755|2018-06-01 04:52:12.654755
NCT00121914|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2005-10-17|2005-07-15|2005-07-21|Estimate|||||||2005-10-17|2005-10-18|Estimate|October 2000||2000-10-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone|Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study With Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone|Unknown status|Active, not recruiting|Phase 3|120||Medical University of Vienna|||||f||||||||||||||2018-06-01 04:52:12.735963|2018-06-01 04:52:12.735963
NCT00121901|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-10-16|2005-07-14|2005-07-21|Estimate|||||||2007-10-16|2007-10-18|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?||Completed||Phase 3|1600|Anticipated|Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:52:12.835106|2018-06-01 04:52:12.835106
NCT00121888|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2014-06-05|2005-07-14|2005-07-21|Estimate|||||||2014-06-05|2014-06-06|Estimate|December 2002||2002-12-31|June 2014|2014-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy|Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy|Completed||Phase 1/Phase 2|60||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:52:12.975711|2018-06-01 04:52:12.975711
NCT00121875|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2009-09-28|2005-07-20|2005-07-21|Estimate|||||||2009-09-28|2009-09-29|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|||||Observational|||Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature|Growth Hormone and Insulin Resistance in Girls With Turner Syndrome or Idiopathic Short Stature|Terminated|||1|Actual|Massachusetts General Hospital|||2|Enrollment was too low.|f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 04:52:13.084292|2018-06-01 04:52:13.084292
NCT00121862|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2006-05-04|2005-07-18|2005-07-21|Estimate|||||||2006-05-04|2006-05-05|Estimate|August 2005||2005-08-31|May 2006|2006-05-31|March 2006||2006-03-31|||||Interventional|||Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite|A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine Compared to the Leish-111f Protein Alone in Montenegro Skin Test-Negative Healthy Adults|Completed||Phase 2|60||IDRI|||||||||||||||||||2018-06-01 04:52:13.172738|2018-06-01 04:52:13.172738
NCT00121849|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2006-05-04|2005-07-15|2005-07-21|Estimate|||||||2006-05-04|2006-05-05|Estimate|August 2005||2005-08-31|May 2006|2006-05-31|February 2006||2006-02-28|||||Interventional|||Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite|A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine in Montenegro Skin Test-Positive Healthy Adults|Completed||Phase 1|12||IDRI|||||||||||||||||||2018-06-01 04:52:13.257231|2018-06-01 04:52:13.257231
NCT00121836|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|2009-12-16||2011-04-25|2005-07-18|2005-07-21|Estimate|2011-02-10|2011-03-04|Estimate||||2011-04-25|2011-04-27|Estimate|June 2005||2005-06-30|April 2011|2011-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer|An Open-label Study of Xeloda Plus Avastin at Time of Disease Progression in Treatment-naïve Women With HER2-negative Metastatic Breast Cancer|Completed||Phase 4|109|Actual|Hoffmann-La Roche|The primary endpoint TTP was changed to overall survival (OS) due to issues regarding tumor assessment data based on RECIST and poor response from investigators to related queries that developed after the planned interim analysis.|1|||f||||||||||||||2018-06-01 04:52:13.375391|2018-06-01 04:52:13.375391
NCT00121823|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2017-01-11|2005-07-18|2005-07-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2004||2004-06-30|January 2017|2017-01-31|December 2004||2004-12-31|||||Interventional|||Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines|Malaria Infection Diagnosed by PCR as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines|Completed||Phase 1/Phase 2|120||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:52:13.959155|2018-06-01 04:52:13.959155
NCT00121810|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|2009-11-18||2011-04-13|2005-07-15|2005-07-21|Estimate|2011-01-31|2011-02-24|Estimate||||2011-04-13|2011-04-15|Estimate|August 2003||2003-08-31|April 2011|2011-04-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients|An Open Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-term on Mycophenolate Mofetil (MMF) (CellCept®) and Sirolimus (Rapamune®)|Completed||Phase 4|305|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:52:14.124432|2018-06-01 04:52:14.124432
NCT00121797|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-17|||2006-11-06|2005-07-17|2005-07-21|Estimate|||||||2006-11-06|2006-11-07|Estimate|January 2004||2004-01-31|July 2005|2005-07-31|June 2005|Anticipated|2005-06-30|||||Interventional|||Peripartum Bacteruria and Urinary Tract Infections (UTI)|Risk Factors for Postpartum Bacteruria, Does Labor Cause UTI?|Unknown status|Recruiting|N/A|1000|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-06-01 04:52:15.087645|2018-06-01 04:52:15.087645
NCT00121784|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2016-11-01|2005-07-15|2005-07-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2005||2005-10-31|November 2016|2016-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients|A Randomized, Open-label Study of the Effect of Replacing CNI With Sirolimus in a Standard Care Regimen of CNI, CellCept, and Steroids on Renal Function in Heart Transplant Patients|Terminated||Phase 4|12|Actual|Hoffmann-La Roche||1||Poor recruitment|f||||||||||||||2018-06-01 04:52:15.18711|2018-06-01 04:52:15.18711
NCT00121771|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2017-01-11|2005-07-18|2005-07-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|January 2017|2017-01-31|July 2004||2004-07-31|||||Interventional|||Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men|A Phase 1 Trial of the Malaria Candidate Vaccines FP9 CS and MVA CS in Adult Gambian Men Aged 18 - 45 Years|Completed||Phase 1|32||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:52:15.293756|2018-06-01 04:52:15.293756
NCT00121758|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2008-06-05|2005-07-18|2005-07-21|Estimate|||||||2008-06-05|2008-06-06|Estimate|September 2004||2004-09-30|June 2008|2008-06-30|December 2007|Actual|2007-12-31|November 2007|Actual|2007-11-30||Interventional|||AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers|Randomised Double Blinded Phase II AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptide (LIPO-5) Versus Placebo in Non Infected HIV Volunteers (ANRS VAC 18)|Completed||Phase 2|156|Anticipated|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:52:15.415634|2018-06-01 04:52:15.415634
NCT00121745|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2007-12-15|2005-07-18|2005-07-21|Estimate|||||||2007-12-15|2007-12-20|Estimate|July 2005||2005-07-31|December 2007|2007-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer|Phase I Evaluation of Safety of Intravenous Infusion of a Pathotropic Vector Bearing a Cytocidal Cyclin G1 Construct (Rexin-G) as Intervention for Locally Advanced and Metastatic Pancreatic Cancer Refractory to Standard Chemotherapy|Terminated||Phase 1|12|Actual|Epeius Biotechnologies||4||poor enrollment|f||||t||||||||||2018-06-01 04:52:15.47355|2018-06-01 04:52:15.47355
NCT00121732|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2015-06-29|2005-07-20|2005-07-21|Estimate|||||||2015-06-29|2015-07-01|Estimate|July 2005||2005-07-31|June 2015|2015-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies|A Phase 1, Two-Arm, Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies|Completed||Phase 1|39|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:52:15.575825|2018-06-01 04:52:15.575825
NCT00121719|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|2016-04-19||2016-04-19|2005-07-20|2005-07-21|Estimate|2016-04-19|2016-05-27|Estimate||||2016-04-19|2016-05-27|Estimate|July 2005||2005-07-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|June 2009|Actual|2009-06-30||Interventional||Intent-to-treat population included all participants who received at least one dose of lenvatinib.|An Open Label Phase I Dose Escalation Study Of E7080|An Open Label Phase I Dose Escalation Study Of E7080|Unknown status|Active, not recruiting|Phase 1|87|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 04:52:15.918578|2018-06-01 04:52:15.918578
NCT00121706|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2006-02-03|2005-07-15|2005-07-21|Estimate|||||||2006-02-03|2006-02-06|Estimate|July 2005||2005-07-31|January 2006|2006-01-31|September 2005||2005-09-30|||||Interventional|||Fast Food Feeding in Youth|Fast Food Feeding in Youth|Completed||N/A|18||Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:52:20.93075|2018-06-01 04:52:20.93075
NCT00121693|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2016-01-26|2005-07-20|2005-07-21|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2003||2003-12-31|January 2016|2016-01-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||The Use of Music Therapy in the Prevention of Falls|Posturographic Changes Associated With Music Therapy and Fall Prevention|Completed||Early Phase 1|266|Actual|Carrick Institute for Graduate Studies||4|||f||||f||||||||No||2018-06-01 04:52:20.991687|2018-06-01 04:52:20.991687
NCT00121680|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2015-12-09|2005-07-20|2005-07-21|Estimate|||||||2015-12-09|2015-12-11|Estimate|July 2005||2005-07-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|September 2011|Actual|2011-09-30||Interventional|||A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma|A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma|Completed||Phase 1|115|Actual|Eisai Inc.||1|||f||||f||||||||||2018-06-01 04:52:21.085779|2018-06-01 04:52:21.085779
NCT00121667|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|2011-03-15|2009-07-30|2015-04-08|2005-07-20|2005-07-21|Estimate|2011-03-15|2011-04-08|Estimate|2010-08-13|2010-08-18|Estimate|2015-04-08|2015-04-29|Estimate|August 2005||2005-08-31|March 2015|2015-03-31|February 2010|Actual|2010-02-28|October 2006|Actual|2006-10-31||Interventional|||Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone|"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone"|Completed||Phase 3|1462|Actual|AstraZeneca||4|||f||||||||||||||2018-06-01 04:52:21.474934|2018-06-01 04:52:21.474934
NCT00121654|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2009-03-09|2005-07-14|2005-07-21|Estimate|||||||2009-03-09|2009-03-10|Estimate|July 2005||2005-07-31|March 2009|2009-03-31|December 2009|Anticipated|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Spinal Cord Stimulation (SCS) in Refractory Angina|Randomized Study on SCS for the Treatment of Refractory Angina Pectoris|Unknown status|Recruiting|Phase 4|60|Anticipated|Catholic University of the Sacred Heart||3|||f||||f||||||||||2018-06-01 04:52:26.154377|2018-06-01 04:52:26.154377
NCT00121641|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|2011-04-12|2009-07-30|2015-03-16|2005-07-15|2005-07-21|Estimate|2011-04-12|2011-05-11|Estimate|2009-11-12|2010-03-04|Estimate|2015-03-16|2015-04-03|Estimate|July 2005||2005-07-31|March 2015|2015-03-31|February 2010|Actual|2010-02-28|August 2006|Actual|2006-08-31||Interventional|||Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 3|1035|Actual|AstraZeneca||5|||f||||||||||||||2018-06-01 04:52:26.435942|2018-06-01 04:52:26.435942
NCT00121628|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2013-10-07|2005-07-15|2005-07-21|Estimate|||||||2013-10-07|2013-10-09|Estimate|July 2005||2005-07-31|October 2013|2013-10-31|October 2010|Actual|2010-10-31|November 2006|Actual|2006-11-30||Interventional|||A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer|A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer|Completed||Phase 2|184|Actual|Amgen|||||||||||||||||||2018-06-01 04:52:31.651179|2018-06-01 04:52:31.651179
NCT00121615|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-03-05|2005-07-15|2005-07-21|Estimate|||||||2009-03-05|2009-03-06|Estimate|October 2004||2004-10-31|March 2009|2009-03-31||||||||Interventional|||Study of Etanercept in the Treatment of Psoriasis in Adult Subjects|An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects|Completed||Phase 3|391||Amgen|||||f||||||||||||||2018-06-01 04:52:31.864417|2018-06-01 04:52:31.864417
NCT00121602|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-18|||2008-02-21|2005-07-18|2005-07-21|Estimate|||||||2008-02-21|2008-02-28|Estimate|March 2005||2005-03-31|February 2008|2008-02-29|October 2006|Actual|2006-10-31|October 2005|Actual|2005-10-31||Interventional|||Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease|Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis|Completed||Phase 3|446|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:52:31.94581|2018-06-01 04:52:31.94581
NCT00121589|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2017-06-30|2005-07-20|2005-07-21|Estimate|||||||2017-06-30|2017-07-02|Actual|July 14, 2005||2005-07-14|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60|Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:52:32.064722|2018-06-01 04:52:32.064722
NCT00121563|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-20|||2008-03-03|2005-07-20|2005-07-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2005||2005-07-31|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Evaluation of a TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect|Evaluation of TNF-Alpha Modulator for Clinical and Molecular Indicators of Analgesic Effect|Completed||Phase 2|90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:52:32.125453|2018-06-01 04:52:32.125453
NCT00121550|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2016-08-10|2005-07-19|2005-07-21|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 1999||1999-10-31|August 2016|2016-08-31|September 2002|Actual|2002-09-30|April 2000|Actual|2000-04-30||Interventional|||The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease|The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial|Completed||Phase 3|4372|Actual|Copenhagen Trial Unit, Center for Clinical Intervention Research||2|||f||||||||||||||2018-06-01 04:52:32.191498|2018-06-01 04:52:32.191498
NCT00121537|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2015-10-07|2005-07-19|2005-07-21|Estimate|||||||2015-10-07|2015-10-08|Estimate|July 2005||2005-07-31|October 2015|2015-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Study to Determine the Utility of Wound Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes|A Prospective Study to Determine the Utility of Vacuum Assisted Closure (VAC) Compared to Conventional Saline Dressing Changes With Regards to Lower Extremity Fasciotomy Wound Healing, Complications, Cost and Patient and Nursing Satisfaction|Terminated||N/A|30||The University of Texas Health Science Center at San Antonio||||terminated, due to lack enrollment,|f||||||||||||||2018-06-01 04:52:32.340253|2018-06-01 04:52:32.340253
NCT00121524|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2015-05-28|2005-07-19|2005-07-21|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2003||2003-01-31|May 2015|2015-05-31|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome|Effects of Epinephrine and I.V. Needle on CPR Outcome|Completed||Phase 2|904|Actual|University of Oslo||2|||f||||t||||||||||2018-06-01 04:52:32.506881|2018-06-01 04:52:32.506881
NCT00121511|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2015-05-26|2005-07-19|2005-07-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2005||2005-07-31|May 2015|2015-05-31|July 2007|Actual|2007-07-31|||||Interventional|||The Effect of Efudex Treatment on Photoaged Skin|The Effect of Efudex (5-fluorouracil) Treatment on Photoaged Skin|Completed||N/A|21|Actual|University of Michigan|||||f||||f||||||||||2018-06-01 04:52:32.68486|2018-06-01 04:52:32.68486
NCT00121498|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2005-09-12|2005-07-19|2005-07-21|Estimate|||||||2005-09-12|2005-09-14|Estimate|November 2002||2002-11-30|December 2004|2004-12-31|September 2003||2003-09-30|||||Interventional|||Preemptive Analgesia for Abdominal Hysterectomy|Preemptive Analgesia for Post Abdominal Hysterectomy Pain Management|Completed||N/A|32||Rambam Health Care Campus|||||f||||||||||||||2018-06-01 04:52:32.780836|2018-06-01 04:52:32.780836
NCT00121485|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|2012-11-13||2016-04-08|2005-07-19|2005-07-21|Estimate|2013-08-22|2013-10-29|Estimate||||2016-04-08|2016-04-12|Estimate|February 2005||2005-02-28|April 2016|2016-04-30|January 2012|Actual|2012-01-31|June 2009|Actual|2009-06-30||Interventional|||Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy|The HeartMate II LVAS Pivotal Study Protocol, Destination Therapy|Completed||N/A|200|Actual|St. Jude Medical||2|||f||||t||||||||||2018-06-01 04:52:32.897209|2018-06-01 04:52:32.897209
NCT00121472|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|2009-05-29||2016-04-08|2005-07-19|2005-07-21|Estimate|2013-03-18|2013-03-19|Estimate||||2016-04-08|2016-05-13|Estimate|March 2005||2005-03-31|April 2016|2016-04-30|May 2010|Actual|2010-05-31|November 2006|Actual|2006-11-30||Interventional|||Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation|The HeartMate II LVAS Pivotal Study Protocol, Bridge to Cardiac Transplantation|Completed||N/A|194|Actual|St. Jude Medical|||||f||||t||||||||||2018-06-01 04:52:33.610853|2018-06-01 04:52:33.610853
NCT00121459|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2015-03-03|2005-07-19|2005-07-21|Estimate|||||||2015-03-03|2015-03-04|Estimate|September 2003||2003-09-30|March 2015|2015-03-31||||||||Interventional|||Effectiveness of the Diaphragm for HIV Prevention|The Latex Diaphragm to Prevent HIV Acquisition Among Women: A Female-Controlled, Physical Barrier of the Cervix|Withdrawn||Phase 3|0|Actual|University of California, San Francisco||||PI left and no data or information is available.|f||||||||||||||2018-06-01 04:52:34.244634|2018-06-01 04:52:34.244634
NCT00121446|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2017-05-18|2005-07-19|2005-07-21|Estimate|||||||2017-05-18|2017-05-19|Actual|July 2003||2003-07-31|July 2005|2005-07-31||||||||Interventional|||Which Therapy for Acute Heart Attacks? (The WEST Study)|Which Early ST Elevation Myocardial Infarction Therapy? The WEST Study|Completed||Phase 2/Phase 3|300||University of Alberta|||||f||||||||||||||2018-06-01 04:52:34.367828|2018-06-01 04:52:34.367828
NCT00121433|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2006-06-23|2005-07-19|2005-07-21|Estimate|||||||2006-06-23|2006-06-27|Estimate|September 2004||2004-09-30|July 2005|2005-07-31|December 2004||2004-12-31|||||Interventional|||Leptin and Endothelial Function|The Role of Leptin in Modulating Vascular Tone and Endothelial Function in Obese and Normal Weight Adults: A Vascular-Protective Effect of Leptin?|Completed||Phase 4|15||University of Michigan|||||||||||||||||||2018-06-01 04:52:34.461227|2018-06-01 04:52:34.461227
NCT00121420|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2014-05-07|2005-07-19|2005-07-21|Estimate|||||||2014-05-07|2014-05-09|Estimate||||May 2014|2014-05-31||||||||Interventional|||Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases|Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases|Terminated||Phase 2|45||Pharmacyclics LLC.|||||f||||||||||||||2018-06-01 04:52:34.509283|2018-06-01 04:52:34.509283
NCT00121407|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2005-07-19|2005-07-19|2005-07-21|Estimate|||||||2005-07-19|2005-07-21|Estimate|March 2002||2002-03-31|July 2005|2005-07-31|August 2005||2005-08-31|||||Interventional|||Visudyne® in Occult (VIO)|A Randomized, Placebo-Controlled, Double-Masked, Multicenter, Phase III Study of the Effect of Visudyne Therapy in Occult With No Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Visudyne in Occult (VIO)|Completed||Phase 3|364||QLT Inc.|||||||||||||||||||2018-06-01 04:52:34.596649|2018-06-01 04:52:34.596649
NCT00121394|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2014-07-29|2005-07-19|2005-07-21|Estimate|||||||2014-07-29|2014-07-31|Estimate|June 2005||2005-06-30|July 2014|2014-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Chlorhexidine Vaginal and Infant Wash in Pakistan|Randomized Trial of Chlorhexidine Vaginal and Infant Wash to Reduce Neonatal Mortality|Completed||Phase 3|5008|Actual|NICHD Global Network for Women's and Children's Health||1|||f||||t||||||||||2018-06-01 04:52:34.722784|2018-06-01 04:52:34.722784
NCT00121381|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2008-01-10|2005-07-19|2005-07-21|Estimate|||||||2008-01-10|2008-01-15|Estimate|May 2005||2005-05-31|January 2008|2008-01-31|January 2007|Actual|2007-01-31|||||Interventional|||Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis|Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis|Completed||Phase 4|400||Novartis||2|||||||||||||||||2018-06-01 04:52:34.808714|2018-06-01 04:52:34.808714
NCT00121368|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2013-11-22|2005-07-19|2005-07-21|Estimate|||||||2013-11-22|2013-11-25|Estimate|February 2004||2004-02-29|November 2013|2013-11-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Observational|||GN Tobacco Use Survey|Survey on Tobacco Use in the GN Sites|Completed|||6000|Actual|NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 04:52:34.939794|2018-06-01 04:52:34.939794
NCT00121355|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2016-10-17|2005-07-19|2005-07-21|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2005||2005-07-31|October 2016|2016-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Novofine Autocover Safety Needle Versus BD Safety Glide|An Open-Label, Multi-Center, Prospective Cross-Over Study of Preference and Safety of NovoFine® Autocover(TM) Needles Compared to BD Safety Glide (TM) Syringes in the Hospital Setting|Completed||Phase 4|83|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:52:35.011721|2018-06-01 04:52:35.011721
NCT00121329|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2005-07-19|2005-07-19|2005-07-21|Estimate|||||||2005-07-19|2005-07-21|Estimate||||July 2005|2005-07-31|December 2004||2004-12-31|||||Interventional|||4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions|4% Intrauterine Lidocaine Infusion for Pain Management in First Trimester Abortions|Completed||N/A|80||Oregon Health and Science University|||||f||||||||||||||2018-06-01 04:52:35.092705|2018-06-01 04:52:35.092705
NCT00121316|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2008-01-10|2005-07-19|2005-07-21|Estimate|||||||2008-01-10|2008-01-15|Estimate|October 2004||2004-10-31|January 2008|2008-01-31|July 2005|Actual|2005-07-31|||||Interventional|||Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients|Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids|Completed||Phase 4|200||Novartis||2|||f||||||||||||||2018-06-01 04:52:35.170402|2018-06-01 04:52:35.170402
NCT00121303|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2016-09-19|2005-07-19|2005-07-21|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|January 2009|Actual|2009-01-31||Interventional|||Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t)|Completed||Phase 3|600|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||4|||f||||||||||||||2018-06-01 04:52:35.271475|2018-06-01 04:52:35.271475
NCT00121290|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2014-02-21|2005-07-19|2005-07-21|Estimate|||||||2014-02-21|2014-02-24|Estimate|February 2005||2005-02-28|April 2013|2013-04-30||||April 2008|Actual|2008-04-30||Interventional|||SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Phase I Dose Escalation Study of Daily x 3 Intravenous SJG-136 in Patients With Advanced Solid Tumors|Completed||Phase 1|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:52:35.434514|2018-06-01 04:52:35.434514
NCT00105833|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2002||2002-07-31|March 2009|2009-03-31|December 2008|Actual|2008-12-31|November 2004|Actual|2004-11-30||Interventional|DEP-PC||Improving Outcomes of Depression in Primary Care|Improving Outcomes of Depression in Primary Care|Completed||N/A|400|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:57:45.940054|2018-06-01 04:57:45.940054
NCT00121277|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2015-07-22|2005-07-19|2005-07-21|Estimate|||||||2015-07-22|2015-07-23|Estimate|September 2005||2005-09-30|July 2015|2015-07-31||||August 2009|Actual|2009-08-31||Interventional|||Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Capecitabine in Patients With Solid Tumors|Completed||Phase 1|28|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:52:35.508431|2018-06-01 04:52:35.508431
NCT00121264|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2014-06-16|2005-07-19|2005-07-21|Estimate|||||||2014-06-16|2014-06-17|Estimate|March 2005||2005-03-31|January 2013|2013-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors|A Phase I Dose-Escalation Study of Intravenous 17-Allylaminogeldanamycin (17-AAG) [NSC 330507and Oral BAY 43-9006 [NSC 724772] Administered in Patients With Pretreated Advanced Solid Tumors|Completed||Phase 1|54|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:52:35.579773|2018-06-01 04:52:35.579773
NCT00121251|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2018-05-11|2005-07-19|2005-07-21|Estimate|||||||2018-05-11|2018-05-14|Actual|April 19, 2005|Actual|2005-04-19|May 2018|2018-05-31|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer|A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma|Completed||Phase 1/Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:52:35.659524|2018-06-01 04:52:35.659524
NCT00121238|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|2015-07-29||2016-03-28|2005-07-19|2005-07-21|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|January 2005||2005-01-31|February 2013|2013-02-28|November 2015|Actual|2015-11-30|November 2010|Actual|2010-11-30||Interventional||16 patients were enrolled but only 13 were analyzed. 1 patient progressed clinically before any treatment.Two patients who received study drug were deemed ineligible as they did not meet entry PSA criteria of three consecutive rises in PSA.|Cilengitide in Treating Patients With Prostate Cancer|Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Patients With Non-Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:52:35.767502|2018-06-01 04:52:35.767502
NCT00121225|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|2014-10-01||2014-10-01|2005-07-19|2005-07-21|Estimate|2014-10-01|2014-10-03|Estimate||||2014-10-01|2014-10-03|Estimate|September 2005||2005-09-30|May 2013|2013-05-31|June 2013|Actual|2013-06-30|March 2009|Actual|2009-03-31||Interventional|||Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma|A Phase II Study of Vorinostat in Patients With Advanced Melanoma|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:52:36.08202|2018-06-01 04:52:36.08202
NCT00121212|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2015-10-28|2005-07-19|2005-07-21|Estimate|||||||2015-10-28|2015-10-30|Estimate|July 2003||2003-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|July 2010|Actual|2010-07-31||Interventional|||Positron Emission Tomography in Prostate Cancer|Positron Emission Tomography in Prostate Cancer|Completed||N/A|179|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-06-01 04:52:36.301516|2018-06-01 04:52:36.301516
NCT00121199|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|2012-10-30||2014-05-06|2005-07-19|2005-07-21|Estimate|2012-11-16|2012-12-19|Estimate||||2014-05-06|2014-05-21|Estimate|June 2005||2005-06-30|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma|Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL|Completed||Phase 2|73|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:52:36.388268|2018-06-01 04:52:36.388268
NCT00121186|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|2012-03-05||2012-03-05|2005-07-19|2005-07-21|Estimate|2012-03-05|2012-04-03|Estimate||||2012-03-05|2012-04-03|Estimate|July 2005||2005-07-31|March 2012|2012-03-31|December 2011|Actual|2011-12-31|January 2008|Actual|2008-01-31||Interventional|||S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma|Nonmyeloablative Allogeneic Stem Cell Transplantation For Relapsed Hodgkin's or Non-Hodgkin's Lymphoma After Autologous Transplantation ( A BMT Study)|Terminated||Phase 2|1|Actual|Southwest Oncology Group||1||poor accrual|f||||f||||||||||2018-06-01 04:52:36.965123|2018-06-01 04:52:36.965123
NCT00121173|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-19|||2013-06-10|2005-07-19|2005-07-21|Estimate|||||||2013-06-10|2013-06-12|Estimate|November 2003||2003-11-30|June 2013|2013-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia|A Phase I/II Clinical Trial of pNGVL4a-Sig/E7 (Detox)/HSP70 for the Treatment of Patients With HPV 16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)|Completed||Phase 1/Phase 2|70|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-06-01 04:52:37.188276|2018-06-01 04:52:37.188276
NCT00121160|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2012-03-26|2005-07-19|2005-07-21|Estimate|||||||2012-03-26|2012-03-27|Estimate|September 2005||2005-09-30|March 2012|2012-03-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response|Can Stress Management Improve Vaccine Immune Response|Completed||Phase 1|126|Actual|Fred Hutchinson Cancer Research Center|||||f||||t||||||||||2018-06-01 04:52:37.378144|2018-06-01 04:52:37.378144
NCT00121147|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2006-02-22|2005-07-19|2005-07-21|Estimate|||||||2006-02-22|2006-02-24|Estimate|September 2003||2003-09-30|July 2005|2005-07-31|October 2005||2005-10-31|||||Interventional|||Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan|A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Month Double-Masked, Multi-Center Trial in the United States|Completed||N/A|200||Hermann Eye Center|||||f||||||||||||||2018-06-01 04:52:37.481657|2018-06-01 04:52:37.481657
NCT00121134|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|2013-08-08||2013-11-26|2005-07-19|2005-07-21|Estimate|2013-08-08|2013-10-14|Estimate||||2013-11-26|2013-12-24|Estimate|June 2005||2005-06-30|November 2013|2013-11-30|May 2011|Actual|2011-05-31|May 2009|Actual|2009-05-31||Interventional|||Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer|Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer|Completed||N/A|164|Actual|Dana-Farber Cancer Institute||4|||f||||t||||||||||2018-06-01 04:52:37.654528|2018-06-01 04:52:37.654528
NCT00121121|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2007-03-14|2005-07-19|2005-07-21|Estimate|||||||2007-03-14|2007-03-15|Estimate|July 2004||2004-07-31|November 2005|2005-11-30|December 2005||2005-12-31|||||Interventional|||Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers|A Phase Ib Vaccine Trial Evaluating the Safety and Immunogenicity of HIV Lipopeptides by Two Administration Routes (Intramuscular And Intradermal) in Healthy Adult Volunteers. ANRS VAC16 Trial|Completed||Phase 1|70||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:38.497837|2018-06-01 04:52:38.497837
NCT00121108|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13||2012-03-08|2012-06-27|2005-07-19|2005-07-21|Estimate||||2012-06-27|2012-07-02|Estimate|2012-06-27|2012-07-02|Estimate|November 2004||2004-11-30|June 2012|2012-06-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States|A Phase 3 Study of MEDI-524 (Motavizumab) for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States|Completed||Phase 3|2127|Actual|MedImmune LLC||2|||f||||t||||||||||2018-06-01 04:52:38.578668|2018-06-01 04:52:38.578668
NCT00121095|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2007-12-17|2005-07-19|2005-07-21|Estimate|||||||2007-12-17|2007-12-21|Estimate|July 2005||2005-07-31|December 2007|2007-12-31|June 2008|Anticipated|2008-06-30|||||Interventional|||Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer|Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer|Unknown status|Recruiting|Phase 1/Phase 2|69|Anticipated|Cytogen Corporation||1|||f||||f||||||||||2018-06-01 04:52:38.663023|2018-06-01 04:52:38.663023
NCT00121069|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2005-07-19|2005-07-19|2005-07-21|Estimate|||||||2005-07-19|2005-07-21|Estimate|September 2002||2002-09-30|July 2005|2005-07-31|September 2004||2004-09-30|||||Interventional|||Study of Escitalopram in the Treatment of Specific Phobia|Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia|Completed||Phase 2/Phase 3|12||Connor, Kathryn M., M.D.|||||||||||||||||||2018-06-01 04:52:38.777041|2018-06-01 04:52:38.777041
NCT00121056|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-12-04|2005-07-19|2005-07-21|Estimate|||||||2008-12-04|2008-12-05|Estimate|September 2002||2002-09-30|December 2008|2008-12-31||||||||Observational|||REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations|Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations (REKinDLE)|Completed|||||Amgen|||||f||||||||||||||2018-06-01 04:52:38.842366|2018-06-01 04:52:38.842366
NCT00121043|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-11-25|2005-07-19|2005-07-21|Estimate|||||||2009-11-25|2009-11-26|Estimate||||December 2007|2007-12-31||||||||Interventional|||Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire|An Open Label, Randomized, Crossover Study to Assess Acceptability and Functionality of SimpleJectTM Vs Pre-Filled Syringe(s) Using Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using A Self-Reported Questionnaire|Completed||Phase 4|||Swedish Orphan Biovitrum|||||f||||||||||||||2018-06-01 04:52:38.892216|2018-06-01 04:52:38.892216
NCT00121030|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-20|2005-07-19|2005-07-21|Estimate|||||||2007-12-20|2007-12-24|Estimate|October 2002||2002-10-31|December 2007|2007-12-31|December 2003||2003-12-31|||||Interventional|||Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy|An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patients With Gynecological Malignancies Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy|Completed||Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:52:38.946408|2018-06-01 04:52:38.946408
NCT00121017|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2006-07-26|2005-07-19|2005-07-21|Estimate|||||||2006-07-26|2006-07-27|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects|A Randomized, Open-Label Study Assessing Safety, Tolerability and Efficacy of an Induction-Maintenance Treatment Strategy Including Lopinavir/Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine Versus Efavirenz Plus Tenofovir Disoproxil Fumarate and Emtricitabine in Antiviral-naïve HIV-1/HCV Co-Infected Subjects|Withdrawn||Phase 2|200||Abbott|||||||||||||||||||2018-06-01 04:52:39.161753|2018-06-01 04:52:39.161753
NCT00121004|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2013-09-04|2005-07-18|2005-07-19|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 2005||2005-07-31|September 2013|2013-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||A Study to Tailor Advance Directives|A Study to Tailor Advance Directives|Completed|||100||University of Chicago|||||f||||f||||||||||2018-06-01 04:52:39.231969|2018-06-01 04:52:39.231969
NCT00120991|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2008-02-29|2005-07-18|2005-07-19|Estimate|||||||2008-02-29|2008-03-03|Estimate|April 2002||2002-04-30|February 2008|2008-02-29|July 2008|Anticipated|2008-07-31|March 2006|Actual|2006-03-31||Interventional|||Best Bypass Surgery (BBS) Trial|Off-Pump Coronary Artery Bypass Grafting Versus Conventional Coronary Artery Bypass Grafting on Postoperative Mortality and Morbidity, A Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 3|341|Actual|Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:52:39.332535|2018-06-01 04:52:39.332535
NCT00120978|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2006-05-08|2005-07-18|2005-07-19|Estimate|||||||2006-05-08|2006-05-09|Estimate|December 2004||2004-12-31|April 2005|2005-04-30|August 2006||2006-08-31|||||Interventional|||Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial|Advair - CRP Study|Unknown status|Recruiting|Phase 4|250||University of British Columbia|||||f||||||||||||||2018-06-01 04:52:39.419309|2018-06-01 04:52:39.419309
NCT00120965|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-01-26|2005-07-18|2005-07-19|Estimate|||||||2011-01-26|2011-01-27|Estimate|June 2004||2004-06-30|January 2011|2011-01-31|March 2005|Actual|2005-03-31|||||Interventional|||AutoPulse Assisted Prehospital International Resuscitation Trial (ASPIRE)|AutoPulse Assisted Prehospital International Resuscitation Trial (ASPIRE)|Terminated||Phase 3|1837|Actual|University of Washington||2||"DSMB recommended termination due to lower survival to discharge in primary population and worse~   discharge CPC scores in the treatment arm than control arm."|f||||t||||||||||2018-06-01 04:52:39.518279|2018-06-01 04:52:39.518279
NCT00120952|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2006-08-04|2005-07-18|2005-07-19|Estimate|||||||2006-08-04|2006-08-07|Estimate|January 2003||2003-01-31|August 2006|2006-08-31|October 2009||2009-10-31|||||Interventional|||A Comparison Between Titanium Femoral Stem and Cobalt-Chromium Femoral Stem in Cemented Hip Arthroplasty|A Comparison Between Titanium Femoral Stem and Cobalt-Chromium Femoral Stem in Cemented Hip Arthroplasty. A Randomized Prospective Roentgen Stereogrammetric Analysis.|Unknown status|Active, not recruiting|N/A|40||University of Aarhus|||||f||||||||||||||2018-06-01 04:52:39.600968|2018-06-01 04:52:39.600968
NCT00120939|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2009-04-02|2005-07-12|2005-07-19|Estimate|||||||2009-04-02|2009-04-03|Estimate||||May 2007|2007-05-31||||||||Interventional|||Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer|Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors|Completed||Phase 1|25||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 04:52:39.730161|2018-06-01 04:52:39.730161
NCT00120926|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2006-09-27|2005-07-18|2005-07-19|Estimate|||||||2006-09-27|2006-09-28|Estimate|August 2005||2005-08-31|September 2006|2006-09-30|June 2006||2006-06-30|||||Interventional|||Dose Comparison of Amino Acids on Growth in Premature Neonates|Randomized Control Trial Evaluating the Effect of Two Different Doses of Amino Acids on Growth and Serum Amino Acids in Premature Neonates Admitted to the NICU|Completed||Phase 3|150||Mednax Center for Research, Education, Quality and Safety|||||f||||||||||||||2018-06-01 04:52:39.835051|2018-06-01 04:52:39.835051
NCT00120913|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2005-07-18|2005-07-18|2005-07-19|Estimate|||||||2005-07-18|2005-07-19|Estimate||||July 2005|2005-07-31|August 2004||2004-08-31|||||Interventional|||Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?||Completed||N/A|160||Oregon Health and Science University|||||f||||||||||||||2018-06-01 04:52:39.888537|2018-06-01 04:52:39.888537
NCT00120900|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-01-18|2005-07-18|2005-07-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|May 2005||2005-05-31|January 2017|2017-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee|A Phase III, 12-week, Multicentre, Double-Blind, Double-Dummy, Randomised, Placebo - and Active Comparator - Contolled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381 XXmg and YYmg Administered Orally Once Daily, in Adults With Osteoarthritis of the Knee|Completed||Phase 3|1340|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:52:39.946642|2018-06-01 04:52:39.946642
NCT00120887|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2007-04-04|2005-07-18|2005-07-19|Estimate|||||||2007-04-04|2007-04-05|Estimate|April 2002||2002-04-30|September 2006|2006-09-30|December 2005||2005-12-31|||||Interventional|||Lupus Atherosclerosis Prevention Study|Lupus Atherosclerosis Prevention Study|Completed||Phase 4|200||Johns Hopkins University|||||f||||||||||||||2018-06-01 04:52:40.0394|2018-06-01 04:52:40.0394
NCT00120874|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|2016-04-28||2016-09-15|2005-07-18|2005-07-19|Estimate|2016-06-03|2016-07-14|Estimate||||2016-09-15|2016-10-25|Estimate|August 2006||2006-08-31|September 2016|2016-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training|Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial|Completed||Phase 4|20|Actual|New York University School of Medicine|The original statistician who worked on this study left the institution prior to completing data analysis. A new statistician has been engaged. In the unlikely event that outcome measures data changes, it will be updated accordingly in this record.|2|||f||||t||||||||||2018-06-01 04:52:40.120286|2018-06-01 04:52:40.120286
NCT00120861|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2010-06-09|2005-07-18|2005-07-19|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 2005||2005-01-31|June 2010|2010-06-30||||||||Interventional|||Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy|A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of NM283 and the Combination of Pegylated Interferon Plus NM283, in Patients With Chronic Hepatitis C Who Have Previously Failed to Respond to Standard Therapy|Completed||Phase 2|||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:52:41.74913|2018-06-01 04:52:41.74913
NCT00120848|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2016-11-02|2005-07-18|2005-07-19|Estimate|||||||2016-11-02|2016-11-04|Estimate|November 2003||2003-11-30|November 2016|2016-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults|Study of the Efficacy of Candidate HPV 16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Adolescent & Young Adult Women in North America and Brazil Vaccinated in Primary Study 580299/001|Completed||Phase 2|776|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:52:41.859732|2018-06-01 04:52:41.859732
NCT00120835|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2010-06-09|2005-07-18|2005-07-19|Estimate|||||||2010-06-09|2010-06-10|Estimate|July 2004||2004-07-31|June 2010|2010-06-30||||||||Interventional|||Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C|An Open-Label, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and the Antiviral Activity of NM283 When Administered Alone and in Combination With Pegylated Interferon Alfa 2b to Treatment-Naive Adults With Genotype-1 Chronic Hepatitis C|Completed||Phase 1/Phase 2|||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:52:42.077207|2018-06-01 04:52:42.077207
NCT00120822|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2017-01-11|2005-07-18|2005-07-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2002||2002-07-31|January 2017|2017-01-31|January 2004||2004-01-31|||||Interventional|||Folic Acid Supplementation in Gambian Primigravidae|A Study of the Effect of Folic Acid Supplementation on the Anti-malarial Action of Sulfadoxine-pyrimethamine When Used for Intermittent Preventive Treatment in Gambian Primigravidae.|Completed||Phase 3|1000||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:52:42.147523|2018-06-01 04:52:42.147523
NCT00120809|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2017-01-11|2005-07-18|2005-07-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2002||2002-07-31|January 2017|2017-01-31|September 2004||2004-09-30|||||Interventional|||Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae|A Randomised, Placebo Controlled Trial of Intermittent Preventative Treatment With Sulfadoxine-pyrimethamine in Gambian Multigravidae.|Completed||Phase 3|3000||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:52:42.223983|2018-06-01 04:52:42.223983
NCT00120796|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2016-07-20|2005-07-18|2005-07-19|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2005||2005-08-31|March 2008|2008-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)|Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection|Terminated||Phase 3|8|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2||poor patient recrutment|f||||t||||||||||2018-06-01 04:52:42.290172|2018-06-01 04:52:42.290172
NCT00120783|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2007-01-17|2005-07-18|2005-07-19|Estimate|||||||2007-01-17|2007-01-18|Estimate|February 2002||2002-02-28|January 2007|2007-01-31|August 2003||2003-08-31|||||Interventional|||Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance|Efficacy and Tolerability of an Antiretroviral bi-Therapy in HIV-1 Infected Patients With Multidrug Resistant HIV ANRS 109 Vista Trial.|Terminated||Phase 2|40||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:42.367967|2018-06-01 04:52:42.367967
NCT00120770|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2007-02-27|2005-07-18|2005-07-19|Estimate|||||||2007-02-27|2007-02-28|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|March 2007||2007-03-31|||||Interventional|||Cellulose Sulfate (CS) Gel and HIV in Nigeria|Randomized Controlled Trial of Cellulose Sulfate Gel and HIV in Nigeria|Terminated||Phase 3|2160||FHI 360||||The study was halted in January 2007 due to safety concerns.|||||||||||||||2018-06-01 04:52:42.439757|2018-06-01 04:52:42.439757
NCT00120757|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2011-12-21|2005-07-18|2005-07-19|Estimate|||||||2011-12-21|2011-12-22|Estimate|October 2004||2004-10-31|December 2011|2011-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)|Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir|Completed||Phase 3|140||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:52:42.527293|2018-06-01 04:52:42.527293
NCT00120744|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2018-04-16|2005-07-18|2005-07-19|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2004||2004-01-31|April 2018|2018-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department|Randomized Trial of the Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Acute Gastroenteritis in a Pediatric Emergency Department|Completed||N/A|||The Hospital for Sick Children|||||f||||||||||||||2018-06-01 04:52:42.623547|2018-06-01 04:52:42.623547
NCT00120731|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2007-06-14|2005-07-18|2005-07-19|Estimate|||||||2007-06-14|2007-06-15|Estimate|July 2005||2005-07-31|July 2005|2005-07-31|May 2007|Actual|2007-05-31|||||Interventional|||Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones|Urinary Chemistry and Acid-Base Effects of Potassium Citrate in Children With Idiopathic Hypercalciuria and Urolithiasis|Completed||N/A|23|Actual|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-06-01 04:52:42.711771|2018-06-01 04:52:42.711771
NCT00120718|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2008-09-26|2005-07-18|2005-07-19|Estimate|||||||2008-09-26|2008-09-30|Estimate|June 2002||2002-06-30|September 2008|2008-09-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||The Effect of Fasudil on Vascular Function in Humans|The Effect of Fasudil on Vascular Function in Humans|Completed||Phase 2|60|Anticipated|Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 04:52:42.792128|2018-06-01 04:52:42.792128
NCT00120705|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-03-24|2005-07-18|2005-07-19|Estimate|||||||2009-03-24|2009-03-25|Estimate|November 2002||2002-11-30|March 2009|2009-03-31|September 2003||2003-09-30|||||Interventional|||Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy|A Randomized, Open-Label, Pilot Study to Evaluate Every Three Week Maintenance Dosing of Darbepoetin Alfa Therapy in Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy|Completed||Phase 2|204||Amgen|||||f||||||||||||||2018-06-01 04:52:42.910538|2018-06-01 04:52:42.910538
NCT00120692|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-20|2005-07-18|2005-07-19|Estimate|||||||2007-12-20|2007-12-24|Estimate|October 2002||2002-10-31|December 2007|2007-12-31|December 2003||2003-12-31|||||Interventional|||Treatment for Patients Suffering From Anemia Due to Chemotherapy|An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy|Completed||Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:52:43.004063|2018-06-01 04:52:43.004063
NCT00120679|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-20|2005-07-18|2005-07-19|Estimate|||||||2007-12-20|2007-12-24|Estimate|October 2002||2002-10-31|December 2007|2007-12-31|December 2003||2003-12-31|||||Interventional|||Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy|An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patient With Non-Small Cell Lung Cancer Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy|Completed||Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:52:43.083862|2018-06-01 04:52:43.083862
NCT00120666|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-16|||2017-06-30|2005-07-16|2005-07-18|Estimate|||||||2017-06-30|2017-07-02|Actual|July 8, 2005||2005-07-08|June 25, 2007|2007-06-25|June 25, 2007||2007-06-25|||||Observational|||Interhemispheric Plasticity in Humans|Interhemispheric Plasticity in Humans|Completed|||108||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:52:43.146479|2018-06-01 04:52:43.146479
NCT00120653|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2005-07-16|2005-07-18|Estimate|||||||2017-06-30|2017-07-02|Actual|July 14, 2005||2005-07-14|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Interventional|||Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)|Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:52:43.199769|2018-06-01 04:52:43.199769
NCT00120640|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2012-09-18|2005-07-11|2005-07-18|Estimate|||||||2012-09-18|2012-09-19|Estimate|July 2005||2005-07-31|September 2012|2012-09-30||||||||Interventional|||Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate||Withdrawn||N/A|0|Actual|Yale University||||funding|f||||||||||||||2018-06-01 04:52:43.253214|2018-06-01 04:52:43.253214
NCT00120627|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|2014-09-23||2015-04-06|2005-07-15|2005-07-18|Estimate|2014-11-20|2014-11-27|Estimate||||2015-04-06|2015-04-28|Estimate|November 2005||2005-11-30|August 2014|2014-08-31|September 2010|Actual|2010-09-30|February 2009|Actual|2009-02-28||Interventional|||Mantram Repetition to Manage PTSD in Veterans|Efficacy of Mantram Repetition on PTSD Symptoms in Veterans|Completed||N/A|146|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:52:43.442314|2018-06-01 04:52:43.442314
NCT00120614|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2009-04-07|2005-07-15|2005-07-18|Estimate|||||||2009-04-07|2009-04-08|Estimate|September 2001||2001-09-30|April 2009|2009-04-30|June 2007||2007-06-30|||||Interventional|||Educational/Behavioral Intervention Program for Parents of Premature Infants|Improving Outcomes of LBW Premature Infants and Parents|Completed||N/A|260||University of Rochester|||||f||||||||||||||2018-06-01 04:52:44.126067|2018-06-01 04:52:44.126067
NCT00120601|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2005-07-15|2005-07-15|2005-07-18|Estimate|||||||2005-07-15|2005-07-18|Estimate|March 2003||2003-03-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Trial for the Treatment of Alcohol Dependence|The Role of Pharmacotherapy in Prevention of Relapse in Alcohol Dependence|Unknown status|Active, not recruiting|Phase 4|200||University of Sydney|||||f||||||||||||||2018-06-01 04:52:44.228317|2018-06-01 04:52:44.228317
NCT00120588|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2013-06-17|2005-07-11|2005-07-18|Estimate|||||||2013-06-17|2013-06-18|Estimate|July 1997||1997-07-31|June 2013|2013-06-30|July 2005|Actual|2005-07-31|||||Interventional|||Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth|Effect of Magnesium Sulfate on the Incidence of Periventricular Leukomalacia in the Very Preterm Neonate|Completed||Phase 4|700||University Hospital, Rouen|||||f||||f||||||||||2018-06-01 04:52:44.30849|2018-06-01 04:52:44.30849
NCT00120575|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2006-12-01|2005-07-11|2005-07-18|Estimate|||||||2006-12-01|2006-12-05|Estimate|January 2005||2005-01-31|December 2006|2006-12-31|September 2008||2008-09-30|||||Interventional|||Hemofiltration for Respiratory Failure After Bone Marrow Transplantation|Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2/Phase 3|112||Stanford University|||||f||||||||||||||2018-06-01 04:52:44.408301|2018-06-01 04:52:44.408301
NCT00120562|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2009-08-27|2005-07-11|2005-07-18|Estimate|||||||2009-08-27|2009-08-28|Estimate|July 2007||2007-07-31|August 2009|2009-08-31||||||||Observational|||Studies of Biological Changes Related to Weight Loss After Gastric Bypass Surgery|A Gene Expression and Metabolic Profile of Weight Loss: Studies of Patients Following Gastric Bypass Surgery|Terminated|||13|Anticipated|Rockefeller University|||||f||||||||||||||2018-06-01 04:52:44.526648|2018-06-01 04:52:44.526648
NCT00120549|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2005-07-15|2005-07-11|2005-07-18|Estimate|||||||2005-07-15|2005-07-19|Estimate|August 2001||2001-08-31|July 2005|2005-07-31|March 2005||2005-03-31|||||Interventional|||Study of Assisted Hatching of Cleavage Stage Embryos|Prospective Randomized Trial of Assisted Hatching of Cleavage Stage Embryos|Completed||N/A|200||Shady Grove Fertility Reproductive Science Center|||||f||||||||||||||2018-06-01 04:52:44.589926|2018-06-01 04:52:44.589926
NCT00120536|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2017-05-16|2005-07-12|2005-07-18|Estimate|||||||2017-05-16|2017-05-18|Actual|June 2005||2005-06-30|May 2017|2017-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|288|Actual|Novartis|||||f||||||||||||||2018-06-01 04:52:44.698539|2018-06-01 04:52:44.698539
NCT00119912|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2018-04-19|2005-07-06|2005-07-14|Estimate|||||||2018-04-19|2018-04-20|Actual|January 1999||1999-01-31|September 2017|2017-09-30|December 2036|Anticipated|2036-12-31|December 2036|Anticipated|2036-12-31||Interventional|||NORCCAP: Norwegian Colorectal Cancer Prevention Trial|Norwegian Colorectal Cancer Prevention Trial|Active, not recruiting||N/A|100000|Actual|Norwegian Department of Health and Social Affairs||3|||f||||t||||||||||2018-06-01 04:52:55.743753|2018-06-01 04:52:55.743753
NCT00120523|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|2012-11-09|2011-08-23|2016-04-26|2005-07-15|2005-07-18|Estimate|2012-12-10|2013-01-16|Estimate|2011-08-23|2011-08-25|Estimate|2016-04-26|2016-05-25|Estimate|April 2004||2004-04-30|April 2016|2016-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis|Five-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 to Less Than 12 Months of Age With Mild to Moderate Atopic Dermatitis|Completed||Phase 3|2418|Actual|MEDA Pharma GmbH & Co. KG||2|||f||||f||||||||No||2018-06-01 04:52:44.885379|2018-06-01 04:52:44.885379
NCT00120510|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2014-10-13|2005-07-15|2005-07-18|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2007||2007-07-31|October 2014|2014-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti|A Randomized Clinical Trial to Determine the Efficacy of Early Versus Standard Antiretroviral Therapy in HIV Infected Adults With CD4+ T Cell Counts Between 200 and 350 Cells/mm3|Completed||N/A|816|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 04:52:46.811915|2018-06-01 04:52:46.811915
NCT00120497|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2011-07-19|2005-07-13|2005-07-18|Estimate|||||||2011-07-19|2011-07-20|Estimate|July 2005||2005-07-31|July 2011|2011-07-31|December 2011|Anticipated|2011-12-31|July 2011|Anticipated|2011-07-31||Observational|||Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight|Growth Hormone and Insulin Resistance in Children With Intrauterine Growth Restriction|Unknown status|Recruiting||12|Anticipated|Massachusetts General Hospital|||||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-06-01 04:52:46.885545|2018-06-01 04:52:46.885545
NCT00120484|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-13|||2010-01-12|2005-07-15|2005-07-18|Estimate|||||||2010-01-12|2010-01-14|Estimate|April 2005||2005-04-30|January 2010|2010-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|||Effects of Vitamin B12 on the Body's Internal Clock|Effect of Vitamin B12 on the Human Circadian Pacemaker|Completed||N/A|10|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 04:52:46.984935|2018-06-01 04:52:46.984935
NCT00120471|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2013-09-12|2005-07-14|2005-07-18|Estimate|||||||2013-09-12|2013-09-13|Estimate|November 2006||2006-11-30|September 2013|2013-09-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Blood Levels of Tenofovir Disoproxil Fumarate in HIV Infected Pregnant Women and Their Babies|A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and Their Infants|Completed||Phase 1|122|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:52:47.095785|2018-06-01 04:52:47.095785
NCT00120458|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-14|||2010-03-01|2005-07-15|2005-07-18|Estimate|||||||2010-03-01|2010-03-02|Estimate|July 2005||2005-07-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety|Black Cohosh Therapy for Menopause-Related Anxiety|Completed||Phase 4|50|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 04:52:47.204424|2018-06-01 04:52:47.204424
NCT00120445|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2012-03-07|2005-07-11|2005-07-18|Estimate|||||||2012-03-07|2012-03-09|Estimate|July 2004||2004-07-31|March 2012|2012-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Comparison of Air and Expansile Gas in Pneumatic Retinopexy|Comparison of Air and Expansile Gas in Pneumatic Retinopexy|Completed||Phase 3|126|Actual|Khon Kaen University||1|||f||||t||||||||||2018-06-01 04:52:47.262182|2018-06-01 04:52:47.262182
NCT00120432|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2012-03-07|2005-07-15|2005-07-18|Estimate|||||||2012-03-07|2012-03-09|Estimate|December 2004||2004-12-31|March 2012|2012-03-31|June 2005|Actual|2005-06-30|||||Interventional|||Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation|Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation|Completed||Phase 3|80|Actual|Khon Kaen University||1|||f||||t||||||||||2018-06-01 04:52:47.358436|2018-06-01 04:52:47.358436
NCT00120419|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2009-07-21|2005-07-15|2005-07-18|Estimate|||||||2009-07-21|2009-07-22|Estimate|April 2005||2005-04-30|January 2006|2006-01-31||||||||Interventional|||Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)||Unknown status|Recruiting|Phase 4|90|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||t||||||||||2018-06-01 04:52:47.536545|2018-06-01 04:52:47.536545
NCT00120406|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|2014-02-05|2011-04-25|2014-07-21|2005-07-11|2005-07-18|Estimate|2014-07-21|2014-08-11|Estimate|2011-04-25|2011-04-29|Estimate|2014-07-21|2014-08-11|Estimate|March 2005||2005-03-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|October 2009|Actual|2009-10-31||Interventional|Zilver PTX||Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery|Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery|Completed||N/A|474|Actual|Cook Group Incorporated||2|||f||||t||||||||||2018-06-01 04:52:47.70952|2018-06-01 04:52:47.70952
NCT00120393|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12||2010-02-03|2010-02-03|2005-07-15|2005-07-18|Estimate||||2010-02-03|2010-02-05|Estimate|2010-02-03|2010-02-05|Estimate|January 2004||2004-01-31|July 2009|2009-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir|A Phase IIIB, Open-label, Randomized, Multi-center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r Based Regimen.|Completed||Phase 3|192|Anticipated|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 04:52:48.342265|2018-06-01 04:52:48.342265
NCT00120380|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2012-08-20|2005-07-15|2005-07-18|Estimate|||||||2012-08-20|2012-08-21|Estimate|September 2004||2004-09-30|January 2006|2006-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)|Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension|Terminated||Phase 4|40|Actual|Hannover Medical School||2||Futility analysis|f||||||||||||||2018-06-01 04:52:48.466147|2018-06-01 04:52:48.466147
NCT00120367|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2011-12-21|2005-07-11|2005-07-18|Estimate|||||||2011-12-21|2011-12-22|Estimate|April 2005||2005-04-30|December 2011|2011-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)|Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial|Completed||Phase 2|30||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:52:48.573278|2018-06-01 04:52:48.573278
NCT00120354|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-15|||2017-06-30|2005-07-14|2005-07-15|Estimate|||||||2017-06-30|2017-07-02|Actual|July 11, 2005||2005-07-11|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Interventional|||Long-Term Lamivudine Therapy for Chronic Hepatitis B|Long-Term Lamivudine Therapy for Chronic Hepatitis B|Completed||Phase 4|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:52:48.686731|2018-06-01 04:52:48.686731
NCT00120341|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-05-30|2005-07-08|2005-07-15|Estimate|||||||2007-05-30|2007-06-01|Estimate|April 2005||2005-04-30|May 2007|2007-05-31|June 2006||2006-06-30|||||Interventional|||Anodyne Therapy in Diabetic Sensory Neuropathy|A Randomized, Double Blind, Placebo Controlled Prospective Study to Evaluate the Effectiveness of Monochromatic Infrared Photo Energy to Improve Diabetic Sensory Neuropathy|Completed||Phase 4|60||Scott and White Hospital & Clinic|||||f||||||||||||||2018-06-01 04:52:48.802873|2018-06-01 04:52:48.802873
NCT00120328|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-10-04|2005-07-07|2005-07-15|Estimate|||||||2007-10-04|2007-10-05|Estimate|July 2005||2005-07-31|October 2007|2007-10-31|February 2007|Actual|2007-02-28|||||Interventional|||To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy|ASCEND - A Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Effect of the Endothelin Receptor Antagonist Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death in Patients With Type 2 Diabetes Mellitus and Diabetic Nephropathy|Terminated||Phase 3|2364||Speedel Pharma Ltd.|||||||||t||||||||||2018-06-01 04:52:48.926236|2018-06-01 04:52:48.926236
NCT00120315|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2009-10-05|2005-07-08|2005-07-15|Estimate|||||||2009-10-05|2009-10-06|Estimate|December 2003||2003-12-31|October 2009|2009-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Proton Pump Inhibitor Treatment Stop|Proton Pump Inhibitor Treatment Stop: Discontinuation of Acid-suppressive Medication Among Long-term Users in a Primary Health Care Setting|Completed||Phase 4|171|Actual|Odense University Hospital||2|||f||||f||||||||||2018-06-01 04:52:49.082921|2018-06-01 04:52:49.082921
NCT00120302|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2008-01-15|2005-07-08|2005-07-15|Estimate|||||||2008-01-15|2008-01-17|Estimate|March 2005||2005-03-31|January 2008|2008-01-31|January 2006|Actual|2006-01-31|||||Interventional|||Quality of Life Study in Adults With Facial Eczema|Quality of Life Study in Adults With Facial Eczema|Completed||Phase 4|76|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:52:49.404989|2018-06-01 04:52:49.404989
NCT00120289|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|2015-06-01||2016-03-08|2005-07-14|2005-07-15|Estimate|2015-06-01|2015-06-17|Estimate||||2016-03-08|2016-04-06|Estimate|September 2005||2005-09-30|March 2016|2016-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional||Intention-to-treat|Niacin Plus Statin to Prevent Vascular Events|AIM HIGH: Niacin Plus Statin to Prevent Vascular Events|Terminated||Phase 3|3414|Actual|Axio Research. LLC||2||"AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in~   preventing primary outcome events."|f||||t||||||||||2018-06-01 04:52:49.620582|2018-06-01 04:52:49.620582
NCT00120276|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2009-05-05|2005-07-07|2005-07-15|Estimate|||||||2009-05-05|2009-05-07|Estimate|June 2004||2004-06-30|May 2008|2008-05-31||||||||Interventional|||RESTOR-MV: Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve|Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve (RESTOR-MV)|Completed||Phase 2|250|Anticipated|Myocor|||||f||||t||||||||||2018-06-01 04:52:52.194934|2018-06-01 04:52:52.194934
NCT00120263|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2006-05-08|2005-07-08|2005-07-15|Estimate|||||||2006-05-08|2006-05-09|Estimate|September 1998||1998-09-30|July 2005|2005-07-31|April 2004||2004-04-30|||||Interventional|||Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma|A Randomized Controlled Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma|Completed||N/A|92||London Health Sciences Centre|||||f||||||||||||||2018-06-01 04:52:52.345307|2018-06-01 04:52:52.345307
NCT00120250|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|2013-07-19||2016-03-24|2005-07-07|2005-07-15|Estimate|2013-12-26|2014-02-12|Estimate||||2016-03-24|2016-04-26|Estimate|June 2005||2005-06-30|March 2016|2016-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional||Baseline data are unavailable for the 3 participants that did not complete the study, and therefore, the baseline data will only reflect the information of the 24 completed participants, instead of the 27 that began baseline.|Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder|Eszopiclone for Sleep Disturbance and Nightmares in Post-Traumatic Stress Disorder|Completed||Phase 4|27|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:52:52.507711|2018-06-01 04:52:52.507711
NCT00120237|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2009-03-17|2005-07-07|2005-07-15|Estimate|||||||2009-03-17|2009-03-19|Estimate|July 2005||2005-07-31|March 2009|2009-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Misoprostol for the Prevention of Postpartum Hemorrhage in Rural Pakistan|A Placebo-Controlled Randomized Trial of Misoprostol in the Management of the Third Stage of Labor in the Home Delivery Setting in Rural Pakistan|Completed||N/A|1600|Actual|Gynuity Health Projects|||||f||||t||||||||||2018-06-01 04:52:52.823825|2018-06-01 04:52:52.823825
NCT00120224|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-04-25|2005-07-07|2005-07-15|Estimate|||||||2007-04-25|2007-04-27|Estimate|May 2005||2005-05-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|||||Observational|||De-Medicalizing Mifepristone Medical Abortion|De-Medicalizing Mifepristone Medical Abortion|Completed|||4410||Gynuity Health Projects|||||f||||||||||||||2018-06-01 04:52:52.896474|2018-06-01 04:52:52.896474
NCT00120211|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2011-10-12|2005-07-08|2005-07-15|Estimate|||||||2011-10-12|2011-10-13|Estimate|September 1998||1998-09-30|October 2011|2011-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer|Phase III Trial of Five Versus Six Fractions Per Week for Head and Neck Cancer|Completed||Phase 3|855|Actual|International Atomic Energy Agency||2|||f||||||||||||||2018-06-01 04:52:52.969387|2018-06-01 04:52:52.969387
NCT00120198|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2007-11-15|2005-07-08|2005-07-15|Estimate|||||||2007-11-15|2007-11-16|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients|A Pilot Study of Cyclophosphamide/Pegylated Liposomal Doxorubicin/Vincristine/Prednisone (CDOP) Plus Rituximab for Treatment of Elderly Patients With Previously Untreated Non-Hodgkin's Lymphoma|Terminated||Phase 2|50|Anticipated|Geriatric Oncology Consortium||||slow accrual|f||||||||||||||2018-06-01 04:52:53.0793|2018-06-01 04:52:53.0793
NCT00120185|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2011-12-21|2005-07-08|2005-07-15|Estimate|||||||2011-12-21|2011-12-22|Estimate|December 2003||2003-12-31|December 2011|2011-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)|Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Naïve HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART|Completed||Phase 2|130||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:52:53.168955|2018-06-01 04:52:53.168955
NCT00120172|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2007-11-15|2005-07-08|2005-07-15|Estimate|||||||2007-11-15|2007-11-16|Estimate|May 2005||2005-05-31|November 2007|2007-11-30|June 2006|Actual|2006-06-30|||||Interventional|||Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer|A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Elderly Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|40|Anticipated|Geriatric Oncology Consortium||||positive results from a larger study with same regimen was released.|f||||||||||||||2018-06-01 04:52:53.287078|2018-06-01 04:52:53.287078
NCT00120159|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-01-14|2005-07-07|2005-07-15|Estimate|||||||2008-01-14|2008-01-15|Estimate|December 2003||2003-12-31|January 2006|2006-01-31||||||||Observational|||Necrotizing Enterocolitis (NEC) Surgical Database|GPRN Neonatal Surgical Database: Necrotizing Enterocolitis (NEC) Protocol|Unknown status|Active, not recruiting||300|Anticipated|Boston Children’s Hospital|||||f||||||||||||||2018-06-01 04:52:53.368981|2018-06-01 04:52:53.368981
NCT00120133|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2008-05-19|2005-07-08|2005-07-15|Estimate|||||||2008-05-19|2008-05-20|Estimate|December 2004||2004-12-31|July 2005|2005-07-31|December 2007|Actual|2007-12-31|||||Interventional|||Atorvastatin (Lipitor) to Prevent Bone Pain|Use of Atorvastatin (Lipitor) to Prevent Bone Pain Following Infusion of Pamidronate or Zoledronic Acid|Completed||N/A|12|Actual|Children's Mercy Hospital Kansas City|||||f||||||||||||||2018-06-01 04:52:53.422728|2018-06-01 04:52:53.422728
NCT00120120|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2009-09-22|2005-07-08|2005-07-15|Estimate|||||||2009-09-22|2009-09-23|Estimate|January 2005||2005-01-31|September 2009|2009-09-30|November 2007|Actual|2007-11-30|October 2007|Actual|2007-10-31||Interventional|||Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy|A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy|Completed||Phase 2/Phase 3|181|Actual|Celgene||2|||f||||t||||||||||2018-06-01 04:52:53.496938|2018-06-01 04:52:53.496938
NCT00120107|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2017-03-10|2005-07-07|2005-07-15|Estimate|||||||2017-03-10|2017-03-14|Actual|July 2003||2003-07-31|March 2017|2017-03-31|April 2005|Actual|2005-04-30|||||Interventional|||Tea's Effect on Atherosclerosis Pilot Study (TEA Study)|Tea's Effect on Atherosclerosis Pilot Study (TEA Study)|Completed||N/A|30||Beth Israel Deaconess Medical Center|||||f||||f|f|f||||||Undecided||2018-06-01 04:52:53.625508|2018-06-01 04:52:53.625508
NCT00120094|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2006-04-10|2005-07-07|2005-07-15|Estimate|||||||2006-04-10|2006-04-11|Estimate|June 2002||2002-06-30|July 2005|2005-07-31|June 2005||2005-06-30|||||Observational|||International Study on Syncope of Uncertain Etiology|ISSUE 2. The Management of Patients With Suspected or Certain Neurally-Mediated Syncope After the Initial Evaluation|Terminated|||400||Arcispedale Santa Maria Nuova-IRCCS|||||f||||||||||||||2018-06-01 04:52:53.957693|2018-06-01 04:52:53.957693
NCT00120081|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2017-05-30|2005-07-07|2005-07-15|Estimate|||||||2017-05-30|2017-05-31|Actual|April 2005||2005-04-30|May 2017|2017-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection|Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection|Completed||Phase 1|36|Actual|Baylor College of Medicine||4|||f||||t||||||||||2018-06-01 04:52:54.081397|2018-06-01 04:52:54.081397
NCT00120068|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2015-04-06|2005-07-01|2005-07-14|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|July 2005|Actual|2005-07-31|March 2005|Actual|2005-03-31||Interventional|||Improving Care for Nursing Home Pneumonia in NHCUs and Veterans' Homes|Improving Care for Nursing Home Pneumonia in NHCUs and Veterans' Homes|Completed||Phase 2|100|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:52:54.178272|2018-06-01 04:52:54.178272
NCT00120055|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2014-12-02|2005-07-07|2005-07-14|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2005||2005-02-28|December 2014|2014-12-31|April 2005||2005-04-30|||||Interventional|||Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity||Completed||Phase 4|||University of Oslo School of Pharmacy|||||f||||||||||||||2018-06-01 04:52:54.285128|2018-06-01 04:52:54.285128
NCT00120042|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|2009-04-01||2009-06-29|2005-07-05|2005-07-14|Estimate|2009-04-03|2009-06-01|Estimate||||2009-06-29|2009-07-09|Estimate|February 2005||2005-02-28|June 2009|2009-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption|Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption|Completed||N/A|251|Actual|The University of Western Australia|Planned interim analysis not performed as mifepristone became available in Australia. Study ceased at 251 women and enough power available to calculate the groups as a single stage analysis.|3|||f||||f||||||||||2018-06-01 04:52:54.378081|2018-06-01 04:52:54.378081
NCT00120029|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2008-09-04|2005-07-06|2005-07-14|Estimate|||||||2008-09-04|2008-09-05|Estimate|January 2004||2004-01-31|June 2008|2008-06-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Peer Counseling for Weight Loss|Peer Counseling for Weight Loss in African American Breast Cancer Survivors|Unknown status|Recruiting|N/A|100|Anticipated|Wayne State University|||||f||||||||||||||2018-06-01 04:52:54.673464|2018-06-01 04:52:54.673464
NCT00120016|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2012-12-19|2005-07-06|2005-07-14|Estimate|||||||2012-12-19|2012-12-20|Estimate|January 2004||2004-01-31|November 2008|2008-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Design and Feasibility of a Mediterranean Diet|Design and Feasibility of a Mediterranean Diet|Completed||N/A|80|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 04:52:54.738307|2018-06-01 04:52:54.738307
NCT00120003|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2011-06-30|2005-07-06|2005-07-14|Estimate|||||||2011-06-30|2011-07-01|Estimate|June 2005||2005-06-30|September 2006|2006-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Scandinavian Candesartan Acute Stroke Trial (SCAST)|Scandinavian Candesartan Acute Stroke Trial|Completed||Phase 3|2500|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-06-01 04:52:55.021706|2018-06-01 04:52:55.021706
NCT00119990|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2008-12-05|2005-07-05|2005-07-14|Estimate|||||||2008-12-05|2008-12-08|Estimate|January 2006||2006-01-31|December 2008|2008-12-31|January 2010|Anticipated|2010-01-31|January 2009|Anticipated|2009-01-31||Interventional|||Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis|Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis; the Effect of Different Dialysates|Terminated||N/A|15|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 04:52:55.18629|2018-06-01 04:52:55.18629
NCT00119977|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2008-01-31|2005-07-05|2005-07-14|Estimate|||||||2008-01-31|2008-02-12|Estimate|October 2003||2003-10-31|January 2008|2008-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Periacetabular Osteotomy.A Prospective Study With Reference to Cartilage, Migration and Bone Density|Periacetabular Osteotomy. A Prospective Study With Reference to Cartilage, Migration and Bone Density|Completed||N/A|35|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 04:52:55.311562|2018-06-01 04:52:55.311562
NCT00119964|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2011-07-25|2005-07-06|2005-07-14|Estimate|||||||2011-07-25|2011-07-27|Estimate|September 2004||2004-09-30|July 2011|2011-07-31|August 2007|Actual|2007-08-31|||||Interventional|||The Healthy Lifestyle Study|Weight Management for a Defined Employee Population Using an Interactive eHealth Portal|Completed||Phase 1|500|Anticipated|Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:52:55.383164|2018-06-01 04:52:55.383164
NCT00119951|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2007-08-02|2005-07-06|2005-07-14|Estimate|||||||2007-08-02|2007-08-03|Estimate|September 2003||2003-09-30|August 2007|2007-08-31|August 2006||2006-08-31|||||Observational|||Health eCommunities - The Impact of Listservs on Cancer Patients|Health eCommunities - The Impact of Listservs on Cancer Patients|Completed|||3360||Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:52:55.447971|2018-06-01 04:52:55.447971
NCT00119938|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2008-08-19|2005-07-06|2005-07-14|Estimate|||||||2008-08-19|2008-08-20|Estimate|September 2004||2004-09-30|July 2007|2007-07-31|December 2006|Actual|2006-12-31|||||Interventional|||An Online System to Improve Diabetes Self-Care|D-STAR (Diabetes-System To Access Records): An Online Patient Portal to Improve and Sustain Diabetes Self-Care|Completed||N/A|331|Actual|Robert Wood Johnson Foundation|||||f||||f||||||||||2018-06-01 04:52:55.50728|2018-06-01 04:52:55.50728
NCT00119925|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2008-10-28|2005-07-07|2005-07-14|Estimate|||||||2008-10-28|2008-10-29|Estimate|October 2005||2005-10-31|October 2008|2008-10-31|May 2009|Anticipated|2009-05-31|February 2009|Anticipated|2009-02-28||Interventional|||"'SPRING'-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists"|Cost Effectiveness of Two Different Strategies to Implement the NVOG Guideline Programme on Subfertility|Unknown status|Recruiting|N/A|5200|Anticipated|Radboud University||2|||f||||||||||||||2018-06-01 04:52:55.581388|2018-06-01 04:52:55.581388
NCT00119899|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2005-08-30|2005-07-06|2005-07-14|Estimate|||||||2005-08-30|2005-08-31|Estimate|March 2002||2002-03-31|August 2005|2005-08-31|June 2005||2005-06-30|||||Interventional|||Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases|Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases|Completed||Phase 3|150||Radboud University|||||f||||||||||||||2018-06-01 04:52:55.881087|2018-06-01 04:52:55.881087
NCT00119886|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2007-04-18|2005-07-06|2005-07-14|Estimate|||||||2007-04-18|2007-04-19|Estimate|April 2005||2005-04-30|April 2007|2007-04-30|June 2008|Anticipated|2008-06-30|||||Interventional|||Botox on Vulvar Vestibulitis||Unknown status|Recruiting|Phase 4|64||Rigshospitalet, Denmark|||||f||||||||||||||2018-06-01 04:52:55.974082|2018-06-01 04:52:55.974082
NCT00119873|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2015-03-03|2005-07-13|2005-07-14|Estimate|||||||2015-03-03|2015-03-04|Estimate||||March 2015|2015-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults|A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade, Multivalent Recombinant Adenoviral Vector HIV Vaccine, VRC-HIVADV014-00-VP, in Healthy, HIV-1 Uninfected Adult Participants Who Have Low Titers of Pre-Existing Ad5 Neutralizing Antibodies|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:52:56.098384|2018-06-01 04:52:56.098384
NCT00119847|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2006-02-22|2005-07-13|2005-07-14|Estimate|||||||2006-02-22|2006-02-23|Estimate|September 2002||2002-09-30|February 2006|2006-02-28||||||||Interventional|||Balloon Catheters and Stents to Prevent Heart Rhythm Irregularities in Individuals Post-Heart Attack|Electrophysiologic Effects of Late PCI (OAT-EP)|Unknown status|Active, not recruiting|N/A|300||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:52:56.179497|2018-06-01 04:52:56.179497
NCT00119834|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2018-04-05|2005-07-13|2005-07-14|Estimate|||||||2018-04-05|2018-04-09|Actual|June 2005|Actual|2005-06-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)|Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs)|Completed|||23472|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t|f|f||||Samples With DNA|"~     DNA sample collection was an optional portion of the project during the first contract period~     (2005-2010). Tissue and Blood specimens were collected at the time of implant, explant or~     exchange of the mechanical circulatory assist device. Intermacs no longer collects blood or~     tissue specimens.~   "|Yes|Individual participant data (IPD) is not available. De-identified datasets may be available upon approval.|2018-06-01 04:52:56.276446|2018-06-01 04:52:56.276446
NCT00119821|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2015-11-30|2005-07-13|2005-07-14|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2004||2004-09-30|July 2011|2011-07-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Strategies to Reduce Weight Gain in Hypertensive Smokers|Weight Gain Prevention in Hypertensive Smokers|Completed||N/A|459|Actual|University of Tennessee||3|||f||||t||||||||||2018-06-01 04:52:56.358328|2018-06-01 04:52:56.358328
NCT00119795|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2017-11-02|2005-07-13|2005-07-14|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2005||2005-08-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|CLIP||Exercise and Weight Loss for Improving Mobility in Older Adults Who Are Obese|Cooperative Lifestyle Intervention Program (CLIP)|Completed||N/A|288|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||No||2018-06-01 04:52:56.448264|2018-06-01 04:52:56.448264
NCT00119782|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2012-08-21|2005-07-13|2005-07-14|Estimate|||||||2012-08-21|2012-08-23|Estimate|September 2004||2004-09-30|August 2012|2012-08-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|PACE||Promoting Activity and Changes in Eating (PACE) to Reduce Obesity|Reducing Obesity at the Workplace: a Randomized Trial|Completed||N/A|3000|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 04:52:56.531681|2018-06-01 04:52:56.531681
NCT00119769|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2008-08-26|2005-07-07|2005-07-14|Estimate|||||||2008-08-26|2008-08-27|Estimate|February 2005||2005-02-28|August 2008|2008-08-31|July 2008|Actual|2008-07-31|May 2007|Actual|2007-05-31||Interventional|||The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients|The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 4|46|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-06-01 04:52:56.606517|2018-06-01 04:52:56.606517
NCT00119756|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2011-06-06|2005-07-07|2005-07-14|Estimate|||||||2011-06-06|2011-06-08|Estimate|June 2005||2005-06-30|April 2010|2010-04-30|November 2006|Actual|2006-11-30|||||Interventional|||A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia|A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Patients With Schizophrenia|Completed||Phase 3|253|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:52:56.707179|2018-06-01 04:52:56.707179
NCT00119743|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2017-03-21|2005-07-06|2005-07-14|Estimate|||||||2017-03-21|2017-03-23|Actual|October 2000||2000-10-31|March 2017|2017-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine|Assess, in Young Children, the Efficacy in Preventing Acute Otitis Media (AOM) of GSK Biologicals Undecavalent Pneumococcal-protein D Conjugate Vaccine, When Administered as a Three Dose Primary Vaccination Course During the First Year of Life With a Booster Dose in the Second Year of Life.|Terminated||Phase 3|5000||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:52:56.945301|2018-06-01 04:52:56.945301
NCT00119730|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2014-04-22|2005-07-07|2005-07-14|Estimate|||||||2014-04-22|2014-04-24|Estimate|February 2005||2005-02-28|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2006|Actual|2006-12-31||Interventional|||Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma|Abbreviated Fludarabine / Mitoxantrone / Rituximab Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma|Completed||Phase 2|30|Actual|Dana-Farber Cancer Institute||1|||f||||||||||||||2018-06-01 04:52:57.173664|2018-06-01 04:52:57.173664
NCT00119717|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2011-05-16|2005-07-07|2005-07-14|Estimate|||||||2011-05-16|2011-05-18|Estimate|June 2005||2005-06-30|May 2011|2011-05-31|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|SENTIS||Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)|Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)|Completed||Phase 3|515|Actual|CoAxia||2|||f||||t||||||||||2018-06-01 04:52:57.29218|2018-06-01 04:52:57.29218
NCT00119704|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2006-05-08|2005-07-06|2005-07-14|Estimate|||||||2006-05-08|2006-05-09|Estimate|September 2002||2002-09-30|June 2005|2005-06-30|March 2005||2005-03-31|||||Interventional|||Treatment of Tennis Elbow With Botulinum Toxin|Treatment of Lateral Epicondylitis With Botulinum Toxin: A Randomized Controlled Trial|Completed||Phase 3|60||Chinese University of Hong Kong|||||f||||||||||||||2018-06-01 04:52:57.548265|2018-06-01 04:52:57.548265
NCT00119691|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2013-09-11|2005-07-07|2005-07-14|Estimate|||||||2013-09-11|2013-09-12|Estimate|April 2003||2003-04-30|September 2013|2013-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction|Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction|Completed||Phase 2|34|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-06-01 04:52:57.617786|2018-06-01 04:52:57.617786
NCT00119678|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2011-01-10||2014-09-11|2005-07-13|2005-07-14|Estimate|2011-04-18|2011-05-09|Estimate||||2014-09-11|2014-09-22|Estimate|September 2005||2005-09-30|September 2014|2014-09-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone|A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept vs Placebo on a Background of Oral Glucocorticosteroids in the Treatment of Subjects With Systemic Lupus Erythematosus and the Prevention of Subsequent Lupus Flares|Completed||Phase 2|183|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 04:52:57.757666|2018-06-01 04:52:57.757666
NCT00119665|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2007-05-16|2005-07-06|2005-07-14|Estimate|||||||2007-05-16|2007-05-17|Estimate|February 2006||2006-02-28|March 2007|2007-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes|A Phase II, Double-Blind, Placebo-Controlled, Randomized Clinical Trial Assessing Toxicity and Efficacy of MF101 for Hot Flashes and Menopausal Symptoms|Completed||Phase 2|180||Bionovo|||||f||||||||||||||2018-06-01 04:52:59.03351|2018-06-01 04:52:59.03351
NCT00119652|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2013-01-03|2005-07-13|2005-07-14|Estimate|||||||2013-01-03|2013-01-04|Estimate|May 2005||2005-05-31|January 2013|2013-01-31|May 2007|Actual|2007-05-31|||||Interventional|EMBOLDEN II||Seroquel in Bipolar Depression Versus SSRI|Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)|Completed||Phase 3|676|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 04:52:59.089657|2018-06-01 04:52:59.089657
NCT00119639|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2009-01-15|2005-07-13|2005-07-14|Estimate|||||||2009-01-15|2009-01-16|Estimate|June 2005||2005-06-30|January 2009|2009-01-31|December 2005|Actual|2005-12-31|||||Interventional|||Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006|A Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of Sorafenib (BAY 43-9006, Nexavar).|Completed||Phase 1|32|Actual|Bayer||1|||f||||||||||||||2018-06-01 04:52:59.211743|2018-06-01 04:52:59.211743
NCT00119626|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2010-11-10|2005-07-13|2005-07-14|Estimate|||||||2010-11-10|2010-11-15|Estimate|June 2003||2003-06-30|November 2010|2010-11-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke|SAINT I (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke.|Completed||Phase 3|1700||AstraZeneca|||||||||||||||||||2018-06-01 04:52:59.28066|2018-06-01 04:52:59.28066
NCT00119613|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2008-08-07|2005-07-07|2005-07-14|Estimate|||||||2008-08-07|2008-08-08|Estimate|December 2002||2002-12-31|August 2008|2008-08-31|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|||A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa|A Randomized, Double Blind, Placebo-Controlled Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa|Completed||Phase 3|600|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 04:52:59.447899|2018-06-01 04:52:59.447899
NCT00119600|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2009-05-07|2005-07-13|2005-07-14|Estimate|||||||2009-05-07|2009-05-11|Estimate||||May 2009|2009-05-31||||||||Interventional|||A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy|A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy|Terminated||Phase 1/Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:52:59.536072|2018-06-01 04:52:59.536072
NCT00119587|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-20|2005-07-13|2005-07-14|Estimate|||||||2007-12-20|2007-12-28|Estimate|August 2002||2002-08-31|December 2007|2007-12-31|September 2003||2003-09-30|||||Interventional|||Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects|A Double-Blind, Randomized, Comparative Study of Darbepoetin Alfa Given Once Weekly or Once Every Other Week for Treatment of Anemia in Hemodialysis Subjects|Completed||Phase 3|||Amgen|||||f||||||||||||||2018-06-01 04:52:59.618938|2018-06-01 04:52:59.618938
NCT00119574|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2015-04-06|2005-07-01|2005-07-13|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2002||2002-01-31|July 2005|2005-07-31|December 2004|Actual|2004-12-31|||||Interventional|||Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)|Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)|Completed||N/A|443|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:52:59.749548|2018-06-01 04:52:59.749548
NCT00119561|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2015-04-06|2005-07-05|2005-07-13|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2005||2005-02-28|July 2014|2014-07-31|January 2014|Actual|2014-01-31|June 2007|Actual|2007-06-30||Interventional|CONNECT||Testing the Effectiveness of Telephone Support for Dementia Caregivers|Testing the Effectiveness of Telephone Support for Dementia Caregivers|Completed||N/A|154|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:52:59.87263|2018-06-01 04:52:59.87263
NCT00119548|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2015-04-06|2005-07-05|2005-07-13|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2005||2005-03-31|April 2009|2009-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling|Improving HIV Screening by Nurse Rapid Testing, Streamlined Counseling|Completed||N/A|251|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:52:59.950573|2018-06-01 04:52:59.950573
NCT00119535|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2015-04-06|2005-07-01|2005-07-13|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2004||2004-08-31|April 2006|2006-04-30|December 2005|Actual|2005-12-31|||||Interventional|||Study to Evaluate the Effectiveness of a Program Developed to Improve Eye Care for Veterans With Diabetes|An Evaluation of a Coordinated Proactive Diabetes Eye Care Program|Completed||N/A|2000|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:53:00.07515|2018-06-01 04:53:00.07515
NCT00119522|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2015-04-06|2005-07-01|2005-07-13|Estimate|||||||2015-04-06|2015-04-07|Estimate|April 2004||2004-04-30|July 2008|2008-07-31|March 2008|Actual|2008-03-31|March 2006|Actual|2006-03-31||Observational|||Epidemiology and Cost of Falls in Veterans With a Spinal Cord Injury|Epidemiology and Cost of Falls in Veterans With Spinal Cord Injury|Completed|||702|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:53:00.260564|2018-06-01 04:53:00.260564
NCT00119509|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|||2007-04-24|2005-07-11|2005-07-13|Estimate|||||||2007-04-24|2007-04-25|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|April 2008|Anticipated|2008-04-30|||||Interventional|||The IMAP Study Improving Management of Mildly Abnormal Pap Smears|HPV DNA Testing Versus Conventional Management for Women With Minor Atypia on Pap Smear: Psychosocial and Quality of Life Outcomes and Development of a Decision Analytic Model|Unknown status|Active, not recruiting|Phase 3|300||University of Sydney|||||f||||||||||||||2018-06-01 04:53:00.365007|2018-06-01 04:53:00.365007
NCT00119496|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2010-01-26|2005-07-12|2005-07-13|Estimate|||||||2010-01-26|2010-01-27|Estimate|July 2005||2005-07-31|November 2007|2007-11-30|June 2007|Actual|2007-06-30|||||Interventional|||Rosiglitazone Versus Theophylline in Asthmatic Smokers|A Clinical Study to Investigate the Effect of Rosiglitazone, Theophylline and Inhaled Corticosteroid, Inflammation and Pulmonary Function in Asthmatic Smokers|Completed||Phase 2/Phase 3|79|Actual|University of Glasgow||4|||f||||f||||||||||2018-06-01 04:53:00.489831|2018-06-01 04:53:00.489831
NCT00119483|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2011-09-02|2005-07-05|2005-07-13|Estimate|||||||2011-09-02|2011-09-05|Estimate|September 2005||2005-09-30|September 2011|2011-09-30|December 2007|Actual|2007-12-31|||||Interventional|||Older Men and Testosterone||Completed||N/A|200||University Hospital of North Norway|||||f||||||||||||||2018-06-01 04:53:00.603053|2018-06-01 04:53:00.603053
NCT00119470|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2007-12-19|2005-07-02|2005-07-13|Estimate|||||||2007-12-19|2007-12-28|Estimate|February 2005||2005-02-28|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||EUS-FNA in the Pre-Operative Evaluation of Patients With Lung Cancer|EUS-FNA in the Pre-Operative Evaluation of Patients With Lung Cancer: A Randomized Trial|Completed||Phase 2|40||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:53:00.68607|2018-06-01 04:53:00.68607
NCT00119457|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2009-06-02|2005-07-05|2005-07-13|Estimate|||||||2009-06-02|2009-06-03|Estimate|January 2005||2005-01-31|June 2009|2009-06-30|April 2006||2006-04-30|||||Interventional|||Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)|A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery|Completed||Phase 2|300||vTv Therapeutics|||||f||||||||||||||2018-06-01 04:53:00.780569|2018-06-01 04:53:00.780569
NCT00119444|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2015-11-19|2005-07-05|2005-07-13|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2004||2004-01-31|September 2009|2009-09-30|August 2009|Actual|2009-08-31|January 2008|Actual|2008-01-31||Interventional|||Evaluation of Acetabular Perfusion After Ganz Osteotomy by Positron Emission Tomography|Evaluation of Acetabular Perfusion After Ganz Osteotomy by Positron Emission Tomography|Completed||N/A|12|Actual|University of Aarhus||1|||f||||f||||||||||2018-06-01 04:53:00.89427|2018-06-01 04:53:00.89427
NCT00119431|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-04|||2009-05-01|2005-07-04|2005-07-13|Estimate|||||||2009-05-01|2009-05-04|Estimate|September 2005||2005-09-30|May 2009|2009-05-31|March 2006|Actual|2006-03-31|||||Interventional|||Kinetics, Efficacy and Safety of C1-Esteraseremmer-N|Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema|Completed||Phase 2|12|Anticipated|Sanquin|||||f||||||||||||||2018-06-01 04:53:00.968826|2018-06-01 04:53:00.968826
NCT00119418|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-04|||2010-10-25|2005-07-04|2005-07-13|Estimate|||||||2010-10-25|2010-10-26|Estimate|November 2004||2004-11-30|July 2005|2005-07-31|February 2006||2006-02-28|||||Interventional|||TU 025 Keishi Bukuryo Gan for Post-menopausal Hot Flash Management|TU 025 Keishi Bukuryo Gan for Post-Menopausal Hot Flash Management|Completed||Phase 2|180|Anticipated|Plotnikoff, Gregory A., M.D.|||||||||||||||||||2018-06-01 04:53:01.025416|2018-06-01 04:53:01.025416
NCT00119405|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|2016-06-13||2017-02-10|2005-07-12|2005-07-13|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|April 2005||2005-04-30|December 2007|2007-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Role of Mitochondria in the Development of HIV Atrophy|Completed|||18|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||f||||||Samples With DNA|"~     Fat and Blood for mitochindrial DNA and different nuclear genes that regulate fat and lipid~     metabolism~   "|||2018-06-01 04:53:01.093954|2018-06-01 04:53:01.093954
NCT00119392|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|2017-04-17||2017-04-17|2005-07-12|2005-07-13|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|June 2004||2004-06-30|April 2017|2017-04-30||||July 2009|Actual|2009-07-31||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma|Active, not recruiting||Phase 2|42|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 04:53:01.282313|2018-06-01 04:53:01.282313
NCT00119379|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-11|2016-12-08||2017-05-15|2005-07-11|2005-07-13|Estimate|2017-04-04|2017-05-12|Actual||||2017-05-15|2017-06-07|Actual|April 2005||2005-04-30|May 2017|2017-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults|Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy|Completed||Phase 2|50|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Small sample size; Lack of control arm where tNRTI therapy was continued without any intervention; Adherence measured by sachet/pill count method.|2|||f||||t||||||||No||2018-06-01 04:53:01.56927|2018-06-01 04:53:01.56927
NCT00119366|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12||2017-04-13|2017-04-13|2005-07-12|2005-07-13|Estimate||||2017-04-13|2017-04-18|Actual|2017-04-13|2017-04-18|Actual|May 2003||2003-05-31|April 2017|2017-04-30||||August 2014|Actual|2014-08-31||Interventional|||Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome|Active, not recruiting||Phase 2|15|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 04:53:01.950361|2018-06-01 04:53:01.950361
NCT00119340|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2010-09-20|2005-07-12|2005-07-13|Estimate|||||||2010-09-20|2010-09-21|Estimate|April 2005||2005-04-30|September 2010|2010-09-30|November 2007|Actual|2007-11-30|||||Interventional|||Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia|Fludarabine and Low-Dose TBI Dose Escalation to Determine the Optimal Regimen for Achieving High Rates Engraftment of Unrelated Donor Peripheral Blood Stem Cell in Patients With Chronic Myeloid Leukemia - A Multi-Center Trial|Completed||Phase 1/Phase 2|75|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:53:02.085644|2018-06-01 04:53:02.085644
NCT00115947|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2006-03-08|2005-06-26|2005-06-27|Estimate|||||||2006-03-08|2006-03-09|Estimate|December 2004||2004-12-31|June 2005|2005-06-30|January 2006||2006-01-31|||||Interventional|||Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites||Completed||Phase 2/Phase 3|||Hvidovre University Hospital|||||f||||||||||||||2018-06-01 04:54:19.410251|2018-06-01 04:54:19.410251
NCT00119314|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2015-05-22|2005-07-12|2005-07-13|Estimate|||||||2015-05-22|2015-05-27|Estimate|July 2004||2004-07-31|April 2011|2011-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin|Carcinoma Unknown Primary: Treatment With Gemcitabine, Docetaxel and Capecitabine (GTX) an Evaluation and Treatment Study of The Cancer Institute of New Jersey Oncology Group|Withdrawn||Phase 2|0|Actual|Rutgers, The State University of New Jersey||||slow accrual|f||||t||||||||||2018-06-01 04:53:02.572198|2018-06-01 04:53:02.572198
NCT00119301|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2013-01-15|2005-07-12|2005-07-13|Estimate|||||||2013-01-15|2013-01-17|Estimate|April 2005||2005-04-30|January 2013|2013-01-31||||April 2007|Actual|2007-04-30||Interventional|||Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma|Phase I Study of High Dose Methotrexate With Simultaneous Trimetrexate and Leucovorin in Patients With Recurrent Osteosarcoma|Completed||Phase 1|18|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 04:53:02.690474|2018-06-01 04:53:02.690474
NCT00119262|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|2011-04-04||2014-04-29|2005-07-12|2005-07-13|Estimate|2011-04-04|2011-04-28|Estimate||||2014-04-29|2014-05-15|Estimate|October 2005||2005-10-31|December 2012|2012-12-31|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer|Phase II Feasibility Trial Incorporating Bevacizumab Into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients With Lymph Node Positive Breast Cancer|Completed||Phase 2|226|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:53:02.780246|2018-06-01 04:53:02.780246
NCT00119249|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2013-01-14|2005-07-12|2005-07-13|Estimate|||||||2013-01-14|2013-01-15|Estimate|June 2005||2005-06-30|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase II Study of BAY 43-9006 (NSC 724772) in Unresectable Stage III and IV Melanoma (IND 69,869)|Completed||Phase 2|74|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:04.421046|2018-06-01 04:53:04.421046
NCT00119236|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-12|||2013-06-03|2005-07-12|2005-07-13|Estimate|||||||2013-06-03|2013-06-04|Estimate|May 2005||2005-05-31|June 2013|2013-06-30||||October 2008|Actual|2008-10-31||Interventional|||17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Labeled Non-Randomized Phase I Study of 17-N-allylamino-17-demethoxy Geldanamycin (17AAG) Administered With Irinotecan (CPT-11) in Patients With Advanced Solid Tumors|Completed||Phase 1|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:04.543692|2018-06-01 04:53:04.543692
NCT00119210|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2011-04-28|2005-07-05|2005-07-13|Estimate|||||||2011-04-28|2011-04-29|Estimate|March 2005||2005-03-31|April 2011|2011-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women|Bupropion for Smoking Cessation in Postpartum Women|Terminated||Phase 4|40|Anticipated|Massachusetts General Hospital||2||"We were unable to recruit sufficient numbers of patients and decided that the study protocol~   was not feasible to implement"|f||||||||||||||2018-06-01 04:53:04.634442|2018-06-01 04:53:04.634442
NCT00119197|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-04|||2008-06-26|2005-07-04|2005-07-13|Estimate|||||||2008-06-26|2008-07-04|Estimate|August 2005||2005-08-31|June 2008|2008-06-30|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata|Safety and Immunogenicity of a Killed, Oral Cholera Vaccine in Indian Subjects in Eastern Kolkata, West Bengal|Completed||Phase 2|200|Actual|International Vaccine Institute||2|||f||||t||||||||||2018-06-01 04:53:04.714608|2018-06-01 04:53:04.714608
NCT00119184|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-03|||2017-11-26|2005-07-12|2005-07-13|Estimate|||||||2017-11-26|2017-11-28|Actual|October 2002||2002-10-31|May 2008|2008-05-31|May 2008|Actual|2008-05-31|March 2006|Actual|2006-03-31||Interventional|||Spinal Analgesia Versus No Analgesia: Study for External Cephalic Version|A Prospective Randomized Study to Examine the Success Rate of External Cephalic Version for Breech Presentation at Term Presentation: Spinal Analgesia Versus No Analgesia|Terminated||Phase 1|140|Actual|Hadassah Medical Organization||2||"Multiparas study terminated due to poor recruitment. Randomization revealed only after decision~   recorded on clinicaltrials.gov"|f||||f||||||||||2018-06-01 04:53:04.790625|2018-06-01 04:53:04.790625
NCT00119171|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|||2008-10-15|2005-07-05|2005-07-13|Estimate|||||||2008-10-15|2008-10-16|Estimate|November 2004||2004-11-30|October 2008|2008-10-31||||||||Interventional|||Ispinesib In Combination With Capecitabine In Patients With Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination With Capecitabine on an Every 21-Day Schedule in Subjects With Advanced Solid Tumors|Completed||Phase 1|30||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:53:04.865279|2018-06-01 04:53:04.865279
NCT00119158|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-05|2010-02-19||2010-07-23|2005-07-05|2005-07-13|Estimate|2010-06-25|2010-07-22|Estimate||||2010-07-23|2010-07-27|Estimate|October 2004||2004-10-31|July 2010|2010-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Combination Therapy for Atopic Dermatitis|An Exploratory Double-blind, Randomized, Vehicle-controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Elidel Cream 1% and Cutivate Cream 0.05% in Patients With Severe Lesions of Atopic Dermatitis (AD)|Completed||Phase 4|90|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 04:53:05.05855|2018-06-01 04:53:05.05855
NCT00119145|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-04|||2017-01-11|2005-07-04|2005-07-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2005||2005-06-30|January 2017|2017-01-31|May 2006|Actual|2006-05-31|||||Interventional|||Kintampo Trial of Combination Therapy for Malaria|A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Malaria Among Children In Ghana|Completed||Phase 4|510|Anticipated|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:53:05.41092|2018-06-01 04:53:05.41092
NCT00119132|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-04|||2017-01-11|2005-07-04|2005-07-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2005||2005-06-30|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effectiveness of Intermittent Preventive Treatment for Malaria in Children|A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana|Completed||Phase 2/Phase 3|2602|Actual|London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:53:05.515539|2018-06-01 04:53:05.515539
NCT00119119|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-04|||2007-01-11|2005-07-04|2005-07-13|Estimate|||||||2007-01-11|2007-01-12|Estimate|February 2002||2002-02-28|January 2007|2007-01-31|December 2006||2006-12-31|||||Interventional|||Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C|Efficacy and Safety of the Association With Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C|Terminated||Phase 3|100||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:53:05.599964|2018-06-01 04:53:05.599964
NCT00119106|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2015-02-04|2005-07-11|2005-07-13|Estimate|||||||2015-02-04|2015-02-05|Estimate|June 2005||2005-06-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|July 2013|Actual|2013-07-31||Interventional|||Bangkok Tenofovir Study|Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand|Completed||Phase 2/Phase 3|2413|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 04:53:05.677527|2018-06-01 04:53:05.677527
NCT00119093|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2012-09-10|2005-07-11|2005-07-13|Estimate|||||||2012-09-10|2012-09-11|Estimate|May 2003||2003-05-31|September 2012|2012-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Home-based AIDS Care Project|Home-based AIDS Care Project, Tororo, Uganda|Terminated||N/A|1000|Actual|Centers for Disease Control and Prevention||||Terminated by IRB for non-compliance with human subject regulations.|f||||f||||||||||2018-06-01 04:53:05.786137|2018-06-01 04:53:05.786137
NCT00119080|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2007-03-16|2005-07-11|2005-07-13|Estimate|||||||2007-03-16|2007-03-19|Estimate|August 2006||2006-08-31|March 2007|2007-03-31|May 2007||2007-05-31|||||Interventional|||Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage|Evaluation of the Effect of Tetravalent (A, C, Y, W-135) Meningococcal Conjugate Vaccine on Serogroup-Specific Carriage of Neisseria Meningitidis|Completed||Phase 4|4000||Centers for Disease Control and Prevention|||||f||||f||||||||||2018-06-01 04:53:05.86114|2018-06-01 04:53:05.86114
NCT00119067|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2014-02-25|2005-07-11|2005-07-13|Estimate|||||||2014-02-25|2014-02-26|Estimate|May 2002||2002-05-31|September 2012|2012-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||CDC Anthrax Vaccine Clinical Trial|Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction|Completed||Phase 4|1560|Actual|Centers for Disease Control and Prevention||6|||f||||||||||||||2018-06-01 04:53:05.936915|2018-06-01 04:53:05.936915
NCT00119054|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2015-04-06|2005-07-01|2005-07-12|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2005||2005-09-30|January 2008|2008-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Effectiveness of Home-Based Health Messaging for Patients With Hypertension and Diabetes|Effectiveness of Care Coordination in Managing Medically Complex Patients|Completed||N/A|302|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:53:06.095539|2018-06-01 04:53:06.095539
NCT00119041|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2014-07-02||2015-05-18|2005-07-01|2005-07-12|Estimate|2015-04-23|2015-05-12|Estimate||||2015-05-18|2015-06-15|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional||"Cohort I will consist of high-risk patients referred to a specialist during the 9-month active intervention and enrollment phase.Cohort II will consist of all other patients with diabetes (i.e., all non-Cohort I patients). We didn't collect gender or the complete age data.~Qualitative interviews with providers"|Diabetes Telemedicine Consultation: A Systems Improvement Intervention|Diabetes Telemedicine Consultation: A Systems Improvement Intervention|Completed||N/A|304|Actual|VA Office of Research and Development|A potential factor jeopardizing both internal and external validity relates to fact that the consultation process may be very dependent on the particular individuals involved.|3|||f||||f||||||||||2018-06-01 04:53:06.226962|2018-06-01 04:53:06.226962
NCT00119028|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2012-04-23|2005-07-11|2005-07-12|Estimate|||||||2012-04-23|2012-04-24|Estimate|April 2005||2005-04-30|April 2012|2012-04-30|October 2009|Actual|2009-10-31|December 2008|Actual|2008-12-31||Interventional|ReTIDES||Expanding and Testing VA Collaborative Care Models for Depression|Expanding and Testing VA Collaborative Care Models for Depression|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1||This study was withdrawn prior to enrollment.|f||||f||||||||||2018-06-01 04:53:06.559927|2018-06-01 04:53:06.559927
NCT00119015|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2012-12-20||2014-01-27|2005-07-01|2005-07-12|Estimate|2013-05-21|2013-05-22|Estimate||||2014-01-27|2014-02-28|Estimate|July 2005||2005-07-31|January 2014|2014-01-31|January 2009|Actual|2009-01-31|June 2008|Actual|2008-06-30||Interventional|||The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis|The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis|Terminated||Phase 4|102|Actual|University of Chicago|Early termination of study due to difficulty recruiting|2||Difficulty in recruitment|f||||f||||||||||2018-06-01 04:53:06.770967|2018-06-01 04:53:06.770967
NCT00119002|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2008-03-13|2005-07-01|2005-07-12|Estimate|||||||2008-03-13|2008-03-14|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis|The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis: A Multicenter Randomized Controlled Trial|Completed||Phase 4|598|Actual|University of Utah||2|||f||||t||||||||||2018-06-01 04:53:07.211594|2018-06-01 04:53:07.211594
NCT00118989|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-02|||2017-04-18|2005-07-02|2005-07-12|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2005||2005-07-31|April 2017|2017-04-30|July 2012|Actual|2012-07-31|September 2010|Actual|2010-09-30||Interventional|||Curcumin for the Chemoprevention of Colorectal Cancer|Phase II Double Blind Placebo-Controlled Trial of Curcuminoids' Effect on Cellular Proliferation, Apoptosis and COX-2 Expression in the Colorectal Mucosa of Subjects With Recently Resected Sporadic Adenomatous Polyps|Terminated||N/A|56|Actual|University of Pennsylvania||2||Could not be completed due to technology problems and cost constraints|f||||f|f|||||||||2018-06-01 04:53:07.399303|2018-06-01 04:53:07.399303
NCT00118976|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2006-11-22|2005-07-01|2005-07-12|Estimate|||||||2006-11-22|2006-11-23|Estimate|March 2005||2005-03-31|November 2006|2006-11-30|September 2006||2006-09-30|||||Interventional|||Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease|Optimal Dose of ACE Inhibitor for Treatment of Diabetic Nephropathy in Type 1 Diabetic Patients With Hypertension and Diabetic Nephropathy|Completed||N/A|60||Steno Diabetes Center|||||f||||||||||||||2018-06-01 04:53:07.533395|2018-06-01 04:53:07.533395
NCT00118963|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2008-12-05|2005-07-01|2005-07-12|Estimate|||||||2008-12-05|2008-12-08|Estimate|January 2003||2003-01-31|December 2008|2008-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes|Effect of Repaglinide Versus Metformin Treatment in Combination With Insulin Biasp30 (Novologmix 70/30) Predinner on Glycemic and Non-Glycemic Cardiovascular Risk-Factors in Non-Obese Patients With Type-2-Diabetes With Unsatisfactory Glycaemic Control With Oral Hypoglycaemic Agents|Completed||Phase 4|102|Actual|Steno Diabetes Center||3|||f||||||||||||||2018-06-01 04:53:07.602362|2018-06-01 04:53:07.602362
NCT00118950|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2008-12-05|2005-07-01|2005-07-12|Estimate|||||||2008-12-05|2008-12-08|Estimate|March 2001||2001-03-31|December 2008|2008-12-31|March 2003||2003-03-31|||||Interventional|||Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet|Effect of Metformin Versus Repaglinide Treatment on Glycemic Control and Non-Glycaemic Cardiovascular Risk Factors in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet|Completed||Phase 4|100||Steno Diabetes Center||4|||f||||||||||||||2018-06-01 04:53:07.712865|2018-06-01 04:53:07.712865
NCT00115401|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2017-06-30|2005-06-21|2005-06-22|Estimate|||||||2017-06-30|2017-07-02|Actual|June 16, 2005||2005-06-16|October 17, 2007|2007-10-17|October 17, 2007||2007-10-17|||||Observational|||Gait Adaptations to Passive Dynamic Ankle-Foot Orthosis Use|Gait Adaptations to Passive Dynamic Ankle-Foot Orthosis Use|Completed|||35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:26.329109|2018-06-01 04:54:26.329109
NCT00118937|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2008-12-05|2005-07-01|2005-07-12|Estimate|||||||2008-12-05|2008-12-08|Estimate|December 2003||2003-12-31|December 2008|2008-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet|Effect of Metformin On Glycaemic Control and Non-Glycaemic Cardiovascular Risk-Factors in Patients With Type-1 Diabetes, With Long-Standing Inadequate Glycaemic Control by Insulin and Diet|Completed||Phase 4|100|Actual|Steno Diabetes Center||3|||f||||||||||||||2018-06-01 04:53:07.884361|2018-06-01 04:53:07.884361
NCT00118924|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2008-01-18|2005-07-11|2005-07-12|Estimate|||||||2008-01-18|2008-01-21|Estimate|July 2005||2005-07-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of Tick-Borne Langat/Dengue 4 Chimera (LGT(TP21)/DEN4), a Live Attenuated Vaccine for Tick-Borne Encephalitis|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 04:53:07.999021|2018-06-01 04:53:07.999021
NCT00118911|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|2010-12-10||2017-12-07|2005-07-08|2005-07-12|Estimate|2011-02-18|2011-03-16|Estimate||||2017-12-07|2018-01-02|Actual|September 2004||2004-09-30|December 2017|2017-12-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder|Efficacy of CBT for Residual ADHD in Adults|Completed||N/A|86|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:53:08.16733|2018-06-01 04:53:08.16733
NCT00118898|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|2010-01-08||2016-01-04|2005-07-11|2005-07-12|Estimate|2010-12-07|2011-01-10|Estimate||||2016-01-04|2016-02-03|Estimate|September 2005||2005-09-30|January 2016|2016-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults|A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects|Completed||Phase 3|1864|Actual|AIDS Clinical Trials Group|HIV-1 drug resistance testing and HLA-B*5701 testing were not standard of care during enrollment. EFV and RTV-boosted ATV were open-label, and blinded FTC/TDF vs. ABC/3TC were unblinded in the >=100,000 cp/mL screening viral load stratum Feb 2008.|4|||f||||t||||||||||2018-06-01 04:53:08.634058|2018-06-01 04:53:08.634058
NCT00118885|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2009-12-09|2005-07-08|2005-07-12|Estimate|||||||2009-12-09|2009-12-11|Estimate|July 2001||2001-07-31|November 2006|2006-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Shingles: Immune Effects of Tai Chi|Behavioral Intervention for Herpes Zoster Risk in Aging|Completed||Phase 2|140||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:53:13.519363|2018-06-01 04:53:13.519363
NCT00118872|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2014-12-22|2005-07-11|2005-07-12|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2006||2006-03-31|December 2007|2007-12-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Beneficial Bacteria to Prevent Malnutrition and Diarrhea in Pakistani Infants|Feasibility Study of Probiotics for Growth Faltering in Pakistan|Completed||N/A|120|Actual|Tufts University||2|||f||||t||||||||||2018-06-01 04:53:13.820734|2018-06-01 04:53:13.820734
NCT00118859|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2009-12-10|2005-07-11|2005-07-12|Estimate|||||||2009-12-10|2009-12-11|Estimate|July 2004||2004-07-31|December 2009|2009-12-31|April 2006||2006-04-30|||||Interventional|||Pilot Study to Test the Effectiveness of Combining Conventional and Complementary Medicine to Treat Low Back Pain|Model of Integrative Care in an Academic Health Center|Completed||N/A|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:53:14.07404|2018-06-01 04:53:14.07404
NCT00118846|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2017-03-28|2005-07-07|2005-07-12|Estimate|||||||2017-03-28|2017-03-30|Actual|March 2004||2004-03-31|March 2017|2017-03-31|March 2009|Actual|2009-03-31|September 2005|Actual|2005-09-30||Interventional|||Women's Isoflavone Soy Health (WISH) Trial|Phytoestrogens and Progression of Atherosclerosis|Completed||Phase 2/Phase 3|350|Actual|University of Southern California||2|||f||||t||||||||||2018-06-01 04:53:14.236407|2018-06-01 04:53:14.236407
NCT00118833|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2007-09-25|2005-07-11|2005-07-12|Estimate|||||||2007-09-25|2007-09-26|Estimate|August 2002||2002-08-31|September 2007|2007-09-30|June 2006|Actual|2006-06-30|||||Interventional|||St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)|Placebo-Controlled Trial of Hypericum Perforatum in the Treatment of Generalized Social Anxiety Disorder (GSAD)|Completed||Phase 2/Phase 3|56|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:53:14.339503|2018-06-01 04:53:14.339503
NCT00118820|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2010-07-14|2005-07-01|2005-07-12|Estimate|||||||2010-07-14|2010-07-16|Estimate|March 2004||2004-03-31|July 2010|2010-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Antibiotic Efficacy in Third Molar Surgery|Antibiotic Efficacy in Third Molar Surgery|Completed||Phase 3|132|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:53:14.401096|2018-06-01 04:53:14.401096
NCT00118807|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2006-01-06|2005-07-01|2005-07-12|Estimate|||||||2006-01-06|2006-01-09|Estimate|August 2003||2003-08-31|June 2003|2003-06-30|February 2004||2004-02-29|||||Interventional|||Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children|Randomized Trial of the Effectiveness of Amodiaquine-Artesunate, Amodiaquine-Sulfadoxine-Pyrimethamine, and Chloroquine-Sulfadoxine-Pyrimethamine, for Treatment of Uncomplicated Malaria in Gambian Children|Completed||Phase 3|1800||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:53:14.481846|2018-06-01 04:53:14.481846
NCT00118794|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2006-01-31|2005-07-01|2005-07-12|Estimate|||||||2006-01-31|2006-02-01|Estimate|September 2004||2004-09-30|January 2005|2005-01-31|June 2005||2005-06-30|||||Interventional|||Lapdap and Coartemether for Uncomplicated Malaria|Randomized Trial of the Safety and Effectiveness of Lapdap and Coartemether for Uncomplicated Malaria in Operational Settings|Completed||Phase 3|1200||London School of Hygiene and Tropical Medicine|||||f||||||||||||||2018-06-01 04:53:14.543774|2018-06-01 04:53:14.543774
NCT00118781|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2005-07-11|2005-07-01|2005-07-12|Estimate|||||||2005-07-11|2005-07-19|Estimate|September 2003||2003-09-30|July 2005|2005-07-31|June 2004||2004-06-30|||||Interventional|||Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia|Randomized, Double-Blind, Placebo-Controlled, Multinational Phase 3 Trial Of Iseganan In Prevention Of Ventilator-Associated Pneumonia|Terminated||Phase 2/Phase 3|900||IntraBiotics Pharmaceuticals|||||||||||||||||||2018-06-01 04:53:14.609115|2018-06-01 04:53:14.609115
NCT00118768|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-02-27|2005-07-08|2005-07-12|Estimate|||||||2009-02-27|2009-03-02|Estimate|August 2005||2005-08-31|February 2009|2009-02-28||||||||Interventional|||A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C|A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of the Combination of Pegylated Interferon Alfa Plus NM283 (Valopicitabine) in Treatment-Naive Patients With Chronic Hepatitis C|Completed||Phase 2|175||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:53:14.69734|2018-06-01 04:53:14.69734
NCT00118755|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2010-04-25||2011-02-09|2005-07-11|2005-07-12|Estimate|2011-02-09|2011-03-03|Estimate||||2011-02-09|2011-03-03|Estimate|July 2005||2005-07-31|February 2011|2011-02-28||||April 2009|Actual|2009-04-30||Interventional|||A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer|A Randomized, Open-label Study of the Effect of 2 Different Treatment Schedules of Xeloda With Eloxatin and Avastin on Progression-free Survival in Treatment-naïve Patients With Locally Advanced or Metastatic Colorectal Cancer|Completed||Phase 2|435|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:53:14.98592|2018-06-01 04:53:14.98592
NCT00118742|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-05-13||2010-07-30|2005-07-11|2005-07-12|Estimate|2010-02-19|2010-03-10|Estimate||||2010-07-30|2010-08-03|Estimate|August 2005||2005-08-31|July 2010|2010-07-31|December 2008|Actual|2008-12-31|July 2008|Actual|2008-07-31||Interventional|||Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant|A Randomized, Open-label Study of the Effect of a Long-term Calcineurin Inhibitor-free Maintenance Regimen With CellCept and Sirolimus on Preservation of Renal Function and Prevention of Acute Rejection in Recipients of an Orthotropic Liver Transplant|Completed||Phase 4|293|Actual|Hoffmann-La Roche|There were no overall limitations and caveats.|2|||f||||||||||||||2018-06-01 04:53:15.654617|2018-06-01 04:53:15.654617
NCT00118729|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2016-09-13|2005-07-11|2005-07-12|Estimate|||||||2016-09-13|2016-09-15|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action|A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg in Adolescent and Adult Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber|Completed||Phase 3|380|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:53:16.5351|2018-06-01 04:53:16.5351
NCT00118716|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2016-09-22|2005-07-01|2005-07-12|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise|A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With Activity-Induced Bronchospasm|Completed||Phase 4|255|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:53:16.641595|2018-06-01 04:53:16.641595
NCT00118703|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2017-03-21||2017-07-14|2005-07-01|2005-07-12|Estimate|2017-03-21|2017-05-02|Actual||||2017-07-14|2017-08-21|Actual|July 1, 2005||2005-07-01|March 2017|2017-03-31|February 9, 2006|Actual|2006-02-09|February 1, 2006|Actual|2006-02-01||Interventional|||Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis|A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis|Completed||Phase 3|350|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:53:16.842161|2018-06-01 04:53:16.842161
NCT00118690|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2016-09-22|2005-07-01|2005-07-12|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise|A Stratified, Multicenter, Randomized, Double-Blind, Parallel Group, 4-Week Comparison of Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg BID Versus Fluticasone Propionate DISKUS 100mcg BID in Pediatric and Adolescent Subjects With Activity-Induced Bronchospasm|Completed||Phase 4|227|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:53:17.406563|2018-06-01 04:53:17.406563
NCT00118677|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2007-08-29|2005-07-01|2005-07-12|Estimate|||||||2007-08-29|2007-08-30|Estimate|February 2003||2003-02-28|August 2007|2007-08-31|May 2007|Actual|2007-05-31|||||Interventional|||Long-Term Supervised Treatment Interruption in HIV-Infected Patients|Long-Term Supervised Treatment Interruption in HIV-Infected Patients Who Started Antiretroviral Treatment With CD4 Over 350/mm3 and Plasma HIV RNA Below 50 000/mL ANRS 116 Trial SALTO|Completed||Phase 3|130||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:53:17.555588|2018-06-01 04:53:17.555588
NCT00118664|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2016-06-13|2005-07-11|2005-07-12|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2005||2005-05-31|June 2016|2016-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|TAMOF||Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children|Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children|Completed|||86|Actual|Children's Healthcare of Atlanta|||||f||||f||||||||No||2018-06-01 04:53:17.612085|2018-06-01 04:53:17.612085
NCT00118651|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2013-09-25|2005-07-01|2005-07-12|Estimate|||||||2013-09-25|2013-09-27|Estimate|October 2004||2004-10-31|June 2005|2005-06-30|May 2005||2005-05-31|||||Observational|||Clinical Indicators of Radiographic Findings in Patients With Suspected Community-Acquired Pneumonia|Clinical Indicators of Radiographic Findings in Patients With Suspected Community-Acquired Pneumonia: Who Needs a Chest X-Ray?|Withdrawn|||0|Actual|David Grant U.S. Air Force Medical Center||||PI location unknown|f||||||||||||||2018-06-01 04:53:17.704016|2018-06-01 04:53:17.704016
NCT00118638|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-04-25|2005-06-30|2005-07-12|Estimate|||||||2013-04-25|2013-04-29|Estimate|March 2004||2004-03-31|April 2013|2013-04-30|January 2005|Actual|2005-01-31|December 2004|Actual|2004-12-31||Interventional|||A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy|A Randomized, Double Blind, Active-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy|Completed||Phase 3|705|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:53:17.763025|2018-06-01 04:53:17.763025
NCT00118625|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2010-06-16|2005-07-01|2005-07-12|Estimate|||||||2010-06-16|2010-06-17|Estimate|July 2005||2005-07-31|June 2010|2010-06-30|September 2005||2005-09-30|||||Interventional|||Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine|A Double-Blind Phase IIa Study to Demonstrate the Contribution of MPL® to Tyrosine Adsorbed Birch + Hazel + Alder Pollen Allergoid (Tree MATA) With a Single-Blind Portion to Evaluate the Residual Allergenicity in Skin Test in Volunteers Allergic to Birch and Hazel and Alder Pollen|Completed||Phase 2|40||Allergy Therapeutics|||||||||||||||||||2018-06-01 04:53:17.836242|2018-06-01 04:53:17.836242
NCT00118612|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2010-06-16|2005-07-11|2005-07-12|Estimate|||||||2010-06-16|2010-06-17|Estimate|July 2005||2005-07-31|June 2010|2010-06-30||||||||Interventional|||Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen|A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Birch + Hazel + Alder Pollen Allergoid With MPL® in Patients Sensitized to Birch, Hazel, Alder Pollen|Completed||Phase 2|68||Allergy Therapeutics|||||||||||||||||||2018-06-01 04:53:17.906673|2018-06-01 04:53:17.906673
NCT00118586|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2018-03-27|2005-07-08|2005-07-11|Estimate|||||||2018-03-27|2018-03-29|Actual|July 7, 2005||2005-07-07|December 5, 2017|2017-12-05||||||||Observational|||Neuropathology of Spasmodic Dysphonia|Neuropathological Basis of Spasmodic Dysphonia and Related Voice Disorders|Active, not recruiting|||97|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:53:17.970696|2018-06-01 04:53:17.970696
NCT00118573|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2015-12-09|2005-06-30|2005-07-11|Estimate|||||||2015-12-09|2015-12-10|Estimate|September 2004||2004-09-30|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|May 2010|Actual|2010-05-31||Interventional|CAESAR||Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair|Randomized Clinical Trial Comparing Surveillance and Selective Surgical Treatment for Abdominal Aortic Aneurysms Less Than 5.5 cm in Diameter Versus Early Endovascular Treatment|Terminated||Phase 4|360|Actual|University Of Perugia||2||lower than anticipated events;slow recruitment;larger than predicted sample size|f||||t||||||||||2018-06-01 04:53:18.036642|2018-06-01 04:53:18.036642
NCT00118560|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-03-16|2005-07-07|2005-07-11|Estimate|||||||2011-03-16|2011-03-17|Estimate|June 2005||2005-06-30|March 2011|2011-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Exercise Training for Patients With Poor Leg Circulation|Perfusion and Metabolism During Exercise in Peripheral Arterial Disease|Completed||N/A|50|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:53:18.365783|2018-06-01 04:53:18.365783
NCT00118547|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2011-08-11|2005-07-07|2005-07-11|Estimate|||||||2011-08-11|2011-08-12|Estimate|September 2005||2005-09-30|August 2011|2011-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Health Behavior Change in Chronic Disease Management|Health Behavior Change in Chronic Disease Management|Completed||N/A|20|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:53:18.449671|2018-06-01 04:53:18.449671
NCT00118534|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2013-08-22||2014-04-18|2005-07-07|2005-07-11|Estimate|2013-12-04|2014-01-27|Estimate||||2014-04-18|2014-05-05|Estimate|July 2004||2004-07-31|April 2014|2014-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Integrating Clinical Practice Guidelines for Smoking Cessation Into Mental Health Care for Veterans With Posttraumatic Stress Disorder|CSP #519 - Integrating Practice Guidelines for Smoking Cessation Into Mental Health Care for PTSD (SCP)|Completed||N/A|943|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:53:18.651234|2018-06-01 04:53:18.651234
NCT00118521|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2013-12-18|2005-07-01|2005-07-11|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2004||2004-05-31|September 2006|2006-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Clinical Study in the Use of Orthotics in Treating Pain in the Front of the Knee|Foot Orthotics in the Treatment of Patellofemoral Pain Syndrome: A Randomised Clinical Trial in Primary Care|Completed||Phase 3|176||The University of Queensland|||||f||||||||||||||2018-06-01 04:53:20.675185|2018-06-01 04:53:20.675185
NCT00118508|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2015-08-10|2005-06-30|2005-07-11|Estimate|||||||2015-08-10|2015-08-13|Estimate|May 2003||2003-05-31|August 2015|2015-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)|The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)|Completed||N/A|87|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-06-01 04:53:20.770135|2018-06-01 04:53:20.770135
NCT00118495|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-07-04|2005-07-08|2005-07-11|Estimate|||||||2007-07-04|2007-07-06|Estimate|March 2006||2006-03-31|July 2007|2007-07-31|March 2007||2007-03-31|||||Interventional|||Zestra in Women With Mixed Sexual Dysfunction|A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial of the Efficacy and Safety of Zestra(TM) in Women With Mixed Desire/Interest/Arousal/Orgasm Disorders|Completed||Phase 3|200||QualiLife Pharmaceuticals|||||f||||t||||||||||2018-06-01 04:53:20.893827|2018-06-01 04:53:20.893827
NCT00118482|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2016-10-26||2017-05-25|2005-06-30|2005-07-11|Estimate|2017-05-25|2017-06-28|Actual||||2017-05-25|2017-06-28|Actual|May 2005||2005-05-31|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||Median age was 30.5 years and 146 were women.|Clinical Trial for the Prevention of Vasovagal Syncope|A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II)|Completed||Phase 4|213|Actual|University of Calgary||2|||f||||t||||||||||2018-06-01 04:53:21.023741|2018-06-01 04:53:21.023741
NCT00118469|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2008-04-01|2005-07-08|2005-07-11|Estimate|||||||2008-04-01|2008-04-03|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|December 2008|Anticipated|2008-12-31|||||Interventional|||Parent Psychoeducation and Cognitive Behavior Therapy for Latino Adolescents With Depression|Parent Psychoeducation Intervention in CBT for Depressed Latino Youth|Unknown status|Recruiting|Phase 2|144|Anticipated|National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 04:53:21.440014|2018-06-01 04:53:21.440014
NCT00118456|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2012-01-05|2005-07-01|2005-07-11|Estimate|||||||2012-01-05|2012-01-09|Estimate|July 2003||2003-07-31|January 2012|2012-01-31||||January 2008|Actual|2008-01-31||Interventional|||Study of Oral AEE788 in Adults With Advanced Cancer|A Phase I/II, Multicenter, Randomized Dose-Escalation Study of Oral AEE788 on Intermittent Dosing Schedules in Adult Patients With Advanced Cancer (Effective Amendment 5) Previously Entitled A Phase IA, Multicenter, Dose-Escalating Study of Oral AEE788 on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Cancer|Completed||Phase 1|189|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:53:21.518358|2018-06-01 04:53:21.518358
NCT00118443|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2013-06-27|2005-07-08|2005-07-11|Estimate|||||||2013-06-27|2013-06-28|Estimate|March 2004||2004-03-31|June 2013|2013-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Evaluation of a School-Based Training Program for Suicide Prevention|RCT of Gatekeeper Training for Suicide Prevention|Completed||Phase 2/Phase 3|50000|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 04:53:21.583992|2018-06-01 04:53:21.583992
NCT00118430|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|2016-05-23||2017-03-28|2005-07-08|2005-07-11|Estimate|2017-03-28|2017-05-09|Actual||||2017-03-28|2017-05-09|Actual|September 2004||2004-09-30|March 2017|2017-03-31|August 2008|Actual|2008-08-31|July 2008|Actual|2008-07-31||Interventional|||Stepped Care for Depression and Musculoskeletal Pain|Stepped Care for Affective Disorders and Musculoskeletal Pain|Completed||Phase 4|500|Actual|Indiana University||3|||f||||t||||||||Yes|Data has been published in multiple publications. Should others wish access to data for publication reasons, we are willing to share|2018-06-01 04:53:21.679081|2018-06-01 04:53:21.679081
NCT00118417|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|2009-06-05||2014-06-05|2005-07-08|2005-07-11|Estimate|2009-06-05|2009-07-28|Estimate||||2014-06-05|2014-06-11|Estimate|March 1999||1999-03-31|June 2014|2014-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Therapies for Treatment-Resistant Panic Disorder Symptoms|Treatment Refractory Panic Disorder|Completed||Phase 2/Phase 3|46|Actual|Massachusetts General Hospital|Power in Phase 2 limited detection to a large effect size. High drop-out for increased SSRI dose may indicate poor tolerability. Effectiveness of adding an SSRI to initial CBT was unexamined, limiting generalization to community treatment decisions.|2|||f||||||||||||||2018-06-01 04:53:22.177882|2018-06-01 04:53:22.177882
NCT00118404|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|2013-12-12||2014-05-13|2005-07-08|2005-07-11|Estimate|2014-05-13|2014-06-05|Estimate||||2014-05-13|2014-06-05|Estimate|March 2000||2000-03-31|May 2014|2014-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||523 adults with recurrent major depressive disorder began acute phase cognitive therapy; only the 241 eligible higher-risk responders were randomized to the 3 arms above.|Cognitive Therapy for Recurrent Depression|Prophylactic Cognitive Therapy for Depression.|Completed||Phase 3|523|Actual|University of Texas Southwestern Medical Center|"To our knowledge in 2014 this is of the largest, cognitive therapy responders who presented with recurrent MDD and were followed longitudinally~Proficient therapists;competency measured.~Generalizability is limited by design characteristics."|3|||f||||t||||||||||2018-06-01 04:53:22.401666|2018-06-01 04:53:22.401666
NCT00118391|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2013-06-28|2005-07-08|2005-07-11|Estimate|||||||2013-06-28|2013-07-01|Estimate|November 2002||2002-11-30|June 2013|2013-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|CBT/CM||Cognitive-Behavioral Treatment of Gambling|Enhanced Cognitive Behavior Therapy for the Treatment of Pathological Gambling|Completed||Phase 1|120||UConn Health|||||f||||t||||||||||2018-06-01 04:53:22.700519|2018-06-01 04:53:22.700519
NCT00118378|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|2012-01-03||2017-04-03|2005-07-08|2005-07-11|Estimate|2014-06-06|2014-06-09|Estimate||||2017-04-03|2017-05-10|Actual|December 2004||2004-12-31|March 2017|2017-03-31|November 2010|Actual|2010-11-30|June 2010|Actual|2010-06-30||Interventional|||Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS|Modafinil Treatment for Fatigue in HIV+ Patients|Completed||Phase 4|115|Actual|New York State Psychiatric Institute|This study was conducted at a single site in an urban setting where most patients have good access to medical care. Women were under-represented despite outreach efforts.|2|||f||||t||||||||||2018-06-01 04:53:22.765062|2018-06-01 04:53:22.765062
NCT00118365|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2014-04-18||2015-01-12|2005-07-08|2005-07-11|Estimate|2015-01-12|2015-01-22|Estimate||||2015-01-12|2015-01-22|Estimate|July 1998||1998-07-31|February 2014|2014-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||Randomized participants|Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps|A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Combination of DFMO and Sulindac to Decrease the Rate of Recurrence of Adenomatous Polyps in the Colon|Completed||Phase 3|375|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:53:23.141131|2018-06-01 04:53:23.141131
NCT00118352|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2017-01-12||2017-04-25|2005-07-08|2005-07-11|Estimate|2017-04-25|2017-05-30|Actual||||2017-04-25|2017-05-30|Actual|March 2005||2005-03-31|April 2017|2017-04-30|May 26, 2015|Actual|2015-05-26|July 2010|Actual|2010-07-31||Interventional|||Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer|Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial|Completed||Phase 2|12|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 04:53:25.97634|2018-06-01 04:53:25.97634
NCT00118339|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2011-08-30|2005-07-08|2005-07-11|Estimate|||||||2011-08-30|2011-09-01|Estimate|July 2003||2003-07-31|August 2011|2011-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma|A Prospective Randomized Pilot Study Using Ice Chips Versus Room Temperature Normal Saline Rinses Orally During Administration of Melphalan to Decrease the Severity and Duration of Oral Mucositis in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplant|Completed||N/A|41|Actual|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:53:26.456557|2018-06-01 04:53:26.456557
NCT00118326|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2010-05-12|2005-07-08|2005-07-11|Estimate|||||||2010-05-12|2010-05-14|Estimate|August 2003||2003-08-31|May 2010|2010-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease|Feasibility of Granulocyte-Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow From Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:53:26.51475|2018-06-01 04:53:26.51475
NCT00118313|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2014-12-18|2005-07-08|2005-07-11|Estimate|||||||2014-12-18|2014-12-19|Estimate|November 2004||2004-11-30|December 2014|2014-12-31||||November 2007|Actual|2007-11-30||Interventional|||Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma|Evaluation of Different Adjuvants for the Transdermal Administration of a Peptide-Based Vaccine in Participants With High-Risk Melanoma|Completed||Phase 1|||University of Virginia|||||f||||t||||||||||2018-06-01 04:53:26.580228|2018-06-01 04:53:26.580228
NCT00118300|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2011-07-07|2005-07-08|2005-07-11|Estimate|||||||2011-07-07|2011-07-08|Estimate|April 2005||2005-04-30|July 2011|2011-07-31||||||||Interventional|||Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer|Phase I Study of Capecitabine (Xeloda) and Radiation Therapy in Patients With Locally Advanced Cervical and Pelvic Malignancies|Withdrawn||Phase 1|0|Actual|Case Comprehensive Cancer Center||||Competing studies|f||||t||||||||||2018-06-01 04:53:26.656085|2018-06-01 04:53:26.656085
NCT00118287|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2017-04-17||2017-04-17|2005-07-08|2005-07-11|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|April 2005||2005-04-30|April 2017|2017-04-30||||October 2008|Actual|2008-10-31||Interventional|||Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes|Therapy of Myelodysplastic Syndrome (MDS) With Azacitidine Given in Combination With Etanercept: A Phase I/II Study.|Completed||Phase 1/Phase 2|32|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 04:53:26.742998|2018-06-01 04:53:26.742998
NCT00118274|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2017-08-31|2005-07-08|2005-07-11|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2005|Actual|2005-03-31|August 2017|2017-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma|A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma|Completed||Phase 1/Phase 2|173|Anticipated|University of Virginia||4|||f|||||t|f||||||||2018-06-01 04:53:27.04535|2018-06-01 04:53:27.04535
NCT00118261|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2012-08-31|2005-07-08|2005-07-11|Estimate|||||||2012-08-31|2012-09-03|Estimate|March 2005||2005-03-31|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer|A Phase IB Study in Patients With Metastatic Colorectal Cancer to Evaluate Pharmacodynamic Effects of Erlotinib and Safety and Efficacy of Erlotinib in Combination With Modified FOLFOX6 (mFOLFOX6) and Bevacizumab|Completed||Phase 1|17|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:53:27.144296|2018-06-01 04:53:27.144296
NCT00118248|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2013-09-20||2016-12-28|2005-07-08|2005-07-11|Estimate|2014-04-04|2014-05-06|Estimate||||2016-12-28|2017-02-15|Actual|December 2004||2004-12-31|December 2016|2016-12-31|April 2012|Actual|2012-04-30|August 2009|Actual|2009-08-31||Interventional|||Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer|A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma|Completed||Phase 2|41|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:27.263291|2018-06-01 04:53:27.263291
NCT00118235|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2014-06-16|2005-07-08|2005-07-11|Estimate|||||||2014-06-16|2014-06-17|Estimate|December 2004||2004-12-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|April 2007|Actual|2007-04-30||Interventional|||Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer|Cisplatin, Irinotecan and Bevacizumab (NSC# 704865) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase II Study|Completed||Phase 2|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:27.626051|2018-06-01 04:53:27.626051
NCT00118222|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2010-06-09|2005-07-08|2005-07-11|Estimate|||||||2010-06-09|2010-06-11|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||High Light and Low Light Dose PDT in Glioma|A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin]|Completed||Phase 3|1|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:53:27.709361|2018-06-01 04:53:27.709361
NCT00118209|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2017-08-07|2005-07-08|2005-07-11|Estimate|||||||2017-08-07|2017-08-09|Actual|May 2005|Actual|2005-05-31|August 2017|2017-08-31||||May 2018|Anticipated|2018-05-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas|Active, not recruiting||Phase 3|523|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 04:53:27.790306|2018-06-01 04:53:27.790306
NCT00118196|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2018-05-07|2005-07-08|2005-07-11|Estimate|||||||2018-05-07|2018-05-11|Actual|April 2005||2005-04-30|May 2018|2018-05-31|August 11, 2006|Actual|2006-08-11|August 11, 2006|Actual|2006-08-11||Interventional|||Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia|A Phase II Study of Arsenic Trioxide in Combination With 5-Azacitidine in Myelodysplastic Syndromes|Terminated||Phase 2|1|Actual|Medical University of South Carolina||||Due to limited resources available to conduct study|f||||t||||||||||2018-06-01 04:53:27.947058|2018-06-01 04:53:27.947058
NCT00118183|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2013-06-03|2005-07-08|2005-07-11|Estimate|||||||2013-06-03|2013-06-04|Estimate|July 2005||2005-07-31|June 2013|2013-06-30||||April 2007|Actual|2007-04-30||Interventional|||Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Trial of Docetaxel Plus Cetuximab and Docetaxel Plus Bortezomib (NSC #681239, IND #58443) in Advanced Non-Small Cell Lung Cancer Patients With Performance Status (PS) 2|Completed||Phase 2|62|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:53:28.007787|2018-06-01 04:53:28.007787
NCT00118170|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2013-01-04|2005-07-08|2005-07-11|Estimate|||||||2013-01-04|2013-01-07|Estimate|October 2004||2004-10-31|January 2013|2013-01-31||||May 2007|Actual|2007-05-31||Interventional|||Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function|Pharmacokinetic and Phase I Study of Sorafenib (BAY 43-9006, NSC 724772, IND 69896) for Solid Tumors and Hematologic Malignancies in Patients With Hepatic or Renal Dysfunction|Completed||Phase 1|150|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:28.092255|2018-06-01 04:53:28.092255
NCT00118157|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2014-11-21||2017-10-27|2005-07-08|2005-07-11|Estimate|2014-11-21|2014-12-03|Estimate||||2017-10-27|2017-12-04|Actual|May 2005||2005-05-31|October 2017|2017-10-31|September 2014|Actual|2014-09-30|July 2011|Actual|2011-07-31||Interventional|||Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen|A Phase II Study of GW572016 and Tamoxifen in Patients With Metastatic Breast Cancer Resistant to Single-Agent Tamoxifen|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)|The main limitation in this study was poor enrollment. The small number of cases makes the interpretation of results difficult.|1|||f||||||||||||||2018-06-01 04:53:28.186445|2018-06-01 04:53:28.186445
NCT00118144|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2014-08-04||2014-08-04|2005-07-08|2005-07-11|Estimate|2014-08-04|2014-08-21|Estimate||||2014-08-04|2014-08-21|Estimate|June 2005||2005-06-30|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer|Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features|Completed||Phase 2|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:28.557942|2018-06-01 04:53:28.557942
NCT00118131|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2013-09-19||2013-09-19|2005-07-08|2005-07-11|Estimate|2013-09-19|2013-11-25|Estimate||||2013-09-19|2013-11-25|Estimate|December 2003||2003-12-31|September 2013|2013-09-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Weekly Docetaxel Together With Weekly Cisplatin in Chemotherapy-Naive Patients With Stage IV or Select Stage IIIB (Malignant Effusion) Non-Small Cell Lung Cancer|Terminated||Phase 2|49|Actual|Rutgers, The State University of New Jersey||1||Slow accrual|f||||f||||||||||2018-06-01 04:53:28.91175|2018-06-01 04:53:28.91175
NCT00118105|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2013-01-02|2005-07-08|2005-07-11|Estimate|||||||2013-01-02|2013-01-03|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer|A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin, and Bevacizumab for Resectable Colorectal Metastases in the Liver|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||1||Budget Constraints|f||||t||||||||||2018-06-01 04:53:29.182417|2018-06-01 04:53:29.182417
NCT00118092|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2016-12-28||2017-03-20|2005-07-08|2005-07-11|Estimate|2016-12-28|2017-02-20|Actual||||2017-03-20|2017-04-18|Actual|January 2005||2005-01-31|March 2017|2017-03-31|February 2008|Actual|2008-02-29|May 2006|Actual|2006-05-31||Interventional|||17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy|A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Hormone-Refractory Metastatic Prostate Cancer|Completed||Phase 2|17|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:29.305606|2018-06-01 04:53:29.305606
NCT00118066|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2015-05-22|2005-07-08|2005-07-11|Estimate|||||||2015-05-22|2015-05-27|Estimate|May 2004||2004-05-31|May 2015|2015-05-31|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia|A Randomized Phase II Trial Of Calcitriol In Patients With Prostatic Intraepithelial Neoplasia|Terminated||Phase 2|12|Actual|Rutgers, The State University of New Jersey||2||Slow accruaL, lack of scientific progress|f||||f||||||||||2018-06-01 04:53:30.466325|2018-06-01 04:53:30.466325
NCT00118053|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2013-09-17||2013-09-17|2005-07-08|2005-07-11|Estimate|2013-09-17|2013-11-20|Estimate||||2013-09-17|2013-11-20|Estimate|April 2005||2005-04-30|September 2013|2013-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer|A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or Inflammatory Breast Cancer|Terminated||Phase 2|5|Actual|Rutgers, The State University of New Jersey||1||slow accrual|f||||f||||||||||2018-06-01 04:53:30.596877|2018-06-01 04:53:30.596877
NCT00118040|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2015-12-10||2017-05-23|2005-07-08|2005-07-11|Estimate|2016-02-23|2016-03-24|Estimate||||2017-05-23|2017-06-15|Actual|June 2005||2005-06-30|May 2017|2017-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer|Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 04:53:30.934959|2018-06-01 04:53:30.934959
NCT00118027|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-01-11|2005-07-08|2005-07-11|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2003||2003-05-31|January 2017|2017-01-31|June 2007|Actual|2007-06-30|||||Interventional|||A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda|A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda|Completed||N/A|2150||London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-06-01 04:53:32.99252|2018-06-01 04:53:32.99252
NCT00118014|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|||2008-05-19|2005-07-01|2005-07-11|Estimate|||||||2008-05-19|2008-05-20|Estimate|January 2000||2000-01-31|May 2008|2008-05-31|August 2004|Actual|2004-08-31|April 2004|Actual|2004-04-30||Interventional|||Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania|Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania|Completed||Phase 4|75|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:53:33.105797|2018-06-01 04:53:33.105797
NCT00118001|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2015-03-31|2005-07-08|2005-07-11|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2001||2001-10-31|June 2005|2005-06-30|July 2006||2006-07-31|||||Interventional|||Psychotherapy of Generalized Anxiety Disorder|Worry Exposure Versus Applied Relaxation in the Treatment of Generalized Anxiety Disorder|Completed||Phase 3|70||German Research Foundation|||||f||||||||||||||2018-06-01 04:53:33.198233|2018-06-01 04:53:33.198233
NCT00117988|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2011-05-05||2014-05-21|2005-07-08|2005-07-11|Estimate|2011-05-05|2011-05-30|Estimate||||2014-05-21|2014-05-30|Estimate|February 2005||2005-02-28|February 2013|2013-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma|A Phase II Study of 17-AAG in Patients With Relapsed/Refractory CD30+ Anaplastic Large Cell Lymphoma (ALCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL), and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL)|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:53:33.409111|2018-06-01 04:53:33.409111
NCT00117975|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|||2016-07-01|2005-07-08|2005-07-11|Estimate|||||||2016-07-01|2016-07-06|Estimate|June 2005||2005-06-30|July 2016|2016-07-31|August 2013|Actual|2013-08-31|June 2007|Actual|2007-06-30||Interventional|||Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|A Phase II Trial of Extended Induction Galiximab (Anti-CD80 Monoclonal Antibody) (IND #12373) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)|Completed||Phase 2|62|Actual|Alliance for Clinical Trials in Oncology|||||f||||f||||||||||2018-06-01 04:53:33.710067|2018-06-01 04:53:33.710067
NCT00117962|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-08|2012-11-05||2016-08-29|2005-07-08|2005-07-11|Estimate|2012-12-10|2013-01-15|Estimate||||2016-08-29|2016-10-07|Estimate|September 2005||2005-09-30|August 2016|2016-08-31|September 2012|Actual|2012-09-30|March 2009|Actual|2009-03-31||Interventional|||Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Randomized Phase II Study of Radiation Therapy, Pemetrexed and Carboplatin With or Without Cetuximab in Stage III Non-Small Cell Lung Cancer|Completed||Phase 2|109|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 04:53:34.028223|2018-06-01 04:53:34.028223
NCT00117949|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-01-22||2011-05-18|2005-06-30|2005-07-11|Estimate|2009-04-15|2009-06-05|Estimate||||2011-05-18|2011-05-23|Estimate|April 2002||2002-04-30|May 2011|2011-05-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486|An Open-Label, Multi-Center, Ascending, Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486|Completed||Phase 2|82|Actual|Ferring Pharmaceuticals||4|||f||||t||||||||||2018-06-01 04:53:35.727612|2018-06-01 04:53:35.727612
NCT00117936|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2018-01-23|2005-07-07|2005-07-11|Estimate|||||||2018-01-23|2018-01-25|Actual|September 30, 2019|Anticipated|2019-09-30|January 2018|2018-01-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|ACORD||Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease|Human Recombinant Fibroblast Growth Factor-1 (FGF-1) for Intramyocardial Injection for the Treatment of Coronary Heart Disease|Not yet recruiting||Phase 2|120|Anticipated|CardioVascular BioTherapeutics, Inc.||4|||f||||t|t|f||||||||2018-06-01 04:53:37.012355|2018-06-01 04:53:37.012355
NCT00117923|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-02-16|2005-06-30|2005-07-11|Estimate|||||||2007-02-16|2007-02-19|Estimate|August 2004||2004-08-31|November 2006|2006-11-30||||||||Interventional|||Study With a Topical Gel to Treat Common Warts in Adults|A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults|Completed||Phase 2|88||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:53:37.262788|2018-06-01 04:53:37.262788
NCT00117910|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-05-15|2005-06-30|2005-07-11|Estimate|||||||2008-05-15|2008-05-16|Estimate|October 2002||2002-10-31|May 2008|2008-05-31|May 2004||2004-05-31|||||Interventional|||Treatment for Elderly Patients With High Risk Breast Cancer|An Open Label, Randomised, Multicentre Study of Pegfilgrastim in Primary Versus Secondary Prophylaxis of Neutropenia as an Adjunct to Chemotherapy in Elderly Subjects With High Risk Breast Cancer.|Completed||Phase 3|||Amgen|||||f||||||||||||||2018-06-01 04:53:37.387804|2018-06-01 04:53:37.387804
NCT00117897|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-07-16|2005-06-30|2005-07-11|Estimate|||||||2009-07-16|2009-07-20|Estimate|July 2002||2002-07-31|July 2009|2009-07-31|February 2004||2004-02-29|||||Interventional|||Treatment for Subjects With Non-Hodgkin's Lymphoma|An Open-Label, Randomized, Parallel, Phase II Study of CHOP Chemotherapy and Rituximab Administered Every 14 Days, With Pegfilgrastim or Filgrastim Support, for the Treatment of Subjects With Non-Hodgkin's Lymphoma|Completed||Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:53:37.477611|2018-06-01 04:53:37.477611
NCT00117884|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01||2016-08-16|2016-08-16|2005-07-08|2005-07-11|Estimate||||2016-08-16|2016-08-19|Estimate|2016-08-16|2016-08-19|Estimate|April 2006||2006-04-30|August 2016|2016-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.|A Randomized, Double-blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities|Terminated||Phase 2|240|Actual|Takeda||11||Lack of efficacy|f||||f||||||||||2018-06-01 04:53:37.557353|2018-06-01 04:53:37.557353
NCT00117871|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-02-16|2005-06-30|2005-07-11|Estimate|||||||2007-02-16|2007-02-19|Estimate|October 2004||2004-10-31|November 2006|2006-11-30||||||||Interventional|||Study With a Topical Gel to Treat Common Warts in Adults|A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults|Completed||Phase 2|48||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:53:37.688365|2018-06-01 04:53:37.688365
NCT00117858|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|||2017-06-30|2005-07-07|2005-07-08|Estimate|||||||2017-06-30|2017-07-02|Actual|June 28, 2005||2005-06-28|May 10, 2007|2007-05-10|May 10, 2007||2007-05-10|||||Interventional|||Double Blind Trial of DC Polarization in FTD|Double Blind Trial of DC Polarization in FTD|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:53:37.752787|2018-06-01 04:53:37.752787
NCT00117845|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-07|2012-09-25||2013-10-31|2005-07-07|2005-07-08|Estimate|2012-09-25|2012-10-25|Estimate||||2013-10-31|2013-11-26|Estimate|July 2005||2005-07-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|December 2011|Actual|2011-12-31||Interventional|||Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia|Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia|Completed||Phase 2|17|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 04:53:37.821878|2018-06-01 04:53:37.821878
NCT00117832|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-09-04|2005-06-30|2005-07-08|Estimate|||||||2013-09-04|2013-09-05|Estimate|March 2005||2005-03-31|September 2013|2013-09-30|October 2006|Actual|2006-10-31|May 2006|Actual|2006-05-31||Interventional|||Nasal Ocular Reflexes Contribute to Eye Symptoms|Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis|Completed||N/A|20||University of Chicago|||||f||||f||||||||||2018-06-01 04:53:38.119939|2018-06-01 04:53:38.119939
NCT00117819|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30||2014-04-09|2014-04-09|2005-06-30|2005-07-08|Estimate||||2014-04-09|2014-05-02|Estimate|2014-04-09|2014-05-02|Estimate|March 2001||2001-03-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease|Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome|Completed||Phase 2|232|Actual|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-06-01 04:53:38.244938|2018-06-01 04:53:38.244938
NCT00117806|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2014-10-24||2016-02-03|2005-07-07|2005-07-08|Estimate|2014-12-30|2015-01-01|Estimate||||2016-02-03|2016-03-03|Estimate|April 2006||2006-04-30|February 2016|2016-02-29|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|SCI-VIP|"AIS DATA-Missing 1 participant for Supported Employment and Treatment As Usual groups.~AIS & Neurologival Level- Missing 1 participant for Supported employment."|Spinal Cord Injury Vocational Integration Program (SCI-VIP)|A Spinal Cord Injury Vocational Integration Program: Implementation and Outcomes|Completed||N/A|249|Actual|VA Office of Research and Development|Majority of sample is male; Potential selection bias (participants who decided to remain in study for second year may be different from those who did not though no statistical significance was detected between groups)|2|||f||||t||||||||||2018-06-01 04:53:38.509288|2018-06-01 04:53:38.509288
NCT00117793|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-01|2013-10-24||2014-07-28|2005-07-07|2005-07-08|Estimate|2014-07-28|2014-08-15|Estimate||||2014-07-28|2014-08-15|Estimate|August 2005||2005-08-31|July 2014|2014-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||The sample population descriptors are based on the participants who completed the study protocol.|Vacuum Suspension: Effects on Tissue Oxygenation, Activity and Fit|Vacuum Suspension: Effects on Tissue Oxygenation, Activity and Fit|Completed||N/A|20|Actual|VA Office of Research and Development|The small number of participants who completed the protocol precluded a statistical analysis on the secondary outcome measures.|2|||f||||f||||||||||2018-06-01 04:53:39.39387|2018-06-01 04:53:39.39387
NCT00117780|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-06-01|2005-06-30|2005-07-08|Estimate|||||||2017-06-01|2017-06-02|Actual|June 2005||2005-06-30|May 2017|2017-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|ADAPT||Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes|Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes|Completed||Phase 4|520|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:53:39.85327|2018-06-01 04:53:39.85327
NCT00117767|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-05-28|2005-06-30|2005-07-08|Estimate|||||||2017-05-28|2017-05-31|Actual|June 2004||2004-06-30|May 2017|2017-05-31||||March 2006|Actual|2006-03-31||Interventional|||Terbinafine Compared to Griseofulvin in Children With Tinea Capitis|Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis|Completed||Phase 3|720||Novartis||2|||||||||||||||||2018-06-01 04:53:40.029691|2018-06-01 04:53:40.029691
NCT00117754|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-02-20|2005-06-30|2005-07-08|Estimate|||||||2007-02-20|2007-02-21|Estimate|July 2004||2004-07-31|August 2006|2006-08-31|April 2006||2006-04-30|||||Interventional|||Terbinafine Compared to Griseofulvin in Children With Tinea Capitis|Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis|Completed||Phase 3|720||Novartis|||||||||||||||||||2018-06-01 04:53:40.131697|2018-06-01 04:53:40.131697
NCT00117741|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2012-01-31|2005-07-07|2005-07-08|Estimate|||||||2012-01-31|2012-02-02|Estimate|June 2004||2004-06-30|January 2012|2012-01-31|April 2010|Actual|2010-04-30|October 2008|Actual|2008-10-31||Interventional|||Evaluation of DBT Compared to Drug Counseling for Opiate Addicts|Evaluation of Dialectical Behavior Therapy (DBT)|Completed||N/A|86|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 04:53:40.210939|2018-06-01 04:53:40.210939
NCT00117728|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|||2007-06-28|2005-07-07|2005-07-08|Estimate|||||||2007-06-28|2007-06-29|Estimate|April 2005||2005-04-30|January 2006|2006-01-31|September 2010|Anticipated|2010-09-30|||||Interventional|||Pediatric Nevirapine Resistance Study|Clinical Relevance of Nevirapine Resistance|Unknown status|Recruiting|Phase 3|250|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:53:40.317715|2018-06-01 04:53:40.317715
NCT00117715|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-06|2017-04-04||2017-08-11|2005-07-07|2005-07-08|Estimate|2017-07-06|2017-08-14|Actual||||2017-08-11|2017-09-12|Actual|October 2000||2000-10-31|August 2017|2017-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body|Developmental Regulation of CYPs 1A2, 2D6, 3A4|Completed|||121|Actual|Children's Mercy Hospital Kansas City|Not all enrolled participants were available for evaluation at every milestone.||||f||||f||||||Samples With DNA|"~     Urine DNA (source: blood or saliva)~   "|||2018-06-01 04:53:40.436234|2018-06-01 04:53:40.436234
NCT00117702|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-06-17|2005-06-30|2005-07-08|Estimate|||||||2009-06-17|2009-06-18|Estimate|October 2005||2005-10-31|June 2009|2009-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus|Prophylaxis of the Graft-Versus-Host-Disease in Patients After Allogeneic Stem Cell Transplantation With a Combination of Tacrolimus and Everolimus|Terminated||Phase 2/Phase 3|24|Actual|Technische Universität Dresden||||safety reasons|f||||t||||||||||2018-06-01 04:53:40.771253|2018-06-01 04:53:40.771253
NCT00117689|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2015-03-17|2005-07-07|2005-07-08|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2005||2005-04-30|March 2015|2015-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection|A Randomized, Controlled, Multi-Center Study of Thymoglobulin Induction Therapy With a Calcineurin Inhibitor Sparing Regimen in Liver Transplant Patients|Completed||Phase 2|75|Actual|Sanofi||2|||f||||||||||||||2018-06-01 04:53:40.851361|2018-06-01 04:53:40.851361
NCT00117676|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2010-02-11||2017-01-16|2005-06-30|2005-07-08|Estimate|2010-04-29|2010-05-19|Estimate||||2017-01-16|2017-03-07|Actual|February 2005||2005-02-28|January 2017|2017-01-31|January 2016|Actual|2016-01-31|April 2007|Actual|2007-04-30||Interventional||Randomized and Treated Analysis Set: all participants who were randomized and received at least one dose of study medication|A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B|A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of Presumed Pre-Core Mutant Chronic Hepatitis B|Completed||Phase 3|382|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 04:53:41.062362|2018-06-01 04:53:41.062362
NCT00117663|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-09-10|2005-06-30|2005-07-08|Estimate|||||||2009-09-10|2009-09-14|Estimate|November 2004||2004-11-30|September 2009|2009-09-30|November 2006|Anticipated|2006-11-30|||||Interventional|||Radiologic Evaluation and Breast Density (READ)|A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of Hormone Replacement Therapy (HRT) on Mammography Assessments and Breast Density|Unknown status|Recruiting|N/A|1500|Anticipated|Kaiser Permanente|||||f||||||||||||||2018-06-01 04:53:43.771575|2018-06-01 04:53:43.771575
NCT00117650|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30||2010-10-02|2015-03-17|2005-06-30|2005-07-08|Estimate||||2010-10-02|2010-10-05|Estimate|2015-03-17|2015-04-03|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|March 2010|Actual|2010-03-31|September 2008|Actual|2008-09-30||Interventional|WALK||Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 in Patients With Intermittent Claudication|Completed||Phase 2|289|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 04:53:43.910119|2018-06-01 04:53:43.910119
NCT00117637|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2010-08-27||2014-10-24|2005-06-30|2005-07-08|Estimate|2010-11-26|2010-12-15|Estimate||||2014-10-24|2014-10-31|Estimate|June 2005||2005-06-30|October 2014|2014-10-31|March 2009|Actual|2009-03-31|September 2006|Actual|2006-09-30||Interventional|||BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma|A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.|Completed||Phase 2|189|Actual|Bayer||2|||f||||t||||||||||2018-06-01 04:53:44.127583|2018-06-01 04:53:44.127583
NCT00117624|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-20|2005-06-30|2005-07-08|Estimate|||||||2007-12-20|2007-12-28|Estimate|December 2002||2002-12-31|December 2007|2007-12-31|December 2003||2003-12-31|||||Interventional|||A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy|A Randomized, Double-Blind, Study of Front-Loading Darbepoetin Alfa Compared With Standard Weekly Administration for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy and Receiving Multicycle Chemotherapy|Completed||Phase 3|||Amgen|||||f||||||||||||||2018-06-01 04:53:46.031521|2018-06-01 04:53:46.031521
NCT00117611|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-09-27|2005-07-06|2005-07-07|Estimate|||||||2013-09-27|2013-09-30|Estimate|July 2005||2005-07-31|September 2013|2013-09-30|January 2009|Actual|2009-01-31|May 2007|Actual|2007-05-31||Interventional|||Xolair in Patients With Chronic Sinusitis|Effects of Anti-IgE Antibody Omalizumab (Xolair) on Patients With Chronic Sinusitis and a Positive Allergen Test|Completed||Phase 4|14|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 04:53:46.094355|2018-06-01 04:53:46.094355
NCT00117598|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2012-02-02|2011-12-01|2015-03-10|2005-06-30|2005-07-07|Estimate|2012-02-02|2012-03-06|Estimate|2011-12-01|2011-12-08|Estimate|2015-03-10|2015-03-30|Estimate|May 2005||2005-05-31|March 2015|2015-03-31|January 2011|Actual|2011-01-31|August 2007|Actual|2007-08-31||Interventional|OPTIMAL||Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)|An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)|Completed||Phase 3|169|Actual|Pfizer|After the primary analysis was completed, efficacy data was no longer collected nor analyzed; Participants were followed for safety up to 6 months after the last dose of temsirolimus.|3|||f||||t||||||||||2018-06-01 04:53:46.261969|2018-06-01 04:53:46.261969
NCT00117585|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2013-11-05||2016-03-18|2005-07-06|2005-07-07|Estimate|2014-06-04|2014-07-04|Estimate||||2016-03-18|2016-04-18|Estimate|November 2005||2005-11-30|March 2016|2016-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Orthostatic Hypotension in Rehabilitation Patients|Orthostatic Hypotension in Rehabilitation Patients|Completed||N/A|341|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:53:47.911913|2018-06-01 04:53:47.911913
NCT00117572|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2018-02-26||2018-04-06|2005-06-30|2005-07-07|Estimate|2018-04-06|2018-04-09|Actual||||2018-04-06|2018-04-09|Actual|November 2004||2004-11-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DeCIDE||Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)|A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer|Completed||Phase 3|285|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:53:48.254229|2018-06-01 04:53:48.254229
NCT00117559|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2014-11-17||2014-12-09|2005-07-06|2005-07-07|Estimate|2014-12-09|2014-12-11|Estimate||||2014-12-09|2014-12-11|Estimate|July 2005||2005-07-31|December 2014|2014-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Improving Quality of Life for Veterans Undergoing Interferon Treatment|Improving Quality of Life for Veterans Undergoing Interferon Treatment|Completed||N/A|19|Actual|VA Office of Research and Development|Small sample size, all male, no in-person comparison group, reporting bias in self-report measures.|2|||f||||f||||||||||2018-06-01 04:53:49.360351|2018-06-01 04:53:49.360351
NCT00117546|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2010-06-07|2005-06-30|2005-07-07|Estimate|||||||2010-06-07|2010-06-08|Estimate|September 2005||2005-09-30|July 2007|2007-07-31|December 2008|Anticipated|2008-12-31|||||Interventional|||Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia|Cardiovascular Performance and Autonomic Reactivity in Formerly Preeclamptic Women With a Contracted Plasma Volume (CAPACITY Trial)|Unknown status|Recruiting|Phase 4|35|Anticipated|Radboud University|||||f||||t||||||||||2018-06-01 04:53:49.607799|2018-06-01 04:53:49.607799
NCT00117533|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2006-05-24|2005-06-30|2005-07-07|Estimate|||||||2006-05-24|2006-05-25|Estimate|September 2005||2005-09-30|September 2005|2005-09-30|June 2007||2007-06-30|||||Interventional|||Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta|A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta|Unknown status|Recruiting|Phase 4|20||National Taiwan University Hospital|||||f||||||||||||||2018-06-01 04:53:49.791023|2018-06-01 04:53:49.791023
NCT00117520|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2006-07-03|2005-06-30|2005-07-07|Estimate|||||||2006-07-03|2006-07-07|Estimate|July 2002||2002-07-31|July 2002|2002-07-31|March 2006||2006-03-31|||||Interventional|||The Effect of Caffeine in Elderly Citizens|The Effect of Caffeine as Endurance Enhancing Drug in the Elderly|Completed||Phase 4|30||Herning Hospital|||||f||||||||||||||2018-06-01 04:53:49.896146|2018-06-01 04:53:49.896146
NCT00117507|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-02-28|2005-06-30|2005-07-07|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2005||2005-04-30|November 2016|2016-11-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients|An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients|Completed||Phase 2|24|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:53:49.974393|2018-06-01 04:53:49.974393
NCT00117494|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-12-21|2005-06-30|2005-07-07|Estimate|||||||2011-12-21|2011-12-22|Estimate|October 2005||2005-10-31|December 2011|2011-12-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)|Randomised Comparative Study of the Efficacy and Safety of Rosuvastatin and Pravastatin in Dyslipidemic Patients Treated With Antiretroviral Agents. Anrs 126|Completed||Phase 4|86||French National Agency for Research on AIDS and Viral Hepatitis|||||f||||||||||||||2018-06-01 04:53:50.119426|2018-06-01 04:53:50.119426
NCT00117481|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2014-05-08|2005-07-06|2005-07-07|Estimate|||||||2014-05-08|2014-05-09|Estimate|June 2005||2005-06-30|May 2014|2014-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain|A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate DR-2001 for the Management of Moderate to Severe Endometriosis-Related Nonmenstrual Pelvic Pain|Completed||Phase 2|90|Anticipated|Teva Pharmaceutical Industries||3|||f||||||||||||||2018-06-01 04:53:50.445212|2018-06-01 04:53:50.445212
NCT00117468|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2014-05-09|2005-07-06|2005-07-07|Estimate|||||||2014-05-09|2014-05-12|Estimate|June 2005||2005-06-30|May 2014|2014-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement|A Phase 2, Single-Center, Open-Label, Randomized, Controlled, Pharmacodynamic Study to Compare DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement|Completed||Phase 2|20|Anticipated|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 04:53:50.854206|2018-06-01 04:53:50.854206
NCT00117455|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-05-15|2005-06-30|2005-07-07|Estimate|||||||2008-05-15|2008-05-16|Estimate||||May 2008|2008-05-31||||||||Interventional|||A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma|A Randomised, Multi-Centre, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Non-Hodgkin's Lymphoma|Completed||Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:53:50.94984|2018-06-01 04:53:50.94984
NCT00117442|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-05-09|2005-06-30|2005-07-07|Estimate|||||||2013-05-09|2013-05-13|Estimate|August 2002||2002-08-31|May 2013|2013-05-31|December 2004|Actual|2004-12-31|August 2004|Actual|2004-08-31||Interventional|||A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood|An Open-Label, Randomised Study of Multi-Cycle, Dose Intensive Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood|Completed||Phase 2|61|Actual|Amgen||4|||f||||||||||||||2018-06-01 04:53:51.028646|2018-06-01 04:53:51.028646
NCT00117429|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2010-02-12|2005-07-06|2005-07-07|Estimate|||||||2010-02-12|2010-02-15|Estimate|June 2005||2005-06-30|February 2010|2010-02-28|January 2010|Actual|2010-01-31|September 2007|Actual|2007-09-30||Interventional|||Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)|A Phase I, Randomized, Double-Blind Clinical Trial of the HIV gp120/NefTat/AS02A Vaccine Candidate in Subjects With Well-Controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 1|20|Anticipated|Marcus Altfeld, M.D., Ph.D.|||||f||||||||||||||2018-06-01 04:53:51.124181|2018-06-01 04:53:51.124181
NCT00117416|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-19|2005-06-30|2005-07-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|February 2003||2003-02-28|December 2007|2007-12-31||||||||Interventional|||Mean Arterial Pressure (MAP) and Renal Perfusion: Evaluation of Critically Ill Patients With Normal Creatinine or Reduced Renal Function|MAP and Renal Perfusion: Evaluation of Critically Ill Patients With Normal Creatinine or Reduced Renal Function|Suspended||N/A|60||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:53:51.287651|2018-06-01 04:53:51.287651
NCT00117403|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-04-01|2005-06-30|2005-07-06|Estimate|||||||2009-04-01|2009-04-03|Estimate|January 2006||2006-01-31|April 2008|2008-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Anti-Oxidant Treatment of Alzheimer's Disease|Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease|Completed||Phase 1|75|Anticipated|National Institute on Aging (NIA)||3|||f||||t||||||||||2018-06-01 04:53:51.523047|2018-06-01 04:53:51.523047
NCT00117390|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-19|2005-06-30|2005-07-06|Estimate|||||||2007-12-19|2007-12-28|Estimate|June 2004||2004-06-30|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Evaluation of the Optimal Technique for Determination of Renal Function of Critically Ill Patients|Evaluation of the Optimal Technique for Determination of the Renal Function of Critically Ill Patients|Completed||N/A|50||University Hospital, Ghent|||||f||||f||||||||||2018-06-01 04:53:51.689673|2018-06-01 04:53:51.689673
NCT00117377|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-13|2005-07-05|2005-07-06|Estimate|||||||2007-12-13|2007-12-17|Estimate|April 2004||2004-04-30|December 2007|2007-12-31|June 2005|Actual|2005-06-30|||||Interventional|||Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis|Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis|Completed||Phase 4|70||Novartis||2|||||||||||||||||2018-06-01 04:53:51.762645|2018-06-01 04:53:51.762645
NCT00117364|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2005-07-05|2005-07-05|2005-07-06|Estimate|||||||2005-07-05|2005-07-06|Estimate|January 2005||2005-01-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Effect of SACCHACHITIN on Healing of a Chronic Wound|Effect of SACCHACHITIN on Healing of Chronic Wound ---A Clinical Trial|Unknown status|Recruiting|Phase 2|30||Min-Sheng General Hospital|||||f||||||||||||||2018-06-01 04:53:51.826715|2018-06-01 04:53:51.826715
NCT00117351|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-02-16|2005-07-05|2005-07-06|Estimate|||||||2011-02-16|2011-02-17|Estimate|April 2005||2005-04-30|February 2011|2011-02-28|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|||VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features|A Multicenter, Open-Label, Phase 2 Study of VELCADE (Bortezomib) for Injection in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma With Bronchioloalveolar Features|Terminated||Phase 2|||Millennium Pharmaceuticals, Inc.||||insufficient efficacy|||||||||||||||2018-06-01 04:53:51.881619|2018-06-01 04:53:51.881619
NCT00117338|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-03-16||2017-03-09|2005-06-30|2005-07-06|Estimate|2009-06-26|2009-08-11|Estimate||||2017-03-09|2017-04-06|Actual|July 2005||2005-07-31|March 2017|2017-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)|A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Pediatric Patients (Ages 6 to 14 Years) With Acute Asthma|Completed||Phase 3|276|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:53:51.944608|2018-06-01 04:53:51.944608
NCT00117325|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2017-08-11||2018-03-07|2005-06-30|2005-07-06|Estimate|2018-03-07|2018-03-13|Actual||||2018-03-07|2018-03-13|Actual|July 11, 2005|Actual|2005-07-11|August 2017|2017-08-31|February 9, 2006|Actual|2006-02-09|February 9, 2006|Actual|2006-02-09||Interventional|||Study Of Adults And Adolescents With Vasomotor Rhinitis|A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis|Completed||Phase 3|352|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:53:52.485815|2018-06-01 04:53:52.485815
NCT00117312|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-01-22||2011-05-18|2005-06-30|2005-07-06|Estimate|2009-03-19|2009-03-20|Estimate||||2011-05-18|2011-05-23|Estimate|October 2002||2002-10-31|May 2011|2011-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients|Terminated||Phase 2|37|Actual|Ferring Pharmaceuticals||4||After 190 weeks [7 patients left] it was terminated for administrative reasons|f||||t||||||||||2018-06-01 04:53:55.410645|2018-06-01 04:53:55.410645
NCT00117299|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2010-05-25|2005-06-30|2005-07-06|Estimate|||||||2010-05-25|2010-05-27|Estimate|September 2004||2004-09-30|May 2010|2010-05-31|January 2009|Actual|2009-01-31|September 2007|Actual|2007-09-30||Interventional|||PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib|A Phase II, Open-Label Study of PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors (GISTs) Resistant to Imatinib Mesylate|Completed||Phase 2|45|Actual|Helsinki University||1|||f||||f||||||||||2018-06-01 04:53:57.249424|2018-06-01 04:53:57.249424
NCT00117286|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2010-09-29||2010-09-29|2005-06-30|2005-07-06|Estimate|2010-09-29|2010-10-21|Estimate||||2010-09-29|2010-10-21|Estimate|March 2005||2005-03-31|September 2010|2010-09-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer|An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Patients With Prostate Cancer|Completed||Phase 2/Phase 3|57|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-06-01 04:53:57.381817|2018-06-01 04:53:57.381817
NCT00117273|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2014-05-08|2005-06-30|2005-07-06|Estimate|||||||2014-05-08|2014-05-09|Estimate|June 2005||2005-06-30|May 2014|2014-05-31|June 2006||2006-06-30|||||Interventional|||A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens|A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills|Completed||Phase 3|36|Anticipated|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 04:53:58.210057|2018-06-01 04:53:58.210057
NCT00117260|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-08-08|2005-06-30|2005-07-06|Estimate|||||||2013-08-08|2013-08-12|Estimate|July 2005||2005-07-31|August 2013|2013-08-31|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||Study to Evaluate the Safety and Efficacy of Seasonale for Treatment of Low Bone Mineral Density|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a 91-Day Extended-Cycle Combination Oral Contraceptive (Seasonale) for the Treatment of Low Bone Mineral Density in Adolescent Females With Secondary Amenorrhea and Osteopenia|Withdrawn||Phase 3|0|Actual|Teva Pharmaceutical Industries||||Sponsor decision|||||||||||||||2018-06-01 04:53:58.286515|2018-06-01 04:53:58.286515
NCT00117247|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-10-15|2005-06-30|2005-07-06|Estimate|||||||2009-10-15|2009-10-16|Estimate|June 2002||2002-06-30|October 2009|2009-10-31|July 2004||2004-07-31|||||Interventional|||A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects|A Study to Assess the Pharmacokinetics and Pharmacodynamics of Repeat-Sose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects|Completed||Phase 1/Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:53:58.348233|2018-06-01 04:53:58.348233
NCT00117234|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2010-12-02|2005-06-30|2005-07-06|Estimate|||||||2010-12-02|2010-12-03|Estimate|September 2002||2002-09-30|December 2010|2010-12-31|July 2004||2004-07-31|||||Interventional|||Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia|A Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia|Completed||N/A|||Amgen|||||f||||||||||||||2018-06-01 04:53:58.416444|2018-06-01 04:53:58.416444
NCT00117221|ClinicalTrials.gov processed this data on May 31, 2018|2005-07-02|||2018-05-12|2005-07-02|2005-07-04|Estimate|||||||2018-05-12|2018-05-15|Actual|June 28, 2005||2005-06-28|February 11, 2014|2014-02-11|February 11, 2014||2014-02-11|||||Observational|||MRI Measurement of Brain Metabolism Across the Sleep-Wake Cycle|MRI Measurement of Brain Metabolism Across the Sleep-Wake Cycle|Completed|||56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:53:58.492762|2018-06-01 04:53:58.492762
NCT00117208|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2010-01-31|2005-07-01|2005-07-04|Estimate|||||||2010-01-31|2010-02-02|Estimate|November 2005||2005-11-30|January 2010|2010-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis|A Cross-Over Comparative Study of Inhaled Mannitol, Alone and in Combination With Daily rhDNase, in Children With Cystic Fibrosis|Completed||Phase 2|20|Actual|Pharmaxis||3|||f||||||||||||||2018-06-01 04:53:58.560494|2018-06-01 04:53:58.560494
NCT00117195|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2012-02-08|2005-06-30|2005-07-04|Estimate|||||||2012-02-08|2012-02-09|Estimate|May 2003||2003-05-31|February 2012|2012-02-29|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|||A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease|Open-Label Validation Study of Neurophysiologic Changes in Individuals With Parkinson's Disease, at Risk for Parkinson's Disease and Healthy Controls|Completed|||620|Actual|Institute for Neurodegenerative Disorders|||1||f||||t||||||Samples Without DNA|"~     In addition, the study will evaluate serum samples for changes in proteins or metabolites~     that may be indicators of early changes associated with Parkinson's disease or parkinsonian~     syndrome.~   "|||2018-06-01 04:53:58.697172|2018-06-01 04:53:58.697172
NCT00117182|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2016-04-18|2005-07-01|2005-07-04|Estimate|||||||2016-04-18|2016-04-20|Estimate|July 2005||2005-07-31|April 2016|2016-04-30|August 2006||2006-08-31|||||Interventional|||Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD|A Phase II Study to Investigate Mannitol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD|Completed||Phase 2|140||Pharmaxis|||||f||||||||||||||2018-06-01 04:53:58.77925|2018-06-01 04:53:58.77925
NCT00117169|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2012-10-12|2005-07-01|2005-07-04|Estimate|||||||2012-10-12|2012-10-15|Estimate|January 2005||2005-01-31|October 2012|2012-10-31|October 2006||2006-10-31|||||Interventional|||Multi-Detector Spiral Computed Tomography Alone Versus Combined Strategy With Lower Limb Compression Ultrasonography in Outpatients Suspected of Pulmonary Embolism|Multi-Detector Spiral Computed Tomography Alone Versus Combined Strategy With Lower Limb Compression Ultrasonography in Outpatients Suspected of Pulmonary Embolism: A Randomised Non-Inferiority Trial [CTEP4]|Completed||N/A|1500||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:53:58.883094|2018-06-01 04:53:58.883094
NCT00117156|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2014-09-26||2016-07-28|2005-06-30|2005-07-04|Estimate|2014-10-03|2014-10-06|Estimate||||2016-07-28|2016-08-01|Estimate|December 2003||2003-12-31|July 2016|2016-07-31|January 2012|Actual|2012-01-31|October 2008|Actual|2008-10-31||Interventional|||Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma|A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma|Completed||Phase 2|26|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:53:58.971922|2018-06-01 04:53:58.971922
NCT00117143|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-05-21|2005-06-30|2005-07-04|Estimate|||||||2009-05-21|2009-05-22|Estimate||||May 2009|2009-05-31||||||||Interventional|||Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)|An Open-Label, Unit Dose-Finding Study Evaluating the Safety and Efficacy of Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)|Completed||Phase 1/Phase 2|||Amgen|||||f||||||||||||||2018-06-01 04:53:59.328955|2018-06-01 04:53:59.328955
NCT00117130|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-01-20|2005-06-30|2005-07-04|Estimate|||||||2011-01-20|2011-01-21|Estimate||||January 2011|2011-01-31||||||||Interventional|||Study to Evaluate Effectiveness of Aranesp®|Aranesp® Monthly Preference Study|Completed||Phase 4|||Amgen|||||f||||||||||||||2018-06-01 04:53:59.393064|2018-06-01 04:53:59.393064
NCT00117117|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-03-24|2005-06-30|2005-07-04|Estimate|||||||2009-03-24|2009-03-25|Estimate|September 2002||2002-09-30|March 2009|2009-03-31|December 2003||2003-12-31|||||Interventional|||A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®|A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®|Completed||Phase 4|2423||Amgen|||||f||||||||||||||2018-06-01 04:53:59.46912|2018-06-01 04:53:59.46912
NCT00117104|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-10-15|2005-06-30|2005-07-04|Estimate|||||||2009-10-15|2009-10-16|Estimate||||October 2009|2009-10-31||||||||Interventional|||Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis|A Multicenter Study Evaluating Once Weekly Intravenous Administration of Aranesp® in Subjects With End Stage Renal Disease on Chronic Hemodialysis|Completed||Phase 4|||Amgen|||||f||||||||||||||2018-06-01 04:53:59.526061|2018-06-01 04:53:59.526061
NCT00117091|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-12-20|2005-06-30|2005-07-04|Estimate|||||||2007-12-20|2007-12-24|Estimate||||December 2007|2007-12-31||||||||Interventional|||Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)|An Open-Label Multicentre Study of Anakinra (Kineret®) in Combination With DMARDS in Subjects With Active Rheumatoid Arthritis (RA)|Completed||Phase 3|||Amgen|||||f||||||||||||||2018-06-01 04:53:59.584407|2018-06-01 04:53:59.584407
NCT00117078|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-09-29|2005-06-30|2005-07-04|Estimate|||||||2008-09-29|2008-09-30|Estimate||||September 2008|2008-09-30||||||||Interventional|||Aranesp® Monthly Preference Study - 2|Aranesp® Monthly Preference Study - 2|Completed||Phase 4|||Amgen|||||f||||||||||||||2018-06-01 04:53:59.646762|2018-06-01 04:53:59.646762
NCT00117065|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-04-24|2005-06-30|2005-07-04|Estimate|||||||2013-04-24|2013-04-26|Estimate||||April 2013|2013-04-30||||||||Interventional|||Study of Transplant Related Anemia Treated With Aranesp® (STRATA)|Study of Transplant Related Anemia Treated With Aranesp® (STRATA)|Completed||Phase 4|||Amgen|||||f||||||||||||||2018-06-01 04:53:59.714502|2018-06-01 04:53:59.714502
NCT00117052|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-05-21|2005-06-30|2005-07-04|Estimate|||||||2013-05-21|2013-05-23|Estimate|September 2004||2004-09-30|May 2013|2013-05-31|February 2006|Actual|2006-02-28|November 2005|Actual|2005-11-30||Interventional|||SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism|SENSOR: Study to InvestigatE Cinacalcet TreatmeNt in Haemodialysis Patients With SecOndary HyperparathyRoidism|Completed||Phase 3|673|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:53:59.781218|2018-06-01 04:53:59.781218
NCT00117039|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-10-14|2005-06-30|2005-07-04|Estimate|||||||2008-10-14|2008-10-15|Estimate|January 2004||2004-01-31|August 2008|2008-08-31|April 2005||2005-04-30|||||Interventional|||A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia|SYNCHRONICITY: A Study to Evaluate the Effectiveness of Aranesp® at 300 Mcg Q3W on Clinical Outcomes in Cancer Patients With Anemia Due to Chemotherapy|Completed||Phase 4|1500||Amgen|||||f||||||||||||||2018-06-01 04:53:59.887936|2018-06-01 04:53:59.887936
NCT00117026|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2013-05-08|2005-06-30|2005-07-04|Estimate|||||||2013-05-08|2013-05-10|Estimate|August 2005||2005-08-31|May 2013|2013-05-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Effects of Vitamin B1 in Type 1 Diabetic Patients|Can Oral Benfotiamine Supplementation Influence Progression of Microvascular Complications in Patients With Type 1 Diabetes?|Completed||Phase 1/Phase 2|67|Actual|Oslo University Hospital||2|||f||||||||||||||2018-06-01 04:53:59.956621|2018-06-01 04:53:59.956621
NCT00117013|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2017-06-30|2005-06-30|2005-07-01|Estimate|||||||2017-06-30|2017-07-02|Actual|June 28, 2005||2005-06-28|August 25, 2011|2011-08-25|October 25, 2010|Actual|2010-10-25|October 25, 2010|Actual|2010-10-25||Interventional|||A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a|A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha|Completed||Phase 1|16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:00.05801|2018-06-01 04:54:00.05801
NCT00115180|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2016-01-05|2005-06-21|2005-06-22|Estimate|||||||2016-01-05|2016-01-07|Estimate|September 2003||2003-09-30|November 2005|2005-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Racial and Ethnic Disparities in Acute Pain Control|Racial and Ethnic Disparities in Acute Pain Control|Completed|||285|Actual|Agency for Healthcare Research and Quality (AHRQ)|||3||f||||f||||||||No||2018-06-01 04:54:28.096838|2018-06-01 04:54:28.096838
NCT00117000|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2006-09-07|2005-06-30|2005-07-01|Estimate|||||||2006-09-07|2006-09-11|Estimate|July 2003||2003-07-31|September 2006|2006-09-30|February 2007||2007-02-28|||||Interventional|||The Effects of Testosterone and Nutritional Supplementation in the Undernourished Elderly|The Effects of Testosterone and Nutritional Supplementation, Alone and Combined, on the Adverse Effects of Under-Nutrition in the Elderly|Unknown status|Active, not recruiting|Phase 3|200||University of Adelaide|||||f||||||||||||||2018-06-01 04:54:00.156394|2018-06-01 04:54:00.156394
NCT00116987|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2015-06-11|2005-06-30|2005-07-01|Estimate|||||||2015-06-11|2015-06-15|Estimate|August 2003||2003-08-31|June 2015|2015-06-30|November 2009|Actual|2009-11-30|September 2008|Actual|2008-09-30||Interventional|||Dual Chamber Versus Single Chamber Cardiac Pacing in People 80 Years of Age and Older|Pacing the Octogenarian Plus Population (POPP) A Comparison of Physiologic Versus Ventricular Pacing in Those Who Are 80 Years of Age and Older|Terminated||N/A|800|Anticipated|University of Calgary||2||Unable to recruit adequate number of participants in required time frame.|f||||f||||||||||2018-06-01 04:54:00.276646|2018-06-01 04:54:00.276646
NCT00116974|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2016-08-12|2005-06-30|2005-07-01|Estimate|||||||2016-08-12|2016-08-15|Estimate|October 2004||2004-10-31|August 2016|2016-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Periodontal Infection and Prematurity Study|Periodontal Infection and Prematurity Study|Terminated||Phase 3|2100|Anticipated|University of Pennsylvania||2||Protocol Expired. Terminated by IRB|f||||||||||||||2018-06-01 04:54:00.376363|2018-06-01 04:54:00.376363
NCT00116961|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2012-02-05|2005-06-30|2005-07-01|Estimate|||||||2012-02-05|2012-02-07|Estimate|June 2005||2005-06-30|February 2012|2012-02-29|December 2007|Actual|2007-12-31|January 2007|Actual|2007-01-31||Interventional|||Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma|A Phase II Study of Combination of Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma|Completed||Phase 2|40|Actual|University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 04:54:00.519283|2018-06-01 04:54:00.519283
NCT00116948|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2014-12-03|2005-06-30|2005-07-01|Estimate|||||||2014-12-03|2014-12-05|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter|A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter|Completed||Phase 4|50|Anticipated|University of Aarhus|||||f||||f||||||||||2018-06-01 04:54:00.587695|2018-06-01 04:54:00.587695
NCT00116935|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-12-28|2005-06-30|2005-07-01|Estimate|||||||2011-12-28|2011-12-30|Estimate|February 2004||2004-02-29|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)|Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence|Completed||Phase 3|400|Actual|Scandinavian Sarcoma Group||2|||f||||f||||||||||2018-06-01 04:54:00.687335|2018-06-01 04:54:00.687335
NCT00116922|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2012-05-22|2005-06-30|2005-07-01|Estimate|||||||2012-05-22|2012-05-24|Estimate|June 2004||2004-06-30|May 2012|2012-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Lifestyle and Combination Medication Therapy Diabetes Prevention Study|CAnadian Normoglycemia Outcomes Evaluation Study|Completed||Phase 3|207|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||1|||f||||t||||||||||2018-06-01 04:54:00.757671|2018-06-01 04:54:00.757671
NCT00116909|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-03-13|2005-06-30|2005-07-01|Estimate|||||||2007-03-13|2007-03-14|Estimate|August 2004||2004-08-31|March 2007|2007-03-31|August 2005||2005-08-31|||||Interventional|||A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy|A Phase II Study of Single-Agent OSI-7904L in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed First-Line Therapy|Completed||Phase 2|85||OSI Pharmaceuticals|||||||||||||||||||2018-06-01 04:54:00.830633|2018-06-01 04:54:00.830633
NCT00116896|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-01-16|2005-06-30|2005-07-01|Estimate|||||||2009-01-16|2009-01-21|Estimate|June 2003||2003-06-30|November 2003|2003-11-30|December 2004||2004-12-31|||||Interventional|||Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors|Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors|Completed||Phase 1|25||OSI Pharmaceuticals|||||||||||||||||||2018-06-01 04:54:00.880079|2018-06-01 04:54:00.880079
NCT00116883|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2016-09-13|2005-06-30|2005-07-01|Estimate|||||||2016-09-13|2016-09-15|Estimate|February 2005||2005-02-28|September 2016|2016-09-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics|A Randomized, Double-blind, Parallel Group, Placebo Controlled, 6-week Study of the Effect of GW685698X Aqueous Nasal Spray 100mcg QD on the Hypothalamic Pituitary Adrenocortical (HPA) Axis in Children 2 to 11 Years of Age With Perennial Allergic Rhinitis (PAR).|Completed||Phase 3|90|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:54:00.924118|2018-06-01 04:54:00.924118
NCT00116870|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2009-12-09|2005-06-30|2005-07-01|Estimate|||||||2009-12-09|2009-12-11|Estimate|June 1985||1985-06-30|June 2005|2005-06-30|February 1992|Actual|1992-02-29|February 1992|Actual|1992-02-29||Interventional|||MARS - Monitored Atherosclerosis Regression Study|A Double-Blind, Placebo-Controlled Angiographic Study to Evaluate the Effect of Lovastatin on the Progression Rate of Atherosclerosis in the Coronary Arteries of Patients With Coronary Heart Disease|Completed||Phase 2/Phase 3|270||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:54:01.126676|2018-06-01 04:54:01.126676
NCT00116857|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2012-07-03||2012-09-11|2005-06-30|2005-07-01|Estimate|2012-09-11|2012-09-12|Estimate||||2012-09-11|2012-09-12|Estimate|February 2005||2005-02-28|September 2012|2012-09-30|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors|Omega-3 for Depression and Other Cardiac Risk Factors|Completed||Phase 3|122|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 04:54:01.198233|2018-06-01 04:54:01.198233
NCT00116844|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2017-03-16||2017-08-02|2005-06-30|2005-07-01|Estimate|2017-08-02|2018-02-12|Actual||||2017-08-02|2018-02-12|Actual|March 29, 2005|Actual|2005-03-29|August 2017|2017-08-31|January 10, 2006|Actual|2006-01-10|January 10, 2006|Actual|2006-01-10||Interventional||The ITTE population was defined as consisting of all participants who received at least one dose of investigational product and at least one safety and/or efficacy evaluation.|VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.|Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH|Completed||Phase 4|73|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:54:01.447978|2018-06-01 04:54:01.447978
NCT00116831|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-08-07||2017-03-21|2005-06-30|2005-07-01|Estimate|2010-03-10|2010-03-31|Estimate||||2017-03-21|2017-03-23|Actual|January 2005||2005-01-31|March 2017|2017-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes|A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)|Completed||Phase 3|672|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:54:02.133568|2018-06-01 04:54:02.133568
NCT00116818|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2016-09-13|2005-06-30|2005-07-01|Estimate|||||||2016-09-13|2016-09-15|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults|A Randomized, Double-blind, Parallel Group, Placebo and Active (Prednisone) Controlled, 6-week Study of the Effect of Fluticasone Furoate Aqueous Nasal Spray 100mcg QD on the Hypothalamic Pituitary Adrenocortical (HPA) Axis in Adolescents and Adults 12 to 65 Years of Age With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|90|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:54:04.032924|2018-06-01 04:54:04.032924
NCT00116805|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2010-02-11||2017-01-26|2005-06-30|2005-07-01|Estimate|2010-04-29|2010-05-19|Estimate||||2017-01-26|2017-03-09|Actual|June 2005|Actual|2005-06-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|May 2007|Actual|2007-05-31||Interventional||Randomized and Treated Analysis Set: all participants who were randomized and received at least one dose of study medication.|A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B|A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B|Completed||Phase 3|266|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-06-01 04:54:04.2724|2018-06-01 04:54:04.2724
NCT00116792|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-05-15|2005-06-30|2005-07-01|Estimate|||||||2007-05-15|2007-05-17|Estimate|March 2004||2004-03-31|May 2007|2007-05-31||||||||Interventional|||PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions|PROVIDENCE: Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions|Unknown status|Active, not recruiting|Phase 2/Phase 3|120|Anticipated|Gold, Herman K., MD|||||||||||||||||||2018-06-01 04:54:06.326673|2018-06-01 04:54:06.326673
NCT00116779|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2009-01-22||2011-12-15|2005-06-30|2005-07-01|Estimate|2009-03-19|2009-03-20|Estimate||||2011-12-15|2011-12-19|Estimate|February 2004||2004-02-29|December 2011|2011-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer|An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles|Completed||Phase 2|127|Actual|Ferring Pharmaceuticals||2|||f||||t||||||||||2018-06-01 04:54:06.485183|2018-06-01 04:54:06.485183
NCT00116766|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2016-09-01|2005-06-30|2005-07-01|Estimate|||||||2016-09-01|2016-09-02|Estimate|July 2005||2005-07-31|February 2007|2007-02-28|September 2006|Actual|2006-09-30|||||Interventional|||Field Evaluation of Plant-based Mosquito Control|Field Evaluation of Malaria Vector Control Using Traditional Plant-based Anti-mosquito Measures in Yunnan Province, P.R. China|Completed||Phase 2|240|Actual|London School of Hygiene and Tropical Medicine|||||f||||f||||||||||2018-06-01 04:54:07.366321|2018-06-01 04:54:07.366321
NCT00116753|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2010-10-06||2010-11-12|2005-06-30|2005-07-01|Estimate|2010-11-12|2010-12-10|Estimate||||2010-11-12|2010-12-10|Estimate|January 2005||2005-01-31|November 2010|2010-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer|An Open-label Multi-center, Randomized Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer|Completed||Phase 2|460|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-06-01 04:54:07.456973|2018-06-01 04:54:07.456973
NCT00116740|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2010-03-24|2005-06-30|2005-07-01|Estimate|||||||2010-03-24|2010-03-25|Estimate|June 2005||2005-06-30|December 2006|2006-12-31|November 2005||2005-11-30|||||Interventional|||Safety and Efficacy of APD356 in the Treatment of Obesity|A 12-Week, Dose-Ranging, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of APD356 in Obese Patients|Completed||Phase 2|400||Arena Pharmaceuticals|||||||||||||||||||2018-06-01 04:54:08.626991|2018-06-01 04:54:08.626991
NCT00116727|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-05-05|2005-06-30|2005-07-01|Estimate|||||||2011-05-05|2011-05-06|Estimate|October 2002||2002-10-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|June 2008|Actual|2008-06-30||Observational|||Rheumatoid Arthritis DMARD Intervention and UtilizationStudy|Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 2)|Completed|||5103|Actual|Amgen|||1||f||||||||||||||2018-06-01 04:54:08.688678|2018-06-01 04:54:08.688678
NCT00116714|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2011-05-05|2005-06-30|2005-07-01|Estimate|||||||2011-05-05|2011-05-06|Estimate|October 2001||2001-10-31|May 2011|2011-05-31|October 2008|Actual|2008-10-31|December 2007|Actual|2007-12-31||Observational|||Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy|Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 1)|Completed|||4968|Actual|Amgen|||1||f||||||||||||||2018-06-01 04:54:08.745002|2018-06-01 04:54:08.745002
NCT00116701|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2008-05-01|2005-06-30|2005-07-01|Estimate|||||||2008-05-01|2008-05-05|Estimate|May 2005||2005-05-31|May 2008|2008-05-31||||||||Interventional|||Treatment for Subjects With Chronic Kidney Disease Receiving Haemodialysis|A Study to Evaluate the Efficacy of Converting From Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects With Chronic Kidney Disease Receiving Haemodialysis|Completed||Phase 3|200||Amgen|||||f||||||||||||||2018-06-01 04:54:08.825214|2018-06-01 04:54:08.825214
NCT00116688|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2011-03-04||2013-11-25|2005-06-30|2005-07-01|Estimate|2011-03-04|2011-04-06|Estimate||||2013-11-25|2013-12-18|Estimate|August 2004||2004-08-31|November 2013|2013-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|Completed||Phase 3|313|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:54:08.91603|2018-06-01 04:54:08.91603
NCT00114426|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2005-08-16|2005-06-14|2005-06-15|Estimate|||||||2005-08-16|2005-08-17|Estimate|January 2002||2002-01-31|February 2005|2005-02-28|December 2004||2004-12-31|||||Interventional|||Effects of NIMV on the Health Status of Chronic Obstructive Pulmonary Disease (COPD )Patients|Effects of Nocturnal Noninvasive Mechanical Ventilation on the Health Status of Patients With COPD|Terminated||Phase 3|40||University of British Columbia|||||f||||||||||||||2018-06-01 04:54:41.788807|2018-06-01 04:54:41.788807
NCT00116675|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-02-16|2005-06-30|2005-07-01|Estimate|||||||2007-02-16|2007-02-19|Estimate|March 2005||2005-03-31|June 2006|2006-06-30|April 2006||2006-04-30|||||Interventional|||Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects|A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects|Completed||Phase 2|84||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:54:09.925298|2018-06-01 04:54:09.925298
NCT00116662|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|||2007-02-16|2005-06-30|2005-07-01|Estimate|||||||2007-02-16|2007-02-19|Estimate|March 2005||2005-03-31|November 2006|2006-11-30||||||||Interventional|||An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects|A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects|Completed||Phase 2|84||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:54:09.995311|2018-06-01 04:54:09.995311
NCT00116649|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-30|2008-10-21||2010-07-14|2005-06-30|2005-07-01|Estimate|2008-11-19|2008-11-25|Estimate||||2010-07-14|2010-07-20|Estimate|June 2005||2005-06-30|July 2010|2010-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis|Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis|Completed||Phase 4|551|Actual|Graceway Pharmaceuticals, LLC||1|||f||||f||||||||||2018-06-01 04:54:10.078359|2018-06-01 04:54:10.078359
NCT00116636|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2017-04-27|2005-06-29|2005-06-30|Estimate|||||||2017-04-27|2017-05-01|Actual|June 2005||2005-06-30|June 2005|2005-06-30|December 2007|Actual|2007-12-31|||||Interventional|||Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients|A Phase II, Open Label, Single Arm Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) as a Single Agent in a Cohort of HIV Positive Adult Patients|Completed||Phase 2|40|Anticipated|Therapeutic Concepts|||||f||||||||||||||2018-06-01 04:54:10.383724|2018-06-01 04:54:10.383724
NCT00116623|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2016-08-12|2005-06-29|2005-06-30|Estimate|||||||2016-08-12|2016-08-15|Estimate|February 2003||2003-02-28|August 2016|2016-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Magnesium Sulfate Versus Indomethacin for Preterm Labor||Terminated||Phase 4|||University of Pennsylvania||||Funding completed|f||||||||||||||2018-06-01 04:54:10.470955|2018-06-01 04:54:10.470955
NCT00116610|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2009-01-19|2005-06-29|2005-06-30|Estimate|||||||2009-01-19|2009-01-21|Estimate|June 2005||2005-06-30|February 2007|2007-02-28|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer|A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer|Completed||Phase 2|75||Poniard Pharmaceuticals|||||f||||||||||||||2018-06-01 04:54:10.518925|2018-06-01 04:54:10.518925
NCT00116597|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2009-12-01|2005-06-29|2005-06-30|Estimate|||||||2009-12-01|2009-12-02|Estimate|November 2002||2002-11-30|December 2009|2009-12-31|December 2008|Actual|2008-12-31|July 2007|Actual|2007-07-31||Interventional|||Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma|Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma|Completed||Phase 1/Phase 2|15|Actual|University Hospital, Basel, Switzerland|||||f||||t||||||||||2018-06-01 04:54:10.628899|2018-06-01 04:54:10.628899
NCT00116584|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2013-06-17|2005-06-29|2005-06-30|Estimate|||||||2013-06-17|2013-06-18|Estimate|December 2004||2004-12-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|March 2008|Actual|2008-03-31||Interventional|||Heliox-Driven Racemic Epinephrine Nebulization in Treatment of Moderate to Severe Bronchiolitis in Pediatric ED Patients|The Use of Heliox Driven Racemic Epinephrine Nebulization in the Treatment of Moderate to Severe Bronchiolitis in Pediatric Emergency Department Patients|Completed||Phase 3|72|Actual|University of Louisville||1|||f||||f||||||||||2018-06-01 04:54:10.797174|2018-06-01 04:54:10.797174
NCT00116571|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2006-10-02|2005-06-29|2005-06-30|Estimate|||||||2006-10-02|2006-10-03|Estimate|May 2005||2005-05-31|May 2006|2006-05-31|December 2006||2006-12-31|||||Interventional|||Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)|A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy With Lemuteporfin in Subjects With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia|Terminated||Phase 2|180||QLT Inc.|||||||||||||||||||2018-06-01 04:54:10.897402|2018-06-01 04:54:10.897402
NCT00116558|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2008-01-08|2005-06-29|2005-06-30|Estimate|||||||2008-01-08|2008-01-15|Estimate|August 2004||2004-08-31|January 2008|2008-01-31|October 2008|Anticipated|2008-10-31|July 2008|Anticipated|2008-07-31||Interventional|||Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation (NIPPV)|Early Treatment of Amyotrophic Lateral Sclerosis With Nutrition and Non-Invasive Positive Pressure Ventilation|Unknown status|Active, not recruiting|N/A|220|Anticipated|National Institute of Neurological Disorders and Stroke (NINDS)||2|||f||||t||||||||||2018-06-01 04:54:10.994811|2018-06-01 04:54:10.994811
NCT00116545|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2009-12-09|2005-06-29|2005-06-30|Estimate|||||||2009-12-09|2009-12-11|Estimate|January 1997||1997-01-31|June 2005|2005-06-30|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||TART - Troglitazone Atherosclerosis Regression Trial|TART - Troglitazone Atherosclerosis Regression Trial|Completed||Phase 2/Phase 3|288||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:54:11.097406|2018-06-01 04:54:11.097406
NCT00116532|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2007-04-23|2005-06-29|2005-06-30|Estimate|||||||2007-04-23|2007-04-24|Estimate|October 2002||2002-10-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)|Escitalopram for the Treatment of Obsessive Compulsive Disorder|Completed||Phase 4|30||Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:54:11.17247|2018-06-01 04:54:11.17247
NCT00116519|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2007-01-24|2005-06-29|2005-06-30|Estimate|||||||2007-01-24|2007-01-26|Estimate|July 2005||2005-07-31|January 2007|2007-01-31|October 2006||2006-10-31|||||Interventional|||A Study in People With Abnormal Fat Levels in the Blood|PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly|Completed||Phase 2|300||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:54:11.243358|2018-06-01 04:54:11.243358
NCT00116506|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2007-12-19|2005-06-29|2005-06-30|Estimate|||||||2007-12-19|2007-12-21|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer|A Phase II Study of Bevacizumab (Avastin™) and Erlotinib (Tarceva™) in Combination With FOLFOX for Patients With Untreated Metastatic Colorectal Cancer|Completed||Phase 2|35||Dana-Farber Cancer Institute|||||f||||||||||||||2018-06-01 04:54:11.401682|2018-06-01 04:54:11.401682
NCT00116493|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2012-04-06|2005-06-29|2005-06-30|Estimate|||||||2012-04-06|2012-04-09|Estimate|April 2004||2004-04-30|April 2012|2012-04-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Severe Anemia Treatment Trials, Pakistan|Evaluation of Anthelminthics and Multivitamins for Treatment of Severe Anemia in Pregnant Women and Children 6-24 Months of Age in Pakistan|Completed||Phase 3|1009|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||t||||||||||2018-06-01 04:54:11.47942|2018-06-01 04:54:11.47942
NCT00116480|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2009-03-17|2005-06-29|2005-06-30|Estimate|||||||2009-03-17|2009-03-19|Estimate|December 2005||2005-12-31|March 2009|2009-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Misoprostol in the Treatment of Postpartum Hemorrhage|Misoprostol in the Treatment of Post Partum Hemorrhage: A Placebo Randomised Controlled Trial in 4 Karachi Hospitals|Completed||N/A|61|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-06-01 04:54:11.579239|2018-06-01 04:54:11.579239
NCT00116467|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2007-12-18|2005-06-29|2005-06-30|Estimate|||||||2007-12-18|2007-12-24|Estimate|March 2001||2001-03-31|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|||Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia|Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line|Completed||Phase 2|55||Cell Genesys|||||||||||||||||||2018-06-01 04:54:11.682775|2018-06-01 04:54:11.682775
NCT00116454|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2013-09-20|2005-06-29|2005-06-30|Estimate|||||||2013-09-20|2013-09-23|Estimate|July 2005||2005-07-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|Lipiocis||Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis|A Randomized and Multicenter Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis|Completed||Phase 3|73|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-06-01 04:54:11.750768|2018-06-01 04:54:11.750768
NCT00116441|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|||2007-12-18|2005-06-29|2005-06-30|Estimate|||||||2007-12-18|2007-12-24|Estimate|October 2000||2000-10-31|December 2007|2007-12-31|October 2004||2004-10-31|||||Interventional|||Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma|Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line|Completed||Phase 1/Phase 2|22||Cell Genesys|||||||||||||||||||2018-06-01 04:54:11.835803|2018-06-01 04:54:11.835803
NCT00116428|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29|2013-02-11||2017-09-22|2005-06-29|2005-06-30|Estimate|2013-02-11|2013-03-14|Estimate||||2017-09-22|2017-10-24|Actual|October 1, 2004|Actual|2004-10-01|September 2017|2017-09-30|March 1, 2011|Actual|2011-03-01|October 1, 2007|Actual|2007-10-01||Interventional|Afib IDE||NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation|NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation|Completed||Phase 3|167|Actual|Biosense Webster, Inc.||2|||f||||t||||||||||2018-06-01 04:54:11.91795|2018-06-01 04:54:11.91795
NCT00116415|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-29||2010-01-27|2011-04-08|2005-06-29|2005-06-30|Estimate||||2010-01-27|2010-02-17|Estimate|2011-04-08|2011-04-22|Estimate|March 2002||2002-03-31|April 2011|2011-04-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy|Daily Antiretroviral Therapy (DART 1): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Didanosine Enteric Coated (Ddl-EC) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Patients|Completed||N/A|65||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:54:12.483664|2018-06-01 04:54:12.483664
NCT00116402|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2014-08-04|2005-06-28|2005-06-29|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2005||2005-01-31|August 2014|2014-08-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations|A Pilot Study of the Mechanism of Synergism Between Fluticasone (FP) and Salmeterol in Preventing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations|Completed||Phase 1|15|Actual|University of Chicago||2|||f||||t||||||||||2018-06-01 04:54:12.577027|2018-06-01 04:54:12.577027
NCT00116389|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2007-06-07|2005-06-28|2005-06-29|Estimate|||||||2007-06-07|2007-06-08|Estimate||||June 2007|2007-06-30||||||||Interventional|||Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas|An Open-Label Phase 2 Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas|Terminated||Phase 2|60||Point Therapeutics||||FDA Hold May 2007|||||||||||||||2018-06-01 04:54:12.668025|2018-06-01 04:54:12.668025
NCT00116376|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2015-11-07|2005-06-28|2005-06-29|Estimate|||||||2015-11-07|2015-11-10|Estimate|January 2004||2004-01-31|November 2015|2015-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)|A Phase I/II, Two-arm, Multicenter, Dose Escalation Study of Oral AEE788 Administered on a Continuous Once Daily Dosing Schedule in Adult Patients With Recurrent or Relapsing Glioblastoma Multiforme|Completed||Phase 1/Phase 2|64|Actual|Novartis||2|||f||||f||||||||||2018-06-01 04:54:12.752636|2018-06-01 04:54:12.752636
NCT00116363|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2008-03-28|2005-06-28|2005-06-29|Estimate|||||||2008-03-28|2008-04-01|Estimate|March 2005||2005-03-31|March 2008|2008-03-31|December 2006|Anticipated|2006-12-31|||||Interventional|||Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma|Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma|Unknown status|Recruiting|Phase 2|25|Anticipated|Introgen Therapeutics|||||t||||t||||||||||2018-06-01 04:54:12.844423|2018-06-01 04:54:12.844423
NCT00116350|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2009-03-17|2005-06-28|2005-06-29|Estimate|||||||2009-03-17|2009-03-19|Estimate|July 2005||2005-07-31|March 2009|2009-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Misoprostol for the Treatment of Postpartum Hemorrhage|Misoprostol for the Treatment of Primary Postpartum Hemorrhage|Completed||N/A|1786|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-06-01 04:54:12.903051|2018-06-01 04:54:12.903051
NCT00116337|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2018-01-30|2005-06-28|2005-06-29|Estimate|||||||2018-01-30|2018-02-01|Actual|September 30, 2004|Actual|2004-09-30|January 2018|2018-01-31|October 31, 2017|Actual|2017-10-31|October 10, 2017|Actual|2017-10-10||Interventional|||Spinal Cord Stimulation to Restore Cough|Spinal Cord Stimulation to Restore Cough|Completed||N/A|17|Actual|Case Western Reserve University||1|||f||||t||||||||||2018-06-01 04:54:12.989989|2018-06-01 04:54:12.989989
NCT00116324|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2007-04-02|2005-06-28|2005-06-29|Estimate|||||||2007-04-02|2007-04-04|Estimate|April 2003||2003-04-30|April 2007|2007-04-30|December 2006|Actual|2006-12-31|||||Interventional|||Predicting the Response to Montelukast by Genetic Variation in Asthmatics|Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism|Completed||Phase 3|150||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:54:13.075101|2018-06-01 04:54:13.075101
NCT00105820|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2003||2003-06-30|February 2007|2007-02-28|March 2006|Actual|2006-03-31|||||Interventional|||Evaluation Study of TIDES Depression Care Quality Improvement Intervention|Well-being Among Veterans Enhancement Study (WAVES)|Completed||N/A|750|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.01174|2018-06-01 04:57:46.01174
NCT00116311|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2007-03-20|2005-06-28|2005-06-29|Estimate|||||||2007-03-20|2007-03-21|Estimate|July 2005||2005-07-31|March 2007|2007-03-31|February 2007||2007-02-28|||||Observational|||Effects of Allergen Inhalation on Adenosine Receptor Expression in Sputum and Peripheral Blood|Effects of Allergen Inhalation on Adenosine Receptor Expression and Mast Cell Activation in Peripheral Blood and Sputum of Asthmatics and Healthy Subjects|Unknown status|Active, not recruiting||20||Groningen Research Institute for Asthma and COPD|||||f||||f||||||||||2018-06-01 04:54:13.129785|2018-06-01 04:54:13.129785
NCT00116298|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28||2010-01-28|2011-04-08|2005-06-28|2005-06-29|Estimate||||2010-01-28|2010-02-01|Estimate|2011-04-08|2011-04-25|Estimate|January 2001||2001-01-31|April 2011|2011-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)|A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies AI455-096 and AI455-099|Completed||Phase 3|900||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:54:13.206613|2018-06-01 04:54:13.206613
NCT00116285|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|||2010-06-16|2005-06-28|2005-06-29|Estimate|||||||2010-06-16|2010-06-17|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|June 2005||2005-06-30|||||Interventional|||Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing|A Single-Blind Phase I Study to Assess the Residual Allergenicity of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL Using Skin Prick Testing|Completed||Phase 1|12||Allergy Therapeutics|||||f||||||||||||||2018-06-01 04:54:13.321533|2018-06-01 04:54:13.321533
NCT00116272|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-28|2015-05-29||2015-08-19|2005-06-28|2005-06-29|Estimate|2015-08-19|2015-09-21|Estimate||||2015-08-19|2015-09-21|Estimate|April 2005||2005-04-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project|OTIS Autoimmune Diseases in Pregnancy Project|Completed|||830|Actual|Amgen|||3||f||||f||||||None Retained|"~     This is a prospective & observational, exposure cohort study~   "|||2018-06-01 04:54:13.431748|2018-06-01 04:54:13.431748
NCT00116259|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2008-08-06|2005-06-27|2005-06-28|Estimate|||||||2008-08-06|2008-08-07|Estimate|March 2005||2005-03-31|August 2008|2008-08-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)|Aripiprazole in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Double Blind Placebo Controlled Trial|Completed||N/A|50|Anticipated|Federal University of Rio Grande do Sul|||||f||||||||||||||2018-06-01 04:54:16.808736|2018-06-01 04:54:16.808736
NCT00116246|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2006-09-07|2005-06-27|2005-06-28|Estimate|||||||2006-09-07|2006-09-08|Estimate|August 2005||2005-08-31|August 2005|2005-08-31|December 2006||2006-12-31|||||Interventional|||McRoberts Manoeuvre Or Pushing Study (McMOPS)||Unknown status|Recruiting|Phase 1|222||University of Melbourne|||||f||||||||||||||2018-06-01 04:54:16.8777|2018-06-01 04:54:16.8777
NCT00116233|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2005-06-27|2005-06-27|2005-06-28|Estimate|||||||2005-06-27|2005-06-28|Estimate||||June 2005|2005-06-30||||||||Interventional|||Pediatric Multicenter Study of REPEL-CV|Peds. Multicenter Study|Unknown status|Recruiting|Phase 2|||SyntheMed|||||||||||||||||||2018-06-01 04:54:16.941772|2018-06-01 04:54:16.941772
NCT00116220|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2017-07-25|2005-06-27|2005-06-28|Estimate|||||||2017-07-25|2017-07-26|Actual|September 1995||1995-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|April 2001|Actual|2001-04-30||Interventional|||Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer|A Phase III Trial of External Beam of Radiotherapy +/- Total Androgen Suppression for High Risk Clinically Organ-Confined Prostate Cancer|Active, not recruiting||Phase 3|226|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 04:54:16.99948|2018-06-01 04:54:16.99948
NCT00116207|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|2014-01-06||2016-06-30|2005-06-27|2005-06-28|Estimate|2015-11-30|2016-01-05|Estimate||||2016-06-30|2016-07-29|Estimate|January 2000||2000-01-31|June 2016|2016-06-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes|Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial|Completed||Phase 3|44|Actual|University of Michigan||2|||f||||t||||||||No||2018-06-01 04:54:17.181787|2018-06-01 04:54:17.181787
NCT00116194|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2010-03-24|2005-06-27|2005-06-28|Estimate|||||||2010-03-24|2010-03-25|Estimate|April 2004||2004-04-30|December 2008|2008-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||The LIFE Study: Lifestyle Interventions and Independence for Elders, Pilot|Physical Exercise to Prevent Disability Pilot Study|Completed||Phase 1/Phase 2|424||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:54:17.493002|2018-06-01 04:54:17.493002
NCT00116181|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2011-03-16|2005-06-27|2005-06-28|Estimate|||||||2011-03-16|2011-03-18|Estimate|October 2004||2004-10-31|March 2011|2011-03-31||||January 2007|Actual|2007-01-31||Interventional|||Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis|A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects With Psoriasis-EASE in Psoriasis|Completed||Phase 3|30|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 04:54:17.577923|2018-06-01 04:54:17.577923
NCT00116168|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|2013-10-17||2013-10-17|2005-06-27|2005-06-28|Estimate|2013-10-17|2013-12-11|Estimate||||2013-10-17|2013-12-11|Estimate|June 2005||2005-06-30|October 2013|2013-10-31|July 2006|Actual|2006-07-31|April 2006|Actual|2006-04-30||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528|A Phase I, Open Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers|Completed||Phase 1|29|Actual|MedImmune LLC||4|||f||||||||||||||2018-06-01 04:54:17.673455|2018-06-01 04:54:17.673455
NCT00116155|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2005-06-27|2005-06-27|2005-06-28|Estimate|||||||2005-06-27|2005-06-28|Estimate||||June 2005|2005-06-30||||||||Interventional|||Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer|A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer|Completed||Phase 1/Phase 2|||Cell Genesys|||||||||||||||||||2018-06-01 04:54:18.269374|2018-06-01 04:54:18.269374
NCT00116142|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2017-07-25|2005-06-27|2005-06-28|Estimate|||||||2017-07-25|2017-07-26|Actual|June 2005||2005-06-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer|Docetaxel Plus 6-month Androgen Suppression and Radiation Therapy Versus 6-month Androgen Suppression and Radiation Therapy for Patients With High Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial|Active, not recruiting||Phase 3|350|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 04:54:18.315584|2018-06-01 04:54:18.315584
NCT00116129|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2012-08-02|2005-06-27|2005-06-28|Estimate|||||||2012-08-02|2012-08-06|Estimate|July 2005||2005-07-31|August 2012|2012-08-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in the Treatment of Primary Fibromyalgia|Completed||Phase 2|64|Actual|Bennett, Robert, M.D.||1|||f||||f||||||||||2018-06-01 04:54:18.380413|2018-06-01 04:54:18.380413
NCT00116116|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27||2010-01-27|2011-04-14|2005-06-27|2005-06-28|Estimate||||2010-01-27|2010-02-15|Estimate|2011-04-14|2011-04-26|Estimate|March 2002||2002-03-31|April 2011|2011-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy|Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release (d4T XR) in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily in Anti-Retroviral Therapy (ART) Naive HIV-Infected Subjects|Completed||Phase 4|70||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:54:18.449909|2018-06-01 04:54:18.449909
NCT00116103|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-27|||2012-06-06|2005-06-27|2005-06-28|Estimate|||||||2012-06-06|2012-06-07|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|April 2006|Actual|2006-04-30|||||Interventional|||A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma|Completed||Phase 2|||Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:54:18.544284|2018-06-01 04:54:18.544284
NCT00116090|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2017-06-30|2005-06-25|2005-06-27|Estimate|||||||2017-06-30|2017-07-02|Actual|June 16, 2005||2005-06-16|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study|Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study|Completed|||6300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:18.681508|2018-06-01 04:54:18.681508
NCT00116077|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2017-06-30|2005-06-25|2005-06-27|Estimate|||||||2017-06-30|2017-07-02|Actual|June 21, 2005||2005-06-21|November 12, 2010|2010-11-12|November 12, 2010||2010-11-12|||||Observational|||Dopamine Receptor Imaging in Mood Disorders|Dopamine Receptor Imaging in Mood Disorders|Completed|||145|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:18.750037|2018-06-01 04:54:18.750037
NCT00116064|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2006-07-20|2005-06-26|2005-06-27|Estimate|||||||2006-07-20|2006-07-21|Estimate|July 2004||2004-07-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions|A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children|Completed||Phase 3|156||University of Malawi College of Medicine|||||f||||||||||||||2018-06-01 04:54:18.807134|2018-06-01 04:54:18.807134
NCT00116051|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2009-07-06|2005-06-26|2005-06-27|Estimate|||||||2009-07-06|2009-07-07|Estimate|September 2004||2004-09-30|July 2009|2009-07-31|April 2006||2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Comparison of Two Surface Materials (Tantalum Versus Titanium Fiber Mesh) of Acetabular Components in Hip Arthroplasty|A Comparison of Two Surface Materials (Tantalum Versus Titanium Fiber Mesh) of Acetabular Components in Hip Arthroplasty|Completed||N/A|50||University of Aarhus|||||f||||t||||||||||2018-06-01 04:54:18.869211|2018-06-01 04:54:18.869211
NCT00116038|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2009-07-06|2005-06-26|2005-06-27|Estimate|||||||2009-07-06|2009-07-07|Estimate|January 2004||2004-01-31|July 2009|2009-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Comparison of Two Metal Surface Finishes on Femoral Components in Hip Arthroplasty|A Comparison of Two Metal Surface Finishes (Proximal-Coated Titanium Surface Versus Mid-Coated Titanium Surface) on Femoral Components in Hip Arthroplasty|Completed||N/A|50||University of Aarhus|||||f||||||||||||||2018-06-01 04:54:18.931415|2018-06-01 04:54:18.931415
NCT00116025|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2007-02-27|2005-06-26|2005-06-27|Estimate|||||||2007-02-27|2007-02-28|Estimate|March 2005||2005-03-31|February 2007|2007-02-28|January 2006||2006-01-31|||||Interventional|||Pharmacokinetics of Ghrelin|Pharmacokinetics of Ghrelin in Normal Subjects|Completed||N/A|17||University of Aarhus|||||f||||f||||||||||2018-06-01 04:54:19.000239|2018-06-01 04:54:19.000239
NCT00116012|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2006-11-27|2005-06-26|2005-06-27|Estimate|||||||2006-11-27|2006-11-29|Estimate|June 2005||2005-06-30|November 2006|2006-11-30||||||||Interventional|||Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32|A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32. Amendment #3 - A Single Arm, Open-Label Study of rNAPc2 With Reduced Doses of Unfractionated Heparin|Completed||Phase 2|300||ARCA Biopharma, Inc.|||||||||||||||||||2018-06-01 04:54:19.06251|2018-06-01 04:54:19.06251
NCT00115999|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2008-01-08|2005-06-26|2005-06-27|Estimate|||||||2008-01-08|2008-01-15|Estimate|April 2005||2005-04-30|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries|Phase 3, Multicenter, Multi-National, Randomized, Partial Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion|Completed||Phase 3|300||ARCA Biopharma, Inc.|||||f||||t||||||||||2018-06-01 04:54:19.126271|2018-06-01 04:54:19.126271
NCT00115986|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2013-08-22|2005-06-26|2005-06-27|Estimate|||||||2013-08-22|2013-08-23|Estimate|March 2005||2005-03-31|January 2007|2007-01-31|February 2006||2006-02-28|||||Interventional|||A/H5N1in Adult - Aventis|A Randomized, Double-Blinded, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Healthy Adults|Completed||Phase 1/Phase 2|452|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:54:19.189447|2018-06-01 04:54:19.189447
NCT00115973|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2016-10-17|2005-06-26|2005-06-27|Estimate|||||||2016-10-17|2016-10-18|Estimate|June 2005||2005-06-30|October 2016|2016-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump|An Open-Label, Stepwise Basal Insulin Dose Titration Study Using Continuous Subcutaneous Insulin Infusion (CSII) in Oral Antidiabetic Drug-Treated Type 2 Diabetes Mellitus Subjects Followed by a 10-Week Out-Patient Maintenance Phase|Completed||Phase 1|71|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:54:19.246667|2018-06-01 04:54:19.246667
NCT00115960|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2012-03-26|2005-06-26|2005-06-27|Estimate|||||||2012-03-26|2012-03-27|Estimate||||March 2012|2012-03-31|July 2008|Actual|2008-07-31|||||Interventional|||Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Gag DNA Vaccine Alone or With IL-15 DNA, Boosted With HIV-1 Gag DNA + IL-15 DNA or HIV-1 Gag DNA + IL-12 DNA, in Healthy, HIV-1 Uninfected Adult Participants|Completed||Phase 1|120|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 04:54:19.316932|2018-06-01 04:54:19.316932
NCT00115934|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|2010-09-14||2016-03-22|2005-06-26|2005-06-27|Estimate|2011-05-27|2011-06-27|Estimate||||2016-03-22|2016-04-20|Estimate|May 2005||2005-05-31|August 2013|2013-08-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network|Trial of Right Ventricular Versus Modified Blalock-Taussig Shunt in Infants With Single Ventricle Defect Undergoing Staged Reconstruction (A Trial Conducted by the Pediatric Heart Network)|Completed||Phase 3|555|Actual|New England Research Institutes|As in all surgical trials comparing two operations, it was not possible to blind the personnel caring for the subjects to the intervention. However, the components of the primary endpoint, death and transplantation, are discrete objective events.|2|||f||||t||||||||||2018-06-01 04:54:19.491352|2018-06-01 04:54:19.491352
NCT00115921|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2017-01-11|2005-06-26|2005-06-27|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2005||2005-07-31|January 2017|2017-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Evaluation of Home-Based Management of Fever in Urban Ugandan Children|Evaluation of Home-Based Management of Fever in Urban Ugandan Children|Completed||N/A|540||London School of Hygiene and Tropical Medicine|||||f||||t||||||||||2018-06-01 04:54:20.090143|2018-06-01 04:54:20.090143
NCT00115908|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2013-11-05|2005-06-26|2005-06-27|Estimate|||||||2013-11-05|2013-11-07|Estimate|May 2005||2005-05-31|November 2013|2013-11-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1|A Phase 2b, Randomized, Multi-Center, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 1|Completed||Phase 2|458|Actual|Human Genome Sciences Inc.|||||f||||t||||||||||2018-06-01 04:54:20.161413|2018-06-01 04:54:20.161413
NCT00115895|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2018-03-01|2005-06-26|2005-06-27|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2000||2000-01-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|October 2004|Actual|2004-10-31||Interventional|||The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy|Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq|Active, not recruiting||Phase 3|160|Actual|Helsinki University||2|||f||||f||||||||||2018-06-01 04:54:20.422371|2018-06-01 04:54:20.422371
NCT00115882|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2016-05-20|2005-06-26|2005-06-27|Estimate|||||||2016-05-20|2016-05-24|Estimate|September 2000||2000-09-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|May 2014|Actual|2014-05-31||Interventional|||Hutchinson Study of High School Smoking|Proactive Smoking Cessation for Adolescents|Completed||Phase 3|2151|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-06-01 04:54:20.506571|2018-06-01 04:54:20.506571
NCT00115869|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|2012-04-30||2012-10-31|2005-06-26|2005-06-27|Estimate|2012-10-31|2012-11-29|Estimate||||2012-10-31|2012-11-29|Estimate|September 1984||1984-09-30|October 2012|2012-10-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|HSPP||Hutchinson Smoking Prevention Project|Hutchinson Smoking Prevention Project|Completed||Phase 3|8388|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-06-01 04:54:20.591868|2018-06-01 04:54:20.591868
NCT00115856|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2015-07-31|2005-06-26|2005-06-27|Estimate|||||||2015-07-31|2015-08-03|Estimate|January 2001||2001-01-31|July 2015|2015-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Imaging of Plaque With Magnetic Resonance Imaging (MRI)|Imaging of Plaque in Atherosclerosis With Intravascular MRI|Completed||N/A|20|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-06-01 04:54:20.807862|2018-06-01 04:54:20.807862
NCT00115843|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2017-04-04|2005-06-26|2005-06-27|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2005||2005-04-30|April 2017|2017-04-30|September 2006||2006-09-30|September 2006||2006-09-30||Interventional|||Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring|Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center|||||f||||||||||||||2018-06-01 04:54:20.871238|2018-06-01 04:54:20.871238
NCT00115830|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2007-04-23|2005-06-26|2005-06-27|Estimate|||||||2007-04-23|2007-04-24|Estimate|December 2004||2004-12-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Rho Kinase in Patients With Atherosclerosis|Rho Kinase in Patients With Atherosclerosis: Effects of Statins - A Double Blind, Randomized Clinical Trial Comparing Rosuvastatin and Atorvastatin|Completed||Phase 3|40||Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 04:54:20.931096|2018-06-01 04:54:20.931096
NCT00115817|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2007-04-23|2005-06-26|2005-06-27|Estimate|||||||2007-04-23|2007-04-24|Estimate|June 2005||2005-06-30|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||The Effects of Atorvastatin in Patients With Atherosclerosis|The Effects of Atorvastatin on the Rho/Rho Kinase Pathway in Patients With Atherosclerosis|Completed||Phase 3|36||Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 04:54:20.984125|2018-06-01 04:54:20.984125
NCT00115804|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|2012-11-07||2017-02-06|2005-06-26|2005-06-27|Estimate|2013-01-15|2013-02-15|Estimate||||2017-02-06|2017-02-10|Actual|June 2005||2005-06-30|February 2017|2017-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia|An Open-Label Clinical Trial of Fluoxetine Treatment of Juvenile Primary Fibromyalgia Syndrome|Completed||Phase 3|6|Actual|University of Cincinnati||1|||f||||f||||||||No||2018-06-01 04:54:21.04761|2018-06-01 04:54:21.04761
NCT00115791|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2008-03-29|2005-06-26|2005-06-27|Estimate|||||||2008-03-29|2008-04-01|Estimate|June 2004||2004-06-30|March 2008|2008-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter|A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter|Completed||Phase 3|276|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:54:21.252411|2018-06-01 04:54:21.252411
NCT00115778|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|||2009-06-18|2005-06-26|2005-06-27|Estimate|||||||2009-06-18|2009-06-19|Estimate|June 2005||2005-06-30|June 2009|2009-06-30|December 2009|Anticipated|2009-12-31|November 2009|Anticipated|2009-11-30||Interventional|||Intravenous Immunoglobulin (IVIG) in Lung Transplantation|IVIG for Acquired Immunodeficiency in Lung Transplant Patients|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|Arcasoy, Selim, M.D.|||||f||||||||||||||2018-06-01 04:54:21.395626|2018-06-01 04:54:21.395626
NCT00115765|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-26|2010-08-19||2013-06-13|2005-06-26|2005-06-27|Estimate|2010-08-19|2010-09-14|Estimate||||2013-06-13|2013-06-20|Estimate|June 2005||2005-06-30|June 2013|2013-06-30|December 2009|Actual|2009-12-31|March 2007|Actual|2007-03-31||Interventional|||PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study|PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer|Completed||Phase 3|1053|Actual|Amgen||4|||f||||||||||||||2018-06-01 04:54:21.520523|2018-06-01 04:54:21.520523
NCT00115752|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2017-06-30|2005-06-23|2005-06-24|Estimate|||||||2017-06-30|2017-07-02|Actual|June 20, 2005||2005-06-20|October 4, 2006|2006-10-04|October 4, 2006||2006-10-04|||||Interventional|||Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain|Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain|Completed||Phase 2|96||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:23.240803|2018-06-01 04:54:23.240803
NCT00115739|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|2012-07-24||2014-03-19|2005-06-23|2005-06-24|Estimate|2014-03-19|2014-04-21|Estimate||||2014-03-19|2014-04-21|Estimate|February 2004||2004-02-29|March 2014|2014-03-31|August 2010|Actual|2010-08-31|May 2008|Actual|2008-05-31||Interventional||11 patients with Anaplastic thyroid cancer were enrolled and were started on imatinib.|Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma|Phase II Trial Evaluating Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients With Anaplastic Thyroid Cancer|Terminated||Phase 2|11|Actual|University of Michigan Cancer Center|Study was closed early due to slow accrual. Planned accrual was 28|1||Study was closed early due to slow accrual|f||||t||||||||||2018-06-01 04:54:23.339916|2018-06-01 04:54:23.339916
NCT00115726|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2008-02-20|2005-06-23|2005-06-24|Estimate|||||||2008-02-20|2008-02-22|Estimate|September 2000||2000-09-30|February 2008|2008-02-29|April 2007|Actual|2007-04-30|February 2006|Actual|2006-02-28||Interventional|||Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure|Randomized Controlled Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure|Completed||Phase 4|198|Actual|University of Calgary||2|||f||||f||||||||||2018-06-01 04:54:23.597185|2018-06-01 04:54:23.597185
NCT00115713|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2007-03-22|2005-06-23|2005-06-24|Estimate|||||||2007-03-22|2007-03-23|Estimate|April 2003||2003-04-30|March 2007|2007-03-31|December 2005|Actual|2005-12-31|||||Interventional|||Effects of Aerobic Exercise Versus Weight Training in Breast Cancer Survivors During Chemotherapy|Comparison of Aerobic Versus Resistance Exercise Training in Enhancing Quality of Life in Early Stage Breast Cancer Survivors Receiving Chemotherapy: A Multi-Centre Randomized Trial|Completed||Phase 3|240||University of Alberta, Physical Education|||||f||||t||||||||||2018-06-01 04:54:23.670964|2018-06-01 04:54:23.670964
NCT00115700|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2017-07-10|2005-06-23|2005-06-24|Estimate|||||||2017-07-10|2017-07-12|Actual|February 2000||2000-02-29|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma|A Randomised Multicentre Trial of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy in Combination With Rituximab (Mabthera®) for Stage I - II Low Grade Follicular Lymphoma|Active, not recruiting||Phase 3|150|Actual|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||f||||||||||2018-06-01 04:54:23.745663|2018-06-01 04:54:23.745663
NCT00115687|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2017-01-11|2005-06-23|2005-06-24|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2002||2002-06-30|May 2010|2010-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Nicotine Replacement Treatment for Pregnant Smokers - 1|Nicotine Replacement Treatment for Pregnant Smokers|Terminated||Phase 2|250|Actual|National Institute on Drug Abuse (NIDA)||2||Efficacy rates did not show large enough differences between treatments|f||||t||||||||||2018-06-01 04:54:23.857668|2018-06-01 04:54:23.857668
NCT00115674|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2015-10-06|2005-06-23|2005-06-24|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 2002||2002-09-30|August 2015|2015-08-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||To Examine Smoking Behavior of Prisoners - 1|Smoking Research With Incarcerated Females|Completed|||360|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 04:54:23.963117|2018-06-01 04:54:23.963117
NCT00115661|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2012-10-16|2005-06-23|2005-06-24|Estimate|||||||2012-10-16|2012-10-17|Estimate|July 2005||2005-07-31|October 2012|2012-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Use of Rosiglitazone in the Treatment of Endometriosis|Treatment of Endometriosis Pain With Rosiglitazone: A Prospective Phase 2 Clinical Trial|Terminated||Phase 2|25|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||||Due to the meta-analysis about CV adverse effects of rosiglitazone.|f||||||||||||||2018-06-01 04:54:24.031353|2018-06-01 04:54:24.031353
NCT00115648|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2014-03-06|2005-06-23|2005-06-24|Estimate|||||||2014-03-06|2014-03-07|Estimate|April 2004||2004-04-30|March 2014|2014-03-31|October 2009|Actual|2009-10-31|August 2007|Actual|2007-08-31||Interventional|||Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission|Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission|Completed||Phase 3|3300|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-06-01 04:54:24.108696|2018-06-01 04:54:24.108696
NCT00115635|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2007-10-01|2005-06-23|2005-06-24|Estimate|||||||2007-10-01|2007-10-02|Estimate|March 2005||2005-03-31|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|||Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer|A Phase I/II Study With Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer|Completed||Phase 1/Phase 2|60|Actual|Herlev Hospital|||||f||||t||||||||||2018-06-01 04:54:24.191783|2018-06-01 04:54:24.191783
NCT00115622|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2016-08-30|2005-06-23|2005-06-24|Estimate|||||||2016-08-30|2016-09-01|Estimate|December 2004||2004-12-31|August 2016|2016-08-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study In Adults And Adolescents With Seasonal Allergic Rhinitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 14 Days in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|304|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:54:24.246477|2018-06-01 04:54:24.246477
NCT00115609|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2011-12-21|2005-06-23|2005-06-24|Estimate|||||||2011-12-21|2011-12-22|Estimate|January 2006||2006-01-31|December 2011|2011-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)|Pilot Trial Evaluating Once Daily Triple Combination Antiretroviral Therapy With Tenofovir-Emtricitabine and Efavirenz in HIV-1 Infected Patients With Mycobacterium Tuberculosis Infection ANRS129 BKVIR|Completed||Phase 3|70|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:54:24.352788|2018-06-01 04:54:24.352788
NCT00115596|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2017-07-18|2005-06-23|2005-06-24|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2005||2005-06-30|July 2017|2017-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Reforming Pediatric Procedural Training|Reforming Pediatric Procedural Training: Developing an Evidence-Based Curriculum|Completed||N/A|38|Actual|Boston Children’s Hospital||2|||f||||||||||||||2018-06-01 04:54:24.48658|2018-06-01 04:54:24.48658
NCT00115583|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2016-12-08|2005-06-23|2005-06-24|Estimate|||||||2016-12-08|2016-12-09|Estimate|November 1998||1998-11-30|December 2016|2016-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries|The Contribution of Endothelin to Vasoreactivity in Atherosclerotic Coronary Arteries|Completed||N/A|200||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:54:24.563434|2018-06-01 04:54:24.563434
NCT00115388|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2014-11-21|2005-06-21|2005-06-22|Estimate|||||||2014-11-21|2014-11-24|Estimate|September 2004||2004-09-30|November 2014|2014-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|POPI||Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease|Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease|Completed||N/A|2531|Actual|St George's, University of London||1|||f||||f||||||||||2018-06-01 04:54:26.377131|2018-06-01 04:54:26.377131
NCT00115570|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2016-05-19|2005-06-23|2005-06-24|Estimate|||||||2016-05-19|2016-05-20|Estimate|April 2005||2005-04-30|May 2016|2016-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents|Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial|Completed||Phase 3|572|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:54:24.619775|2018-06-01 04:54:24.619775
NCT00115557|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-23|||2010-08-11|2005-06-23|2005-06-24|Estimate|||||||2010-08-11|2010-08-12|Estimate|October 2004||2004-10-31|September 2007|2007-09-30|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||Delivery of Preventive Services in Primary Care|Delivery of Preventive Services in Primary Care|Completed||N/A|24|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||f||||||||||2018-06-01 04:54:24.696958|2018-06-01 04:54:24.696958
NCT00115544|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2016-02-09|2005-06-22|2005-06-23|Estimate|||||||2016-02-09|2016-02-11|Estimate|September 2005||2005-09-30|February 2016|2016-02-29|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Safety and Pharmacology of Stanate|An Open-Label Study of the Safety and Clinical Pharmacology of Stanate® in Infants At-Risk for Exchange Transfusion|Completed||Phase 2|55|Actual|InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company||3|||f||||t||||||||||2018-06-01 04:54:24.764769|2018-06-01 04:54:24.764769
NCT00115531|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2014-12-18|2005-06-22|2005-06-23|Estimate|||||||2014-12-18|2014-12-19|Estimate|April 2005||2005-04-30|February 2007|2007-02-28|November 2005||2005-11-30|||||Interventional|||Eldery High Dose TIV 2005|Comparisons of the Reactogenicity and Immunogenicity in Ambulatory Elderly Subjects of a Standard-Dose Fluzone® (15 µg HA/Virus Strain) and a High-Dose (60 µg HA/Virus Strain) of a Trivalent Inactivated Influenza Virus Vaccine|Completed||Phase 2|414|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:54:24.839351|2018-06-01 04:54:24.839351
NCT00115518|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2011-08-03|2005-06-22|2005-06-23|Estimate|||||||2011-08-03|2011-08-05|Estimate|May 2005||2005-05-31|February 2011|2011-02-28|August 2010|Actual|2010-08-31|June 2009|Actual|2009-06-30||Interventional|||Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Locoregional Radiotherapy in Combination With Cetuximab in Inoperable Non-Small Cell Lung Cancer Stage III|Completed||Phase 2|30|Actual|Heidelberg University|||||f||||f||||||||||2018-06-01 04:54:24.917444|2018-06-01 04:54:24.917444
NCT00115505|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2017-08-16|2005-06-22|2005-06-23|Estimate|||||||2017-08-16|2017-08-18|Actual|October 2005||2005-10-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Observational|||Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer|Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer With 0-3 Positive Axillary Lymph Nodes|Completed|||307|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 04:54:25.014387|2018-06-01 04:54:25.014387
NCT00115492|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2017-01-19|2005-06-22|2005-06-23|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2004||2004-12-31|January 2017|2017-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations|A Randomized, Double-Blind, Parallel Group, 52-Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50mcg BID With Salmeterol Diskus 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|797|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:54:25.563637|2018-06-01 04:54:25.563637
NCT00115479|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2006-05-03|2005-06-22|2005-06-23|Estimate|||||||2006-05-03|2006-05-04|Estimate|March 2002||2002-03-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients|KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients|Completed||Phase 2|1200||Katholieke Universiteit Leuven|||||f||||||||||||||2018-06-01 04:54:25.856172|2018-06-01 04:54:25.856172
NCT00115466|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2005-06-23|2005-06-22|2005-06-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2004||2004-10-31|June 2005|2005-06-30|July 2006||2006-07-31|||||Interventional|||Autologous Stem Cells Derived From Lipoaspirates for the Non-Surgical Treatment of Complex Perianal Fistula|Phase II Clinical Trial, Multicentre, Randomised and Comparative, to Evaluate the Efficacy and Safety of a New Therapy With Autologous Stem Cells Derived From Lipoaspirates for the Non-Surgical Treatment of Complex Perianal Fistula|Unknown status|Active, not recruiting|Phase 2|50||Cellerix|||||f||||||||||||||2018-06-01 04:54:25.925169|2018-06-01 04:54:25.925169
NCT00115453|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2008-08-14|2005-06-22|2005-06-23|Estimate|||||||2008-08-14|2008-08-18|Estimate|May 1999||1999-05-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma|Boron Neutron Capture Therapy in the Treatment of Glioblastoma Multiforme|Terminated||Phase 1/Phase 2|50|Actual|Boneca Corporation||1||Slow accrual|f||||f||||||||||2018-06-01 04:54:25.988984|2018-06-01 04:54:25.988984
NCT00115440|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2009-01-27|2005-06-22|2005-06-23|Estimate|||||||2009-01-27|2009-01-28|Estimate|March 2001||2001-03-31|September 2007|2007-09-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||BNCT to Treat Glioma That Has Progressed Following Radiotherapy|BPA-Mediated Boron Neutron Capture Therapy (BNCT) in the Treatment of Glioblastoma or Anaplastic Astrocytoma Progressing After Conventional External Beam Radiotherapy|Completed||Phase 1/Phase 2|22|Actual|Boneca Corporation||1|||f||||f||||||||||2018-06-01 04:54:26.064071|2018-06-01 04:54:26.064071
NCT00115427|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2008-01-10|2005-06-22|2005-06-23|Estimate|||||||2008-01-10|2008-01-11|Estimate|March 2003||2003-03-31|January 2008|2008-01-31||||||||Interventional|||Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease|Completed||Phase 1|||Amgen|||||||||||||||||||2018-06-01 04:54:26.14087|2018-06-01 04:54:26.14087
NCT00115414|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-22|||2008-07-31|2005-06-22|2005-06-23|Estimate|||||||2008-07-31|2008-08-01|Estimate||||July 2008|2008-07-31||||||||Interventional|||Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)|A Randomized, Double-Blind, Phase 2 Study Evaluating the Safety of Same Day Versus Next Day Administration of Pegfilgrastim With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) in Women With Breast Cancer|Completed||Phase 2|||Amgen|||||||||||||||||||2018-06-01 04:54:26.198511|2018-06-01 04:54:26.198511
NCT00019500|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2005-06-22|2005-06-23|Estimate|||||||2013-06-18|2013-06-20|Estimate|December 1998||1998-12-31|April 2009|2009-04-30|June 2005|Actual|2005-06-30|||||Interventional|||Raloxifene in Preventing Breast Cancer in Premenopausal Women|A Randomized Phase II Trial of Two Doses of Raloxifene in Pre-Menopausal Women at High Risk For Developing Invasive Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:54:26.263088|2018-06-01 04:54:26.263088
NCT00115375|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2009-03-24|2005-06-21|2005-06-22|Estimate|||||||2009-03-24|2009-03-25|Estimate|January 2004||2004-01-31|March 2009|2009-03-31|April 2006|Actual|2006-04-30|||||Interventional|||Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)|Dose-Ranging Pharmacodynamic Assessment of Platelet Aggregation Inhibition With Clopidogrel in Children of Blalock-Taussig Shunt Age Categories (Neonates and Infants/Toddlers)|Completed||Phase 2|92|Actual|Sanofi|||||||||||||||||||2018-06-01 04:54:26.4399|2018-06-01 04:54:26.4399
NCT00115362|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2007-09-21|2005-06-21|2005-06-22|Estimate|||||||2007-09-21|2007-09-24|Estimate|July 2005||2005-07-31|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Serotonin Effect in Functional Dyspepsia|Serotonin Effect in Non-Ulcer Dyspepsia|Completed||N/A|300|Anticipated|Radboud University|||||f||||||||||||||2018-06-01 04:54:26.502029|2018-06-01 04:54:26.502029
NCT00115349|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|2013-05-16||2018-02-01|2005-06-21|2005-06-22|Estimate|2013-12-12|2014-01-14|Estimate||||2018-02-01|2018-03-01|Actual|June 2005||2005-06-30|January 2014|2014-01-31|April 2009|Actual|2009-04-30|July 2008|Actual|2008-07-31||Interventional|||Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases|Thalassemia Clinical Research Network - Cardiac L1/DFO Trial|Terminated||Phase 2|20|Actual|New England Research Institutes|The study was stopped early by NHLBI when analysis of the interim data confirmed a required sample size of 86 that was not achievable within the required time frame within the participating or planned centres.|2||due to low enrollment|f||||t||||||||||2018-06-01 04:54:26.573863|2018-06-01 04:54:26.573863
NCT00115336|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2013-01-18|2005-06-21|2005-06-22|Estimate|||||||2013-01-18|2013-01-21|Estimate|January 2005||2005-01-31|January 2013|2013-01-31|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease|Ketorolac Versus Ibuprofen for the Painful Crisis of Sickle Cell Disease - Southwestern Comprehensive Sickle Cell Center|Terminated||Phase 4|12|Actual|University of Texas Southwestern Medical Center||2||Poor accrual|f||||t||||||||||2018-06-01 04:54:27.02348|2018-06-01 04:54:27.02348
NCT00115323|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2013-12-20|2005-06-21|2005-06-22|Estimate|||||||2013-12-20|2013-12-23|Estimate|May 2005||2005-05-31|December 2013|2013-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Comparison of Two Medication Adherence Strategies to Improve Asthma Treatment Adherence|Individualized Interventions to Improve Asthma Adherence|Completed||N/A|397|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 04:54:27.100803|2018-06-01 04:54:27.100803
NCT00115310|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2008-03-04|2005-06-21|2005-06-22|Estimate|||||||2008-03-04|2008-03-06|Estimate|June 2005||2005-06-30|March 2008|2008-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|Completed||Phase 3|400||NeurogesX|||||||||||||||||||2018-06-01 04:54:27.168676|2018-06-01 04:54:27.168676
NCT00115297|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|2016-12-12||2017-02-03|2005-06-21|2005-06-22|Estimate|2016-12-12|2017-02-06|Estimate||||2017-02-03|2017-03-14|Actual|September 2004||2004-09-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Montelukast for Early Life Wheezing|Effects of Montelukast on Early Life Wheezing|Completed||Phase 2/Phase 3|62|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-06-01 04:54:27.238118|2018-06-01 04:54:27.238118
NCT00115284|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2009-02-12|2005-06-21|2005-06-22|Estimate|||||||2009-02-12|2009-02-13|Estimate|January 2005||2005-01-31|February 2009|2009-02-28|December 2006|Actual|2006-12-31|July 2006|Actual|2006-07-31||Interventional|||Changes in Physician Performance Through Continuous Professional Development|An Evaluation of Changes in Physician Performance Through Continuous Professional Development|Completed||N/A|40||Henry Ford Health System|||||f||||||||||||||2018-06-01 04:54:27.505486|2018-06-01 04:54:27.505486
NCT00115271|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2014-08-22|2005-06-21|2005-06-22|Estimate|||||||2014-08-22|2014-08-26|Estimate|January 1999||1999-01-31|August 2014|2014-08-31|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Antenatal Micronutrient Supplementation and Birth Weight|Maternal Micronutrient Supplementation to Reduce Low Birth Weight and Infant and Maternal Morbidity in Rural Nepal|Completed||Phase 3|5000||Johns Hopkins Bloomberg School of Public Health|||||f||||||||||||||2018-06-01 04:54:27.617667|2018-06-01 04:54:27.617667
NCT00115258|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2013-02-12|2005-06-21|2005-06-22|Estimate|||||||2013-02-12|2013-02-13|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Nutrition Support in Pediatric Stem Cell Transplantation|Nutrition Support in Pediatric Stem Cell Transplantation - A Randomized, Controlled Trial|Completed||Phase 3|26|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-06-01 04:54:27.685948|2018-06-01 04:54:27.685948
NCT00115245|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2015-05-08|2005-06-21|2005-06-22|Estimate|||||||2015-05-08|2015-05-12|Estimate|November 2004||2004-11-30|May 2015|2015-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B|A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B|Completed||Phase 3|||Novartis|||||f||||||||||||||2018-06-01 04:54:27.753286|2018-06-01 04:54:27.753286
NCT00115232|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2008-01-14|2005-06-21|2005-06-22|Estimate|||||||2008-01-14|2008-01-16|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Observational|||Inflammatory Profiles of Children at High Risk for Atherosclerosis|Inflammatory Profiles of Children at High Risk for Atherosclerosis|Completed|||300|Actual|Boston Children’s Hospital|||4||f||||f||||||Samples Without DNA|"~     Fasting serum samples, frozen.~   "|||2018-06-01 04:54:27.822824|2018-06-01 04:54:27.822824
NCT00115219|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2013-05-28|2005-06-21|2005-06-22|Estimate|||||||2013-05-28|2013-05-30|Estimate|May 2005||2005-05-31|May 2013|2013-05-31||||||||Interventional|||Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)|A Multi-center, Randomized, Double-Blind, Active-Controlled Study Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis Subjects Who Are Sub-optimal Responders to Etanercept 50 mg Once Weekly (QW)|Completed||Phase 4|200||Amgen|||||||||||||||||||2018-06-01 04:54:27.890629|2018-06-01 04:54:27.890629
NCT00115206|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2009-04-02|2005-06-21|2005-06-22|Estimate|||||||2009-04-02|2009-04-06|Estimate|July 2002||2002-07-31|April 2009|2009-04-30|July 2004||2004-07-31|||||Interventional|||Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy|A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC|Completed||Phase 4|||Amgen|||||||||||||||||||2018-06-01 04:54:27.955483|2018-06-01 04:54:27.955483
NCT00115193|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2013-08-27|2005-06-21|2005-06-22|Estimate|||||||2013-08-27|2013-08-29|Estimate|February 2003||2003-02-28|August 2013|2013-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma|A Multicenter, Double-Blind, Randomized Study of Pegfilgrastim Administered on the Same Day or the Next Day of R-Chop Chemotherapy in Subjects With Non-Hodgkin's Lymphoma|Completed||Phase 2|77|Actual|Amgen||2|||f||||t||||||||||2018-06-01 04:54:28.030778|2018-06-01 04:54:28.030778
NCT00115167|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2009-05-07|2005-06-21|2005-06-22|Estimate|||||||2009-05-07|2009-05-11|Estimate|August 2004||2004-08-31|May 2009|2009-05-31|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study|A Multicenter, Randomised, Double-Blind, Placebo-Controlled Roll Over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer|Completed||Phase 3|371|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:54:28.168629|2018-06-01 04:54:28.168629
NCT00115154|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2007-02-16|2005-06-21|2005-06-22|Estimate|||||||2007-02-16|2007-02-19|Estimate|May 2005||2005-05-31|February 2007|2007-02-28|September 2006||2006-09-30|||||Interventional|||Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands|Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities|Completed||Phase 4|270||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:54:28.241346|2018-06-01 04:54:28.241346
NCT00115141|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2007-02-16|2005-06-21|2005-06-22|Estimate|||||||2007-02-16|2007-02-19|Estimate|April 2004||2004-04-30|November 2006|2006-11-30||||||||Interventional|||Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults|A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults|Completed||Phase 2|88||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:54:28.316187|2018-06-01 04:54:28.316187
NCT00115128|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-21|||2013-05-10|2005-06-21|2005-06-22|Estimate|||||||2013-05-10|2013-05-13|Estimate|November 2003||2003-11-30|May 2013|2013-05-31|September 2007|Actual|2007-09-30|May 2007|Actual|2007-05-31||Observational|||Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors|Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors|Completed|||309|Actual|Amgen|||1||f||||||||||None Retained|"~     none collected~   "|||2018-06-01 04:54:28.378089|2018-06-01 04:54:28.378089
NCT00115115|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2009-04-22|2005-06-20|2005-06-21|Estimate|||||||2009-04-22|2009-04-23|Estimate|March 2004||2004-03-31|April 2009|2009-04-30|March 2009|Actual|2009-03-31|December 2007|Actual|2007-12-31||Interventional|||Donor Dopamine and Initial Graft Function|Prospective Randomized Trial to Evaluate the Efficacy of Donor Preconditioning With Dopamine on Initial Graft Function After Kidney Transplantation|Completed||Phase 4|487|Actual|Universitätsmedizin Mannheim|||||f||||f||||||||||2018-06-01 04:54:28.439047|2018-06-01 04:54:28.439047
NCT00115102|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2006-06-15|2005-06-20|2005-06-21|Estimate|||||||2006-06-15|2006-06-20|Estimate|March 2004||2004-03-31|June 2006|2006-06-30|October 2005||2005-10-31|||||Interventional|||Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls||Completed||Phase 4|20||University of Aarhus|||||f||||||||||||||2018-06-01 04:54:28.504399|2018-06-01 04:54:28.504399
NCT00115089|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2005-11-09|2005-06-20|2005-06-21|Estimate|||||||2005-11-09|2005-11-11|Estimate|July 2005||2005-07-31|November 2005|2005-11-30|September 2005||2005-09-30|||||Interventional|||7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis|A Phase II Multi-Center, Randomized, Double-Blind, Active and Placebo-Controlled 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis|Completed||Phase 2|375||Rigel Pharmaceuticals|||||||||||||||||||2018-06-01 04:54:28.560402|2018-06-01 04:54:28.560402
NCT00115076|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2012-05-31|2005-06-20|2005-06-21|Estimate|||||||2012-05-31|2012-06-01|Estimate|October 2003||2003-10-31|May 2012|2012-05-31||||May 2007|Actual|2007-05-31||Interventional|||Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis|A Phase IIIB Study to Evaluate the Mechanism of Action of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy|Completed||Phase 3|31|Actual|Rockefeller University||1|||f||||f||||||||||2018-06-01 04:54:28.614148|2018-06-01 04:54:28.614148
NCT00115063|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|2010-03-01||2016-01-22|2005-06-20|2005-06-21|Estimate|2010-05-06|2010-06-07|Estimate||||2016-01-22|2016-02-22|Estimate|July 2005||2005-07-31|January 2016|2016-01-31|January 2008|Actual|2008-01-31|December 2007|Actual|2007-12-31||Interventional|LOSS||LOSS- Louisiana Obese Subjects Study|Loss - Louisiana Obese Subjects Study|Terminated||Phase 4|390|Actual|Pennington Biomedical Research Center|The study was stopped prematurely for efforts to be focused on assisting the Office of Group Benefits (OGB) in translating a policy that would allow for physician certification in order to offer participants the intensive treatment.|2||ethical issues of continuing control group without treatment|f||||t||||||||||2018-06-01 04:54:28.687629|2018-06-01 04:54:28.687629
NCT00115050|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20||2011-06-02|2011-06-02|2005-06-20|2005-06-21|Estimate||||2011-06-02|2011-06-10|Estimate|2011-06-02|2011-06-10|Estimate|June 2005||2005-06-30|June 2011|2011-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options|Open-label Safety Study of TMC114 in Combination With Low Dose RTV and Other ARVs in Highly Experienced HIV-1 Infected Patients With Limited or no Treatment Options.|Completed||Phase 3|260|Actual|Tibotec Pharmaceuticals, Ireland|||||||||||||||||||2018-06-01 04:54:29.053578|2018-06-01 04:54:29.053578
NCT00115037|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2011-08-04|2005-06-20|2005-06-21|Estimate|||||||2011-08-04|2011-08-05|Estimate|September 2003||2003-09-30|August 2011|2011-08-31|July 2008|Actual|2008-07-31|April 2008|Actual|2008-04-30||Interventional|EXTEND||Managing Alcoholism in People Who Do Not Respond to Naltrexone|Non-Response to Naltrexone (NTX): Next Steps in Managing Alcoholism|Completed||Phase 4|302|Actual|University of Pennsylvania||5|||f||||t||||||||||2018-06-01 04:54:29.104517|2018-06-01 04:54:29.104517
NCT00115024|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2009-12-09|2005-06-20|2005-06-21|Estimate|||||||2009-12-09|2009-12-11|Estimate|April 1994||1994-04-30|June 2005|2005-06-30|November 1998|Actual|1998-11-30|November 1998|Actual|1998-11-30||Interventional|||EPAT: Estrogen in the Prevention of Atherosclerosis Trial|Estrogen in the Prevention of Atherosclerosis Trial|Completed||Phase 2/Phase 3|222||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:54:29.179108|2018-06-01 04:54:29.179108
NCT00115011|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2008-05-19|2005-06-20|2005-06-21|Estimate|||||||2008-05-19|2008-05-20|Estimate|September 2002||2002-09-30|May 2008|2008-05-31|November 2005|Actual|2005-11-30|||||Interventional|||Escitalopram for the Treatment of Self-Injurious Skin Picking|Escitalopram for the Treatment of Self-Injurious Skin Picking|Completed||Phase 4|30|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:54:29.229793|2018-06-01 04:54:29.229793
NCT00114998|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2012-07-31|2005-06-20|2005-06-21|Estimate|||||||2012-07-31|2012-08-01|Estimate|June 2005||2005-06-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||CV Disease in Adolescents With Type 2 Diabetes|CV Disease in Adolescents With Type 2 Diabetes|Completed|||750|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-06-01 04:54:29.402974|2018-06-01 04:54:29.402974
NCT00113854|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2005-06-23|2005-06-10|2005-06-13|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2004||2004-10-31|June 2005|2005-06-30|May 2005||2005-05-31|||||Interventional|||Mannitol as Adjunct Therapy for Childhood Cerebral Malaria|Effect of Mannitol as Adjunct Therapy on the Clinical Outcome of Childhood Cerebral Malaria in Mulago Hospital: A Randomised Clinical Trial|Unknown status|Active, not recruiting|Phase 3|156||Makerere University|||||f||||||||||||||2018-06-01 04:54:52.14684|2018-06-01 04:54:52.14684
NCT00114985|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2017-07-26|2005-06-20|2005-06-21|Estimate|||||||2017-07-26|2017-07-28|Actual|April 2001||2001-04-30|July 2017|2017-07-31|October 2008|Actual|2008-10-31|January 2005|Actual|2005-01-31||Interventional|||Prostate Immobilization Device Used During Radiation Treatments to Decrease Rectal Bleeding|A Phase II Study of Late Rectal Toxicity Following 3-D Conformal External Beam Radiation Therapy Performed Using a Prostate Immobilization Device|Completed||Phase 2|100|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 04:54:29.460513|2018-06-01 04:54:29.460513
NCT00114972|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|2009-03-27||2010-05-27|2005-06-20|2005-06-21|Estimate|2010-05-27|2010-06-23|Estimate||||2010-05-27|2010-06-23|Estimate|March 2005||2005-03-31|May 2010|2010-05-31|May 2012|Anticipated|2012-05-31|April 2008|Actual|2008-04-30||Interventional|SYNTAX||SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries|SYNTAX Study: SYNergy Between PCI With TAXUS and Cardiac Surgery|Unknown status|Active, not recruiting|Phase 3|1800|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-06-01 04:54:29.586216|2018-06-01 04:54:29.586216
NCT00114959|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|2015-01-08|2012-05-03|2015-01-08|2005-06-20|2005-06-21|Estimate|2015-01-08|2015-01-15|Estimate|2012-05-03|2012-05-08|Estimate|2015-01-08|2015-01-15|Estimate|October 2005||2005-10-31|January 2015|2015-01-31|March 2009|Actual|2009-03-31|June 2008|Actual|2008-06-30||Interventional|||Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)|A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase|Terminated||Phase 2|15|Actual|Teva Pharmaceutical Industries|This study was intended to follow a Simon two stage design to test 18 patients in each stratum (chronic, accelerated and blast phase) for efficacy. Only 15 were enrolled, an insufficient number for a formal statistical analysis of efficacy.|1||Poor enrollment|f||||f||||||||||2018-06-01 04:54:30.944685|2018-06-01 04:54:30.944685
NCT00114946|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2006-05-26|2005-06-20|2005-06-21|Estimate|||||||2006-05-26|2006-05-29|Estimate|May 2005||2005-05-31|May 2006|2006-05-31|December 2007||2007-12-31|||||Interventional|||A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer|A Randomized, Open-Label Trial Comparing Two Avastin (Bevacizumab)-Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer|Terminated||Phase 4|800||Genentech, Inc.|||||f||||||||||||||2018-06-01 04:54:31.315982|2018-06-01 04:54:31.315982
NCT00114933|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2008-03-20|2005-06-20|2005-06-21|Estimate|||||||2008-03-20|2008-03-21|Estimate|January 2005||2005-01-31|September 2005|2005-09-30|May 2007||2007-05-31|||||Interventional|||"OK 2004 Study (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects"|Phase III-IV, Comparative, Randomized, Open-Label, Study to Evaluate Safety and Efficacy of Suspending Nucleosides From a Triple-Drug Therapy Based on Lopinavir/Ritonavir Versus Continuing Triple-Drug Therapy in HIV-Infected Subjects With Undetectable Plasma HIV Viremia for Six Months|Completed||Phase 4|200||Arribas, Jose R., M.D.|||||f||||||||||||||2018-06-01 04:54:31.364985|2018-06-01 04:54:31.364985
NCT00114920|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-20|||2007-02-16|2005-06-20|2005-06-21|Estimate|||||||2007-02-16|2007-02-19|Estimate|March 2004||2004-03-31|November 2006|2006-11-30||||||||Interventional|||Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults|A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults|Completed||Phase 2|88||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:54:31.443486|2018-06-01 04:54:31.443486
NCT00114907|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2007-04-05|2005-06-17|2005-06-20|Estimate|||||||2007-04-05|2007-04-06|Estimate|June 2005||2005-06-30|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Effects of Black Tea on Cardiovascular Disease in the Mauritian Population|Effects of Black Tea on Cardiovascular Disease in the Mauritian Population|Completed||N/A|270||University of Mauritius|||||f||||||||||||||2018-06-01 04:54:31.588814|2018-06-01 04:54:31.588814
NCT00114894|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2009-08-12|2005-06-17|2005-06-20|Estimate|||||||2009-08-12|2009-08-13|Estimate|April 2004||2004-04-30|August 2009|2009-08-31|February 2006|Actual|2006-02-28|January 2006|Actual|2006-01-31||Interventional|||Prevention of Jellyfish Stings|Field Study of the Prevention of Jellyfish Stings With a Topical Sting Inhibitor|Completed||Phase 3|12|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 04:54:31.641214|2018-06-01 04:54:31.641214
NCT00114881|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2018-01-08|2005-06-17|2005-06-20|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2005||2005-01-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|URECA||Urban Environmental Factors and Childhood Asthma|Urban Environment and Childhood Asthma (URECA)|Active, not recruiting|||609|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     -  Sample of umbilical cord blood (mother)~        -  Maternal blood sample~        -  Blood and nasal mucus collection (infant through age 14 or 16 years)~        -  DNA sample of mother and child~        -  Urine sample~        -  Saliva sample~        -  Induced sputum sample~        -  Nasal epithelial cells sample~   "|||2018-06-01 04:54:31.724843|2018-06-01 04:54:31.724843
NCT00114868|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2017-03-01|2005-06-17|2005-06-20|Estimate|||||||2017-03-01|2017-03-03|Actual|June 1998||1998-06-30|January 2010|2010-01-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Vitamin A Supplementation in Newborns Study|Vitamin A Supplementation in Newborns Study|Completed||Phase 3|14035|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-06-01 04:54:31.799742|2018-06-01 04:54:31.799742
NCT00114855|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2011-07-03|2005-06-17|2005-06-20|Estimate|||||||2011-07-03|2011-07-06|Estimate|March 2005||2005-03-31|February 2009|2009-02-28|June 2006|Actual|2006-06-30|December 2005|Actual|2005-12-31||Interventional|||The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose|A Single-Centre, Randomised Double-Blind Placebo-Controlled Study to Measure the Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose|Completed||N/A|40||Oslo University Hospital|||||f||||||||||||||2018-06-01 04:54:31.861537|2018-06-01 04:54:31.861537
NCT00114842|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2007-09-19|2005-06-17|2005-06-20|Estimate|||||||2007-09-19|2007-09-20|Estimate|March 2006||2006-03-31|September 2007|2007-09-30|March 2007|Actual|2007-03-31|||||Interventional|||Magnetic Resonance (MR) Colonography With Fecal Tagging|MR Colonography With Fecal Tagging: A Prospective, Randomized Study|Completed||Phase 4|60|Anticipated|Herlev Hospital|||||f||||||||||||||2018-06-01 04:54:31.912774|2018-06-01 04:54:31.912774
NCT00114829|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2006-03-08|2005-06-17|2005-06-20|Estimate|||||||2006-03-08|2006-03-09|Estimate|July 2005||2005-07-31|May 2005|2005-05-31||||||||Interventional|||Preoperative Assessment of Colon Tumor|Preoperative Assessment of Colon Tumor: A Prospective, Blinded Study.|Unknown status|Recruiting|Phase 4|60||Herlev Hospital|||||f||||||||||||||2018-06-01 04:54:31.96074|2018-06-01 04:54:31.96074
NCT00114634|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|2010-03-19||2015-12-24|2005-06-15|2005-06-16|Estimate|2014-03-03|2014-04-09|Estimate||||2015-12-24|2016-01-29|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome|Short-Term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome|Completed||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)|Poor power due to low enrollment|2|||f||||f||||||||||2018-06-01 04:54:37.805374|2018-06-01 04:54:37.805374
NCT00114816|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2007-05-18|2005-06-17|2005-06-20|Estimate|||||||2007-05-18|2007-05-21|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer|A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer|Completed||Phase 3|1500|Anticipated|Finnish Breast Cancer Group|||||f||||||||||||||2018-06-01 04:54:32.014679|2018-06-01 04:54:32.014679
NCT00114803|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2007-12-04|2005-06-17|2005-06-20|Estimate|||||||2007-12-04|2007-12-05|Estimate|January 2004||2004-01-31|April 2007|2007-04-30|October 2006|Actual|2006-10-31|||||Interventional|||Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease|Use of Intranasally Administered Calcitonin in the Treatment of Osteopenia and Osteoporosis in Children, Adolescents and Young Adults With IBD: A Pilot Study|Completed||N/A|66||Boston Children’s Hospital|||||||||||||||||||2018-06-01 04:54:32.062916|2018-06-01 04:54:32.062916
NCT00114790|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2013-05-03|2005-06-17|2005-06-20|Estimate|||||||2013-05-03|2013-05-06|Estimate|December 2003||2003-12-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|October 2008|Actual|2008-10-31||Interventional|||Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment Head and Neck Tumors|Boronophenylalanine (BPA)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Inoperable and Irradiated Head and Neck Tumors: A Feasibility Study|Completed||Phase 1/Phase 2|30|Actual|Boneca Corporation||1|||f||||f||||||||||2018-06-01 04:54:32.109639|2018-06-01 04:54:32.109639
NCT00114777|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|2017-01-04|2010-04-29|2017-06-28|2005-06-17|2005-06-20|Estimate|2017-06-28|2017-07-07|Actual|2010-04-29|2010-05-03|Estimate|2017-06-28|2017-07-07|Actual|February 2005||2005-02-28|June 2017|2017-06-30|September 2014|Actual|2014-09-30|May 2008|Actual|2008-05-31||Interventional|BENEFIT-EXT||Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant|Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)|Completed||Phase 3|595|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-06-01 04:54:32.284128|2018-06-01 04:54:32.284128
NCT00114764|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2008-10-30|2005-06-17|2005-06-20|Estimate|||||||2008-10-30|2008-10-31|Estimate|March 2003||2003-03-31|October 2008|2008-10-31|August 2004|Actual|2004-08-31|April 2004|Actual|2004-04-30||Interventional|||Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)|A Multicentre, Double-Blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)|Completed||Phase 2|84|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:54:37.107634|2018-06-01 04:54:37.107634
NCT00114738|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-17|||2017-12-29|2005-06-16|2005-06-17|Estimate|||||||2017-12-29|2018-01-02|Actual|June 15, 2005||2005-06-15|December 9, 2017|2017-12-09|August 11, 2020|Anticipated|2020-08-11|August 11, 2016|Actual|2016-08-11||Interventional|||EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma|Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics|Active, not recruiting||Phase 2|53|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 04:54:37.168206|2018-06-01 04:54:37.168206
NCT00114725|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-16|||2005-06-23|2005-06-16|2005-06-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2004||2004-03-31|June 2005|2005-06-30|October 2004||2004-10-31|||||Interventional|||Laser-Assisted Versus Conventional Intracytoplasmic Sperm Injection|Laser-Assisted Versus Conventional Intracytoplasmic Sperm Injection|Completed||N/A|60||Shady Grove Fertility Reproductive Science Center|||||f||||||||||||||2018-06-01 04:54:37.239669|2018-06-01 04:54:37.239669
NCT00114712|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-16|||2018-03-14|2005-06-16|2005-06-17|Estimate|||||||2018-03-14|2018-03-16|Actual|January 2004||2004-01-31|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31|12 Months|Observational [Patient Registry]|RPR||The Ribavirin Pregnancy Registry|The Ribavirin Pregnancy Registry|Recruiting|||600|Anticipated|INC Research|||||f||||t|f|f||||||Yes|A condensed version of the annual interim report is available to healthcare providers upon request.|2018-06-01 04:54:37.380644|2018-06-01 04:54:37.380644
NCT00114699|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-16|||2013-08-01|2005-06-16|2005-06-17|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2005||2005-04-30|August 2013|2013-08-31|April 2006|Actual|2006-04-30|||||Interventional|||Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy|A Phase 1, Randomized, Placebo-Controlled, Single-Injection, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ccr5mab004 (Human Monoclonal Igg4 Antibody To Ccr5) in Hiv-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy|Completed||Phase 1|40||Human Genome Sciences Inc.|||||||||||||||||||2018-06-01 04:54:37.458409|2018-06-01 04:54:37.458409
NCT00114686|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-16|||2013-01-03|2005-06-16|2005-06-17|Estimate|||||||2013-01-03|2013-01-04|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|April 2007|Actual|2007-04-30|||||Interventional|||Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder|A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder|Completed||Phase 3|350||AstraZeneca|||||f||||||||||||||2018-06-01 04:54:37.524716|2018-06-01 04:54:37.524716
NCT00114673|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-16|||2007-02-16|2005-06-16|2005-06-17|Estimate|||||||2007-02-16|2007-02-19|Estimate|June 2005||2005-06-30|January 2006|2006-01-31||||||||Observational|||A Study to Validate Cosmetic Outcome Scales Used to Rate Uneven Skin Color and Wrinkling|A Multicenter Study to Validate Cosmetic Outcome Scales Used to Assess Irregular Skin Pigmentation and Wrinkling|Completed|||48||Graceway Pharmaceuticals, LLC|||||f||||||||||||||2018-06-01 04:54:37.621949|2018-06-01 04:54:37.621949
NCT00114660|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-16|||2009-03-05|2005-06-16|2005-06-17|Estimate|||||||2009-03-05|2009-03-06|Estimate|November 2004||2004-11-30|March 2007|2007-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Cocoa Butter for Prevention of Stretch Marks|Topical Application of Cocoa Butter for Prevention of Striae Gravidarum|Completed||N/A|200||American University of Beirut Medical Center|||||f||||||||||||||2018-06-01 04:54:37.677295|2018-06-01 04:54:37.677295
NCT00114647|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2018-04-18|2005-06-15|2005-06-16|Estimate|||||||2018-04-18|2018-04-19|Actual|October 19, 1981||1981-10-19|November 9, 2017|2017-11-09||||||||Observational|||Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies|Procedures to Obtain Plasma, Lymphocytes, or Other Specimens for Research Studies|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:37.736928|2018-06-01 04:54:37.736928
NCT00114621|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2017-06-30|2005-06-15|2005-06-16|Estimate|||||||2017-06-30|2017-07-02|Actual|September 8, 2004||2004-09-08|March 16, 2012|2012-03-16|May 25, 2011|Actual|2011-05-25|||||Interventional|||Anthrax Vaccine Clinical Trials|Anthrax Vaccine Clinical Trials|Completed||Phase 1|93|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:38.012916|2018-06-01 04:54:38.012916
NCT00114608|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2008-03-10|2005-06-15|2005-06-16|Estimate|||||||2008-03-10|2008-03-11|Estimate|June 2005||2005-06-30|March 2008|2008-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Venous Blood Flow Velocity: Electrical Foot Stimulation Compared to Intermittent Pneumatic Compression of the Foot|Venous Blood Flow Velocity: Electrical Foot Stimulation Compared to Intermittent Pneumatic Compression of the Foot|Completed||Phase 1|40|Actual|University at Buffalo||1|||f||||t||||||||||2018-06-01 04:54:38.083796|2018-06-01 04:54:38.083796
NCT00114595|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2005-06-23|2005-06-15|2005-06-16|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2003||2003-04-30|June 2005|2005-06-30|March 2005||2005-03-31|||||Interventional|||Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia|A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia|Completed||Phase 4|84||University of Stellenbosch|||||f||||||||||||||2018-06-01 04:54:38.150106|2018-06-01 04:54:38.150106
NCT00114582|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2009-02-12|2005-06-15|2005-06-16|Estimate|||||||2009-02-12|2009-02-13|Estimate|April 2002||2002-04-30|February 2009|2009-02-28|December 2003||2003-12-31|||||Interventional|||Optimizing the Ambiance During Mealtimes in Dutch Nursing Homes|Optimizing the Ambiance During Mealtimes in Dutch Nursing Homes|Completed||Phase 2|120||Wageningen University|||||f||||||||||||||2018-06-01 04:54:38.399564|2018-06-01 04:54:38.399564
NCT00114569|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2016-05-20|2005-06-15|2005-06-16|Estimate|||||||2016-05-20|2016-05-23|Estimate|March 2005||2005-03-31|May 2009|2009-05-31|February 2009|Actual|2009-02-28|April 2007|Actual|2007-04-30||Interventional|||Lorazepam for the Treatment of Status Epilepticus in Children|Use of Lorazepam for the Treatment of Status Epilepticus|Completed||Phase 1|69|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||||||2018-06-01 04:54:38.455527|2018-06-01 04:54:38.455527
NCT00114556|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2006-05-08|2005-06-15|2005-06-16|Estimate|||||||2006-05-08|2006-05-09|Estimate|February 2000||2000-02-29|December 2004|2004-12-31|August 2004||2004-08-31|||||Interventional|||The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients|The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients – A Prospective, Randomised, Controlled Clinical Trial|Completed||Phase 4|100||Royal Prince Alfred Hospital, Sydney, Australia|||||f||||||||||||||2018-06-01 04:54:38.521023|2018-06-01 04:54:38.521023
NCT00114543|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2017-09-22|2005-06-15|2005-06-16|Estimate|||||||2017-09-22|2017-09-26|Actual|September 2002||2002-09-30|September 2017|2017-09-30|November 2007|Actual|2007-11-30|April 2005|Actual|2005-04-30||Interventional|Phototherapy||Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight|A Randomized Trial of Aggressive or Conservative Phototherapy for Extremely Low Birth Weight Infants|Completed||Phase 3|1974|Actual|NICHD Neonatal Research Network||4|||f||||t||||||||||2018-06-01 04:54:38.590288|2018-06-01 04:54:38.590288
NCT00114530|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|2017-05-05||2018-01-04|2005-06-15|2005-06-16|Estimate|2017-06-16|2017-07-14|Actual||||2018-01-04|2018-01-29|Actual|June 2005||2005-06-30|January 2018|2018-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Randomized intent to treat|Scleroderma: Cyclophosphamide or Transplantation (SCOT)|A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01)|Completed||Phase 2/Phase 3|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Results are applicable for SSc with severe internal organ disease and may not be generalizable to all those with dcSSc. The hierarchical components of the GRCS are specific to this SSc population and may not be generalizable to other SSc populations.|2|||f||||t||||||||Yes|The plan is to share IPD in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts. This archive is in support of the NIH mission to share data with the public. Data shared through ImmPort has been provided by NIH-funded programs, other research organizations and individual scientists ensuring these discoveries will be the foundation of future research.|2018-06-01 04:54:38.811903|2018-06-01 04:54:38.811903
NCT00114517|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|2017-04-17||2017-06-05|2005-06-15|2005-06-16|Estimate|2017-06-05|2017-06-08|Actual||||2017-06-05|2017-06-08|Actual|July 2004||2004-07-31|June 2017|2017-06-30|March 5, 2013|Actual|2013-03-05|February 12, 2013|Actual|2013-02-12||Interventional|||ELITE: Early Versus Late Intervention Trial With Estradiol|Biologic Response of Menopausal Women to 17B-Estradiol|Completed||Phase 2/Phase 3|643|Actual|University of Southern California||2|||f||||t||||||||||2018-06-01 04:54:40.751782|2018-06-01 04:54:40.751782
NCT00114504|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|2015-03-31||2015-05-13|2005-06-15|2005-06-16|Estimate|2015-05-13|2015-06-01|Estimate||||2015-05-13|2015-06-01|Estimate|September 2004||2004-09-30|May 2015|2015-05-31|April 2009|Actual|2009-04-30|April 2007|Actual|2007-04-30||Interventional|||Detection of Plaque Inflammation by Positron Emission Tomography (PET)-Effects of Simvastatin on Plaque Inflammation|Detection of Atherosclerotic Plaque Inflammation and Visualization of Anti-inflammatory Effects of Statins on Plaque Inflammation by FDG-PET|Completed||N/A|43|Actual|Kurume University||2|||f||||f||||||||||2018-06-01 04:54:41.221583|2018-06-01 04:54:41.221583
NCT00114491|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2006-10-30|2005-06-15|2005-06-16|Estimate|||||||2006-10-30|2006-10-31|Estimate|September 2003||2003-09-30|October 2006|2006-10-31|May 2005||2005-05-31|||||Observational|||Rosuvastatin Affecting Aortic Valve Endothelium|Rosuvastatin Affecting Aortic Valve Endothelium - RAAVE|Completed|||200||Hospital Pedro Hispano|||||f||||||||||||||2018-06-01 04:54:41.404817|2018-06-01 04:54:41.404817
NCT00114478|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-15|||2008-01-23|2005-06-15|2005-06-16|Estimate|||||||2008-01-23|2008-01-25|Estimate|November 2003||2003-11-30|January 2008|2008-01-31|May 2006||2006-05-31|||||Interventional|||Trial of Epinephrine and Albuterol in Bronchiolitis|Randomized Controlled Trial of Epinephrine and Albuterol in Bronchiolitis|Unknown status|Active, not recruiting|N/A|600||Kern Medical Center|||||f||||||||||||||2018-06-01 04:54:41.465748|2018-06-01 04:54:41.465748
NCT00114465|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2009-09-17|2005-06-14|2005-06-15|Estimate|||||||2009-09-17|2009-09-18|Estimate|June 2005||2005-06-30|September 2009|2009-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease|Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease|Completed||Phase 4|38|Actual|Orphan Australia||2|||f||||t||||||||||2018-06-01 04:54:41.547903|2018-06-01 04:54:41.547903
NCT00114452|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2014-12-02|2005-06-14|2005-06-15|Estimate|||||||2014-12-02|2014-12-04|Estimate|February 2005||2005-02-28|December 2014|2014-12-31|February 2009|Actual|2009-02-28|October 2006|Actual|2006-10-31||Interventional|||Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction|A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose Escalation, Multicenter Study to Determine the Safety of Intravenous Ex-vivo Cultured Adult Human Mesenchymal Stem Cells (Provacel) Following Acute Myocardial Infarction|Completed||Phase 1|53|Actual|Mesoblast, Ltd.||1|||f||||||||||||||2018-06-01 04:54:41.630265|2018-06-01 04:54:41.630265
NCT00114439|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2007-09-26|2005-06-14|2005-06-15|Estimate|||||||2007-09-26|2007-09-27|Estimate|September 2005||2005-09-30|September 2007|2007-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Lithium Cannabis Withdrawal Study|An Open Label Trial of Lithium for the Management of Cannabis Withdrawal|Completed||Phase 2|25|Anticipated|Sydney South West Area Health Service|||||f||||||||||||||2018-06-01 04:54:41.723081|2018-06-01 04:54:41.723081
NCT00114413|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2017-02-08|2005-06-14|2005-06-15|Estimate|||||||2017-02-08|2017-02-10|Actual|August 2004||2004-08-31|February 2017|2017-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Evaluation of an Asthma Treatment Strategy Based on Exhaled Nitric Oxide Measurements in Adolescents|Asthma Control Evaluation (ACE): A Biomarker-Based Approach to Improving Asthma Control and Mechanistic Studies (DAIT ICAC-02)|Completed||N/A|547|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 04:54:41.843959|2018-06-01 04:54:41.843959
NCT00114400|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2009-12-09|2005-06-14|2005-06-15|Estimate|||||||2009-12-09|2009-12-11|Estimate|November 2000||2000-11-30|February 2007|2007-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||BVAIT: B-Vitamin Atherosclerosis Intervention Trial|B-Vitamin Atherosclerosis Intervention Trial (BVAIT)|Completed||Phase 2/Phase 3|506||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:54:41.942675|2018-06-01 04:54:41.942675
NCT00114387|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2009-12-09|2005-06-14|2005-06-15|Estimate|||||||2009-12-09|2009-12-11|Estimate|July 1996||1996-07-31|June 2005|2005-06-30|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||VEAPS: Vitamin E Atherosclerosis Prevention Study|VEAPS: Vitamin E Atherosclerosis Prevention Study|Completed||Phase 2/Phase 3|353||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:54:42.003473|2018-06-01 04:54:42.003473
NCT00114374|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2014-06-05|2005-06-14|2005-06-15|Estimate|||||||2014-06-05|2014-06-09|Estimate|June 2005||2005-06-30|June 2014|2014-06-30|June 2007|Actual|2007-06-30|||||Interventional|||SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims|SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and Posttraumatic Stress Disorder in Physical Trauma Victims in the Medical Setting|Terminated||Phase 3|60|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:54:42.064878|2018-06-01 04:54:42.064878
NCT00114361|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2010-06-18|2005-06-14|2005-06-15|Estimate|||||||2010-06-18|2010-06-22|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|May 2008|Actual|2008-05-31||Interventional|||48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection|Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study)|Completed||Phase 3|138|Actual|Foundation for Liver Research||2|||f||||t||||||||||2018-06-01 04:54:42.130632|2018-06-01 04:54:42.130632
NCT00114348|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2013-02-01|2005-06-14|2005-06-15|Estimate|||||||2013-02-01|2013-02-04|Estimate|August 2003||2003-08-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia|ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia|Completed||Phase 4|338|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-06-01 04:54:42.203231|2018-06-01 04:54:42.203231
NCT00114335|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2008-10-09|2005-06-14|2005-06-15|Estimate|||||||2008-10-09|2008-10-10|Estimate|May 2005||2005-05-31|October 2008|2008-10-31|July 2005|Actual|2005-07-31|||||Observational|||Epidemiologic Data of Patients in a Teaching Hospital|Prevalence of Impaired Renal Function in Medical Inpatients|Completed|||352|Actual|Luzerner Kantonsspital|||||f||||||||||||||2018-06-01 04:54:42.271826|2018-06-01 04:54:42.271826
NCT00114322|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-14|||2007-01-12|2005-06-14|2005-06-15|Estimate|||||||2007-01-12|2007-01-15|Estimate|May 2005||2005-05-31|June 2005|2005-06-30||||||||Interventional|||Light-Emitting Diode (LED) Light for Seasonal Affective Disorder (SAD) Treatment|Comparing Wavelengths Using LED Light for SAD Treatment|Unknown status|Recruiting|N/A|24||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:54:42.324291|2018-06-01 04:54:42.324291
NCT00114309|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2009-04-01|2005-06-13|2005-06-14|Estimate|||||||2009-04-01|2009-04-03|Estimate|November 2004||2004-11-30|April 2009|2009-04-30|August 2009|Anticipated|2009-08-31|March 2009|Actual|2009-03-31||Interventional|||131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma|A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma|Unknown status|Active, not recruiting|Phase 2|66|Anticipated|TransMolecular||2|||f||||||||||||||2018-06-01 04:54:42.389041|2018-06-01 04:54:42.389041
NCT00114296|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2013-09-16|2005-06-13|2005-06-14|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2005||2005-04-30|July 2006|2006-07-31||||||||Interventional|||Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer|A Pilot Study to Evaluate the Effects of Omega-3 Fatty Acids on Intermediate Markers of Breast Cancer|Unknown status|Active, not recruiting|N/A|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:54:42.474798|2018-06-01 04:54:42.474798
NCT00114283|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2015-04-14|2005-06-13|2005-06-14|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2005||2005-03-31|November 2012|2012-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:54:42.689987|2018-06-01 04:54:42.689987
NCT00114270|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2013-03-25|2005-06-13|2005-06-14|Estimate|||||||2013-03-25|2013-03-26|Estimate|May 2004||2004-05-31|April 2006|2006-04-30|June 2007|Actual|2007-06-30|||||Interventional|||Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density|Evaluating the Effect of Letrozole With or Without Concomitant Zoledronic Acid on Estrogen Responsive Targets in Postmenopausal Women|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:54:42.77141|2018-06-01 04:54:42.77141
NCT00114257|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2013-02-08|2005-06-13|2005-06-14|Estimate|||||||2013-02-08|2013-02-11|Estimate|May 2005||2005-05-31|September 2006|2006-09-30||||September 2006|Actual|2006-09-30||Interventional|||Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders|A Phase I Study of 5-AZA-2'-Deoxycytidine and Depsipeptide in Patients With Relapsed/Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disease|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:54:42.832735|2018-06-01 04:54:42.832735
NCT00114244|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|2015-01-06||2015-01-06|2005-06-13|2005-06-14|Estimate|2015-01-06|2015-01-14|Estimate||||2015-01-06|2015-01-14|Estimate|December 2004||2004-12-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer|A Randomized Phase II Study of BAY 43-9006 in Combination With Gemcitabine in Metastatic Pancreatic Carcinoma|Completed||Phase 2|52|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:54:42.945825|2018-06-01 04:54:42.945825
NCT00111475|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2008-11-20|2005-05-20|2005-05-23|Estimate|||||||2008-11-20|2008-11-21|Estimate||||November 2008|2008-11-30||||||||Interventional|||Evaluating the Safety and Efficacy of AMG531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura(ITP)|A Dose-Finding Study Evaluating the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)|Completed||Phase 2|||Amgen|||||||||||||||||||2018-06-01 04:55:59.212056|2018-06-01 04:55:59.212056
NCT00114231|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|2018-02-21||2018-02-21|2005-06-13|2005-06-14|Estimate|2018-02-21|2018-03-29|Actual||||2018-02-21|2018-03-29|Actual|May 2006||2006-05-31|February 2018|2018-02-28|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer|A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer|Completed||Phase 2|90|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 04:54:43.516705|2018-06-01 04:54:43.516705
NCT00114218|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2014-12-23|2005-06-13|2005-06-14|Estimate|||||||2014-12-23|2014-12-25|Estimate|March 2005||2005-03-31|December 2014|2014-12-31||||July 2010|Actual|2010-07-31||Interventional|||Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus|Completed||Phase 2|28|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 04:54:44.039753|2018-06-01 04:54:44.039753
NCT00114205|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2010-03-17|2005-06-13|2005-06-14|Estimate|||||||2010-03-17|2010-03-18|Estimate|July 2003||2003-07-31|August 2006|2006-08-31||||||||Interventional|||Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion|Phase I Trial of Intrapleural Docetaxel Administered Via an Implantable Catheter in Subjects With a Malignant Pleural Effusion|Completed||Phase 1|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:54:44.109678|2018-06-01 04:54:44.109678
NCT00114192|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2010-01-29|2005-06-13|2005-06-14|Estimate|||||||2010-01-29|2010-02-01|Estimate|June 2004||2004-06-30|January 2010|2010-01-31||||June 2007|Actual|2007-06-30||Interventional|||Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-Small Cell Lung Cancer|Completed||Phase 2|37|Anticipated|University of Virginia|||||f||||t||||||||||2018-06-01 04:54:44.165758|2018-06-01 04:54:44.165758
NCT00114179|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2015-04-14|2005-06-13|2005-06-14|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2005||2005-01-31|December 2013|2013-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|A Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab For Locally Advanced Pancreatic Cancer|Completed||Phase 2|82|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:54:44.224295|2018-06-01 04:54:44.224295
NCT00114166|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|2014-05-27||2014-05-27|2005-06-13|2005-06-14|Estimate|2014-05-27|2014-06-26|Estimate||||2014-05-27|2014-06-26|Estimate|January 2005||2005-01-31|May 2014|2014-05-31||||January 2011|Actual|2011-01-31||Interventional||Total number eligible and evaluable participants from Regimen I and Regimen II|Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily x 5 Every 3 Weeks vs Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed||Phase 2|81|Actual|Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 04:54:44.330794|2018-06-01 04:54:44.330794
NCT00114153|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2009-11-25|2005-06-13|2005-06-14|Estimate|||||||2009-11-25|2009-11-26|Estimate|June 2003||2003-06-30|April 2007|2007-04-30||||||||Interventional|||Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Phase I Trial of Induction Paraplatin® and Xeloda® Followed by Concurrent Paraplatin and Xeloda With Intensity Modulated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|48|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:54:44.934195|2018-06-01 04:54:44.934195
NCT00114140|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|2017-01-17||2017-11-06|2005-06-13|2005-06-14|Estimate|2017-10-02|2017-11-06|Actual||||2017-11-06|2017-12-08|Actual|January 2005||2005-01-31|November 2017|2017-11-30||||February 2013|Actual|2013-02-28||Interventional||Eligible patients|Temozolomide and Radiation Therapy in Treating Patients With Gliomas|A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas|Active, not recruiting||Phase 2|136|Actual|Radiation Therapy Oncology Group|Quality of life endpoint was added via an amendment while study was in progress.|1|||f||||t||||||||||2018-06-01 04:54:45.039795|2018-06-01 04:54:45.039795
NCT00114127|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|2012-01-27||2014-06-05|2005-06-13|2005-06-14|Estimate|2012-05-03|2012-06-07|Estimate||||2014-06-05|2014-06-10|Estimate|June 2004||2004-06-30|June 2014|2014-06-30|July 2010|Actual|2010-07-31|November 2008|Actual|2008-11-30||Interventional|||Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome|Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome|Completed||Phase 3|28|Actual|Massachusetts General Hospital|Open-label in phase Phase 1; Limited power due to small sample size.|3|||f||||||||||||||2018-06-01 04:54:45.611455|2018-06-01 04:54:45.611455
NCT00114114|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2018-03-02|2005-06-13|2005-06-14|Estimate|||||||2018-03-02|2018-03-06|Actual|September 2004||2004-09-30|March 2018|2018-03-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Dose-Response of Gonadal Steroids and Bone Turnover in Men|Dose-Response of Gonadal Steroids and Bone Turnover in Men|Completed||N/A|619|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 04:54:46.146756|2018-06-01 04:54:46.146756
NCT00114101|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|2013-03-28||2018-04-20|2005-06-13|2005-06-14|Estimate|2013-05-28|2013-07-01|Estimate||||2018-04-20|2018-05-21|Actual|December 15, 2004|Actual|2004-12-15|April 2018|2018-04-30||||December 31, 2012|Actual|2012-12-31||Interventional|||Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant|A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma|Active, not recruiting||Phase 3|460|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 04:54:46.31738|2018-06-01 04:54:46.31738
NCT00114088|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2005-06-23|2005-06-13|2005-06-14|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1997||1997-11-30|June 2005|2005-06-30|January 2004||2004-01-31|||||Interventional|||Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB)|Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB)|Completed||Phase 3|242||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:54:47.34101|2018-06-01 04:54:47.34101
NCT00114075|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2012-07-17|2005-06-13|2005-06-14|Estimate|||||||2012-07-17|2012-07-18|Estimate|January 2005||2005-01-31|August 2011|2011-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effects of Walking Analysis on Surgical Outcomes|Impact of Gait Analysis on Surgical Outcomes|Completed||Phase 2|186|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||f||||||||||2018-06-01 04:54:47.394459|2018-06-01 04:54:47.394459
NCT00114062|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2016-11-28|2005-06-13|2005-06-14|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2005||2005-09-30|November 2016|2016-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study to Treat Uveitis Associated Macular Edema|A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose Ranging Pilot Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Uveitis Associated Macular Edema|Terminated||Phase 2|15|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:54:47.460653|2018-06-01 04:54:47.460653
NCT00114049|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2017-01-18|2005-06-13|2005-06-14|Estimate|||||||2017-01-18|2017-01-19|Estimate|December 2004||2004-12-31|January 2017|2017-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Dental Pain (Following Third Molar Tooth Extraction) Study|A Pivotal Phase III, Single Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Investigate the Efficacy and Safety of Single Oral Doses of 10mg, 25mg, 50mg and 70mg GW406381 and 550mg Naproxen Sodium in Subjects With Pain Following Third Molar Tooth Extraction|Completed||Phase 3|300||GlaxoSmithKline|||||||||||||||||||2018-06-01 04:54:47.517379|2018-06-01 04:54:47.517379
NCT00114036|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2005-06-23|2005-06-13|2005-06-14|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2002||2002-08-31|June 2005|2005-06-30|December 2005||2005-12-31|||||Interventional|||Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)|Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)|Unknown status|Active, not recruiting|N/A|||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:54:47.574303|2018-06-01 04:54:47.574303
NCT00114023|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-13|||2007-02-16|2005-06-13|2005-06-14|Estimate|||||||2007-02-16|2007-02-19|Estimate|January 2005||2005-01-31|October 2006|2006-10-31||||||||Observational|||1-Year Follow up to the 1473-IMIQ Study|A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study|Completed|||84||Graceway Pharmaceuticals, LLC|||||||||||||||||||2018-06-01 04:54:47.632624|2018-06-01 04:54:47.632624
NCT00114010|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-11|||2017-06-30|2005-06-11|2005-06-13|Estimate|||||||2017-06-30|2017-07-02|Actual|April 1, 2005||2005-04-01|August 19, 2010|2010-08-19|December 22, 2006|Actual|2006-12-22|December 22, 2006|Actual|2006-12-22||Interventional|||Experimental Vaccine for Malaria|Phase 1 Study of the Safety of Immunization of Naive Individuals With AMA1-C1/Alhydrogel [R], an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria, and the Effect of Immunization on Antigen-specific Memory and Plasma B Cells and T Cells|Completed||Phase 1|13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:47.681021|2018-06-01 04:54:47.681021
NCT00113997|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-11|||2008-03-03|2005-06-11|2005-06-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2005||2005-06-30|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Safety and Dosing Evaluation of REG1 Anticoagulation System|The Healthy Volunteer Evaluation of an Aptamer-RNA Target to Factor IXa|Completed||Phase 1|106||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:47.732181|2018-06-01 04:54:47.732181
NCT00113984|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-11|||2018-05-11|2005-06-11|2005-06-13|Estimate|||||||2018-05-11|2018-05-14|Actual|June 8, 2005||2005-06-08|November 7, 2012|2012-11-07|December 1, 2011|Actual|2011-12-01|February 1, 2008|Actual|2008-02-01||Interventional|||Vaccine and Antibody Treatment of Prostate Cancer|Phase I Trial of a PSA Based Vaccine and an Anti-CTLA-4 Antibody in Adults With Metastatic Androgen Independent Prostrate Cancer|Completed||Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:54:47.780749|2018-06-01 04:54:47.780749
NCT00113971|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2012-03-30|2005-06-10|2005-06-13|Estimate|||||||2012-03-30|2012-04-03|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|June 2007|Actual|2007-06-30|March 2007|Actual|2007-03-31||Interventional|||Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)|A Randomized Phase II Pharmacokinetics/Pharmacodynamics Study of Epratuzumab in Patients With Systemic Lupus Erythematosus|Terminated||Phase 2|20||UCB Pharma|||||f||||||||||||||2018-06-01 04:54:47.850315|2018-06-01 04:54:47.850315
NCT00113958|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2013-05-10|2005-06-10|2005-06-13|Estimate|||||||2013-05-10|2013-05-13|Estimate||||May 2013|2013-05-31||||||||Interventional|||Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels|Cinacalcet Open Label Study to Reach K/DOQI Levels|Completed||Phase 2|||Amgen|||||||||||||||||||2018-06-01 04:54:48.859448|2018-06-01 04:54:48.859448
NCT00113945|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2013-05-10|2005-06-10|2005-06-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|July 2003||2003-07-31|May 2013|2013-05-31||||||||Interventional|||Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)|TARGET: Treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Patients on CinacalceT|Completed||Phase 2|360||Amgen|||||||||||||||||||2018-06-01 04:54:48.923764|2018-06-01 04:54:48.923764
NCT00113932|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2011-09-01|2005-06-10|2005-06-13|Estimate|||||||2011-09-01|2011-09-02|Estimate|December 2003||2003-12-31|September 2011|2011-09-30|July 2010|Actual|2010-07-31|February 2009|Actual|2009-02-28||Interventional|||UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma|UARK 2003-41: A Phase II Study of High-Dose Density Therapy With Tandem Autologous Transplants for Patients With Multiple Myeloma|Completed||Phase 2|140|Actual|University of Arkansas|||||f||||t||||||||||2018-06-01 04:54:49.000769|2018-06-01 04:54:49.000769
NCT00113919|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|2011-04-14||2017-09-14|2005-06-10|2005-06-13|Estimate|2011-05-18|2011-06-20|Estimate||||2017-09-14|2017-10-16|Actual|June 2004||2004-06-30|September 2017|2017-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients|UARK 2003-25: A Phase I/II Open Label Study of IV Busulfan (Busulfex®) in Multiple Myeloma Patients Older Than 65 Years of Age or With Renal Insufficiency|Terminated||Phase 1/Phase 2|14|Actual|University of Arkansas|"Early termination, only 5 of the 14 completed, reasons as follows:~Death Unrelated to Protocol Adverse Event Relapse Patient Choice"|1||Due to poor accrual|f||||t||||||||||2018-06-01 04:54:49.072874|2018-06-01 04:54:49.072874
NCT00113906|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2014-02-10|2005-06-10|2005-06-13|Estimate|||||||2014-02-10|2014-02-11|Estimate|March 2005||2005-03-31|June 2005|2005-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Melatonin Treatment After Laparoscopic Cholecystectomy|The Effect of Melatonin Treatment on Postoperative Fatigue and Sleep Disturbances: A Placebo Controlled Randomized Clinical Trial|Completed||Phase 2/Phase 3|200||University Hospital, Gentofte, Copenhagen|||||f||||t||||||||||2018-06-01 04:54:49.236067|2018-06-01 04:54:49.236067
NCT00113893|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10||2013-09-13|2013-10-15|2005-06-10|2005-06-13|Estimate||||2013-09-13|2013-09-19|Estimate|2013-10-15|2013-11-07|Estimate|May 2005||2005-05-31|October 2013|2013-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.|A Randomized, MultiCenter, Open-Label, Modified Dose-Ascension, Parallel Study of the Safety, Tolerability, and Efficacy of Oral SCIO-469 in Patients With Myelodysplastic Syndromes|Completed||Phase 2|62|Actual|Scios, Inc.||4|||f||||||||||||||2018-06-01 04:54:49.42701|2018-06-01 04:54:49.42701
NCT00113880|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|2012-04-02||2012-12-03|2005-06-10|2005-06-13|Estimate|2012-12-03|2013-01-08|Estimate||||2012-12-03|2013-01-08|Estimate|October 2003||2003-10-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|September 2008|Actual|2008-09-30||Observational|||A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults|Post-Marketing Evaluation of the Safety of Influenza Virus Vaccine Live, Intranasal (FluMist) in Healthy Children and Healthy Adults 5-49 Years of Age|Completed|||63061|Actual|MedImmune LLC|||3||f||||f||||||||||2018-06-01 04:54:49.869497|2018-06-01 04:54:49.869497
NCT00113867|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2009-12-09|2005-06-10|2005-06-13|Estimate|||||||2009-12-09|2009-12-11|Estimate|September 2003||2003-09-30|November 2006|2006-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Effects of Hormonal Infertility Treatment on Cognition in Pre-Menopausal Women|Effects of Hormonal Infertility Treatment on Cognition in Pre-Menopausal Women|Completed|||80||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:54:52.048114|2018-06-01 04:54:52.048114
NCT00113841|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|2011-09-13||2011-11-15|2005-06-10|2005-06-13|Estimate|2011-09-13|2011-10-19|Estimate||||2011-11-15|2011-11-23|Estimate|November 2004||2004-11-30|November 2011|2011-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma|Pilot Study of Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma|Completed||N/A|42|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 04:54:52.250932|2018-06-01 04:54:52.250932
NCT00113828|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2018-03-14|2005-06-10|2005-06-13|Estimate|||||||2018-03-14|2018-03-15|Actual|December 2004||2004-12-31|March 2018|2018-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies|Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies|Terminated||Phase 2|5|Actual|Massachusetts General Hospital||1||Insufficient accrual|f||||t||||||||No||2018-06-01 04:54:52.573312|2018-06-01 04:54:52.573312
NCT00113815|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2014-03-25|2005-06-10|2005-06-13|Estimate|||||||2014-03-25|2014-03-26|Estimate|May 2005||2005-05-31|March 2014|2014-03-31|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures|A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1-24 Months of Age) With Refractory Partial-Onset Seizures|Completed||Phase 3|118|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||||||||||||2018-06-01 04:54:52.784537|2018-06-01 04:54:52.784537
NCT00113802|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2008-02-04|2005-06-10|2005-06-13|Estimate|||||||2008-02-04|2008-02-06|Estimate|August 2004||2004-08-31|February 2008|2008-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia|A Phase II, Single-Arm Trial of Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients With Waldenstrom's Macroglobulinemia|Terminated||Phase 2|31||Immunomedics, Inc.||||low accrual|||||||||||||||2018-06-01 04:54:53.030502|2018-06-01 04:54:53.030502
NCT00113789|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2009-02-12|2005-06-10|2005-06-13|Estimate|||||||2009-02-12|2009-02-13|Estimate|October 2003||2003-10-31|February 2009|2009-02-28|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer|Randomized, Phase 2 Study of Pegfilgrastim Given on the Last Day of a Multi-Day Topotecan Regimen or the Day After in Subjects With Relapsed or Refractory Ovarian Cancer|Completed||Phase 2|21|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:54:53.093441|2018-06-01 04:54:53.093441
NCT00113776|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2011-01-20|2005-06-10|2005-06-13|Estimate|||||||2011-01-20|2011-01-21|Estimate||||January 2011|2011-01-31||||||||Interventional|||Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer|A Multicenter, Open-label, Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects With Metastatic Colorectal Cancer|Completed||Phase 2|||Amgen|||||||||||||||||||2018-06-01 04:54:53.206575|2018-06-01 04:54:53.206575
NCT00113763|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|2010-08-06||2014-07-15|2005-06-10|2005-06-13|Estimate|2013-11-13|2014-01-03|Estimate||||2014-07-15|2014-07-23|Estimate|January 2004||2004-01-31|July 2014|2014-07-31|June 2009|Actual|2009-06-30|October 2008|Actual|2008-10-31||Interventional|||Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer|An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer|Completed||Phase 3|463|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:54:53.346912|2018-06-01 04:54:53.346912
NCT00113750|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-10|||2010-06-16|2005-06-10|2005-06-13|Estimate|||||||2010-06-16|2010-06-17|Estimate|July 2005||2005-07-31|June 2010|2010-06-30|December 2005||2005-12-31|||||Interventional|||Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen|A Multicenter, Single-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Induction of Immunogenicity With Different Doses of Tree MATA in Subjects Allergic to Tree Pollen|Completed||Phase 2|70||Allergy Therapeutics|||||||||||||||||||2018-06-01 04:54:54.509409|2018-06-01 04:54:54.509409
NCT00113737|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2016-02-17|2005-06-09|2005-06-10|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 1998||1998-02-28|June 2005|2005-06-30|January 2002|Actual|2002-01-31|||||Interventional|||Fluoxetine as a Quit Smoking AID for Depression Prone||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:54:54.655378|2018-06-01 04:54:54.655378
NCT00113724|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2009-06-03|2005-06-09|2005-06-10|Estimate|||||||2009-06-03|2009-06-04|Estimate|May 2005||2005-05-31|June 2009|2009-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of TPI 287 in Patients With Advanced Malignancies|A Phase I, Open-Label, Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies|Completed||Phase 1|48|Anticipated|Cortice Biosciences, Inc.|||||t||||f||||||||||2018-06-01 04:54:54.836162|2018-06-01 04:54:54.836162
NCT00113711|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2016-05-12|2005-06-09|2005-06-10|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1995||1995-01-31|June 2005|2005-06-30|August 1999|Actual|1999-08-31|||||Interventional|||Promoting Smoking Cessation and Reducing Weight Gain||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:54:54.959014|2018-06-01 04:54:54.959014
NCT00113698|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2014-03-11|2005-06-09|2005-06-10|Estimate|||||||2014-03-11|2014-03-13|Estimate|December 2004||2004-12-31|March 2014|2014-03-31|January 2006|Actual|2006-01-31|November 2005|Actual|2005-11-30||Interventional|AceiMR||Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation|Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD|Terminated||Phase 3|5|Actual|University of Utah||2||lower than expected enrollment|f||||t||||||||||2018-06-01 04:54:55.09643|2018-06-01 04:54:55.09643
NCT00113685|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2016-02-08|2005-06-09|2005-06-10|Estimate|||||||2016-02-08|2016-02-09|Estimate|April 2003||2003-04-30|April 2007|2007-04-30|March 2007||2007-03-31|||||Interventional|||Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury|Effect of Hypertonic Resuscitation for Blunt Trauma|Completed||N/A|209||University of Washington|||||f||||||||||||||2018-06-01 04:54:55.294699|2018-06-01 04:54:55.294699
NCT00113672|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2013-04-02|2005-06-09|2005-06-10|Estimate|||||||2013-04-02|2013-04-04|Estimate|August 2004||2004-08-31|April 2013|2013-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|MBC||Make Better Choices Study|Multiple Behavior Change in Diet and Activity|Completed||N/A|204|Actual|Northwestern University||4|||f||||t||||||||||2018-06-01 04:54:55.40026|2018-06-01 04:54:55.40026
NCT00113659|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2015-02-27|2005-06-09|2005-06-10|Estimate|||||||2015-02-27|2015-03-03|Estimate|June 2005||2005-06-30|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|May 2014|Actual|2014-05-31||Interventional|||Use of a Probiotic Supplement to Prevent Asthma in Infants|Trial of Infant Probiotic Supplementation to Prevent Asthma|Unknown status|Active, not recruiting|N/A|203|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 04:54:55.497784|2018-06-01 04:54:55.497784
NCT00113646|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2018-03-14|2005-06-09|2005-06-10|Estimate|||||||2018-03-14|2018-03-16|Actual|November 2002||2002-11-30|March 2018|2018-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies|Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies|Terminated||Phase 2|14|Actual|Massachusetts General Hospital||||Expiration of MEDI-507|f||||||||||||||2018-06-01 04:54:55.638066|2018-06-01 04:54:55.638066
NCT00113633|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2014-03-03|2005-06-09|2005-06-10|Estimate|||||||2014-03-03|2014-03-04|Estimate|September 2003||2003-09-30|March 2014|2014-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Educational Video for Improving Follow-up After an Emergency Department Visit for Asthma|A Three-part Intervention to Improve Regular Care for Asthma After a Pediatric Emergency Department Visit: A Randomized Clinical Trial|Completed||N/A|439|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-06-01 04:54:55.722219|2018-06-01 04:54:55.722219
NCT00113620|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2016-07-13|2005-06-09|2005-06-10|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2005||2005-07-31|July 2016|2016-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy|A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dextromethorphan and Quinidine at Two Dose Levels in the Treatment of the Pain of Diabetic Neuropathy|Completed||Phase 3|450|Anticipated|Avanir Pharmaceuticals|||||||||||||||||||2018-06-01 04:54:55.855094|2018-06-01 04:54:55.855094
NCT00113607|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|2013-06-18|2012-04-10|2014-06-18|2005-06-09|2005-06-10|Estimate|2013-06-18|2013-08-23|Estimate|2012-04-10|2012-04-11|Estimate|2014-06-18|2014-06-27|Estimate|April 2005||2005-04-30|June 2014|2014-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer|An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS With DOXIL/CAELYX Alone in Subjects With Advanced Relapsed Ovarian Cancer|Completed||Phase 3|672|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||t||||||||||2018-06-01 04:54:56.057496|2018-06-01 04:54:56.057496
NCT00113594|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2007-11-05|2005-06-09|2005-06-10|Estimate|||||||2007-11-05|2007-11-06|Estimate|June 2005||2005-06-30|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder|Population Pharmacokinetic Study in Adolescent Patients With Schizophrenia or Bipolar I Disorder Treated With Olanzapine|Completed||Phase 3|100||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:54:58.633736|2018-06-01 04:54:58.633736
NCT00113581|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-09|||2014-02-17|2005-06-09|2005-06-10|Estimate|||||||2014-02-17|2014-02-19|Estimate|October 2002||2002-10-31|February 2014|2014-02-28|January 2007|Actual|2007-01-31|May 2006|Actual|2006-05-31||Interventional|||Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer|A Phase I Study to Determine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Three Doses of Humanised EGFR Antibody EMD 72000 in Combination With ECX in Patients With Advanced Oesophagogastric Adenocarcinoma|Completed||Phase 1|26||Merck KGaA|||||f||||||||||||||2018-06-01 04:54:58.763034|2018-06-01 04:54:58.763034
NCT00113568|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|2009-12-11||2010-06-09|2005-06-08|2005-06-09|Estimate|2009-12-11|2010-01-20|Estimate||||2010-06-09|2010-06-15|Estimate|June 2005||2005-06-30|June 2010|2010-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Safety Study of XP12B in Women With Menorrhagia|Multicenter Study to Evaluate the Safety of XP12B in Women With Heavy Menstrual Bleeding Associated With Menorrhagia|Completed||Phase 3|784|Actual|Ferring Pharmaceuticals||1|||f||||t||||||||||2018-06-01 04:54:58.952168|2018-06-01 04:54:58.952168
NCT00113555|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|||2011-06-10|2005-06-08|2005-06-09|Estimate|||||||2011-06-10|2011-06-13|Estimate|December 2001||2001-12-31|May 2011|2011-05-31|November 2010|Actual|2010-11-30|July 2008|Actual|2008-07-31||Interventional|ACT||Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence|Clinical Investigation of an Adjustable Continence Therapy (ACT) Periurethral Prosthetic System for Treatment of Female Stress Urinary Incontinence With or Without Hypermobility|Completed||Phase 2/Phase 3|221|Actual|Uromedica||1|||f||||f||||||||||2018-06-01 04:54:59.480189|2018-06-01 04:54:59.480189
NCT00113542|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|||2015-05-20|2005-06-08|2005-06-09|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2004||2004-06-30|August 2008|2008-08-31|June 2005||2005-06-30|||||Interventional|||A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris|An Open Label Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris|Completed||Phase 2|10||University of Michigan|||||||||||||||||||2018-06-01 04:54:59.642149|2018-06-01 04:54:59.642149
NCT00113529|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|2010-03-01||2011-08-25|2005-06-08|2005-06-09|Estimate|2010-03-01|2010-03-31|Estimate||||2011-08-25|2011-08-29|Estimate|October 2004||2004-10-31|August 2011|2011-08-31|October 2008|Actual|2008-10-31|September 2007|Actual|2007-09-30||Interventional|||Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma|A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|42|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:54:59.849492|2018-06-01 04:54:59.849492
NCT00113516|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|2010-03-08||2010-05-14|2005-06-08|2005-06-09|Estimate|2010-04-02|2010-05-10|Estimate||||2010-05-14|2010-05-18|Estimate|September 2005||2005-09-30|May 2010|2010-05-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer|Phase 2 Study Of SU011248 As Consolidation Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|84|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:55:00.896874|2018-06-01 04:55:00.896874
NCT00113503|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|||2017-10-04|2005-06-08|2005-06-09|Estimate|||||||2017-10-04|2017-10-06|Actual|July 2005|Actual|2005-07-31|October 2017|2017-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Imuran Dosing in Crohn's Disease Study|A Multi-site Trial of Azathioprine Dosing in Crohn's Disease|Terminated||Phase 2|50|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||Insufficient enrollment|f||||t|t|f||||||||2018-06-01 04:55:02.862633|2018-06-01 04:55:02.862633
NCT00113490|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|2013-04-03||2013-04-03|2005-06-08|2005-06-09|Estimate|2013-04-03|2013-05-22|Estimate||||2013-04-03|2013-05-22|Estimate|May 2005||2005-05-31|April 2013|2013-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children|A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), After Dosing for a Second Season in Children Who Previously Received MEDI-524 in Protocol MI-CP104|Completed||Phase 1/Phase 2|136|Actual|MedImmune LLC||2|||f||||f||||||||||2018-06-01 04:55:03.042123|2018-06-01 04:55:03.042123
NCT00111267|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-18|||2005-06-23|2005-05-18|2005-05-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2003||2003-05-31|May 2005|2005-05-31|January 2005||2005-01-31|||||Interventional|||Oral Vitamin B12 Supplementation and Cognitive Performance in Elderly People|The Effect of Oral Vitamin B12 Supplementation on Cognitive Performance in Elderly People: the Brain12 Study|Completed||N/A|165||Wageningen University|||||f||||||||||||||2018-06-01 04:56:00.379444|2018-06-01 04:56:00.379444
NCT00113477|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-08|||2011-06-30|2005-06-08|2005-06-09|Estimate|||||||2011-06-30|2011-07-01|Estimate|May 2005||2005-05-31|September 2008|2008-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy|A Single-Centre, Randomised Double-Blind Placebo-Controlled Study to Measure the Effect of Q10 and Selen Supplement on Muscular Adverse Events in Statin Therapy|Completed||Phase 4|40|Anticipated|Oslo University Hospital|||||f||||||||||||||2018-06-01 04:55:03.566135|2018-06-01 04:55:03.566135
NCT00113464|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|||2017-06-30|2005-06-07|2005-06-08|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2, 2005||2005-06-02|April 13, 2007|2007-04-13|April 13, 2007||2007-04-13|||||Observational|||Developing Newborn Screening for Infants With Primary Immunodeficiency|Developing Newborn Screening for Infants With Primary Immunodeficiency|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:55:03.733177|2018-06-01 04:55:03.733177
NCT00113451|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|||2005-06-23|2005-06-07|2005-06-08|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2004||2004-01-31|June 2005|2005-06-30|May 2005||2005-05-31|||||Observational|||Radial Artery Bypass Graft Study of Tromsø|Radial Artery Bypass Graft Study of Tromsø|Completed|||119||University Hospital of North Norway|||||f||||||||||||||2018-06-01 04:55:03.811993|2018-06-01 04:55:03.811993
NCT00113438|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07||2011-10-28|2011-10-28|2005-06-07|2005-06-08|Estimate||||2011-10-28|2011-11-01|Estimate|2011-10-28|2011-11-01|Estimate|March 2005||2005-03-31|October 2011|2011-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors|A Randomized Open-Labeled Phase II Study of Combretastatin A-4 Phosphate in Combination With Paclitaxel and Carboplatin to Evaluate the Safety and Efficacy in Subjects With Advanced Imageable Malignancies|Completed||Phase 2|13|Actual|Mateon Therapeutics||2|||f||||f||||||||||2018-06-01 04:55:03.929966|2018-06-01 04:55:03.929966
NCT00113425|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2016-04-07||2016-08-22|2005-06-07|2005-06-08|Estimate|2016-08-22|2016-10-18|Estimate||||2016-08-22|2016-10-18|Estimate|August 2005||2005-08-31|August 2016|2016-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Non-cutting Laser Therapy in the Treatment of Acne|Photodynamic Therapy in the Treatment of Acne Vulgaris|Completed||Phase 2|44|Actual|University of Michigan||2|||f||||f||||||||No||2018-06-01 04:55:05.068123|2018-06-01 04:55:05.068123
NCT00113412|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|||2006-03-21|2005-06-07|2005-06-08|Estimate|||||||2006-03-21|2006-03-22|Estimate|May 2005||2005-05-31|March 2006|2006-03-31||||||||Interventional|||A Study of an Oral Entry Inhibitor, SP01A, in Treatment-Experienced HIV-Infected Patients|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study Of Orally Administered SP01A As Monotherapy Treatment Of HIV-Infected Patients|Unknown status|Active, not recruiting|Phase 2|32||Samaritan Pharmaceuticals, Inc|||||||||||||||||||2018-06-01 04:55:05.484205|2018-06-01 04:55:05.484205
NCT00113399|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2012-11-27||2013-06-26|2005-06-07|2005-06-08|Estimate|2012-11-28|2012-12-31|Estimate||||2013-06-26|2013-07-02|Estimate|April 2005||2005-04-30|June 2013|2013-06-30||||February 2009|Actual|2009-02-28||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery|A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone|Terminated||Phase 3|15|Actual|Radiation Therapy Oncology Group|This study terminated early with 15 subjects out of 240 subjects accrued, therefore no analysis was performed.|2||Terminated early due to low accrual.|f||||t||||||||||2018-06-01 04:55:05.675324|2018-06-01 04:55:05.675324
NCT00113386|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2012-11-27||2013-06-21|2005-06-07|2005-06-08|Estimate|2012-11-27|2012-12-27|Estimate||||2013-06-21|2013-06-28|Estimate|April 2005||2005-04-30|June 2013|2013-06-30||||February 2009|Actual|2009-02-28||Interventional|||Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer|Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer|Terminated||Phase 3|19|Actual|Radiation Therapy Oncology Group|This study terminated early with 19 out of 574 subjects accrued. Therefore no analysis was performed.|2||This study terminated early due to low accrual.|f||||t||||||||||2018-06-01 04:55:06.586813|2018-06-01 04:55:06.586813
NCT00113373|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2015-05-28||2015-05-28|2005-06-07|2005-06-08|Estimate|2015-05-28|2015-06-11|Estimate||||2015-05-28|2015-06-11|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||Eligible and treated patients.|Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer|A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|28|Actual|National Cancer Institute (NCI)|The clinical trial was a two-stage design, accruing approximately 25 patients in each stage. Early termination of the study would result if warranted from an interim futility analysis. This study stopped early for lack of treatment efficacy.|1|||f||||||||||||||2018-06-01 04:55:07.425705|2018-06-01 04:55:07.425705
NCT00113360|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2009-08-12||2012-08-01|2005-06-07|2005-06-08|Estimate|2010-11-08|2010-12-07|Estimate||||2012-08-01|2012-08-07|Estimate|January 2005||2005-01-31|August 2012|2012-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma|Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)|Completed||Phase 2|67|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:55:07.937009|2018-06-01 04:55:07.937009
NCT00113347|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|||2012-02-23|2005-06-07|2005-06-08|Estimate|||||||2012-02-23|2012-02-27|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)|Phase I Evaluation of Erlotinib and Docetaxel With Concomitant Boost Radiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:55:08.42548|2018-06-01 04:55:08.42548
NCT00113334|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2009-04-24||2014-07-14|2005-06-07|2005-06-08|Estimate|2009-04-24|2009-06-12|Estimate||||2014-07-14|2014-08-07|Estimate|April 2005||2005-04-30|July 2014|2014-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer|A Phase 1b/2 Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer|Completed||Phase 1/Phase 2|6|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:55:08.710578|2018-06-01 04:55:08.710578
NCT00113321|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2009-09-25||2012-08-01|2005-06-07|2005-06-08|Estimate|2011-01-24|2011-02-21|Estimate||||2012-08-01|2012-08-07|Estimate|March 2005||2005-03-31|August 2012|2012-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure|Phase II Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS) Post Azacytidine (AZA) Failure|Terminated||Phase 2|16|Actual|M.D. Anderson Cancer Center||1||Low Accrual|f||||f||||||||||2018-06-01 04:55:09.058383|2018-06-01 04:55:09.058383
NCT00113308|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|||2017-03-13|2005-06-07|2005-06-08|Estimate|||||||2017-03-13|2017-03-14|Actual|June 2005||2005-06-30|March 2017|2017-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis|A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis|Completed||Phase 3|2208|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:55:09.506282|2018-06-01 04:55:09.506282
NCT00113295|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2013-05-16||2014-03-20|2005-06-07|2005-06-08|Estimate|2014-03-20|2014-04-23|Estimate||||2014-03-20|2014-04-23|Estimate|February 2004||2004-02-29|March 2014|2014-03-31|November 2007|Actual|2007-11-30|February 2007|Actual|2007-02-28||Interventional||Eligible participants were men or women aged 18 and older with a primary diagnosis of DSM-IV GAD.|Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder|Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder|Completed||Phase 4|50|Actual|Massachusetts General Hospital|"Relatively small sample size of the randomized controlled phase (phase 2); conclusions from the study are limited to low power; improvement in Phase I open label paroxetine CR may include placebo response to ancillary aspects of a treatment study."|2|||f||||t||||||||||2018-06-01 04:55:10.356354|2018-06-01 04:55:10.356354
NCT00113282|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|||2011-12-21|2005-06-07|2005-06-08|Estimate|||||||2011-12-21|2011-12-22|Estimate|June 2004||2004-06-30|June 2009|2009-06-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)|Study of the Immunological Efficacy of Adding Subcutaneous Interleukin-2 (IL-2) to an Optimized Antiretroviral Regimen in HIV-1-infected Subjects Experiencing Therapeutic Failure on an Ongoing Antiretroviral Combination With a CD4 Cell Count ≤ 200/mm3 ANRS 123 Trial|Completed||Phase 2|57|Actual|French National Agency for Research on AIDS and Viral Hepatitis|||||f||||t||||||||||2018-06-01 04:55:11.354571|2018-06-01 04:55:11.354571
NCT00113269|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-07|2011-06-07||2011-08-09|2005-06-07|2005-06-08|Estimate|2011-06-07|2011-07-08|Estimate||||2011-08-09|2011-08-11|Estimate|May 2005||2005-05-31|August 2011|2011-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|INTAC||Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients|Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients|Completed||Phase 4|501|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|4|||f||||t||||||||||2018-06-01 04:55:11.658066|2018-06-01 04:55:11.658066
NCT00113256|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06|||2013-01-22|2005-06-06|2005-06-07|Estimate|||||||2013-01-22|2013-01-23|Estimate|February 2005||2005-02-28|October 2009|2009-10-31||||February 2006|Actual|2006-02-28||Interventional|||Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer|Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy|Terminated||Phase 2/Phase 3|39|Actual|Astex Pharmaceuticals|||||f||||||||||||||2018-06-01 04:55:14.82923|2018-06-01 04:55:14.82923
NCT00113243|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06|||2005-06-23|2005-06-06|2005-06-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2004||2004-12-31|June 2005|2005-06-30|December 2007||2007-12-31|||||Interventional|||Safety Study of Using Stem Cells to Stimulate Development of New Blood Vessels in Peripheral Vascular Disease|Phase I Study of Stem Cell Mediated Angiogenesis for Limb Threatening Ischemia|Unknown status|Recruiting|Phase 1|20||Murphy, Michael P., MD|||||||||||||||||||2018-06-01 04:55:14.969492|2018-06-01 04:55:14.969492
NCT00113230|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06|2009-04-17||2012-07-31|2005-06-06|2005-06-07|Estimate|2009-10-13|2009-11-13|Estimate||||2012-07-31|2012-08-07|Estimate|February 2005||2005-02-28|July 2012|2012-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer|Phase II Trial Of Neoadjuvant Concurrent Capecitabine, RHUMAB VEGF (Avastin) And Radiotherapy In Patients Presenting With Locally Advanced Rectal Cancer|Completed||Phase 2|25|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:55:15.109188|2018-06-01 04:55:15.109188
NCT00113217|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06|2013-09-04||2013-12-02|2005-06-06|2005-06-07|Estimate|2013-12-02|2014-01-14|Estimate||||2013-12-02|2014-01-14|Estimate|February 2005||2005-02-28|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma|A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMab VEGF (Bevacizumab) for Renal Cell Carcinoma|Completed||Phase 2|52|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:55:15.369272|2018-06-01 04:55:15.369272
NCT00113204|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06|||2008-05-15|2005-06-06|2005-06-07|Estimate|||||||2008-05-15|2008-05-20|Estimate|June 2005||2005-06-30|May 2008|2008-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|IPi-504-01||Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma|A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma|Completed||Phase 1|18|Actual|Infinity Pharmaceuticals, Inc.|||||f||||f||||||||||2018-06-01 04:55:15.600988|2018-06-01 04:55:15.600988
NCT00113191|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06||2012-07-26|2012-07-26|2005-06-06|2005-06-07|Estimate||||2012-07-26|2012-08-02|Estimate|2012-07-26|2012-08-02|Estimate|May 2004||2004-05-31|July 2012|2012-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants|A Phase III, Randomized, Double-blind, Multi-center Clinical Trial Comparing the Safety and Efficacy of Veronate® Versus Placebo for the Prevention of Nosocomial Staphylococcal Sepsis in Premature Infants (Birth Weight 500 - 1250 g)|Completed||N/A|2000||Bristol-Myers Squibb|||||f||||t||||||||||2018-06-01 04:55:15.686828|2018-06-01 04:55:15.686828
NCT00113178|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06|||2011-02-23|2005-06-06|2005-06-07|Estimate|||||||2011-02-23|2011-02-24|Estimate|January 2004||2004-01-31|February 2011|2011-02-28|June 2005|Actual|2005-06-30|||||Interventional|||Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial Flutter|Clinical Study to Evaluate the Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Cavo-Tricuspid Valve Isthmus-Dependent Atrial Flutter|Completed||Phase 3|160||Boston Scientific Corporation|||||||||||||||||||2018-06-01 04:55:15.833525|2018-06-01 04:55:15.833525
NCT00112749|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2016-02-12|2005-06-02|2005-06-03|Estimate|||||||2016-02-12|2016-02-15|Estimate|February 2005||2005-02-28|February 2016|2016-02-29|November 2012|Actual|2012-11-30|January 2007|Actual|2007-01-31||Interventional|||Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer|Does Blocking Proinflammatory Cytokines Diminish Cancer-Related Fatigue?|Terminated||Phase 2|7|Actual|Jonsson Comprehensive Cancer Center||1||"Recruitment stopped due to slow accrual and lack of evidence of need for further continuation~   of protocol in inpatient setting."|f||||t||||||||||2018-06-01 04:55:22.649202|2018-06-01 04:55:22.649202
NCT00113165|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-06|||2016-12-02|2005-06-06|2005-06-07|Estimate|||||||2016-12-02|2016-12-05|Estimate|October 2004||2004-10-31|December 2016|2016-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures|A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures|Completed||Phase 3|244|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:55:16.086064|2018-06-01 04:55:16.086064
NCT00113152|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2017-06-30|2005-06-03|2005-06-06|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2, 2005||2005-06-02|October 2, 2007|2007-10-02|October 2, 2007||2007-10-02|||||Observational|||Heart Disease in Sickle Cell Anemia|Are Left Ventricular Abnormalities Associated With Pulmonary Hypertension in Sickle Cell Anemia?|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:55:16.443944|2018-06-01 04:55:16.443944
NCT00113139|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2014-07-11|2005-06-03|2005-06-06|Estimate|||||||2014-07-11|2014-07-14|Estimate|September 2000||2000-09-30|March 2014|2014-03-31|August 2008|Actual|2008-08-31|August 2007|Actual|2007-08-31||Interventional|INSPIRE||Investigational Study of Psychological Intervention in Recipients of Lung Transplant (INSPIRE)|An Investigation to Examine a Telephone Based Stress Management and Coping Skills Intervention for Patients Waiting for Lung Transplant|Completed||N/A|389|Actual|Duke University||2|||f||||t||||||||||2018-06-01 04:55:16.502529|2018-06-01 04:55:16.502529
NCT00113126|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2006-11-28|2005-06-03|2005-06-06|Estimate|||||||2006-11-28|2006-11-29|Estimate|January 2002||2002-01-31|June 2005|2005-06-30|October 2005||2005-10-31|||||Interventional|||Staccato: A Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection|A Randomized Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection|Completed||N/A|526||University Hospital, Geneva|||||f||||||||||||||2018-06-01 04:55:16.567252|2018-06-01 04:55:16.567252
NCT00113113|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2013-01-22|2005-06-03|2005-06-06|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2001||2001-08-31|June 2005|2005-06-30||||||||Interventional|||Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction|Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction|Completed||Phase 1|54|Anticipated|Astex Pharmaceuticals|||||f||||||||||||||2018-06-01 04:55:16.628109|2018-06-01 04:55:16.628109
NCT00113100|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2015-05-20|2005-06-03|2005-06-06|Estimate|||||||2015-05-20|2015-05-21|Estimate|August 2004||2004-08-31|August 2008|2008-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Mechanisms of Skin Repair by Topical Estrogen|Mechanisms of Skin Repair by Topical Estrogen in Vivo|Completed||N/A|152|Actual|University of Michigan|||||f||||||||||||||2018-06-01 04:55:16.691398|2018-06-01 04:55:16.691398
NCT00113087|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|2009-09-04||2010-09-16|2005-06-03|2005-06-06|Estimate|2010-09-14|2010-09-16|Estimate||||2010-09-16|2010-09-28|Estimate|August 2003||2003-08-31|September 2009|2009-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|ISV||Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network|Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)|Completed||Phase 3|230|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 04:55:16.809009|2018-06-01 04:55:16.809009
NCT00113074|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2013-01-07|2005-06-03|2005-06-06|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2004||2004-09-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Preventing Weight Gain and Controlling Blood Pressure During Smoking Cessation in Hypertensive Smokers|Blood Pressure Control in Hypertensive Smokers|Completed||N/A|376|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 04:55:17.640461|2018-06-01 04:55:17.640461
NCT00113061|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2016-07-28|2005-06-03|2005-06-06|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2004||2004-07-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|||Effect of Exercise on Elevated C-reactive Protein Concentrations in Formerly Inactive Adults|INFLAME: Inflammation and Exercise|Completed||N/A|162||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:55:17.714546|2018-06-01 04:55:17.714546
NCT00113048|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2014-02-04|2005-06-03|2005-06-06|Estimate|||||||2014-02-04|2014-02-05|Estimate|December 2003||2003-12-31|February 2014|2014-02-28|September 2005||2005-09-30|||||Interventional|||Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies|A Phase I Study of Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies|Terminated||Phase 1|24||Sanofi|||||||||||||||||||2018-06-01 04:55:17.765806|2018-06-01 04:55:17.765806
NCT00113035|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-03|||2015-05-04|2005-06-03|2005-06-06|Estimate|||||||2015-05-04|2015-05-05|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|October 2005|Actual|2005-10-31|||||Observational|||Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease|Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)|Completed|||60||Sanofi|||1||||||||||||||||2018-06-01 04:55:17.924076|2018-06-01 04:55:17.924076
NCT00113022|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2011-04-13||2012-07-09|2005-06-02|2005-06-03|Estimate|2012-06-05|2012-07-06|Estimate||||2012-07-09|2012-07-13|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Org 24448 to Treat Major Depression|An Investigation of the Antidepressant Efficacy and Safety of an AMPAkine (Org 24448) in Major Depressive Disorder, A Double-Blind, Placebo-Controlled, Randomized Study|Terminated||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||2||Terminated due to concerns about adverse events in separate study.|f||||t||||||||||2018-06-01 04:55:17.992227|2018-06-01 04:55:17.992227
NCT00113009|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2007-11-21|2005-06-02|2005-06-03|Estimate|||||||2007-11-21|2007-11-22|Estimate|March 2005||2005-03-31|March 2006|2006-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease|A Phase II, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease|Completed||Phase 2|148||Valentis|||||||||||||||||||2018-06-01 04:55:18.220979|2018-06-01 04:55:18.220979
NCT00112996|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2014-04-07|2005-06-02|2005-06-03|Estimate|||||||2014-04-07|2014-04-08|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer|Prevention of Cisplatin- or Oxaliplatin-Induced Peripheral Neuropathy With Alpha-Lipoic Acid: A Placebo-Controlled Phase III Trial|Completed||Phase 3|244|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 04:55:18.311526|2018-06-01 04:55:18.311526
NCT00112983|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-05-29|2005-06-02|2005-06-03|Estimate|||||||2013-05-29|2013-05-30|Estimate|November 2004||2004-11-30|June 2005|2005-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria|TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:18.388434|2018-06-01 04:55:18.388434
NCT00112957|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2018-02-13||2018-03-15|2005-06-02|2005-06-03|Estimate|2018-03-15|2018-03-19|Actual||||2018-03-15|2018-03-19|Actual|December 2004|Actual|2004-12-31|March 2018|2018-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||The Safety Analysis Set includes all patients who received at least 1 injection with rV-NY-ESO-1 or rF-NY-ESO-1.|Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer|Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen|Completed||Phase 2|23|Actual|Ludwig Institute for Cancer Research||1|||f||||f|t|f|||f|||Undecided||2018-06-01 04:55:18.520079|2018-06-01 04:55:18.520079
NCT00112931|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2017-10-24|2005-06-02|2005-06-03|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2004||2004-09-30|October 2017|2017-10-31|May 2022|Anticipated|2022-05-31|March 2014|Actual|2014-03-31||Interventional|||Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma|An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma|Active, not recruiting||Phase 3|600|Anticipated|University College, London||2|||f||||t||||||||Undecided||2018-06-01 04:55:18.961719|2018-06-01 04:55:18.961719
NCT00112918|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2012-06-01||2013-06-19|2005-06-02|2005-06-03|Estimate|2012-08-06|2012-09-06|Estimate||||2013-06-19|2013-08-27|Estimate|December 2004||2004-12-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2010|Actual|2010-06-30||Interventional||Baseline Measures are based on the Intent-to-Treat - Stage III Disease Patient Population.|Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer|A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma: The AVANT Study|Completed||Phase 3|3451|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 04:55:19.180474|2018-06-01 04:55:19.180474
NCT00112905|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2010-12-30||2014-05-20|2005-06-02|2005-06-03|Estimate|2011-03-04|2011-04-04|Estimate||||2014-05-20|2014-05-30|Estimate|October 2005||2005-10-31|December 2012|2012-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium|Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer|Terminated||Phase 2|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:55:20.813659|2018-06-01 04:55:20.813659
NCT00112892|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2014-01-10|2005-06-02|2005-06-03|Estimate|||||||2014-01-10|2014-01-13|Estimate|August 2004||2004-08-31|January 2014|2014-01-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetic Study of Selenomethionine With Fixed Dose Irinotecan in Advanced Solid Tumors|Completed||Phase 1|36|Anticipated|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 04:55:21.02349|2018-06-01 04:55:21.02349
NCT00112879|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-07-09|2005-06-02|2005-06-03|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma|Phase II Study of Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Patients With Previously Untreated High-Risk or Relapsed or Refractory Multiple Myeloma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:21.078424|2018-06-01 04:55:21.078424
NCT00112866|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2016-10-07||2017-05-16|2005-06-02|2005-06-03|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|January 2005||2005-01-31|May 2017|2017-05-31|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional||26 patients evaluated for toxicity and efficacy. 1 patient deemed ineligible and 3 patients did not re-start treatment post surgery.|Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme|Phase II Trial of EMD 121974 for Recurrent Glioblastoma: A Clinical Trial With Tissue Correlates of Response|Terminated||Phase 2|30|Actual|National Cancer Institute (NCI)|Study closed early due to slow accrual. Molecular analyses evaluating alterations were planned for the study, unfortunately, majority of tumor samples were too small to do analysis and also there were unforeseen freezer issues.|2||due to poor accrual|f||||t||||||||No||2018-06-01 04:55:21.136542|2018-06-01 04:55:21.136542
NCT00112853|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-01-08|2005-06-02|2005-06-03|Estimate|||||||2013-01-08|2013-01-09|Estimate|March 2005||2005-03-31|January 2013|2013-01-31||||May 2009|Actual|2009-05-31||Interventional|||Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Trial of Oral Etoposide in Combination With the Farnesyltransferase Inhibitor R115777 (ZARNESTRA, Tipifarnib, NSC #702818, IND #58,359) in Elderly Adults With Newly Diagnosed Acute Myelogenous Leukemia (AML)|Completed||Phase 1|100|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:55:21.588438|2018-06-01 04:55:21.588438
NCT00112840|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2014-01-06||2015-10-22|2005-06-02|2005-06-03|Estimate|2014-09-04|2014-09-11|Estimate||||2015-10-22|2015-11-16|Estimate|May 2005||2005-05-31|July 2015|2015-07-31|September 2015|Actual|2015-09-30|August 2010|Actual|2010-08-31||Interventional|||CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma|Completed||Phase 1/Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:55:21.73957|2018-06-01 04:55:21.73957
NCT00112827|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2018-05-16|2005-06-02|2005-06-03|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2004|Actual|2004-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma|Tandem High-Dose Therapy With Melphalan and Total Marrow Irradiation (TMI) With Peripheral Blood Progenitor Cell Support and Lenalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial|Active, not recruiting||Phase 1/Phase 2|86|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 04:55:22.505432|2018-06-01 04:55:22.505432
NCT00112775|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2011-06-04|2005-06-02|2005-06-03|Estimate|||||||2011-06-04|2011-06-07|Estimate|March 2005||2005-03-31|April 2006|2006-04-30||||||||Interventional|||BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate|A Randomized Multi-Center Open Label Study of BMS-354825 vs Imatinib Mesylate (Gleevec®) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Iamtinib at a Dose of 400-600 mg/d|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:22.585911|2018-06-01 04:55:22.585911
NCT00111683|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2015-08-21|2005-05-24|2005-05-25|Estimate|||||||2015-08-21|2015-08-25|Estimate|June 2005||2005-06-30|August 2015|2015-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||MK0457 in Patients With Leukemia (0457-003)|A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia|Completed||Phase 1|28|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 04:55:57.431246|2018-06-01 04:55:57.431246
NCT00112736|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2015-04-28||2015-05-29|2005-06-02|2005-06-03|Estimate|2015-05-29|2015-06-15|Estimate||||2015-05-29|2015-06-15|Estimate|April 2005||2005-04-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2010|Actual|2010-04-30||Interventional||"pts had to meet eligibility criteria and recieve at least one dose of treatment.~22 eligible pts enrolled in phase 1, but 1 pt declined before starting any treatment and was excluded from analysis - 12 pts were treated at MTD and thus included in the Phase 2 analysis, hence only 9 patients remained for analysis for phase 1"|Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma|Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma|Completed||Phase 1/Phase 2|69|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 04:55:22.725564|2018-06-01 04:55:22.725564
NCT00112723|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2015-03-23||2016-06-27|2005-06-02|2005-06-03|Estimate|2016-06-27|2016-08-08|Estimate||||2016-06-27|2016-08-08|Estimate|December 2005||2005-12-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|February 2011|Actual|2011-02-28||Interventional|||Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma|A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma|Terminated||Phase 1/Phase 2|46|Actual|National Cancer Institute (NCI)||1||Administratively Complete|f||||||||||||||2018-06-01 04:55:23.152812|2018-06-01 04:55:23.152812
NCT00112710|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-08-23|2005-06-02|2005-06-03|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2005||2005-03-31|May 2007|2007-05-31||||||||Interventional|||Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 3|1350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:23.439869|2018-06-01 04:55:23.439869
NCT00112697|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2011-11-01|2005-06-02|2005-06-03|Estimate|||||||2011-11-01|2011-11-02|Estimate|December 2002||2002-12-31|December 2006|2006-12-31||||||||Interventional|||Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery|Randomized Phase II Trial Evaluating [Radiotherapy-Docetaxel-5 Fluorouracil] Association Versus [Radiotherapy-Docetaxel-Cisplatin] Association in Non Resecables First Line of Chemotherapy in Metastatics Pancreas Cancers Patients|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:23.502568|2018-06-01 04:55:23.502568
NCT00112684|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2014-02-21|2005-06-02|2005-06-03|Estimate|||||||2014-02-21|2014-02-24|Estimate|February 2006||2006-02-28|November 2011|2011-11-30||||July 2012|Actual|2012-07-31||Interventional|||Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Pilot Study of Flavopiridol in Patients With Advanced Solid Tumors|Terminated||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:55:23.570775|2018-06-01 04:55:23.570775
NCT00112671|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2015-08-04||2015-08-04|2005-06-02|2005-06-03|Estimate|2015-08-04|2015-09-03|Estimate||||2015-08-04|2015-09-03|Estimate|April 2005||2005-04-30|May 2013|2013-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||All participants|Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract|A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)|Completed||Phase 2|17|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:55:23.643584|2018-06-01 04:55:23.643584
NCT00112658|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2011-05-19|2005-06-02|2005-06-03|Estimate|||||||2011-05-19|2011-05-20|Estimate|November 2004||2004-11-30|December 2006|2006-12-31||||||||Interventional|||Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer|Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients|Unknown status|Active, not recruiting|Phase 2/Phase 3|348|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:23.80114|2018-06-01 04:55:23.80114
NCT00112645|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-07-17|2005-06-02|2005-06-03|Estimate|||||||2013-07-17|2013-07-18|Estimate|April 2005||2005-04-30|February 2011|2011-02-28|February 2011|Actual|2011-02-28|April 2010|Actual|2010-04-30||Interventional|||Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors|A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Pediatric Solid Tumors With Relapsed or Therapy Refractory Disease|Completed||Phase 1|10|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:23.901647|2018-06-01 04:55:23.901647
NCT00112632|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2012-03-07|2005-06-02|2005-06-03|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2005||2005-02-28|March 2012|2012-03-31||||||||Interventional|||Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor|Open-Label Trial of Neoadjuvant Imatinib Mesylate (Glivec) in Patients With Locally Advanced Malignant Gastrointestinal Stromal Tumors (GIST) Expressing c-Kit or Platelet-Derived Growth Factor Receptor-alpha|Completed||Phase 2|40|Anticipated|Technische Universität München|||||f||||||||||||||2018-06-01 04:55:23.960983|2018-06-01 04:55:23.960983
NCT00112619|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2011-06-29|2005-06-02|2005-06-03|Estimate|||||||2011-06-29|2011-06-30|Estimate|August 2005||2005-08-31|June 2011|2011-06-30||||August 2010|Actual|2010-08-31||Interventional|||Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors|A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children With Neoplastic Meningitis|Terminated||Phase 1|19|Actual|Pediatric Brain Tumor Consortium||||Slow accrual and company withdrawing support to supply the drug|f||||t||||||||||2018-06-01 04:55:25.021229|2018-06-01 04:55:25.021229
NCT00112593|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2017-04-17||2017-04-17|2005-06-02|2005-06-03|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|November 1999||1999-11-30|April 2017|2017-04-30||||November 2014|Actual|2014-11-30||Interventional|||Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer|Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil|Completed||N/A|5|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 04:55:25.124591|2018-06-01 04:55:25.124591
NCT00112580|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02||2015-09-23|2015-09-23|2005-06-02|2005-06-03|Estimate||||2015-09-23|2015-10-12|Estimate|2015-09-23|2015-10-12|Estimate|July 2005||2005-07-31|September 2015|2015-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery|Phase II Trial of Single Agent Ipilimumab (MDX-010 Anti CTLA-4) for Subjects With Locally Advanced or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|82|Anticipated|Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:55:25.332164|2018-06-01 04:55:25.332164
NCT00112567|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2010-09-17|2005-06-02|2005-06-03|Estimate|||||||2010-09-17|2010-09-21|Estimate|April 2003||2003-04-30|September 2010|2010-09-30|July 2007||2007-07-31|||||Interventional|||Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer|A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants|Completed||Phase 1/Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:55:25.391954|2018-06-01 04:55:25.391954
NCT00112554|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-11-05|2005-06-02|2005-06-03|Estimate|||||||2013-11-05|2013-11-06|Estimate|March 2005||2005-03-31|February 2009|2009-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse|Completed||Phase 3|420|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:55:25.558564|2018-06-01 04:55:25.558564
NCT00112528|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2016-12-09|2005-06-02|2005-06-03|Estimate|||||||2016-12-09|2016-12-13|Estimate|June 2005||2005-06-30|December 2016|2016-12-31|November 2010|Actual|2010-11-30|August 2006|Actual|2006-08-31||Interventional|||Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer|Phase II Trial of Bevacizumab, Gemcitabine, Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|53|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:55:25.771616|2018-06-01 04:55:25.771616
NCT00112515|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2009-08-19|2005-06-02|2005-06-03|Estimate|||||||2009-08-19|2009-08-20|Estimate|February 2004||2004-02-29|May 2006|2006-05-31||||||||Interventional|||Modafinil in Treating Fatigue in Patients With Cancer|Pilot Study Evaluating the Safety and Efficacy of Modafinil in Improving Fatigue, Mood, Cognitive Ability, Functional Status, and Quality of Life of Cancer Patients|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:26.157955|2018-06-01 04:55:26.157955
NCT00112502|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2014-09-23|2005-06-02|2005-06-03|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2005||2005-09-30|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme|A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme|Completed||Phase 2|178|Actual|M.D. Anderson Cancer Center||8|||f||||f||||||||||2018-06-01 04:55:26.237989|2018-06-01 04:55:26.237989
NCT00112489|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2014-04-11||2014-04-11|2005-06-02|2005-06-03|Estimate|2014-04-11|2014-05-12|Estimate||||2014-04-11|2014-05-12|Estimate|May 2005||2005-05-31|April 2014|2014-04-30||||July 2010|Actual|2010-07-31||Interventional||Total eligible and treated participants|Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer|A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma|Completed||Phase 2|55|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 04:55:26.400644|2018-06-01 04:55:26.400644
NCT00112476|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-05-01|2005-06-02|2005-06-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2005||2005-03-31|May 2013|2013-05-31||||July 2010|Actual|2010-07-31||Interventional|||Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors|A Phase I Study of Intravenous CCI-779 in Combination With Bryostatin-1 in Solid Tumors (10038414)|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:55:26.818106|2018-06-01 04:55:26.818106
NCT00112463|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2017-04-04||2017-05-18|2005-06-02|2005-06-03|Estimate|2017-04-04|2017-05-12|Actual||||2017-05-18|2017-06-14|Actual|January 7, 2005|Actual|2005-01-07|May 2017|2017-05-31|October 23, 2008|Actual|2008-10-23|October 23, 2008|Actual|2008-10-23||Interventional||All registered participants|Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma|A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||No||2018-06-01 04:55:26.911138|2018-06-01 04:55:26.911138
NCT00112437|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2010-04-13||2017-12-21|2005-06-02|2005-06-03|Estimate|2010-04-13|2010-05-13|Estimate||||2017-12-21|2018-01-24|Actual|June 24, 2005|Actual|2005-06-24|December 2017|2017-12-31|January 20, 2016|Actual|2016-01-20|December 26, 2007|Actual|2007-12-26||Interventional|||A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin K Inhibitor) in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 2|399|Actual|Merck Sharp & Dohme Corp.||5|||f|||||t|f||||||||2018-06-01 04:55:27.517438|2018-06-01 04:55:27.517438
NCT00112424|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2008-01-29|2005-06-02|2005-06-03|Estimate|||||||2008-01-29|2008-01-31|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|January 2008|Actual|2008-01-31|June 2006|Actual|2006-06-30||Interventional|||Trial of Cardiac Magnetic Resonance Imaging (MRI) Versus Cardiac Catheterization Prior to Glenn Operation|Clinical Trial of Cardiac Magnetic Resonance Imaging in Routine Evaluation Prior to Superior Cavo-Pulmonary Anastomosis|Completed||N/A|80|Actual|Boston Children’s Hospital|||||f||||t||||||||||2018-06-01 04:55:36.305043|2018-06-01 04:55:36.305043
NCT00112411|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2012-07-03|2005-06-02|2005-06-03|Estimate|||||||2012-07-03|2012-07-04|Estimate|June 2005||2005-06-30|December 2005|2005-12-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics|Dose-ranging Double-blind, Placebo-controlled Efficacy Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics|Completed||Phase 2|||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:55:36.373694|2018-06-01 04:55:36.373694
NCT00112398|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2013-03-10|2005-06-02|2005-06-03|Estimate|||||||2013-03-10|2013-03-12|Estimate|May 2005||2005-05-31|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Head Injury Retrieval Trial|Randomised, Controlled Trial of Physician Prehospital Management of Severe Blunt Head Injury|Terminated||N/A|338|Actual|CareFlight||2||"Inadequate recruitment rate combined with a high rate of patients dropping in to the treatment~   group from standard care"|f||||t||||||||||2018-06-01 04:55:36.433188|2018-06-01 04:55:36.433188
NCT00112385|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|2011-04-25||2011-05-23|2005-06-02|2005-06-03|Estimate|2011-05-23|2011-06-21|Estimate||||2011-05-23|2011-06-21|Estimate|March 2006||2006-03-31|May 2011|2011-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Pilot Study of Etanercept in Dermatomyositis|A Pilot Study of Etanercept in Dermatomyositis|Completed||Phase 1|16|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-06-01 04:55:36.572777|2018-06-01 04:55:36.572777
NCT00111670|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2016-11-01|2005-05-24|2005-05-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2005||2005-06-30|November 2016|2016-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes|A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes|Completed||Phase 2|291|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-06-01 04:55:57.524009|2018-06-01 04:55:57.524009
NCT00112372|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-02|||2015-02-11|2005-06-02|2005-06-03|Estimate|||||||2015-02-11|2015-02-12|Estimate|May 2005||2005-05-31|February 2015|2015-02-28|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional|||Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)|A Phase I/IIa, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of AP23573 When Administered Orally in Patients With Refractory or Advanced Malignancies|Completed||Phase 1|147|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 04:55:37.548048|2018-06-01 04:55:37.548048
NCT00112359|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|2010-09-10||2011-03-21|2005-06-01|2005-06-02|Estimate|2011-03-21|2011-04-21|Estimate||||2011-03-21|2011-04-21|Estimate|May 2005||2005-05-31|March 2011|2011-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|AIR-CF1||International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa|A Phase 3, Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary Pseudomonas Aeruginosa (AIR-CF1)|Completed||Phase 3|166|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 04:55:37.661689|2018-06-01 04:55:37.661689
NCT00112346|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|||2015-10-26|2005-06-01|2005-06-02|Estimate|||||||2015-10-26|2015-10-28|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|A Randomized Multicenter Phase II Study of Gemcitabine/Platinum/Cetuximab Versus Gemcitabine/Platinum as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|120||Eli Lilly and Company||2|||f||||||||||||||2018-06-01 04:55:38.552099|2018-06-01 04:55:38.552099
NCT00112333|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|||2011-07-19|2005-06-01|2005-06-02|Estimate|||||||2011-07-19|2011-07-20|Estimate|October 2003||2003-10-31|July 2011|2011-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Defining Central Circuits of Pain|Defining Central Circuits of Visceral Pain|Completed||N/A|60|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 04:55:38.665128|2018-06-01 04:55:38.665128
NCT00112320|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|||2012-12-03|2005-06-01|2005-06-02|Estimate|||||||2012-12-03|2012-12-04|Estimate|April 2004||2004-04-30|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparison of Two Pulmonary Valve Replacement Methods to Treat Tetralogy of Fallot|Randomized Trial of Pulmonary Valve Replacement in Tetralogy of Fallot|Completed||N/A|68|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-06-01 04:55:38.732335|2018-06-01 04:55:38.732335
NCT00112307|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|||2009-09-15|2005-06-01|2005-06-02|Estimate|||||||2009-09-15|2009-09-17|Estimate|March 2003||2003-03-31|September 2009|2009-09-30|October 2005||2005-10-31|||||Interventional|||Magnetic Resonance Imaging Guided Gynecologic Brachytherapy|Pilot Study of Magnetic Resonance Imaging Guided Brachytherapy|Completed||N/A|15||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 04:55:38.862663|2018-06-01 04:55:38.862663
NCT00112294|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|2010-06-30||2015-11-24|2005-06-01|2005-06-02|Estimate|2010-09-07|2010-10-05|Estimate||||2015-11-24|2015-12-24|Estimate|December 2004||2004-12-31|November 2015|2015-11-30|August 2008|Actual|2008-08-31|April 2007|Actual|2007-04-30||Interventional|||Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|A Randomized Multicenter Phase III Study of Taxane/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|755|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:55:39.01116|2018-06-01 04:55:39.01116
NCT00112281|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|||2006-08-02|2005-06-01|2005-06-02|Estimate|||||||2006-08-02|2006-08-04|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|January 2007||2007-01-31|||||Interventional|||A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack|A Phase III International, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition With Tilarginine Acetate Injection in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction, or the TRIUMPH Trial|Terminated||Phase 3|658||Arginox Pharmaceuticals|||||||||||||||||||2018-06-01 04:55:40.378148|2018-06-01 04:55:40.378148
NCT00112268|ClinicalTrials.gov processed this data on May 31, 2018|2005-06-01|||2006-10-26|2005-06-01|2005-06-02|Estimate|||||||2006-10-26|2006-10-27|Estimate|June 2005||2005-06-30|October 2006|2006-10-31|July 2006||2006-07-31|||||Interventional|||Quitlink : A Leveraging Solution to Tobacco Counseling|Quitlink : A Leveraging Solution to Tobacco Counseling|Completed||Phase 3|3200||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:55:40.638825|2018-06-01 04:55:40.638825
NCT00112255|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-31|||2018-01-16|2005-05-31|2005-06-01|Estimate|||||||2018-01-16|2018-01-17|Actual|March 2001||2001-03-31|January 2018|2018-01-31|December 2002||2002-12-31|||||Interventional|||Partner Notification for Chlamydia in Primary Care|Partner Notification for Chlamydia in Primary Care: Randomised Controlled Trial and Economic Evaluation|Completed||Phase 3|214||University of Bristol|||||f||||||||||||||2018-06-01 04:55:40.715322|2018-06-01 04:55:40.715322
NCT00112242|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-31|||2013-04-19|2005-05-31|2005-06-01|Estimate|||||||2013-04-19|2013-04-22|Estimate|February 2004||2004-02-29|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Immunotherapy of Stage III/IV Melanoma Patients|Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant|Completed||Phase 1|38|Actual|Centre Hospitalier Universitaire Vaudois||5|||f||||f||||||||||2018-06-01 04:55:40.782814|2018-06-01 04:55:40.782814
NCT00112229|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-31|||2013-04-19|2005-05-31|2005-06-01|Estimate|||||||2013-04-19|2013-04-22|Estimate|April 2003||2003-04-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|August 2011|Actual|2011-08-31||Interventional|||Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients|Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients With CpG7909, Tumor Antigenic Peptides and Montanide|Completed||Phase 1|29|Actual|Centre Hospitalier Universitaire Vaudois||4|||f||||||||||||||2018-06-01 04:55:40.86681|2018-06-01 04:55:40.86681
NCT00112216|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-31|||2013-04-23|2005-05-31|2005-06-01|Estimate|||||||2013-04-23|2013-04-24|Estimate|May 1999||1999-05-31|March 2009|2009-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Immunotherapy of Melanoma Patients|Specific Immunotherapy of Skin Melanoma Patients With Antigenic Peptides and Immunological Analysis of the Vaccine Site Sentinel Lymph Node|Completed||Phase 1|9|Actual|Centre Hospitalier Universitaire Vaudois|||||f||||f||||||||||2018-06-01 04:55:40.9498|2018-06-01 04:55:40.9498
NCT00112203|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-31|||2017-02-06|2005-05-31|2005-06-01|Estimate|||||||2017-02-06|2017-02-08|Estimate|November 2004||2004-11-30|February 2017|2017-02-28|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia|A Multicentre, Open-Label Extension Phase to Study the Long-Term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia|Completed||Phase 3|466|Actual|Forest Laboratories|||||f||||f||||||||||2018-06-01 04:55:41.028442|2018-06-01 04:55:41.028442
NCT00112190|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-31|||2017-02-06|2005-05-31|2005-06-01|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2004||2004-07-31|February 2017|2017-02-28|March 2006|Actual|2006-03-31|March 2005|Actual|2005-03-31||Interventional|||Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal|A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia|Completed||Phase 3|645|Actual|Forest Laboratories|||||f||||t||||||||||2018-06-01 04:55:41.095979|2018-06-01 04:55:41.095979
NCT00112177|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-31|||2017-02-06|2005-05-31|2005-06-01|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2004||2004-07-31|February 2017|2017-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal|A Multicentre, Randomized, Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Itopride HCl in Patients Suffering From Functional Dyspepsia|Completed||Phase 3|500||Forest Laboratories|||||f||||f||||||||||2018-06-01 04:55:41.157834|2018-06-01 04:55:41.157834
NCT00112164|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2014-03-11|2005-05-27|2005-05-30|Estimate|||||||2014-03-11|2014-03-13|Estimate|January 2005||2005-01-31|March 2014|2014-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Activated Protein C to Treat Acute Lung Injuries|Prospective, Randomized Phase II Clinical Trial of Activated Protein C (Xigris) Versus Placebo for the Treatment of Acute Lung Injury|Terminated||Phase 2|90|Anticipated|University of California, San Francisco||||Per recommendation of the NHLBI DSMB|f||||||||||||||2018-06-01 04:55:41.216996|2018-06-01 04:55:41.216996
NCT00112151|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|2015-11-04||2015-12-14|2005-05-27|2005-05-30|Estimate|2015-12-14|2016-01-20|Estimate||||2015-12-14|2016-01-20|Estimate|January 2005||2005-01-31|November 2015|2015-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||TEAM: Testosterone Supplementation and Exercise in Elderly Men|Testosterone Supplementation and Exercise in Elderly Men|Completed||Phase 2|167|Actual|University of Colorado, Denver||6|||f||||t||||||||||2018-06-01 04:55:41.310683|2018-06-01 04:55:41.310683
NCT00112138|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2011-05-20|2005-05-27|2005-05-30|Estimate|||||||2011-05-20|2011-05-23|Estimate|March 2004||2004-03-31|May 2011|2011-05-31|February 2006||2006-02-28|||||Interventional|||Gabapentin for the Treatment of Hot Flashes in Menopausal Women|Effectiveness and Safety of Gabapentin for the Treatment of Hot Flashes in Menopausal Women: A Randomized Controlled Trial|Completed||Phase 3|200||North Toronto Primary Care Research Network|||||f||||||||||||||2018-06-01 04:55:41.823085|2018-06-01 04:55:41.823085
NCT00112125|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2018-02-28|2005-05-27|2005-05-30|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2005||2005-02-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5|Evaluation of the Safety and Efficacy of the OPTIMIZER System With Active Fixation Leads in Subjects With Heart Failure Resulting From Systolic Dysfunction: FIX-HF-5|Active, not recruiting||Phase 2/Phase 3|428|Actual|Impulse Dynamics||2|||f||||t||||||||||2018-06-01 04:55:41.884164|2018-06-01 04:55:41.884164
NCT00112112|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|2012-02-27||2017-06-29|2005-05-27|2005-05-30|Estimate|2012-07-31|2012-09-03|Estimate||||2017-06-29|2017-08-14|Actual|August 1, 2005|Actual|2005-08-01|June 2017|2017-06-30|May 1, 2008|Actual|2008-05-01|March 1, 2008|Actual|2008-03-01||Interventional|||Safety Study to Evaluate FluMist in Immunocompromised Children|A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age|Completed||Phase 1|20|Actual|MedImmune LLC||2|||f||||t|t|f||||||||2018-06-01 04:55:41.993432|2018-06-01 04:55:41.993432
NCT00112099|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2016-09-20|2005-05-27|2005-05-30|Estimate|||||||2016-09-20|2016-09-22|Estimate|June 2002||2002-06-30|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110|Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: JCOG0110|Completed||Phase 3|500|Actual|Japan Clinical Oncology Group||2|||f||||t||||||||||2018-06-01 04:55:43.0934|2018-06-01 04:55:43.0934
NCT00112086|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2016-08-30|2005-05-27|2005-05-30|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2003||2003-01-31|August 2016|2016-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206|Feasibility Study of Neoadjuvant Chemotherapy Followed by Interval Cytoreductive Surgery for Stage III/IV Ovarian, Tubal and Peritoneal Cancers: JCOG0206|Completed||Phase 2|56|Actual|Japan Clinical Oncology Group|||||f||||t||||||||||2018-06-01 04:55:43.285657|2018-06-01 04:55:43.285657
NCT00112073|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27||2012-03-12|2012-03-12|2005-05-27|2005-05-30|Estimate||||2012-03-12|2012-03-14|Estimate|2012-03-12|2012-03-14|Estimate|April 2005||2005-04-30|March 2012|2012-03-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||AAB-001 in Patients With Mild to Moderate Alzheimer's Disease|A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD|Completed||Phase 2|234|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC||8|||f||||||||||||||2018-06-01 04:55:43.39465|2018-06-01 04:55:43.39465
NCT00112060|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2014-03-27|2005-05-27|2005-05-30|Estimate|||||||2014-03-27|2014-03-31|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase I/II, Open-Label, Multicenter Study of Single Agent PT-523 in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 1/Phase 2|0|Actual|Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 04:55:43.534466|2018-06-01 04:55:43.534466
NCT00112047|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|2010-06-22||2010-10-11|2005-05-27|2005-05-30|Estimate|2010-10-11|2010-10-13|Estimate||||2010-10-11|2010-10-13|Estimate|July 2003||2003-07-31|October 2010|2010-10-31|June 2009|Actual|2009-06-30|February 2005|Actual|2005-02-28||Interventional|||Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects|A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz|Completed||Phase 3|517|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 04:55:43.747394|2018-06-01 04:55:43.747394
NCT00112034|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2008-05-05|2005-05-27|2005-05-30|Estimate|||||||2008-05-05|2008-05-09|Estimate|June 2003||2003-06-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|June 2006|Actual|2006-06-30||Interventional|||"AVONEX® Combination Trial - ACT"|A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.|Completed||Phase 4|350||Biogen|||||f||||||||||||||2018-06-01 04:55:45.38876|2018-06-01 04:55:45.38876
NCT00112021|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2015-04-09|2005-05-27|2005-05-30|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects|A Phase 2B, Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects|Completed||Phase 2|400|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:55:45.450859|2018-06-01 04:55:45.450859
NCT00112008|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2009-07-09|2005-05-27|2005-05-30|Estimate|||||||2009-07-09|2009-07-10|Estimate|May 2004||2004-05-31|July 2009|2009-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis|A Multi-Center, Single-Arm Study Evaluating De Novo Once Every Two Week Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis|Completed||Phase 3|100|Anticipated|Amgen||1|||f||||||||||||||2018-06-01 04:55:45.550334|2018-06-01 04:55:45.550334
NCT00111995|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2008-08-07|2005-05-27|2005-05-30|Estimate|||||||2008-08-07|2008-08-08|Estimate|May 2002||2002-05-31|August 2008|2008-08-31||||||||Interventional|||Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis|A Randomized, Double-Blind Study Comparing Aranesp® (Darbepoetin Alfa) and Recombinant Human Erythropoietin (rHuEPO) in the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis|Completed||Phase 4|400||Amgen|||||||||||||||||||2018-06-01 04:55:45.613467|2018-06-01 04:55:45.613467
NCT00111982|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-27|||2010-02-25|2005-05-27|2005-05-30|Estimate|||||||2010-02-25|2010-02-26|Estimate|December 2003||2003-12-31|February 2010|2010-02-28|February 2006|Actual|2006-02-28|November 2005|Actual|2005-11-30||Interventional|||Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin|Multi-Center, Open-Label Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin (Protocol 20020168)|Completed||Phase 1/Phase 2|34|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:55:45.680118|2018-06-01 04:55:45.680118
NCT00111969|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2006-06-28|2005-05-26|2005-05-27|Estimate|||||||2006-06-28|2006-07-04|Estimate|June 2003||2003-06-30|June 2006|2006-06-30|November 2005||2005-11-30|||||Interventional|||ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy|A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of the Celacade™ System on Mortality and Morbidity in Patients With Chronic Heart Failure|Completed||Phase 3|2016||Vasogen|||||||||||||||||||2018-06-01 04:55:45.73167|2018-06-01 04:55:45.73167
NCT00111956|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2017-10-04|2005-05-26|2005-05-27|Estimate|||||||2017-10-04|2017-10-06|Actual|April 2004|Actual|2004-04-30|October 2017|2017-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome|Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome|Completed||Phase 2/Phase 3|56|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||||||||t|f||||||||2018-06-01 04:55:45.776473|2018-06-01 04:55:45.776473
NCT00111943|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2012-03-26|2005-05-26|2005-05-27|Estimate|||||||2012-03-26|2012-03-27|Estimate||||March 2012|2012-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Safety and Acceptability of a Vaginal Microbicide|Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel|Completed||Phase 2|200|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:55:45.839496|2018-06-01 04:55:45.839496
NCT00111930|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2009-12-09|2005-05-26|2005-05-27|Estimate|||||||2009-12-09|2009-12-11|Estimate|August 2000||2000-08-31|February 2009|2009-02-28|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Biological Effects of Dehydroepiandrosterone (DHEA) in the Elderly|Biological Effects of DHEA in the Elderly|Completed||N/A|144||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:55:45.905159|2018-06-01 04:55:45.905159
NCT00111917|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|2013-10-29||2016-05-03|2005-05-26|2005-05-27|Estimate|2014-09-24|2014-09-25|Estimate||||2016-05-03|2016-06-02|Estimate|February 2005||2005-02-28|March 2016|2016-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|BISCIT||Beryllium Infliximab Study: Clinical Interventional Trial|Clinical Efficacy of Remicade in Chronic Beryllium Disease: A Randomized, Double-Blind, Placebo-Controlled, Investigator Initiated Trial|Terminated||Phase 1/Phase 2|13|Actual|Maier, Lisa, M.D.|Although our goal was 20 CBD subjects, only 11 subjects were enrolled, 8:3 in the infliximab:placebo treatment arms as the study was stopped by the sponsor due to slow recruitment.|2||Not enough patients meeting criteria to enroll in the time period|f||||t||||||||||2018-06-01 04:55:45.962081|2018-06-01 04:55:45.962081
NCT00111904|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2011-12-13|2005-05-26|2005-05-27|Estimate|||||||2011-12-13|2011-12-14|Estimate|May 2005||2005-05-31|June 2009|2009-06-30||||August 2007|Actual|2007-08-31||Interventional|||Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer|Phase II Clinical Trial of Genexol -PM in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|43|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:55:47.07853|2018-06-01 04:55:47.07853
NCT00111891|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2017-02-16|2005-05-26|2005-05-27|Estimate|||||||2017-02-16|2017-02-17|Actual|June 2005||2005-06-30|February 2017|2017-02-28|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)|A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects|Completed||Phase 2|575|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:55:47.141315|2018-06-01 04:55:47.141315
NCT00111878|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2007-07-02|2005-05-26|2005-05-27|Estimate|||||||2007-07-02|2007-07-03|Estimate|April 2005||2005-04-30|July 2007|2007-07-31|December 2005||2005-12-31|||||Observational|||Study to Evaluate MEDI-534 in Healthy Adults|Dose-Escalating Study to Evaluate MEDI-534 in Healthy Adults|Completed|||120||MedImmune LLC|||||||||||||||||||2018-06-01 04:55:47.202451|2018-06-01 04:55:47.202451
NCT00111865|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2008-08-22|2005-05-26|2005-05-27|Estimate|||||||2008-08-22|2008-08-26|Estimate|April 2005||2005-04-30|August 2008|2008-08-31|April 2009|Anticipated|2009-04-30|August 2008|Actual|2008-08-31||Interventional|HELP||Healthy Exercise for Lymphoma Patients (HELP)|Randomized Controlled Trial of Exercise in Lymphoma Patients|Unknown status|Active, not recruiting|Phase 3|122|Actual|Lance Armstrong Foundation||2|||f||||f||||||||||2018-06-01 04:55:47.260335|2018-06-01 04:55:47.260335
NCT00111852|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|||2012-03-19|2005-05-26|2005-05-27|Estimate|||||||2012-03-19|2012-03-20|Estimate|April 2005||2005-04-30|March 2012|2012-03-31||||March 2007|Actual|2007-03-31||Interventional|||Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)|A Prospective, Randomized, Double-blind, Placebo-controlled, Single Bolus, Multinational, Multi-center, Parallel Group, Dose-ranging Study of Desmoteplase (INN) in the Indication of Acute Stroke|Completed||Phase 3|193|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 04:55:47.346373|2018-06-01 04:55:47.346373
NCT00111839|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-26|2017-08-24||2018-04-05|2005-05-26|2005-05-27|Estimate|2018-04-05|2018-04-06|Actual||||2018-04-05|2018-04-06|Actual|May 31, 2005|Actual|2005-05-31|April 2018|2018-04-30|March 31, 2009|Actual|2009-03-31|July 31, 2007|Actual|2007-07-31||Interventional||Intent to treat (ITT) population included all randomized participants who received at least one infusion of study treatment.|Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer|Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine|Completed||Phase 2|150|Actual|EMD Serono|For serious adverse events (SAEs), due diligence was done and all potential information sources have been exhausted, no further information could be retrieved apart from what is currently reported.|3|||f||||f||||||||||2018-06-01 04:55:48.208787|2018-06-01 04:55:48.208787
NCT00111826|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-25|||2010-03-30|2005-05-25|2005-05-26|Estimate|||||||2010-03-30|2010-03-31|Estimate|January 2003||2003-01-31|November 2007|2007-11-30|December 2005||2005-12-31|||||Interventional|||SIMPADICO - Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes|Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of the Celacade™ System in Improving Walking Distance in Patients With Intermittent Claudication Secondary to Peripheral Arterial Disease|Terminated||Phase 3|500||Vasogen|||||||||||||||||||2018-06-01 04:55:48.573575|2018-06-01 04:55:48.573575
NCT00111813|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-25|2011-03-10||2015-05-05|2005-05-25|2005-05-26|Estimate|2011-03-10|2011-04-06|Estimate||||2015-05-05|2015-05-21|Estimate|September 2005||2005-09-30|May 2015|2015-05-31|May 2011|Actual|2011-05-31|December 2009|Actual|2009-12-31||Interventional|||Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))|Phase I Clinical Trial of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma|Completed||Phase 1|34|Actual|Merck Sharp & Dohme Corp.||6|||f||||||||||||||2018-06-01 04:55:48.781863|2018-06-01 04:55:48.781863
NCT00111800|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-25|2017-07-20||2018-03-19|2005-05-25|2005-05-26|Estimate|2018-03-07|2018-03-13|Actual||||2018-03-19|2018-03-21|Actual|April 28, 2005|Actual|2005-04-28|March 2018|2018-03-31|July 21, 2006|Actual|2006-07-21|July 1, 2006|Actual|2006-07-01||Interventional|||A New Oral Treatment For Type II Diabetes Mellitus|A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment Extension|Completed||Phase 2|375|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:55:50.267462|2018-06-01 04:55:50.267462
NCT00111787|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-25|||2017-05-27|2005-05-25|2005-05-26|Estimate|||||||2017-05-27|2017-05-31|Actual|April 11, 2005|Actual|2005-04-11|May 2017|2017-05-31|November 1, 2006|Actual|2006-11-01|November 1, 2006|Actual|2006-11-01||Interventional|||Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer|A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination With Paclitaxel as Neoadjuvant Therapy in Patients With Newly Diagnosed Inflammatory Breast Cancer|Completed||Phase 2|49|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:55:56.07012|2018-06-01 04:55:56.07012
NCT00111774|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-25|||2013-05-10|2005-05-25|2005-05-26|Estimate|||||||2013-05-10|2013-05-14|Estimate|March 2002||2002-03-31|May 2013|2013-05-31||||||||Interventional|||Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma|An Open Label Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of ABX-EGF in Patients With Metastatic Colorectal Carcinoma|Completed||Phase 2|150||Amgen|||||||||||||||||||2018-06-01 04:55:56.185965|2018-06-01 04:55:56.185965
NCT00111761|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-25|2010-08-06||2013-11-15|2005-05-25|2005-05-26|Estimate|2011-05-05|2011-06-03|Estimate||||2013-11-15|2013-12-12|Estimate|July 2002||2002-07-31|November 2013|2013-11-30|October 2008|Actual|2008-10-31|February 2008|Actual|2008-02-29||Interventional|||Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer|A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer|Completed||Phase 2|43|Actual|Amgen||2|||f||||t||||||||||2018-06-01 04:55:56.274426|2018-06-01 04:55:56.274426
NCT00111748|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2015-10-02|2005-05-24|2005-05-25|Estimate|||||||2015-10-02|2015-10-06|Estimate|February 2005||2005-02-28|October 2015|2015-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients|UARK 2005-01, A Phase III Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients|Completed||Phase 3|180|Anticipated|University of Arkansas||2|||f||||||||||||||2018-06-01 04:55:56.969407|2018-06-01 04:55:56.969407
NCT00111735|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2005-06-23|2005-05-24|2005-05-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2003||2003-04-30|May 2005|2005-05-31|March 2005||2005-03-31|||||Interventional|||Thyroxine Titration Study|What is the Optimal Serum TSH Concentration During Thyroxine Treatment for Primary Hypothyroidism? Effects of Fine Titration of Thyroxine Dosage on Wellbeing, Quality of Life and Cognitive Function|Unknown status|Active, not recruiting|Phase 4|55||Sir Charles Gairdner Hospital|||||f||||||||||||||2018-06-01 04:55:57.038283|2018-06-01 04:55:57.038283
NCT00111722|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2017-03-31|2005-05-24|2005-05-25|Estimate|||||||2017-03-31|2017-04-04|Actual|May 27, 2005|Actual|2005-05-27|March 2017|2017-03-31|February 23, 2006|Actual|2006-02-23|February 15, 2006|Actual|2006-02-15||Interventional|||Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine|Completed||Phase 3|393|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:55:57.253238|2018-06-01 04:55:57.253238
NCT00111709|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2017-03-31|2005-05-24|2005-05-25|Estimate|||||||2017-03-31|2017-04-04|Actual|May 27, 2005|Actual|2005-05-27|March 2017|2017-03-31|February 26, 2006|Actual|2006-02-26|February 24, 2006|Actual|2006-02-24||Interventional|||Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine|Completed||Phase 3|393|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:55:57.307034|2018-06-01 04:55:57.307034
NCT00111696|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2012-03-13|2005-05-24|2005-05-25|Estimate|||||||2012-03-13|2012-03-14|Estimate|May 2005||2005-05-31|March 2012|2012-03-31|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma|Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Advanced Malignant Melanoma|Completed||Phase 1|18|Actual|MedImmune LLC||1|||f||||f||||||||||2018-06-01 04:55:57.370274|2018-06-01 04:55:57.370274
NCT00111657|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|2012-12-12||2014-09-24|2005-05-24|2005-05-25|Estimate|2012-12-12|2013-01-18|Estimate||||2014-09-24|2014-10-03|Estimate|December 2004||2004-12-31|September 2014|2014-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout|A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout|Completed||Phase 2|30|Actual|Duke University||1|||f||||f||||||||||2018-06-01 04:55:57.653245|2018-06-01 04:55:57.653245
NCT00111644|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2016-11-01|2005-05-24|2005-05-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2005||2005-03-31|November 2016|2016-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia|A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia|Completed||Phase 2|302|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 04:55:57.973732|2018-06-01 04:55:57.973732
NCT00111631|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2016-11-01|2005-05-24|2005-05-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2005||2005-05-31|November 2016|2016-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes|A Randomized, Double-blind Study of the Effect of the DPP-IV Inhibitor on HbA1c and Safety in Patients With Type 2 Diabetes Treated With a Stable Dose of Metformin|Completed||Phase 2|218|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 04:55:58.132458|2018-06-01 04:55:58.132458
NCT00111618|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-24|||2009-01-29|2005-05-24|2005-05-25|Estimate|||||||2009-01-29|2009-01-30|Estimate|May 2005||2005-05-31|January 2009|2009-01-31|August 2008|Actual|2008-08-31|June 2007|Actual|2007-06-30||Interventional|||Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer|An Open Label, Randomized, Phase II Study of AS1404 in Combination With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer|Completed||Phase 2|70|Anticipated|Antisoma Research|||||||||||||||||||2018-06-01 04:55:58.247382|2018-06-01 04:55:58.247382
NCT00111605|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-23|||2012-09-07|2005-05-23|2005-05-24|Estimate|||||||2012-09-07|2012-09-10|Estimate||||September 2012|2012-09-30|May 2008|Actual|2008-05-31|||||Interventional|||Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine With or Without IL-12 DNA Adjuvant, Boosted With Homologous Plasmids in Healthy, HIV-1 Uninfected Adult Participants|Completed||Phase 1|144|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 04:55:58.341254|2018-06-01 04:55:58.341254
NCT00111592|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-23|||2016-11-08|2005-05-23|2005-05-24|Estimate|||||||2016-11-08|2016-11-09|Estimate|August 2000||2000-08-31|November 2007|2007-11-30|December 2004|Actual|2004-12-31|||||Interventional|||Effectiveness of a Treatment Protocol for Lower Urinary Tract Symptoms in General Practice|Effectiveness of a Treatment Protocol for Lower Urinary Tract Symptoms in General Practice|Completed||N/A|208|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-06-01 04:55:58.428311|2018-06-01 04:55:58.428311
NCT00111579|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-23|||2008-07-22|2005-05-23|2005-05-24|Estimate|||||||2008-07-22|2008-07-24|Estimate|May 2005||2005-05-31|July 2008|2008-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)|A Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With Trivalent Inactivated Vaccine (TIV) in Children 6 to <36 Months of Age|Completed||Phase 2|52||MedImmune LLC||2|||f||||f||||||||||2018-06-01 04:55:58.497071|2018-06-01 04:55:58.497071
NCT00111566|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-23|||2013-11-27|2005-05-23|2005-05-24|Estimate|||||||2013-11-27|2013-11-28|Estimate|December 2004||2004-12-31|November 2013|2013-11-30|August 2007|Actual|2007-08-31|July 2007|Actual|2007-07-31||Interventional|||BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention|Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention|Completed||Phase 4|624|Actual|Cardiology Research UBC||2|||f||||f||||||||||2018-06-01 04:55:58.560678|2018-06-01 04:55:58.560678
NCT00111553|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-23|||2007-02-13|2005-05-23|2005-05-24|Estimate|||||||2007-02-13|2007-02-15|Estimate|October 2004||2004-10-31|February 2007|2007-02-28|August 2006||2006-08-31|||||Interventional|||Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis|Randomized, Double-Blind, Adjuvant- and Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine With Meglumine Antimoniate (Glucantime) in Cutaneous Leishmaniasis|Completed||Phase 1|45||IDRI|||||||||||||||||||2018-06-01 04:55:58.628229|2018-06-01 04:55:58.628229
NCT00111540|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-23|||2015-02-19|2005-05-23|2005-05-24|Estimate|||||||2015-02-19|2015-02-23|Estimate|November 2002||2002-11-30|January 2015|2015-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes|An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|456|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 04:55:58.69237|2018-06-01 04:55:58.69237
NCT00111527|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2010-03-22|2005-05-20|2005-05-23|Estimate|||||||2010-03-22|2010-03-23|Estimate|May 2005||2005-05-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||APAF: Assessment of Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation|An Assessment of the Echo-guided Optimal Cardiac Resynchronization Therapy in Patients Undergoing 'Ablate And Pace' Therapy for Permanent Atrial Fibrillation|Completed||Phase 3|458|Anticipated|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||f||||||||||2018-06-01 04:55:58.933699|2018-06-01 04:55:58.933699
NCT00111514|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2007-02-13|2005-05-20|2005-05-23|Estimate|||||||2007-02-13|2007-02-15|Estimate|July 2004||2004-07-31|February 2007|2007-02-28|May 2006||2006-05-31|||||Interventional|||Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety, Tolerability, and Immunogenicity of Leish-111f + MPL-SE Vaccine in Combination With Pentavalent Antimony in Treatment of Mucosal Leishmaniasis|Completed||Phase 1|48||IDRI|||||||||||||||||||2018-06-01 04:55:59.004337|2018-06-01 04:55:59.004337
NCT00111501|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2015-03-05|2005-05-20|2005-05-23|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2002||2002-09-30|March 2015|2015-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||LGBT Internet Based Smoking Treatment - 1|LGBT Internet Based Smoking Treatment|Completed||Phase 3|792|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-06-01 04:55:59.069203|2018-06-01 04:55:59.069203
NCT00111488|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2016-01-05|2005-05-20|2005-05-23|Estimate|||||||2016-01-05|2016-01-06|Estimate|June 2005||2005-06-30|May 2014|2014-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Guidant Microwave Ablation System for the Treatment of Atrial Fibrillation|Randomized Study of Surgical Ablation With Microwave Energy for the Treatment of Atrial Fibrillation|Terminated||Phase 3|200||Boston Scientific Corporation||||Slow enrollment|||||||||||||||2018-06-01 04:55:59.133463|2018-06-01 04:55:59.133463
NCT00111462|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2013-05-06|2005-05-20|2005-05-23|Estimate|||||||2013-05-06|2013-05-08|Estimate||||May 2013|2013-05-31||||||||Interventional|||Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy|A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) Using Fixed and Weight-Based Dosing for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy|Completed||Phase 2|||Amgen|||||||||||||||||||2018-06-01 04:55:59.325432|2018-06-01 04:55:59.325432
NCT00111449|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2013-05-13|2005-05-20|2005-05-23|Estimate|||||||2013-05-13|2013-05-15|Estimate|June 2003||2003-06-30|May 2013|2013-05-31||||||||Interventional|||Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis|A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis|Completed||Phase 3|600||Amgen|||||||||||||||||||2018-06-01 04:55:59.382915|2018-06-01 04:55:59.382915
NCT00111436|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2013-04-24|2005-05-20|2005-05-23|Estimate|||||||2013-04-24|2013-04-26|Estimate|April 2003||2003-04-30|April 2013|2013-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects|An Open-Label, Long-Term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects|Completed||Phase 3|912|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:55:59.462013|2018-06-01 04:55:59.462013
NCT00111423|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2009-03-04|2005-05-20|2005-05-23|Estimate|||||||2009-03-04|2009-03-06|Estimate|August 2002||2002-08-31|December 2007|2007-12-31||||||||Interventional|||Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)|Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA)|Completed||Phase 2|216||Amgen|||||||||||||||||||2018-06-01 04:55:59.532969|2018-06-01 04:55:59.532969
NCT00111410|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-20|||2016-08-10|2005-05-20|2005-05-23|Estimate|||||||2016-08-10|2016-08-11|Estimate||||August 2016|2016-08-31|November 2003|Actual|2003-11-30|||||Interventional|||Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)|A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA)|Completed||Phase 4|||Swedish Orphan Biovitrum|||||f||||||||||||||2018-06-01 04:55:59.582775|2018-06-01 04:55:59.582775
NCT00111397|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2017-06-30|2005-05-19|2005-05-20|Estimate|||||||2017-06-30|2017-07-02|Actual|May 13, 2005||2005-05-13|August 4, 2010|2010-08-04|August 4, 2010|Actual|2010-08-04|August 4, 2010|Actual|2010-08-04||Interventional|||Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection|A Study of Adjuvant Cytokine Therapy in Pulmonary Mycobacterium Avium Complex and Other Pulmonary Nontuberculous Mycobacterial Infections|Completed||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:55:59.653739|2018-06-01 04:55:59.653739
NCT00111384|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2018-03-27|2005-05-19|2005-05-20|Estimate|||||||2018-03-27|2018-03-29|Actual|May 13, 2005||2005-05-13|September 27, 2017|2017-09-27||||||||Observational|||Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)|Variation in Gene Expression in Neurofibromatosis Type 1|Active, not recruiting|||313|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:55:59.720534|2018-06-01 04:55:59.720534
NCT00111371|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2014-12-04|2005-05-19|2005-05-20|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2005||2005-01-31|September 2006|2006-09-30|October 2015|Anticipated|2015-10-31|||||Interventional|||Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia|Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia)|Unknown status|Recruiting|Phase 4|100|Anticipated|University Hospital Muenster|||||f||||||||||||||2018-06-01 04:55:59.791306|2018-06-01 04:55:59.791306
NCT00111358|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2011-04-15|2005-05-19|2005-05-20|Estimate|||||||2011-04-15|2011-04-18|Estimate|June 2003||2003-06-30|April 2011|2011-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study of Lifestyle Modification in HIV Lipodystrophy|The Effects of a Lifestyle Modification Program (REACH) in Patients With HIV and Metabolic Syndrome|Completed||N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-06-01 04:55:59.870232|2018-06-01 04:55:59.870232
NCT00111345|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2012-05-21|2005-05-19|2005-05-20|Estimate|||||||2012-05-21|2012-05-23|Estimate|March 2004||2004-03-31|March 2012|2012-03-31|March 2017|Anticipated|2017-03-31|March 2012|Actual|2012-03-31||Interventional|||Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents|Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents|Unknown status|Active, not recruiting|Phase 2/Phase 3|550|Actual|University Hospital Muenster||4|||f||||t||||||||||2018-06-01 04:55:59.960529|2018-06-01 04:55:59.960529
NCT00111332|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2010-04-12|2005-05-19|2005-05-20|Estimate|||||||2010-04-12|2010-04-14|Estimate|November 2002||2002-11-30|April 2010|2010-04-30|July 2005|Actual|2005-07-31|||||Interventional|||Study of Home-Based Resistance and Strength Training in HIV-Infected Women|Exercise Effects in HIV-Infected Women|Completed||N/A|40||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 04:56:00.052664|2018-06-01 04:56:00.052664
NCT00111319|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2009-03-25|2005-05-19|2005-05-20|Estimate|||||||2009-03-25|2009-03-26|Estimate|December 2004||2004-12-31|March 2009|2009-03-31||||July 2007|Actual|2007-07-31||Interventional|||VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma|An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma|Completed||Phase 3|||Millennium Pharmaceuticals, Inc.|||||t||||||||||||||2018-06-01 04:56:00.113047|2018-06-01 04:56:00.113047
NCT00111306|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-19|||2011-11-07|2005-05-19|2005-05-20|Estimate|||||||2011-11-07|2011-11-08|Estimate|June 2005||2005-06-30|November 2011|2011-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of Epratuzumab in Systemic Lupus Erythematosus|A Phase III, Randomized, Double-Blind. Placebo-Controlled, Multi-Center Study of Systemic Lupus Erythematosus With Acute Severe SLE Flares Excluding Renal or Neurological Systems|Terminated||Phase 3|510||UCB Pharma|||||f||||||||||||||2018-06-01 04:56:00.185703|2018-06-01 04:56:00.185703
NCT00111293|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-18|||2017-06-30|2005-05-18|2005-05-19|Estimate|||||||2017-06-30|2017-07-02|Actual|May 16, 2005||2005-05-16|May 14, 2010|2010-05-14|May 14, 2010||2010-05-14|||||Observational|||Attention and Visual Perception|Top-Down Attentional Control of Visual Processing|Completed|||8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:00.27133|2018-06-01 04:56:00.27133
NCT00111280|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-18|||2011-05-18|2005-05-18|2005-05-19|Estimate|||||||2011-05-18|2011-05-19|Estimate|September 2004||2004-09-30|April 2010|2010-04-30|March 2007|Actual|2007-03-31|||||Interventional|||TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial|HIV-1 Infected Subjects Who Were Randomized in Any Sponsor-selected TMC125 Trial to an Active Control Arm and Either Virologically Failed or Completed the Entire Treatment Period, or to Placebo Arm and Were Treated for at Least 48 Weeks.|Completed||Phase 2|48|Actual|Tibotec Pharmaceuticals, Ireland|||||||||||||||||||2018-06-01 04:56:00.322189|2018-06-01 04:56:00.322189
NCT00111241|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-18|||2009-09-17|2005-05-18|2005-05-19|Estimate|||||||2009-09-17|2009-09-18|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|December 2010|Anticipated|2010-12-31|May 2010|Anticipated|2010-05-31||Observational|||Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors|Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls|Unknown status|Active, not recruiting||170|Anticipated|Monash University|||||f||||||||||||||2018-06-01 04:56:00.496143|2018-06-01 04:56:00.496143
NCT00111228|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-18|||2006-10-24|2005-05-18|2005-05-19|Estimate|||||||2006-10-24|2006-10-25|Estimate|October 2004||2004-10-31|October 2006|2006-10-31|May 2005||2005-05-31|||||Interventional|||The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-Time Values of Guardian RT|Randomised, Controlled, Multi-Centric, Clinical Study to Assess Whether Type 1 Diabetic Patients in Poor Glycemic Control Can Improve Using the Real-Time Values of Guardian T Versus Conventional Self-Monitoring Blood Glucose|Completed||Phase 4|162||Medtronic|||||f||||||||||||||2018-06-01 04:56:00.575938|2018-06-01 04:56:00.575938
NCT00111215|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-18|||2007-03-12|2005-05-18|2005-05-19|Estimate|||||||2007-03-12|2007-03-13|Estimate|January 2001||2001-01-31|June 2006|2006-06-30|September 2006||2006-09-30|||||Interventional|||Treatment and Management of Women With Bleeding Disorders|Treatment and Management of Women With Bleeding Disorders|Completed||N/A|100||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 04:56:00.64037|2018-06-01 04:56:00.64037
NCT00111202|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2005-09-28|2005-05-17|2005-05-18|Estimate|||||||2005-09-28|2005-09-30|Estimate|May 2005||2005-05-31|May 2005|2005-05-31|June 2006||2006-06-30|||||Observational|||Schizophrenia and Genetic Counseling|Schizophrenia and Genetic Counseling: A Survey of People With Schizophrenia and Their Relatives|Unknown status|Active, not recruiting||100||Sarah Lawrence College|||||f||||||||||||||2018-06-01 04:56:00.696321|2018-06-01 04:56:00.696321
NCT00111189|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2014-06-19|2005-05-17|2005-05-18|Estimate|||||||2014-06-19|2014-06-20|Estimate|February 2005||2005-02-28|June 2014|2014-06-30|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Interventional|||A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.|A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion.|Completed||Phase 3|414|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 04:56:00.743984|2018-06-01 04:56:00.743984
NCT00111176|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2014-08-15|2005-05-17|2005-05-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|March 2004||2004-03-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|July 2007|Actual|2007-07-31||Interventional|STARZ-TX2||STARZ-TX2 Clinical Study: Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft|Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft|Completed||N/A|260|Actual|Cook Group Incorporated||2|||f||||t||||||||||2018-06-01 04:56:00.856846|2018-06-01 04:56:00.856846
NCT00111163|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2012-09-26|2005-05-17|2005-05-18|Estimate|||||||2012-09-26|2012-09-27|Estimate|March 2004||2004-03-31|September 2012|2012-09-30|March 2008|Actual|2008-03-31|March 2006|Actual|2006-03-31||Interventional|||Intermittent Preventive Treatment With Antimalarials in Kenyan Infants|Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya|Completed||N/A|1516||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 04:56:01.066472|2018-06-01 04:56:01.066472
NCT00111150|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2007-03-16|2005-05-17|2005-05-18|Estimate|||||||2007-03-16|2007-03-19|Estimate|September 2005||2005-09-30|March 2007|2007-03-31|March 2007|Actual|2007-03-31|||||Interventional|||Botswana Tenofovir Oral HIV Prophylaxis Trial|Study of the Safety and Efficacy of Daily Tenofovir Disoproxil Fumarate for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana|Terminated||Phase 2/Phase 3|1200||Centers for Disease Control and Prevention||||Consenting participants entered tenofovir/emtricitabine oral prophylaxis trial|f||||t||||||||||2018-06-01 04:56:01.132845|2018-06-01 04:56:01.132845
NCT00111137|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2008-02-20|2005-05-17|2005-05-18|Estimate|||||||2008-02-20|2008-02-28|Estimate|February 2003||2003-02-28|February 2008|2008-02-29|April 2004|Actual|2004-04-30|November 2003|Actual|2003-11-30||Interventional|||Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy|A Randomized, Open Label Study to Assess Time to Hemoglobin Response of a Front Load Dosing Regimen for Darbepoetin Alfa Compared to a Weekly Dose Regimen for Recombinant Human Erythropoietin in Patients With Non-Myeloid Malignancies Receiving Chemotherapy|Completed||Phase 3|718|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:56:01.192674|2018-06-01 04:56:01.192674
NCT00111124|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2013-05-13|2005-05-17|2005-05-18|Estimate|||||||2013-05-13|2013-05-15|Estimate||||May 2013|2013-05-31||||||||Interventional|||Enbrel® in Psoriatic Arthritis|Enbrel® in Psoriatic Arthritis|Completed||Phase 4|||Amgen|||||||||||||||||||2018-06-01 04:56:01.255234|2018-06-01 04:56:01.255234
NCT00111111|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2009-05-28|2005-05-17|2005-05-18|Estimate|||||||2009-05-28|2009-05-29|Estimate||||May 2009|2009-05-31||||||||Interventional|||An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis|A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects With Psoriasis|Completed||Phase 3|||Amgen|||||||||||||||||||2018-06-01 04:56:01.312026|2018-06-01 04:56:01.312026
NCT00111098|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2008-08-07|2005-05-17|2005-05-18|Estimate|||||||2008-08-07|2008-08-08|Estimate|March 2004||2004-03-31|August 2008|2008-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis|A Multicenter, Single Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing In Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis|Completed||Phase 3|150|Anticipated|Amgen||1|||f||||||||||||||2018-06-01 04:56:01.369652|2018-06-01 04:56:01.369652
NCT00111085|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-17|||2017-10-26|2005-05-17|2005-05-18|Estimate|||||||2017-10-26|2017-10-30|Actual|January 10, 2005|Actual|2005-01-10|October 2017|2017-10-31|March 30, 2006|Actual|2006-03-30|March 30, 2006|Actual|2006-03-30||Interventional|CONSCIOUS-1||Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)|A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist|Completed||Phase 2|413|Actual|Actelion||4|||f||||||||||||||2018-06-01 04:56:01.503138|2018-06-01 04:56:01.503138
NCT00111059|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2005-06-23|2005-05-16|2005-05-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2005||2005-01-31|May 2005|2005-05-31|April 2006||2006-04-30|||||Observational|||Primary Prevention Study: Study on Obesity, Cardiovascular and Psycho-Social Characteristics in the City of Merzig|Cross-Sectional Case-Control Study on Obesity, Cardiovascular and Psycho-Social Characteristics in the City of Merzig|Unknown status|Recruiting||600||University Hospital, Saarland|||||f||||||||||||||2018-06-01 04:56:01.608325|2018-06-01 04:56:01.608325
NCT00111046|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2005-11-09|2005-05-16|2005-05-17|Estimate|||||||2005-11-09|2005-11-10|Estimate|February 2001||2001-02-28|May 2005|2005-05-31|February 2004||2004-02-29|||||Interventional|||Pain Relief - Tramadol Versus Ibuprofen|Post-Operative Pain Relief Following Insertion of Radioactive Plaque for Choroidal Melanoma: Randomised Control Trial of Tramadol Vs Ibuprofen: A Pilot Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|40||Royal Liverpool University Hospital|||||f||||||||||||||2018-06-01 04:56:01.684133|2018-06-01 04:56:01.684133
NCT00111020|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2014-08-05|2005-05-16|2005-05-17|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2005||2005-06-30|August 2014|2014-08-31|October 2008|Actual|2008-10-31|June 2007|Actual|2007-06-30||Interventional|||Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma|Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 3|2567|Actual|Bayer||1|||t||||f||||||||||2018-06-01 04:56:01.817455|2018-06-01 04:56:01.817455
NCT00111007|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|2011-01-27||2014-10-23|2005-05-16|2005-05-17|Estimate|2011-01-27|2011-02-23|Estimate||||2014-10-23|2014-10-31|Estimate|May 2005||2005-05-31|October 2014|2014-10-31|January 2009|Actual|2009-01-31|September 2006|Actual|2006-09-30||Interventional|||A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma|Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma.|Completed||Phase 3|270|Actual|Bayer|Metastatic melanoma is notorious for its resistance to chemotherapy. Thus, it is unlikely that inhibition of a single factor or pathway would produce a sustained clinical effect in patients with previously treated, highly refractory disease.|2|||f||||t||||||||||2018-06-01 04:56:02.339086|2018-06-01 04:56:02.339086
NCT00110994|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|2011-01-26||2015-05-13|2005-05-16|2005-05-17|Estimate|2011-04-29|2011-06-01|Estimate||||2015-05-13|2015-06-08|Estimate|April 2005||2005-04-30|May 2015|2015-05-31|March 2008|Actual|2008-03-31|October 2006|Actual|2006-10-31||Interventional|||Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma|Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Dacarbazine (DTIC) Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma|Completed||Phase 2|101|Actual|Bayer||2|||f||||t||||||||||2018-06-01 04:56:03.153604|2018-06-01 04:56:03.153604
NCT00110981|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2013-05-22|2005-05-16|2005-05-17|Estimate|||||||2013-05-22|2013-05-24|Estimate|March 2005||2005-03-31|May 2013|2013-05-31|March 2006|Actual|2006-03-31|February 2006|Actual|2006-02-28||Interventional|||Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis|A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis|Completed||Phase 4|86|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:56:03.732671|2018-06-01 04:56:03.732671
NCT00110968|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2017-02-06|2005-05-16|2005-05-17|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2004||2004-09-30|February 2017|2017-02-28|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia|A Multicentre, Open-label Extension Phase to Study the Long-term Safety and Efficacy of Itopride HCl in Patients Suffering From Functional Dyspepsia|Completed||Phase 3|300||Forest Laboratories|||||f||||||||||||||2018-06-01 04:56:03.801448|2018-06-01 04:56:03.801448
NCT00110955|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2010-01-14|2005-05-16|2005-05-17|Estimate|||||||2010-01-14|2010-01-15|Estimate|February 2004||2004-02-29|January 2010|2010-01-31|April 2005|Actual|2005-04-30|March 2005|Actual|2005-03-31||Interventional|||Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy|A Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy|Completed||Phase 3|391|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:56:03.84803|2018-06-01 04:56:03.84803
NCT00110942|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2008-06-20|2005-05-16|2005-05-17|Estimate|||||||2008-06-20|2008-06-23|Estimate|February 2005||2005-02-28|June 2008|2008-06-30|November 2005|Actual|2005-11-30|June 2005|Actual|2005-06-30||Interventional|||Treatment for Patients With Osteoarthritis (OA)|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Systemic AMG 108 in Subjects With Osteoarthritis (OA)|Completed||Phase 2|160|Actual|Amgen||4|||f||||||||||||||2018-06-01 04:56:04.839578|2018-06-01 04:56:04.839578
NCT00110929|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2010-04-22|2005-05-16|2005-05-17|Estimate|||||||2010-04-22|2010-04-23|Estimate|November 2002||2002-11-30|April 2010|2010-04-30||||||||Interventional|||Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)|A Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D Regimens Are Used in Subjects With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)|Completed||Phase 2|850||Amgen|||||||||||||||||||2018-06-01 04:56:04.9025|2018-06-01 04:56:04.9025
NCT00110916|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2008-02-20|2005-05-16|2005-05-17|Estimate|||||||2008-02-20|2008-02-22|Estimate|June 2004||2004-06-30|February 2008|2008-02-29|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Treatment for Patients With Osteoarthritis (OA) of the Knee|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Intra-Articular metHuIL-1ra (Anakinra) in Subjects With Osteoarthritis (OA) of the Knee|Completed||Phase 2|165|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 04:56:04.961555|2018-06-01 04:56:04.961555
NCT00110903|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2013-04-24|2005-05-16|2005-05-17|Estimate|||||||2013-04-24|2013-04-26|Estimate||||April 2013|2013-04-30||||||||Interventional|||Treatment for Subjects With Active Rheumatoid Arthritis (RA)|Open-Label Study to Assess the Safety of Etanercept Liquid Administered Once Weekly in Subjects With Active Rheumatoid Arthritis (RA)|Completed||Phase 3|||Amgen|||||||||||||||||||2018-06-01 04:56:05.02156|2018-06-01 04:56:05.02156
NCT00110890|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|2010-10-15||2011-02-11|2005-05-16|2005-05-17|Estimate|2011-02-11|2011-03-07|Estimate||||2011-02-11|2011-03-07|Estimate|May 2004||2004-05-31|February 2011|2011-02-28|September 2007|Actual|2007-09-30|April 2005|Actual|2005-04-30||Interventional|||A Research Study for Patients With End-Stage Renal Disease (ESRD)|An Open-Label, Randomised Study Using Cinacalcet to Improve Achievement of Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With ESRD|Completed||Phase 4|552|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:56:05.12242|2018-06-01 04:56:05.12242
NCT00111072|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-16|||2008-03-03|2005-05-14|2005-05-16|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2005||2005-05-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Dexamethasone to Treat Oral Lichen Planus|Dexamethasone 0.01% Solution for the Treatment of Oral Lichen Planus|Completed||Phase 2|70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:06.49693|2018-06-01 04:56:06.49693
NCT00110877|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|||2015-07-01|2005-05-13|2005-05-16|Estimate|||||||2015-07-01|2015-07-03|Estimate|April 2005||2005-04-30|July 2015|2015-07-31|October 2011|Actual|2011-10-31|January 2007|Actual|2007-01-31||Interventional|||TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients|A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients|Completed||Phase 3|604|Actual|Tibotec Pharmaceuticals, Ireland||2|||f||||t||||||||||2018-06-01 04:56:06.586743|2018-06-01 04:56:06.586743
NCT00110864|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|||2007-08-21|2005-05-13|2005-05-16|Estimate|||||||2007-08-21|2007-08-23|Estimate|May 2005||2005-05-31|August 2007|2007-08-31|April 2007|Actual|2007-04-30|||||Interventional|||Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes|Completed||Phase 2|90|Anticipated|Wellstat Therapeutics|||||||||||||||||||2018-06-01 04:56:06.878263|2018-06-01 04:56:06.878263
NCT00110851|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|||2007-08-21|2005-05-13|2005-05-16|Estimate|||||||2007-08-21|2007-08-23|Estimate|April 2005||2005-04-30|August 2007|2007-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) Therapy|Completed||Phase 2|90|Anticipated|Wellstat Therapeutics|||||||||||||||||||2018-06-01 04:56:06.968428|2018-06-01 04:56:06.968428
NCT00110838|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|||2006-07-20|2005-05-13|2005-05-16|Estimate|||||||2006-07-20|2006-07-21|Estimate|October 2001||2001-10-31|May 2005|2005-05-31|January 2005||2005-01-31|||||Interventional|||SOFA: Study on Omega-3 Fatty Acids and Ventricular Arrhythmia|Study on Omega-3 Fatty Acids and Ventricular Arrhythmia, a Parallel, Placebo-Controlled, Double Blind Intervention Study|Completed||Phase 3|546||Wageningen Centre for Food Sciences|||||f||||||||||||||2018-06-01 04:56:07.058595|2018-06-01 04:56:07.058595
NCT00110825|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|||2017-01-11|2005-05-13|2005-05-16|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2004||2004-02-29|June 2009|2009-06-30|June 2009|Actual|2009-06-30|March 2006|Actual|2006-03-31||Interventional|||Behavioral Smoking Cessation Treatment - 1|Behavioral Maintenance Treatment for Smoking Cessation|Completed||N/A|304|Actual|National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 04:56:07.147181|2018-06-01 04:56:07.147181
NCT00110812|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|2012-12-12|2010-01-30|2014-04-07|2005-05-13|2005-05-16|Estimate|2014-04-07|2014-05-12|Estimate|2010-01-30|2010-02-02|Estimate|2014-04-07|2014-05-12|Estimate|September 2005||2005-09-30|April 2014|2014-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|STALWART||Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People|STALWART: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 With and Without Concomitant Antiretroviral Therapy in Patients With HIV-1 Infection and CD4+ Cell Counts of 300 Cells/mm3 or More|Completed||Phase 2|267|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|All randomized patients were followed through 28 Feb 2009. A subset of 222 consenting patients were followed 2 additional years, through 28 Feb 2011.|3|||f||||t||||||||||2018-06-01 04:56:07.269975|2018-06-01 04:56:07.269975
NCT00110799|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|||2012-05-31|2005-05-13|2005-05-16|Estimate|||||||2012-05-31|2012-06-04|Estimate|April 2005||2005-04-30|March 2011|2011-03-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C|A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group, Phase II Study to Assess Efficacy, Safety/Tolerability, and Pharmacokinetics of a Thrombopoietin Receptor Agonist, SB-497115-GR, When Administered as 30, 50, and 75 mg Once Daily for 12 Weeks in Subjects With|Completed||Phase 2|75|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 04:56:09.933187|2018-06-01 04:56:09.933187
NCT00110786|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-13|||2010-06-16|2005-05-13|2005-05-16|Estimate|||||||2010-06-16|2010-06-17|Estimate|May 2005||2005-05-31|September 2009|2009-09-30|December 2005||2005-12-31|||||Interventional|||Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy|A Double Blind Study to Investigate the Clinical Efficacy and Safety of Ragweed MATAMPL (Allergy Therapeutics®), Pollinex®-R (Allergy Therapeutics®) and Placebo in Patients With Seasonal Allergic Rhinitis With Ragweed Allergy, in an Environmental Exposure Chamber (EEC) Model, With Follow-Up During a Natural Ragweed Pollen Season|Completed||Phase 2|240||Allergy Therapeutics|||||f||||||||||||||2018-06-01 04:56:10.308341|2018-06-01 04:56:10.308341
NCT00110773|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2012-06-04|2005-05-12|2005-05-13|Estimate|||||||2012-06-04|2012-06-05|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Pulsed Dye Laser (PDL) Therapy in Adults|A Randomized, Double-Blind, Placebo Controlled, Parallel Study Evaluating the Efficacy of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) to Provide Local Dermal Anesthesia for Pulsed Dye Laser Therapy in Adults|Completed||Phase 3|80|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 04:56:10.406428|2018-06-01 04:56:10.406428
NCT00110760|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2012-06-04|2005-05-12|2005-05-13|Estimate|||||||2012-06-04|2012-06-05|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face|Randomized, Double-Blind, Placebo Controlled, Paired Study Evaluating S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream)for Induction of Local Dermal Anesthesia for Dermal Filler Injection on the Face of Adults|Completed||Phase 3|70|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 04:56:10.594715|2018-06-01 04:56:10.594715
NCT00110747|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2012-06-04|2005-05-12|2005-05-13|Estimate|||||||2012-06-04|2012-06-05|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults|A Randomized, Double-Blind, Placebo Controlled, Paired Study Evaluating the Efficacy of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) in Providing Local Dermal Anesthesia for Non-Ablative Facial Laser Resurfacing in Adults|Completed||Phase 3|54|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 04:56:10.69796|2018-06-01 04:56:10.69796
NCT00110734|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2005-09-21|2005-05-12|2005-05-13|Estimate|||||||2005-09-21|2005-09-23|Estimate||||September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Laser-Assisted Tattoo Removal in Adults|A Randomized, Double-Blind, Placebo Controlled, Paired Study Evaluating S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) for Induction of Local Dermal Anesthesia for Laser-Assisted Tattoo Removal in Adults|Completed||Phase 3|60||ZARS Pharma Inc.|||||||||||||||||||2018-06-01 04:56:10.78207|2018-06-01 04:56:10.78207
NCT00110721|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2012-03-05|2005-05-12|2005-05-13|Estimate|||||||2012-03-05|2012-03-06|Estimate|May 2005||2005-05-31|March 2012|2012-03-31|February 2008|Actual|2008-02-29|June 2007|Actual|2007-06-30||Interventional|||GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer|A Phase II, Multi-Center, Open-Label Trial to Evaluate the Efficacy and Safety of Intravenous GM-CT-01 in Combination With 5-Fluorouracil When Administered in Monthly Cycles as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer|Terminated||Phase 2|20|Actual|Galectin Therapeutics Inc.||||Study protocol amended to a new treatment regimen: study DAVFU-006.|f||||f||||||||||2018-06-01 04:56:10.936871|2018-06-01 04:56:10.936871
NCT00110708|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2006-02-20|2005-05-12|2005-05-13|Estimate|||||||2006-02-20|2006-02-22|Estimate|April 2005||2005-04-30|February 2006|2006-02-28|June 2006||2006-06-30|||||Interventional|||Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism|A Randomized, Placebo-Controlled Phase II Trial Evaluating Safety and Efficacy of Oral Human Immunoglobulin in the Treatment of Gastrointestinal Dysfunction Associated With Autistic Disorder in Pediatric Patients From 2 to 18 Years of Age|Unknown status|Active, not recruiting|Phase 2|120||PediaMed Pharmaceuticals|||||||||||||||||||2018-06-01 04:56:11.029718|2018-06-01 04:56:11.029718
NCT00110695|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2010-03-24|2005-05-12|2005-05-13|Estimate|||||||2010-03-24|2010-03-26|Estimate|April 2005||2005-04-30|March 2010|2010-03-31|July 2008|Actual|2008-07-31|December 2006|Actual|2006-12-31||Interventional|||Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer|A Phase 2 Study of Neoadjuvant Chemotherapy With Sequential Weekly Nanoparticle Albumin Bound Paclitaxel (Abraxane) Followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) in Locally Advanced Breast Cancer|Completed||Phase 2|66|Actual|NSABP Foundation Inc||1|||f||||f||||||||||2018-06-01 04:56:11.127178|2018-06-01 04:56:11.127178
NCT00110682|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2008-04-21|2005-05-12|2005-05-13|Estimate|||||||2008-04-21|2008-04-24|Estimate|April 2005||2005-04-30|April 2008|2008-04-30|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses|A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up|Completed||Phase 4|60||Derm Research @ 888 Inc.|||||f||||t||||||||||2018-06-01 04:56:11.203882|2018-06-01 04:56:11.203882
NCT00110669|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2011-10-26|2005-05-12|2005-05-13|Estimate|||||||2011-10-26|2011-10-27|Estimate|January 2004||2004-01-31|October 2011|2011-10-31|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Interventional|||High-dose Prednisone in Duchenne Muscular Dystrophy|A Randomized Study of Daily vs. High-dose Weekly Prednisone Therapy in Duchenne Muscular Dystrophy|Completed||Phase 3|64|Actual|Cooperative International Neuromuscular Research Group||2|||f||||t||||||||||2018-06-01 04:56:11.409208|2018-06-01 04:56:11.409208
NCT00110656|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-12|||2011-01-20|2005-05-12|2005-05-13|Estimate|||||||2011-01-20|2011-01-21|Estimate|March 2004||2004-03-31|January 2011|2011-01-31|October 2004|Actual|2004-10-31|September 2004|Actual|2004-09-30||Observational|||Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation|A Retrospective Follow Up Study to Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation|Completed|||38|Actual|Amgen|||1||f||||||||||None Retained|"~     Retrospective data collected.~   "|||2018-06-01 04:56:11.509028|2018-06-01 04:56:11.509028
NCT00110643|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-11|||2015-04-30|2005-05-11|2005-05-12|Estimate|||||||2015-04-30|2015-05-04|Estimate|February 2003||2003-02-28|April 2015|2015-04-30|December 2005||2005-12-31|||||Interventional|||Infrared Non-Cutting Laser Therapy for Acne|CoolTouch Non-ablative Laser Therapy for Acne Vulgaris|Completed||Phase 2/Phase 3|50||University of Michigan|||||f||||f||||||||||2018-06-01 04:56:11.600268|2018-06-01 04:56:11.600268
NCT00110630|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-11|||2017-01-11|2005-05-10|2005-05-11|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2005||2005-06-30|September 2008|2008-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|STOP||Smoking Treatment of Prisoners|"Smoking Treatment of Prisoners: Project STOP"|Completed||Phase 3|250|Actual|National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 04:56:11.723657|2018-06-01 04:56:11.723657
NCT00110617|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|2011-01-11||2011-05-23|2005-05-10|2005-05-11|Estimate|2011-03-31|2011-05-02|Estimate||||2011-05-23|2011-05-26|Estimate|May 2005||2005-05-31|May 2011|2011-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients|A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients With Iron Overload From Repeated Blood Transfusions|Completed||Phase 2|212|Actual|Novartis|Due to severe good clinical practice violations, data from 9 participants recruited for Center 512 was excluded from the main analysis of the study.|2|||f||||||||||||||2018-06-01 04:56:11.892802|2018-06-01 04:56:11.892802
NCT00110604|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|||2008-12-29|2005-05-10|2005-05-11|Estimate|||||||2008-12-29|2008-12-31|Estimate|September 2000||2000-09-30|May 2005|2005-05-31|December 2004||2004-12-31|||||Interventional|||The Effect of Folic Acid on Atherosclerosis, Cognitive Performance and Hearing|The Folic Acid and Carotid Intima-Media Thickness (FACIT) Study: A Randomized Controlled Trial|Completed||N/A|835||Wageningen University|||||f||||||||||||||2018-06-01 04:56:13.380788|2018-06-01 04:56:13.380788
NCT00110591|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|||2015-12-14|2005-05-10|2005-05-11|Estimate|||||||2015-12-14|2015-12-15|Estimate|April 2004||2004-04-30|December 2015|2015-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers|A Phase I, Randomized, Double Blind, Placebo Controlled, Single-Dose, Rising Dose Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO 140 in Healthy Volunteers|Completed||Phase 1|20|Actual|CytoDyn, Inc.||5|||f||||f||||||||||2018-06-01 04:56:13.452882|2018-06-01 04:56:13.452882
NCT00110578|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|||2008-08-07|2005-05-10|2005-05-11|Estimate|||||||2008-08-07|2008-08-08|Estimate|September 1998||1998-09-30|July 2007|2007-07-31|April 2005||2005-04-30|||||Interventional|||Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults|Safety and Antiviral Efficacy of Cellular Adoptive Immunotherapy With Autologous CD8+ HIV-Specific Cytotoxic T Cells Combined With Interleukin-2 For HIV Seropositive Individuals|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:56:13.556188|2018-06-01 04:56:13.556188
NCT00110565|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|||2008-08-04|2005-05-10|2005-05-11|Estimate|||||||2008-08-04|2008-08-06|Estimate|January 2005||2005-01-31|August 2008|2008-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effects of Pulsed Magnetic Pads on Rheumatoid Arthritis Symptoms in Postmenopausal Women|Pulsed Electromagnetic Field (PEMF) Efficacy in Reducing Rheumatoid Arthritis Symptoms|Completed||Phase 2|87||National Center for Complementary and Integrative Health (NCCIH)|||||f||||f||||||||||2018-06-01 04:56:13.642511|2018-06-01 04:56:13.642511
NCT00110552|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|||2014-10-27|2005-05-10|2005-05-11|Estimate|||||||2014-10-27|2014-10-29|Estimate|July 2005||2005-07-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients|Effects of a Cognitive Enhancer on Memory and Cognitive Performance|Completed||Phase 1|111|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-06-01 04:56:13.883409|2018-06-01 04:56:13.883409
NCT00110539|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|||2012-05-23|2005-05-10|2005-05-11|Estimate|||||||2012-05-23|2012-05-24|Estimate|February 2004||2004-02-29|August 2006|2006-08-31|December 2004||2004-12-31|||||Interventional|||Effectiveness of an Internet-Based Curriculum in Increasing Health Care Providers' Knowledge of Herbs and Dietary Supplements|Internet-Based Curriculum About Herbs and Dietary Supplements|Completed||N/A|1500||National Library of Medicine (NLM)|||||f||||||||||||||2018-06-01 04:56:13.99547|2018-06-01 04:56:13.99547
NCT00110526|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|||2013-10-23|2005-05-10|2005-05-11|Estimate|||||||2013-10-23|2013-10-24|Estimate|April 2005||2005-04-30|October 2013|2013-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Gene Therapy for Prostate Cancer That Returns After Radiation Therapy|Phase I Trial of Adenovirus- Mediated IL-12 Gene Transduction in Patients With Radiorecurrent Prostate Cancer|Withdrawn||Phase 1|0|Actual|Icahn School of Medicine at Mount Sinai||1||No participants met eligibility requirements|f||||t||||||||||2018-06-01 04:56:14.087082|2018-06-01 04:56:14.087082
NCT00110513|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-10|2012-03-19||2012-08-10|2005-05-10|2005-05-11|Estimate|2012-04-13|2012-05-11|Estimate||||2012-08-10|2012-08-17|Estimate|April 2005||2005-04-30|August 2012|2012-08-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery|A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin Alfa in Hereditary Antithrombin (AT) Deficient Patients in High-Risk Situations for Thrombosis|Completed||Phase 3|18|Actual|rEVO Biologics||1|||f||||f||||||||||2018-06-01 04:56:14.32599|2018-06-01 04:56:14.32599
NCT00110500|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-09|||2011-06-06|2005-05-09|2005-05-10|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2005||2005-04-30|June 2011|2011-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy|A Phase I Dose-Escalation Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy|Completed||Phase 1|12|Anticipated|Sangamo Therapeutics|||||||||||||||||||2018-06-01 04:56:14.662598|2018-06-01 04:56:14.662598
NCT00110487|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-09|||2015-04-30|2005-05-09|2005-05-10|Estimate|||||||2015-04-30|2015-05-01|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women|A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Effect of ERB-041 in the Reduction of Symptoms Associated With Endometriosis in Reproductive-Age Women|Completed||Phase 2|200||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 04:56:14.780362|2018-06-01 04:56:14.780362
NCT00110474|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-09|||2006-09-18|2005-05-09|2005-05-10|Estimate|||||||2006-09-18|2006-09-19|Estimate|May 2000||2000-05-31|September 2006|2006-09-30|December 2002||2002-12-31|||||Interventional|||Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis|Efficacy and Safety of Glucosamine Sulfate Versus a Pure Analgesic (Acetaminophen/Paracetamol) and Placebo in Patients Suffering From Osteoarthritis of the Knee|Completed||Phase 3|300||Rottapharm|||||f||||||||||||||2018-06-01 04:56:14.939853|2018-06-01 04:56:14.939853
NCT00110461|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-09|2011-08-11||2012-04-19|2005-05-09|2005-05-10|Estimate|2012-04-19|2012-05-21|Estimate||||2012-04-19|2012-05-21|Estimate|March 2005||2005-03-31|April 2012|2012-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Aripiprazole in Children and Adolescents With Bipolar I Disorder|A Phase III Trial to Test the Safety and Efficacy of Two Doses of Aripiprazole in Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features|Completed||Phase 3|296|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|Primary efficacy endpoint is change from baseline in Y-MRS total score. Only randomized subjects with both baseline and 1+ post-baseline were included in primary efficacy analysis so # randomized is different from # included in the efficacy analysis.|3|||f||||||||||||||2018-06-01 04:56:15.086053|2018-06-01 04:56:15.086053
NCT00110448|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-09|||2016-10-31|2005-05-09|2005-05-10|Estimate|||||||2016-10-31|2016-11-02|Estimate|December 2002||2002-12-31|August 2008|2008-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial|Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial|Completed||Phase 4|2539|Actual|Kumamoto University||2|||f||||t||||||||||2018-06-01 04:56:16.861974|2018-06-01 04:56:16.861974
NCT00110435|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-09|||2017-03-13|2005-05-09|2005-05-10|Estimate|||||||2017-03-13|2017-03-14|Actual|May 2005||2005-05-31|March 2017|2017-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)|A Multicenter, Randomized, Double-blind, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypercholesterolemia|Completed||Phase 3|1229|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:56:16.960526|2018-06-01 04:56:16.960526
NCT00110422|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-09||2010-02-15|2011-04-07|2005-05-09|2005-05-10|Estimate||||2010-02-15|2010-02-17|Estimate|2011-04-07|2011-04-15|Estimate|November 2005||2005-11-30|June 2010|2010-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome|Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome|Completed||Phase 4|400||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 04:56:17.064009|2018-06-01 04:56:17.064009
NCT00110409|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-06|||2013-06-07|2005-05-06|2005-05-09|Estimate|||||||2013-06-07|2013-06-10|Estimate|January 2005||2005-01-31|June 2013|2013-06-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Asthma Patient Education in the Emergency Room|Trial of Asthma Patient Education in the Emergency Room|Completed||N/A|296|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-06-01 04:56:17.202158|2018-06-01 04:56:17.202158
NCT00110396|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-06|2010-04-30||2015-06-18|2005-05-06|2005-05-09|Estimate|2010-06-14|2010-07-09|Estimate||||2015-06-18|2015-07-15|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|RNF||Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis|A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis|Completed||Phase 3|260|Actual|EMD Serono||1|||f||||||||||||||2018-06-01 04:56:17.319603|2018-06-01 04:56:17.319603
NCT00110383|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-06|||2014-03-02|2005-05-06|2005-05-09|Estimate|||||||2014-03-02|2014-03-04|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Comparison of School-Based Supervised Versus Parental Supervised Asthma Therapy|Effectiveness of School Based Supervised Asthma Therapy|Completed||N/A|295|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 04:56:17.658541|2018-06-01 04:56:17.658541
NCT00110370|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-06|||2007-11-26|2005-05-06|2005-05-09|Estimate|||||||2007-11-26|2007-11-27|Estimate|April 2004||2004-04-30|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes|A Comparison of Prandial Insulin Lispro Mixtures Therapy to Glargine Basal-Bolus Therapy With Insulin Lispro on the Overall Glycemic Control of Patients With Type 2 Diabetes Previously Treated With Oral Agents Combined With Insulin Glargine|Completed||Phase 4|300||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:56:17.7688|2018-06-01 04:56:17.7688
NCT00108316|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2013-09-25|2005-04-14|2005-04-15|Estimate|||||||2013-09-25|2013-09-27|Estimate|January 2004||2004-01-31|September 2013|2013-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Determinants in Antidepressant Outcomes|SERT Affinity Determinants in Antidepressant Outcomes|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1||Study PI resigned|f||||||||||||||2018-06-01 04:56:54.064295|2018-06-01 04:56:54.064295
NCT00110357|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-06|2009-04-21||2015-11-24|2005-05-06|2005-05-09|Estimate|2009-08-10|2009-08-11|Estimate||||2015-11-24|2015-12-24|Estimate|August 2005||2005-08-31|November 2015|2015-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors|Phase I Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors|Completed||Phase 1|48|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 04:56:17.9927|2018-06-01 04:56:17.9927
NCT00110344|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-06|||2013-10-10|2005-05-06|2005-05-09|Estimate|||||||2013-10-10|2013-10-11|Estimate|November 2005||2005-11-30|October 2013|2013-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Research Study for Patients With Metastatic Renal Cell Carcinoma|A Phase II Study of BAY 43-9006 Prior to and Following Nephrectomy in Patients With Metastatic Renal Cell Carcinoma.|Terminated||Phase 2|1|Actual|Bayer||2|||f||||f||||||||||2018-06-01 04:56:20.098397|2018-06-01 04:56:20.098397
NCT00110331|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-05|||2018-05-19|2005-05-05|2005-05-06|Estimate|||||||2018-05-19|2018-05-22|Actual|May 3, 2005||2005-05-03|September 9, 2014|2014-09-09|September 9, 2014||2014-09-09|||||Observational|||Central Nervous System Disease in HIV-infected Children on HAART||Completed|||21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:20.213675|2018-06-01 04:56:20.213675
NCT00110318|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-05|||2013-12-09|2005-05-05|2005-05-06|Estimate|||||||2013-12-09|2013-12-11|Estimate|March 2002||2002-03-31|December 2013|2013-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Trial of Physiotherapy and Corticosteroid Injections in Lateral Epicondylalgia|A Pragmatic, Randomised Controlled Trial of Physiotherapy and Corticosteroid Injections in Lateral Epicondylalgia|Completed||Phase 3|198||The University of Queensland|||||f||||||||||||||2018-06-01 04:56:20.398984|2018-06-01 04:56:20.398984
NCT00110305|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-05|2013-04-26||2014-06-11|2005-05-05|2005-05-06|Estimate|2013-08-21|2013-10-28|Estimate||||2014-06-11|2014-06-25|Estimate|June 2005||2005-06-30|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines|A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects|Completed||Phase 2|368|Actual|Tibotec Pharmaceuticals, Ireland||4|||f||||t||||||||||2018-06-01 04:56:20.533869|2018-06-01 04:56:20.533869
NCT00110292|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-05|||2005-06-23|2005-05-05|2005-05-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2002||2002-03-31|May 2005|2005-05-31|February 2006||2006-02-28|||||Interventional|||Preventing Learning Problems in Young Children: A Public Health and Physician-Based Outreach|An RCT of a Low-Intensity Intervention to Reduce Delay|Unknown status|Active, not recruiting|Phase 1|600||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:56:22.078719|2018-06-01 04:56:22.078719
NCT00110279|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-05|||2008-01-18|2005-05-05|2005-05-06|Estimate|||||||2008-01-18|2008-01-21|Estimate|June 2005||2005-06-30|January 2008|2008-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)|Phase I Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study A)|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 04:56:22.134317|2018-06-01 04:56:22.134317
NCT00110266|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-04|||2016-11-16|2005-05-04|2005-05-05|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2005||2005-05-31|November 2016|2016-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients|An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring|Completed||Phase 2|176|Actual|Novartis||1|||f||||f||||||||||2018-06-01 04:56:22.235062|2018-06-01 04:56:22.235062
NCT00110253|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-04|||2012-06-04|2005-05-04|2005-05-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|June 2005||2005-06-30|June 2012|2012-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Duration of Skin Numbing Effect Created by the S-Caine™ Peel|A Randomized, Double-Blind, Paired, Placebo Controlled Study Evaluating the Duration of Anesthetic Effect Produced by the S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) When Applied for 30 and 60 Minutes|Completed||Phase 3|40|Actual|ZARS Pharma Inc.||1|||f||||f||||||||||2018-06-01 04:56:22.444634|2018-06-01 04:56:22.444634
NCT00110240|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-04|||2012-05-04|2005-05-04|2005-05-05|Estimate|||||||2012-05-04|2012-05-07|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|594|Actual|Novartis|||||f||||||||||||||2018-06-01 04:56:22.544831|2018-06-01 04:56:22.544831
NCT00110227|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-04|||2017-02-23|2005-05-04|2005-05-05|Estimate|||||||2017-02-23|2017-02-27|Actual|September 2005||2005-09-30|February 2017|2017-02-28|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|NEXT-Heart||Tai Chi Mind-Body Therapy for Chronic Heart Failure|Tai Chi Mind-Body Therapy for Chronic Heart Failure|Completed||Phase 3|100|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-06-01 04:56:22.718611|2018-06-01 04:56:22.718611
NCT00110214|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-04|2013-03-07||2014-04-21|2005-05-04|2005-05-05|Estimate|2013-03-07|2013-04-17|Estimate||||2014-04-21|2014-05-09|Estimate|April 2005||2005-04-30|December 2012|2012-12-31|August 2011|Actual|2011-08-31|March 2010|Actual|2010-03-31||Interventional|||Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy|A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Doctaxel and Prednisone With and Without Bevacizumab (IND #7921, NSC #704865) in Men With Hormone Refractory Prostate Cancer|Completed||Phase 3|1050|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:56:22.888538|2018-06-01 04:56:22.888538
NCT00110201|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-04|||2005-06-23|2005-05-04|2005-05-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2005||2005-03-31|May 2005|2005-05-31|December 2007||2007-12-31|||||Interventional|||The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure|Prophylactic Use of Nesiritide (Brain Natriuretic Peptide, BNP) for the Prevention of Acute Renal Failure in Thoracic Aortic Aneurysm Surgery Patients|Unknown status|Recruiting|Phase 3|124||Ejaz, Abulate A, MD|||||||||||||||||||2018-06-01 04:56:23.918716|2018-06-01 04:56:23.918716
NCT00110188|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-04|||2015-11-18|2005-05-04|2005-05-05|Estimate|||||||2015-11-18|2015-11-20|Estimate|May 2005||2005-05-31|November 2015|2015-11-30|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)|A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)|Completed||Phase 2|39|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-06-01 04:56:23.991369|2018-06-01 04:56:23.991369
NCT00110175|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2017-06-30|2005-05-03|2005-05-04|Estimate|||||||2017-06-30|2017-07-02|Actual|April 28, 2005||2005-04-28|March 27, 2008|2008-03-27|March 27, 2008||2008-03-27|||||Observational|||Motor Performance in Chronic Stroke Patients|Improvement of Motor Performance in Chronic Stroke Patients by Combined Transcranial DC Stimulation and Somatosensory Stimulation|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:24.142348|2018-06-01 04:56:24.142348
NCT00110162|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2013-08-06|2005-05-03|2005-05-04|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2004||2004-10-31|June 2009|2009-06-30||||December 2009|Anticipated|2009-12-31||Interventional|||Androgen Deprivation Therapy in Treating Patients With Prostate Cancer|A Collaborative Randomized Phase III Trial: The Timing of Intervention With Androgen Deprivation in Prostate Cancer Patients With Rising PSA|Unknown status|Recruiting|Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:56:25.211008|2018-06-01 04:56:25.211008
NCT00110149|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2017-04-11||2017-10-19|2005-05-03|2005-05-04|Estimate|2017-10-19|2017-11-21|Actual||||2017-10-19|2017-11-21|Actual|May 2004||2004-05-31|October 2017|2017-10-31|March 2015|Actual|2015-03-31|May 2012|Actual|2012-05-31||Interventional|||Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as First Line Treatment in Indolent Non-Hodgkin's Lymphoma|Terminated||Phase 2|12|Actual|Beth Israel Deaconess Medical Center|This trial was stopped abruptly when the makers of the investigational agent sold the company and the agent was not available for a significant period of time. Attempts were made to follow all patients for 12 months after treatment.|1||Company withdrew drug supply|f|||||t|f|||f|||No||2018-06-01 04:56:25.365471|2018-06-01 04:56:25.365471
NCT00110136|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2014-09-04||2017-01-18|2005-05-03|2005-05-04|Estimate|2014-12-17|2014-12-29|Estimate||||2017-01-18|2017-03-03|Actual|March 2006||2006-03-31|December 2014|2014-12-31|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional||All registered participants are used in the analysis.|St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer|A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer|Terminated||Phase 2|9|Actual|Wake Forest University Health Sciences|This study was stopped early due to concerns about the interaction between St. John's wort and tamoxifen.|1||Stopped due to concerns about interaction between St. John's wort and Tamoxifen.|f||||t||||||||||2018-06-01 04:56:25.731031|2018-06-01 04:56:25.731031
NCT00110123|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2012-09-20|2005-05-03|2005-05-04|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2005||2005-01-31|September 2012|2012-09-30||||June 2011|Actual|2011-06-30||Interventional|||Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma|Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group|Terminated||Phase 3|171|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 04:56:26.206128|2018-06-01 04:56:26.206128
NCT00110110|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2018-04-13|2005-05-03|2005-05-04|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2004|Actual|2004-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 20, 2016|Actual|2016-04-20||Interventional|||Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma|Multicenter Phase II Study for International Intraocular Retinoblastoma Classification Groups B, C & D Tumors Treated With Carboplatin-Etoposide-Vincristine-Cyclosporine-Focal Therapy Multimodality Protocol (OCRN Multicenter RB 2003)|Active, not recruiting||Phase 2|71|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||No||2018-06-01 04:56:26.364773|2018-06-01 04:56:26.364773
NCT00110084|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2011-03-29||2011-05-31|2005-05-03|2005-05-04|Estimate|2011-04-29|2011-05-26|Estimate||||2011-05-31|2011-06-02|Estimate|August 2005||2005-08-31|May 2011|2011-05-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|||ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer|Phase II Trial of Weekly Nab (Nanoparticle Albumin Bound)-Paclitaxel (Nab-paclitaxel) (Abraxane®) in Combination With Gemcitabine in Patients With Metastatic Breast Cancer|Completed||Phase 2|50|Actual|Mayo Clinic||1|||f||||t||||||||||2018-06-01 04:56:26.632526|2018-06-01 04:56:26.632526
NCT00110071|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2014-08-04|2005-05-03|2005-05-04|Estimate|||||||2014-08-04|2014-08-06|Estimate|January 2005||2005-01-31|August 2014|2014-08-31||||June 2011|Actual|2011-06-30||Interventional|||Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma|A Clinical Trial Evaluating I131-Tositumomab (Anti-CD20) With Escalating Doses of Fludarabine Followed by Autologous or Syngeneic Stem Cell Transplantation for Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma in Patients 60 Years of Age and Older|Completed||Phase 1|38|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 04:56:27.551095|2018-06-01 04:56:27.551095
NCT00110058|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2011-11-15|2005-05-03|2005-05-04|Estimate|||||||2011-11-15|2011-11-17|Estimate|February 2005||2005-02-28|November 2011|2011-11-30|July 2006|Actual|2006-07-31|||||Interventional|||Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia|A Multi-Center Phase II Study of Nonmyeloablative Conditioning With TBI and Fludarabine for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Chronic Myeloid Leukemia in Chronic and Accelerated Phase|Completed||Phase 2|40|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:56:27.707114|2018-06-01 04:56:27.707114
NCT00110045|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2012-09-20|2005-05-03|2005-05-04|Estimate|||||||2012-09-20|2012-09-24|Estimate|February 2005||2005-02-28|September 2012|2012-09-30||||March 2008|Actual|2008-03-31||Interventional|||Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant|A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)|Completed||Phase 2|171|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:56:27.85724|2018-06-01 04:56:27.85724
NCT00110032|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2013-01-15|2005-05-03|2005-05-04|Estimate|||||||2013-01-15|2013-01-16|Estimate|June 2005||2005-06-30|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors|Microenvironment: Imaging/Implications in Brain Tumors; A Preliminary Investigation of the Biodistribution of [F-18]-EF5 in Patients With Brain Tumors|Terminated||Phase 1|46|Actual|National Cancer Institute (NCI)||3||Administratively complete.|f||||||||||||||2018-06-01 04:56:28.060674|2018-06-01 04:56:28.060674
NCT00110019|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2012-08-28||2015-09-28|2005-05-03|2005-05-04|Estimate|2012-08-28|2012-09-27|Estimate||||2015-09-28|2015-10-19|Estimate|June 2005||2005-06-30|July 2015|2015-07-31|August 2012|Actual|2012-08-31|January 2011|Actual|2011-01-31||Interventional|||Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery|A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma|Completed||Phase 3|823|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 04:56:28.279042|2018-06-01 04:56:28.279042
NCT00110006|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2010-06-10|2005-05-03|2005-05-04|Estimate|||||||2010-06-10|2010-06-11|Estimate|December 2004||2004-12-31|June 2010|2010-06-30||||||||Interventional|||Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma|Prognostic Significance of Early Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F] FDG) in Intermediate and High Grade Non-Hodgkin's Lymphoma|Withdrawn||N/A|0|Actual|Case Comprehensive Cancer Center||||No accrual|f||||t||||||||||2018-06-01 04:56:29.585298|2018-06-01 04:56:29.585298
NCT00109993|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2010-06-10|2005-05-03|2005-05-04|Estimate|||||||2010-06-10|2010-06-11|Estimate|January 2005||2005-01-31|June 2010|2010-06-30|May 2007|Actual|2007-05-31|June 2006|Actual|2006-06-30||Interventional|||Campath-1H + FK506 and Methylprednisolone for GVHD|Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease|Completed||Phase 2|34|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:56:29.712593|2018-06-01 04:56:29.712593
NCT00109980|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2013-10-30|2005-05-03|2005-05-04|Estimate|||||||2013-10-30|2013-11-01|Estimate|March 2005||2005-03-31|October 2013|2013-10-31||||July 2011|Actual|2011-07-31||Observational|||Medicinal Plant Use for Treating Inflammation Among Dominicans in New York City and the Dominican Republic|Dominican Herbal Medicine: Plants Used for Inflammation|Completed|||320|Actual|New York Botanical Garden|||||f||||f||||||||||2018-06-01 04:56:29.860243|2018-06-01 04:56:29.860243
NCT00109967|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2013-12-03||2014-03-21|2005-05-03|2005-05-04|Estimate|2013-12-03|2014-01-22|Estimate||||2014-03-21|2014-04-17|Estimate|May 2005||2005-05-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|September 2009|Actual|2009-09-30||Interventional|||CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study of CCI-779 in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma|Completed||Phase 2|71|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:56:29.987272|2018-06-01 04:56:29.987272
NCT00109954|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2016-01-15|2005-05-03|2005-05-04|Estimate|||||||2016-01-15|2016-01-18|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery|A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)|Completed||Phase 3|120|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-06-01 04:56:31.055652|2018-06-01 04:56:31.055652
NCT00109941|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2013-05-16|2005-05-03|2005-05-04|Estimate|||||||2013-05-16|2013-05-17|Estimate|October 2003||2003-10-31|March 2013|2013-03-31|April 2009|Actual|2009-04-30|September 2007|Actual|2007-09-30||Interventional|OGF||Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery|Treatment of Advanced Pancreatic Cancer With Opioid Growth Factor (OGF): Phase II|Completed||Phase 2|25|Actual|Penn State University||1|||f||||t||||||||||2018-06-01 04:56:31.145092|2018-06-01 04:56:31.145092
NCT00109928|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2014-06-11||2014-09-18|2005-05-03|2005-05-04|Estimate|2014-08-19|2014-08-29|Estimate||||2014-09-18|2014-10-01|Estimate|September 2005||2005-09-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|June 2012|Actual|2012-06-30||Interventional||Peripheral T-cell lymphomas (PTCLs) with stage II bulky, III or IV with extra-nodal, nodal and transformed cutaneous presentations were eligible.|S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma|Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|34|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 04:56:31.251999|2018-06-01 04:56:31.251999
NCT00109889|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2017-04-21|2005-05-03|2005-05-04|Estimate|||||||2017-04-21|2017-04-24|Actual|April 2005||2005-04-30|April 2017|2017-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma|A Prospective Observational Study of Patients With Solitary Plasmacytoma Using a Modified Staging System Supplemented by an MRI and Whole Body FDG-PET Scan|Terminated||Phase 2|2|Actual|Southwest Oncology Group||1||poor accrual|f||||f||||||||||2018-06-01 04:56:31.816635|2018-06-01 04:56:31.816635
NCT00109876|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2016-11-29||2017-01-26|2005-05-03|2005-05-04|Estimate|2016-11-29|2017-01-24|Estimate||||2017-01-26|2017-03-08|Actual|September 2006||2006-09-30|January 2017|2017-01-31|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Interventional||All enrolled participants who met the eligibility criteria.|Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer|A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer|Completed||N/A|54|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 04:56:31.965845|2018-06-01 04:56:31.965845
NCT00109863|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2015-02-13|2005-05-03|2005-05-04|Estimate|||||||2015-02-13|2015-02-16|Estimate|May 2005||2005-05-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|July 2007|Actual|2007-07-31||Interventional|||Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma|Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma|Completed||Phase 2|14|Actual|University of Wisconsin, Madison||1|||f||||||||||||||2018-06-01 04:56:32.399696|2018-06-01 04:56:32.399696
NCT00109850|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2012-06-14||2015-11-16|2005-05-03|2005-05-04|Estimate|2012-07-20|2012-08-23|Estimate||||2015-11-16|2015-11-18|Estimate|May 2005||2005-05-31|November 2015|2015-11-30|May 2012|Actual|2012-05-31|September 2009|Actual|2009-09-30||Interventional|||S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer|Cetuximab Plus Cisplatin, Irinotecan and Thoracic Radiotherapy (TRT) for Locally Advanced (Non-Metastatic), Clinically Unresectable Esophageal Cancer: A Phase II Trial With Molecular Correlates|Terminated||Phase 2|22|Actual|Southwest Oncology Group||1||Closed due to poor accrual|f||||t||||||||||2018-06-01 04:56:32.511235|2018-06-01 04:56:32.511235
NCT00109837|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2012-04-04||2015-03-05|2005-05-03|2005-05-04|Estimate|2012-07-23|2012-08-23|Estimate||||2015-03-05|2015-03-25|Estimate|April 2005||2005-04-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2010|Actual|2010-11-30||Interventional|||S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy|Completed||Phase 2|79|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 04:56:33.18482|2018-06-01 04:56:33.18482
NCT00109824|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2013-06-03|2005-05-03|2005-05-04|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2006||2006-03-31|June 2013|2013-06-30||||March 2009|Actual|2009-03-31||Interventional|||Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:56:34.000518|2018-06-01 04:56:34.000518
NCT00109811|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2013-01-22|2005-05-03|2005-05-04|Estimate|||||||2013-01-22|2013-01-23|Estimate|March 2005||2005-03-31|January 2013|2013-01-31||||September 2007|Actual|2007-09-30||Interventional|||Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer|A Phase 2 Study of Prostate Specific Antigen Peptide 3A (PSA: 154-163(155L) ) (NSC # 722932, IND#9787) With Montanide ISA-51(NSC #675756, IND #9787) or Montanide® ISA 51 VG (NSC 737063) Vaccination in Prostate Cancer Recurrent|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:56:34.12775|2018-06-01 04:56:34.12775
NCT00109798|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2017-09-15|2005-05-03|2005-05-04|Estimate|||||||2017-09-15|2017-09-19|Actual|March 2005||2005-03-31|September 2017|2017-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma|Phase II Trial of Salvage Chemotherapy With Temozolomide in Combination With Topotecan for Primary CNS Lymphoma|Withdrawn||N/A|0|Actual|The Methodist Hospital System||1||Sub-Investigator reloacted to another institution|f||||f||||||||No||2018-06-01 04:56:34.246401|2018-06-01 04:56:34.246401
NCT00109785|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2015-12-23|2005-05-03|2005-05-04|Estimate|||||||2015-12-23|2015-12-24|Estimate|March 1997||1997-03-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||PET Scans in Patients With Locally Advanced Breast Cancer|Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis|Completed||Phase 1|8|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 04:56:34.364177|2018-06-01 04:56:34.364177
NCT00109772|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|2013-05-07||2013-08-26|2005-05-03|2005-05-04|Estimate|2013-08-26|2013-08-28|Estimate||||2013-08-26|2013-08-28|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|CRPS-002|Safety population|Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1|A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1|Terminated||Phase 2|184|Actual|Celgene||2||Interim analysis showed the primary outcome was not reached|f||||t||||||||||2018-06-01 04:56:34.510029|2018-06-01 04:56:34.510029
NCT00109759|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-03|||2010-06-16|2005-05-03|2005-05-04|Estimate|||||||2010-06-16|2010-06-17|Estimate|May 2005||2005-05-31|June 2010|2010-06-30|June 2005||2005-06-30|||||Interventional|||Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)|A Double-Blind Phase I Study to Evaluate the Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL® in Healthy Volunteers.|Withdrawn||Phase 1|15||Allergy Therapeutics|||||f||||||||||||||2018-06-01 04:56:35.182637|2018-06-01 04:56:35.182637
NCT00109746|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-02|||2016-03-22|2005-05-02|2005-05-03|Estimate|||||||2016-03-22|2016-03-23|Estimate|November 2005||2005-11-30|May 2013|2013-05-31|June 2010|Actual|2010-06-30|May 2009|Actual|2009-05-31||Interventional|NT||Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults|A Novel Therapy for Glucose Intolerance in HIV Disease|Completed||Phase 1/Phase 2|39|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 04:56:35.345044|2018-06-01 04:56:35.345044
NCT00109733|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-02|2010-05-19||2013-08-04|2005-05-02|2005-05-03|Estimate|2010-05-19|2010-06-22|Estimate||||2013-08-04|2013-08-07|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|July 2006|Actual|2006-07-31|June 2006|Actual|2006-06-30||Interventional|||Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency|A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS)|Completed||Phase 3|31|Actual|EMD Serono||2|||f||||||||||||||2018-06-01 04:56:35.448763|2018-06-01 04:56:35.448763
NCT00109720|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-02|||2010-01-14|2005-05-02|2005-05-03|Estimate|||||||2010-01-14|2010-01-15|Estimate|August 2002||2002-08-31|January 2010|2010-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Evaluation of Diabetes Self-Management Consultant Care|Evaluation of Diabetes Self-Management Consultant Care|Completed||N/A|310|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 04:56:35.832275|2018-06-01 04:56:35.832275
NCT00109707|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-02|||2016-04-27|2005-05-02|2005-05-03|Estimate|||||||2016-04-27|2016-04-29|Estimate|May 2004||2004-05-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers|A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies.|Completed||Phase 1/Phase 2|942|Actual|Novartis||6|||f||||||||||||||2018-06-01 04:56:35.969781|2018-06-01 04:56:35.969781
NCT00109681|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-02||2010-02-11|2010-02-11|2005-05-02|2005-05-03|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|April 2005||2005-04-30|February 2010|2010-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis|A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Pilot Efficacy of Iloprost Inhalation Solution in Adults With Abnormal Pulmonary Arterial Pressure and Exercise Limitation Associated With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 2|50||Actelion|||||||||t||||||||||2018-06-01 04:56:36.166544|2018-06-01 04:56:36.166544
NCT00109668|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-02|||2014-05-09|2005-05-02|2005-05-03|Estimate|||||||2014-05-09|2014-05-12|Estimate|July 2004||2004-07-31|May 2014|2014-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Evaluation of Two Doses of QVAR Versus Placebo by Breath Operated and Metered Dose Inhalers in Moderate Asthmatic Adolescents and Adults on a Stable Regimen of Inhaled Corticosteroids||Completed||Phase 3|415||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:56:36.240119|2018-06-01 04:56:36.240119
NCT00109655|ClinicalTrials.gov processed this data on May 31, 2018|2005-05-02|||2008-10-01|2005-05-02|2005-05-03|Estimate|||||||2008-10-01|2008-10-03|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|September 2010|Anticipated|2010-09-30|October 2008|Anticipated|2008-10-31||Interventional|||Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure|A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure|Unknown status|Active, not recruiting|Phase 1|75|Anticipated|Cell Genesys||1|||f||||||||||||||2018-06-01 04:56:36.344055|2018-06-01 04:56:36.344055
NCT00109642|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-29|||2017-06-30|2005-04-29|2005-05-02|Estimate|||||||2017-06-30|2017-07-02|Actual|April 26, 2005||2005-04-26|June 8, 2009|2009-06-08|March 15, 2009|Actual|2009-03-15|March 15, 2009|Actual|2009-03-15||Observational|||The Role of Norepinephrine in Emotional Processing|Investigating the Role of Norepinephrine in Emotional Processing Through Alpha-2 Adrenergic Receptor Modulation|Completed|||216||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:36.643719|2018-06-01 04:56:36.643719
NCT00109629|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-29|||2017-06-30|2005-04-29|2005-05-02|Estimate|||||||2017-06-30|2017-07-02|Actual|April 26, 2005||2005-04-26|January 22, 2008|2008-01-22|January 22, 2008||2008-01-22|||||Interventional|||"Prime-Boost Vaccine Schedule for Prevention of HIV Infection"|VRC 008: A Phase I Clinical Trial of a Prime-Boost HIV-1 Vaccination Schedule: Multiclade DNA Vaccine, VRC-HIVDNA016-00-VP, Followed by Multiclade Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:36.697136|2018-06-01 04:56:36.697136
NCT00109616|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-29|||2013-04-30|2005-04-29|2005-05-02|Estimate|||||||2013-04-30|2013-05-01|Estimate|October 2002||2002-10-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||Community Trial of Newborn Skin and Umbilical Cord Cleansing on Neonatal Mortality in Nepal|Newborn Antiseptic Washing and Neonatal Mortality-Nepal|Completed||Phase 3|17000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:56:36.752429|2018-06-01 04:56:36.752429
NCT00109603|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-29|||2012-10-26|2005-04-29|2005-05-02|Estimate|||||||2012-10-26|2012-10-30|Estimate|May 2005||2005-05-31|October 2012|2012-10-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy|A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects|Completed||N/A|17|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:56:36.829842|2018-06-01 04:56:36.829842
NCT00109590|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-29|2012-06-26|2010-01-20|2014-12-30|2005-04-29|2005-05-02|Estimate|2012-11-05|2012-11-06|Estimate|2010-01-20|2010-01-22|Estimate|2014-12-30|2015-01-13|Estimate|June 2006||2006-06-30|December 2014|2014-12-31|November 2009|Actual|2009-11-30|October 2008|Actual|2008-10-31||Interventional|||Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth|Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Didanosine/Lopinavir/Ritonavir|Completed||Phase 2|175|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 04:56:36.983652|2018-06-01 04:56:36.983652
NCT00109577|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|2012-06-25||2012-09-11|2005-04-28|2005-04-29|Estimate|2012-08-10|2012-09-11|Estimate||||2012-09-11|2012-09-18|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder|Randomized Placebo-controlled Phase II Trial of MCN36 in Adults With Bipolar Disorder|Terminated||Phase 2|40|Actual|University of Calgary||2||Unable to recruit large enough sample; large expectancy effects but no adverse events|f||||t||||||||||2018-06-01 04:56:38.276496|2018-06-01 04:56:38.276496
NCT00109564|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|||2008-07-17|2005-04-28|2005-04-29|Estimate|||||||2008-07-17|2008-07-18|Estimate|January 2005||2005-01-31|July 2008|2008-07-31|October 2005||2005-10-31|||||Interventional|||A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)|A Safety and Efficacy Study of TC-1734-112 in Subjects With Age Associated Memory Impairment (AAMI)|Completed||Phase 2|174||Targacept Inc.|||||||||||||||||||2018-06-01 04:56:38.458851|2018-06-01 04:56:38.458851
NCT00109551|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|||2013-04-30|2005-04-28|2005-04-29|Estimate|||||||2013-04-30|2013-05-01|Estimate|October 2001||2001-10-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||Community Trial of Zinc Supplementation on Preschool Child Mortality and Morbidity in Southern Nepal|Zinc Supplementation Impact on Child Mortality--Nepal|Completed||Phase 3|58000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 04:56:38.660386|2018-06-01 04:56:38.660386
NCT00109538|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28||2009-04-14|2015-04-09|2005-04-28|2005-04-29|Estimate||||2009-10-16|2009-10-20|Estimate|2015-04-09|2015-05-01|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)|A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusion Dependent With or Without Anemia|Terminated||Phase 3|47|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-06-01 04:56:38.734067|2018-06-01 04:56:38.734067
NCT00109525|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|||2017-09-22|2005-04-28|2005-04-29|Estimate|||||||2017-09-22|2017-09-26|Actual|March 2004||2004-03-31|September 2017|2017-09-30|December 2009|Actual|2009-12-31|July 2007|Actual|2007-07-31||Observational|Candida||Early Diagnosis of Candidiasis in Premature Infants|Early Diagnosis of Nosocomial Candidiasis Study|Completed|||1500|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-06-01 04:56:38.817627|2018-06-01 04:56:38.817627
NCT00109512|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|||2012-02-21|2005-04-28|2005-04-29|Estimate|||||||2012-02-21|2012-02-22|Estimate|April 2005||2005-04-30|February 2012|2012-02-29|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Endometriosis Trial: Study of NBI-56418 in Endometriosis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NBI-56418 in Endometriosis|Completed||Phase 2|76|Actual|Abbott||3|||f||||||||||||||2018-06-01 04:56:38.939594|2018-06-01 04:56:38.939594
NCT00109499|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|||2011-05-11|2005-04-28|2005-04-29|Estimate|||||||2011-05-11|2011-05-12|Estimate||||May 2011|2011-05-31||||||||Interventional|||Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)|An Open-label, Phase I, Single Administration, Dose- Escalation Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)|Completed||Phase 1|||GenVec|||||||||||||||||||2018-06-01 04:56:39.021805|2018-06-01 04:56:39.021805
NCT00109486|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|||2016-09-13|2005-04-28|2005-04-29|Estimate|||||||2016-09-13|2016-09-15|Estimate|April 2005||2005-04-30|September 2016|2016-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Safety Study To Assess Growth In Children With Seasonal Allergic And/Or Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray|A Randomised, Double-Blind, Placebo-Controlled, Two-Week Crossover, Knemometric Assessment of the Effect of Fluticasone Furoate Nasal Spray 100mcg Once Daily on Short-Term Growth in Children Aged 6 to 11 Years With Seasonal and/or Perennial Allergic Rhinitis|Completed||Phase 3|56|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:56:39.14403|2018-06-01 04:56:39.14403
NCT00109473|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-28|2011-06-24||2017-01-11|2005-04-28|2005-04-29|Estimate|2011-08-12|2011-09-16|Estimate||||2017-01-11|2017-01-12|Estimate|April 2005||2005-04-30|January 2017|2017-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Trial of Growth Hormone Therapy in Pediatric Crohn's Disease|A Phase II Randomized Trial of Growth Hormone Therapy in Pediatric Crohn's Disease|Completed||Phase 2|22|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 04:56:39.250321|2018-06-01 04:56:39.250321
NCT00024635|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-23|||2018-04-24|2005-04-28|2005-04-29|Estimate|||||||2018-04-24|2018-04-25|Actual|September 21, 2001||2001-09-21|April 19, 2018|2018-04-19||||||||Observational|||Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers|The Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers|Recruiting|||16000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:39.772198|2018-06-01 04:56:39.772198
NCT00109460|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2015-05-11|2005-04-27|2005-04-28|Estimate|||||||2015-05-11|2015-05-13|Estimate|March 2003||2003-03-31|May 2015|2015-05-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Tobacco Cessation Field Study for Adults in Recovery - 1|Tobacco Cessation Clinical Field Study for Adults in Alcohol Abuse Recovery|Completed||Phase 2|203|Actual|Inflexxion, Inc.|||||f||||t||||||||||2018-06-01 04:56:39.836288|2018-06-01 04:56:39.836288
NCT00109434|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2016-09-02|2005-04-27|2005-04-28|Estimate|||||||2016-09-02|2016-09-05|Estimate|June 2004||2004-06-30|September 2016|2016-09-30|November 2004||2004-11-30|||||Observational|||Study to Determine the Relationship Between Exercise and Hypoglycemia in Children With Type 1 Diabetes|The Effect of Exercise on the Development of Hypoglycemia in Children With Type 1 Diabetes; A Study Being Conducted by the Diabetes Research in Children Network|Completed|||50||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 04:56:39.900057|2018-06-01 04:56:39.900057
NCT00109421|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2017-02-27|2005-04-27|2005-04-28|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2004||2004-11-30|February 2016|2016-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females|PROJECT ÒRÉ: An Innovative Friendship Based HIV/STI Intervention for High Risk African American Females|Completed||N/A|420|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-06-01 04:56:39.96786|2018-06-01 04:56:39.96786
NCT00109408|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2016-11-01|2005-04-27|2005-04-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2005||2005-07-31|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis|A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Monotherapy Versus Methotrexate Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis|Completed||Phase 3|673|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:56:40.049856|2018-06-01 04:56:40.049856
NCT00109395|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2016-05-20|2005-04-27|2005-04-28|Estimate|||||||2016-05-20|2016-05-23|Estimate|September 2004||2004-09-30|November 2011|2011-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Lorazepam Sedation for Critically Ill Children|A Randomized Controlled Trial Comparing Lorazepam With Midazolam for Sedation of Mechanically Ventilated Pediatric Patients|Completed||Phase 2/Phase 3|179|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||3|||f||||t||||||||||2018-06-01 04:56:40.449271|2018-06-01 04:56:40.449271
NCT00109382|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2008-04-07|2005-04-26|2005-04-27|Estimate|||||||2008-04-07|2008-04-08|Estimate|May 2003||2003-05-31|June 2007|2007-06-30|February 2007|Actual|2007-02-28|||||Interventional|||Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)|Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)|Completed||Phase 2/Phase 3|500|Anticipated|University of Calgary|||||f||||||||||||||2018-06-01 04:56:40.577553|2018-06-01 04:56:40.577553
NCT00109369|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2011-01-31|2005-04-26|2005-04-27|Estimate|||||||2011-01-31|2011-02-01|Estimate|June 2003||2003-06-30|January 2011|2011-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Vermont Diabetes Information System|Vermont Diabetes Information System|Completed||N/A|7500|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 04:56:40.753252|2018-06-01 04:56:40.753252
NCT00109356|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2007-05-04|2005-04-26|2005-04-27|Estimate|||||||2007-05-04|2007-05-07|Estimate|March 2005||2005-03-31|May 2007|2007-05-31|March 2007||2007-03-31|||||Interventional|||Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia|A Phase 1/2, Open Label, Dose Escalation Study of AQ4N for Safety, Tolerability, Pharmacokinetics and Activity in Patients With Lymphoid Neoplasms|Unknown status|Active, not recruiting|Phase 1/Phase 2|55||Novacea|||||||||||||||||||2018-06-01 04:56:40.841769|2018-06-01 04:56:40.841769
NCT00109343|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|2009-09-23||2017-03-15|2005-04-26|2005-04-27|Estimate|2010-01-25|2010-02-10|Estimate||||2017-03-15|2017-04-12|Actual|March 2006||2006-03-31|March 2017|2017-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)|An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age|Completed||Phase 3|1027|Actual|Merck Sharp & Dohme Corp.|One subject (Group 3-ProQuad™ followed by PREVNAR™) was diagnosed (Day 8) with Stage IV neuroblastoma (considered not related to study vaccine by investigator) and discontinued from the study. Subject died (Day 218) due to neuroblastoma.|3|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:56:40.931239|2018-06-01 04:56:40.931239
NCT00109330|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2016-09-08|2005-04-26|2005-04-27|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2002||2002-11-30|September 2016|2016-09-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine|A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)|Completed||Phase 3|4116|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:56:41.535216|2018-06-01 04:56:41.535216
NCT00109317|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2013-06-19|2005-04-26|2005-04-27|Estimate|||||||2013-06-19|2013-06-21|Estimate|September 2002||2002-09-30|June 2013|2013-06-30|February 2003|Actual|2003-02-28|||||Interventional|||A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy|A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy|Completed||Phase 3|686|Actual|Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:41.647562|2018-06-01 04:56:41.647562
NCT00109304|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2015-09-17|2005-04-26|2005-04-27|Estimate|||||||2015-09-17|2015-09-18|Estimate|July 2005||2005-07-31|September 2015|2015-09-30|December 2006||2006-12-31|||||Interventional|||Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine|Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE IA/B V3526 in VEE-Naive Healthy Volunteers After Single Dose Subcutaneous Administration|Withdrawn||Phase 1|0|Actual|DynPort Vaccine Company LLC, A CSC Company||||Funding withdrawn|f||||t||||||||||2018-06-01 04:56:41.6894|2018-06-01 04:56:41.6894
NCT00109291|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-27|||2012-12-19|2005-04-26|2005-04-27|Estimate|||||||2012-12-19|2012-12-21|Estimate|March 2005||2005-03-31|December 2012|2012-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Patients With Chronic Kidney Disease Who Are Not on Dialysis and Who Have Not Had Prior Erythropoiesis Stimulating Agent (ESA) Treatment|Terminated||Phase 2|17|Actual|Affymax||4||Due to slow enrollment|f||||f||||||||||2018-06-01 04:56:41.745145|2018-06-01 04:56:41.745145
NCT00109278|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2017-03-14|2005-04-25|2005-04-26|Estimate|||||||2017-03-14|2017-03-15|Actual|October 2004||2004-10-31|March 2017|2017-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)|A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age|Completed||Phase 2|1100|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:56:41.810382|2018-06-01 04:56:41.810382
NCT00109265|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2015-07-01|2005-04-25|2005-04-26|Estimate|||||||2015-07-01|2015-07-02|Estimate|May 2001||2001-05-31|June 2013|2013-06-30|October 2002|Actual|2002-10-31|||||Interventional|||A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy|A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy|Completed||Phase 2|||Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:41.858397|2018-06-01 04:56:41.858397
NCT00109252|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2013-06-19|2005-04-25|2005-04-26|Estimate|||||||2013-06-19|2013-06-21|Estimate|January 2002||2002-01-31|June 2013|2013-06-30|April 2003|Actual|2003-04-30|||||Interventional|||A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g|Completed||Phase 3|0||Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:41.897829|2018-06-01 04:56:41.897829
NCT00109239|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2014-06-16|2005-04-25|2005-04-26|Estimate|||||||2014-06-16|2014-06-18|Estimate|November 2000||2000-11-30|June 2013|2013-06-30|September 2002|Actual|2002-09-30|||||Interventional|||A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer|A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer|Completed||Phase 3|||Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:41.931247|2018-06-01 04:56:41.931247
NCT00109226|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2014-04-07|2005-04-25|2005-04-26|Estimate|||||||2014-04-07|2014-04-08|Estimate|August 2000||2000-08-31|April 2014|2014-04-30|September 2003|Actual|2003-09-30|||||Interventional|||A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer|A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-Fluorouracil and Leucovorin Chemotherapy in Subjects With Metastatic Colorectal Cancer Who Are Not Optimal Candidates for First Line CPT-11|Completed||Phase 2|||Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:41.969662|2018-06-01 04:56:41.969662
NCT00109213|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2015-12-02|2005-04-25|2005-04-26|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2002||2002-05-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|September 2009|Actual|2009-09-30||Interventional|SLIP||Greenwich Lumbar Stenosis SLIP Study|Greenwich Lumbar Stenosis SLIP Study: A Multi-center, Randomized, Prospective Clinical Trial Comparing Spinal Laminectomy to Laminectomy With Instrumented Pedicle Screw Fusion for Lumbar Stenosis With Grade I Spondylolisthesis|Completed||Phase 3|66|Actual|Greenwich Hospital||2|||f||||t||||||||||2018-06-01 04:56:42.012148|2018-06-01 04:56:42.012148
NCT00109200|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2013-06-19|2005-04-25|2005-04-26|Estimate|||||||2013-06-19|2013-06-21|Estimate|May 2003||2003-05-31|June 2013|2013-06-30|September 2003|Actual|2003-09-30|||||Interventional|||A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma|A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study|Completed||Phase 3|||Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:42.074123|2018-06-01 04:56:42.074123
NCT00109187|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-26|||2013-06-19|2005-04-25|2005-04-26|Estimate|||||||2013-06-19|2013-06-21|Estimate|June 2002||2002-06-30|June 2013|2013-06-30|April 2003|Actual|2003-04-30|||||Interventional|||An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g|Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO)|Completed||Phase 3|0||Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:42.222815|2018-06-01 04:56:42.222815
NCT00109174|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2018-05-23|2005-04-22|2005-04-25|Estimate|||||||2018-05-23|2018-05-24|Actual|April 21, 2005||2005-04-21|April 26, 2018|2018-04-26|April 23, 2019|Anticipated|2019-04-23|April 23, 2019|Anticipated|2019-04-23||Interventional|||MRS Measurement of Glutamate and GABA Metabolism in Brain|MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain|Recruiting||N/A|200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:42.266514|2018-06-01 04:56:42.266514
NCT00109161|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2008-08-02|2005-04-22|2005-04-25|Estimate|||||||2008-08-02|2008-08-05|Estimate|April 2005||2005-04-30|August 2008|2008-08-31|October 2006||2006-10-31|||||Interventional|||Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis|A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis|Completed||Phase 2|270||Facet Biotech|||||||||||||||||||2018-06-01 04:56:42.353664|2018-06-01 04:56:42.353664
NCT00109148|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2015-09-08|2005-04-22|2005-04-25|Estimate|||||||2015-09-08|2015-09-09|Estimate|July 2004||2004-07-31|September 2015|2015-09-30|February 2005|Actual|2005-02-28|January 2005|Actual|2005-01-31||Interventional|||An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)|A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients|Completed||Phase 2|500|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:56:42.47126|2018-06-01 04:56:42.47126
NCT00109135|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2015-09-24|2005-04-22|2005-04-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|January 2005||2005-01-31|September 2015|2015-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)|A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation|Completed||Phase 2|300|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:56:42.523248|2018-06-01 04:56:42.523248
NCT00109122|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2017-03-14|2005-04-22|2005-04-25|Estimate|||||||2017-03-14|2017-03-15|Actual|November 2001||2001-11-30|March 2017|2017-03-31|July 2006|Actual|2006-07-31|February 2003|Actual|2003-02-28||Interventional|||Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)|A Double-Blind, Placebo-Controled, Randomized Study to Evaluate Safety, Tolerability, and Immunogenicity After 1 and 2 Doses of Zoster Vaccine|Completed||Phase 2|180|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:56:42.588352|2018-06-01 04:56:42.588352
NCT00109109|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2017-04-03|2005-04-22|2005-04-25|Estimate|||||||2017-04-03|2017-04-05|Actual|December 1, 2003|Actual|2003-12-01|April 2017|2017-04-30|February 14, 2006|Actual|2006-02-14|February 14, 2006|Actual|2006-02-14||Interventional|||A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)|Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma|Terminated||Phase 1|60||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:56:42.733198|2018-06-01 04:56:42.733198
NCT00109096|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2007-05-16|2005-04-22|2005-04-25|Estimate|||||||2007-05-16|2007-05-17|Estimate|June 2005||2005-06-30|May 2007|2007-05-31|March 2007|Actual|2007-03-31|||||Interventional|||Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy|A Randomized, Double-Blind Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer|Completed||Phase 2|100|Anticipated|Eli Lilly and Company|||||||||||||||||||2018-06-01 04:56:42.803714|2018-06-01 04:56:42.803714
NCT00109083|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2012-08-01|2005-04-22|2005-04-25|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 2002||2002-03-31|August 2012|2012-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine|Completed||Phase 2|300||SK Life Science|||||f||||||||||||||2018-06-01 04:56:42.908447|2018-06-01 04:56:42.908447
NCT00109070|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2013-06-19|2005-04-22|2005-04-25|Estimate|||||||2013-06-19|2013-06-21|Estimate|September 2000||2000-09-30|June 2013|2013-06-30|April 2003|Actual|2003-04-30|||||Interventional|||A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer|A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer|Completed||Phase 3|||Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:43.008829|2018-06-01 04:56:43.008829
NCT00109057|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2013-06-19|2005-04-22|2005-04-25|Estimate|||||||2013-06-19|2013-06-21|Estimate|February 1998||1998-02-28|June 2013|2013-06-30|February 2004|Actual|2004-02-29|||||Interventional|||An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study|An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated With rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study|Completed||Phase 2|56|Actual|Genentech, Inc.|||||||||||||||||||2018-06-01 04:56:43.07098|2018-06-01 04:56:43.07098
NCT00109044|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|||2012-03-01|2005-04-22|2005-04-25|Estimate|||||||2012-03-01|2012-03-05|Estimate|March 2005||2005-03-31|March 2012|2012-03-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder|Fixed Dose Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder|Completed||Phase 3|540||Forest Laboratories|||||f||||||||||||||2018-06-01 04:56:43.123715|2018-06-01 04:56:43.123715
NCT00109031|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-22|2014-01-24||2014-09-12|2005-04-22|2005-04-25|Estimate|2014-09-12|2014-09-15|Estimate||||2014-09-12|2014-09-15|Estimate|January 2005||2005-01-31|September 2014|2014-09-30|December 2010|Actual|2010-12-31|February 2006|Actual|2006-02-28||Interventional||Primary Analysis Set (all randomized participants who signed informed consent before invasive, protocol-specified procedures).|Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)|A Randomized, Blinded, Active-control Trial of Palifermin (rHuKGF) to Evaluate Oral Mucositis in Subjects With Hematologic Malignancies Undergoing Fractionated Total Body Irradiation (fTBI) and High Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation|Completed||Phase 3|47|Actual|Swedish Orphan Biovitrum||4|||f||||t||||||||||2018-06-01 04:56:43.257301|2018-06-01 04:56:43.257301
NCT00109018|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-21|||2017-06-30|2005-04-21|2005-04-22|Estimate|||||||2017-06-30|2017-07-02|Actual|April 19, 2005||2005-04-19|April 15, 2009|2009-04-15|April 15, 2009||2009-04-15|||||Observational|||Biomarkers for Cardiovascular Disease|Nitrite as a Marker of Cardiovascular Risk; Development of Novel Biomarkers in Patients With Coronary Artery Disease|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:44.545508|2018-06-01 04:56:44.545508
NCT00109005|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-21|2012-08-29||2016-11-14|2005-04-21|2005-04-22|Estimate|2012-09-28|2012-10-30|Estimate||||2016-11-14|2017-01-02|Estimate|April 2005||2005-04-30|November 2016|2016-11-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma|A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma|Completed||Phase 2|17|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||No||2018-06-01 04:56:44.623098|2018-06-01 04:56:44.623098
NCT00108992|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-21|||2007-01-04|2005-04-21|2005-04-22|Estimate|||||||2007-01-04|2007-01-05|Estimate|February 2004||2004-02-29|January 2007|2007-01-31|September 2005||2005-09-30|||||Interventional|||Efficacy and Safety of Topical Diclofenac Combined With Oral Diclofenac in the Treatment of Knee Osteoarthritis||Completed||Phase 3|750||Nuvo Research Inc.|||||f||||||||||||||2018-06-01 04:56:45.024439|2018-06-01 04:56:45.024439
NCT00108979|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-21|||2012-03-01|2005-04-21|2005-04-22|Estimate|||||||2012-03-01|2012-03-05|Estimate|March 2005||2005-03-31|March 2012|2012-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study of Escitalopram in Adult Patients With Major Depressive Disorder|Double-Blind Study of Escitalopram in Adult Patients With Major Depressive Disorder|Completed||Phase 3|240||Forest Laboratories|||||||||||||||||||2018-06-01 04:56:45.098351|2018-06-01 04:56:45.098351
NCT00108771|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18|||2012-06-04|2005-04-18|2005-04-19|Estimate|||||||2012-06-04|2012-06-05|Estimate|April 2004||2004-04-30|June 2012|2012-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain|Double-Blind, Parallel, Randomized, Placebo-Controlled 12-Week Efficacy and Safety Assessment of ZR-02-01 in the Treatment of Chronic, Moderate to Severe Osteoarthritis (OA) Pain|Completed||Phase 2|202|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 04:56:49.419668|2018-06-01 04:56:49.419668
NCT00108953|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-21|2009-04-23||2014-10-24|2005-04-21|2005-04-22|Estimate|2009-04-23|2009-06-11|Estimate||||2014-10-24|2014-10-31|Estimate|April 2005||2005-04-30|October 2014|2014-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma|A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.|Completed||Phase 2|96|Actual|Bayer|The study had been prematurely terminated by the sponsor because positive results were obtained in another Nexavar trial (Phase 3 study 100554 NCT00105443). NCI-CTC was translated to MedDRA for SOCs only.|2|||f||||f||||||||||2018-06-01 04:56:45.17762|2018-06-01 04:56:45.17762
NCT00108940|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-20|||2011-09-23|2005-04-20|2005-04-21|Estimate|||||||2011-09-23|2011-09-27|Estimate|December 2000||2000-12-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|June 2009|Actual|2009-06-30||Observational|SWISS||Siblings With Ischemic Stroke Study|Siblings With Ischemic Stroke Study|Completed|||900|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 04:56:46.792105|2018-06-01 04:56:46.792105
NCT00108927|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-20|||2010-03-01|2005-04-20|2005-04-21|Estimate|||||||2010-03-01|2010-03-02|Estimate|December 2003||2003-12-31|March 2010|2010-03-31|December 2005||2005-12-31|||||Observational|||Improving Diabetes in Primary Care (IMPACT)|Improving Diabetes Through Primary Care Translation (IMPACT)|Completed|||6000||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:56:46.878567|2018-06-01 04:56:46.878567
NCT00108914|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-20|||2017-01-18|2005-04-20|2005-04-21|Estimate|||||||2017-01-18|2017-01-19|Estimate|February 2005||2005-02-28|January 2017|2017-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Perennial Allergic Rhinitis Study In Pediatric Subjects|A Two Week Randomized, Double Blind Placebo Controlled, Parallel Group Study of GW685698X Aqueous Nasal Spray 100mcg and 50mcg QD in Pediatric Subjects With Perennial Allergic Rhinitis|Completed||Phase 3|558|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:56:46.949248|2018-06-01 04:56:46.949248
NCT00108901|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-20|||2014-12-22|2005-04-20|2005-04-21|Estimate|||||||2014-12-22|2014-12-24|Estimate|June 2003||2003-06-30|December 2014|2014-12-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||The Medical College of Georgia PLAY Project: Exercise Dose and Insulin Sensitivity in Obese Children|Exercise Dose and Insulin Sensitivity in Obese Children|Completed||Phase 2|222|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||f||||||||||2018-06-01 04:56:47.213166|2018-06-01 04:56:47.213166
NCT00108875|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-19|||2006-07-27|2005-04-19|2005-04-20|Estimate|||||||2006-07-27|2006-07-28|Estimate|April 2003||2003-04-30|June 2005|2005-06-30||||||||Interventional|||Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer|Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides|Unknown status|Recruiting|Phase 1/Phase 2|70||Julius-Maximilians University|||||f||||||||||||||2018-06-01 04:56:47.302055|2018-06-01 04:56:47.302055
NCT00108862|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-19|2011-09-27||2016-01-04|2005-04-19|2005-04-20|Estimate|2011-09-27|2011-11-02|Estimate||||2016-01-04|2016-01-05|Estimate|August 2006||2006-08-31|January 2016|2016-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|STRIDE||Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis|A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3|Completed||Phase 4|809|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-06-01 04:56:47.445569|2018-06-01 04:56:47.445569
NCT00108849|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-19|||2017-02-06|2005-04-19|2005-04-20|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2005||2005-03-31|February 2017|2017-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms|A 12 Month Double-blind, Randomized, Parallel-group, Placebo-controlled, Multi-center Trial to Investigate the Efficacy and Safety of Vagifem Low Dose (10 mcg 17beta-estradiol Vaginal Tablet) for the Treatment of Postmenopausal Atrophic Vaginitis Symptoms|Completed||Phase 3|309|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:56:48.380864|2018-06-01 04:56:48.380864
NCT00108836|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-19|||2010-05-19|2005-04-19|2005-04-20|Estimate|||||||2010-05-19|2010-05-20|Estimate|March 2005||2005-03-31|November 2007|2007-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder|Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder|Completed||Phase 2|400||Novartis|||||||||||||||||||2018-06-01 04:56:48.625024|2018-06-01 04:56:48.625024
NCT00108823|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-19|||2016-10-24|2005-04-19|2005-04-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2004||2004-10-31|September 2016|2016-09-30||||||||Interventional|||The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)|A 24-week, Double Blind, Randomized Study to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Parameters Indicative of Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|550||AstraZeneca|||||f||||||||||||||2018-06-01 04:56:48.772102|2018-06-01 04:56:48.772102
NCT00108810|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18||2012-03-14|2012-05-30|2005-04-18|2005-04-19|Estimate||||2012-05-30|2012-06-05|Estimate|2012-05-30|2012-06-05|Estimate|April 2005||2005-04-30|May 2012|2012-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee|Randomized, Double-Blind, Parallel, Placebo Controlled 4 Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of Transdermal Ketoprofen When Administered With Controlled Heat in Patients With Mild to Moderate OA Pain of the Knee|Completed||Phase 2|118|Actual|ZARS Pharma Inc.||2|||f||||f||||||||||2018-06-01 04:56:48.86615|2018-06-01 04:56:48.86615
NCT00108797|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18|||2017-01-11|2005-04-18|2005-04-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2001||2001-09-30|January 2017|2017-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Trial of NovoSeven® in Haemophilia - Joint Bleeds|NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®|Completed||Phase 4|42|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:56:48.995006|2018-06-01 04:56:48.995006
NCT00108784|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18|||2010-01-12|2005-04-18|2005-04-19|Estimate|||||||2010-01-12|2010-01-13|Estimate|March 2003||2003-03-31|January 2010|2010-01-31|July 2004||2004-07-31|||||Interventional|||Factors Affecting Caloric Regulation in Human Feeding|The Effect of Decreases in Energy Density on Weight Loss and Weight Maintenance|Completed||N/A|100||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:56:49.312103|2018-06-01 04:56:49.312103
NCT00108329|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2003||2003-04-30|April 2007|2007-04-30|March 2006||2006-03-31|||||Interventional|||Weight Loss in Diabetic, Older Obese Adults|5449 Genetics, Weight Loss and Glucose Metabolism in Older Obese Men|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:53.99062|2018-06-01 04:56:53.99062
NCT00108758|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18|||2017-01-11|2005-04-18|2005-04-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2004||2004-03-31|January 2017|2017-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia|Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors|Completed||Phase 2|23|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:56:49.607192|2018-06-01 04:56:49.607192
NCT00108745|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18|||2017-05-03|2005-04-18|2005-04-19|Estimate|||||||2017-05-03|2017-05-08|Actual|March 2005||2005-03-31|May 2017|2017-05-31||||January 2022|Anticipated|2022-01-31||Interventional|||Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer|A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy|Active, not recruiting||Phase 3|1100|Anticipated|Gynecologic Oncology Group||3|||f||||t||||||||||2018-06-01 04:56:49.811461|2018-06-01 04:56:49.811461
NCT00108732|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18|2012-10-19||2015-06-03|2005-04-18|2005-04-19|Estimate|2013-02-25|2013-04-04|Estimate||||2015-06-03|2015-06-30|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer|A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:56:50.482404|2018-06-01 04:56:50.482404
NCT00108706|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-18|||2006-09-11|2005-04-18|2005-04-19|Estimate|||||||2006-09-11|2006-09-13|Estimate|December 2004||2004-12-31|September 2006|2006-09-30|September 2007||2007-09-30|||||Interventional|||Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)|Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)|Unknown status|Active, not recruiting|Phase 4|50||City Hospitals Sunderland NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:56:50.777059|2018-06-01 04:56:50.777059
NCT00108680|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-16|||2017-06-30|2005-04-16|2005-04-18|Estimate|||||||2017-06-30|2017-07-02|Actual|April 13, 2005||2005-04-13|January 14, 2011|2011-01-14|January 14, 2011||2011-01-14|||||Observational|||Effects of Two Different Kinds of Exercise on Stroke Rehabilitation|Effects of Unilateral and Bilateral Training on Motor Function in Chronic Stroke|Completed|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:50.850006|2018-06-01 04:56:50.850006
NCT00108667|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2008-03-03|2005-04-15|2005-04-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2005||2005-04-30|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Talampanel to Treat Parkinson's Disease|AMPA Receptor Antagonist Treatment of Parkinson's Disease|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:50.901671|2018-06-01 04:56:50.901671
NCT00108654|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2017-06-30|2005-04-15|2005-04-18|Estimate|||||||2017-06-30|2017-07-02|Actual|April 13, 2005||2005-04-13|January 15, 2008|2008-01-15|January 15, 2008||2008-01-15|||||Interventional|||Vaccine Treatment for HIV-Infection|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects Who Where Previously Immunized With VRC-HIVDNA016-00-VP in VRC 00|Completed||Phase 1|14||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:50.962303|2018-06-01 04:56:50.962303
NCT00108628|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|2014-12-03||2015-02-17|2005-04-15|2005-04-18|Estimate|2015-02-17|2015-02-18|Estimate||||2015-02-17|2015-02-18|Estimate|April 2004||2004-04-30|February 2015|2015-02-28|July 2013|Actual|2013-07-31|September 2008|Actual|2008-09-30||Interventional|||Cognitive Behavioral Treatments for Post-traumatic Stress Disorder (PTSD) Sleep Disturbance|7857 Cognitive - Behavioral Treatments for PTSD Sleep Disturbance|Completed||N/A|134|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:56:51.027213|2018-06-01 04:56:51.027213
NCT00108615|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2008-04-23|2005-04-15|2005-04-18|Estimate|||||||2008-04-23|2008-04-25|Estimate|January 2004||2004-01-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|April 2007|Actual|2007-04-30||Interventional|||Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance|Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance|Completed||Phase 4|48|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:56:51.340348|2018-06-01 04:56:51.340348
NCT00108602|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2015-06-25|2005-04-15|2005-04-18|Estimate|||||||2015-06-25|2015-06-26|Estimate|May 2007||2007-05-31|June 2015|2015-06-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Sleep Apnea: Mechanism and Cerebrovascular Consequences|Sleep Apnea: Mechanism and Cerebrovascular Consequences|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1||This study of the overall grant was not pursued as the aims were changed|f||||||||||||||2018-06-01 04:56:51.468471|2018-06-01 04:56:51.468471
NCT00108589|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2009-01-20|2005-04-15|2005-04-18|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2004||2004-01-31|May 2007|2007-05-31|December 2006||2006-12-31|||||Interventional|||S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis|S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis|Completed||Phase 3|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:51.574625|2018-06-01 04:56:51.574625
NCT00108576|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2015-10-20|2005-04-15|2005-04-18|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2003||2003-10-31|October 2015|2015-10-31|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Interventional|||Divalproex Sodium in the Treatment of PTSD (Post-Traumatic Stress Disorder)|Divalproex Sodium in the Treatment of PTSD: A Placebo-Controlled Study|Completed||Phase 3|101|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:56:51.632483|2018-06-01 04:56:51.632483
NCT00108563|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2009-01-20|2005-04-15|2005-04-18|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2003||2003-10-31|May 2007|2007-05-31|September 2006||2006-09-30|||||Interventional|||VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients|VISN 20 Prophylactic Treatment of IFN-Induced Depression in Hepatitis C|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:51.773353|2018-06-01 04:56:51.773353
NCT00108550|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|2013-07-15||2013-12-20|2005-04-15|2005-04-18|Estimate|2013-12-20|2014-02-10|Estimate||||2013-12-20|2014-02-10|Estimate|October 2004||2004-10-31|December 2013|2013-12-31|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|||Chronic Low Back Pain Research Project|Efficacy of Antidepressants in Chronic Back Pain|Completed||Phase 2|108|Actual|VA Office of Research and Development|Limitations include small sample size, high rate of early termination, and moderate baseline levels of pain intensity and disability in everyday function which may have limited ability to detect an effect.|2|||f||||t||||||||||2018-06-01 04:56:51.842549|2018-06-01 04:56:51.842549
NCT00108537|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2008-04-02|2005-04-15|2005-04-18|Estimate|||||||2008-04-02|2008-04-04|Estimate|October 2003||2003-10-31|October 2006|2006-10-31|September 2005||2005-09-30|||||Interventional|||Non-Nicotine Agents for Smoking Cessation|Non-Nicotine Agents for Smoking Cessation|Completed||Phase 3|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:52.155935|2018-06-01 04:56:52.155935
NCT00108524|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|2013-09-26||2014-03-26|2005-04-15|2005-04-18|Estimate|2013-09-26|2013-12-12|Estimate||||2014-03-26|2014-04-17|Estimate|July 2004||2004-07-31|March 2014|2014-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional||160 participants were randomized (81 allocated to LCKD, 79 to Orlistat plus LFD). 14 did not receive the intervention. 33 discontinued the intervention. Out of the 146 participants analyzed, 113 completed the intervention.|A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss|A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss|Completed||N/A|146|Actual|VA Office of Research and Development|We provided orlistat at no cost. This could have increased dietary adherence, attendance, and/or retention compared with the LCKD and may lead to different results than what might be seen in patients who must pay for orlistat.|2|||f||||f||||||||||2018-06-01 04:56:52.226854|2018-06-01 04:56:52.226854
NCT00108511|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2009-01-20|2005-04-15|2005-04-18|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2004||2004-10-31|May 2007|2007-05-31|September 2007||2007-09-30|||||Interventional|||Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides|Effect of Gemfibrozil on Serum GPI Phospholipase D and Triglycerides|Completed||Phase 1|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:52.452215|2018-06-01 04:56:52.452215
NCT00108498|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2009-01-20|2005-04-15|2005-04-18|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2003||2003-10-31|May 2007|2007-05-31|March 2007||2007-03-31|||||Interventional|||New Pharmacological Treatment for Obstructive Sleep Apnea|New Pharmacological Treatment for Obstructive Sleep Apnea|Completed||Phase 1|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:52.520158|2018-06-01 04:56:52.520158
NCT00108485|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|2015-09-04||2016-05-17|2005-04-15|2005-04-18|Estimate|2016-04-07|2016-05-12|Estimate||||2016-05-17|2016-06-22|Estimate|April 2005||2005-04-30|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy|Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment|Terminated||Phase 3|9|Actual|University of Miami|Early termination of study lead to small number of subjects analyzed.|2||Unable to recruit sufficient study subjects|f||||f||||||||||2018-06-01 04:56:52.593285|2018-06-01 04:56:52.593285
NCT00108459|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2009-01-20|2005-04-15|2005-04-18|Estimate|||||||2009-01-20|2009-01-21|Estimate|September 2004||2004-09-30|July 2007|2007-07-31|December 2007||2007-12-31|||||Interventional|||Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes|Safety and Efficacy of Low Carbohydrate Diet in Obesity and Type 2 DM: RCT|Completed||Phase 3|156|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:52.822102|2018-06-01 04:56:52.822102
NCT00108446|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|||2009-01-20|2005-04-15|2005-04-18|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2003||2003-10-31|May 2007|2007-05-31|March 2006||2006-03-31|||||Interventional|||Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome|Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:52.90348|2018-06-01 04:56:52.90348
NCT00108433|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-15|2012-06-28||2012-06-28|2005-04-15|2005-04-18|Estimate|2012-06-28|2012-08-07|Estimate||||2012-06-28|2012-08-07|Estimate|September 2005||2005-09-30|June 2012|2012-06-30|September 2006|Actual|2006-09-30|||||Interventional|||Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections|Linezolid vs Vancomycin/Cefazolin in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections|Terminated||Phase 3|61|Actual|Pfizer|Efficacy results were not reported because the study was prematurely terminated.|||See Detailed Description|f||||||||||||||2018-06-01 04:56:52.981001|2018-06-01 04:56:52.981001
NCT00108420|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2003||2003-10-31|May 2007|2007-05-31|March 2007||2007-03-31|||||Interventional|||Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance|Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:53.279059|2018-06-01 04:56:53.279059
NCT00108407|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-03-04|2005-04-14|2005-04-15|Estimate|||||||2009-03-04|2009-03-06|Estimate|October 2004||2004-10-31|March 2009|2009-03-31||||||||Interventional|||Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse|Integrated CBT for Substance Use and Depressive Disorders|Completed||N/A|||VA Office of Research and Development||2|||f||||||||||||||2018-06-01 04:56:53.333061|2018-06-01 04:56:53.333061
NCT00108394|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2002||2002-10-31|March 2008|2008-03-31|September 2007||2007-09-30|||||Interventional|||Osteopenia and Renal Osteodystrophy: Evaluation and Management|Osteopenia and Renal Osteodystrophy: Evaluation and Management|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:53.392308|2018-06-01 04:56:53.392308
NCT00108381|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2014-07-01|2005-04-14|2005-04-15|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2004||2004-01-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|February 2010|Actual|2010-02-28||Interventional|||Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain|Efficacy of Tailored Cognitive-Behavioral Therapy for Chronic Back Pain|Completed||N/A|162|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:56:53.439207|2018-06-01 04:56:53.439207
NCT00108368|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2003||2003-10-31|September 2007|2007-09-30|March 2006||2006-03-31|||||Interventional|||The Effects of Risperidone and Olanzapine on Thinking|The Cognitive Effects of Risperidone and Olanzapine|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:53.495347|2018-06-01 04:56:53.495347
NCT00108355|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|2013-12-11||2014-02-03|2005-04-14|2005-04-15|Estimate|2014-02-03|2014-03-06|Estimate||||2014-02-03|2014-03-06|Estimate|December 2003||2003-12-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Interventional|||Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis|Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis|Completed||Phase 4|29|Actual|VA Office of Research and Development|Difficulty to enroll patient population lead to small sample size. Midodrine not titrated for a goal increase in mean arterial pressure. Blood tests for day 6 assessment of post paracentesis circulatory dysfunction not available for all patients.|2|||f||||t||||||||||2018-06-01 04:56:53.552074|2018-06-01 04:56:53.552074
NCT00108342|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|2013-12-19||2014-06-02|2005-04-14|2005-04-15|Estimate|2014-06-02|2014-06-04|Estimate||||2014-06-02|2014-06-04|Estimate|October 2007||2007-10-31|June 2014|2014-06-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|NDS||Nicotine Delivery Systems: Research & Treatment|Nicotine Delivery Systems: Research and Treatment|Terminated||N/A|25|Actual|VA Office of Research and Development|Limitations of the study: early termination of the study occurred due to widespread comorbidities precluding recruitment and enrollment of Veterans in this NRT trial. Specifically, the sample size was too small for any data analyses.|2||Common comorbidities of Veterans precluded sufficient recruitment and enrollment.|f||||f||||||||||2018-06-01 04:56:53.786585|2018-06-01 04:56:53.786585
NCT00108303|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|2014-11-03||2015-12-02|2005-04-14|2005-04-15|Estimate|2015-12-02|2016-01-07|Estimate||||2015-12-02|2016-01-07|Estimate|January 2004||2004-01-31|December 2015|2015-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes|Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes in Individuals Extensively Diagnosed and Genotyped|Completed|||538|Actual|VA Office of Research and Development|Genetic linkage and association do not replicate well across studies. This study should be viewed in this context.||1||f||||f||||||Samples With DNA|"~     dna~   "|||2018-06-01 04:56:54.25792|2018-06-01 04:56:54.25792
NCT00108290|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2008-04-02|2005-04-14|2005-04-15|Estimate|||||||2008-04-02|2008-04-04|Estimate|April 2004||2004-04-30|April 2007|2007-04-30|March 2007||2007-03-31|||||Interventional|||Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer|Chemohormone Therapy Prior to Prostatectomy in High Risk Prostate Cancer|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:54.79679|2018-06-01 04:56:54.79679
NCT00108277|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|2014-12-16||2015-01-07|2005-04-14|2005-04-15|Estimate|2015-01-06|2015-01-08|Estimate||||2015-01-07|2015-01-19|Estimate|April 2005||2005-04-30|January 2015|2015-01-31|September 2010|Actual|2010-09-30|December 2008|Actual|2008-12-31||Interventional|||Respiratory Dysregulation and Breathing Training in Anxious Outpatients|Respiratory Dysregulation and Breathing Training in Anxious Outpatients|Completed||N/A|92|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:56:54.857901|2018-06-01 04:56:54.857901
NCT00108264|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate||||May 2007|2007-05-31|September 2005||2005-09-30|||||Interventional|||Tumor RNA Transfected Dendritic Cell Vaccines|Tumor RNA Transfected Dendritic Cell Vaccines|Completed||Phase 1|||VA Office of Research and Development|||||||||||||||||||2018-06-01 04:56:55.141148|2018-06-01 04:56:55.141148
NCT00108251|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2011-09-07|2005-04-14|2005-04-15|Estimate|||||||2011-09-07|2011-09-08|Estimate|August 2004||2004-08-31|September 2011|2011-09-30|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||Aldosterone Antagonism in Diastolic Heart Failure|Aldosterone Antagonism in Diastolic Heart Failure|Completed||Phase 4|48|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:56:55.195434|2018-06-01 04:56:55.195434
NCT00108238|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2003||2003-04-30|April 2007|2007-04-30|December 2006||2006-12-31|||||Interventional|||Estrogen Alternatives Study|Estrogen Alternatives and Vascular Function in Post-Menopausal Women|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:55.27732|2018-06-01 04:56:55.27732
NCT00108225|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2014-06-30|2005-04-14|2005-04-15|Estimate|||||||2014-06-30|2014-07-01|Estimate|July 2004||2004-07-31|June 2014|2014-06-30|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)|2895 Effect of a High Protein Diet on the 24-hr Profile of Ghrelin, GH and IGF-1|Completed||N/A|8|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:56:55.339028|2018-06-01 04:56:55.339028
NCT00108212|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|December 2007||2007-12-31|||||Interventional|||Effect of Diet on Men and Women With Genetic Alterations Associated With Abnormal Blood Tests|Clinical Implications of Genetic Alterations in TG Rich Lipoproteins|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:55.422722|2018-06-01 04:56:55.422722
NCT00108199|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-01-20|2005-04-14|2005-04-15|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2001||2001-10-31|May 2007|2007-05-31|September 2004||2004-09-30|||||Interventional|||Generalization of Training in Schizophrenia|Generalization of Training in Schizophrenia|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:56:55.476476|2018-06-01 04:56:55.476476
NCT00108186|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2014-10-28|2005-04-14|2005-04-15|Estimate|||||||2014-10-28|2014-10-29|Estimate|October 2004||2004-10-31|October 2014|2014-10-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Celecoxib Treatment for Lung Cancer|Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer|Withdrawn||Phase 1|0|Actual|VA Office of Research and Development||1||Couldn't accrue patients|f||||t||||||||||2018-06-01 04:56:55.531041|2018-06-01 04:56:55.531041
NCT00108173|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2013-04-05|2005-04-14|2005-04-15|Estimate|||||||2013-04-05|2013-04-09|Estimate|October 2002||2002-10-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|April 2007|Actual|2007-04-30||Interventional|||Brain Reaction to Treatment of Nicotine Dependence|Neural Substrates of Treatment for Nicotine Dependence|Completed||Phase 1|104|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:56:55.594509|2018-06-01 04:56:55.594509
NCT00108160|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|2013-12-16||2014-03-20|2005-04-14|2005-04-15|Estimate|2013-12-16|2014-02-04|Estimate||||2014-03-20|2014-04-16|Estimate|April 2005||2005-04-30|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Preventing Staphylococcal (Staph) Infection|Intermittent Mupirocin to Prevent Staphylococcal Infection|Completed||Phase 4|146|Actual|VA Office of Research and Development|The study is underpowered to detect differences between the two treatment arms. We achieved only 75% of target enrollment, and 41.1% dropped out before reaching a primary endpoint. Our re-infection rate was also lower than anticipated (14.4%).|2|||f||||f||||||||||2018-06-01 04:56:55.6942|2018-06-01 04:56:55.6942
NCT00108147|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2009-03-04|2005-04-14|2005-04-15|Estimate|||||||2009-03-04|2009-03-06|Estimate|October 2003||2003-10-31|March 2009|2009-03-31||||||||Interventional|||Functional Circuit Training in Older Adults With Congestive Heart Failure|Functional Circuit Training in Older Adults With Congestive Heart Failure|Completed||N/A|||VA Office of Research and Development||3|||f||||||||||||||2018-06-01 04:56:55.940406|2018-06-01 04:56:55.940406
NCT00108134|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2008-12-22|2005-04-14|2005-04-15|Estimate|||||||2008-12-22|2008-12-24|Estimate|March 2005||2005-03-31|December 2008|2008-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Superficial Basal Cell Carcinoma|Completed||Phase 2|60||Peplin|||||f||||||||||||||2018-06-01 04:56:55.998081|2018-06-01 04:56:55.998081
NCT00108121|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2015-01-16|2005-04-14|2005-04-15|Estimate|||||||2015-01-16|2015-01-19|Estimate|March 2005||2005-03-31|January 2015|2015-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma|A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma|Completed||Phase 2|60||Peplin|||||f||||||||||||||2018-06-01 04:56:56.07786|2018-06-01 04:56:56.07786
NCT00100919|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2017-06-30|2005-01-06|2005-01-07|Estimate|||||||2017-06-30|2017-07-02|Actual|January 4, 2005||2005-01-04|July 6, 2010|2010-07-06|July 6, 2010||2010-07-06|||||Observational|||Sensing of Leg Position and Movement|Coupled Joint Proprioception and Multi-Joint Movement in the Lower Extremity: A Pilot Study|Completed|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:18.208921|2018-06-01 04:59:18.208921
NCT00108108|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-14|||2012-09-28|2005-04-14|2005-04-15|Estimate|||||||2012-09-28|2012-10-01|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy|An Open-label,Multi-center, Phase l/ll Study of Anti-CD40 Monoclonal Antibody (HCD122) Administered Intravenously to Subjects With Advanced Chronic Lymphocytic Leukemia That is Refractory or Relapsed After at Least One Previous Fludarabine-containing Chemotherapy Regimen|Terminated||Phase 1|26|Actual|Novartis||1||Slow enrollment and minimal preliminary biological and clinical efficacy.|f||||f||||||||||2018-06-01 04:56:56.150555|2018-06-01 04:56:56.150555
NCT00108095|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-13|||2017-01-19|2005-04-13|2005-04-14|Estimate|||||||2017-01-19|2017-01-20|Estimate|October 2004||2004-10-31|January 2017|2017-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk|Completed||Phase 2|701|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:56:56.23184|2018-06-01 04:56:56.23184
NCT00108082|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-13|2009-08-13||2016-11-04|2005-04-13|2005-04-14|Estimate|2009-09-30|2009-11-09|Estimate||||2016-11-04|2016-12-16|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||The CLEVER Study - Coreg And Left Ventricular Mass Regression|A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients With Left Ventricular Hypertrophy (LVH).|Completed||Phase 3|287|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:56:56.417704|2018-06-01 04:56:56.417704
NCT00108069|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-12|2014-03-06||2015-10-13|2005-04-12|2005-04-13|Estimate|2014-05-13|2014-06-12|Estimate||||2015-10-13|2015-11-05|Estimate|April 2005||2005-04-30|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||One participant in the AG cohort was not evaluable/did not receive study drug.|Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors|A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas|Completed||Phase 2|43|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 04:56:57.245417|2018-06-01 04:56:57.245417
NCT00108056|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-12|||2018-05-17|2005-04-12|2005-04-13|Estimate|||||||2018-05-17|2018-05-18|Actual|April 7, 2005||2005-04-07|April 1, 2014|2014-04-01|April 1, 2014|Actual|2014-04-01|April 1, 2014|Actual|2014-04-01||Interventional|||Enzastaurin to Treat Recurrent Brain Tumor|A Phase I Trial of Enzastaurin (LY317615) in Patients With Recurrent Gliomas|Terminated||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:56:58.082903|2018-06-01 04:56:58.082903
NCT00108043|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-12|||2015-12-02|2005-04-12|2005-04-13|Estimate|||||||2015-12-02|2015-12-03|Estimate|March 2004||2004-03-31|December 2015|2015-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Orthostatic Tolerance During FES (Functional Electrical Stimulation)-Walking in Paraplegia|Orthostatic Tolerance During FES-evoked Stepping in Paraplegia: A Safety and Viability Study|Completed||Phase 1|10|Anticipated|University of Sydney|||||f||||||||||||||2018-06-01 04:56:58.1459|2018-06-01 04:56:58.1459
NCT00108030|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-12|||2015-12-02|2005-04-12|2005-04-13|Estimate|||||||2015-12-02|2015-12-03|Estimate|March 2004||2004-03-31|December 2015|2015-12-31|December 2006|Actual|2006-12-31|||||Interventional|||PBWST (Partial Body-Weight Supported Treadmill Training) and Muscle Power Training After Sub-acute Stroke|A RCT of Power Training and Treadmill Training to Improve Walking Ability in Sub-acute Stroke Patients|Completed||Phase 2/Phase 3|102|Anticipated|University of Sydney|||||f||||||||||||||2018-06-01 04:56:58.207492|2018-06-01 04:56:58.207492
NCT00108017|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-12|||2015-05-12|2005-04-12|2005-04-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|April 2005||2005-04-30|May 2015|2015-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)|Randomized, Multicenter, Dbl-Masked, Parallel Study Evaluating the 24 Hr. Diurnal Ocular Hypotensive Effect of 2% Dorzolamide Hydrochloride/0.5% Timolol Maleate Combo. Ophthalmic Sol. in Patients w/ Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|330|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:56:58.27729|2018-06-01 04:56:58.27729
NCT00108004|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-12|||2015-05-20|2005-04-12|2005-04-13|Estimate|||||||2015-05-20|2015-05-21|Estimate|April 2003||2003-04-30|May 2015|2015-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus|A Phase 3B, Multicenter, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Insulin Therapy|Completed||Phase 3|400|Anticipated|AstraZeneca||1|||f||||||||||||||2018-06-01 04:56:58.354618|2018-06-01 04:56:58.354618
NCT00107991|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|2011-01-04||2018-03-19|2005-04-11|2005-04-12|Estimate|2011-01-04|2011-01-14|Estimate||||2018-03-19|2018-03-21|Actual|April 2005||2005-04-30|March 2018|2018-03-31|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|||Etanercept for Treatment of Hidradenitis|A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa|Completed||Phase 2|15|Actual|University of Pennsylvania|This study did not have a control group, and therefore, it is possible that observed benefits could be as a result of natural remission or a placebo effect.|1|||f||||f||||||||||2018-06-01 04:56:58.481816|2018-06-01 04:56:58.481816
NCT00107978|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|2009-11-03||2010-12-10|2005-04-11|2005-04-12|Estimate|2010-01-08|2010-02-01|Estimate||||2010-12-10|2010-12-28|Estimate|February 2005||2005-02-28|December 2010|2010-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|ATLAS2||Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus|Completed||Phase 3|1035|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||t||||||||||2018-06-01 04:56:58.752036|2018-06-01 04:56:58.752036
NCT00107965|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|||2015-03-24|2005-04-11|2005-04-12|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2005||2005-03-31|March 2015|2015-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses|A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Actinic Keratoses|Completed||Phase 2|60||Peplin||8|||f||||||||||||||2018-06-01 04:56:59.423465|2018-06-01 04:56:59.423465
NCT00107952|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|2009-11-03||2014-08-13|2005-04-11|2005-04-12|Estimate|2009-11-03|2009-12-08|Estimate||||2014-08-13|2014-08-18|Estimate|February 2005||2005-02-28|August 2014|2014-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|ATTAIN1||Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus|Completed||Phase 3|761|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||t||||||||||2018-06-01 04:56:59.523256|2018-06-01 04:56:59.523256
NCT00107939|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|||2017-03-20|2005-04-11|2005-04-12|Estimate|||||||2017-03-20|2017-03-22|Actual|November 2004||2004-11-30|March 2017|2017-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Licarbazepine 750 ¿ 2000 mg/d as Adjunctive Therapy to an Atypical Antipsychotic in the Treatment of Manic Episodes of Bipolar I Disorder Over 6 Weeks|Completed||Phase 3|453|Actual|Novartis|||||f||||||||||||||2018-06-01 04:57:01.602198|2018-06-01 04:57:01.602198
NCT00107926|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|||2017-03-20|2005-04-11|2005-04-12|Estimate|||||||2017-03-20|2017-03-22|Actual|October 2004||2004-10-31|March 2017|2017-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|Completed||Phase 3|343|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:57:01.928675|2018-06-01 04:57:01.928675
NCT00107913|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|||2005-06-23|2005-04-11|2005-04-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2001||2001-09-30|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura|Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura|Unknown status|Recruiting|Phase 2|10||Hematology and Oncology Specialists|||||f||||||||||||||2018-06-01 04:57:02.328603|2018-06-01 04:57:02.328603
NCT00107900|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|2015-02-05||2015-02-26|2005-04-11|2005-04-12|Estimate|2015-02-26|2015-03-02|Estimate||||2015-02-26|2015-03-02|Estimate|January 2005||2005-01-31|February 2015|2015-02-28|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement|A Phase IIa, Multi-center, Multi-national, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty|Completed||Phase 2|606|Actual|Daiichi Sankyo, Inc.||6|||f||||||||||||||2018-06-01 04:57:02.440574|2018-06-01 04:57:02.440574
NCT00107887|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|||2011-06-14|2005-04-11|2005-04-12|Estimate|||||||2011-06-14|2011-06-15|Estimate|June 2005||2005-06-30|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)|Impact of TB Preventive Therapy for HIV/TB Co-infected Patients With Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial|Completed||Phase 4|17415|Actual|Communicable Disease Program, Brazil||2|||f||||t||||||||||2018-06-01 04:57:03.443378|2018-06-01 04:57:03.443378
NCT00107874|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|||2005-06-23|2005-04-11|2005-04-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1999||1999-01-31|April 2005|2005-04-30|February 2002||2002-02-28|||||Interventional|||Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-Scheduled Cesarean Section|Oral Misoprostol as a Second-Line Alternative to Intravenous Oxytocin in Preventing Postoperative Blood Loss After Non-Scheduled Cesarean Section: a Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 2|56||Basel Women’s University Hospital|||||f||||||||||||||2018-06-01 04:57:03.51044|2018-06-01 04:57:03.51044
NCT00107861|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-11|||2009-07-10|2005-04-11|2005-04-12|Estimate|||||||2009-07-10|2009-07-14|Estimate|May 2005||2005-05-31|July 2009|2009-07-31|September 2006|Actual|2006-09-30|||||Interventional|||Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases|A Phase I/II Study of Interferon-Beta Gene Transfer (Ad.hIFN-β) in the Treatment of Refractory Colorectal Carcinoma With Liver Metastases|Completed||Phase 1/Phase 2|44||Biogen|||||||||||||||||||2018-06-01 04:57:03.581967|2018-06-01 04:57:03.581967
NCT00107848|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-08|||2014-05-08|2005-04-08|2005-04-11|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2004||2004-10-31|May 2014|2014-05-31|September 2005||2005-09-30|||||Interventional|||PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome|A 1 Year Open Label, Flexible Dosage Extension Study to Assess the Safety and Continued Effectiveness of PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome|Completed||Phase 3|280||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:57:03.651802|2018-06-01 04:57:03.651802
NCT00107835|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-08|||2012-06-04|2005-04-08|2005-04-11|Estimate|||||||2012-06-04|2012-06-06|Estimate|May 2005||2005-05-31|June 2012|2012-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults|An Open-Label Safety Study to Evaluate the Use of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) in Adult Patients Undergoing a Minor or Major Dermal Procedure|Completed||Phase 3|408|Actual|ZARS Pharma Inc.||1|||f||||f||||||||||2018-06-01 04:57:03.888111|2018-06-01 04:57:03.888111
NCT00107822|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-08|||2005-10-05|2005-04-08|2005-04-11|Estimate|||||||2005-10-05|2005-10-06|Estimate|April 2005||2005-04-30|October 2005|2005-10-31|May 2005||2005-05-31|||||Interventional|||Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children|An Open-Label Safety Study to Evaluate the Use of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) in Pediatric Patients Undergoing a Minor or Major Dermal Procedure|Completed||Phase 3|80||ZARS Pharma Inc.|||||||||||||||||||2018-06-01 04:57:03.97557|2018-06-01 04:57:03.97557
NCT00107809|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-08|||2014-05-08|2005-04-08|2005-04-11|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2004||2004-10-31|May 2014|2014-05-31|September 2005||2005-09-30|||||Interventional|||Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of PROVIGIL ® (Modafinil) Treatment (100, 200, and 400 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome|Completed||Phase 3|140||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:57:04.069629|2018-06-01 04:57:04.069629
NCT00107627|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-06|||2009-06-24|2005-04-06|2005-04-07|Estimate|||||||2009-06-24|2009-06-25|Estimate|March 2005||2005-03-31|June 2009|2009-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery|Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery|Completed||Phase 3|90|Actual|Queensland Centre for Gynaecological Cancer||3|||f||||f||||||||||2018-06-01 04:57:07.997802|2018-06-01 04:57:07.997802
NCT00107796|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-08|||2012-08-22|2005-04-08|2005-04-11|Estimate|||||||2012-08-22|2012-08-24|Estimate|October 2004||2004-10-31|May 2006|2006-05-31|September 2005||2005-09-30|||||Interventional|||Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of PROVIGIL ® (Modafinil) Treatment (100, 200, and 400 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy|Completed||Phase 3|140||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:57:04.258293|2018-06-01 04:57:04.258293
NCT00107783|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-07|2010-12-20||2010-12-20|2005-04-07|2005-04-08|Estimate|2010-12-20|2011-01-19|Estimate||||2010-12-20|2011-01-19|Estimate|January 2005||2005-01-31|December 2010|2010-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Long-Term Study of Nitisinone to Treat Alkaptonuria|Long-Term Clinical Trial of Nitisinone in Alkaptonuria|Completed||Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)|Small number of patients involved in study and several patients dropped out; primary outcome parameter selection possibly inappropriate because hip joint damage that is already present may be irreversible.|2|||f||||t||||||||||2018-06-01 04:57:04.581618|2018-06-01 04:57:04.581618
NCT00107770|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-07|||2010-01-08|2005-04-07|2005-04-08|Estimate|||||||2010-01-08|2010-01-11|Estimate|April 2005||2005-04-30|October 2008|2008-10-31|September 2007|Actual|2007-09-30|November 2006|Actual|2006-11-30||Interventional|||Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)|Safety and Dose Escalating Study of Oral Sodium Phenylbutyrate in Subjects With Amyotrophic Lateral Sclerosis|Completed||Phase 1/Phase 2|40|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:05.046225|2018-06-01 04:57:05.046225
NCT00107757|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-07|||2016-09-13|2005-04-07|2005-04-08|Estimate|||||||2016-09-13|2016-09-15|Estimate|March 2005||2005-03-31|September 2016|2016-09-30|November 2005|Actual|2005-11-30|||||Interventional|||Seasonal Allergic Rhinitis In Pediatric Subjects|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg and 100mcg for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 3|576||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:57:05.215317|2018-06-01 04:57:05.215317
NCT00107744|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-07|||2005-06-23|2005-04-07|2005-04-08|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|April 2005|2005-04-30|January 2004||2004-01-31|||||Interventional|||Clinical Trial of Protein and Blood Pressure|Clinical Trial of Protein and Blood Pressure|Completed||Phase 3|300||Tulane University Health Sciences Center|||||f||||||||||||||2018-06-01 04:57:05.520443|2018-06-01 04:57:05.520443
NCT00107731|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-07|||2009-03-24|2005-04-07|2005-04-08|Estimate|||||||2009-03-24|2009-03-25|Estimate|April 2004||2004-04-30|March 2009|2009-03-31|October 2006|Actual|2006-10-31|||||Interventional|||Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder|A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated)|Completed||Phase 3|710||AstraZeneca|||||f||||||||||||||2018-06-01 04:57:05.607718|2018-06-01 04:57:05.607718
NCT00107718|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-07|||2017-07-25|2005-04-07|2005-04-08|Estimate|||||||2017-07-25|2017-07-27|Actual|November 15, 2004|Actual|2004-11-15|July 2017|2017-07-31|May 19, 2006|Actual|2006-05-19|May 19, 2006|Actual|2006-05-19||Interventional|||Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma|A Phase II Study of IL-18 in Melanoma Patients|Completed||Phase 2|64|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 04:57:05.88368|2018-06-01 04:57:05.88368
NCT00107705|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-07|||2010-06-16|2005-04-07|2005-04-08|Estimate|||||||2010-06-16|2010-06-17|Estimate|April 2005||2005-04-30|June 2010|2010-06-30|May 2005||2005-05-31|||||Interventional|||Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing|A Single-blind Phase I Study to Assess the Residual Allergenicity of Tree (Birch, Hazel and Alder) Pollen Allergoid Using Skin Prick Testing|Completed||Phase 1|12||Allergy Therapeutics|||||f||||||||||||||2018-06-01 04:57:05.976706|2018-06-01 04:57:05.976706
NCT00107692|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-06|||2006-09-11|2005-04-06|2005-04-07|Estimate|||||||2006-09-11|2006-09-13|Estimate|March 2005||2005-03-31|September 2006|2006-09-30|October 2007||2007-10-31|||||Interventional|||Can a Physical Activity Skill Development and Parent-Centered Dietary Intervention Help Combat Child Obesity?|Effect of a Weight Management Program for Overweight and Obese Children: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|216||University of Wollongong|||||f||||||||||||||2018-06-01 04:57:06.036237|2018-06-01 04:57:06.036237
NCT00107679|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-06|||2014-04-15|2005-04-06|2005-04-07|Estimate|||||||2014-04-15|2014-04-17|Estimate|February 2005||2005-02-28|April 2014|2014-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||A Study of Anal Cancer Development in HIV Infected People|Anal Dysplasia: A Substudy of a Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)|Completed|||560||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:57:06.123349|2018-06-01 04:57:06.123349
NCT00107666|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-06|||2006-03-15|2005-04-06|2005-04-07|Estimate|||||||2006-03-15|2006-03-17|Estimate|April 2005||2005-04-30|March 2006|2006-03-31|April 2006||2006-04-30|||||Interventional|||CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Proof of Concept Clinical Study of CTI-01 in Patients Undergoing Major Cardiac Surgery With Cardiopulmonary Bypass|Terminated||Phase 2|150||Critical Therapeutics|||||||||||||||||||2018-06-01 04:57:06.216706|2018-06-01 04:57:06.216706
NCT00107653|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-06|2016-03-16||2016-05-13|2005-04-06|2005-04-07|Estimate|2016-05-13|2016-06-21|Estimate||||2016-05-13|2016-06-21|Estimate|October 2004||2004-10-31|May 2016|2016-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.|A Prospective, Multicenter, Open-label, Comparative, Efficacy Study of Pegasys® Plus Copegus® in Treatment-naïve Latino Patients With Chronic Hepatitis C-genotype 1, as Compared to Treatment-naïve Non- Latino Caucasian Patients With Chronic Hepatitis C-genotype 1|Completed||Phase 4|569|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:57:06.536444|2018-06-01 04:57:06.536444
NCT00107640|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-06|||2012-08-11|2005-04-06|2005-04-07|Estimate|||||||2012-08-11|2012-08-14|Estimate|May 2005||2005-05-31|September 2010|2010-09-30|September 2009|Actual|2009-09-30|September 2008|Actual|2008-09-30||Interventional|||Project SHARE (Senior Health and Alcohol Risk Education)|Costs of Preventing Alcohol Problems in Older Adults|Completed||Phase 2|1186|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 04:57:07.912639|2018-06-01 04:57:07.912639
NCT00106483|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-24|||2015-03-18|2005-03-24|2005-03-25|Estimate|||||||2015-03-18|2015-03-19|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Autoimmunity and Coronary Artery Disease - Ancillary to CARDIA||Completed|||3020|Actual|Northwestern University|||1||f||||||||||||||2018-06-01 04:57:31.668632|2018-06-01 04:57:31.668632
NCT00107614|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2011-04-15||2011-08-24|2005-04-05|2005-04-06|Estimate|2011-06-17|2011-07-15|Estimate||||2011-08-24|2011-08-26|Estimate|November 2002||2002-11-30|August 2011|2011-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients|UARK 2002-10, A Phase II Study of DT PACE Induction, Followed by Tandem Autologous Transplant and Maintenance Therapy for Patients With Advanced and/or Symptomatic Waldenstrom's Macroglobulinemia|Terminated||Phase 2|12|Actual|University of Arkansas|Early termination due to small numbers of subjects enrolled. Only one participant completed the study. Other participants came off study due to death, toxicity, physician choice, or patient choice.|1||Terminated due to poor accrual.|f||||t||||||||||2018-06-01 04:57:08.12808|2018-06-01 04:57:08.12808
NCT00107601|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2008-06-26|2005-04-05|2005-04-06|Estimate|||||||2008-06-26|2008-06-27|Estimate|October 2004||2004-10-31|February 2006|2006-02-28|May 2006||2006-05-31|||||Interventional|||Glucontrol Study: Comparing the Effects of Two Glucose Control Regimens by Insulin in Intensive Care Unit Patients|A Multi-Center Study Comparing the Effects of Two Glucose Control Regimens by Insulin in Intensive Care Unit Patients|Completed||N/A|3500||University Hospital of Liege|||||f||||||||||||||2018-06-01 04:57:08.315457|2018-06-01 04:57:08.315457
NCT00107588|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2017-07-27|2005-04-05|2005-04-06|Estimate|||||||2017-07-27|2017-07-28|Actual|February 2007||2007-02-28|July 2017|2017-07-31|August 2012|Actual|2012-08-31|April 2011|Actual|2011-04-30||Interventional|MTP-3||Marijuana Treatment Project - 3|Contingency Management for Marijuana Dependence|Completed||N/A|215|Actual|UConn Health||3|||f||||t||||||||||2018-06-01 04:57:08.422754|2018-06-01 04:57:08.422754
NCT00107575|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2009-11-30||2016-09-20|2005-04-05|2005-04-06|Estimate|2010-01-07|2010-01-11|Estimate||||2016-09-20|2016-10-26|Estimate|August 2003||2003-08-31|September 2016|2016-09-30|April 2008|Actual|2008-04-30|June 2007|Actual|2007-06-30||Interventional|||Improving Smoking Cessation Outcomes in Heavy Drinkers - 1|Improving Smoking Cessation Outcomes in Heavy Drinkers|Completed||Phase 2|236|Actual|Brown University||2|||f||||f||||||||||2018-06-01 04:57:08.635266|2018-06-01 04:57:08.635266
NCT00107562|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2017-02-27|2005-04-05|2005-04-06|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2005||2005-02-28|February 2016|2016-02-29|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Adolescent Safer Sex Social Network Intervention|Adolescent Safer Sex Social Network Intervention|Completed||N/A|200|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-06-01 04:57:09.076946|2018-06-01 04:57:09.076946
NCT00107549|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2012-05-17|2005-04-05|2005-04-06|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|February 2009|Actual|2009-02-28|||||Interventional|||Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy|A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of Recombinant HIV-1 Vaccines in HIV-1 Infected Young Adults With Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 04:57:09.221095|2018-06-01 04:57:09.221095
NCT00107536|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2014-10-24||2015-04-08|2005-04-05|2005-04-06|Estimate|2015-04-08|2015-04-29|Estimate||||2015-04-08|2015-04-29|Estimate|October 2005||2005-10-31|March 2015|2015-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer|A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas|Completed||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:57:09.354022|2018-06-01 04:57:09.354022
NCT00107523|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2010-09-20|2005-04-05|2005-04-06|Estimate|||||||2010-09-20|2010-09-21|Estimate|January 2005||2005-01-31|September 2010|2010-09-30|October 2005|Actual|2005-10-31|||||Interventional|||Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia|A Phase I Trial Evaluating the Effect of the Addition of HMGCoA-Reductase Inhibition With Pravastatin to Salvage Chemotherapy Idarubicin-HDAC in Patients With Relapsed or Refractory Acute Myelogenous Leukemia|Completed||Phase 1|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:57:09.867318|2018-06-01 04:57:09.867318
NCT00107510|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2016-07-01|2005-04-05|2005-04-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|August 2005||2005-08-31|July 2016|2016-07-31||||September 2007|Actual|2007-09-30||Interventional|||Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer|Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer|Completed||Phase 2|58|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:57:10.091132|2018-06-01 04:57:10.091132
NCT00107497|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2009-02-06|2005-04-05|2005-04-06|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2005||2005-01-31|May 2007|2007-05-31||||||||Interventional|||Radiation Therapy in Treating Women With Localized Breast Cancer|Prospective Randomised Clinical Trial Testing 5.7 Gy and 6.0 Gy Fractions of Whole Breast Radiotherapy in Terms of Late Normal Tissue Responses and Tumour Control - FAST|Completed||N/A|900|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:57:10.350216|2018-06-01 04:57:10.350216
NCT00107484|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2010-04-30|2005-04-05|2005-04-06|Estimate|||||||2010-04-30|2010-05-03|Estimate|September 2005||2005-09-30|April 2010|2010-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer|Phase II Study of Combidex in Axillary Node Staging in Breast Cancer|Completed||Phase 2|3|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 04:57:10.455629|2018-06-01 04:57:10.455629
NCT00107471|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2013-12-09|2005-04-05|2005-04-06|Estimate|||||||2013-12-09|2013-12-10|Estimate|October 2005||2005-10-31|December 2013|2013-12-31||||October 2007|Actual|2007-10-31||Interventional|||Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma|A Phase I/II Study of Topotecan With G-CSF and Radiation Therapy in Children With Malignant Intrinsic Pontine Brainstem Gliomas of Childhood|Terminated||Phase 1/Phase 2|7|Actual|Children's Oncology Group||2||"The unpromising experience of the French group with topotecan given at a dosage of 0.4~   mg/m2/day over 30 mins w/in 1 hr of radiation (Cancer 2005; 104: 2792)."|f||||t||||||||||2018-06-01 04:57:10.561013|2018-06-01 04:57:10.561013
NCT00107458|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2014-08-06|2005-04-05|2005-04-06|Estimate|||||||2014-08-06|2014-08-07|Estimate|May 2005||2005-05-31|August 2014|2014-08-31|March 2012|Actual|2012-03-31|October 2007|Actual|2007-10-31||Interventional|||Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors|A Phase I Study of Valproic Acid in Children With Recurrent/Progressive Solid Tumors Including CNS Tumors|Completed||Phase 1|26|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 04:57:10.936682|2018-06-01 04:57:10.936682
NCT00107445|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2013-01-15|2005-04-05|2005-04-06|Estimate|||||||2013-01-15|2013-01-16|Estimate|February 2005||2005-02-28|January 2013|2013-01-31||||September 2005|Actual|2005-09-30||Interventional|||EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer|Evaluation of Hypoxia by EF5 Binding in Gynecologic Cancer|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:57:11.060003|2018-06-01 04:57:11.060003
NCT00107432|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2013-06-04|2005-04-05|2005-04-06|Estimate|||||||2013-06-04|2013-06-05|Estimate|October 2004||2004-10-31|June 2013|2013-06-30||||June 2007|Actual|2007-06-30||Interventional|||Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.|A Phase II Study of BAY 43-9006 (NSC #724772) in Patients With Malignant Mesothelioma|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:57:11.137012|2018-06-01 04:57:11.137012
NCT00107419|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2012-01-13|2005-04-05|2005-04-06|Estimate|||||||2012-01-13|2012-01-18|Estimate|September 2005||2005-09-30|January 2012|2012-01-31|August 2009|Actual|2009-08-31|May 2007|Actual|2007-05-31||Interventional|||S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma|Phase II Trial of Pemetrexed for Advanced Chondrosarcomas|Completed||Phase 2|75|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 04:57:11.295872|2018-06-01 04:57:11.295872
NCT00107393|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2013-07-09|2005-04-05|2005-04-06|Estimate|||||||2013-07-09|2013-07-10|Estimate|June 2003||2003-06-30|October 2006|2006-10-31|November 2008|Actual|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer|Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression|Completed||Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:57:11.48542|2018-06-01 04:57:11.48542
NCT00107380|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2013-12-23||2016-02-04|2005-04-05|2005-04-06|Estimate|2013-12-23|2014-02-11|Estimate||||2016-02-04|2016-03-07|Estimate|November 2005||2005-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2013|Actual|2013-11-30||Interventional||All eligible patients who started treatment were included in the analysis|S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients ≥ Age 60 With Advanced Stage Diffuse Large B-Cell NHL: A Phase II Study|Completed||Phase 2|86|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 04:57:11.614025|2018-06-01 04:57:11.614025
NCT00107367|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2014-01-09|2005-04-05|2005-04-06|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2004||2004-04-30|July 2009|2009-07-31||||April 2010|Anticipated|2010-04-30||Interventional|||Radiation Therapy in Treating Patients Who Are Undergoing Surgery to Remove a Metastatic Brain Tumor|A Phase I/II Study Utilizing the Zeiss INTRABEAM System for the Treatment of a Resected Solitary Brain Metastasis|Unknown status|Recruiting|Phase 1/Phase 2|62|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:57:12.171433|2018-06-01 04:57:12.171433
NCT00107354|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2010-09-16|2005-04-05|2005-04-06|Estimate|||||||2010-09-16|2010-09-20|Estimate|December 1998||1998-12-31|September 2010|2010-09-30||||August 2009|Actual|2009-08-31||Interventional|||Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant|Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant|Completed||Phase 1|||Fred Hutchinson Cancer Research Center|||||||||||||||||||2018-06-01 04:57:12.226189|2018-06-01 04:57:12.226189
NCT00107341|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2016-12-09|2005-04-05|2005-04-06|Estimate|||||||2016-12-09|2016-12-13|Estimate|August 2005||2005-08-31|December 2016|2016-12-31|May 2008|Actual|2008-05-31|February 2007|Actual|2007-02-28||Interventional|||Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for Metastatic Adenocarcinoma of the Lower Esophagus, Gastroesophageal Junction, and Gastric Cardia|Completed||Phase 2|37|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:57:12.334374|2018-06-01 04:57:12.334374
NCT00107315|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2014-01-08||2014-06-03|2005-04-05|2005-04-06|Estimate|2014-06-03|2014-07-04|Estimate||||2014-06-03|2014-07-04|Estimate|July 2004||2004-07-31|June 2014|2014-06-30||||June 2008|Actual|2008-06-30||Interventional||All treated and eligible patients|Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer|A Phase II Study of Capecitabine and Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|16|Actual|Roswell Park Cancer Institute|Due to the study's early termination, as a result of low accrual, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.|1||Terminated due to low accrual|f||||||||||||||2018-06-01 04:57:12.443029|2018-06-01 04:57:12.443029
NCT00107289|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2017-06-01|2005-04-05|2005-04-06|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2006|Actual|2006-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma|Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors|Recruiting||Phase 2|80|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 04:57:12.692999|2018-06-01 04:57:12.692999
NCT00107276|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2012-11-15||2013-07-03|2005-04-05|2005-04-06|Estimate|2013-05-22|2013-06-27|Estimate||||2013-07-03|2013-07-18|Estimate|August 2005||2005-08-31|July 2013|2013-07-31|August 2009|Actual|2009-08-31|March 2008|Actual|2008-03-31||Interventional|||S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer|Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients With Metastatic Breast Cancer|Completed||Phase 2|112|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 04:57:12.939676|2018-06-01 04:57:12.939676
NCT00107263|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2016-12-02|2005-04-05|2005-04-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|January 2005||2005-01-31|December 2016|2016-12-31|August 2012|Actual|2012-08-31|March 2007|Actual|2007-03-31||Interventional|||Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer|A Randomized, Controlled, Open-Label Trial of Empiric Prophylactic vs. Delayed Use of Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women With Breast Cancer Initiating Therapy With Letrozole After Tamoxifen|Completed||Phase 3|558|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 04:57:13.45429|2018-06-01 04:57:13.45429
NCT00107250|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2016-11-25|2005-04-05|2005-04-06|Estimate|||||||2016-11-25|2016-11-28|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||AZD2171 and Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)|A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer or Other Tumor Types Suitable for Treatment With Capecitabine|Completed||Phase 1|50|Actual|Canadian Cancer Trials Group|||||f||||t||||||||||2018-06-01 04:57:13.549272|2018-06-01 04:57:13.549272
NCT00107237|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2013-06-11|2005-04-05|2005-04-06|Estimate|||||||2013-06-11|2013-06-12|Estimate|October 2003||2003-10-31|June 2013|2013-06-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme|A Phase IB/II Multicenter, Two-Arm, Dose-Escalation Study of Oral AEE788 Administered in Combination With Oral RAD001 on a Continuous Once Daily Dosing Schedule in Adult Patients With First or Second Recurrent or Relapsing Glioblastoma Multiforme|Completed||Phase 1/Phase 2|16|Actual|Novartis||2|||||||||||||||||2018-06-01 04:57:13.643094|2018-06-01 04:57:13.643094
NCT00107211|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2014-09-16|2005-04-05|2005-04-06|Estimate|||||||2014-09-16|2014-09-17|Estimate|January 2005||2005-01-31|September 2014|2014-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast|A HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS|Completed||Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-06-01 04:57:13.727939|2018-06-01 04:57:13.727939
NCT00107198|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2016-06-30||2016-12-20|2005-04-05|2005-04-06|Estimate|2016-06-30|2016-08-10|Estimate||||2016-12-20|2017-02-09|Estimate|January 2006||2006-01-31|March 2016|2016-03-31||||November 2012|Actual|2012-11-30||Interventional|||Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease|Treatment of Children With Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD)|Unknown status|Active, not recruiting|N/A|188|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 04:57:13.827605|2018-06-01 04:57:13.827605
NCT00107185|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2012-08-02|2005-04-05|2005-04-06|Estimate|||||||2012-08-02|2012-08-06|Estimate|January 2005||2005-01-31|August 2012|2012-08-31|March 2010|Actual|2010-03-31|October 2009|Actual|2009-10-31||Interventional|||Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma|Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients|Completed||Phase 1|7|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 04:57:14.29796|2018-06-01 04:57:14.29796
NCT00107172|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2015-09-02||2017-08-29|2005-04-05|2005-04-06|Estimate|2016-10-31|2016-12-23|Estimate||||2017-08-29|2017-09-26|Actual|July 2005||2005-07-31|August 2017|2017-08-31||||April 2013|Actual|2013-04-30||Interventional||All intent-to-treat (ITT) participants.|Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer|A Randomized Phase III Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High Risk Patients With Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller|Active, not recruiting||Phase 3|224|Actual|Alliance for Clinical Trials in Oncology||2|||f||||||||||||||2018-06-01 04:57:14.405913|2018-06-01 04:57:14.405913
NCT00107159|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2013-11-05|2005-04-05|2005-04-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 2005||2005-01-31|April 2007|2007-04-30|September 2010|Actual|2010-09-30|||||Interventional|||Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma|A Phase II Study Of Matured Dendritic Cells Pulsed Ex Vivo With 3 Melanoma Cell Line Lysates (IDD-3) in Patients With In-Transit or Metastatic Melanoma|Completed||Phase 2|37|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:57:15.400914|2018-06-01 04:57:15.400914
NCT00107120|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|2009-04-21||2012-04-04|2005-04-05|2005-04-06|Estimate|2009-09-25|2009-11-04|Estimate||||2012-04-04|2012-04-06|Estimate|March 2005||2005-03-31|April 2012|2012-04-30||||May 2007|Actual|2007-05-31||Interventional|||The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder|A Double-blind Flexible Dose Study of Escitalopram in Pediatric Patients With Major Depressive Disorder|Completed||Phase 3|312|Actual|Forest Laboratories||2|||f||||||||||||||2018-06-01 04:57:15.510799|2018-06-01 04:57:15.510799
NCT00107107|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2015-09-22|2005-04-05|2005-04-06|Estimate|||||||2015-09-22|2015-09-23|Estimate|November 2002||2002-11-30|August 2015|2015-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus|A Multicenter, Open-Label, Extension Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus Completing Protocol 137-150|Completed||Phase 3|190|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 04:57:16.082214|2018-06-01 04:57:16.082214
NCT00107094|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-05|||2007-07-18|2005-04-05|2005-04-06|Estimate|||||||2007-07-18|2007-07-20|Estimate|March 2005||2005-03-31|July 2007|2007-07-31||||||||Interventional|||Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer|An Open Label, Pilot Study of Dose-Dense Adriamycin Plus Cyclophosphamide (AC) Followed by ABI-007 as Adjuvant Therapy for Patients With Breast Cancer|Completed||Phase 1|30||Celgene Corporation|||||||||||||||||||2018-06-01 04:57:16.207217|2018-06-01 04:57:16.207217
NCT00107081|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-04|||2014-12-23|2005-04-04|2005-04-05|Estimate|||||||2014-12-23|2014-12-24|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting|A Prospective Multi-Center Study on Pediatric Patients With Fever in Severe Chemotherapy Induced Neutropenia, Including a Randomized Comparison of Outpatient Management and Oral Antimicrobial Therapy Versus Inpatient Management and Intravenous Antimicrobial Therapy in a Subgroup With Low Risk of Adverse Events (Low-Risk Subgroup Study)|Terminated||Phase 3|70|Actual|Swiss Pediatric Oncology Group||2||Accrual goal for interventional part not achievable|f||||f||||||||||2018-06-01 04:57:16.29957|2018-06-01 04:57:16.29957
NCT00107068|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-04|||2015-12-02|2005-04-04|2005-04-05|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2001||2001-01-31|December 2015|2015-12-31|May 2004|Actual|2004-05-31|March 2003|Actual|2003-03-31||Interventional|||Exercise Training and Walking Ability After Chronic Stroke|Does Aerobic or Resistance Exercise Training Improve Walking Ability in Chronic Stroke Patients?|Completed||N/A|48||University of Sydney|||||f||||||||||||||2018-06-01 04:57:16.468867|2018-06-01 04:57:16.468867
NCT00107055|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-04|||2005-06-23|2005-04-04|2005-04-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2003||2003-12-31|June 2005|2005-06-30|April 2005||2005-04-30|||||Interventional|||Study of REN-1654 in Patients With Sciatica Pain|REN-1654 in Sciatica: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study in Subjects With Pain Due to Lumbosacral Radiculopathy|Unknown status|Active, not recruiting|Phase 2|72||Renovis|||||||||||||||||||2018-06-01 04:57:16.564723|2018-06-01 04:57:16.564723
NCT00107042|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-04|2011-09-05||2017-02-27|2005-04-04|2005-04-05|Estimate|2012-10-26|2012-12-04|Estimate||||2017-02-27|2017-03-29|Actual|February 2004||2004-02-29|March 2016|2016-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths|Hepatitis B Vaccination in Youth at Adolescent Trial Network Sites: Effectiveness of Two Strategies and Evaluation of Tools To be Used in Future HIV Prevention Trials.|Completed||Phase 2|123|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 04:57:16.749919|2018-06-01 04:57:16.749919
NCT00106470|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-24|||2012-12-12|2005-03-24|2005-03-25|Estimate|||||||2012-12-12|2012-12-17|Estimate|February 2005||2005-02-28|December 2012|2012-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Genetic Factors That Influence Chronic Obstructive Pulmonary Disease in Hispanics|Genetic Epidemiology of COPD in Costa Rica|Completed|||679|Actual|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-06-01 04:57:31.721363|2018-06-01 04:57:31.721363
NCT00107029|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-04|||2017-02-27|2005-04-04|2005-04-05|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2002||2002-12-31|February 2016|2016-02-29|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth|Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles|Completed|||113|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples Without DNA|"~     Biomedical HIV-1 related data and samples are available for the time the subjects were~     enrolled in REACH. HIV-1 genotyping will certainly be possible from these retrospective~     samples and the stored PBMCs will be evaluated for usefulness in the HIV-1 specific assays.~     Prospectively, samples will be collected every six months over a two-year period to evaluate~     both HIV-1 specific CD8+ T cell responses and the dominant HIV-1 genotype longitudinally.~   "|||2018-06-01 04:57:17.805861|2018-06-01 04:57:17.805861
NCT00107016|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-04|||2013-02-28|2005-04-04|2005-04-05|Estimate|||||||2013-02-28|2013-03-04|Estimate|March 2005||2005-03-31|February 2013|2013-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women|A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women|Completed||Phase 2|267|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:57:17.886541|2018-06-01 04:57:17.886541
NCT00107003|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-02|||2017-10-05|2005-04-02|2005-04-04|Estimate|||||||2017-10-05|2017-10-06|Actual|March 30, 2005||2005-03-30|November 30, 2012|2012-11-30|November 30, 2012|Actual|2012-11-30|December 5, 2007|Actual|2007-12-05||Interventional|||GW572016 to Treat Recurrent Malignant Brain Tumors|A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma|Completed||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:18.010642|2018-06-01 04:57:18.010642
NCT00106977|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-01|||2018-05-22|2005-04-01|2005-04-04|Estimate|||||||2018-05-22|2018-05-23|Actual|March 31, 2005||2005-03-31|May 7, 2018|2018-05-07||||||||Observational|||Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)|Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:18.12117|2018-06-01 04:57:18.12117
NCT00106964|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-01|2012-10-26||2017-02-27|2005-04-01|2005-04-04|Estimate|2013-04-30|2013-06-28|Estimate||||2017-02-27|2017-03-29|Actual|January 2004||2004-01-31|February 2016|2016-02-29|June 2009|Actual|2009-06-30|January 2008|Actual|2008-01-31||Interventional|||Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth|A Randomized, Open-Label Trial of Three Hepatitis B Vaccination Schemas in HIV-Positive Youth|Completed||Phase 4|371|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-06-01 04:57:18.203217|2018-06-01 04:57:18.203217
NCT00106951|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-01|||2012-01-29|2005-04-01|2005-04-04|Estimate|||||||2012-01-29|2012-01-31|Estimate|April 2005||2005-04-30|January 2012|2012-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Effects of Neighborhood SES on Coronary Heart Disease Burden in Communities - Ancillary to ARIC|Effects of Neighborhood SES on Coronary Heart Disease Burden in Communities - Ancillary to ARIC|Completed|||12000|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 04:57:18.718985|2018-06-01 04:57:18.718985
NCT00106938|ClinicalTrials.gov processed this data on May 31, 2018|2005-04-01|2014-04-02||2017-06-20|2005-04-01|2005-04-04|Estimate|2014-10-13|2014-10-21|Estimate||||2017-06-20|2017-07-19|Actual|April 2005||2005-04-30|June 2017|2017-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ACT I||Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)|Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)|Terminated||N/A|1663|Actual|Abbott Vascular||2||Business decision and not a result of any patient or product safety issues.|f||||||||||||||2018-06-01 04:57:18.819133|2018-06-01 04:57:18.819133
NCT00106925|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2018-05-24|2005-03-31|2005-04-01|Estimate|||||||2018-05-24|2018-05-25|Actual|March 30, 2005||2005-03-30|May 21, 2018|2018-05-21||||||||Observational|||Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants|Long-Term Evaluation and Follow Up Care of Patients Treated With Allogeneic Stem Cell Transplants|Recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:21.044848|2018-06-01 04:57:21.044848
NCT00106912|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2017-06-30|2005-03-31|2005-04-01|Estimate|||||||2017-06-30|2017-07-02|Actual|March 28, 2005||2005-03-28|March 27, 2008|2008-03-27|March 27, 2008||2008-03-27|||||Observational|||Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity|A Study to Collect Normative Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity|Completed|||35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:21.115903|2018-06-01 04:57:21.115903
NCT00106899|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2014-09-15|2005-03-31|2005-04-01|Estimate|||||||2014-09-15|2014-09-16|Estimate|July 2005||2005-07-31|September 2014|2014-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||ADNI: Alzheimer's Disease Neuroimaging Initiative|Alzheimer's Disease Neuroimaging Initiative|Completed|||818|Actual|Alzheimer's Disease Cooperative Study (ADCS)|||3||f||||t||||||Samples With DNA|"~     blood, urine, cerebrospinal fluid~   "|||2018-06-01 04:57:21.188846|2018-06-01 04:57:21.188846
NCT00106886|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2005-09-16|2005-03-31|2005-04-01|Estimate|||||||2005-09-16|2005-09-20|Estimate|December 1999||1999-12-31|March 2005|2005-03-31|October 2005||2005-10-31|||||Interventional|||HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)|HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)|Unknown status|Active, not recruiting|Phase 4|5000||McMaster University|||||f||||||||||||||2018-06-01 04:57:21.331968|2018-06-01 04:57:21.331968
NCT00106860|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2008-01-07|2005-03-31|2005-04-01|Estimate|||||||2008-01-07|2008-01-09|Estimate|March 2005||2005-03-31|January 2008|2008-01-31|March 2006||2006-03-31|||||Interventional|||A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder|A Long-Term, Open Label, Safety and Efficacy Study of an Experimental Medication in Adults With Generalized Anxiety Disorder (GAD)|Completed||Phase 3|158||Jazz Pharmaceuticals|||||||||||||||||||2018-06-01 04:57:21.39652|2018-06-01 04:57:21.39652
NCT00106847|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2011-05-16|2005-03-31|2005-04-01|Estimate|||||||2011-05-16|2011-05-17|Estimate|January 2003||2003-01-31|April 2010|2010-04-30|July 2005|Actual|2005-07-31|||||Interventional|||A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance InfliximabTherapy in Patients With Plaque-Type Psoriasis|Completed||Phase 3|683|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:57:21.458085|2018-06-01 04:57:21.458085
NCT00106457|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-24|||2016-07-11|2005-03-24|2005-03-25|Estimate|||||||2016-07-11|2016-07-12|Estimate|February 2005||2005-02-28|November 2008|2008-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||20 Year Changes in Fitness & Cardiovascular Disease Risk - Ancillary to CARDIA||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:57:31.812432|2018-06-01 04:57:31.812432
NCT00106834|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2011-05-18|2005-03-31|2005-04-01|Estimate|||||||2011-05-18|2011-05-19|Estimate||||March 2010|2010-03-31|October 2004|Actual|2004-10-31|||||Interventional|||A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction and Maintenance Therapy in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|378|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 04:57:21.599115|2018-06-01 04:57:21.599115
NCT00106821|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31|||2013-10-31|2005-03-31|2005-04-01|Estimate|||||||2013-10-31|2013-11-01|Estimate|June 2004||2004-06-30|October 2013|2013-10-31||||August 2005|Actual|2005-08-31||Interventional|||Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease|An 8 Week Randomized, Placebo Controlled, Double-blind Study to Assess the Efficacy of Tiotropium Inhalation Capsules in Patients of African Descent With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|166|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 04:57:21.65727|2018-06-01 04:57:21.65727
NCT00106808|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-31||2010-09-10|2010-09-10|2005-03-31|2005-04-01|Estimate||||2010-09-10|2010-09-14|Estimate|2010-09-10|2010-09-14|Estimate|August 2005||2005-08-31|September 2007|2007-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes|A Phase 3, Randomized, Double-blind, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar (BMS-298585) Compared to Pioglitazone in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 3|1440||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:57:21.775599|2018-06-01 04:57:21.775599
NCT00106795|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-30|||2017-10-05|2005-03-30|2005-03-31|Estimate|||||||2017-10-05|2017-10-06|Actual|March 22, 2005||2005-03-22|April 10, 2014|2014-04-10|April 10, 2014||2014-04-10|||||Observational|||Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS|Assessing the Relationship Between Fatigue and Mitochondrial Toxicity in Patients With HIV/AIDS|Completed|||82|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:22.101632|2018-06-01 04:57:22.101632
NCT00106782|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-29|||2017-06-30|2005-03-29|2005-03-30|Estimate|||||||2017-06-30|2017-07-02|Actual|March 18, 2005||2005-03-18|May 14, 2010|2010-05-14|May 14, 2010|Actual|2010-05-14|May 14, 2010|Actual|2010-05-14||Interventional|||Transcranial Electrical Polarization to Treat Focal Hand Dystonia|Placebo Controlled Study of the Therapeutic Effect of the Transcranial Electrical Polarization in Patients With Focal Hand Dystonia|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 04:57:22.189032|2018-06-01 04:57:22.189032
NCT00106769|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-29|||2017-06-30|2005-03-29|2005-03-30|Estimate|||||||2017-06-30|2017-07-02|Actual|March 22, 2005||2005-03-22|January 15, 2008|2008-01-15|January 15, 2008||2008-01-15|||||Interventional|||Vaccine to Prevent West Nile Virus Disease|A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00 VP, in Healthy Adult Volunteers|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:22.259319|2018-06-01 04:57:22.259319
NCT00106756|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-29|||2017-06-30|2005-03-29|2005-03-30|Estimate|||||||2017-06-30|2017-07-02|Actual|March 18, 2005||2005-03-18|June 26, 2009|2009-06-26|November 1, 2006|Actual|2006-11-01|November 1, 2006|Actual|2006-11-01||Observational|||Clinical and Genetic Studies of Familial Exudative Vitreoretinopathy|Familial Exudative Vitreoretinopathy Clinical and Molecular Studies|Completed|||105||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:22.317746|2018-06-01 04:57:22.317746
NCT00106743|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-29|||2018-05-08|2005-03-29|2005-03-30|Estimate|||||||2018-05-08|2018-05-09|Actual|March 21, 2005||2005-03-21|April 27, 2018|2018-04-27||||||||Observational|||Natural History and Genetic Studies of Usher Syndrome|Natural History and Genetic Studies of Usher Syndrome|Active, not recruiting|||249|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:22.367963|2018-06-01 04:57:22.367963
NCT00106717|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-29|||2008-03-19|2005-03-29|2005-03-30|Estimate|||||||2008-03-19|2008-03-20|Estimate|January 2004||2004-01-31|March 2005|2005-03-31|August 2006|Actual|2006-08-31|||||Interventional|||Effectiveness of Narrative Medicine on Pain Intensity and Quality of Life|Effectiveness of Narrative Medicine on Pain Intensity and Quality of Life|Completed||N/A|210||Javeriana University|||||f||||||||||||||2018-06-01 04:57:22.44742|2018-06-01 04:57:22.44742
NCT00106704|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-29|2010-11-19||2015-06-04|2005-03-29|2005-03-30|Estimate|2010-11-19|2010-12-17|Estimate||||2015-06-04|2015-07-01|Estimate|March 2005||2005-03-31|June 2015|2015-06-30|January 2007|Actual|2007-01-31|June 2006|Actual|2006-06-30||Interventional|||Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)|A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Glimepiride Alone or in Combination With Metformin|Completed||Phase 3|441|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 04:57:22.596388|2018-06-01 04:57:22.596388
NCT00106691|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-29|||2013-01-31|2005-03-29|2005-03-30|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2005||2005-01-31|January 2013|2013-01-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate for the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)|Completed||Phase 3|1590|Actual|GTx||2|||f||||t||||||||||2018-06-01 04:57:23.051806|2018-06-01 04:57:23.051806
NCT00106678|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-28|||2017-02-27|2005-03-28|2005-03-29|Estimate|||||||2017-02-27|2017-03-01|Actual|June 2004||2004-06-30|February 2016|2016-02-29|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Observational|||Typology of Adherence in Adolescents: Phase II|Typology of Adherence in Adolescents: Phase II|Completed|||1200|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-06-01 04:57:23.215143|2018-06-01 04:57:23.215143
NCT00106665|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-28|||2016-01-15|2005-03-28|2005-03-29|Estimate|||||||2016-01-15|2016-01-18|Estimate|June 2005||2005-06-30|January 2016|2016-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||New Onset Weakness in Critically Ill Patients and the Risk of Death and Recurrent ICU Admission|Intensive Care Unit(ICU)-Acquired Paresis and the Risk for Mortality and Recurrent ICU Admission (Weakness and ICU Readmission Evaluation-WIRE)|Completed|||170|Actual|Ohio State University|||||f||||f||||||||||2018-06-01 04:57:23.297109|2018-06-01 04:57:23.297109
NCT00106652|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-28|||2017-09-20|2005-03-28|2005-03-29|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2001||2001-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Childhood Autism Risks From Genetics and the Environment (The CHARGE Study)|Environmental Factors in the Etiology of Autism|Completed|||2000|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 04:57:23.366594|2018-06-01 04:57:23.366594
NCT00106431|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-24|2010-03-02|2009-10-01|2011-03-14|2005-03-24|2005-03-25|Estimate|2010-03-30|2010-04-23|Estimate|2009-10-01|2009-10-05|Estimate|2011-03-14|2011-03-16|Estimate|January 2005||2005-01-31|March 2011|2011-03-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)|A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma|Completed||Phase 2|102|Actual|Celgene|||||f||||t||||||||||2018-06-01 04:57:31.867707|2018-06-01 04:57:31.867707
NCT00106639|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-28|2012-12-06||2013-02-06|2005-03-28|2005-03-29|Estimate|2013-02-06|2013-03-12|Estimate||||2013-02-06|2013-03-12|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients|A 6-Month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study Of 2 Dose Levels Of CP-690,550 Administered Concomitantly With IL-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil And Corticosteroids Versus A Tacrolimus-Based Immunosuppressive Regimen For The Prevention Of Allograft Rejection In De Novo Renal Allograft Recipients|Completed||Phase 2|61|Actual|Pfizer|Results for first BPAR, BPCAN, treatment and efficacy failure, rejection, clinically significant infections, NODM and discontinuation reported as number and not percentage as planned. Stage 2 of study was not conducted due to administrative reasons.|3|||f||||t||||||||||2018-06-01 04:57:23.567634|2018-06-01 04:57:23.567634
NCT00106626|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-28|2008-11-25||2009-03-16|2005-03-28|2005-03-29|Estimate|2009-03-16|2009-04-22|Estimate||||2009-03-16|2009-04-22|Estimate|August 2005||2005-08-31|March 2009|2009-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors|Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer|Completed||Phase 1|52|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 04:57:25.937208|2018-06-01 04:57:25.937208
NCT00106613|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-28|||2012-08-30|2005-03-28|2005-03-29|Estimate|||||||2012-08-30|2012-08-31|Estimate|May 2003||2003-05-31|August 2012|2012-08-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||A Research Study for Patients With Metastatic Renal Cell Carcinoma|An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Patients With Metastatic Renal Cell Carcinoma That is Progressive Following or During Immunotherapy|Completed||Phase 2|30|Actual|Celgene||1|||f||||f||||||||||2018-06-01 04:57:26.22843|2018-06-01 04:57:26.22843
NCT00106600|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-28|||2007-08-21|2005-03-28|2005-03-29|Estimate|||||||2007-08-21|2007-08-22|Estimate|March 2005||2005-03-31|August 2007|2007-08-31|March 2007||2007-03-31|||||Interventional|||Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)|A Phase I/II Study of Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)|Completed||Phase 1/Phase 2|119||CTI BioPharma|||||||||||||||||||2018-06-01 04:57:26.382895|2018-06-01 04:57:26.382895
NCT00106587|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|||2005-11-09|2005-03-25|2005-03-28|Estimate|||||||2005-11-09|2005-11-11|Estimate|December 2003||2003-12-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH – ISR I)|Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons|Completed||Phase 1/Phase 2|52||University Hospital, Saarland|||||f||||||||||||||2018-06-01 04:57:26.43556|2018-06-01 04:57:26.43556
NCT00106574|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|||2016-11-01|2005-03-25|2005-03-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2005||2005-04-30|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind Study of the Effect of Tocilizumab on Reduction in Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to DMARD Therapy|Completed||Phase 3|1220|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:57:26.507589|2018-06-01 04:57:26.507589
NCT00106561|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|||2005-06-23|2005-03-25|2005-03-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2002||2002-01-31|March 2005|2005-03-31|September 2004||2004-09-30|||||Interventional|||Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney|A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker|Completed||Phase 2/Phase 3|60||Melbourne Health|||||f||||||||||||||2018-06-01 04:57:26.727132|2018-06-01 04:57:26.727132
NCT00106548|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|||2010-06-10|2005-03-25|2005-03-28|Estimate|||||||2010-06-10|2010-06-11|Estimate||||June 2010|2010-06-30|October 2007|Actual|2007-10-31|||||Interventional|||A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|623|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 04:57:26.803896|2018-06-01 04:57:26.803896
NCT00106535|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|2010-02-09||2013-12-18|2005-03-25|2005-03-28|Estimate|2011-05-06|2011-06-07|Estimate||||2013-12-18|2014-02-06|Estimate|January 2005||2005-01-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|May 2007|Actual|2007-05-31||Interventional||Baseline measures are based on the Intent-to-treat population that included all randomized participants who received study drug.|A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)|A Randomized, Double-blind Study of Safety and Prevention of Structural Joint Damage During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|1196|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 04:57:27.361616|2018-06-01 04:57:27.361616
NCT00106522|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|||2016-11-01|2005-03-25|2005-03-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2005||2005-05-31|November 2016|2016-11-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy|A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy|Completed||Phase 3|499|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 04:57:30.860029|2018-06-01 04:57:30.860029
NCT00106509|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|||2015-03-04|2005-03-25|2005-03-28|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2005||2005-03-31|March 2015|2015-03-31|February 2007|Actual|2007-02-28|||||Interventional|||A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea|A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea|Completed||Phase 3|520||Sanofi|||||||||||||||||||2018-06-01 04:57:31.238275|2018-06-01 04:57:31.238275
NCT00106496|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-25|||2014-09-17|2005-03-25|2005-03-28|Estimate|||||||2014-09-17|2014-09-18|Estimate|October 2004||2004-10-31|September 2014|2014-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis|A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis|Completed||Phase 4|410|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-06-01 04:57:31.537331|2018-06-01 04:57:31.537331
NCT00106418|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-24|||2016-10-28|2005-03-24|2005-03-25|Estimate|||||||2016-10-28|2016-11-01|Estimate|May 2003||2003-05-31|October 2016|2016-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Research Study for Patients With Prostate Cancer|An Exploratory Phase II, Multicenter, Open-label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA|Completed||Phase 2|35|Actual|Celgene Corporation||1|||f||||||||||||||2018-06-01 04:57:32.435503|2018-06-01 04:57:32.435503
NCT00106405|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-24|||2012-03-01|2005-03-24|2005-03-25|Estimate|||||||2012-03-01|2012-03-05|Estimate|February 2005||2005-02-28|March 2012|2012-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder|A Pilot Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder|Completed||Phase 2|35|Actual|Forest Laboratories|||||||||||||||||||2018-06-01 04:57:32.502514|2018-06-01 04:57:32.502514
NCT00106392|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-23|2010-09-30||2010-11-15|2005-03-23|2005-03-24|Estimate|2010-09-30|2010-10-28|Estimate||||2010-11-15|2010-11-23|Estimate|February 2005||2005-02-28|November 2010|2010-11-30|November 2008|Actual|2008-11-30|April 2008|Actual|2008-04-30||Interventional|||A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy|Completed||Phase 4|131|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|2|||f||||t||||||||||2018-06-01 04:57:32.578939|2018-06-01 04:57:32.578939
NCT00106379|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-23|||2010-02-01|2005-03-23|2005-03-24|Estimate|||||||2010-02-01|2010-02-02|Estimate|October 2004||2004-10-31|April 2008|2008-04-30|January 2007|Actual|2007-01-31|||||Interventional|||Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients|A Phase 4, Single-Arm Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Combination With Emtricitabine in HIV-1 Infected Patients Experiencing Various Degrees of Renal Impairment|Completed||Phase 4|52||Gilead Sciences|||||||||||||||||||2018-06-01 04:57:32.969075|2018-06-01 04:57:32.969075
NCT00106366|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-22|||2017-01-30|2005-03-22|2005-03-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2005||2005-03-31|January 2017|2017-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes|Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes|Completed||Phase 3|389|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:57:33.054636|2018-06-01 04:57:33.054636
NCT00106353|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-22|2010-11-05||2013-01-04|2005-03-22|2005-03-23|Estimate|2010-12-10|2011-01-11|Estimate||||2013-01-04|2013-02-08|Estimate|March 2005||2005-03-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|October 2009|Actual|2009-10-31||Interventional|||Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors|A Phase I/II Safety and Exploratory Pharmacogenomic/Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects With Relapsed/Refractory Solid Tumors|Completed||Phase 1/Phase 2|71|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 04:57:33.3401|2018-06-01 04:57:33.3401
NCT00106340|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-22||2012-10-22|2012-12-28|2005-03-22|2005-03-23|Estimate||||2012-10-22|2012-10-29|Estimate|2012-12-28|2013-01-01|Estimate|March 2005||2005-03-31|December 2012|2012-12-31||||May 2008|Actual|2008-05-31||Interventional|||Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes|Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes|Completed||Phase 3|3118|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:57:36.553953|2018-06-01 04:57:36.553953
NCT00106327|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-22|||2012-07-24|2005-03-22|2005-03-23|Estimate|||||||2012-07-24|2012-07-25|Estimate|September 2003||2003-09-30|July 2012|2012-07-31|March 2009|Actual|2009-03-31|July 2008|Actual|2008-07-31||Interventional|||Improving Functioning in Peripheral Arterial Disease|Improving Functioning in Peripheral Arterial Disease|Completed||N/A|156|Actual|Northwestern University||3|||f||||||||||||||2018-06-01 04:57:36.630065|2018-06-01 04:57:36.630065
NCT00106314|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-22|||2007-10-17|2005-03-22|2005-03-23|Estimate|||||||2007-10-17|2007-10-19|Estimate|January 2005||2005-01-31|October 2007|2007-10-31|October 2006|Actual|2006-10-31|||||Interventional|||An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease|A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease|Completed||Phase 2|75||Inflabloc Pharmaceuticals|||||||||||||||||||2018-06-01 04:57:36.829038|2018-06-01 04:57:36.829038
NCT00106301|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-22|||2016-03-30|2005-03-22|2005-03-23|Estimate|||||||2016-03-30|2016-03-31|Estimate|April 2004||2004-04-30|March 2016|2016-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228|A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Have Completed a Prior Clinical Study With FK228|Completed||Phase 2|2|Actual|Celgene Corporation||1|||f||||f||||||||||2018-06-01 04:57:36.973342|2018-06-01 04:57:36.973342
NCT00106288|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-22|||2014-09-17|2005-03-22|2005-03-23|Estimate|||||||2014-09-17|2014-09-18|Estimate|January 2003||2003-01-31|September 2014|2014-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia|A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia|Completed||Phase 3|637|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-06-01 04:57:37.057823|2018-06-01 04:57:37.057823
NCT00106275|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2006-01-30|2005-03-21|2005-03-22|Estimate|||||||2006-01-30|2006-01-31|Estimate|November 2003||2003-11-30|November 2005|2005-11-30|November 2006||2006-11-30|||||Interventional|||Mindfulness-Based Stress Reduction Program as an Intervention in Patients With Fibromyalgia|Mindfulness-Based Stress Reduction Program as an Intervention in Patients With Fibromyalgia: A Three-Armed Randomized Clinical Study|Unknown status|Active, not recruiting|N/A|180||University Hospital Freiburg|||||f||||||||||||||2018-06-01 04:57:37.248473|2018-06-01 04:57:37.248473
NCT00106262|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2007-04-17|2005-03-21|2005-03-22|Estimate|||||||2007-04-17|2007-04-18|Estimate|March 2005||2005-03-31|April 2007|2007-04-30|March 2007|Actual|2007-03-31|||||Interventional|||Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer|A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer|Terminated||Phase 2|38||Women and Infants Hospital of Rhode Island||||Lack of accrual|f||||||||||||||2018-06-01 04:57:37.309424|2018-06-01 04:57:37.309424
NCT00105872|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-17|||2015-04-06|2005-03-17|2005-03-18|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2002||2002-03-31|March 2007|2007-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Behavioral Insomnia Therapy in Primary Care|Behavioral Insomnia Therapy in Primary Care|Completed||N/A|100|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:45.364714|2018-06-01 04:57:45.364714
NCT00106249|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|2016-09-06||2016-12-01|2005-03-21|2005-03-22|Estimate|2016-12-01|2017-01-27|Estimate||||2016-12-01|2017-01-27|Estimate|November 2004||2004-11-30|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||A total of 22 patients with at least 1 follow up were included in the final analyses. Four subjects only had baseline measure. The reason for them to withdraw from the study was their inability to attend daily treatment sessions due to schedule conflict with their job and long commute to the TMS laboratory.|Transcranial Magnetic Stimulation (TMS) and Obsessive Compulsive Disorder (OCD)|Treatment of Obsessive Compulsive Disorder (OCD) With Transcranial Magnetic Stimulation (TMS)|Completed||Phase 2|27|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-06-01 04:57:37.395583|2018-06-01 04:57:37.395583
NCT00106236|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2009-07-13|2005-03-21|2005-03-22|Estimate|||||||2009-07-13|2009-07-14|Estimate|April 2003||2003-04-30|March 2005|2005-03-31|April 2004||2004-04-30|||||Interventional|||Efficacy of Exercise at a Fitness Club for Cardiovascular Risk Reduction|Sapporo Fitness Club Trial (SFCT): A Randomized Controlled Trial to Test the Efficacy of Exercise at a Fitness Club for the Reduction of Cardiovascular Risk Factors|Completed||Phase 1/Phase 2|561||Sapporo Health Promotion Foundation|||||f||||||||||||||2018-06-01 04:57:37.602352|2018-06-01 04:57:37.602352
NCT00106223|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2012-01-03|2005-03-21|2005-03-22|Estimate|||||||2012-01-03|2012-01-05|Estimate|April 2004||2004-04-30|January 2012|2012-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Treatment Study Investigating New Cognitive Behavioral Therapy Treatment Manual for Body Dysmorphic Disorder|A Randomized Waitlist Controlled Treatment Trial Investigating CBT for Body Dysmorphic Disorder|Completed||N/A|36|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:57:37.661043|2018-06-01 04:57:37.661043
NCT00106210|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2013-07-03|2005-03-21|2005-03-22|Estimate|||||||2013-07-03|2013-07-08|Estimate|May 2003||2003-05-31|July 2013|2013-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||School- and Home-Based Early Intervention for Toddlers With Autism|Early Detection, Intervention, and Neurobiology in Autism: Early Intervention Portion|Completed||N/A|50|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||||2018-06-01 04:57:37.748478|2018-06-01 04:57:37.748478
NCT00106197|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2013-08-29|2005-03-21|2005-03-22|Estimate|||||||2013-08-29|2013-08-30|Estimate|June 2004||2004-06-30|August 2013|2013-08-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression|Treatment Prediction in Adolescent and Adult Depression|Unknown status|Active, not recruiting|Phase 4|130|Anticipated|Meharry Medical College||1|||f||||t||||||||||2018-06-01 04:57:37.821859|2018-06-01 04:57:37.821859
NCT00106184|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|2013-10-10||2015-03-03|2005-03-21|2005-03-22|Estimate|2015-03-03|2015-03-04|Estimate||||2015-03-03|2015-03-04|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|August 2010|Actual|2010-08-31|February 2010|Actual|2010-02-28||Interventional||3 subjects in Group A and 2 subjects in Group B were excluded from analysis due to withdrawing from the study. These subjects either did not receive a full dose of study drug at week 0 or no study drug at all.|Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)|Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM)|Completed||Phase 2|200|Actual|University of Pittsburgh|There was an overestimate of the rapidity of the rituximab response and an underestimate of DOI in those receiving placebo.|6|||f||||t||||||||||2018-06-01 04:57:37.917446|2018-06-01 04:57:37.917446
NCT00106171|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2011-02-17|2005-03-21|2005-03-22|Estimate|||||||2011-02-17|2011-02-18|Estimate|February 2005||2005-02-28|February 2011|2011-02-28|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Anti-HIV Medications for People Recently Infected With HIV|A Randomized Trial of HAART in Acute/Early HIV Infection|Completed||Phase 4|180|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:57:38.546599|2018-06-01 04:57:38.546599
NCT00106158|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2010-11-04|2005-03-21|2005-03-22|Estimate|||||||2010-11-04|2010-11-05|Estimate|June 2004||2004-06-30|August 2007|2007-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1|Immunization of Patients With Tumors Expressing NY-ESO-1 or LAGE Antigen With Complex of NY-ESO-1 Protein and Cholesterol-bearing Hydrophobized Pullulan (CHP)|Completed||Phase 1|9|Anticipated|Ludwig Institute for Cancer Research|||||f||||||||||||||2018-06-01 04:57:38.621061|2018-06-01 04:57:38.621061
NCT00106145|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-21|||2015-01-29|2005-03-21|2005-03-22|Estimate|||||||2015-01-29|2015-01-30|Estimate|April 2005||2005-04-30|January 2015|2015-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)|A Phase I Study of MK0752, a Notch Inhibitor, in Patients With Metastatic or Locally Advanced Breast Cancer and Other Solid Tumors|Completed||Phase 1|103|Actual|Merck Sharp & Dohme Corp.||5|||f||||||||||||||2018-06-01 04:57:38.703569|2018-06-01 04:57:38.703569
NCT00106132|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-19|||2008-03-03|2005-03-19|2005-03-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2005||2005-03-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage|The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study|Completed||Phase 3|1260||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:38.77071|2018-06-01 04:57:38.77071
NCT00106119|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-19|2014-11-12||2015-02-20|2005-03-19|2005-03-21|Estimate|2015-02-20|2015-02-23|Estimate||||2015-02-20|2015-02-23|Estimate|March 2005||2005-03-31|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Subjects who completed the study|Thyroid and Glucose and Energy Metabolism|Peripheral Thyroid Hormone Conversion and Glucose and Energy Metabolism|Completed||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 04:57:38.842006|2018-06-01 04:57:38.842006
NCT00106106|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-19|2011-11-30||2012-01-10|2005-03-19|2005-03-21|Estimate|2011-11-30|2012-01-05|Estimate||||2012-01-10|2012-01-12|Estimate|March 2005||2005-03-31|January 2012|2012-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Acamprosate to Reduce Symptoms of Alcohol Withdrawal|Acamprosate for Central Nervous System Hyperexcitability and Neuroadaptation in Alcohol Withdrawal|Completed||Phase 2|56|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 04:57:39.179479|2018-06-01 04:57:39.179479
NCT00106093|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-19|||2017-10-05|2005-03-19|2005-03-21|Estimate|||||||2017-10-05|2017-10-06|Actual|March 16, 2005||2005-03-16|September 8, 2015|2015-09-08|September 8, 2015||2015-09-08|||||Observational|||Alcoholism Assessment and Treatment|Assessment and Treatment of People With Alcohol Drinking Problems|Completed|||1192|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:39.448662|2018-06-01 04:57:39.448662
NCT00105859|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-17|||2010-05-06|2005-03-17|2005-03-18|Estimate|||||||2010-05-06|2010-05-10|Estimate||||June 2005|2005-06-30||||||||Interventional|||Preventing Pressure Ulcers in Veterans With Spinal Cord Injury (SCI)|Preventing Pressure Ulcers in Veterans With Spinal Cord Injury (SCI)|Terminated||N/A|278|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:45.435452|2018-06-01 04:57:45.435452
NCT00106080|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|2014-08-06||2015-04-06|2005-03-18|2005-03-21|Estimate|2014-11-07|2014-11-11|Estimate||||2015-04-06|2015-04-24|Estimate|November 2004||2004-11-30|May 2014|2014-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||42 clinicians were randomized to the intervention group. 50 clinicians were randomized to the control group. 376 patients were enrolled and assigned to their clinician's treatment group.|Improving the Quality of End-of-Life Communication for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Improving the Quality of End-of-Life Communication for Patients With COPD|Completed||N/A|376|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:57:39.522617|2018-06-01 04:57:39.522617
NCT00106067|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2015-04-06|2005-03-18|2005-03-21|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2004||2004-06-30|April 2009|2009-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|A&SC||Aging and Family Outcomes in Supportive Care of Advanced Cancer Patients|Aging and Family Outcomes in Supportive Care of Advanced Cancer Patients|Completed||N/A|559|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:57:39.754198|2018-06-01 04:57:39.754198
NCT00106054|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2010-08-26|2005-03-18|2005-03-21|Estimate|||||||2010-08-26|2010-08-27|Estimate|January 2006||2006-01-31|August 2010|2010-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases|An Open-Label, Multi-Center Phase II Trial of Neoadjuvant Irinotecan in Combination With Infusional 5-FU, Leucovorin (Folfiri) Plus Bevacizumab in Patients With Unresectable Hepatic-Only Metastases of Colorectal Carcinoma|Terminated||Phase 2|2|Actual|Pfizer||||"After 1 year only 2 subjects enrolled and treated thus no meaningful efficacy analyses could be~   performed."|f||||||||||||||2018-06-01 04:57:39.814566|2018-06-01 04:57:39.814566
NCT00106041|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2015-04-06|2005-03-18|2005-03-21|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2004||2004-08-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|November 2007|Actual|2007-11-30||Interventional|||Study to Improve Care for Veterans During Serious Illness|Randomized Trial of Care Management to Improve End of Life Care|Completed||N/A|400|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:39.864485|2018-06-01 04:57:39.864485
NCT00106028|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|2009-04-15||2013-04-15|2005-03-18|2005-03-21|Estimate|2010-05-19|2010-06-28|Estimate||||2013-04-15|2013-04-22|Estimate|November 2004||2004-11-30|April 2013|2013-04-30|March 2010|Actual|2010-03-31|April 2008|Actual|2008-04-30||Interventional|||Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children|Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children|Completed||Phase 3|143|Actual|Warner Chilcott|The clinical meaningfulness of new fractures in the thoracic spine scored as Genant Grade I is unclear, thus the morphometric vertebral fracture data are evaluated further.|2|||f||||f||||||||||2018-06-01 04:57:39.98213|2018-06-01 04:57:39.98213
NCT00106015|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2018-01-03|2005-03-18|2005-03-21|Estimate|||||||2018-01-03|2018-01-05|Actual|September 2004|Actual|2004-09-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|DBAR||Diamond Blackfan Anemia Registry (DBAR)|Diamond Blackfan Anemia Registry (DBAR)|Recruiting|||850|Anticipated|Northwell Health|||||f||||||||||||||2018-06-01 04:57:41.540905|2018-06-01 04:57:41.540905
NCT00106002|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|2008-12-23||2009-05-29|2005-03-18|2005-03-21|Estimate|2009-05-29|2009-06-01|Estimate||||2009-05-29|2009-06-01|Estimate|April 2005||2005-04-30|April 2009|2009-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer|A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer|Completed||Phase 2|37|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-06-01 04:57:41.635523|2018-06-01 04:57:41.635523
NCT00105989|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|2009-01-23||2009-07-21|2005-03-18|2005-03-21|Estimate|2009-06-05|2009-07-17|Estimate||||2009-07-21|2009-07-28|Estimate|March 2005||2005-03-31|July 2009|2009-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder|Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder|Completed||Phase 3|514|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 04:57:42.025394|2018-06-01 04:57:42.025394
NCT00105976|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2008-07-10|2005-03-18|2005-03-21|Estimate|||||||2008-07-10|2008-07-11|Estimate|February 2005||2005-02-28|July 2008|2008-07-31||||||||Interventional|||Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)|A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate|Completed||Phase 2|260||Merrimack Pharmaceuticals|||||||||||||||||||2018-06-01 04:57:44.583307|2018-06-01 04:57:44.583307
NCT00105963|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2005-06-23|2005-03-18|2005-03-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2005||2005-01-31|March 2005|2005-03-31|August 2006||2006-08-31|||||Interventional|||Prevention of Shaken Baby Syndrome|Parents Helping Infants Study: Preventing Shaken Baby Syndrome and Child Abuse|Unknown status|Recruiting|N/A|3000||Harborview Injury Prevention and Research Center|||||f||||||||||||||2018-06-01 04:57:44.666746|2018-06-01 04:57:44.666746
NCT00105950|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2015-09-24|2005-03-18|2005-03-21|Estimate|||||||2015-09-24|2015-09-28|Estimate|March 2005||2005-03-31|May 2015|2015-05-31|May 2010|Actual|2010-05-31|September 2007|Actual|2007-09-30||Interventional|||Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer|A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients With Relapsed or Refractory Inflammatory Breast Cancer|Completed||Phase 2|126|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-06-01 04:57:44.84517|2018-06-01 04:57:44.84517
NCT00105937|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-18|||2012-06-27|2005-03-18|2005-03-21|Estimate|||||||2012-06-27|2012-06-29|Estimate|April 2004||2004-04-30|May 2007|2007-05-31|November 2006||2006-11-30|||||Interventional|||OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients|Multi-center, Open Label, Long-term Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients|Completed||Phase 3|300||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 04:57:44.968349|2018-06-01 04:57:44.968349
NCT00105911|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-17|||2015-04-06|2005-03-17|2005-03-18|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2002||2002-07-31|February 2007|2007-02-28|June 2005|Actual|2005-06-30|||||Interventional|||A Cognitive-Behavioral Intervention for Depression and Anxiety in COPD|A Cognitive-Behavioral Intervention for Depression and Anxiety in COPD|Completed||N/A|222|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:45.079456|2018-06-01 04:57:45.079456
NCT00105898|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-17|||2015-04-06|2005-03-17|2005-03-18|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2005||2005-02-28|August 2010|2010-08-31|June 2010|Actual|2010-06-30|April 2007|Actual|2007-04-30||Interventional|||Internet-based Diabetes Education and Case Management|Internet-based Diabetes Education and Case Management|Completed||N/A|152|Actual|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 04:57:45.146512|2018-06-01 04:57:45.146512
NCT00105885|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-17|||2014-02-06|2005-03-17|2005-03-18|Estimate|||||||2014-02-06|2014-02-10|Estimate|November 2003||2003-11-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|Telepsych||Telephone Care as a Substitute for Routine Psychiatric Medication|Telephone Care as a Substitute for Routine Psychiatric Medication Management|Completed||N/A|324|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:57:45.287098|2018-06-01 04:57:45.287098
NCT00105807|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2002||2002-07-31|February 2007|2007-02-28|April 2006|Actual|2006-04-30|||||Interventional|||The Effect of Exercise on Muscle, Function and Cost in VA Nursing Home Residents|The Effect of Exercise on Muscle, Function and Cost in VA Nursing Home Residents|Completed||Phase 2|120|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.107301|2018-06-01 04:57:46.107301
NCT00105794|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2004||2004-03-31|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Psychiatric Advance Directives for Improved Mental Health Care|Psychiatric Advance Directives for Improved Healthcare|Completed||N/A|360|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.163838|2018-06-01 04:57:46.163838
NCT00105781|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2002||2002-11-30|May 2007|2007-05-31|February 2006|Actual|2006-02-28|||||Interventional|||Nurse Physical Activity Counseling in Primary Care|Nurse Physical Activity Counseling in Primary Care|Completed||N/A|240|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.232832|2018-06-01 04:57:46.232832
NCT00105768|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2002||2002-07-31|March 2007|2007-03-31|October 2005|Actual|2005-10-31|||||Interventional|||Effectiveness of Advisor-Teller Money Manager|Effectiveness of Advisor - Teller Money Manager (ATM)|Completed||Phase 1/Phase 2|120|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.298539|2018-06-01 04:57:46.298539
NCT00105755|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2003||2003-01-31|April 2015|2015-04-30|February 2006|Actual|2006-02-28|||||Interventional|||Dermal Thermometry and Self-Care of High Risk Diabetic Patients|Dermal Thermometry and Self-Care of High Risk Diabetic Patients|Completed||N/A|400|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.361208|2018-06-01 04:57:46.361208
NCT00105742|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate||||July 2006|2006-07-31|June 2005|Actual|2005-06-30|||||Interventional|||Audiology Visits After Screening for Hearing Loss: An RCT|Audiology Visits After Screening for Hearing Loss: An RCT|Completed||Phase 2|1400|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.508685|2018-06-01 04:57:46.508685
NCT00105729|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2003||2003-01-31|September 2006|2006-09-30|April 2005|Actual|2005-04-30|||||Interventional|||Substance Abuse Self-Help Group Referral: Outcomes and Services Use|Substance Abuse Self-Help Group Referral: Outcome and Services Use|Completed||N/A|345|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.587267|2018-06-01 04:57:46.587267
NCT00105716|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2002||2002-03-31|April 2006|2006-04-30|April 2005|Actual|2005-04-30|||||Interventional|||Study to Lower Veterans BP: Patient/Physician Intervention|Study to Lower Veterans Blood Pressure: Patient/Physician Intervention|Completed||N/A|544|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.661156|2018-06-01 04:57:46.661156
NCT00105703|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2002||2002-02-28|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|CHF ENCORE||Evaluation of a Nurse Case Management Model for Chronic Heart Failure|Evaluation of a Nurse Case Management Model for Chronic Heart Failure|Completed||N/A|969|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.746592|2018-06-01 04:57:46.746592
NCT00105690|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|April 2003||2003-04-30|September 2006|2006-09-30|October 2004|Actual|2004-10-31|||||Interventional|||TEAM Study to Improve Depression Care in Rural CBOCs|Telemedicine Intervention to Improve Depression Care in Rural CBOCs|Completed||N/A|400|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:46.821814|2018-06-01 04:57:46.821814
NCT00105677|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2004||2004-08-31|October 2006|2006-10-31|September 2006|Actual|2006-09-30|||||Observational|||Understanding the Differences in the Management of Patients With Arthritis of the Knee or Hip|Reasons for Disparities in Joint Replacement Utilization|Completed|||980|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:57:46.887381|2018-06-01 04:57:46.887381
NCT00105664|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2004||2004-10-31|October 2007|2007-10-31|July 2007|Actual|2007-07-31|||||Interventional|C3P||Collaborative Cardiac Care Project|Collaborative Cardiac Care Project (C3P)|Completed||N/A|287|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 04:57:46.947687|2018-06-01 04:57:46.947687
NCT00105651|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2004|Actual|2004-03-31|||||Interventional|||A Smoking, Alcohol, and Depression Intervention for Head and Neck Cancer|A Smoking, Alcohol, and Depression Intervention for Head and Neck Cancer|Completed||N/A|128|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:47.033969|2018-06-01 04:57:47.033969
NCT00105638|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2005||2005-09-30|November 2007|2007-11-30|April 2007|Actual|2007-04-30|||||Interventional|||Telehealth Education Program for Caregivers of Veterans With Dementia|A Telehealth Education Program for Caregivers of Veterans With Dementia|Completed||N/A|160|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:47.094807|2018-06-01 04:57:47.094807
NCT00105625|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-16|||2015-04-06|2005-03-16|2005-03-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2003||2003-03-31|June 2008|2008-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||VA Nutrition Study on Immune Function|Immunocompetency and Nutritive Status in Inpatient Gero-Rehabilitation|Completed|||100|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 04:57:47.159593|2018-06-01 04:57:47.159593
NCT00105612|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|||2009-12-23|2005-03-15|2005-03-16|Estimate|||||||2009-12-23|2009-12-29|Estimate|September 2004||2004-09-30|December 2009|2009-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Memory Aid for Informed Consent in Alzheimer's Research|Improving Informed Consent in Alzheimer's Disease Research|Completed||N/A|110||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:57:47.21363|2018-06-01 04:57:47.21363
NCT00105599|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|||2015-04-06|2005-03-15|2005-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2004|Actual|2004-09-30|||||Interventional|||Effectiveness of the FairCare System for Patients With Advanced Illness|Effectiveness of the FairCare System for Patients With Advanced Illness|Completed||Phase 2|140|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 04:57:47.408818|2018-06-01 04:57:47.408818
NCT00104507|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2010-02-01|2005-03-01|2005-03-02|Estimate|||||||2010-02-01|2010-02-02|Estimate|December 2004||2004-12-31|December 2006|2006-12-31|May 2005||2005-05-31|||||Interventional|||Safety and Efficacy of APD356 in the Treatment of Obesity|A 4-Week, Dose-ranging, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of APD356 in Obese Patients|Completed||Phase 2|400||Arena Pharmaceuticals|||||||||||||||||||2018-06-01 04:58:11.261637|2018-06-01 04:58:11.261637
NCT00105586|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|2009-08-03||2017-05-04|2005-03-15|2005-03-16|Estimate|2017-05-04|2017-05-08|Actual||||2017-05-04|2017-05-08|Actual|December 2004||2004-12-31|May 2017|2017-05-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|||Drug Therapy for Generalized Anxiety Disorder Among the Elderly|Pharmacotherapy of Late-Life Generalized Anxiety Disorder|Completed||Phase 4|177|Actual|University of Pittsburgh||2|||f||||f||||||||Yes|interested investigators should contact the PI directly via email.|2018-06-01 04:57:47.479923|2018-06-01 04:57:47.479923
NCT00105573|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|||2013-04-29|2005-03-15|2005-03-16|Estimate|||||||2013-04-29|2013-04-30|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Interventions for Depressed Low Income Mothers and Their Infants|Prevention for Infants of Low-Income Depressed Mothers|Completed||N/A|218|Actual|University of Rochester||3|||f||||t||||||||||2018-06-01 04:57:47.726307|2018-06-01 04:57:47.726307
NCT00105560|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|2017-03-26||2017-09-13|2005-03-15|2005-03-16|Estimate|2017-07-21|2017-08-21|Actual||||2017-09-13|2017-10-16|Actual|May 2002|Actual|2002-05-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2012|Actual|2012-12-31||Interventional|||Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma|Phase II Study of Craniospinal and Posterior Fossa Irradiation Using Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma: Assessment of Acute and Long Term Sequelae|Active, not recruiting||N/A|59|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 04:57:47.832851|2018-06-01 04:57:47.832851
NCT00105547|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|||2009-05-03|2005-03-15|2005-03-16|Estimate|||||||2009-05-03|2009-05-05|Estimate|February 2005||2005-02-28|May 2009|2009-05-31|May 2008|Actual|2008-05-31|||||Interventional|||Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's|Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type|Completed||Phase 3|1600|Actual|Myrexis Inc.||2|||f||||t||||||||||2018-06-01 04:57:48.436423|2018-06-01 04:57:48.436423
NCT00105534|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|2011-08-01||2013-10-29|2005-03-15|2005-03-16|Estimate|2011-09-20|2011-10-27|Estimate||||2013-10-29|2013-11-21|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)|A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis|Completed||Phase 3|685|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:57:48.652997|2018-06-01 04:57:48.652997
NCT00105521|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|2017-09-04||2017-09-04|2005-03-15|2005-03-16|Estimate|2017-09-04|2018-04-02|Actual||||2017-09-04|2018-04-02|Actual|September 30, 2004|Actual|2004-09-30|September 2017|2017-09-30|March 31, 2006|Actual|2006-03-31|March 31, 2006|Actual|2006-03-31||Interventional||All randomized participants.|Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia|A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia|Completed||Phase 3|398|Actual|EMD Serono|For SAEs, due diligence was done and all potential information sources have been exhausted, no further information could be retrieved apart from what is currently reported.|4|||f||||||||||||||2018-06-01 04:57:48.999609|2018-06-01 04:57:48.999609
NCT00105508|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|||2017-01-19|2005-03-15|2005-03-16|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2004||2004-09-30|January 2017|2017-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia|A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia|Completed||Phase 3|611|Actual|EMD Serono|||||||||||||||||||2018-06-01 04:57:49.338809|2018-06-01 04:57:49.338809
NCT00105495|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-15|||2016-01-04|2005-03-15|2005-03-16|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2002||2002-12-31|October 2006|2006-10-31|October 2004||2004-10-31|||||Interventional|||Efficacy Study in Removing Excess Iron From the Heart|Randomized Trial Comparing the Relative Efficacy of Deferiprone to That of Deferoxamine in Removing Excess Cardiac Iron in Thalassemia Major Patients|Completed||Phase 4|60||ApoPharma|||||f||||||||||||||2018-06-01 04:57:49.41943|2018-06-01 04:57:49.41943
NCT00105482|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-14|2013-01-28||2013-01-28|2005-03-14|2005-03-15|Estimate|2013-01-28|2013-03-05|Estimate||||2013-01-28|2013-03-05|Estimate|January 2005||2005-01-31|January 2013|2013-01-31|October 2009|Actual|2009-10-31|April 2009|Actual|2009-04-30||Interventional|||Targeted Interventions for Weight-Concerned Smokers|Testing the Effectiveness of Low Dose Naltrexone for Smoking Cessation and Minimization of Post-cessation Weight Gain|Completed||Phase 2|172|Actual|Yale University||2|||f||||t||||||||||2018-06-01 04:57:49.479145|2018-06-01 04:57:49.479145
NCT00105469|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-14|2011-08-01||2013-11-21|2005-03-14|2005-03-15|Estimate|2011-09-20|2011-10-27|Estimate||||2013-11-21|2013-12-16|Estimate|July 2004||2004-07-31|November 2013|2013-11-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)|A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis|Completed||Phase 3|743|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:57:49.720866|2018-06-01 04:57:49.720866
NCT00105456|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-14|||2010-05-04|2005-03-14|2005-03-15|Estimate|||||||2010-05-04|2010-05-06|Estimate|March 2003||2003-03-31|May 2010|2010-05-31|May 2009|Actual|2009-05-31|||||Observational|||A Study of Patients With HER2-Positive Metastatic Breast Cancer|registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer|Completed|||1000||Genentech, Inc.|||||f||||||||||||||2018-06-01 04:57:50.825667|2018-06-01 04:57:50.825667
NCT00105443|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-14|2009-12-11||2014-10-24|2005-03-14|2005-03-15|Estimate|2010-09-07|2010-09-27|Estimate||||2014-10-24|2014-10-31|Estimate|March 2005||2005-03-31|October 2014|2014-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|SHARP||A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 3|602|Actual|Bayer||2|||f||||t||||||||||2018-06-01 04:57:50.996269|2018-06-01 04:57:50.996269
NCT00105430|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2006-07-04|2005-03-11|2005-03-14|Estimate|||||||2006-07-04|2006-07-06|Estimate|March 2005||2005-03-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||Deep Brain Stimulation for Cervical Dystonia|Deep Brain Stimulation of the Globus Pallidus Interna or the Subthalamic Nucleus for Treatment of Generalized Primary Dystonia|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:53.609693|2018-06-01 04:57:53.609693
NCT00104494|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2015-07-29|2005-03-01|2005-03-02|Estimate|||||||2015-07-29|2015-07-30|Estimate|May 2004||2004-05-31|March 2005|2005-03-31|September 2007|Actual|2007-09-30|||||Interventional|||Zinc Homeostasis and Kinetics in Children With Cystic Fibrosis (CF)|Zinc Homeostasis and Kinetics in Children With CF|Completed||N/A|30|Actual|Cystic Fibrosis Foundation Therapeutics||3|||f||||t||||||||||2018-06-01 04:58:11.315935|2018-06-01 04:58:11.315935
NCT00105417|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2008-03-03|2005-03-11|2005-03-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2005||2005-03-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment|A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment (A5214)|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:53.704054|2018-06-01 04:57:53.704054
NCT00105404|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2017-06-30|2005-03-11|2005-03-14|Estimate|||||||2017-06-30|2017-07-02|Actual|March 9, 2005||2005-03-09|October 30, 2006|2006-10-30|October 30, 2006||2006-10-30|||||Interventional|||Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation|A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema|Completed||Phase 3|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:53.901198|2018-06-01 04:57:53.901198
NCT00105378|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2007-08-09|2005-03-11|2005-03-14|Estimate|||||||2007-08-09|2007-08-10|Estimate|April 2003||2003-04-30|August 2007|2007-08-31|July 2005|Actual|2005-07-31|||||Interventional|||Dutch EASYcare Study|Effectiveness of EASYcare-Based Geriatric Intermediate Care|Completed||N/A|155|Actual|Radboud University|||||f||||||||||||||2018-06-01 04:57:53.969411|2018-06-01 04:57:53.969411
NCT00105365|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2015-10-20|2005-03-11|2005-03-14|Estimate|||||||2015-10-20|2015-10-21|Estimate|March 2004||2004-03-31|October 2015|2015-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Shoe Modification and Knee Osteoarthritis|Shoe Modification and Knee Osteoarthritis|Completed||N/A|40|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 04:57:54.150042|2018-06-01 04:57:54.150042
NCT00105352|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2016-06-01|2005-03-11|2005-03-14|Estimate|||||||2016-06-01|2016-06-02|Estimate|November 2004||2004-11-30|June 2016|2016-06-30|November 2005|Actual|2005-11-30|||||Interventional|||Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials|Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials|Completed||N/A|120||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 04:57:54.2558|2018-06-01 04:57:54.2558
NCT00105339|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2017-02-27|2005-03-11|2005-03-14|Estimate|||||||2017-02-27|2017-03-01|Actual|December 2003||2003-12-31|February 2016|2016-02-29|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Observational|||Simplified Consent for HIV Vaccine Trials|Simplified Consent for HIV Vaccine Trials|Completed|||255|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-06-01 04:57:54.420733|2018-06-01 04:57:54.420733
NCT00105326|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2010-05-20|2005-03-11|2005-03-14|Estimate|||||||2010-05-20|2010-05-24|Estimate|February 2005||2005-02-28|May 2010|2010-05-31|August 2005|Actual|2005-08-31|||||Interventional|||Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients|A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia|Completed||Phase 2|5|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:57:54.504857|2018-06-01 04:57:54.504857
NCT00105313|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2007-06-12|2005-03-11|2005-03-14|Estimate|||||||2007-06-12|2007-06-14|Estimate|February 2005||2005-02-28|June 2007|2007-06-30||||||||Interventional|||Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia|A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia|Terminated||Phase 1|80|Anticipated|MedImmune LLC||||"After review of safety events and have decided that further dose escalation of MEDI-507 as a~   single agent is not feasible."|||||||||||||||2018-06-01 04:57:54.568419|2018-06-01 04:57:54.568419
NCT00105300|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2006-08-13|2005-03-11|2005-03-14|Estimate|||||||2006-08-13|2006-08-15|Estimate|October 2004||2004-10-31|August 2006|2006-08-31||||||||Interventional|||Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Moderate to Severe Crohn's Disease Who Have Lost Response or Are Intolerant to Infliximab|Completed||Phase 3|300||Abbott|||||||||||||||||||2018-06-01 04:57:54.646112|2018-06-01 04:57:54.646112
NCT00105287|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-11|||2014-05-08|2005-03-11|2005-03-14|Estimate|||||||2014-05-08|2014-05-09|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Interventional|||Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients|Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients|Completed||Phase 3|100||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:57:54.945189|2018-06-01 04:57:54.945189
NCT00105274|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-10|||2017-06-30|2005-03-10|2005-03-11|Estimate|||||||2017-06-30|2017-07-02|Actual|March 7, 2005||2005-03-07|February 2, 2010|2010-02-02|February 2, 2010||2010-02-02|||||Observational|||Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study|Intermediate Phenotype and Genetic Mechanisms for Psychosis and Cognitive Disturbance in 22q11.2-Hemideletion Syndrome|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:55.073326|2018-06-01 04:57:55.073326
NCT00105248|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-10|||2016-05-10|2005-03-10|2005-03-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2004||2004-01-31|May 2016|2016-05-31|June 2004||2004-06-30|||||Interventional|||Patient Centered Communication Training to Reduce Antibiotic Use in Acute Respiratory Tract Infections|Multidimensional Intervention Program to Reduce Antibiotic Prescriptions for Acute Respiratory Tract Infections in Adults: a Randomized Controlled Trial in Primary Care|Completed||N/A|900||University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-06-01 04:57:55.145345|2018-06-01 04:57:55.145345
NCT00105235|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-10|2012-03-02||2012-11-23|2005-03-10|2005-03-11|Estimate|2012-03-02|2012-04-05|Estimate||||2012-11-23|2012-12-27|Estimate|June 2005||2005-06-30|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2007|Actual|2007-03-31||Interventional|TILT||Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients|A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation (ITN024ST)|Completed||Phase 2|27|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|This study was converted to a pilot study on May 23, 2006. Only 27 of the planned 211 participants were enrolled, thus reducing the number of subjects available for analysis.|1|||f||||t||||||||||2018-06-01 04:57:55.254355|2018-06-01 04:57:55.254355
NCT00105222|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-09|||2018-02-15|2005-03-09|2005-03-10|Estimate|||||||2018-02-15|2018-02-16|Estimate|March 8, 2005||2005-03-08|August 16, 2013|2013-08-16|August 16, 2013|Actual|2013-08-16|August 16, 2013|Actual|2013-08-16||Interventional|||Effect of Nitrite on Exercise Physiology and Metabolism|Evaluation of Systemic Nitrite Infusion and Its Effect on Exercise Physiology and Metabolism|Terminated||Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:57:56.036867|2018-06-01 04:57:56.036867
NCT00104481|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2011-12-07|2005-03-01|2005-03-02|Estimate|||||||2011-12-07|2011-12-08|Estimate|January 2005||2005-01-31|March 2007|2007-03-31|August 2007||2007-08-31|||||Interventional|||Group Counseling for Smoking Cessation|Cognitive Behavior Therapy for Smoking Cessation|Completed||Phase 1/Phase 2|240||American University|||||f||||||||||||||2018-06-01 04:58:11.374048|2018-06-01 04:58:11.374048
NCT00105209|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-09|||2005-06-23|2005-03-09|2005-03-10|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2002||2002-04-30|March 2005|2005-03-31|December 2003||2003-12-31|||||Interventional|||A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension|A Double-Blind, Placebo-Controlled, Three Treatment Cross-Over Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension|Completed||Phase 2|20||Kawut, Steven, MD|||||f||||||||||||||2018-06-01 04:57:56.10853|2018-06-01 04:57:56.10853
NCT00105196|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-09|2009-03-27||2013-11-07|2005-03-09|2005-03-10|Estimate|2009-03-27|2009-05-18|Estimate||||2013-11-07|2013-12-02|Estimate|March 2005||2005-03-31|April 2011|2011-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of Aripiprazole in Patients With Major Depressive Disorder|A Study of Aripiprazole in Patients With Major Depressive Disorder|Completed||Phase 3|349|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-06-01 04:57:56.208235|2018-06-01 04:57:56.208235
NCT00105183|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-08|2012-03-07||2012-06-07|2005-03-08|2005-03-09|Estimate|2012-05-04|2012-06-08|Estimate||||2012-06-07|2012-06-11|Estimate|January 2005||2005-01-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|||EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection|A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s)|Completed||Phase 3|223|Actual|Neovii Biotech|Interim analysis: Dropped 5mg/kg arm. Study was insufficiently powered & focus shifted to safety endpoints. Eliminated some secondary endpoints eg. steroid resistant&antibody treated rejection,CNI&antiproliferative agent, bronchiolitis obliterans.|3|||f||||t||||||||||2018-06-01 04:57:56.926212|2018-06-01 04:57:56.926212
NCT00105170|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-08|||2013-04-25|2005-03-08|2005-03-09|Estimate|||||||2013-04-25|2013-04-26|Estimate|January 2005||2005-01-31|April 2013|2013-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors|A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors|Terminated||Phase 1|13|Actual|Biogen|||||||||||||||||||2018-06-01 04:57:58.723449|2018-06-01 04:57:58.723449
NCT00105157|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-08|2009-09-14||2015-12-03|2005-03-08|2005-03-09|Estimate|2010-03-29|2010-04-12|Estimate||||2015-12-03|2015-12-04|Estimate|March 2005||2005-03-31|December 2015|2015-12-31|July 2009|Actual|2009-07-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)|Multicenter Study to Evaluate the Safety and Efficacy of MK0518 in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance|Completed||Phase 2|179|Actual|Merck Sharp & Dohme Corp.|Due to a 3:1 randomization of MK-0518 to placebo and more discontinuations for placebo in the doubleblind phase, exposure for MK-0518 and placebo differs significantly with follow-up times of 336.3 and 39.7 patient-years, respectively.|4|||f||||||||||||||2018-06-01 04:57:58.879691|2018-06-01 04:57:58.879691
NCT00105144|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-07|||2014-09-17|2005-03-07|2005-03-08|Estimate|||||||2014-09-17|2014-09-18|Estimate|September 2004||2004-09-30|September 2014|2014-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of Micafungin in Patients With Invasive Candidiasis or Candidemia|A Phase 3, Randomized, Double-Blind, Comparative Study of Micafungin (FK463) Versus Caspofungin as Antifungal Treatment in Patients With Invasive Candidiasis or Candidemia|Completed||Phase 3|611|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-06-01 04:58:00.978449|2018-06-01 04:58:00.978449
NCT00105131|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-05|||2008-03-03|2005-03-05|2005-03-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2005||2005-03-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Genetic Characterization of Parkinson's Disease|Genetic Characterization of Parkinson's Disease|Completed|||2500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:01.384984|2018-06-01 04:58:01.384984
NCT00105118|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-04|||2008-03-03|2005-03-04|2005-03-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2005||2005-03-31|February 2006|2006-02-28|February 2006||2006-02-28|||||Observational|||Effect of Transcranial Magnetic Stimulation on Memory|10 Hz rTMS to Subject Specific Regions of Cerebral Cortex Improves Memory in Healthy Subjects|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:01.433977|2018-06-01 04:58:01.433977
NCT00105105|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-04|||2009-12-10|2005-03-04|2005-03-07|Estimate|||||||2009-12-10|2009-12-11|Estimate|April 2003||2003-04-30|September 2005|2005-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Mifepristone as Adjunctive Therapy in Alzheimer's Disease|A Double-blind, Placebo-controlled Trial of the Safety and Efficacy of C-1073 (Mifepristone) as Adjunctive Therapy in Alzheimer's Disease|Terminated||Phase 2|160||National Institute on Aging (NIA)|||||||||||||||||||2018-06-01 04:58:01.490644|2018-06-01 04:58:01.490644
NCT00105092|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-04|||2007-04-27|2005-03-04|2005-03-07|Estimate|||||||2007-04-27|2007-05-01|Estimate|March 2005||2005-03-31|April 2007|2007-04-30|February 2007|Actual|2007-02-28|||||Interventional|||Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.|A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer|Completed||Phase 2|50||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:58:01.570984|2018-06-01 04:58:01.570984
NCT00105079|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-04|2011-03-29||2011-09-23|2005-03-04|2005-03-07|Estimate|2011-09-23|2011-11-02|Estimate||||2011-09-23|2011-11-02|Estimate|April 2005||2005-04-30|September 2011|2011-09-30|July 2008|Actual|2008-07-31|August 2007|Actual|2007-08-31||Interventional|||GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection|A 48-week, Randomized, Open-label, 2-arm Study to Compare the Efficacy of Saquinavir/Ritonavir Twice Daily (BID) Plus Emtricitabine/Tenofovir Once Daily (QD) Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients (GEMINI Study)|Completed||Phase 3|337|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:58:01.709177|2018-06-01 04:58:01.709177
NCT00105066|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2013-04-25||2017-01-12|2005-03-03|2005-03-04|Estimate|2017-01-12|2017-01-18|Estimate||||2017-01-12|2017-01-18|Estimate|January 2004||2004-01-31|January 2017|2017-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Effects of Metformin on Blood Vessel Structure and Function|The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)|Completed||Phase 2|77|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 04:58:02.176541|2018-06-01 04:58:02.176541
NCT00105053|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2009-06-30|2005-03-03|2005-03-04|Estimate|||||||2009-06-30|2009-07-02|Estimate|March 2005||2005-03-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Vaccine Treatment for Hormone Refractory Prostate Cancer|A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 1/Phase 2|8|Actual|NewLink Genetics Corporation||1|||f||||f||||||||||2018-06-01 04:58:02.41756|2018-06-01 04:58:02.41756
NCT00105040|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2015-02-27|2005-03-03|2005-03-04|Estimate|||||||2015-02-27|2015-03-02|Estimate|September 2004||2004-09-30|February 2015|2015-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures|A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures|Completed||Phase 2|87|Actual|UCB Pharma||2|||f||||f||||||||||2018-06-01 04:58:02.484352|2018-06-01 04:58:02.484352
NCT00105027|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2010-11-09||2018-04-06|2005-03-03|2005-03-04|Estimate|2010-12-16|2011-01-19|Estimate||||2018-04-06|2018-05-02|Actual|October 2004||2004-10-31|April 2018|2018-04-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|SCORE||The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study|The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema|Completed||Phase 3|682|Actual|The EMMES Corporation||6|||f||||t||||||||Yes|Data sets will be provided to qualified investigators under a Data Use Agreement.|2018-06-01 04:58:02.794478|2018-06-01 04:58:02.794478
NCT00105001|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2015-08-13||2018-02-08|2005-03-03|2005-03-04|Estimate|2015-08-13|2015-09-15|Estimate||||2018-02-08|2018-03-08|Actual|November 2004||2004-11-30|February 2018|2018-02-28|May 8, 2015|Actual|2015-05-08|May 2011|Actual|2011-05-31||Interventional|||Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer|A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial|Completed||Phase 2|210|Actual|Fred Hutchinson Cancer Research Center||3|||f||||t||||||||||2018-06-01 04:58:04.727971|2018-06-01 04:58:04.727971
NCT00104988|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2012-08-20|2005-03-03|2005-03-04|Estimate|||||||2012-08-20|2012-08-22|Estimate|June 2005||2005-06-30|August 2012|2012-08-31|August 2009|Actual|2009-08-31|July 2007|Actual|2007-07-31||Interventional|||S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery|A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma|Completed||Phase 2|64|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 04:58:05.340406|2018-06-01 04:58:05.340406
NCT00104975|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2016-12-13|2005-03-03|2005-03-04|Estimate|||||||2016-12-13|2016-12-15|Estimate|February 2005||2005-02-28|December 2016|2016-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer|Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells|Completed||Phase 1|20|Anticipated|Yale University|||||f||||||||||||||2018-06-01 04:58:05.627408|2018-06-01 04:58:05.627408
NCT00104962|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2014-06-10|2005-03-03|2005-03-04|Estimate|||||||2014-06-10|2014-06-11|Estimate|March 2005||2005-03-31|December 2012|2012-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes|Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:58:05.699301|2018-06-01 04:58:05.699301
NCT00104949|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-06-21|2005-03-03|2005-03-04|Estimate|||||||2013-06-21|2013-06-24|Estimate|July 2005||2005-07-31|December 2006|2006-12-31|August 2007|Actual|2007-08-31|||||Interventional|||Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma|Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:58:05.764969|2018-06-01 04:58:05.764969
NCT00104936|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2012-09-20|2005-03-03|2005-03-04|Estimate|||||||2012-09-20|2012-09-24|Estimate|December 2004||2004-12-31|September 2012|2012-09-30||||November 2006|Actual|2006-11-30||Interventional|||Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery|Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study|Terminated||Phase 3|9|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 04:58:05.816487|2018-06-01 04:58:05.816487
NCT00104923|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2017-07-18|2005-03-03|2005-03-04|Estimate|||||||2017-07-18|2017-07-19|Actual|February 2005||2005-02-28|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer|Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies|Completed||Phase 1|29|Actual|California Cancer Consortium|||||f||||t||||||||||2018-06-01 04:58:05.880429|2018-06-01 04:58:05.880429
NCT00104910|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2014-12-29|2005-03-03|2005-03-04|Estimate|||||||2014-12-29|2014-12-31|Estimate|January 2005||2005-01-31|December 2014|2014-12-31||||January 2013|Actual|2013-01-31||Interventional|||Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer|A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer|Completed||Phase 1|64|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 04:58:05.954167|2018-06-01 04:58:05.954167
NCT00104897|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-06-25|2005-03-03|2005-03-04|Estimate|||||||2013-06-25|2013-06-26|Estimate|March 2005||2005-03-31|March 2008|2008-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma|A Phase II Trial to Assess the Activity of 17-allylamino, 17-demethoxygeldanamycin (17-AAG) in Patients With Metastatic (M1, M1b & M1c) Malignant Melanoma|Completed||Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:06.037487|2018-06-01 04:58:06.037487
NCT00104884|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2015-12-15||2016-02-01|2005-03-03|2005-03-04|Estimate|2016-02-01|2016-03-02|Estimate||||2016-02-01|2016-03-02|Estimate|January 2005||2005-01-31|February 2016|2016-02-29|March 2009|Actual|2009-03-31|May 2006|Actual|2006-05-31||Interventional||All enrolled patients|FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma|Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma|Terminated||Phase 2|4|Actual|Eastern Cooperative Oncology Group||1||The study was terminated on May 17, 2006 due to slow accrual.|f||||f||||||||No||2018-06-01 04:58:06.096506|2018-06-01 04:58:06.096506
NCT00100321|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-28|||2018-05-12|2004-12-28|2004-12-29|Estimate|||||||2018-05-12|2018-05-15|Actual|December 21, 2004||2004-12-21|November 20, 2012|2012-11-20|November 20, 2012||2012-11-20|||||Observational|||Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study|Immunologic Studies of Tumors of the Pancreas|Terminated|||25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:25.424624|2018-06-01 04:59:25.424624
NCT00104871|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2013-11-20||2014-10-24|2005-03-03|2005-03-04|Estimate|2014-06-19|2014-06-25|Estimate||||2014-10-24|2014-11-03|Estimate|December 2004||2004-12-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|May 2010|Actual|2010-05-31||Interventional|||Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy|A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma|Completed||Phase 2|24|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 04:58:06.457415|2018-06-01 04:58:06.457415
NCT00104858|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2018-03-26|2005-03-03|2005-03-04|Estimate|||||||2018-03-26|2018-03-27|Actual|December 2004|Actual|2004-12-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial|Active, not recruiting||Phase 2|94|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 04:58:06.739171|2018-06-01 04:58:06.739171
NCT00104845|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-03-11|2005-03-03|2005-03-04|Estimate|||||||2013-03-11|2013-03-12|Estimate|September 2004||2004-09-30|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma|Injection of AJCC Stage IIB, IIC, III, and IV Melanoma Patients With Human and Mouse gp100 DNA: A Phase I Trial to Assess Safety and Immune Response|Completed||Phase 1|19|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 04:58:06.85123|2018-06-01 04:58:06.85123
NCT00104819|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-08-01|2005-03-03|2005-03-04|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2004||2004-09-30|August 2008|2008-08-31||||June 2011|Anticipated|2011-06-30||Interventional|||Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma|Phase II Trial of FavId™ (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06|Terminated||Phase 2|238|Anticipated|National Cancer Institute (NCI)||||Withdrawn as company has shut down and filed for bankruptcy|f||||||||||||||2018-06-01 04:58:07.004901|2018-06-01 04:58:07.004901
NCT00104806|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2017-05-25|2005-03-03|2005-03-04|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2004||2004-11-30|July 2012|2012-07-31|May 2010|Actual|2010-05-31|January 2006|Actual|2006-01-31||Interventional|||Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes|Phase II Trial of Arsenic Trioxide and Dose-Escalated Cholecalciferol in Myelodysplastic Syndrome|Terminated||Phase 2|5|Actual|Wake Forest University Health Sciences||||sponsor discontinues support|f||||f|t|f||||||||2018-06-01 04:58:07.153305|2018-06-01 04:58:07.153305
NCT00104793|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-05-29|2005-03-03|2005-03-04|Estimate|||||||2013-05-29|2013-05-30|Estimate|June 2003||2003-06-30|October 2007|2007-10-31|November 2008|Actual|2008-11-30|February 2007|Actual|2007-02-28||Interventional|||Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer|Phase II Study of Weekly Irinotecan and Carboplatin in Extensive-Stage Small-Cell Lung Cancer|Completed||Phase 2|55|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:07.22644|2018-06-01 04:58:07.22644
NCT00104780|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-11-05|2005-03-03|2005-03-04|Estimate|||||||2013-11-05|2013-11-06|Estimate|December 2004||2004-12-31|March 2006|2006-03-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Phase II, Open Label, Multi-center Study of EP2101 Therapeutic Vaccine in Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:07.303253|2018-06-01 04:58:07.303253
NCT00104767|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2015-10-01|2005-03-03|2005-03-04|Estimate|||||||2015-10-01|2015-10-02|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase I Trial to Evaluate Cyclooxygenase 2 Inhibitor-Mediated Modulation of T Regulatory Cells in Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|7|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 04:58:07.375662|2018-06-01 04:58:07.375662
NCT00104754|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2016-07-19|2005-03-03|2005-03-04|Estimate|||||||2016-07-19|2016-07-20|Estimate||||July 2016|2016-07-31||||||||Interventional|||Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer|Phase II Trial of Liposome Encapsulated SN38 (LE-SN38) in the Treatment of Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Alliance for Clinical Trials in Oncology||1|||f||||||||||||||2018-06-01 04:58:07.452146|2018-06-01 04:58:07.452146
NCT00104741|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2011-02-18|2005-03-03|2005-03-04|Estimate|||||||2011-02-18|2011-02-21|Estimate|July 2004||2004-07-31|April 2008|2008-04-30||||||||Interventional|||Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer|Multicentre Randomized Trial Assessing the Efficacy of a Short Neoadjuvant and Concomitant Hormone Therapy to an Exclusive Curative Cornformational Radiotherapy of Locolized Prostate Cancer With Intermediate Prognosis|Unknown status|Recruiting|Phase 3|450|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:07.530413|2018-06-01 04:58:07.530413
NCT00104728|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2012-10-01||2012-10-01|2005-03-03|2005-03-04|Estimate|2012-10-01|2012-10-31|Estimate||||2012-10-01|2012-10-31|Estimate|October 2004||2004-10-31|September 2012|2012-09-30|March 2009|Actual|2009-03-31|May 2008|Actual|2008-05-31||Interventional|||Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates|Pilot Neoadjuvant Study of ZD1839 (IRESSA®) as Single Agent Preoperative Therapy for Clinical Stage 1A and 1B (T1-2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) With Molecular Correlates|Terminated||N/A|42|Actual|H. Lee Moffitt Cancer Center and Research Institute|Pilot study. At the time of interim analysis, the second early stopping rule was invoked for lack of activity (not enough responses to continue). Study closed to accrual 5/9/08.|1||Early Stopping Rule: Would not meet interim analysis goal to proceed with enrollment|f||||f||||||||||2018-06-01 04:58:07.655768|2018-06-01 04:58:07.655768
NCT00104715|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2010-11-06|2005-03-03|2005-03-04|Estimate|||||||2010-11-06|2010-11-09|Estimate|October 2004||2004-10-31|April 2008|2008-04-30||||||||Interventional|||Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer|Randomized Phase III Trial Comparing an Association of Hormonal Treatment and Docetaxel Versus the Hormonal Treatment Alone in Metastatic Prostate Cancers|Unknown status|Active, not recruiting|Phase 3|378|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:07.775688|2018-06-01 04:58:07.775688
NCT00104702|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-09-02|2005-03-03|2005-03-04|Estimate|||||||2013-09-02|2013-09-04|Estimate|July 2004||2004-07-31|September 2013|2013-09-30|March 2011|Actual|2011-03-31|April 2008|Actual|2008-04-30||Interventional|GERICO03||Radiation Therapy in Treating Older Women Who Are Undergoing Surgery for Stage I or Stage II Breast Cancer|Radio-Surgical Treatment of Breast Cancer of Women Aged Over 70: Phase II Trial of Feasibility and Reproducibility of a Concentrated and Focalized Radiotherapy|Completed||Phase 2|46|Actual|UNICANCER||1|||f||||||||||||||2018-06-01 04:58:07.868132|2018-06-01 04:58:07.868132
NCT00104689|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2008-07-23|2005-03-03|2005-03-04|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2003||2003-07-31|December 2006|2006-12-31||||||||Interventional|||Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer|Phase II Trial Assessing the Impact on the Activity of Daily Living of an Oral Chemotherapy by Capecitabine Associated With an Intravenous Chemotherapy by Oxaliplatin as First Line Treatment of Metastatic Colorectal Adenocarcinoma of Patients Aged Over 70|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:08.097998|2018-06-01 04:58:08.097998
NCT00104676|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2009-12-13|2005-03-03|2005-03-04|Estimate|||||||2009-12-13|2009-12-15|Estimate|November 2003||2003-11-30|November 2008|2008-11-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors|A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors|Unknown status|Recruiting|Phase 3|260|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:58:08.181578|2018-06-01 04:58:08.181578
NCT00104663|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2015-04-06|2005-03-03|2005-03-04|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2004||2004-06-30|April 2015|2015-04-30|March 2007||2007-03-31|||||Interventional|||PRION-1: Quinacrine for Human Prion Disease|PRION-1: Quinacrine for Human Prion Disease. A Partially Randomized Patient Preference Trial to Evaluate the Activity and Safety of Quinacrine in Human Prion Disease|Completed||N/A|160||Medical Research Council|||||f||||||||||||||2018-06-01 04:58:08.308917|2018-06-01 04:58:08.308917
NCT00104650|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2010-12-09|2009-11-19|2011-01-20|2005-03-03|2005-03-04|Estimate|2010-12-09|2011-01-07|Estimate|2009-11-19|2009-11-23|Estimate|2011-01-20|2011-01-24|Estimate|January 2005||2005-01-31|January 2011|2011-01-31|March 2010|Actual|2010-03-31|January 2008|Actual|2008-01-31||Interventional|||Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates|A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates|Completed||Phase 2|111|Actual|Amgen||3|||f||||||||||||||2018-06-01 04:58:08.423212|2018-06-01 04:58:08.423212
NCT00104637|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|2012-04-04||2012-05-18|2005-03-03|2005-03-04|Estimate|2012-05-18|2012-05-21|Estimate||||2012-05-18|2012-05-21|Estimate|February 2005||2005-02-28|May 2012|2012-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Sildenafil for Chronic Obstructive Pulmonary Disease|A Double-blind, Placebo-controlled, Crossover Study of Sildenafil in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|10|Actual|Kawut, Steven, MD|The study had slow enrollment.|2|||f||||t||||||||||2018-06-01 04:58:09.486594|2018-06-01 04:58:09.486594
NCT00104624|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-03|||2013-09-02|2005-03-03|2005-03-04|Estimate|||||||2013-09-02|2013-09-04|Estimate|May 2005||2005-05-31|September 2013|2013-09-30|July 2008|Actual|2008-07-31|July 2007|Actual|2007-07-31||Interventional|||Docetaxel in Treating Older Women With Metastatic Breast Cancer|Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy With Biweekly Docetaxel in the Treatment of Metastatic Breast Cancer in Patients Over 70|Terminated||Phase 2|53|Anticipated|UNICANCER||||Toxicity issues|f||||f||||||||||2018-06-01 04:58:09.73598|2018-06-01 04:58:09.73598
NCT00104611|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-02|||2013-09-19|2005-03-02|2005-03-03|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2004||2004-01-31|September 2013|2013-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder|A Randomized, Parallel-Group, Sham-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of the Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic Stimulation (rTMS) System in Patients With Major Depression|Completed||Phase 3|286|Actual|Neuronetics||2|||f||||t||||||||||2018-06-01 04:58:09.798798|2018-06-01 04:58:09.798798
NCT00104598|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2013-08-07|2005-03-01|2005-03-02|Estimate|||||||2013-08-07|2013-08-09|Estimate|September 2000||2000-09-30|August 2013|2013-08-31|December 2006|Actual|2006-12-31|September 2004|Actual|2004-09-30||Interventional|||Framing Messages for Smoking Cessation With Bupropion - 6|Framing Messages for Smoking Cessation With Buproprion|Completed||N/A|252|Actual|Yale University||2|||f||||f||||||||||2018-06-01 04:58:09.985691|2018-06-01 04:58:09.985691
NCT00104585|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2012-01-18|2005-03-01|2005-03-02|Estimate|||||||2012-01-18|2012-01-19|Estimate|July 2004||2004-07-31|January 2012|2012-01-31||||September 2012|Anticipated|2012-09-30||Observational|||Consortium On Risk for Early-onset Parkinson's Disease (CORE PD)|Genetic Epidemiology of Parkinson's Disease|Unknown status|Recruiting||800|Anticipated|Columbia University|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 04:58:10.052594|2018-06-01 04:58:10.052594
NCT00104572|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|2015-05-04||2016-03-11|2005-03-01|2005-03-02|Estimate|2016-02-10|2016-03-09|Estimate||||2016-03-11|2016-04-12|Estimate|March 2004||2004-03-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial.|The Effects of Aromatase Inhibition and Testosterone Replacement in Sex Steroids, Pituitary Hormones, Markers of Bone Turnover, Muscle Strength, and Cognition in Older Men|Completed||Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||||2018-06-01 04:58:10.149352|2018-06-01 04:58:10.149352
NCT00104559|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2008-09-25|2005-03-01|2005-03-02|Estimate|||||||2008-09-25|2008-09-26|Estimate|January 2005||2005-01-31|September 2008|2008-09-30|March 2009|Anticipated|2009-03-31|July 2007|Anticipated|2007-07-31||Interventional|||Computer-Generated Vs. Standard Informed Consent for HIV Research Studies|Interactive Multimedia Informed Consent (iMIC) for HIV Research|Unknown status|Active, not recruiting|N/A|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:58:10.560979|2018-06-01 04:58:10.560979
NCT00104546|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2008-01-23|2005-03-01|2005-03-02|Estimate|||||||2008-01-23|2008-01-25|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Vitamin K Injections for the Treatment of Painful Menstruation|Vitamin K Injection Treatment for Primary Dysmenorrhea: A Controlled Pilot Study|Completed||Phase 1|36||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:58:10.622614|2018-06-01 04:58:10.622614
NCT00104533|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|||2008-03-19|2005-03-01|2005-03-02|Estimate|||||||2008-03-19|2008-03-20|Estimate|September 2004||2004-09-30|March 2005|2005-03-31|September 2005|Actual|2005-09-30|||||Interventional|||Effectiveness of Magnetic Therapy on Pain Intensity|Effectiveness of Magnetic Therapy on Pain Intensity|Completed||Phase 3|164||Javeriana University|||||f||||||||||||||2018-06-01 04:58:10.734674|2018-06-01 04:58:10.734674
NCT00104520|ClinicalTrials.gov processed this data on May 31, 2018|2005-03-01|2010-09-10||2011-02-16|2005-03-01|2005-03-02|Estimate|2011-02-16|2011-03-11|Estimate||||2011-02-16|2011-03-11|Estimate|February 2005||2005-02-28|September 2010|2010-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|AIR-CF2||Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa|A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary P. Aeruginosa Requiring Frequent Antibiotics (AIR-CF2)|Completed||Phase 3|211|Actual|Gilead Sciences|The study was designed such that participants were discontinued from study participation upon meeting the primary endpoint (time to need for inhaled or IV antipseudomonal antibiotics).|2|||f||||t||||||||||2018-06-01 04:58:10.813678|2018-06-01 04:58:10.813678
NCT00104468|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|||2008-01-14|2005-02-28|2005-03-01|Estimate|||||||2008-01-14|2008-01-17|Estimate|April 2003||2003-04-30|January 2008|2008-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)|An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia|Terminated||Phase 1/Phase 2|50||SGX Pharmaceuticals, Inc.||||Trial stopped June 2007|||||||||||||||2018-06-01 04:58:11.428608|2018-06-01 04:58:11.428608
NCT00104455|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|||2017-01-11|2005-02-28|2005-03-01|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2004||2004-06-30|January 2017|2017-01-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Dose Response to Recombinant Factor VIIa When Administered for Bleed|Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers|Completed||Phase 1|64|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:58:11.474739|2018-06-01 04:58:11.474739
NCT00104442|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|||2007-12-17|2005-02-28|2005-03-01|Estimate|||||||2007-12-17|2007-12-21|Estimate|October 2003||2003-10-31|December 2007|2007-12-31|April 2006|Actual|2006-04-30|||||Interventional|||Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease|Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease|Completed||Phase 4|80||Novartis|||||||||||||||||||2018-06-01 04:58:11.525767|2018-06-01 04:58:11.525767
NCT00104429|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|||2017-05-25|2005-02-28|2005-03-01|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2005||2005-01-31|May 2017|2017-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||GW873140 In Combination With Combivir In HIV Infected Subjects|A PhaseIIb, 96 Week, Randomised, Partially Double-blinded, Multicentre, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of GW873140 in Combination With COMBIVIR (Lamivudine and Zidovudine) Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy Naive Adults|Terminated||Phase 2|125||ViiV Healthcare|||||f||||||||||||||2018-06-01 04:58:11.574671|2018-06-01 04:58:11.574671
NCT00104416|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|2010-04-16||2016-11-15|2005-02-28|2005-03-01|Estimate|2010-04-16|2010-05-18|Estimate||||2016-11-15|2017-01-02|Estimate|December 2004||2004-12-31|November 2016|2016-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures|A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures|Completed||Phase 3|153|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:58:11.951392|2018-06-01 04:58:11.951392
NCT00104403|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|||2015-04-15|2005-02-28|2005-03-01|Estimate|||||||2015-04-15|2015-04-16|Estimate|December 2004||2004-12-31|April 2015|2015-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy|A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral NeuroKinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea|Completed||Phase 2|722|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:58:12.950559|2018-06-01 04:58:12.950559
NCT00104390|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|||2010-06-09|2005-02-28|2005-03-01|Estimate|||||||2010-06-09|2010-06-10|Estimate|March 2005||2005-03-31|June 2010|2010-06-30|April 2005||2005-04-30|||||Interventional|||Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing|A Single-blind Phase 1 Study to Assess the Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing|Completed||Phase 1|14||Allergy Therapeutics|||||||||||||||||||2018-06-01 04:58:13.13172|2018-06-01 04:58:13.13172
NCT00104377|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-28|||2010-06-16|2005-02-28|2005-03-01|Estimate|||||||2010-06-16|2010-06-17|Estimate|March 2005||2005-03-31|September 2009|2009-09-30|November 2005||2005-11-30|||||Interventional|||Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen|A Multicenter, Single-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen|Completed||Phase 2|70||Allergy Therapeutics|||||||||||||||||||2018-06-01 04:58:13.29402|2018-06-01 04:58:13.29402
NCT00104364|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-25|||2015-01-29|2005-02-25|2005-02-28|Estimate|||||||2015-01-29|2015-01-30|Estimate|May 2005||2005-05-31|January 2015|2015-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)|An Open-label, Dose Escalation Phase I/II Trial of a KSP Inhibitor Given as a Constant 24-Hour Infusion in Patients With Advanced Solid Tumors|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:58:13.361005|2018-06-01 04:58:13.361005
NCT00104338|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|||2012-06-06|2005-02-24|2005-02-25|Estimate|||||||2012-06-06|2012-06-07|Estimate|January 2005||2005-01-31|June 2012|2012-06-30|August 2006|Actual|2006-08-31|||||Interventional|||Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy|A Phase 2, Proof of Concept, Randomized, Open-label, Two-arm, Parallel Group, Multi-center Study to Assess the Efficacy and Safety of FK778 Compared With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy|Terminated||Phase 2|45||Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:58:13.418156|2018-06-01 04:58:13.418156
NCT00104325|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|||2018-03-20|2005-02-24|2005-02-25|Estimate|||||||2018-03-20|2018-03-21|Actual|January 31, 2003||2003-01-31|March 15, 2018|2018-03-15||||||||Observational|||Cytapheresis of Volunteer Donors|Cytapheresis of Volunteer Donors|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:13.494238|2018-06-01 04:58:13.494238
NCT00104312|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|||2009-05-28|2005-02-24|2005-02-25|Estimate|||||||2009-05-28|2009-05-29|Estimate|April 2001||2001-04-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Osteoarthritis: Weakness From Inflammation|Weakness From Inflammation: A Basis of Disability From Knee Osteoarthritis|Completed|||88|Anticipated|National Institute on Aging (NIA)|||2||f||||||||||Samples Without DNA|"~     Synovial fluid and tissue blood serum muscle biopsy~   "|||2018-06-01 04:58:13.55795|2018-06-01 04:58:13.55795
NCT00104091|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-22|||2011-05-20|2005-02-22|2005-02-23|Estimate|||||||2011-05-20|2011-05-23|Estimate|December 2004||2004-12-31|May 2011|2011-05-31|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors|A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection|Completed||Phase 2|56|Anticipated|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 04:58:17.174614|2018-06-01 04:58:17.174614
NCT00104299|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|2011-02-02||2017-03-23|2005-02-24|2005-02-25|Estimate|2011-07-27|2011-08-25|Estimate||||2017-03-23|2017-04-21|Actual|January 2005||2005-01-31|March 2017|2017-03-31|January 2010|Actual|2010-01-31|December 2008|Actual|2008-12-31||Interventional|RAVE||Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis|Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)|Completed||Phase 2/Phase 3|197|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal.|2018-06-01 04:58:13.658222|2018-06-01 04:58:13.658222
NCT00104286|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|||2006-11-01|2005-02-24|2005-02-25|Estimate|||||||2006-11-01|2006-11-03|Estimate|January 2003||2003-01-31|November 2006|2006-11-30|November 2005||2005-11-30|||||Interventional|||Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors|An Open-Label, Single-Arm, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With an Advanced Solid Malignancy|Terminated||Phase 1/Phase 2|50||SGX Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 04:58:14.585273|2018-06-01 04:58:14.585273
NCT00104273|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|||2009-07-14|2005-02-24|2005-02-25|Estimate|||||||2009-07-14|2009-07-15|Estimate|August 2004||2004-08-31|April 2008|2008-04-30||||March 2007|Actual|2007-03-31||Interventional|||Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)|A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type|Completed||Phase 2|376|Actual|Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 04:58:14.647946|2018-06-01 04:58:14.647946
NCT00104260|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|||2007-04-05|2005-02-24|2005-02-25|Estimate|||||||2007-04-05|2007-04-09|Estimate|December 2004||2004-12-31|April 2007|2007-04-30|November 2005|Actual|2005-11-30|||||Interventional|||Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria|A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels|Completed||Phase 2|700||BioMarin Pharmaceutical|||||||||||||||||||2018-06-01 04:58:14.762591|2018-06-01 04:58:14.762591
NCT00104247|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|2009-01-29||2014-07-15|2005-02-24|2005-02-25|Estimate|2009-03-12|2009-04-16|Estimate||||2014-07-15|2014-07-23|Estimate|March 2005||2005-03-31|July 2014|2014-07-31|February 2006|Actual|2006-02-28|||||Interventional|||Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels|Completed||Phase 3|89|Actual|BioMarin Pharmaceutical|||||||||||||||||||2018-06-01 04:58:14.823533|2018-06-01 04:58:14.823533
NCT00104234|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-24|2009-02-04||2010-01-26|2005-02-24|2005-02-25|Estimate|2009-03-05|2009-03-06|Estimate||||2010-01-26|2010-02-02|Estimate|February 2004||2004-02-29|January 2010|2010-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study of rhASB in Patients With Mucopolysaccharidosis VI|A Multicenter, Multinational Open-Label Extension Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With Mucopolysaccharidosis VI|Completed||Phase 3|39|Actual|BioMarin Pharmaceutical||2|||||||||||||||||2018-06-01 04:58:15.059773|2018-06-01 04:58:15.059773
NCT00104195|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-23|||2014-04-15|2005-02-23|2005-02-24|Estimate|||||||2014-04-15|2014-04-16|Estimate|February 2004||2004-02-29|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions|Decision-Making Processes and Brain Function in Anxiety-Disordered and Non-Anxious Youth|Completed|||127|Actual|New York University School of Medicine|||||f||||f||||||||||2018-06-01 04:58:15.592623|2018-06-01 04:58:15.592623
NCT00104182|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-23|||2017-01-27|2005-02-23|2005-02-24|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 2005||2005-02-28|January 2017|2017-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening as Add-on to Oral Antidiabetic Drug(s) in Patients With Type 2 Diabetes|Completed||Phase 3|503|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:58:15.66845|2018-06-01 04:58:15.66845
NCT00104169|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-23|||2008-08-28|2005-02-23|2005-02-24|Estimate|||||||2008-08-28|2008-08-29|Estimate|August 2004||2004-08-31|August 2008|2008-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Idiopathic Anemia of Aging (IAA)|Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA)|Terminated||Phase 2|0|Actual|National Institute on Aging (NIA)||||No subject accrual|f||||||||||||||2018-06-01 04:58:15.931737|2018-06-01 04:58:15.931737
NCT00104156|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-23|||2008-01-23|2005-02-23|2005-02-24|Estimate|||||||2008-01-23|2008-01-25|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Qigong Therapy for Individuals With Knee Osteoarthritis|Qigong Therapy for Osteoarthritis at Knees|Completed||Phase 2|100||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:58:16.003659|2018-06-01 04:58:16.003659
NCT00104143|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-23|||2016-08-23|2005-02-23|2005-02-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|October 2007||2007-10-31|August 2016|2016-08-31||||||||Interventional|||A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.|A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis.|Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche|||||f||||||||||||||2018-06-01 04:58:16.075943|2018-06-01 04:58:16.075943
NCT00104130|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-23|||2008-09-16|2005-02-23|2005-02-24|Estimate|||||||2008-09-16|2008-09-17|Estimate|December 2004||2004-12-31|September 2008|2008-09-30|February 2005||2005-02-28|||||Interventional|||Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer|A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease|Terminated||Phase 2|53||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:58:16.197209|2018-06-01 04:58:16.197209
NCT00104117|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-23|||2010-02-18|2005-02-23|2005-02-24|Estimate|||||||2010-02-18|2010-02-19|Estimate|November 2004||2004-11-30|February 2010|2010-02-28|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Study of XL999 in Adults With Solid Tumors|A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Solid Tumors|Completed||Phase 1|52|Actual|Symphony Evolution, Inc.|||||f||||t||||||||||2018-06-01 04:58:16.265988|2018-06-01 04:58:16.265988
NCT00104104|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-22|2011-01-06||2011-06-27|2005-02-22|2005-02-23|Estimate|2011-05-04|2011-06-06|Estimate||||2011-06-27|2011-06-29|Estimate|October 2004||2004-10-31|June 2011|2011-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Multiple Myeloma Trial in Patients With Bone Metastases|A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases|Completed||Phase 4|179|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:58:16.374699|2018-06-01 04:58:16.374699
NCT00104065|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-22|||2016-03-14|2005-02-22|2005-02-23|Estimate|||||||2016-03-14|2016-03-15|Estimate|January 2005||2005-01-31|February 2016|2016-02-29|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant|Completed||Phase 2|||Celldex Therapeutics|||||f||||||||||||||2018-06-01 04:58:17.294217|2018-06-01 04:58:17.294217
NCT00104052|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-22|2008-11-14||2017-03-07|2005-02-22|2005-02-23|Estimate|2009-02-05|2009-03-09|Estimate||||2017-03-07|2017-04-04|Actual|February 2005||2005-02-28|March 2017|2017-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)|Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C|Completed||Phase 3|107|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 04:58:17.483132|2018-06-01 04:58:17.483132
NCT00104039|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-19|||2018-05-18|2005-02-19|2005-02-21|Estimate|||||||2018-05-18|2018-05-21|Actual|February 17, 2005||2005-02-17|July 21, 2016|2016-07-21|July 21, 2016||2016-07-21|||||Observational|||Brain Changes in Children and Adolescents With Behavioral Problems|Investigating the Neuro-Cognitive Underpinnings of the Emotional Dysfunction Linked to Childhood Behavioral Disturbance|Completed|||318|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:17.649461|2018-06-01 04:58:17.649461
NCT00104026|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-18|||2017-06-30|2005-02-18|2005-02-21|Estimate|||||||2017-06-30|2017-07-02|Actual|February 15, 2005||2005-02-15|April 19, 2011|2011-04-19|April 19, 2011||2011-04-19|||||Observational|||Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth|Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth|Completed|||45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:17.707165|2018-06-01 04:58:17.707165
NCT00104013|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-18|||2008-08-20|2005-02-18|2005-02-21|Estimate|||||||2008-08-20|2008-08-21|Estimate|November 2003||2003-11-30|August 2008|2008-08-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type|Completed||Phase 3|1455|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:58:17.759222|2018-06-01 04:58:17.759222
NCT00104000|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-17|||2008-03-03|2005-02-17|2005-02-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2005||2005-02-28|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Effect of Surface Electrical Stimulation on Movement of the Larynx|The Effect of Surface Electrical Stimulation on Hyo-Laryngeal Movement in Healthy Individuals at Rest and During Swallow|Completed|||47||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:17.857392|2018-06-01 04:58:17.857392
NCT00103987|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-17|||2017-06-30|2005-02-17|2005-02-18|Estimate|||||||2017-06-30|2017-07-02|Actual|February 14, 2005||2005-02-14|November 12, 2010|2010-11-12|November 12, 2010||2010-11-12|||||Observational|||Neurobiological Mechanisms in Panic Disorder|Neurobiological Mechanisms in Panic Disorder: Behavioral, Genetic, & Neural Correlates of Noradrenergic Function|Completed|||54|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:17.907039|2018-06-01 04:58:17.907039
NCT00103974|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-17|||2008-04-04|2005-02-17|2005-02-18|Estimate|||||||2008-04-04|2008-04-07|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|March 2007||2007-03-31|||||Interventional|||Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis|A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis|Completed||Phase 1|30||Bayhill Therapeutics|||||||||||||||||||2018-06-01 04:58:17.951565|2018-06-01 04:58:17.951565
NCT00103961|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-17|||2008-09-25|2005-02-17|2005-02-18|Estimate|||||||2008-09-25|2008-09-26|Estimate|January 2004||2004-01-31|September 2008|2008-09-30|December 2014|Anticipated|2014-12-31|October 2007|Actual|2007-10-31||Observational|||An Observational Study of People Who Have Recently Been Infected With HIV|Primary HIV & Early Disease Research: American Cohort (PHAEDRA) AIEDRP|Unknown status|Active, not recruiting||500|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Blood collection~   "|||2018-06-01 04:58:18.00769|2018-06-01 04:58:18.00769
NCT00103948|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-17|||2015-11-02|2005-02-17|2005-02-18|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2005||2005-02-28|November 2015|2015-11-30|February 2007|Actual|2007-02-28|October 2006|Actual|2006-10-31||Interventional|||The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment|An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment|Completed||Phase 2|165|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 04:58:18.074762|2018-06-01 04:58:18.074762
NCT00103935|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-17|||2015-02-23|2005-02-17|2005-02-18|Estimate|||||||2015-02-23|2015-02-24|Estimate|February 2005||2005-02-28|January 2015|2015-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Pharmacokinetics of Exenatide Long-Acting Release Administered Weekly in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|45|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 04:58:18.122298|2018-06-01 04:58:18.122298
NCT00103922|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-17|||2016-10-26|2005-02-17|2005-02-18|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2004||2004-11-30|October 2016|2016-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)|A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO® (15mg BID) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|600|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:58:18.201574|2018-06-01 04:58:18.201574
NCT00103896|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-15|||2017-02-27|2005-02-15|2005-02-16|Estimate|||||||2017-02-27|2017-03-01|Actual|September 2003||2003-09-30|July 2016|2016-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Connect to Protect Partnerships for Youth Prevention Interventions: Phase II|Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II|Completed|||16706|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-06-01 04:58:19.355648|2018-06-01 04:58:19.355648
NCT00103883|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-15|||2017-02-27|2005-02-15|2005-02-16|Estimate|||||||2017-02-27|2017-03-01|Actual|February 2003||2003-02-28|February 2016|2016-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||A Novel Method to Determine HIV Incidence Among Youth|A Novel Method to Determine HIV Incidence Among Youth|Completed|||440|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||Samples Without DNA|"~     Phenotypic and genotypic testing for antiretroviral drug (ART) resistance will be done on~     stored samples from all subjects who are identified as recently infected by the serum based~     DV S/LS reference method. An assay for viral replication fitness will also be done on these~     same samples. This testing will provide a recent assessment of prevalence of transmitted ART~     resistant HIV-1 in this population.~   "|||2018-06-01 04:58:20.192638|2018-06-01 04:58:20.192638
NCT00103870|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-15|||2009-12-08|2005-02-15|2005-02-16|Estimate|||||||2009-12-08|2009-12-09|Estimate|February 2005||2005-02-28|December 2009|2009-12-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Mind Engagement With Music for Nondrug Pain Relief|Music Engagement for Non-Pharmacological Analgesia R21 AT001586-01|Completed||Phase 1|120|Anticipated|University of Utah|||||f||||||||||||||2018-06-01 04:58:20.280435|2018-06-01 04:58:20.280435
NCT00103857|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-15|2009-02-19||2017-03-31|2005-02-15|2005-02-16|Estimate|2009-03-27|2009-05-19|Estimate||||2017-03-31|2017-05-05|Actual|March 17, 2005|Actual|2005-03-17|March 2017|2017-03-31|February 21, 2008|Actual|2008-02-21|July 25, 2006|Actual|2006-07-25||Interventional|||MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)|A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 3|1208|Actual|Merck Sharp & Dohme Corp.|Non-serious adverse experience results represent those events included in the primary safety analysis for this study (i.e., events that occurred prior to the initiation of glycemic rescue therapy).|7|||f||||f||||||||||2018-06-01 04:58:20.408466|2018-06-01 04:58:20.408466
NCT00103844|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-15|2009-12-02||2010-08-03|2005-02-15|2005-02-16|Estimate|2009-12-02|2010-01-07|Estimate||||2010-08-03|2010-08-10|Estimate|February 2005||2005-02-28|June 2010|2010-06-30|March 2008|Actual|2008-03-31|August 2006|Actual|2006-08-31||Interventional|||Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia|A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d|Completed||Phase 2|150|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 04:58:22.101592|2018-06-01 04:58:22.101592
NCT00103831|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-15||2010-02-27|2010-02-27|2005-02-15|2005-02-16|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate||||August 2008|2008-08-31||||May 2005|Actual|2005-05-31||Interventional|||Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer|Phase I Alimta Combination With BMS-275183 (Oral Taxane)|Completed||Phase 1/Phase 2|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 04:58:23.068946|2018-06-01 04:58:23.068946
NCT00103818|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-15|||2015-01-13|2005-02-15|2005-02-16|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2005||2005-02-28|January 2015|2015-01-31|October 2006|Actual|2006-10-31|||||Interventional|||An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy Study of MK0928 15 mg and 10 mg in the Treatment of Adult Outpatients With Primary Insomnia|Completed||Phase 3|900|Actual|H. Lundbeck A/S|||||f||||||||||||||2018-06-01 04:58:23.120249|2018-06-01 04:58:23.120249
NCT00103805|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2014-05-20|2005-02-14|2005-02-15|Estimate|||||||2014-05-20|2014-05-21|Estimate|March 2003||2003-03-31|May 2014|2014-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Improved Language Acquisition With Levodopa|Improved Language Acquisition With Levodopa|Completed||Phase 4|20||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:58:23.173916|2018-06-01 04:58:23.173916
NCT00103792|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2009-02-12|2005-02-14|2005-02-15|Estimate|||||||2009-02-12|2009-02-16|Estimate|December 2004||2004-12-31|February 2009|2009-02-28|January 2012|Anticipated|2012-01-31|January 2010|Anticipated|2010-01-31||Interventional|||Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)|Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis|Unknown status|Recruiting|Phase 3|90|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-06-01 04:58:23.333634|2018-06-01 04:58:23.333634
NCT00103779|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2014-12-17|2005-02-14|2005-02-15|Estimate|||||||2014-12-17|2014-12-18|Estimate|December 2004||2004-12-31|December 2014|2014-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma|A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Non-Hodgkin's Lymphoma|Completed||Phase 1|50|Actual|Seattle Genetics, Inc.||1|||t||||f||||||||||2018-06-01 04:58:23.419075|2018-06-01 04:58:23.419075
NCT00103766|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2006-07-31|2005-02-14|2005-02-15|Estimate|||||||2006-07-31|2006-08-01|Estimate|October 2004||2004-10-31|July 2006|2006-07-31||||||||Interventional|||Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion|Randomized Comparison of Two Dose and Frequency Regimens of Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion|Unknown status|Recruiting|N/A|75||O'Brien, Jeana D., MD, FACP, FCCP|||||||||||||||||||2018-06-01 04:58:23.493881|2018-06-01 04:58:23.493881
NCT00103753|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2005-06-23|2005-02-14|2005-02-15|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2004||2004-05-31|February 2005|2005-02-28|June 2005||2005-06-30|||||Interventional|||Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major|A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance|Unknown status|Active, not recruiting|Phase 4|65||Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-06-01 04:58:23.557211|2018-06-01 04:58:23.557211
NCT00103740|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|2012-04-05||2012-05-29|2005-02-14|2005-02-15|Estimate|2012-04-05|2012-05-02|Estimate||||2012-05-29|2012-06-04|Estimate|April 2002||2002-04-30|May 2012|2012-05-31|April 2011|Actual|2011-04-30|December 2003|Actual|2003-12-31||Interventional|||Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period|Randomized, Double-Blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observation Period|Completed||Phase 3|185|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:58:23.645554|2018-06-01 04:58:23.645554
NCT00103727|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2015-04-27|2005-02-14|2005-02-15|Estimate|||||||2015-04-27|2015-04-29|Estimate|December 2004||2004-12-31|April 2015|2015-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia|A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia|Completed||Phase 2|282|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 04:58:24.139617|2018-06-01 04:58:24.139617
NCT00103714|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2015-10-19|2005-02-14|2005-02-15|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Cystic Fibrosis Lung Disease|Completed||Phase 2|72|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:58:24.240008|2018-06-01 04:58:24.240008
NCT00103701|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-14|||2011-04-13|2005-02-14|2005-02-15|Estimate|||||||2011-04-13|2011-04-14|Estimate|November 2003||2003-11-30|April 2011|2011-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia|Phase I Study of BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia|Completed||Phase 1|||Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 04:58:24.291566|2018-06-01 04:58:24.291566
NCT00103675|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-11|||2007-02-26|2005-02-11|2005-02-14|Estimate|||||||2007-02-26|2007-02-27|Estimate|September 2004||2004-09-30|February 2007|2007-02-28|February 2007||2007-02-28|||||Interventional|||Sensor Measurement of Acupuncture Needle Manipulation|Acupuncture Needling Torque Sensor|Completed||Phase 1|30||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:58:24.353488|2018-06-01 04:58:24.353488
NCT00103662|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-11|2009-02-02||2014-02-10|2005-02-11|2005-02-14|Estimate|2010-09-08|2010-09-29|Estimate||||2014-02-10|2014-03-13|Estimate|January 2005||2005-01-31|February 2014|2014-02-28|January 2008|Actual|2008-01-31|October 2006|Actual|2006-10-31||Interventional|||Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 6*10^6 CD34+ Cells/kg in Multiple Myeloma Patients for Autologous Transplantation|Completed||Phase 3|302|Actual|Sanofi||2|||f||||f||||||||||2018-06-01 04:58:24.446196|2018-06-01 04:58:24.446196
NCT00103649|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-11|||2008-08-20|2005-02-11|2005-02-14|Estimate|||||||2008-08-20|2008-08-21|Estimate|November 2003||2003-11-30|August 2008|2008-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type|Completed||Phase 3|1306|Actual|Sanofi|||||f||||||||||||||2018-06-01 04:58:25.292837|2018-06-01 04:58:25.292837
NCT00103636|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-11|||2005-06-23|2005-02-11|2005-02-14|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2004||2004-03-31|February 2005|2005-02-28|December 2004||2004-12-31|||||Interventional|||Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change|Peripheral Venous Catheter Trial: 3 Day Versus No Routine Change|Unknown status|Active, not recruiting|Phase 2/Phase 3|200||Royal Brisbane and Women's Hospital|||||f||||||||||||||2018-06-01 04:58:25.551968|2018-06-01 04:58:25.551968
NCT00103623|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-11|||2006-09-18|2005-02-11|2005-02-14|Estimate|||||||2006-09-18|2006-09-19|Estimate|June 2004||2004-06-30|September 2006|2006-09-30|December 2008||2008-12-31|||||Interventional|||The Plenaxis® Experience Study|Incidence of Immediate Onset Systemic Allergic Reactions in Patients Treated With Plenaxis®|Suspended||Phase 4|2000||PRAECIS Pharmaceuticals Inc.|||||||||||||||||||2018-06-01 04:58:25.624666|2018-06-01 04:58:25.624666
NCT00103610|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-11|2009-02-06||2014-02-10|2005-02-11|2005-02-14|Estimate|2010-09-08|2010-09-29|Estimate||||2014-02-10|2014-03-13|Estimate|January 2005||2005-01-31|February 2014|2014-02-28|December 2007|Actual|2007-12-31|July 2006|Actual|2006-07-31||Interventional|||Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 5 * 10^6 CD34+ Cells/kg in Non-Hodgkin's Lymphoma Patients for Autologous Transplantation|Completed||Phase 3|298|Actual|Sanofi||2|||||||||||||||||2018-06-01 04:58:25.791147|2018-06-01 04:58:25.791147
NCT00103597|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-11|||2005-10-19|2005-02-11|2005-02-14|Estimate|||||||2005-10-19|2005-10-20|Estimate|January 2005||2005-01-31|July 2005|2005-07-31|September 2005||2005-09-30|||||Interventional|||Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy|Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy|Completed||Phase 1|50||Royal Brisbane and Women's Hospital|||||f||||||||||||||2018-06-01 04:58:26.628138|2018-06-01 04:58:26.628138
NCT00103584|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-10|||2007-01-11|2005-02-10|2005-02-11|Estimate|||||||2007-01-11|2007-01-15|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|July 2006||2006-07-31|||||Interventional|||Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers|A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1/Phase 2|150||VaxGen|||||||||||||||||||2018-06-01 04:58:26.680382|2018-06-01 04:58:26.680382
NCT00103571|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-10|||2007-11-05|2005-02-10|2005-02-11|Estimate|||||||2007-11-05|2007-11-06|Estimate|July 2004||2004-07-31|November 2007|2007-11-30|August 2006|Actual|2006-08-31|||||Interventional|||Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia|Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia|Completed||Phase 4|600||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:58:26.728532|2018-06-01 04:58:26.728532
NCT00103558|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-10||2015-09-17|2015-09-17|2005-02-10|2005-02-11|Estimate||||2015-09-17|2015-10-02|Estimate|2015-09-17|2015-10-02|Estimate|March 2004||2004-03-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)|A Phase I/II Study of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|31|Actual|Biogen|||||f||||t||||||||||2018-06-01 04:58:26.787391|2018-06-01 04:58:26.787391
NCT00103545|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-10|||2006-09-29|2005-02-10|2005-02-11|Estimate|||||||2006-09-29|2006-10-02|Estimate|July 2003||2003-07-31|February 2006|2006-02-28|August 2004||2004-08-31|||||Interventional|||Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response|A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer|Completed||Phase 1/Phase 2|36||AGO Study Group|||||f||||||||||||||2018-06-01 04:58:26.850117|2018-06-01 04:58:26.850117
NCT00103532|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-09|||2017-02-27|2005-02-09|2005-02-10|Estimate|||||||2017-02-27|2017-03-01|Actual|March 2005||2005-03-31|February 2016|2016-02-29|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth|Motivational Enhancement to Promote Health and Reduce Risk in HIV-Infected Youth|Completed||N/A|225|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-06-01 04:58:26.912705|2018-06-01 04:58:26.912705
NCT00102219|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-25|||2007-11-28|2005-01-25|2005-01-26|Estimate|||||||2007-11-28|2007-11-30|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|October 2007|Actual|2007-10-31|||||Interventional|||A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer|A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer|Completed||Phase 2|77|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 04:58:51.240648|2018-06-01 04:58:51.240648
NCT00103519|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-09|||2013-03-27|2005-02-09|2005-02-10|Estimate|||||||2013-03-27|2013-03-29|Estimate|December 2004||2004-12-31|November 2006|2006-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of DITPA in Patients With Congestive Heart Failure|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients With NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels|Terminated||Phase 2|86|Actual|Titan Pharmaceuticals||3||Study terminated for reasons unrelated to safety or efficacy.|f||||||||||||||2018-06-01 04:58:27.074485|2018-06-01 04:58:27.074485
NCT00103506|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-09|2015-05-08||2015-09-28|2005-02-09|2005-02-10|Estimate|2015-05-08|2015-05-25|Estimate||||2015-09-28|2015-10-19|Estimate|December 2004||2004-12-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma|A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma|Completed||Phase 3|646|Actual|Janssen Research & Development, LLC|Study stopped in terms of primary endpoint based on its results at planned interim analysis (28 Apr 2006). However, Long-term follow-up for survival continued until 16 May 2014.|2|||f||||t||||||||||2018-06-01 04:58:27.223855|2018-06-01 04:58:27.223855
NCT00103493|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-09|||2010-11-19|2005-02-09|2005-02-10|Estimate|||||||2010-11-19|2010-11-22|Estimate|October 2004||2004-10-31|July 2009|2009-07-31|August 2005|Actual|2005-08-31|||||Interventional|||Oral Health Education Program|Efficacy of a Tailored Oral Health Education Program|Completed||Phase 3|1021|Actual|Temple University|||||f||||||||||||||2018-06-01 04:58:28.419166|2018-06-01 04:58:28.419166
NCT00103467|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-08|||2005-06-23|2005-02-08|2005-02-09|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2003||2003-06-30|February 2005|2005-02-28||||||||Interventional|||Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine|A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine|Completed||Phase 1|100||VaxGen|||||||||||||||||||2018-06-01 04:58:28.471229|2018-06-01 04:58:28.471229
NCT00103454|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-08|||2016-09-15|2005-02-08|2005-02-09|Estimate|||||||2016-09-15|2016-09-19|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 4 Weeks in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|288|Actual|GlaxoSmithKline||1|||f||||||||||||Yes||2018-06-01 04:58:28.526623|2018-06-01 04:58:28.526623
NCT00103428|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-08|||2006-01-31|2005-02-08|2005-02-09|Estimate|||||||2006-01-31|2006-02-02|Estimate|August 2004||2004-08-31|January 2006|2006-01-31||||||||Interventional|||Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase 1/2a Dose-Escalation Trial of Intravenous CG7870 in Combination With Docetaxel in Chemotherapy-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer|Terminated||Phase 1/Phase 2|69||Cell Genesys|||||||||||||||||||2018-06-01 04:58:28.643955|2018-06-01 04:58:28.643955
NCT00103415|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-08|||2006-07-12|2005-02-08|2005-02-09|Estimate|||||||2006-07-12|2006-07-13|Estimate|February 2005||2005-02-28|February 2005|2005-02-28|February 2007||2007-02-28|||||Interventional|||Trial Investigating the Effect of Different Exercise Forms on Depression|Randomized Clinical Trial Investigating the Effect of Different Exercise Forms on Depression|Unknown status|Active, not recruiting|N/A|300||Demostudiet|||||f||||||||||||||2018-06-01 04:58:28.702273|2018-06-01 04:58:28.702273
NCT00103402|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2011-04-25|2005-02-07|2005-02-08|Estimate|||||||2011-04-25|2011-04-26|Estimate|February 2005||2005-02-28|April 2011|2011-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome|A Randomized Multicenter Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients|Completed||Phase 3|270|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 04:58:28.829965|2018-06-01 04:58:28.829965
NCT00103389|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2016-08-30|2005-02-07|2005-02-08|Estimate|||||||2016-08-30|2016-08-31|Estimate|February 2004||2004-02-29|August 2016|2016-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer|Completed||Phase 2|98|Actual|Medigen Biotechnology Corporation||2|||f||||f||||||||No||2018-06-01 04:58:28.925226|2018-06-01 04:58:28.925226
NCT00103376|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2012-04-26|2005-02-07|2005-02-08|Estimate|||||||2012-04-26|2012-04-30|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer|VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer|Completed||Phase 2|42|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 04:58:29.022005|2018-06-01 04:58:29.022005
NCT00103363|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2014-05-05|2005-02-07|2005-02-08|Estimate|||||||2014-05-05|2014-05-07|Estimate|February 1993||1993-02-28|May 2014|2014-05-31|February 1994|Actual|1994-02-28|February 1994|Actual|1994-02-28||Interventional|||Sputum Cytology in Screening Heavy Smokers For Lung Cancer|Lung Cancer Screening and Tissue Procurement|Completed||Phase 2|3270|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-06-01 04:58:29.094979|2018-06-01 04:58:29.094979
NCT00103350|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2008-05-16|2005-02-07|2005-02-08|Estimate|||||||2008-05-16|2008-05-20|Estimate|January 2005||2005-01-31|May 2008|2008-05-31|January 2008|Actual|2008-01-31|December 2006|Actual|2006-12-31||Interventional|||Safety of TG100-115 for Heart Attack Treated With Angioplasty|A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Prospective Study to Evaluate the Safety and Potential Efficacy of Single, Increasing Doses of TG100-115 in Subjects Undergoing Percutaneous Coronary Intervention for Acute Anterior ST Elevation Myocardial Infarction|Completed||Phase 1/Phase 2|100||TargeGen|||||f||||||||||||||2018-06-01 04:58:29.148601|2018-06-01 04:58:29.148601
NCT00103337|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-02-27|2005-02-07|2005-02-08|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2005||2005-01-31|February 2013|2013-02-28||||October 2007|Actual|2007-10-31||Interventional|||Cilengitide in Treating Patients With Metastatic Prostate Cancer|Phase II Evaluation of EMD121974 (NSC 707544, Cilengitide) in Asymptomatic Patients With Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|106|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:58:29.193792|2018-06-01 04:58:29.193792
NCT00103324|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-01-16|2005-02-07|2005-02-08|Estimate|||||||2013-01-16|2013-01-17|Estimate|December 2004||2004-12-31|January 2013|2013-01-31||||May 2007|Actual|2007-05-31||Interventional|||S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer|Phase II Study of GW572016 (NSC-727989) as First Line Therapy in Patients With Advanced or Metastatic Gastric Cancer|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:58:29.251857|2018-06-01 04:58:29.251857
NCT00103311|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|2015-02-13||2015-02-13|2005-02-07|2005-02-08|Estimate|2015-02-13|2015-03-02|Estimate||||2015-02-13|2015-03-02|Estimate|January 2005||2005-01-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|January 2010|Actual|2010-01-31||Interventional|||SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer|A Randomized Phase II Non-Comparative Study of SB-715992 Given Weekly or Every Three Weeks in Advanced or Metastatic Colorectal Cancer|Completed||Phase 2|64|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:58:29.324693|2018-06-01 04:58:29.324693
NCT00103298|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-06-18|2005-02-07|2005-02-08|Estimate|||||||2013-06-18|2013-06-20|Estimate|December 2004||2004-12-31|February 2006|2006-02-28|July 2006|Actual|2006-07-31|||||Interventional|||Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer|A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:30.598288|2018-06-01 04:58:30.598288
NCT00103285|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2016-05-26|2005-02-07|2005-02-08|Estimate|||||||2016-05-26|2016-05-30|Estimate|April 2005||2005-04-30|May 2016|2016-05-31||||December 2013|Actual|2013-12-31||Interventional|||Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)|Unknown status|Active, not recruiting|Phase 3|5377|Actual|Children's Oncology Group||8|||f||||t||||||||||2018-06-01 04:58:30.735082|2018-06-01 04:58:30.735082
NCT00103272|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-06-03|2005-02-07|2005-02-08|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2005||2005-04-30|June 2013|2013-06-30||||April 2008|Actual|2008-04-30||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer|A Phase I Study of PS-341 (Velcade, Bortezomib) in Combination With 17-allylamino-17-demethoxygeldanamycin (17-AAG) in Patients With Relapsed or Refractory Hematologic Malignancies|Terminated||Phase 1|74|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:58:31.245082|2018-06-01 04:58:31.245082
NCT00103259|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|2012-11-24||2014-05-07|2005-02-07|2005-02-08|Estimate|2012-11-27|2012-12-27|Estimate||||2014-05-07|2014-05-23|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|71|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 04:58:31.369467|2018-06-01 04:58:31.369467
NCT00103246|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2011-01-19|2005-02-07|2005-02-08|Estimate|||||||2011-01-19|2011-01-20|Estimate|September 2004||2004-09-30|January 2011|2011-01-31|August 2010|Actual|2010-08-31|December 2008|Actual|2008-12-31||Interventional|||Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides|Phase I Clinical Trial Using Topical Silicon Phthalocyanine (Pc 4) Photodynamic Therapy (PDT) for the Treatment of Pre-Malignant and Malignant Skin Conditions|Completed||Phase 1|43|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 04:58:31.841698|2018-06-01 04:58:31.841698
NCT00103233|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-06-21|2005-02-07|2005-02-08|Estimate|||||||2013-06-21|2013-06-24|Estimate|December 2004||2004-12-31|August 2005|2005-08-31|April 2006|Actual|2006-04-30|||||Interventional|||Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer|A Randomized Study of Weekly Vinorelbine (Navelbine®) Alone or in Combination With Trastuzumab (Herceptin®) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III|Completed||Phase 3|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:58:31.938543|2018-06-01 04:58:31.938543
NCT00103220|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-12-10|2005-02-07|2005-02-08|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2004||2004-11-30|December 2013|2013-12-31||||February 2007|Actual|2007-02-28||Interventional|||SJG-136 in Treating Patients With Advanced Solid Tumors|A Phase I Study With SJG-136 (NSC #694501) in Patients With an Advanced Solid Tumor|Completed||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:58:32.056395|2018-06-01 04:58:32.056395
NCT00103207|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|2012-12-03||2012-12-03|2005-02-07|2005-02-08|Estimate|2012-12-03|2013-01-04|Estimate||||2012-12-03|2013-01-04|Estimate|August 2005||2005-08-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|April 2010|Actual|2010-04-30||Interventional|||Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer|Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features|Completed||Phase 2|72|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 04:58:32.171001|2018-06-01 04:58:32.171001
NCT00103194|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|2011-11-03||2014-09-19|2005-02-07|2005-02-08|Estimate|2012-03-19|2012-04-13|Estimate||||2014-09-19|2014-09-30|Estimate|September 2005||2005-09-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer|Phase II Trial of GW572016 in Patients With Recurrent Prostate Cancer as Evident by a Rising PSA|Completed||Phase 2|49|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:58:32.673602|2018-06-01 04:58:32.673602
NCT00103181|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2017-05-12|2005-02-07|2005-02-08|Estimate|||||||2017-05-12|2017-05-16|Actual|March 2005||2005-03-31|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer|A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer|Active, not recruiting||N/A|4216|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 04:58:32.953691|2018-06-01 04:58:32.953691
NCT00103168|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-10-28|2005-02-07|2005-02-08|Estimate|||||||2013-10-28|2013-10-29|Estimate|December 2004||2004-12-31|October 2013|2013-10-31||||October 2008|Actual|2008-10-31||Interventional|||Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor|Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib Mesylate (Glivec) Versus No Further Therapy After Complete Surgery|Unknown status|Active, not recruiting|Phase 3|750|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:58:33.674464|2018-06-01 04:58:33.674464
NCT00103155|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2013-09-19|2005-02-07|2005-02-08|Estimate|||||||2013-09-19|2013-09-20|Estimate|September 2004||2004-09-30|August 2005|2005-08-31||||||||Interventional|||Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer|Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:58:33.827792|2018-06-01 04:58:33.827792
NCT00103142|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|2014-01-16||2015-10-11|2005-02-07|2005-02-08|Estimate|2014-02-28|2014-04-07|Estimate||||2015-10-11|2015-10-14|Estimate|February 2005||2005-02-28|October 2015|2015-10-31|March 2013|Actual|2013-03-31|June 2009|Actual|2009-06-30||Interventional||37 PANVAC-V + PANVAC-F + DC arm patients and 37 PANVAC-V + PANVAC-F + GM-CSF arm. One participant in PANVAC-V + PANVAC-F + DC Arm was consented and contributed baseline data, but was not considered to have started or enrolled in the study patients signed consent.|Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer|A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma|Completed||Phase 2|74|Actual|Duke University||2|||f||||t||||||||||2018-06-01 04:58:33.907976|2018-06-01 04:58:33.907976
NCT00103116|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|2013-11-07||2017-03-30|2005-02-07|2005-02-08|Estimate|2017-03-30|2017-04-04|Actual||||2017-03-30|2017-04-04|Actual|October 2004||2004-10-31|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer|Autologous Dendritic Cell Vaccines in Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|32|Actual|University of Kentucky||1|||f||||f||||||||||2018-06-01 04:58:34.176125|2018-06-01 04:58:34.176125
NCT00103103|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2010-10-11|2005-02-07|2005-02-08|Estimate|||||||2010-10-11|2010-10-13|Estimate|March 2005||2005-03-31|October 2010|2010-10-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer|A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma|Terminated||Phase 2|||California Cancer Consortium|||||f||||||||||||||2018-06-01 04:58:34.30494|2018-06-01 04:58:34.30494
NCT00103090|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2012-11-12|2005-02-07|2005-02-08|Estimate|||||||2012-11-12|2012-11-14|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|November 2006|Actual|2006-11-30|January 2006|Actual|2006-01-31||Interventional|||Fenretinide and Lonafarnib in Treating Patients With Advanced or Recurrent Head and Neck Cancer|A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||1||Slow Accrual.|f||||f||||||||||2018-06-01 04:58:34.366134|2018-06-01 04:58:34.366134
NCT00103051|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2012-07-13|2005-02-07|2005-02-08|Estimate|||||||2012-07-13|2012-07-16|Estimate|December 2004||2004-12-31|July 2012|2012-07-31||||November 2005|Actual|2005-11-30||Interventional|||Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer|Phase II Study With Gefitinib (Sequentially) Following Gemcitabine/Cisplatin as Induction Regimen for Patients With Stage IIIA N2 NSCLC|Completed||Phase 2|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:58:34.468995|2018-06-01 04:58:34.468995
NCT00103038|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-07|||2017-04-19|2005-02-07|2005-02-08|Estimate|||||||2017-04-19|2017-04-21|Actual|February 2004||2004-02-29|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases|NCI-Sponsored Multi-Disciplinary Study for MR Imaging of Intravenous Superparamagnetic Crystalline Particle Ferumoxytol in Primary High-Grade Brain Tumors and/or Cerebral Metastases|Active, not recruiting||N/A|155|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 04:58:34.530993|2018-06-01 04:58:34.530993
NCT00103025|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-05|||2017-06-30|2005-02-05|2005-02-07|Estimate|||||||2017-06-30|2017-07-02|Actual|February 4, 2005||2005-02-04|May 10, 2011|2011-05-10|May 10, 2011|Actual|2011-05-10|May 10, 2011|Actual|2011-05-10||Interventional|||Nitrite Infusion in Healthy Volunteers|Evaluation of the Mechanism of NO Formation and Pharmacokinetics of Long-Term Intravenous Nitrite Infusion in Healthy Volunteers|Completed||Phase 1|12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:34.669273|2018-06-01 04:58:34.669273
NCT00103012|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-05|2011-12-12||2012-03-13|2005-02-05|2005-02-07|Estimate|2012-03-13|2012-04-16|Estimate||||2012-03-13|2012-04-16|Estimate|January 2005||2005-01-31|March 2012|2012-03-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers|The Influence of Concurrent Administration of Echinacea Purpurea, Ginkgo Biloba, or Panax Ginseng on the Steady State Pharmacokinetic Profile of Lopinavir/Ritonavir in Healthy Volunteers|Completed||Phase 4|47|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||||2018-06-01 04:58:34.743438|2018-06-01 04:58:34.743438
NCT00102999|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2017-06-30|2005-02-04|2005-02-07|Estimate|||||||2017-06-30|2017-07-02|Actual|January 31, 2005||2005-01-31|January 22, 2009|2009-01-22|January 22, 2009||2009-01-22|||||Observational|||Brain Function in Focal Dystonia|Impaired Motor Learning and LTP/LTD-like Plasticity in Dystonia, Are Associated With Abnormal Modulation of Cortical Excitability by Somatosensory Volleys|Completed|||118||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:35.086529|2018-06-01 04:58:35.086529
NCT00102986|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2015-12-02|2005-02-04|2005-02-07|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2005||2005-10-31|December 2015|2015-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women|Sex Differences in Lopinavir/Ritonavir Pharmacokinetics Among HIV-1-Infected Men and Women|Completed||N/A|116|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:58:35.151181|2018-06-01 04:58:35.151181
NCT00102973|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2012-05-30|2005-02-04|2005-02-07|Estimate|||||||2012-05-30|2012-05-31|Estimate|December 2004||2004-12-31|June 2006|2006-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer|Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]|Completed||Phase 3|244|Actual|Telik||2|||f||||||||||||||2018-06-01 04:58:35.296306|2018-06-01 04:58:35.296306
NCT00102960|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2014-07-21|2005-02-04|2005-02-07|Estimate|||||||2014-07-21|2014-07-22|Estimate|July 2005||2005-07-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth|A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting|Completed||Phase 3|451|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 04:58:35.722525|2018-06-01 04:58:35.722525
NCT00102947|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2016-07-22|2005-02-04|2005-02-07|Estimate|||||||2016-07-22|2016-07-25|Estimate|January 2005||2005-01-31|July 2016|2016-07-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections|An Open Label Phase 4 Trial to Further Evaluate the Pharmacokinetic Profile of Intravenous Daptomycin, and a Comparison of the Safety and Efficacy of Daptomycin Versus Comparator in the Treatment of Adult Patients With Renal Impairment and Complicated Skin and Skin Structure Infections Due, at Least in Part, to Gram-positive Bacteria|Terminated||Phase 4|72||Cubist Pharmaceuticals LLC|||||||||||||||||||2018-06-01 04:58:35.88543|2018-06-01 04:58:35.88543
NCT00102934|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2008-09-16|2005-02-04|2005-02-07|Estimate|||||||2008-09-16|2008-09-17|Estimate|March 2003||2003-03-31|September 2008|2008-09-30|March 2009|Anticipated|2009-03-31|December 2005|Actual|2005-12-31||Interventional|||Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus|Treatment Intensification in HIV-1 Patients With Multi-Drug Resistant Virus|Unknown status|Active, not recruiting|N/A|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 04:58:35.962706|2018-06-01 04:58:35.962706
NCT00102921|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2006-03-12|2005-02-04|2005-02-07|Estimate|||||||2006-03-12|2006-03-14|Estimate|August 2004||2004-08-31|March 2006|2006-03-31|December 2005||2005-12-31|||||Interventional|||Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn’s Disease|Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn’s Disease|Completed||Phase 2|70||ChemoCentryx|||||||||||||||||||2018-06-01 04:58:36.043495|2018-06-01 04:58:36.043495
NCT00102908|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-04|||2008-09-25|2005-02-04|2005-02-07|Estimate|||||||2008-09-25|2008-09-26|Estimate|May 2005||2005-05-31|September 2008|2008-09-30|December 2009|Anticipated|2009-12-31|October 2007|Anticipated|2007-10-31||Interventional|||Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density|Bisphosphonate Therapy for HIV-Associated Osteopenia|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 04:58:36.121835|2018-06-01 04:58:36.121835
NCT00102895|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-03|||2010-08-26|2005-02-03|2005-02-04|Estimate|||||||2010-08-26|2010-08-27|Estimate|April 2005||2005-04-30|August 2010|2010-08-31|September 2005|Actual|2005-09-30|||||Interventional|||A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer|An Open-Label, Multi-Center, Phase 2 Study Of Cp 724,714 In Patients With Her2 Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy For Metastatic Disease And Is Previously Untreated With A Her2 Inhibitor|Terminated||Phase 2|25||Pfizer||||See Detailed Description|f||||||||||||||2018-06-01 04:58:36.291232|2018-06-01 04:58:36.291232
NCT00102882|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-03|||2017-02-02|2005-02-03|2005-02-04|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2004||2004-10-31|February 2017|2017-02-28|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate|Randomized, Double-Blind Comparison of Advair 100/50 BID vs Salmeterol BID vs Albuterol QID in Subjects With ARG/ARG Genotype 12 Years of Age and Older With Presistent Asthma on Short-Acting Beta2-Agonists Alone|Completed||Phase 4|547|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:58:36.402353|2018-06-01 04:58:36.402353
NCT00102869|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-03|||2013-10-04|2005-02-03|2005-02-04|Estimate|||||||2013-10-04|2013-10-07|Estimate|January 2005||2005-01-31|June 2008|2008-06-30|December 2008|Actual|2008-12-31|February 2007|Actual|2007-02-28||Interventional|||Dopaminergic Enhancement of Learning and Memory in Aphasia|Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia)|Completed||Phase 4|12|Actual|University Hospital Muenster|||||f||||t||||||||||2018-06-01 04:58:36.6164|2018-06-01 04:58:36.6164
NCT00102856|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-03|||2010-06-23|2005-02-03|2005-02-04|Estimate|||||||2010-06-23|2010-06-24|Estimate|January 2005||2005-01-31|September 2006|2006-09-30|June 2006||2006-06-30|||||Interventional|||Neuromodulation and Language Acquisition (Stage Ib)|Neuromodulation and Language Acquisition (KS-Neuromod_01, Stage Ib)|Suspended||Phase 4|60||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:58:36.765105|2018-06-01 04:58:36.765105
NCT00102843|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-03|||2005-08-02|2005-02-03|2005-02-04|Estimate|||||||2005-08-02|2005-08-03|Estimate|October 2002||2002-10-31|August 2005|2005-08-31|June 2003||2003-06-30|||||Interventional|||Effect of Betaine and Folic Acid on Vascular Function in Healthy Humans|Effect of Lowering of Fasting Plasma Homocysteine Concentrations Through Supplementation With Betaine or Folic Acid on Vascular Function in Healthy Volunteers|Completed||N/A|40||Wageningen Centre for Food Sciences|||||f||||||||||||||2018-06-01 04:58:36.865721|2018-06-01 04:58:36.865721
NCT00102830|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-03|||2010-08-19|2005-02-03|2005-02-04|Estimate|||||||2010-08-19|2010-08-20|Estimate||||August 2010|2010-08-31||||||||Interventional|||Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors|A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of AMG 386 in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|||Amgen|||||||||||||||||||2018-06-01 04:58:36.962233|2018-06-01 04:58:36.962233
NCT00102817|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2017-01-17|2005-02-01|2005-02-02|Estimate|||||||2017-01-17|2017-01-18|Estimate|May 2003||2003-05-31|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children|Somatropin (Norditropin) in Children With Growth Failure Associated With ICF Deficiency.|Completed||Phase 3|149|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:58:37.055874|2018-06-01 04:58:37.055874
NCT00102804|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|2014-12-17||2014-12-17|2005-02-01|2005-02-02|Estimate|2014-12-17|2014-12-29|Estimate||||2014-12-17|2014-12-29|Estimate|March 2005||2005-03-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|August 2007|Actual|2007-08-31||Interventional||Participants who signed the ICF and completed the randomized process are reported according to the treatment arm to which they were randomized.|Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)|A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|663|Actual|Eli Lilly and Company|Four participants (pts) assigned to placebo received pemetrexed; pts analyzed for efficacy as randomized. Three treated pts did not sign ICF, 1 treated pt signed ICF but did not complete entire randomization process; pts excluded from all analyses.|2|||f||||t||||||||||2018-06-01 04:58:37.280509|2018-06-01 04:58:37.280509
NCT00102791|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2008-03-26|2005-02-01|2005-02-02|Estimate|||||||2008-03-26|2008-03-27|Estimate|February 2005||2005-02-28|September 2007|2007-09-30|June 2007|Actual|2007-06-30|||||Interventional|ASSERT||A Stratified Sickle Event Randomized Trial (ASSERT)|A Phase III Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 With or Without HU Therapy in Patients With Sickle Cell Disease Who Have Had =>2 Acute Sickle-Related Painful Crises Within the Preceding 12 Months|Terminated||Phase 3|297|Actual|Icagen||||Because of the low probability of achieving the primary endpoint.|f||||t||||||||||2018-06-01 04:58:39.094538|2018-06-01 04:58:39.094538
NCT00102778|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2017-05-25|2005-02-01|2005-02-02|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2004||2004-12-31|May 2017|2017-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||GW873140 In Combination With Kaletra In HIV Infected Subjects|A Phase IIb, 96 Week, Randomized, Open-label Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination With Kaletra (Lopinavir and Ritonavir) in HIV-1 Infected Antiretroviral Therapy naïve Subjects|Terminated||Phase 2|175||ViiV Healthcare|||||||||||||||||||2018-06-01 04:58:39.356266|2018-06-01 04:58:39.356266
NCT00102765|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2017-01-16|2005-02-01|2005-02-02|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2004||2004-11-30|January 2017|2017-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study Of Asthma In Patients Of African Descent|A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmeterol 100/50mcg DISKUS® BID or Fluticasone Propionate 100mcg DISKUS® BID Alone|Completed||Phase 4|479|Actual|GlaxoSmithKline|||||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 04:58:39.608292|2018-06-01 04:58:39.608292
NCT00102752|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2009-04-28|2005-02-01|2005-02-02|Estimate|||||||2009-04-28|2009-04-30|Estimate|December 2004||2004-12-31|April 2009|2009-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer|A Phase 1/2 Dose-Escalation Study of the Safety, Efficacy and Pharmacokinetics of Glufosfamide in Combination With Gemcitabine in Advanced Solid Tumors and Pancreatic Adenocarcinoma|Completed||Phase 1/Phase 2|47||Threshold Pharmaceuticals|||||||||||||||||||2018-06-01 04:58:39.894553|2018-06-01 04:58:39.894553
NCT00102739|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2013-04-11|2005-02-01|2005-02-02|Estimate|||||||2013-04-11|2013-04-15|Estimate|February 2005||2005-02-28|November 2012|2012-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)|See Detailed Description|Completed||Phase 2|99|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 04:58:40.002499|2018-06-01 04:58:40.002499
NCT00102726|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2017-03-21|2005-02-01|2005-02-02|Estimate|||||||2017-03-21|2017-03-23|Actual|February 2005||2005-02-28|March 2017|2017-03-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy|Completed||Phase 2|183|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 04:58:40.181573|2018-06-01 04:58:40.181573
NCT00102713|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2007-05-17|2005-02-01|2005-02-02|Estimate|||||||2007-05-17|2007-05-21|Estimate|February 2005||2005-02-28|May 2007|2007-05-31||||||||Interventional|||A Study for Treatment of Partial Seizures in Children|An Open Label Study for Treatment of Partial Seizures in Children|Completed||Phase 3|50||Abbott|||||||||||||||||||2018-06-01 04:58:40.38253|2018-06-01 04:58:40.38253
NCT00102700|ClinicalTrials.gov processed this data on May 31, 2018|2005-02-01|||2009-04-28|2005-02-01|2005-02-02|Estimate|||||||2009-04-28|2009-04-29|Estimate|January 2005||2005-01-31|April 2009|2009-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer|A Phase II Study of ARQ 501 in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|66||ArQule|||||||||||||||||||2018-06-01 04:58:40.552952|2018-06-01 04:58:40.552952
NCT00102687|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-31|2010-05-03||2010-06-22|2005-01-31|2005-02-01|Estimate|2010-05-03|2010-05-28|Estimate||||2010-06-22|2010-07-07|Estimate|January 2005||2005-01-31|June 2010|2010-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes|A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes|Completed||Phase 2|151|Actual|Celgene||5|||f||||f||||||||||2018-06-01 04:58:40.739333|2018-06-01 04:58:40.739333
NCT00102674|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-31|||2011-08-15|2005-01-31|2005-02-01|Estimate|||||||2011-08-15|2011-08-16|Estimate|March 2005||2005-03-31|March 2005|2005-03-31|May 2005||2005-05-31|||||Interventional|||Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor|The Pharmacokinetics and Pharmacodynamics of a Cangrelor Bolus Plus Infusion in Healthy Volunteers|Completed||Phase 1|40||The Medicines Company|||||||||||||||||||2018-06-01 04:58:43.796544|2018-06-01 04:58:43.796544
NCT00102661|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-31|||2012-07-27|2005-01-31|2005-02-01|Estimate|||||||2012-07-27|2012-07-31|Estimate|October 2002||2002-10-31|July 2012|2012-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia|Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia|Completed||Phase 2|10|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:58:43.878143|2018-06-01 04:58:43.878143
NCT00102648|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-31|||2018-05-02|2005-01-31|2005-02-01|Estimate|||||||2018-05-02|2018-05-07|Actual|December 2004|Actual|2004-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sarasar and Temodar for Glioblastoma Multiforme Patients|Phase I/Ib Study of Sarasar and Temodar in Patients With Recurrent or Temodar-Refractory Glioblastoma Multiforme|Active, not recruiting||Phase 1|35|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 04:58:43.971505|2018-06-01 04:58:43.971505
NCT00102635|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-31|||2012-07-27|2005-01-31|2005-02-01|Estimate|||||||2012-07-27|2012-07-31|Estimate|January 2005||2005-01-31|July 2012|2012-07-31|November 2006|Actual|2006-11-30|January 2006|Actual|2006-01-31||Interventional|||4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||t||||||||||2018-06-01 04:58:44.091085|2018-06-01 04:58:44.091085
NCT00102622|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-31|||2014-06-04|2005-01-31|2005-02-01|Estimate|||||||2014-06-04|2014-06-06|Estimate|December 2004||2004-12-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer|Phase I of Phase I/II Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer|Terminated||Phase 1|18|Actual|M.D. Anderson Cancer Center||2||Phase I/II study that did not progress to Phase II due to low accrual.|f||||t||||||||||2018-06-01 04:58:44.203442|2018-06-01 04:58:44.203442
NCT00102609|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-31|||2013-01-09|2005-01-31|2005-02-01|Estimate|||||||2013-01-09|2013-01-10|Estimate|April 2005||2005-04-30|January 2013|2013-01-31|October 2007|Actual|2007-10-31|||||Interventional|||A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma|A Phase I Study to Determine the Dose of the Combination of Yondelis and Doxorubicin for Which Neutropenia is Manageable With the Support of Granulocyte-Colony Stimulation Factor in Subjects With Recurrent or Persistent Soft Tissue Sarcoma|Completed||Phase 1|41|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 04:58:45.066228|2018-06-01 04:58:45.066228
NCT00101855|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-14|||2005-06-23|2005-01-14|2005-01-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2003||2003-10-31|January 2005|2005-01-31|June 2006||2006-06-30|||||Interventional|||Can Parental Activation Over the Internet Improve Pediatric Preventive Care?|Parent Initiated Prevention Program|Unknown status|Active, not recruiting|N/A|2000||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-06-01 04:58:58.894997|2018-06-01 04:58:58.894997
NCT00102596|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-30|2010-11-10||2012-01-31|2005-01-29|2005-01-31|Estimate|2012-01-31|2012-02-01|Estimate||||2012-01-31|2012-02-01|Estimate|January 2005||2005-01-31|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor|Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor|Completed||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)|Enrollment to study was ended early, as evidence became available, that a metabolite of the study substance promised significantly higher feasibility for treatment in ET.||||f||||f||||||||||2018-06-01 04:58:45.231182|2018-06-01 04:58:45.231182
NCT00102583|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2017-06-30|2005-01-28|2005-01-31|Estimate|||||||2017-06-30|2017-07-02|Actual|October 14, 2004||2004-10-14|March 15, 2011|2011-03-15|March 15, 2011|Actual|2011-03-15|March 15, 2011|Actual|2011-03-15||Interventional|||Cyclosporine Implant for Ocular Graft-Versus-Host Disease|A Phase I Clinical Trial to Study the Safety of a Sustained-Release Subconjunctival Cyclosporine Implant for Ocular Graft-vs-Host Disease (GVHD1)|Completed||Phase 1|4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:45.681872|2018-06-01 04:58:45.681872
NCT00102570|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2017-06-30|2005-01-28|2005-01-31|Estimate|||||||2017-06-30|2017-07-02|Actual|January 26, 2005||2005-01-26|August 10, 2010|2010-08-10|August 10, 2010||2010-08-10|||||Observational|||Clinical and Immunological Evaluation of Children With Allergies|Clinical and Immunological Evaluation of Children With Allergic Disease|Completed|||270|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:45.753661|2018-06-01 04:58:45.753661
NCT00102557|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2008-03-03|2005-01-28|2005-01-31|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2005||2005-01-31|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus|Hydroxychloroquine Versus Clobetasol 0.05% Rinse for the Treatment of Oral Lichen Planus|Completed||Phase 2|74||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:45.815636|2018-06-01 04:58:45.815636
NCT00102544|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2018-05-09|2005-01-28|2005-01-31|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 27, 2005||2005-01-27|December 1, 2017|2017-12-01|January 2, 2022|Anticipated|2022-01-02|January 15, 2020|Anticipated|2020-01-15||Interventional|||Use of Tracking Devices to Locate Abnormalities During Invasive Procedures|Electromagnetic Tracking of Devices During Interventional Procedures|Recruiting||Phase 3|3195|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 04:58:46.028323|2018-06-01 04:58:46.028323
NCT00102531|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|2017-07-05||2017-07-05|2005-01-28|2005-01-31|Estimate|2017-07-05|2017-08-01|Actual||||2017-07-05|2017-08-01|Actual|January 12, 2005|Actual|2005-01-12|July 2017|2017-07-31|March 17, 2008|Actual|2008-03-17|March 2008|Actual|2008-03-31||Interventional|||Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung|Phase Ib/IIa Study of SLIT Cisplatin by Inhalation in the Treatment of Patients Wtih Relapsed/Progressive Osteosarcoma Metastatic to the Lung|Completed||Phase 1/Phase 2|19|Actual|Insmed Incorporated||2|||f|||||t|f||||||Undecided||2018-06-01 04:58:46.146221|2018-06-01 04:58:46.146221
NCT00102518|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|2012-05-16||2012-07-31|2005-01-28|2005-01-31|Estimate|2012-07-31|2012-08-31|Estimate||||2012-07-31|2012-08-31|Estimate|September 2004||2004-09-30|July 2012|2012-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|APEX 241||Aripiprazole Open-Label, Safety and Tolerability Study|A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) in the Treatment of Adolescent Patients With Schizophrenia and Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features|Completed||Phase 3|325|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-06-01 04:58:46.649612|2018-06-01 04:58:46.649612
NCT00102505|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2009-04-02|2005-01-28|2005-01-31|Estimate|||||||2009-04-02|2009-04-03|Estimate|November 2004||2004-11-30|April 2009|2009-04-30||||||||Interventional|||A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)|Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|36||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 04:58:47.034346|2018-06-01 04:58:47.034346
NCT00102492|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2015-04-14|2005-01-28|2005-01-31|Estimate|||||||2015-04-14|2015-04-16|Estimate|October 2004||2004-10-31|April 2015|2015-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Study Of GW679769 In Major Depressive Disorder|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.|Completed||Phase 2|356|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 04:58:47.116506|2018-06-01 04:58:47.116506
NCT00102479|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2006-04-13|2005-01-28|2005-01-31|Estimate|||||||2006-04-13|2006-04-17|Estimate|July 2004||2004-07-31|April 2006|2006-04-30|July 2005||2005-07-31|||||Interventional|||Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents|A Phase II Study to Test PK Tolerability in Children and Adolescents|Completed||Phase 2|||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 04:58:47.251204|2018-06-01 04:58:47.251204
NCT00102466|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29||2013-01-02|2017-05-15|2005-01-28|2005-01-31|Estimate||||2013-01-02|2013-01-04|Estimate|2017-05-15|2017-05-17|Actual|January 2005||2005-01-31|May 2017|2017-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes|Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes|Completed||Phase 3|1007|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:58:47.301179|2018-06-01 04:58:47.301179
NCT00102453|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2011-10-26|2005-01-28|2005-01-31|Estimate|||||||2011-10-26|2011-10-27|Estimate|March 2002||2002-03-31|October 2011|2011-10-31|May 2007|Actual|2007-05-31|July 2006|Actual|2006-07-31||Interventional|||Pentoxifylline in Duchenne Muscular Dystrophy|An Open-Label Pilot Study of Pentoxifylline in Steroid-naive Duchenne Muscular Dystrophy|Completed||Phase 1/Phase 2|17|Actual|Cooperative International Neuromuscular Research Group||1|||f||||t||||||||||2018-06-01 04:58:47.471317|2018-06-01 04:58:47.471317
NCT00102440|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|2009-03-12||2012-01-31|2005-01-28|2005-01-31|Estimate|2009-05-26|2009-07-16|Estimate||||2012-01-31|2012-02-02|Estimate|July 2002||2002-07-31|January 2012|2012-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|FACT||Febuxostat Versus Allopurinol Control Trial in Subjects With Gout|A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout|Completed||Phase 3|760|Actual|Takeda||3|||f||||f||||||||||2018-06-01 04:58:47.624305|2018-06-01 04:58:47.624305
NCT00102427|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2014-01-21|2005-01-28|2005-01-31|Estimate|||||||2014-01-21|2014-01-22|Estimate|July 2000||2000-07-31|January 2014|2014-01-31|May 2003||2003-05-31|||||Interventional|||Improving Quality of Primary Care for Patients With Anxiety and/or Panic Disorders|Improving Quality of Primary Care for Anxiety Disorders|Completed||Phase 2/Phase 3|||University of Pittsburgh|||||f||||||||||||||2018-06-01 04:58:49.366316|2018-06-01 04:58:49.366316
NCT00102414|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2006-11-13|2005-01-28|2005-01-31|Estimate|||||||2006-11-13|2006-11-14|Estimate|September 1999||1999-09-30|January 2005|2005-01-31|November 2004||2004-11-30|||||Interventional|||Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer|A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy|Completed||Phase 3|356||AGO Study Group|||||f||||||||||||||2018-06-01 04:58:49.435186|2018-06-01 04:58:49.435186
NCT00102401|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2007-08-13|2005-01-28|2005-01-31|Estimate|||||||2007-08-13|2007-08-14|Estimate|September 2003||2003-09-30|August 2007|2007-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Internet-Based and Established Dyspnea Self-Management Programs in Chronic Obstructive Pulmonary Disease (COPD) Patients|Comparing the Effects of an Internet-Based to an Established Dyspnea Self-Management Program on Dyspnea, Exercise Behavior, and Pulmonary Exacerbations in Patients With COPD|Completed||N/A|50|Actual|Robert Wood Johnson Foundation|||||f||||||||||||||2018-06-01 04:58:49.5055|2018-06-01 04:58:49.5055
NCT00102388|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2016-11-16|2005-01-28|2005-01-31|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2005||2005-01-31|November 2016|2016-11-30||||March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|1092|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:58:49.652232|2018-06-01 04:58:49.652232
NCT00102375|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-29|||2006-08-03|2005-01-28|2005-01-31|Estimate|||||||2006-08-03|2006-08-04|Estimate|December 1999||1999-12-31|February 2006|2006-02-28|October 2004||2004-10-31|||||Interventional|||Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer|Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan|Completed||Phase 3|900||AGO Study Group|||||f||||||||||||||2018-06-01 04:58:49.75945|2018-06-01 04:58:49.75945
NCT00102362|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-27|||2017-01-11|2005-01-27|2005-01-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2004||2004-12-31|October 2016|2016-10-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Job-Seekers Training for Patients With Drug Dependence - 1|Job Seekers Training for Patients With Drug Dependence|Completed||Phase 3|627||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 04:58:49.97568|2018-06-01 04:58:49.97568
NCT00102349|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-27|||2017-01-11|2005-01-27|2005-01-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2004||2004-11-30|October 2016|2016-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||HIV and HCV Intervention In Drug Treatment Settings - 1|HIV and HCV Intervention in Drug Treatment Settings|Completed||Phase 3|706||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 04:58:50.131904|2018-06-01 04:58:50.131904
NCT00102336|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-27|||2009-05-07|2005-01-27|2005-01-28|Estimate|||||||2009-05-07|2009-05-11|Estimate|April 2005||2005-04-30|May 2009|2009-05-31|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy|A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy|Completed||Phase 3|62|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:58:50.256035|2018-06-01 04:58:50.256035
NCT00102323|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-27|||2009-01-09|2005-01-27|2005-01-28|Estimate|||||||2009-01-09|2009-01-12|Estimate|March 2005||2005-03-31|January 2009|2009-01-31|March 2007|Actual|2007-03-31|September 2006|Actual|2006-09-30||Interventional|||AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy|A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy|Completed||Phase 3|63|Actual|Amgen||2|||f||||||||||||||2018-06-01 04:58:50.367591|2018-06-01 04:58:50.367591
NCT00102310|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-26|||2018-01-08|2005-01-26|2005-01-27|Estimate|||||||2018-01-08|2018-01-10|Actual|March 10, 2004|Actual|2004-03-10|June 2015|2015-06-30|March 11, 2006|Actual|2006-03-11|March 11, 2006|Actual|2006-03-11||Interventional|||YM443 in Subjects With Functional Dyspepsia|A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group, Dose Ranging Study of YM443 in Subjects With Functional Dyspepsia|Completed||Phase 2|416|Actual|Astellas Pharma Inc|||||||||||||||||||2018-06-01 04:58:50.570493|2018-06-01 04:58:50.570493
NCT00102297|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-26|||2007-12-10|2005-01-26|2005-01-27|Estimate|||||||2007-12-10|2007-12-12|Estimate|January 2005||2005-01-31|December 2007|2007-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus|A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus|Completed||Phase 1|20|Anticipated|FibroGen|||||f||||||||||||||2018-06-01 04:58:50.693952|2018-06-01 04:58:50.693952
NCT00102284|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-26|||2010-01-26|2005-01-26|2005-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|March 2004||2004-03-31|September 2006|2006-09-30|April 2005||2005-04-30|||||Interventional|||Neuromodulation and Language Acquisition (Project Stage Ia)|Improved Language Acquisition Through Neuromodulation, Project Stage Ia|Terminated||Phase 4|100||University Hospital Muenster|||||f||||||||||||||2018-06-01 04:58:50.756239|2018-06-01 04:58:50.756239
NCT00102271|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-25|||2017-06-30|2005-01-25|2005-01-26|Estimate|||||||2017-06-30|2017-07-02|Actual|January 19, 2005||2005-01-19|April 12, 2011|2011-04-12|April 12, 2011|Actual|2011-04-12|||||Interventional|||Nitrite Infusion Studies|Evaluation of the Mechanism of NO Formation and Pharmacokinetics of Systemic Nitrite Infusion|Completed||Phase 1|36|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:50.862615|2018-06-01 04:58:50.862615
NCT00102258|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-25|||2017-06-30|2005-01-25|2005-01-26|Estimate|||||||2017-06-30|2017-07-02|Actual|January 19, 2005||2005-01-19|October 2, 2007|2007-10-02|October 2, 2007||2007-10-02|||||Interventional|||Role of Nutrition and Hormones in Boys With Disordered Growth|Nutrients and Hormones: Effects in Boys With Disordered Growth - Pilot Study|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:50.92919|2018-06-01 04:58:50.92919
NCT00102245|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-25|||2018-02-13|2005-01-25|2005-01-26|Estimate|||||||2018-02-13|2018-02-14|Actual|January 18, 2005||2005-01-18|August 4, 2017|2017-08-04|August 4, 2017||2017-08-04|||||Observational|||Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes|Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes|Terminated|||334|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:50.995896|2018-06-01 04:58:50.995896
NCT00102232|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-25|||2005-06-23|2005-01-25|2005-01-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2003||2003-05-31|January 2005|2005-01-31|July 2003||2003-07-31|||||Interventional|||Effect of Phosphatidylcholine on Plasma Homocysteine in Healthy Volunteers|Effect of Choline Supplemented as Phosphatidylcholine on Post-Methionine Loading and Fasting Concentrations of Plasma Homocysteine in Healthy Volunteers|Completed||N/A|26||Wageningen Centre for Food Sciences|||||f||||||||||||||2018-06-01 04:58:51.13674|2018-06-01 04:58:51.13674
NCT00102206|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-25|||2012-05-17|2005-01-25|2005-01-26|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|May 2007|Actual|2007-05-31|||||Interventional|||A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy|A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Two Antiretroviral Therapeutic Strategies: A Dual PI-Based HAART Regimen Versus a Multi-NRTI ART Regimen, in ART-Experienced Children and Youth Who Have Experienced Virologic Failure|Completed||Phase 2|6|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:58:51.471444|2018-06-01 04:58:51.471444
NCT00102193|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-24|||2008-09-05|2005-01-24|2005-01-25|Estimate|||||||2008-09-05|2008-09-08|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study for the Treatment of Ulcerative Colitis With Adacolumn|A Randomized, Prospective, Double-Blinded, Placebo-Controlled (Sham-Controlled) Study to Evaluate the Safety and Effectiveness of the Adacolumn Apheresis System for the Treatment of Moderate to Severe Ulcerative Colitis|Completed||Phase 3|168||Otsuka America Pharmaceutical|||||||||||||||||||2018-06-01 04:58:51.606212|2018-06-01 04:58:51.606212
NCT00102180|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-21|||2015-11-30|2005-01-21|2005-01-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2005||2005-01-31|November 2015|2015-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Drug-Induced Sudden Death & Ventricular Arrhythmia||Completed|||31000000|Actual|University of Pennsylvania|||||f||||f||||||||||2018-06-01 04:58:51.72056|2018-06-01 04:58:51.72056
NCT00102167|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-21|||2015-01-13|2005-01-21|2005-01-24|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2005||2005-02-28|January 2015|2015-01-31|December 2005|Actual|2005-12-31|||||Interventional|||Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia|Completed||Phase 3|663|Actual|H. Lundbeck A/S|||||f||||||||||||||2018-06-01 04:58:51.778231|2018-06-01 04:58:51.778231
NCT00102154|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-21|||2015-01-13|2005-01-21|2005-01-24|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2005||2005-01-31|August 2014|2014-08-31||||||||Interventional|||An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia|Withdrawn||Phase 3|0|Actual|H. Lundbeck A/S|||||f||||||||||||||2018-06-01 04:58:51.853567|2018-06-01 04:58:51.853567
NCT00102141|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-21|||2014-12-11|2005-01-21|2005-01-24|Estimate|||||||2014-12-11|2014-12-15|Estimate|April 2004||2004-04-30|December 2014|2014-12-31|July 2005|Actual|2005-07-31|||||Interventional|||Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women|A Multicenter, Double-blind, Randomized, Placebo-controlled Study Comparing 3 Continuous Oral Angeliq (Drospirenone 3 mg/17ß-estradiol 1 mg, Drospirenone 2 mg /17ß-estradiol 1 mg, Drospirenone 1 mg /17ß-estradiol 1 mg) Combinations and 17ß-estradiol (1 mg) With Placebo for a Treatment Period of 8 Weeks on Ambulatory and Office Cuff Blood Pressure in Postmenopausal Women With Stage 1 or Stage 2 Essential Hypertension|Completed||Phase 3|750|Actual|Bayer||5|||f||||f||||||||||2018-06-01 04:58:51.935099|2018-06-01 04:58:51.935099
NCT00102128|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-21|||2015-05-21|2005-01-21|2005-01-24|Estimate|||||||2015-05-21|2015-05-22|Estimate|November 2002||2002-11-30|May 2015|2015-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.|Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure|Terminated||Phase 2|||Sanofi||||DMC recommended stop|f||||||||||||||2018-06-01 04:58:52.101817|2018-06-01 04:58:52.101817
NCT00102115|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-21|||2010-03-11|2005-01-21|2005-01-24|Estimate|||||||2010-03-11|2010-03-12|Estimate|December 2004||2004-12-31|December 2005|2005-12-31|January 2006||2006-01-31|||||Interventional|||Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease|Phase 1 Dose Ranging Study to Evaluate Safety and Tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in Subjects With Advanced Age-Related Macular Disease|Terminated||Phase 1|27||Light Sciences LLC|||||||||||||||||||2018-06-01 04:58:52.290713|2018-06-01 04:58:52.290713
NCT00102102|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-20|||2008-03-03|2005-01-20|2005-01-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2005||2005-01-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Role of Substance P in Post-Traumatic Stress Disorder|PET Evaluation of NK1 Receptor Using [18F]SPA-RQ in Post-Traumatic Stress Disorder|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:52.421487|2018-06-01 04:58:52.421487
NCT00102089|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-20|||2017-06-30|2005-01-20|2005-01-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 18, 2005||2005-01-18|October 10, 2007|2007-10-10|October 10, 2007||2007-10-10|||||Interventional|||HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Booster Dose of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Subjects Who Were Previously Immunized With VRC-HIVDNA009-00-VP in VRC 004|Completed||Phase 1|32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:52.514817|2018-06-01 04:58:52.514817
NCT00102076|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-19|||2017-06-30|2005-01-19|2005-01-20|Estimate|||||||2017-06-30|2017-07-02|Actual|November 16, 2001||2001-11-16|September 18, 2006|2006-09-18|September 18, 2006||2006-09-18|||||Observational|||Implementing the Assent Requirement for Research With Children|Implementing the Assent Requirement for Research With Children|Completed|||800||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:58:52.719014|2018-06-01 04:58:52.719014
NCT00102063|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-19|2012-05-11||2012-08-06|2005-01-19|2005-01-20|Estimate|2012-06-26|2012-08-01|Estimate||||2012-08-06|2012-08-10|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|APEX 239||Aripiprazole in Adolescents With Schizophrenia|Aripiprazole in Adolescents With Schizophrenia|Completed||Phase 3|302|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||||||||||||2018-06-01 04:58:52.840571|2018-06-01 04:58:52.840571
NCT00102050|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-19|||2006-05-17|2005-01-19|2005-01-20|Estimate|||||||2006-05-17|2006-05-19|Estimate|April 2003||2003-04-30|May 2006|2006-05-31|April 2006||2006-04-30|||||Interventional|||Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication|A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication|Completed||Phase 2|390||Nissan Chemical Industries|||||||||||||||||||2018-06-01 04:58:53.692507|2018-06-01 04:58:53.692507
NCT00102037|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-19|||2017-01-12|2005-01-19|2005-01-20|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2004||2004-07-31|January 2017|2017-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Use of Activated Recombinant FVII in Spinal Surgery|Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery|Completed||Phase 2|50|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:58:53.801022|2018-06-01 04:58:53.801022
NCT00102024|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-19|||2010-08-25|2005-01-19|2005-01-20|Estimate|||||||2010-08-25|2010-08-27|Estimate|January 2005||2005-01-31|August 2010|2010-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma|A Phase I/II, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Single Dose 90Y-Labeled IDEC-159, Humanized, Domain Deleted, Anti TAG-72 Monoclonal Antibody, in Subjects With Metastatic Colorectal Adenocarcinoma|Terminated||Phase 1/Phase 2|30||Biogen|||||||||||||||||||2018-06-01 04:58:53.913541|2018-06-01 04:58:53.913541
NCT00102011|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2017-09-13|2005-01-18|2005-01-19|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2000||2000-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|00-046||Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer|Colonoscopy Screening Trial|Active, not recruiting||Phase 3|4952|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-06-01 04:58:54.065187|2018-06-01 04:58:54.065187
NCT00101998|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2017-08-29|2005-01-18|2005-01-19|Estimate|||||||2017-08-29|2017-08-30|Actual|October 1, 2003|Actual|2003-10-01|August 2017|2017-08-31|May 1, 2006|Actual|2006-05-01|May 1, 2006|Actual|2006-05-01||Interventional|||Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects|Completed||Phase 2|233|Actual|Cubist Pharmaceuticals LLC||4|||||||||||||||||2018-06-01 04:58:54.201931|2018-06-01 04:58:54.201931
NCT00101985|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2015-04-10|2005-01-18|2005-01-19|Estimate|||||||2015-04-10|2015-04-13|Estimate|October 2004||2004-10-31|April 2015|2015-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)|An Eight-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome|Completed||Phase 2|741|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:58:54.836331|2018-06-01 04:58:54.836331
NCT00101972|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2012-04-18|2005-01-18|2005-01-19|Estimate|||||||2012-04-18|2012-04-20|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma|A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma|Completed||Phase 1|53|Actual|MacroGenics||1|||f||||f||||||||||2018-06-01 04:58:55.132945|2018-06-01 04:58:55.132945
NCT00101959|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2013-08-04|2005-01-18|2005-01-19|Estimate|||||||2013-08-04|2013-08-06|Estimate|November 2004||2004-11-30|August 2013|2013-08-31||||||||Interventional|||Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects|An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-ß-1a 30 Mcg qw IM (Avonex®) or Glatiramer Acetate 20 mg qd SC (Copaxone®) to Those Randomized to IFN-ß-1a 44 Mcg Tiw SC (Rebif®), in a Multicenter Study of Subjects With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy|Withdrawn||Phase 4|0|Actual|EMD Serono|||||||||||||||||||2018-06-01 04:58:55.269283|2018-06-01 04:58:55.269283
NCT00101946|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2015-04-10|2005-01-18|2005-01-19|Estimate|||||||2015-04-10|2015-04-13|Estimate|October 2004||2004-10-31|April 2015|2015-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease|Completed||Phase 2|17|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 04:58:55.391429|2018-06-01 04:58:55.391429
NCT00101933|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|2012-10-01|2009-05-26|2018-02-21|2005-01-18|2005-01-19|Estimate|2012-12-11|2013-01-21|Estimate|2009-10-05|2009-10-07|Estimate|2018-02-21|2018-03-22|Actual|December 2003|Actual|2003-12-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|June 2008|Actual|2008-06-30||Interventional|||SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy|SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy|Completed||Phase 3|157|Actual|MedtronicNeuro|No limitations leading to unreliable data were identified.|2|||f||||t||||||||||2018-06-01 04:58:55.517067|2018-06-01 04:58:55.517067
NCT00101920|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2010-10-14|2005-01-18|2005-01-19|Estimate|||||||2010-10-14|2010-10-15|Estimate|June 2003||2003-06-30|October 2010|2010-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)|A Clinical Trial of the Safety and Efficacy of ABX-EGF as Second Line Treatment for Advanced Non-Small Lung Cancer|Completed||Phase 2|50|Actual|Amgen||1|||f||||||||||||||2018-06-01 04:58:56.075937|2018-06-01 04:58:56.075937
NCT00101907|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|2010-08-13||2014-02-03|2005-01-18|2005-01-19|Estimate|2014-02-03|2014-03-20|Estimate||||2014-02-03|2014-03-20|Estimate|December 2004||2004-12-31|February 2014|2014-02-28|April 2008|Actual|2008-04-30|June 2007|Actual|2007-06-30||Interventional|||Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer|An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Subjects With Advanced Cancer|Terminated||Phase 1|41|Actual|Amgen||6||Study terminated per recommendation of Data Review Team|f||||||||||||||2018-06-01 04:58:56.224719|2018-06-01 04:58:56.224719
NCT00101894|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2012-09-13|2005-01-18|2005-01-19|Estimate|||||||2012-09-13|2012-09-17|Estimate|December 2004||2004-12-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|April 2010|Actual|2010-04-30||Interventional|||Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer|An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer|Completed||Phase 1|119|Actual|Amgen||14|||f||||f||||||||||2018-06-01 04:58:58.139941|2018-06-01 04:58:58.139941
NCT00101881|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-18|||2008-09-30|2005-01-18|2005-01-19|Estimate|||||||2008-09-30|2008-10-02|Estimate|November 2002||2002-11-30|September 2008|2008-09-30|January 2005|Actual|2005-01-31|||||Interventional|||Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER)|Transthoracic Incremental Monophasic Versus Biphasic by Emergency Responders (TIMBER)|Completed||Phase 4|168|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 04:58:58.280725|2018-06-01 04:58:58.280725
NCT00101868|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-14|2012-03-18||2012-04-16|2005-01-14|2005-01-17|Estimate|2012-04-16|2012-05-15|Estimate||||2012-04-16|2012-05-15|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Value of Technology to Transfer Discharge Information|Value of Technology to Transfer Discharge Information|Completed||N/A|631|Actual|Agency for Healthcare Research and Quality (AHRQ)|Required medication reconciliation in both groups might have reduced the adverse event rates in both groups.|2|||f||||f||||||||||2018-06-01 04:58:58.407008|2018-06-01 04:58:58.407008
NCT00101842|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-14|||2006-08-24|2005-01-14|2005-01-17|Estimate|||||||2006-08-24|2006-08-29|Estimate|December 2004||2004-12-31|August 2006|2006-08-31|July 2006||2006-07-31|||||Interventional|||Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer|Phase I/II Study of Gemzar and Platinol Followed by Alimta and Gemzar in Patients With Advanced or Metastatic Bladder Cancer|Completed||Phase 1/Phase 2|61||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:58:58.99119|2018-06-01 04:58:58.99119
NCT00101829|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-13|||2017-10-18|2005-01-13|2005-01-14|Estimate|||||||2017-10-18|2017-10-20|Actual|April 2004||2004-04-30|October 2017|2017-10-31|August 2009|Actual|2009-08-31|August 2006|Actual|2006-08-31||Interventional|||Anti-CD20 Antibody Therapy for Sjogren's Syndrome|An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome|Completed||Phase 1|12|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 04:58:59.091498|2018-06-01 04:58:59.091498
NCT00101816|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-13|2009-12-15||2010-08-03|2005-01-13|2005-01-14|Estimate|2010-02-17|2010-03-02|Estimate||||2010-08-03|2010-08-10|Estimate|December 2004||2004-12-31|June 2010|2010-06-30|March 2008|Actual|2008-03-31|August 2006|Actual|2006-08-31||Interventional|||Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate|A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate|Completed||Phase 2|124|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:58:59.281604|2018-06-01 04:58:59.281604
NCT00101803|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-13|||2017-05-15|2005-01-13|2005-01-14|Estimate|||||||2017-05-15|2017-05-17|Actual|January 2005||2005-01-31|May 2017|2017-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|527|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:00.925234|2018-06-01 04:59:00.925234
NCT00101790|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-13|||2010-01-06|2005-01-13|2005-01-14|Estimate|||||||2010-01-06|2010-01-07|Estimate|September 2003||2003-09-30|January 2010|2010-01-31|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||A Pilot Trial of Intravenous (IV) Pamidronate for Low Back Pain|A Pilot Trial of IV Pamidronate for Low Back Pain|Unknown status|Active, not recruiting|Phase 1|44|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-06-01 04:59:01.008443|2018-06-01 04:59:01.008443
NCT00101777|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2008-03-03|2005-01-12|2005-01-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Ventilatory Physiology in Children at Risk for Anxiety|Ventilatory Physiology in Children at Risk for Anxiety|Completed|||479||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:01.12525|2018-06-01 04:59:01.12525
NCT00101764|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2017-06-30|2005-01-12|2005-01-13|Estimate|||||||2017-06-30|2017-07-02|Actual|January 5, 2005||2005-01-05|May 20, 2008|2008-05-20|May 20, 2008||2008-05-20|||||Interventional|||Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders|Phase I Study of Intravitreal Injections Versus Anterior Sub-Tenon Injections of Triamcinolone Acetonide Formulation for Macular Edema in Retinal Disorders|Completed||Phase 1|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:01.288|2018-06-01 04:59:01.288
NCT00101751|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2014-10-16|2005-01-12|2005-01-13|Estimate|||||||2014-10-16|2014-10-17|Estimate|October 2004||2004-10-31|October 2014|2014-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|INITIATE plus||INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study|Efficacy and Safety of a Standard Titration Algorithm Coupled With a Conventional Dietary Intervention or Intensive Dietary Intervention Versus a Standard Titration Algorithm, Alone, in Patients With Type 2 Diabetes Initiating NovoLog® Mix 70/30 Therapy|Completed||Phase 4|4877|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 04:59:01.35968|2018-06-01 04:59:01.35968
NCT00101738|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2011-01-28|2005-01-12|2005-01-13|Estimate|||||||2011-01-28|2011-01-31|Estimate|March 2003||2003-03-31|January 2011|2011-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Freedom Study: Myfortic in Kidney Transplant Patients|Study to Investigate the Clinical Outcomes of Different Regimens of Myfortic® in De Novo Kidney Tx Pts Using Simulect® and Neoral® With or Without Steroids|Completed||Phase 3|342|Actual|Novartis|||||||||||||||||||2018-06-01 04:59:01.424879|2018-06-01 04:59:01.424879
NCT00101725|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2010-11-19|2005-01-12|2005-01-13|Estimate|||||||2010-11-19|2010-11-22|Estimate|December 2004||2004-12-31|November 2010|2010-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN 002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)|Completed||Phase 2|245|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||||2018-06-01 04:59:01.549556|2018-06-01 04:59:01.549556
NCT00101712|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2012-05-04|2005-01-12|2005-01-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|October 2004||2004-10-31|May 2012|2012-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia|Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia|Completed||Phase 3|274|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:59:01.649611|2018-06-01 04:59:01.649611
NCT00101699|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2006-08-17|2005-01-12|2005-01-13|Estimate|||||||2006-08-17|2006-08-18|Estimate|November 2001||2001-11-30|January 2005|2005-01-31|August 2003||2003-08-31|||||Observational|||Effects of Soy Consumption on Symptoms of Menopause|Influence of Soy Consumption on Menopause|Completed|||120||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 04:59:01.717268|2018-06-01 04:59:01.717268
NCT00101686|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|2009-10-20||2010-01-04|2005-01-12|2005-01-13|Estimate|2009-10-22|2009-11-26|Estimate||||2010-01-04|2010-01-12|Estimate|February 2003||2003-02-28|January 2010|2010-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.|A Randomized, Multi-Center Phase III Trial Of Irinotecan In Combination With Three Different Methods Of Administration Of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5-FU (Day 1 & 8), And Oral Capecitabine (Day 1-14); With Celecoxib Versus Placebo As First-Line Treatment For Patients With Metastatic Colorectal Cancer Study Amended April 23, 2004 To Include Bevacizumab|Completed||Phase 3|547|Actual|Pfizer||5|||f||||t||||||||||2018-06-01 04:59:01.85734|2018-06-01 04:59:01.85734
NCT00101673|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2012-05-04|2005-01-12|2005-01-13|Estimate|||||||2012-05-04|2012-05-07|Estimate|March 2004||2004-03-31|May 2012|2012-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%|Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%|Completed||Phase 3|251|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:04.928227|2018-06-01 04:59:04.928227
NCT00101660|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|2009-12-22||2012-02-29|2005-01-12|2005-01-13|Estimate|2010-02-09|2010-02-24|Estimate||||2012-02-29|2012-03-02|Estimate|February 2005||2005-02-28|February 2012|2012-02-29|April 2008|Actual|2008-04-30|September 2006|Actual|2006-09-30||Interventional|||Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib|A Phase II Study to Determine the Activity of BMS-354825 in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who Are Intolerant of Imatinib|Completed||Phase 2|387|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:59:05.137309|2018-06-01 04:59:05.137309
NCT00101647|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|2009-12-22||2011-04-13|2005-01-12|2005-01-13|Estimate|2010-02-17|2010-03-02|Estimate||||2011-04-13|2011-04-15|Estimate|December 2004||2004-12-31|April 2011|2011-04-30|March 2008|Actual|2008-03-31|August 2006|Actual|2006-08-31||Interventional|||Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia|A Phase II Study of BMS-354825 in Subjects With Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate|Completed||Phase 2|197|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:59:06.517355|2018-06-01 04:59:06.517355
NCT00101634|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2011-06-06|2005-01-12|2005-01-13|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 2004||2004-12-31|January 2011|2011-01-31|March 2006|Actual|2006-03-31|||||Interventional|||Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia|Completed||Phase 3|518|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 04:59:08.321217|2018-06-01 04:59:08.321217
NCT00101621|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2006-02-08|2005-01-12|2005-01-13|Estimate|||||||2006-02-08|2006-02-09|Estimate|August 2004||2004-08-31|February 2006|2006-02-28|August 2005||2005-08-31|||||Interventional|||Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain|A Randomized, Double-Blind, Placebo Controlled, Multi-Center, Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent in a Cancer Pain Model|Terminated||Phase 2|24||MetaPhore Pharmaceuticals|||||||||||||||||||2018-06-01 04:59:08.448479|2018-06-01 04:59:08.448479
NCT00101608|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12||2010-02-27|2010-02-27|2005-01-12|2005-01-13|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|January 2005||2005-01-31|August 2008|2008-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium|A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium|Completed||Phase 2|150|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:59:08.522167|2018-06-01 04:59:08.522167
NCT00101595|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12||2010-02-04|2011-04-07|2005-01-12|2005-01-13|Estimate||||2010-02-04|2010-02-08|Estimate|2011-04-07|2011-04-14|Estimate|January 2005||2005-01-31|April 2011|2011-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate|Completed||Phase 2|96|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-06-01 04:59:08.746987|2018-06-01 04:59:08.746987
NCT00101582|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|2014-01-03||2016-08-19|2005-01-12|2005-01-13|Estimate|2014-09-12|2014-09-15|Estimate||||2016-08-19|2016-09-27|Estimate|August 2005||2005-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|September 2007|Actual|2007-09-30||Interventional|||Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer|Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT)|Completed||Phase 3|188|Actual|Swedish Orphan Biovitrum||2|||f||||t||||||||||2018-06-01 04:59:09.03794|2018-06-01 04:59:09.03794
NCT00101569|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-12|||2013-11-07|2005-01-12|2005-01-13|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2004||2004-03-31|July 2008|2008-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Aripiprazole Oral Acceptability Trial|Aripiprazole Oral Acceptability Trial|Completed||Phase 3|59||Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 04:59:09.887033|2018-06-01 04:59:09.887033
NCT00101543|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2009-02-03|2005-01-10|2005-01-11|Estimate|||||||2009-02-03|2009-02-05|Estimate|August 2003||2003-08-31|January 2005|2005-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training|Gait Training For Acute Stroke: FNS and Weight Supported Treadmill Training|Completed||Phase 4|70|Anticipated|VA Office of Research and Development|||||||||||||||||||2018-06-01 04:59:09.96681|2018-06-01 04:59:09.96681
NCT00101530|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2015-09-29|2005-01-10|2005-01-11|Estimate|||||||2015-09-29|2015-10-01|Estimate|September 2004||2004-09-30|September 2015|2015-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|LUCHAR||Improving Prevention of Heart Disease in Latinos|Partnership Programs to Reduce Cardiovascular Disparities - Latinos Using Cardio Health Actions to Reduce Risk|Completed|||179|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-06-01 04:59:10.029576|2018-06-01 04:59:10.029576
NCT00101517|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2014-09-12|2005-01-10|2005-01-11|Estimate|||||||2014-09-12|2014-09-16|Estimate|September 2004||2004-09-30|September 2014|2014-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|META-HEALTH||Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease|Partnership Programs to Reduce Cardiovascular Disparities - Morehouse-Emory Partnership|Completed|||4024|Actual|Emory University|||||f||||t||||||||||2018-06-01 04:59:10.092927|2018-06-01 04:59:10.092927
NCT00101504|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2016-07-11|2005-01-10|2005-01-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2004||2004-09-30|April 2006|2006-04-30|August 2009|Actual|2009-08-31|||||Observational|||Hypertension Education and Treatment Partnership for Reducing Ethnic Differences in the Risk of Cardiovascular Disease|Partnership Programs to Reduce Cardiovascular Disparities - Hypertension Education and Treatment (HEAT)|Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 04:59:10.164019|2018-06-01 04:59:10.164019
NCT00101491|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2016-07-11|2005-01-10|2005-01-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|August 2010|Actual|2010-08-31|September 2009|Actual|2009-09-30||Interventional|||STORIES-Stories to Communicate Risk About Tobacco|Partnership Programs to Reduce Cardiovascular Disparities - Deep South Partnerships for Prevention of CVD Disparities|Completed||N/A|300|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 04:59:10.270079|2018-06-01 04:59:10.270079
NCT00101478|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2017-03-28|2005-01-10|2005-01-11|Estimate|||||||2017-03-28|2017-03-30|Actual|September 2004|Actual|2004-09-30|March 2017|2017-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Improving Cardiovascular Treatment Approaches Among Minorities|Partnership Programs to Reduce Cardiovascular Disparities - Baltimore Partnership|Completed|||823|Actual|University of Maryland|||||f||||t||||||||||2018-06-01 04:59:10.356018|2018-06-01 04:59:10.356018
NCT00101465|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2013-07-02|2005-01-10|2005-01-11|Estimate|||||||2013-07-02|2013-07-03|Estimate|September 2004||2004-09-30|July 2009|2009-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Partnership Programs for Reducing Cardiovascular Disparities in Native Hawaiians|Partnership Programs to Reduce Cardiovascular Disparities - Heart Failure Disparities in Native Hawaiians|Completed|||276|Anticipated|University of Hawaii|||||f||||||||||||||2018-06-01 04:59:10.448228|2018-06-01 04:59:10.448228
NCT00101452|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|2012-06-13||2017-03-06|2005-01-10|2005-01-11|Estimate|2012-11-29|2012-12-31|Estimate||||2017-03-06|2017-04-04|Actual|April 2005||2005-04-30|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression|A Double-Blind, Placebo-Controlled Study of the Alternative Therapy S-Adenosyl-L-Methionine (SAMe) vs Escitalopram in Major Depressive Disorder (MDD)|Completed||N/A|199|Actual|Massachusetts General Hospital||3|||f||||t||||||||Undecided||2018-06-01 04:59:10.541626|2018-06-01 04:59:10.541626
NCT00101439|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|2016-03-15||2017-03-06|2005-01-10|2005-01-11|Estimate|2016-05-03|2016-06-10|Estimate||||2017-03-06|2017-04-04|Actual|November 2005||2005-11-30|March 2017|2017-03-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|||A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Postprandial Lipoprotein Response in Patients With Primary Hypercholesterolemia|Completed||Phase 3|58|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 04:59:10.857753|2018-06-01 04:59:10.857753
NCT00101426|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2008-01-10|2005-01-10|2005-01-11|Estimate|||||||2008-01-10|2008-01-14|Estimate|October 2004||2004-10-31|January 2008|2008-01-31|September 2006||2006-09-30|||||Interventional|||Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy||Completed||Phase 3|500||Sumitomo Dainippon Pharma Co., Ltd.|||||||||||||||||||2018-06-01 04:59:11.136083|2018-06-01 04:59:11.136083
NCT00101413|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|2009-04-17||2013-09-29|2005-01-10|2005-01-11|Estimate|2010-03-10|2010-04-08|Estimate||||2013-09-29|2013-10-30|Estimate|April 2004||2004-04-30|September 2013|2013-09-30|April 2008|Actual|2008-04-30|June 2005|Actual|2005-06-30||Interventional|||BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)|A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma|Completed||Phase 2|52|Actual|Bayer|Due to rapid enrollment, no IA (interim analysis) was performed.|1|||f||||f||||||||||2018-06-01 04:59:11.201339|2018-06-01 04:59:11.201339
NCT00101400|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|2009-01-30||2013-11-19|2005-01-10|2005-01-11|Estimate|2009-05-04|2009-06-23|Estimate||||2013-11-19|2013-12-13|Estimate|February 2004||2004-02-29|November 2013|2013-11-30|January 2008|Actual|2008-01-31|January 2006|Actual|2006-01-31||Interventional|||BAY43-9006 - Phase II in Advanced Breast Cancer|A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Subjects With Metastatic Breast Cancer.|Completed||Phase 2|54|Actual|Bayer|Subjects had advanced disease and were heavily pretreated. Not all adverse events mentioned were assessed as drug-related. NCI-CTCAE was translated to Medical Dictionary for Regulatory Activities (MedDRA) for System Organ Classes (SOCs) only.|1|||f||||f||||||||||2018-06-01 04:59:11.473763|2018-06-01 04:59:11.473763
NCT00101387|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-10|||2011-02-17|2005-01-10|2005-01-11|Estimate|||||||2011-02-17|2011-02-18|Estimate|September 2003||2003-09-30|February 2011|2011-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Effects of Lumbar PENS and Exercise in Older Adults With Chronic Low Back Pain|Functional Impact of PENS for 65+ Chronic Low Back Pain|Completed||Phase 3|200|Actual|University of Pittsburgh||4|||f||||t||||||||||2018-06-01 04:59:11.898772|2018-06-01 04:59:11.898772
NCT00101374|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2017-06-30|2005-01-07|2005-01-10|Estimate|||||||2017-06-30|2017-07-02|Actual|January 5, 2005||2005-01-05|February 2, 2010|2010-02-02|May 21, 2008|Actual|2008-05-21|May 21, 2008|Actual|2008-05-21||Interventional|||Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Leflunomide on HIV-1 Associated Immune Proliferation In Vivo|Completed||Phase 1|41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:11.995692|2018-06-01 04:59:11.995692
NCT00101361|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|2013-06-27||2013-11-26|2005-01-07|2005-01-10|Estimate|2013-09-23|2013-11-25|Estimate||||2013-11-26|2013-12-20|Estimate|August 2005||2005-08-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||overall baseline participants were determined by number of participants that were eligible after screening based on a pressure ulcer that is defined as hard-to-heal or worsening at randomization.|Oxandrolone to Heal Pressure Ulcers|CSP #535 - Anabolic Steroid Therapy on Pressure Ulcer Healing in Persons With Spinal Cord Injury|Terminated||Phase 3|212|Actual|VA Office of Research and Development|Selection of severe wounds may have reduced treatment response. The study was terminated after a futility analysis showed a low probability of detecting a significant difference between groups.|2||futility analysis showed low probability of detecting a significant difference|f||||t||||||||||2018-06-01 04:59:12.064928|2018-06-01 04:59:12.064928
NCT00101348|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2014-06-10|2005-01-07|2005-01-10|Estimate|||||||2014-06-10|2014-06-11|Estimate|January 2005||2005-01-31|December 2012|2012-12-31|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer|A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|66|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:12.351472|2018-06-01 04:59:12.351472
NCT00101335|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-07-09|2005-01-07|2005-01-10|Estimate|||||||2013-07-09|2013-07-11|Estimate|November 2003||2003-11-30|July 2013|2013-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia|A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia|Completed||Phase 2|||Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 04:59:12.4494|2018-06-01 04:59:12.4494
NCT00101309|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-12-17|2005-01-07|2005-01-10|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2004||2004-11-30|November 2007|2007-11-30||||November 2007|Anticipated|2007-11-30||Interventional|||Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma|A Phase I Pilot Study of Tumor Cell - B Lymphoblastoid Cell Line Vaccination in Pediatric Subjects With Relapsed Ewing's Sarcoma and Neuroblastoma|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:12.512945|2018-06-01 04:59:12.512945
NCT00101296|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-02-01|2005-01-07|2005-01-10|Estimate|||||||2013-02-01|2013-02-04|Estimate|October 2004||2004-10-31|January 2013|2013-01-31||||May 2011|Actual|2011-05-31||Interventional|||Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:12.570704|2018-06-01 04:59:12.570704
NCT00101283|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|2010-02-12||2012-11-30|2005-01-07|2005-01-10|Estimate|2010-02-12|2010-03-04|Estimate||||2012-11-30|2012-12-04|Estimate|November 2005||2005-11-30|November 2012|2012-11-30|May 2011|Actual|2011-05-31|September 2009|Actual|2009-09-30||Interventional|||Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma|Pemetrexed Plus Gemcitabine Or Carboplatin In Patients With Advanced Malignant Mesothelioma: A Randomized Phase II Trial|Completed||Phase 2|32|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 04:59:12.65126|2018-06-01 04:59:12.65126
NCT00101270|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-06-04|2005-01-07|2005-01-10|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2005||2005-03-31|June 2013|2013-06-30||||September 2007|Actual|2007-09-30||Interventional|||Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas|A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:13.166635|2018-06-01 04:59:13.166635
NCT00101257|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2010-05-05|2005-01-07|2005-01-10|Estimate|||||||2010-05-05|2010-05-07|Estimate|October 2004||2004-10-31|May 2010|2010-05-31|March 2010|Actual|2010-03-31|||||Interventional|||Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD4+ Antigen-Specific T Cell Clones for Patients With Advanced Ovarian Cancer|Completed||Phase 1|18|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:59:13.276547|2018-06-01 04:59:13.276547
NCT00101244|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-01-11|2005-01-07|2005-01-10|Estimate|||||||2013-01-11|2013-01-14|Estimate|November 2004||2004-11-30|January 2013|2013-01-31||||February 2010|Actual|2010-02-28||Interventional|||SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma|A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Days 1-3 of a 21-Day Cycle in Patients With Solid Tumors|Terminated||Phase 1|31|Actual|National Cancer Institute (NCI)||1||Administratively Complete.|f||||||||||||||2018-06-01 04:59:13.346427|2018-06-01 04:59:13.346427
NCT00101231|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-06-03|2005-01-07|2005-01-10|Estimate|||||||2013-06-03|2013-06-04|Estimate|October 2004||2004-10-31|June 2013|2013-06-30||||November 2012|Actual|2012-11-30||Interventional|||Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia|A Dose Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With Relapsed and Refractory Acute Leukemias|Terminated||Phase 1|88|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:13.428238|2018-06-01 04:59:13.428238
NCT00101205|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2014-02-21|2005-01-07|2005-01-10|Estimate|||||||2014-02-21|2014-02-24|Estimate|November 2004||2004-11-30|April 2013|2013-04-30||||January 2012|Actual|2012-01-31||Interventional|||Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma|A Phase I Trial of the Combination of Oxaliplatin (NSC 266046, IND 57004), Ifosfamide, and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas|Terminated||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:13.514494|2018-06-01 04:59:13.514494
NCT00101192|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|2014-02-03||2014-02-03|2005-01-07|2005-01-10|Estimate|2014-02-03|2014-03-17|Estimate||||2014-02-03|2014-03-17|Estimate|September 2004||2004-09-30|February 2014|2014-02-28||||July 2011|Actual|2011-07-31||Interventional||Eligible and evaluable participants|Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix|Completed||Phase 2|76|Actual|Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 04:59:13.714312|2018-06-01 04:59:13.714312
NCT00101179|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2018-04-20|2005-01-07|2005-01-10|Estimate|||||||2018-04-20|2018-04-23|Actual|November 3, 2004|Actual|2004-11-03|April 2018|2018-04-30||||April 30, 2011|Actual|2011-04-30||Interventional|||MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia|A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 1|63|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:14.098689|2018-06-01 04:59:14.098689
NCT00101166|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|2012-10-18||2018-01-31|2005-01-07|2005-01-10|Estimate|2012-10-18|2012-11-16|Estimate||||2018-01-31|2018-02-28|Actual|October 2004||2004-10-31|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma|A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Malignant Melanoma|Completed||Phase 2|43|Actual|H. Lee Moffitt Cancer Center and Research Institute|Due to the heterogeneity of the patient population, results were mainly descriptive in nature.|1|||f||||f||||||||||2018-06-01 04:59:14.234303|2018-06-01 04:59:14.234303
NCT00101153|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2015-07-22|2005-01-07|2005-01-10|Estimate|||||||2015-07-22|2015-07-23|Estimate|April 2007||2007-04-30|July 2015|2015-07-31||||March 2010|Actual|2010-03-31||Interventional|||Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia|A Phase I Study Of Therapy With The Farnesyl Transferase Inhibitor R115777 (Zarnestra) Combined With Conventional Induction And Consolidation Chemotherapy For Previously Untreated Patients Over Age 55 With Acute Myeloid Leukemia (AML)|Completed||Phase 1|24|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 04:59:14.423785|2018-06-01 04:59:14.423785
NCT00101140|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2017-10-18|2005-01-07|2005-01-10|Estimate|||||||2017-10-18|2017-10-19|Actual||||October 2017|2017-10-31||||||||Interventional|||Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission|Phase II Study of Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia in First Remission|Withdrawn||Phase 2|0|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 04:59:14.610867|2018-06-01 04:59:14.610867
NCT00101127|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2014-02-12|2005-01-07|2005-01-10|Estimate|||||||2014-02-12|2014-02-14|Estimate|December 2003||2003-12-31|February 2014|2014-02-28||||July 2006|Actual|2006-07-31||Interventional|||Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma|A Phase II Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 04:59:14.733963|2018-06-01 04:59:14.733963
NCT00101114|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-02-27|2005-01-07|2005-01-10|Estimate|||||||2013-02-27|2013-02-28|Estimate|September 2004||2004-09-30|February 2013|2013-02-28||||May 2006|Actual|2006-05-31||Interventional|||Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer|A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination With Interferon-Alpha 2B in Patients With Advanced Renal Cancer|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:14.922302|2018-06-01 04:59:14.922302
NCT00101101|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|2013-06-20||2018-01-09|2005-01-07|2005-01-10|Estimate|2013-06-20|2013-09-04|Estimate||||2018-01-09|2018-02-05|Actual|July 2004||2004-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2012|Actual|2012-10-31||Interventional||All participants who started the study.|Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma|A Phase II Trial Using a Universal GM-CSF-Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-Based Vaccines for Patients With Mantle Cell Lymphoma|Active, not recruiting||Phase 2|43|Actual|H. Lee Moffitt Cancer Center and Research Institute|With a median follow-up of 67 months, the median overall survival (OS) has not yet been reached.|1|||f||||f||||||||||2018-06-01 04:59:15.021762|2018-06-01 04:59:15.021762
NCT00101088|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-01-11|2005-01-07|2005-01-10|Estimate|||||||2013-01-11|2013-01-14|Estimate|April 2005||2005-04-30|January 2013|2013-01-31||||June 2010|Actual|2010-06-30||Interventional|||Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase I Study of CCI-779 in Combination With Imatinib Mesylate in Chronic Myelogenous Leukemia|Terminated||Phase 1|21|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:59:15.267487|2018-06-01 04:59:15.267487
NCT00101075|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2017-02-24|2005-01-07|2005-01-10|Estimate|||||||2017-02-24|2017-02-27|Actual|October 2004||2004-10-31|February 2017|2017-02-28|March 2008|Actual|2008-03-31|March 2007|Actual|2007-03-31||Interventional|||Title XELOX FOR SALIVARY GLAND CANCERS|Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers|Terminated||Phase 2|9|Actual|Dana-Farber Cancer Institute||1||Slow Accrual|f||||t||||||||No||2018-06-01 04:59:15.353543|2018-06-01 04:59:15.353543
NCT00101062|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2011-06-03|2005-01-07|2005-01-10|Estimate|||||||2011-06-03|2011-06-08|Estimate|January 2004||2004-01-31|June 2011|2011-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|Phase II Study of Letrozole (Femara) and Celecoxib (Celebrex) in Postmenopausal Women With Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer|Terminated||Phase 2|||Rutgers, The State University of New Jersey||||study drug unavailable|f||||t||||||||||2018-06-01 04:59:15.456848|2018-06-01 04:59:15.456848
NCT00101036|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|2014-07-21||2018-03-22|2005-01-07|2005-01-10|Estimate|2014-12-18|2015-01-05|Estimate||||2018-03-22|2018-04-20|Actual|November 2004||2004-11-30|March 2018|2018-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery|A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers|Completed||Phase 2|57|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:15.56032|2018-06-01 04:59:15.56032
NCT00101010|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2014-09-10|2005-01-07|2005-01-10|Estimate|||||||2014-09-10|2014-09-11|Estimate|September 2005||2005-09-30|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma|A Phase II Study Of Rituximab-CHOP With Pegylated Liposomal Doxorubicin In Patients Older Than 60 Years Of Age With Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|80|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 04:59:16.060532|2018-06-01 04:59:16.060532
NCT00100997|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-07-09|2005-01-07|2005-01-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|October 2004||2004-10-31|May 2005|2005-05-31|October 2006|Actual|2006-10-31|||||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate|A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered CNF1010 )17-(Allylamino)-17-Demethoxygeldanamycin [17-AAG]) in Patients With Gleevec-Resistent Chronic Myelogenous Leukemia|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:16.145859|2018-06-01 04:59:16.145859
NCT00100984|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2017-06-19|2005-01-07|2005-01-10|Estimate|||||||2017-06-19|2017-06-20|Actual|July 21, 2004|Actual|2004-07-21|December 2005|2005-12-31|July 16, 2005|Actual|2005-07-16|July 16, 2005|Actual|2005-07-16||Interventional|||A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1||Terminated||Phase 4|8|Actual|Hoffmann-La Roche||||Insufficient enrollment|||||||||||||||2018-06-01 04:59:16.20144|2018-06-01 04:59:16.20144
NCT00100971|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2013-01-03|2005-01-07|2005-01-10|Estimate|||||||2013-01-03|2013-01-04|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia|Dendritic/Leukemic Fusion Cell Vaccine Therapy For AML Patients In First Remission; A Phase I Clinical Trial|Terminated||Phase 1|9||Boston Medical Center||||Protocol is withdrawn due to inadequate accrual|f||||||||||||||2018-06-01 04:59:16.343505|2018-06-01 04:59:16.343505
NCT00100958|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2008-07-23|2005-01-07|2005-01-10|Estimate|||||||2008-07-23|2008-07-24|Estimate|November 2004||2004-11-30|May 2006|2006-05-31||||||||Interventional|||Indole-3-Carbinol in Preventing Cancer in Healthy Participants|Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-Indolymethane (DIM) Nutritional Product|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:16.402283|2018-06-01 04:59:16.402283
NCT00100945|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|||2016-12-09|2005-01-07|2005-01-10|Estimate|||||||2016-12-09|2016-12-13|Estimate|July 2005||2005-07-31|December 2016|2016-12-31|October 2009|Actual|2009-10-31|August 2007|Actual|2007-08-31||Interventional|||Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer|A Phase II Study Of Maintenance ZD1839 (IRESSA) In Patients With Locally Advanced Esophageal Cancer After Treatment Given With Curative Intent|Completed||Phase 2|70|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:59:16.472949|2018-06-01 04:59:16.472949
NCT00100932|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-07|2011-12-26||2012-03-22|2005-01-07|2005-01-10|Estimate|2011-12-26|2012-01-31|Estimate||||2012-03-22|2012-03-27|Estimate|December 2004||2004-12-31|March 2012|2012-03-31||||June 2008|Actual|2008-06-30||Interventional|||Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy|Phase II Study of E7389, a Halichondrin B Analog, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Who Progressed During or After Platinum-Based Doublet Chemotherapy Stratified for Prior Taxane Therapy|Completed||Phase 2|106|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 04:59:16.669125|2018-06-01 04:59:16.669125
NCT00100906|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2013-08-15|2005-01-06|2005-01-07|Estimate|||||||2013-08-15|2013-08-16|Estimate|August 2004||2004-08-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|June 2006|Actual|2006-06-30||Interventional|||Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer|Randomized Phase II Trial Of Sequential ATRA Then IL-2 For Modulation Of Dendritic Cells And Treatment Of Metastatic Renal Cancer|Completed||Phase 2|18|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f||||||||||2018-06-01 04:59:18.279712|2018-06-01 04:59:18.279712
NCT00100893|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2015-06-03|2005-01-06|2005-01-07|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer|A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer|Completed||Phase 1|37|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 04:59:18.370663|2018-06-01 04:59:18.370663
NCT00100880|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2013-09-27|2005-01-06|2005-01-07|Estimate|||||||2013-09-27|2013-09-30|Estimate|November 2004||2004-11-30|September 2013|2013-09-30||||November 2010|Actual|2010-11-30||Interventional|||Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors|A Phase I Trial of CC-5013 (Lenalidomide) in Pediatric Patients With Recurrent or Refractory Primary CNS Tumors|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:18.457334|2018-06-01 04:59:18.457334
NCT00100867|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2016-03-31|2005-01-06|2005-01-07|Estimate|||||||2016-03-31|2016-04-01|Estimate|June 2006||2006-06-30|March 2016|2016-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Effects of Maternal Anti-HIV Treatment on Infants Born to HIV-Infected Women|Assessment of Safety and Toxicity Among Infants Born to HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World|Completed|||236|Actual|AIDS Clinical Trials Group|||||f||||||||||Samples With DNA|"~     Blood and urine collection~   "|||2018-06-01 04:59:18.562107|2018-06-01 04:59:18.562107
NCT00100854|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2018-01-05|2005-01-06|2005-01-07|Estimate|||||||2018-01-05|2018-01-09|Actual|October 28, 2004|Actual|2004-10-28|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized, Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva®) and Fulvestrant (Faslodex®) Versus Erlotinib (Tarceva®) Alone in Advanced Non-Small Cell Lung Cancer Patients|Active, not recruiting||Phase 2|50|Anticipated|Translational Oncology Research International||2|||f||||t||||||||||2018-06-01 04:59:18.665617|2018-06-01 04:59:18.665617
NCT00100841|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|2015-06-26||2015-06-26|2005-01-06|2005-01-07|Estimate|2015-06-26|2015-07-27|Estimate||||2015-06-26|2015-07-27|Estimate|November 2004||2004-11-30|July 2013|2013-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer|Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer|Completed||Phase 2|66|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:59:18.754712|2018-06-01 04:59:18.754712
NCT00100828|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2016-10-12|2005-01-06|2005-01-07|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2004||2004-11-30|October 2016|2016-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer|Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer|Completed||Phase 2|6|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-06-01 04:59:19.773819|2018-06-01 04:59:19.773819
NCT00100815|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|2015-09-28||2015-11-19|2005-01-06|2005-01-07|Estimate|2015-11-19|2015-12-24|Estimate||||2015-11-19|2015-12-24|Estimate|August 2004||2004-08-31|November 2015|2015-11-30||||August 2008|Actual|2008-08-31||Interventional||All treated and eligible patients|Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer|Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer|Completed||Phase 2|50|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 04:59:19.889611|2018-06-01 04:59:19.889611
NCT00100802|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|2016-11-18||2017-01-12|2005-01-06|2005-01-07|Estimate|2016-11-18|2017-01-13|Estimate||||2017-01-12|2017-02-27|Actual|July 2005||2005-07-31|November 2016|2016-11-30||||September 2012|Actual|2012-09-30||Interventional|||Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas|A Phase II Study of Concurrent Radiation and Temozolomide Followed By Temozolomide and CCNU in the Treatment of Children With High-Grade Glioma|Active, not recruiting||Phase 2|118|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 04:59:20.487428|2018-06-01 04:59:20.487428
NCT00100789|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|2012-07-12||2012-08-29|2005-01-06|2005-01-07|Estimate|2012-08-29|2012-10-01|Estimate||||2012-08-29|2012-10-01|Estimate|January 2005||2005-01-31|August 2012|2012-08-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer|A Phase II Study of Biweekly Gemcitabine and Paclitaxel (GEMTAX) Combination in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|67|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 04:59:21.241096|2018-06-01 04:59:21.241096
NCT00100776|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2007-01-24|2005-01-06|2005-01-07|Estimate|||||||2007-01-24|2007-01-26|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|November 2005||2005-11-30|||||Interventional|||Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder|Efficacy of High Dose Olanzapine in a Controlled Fixed Dose-Response Trial for the Treatment of Schizophrenia and Schizoaffective Disorder|Completed||Phase 4|600||Eli Lilly and Company|||||||||||||||||||2018-06-01 04:59:21.934423|2018-06-01 04:59:21.934423
NCT00100750|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2015-01-12|2005-01-06|2005-01-07|Estimate|||||||2015-01-12|2015-01-13|Estimate|September 2005||2005-09-30|October 2014|2014-10-31|January 2010|Actual|2010-01-31|October 2007|Actual|2007-10-31||Interventional|||Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer|Gemcitabine and R115777 Combination Therapy for Metastatic Breast Cancer|Completed||Phase 1/Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 04:59:22.046802|2018-06-01 04:59:22.046802
NCT00100737|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-06|||2006-02-02|2005-01-06|2005-01-07|Estimate|||||||2006-02-02|2006-02-06|Estimate||||February 2006|2006-02-28||||||||Interventional|||Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin’s Lymphoma (NHL)|A Phase 2 Randomized, Open-Label, Controlled Trial of the Addition of 8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab in the Treatment of Rituximab Naïve Subjects With Follicular Non-Hodgkin’s Lymphoma, Refractory or Relapsed After Previous Chemotherapy|Terminated||Phase 2|300||Chiron Corporation|||||||||||||||||||2018-06-01 04:59:22.121834|2018-06-01 04:59:22.121834
NCT00100724|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-05|||2006-01-10|2005-01-05|2005-01-06|Estimate|||||||2006-01-10|2006-01-12|Estimate|April 2004||2004-04-30|January 2006|2006-01-31|July 2005||2005-07-31|||||Interventional|||Trial of rPA-102 Vaccine in Healthy Adult Volunteers|A Phase 2 Multi-Center, Randomized Dose-Finding Trial of rPA-102 Vaccine in Healthy Adult Volunteers|Completed||Phase 2|480||VaxGen|||||||||||||||||||2018-06-01 04:59:22.182251|2018-06-01 04:59:22.182251
NCT00100711|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-04||2014-04-14|2014-05-07|2005-01-04|2005-01-05|Estimate||||2014-05-07|2014-05-23|Estimate|2014-05-07|2014-05-23|Estimate|October 2004||2004-10-31|May 2014|2014-05-31||||February 2010|Actual|2010-02-28||Interventional|||Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease|Terminated||Phase 2|27||Pharmacyclics LLC.|||||f||||||||||||||2018-06-01 04:59:22.279419|2018-06-01 04:59:22.279419
NCT00100698|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-04|2010-04-09||2010-07-22|2005-01-04|2005-01-05|Estimate|2010-07-19|2010-07-22|Estimate||||2010-07-22|2010-07-27|Estimate|January 2004||2004-01-31|July 2010|2010-07-31|April 2009|Actual|2009-04-30|October 2007|Actual|2007-10-31||Interventional|||Physiologic Growth Hormone Effects in HIV Lipodystrophy|Physiologic Growth Hormone Effects in HIV Lipodystrophy|Completed||N/A|56|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 04:59:22.379252|2018-06-01 04:59:22.379252
NCT00100685|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-04|||2012-04-25|2005-01-04|2005-01-05|Estimate|||||||2012-04-25|2012-04-27|Estimate|January 2005||2005-01-31|April 2012|2012-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)|Phase 2 Open-Label Study of Volociximab (M200) in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|48|Actual|Abbott||2|||f||||t||||||||||2018-06-01 04:59:22.949291|2018-06-01 04:59:22.949291
NCT00100672|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-04|||2011-06-30|2005-01-04|2005-01-05|Estimate|||||||2011-06-30|2011-07-04|Estimate|December 2004||2004-12-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|October 2009|Actual|2009-10-31||Interventional|||Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer|Phase I Study of an Easy-to-Use Intravenous Formulation of Liposome Entrapped C-raf Antisense Oligonucleotide (LErafAON-ETU) Administered on a Weekly Schedule in Patients With Advanced Cancer|Completed||Phase 1|40||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 04:59:23.06121|2018-06-01 04:59:23.06121
NCT00100659|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-04|2013-05-10||2013-07-10|2005-01-04|2005-01-05|Estimate|2013-05-10|2013-07-01|Estimate||||2013-07-10|2013-07-19|Estimate|December 2004||2004-12-31|July 2013|2013-07-31|February 2010|Actual|2010-02-28|August 2008|Actual|2008-08-31||Interventional|||PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C|Pegylated Interferon +/- Ribavirin for Children With Hepatitis C|Completed||Phase 3|114|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||||||||||||2018-06-01 04:59:23.14551|2018-06-01 04:59:23.14551
NCT00100646|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-04|||2014-08-26|2005-01-04|2005-01-05|Estimate|||||||2014-08-26|2014-08-27|Estimate|March 2007||2007-03-31|November 2013|2013-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa|A Randomized Clinical Trial Assessing Continuous HAART Versus Interrupted HAART in a Resource Poor Clinic|Completed||N/A|30|Actual|The Wistar Institute||2|||f||||t||||||||||2018-06-01 04:59:23.41496|2018-06-01 04:59:23.41496
NCT00100633|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-04|||2008-09-29|2005-01-04|2005-01-05|Estimate|||||||2008-09-29|2008-10-01|Estimate|December 2004||2004-12-31|December 2007|2007-12-31|October 2007|Actual|2007-10-31|February 2007|Actual|2007-02-28||Interventional|||Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected People|Immunologic Effects of CpG ODN Administration to HIV Uninfected and HIV Infected Patients|Completed||Phase 1/Phase 2|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:59:23.508538|2018-06-01 04:59:23.508538
NCT00100620|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-03|||2017-05-15|2005-01-03|2005-01-04|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2004||2004-06-30|May 2017|2017-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis|Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis|Completed||Phase 3|802||Novartis|||||||||||||||||||2018-06-01 04:59:23.587119|2018-06-01 04:59:23.587119
NCT00100607|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-03|||2012-05-07|2005-01-03|2005-01-04|Estimate|||||||2012-05-07|2012-05-08|Estimate|February 2004||2004-02-29|May 2012|2012-05-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis|Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis|Completed||Phase 2|676|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:23.746817|2018-06-01 04:59:23.746817
NCT00100594|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-03|||2011-02-22|2005-01-03|2005-01-04|Estimate|||||||2011-02-22|2011-02-23|Estimate|May 2005||2005-05-31|February 2011|2011-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China|A Feasibility Study of Lamivudine/Zidovudine (3TC/ZDV) Plus Efavirenz (EFV) as Initial Therapy of HIV-1 Infected Patients in a Rural Area of China|Completed||N/A|100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:59:23.81384|2018-06-01 04:59:23.81384
NCT00100581|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-03|||2012-05-17|2005-01-03|2005-01-04|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|January 2007|Actual|2007-01-31|||||Interventional|||Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults|An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin|Completed||N/A|2|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:59:23.883641|2018-06-01 04:59:23.883641
NCT00100568|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-03|||2013-09-04|2005-01-03|2005-01-04|Estimate|||||||2013-09-04|2013-09-06|Estimate|July 2006||2006-07-31|September 2013|2013-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal|A Pilot Study of Safety, Effectiveness, and Adherence of Lamivudine/Zidovudine and Efavirenz (3TC/ZDV + EFV) to Treat HIV-1 Infection in Senegal|Completed||N/A|44|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 04:59:23.972244|2018-06-01 04:59:23.972244
NCT00100555|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-03|||2012-04-26|2005-01-03|2005-01-04|Estimate|||||||2012-04-26|2012-04-27|Estimate|June 2004||2004-06-30|April 2012|2012-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate|A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate|Completed||Phase 3|120||Novartis|||||||||||||||||||2018-06-01 04:59:24.099268|2018-06-01 04:59:24.099268
NCT00100542|ClinicalTrials.gov processed this data on May 31, 2018|2005-01-03|||2011-01-20|2005-01-03|2005-01-04|Estimate|||||||2011-01-20|2011-01-21|Estimate|April 2005||2005-04-30|January 2011|2011-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||Psychiatric Problems in Children and Adolescents Infected With HIV at Birth|Psychiatric Co-Morbidity in Perinatally HIV-Infected Children and Adolescents|Completed|||800|Anticipated|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||1||f||||||||||||||2018-06-01 04:59:24.183007|2018-06-01 04:59:24.183007
NCT00100113|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-22|||2017-01-10|2004-12-22|2004-12-23|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2004||2004-06-30|March 2005|2005-03-31|June 2005||2005-06-30|||||Interventional|||Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1|Study of Interactions Between GBR 12909 and Cocaine|Unknown status|Active, not recruiting|Phase 1|24||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 04:59:27.106806|2018-06-01 04:59:27.106806
NCT00100529|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-31|||2018-05-19|2004-12-31|2005-01-03|Estimate|||||||2018-05-19|2018-05-22|Actual|December 21, 2004||2004-12-21|June 29, 2012|2012-06-29|June 29, 2012||2012-06-29|||||Observational|||Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations|Stereo Photogrammetry Soft Tissue in Normal Individuals and Patients With Craniofacial Dysmorphologies|Completed|||1813|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:24.300731|2018-06-01 04:59:24.300731
NCT00100516|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-31|||2017-06-30|2004-12-31|2005-01-03|Estimate|||||||2017-06-30|2017-07-02|Actual|December 23, 2004||2004-12-23|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Observational|||Donor Recipient Kidney Function Following Open Surgical vs. Laparoscopic Kidney Donation|Infrared Image Guided Minimally Invasive Live Donor Kidney Donation for Kidney Transplantation|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:24.390653|2018-06-01 04:59:24.390653
NCT00100503|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-31|||2017-06-30|2004-12-31|2005-01-03|Estimate|||||||2017-06-30|2017-07-02|Actual|December 27, 2004||2004-12-27|August 30, 2006|2006-08-30|August 30, 2006||2006-08-30|||||Observational|||Brain Reorganization Following Constraint-Induced Therapy in Children With Cerebral Palsy|Cortical Reorganization Following Pediatric Constraint-Induced Therapy|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:24.483561|2018-06-01 04:59:24.483561
NCT00100490|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2009-01-20|2004-12-30|2004-12-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|December 2004|2004-12-31|September 2002||2002-09-30|||||Observational|||Immune and Endocrine Function in Post-Traumatic Stress Disorder|Immune and Endocrine Function in Post-Traumatic Stress Disorder|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:59:24.533859|2018-06-01 04:59:24.533859
NCT00100477|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2013-09-24|2004-12-30|2004-12-31|Estimate|||||||2013-09-24|2013-09-25|Estimate|August 1998||1998-08-31|September 2013|2013-09-30|June 2001|Actual|2001-06-30|January 2001|Actual|2001-01-31||Interventional|||Use of Topotecan in Patients With Refractory Acute Leukemia|Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia|Completed||Phase 2|10|Actual|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 04:59:24.573153|2018-06-01 04:59:24.573153
NCT00100464|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2013-09-16|2004-12-30|2004-12-31|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 2000||2000-11-30|September 2013|2013-09-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Serotonin and the Upper Airway in Obstructive Sleep Apnea|Serotonin and the Upper Airway in Obstructive Sleep Apnea|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:59:24.627399|2018-06-01 04:59:24.627399
NCT00100451|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2009-01-20|2004-12-30|2004-12-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|June 1994||1994-06-30|December 2004|2004-12-31|June 2001||2001-06-30|||||Interventional|||Aging, Exercise, and Hormonal Influences of Fat Metabolism|Aging, Exercise, and Hormonal Influences of Fat Metabolism|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:59:24.69357|2018-06-01 04:59:24.69357
NCT00100438|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2009-01-20|2004-12-30|2004-12-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1998||1998-10-31|December 2004|2004-12-31|September 2002||2002-09-30|||||Observational|||Incidence of Parkinson's Disease Among Veterans|Incidence of Parkinson's Disease Among Veterans|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:59:24.736022|2018-06-01 04:59:24.736022
NCT00100425|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2009-01-20|2004-12-30|2004-12-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|September 2000||2000-09-30|December 2004|2004-12-31||||||||Interventional|||Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome|Central Nervous System Modulation of Visceral Pain in Persian Gulf War Syndrome|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:59:24.853377|2018-06-01 04:59:24.853377
NCT00100412|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2009-01-20|2004-12-30|2004-12-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|December 2004|2004-12-31|September 2002||2002-09-30|||||Interventional|||Hyporeactivity and Gulf War Illness|Cardiovascular Hyporeactivity and Fatiguing Illness in Gulf War Veterans|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 04:59:24.903995|2018-06-01 04:59:24.903995
NCT00100399|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2010-08-26|2004-12-30|2004-12-31|Estimate|||||||2010-08-26|2010-08-27|Estimate|December 2004||2004-12-31|March 2007|2007-03-31|December 2004||2004-12-31|||||Interventional|||Fluarix Immunogenicity and Safety Trial|A Randomized, Double-blinded, Placebo Controlled Phase III Study to Evaluate the Immunogenicity and Safety of GSK Bio Influenza Vaccine (Fluarix) Administered Intramuscularly in Healthy Adults|Completed||Phase 3|1050||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:59:24.959495|2018-06-01 04:59:24.959495
NCT00100386|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2011-06-09|2004-12-30|2004-12-31|Estimate|||||||2011-06-09|2011-06-10|Estimate|March 2005||2005-03-31|October 2007|2007-10-31|August 2006||2006-08-31|||||Interventional|||Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial|Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) Trial|Completed||N/A|30000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:59:25.01951|2018-06-01 04:59:25.01951
NCT00100373|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-30|||2010-08-26|2004-12-30|2004-12-31|Estimate|||||||2010-08-26|2010-08-27|Estimate|September 2004||2004-09-30|February 2007|2007-02-28|May 2005||2005-05-31|||||Interventional|||RSV Challenge in Healthy Adults|Characterization of the Immune Response and Viral Shedding to Experimental Infection With Respiratory Syncytial Virus, Strain A-2, in Healthy Adults Ages 21 to 40 Years Old|Completed||N/A|13||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:59:25.137034|2018-06-01 04:59:25.137034
NCT00100360|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-29|||2017-10-05|2004-12-29|2004-12-30|Estimate|||||||2017-10-05|2017-10-06|Actual|December 22, 2004||2004-12-22|December 15, 2016|2016-12-15|December 15, 2016||2016-12-15|||||Observational|||Hormonal Causes of Menstrual-Related Mood Disorders|5HT1A and SERT Imaging During Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Estrogen and Progesterone Replacement|Completed|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:25.231051|2018-06-01 04:59:25.231051
NCT00100347|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-29|||2007-07-23|2004-12-29|2004-12-30|Estimate|||||||2007-07-23|2007-07-25|Estimate|December 2004||2004-12-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors|A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin’s Lymphoma and Solid Tumors|Terminated||Phase 1|45|Actual|PRAECIS Pharmaceuticals Inc.||||terminated due to corporate transaction.|f||||f||||||||||2018-06-01 04:59:25.305319|2018-06-01 04:59:25.305319
NCT00100334|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-29|||2006-09-18|2004-12-29|2004-12-30|Estimate|||||||2006-09-18|2006-09-19|Estimate|December 2004||2004-12-31|September 2006|2006-09-30|August 2005||2005-08-31|||||Interventional|||Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease|Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease|Completed||Phase 1/Phase 2|24||PRAECIS Pharmaceuticals Inc.|||||||||||||||||||2018-06-01 04:59:25.375121|2018-06-01 04:59:25.375121
NCT00100100|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-22|||2017-01-11|2004-12-22|2004-12-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2004||2004-10-31|July 2008|2008-07-31|December 2006||2006-12-31|||||Interventional|||Modafinil for the Treatment of Cocaine Dependence - 1|Modafinil for the Treatment of Cocaine Dependence|Completed||Phase 2|210||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 04:59:27.160903|2018-06-01 04:59:27.160903
NCT00100308|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-28|||2008-01-08|2004-12-28|2004-12-29|Estimate|||||||2008-01-08|2008-01-15|Estimate|July 2005||2005-07-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Unfractioned Heparin for Treatment of Sepsis|Unfractioned Heparin for Treatment of Sepsis: A Randomized Clinical Trial (The HETRASE Study)|Completed||Phase 3|319|Actual|Universidad de Antioquia||2|||f||||t||||||||||2018-06-01 04:59:25.481084|2018-06-01 04:59:25.481084
NCT00100295|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-28|||2007-10-24|2004-12-28|2004-12-29|Estimate|||||||2007-10-24|2007-10-26|Estimate|February 2005||2005-02-28|October 2007|2007-10-31|November 2006|Actual|2006-11-30|||||Interventional|||Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)|Controlled Trial of an Herbal Treatment for Juvenile Attention Deficit Hyperactivity Disorder|Completed||Phase 2|59|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 04:59:25.572219|2018-06-01 04:59:25.572219
NCT00100282|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-27|||2006-09-18|2004-12-27|2004-12-28|Estimate|||||||2006-09-18|2006-09-19|Estimate|May 2003||2003-05-31|September 2006|2006-09-30|June 2005||2005-06-30|||||Interventional|||Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease|Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease|Completed||Phase 1|125||PRAECIS Pharmaceuticals Inc.|||||||||||||||||||2018-06-01 04:59:25.662285|2018-06-01 04:59:25.662285
NCT00100269|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-27|||2006-05-01|2004-12-27|2004-12-28|Estimate|||||||2006-05-01|2006-05-03|Estimate|December 2004||2004-12-31|June 2005|2005-06-30|March 2006||2006-03-31|||||Interventional|||Menevit Study: Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility|A Randomized Control Trial of the Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility|Completed||Phase 3|60||Repromed|||||f||||||||||||||2018-06-01 04:59:25.719561|2018-06-01 04:59:25.719561
NCT00100256|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-27|||2017-08-11|2004-12-27|2004-12-28|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2004||2004-01-31|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|June 2004||2004-06-30||Interventional|||Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy|Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy|Active, not recruiting||Phase 1/Phase 2|60|Actual|Andarix Pharmaceuticals||1|||f||||||||||||||2018-06-01 04:59:25.81965|2018-06-01 04:59:25.81965
NCT00100243|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-27|||2006-09-18|2004-12-27|2004-12-28|Estimate|||||||2006-09-18|2006-09-19|Estimate|May 2004||2004-05-31|September 2006|2006-09-30|September 2005||2005-09-30|||||Interventional|||Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy|Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy|Completed||Phase 2|22||PRAECIS Pharmaceuticals Inc.|||||||||||||||||||2018-06-01 04:59:25.894393|2018-06-01 04:59:25.894393
NCT00100230|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-27|2014-08-25|2013-09-17|2015-03-04|2004-12-27|2004-12-28|Estimate|2015-03-04|2015-03-17|Estimate|2013-10-10|2013-11-05|Estimate|2015-03-04|2015-03-17|Estimate|September 2004||2004-09-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|May 2012|Actual|2012-05-31||Interventional||males with X-linked retinitis pigmentosa|DHA and X-Linked Retinitis Pigmentosa|Investigation of Effectiveness and Safety of High Dose Docosahexaenoic Acid (DHA) in X-Linked Retinitis Pigmentosa|Completed||Phase 2|78|Actual|Retina Foundation of the Southwest|A lower than expected event rate for the primary outcome measure was the major trial limitation.|2|||f||||t||||||||||2018-06-01 04:59:25.972939|2018-06-01 04:59:25.972939
NCT00100217|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|||2017-06-30|2004-12-23|2004-12-24|Estimate|||||||2017-06-30|2017-07-02|Actual|December 21, 2004||2004-12-21|June 25, 2010|2010-06-25|June 25, 2010||2010-06-25|||||Observational|||Evaluation of Patients With Critical Illness|Evaluation of Patients With Critical Illness: Intensive Care Training Protocol|Completed|||1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:26.313157|2018-06-01 04:59:26.313157
NCT00100204|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|||2017-06-30|2004-12-23|2004-12-24|Estimate|||||||2017-06-30|2017-07-02|Actual|December 21, 2004||2004-12-21|April 19, 2011|2011-04-19|April 19, 2011||2011-04-19|||||Observational|||Salivary Proteins in Disease and Health|Salivary Proteomics in Disease and Health|Completed|||264|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:26.360124|2018-06-01 04:59:26.360124
NCT00100191|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|||2005-06-23|2004-12-23|2004-12-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2002||2002-02-28|December 2004|2004-12-31|April 2006||2006-04-30|||||Interventional|||Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids|EMMY Trial: a Randomized Comparison of Uterine Artery Embolization and Hysterectomy for the Treatment of Symptomatic Uterine Fibroids|Completed||Phase 3|120||ZonMw: The Netherlands Organisation for Health Research and Development|||||f||||||||||||||2018-06-01 04:59:26.411262|2018-06-01 04:59:26.411262
NCT00100178|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|2016-05-13||2016-07-07|2004-12-23|2004-12-24|Estimate|2016-07-07|2016-08-16|Estimate||||2016-07-07|2016-08-16|Estimate|May 2004||2004-05-31|July 2016|2016-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial|New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial (Preservation of Pancreatic Production of Insulin Through Immunosuppression-POPPII #1)|Completed||Phase 2|126|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||||||||||||2018-06-01 04:59:26.500216|2018-06-01 04:59:26.500216
NCT00100165|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|||2015-12-04|2004-12-23|2004-12-24|Estimate|||||||2015-12-04|2015-12-07|Estimate|January 2005||2005-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of DMXB-A in Schizophrenia|Phase 2 Trial of 3-2,4 Dimethoxybenzylidene Anabaseine in Schizophrenia|Unknown status|Recruiting|Phase 2|36|Anticipated|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:59:26.849057|2018-06-01 04:59:26.849057
NCT00100152|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|||2015-05-25|2004-12-23|2004-12-24|Estimate|||||||2015-05-25|2015-05-27|Estimate|February 2005||2005-02-28|May 2015|2015-05-31|October 2006|Actual|2006-10-31|September 2006|Actual|2006-09-30||Interventional|||A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)|A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma|Terminated||Phase 1|50||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:59:26.93248|2018-06-01 04:59:26.93248
NCT00100139|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|||2011-06-30|2004-12-23|2004-12-24|Estimate|||||||2011-06-30|2011-07-04|Estimate|November 2004||2004-11-30|June 2011|2011-06-30|June 2010|Actual|2010-06-30|November 2006|Actual|2006-11-30||Interventional|||Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer|A Randomized Two-Period Crossover, Clinical Bioequivalence Study Comparing the Pharmacokinetics of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation Versus Taxol® in Patients With Advanced Cancer|Completed||Phase 1|48||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 04:59:26.981244|2018-06-01 04:59:26.981244
NCT00100126|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-23|||2006-10-23|2004-12-23|2004-12-24|Estimate|||||||2006-10-23|2006-10-25|Estimate|December 2004||2004-12-31|April 2005|2005-04-30|June 2005||2005-06-30|||||Interventional|||APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat|A Phase III, Investigator Blind, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of APC-231 Sprinkle QD for 7 Days vs Penicillin VK 10 mg/kg QID for 10 Days in Pediatric Patients With Streptococcus Pyogenes|Completed||Phase 3|500||Advancis Pharmaceutical Corporation|||||||||||||||||||2018-06-01 04:59:27.050598|2018-06-01 04:59:27.050598
NCT00100087|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-22|||2005-06-23|2004-12-22|2004-12-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2004||2004-10-31|January 2005|2005-01-31||||||||Interventional|||Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System|A Safety and Feasibility Study of the TheraSight(TM) Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration|Unknown status|Recruiting|Phase 1/Phase 2|30||Theragenics Corporation|||||||||||||||||||2018-06-01 04:59:27.319178|2018-06-01 04:59:27.319178
NCT00100074|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-22|||2017-01-10|2004-12-22|2004-12-23|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2004||2004-09-30|December 2004|2004-12-31|April 2005||2005-04-30|||||Interventional|||To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1|Safety and Tolerability Study of Sublingual Lobeline|Unknown status|Active, not recruiting|Phase 1|8||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 04:59:27.402863|2018-06-01 04:59:27.402863
NCT00100061|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-22|||2013-03-11|2004-12-22|2004-12-23|Estimate|||||||2013-03-11|2013-03-12|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Effects of Cranberry-Containing Products in Women With Recurrent Urinary Tract Infections (UTIs)|Dose Response to Cranberry of Women With Recurrent UTIs|Unknown status|Active, not recruiting|Phase 2|350|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 04:59:27.466134|2018-06-01 04:59:27.466134
NCT00100048|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-22|2010-01-21||2015-09-04|2004-12-22|2004-12-23|Estimate|2010-03-25|2010-03-29|Estimate||||2015-09-04|2015-09-09|Estimate|January 2005||2005-01-31|September 2015|2015-09-30|July 2010|Actual|2010-07-31|October 2006|Actual|2006-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)|Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients|Completed||Phase 2|206|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-06-01 04:59:27.609711|2018-06-01 04:59:27.609711
NCT00100035|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-22|||2008-04-21|2004-12-22|2004-12-23|Estimate|||||||2008-04-21|2008-04-22|Estimate|August 2004||2004-08-31|April 2008|2008-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Polarity Therapy for American Indian Caregivers of Dementia Patients|Polarity Therapy for Dementia Caregivers|Completed||Phase 1|50||National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 04:59:29.159028|2018-06-01 04:59:29.159028
NCT00100009|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2017-06-30|2004-12-21|2004-12-22|Estimate|||||||2017-06-30|2017-07-02|Actual|December 9, 2004||2004-12-09|December 20, 2006|2006-12-20|December 20, 2006||2006-12-20|||||Interventional|||Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration|Multi-Center, Randomized, Phase II/III Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants With Neovascular Age-Related Macular Degeneration|Completed||Phase 3|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:29.212749|2018-06-01 04:59:29.212749
NCT00099996|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2008-03-03|2004-12-21|2004-12-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2004||2004-12-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia|A Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia|Completed||Phase 3|3||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:29.314352|2018-06-01 04:59:29.314352
NCT00099983|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|2013-08-06||2014-08-05|2004-12-21|2004-12-22|Estimate|2014-08-05|2014-08-22|Estimate||||2014-08-05|2014-08-22|Estimate|October 2006||2006-10-31|August 2014|2014-08-31|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|CSP #504|"Valid diagnostic baseline data were collected on 267 patients randomized to receive risperidone (n=133) and placebo (n=134). The 29 patients with missing source documents as reported in Participant Flow were not included in any analyses."|Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder|CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder|Completed||Phase 2|296|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 04:59:29.373712|2018-06-01 04:59:29.373712
NCT00099970|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2008-08-02|2004-12-21|2004-12-22|Estimate|||||||2008-08-02|2008-08-05|Estimate|December 2004||2004-12-31|August 2008|2008-08-31|March 2006||2006-03-31|||||Interventional|||Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy|Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo|Completed||Phase 2|40||Facet Biotech|||||||||||||||||||2018-06-01 04:59:29.624146|2018-06-01 04:59:29.624146
NCT00099957|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2012-05-01|2004-12-21|2004-12-22|Estimate|||||||2012-05-01|2012-05-02|Estimate|September 2003||2003-09-30|May 2012|2012-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes|A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes|Completed||Phase 2|38||Novartis|||||||||||||||||||2018-06-01 04:59:29.683396|2018-06-01 04:59:29.683396
NCT00099944|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2012-05-03|2004-12-21|2004-12-22|Estimate|||||||2012-05-03|2012-05-07|Estimate|May 2004||2004-05-31|May 2012|2012-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes|Completed||Phase 3|515|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:59:29.736071|2018-06-01 04:59:29.736071
NCT00099931|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2012-05-04|2004-12-21|2004-12-22|Estimate|||||||2012-05-04|2012-05-07|Estimate|May 2004||2004-05-31|May 2012|2012-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes|Completed||Phase 3|254|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:30.749111|2018-06-01 04:59:30.749111
NCT00099918|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2017-05-15|2004-12-21|2004-12-22|Estimate|||||||2017-05-15|2017-05-17|Actual|May 2004||2004-05-31|May 2017|2017-05-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|717|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:30.801152|2018-06-01 04:59:30.801152
NCT00099905|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2012-05-01|2004-12-21|2004-12-22|Estimate|||||||2012-05-01|2012-05-02|Estimate|April 2004||2004-04-30|May 2012|2012-05-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes|A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes|Completed||Phase 3|639|Actual|Novartis|||||||||||||||||||2018-06-01 04:59:30.854326|2018-06-01 04:59:30.854326
NCT00099892|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2017-07-31|2004-12-21|2004-12-22|Estimate|||||||2017-07-31|2017-08-02|Actual|May 2004||2004-05-31|July 2017|2017-07-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes|Completed||Phase 3|544|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:30.90705|2018-06-01 04:59:30.90705
NCT00099879|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21||2010-02-27|2010-02-27|2004-12-21|2004-12-22|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate||||August 2007|2007-08-31||||March 2006|Actual|2006-03-31||Interventional|||Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer|A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer|Terminated||Phase 2|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 04:59:30.965596|2018-06-01 04:59:30.965596
NCT00099866|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2012-05-04|2004-12-21|2004-12-22|Estimate|||||||2012-05-04|2012-05-07|Estimate|January 2004||2004-01-31|May 2012|2012-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes|Completed||Phase 3|570|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:59:31.031189|2018-06-01 04:59:31.031189
NCT00099853|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21||2012-12-28|2013-01-02|2004-12-21|2004-12-22|Estimate||||2012-12-28|2013-01-01|Estimate|2013-01-02|2013-01-04|Estimate|May 2004||2004-05-31|January 2013|2013-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes|Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes|Completed||Phase 3|362|Actual|Novartis||3|||f||||||||||||||2018-06-01 04:59:31.172726|2018-06-01 04:59:31.172726
NCT00099840|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2007-04-24|2004-12-20|2004-12-21|Estimate|||||||2007-04-24|2007-04-25|Estimate|December 2004||2004-12-31|January 2006|2006-01-31|April 2006|Actual|2006-04-30|||||Interventional|||Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study|Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections in Primary Care - A Randomized Controlled Trial|Completed||N/A|400||University Hospital, Basel, Switzerland|||||f||||||||||||||2018-06-01 04:59:31.244666|2018-06-01 04:59:31.244666
NCT00099827|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2011-10-14|2004-12-20|2004-12-21|Estimate|||||||2011-10-14|2011-10-18|Estimate|October 2003||2003-10-31|October 2011|2011-10-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Teen Depression Awareness Project (TDAP)|Teen Depression Awareness Project- This Project Examines the Services Used by Teens Identified in Primary Care Settings With Depression|Completed||Phase 1|368|Actual|RAND|||||f||||f||||||||||2018-06-01 04:59:31.311593|2018-06-01 04:59:31.311593
NCT00099814|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2010-06-28|2004-12-20|2004-12-21|Estimate|||||||2010-06-28|2010-06-29|Estimate|March 2004||2004-03-31|June 2010|2010-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Periodontal Ligament Stress Level and Tooth Movement|Clinical/Numerical Study of the Effects of Periodontal Ligament Stress Level on the Rate Bodily Tooth Movement|Completed||Phase 1|20||University of Alberta, Graduate Orthodontic Program|||||f||||f||||||||||2018-06-01 04:59:31.391603|2018-06-01 04:59:31.391603
NCT00099801|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2017-06-05|2004-12-20|2004-12-21|Estimate|||||||2017-06-05|2017-06-07|Actual|January 2005||2005-01-31|June 2017|2017-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant|Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant|Completed||Phase 3|||Novartis|||||||||||||||||||2018-06-01 04:59:31.451853|2018-06-01 04:59:31.451853
NCT00099788|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-21|||2009-11-24|2004-12-20|2004-12-21|Estimate|||||||2009-11-24|2009-11-26|Estimate|October 2004||2004-10-31|November 2009|2009-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes|Completed||Phase 3|6560|Actual|Gilead Sciences||2|||f||||t||||||||||2018-06-01 04:59:31.514007|2018-06-01 04:59:31.514007
NCT00099775|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-18|||2008-03-03|2004-12-18|2004-12-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2004||2004-12-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units|A Randomized Double-Masked Trial of Caspofungin Versus Placebo as Prophylaxis of Invasive Candidiasis in High-Risk Adults in the Critical Care Setting|Completed||Phase 3|1200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:31.589725|2018-06-01 04:59:31.589725
NCT00099762|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2017-06-30|2004-12-17|2004-12-20|Estimate|||||||2017-06-30|2017-07-02|Actual|December 15, 2004||2004-12-15|September 2, 2009|2009-09-02||||September 2, 2009|Actual|2009-09-02||Observational|||Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia|Selective Venous Catheterization for the Localization of Phosphaturic Mesenchymal Tumors|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:31.652348|2018-06-01 04:59:31.652348
NCT00099749|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2017-02-21|2004-12-17|2004-12-20|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2003||2003-11-30|February 2017|2017-02-28||||April 2006|Actual|2006-04-30||Interventional|||Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant|Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant|Completed||Phase 2/Phase 3|255||Novartis|||||||||||||||||||2018-06-01 04:59:31.701325|2018-06-01 04:59:31.701325
NCT00099736|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2017-08-17|2004-12-17|2004-12-20|Estimate|||||||2017-08-17|2017-08-22|Actual|May 7, 2003||2003-05-07|August 2017|2017-08-31|September 19, 2005|Actual|2005-09-19|September 19, 2005|Actual|2005-09-19||Interventional|||Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant|Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant|Completed||Phase 3|696|Actual|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 04:59:31.770058|2018-06-01 04:59:31.770058
NCT00099723|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2010-02-10|2004-12-17|2004-12-20|Estimate|||||||2010-02-10|2010-02-11|Estimate|October 2004||2004-10-31|December 2004|2004-12-31|December 2005|Anticipated|2005-12-31|||||Interventional|||The Effect of a Probiotic on Hepatic Steatosis|The Effect of a Probiotic on Hepatic Steatosis|Terminated||Phase 1|30|Anticipated|VSL Pharmaceuticals||||The hypothesis that probiotics would reduce hepatic steatosis in humans was not supported|||||||||||||||2018-06-01 04:59:31.873644|2018-06-01 04:59:31.873644
NCT00099710|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2009-12-02|2004-12-17|2004-12-20|Estimate|||||||2009-12-02|2009-12-03|Estimate|July 2003||2003-07-31|December 2009|2009-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Curcumin in Patients With Mild to Moderate Alzheimer's Disease|A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Two Doses of Curcumin C3 Complex Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|33|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:59:31.919516|2018-06-01 04:59:31.919516
NCT00099697|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2009-12-09|2004-12-17|2004-12-20|Estimate|||||||2009-12-09|2009-12-11|Estimate|June 2001||2001-06-30|December 2004|2004-12-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans|Biologic Effects of DHEA in Humans|Completed||N/A|56||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:59:32.054423|2018-06-01 04:59:32.054423
NCT00099684|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2012-10-26|2004-12-17|2004-12-20|Estimate|||||||2012-10-26|2012-10-29|Estimate|November 2005||2005-11-30|October 2012|2012-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults|A Pilot Study of the Safety, Efficacy, and Tolerability of Ezetimibe (Zetia) in Combination With Statin Therapy for the Treatment of Elevated LDL Cholesterol in HIV-Infected Subjects|Completed||N/A|44|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 04:59:32.124635|2018-06-01 04:59:32.124635
NCT00099671|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2013-07-30|2004-12-17|2004-12-20|Estimate|||||||2013-07-30|2013-07-31|Estimate|April 2005||2005-04-30|July 2013|2013-07-31|April 2007|Actual|2007-04-30|||||Interventional|||Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs|A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment|Completed||Phase 1|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:59:32.254043|2018-06-01 04:59:32.254043
NCT00099658|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2011-02-14|2004-12-17|2004-12-20|Estimate|||||||2011-02-14|2011-02-15|Estimate|April 2005||2005-04-30|February 2011|2011-02-28|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children|Evaluation of Quantitative and Qualitative Antibody Responses to Streptococcus Pneumoniae and Haemophilus Influenzae Type b Conjugate Vaccines Amongst HIV-1-Exposed-Infected Children That Are Receiving Vs. Those Not Receiving Antiretroviral Therapy, as Well as Among HIV-1-Exposed-Uninfected Children and HIV-1-Unexposed-Uninfected Children|Unknown status|Active, not recruiting|N/A|579|Actual|CIPRA SA||5|||f||||t||||||||||2018-06-01 04:59:32.330419|2018-06-01 04:59:32.330419
NCT00099645|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2012-05-17|2004-12-17|2004-12-20|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|August 2005|Actual|2005-08-31|||||Interventional|||Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People|A Randomized, Placebo-Controlled, Phase I/II Trial of the Anti-HIV Activity and Safety of VGX-410 (Mifepristone) at Three Dose Levels in HIV-1 Infected Subjects|Completed||Phase 1/Phase 2|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 04:59:32.413221|2018-06-01 04:59:32.413221
NCT00099632|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|2011-12-06||2015-12-29|2004-12-17|2004-12-20|Estimate|2012-01-18|2012-01-19|Estimate||||2015-12-29|2016-02-02|Estimate|March 2006||2006-03-31|December 2015|2015-12-31|November 2011|Actual|2011-11-30|April 2010|Actual|2010-04-30||Interventional|||Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy|Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine|Completed||Phase 2|484|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-06-01 04:59:32.528606|2018-06-01 04:59:32.528606
NCT00099619|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2015-02-20|2004-12-17|2004-12-20|Estimate|||||||2015-02-20|2015-02-23|Estimate|September 2004||2004-09-30|January 2015|2015-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy|Efficacy of Exenatide Compared With Insulin Glargine in Patients With Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy|Completed||Phase 3|138|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:59:33.576339|2018-06-01 04:59:33.576339
NCT00099606|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2011-04-18|2004-12-17|2004-12-20|Estimate|||||||2011-04-18|2011-04-19|Estimate|July 2004||2004-07-31|April 2011|2011-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Phase I (PH I) Mad Refractory Solid Tumor Study|A Phase I Dose-Escalation Study of BMS-354825 in Patients With Refractory Solid Tumors|Completed||Phase 1|60||Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 04:59:33.676247|2018-06-01 04:59:33.676247
NCT00099593|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2015-03-24|2004-12-17|2004-12-20|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2004||2004-09-30|December 2006|2006-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Immunization Against Tumor Cells in Sezary Syndrome|Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells|Completed||Phase 2|17|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 04:59:33.738786|2018-06-01 04:59:33.738786
NCT00099580|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-17|||2015-01-16|2004-12-17|2004-12-20|Estimate|||||||2015-01-16|2015-01-19|Estimate|March 2005||2005-03-31|December 2014|2014-12-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure|PROCLAIM: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Examine the Effects of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure|Completed||Phase 2|61|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:59:33.882215|2018-06-01 04:59:33.882215
NCT00099567|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-16|||2005-10-31|2004-12-16|2004-12-17|Estimate|||||||2005-10-31|2005-11-01|Estimate|January 1997||1997-01-31|December 2004|2004-12-31|December 2002||2002-12-31|||||Observational|||Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline|Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline|Completed|||2632||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:59:33.985394|2018-06-01 04:59:33.985394
NCT00099554|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-16|||2009-11-12|2004-12-16|2004-12-17|Estimate|||||||2009-11-12|2009-11-13|Estimate|May 2004||2004-05-31|November 2009|2009-11-30||||||||Interventional|||Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)|A Phase 4, Open-Label, Single Arm, Observational Study Evaluating the Effectiveness and Safety of Enbrel® (Etanercept) 50 mg Once Weekly in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)|Completed||Phase 4|200||Amgen|||||||||||||||||||2018-06-01 04:59:34.042591|2018-06-01 04:59:34.042591
NCT00099541|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-15|||2009-11-20|2004-12-15|2004-12-16|Estimate|||||||2009-11-20|2009-11-23|Estimate|November 2004||2004-11-30|November 2009|2009-11-30|November 2007||2007-11-30|||||Interventional|||Non-small Cell Lung Cancer Registry|A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis|Completed||Phase 4|300||Novartis|||||f||||||||||||||2018-06-01 04:59:34.133672|2018-06-01 04:59:34.133672
NCT00099528|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-15|||2010-07-28|2004-12-15|2004-12-16|Estimate|||||||2010-07-28|2010-07-29|Estimate|August 2003||2003-08-31|March 2005|2005-03-31|December 2004||2004-12-31|||||Interventional|||Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia|REN-1654 in Post-Herpetic Neuralgia: a Multi-Center, Placebo Controlled, 3-week Dose-Finding Study, With a 3-Week Active-Treatment Extension|Unknown status|Active, not recruiting|Phase 2|90||Renovis|||||||||||||||||||2018-06-01 04:59:34.33725|2018-06-01 04:59:34.33725
NCT00099515|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-15|||2007-12-18|2004-12-15|2004-12-16|Estimate|||||||2007-12-18|2007-12-21|Estimate|November 2004||2004-11-30|December 2007|2007-12-31|September 2005|Actual|2005-09-30|||||Interventional|IDAP||Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)|Standard Training Versus Intensive Training for HIIP Delivery System Usage in Insulin-Naïve Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|97|Actual|Eli Lilly and Company||2|||||||f||||||||||2018-06-01 04:59:34.414682|2018-06-01 04:59:34.414682
NCT00099502|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-15|||2008-12-18|2004-12-15|2004-12-16|Estimate|||||||2008-12-18|2008-12-19|Estimate|November 2003||2003-11-30|December 2008|2008-12-31|August 2007|Actual|2007-08-31|||||Interventional|||BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients|International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.|Completed||Phase 3|2244|Actual|Bayer||3|||f||||t||||||||||2018-06-01 04:59:34.516169|2018-06-01 04:59:34.516169
NCT00099489|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-15|||2010-03-04|2004-12-15|2004-12-16|Estimate|||||||2010-03-04|2010-03-05|Estimate|February 2004||2004-02-29|March 2010|2010-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|Completed||Phase 2|67||Biogen|||||||||||||||||||2018-06-01 04:59:34.879486|2018-06-01 04:59:34.879486
NCT00099476|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-14|||2017-06-30|2004-12-14|2004-12-15|Estimate|||||||2017-06-30|2017-07-02|Actual|December 10, 2004||2004-12-10|April 16, 2009|2009-04-16|April 16, 2009||2009-04-16|||||Interventional|||Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure|Effects of Cocoa Consumption on Insulin Sensitivity and Capillary Recruitment in Subjects With Essential Hypertension|Completed||Phase 1|65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:35.025045|2018-06-01 04:59:35.025045
NCT00099463|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-14|||2017-06-30|2004-12-14|2004-12-15|Estimate|||||||2017-06-30|2017-07-02|Actual|December 9, 2004||2004-12-09|August 22, 2007|2007-08-22|August 22, 2007||2007-08-22|||||Interventional|||Phase I Study of a Vaccine for Severe Acute Respiratory Syndrome (SARS)|A Phase I Study of the Safety and Immunogenicity of a SARS Recombinant DNA Plasmid Vaccine, VRC-SRSDNA015-00-VP, in Healthy Adult Volunteers|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:35.086913|2018-06-01 04:59:35.086913
NCT00099450|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-14|||2015-01-19|2004-12-14|2004-12-15|Estimate|||||||2015-01-19|2015-01-21|Estimate|December 2004||2004-12-31|January 2015|2015-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers|Single-Center, Open-Labeled Dose Escalation Followed by Randomized, Double-Blind, Placebo-Controlled Cohort Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers|Completed||Phase 1|48|Anticipated|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 04:59:35.164703|2018-06-01 04:59:35.164703
NCT00099437|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-13|2010-02-23||2018-03-01|2004-12-13|2004-12-14|Estimate|2010-05-12|2010-06-15|Estimate||||2018-03-01|2018-03-05|Actual|February 8, 2005|Actual|2005-02-08|February 2018|2018-02-28|January 2, 2019|Anticipated|2019-01-02|February 27, 2009|Actual|2009-02-27||Interventional|CONFIRM||Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.|A Randomised, Double-Blind, Parallel-group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Fulvestrant (FASLODEX™) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy|Active, not recruiting||Phase 3|736|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 04:59:35.270046|2018-06-01 04:59:35.270046
NCT00099424|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-13|||2008-06-04|2004-12-13|2004-12-14|Estimate|||||||2008-06-04|2008-06-05|Estimate|February 2004||2004-02-29|June 2008|2008-06-30|August 2005||2005-08-31|||||Interventional|||Exercise Training in Sarcoidosis (EXTRAS Study)|EXercise TRAining in Sarcoidosis (EXTRAS Study): A Prospective, Randomized, Controlled, Crossover Trial|Completed||N/A|30||University Hospital, Gasthuisberg|||||f||||||||||||||2018-06-01 04:59:35.84297|2018-06-01 04:59:35.84297
NCT00099411|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-13|||2017-04-25|2004-12-13|2004-12-14|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2004|Actual|2004-01-31|April 2017|2017-04-30|June 30, 2007|Actual|2007-06-30|June 30, 2007|Actual|2007-06-30||Observational|||Heart Muscle Viability and Remodeling in Individuals Post-Heart Attack|Myocardial Viability and Remodeling in the Occluded Artery Trial (OAT)-Ancillary to OAT|Completed|||124|Actual|Tufts Medical Center|||||f||||t|f|f||||||No||2018-06-01 04:59:35.898449|2018-06-01 04:59:35.898449
NCT00099385|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-13|||2012-02-15|2004-12-13|2004-12-14|Estimate|||||||2012-02-15|2012-02-17|Estimate|September 2004||2004-09-30|February 2012|2012-02-29|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Comprehensive Elementary School Risk Prevention|Comprehensive Elementary School Risk Prevention|Completed||N/A|2620|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 04:59:35.942696|2018-06-01 04:59:35.942696
NCT00099372|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2018-04-30|2004-12-10|2004-12-13|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2004||2004-05-31|April 2018|2018-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse|Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse: The Extended Colpopexy and Urinary Reduction Efforts (E-CARE) Study|Terminated|||215|Actual|NICHD Pelvic Floor Disorders Network|||2|resource and prioritization change as Network transition to a new funding cycle|f||||t||||||||||2018-06-01 04:59:35.991431|2018-06-01 04:59:35.991431
NCT00099359|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|2012-04-25||2012-10-26|2004-12-10|2004-12-13|Estimate|2012-10-26|2012-12-04|Estimate||||2012-10-26|2012-12-04|Estimate|February 2004||2004-02-29|February 2011|2011-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission|Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission|Completed||Phase 3|1735|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||3|||f||||t||||||||||2018-06-01 04:59:36.089235|2018-06-01 04:59:36.089235
NCT00099346|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2015-06-16|2004-12-10|2004-12-13|Estimate|||||||2015-06-16|2015-06-17|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)|A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors|Terminated||Phase 1|||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 04:59:37.206631|2018-06-01 04:59:37.206631
NCT00099333|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2015-02-20|2004-12-10|2004-12-13|Estimate|||||||2015-02-20|2015-02-23|Estimate|February 2004||2004-02-29|January 2015|2015-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents|An Exploratory Study of the Safety of Substituting Exenatide for Insulin in Patients With Type 2 Diabetes Who Have Been Using Insulin in Combination With Oral Antidiabetic Therapy|Completed||Phase 2|49|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:59:37.276805|2018-06-01 04:59:37.276805
NCT00099320|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2015-02-20|2004-12-10|2004-12-13|Estimate|||||||2015-02-20|2015-02-23|Estimate|May 2004||2004-05-31|January 2015|2015-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin|Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin|Completed||Phase 3|182|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 04:59:37.387546|2018-06-01 04:59:37.387546
NCT00099307|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2017-06-30|2004-12-09|2004-12-10|Estimate|||||||2017-06-30|2017-07-02|Actual|December 8, 2004||2004-12-08|September 28, 2011|2011-09-28|September 28, 2011||2011-09-28|||||Observational|||Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis|An Exploratory Study on Detection of Cortical Damage in Patients With Multiple Sclerosis Using Magnetic Resonance Imaging|Completed|||94|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 04:59:37.544018|2018-06-01 04:59:37.544018
NCT00099294|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2009-04-28|2004-12-09|2004-12-10|Estimate|||||||2009-04-28|2009-04-30|Estimate|September 2004||2004-09-30|April 2009|2009-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer|A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine|Completed||Phase 3|300||Threshold Pharmaceuticals|||||||||||||||||||2018-06-01 04:59:37.641093|2018-06-01 04:59:37.641093
NCT00099281|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2007-02-27|2004-12-09|2004-12-10|Estimate|||||||2007-02-27|2007-02-28|Estimate|May 2004||2004-05-31|February 2007|2007-02-28|June 2006||2006-06-30|||||Interventional|||DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer|A Phase III Study of DPPE Combined With Epirubicin and Cyclophosphamide vs Epirubicin and Cyclophosphamide Alone as First Line Treatment in Metastatic/Recurrent Breast Cancer|Terminated||Phase 3|700||YM BioSciences|||||||||||||||||||2018-06-01 04:59:38.024796|2018-06-01 04:59:38.024796
NCT00099268|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|2010-12-15||2012-04-19|2004-12-09|2004-12-10|Estimate|2011-02-14|2011-03-08|Estimate||||2012-04-19|2012-04-23|Estimate|September 2004||2004-09-30|April 2012|2012-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|STRIDE-PD||Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy|A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy|Completed||Phase 3|747|Actual|Novartis||2|||f||||||||||||||2018-06-01 04:59:38.383748|2018-06-01 04:59:38.383748
NCT00099255|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2014-12-17|2004-12-09|2004-12-10|Estimate|||||||2014-12-17|2014-12-18|Estimate|September 2004||2004-09-30|December 2014|2014-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma|A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis|Completed||Phase 2|40||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 04:59:39.286677|2018-06-01 04:59:39.286677
NCT00099242|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2017-10-12|2004-12-09|2004-12-10|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2003||2003-11-30|October 2017|2017-10-31|January 2006|Actual|2006-01-31|||||Interventional|||Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease|Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease|Completed||Phase 3|1040||Novartis|||||||||||||||||||2018-06-01 04:59:39.559623|2018-06-01 04:59:39.559623
NCT00099229|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2017-02-21|2004-12-09|2004-12-10|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2004||2004-11-30|February 2017|2017-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Tolerability of Licarbazepine 1000-2000mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Over 3 Weeks|Completed||Phase 3|320|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:39.735568|2018-06-01 04:59:39.735568
NCT00099216|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2011-11-16|2004-12-09|2004-12-10|Estimate|||||||2011-11-16|2011-11-17|Estimate|August 2001||2001-08-31|November 2011|2011-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia|Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia|Completed||Phase 3|708|Actual|Novartis|||||f||||||||||||||2018-06-01 04:59:39.848616|2018-06-01 04:59:39.848616
NCT00099203|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2017-08-14|2004-12-09|2004-12-10|Estimate|||||||2017-08-14|2017-08-16|Actual|July 2005||2005-07-31|August 2017|2017-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease|A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain|Terminated||Phase 3|163|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:59:40.099613|2018-06-01 04:59:40.099613
NCT00099190|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2009-04-27|2004-12-09|2004-12-10|Estimate|||||||2009-04-27|2009-04-28|Estimate|December 2004||2004-12-31|April 2009|2009-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||ARQ 501 in Combination With Docetaxel in Patients With Cancer|A Phase Ib Safety and Pharmacokinetic Study of ARQ 501 in Combination With Docetaxol in Adult Patients With Locally Advanced or Metastatic Carcinoma|Completed||Phase 1|50||ArQule|||||||||||||||||||2018-06-01 04:59:40.330917|2018-06-01 04:59:40.330917
NCT00099177|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-10|||2017-08-14|2004-12-09|2004-12-10|Estimate|||||||2017-08-14|2017-08-16|Actual|August 2005||2005-08-31|August 2017|2017-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain|A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain|Terminated||Phase 3|96|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 04:59:40.449154|2018-06-01 04:59:40.449154
NCT00099164|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2016-09-26|2004-12-08|2004-12-09|Estimate|||||||2016-09-26|2016-09-28|Estimate|April 2004||2004-04-30|September 2016|2016-09-30|September 2007|Actual|2007-09-30|August 2006|Actual|2006-08-31||Interventional|||Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)|A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS)|Completed||Phase 3|795|Actual|The George Washington University Biostatistics Center|||||f||||t||||||||Yes|The data will be shared after completion and publication of the main analyses in accordance with NIH policy. The dataset can be obtained by emailing mfmudatasets@bsc.gwu.edu.|2018-06-01 04:59:40.595842|2018-06-01 04:59:40.595842
NCT00099151|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2009-12-09|2004-12-08|2004-12-09|Estimate|||||||2009-12-09|2009-12-11|Estimate|March 2002||2002-03-31|December 2004|2004-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||CALERIE (PBRC, Baton Rouge) - Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy|Metabolic Adaptations to Six Month Caloric Restriction|Completed||N/A|48||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:59:40.70748|2018-06-01 04:59:40.70748
NCT00099138|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2009-12-09|2004-12-08|2004-12-09|Estimate|||||||2009-12-09|2009-12-11|Estimate|March 2002||2002-03-31|February 2006|2006-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||CALERIE (Washington University): Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy|Caloric Restriction and Aging in Humans|Completed||Phase 1|48||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:59:40.824543|2018-06-01 04:59:40.824543
NCT00099125|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2014-01-23|2004-12-08|2004-12-09|Estimate|||||||2014-01-23|2014-01-24|Estimate|November 2004||2004-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|October 2006|Actual|2006-10-31||Interventional|||Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Study Of Radiation Therapy Plus Low Dose Temozolomide Followed By Temozolomide Plus Irinotecan For Glioblastoma Multiforme|Completed||Phase 2|170|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 04:59:40.960222|2018-06-01 04:59:40.960222
NCT00099112|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2015-04-29|2004-12-08|2004-12-09|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2004||2004-02-29|November 2005|2005-11-30||||||||Observational|||Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II|Transcriptional Profiling of the Epidermal Response to Solar-Simulated Ultraviolet Radiation|Completed|||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:41.156239|2018-06-01 04:59:41.156239
NCT00099099|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2009-12-09|2004-12-08|2004-12-09|Estimate|||||||2009-12-09|2009-12-11|Estimate|March 2002||2002-03-31|February 2006|2006-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||CALERIE (Tufts) - Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy|Dietary Energy Restriction and Metabolic Aging in Humans|Completed||Phase 1|44||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 04:59:41.201959|2018-06-01 04:59:41.201959
NCT00099086|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2018-02-27|2004-12-08|2004-12-09|Estimate|||||||2018-02-27|2018-03-01|Actual|July 2010||2010-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|January 2011|Actual|2011-01-31||Interventional|||Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer|Phase I Trial of Concurrent Taxotere With Radiation Therapy and Hormonal Therapy For Clinically Localized High Risk Prostate Cancer|Active, not recruiting||Phase 1|20|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-06-01 04:59:41.246136|2018-06-01 04:59:41.246136
NCT00099060|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2014-01-24|2004-12-08|2004-12-09|Estimate|||||||2014-01-24|2014-01-27|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase I/II Study of GW572016 in Patients With Recurrent Malignant Glioma|Completed||Phase 1/Phase 2|24|Actual|National Cancer Institute (NCI)|||||f||||f||||||||||2018-06-01 04:59:41.394441|2018-06-01 04:59:41.394441
NCT00099047|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2014-12-16||2016-12-28|2004-12-08|2004-12-09|Estimate|2015-06-04|2015-06-09|Estimate||||2016-12-28|2016-12-30|Estimate|November 2004||2004-11-30|December 2016|2016-12-31|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional||Asymptomatic adult patients with a serum monoclonal protein >1g/dL from each of the participating centers between August 2005 and April 2008 were randomized to either celecoxib or placebo in a double-blind, 1:1 fashion|Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma|Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)|No overall limitations or caveats for this trial.|2|||f||||t||||||||||2018-06-01 04:59:41.48017|2018-06-01 04:59:41.48017
NCT00099021|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2009-10-13||2016-12-28|2004-12-08|2004-12-09|Estimate|2009-10-13|2009-11-25|Estimate||||2016-12-28|2016-12-30|Estimate|June 2003||2003-06-30|December 2016|2016-12-31|January 2010|Actual|2010-01-31|September 2008|Actual|2008-09-30||Interventional|||Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia|A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)|"Study was closed prior to full accrual because results were very good and funding was discontinued (R-01 application was filed.)~Immunohistochemistry (Outcomes #4 through #12) were not done due to laboratory limitations of time."|1|||f||||||||||||||2018-06-01 04:59:41.792394|2018-06-01 04:59:41.792394
NCT00099008|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2013-05-17|2004-12-08|2004-12-09|Estimate|||||||2013-05-17|2013-05-21|Estimate|March 2004||2004-03-31|May 2013|2013-05-31|July 2006|Actual|2006-07-31|July 2005|Actual|2005-07-31||Interventional|||Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women|Phase I Multiple Dose Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women|Completed||Phase 1|30|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 04:59:42.066668|2018-06-01 04:59:42.066668
NCT00098995|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2013-06-25|2004-12-08|2004-12-09|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 2004||2004-12-31|November 2006|2006-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer|A Phase I Study Of Tirapazamine In Combination With Radiation And Weekly Cisplatin In Patients With Locally Advanced Cervical Cancer|Completed||Phase 1|22|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 04:59:42.127841|2018-06-01 04:59:42.127841
NCT00098982|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2013-06-11|2004-12-08|2004-12-09|Estimate|||||||2013-06-11|2013-06-12|Estimate|September 2004||2004-09-30|June 2013|2013-06-30||||January 2007|Actual|2007-01-31||Interventional|||Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer|Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer|Completed||Phase 1|16|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:59:42.184574|2018-06-01 04:59:42.184574
NCT00098969|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2012-12-13|2004-12-08|2004-12-09|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 2004||2004-09-30|March 2010|2010-03-31||||||||Interventional|IRB 2004-535||UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants|Phase I Single-Dose Safety and Phamacokinetics Clinical Study of Resveratrol AKA IRB 2003-424|Completed||Phase 1|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:42.248304|2018-06-01 04:59:42.248304
NCT00098956|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2015-08-10||2015-08-10|2004-12-08|2004-12-09|Estimate|2015-08-10|2015-09-09|Estimate||||2015-08-10|2015-09-09|Estimate|January 2005||2005-01-31|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer|A Phase II Study of UCN-01 in Combination With Topotecan in Patients With SCLC Who Relapsed or Progressed &gt;= 3 Months After Completing First-Line Platinum-Based Chemotherapy|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:42.306141|2018-06-01 04:59:42.306141
NCT00098943|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2012-09-20|2004-12-08|2004-12-09|Estimate|||||||2012-09-20|2012-09-24|Estimate|September 2004||2004-09-30|September 2012|2012-09-30||||November 2007|Actual|2007-11-30||Interventional|||NGR-TNF in Treating Patients With Advanced Solid Tumors|Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor|Completed||Phase 1|70|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 04:59:42.449966|2018-06-01 04:59:42.449966
NCT00098917|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2008-01-24|2004-12-08|2004-12-09|Estimate|||||||2008-01-24|2008-01-28|Estimate|February 2005||2005-02-28|April 2007|2007-04-30||||||||Interventional|||Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|A Phase I Clinical Trial of Mature Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells for the Treatment of Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|15||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:43.450445|2018-06-01 04:59:43.450445
NCT00098891|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2013-01-23|2004-12-08|2004-12-09|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2004||2004-10-31|January 2013|2013-01-31||||March 2008|Actual|2008-03-31||Interventional|||MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas|A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995, IND 61,198), in Combination With 13-Cis-Retinoic Acid in Metastatic Progressive Cancer.|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:43.526546|2018-06-01 04:59:43.526546
NCT00098878|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2013-08-06|2004-12-08|2004-12-09|Estimate|||||||2013-08-06|2013-08-07|Estimate|March 2004||2004-03-31|July 2009|2009-07-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers|Completed||Phase 3|1300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:43.634301|2018-06-01 04:59:43.634301
NCT00098865|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2012-12-15||2014-09-28|2004-12-08|2004-12-09|Estimate|2014-09-19|2014-09-25|Estimate||||2014-09-28|2014-10-07|Estimate|September 2002||2002-09-30|September 2014|2014-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||The analysis population represents all enrolled and treated patients.|Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma|A Phase II Pilot Study Of Thalidomide With Temozolomide In Patients With Relapsed Or Progressive Brain Tumors Or Neuroblastoma|Completed||Phase 2|15|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-06-01 04:59:44.565234|2018-06-01 04:59:44.565234
NCT00098852|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2014-01-03|2004-12-08|2004-12-09|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2004||2004-10-31|January 2009|2009-01-31||||June 2010|Anticipated|2010-06-30||Interventional|||Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer|A Pilot Study of Rosiglitazone in Patients With Incurable Differentiated Thyroid Cancer|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:44.826106|2018-06-01 04:59:44.826106
NCT00098839|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2015-03-03||2017-11-14|2004-12-08|2004-12-09|Estimate|2015-03-24|2015-03-26|Estimate||||2017-11-14|2017-12-12|Actual|February 2005||2005-02-28|November 2017|2017-11-30|April 2011||2011-04-30|April 2011|Actual|2011-04-30||Interventional||Ineligible patients (2) are not included in baseline population.|Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)|A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 1/Phase 2|134|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 04:59:44.95249|2018-06-01 04:59:44.95249
NCT00098826|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2013-01-10|2004-12-08|2004-12-09|Estimate|||||||2013-01-10|2013-01-11|Estimate|December 2004||2004-12-31|January 2013|2013-01-31||||May 2008|Actual|2008-05-31||Interventional|||SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes|Phase I and Pharmacodynamic Study of SB-715992 in Acute Leukemias|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:45.933318|2018-06-01 04:59:45.933318
NCT00098813|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2013-10-29||2014-05-13|2004-12-08|2004-12-09|Estimate|2013-10-29|2013-12-19|Estimate||||2014-05-13|2014-05-28|Estimate|October 2004||2004-10-31|October 2013|2013-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine|A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma|Completed||Phase 2|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:46.022586|2018-06-01 04:59:46.022586
NCT00094731|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2009-12-09|2004-10-21|2004-10-22|Estimate|||||||2009-12-09|2009-12-11|Estimate|March 2001||2001-03-31|February 2006|2006-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||SeniorWISE: Improving Everyday Memory in At-Risk Elderly|Improving Everyday Memory in At-Risk Elderly|Completed||Phase 3|260||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:02:01.069824|2018-06-01 05:02:01.069824
NCT00098800|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2010-03-23|2004-12-08|2004-12-09|Estimate|||||||2010-03-23|2010-03-24|Estimate|October 2004||2004-10-31|November 2006|2006-11-30|November 2006|Actual|2006-11-30|August 2006|Actual|2006-08-31||Interventional|||Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries|A Multicenter Randomized Double-Blinded Trial for Chemoprevention of Ovarian Cancer: Modulation of Biomarkers and Spectral Properties Using Contrast Enhanced Ultrasound in High-Risk Women Using Fenretinide (4-HPR)|Completed||N/A|40|Anticipated|University of Arizona|||||||||||||||||||2018-06-01 04:59:46.19365|2018-06-01 04:59:46.19365
NCT00098787|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2014-05-27||2015-10-06|2004-12-08|2004-12-09|Estimate|2014-05-27|2014-06-27|Estimate||||2015-10-06|2015-10-08|Estimate|July 2005||2005-07-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|November 2013|Actual|2013-11-30||Interventional||Eligible and treated patients|Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer|Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients With Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|247|Actual|Eastern Cooperative Oncology Group||3|||f||||t||||||||||2018-06-01 04:59:46.297178|2018-06-01 04:59:46.297178
NCT00098774|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|2014-06-26||2016-07-01|2004-12-08|2004-12-09|Estimate|2014-09-11|2014-09-12|Estimate||||2016-07-01|2016-07-06|Estimate|October 2004||2004-10-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|January 2010|Actual|2010-01-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma|Intensive Chemotherapy And Immunotherapy In Patients With Newly Diagnosed Primary CNS Lymphoma|Completed||Phase 2|47|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:59:47.217343|2018-06-01 04:59:47.217343
NCT00098761|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-08|||2011-06-29|2004-12-08|2004-12-09|Estimate|||||||2011-06-29|2011-06-30|Estimate|February 2005||2005-02-28|June 2011|2011-06-30|February 2008|Actual|2008-02-29|October 2006|Actual|2006-10-31||Interventional|||VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors|Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent, Progressive Or Refractory Primary Brain Tumors|Completed||Phase 1|42|Actual|Pediatric Brain Tumor Consortium|||||f||||t||||||||||2018-06-01 04:59:47.677264|2018-06-01 04:59:47.677264
NCT00098748|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|2010-03-25||2010-11-19|2004-12-07|2004-12-08|Estimate|2010-10-14|2010-10-21|Estimate||||2010-11-19|2010-12-07|Estimate|November 2004||2004-11-30|November 2010|2010-11-30|April 2009|Actual|2009-04-30|December 2005|Actual|2005-12-31||Interventional|||Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects|A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects|Completed||Phase 2/Phase 3|190|Actual|ViiV Healthcare||3|||f||||t||||||||||2018-06-01 04:59:47.87249|2018-06-01 04:59:47.87249
NCT00098735|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2016-11-16|2004-12-07|2004-12-08|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2004||2004-04-30|November 2016|2016-11-30||||April 2006|Actual|2006-04-30||Interventional|||Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation|Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation|Completed||Phase 3|140||Novartis|||||||||||||||||||2018-06-01 04:59:49.081777|2018-06-01 04:59:49.081777
NCT00098722|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|2012-04-16||2012-04-16|2004-12-07|2004-12-08|Estimate|2012-04-16|2012-05-16|Estimate||||2012-04-16|2012-05-16|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2007|Actual|2007-04-30||Interventional|MOTIVATE 2||Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects|Completed||Phase 2/Phase 3|474|Actual|ViiV Healthcare||3|||f||||t||||||||||2018-06-01 04:59:49.277124|2018-06-01 04:59:49.277124
NCT00098709|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2017-12-26|2004-12-07|2004-12-08|Estimate|||||||2017-12-26|2017-12-28|Actual|May 2002||2002-05-31|December 2017|2017-12-31|February 2005||2005-02-28|||||Interventional|||Fetal Pulse Oximetry Trial (FOX)|A Randomized Clinical Trial of Fetal Pulse Oximetry|Terminated||Phase 3|10000||The George Washington University Biostatistics Center|||||||||||||||||||2018-06-01 04:59:51.778566|2018-06-01 04:59:51.778566
NCT00098683|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2014-02-11|2004-12-07|2004-12-08|Estimate|||||||2014-02-11|2014-02-13|Estimate|January 2005||2005-01-31|February 2014|2014-02-28|October 2009|Actual|2009-10-31|October 2007|Actual|2007-10-31||Interventional|||Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes|A Phase II Study Of Amifostine In Children With Myelodysplastic Syndrome|Completed||Phase 2|10|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 04:59:51.938139|2018-06-01 04:59:51.938139
NCT00098670|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|2012-11-05||2014-05-06|2004-12-07|2004-12-08|Estimate|2012-11-05|2012-12-03|Estimate||||2014-05-06|2014-05-21|Estimate|October 2004||2004-10-31|December 2012|2012-12-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Fludarabine + Rituximab Induction Followed by Alemtuzumab (Campath-1H, NSC #715969, IND #10864) Administered Subcutaneously as Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|102|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:52.129793|2018-06-01 04:59:52.129793
NCT00098631|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2014-01-06|2004-12-07|2004-12-08|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2004||2004-10-31|January 2014|2014-01-31||||December 2006|Actual|2006-12-31||Interventional|||Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN)|Completed||Phase 2|88|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:53.064337|2018-06-01 04:59:53.064337
NCT00098618|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-07-01|2004-12-07|2004-12-08|Estimate|||||||2013-07-01|2013-07-02|Estimate|October 2004||2004-10-31|July 2013|2013-07-31||||January 2006|Actual|2006-01-31||Interventional|||Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer|A Phase 2 Study Of BAY 43-9006 In Combination With Interferon Alfa-2b In Metastatic Renal Cell Cancer|Terminated||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:53.142498|2018-06-01 04:59:53.142498
NCT00098605|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-06-04|2004-12-07|2004-12-08|Estimate|||||||2013-06-04|2013-06-06|Estimate|October 2004||2004-10-31|June 2013|2013-06-30||||September 2006|Actual|2006-09-30||Interventional|||Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases|A Phase 2 Study of GW572016 for Brain Metastases in Patients With HER2-Positive Breast Cancer|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:53.219087|2018-06-01 04:59:53.219087
NCT00098579|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-03-18|2004-12-07|2004-12-08|Estimate|||||||2013-03-18|2013-03-19|Estimate|October 2004||2004-10-31|March 2013|2013-03-31||||July 2011|Actual|2011-07-31||Interventional|||Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery|Phase I Trial of Doxorubicin and Alvocidib (Flavopiridol; NCI Supplied Agent, NSC 649890) in the Treatment of Metastatic Sarcoma|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:53.294354|2018-06-01 04:59:53.294354
NCT00098566|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2015-10-13|2004-12-07|2004-12-08|Estimate|||||||2015-10-13|2015-10-14|Estimate|December 2002||2002-12-31|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Long-Term Follow-Up Study Evaluating the Efficacy and Delayed Toxicities of Radioiodinated Tositumomab (Anti-CD20 Antibody) Followed by Autologous Transplantation for Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed|||36|Actual|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 04:59:53.368055|2018-06-01 04:59:53.368055
NCT00098553|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2016-07-01|2004-12-07|2004-12-08|Estimate|||||||2016-07-01|2016-07-06|Estimate|April 2005||2005-04-30|July 2016|2016-07-31|February 2010|Actual|2010-02-28|July 2007|Actual|2007-07-31||Interventional|||Everolimus in Treating Patients With Stage IV Melanoma|Phase II Trial Of RAD-001 In Metastatic Malignant Melanoma|Completed||Phase 2|53|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 04:59:53.43975|2018-06-01 04:59:53.43975
NCT00098540|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2016-12-28|2004-12-07|2004-12-08|Estimate|||||||2016-12-28|2016-12-29|Estimate|December 2004||2004-12-31|December 2016|2016-12-31||||May 2007|Actual|2007-05-31||Interventional|||Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study of the Raf Kinase Inhibitor BAY43-9006 in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:53.704956|2018-06-01 04:59:53.704956
NCT00098527|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-07-01|2004-12-07|2004-12-08|Estimate|||||||2013-07-01|2013-07-02|Estimate|October 2004||2004-10-31|July 2013|2013-07-31||||September 2005|Actual|2005-09-30||Interventional|||FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer|A Phase 2 Study of Single Agent Depsipeptide (FK228) in Gastric and Esophageal Cancers|Terminated||Phase 2|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:53.766361|2018-06-01 04:59:53.766361
NCT00098514|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2017-12-14|2004-12-07|2004-12-08|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2003|Actual|2003-12-31|December 2017|2017-12-31|May 2011|Actual|2011-05-31|March 2007|Actual|2007-03-31||Interventional|||Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors|A Phase I Study Of PT523 In Patients With Solid Tumors|Completed||Phase 1|53|Actual|Dana-Farber Cancer Institute||7|||f||||t|t|f|||f|||||2018-06-01 04:59:53.900045|2018-06-01 04:59:53.900045
NCT00098501|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-06-03|2004-12-07|2004-12-08|Estimate|||||||2013-06-03|2013-06-04|Estimate|October 2004||2004-10-31|June 2013|2013-06-30||||October 2007|Actual|2007-10-31||Interventional|||CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors|A Phase 1 Trial of CCI-779 in Combination With EKB-569, an EGFR Inhibitor, in Patients With Solid Tumors|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:53.981343|2018-06-01 04:59:53.981343
NCT00098488|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-06-03|2004-12-07|2004-12-08|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2005||2005-04-30|June 2013|2013-06-30||||April 2008|Actual|2008-04-30||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia|A Phase 1 Study of 17-allylamino-17-demethoxygeldanamycin (17-AAG) (NSC 330507; IND 57,966) and Rituximab in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:54.196409|2018-06-01 04:59:54.196409
NCT00098475|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|2013-08-30||2018-04-12|2004-12-07|2004-12-08|Estimate|2013-12-05|2014-01-22|Estimate||||2018-04-12|2018-04-13|Actual|October 26, 2004|Actual|2004-10-26|February 2018|2018-02-28||||November 30, 2008|Actual|2008-11-30||Interventional|||Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma|A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma With Thalidomide Plus Dexamethasone Salvage Therapy for Non-responders|Active, not recruiting||Phase 3|452|Actual|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-06-01 04:59:54.363315|2018-06-01 04:59:54.363315
NCT00098462|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2012-10-02|2004-12-07|2004-12-08|Estimate|||||||2012-10-02|2012-10-04|Estimate|October 2004||2004-10-31|October 2012|2012-10-31||||||||Interventional|||Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase I/II Trial of ZD1839 (Iressa®) and Rapamycin (Rapamune) in Patients With Advanced Non Small Cell Lung Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||||Withdrawn as study never opened|f||||||||||||||2018-06-01 04:59:55.990611|2018-06-01 04:59:55.990611
NCT00098436|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-07-17|2004-12-07|2004-12-08|Estimate|||||||2013-07-17|2013-07-18|Estimate|September 2004||2004-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|October 2006|Actual|2006-10-31||Interventional|||Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias|A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies|Completed||Phase 1|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:56.104389|2018-06-01 04:59:56.104389
NCT00098423|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-09-27|2004-12-07|2004-12-08|Estimate|||||||2013-09-27|2013-09-30|Estimate|November 2004||2004-11-30|September 2013|2013-09-30||||May 2009|Actual|2009-05-31||Interventional|||Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes|A Phase I And Pharmacological Trial Of 17-Allylamino -17-demethoxygeldanamycin (17-AAG) And Cytarabine In Refractory Leukemia And Myelodysplastic Syndrome|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:56.171326|2018-06-01 04:59:56.171326
NCT00098397|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-01-23|2004-12-07|2004-12-08|Estimate|||||||2013-01-23|2013-01-24|Estimate|February 2005||2005-02-28|January 2013|2013-01-31||||September 2005|Actual|2005-09-30||Interventional|||FR901228 in Treating Patients With Metastatic Breast Cancer|A Phase II Study Of Single Agent Depsipeptide (FK228) In Breast Cancer|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 04:59:56.253111|2018-06-01 04:59:56.253111
NCT00098384|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2006-05-08|2004-12-07|2004-12-08|Estimate|||||||2006-05-08|2006-05-09|Estimate|June 2003||2003-06-30|December 2004|2004-12-31|September 2003||2003-09-30|||||Interventional|||Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea|A Randomized, Double-Blind, Single Center, Comparative Dose Ranging Study of Rifaximin Vs. Placebo in the Prevention of Travelers' Diarrhea Due to Enteropathogenic Bacteria|Completed||Phase 2|220||DuPont, Hurbert L., MD|||||||||||||||||||2018-06-01 04:59:56.312249|2018-06-01 04:59:56.312249
NCT00098371|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|2015-07-14||2016-08-31|2004-12-07|2004-12-08|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|April 2005||2005-04-30|August 2016|2016-08-31|November 2012|Actual|2012-11-30|June 2009|Actual|2009-06-30||Interventional|||Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia|A Phase II Study of Flavopiridol Administered as a 30 Minute Loading Dose Followed by a 4-Hour Continuous Infusion in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From CLL|Terminated||Phase 2|64|Actual|National Cancer Institute (NCI)||1||CTEP Initiated Action.|f||||||||||||||2018-06-01 04:59:56.378764|2018-06-01 04:59:56.378764
NCT00098358|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2007-02-05|2004-12-07|2004-12-08|Estimate|||||||2007-02-05|2007-02-07|Estimate|November 2004||2004-11-30|February 2007|2007-02-28|May 2005||2005-05-31|||||Interventional|||Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Proof of Concept Study of Zileuton IR in Patients With Moderate to Severe Facial Acne Vulgaris|Unknown status|Active, not recruiting|Phase 2|90||Critical Therapeutics|||||||||||||||||||2018-06-01 04:59:56.645845|2018-06-01 04:59:56.645845
NCT00098345|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|2011-04-27||2018-04-06|2004-12-07|2004-12-08|Estimate|2011-04-27|2011-05-24|Estimate||||2018-04-06|2018-05-07|Actual|November 2004||2004-11-30|April 2018|2018-04-30|April 19, 2017|Actual|2017-04-19|February 2008|Actual|2008-02-29||Interventional|||Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer|An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.|Completed||Phase 2|40|Actual|Sanofi||1|||f||||||||||||||2018-06-01 04:59:56.721234|2018-06-01 04:59:56.721234
NCT00098332|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-07|||2013-07-09|2004-12-07|2004-12-08|Estimate|||||||2013-07-09|2013-07-10|Estimate|November 2004||2004-11-30|June 2007|2007-06-30|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma|A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 04:59:57.968105|2018-06-01 04:59:57.968105
NCT00098319|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-06|||2013-12-16|2004-12-06|2004-12-07|Estimate|||||||2013-12-16|2013-12-17|Estimate|January 2004||2004-01-31|December 2013|2013-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Oral Cleft Prevention Trial in Brazil|Oral Cleft Prevention Trial in Brazil|Completed||Phase 3|2200|Anticipated|NICHD Global Network for Women's and Children's Health|||||f||||||||||||||2018-06-01 04:59:58.054628|2018-06-01 04:59:58.054628
NCT00098306|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-06|2012-04-02||2012-04-02|2004-12-06|2004-12-07|Estimate|2012-04-02|2012-04-27|Estimate||||2012-04-02|2012-04-27|Estimate|November 2004||2004-11-30|April 2012|2012-04-30|April 2011|Actual|2011-04-30|April 2007|Actual|2007-04-30||Interventional|MOTIVATE 1||Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.|Completed||Phase 2/Phase 3|601|Actual|ViiV Healthcare||3|||f||||t||||||||||2018-06-01 04:59:58.263022|2018-06-01 04:59:58.263022
NCT00098293|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-06|2012-07-09||2013-08-07|2004-12-06|2004-12-07|Estimate|2012-09-05|2012-10-05|Estimate||||2013-08-07|2013-10-09|Estimate|November 2004||2004-11-30|August 2013|2013-08-31|December 2012|Actual|2012-12-31|April 2007|Actual|2007-04-30||Interventional|MERIT||Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine|A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects|Completed||Phase 3|916|Actual|ViiV Healthcare|Following DSMB decision to discontinue maraviroc 300 mg once daily, inferential statistical analyses was performed between maraviroc 300 mg twice daily and efavirenz 600 mg once daily only. Data at Week 24 was not analyzed as planned in protocol.|3|||f||||t||||||||||2018-06-01 05:00:01.519351|2018-06-01 05:00:01.519351
NCT00098280|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2008-03-03|2004-12-03|2004-12-06|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2004||2004-12-31|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria|A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients|Completed||Phase 3|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:05.035451|2018-06-01 05:00:05.035451
NCT00098267|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2017-06-30|2004-12-03|2004-12-06|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2, 2004||2004-12-02|August 3, 2009|2009-08-03|August 3, 2009|Actual|2009-08-03|August 3, 2009|Actual|2009-08-03||Observational|||Collection of Dental Plaque and Saliva for Studies of Bacterial Colonization of Teeth|Collection of Dental Plaque and Saliva for Studies of Oral Microbial Colonization|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:05.126799|2018-06-01 05:00:05.126799
NCT00098254|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|2011-10-06||2012-04-03|2004-12-03|2004-12-06|Estimate|2012-04-03|2012-05-02|Estimate||||2012-04-03|2012-05-02|Estimate|December 2004||2004-12-31|April 2012|2012-04-30|January 2011|Actual|2011-01-31|November 2009|Actual|2009-11-30||Interventional|||BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer|Phase II Study of Bay 43-9006 (Sorafenib) With Evaluation of RAS Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer|Completed||Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:00:05.220537|2018-06-01 05:00:05.220537
NCT00098241|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2017-02-21|2004-12-03|2004-12-06|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2000||2000-06-30|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients|Multicenter Trial of the Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients|Completed||Phase 3|45|Anticipated|Novartis|||||f||||||||||||||2018-06-01 05:00:05.970618|2018-06-01 05:00:05.970618
NCT00098228|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2011-10-24|2004-12-03|2004-12-06|Estimate|||||||2011-10-24|2011-10-25|Estimate|July 2004||2004-07-31|October 2011|2011-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Dose-Ranging Study in Patients With COPD|Completed||Phase 2|686|Actual|Novartis|||||||||||||||||||2018-06-01 05:00:06.109004|2018-06-01 05:00:06.109004
NCT00098215|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2005-11-09|2004-12-03|2004-12-06|Estimate|||||||2005-11-09|2005-11-10|Estimate|March 2001||2001-03-31|December 2004|2004-12-31|February 2006||2006-02-28|||||Interventional|||Pediatric Residency Training On Tobacco|Pediatric Residency Training on Tobacco|Unknown status|Recruiting|Phase 2|4000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:00:06.287386|2018-06-01 05:00:06.287386
NCT00098202|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2013-12-16|2004-12-03|2004-12-06|Estimate|||||||2013-12-16|2013-12-17|Estimate|March 2003||2003-03-31|December 2013|2013-12-31|April 2007|Actual|2007-04-30|||||Interventional|||Randomized Placebo-Controlled Trial (RPCT) of Maize/Zinc in Guatemala|Randomized Placebo-Controlled Trial (RPCT) of Maize/Zinc in Guatemala|Completed||Phase 3|420|Anticipated|NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 05:00:06.441131|2018-06-01 05:00:06.441131
NCT00098189|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2006-08-29|2004-12-03|2004-12-06|Estimate|||||||2006-08-29|2006-08-31|Estimate|July 2004||2004-07-31|August 2006|2006-08-31||||||||Observational|||Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis|A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis|Completed|||||Novartis|||||||||||||||||||2018-06-01 05:00:06.553758|2018-06-01 05:00:06.553758
NCT00098163|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2012-05-03|2004-12-03|2004-12-06|Estimate|||||||2012-05-03|2012-05-04|Estimate||||May 2012|2012-05-31|May 2009|Actual|2009-05-31|||||Interventional|||Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers|A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:00:06.632312|2018-06-01 05:00:06.632312
NCT00098150|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2006-08-29|2004-12-03|2004-12-06|Estimate|||||||2006-08-29|2006-08-31|Estimate|July 2004||2004-07-31|August 2006|2006-08-31||||||||Observational|||Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Atopic Dermatitis|A Follow-Up Study of Patients Previously Treated in a Core Study With Pimecrolimus Tablets for Atopic Dermatitis|Completed|||66||Novartis|||||||||||||||||||2018-06-01 05:00:06.743372|2018-06-01 05:00:06.743372
NCT00098137|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2012-09-10|2004-12-03|2004-12-06|Estimate|||||||2012-09-10|2012-09-11|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation|Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial (ANTIPAF Trial)|Completed||Phase 3|422|Actual|Atrial Fibrillation Network||2|||f||||t||||||||||2018-06-01 05:00:06.786513|2018-06-01 05:00:06.786513
NCT00098124|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2007-12-18|2004-12-03|2004-12-06|Estimate|||||||2007-12-18|2007-12-24|Estimate|November 2004||2004-11-30|December 2007|2007-12-31|December 2006||2006-12-31|||||Interventional|||Study of Milnacipran for the Treatment of Fibromyalgia|A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Milnacipran for the Treatment of Fibromyalgia|Completed||Phase 3|1200||Forest Laboratories|||||||||||||||||||2018-06-01 05:00:06.889345|2018-06-01 05:00:06.889345
NCT00098111|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2014-02-19|2004-12-03|2004-12-06|Estimate|||||||2014-02-19|2014-02-21|Estimate|April 2005||2005-04-30|February 2014|2014-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease|A Double-Blinded, Randomized, Parallel Arm, Dose Ranging Study of IMURAN in Subjects With Active Crohn's Disease Requiring Treatment With Prednisone: A Crohn's Disease Optimal Range Dose of IMURAN Study (ACORDIS)|Terminated||Phase 3|31|Actual|Massachusetts General Hospital||3||Lack of recruitment|f||||||||||||||2018-06-01 05:00:07.321764|2018-06-01 05:00:07.321764
NCT00098098|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2012-08-22|2004-12-03|2004-12-06|Estimate|||||||2012-08-22|2012-08-23|Estimate|August 2004||2004-08-31|August 2012|2012-08-31|August 2005|Actual|2005-08-31|||||Interventional|||Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults|A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults|Completed||Phase 1|44|Anticipated|DynPort Vaccine Company LLC, A CSC Company|||||||||||||||||||2018-06-01 05:00:07.421724|2018-06-01 05:00:07.421724
NCT00098085|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-03|||2009-03-06|2004-12-03|2004-12-06|Estimate|||||||2009-03-06|2009-03-09|Estimate|September 2003||2003-09-30|March 2009|2009-03-31||||November 2007|Actual|2007-11-30||Interventional|||Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer|A Phase II Study of the Feasibility to Derive Autologous Vaccine (HSPPC-96) From Tumor Tissue for Clinical Administration in Patients With Resectable Non-Small Cell Lung Cancer|Completed||Phase 2|20||Agenus Inc.|||||||||||||||||||2018-06-01 05:00:07.489569|2018-06-01 05:00:07.489569
NCT00098072|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-02|||2018-03-27|2004-12-02|2004-12-03|Estimate|||||||2018-03-27|2018-03-29|Actual|December 1, 2004||2004-12-01|November 27, 2017|2017-11-27|July 8, 2009|Actual|2009-07-08|July 8, 2009|Actual|2009-07-08||Interventional|||Endothelial Cell Dysfunction in Pulmonary Hypertension|Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic Targets|Completed||Phase 1|27|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:07.67004|2018-06-01 05:00:07.67004
NCT00098059|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-02|2009-02-02||2013-04-18|2004-12-02|2004-12-03|Estimate|2009-03-20|2009-05-06|Estimate||||2013-04-18|2013-04-25|Estimate|February 2005||2005-02-28|April 2013|2013-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection|A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herpes Simplex Infection|Completed||Phase 3|74|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:00:07.7766|2018-06-01 05:00:07.7766
NCT00098046|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-02|||2007-09-25|2004-12-02|2004-12-03|Estimate|||||||2007-09-25|2007-09-26|Estimate|July 2005||2005-07-31|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection|Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection|Completed||Phase 3|76|Anticipated|Novartis|||||||||||||||||||2018-06-01 05:00:08.722024|2018-06-01 05:00:08.722024
NCT00098033|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-02|||2015-03-24|2004-12-02|2004-12-03|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2002||2002-09-30|December 2004|2004-12-31|September 2005||2005-09-30|||||Interventional|||Investigation of Clofarabine in Acute Leukemias|Phase II Clinical and Pharmacodynamic Investigation of Clofarabine in Acute Leukemias|Completed||Phase 2|64||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:00:08.978112|2018-06-01 05:00:08.978112
NCT00098020|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|2017-06-08||2017-12-12|2004-12-01|2004-12-02|Estimate|2017-12-12|2017-12-13|Actual||||2017-12-12|2017-12-13|Actual|November 26, 2004||2004-11-26|October 4, 2017|2017-10-04|June 27, 2016|Actual|2016-06-27|June 27, 2016|Actual|2016-06-27||Interventional|||Podocyte Retinoids|Retinoids for Podocyte Disease|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||Yes|The stored samples for this trial include plasma, urine, and renal biopsy samples. The plasma and urine are collected for cytokine measurement. Renal biopsy is done to evaluate histologic and ultrastructural changes. Samples/Data will be shared with collaborating investigators.|2018-06-01 05:00:09.134945|2018-06-01 05:00:09.134945
NCT00094133|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-14|||2013-09-19|2004-10-14|2004-10-15|Estimate|||||||2013-09-19|2013-09-20|Estimate|April 2006||2006-04-30|September 2007|2007-09-30||||||||Interventional|||Hypnosis in Treating Hot Flashes in Breast Cancer Survivors|Hypnosis for Hot Flashes in Breast Cancer Survivors|Unknown status|Recruiting|N/A|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:02:20.107679|2018-06-01 05:02:20.107679
NCT00098007|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2017-02-20|2004-12-01|2004-12-02|Estimate|||||||2017-02-20|2017-02-23|Actual|August 9, 2004||2004-08-09|February 2017|2017-02-28|January 8, 2007|Actual|2007-01-08|January 8, 2007|Actual|2007-01-08||Interventional|||A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients|Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in Addition to Certican and Steroids in de Novo Heart Transplant Recipients|Completed||Phase 3|199|Actual|Novartis|||||||||||||||||||2018-06-01 05:00:09.630704|2018-06-01 05:00:09.630704
NCT00097994|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2014-05-19|2004-12-01|2004-12-02|Estimate|||||||2014-05-19|2014-05-20|Estimate|December 2004||2004-12-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Does Menopause Matter?|Does Menopause Matter?|Completed|||732|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:00:09.788401|2018-06-01 05:00:09.788401
NCT00097981|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|2008-10-02||2017-02-20|2004-12-01|2004-12-02|Estimate|2008-11-26|2008-11-27|Estimate||||2017-02-20|2017-04-07|Actual|January 2005||2005-01-31|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma|A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Subjects With Newly Diagnosed Multiple Myeloma|Completed||Phase 3|225|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||t||||||||||2018-06-01 05:00:09.979649|2018-06-01 05:00:09.979649
NCT00097968|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2010-07-09|2004-12-01|2004-12-02|Estimate|||||||2010-07-09|2010-07-12|Estimate|August 2004||2004-08-31|July 2010|2010-07-31||||April 2005|Actual|2005-04-30||Interventional|||Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy|An Open-Label, Single Arm, Pilot Study of the Renal Safety of Everolimus in Addition to Neoral® in Cardiac Transplant Recipients With Established Allograft Vasculopathy|Completed||Phase 3|||Novartis|||||||||||||||||||2018-06-01 05:00:10.784585|2018-06-01 05:00:10.784585
NCT00097955|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2017-05-15|2004-12-01|2004-12-02|Estimate|||||||2017-05-15|2017-05-17|Actual|October 2004||2004-10-31|May 2017|2017-05-31|April 2007||2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria|Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria|Completed||Phase 2|496||Novartis|||||f||||||||||||||2018-06-01 05:00:10.848204|2018-06-01 05:00:10.848204
NCT00097942|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2012-03-01|2004-12-01|2004-12-02|Estimate|||||||2012-03-01|2012-03-05|Estimate|August 2004||2004-08-31|March 2012|2012-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment to Atypical Antipsychotics in Schizophrenia Patients With Persistent Residual Symptoms|Completed||Phase 2|138|Actual|Forest Laboratories|||||||||||||||||||2018-06-01 05:00:10.994951|2018-06-01 05:00:10.994951
NCT00097929|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2017-04-05|2004-12-01|2004-12-02|Estimate|||||||2017-04-05|2017-04-07|Actual|May 1, 2005|Actual|2005-05-01|April 2017|2017-04-30|July 31, 2006|Actual|2006-07-31|July 31, 2006|Actual|2006-07-31||Interventional|||An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)|A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 2|18|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:00:11.073189|2018-06-01 05:00:11.073189
NCT00097916|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2012-03-01|2004-12-01|2004-12-02|Estimate|||||||2012-03-01|2012-03-05|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimer's Disease|Completed||Phase 3|34|Actual|Forest Laboratories|||||||||||||||||||2018-06-01 05:00:11.150683|2018-06-01 05:00:11.150683
NCT00097903|ClinicalTrials.gov processed this data on May 31, 2018|2004-12-01|||2017-09-20|2004-12-01|2004-12-02|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2004||2004-05-31|September 2017|2017-09-30|May 2013|Actual|2013-05-31|October 2011|Actual|2011-10-31||Interventional|||Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer|"Phase 1 Trial of Oral Karenitecin® in Patients With Solid Tumors"|Completed||Phase 1|32|Actual|BioNumerik Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 05:00:11.220643|2018-06-01 05:00:11.220643
NCT00097890|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2008-03-03|2004-11-30|2004-12-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2004||2004-11-30|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Replagal Enzyme Replacement Therapy for Adults With Fabry Disease|An Open Label Six-Month Maintenance Clinical Trial of Replagal Enzyme Replacement Therapy in Patients With Fabry Disease Who Have Completed TKT027|Completed||Phase 4|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:11.317634|2018-06-01 05:00:11.317634
NCT00097877|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2017-01-10|2004-11-30|2004-12-01|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes|Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Combination With Metformin in Subjects With Type 2 Diabetes|Completed||Phase 3|293|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:00:11.399867|2018-06-01 05:00:11.399867
NCT00097851|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2016-03-30|2004-11-30|2004-12-01|Estimate|||||||2016-03-30|2016-03-31|Estimate|February 2004||2004-02-29|March 2016|2016-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)|Phase II Trial of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer|Completed||Phase 2|100||Medigen Biotechnology Corporation|||||||||||||||||||2018-06-01 05:00:11.5632|2018-06-01 05:00:11.5632
NCT00097838|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2012-06-27|2004-11-30|2004-12-01|Estimate|||||||2012-06-27|2012-07-02|Estimate|October 2004||2004-10-31|June 2012|2012-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults|A Phase I, Dose Escalation, Safety, and Immunogenicity Trial of an Alphavirus Replicon HIV-1 Subtype C Gag Vaccine (AVX101) in Healthy HIV-1 Uninfected Adult Participants|Completed||Phase 1|96|Actual|AlphaVax, Inc.||5|||f||||||||||||||2018-06-01 05:00:11.667286|2018-06-01 05:00:11.667286
NCT00097825|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2012-04-26|2004-11-30|2004-12-01|Estimate|||||||2012-04-26|2012-04-27|Estimate|April 2004||2004-04-30|April 2012|2012-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men|Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men|Completed||Phase 3|288||Novartis|||||||||||||||||||2018-06-01 05:00:11.780515|2018-06-01 05:00:11.780515
NCT00097812|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2012-04-26|2004-11-30|2004-12-01|Estimate|||||||2012-04-26|2012-04-27|Estimate|May 2004||2004-05-31|April 2012|2012-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid|A Study to Assess the Safety, Tolerability, and Efficacy of Switching Patients Currently on Oral Bisphosphonate to Zoledronic Acid|Completed||Phase 3|220||Novartis|||||||||||||||||||2018-06-01 05:00:11.86998|2018-06-01 05:00:11.86998
NCT00097799|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2016-11-29|2004-11-30|2004-12-01|Estimate|||||||2016-11-29|2016-11-30|Estimate|December 2004||2004-12-31|October 2013|2013-10-31||||August 2005|Actual|2005-08-31||Expanded Access|||Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection|An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)|Approved for marketing|||||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 05:00:11.957871|2018-06-01 05:00:11.957871
NCT00097786|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|2011-01-14||2011-06-27|2004-11-30|2004-12-01|Estimate|2011-04-26|2011-05-24|Estimate||||2011-06-27|2011-06-29|Estimate|January 2002||2002-01-31|June 2011|2011-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|Navigator||Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications|A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)|Completed||Phase 3|9306|Actual|Novartis||4|||f||||t||||||||||2018-06-01 05:00:12.661247|2018-06-01 05:00:12.661247
NCT00097773|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|2013-06-11||2014-01-28|2004-11-30|2004-12-01|Estimate|2013-10-14|2013-11-07|Estimate||||2014-01-28|2014-02-28|Estimate|September 2004||2004-09-30|January 2014|2014-01-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|EPIC|Intent to Treat|Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis|Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis|Completed||Phase 2|304|Actual|Seattle Children's Hospital||4|||f||||t||||||||||2018-06-01 05:00:21.771865|2018-06-01 05:00:21.771865
NCT00097760|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2009-06-17|2004-11-30|2004-12-01|Estimate|||||||2009-06-17|2009-06-18|Estimate|June 2003||2003-06-30|June 2009|2009-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis|Safety Study of Natalizumab in Combination With Glatiramer Acetate (GA)|Completed||Phase 2|110|Actual|Biogen||2|||f||||t||||||||||2018-06-01 05:00:24.488961|2018-06-01 05:00:24.488961
NCT00097747|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-30|||2012-12-19|2004-11-30|2004-12-01|Estimate|||||||2012-12-19|2012-12-21|Estimate|August 2004||2004-08-31|December 2012|2012-12-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers|A Phase 1, Double-blind, Placebo-controlled, Dose Escalation Study of the Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers|Completed||Phase 1|28|Actual|Affymax||4|||f||||f||||||||||2018-06-01 05:00:24.605219|2018-06-01 05:00:24.605219
NCT00097734|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-29|||2006-02-12|2004-11-29|2004-11-30|Estimate|||||||2006-02-12|2006-02-14|Estimate|July 2004||2004-07-31|February 2006|2006-02-28|June 2007||2007-06-30|||||Interventional|||Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis|A Prospective, Multicenter, Open-Label, Randomized Clinical Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis|Unknown status|Recruiting|Phase 4|540||Klinikum Hanover-Siloah Hospital|||||f||||||||||||||2018-06-01 05:00:24.826918|2018-06-01 05:00:24.826918
NCT00097721|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-29|2012-01-09||2013-04-03|2004-11-29|2004-11-30|Estimate|2013-02-06|2013-03-15|Estimate||||2013-04-03|2013-04-22|Estimate|September 2004||2004-09-30|April 2013|2013-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study of E7389 in Advanced/Metastatic Breast Cancer Patients|A Phase II Open Label Study of E7389 (Halichondrin B Analog) in Patients With Advanced/Metastatic Breast Cancer Previously Treated With Chemotherapy Including An Anthracycline and A Taxane|Completed||Phase 2|104|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 05:00:25.017977|2018-06-01 05:00:25.017977
NCT00097708|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-29|2011-09-14||2014-10-01|2004-11-29|2004-11-30|Estimate|2014-10-01|2014-10-03|Estimate||||2014-10-01|2014-10-03|Estimate|November 2004||2004-11-30|October 2014|2014-10-31|December 2005||2005-12-31|||||Interventional|||Experimental Medication For the Treatment of Generalized Anxiety Disorder|A Double-Blind, Placebo Controlled Trial of an Experimental Medication For the Treatment of Generalized Anxiety Disorder|Completed||Phase 3|511|Actual|Jazz Pharmaceuticals|||||||||||||||||||2018-06-01 05:00:26.006859|2018-06-01 05:00:26.006859
NCT00097695|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-26|2011-01-24||2014-05-22|2004-11-26|2004-11-29|Estimate|2013-11-04|2013-12-24|Estimate||||2014-05-22|2014-06-05|Estimate|August 2004||2004-08-31|May 2014|2014-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema|Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema|Completed||Phase 3|84|Actual|Shire||4|||f||||f||||||||||2018-06-01 05:00:26.681717|2018-06-01 05:00:26.681717
NCT00097682|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2017-06-30|2004-11-24|2004-11-25|Estimate|||||||2017-06-30|2017-07-02|Actual|November 18, 2004||2004-11-18|October 2, 2007|2007-10-02|October 2, 2007||2007-10-02|||||Observational|||Views of Cancer Patients Regarding Financial Conflicts of Interest|Ethics Study to Understand the Views of Cancer Patients Regarding Financial Conflicts of Interest in Research|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:27.224904|2018-06-01 05:00:27.224904
NCT00097669|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2010-02-24|2004-11-24|2004-11-25|Estimate|||||||2010-02-24|2010-02-26|Estimate|November 1998||1998-11-30|February 2010|2010-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||VITATOPS: A Study of VITAmins TO Prevent Stroke|VITATOPS - A Study of VITAmins TO Prevent Stroke|Completed||N/A|8000|Anticipated|VITATOPS|||||f||||t||||||||||2018-06-01 05:00:27.396058|2018-06-01 05:00:27.396058
NCT00097656|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2018-01-25|2004-11-24|2004-11-25|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2004||2004-02-29|January 2018|2018-01-31|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk|MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk|Completed||N/A|1800|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-06-01 05:00:27.717827|2018-06-01 05:00:27.717827
NCT00097643|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2008-08-12|2004-11-24|2004-11-25|Estimate|||||||2008-08-12|2008-08-13|Estimate|September 2000||2000-09-30|August 2008|2008-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Problem Solving/Physical Interventions and Aging|Problem Solving/Physical Interventions and Aging|Completed||Phase 3|273||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:00:27.886624|2018-06-01 05:00:27.886624
NCT00097630|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2009-12-09|2004-11-24|2004-11-25|Estimate|||||||2009-12-09|2009-12-11|Estimate|October 2003||2003-10-31|August 2008|2008-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||ABC Trial: Awakening and Breathing Controlled|Cognitive Impairment in the ICU: Evaluation and Outcomes|Completed||N/A|334||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:00:29.096259|2018-06-01 05:00:29.096259
NCT00097617|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2012-11-13|2004-11-24|2004-11-25|Estimate|||||||2012-11-13|2012-11-14|Estimate|March 2002||2002-03-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)|National Cooperative Growth Study (NCGS) of Nutropin AQ, Nutropin, and Protropin in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)|Completed|||395|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:29.210719|2018-06-01 05:00:29.210719
NCT00097604|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2010-07-28|2004-11-24|2004-11-25|Estimate|||||||2010-07-28|2010-07-29|Estimate|September 2004||2004-09-30|December 2009|2009-12-31|April 2008|Actual|2008-04-30|April 2006|Actual|2006-04-30||Interventional|||Effects of Valerian on Sleep in Healthy Older Adults|Valerian for Sleep Disturbance in Healthy Older Adults|Completed||Phase 2|18|Actual|University of Washington||2|||f||||t||||||||||2018-06-01 05:00:29.294622|2018-06-01 05:00:29.294622
NCT00097591|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|2010-04-19||2010-08-25|2004-11-24|2004-11-25|Estimate|2010-08-25|2010-09-16|Estimate||||2010-08-25|2010-09-16|Estimate|November 2004||2004-11-30|August 2010|2010-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention|A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention|Completed||Phase 3|13619|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 05:00:29.578422|2018-06-01 05:00:29.578422
NCT00097578|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2013-03-26|2004-11-24|2004-11-25|Estimate|||||||2013-03-26|2013-03-28|Estimate|March 2004||2004-03-31|March 2013|2013-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma|An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Adenocarcinoma|Completed|||1953|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:33.824376|2018-06-01 05:00:33.824376
NCT00097565|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2017-03-21|2004-11-24|2004-11-25|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2004|Actual|2004-03-31|March 2017|2017-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma|The National Lymphocare Study: An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma|Completed|||2740|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:33.927594|2018-06-01 05:00:33.927594
NCT00097552|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2012-11-13|2004-11-24|2004-11-25|Estimate|||||||2012-11-13|2012-11-14|Estimate|May 1997||1997-05-31|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone|Characterization of Subjects With Turner Syndrome Treated With Growth Hormone in the National Cooperative Growth Study (NCGS)|Completed|||1696|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:34.03148|2018-06-01 05:00:34.03148
NCT00097539|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|2016-10-13||2016-12-21|2004-11-24|2004-11-25|Estimate|2016-12-21|2017-02-15|Actual||||2016-12-21|2017-02-15|Actual|October 1985||1985-10-31|December 2016|2016-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational||Safety evaluable population included all participants enrolled in the study.|National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin|Genentech National Cooperative Growth Study (NCGS) Post-Marketing Surveillance Program For Nutropin AQ® (Somatropin [rDNA Origin] Injection), Nutropin® (Somatropin [rDNA Origin] for Injection), and Protropin® (Somatrem for Injection)|Completed|||65205|Actual|Genentech, Inc.|||1||f||||||||||||||2018-06-01 05:00:34.583287|2018-06-01 05:00:34.583287
NCT00097526|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2012-11-13|2004-11-24|2004-11-25|Estimate|||||||2012-11-13|2012-11-14|Estimate|April 2000||2000-04-30|November 2012|2012-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)|Bone Mineral Density in Adolescent Subjects With Growth Hormone Deficiency Who Are Completing Treatment With Nutropin AQ, Nutropin, or Protropin in the National Cooperative Growth Study (NCGS)|Completed|||125|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:48.664844|2018-06-01 05:00:48.664844
NCT00097513|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2010-11-11|2004-11-24|2004-11-25|Estimate|||||||2010-11-11|2010-11-15|Estimate|February 2003||2003-02-28|November 2010|2010-11-30|June 2006|Actual|2006-06-30|||||Observational|||National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients|National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Subjects|Completed|||||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:48.722817|2018-06-01 05:00:48.722817
NCT00097500|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|2010-12-24||2015-03-19|2004-11-24|2004-11-25|Estimate|2010-12-24|2011-01-10|Estimate||||2015-03-19|2015-04-07|Estimate|September 2004||2004-09-30|March 2015|2015-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes|A Phase 3, Randomized, Open Label, Comparator-Controlled, Parallel Group, Multicenter Study to Compare the Effects of Exenatide and Insulin Glargine on Beta Cell Function and Cardiovascular Risk Markers in Subjects With Type 2 Diabetes Treated With Metformin Who Have Not Achieved Target HbA1c|Completed||Phase 3|69|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 05:00:48.96937|2018-06-01 05:00:48.96937
NCT00097487|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-24|||2018-02-28|2004-11-24|2004-11-25|Estimate|||||||2018-02-28|2018-03-02|Actual|November 30, 2000|Actual|2000-11-30|February 2018|2018-02-28|September 30, 2004|Actual|2004-09-30|||||Observational|||A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane|Clinical Outcomes in Patients With HER2 Gene-Amplified Metastatic Breast Cancer Treated With First Line Herceptin in Combination With a Taxane: A Phase IV, Prospective, Community Based Study|Completed|||1000||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:49.475799|2018-06-01 05:00:49.475799
NCT00097474|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-23|||2018-03-27|2004-11-23|2004-11-24|Estimate|||||||2018-03-27|2018-03-29|Actual|November 22, 2004||2004-11-22|July 27, 2017|2017-07-27|November 14, 2007|Actual|2007-11-14|November 14, 2007|Actual|2007-11-14||Interventional|||Effects of Hydrocortisone, Melatonin, and Placebo on Jet Lag|The Effects of Hydrocortisone, Melatonin, and Placebo on Symptoms of Jet Lag|Completed||Phase 2|57|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-06-01 05:00:49.527608|2018-06-01 05:00:49.527608
NCT00097461|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-23|||2017-10-05|2004-11-23|2004-11-24|Estimate|||||||2017-10-05|2017-10-06|Actual|September 28, 2004||2004-09-28|April 18, 2017|2017-04-18|April 18, 2017||2017-04-18|||||Observational|||Revising Employee Benefits for the Sake of Health|Revising Employee Benefits for the Sake of Health|Completed|||408|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:49.633135|2018-06-01 05:00:49.633135
NCT00097448|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-23|2012-11-08||2017-04-03|2004-11-23|2004-11-24|Estimate|2013-02-27|2013-04-04|Estimate||||2017-04-03|2017-04-04|Actual|December 2004||2004-12-31|April 2017|2017-04-30|March 2011|Actual|2011-03-31|October 2009|Actual|2009-10-31||Interventional|SSNHL||Sudden Deafness Treatment Trial|Sudden Hearing Loss Multicenter Treatment Trial|Completed||Phase 3|255|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||||2018-06-01 05:00:49.846571|2018-06-01 05:00:49.846571
NCT00097435|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-23|||2013-08-01|2004-11-23|2004-11-24|Estimate|||||||2013-08-01|2013-08-02|Estimate|October 2004||2004-10-31|August 2013|2013-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C|A Multi-Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C|Completed||Phase 2|115|Actual|Human Genome Sciences Inc.|||||f||||||||||||||2018-06-01 05:00:50.20345|2018-06-01 05:00:50.20345
NCT00097422|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-23|||2017-03-23|2004-11-23|2004-11-24|Estimate|||||||2017-03-23|2017-03-27|Actual|November 1, 2004|Actual|2004-11-01|March 2017|2017-03-31|April 1, 2005|Actual|2005-04-01|April 1, 2005|Actual|2005-04-01||Interventional|||OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)|An Open-Label, Dose Ranging, Randomized Clinical Evaluation of OPT-80 in Patients With Clostridium Difficile-Associated Diarrhea (CDAD)|Completed||Phase 2|||Optimer Pharmaceuticals LLC|||||||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:00:50.286464|2018-06-01 05:00:50.286464
NCT00097409|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-23|||2010-10-01|2004-11-23|2004-11-24|Estimate|||||||2010-10-01|2010-10-04|Estimate|December 2004||2004-12-31|October 2010|2010-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer|A Phase II, Open-Label Study of Ispinesib in Subjects With Platinum/Taxane-Refractory or Resistant Relapsed Ovarian Cancer|Completed||Phase 2|35|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 05:00:50.35173|2018-06-01 05:00:50.35173
NCT00097396|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-23|||2011-06-29|2004-11-23|2004-11-24|Estimate|||||||2011-06-29|2011-06-30|Estimate|November 2004||2004-11-30|June 2011|2011-06-30|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|||Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V|A Phase 1, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant Plague Vaccine rF1V in Healthy Volunteers|Completed||Phase 1|40||DynPort Vaccine Company LLC, A CSC Company|||||f||||t||||||||||2018-06-01 05:00:50.436138|2018-06-01 05:00:50.436138
NCT00097383|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-22|||2006-07-18|2004-11-22|2004-11-23|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer|A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:00:50.518301|2018-06-01 05:00:50.518301
NCT00097370|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-22|2015-11-09|2012-03-15|2017-06-07|2004-11-22|2004-11-23|Estimate|2015-11-09|2015-12-15|Estimate|2012-03-15|2012-03-19|Estimate|2017-06-07|2017-07-07|Actual|September 30, 2004|Actual|2004-09-30|June 2017|2017-06-30|September 29, 2010|Actual|2010-09-29|September 29, 2010|Actual|2010-09-29||Interventional|||Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome|An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes|Terminated||Phase 3|78|Actual|GlaxoSmithKline||1||"Study terminated by sponsor (29 Sep 2010). Subjects eligible to continue mepolizumab treatment~   were transferred into the compassionate use program (MHE104317)"|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:00:50.743799|2018-06-01 05:00:50.743799
NCT00097357|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-22||2010-02-27|2010-02-27|2004-11-22|2004-11-23|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate|October 2004||2004-10-31|November 2008|2008-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery|A Phase 2 Randomized, Double-Blinded (BMS-562247 and Enoxaparin), Active-Controlled (Enoxaparin and Warfarin), Parallel-Arm, Dose-Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery|Completed||Phase 2/Phase 3|1238|Actual|Bristol-Myers Squibb||8|||f||||||||||||||2018-06-01 05:00:51.433966|2018-06-01 05:00:51.433966
NCT00097344|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-22|||2007-08-21|2004-11-22|2004-11-23|Estimate|||||||2007-08-21|2007-08-23|Estimate|December 2004||2004-12-31|August 2007|2007-08-31|August 2006||2006-08-31|||||Interventional|||The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer|Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer|Terminated||Phase 3|842||Intarcia Therapeutics||||Identical study Biomed 777-CLP-029 did not meet superiority endpoint|f||||||||||||||2018-06-01 05:00:51.833408|2018-06-01 05:00:51.833408
NCT00097331|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-22|||2015-04-10|2004-11-22|2004-11-23|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2004||2004-09-30|April 2015|2015-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis|Completed||Phase 2|261|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:00:52.112728|2018-06-01 05:00:52.112728
NCT00097318|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-20|||2017-06-30|2004-11-19|2004-11-22|Estimate|||||||2017-06-30|2017-07-02|Actual|November 17, 2004||2004-11-17|April 8, 2011|2011-04-08|April 8, 2011|Actual|2011-04-08|||||Interventional|||Safety Study of Interferon Beta 1a to for Acute Stroke|Recombinant Human Interferon Beta-1a in Acute Ischemic Stroke: A Dose Escalation and Safety Study|Completed||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:52.211775|2018-06-01 05:00:52.211775
NCT00097305|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-19|||2007-09-07|2004-11-19|2004-11-22|Estimate|||||||2007-09-07|2007-09-11|Estimate|September 2002||2002-09-30|August 2006|2006-08-31||||||||Interventional|||Body-Oriented Therapy for Sexual Abuse Recovery|Delving Intervention and Mindbody Integration|Completed||Phase 2|24||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:00:52.281607|2018-06-01 05:00:52.281607
NCT00097292|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-19|||2018-01-04|2004-11-19|2004-11-22|Estimate|||||||2018-01-04|2018-01-08|Actual|February 2004||2004-02-29|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Pathway to Prevention Study|Natural History Study of the Development of Type 1 Diabetes|Recruiting|||75000|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||2||f||||t||||||||||2018-06-01 05:00:52.356941|2018-06-01 05:00:52.356941
NCT00097279|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-19|||2017-01-10|2004-11-19|2004-11-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2004||2004-08-31|January 2017|2017-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|ACTION||Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes|A Multicenter, Open-Label, Randomised Trial to Compare the Efficacy and Safety of NovoLog Mix 70/30 BID in Combination With Metformin and Pioglitazone to Metformin and Pioglitazone Alone in Insulin Naïve Subjects With Type 2 Diabetes|Completed||Phase 3|230|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:00:52.546361|2018-06-01 05:00:52.546361
NCT00097266|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-19|||2013-11-07|2004-11-19|2004-11-22|Estimate|||||||2013-11-07|2013-11-08|Estimate|December 2004||2004-12-31|July 2010|2010-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study of Aripiprazole in Patients With Acute Bipolar Mania|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder|Completed||Phase 3|615||Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||||||||||||2018-06-01 05:00:52.718612|2018-06-01 05:00:52.718612
NCT00097253|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-19|2009-04-23||2010-02-12|2004-11-19|2004-11-22|Estimate|2010-01-15|2010-02-04|Estimate||||2010-02-12|2010-02-18|Estimate|August 2005||2005-08-31|February 2010|2010-02-28|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||The Effects of Smell on Mood and Physical Responses|Psychoneuroimmunology and Mind-Body Medicine: Olfaction, Mood, and Physiological Responses|Completed||Phase 1|56|Actual|National Center for Complementary and Integrative Health (NCCIH)||3|||f||||t||||||||||2018-06-01 05:00:52.865691|2018-06-01 05:00:52.865691
NCT00097240|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-19|||2010-08-02|2004-11-19|2004-11-22|Estimate|||||||2010-08-02|2010-08-04|Estimate|January 2005||2005-01-31|August 2010|2010-08-31|September 2009|Actual|2009-09-30|||||Observational|FOLLOW||An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)|The Raptiva Pregnancy Registry: An Observational Study of the Use and Safety of Raptiva (Efalizumab) During Pregnancy|Completed|||18|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:53.116631|2018-06-01 05:00:53.116631
NCT00097227|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-18|||2010-04-08|2004-11-18|2004-11-19|Estimate|||||||2010-04-08|2010-04-09|Estimate|November 2004||2004-11-30|April 2010|2010-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Randomized Phase II Trial of Two Dose Schedules of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-small Cell Lung Cancer|Completed||Phase 2|165|Actual|ImClone LLC||2|||f||||f||||||||||2018-06-01 05:00:53.16633|2018-06-01 05:00:53.16633
NCT00097214|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-18|||2010-04-08|2004-11-18|2004-11-19|Estimate|||||||2010-04-08|2010-04-09|Estimate|November 2004||2004-11-30|April 2010|2010-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)|A Phase II Trial of Carboplatin Plus Cetuximab for the Treatment of Stage IIIb/IV Non-Small Cell Lung Cancer|Completed||Phase 2|57|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 05:00:53.363493|2018-06-01 05:00:53.363493
NCT00097188|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-18|||2014-02-28|2004-11-18|2004-11-19|Estimate|||||||2014-02-28|2014-03-04|Estimate|December 2004||2004-12-31|February 2014|2014-02-28|December 2006|Actual|2006-12-31|||||Interventional|||A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis|A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis|Completed||Phase 2|104|Actual|Genentech, Inc.|||||||||||||||||||2018-06-01 05:00:53.4656|2018-06-01 05:00:53.4656
NCT00097175|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2018-05-23|2004-11-17|2004-11-18|Estimate|||||||2018-05-23|2018-05-24|Actual|November 10, 2004||2004-11-10|January 15, 2014|2014-01-15|January 15, 2014||2014-01-15|||||Observational|||Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders|The Effects of Mood and Tryptophan Depletion on the Neural Correlates of Affective Shifting in Mood Disorders|Completed|||95|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:53.575086|2018-06-01 05:00:53.575086
NCT00097162|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2006-06-23|2004-11-17|2004-11-18|Estimate|||||||2006-06-23|2006-06-26|Estimate|November 2004||2004-11-30|June 2006|2006-06-30|June 2006||2006-06-30|||||Interventional|||Visual Cortex Stimulation in Patients With Amblyopia|Investigation of Visual Plasticity by a Direct Current Stimulation of Occipital Cortex in Adult Amblyopia|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:53.630333|2018-06-01 05:00:53.630333
NCT00097149|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2013-12-16|2004-11-17|2004-11-18|Estimate|||||||2013-12-16|2013-12-17|Estimate|May 2003||2003-05-31|December 2013|2013-12-31|May 2006|Actual|2006-05-31|||||Interventional|||Systematic Pediatric Care for Oral Clefts - South America|Systematic Pediatric Care for Oral Clefts - South America|Completed||N/A|696||NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 05:00:53.693467|2018-06-01 05:00:53.693467
NCT00097123|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2014-07-29|2004-11-17|2004-11-18|Estimate|||||||2014-07-29|2014-07-31|Estimate|September 2002||2002-09-30|July 2014|2014-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||RCT of Misoprostol for Postpartum Hemorrhage in India|RCT of Misoprostol for Postpartum Hemorrhage in India|Completed||N/A|1600|Anticipated|NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 05:00:53.774147|2018-06-01 05:00:53.774147
NCT00097110|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2013-11-22|2004-11-17|2004-11-18|Estimate|||||||2013-11-22|2013-11-25|Estimate|July 2003||2003-07-31|November 2013|2013-11-30|December 2006|Actual|2006-12-31|||||Interventional|||RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil|RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil|Completed||Phase 3|734||NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 05:00:53.927245|2018-06-01 05:00:53.927245
NCT00097097|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2014-07-29|2004-11-17|2004-11-18|Estimate|||||||2014-07-29|2014-07-31|Estimate|October 2004||2004-10-31|July 2014|2014-07-31|November 2006|Actual|2006-11-30|||||Interventional|||Neonatal Resuscitation in Zambia|Neonatal Resuscitation in Zambia|Completed||Phase 3|40000||NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 05:00:54.058532|2018-06-01 05:00:54.058532
NCT00097084|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2017-01-26|2004-11-17|2004-11-18|Estimate|||||||2017-01-26|2017-01-27|Estimate|September 2004||2004-09-30|January 2017|2017-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes|Completed||Phase 3|324|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:00:54.155698|2018-06-01 05:00:54.155698
NCT00097071|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2016-12-21|2004-11-17|2004-11-18|Estimate|||||||2016-12-21|2016-12-22|Estimate|October 2004||2004-10-31|December 2016|2016-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents|Safety and Efficacy of Insulin Aspart Versus Insulin Lispro in Insulin Pumps in Children and Adolescents With Type 1 Diabetes|Completed||Phase 3|299|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:00:54.43478|2018-06-01 05:00:54.43478
NCT00097058|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2014-11-17|2004-11-17|2004-11-18|Estimate|||||||2014-11-17|2014-11-19|Estimate|August 2003||2003-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Estrogen Use in Protection From Cognitive Decline|Estrogen Use in Protection From Cognitive Decline|Completed|||71|Anticipated|Stanford University|||2||f||||t||||||Samples With DNA|"~     whole blood serum urine~   "|||2018-06-01 05:00:54.655876|2018-06-01 05:00:54.655876
NCT00097045|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2007-08-21|2004-11-17|2004-11-18|Estimate|||||||2007-08-21|2007-08-23|Estimate|November 2004||2004-11-30|August 2007|2007-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C|Phase 2 Study of Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C|Completed||Phase 2|90||Intarcia Therapeutics|||||f||||||||||||||2018-06-01 05:00:54.736146|2018-06-01 05:00:54.736146
NCT00097032|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2011-05-20|2004-11-17|2004-11-18|Estimate|||||||2011-05-20|2011-05-24|Estimate|October 2004||2004-10-31|March 2010|2010-03-31|May 2005|Actual|2005-05-31|||||Interventional|||Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients|Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients.|Completed||Phase 3|30|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:00:54.817427|2018-06-01 05:00:54.817427
NCT00097019|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2017-05-15|2004-11-17|2004-11-18|Estimate|||||||2017-05-15|2017-05-16|Actual|February 2005|Actual|2005-02-28|May 2017|2017-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed|A Multicenter, Single-Arm, Phase II Trial of Bevacizumab in Subjects With Platinum-Resistant Epithelial Carcinoma of the Ovary or Primary Peritoneal Carcinoma for Whom Subsequent Doxil or Topotecan Therapy Has Failed|Completed||Phase 2|53||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:54.891648|2018-06-01 05:00:54.891648
NCT00097006|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2016-04-14|2004-11-17|2004-11-18|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 2004||2004-09-30|September 2009|2009-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Retrovirus Epidemiology Donor Study-II (REDS-II)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:00:54.95427|2018-06-01 05:00:54.95427
NCT00096993|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|2015-05-26||2015-06-08|2004-11-17|2004-11-18|Estimate|2015-06-08|2015-06-10|Estimate||||2015-06-08|2015-06-10|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional||Safety population: All participants who received any amount of study treatment.|A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Pertuzumab (rhuMAb 2C4) in Combination With Gemcitabine and the Effect of Tumor-Based HER2 Activation in Subjects With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Completed||Phase 2|131|Actual|Genentech, Inc.||2|||f||||f||||||||||2018-06-01 05:00:55.106668|2018-06-01 05:00:55.106668
NCT00096980|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2013-06-19|2004-11-17|2004-11-18|Estimate|||||||2013-06-19|2013-06-21|Estimate|February 2001||2001-02-28|June 2013|2013-06-30|May 2004|Actual|2004-05-31|||||Interventional|||A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies|An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment|Completed||Phase 4|300||Genentech, Inc.|||||||||||||||||||2018-06-01 05:00:55.69901|2018-06-01 05:00:55.69901
NCT00096967|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2014-03-25|2004-11-17|2004-11-18|Estimate|||||||2014-03-25|2014-03-26|Estimate|October 2002||2002-10-31|March 2014|2014-03-31|July 2004|Actual|2004-07-31|||||Interventional|||A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study|An Open-Label, Multicenter Extension Study of rhuMAb VEGF (Bevacizumab) in Subjects Treated in a Previous Genentech-Sponsored Cancer Study|Completed||Phase 3|100||Genentech, Inc.|||||||||||||||||||2018-06-01 05:00:55.743516|2018-06-01 05:00:55.743516
NCT00096954|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|2011-08-08||2017-05-16|2004-11-17|2004-11-18|Estimate|2011-11-03|2011-12-08|Estimate||||2017-05-16|2017-06-14|Actual|February 2006|Actual|2006-02-28|May 2017|2017-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|EXACT||A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)|A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)|Completed||Phase 4|333|Actual|Genentech, Inc.|This is a stand-alone study to fulfill one of the post-marketing commitments.|2|||f||||||||||||||2018-06-01 05:00:55.796484|2018-06-01 05:00:55.796484
NCT00096941|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|2015-05-27||2015-05-29|2004-11-17|2004-11-18|Estimate|2015-05-29|2015-06-11|Estimate||||2015-05-29|2015-06-11|Estimate|May 2005||2005-05-31|May 2015|2015-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional||Safety population: Participants who received at least 1 dose of pertuzumab.|A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study|An Open-Label, Multicenter Extension Study of Pertuzumab (rhuMAb 2C4) in Subjects Treated With Pertuzumab in a Previous Genentech-Sponsored Phase II Cancer Study|Completed||Phase 2|3|Actual|Genentech, Inc.||1|||f||||||||||||||2018-06-01 05:00:56.0143|2018-06-01 05:00:56.0143
NCT00096928|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2015-07-01|2004-11-17|2004-11-18|Estimate|||||||2015-07-01|2015-07-02|Estimate|March 2005||2005-03-31|March 2011|2011-03-31|October 2009|Actual|2009-10-31|||||Observational|RESPONSE||A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)|Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)|Completed|||1846|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:00:56.299304|2018-06-01 05:00:56.299304
NCT00096915|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-17|||2009-05-21|2004-11-17|2004-11-18|Estimate|||||||2009-05-21|2009-05-22|Estimate|October 2004||2004-10-31|May 2009|2009-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis|A Multicenter, Single-Arm Study Evaluating Once Monthly Darbepoetin Alfa Dosing in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis|Completed||Phase 3|110|Actual|Amgen||1|||f||||||||||||||2018-06-01 05:00:56.676484|2018-06-01 05:00:56.676484
NCT00096902|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-16|||2017-06-30|2004-11-16|2004-11-17|Estimate|||||||2017-06-30|2017-07-02|Actual|November 8, 2004||2004-11-08|September 11, 2006|2006-09-11|September 11, 2006||2006-09-11|||||Interventional|||Non-Pharmacologic Therapy for Neurocardiogenic Syncope|Non-Pharmacologic Therapy for Neurocardiogenic Syncope|Completed||Phase 2|45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:56.757879|2018-06-01 05:00:56.757879
NCT00096876|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-16|||2008-06-09|2004-11-16|2004-11-17|Estimate|||||||2008-06-09|2008-06-11|Estimate|October 2004||2004-10-31|June 2008|2008-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients|Screening Evaluations for Neurologic Syndromes: Olfactory Testing in Relatives of Parkinson's Disease Patients|Completed|||600|Anticipated|Institute for Neurodegenerative Disorders|||||f||||||||||||||2018-06-01 05:00:56.827033|2018-06-01 05:00:56.827033
NCT00096863|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-16|||2016-01-28|2004-11-16|2004-11-17|Estimate|||||||2016-01-28|2016-01-29|Estimate|December 2004||2004-12-31|January 2016|2016-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||The MIND Study: Modifying the INcidence of Delirium|Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone|Completed||Phase 2|102|Actual|Vanderbilt University||3|||f||||t||||||||||2018-06-01 05:00:56.90481|2018-06-01 05:00:56.90481
NCT00095797|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-02-07|2004-11-08|2004-11-09|Estimate|||||||2013-02-07|2013-02-08|Estimate|October 2004||2004-10-31|February 2013|2013-02-28||||March 2007|Actual|2007-03-31||Interventional|||XK469R in Treating Patients With Refractory Hematologic Cancer|A Phase I Study of XK469R (NSC 698215) in Patients With Refractory Hematologic Malignancies|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:17.975257|2018-06-01 05:01:17.975257
NCT00096850|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-16|||2012-05-17|2004-11-16|2004-11-17|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|December 2007|Actual|2007-12-31|||||Interventional|||Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults|Safety, Tolerability, and Pharmacokinetic Interactions of Atazanavir and Rifampin in Healthy Volunteers|Completed||N/A|18|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:00:57.017844|2018-06-01 05:00:57.017844
NCT00096837|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-16|||2006-06-07|2004-11-16|2004-11-17|Estimate|||||||2006-06-07|2006-06-08|Estimate||||June 2006|2006-06-30||||||||Interventional|||A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma|An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|25||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 05:00:57.117379|2018-06-01 05:00:57.117379
NCT00096824|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-15|||2015-03-17|2004-11-15|2004-11-16|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2006||2006-02-28|March 2015|2015-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||A Study of Dementia and Neurological Problems in HIV Infected Patients Who Are Participating in ACTG A5175|International Neurological Study: A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combination for Initial Treatment of HIV-1 Infected Individuals From Diverse Areas of the World)|Completed|||860|Actual|AIDS Clinical Trials Group|||1||f||||t||||||||||2018-06-01 05:00:57.192931|2018-06-01 05:00:57.192931
NCT00096811|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-15|||2016-09-20|2004-11-15|2004-11-16|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|August 2008|Actual|2008-08-31|August 2008|Anticipated|2008-08-31||Expanded Access|||Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program|A Treatment Use Protocol of Entecavir in Subjects With Chronic Hepatitis B Infection Who Have Failed or Who Are Intolerant of Available Therapies|No longer available|||||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:00:57.291456|2018-06-01 05:00:57.291456
NCT00096798|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-15|||2008-01-15|2004-11-15|2004-11-16|Estimate|||||||2008-01-15|2008-01-17|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression|A Double-Blind, Placebo-Controlled Study of Ethyl Eicosapentanoic Acid (Ethyl-EPA) in Major Depressive Disorder|Completed||Phase 3|80|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:00:57.366406|2018-06-01 05:00:57.366406
NCT00096785|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-15|2009-07-02||2010-08-04|2004-11-15|2004-11-16|Estimate|2009-12-02|2010-01-06|Estimate||||2010-08-04|2010-08-10|Estimate|December 2004||2004-12-31|June 2010|2010-06-30|April 2008|Actual|2008-04-30|January 2006|Actual|2006-01-31||Interventional|||Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection|Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection|Completed||Phase 3|69|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 05:00:57.457487|2018-06-01 05:00:57.457487
NCT00096772|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-15|||2014-05-16|2004-11-15|2004-11-16|Estimate|||||||2014-05-16|2014-05-19|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Collection of Blood Samples From HIV Infected People|Collection and Use of Blood For Genetic and Other Related Analyses (The GENOMICS Protocol)|Completed|||2502|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 05:00:58.007464|2018-06-01 05:00:58.007464
NCT00096759|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-15|||2013-03-21|2004-11-15|2004-11-16|Estimate|||||||2013-03-21|2013-03-22|Estimate|November 2004||2004-11-30|March 2013|2013-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Comparing Tai Chi Chih and Relaxation Therapy in the Treatment of Rheumatoid Arthritis|Efficacy of CAM Interventions in Rheumatoid Arthritis|Completed||Phase 2/Phase 3|100|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:00:58.1576|2018-06-01 05:00:58.1576
NCT00096746|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-15|||2011-04-12|2004-11-15|2004-11-16|Estimate|||||||2011-04-12|2011-04-13|Estimate|November 2004||2004-11-30|April 2011|2011-04-30|September 2006||2006-09-30|September 2006|Actual|2006-09-30||Observational|||Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects|An Exploratory Study of the Effect of the Atazanavir (ATV) I50L Mutation on Subsequent Treatment Response|Completed|||200||Bristol-Myers Squibb|||2||f||||f||||||||||2018-06-01 05:00:58.220436|2018-06-01 05:00:58.220436
NCT00096733|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2017-08-27|2004-11-12|2004-11-15|Estimate|||||||2017-08-27|2017-08-29|Actual|October 2004||2004-10-31|August 2017|2017-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|A2ALL-1||Adult-to-Adult Living Donor Liver Transplantation Study|Adult-to-Adult Living Donor Liver Transplantation Cohort Study|Completed|||2470|Actual|Arbor Research Collaborative for Health|||2||f||||t||||||Samples With DNA|"~     whole blood, serum, fixed tissue samples, frozen tissue samples~   "|||2018-06-01 05:00:58.341658|2018-06-01 05:00:58.341658
NCT00096720|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2010-09-28|2004-11-12|2004-11-15|Estimate|||||||2010-09-28|2010-09-29|Estimate|February 2004||2004-02-29|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease|Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's|Completed||Phase 2|112|Actual|Institute for Neurodegenerative Disorders|||||f||||f||||||||||2018-06-01 05:00:58.435283|2018-06-01 05:00:58.435283
NCT00096707|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2009-04-28|2004-11-12|2004-11-15|Estimate|||||||2009-04-28|2009-04-29|Estimate|February 2004||2004-02-29|April 2009|2009-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors|Phase I Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) Alone and in Combination With Docetaxel in Subjects With Advanced Solid Malignancies|Completed||Phase 1|50|Anticipated|Threshold Pharmaceuticals|||||||||||||||||||2018-06-01 05:00:58.522821|2018-06-01 05:00:58.522821
NCT00096694|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2012-05-17|2004-11-12|2004-11-15|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|September 2005|Actual|2005-09-30|||||Interventional|||Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women|A Pilot Study Evaluating the Effect of the Levonorgestrel-Releasing Intrauterine Device on Genital HIV Shedding in HIV-1-Infected Women|Completed||N/A|41||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:00:58.584372|2018-06-01 05:00:58.584372
NCT00096681|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|2011-01-14||2011-02-17|2004-11-12|2004-11-15|Estimate|2011-01-21|2011-02-17|Estimate||||2011-02-17|2011-03-14|Estimate|February 2005||2005-02-28|February 2011|2011-02-28|February 2006|Actual|2006-02-28|August 2005|Actual|2005-08-31||Observational|||Prevalence of HIV and Tuberculosis in Masiphumelele Township, Cape Town, South Africa|Protocol for Cross-Sectional Survey of Acid-Fast Bacilli (AFB) Smear Positive and/or Culture Positive Tuberculosis in the Masiphumelele Township|Completed|||762|Actual|CIPRA SA|||||f||||f||||||Samples With DNA|"~     Sputum samples~   "|||2018-06-01 05:00:58.751125|2018-06-01 05:00:58.751125
NCT00096668|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2009-06-02|2004-11-12|2004-11-15|Estimate|||||||2009-06-02|2009-06-04|Estimate|October 2004||2004-10-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer|A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(R) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) as Initial Treatment of Patients With Metastatic Breast Cancer|Completed||Phase 2|47|Actual|Achieve Life Sciences||1|||f||||||||||||||2018-06-01 05:00:58.888076|2018-06-01 05:00:58.888076
NCT00096655|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2011-05-16|2004-11-12|2004-11-15|Estimate|||||||2011-05-16|2011-05-17|Estimate|May 2002||2002-05-31|March 2010|2010-03-31|August 2007|Actual|2007-08-31|||||Interventional|||A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis|A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis|Completed||Phase 3|364|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:00:58.959937|2018-06-01 05:00:58.959937
NCT00096642|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2011-08-04|2004-11-12|2004-11-15|Estimate|||||||2011-08-04|2011-08-05|Estimate|June 2002||2002-06-30|August 2011|2011-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Cognitive Behavioral Therapy for Early-Onset Depression|Comprehensive Treatment for Depressed Youth: An Outcome Evaluation Study|Completed||N/A|30|Actual|Centre for Addiction and Mental Health|||||f||||f||||||||||2018-06-01 05:00:59.037459|2018-06-01 05:00:59.037459
NCT00096629|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2018-04-24|2004-11-12|2004-11-15|Estimate|||||||2018-04-24|2018-04-25|Actual|November 2003||2003-11-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Vaccine Therapy in Treating Patients With Kidney Cancer|Injection of Renal Cell Carcinoma Patients With Human and Mouse Prostate Specific Membrane Antigen (PSMA) DNA: A Phase I Trial to Assess Safety and Immune Response|Completed||Phase 1|15|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 05:00:59.116295|2018-06-01 05:00:59.116295
NCT00096616|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2013-10-31|2004-11-12|2004-11-15|Estimate|||||||2013-10-31|2013-11-01|Estimate|November 2004||2004-11-30|October 2013|2013-10-31||||March 2006|Actual|2006-03-31||Interventional|||Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma|A Single Dose, Randomized, Double-blind Crossover Comparison of Combivent CFC MDI and Albuterol HFA MDI in Patients With Moderate to Severe Persistent Asthma and Persistent Symptoms Despite Treatment With Inhaled Corticosteroids|Completed||Phase 2|113|Actual|Boehringer Ingelheim|||||||||||||||||||2018-06-01 05:00:59.195844|2018-06-01 05:00:59.195844
NCT00096603|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-12|||2014-03-19|2004-11-12|2004-11-15|Estimate|||||||2014-03-19|2014-03-20|Estimate|October 2002||2002-10-31|March 2014|2014-03-31|July 2004|Actual|2004-07-31|||||Interventional|||A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g|An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g|Completed||Phase 3|450||Genentech, Inc.|||||||||||||||||||2018-06-01 05:00:59.365233|2018-06-01 05:00:59.365233
NCT00096590|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-11|||2009-05-09|2004-11-11|2004-11-12|Estimate|||||||2009-05-09|2009-05-12|Estimate|November 2004||2004-11-30|June 2007|2007-06-30||||||||Observational|||Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery|Evaluation of a Novel Blood Test Hypercoagulability in Surgical Patients With Metastatic Carcinoma: A Pilot Study|Completed|||60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:00:59.425714|2018-06-01 05:00:59.425714
NCT00096564|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-10|||2017-06-30|2004-11-10|2004-11-11|Estimate|||||||2017-06-30|2017-07-02|Actual|November 9, 2004||2004-11-09|August 20, 2008|2008-08-20|August 20, 2008||2008-08-20|||||Observational|||Brain Activities Associated With Different Facial Expressions Using Blood Oxygenation Level Dependent Functional MRI|Functional MRI Study of Brain Activation With Observation of Facial Expressions|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:59.515063|2018-06-01 05:00:59.515063
NCT00096551|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2017-06-30|2004-11-09|2004-11-10|Estimate|||||||2017-06-30|2017-07-02|Actual|November 1, 2004||2004-11-01|July 25, 2011|2011-07-25|July 25, 2011|Actual|2011-07-25|December 11, 2009|Actual|2009-12-11||Interventional|||A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy|A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer and Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy|Completed||Phase 1|21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:00:59.59125|2018-06-01 05:00:59.59125
NCT00096538|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2015-10-21||2015-10-21|2004-11-09|2004-11-10|Estimate|2015-10-21|2015-11-25|Estimate||||2015-10-21|2015-11-25|Estimate|April 2004||2004-04-30|October 2015|2015-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma|Pilot Study Of Valganciclovir In Patients With Classic, Non-HIV-Associated Kaposi's Sarcoma|Completed||N/A|6|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:00:59.696173|2018-06-01 05:00:59.696173
NCT00096525|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-01-15|2004-11-09|2004-11-10|Estimate|||||||2013-01-15|2013-01-17|Estimate|July 2004||2004-07-31|January 2013|2013-01-31||||August 2005|Actual|2005-08-31||Interventional|||Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer|Phase II Trial of CC-5013 in Patients With Advanced Renal Cell Carcinoma With Either No Prior Treatment or One Prior Treatment Regimen|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:00:59.939609|2018-06-01 05:00:59.939609
NCT00096512|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-02-27|2004-11-09|2004-11-10|Estimate|||||||2013-02-27|2013-02-28|Estimate|October 2004||2004-10-31|February 2013|2013-02-28||||May 2006|Actual|2006-05-31||Interventional|||S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:00.029729|2018-06-01 05:01:00.029729
NCT00096499|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-01-24|2004-11-09|2004-11-10|Estimate|||||||2013-01-24|2013-01-25|Estimate|April 2005||2005-04-30|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel|A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:00.128586|2018-06-01 05:01:00.128586
NCT00096486|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2015-12-15||2015-12-15|2004-11-09|2004-11-10|Estimate|2015-12-15|2016-01-21|Estimate||||2015-12-15|2016-01-21|Estimate|May 2004||2004-05-31|December 2015|2015-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer|A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|74|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:01:00.233012|2018-06-01 05:01:00.233012
NCT00096473|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2011-03-31|2004-11-09|2004-11-10|Estimate|||||||2011-03-31|2011-04-01|Estimate|January 2001||2001-01-31|March 2011|2011-03-31|September 2005|Actual|2005-09-30|June 2005|Actual|2005-06-30||Interventional|||Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease|A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period|Completed||Phase 3|229|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 05:01:00.713971|2018-06-01 05:01:00.713971
NCT00096460|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2011-08-16||2016-08-01|2004-11-09|2004-11-10|Estimate|2012-08-15|2012-09-17|Estimate||||2016-08-01|2016-09-12|Estimate|August 2004||2004-08-31|August 2016|2016-08-31|March 2009|Actual|2009-03-31|March 2006|Actual|2006-03-31||Interventional|||Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)|Autologous Versus Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Chemosensitive Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response or First Partial Response (BMT CTN #0202)|Terminated||Phase 2/Phase 3|30|Actual|Medical College of Wisconsin||2||lower than anticipated accrual|f||||t||||||||Yes||2018-06-01 05:01:00.834749|2018-06-01 05:01:00.834749
NCT00096447|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2015-06-03||2017-10-27|2004-11-09|2004-11-10|Estimate|2015-08-18|2015-09-18|Estimate||||2017-10-27|2017-12-04|Actual|November 2004||2004-11-30|October 2017|2017-10-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||Eligible and treated patients.|Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation Of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) In The Treatment Of Persistent Or Recurrent Endometrial Carcinoma|Completed||Phase 2|31|Actual|National Cancer Institute (NCI)|The clinical trial was a two-stage design, accruing approximately 25 patients in each stage. Results from a planned interim futility analysis resulted in the early closure of the study. This study stopped early for lack of treatment efficacy.|1|||f||||||||||||||2018-06-01 05:01:01.279677|2018-06-01 05:01:01.279677
NCT00096434|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-10-07|2004-11-09|2004-11-10|Estimate|||||||2013-10-07|2013-10-08|Estimate|September 2004||2004-09-30|October 2013|2013-10-31||||June 2006|Actual|2006-06-30||Interventional|||Sorafenib in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane|Completed||Phase 2|42|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:01.915095|2018-06-01 05:01:01.915095
NCT00096421|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2006-10-24|2004-11-09|2004-11-10|Estimate|||||||2006-10-24|2006-10-26|Estimate|July 2003||2003-07-31|October 2006|2006-10-31|September 2006||2006-09-30|||||Interventional|||Tight Glycemic Control in Critical Care Patients|Tight Glycemic Control in Patients Hospitalized in a Medical-Surgery Intensive Care Unit: A Randomized Study|Completed||Phase 3|504||Hospital Pablo Tobón Uribe|||||f||||||||||||||2018-06-01 05:01:02.021688|2018-06-01 05:01:02.021688
NCT00096408|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2018-04-03|2004-11-08|2004-11-09|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2005||2005-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 2016|Actual|2016-04-30||Interventional|||Laparoscopic Approach to Cancer of the Endometrium|LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial|Active, not recruiting||Phase 3|760|Actual|Queensland Centre for Gynaecological Cancer||2|||f||||t||||||||Undecided||2018-06-01 05:01:02.120991|2018-06-01 05:01:02.120991
NCT00096395|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-06-11|2004-11-08|2004-11-09|Estimate|||||||2013-06-11|2013-06-13|Estimate|September 2004||2004-09-30|May 2013|2013-05-31||||February 2007|Actual|2007-02-28||Interventional|||Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer|A Phase 2 Study of BAY 43-9006 in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer|Completed||Phase 2|33|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:02.391417|2018-06-01 05:01:02.391417
NCT00096382|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2012-11-20||2015-10-06|2004-11-08|2004-11-09|Estimate|2013-03-25|2013-03-27|Estimate||||2015-10-06|2015-10-28|Estimate|September 2004||2004-09-30|September 2015|2015-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma Using a Transplant of Autologous Lymphocytes Reactive With Tumor Following a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy, Total Body Irradiation and Reconstitution With CD34+ Cells|Completed||Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:01:02.506063|2018-06-01 05:01:02.506063
NCT00096369|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2008-05-23|2004-11-08|2004-11-09|Estimate|||||||2008-05-23|2008-05-27|Estimate|February 2002||2002-02-28|May 2007|2007-05-31||||||||Interventional|||Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer|An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers That Are Modulated by Tamoxifen vs. Placebo in Women With an Increased Risk for Breast Cancer|Unknown status|Active, not recruiting|Phase 2|130|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:01:04.243267|2018-06-01 05:01:04.243267
NCT00096356|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2014-09-08||2017-05-25|2004-11-08|2004-11-09|Estimate|2014-12-17|2014-12-29|Estimate||||2017-05-25|2017-06-20|Actual|August 2004||2004-08-31|December 2014|2014-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CoQ10|All participants|Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer|A Randomized Double-Blind Placebo-Controlled Study Of Oral Coenzyme Q10 To Relieve Self-Reported Cancer Treatment Related Fatigue In Breast Cancer Patients|Completed||N/A|236|Actual|Wake Forest University Health Sciences||2|||f||||t|f|f||||||||2018-06-01 05:01:04.352284|2018-06-01 05:01:04.352284
NCT00096343|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-12-02|2004-11-08|2004-11-09|Estimate|||||||2013-12-02|2013-12-04|Estimate|October 2002||2002-10-31|November 2012|2012-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer|A Phase II Trial of Pre-Operative Taxol and Carboplatin in Women With Newly Diagnosed Locally Advanced Operable Breast Cancer|Completed||Phase 2|31|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:01:04.866264|2018-06-01 05:01:04.866264
NCT00096330|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2014-01-10|2004-11-08|2004-11-09|Estimate|||||||2014-01-10|2014-01-13|Estimate|September 2004||2004-09-30|January 2014|2014-01-31|March 2008|Actual|2008-03-31|February 2007|Actual|2007-02-28||Interventional|||Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer|Phase I Clinical Study of Folate|Completed||Phase 1|20|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:01:04.941644|2018-06-01 05:01:04.941644
NCT00096317|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2008-11-12|2004-11-08|2004-11-09|Estimate|||||||2008-11-12|2008-11-13|Estimate|March 2003||2003-03-31|January 2006|2006-01-31||||||||Interventional|||Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors|Effect Of Ketoconazole On The Pharmacokinetics Of BMS-247550 In Patients With Advanced Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:01:05.005347|2018-06-01 05:01:05.005347
NCT00096304|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2018-04-06|2004-11-08|2004-11-09|Estimate|||||||2018-04-06|2018-04-10|Actual|June 8, 2004|Actual|2004-06-08|April 2018|2018-04-30|November 30, 2007|Actual|2007-11-30|September 6, 2006|Actual|2006-09-06||Interventional|||Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer|Phase I Trial of Epirubicin and Taxotere in Patients With Metastatic Androgen Independent Prostate Cancer|Terminated||Phase 1|36|Anticipated|Medical University of South Carolina||||Low accrual|f||||t|t|f|||f|||||2018-06-01 05:01:05.077448|2018-06-01 05:01:05.077448
NCT00096291|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2017-04-07|2004-11-08|2004-11-09|Estimate|||||||2017-04-07|2017-04-10|Actual|February 2000||2000-02-29|April 2017|2017-04-30||||March 2005|Actual|2005-03-31||Interventional|||Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer|Neoadjuvant Chemotherapy in Palpable Breast Cancer: Evaluation of Physiologic, Radiologic, and Molecular Markers in Predicting Response|Completed||Phase 2|62|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 05:01:05.150239|2018-06-01 05:01:05.150239
NCT00096278|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2012-10-31||2014-05-16|2004-11-08|2004-11-09|Estimate|2012-11-30|2012-12-03|Estimate||||2014-05-16|2014-05-29|Estimate|September 2004||2004-09-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|March 2009|Actual|2009-03-31||Interventional|||Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer|A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon|Completed||Phase 3|2710|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:01:05.27686|2018-06-01 05:01:05.27686
NCT00096265|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2013-03-05||2018-02-09|2004-11-08|2004-11-09|Estimate|2013-03-05|2013-04-16|Estimate||||2018-02-09|2018-03-09|Actual|October 6, 2004|Actual|2004-10-06|February 2018|2018-02-28|April 1, 2012|Actual|2012-04-01|June 14, 2011|Actual|2011-06-14||Interventional|||Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer|A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases|Terminated||Phase 3|126|Actual|National Cancer Institute (NCI)|This study stopped accrual early due to unmet targeted accrual goals with 126 subjects accrued out of 381 planned.|3|||f||||||||||||||2018-06-01 05:01:06.076426|2018-06-01 05:01:06.076426
NCT00096239|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-12-18|2004-11-08|2004-11-09|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2004||2004-12-31|February 2005|2005-02-28|February 2005|Actual|2005-02-28|||||Interventional|||CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Phase II Open-Label, Multi-Center Study of CP-547, 632, an Oral Tyrosine Kinase Inhibitor of VEGFR-2, in Subjects With Recurrent or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, or Fallopian Tube Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:01:07.363396|2018-06-01 05:01:07.363396
NCT00096226|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2014-01-16||2015-11-14|2004-11-08|2004-11-09|Estimate|2014-01-16|2014-02-27|Estimate||||2015-11-14|2015-11-17|Estimate|September 2004||2004-09-30|November 2015|2015-11-30||||April 2012|Actual|2012-04-30||Interventional||All eligible patients who started protocol treatment.|Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer|A Phase II Trial Of Neoadjuvant Therapy With Concurrent Chemotherapy And High Dose Radiotherapy Followed By Surgical Resection And Consolidative Therapy For Locally Advanced Non-Small Cell Lung Carcinoma|Completed||Phase 2|60|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:01:07.459113|2018-06-01 05:01:07.459113
NCT00096213|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2012-01-13|2004-11-08|2004-11-09|Estimate|||||||2012-01-13|2012-01-18|Estimate|December 2004||2004-12-31|January 2012|2012-01-31|August 2009|Actual|2009-08-31|April 2006|Actual|2006-04-30||Interventional|||S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone|A Phase II Surgical Trial Of Intralesional Resection Of Low-Grade Intracompartmental Chondrosarcoma Of Bone|Completed||Phase 2|60|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:01:07.98192|2018-06-01 05:01:07.98192
NCT00096200|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2012-11-08||2015-04-14|2004-11-08|2004-11-09|Estimate|2012-11-08|2012-12-13|Estimate||||2015-04-14|2015-05-05|Estimate|August 2004||2004-08-31|February 2014|2014-02-28||||August 2012|Actual|2012-08-31||Interventional|||Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)|Principal Investigator did not collect data on secondary outcomes because not relevant.|2|||f||||||||||||||2018-06-01 05:01:08.147761|2018-06-01 05:01:08.147761
NCT00096187|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2018-04-11|2004-11-08|2004-11-09|Estimate|||||||2018-04-11|2018-04-12|Actual|July 2005||2005-07-31|April 2018|2018-04-30||||July 23, 2007|Actual|2007-07-23||Interventional|||Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy|A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor|Terminated||Phase 2|55|Anticipated|Gynecologic Oncology Group|||||||||||||||||||2018-06-01 05:01:08.878837|2018-06-01 05:01:08.878837
NCT00096174|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2011-02-28||2015-08-03|2004-11-08|2004-11-09|Estimate|2011-02-28|2011-03-25|Estimate||||2015-08-03|2015-08-21|Estimate|December 2004||2004-12-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2009|Actual|2009-07-31||Interventional|||Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck|Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck|Unknown status|Active, not recruiting|Phase 2|69|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:01:08.9968|2018-06-01 05:01:08.9968
NCT00096161|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2017-01-27||2017-03-24|2004-11-08|2004-11-09|Estimate|2017-03-24|2017-05-04|Actual||||2017-03-24|2017-05-04|Actual|May 2003||2003-05-31|March 2017|2017-03-31||||February 2015|Actual|2015-02-28||Interventional|||Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant|Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial|Active, not recruiting||Phase 2|36|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:01:09.38763|2018-06-01 05:01:09.38763
NCT00096148|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-01-23|2004-11-08|2004-11-09|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2004||2004-10-31|January 2013|2013-01-31||||November 2006|Actual|2006-11-30||Interventional|||Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Randomized Phase II Trial of Idarubicin + Ara-C +/- Bevacizumab in Patients Age < 60 With Untreated Acute Myeloid Leukemia|Terminated||Phase 2|120|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:01:09.881616|2018-06-01 05:01:09.881616
NCT00096135|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2015-07-10||2017-02-14|2004-11-08|2004-11-09|Estimate|2015-07-10|2015-08-06|Estimate||||2017-02-14|2017-03-21|Actual|November 2004||2004-11-30|February 2017|2017-02-28||||September 2013|Actual|2013-09-30||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes|Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months)|Completed||N/A|168|Actual|Children's Oncology Group|The COG SDC reviewed the NLM notification related to ct.gov AE/SAE reporting. The information in ‘Additional Description’ is accurate with respect to data supplied to ct.gov.COG plans to submit data AE/SAE data consistent with the text in this field.|2|||f||||t||||||||||2018-06-01 05:01:10.003618|2018-06-01 05:01:10.003618
NCT00096122|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2011-06-13||2014-05-09|2004-11-08|2004-11-09|Estimate|2011-06-14|2011-07-15|Estimate||||2014-05-09|2014-05-26|Estimate|September 2004||2004-09-30|June 2013|2013-06-30|February 2010|Actual|2010-02-28|September 2006|Actual|2006-09-30||Interventional|||Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia|PHASE I-II STUDY OF IDARUBICIN, CYTARABINE AND R115777 (TIPIFARNIB, ZARNESTRA; 702818; IND 58359), A FARNESYLTRANSFERASE INHIBITOR, IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS|Completed||Phase 1/Phase 2|95|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:10.94942|2018-06-01 05:01:10.94942
NCT00096109|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2015-05-11||2016-11-18|2004-11-08|2004-11-09|Estimate|2016-11-18|2017-01-16|Estimate||||2016-11-18|2017-01-16|Estimate|September 2005||2005-09-30|November 2016|2016-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer|A Phase II Clinical Trial of 17-Allyamino-17-Demethoxygeldanamycin (17-AAG) in Chemotherapy Refractory Metastatic Breast Cancer|Terminated||Phase 2|11|Actual|National Cancer Institute (NCI)|Because of the frequency of toxicities experienced by the pts & lack of response, study closed to accrual before all 17 planned pts were enrolled. It was proposed to analyze outcome by HER2 status,but no HER2 data was collected.|1||Closed to accrual before all 12 planned patients were enrolled.|f||||||||||||||2018-06-01 05:01:11.179139|2018-06-01 05:01:11.179139
NCT00096096|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2010-05-12|2004-11-08|2004-11-09|Estimate|||||||2010-05-12|2010-05-13|Estimate|August 2004||2004-08-31|May 2010|2010-05-31||||May 2006|Actual|2006-05-31||Interventional|||Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation|A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:01:11.431606|2018-06-01 05:01:11.431606
NCT00096083|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-10-22|2004-11-08|2004-11-09|Estimate|||||||2013-10-22|2013-10-23|Estimate|September 2004||2004-09-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer|A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver|Completed||Phase 2|56|Actual|Delcath Systems Inc.||1|||f||||||||||||||2018-06-01 05:01:11.51087|2018-06-01 05:01:11.51087
NCT00096070|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-07-15|2004-11-08|2004-11-09|Estimate|||||||2013-07-15|2013-07-16|Estimate|December 2004||2004-12-31|June 2013|2013-06-30||||April 2007|Actual|2007-04-30||Interventional|||Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer|Phase II Study of Oxaliplatin, Continuous 5-Fluorouracil and External Beam Radiation Followed by Gemcitabine in Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:11.592838|2018-06-01 05:01:11.592838
NCT00096057|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-06-25|2004-11-08|2004-11-09|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2004||2004-05-31|April 2007|2007-04-30|December 2007|Actual|2007-12-31|||||Interventional|||Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer|An Open Label Phase I Study of Humanized Human Milk Fat Globule-1 (huHMFG1) Antibody in Patients With Locally Advanced or Metastatic Breast Cancer (TOPCAT)|Completed||Phase 1|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:01:11.675582|2018-06-01 05:01:11.675582
NCT00096044|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2017-04-24||2017-06-09|2004-11-08|2004-11-09|Estimate|2017-06-09|2017-07-11|Actual||||2017-06-09|2017-07-11|Actual|March 2004||2004-03-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||All treated and eligible patients|Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|CC-5013 Alone or in Combination With Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|45|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 05:01:11.790144|2018-06-01 05:01:11.790144
NCT00096031|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2012-04-04||2012-04-04|2004-11-08|2004-11-09|Estimate|2012-04-04|2012-05-01|Estimate||||2012-04-04|2012-05-01|Estimate|October 2004||2004-10-31|April 2012|2012-04-30|January 2010|Actual|2010-01-31|January 2008|Actual|2008-01-31||Interventional|||S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer|Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II|Completed||Phase 2|63|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:01:12.336147|2018-06-01 05:01:12.336147
NCT00096018|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2013-01-28||2013-09-19|2004-11-08|2004-11-09|Estimate|2013-01-28|2013-03-05|Estimate||||2013-09-19|2013-10-24|Estimate|May 2002||2002-05-31|September 2013|2013-09-30|May 2012|Actual|2012-05-31|November 2010|Actual|2010-11-30||Interventional||Treated Patients|Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia|A Phase I/II Study of Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients With Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|43|Actual|Roswell Park Cancer Institute|The study was stopped early due to low accrual.|1|||f||||t||||||||||2018-06-01 05:01:12.881348|2018-06-01 05:01:12.881348
NCT00096005|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2014-02-21|2004-11-08|2004-11-09|Estimate|||||||2014-02-21|2014-02-24|Estimate|November 2004||2004-11-30|October 2011|2011-10-31||||March 2010|Actual|2010-03-31||Interventional|||Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial Of 17-Allylaminogeldanamycin (17-AAG) And PS341 In Advanced Malignancies|Terminated||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:13.623297|2018-06-01 05:01:13.623297
NCT00095992|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2011-09-26|2004-11-08|2004-11-09|Estimate|||||||2011-09-26|2011-09-27|Estimate|November 2004||2004-11-30|September 2011|2011-09-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer|A Phase II Study Of SB-715992 (NSC 727990) In Patients With Locally Advanced, Recurrent Or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|15|Actual|Canadian Cancer Trials Group|||||f||||f||||||||||2018-06-01 05:01:13.726581|2018-06-01 05:01:13.726581
NCT00095979|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2015-05-05||2018-04-19|2004-11-08|2004-11-09|Estimate|2015-05-05|2015-05-21|Estimate||||2018-04-19|2018-05-18|Actual|May 2005||2005-05-31|April 2018|2018-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Eligible and treated patients|Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|52|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:13.838518|2018-06-01 05:01:13.838518
NCT00095966|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-07-01|2004-11-08|2004-11-09|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2004||2004-09-30|July 2013|2013-07-31||||September 2005|Actual|2005-09-30||Interventional|||Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:14.335314|2018-06-01 05:01:14.335314
NCT00095953|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-05-16|2004-11-08|2004-11-09|Estimate|||||||2013-05-16|2013-05-17|Estimate|November 2004||2004-11-30|September 2011|2011-09-30|September 2008|Actual|2008-09-30|September 2006|Actual|2006-09-30||Interventional|||SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma|A Phase II Study of SB-715992 (NSC 727990) in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma|Completed||Phase 2|17|Actual|National Cancer Institute (NCI)|||||f||||f||||||||||2018-06-01 05:01:14.403796|2018-06-01 05:01:14.403796
NCT00095940|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2011-08-02||2014-05-07|2004-11-08|2004-11-09|Estimate|2012-01-03|2012-02-06|Estimate||||2014-05-07|2014-05-23|Estimate|October 2004||2004-10-31|January 2013|2013-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors|Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma|Completed||Phase 1/Phase 2|52|Actual|National Cancer Institute (NCI)|Accrual to the Molecular Biology phase (MBP) was contingent upon accrual being open for the Phase II since some participants in the MBP could be counted in the phase II. The phase II enrolled rapidly thus limiting enrollment to the MBP.|1|||f||||||||||||||2018-06-01 05:01:14.500047|2018-06-01 05:01:14.500047
NCT00095927|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2017-01-03|2004-11-08|2004-11-09|Estimate|||||||2017-01-03|2017-01-04|Estimate|May 2003||2003-05-31|January 2017|2017-01-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Randomized Amifostine For SCCHN|Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|58|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 05:01:16.523645|2018-06-01 05:01:16.523645
NCT00095914|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2012-03-14|2004-11-08|2004-11-09|Estimate|||||||2012-03-14|2012-03-15|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|March 2009|Actual|2009-03-31|May 2007|Actual|2007-05-31||Interventional|||Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors|Completed||Phase 1|||National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:01:16.638381|2018-06-01 05:01:16.638381
NCT00095901|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2018-03-28|2004-11-08|2004-11-09|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2004||2004-06-30|March 2018|2018-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Capecitabine For Nasopharyngeal Cancer|A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|3|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 05:01:16.709228|2018-06-01 05:01:16.709228
NCT00095888|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-01-15|2004-11-08|2004-11-09|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2004||2004-10-31|January 2013|2013-01-31||||June 2006|Actual|2006-06-30||Interventional|||3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer|A Phase II Trial Of Gemcitabine And Triapine In Refractory Metastatic Breast Cancer|Terminated||Phase 2|68|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:01:16.803169|2018-06-01 05:01:16.803169
NCT00095875|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2013-05-15||2013-10-25|2004-11-08|2004-11-09|Estimate|2013-05-15|2013-07-02|Estimate||||2013-10-25|2013-11-19|Estimate|August 2004||2004-08-31|October 2013|2013-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)|A Randomized Phase III Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatinum-Based Chemoradiotherapy [PARADIGM TRIAL]|Completed||Phase 3|145|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-06-01 05:01:16.916234|2018-06-01 05:01:16.916234
NCT00095862|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2018-02-01|2004-11-08|2004-11-09|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2004||2004-11-30|October 2011|2011-10-31||||||||Interventional|||Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers|A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor|Terminated||Phase 1/Phase 2|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:01:17.332655|2018-06-01 05:01:17.332655
NCT00095836|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2017-03-01||2017-05-02|2004-11-08|2004-11-09|Estimate|2017-05-02|2017-05-31|Actual||||2017-05-02|2017-05-31|Actual|March 2003|Actual|2003-03-31|May 2017|2017-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy|A Phase II Study of ZD 1839 (IRESSA®) in Patients With Advanced Thyroid Cancer|Completed||Phase 2|27|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 05:01:17.456127|2018-06-01 05:01:17.456127
NCT00095823|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-11-22|2004-11-08|2004-11-09|Estimate|||||||2013-11-22|2013-11-25|Estimate|June 2004||2004-06-30|November 2013|2013-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.|Completed||Phase 3|1200||Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:01:17.805069|2018-06-01 05:01:17.805069
NCT00095810|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-11-07|2004-11-08|2004-11-09|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 2003||2003-07-31|December 2010|2010-12-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease|An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease|Completed||Phase 4|50||Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-06-01 05:01:17.901798|2018-06-01 05:01:17.901798
NCT00095784|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|2014-07-09||2018-04-20|2004-11-08|2004-11-09|Estimate|2014-12-23|2015-01-05|Estimate||||2018-04-20|2018-05-21|Actual|September 29, 2004|Actual|2004-09-29|April 2018|2018-04-30||||July 1, 2008|Actual|2008-07-01||Interventional|||Decitabine in Treating Patients With Myelofibrosis|A Phase II Study of Decitabine in Myelofibrosis|Active, not recruiting||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:18.10654|2018-06-01 05:01:18.10654
NCT00095771|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2011-04-21|2004-11-08|2004-11-09|Estimate|||||||2011-04-21|2011-04-22|Estimate|November 2004||2004-11-30|April 2011|2011-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas|A Phase I Trial of Arsenic Trioxide in the Treatment of Infiltrating Gliomas of Childhood|Completed||Phase 1|36|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||t||||||||||2018-06-01 05:01:18.633505|2018-06-01 05:01:18.633505
NCT00095758|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-11-22|2004-11-08|2004-11-09|Estimate|||||||2013-11-22|2013-11-25|Estimate|September 2004||2004-09-30|November 2013|2013-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder|A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder|Completed||Phase 3|1200||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 05:01:18.758603|2018-06-01 05:01:18.758603
NCT00095745|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-11-07|2004-11-08|2004-11-09|Estimate|||||||2013-11-07|2013-11-08|Estimate|September 2004||2004-09-30|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder|A Multicenter, Long-Term, Open-label, Study to Assess the Safety and Tolerability of Aripiprazole as an Adjunctive Therapy in the Treatment of Outpatients With Major Depressive Disorder|Completed||Phase 3|1002|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-06-01 05:01:18.886928|2018-06-01 05:01:18.886928
NCT00095732|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2014-10-15|2004-11-08|2004-11-09|Estimate|||||||2014-10-15|2014-10-17|Estimate|June 2004||2004-06-30|October 2014|2014-10-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency|A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency|Completed||Phase 2|129|Actual|Anthera Pharmaceuticals||3|||f||||t||||||||||2018-06-01 05:01:19.041035|2018-06-01 05:01:19.041035
NCT00095719|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-09|||2013-11-07|2004-11-08|2004-11-09|Estimate|||||||2013-11-07|2013-11-11|Estimate|December 2003||2003-12-31|August 2008|2008-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia|A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia|Completed||Phase 3|125||Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 05:01:19.154041|2018-06-01 05:01:19.154041
NCT00095706|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2015-09-23|2004-11-05|2004-11-08|Estimate|||||||2015-09-23|2015-09-25|Estimate|June 2003||2003-06-30|September 2015|2015-09-30|January 2012|Actual|2012-01-31|April 2007|Actual|2007-04-30||Interventional|||Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)|Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor|Completed||Phase 1/Phase 2|50|Anticipated|Translational Oncology Research International|||||f||||t||||||||||2018-06-01 05:01:19.25556|2018-06-01 05:01:19.25556
NCT00095693|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2014-01-15|2004-11-05|2004-11-08|Estimate|||||||2014-01-15|2014-01-16|Estimate|October 2004||2004-10-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|August 2005|Actual|2005-08-31||Interventional|||Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer|Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:19.356698|2018-06-01 05:01:19.356698
NCT00095680|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2010-10-21|2004-11-05|2004-11-08|Estimate|||||||2010-10-21|2010-10-22|Estimate|November 2004||2004-11-30|October 2010|2010-10-31|February 2006|Actual|2006-02-28|||||Interventional|||Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma|A 24-week, Open-label Extension Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed Refractory Patients With Multiple Myeloma|Completed||Phase 2|30|Actual|Scios, Inc.||2|||f||||||||||||||2018-06-01 05:01:19.44013|2018-06-01 05:01:19.44013
NCT00095667|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2013-05-07|2004-11-05|2004-11-08|Estimate|||||||2013-05-07|2013-05-08|Estimate|November 2004||2004-11-30|May 2013|2013-05-31||||November 2007|Actual|2007-11-30||Interventional|||Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer|A Phase 2 Study of GW572016 in Hormone Naive Recurrent or Metastatic Hormone Sensitive Prostate Cancer|Completed||Phase 2|41|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:19.506315|2018-06-01 05:01:19.506315
NCT00095654|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2009-11-09|2004-11-05|2004-11-08|Estimate|||||||2009-11-09|2009-11-10|Estimate|July 2001||2001-07-31|November 2009|2009-11-30|October 2006|Actual|2006-10-31|||||Interventional|||The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial|The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial|Completed||Phase 3|5000||Gerstein, Hertzel, MD|||||||||||||||||||2018-06-01 05:01:19.575452|2018-06-01 05:01:19.575452
NCT00095641|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2013-11-07|2004-11-05|2004-11-08|Estimate|||||||2013-11-07|2013-11-08|Estimate||||November 2013|2013-11-30||||||||Interventional|||S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer|S0225: Phase II Study of Adjuvant Low-Dose Capecitabine After Salvage Surgery in Patients With Locally Recurrent or Persistent Squamous Cell Carcinoma of the Head and Neck|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||||no longer studying this disease site|f||||t||||||||||2018-06-01 05:01:19.632075|2018-06-01 05:01:19.632075
NCT00095628|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|2015-06-19||2017-01-13|2004-11-05|2004-11-08|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|January 2005||2005-01-31|January 2017|2017-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||A total of 21 patients were enrolled onto the study. One patient was ineligible due to disease progression prior to treatment. So a total of 20 evaluable patients were analyzed|SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:19.693968|2018-06-01 05:01:19.693968
NCT00095589|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2009-02-26|2004-11-05|2004-11-08|Estimate|||||||2009-02-26|2009-02-27|Estimate|August 2004||2004-08-31|February 2009|2009-02-28||||June 2009|Anticipated|2009-06-30||Interventional|||Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer|Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-Institutional Study|Unknown status|Active, not recruiting|N/A|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:01:20.010703|2018-06-01 05:01:20.010703
NCT00095576|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|2011-07-20||2015-10-05|2004-11-05|2004-11-08|Estimate|2011-07-20|2011-08-15|Estimate||||2015-10-05|2015-10-06|Estimate|November 2004||2004-11-30|October 2015|2015-10-31|September 2009|Actual|2009-09-30|September 2007|Actual|2007-09-30||Interventional|||Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5 HIV-1 Gag/Pol/Nef) in Adults at High Risk of HIV-1 Infection|Terminated||Phase 2|3000|Actual|Merck Sharp & Dohme Corp.|The DSMB (Data & Safety Monitoring Board) reviewed interim data which demonstrated that the investigational vaccine was not effective, and all vaccinations were halted. Long term follow up was available for participants in V520-030.|2|||f||||t||||||||||2018-06-01 05:01:20.120617|2018-06-01 05:01:20.120617
NCT00095563|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|2015-07-30||2017-03-06|2004-11-05|2004-11-08|Estimate|2017-03-06|2017-04-18|Actual||||2017-03-06|2017-04-18|Actual|September 2004||2004-09-30|March 2017|2017-03-31|June 2009|Actual|2009-06-30|February 2009|Actual|2009-02-28||Interventional|||Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers|A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:01:20.549597|2018-06-01 05:01:20.549597
NCT00095550|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05||2010-02-15|2011-04-07|2004-11-05|2004-11-08|Estimate||||2010-02-15|2010-02-17|Estimate|2011-04-07|2011-04-15|Estimate|October 2004||2004-10-31|August 2008|2008-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension|The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients With Moderate Hypertension|Completed||Phase 3|496|Anticipated|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:01:20.994631|2018-06-01 05:01:20.994631
NCT00095537|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2010-02-27|2004-11-05|2004-11-08|Estimate|||||||2010-02-27|2010-03-02|Estimate|March 2004||2004-03-31|October 2008|2008-10-31||||May 2006|Actual|2006-05-31||Interventional|||BMS-599626 in Patients With Advanced Solid Malignancies|Phase I Study of BMS-599626 in Patients With Advanced Solid Malignancies, Including Malignancies That Express HER2 at the Maximum Tolerated Dose and/or Recommended Phase II Dose|Completed||Phase 1|60||Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 05:01:21.205975|2018-06-01 05:01:21.205975
NCT00095524|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2013-11-07|2004-11-05|2004-11-08|Estimate|||||||2013-11-07|2013-11-11|Estimate|March 2004||2004-03-31|May 2008|2008-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder|A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|300||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||f||||||||||||||2018-06-01 05:01:21.265601|2018-06-01 05:01:21.265601
NCT00095511|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2013-11-07|2004-11-05|2004-11-08|Estimate|||||||2013-11-07|2013-11-11|Estimate|June 2004||2004-06-30|May 2008|2008-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Aripiprazole in Patients With Acute Mania|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder|Completed||Phase 3|615||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||f||||||||||||||2018-06-01 05:01:21.386096|2018-06-01 05:01:21.386096
NCT00095498|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|2010-06-25|2009-11-23|2017-02-07|2004-11-05|2004-11-08|Estimate|2013-12-12|2014-01-13|Estimate|2009-11-23|2009-11-25|Estimate|2017-02-07|2017-03-15|Actual|August 2004||2004-08-31|February 2017|2017-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis|Completed||Phase 2|227|Actual|Amgen||3|||f||||||||||||||2018-06-01 05:01:21.660659|2018-06-01 05:01:21.660659
NCT00095485|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-05|||2008-03-03|2004-11-05|2004-11-08|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2004||2004-11-30|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Impact of Move to Clinical Research Center on Physical Activity of Employees|Impact of Move to CRC on Physical Activity of Employees|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:24.884014|2018-06-01 05:01:24.884014
NCT00095472|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-04|||2018-05-11|2004-11-04|2004-11-05|Estimate|||||||2018-05-11|2018-05-14|Actual|November 1, 2004||2004-11-01|December 7, 2015|2015-12-07|August 24, 2007|Actual|2007-08-24|August 24, 2007|Actual|2007-08-24||Interventional|||Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease|Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease|Completed||Phase 1|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:24.93712|2018-06-01 05:01:24.93712
NCT00095459|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-04|||2018-05-19|2004-11-04|2004-11-05|Estimate|||||||2018-05-19|2018-05-22|Actual|November 2, 2004||2004-11-02|April 23, 2014|2014-04-23|July 20, 2012|Actual|2012-07-20|November 1, 2005|Actual|2005-11-01||Interventional|||BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors|A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis|Completed||Phase 1|57|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:25.00497|2018-06-01 05:01:25.00497
NCT00095446|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-04|||2017-01-02|2004-11-04|2004-11-05|Estimate|||||||2017-01-02|2017-01-04|Estimate|July 2004||2004-07-31|January 2017|2017-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes|An Open-Label, Multi Center, Clinical Trial: External Continuous Subcutaneous Infusion of Insulin Using Insulin Aspart (NovoLog®) in Subjects With Type 1 and Insulin Requiring Type 2 Diabetes|Completed||Phase 4|513|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:01:25.084493|2018-06-01 05:01:25.084493
NCT00095433|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-04|||2014-03-25|2004-11-04|2004-11-05|Estimate|||||||2014-03-25|2014-03-26|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)|An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase I/II rhuFab V2 Study|Completed||Phase 3|100||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:01:25.160846|2018-06-01 05:01:25.160846
NCT00095420|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-04|||2013-05-13|2004-11-04|2004-11-05|Estimate|||||||2013-05-13|2013-05-14|Estimate|September 2003||2003-09-30|May 2013|2013-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Relationship Training for Children With Autism and Their Peers|Peer Related School Interventions in Autism|Completed||N/A|60|Actual|University of California, Los Angeles||4|||f||||t||||||||||2018-06-01 05:01:25.221961|2018-06-01 05:01:25.221961
NCT00095407|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-03|||2017-06-30|2004-11-03|2004-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|October 29, 2004||2004-10-29|December 29, 2011|2011-12-29|December 29, 2011||2011-12-29|||||Observational|||The Functional Anatomy of Personality Trait Knowledge: An fMRI Study|The Functional Anatomy of Personality Trait Knowledge: an fMRI Study|Completed|||190|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:25.298775|2018-06-01 05:01:25.298775
NCT00095394|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-03||2010-02-15|2011-04-07|2004-11-03|2004-11-04|Estimate||||2010-02-15|2010-02-17|Estimate|2011-04-07|2011-04-15|Estimate|September 2004||2004-09-30|August 2008|2008-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension|The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension|Completed||Phase 3|645|Anticipated|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 05:01:25.408365|2018-06-01 05:01:25.408365
NCT00095381|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-03|||2012-01-18|2004-11-03|2004-11-04|Estimate|||||||2012-01-18|2012-01-19|Estimate|March 2004||2004-03-31|January 2012|2012-01-31|December 2007|Actual|2007-12-31|March 2007|Actual|2007-03-31||Interventional|||Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia|A Phase II, Multi-Center Open-Label, Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride (BCX-1777) Use|Completed||Phase 2|20||BioCryst Pharmaceuticals|||||f||||||||||||||2018-06-01 05:01:25.876481|2018-06-01 05:01:25.876481
NCT00095368|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-03|||2006-12-06|2004-11-03|2004-11-04|Estimate|||||||2006-12-06|2006-12-08|Estimate|October 2004||2004-10-31|April 2005|2005-04-30|May 2005||2005-05-31|||||Interventional|||APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat|A Phase III, Randomized, Double-Blind, Double-Dummy Multicenter Study to Evaluate the Efficacy and Safety of 775 mg APC-111 MP Tablet QD for 7 Days vs Penicillin VK 250 mg QID for 10 Days in Patients With Streptococcus Pyogenes|Completed||Phase 3|500||Advancis Pharmaceutical Corporation|||||f||||||||||||||2018-06-01 05:01:25.960942|2018-06-01 05:01:25.960942
NCT00095355|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02|||2008-03-03|2004-11-02|2004-11-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2004||2004-10-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease|Stimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's Disease|Completed||Phase 2|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:26.017616|2018-06-01 05:01:26.017616
NCT00095342|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02|||2009-09-08|2004-11-02|2004-11-03|Estimate|||||||2009-09-08|2009-09-10|Estimate||||September 2009|2009-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study Evaluating TMI-005 in Active Rheumatoid Arthritis|A Double-Blind, Placebo-Controlled, Parallel, Randomized Study to Evaluate the Efficacy and Safety of 3 Oral Dose Levels of TMI-005 in Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate|Completed||Phase 2|390|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:01:26.070785|2018-06-01 05:01:26.070785
NCT00095329|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02|||2016-09-20|2004-11-02|2004-11-03|Estimate|||||||2016-09-20|2016-09-22|Estimate|May 2003||2003-05-31|September 2016|2016-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor|A Phase I/II, Open-Label Pilot Trial to Evaluate the Safety of Rapamune (Sirolimus) in Patients With Multiple Sclerosis|Terminated||Phase 1/Phase 2|14|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1||Due to slow recruitment.|f||||t||||||||||2018-06-01 05:01:26.125298|2018-06-01 05:01:26.125298
NCT00095316|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02|||2014-12-04|2004-11-02|2004-11-03|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2004||2004-10-31|June 2006|2006-06-30|September 2006||2006-09-30|||||Interventional|||Caspofungin Study for Fungal Infections in Adults in Critical Care Settings|A Randomized, Double-Masked Trial of Caspofungin Versus Placebo as Prophylaxis of Invasive Candidiasis in High-Risk Adults in the Critical Care Setting|Terminated||Phase 3|1200|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:01:26.219255|2018-06-01 05:01:26.219255
NCT00095303|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02|2014-05-17||2015-06-10|2004-11-02|2004-11-03|Estimate|2015-06-10|2015-07-07|Estimate||||2015-06-10|2015-07-07|Estimate|August 2004||2004-08-31|June 2015|2015-06-30|August 2011|Actual|2011-08-31|January 2008|Actual|2008-01-31||Interventional|BSFT|Main Study|Brief Strategic Family Therapy for Adolescent Drug Abusers|Brief Strategic Family Therapy for Adolescent Drug Abusers|Completed||Phase 3|480|Actual|University of Miami|Main Study: Low rates self-reported drug use leading to only examination of prevention of relapse/escalation of drug use Follow Up Study: Variability between the time of participation in main and follow up, so no direct casuality could be concluded|2|||f||||t||||||||||2018-06-01 05:01:26.587148|2018-06-01 05:01:26.587148
NCT00095290|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02||2010-02-15|2011-04-07|2004-11-02|2004-11-03|Estimate||||2010-02-15|2010-02-17|Estimate|2011-04-07|2011-04-15|Estimate|September 2004||2004-09-30|September 2008|2008-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria|Irbesartan Versus Placebo in Combination With Standard Cardiovascular Protection ACE-I Therapy With Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk|Completed||Phase 4|400||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 05:01:27.404616|2018-06-01 05:01:27.404616
NCT00095277|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02|||2009-03-12|2004-11-02|2004-11-03|Estimate|||||||2009-03-12|2009-03-13|Estimate|October 2004||2004-10-31|March 2009|2009-03-31||||||||Interventional|||Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer|Completed||Phase 2|220||Amgen|||||||||||||||||||2018-06-01 05:01:27.602434|2018-06-01 05:01:27.602434
NCT00095264|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-02|||2010-01-14|2004-11-02|2004-11-03|Estimate|||||||2010-01-14|2010-01-15|Estimate|October 2004||2004-10-31|January 2010|2010-01-31||||||||Interventional|||A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome|A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome|Completed||Phase 2|209||Amgen|||||||||||||||||||2018-06-01 05:01:27.666553|2018-06-01 05:01:27.666553
NCT00095251|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|||2017-03-22|2004-11-01|2004-11-02|Estimate|||||||2017-03-22|2017-03-23|Actual|August 2004||2004-08-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|August 2007|Actual|2007-08-31||Interventional|||MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status|A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status|Active, not recruiting||Phase 2|100|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-06-01 05:01:27.733389|2018-06-01 05:01:27.733389
NCT00095238|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|2009-12-16||2015-03-18|2004-11-01|2004-11-02|Estimate|2010-05-05|2010-06-08|Estimate||||2015-03-18|2015-04-07|Estimate|June 2002||2002-06-30|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)|Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)|Completed||Phase 3|4128|Actual|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 05:01:27.962132|2018-06-01 05:01:27.962132
NCT00095225|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|||2008-01-23|2004-11-01|2004-11-02|Estimate|||||||2008-01-23|2008-01-29|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|November 2006|Actual|2006-11-30|||||Interventional|||A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)|A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy (Docetaxel or Pemetrexed) or Tarceva (Erlotinib) Compared With Chemotherapy (Docetaxel or Pemetrexed) Alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer|Completed||Phase 2|122|Actual|Genentech, Inc.|||||||||||||||||||2018-06-01 05:01:31.870058|2018-06-01 05:01:31.870058
NCT00095212|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|2010-01-21||2010-04-09|2004-11-01|2004-11-02|Estimate|2010-03-01|2010-03-15|Estimate||||2010-04-09|2010-04-14|Estimate|September 2004||2004-09-30|April 2010|2010-04-30|February 2009|Actual|2009-02-28|April 2008|Actual|2008-04-30||Interventional|||Androgen Effects in HIV-infected Women|Androgen Effects in HIV-infected Women|Completed||N/A|25|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 05:01:31.991444|2018-06-01 05:01:31.991444
NCT00095199|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|2012-06-19||2012-09-13|2004-11-01|2004-11-02|Estimate|2012-09-13|2012-10-15|Estimate||||2012-09-13|2012-10-15|Estimate|January 2005||2005-01-31|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer|Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy|Completed||Phase 3|939|Actual|Eli Lilly and Company||4|||f||||t||||||||||2018-06-01 05:01:32.539675|2018-06-01 05:01:32.539675
NCT00095186|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|||2008-04-08|2004-11-01|2004-11-02|Estimate|||||||2008-04-08|2008-04-10|Estimate|September 2004||2004-09-30|April 2008|2008-04-30|March 2007||2007-03-31|||||Interventional|||Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma|A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant Human Lactoferrin (rhLF) Monotherapy in Patients With Advanced Renal Cell Carcinoma (RCC), Who Have Failed at Least One Regimen of Systemic Therapy for RCC|Completed||Phase 2|40||Agennix|||||||||||||||||||2018-06-01 05:01:34.901826|2018-06-01 05:01:34.901826
NCT00095173|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|2016-09-22||2016-11-22|2004-11-01|2004-11-02|Estimate|2016-11-22|2017-01-18|Estimate||||2016-11-22|2017-01-18|Estimate|December 2003||2003-12-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|June 2006|Actual|2006-06-30||Interventional||All treated participants in the Lead-In Phase (Period A)|BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis|A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA)|Completed||Phase 3|214|Actual|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:01:35.052359|2018-06-01 05:01:35.052359
NCT00095160|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|||2017-11-27|2004-11-01|2004-11-02|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2003||2003-10-31|November 2017|2017-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors|Phase I, Open Label Safety, Pharmacokinetic, and Pharmacodynamic Dose Escalation/De-escalation Study of 852A Administered Intravenously to Subjects With Refractory Solid Organ Tumors|Completed||Phase 1|42||Masonic Cancer Center, University of Minnesota|||||f||||||||||||||2018-06-01 05:01:36.614412|2018-06-01 05:01:36.614412
NCT00095147|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|2010-10-26||2015-03-04|2004-11-01|2004-11-02|Estimate|2010-12-21|2011-01-21|Estimate||||2015-03-04|2015-03-24|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis|A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate|Completed||Phase 3|431|Actual|Bristol-Myers Squibb||5|||f||||||||||||||2018-06-01 05:01:36.836226|2018-06-01 05:01:36.836226
NCT00095134|ClinicalTrials.gov processed this data on May 31, 2018|2004-11-01|||2011-12-05|2004-10-29|2004-11-01|Estimate|||||||2011-12-05|2011-12-06|Estimate|October 2004||2004-10-31|December 2011|2011-12-31|November 2005|Actual|2005-11-30|||||Interventional|||Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy|A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy|Completed||Phase 3|630|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:01:42.697095|2018-06-01 05:01:42.697095
NCT00095121|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|2011-04-08||2012-05-16|2004-10-29|2004-11-01|Estimate|2011-06-01|2011-06-03|Estimate||||2012-05-16|2012-05-22|Estimate|June 2004||2004-06-30|May 2012|2012-05-31|April 2010|Actual|2010-04-30|May 2006|Actual|2006-05-31||Interventional|||Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B|A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2 to Less Than 18) With Chronic Hepatitis B|Completed||Phase 3|173|Actual|Gilead Sciences||2|||f||||||||||||||2018-06-01 05:01:43.456764|2018-06-01 05:01:43.456764
NCT00095108|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|||2009-03-06|2004-10-29|2004-11-01|Estimate|||||||2009-03-06|2009-03-09|Estimate|May 2004||2004-05-31|March 2009|2009-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer|A Phase 1 Open-Label Study of the Safety and Pharmacokinetics of Recombinant Human Interleukin-21 (rIL-21) in Subjects With Metastatic Melanoma or Metastatic Renal Cell Carcinoma|Completed||Phase 1|43|Actual|ZymoGenetics|||||f||||||||||||||2018-06-01 05:01:49.832773|2018-06-01 05:01:49.832773
NCT00095095|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|||2018-02-09|2004-10-29|2004-11-01|Estimate|||||||2018-02-09|2018-02-13|Actual|October 2004||2004-10-31|March 2005|2005-03-31|May 2006||2006-05-31|||||Interventional|||Lumbar Interbody Fusion Using the Telamon® Peek™ Versus the Telamon® Hydrosorb™ Fusion Device|Lumbar Interbody Fusion Using The Telamon® Peek™ Versus The Telamon® Hydrosorb™ Fusion Device - A Prospective, Randomized Controlled Trial To Assess Surgical And Clinical Outcomes|Terminated||Phase 4|102||Medtronic Spinal and Biologics|||||f||||||||||||||2018-06-01 05:01:50.058751|2018-06-01 05:01:50.058751
NCT00095082|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|||2017-01-26|2004-10-29|2004-11-01|Estimate|||||||2017-01-26|2017-01-27|Estimate|September 2004||2004-09-30|January 2017|2017-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes|Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes|Completed||Phase 3|447|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:01:50.204407|2018-06-01 05:01:50.204407
NCT00095069|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|||2015-01-13|2004-10-29|2004-11-01|Estimate|||||||2015-01-13|2015-01-14|Estimate|October 2004||2004-10-31|January 2015|2015-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Groups Efficacy and Safety Extension Study of MK0928 in the Treatment of Adult Outpatients With Primary Insomnia|Completed||Phase 3|600||H. Lundbeck A/S|||||f||||||||||||||2018-06-01 05:01:50.546269|2018-06-01 05:01:50.546269
NCT00095056|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|2010-06-22||2015-03-12|2004-10-29|2004-11-01|Estimate|2010-06-22|2010-07-23|Estimate||||2015-03-12|2015-04-02|Estimate|October 2004||2004-10-31|March 2015|2015-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)|Sitagliptin Study in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency|Completed||Phase 3|91|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 05:01:50.721585|2018-06-01 05:01:50.721585
NCT00095043|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|||2016-11-16|2004-10-29|2004-11-01|Estimate|||||||2016-11-16|2016-11-17|Estimate|October 2004||2004-10-31|November 2016|2016-11-30||||June 2006|Actual|2006-06-30||Interventional|||Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)|A 12-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Multicenter Long-Term Safety Study of MK0928 in the Treatment of Elderly Outpatients With Primary Insomnia|Completed||Phase 3|320||H. Lundbeck A/S|||||f||||||||||||||2018-06-01 05:01:51.532787|2018-06-01 05:01:51.532787
NCT00095030|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29||2010-09-10|2010-09-10|2004-10-29|2004-11-01|Estimate||||2010-09-10|2010-09-14|Estimate|2010-09-10|2010-09-14|Estimate|February 2004||2004-02-29|September 2007|2007-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone|A Phase 3, Randomized, Three-Arm, Double-blind, Active Controlled, Parallel Group, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Subjects Wtih Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone|Completed||Phase 3|1752||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:01:51.645989|2018-06-01 05:01:51.645989
NCT00095017|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|||2015-07-29|2004-10-29|2004-11-01|Estimate|||||||2015-07-29|2015-07-30|Estimate|November 2004||2004-11-30|July 2015|2015-07-31||||||||Interventional|||Safety and Efficacy of an Investigational Drug Versus Placebo in the Treatment of Cancer Pain (0663-083)|A 4 Week Randomized, Placebo-Controlled, Parallel Group, Double-Blind Pilot Study to Assess the Safety and Efficacy of Etoricoxib 90 mg Versus Placebo in the Treatment of Cancer Pain|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:01:52.071545|2018-06-01 05:01:52.071545
NCT00095004|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29|||2017-03-31|2004-10-29|2004-11-01|Estimate|||||||2017-03-31|2017-04-04|Actual|October 21, 2004|Actual|2004-10-21|March 2017|2017-03-31|April 4, 2005|Actual|2005-04-04|April 1, 2005|Actual|2005-04-01||Interventional|||Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild|Completed||Phase 3|167|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:01:52.164209|2018-06-01 05:01:52.164209
NCT00094991|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-29||2010-09-10|2010-09-10|2004-10-29|2004-11-01|Estimate||||2010-09-10|2010-09-14|Estimate|2010-09-10|2010-09-14|Estimate|May 2004||2004-05-31|September 2007|2007-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes|Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients|Completed||Phase 3|42||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:01:52.478157|2018-06-01 05:01:52.478157
NCT00094978|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|||2018-05-16|2004-10-28|2004-10-29|Estimate|||||||2018-05-16|2018-05-17|Actual|October 25, 2004||2004-10-25|May 20, 2013|2013-05-20|May 20, 2013|Actual|2013-05-20|May 20, 2013|Actual|2013-05-20||Interventional|||Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum|Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum|Terminated||Phase 1|23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:52.570882|2018-06-01 05:01:52.570882
NCT00094965|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|||2009-03-27|2004-10-28|2004-10-29|Estimate|||||||2009-03-27|2009-03-30|Estimate|September 2004||2004-09-30|March 2009|2009-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|FOLFOX4||Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function|Phase II Trial of Oxaliplatin in Combination With Bolus/Infusional 5FU/LV (FOLFOX4) in Patients With Advanced Gastrointestinal (GI) Cancers With Varying Degrees of Renal Impairment|Completed||Phase 2|43|Actual|Sanofi||1|||f||||||||||||||2018-06-01 05:01:52.725714|2018-06-01 05:01:52.725714
NCT00094952|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|||2009-09-16|2004-10-28|2004-10-29|Estimate|||||||2009-09-16|2009-09-18|Estimate|April 2003||2003-04-30|September 2009|2009-09-30|March 2008||2008-03-31|||||Observational|||Biomarkers and Early Alzheimer's Disease|Biomarkers and Early Alzheimer's Disease|Unknown status|Recruiting||80|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:01:52.879451|2018-06-01 05:01:52.879451
NCT00094939|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|||2009-12-10|2004-10-28|2004-10-29|Estimate|||||||2009-12-10|2009-12-14|Estimate|September 2003||2003-09-30|September 2009|2009-09-30|August 2008||2008-08-31|||||Observational|||Predictors of Cognitive Decline in Normal Aging|Predictors of Cognitive Decline in Normal Aging|Unknown status|Recruiting||170|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:01:53.133721|2018-06-01 05:01:53.133721
NCT00094926|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|||2011-05-17|2004-10-28|2004-10-29|Estimate|||||||2011-05-17|2011-05-19|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|February 2007|Actual|2007-02-28|||||Interventional|||A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.|A Prospective, Randomized, Double-blind, Placebo-controlled Study of the Effectiveness and Safety of RISPERDAL CONSTA Augmentation in Adult Patients With Frequently-relapsing Bipolar Disorder|Completed||Phase 3|275|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 05:01:53.246063|2018-06-01 05:01:53.246063
NCT00094913|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|||2009-05-26|2004-10-28|2004-10-29|Estimate|||||||2009-05-26|2009-05-27|Estimate|May 2004||2004-05-31|July 2007|2007-07-31|April 2005||2005-04-30|||||Observational|||PET Changes in Alzheimer's Disease (AD)|Clinical Correlates of Longitudinal PET Changes in Alzheimer's Disease (AD)|Unknown status|Active, not recruiting||105|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:01:53.3462|2018-06-01 05:01:53.3462
NCT00094744|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-22|||2010-09-08|2004-10-22|2004-10-25|Estimate|||||||2010-09-08|2010-09-09|Estimate|May 2001||2001-05-31|September 2010|2010-09-30|September 2003|Actual|2003-09-30|July 2003|Actual|2003-07-31||Interventional|||Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia|A Randomized Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia|Completed||Phase 3|175|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 05:02:00.826062|2018-06-01 05:02:00.826062
NCT00094900|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|2013-03-19||2014-01-30|2004-10-27|2004-10-28|Estimate|2013-05-31|2013-07-10|Estimate||||2014-01-30|2014-03-04|Estimate|October 2004||2004-10-31|January 2014|2014-01-31|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Interleukin-1 Trap to Treat Autoinflammatory Diseases|Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis|Completed||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)|"Secondary outcome analyses will be stratified based on primary outcome results - responders and non-responders.~1 subject with Familial Mediterranean Fever (FMF) was recruited but outcomes were not collected due to insufficient accrual of FMF cases."|1|||f||||||||||||||2018-06-01 05:01:53.600185|2018-06-01 05:01:53.600185
NCT00094887|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-28|2009-12-04||2017-10-25|2004-10-27|2004-10-28|Estimate|2010-04-22|2010-04-23|Estimate||||2017-10-25|2017-12-02|Actual|October 2004||2004-10-31|October 2017|2017-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises|A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis|Completed||Phase 2|150|Actual|Mallinckrodt||2|||f||||t||||||||||2018-06-01 05:01:54.981918|2018-06-01 05:01:54.981918
NCT00094874|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-27|||2005-06-23|2004-10-27|2004-10-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2004||2004-09-30|October 2004|2004-10-31|September 2005||2005-09-30|||||Interventional|||Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms|A Double-Blind, Randomized Study of Puncturing Versus Non-Puncturing Acupuncture for the Treatment of Interstitial Cystitis Symptoms|Unknown status|Recruiting|Phase 3|60||The Mary Elizabeth Groff Surgical Medical Research and Education Charitable Trust|||||f||||||||||||||2018-06-01 05:01:55.285922|2018-06-01 05:01:55.285922
NCT00094861|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-27|2014-01-24||2017-02-02|2004-10-26|2004-10-27|Estimate|2014-01-24|2014-03-06|Estimate||||2017-02-02|2017-03-14|Actual|January 2005||2005-01-31|February 2017|2017-02-28|January 2014|Actual|2014-01-31|December 2007|Actual|2007-12-31||Interventional|||Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|100|Actual|Swedish Orphan Biovitrum||2|||f||||t||||||||||2018-06-01 05:01:55.383495|2018-06-01 05:01:55.383495
NCT00094848|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-27|||2013-08-01|2004-10-26|2004-10-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|June 2004||2004-06-30|August 2013|2013-08-31|May 2007|Actual|2007-05-31|December 2006|Actual|2006-12-31||Interventional|||Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)|A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|||Human Genome Sciences Inc.|||||f||||||||||||||2018-06-01 05:01:56.27691|2018-06-01 05:01:56.27691
NCT00094835|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-27|2010-08-13||2016-02-26|2004-10-26|2004-10-27|Estimate|2014-02-06|2014-03-24|Estimate||||2016-02-26|2016-03-24|Estimate|January 2005||2005-01-31|February 2016|2016-02-29|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional||The analysis is based on the Safety Analysis Set which consists of all consented participants who received at least one dose of motesanib.|Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|An Open-label, Dose-finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|51|Actual|Amgen||3|||f||||||||||||||2018-06-01 05:01:56.442931|2018-06-01 05:01:56.442931
NCT00094822|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-27|||2009-02-12|2004-10-26|2004-10-27|Estimate|||||||2009-02-12|2009-02-13|Estimate|July 2003||2003-07-31|February 2009|2009-02-28|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Observational|||Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)|Pegfilgrastim Given Same Day as or Day After Carboplatin and Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Completed|||90|Actual|Amgen|||2||f||||||||||||||2018-06-01 05:01:58.381236|2018-06-01 05:01:58.381236
NCT00094809|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-26|2010-12-16||2013-05-10|2004-10-25|2004-10-26|Estimate|2010-12-16|2011-01-06|Estimate||||2013-05-10|2013-05-14|Estimate|February 2003||2003-02-28|May 2013|2013-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer|Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer|Completed||Phase 2|252|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:01:58.4641|2018-06-01 05:01:58.4641
NCT00094796|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-22|||2017-06-30|2004-10-22|2004-10-25|Estimate|||||||2017-06-30|2017-07-02|Actual|October 20, 2004||2004-10-20|September 3, 2008|2008-09-03|September 3, 2008||2008-09-03|||||Interventional|||Rosiglitazone to Reverse Metabolic Defects in Diabetes|Evaluation of Rosiglitazone in Reversing Metabolic Defects of Pre-Diabetes and Type 2 Diabetes Mellitus|Completed||Phase 2|70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:59.254796|2018-06-01 05:01:59.254796
NCT00094783|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-22|||2017-06-30|2004-10-22|2004-10-25|Estimate|||||||2017-06-30|2017-07-02|Actual|October 20, 2004||2004-10-20|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Interventional|||MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs|Real-Time MRI-Guided Percutaneous Intervention for Aorto-illac and Femoropopliteal, Artery Stenosis|Completed||Phase 1|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:01:59.337336|2018-06-01 05:01:59.337336
NCT00094770|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-22|2009-09-24||2016-08-25|2004-10-22|2004-10-25|Estimate|2009-11-18|2009-12-22|Estimate||||2016-08-25|2016-08-26|Estimate|September 2004||2004-09-30|August 2016|2016-08-31|May 2007|Actual|2007-05-31|May 2006|Actual|2006-05-31||Interventional|||An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)|A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|1172|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 05:01:59.442072|2018-06-01 05:01:59.442072
NCT00094757|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-22|2010-06-22||2016-11-28|2004-10-22|2004-10-25|Estimate|2010-06-22|2010-07-21|Estimate||||2016-11-28|2017-01-13|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)|A Multicenter, Randomized, Double-Blind Study of MK0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 3|521|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 05:02:00.245619|2018-06-01 05:02:00.245619
NCT00094718|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2012-12-31|2004-10-21|2004-10-22|Estimate|||||||2012-12-31|2013-01-03|Estimate|February 2005||2005-02-28|December 2012|2012-12-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of West Nile/Dengue-4 3'delta30 Chimeric Virus Vaccine (WN/DEN4-3'delta30), a Live Attenuated Vaccine for West Nile Encephalitis|Completed||Phase 1|56|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-06-01 05:02:01.207483|2018-06-01 05:02:01.207483
NCT00094705|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2008-01-18|2004-10-21|2004-10-22|Estimate|||||||2008-01-18|2008-01-21|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 05:02:01.344835|2018-06-01 05:02:01.344835
NCT00094692|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2010-03-23|2004-10-21|2004-10-22|Estimate|||||||2010-03-23|2010-03-24|Estimate|October 2002||2002-10-31|May 2007|2007-05-31|December 2005|Actual|2005-12-31|||||Interventional|||An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old|An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds|Completed||Phase 3|507||Jaeb Center for Health Research|||||f||||t||||||||||2018-06-01 05:02:01.623192|2018-06-01 05:02:01.623192
NCT00094679|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2010-09-08|2004-10-21|2004-10-22|Estimate|||||||2010-09-08|2010-09-09|Estimate|May 2001||2001-05-31|September 2010|2010-09-30|September 2002|Actual|2002-09-30|July 2002|Actual|2002-07-31||Interventional|ATS2B||Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia|A Randomized Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia|Completed||Phase 3|189|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 05:02:01.693112|2018-06-01 05:02:01.693112
NCT00094666|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2015-01-13|2004-10-21|2004-10-22|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2004||2004-11-30|January 2015|2015-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Elderly Patients With Primary Insomnia|Terminated||Phase 3|465||H. Lundbeck A/S|||||f||||||||||||||2018-06-01 05:02:01.836942|2018-06-01 05:02:01.836942
NCT00094653|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|2011-04-22|2010-09-10|2011-06-29|2004-10-21|2004-10-22|Estimate|2011-05-24|2011-06-23|Estimate|2010-09-10|2010-09-14|Estimate|2011-06-29|2011-07-11|Estimate|September 2004||2004-09-30|June 2011|2011-06-30|October 2009|Actual|2009-10-31|August 2009|Actual|2009-08-31||Interventional|||MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma|A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma|Completed||Phase 3|1783|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-06-01 05:02:01.997585|2018-06-01 05:02:01.997585
NCT00094640|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2006-07-18|2004-10-21|2004-10-22|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||Pharmacokinetic Characterization of Intramuscular Olanzapine Depot||Completed||Phase 1|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:02:04.933323|2018-06-01 05:02:04.933323
NCT00094627|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2015-01-13|2004-10-21|2004-10-22|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2004||2004-11-30|January 2015|2015-01-31|April 2006|Actual|2006-04-30|||||Interventional|||Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Adult Patients With Primary Insomnia|Completed||Phase 3|465|Actual|H. Lundbeck A/S|||||f||||||||||||||2018-06-01 05:02:05.009452|2018-06-01 05:02:05.009452
NCT00094614|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-21|||2010-03-24|2004-10-21|2004-10-22|Estimate|||||||2010-03-24|2010-03-25|Estimate|June 2002||2002-06-30|April 2006|2006-04-30|April 2003||2003-04-30|||||Interventional|||Trial Comparing Daily Atropine Versus Weekend Atropine|A Randomized Trial Comparing Daily Atropine Versus Weekend Atropine|Completed||Phase 4|168||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 05:02:05.088485|2018-06-01 05:02:05.088485
NCT00094601|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-20|||2017-06-30|2004-10-20|2004-10-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 18, 2004||2004-10-18|January 22, 2008|2008-01-22|January 22, 2008||2008-01-22|||||Observational|||Relationship of Dopamine to Cognitive Function in Parkinson's Disease|Cognitive Function in Parkinson's Disease: Relationship to Cortical Dopamine Synthesis and Dopamine D1 Receptors|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:05.161782|2018-06-01 05:02:05.161782
NCT00094575|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-20|2013-09-16||2016-02-08|2004-10-20|2004-10-21|Estimate|2013-12-05|2013-12-31|Estimate||||2016-02-08|2016-03-07|Estimate|October 2002||2002-10-31|February 2016|2016-02-29|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|OVER||Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)|CSP #498 - Open Versus Endovascular Repair (OVER) Trial for Abdominal Aortic Aneurysms|Completed||Phase 4|881|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:02:05.330473|2018-06-01 05:02:05.330473
NCT00094562|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-20|||2008-04-21|2004-10-20|2004-10-21|Estimate|||||||2008-04-21|2008-04-22|Estimate|June 2004||2004-06-30|April 2008|2008-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss|AAFA™ Fish Oil Nutritional Supplementation to Maintain Body Weight in Patients With Disease-Related Weight Loss|Completed||Phase 2|60|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||||||t||||||||||2018-06-01 05:02:07.622707|2018-06-01 05:02:07.622707
NCT00094549|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-20|||2007-01-24|2004-10-20|2004-10-21|Estimate|||||||2007-01-24|2007-01-26|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|December 2006||2006-12-31|||||Interventional|||Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder|Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder|Completed||Phase 4|500||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:02:07.705288|2018-06-01 05:02:07.705288
NCT00094536|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-20|2010-03-09||2017-03-01|2004-10-20|2004-10-21|Estimate|2017-03-01|2017-03-03|Actual||||2017-03-01|2017-03-03|Actual|April 2004||2004-04-30|March 2017|2017-03-31|June 2009|Actual|2009-06-30|October 2007|Actual|2007-10-31||Interventional|||Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System|A Study to Evaluate the Effectiveness of Extended Treatment Regimens With the Her Option® Cryoablation Therapy System for Treatment of Menorrhagia|Completed||Phase 4|82|Actual|CooperSurgical Inc.|"The primary endpoint was assessed using a validated diary completed by the subject prior to each visit, which has inherent weaknesses as an objective measure of blood loss.~Use of historical control limits comparison of outcomes across studies."|1|||f||||f||||||||Undecided||2018-06-01 05:02:07.857313|2018-06-01 05:02:07.857313
NCT00094523|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-20|||2018-04-16|2004-10-20|2004-10-21|Estimate|||||||2018-04-16|2018-04-18|Actual|December 14, 2004|Actual|2004-12-14|April 2018|2018-04-30|June 29, 2007|Actual|2007-06-29|June 29, 2007|Actual|2007-06-29||Interventional|||Fosamprenavir Versus Other Protease Inhibitors|A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks|Completed||Phase 3|314|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-06-01 05:02:08.193581|2018-06-01 05:02:08.193581
NCT00094510|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-19|||2017-06-30|2004-10-19|2004-10-20|Estimate|||||||2017-06-30|2017-07-02|Actual|October 14, 2004||2004-10-14|September 3, 2010|2010-09-03|September 3, 2010||2010-09-03|||||Observational|||Effect of Gabapentin on GABA Concentration and Emotional Processing|The Effect of Gabapentin on Prefrontal GABA Concentration and Emotional Processing in Healthy Humans|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:08.360855|2018-06-01 05:02:08.360855
NCT00094497|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-19|2016-09-19||2016-09-19|2004-10-19|2004-10-20|Estimate|2016-09-19|2016-09-21|Estimate||||2016-09-19|2016-09-21|Estimate|June 2004||2004-06-30|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)|First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment|Completed||Phase 3|304|Actual|Collaborative Group for Adrenocortical Carcinoma Treatment||2|||f||||t||||||||||2018-06-01 05:02:08.447202|2018-06-01 05:02:08.447202
NCT00094484|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-19|||2013-05-06|2004-10-19|2004-10-20|Estimate|||||||2013-05-06|2013-05-08|Estimate|October 2004||2004-10-31|May 2013|2013-05-31||||||||Interventional|||Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis|A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis|Completed||Phase 3|400||Amgen|||||||||||||||||||2018-06-01 05:02:08.852851|2018-06-01 05:02:08.852851
NCT00094458|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-19|2009-04-30||2016-12-15|2004-10-19|2004-10-20|Estimate|2009-05-04|2009-06-23|Estimate||||2016-12-15|2017-02-09|Estimate|March 2005||2005-03-31|December 2016|2016-12-31|December 2009|Actual|2009-12-31|April 2008|Actual|2008-04-30||Interventional|||Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC|Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE� (Infliximab) and REMICADE Plus Azathioprine to Azathioprine in the Treatment of Patients With Crohn's Disease Naive to Both Immunomodulators and Biologic Therapy|Completed||Phase 3|508|Actual|Centocor Ortho Biotech Services, L.L.C.||3|||f||||f||||||||||2018-06-01 05:02:08.97087|2018-06-01 05:02:08.97087
NCT00094445|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-18|||2014-04-29|2004-10-18|2004-10-19|Estimate|||||||2014-04-29|2014-04-30|Estimate|November 2004||2004-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Trial of Curcumin in Advanced Pancreatic Cancer|Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|50|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:02:11.854103|2018-06-01 05:02:11.854103
NCT00094432|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-18|||2013-11-07|2004-10-18|2004-10-19|Estimate|||||||2013-11-07|2013-11-11|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST.|Completed||Phase 3|650||Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 05:02:11.928272|2018-06-01 05:02:11.928272
NCT00094419|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-18|||2008-08-11|2004-10-18|2004-10-19|Estimate|||||||2008-08-11|2008-08-12|Estimate|November 2004||2004-11-30|August 2008|2008-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Complementary and Alternative Medicine Use in Low-Income African American and Caucasian Adults With Asthma|The Role of Complementary and Alternative Medicine (CAM), Folk Care and Faith-Based Approaches in the Home Management of Persistent Asthma in Low-Income African American and Caucasian Adults|Completed|||50|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:02:12.16313|2018-06-01 05:02:12.16313
NCT00094406|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-16|||2018-05-24|2004-10-16|2004-10-18|Estimate|||||||2018-05-24|2018-05-25|Actual|October 13, 2004||2004-10-13|April 19, 2016|2016-04-19|March 11, 2010|Actual|2010-03-11|March 11, 2010|Actual|2010-03-11||Interventional|||Carbon Monoxide to Prevent Lung Inflammation|Effects of Inhaled Carbon Monoxide on Pulmonary Inflammatory Responses Following Endotoxin Instillation|Completed||Phase 1|35|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:12.223117|2018-06-01 05:02:12.223117
NCT00094393|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-16|||2018-05-23|2004-10-16|2004-10-18|Estimate|||||||2018-05-23|2018-05-24|Actual|October 14, 2004||2004-10-14|May 22, 2018|2018-05-22|May 22, 2018||2018-05-22|||||Observational|||Clinical Studies of Progeria|Clinical Investigations Into Hutchison-Gilford Progeria Syndrome|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:12.285947|2018-06-01 05:02:12.285947
NCT00094380|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-16|||2017-01-10|2004-10-16|2004-10-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2004||2004-09-30|January 2017|2017-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)|Treatment of Systemic Lupus Erythematosus With CTLA4-IgG4m Plus Cyclophosphamide: A Phase I/IIA Study|Completed||Phase 1/Phase 2|6|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||Yes|Participant level data and additional relevant materials are available to the public in 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials publicly available.|2018-06-01 05:02:12.349226|2018-06-01 05:02:12.349226
NCT00094367|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-16|||2010-09-29|2004-10-16|2004-10-18|Estimate|||||||2010-09-29|2010-09-30|Estimate|July 2004||2004-07-31|September 2010|2010-09-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)|See Detailed Description|Completed||Phase 3|900||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:02:12.497815|2018-06-01 05:02:12.497815
NCT00094354|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-16|||2009-03-26|2004-10-16|2004-10-18|Estimate|||||||2009-03-26|2009-03-27|Estimate|October 2004||2004-10-31|January 2009|2009-01-31|April 2006|Actual|2006-04-30|March 2005|Actual|2005-03-31||Observational|||HIV Assessment in Fuyang, Anhui Province, China|A Qualitative Study for the Development of an Intervention Among HIV-Positive Former Plasma Donors (FPDs) in Fuyang, Anhui Province, China|Completed|||111|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||f||||||||||2018-06-01 05:02:12.880623|2018-06-01 05:02:12.880623
NCT00094341|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-16|||2008-12-04|2004-10-16|2004-10-18|Estimate|||||||2008-12-04|2008-12-05|Estimate|October 2004||2004-10-31|December 2008|2008-12-31||||||||Interventional|||Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes|An Open-Label, Randomized, Crossover Study to Assess Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes|Completed||Phase 4|215||Amgen|||||||||||||||||||2018-06-01 05:02:12.937516|2018-06-01 05:02:12.937516
NCT00094328|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-16|2009-05-19||2018-02-14|2004-10-16|2004-10-18|Estimate|2009-05-19|2009-07-09|Estimate||||2018-02-14|2018-03-14|Actual|November 22, 2004|Actual|2004-11-22|January 2018|2018-01-31|December 6, 2017|Actual|2017-12-06|May 22, 2008|Actual|2008-05-22||Interventional|BATT||Pediatrics Testotoxicosis Study [Bicalutamide Anastrozole Treatment for Testotoxicosis]|An Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis|Completed||Phase 2|14|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 05:02:13.016159|2018-06-01 05:02:13.016159
NCT00094315|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2017-01-10|2004-10-14|2004-10-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2004||2004-09-30|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1|Cocaine Relapse Prevention II|Unknown status|Active, not recruiting|Phase 1|16||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:02:14.61342|2018-06-01 05:02:14.61342
NCT00094302|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|2014-12-01||2015-02-11|2004-10-14|2004-10-15|Estimate|2015-02-11|2015-03-02|Estimate||||2015-02-11|2015-03-02|Estimate|August 2006||2006-08-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TOPCAT||Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function|Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)|Completed||Phase 3|3445|Actual|New England Research Institutes||2|||f||||t||||||||||2018-06-01 05:02:14.95384|2018-06-01 05:02:14.95384
NCT00094289|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2017-01-10|2004-10-14|2004-10-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2004||2004-08-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Interactions Between Cocaine and Ethanol and Disulfiram - 1|Interactions Between IV Cocaine and Ethanol and Oral Disulfiram|Unknown status|Active, not recruiting|Phase 1|16||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:02:18.857566|2018-06-01 05:02:18.857566
NCT00094276|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2018-04-24|2004-10-14|2004-10-15|Estimate|||||||2018-04-24|2018-04-25|Actual|September 2004||2004-09-30|April 2018|2018-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Intervention for Improving Asthma Care for Minority Children in Head Start|Improving Asthma Care for Minority Children in Head Start|Completed||N/A|336|Actual|Johns Hopkins University||4|||f||||t||||||||||2018-06-01 05:02:18.924705|2018-06-01 05:02:18.924705
NCT00094263|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2016-02-17|2004-10-14|2004-10-15|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Long-Term Predictors of Morbidity in Older Age||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:02:19.113539|2018-06-01 05:02:19.113539
NCT00094250|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2016-07-28|2004-10-14|2004-10-15|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2006||2006-07-31|February 2009|2009-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||HEARTS: Heart, Exercise, and Resistance Training Study|More Effective Exercise Modalities in Older Congestive Heart Failure Patients|Withdrawn||N/A|200|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||||Study was closed due to administrative reasons; study did not enroll any participants.|f||||||||||||||2018-06-01 05:02:19.195036|2018-06-01 05:02:19.195036
NCT00094237|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2017-04-21|2004-10-14|2004-10-15|Estimate|||||||2017-04-21|2017-04-25|Actual|September 2004||2004-09-30|December 2015|2015-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke|Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke|Completed|||3200|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 05:02:19.296178|2018-06-01 05:02:19.296178
NCT00094211|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2009-02-13|2004-10-14|2004-10-15|Estimate|||||||2009-02-13|2009-02-16|Estimate|September 2004||2004-09-30|February 2009|2009-02-28|June 2009|Anticipated|2009-06-30|||||Observational|||Understanding the Impact of Neighborhood Type on Physical Activity in Older Adults|Neighborhood Impact on Physical Activity in Older Adults|Unknown status|Active, not recruiting||985|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t||||||||||2018-06-01 05:02:19.342215|2018-06-01 05:02:19.342215
NCT00094198|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2008-08-20|2004-10-14|2004-10-15|Estimate|||||||2008-08-20|2008-08-21|Estimate|September 2003||2003-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Pharmacogenetics and Cardiovascular Events||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:02:19.422571|2018-06-01 05:02:19.422571
NCT00094185|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-15|||2012-12-18|2004-10-14|2004-10-15|Estimate|||||||2012-12-18|2012-12-20|Estimate|May 2004||2004-05-31|December 2012|2012-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Clotting Genetic Variants, Hormones, and Venous Thrombosis||Completed|||1000|Actual|University of Washington|||1||f||||||||||||||2018-06-01 05:02:19.504018|2018-06-01 05:02:19.504018
NCT00094172|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-14|2011-09-29||2017-03-28|2004-10-14|2004-10-15|Estimate|2011-09-29|2011-11-03|Estimate||||2017-03-28|2017-04-28|Actual|May 2005||2005-05-31|March 2017|2017-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|STAYCIS||Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)|Completed||Phase 2|82|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Data access is provided to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal that makes data from the consortium's clinical trials available to the public.|2018-06-01 05:02:19.580794|2018-06-01 05:02:19.580794
NCT00094159|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-14|||2007-05-09|2004-10-14|2004-10-15|Estimate|||||||2007-05-09|2007-05-10|Estimate|October 2004||2004-10-31|May 2007|2007-05-31||||||||Interventional|||Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors|Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Pharmacokinetic Profiles of Weekly Intravenous Administrations of SNS-595 in Patients With Advanced Malignancies|Completed||Phase 1|||Sunesis Pharmaceuticals|||||||||||||||||||2018-06-01 05:02:19.986977|2018-06-01 05:02:19.986977
NCT00094146|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-14|||2009-09-21|2004-10-14|2004-10-15|Estimate|||||||2009-09-21|2009-09-22|Estimate|January 2002||2002-01-31|October 2004|2004-10-31|December 2002||2002-12-31|||||Interventional|||Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity||Completed||Phase 2|160||Novartis|||||||||||||||||||2018-06-01 05:02:20.04461|2018-06-01 05:02:20.04461
NCT00094120|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-11|||2008-01-08|2004-10-13|2004-10-14|Estimate|||||||2008-01-08|2008-01-09|Estimate|October 2004||2004-10-31|November 2007|2007-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||"MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With Wet Age-Related Macular Degeneration (AMD)"|"Safety and Efficacy of MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With Wet Age-Related Macular Degeneration (AMD)"|Terminated||Phase 2|60||Genaera Corporation|||||||||||||||||||2018-06-01 05:02:20.171864|2018-06-01 05:02:20.171864
NCT00094107|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-11|2012-02-25|2009-03-20|2012-06-21|2004-10-13|2004-10-14|Estimate|2012-02-25|2012-03-30|Estimate|2009-09-24|2009-09-28|Estimate|2012-06-21|2012-06-26|Estimate|December 2004||2004-12-31|June 2012|2012-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma|Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma|Completed||Phase 2|32|Actual|Pfizer|Population pharmacokinetic and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.|1|||f||||t||||||||||2018-06-01 05:02:20.237647|2018-06-01 05:02:20.237647
NCT00094094|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-11|2012-02-25||2012-06-21|2004-10-13|2004-10-14|Estimate|2012-02-25|2012-03-16|Estimate||||2012-06-21|2012-06-26|Estimate|February 2005||2005-02-28|June 2012|2012-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer|Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later- Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|32|Actual|Pfizer|Population pharmacokinetics and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib Phase 2 studies would be pooled together in a separate report.|1|||f||||||||||||||2018-06-01 05:02:20.823702|2018-06-01 05:02:20.823702
NCT00094081|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-11|||2010-02-12|2004-10-13|2004-10-14|Estimate|||||||2010-02-12|2010-02-15|Estimate|October 2002||2002-10-31|February 2010|2010-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer|Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer|Completed||Phase 3|861|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:02:21.088211|2018-06-01 05:02:21.088211
NCT00091468|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-09|||2008-01-07|2004-10-13|2004-10-14|Estimate|||||||2008-01-07|2008-01-15|Estimate|September 2003||2003-09-30|January 2008|2008-01-31|July 2008|Anticipated|2008-07-31|July 2008|Anticipated|2008-07-31||Interventional|||Nicotine Treatment of Mild Cognitive Impairment (MCI)|Double-Blind Treatment of Mild Cognitive Impairment (MCI) With Transdermal Nicotine or Transdermal Placebo|Unknown status|Active, not recruiting|Phase 1|75|Anticipated|National Institute on Aging (NIA)||2|||f||||t||||||||||2018-06-01 05:02:21.22569|2018-06-01 05:02:21.22569
NCT00081627|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2007-11-26|2004-10-13|2004-10-14|Estimate|||||||2007-11-26|2007-11-27|Estimate|April 2004||2004-04-30|November 2007|2007-11-30|January 2007|Actual|2007-01-31|||||Interventional|||Clinical Trial in Patients With Metastatic Colorectal Cancer|COFU: A Multi-Center Phase II Clinical Trial to Evaluate the Safety and Efficacy of Weekly Treatment With CoFactor and 5-Fluorouracil in Patients With Metastatic Colorectal Carcinoma|Completed||Phase 2|48||Mast Therapeutics, Inc.|||||f||||||||||||||2018-06-01 05:02:21.313466|2018-06-01 05:02:21.313466
NCT00094068|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-09|||2008-03-03|2004-10-08|2004-10-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2004||2004-10-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Observational|||The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients|A Pilot Study to Detect the Effect of Sildenafil Citrate on Cerebral Blood Perfusion in Multiple Sclerosis Patients by Perfusion MRI|Completed|||76||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:21.378444|2018-06-01 05:02:21.378444
NCT00094055|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-08|2012-02-25|2009-03-20|2012-06-21|2004-10-08|2004-10-11|Estimate|2012-02-25|2012-03-30|Estimate|2009-09-24|2009-09-28|Estimate|2012-06-21|2012-06-26|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer|Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment|Completed||Phase 2|60|Actual|Pfizer|Population pharmacokinetics and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.|1|||f||||f||||||||||2018-06-01 05:02:21.45454|2018-06-01 05:02:21.45454
NCT00094042|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-08|||2010-01-26|2004-10-08|2004-10-11|Estimate|||||||2010-01-26|2010-01-27|Estimate|January 2002||2002-01-31|August 2008|2008-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Work and Iron Status Evaluation|Work and Iron Status Evaluation (WISE)|Completed||N/A|16000||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:02:21.857056|2018-06-01 05:02:21.857056
NCT00094029|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-08|||2012-03-08|2004-10-08|2004-10-11|Estimate|||||||2012-03-08|2012-03-09|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Expanded Access|||A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248|A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate|Approved for marketing|||||Pfizer|||||||||f||||||||||2018-06-01 05:02:21.934378|2018-06-01 05:02:21.934378
NCT00094016|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-08|||2014-05-09|2004-10-08|2004-10-11|Estimate|||||||2014-05-09|2014-05-12|Estimate|October 2004||2004-10-31|May 2014|2014-05-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children|Safety and Efficacy Evaluation of Two Doses of HFA-Propelled Beclomethasone Dipropionate (QVAR) Versus Placebo by Breath Operated and Metered Dose Inhalers in Mild to Moderate Asthmatic Children|Completed||Phase 3|440||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 05:02:22.148542|2018-06-01 05:02:22.148542
NCT00094003|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-08|||2005-11-09|2004-10-08|2004-10-11|Estimate|||||||2005-11-09|2005-11-11|Estimate|September 2002||2002-09-30|November 2005|2005-11-30||||||||Interventional|||Study of NS-9 in Patients With Liver Metastases|A Phase I, Open-Label, Dose Escalation Study of Intravenously Administered NS-9 in Subjects With Liver Metastases From Various Primary Cancers|Completed||Phase 1|20||NS Pharma, Inc.|||||||||||||||||||2018-06-01 05:02:22.235345|2018-06-01 05:02:22.235345
NCT00093990|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2016-09-13|2004-10-08|2004-10-11|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2004||2004-01-31|September 2016|2016-09-30|October 2007|Actual|2007-10-31|||||Interventional|||Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)|A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or Older (Farnesyl Transferase Inhibition Global Human Trials AML 301 [F.I.G.H.T. AML 301])|Completed||Phase 3|457|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:02:22.28326|2018-06-01 05:02:22.28326
NCT00093977|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2013-05-22|2004-10-08|2004-10-11|Estimate|||||||2013-05-22|2013-05-24|Estimate|October 2004||2004-10-31|May 2013|2013-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease|An Open-label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects With Chronic Kidney Disease|Completed||Phase 3|1100|Anticipated|Amgen||1|||f||||||||||||||2018-06-01 05:02:22.338811|2018-06-01 05:02:22.338811
NCT00093964|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2015-12-02|2004-10-08|2004-10-11|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2004||2004-10-31|December 2015|2015-12-31|December 2007|Actual|2007-12-31|April 2006|Actual|2006-04-30||Interventional|||Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)|A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.|Completed||Phase 2|81|Actual|EMD Serono||2|||f||||f||||||||||2018-06-01 05:02:22.39776|2018-06-01 05:02:22.39776
NCT00093951|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2009-12-10|2004-10-07|2004-10-08|Estimate|||||||2009-12-10|2009-12-11|Estimate|April 2004||2004-04-30|February 2009|2009-02-28|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|280||National Institute on Aging (NIA)|||||||||||||||||||2018-06-01 05:02:22.483957|2018-06-01 05:02:22.483957
NCT00093938|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2010-01-12|2004-10-07|2004-10-08|Estimate|||||||2010-01-12|2010-01-14|Estimate|December 2004||2004-12-31|January 2010|2010-01-31||||||||Interventional|||Cranberry Juice for Preventing Bacteria in Urine During Pregnancy|Cranberry for Prevention of Bacteriuria in Pregnancy|Completed||Phase 1|360|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:02:22.75593|2018-06-01 05:02:22.75593
NCT00093925|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2014-05-05|2004-10-07|2004-10-08|Estimate|||||||2014-05-05|2014-05-06|Estimate|May 2004||2004-05-31|May 2014|2014-05-31|September 2006|Actual|2006-09-30|July 2006|Actual|2006-07-31||Interventional|ECLIPSE-NIC||Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)|Evaluation of Clevidipine in the Postoperative Treatment of Hypertension Assessing Safety Events (With Nicardipine as Active Comparator) (ECLIPSE-NIC)|Completed||Phase 3|739|Actual|The Medicines Company||2|||f||||t||||||||||2018-06-01 05:02:22.821068|2018-06-01 05:02:22.821068
NCT00093912|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2014-05-05|2004-10-07|2004-10-08|Estimate|||||||2014-05-05|2014-05-06|Estimate|June 2004||2004-06-30|May 2014|2014-05-31|November 2006|Actual|2006-11-30|October 2006|Actual|2006-10-31||Interventional|ECLISPE-SNP||Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)|Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Sodium Nitroprusside as Active Comparator) (ECLISPE-SNP)|Completed||Phase 3|739|Actual|The Medicines Company||2|||f||||t||||||||||2018-06-01 05:02:22.940237|2018-06-01 05:02:22.940237
NCT00093899|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2017-03-13|2004-10-07|2004-10-08|Estimate|||||||2017-03-13|2017-03-14|Actual|November 2004||2004-11-30|March 2017|2017-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)|A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia|Completed||Phase 3|611|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:23.19972|2018-06-01 05:02:23.19972
NCT00093886|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-07|||2014-05-05|2004-10-07|2004-10-08|Estimate|||||||2014-05-05|2014-05-06|Estimate|April 2004||2004-04-30|May 2014|2014-05-31|April 2005|Actual|2005-04-30|March 2005|Actual|2005-03-31||Interventional|ECLIPSE-NTG||Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)|Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Nitroglycerin as Active Comparator) (ECLIPSE-NTG)|Completed||Phase 3|629|Actual|The Medicines Company||2|||f||||t||||||||||2018-06-01 05:02:23.343345|2018-06-01 05:02:23.343345
NCT00093873|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-05-13|2004-10-07|2004-10-08|Estimate|||||||2013-05-13|2013-05-15|Estimate|July 2003||2003-07-31|May 2013|2013-05-31|December 2006|Actual|2006-12-31|February 2006|Actual|2006-02-28||Interventional|||Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors|A Phase 1, First in Human, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 706 in Subjects With Advanced Solid Tumors|Completed||Phase 1|71|Actual|Amgen||1|||f||||||||||||||2018-06-01 05:02:23.5484|2018-06-01 05:02:23.5484
NCT00093847|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2012-04-25||2014-10-10|2004-10-07|2004-10-08|Estimate|2014-10-10|2014-10-13|Estimate||||2014-10-10|2014-10-13|Estimate|May 2004||2004-05-31|October 2014|2014-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression|S-adenosyl Methionine (SAMe) Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) for Treatment-Resistant Depression (TRD)|Completed||Phase 2|73|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 05:02:23.685949|2018-06-01 05:02:23.685949
NCT00093834|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2011-07-19|2004-10-07|2004-10-08|Estimate|||||||2011-07-19|2011-07-20|Estimate|January 2004||2004-01-31|April 2011|2011-04-30||||August 2008|Actual|2008-08-31||Interventional|||Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer|A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence With Immunomodulatory Doses of Cyclophosphamide and Doxorubicin|Completed||Phase 1|60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:02:24.189182|2018-06-01 05:02:24.189182
NCT00093821|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-06-03|2004-10-07|2004-10-08|Estimate|||||||2013-06-03|2013-06-04|Estimate|September 2004||2004-09-30|June 2013|2013-06-30||||August 2007|Actual|2007-08-31||Interventional|||Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors|A Multicenter Phase I Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) in Patients With Recurrent/Refractory Pediatric Solid Tumors (Ewing's Sarcoma, Desmoplastic Small Round Cell Tumor, Osteosarcoma, Neuroblastoma, and Rhabdomyosarcoma) and Leukemia|Completed||Phase 1|70|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:02:24.34751|2018-06-01 05:02:24.34751
NCT00093808|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2016-11-28||2017-01-23|2004-10-07|2004-10-08|Estimate|2016-11-28|2017-01-23|Estimate||||2017-01-23|2017-03-06|Actual|August 2004||2004-08-31|January 2017|2017-01-31|May 2013|Actual|2013-05-31|December 2008|Actual|2008-12-31||Interventional||Patients who completed the study or deemed a protocol violation were included in all analyses unless otherwise specified.|Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer|Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer|Completed||Phase 2|47|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:02:24.53067|2018-06-01 05:02:24.53067
NCT00093795|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2017-11-13||2017-12-11|2004-10-07|2004-10-08|Estimate|2017-11-13|2017-12-12|Actual||||2017-12-11|2018-01-11|Actual|October 2004||2004-10-31|December 2017|2017-12-31|June 2016|Actual|2016-06-30|March 2012|Actual|2012-03-31||Interventional|||Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer|A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC→P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC→PG)|Completed||Phase 3|4894|Actual|NSABP Foundation Inc||3|||f||||t||||||||||2018-06-01 05:02:25.177266|2018-06-01 05:02:25.177266
NCT00093782|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2015-06-11||2016-12-14|2004-10-07|2004-10-08|Estimate|2016-10-18|2016-12-12|Estimate||||2016-12-14|2017-02-07|Estimate|December 2003||2003-12-31|December 2016|2016-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional||Number of participants accrued|Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma|A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas|Completed||Phase 2|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:02:26.034074|2018-06-01 05:02:26.034074
NCT00093769|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2012-10-03|2004-10-07|2004-10-08|Estimate|||||||2012-10-03|2012-10-04|Estimate|August 2004||2004-08-31|October 2012|2012-10-31||||August 2005|Actual|2005-08-31||Interventional|||Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study of VELCADE With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma|Completed||Phase 2|15|Actual|Jonsson Comprehensive Cancer Center||1|||f||||||||||||||2018-06-01 05:02:26.535324|2018-06-01 05:02:26.535324
NCT00093756|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2013-11-25||2017-11-02|2004-10-07|2004-10-08|Estimate|2014-12-03|2014-12-08|Estimate||||2017-11-02|2017-12-07|Actual|September 2004||2004-09-30|November 2017|2017-11-30|May 2013|Actual|2013-05-31|January 2012|Actual|2012-01-31||Interventional|||Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer|Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|52|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:02:26.706286|2018-06-01 05:02:26.706286
NCT00093743|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2017-02-16|2004-10-07|2004-10-08|Estimate|||||||2017-02-16|2017-02-20|Actual|January 2000||2000-01-31|February 2017|2017-02-28||||September 2007|Actual|2007-09-30||Interventional|||Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia|Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial|Completed||Phase 1|2|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:02:28.563364|2018-06-01 05:02:28.563364
NCT00093730|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2012-10-03|2004-10-07|2004-10-08|Estimate|||||||2012-10-03|2012-10-04|Estimate|August 2004||2004-08-31|October 2012|2012-10-31||||April 2006|Actual|2006-04-30||Interventional|||BMS-599626 in Treating Patients With Metastatic Solid Tumors|Phase I Study Of BMS-599626 In Patients With Advanced Solid Malignancies That Express Her2|Completed||Phase 1|9|Actual|Jonsson Comprehensive Cancer Center||1|||f||||||||||||||2018-06-01 05:02:29.543522|2018-06-01 05:02:29.543522
NCT00093704|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2015-10-01|2004-10-07|2004-10-08|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2005||2005-03-31|August 2012|2012-08-31||||July 2010|Actual|2010-07-31||Interventional|||Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma|EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir|Terminated||Phase 1|1|Actual|Jonsson Comprehensive Cancer Center||1||study could not recruit any more patients|f||||t||||||||||2018-06-01 05:02:29.713213|2018-06-01 05:02:29.713213
NCT00093678|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2015-10-06|2004-10-07|2004-10-08|Estimate|||||||2015-10-06|2015-10-08|Estimate||||October 2015|2015-10-31||||||||Interventional|||Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer|A Randomized, Double Blind, Placebo-Controlled Trial of Celecoxib in Patients With Advanced Cancer|Withdrawn||N/A|0|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:02:29.907589|2018-06-01 05:02:29.907589
NCT00093665|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-05-14|2004-10-07|2004-10-08|Estimate|||||||2013-05-14|2013-05-15|Estimate|November 2003||2003-11-30|October 2006|2006-10-31||||||||Interventional|||Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer|A Phase II Study Of Alternating Chemoradiotherapy For Nasopharyngeal Cancer Using Cisplatin And 5-Fluorouracil|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:02:29.988465|2018-06-01 05:02:29.988465
NCT00093652|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2015-10-05|2004-10-07|2004-10-08|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2003||2003-05-31|October 2015|2015-10-31||||May 2006|Actual|2006-05-31||Interventional|||Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer|ZD1839 (IRESSA®) With Oxaliplatin and Radiotherapy for Esophageal Carcinoma. A Phase I/II Study With Biologic Correlates|Terminated||Phase 1/Phase 2|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:02:30.223339|2018-06-01 05:02:30.223339
NCT00093639|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-04-30|2004-10-07|2004-10-08|Estimate|||||||2013-04-30|2013-05-01|Estimate|August 2004||2004-08-31|April 2013|2013-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate|A Phase I-II, Study of RAD001 in Combination With Imatinib (Glivec®/Gleevec™) in Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase Who Are Not In Complete Cytogenetic Response to Imatinib-Alone at Study Entry|Completed||Phase 1/Phase 2|||Novartis|||||f||||||||||||||2018-06-01 05:02:30.361262|2018-06-01 05:02:30.361262
NCT00093626|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2015-05-18|2004-10-07|2004-10-08|Estimate|||||||2015-05-18|2015-05-19|Estimate|October 2004||2004-10-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|September 2007|Actual|2007-09-30||Interventional|||Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer|A Phase II Evaluation of BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|73|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:02:30.55624|2018-06-01 05:02:30.55624
NCT00093613|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2014-05-29|2004-10-07|2004-10-08|Estimate|||||||2014-05-29|2014-05-30|Estimate|December 2004||2004-12-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|October 2010|Actual|2010-10-31||Interventional|||Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma|A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma|Completed||Phase 1|47|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:02:30.730717|2018-06-01 05:02:30.730717
NCT00093197|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-04|||2011-08-31|2004-10-06|2004-10-07|Estimate|||||||2011-08-31|2011-09-02|Estimate|September 2004||2004-09-30|August 2011|2011-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack|Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction|Completed||Phase 1/Phase 2|154|Actual|KAI Pharmaceuticals||5|||f||||t||||||||||2018-06-01 05:02:36.256516|2018-06-01 05:02:36.256516
NCT00093600|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2015-03-09|2004-10-07|2004-10-08|Estimate|||||||2015-03-09|2015-03-17|Estimate|February 2004||2004-02-29|March 2015|2015-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase IB, Open-Label Study to Determine the Safety and Pharmacokinetics of Twice Daily Oral Dosing of PKC412 Administered in Combinations Sequentially and Concomitantly With Daunorubicin and Cytarabine for Standard Induction Therapy, and High Dose Cytarabine for Consolidation in Patients With Acute Myeloid Leukemia (AML)|Completed||Phase 1|69|Actual|Novartis||2|||f||||f||||||||||2018-06-01 05:02:30.906057|2018-06-01 05:02:30.906057
NCT00093587|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-11-05|2004-10-07|2004-10-08|Estimate|||||||2013-11-05|2013-11-06|Estimate|August 2004||2004-08-31|January 2006|2006-01-31||||||||Interventional|||Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia|Pilot Trial of Two Dose Levels of Thymoglobulin® as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor (MRD) Stem Cell Transplant With Cyclosporine (CsA) as Posttransplant Graft vs Host Disease (GvHD) Prophylaxis|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:02:31.137898|2018-06-01 05:02:31.137898
NCT00093561|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-06-25|2004-10-07|2004-10-08|Estimate|||||||2013-06-25|2013-06-26|Estimate|August 2004||2004-08-31|November 2006|2006-11-30|February 2006|Actual|2006-02-28|||||Interventional|||Lycopene in Preventing Prostate Cancer in Healthy Participants|Phase I Single Dose Pharmacokinetic Study of the Dietary Supplement Lycopene Delivered in Capsule Form to Healthy Male Volunteers Between 18 and 45 Years of Age|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:02:31.227995|2018-06-01 05:02:31.227995
NCT00093548|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2012-10-03|2004-10-07|2004-10-08|Estimate|||||||2012-10-03|2012-10-04|Estimate||||October 2012|2012-10-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer|A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma (AFP Prime-Boost Protocol)|Withdrawn||Phase 1/Phase 2|0|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:02:31.349773|2018-06-01 05:02:31.349773
NCT00093522|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-12-18|2004-10-07|2004-10-08|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 2004||2004-08-31|May 2007|2007-05-31||||||||Interventional|||Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer|A Phase II Pilot Study of Tumor-Loaded Dendritic Cells Alone or Following a Non-Myeloablative Conditioning Regimen in Patients With Metastatic Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|28|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:02:31.466509|2018-06-01 05:02:31.466509
NCT00093509|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2014-08-29|2004-10-07|2004-10-08|Estimate|||||||2014-08-29|2014-09-01|Estimate|November 1999||1999-11-30|August 2014|2014-08-31|October 2009|Actual|2009-10-31|July 2007|Actual|2007-07-31||Interventional|||MRI Sarcoma Non Invasive Thermometry|Magnetic Resonance Based Non-Invasive Thermometry for Hyperthermic Treatment of Extremity Soft Tissue Sarcomas: A Multimodal Phase I/II Study|Completed||Phase 1/Phase 2|15|Actual|Duke University||1|||f||||f||||||||||2018-06-01 05:02:31.579178|2018-06-01 05:02:31.579178
NCT00093496|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2013-03-22||2014-05-02|2004-10-07|2004-10-08|Estimate|2013-05-24|2013-07-10|Estimate||||2014-05-02|2014-05-20|Estimate|October 2007||2007-10-31|October 2011|2011-10-31|March 2012|Actual|2012-03-31|April 2010|Actual|2010-04-30||Interventional|||Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer|A Phase II Trial Of Gemcitabine in Combination With 17-Allylaminogeldamycin (17-AAG) In Advanced Epithelial Ovarian And Primary Peritoneal Carcinoma|Completed||Phase 2|29|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:02:31.845536|2018-06-01 05:02:31.845536
NCT00093483|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2014-01-10|2004-10-07|2004-10-08|Estimate|||||||2014-01-10|2014-01-13|Estimate|April 2002||2002-04-30|January 2014|2014-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia|Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients < 60 Years Old - A Phase I Study|Completed||Phase 1|61|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:02:32.28577|2018-06-01 05:02:32.28577
NCT00093470|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2015-10-13||2018-03-20|2004-10-07|2004-10-08|Estimate|2015-10-13|2015-11-10|Estimate||||2018-03-20|2018-04-19|Actual|August 18, 2004|Actual|2004-08-18|March 2018|2018-03-31||||February 20, 2015|Actual|2015-02-20||Interventional||All randomized patients|Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission|A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission|Completed||Phase 3|144|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 05:02:32.476845|2018-06-01 05:02:32.476845
NCT00093457|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2011-09-27|2004-10-07|2004-10-08|Estimate|||||||2011-09-27|2011-09-28|Estimate|July 2004||2004-07-31|September 2011|2011-09-30|January 2011|Actual|2011-01-31|September 2006|Actual|2006-09-30||Interventional|||Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer|A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|28|Actual|Canadian Cancer Trials Group|||||f||||f||||||||||2018-06-01 05:02:33.740617|2018-06-01 05:02:33.740617
NCT00093444|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2012-03-14|2004-10-07|2004-10-08|Estimate|||||||2012-03-14|2012-03-15|Estimate|September 2004||2004-09-30|March 2012|2012-03-31|January 2010|Actual|2010-01-31|||||Interventional|||Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors|A Phase I Dose Escalation Study Of Heat Activated Liposome Delivery Of Doxorubicin And Radiofrequency Ablation Of Primary And Metastatic Tumors Of The Liver|Completed||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:02:33.835151|2018-06-01 05:02:33.835151
NCT00093418|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-01-14|2004-10-07|2004-10-08|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2004||2004-09-30|January 2013|2013-01-31||||June 2006|Actual|2006-06-30||Interventional|||S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia|Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older|Completed||Phase 2|296|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 05:02:33.901012|2018-06-01 05:02:33.901012
NCT00093405|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2013-06-21|2004-10-07|2004-10-08|Estimate|||||||2013-06-21|2013-06-24|Estimate|August 2004||2004-08-31|November 2005|2005-11-30|November 2005|Actual|2005-11-30|||||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG)In Metastatic Renal Cell Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:02:34.004606|2018-06-01 05:02:34.004606
NCT00093379|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|2013-10-15||2014-03-12|2004-10-07|2004-10-08|Estimate|2014-03-12|2014-04-17|Estimate||||2014-03-12|2014-04-17|Estimate|April 2004||2004-04-30|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer|A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal|Completed||Phase 2|20|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:02:34.103137|2018-06-01 05:02:34.103137
NCT00093366|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2011-11-28|2004-10-07|2004-10-08|Estimate|||||||2011-11-28|2011-11-30|Estimate|June 2004||2004-06-30|November 2011|2011-11-30|July 2006|Actual|2006-07-31|||||Interventional|||Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes|Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study|Completed||Phase 1/Phase 2|32|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:02:34.489|2018-06-01 05:02:34.489
NCT00093353|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2010-10-14|2004-10-07|2004-10-08|Estimate|||||||2010-10-14|2010-10-15|Estimate|May 2004||2004-05-31|May 2009|2009-05-31||||July 2006|Actual|2006-07-31||Interventional|||N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma|A Phase I Study Of Oral Irinotecan, Temozolomide, Cefixime In Children With Recurrent/Resistant High-Risk Neuroblastoma|Completed||Phase 1|30|Anticipated|Children's Hospital Los Angeles|||||f||||t||||||||||2018-06-01 05:02:34.626687|2018-06-01 05:02:34.626687
NCT00093327|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2006-08-17|2004-10-07|2004-10-08|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2003||2003-09-30|August 2006|2006-08-31|April 2006||2006-04-30|||||Interventional|||Acupuncture for Irritable Bowel Syndrome (IBS)|Acupuncture for Irritable Bowel Syndrome (IBS) Trial|Completed||Phase 2|287||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:02:34.765239|2018-06-01 05:02:34.765239
NCT00093314|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2015-04-20|2004-10-07|2004-10-08|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2004||2004-10-31|January 2007|2007-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||HuMax-CD20 in Chronic Lymphocytic Leukemia|An Open-labeled, International, Multicenter, Dose Escalating, Phase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Withdrawn||Phase 1/Phase 2|0|Actual|GlaxoSmithKline||||Acquired asset|||||||||||||||2018-06-01 05:02:34.903748|2018-06-01 05:02:34.903748
NCT00093860|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-06|||2008-03-03|2004-10-06|2004-10-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2004||2004-10-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance|Propranolol for Syncope With Sympathoadrenal Imbalance in Children|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:34.970057|2018-06-01 05:02:34.970057
NCT00093301|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-05|||2005-06-23|2004-10-06|2004-10-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2004||2004-10-31|October 2004|2004-10-31|April 2006||2006-04-30|||||Interventional|||Levosimendan Versus Dobutamine in Shock Patients|Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study|Unknown status|Recruiting|Phase 2/Phase 3|40||Wentworth Area Health Services|||||f||||||||||||||2018-06-01 05:02:35.139179|2018-06-01 05:02:35.139179
NCT00093288|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-05|||2013-08-29|2004-10-06|2004-10-07|Estimate|||||||2013-08-29|2013-09-02|Estimate|June 2004||2004-06-30|August 2013|2013-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Major Depressive Disorder In The Elderly|A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg Once Daily) in Elderly Subjects With Major Depressive Disorder|Completed||Phase 3|364||GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:02:35.321446|2018-06-01 05:02:35.321446
NCT00093275|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-05|||2008-08-20|2004-10-06|2004-10-07|Estimate|||||||2008-08-20|2008-08-21|Estimate|October 2004||2004-10-31|August 2008|2008-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||HP184 in Chronic Spinal Cord Injury Subjects|A Phase II, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of HP184 Administered Orally Once Daily for Twenty-Four Weeks in Adult Subjects With Chronic Spinal Cord Injury (CSCI)|Completed||Phase 2|262|Actual|Sanofi|||||||||||||||||||2018-06-01 05:02:35.485578|2018-06-01 05:02:35.485578
NCT00093262|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-05|||2014-05-07|2004-10-06|2004-10-07|Estimate|||||||2014-05-07|2014-05-08|Estimate|December 2003||2003-12-31|May 2014|2014-05-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|ESCAPE-2||Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)|Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)|Completed||Phase 3|206|Actual|The Medicines Company||2|||||||t||||||||||2018-06-01 05:02:35.61664|2018-06-01 05:02:35.61664
NCT00093249|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-05|||2014-08-21|2004-10-06|2004-10-07|Estimate|||||||2014-08-21|2014-08-22|Estimate|January 2004||2004-01-31|August 2014|2014-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|ESCAPE-1||Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)|Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)|Completed||Phase 3|105|Actual|The Medicines Company||2|||f||||t||||||||||2018-06-01 05:02:35.796032|2018-06-01 05:02:35.796032
NCT00093236|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-05|||2017-04-19|2004-10-06|2004-10-07|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2004||2004-09-30|April 2017|2017-04-30|December 8, 2012|Actual|2012-12-08|April 2011|Actual|2011-04-30||Interventional|||Impact of Gum Infection on Heart Disease|Systemic Endothelial Consequences of Periodontal Disease|Completed||N/A|174|Actual|Boston University||2|||f||||t||||||||No||2018-06-01 05:02:35.962522|2018-06-01 05:02:35.962522
NCT00093223|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-04|||2016-03-30|2004-10-06|2004-10-07|Estimate|||||||2016-03-30|2016-03-31|Estimate|September 2001||2001-09-30|March 2016|2016-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Safety Study of ABI-007 for In-Stent Restenosis|A Phase II Safety Study of Systemic Nanoparticle Paclitaxel (ABI-007)for In-Stent Restenosis|Completed||Phase 2|76|Actual|Celgene Corporation||2|||f||||t||||||||||2018-06-01 05:02:36.070957|2018-06-01 05:02:36.070957
NCT00093210|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-04|||2007-12-03|2004-10-06|2004-10-07|Estimate|||||||2007-12-03|2007-12-05|Estimate||||December 2007|2007-12-31|September 2005|Actual|2005-09-30|||||Interventional|||Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B|A Double-Blind, Randomized, Crossover Evaluation of the Pharmacokinetics of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R); and an Open-Label Safety and Efficacy Evaluation of rFIX-R in Previously Treated Patients With Moderate to Severe (FIX:C≤2%) Hemophilia B|Completed||Phase 3|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:02:36.150329|2018-06-01 05:02:36.150329
NCT00091533|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-09|||2017-06-30|2004-09-09|2004-09-10|Estimate|||||||2017-06-30|2017-07-02|Actual|September 3, 2004||2004-09-03|September 2, 2008|2008-09-02|September 2, 2008||2008-09-02|||||Observational|||Neural Correlates of Observation of Tactile Stimulation in Healthy Subjects|Neural Correlates of Observation of Tactile Stimulation in Healthy Subjects|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:03:34.117899|2018-06-01 05:03:34.117899
NCT00093184|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-04|||2006-02-08|2004-10-06|2004-10-07|Estimate|||||||2006-02-08|2006-02-09|Estimate|April 2004||2004-04-30|February 2006|2006-02-28|December 2005||2005-12-31|||||Interventional|||Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI|A Study Evaluating the Safety and Efficacy of Bivalirudin in the Management of Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary PCI (BIAMI)|Completed||Phase 3|300||The Medicines Company|||||||||||||||||||2018-06-01 05:02:36.370209|2018-06-01 05:02:36.370209
NCT00093171|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-04|||2009-08-20|2004-10-06|2004-10-07|Estimate|||||||2009-08-20|2009-08-21|Estimate||||August 2009|2009-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study Evaluating rFIX; BeneFIX® in Hemophilia B|An Open-label Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Previously Treated Patients (PTPs) With Hemophilia B (FIX:C ≤2%)|Completed||Phase 3|23|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:02:36.443824|2018-06-01 05:02:36.443824
NCT00093158|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-04|||2007-08-20|2004-10-06|2004-10-07|Estimate|||||||2007-08-20|2007-08-21|Estimate|August 2003||2003-08-31|August 2007|2007-08-31|January 2007|Actual|2007-01-31|||||Interventional|||Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)|The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation|Completed||Phase 3|13800||The Medicines Company|||||||||||||||||||2018-06-01 05:02:36.527125|2018-06-01 05:02:36.527125
NCT00093145|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-04|2013-05-07||2013-07-15|2004-10-04|2004-10-05|Estimate|2013-07-15|2013-07-17|Estimate||||2013-07-15|2013-07-17|Estimate|June 2004||2004-06-30|July 2013|2013-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer|A Phase II Study of Weekly Dose-Dense Nanoparticle Paclitaxel (ABI-007), Carboplatin With Herceptin® As First-Line Therapy of Advanced HER-2 Positive Breast Cancer|Completed||Phase 2|32|Actual|Celgene||1|||f||||f||||||||||2018-06-01 05:02:36.733517|2018-06-01 05:02:36.733517
NCT00002543|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2004-10-04|2004-10-05|Estimate|||||||2013-07-17|2013-07-18|Estimate|February 1995||1995-02-28|May 2007|2007-05-31|October 2004|Actual|2004-10-31|||||Interventional|||Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors|GALLIUM NITRATE FOR THE TREATMENT OF MALIGNANT TUMORS, A PHASE I STUDY|Completed||Phase 1|3|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:02:37.35548|2018-06-01 05:02:37.35548
NCT00002524|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-10-04|2004-10-05|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 1993||1993-06-30|July 2012|2012-07-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma|Pilot Study in AIDS-Related Lymphomas|Completed||Phase 2|46|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:02:37.48281|2018-06-01 05:02:37.48281
NCT00093132|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-01||2012-08-09|2012-08-09|2004-10-01|2004-10-04|Estimate||||2012-08-09|2012-08-17|Estimate|2012-08-09|2012-08-17|Estimate|August 2004||2004-08-31|August 2012|2012-08-31|February 2009|Actual|2009-02-28|January 2009|Actual|2009-01-31||Interventional|||Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy|A Phase 1/2 Study With Satraplatin and Simultaneous Radiation in Locally Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|20|Actual|Agennix||1||Sponsor decided to discontinue study drug development.|f||||||||||||||2018-06-01 05:02:37.682908|2018-06-01 05:02:37.682908
NCT00093119|ClinicalTrials.gov processed this data on May 31, 2018|2004-10-01|||2017-04-25|2004-10-01|2004-10-04|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2003||2003-07-31|April 2017|2017-04-30||||February 2005|Actual|2005-02-28||Interventional|||Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma|A Phase II Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma|Completed||Phase 2|75|Actual|Celgene|||||f||||||||||||||2018-06-01 05:02:37.826907|2018-06-01 05:02:37.826907
NCT00093093|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-30|||2012-06-21|2004-10-01|2004-10-04|Estimate|||||||2012-06-21|2012-06-22|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|VISER2||Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive|Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C|Completed||Phase 3|900||Valeant Pharmaceuticals International, Inc.|||||f||||||||||||||2018-06-01 05:02:37.982827|2018-06-01 05:02:37.982827
NCT00093080|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-30|||2015-02-12|2004-10-01|2004-10-04|Estimate|||||||2015-02-12|2015-02-13|Estimate|October 2004||2004-10-31|February 2015|2015-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)|A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma|Completed||Phase 2|216|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 05:02:38.238233|2018-06-01 05:02:38.238233
NCT00093067|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-30|||2017-02-09|2004-09-30|2004-10-01|Estimate|||||||2017-02-09|2017-02-13|Actual|March 2002||2002-03-31|February 2017|2017-02-28|February 2005|Actual|2005-02-28|November 2004|Actual|2004-11-30||Interventional|||Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus|A Phase 3, Multicenter, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of Daptomycin Compared to Conventional Therapy In the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to Staph Aureus|Completed||Phase 3|||Cubist Pharmaceuticals LLC|||||f||||||||||||||2018-06-01 05:02:38.326511|2018-06-01 05:02:38.326511
NCT00093054|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-30||2015-04-14|2015-04-14|2004-09-30|2004-10-01|Estimate||||2015-04-14|2015-05-05|Estimate|2015-04-14|2015-05-05|Estimate|November 2004||2004-11-30|April 2015|2015-04-30|December 2009|Actual|2009-12-31|March 2008|Actual|2008-03-31||Interventional|||Cranberry Juice for Treatment of Urinary Tract Infections|Cranberry Juice and Urinary Tract Infections|Completed||Phase 2/Phase 3|319|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 05:02:38.475798|2018-06-01 05:02:38.475798
NCT00093041|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-30|2011-09-12||2011-11-17|2004-09-30|2004-10-01|Estimate|2011-11-17|2011-12-22|Estimate||||2011-11-17|2011-12-22|Estimate|December 2003||2003-12-31|November 2011|2011-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Zalutumumab in Head and Neck Cancer|An Open, Single Dose Escalation Study Followed by a Multiple Dose Extension of Anti-EGF Receptor Human Monoclonal Antibody (Zalutumumab) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 1/Phase 2|28|Actual|Genmab|The study comprised a single-dose escalation part for assessment of safety and a repeat dose extension including 4 weekly infusions. Please see the referred publication by Bastholt at al 2007 for detailed results.|6|||f||||||||||||||2018-06-01 05:02:38.66045|2018-06-01 05:02:38.66045
NCT00093028|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-29|||2010-07-01|2004-09-30|2004-10-01|Estimate|||||||2010-07-01|2010-07-02|Estimate|January 2004||2004-01-31|July 2010|2010-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II|UARK 2003-35, A Phase III Study of Bortezomib Versus Bortezomib in Two Doses in Combination With Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (UARK 98-026)|Completed||Phase 3|315|Actual|University of Arkansas|||||f||||f||||||||||2018-06-01 05:02:39.381676|2018-06-01 05:02:39.381676
NCT00091520|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-09|||2011-05-19|2004-09-30|2004-10-01|Estimate|||||||2011-05-19|2011-05-20|Estimate|April 2004||2004-04-30|March 2010|2010-03-31|December 2006|Actual|2006-12-31|||||Interventional|||A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart Failure|Follow-up Serial Infusions of Natrecor(Nesiritide) in the Management of Patients With Heart Failure-FUSION II|Completed||Phase 2|920|Actual|Scios, Inc.|||||||||||||||||||2018-06-01 05:02:39.514221|2018-06-01 05:02:39.514221
NCT00093015|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-28|2010-08-06||2017-05-16|2004-09-28|2004-09-29|Estimate|2010-08-06|2010-09-02|Estimate||||2017-05-16|2017-06-14|Actual|August 2004||2004-08-31|May 2017|2017-05-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)|Trial to Reduce Cardiovascular Events With Aranesp® Therapy|Completed||Phase 3|4038|Actual|Amgen|4047 subjects were enrolled, but before unblinding, all information from 9 subjects was excluded from two sites (3 and 6 subjects, respectively) that did not adhere to Good Clinical Practice guidelines. 4038 subjects were analyzed and reported.|2|||f||||||||||||||2018-06-01 05:02:39.702977|2018-06-01 05:02:39.702977
NCT00093002|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-28|||2008-06-11|2004-09-28|2004-09-29|Estimate|||||||2008-06-11|2008-06-12|Estimate|June 2004||2004-06-30|June 2008|2008-06-30|July 2007|Actual|2007-07-31|||||Interventional|||Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer|A Randomized, Open-Label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX®) 500 mg With Fulvestrant (FASLODEX®) 250 mg When Given as Neoadjuvant Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0).|Completed||Phase 2|179|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 05:02:43.18115|2018-06-01 05:02:43.18115
NCT00092989|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-28|||2017-03-09|2004-09-28|2004-09-29|Estimate|||||||2017-03-09|2017-03-13|Actual|July 2004||2004-07-31|March 2017|2017-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)|A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma|Completed||Phase 3|650|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 05:02:43.379437|2018-06-01 05:02:43.379437
NCT00092976|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-28|||2007-12-19|2004-09-28|2004-09-29|Estimate|||||||2007-12-19|2007-12-28|Estimate|February 2003||2003-02-28|May 2006|2006-05-31|July 2007|Actual|2007-07-31|||||Interventional|||Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery|A Phase IV Study of the Safety and Efficacy of ReFacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) in Subjects With Hemophilia A Undergoing Major Surgery Monitored Using the Chromogenic Substrate Assay at the Local Laboratory|Completed||Phase 4|15|Anticipated|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:02:43.531052|2018-06-01 05:02:43.531052
NCT00092963|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-28|||2017-03-31|2004-09-28|2004-09-29|Estimate|||||||2017-03-31|2017-04-04|Actual|August 17, 2004|Actual|2004-08-17|March 2017|2017-03-31|January 14, 2005|Actual|2005-01-14|January 14, 2005|Actual|2005-01-14||Interventional|||Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)|A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild|Completed||Phase 3|529|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:43.670808|2018-06-01 05:02:43.670808
NCT00092924|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-24|||2013-08-01|2004-09-27|2004-09-28|Estimate|||||||2013-08-01|2013-08-02|Estimate||||August 2013|2013-08-31|March 2005|Actual|2005-03-31|January 2005|Actual|2005-01-31||Interventional|||Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)|A Phase 2, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of TRM-1 (Fully Human Monoclonal Antibody To TRAIL-R1) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer|Completed||Phase 2|||Human Genome Sciences Inc.|||||||||||||||||||2018-06-01 05:02:43.817581|2018-06-01 05:02:43.817581
NCT00092911|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-24|||2009-08-18|2004-09-27|2004-09-28|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|244|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:02:43.94623|2018-06-01 05:02:43.94623
NCT00092898|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-07|2004-09-27|2004-09-28|Estimate|||||||2017-03-07|2017-03-10|Actual|October 2004||2004-10-31|March 2017|2017-03-31|October 2005|Actual|2005-10-31|September 2005|Actual|2005-09-30||Interventional|||An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous Sitosterolemia|Completed||Phase 3|30|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:44.034454|2018-06-01 05:02:44.034454
NCT00092885|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-17|2004-09-27|2004-09-28|Estimate|||||||2017-03-17|2017-03-21|Actual|March 2003||2003-03-31|March 2017|2017-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)|A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma|Completed||Phase 3|831|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:44.219398|2018-06-01 05:02:44.219398
NCT00092872|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2015-01-29|2004-09-27|2004-09-28|Estimate|||||||2015-01-29|2015-01-30|Estimate|November 2003||2003-11-30|January 2015|2015-01-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients|Completed||Phase 3|359|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:44.382922|2018-06-01 05:02:44.382922
NCT00092859|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2016-12-30|2004-09-27|2004-09-28|Estimate|||||||2016-12-30|2017-01-02|Estimate|August 2003||2003-08-31|December 2016|2016-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients|Completed||Phase 3|1500|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:44.520383|2018-06-01 05:02:44.520383
NCT00092846|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-09-28|2004-09-27|2004-09-28|Estimate|||||||2017-09-28|2017-10-02|Actual|December 4, 2002|Actual|2002-12-04|September 2017|2017-09-30||||September 1, 2003|Actual|2003-09-01||Interventional|||A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)|A Consumer Use Study of OTC Lovastatin (CUSTOM): A 6-Month Consumer Behavior Study of the Lovastatin OTC Self-Management System|Completed||Phase 3|1000|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:44.604405|2018-06-01 05:02:44.604405
NCT00092833|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-02-24|2004-09-27|2004-09-28|Estimate|||||||2017-02-24|2017-02-28|Actual|July 2002||2002-07-31|February 2017|2017-02-28|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)|An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia|Terminated||Phase 3|49|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 05:02:44.879682|2018-06-01 05:02:44.879682
NCT00092820|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-05-10|2004-09-27|2004-09-28|Estimate|||||||2017-05-10|2017-05-11|Actual|February 12, 2001|Actual|2001-02-12|May 2017|2017-05-31|November 30, 2004|Actual|2004-11-30|September 18, 2001|Actual|2001-09-18||Interventional|||Sitosterolemia Extension Study (0653-004)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia|Completed||Phase 3|58|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:44.986231|2018-06-01 05:02:44.986231
NCT00092807|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-05-10|2004-09-27|2004-09-28|Estimate|||||||2017-05-10|2017-05-11|Actual|February 12, 2001|Actual|2001-02-12|May 2017|2017-05-31|November 30, 2004|Actual|2004-11-30|September 18, 2001|Actual|2001-09-18||Interventional|||Sitosterolemia Extension Study (0653-003)(COMPLETED)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension|Completed||Phase 3|37|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:45.151817|2018-06-01 05:02:45.151817
NCT00092781|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-04-06|2004-09-27|2004-09-28|Estimate|||||||2017-04-06|2017-04-10|Actual|March 1, 2004|Actual|2004-03-01|April 2017|2017-04-30|February 1, 2005|Actual|2005-02-01|February 1, 2005|Actual|2005-02-01||Interventional|||A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)|A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 2)|Completed||Phase 3|500|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:45.307513|2018-06-01 05:02:45.307513
NCT00092768|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-04-06|2004-09-27|2004-09-28|Estimate|||||||2017-04-06|2017-04-10|Actual|March 1, 2004|Actual|2004-03-01|April 2017|2017-04-30|February 1, 2005|Actual|2005-02-01|February 1, 2005|Actual|2005-02-01||Interventional|||A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)|A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)|Completed||Phase 3|500|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:45.419574|2018-06-01 05:02:45.419574
NCT00092755|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-04-06|2004-09-27|2004-09-28|Estimate|||||||2017-04-06|2017-04-10|Actual|April 9, 2003|Actual|2003-04-09|April 2017|2017-04-30|November 13, 2003|Actual|2003-11-13|November 13, 2003|Actual|2003-11-13||Interventional|||An Investigational Drug in Patients With Osteoarthritis (0663-073)|A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 2)|Completed||Phase 3|548|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:45.54223|2018-06-01 05:02:45.54223
NCT00092742|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2015-06-29|2004-09-27|2004-09-28|Estimate|||||||2015-06-29|2015-06-30|Estimate|February 2003||2003-02-28|June 2015|2015-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)|A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 75 mg b.i.d. in Patients With Rheumatoid Arthritis|Completed||Phase 3|4086|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:45.676868|2018-06-01 05:02:45.676868
NCT00092729|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-04-06|2004-09-27|2004-09-28|Estimate|||||||2017-04-06|2017-04-10|Actual|June 7, 2002|Actual|2002-06-07|April 2017|2017-04-30|December 6, 2002|Actual|2002-12-06|December 6, 2002|Actual|2002-12-06||Interventional|||An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)|A Randomized, Placebo-and Active-Comparator-Controlled Study of Etoricoxib 120 mg in the Treatment of Primary Dysmenorrhea|Completed||Phase 3|129|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 05:02:45.831814|2018-06-01 05:02:45.831814
NCT00092716|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-02-28|2004-09-27|2004-09-28|Estimate|||||||2017-02-28|2017-03-01|Actual|May 2002||2002-05-31|February 2017|2017-02-28|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)|A Multicenter, Double-Blind, Randomized, Parallel Group, 28-Week Study to Evaluate the Efficacy and Safety of Ezetimibe and Simvastatin Co-administration Versus Atorvastatin in Patients With Hypercholesteremia|Completed||Phase 3|655|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:46.07051|2018-06-01 05:02:46.07051
NCT00092703|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-04-06|2004-09-27|2004-09-28|Estimate|||||||2017-04-06|2017-04-10|Actual|June 27, 2002|Actual|2002-06-27|April 2017|2017-04-30|November 1, 2003|Actual|2003-11-01|November 1, 2003|Actual|2003-11-01||Interventional|||Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)|A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis|Completed||Phase 3|6000||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:46.200913|2018-06-01 05:02:46.200913
NCT00092690|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-10|2004-09-27|2004-09-28|Estimate|||||||2017-03-10|2017-03-13|Actual|June 2003||2003-06-30|March 2017|2017-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia|Completed||Phase 3|1902|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:02:46.2736|2018-06-01 05:02:46.2736
NCT00092300|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2015-07-31|2004-09-27|2004-09-28|Estimate|||||||2015-07-31|2015-08-04|Estimate|May 2002||2002-05-31|July 2015|2015-07-31||||September 2002|Actual|2002-09-30||Interventional|||A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Single Dose Study of the Effect of Rofecoxib 50 mg and Valdecoxib 20 mg in Patients With Postoperative Dental Pain|Completed||Phase 3|450||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:53.377954|2018-06-01 05:02:53.377954
NCT00004875|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2011-02-18|2004-07-23|2004-07-26|Estimate|||||||2011-02-18|2011-02-21|Estimate|July 1996||1996-07-31|February 2011|2011-02-28|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Observational|||Heparin or Enoxaparin in Patients With Cancer|Release of TFPI by Anticoagulants in Cancer Patients by Standard or LMW Heparin|Completed|||6|Actual|Northwestern University|||2||f||||t||||||||||2018-06-01 05:05:50.901453|2018-06-01 05:05:50.901453
NCT00092677|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|2009-03-31||2017-03-09|2004-09-27|2004-09-28|Estimate|2009-03-31|2009-05-27|Estimate||||2017-03-09|2017-04-06|Actual|January 2001||2001-01-31|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Ezetimibe + Simvastatin on Clinical Outcomes in Patients With Aortic Stenosis|Completed||Phase 3|1873|Actual|Merck Sharp & Dohme Corp.|It is important to note that several of the ischemic outcomes making up the composite ischemic endpoint can occur as a causal consequence of aortic stenosis progression itself, or in association with its standard treatment (aortic valve replacement).|2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:02:46.485524|2018-06-01 05:02:46.485524
NCT00092664|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-09|2004-09-27|2004-09-28|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2003||2003-01-31|March 2017|2017-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)|"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia"|Completed||Phase 3|1104|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:49.221598|2018-06-01 05:02:49.221598
NCT00092651|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-09|2004-09-27|2004-09-28|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2002||2002-09-30|March 2017|2017-03-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)|"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia"|Completed||Phase 3|1398|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:49.42484|2018-06-01 05:02:49.42484
NCT00092586|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-02-24|2004-09-27|2004-09-28|Estimate|||||||2017-02-24|2017-02-28|Actual|September 2002||2002-09-30|February 2017|2017-02-28|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)|A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level|Completed||Phase 3|2904|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:49.506099|2018-06-01 05:02:49.506099
NCT00092573|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-02-24|2004-09-27|2004-09-28|Estimate|||||||2017-02-24|2017-02-28|Actual|April 2003||2003-04-30|February 2017|2017-02-28|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)|Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia|Completed||Phase 3|576|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:49.677916|2018-06-01 05:02:49.677916
NCT00092560|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-02-24|2004-09-27|2004-09-28|Estimate|||||||2017-02-24|2017-02-28|Actual|December 2002||2002-12-31|February 2017|2017-02-28|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)|Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia|Completed||Phase 3|587|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:49.907102|2018-06-01 05:02:49.907102
NCT00092547|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|2009-11-03||2018-01-22|2004-09-27|2004-09-28|Estimate|2010-04-09|2010-05-04|Estimate||||2018-01-22|2018-02-20|Estimate|October 8, 2003|Actual|2003-10-08|January 2018|2018-01-31|June 1, 2015|Actual|2015-06-01|November 3, 2005|Actual|2005-11-03||Interventional|||A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)|A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study).|Completed||Phase 3|1781|Actual|Merck Sharp & Dohme Corp.|The difference between the prior and final data is a minor change in the definition of the per-protocol immunogenicity population, which was applied down to the base study. Also, protocol violators were identified and excluded from the analysis.|3|||f||||f||||||||||2018-06-01 05:02:50.087469|2018-06-01 05:02:50.087469
NCT00092534|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|2009-07-20||2018-01-23|2004-09-27|2004-09-28|Estimate|2009-10-15|2009-11-26|Estimate||||2018-01-23|2018-02-21|Estimate|June 14, 2002|Actual|2002-06-14|January 2018|2018-01-31|March 31, 2017|Actual|2017-03-31|July 31, 2007|Actual|2007-07-31||Interventional|||Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015)|A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety Immunogenicity and Efficacy on the Incidence of HPV 16/18-Related CIN2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18,) L1 Virus-Like Particle (VLP) Vaccine (V501, Gardasil) in 16- to 23-Year Old Women - The F.U.T.U.R.E. II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)|Completed||Phase 3|12167|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:02:51.333525|2018-06-01 05:02:51.333525
NCT00092521|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|2009-08-03||2015-09-24|2004-09-27|2004-09-28|Estimate|2009-10-19|2009-11-20|Estimate||||2015-09-24|2015-09-25|Estimate|December 2001||2001-12-31|September 2015|2015-09-30|January 2009|Actual|2009-01-31|July 2007|Actual|2007-07-31||Interventional|||Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)|A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women|Completed||Phase 3|5759|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 05:02:52.183274|2018-06-01 05:02:52.183274
NCT00092508|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2007-06-19|2004-09-27|2004-09-28|Estimate|||||||2007-06-19|2007-06-21|Estimate|May 2004||2004-05-31|June 2007|2007-06-30|May 2007||2007-05-31|||||Interventional|||CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission|Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25 mg QD and 50 mg QD of OPC-6335 Oral Tablets and 800 mg BID of Asacol® in the Maintenance of Ulcerative Colitis Remission|Completed||Phase 3|1725|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:02:53.269156|2018-06-01 05:02:53.269156
NCT00092950|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-24|||2017-06-30|2004-09-24|2004-09-27|Estimate|||||||2017-06-30|2017-07-02|Actual|September 23, 2004||2004-09-23|September 28, 2011|2011-09-28|December 7, 2009|Actual|2009-12-07|December 7, 2009|Actual|2009-12-07||Interventional|||Exercise in Women at Risk for Breast Cancer|A Pilot Study of a Three Month Intervention for Increasing Physical Activity in Sedentary Women at Risk for Breast Cancer|Completed||Phase 2|88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:53.640081|2018-06-01 05:02:53.640081
NCT00092937|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-24|||2017-06-30|2004-09-24|2004-09-27|Estimate|||||||2017-06-30|2017-07-02|Actual|September 23, 2004||2004-09-23|April 6, 2010|2010-04-06|April 6, 2010|Actual|2010-04-06|April 6, 2010|Actual|2010-04-06||Interventional|||Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant|Secondary Transplantation Using Moderate Dose Busulfan as Conditioning for a Patient With Partial Reconstitution Post Initial Allogeneic Transplantation|Completed||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:02:53.741461|2018-06-01 05:02:53.741461
NCT00092638|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-09|2004-09-24|2004-09-27|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2003||2003-05-31|March 2017|2017-03-31|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.|Completed||Phase 3|450|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:53.872897|2018-06-01 05:02:53.872897
NCT00092625|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-09|2004-09-24|2004-09-27|Estimate|||||||2017-03-09|2017-03-13|Actual|March 2003||2003-03-31|March 2017|2017-03-31|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.|Completed||Phase 3|442|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:53.979141|2018-06-01 05:02:53.979141
NCT00092612|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-09|2004-09-24|2004-09-27|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2003||2003-05-31|March 2017|2017-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.|Completed||Phase 3|372|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:54.10674|2018-06-01 05:02:54.10674
NCT00092599|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-23|||2017-03-09|2004-09-24|2004-09-27|Estimate|||||||2017-03-09|2017-03-13|Actual|February 2003||2003-02-28|March 2017|2017-03-31|July 2004|Actual|2004-07-31|June 2004|Actual|2004-06-30||Interventional|||Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.|Completed||Phase 3|410|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:54.256156|2018-06-01 05:02:54.256156
NCT00092495|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|2010-02-15||2014-12-29|2004-09-24|2004-09-27|Estimate|2010-02-15|2010-03-08|Estimate||||2014-12-29|2015-01-13|Estimate|December 2002||2002-12-31|December 2014|2014-12-31|February 2009|Actual|2009-02-28|September 2004|Actual|2004-09-30||Interventional|||Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)|A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine|Completed||Phase 3|3055|Actual|Merck Sharp & Dohme Corp.|Of note, the number of subjects who completed the Vaccination Period (N=1441) is slightly higher than that specified in the publication by Block, et al (2006; N=1430). The data provided here is based on final data.|4|||f||||||||||||||2018-06-01 05:02:54.395665|2018-06-01 05:02:54.395665
NCT00092482|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2017-03-20|2004-09-24|2004-09-27|Estimate|||||||2017-03-20|2017-03-22|Actual|June 28, 2002|Actual|2002-06-28|March 2017|2017-03-31|August 15, 2008|Actual|2008-08-15|June 30, 2004|Actual|2004-06-30||Interventional|||Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)|Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)|Completed||Phase 3|3882|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:56.267305|2018-06-01 05:02:56.267305
NCT00092469|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2015-10-06|2004-09-24|2004-09-27|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2002||2002-03-31|October 2015|2015-10-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)|A Registration Study of the Safety, Tolerability, and Immunogenicity of V441 in Healthy Infants in Taiwan|Completed||Phase 3|151||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:56.406264|2018-06-01 05:02:56.406264
NCT00092456|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|2009-06-19||2015-09-18|2004-09-24|2004-09-27|Estimate|2011-03-11|2011-04-12|Estimate||||2015-09-18|2015-10-05|Estimate|May 2003||2003-05-31|September 2015|2015-09-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Consistency Lots Vaccine Study (V260-009)|Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants|Completed||Phase 3|793|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 05:02:56.58911|2018-06-01 05:02:56.58911
NCT00092443|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|2009-05-19||2015-09-11|2004-09-24|2004-09-27|Estimate|2009-05-19|2009-07-10|Estimate||||2015-09-11|2015-09-14|Estimate|September 2002||2002-09-30|September 2015|2015-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Dose Confirmation Efficacy Study (V260-007)|Study of the Efficacy, Safety, and Immunogenicity of V260 at Expiry|Completed||Phase 3|1312|Actual|Merck Sharp & Dohme Corp.|Safety has been reported in the literature.|2|||f||||||||||||||2018-06-01 05:02:57.715011|2018-06-01 05:02:57.715011
NCT00092430|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2017-03-15|2004-09-24|2004-09-27|Estimate|||||||2017-03-15|2017-03-16|Actual|September 2002||2002-09-30|March 2017|2017-03-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)|A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children|Completed||Phase 3|1200||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:58.235596|2018-06-01 05:02:58.235596
NCT00092417|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|2010-05-12||2015-10-06|2004-09-24|2004-09-27|Estimate|2010-05-12|2010-06-10|Estimate||||2015-10-06|2015-10-07|Estimate|October 2003||2003-10-31|October 2015|2015-10-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)|Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Virus Vaccine Live (Oka/Merck)Among Adults 50 Years of Age or Older|Completed||Phase 3|695|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:02:58.313477|2018-06-01 05:02:58.313477
NCT00092404|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2017-03-14|2004-09-24|2004-09-27|Estimate|||||||2017-03-14|2017-03-15|Actual|December 2001||2001-12-31|March 2017|2017-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)|A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age|Completed||Phase 2|1210|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:58.819608|2018-06-01 05:02:58.819608
NCT00092391|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2015-10-22|2004-09-24|2004-09-27|Estimate|||||||2015-10-22|2015-10-23|Estimate|February 1999||1999-02-28|October 2015|2015-10-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)|A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age|Completed||Phase 3|1997|Actual|Merck Sharp & Dohme Corp.||3|||f||||||||||||||2018-06-01 05:02:58.906365|2018-06-01 05:02:58.906365
NCT00092378|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2017-05-05|2004-09-24|2004-09-27|Estimate|||||||2017-05-05|2017-05-09|Actual|September 1, 2003|Actual|2003-09-01|May 2017|2017-05-31|December 1, 2003|Actual|2003-12-01|December 1, 2003|Actual|2003-12-01||Interventional|||A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Parallel-Group Study of Rofecoxib and Diclofenac Sodium in the Treatment of Post-Bunionectomy Surgery Pain|Completed||Phase 3|251|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:59.000545|2018-06-01 05:02:59.000545
NCT00092365|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2017-05-05|2004-09-24|2004-09-27|Estimate|||||||2017-05-05|2017-05-09|Actual|April 1, 2003|Actual|2003-04-01|May 2017|2017-05-31|November 1, 2003|Actual|2003-11-01|November 1, 2003|Actual|2003-11-01||Interventional|||A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)|A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee|Completed||Phase 3|413|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:59.141736|2018-06-01 05:02:59.141736
NCT00092352|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2017-05-05|2004-09-24|2004-09-27|Estimate|||||||2017-05-05|2017-05-09|Actual|April 29, 2003|Actual|2003-04-29|May 2017|2017-05-31|December 1, 2003|Actual|2003-12-01|December 1, 2003|Actual|2003-12-01||Interventional|||A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)|A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee|Completed||Phase 3|395|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:59.236555|2018-06-01 05:02:59.236555
NCT00092339|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2017-05-05|2004-09-24|2004-09-27|Estimate|||||||2017-05-05|2017-05-09|Actual|August 1, 2002|Actual|2002-08-01|May 2017|2017-05-31|September 15, 2002|Actual|2002-09-15|September 15, 2002|Actual|2002-09-15||Interventional|||A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effects of Rofecoxib 50 mg and Valdecoxib 40 mg in Patients With Postoperative Dental Pain|Completed||Phase 3|125|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:59.325366|2018-06-01 05:02:59.325366
NCT00092326|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2016-02-19|2004-09-24|2004-09-27|Estimate|||||||2016-02-19|2016-02-22|Estimate|June 2002||2002-06-30|February 2016|2016-02-29|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain|Completed||Phase 3|269|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:59.470843|2018-06-01 05:02:59.470843
NCT00092313|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2015-11-24|2004-09-24|2004-09-27|Estimate|||||||2015-11-24|2015-11-25|Estimate|June 2002||2002-06-30|November 2015|2015-11-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)|A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain|Completed||Phase 3|271|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:02:59.626422|2018-06-01 05:02:59.626422
NCT00092287|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2008-02-25|2004-09-24|2004-09-27|Estimate|||||||2008-02-25|2008-02-27|Estimate|July 2004||2004-07-31|February 2008|2008-02-29|October 2004|Actual|2004-10-31|||||Interventional|||Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome|A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome|Terminated||Phase 3|196||Ipsen|||||||||||||||||||2018-06-01 05:02:59.694754|2018-06-01 05:02:59.694754
NCT00092274|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-22|||2015-04-20|2004-09-24|2004-09-27|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2004||2004-09-30|January 2005|2005-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma|An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II|Withdrawn||Phase 1/Phase 2|0|Actual|GlaxoSmithKline||||Acquired asset|||||||||||||||2018-06-01 05:02:59.81123|2018-06-01 05:02:59.81123
NCT00092001|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2008-10-15|2004-09-24|2004-09-27|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2005||2005-01-31|October 2008|2008-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer|A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|111|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 05:02:59.896898|2018-06-01 05:02:59.896898
NCT00091650|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-14|||2006-07-21|2004-09-24|2004-09-27|Estimate|||||||2006-07-21|2006-07-24|Estimate|March 2004||2004-03-31|July 2006|2006-07-31|November 2005||2005-11-30|||||Interventional|||Olanzapine in Patients With Borderline Personality Disorder|Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo|Completed||Phase 3|300||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:03:00.065569|2018-06-01 05:03:00.065569
NCT00092209|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2015-03-17|2004-09-23|2004-09-24|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2002||2002-04-30|March 2015|2015-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)|A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of the Anti-Hypertensive Efficacy and Safety of Losartan Monotherapy as Compared to HCTZ Monotherapy and to the Combination of Losartan and HCTZ in Japanese Patients With Essential Hypertension|Completed||Phase 3|840||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:00.298113|2018-06-01 05:03:00.298113
NCT00092196|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-05-02|2004-09-23|2004-09-24|Estimate|||||||2017-05-02|2017-05-05|Actual|December 1, 2002|Actual|2002-12-01|May 2017|2017-05-31|December 1, 2004|Actual|2004-12-01|December 1, 2004|Actual|2004-12-01||Interventional|||Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)|Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy|Completed||Phase 3|820|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:00.431235|2018-06-01 05:03:00.431235
NCT00092183|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-05-02|2004-09-23|2004-09-24|Estimate|||||||2017-05-02|2017-05-05|Actual|October 10, 2002|Actual|2002-10-10|May 2017|2017-05-31|February 11, 2004|Actual|2004-02-11|December 1, 2003|Actual|2003-12-01||Interventional|||An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)|A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy|Completed||Phase 4|866|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:00.54683|2018-06-01 05:03:00.54683
NCT00092170|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-02-16|2004-09-23|2004-09-24|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2002||2002-03-31|February 2017|2017-02-28|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038)|A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients|Completed||Phase 2|100||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:00.884173|2018-06-01 05:03:00.884173
NCT00092157|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-04-10|2004-09-23|2004-09-24|Estimate|||||||2017-04-10|2017-04-12|Actual|May 1, 2002|Actual|2002-05-01|April 2017|2017-04-30|March 4, 2003|Actual|2003-03-04|March 3, 2003|Actual|2003-03-03||Interventional|||Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)|A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patients With Combined Hyperlipidemia-Simvastatin and Fenofibrate Efficacy Trial (SAFARI)|Completed||Phase 3|571|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:01.037671|2018-06-01 05:03:01.037671
NCT00092144|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-09-14|2004-09-23|2004-09-24|Estimate|||||||2017-09-14|2017-09-15|Actual|February 26, 2004|Actual|2004-02-26|September 2017|2017-09-30|June 15, 2004|Actual|2004-06-15|June 15, 2004|Actual|2004-06-15||Interventional|||Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Clinical Effect of Oral MK0476 Vs Placebo During the Allergy Season in Patients With Seasonal Aeroallergen Sensitivity and Chronic Asthma Which is Also Active During Allergy Season|Completed||Phase 3|500|Anticipated|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:01.164633|2018-06-01 05:03:01.164633
NCT00092131|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|2009-09-24||2015-06-22|2004-09-23|2004-09-24|Estimate|2010-05-14|2010-06-17|Estimate||||2015-06-22|2015-07-15|Estimate|June 2003||2003-06-30|June 2015|2015-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 2-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast on Exercise-Induced Bronchospasm|Completed||Phase 3|51|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:03:01.327422|2018-06-01 05:03:01.327422
NCT00092118|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|2009-09-10||2015-05-25|2004-09-23|2004-09-24|Estimate|2010-06-29|2010-07-23|Estimate||||2015-05-25|2015-06-19|Estimate|October 2003||2003-10-31|May 2015|2015-05-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis|Completed||Phase 3|1992|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:03:01.828118|2018-06-01 05:03:01.828118
NCT00092105|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-03-24|2004-09-23|2004-09-24|Estimate|||||||2017-03-24|2017-03-28|Actual|April 1, 2002|Actual|2002-04-01|March 2017|2017-03-31|January 28, 2003|Actual|2003-01-28|January 1, 2003|Actual|2003-01-01||Interventional|||Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)|A Multicenter, Double-Blind, Randomized, Crossover Study Investigating the Clinical Effect of Montelukast in Patients With Concomitant Asthma and Allergic Rhinitis Upon Controlled Exposure to Cat Allergen|Completed||Phase 3|58|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:02.180977|2018-06-01 05:03:02.180977
NCT00092092|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-03-17|2004-09-23|2004-09-24|Estimate|||||||2017-03-17|2017-03-21|Actual|October 2002||2002-10-31|March 2017|2017-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)|A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 2-Arm, 2X2 Crossover Study Comparing the Effects of Montelukast, Inhaled Budesonide, and Placebo on Lower Leg Growth in Children (Prepubertal, Tanner Stage I) With Mild Asthma|Completed||Phase 4|71|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-06-01 05:03:02.295012|2018-06-01 05:03:02.295012
NCT00092079|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2014-11-07|2004-09-23|2004-09-24|Estimate|||||||2014-11-07|2014-11-11|Estimate|January 2004||2004-01-31|November 2014|2014-11-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)|A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporosis|Completed||Phase 3|652|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:02.454367|2018-06-01 05:03:02.454367
NCT00091728|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-16|||2005-11-04|2004-09-17|2004-09-20|Estimate|||||||2005-11-04|2005-11-07|Estimate|September 1997||1997-09-30|September 2004|2004-09-30|August 2001||2001-08-31|||||Observational|||Hormonal Contraception and Risk of Chlamydia and Gonorrhea|Hormonal Contraception, Cervical Ectopy, and STDs|Terminated|||1200||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:03:17.708372|2018-06-01 05:03:17.708372
NCT00092066|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-03-31|2004-09-23|2004-09-24|Estimate|||||||2017-03-31|2017-04-04|Actual|September 24, 2003|Actual|2003-09-24|March 2017|2017-03-31|May 1, 2004|Actual|2004-05-01|May 1, 2004|Actual|2004-05-01||Interventional|||A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)|A 15-Week, Double-Blind, Randomized, Active-Controlled, Multi-Center Study With 24-Week Extension to Evaluate the Safety, Tolerability, Efficacy of Alendronate 70 mg Plus Vitamin D3 2800 IU Combination Tablet in Men and Postmenopausal Women With Osteoporosis|Completed||Phase 3|717|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:02.568908|2018-06-01 05:03:02.568908
NCT00092053|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2016-01-06|2004-09-23|2004-09-24|Estimate|||||||2016-01-06|2016-01-07|Estimate|December 2004||2004-12-31|January 2016|2016-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Study of Investigational Drug in Osteoporosis (MK-0217-908)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis|Completed||Phase 3|203|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 05:03:02.662001|2018-06-01 05:03:02.662001
NCT00092040|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-03-24|2004-09-23|2004-09-24|Estimate|||||||2017-03-24|2017-03-28|Actual|March 18, 2003|Actual|2003-03-18|March 2017|2017-03-31|September 28, 2005|Actual|2005-09-28|October 18, 2004|Actual|2004-10-18||Interventional|||A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)|A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis|Completed||Phase 3|936|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:02.7611|2018-06-01 05:03:02.7611
NCT00092027|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-03-24|2004-09-23|2004-09-24|Estimate|||||||2017-03-24|2017-03-28|Actual|March 19, 2003|Actual|2003-03-19|March 2017|2017-03-31|March 15, 2004|Actual|2004-03-15|March 15, 2004|Actual|2004-03-15||Interventional|||A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)|A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Compare the Safety and Tolerability of an Oral Buffered Solution of Alendronate Sodium 70 mg Once-Weekly Versus Placebo for the Treatment of Osteoporosis in Postmenopausal Women|Completed||Phase 3|454|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:02.838447|2018-06-01 05:03:02.838447
NCT00092014|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2017-03-28|2004-09-23|2004-09-24|Estimate|||||||2017-03-28|2017-03-29|Actual|September 1, 2002|Actual|2002-09-01|March 2017|2017-03-31|April 1, 2004|Actual|2004-04-01|April 1, 2004|Actual|2004-04-01||Interventional|FACT||A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)|A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis|Completed||Phase 3|1053|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:03:02.906581|2018-06-01 05:03:02.906581
NCT00091962|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-20|2016-01-25||2016-03-14|2004-09-22|2004-09-23|Estimate|2016-03-14|2016-04-14|Estimate||||2016-03-14|2016-04-14|Estimate|August 2003||2003-08-31|March 2016|2016-03-31|December 2009|Actual|2009-12-31|June 2008|Actual|2008-06-30||Interventional|||Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery|Treatment of Depression Following Bypass Surgery|Completed||N/A|453|Actual|University of Pittsburgh|Selection bias if patients with severe depression were less likely to participate in our screening procedure. Also, the trial recruited just from one U.S. region.|3|||f||||t||||||||||2018-06-01 05:03:03.248307|2018-06-01 05:03:03.248307
NCT00092235|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2018-05-22|2004-09-21|2004-09-22|Estimate|||||||2018-05-22|2018-05-23|Actual|September 20, 2004||2004-09-20|May 4, 2018|2018-05-04||||||||Observational|||Factors Determining Outcomes in Patients With Graft-Versus-Host Disease|Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease|Recruiting|||550|Anticipated|National Institutes of Health Clinical Center (CC)|||4||f||||||||||||||2018-06-01 05:03:03.926312|2018-06-01 05:03:03.926312
NCT00092222|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2018-05-22|2004-09-21|2004-09-22|Estimate|||||||2018-05-22|2018-05-23|Actual|September 20, 2004||2004-09-20|May 17, 2018|2018-05-17|October 1, 2020|Anticipated|2020-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity|Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity|Recruiting||Phase 2|65|Anticipated|National Institutes of Health Clinical Center (CC)||5|||f||||||||||||||2018-06-01 05:03:04.032241|2018-06-01 05:03:04.032241
NCT00091988|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-21|||2010-03-02|2004-09-21|2004-09-22|Estimate|||||||2010-03-02|2010-03-03|Estimate|July 2004||2004-07-31|March 2010|2010-03-31|November 2007|Actual|2007-11-30|||||Interventional|||Program to Reduce Incontinence by Diet and Exercise (PRIDE)|Program to Reduce Incontinence by Diet and Exercise|Completed||N/A|330|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 05:03:04.174947|2018-06-01 05:03:04.174947
NCT00091975|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-20|||2011-01-17|2004-09-21|2004-09-22|Estimate|||||||2011-01-17|2011-01-19|Estimate|August 2004||2004-08-31|July 2006|2006-07-31||||||||Interventional|||Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis|A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Evaluate the Safety and Efficacy of Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis|Completed||Phase 3|78||Abbott|||||||||||||||||||2018-06-01 05:03:04.283255|2018-06-01 05:03:04.283255
NCT00091949|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-20|2016-07-19||2016-09-09|2004-09-21|2004-09-22|Estimate|2016-09-09|2016-10-28|Estimate||||2016-09-09|2016-10-28|Estimate|February 2005||2005-02-28|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|IRIS||Insulin Resistance Intervention After Stroke Trial|Insulin Resistance Intervention After Stroke (IRIS) Trial|Completed||Phase 3|3876|Actual|Yale University||2|||f||||t||||||||Yes||2018-06-01 05:03:04.438444|2018-06-01 05:03:04.438444
NCT00091923|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-20|||2010-03-23|2004-09-21|2004-09-22|Estimate|||||||2010-03-23|2010-03-24|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|December 2005|Actual|2005-12-31|||||Interventional|||Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children|A Randomized Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children 3 to <7 Years Old|Completed||Phase 3|268||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 05:03:06.113559|2018-06-01 05:03:06.113559
NCT00091546|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-10|||2016-02-01|2004-09-10|2004-09-13|Estimate|||||||2016-02-01|2016-02-02|Estimate|August 2003||2003-08-31|February 2016|2016-02-29|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Genetic and Environmental Characteristics of Primary Pulmonary Hypertension|Genetic and Environmental Pathogenesis of PPH|Completed|||3000|Actual|Vanderbilt University|||||f||||f||||||Samples With DNA|"~     Specimens from 100 families affected by PPH~   "|Yes||2018-06-01 05:03:23.325956|2018-06-01 05:03:23.325956
NCT00091936|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-20|||2010-03-26|2004-09-20|2004-09-21|Estimate|||||||2010-03-26|2010-03-29|Estimate|August 2009||2009-08-31|January 2007|2007-01-31||||||||Interventional|||Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings|Implementing Anti-Retroviral Therapy in Resource-Constrained Settings: A Randomized Controlled Trial to Assess the Effect of Integrated Tuberculosis and HIV Care on the Incidence of AIDS-Defining Conditions or Mortality in Subjects Co-Infected With Tuberculosis and HIV|Completed||N/A|592|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:03:07.025221|2018-06-01 05:03:07.025221
NCT00091910|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-19|||2011-06-06|2004-09-20|2004-09-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|September 2003||2003-09-30|April 2010|2010-04-30|June 2006|Actual|2006-06-30|||||Interventional|||Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Epoetin Alfa in Critically Ill Subjects|Completed||Phase 3|1460|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:03:07.174301|2018-06-01 05:03:07.174301
NCT00091858|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|||2013-05-06|2004-09-20|2004-09-21|Estimate|||||||2013-05-06|2013-05-08|Estimate|April 2004||2004-04-30|May 2013|2013-05-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer|Completed||Phase 3|1000||Amgen||2|||f||||||||||||||2018-06-01 05:03:07.290284|2018-06-01 05:03:07.290284
NCT00091845|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|||2009-07-06|2004-09-20|2004-09-21|Estimate|||||||2009-07-06|2009-07-08|Estimate|November 2004||2004-11-30|July 2009|2009-07-31|November 2004|Actual|2004-11-30|||||Interventional|||An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease|An Exploratory Study of the Safety, Tolerability, Pharmacokinetics and Potential Effectiveness of AVI-4020 Injection in Patients Presenting With Presumptive Acute Neuroinvasive West Nile Virus (WNV) Disease|Terminated||Phase 1|50|Anticipated|Sarepta Therapeutics||||Due to limited pool of eligble WNV patients|||||||||||||||2018-06-01 05:03:07.460969|2018-06-01 05:03:07.460969
NCT00091832|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|2010-12-09|2009-11-23|2013-12-20|2004-09-20|2004-09-21|Estimate|2010-12-09|2011-01-07|Estimate|2009-11-23|2009-11-25|Estimate|2013-12-20|2014-01-28|Estimate|September 2004||2004-09-30|December 2013|2013-12-31|October 2006|Actual|2006-10-31|November 2005|Actual|2005-11-30||Interventional|||Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer|A Randomized Active-controlled Study of AMG 162 in Breast Cancer Subjects With Bone Metastasis Who Have Not Previously Been Treated With Bisphosphonate Therapy.|Completed||Phase 2|255|Actual|Amgen||6|||f||||||||||||||2018-06-01 05:03:07.662996|2018-06-01 05:03:07.662996
NCT00091819|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|2009-11-03||2010-12-10|2004-09-20|2004-09-21|Estimate|2009-11-03|2009-12-08|Estimate||||2010-12-10|2010-12-28|Estimate|January 2005||2005-01-31|December 2010|2010-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|ATLAS1||Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus|A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus|Completed||Phase 3|862|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||f||||||||||2018-06-01 05:03:12.953127|2018-06-01 05:03:12.953127
NCT00091806|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|||2009-07-09|2004-09-20|2004-09-21|Estimate|||||||2009-07-09|2009-07-10|Estimate|August 2004||2004-08-31|July 2009|2009-07-31|October 2006|Actual|2006-10-31|April 2006|Actual|2006-04-30||Interventional|||Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors|An Open-Label, Clinical Trial Evaluating the Safety and Pharmacokinetics of Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors|Completed||Phase 1|86|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:03:15.929557|2018-06-01 05:03:15.929557
NCT00091793|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|2009-12-22|2009-11-23|2010-12-22|2004-09-20|2004-09-21|Estimate|2009-12-22|2010-01-26|Estimate|2009-11-23|2009-11-25|Estimate|2010-12-22|2010-12-31|Estimate|August 2004||2004-08-31|December 2010|2010-12-31|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis|A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis|Completed||Phase 3|332|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:03:16.113453|2018-06-01 05:03:16.113453
NCT00091897|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-18|||2011-08-30|2004-09-18|2004-09-20|Estimate|||||||2011-08-30|2011-08-31|Estimate|September 2004||2004-09-30|August 2011|2011-08-31|May 2009|Actual|2009-05-31|July 2007|Actual|2007-07-31||Interventional|||Rituximab to Treat Stiff Person Syndrome|Efficacy of Rituximab in Patients With Stiff Person Syndrome With Anti-GAD Antibodies: A Randomized Placebo-Controlled Trial|Completed||Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:03:16.975961|2018-06-01 05:03:16.975961
NCT00091884|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|||2008-03-03|2004-09-17|2004-09-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2004||2004-07-31|April 2005|2005-04-30|April 2005||2005-04-30|||||Observational|||Efficacy of Elevated CD4 Counts on CMV Retinitis|Efficacy of Elevated CD4 Cell Counts on CMV Retinitis|Completed|||15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:03:17.149801|2018-06-01 05:03:17.149801
NCT00091871|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-17|||2018-03-27|2004-09-17|2004-09-20|Estimate|||||||2018-03-27|2018-03-29|Actual|September 15, 2004||2004-09-15|November 7, 2017|2017-11-07||||||||Observational|||A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression|A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression|Recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:03:17.235818|2018-06-01 05:03:17.235818
NCT00091780|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-16|||2014-02-19|2004-09-17|2004-09-20|Estimate|||||||2014-02-19|2014-02-20|Estimate|September 2004||2004-09-30|February 2014|2014-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Epidemiology of Breast Arterial Calcification||Completed|||||Mayo Clinic|||||f||||||||||||||2018-06-01 05:03:17.33283|2018-06-01 05:03:17.33283
NCT00091767|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-16|||2016-07-11|2004-09-17|2004-09-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2004||2004-09-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Genetic Studies in Difficult to Treat Asthma: TENOR||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:03:17.401658|2018-06-01 05:03:17.401658
NCT00091754|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-16|||2008-07-23|2004-09-17|2004-09-20|Estimate|||||||2008-07-23|2008-07-24|Estimate|September 2004||2004-09-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Atherosclerosis, Plaque and CVD in Communities||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:03:17.530896|2018-06-01 05:03:17.530896
NCT00091741|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-16|||2009-07-21|2004-09-17|2004-09-20|Estimate|||||||2009-07-21|2009-07-22|Estimate||||September 2004|2004-09-30|October 2004|Actual|2004-10-31|||||Interventional|||Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects|A Phase I Pilot Study to Evaluate Safety and Efficacy of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects Who Are in Virologic Failure and Who Have Failed to Respond to Standard Antiretroviral Therapy|Completed||Phase 1|10|Anticipated|Georgetown University|||||||||||||||||||2018-06-01 05:03:17.579615|2018-06-01 05:03:17.579615
NCT00091715|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-16|||2011-08-26|2004-09-17|2004-09-20|Estimate|||||||2011-08-26|2011-08-30|Estimate|April 2004||2004-04-30|August 2011|2011-08-31|February 2011|Actual|2011-02-28|November 2006|Actual|2006-11-30||Interventional|||Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)|Completed||Phase 3|185|Actual|Actelion||2|||f||||||||||||||2018-06-01 05:03:17.845333|2018-06-01 05:03:17.845333
NCT00091702|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-16|||2012-05-16|2004-09-17|2004-09-20|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|January 2006|Actual|2006-01-31|||||Interventional|||Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents|A Phase I/II Randomized Trial of the Safety and Immunogenicity of Cold Adapted Influenza Vaccine (FluMist) in HIV-Infected Children and Adolescents|Completed||Phase 1/Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:03:18.035261|2018-06-01 05:03:18.035261
NCT00091689|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-15|||2008-10-24|2004-09-16|2004-09-17|Estimate|||||||2008-10-24|2008-10-27|Estimate|September 2004||2004-09-30|October 2008|2008-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions||Completed||Phase 1|||Pfizer|||||||||||||||||||2018-06-01 05:03:18.220861|2018-06-01 05:03:18.220861
NCT00091676|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-15|||2012-02-01|2004-09-16|2004-09-17|Estimate|||||||2012-02-01|2012-02-03|Estimate|January 2000||2000-01-31|February 2012|2012-02-29|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|BiovaxID||Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma|Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission|Unknown status|Active, not recruiting|Phase 3|629|Anticipated|Biovest International||2|||f||||t||||||||||2018-06-01 05:03:18.316378|2018-06-01 05:03:18.316378
NCT00091663|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-15|||2014-02-28|2004-09-15|2004-09-16|Estimate|||||||2014-02-28|2014-03-04|Estimate|August 2004||2004-08-31|February 2014|2014-02-28|August 2005|Actual|2005-08-31|||||Interventional|||A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|A Multicenter, Open-Label, Phase IIIb Trial of Tarceva (Erlotinib Hydrochloride) in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|5000||Genentech, Inc.|||||||||||||||||||2018-06-01 05:03:18.503032|2018-06-01 05:03:18.503032
NCT00091637|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-14|||2011-08-04|2004-09-15|2004-09-16|Estimate|||||||2011-08-04|2011-08-05|Estimate|April 2004||2004-04-30|August 2011|2011-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)|APEX-AMI - Pexelizumab in Conjunction With Angioplasty|Completed||Phase 3|5745|Actual|Procter and Gamble||2|||f||||t||||||||||2018-06-01 05:03:19.012144|2018-06-01 05:03:19.012144
NCT00004905|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-05-29|2004-09-15|2004-09-16|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 1999||1999-10-31|February 2001|2001-02-28|September 2004|Actual|2004-09-30|||||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia|Pilot Study of Intensive Chemotherapy Followed by Peripheral Blood Stem Cell Harvesting for Autotransplantation of Adults With Chronic Myelogenous Leukemia and High Risk Acute Leukemia|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:19.650394|2018-06-01 05:03:19.650394
NCT00004209|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-08-06|2004-09-15|2004-09-16|Estimate|||||||2013-08-06|2013-08-07|Estimate|May 1998||1998-05-31|June 2007|2007-06-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Randomized Study of MVP 3 Versus 6 Cycles in Advanced Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:19.729672|2018-06-01 05:03:19.729672
NCT00004195|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2015-06-12|2004-09-15|2004-09-16|Estimate|||||||2015-06-12|2015-06-15|Estimate|September 1998||1998-09-30|June 2015|2015-06-30|May 2001|Actual|2001-05-31|October 1999|Actual|1999-10-31||Interventional|||Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer|Evaluation of Dihydropyrimidine Dehydrogenase (DPD) Activity in Surgically Resected Primary and Metastatic Colorectal Cancer After 48 hr Pretreatment With Eniluracil|Completed||Phase 2|28|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 05:03:19.783569|2018-06-01 05:03:19.783569
NCT00004194|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-12-17|2004-09-15|2004-09-16|Estimate|||||||2013-12-17|2013-12-18|Estimate||||April 2000|2000-04-30||||||||Interventional|||Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease|A Phase I-II Study for the Treatment of Steroid Resistant GVHD With Fludarabine|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:19.891398|2018-06-01 05:03:19.891398
NCT00004184|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-04-11|2004-09-15|2004-09-16|Estimate|||||||2013-04-11|2013-04-12|Estimate|August 1998||1998-08-31|March 2013|2013-03-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase I/II Trial of a Human Anti-Idiotypic Monoclonal Antibody Vaccine (4B5) Which Mimics the GD2 Antigen, in Patients With Melanoma|Completed||Phase 1/Phase 2|50|Anticipated|University of Alabama at Birmingham||2|||||||t||||||||||2018-06-01 05:03:20.012551|2018-06-01 05:03:20.012551
NCT00004172|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-02-16|2012-06-08|2004-09-15|2004-09-16|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer|Peripheral Stem Cell Transplantation Protocol for Patients With Previously Treated Advanced Breast Cancer - A Phase II Pilot Study|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:03:20.134686|2018-06-01 05:03:20.134686
NCT00091624|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-13|||2016-11-30|2004-09-14|2004-09-15|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2003||2003-03-31|November 2016|2016-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)|A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)|Completed||Phase 1|77|Actual|Celgene Corporation|||||f||||f||||||||||2018-06-01 05:03:20.232161|2018-06-01 05:03:20.232161
NCT00091598|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-10|||2010-03-04|2004-09-13|2004-09-14|Estimate|||||||2010-03-04|2010-03-08|Estimate|January 2004||2004-01-31|March 2010|2010-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)|ARIES 1 and ARIES 2: Ambrisentan in PAH - A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 3|372||Gilead Sciences|||||t||||||||||||||2018-06-01 05:03:20.423305|2018-06-01 05:03:20.423305
NCT00087477|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2005-08-26|2004-07-12|2004-07-13|Estimate|||||||2005-08-26|2005-08-30|Estimate|January 2004||2004-01-31|August 2005|2005-08-31|August 2004||2004-08-31|||||Interventional|||A Pilot Study of Pivanex in Patients With Malignant Melanoma|A Pilot Study of Pivanex, a Histone Deacetylase Inhibitor, in Patients With Malignant Melanoma|Terminated||Phase 1/Phase 2|14||Titan Pharmaceuticals|||||||||||||||||||2018-06-01 05:06:38.836004|2018-06-01 05:06:38.836004
NCT00091585|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-10|||2007-05-09|2004-09-13|2004-09-14|Estimate|||||||2007-05-09|2007-05-10|Estimate|June 2004||2004-06-30|May 2007|2007-05-31|November 2006||2006-11-30|||||Interventional|||Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.|Phase I Open-Label, Multicenter, Dose-Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of Intravenous Administration of SNS-595 in Patients With Advanced Malignancies|Completed||Phase 1|||Sunesis Pharmaceuticals|||||||||||||||||||2018-06-01 05:03:20.585919|2018-06-01 05:03:20.585919
NCT00091572|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-10|2008-12-19||2017-05-12|2004-09-13|2004-09-14|Estimate|2009-02-05|2009-03-12|Estimate||||2017-05-12|2017-06-06|Actual|October 20, 2004|Actual|2004-10-20|May 2017|2017-05-31|December 31, 2007|Actual|2007-12-31|December 31, 2007|Actual|2007-12-31||Interventional|||Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)|Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group|Completed||Phase 3|859|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:03:20.71885|2018-06-01 05:03:20.71885
NCT00091559|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-10|||2017-04-03|2004-09-13|2004-09-14|Estimate|||||||2017-04-03|2017-04-05|Actual|February 3, 2005|Actual|2005-02-03|April 2017|2017-04-30|March 13, 2006|Actual|2006-03-13|November 23, 2005|Actual|2005-11-23||Interventional|||Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)|Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma|Completed||Phase 2|74|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:03:21.741101|2018-06-01 05:03:21.741101
NCT00004089|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-07-09|2004-09-13|2004-09-14|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 1999||1999-08-31|January 2011|2011-01-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer|A Multicenter Phase II Study of Intensified Concomitant Chemoradiotherapy for Patients With Anaplastic Thyroid Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:21.891288|2018-06-01 05:03:21.891288
NCT00004083|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-03-25|2004-09-13|2004-09-14|Estimate|||||||2011-03-25|2011-03-28|Estimate|February 1999||1999-02-28|March 2011|2011-03-31||||December 1999|Actual|1999-12-31||Interventional|||Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer|A Phase II Pilot Study of SPI-77 (Stealth Liposomal Cisplatin) in Patients With Recurrent Platinum-Sensitive Ovarian Cancer|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:03:21.989339|2018-06-01 05:03:21.989339
NCT00004014|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-08-13|2004-09-13|2004-09-14|Estimate|||||||2010-08-13|2010-08-16|Estimate|April 1999||1999-04-30|August 2010|2010-08-31|November 2001|Actual|2001-11-30|January 2000|Actual|2000-01-31||Interventional|||Liposomal Doxorubicin in Treating Patients With Prostate Cancer|Liposome-Encapsulated Doxorubicin (LED) in Hormone Refractory Prostate Carcinoma, Phase II|Completed||Phase 2|10|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:03:22.093273|2018-06-01 05:03:22.093273
NCT00003956|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-02|2004-09-13|2004-09-14|Estimate|||||||2013-04-02|2013-04-04|Estimate|April 1999||1999-04-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|January 2001|Actual|2001-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I Study of Continuous Oral Administration of SCH 66336 and 5-Fluorouracil/Leucovorin (5FU/LV) in Patients With Advanced Cancer|Completed||Phase 1|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:22.19598|2018-06-01 05:03:22.19598
NCT00003858|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-09-13|2004-09-14|Estimate|||||||2016-07-12|2016-07-13|Estimate||||July 2016|2016-07-31||||||||Interventional|||Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence|A Phase II Trial of Adjuvant Mitoxantrone (NSC #301739) for High Risk Patients Following Radical Prostatectomy|Withdrawn||Phase 2|0|Actual|Alliance for Clinical Trials in Oncology||1||The study was not activated.|f||||||||||||||2018-06-01 05:03:22.293359|2018-06-01 05:03:22.293359
NCT00003842|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-09-13|2004-09-14|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 1999||1999-03-31|June 1999|1999-06-30||||||||Interventional|||IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma|A Phase I Study of a Recombinant Chimeric Protein Composed of Circularly Permuted IL-4 and a Mutated Form of the Pseudomonas Exotoxin Termed IL-4(38-37)-PE38KDEL (IL-4 Toxin) for the Treatment of Recurrent Malignant Astrocytoma|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:22.474686|2018-06-01 05:03:22.474686
NCT00003780|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-09-13|2004-09-14|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 1998||1998-12-31|May 2007|2007-05-31||||||||Interventional|||Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas|An Open Label Randomized Trial Comparing the Safety and Efficacy of Systemic Chemotherapy (Gemcitabine) to Immunotherapy (CYTOIMPLANT - Intra Tumor Implants of Allogeneic Peripheral Blood Mononuclear Cells Sensitized Against Patient Alloantigens by Mixed Lymphocyte Culture) as First Line Therapy for Patients With Unresectable Locally Advanced, and Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:22.612322|2018-06-01 05:03:22.612322
NCT00003775|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-12|2004-09-13|2004-09-14|Estimate|||||||2012-09-12|2012-09-13|Estimate|December 1998||1998-12-31|September 2012|2012-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse|A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse|Completed||Phase 2|60|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:03:22.779603|2018-06-01 05:03:22.779603
NCT00003714|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-02-20|2004-09-13|2004-09-14|Estimate|||||||2012-02-20|2012-02-22|Estimate||||February 2012|2012-02-29||||||||Interventional|||Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer|Phase II Trial of Pyrazoloacridine (PZA) in Previously Untreated Hepatocellular Carcinoma (HCC) Patients|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Withdrawn|f||||f||||||||||2018-06-01 05:03:22.874271|2018-06-01 05:03:22.874271
NCT00003711|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-29|2004-09-13|2004-09-14|Estimate|||||||2013-05-29|2013-05-30|Estimate|September 1997||1997-09-30|April 2000|2000-04-30|September 2004|Actual|2004-09-30|||||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors|A Phase I Trial of LY231514 With Irinotecan Administered Intravenously Every 21 Days in Patients With Metastatic Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:23.042265|2018-06-01 05:03:23.042265
NCT00091611|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-11|||2012-10-25|2004-09-11|2004-09-13|Estimate|||||||2012-10-25|2012-10-26|Estimate|September 2004||2004-09-30|October 2012|2012-10-31|March 2008|Actual|2008-03-31|April 2006|Actual|2006-04-30||Interventional|||Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer|Phase II Study in Metastatic Renal Cell Cancer Using Cultured, Tumor-Reactive Lymphocytes and Interleukin-2|Terminated||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)||||This study was terminated due to low accrual.|f||||||||||||||2018-06-01 05:03:23.19497|2018-06-01 05:03:23.19497
NCT00091507|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-09|2012-11-13||2016-02-03|2004-09-10|2004-09-13|Estimate|2012-12-19|2013-01-30|Estimate||||2016-02-03|2016-03-02|Estimate|November 2006||2006-11-30|February 2016|2016-02-29|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|IMMEDIATE||IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.|Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care Trial|Completed||Phase 3|911|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-06-01 05:03:23.566109|2018-06-01 05:03:23.566109
NCT00091494|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-09|||2016-04-08|2004-09-10|2004-09-13|Estimate|||||||2016-04-08|2016-04-11|Estimate|September 2004||2004-09-30|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Socioeconomic Patterning of Inflammation and Hemostasis - Ancillary to MESA||Completed|||1000|Anticipated|University of Michigan|||||f||||||||||||||2018-06-01 05:03:24.142062|2018-06-01 05:03:24.142062
NCT00091481|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-09|||2007-09-23|2004-09-10|2004-09-13|Estimate|||||||2007-09-23|2007-09-26|Estimate|June 2003||2003-06-30|September 2007|2007-09-30||||||||Interventional|||Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis|A Randomized, Active-Controlled, Double-Blind Multi-Center Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis|Completed||Phase 4|201|Actual|Abbott|||||||||||||||||||2018-06-01 05:03:24.195021|2018-06-01 05:03:24.195021
NCT00091442|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-08|2009-12-15||2014-04-02|2004-09-10|2004-09-13|Estimate|2012-08-30|2012-10-02|Estimate||||2014-04-02|2014-04-21|Estimate|September 2004||2004-09-30|April 2014|2014-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer|A Randomized Controlled Study of Docetaxel Monotherapy or Docetaxel and DOXIL for the Treatment of Advanced Breast Cancer|Completed||Phase 3|751|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||t||||||||||2018-06-01 05:03:24.509396|2018-06-01 05:03:24.509396
NCT00004057|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-20|2004-09-10|2004-09-13|Estimate|||||||2013-06-20|2013-06-21|Estimate|December 1998||1998-12-31|June 2013|2013-06-30|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas|A Phase I and Pharmacokinetic Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of Combination Therapy With Paclitaxel and L-778,123 in Patients With Recurrent or Refractory Solid Malignancies|Completed||Phase 1|40|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:03:25.671818|2018-06-01 05:03:25.671818
NCT00004036|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-12-18|2004-09-10|2004-09-13|Estimate|||||||2013-12-18|2013-12-19|Estimate|November 1997||1997-11-30|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer|Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:25.824256|2018-06-01 05:03:25.824256
NCT00004022|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-09-10|2004-09-13|Estimate|||||||2013-04-03|2013-04-05|Estimate|June 1997||1997-06-30|April 2013|2013-04-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma|Immunotherapy for Malignant Melanoma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:03:26.002966|2018-06-01 05:03:26.002966
NCT00003673|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-21|2004-09-10|2004-09-13|Estimate|||||||2012-08-21|2012-08-22|Estimate|March 1998||1998-03-31|August 2012|2012-08-31|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse|A Study of the Safety of CMA-676 in Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) in First Relapse|Completed||Phase 2|55|Anticipated|Pfizer|||||f||||||||||||||2018-06-01 05:03:26.123481|2018-06-01 05:03:26.123481
NCT00003671|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-24|2004-09-10|2004-09-13|Estimate|||||||2014-07-24|2014-07-25|Estimate|December 1998||1998-12-31|July 2014|2014-07-31|February 2009|Actual|2009-02-28|November 2002|Actual|2002-11-30||Interventional|||Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia|Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study|Completed||Phase 2|59|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:03:26.264548|2018-06-01 05:03:26.264548
NCT00003666|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2004-09-10|2004-09-13|Estimate|||||||2016-07-19|2016-07-20|Estimate|November 1998||1998-11-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|September 2004|Actual|2004-09-30||Interventional|||Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer|Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer|Completed||Phase 2|36|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:03:26.638856|2018-06-01 05:03:26.638856
NCT00003634|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-09-10|2004-09-13|Estimate|||||||2013-11-05|2013-11-06|Estimate|April 1998||1998-04-30|May 2007|2007-05-31||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy|A Double-Blind Placebo Controlled Trial of Intravenous OvaRex MAb-B43.13 as Post Chemotherapy Consolidation for Ovarian Tubal and Peritoneal Carcinoma|Unknown status|Active, not recruiting|Phase 2|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:26.855698|2018-06-01 05:03:26.855698
NCT00003625|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-25|2004-09-10|2004-09-13|Estimate|||||||2014-07-25|2014-07-28|Estimate|December 1998||1998-12-31|July 2014|2014-07-31|April 2006|Actual|2006-04-30|February 2001|Actual|2001-02-28||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma|Vincristine, Etoposide and Cyclosporine A in Concert With Standard Dose Radiation Therapy in Diffuse Intrinsic Brain Stem Glioma - A Phase I Study of Dose Escalation of Vincristine|Completed||Phase 1|7|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:03:27.193404|2018-06-01 05:03:27.193404
NCT00003599|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-02-17|2004-09-10|2004-09-13|Estimate|||||||2012-02-17|2012-02-22|Estimate||||February 2012|2012-02-29||||||||Interventional|||Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer|A Randomized Study of the Effect of Alpha-tocopherol (AT) on 13-cis-retinoic Acid (13-cRA) Toxicity in a Preliminary Chemoprevention Trial in Former and Current Smokers|Withdrawn||Phase 3|0|Actual|M.D. Anderson Cancer Center||2||Withdrawn study.|f||||f||||||||||2018-06-01 05:03:27.586722|2018-06-01 05:03:27.586722
NCT00003591|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-11|2004-09-10|2004-09-13|Estimate|||||||2013-11-11|2013-11-13|Estimate|November 1998||1998-11-30|November 2013|2013-11-30|October 2005|Actual|2005-10-31|June 2001|Actual|2001-06-30||Interventional|||Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer|A Phase II Trial of External Irradiation (50.4 GY) and Weekly Paclitaxel (Taxol) for Non-Metastatic, Unresectable Pancreatic Cancer|Completed||Phase 2|122|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:03:27.899054|2018-06-01 05:03:27.899054
NCT00003587|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-05|2004-09-10|2004-09-13|Estimate|||||||2012-10-05|2012-10-08|Estimate|October 1998||1998-10-31|October 2012|2012-10-31|January 2007|Actual|2007-01-31|January 2001|Actual|2001-01-31||Interventional|||S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Randomized Phase II Trial of Carboplatin/Gemcitabine Followed By Paclitaxel or Cisplatin/Vinorelbine Followed by Docetaxel in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|204|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:03:28.495397|2018-06-01 05:03:28.495397
NCT00003564|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-02-17|2004-09-10|2004-09-13|Estimate|||||||2012-02-17|2012-02-22|Estimate||||February 2012|2012-02-29||||||||Interventional|||Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas|Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas|Withdrawn||Phase 3|0|Actual|M.D. Anderson Cancer Center||2||Study withdrawn.|f||||f||||||||||2018-06-01 05:03:28.760943|2018-06-01 05:03:28.760943
NCT00003551|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-09-10|2004-09-13|Estimate|||||||2013-06-20|2013-06-21|Estimate|August 1998||1998-08-31|July 2000|2000-07-31|September 2004|Actual|2004-09-30|||||Interventional|||Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer|A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:29.137596|2018-06-01 05:03:29.137596
NCT00003546|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2004-09-10|2004-09-13|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 1998||1998-09-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|December 2003|Actual|2003-12-31||Interventional|||Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer|Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas|Completed||Phase 2|43|Actual|Alliance for Clinical Trials in Oncology||1|||f||||||||||||||2018-06-01 05:03:29.234393|2018-06-01 05:03:29.234393
NCT00003451|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-31|2004-09-10|2004-09-13|Estimate|||||||2013-01-31|2013-02-01|Estimate|August 1998||1998-08-31|July 2007|2007-07-31||||December 2001|Actual|2001-12-31||Interventional|||Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer|Phase I Trial of Interleukin-12 Followed by Interferon-Alpha|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:03:30.590735|2018-06-01 05:03:30.590735
NCT00003441|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-09-10|2004-09-13|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 1998||1998-08-31|July 2012|2012-07-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Irofulven in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of MGI-114 (NSC# 683863) Administered Intravenously for Five Days Every 28 Days to Patients With Metastatic Colorectal Cancer|Completed||Phase 2|26|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:03:30.760566|2018-06-01 05:03:30.760566
NCT00003430|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-09-10|2004-09-13|Estimate|||||||2013-06-24|2013-06-25|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors|A Pharmacokinetic Study Evaluating the Safety, Tolerability and Maximally Tolerated Dose of 7-Day Continuous Infusions of L-778,123 in Patients With Recurrent of Refractory Solid Malignancies|Completed||Phase 1|40|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:03:31.104595|2018-06-01 05:03:31.104595
NCT00003428|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-09-10|2004-09-13|Estimate|||||||2013-06-20|2013-06-24|Estimate|May 1998||1998-05-31|June 2013|2013-06-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Hormone Therapy in Treating Women With Breast Cancer|Phase II Randomized Double-Blind Evaluation of Two Dose Levels of LY353381 Hydrochloride Administered to Women With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|114|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:03:31.290824|2018-06-01 05:03:31.290824
NCT00003353|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-09-10|2004-09-13|Estimate|||||||2013-08-22|2013-08-23|Estimate|July 1998||1998-07-31|August 2013|2013-08-31||||December 2002|Actual|2002-12-31||Interventional|||High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis|A Phase II Study of High-Dose Melphalan With Hematopoietic Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:03:32.784639|2018-06-01 05:03:32.784639
NCT00003344|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-05-11|2004-09-10|2004-09-13|Estimate|||||||2018-05-11|2018-05-16|Actual|August 1998||1998-08-31|May 2018|2018-05-31|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer|Phase I-II Study of Weekly CPT-11 and Radiation Therapy for Unresectable or Locally Recurrent Large Bowel Cancer|Completed||Phase 1/Phase 2|49||Medical University of South Carolina|||||f||||t||||||||||2018-06-01 05:03:33.258159|2018-06-01 05:03:33.258159
NCT00003339|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-09-10|2004-09-13|Estimate|||||||2014-05-20|2014-05-22|Estimate|November 1998||1998-11-30|May 2014|2014-05-31|September 2004|Actual|2004-09-30|November 1999|Actual|1999-11-30||Interventional|||Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma|A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma|Completed||Phase 2|48|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:03:33.476142|2018-06-01 05:03:33.476142
NCT00003331|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-25|2004-09-10|2004-09-13|Estimate|||||||2011-03-25|2011-03-28|Estimate|January 1998||1998-01-31|March 2011|2011-03-31||||November 2001|Actual|2001-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies|Completed||Phase 1|30|Anticipated|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:03:33.636246|2018-06-01 05:03:33.636246
NCT00003288|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-09-10|2004-09-13|Estimate|||||||2013-02-04|2013-02-05|Estimate|August 1998||1998-08-31|April 2000|2000-04-30||||June 2003|Actual|2003-06-30||Interventional|||Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors|A Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:03:33.746865|2018-06-01 05:03:33.746865
NCT00003263|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-16|2004-09-10|2004-09-13|Estimate|||||||2013-04-16|2013-04-17|Estimate|August 1996||1996-08-31|April 2013|2013-04-30|November 2000|Actual|2000-11-30|December 1999|Actual|1999-12-31||Interventional|||Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma|Phase I Combined Modality Protocol for Malignant Mesothelioma: Cisplatin & rIFN-alpha-2b Followed by Surgical Resection (Debulking), and Post-Op Concurrent Chemoradiotherapy With Cisplatin, +/- rIFN-alpha-2b|Completed||Phase 1|6|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:03:33.910852|2018-06-01 05:03:33.910852
NCT00091429|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-08|||2009-11-24|2004-09-09|2004-09-10|Estimate|||||||2009-11-24|2009-11-26|Estimate|August 2004||2004-08-31|November 2009|2009-11-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day|Completed||Phase 3|500||Gilead Sciences|||||f||||||||||||||2018-06-01 05:03:34.181698|2018-06-01 05:03:34.181698
NCT00003257|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-09-09|2004-09-10|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1998||1998-01-31|April 2000|2000-04-30||||||||Interventional|||Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer|A Phase II, Multicenter, Open Label Study to Evaluate Effectiveness and Safety of AdCMV-p53 Administered by Intra-Tumoral Injections in 39 Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Unknown status|Active, not recruiting|Phase 2|39|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:34.292139|2018-06-01 05:03:34.292139
NCT00003252|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-25|2004-09-09|2004-09-10|Estimate|||||||2013-03-25|2013-03-26|Estimate|December 1997||1997-12-31|April 2000|2000-04-30|September 2004|Actual|2004-09-30|||||Interventional|||Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy|A Phase IV Open Label Study of the Effects of a Five Minute Infusion Time for Ethyol (Amifostine) in Patients Undergoing Chemotherapy|Completed||Phase 4|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:34.38378|2018-06-01 05:03:34.38378
NCT00003248|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2004-09-09|2004-09-10|Estimate|||||||2016-07-19|2016-07-20|Estimate|March 1998||1998-03-31|July 2016|2016-07-31|June 2010|Actual|2010-06-30|April 2003|Actual|2003-04-30||Interventional|||Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia|A Randomized Phase II Study of Concurrent Fludarabine + Chimeric Anti-CD20 Monoclonal Antibody IDEC-C2B8 (Rituximab) [NSC# 687451] Induction Followed By Rituximab Consolidation In Untreated Patients With B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|104|Actual|Alliance for Clinical Trials in Oncology||2|||f||||||||||||||2018-06-01 05:03:34.524391|2018-06-01 05:03:34.524391
NCT00003241|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-09-09|2004-09-10|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 1998||1998-05-31|April 2000|2000-04-30|September 2004|Actual|2004-09-30|||||Interventional|||Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors|Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:35.615317|2018-06-01 05:03:35.615317
NCT00003223|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-20|2004-09-09|2004-09-10|Estimate|||||||2012-07-20|2012-07-24|Estimate|December 1997||1997-12-31|July 2012|2012-07-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth|A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia|Terminated||Phase 2|5|Actual|Southwest Oncology Group||1||Closed due to poor accrual.|f||||f||||||||||2018-06-01 05:03:35.801518|2018-06-01 05:03:35.801518
NCT00091416|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-08|||2012-05-03|2004-09-08|2004-09-09|Estimate|||||||2012-05-03|2012-05-04|Estimate||||May 2012|2012-05-31|May 2006|Actual|2006-05-31|||||Interventional|||Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052|A Phase I Clinical Trial to Evaluate the Safety of a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Administered to Healthy, HIV-1 Uninfected, Adult Participants Who Received DNA Plasmid Vaccine or Placebo in the HVTN 052 Clinical Trial|Completed||Phase 1|70|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:03:36.106636|2018-06-01 05:03:36.106636
NCT00091390|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2014-10-31||2017-05-03|2004-09-08|2004-09-09|Estimate|2014-10-31|2014-11-14|Estimate||||2017-05-03|2017-06-01|Actual|July 2004||2004-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|January 2008|Actual|2008-01-31||Interventional||All eligible patients.|Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer|Phase II Trial Of Combined High Dose Rate Brachytherapy And External Beam Radiotherapy For Adenocarcinoma Of The Prostate|Completed||Phase 2|129|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:03:36.27463|2018-06-01 05:03:36.27463
NCT00091377|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2016-07-13|2004-09-08|2004-09-09|Estimate|||||||2016-07-13|2016-07-14|Estimate|August 2004||2004-08-31|July 2016|2016-07-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|||Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resistant|Completed||Phase 1/Phase 2|65|Actual|MEI Pharma, Inc.||2|||f||||f||||||||||2018-06-01 05:03:37.519085|2018-06-01 05:03:37.519085
NCT00091351|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2016-07-01|2004-09-08|2004-09-09|Estimate|||||||2016-07-01|2016-07-06|Estimate|August 2004||2004-08-31|July 2016|2016-07-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis|A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS)|Completed||Phase 3|370|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:03:37.670138|2018-06-01 05:03:37.670138
NCT00091338|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2015-04-29|2004-09-08|2004-09-09|Estimate|||||||2015-04-29|2015-04-30|Estimate|August 2004||2004-08-31|January 2005|2005-01-31||||||||Interventional|||Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma|"A Study of Subcutaneous CYT 99 007 (Interleukin-7) in Conjunction With Peptide Immunization in Patients With Metastatic Melanoma"|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:03:38.016011|2018-06-01 05:03:38.016011
NCT00091325|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2010-01-15|2004-09-08|2004-09-09|Estimate|||||||2010-01-15|2010-01-20|Estimate|October 2004||2004-10-31|January 2010|2010-01-31||||March 2005|Actual|2005-03-31||Interventional|||Green Tea Extract (Polyphenon E) in Preventing Cancer in Healthy Participants|Phase I Drug Interaction Clinical Study of Polyphenon E|Completed||Phase 1|||University of Arizona|||||f||||||||||||||2018-06-01 05:03:38.119184|2018-06-01 05:03:38.119184
NCT00091312|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2009-02-06|2004-09-08|2004-09-09|Estimate|||||||2009-02-06|2009-02-09|Estimate|June 2004||2004-06-30|December 2006|2006-12-31||||||||Interventional|||Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer|Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors|Unknown status|Active, not recruiting|Phase 3|1976|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:38.193536|2018-06-01 05:03:38.193536
NCT00091299|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2015-10-01|2004-09-08|2004-09-09|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2004||2004-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors|An Open Label, Non Randomized , One Sequence, Add-On Study to Investigate the Effects of PTK787/ZK 222584 on the Pharmacokinetics and Pharmacodynamics of Warfarin at Steady-States in Cancer Patients|Completed||Phase 1|24|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:03:38.477129|2018-06-01 05:03:38.477129
NCT00091286|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2010-11-13|2004-09-08|2004-09-09|Estimate|||||||2010-11-13|2010-11-16|Estimate|March 2003||2003-03-31|October 2007|2007-10-31||||April 2011|Anticipated|2011-04-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer|Evaluation of the Immunogenicity of Vaccination With HER-2/Neu and CEA Derived Synthetic Peptides With GM-CSF-in-Adjuvant, in Patients With Stage IIB, III, or IV Colorectal Cancer|Unknown status|Active, not recruiting|N/A|15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:38.598877|2018-06-01 05:03:38.598877
NCT00091273|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2014-05-19||2014-05-19|2004-09-08|2004-09-09|Estimate|2014-05-19|2014-06-20|Estimate||||2014-05-19|2014-06-20|Estimate|June 2004||2004-06-30|May 2014|2014-05-31|June 2007|Actual|2007-06-30|February 2006|Actual|2006-02-28||Interventional|||Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer|Evaluation of Safety and Immunogenicity of a Peptide Vaccine in Patients With Epithelial Ovarian or Primary Peritoneal Cancer|Completed||Phase 1|9|Actual|University of Virginia|||||f||||t||||||||||2018-06-01 05:03:38.752852|2018-06-01 05:03:38.752852
NCT00091260|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2016-09-09||2016-12-28|2004-09-08|2004-09-09|Estimate|2016-12-28|2017-02-20|Actual||||2016-12-28|2017-02-20|Actual|January 2004||2004-01-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|July 2012|Actual|2012-07-31||Interventional|||CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis|A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis|Completed||Phase 2|82|Actual|Boston Medical Center||1|||f||||t||||||||No||2018-06-01 05:03:39.072918|2018-06-01 05:03:39.072918
NCT00091247|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2017-03-14|2004-09-08|2004-09-09|Estimate|||||||2017-03-14|2017-03-16|Actual|December 2004||2004-12-31|March 2017|2017-03-31|July 2009|Actual|2009-07-31|August 2005|Actual|2005-08-31||Interventional|||Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer|An Exploratory, Placebo-Controlled Trial of Prophylactic Tetracycline for Gefitinib-or Cetuximab-Induced Skin Rash (or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash)|Completed||N/A|130|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:03:40.265723|2018-06-01 05:03:40.265723
NCT00091234|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2012-07-23|2004-09-08|2004-09-09|Estimate|||||||2012-07-23|2012-07-24|Estimate|June 2004||2004-06-30|July 2012|2012-07-31||||December 2013|Anticipated|2013-12-31||Interventional|AML-19||Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP|Unknown status|Recruiting|Phase 2/Phase 3|279|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||t||||||||||2018-06-01 05:03:41.139175|2018-06-01 05:03:41.139175
NCT00091195|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-03-18|2004-09-08|2004-09-09|Estimate|||||||2013-03-18|2013-03-19|Estimate|September 2004||2004-09-30|March 2013|2013-03-31||||March 2007|Actual|2007-03-31||Interventional|||Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer|A Phase II Study Of Single Agent Depsipeptide (FK228) In Recurrent, Platinum Sensitive Adeno-Carcinoma Of The Ovary Or Peritoneum|Terminated||Phase 2|51|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:03:42.149069|2018-06-01 05:03:42.149069
NCT00091182|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-06-04|2004-09-08|2004-09-09|Estimate|||||||2013-06-04|2013-06-05|Estimate|October 2004||2004-10-31|June 2013|2013-06-30||||February 2006|Actual|2006-02-28||Interventional|||Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment|A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors|Completed||Phase 2|180|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:03:42.617072|2018-06-01 05:03:42.617072
NCT00091169|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2016-02-02||2016-05-03|2004-09-07|2004-09-08|Estimate|2016-05-03|2016-05-30|Estimate||||2016-05-03|2016-05-30|Estimate|November 2005||2005-11-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|March 2008|Actual|2008-03-31||Interventional||All randomized patients|Levocarnitine in Treating Fatigue in Cancer Patients|Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients With Cancer|Completed||Phase 3|376|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 05:03:42.892957|2018-06-01 05:03:42.892957
NCT00091156|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2012-07-13|2004-09-07|2004-09-08|Estimate|||||||2012-07-13|2012-07-16|Estimate|May 2004||2004-05-31|July 2012|2012-07-31||||July 2008|Actual|2008-07-31||Interventional|||Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa™) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 3|598|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:03:43.801657|2018-06-01 05:03:43.801657
NCT00091143|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-04-02|2004-09-07|2004-09-08|Estimate|||||||2013-04-02|2013-04-04|Estimate|July 2004||2004-07-31|August 2009|2009-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma|A Pilot Trial of Therapeutic Vaccination With a Modified gp100 Melanoma Peptide (gp100:209-217(210M)), Montanide ISA 51, and KLH With Reconstitution After Chemotherapy to Induce Lymphopenia in Patients With Metastatic Melanoma|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:43.996034|2018-06-01 05:03:43.996034
NCT00091130|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-05-31|2004-09-07|2004-09-08|Estimate|||||||2013-05-31|2013-06-03|Estimate|September 2004||2004-09-30|March 2013|2013-03-31||||June 2007|Actual|2007-06-30||Interventional|||SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells|An Exploratory Study to Evaluate the Effect of HPV 16 Vaccine on the Reduction of Viral Load in HPV 16 Positive Women With Persistent Viral Infection, But Low Grade Disease (ASCUS/LSIL)|Completed||Phase 2|139|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:03:44.061335|2018-06-01 05:03:44.061335
NCT00091117|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-12-13|2004-09-07|2004-09-08|Estimate|||||||2013-12-13|2013-12-16|Estimate|July 2004||2004-07-31|December 2013|2013-12-31||||March 2013|Actual|2013-03-31||Interventional|||Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction|A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEPSponsored Organ Dysfunction Working Group|Completed||Phase 1|80|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:03:44.22514|2018-06-01 05:03:44.22514
NCT00091104|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2012-03-14|2004-09-07|2004-09-08|Estimate|||||||2012-03-14|2012-03-15|Estimate|July 2004||2004-07-31|March 2012|2012-03-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma|A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes and Subsequent Peptide Immunization|Completed||Phase 1|136|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:03:44.332161|2018-06-01 05:03:44.332161
NCT00091091|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2017-02-13|2004-09-07|2004-09-08|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2004||2004-12-31|February 2017|2017-02-28||||June 27, 2011|Actual|2011-06-27||Observational|||Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma|Health-Related Outcomes For Hodgkin's Disease Survivors|Completed|||530|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 05:03:44.471139|2018-06-01 05:03:44.471139
NCT00091078|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-06-04|2004-09-07|2004-09-08|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2005||2005-09-30|June 2013|2013-06-30||||July 2006|Actual|2006-07-31||Interventional|||Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery|A Phase IIA Study to Determine the Safety and Efficacy of A NCI-Supplied Agent: G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients With Refractory or Relapsed Gastrointestinal Stromal Tumor|Terminated||Phase 2|96|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:03:44.586082|2018-06-01 05:03:44.586082
NCT00091052|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-03-25|2004-09-07|2004-09-08|Estimate|||||||2013-03-25|2013-03-26|Estimate|July 2004||2004-07-31|May 2006|2006-05-31|June 2006|Actual|2006-06-30|||||Interventional|||Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors|Contrast-Enhanced Radiotherapy With GM-CSF Immune Stimulation - Phase I/II Clinical Center Treatment Trial|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:44.67847|2018-06-01 05:03:44.67847
NCT00091039|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-06-18|2004-09-07|2004-09-08|Estimate|||||||2013-06-18|2013-06-20|Estimate|August 2004||2004-08-31|December 2005|2005-12-31|February 2006|Actual|2006-02-28|||||Interventional|||Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery|A Pilot Trial of a CEA/TRICOM-Based Vaccine in Combination With Combined Chemotherapy/Radiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)|Completed||N/A|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:03:44.767396|2018-06-01 05:03:44.767396
NCT00091026|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2013-08-06||2014-04-28|2004-09-07|2004-09-08|Estimate|2013-09-17|2013-11-20|Estimate||||2014-04-28|2014-05-15|Estimate|July 2004||2004-07-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||Four patients who never received treatment are excluded.|Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer|A Randomized Phase II Study of Bevacizumab (NSC# 704865) and Gemcitabine in Combination With Either Cetuximab (NSC# 714692) or OSI-774 (NSC# 718781) in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|143|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:03:44.856966|2018-06-01 05:03:44.856966
NCT00090987|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2011-05-25||2018-02-05|2004-09-07|2004-09-08|Estimate|2011-06-24|2011-07-26|Estimate||||2018-02-05|2018-03-06|Actual|June 2005||2005-06-30|January 2018|2018-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma|Completed||Phase 2|30|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 05:03:45.354961|2018-06-01 05:03:45.354961
NCT00090974|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2009-08-19|2004-09-07|2004-09-08|Estimate|||||||2009-08-19|2009-08-20|Estimate|December 2004||2004-12-31|January 2006|2006-01-31||||||||Observational|||Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer|Quality Of Life Companion Study For JMA27 (NCIC-MA.27): A Randomized Phase III Trial Of Exemestane Versus Anastrozole With Or Without Celecoxib In Postmenopausal Women With Receptor Positive Primary Breast Cancer|Unknown status|Active, not recruiting||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:45.659608|2018-06-01 05:03:45.659608
NCT00090961|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2012-10-31|2004-09-07|2004-09-08|Estimate|||||||2012-10-31|2012-11-01|Estimate|September 2004||2004-09-30|October 2012|2012-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer|A Randomized Trial Assessing the Effects of Exercise on Patients With Locally Advanced Lung Cancer Undergoing Curative Intent Combined Modality Therapy|Terminated||N/A|2|Actual|Southwest Oncology Group||2||Closed early due to poor accrual.|f||||f||||||||||2018-06-01 05:03:46.10849|2018-06-01 05:03:46.10849
NCT00090909|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2013-01-07|2004-09-07|2004-09-08|Estimate|||||||2013-01-07|2013-01-08|Estimate|June 2003||2003-06-30|January 2013|2013-01-31||||March 2005|Actual|2005-03-31||Interventional|||Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study Of Gemcitabine, Cisplatin, and Dexamethasone In Patients With Relapsed Or Refractory Hodgkin Lymphoma|Completed||Phase 2|1|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:03:46.285776|2018-06-01 05:03:46.285776
NCT00090896|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2015-10-28|2004-09-07|2004-09-08|Estimate|||||||2015-10-28|2015-10-30|Estimate|April 2004||2004-04-30|August 2012|2012-08-31|October 2009|Actual|2009-10-31|July 2008|Actual|2008-07-31||Interventional|||CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery|A Phase I, Open Label, Study To Evaluate The Safety And Immune Function Effects Of CP-675,206 In Combination With MART-1 Peptide-Pulsed Dendritic Cells In Patients With Advanced Melanoma|Completed||Phase 1|18|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:03:46.362342|2018-06-01 05:03:46.362342
NCT00090870|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|||2012-04-26|2004-09-07|2004-09-08|Estimate|||||||2012-04-26|2012-04-30|Estimate|April 2002||2002-04-30|April 2012|2012-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Of Peg-Intron, GM-CSF And Thalidomide In Metastatic Renal Cell Carcinoma|Completed||Phase 2|25|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 05:03:46.440291|2018-06-01 05:03:46.440291
NCT00003170|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-13|2004-09-03|2004-09-06|Estimate|||||||2016-07-13|2016-07-14|Estimate|February 1998||1998-02-28|July 2016|2016-07-31|June 2003|Actual|2003-06-30|May 2003|Actual|2003-05-31||Interventional|||Glutamine in Preventing Acute Diarrhea in Patients With Pelvic Cancer|Phase III Double-Blind Study of Glutamine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy|Completed||Phase 3|129|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:03:52.377352|2018-06-01 05:03:52.377352
NCT00090857|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2017-01-18||2018-03-05|2004-09-07|2004-09-08|Estimate|2017-05-29|2017-06-29|Actual||||2018-03-05|2018-03-30|Actual|February 2002|Actual|2002-02-28|March 2018|2018-03-31|March 2013|Actual|2013-03-31|August 2008|Actual|2008-08-31||Interventional|WISE||Letrozole in Preventing Breast Cancer in Postmenopausal Women|A Pilot Study of Aromatase Inhibitors for Women at Increased Risk of Breast Cancer Based on Estradiol Levels|Completed||Phase 2|49|Actual|Dana-Farber Cancer Institute|Results on this study are limited due to the age of the trial and the prior departure of the coordinator who assisted with the data collection. The accrual goal was not met with many participants eligible upon screening declining randomization.|2|||f||||t||||||||No||2018-06-01 05:03:46.545924|2018-06-01 05:03:46.545924
NCT00090844|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-07|2012-11-30||2013-01-23|2004-09-07|2004-09-08|Estimate|2012-12-14|2013-01-21|Estimate||||2013-01-23|2013-01-31|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer|Preservation of Ovarian Function in Young Women Treated With (Neo) Adjuvant Chemotherapy for Breast Cancer: A Randomized Trial Using the Gonadotropin-releasing Hormone (GnRH) Agonist (Triptorelin) During Chemotherapy|Terminated||Phase 2|49|Actual|University of South Florida|Study closed to accrual early due to futility|2||Early closure due to low accrual|f||||t||||||||||2018-06-01 05:03:47.063662|2018-06-01 05:03:47.063662
NCT00090831|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-03|||2018-05-23|2004-09-03|2004-09-06|Estimate|||||||2018-05-23|2018-05-24|Actual|August 31, 2004||2004-08-31|September 17, 2012|2012-09-17|September 17, 2012||2012-09-17|||||Observational|||Investigating the Role of Serotonin in Emotional Processing Through the Use of Tryptophan Depletion|Investigating the Role of Serotonin in Emotional Processing Through the Use of Tryptophan Depletion|Completed|||91|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:03:47.513416|2018-06-01 05:03:47.513416
NCT00090818|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-03|||2017-06-30|2004-09-03|2004-09-06|Estimate|||||||2017-06-30|2017-07-02|Actual|September 1, 2004||2004-09-01|October 28, 2010|2010-10-28|October 28, 2010||2010-10-28|||||Observational|||Clinical Research Core Dental Screening Protocol|Clinical Research Core Dental Screening Protocol|Completed|||441|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:03:47.562121|2018-06-01 05:03:47.562121
NCT00090779|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-03|2012-07-02||2012-11-16|2004-09-03|2004-09-06|Estimate|2012-11-16|2012-12-18|Estimate||||2012-11-16|2012-12-18|Estimate|January 2005||2005-01-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|July 2009|Actual|2009-07-31||Interventional|||Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV|The SETPOINT Study - A Randomized Study of the Effect of Immediate Treatment With Potent Antiretroviral Therapy Versus Observation With Treatment as Indicated in Newly Infected HIV-1 Infected Subjects: Does Early Therapy After the Virologic Setpoint?|Terminated||Phase 2|130|Actual|AIDS Clinical Trials Group||2||"The DSMB concluded that the findings regarding the primary analysis would persist and that no~   additional study goals would be achieved by continuing the study."|f||||t||||||||||2018-06-01 05:03:47.655989|2018-06-01 05:03:47.655989
NCT00090766|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-03|2016-06-24||2016-09-14|2004-09-03|2004-09-06|Estimate|2016-09-14|2016-10-31|Estimate||||2016-09-14|2016-10-31|Estimate|May 2004||2004-05-31|March 2016|2016-03-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional||Safety population included all participants who received at least one dose of valganciclovir|A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients|Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients|Completed||Phase 2/Phase 3|63|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 05:03:48.399187|2018-06-01 05:03:48.399187
NCT00090753|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-03|2011-12-01||2012-02-10|2004-09-03|2004-09-06|Estimate|2011-12-01|2012-01-05|Estimate||||2012-02-10|2012-02-14|Estimate|October 2004||2004-10-31|February 2012|2012-02-29|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia|An Open-label, Multi-center Study to Document the Efficacy, Safety, and Tolerability of Long-term Administration of RO0503821 in Patients With Chronic Renal Anemia|Completed||Phase 3|1228|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:03:49.55226|2018-06-01 05:03:49.55226
NCT00090740|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-03|||2013-01-23|2004-09-03|2004-09-06|Estimate|||||||2013-01-23|2013-01-25|Estimate|September 2004||2004-09-30|January 2013|2013-01-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Observational|||Genetic Risk Factors for Severe Asthma|Genetic Risk Factors for Severe Asthma|Completed|||600|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     40 mL blood~   "|||2018-06-01 05:03:51.790282|2018-06-01 05:03:51.790282
NCT00090727|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-02|||2006-10-31|2004-09-03|2004-09-06|Estimate|||||||2006-10-31|2006-11-02|Estimate|August 2004||2004-08-31|April 2005|2005-04-30||||||||Interventional|||Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies|Unknown status|Active, not recruiting|Phase 1|45||Novacea|||||||||||||||||||2018-06-01 05:03:51.849126|2018-06-01 05:03:51.849126
NCT00090714|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-02|||2006-04-18|2004-09-03|2004-09-06|Estimate|||||||2006-04-18|2006-04-20|Estimate|August 2004||2004-08-31|April 2006|2006-04-30||||||||Interventional|||To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter||Unknown status|Active, not recruiting|Phase 2|404||Corautus Genetics|||||||||||||||||||2018-06-01 05:03:51.902984|2018-06-01 05:03:51.902984
NCT00090701|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-02|||2012-05-09|2004-09-03|2004-09-06|Estimate|||||||2012-05-09|2012-05-10|Estimate|September 2004||2004-09-30|May 2012|2012-05-31||||||||Interventional|||A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer|A Phase 2, Open-Label, Multicenter Study Of The GARFT Inhibitor AG2037 In Patients With MetastatIC Non Small Cell Lung Cancer Who Failed Two Or Three Prior Treatments|Withdrawn||Phase 2|0|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:03:51.979243|2018-06-01 05:03:51.979243
NCT00003217|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2004-09-03|2004-09-06|Estimate|||||||2014-07-23|2014-07-25|Estimate|March 1998||1998-03-31|July 2014|2014-07-31|September 2006|Actual|2006-09-30|October 2004|Actual|2004-10-31||Interventional|||Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia|A Pilot Study of Dose Intensification of Methotrexate and Cyclophosphamide in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Non-Hodgkins Lymphoma and B-Cell All- A Limited Institution Phase III Pilot Study|Completed||Phase 1|20|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:03:52.095004|2018-06-01 05:03:52.095004
NCT00003172|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-09-03|2004-09-06|Estimate|||||||2013-06-20|2013-06-21|Estimate|December 1997||1997-12-31|September 2002|2002-09-30|September 2004|Actual|2004-09-30|||||Interventional|||Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer|Randomized Phase II Trial of Either 5-Fluorouracil, Recombinant Alfa-2a-Interferon and Intravenous Hydroxyurea With Filgrastim Support (FHIG) or Doxorubicin/Docetaxel (Dd) in Patients With Advanced Gastric Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:52.226216|2018-06-01 05:03:52.226216
NCT00003139|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-11-14|2004-09-03|2004-09-06|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 1998||1998-03-31|November 2015|2015-11-30|October 2002|Actual|2002-10-31|January 2001|Actual|2001-01-31||Interventional|||Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer|A Phase III Study to Test the Efficacy of the Prophylactic Use of Oral Pilocarpine to Reduce Hyposalivation and Mucositis Associated With Curative Radiation Therapy in Head and Neck Cancer Patients|Completed||Phase 3|249|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:03:52.491315|2018-06-01 05:03:52.491315
NCT00003134|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-05|2004-09-03|2004-09-06|Estimate|||||||2016-12-05|2016-12-07|Estimate|January 1998||1998-01-31|December 2016|2016-12-31|January 2009|Actual|2009-01-31|October 2001|Actual|2001-10-31||Interventional|||Irinotecan in Treating Patients With Recurrent Glioma|A Phase II Trial of Irinotecan in Recurrent Glioma|Completed||Phase 2|64|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:03:53.156203|2018-06-01 05:03:53.156203
NCT00003100|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-09-03|2004-09-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1996||1996-10-31|June 2000|2000-06-30||||||||Interventional|||Dietary Soy Isoflavones for the Prevention of Cancer|Metabolic Fate and Plasma Kinetics of Dietary Soy Isoflavones|Unknown status|Active, not recruiting|N/A|90|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:53.256328|2018-06-01 05:03:53.256328
NCT00003088|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-09-03|2004-09-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|September 1997||1997-09-30|July 2016|2016-07-31|June 2003|Actual|2003-06-30|April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Breast Cancer|A Randomized Phase III Trial of Sequential Chemotherapy Using Doxorubicin, Paclitaxel, and Cyclophosphamide or Concurrent Doxorubicin and Cyclophosphamide Followed by Paclitaxel at 14 or 21 Day Intervals in Women With Node Positive Stage II/IIIA Breast Cancer|Completed||Phase 3|2005|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-06-01 05:03:53.313103|2018-06-01 05:03:53.313103
NCT00003072|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-19|2004-09-03|2004-09-06|Estimate|||||||2012-09-19|2012-09-21|Estimate|May 1997||1997-05-31|September 2012|2012-09-30|October 1998|Actual|1998-10-31|October 1998|Actual|1998-10-31||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer|Amifostine (Ethyol) as a Protectant in Metastatic Ovarian and Non-Small Cell Lung Cancer in Paclitaxel/Carboplatin-Treated Patients: A Comparative Trial|Completed||Phase 2|80|Anticipated|University of California, San Francisco|||||f||||||||||||||2018-06-01 05:03:53.484868|2018-06-01 05:03:53.484868
NCT00003048|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-09-03|2004-09-06|Estimate|||||||2012-07-27|2012-07-30|Estimate|May 1997||1997-05-31|July 2012|2012-07-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Amifostine in Treating Patients With Myelodysplastic Syndrome|Phase II Study of Intravenous Amifostine in Myelodysplastic Syndrome|Completed||Phase 2|12|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:03:53.554432|2018-06-01 05:03:53.554432
NCT00003039|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-09-03|2004-09-06|Estimate|||||||2013-02-04|2013-02-05|Estimate|September 1997||1997-09-30|April 2000|2000-04-30||||April 2000|Actual|2000-04-30||Interventional|||Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma|A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients With Previously Treated Intermediate and High Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:03:53.645415|2018-06-01 05:03:53.645415
NCT00090688|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-02|||2016-12-27|2004-09-02|2004-09-03|Estimate|||||||2016-12-27|2016-12-28|Estimate|August 2004||2004-08-31|January 2006|2006-01-31||||||||Interventional|||Phase 1 meCS6 + LT(R192G) Vaccine Study|Safety and Immunogenicity of Oral Microencapsulated CS6 Vaccine and LT(R192G) Adjuvant in Volunteers|Withdrawn||Phase 1|0|Actual|U.S. Army Medical Research and Materiel Command||||IND was terminated for being inactive for more than five years|||||||||||||||2018-06-01 05:03:53.750733|2018-06-01 05:03:53.750733
NCT00090675|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-02|||2013-01-28|2004-09-02|2004-09-03|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|November 2007|Anticipated|2007-11-30|November 2007|Anticipated|2007-11-30||Interventional|IMAC/Herbst||Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase IIIb Randomized, Double-Blind Study Comparing Maintenance ZD1839 (IRESSA®) or Placebo Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer|Withdrawn||Phase 3|0|Actual|AstraZeneca||||No patients randomised|||||||||||||||2018-06-01 05:03:53.830592|2018-06-01 05:03:53.830592
NCT00003005|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-12|2004-09-02|2004-09-03|Estimate|||||||2012-06-12|2012-06-13|Estimate|December 1997||1997-12-31|June 2000|2000-06-30|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia|A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia|Completed||Phase 1|14|Actual|Boston Medical Center||1|||f||||t||||||||||2018-06-01 05:03:53.930612|2018-06-01 05:03:53.930612
NCT00002993|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-08|2004-09-02|2004-09-03|Estimate|||||||2013-07-08|2013-07-09|Estimate|August 1997||1997-08-31|May 2006|2006-05-31||||January 2000|Actual|2000-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus|Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas|Terminated||Phase 2|30|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:03:54.072122|2018-06-01 05:03:54.072122
NCT00002980|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-13|2004-09-02|2004-09-03|Estimate|||||||2013-02-13|2013-02-15|Estimate|May 1997||1997-05-31|May 2007|2007-05-31||||||||Interventional|||Decitabine in Treating Patients With Melanoma or Other Advanced Cancer|A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:54.189693|2018-06-01 05:03:54.189693
NCT00002967|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-09-02|2004-09-03|Estimate|||||||2013-06-20|2013-06-21|Estimate|May 1997||1997-05-31|June 2012|2012-06-30|March 2006|Actual|2006-03-31|||||Interventional|||Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer|A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients With Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:54.403212|2018-06-01 05:03:54.403212
NCT00002946|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-09-02|2004-09-03|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 1997||1997-10-31|January 2013|2013-01-31||||April 2002|Actual|2002-04-30||Interventional|||Penclomedine in Treating Patients With Solid Tumors or Lymphoma|A Phase I Trial of Oral Penclomedine|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:03:54.7503|2018-06-01 05:03:54.7503
NCT00002942|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-18|2004-09-02|2004-09-03|Estimate|||||||2017-01-18|2017-01-19|Estimate|June 1996||1996-06-30|July 2012|2012-07-31|December 2003|Actual|2003-12-31|January 2000|Actual|2000-01-31||Interventional|||Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer|Randomized Phase III Trial of G-CSF Primed Autologous Bone Marrow Versus Peripheral Blood Progenitor Cells (PBPC) as Hematopoietic Support for High-Dose Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Therapy in Poor Prognosis Breast Cancer|Completed||Phase 3|136|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-06-01 05:03:54.873455|2018-06-01 05:03:54.873455
NCT00002937|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-04|2004-09-02|2004-09-03|Estimate|||||||2010-01-04|2010-01-06|Estimate|June 1996||1996-06-30|January 2010|2010-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer|A Phase II Randomized Study of Paclitaxel Versus Paclitaxel + PSC833 for Advanced Breast Cancer (Recurring Less Than 6 Months Since Adjuvant or as Second Line for Advanced Disease|Completed||Phase 2|70|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:03:54.967876|2018-06-01 05:03:54.967876
NCT00002932|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-11-19|2004-09-02|2004-09-03|Estimate|||||||2014-11-19|2014-11-21|Estimate|May 1997||1997-05-31|November 2014|2014-11-30|March 2005|Actual|2005-03-31|March 2001|Actual|2001-03-31||Interventional|||Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck|Phase II Multi-Institutional Trial of Targeted Supradose Cisplatin Chemoradiation for Stage IV Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|60|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:03:55.105462|2018-06-01 05:03:55.105462
NCT00002904|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-09-02|2004-09-03|Estimate|||||||2012-06-29|2012-07-02|Estimate|February 1996||1996-02-29|June 2012|2012-06-30||||||||Interventional|||Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors|PHASE I CLINICAL AND PHARMACOKINETIC STUDY TO DETERMINE THE SAFETY OF ECTEINASCIDIN-743 (ET-743) ADMINISTERED AS A SINGLE INTRAVENOUS INFUSION OVER 60 MINUTES EVERY 21 DAYS IN PATIENTS WITH SOLID TUMORS|Completed||Phase 1|40|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:03:55.223347|2018-06-01 05:03:55.223347
NCT00002897|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-09-02|2004-09-03|Estimate|||||||2013-09-19|2013-09-20|Estimate|July 1992||1992-07-31|May 2007|2007-05-31|June 2001|Actual|2001-06-30|||||Interventional|||Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus|RANDOMIZED STUDY OF PREOPERATIVE CHEMOTHERAPY VERSUS SURGERY ALONE IN ESOPHAGUS CANCER|Completed||Phase 3|240|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:55.350774|2018-06-01 05:03:55.350774
NCT00090662|ClinicalTrials.gov processed this data on May 31, 2018|2004-09-01|||2018-03-27|2004-09-01|2004-09-02|Estimate|||||||2018-03-27|2018-03-29|Actual|August 31, 2004||2004-08-31|November 17, 2017|2017-11-17||||||||Observational|||Collection of Peripheral Blood and Bone Marrow From Healthy Donors for Use in In Vitro Research|Collection of Peripheral Blood, Urine, Sputum, and Bone Marrow From Healthy Donors for Use in In Vitro Research|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:03:55.430513|2018-06-01 05:03:55.430513
NCT00002873|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2004-09-01|2004-09-02|Estimate|||||||2013-07-17|2013-07-19|Estimate|May 1997||1997-05-31|February 2008|2008-02-29||||June 2007|Actual|2007-06-30||Interventional|||Radiation Therapy in Treating Women With Stage I or Stage II Breast Cancer|A PHASE I/II TRIAL TO EVALUATE BRACHYTHERAPY AS THE SOLE METHOD OF RADIATION THERAPY FOR STAGE I AND II BREAST CARCINOMA|Completed||Phase 1/Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:03:55.593266|2018-06-01 05:03:55.593266
NCT00002872|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-28|2004-09-01|2004-09-02|Estimate|||||||2013-08-28|2013-08-29|Estimate|November 1996||1996-11-30|August 2013|2013-08-31||||February 2003|Actual|2003-02-28||Interventional|||Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions|A PROSPECTIVE RANDOMIZED TRIAL OF BLEOMYCIN VS. DOXYCYCLINE VS. TALC FOR THE INTRAPLEURAL TREATMENT OF MALIGNANT PLEURAL EFFUSIONS|Completed||Phase 3|480|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:03:55.92105|2018-06-01 05:03:55.92105
NCT00002811|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-09-01|2004-09-02|Estimate|||||||2013-11-05|2013-11-06|Estimate|July 1996||1996-07-31|May 2007|2007-05-31||||||||Interventional|||T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum|A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES|Unknown status|Active, not recruiting|Phase 3|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:55.996285|2018-06-01 05:03:55.996285
NCT00002805|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2004-09-01|2004-09-02|Estimate|||||||2014-07-23|2014-07-24|Estimate|August 1997||1997-08-31|July 2014|2014-07-31|June 2008|Actual|2008-06-30|May 2001|Actual|2001-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|Acute Myeloid Leukemia Salvage Therapy for Patients in First Relapse or Who Fail to Achieve an Initial Remission or Who Develop AML as a Second Malignant Neoplasm|Completed||Phase 2|115|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:03:56.059582|2018-06-01 05:03:56.059582
NCT00002793|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-09-01|2004-09-02|Estimate|||||||2013-09-16|2013-09-17|Estimate|January 1991||1991-01-31|May 2007|2007-05-31||||||||Interventional|||Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer|PALLIATIVE LOCAL CHEMOTHERAPY FOR NON-RESECTABLE LIVER METASTASES FROM COLORECTAL CARCINOMA, A RANDOMISED PHASE III STUDY|Unknown status|Active, not recruiting|Phase 3|336|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:56.363578|2018-06-01 05:03:56.363578
NCT00002791|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-23|2004-09-01|2004-09-02|Estimate|||||||2014-01-23|2014-01-24|Estimate|February 1997||1997-02-28|January 2014|2014-01-31|November 2013|Actual|2013-11-30|May 2002|Actual|2002-05-31||Interventional|||Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma|A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY AND RADIATION THERAPY IN THE MANAGEMENT OF HIGH-RISK, HIGH-GRADE, SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND BODY WALL|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:03:56.500965|2018-06-01 05:03:56.500965
NCT00002790|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-03-04|2004-09-01|2004-09-02|Estimate|||||||2015-03-04|2015-03-06|Estimate|March 1996||1996-03-31|March 2015|2015-03-31||||||||Interventional|||Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant|A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS) IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FROM RELATED DONORS MISMATCHED FOR ONE HLA ANTIGEN IN THE DIRECTION OF GRAFT-VERSUS-HOST DISEASE (GVHD)|Withdrawn||Phase 1/Phase 2|0|Actual|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:03:57.028136|2018-06-01 05:03:57.028136
NCT00002781|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-09-01|2004-09-02|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 1996||1996-04-30|April 2000|2000-04-30||||||||Interventional|||Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma|PROCEDURES FOR BNCT PHASE-I STUDY OF MELANOMA IN THE EXTREMITIES|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:57.096141|2018-06-01 05:03:57.096141
NCT00002775|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-09-01|2004-09-02|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 1998||1998-02-28|April 2000|2000-04-30||||||||Interventional|||Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|PHASE I/II STUDY OF DOCETAXEL (TAXOTERE) AND ESTRAMUSTINE COMBINATION CHEMOTHERAPY IN PATIENTS WITH PROSTATE CANCER|Unknown status|Active, not recruiting|Phase 1/Phase 2|37|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:57.158369|2018-06-01 05:03:57.158369
NCT00002767|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-09-01|2004-09-02|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 1996||1996-01-31|May 2007|2007-05-31||||||||Interventional|||Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma|PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:57.227169|2018-06-01 05:03:57.227169
NCT00090649|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-31|||2009-08-18|2004-08-31|2004-09-01|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Of DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|369|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:03:57.305729|2018-06-01 05:03:57.305729
NCT00090623|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-30|||2013-06-19|2004-08-31|2004-09-01|Estimate|||||||2013-06-19|2013-06-21|Estimate|August 2004||2004-08-31|June 2013|2013-06-30|March 2007|Actual|2007-03-31|||||Interventional|||A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)|A Phase IIIb, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization (CNV) With or Without Classic CNV Secondary to Age Related Macular Degeneration|Completed||Phase 3|180||Genentech, Inc.|||||||||||||||||||2018-06-01 05:03:57.348801|2018-06-01 05:03:57.348801
NCT00002744|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-02-07|2004-08-31|2004-09-01|Estimate|||||||2017-02-07|2017-02-09|Estimate|May 1996||1996-05-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia|Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia|Completed||Phase 3|1970|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:03:57.41274|2018-06-01 05:03:57.41274
NCT00002735|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-09-28|2004-08-31|2004-09-01|Estimate|||||||2015-09-28|2015-09-30|Estimate|April 1996||1996-04-30|September 2015|2015-09-30|March 2005|Actual|2005-03-31|April 2004|Actual|2004-04-30||Interventional|||SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue|Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II|Terminated||Phase 2|68|Actual|Southwest Oncology Group||1||Terminated due to poor accrual.|f||||t||||||||||2018-06-01 05:03:57.694406|2018-06-01 05:03:57.694406
NCT00002730|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-30|2004-08-31|2004-09-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 1996||1996-06-30|January 2017|2017-01-31||||||||Interventional|||Chemotherapy in Treating Children With Neuroblastoma|PILOT STUDY OF BUTHIONINE SULFOXIMINE (BSO) IN COMBINATION WITH MELPHALAN FOR HIGH RISK NEUROBLASTOMA PATIENTS|Completed||Phase 1|||Children's Hospital Los Angeles|||||f||||||||||||||2018-06-01 05:03:57.808502|2018-06-01 05:03:57.808502
NCT00002703|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-08-31|2004-09-01|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 1996||1996-01-31|April 2012|2012-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer|A PHASE III TRIAL EMPLOYING CONFORMAL PHOTONS WITH PROTON BOOST IN EARLY STAGE PROSTATE CANCER: CONVENTIONAL DOSE COMPARED TO HIGH DOSE IRRADIATION|Completed||Phase 3|390|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:03:57.868727|2018-06-01 05:03:57.868727
NCT00090610|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-27|2012-11-21||2015-02-05|2004-08-30|2004-08-31|Estimate|2012-12-31|2013-02-04|Estimate||||2015-02-05|2015-02-25|Estimate|October 2003||2003-10-31|December 2012|2012-12-31|October 2009|Actual|2009-10-31|March 2009|Actual|2009-03-31||Interventional|||Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer|Multicenter, Randomized, Phase II Comparative Study to Compare Efficacy & Safety of Taxotere®/Carboplatin Combination Therapy vs Sequential Therapy w/ Taxotere® Then Carboplatin as Second-line Treatment of Patients w/ Relapsed, Platinum-sensitive Ovarian Cancer|Completed||Phase 2|150|Actual|Duke University||2|||f||||t||||||||||2018-06-01 05:03:57.977167|2018-06-01 05:03:57.977167
NCT00090584|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-27|2012-08-27||2013-05-08|2004-08-30|2004-08-31|Estimate|2013-05-08|2013-06-17|Estimate||||2013-05-08|2013-06-17|Estimate|August 2004||2004-08-31|May 2013|2013-05-31|August 2006|Actual|2006-08-31|December 2005|Actual|2005-12-31||Interventional|BE-DRI||Behavior Enhances Drug Reduction of Incontinence (BE-DRI)|Behavior Enhances Drug Reduction of Incontinence|Completed||N/A|307|Actual|New England Research Institutes|Ony 68% of participants completed assigned treatment.|2|||f||||t||||||||||2018-06-01 05:03:58.31516|2018-06-01 05:03:58.31516
NCT00090532|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2011-05-26|2004-08-30|2004-08-31|Estimate|||||||2011-05-26|2011-05-27|Estimate|January 2004||2004-01-31|May 2011|2011-05-31|August 2006|Actual|2006-08-31|||||Interventional|||A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration|A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety an Efficacy of AG-013958 in Subjects With Subfoveal Choroidal Neovascularization Associated With Age-related Macular Degeneration|Terminated||Phase 1/Phase 2|155||Pfizer||||This study was terminated due to a lack of efficacy.|||||||||||||||2018-06-01 05:03:58.71059|2018-06-01 05:03:58.71059
NCT00090519|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|2015-12-22|2011-02-25|2016-08-25|2004-08-30|2004-08-31|Estimate|2016-05-13|2016-05-16|Estimate|2011-02-25|2011-03-11|Estimate|2016-08-25|2016-10-06|Estimate|February 2004||2004-02-29|August 2016|2016-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Reduction in the Occurrence of Center-Involved Diabetic Macular Edema|Reduction in the Occurrence of Center-Involved Diabetic Macular Edema|Completed||Phase 3|731|Actual|Chromaderm, Inc.||2|||f||||f||||||||||2018-06-01 05:03:59.835511|2018-06-01 05:03:59.835511
NCT00090493|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|2013-01-25||2013-05-16|2004-08-30|2004-08-31|Estimate|2013-05-16|2013-06-24|Estimate||||2013-05-16|2013-06-24|Estimate|June 2004||2004-06-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|July 2007|Actual|2007-07-31||Interventional|||Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma|UARK 2003-26, A Pilot Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combination With DTPACE Chemotherapy and Autologous Transplantation in Multiple Myeloma|Completed||Phase 2/Phase 3|4|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 05:04:01.248125|2018-06-01 05:04:01.248125
NCT00090441|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2013-01-03|2004-08-27|2004-08-30|Estimate|||||||2013-01-03|2013-01-04|Estimate|August 2004||2004-08-31|December 2012|2012-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Risk Burden of Lipoprotein Metabolic Gene Haplotypes||Completed|||4303|Actual|Intermountain Health Care, Inc.|||||f||||f||||||||||2018-06-01 05:04:03.272533|2018-06-01 05:04:03.272533
NCT00090480|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2009-06-30|2004-08-30|2004-08-31|Estimate|||||||2009-06-30|2009-07-02|Estimate|August 2004||2004-08-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Vaccine Treatment for Advanced Breast Cancer|A Phase I/II Study of an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Relapsed or Refractory Breast Cancer|Terminated||Phase 1/Phase 2|3|Actual|NewLink Genetics Corporation||1||Enrollment goals unable to be reached.|f||||f||||||||||2018-06-01 05:04:01.39203|2018-06-01 05:04:01.39203
NCT00002659|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-08-30|2004-08-31|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 1995||1995-05-31|May 2007|2007-05-31||||||||Interventional|||Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer|A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:01.472251|2018-06-01 05:04:01.472251
NCT00002631|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-18|2004-08-30|2004-08-31|Estimate|||||||2013-11-18|2013-11-19|Estimate|June 1995||1995-06-30|November 2013|2013-11-30||||September 1999|Actual|1999-09-30||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus|A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY|Completed||Phase 3|298|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:04:01.661411|2018-06-01 05:04:01.661411
NCT00002628|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-09|2004-08-30|2004-08-31|Estimate|||||||2014-01-09|2014-01-10|Estimate|November 1994||1994-11-30|April 2000|2000-04-30||||||||Interventional|||Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer|PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO THE HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH BREAST CANCER|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:01.763581|2018-06-01 05:04:01.763581
NCT00002622|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-27|2004-08-30|2004-08-31|Estimate|||||||2016-06-27|2016-06-28|Estimate|December 1994||1994-12-31|June 2016|2016-06-30|January 2006|Actual|2006-01-31|March 2005|Actual|2005-03-31||Interventional|||Talc in Treating Patients With Malignant Pleural Effusion|Sclerosis of Pleural Effusions by Talc Thoracoscopy Versus Talc Slurry: A Phase III Study|Completed||Phase 3|501|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:04:01.893629|2018-06-01 05:04:01.893629
NCT00002616|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-08-30|2004-08-31|Estimate|||||||2013-09-19|2013-09-20|Estimate|February 1995||1995-02-28|September 2000|2000-09-30||||||||Interventional|||Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer|A PILOT TRIAL OF INTERLEUKIN-2 WITH G-CSF AS PRIMING THERAPY FOR PERIPHERAL BLOOD STEM CELL HARVESTING IN PATIENTS WITH ADVANCED BREAST CANCER: STAMP V HIGH DOSE CHEMOTHERAPY, STEM CELL INFUSION AND POST-INFUSION G-CSF AND INTERLEUKIN-2|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:02.356138|2018-06-01 05:04:02.356138
NCT00002593|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-02|2004-08-30|2004-08-31|Estimate|||||||2013-01-02|2013-01-03|Estimate|December 1994||1994-12-31|January 2013|2013-01-31|March 2005|Actual|2005-03-31|December 1999|Actual|1999-12-31||Interventional|||S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed|Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer|Completed||Phase 3|1135|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:04:02.432399|2018-06-01 05:04:02.432399
NCT00002570|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-11-25|2004-08-30|2004-08-31|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 1994||1994-07-31|September 2011|2011-09-30|February 2009|Actual|2009-02-28|November 2000|Actual|2000-11-30||Interventional|||Immediate Compared With Delayed Chemotherapy in Treating Patients With Advanced Colorectal Cancer Without Signs or Symptoms of Disease|A PHASE III STUDY OF IMMEDIATE VERSUS DELAYED CHEMOTHERAPY FOR ASYMPTOMATIC ADVANCED COLORECTAL CANCER|Completed||Phase 3|67|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:04:02.667674|2018-06-01 05:04:02.667674
NCT00002554|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-29|2004-08-30|2004-08-31|Estimate|||||||2010-03-29|2010-03-30|Estimate|November 1993||1993-11-30|March 2010|2010-03-31|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse|RADIOLABELED BC8 (ANTI-CD45) ANTIBODY COMBINED WITH BUSULFAN AND CYCLOPHOSPHAMIDE AS TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA IN FIRST OR SECOND REMISSION OR UNTREATED FIRST RELAPSE FOLLOWED BY HLA-IDENTICAL RELATED MARROW TRANSPLANTATION|Completed||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:04:02.805386|2018-06-01 05:04:02.805386
NCT00002527|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-08-30|2004-08-31|Estimate|||||||2016-07-01|2016-07-04|Estimate|May 1993||1993-05-31|July 2016|2016-07-31|January 2006|Actual|2006-01-31|March 2003|Actual|2003-03-31||Interventional|||Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed|Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study|Completed||Phase 3|635|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:04:02.895741|2018-06-01 05:04:02.895741
NCT00002509|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-30|2004-08-30|2004-08-31|Estimate|||||||2010-09-30|2010-10-01|Estimate|November 1991||1991-11-30|September 2010|2010-09-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer|HIGH-DOSE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CARBOPLATIN FOLLOWED BY RESCUE WITH AUTOLOGOUS BONE MARROW AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH POOR PROGNOSIS BREAST CANCER|Completed||Phase 1/Phase 2|||Temple University|||||f||||||||||||||2018-06-01 05:04:03.058056|2018-06-01 05:04:03.058056
NCT00090571|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-27|||2009-06-05|2004-08-27|2004-08-30|Estimate|||||||2009-06-05|2009-06-09|Estimate|October 1994||1994-10-31|June 2009|2009-06-30||||September 2009|Anticipated|2009-09-30||Observational|||Juvenile Rheumatoid Arthritis Research Registry|Research Registry for Juvenile Arthritis|Unknown status|Recruiting||200|Anticipated|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, Pax gene~   "|||2018-06-01 05:04:03.128321|2018-06-01 05:04:03.128321
NCT00090467|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2013-07-26|2004-08-27|2004-08-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|August 2004||2004-08-31|July 2013|2013-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Biochemical and Genetic Markers of Hypertension in Women||Completed|||1600|Actual|Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:04:03.194282|2018-06-01 05:04:03.194282
NCT00090454|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2017-07-20|2004-08-27|2004-08-30|Estimate|||||||2017-07-20|2017-07-24|Actual|August 2004||2004-08-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Genetic Markers of CHD Risk in Men and Women||Completed|||||State University of New York at Buffalo|||||f||||||||||||||2018-06-01 05:04:03.235389|2018-06-01 05:04:03.235389
NCT00090376|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2008-11-06|2004-08-27|2004-08-30|Estimate|||||||2008-11-06|2008-11-07|Estimate|December 2003||2003-12-31|November 2008|2008-11-30||||||||Interventional|||Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy|Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3 Arm, 12-Month Study to Evaluate the Effects of GPI 1485 on Erectile Function in Patients Undergoing Bilateral Nerve-Sparing Radical Retropubic Prostatectomy for Prostatic Carcinoma|Completed||Phase 2|240||Eisai Inc.|||||f||||||||||||||2018-06-01 05:04:03.317735|2018-06-01 05:04:03.317735
NCT00090363|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|2012-04-26|2011-05-23|2013-01-03|2004-08-27|2004-08-30|Estimate|2012-08-01|2012-09-03|Estimate|2011-05-23|2011-06-01|Estimate|2013-01-03|2013-01-08|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|December 2008|Actual|2008-12-31||Interventional|||ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)|Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)|Completed||Phase 2|447|Actual|AstraZeneca|‘Final analysis’ results (data cut-off 18th December 2008) should be considered in context with the longevity of the follow-up (median duration approximately 22 months) relative to only approximately 4 months median duration of study treatment.|3|||f||||||||||||||2018-06-01 05:04:03.420331|2018-06-01 05:04:03.420331
NCT00090324|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2013-01-03|2004-08-27|2004-08-30|Estimate|||||||2013-01-03|2013-01-04|Estimate|September 2004||2004-09-30|January 2013|2013-01-31|June 2007|Actual|2007-06-30|||||Interventional|ANCHOR 112||Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia|A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets Compared With Placebo in Adolescents With Schizophrenia (Abbreviated)|Completed||Phase 3|249|Anticipated|AstraZeneca|||||f||||||||||||||2018-06-01 05:04:04.397201|2018-06-01 05:04:04.397201
NCT00090311|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2013-01-03|2004-08-27|2004-08-30|Estimate|||||||2013-01-03|2013-01-04|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|July 2006|Actual|2006-07-31|||||Interventional|ANCHOR 149||Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania|A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbreviated)|Completed||Phase 3|220|Actual|AstraZeneca|||||||||||||||||||2018-06-01 05:04:04.524547|2018-06-01 05:04:04.524547
NCT00090298|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2017-03-10|2004-08-27|2004-08-30|Estimate|||||||2017-03-10|2017-03-13|Actual|April 2004||2004-04-30|March 2017|2017-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia|Completed||Phase 3|2815|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:04.654073|2018-06-01 05:04:04.654073
NCT00004915|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-16|2012-05-31|2004-08-27|2004-08-30|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-31|2012-06-06|Estimate|November 1998||1998-11-30|May 2012|2012-05-31|February 2000|Actual|2000-02-29|February 2000|Actual|2000-02-29||Interventional|||Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer|Phase II Study of Raloxifene in Recurrent Endometrial Cancer|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:04:04.744219|2018-06-01 05:04:04.744219
NCT00004201|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-02-01|2004-08-27|2004-08-30|Estimate|||||||2013-02-01|2013-02-04|Estimate||||June 2007|2007-06-30|August 2004|Actual|2004-08-31|||||Interventional|||Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer|A Randomized Phase II Trial of Cisplatin or Carboplatin With Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:04.866738|2018-06-01 05:04:04.866738
NCT00004090|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-07-09|2004-08-27|2004-08-30|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 1999||1999-08-31|January 2011|2011-01-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors|Gemcitabine (10 mg/m2/Min) and Cisplatin: A Phase I Study|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:04.927694|2018-06-01 05:04:04.927694
NCT00004029|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-08|2004-08-27|2004-08-30|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 1996||1996-12-31|June 2006|2006-06-30||||May 2006|Actual|2006-05-31||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer|A PHASE I TRIAL OF RECOMBINANT VACCINIA VIRUS THAT EXPRESSES PSA IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE|Completed||Phase 1|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:04:05.023086|2018-06-01 05:04:05.023086
NCT00002489|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-08-27|2004-08-30|Estimate|||||||2013-06-24|2013-06-26|Estimate|October 1991||1991-10-31|June 2013|2013-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors|PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:05.185589|2018-06-01 05:04:05.185589
NCT00002488|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-08-27|2004-08-30|Estimate|||||||2013-09-16|2013-09-17|Estimate|December 1991||1991-12-31|April 2000|2000-04-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy|INTENSIFICATION WITH HIGH DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN FOR INTERMEDIATE OR HIGH GRADE LYMPHOMA PATIENTS WHO FAILED PRIMARY COMBINATION CHEMOTHERAPY|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:05.300967|2018-06-01 05:04:05.300967
NCT00002487|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-08-27|2004-08-30|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1991||1991-07-31|April 2000|2000-04-30||||||||Interventional|||Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer|INTRAPERITONEAL METHOTREXATE AND DIPYRIDAMOLE AS SALVAGE TREATMENT FOR ADVANCED OVARIAN CARCINOMA|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:05.358701|2018-06-01 05:04:05.358701
NCT00002471|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2004-08-27|2004-08-30|Estimate|||||||2013-06-19|2013-06-20|Estimate|February 1990||1990-02-28|June 2013|2013-06-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:05.442405|2018-06-01 05:04:05.442405
NCT00002458|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-04|2004-08-27|2004-08-30|Estimate|||||||2013-06-04|2013-06-05|Estimate|November 1987||1987-11-30|June 2013|2013-06-30|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission|Phase II Study of Adjuvant Therapy With Antiganglioside GD2-Specific Mouse Monoclonal Antibody 3F8 for Metastatic Neuroblastoma in Second Remission|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:05.555624|2018-06-01 05:04:05.555624
NCT00090558|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-27|||2008-03-03|2004-08-26|2004-08-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2004||2004-08-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease|Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:04:05.631746|2018-06-01 05:04:05.631746
NCT00090545|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-27|2012-07-23||2012-08-28|2004-08-26|2004-08-27|Estimate|2012-08-28|2012-09-28|Estimate||||2012-08-28|2012-09-28|Estimate|August 2004||2004-08-31|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer|A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer|Completed||Phase 2|46|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:04:05.727813|2018-06-01 05:04:05.727813
NCT00090506|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2008-01-23|2004-08-26|2004-08-27|Estimate|||||||2008-01-23|2008-01-25|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Yoga for Treating People at Risk for Diabetes or With Both HIV and Depression|Yoga, Health, and Meditation|Completed||Phase 1|50||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:04:06.337796|2018-06-01 05:04:06.337796
NCT00090428|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2013-01-31|2004-08-26|2004-08-27|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2004||2004-01-31|January 2013|2013-01-31|February 2009|Actual|2009-02-28|October 2008|Actual|2008-10-31||Interventional|||Diet and Behavior in Young Children With Autism|Diet and Behavior in Young Children With Autism|Completed||Phase 1|21|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 05:04:06.434531|2018-06-01 05:04:06.434531
NCT00090415|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-26|||2012-06-15|2004-08-26|2004-08-27|Estimate|||||||2012-06-15|2012-06-19|Estimate|April 2003||2003-04-30|June 2012|2012-06-30||||April 2008|Actual|2008-04-30||Interventional|||Early Characteristics of Autism|UW STAART Center of Excellence|Completed||Phase 1|48|Actual|University of Washington||2|||f||||f||||||||||2018-06-01 05:04:06.51586|2018-06-01 05:04:06.51586
NCT00090285|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|2009-10-14|2009-10-07|2018-03-23|2004-08-26|2004-08-27|Estimate|2009-10-14|2009-11-19|Estimate|2009-10-07|2009-10-12|Estimate|2018-03-23|2018-04-24|Actual|September 3, 2004|Actual|2004-09-03|March 2018|2018-03-31|April 3, 2017|Actual|2017-04-03|July 31, 2009|Actual|2009-07-31||Interventional|||An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)|An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men|Completed||Phase 3|4065|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:04:06.826718|2018-06-01 05:04:06.826718
NCT00090272|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2017-02-16|2004-08-26|2004-08-27|Estimate|||||||2017-02-16|2017-02-17|Actual|April 2002||2002-04-30|February 2017|2017-02-28|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)|A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Ertapenem Sodium (MK0826) Versus Cefotetan for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery|Completed||Phase 3|952|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:08.112065|2018-06-01 05:04:08.112065
NCT00090259|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|2010-06-30||2017-03-31|2004-08-26|2004-08-27|Estimate|2010-06-30|2010-08-02|Estimate||||2017-03-31|2017-05-05|Actual|December 19, 2001|Actual|2001-12-19|March 2017|2017-03-31|May 13, 2009|Actual|2009-05-13|March 31, 2009|Actual|2009-03-31||Interventional|||Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)|A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment|Completed||Phase 3|3834|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:04:08.306496|2018-06-01 05:04:08.306496
NCT00090246|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2017-05-02|2004-08-26|2004-08-27|Estimate|||||||2017-05-02|2017-05-05|Actual|May 13, 2004|Actual|2004-05-13|May 2017|2017-05-31|April 20, 2005|Actual|2005-04-20|April 6, 2005|Actual|2005-04-06||Interventional|||2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)|A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting|Completed||Phase 3|922|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:10.850023|2018-06-01 05:04:10.850023
NCT00090233|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|2009-06-29||2015-09-18|2004-08-26|2004-08-27|Estimate|2011-04-06|2011-05-05|Estimate||||2015-09-18|2015-10-05|Estimate|January 2001||2001-01-31|September 2015|2015-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Rotavirus Efficacy and Safety Trial (REST)(V260-006)|Safety and Efficacy of Pentavalent (G1, G2, G3, G4 , and P1) Human-Bovine Reassortant Rotavirus Vaccine in Healthy Infants|Completed||Phase 3|69274|Actual|Merck Sharp & Dohme Corp.|70,301 participants randomized, 69,274 evaluated, when DSMB first recommended ending enrollment.|2|||f||||||||||||||2018-06-01 05:04:11.071119|2018-06-01 05:04:11.071119
NCT00090220|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|2009-10-30|2009-10-29|2017-03-23|2004-08-26|2004-08-27|Estimate|2010-01-05|2010-02-01|Estimate|2009-10-29|2009-11-02|Estimate|2017-03-23|2017-04-21|Actual|June 16, 2004|Actual|2004-06-16|March 2017|2017-03-31|November 12, 2015|Actual|2015-11-12|May 21, 2009|Actual|2009-05-21||Interventional||All randomized participants|A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)|Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study|Completed||Phase 3|3819|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:04:13.994645|2018-06-01 05:04:13.994645
NCT00088673|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2007-02-27|2004-08-02|2004-08-03|Estimate|||||||2007-02-27|2007-02-28|Estimate|June 2004||2004-06-30|February 2007|2007-02-28||||||||Interventional|||Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease|A Phase III Study of the Efficacy and Safety of 3APS in Patients With Mild to Moderate Alzheimer’s Disease|Unknown status|Active, not recruiting|Phase 3|950||Bellus Health Inc|||||||||t||||||||||2018-06-01 05:05:26.478825|2018-06-01 05:05:26.478825
NCT00090207|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2017-04-20|2004-08-26|2004-08-27|Estimate|||||||2017-04-20|2017-04-24|Actual|January 13, 2004|Actual|2004-01-13|April 2017|2017-04-30|September 30, 2004|Actual|2004-09-30|September 30, 2004|Actual|2004-09-30||Interventional|||Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)|A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Safety, Tolerability and Efficacy of Aprepitant Regimen Compared to Ondansetron Regimen for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With High Dose Cisplatin in Cycle 1|Completed||Phase 4|477|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:15.668035|2018-06-01 05:04:15.668035
NCT00090181|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2015-11-27|2004-08-26|2004-08-27|Estimate|||||||2015-11-27|2015-11-30|Estimate|June 2004||2004-06-30|November 2015|2015-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)|A Double-Blind, Parallel-group, 4-Week Trial to Assess the Efficacy and Safety of Etoricoxib 60 mg and Diclofenac 150 mg in Patients With Chronic Low Back Pain|Completed||Phase 4|401|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:15.734616|2018-06-01 05:04:15.734616
NCT00090168|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2017-04-05|2004-08-26|2004-08-27|Estimate|||||||2017-04-05|2017-04-07|Actual|January 27, 2004|Actual|2004-01-27|April 2017|2017-04-30|November 10, 2004|Actual|2004-11-10|October 20, 2004|Actual|2004-10-20||Interventional|||Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)|A Multicenter Study to Assess the Cholesterol Lowering Level of Switching to an Investigational Drug Compared to Doubling the Dose of an Investigational Drug in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease|Completed||Phase 3|435|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:15.812034|2018-06-01 05:04:15.812034
NCT00090155|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24|||2017-05-02|2004-08-26|2004-08-27|Estimate|||||||2017-05-02|2017-05-05|Actual|September 26, 2003|Actual|2003-09-26|May 2017|2017-05-31|November 24, 2004|Actual|2004-11-24|November 24, 2004|Actual|2004-11-24||Interventional|||2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)|A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of 2 Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting|Completed||Phase 3|805|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:15.899069|2018-06-01 05:04:15.899069
NCT00004026|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-08-26|2004-08-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|December 1998||1998-12-31|June 2007|2007-06-30||||||||Interventional|||CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy|A Phase II Study of CT-2584 Mesylate in Patients With Hormone Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:16.000148|2018-06-01 05:04:16.000148
NCT00004009|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-28|2004-08-26|2004-08-27|Estimate|||||||2017-03-28|2017-03-30|Actual|June 1999|Actual|1999-06-30|March 2017|2017-03-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia|A Phase I Study to Determine Biological Endpoints of Up to 21 Day Dosing of the Farnesyltransferase Inhibitor R115777 (IND# 52,302) for Refractory and Relapsed Adult Leukemias (Summary Last Modified 9/1999)|Completed||Phase 1|||University of Maryland|||||f||||||||||||||2018-06-01 05:04:16.098499|2018-06-01 05:04:16.098499
NCT00003989|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-08-26|2004-08-27|Estimate|||||||2012-07-10|2012-07-11|Estimate|June 1998||1998-06-30|July 2012|2012-07-31||||||||Interventional|||ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma|Phase II Trial With ISIS 3521/CGP 64128A in Patients With Malignant Melanoma and Non Small Cell Lung Cancer|Completed||Phase 2|50|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:04:16.184575|2018-06-01 05:04:16.184575
NCT00003962|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-01|2004-08-26|2004-08-27|Estimate|||||||2014-05-01|2014-05-02|Estimate|April 1998||1998-04-30|May 2014|2014-05-31|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|||Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Dose Finding Study of Toxicity and Immunomodulatory Effects of Interleukin-2 Following Allogeneic Bone Marrow Transplantation in Patients at High Risk for Relapse|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:04:16.276261|2018-06-01 05:04:16.276261
NCT00003778|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-08-26|2004-08-27|Estimate|||||||2013-02-07|2013-02-08|Estimate|April 1999||1999-04-30|September 2000|2000-09-30||||July 2000|Actual|2000-07-31||Interventional|||Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma|Phase II Trial of Dolastatin-10 in Patients With Previously Untreated Recurrent/Metastatic Sarcoma|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:04:16.338981|2018-06-01 05:04:16.338981
NCT00090402|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|2009-12-02||2017-06-21|2004-08-25|2004-08-26|Estimate|2010-02-03|2010-02-26|Estimate||||2017-06-21|2017-07-21|Actual|April 2004|Actual|2004-04-30|June 2017|2017-06-30|August 2007|Actual|2007-08-31|January 3, 2006|Actual|2006-01-03||Interventional|||Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease|Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease|Completed||Phase 1/Phase 2|39|Actual|Oregon Health and Science University||3|||f||||t||||||||No||2018-06-01 05:04:16.425684|2018-06-01 05:04:16.425684
NCT00090389|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2008-01-23|2004-08-25|2004-08-26|Estimate|||||||2008-01-23|2008-01-25|Estimate|January 2005||2005-01-31|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Acupuncture for Women's Health Conditions|New England School of Acupuncture (NESA) Acupuncture Research Collaborative|Completed||Phase 1|50||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:04:16.872979|2018-06-01 05:04:16.872979
NCT00090337|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2013-03-06|2004-08-25|2004-08-26|Estimate|||||||2013-03-06|2013-03-07|Estimate|November 2003||2003-11-30|March 2013|2013-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer|Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial|Completed||Phase 3|73|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 05:04:16.938396|2018-06-01 05:04:16.938396
NCT00003378|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-08|2004-08-25|2004-08-26|Estimate|||||||2013-07-08|2013-07-09|Estimate|August 1998||1998-08-31|December 2011|2011-12-31||||February 2000|Actual|2000-02-29||Interventional|||Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer|A Phase I Feasibility Trial of Carboplatin, Paclitaxel, and Gemcitabine in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma|Terminated||Phase 1|45|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:04:23.741467|2018-06-01 05:04:23.741467
NCT00090194|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-25|||2017-01-10|2004-08-25|2004-08-26|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2003||2003-06-30|January 2017|2017-01-31|March 2004|Actual|2004-03-31|||||Interventional|||Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%|Evaluation of Immune Globulin Intravenous (Human), 10%, Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients|Terminated||Phase 2|56|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:04:17.041204|2018-06-01 05:04:17.041204
NCT00090142|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24|2009-09-22||2015-07-29|2004-08-25|2004-08-26|Estimate|2010-10-06|2010-10-29|Estimate||||2015-07-29|2015-07-30|Estimate|May 2004||2004-05-31|July 2015|2015-07-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 2-Period, Crossover Study to Evaluate the Effects of a Single Dose of Montelukast on Exercise-Induced Bronchospasm|Completed||Phase 3|62|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:04:17.166938|2018-06-01 05:04:17.166938
NCT00090129|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24|||2013-10-21|2004-08-25|2004-08-26|Estimate|||||||2013-10-21|2013-10-22|Estimate|September 2004||2004-09-30|October 2013|2013-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis|A Multicentre, Randomised, Double-blind, Placebo Controlled Phase III Study of Subcutaneously Administered Onercept in the Treatment and Re-treatment of Subjects With Moderate to Severe Plaque Psoriasis|Terminated||Phase 3|854|Actual|EMD Serono||2||"The risk-benefit ratio for the use of onercept in this condition was not sufficiently favorable~   to justify continued development"|||||||||||||||2018-06-01 05:04:17.509864|2018-06-01 05:04:17.509864
NCT00090116|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24|||2012-03-01|2004-08-25|2004-08-26|Estimate|||||||2012-03-01|2012-03-05|Estimate|March 2003||2003-03-31|March 2012|2012-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease|A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type|Completed||Phase 3|400||Forest Laboratories|||||||||||||||||||2018-06-01 05:04:17.636962|2018-06-01 05:04:17.636962
NCT00090103|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24|2010-02-26||2017-01-16|2004-08-25|2004-08-26|Estimate|2010-02-26|2010-03-16|Estimate||||2017-01-16|2017-02-28|Actual|November 2003||2003-11-30|January 2017|2017-01-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment|A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia|Completed||Phase 3|4844|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-06-01 05:04:18.205255|2018-06-01 05:04:18.205255
NCT00090077|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24|||2006-02-24|2004-08-25|2004-08-26|Estimate|||||||2006-02-24|2006-02-27|Estimate|April 2004||2004-04-30|February 2006|2006-02-28||||||||Interventional|||Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults|A Phase I, Multicenter, Randomized, Parallel, Double-Blinded Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Dosage Regimens of GW695634G Monotherapy Versus Placebo Over 10 Days in ART-Naive HIV-1 Infected Adults.|Completed||Phase 1|50||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:04:22.889741|2018-06-01 05:04:22.889741
NCT00003654|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-08-25|2004-08-26|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 1997||1997-09-30|December 2006|2006-12-31||||||||Interventional|||Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer|Diagnostic Study of Patent Blue V Dye to Identify Sentinel Lymph Nodes in Patients With Stage I or IIA Breast Cancer|Unknown status|Active, not recruiting|N/A|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:22.964234|2018-06-01 05:04:22.964234
NCT00003601|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-08-25|2004-08-26|Estimate|||||||2008-07-23|2008-07-24|Estimate|September 1998||1998-09-30|March 2008|2008-03-31||||March 2000|Actual|2000-03-31||Interventional|||Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome|A Phase II Double-Blind Study of Topical Tretinoin With or Without Oral 4-HPR (Fenretinide) in Patients With the Dysplastic Nevus Syndrome|Completed||Phase 2|38|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:23.032617|2018-06-01 05:04:23.032617
NCT00003588|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-08-25|2004-08-26|Estimate|||||||2013-02-07|2013-02-08|Estimate|September 1998||1998-09-30|June 2002|2002-06-30||||March 2002|Actual|2002-03-31||Interventional|||Gene Therapy in Treating Patients With Ovarian Cancer|A Phase I Study of Ad-p53 (NSC# 683550) for Patients With Platinum- and Paclitaxel-Resistant Epithelial Ovarian Cancer|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:04:23.086213|2018-06-01 05:04:23.086213
NCT00003519|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-27|2004-08-25|2004-08-26|Estimate|||||||2010-01-27|2010-01-28|Estimate|August 1998||1998-08-31|January 2010|2010-01-31||||January 2007|Actual|2007-01-31||Interventional|||Combination Chemotherapy in Treating Women With Breast Cancer|Phase III Study of Adriamycin/Taxotere Versus Adriamycin/Cytoxan for the Adjuvant Treatment of Node Positive or High Risk Node Negative Breast Cancer|Completed||Phase 3|2778|Anticipated|Eastern Cooperative Oncology Group|||||||||t||||||||||2018-06-01 05:04:23.159365|2018-06-01 05:04:23.159365
NCT00003406|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-25|2004-08-25|2004-08-26|Estimate|||||||2013-03-25|2013-03-26|Estimate|October 1997||1997-10-31|July 2007|2007-07-31|March 2000|Actual|2000-03-31|||||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer|A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies|Completed||Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:23.507685|2018-06-01 05:04:23.507685
NCT00003390|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-08-25|2004-08-26|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 1998||1998-06-30|May 2000|2000-05-31|August 2004|Actual|2004-08-31|||||Interventional|||6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer|A Phase II Trial of 6-Hydroxymethylacylfulvene (MGI-114) in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:23.654649|2018-06-01 05:04:23.654649
NCT00003362|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-08-25|2004-08-26|Estimate|||||||2013-06-24|2013-06-25|Estimate|May 1998||1998-05-31|June 2013|2013-06-30|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma|Pilot Trial of Multi-Epitope Melanoma Peptide Vaccine Using GM-CSF, Montanide and QS-21 as Adjuvants|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:23.887081|2018-06-01 05:04:23.887081
NCT00003315|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-08-25|2004-08-26|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 1997||1997-07-31|May 2007|2007-05-31|December 1997|Actual|1997-12-31|||||Interventional|||Liposomal Amphotericin B With or Without Sargramostim in Treating Patients With Invasive Fungal Infection|Supplementary Protocol for Patients With Invasive Fungal Infection, Entered Into AML 11, AML 12 and UKALL XII (Or Their Successors)|Completed||Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:23.948351|2018-06-01 05:04:23.948351
NCT00003304|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-05|2004-08-25|2004-08-26|Estimate|||||||2012-03-05|2012-03-06|Estimate|April 1998||1998-04-30|March 2012|2012-03-31||||March 2000|Actual|2000-03-31||Interventional|||Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors|Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy|Completed||Phase 2|29|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:04:24.017747|2018-06-01 05:04:24.017747
NCT00090090|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24|||2008-01-08|2004-08-24|2004-08-25|Estimate|||||||2008-01-08|2008-01-15|Estimate|April 2004||2004-04-30|January 2008|2008-01-31|October 2006|Actual|2006-10-31|||||Interventional|||Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|114||Spectrum Pharmaceuticals, Inc|||||f||||f||||||||||2018-06-01 05:04:24.145955|2018-06-01 05:04:24.145955
NCT00090064|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-24||2011-07-31|2015-11-12|2004-08-24|2004-08-25|Estimate||||2011-08-05|2011-08-15|Estimate|2015-11-12|2015-12-10|Estimate|March 2004||2004-03-31|February 2014|2014-02-28|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||A Test of MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder|Phase II Clinical Trial Testing the Safety and Efficacy of 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Chronic Posttraumatic Stress Disorder|Completed||Phase 2|23|Actual|Multidisciplinary Association for Psychedelic Studies||2|||f||||t||||||||||2018-06-01 05:04:24.205474|2018-06-01 05:04:24.205474
NCT00090051|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-23|2009-12-22|2009-07-09|2017-07-05|2004-08-24|2004-08-25|Estimate|2011-12-15|2012-01-23|Estimate|2009-09-10|2009-09-11|Estimate|2017-07-05|2017-08-01|Actual|July 31, 2003|Actual|2003-07-31|July 2017|2017-07-31|May 31, 2012|Actual|2012-05-31|July 23, 2008|Actual|2008-07-23||Interventional|||FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients|Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL|Completed||Phase 3|552|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-06-01 05:04:24.552416|2018-06-01 05:04:24.552416
NCT00003279|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-05|2004-08-24|2004-08-25|Estimate|||||||2012-03-05|2012-03-06|Estimate|March 1998||1998-03-31|March 2012|2012-03-31||||January 2000|Actual|2000-01-31||Interventional|SILVA||Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG|Completed||Phase 3|500|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:04:25.68607|2018-06-01 05:04:25.68607
NCT00003260|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-01-10|2004-08-24|2004-08-25|Estimate|||||||2009-01-10|2009-01-13|Estimate|January 1998||1998-01-31|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer|Multicentre Phase III Comparing To Therapeutic Sequence: Folfiri Following of Folfox6 (Group A) and Folfox6 Following Of (Group B) For Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 3|109|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:25.962538|2018-06-01 05:04:25.962538
NCT00003237|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-08-24|2004-08-25|Estimate|||||||2010-01-26|2010-01-27|Estimate|March 1998||1998-03-31|January 2010|2010-01-31||||October 2003|Actual|2003-10-31||Interventional|||Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach|Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia|Completed||Phase 2|55|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:04:26.032716|2018-06-01 05:04:26.032716
NCT00003229|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-22|2004-08-24|2004-08-25|Estimate|||||||2013-03-22|2013-03-25|Estimate|July 1997||1997-07-31|March 2013|2013-03-31|February 2005|Actual|2005-02-28|April 2000|Actual|2000-04-30||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal|A Phase I-II Trial of Antigen-Pulsed Autologous Dendritic Cells for Induction of Anti-Tumor Immunity in Patients Completing Lymphadenectomy for Metastatic Melanoma|Completed||Phase 1/Phase 2|||Duke University|||||f||||||||||||||2018-06-01 05:04:26.146073|2018-06-01 05:04:26.146073
NCT00003224|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-01-22||2014-11-18|2004-08-24|2004-08-25|Estimate|2014-11-18|2014-11-20|Estimate||||2014-11-18|2014-11-20|Estimate|February 1996||1996-02-29|November 2014|2014-11-30||||August 2000|Actual|2000-08-31||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With a Synthetic Melanoma Peptide in Patients With High Risk Melanoma|Completed||Phase 1|22|Actual|University of Virginia||6|||f||||t||||||||||2018-06-01 05:04:26.218411|2018-06-01 05:04:26.218411
NCT00090038|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-23|||2009-10-16|2004-08-23|2004-08-24|Estimate|||||||2009-10-16|2009-10-20|Estimate|October 2003||2003-10-31|October 2009|2009-10-31|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma|A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens|Completed||Phase 4|168|Actual|Biogen||2|||f||||f||||||||||2018-06-01 05:04:26.761786|2018-06-01 05:04:26.761786
NCT00003151|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-08-23|2004-08-24|Estimate|||||||2012-06-29|2012-07-02|Estimate|September 1997||1997-09-30|June 2012|2012-06-30||||October 1998|Actual|1998-10-31||Interventional|||Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma|A Phase II Clinical Trial of Anti-Helicobacter Pylori Treatment in Endoscopically Diagnosed Low-Grade Localized Gastric Lymphoma|Completed||Phase 2|96|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:04:26.871808|2018-06-01 05:04:26.871808
NCT00003147|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-02-04|2004-08-23|2004-08-24|Estimate|||||||2013-02-04|2013-02-05|Estimate|February 1998||1998-02-28|May 2000|2000-05-31||||June 2003|Actual|2003-06-30||Interventional|||Gene Therapy in Treating Patients With Cancer of The Liver|Phase I Study of Percutaneous Injections of Adeno-Virus p53 Construct (ADENO-p53) for Hepatocellular Carcinoma|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:04:26.953967|2018-06-01 05:04:26.953967
NCT00089999|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-18|2014-08-18|2010-10-13|2017-01-16|2004-08-20|2004-08-23|Estimate|2014-08-18|2014-08-29|Estimate|2011-02-07|2011-02-10|Estimate|2017-01-16|2017-02-28|Actual|June 2004||2004-06-30|January 2017|2017-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer|A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients With Advanced or Metastatic Breast Cancer|Completed||Phase 2|138|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-06-01 05:04:28.777067|2018-06-01 05:04:28.777067
NCT00003136|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-08-23|2004-08-24|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 1996||1996-12-31|February 2013|2013-02-28|October 2001|Actual|2001-10-31|December 2000|Actual|2000-12-31||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer|A Phase I/II Dose Escalation Trial of Carboplatin With Amifostine Pretreatment to Augment High Dose Cyclophosphamide With Autologous Peripheral Blood Stem Cell Support for the Treatment of Patients With Epithelial Ovarian Cancer|Completed||Phase 1/Phase 2|11|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:04:27.017006|2018-06-01 05:04:27.017006
NCT00003131|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-21|2004-08-23|2004-08-24|Estimate|||||||2012-08-21|2012-08-22|Estimate|February 1997||1997-02-28|August 2012|2012-08-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse|A Study of the Efficacy and Safety of CMA-676 as Single Agent Treatment of Patients With Acute Myeloid Leukemia (AML) in First Relapse|Completed||Phase 2|55|Anticipated|Pfizer|||||f||||||||||||||2018-06-01 05:04:27.087728|2018-06-01 05:04:27.087728
NCT00002969|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-20|2004-08-23|2004-08-24|Estimate|||||||2012-07-20|2012-07-24|Estimate|May 1997||1997-05-31|July 2012|2012-07-31|January 2007|Actual|2007-01-31|January 2004|Actual|2004-01-31||Interventional|||S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)|Completed||Phase 2|60|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 05:04:27.173727|2018-06-01 05:04:27.173727
NCT00002960|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-02-03|2004-08-23|2004-08-24|Estimate|||||||2016-02-03|2016-02-04|Estimate|June 1999||1999-06-30|February 2016|2016-02-29|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)|A Phase I Study in Patients With Peritoneal Carcinomatosis Using SCH 58500 (rAd/p53) Administered by Single Intraperitoneal Instillation|Completed||Phase 1|59|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:04:27.527072|2018-06-01 05:04:27.527072
NCT00002888|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-08-23|2004-08-24|Estimate|||||||2013-06-20|2013-06-21|Estimate|March 1997||1997-03-31|May 2007|2007-05-31|August 2004|Actual|2004-08-31|||||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer|A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:27.606481|2018-06-01 05:04:27.606481
NCT00002881|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-06|2004-08-23|2004-08-24|Estimate|||||||2010-11-06|2010-11-09|Estimate|October 1996||1996-10-31|May 2007|2007-05-31||||April 1998|Actual|1998-04-30||Interventional|||Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer|PHASE III TRIAL OF ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE + SURAMIN + HYDROCORTISONE VS ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE IN PATIENTS WITH METASTATIC PROSTATE CANCER|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:27.773914|2018-06-01 05:04:27.773914
NCT00002879|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-05|2004-08-23|2004-08-24|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 1996||1996-11-30|December 2016|2016-12-31|December 2008|Actual|2008-12-31|April 2005|Actual|2005-04-30||Interventional|||Cladribine in Patients With Mantle Cell Lymphoma|A PHASE II TRIAL OF 2-CDA IN PREVIOUSLY TREATED OR UNTREATED PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)|Completed||Phase 2|51|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:04:27.921574|2018-06-01 05:04:27.921574
NCT00002845|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-08-23|2004-08-24|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 1995||1995-09-30|May 2000|2000-05-31||||||||Interventional|||Interleukin-2 in Treating Patients With Metastatic Melanoma|TREATMENT OF METASTATIC MELANOMA WITH RECOMBINANT INTERLEUKIN-2|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:28.039833|2018-06-01 05:04:28.039833
NCT00002783|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2004-08-23|2004-08-24|Estimate|||||||2013-07-01|2013-07-03|Estimate|May 1996||1996-05-31|July 2013|2013-07-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer|A PHASE II TRIAL OF NEOADJUVANT CISPLATIN-FLUOROURACIL CHEMOTHERAPY, SURGERY, AND INTRAPERITONEAL (IP) FLOXURIDINE (FUdR) PLUS LEUCOVORIN IN PATIENTS WITH GASTRIC CANCER|Completed||Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:28.098623|2018-06-01 05:04:28.098623
NCT00002755|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-08-23|2004-08-24|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 1995||1995-11-30|May 2007|2007-05-31|June 1999|Actual|1999-06-30|||||Interventional|||Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer|PROSPECTIVE RANDOMISED EVALUATION OF HIGH-INTENSITY CHEMOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR SUPPORT IN PATIENTS WITH HIGH RISK BREAST CANCER|Completed||Phase 3|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:28.169333|2018-06-01 05:04:28.169333
NCT00002742|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-25|2004-08-23|2004-08-24|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 1996||1996-01-31|July 2007|2007-07-31|September 2007|Actual|2007-09-30|||||Interventional|||Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer|A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:28.277915|2018-06-01 05:04:28.277915
NCT00002711|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2004-08-23|2004-08-24|Estimate|||||||2013-07-01|2013-07-03|Estimate|October 1995||1995-10-31|July 2013|2013-07-31|October 2000|Actual|2000-10-31|October 2000|Actual|2000-10-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus|A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL|Completed||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:28.42806|2018-06-01 05:04:28.42806
NCT00090025|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-19|||2009-01-13|2004-08-20|2004-08-23|Estimate|||||||2009-01-13|2009-01-14|Estimate|September 2004||2004-09-30|January 2009|2009-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors|A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery|Terminated||Phase 3|248|Actual|Helsinn Healthcare SA||2||Futility reasons after Independent Data Monitoring Committee interim analysis|f||||t||||||||||2018-06-01 05:04:28.531492|2018-06-01 05:04:28.531492
NCT00090012|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-18|||2007-11-05|2004-08-20|2004-08-23|Estimate|||||||2007-11-05|2007-11-06|Estimate|July 2004||2004-07-31|November 2007|2007-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder|The Comparison of Efficacy and Safety of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder|Completed||Phase 4|340||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:04:28.6615|2018-06-01 05:04:28.6615
NCT00089986|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-18|2017-03-23||2017-07-14|2004-08-20|2004-08-23|Estimate|2017-03-23|2017-05-04|Actual||||2017-07-14|2017-08-21|Actual|September 1, 2004||2004-09-01|July 2017|2017-07-31|April 15, 2007|Actual|2007-04-15|April 1, 2007|Actual|2007-04-01||Interventional|||GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults|A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults|Completed||Phase 2|1415|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:04:29.551116|2018-06-01 05:04:29.551116
NCT00005024|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-01-03|2004-08-20|2004-08-23|Estimate|||||||2014-01-03|2014-01-06|Estimate||||June 2007|2007-06-30||||||||Interventional|||Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease|A Double-blind, Multicenter, Parallel Study Comparing the Efficacy and Safety of Kytril Tablets With Placebo, in the Prevention of Nausea and Vomiting During the Days Following Administration of IV Cyclophosphamide-based or Carboplatin-based Chemotherapy in Patients With Malignant Disease|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:31.113485|2018-06-01 05:04:31.113485
NCT00004906|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-05-29|2004-08-20|2004-08-23|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 1999||1999-10-31|November 2007|2007-11-30|June 2001|Actual|2001-06-30|||||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer|A Phase II Multi-Institution Study of Docetaxel and Doxorubicin as Induction Therapy Followed by Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support for Women With Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:31.301094|2018-06-01 05:04:31.301094
NCT00002674|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-31|2004-08-20|2004-08-23|Estimate|||||||2010-03-31|2010-04-02|Estimate|October 1994||1994-10-31|March 2010|2010-03-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia|CYTOREDUCTIVE CHEMOTHERAPY WITH MITOXANTRONE, CYTOSINE ARABINOSIDE AND ETOPOSIDE FOLLOWED BY RECOMBINANT HUMAN G-CSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA|Completed||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:04:31.377987|2018-06-01 05:04:31.377987
NCT00002634|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2004-08-20|2004-08-23|Estimate|||||||2013-07-01|2013-07-03|Estimate|February 1995||1995-02-28|July 2013|2013-07-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma|N7: EVALUATION OF MAXIMAL CHEMOTHERAPY DOSE INTENSITY PLUS MONOCLONAL ANTIBODY 3F8 IN THE TREATMENT OF NEUROBLASTOMA|Completed||Phase 2|45|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:31.443446|2018-06-01 05:04:31.443446
NCT00002579|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-08-20|2004-08-23|Estimate|||||||2013-11-05|2013-11-06|Estimate|March 1993||1993-03-31|May 2007|2007-05-31||||||||Interventional|||Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer|PROTOCOL FOR THE SCOTTISH CHEMO-ENDOCRINE TRIAL D|Completed||Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:31.528752|2018-06-01 05:04:31.528752
NCT00002510|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-30|2004-08-20|2004-08-23|Estimate|||||||2010-09-30|2010-10-01|Estimate|April 1992||1992-04-30|September 2010|2010-09-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY RESCUE WITH MOBILIZED AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH LOW-GRADE, TRANSFORMED, OR FOLLICULAR LARGE CELL NON-HODGKIN'S LYMPHOMA|Completed||Phase 1/Phase 2|||Temple University|||||f||||||||||||||2018-06-01 05:04:31.60544|2018-06-01 05:04:31.60544
NCT00002499|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-08-20|2004-08-23|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 1990||1990-01-31|May 2000|2000-05-31||||||||Interventional|||Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia|TREATMENT OF ALL IN FIRST BONE MARROW RELAPSE AFTER BFM PROTOCOLS|Unknown status|Active, not recruiting|Phase 2/Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:31.684103|2018-06-01 05:04:31.684103
NCT00002498|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-08-20|2004-08-23|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 1992||1992-07-31|May 2000|2000-05-31||||||||Interventional|||Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer|CMF AND MITOXANTRONE IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER, A RANDOMIZED PHASE II STUDY|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:31.816417|2018-06-01 05:04:31.816417
NCT00002493|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-12|2004-08-20|2004-08-23|Estimate|||||||2014-02-12|2014-02-14|Estimate|May 1992||1992-05-31|February 2014|2014-02-28||||April 2001|Actual|2001-04-30||Interventional|||Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer|WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III|Completed||Phase 3|||Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 05:04:31.913072|2018-06-01 05:04:31.913072
NCT00002479|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01||2011-02-16|2012-05-17|2004-08-20|2004-08-23|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-17|2012-05-30|Estimate|October 1991||1991-10-31|May 2012|2012-05-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome|Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:04:32.113902|2018-06-01 05:04:32.113902
NCT00089973|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-18|2017-04-10||2017-08-18|2004-08-19|2004-08-20|Estimate|2017-08-18|2018-02-26|Actual||||2017-08-18|2018-02-26|Actual|June 30, 2004|Actual|2004-06-30|August 2017|2017-08-31|August 25, 2006|Actual|2006-08-25|August 25, 2006|Actual|2006-08-25||Interventional|||Study Of Ispinesib In Subjects With Breast Cancer|Phase II, Open Label Study of Ispinesib in Subjects With Advanced or Metastatic Breast Cancer|Completed||Phase 2|50|Actual|GlaxoSmithKline||1|||||||f||||||||||2018-06-01 05:04:32.231272|2018-06-01 05:04:32.231272
NCT00089960|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-18|||2013-04-25|2004-08-19|2004-08-20|Estimate|||||||2013-04-25|2013-04-29|Estimate|October 2004||2004-10-31|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2006|Actual|2006-06-30||Interventional|||Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)|An Open Label Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) Who Developed Progressive Disease or Relapsed While on Imatinib Mesylate|Completed||Phase 2|138|Actual|Amgen||1|||t||||||||||||||2018-06-01 05:04:32.6557|2018-06-01 05:04:32.6557
NCT00089947|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-18|||2015-03-16|2004-08-19|2004-08-20|Estimate|||||||2015-03-16|2015-03-18|Estimate|June 2003||2003-06-30|March 2015|2015-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection|Randomized, Prospective, Phase 2 Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Protocol With Standard Corticosteroid Therapy in Living Donor Renal Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy|Completed||Phase 2|150||Sanofi|||||||||||||||||||2018-06-01 05:04:32.73877|2018-06-01 05:04:32.73877
NCT00089921|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-17|||2010-10-15|2004-08-19|2004-08-20|Estimate|||||||2010-10-15|2010-10-18|Estimate|July 2004||2004-07-31|October 2010|2010-10-31|October 2005|Actual|2005-10-31|||||Interventional|||SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate|A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469 in Subjects With Active Rheumatoid Arthritis Who Are Not Receiving DMARDs Other Than Hydroxychloroquine|Completed||Phase 2|302|Actual|Scios, Inc.||4|||f||||||||||||||2018-06-01 05:04:32.826943|2018-06-01 05:04:32.826943
NCT00004900|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-05-29|2004-08-19|2004-08-20|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 1999||1999-10-31|October 2007|2007-10-31|August 2004|Actual|2004-08-31|||||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer|A Phase II Pilot Study of Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support Without Conventional-Dose Induction Chemotherapy for Women With Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:32.893635|2018-06-01 05:04:32.893635
NCT00004182|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21||2011-02-16|2012-05-31|2004-08-19|2004-08-20|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-31|2012-06-06|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer|Phase II Study for the Evaluation of CPT-11 (Irinotecan, Camptosar) in Patients With Metastatic or Recurrent Breast Cancer|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:04:32.951197|2018-06-01 05:04:32.951197
NCT00004136|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-07-27|2004-08-19|2004-08-20|Estimate|||||||2012-07-27|2012-07-30|Estimate|November 1999||1999-11-30|July 2012|2012-07-31|January 2006|Actual|2006-01-31|April 2000|Actual|2000-04-30||Interventional|||Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer|A Phase II Study of Radiofrequency Ablation of Unresectable Liver Tumors|Completed||Phase 2|59|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:04:33.002833|2018-06-01 05:04:33.002833
NCT00004042|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-07-17|2004-08-19|2004-08-20|Estimate|||||||2013-07-17|2013-07-18|Estimate|November 1998||1998-11-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|July 2001|Actual|2001-07-31||Interventional|||Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer|A Phase I Dose-Escalation Study of BIBH-1 in Patients With Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer|Completed||Phase 1|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:33.091054|2018-06-01 05:04:33.091054
NCT00003974|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-03|2004-08-19|2004-08-20|Estimate|||||||2011-03-03|2011-03-07|Estimate|August 1997||1997-08-31|March 2011|2011-03-31|November 2000|Actual|2000-11-30|June 1998|Actual|1998-06-30||Interventional|||Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma|An Evaluation of the Immunological Parameters Associated With a Skin-Test and Immunization of Lung and Mesothelioma Cancer Patients With Autologous Lung Tumor Associated Antigen: Characterization of the Patients' Cytolytic and Helper T Cell Reactivity for Identification of the Specific Antigen(s): A Pilot Study|Completed||Phase 1|20|Anticipated|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:04:33.152864|2018-06-01 05:04:33.152864
NCT00089908|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-17|||2008-01-17|2004-08-18|2004-08-19|Estimate|||||||2008-01-17|2008-01-18|Estimate|September 2004||2004-09-30|January 2008|2008-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults|Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-06-01 05:04:33.333193|2018-06-01 05:04:33.333193
NCT00089895|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-17|2009-11-13||2017-04-03|2004-08-18|2004-08-19|Estimate|2009-11-13|2009-12-21|Estimate||||2017-04-03|2017-05-09|Actual|November 1, 2004|Actual|2004-11-01|April 2017|2017-04-30|November 1, 2008|Actual|2008-11-01|November 1, 2008|Actual|2008-11-01||Interventional|||EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)|Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)|Completed||Phase 3|9406|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:04:33.434486|2018-06-01 05:04:33.434486
NCT00089882|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-17|||2009-07-22|2004-08-17|2004-08-18|Estimate|||||||2009-07-22|2009-07-23|Estimate|May 2003||2003-05-31|July 2009|2009-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II|Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II|Completed|||360||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:04:33.88241|2018-06-01 05:04:33.88241
NCT00089869|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-16|||2006-07-18|2004-08-17|2004-08-18|Estimate|||||||2006-07-18|2006-07-20|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia||Completed||Phase 1/Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:04:33.956094|2018-06-01 05:04:33.956094
NCT00089856|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-16|||2008-11-03|2004-08-17|2004-08-18|Estimate|||||||2008-11-03|2008-11-05|Estimate|July 2004||2004-07-31|November 2008|2008-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer|A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve|Terminated||Phase 3|626|Actual|Cell Genesys||2||Based on futility analysis showing <30% chance of meeting primary endpoint.|f||||||||||||||2018-06-01 05:04:34.039116|2018-06-01 05:04:34.039116
NCT00003951|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-15|2004-08-17|2004-08-18|Estimate|||||||2012-05-15|2012-05-16|Estimate|June 1999||1999-06-30|May 2012|2012-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Carcinoma of the Pancreas|Completed||Phase 2|37|Anticipated|Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:04:35.192233|2018-06-01 05:04:35.192233
NCT00003897|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-07-22|2004-08-17|2004-08-18|Estimate|||||||2015-07-22|2015-07-23|Estimate|May 1999||1999-05-31|July 2015|2015-07-31|December 2006|Actual|2006-12-31|March 2001|Actual|2001-03-31||Interventional|||Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma|Phase I Trial of Immunization Using Particle-Mediated Transfer of Genes for GP-100 and GM-CSF Into Uninvolved Skin of Patients With Melanoma (Summary Last Modified 7/1999)|Completed||Phase 1|18|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:04:35.255233|2018-06-01 05:04:35.255233
NCT00003885|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-08-17|2004-08-18|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 1997||1997-11-30|June 2000|2000-06-30||||||||Interventional|||Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma|Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:35.317201|2018-06-01 05:04:35.317201
NCT00003776|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-08-17|2004-08-18|Estimate|||||||2013-06-20|2013-06-21|Estimate|December 1998||1998-12-31|June 2013|2013-06-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma|A Phase II Window Study of Trimetrexate With Simultaneous Leucovorin Protection in the Treatment of Newly Diagnosed Patients With Metastatic Osteosarcoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:35.380535|2018-06-01 05:04:35.380535
NCT00003751|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-01|2004-08-17|2004-08-18|Estimate|||||||2012-05-01|2012-05-03|Estimate|March 1999||1999-03-31|May 2012|2012-05-31|July 2005|Actual|2005-07-31|June 2004|Actual|2004-06-30||Interventional|||Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma|Phase II Study of Penicillamine and Reduction of Copper for Angiosuppressive Therapy of Adults With Newly Diagnosed Glioblastoma|Completed||Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:04:35.446639|2018-06-01 05:04:35.446639
NCT00089843|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-16|2011-11-09||2012-05-01|2004-08-16|2004-08-17|Estimate|2012-05-01|2012-06-01|Estimate||||2012-05-01|2012-06-01|Estimate|June 2003||2003-06-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Bone Loss in Women With Anorexia Nervosa|IGF-1 and Bone Loss in Women Anorexia Nervosa|Completed||Phase 2/Phase 3|77|Actual|Massachusetts General Hospital||4|||f||||t||||||||||2018-06-01 05:04:35.538964|2018-06-01 05:04:35.538964
NCT00089830|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-16|||2007-11-27|2004-08-16|2004-08-17|Estimate|||||||2007-11-27|2007-11-28|Estimate|August 2004||2004-08-31|November 2007|2007-11-30|May 2007|Actual|2007-05-31|||||Interventional|||"A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat Wet Age-Related Macular Degeneration"||Terminated||Phase 2|120||Genaera Corporation|||||||||||||||||||2018-06-01 05:04:36.665567|2018-06-01 05:04:36.665567
NCT00089804|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-13|||2009-03-30|2004-08-16|2004-08-17|Estimate|||||||2009-03-30|2009-04-01|Estimate|October 2004||2004-10-31|March 2009|2009-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|ASPEN||Study of LJP 394 in Lupus Patients With History of Renal Disease|A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease|Terminated||Phase 3|943|Actual|La Jolla Pharmaceutical Company||3||Interim efficacy analysis indicated it would be futile to continue study.|f||||t||||||||||2018-06-01 05:04:36.975679|2018-06-01 05:04:36.975679
NCT00003709|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-07|2004-08-16|2004-08-17|Estimate|||||||2012-08-07|2012-08-09|Estimate|October 1998||1998-10-31|August 2012|2012-08-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetic Study of FB-642 Administered Orally on a Weekly Schedule to Patients With Advanced Solid Tumors|Completed||Phase 1|25|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:04:37.846129|2018-06-01 05:04:37.846129
NCT00003686|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-30|2004-08-16|2004-08-17|Estimate|||||||2013-05-30|2013-06-03|Estimate|August 1998||1998-08-31|January 2012|2012-01-31|November 1999|Actual|1999-11-30|October 1999|Actual|1999-10-31||Interventional|||Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids|A Double Blind Phase III Study of Oral Pilocarpine for Opioid-Induced Dry Mouth|Terminated||Phase 3|4|Actual|Canadian Cancer Trials Group||2||Terminated due to poor accrual.|f||||t||||||||||2018-06-01 05:04:37.982898|2018-06-01 05:04:37.982898
NCT00003684|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-11|2004-08-16|2004-08-17|Estimate|||||||2013-11-11|2013-11-13|Estimate|March 1998||1998-03-31|March 2010|2010-03-31|December 2008|Actual|2008-12-31|||||Interventional|||Theophylline in Treating Cancer Patients With Shortness of Breath|A Phase III Double-Blind Study of Theophylline Versus Placebo for the Treatment of Dyspnea in Cancer Patients|Completed||Phase 3|60|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:04:38.134372|2018-06-01 05:04:38.134372
NCT00003626|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-08-16|2004-08-17|Estimate|||||||2013-04-03|2013-04-05|Estimate|October 1998||1998-10-31|April 2013|2013-04-30|May 2000|Actual|2000-05-31|December 1999|Actual|1999-12-31||Interventional|||Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy|Phase II Evaluation of Dolastatin-10 in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:04:38.287709|2018-06-01 05:04:38.287709
NCT00003556|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-08-16|2004-08-17|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 1999||1999-01-31|February 2013|2013-02-28||||May 2001|Actual|2001-05-31||Interventional|||Vaccine Therapy in Treating Patients With Melanoma|Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) or a Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With Surgically Incurable Melanoma|Completed||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:04:38.464334|2018-06-01 05:04:38.464334
NCT00089791|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-13|2010-07-02|2009-11-23|2017-05-10|2004-08-13|2004-08-16|Estimate|2013-11-22|2014-01-10|Estimate|2009-11-23|2009-11-25|Estimate|2017-05-10|2017-06-09|Actual|August 1, 2004|Actual|2004-08-01|May 2017|2017-05-31|July 1, 2008|Actual|2008-07-01|May 1, 2008|Actual|2008-05-01||Interventional|||A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis|A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)|Completed||Phase 3|7808|Actual|Amgen||2|||f||||t||||||||||2018-06-01 05:04:38.772919|2018-06-01 05:04:38.772919
NCT00089752|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-12|2009-09-18||2017-06-26|2004-08-13|2004-08-16|Estimate|2017-06-26|2017-07-24|Actual||||2017-06-26|2017-07-24|Actual|September 2003||2003-09-30|June 2017|2017-06-30|November 2008|Actual|2008-11-30|August 2008|Actual|2008-08-31||Interventional|CATNAP||Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea|Impact of CPAP on Functional Outcomes in Milder Obstructive Sleep Apnea (CATNAP)|Completed||N/A|281|Actual|University of Pennsylvania|Post-randomization adverse events are summarized by treatment arm & body system.The CTC-AE (Publish Date December 12, 2003) was utilized for coding verbatim (raw) adverse event data with a MedDRA code, Body System, AE/Supraordinate term & Grade.|2|||f||||t||||||||Yes|Petition of Principal Investigator with document outlining purpose of secondary analysis and use of the data, which is then reviewed with co-investigators for overall approval.|2018-06-01 05:04:41.994151|2018-06-01 05:04:41.994151
NCT00088569|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-29|||2008-03-03|2004-07-29|2004-07-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2004||2004-07-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Observational|||Effect of Direct Current Polarization on Brain Function|Measuring the Brain Effects of DC Polarization With O-15 PET|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:33.992375|2018-06-01 05:05:33.992375
NCT00003555|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-08-13|2004-08-16|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 1998||1998-07-31|May 2006|2006-05-31|May 2003|Actual|2003-05-31|||||Interventional|||Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors|Use of Weekly One Hour Paclitaxel Infusion With Dose Escalation for Recurrent and Resistant Cancers, Using Amifostine as a Cytoprotector|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:42.945647|2018-06-01 05:04:42.945647
NCT00003543|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-08-13|2004-08-16|Estimate|||||||2013-06-25|2013-06-27|Estimate|June 1998||1998-06-30|June 2013|2013-06-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|Phase I Study of Combination Immunochemotherapy in Patients With Advanced Colorectal Carcinoma|Completed||Phase 1|18|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:43.201188|2018-06-01 05:04:43.201188
NCT00003400|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-28|2004-08-13|2004-08-16|Estimate|||||||2017-03-28|2017-03-30|Actual|September 1998|Actual|1998-09-30|March 2017|2017-03-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer|High Dose Chemotherapy With Stem Cell Rescue Followed By Consolidation Treatment in Patients With Metastatic Hormone-Refractory Prostate Cancer|Completed||Phase 2|45|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 05:04:43.635153|2018-06-01 05:04:43.635153
NCT00003395|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-08-13|2004-08-16|Estimate|||||||2013-06-24|2013-06-25|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer|Dose-Ranging Study of Arsenic Trioxide in Advanced Hematologic Cancers|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:44.085785|2018-06-01 05:04:44.085785
NCT00003380|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-07|2004-08-13|2004-08-16|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 1998||1998-05-31|October 2002|2002-10-31||||July 2002|Actual|2002-07-31||Interventional|||Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase I Study of Liposomal Doxorubicin (Doxil) and Prolonged Etoposide As Second Line Therapy in Ovarian, Tubal and Peritoneal Carcinoma|Terminated||Phase 1|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:04:44.402374|2018-06-01 05:04:44.402374
NCT00003360|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-15|2004-08-13|2004-08-16|Estimate|||||||2013-01-15|2013-01-16|Estimate|April 1998||1998-04-30|January 2013|2013-01-31||||August 2000|Actual|2000-08-31||Interventional|||Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer|Phase I Study of 131I-Labeled Humanized Antibody A33 in Patients With Advanced Colorectal Carcinoma|Completed||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:44.85295|2018-06-01 05:04:44.85295
NCT00003357|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-12-11|2004-08-13|2004-08-16|Estimate|||||||2012-12-11|2012-12-13|Estimate|January 1998||1998-01-31|December 2012|2012-12-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease|Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate Plus the Immunological Adjuvant QS21|Completed||Phase 1|9|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:45.111781|2018-06-01 05:04:45.111781
NCT00003348|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2004-08-13|2004-08-16|Estimate|||||||2013-02-15|2013-02-20|Estimate|May 1998||1998-05-31|February 2013|2013-02-28|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain|Phase I Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent, Persistent or Progressive Cerebral Anaplastic Gliomas|Completed||Phase 1|56|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:04:45.385438|2018-06-01 05:04:45.385438
NCT00003340|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-01|2004-08-13|2004-08-16|Estimate|||||||2014-05-01|2014-05-02|Estimate|November 1997||1997-11-30|May 2014|2014-05-31|February 2000|Actual|2000-02-29|February 2000|Actual|2000-02-29||Interventional|||Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia|A Phase II Study of Cyclophosphamide Followed by Topotecan in Patients With Refractory or Relapsed Acute Myelogenous Leukemia|Completed||Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:04:45.694928|2018-06-01 05:04:45.694928
NCT00003312|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-23|2004-08-13|2004-08-16|Estimate|||||||2014-01-23|2014-01-24|Estimate|September 1998||1998-09-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|January 2004|Actual|2004-01-31||Interventional|||Brachytherapy in Treating Patients With Prostate Cancer|Phase II Trial of Transrectal Ultrasound Guided Permanent Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate|Completed||Phase 2|95|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:04:46.015049|2018-06-01 05:04:46.015049
NCT00089778|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-12|2012-06-25||2017-07-03|2004-08-12|2004-08-13|Estimate|2012-09-11|2012-10-11|Estimate||||2017-07-03|2017-08-01|Actual|September 10, 2004|Actual|2004-09-10|July 2017|2017-07-31|August 5, 2008|Actual|2008-08-05|August 5, 2008|Actual|2008-08-05||Interventional|||Vaccine Treatment of Kidney Cancer|Immunization of Patients With Renal Cancer Using HLA-A2 and HLA-A3-Binding Peptides From Fibroblast Growth Factors 5 (FGF-5)|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||3||fewer tumors than expected expressed FGF-5, led to end of accrual to cohorts A&B|f||||f|t|f||||||No||2018-06-01 05:04:47.633047|2018-06-01 05:04:47.633047
NCT00089765|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-12|||2017-06-30|2004-08-12|2004-08-13|Estimate|||||||2017-06-30|2017-07-02|Actual|August 10, 2004||2004-08-10|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome|Pilot Study of Intravitreal Injection of Ranibizumab (rhuFAB V2) for Advanced Ocular Disease of Von Hippel-Lindau (VHL) Disease|Completed||Phase 1|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:04:49.556121|2018-06-01 05:04:49.556121
NCT00003294|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-03|2004-08-12|2004-08-13|Estimate|||||||2011-03-03|2011-03-07|Estimate|May 1997||1997-05-31|March 2011|2011-03-31|May 2004|Actual|2004-05-31|April 1999|Actual|1999-04-30||Interventional|||Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer|Initial Clinical Evaluation of the Combination of Paclitaxel and Carboplatin With Modulation of Toxicity With GCSF and Amifostine|Completed||Phase 1|24|Anticipated|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:04:49.695872|2018-06-01 05:04:49.695872
NCT00003284|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-08-12|2004-08-13|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 1998||1998-01-31|June 2000|2000-06-30||||||||Interventional|||High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer|Tandem Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) After High Dose Paclitaxel Followed by Ifosfamide, Carboplatin, and Etoposide (ICE) for the Treatment of Lung Cancer|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:49.782769|2018-06-01 05:04:49.782769
NCT00003251|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-08-12|2004-08-13|Estimate|||||||2013-12-03|2013-12-04|Estimate|December 1997||1997-12-31|June 2000|2000-06-30||||||||Interventional|||Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer|A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|46|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:49.935364|2018-06-01 05:04:49.935364
NCT00003220|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-08-12|2004-08-13|Estimate|||||||2013-04-03|2013-04-05|Estimate|February 1998||1998-02-28|April 2013|2013-04-30|June 2001|Actual|2001-06-30|November 2000|Actual|2000-11-30||Interventional|||Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer|Phase II Study of Bryostatin 1 in Patients With Metastatic Colo-Rectal Adenocarcinoma|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:04:50.144645|2018-06-01 05:04:50.144645
NCT00003200|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-17|2004-08-12|2004-08-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|October 1995||1995-10-31|January 2017|2017-01-31|June 2008|Actual|2008-06-30|October 2006|Actual|2006-10-31||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck|Taxotere Plus Concurrent Radiotherapy After Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck (TAXT-XRT)|Completed||Phase 1|22|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 05:04:50.585862|2018-06-01 05:04:50.585862
NCT00089739|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-11|||2017-06-30|2004-08-11|2004-08-12|Estimate|||||||2017-06-30|2017-07-02|Actual|August 9, 2004||2004-08-09|October 28, 2008|2008-10-28|October 28, 2008||2008-10-28|||||Observational|||Immune Indicators of Uveitis|Use of Immune Cell Markers, Cytokines, Transcription Factors and Surface CD Markers as Markers of Ocular Inflammatory Activity|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:04:51.309776|2018-06-01 05:04:51.309776
NCT00089726|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-11|||2007-12-18|2004-08-11|2004-08-12|Estimate|||||||2007-12-18|2007-12-24|Estimate|March 2003||2003-03-31|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|||A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)|A Phase II Randomized Study of GM-CSF Gene-Modified Autologous Tumor Vaccine (CG8123) With and Without Low-Dose Cyclophosphamide in Advanced Stage Non-Small Cell Lung Cancer|Completed||Phase 2|100||Cell Genesys|||||||||||||||||||2018-06-01 05:04:51.62379|2018-06-01 05:04:51.62379
NCT00089713|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-10|||2010-02-05|2004-08-11|2004-08-12|Estimate|||||||2010-02-05|2010-02-08|Estimate|March 2004||2004-03-31|June 2005|2005-06-30||||||||Interventional|||Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)|Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients|Terminated||Phase 2|392||Synvista Therapeutics, Inc|||||||||||||||||||2018-06-01 05:04:51.89381|2018-06-01 05:04:51.89381
NCT00089700|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-10|||2005-06-23|2004-08-11|2004-08-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2004||2004-03-31|February 2005|2005-02-28||||||||Interventional|||TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Three-Arm Study of the Anti-CD4 Monoclonal Antibody TNX-355 With Optimized Background Therapy in Treatment-Experienced Subjects Infected With HIV-1|Unknown status|Active, not recruiting|Phase 2|80||Tanox|||||||||||||||||||2018-06-01 05:04:52.968391|2018-06-01 05:04:52.968391
NCT00003197|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-08-11|2004-08-12|Estimate|||||||2013-06-24|2013-06-26|Estimate|December 1997||1997-12-31|June 2013|2013-06-30|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|||Green Tea Extract in Treating Patients With Advanced Solid Tumors|Phase I Evaluation of Green Tea Extract in Adults With Advanced Solid Tumors|Completed||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:53.680723|2018-06-01 05:04:53.680723
NCT00003123|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-08-11|2004-08-12|Estimate|||||||2013-11-05|2013-11-06|Estimate|August 1997||1997-08-31|January 2004|2004-01-31||||||||Interventional|||Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome|A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:53.93633|2018-06-01 05:04:53.93633
NCT00003115|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-02-22|2004-08-11|2004-08-12|Estimate|||||||2011-02-22|2011-02-23|Estimate|June 1996||1996-06-30|February 2011|2011-02-28|February 2004|Actual|2004-02-29|January 2003|Actual|2003-01-31||Interventional|||Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy|Spinal Effects of Epidural Hydromorphone|Completed||Phase 3|40|Anticipated|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:04:54.409747|2018-06-01 05:04:54.409747
NCT00003102|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-12-02|2004-08-11|2004-08-12|Estimate|||||||2009-12-02|2009-12-03|Estimate|July 1997||1997-07-31|December 2009|2009-12-31||||August 2000|Actual|2000-08-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer|Phase I/II Study of 131-I-Labeled Chimeric Antibody G250 (131-I-cG250) in Patients With Advanced Renal Carcinoma|Completed||Phase 1/Phase 2|48|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:54.762897|2018-06-01 05:04:54.762897
NCT00003058|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-02-09|2004-08-11|2004-08-12|Estimate|||||||2017-02-09|2017-02-13|Actual|June 1997||1997-06-30|February 2017|2017-02-28|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Troglitazone in Treating Patients With Liposarcoma|Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma|Completed||Phase 2|85|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 05:04:55.261183|2018-06-01 05:04:55.261183
NCT00003044|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-08-11|2004-08-12|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 1996||1996-09-30|April 2000|2000-04-30||||||||Interventional|||Chemotherapy in Treating Patients With Liver Cancer|A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010) Administered to Patients With Unresectable Primary Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 2|55|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:04:55.661738|2018-06-01 05:04:55.661738
NCT00003025|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2004-08-11|2004-08-12|Estimate|||||||2013-07-01|2013-07-03|Estimate|March 1997||1997-03-31|July 2013|2013-07-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer|A Phase I Pilot Trial of Immunotherapy With Autologous Tumor-Derived gp96 Heat Shock Protein - Peptide Complex (HSPPC-96) in Patients With Resected Pancreatic Adenocarcinoma|Completed||Phase 1|16|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:04:55.9794|2018-06-01 05:04:55.9794
NCT00003003|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-03-15|2004-08-11|2004-08-12|Estimate|||||||2018-03-15|2018-03-19|Actual|September 1996||1996-09-30|June 2000|2000-06-30|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia|A Pilot Clinical Trial of Mitomycin C Modulation of Multidrug Resistance Proteins and a Phase I Evaluation of Mitomycin C and Mitoxantrone in Patients With Acute Myelogenous Leukemia|Completed||Phase 1|29|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 05:04:56.288663|2018-06-01 05:04:56.288663
NCT00002955|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-08-11|2004-08-12|Estimate|||||||2014-05-20|2014-05-22|Estimate|August 1995||1995-08-31|May 2014|2014-05-31|June 2006|Actual|2006-06-30|May 2000|Actual|2000-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas|Modulation of 5-Fluorouracil With Trimetrexate and Leucovorin in Advanced Pancreatic Cancer|Completed||Phase 2|21|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:04:56.730617|2018-06-01 05:04:56.730617
NCT00002933|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-09|2004-08-11|2004-08-12|Estimate|||||||2010-06-09|2010-06-10|Estimate|September 1996||1996-09-30|June 2010|2010-06-30|January 2001|Actual|2001-01-31|July 2000|Actual|2000-07-31||Interventional|||Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer|CWRU 1296: Biochemical and Pharmacokinetic Predictors of Colon Cancer Response to a Topoisomerase I Directed Treatment With Irinotecan|Completed||Phase 2|21|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:04:56.983842|2018-06-01 05:04:56.983842
NCT00089687|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-10|||2017-01-10|2004-08-10|2004-08-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|April 2004||2004-04-30|January 2005|2005-01-31|May 2005||2005-05-31|||||Interventional|||GBR 12909 Study in Cocaine Experienced African American Volunteers - 1|GBR 12909 Study in Cocaine Experienced African American Volunteers|Unknown status|Active, not recruiting|Phase 1|10||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:04:57.097543|2018-06-01 05:04:57.097543
NCT00089674|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-09|2010-07-02|2009-11-23|2016-02-22|2004-08-10|2004-08-11|Estimate|2014-05-08|2014-06-03|Estimate|2009-11-23|2009-11-25|Estimate|2016-02-22|2016-03-21|Estimate|August 2004||2004-08-31|February 2016|2016-02-29|July 2010|Actual|2010-07-31|June 2008|Actual|2008-06-30||Interventional|||AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer|Completed||Phase 3|1468|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:04:57.239096|2018-06-01 05:04:57.239096
NCT00089661|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-09|2009-12-22|2009-11-19|2013-07-23|2004-08-10|2004-08-11|Estimate|2009-12-22|2010-01-26|Estimate|2009-11-19|2009-11-23|Estimate|2013-07-23|2013-07-30|Estimate|October 2004||2004-10-31|July 2013|2013-07-31|December 2009|Actual|2009-12-31|June 2006|Actual|2006-06-30||Interventional|||AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer|Completed||Phase 3|252|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:04:59.115082|2018-06-01 05:04:59.115082
NCT00089648|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-09|2009-11-16||2010-01-06|2004-08-10|2004-08-11|Estimate|2009-11-16|2009-12-21|Estimate||||2010-01-06|2010-01-12|Estimate|December 2004||2004-12-31|January 2010|2010-01-31|March 2008|Actual|2008-03-31|January 2007|Actual|2007-01-31||Interventional|||SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma|A Phase 2 Study Of SU011248 In The Treatment Of Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma|Completed||Phase 2|61|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 05:04:59.874014|2018-06-01 05:04:59.874014
NCT00089635|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-09|2010-08-06||2013-10-07|2004-08-10|2004-08-11|Estimate|2013-10-07|2013-12-05|Estimate||||2013-10-07|2013-12-05|Estimate|August 2004||2004-08-31|October 2013|2013-10-31|December 2008|Actual|2008-12-31|May 2007|Actual|2007-05-31||Interventional|||ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer|A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy|Completed||Phase 2|203|Actual|Amgen||1|||f||||||||||||||2018-06-01 05:05:00.660548|2018-06-01 05:05:00.660548
NCT00002914|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-25|2004-08-10|2004-08-11|Estimate|||||||2010-01-25|2010-01-27|Estimate|May 1997||1997-05-31|January 2010|2010-01-31|March 2004|Actual|2004-03-31|June 2001|Actual|2001-06-30||Interventional|||Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract|PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM|Completed||Phase 2|40|Anticipated|Eastern Cooperative Oncology Group|||||||||f||||||||||2018-06-01 05:05:01.091613|2018-06-01 05:05:01.091613
NCT00002909|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-08-10|2004-08-11|Estimate|||||||2013-02-04|2013-02-05|Estimate|February 1997||1997-02-28|February 2001|2001-02-28||||October 2000|Actual|2000-10-31||Interventional|||Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma|A PHASE I CLINICAL AND PHARMACOLOGIC EVALUATION OF PHENYLBUTYRATE IN PATIENTS WITH REFRACTORY SOLID TUMORS: STUDY OF CONTINUOUS EXPOSURE ORAL PHENYLBUTYRATE ON A THREE TIMES DAILY SCHEDULE|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:01.245423|2018-06-01 05:05:01.245423
NCT00002890|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-08-10|2004-08-11|Estimate|||||||2013-06-24|2013-06-25|Estimate|October 1996||1996-10-31|June 2013|2013-06-30|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia|PHASE I DOSE-ESCALATION TRIAL OF YTTRIUM-90-LABELED HuM195 (HUMANIZED ANTI-CD33) IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES|Completed||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:01.378194|2018-06-01 05:05:01.378194
NCT00002865|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-12|2004-08-10|2004-08-11|Estimate|||||||2017-01-12|2017-01-13|Estimate|April 1995||1995-04-30|September 2015|2015-09-30|August 2001|Actual|2001-08-31|June 2000|Actual|2000-06-30||Interventional|||High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia|HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN|Completed||Phase 2|25|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 05:05:01.473088|2018-06-01 05:05:01.473088
NCT00002749|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-10-12|2004-08-10|2004-08-11|Estimate|||||||2009-10-12|2009-10-14|Estimate|February 1993||1993-02-28|October 2009|2009-10-31|March 2000|Actual|2000-03-31|||||Interventional|||Carboplatin in Patients With Progressive Gliomas|PHASE II STUDY OF CARBOPLATIN (CBDCA) IN THE TREATMENT OF CHILDREN AND ADULTS WITH PROGRESSIVE LOW GRADE GLIOMAS|Completed||Phase 2|25|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:05:01.616224|2018-06-01 05:05:01.616224
NCT00002655|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-19|2004-08-10|2004-08-11|Estimate|||||||2013-07-19|2013-07-22|Estimate|March 1995||1995-03-31|July 2013|2013-07-31|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Cryosurgery in Treating Patients With Liver Cancer or Liver Metastases|Cryosurgical Destruction of Surgically Incurable Liver Tumors|Completed||Phase 2|||University of Colorado, Denver|||||f||||t||||||||||2018-06-01 05:05:01.744204|2018-06-01 05:05:01.744204
NCT00002635|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-24|2004-08-10|2004-08-11|Estimate|||||||2013-07-24|2013-07-26|Estimate|May 1995||1995-05-31|March 2001|2001-03-31|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||Aminocamptothecin in Treating Patients With T-cell Lymphoma|PHASE II TRIAL OF 9-AMINOCAMPTOTHECIN IN ADVANCED CUTANEOUS T CELL LYMPHOMA|Completed||Phase 2|12|Actual|Yale University|||||f||||f||||||||||2018-06-01 05:05:02.020133|2018-06-01 05:05:02.020133
NCT00002619|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-08|2004-08-10|2004-08-11|Estimate|||||||2012-11-08|2012-11-09|Estimate|September 1994||1994-09-30|June 2000|2000-06-30||||April 2000|Actual|2000-04-30||Interventional|||Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors|A TRIAL OF INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RECONSTITUTION FOR PATIENTS BETWEEN SIX AND SIXTY YEARS OF AGE, WITH NON-PROGRESSIVE GLIOBLASTOMA MULTIFORME OR DIFFUSE INTRINSIC BRAINSTEM TUMORS, FOLLOWING INITIAL LOCAL-FIELD IRRADIATION|Completed||Phase 2|60|Anticipated|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:05:02.123085|2018-06-01 05:05:02.123085
NCT00002609|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-08-10|2004-08-11|Estimate|||||||2013-06-20|2013-06-24|Estimate|August 1994||1994-08-31|June 2013|2013-06-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission|PHASE II TRIAL OF POST-REMISSION THERAPY WITH HuM195 AND CYTOTOXIC CHEMOTHERAPY FOR ACUTE PROMYELOCYTIC LEUKEMIA|Completed||Phase 2|40|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:02.238078|2018-06-01 05:05:02.238078
NCT00002585|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-09|2004-08-10|2004-08-11|Estimate|||||||2012-03-09|2012-03-12|Estimate|February 1994||1994-02-28|March 2012|2012-03-31|January 2001|Actual|2001-01-31|October 1999|Actual|1999-10-31||Interventional|||Pyrazoloacridine in Treating Women With Metastatic Breast Cancer|PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH METASTATIC BREAST CANCER|Completed||Phase 2|20|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||f||||||||||2018-06-01 05:05:02.547815|2018-06-01 05:05:02.547815
NCT00089596|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-06|||2007-04-11|2004-08-09|2004-08-10|Estimate|||||||2007-04-11|2007-04-12|Estimate|March 2004||2004-03-31|April 2007|2007-04-30|October 2006||2006-10-31|||||Interventional|||Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers|A Safety Study of Infusion of Ex Vivo Selectively Amplified Unrelated Cord Blood Stem Cells in Subjects With Hematological Malignancies Receiving Unrelated Cord Blood Transplantation|Completed||Phase 1/Phase 2|10||ViaCell|||||f||||||||||||||2018-06-01 05:05:02.625729|2018-06-01 05:05:02.625729
NCT00089583|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-06|2012-02-24||2017-01-20|2004-08-09|2004-08-10|Estimate|2012-05-17|2012-06-21|Estimate||||2017-01-20|2017-03-07|Actual|July 2004||2004-07-31|January 2017|2017-01-31|July 2013|Actual|2013-07-31|March 2011|Actual|2011-03-31||Interventional|||48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection|A 48 Week, Phase II, Non-Comparative, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir BID When Administered to HIV-1 Infected, PI-Naïve and Experienced, Pediatric Subjects, 2 to 18 Years Old and of GW433908 BID Administered to PI-Naïve, Pediatric Subjects 2 to < 6 Years Old|Completed||Phase 2|110|Actual|ViiV Healthcare||2|||f||||t||||||||||2018-06-01 05:05:02.822475|2018-06-01 05:05:02.822475
NCT00005626|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-09-24|2004-08-09|2004-08-10|Estimate|||||||2012-09-24|2012-09-25|Estimate|February 1998||1998-02-28|September 2012|2012-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)|Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies|Completed||Phase 2|10|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:05:04.885531|2018-06-01 05:05:04.885531
NCT00005607|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-12-18|2004-08-09|2004-08-10|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2000||2000-02-29|July 2000|2000-07-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus|A Phase II Study of CPT-11 and 5-FU/LCV in Patients With Previously Untreated Gastric Adenocarcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:04.966798|2018-06-01 05:05:04.966798
NCT00002574|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-08-09|2004-08-10|Estimate|||||||2013-02-04|2013-02-05|Estimate|September 1994||1994-09-30|October 2001|2001-10-31||||June 2001|Actual|2001-06-30||Interventional|||Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia|PHASE II STUDY OF SIMULTANEOUS HOMOHARRINGTONINE (NSC 141633) AND ALPHA INTERFERON (IFN-A) THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA (CML)|Completed||Phase 2|87|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:05.138501|2018-06-01 05:05:05.138501
NCT00002562|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2004-08-09|2004-08-10|Estimate|||||||2013-06-19|2013-06-20|Estimate|March 1994||1994-03-31|December 2005|2005-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer|EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA|Completed||Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:05.234361|2018-06-01 05:05:05.234361
NCT00002507|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-24|2004-08-09|2004-08-10|Estimate|||||||2013-07-24|2013-07-25|Estimate|November 1992||1992-11-30|June 2000|2000-06-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer|RADIATION WITH MITOMYCIN C OR PORFIROMYCIN IN THE TREATMENT OF CANCER OF THE HEAD AND NECK AREA|Completed||Phase 3|||Yale University|||||f||||||||||||||2018-06-01 05:05:05.357123|2018-06-01 05:05:05.357123
NCT00089622|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-06|||2017-06-30|2004-08-06|2004-08-09|Estimate|||||||2017-06-30|2017-07-02|Actual|August 4, 2004||2004-08-04|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Interventional|||Lisuride Patch to Treat Parkinson's Disease|Transcutaneous Lisuride Therapy of Parkinson's Disease|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:05.426003|2018-06-01 05:05:05.426003
NCT00089609|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-06|2012-10-12||2018-03-22|2004-08-06|2004-08-09|Estimate|2012-10-12|2012-11-14|Estimate||||2018-03-22|2018-04-20|Actual|April 19, 2005|Actual|2005-04-19|March 2018|2018-03-31|January 9, 2018|Actual|2018-01-09|December 31, 2011|Actual|2011-12-31||Interventional|||Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer|A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients With Androgen-Independent Prostate Cancer|Completed||Phase 2|73|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||t|||No||2018-06-01 05:05:05.528092|2018-06-01 05:05:05.528092
NCT00089570|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-06|||2017-10-25|2004-08-06|2004-08-09|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2004||2004-06-30|October 2017|2017-10-31|September 2006|Actual|2006-09-30|March 2006|Actual|2006-03-31||Interventional|||Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1|Completed||Phase 3|112|Actual|Mallinckrodt||2|||f||||t||||||||||2018-06-01 05:05:07.401924|2018-06-01 05:05:07.401924
NCT00089557|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-06|||2005-06-23|2004-08-06|2004-08-09|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 2004|2004-09-30||||||||Interventional|||An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain|An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain|Terminated||Phase 2|||NeurogesX|||||||||||||||||||2018-06-01 05:05:07.537902|2018-06-01 05:05:07.537902
NCT00089544|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-06|2013-03-13||2018-03-16|2004-08-06|2004-08-09|Estimate|2013-05-15|2013-07-10|Estimate||||2018-03-16|2018-04-13|Actual|June 17, 2004|Actual|2004-06-17|March 2018|2018-03-31|November 5, 2013|Actual|2013-11-05|September 27, 2011|Actual|2011-09-27||Interventional||All eligible patients who started treatment.|Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall|A Pilot Phase II Study of Pre-Operative Radiation Therapy and Thalidomide (IND 48832; NSC 66847) for Low Grade Primary Soft Tissue Sarcoma or Pre-Operative MAID/Thalidomide/Radiation Therapy for High/Intermediate Grade Primary Soft Tissue Sarcoma of the Extremity or Body Wall|Terminated||Phase 2|23|Actual|National Cancer Institute (NCI)|This study closed early due to unacceptably high rate of thromboembolic events in Cohort A and due to low accrual in Cohort B. For this reason efficacy endpoints other than response to pre-operative therapy were not reported.|2|||f||||||||||||||2018-06-01 05:05:07.629225|2018-06-01 05:05:07.629225
NCT00005591|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-12-11|2004-08-06|2004-08-09|Estimate|||||||2013-12-11|2013-12-13|Estimate|October 1999||1999-10-31|April 2007|2007-04-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas|Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody C225 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer|Withdrawn||Phase 2|0|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 05:05:08.296041|2018-06-01 05:05:08.296041
NCT00005076|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-04-10|2004-08-06|2004-08-09|Estimate|||||||2013-04-10|2013-04-12|Estimate|October 1999||1999-10-31|April 2013|2013-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer|Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Chemotherapy in Patients With Advanced Colorectal Carcinoma|Completed||Phase 2|110|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:05:08.380334|2018-06-01 05:05:08.380334
NCT00005070|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-06-18|2004-08-06|2004-08-09|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer|A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:08.458818|2018-06-01 05:05:08.458818
NCT00005057|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2015-04-28|2004-08-06|2004-08-09|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2000||2000-03-31|December 2002|2002-12-31||||||||Interventional|||Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma|A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:08.530449|2018-06-01 05:05:08.530449
NCT00005056|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-06-25|2004-08-06|2004-08-09|Estimate|||||||2013-06-25|2013-06-26|Estimate|March 1999||1999-03-31|June 2006|2006-06-30|July 2006|Actual|2006-07-31|||||Interventional|||Bryostatin 1 In Treating Patients With Progressive Kidney Cancer|A Phase II Trial of Bryostatin-1 in Hypernephroma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:08.622596|2018-06-01 05:05:08.622596
NCT00004937|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-07-10|2004-08-06|2004-08-09|Estimate|||||||2012-07-10|2012-07-11|Estimate|October 1999||1999-10-31|July 2012|2012-07-31||||May 2000|Actual|2000-05-31||Interventional|||Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme|Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme|Completed||Phase 2|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:05:08.709652|2018-06-01 05:05:08.709652
NCT00004219|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-08-01|2004-08-06|2004-08-09|Estimate|||||||2013-08-01|2013-08-02|Estimate||||June 2007|2007-06-30||||||||Interventional|||Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma|A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:08.786869|2018-06-01 05:05:08.786869
NCT00004215|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-06-18|2004-08-06|2004-08-09|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 1999||1999-08-31|June 2013|2013-06-30|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia|"Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin 7+3 Regimen"|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:08.858676|2018-06-01 05:05:08.858676
NCT00004207|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2014-06-23|2004-08-06|2004-08-09|Estimate|||||||2014-06-23|2014-06-24|Estimate|December 1997||1997-12-31|July 2000|2000-07-31||||||||Interventional|||Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer|A Phase I Study to Determine the Maximum Tolerated Dose of Daunoxome as Therapy for the Treatment of Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:08.940571|2018-06-01 05:05:08.940571
NCT00089531|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|||2017-06-30|2004-08-05|2004-08-06|Estimate|||||||2017-06-30|2017-07-02|Actual|August 2, 2004||2004-08-02|January 15, 2008|2008-01-15|January 15, 2008||2008-01-15|||||Interventional|||Candidate HIV Vaccine|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a 6-Plasmid Multiclade HIV-1 DNA Vaccine, VRC-HIVDNA016-00-VP, in Uninfected Adult Volunteers|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:09.006221|2018-06-01 05:05:09.006221
NCT00089518|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|||2015-03-05|2004-08-05|2004-08-06|Estimate|||||||2015-03-05|2015-03-09|Estimate||||August 2009|2009-08-31||||||||Interventional|||Optimal Treatment for Kidney Disease in HIV Infected Adults|A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of an Angiotensin Receptor Blocker (Valsartan) and Highly Active Antiretroviral Therapy (HAART) Versus HAART Alone for the Treatment of HIV-Associated Nephropathy|Withdrawn||Phase 3|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:05:09.075221|2018-06-01 05:05:09.075221
NCT00089505|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|2010-08-30||2016-01-04|2004-08-05|2004-08-06|Estimate|2011-01-07|2011-02-04|Estimate||||2016-01-04|2016-02-03|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|February 2011|Actual|2011-02-28|August 2010|Actual|2010-08-31||Interventional|OCTANE||NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission|Optimal Combination Therapy After Nevirapine Exposure|Completed||Phase 3|745|Actual|AIDS Clinical Trials Group||4|||f||||t||||||||||2018-06-01 05:05:09.218052|2018-06-01 05:05:09.218052
NCT00089492|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|||2016-11-01|2004-08-05|2004-08-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2004||2004-07-31|November 2016|2016-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients|A Phase II Open-label, Randomized, Active-controlled Study Comparing the Efficacy and Safety of Once Daily Enfuvirtide Dosing Versus the Currently Recommended Twice Daily Dosing in HIV-1 Infected Treatment-experienced Patients.|Completed||Phase 2|64|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:05:10.847847|2018-06-01 05:05:10.847847
NCT00089479|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|2011-03-31||2012-12-19|2004-08-05|2004-08-06|Estimate|2011-05-24|2011-06-23|Estimate||||2012-12-19|2012-12-21|Estimate|August 2002||2002-08-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|June 2010|Actual|2010-06-30||Interventional|||A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer|A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer|Completed||Phase 3|2611|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:05:10.994827|2018-06-01 05:05:10.994827
NCT00089466|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05||2009-11-16|2012-10-26|2004-08-05|2004-08-06|Estimate||||2009-11-16|2009-11-18|Estimate|2012-10-26|2012-10-31|Estimate|November 2004||2004-11-30|October 2012|2012-10-31|January 2009|Actual|2009-01-31|June 2006|Actual|2006-06-30||Interventional|||Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients|Phase IB/IIA Dose-Finding Safety and Activity Study of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor) in HIV-Infected Subjects|Completed||Phase 1/Phase 2|6|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||||||||||||2018-06-01 05:05:11.92698|2018-06-01 05:05:11.92698
NCT00089453|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|||2012-04-17|2004-08-05|2004-08-06|Estimate|||||||2012-04-17|2012-04-19|Estimate|September 2003||2003-09-30|April 2012|2012-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant|UARK 2003-18, A Phase II Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant in Relapsed Multiple Myeloma|Completed||Phase 1|10|Actual|University of Arkansas|||||f||||f||||||||||2018-06-01 05:05:12.018977|2018-06-01 05:05:12.018977
NCT00089440|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|||2017-01-10|2004-08-05|2004-08-06|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2004||2004-06-30|July 2005|2005-07-31|March 2005||2005-03-31|||||Interventional|||Assessment of Interactions Between Methamphetamine and Aripiprazole - 1|Assessment of Interactions Between IV Methamphetamine and Aripiprazole|Unknown status|Active, not recruiting|Phase 1|17||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:05:12.104662|2018-06-01 05:05:12.104662
NCT00089427|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-05|||2011-06-30|2004-08-05|2004-08-06|Estimate|||||||2011-06-30|2011-07-04|Estimate|July 2004||2004-07-31|April 2011|2011-04-30||||July 2007|Actual|2007-07-31||Interventional|||IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma|Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma|Completed||Phase 1|24||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:05:12.170866|2018-06-01 05:05:12.170866
NCT00089414|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2013-01-14||2017-07-26|2004-08-04|2004-08-05|Estimate|2016-11-02|2017-01-02|Estimate||||2017-07-26|2017-08-25|Actual|July 2004||2004-07-31|July 2017|2017-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives|The Treatment of Menstrually-Related Mood Disorders With Extended Versus Interrupted Oral Contraceptives|Terminated||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|Protocol terminated after receiving information from manufacturer (Pharma) that CDB-2914 crosses the blood-brain barrier, invalidating Arm #3 due to potential CNS effect of the compound on behavior.|3||"Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of~   protocol."|f||||f||||||||||2018-06-01 05:05:12.252191|2018-06-01 05:05:12.252191
NCT00089401|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2012-05-11|2004-08-04|2004-08-05|Estimate|||||||2012-05-11|2012-05-14|Estimate|July 2004||2004-07-31|May 2012|2012-05-31|March 2008|Actual|2008-03-31|November 2006|Actual|2006-11-30||Interventional|||Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver|A Phase II Trial Of Isolated Hepatic Perfusion (IHP) With Melphalan For Subjects With Metastatic Unresectable Colorectal Cancers Of The Liver With Disease Refractory To First Line Systemic Chemotherapy|Completed||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:12.544264|2018-06-01 05:05:12.544264
NCT00089388|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-01-23|2004-08-04|2004-08-05|Estimate|||||||2013-01-23|2013-01-24|Estimate|July 2004||2004-07-31|January 2013|2013-01-31||||June 2006|Actual|2006-06-30||Interventional|||Cilengitide in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of EMD 121974 as Maintenance Therapy for Patinets With Acute Myeloid Leukemia in Complete Remission|Terminated||Phase 2|70|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:05:12.612934|2018-06-01 05:05:12.612934
NCT00089362|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-04-09|2004-08-04|2004-08-05|Estimate|||||||2013-04-09|2013-04-10|Estimate|July 2004||2004-07-31|April 2013|2013-04-30||||January 2008|Actual|2008-01-31||Interventional|||Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors|Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors.|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:12.694074|2018-06-01 05:05:12.694074
NCT00089349|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-06-04|2004-08-04|2004-08-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|July 2004||2004-07-31|June 2013|2013-06-30||||September 2006|Actual|2006-09-30||Interventional|||Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia|A Phase II Study of Campath-1H in Children With Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:12.801109|2018-06-01 05:05:12.801109
NCT00089323|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2016-06-02|2004-08-04|2004-08-05|Estimate|||||||2016-06-02|2016-06-03|Estimate|January 2007||2007-01-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer|Bone Marrow Analysis In Early-Stage Breast Cancer|Active, not recruiting||N/A|1630|Actual|NSABP Foundation Inc||1|||f||||f||||||||||2018-06-01 05:05:12.910876|2018-06-01 05:05:12.910876
NCT00089310|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2016-06-28|2004-08-04|2004-08-05|Estimate|||||||2016-06-28|2016-06-30|Estimate|September 2004||2004-09-30|June 2016|2016-06-30|April 2009|Actual|2009-04-30|February 2007|Actual|2007-02-28||Interventional|||Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer|Intraoperative Sentinel Node Mapping In Non-Small Cell Lung Cancer|Completed||N/A|46|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:05:13.058961|2018-06-01 05:05:13.058961
NCT00089297|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2012-12-31||2013-02-07|2004-08-04|2004-08-05|Estimate|2013-02-07|2013-03-11|Estimate||||2013-02-07|2013-03-11|Estimate|December 2004||2004-12-31|December 2012|2012-12-31|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Interventional|||Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer|Phase II Evaluation of Cetuximab (C225) Combined With Induction Paclitaxel and Carboplatin Followed by C225, Paclitaxel, Carboplatin, and Radiation for Stage III/IV Operable Squamous Cancer of the Head and Neck|Completed||Phase 2|74|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:05:13.201375|2018-06-01 05:05:13.201375
NCT00089284|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2011-04-11|2004-08-04|2004-08-05|Estimate|||||||2011-04-11|2011-04-12|Estimate|September 2003||2003-09-30|April 2011|2011-04-30|April 2012|Anticipated|2012-04-30|December 2007|Actual|2007-12-31||Interventional|||Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL|A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90-Yttrium- Zevalin and the Redox- Modulating Agent, Motexafin Gadolinium (MGd)|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Actual|Northwestern University||1|||f||||t||||||||||2018-06-01 05:05:13.57546|2018-06-01 05:05:13.57546
NCT00089271|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-01-24|2004-08-04|2004-08-05|Estimate|||||||2013-01-24|2013-01-25|Estimate|July 2004||2004-07-31|January 2013|2013-01-31||||June 2010|Actual|2010-06-30||Interventional|||17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas|A Phase I Study Of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin, (17-DMAG) (NSC 707545) In Patients With Advanced Solid Tumors|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:13.669854|2018-06-01 05:05:13.669854
NCT00089258|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-01-15|2004-08-04|2004-08-05|Estimate|||||||2013-01-15|2013-01-17|Estimate|July 2004||2004-07-31|January 2013|2013-01-31||||November 2006|Actual|2006-11-30||Interventional|||Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment|Phase II Study of Anti-GD2 3F8 Antibody and Biologic Response Modifiers for High-risk Neuroblastoma|Completed||Phase 2|74|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:13.757459|2018-06-01 05:05:13.757459
NCT00089245|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2018-04-13|2004-08-04|2004-08-05|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2004||2004-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer|Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms|Recruiting||Phase 1|120|Anticipated|Y-mAbs Therapeutics||1|||f||||||||||||||2018-06-01 05:05:13.818318|2018-06-01 05:05:13.818318
NCT00089219|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2014-11-18|2004-08-04|2004-08-05|Estimate|||||||2014-11-18|2014-11-20|Estimate|July 2003||2003-07-31|November 2014|2014-11-30||||May 2006|Actual|2006-05-31||Interventional|||Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma|Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma|Completed||Phase 1/Phase 2|39|Actual|University of Virginia||3|||f||||t||||||||||2018-06-01 05:05:13.901721|2018-06-01 05:05:13.901721
NCT00089206|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2014-12-18|2004-08-04|2004-08-05|Estimate|||||||2014-12-18|2014-12-19|Estimate|August 2002||2002-08-31|December 2014|2014-12-31||||November 2005|Actual|2005-11-30||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery|Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma|Completed||Phase 2|7|Actual|University of Virginia|||||f||||t||||||||||2018-06-01 05:05:13.993556|2018-06-01 05:05:13.993556
NCT00089193|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2014-12-18|2004-08-04|2004-08-05|Estimate|||||||2014-12-18|2014-12-23|Estimate|September 2003||2003-09-30|December 2014|2014-12-31||||February 2007|Actual|2007-02-28||Interventional|||Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma|Evaluation of GM-CSF-in-Adjuvant and the Number of Vaccine Sites on Immunization With Multiple Synthetic Melanoma Peptides|Completed||Phase 2|||University of Virginia|||||f||||t||||||||||2018-06-01 05:05:14.091424|2018-06-01 05:05:14.091424
NCT00089180|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2015-12-03|2004-08-04|2004-08-05|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2004||2004-03-31|June 2013|2013-06-30||||January 2007|Actual|2007-01-31||Interventional|||T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant|A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer|Completed||Phase 2|100|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:05:14.187692|2018-06-01 05:05:14.187692
NCT00089167|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-01-15|2004-08-04|2004-08-05|Estimate|||||||2013-01-15|2013-01-16|Estimate|May 2002||2002-05-31|January 2013|2013-01-31||||December 2007|Actual|2007-12-31||Interventional|||Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis|Risk Adapted Intravenous Melphalan and Adjuvant Thalidomide and Dexamethasone for Untreated Patients With Primary Systemic Amyloidosis|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:14.282469|2018-06-01 05:05:14.282469
NCT00089154|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-07-15|2004-08-04|2004-08-05|Estimate|||||||2013-07-15|2013-07-16|Estimate|August 2004||2004-08-31|June 2013|2013-06-30||||October 2005|Actual|2005-10-31||Interventional|||Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of Thrice Weekly Apolizumab in Patients With Chronic Lymphocytic Leukemia : CRC Master Protocol|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:14.370319|2018-06-01 05:05:14.370319
NCT00089141|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2009-07-15||2013-05-01|2004-08-04|2004-08-05|Estimate|2009-07-15|2009-08-26|Estimate||||2013-05-01|2013-05-03|Estimate|May 2004||2004-05-31|August 2009|2009-08-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)|A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease|Terminated||Phase 3|151|Actual|Fred Hutchinson Cancer Research Center||2||Low probability of positive outcome|f||||t||||||||||2018-06-01 05:05:14.47895|2018-06-01 05:05:14.47895
NCT00089128|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2012-04-26|2004-08-04|2004-08-05|Estimate|||||||2012-04-26|2012-04-30|Estimate|November 2001||2001-11-30|April 2012|2012-04-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer|Phase II Study Of Gemcitabine And CPT-11 (Irinotecan) In Locally Advanced Or Metastatic Bladder Cancer|Completed||Phase 2|25|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 05:05:14.898015|2018-06-01 05:05:14.898015
NCT00088959|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2014-10-09|2004-08-04|2004-08-05|Estimate|||||||2014-10-09|2014-10-10|Estimate|December 2003||2003-12-31|April 2013|2013-04-30|November 2010|Actual|2010-11-30|January 2009|Actual|2009-01-31||Interventional|||Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase I Study of Erlotinib and Celecoxib in Former Smokers With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 05:05:17.121558|2018-06-01 05:05:17.121558
NCT00089115|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-08-01|2004-08-04|2004-08-05|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2004||2004-07-31|February 2006|2006-02-28||||||||Interventional|||Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|Phase III, Randomized, Double Blind, Placebo-Controlled Trial of Favldand GM-CSF Versus Placebo and GM-CSF Following Rituximab in Subjects With Follicular B-Cell Non-Hodgkin's Lymphoma|Terminated||Phase 3|||National Cancer Institute (NCI)||||Withdrawn as company has shut down and filed for bankruptcy|f||||||||||||||2018-06-01 05:05:14.984724|2018-06-01 05:05:14.984724
NCT00089102|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2012-04-26|2004-08-04|2004-08-05|Estimate|||||||2012-04-26|2012-04-30|Estimate|September 2003||2003-09-30|April 2012|2012-04-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer|Phase II Study of Gemcitabine and CPT-11 (Irinotecan) in Unresectable or Metastatic Renal Cell Carcinoma|Completed||Phase 2|36|Anticipated|Medical University of South Carolina|||||f||||t||||||||||2018-06-01 05:05:15.154203|2018-06-01 05:05:15.154203
NCT00089089|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-01-04|2004-08-04|2004-08-05|Estimate|||||||2013-01-04|2013-01-07|Estimate|September 2004||2004-09-30|January 2013|2013-01-31||||March 2008|Actual|2008-03-31||Interventional|||Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas|Phase I Study of Prolonged Low Dose Decitabine (5-Aza-Deoxycytidine, NSC #127716) in Patients With Biopsiable Advanced Cancers Refractory to Standard Therapy|Terminated||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:15.220046|2018-06-01 05:05:15.220046
NCT00089076|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2012-05-11||2014-05-22|2004-08-04|2004-08-05|Estimate|2012-09-18|2012-10-19|Estimate||||2014-05-22|2014-05-30|Estimate|June 2004||2004-06-30|December 2012|2012-12-31|October 2009|Actual|2009-10-31|July 2008|Actual|2008-07-31||Interventional|||MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma|Phase I/II Study of Anti-CTLA-4 Monoclonal Antibody (MDX-010) in B-cell Non-Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:15.294724|2018-06-01 05:05:15.294724
NCT00089063|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2015-04-14|2004-08-04|2004-08-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2004||2004-06-30|October 2013|2013-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma|A Randomized Phase II Continuation Booster Trial After A Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 and ISA 51 VG With Or Without GM-CSF For Patients With Resected Stages IIB/C, III And IV Melanoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:05:15.671739|2018-06-01 05:05:15.671739
NCT00089050|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2011-11-28|2004-08-04|2004-08-05|Estimate|||||||2011-11-28|2011-11-30|Estimate|May 2004||2004-05-31|November 2011|2011-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia|A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:05:15.757569|2018-06-01 05:05:15.757569
NCT00089037|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2011-07-13|2004-08-04|2004-08-05|Estimate|||||||2011-07-13|2011-07-15|Estimate|June 2003||2003-06-30|July 2011|2011-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation|A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:05:15.832254|2018-06-01 05:05:15.832254
NCT00089024|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2010-06-01|2004-08-04|2004-08-05|Estimate|||||||2010-06-01|2010-06-03|Estimate|February 2004||2004-02-29|June 2010|2010-06-30||||December 2013|Anticipated|2013-12-31||Interventional|||Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase II Study Of Neo-Adjuvant Chemotherapy And Radiation In Patients With Locally Advanced Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|University of Nebraska|||||f||||t||||||||||2018-06-01 05:05:15.920872|2018-06-01 05:05:15.920872
NCT00089011|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2017-04-14||2017-12-05|2004-08-04|2004-08-05|Estimate|2017-04-14|2017-05-22|Actual||||2017-12-05|2018-01-02|Actual|April 2004||2004-04-30|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|March 2014|Actual|2014-03-31||Interventional|||Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer|A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil|Active, not recruiting||Phase 2|150|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 05:05:16.017878|2018-06-01 05:05:16.017878
NCT00088998|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2016-12-05|2004-08-04|2004-08-05|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2004||2004-12-31|December 2016|2016-12-31|December 2010|Actual|2010-12-31|August 2006|Actual|2006-08-31||Interventional|||Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer|Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer|Completed||Phase 2|46|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:05:16.500695|2018-06-01 05:05:16.500695
NCT00088985|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2017-03-28||2017-05-26|2004-08-04|2004-08-05|Estimate|2017-03-28|2017-05-09|Actual||||2017-05-26|2017-06-20|Actual|January 2004||2004-01-31|May 2017|2017-05-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer|Phase II Trial Evaluating The Efficacy Of A Multiepitope Dendritic Cell Vaccine Given With Trastuzumab And Vinorelbine For The Treatment Of Women With Metastatic Breast Cancer That Express HLA-A0201|Terminated||Phase 2|56|Actual|UNC Lineberger Comprehensive Cancer Center|Study was terminated due to unavailable funding.|1||Funding unavailable|f||||t||||||||||2018-06-01 05:05:16.60547|2018-06-01 05:05:16.60547
NCT00088972|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2012-11-09||2017-12-06|2004-08-04|2004-08-05|Estimate|2013-02-27|2013-04-09|Estimate||||2017-12-06|2018-01-02|Actual|November 2004||2004-11-30|December 2017|2017-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women|Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer|Terminated||Phase 2|8|Actual|Southwest Oncology Group||2||Study closed due to poor accrual.|f||||t||||||||||2018-06-01 05:05:16.848267|2018-06-01 05:05:16.848267
NCT00086060|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-22|||2011-10-06|2004-06-22|2004-06-23|Estimate|||||||2011-10-06|2011-10-10|Estimate|May 2004||2004-05-31|October 2011|2011-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Pain Management Techniques for Fibromyalgia|Locus of Pain Control: Neural Substrates and Modifiability|Completed||Phase 1/Phase 2|97|Actual|University of Michigan||4|||f||||f||||||||||2018-06-01 05:07:49.652512|2018-06-01 05:07:49.652512
NCT00088946|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2015-10-28|2004-08-04|2004-08-05|Estimate|||||||2015-10-28|2015-10-30|Estimate|May 2004||2004-05-31|August 2012|2012-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer|Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer|Completed||Phase 2|17|Actual|Jonsson Comprehensive Cancer Center||3|||f||||t||||||||||2018-06-01 05:05:17.210579|2018-06-01 05:05:17.210579
NCT00088933|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2014-03-28|2004-08-04|2004-08-05|Estimate|||||||2014-03-28|2014-03-31|Estimate|June 2004||2004-06-30|March 2013|2013-03-31||||November 2007|Actual|2007-11-30||Interventional|||Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer|Randomized Single Institution Pilot Study of Vaccinia-CEA(6D)-TRICOM and Fowlpox-CEA(6D)-TRICOM With GM-CSF in Combination With Docetaxel in Patients With CEA-Bearing Cancers|Terminated||Phase 1|60|Actual|National Cancer Institute (NCI)||6|||f||||||||||||||2018-06-01 05:05:17.311854|2018-06-01 05:05:17.311854
NCT00088907|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2015-03-20||2015-04-21|2004-08-04|2004-08-05|Estimate|2015-04-21|2015-05-06|Estimate||||2015-04-21|2015-05-06|Estimate|August 2004||2004-08-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|May 2009|Actual|2009-05-31||Interventional||The primary population was eligible and treated patients in the study. All study results were based on the primary population except for adverse event results. In total, 136 patients enrolled on arm I, but 19 patients were ineligible/no protocol therapy. 134 patients entered arm II, 12 of them were not eligible/not starting protocol therapy.|Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer|Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer|Terminated||Phase 3|270|Actual|National Cancer Institute (NCI)||2||"It was unlikely that the primary endpoint would be reached based on the fifth interim analysis~   results."|f||||t||||||||||2018-06-01 05:05:17.443237|2018-06-01 05:05:17.443237
NCT00088894|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-06-04|2004-08-04|2004-08-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|June 2004||2004-06-30|June 2013|2013-06-30||||June 2006|Actual|2006-06-30||Interventional|||Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Randomized Phase III Trial Of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7621) Versus Gemcitabine Plus Placebo In Patients With Advanced Pancreatic Cancer|Completed||Phase 3|590|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:05:17.972145|2018-06-01 05:05:17.972145
NCT00088881|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|2014-12-16||2017-04-20|2004-08-04|2004-08-05|Estimate|2015-02-17|2015-02-18|Estimate||||2017-04-20|2017-05-25|Actual|December 2004||2004-12-31|April 2017|2017-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional||Eligible and treated patients|Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma|A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients With Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma|Terminated||Phase 2|62|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 05:05:18.079751|2018-06-01 05:05:18.079751
NCT00088868|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2012-03-14|2004-08-04|2004-08-05|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2004||2004-06-30|March 2012|2012-03-31|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma|A Phase I Study Of 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) With Evaluation Of Hsp90 Client Proteins In Subjects With Solid Tumors And Lymphomas|Completed||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:05:18.501644|2018-06-01 05:05:18.501644
NCT00088855|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2018-03-02|2004-08-04|2004-08-05|Estimate|||||||2018-03-02|2018-03-05|Actual|June 15, 2004|Actual|2004-06-15|February 2018|2018-02-28||||October 31, 2006|Actual|2006-10-31||Interventional|||Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma|Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma|Active, not recruiting||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:18.678735|2018-06-01 05:05:18.678735
NCT00088829|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2017-07-17|2004-08-04|2004-08-05|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2001||2001-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer|A Pilot Study to Establish a Standardized Protocol for Gene Microarray Analysis in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer: Identifying Factors Predictive of a Response to Paclitaxel|Terminated||Phase 2|22|Actual|Georgetown University||1||Investigator left institution|f||||f||||||||||2018-06-01 05:05:18.819928|2018-06-01 05:05:18.819928
NCT00088816|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-09-16|2004-08-04|2004-08-05|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2003||2003-04-30|March 2008|2008-03-31||||March 2008|Anticipated|2008-03-31||Interventional|||S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer|Phase II Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:18.914027|2018-06-01 05:05:18.914027
NCT00088803|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2016-05-17|2004-08-04|2004-08-05|Estimate|||||||2016-05-17|2016-05-19|Estimate|August 2004||2004-08-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||DNA Variations in the Gene in Young Patients With Wilms' Tumor|The Incidence, Inheritance, and Prognostic Significance of Polymorphisms in the RASSF1A Gene in Children With Wilms Tumors|Completed|||471|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-06-01 05:05:19.034108|2018-06-01 05:05:19.034108
NCT00088790|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2011-01-25|2004-08-04|2004-08-05|Estimate|||||||2011-01-25|2011-01-26|Estimate|July 2004||2004-07-31|January 2011|2011-01-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||AZD5438 in Patients With Advanced Solid Malignancies|Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies|Completed||Phase 1|||AstraZeneca|||||||||||||||||||2018-06-01 05:05:19.460954|2018-06-01 05:05:19.460954
NCT00088777|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2011-08-10|2004-08-04|2004-08-05|Estimate|||||||2011-08-10|2011-08-12|Estimate|January 2005||2005-01-31|August 2011|2011-08-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Nondrug Treatment Programs for Adults With Fibromyalgia|Behavioral Preparation for Treating Fibromyalgia|Completed||Phase 2|300|Anticipated|University of Utah||2|||f||||||||||||||2018-06-01 05:05:19.51599|2018-06-01 05:05:19.51599
NCT00088764|ClinicalTrials.gov processed this data on May 31, 2018|2004-08-04|||2013-08-13|2004-08-04|2004-08-05|Estimate|||||||2013-08-13|2013-08-15|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Interventional|||Pain and Stress Management for People With Rheumatoid Arthritis|Disclosure and Skills Training for Rheumatoid Arthritis|Completed||Phase 2|280|Actual|Wayne State University||2|||f||||t||||||||||2018-06-01 05:05:19.588368|2018-06-01 05:05:19.588368
NCT00004193|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-04-10|2004-08-04|2004-08-05|Estimate|||||||2013-04-10|2013-04-12|Estimate|January 1999||1999-01-31|April 2013|2013-04-30|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer|Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Patients With Advanced Colorectal Cancer|Terminated||Phase 2|25|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:05:19.66657|2018-06-01 05:05:19.66657
NCT00004187|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2012-05-14|2004-08-04|2004-08-05|Estimate|||||||2012-05-14|2012-05-15|Estimate|June 1999||1999-06-30|May 2012|2012-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer|A Phase I-II Study of Capecitabine and Oxaliplatin in Chemotherapy-Naive and Thymidylate Synthase Inhibitor Pretreated Advanced or Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|||Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:05:19.74504|2018-06-01 05:05:19.74504
NCT00004186|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-04-10|2004-08-04|2004-08-05|Estimate|||||||2013-04-10|2013-04-12|Estimate|December 1996||1996-12-31|April 2013|2013-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer|Phase I/IIA Study of Sequential Ifosfamide and Topotecan in Patients With Small Cell Lung Cancer|Completed||Phase 1/Phase 2|55|Anticipated|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 05:05:19.817068|2018-06-01 05:05:19.817068
NCT00004162|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-04-10|2004-08-04|2004-08-05|Estimate|||||||2013-04-10|2013-04-12|Estimate|June 1997||1997-06-30|April 2013|2013-04-30|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma|Phase I Trial of Liposomal Doxorubicin (Doxil) Based Combination Chemotherapy Regimen in AIDS-Associated Non-Hodgkin's Lymphoma|Completed||Phase 1|48|Anticipated|University of Alabama at Birmingham||8|||f||||t||||||||||2018-06-01 05:05:19.90067|2018-06-01 05:05:19.90067
NCT00004096|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-01-28|2012-05-31|2004-08-04|2004-08-05|Estimate||||2011-01-28|2011-02-07|Estimate|2012-05-31|2012-06-06|Estimate|August 1999||1999-08-31|May 2012|2012-05-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase I/II Study of Carboplatin and Navelbine for Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:05:19.994452|2018-06-01 05:05:19.994452
NCT00004080|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2009-02-06|2004-08-04|2004-08-05|Estimate|||||||2009-02-06|2009-02-09|Estimate|December 1999||1999-12-31|August 2001|2001-08-31||||||||Interventional|||Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors|Assessment of the Safety and Transduction Efficiency of SCH58500, An Adenoviral Vector p53 Delivery System, to Patients With Recurrent Malignant Brain Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:20.055488|2018-06-01 05:05:20.055488
NCT00004064|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-11-05|2004-08-04|2004-08-05|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 1998||1998-11-30|June 2007|2007-06-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX MabB43.13 in Ovarian Cancer Patients With an Elevated Serum CA 125 But Without Other Evidence of Disease|Unknown status|Active, not recruiting|Phase 2|102|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:20.104744|2018-06-01 05:05:20.104744
NCT00004040|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2015-08-17|2004-08-04|2004-08-05|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 1998||1998-06-30|August 2015|2015-08-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy|Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma Whose Disease Has Been Controlled With Chemotherapy: Rituximab Anti-CD20 Monoclonal Antibody or Interferon Alpha 2-b as Maintenance Therapy|Withdrawn||Phase 2|0|Actual|Hoag Memorial Hospital Presbyterian||||no patient accruals|f||||f||||||||||2018-06-01 05:05:20.186462|2018-06-01 05:05:20.186462
NCT00004039|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2015-08-17|2004-08-04|2004-08-05|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 1998||1998-06-30|August 2015|2015-08-31|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma|Phase II Trials of CHOP Chemotherapy and Interferon Alpha or Rituximab Anti-CD20 Monoclonal Antibody as Initial Treatment of Patients With Stage III and IV High-Risk Indolent B-Cell Lymphoma and Intermediate Grade B-Cell Lymphoma|Withdrawn||Phase 2|0|Actual|Hoag Memorial Hospital Presbyterian||||No patient accruals|f||||f||||||||||2018-06-01 05:05:20.247812|2018-06-01 05:05:20.247812
NCT00003957|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-16|2004-08-04|2004-08-05|Estimate|||||||2013-04-16|2013-04-17|Estimate|December 1998||1998-12-31|April 2013|2013-04-30|August 2001|Actual|2001-08-31|September 2000|Actual|2000-09-30||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|A Phase II Trial of Multiple Cycles of Sequential High Dose Chemotherapy for Patients With Chemotherapy Sensitive Relapsed Non-Hodgkin's Lymphoma|Completed||Phase 2|3|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:05:20.311395|2018-06-01 05:05:20.311395
NCT00003892|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-08-04|2004-08-05|Estimate|||||||2012-09-20|2012-09-24|Estimate|February 1999||1999-02-28|July 2012|2012-07-31|September 2008|Actual|2008-09-30|October 2000|Actual|2000-10-31||Interventional|||ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer|Phase II Study of CGP 69846A (ISIS 5132) in Recurrent Epithelial Ovarian Cancer|Completed||Phase 2|22|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-06-01 05:05:20.394073|2018-06-01 05:05:20.394073
NCT00003828|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-20|2004-08-03|2004-08-04|Estimate|||||||2012-08-20|2012-08-22|Estimate|May 1999||1999-05-31|August 2012|2012-08-31|March 2004|Actual|2004-03-31|December 2001|Actual|2001-12-31||Interventional|||S9804: Vinorelbine in Treating Patients With Stage IV Melanoma|Evaluation of Vinorelbine Tartrate (Navelbine) in Patients With Disseminated Malignant Melanoma and One Prior Systemic Therapy|Completed||Phase 2|24|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:05:20.577786|2018-06-01 05:05:20.577786
NCT00003821|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-08-03|2004-08-04|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 1998||1998-01-31|July 2000|2000-07-31||||||||Interventional|||Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer|Phase II Trial of Aminopterin in Patients With Persistent or Recurrent Endometrial Carcinoma|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:21.670861|2018-06-01 05:05:21.670861
NCT00003810|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-08-03|2004-08-04|Estimate|||||||2013-08-22|2013-08-23|Estimate|April 1999||1999-04-30|August 2013|2013-08-31||||May 2002|Actual|2002-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas|A Phase II Study of Gemcitabine and Docetaxel in Pancreatic Adenocarcinoma|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:05:21.746841|2018-06-01 05:05:21.746841
NCT00003798|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-13|2004-08-03|2004-08-04|Estimate|||||||2012-11-13|2012-11-14|Estimate|April 2000||2000-04-30|November 2012|2012-11-30||||||||Interventional|||Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery|Phase I Study Involving Gadolinium Texaphyrin (NSC 695238) in Patients With Pancreatic and Periampullary Adenocarcinoma Receiving Radiotherapy for Unresectable Disease|Completed||Phase 1|45|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:05:21.833963|2018-06-01 05:05:21.833963
NCT00003786|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-03-06|2004-08-03|2004-08-04|Estimate|||||||2014-03-06|2014-03-07|Estimate|April 1999||1999-04-30|March 2014|2014-03-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase II Trial of MGI-114 (NSC# 683863) Administered as a 5-Minute Infusion Daily for Five Days Every 4 Weeks in Patients With Previously Untreated Advanced Colorectal Cancer|Withdrawn||Phase 2|0|Actual|University of Chicago||1||NO participants|f||||f||||||||||2018-06-01 05:05:21.902954|2018-06-01 05:05:21.902954
NCT00003784|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-23|2004-08-03|2004-08-04|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 1999||1999-05-31|January 2013|2013-01-31||||January 2003|Actual|2003-01-31||Interventional|||S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas|Completed||Phase 2|102|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 05:05:22.00997|2018-06-01 05:05:22.00997
NCT00003760|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-07|2004-08-03|2004-08-04|Estimate|||||||2012-08-07|2012-08-09|Estimate|November 1998||1998-11-30|August 2012|2012-08-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer|A Phase II Trial of MGI 114 in Patients With Advanced Pancreatic Adenocarcinoma|Completed||Phase 2|3|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:05:23.543039|2018-06-01 05:05:23.543039
NCT00003708|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-07|2004-08-03|2004-08-04|Estimate|||||||2012-08-07|2012-08-09|Estimate|July 1998||1998-07-31|August 2012|2012-08-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Study of Cyclic Oral Administration of SCH 52365 for 21 of 28 Days in Patients With Advanced Solid Malignancies|Completed||Phase 1|32|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:05:23.854396|2018-06-01 05:05:23.854396
NCT00003681|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-05-09|2004-08-03|2004-08-04|Estimate|||||||2009-05-09|2009-05-12|Estimate|August 1998||1998-08-31|July 2000|2000-07-31||||||||Interventional|||Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome|Phase II Multicenter Study of Amifostine in Patients With Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:23.92404|2018-06-01 05:05:23.92404
NCT00003663|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-08-17|2004-08-03|2004-08-04|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 1998||1998-06-30|August 2015|2015-08-31|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma|Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma|Withdrawn||Phase 2|0|Actual|Hoag Memorial Hospital Presbyterian||||no patient accrual|f||||f||||||||||2018-06-01 05:05:24.077502|2018-06-01 05:05:24.077502
NCT00003662|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-03|2004-08-03|2004-08-04|Estimate|||||||2011-03-03|2011-03-07|Estimate|August 1998||1998-08-31|March 2011|2011-03-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases|Completed||Phase 2|90|Anticipated|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:05:24.213127|2018-06-01 05:05:24.213127
NCT00003661|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-03|2004-08-03|2004-08-04|Estimate|||||||2011-03-03|2011-03-07|Estimate|June 1998||1998-06-30|March 2011|2011-03-31|March 2006|Actual|2006-03-31|November 1999|Actual|1999-11-30||Interventional|||Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children and Adults With Hematologic Malignancies|Completed||Phase 2|3|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:05:24.608439|2018-06-01 05:05:24.608439
NCT00003605|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-08-17|2004-08-03|2004-08-04|Estimate|||||||2015-08-17|2015-08-19|Estimate|May 1998||1998-05-31|August 2015|2015-08-31|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma|Rituximab Anti-CD20 Monoclonal Antibody Plus Oral Cyclophosphamide as Initial Treatment of Indolent Lymphoma|Withdrawn||Phase 2|0|Actual|Hoag Memorial Hospital Presbyterian||||no patient accrual|f||||f||||||||||2018-06-01 05:05:25.34025|2018-06-01 05:05:25.34025
NCT00003542|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-08-03|2004-08-04|Estimate|||||||2013-06-24|2013-06-25|Estimate|May 1998||1998-05-31|June 2013|2013-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Interferon Alfa in Treating Patients With Advanced Kidney Cancer|Phase I/II Study of Subcutaneous Administration of Pegylated-Interferon Alpha-2A (RO 25-8310) in Previously Untreated Patients With Locally Advanced or Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|58|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:25.655216|2018-06-01 05:05:25.655216
NCT00003539|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-08-03|2004-08-04|Estimate|||||||2013-06-20|2013-06-24|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer|Phase II Study of Weekly 1-Hour Paclitaxel (Taxol) Plus Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in the Treatment of Patients With Metastatic Breast Cancer|Completed||Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:26.155077|2018-06-01 05:05:26.155077
NCT00003431|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-04|2004-08-03|2004-08-04|Estimate|||||||2013-03-04|2013-03-05|Estimate|June 1998||1998-06-30|March 2013|2013-03-31|May 2001|Actual|2001-05-31|||||Interventional|||Flt3L in Treating Patients With Metastatic Colorectal Cancer|Pilot Study of FLT3 Ligand Prior to Resection of Hepatic Metastases of Colorectal Cancer|Completed||Phase 1|||Duke University|||||f||||||||||||||2018-06-01 05:05:26.325538|2018-06-01 05:05:26.325538
NCT00003424|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-08-03|2004-08-04|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 1997||1997-04-30|August 2009|2009-08-31|August 2009|Actual|2009-08-31|June 2000|Actual|2000-06-30||Interventional|||Tamoxifen in Treating Patients With Primary Liver Cancer|Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma|Completed||Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:26.39237|2018-06-01 05:05:26.39237
NCT00003416|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-03-05|2004-08-02|2004-08-03|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 1998||1998-09-30|March 2015|2015-03-31|January 2004|Actual|2004-01-31|August 2000|Actual|2000-08-31||Interventional|||S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia|S9805, Phase II Study of Tandem High Dose Melphalan Supported by Peripheral Blood Stem Cell Support in Waldenstrom's Macroglobulinemia (WM)|Completed||Phase 2|9|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:05:26.633573|2018-06-01 05:05:26.633573
NCT00003415|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2004-08-02|2004-08-03|Estimate|||||||2013-01-30|2013-01-31|Estimate|September 1998||1998-09-30|July 2000|2000-07-31|November 2002|Actual|2002-11-30|||||Interventional|||Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome|Phase I/II Study of Combined Treatment With Amifostine (Ethyol) and Topotecan (Hycamtin MS) in Patients With Myelodysplastic Syndrome|Completed||Phase 1/Phase 2|26|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:26.925339|2018-06-01 05:05:26.925339
NCT00003413|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-09-23|2004-08-02|2004-08-03|Estimate|||||||2009-09-23|2009-09-24|Estimate|September 1998||1998-09-30|September 2009|2009-09-30|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer|High Dose Chemotherapy With Stem Cell Rescue in Recently Diagnosed Patients With Advanced (Stage III and IV) Ovarian Cancer With > 1 cm Residual Disease After Debulking Surgery|Completed||Phase 2|32|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 05:05:27.012446|2018-06-01 05:05:27.012446
NCT00088751|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-31|||2017-06-30|2004-07-31|2004-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|July 23, 2004||2004-07-23|June 1, 2009|2009-06-01|June 1, 2009||2009-06-01|||||Observational|||Treatment Study of Frontotemporal Dementia|Treatment Study for Frontotemporal Dementia|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:27.350485|2018-06-01 05:05:27.350485
NCT00088738|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2017-06-30|2004-07-30|2004-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|July 27, 2004||2004-07-27|September 10, 2008|2008-09-10|September 10, 2008||2008-09-10|||||Interventional|||Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ|Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F] SPA-RQ|Completed||Phase 1|84||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:27.489468|2018-06-01 05:05:27.489468
NCT00088712|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2018-05-12|2004-07-30|2004-08-02|Estimate|||||||2018-05-12|2018-05-15|Actual|July 28, 2004||2004-07-28|September 19, 2017|2017-09-19||||||||Observational|||Event Related Potentials in Infants and Adults|Event Related Potentials From Infancy to Adulthood Event Related Potentials From Infancy to Adulthood|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:27.653009|2018-06-01 05:05:27.653009
NCT00088699|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2018-03-14|2004-07-30|2004-08-02|Estimate|||||||2018-03-14|2018-03-15|Actual|July 26, 2004||2004-07-26|July 31, 2017|2017-07-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Rapid Antidepressant Effects of Ketamine in Major Depression|Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist|Completed||Phase 1/Phase 2|233|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:27.981344|2018-06-01 05:05:27.981344
NCT00088686|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2008-03-03|2004-07-30|2004-08-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2004||2004-07-31|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Capsaicin to Control Pain Following Third Molar Extraction|Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia|Completed||Phase 2|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:28.180638|2018-06-01 05:05:28.180638
NCT00088660|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2006-02-07|2004-07-30|2004-08-02|Estimate|||||||2006-02-07|2006-02-08|Estimate|June 2004||2004-06-30|February 2006|2006-02-28||||||||Interventional|||PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen|A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™-VF in Combination With GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients With Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen|Unknown status|Active, not recruiting|Phase 3|250||Therion Biologics Corporation|||||||||||||||||||2018-06-01 05:05:28.597393|2018-06-01 05:05:28.597393
NCT00088647|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2006-12-07|2004-07-30|2004-08-02|Estimate|||||||2006-12-07|2006-12-08|Estimate||||December 2006|2006-12-31||||||||Interventional|||Study Evaluating MST-997 in Advanced Malignant Solid Tumors|A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Intralipid 20% Administered Weekly in Subjects With Advanced Malignant Solid Tumors|Terminated||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:05:28.852221|2018-06-01 05:05:28.852221
NCT00088634|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|2011-02-01||2016-03-10|2004-07-30|2004-08-02|Estimate|2011-02-03|2011-03-01|Estimate||||2016-03-10|2016-04-08|Estimate|May 2004||2004-05-31|March 2016|2016-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia|A Double-blind Fixed-dose Study of Lurasidone (SM-13496) and Placebo in the Treatment of Schizophrenia|Completed||Phase 2|180|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 05:05:28.971488|2018-06-01 05:05:28.971488
NCT00088621|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|2011-02-11||2014-03-31|2004-07-30|2004-08-02|Estimate|2011-04-11|2011-05-06|Estimate||||2014-03-31|2014-04-17|Estimate|July 2004||2004-07-31|March 2014|2014-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia|An Open-Label, Multicenter, Twelve-Month Study of Safety and Tolerability in the Treatment of Schizophrenia|Completed||Phase 2|61|Actual|Sunovion||1|||f||||f||||||||||2018-06-01 05:05:29.791464|2018-06-01 05:05:29.791464
NCT00088608|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2016-11-03|2004-07-30|2004-08-02|Estimate|||||||2016-11-03|2016-11-07|Estimate|April 2004||2004-04-30|November 2016|2016-11-30||||June 2006|Actual|2006-06-30||Interventional|||A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease|A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease|Completed||Phase 2|26|Actual|Novartis|||||f||||||||||||||2018-06-01 05:05:30.373236|2018-06-01 05:05:30.373236
NCT00088595|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|2011-01-21||2012-05-29|2004-07-30|2004-08-02|Estimate|2011-04-12|2011-05-06|Estimate||||2012-05-29|2012-06-04|Estimate|January 2004||2004-01-31|May 2012|2012-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors|An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors|Completed||Phase 2|45|Actual|Novartis|No formal statistical comparisons were performed for this study. Summary statistics were provided to compare the different doses administered for the primary and secondary endpoints.|1|||f||||t||||||||||2018-06-01 05:05:30.562494|2018-06-01 05:05:30.562494
NCT00088582|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-30|||2016-11-03|2004-07-30|2004-08-02|Estimate|||||||2016-11-03|2016-11-07|Estimate|March 2004||2004-03-31|November 2016|2016-11-30||||October 2005|Actual|2005-10-31||Interventional|||Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients|A Multicenter, Randomized, Crossover, Open Label Dose Finding Study to Compare the Safety, Efficacy and PK/PD Relationship of Multiple Doses of SOM230 and Sandostatin in Acromegalic Patients|Completed||Phase 2|62|Actual|Novartis||2|||f||||f||||||||||2018-06-01 05:05:31.297202|2018-06-01 05:05:31.297202
NCT00003358|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-15|2004-07-30|2004-08-02|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 1998||1998-01-31|January 2013|2013-01-31||||January 2001|Actual|2001-01-31||Interventional|||Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Phase I Trial Intraperitoneal Cisplatin With Intraperitoneal Gemcitabine in Patients With Epithelial Ovarian Carcinoma|Completed||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:31.481846|2018-06-01 05:05:31.481846
NCT00003305|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-07-30|2004-08-02|Estimate|||||||2014-01-03|2014-01-06|Estimate|July 1997||1997-07-31|August 2008|2008-08-31|September 2007|Actual|2007-09-30|||||Interventional|||Aminopterin in Treating Patients With Refractory Leukemia|A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia|Completed||Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:31.645202|2018-06-01 05:05:31.645202
NCT00003259|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2004-07-30|2004-08-02|Estimate|||||||2012-05-14|2012-05-15|Estimate|October 1997||1997-10-31|May 2012|2012-05-31|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Vinorelbine in Treating Patients With Metastatic Prostate Cancer|Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma Phase II Trials Protocol 4: Vinorelbine|Completed||Phase 2|40|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:05:31.855667|2018-06-01 05:05:31.855667
NCT00003256|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-07-30|2004-08-02|Estimate|||||||2013-02-08|2013-02-11|Estimate|May 1998||1998-05-31|January 2013|2013-01-31|April 2004|Actual|2004-04-30|July 2002|Actual|2002-07-31||Interventional|||Flavopiridol in Treating Patients With Recurrent Prostate Cancer|A Phase II Trial of Flavopiridol in Patients With Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:05:32.049029|2018-06-01 05:05:32.049029
NCT00003214|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2004-07-30|2004-08-02|Estimate|||||||2012-05-14|2012-05-15|Estimate|July 1996||1996-07-31|May 2012|2012-05-31|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer|Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III)|Completed||Phase 3|300|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:05:32.294463|2018-06-01 05:05:32.294463
NCT00003213|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-07-30|2004-08-02|Estimate|||||||2012-07-10|2012-07-11|Estimate|May 1996||1996-05-31|July 2012|2012-07-31|August 1999|Actual|1999-08-31|April 1999|Actual|1999-04-30||Interventional|||Drugs to Reduce the Side Effects of Chemotherapy|A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis|Completed||Phase 3|267|Actual|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||||2018-06-01 05:05:32.505204|2018-06-01 05:05:32.505204
NCT00003182|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-07-30|2004-08-02|Estimate|||||||2013-12-03|2013-12-04|Estimate|March 1997||1997-03-31|July 2000|2000-07-31||||||||Interventional|||Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck|A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma)|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:32.756617|2018-06-01 05:05:32.756617
NCT00003158|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-20|2004-07-30|2004-08-02|Estimate|||||||2012-07-20|2012-07-24|Estimate|February 1998||1998-02-28|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2002|Actual|2002-12-31||Interventional|||S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer|A Phase II Trial of Concurrent Carboplatin/VP-16 and Radiation Followed by Paclitaxel (Taxol) for Poor-Risk Stage III Non-Small Cell Lung Cancer|Completed||Phase 2|96|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 05:05:32.931311|2018-06-01 05:05:32.931311
NCT00003152|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-07-30|2004-08-02|Estimate|||||||2012-06-29|2012-07-02|Estimate|March 1997||1997-03-31|June 2012|2012-06-30||||November 1999|Actual|1999-11-30||Interventional|||Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma|Marrow-Ablative Chemo-Radiotherapy and Autologous Stem Cell Transplantation Followed by Interferon-Alpha Maintenance Treatment Versus Interferon-Alpha Maintenance Treatment Alone After a Chemotherapy-Induced Remission in Patients With Stages III or IV Follicular Non-Hodgkin's Lymphoma. A Prospective, Randomized, Phase III Clinical Trial.|Terminated||Phase 3|469|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:05:33.273163|2018-06-01 05:05:33.273163
NCT00003097|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-07-30|2004-08-02|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 1989||1989-04-30|October 2007|2007-10-31||||||||Interventional|||Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer|Skin Cancer Prophylaxis by Low-Fat Dietary Intervention|Unknown status|Active, not recruiting|Phase 2|175|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:33.389793|2018-06-01 05:05:33.389793
NCT00003090|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-07-30|2004-08-02|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 1996||1996-01-31|July 2000|2000-07-31||||||||Interventional|||Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer|Phase II Trial of Bolus Interleukin-2 in Previously Treated Lung Cancer|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:33.584089|2018-06-01 05:05:33.584089
NCT00003087|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-07-30|2004-08-02|Estimate|||||||2013-06-24|2013-06-25|Estimate|August 1997||1997-08-31|June 2013|2013-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Combination Chemotherapy, Radiation Therapy and Surgery in Treating Patients With Cancer of the Esophagus|Phase II Trial of Preoperative Combined Modality Therapy for Localized Esophageal Carcinoma: Cisplatin-Paclitaxel Followed by Radiation Therapy With Concurrent Cisplatin and Paclitaxel|Completed||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:33.671755|2018-06-01 05:05:33.671755
NCT00003068|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2004-07-30|2004-08-02|Estimate|||||||2013-01-30|2013-01-31|Estimate|June 1997||1997-06-30|May 2006|2006-05-31|November 2002|Actual|2002-11-30|||||Interventional|||High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer|An Out Patient Dose Escalation Trial of High Dose Mitoxantrone, Thiotepa and Cyclophosphamide Plus Autologous Blood Cell Rescue and Amifostine Cytoprotection|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:33.825419|2018-06-01 05:05:33.825419
NCT00088556|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-29|||2012-05-30|2004-07-29|2004-07-30|Estimate|||||||2012-05-30|2012-05-31|Estimate|August 2004||2004-08-31|June 2011|2011-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer|Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|100|Actual|Telik||1|||f||||||||||||||2018-06-01 05:05:34.156946|2018-06-01 05:05:34.156946
NCT00088543|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-29|||2015-03-16|2004-07-29|2004-07-30|Estimate|||||||2015-03-16|2015-03-18|Estimate|March 2004||2004-03-31|March 2015|2015-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant|Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-transplant Graft vs. Host Disease (GvHD) Prophylaxis|Completed||N/A|60|Actual|Sanofi||2|||f||||||||||||||2018-06-01 05:05:34.296691|2018-06-01 05:05:34.296691
NCT00003055|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-07-29|2004-07-30|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 1997||1997-06-30|June 2013|2013-06-30|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer|Phase II Trial of Cisplatin and Irinotecan in Patients With Advanced Esophageal Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:34.43183|2018-06-01 05:05:34.43183
NCT00003050|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-07-29|2004-07-30|Estimate|||||||2014-05-20|2014-05-22|Estimate|April 1997||1997-04-30|May 2014|2014-05-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer|Weekly Paclitaxel During Radiation Therapy for Locally Advanced Breat Cancer|Completed||Phase 2|46|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:05:34.699188|2018-06-01 05:05:34.699188
NCT00003002|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-12-12|2004-07-29|2004-07-30|Estimate|||||||2012-12-12|2012-12-13|Estimate|April 1996||1996-04-30|December 2012|2012-12-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer|A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers|Completed||Phase 1|60|Actual|University of Washington|||||f||||||||||||||2018-06-01 05:05:35.025469|2018-06-01 05:05:35.025469
NCT00003000|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-12|2004-07-29|2004-07-30|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 1992||1992-05-31|October 2015|2015-10-31|June 2001|Actual|2001-06-30|January 2001|Actual|2001-01-31||Observational|||Morphine for the Treatment of Pain in Patients With Breast Cancer|Peripheral Effects of Opioid Analgesia in Patients Undergoing Axillary Node Dissection|Completed|||18|Anticipated|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:05:35.374905|2018-06-01 05:05:35.374905
NCT00002984|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-22|2004-07-29|2004-07-30|Estimate|||||||2012-05-22|2012-05-24|Estimate|March 1997||1997-03-31|May 2012|2012-05-31|January 2007|Actual|2007-01-31|May 2006|Actual|2006-05-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus|Paclitaxel Combined With 5-FU and Cisplatin Concomitant With Radiotherapy in the Management of Locally Advanced or Metastatic Esophageal Cancer (Adenocarcinoma and Squamous Histologies) - A Phase I/Modified Phase II Trial|Completed||Phase 1/Phase 2|26|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:05:35.533741|2018-06-01 05:05:35.533741
NCT00002921|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-03|2004-07-29|2004-07-30|Estimate|||||||2012-10-03|2012-10-05|Estimate|March 1997||1997-03-31|October 2012|2012-10-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery|Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II|Terminated||Phase 2|13|Actual|Southwest Oncology Group||1||Permanently Closed Due to Lack of Accrual|f||||f||||||||||2018-06-01 05:05:36.018992|2018-06-01 05:05:36.018992
NCT00002833|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-07-29|2004-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|October 1994||1994-10-31|July 2012|2012-07-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia|Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis|Completed||Phase 2|53|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:05:36.401022|2018-06-01 05:05:36.401022
NCT00088530|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-28|2017-03-11||2017-04-27|2004-07-28|2004-07-29|Estimate|2017-04-27|2017-06-01|Actual||||2017-04-27|2017-06-01|Actual|July 2004||2004-07-31|April 2017|2017-04-30|July 2010|Actual|2010-07-31|February 2010|Actual|2010-02-28||Interventional|||BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)|Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma: A Randomized, Controlled, Phase III Comparative Trial|Completed||Phase 3|140|Actual|CTI BioPharma||2|||f||||t||||||||||2018-06-01 05:05:36.692342|2018-06-01 05:05:36.692342
NCT00002832|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-07-28|2004-07-29|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 1995||1995-08-31|July 2012|2012-07-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia|Phase I/II Trial of Decitabine and Allogeneic Peripheral Blood Stem Cells Transplantation for Treatment of Relapse Post Allogeneic Bone Marrow Transplantation|Completed||Phase 1/Phase 2|14|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:05:38.886529|2018-06-01 05:05:38.886529
NCT00002831|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-07-28|2004-07-29|Estimate|||||||2012-07-27|2012-07-31|Estimate|July 1994||1994-07-31|July 2012|2012-07-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia|A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies|Completed||Phase 1/Phase 2|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:05:39.17856|2018-06-01 05:05:39.17856
NCT00002824|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-07-28|2004-07-29|Estimate|||||||2009-02-06|2009-02-09|Estimate|February 1996||1996-02-29|July 2000|2000-07-31||||||||Interventional|||Gene Therapy in Treating Patients With Primary Brain Tumors|A PHASE I TRIAL OF HSV-TK ADENOVIRUS GENE THERAPY FOR PRIMARY BRAIN TUMORS|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:39.579375|2018-06-01 05:05:39.579375
NCT00088348|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2017-06-30|2004-07-23|2004-07-26|Estimate|||||||2017-06-30|2017-07-02|Actual|July 13, 2004||2004-07-13|August 20, 2008|2008-08-20|August 20, 2008||2008-08-20|||||Observational|||Screening for Research Subjects With Anterior Segment Diseases|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Anterior Segment Disease|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:47.900453|2018-06-01 05:05:47.900453
NCT00002784|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-07-28|2004-07-29|Estimate|||||||2013-04-03|2013-04-04|Estimate|June 1996||1996-06-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|15-95||High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer|Randomized Trial of High-dose Epirubicin and Cyclophosphamide x 3 Supported by Peripheral Blood Progenitor Cells Versus Anthracycline and Cyclophosphamide x 4 Followed by Cyclophosphamide, Methotrexate, and 5-fluorouracil x 3 as Adjuvant Treatment for High Risk Operable Stage ii and Stage Iii Breast Cancer in Premenopausal and Young Postmenopausal (Less Than or Equal to 65 Yrs) Patients.|Completed||Phase 3|344|Actual|International Breast Cancer Study Group||2|||f||||t||||||||||2018-06-01 05:05:39.77149|2018-06-01 05:05:39.77149
NCT00002779|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-14|2004-07-28|2004-07-29|Estimate|||||||2016-12-14|2016-12-15|Estimate|February 1998||1998-02-28|December 2016|2016-12-31|June 2015|Actual|2015-06-30|July 2000|Actual|2000-07-31||Interventional|||Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma|PHASE II TRIAL OF FLUDARABINE AND SANDOSTATIN FOR RELAPSED LOW-GRADE NON-HODGKIN'S LYMPHOMA|Completed||Phase 2|34|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:05:40.02249|2018-06-01 05:05:40.02249
NCT00002754|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2004-07-28|2004-07-29|Estimate|||||||2013-02-15|2013-02-20|Estimate|February 1993||1993-02-28|February 2013|2013-02-28|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors|PHASE I STUDY OF MONOCLONAL ANTIBODY FRAGMENT 131I MEL-14 F(AB')2 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT MELANOMA AND OTHER BRAIN TUMORS|Completed||Phase 1|6|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:05:40.223635|2018-06-01 05:05:40.223635
NCT00002753|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2004-07-28|2004-07-29|Estimate|||||||2013-02-15|2013-02-18|Estimate|November 1991||1991-11-30|February 2013|2013-02-28|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas|PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS|Completed||Phase 1|6|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:05:40.375486|2018-06-01 05:05:40.375486
NCT00002688|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-07-28|2004-07-29|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 1995||1995-02-28|May 2007|2007-05-31||||||||Interventional|||Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:40.520737|2018-06-01 05:05:40.520737
NCT00002675|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-26|2004-07-28|2004-07-29|Estimate|||||||2013-06-26|2013-06-28|Estimate|May 1995||1995-05-31|June 2013|2013-06-30|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Chemotherapy in Treating Patients With Retinoblastoma|A TRIAL OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH INTRAOCULAR RETINOBLASTOMA|Completed||Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:40.772306|2018-06-01 05:05:40.772306
NCT00002665|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-03-05|2004-07-28|2004-07-29|Estimate|||||||2015-03-05|2015-03-06|Estimate|July 1995||1995-07-31|March 2015|2015-03-31|December 2003|Actual|2003-12-31|December 2001|Actual|2001-12-31||Interventional|||SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia|TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FIRST COMPLETE REMISSION|Completed||Phase 2|50|Anticipated|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:05:41.009711|2018-06-01 05:05:41.009711
NCT00002630|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-07-28|2004-07-29|Estimate|||||||2011-05-10|2011-05-11|Estimate|June 1993||1993-06-30|May 2011|2011-05-31|May 2001|Actual|2001-05-31|February 1999|Actual|1999-02-28||Interventional|||High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse|HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA|Completed||Phase 2|50|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 05:05:41.32815|2018-06-01 05:05:41.32815
NCT00002627|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-09|2004-07-28|2004-07-29|Estimate|||||||2014-01-09|2014-01-10|Estimate|November 1994||1994-11-30|July 2000|2000-07-31||||||||Interventional|||Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer|PHASE I/II TRIAL OF THE ADDITION OF TAXOL TO HIGH DOSE CARBOPLATIN AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL SUPPORT IN PATIENTS WITH HIGH RISK STAGE II AND III BREAST CANCER|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:41.472767|2018-06-01 05:05:41.472767
NCT00002618|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2004-07-28|2004-07-29|Estimate|||||||2014-07-23|2014-07-24|Estimate|December 1994||1994-12-31|July 2014|2014-07-31|September 2006|Actual|2006-09-30|September 2000|Actual|2000-09-30||Interventional|||Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma|A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin|Completed||Phase 3|242|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:05:41.663623|2018-06-01 05:05:41.663623
NCT00002604|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-07-07|2004-07-28|2004-07-29|Estimate|||||||2010-07-07|2010-07-08|Estimate|January 1996||1996-01-31|July 2010|2010-07-31|February 2004|Actual|2004-02-29|July 2000|Actual|2000-07-31||Interventional|||O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors|Phase I Trial of O6 Benzylguanine and BCNU; A Biochemical Modulation Trial Based Upon Depletion of O6 Alkylguanine DNA Alkyltransferase Directed DNA Repair|Completed||Phase 1|28|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:05:42.009438|2018-06-01 05:05:42.009438
NCT00002588|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-09|2004-07-28|2004-07-29|Estimate|||||||2010-06-09|2010-06-11|Estimate|August 1994||1994-08-31|June 2010|2010-06-30|January 2001|Actual|2001-01-31|July 2000|Actual|2000-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia|Phase I Trial of Sequential Topotecan(NSC 609699)and Etoposide for Patients With Relapsed, Refractory,or High Risk Acute Myeloid or Lymphoid Leukemia|Completed||Phase 1|30|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:05:42.105781|2018-06-01 05:05:42.105781
NCT00002572|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-28|2004-07-28|2004-07-29|Estimate|||||||2013-05-28|2013-05-30|Estimate|November 1994||1994-11-30|July 2000|2000-07-31|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors|Intracavitary Allogenic Cytotoxic T Lymphocytes and Human Recombinant Interleukin-2 Therapy for Recurrent Primary Brain Tumors|Completed||Phase 1|10|Anticipated|University of Colorado, Denver|||||f||||||||||||||2018-06-01 05:05:42.263241|2018-06-01 05:05:42.263241
NCT00002542|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-03-21|2004-07-28|2004-07-29|Estimate|||||||2016-03-21|2016-03-22|Estimate|July 1993||1993-07-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Tamoxifen in Treating Women With High-Risk Breast Cancer|DOUBLE-BLIND RANDOMIZED TRIAL OF TAMOXIFEN VERSUS PLACEBO IN PATIENTS WITH NODE POSITIVE BREAST CANCER WHO HAVE COMPLETED CMF, CEF OR AC ADJUVANT CHEMOTHERAPY|Completed||Phase 3|800|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:05:42.359119|2018-06-01 05:05:42.359119
NCT00002535|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-07-28|2004-07-29|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 1993||1993-07-31|August 2000|2000-08-31|July 2004|Actual|2004-07-31|||||Interventional|||Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma|TUMOR INFILTRATING LYMPHOCYTE THERAPY FOR ADVANCED MELANOMA USING IMMUNOMODULATION, A PHASE II STUDY|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:42.556092|2018-06-01 05:05:42.556092
NCT00002529|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-07-28|2004-07-29|Estimate|||||||2013-04-03|2013-04-04|Estimate|May 1993||1993-05-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|12-93||Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer|Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.|Completed||Phase 3|452|Actual|International Breast Cancer Study Group||6|||f||||t||||||||||2018-06-01 05:05:43.542556|2018-06-01 05:05:43.542556
NCT00088517|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-27|||2008-03-03|2004-07-27|2004-07-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2004||2004-07-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112|Whole Body Study of [11C]NNC-112 PET Imaging of Dopamine D1 Receptors|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:43.69712|2018-06-01 05:05:43.69712
NCT00088504|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-27|||2007-12-17|2004-07-27|2004-07-28|Estimate|||||||2007-12-17|2007-12-21|Estimate|July 2004||2004-07-31|December 2007|2007-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C|A Phase 2b Study of Merimepodib in Combination With Pegylated Interferon Alfa-2a (Pegasys®) and Ribavirin in Subjects With Chronic Hepatitis C Non-Responsive to Prior Therapy With Pegylated Interferon Alfa and Ribavirin|Completed||Phase 2|315||Vertex Pharmaceuticals Incorporated|||||f||||||||||||||2018-06-01 05:05:43.830669|2018-06-01 05:05:43.830669
NCT00088491|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-26|||2007-06-20|2004-07-27|2004-07-28|Estimate|||||||2007-06-20|2007-06-22|Estimate|June 2004||2004-06-30|June 2007|2007-06-30|October 2006|Actual|2006-10-31|||||Interventional|||Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia|A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia|Completed||Phase 3|1205|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 05:05:44.127922|2018-06-01 05:05:44.127922
NCT00088478|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-26|||2007-06-11|2004-07-27|2004-07-28|Estimate|||||||2007-06-11|2007-06-12|Estimate|June 2004||2004-06-30|June 2007|2007-06-30|April 2005|Actual|2005-04-30|||||Interventional|||Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia|A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia|Completed||Phase 3|402|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 05:05:44.367413|2018-06-01 05:05:44.367413
NCT00088465|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-26|2011-10-14||2011-12-09|2004-07-26|2004-07-27|Estimate|2011-12-09|2012-01-11|Estimate||||2011-12-09|2012-01-11|Estimate|August 2004||2004-08-31|December 2011|2011-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder|An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|931|Actual|Eli Lilly and Company||1|||f||||||||||||||2018-06-01 05:05:44.648835|2018-06-01 05:05:44.648835
NCT00088452|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-26|||2017-02-03|2004-07-26|2004-07-27|Estimate|||||||2017-02-03|2017-02-06|Estimate|July 2004|Actual|2004-07-31|February 2017|2017-02-28|August 31, 2016|Actual|2016-08-31|January 2013|Actual|2013-01-31||Interventional|||Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study|Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study|Completed||Phase 3|453|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-06-01 05:05:45.893504|2018-06-01 05:05:45.893504
NCT00088426|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2018-04-03|2004-07-23|2004-07-26|Estimate|||||||2018-04-03|2018-04-04|Actual|April 1, 2004||2004-04-01|March 20, 2018|2018-03-20||||||||Observational|||Clinical and Genetic Studies on Holoprosencephaly|Clinical and Genetic Studies on Holoprosencephaly|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:46.238528|2018-06-01 05:05:46.238528
NCT00088413|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2018-05-18|2004-07-23|2004-07-26|Estimate|||||||2018-05-18|2018-05-21|Actual|July 21, 2004||2004-07-21|January 23, 2018|2018-01-23|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer|An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma|Active, not recruiting||Phase 2|51|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 05:05:46.420179|2018-06-01 05:05:46.420179
NCT00088400|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2016-09-21|2004-07-23|2004-07-26|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2004||2004-07-31|September 2016|2016-09-30|November 2005||2005-11-30|||||Interventional|||Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors|A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme|Completed||Phase 3|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:46.594312|2018-06-01 05:05:46.594312
NCT00088387|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2008-03-03|2004-07-23|2004-07-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2004||2004-07-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Effect of Lithium and Divalproex in Alzheimer's Disease|Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's Disease|Completed||Phase 2|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:46.819957|2018-06-01 05:05:46.819957
NCT00088374|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|2011-05-24||2012-07-23|2004-07-23|2004-07-26|Estimate|2011-08-19|2011-09-29|Estimate||||2012-07-23|2012-07-27|Estimate|July 2004||2004-07-31|July 2012|2012-07-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease|A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Von Hippel Lindau Disease and Renal Tumors|Completed||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)|Study did not meet accrual.|1|||f||||f||||||||||2018-06-01 05:05:47.078879|2018-06-01 05:05:47.078879
NCT00088361|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2008-03-03|2004-07-23|2004-07-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2004||2004-07-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Observational|||Effect of Respiratory Motion on Positron Emission Tomography Imaging|The Effects of Respiratory Motion on CT Based Attenuation Correction of Positron Emission Tomography Data: Liver and Heart Studies|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:47.842652|2018-06-01 05:05:47.842652
NCT00088309|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2008-03-03|2004-07-23|2004-07-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2004||2004-06-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Effect of Tenofovir DF on Bone Metabolism in Children|Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:48.107865|2018-06-01 05:05:48.107865
NCT00088296|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2017-06-30|2004-07-23|2004-07-26|Estimate|||||||2017-06-30|2017-07-02|Actual|July 13, 2004||2004-07-13|October 18, 2007|2007-10-18|October 18, 2007||2007-10-18|||||Interventional|||Effects of Osteoarthritis Pain, Morphine, and Placebo on Neuroendocrine Function in Men|Effects of Osteoarthritis Pain, Morphine and Placebo on Neuro-Endocrine Function in Men|Completed||Phase 2|72||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:05:48.217632|2018-06-01 05:05:48.217632
NCT00088283|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2007-01-17|2004-07-23|2004-07-26|Estimate|||||||2007-01-17|2007-01-19|Estimate|May 2004||2004-05-31|January 2007|2007-01-31||||||||Interventional|||Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)|A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO|Completed||Phase 2|90||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 05:05:48.29143|2018-06-01 05:05:48.29143
NCT00088270|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2006-02-17|2004-07-23|2004-07-26|Estimate|||||||2006-02-17|2006-02-22|Estimate|August 2004||2004-08-31|May 2004|2004-05-31|August 2005||2005-08-31|||||Interventional|||A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer|A Randomized, Open Label, Phase II Study of OSI-7904L Versus 5-FU/LV as First-Line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract|Completed||Phase 2|58||OSI Pharmaceuticals|||||||||||||||||||2018-06-01 05:05:48.568504|2018-06-01 05:05:48.568504
NCT00088257|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-23|||2013-12-12|2004-07-23|2004-07-26|Estimate|||||||2013-12-12|2013-12-13|Estimate|August 2004||2004-08-31|December 2013|2013-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational|||Maternal Fatty Acids, Child Obesity, and Asthma Immunity|Maternal Fatty Acids, Child Obesity, and Asthma Immunity|Completed|||411|Actual|Harvard Pilgrim Health Care|||1||f||||||||||||||2018-06-01 05:05:48.775301|2018-06-01 05:05:48.775301
NCT00005884|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2015-09-30|2004-07-23|2004-07-26|Estimate|||||||2015-09-30|2015-10-02|Estimate||||September 2015|2015-09-30||||December 2000|Actual|2000-12-31||Interventional|||Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer|Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial|Completed||Phase 3|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:05:48.951292|2018-06-01 05:05:48.951292
NCT00005852|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-12-10|2004-07-23|2004-07-26|Estimate|||||||2012-12-10|2012-12-11|Estimate|June 1996||1996-06-30|December 2012|2012-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant|Allogeneic Bone Marrow Transplantation for Marrow Failure States|Terminated||Phase 2|||H. Lee Moffitt Cancer Center and Research Institute||||low accrual|f||||f||||||||||2018-06-01 05:05:49.15601|2018-06-01 05:05:49.15601
NCT00005805|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-17|2004-07-23|2004-07-26|Estimate|||||||2013-01-17|2013-01-18|Estimate|December 1999||1999-12-31|January 2013|2013-01-31||||June 2000|Actual|2000-06-30||Interventional|||St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer|Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 3|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:49.352969|2018-06-01 05:05:49.352969
NCT00005633|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-18|2004-07-23|2004-07-26|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 1999||1999-06-30|June 2013|2013-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Vaccination of Melanoma Patients With Tyrosinase YMD and gp100 IMD-Javelin Fusion Peptides/HSP70 Complexes: A Trial Comparing the Immunogenicity of Three Doses|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:05:49.652931|2018-06-01 05:05:49.652931
NCT00005624|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-09-21|2004-07-23|2004-07-26|Estimate|||||||2012-09-21|2012-09-25|Estimate|August 1997||1997-08-31|September 2012|2012-09-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||CI-994 in Treating Patients With Advanced Myeloma|A Multicenter Phase 2 Study of Oral N-Acetyl Dinaline (CI-994) in the Treatment of Patients With Advanced Myeloma|Completed||Phase 2|6|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:05:49.796599|2018-06-01 05:05:49.796599
NCT00005614|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-09-21|2004-07-23|2004-07-26|Estimate|||||||2012-09-21|2012-09-25|Estimate|August 1999||1999-08-31|September 2012|2012-09-30|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|||Management of Metastatic Breast Cancer in Frail Patients|Management of Metastatic Breast Cancer in Frail Patients|Withdrawn||Phase 2|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||no accrual|f||||f||||||||||2018-06-01 05:05:50.098413|2018-06-01 05:05:50.098413
NCT00005611|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2008-07-23|2004-07-23|2004-07-26|Estimate|||||||2008-07-23|2008-07-24|Estimate||||August 2000|2000-08-31||||||||Interventional|||BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment|Phase I Study of BMS-188797 in Patients With Advanced Malignancies|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:50.250227|2018-06-01 05:05:50.250227
NCT00004902|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-16|2012-05-17|2004-07-23|2004-07-26|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-17|2012-05-30|Estimate|January 1998||1998-01-31|May 2012|2012-05-31|November 1999|Actual|1999-11-30|November 1999|Actual|1999-11-30||Interventional|||Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma|Phase II Pilot Evaluation of Infusional 8 Cl-cAMP in the Treatment of Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:05:50.385602|2018-06-01 05:05:50.385602
NCT00004901|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-06-25|2004-07-23|2004-07-26|Estimate|||||||2013-06-25|2013-06-26|Estimate|October 1999||1999-10-31|August 2000|2000-08-31|July 2004|Actual|2004-07-31|||||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer|A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:50.526443|2018-06-01 05:05:50.526443
NCT00004897|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-05-25|2012-06-08|2004-07-23|2004-07-26|Estimate||||2011-05-25|2011-06-02|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer|PFL-Alpha Chemotherapy Followed by Surgery or FHX for Early Stage Esophageal Cancer - A Pilot Project|Terminated||Phase 2|||Northwestern University||||Institutional Review Board requested termination - all patients deceased and no new accrual.|f||||||||||||||2018-06-01 05:05:50.656237|2018-06-01 05:05:50.656237
NCT00004265|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-12-03|2004-07-23|2004-07-26|Estimate|||||||2013-12-03|2013-12-04|Estimate|February 1999||1999-02-28|August 2000|2000-08-31||||||||Interventional|||Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer|Phase II Study of Weekly Paclitaxel as Second-Line Therapy in Patients With Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:51.064475|2018-06-01 05:05:51.064475
NCT00004264|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-12-03|2004-07-23|2004-07-26|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 1997||1997-07-31|August 2000|2000-08-31||||||||Interventional|||Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase I/II Trial of Amifostine, High-Dose Cisplatin and Docetaxel in Patients With Advanced Lung Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:51.124157|2018-06-01 05:05:51.124157
NCT00004263|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2012-07-27|2004-07-23|2004-07-26|Estimate|||||||2012-07-27|2012-07-30|Estimate|December 1999||1999-12-31|July 2012|2012-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Phase I Study of UCN-01 and Cytarabine (ARA-C) in Patients With Acute Myelogenous Leukemia, and Myelodysplastic Syndromes|Completed||Phase 1|16|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:05:51.262503|2018-06-01 05:05:51.262503
NCT00004258|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2014-09-16|2004-07-23|2004-07-26|Estimate|||||||2014-09-16|2014-09-17|Estimate|December 1999||1999-12-31|September 2014|2014-09-30|September 2001|Actual|2001-09-30|August 2001|Actual|2001-08-31||Interventional|||EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer|A Phase I Trial of EMD 121974 in Patients With Advanced or Metastatic Cancer|Completed||Phase 1|40|Anticipated|Indiana University|||||f||||||||||||||2018-06-01 05:05:51.394406|2018-06-01 05:05:51.394406
NCT00004169|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-07-01|2012-06-21|2004-07-23|2004-07-26|Estimate||||2011-07-01|2011-07-14|Estimate|2012-06-21|2012-07-02|Estimate|November 1993||1993-11-30|June 2012|2012-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease|High-Dose Chemoradiotherapy With Stem Cell Support in Patients With Relapsed or Refractory Hodgkin's Disease|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:05:51.635906|2018-06-01 05:05:51.635906
NCT00004159|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-11-18|2004-07-23|2004-07-26|Estimate|||||||2013-11-18|2013-11-20|Estimate|February 2000||2000-02-29|March 2013|2013-03-31|February 2000|Actual|2000-02-29|February 2000|Actual|2000-02-29||Interventional|||Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor|Biweekly Gemcitabine and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer and Solid Tumors: A Phase I/IIa Study|Terminated||Phase 1/Phase 2|54|Actual|University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 05:05:51.778395|2018-06-01 05:05:51.778395
NCT00003942|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-07-23|2004-07-26|Estimate|||||||2013-12-03|2013-12-04|Estimate|November 1998||1998-11-30|August 2000|2000-08-31||||||||Interventional|||Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support|Unknown status|Active, not recruiting|Phase 1/Phase 2|15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:51.976051|2018-06-01 05:05:51.976051
NCT00003936|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-04-09|2004-07-23|2004-07-26|Estimate|||||||2014-04-09|2014-04-11|Estimate|June 1999||1999-06-30|April 2014|2014-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease|Phase II Clinical Evaluation of Bryostatin 1 in Patients With Hodgkin's Disease|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:05:52.113535|2018-06-01 05:05:52.113535
NCT00003929|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-16|2004-07-23|2004-07-26|Estimate|||||||2012-03-16|2012-03-20|Estimate|June 1998||1998-06-30|March 2012|2012-03-31||||March 2000|Actual|2000-03-31||Interventional|||Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Combined Modality Therapy of AIDS-Related and Immunocompetent Primary CNS Lymphoma (PCL) Using Filgrastim (G-CSF)|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:05:52.170056|2018-06-01 05:05:52.170056
NCT00002506|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-07-23|2004-07-26|Estimate|||||||2011-05-10|2011-05-12|Estimate|August 1992||1992-08-31|May 2011|2011-05-31|February 1999|Actual|1999-02-28|January 1996|Actual|1996-01-31||Interventional|||Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer|ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS|Completed||Phase 2|||Hoag Memorial Hospital Presbyterian|||||f||||f||||||||||2018-06-01 05:05:52.27609|2018-06-01 05:05:52.27609
NCT00002504|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-07-23|2004-07-26|Estimate|||||||2011-05-10|2011-05-12|Estimate|August 1992||1992-08-31|May 2011|2011-05-31|February 1999|Actual|1999-02-28|February 1998|Actual|1998-02-28||Interventional|||Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer|OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER|Completed||Phase 2|||Hoag Memorial Hospital Presbyterian|||||f||||f||||||||||2018-06-01 05:05:52.427862|2018-06-01 05:05:52.427862
NCT00002462|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-07-26|2004-07-23|2004-07-26|Estimate|||||||2017-07-26|2017-07-27|Actual|September 1989||1989-09-30|July 2017|2017-07-31||||May 2000|Actual|2000-05-31||Interventional|||RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease|Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease|Active, not recruiting||Phase 3|615|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:05:52.677446|2018-06-01 05:05:52.677446
NCT00088231|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-22|||2012-01-19|2004-07-22|2004-07-23|Estimate|||||||2012-01-19|2012-01-20|Estimate|July 2004||2004-07-31|January 2012|2012-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP|Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients With Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia- Blastic Phase (CML-BP)|Completed||Phase 1/Phase 2|9|Actual|M.D. Anderson Cancer Center||2|||f||||||||||||||2018-06-01 05:05:52.974699|2018-06-01 05:05:52.974699
NCT00088218|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-22|2009-09-25||2012-08-01|2004-07-22|2004-07-23|Estimate|2011-04-14|2011-05-09|Estimate||||2012-08-01|2012-08-07|Estimate|July 2004||2004-07-31|April 2011|2011-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).|Randomized Phase II Study of Clofarabine Alone Versus Clofarabine in Combination With Low-Dose Cytarabine in Previously Untreated Patients >= 60 Years With AML and High-Risk MDS|Completed||Phase 2|95|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:05:53.129206|2018-06-01 05:05:53.129206
NCT00088205|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-22||2009-06-10|2009-10-05|2004-07-22|2004-07-23|Estimate||||2009-10-05|2009-10-07|Estimate|2009-10-05|2009-10-07|Estimate|March 2004||2004-03-31|October 2009|2009-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma|A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma|Completed||Phase 2|61|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 05:05:53.647225|2018-06-01 05:05:53.647225
NCT00088179|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-21||2017-02-15|2018-02-20|2004-07-22|2004-07-23|Estimate||||2017-02-15|2017-02-16|Actual|2018-02-20|2018-02-22|Actual|July 2004|Actual|2004-07-31|February 2018|2018-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)|A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)|Completed||Phase 3|4000||Alexion Pharmaceuticals|||||||||||||||||||2018-06-01 05:05:53.925778|2018-06-01 05:05:53.925778
NCT00087997|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-19|||2006-06-19|2004-07-22|2004-07-23|Estimate|||||||2006-06-19|2006-06-20|Estimate|July 2004||2004-07-31|June 2006|2006-06-30|October 2005||2005-10-31|||||Interventional|||A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas||Completed||Phase 2|80||Synta Pharmaceuticals Corp.|||||||||||||||||||2018-06-01 05:05:54.388586|2018-06-01 05:05:54.388586
NCT00088192|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-21|||2005-08-29|2004-07-21|2004-07-22|Estimate|||||||2005-08-29|2005-08-30|Estimate|July 2004||2004-07-31|August 2005|2005-08-31||||||||Interventional|||Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)|An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD)|Completed||N/A|||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 05:05:54.640069|2018-06-01 05:05:54.640069
NCT00088166|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-20|2011-10-13||2014-07-22|2004-07-21|2004-07-22|Estimate|2014-07-22|2014-08-13|Estimate||||2014-07-22|2014-08-13|Estimate|May 2004||2004-05-31|July 2014|2014-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors|A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone|Completed||Phase 3|200|Actual|Celtic Pharma Development Services||2|||f||||t||||||||||2018-06-01 05:05:54.81392|2018-06-01 05:05:54.81392
NCT00003884|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-20|2004-07-21|2004-07-22|Estimate|||||||2013-02-20|2013-02-21|Estimate|August 1998||1998-08-31|February 2013|2013-02-28|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer|Completed||Phase 3|600|Anticipated|Novartis|||||f||||||||||||||2018-06-01 05:05:55.98312|2018-06-01 05:05:55.98312
NCT00003812|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2004-07-21|2004-07-22|Estimate|||||||2016-07-19|2016-07-20|Estimate|March 1999||1999-03-31|July 2016|2016-07-31|March 2006|Actual|2006-03-31|June 2004|Actual|2004-06-30||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Topotecan/Paclitaxel Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer: A Phase II Study|Completed||Phase 2|75|Actual|Alliance for Clinical Trials in Oncology||1|||f||||||||||||||2018-06-01 05:05:56.623071|2018-06-01 05:05:56.623071
NCT00003808|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-07-21|2004-07-22|Estimate|||||||2013-08-22|2013-08-23|Estimate|May 1999||1999-05-31|August 2013|2013-08-31||||September 2002|Actual|2002-09-30||Interventional|||Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia|Phase II Study of Theophylline in Chronic Lymphocytic Leukemia|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:05:57.246043|2018-06-01 05:05:57.246043
NCT00003781|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-04-26|2004-07-21|2004-07-22|Estimate|||||||2017-04-26|2017-04-28|Actual|December 1998||1998-12-31|April 2017|2017-04-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Docetaxel in Treating Patients With Stage IV Prostate Cancer|Phase II Study of Weekly Docetaxel (Taxotere) in Hormone Refractory Metastatic Prostate Cancer|Completed||Phase 2|25|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 05:05:57.715156|2018-06-01 05:05:57.715156
NCT00003763|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-04-03|2004-07-21|2004-07-22|Estimate|||||||2017-04-03|2017-04-04|Actual|January 1999||1999-01-31|April 2017|2017-04-30||||||||Interventional|||Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer|A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors|Completed||N/A|||Endocyte|||||f||||f|t|f||||||No||2018-06-01 05:05:58.063199|2018-06-01 05:05:58.063199
NCT00003748|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-28|2004-07-21|2004-07-22|Estimate|||||||2015-10-28|2015-10-30|Estimate|August 1998||1998-08-31|July 2012|2012-07-31|January 2005|Actual|2005-01-31|June 2000|Actual|2000-06-30||Interventional|||Irinotecan in Treating Patients With Esophageal or Stomach Cancer|Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia|Completed||Phase 2|40|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 05:05:58.355934|2018-06-01 05:05:58.355934
NCT00003725|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-07-21|2004-07-22|Estimate|||||||2013-11-05|2013-11-06|Estimate|December 1996||1996-12-31|May 2007|2007-05-31||||||||Interventional|||Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer|Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:05:58.792956|2018-06-01 05:05:58.792956
NCT00003677|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-07-21|2004-07-22|Estimate|||||||2012-07-27|2012-07-30|Estimate|March 1999||1999-03-31|July 2012|2012-07-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer|Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|9|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:05:59.248801|2018-06-01 05:05:59.248801
NCT00003675|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2004-07-21|2004-07-22|Estimate|||||||2016-07-19|2016-07-20|Estimate|March 1999||1999-03-31|July 2016|2016-07-31|April 2009|Actual|2009-04-30|January 2002|Actual|2002-01-31||Interventional|||Topotecan in Treating Patients With Myelodysplastic Syndrome|A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)|Completed||Phase 2|100|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:05:59.68774|2018-06-01 05:05:59.68774
NCT00003610|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-07-21|2004-07-22|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 1998||1998-10-31|July 2016|2016-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Capsaicin Lozenges in Treating Patients With Mucositis Caused by Radiation Therapy|Phase III Comparison of Oral Capsaicin Lozenge Versus Placebo Lozenge for Radiation-Induced Mucositis|Completed||Phase 3|18|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:06:00.362739|2018-06-01 05:06:00.362739
NCT00003585|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-09|2004-07-21|2004-07-22|Estimate|||||||2013-12-09|2013-12-10|Estimate|August 1996||1996-08-31|December 2013|2013-12-31|August 2002|Actual|2002-08-31|August 2001|Actual|2001-08-31||Interventional|||Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer|A Phase I/II Pilot Study of a Novel Four Drug Regimen for the Treatment of Advanced Renal Cell Carcinoma: FUNIL-cRA|Completed||Phase 1/Phase 2|35|Anticipated|University of New Mexico|||||f||||f||||||||||2018-06-01 05:06:00.76835|2018-06-01 05:06:00.76835
NCT00003557|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-03-05|2004-07-21|2004-07-22|Estimate|||||||2014-03-05|2014-03-06|Estimate|January 1999||1999-01-31|March 2014|2014-03-31|August 2003|Actual|2003-08-31|June 2000|Actual|2000-06-30||Interventional|||Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer|A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer|Completed||Phase 2|16|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:06:01.076318|2018-06-01 05:06:01.076318
NCT00003392|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-02-19|2004-07-21|2004-07-22|Estimate|||||||2012-02-19|2012-02-22|Estimate|September 1997||1997-09-30|February 2012|2012-02-29|January 2003|Actual|2003-01-31|August 2002|Actual|2002-08-31||Interventional|||High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer|Multiple Cycles of High Dose Chemotherapy Supported With Filgrastim and Peripheral Blood Progenitor Cells in Patients With Metastatic Breast Cancer|Completed||Phase 2|61|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:06:01.500957|2018-06-01 05:06:01.500957
NCT00003391|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-10-09|2004-07-21|2004-07-22|Estimate|||||||2009-10-09|2009-10-12|Estimate|June 1998||1998-06-30|October 2009|2009-10-31||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Phase I Trial of Monoclonal Antibody muJ591 in Patients With Hormone-Independent Prostate Cancer|Completed||Phase 1|30|Anticipated|Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 05:06:03.769641|2018-06-01 05:06:03.769641
NCT00003267|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-07-21|2004-07-22|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 1998||1998-02-28|July 2012|2012-07-31||||July 2000|Actual|2000-07-31||Interventional|||Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer|A Randomized Phase III Trial for Evaluation of Usefulness of Pelvic Drains After Radical Hysterectomy and Node Dissection (RHND)|Completed||Phase 3|214|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:06:04.087726|2018-06-01 05:06:04.087726
NCT00088153|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-20|2011-07-06||2011-10-06|2004-07-20|2004-07-21|Estimate|2011-10-06|2011-10-10|Estimate||||2011-10-06|2011-10-10|Estimate|July 2003||2003-07-31|September 2011|2011-09-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Effects of Anorexia Nervosa on Bone Mass in Adolescents|Effects of Anorexia Nervosa on Peak Bone Mass|Completed||Phase 2/Phase 3|110|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 05:06:04.496302|2018-06-01 05:06:04.496302
NCT00088140|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-20|||2012-08-09|2004-07-20|2004-07-21|Estimate|||||||2012-08-09|2012-08-13|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients|A Dose Response Study of a Caspase Inhibitor in Hepatitis C Patients|Completed||Phase 2|204|Actual|Conatus Pharmaceuticals Inc.||4|||||||t||||||||||2018-06-01 05:06:06.152352|2018-06-01 05:06:06.152352
NCT00088114|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-20|||2014-03-05|2004-07-20|2004-07-21|Estimate|||||||2014-03-05|2014-03-06|Estimate|January 2003||2003-01-31|March 2014|2014-03-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||STA-4783 and Paclitaxel for Treatment of Solid Tumors|A Phase I Trial of STA-4783 in Patients Receiving Paclitaxel for Treatment of Solid Tumors|Completed||Phase 1|50||Synta Pharmaceuticals Corp.|||||f||||||||||||||2018-06-01 05:06:06.751808|2018-06-01 05:06:06.751808
NCT00088101|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-20|||2008-12-03|2004-07-20|2004-07-21|Estimate|||||||2008-12-03|2008-12-04|Estimate|February 2004||2004-02-29|December 2008|2008-12-31|December 2004||2004-12-31|||||Interventional|||STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors|Phase I Trial of STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematological Malignancies and Patients With Solid Tumors|Completed||Phase 1|42||Synta Pharmaceuticals Corp.|||||||||||||||||||2018-06-01 05:06:07.036751|2018-06-01 05:06:07.036751
NCT00088088|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-20|||2008-12-03|2004-07-20|2004-07-21|Estimate|||||||2008-12-03|2008-12-04|Estimate|March 2004||2004-03-31|December 2008|2008-12-31|March 2005||2005-03-31|||||Interventional|||STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)|A Phase I/II Trial of STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|86||Synta Pharmaceuticals Corp.|||||||||||||||||||2018-06-01 05:06:07.364737|2018-06-01 05:06:07.364737
NCT00088075|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-19|||2011-06-06|2004-07-20|2004-07-21|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2004||2004-08-31|January 2011|2011-01-31|December 2005|Actual|2005-12-31|||||Interventional|||Investigate Risperidone for the Treatment of Schizophrenia in Adolescents|A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents|Completed||Phase 3|160|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:06:07.653838|2018-06-01 05:06:07.653838
NCT00088062|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-19|||2005-06-23|2004-07-20|2004-07-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2004||2004-02-29|May 2005|2005-05-31|November 2004||2004-11-30|||||Interventional|||STA-5326 in Crohn's Disease Patients|A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450|Completed||Phase 1/Phase 2|48||Synta Pharmaceuticals Corp.|||||||||||||||||||2018-06-01 05:06:08.079311|2018-06-01 05:06:08.079311
NCT00088049|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-19|||2007-07-16|2004-07-20|2004-07-21|Estimate|||||||2007-07-16|2007-07-18|Estimate|October 2003||2003-10-31|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia|A Randomized Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia|Completed||Phase 4|560||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:06:08.444308|2018-06-01 05:06:08.444308
NCT00088036|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-19|||2006-07-21|2004-07-20|2004-07-21|Estimate|||||||2006-07-21|2006-07-24|Estimate|February 2004||2004-02-29|July 2006|2006-07-31|January 2006||2006-01-31|||||Interventional|||Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder|Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo|Completed||Phase 3|450||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:06:08.886505|2018-06-01 05:06:08.886505
NCT00003238|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-15|2004-07-20|2004-07-21|Estimate|||||||2013-08-15|2013-08-19|Estimate|February 1998||1998-02-28|August 2013|2013-08-31||||October 2001|Actual|2001-10-31||Interventional|||Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:06:09.23096|2018-06-01 05:06:09.23096
NCT00003225|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-09-30|2004-07-20|2004-07-21|Estimate|||||||2015-09-30|2015-10-02|Estimate|July 1997||1997-07-31|July 2012|2012-07-31|June 2001|Actual|2001-06-30|March 2000|Actual|2000-03-31||Interventional|||Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer|Phase I/II Trial to Evaluate Ethyol as a Protective Agent for Irinotecan (CPT-11) Toxicities in Patients With Advanced Colorectal Cancer|Completed||Phase 1/Phase 2|23|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 05:06:09.521677|2018-06-01 05:06:09.521677
NCT00088023|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-19|||2014-03-27|2004-07-19|2004-07-20|Estimate|||||||2014-03-27|2014-03-31|Estimate|March 2004||2004-03-31|March 2014|2014-03-31|December 2005||2005-12-31|||||Interventional|||Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness|A Phase I Study of PT-523 in Patients With Solid Tumors|Terminated||Phase 1|40||Spectrum Pharmaceuticals, Inc|||||||||||||||||||2018-06-01 05:06:09.912808|2018-06-01 05:06:09.912808
NCT00088010|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-19||2010-05-27|2010-05-27|2004-07-19|2004-07-20|Estimate||||2010-05-27|2010-06-02|Estimate|2010-05-27|2010-06-02|Estimate|June 2004||2004-06-30|May 2010|2010-05-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer|Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.|Completed||Phase 3|9369|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 05:06:10.226842|2018-06-01 05:06:10.226842
NCT00087984|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-16||2013-01-22|2013-02-14|2004-07-19|2004-07-20|Estimate||||2013-02-14|2013-02-18|Estimate|2013-02-14|2013-02-18|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||RNA-Loaded Dendritic Cell Cancer Vaccine|A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 1/Phase 2|26|Actual|Argos Therapeutics||1|||f||||||||||||||2018-06-01 05:06:10.668549|2018-06-01 05:06:10.668549
NCT00087958|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-16|||2009-04-30|2004-07-19|2004-07-20|Estimate|||||||2009-04-30|2009-05-01|Estimate|August 2004||2004-08-31|April 2009|2009-04-30|April 2009|Actual|2009-04-30|February 2007|Actual|2007-02-28||Interventional|||Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment|Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine|Completed||Phase 2|168|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:06:10.988177|2018-06-01 05:06:10.988177
NCT00087945|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-16|||2013-10-04|2004-07-16|2004-07-19|Estimate|||||||2013-10-04|2013-10-08|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|December 2004|Actual|2004-12-31|||||Interventional|||Blood Levels of Abacavir in HIV Infected Adolescents|Abacavir Pharmacokinetics During Chronic Therapy in HIV-1 Infected Adolescents and Young Adults|Completed||N/A|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:06:11.326912|2018-06-01 05:06:11.326912
NCT00087919|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-15|||2008-07-01|2004-07-16|2004-07-19|Estimate|||||||2008-07-01|2008-07-02|Estimate|July 2004||2004-07-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Defining an Obesity QTL on Chromosome 3q||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:06:11.630075|2018-06-01 05:06:11.630075
NCT00087906|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-15|||2015-12-22|2004-07-16|2004-07-19|Estimate|||||||2015-12-22|2015-12-24|Estimate|July 2004||2004-07-31|December 2015|2015-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Disability and Health Outcomes in COPD|Disability and Health Outcomes in COPD|Completed|||1589|Actual|University of California, San Francisco|||||f||||f||||||||No||2018-06-01 05:06:11.80622|2018-06-01 05:06:11.80622
NCT00087893|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-15|||2013-09-26|2004-07-16|2004-07-19|Estimate|||||||2013-09-26|2013-09-27|Estimate|July 2004||2004-07-31|September 2013|2013-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Epidemiology of Vascular Inflammation & Atherosclerosis||Completed|||931|Actual|University of Vermont|||||f||||||||||||||2018-06-01 05:06:12.005163|2018-06-01 05:06:12.005163
NCT00087880|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-15|||2017-01-11|2004-07-16|2004-07-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2002||2002-12-31|March 2016|2016-03-31|September 2009|Actual|2009-09-30|January 2005|Actual|2005-01-31||Interventional|||Maintaining Abstinence in Chronic Cigarette Smokers - 1|Maintaining Abstinence in Chronic Cigarette Smokers|Completed||Phase 2|407|Actual|National Institute on Drug Abuse (NIDA)||5|||f||||f||||||||||2018-06-01 05:06:12.203481|2018-06-01 05:06:12.203481
NCT00087867|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-14|||2010-10-15|2004-07-16|2004-07-19|Estimate|||||||2010-10-15|2010-10-18|Estimate|June 2004||2004-06-30|October 2010|2010-10-31|September 2005|Actual|2005-09-30|||||Interventional|||Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma|An Open-label Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed, Refractory Patients With Multiple Myeloma|Completed||Phase 2|62|Actual|Scios, Inc.||2|||f||||||||||||||2018-06-01 05:06:12.542918|2018-06-01 05:06:12.542918
NCT00005996|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-12-18|2004-07-16|2004-07-19|Estimate|||||||2013-12-18|2013-12-19|Estimate||||September 2000|2000-09-30||||||||Interventional|||SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I Study of SU5416 in Combination With Gemcitabine/Cisplatin in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:12.801121|2018-06-01 05:06:12.801121
NCT00005806|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-17|2004-07-16|2004-07-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|September 1999||1999-09-30|June 2013|2013-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Pilot Trial of Daily Oral ZD1839 (Iressa) With Standard Doses of Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:06:13.019719|2018-06-01 05:06:13.019719
NCT00005632|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-01-30|2004-07-16|2004-07-19|Estimate|||||||2013-01-30|2013-01-31|Estimate|June 1999||1999-06-30|January 2013|2013-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer|Vaccination of Prostate Cancer Patients With MUC-1-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Examining the Immunogenicity of MUC-1 Glycopeptide Conjugate|Completed||Phase 1|27|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:06:13.28595|2018-06-01 05:06:13.28595
NCT00005619|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2011-02-18|2004-07-16|2004-07-19|Estimate|||||||2011-02-18|2011-02-21|Estimate|February 2000||2000-02-29|February 2011|2011-02-28|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Observational|||Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia|Detection of Hairy Cell Leukemia Minimal Residual Disease: Detection by Flow Cytometry|Completed|||16|Actual|Northwestern University|||||f||||||||||||||2018-06-01 05:06:13.575819|2018-06-01 05:06:13.575819
NCT00005042|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-08-28|2004-07-16|2004-07-19|Estimate|||||||2014-08-28|2014-08-29|Estimate|January 2000||2000-01-31|August 2014|2014-08-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma|A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma|Completed||Phase 2|||AIDS Malignancy Consortium|||||f||||f||||||||||2018-06-01 05:06:13.829896|2018-06-01 05:06:13.829896
NCT00005029|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2018-04-11|2004-07-16|2004-07-19|Estimate|||||||2018-04-11|2018-04-12|Actual|February 2000||2000-02-29|April 2018|2018-04-30||||January 2004|Actual|2004-01-31||Interventional|||Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Evaluation of Three-Day Topotecan (NSC 609699) in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:06:14.140793|2018-06-01 05:06:14.140793
NCT00004199|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2012-08-07|2004-07-16|2004-07-19|Estimate|||||||2012-08-07|2012-08-08|Estimate|March 1999||1999-03-31|August 2012|2012-08-31||||July 2001|Actual|2001-07-31||Interventional|||Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor Prinomastat (AG3340) in Combination With Gemcitabine and Cisplatin in Patients Having Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 05:06:14.532565|2018-06-01 05:06:14.532565
NCT00004164|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2009-02-06|2004-07-16|2004-07-19|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 1999||1999-08-31|September 2000|2000-09-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx|A Phase II Trial of Docetaxel, Cisplatin, 5-FU, and Leucovorin for Carcinoma of the Nasopharnyx|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:14.809677|2018-06-01 05:06:14.809677
NCT00004160|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-11-25|2004-07-16|2004-07-19|Estimate|||||||2013-11-25|2013-11-26|Estimate|February 2000||2000-02-29|October 2005|2005-10-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed|Sequential and Concomitant Chemoradiotherapy With Gemcitabine-Based Chemotherapy for Inoperable Stage IIIa and IIIb Non-Small Cell Lung Cancer: A Phase I/IIa Study|Completed||Phase 1/Phase 2|72|Actual|University of Alabama at Birmingham||5|||f||||t||||||||||2018-06-01 05:06:15.052657|2018-06-01 05:06:15.052657
NCT00004158|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2010-09-17|2004-07-16|2004-07-19|Estimate|||||||2010-09-17|2010-09-21|Estimate|June 1999||1999-06-30|September 2010|2010-09-30|January 2006|Actual|2006-01-31|||||Interventional|||Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase I/II Study of Targeted Radiotherapy Using Holmium-166-DOTMP With Melphalan and Peripheral Blood Stem Cell Transplantation for Treatment of Multiple Myeloma|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:06:15.66438|2018-06-01 05:06:15.66438
NCT00004104|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2016-03-30|2004-07-16|2004-07-19|Estimate|||||||2016-03-30|2016-03-31|Estimate|June 1998||1998-06-30|March 2016|2016-03-31||||July 2000|Actual|2000-07-31||Interventional|||Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma|Phase II Trial of the Effects of Interferon Alfa-2b on the Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Patients With Stage III Malignant Melanoma|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:06:15.854089|2018-06-01 05:06:15.854089
NCT00004060|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-05-15|2004-07-16|2004-07-19|Estimate|||||||2012-05-15|2012-05-16|Estimate|July 1999||1999-07-31|May 2012|2012-05-31|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane and Topotecan|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:06:16.115366|2018-06-01 05:06:16.115366
NCT00004047|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-05-15|2004-07-16|2004-07-19|Estimate|||||||2012-05-15|2012-05-16|Estimate|June 1999||1999-06-30|May 2012|2012-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Chemotherapy in Treating Patients Who Have Hematologic Cancer|A Phase I Study of Intravenous DX-8951f in Patients With Advanced Myelodysplastic Syndromes, Refractory Acute Leukemia, Refractory or Transformed Chronic Lymphocytic Leukemia, and Chronic Myelogenous Leukemia in Blastic Phase|Completed||Phase 1|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:06:16.401695|2018-06-01 05:06:16.401695
NCT00004041|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2009-02-06|2004-07-16|2004-07-19|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1999||1999-03-31|December 2002|2002-12-31||||||||Interventional|||Gene Therapy in Treating Patients With Recurrent Malignant Gliomas|Phase I Trial of Adenovirus-Mediated Wild-Type P53 Gene Therapy for Malignant Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:16.571299|2018-06-01 05:06:16.571299
NCT00003881|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-07-16|2004-07-19|Estimate|||||||2013-06-20|2013-06-21|Estimate|May 1999||1999-05-31|March 2004|2004-03-31|July 2004|Actual|2004-07-31|||||Interventional|||Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:16.857359|2018-06-01 05:06:16.857359
NCT00003219|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-08|2004-07-16|2004-07-19|Estimate|||||||2012-10-08|2012-10-10|Estimate|May 1998||1998-05-31|October 2012|2012-10-31|May 1998|Actual|1998-05-31|May 1998|Actual|1998-05-31||Interventional|||Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer|A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily in Patients With Metastatic Breast Cancer|Completed||Phase 2|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:06:17.104693|2018-06-01 05:06:17.104693
NCT00003196|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-10-23|2004-07-16|2004-07-19|Estimate|||||||2017-10-23|2017-10-25|Actual|September 1997||1997-09-30|October 2017|2017-10-31||||April 2002|Actual|2002-04-30||Interventional|||Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma|Induction of Mixed Hematopoietic Chimerism in Older Patients With B-Cell Malignancies and in Selected Other Diseases, Using Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion: A Pilot Study.|Active, not recruiting||N/A|63|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:06:17.191495|2018-06-01 05:06:17.191495
NCT00003171|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-07-16|2004-07-19|Estimate|||||||2013-04-03|2013-04-05|Estimate|May 1998||1998-05-31|April 2013|2013-04-30|June 2003|Actual|2003-06-30|July 1999|Actual|1999-07-31||Interventional|||Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome|Phase II Clinical Evaluation of Bryostatin 1 in Patients With Myelodysplastic Syndrome|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:06:17.330446|2018-06-01 05:06:17.330446
NCT00003082|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-12|2004-07-16|2004-07-19|Estimate|||||||2010-03-12|2010-03-16|Estimate|December 1997||1997-12-31|May 2007|2007-05-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer|A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients|Completed||Phase 1|27|Anticipated|University of Arizona|||||f||||||||||||||2018-06-01 05:06:17.423863|2018-06-01 05:06:17.423863
NCT00003057|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-05-09|2004-07-16|2004-07-19|Estimate|||||||2009-05-09|2009-05-12|Estimate|November 1996||1996-11-30|January 2009|2009-01-31||||May 2000|Actual|2000-05-31||Interventional|||Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer|Randomized Trial of High-Dose Versus Conventional Dose Octreotide Acetate Versus Loperamide in the Treatment of Chemotherpay-Related Diarrhea in Patients With Colorectal Cancer|Completed||Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:17.546685|2018-06-01 05:06:17.546685
NCT00002998|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-07-16|2004-07-19|Estimate|||||||2016-07-12|2016-07-13|Estimate|August 1997||1997-08-31|July 2016|2016-07-31|May 2006|Actual|2006-05-31|April 2005|Actual|2005-04-30||Interventional|||Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer|Phase II Study of Gemcitabine (GEMZAR) and Cisplatin (CDDP) in Advanced Breast Cancer|Completed||Phase 2|59|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:06:17.674749|2018-06-01 05:06:17.674749
NCT00002994|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-27|2004-07-16|2004-07-19|Estimate|||||||2016-06-27|2016-06-28|Estimate|July 1997||1997-07-31|June 2016|2016-06-30|April 2002|Actual|2002-04-30|March 2000|Actual|2000-03-31||Interventional|||Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors|A Pilot Study of Low-Dose Interleukin-2 Plus Recombinant Human Anti-HER2 Monoclonal Antibody in Solid Tumors|Completed||Phase 1|355|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:06:17.797502|2018-06-01 05:06:17.797502
NCT00002956|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-03-18|2004-07-16|2004-07-19|Estimate|||||||2016-03-18|2016-03-21|Estimate|November 1996||1996-11-30|November 2012|2012-11-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants|A Phase I Pilot Trial to Evaluate the Toxicity of Allogeneic Epstein-Barr Virus Specific T-Lymphocytes for the Treatment of EBV-Associated Lymphoproliferative Diseases in Organ Transplant Recipients|Withdrawn||Phase 1|0|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:06:17.91688|2018-06-01 05:06:17.91688
NCT00002925|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-29|2004-07-16|2004-07-19|Estimate|||||||2012-11-29|2012-11-30|Estimate|February 1997||1997-02-28|March 2011|2011-03-31|June 2010|Actual|2010-06-30|November 2003|Actual|2003-11-30||Interventional|||Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia|Phase I Study of MDR Modulation With PSC-833 (NSC# 648265) With a Pilot Study of Cytogenetic Risk-Adapted Consolidation Followed by a Phase II Pilot Study of Immunotherapy With RIL-2 (NSC # 373364) in Previously Untreated Patients With AML< 60 Years|Completed||Phase 1/Phase 2|410|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 05:06:17.990429|2018-06-01 05:06:17.990429
NCT00002908|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-07-16|2004-07-19|Estimate|||||||2013-04-03|2013-04-05|Estimate|December 1996||1996-12-31|April 2013|2013-04-30|November 2001|Actual|2001-11-30|February 2000|Actual|2000-02-29||Interventional|||Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA AND CLL|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:06:18.114077|2018-06-01 05:06:18.114077
NCT00002907|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-07-16|2004-07-19|Estimate|||||||2013-04-03|2013-04-05|Estimate|January 1997||1997-01-31|April 2013|2013-04-30|November 2000|Actual|2000-11-30|January 1999|Actual|1999-01-31||Interventional|||Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma|PHASE II CLINICAL EVALUATION OF BRYOSTATIN 1 IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:06:18.267984|2018-06-01 05:06:18.267984
NCT00002862|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-07-16|2004-07-19|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 1996||1996-10-31|September 2000|2000-09-30||||April 2001|Actual|2001-04-30||Interventional|||Perillyl Alcohol in Treating Patients With Refractory Cancer|A PHASE I STUDY OF PERILLYL ALCOHOL IN PATIENTS WITH REFRACTORY MALIGNANCIES (NSC #641066)|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:18.348598|2018-06-01 05:06:18.348598
NCT00002763|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-11-15|2004-07-16|2004-07-19|Estimate|||||||2011-11-15|2011-11-16|Estimate|April 1996||1996-04-30|November 2011|2011-11-30||||||||Interventional|||High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma|POST-OPERATIVE ADJUVANT INTERFERON-ALFA-2B (INTRON-A) TREATMENT AFTER RESECTION OF THICK PRIMARY MELANOMA AND/OR REGIONAL LYMPHNODE METASTASES 'INTERMEDIATE-HIGH DOSE' VS INTERMEDIATE-LOW DOSE' IFN-ALFA VS OBSERVATION: A 3-ARM MULTICENTER RANDOMIZED PHASE III TRIAL|Unknown status|Active, not recruiting|Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:18.461786|2018-06-01 05:06:18.461786
NCT00002760|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-27|2004-07-16|2004-07-19|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 1996||1996-08-31|June 2016|2016-06-30|April 2009|Actual|2009-04-30|March 2004|Actual|2004-03-31||Interventional|||Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer|A PHASE III TWO-ARM RANDOMIZED STUDY COMPARING ANTIANDROGEN WITHDRAWAL ALONE VERSUS ANTIANDROGEN WITHDRAWAL COMBINED WITH KETOCONAZOLE AND HYDROCORTISON IN PATIENTS WITH ADVANCED PROSTAGE CANCER|Completed||Phase 3|260|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:06:18.649546|2018-06-01 05:06:18.649546
NCT00002667|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-02-23|2004-07-16|2004-07-19|Estimate|||||||2010-02-23|2010-02-24|Estimate|July 1995||1995-07-31|May 2006|2006-05-31||||||||Interventional|||Early Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung Cancer|EARLY DETECTION OF SECOND PRIMARY LUNG CANCERS BY SPUTUM CYTOLOGY IMMUNOSTAINING|Unknown status|Active, not recruiting|N/A|1100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:18.759072|2018-06-01 05:06:18.759072
NCT00002620|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-07-16|2004-07-19|Estimate|||||||2012-06-29|2012-07-02|Estimate|November 1994||1994-11-30|June 2012|2012-06-30||||June 2000|Actual|2000-06-30||Interventional|||Radiation Therapy in Treating Patients With Brain Cancer|EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY|Completed||Phase 3|212|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:06:18.841138|2018-06-01 05:06:18.841138
NCT00002563|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-08|2004-07-16|2004-07-19|Estimate|||||||2013-04-08|2013-04-10|Estimate|April 1994||1994-04-30|April 2013|2013-04-30|May 2005|Actual|2005-05-31|September 2003|Actual|2003-09-30||Observational|||SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease|Health Status and Quality of Life in Patients With Early Stage Hodgkin's Disease: A Companion Study to SWOG-9133|Completed|||263|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 05:06:18.937056|2018-06-01 05:06:18.937056
NCT00002557|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-07-16|2004-07-19|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 1993||1993-06-30|August 2000|2000-08-31||||||||Interventional|||Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides|PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME|Unknown status|Active, not recruiting|Phase 2|3|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:19.019539|2018-06-01 05:06:19.019539
NCT00002549|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-12-22|2004-07-16|2004-07-19|Estimate|||||||2009-12-22|2009-12-23|Estimate|November 1993||1993-11-30|December 2009|2009-12-31||||||||Interventional|||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia|RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL|Unknown status|Active, not recruiting|Phase 3|1520|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:19.111394|2018-06-01 05:06:19.111394
NCT00002545|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-09|2004-07-16|2004-07-19|Estimate|||||||2013-08-09|2013-08-13|Estimate|February 1994||1994-02-28|August 2013|2013-08-31||||December 2004|Actual|2004-12-31||Interventional|||Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme|A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME|Completed||Phase 3|200|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:06:19.346641|2018-06-01 05:06:19.346641
NCT00002502|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-26|2004-07-16|2004-07-19|Estimate|||||||2013-06-26|2013-06-27|Estimate|July 1992||1992-07-31|June 2013|2013-06-30|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome|BUSULFAN AND CYCLOPHOSPHAMIDE FOR CYTOREDUCTION OF PATIENTS WITH ACUTE AND CHRONIC LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION WHO CANNOT BE TREATED WITH TOTAL BODY IRRADIATION|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:06:19.700005|2018-06-01 05:06:19.700005
NCT00002495|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-02-16|2004-07-16|2004-07-19|Estimate|||||||2017-02-16|2017-02-20|Actual|September 1992||1992-09-30|February 2017|2017-02-28|April 2014|Actual|2014-04-30|November 2000|Actual|2000-11-30||Interventional|||SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease|Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin, Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease|Completed||Phase 3|348|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:06:19.87356|2018-06-01 05:06:19.87356
NCT00002465|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-07-16|2004-07-19|Estimate|||||||2013-11-05|2013-11-06|Estimate|December 1987||1987-12-31|July 2007|2007-07-31||||||||Interventional|||High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma|Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:20.022915|2018-06-01 05:06:20.022915
NCT00087932|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-15|||2006-08-17|2004-07-15|2004-07-16|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2001||2001-09-30|August 2006|2006-08-31|August 2003||2003-08-31|||||Observational|||Socioeconomic Influences on Complementary and Alternative Medicine Use in Cancer Treatment|Socioeconomic Diversity of CAM Integration in Oncology|Completed|||300||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:06:20.099993|2018-06-01 05:06:20.099993
NCT00087854|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-14|||2008-04-21|2004-07-15|2004-07-16|Estimate|||||||2008-04-21|2008-04-23|Estimate|March 2004||2004-03-31|April 2008|2008-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study of Individualized Amonafide to Treat Prostate Cancer|Dose-Defining Study of a NAT2 Phenotype-Based Dosing Regimen of Intravenous Amonafide L-Malate Administered Weekly in Men With Androgen-Independent Prostate Cancer (AIPC)|Completed||Phase 1/Phase 2|40||Xanthus Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:06:20.171988|2018-06-01 05:06:20.171988
NCT00087841|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-14|||2008-01-15|2004-07-15|2004-07-16|Estimate|||||||2008-01-15|2008-01-17|Estimate|April 2002||2002-04-30|January 2008|2008-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Self-Hypnotic Relaxation Therapy During Invasive Procedures|Midcareer Development of Nonpharmacologic Analgesia|Completed||Phase 2|390||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:06:20.270122|2018-06-01 05:06:20.270122
NCT00087828|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-14|||2006-08-16|2004-07-15|2004-07-16|Estimate|||||||2006-08-16|2006-08-18|Estimate|November 2000||2000-11-30|August 2006|2006-08-31|June 2005||2005-06-30|||||Interventional|||Identification of the Cranberry Juice Compounds That Prevent Urinary Tract Infections|Cranberry Juice Metabolites in Urine|Completed||N/A|5||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:06:20.341721|2018-06-01 05:06:20.341721
NCT00087815|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-14|||2013-12-17|2004-07-15|2004-07-16|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2003||2003-09-30|July 2007|2007-07-31|June 2005||2005-06-30|||||Interventional|||Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain|Complimentary Hyperbaric Oxygen for Brain Radionecrosis|Unknown status|Active, not recruiting|N/A|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:20.416896|2018-06-01 05:06:20.416896
NCT00087802|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-13|||2009-04-15|2004-07-15|2004-07-16|Estimate|||||||2009-04-15|2009-04-16|Estimate|March 2004||2004-03-31|April 2009|2009-04-30||||May 2007|Actual|2007-05-31||Interventional|||Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)|A Phase III Randomized Trial of Gemcitabine/Oxaliplatin (GEMOX) Versus Carboplatin/Paclitaxel (CP) as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|383|Actual|Sanofi||2|||f||||||||||||||2018-06-01 05:06:20.523992|2018-06-01 05:06:20.523992
NCT00087789|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-13|||2016-10-27|2004-07-15|2004-07-16|Estimate|||||||2016-10-27|2016-10-31|Estimate|June 2004||2004-06-30|October 2016|2016-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease|A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|10|Actual|Sangamo Therapeutics|||||f||||t||||||||||2018-06-01 05:06:20.720421|2018-06-01 05:06:20.720421
NCT00087776|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-13|||2018-01-22|2004-07-15|2004-07-16|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2002||2002-10-31|January 2018|2018-01-31||||October 2007|Actual|2007-10-31||Interventional|||Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma|Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma|Completed||N/A|575|Anticipated|Luitpold Pharmaceuticals|||||||||||||||||||2018-06-01 05:06:20.799139|2018-06-01 05:06:20.799139
NCT00087763|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-13|||2006-05-02|2004-07-15|2004-07-16|Estimate|||||||2006-05-02|2006-05-03|Estimate|March 2004||2004-03-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)|A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)|Completed||Phase 2|135||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 05:06:20.846761|2018-06-01 05:06:20.846761
NCT00087750|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-13|||2017-01-10|2004-07-15|2004-07-16|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2003||2003-10-31|March 2005|2005-03-31||||||||Interventional|||Interaction Between Cocaine and Quetiapine - 1|Interaction Between IV Cocaine and Quetiapine|Unknown status|Active, not recruiting|Phase 1|12||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:06:20.903773|2018-06-01 05:06:20.903773
NCT00087737|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-13|||2009-08-18|2004-07-15|2004-07-16|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|369|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:06:20.961874|2018-06-01 05:06:20.961874
NCT00087711|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|||2016-11-21|2004-07-15|2004-07-16|Estimate|||||||2016-11-21|2016-11-22|Estimate|July 2004||2004-07-31|November 2016|2016-11-30|March 2008|Actual|2008-03-31|January 2007|Actual|2007-01-31||Interventional|||A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|1713|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 05:06:21.04758|2018-06-01 05:06:21.04758
NCT00087698|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2009-02-16||2009-05-01|2004-07-15|2004-07-16|Estimate|2009-02-16|2009-03-17|Estimate||||2009-05-01|2009-05-12|Estimate|September 2003||2003-09-30|May 2009|2009-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma|A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (Alimta) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma|Completed||Phase 2|77|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 05:06:21.309666|2018-06-01 05:06:21.309666
NCT00082511|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-11|||2008-01-10|2004-07-15|2004-07-16|Estimate|||||||2008-01-10|2008-01-14|Estimate|July 2003||2003-07-31|January 2008|2008-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids|A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids|Completed||Phase 3|114|Actual|Genelabs Technologies|||||f||||f||||||||||2018-06-01 05:06:21.639066|2018-06-01 05:06:21.639066
NCT00003877|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-03|2004-07-15|2004-07-16|Estimate|||||||2011-03-03|2011-03-07|Estimate|September 1998||1998-09-30|March 2011|2011-03-31|December 2000|Actual|2000-12-31|February 2000|Actual|2000-02-29||Interventional|||Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer|A Phase I/II Study in Metastatic Breast Cancer Patients Infused With Stromagen and Isolated, Mobilized, Autologous Peripheral Blood CD34+ Progenitor Cells After High-Dose Chemotherapy|Completed||Phase 1/Phase 2|30|Anticipated|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:06:22.697663|2018-06-01 05:06:22.697663
NCT00003874|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-11-28|2004-07-15|2004-07-16|Estimate|||||||2011-11-28|2011-11-29|Estimate|February 1999||1999-02-28|November 2011|2011-11-30|September 2001||2001-09-30|||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia|A Phase I/II Study of Combined Enrichment of CD34+ Cells and Depletion of B-Cells From Peripheral Blood Stem Cell Components for Patients With B-Lymphoid Malignancies|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:06:22.770492|2018-06-01 05:06:22.770492
NCT00003873|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-23|2004-07-15|2004-07-16|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 1999||1999-04-30|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer|Phase III Trial Comparing a 28 Day Schedule of Daily Oral 5-FU Plus Eniluracil to Protracted Intravenous Infusion in Previously Untreated Patients With Advanced Colorectal Cancer|Completed||Phase 3|950|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:06:22.833602|2018-06-01 05:06:22.833602
NCT00003853|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-09|2004-07-15|2004-07-16|Estimate|||||||2012-11-09|2012-11-12|Estimate|April 1999||1999-04-30|May 2011|2011-05-31|August 2001|Actual|2001-08-31|August 2000|Actual|2000-08-31||Interventional|||4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis|Phase II Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL)|Completed||Phase 2|45|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:22.922765|2018-06-01 05:06:22.922765
NCT00003805|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-07-15|2004-07-16|Estimate|||||||2012-09-20|2012-09-24|Estimate|November 1997||1997-11-30|September 2012|2012-09-30||||June 2000|Actual|2000-06-30||Interventional|||Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count|Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam|Completed||Phase 3|859|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:06:23.043469|2018-06-01 05:06:23.043469
NCT00003804|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-06-23|2004-07-15|2004-07-16|Estimate|||||||2014-06-23|2014-06-24|Estimate|July 1993||1993-07-31|April 2012|2012-04-30||||||||Interventional|||Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor|Nephroblastoma Clinical Trial and Study|Unknown status|Active, not recruiting|Phase 3|350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:23.299017|2018-06-01 05:06:23.299017
NCT00003792|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-07-15|2004-07-16|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 1999||1999-04-30|October 2006|2006-10-31|October 2006|Actual|2006-10-31|||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:23.470955|2018-06-01 05:06:23.470955
NCT00003743|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-07-15|2004-07-16|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 1997||1997-03-31|May 2007|2007-05-31||||||||Interventional|||Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation|Multicenter Observer-Blind Randomized Phase II Parallel Study Comparing Three Doses of Subcutaneous Interleukin 2 After Megatherapy and Peripheral Stem Cell Reinfusion in Stage 4 Neuroblastoma in Patients Over 1 Year of Age|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:23.557904|2018-06-01 05:06:23.557904
NCT00003664|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-07-15|2004-07-16|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 1998||1998-10-31|September 2000|2000-09-30||||||||Interventional|||Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically|Combination Chemobiotherapy With Gemcitabine, 5-Fluorouracil, Interleukin-2 and Alpha Interferon in Patients With Metastatic or Unresectable Renal Cell Cancer. A Phase II Study|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:23.636726|2018-06-01 05:06:23.636726
NCT00003639|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-07-15|2004-07-16|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 1993||1993-11-30|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma|Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:23.720719|2018-06-01 05:06:23.720719
NCT00003604|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-07-15|2004-07-16|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 1997||1997-10-31|September 2000|2000-09-30||||||||Interventional|||Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery|A Multi-Center Adjuvant Trial of Outpatient Moderate-Dose Bolus Interleukin-2 for Renal Cancer|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:23.834555|2018-06-01 05:06:23.834555
NCT00003359|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-07-15|2004-07-16|Estimate|||||||2013-06-24|2013-06-25|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||T138067 Sodium in Treating Patients With Advanced Refractory Cancer|Phase I Dose Escalation Study to Evaluate the Safety of T138067-Sodium in Patients With Advanced Refractory Cancer|Completed||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:06:23.913657|2018-06-01 05:06:23.913657
NCT00003343|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-07|2004-07-15|2004-07-16|Estimate|||||||2012-08-07|2012-08-08|Estimate|March 1998||1998-03-31|August 2012|2012-08-31||||January 2001|Actual|2001-01-31||Interventional|||Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor AG3340 in Combination With Mitoxantrone and Prednisone With Provision for Subsequent Change in Therapy in Patients Having Hormone-Refractory Prostate Cancer|Completed||Phase 3|525|Anticipated|Pfizer|||||f||||||||||||||2018-06-01 05:06:23.973078|2018-06-01 05:06:23.973078
NCT00003328|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-05-20|2004-07-15|2004-07-16|Estimate|||||||2010-05-20|2010-05-21|Estimate|December 1997||1997-12-31|May 2010|2010-05-31||||||||Interventional|||Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase III Double-Blind, Randomised, Placebo-Controlled Study of Porfiromycin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Cancer|Completed||Phase 3|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:24.04295|2018-06-01 05:06:24.04295
NCT00087724|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|||2012-06-06|2004-07-13|2004-07-14|Estimate|||||||2012-06-06|2012-06-07|Estimate|July 2004||2004-07-31|June 2012|2012-06-30|September 2006|Actual|2006-09-30|||||Interventional|||A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease|Terminated||Phase 2|510||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:06:24.147549|2018-06-01 05:06:24.147549
NCT00087685|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2015-12-01||2016-01-06|2004-07-13|2004-07-14|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|June 2004||2004-06-30|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||RAD001 in Recurrent Endometrial Cancer Patients|A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer|Completed||Phase 2|35|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:06:24.421933|2018-06-01 05:06:24.421933
NCT00087672|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2009-09-15||2012-08-01|2004-07-13|2004-07-14|Estimate|2011-01-24|2011-02-21|Estimate||||2012-08-01|2012-08-07|Estimate|July 2004||2004-07-31|August 2012|2012-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||A Phase II Study of CC-5013 in Myelofibrosis|Phase II Study of CC-5013 in Myelofibrosis|Completed||Phase 2|41|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:06:24.761157|2018-06-01 05:06:24.761157
NCT00087659|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|||2009-11-20|2004-07-13|2004-07-14|Estimate|||||||2009-11-20|2009-11-23|Estimate|December 2003||2003-12-31|November 2009|2009-11-30|May 2007|Actual|2007-05-31|||||Interventional|||A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy||Completed||N/A|||Novartis|||||||||||||||||||2018-06-01 05:06:25.090379|2018-06-01 05:06:25.090379
NCT00087646|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2015-12-10||2015-12-10|2004-07-13|2004-07-14|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|September 2003||2003-09-30|December 2015|2015-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Intent-to-treat analysis population (ITT) included, all participants randomized who received at least one dose of study medication.|REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy|A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy|Completed||Phase 4|948|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 05:06:25.275176|2018-06-01 05:06:25.275176
NCT00087633|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2009-10-14||2018-02-28|2004-07-13|2004-07-14|Estimate|2010-12-22|2011-01-24|Estimate||||2018-02-28|2018-03-29|Actual|October 2004||2004-10-31|February 2018|2018-02-28|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.|A Randomized, Open-label Study of Prophylactic Administration of PEGASYS Plus Ribavirin After Liver Transplantation on Hepatitis C Recurrence in Patients With Hepatitis C|Completed||Phase 4|115|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:06:26.625585|2018-06-01 05:06:26.625585
NCT00087620|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|||2017-02-02|2004-07-13|2004-07-14|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2004|Actual|2004-09-30|February 2017|2017-02-28|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer||Terminated||Phase 4|||Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:06:27.018183|2018-06-01 05:06:27.018183
NCT00087607|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2016-04-05||2016-05-24|2004-07-13|2004-07-14|Estimate|2016-05-24|2016-07-01|Estimate||||2016-05-24|2016-07-01|Estimate|January 2004||2004-01-31|May 2016|2016-05-31|April 2006|Actual|2006-04-30|March 2006|Actual|2006-03-31||Interventional||Baseline characteristics were described for the Intent-to-Treat (ITT) Population, which included all participants who were randomized and received at least one dose of study medication (Pegylated interferon [PEG-IFN] or ribavirin).|Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).|A Prospective, Randomized, Open-label Study Evaluating the Viral Kinetics and Pharmacokinetics of Pegasys® Plus Copegus® and PEG-Intron® Plus Rebetol® in Interferon-naïve Patients With Chronic Hepatitis C.|Completed||Phase 4|385|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:06:27.181398|2018-06-01 05:06:27.181398
NCT00087594|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2015-12-03||2016-02-04|2004-07-13|2004-07-14|Estimate|2016-02-04|2016-03-04|Estimate||||2016-02-04|2016-03-04|Estimate|November 2003||2003-11-30|February 2016|2016-02-29|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional||Intent-to-treat (ITT) Population included all enrolled participants who received at least one dose of study medication.|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.|An Open-Label, Multi-Center, Randomized, Safety, Feasibility and Tolerability Pilot Study of Pegasys® (Peginterferon Alfa-2a) Plus Copegus® (Ribavirin) in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Program.|Completed||Phase 4|48|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:06:28.754899|2018-06-01 05:06:28.754899
NCT00087581|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|||2016-11-03|2004-07-13|2004-07-14|Estimate|||||||2016-11-03|2016-11-07|Estimate|June 2004||2004-06-30|September 2016|2016-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation|An Open-Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose Versus Concentration Controlled Cellcept® Regimens for Patients Following a Single Organ Renal Transplantation in Combination With Full Dose and Reduced Dose Calcineurin Inhibitors|Completed||Phase 4|720|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 05:06:29.775504|2018-06-01 05:06:29.775504
NCT00087568|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2016-02-03||2016-05-02|2004-07-13|2004-07-14|Estimate|2016-05-02|2016-06-08|Estimate||||2016-05-02|2016-06-08|Estimate|January 2003||2003-01-31|May 2016|2016-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional||Intent-to-treat (ITT) Population included all enrolled participants who received at least one dose of study medication (Pegasys or ribavirin).|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin|An Open-label, Multicenter, Efficacy and Safety Study of Pegasys® Plus Ribavirin in Patients With Chronic HCV Infection Who Are Unable to Tolerate or Who Do Not Respond to 12 Weeks of Therapy With PEGIntron ® Plus Ribavirin|Completed||Phase 4|57|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:06:30.105159|2018-06-01 05:06:30.105159
NCT00087555|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-12|2011-10-17||2012-01-20|2004-07-13|2004-07-14|Estimate|2011-12-05|2012-01-10|Estimate||||2012-01-20|2012-01-24|Estimate|July 2004||2004-07-31|January 2012|2012-01-31|January 2006|Actual|2006-01-31|April 2005|Actual|2005-04-30||Interventional|||Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem(R) (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia|Completed||Phase 2|195|Actual|Jazz Pharmaceuticals||3|||f||||f||||||||||2018-06-01 05:06:31.244868|2018-06-01 05:06:31.244868
NCT00087542|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-09|||2005-12-05|2004-07-13|2004-07-14|Estimate|||||||2005-12-05|2005-12-07|Estimate|March 2004||2004-03-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug||Completed||Phase 2|60||ACADIA Pharmaceuticals Inc.|||||||||||||||||||2018-06-01 05:06:32.949195|2018-06-01 05:06:32.949195
NCT00087529|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-09|2015-08-10||2015-08-10|2004-07-12|2004-07-13|Estimate|2015-08-10|2015-09-09|Estimate||||2015-08-10|2015-09-09|Estimate|June 2004||2004-06-30|August 2015|2015-08-31||||October 2007|Actual|2007-10-31||Interventional|OLYMPUS|Intent-to-Treat (ITT) Population: All randomized participants, with groups defined by treatment assigned at randomization.|A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis|A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis|Completed||Phase 2/Phase 3|439|Actual|Genentech, Inc.||2|||f||||||||||||||2018-06-01 05:06:33.139565|2018-06-01 05:06:33.139565
NCT00087516|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-09|2010-05-10||2015-06-08|2004-07-12|2004-07-13|Estimate|2010-05-10|2010-06-08|Estimate||||2015-06-08|2015-07-03|Estimate|June 2004||2004-06-30|June 2015|2015-06-30|February 2007|Actual|2007-02-28|July 2005|Actual|2005-07-31||Interventional|||Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK0431 Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Completed||Phase 3|741|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-06-01 05:06:33.591823|2018-06-01 05:06:33.591823
NCT00087503|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-09|||2008-03-27|2004-07-12|2004-07-13|Estimate|||||||2008-03-27|2008-04-01|Estimate|April 2004||2004-04-30|March 2008|2008-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy|A Phase II Efficacy And Safety Study Intravenous Edotecarin In Patients With Advanced Gastric Cancer That Has Progressed Or Recurred After Prior Fluropyrimidine-Based Chemotherapy|Completed||Phase 2|28||Pfizer|||||f||||||||||||||2018-06-01 05:06:35.415288|2018-06-01 05:06:35.415288
NCT00087490|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-09|2012-06-29||2012-06-29|2004-07-12|2004-07-13|Estimate|2012-06-29|2012-08-08|Estimate||||2012-06-29|2012-08-08|Estimate|October 2004||2004-10-31|June 2012|2012-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)|Linezolid in the Treatment of Subjects With Complicated Skin and Soft Tissue Infections Proven to be Due to Methicillin-Resistant Staphylococcus Aureus|Completed||Phase 4|1077|Actual|Pfizer|Comparing duration of intravenous (IV) therapy for linezolid (LZD) and vancomycin (VAN) in study, participants in LZD group had option to switch to oral therapy while those in VAN group had to remain on IV therapy until completion of study treatment.||||f||||||||||||||2018-06-01 05:06:35.866879|2018-06-01 05:06:35.866879
NCT00087464|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2012-05-17|2004-07-12|2004-07-13|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31||||||||Interventional|||Three Month Course of Anti-HIV Medications for People Recently Infected With HIV|Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection?|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||||study was withdrawn before any participants were recruited and enrolled|||||||||||||||2018-06-01 05:06:38.959224|2018-06-01 05:06:38.959224
NCT00087451|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2015-08-18|2004-07-12|2004-07-13|Estimate|||||||2015-08-18|2015-08-19|Estimate|July 2004||2004-07-31|August 2015|2015-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)|A Phase I Sequential Ascending Dose Trial of AP23573 in Patients With Progressive or Recurrent Malignant Glioma|Completed||Phase 1|11|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:06:39.129373|2018-06-01 05:06:39.129373
NCT00086710|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2005-06-23|2004-07-12|2004-07-13|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2004|2004-04-30||||||||Interventional|||Study of Enfuvirtide in HIV-Positive Subjects|An Open-label, Randomized, Cross-over Study in HIV-Positive Subjects to Determine and Compare the Single-dose Pharmacokinetics of Enfuvirtide after a Single 90 mg SC Administration|Completed||Phase 1|26||Trimeris|||||||||||||||||||2018-06-01 05:06:39.351623|2018-06-01 05:06:39.351623
NCT00086645|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-07|||2017-03-08|2004-07-12|2004-07-13|Estimate|||||||2017-03-08|2017-03-10|Actual|April 2004||2004-04-30|March 2017|2017-03-31|April 2007|Actual|2007-04-30|October 2006|Actual|2006-10-31||Interventional|||Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)|Citalopram Treatment in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior|Completed||Phase 2|149|Actual|Boston University||2|||f||||t||||||||||2018-06-01 05:06:39.54336|2018-06-01 05:06:39.54336
NCT00003589|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-05|2004-07-12|2004-07-13|Estimate|||||||2012-03-05|2012-03-06|Estimate|August 1998||1998-08-31|March 2012|2012-03-31||||July 2000|Actual|2000-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|Randomized Study With New Combination Chemotherapies in Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|450|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:06:39.920769|2018-06-01 05:06:39.920769
NCT00087438|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|2014-02-25||2016-12-30|2004-07-09|2004-07-12|Estimate|2014-02-25|2014-04-07|Estimate||||2016-12-30|2017-02-17|Actual|May 2004||2004-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2010|Actual|2010-03-31||Interventional||All eligible patients who received protocol treatment.|Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer|A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I/II Non-Small Cell Lung Cancer|Completed||Phase 2|59|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:06:40.318152|2018-06-01 05:06:40.318152
NCT00087425|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2015-04-29|2004-07-09|2004-07-12|Estimate|||||||2015-04-29|2015-04-30|Estimate|July 2004||2004-07-31|January 2007|2007-01-31||||October 2007|Actual|2007-10-31||Interventional|||Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase II Trial Of Bryostatin-1 In Combination With Rituximab In Rituximab-Refractory Indolent B-cell Non Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia|Completed||Phase 2|48|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:06:41.002132|2018-06-01 05:06:41.002132
NCT00087412|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-02-27|2004-07-09|2004-07-12|Estimate|||||||2013-02-27|2013-02-28|Estimate|September 2004||2004-09-30|February 2013|2013-02-28||||July 2007|Actual|2007-07-31||Interventional|||S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer|Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2|Completed||Phase 2|65|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:41.103641|2018-06-01 05:06:41.103641
NCT00087399|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2016-07-12|2004-07-09|2004-07-12|Estimate|||||||2016-07-12|2016-07-14|Estimate|November 2004||2004-11-30|July 2016|2016-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy|A Phase III Randomized, Trial of Gabapentin Alone or in Conjunction With an Antidepressant in the Management of Hot Flashes in Women Who Have Inadequate Control With an Antidepressant Alone|Completed||Phase 3|118|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:06:41.340292|2018-06-01 05:06:41.340292
NCT00087386|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-04-09|2004-07-09|2004-07-12|Estimate|||||||2013-04-09|2013-04-10|Estimate|June 2004||2004-06-30|April 2013|2013-04-30||||February 2007|Actual|2007-02-28||Interventional|||Tanespimycin in Treating Patients With Stage III-IV Melanoma|Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients|Terminated||Phase 2|50|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:42.034649|2018-06-01 05:06:42.034649
NCT00087373|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2014-06-06|2004-07-09|2004-07-12|Estimate|||||||2014-06-06|2014-06-09|Estimate|June 2004||2004-06-30|December 2012|2012-12-31||||February 2006|Actual|2006-02-28||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|Phase II Study of Intratumoral Injection of rF-TRICOMTM in Patients With Metastatic Melanoma Who Have Detectable Tumor Associated T Cells|Terminated||Phase 2|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:42.250971|2018-06-01 05:06:42.250971
NCT00087360|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-07-10|2004-07-09|2004-07-12|Estimate|||||||2013-07-10|2013-07-11|Estimate|November 2003||2003-11-30|July 2013|2013-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants|Providing Genetic And Environmental Cancer Risk Assessment In Primary Care|Completed||N/A|||Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:06:42.556573|2018-06-01 05:06:42.556573
NCT00087347|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-05-12|2004-07-09|2004-07-12|Estimate|||||||2013-05-12|2013-05-14|Estimate|September 2004||2004-09-30|May 2013|2013-05-31||||September 2006|Actual|2006-09-30||Observational|||Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer|An NCI-Sponsored Exploratory Study For Determining Optimum Timing For The Imaging Of Intravenous Superparamagnetic Particle Ferumoxytol (Code7228) For The Differentiation of Metastatic and Non Metastatic Lymph Nodes in Patients With Known Primary Cancer Scheduled For Possible Surgical Lymph Node Biopsy/Dissection|Completed|||14|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 05:06:43.031133|2018-06-01 05:06:43.031133
NCT00087334|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-31|2004-07-09|2004-07-12|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2004||2004-01-31|January 2013|2013-01-31||||November 2005|Actual|2005-11-30||Interventional|||Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer|A Phase I/II Study of Capecitabine (XELODA®, Roche) Plus Oxaliplatin (Eloxatin®, Sanofi) Plus ZD 1893 (IRESSA®) in the Treatment of Metastatic Colorectal Cancer|Terminated||Phase 1/Phase 2|10|Actual|Roswell Park Cancer Institute||||Withdrawn due to poor/low accrual|f||||||||||||||2018-06-01 05:06:43.33368|2018-06-01 05:06:43.33368
NCT00087295|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2012-10-31|2004-07-09|2004-07-12|Estimate|||||||2012-10-31|2012-11-02|Estimate|June 2004||2004-06-30|October 2012|2012-10-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium|A Phase II Study of Depsipeptide (NSC-630176) In Patients With Advanced Transitional Cell Carcinoma Of The Urinary Tract Who Have Progressed After Receiving One Prior Chemotherapy Regimen For Advanced Disease|Terminated||Phase 2|6|Actual|Southwest Oncology Group||1||Permanently Closed Due to Poor Accrual|f||||f||||||||||2018-06-01 05:06:43.522126|2018-06-01 05:06:43.522126
NCT00087282|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-06-21|2004-07-09|2004-07-12|Estimate|||||||2013-06-21|2013-06-24|Estimate|June 2004||2004-06-30|May 2005|2005-05-31|July 2006|Actual|2006-07-31|||||Interventional|||Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer|A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:43.87476|2018-06-01 05:06:43.87476
NCT00087269|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-06-04|2004-07-09|2004-07-12|Estimate|||||||2013-06-04|2013-06-06|Estimate|December 2004||2004-12-31|June 2013|2013-06-30||||April 2006|Actual|2006-04-30||Interventional|||Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection|Phase II Study to Evaluate the Tumor Biochemical Effects of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Erlotinib) Administered Prior to Surgical Resection in Patients With Early Stage Non-Small Cell Lung Cancer|Terminated||Phase 2|110|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:44.012339|2018-06-01 05:06:44.012339
NCT00087256|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-04|2004-07-09|2004-07-12|Estimate|||||||2013-01-04|2013-01-07|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer|Celecoxib Polyp Prevention Trial in Participants With Resected Stage I Colon Cancer|Terminated||Phase 3|18|Actual|NSABP Foundation Inc||2||For scientific, logistic, and administrative reasons.|f||||f||||||||||2018-06-01 05:06:44.238441|2018-06-01 05:06:44.238441
NCT00087217|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-24|2004-07-09|2004-07-12|Estimate|||||||2013-01-24|2013-01-25|Estimate|May 2004||2004-05-31|January 2013|2013-01-31||||June 2008|Actual|2008-06-30||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor|Phase I Study of 17- Allylamino-17 Demethoxygeldanamycin (17-AAG) in Combination With Paclitaxel in Advanced Solid Malignancies|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:44.581864|2018-06-01 05:06:44.581864
NCT00087204|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-22|2004-07-09|2004-07-12|Estimate|||||||2013-01-22|2013-01-23|Estimate|May 2004||2004-05-31|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia|A Phase I Study Of XL119 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:44.914903|2018-06-01 05:06:44.914903
NCT00087191|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-15|2004-07-09|2004-07-12|Estimate|||||||2013-01-15|2013-01-16|Estimate|May 2004||2004-05-31|January 2013|2013-01-31||||January 2006|Actual|2006-01-31||Interventional|||EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer|Distribution Of The Photosensitizer Motexafin Lutetium And Hypoxia In Patients With Malignancies|Terminated||N/A|30|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:06:45.024856|2018-06-01 05:06:45.024856
NCT00087178|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2016-06-03|2004-07-09|2004-07-12|Estimate|||||||2016-06-03|2016-06-06|Estimate|May 2004||2004-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2014|Actual|2014-03-31||Interventional|||Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer|A Clinical Trial Of Adjuvant Therapy Comparing Six Cycles Of 5-Fluorouracil, Epirubicin And Cyclophosphamide (FEC) To Four Cycles Of Adriamycin And Cyclophosphamide (AC) In Patients With Node-Negative Breast Cancer|Completed||Phase 3|2722|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 05:06:45.260873|2018-06-01 05:06:45.260873
NCT00087165|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2011-08-18|2004-07-09|2004-07-12|Estimate|||||||2011-08-18|2011-08-19|Estimate|January 2005||2005-01-31|November 2005|2005-11-30||||||||Interventional|||GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer|A Phase II Study of GTI-2040 in Combination With Docetaxel and Prednisone in Hormone-Refractory Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:06:46.6352|2018-06-01 05:06:46.6352
NCT00087152|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|2011-07-13||2014-05-12|2004-07-09|2004-07-12|Estimate|2014-05-12|2014-06-09|Estimate||||2014-05-12|2014-06-09|Estimate|June 2004||2004-06-30|February 2013|2013-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer|Phase II Trial Of Imatinib Mesylate (Gleevec®) (NSC-716051) In Combination With Capecitabine (Xeloda®) (NSC-712807) In Metastatic Breast Cancer|Completed||Phase 2|27|Actual|National Cancer Institute (NCI)|Two-stage design, but did not have enough confirmed responses after the first stage to launch the second stage.|1|||f||||f||||||||||2018-06-01 05:06:46.82062|2018-06-01 05:06:46.82062
NCT00087139|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|2012-11-25||2014-04-21|2004-07-09|2004-07-12|Estimate|2012-11-27|2012-12-27|Estimate||||2014-04-21|2014-05-09|Estimate|September 2004||2004-09-30|April 2013|2013-04-30|February 2011|Actual|2011-02-28|April 2009|Actual|2009-04-30||Interventional|||Ixabepilone in Treating Patients With Metastatic Prostate Cancer|Phase II Study of a Weekly Schedule of BMS-247550 for Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|124|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:47.549613|2018-06-01 05:06:47.549613
NCT00087126|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2015-05-29|2004-07-09|2004-07-12|Estimate|||||||2015-05-29|2015-06-01|Estimate|February 2005||2005-02-28|May 2015|2015-05-31||||January 2010|Actual|2010-01-31||Interventional|||Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin®, NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix|Completed||Phase 2|27|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 05:06:48.46605|2018-06-01 05:06:48.46605
NCT00087113|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2014-02-12|2004-07-09|2004-07-12|Estimate|||||||2014-02-12|2014-02-14|Estimate|August 2004||2004-08-31|February 2014|2014-02-28||||June 2006|Actual|2006-06-30||Interventional|||Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix|A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231517, IND #40061) In the Treatment Of Recurrent Carcinoma Of The Cervix|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:06:48.67323|2018-06-01 05:06:48.67323
NCT00087100|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2014-02-12|2004-07-09|2004-07-12|Estimate|||||||2014-02-12|2014-02-14|Estimate|May 2006||2006-05-31|February 2014|2014-02-28||||August 2007|Actual|2007-08-31||Interventional|||Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer|A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Endometrial Carcinoma|Completed||Phase 2|51|Anticipated|Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 05:06:48.817734|2018-06-01 05:06:48.817734
NCT00087087|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2014-02-12|2004-07-09|2004-07-12|Estimate|||||||2014-02-12|2014-02-14|Estimate|July 2004||2004-07-31|February 2014|2014-02-28||||December 2006|Actual|2006-12-31||Interventional|||Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation Of Pemetrexed (ALIMTA LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma|Completed||Phase 2|51|Anticipated|Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 05:06:49.242448|2018-06-01 05:06:49.242448
NCT00087074|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-06-03|2004-07-09|2004-07-12|Estimate|||||||2013-06-03|2013-06-04|Estimate|June 2004||2004-06-30|June 2013|2013-06-30||||December 2005|Actual|2005-12-31||Interventional|||CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor|A Trial of CCI-779 in Patients With Soft Tissue Sarcoma.|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:49.536695|2018-06-01 05:06:49.536695
NCT00087061|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-07-17|2004-07-09|2004-07-12|Estimate|||||||2013-07-17|2013-07-18|Estimate|May 2004||2004-05-31|May 2005|2005-05-31|June 2005|Actual|2005-06-30|||||Interventional|||Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma|Oral ST1481 in Adults With Malignant Glioma: A Phase I-II Clinical Trial|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:49.72665|2018-06-01 05:06:49.72665
NCT00087048|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2016-03-21|2004-07-09|2004-07-12|Estimate|||||||2016-03-21|2016-03-22|Estimate|April 2004||2004-04-30|March 2016|2016-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer|The Use Of Weekly Topotecan As Second Line Therapy In Small Cell Lung Cancer|Terminated||Phase 2|1|Actual|Case Comprehensive Cancer Center||||Slow accrual|f||||t||||||||||2018-06-01 05:06:49.941009|2018-06-01 05:06:49.941009
NCT00087035|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2015-10-01|2004-07-09|2004-07-12|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2004||2004-05-31|August 2012|2012-08-31|March 2008|Actual|2008-03-31|June 2006|Actual|2006-06-30||Interventional|||Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer|Phase II Trial Of TAXOTERE + TARCEVA™ To Treat HRPC In Men ≥ 65 Years Of Age|Completed||Phase 2|1|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:06:50.215488|2018-06-01 05:06:50.215488
NCT00087022|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08||2014-01-28|2014-01-28|2004-07-09|2004-07-12|Estimate||||2014-01-28|2014-02-28|Estimate|2014-01-28|2014-02-28|Estimate|July 2004||2004-07-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer|A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)|Completed||Phase 3|864|Actual|Wilex||2|||f||||t||||||||||2018-06-01 05:06:50.691215|2018-06-01 05:06:50.691215
NCT00087009|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-03-18|2004-07-09|2004-07-12|Estimate|||||||2013-03-18|2013-03-19|Estimate|May 2004||2004-05-31|March 2013|2013-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation|Phase I Study of Oral ß-Glucan and Intravenous Rituximab Among Children and Adolescents With Relapsed CD20-Positive Lymphoma or Leukemia, or Post-Transplant Lymphoproliferative Disease|Terminated||Phase 1|3|Actual|Memorial Sloan Kettering Cancer Center||2||Lack of Accrual|f||||||||||||||2018-06-01 05:06:51.027795|2018-06-01 05:06:51.027795
NCT00086996|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|2012-03-05||2013-09-04|2004-07-09|2004-07-12|Estimate|2012-03-05|2012-04-03|Estimate||||2013-09-04|2013-10-11|Estimate|September 2004||2004-09-30|September 2013|2013-09-30|August 2011|Actual|2011-08-31|August 2009|Actual|2009-08-31||Interventional|||S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction|Oxaliplatin (NSC-266046) Plus Protracted Infusion 5-Fluorouracil And Radiation For Potentially Curable Esophageal Cancer: A Phase II Trial With Molecular Correlates|Completed||Phase 2|98|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:06:51.527285|2018-06-01 05:06:51.527285
NCT00086983|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-09|2004-07-09|2004-07-12|Estimate|||||||2013-01-09|2013-01-10|Estimate|May 2004||2004-05-31|January 2013|2013-01-31||||September 2006|Actual|2006-09-30||Interventional|||Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors|A Phase I Study of XL119 (Rebeccamycin Analogue) in Combination With Oxaliplatin in Patients With Refractory Solid Tumors|Terminated||Phase 1|15|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:53.073935|2018-06-01 05:06:53.073935
NCT00086970|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-23|2004-07-09|2004-07-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|June 2004||2004-06-30|January 2013|2013-01-31||||November 2005|Actual|2005-11-30||Interventional|||Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors|A Phase I Study Of BG In Combination With Ifosfamide For Advanced Solid Tumors|Terminated||Phase 1|32|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:06:53.381033|2018-06-01 05:06:53.381033
NCT00086957|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|2016-11-04||2017-01-06|2004-07-09|2004-07-12|Estimate|2017-01-06|2017-02-27|Actual||||2017-01-06|2017-02-27|Actual|January 2004||2004-01-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer|Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma|Completed||Phase 1/Phase 2|31|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 05:06:53.79926|2018-06-01 05:06:53.79926
NCT00086944|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-23|2004-07-09|2004-07-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2004||2004-05-31|January 2013|2013-01-31||||July 2006|Actual|2006-07-31||Interventional|||Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase I/II Study of G3139 (Genasense) in Combination With RICE Chemotherapy in Relapsed B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:55.457662|2018-06-01 05:06:55.457662
NCT00086931|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-03-07|2004-07-09|2004-07-12|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 2003||2003-09-30|March 2013|2013-03-31|May 2010|Actual|2010-05-31|May 2007|Actual|2007-05-31||Interventional|||Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum|A Phase I/II Study of Weekly Intravenous Oxaliplatin in Combination With Oral Daily Capecitabine and Radiation Therapy in the Neoadjuvant Treatment of Rectal Cancer|Completed||Phase 1/Phase 2|37|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:06:55.796573|2018-06-01 05:06:55.796573
NCT00086892|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2014-02-12|2004-07-09|2004-07-12|Estimate|||||||2014-02-12|2014-02-14|Estimate|June 2004||2004-06-30|February 2014|2014-02-28||||April 2006|Actual|2006-04-30||Interventional|||Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240) in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 05:06:56.159937|2018-06-01 05:06:56.159937
NCT00086879|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2017-07-26|2004-07-09|2004-07-12|Estimate|||||||2017-07-26|2017-07-27|Actual|May 2004||2004-05-31|July 2017|2017-07-31|March 2011|Actual|2011-03-31|March 2006|Actual|2006-03-31||Interventional|||Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme|Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|110|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:06:56.786956|2018-06-01 05:06:56.786956
NCT00086866|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2015-02-09|2004-07-09|2004-07-12|Estimate|||||||2015-02-09|2015-02-10|Estimate|May 2004||2004-05-31|February 2015|2015-02-28||||January 2007|Actual|2007-01-31||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery|Randomized, Open Phase II Study of Immunization With the Recombinant MAGE-3 Protein Combined With Adjuvant AS02B or AS15 in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma|Unknown status|Active, not recruiting|Phase 2|165|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:06:57.079003|2018-06-01 05:06:57.079003
NCT00086840|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-01-23|2004-07-09|2004-07-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2004||2004-05-31|January 2013|2013-01-31||||August 2005|Actual|2005-08-31||Interventional|||CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase II Study of CCI-779 in Patients With Relapsed, Refractory or Transformed Chronic Lymphocytic Leukemia|Terminated||Phase 2|60|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:06:57.488777|2018-06-01 05:06:57.488777
NCT00086827|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2014-04-09|2004-07-09|2004-07-12|Estimate|||||||2014-04-09|2014-04-10|Estimate|May 2004||2004-05-31|December 2012|2012-12-31||||November 2006|Actual|2006-11-30||Interventional|||Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of Single Agent Depsipeptide (FK228) (NSC 630176; IND 51,810) in Relapsed Small Cell Lung Cancer|Completed||Phase 2|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:06:57.770951|2018-06-01 05:06:57.770951
NCT00086801|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2016-06-30|2004-07-09|2004-07-12|Estimate|||||||2016-06-30|2016-07-01|Estimate|May 2004||2004-05-31|June 2016|2016-06-30|May 2011|Actual|2011-05-31|March 2007|Actual|2007-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma|Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma|Completed||Phase 2|104|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:06:58.070288|2018-06-01 05:06:58.070288
NCT00086775|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-08-01|2004-07-09|2004-07-12|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2003||2003-07-31|October 2009|2009-10-31|October 2009|Actual|2009-10-31|June 2005|Actual|2005-06-30||Interventional|||Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia|Phase II Trial Comparing Combination Treatment With Fludarabine and Alemtuzumab to Fludarabine and Rituximab in Patients With B-Cell Chronic Lymphocytic Leukemia Requiring Treatment After First Line Therapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:06:58.533259|2018-06-01 05:06:58.533259
NCT00086762|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2018-05-03|2004-07-09|2004-07-12|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2004|Actual|2004-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors|Chemotherapy and Mindfulness Relaxation: A Randomized Trial at M.D. Anderson Cancer Center and M.D. Anderson Community Clinical Oncology Program|Active, not recruiting||N/A|474|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:06:58.818961|2018-06-01 05:06:58.818961
NCT00086749|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2012-07-10|2004-07-09|2004-07-12|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 2003||2003-02-28|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer|A Prospective Study Of The Effect Of Tamoxifen On Breast Density In Premenopausal Women|Completed|||53|Actual|Northwestern University|||1||f||||||||||||||2018-06-01 05:06:59.03083|2018-06-01 05:06:59.03083
NCT00086736|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08|||2013-11-17|2004-07-09|2004-07-12|Estimate|||||||2013-11-17|2013-11-19|Estimate|November 2001||2001-11-30|July 2013|2013-07-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy|A Randomized, Placebo-Controlled Phase IIb Clinical Trial of 2-Difluoromethylornithine (DFMO) Versus Bicalutamide (CASODEX) Alone and in Combination in Patients With Prostate Cancer in the Period Prior to Radical Prostatectomy or Brachytherapy: Modulation of Tissue and Molecular Biomarkers in Human Prostate Tissue Serum|Completed||Phase 2|34|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-06-01 05:06:59.265152|2018-06-01 05:06:59.265152
NCT00086723|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-08||2011-02-18|2012-06-07|2004-07-09|2004-07-12|Estimate||||2011-02-18|2011-02-25|Estimate|2012-06-07|2012-06-11|Estimate|July 2003||2003-07-31|June 2012|2012-06-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer|Phase I/II Trial of In Vivo Angiostatin Generation With Tissue Plasminogen Activator (tPA) and Captopril in Patients With Progressive, Metastatic Cancer|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:06:59.577005|2018-06-01 05:06:59.577005
NCT00086684|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-07|2012-05-31||2014-04-02|2004-07-08|2004-07-09|Estimate|2012-05-31|2012-07-06|Estimate||||2014-04-02|2014-04-21|Estimate|September 2003||2003-09-30|April 2014|2014-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis|Randomized, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of the Efficacy and Tolerability of Two Different Doses of ELMIRON for the Treatment of Interstitial Cystitis|Terminated||Phase 4|369|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3||"Interim Analysis showed that study continuation was futile. No safety concerns were raised~   during the trial."|f||||f||||||||||2018-06-01 05:06:59.92612|2018-06-01 05:06:59.92612
NCT00086671|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-07||2011-08-24|2013-01-02|2004-07-08|2004-07-09|Estimate||||2011-08-24|2011-08-29|Estimate|2013-01-02|2013-01-04|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)|A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase|Completed||Phase 2|215|Actual|AbbVie||3|||f||||t||||||||||2018-06-01 05:07:02.475144|2018-06-01 05:07:02.475144
NCT00086658|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-07|||2015-04-16|2004-07-08|2004-07-09|Estimate|||||||2015-04-16|2015-04-17|Estimate|March 2004||2004-03-31|April 2015|2015-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)|A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES|Completed||Phase 2|86|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 05:07:02.650636|2018-06-01 05:07:02.650636
NCT00086632|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-07|||2007-12-13|2004-07-08|2004-07-09|Estimate|||||||2007-12-13|2007-12-18|Estimate|July 2004||2004-07-31|January 2006|2006-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment|An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-Based Front-Line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin|Terminated||Phase 2|40||Unither Pharmaceuticals||||closed by sponser|||||||||||||||2018-06-01 05:07:02.767421|2018-06-01 05:07:02.767421
NCT00086606|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-06|||2013-01-17|2004-07-08|2004-07-09|Estimate|||||||2013-01-17|2013-01-21|Estimate|June 2004||2004-06-30|January 2013|2013-01-31|April 2006|Actual|2006-04-30|||||Interventional|||A Safety and Efficacy Study of Xolair in Peanut Allergy|A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Oral Food Challenge Trial of Xolair (Omalizumab) in Peanut Allergy|Terminated||Phase 2|150||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:07:02.866031|2018-06-01 05:07:02.866031
NCT00086619|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-07|2012-06-07||2013-09-26|2004-07-07|2004-07-08|Estimate|2013-07-25|2013-09-26|Estimate||||2013-09-26|2013-10-30|Estimate|May 2004||2004-05-31|September 2013|2013-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women|Evaluation of Factors That Affect Skeletal Responses to PTH|Completed||Phase 2|80|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-06-01 05:07:03.052656|2018-06-01 05:07:03.052656
NCT00086593|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-06|||2016-10-05|2004-07-07|2004-07-08|Estimate|||||||2016-10-05|2016-10-07|Estimate|May 2004||2004-05-31|October 2016|2016-10-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia|A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of a Flexible Dose of Lamotrigine Compared to Placebo as an Adjunctive Therapy to an Atypical Antipsychotic Agent(s) in Subjects With Schizophrenia|Completed||Phase 3|209|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:07:05.110789|2018-06-01 05:07:05.110789
NCT00086580|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-06|2011-06-13||2014-02-10|2004-07-07|2004-07-08|Estimate|2011-07-18|2011-08-11|Estimate||||2014-02-10|2014-03-13|Estimate|July 2004||2004-07-31|February 2014|2014-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients|A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 3|335|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 05:07:05.509787|2018-06-01 05:07:05.509787
NCT00003297|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-22|2004-07-07|2004-07-08|Estimate|||||||2011-03-22|2011-03-24|Estimate|December 1997||1997-12-31|September 2000|2000-09-30|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer|Phase I/II Study of High Dose Topotecan, Mitoxantrone and Thiotepa (TMT) Followed by Autologous Stem Cell Transplant in Patients With Recurrent Platinum Resistant Ovarian Cancer|Completed||Phase 1/Phase 2|50|Anticipated|Georgetown University|||||f||||f||||||||||2018-06-01 05:07:09.219914|2018-06-01 05:07:09.219914
NCT00003296|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-07-07|2004-07-08|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1998||1998-01-31|September 2000|2000-09-30||||||||Interventional|||Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer|Phase II Study of TLC D-99 for Hepatobiliary Carcinomas|Unknown status|Active, not recruiting|Phase 2|26|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:09.3612|2018-06-01 05:07:09.3612
NCT00003230|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2004-07-07|2004-07-08|Estimate|||||||2012-05-14|2012-05-15|Estimate|January 1998||1998-01-31|May 2012|2012-05-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia|Paclitaxol (Taxol) for Refractory or Relapsed Acute Leukemia in Elderly Patients, and Blast Crisis of Chronic Myelogenous Leukemia: A Multicenter Phase I/II Study|Completed||Phase 1/Phase 2|33|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:07:09.501435|2018-06-01 05:07:09.501435
NCT00003198|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-07-07|2004-07-08|Estimate|||||||2013-06-25|2013-06-27|Estimate|November 1997||1997-11-30|June 2013|2013-06-30|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors|A Phase I Dose-Escalation Study of Topotecan and Ifosfamide in Patients With Refractory Non-Hematologic Malignancies.|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:07:09.666902|2018-06-01 05:07:09.666902
NCT00003109|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-16|2004-07-07|2004-07-08|Estimate|||||||2013-04-16|2013-04-17|Estimate|December 1997||1997-12-31|April 2013|2013-04-30|January 2001|Actual|2001-01-31|October 2000|Actual|2000-10-31||Interventional|||Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors|Phase I Pharmacokinetic and Pharmacodynamic Trial of Irinotecan in Combination With Tomudex in Patients With Refractory Solid Malignancies|Completed||Phase 1|39|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:07:09.820117|2018-06-01 05:07:09.820117
NCT00086541|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-02|||2007-05-03|2004-07-06|2004-07-07|Estimate|||||||2007-05-03|2007-05-07|Estimate|June 2004||2004-06-30|May 2007|2007-05-31|January 2007|Actual|2007-01-31|||||Interventional|||Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy|A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa Plus Ribavirin Therapy|Completed||Phase 3|515|Actual|Valeant Pharmaceuticals International, Inc.|||||||||||||||||||2018-06-01 05:07:09.959591|2018-06-01 05:07:09.959591
NCT00086528|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-02|||2011-10-17|2004-07-06|2004-07-07|Estimate|||||||2011-10-17|2011-10-18|Estimate|June 2004||2004-06-30|October 2011|2011-10-31|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors|A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors|Completed||Phase 1|41|Actual|Kadmon Corporation, LLC|||||f||||t||||||||||2018-06-01 05:07:10.088382|2018-06-01 05:07:10.088382
NCT00086411|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|2013-06-24||2014-01-24|2004-07-06|2004-07-07|Estimate|2014-01-24|2014-03-11|Estimate||||2014-01-24|2014-03-11|Estimate|September 2003||2003-09-30|January 2014|2014-01-31|June 2009|Actual|2009-06-30|April 2008|Actual|2008-04-30||Interventional|||Comparing Smoking Treatment Programs for Lighter Smokers - 1|Comparing Smoking Treatment Programs for Lighter Smokers|Completed||Phase 2|260|Actual|University of Pennsylvania|Missing data from some early terminations from treatment (i.e., 2 or less visits) may reflect dissatisfaction with counseling assignment or medication effects.|4|||f||||t||||||||||2018-06-01 05:07:10.237185|2018-06-01 05:07:10.237185
NCT00086398|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|||2005-11-03|2004-07-06|2004-07-07|Estimate|||||||2005-11-03|2005-11-07|Estimate|September 2001||2001-09-30|November 2005|2005-11-30||||||||Interventional|||Psychotherapy Enhancement for Therapeutic Community (TC) Retention - 1|Psychotherapy Enhancement for TC Retention|Unknown status|Recruiting|Phase 2|100||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:07:10.901872|2018-06-01 05:07:10.901872
NCT00086385|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|2013-07-29||2015-03-03|2004-07-06|2004-07-07|Estimate|2013-08-02|2013-10-10|Estimate||||2015-03-03|2015-03-23|Estimate|September 2001||2001-09-30|March 2015|2015-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Maintaining Nonsmoking: Older Smokers - 1|Maintaining Nonsmoking: Older Smokers|Completed||Phase 3|403|Actual|University of California, San Francisco|The limitations of this study include generalizability, as the population treated was relatively well-educated, willing to participate in research and to attend treatment sessions.|4|||f||||f||||||||||2018-06-01 05:07:11.024085|2018-06-01 05:07:11.024085
NCT00003091|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-07-06|2004-07-07|Estimate|||||||2011-05-10|2011-05-12|Estimate|January 1996||1996-01-31|May 2011|2011-05-31|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma|Treatment of Metastatic Renal Cell Carcinoma and Melanoma With Subsequential High-Dose Subcutaneous Interferon Alfa-2b and High-Dose Bolus and Continuous Intravenous Interleukin-2|Completed||Phase 2|40|Anticipated|Hoag Memorial Hospital Presbyterian|||||f||||f||||||||||2018-06-01 05:07:11.717558|2018-06-01 05:07:11.717558
NCT00002953|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-07-06|2004-07-07|Estimate|||||||2013-12-03|2013-12-04|Estimate|December 1996||1996-12-31|December 2005|2005-12-31|November 2005|Actual|2005-11-30|||||Interventional|||Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer|A Radomized Trial of Epirubicin & Cyclophosphamide vs. Epirubicin & Paclitaxel in the Treatment of Women With Metastatic Breast Cancer|Completed||Phase 3|704|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:12.10248|2018-06-01 05:07:12.10248
NCT00002922|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-28|2004-07-06|2004-07-07|Estimate|||||||2013-08-28|2013-08-29|Estimate|January 1997||1997-01-31|August 2013|2013-08-31||||September 2001|Actual|2001-09-30||Interventional|||Paclitaxel in Treating Patients With Advanced Head and Neck Cancer|Phase II Evaluation of Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:07:12.390356|2018-06-01 05:07:12.390356
NCT00002863|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-07-06|2004-07-07|Estimate|||||||2014-05-20|2014-05-22|Estimate|June 1996||1996-06-30|May 2014|2014-05-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Cryosurgery in Treating Patients With Soft Tissue Sarcoma|PHASE I FEASIBILITY TRIAL OF CRYOSURGICAL ABLATION OF SOFT TISSUE SARCOMAS OF THE EXTREMETY|Terminated||Phase 1|19|Actual|University of Southern California||||Insufficient Accrual|f||||t||||||||||2018-06-01 05:07:12.668233|2018-06-01 05:07:12.668233
NCT00086567|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-02|||2018-04-24|2004-07-02|2004-07-05|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2, 2004||2004-07-02|April 5, 2018|2018-04-05||||||||Observational|||Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers|A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse|Completed|||119|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:07:12.904338|2018-06-01 05:07:12.904338
NCT00086554|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-02|||2017-06-30|2004-07-02|2004-07-05|Estimate|||||||2017-06-30|2017-07-02|Actual|July 1, 2004||2004-07-01|January 8, 2010|2010-01-08|January 8, 2010||2010-01-08|||||Observational|||Collection of Specimens for Study of Inflammatory Bowel Disease|Procurement of Clinical Specimens for Immunologic or Genetic Studies in Inflammatory Bowel Diseases|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:07:13.163115|2018-06-01 05:07:13.163115
NCT00086515|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-02|2010-11-19||2017-03-31|2004-07-02|2004-07-05|Estimate|2010-11-19|2010-12-17|Estimate||||2017-03-31|2017-05-05|Actual|June 30, 2004|Actual|2004-06-30|March 2017|2017-03-31|February 2, 2007|Actual|2007-02-02|July 20, 2005|Actual|2005-07-20||Interventional|||Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy|Completed||Phase 3|701|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 05:07:13.426857|2018-06-01 05:07:13.426857
NCT00086502|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-02|2010-03-30||2016-02-04|2004-07-02|2004-07-05|Estimate|2010-03-30|2010-04-19|Estimate||||2016-02-04|2016-02-05|Estimate|June 2004||2004-06-30|February 2016|2016-02-29|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy|Completed||Phase 3|353|Actual|Merck Sharp & Dohme Corp.||2|||f||||||||||||||2018-06-01 05:07:15.34768|2018-06-01 05:07:15.34768
NCT00086489|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|||2012-06-05|2004-07-02|2004-07-05|Estimate|||||||2012-06-05|2012-06-06|Estimate|August 2003||2003-08-31|June 2012|2012-06-30|May 2009|Actual|2009-05-31|May 2007|Actual|2007-05-31||Interventional|||CP-675,206 In Patients With Advanced Melanoma|Phase 1 Open Label, Non-Randomized, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immune Function Effects, And Efficacy Of Multiple Doses Of CP-675,206 In Patients With Advanced Melanoma, And Phase 2, Open Label, Randomized Study To Evaluate the Efficacy, Safety, Tolerability And Pharmacokinetics Of 2 Regimens Of CP-675,206 In Patients With Advanced Melanoma.|Completed||Phase 2|118|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 05:07:16.442996|2018-06-01 05:07:16.442996
NCT00086463|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|||2011-03-31|2004-07-02|2004-07-05|Estimate|||||||2011-03-31|2011-04-01|Estimate|June 2004||2004-06-30|March 2011|2011-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)|A Safety and Pilot Efficacy Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With PAH|Completed||Phase 2|60||Actelion|||||||||||||||||||2018-06-01 05:07:16.763498|2018-06-01 05:07:16.763498
NCT00002751|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2004-06-30|2004-07-01|Estimate|||||||2013-06-19|2013-06-20|Estimate|July 1989||1989-07-31|October 2009|2009-10-31|May 2004|Actual|2004-05-31|||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Brain Metastases|PROTOCOL FOR A PHASE I STUDY OF INTRATHECAL MONOCLONAL ANTIBODY FRAGMENT 131I Me1-14 F(ab')2 IN PATIENTS WITH NEOPLASMS METASTATIC TO THE LEPTOMENINGES|Completed||Phase 1/Phase 2|6|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:07:27.083507|2018-06-01 05:07:27.083507
NCT00086450|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|2016-09-13||2016-12-09|2004-07-02|2004-07-05|Estimate|2016-12-09|2017-02-06|Estimate||||2016-12-09|2017-02-06|Estimate|April 2004||2004-04-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|July 2012|Actual|2012-07-31||Interventional|||Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes (FREEDOM)|Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)|Active, not recruiting||Phase 3|1900|Actual|Icahn School of Medicine at Mount Sinai|Since the trial was not blinded, patients may have been treated differently on the basis of their surgical procedure.|2|||f||||t||||||||||2018-06-01 05:07:17.172457|2018-06-01 05:07:17.172457
NCT00086437|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|||2015-12-02|2004-07-02|2004-07-05|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2004||2004-07-31|December 2015|2015-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||Pharmacogenetics of Hypertriglyceridemia in Hispanics|Pharmacogenetics of Hypertriglyceridemia in Hispanics|Completed|||274|Actual|University of California, Los Angeles|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-06-01 05:07:17.849303|2018-06-01 05:07:17.849303
NCT00086424|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|||2008-04-22|2004-07-02|2004-07-05|Estimate|||||||2008-04-22|2008-04-23|Estimate|July 2004||2004-07-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Epidemiology of Insulin Growth Factor (IGF) and Cardiovascular Events||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:07:17.905764|2018-06-01 05:07:17.905764
NCT00002999|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-05-22|2004-07-02|2004-07-05|Estimate|||||||2015-05-22|2015-05-27|Estimate||||May 2015|2015-05-31||||||||Interventional|||S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx|S9715, Study of Patients With Advanced Nasopharyngeal Cancers Treated With Chemo-Radiotherapy, Phase II|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 05:07:18.20625|2018-06-01 05:07:18.20625
NCT00086476|ClinicalTrials.gov processed this data on May 31, 2018|2004-07-01|||2017-06-30|2004-07-01|2004-07-02|Estimate|||||||2017-06-30|2017-07-02|Actual|June 29, 2004||2004-06-29|June 13, 2011|2011-06-13|June 13, 2011||2011-06-13|||||Observational|||Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles|Investigations of Megakaryocytes From Patients With Abnormal Platelet Vesicles|Completed|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:07:18.503578|2018-06-01 05:07:18.503578
NCT00086346|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-30|2009-07-06||2010-04-20|2004-07-01|2004-07-02|Estimate|2009-07-31|2009-09-07|Estimate||||2010-04-20|2010-04-28|Estimate|December 2002||2002-12-31|April 2010|2010-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients|A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy|Terminated||Phase 3|607|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 05:07:18.915894|2018-06-01 05:07:18.915894
NCT00086333|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-30|||2011-10-21|2004-07-01|2004-07-02|Estimate|||||||2011-10-21|2011-10-24|Estimate|July 2004||2004-07-31|October 2011|2011-10-31|December 2005|Actual|2005-12-31|||||Interventional|||FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma|A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent|Completed||Phase 2|30||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 05:07:21.363285|2018-06-01 05:07:21.363285
NCT00086372|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-30|||2012-10-26|2004-06-30|2004-07-01|Estimate|||||||2012-10-26|2012-10-29|Estimate|July 2003||2003-07-31|October 2012|2012-10-31|April 2007|Actual|2007-04-30|||||Observational|||Long-term Follow-up of HIV Infected Patients Identified During Early Infection|Acute HIV Infection and Early Disease Research Program (AIEDRP) CORE01 Database|Completed|||157|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:07:21.621039|2018-06-01 05:07:21.621039
NCT00086359|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-30|||2014-12-22|2004-06-30|2004-07-01|Estimate|||||||2014-12-22|2014-12-23|Estimate|July 2004||2004-07-31|December 2014|2014-12-31|September 2007|Actual|2007-09-30|||||Interventional|||Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV|A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV|Completed||Phase 3|19|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:07:21.942798|2018-06-01 05:07:21.942798
NCT00086320|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-30|||2011-06-06|2004-06-30|2004-07-01|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|August 2005|Actual|2005-08-31|||||Interventional|||A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia|Completed||Phase 3|111|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:07:22.295315|2018-06-01 05:07:22.295315
NCT00086281|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-29|2011-11-11||2012-01-20|2004-06-30|2004-07-01|Estimate|2012-01-20|2012-02-24|Estimate||||2012-01-20|2012-02-24|Estimate|November 2003||2003-11-30|January 2012|2012-01-31|November 2005|Actual|2005-11-30|June 2005|Actual|2005-06-30||Interventional|||Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients|Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients|Completed||Phase 4|60|Actual|Jazz Pharmaceuticals||4|||f||||f||||||||||2018-06-01 05:07:22.620071|2018-06-01 05:07:22.620071
NCT00086268|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-29|||2017-09-12|2004-06-30|2004-07-01|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2004||2004-04-30|September 2017|2017-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|ZPACT||Non-small Cell Lung Cancer Study US75 (Z-PACT)||Completed||Phase 3|250|Actual|Novartis||2|||f||||||||||||||2018-06-01 05:07:25.575854|2018-06-01 05:07:25.575854
NCT00002837|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-06-30|2004-07-01|Estimate|||||||2012-07-27|2012-07-31|Estimate|September 1995||1995-09-30|July 2012|2012-07-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer|Phase I-II Study of Dose Intense Doxorubicin, Paclitaxel And Cyclophosphamide With Peripheral Blood Progenitor Cells (PBPC) And Cytokine Support In Patients With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:07:26.268117|2018-06-01 05:07:26.268117
NCT00002804|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-24|2004-06-30|2004-07-01|Estimate|||||||2014-07-24|2014-07-25|Estimate|September 1996||1996-09-30|July 2014|2014-07-31|April 2006|Actual|2006-04-30|June 2000|Actual|2000-06-30||Interventional|||Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma|Phase II Study of Neoadjuvant Vincristine, Ifosfamide, Doxorubicin, and AND G-CSF in Children With Advanced Stage Non-Rhabdomyosarcoma Soft Tissue Sarcomas|Completed||Phase 2|43|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:07:26.656847|2018-06-01 05:07:26.656847
NCT00002733|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-06-30|2004-07-01|Estimate|||||||2011-05-10|2011-05-11|Estimate|January 1996||1996-01-31|May 2011|2011-05-31|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Biological Therapy in Treating Patients With Metastatic Cancer|ALPHA INTERFERON, TUMOR INFILTRATING LYMPHOCYTES, AND INTERLEUKIN-2 IN THE TREATMENT OF CANCER|Completed||Phase 2|30|Anticipated|Hoag Memorial Hospital Presbyterian|||||f||||||||||||||2018-06-01 05:07:27.37822|2018-06-01 05:07:27.37822
NCT00002705|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-31|2004-06-30|2004-07-01|Estimate|||||||2013-01-31|2013-02-01|Estimate|April 1996||1996-04-30|May 2001|2001-05-31||||January 2001|Actual|2001-01-31||Interventional|||Topotecan in Treating Children With Refractory Leukemia|TOPOTECAN FOR CHILDREN WITH REFRACTORY LEUKEMIA, A PEDIATRIC ONCOLOGY GROUP PHASE I COOPERATIVE AGREEMENT STUDY|Completed||Phase 1|3|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:07:27.688416|2018-06-01 05:07:27.688416
NCT00002704|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-31|2004-06-30|2004-07-01|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 1996||1996-01-31|November 2007|2007-11-30||||June 2004|Actual|2004-06-30||Interventional|||Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia|TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY|Completed||Phase 2|156|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:07:28.042459|2018-06-01 05:07:28.042459
NCT00002691|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-06-30|2004-07-01|Estimate|||||||2013-06-24|2013-06-25|Estimate|August 1995||1995-08-31|June 2013|2013-06-30|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|||Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma|LSA5 PROTOCOL FOR THE TREATMENT OF ADVANCED PEDIATRIC AND ADOLESCENT NON-HODGKIN'S LYMPHOMA (NHL)|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:07:28.596018|2018-06-01 05:07:28.596018
NCT00002654|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-06|2004-06-30|2004-07-01|Estimate|||||||2013-03-06|2013-03-07|Estimate|April 1994||1994-04-30|March 2013|2013-03-31|July 2000|Actual|2000-07-31|March 1999|Actual|1999-03-31||Interventional|||Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer|Phase III Study of Hyperfractionated Radiation Therapy With or Without Simultaneaous Application of CIS-Platinum in Patients With Moderately Advanced to Advanced Cancers of the Head and Neck|Completed||Phase 3|224|Actual|Swiss Group for Clinical Cancer Research|||||f||||f||||||||||2018-06-01 05:07:28.870754|2018-06-01 05:07:28.870754
NCT00086307|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-29|2012-06-07||2013-01-11|2004-06-29|2004-06-30|Estimate|2012-06-07|2012-07-12|Estimate||||2013-01-11|2013-01-28|Estimate|June 2004||2004-06-30|January 2013|2013-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Lexapro and Pramipexole and to Treat Major Depression|Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study|Completed||Phase 2|39|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||||2018-06-01 05:07:29.187137|2018-06-01 05:07:29.187137
NCT00086294|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-29|||2017-06-30|2004-06-29|2004-06-30|Estimate|||||||2017-06-30|2017-07-02|Actual|June 25, 2004||2004-06-25|November 15, 2007|2007-11-15|November 15, 2007||2007-11-15|||||Interventional|||ACP-103 to Treat Parkinson's Disease|5HT2A/C Serotonin Blockade in Parkinson's Disease|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:07:30.66424|2018-06-01 05:07:30.66424
NCT00086255|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-29|||2017-01-11|2004-06-29|2004-06-30|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2002||2002-10-31|August 2008|2008-08-31|June 2004||2004-06-30|||||Interventional|||Tiagabine for the Treatment of Cocaine Dependence - 1|Tiagabine for the Treatment of Cocaine Dependence|Completed||Phase 2|140||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:07:30.920351|2018-06-01 05:07:30.920351
NCT00086216|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-28|||2007-12-20|2004-06-29|2004-06-30|Estimate|||||||2007-12-20|2007-12-21|Estimate|May 2004||2004-05-31|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma|An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma|Completed||Phase 1/Phase 2|30|Actual|Callisto Pharmaceuticals|||||f||||f||||||||||2018-06-01 05:07:31.186897|2018-06-01 05:07:31.186897
NCT00002642|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-05|2004-06-29|2004-06-30|Estimate|||||||2012-10-05|2012-10-08|Estimate|April 1995||1995-04-30|October 2012|2012-10-31|July 2004|Actual|2004-07-31|January 2001|Actual|2001-01-31||Interventional|||SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer|Induction Chemoradiotherapy Followed by Surgical Resection for Non-small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors): A Phase II Trial|Completed||Phase 2|116|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:07:31.49684|2018-06-01 05:07:31.49684
NCT00002565|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-05|2004-06-29|2004-06-30|Estimate|||||||2012-10-05|2012-10-08|Estimate|May 1994||1994-05-31|October 2012|2012-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma|"RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY (ATT) VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5"|Completed||Phase 3|61|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:07:31.7681|2018-06-01 05:07:31.7681
NCT00086242|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-28|||2009-07-20|2004-06-28|2004-06-29|Estimate|||||||2009-07-20|2009-07-21|Estimate||||November 2006|2006-11-30||||||||Interventional|||Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stage I, Stage II, or Stage III Cervical Cancer|Stress-Immune Response and Cervical Cancer|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:32.104617|2018-06-01 05:07:32.104617
NCT00086229|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-28|||2006-08-16|2004-06-28|2004-06-29|Estimate|||||||2006-08-16|2006-08-18|Estimate|April 2004||2004-04-30|August 2006|2006-08-31|January 2006||2006-01-31|||||Interventional|||Absorption and Distribution of Glucosamine and Chondroitin|A Pharmacokinetic Study of Glucosamine and Chondroitin|Completed||N/A|70||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:07:32.237876|2018-06-01 05:07:32.237876
NCT00086203|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-28|||2015-03-24|2004-06-28|2004-06-29|Estimate|||||||2015-03-24|2015-03-25|Estimate||||August 2006|2006-08-31|September 2007||2007-09-30|||||Interventional|||Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)||Completed||Phase 2|||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:07:32.502051|2018-06-01 05:07:32.502051
NCT00086190|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-28|2012-01-11||2013-01-03|2004-06-28|2004-06-29|Estimate|2013-01-03|2013-01-04|Estimate||||2013-01-03|2013-01-04|Estimate|June 2005||2005-06-30|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|SAD-PD||Study of Antidepressants in Parkinson's Disease|Study of Antidepressants in Parkinson's Disease|Completed||Phase 3|115|Actual|University of Rochester||3|||f||||t||||||||||2018-06-01 05:07:32.80514|2018-06-01 05:07:32.80514
NCT00003127|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-13|2004-06-23|2004-06-24|Estimate|||||||2012-06-13|2012-06-14|Estimate|February 1998||1998-02-28|June 2012|2012-06-30|July 2004|Actual|2004-07-31|April 2003|Actual|2003-04-30||Interventional|||S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer|Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma|Completed||Phase 2|57|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:07:48.854518|2018-06-01 05:07:48.854518
NCT00086177|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-25|||2010-08-18|2004-06-28|2004-06-29|Estimate|||||||2010-08-18|2010-08-19|Estimate|April 2004||2004-04-30|August 2010|2010-08-31|March 2009|Actual|2009-03-31|January 2007|Actual|2007-01-31||Interventional|||Vaginal Progesterone to Reduce the Risk of Another Preterm Birth|A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery|Completed||Phase 3|636|Actual|Juniper Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-06-01 05:07:37.713258|2018-06-01 05:07:37.713258
NCT00086164|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-25|||2005-07-14|2004-06-28|2004-06-29|Estimate|||||||2005-07-14|2005-07-19|Estimate|May 2004||2004-05-31|July 2005|2005-07-31||||||||Interventional|||Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis|A Phase 1/2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene (PTFE) Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis|Terminated||Phase 1/Phase 2|||Anesiva, Inc.|||||||||||||||||||2018-06-01 05:07:38.131622|2018-06-01 05:07:38.131622
NCT00086151|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-25|||2016-07-28|2004-06-28|2004-06-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Identifying Low-Risk Patients With Pulmonary Embolism||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:07:38.343961|2018-06-01 05:07:38.343961
NCT00086138|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-25|2016-03-08||2017-02-28|2004-06-25|2004-06-28|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|July 2004||2004-07-31|February 2017|2017-02-28|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|DIADS-2||Depression in Alzheimer's Disease-2|Depression in Alzheimer's Disease (DIADS-2)|Completed||Phase 2/Phase 3|131|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 05:07:38.609904|2018-06-01 05:07:38.609904
NCT00086125|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-24|||2015-08-18|2004-06-25|2004-06-28|Estimate|||||||2015-08-18|2015-08-19|Estimate|June 2004||2004-06-30|August 2015|2015-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)|A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies|Completed||Phase 2|57|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 05:07:39.692861|2018-06-01 05:07:39.692861
NCT00086112|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-24|||2012-07-19|2004-06-25|2004-06-28|Estimate|||||||2012-07-19|2012-07-23|Estimate||||July 2012|2012-07-31|June 2005|Actual|2005-06-30|||||Interventional|||Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.|A Double-blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone Versus Adjunctive Placebo in Generalized Anxiety Disorder Sub-optimally Responsive to Standard Psychotropic Therapy|Completed||Phase 3|301|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:07:40.009996|2018-06-01 05:07:40.009996
NCT00006041|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-17|2004-06-25|2004-06-28|Estimate|||||||2013-06-17|2013-06-19|Estimate|February 2000||2000-02-29|June 2013|2013-06-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer|Vaccination of Patients Who Have Ovarian, Fallopian Tube or Peritoneal Cancer With Glycosylated MUC-1-KLH Conjugate Plus the Immunological Adjuvant QS-21|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:07:40.275716|2018-06-01 05:07:40.275716
NCT00005975|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2015-11-17|2004-06-25|2004-06-28|Estimate|||||||2015-11-17|2015-11-18|Estimate|April 1998||1998-04-30|November 2015|2015-11-30|March 2002|Actual|2002-03-31|September 2001|Actual|2001-09-30||Interventional|||S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer|A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626|Completed||Phase 3|288|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:07:40.528571|2018-06-01 05:07:40.528571
NCT00005854|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2011-11-28|2004-06-25|2004-06-28|Estimate|||||||2011-11-28|2011-11-30|Estimate|December 1999||1999-12-31|November 2011|2011-11-30|October 2000|Actual|2000-10-31|||||Interventional|||Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Transplantation of HLA Haploidentical Marrow Cells After Ex Vivo Exposure to Recipient Alloantigen in Presence of CTLA4-Ig - A Phase II Study of Tolerance Induction in Donor T Cells by Blockade of the CD80/CD86:CD28 Costimulatory Signal|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:07:40.842655|2018-06-01 05:07:40.842655
NCT00002505|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-06-25|2004-06-28|Estimate|||||||2011-05-10|2011-05-12|Estimate|August 1992||1992-08-31|May 2011|2011-05-31|May 2006|Actual|2006-05-31|August 2002|Actual|2002-08-31||Interventional|||Tumor Cell Vaccine in Treating Patients With Advanced Cancer|RANDOMIZED PHASE II TRIAL OF AUTOLOGOUS TUMOR CELL VACCINE|Completed||Phase 2|||Hoag Memorial Hospital Presbyterian|||||f||||f||||||||||2018-06-01 05:07:41.109771|2018-06-01 05:07:41.109771
NCT00002482|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-06-25|2004-06-28|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 1991||1991-06-30|July 2007|2007-07-31||||||||Interventional|||Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer|A PHASE I-II TRIAL OF MUROMONAB (OKT-3) WITH LOW-DOSE CYCLOPHOSPHAMIDE|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:41.364061|2018-06-01 05:07:41.364061
NCT00086099|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-23|||2009-01-28|2004-06-24|2004-06-25|Estimate|||||||2009-01-28|2009-01-29|Estimate|July 2004||2004-07-31|January 2009|2009-01-31|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia|A Phase IB/II, Randomized, Open-Label, Multicenter Study Evaluating Whether the Addition of Amifostine (Ethyol®) Will Enable the Safe Increase in Dose Intensity of Idarubicin in Combination With Cytosine Arabinoside in Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|54|Actual|MedImmune LLC||2|||f||||||||||||||2018-06-01 05:07:41.751228|2018-06-01 05:07:41.751228
NCT00005613|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-03|2004-06-24|2004-06-25|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 1996||1996-03-31|June 2013|2013-06-30|June 2010|Actual|2010-06-30|October 2006|Actual|2006-10-31||Interventional|CBV||Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Prospective, Comparative Trial of Allogeneic Versus Autologous Stem Cell Transplantation for High Risk Lymphoma|Completed||Phase 2|147|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 05:07:42.110372|2018-06-01 05:07:42.110372
NCT00004202|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-05-08|2004-06-24|2004-06-25|Estimate|||||||2013-05-08|2013-05-10|Estimate|October 1998||1998-10-31|May 2013|2013-05-31||||||||Interventional|||Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer|A Phase II Study of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Radiation Therapy With RSR13 for Locally Advanced Inoperable Non-Small Cell Lung Cancer|Completed||Phase 2|||Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 05:07:42.451788|2018-06-01 05:07:42.451788
NCT00004197|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2018-01-13|2004-06-24|2004-06-25|Estimate|||||||2018-01-13|2018-01-17|Actual|June 1999||1999-06-30|January 2018|2018-01-31|November 2003|Actual|2003-11-30|January 2002|Actual|2002-01-31||Interventional|||Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma|A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma|Completed||Phase 2|||University of Nebraska|||||f||||||||||||||2018-06-01 05:07:42.670582|2018-06-01 05:07:42.670582
NCT00004192|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2018-01-13|2004-06-24|2004-06-25|Estimate|||||||2018-01-13|2018-01-17|Actual|May 2000||2000-05-31|January 2018|2018-01-31|March 2001|Actual|2001-03-31|February 2001|Actual|2001-02-28||Interventional|||Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma|A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma|Completed||Phase 2|60|Anticipated|University of Nebraska|||||f||||||||||||||2018-06-01 05:07:42.881078|2018-06-01 05:07:42.881078
NCT00003995|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-06-24|2004-06-25|Estimate|||||||2013-02-07|2013-02-08|Estimate|September 1999||1999-09-30|June 2007|2007-06-30||||March 2006|Actual|2006-03-31||Interventional|||Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2|Phase II and Pharmacokinetic Study of CPT-11 and Trastuzumab (RhuMab HER2, Herceptin) in Advanced Colo-Rectal Cancer With p185 HER 2 Overexpression|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:07:43.03696|2018-06-01 05:07:43.03696
NCT00003946|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-07|2004-06-24|2004-06-25|Estimate|||||||2013-06-07|2013-06-10|Estimate|August 1999||1999-08-31|July 2004|2004-07-31||||June 2003|Actual|2003-06-30||Interventional|||Danazol in Treating Patients With Advanced or Recurrent Endometrial Cancer|Phase II Study of Danazol in Advanced or Recurrent Endometrial Cancer|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:07:43.300593|2018-06-01 05:07:43.300593
NCT00086086|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-23|||2017-02-07|2004-06-23|2004-06-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|August 2003||2003-08-31|February 2017|2017-02-28||||||||Interventional|||Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Effects of Treatment With 2 Regimens of Subcutaneous Darbepoetin Alfa (Weight-based Dosing and Fixed Dosing) on Hemoglobin Concentration Response in Subjects With Symptomatic CHF and Anaemia|Completed||Phase 2|150||Amgen|||||||||||||||||||2018-06-01 05:07:44.315113|2018-06-01 05:07:44.315113
NCT00086073|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-22|||2011-02-15|2004-06-23|2004-06-24|Estimate|||||||2011-02-15|2011-02-16|Estimate|August 1998||1998-08-31|November 2010|2010-11-30|January 2011|Actual|2011-01-31|||||Observational|PROGENI||Parkinson's Research: The Organized Genetics Initiative|Parkinson's Disease Collaborative Study of Genetic Linkage|Completed|||1800|Anticipated|Indiana University|||||f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-06-01 05:07:44.646461|2018-06-01 05:07:44.646461
NCT00003762|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2016-07-12|2004-06-23|2004-06-24|Estimate|||||||2016-07-12|2016-07-13|Estimate|February 1999||1999-02-28|July 2016|2016-07-31|May 2008|Actual|2008-05-31|February 2003|Actual|2003-02-28||Interventional|||Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Randomized Phase II Study of Docetaxel and Gemcitabine for Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 2|106|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-06-01 05:07:45.028969|2018-06-01 05:07:45.028969
NCT00003723|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-05|2004-06-23|2004-06-24|Estimate|||||||2012-10-05|2012-10-08|Estimate|February 1999||1999-02-28|October 2012|2012-10-31|December 2007|Actual|2007-12-31|June 2007|Actual|2007-06-30||Interventional|||S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery|Phase II Study of Gemcitabine and Cisplatin in Unresectable Malignant Mesothelioma|Completed||Phase 2|57|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:07:45.545599|2018-06-01 05:07:45.545599
NCT00003691|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-08|2004-06-23|2004-06-24|Estimate|||||||2013-07-08|2013-07-09|Estimate|December 1998||1998-12-31|September 2010|2010-09-30||||June 2004|Actual|2004-06-30||Interventional|||Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|A Randomized Study of Doxorubicin Plus Cisplatin Versus Doxorubicin Plus Cisplatin Plus 3-Hour Paclitaxel With G-CSF Support in Patients With Primary Stage III & IV or Recurrent Endometrial Carcinoma|Completed||Phase 3|240|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:07:46.136963|2018-06-01 05:07:46.136963
NCT00003667|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-06-23|2004-06-24|Estimate|||||||2013-06-24|2013-06-25|Estimate|September 1998||1998-09-30|June 2013|2013-06-30|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma|Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane With and Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:07:46.582118|2018-06-01 05:07:46.582118
NCT00003630|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-06-23|2004-06-24|Estimate|||||||2013-06-20|2013-06-24|Estimate|August 1998||1998-08-31|June 2013|2013-06-30|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Arsenic Trioxide in Treating Patients With Advanced Solid Tumors|Phase I Study of Arsenic Trioxide|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:07:46.828354|2018-06-01 05:07:46.828354
NCT00003549|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-05|2004-06-23|2004-06-24|Estimate|||||||2012-10-05|2012-10-08|Estimate|October 1998||1998-10-31|October 2012|2012-10-31|January 2003|Actual|2003-01-31|September 2001|Actual|2001-09-30||Interventional|||S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer|A Phase II Trial of Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)|Completed||Phase 2|80|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 05:07:47.137443|2018-06-01 05:07:47.137443
NCT00003369|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-13|2004-06-23|2004-06-24|Estimate|||||||2012-06-13|2012-06-14|Estimate|August 1998||1998-08-31|June 2012|2012-06-30|July 2004|Actual|2004-07-31|October 2003|Actual|2003-10-31||Interventional|||S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer|Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer|Completed||Phase 2|56|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:07:47.577588|2018-06-01 05:07:47.577588
NCT00003317|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-06-23|2004-06-24|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 1998||1998-05-31|July 2016|2016-07-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|A Phase III Study of Surgical Resection and Chemotherapy (Paclitaxel and Carboplatin) With or Without Adjuvant Radiotherapy for Resected Stage IIIA Non-Small Cell Lung Cancer|Completed||Phase 3|480|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:07:48.465384|2018-06-01 05:07:48.465384
NCT00086047|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-22|2011-08-12||2017-08-23|2004-06-22|2004-06-23|Estimate|2013-11-01|2013-11-06|Estimate||||2017-08-23|2017-09-20|Actual|July 2004||2004-07-31|August 2017|2017-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Coping Skills Training for Adolescents With Fibromyalgia|Randomized Clinical Trial in Juvenile Fibromyalgia|Completed||Phase 3|114|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-06-01 05:07:49.992125|2018-06-01 05:07:49.992125
NCT00086034|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-21|||2007-05-11|2004-06-22|2004-06-23|Estimate|||||||2007-05-11|2007-05-15|Estimate||||May 2007|2007-05-31||||||||Interventional|||Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma|Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|Completed||Phase 2|35||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 05:07:51.270874|2018-06-01 05:07:51.270874
NCT00003078|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-08|2004-06-22|2004-06-23|Estimate|||||||2013-07-08|2013-07-09|Estimate|October 1997||1997-10-31|April 2011|2011-04-30||||November 2005|Actual|2005-11-30||Interventional|||Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix|A Randomized Comparison of Radiation vs Radiation Plus Weekly Cisplatin vs Radiation Plus PVI (Protracted Venous Infusion) 5-FU in Patients With Stage II-B, III-B, and IV-A Carcinoma of the Cervix With Negative Paraaortic Nodes|Completed||Phase 3|870|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:07:51.62338|2018-06-01 05:07:51.62338
NCT00002844|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-06-22|2004-06-23|Estimate|||||||2012-07-27|2012-07-30|Estimate|March 1991||1991-03-31|July 2012|2012-07-31|June 2002|Actual|2002-06-30|July 2000|Actual|2000-07-31||Interventional|||Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia|Bone Marrow Transplantation for Chronic Lymphocytic Leukemia|Completed||Phase 2|49|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:07:52.112041|2018-06-01 05:07:52.112041
NCT00002816|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-21|2004-06-22|2004-06-23|Estimate|||||||2013-08-21|2013-08-22|Estimate|December 1996||1996-12-31|August 2013|2013-08-31|April 2006|Actual|2006-04-30|November 2002|Actual|2002-11-30||Interventional|||Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia|EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY|Completed||Phase 3|120|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:07:52.270553|2018-06-01 05:07:52.270553
NCT00002747|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-06-22|2004-06-23|Estimate|||||||2013-09-19|2013-09-20|Estimate|September 1992||1992-09-30|May 2007|2007-05-31||||||||Interventional|||Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer|RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY|Unknown status|Active, not recruiting|Phase 3|240|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:53.154088|2018-06-01 05:07:53.154088
NCT00002725|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-06-22|2004-06-23|Estimate|||||||2013-02-04|2013-02-05|Estimate|August 1996||1996-08-31|October 2000|2000-10-31||||April 2000|Actual|2000-04-30||Interventional|||Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|PHASE II EVALUATION OF BRYOSTATIN-1 (NSC 339555) IN NON-HODGKIN'S LYMPHOMA|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:07:54.412171|2018-06-01 05:07:54.412171
NCT00086021|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-21|||2007-06-08|2004-06-21|2004-06-22|Estimate|||||||2007-06-08|2007-06-11|Estimate|February 2002||2002-02-28|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Acupuncture for the Treatment of Chronic Daily Headaches|Acupuncture for the Treatment of Chronic Daily Headaches|Completed||N/A|74||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:07:55.018623|2018-06-01 05:07:55.018623
NCT00085969|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-18|||2015-02-19|2004-06-21|2004-06-22|Estimate|||||||2015-02-19|2015-02-23|Estimate|September 2003||2003-09-30|January 2015|2015-01-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|99|Actual|AstraZeneca||6|||f||||f||||||||||2018-06-01 05:07:55.123434|2018-06-01 05:07:55.123434
NCT00085956|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-18|||2007-03-07|2004-06-21|2004-06-22|Estimate|||||||2007-03-07|2007-03-09|Estimate|April 2004||2004-04-30|March 2007|2007-03-31|February 2007||2007-02-28|||||Interventional|||Effects of Arzoxifene on Bone Mass and the Uterus|Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women.|Completed||Phase 3|300||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:07:55.36987|2018-06-01 05:07:55.36987
NCT00006241|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2011-11-28|2004-06-21|2004-06-22|Estimate|||||||2011-11-28|2011-11-30|Estimate|March 2000||2000-03-31|November 2011|2011-11-30|October 2000|Actual|2000-10-31|||||Interventional|||Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma|A Pivotal Study to Determine the Safety and Efficacy of Using B-Cell High Density Microparticles (BCell-HDM) to Deplete B-Cells From Peripheral Blood Stem Cell Collections Without Compromising the Time to Neutrophil and Platelet Engraftment in Patients With Relapsed Low or Intermediate Grade B-Cell Non-Hodgkin's Lymphoma Given Autologous Peripheral Blood Stem Cell Transplants After High-Dose Chemotherapy|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:07:55.57712|2018-06-01 05:07:55.57712
NCT00006235|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-07-08|2004-06-21|2004-06-22|Estimate|||||||2013-07-08|2013-07-09|Estimate||||February 2006|2006-02-28||||February 2006|Actual|2006-02-28||Interventional|||Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I Trial of Combination Carboplatin and Lipsomal Doxorubicin (Doxil) In Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Completed||Phase 1|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:07:55.862707|2018-06-01 05:07:55.862707
NCT00006214|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2016-07-12|2004-06-21|2004-06-22|Estimate|||||||2016-07-12|2016-07-13|Estimate|August 2000||2000-08-31|July 2016|2016-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate|Short-Term Chemoprevention Trial in Men With Prostatic Intraepithelial Neoplasia Using Flutamide as an Androgen Deprivation Agent|Completed||Phase 2|63|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:07:55.953294|2018-06-01 05:07:55.953294
NCT00006117|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2009-10-29|2004-06-21|2004-06-22|Estimate|||||||2009-10-29|2009-10-30|Estimate|September 1999||1999-09-30|October 2009|2009-10-31||||||||Interventional|||Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase II Study of Gemcitabine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:56.088277|2018-06-01 05:07:56.088277
NCT00005069|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-06-18|2004-05-25|2004-05-26|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of Arsenic Trioxide (NSC #706363) in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:09:42.864703|2018-06-01 05:09:42.864703
NCT00006116|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2008-07-23|2004-06-21|2004-06-22|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 1999||1999-04-30|November 2000|2000-11-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:56.274492|2018-06-01 05:07:56.274492
NCT00006088|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-09-19|2004-06-21|2004-06-22|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 2000||2000-06-30|November 2000|2000-11-30||||||||Interventional|||Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors|A Phase I Absolute Bioavailability Study of Oral NAVELBINE (Vinorelbine Tartrate) in Patients With Solid Tumors|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:56.40097|2018-06-01 05:07:56.40097
NCT00002717|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2004-06-21|2004-06-22|Estimate|||||||2013-05-24|2013-05-27|Estimate|March 1996||1996-03-31|January 2010|2010-01-31||||October 2007|Actual|2007-10-31||Interventional|||Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer|A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma|Completed||Phase 3|324|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:07:56.474234|2018-06-01 05:07:56.474234
NCT00002657|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-22|2004-06-21|2004-06-22|Estimate|||||||2013-01-22|2013-01-24|Estimate|May 1995||1995-05-31|January 2013|2013-01-31|July 2011|Actual|2011-07-31|November 2003|Actual|2003-11-30||Interventional|||SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant|Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and Promace-Cytabom For Treatment of Post-Cardiac Transplant Lymphoproliferation.|Completed||Phase 2|20|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:07:56.781541|2018-06-01 05:07:56.781541
NCT00085995|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-18|||2018-04-03|2004-06-18|2004-06-21|Estimate|||||||2018-04-03|2018-04-04|Actual|June 17, 2004||2004-06-17|March 22, 2018|2018-03-22||||||||Observational|||Progression of Spinal Fusion in Ankylosing Spondylitis|Progression of Spinal Fusion in Ankylosing Spondylitis|Recruiting|||75|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:07:57.142486|2018-06-01 05:07:57.142486
NCT00085982|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-18|||2018-05-12|2004-06-18|2004-06-21|Estimate|||||||2018-05-12|2018-05-15|Actual|July 28, 2003||2003-07-28|March 20, 2018|2018-03-20|January 1, 2030|Anticipated|2030-01-01|January 1, 2030|Anticipated|2030-01-01||Interventional|||Effect of Leptin Therapy in the Treatment of Severe Insulin Resistance|Effect of Leptin Therapy in the Treatment of Severe Insulin Resistance|Recruiting||Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:07:57.267188|2018-06-01 05:07:57.267188
NCT00085943|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-17|||2011-05-12|2004-06-18|2004-06-21|Estimate|||||||2011-05-12|2011-05-16|Estimate|May 2004||2004-05-31|May 2011|2011-05-31||||||||Interventional|||KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks|See Detailed Description|Completed||Phase 3|866||GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:07:57.428748|2018-06-01 05:07:57.428748
NCT00085930|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-17|||2018-05-01|2004-06-18|2004-06-21|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2003||2003-04-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|January 2010|Actual|2010-01-31||Interventional|NESTLES||Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients|Administration of Peripheral Blood T-Cells and EBV Specific CTLs Transduced to Express GD-2 Specific Chimeric T Cell Receptors to Patients With Neuroblastoma|Active, not recruiting||Phase 1|19|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-06-01 05:07:57.755018|2018-06-01 05:07:57.755018
NCT00006035|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-09-16|2004-06-18|2004-06-21|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2000||2000-06-30|November 2000|2000-11-30||||||||Interventional|||Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma|An Open Label Lesion Controlled Study of Electroporation Therapy (EPT) for the Treatment of Cutaneous Metastatic Melanoma Using the Genetronics, Inc. Medpulser System and Bleomycin|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:57.879607|2018-06-01 05:07:57.879607
NCT00006033|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-29|2004-06-18|2004-06-21|Estimate|||||||2013-05-29|2013-05-30|Estimate|June 2000||2000-06-30|January 2001|2001-01-31|June 2004|Actual|2004-06-30|||||Interventional|||Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer|Protocol IL-2001: A Multi-Center, Open-Label, Randomized Study of the Efficacy and Safety of Multiple Intratumoral Injections of hIl-2 Plasmid (1.8 mg) Formulated With DOTMA/Cholesterol [Ratio 1:0.5(-/+)] Liposomes in Patients With Unresctable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:07:58.033729|2018-06-01 05:07:58.033729
NCT00005993|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-11-27|2004-06-18|2004-06-21|Estimate|||||||2017-11-27|2017-11-29|Actual|May 1999||1999-05-31|November 2017|2017-11-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer|Immunotherapy With Subcutaneous Il-2 and Stem Cell Factor (SCF) for Patients With Lymphoma or Breast Cancer After Autologous Transplantation|Terminated||Phase 1|||Masonic Cancer Center, University of Minnesota|||||f||||t||||||||||2018-06-01 05:07:58.246085|2018-06-01 05:07:58.246085
NCT00005968|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-28|2004-06-18|2004-06-21|Estimate|||||||2013-05-28|2013-05-30|Estimate|November 1999||1999-11-30|December 2002|2002-12-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Irofulven in Treating Patients With Stage IV Melanoma|A Multicenter Phase II Trial of MGI-114 in Patients With Stage IV Malignant Melanoma|Completed||Phase 2|||University of Colorado, Denver|||||f||||f||||||||||2018-06-01 05:07:58.40863|2018-06-01 05:07:58.40863
NCT00085904|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-16|||2008-10-09|2004-06-17|2004-06-18|Estimate|||||||2008-10-09|2008-10-13|Estimate|April 2004||2004-04-30|October 2008|2008-10-31||||||||Interventional|||Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas|A Phase I, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Five Daily Intravenous Infusions Repeated Every 28 Days in Adult Patients With Solid Tumors and Lymphomas|Completed||Phase 1|12|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 05:07:58.544614|2018-06-01 05:07:58.544614
NCT00085891|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-16|||2009-03-24|2004-06-17|2004-06-18|Estimate|||||||2009-03-24|2009-03-25|Estimate|June 2004||2004-06-30|March 2009|2009-03-31|September 2005|Actual|2005-09-30|||||Interventional|||Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia|A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia|Completed||Phase 3|535||AstraZeneca|||||||||||||||||||2018-06-01 05:07:58.627522|2018-06-01 05:07:58.627522
NCT00085878|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-16|||2008-10-15|2004-06-17|2004-06-18|Estimate|||||||2008-10-15|2008-10-16|Estimate|January 2003||2003-01-31|October 2008|2008-10-31||||||||Interventional|||Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors|A Phase I, Dose Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Daily Subcutaneous Injections in Adult Patients With Solid Tumors|Completed||Phase 1|25|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 05:07:58.784073|2018-06-01 05:07:58.784073
NCT00083421|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-24|||2012-06-12|2004-06-17|2004-06-18|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|July 2007|Actual|2007-07-31|||||Interventional|||Effects of ONO-2506PO in Patients With Alzheimer's Disease|Effects of ONO-2506PO in Patients With Alzheimer's Disease|Completed||Phase 2|647|Actual|Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 05:07:58.900871|2018-06-01 05:07:58.900871
NCT00005829|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-12-05|2004-06-17|2004-06-18|Estimate|||||||2016-12-05|2016-12-07|Estimate|February 2000||2000-02-29|December 2016|2016-12-31|April 2008|Actual|2008-04-30|October 2002|Actual|2002-10-31||Interventional|||Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia|Phase II Study of Gemcitabine for Relapsed B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|22|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:07:59.065856|2018-06-01 05:07:59.065856
NCT00005826|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-09-20|2004-06-17|2004-06-18|Estimate|||||||2012-09-20|2012-09-24|Estimate|March 2000||2000-03-31|September 2012|2012-09-30||||September 2000|Actual|2000-09-30||Interventional|||Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme|"Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a 5 Days On-2 Days Off Oral Treatment in Glioblastoma Multiforme"|Completed||Phase 2|17|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:07:59.140695|2018-06-01 05:07:59.140695
NCT00005616|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-18|2004-06-17|2004-06-18|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 1999||1999-09-30|June 2013|2013-06-30|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer|A Phase I Single Dose-Escalation Study of BIBH-1 in Patients With Colorectal Cancer Scheduled for Surgical Resection|Completed||Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:07:59.235542|2018-06-01 05:07:59.235542
NCT00005093|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-08-08|2004-06-17|2004-06-18|Estimate|||||||2012-08-08|2012-08-10|Estimate|December 1999||1999-12-31|August 2012|2012-08-31|May 2001|Actual|2001-05-31|||||Interventional|||Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer|A Randomized Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion as Second-Line Treatment of Patients With Advanced Nonsmall Cell Lung Cancer|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 05:08:00.363604|2018-06-01 05:08:00.363604
NCT00005073|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-04-30|2004-06-17|2004-06-18|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 1999||1999-09-30|April 2013|2013-04-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms|A Randomized Double-Blind Placebo Controlled Phase III Trial Evaluating Zoledronate Plus Standard Therapy Versus Placebo Plus Standard Therapy in Patients With Recurrent Carcinoma of the Prostate Who Are Asymptomatic With Castrate Levels of Testosterone and Have Rising PSA Levels Without Radiologically-Evident Metastatic Disease|Terminated||Phase 3|544|Actual|Novartis|||||f||||||||||||||2018-06-01 05:08:00.465217|2018-06-01 05:08:00.465217
NCT00005048|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-11-08|2004-06-17|2004-06-18|Estimate|||||||2012-11-08|2012-11-09|Estimate|April 1997||1997-04-30|November 2000|2000-11-30||||August 2000|Actual|2000-08-31||Interventional|||Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Safety and Efficacy of One Hour Weekly Taxol Infusion and Estramustine in Hormone Refractory Prostate Cancer|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:08:00.586962|2018-06-01 05:08:00.586962
NCT00005041|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-11-08|2004-06-17|2004-06-18|Estimate|||||||2012-11-08|2012-11-09|Estimate|September 1999||1999-09-30|November 2000|2000-11-30||||May 2000|Actual|2000-05-31||Interventional|||R115777 in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study to Determine the Antitumor Activity of Farnesyltransferase Inhibitor R115777 in Subjects With Relapsed Small Cell Lung Cancer|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:08:00.654587|2018-06-01 05:08:00.654587
NCT00004929|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-01-30|2004-06-17|2004-06-18|Estimate|||||||2013-01-30|2013-01-31|Estimate|September 1999||1999-09-30|January 2013|2013-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer|Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Examining the Immunogenicity of Glycosylated MUC-2-KLH Peptide Conjugate Vaccine|Completed||Phase 1|15|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:08:00.742661|2018-06-01 05:08:00.742661
NCT00004861|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-08-08|2004-06-17|2004-06-18|Estimate|||||||2012-08-08|2012-08-10|Estimate|October 1999||1999-10-31|August 2012|2012-08-31|September 2001|Actual|2001-09-30|||||Interventional|||Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion in the Treatment of Patients With Advanced Pancreatic Cancer|Completed||Phase 2|||Pfizer|||||f||||||||||||||2018-06-01 05:08:00.94645|2018-06-01 05:08:00.94645
NCT00004260|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2011-08-02|2004-06-17|2004-06-18|Estimate|||||||2011-08-02|2011-08-03|Estimate|October 1999||1999-10-31|August 2011|2011-08-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|Phase I Study of Interleukin-12 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma|Completed||Phase 1|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:08:01.147605|2018-06-01 05:08:01.147605
NCT00004217|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2015-03-05|2004-06-17|2004-06-18|Estimate|||||||2015-03-05|2015-03-06|Estimate|February 2000||2000-02-29|March 2015|2015-03-31|March 2006|Actual|2006-03-31|May 2001|Actual|2001-05-31||Interventional|||S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older|Completed||Phase 2|55|Anticipated|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:08:01.359938|2018-06-01 05:08:01.359938
NCT00085917|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-16|2010-04-12||2011-06-21|2004-06-16|2004-06-17|Estimate|2011-05-13|2011-06-15|Estimate||||2011-06-21|2011-06-27|Estimate|June 2004||2004-06-30|June 2011|2011-06-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|PIFNPK||Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients|A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Twice-Weekly Peginterferon Alpha 2a and Ribavirin Induction Therapy for Chronic Hepatitis C in Patients Who Are Coinfected With HIV-1|Completed||Phase 2|29|Actual|National Institutes of Health Clinical Center (CC)|Small number of enrolled participants|2|||f||||f||||||||||2018-06-01 05:08:01.645676|2018-06-01 05:08:01.645676
NCT00085852|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-15|||2008-02-27|2004-06-16|2004-06-17|Estimate|||||||2008-02-27|2008-03-06|Estimate|April 2005||2005-04-30|February 2008|2008-02-29|June 2007|Actual|2007-06-30|October 2006|Actual|2006-10-31||Interventional|||US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation|Phase 1 Study of the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System in Patients With Advanced Heterogeneous Emphysema|Completed||Phase 1|6|Actual|Aeris Therapeutics||1|||f||||t||||||||||2018-06-01 05:08:02.113316|2018-06-01 05:08:02.113316
NCT00085839|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-15|2011-03-28||2012-08-06|2004-06-16|2004-06-17|Estimate|2011-03-28|2011-04-22|Estimate||||2012-08-06|2012-08-09|Estimate|February 2004||2004-02-29|August 2012|2012-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2|A Randomized Phase II Study of Single Agent Erlotinib [Tarceva (TM), OSI-774] Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status|Completed||Phase 2|103|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-06-01 05:08:02.282755|2018-06-01 05:08:02.282755
NCT00085826|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-15|||2011-10-18|2004-06-16|2004-06-17|Estimate|||||||2011-10-18|2011-10-20|Estimate|April 2001||2001-04-30|October 2011|2011-10-31|December 2004|Actual|2004-12-31|||||Interventional|||A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients|A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) Versus Taxotere (Docetaxel) and Placebo in Non-Small Cell Lung Cancer (NSCLC) Patients After Failure of Prior Platinum-Based Chemotherapy|Completed||Phase 3|600||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:08:03.099495|2018-06-01 05:08:03.099495
NCT00085813|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|||2010-10-01|2004-06-16|2004-06-17|Estimate|||||||2010-10-01|2010-10-04|Estimate|December 2003||2003-12-31|October 2010|2010-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer|A Phase II, Open-Label Study of Ispinesib in Subjects With Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|70||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:08:03.383545|2018-06-01 05:08:03.383545
NCT00085800|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|||2018-05-14|2004-06-16|2004-06-17|Estimate|||||||2018-05-14|2018-05-15|Actual|May 2004||2004-05-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Dietary Fiber and Cardiovascular Inflammatory Markers||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:08:03.541978|2018-06-01 05:08:03.541978
NCT00085787|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|||2012-09-28|2004-06-16|2004-06-17|Estimate|||||||2012-09-28|2012-10-01|Estimate|June 2004||2004-06-30|September 2012|2012-09-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study of ARRY-142886 in Patients With Advanced Cancer||Completed||Phase 1|57|Actual|Array BioPharma||1|||f||||||||||||||2018-06-01 05:08:03.600133|2018-06-01 05:08:03.600133
NCT00085774|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|||2015-03-19|2004-06-16|2004-06-17|Estimate|||||||2015-03-19|2015-03-20|Estimate|June 2004||2004-06-30|March 2015|2015-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma|A Single-Dose Efficacy Comparison of Albuterol Hydrofluoroalkane (HFA) Breath-operated Inhaler (BOI) (Volare Easi-Breathe™) and Albuterol HFA Meter Dose Inhaler (MDI) (Volare™) in Adolescents and Adults With Exercise-Induced Bronchospasm|Completed||Phase 3|24|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-06-01 05:08:03.691068|2018-06-01 05:08:03.691068
NCT00085761|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|||2008-03-04|2004-06-16|2004-06-17|Estimate|||||||2008-03-04|2008-03-06|Estimate||||March 2008|2008-03-31||||||||Interventional|||Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy|An International, Multicenter, Randomized, Double-Blind, 12-Week Controlled Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy|Terminated||Phase 3|||NeurogesX||||Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes|||||||||||||||2018-06-01 05:08:03.85576|2018-06-01 05:08:03.85576
NCT00004251|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2012-09-20|2004-06-16|2004-06-17|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2000||2000-01-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|September 2002|Actual|2002-09-30||Interventional|||Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer|A Phase II Study of Letrozole in Patients With Advanced or Recurrent Endometrial Cancer|Completed||Phase 2|33|Actual|Canadian Cancer Trials Group||1|||f||||||||||||||2018-06-01 05:08:03.971612|2018-06-01 05:08:03.971612
NCT00004076|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-12-18|2004-06-16|2004-06-17|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 1999||1999-06-30|November 2000|2000-11-30||||||||Interventional|||PNU 166148 in Treating Patients With Metastatic Solid Tumors|A Phase I Study to Evaluate MAG-CPT (PNU 166148) Given as One Single Intravenous Administration Every 4 Weeks in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:04.089179|2018-06-01 05:08:04.089179
NCT00004043|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2017-04-26|2004-06-16|2004-06-17|Estimate|||||||2017-04-26|2017-04-28|Actual|February 1999||1999-02-28|April 2017|2017-04-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer|Phase II Study of Pulse Calcitriol in Patients With Rising PSA After Definitive Treatment for Prostate Cancer|Completed||Phase 2|25|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 05:08:04.182858|2018-06-01 05:08:04.182858
NCT00003996|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-05|2004-06-16|2004-06-17|Estimate|||||||2016-12-05|2016-12-07|Estimate|May 1999||1999-05-31|December 2016|2016-12-31|May 2008|Actual|2008-05-31|August 2001|Actual|2001-08-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Trial of Pre-irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 4 Astrocytoma (Glioblastoma)|Completed||Phase 2|93|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:08:04.292062|2018-06-01 05:08:04.292062
NCT00003920|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2004-06-16|2004-06-17|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 1996||1996-04-30|November 2000|2000-11-30||||||||Interventional|||Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer|Pharmacokinetic/Dosimetry/MTNTD Study of 111In/90Y-2IT-BAD-m170 for Therapy in Metastatic Breast Cancer Patients With Post Therapy Support of Autologous Pretherapy Apheresed Peripheral Blood Stem Cells and Cyclosporin A Given for Suppression of HAMA Response|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:04.432876|2018-06-01 05:08:04.432876
NCT00003898|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-02-25|2004-06-16|2004-06-17|Estimate|||||||2011-02-25|2011-03-01|Estimate|January 1999||1999-01-31|February 2011|2011-02-28|January 2004|Actual|2004-01-31|June 2003|Actual|2003-06-30||Interventional|||Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation|The Use of Supplemental Oral Glutamine (GLN) to Decrease Morbidity in Patients Undergoing Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Study|Completed||Phase 2|120|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:08:04.519547|2018-06-01 05:08:04.519547
NCT00003894|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-03|2004-06-16|2004-06-17|Estimate|||||||2011-03-03|2011-03-07|Estimate|March 1999||1999-03-31|March 2011|2011-03-31|June 2002|Actual|2002-06-30|January 2000|Actual|2000-01-31||Interventional|||Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant|Thalidomide vs. Placebo for Steroid Dependent or Refractory Chronic Graft vs. Host Disease (cGVHD) IND #42782|Completed||Phase 2|36|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:08:04.701469|2018-06-01 05:08:04.701469
NCT00003891|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-11-07|2004-06-16|2004-06-17|Estimate|||||||2010-11-07|2010-11-09|Estimate|February 1999||1999-02-28|March 2010|2010-03-31|September 2009|Actual|2009-09-30|||||Interventional|||Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors|A Phase I Study of NX211 Given as an IV Infusion Days 1, 2 and 3 Every 3 Weeks in Patients With Solid Tumors|Completed||Phase 1|25|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:08:04.826355|2018-06-01 05:08:04.826355
NCT00085865|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-15|||2008-03-03|2004-06-15|2004-06-16|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2004||2004-06-30|July 2006|2006-07-31|July 2006||2006-07-31|||||Observational|||Serotonin Transporters in Alcoholism|PET Evaluation of Serotonin Transporters Using [C-11] DASB in Alcoholism|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:08:05.0086|2018-06-01 05:08:05.0086
NCT00085748|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|||2011-06-06|2004-06-15|2004-06-16|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2004||2004-08-31|November 2010|2010-11-30|May 2005|Actual|2005-05-31|||||Interventional|||Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia|A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia|Completed||Phase 3|114|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:08:05.20648|2018-06-01 05:08:05.20648
NCT00085735|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|2017-02-22||2017-05-16|2004-06-15|2004-06-16|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|April 2004||2004-04-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Only eligible patients are included in each of the 6 groups for baseline characteristics.|Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma|A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial|Completed||Phase 3|549|Actual|Children's Oncology Group||6|||f||||||||||||||2018-06-01 05:08:05.542076|2018-06-01 05:08:05.542076
NCT00085722|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|||2015-10-09|2004-06-15|2004-06-16|Estimate|||||||2015-10-09|2015-10-12|Estimate|July 2004||2004-07-31|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|November 2008|Actual|2008-11-30||Interventional|||Joint Injections for Osteoarthritic Knee Pain|The Efficacy of Prolotherapy in Osteoarthritic Knee Pain|Unknown status|Active, not recruiting|Phase 1/Phase 2|111|Anticipated|University of Wisconsin, Madison||3|||f||||t||||||||||2018-06-01 05:08:10.399853|2018-06-01 05:08:10.399853
NCT00085709|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-14|2012-06-05||2015-09-25|2004-06-15|2004-06-16|Estimate|2012-07-23|2012-08-27|Estimate||||2015-09-25|2015-09-30|Estimate|July 2004||2004-07-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|March 2010|Actual|2010-03-31||Interventional|||S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML|A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)|Completed||Phase 3|637|Actual|Southwest Oncology Group||4|||f||||t||||||||||2018-06-01 05:08:10.765515|2018-06-01 05:08:10.765515
NCT00085644|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2009-11-30||2011-04-18|2004-06-15|2004-06-16|Estimate|2010-02-12|2010-03-11|Estimate||||2011-04-18|2011-04-21|Estimate|January 2004||2004-01-31|April 2011|2011-04-30|July 2009|Actual|2009-07-31|December 2004|Actual|2004-12-31||Interventional|ATLAS||Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis|A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis|Completed||Phase 3|315|Actual|Abbott|Interim results are shown for subjects after 12 weeks for efficacy parameters and 24 weeks for safety parameters. Subjects who discontinued the study before Week 12 and subjects with missing values were classified as nonresponders for efficacy.|2|||f||||f||||||||||2018-06-01 05:08:13.539858|2018-06-01 05:08:13.539858
NCT00003871|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-06-15|2004-06-16|Estimate|||||||2010-01-26|2010-01-27|Estimate|August 1999||1999-08-31|January 2010|2010-01-31||||June 2002|Actual|2002-06-30||Interventional|||PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer|Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer|Completed||Phase 2|60|Anticipated|Eastern Cooperative Oncology Group|||||||||f||||||||||2018-06-01 05:08:15.224941|2018-06-01 05:08:15.224941
NCT00003860|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-06-15|2004-06-16|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 1998||1998-09-30|December 1999|1999-12-31||||||||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer|Intensive Chemotherapy With Peripheral Blood Stem Cell Support for Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:15.423721|2018-06-01 05:08:15.423721
NCT00003847|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-04|2004-06-15|2004-06-16|Estimate|||||||2013-09-04|2013-09-05|Estimate|December 1998||1998-12-31|September 2013|2013-09-30||||February 2001|Actual|2001-02-28||Interventional|||VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer|A Phase II Study of the Safety, Efficacy and Pharmacokinetics of VX-710 in Combination With Doxorubicin and Vincristine in Patients With Small Cell Lung Cancer (SCLC)|Terminated||Phase 2|36|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||||||||||||2018-06-01 05:08:15.635329|2018-06-01 05:08:15.635329
NCT00003829|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-05|2004-06-15|2004-06-16|Estimate|||||||2016-12-05|2016-12-07|Estimate|August 1999||1999-08-31|December 2016|2016-12-31|October 2008|Actual|2008-10-31|May 2001|Actual|2001-05-31||Interventional|||Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia|A Phase II Study of Alternating Cycles of Fludarabine and Cyclophosphamide in Previously Untreated Patients With B-cell CLL|Completed||Phase 2|34|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:08:15.867433|2018-06-01 05:08:15.867433
NCT00003720|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-22|2004-06-15|2004-06-16|Estimate|||||||2012-08-22|2012-08-23|Estimate|July 1998||1998-07-31|August 2012|2012-08-31||||||||Interventional|||SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma|A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma|Completed||Phase 1|||Pfizer|||||f||||||||||||||2018-06-01 05:08:16.081266|2018-06-01 05:08:16.081266
NCT00003624|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-10|2004-06-15|2004-06-16|Estimate|||||||2013-04-10|2013-04-11|Estimate|December 1998||1998-12-31|May 2006|2006-05-31||||January 2004|Actual|2004-01-31||Interventional|||Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer|A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:08:16.200936|2018-06-01 05:08:16.200936
NCT00003592|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-01-28|2004-06-15|2004-06-16|Estimate|||||||2009-01-28|2009-01-29|Estimate|September 1998||1998-09-30|January 2009|2009-01-31||||August 2000|Actual|2000-08-31||Interventional|||Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer|Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|230|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:16.353607|2018-06-01 05:08:16.353607
NCT00003574|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-06-15|2004-06-16|Estimate|||||||2013-06-20|2013-06-21|Estimate|April 1999||1999-04-30|November 2000|2000-11-30|June 2004|Actual|2004-06-30|||||Interventional|||Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors|A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima GliaSite RTS, a Radiation Delivery System, in Patients With Recurrent Malignant Brain Tumors Undergoing Surgical Resection|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:16.453587|2018-06-01 05:08:16.453587
NCT00003381|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-06-15|2004-06-16|Estimate|||||||2016-07-01|2016-07-06|Estimate|July 1998||1998-07-31|July 2016|2016-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Observational|||Quality of Life Assessment of Patients Receiving Treatment for Esophageal Cancer [Companion to CALGB-9781]|Quality of Life and Cost Analysis of a Prospective Randomized Phase III Trial Comparing Trimodality Therapy to Surgery Alone for Esophageal Cancer [Companion to CALGB-9781]|Terminated|||56|Actual|Alliance for Clinical Trials in Oncology||||companion study to CALGB-9781 which closed administratively due to poor accrual|f||||f||||||||||2018-06-01 05:08:16.598547|2018-06-01 05:08:16.598547
NCT00003254|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-06|2004-06-15|2004-06-16|Estimate|||||||2012-03-06|2012-03-08|Estimate|April 1998||1998-04-30|March 2012|2012-03-31|October 2003|Actual|2003-10-31|November 2002|Actual|2002-11-30||Interventional|||SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil|A Phase II Trial of 5-Fluorouracil Plus 776C85 in Patients With Advanced Resistant Colorectal Cancer|Completed||Phase 2|75|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:08:16.780694|2018-06-01 05:08:16.780694
NCT00003242|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-06-15|2004-06-16|Estimate|||||||2013-06-20|2013-06-24|Estimate|February 1998||1998-02-28|June 2013|2013-06-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors|An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Bryostatin-1 Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:08:17.035213|2018-06-01 05:08:17.035213
NCT00003206|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-06-15|2004-06-16|Estimate|||||||2013-08-22|2013-08-23|Estimate|April 1998||1998-04-30|August 2013|2013-08-31||||July 2001|Actual|2001-07-31||Interventional|||Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer|A Phase II Trial of Carboplatin Plus Paclitaxel in the Treatment of Locally Recurrent or Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:08:17.180581|2018-06-01 05:08:17.180581
NCT00003143|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-03|2004-06-15|2004-06-16|Estimate|||||||2012-10-03|2012-10-04|Estimate|November 1997||1997-11-30|October 2012|2012-10-31||||December 2000|Actual|2000-12-31||Interventional|||Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation|A Randomized Study of Ethyol (Amifostine) With Platinum Based Salvage Chemotherapy in Patients With Lymphoma Undergoing Autologous Stem Cell Transplantation|Completed||Phase 2|20|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-06-01 05:08:18.108593|2018-06-01 05:08:18.108593
NCT00003099|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-06-15|2004-06-16|Estimate|||||||2012-07-27|2012-07-30|Estimate|May 1996||1996-05-31|July 2012|2012-07-31|January 2003|Actual|2003-01-31|June 2000|Actual|2000-06-30||Interventional|||Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer|Phase II Clinical Trial of N-(4-hydroxyphenyl) Retinamide (4-HPR) and Tamoxifen in Breast Neoplasia, Administration During the Period Between the Diagnostic Core Biopsy and Definitive Surgery|Completed||Phase 2|52|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:08:18.278606|2018-06-01 05:08:18.278606
NCT00003085|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-06-15|2004-06-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|September 1996||1996-09-30|May 2014|2014-05-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer|Minimal Access Surgery for Pancreas Cancer: A Phase II Trial Study I: Staging of Pancreas Cancer|Terminated||Phase 2|28|Actual|University of Southern California||||Insufficient Accrual|f||||t||||||||||2018-06-01 05:08:18.464158|2018-06-01 05:08:18.464158
NCT00003028|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-06-15|2004-06-16|Estimate|||||||2012-06-29|2012-07-02|Estimate|April 1997||1997-04-30|June 2012|2012-06-30||||||||Interventional|||MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors|Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every 3 Weeks|Completed||Phase 1|5|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:08:18.537432|2018-06-01 05:08:18.537432
NCT00003009|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-06-15|2004-06-16|Estimate|||||||2014-05-20|2014-05-22|Estimate|February 1996||1996-02-29|May 2014|2014-05-31|August 2000|Actual|2000-08-31|August 2000|Actual|2000-08-31||Interventional|||Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer|A Phase I Study of Inhalation of Interleukin-2 (IL-2) in Patients With Metastatic or Unresectable Cancer|Terminated||Phase 1|16|Actual|University of Southern California||||Insufficient Accrual|f||||t||||||||||2018-06-01 05:08:18.764597|2018-06-01 05:08:18.764597
NCT00002973|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-09-30|2004-06-15|2004-06-16|Estimate|||||||2015-09-30|2015-10-02|Estimate|December 1995||1995-12-31|September 2015|2015-09-30|December 2000|Actual|2000-12-31|May 2000|Actual|2000-05-31||Interventional|||Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma|Phase II Evaluation of IV Melphalan (L-PAM) and Whole Body Hyperthermia (WBH) for Malignant Melanoma|Completed||Phase 2|34|Anticipated|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:08:18.940758|2018-06-01 05:08:18.940758
NCT00002949|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-04|2004-06-15|2004-06-16|Estimate|||||||2013-09-04|2013-09-05|Estimate|July 1996||1996-07-31|September 2013|2013-09-30|May 2001|Actual|2001-05-31|November 2000|Actual|2000-11-30||Interventional|||Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis|Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies|Completed||Phase 1|33|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:08:19.063546|2018-06-01 05:08:19.063546
NCT00002915|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-08-05|2004-06-15|2004-06-16|Estimate|||||||2010-08-05|2010-08-09|Estimate|December 1996||1996-12-31|August 2010|2010-08-31||||||||Interventional|||Penclomedine in Treating Patients With Advanced Solid Tumors|A PHASE I AND PHARMACOLOGICAL STUDY OF PENCLOMEDINE (NSC#338720, IND#43409) ADMINISTERED DAILY BY MOUTH FOR FIVE CONSECUTIVE DAYS IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:08:19.31412|2018-06-01 05:08:19.31412
NCT00002864|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-06-15|2004-06-16|Estimate|||||||2012-09-20|2012-09-24|Estimate|August 1996||1996-08-31|September 2011|2011-09-30|April 2010|Actual|2010-04-30|October 2007|Actual|2007-10-31||Interventional|||Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer|A RANDOMIZED TRIAL OF ANTIESTROGEN THERAPY VERSUS COMBINED ANTIESTROGEN AND OCTREOTIDE LAR THERAPY IN THE ADJUVANT TREATMENT OF BREAST CANCER IN POST-MENOPAUSAL WOMEN|Completed||Phase 3|667|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:08:19.436392|2018-06-01 05:08:19.436392
NCT00002838|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-06-15|2004-06-16|Estimate|||||||2012-07-27|2012-07-31|Estimate|December 1995||1995-12-31|July 2012|2012-07-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia|Phase I/II Pilot Study of Allogeneic Peripheral Blood Stem Cell Infusion For Patients With High Risk Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|13|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:08:19.775442|2018-06-01 05:08:19.775442
NCT00002785|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2004-06-15|2004-06-16|Estimate|||||||2014-07-23|2014-07-24|Estimate|July 1996||1996-07-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|August 2000|Actual|2000-08-31||Interventional|||Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia|Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age.|Completed||Phase 2|||Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:08:20.149152|2018-06-01 05:08:20.149152
NCT00002740|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2004-06-15|2004-06-16|Estimate|||||||2014-07-23|2014-07-24|Estimate|May 1996||1996-05-31|July 2014|2014-07-31|September 2005|Actual|2005-09-30|March 2004|Actual|2004-03-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma|Phase I Pilot Study of Multiple Cycles of High Dose Chemotherapy With Peripheral Blood Stem Cell Infusions In Advanced Stage Neuroblastoma|Completed||Phase 1|30|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:08:20.496769|2018-06-01 05:08:20.496769
NCT00085696|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-11|||2008-02-07|2004-06-14|2004-06-15|Estimate|||||||2008-02-07|2008-02-11|Estimate|May 2004||2004-05-31|February 2008|2008-02-29||||April 2006|Actual|2006-04-30||Interventional|||VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma|A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma|Completed||Phase 2|66||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:08:20.709324|2018-06-01 05:08:20.709324
NCT00085683|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2008-03-03|2004-06-10|2004-06-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2004||2004-06-30|July 2005|2005-07-31|July 2005||2005-07-31|||||Observational|||Herpes Virus-6 and Epilepsy|Human Herpesvirus-6 and Its Effect on the GABA/Glutamate Balance in the Cerebrospinal Fluid and in the Brain From Patients With Epilepsy|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:08:20.818153|2018-06-01 05:08:20.818153
NCT00085670|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2018-03-27|2004-06-10|2004-06-11|Estimate|||||||2018-03-27|2018-03-29|Actual|June 10, 2004||2004-06-10|September 29, 2017|2017-09-29||||||||Observational|||Cytokine Gene Polymorphisms in Bone Marrow Failure|Cytokine Gene Polymorphisms in Bone Marrow Failure|Completed|||79|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:08:20.890188|2018-06-01 05:08:20.890188
NCT00085657|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2017-06-30|2004-06-10|2004-06-11|Estimate|||||||2017-06-30|2017-07-02|Actual|June 9, 2004||2004-06-09|May 21, 2009|2009-05-21|May 21, 2009||2009-05-21|||||Observational|||Brain Electrical Stimulation to Enhance Recovery After Stroke|Enhancement of Rehabilitative Treatment-Dependent Functional Recovery After Stroke by Transcranial Direct Current Stimulation (tDCS)|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:08:21.12609|2018-06-01 05:08:21.12609
NCT00085631|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2013-04-10||2013-07-10|2004-06-10|2004-06-11|Estimate|2013-07-10|2013-09-17|Estimate||||2013-07-10|2013-09-17|Estimate|March 2003||2003-03-31|July 2013|2013-07-31|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer|An International Multi Center Phase III Study of Chemoradiotherapy Versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer|Terminated||Phase 3|101|Actual|Duke University|There are integrity issues with the currently available data, involving international institutions, in that several pieces of information relating to patient accrual and outcomes cannot be verified.|2||Study was closed because of slow accrual|f||||f||||||||||2018-06-01 05:08:21.344758|2018-06-01 05:08:21.344758
NCT00085579|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-12-11|2004-06-10|2004-06-11|Estimate|||||||2012-12-11|2012-12-12|Estimate|March 2004||2004-03-31|December 2012|2012-12-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase II Study of Maintenance Biotherapy With Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor in Patients With Metastatic Melanoma With a Partial Response or Stable Disease After Systemic Therapy|Withdrawn||Phase 2|0|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:08:21.912796|2018-06-01 05:08:21.912796
NCT00085566|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2015-12-15||2015-12-15|2004-06-10|2004-06-11|Estimate|2015-12-15|2016-01-20|Estimate||||2015-12-15|2016-01-20|Estimate|March 2004||2004-03-31|December 2015|2015-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer|A Phase I/II Trial to Assess the Tolerability of RAD 001 With Gefitinib in Patients With Glioblastoma Multiforme and Prostate Cancer and Efficacy in Patients With Castrate Metastatic Prostate Cancer|Completed||Phase 1/Phase 2|61|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:08:22.06052|2018-06-01 05:08:22.06052
NCT00085553|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2018-05-17|2004-06-10|2004-06-11|Estimate|||||||2018-05-17|2018-05-18|Actual|May 20, 2004|Actual|2004-05-20|May 2018|2018-05-31|May 16, 2018|Actual|2018-05-16|May 7, 2008|Actual|2008-05-07||Interventional|||Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors|Phase I Trial of R115777 and OSI-774 in Patients With Advanced Solid Tumors|Completed||Phase 1|29|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:22.879783|2018-06-01 05:08:22.879783
NCT00003614|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-08-22|2004-05-21|2004-05-24|Estimate|||||||2013-08-22|2013-08-23|Estimate|December 1998||1998-12-31|August 2013|2013-08-31||||April 2005|Actual|2005-04-30||Interventional|||Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|Phase II Study of Weekly Paclitaxel by 1-HR Infusion Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:09:56.033629|2018-06-01 05:09:56.033629
NCT00085540|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2016-09-23||2016-11-15|2004-06-10|2004-06-11|Estimate|2016-09-23|2016-11-15|Estimate||||2016-11-15|2017-01-02|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|March 2009|Actual|2009-03-31|December 2008|Actual|2008-12-31||Interventional||two patients were removed from the analysis due to one withdrawing consent and one was deemed ineligible.|FR901228 in Treating Patients With Recurrent High-Grade Gliomas|A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas|Completed||Phase 1/Phase 2|50|Actual|National Cancer Institute (NCI)|Dose escalation was terminated after 2 dose levels because PK parameters of romidepsin in pts receiving EIAEDs were similar to those reported in Adults not receiving CYP34A inducing drugs, we wanted to avoid the expected dose limiting toxicity.|2|||f||||t||||||||No||2018-06-01 05:08:23.020349|2018-06-01 05:08:23.020349
NCT00085527|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-09-04|2004-06-10|2004-06-11|Estimate|||||||2013-09-04|2013-09-05|Estimate|May 2005||2005-05-31|September 2013|2013-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer|A Phase II Study Of Depsipeptide In Patients With Relapsed Or Refractory Ovarian Carcinoma|Withdrawn||Phase 2|0|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:08:23.383467|2018-06-01 05:08:23.383467
NCT00085501|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-10-30|2004-06-10|2004-06-11|Estimate|||||||2012-10-30|2012-11-01|Estimate|July 2004||2004-07-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|August 2007|Actual|2007-08-31||Interventional|||S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Selection Design Trial Of Concurrent Chemotherapy + Cetuximab Vs. Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|242|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:08:23.50519|2018-06-01 05:08:23.50519
NCT00085488|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2015-01-30|2004-06-10|2004-06-11|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2004||2004-02-29|October 2005|2005-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|En Vivo Matured Dendritic Cell Therapy in Patients With Melanoma|Completed||Phase 1|||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:08:24.857216|2018-06-01 05:08:24.857216
NCT00085475|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-09-20|2004-06-10|2004-06-11|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 2004||2004-04-30|September 2012|2012-09-30||||April 2007|Actual|2007-04-30||Interventional|||Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma|Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)|Completed||Phase 2|17|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:08:24.932509|2018-06-01 05:08:24.932509
NCT00085462|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-06-21|2004-06-10|2004-06-11|Estimate|||||||2012-06-21|2012-06-22|Estimate|May 2004||2004-05-31|June 2012|2012-06-30|September 2008|Actual|2008-09-30|May 2007|Actual|2007-05-31||Interventional|||Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma by Lymphodepleting Conditioning Followed by Infusion of TCR-Gene Engineered Lymphocytes and Subsequent Fowlpox gp100 Vaccination|Completed||Phase 1|61|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:08:25.119733|2018-06-01 05:08:25.119733
NCT00085449|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2016-07-01|2004-06-10|2004-06-11|Estimate|||||||2016-07-01|2016-07-06|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer|A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells|Completed||Phase 1/Phase 2|56|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:08:25.252625|2018-06-01 05:08:25.252625
NCT00085436|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2013-04-24||2013-04-24|2004-06-10|2004-06-11|Estimate|2013-04-24|2013-06-10|Estimate||||2013-04-24|2013-06-10|Estimate|December 2003||2003-12-31|October 2011|2011-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC|A Phase II Study Of Autologous Tumor/DC Vaccine (DC Vaccine) Combined With Interleukin-2 (IL-2) And Interferon-α-2a (IFNα-2a) In Patients With Metastatic Renal Cell Carcinoma (RCC)|Completed||Phase 2|18|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||||2018-06-01 05:08:25.42476|2018-06-01 05:08:25.42476
NCT00085423|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2012-01-26||2013-04-09|2004-06-10|2004-06-11|Estimate|2013-04-09|2013-04-10|Estimate||||2013-04-09|2013-04-10|Estimate|February 2004||2004-02-29|April 2013|2013-04-30|February 2010|Actual|2010-02-28|December 2008|Actual|2008-12-31||Interventional|||Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma|"High Dose Interleukin-2 (IL-2) Therapy In Lymphodepleted Primed Patients With Metastatic Melanoma"|Completed||Phase 2|20|Actual|Dartmouth-Hitchcock Medical Center|This was the first stage of a two-stage phase II study and continuation to next stage required 4 of 18 particpant having an objective response. Only 3 objective responses were noted and the study was terminated at stage 1.|1|||f||||t||||||||||2018-06-01 05:08:25.632268|2018-06-01 05:08:25.632268
NCT00085410|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2013-07-09||2017-06-13|2004-06-10|2004-06-11|Estimate|2017-05-15|2017-06-14|Actual||||2017-06-13|2017-07-02|Actual|January 2004||2004-01-31|June 2017|2017-06-30|April 2010|Actual|2010-04-30|August 2008|Actual|2008-08-31||Interventional|||Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder|Phase II and Pharmacodynamic Study of PS-341 in Patients With Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder|Terminated||Phase 2|20|Actual|National Cancer Institute (NCI)|The trial was discontinued early due to no confirmed partial responses.|1||The trial was discontinued early due to no confirmed partial responses.|f||||||||||||||2018-06-01 05:08:25.857017|2018-06-01 05:08:25.857017
NCT00085397|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2009-02-06|2004-06-10|2004-06-11|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 2004||2004-03-31|April 2008|2008-04-30||||||||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Randomized Phase II Study of Immunization Against Melanoma Comparing Autologous Dendritic Cells Pulsed With gp100 Peptide to Autologous Dendritic Cells Fused With Autologous Tumor Cells|Unknown status|Recruiting|Phase 2|40|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:08:26.409259|2018-06-01 05:08:26.409259
NCT00085384|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-08-01|2004-06-10|2004-06-11|Estimate|||||||2012-08-01|2012-08-02|Estimate|July 2002||2002-07-31|August 2012|2012-08-31|April 2007|Actual|2007-04-30|November 2005|Actual|2005-11-30||Interventional|||PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer|A Phase I/II Study to Evaluate the Optimum Dose of Pegylated-Interferon (PEG INTRON) in Patients With Platinum Resistant Ovarian, Peritoneal or Fallopian Tube Cancer|Terminated||Phase 1/Phase 2|30|Actual|M.D. Anderson Cancer Center||3||Terminated due to slow accrual.|f||||f||||||||||2018-06-01 05:08:26.619096|2018-06-01 05:08:26.619096
NCT00085371|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-10-07|2004-06-10|2004-06-11|Estimate|||||||2013-10-07|2013-10-08|Estimate|July 2004||2004-07-31|October 2013|2013-10-31||||July 2006|Actual|2006-07-31||Interventional|||Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas|A Phase II Study Of Triapine For Advanced Adenocarcinoma Of The Pancreas|Completed||Phase 2|116|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:26.775371|2018-06-01 05:08:26.775371
NCT00085358|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-03-18|2004-06-10|2004-06-11|Estimate|||||||2013-03-18|2013-03-19|Estimate|May 2004||2004-05-31|March 2013|2013-03-31||||May 2011|Actual|2011-05-31||Interventional|||Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)|A Phase I Trial of Intravenous Paclitaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Paclitaxel, Intraperitoneal Carboplatin, Intraperitoneal Paclitaxel and CTEP-Supplied Agent Bevacizumab (NSC 704865, IND 7921) in Patients With Previously Untreated Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:26.985489|2018-06-01 05:08:26.985489
NCT00085345|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-07-09|2004-06-10|2004-06-11|Estimate|||||||2013-07-09|2013-07-10|Estimate||||July 2006|2006-07-31||||||||Interventional|||Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Study of Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients With Relapsed or Refractory Multiple Myeloma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:27.190924|2018-06-01 05:08:27.190924
NCT00085332|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-01-10|2004-06-10|2004-06-11|Estimate|||||||2014-01-10|2014-01-13|Estimate|July 2004||2004-07-31|January 2014|2014-01-31||||December 2005|Actual|2005-12-31||Interventional|||Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)|A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 05:08:27.330522|2018-06-01 05:08:27.330522
NCT00085306|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2015-10-01|2004-06-10|2004-06-11|Estimate|||||||2015-10-01|2015-10-02|Estimate|April 2004||2004-04-30|October 2015|2015-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma|Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma|Completed||Phase 2|21|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:08:27.557002|2018-06-01 05:08:27.557002
NCT00085293|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2014-08-20||2014-08-20|2004-06-10|2004-06-11|Estimate|2014-08-20|2014-09-01|Estimate||||2014-08-20|2014-09-01|Estimate|May 2004||2004-05-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional||Participants who received at least one dose of therapy.|Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131|Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 05:08:27.669848|2018-06-01 05:08:27.669848
NCT00085280|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-03-28|2004-06-10|2004-06-11|Estimate|||||||2014-03-28|2014-03-31|Estimate|September 2004||2004-09-30|January 2013|2013-01-31||||October 2006|Actual|2006-10-31||Interventional|||Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Pilot Study to Determine if Downstream Markers of EGFR Linked Signaling Pathways Predict Response to OSI-774 (Erlotinib) in the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer|Completed||N/A|129|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:27.992396|2018-06-01 05:08:27.992396
NCT00085254|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2015-05-05||2016-01-28|2004-06-10|2004-06-11|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|April 2005||2005-04-30|October 2015|2015-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||pt had undergone previous surgery and had histological diagnosis of glioblastoma. All pt 18 years or older and KPS greater or equal to 60%|Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 1/Phase 2|112|Actual|National Cancer Institute (NCI)|Study is safety run-in / phase 2 study. Pre-defined doses in safety run-in, 500, 1000 & 2000mg. Safety run-in is under an assumption of low probability of DLT with these dosages. NO actual MTD was defined in the safety run in, all doses were safe.|3|||f||||t||||||||||2018-06-01 05:08:28.213269|2018-06-01 05:08:28.213269
NCT00085228|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-09-20|2004-06-10|2004-06-11|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 2004||2004-04-30|September 2012|2012-09-30||||January 2006|Actual|2006-01-31||Interventional|||Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate|Randomized Phase II Trial of Docetaxel (Taxotere) and Oblimersen (Antisense Oligonucleotide Directed to BCL-2) Versus Taxotere Alone in Patients With Hormone-Refractory Prostate Cancer|Completed||Phase 2|116|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:08:29.317291|2018-06-01 05:08:29.317291
NCT00085202|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2013-11-04||2017-12-21|2004-06-10|2004-06-11|Estimate|2014-01-09|2014-02-27|Estimate||||2017-12-21|2018-01-23|Actual|August 2003||2003-08-31|December 2017|2017-12-31|January 2023|Anticipated|2023-01-31|December 2016|Actual|2016-12-31||Interventional||Participants had a diagnosis of medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), PNET variants (ependymoblastoma, pineoblastoma, CNS neuroblastoma), or atypical teratoid rhabdoid tumor (ATRT).|Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor|Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor|Active, not recruiting||Phase 3|416|Actual|St. Jude Children's Research Hospital|The study is ongoing. Participant flow and adverse events will be updated as additional outcomes are reported.|2|||f||||f|t|f||||||||2018-06-01 05:08:29.518445|2018-06-01 05:08:29.518445
NCT00085189|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-05-20|2004-06-10|2004-06-11|Estimate|||||||2014-05-20|2014-05-22|Estimate|May 2004||2004-05-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma|A PHASE II TRIAL OF A VACCINE COMBINING MULTIPLE CLASS I PEPTIDES WITH MONTANIDE ISA 51 OR ISA 51 VG AND CpG ADJUVANT 7909 FOR PATIENTS WITH RESECTED STAGES IIC/III AND IV MELANOMA|Completed||Phase 2|42|Actual|University of Southern California||2|||f||||||||||||||2018-06-01 05:08:30.631615|2018-06-01 05:08:30.631615
NCT00002902|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-05-21|2004-05-24|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 1997||1997-04-30|July 2002|2002-07-31||||||||Interventional|||Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors|PHASE I TRIAL OF IRINOTECAN AND TOMUDEX IN COMBINATION ON AN EVERY THREE WEEK SCHEDULE|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:01.00597|2018-06-01 05:10:01.00597
NCT00085176|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-01-29|2004-06-10|2004-06-11|Estimate|||||||2014-01-29|2014-01-30|Estimate|May 2004||2004-05-31|January 2014|2014-01-31|January 2011|Actual|2011-01-31|September 2009|Actual|2009-09-30||Observational|||Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia|Neurobehavioral Outcomes in Childhood Acute Lymphoblastic Leukemia. A Limited Non-Therapeutic Study|Completed|||286|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:08:30.805838|2018-06-01 05:08:30.805838
NCT00085163|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2015-10-19|2004-06-10|2004-06-11|Estimate|||||||2015-10-19|2015-10-20|Estimate|March 2004||2004-03-31|October 2015|2015-10-31||||November 2005|Actual|2005-11-30||Interventional|||Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon|Multicenter, Double-Blind, Placebo-Controlled Randomized Phase III Study of Adjuvant Therapy With Celecoxib in Combination With Chemotherapy in Patients With Curatively Resected Stage III Colon Cancer|Completed||Phase 3|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:08:30.983412|2018-06-01 05:08:30.983412
NCT00085150|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2015-04-29|2004-06-10|2004-06-11|Estimate|||||||2015-04-29|2015-04-30|Estimate|April 2004||2004-04-30|February 2007|2007-02-28||||||||Interventional|||LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma|Pediatric Phase I Trial of LMB-2 for Refractory CD25-Positive Leukemias and Lymphomas|Completed||Phase 1|40|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:08:31.16397|2018-06-01 05:08:31.16397
NCT00085124|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-06-04|2004-06-10|2004-06-11|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2003||2003-12-31|June 2013|2013-06-30||||June 2007|Actual|2007-06-30||Interventional|||Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia|A Phase III Study of Daunorubicin and Cytarabine +/- G3139 (Genasense, Oblimersen Sodium, NSC #683428, IND #58842), a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients With Acute Myeloid Leukemia (AML) &gt; / = 60 Years|Completed||Phase 3|500|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:08:31.290433|2018-06-01 05:08:31.290433
NCT00085111|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-06-04|2004-06-10|2004-06-11|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2003||2003-12-31|June 2013|2013-06-30||||October 2005|Actual|2005-10-31||Interventional|||Bevacizumab in Treating Young Patients With Refractory Solid Tumors|A Phase I Study of Bevacizumab in Refractory Solid Tumors|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:31.493718|2018-06-01 05:08:31.493718
NCT00085098|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2013-06-07||2017-02-07|2004-06-10|2004-06-11|Estimate|2013-08-30|2013-11-06|Estimate||||2017-02-07|2017-03-15|Actual|January 2007||2007-01-31|February 2017|2017-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor|Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma|Completed||Phase 3|24|Actual|Children's Oncology Group|Study closed early due to slow accrual. Analysis plans were not carried out (lack of statistical precision compromised the ability to draw appropriate conclusions). Reported Primary Outcome Measure data reflects data collection through May 2009.|2|||f||||t||||||||||2018-06-01 05:08:31.688166|2018-06-01 05:08:31.688166
NCT00085059|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-07-17|2004-06-10|2004-06-11|Estimate|||||||2012-07-17|2012-07-18|Estimate|April 2004||2004-04-30|July 2012|2012-07-31||||October 2006|Actual|2006-10-31||Interventional|||Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma|Early Phase II Study On BNCT In Metastatic Malignant Melanoma Using The Boron Carrier BPA|Terminated||Phase 2|4|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:08:32.92091|2018-06-01 05:08:32.92091
NCT00085020|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2015-10-01|2004-06-10|2004-06-11|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2004||2004-03-31|August 2012|2012-08-31|February 2005|Actual|2005-02-28|December 2004|Actual|2004-12-31||Interventional|||GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu|A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Trastuzumab [Herceptin†]|Completed||Phase 1|13|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:08:33.100677|2018-06-01 05:08:33.100677
NCT00084981|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-09-27|2004-06-10|2004-06-11|Estimate|||||||2013-09-27|2013-09-30|Estimate|April 2004||2004-04-30|September 2013|2013-09-30||||February 2013|Actual|2013-02-28||Interventional|||Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer|A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Non-Small Cell Lung Cancer|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:33.291092|2018-06-01 05:08:33.291092
NCT00084942|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-01-11|2004-06-10|2004-06-11|Estimate|||||||2012-01-11|2012-01-12|Estimate|October 2002||2002-10-31|January 2012|2012-01-31|November 2006|Actual|2006-11-30|May 2004|Actual|2004-05-31||Interventional|||Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder|A Phase II Study of Gemcitabine in Combination With Capecitabine in Advanced Cholangiocarcinoma|Completed||Phase 2|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:08:33.526629|2018-06-01 05:08:33.526629
NCT00084929|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-10-07|2004-06-10|2004-06-11|Estimate|||||||2013-10-07|2013-10-08|Estimate|February 2005||2005-02-28|October 2013|2013-10-31||||September 2008|Actual|2008-09-30||Interventional|ACRIN 6664||Computed Tomographic Colonography in Screening Healthy Participants for Colorectal Cancer|National CT Colonography Trial|Completed||Phase 2/Phase 3|2607|Actual|American College of Radiology Imaging Network||1|||f||||t||||||||||2018-06-01 05:08:33.682793|2018-06-01 05:08:33.682793
NCT00084916|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-01-22|2004-06-10|2004-06-11|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2004||2004-04-30|January 2013|2013-01-31||||March 2007|Actual|2007-03-31||Interventional|||CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase|A Phase II Study Of CCI-779 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Or Chronic Myeloid Leukemia In Blastic-Phase|Completed||Phase 2|74|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:33.849353|2018-06-01 05:08:33.849353
NCT00084903|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-08-01|2004-06-10|2004-06-11|Estimate|||||||2012-08-01|2012-08-02|Estimate|April 1998||1998-04-30|August 2012|2012-08-31|February 2009|Actual|2009-02-28|July 2007|Actual|2007-07-31||Interventional|||Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears|Pathological Correlation of Colposcopically Directed Biopsies to Fluorescence EEM of the Normal Human Cervix|Completed||N/A|1070|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:08:34.067664|2018-06-01 05:08:34.067664
NCT00080054|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-22|||2009-04-02|2004-03-22|2004-03-23|Estimate|||||||2009-04-02|2009-04-03|Estimate||||January 2007|2007-01-31||||||||Interventional|||A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas|Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Temozolomide for Treatment of Malignant Gliomas|Completed||Phase 1|24||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 05:12:04.694687|2018-06-01 05:12:04.694687
NCT00084890|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2017-05-25|2004-06-10|2004-06-11|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2003||2003-11-30|July 2012|2012-07-31|April 2010|Actual|2010-04-30|March 2007|Actual|2007-03-31||Interventional|||Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix|Weekly Docetaxel and Carboplatin in Patients With Recurrent Squamous Carcinoma of the Cervix: A Phase I/II Study|Terminated||Phase 1|15|Actual|Wake Forest University Health Sciences||||slow accrual|f||||f|t|f||||||||2018-06-01 05:08:34.241907|2018-06-01 05:08:34.241907
NCT00084877|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-05-15|2004-06-10|2004-06-11|Estimate|||||||2013-05-15|2013-05-16|Estimate|March 2004||2004-03-31|May 2013|2013-05-31||||July 2008|Actual|2008-07-31||Interventional|||Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Triapine® in Combination With Irinotecan in Refractory Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:34.509725|2018-06-01 05:08:34.509725
NCT00084864|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2017-03-30||2017-05-11|2004-06-10|2004-06-11|Estimate|2017-05-11|2017-06-12|Actual||||2017-05-11|2017-06-12|Actual|September 2002||2002-09-30|May 2017|2017-05-31|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional||All treated and eligible patients|Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate|A Pilot Trial of Calcitriol in Localized Prostate Cancer: Investigation of Biologic Effects and Potential Intermediate Endpoints|Terminated||Phase 2|25|Actual|Roswell Park Cancer Institute|Study was activated prior to Roswell Park Cancer Institute (RPCI) putting a system in place to centralize data entry and data management. Data entry was done by PI's staff. PI left institute and left incomplete data.|4||sample size is too small to draw a conclusion|f||||t||||||||||2018-06-01 05:08:34.739149|2018-06-01 05:08:34.739149
NCT00084838|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2012-12-14||2015-12-18|2004-06-10|2004-06-11|Estimate|2015-12-18|2015-12-24|Estimate||||2015-12-18|2015-12-24|Estimate|February 2003||2003-02-28|December 2015|2015-12-31|March 2013|Actual|2013-03-31|February 2008|Actual|2008-02-29||Interventional|||Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT|A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor|Completed||Phase 2|25|Actual|Dana-Farber Cancer Institute|None. Trial was completed.|1|||f||||t||||||||||2018-06-01 05:08:35.673174|2018-06-01 05:08:35.673174
NCT00084825|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-10-24|2004-06-10|2004-06-11|Estimate|||||||2012-10-24|2012-10-26|Estimate|May 2003||2003-05-31|October 2012|2012-10-31|June 2008|Actual|2008-06-30|July 2006|Actual|2006-07-31||Interventional|||Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008|Crossover From Docetaxel and Placebo to Docetaxel and Imatinib in Patients With Androgen-Independent Prostate Cancer With Bone Metastases: Extension Trial to ID03-0008|Completed||Phase 2|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:08:36.318721|2018-06-01 05:08:36.318721
NCT00084812|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-03-21|2004-06-10|2004-06-11|Estimate|||||||2013-03-21|2013-03-22|Estimate|March 2004||2004-03-31|March 2013|2013-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Safingol Administered With Cisplatin in Patients With Advanced Solid Tumors|Completed||Phase 1|43|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:08:36.460033|2018-06-01 05:08:36.460033
NCT00084799|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2015-06-15|2004-06-10|2004-06-11|Estimate|||||||2015-06-15|2015-06-16|Estimate|February 2004||2004-02-29|June 2015|2015-06-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer|A Multiple-Dose Targeting Study of hu3S193 in Patients With Small Cell Lung Cancer|Completed||Phase 1|||Ludwig Institute for Cancer Research|||||f||||f||||||||||2018-06-01 05:08:36.595252|2018-06-01 05:08:36.595252
NCT00084786|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-01-15|2004-06-10|2004-06-11|Estimate|||||||2013-01-15|2013-01-17|Estimate|March 2004||2004-03-31|January 2013|2013-01-31||||July 2006|Actual|2006-07-31||Interventional|||Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation of ZD1839 (Iressa®) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:08:36.829692|2018-06-01 05:08:36.829692
NCT00084773|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2015-12-21|2004-06-10|2004-06-11|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2004||2004-03-31|December 2015|2015-12-31|March 2010|Actual|2010-03-31|January 2007|Actual|2007-01-31||Interventional|||Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer|A Pilot Clinical Trial of Preoperative Cetuximab With Concurrent Continuous Infusion Fluorouracil and Pelvic Radiation in Patients With Local-Regionally Advanced Rectal Cancer|Completed||N/A|28|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:08:36.915488|2018-06-01 05:08:36.915488
NCT00084747|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2016-01-20||2016-02-17|2004-06-10|2004-06-11|Estimate|2016-02-17|2016-03-15|Estimate||||2016-02-17|2016-03-15|Estimate|June 2004||2004-06-30|February 2016|2016-02-29|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma|Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation With VELCADE Maintenance as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma|Completed||Phase 1/Phase 2|30|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:08:37.087086|2018-06-01 05:08:37.087086
NCT00084734|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-01-10|2004-06-10|2004-06-11|Estimate|||||||2014-01-10|2014-01-13|Estimate|May 2002||2002-05-31|January 2014|2014-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetics Study of Docetaxel in Combination With Capecitabine and Cisplatin in Solid Tumors|Completed||Phase 1|61|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:08:37.297425|2018-06-01 05:08:37.297425
NCT00084721|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-01-30|2004-06-10|2004-06-11|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 2005||2005-03-31|January 2013|2013-01-31||||October 2005|Actual|2005-10-31||Interventional|||Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer|A Phase I Study of Irinotecan in Combination With Fixed Dose Celecoxib in Patients With Advanced Colorectal Cancer|Completed||Phase 1|2|Actual|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:08:37.384238|2018-06-01 05:08:37.384238
NCT00084708|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-01-10|2004-06-10|2004-06-11|Estimate|||||||2014-01-10|2014-01-13|Estimate|November 2002||2002-11-30|January 2014|2014-01-31|May 2007|Actual|2007-05-31|October 2006|Actual|2006-10-31||Interventional|||Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors|A Phase I Study of Intravenous (IV) Calcitriol in Combination With ZD1839 (IRESSA®) in Refractory Solid Tumors|Completed||Phase 1|53|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:08:37.54945|2018-06-01 05:08:37.54945
NCT00084695|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-01-09|2004-06-10|2004-06-11|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2003||2003-09-30|October 2008|2008-10-31||||December 2012|Anticipated|2012-12-31||Interventional|||Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases|The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells|Unknown status|Recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 05:08:37.664211|2018-06-01 05:08:37.664211
NCT00084682|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2015-04-29||2015-04-29|2004-06-10|2004-06-11|Estimate|2015-04-29|2015-05-19|Estimate||||2015-04-29|2015-05-19|Estimate|April 2004||2004-04-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|November 2008|Actual|2008-11-30||Interventional|||Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|14|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:08:37.805663|2018-06-01 05:08:37.805663
NCT00084669|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2010-04-27|2004-06-10|2004-06-11|Estimate|||||||2010-04-27|2010-04-28|Estimate|May 2004||2004-05-31|April 2010|2010-04-30|March 2010|Actual|2010-03-31|October 2007|Actual|2007-10-31||Interventional|||Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer|Targeting Insomnia to Enhance Hot Flush Treatment in Women Receiving Therapy for Breast Cancer or Breast Cancer Risk-Reduction|Completed||N/A|119|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-06-01 05:08:38.147558|2018-06-01 05:08:38.147558
NCT00084656|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2010-04-23|2004-06-10|2004-06-11|Estimate|||||||2010-04-23|2010-04-26|Estimate|May 2004||2004-05-31|April 2010|2010-04-30||||October 2009|Actual|2009-10-31||Interventional|||Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma|An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma|Completed||Phase 2|75|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-06-01 05:08:38.289585|2018-06-01 05:08:38.289585
NCT00084643|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-03-26|2004-06-10|2004-06-11|Estimate|||||||2013-03-26|2013-03-27|Estimate|May 2004||2004-05-31|January 2013|2013-01-31||||April 2008|Actual|2008-04-30||Interventional|||GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors|A Phase I Study of GTI-2040 in Combination With Oxaliplatin and Capecitabine in Patients With Advanced Metastatic Solid Tumors|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:38.49819|2018-06-01 05:08:38.49819
NCT00084630|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-02-27|2004-06-10|2004-06-11|Estimate|||||||2013-02-27|2013-02-28|Estimate|May 2004||2004-05-31|February 2013|2013-02-28||||July 2007|Actual|2007-07-31||Interventional|||Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans|A Phase II Study of Imatinib (NSC-716051) in Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:38.619062|2018-06-01 05:08:38.619062
NCT00084617|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2015-04-15||2015-04-15|2004-06-10|2004-06-11|Estimate|2015-04-15|2015-05-01|Estimate||||2015-04-15|2015-05-01|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma|Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma|Completed||Phase 2|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:38.802816|2018-06-01 05:08:38.802816
NCT00084604|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-06-03|2004-06-10|2004-06-11|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2004||2004-04-30|June 2013|2013-06-30||||October 2007|Actual|2007-10-31||Interventional|||Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|A Multicenter, Open-Label, Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Completed||Phase 2|47|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:39.266712|2018-06-01 05:08:39.266712
NCT00084591|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2010-02-11|2004-06-10|2004-06-11|Estimate|||||||2010-02-11|2010-02-12|Estimate|December 2003||2003-12-31|February 2010|2010-02-28|February 2007|Actual|2007-02-28|||||Interventional|||Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer|Phase I Study of Preoperative Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer|Completed||Phase 1|||Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:08:39.426516|2018-06-01 05:08:39.426516
NCT00084578|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-07-12|2004-06-10|2004-06-11|Estimate|||||||2013-07-12|2013-07-15|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder|A Randomized Trial of Celecoxib and Rosiglitazone, Alone and in Combination, in Patients With Early Stage Non-Invasive Bladder Carcinoma Undergoing Cystoscopic Surveillance and in Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy|Withdrawn||N/A|0|Actual|Fox Chase Cancer Center||||Withdrawn due to drug toxicity|f||||f||||||||||2018-06-01 05:08:39.588853|2018-06-01 05:08:39.588853
NCT00084565|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-07-09|2004-06-10|2004-06-11|Estimate|||||||2013-07-09|2013-07-10|Estimate|November 2003||2003-11-30|July 2013|2013-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer|Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma|Withdrawn||Phase 2|0|Actual|Fox Chase Cancer Center||||Study was never activated at Fox Chase Cancer Center.|f||||f||||||||||2018-06-01 05:08:39.786866|2018-06-01 05:08:39.786866
NCT00084552|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2016-03-01|2004-06-10|2004-06-11|Estimate|||||||2016-03-01|2016-03-03|Estimate|December 2003||2003-12-31|March 2016|2016-03-31||||August 2013|Actual|2013-08-31||Interventional|||Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer|Outcomes Following Intensity Modulated Radiation Therapy With And Without Erectile Tissue Dose Sparing For Favorable To Intermediate Risk Prostate Cancer|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Fox Chase Cancer Center||2|||f||||f||||||||||2018-06-01 05:08:39.903677|2018-06-01 05:08:39.903677
NCT00084539|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2016-03-01|2004-06-10|2004-06-11|Estimate|||||||2016-03-01|2016-03-03|Estimate|November 2003||2003-11-30|March 2016|2016-03-31||||November 2005|Actual|2005-11-30||Interventional|||Adjuvant Hypofractionated Intensity-Modulated Radiation Therapy With Incorporated Boost in Treating Patients With Early-Stage Breast Cancer|Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost in Early Stage Breast Cancer|Completed||Phase 2|78|Actual|Fox Chase Cancer Center||1|||f||||f||||||||||2018-06-01 05:08:40.056478|2018-06-01 05:08:40.056478
NCT00084526|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2010-02-11|2004-06-10|2004-06-11|Estimate|||||||2010-02-11|2010-02-12|Estimate|November 2003||2003-11-30|February 2010|2010-02-28|February 2007|Actual|2007-02-28|||||Interventional|||Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer|Evaluation of Daily CT Scans Using CT on Rails for Localization in the Treatment of Prostate Cancer|Completed||Phase 1/Phase 2|40|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:08:40.266484|2018-06-01 05:08:40.266484
NCT00084513|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2010-02-11|2004-06-10|2004-06-11|Estimate|||||||2010-02-11|2010-02-12|Estimate|August 2004||2004-08-31|February 2010|2010-02-28|March 2007|Actual|2007-03-31|||||Interventional|||Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer|Phase I of Trastuzumab and Imatinib Mesylate (Gleevec®, Formerly Known as STI-571) in Patients With Recurrent or Metastatic Her-2/Neu Expressing Cancer|Completed||Phase 1|18|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:08:40.508434|2018-06-01 05:08:40.508434
NCT00084487|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2013-11-12||2014-05-07|2004-06-10|2004-06-11|Estimate|2013-11-12|2014-01-01|Estimate||||2014-05-07|2014-05-23|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||One patient died prior to start of treatment and is not included on any data analysis.|Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy|"Phase II Trial of XL119 (Rebeccamycin Analogue) in Relapsed Sensitive Small Cell Lung Cancer"|Terminated||Phase 2|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:40.818289|2018-06-01 05:08:40.818289
NCT00084461|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-06-03|2004-06-10|2004-06-11|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2004||2004-03-31|June 2013|2013-06-30||||October 2004|Actual|2004-10-31||Interventional|||Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors|Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:42.415223|2018-06-01 05:08:42.415223
NCT00084448|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-07-08|2004-06-10|2004-06-11|Estimate|||||||2013-07-08|2013-07-09|Estimate|April 2004||2004-04-30|June 2005|2005-06-30||||May 2005|Actual|2005-05-31||Interventional|||Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation of Weekly Paclitaxel (NSC #673089) and Celecoxib (Celebrex®, NSC #719627) in the Treatment of Recurrent or Persistent Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Cancer|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:08:42.598963|2018-06-01 05:08:42.598963
NCT00084435|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2012-06-13|2004-06-10|2004-06-11|Estimate|||||||2012-06-13|2012-06-14|Estimate|July 2005||2005-07-31|June 2012|2012-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|S0217||S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer|Adjuvant Chemo-RT With Cisplatin (NSC-119875) and Docetaxel (NSC-628503) After Complete Resection of Locally Advanced (Stage III and IV) Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||1||Poor accrual and suspension of head and neck committee|f||||f||||||||||2018-06-01 05:08:42.72753|2018-06-01 05:08:42.72753
NCT00084422|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2014-08-28|2004-06-10|2004-06-11|Estimate|||||||2014-08-28|2014-08-29|Estimate|August 2003||2003-08-31|August 2014|2014-08-31|February 2011|Actual|2011-02-28|September 2009|Actual|2009-09-30||Interventional|||N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma|A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)|Completed||Phase 1|47|Actual|New Approaches to Neuroblastoma Therapy Consortium|||||f||||t||||||||||2018-06-01 05:08:43.378883|2018-06-01 05:08:43.378883
NCT00084409|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2012-11-26||2017-10-24|2004-06-10|2004-06-11|Estimate|2013-01-09|2013-02-13|Estimate||||2017-10-24|2017-11-30|Actual|November 2001||2001-11-30|October 2017|2017-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease|A Randomized Phase II Chemoprevention Study of Iloprost Versus Placebo in Patients at High Risk for Lung Cancer|Completed||Phase 2|152|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-06-01 05:08:43.705284|2018-06-01 05:08:43.705284
NCT00084396|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2016-09-23|2004-06-10|2004-06-11|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 2003||2003-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|March 2007|Actual|2007-03-31||Interventional|||Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer|A Phase 2 Trial Of 4 Months Preoperative Letrozole 2.5 mg Daily For Postmenopausal Women With Estrogen Receptor Positive And/Or Progesterone Receptor Positive T2, T3, T4a-c, N0-2, M0 Breast Cancer- Novel Biomarkers for Aromatase Inhibitor Therapy|Completed||Phase 2|115|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-06-01 05:08:44.808461|2018-06-01 05:08:44.808461
NCT00084383|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2013-03-01||2013-07-17|2004-06-10|2004-06-11|Estimate|2013-06-10|2013-07-15|Estimate||||2013-07-17|2013-07-22|Estimate|January 2002||2002-01-31|July 2013|2013-07-31|July 2006|Actual|2006-07-31|December 2005|Actual|2005-12-31||Interventional|||Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas|A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Adjuvant Chemoradiotherapy for the Treatment of Adenocarcinoma of the Pancreas|Completed||Phase 2|60|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 05:08:45.012751|2018-06-01 05:08:45.012751
NCT00084370|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|||2013-08-21|2004-06-10|2004-06-11|Estimate|||||||2013-08-21|2013-08-22|Estimate|June 2002||2002-06-30|August 2013|2013-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy|Molecular Alterations in Human Ovarian Epithelium Induced by Chemopreventive Agents in Patients at Elevated Inherited Risk of Ovarian Cancer: A Controlled Pilot Study in Ovarian Cancer Chemoprevention|Withdrawn||N/A|0|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 05:08:45.499935|2018-06-01 05:08:45.499935
NCT00084344|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10||2011-02-16|2012-05-17|2004-06-10|2004-06-11|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-17|2012-05-30|Estimate|April 2003||2003-04-30|May 2012|2012-05-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women|A Prospective, Randomized, Placebo-Controlled Trial of the Effects of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women|Completed||N/A|||Northwestern University|||||f||||t||||||||||2018-06-01 05:08:45.632334|2018-06-01 05:08:45.632334
NCT00004126|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-08|2004-05-20|2004-05-21|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 1999||1999-11-30|February 2013|2013-02-28|August 2003|Actual|2003-08-31|January 2001|Actual|2001-01-31||Interventional|||Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer|A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Non-Small Cell Lung Cancer|Completed||Phase 2|38|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:10:07.459859|2018-06-01 05:10:07.459859
NCT00084318|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-10|2016-06-14||2016-12-30|2004-06-10|2004-06-11|Estimate|2016-11-18|2016-11-22|Estimate||||2016-12-30|2017-02-17|Actual|April 2004||2004-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2009|Actual|2009-03-31||Interventional||Eligible patients who started protocol treatment and did not withdraw consent.|Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck|A Phase II Randomized Trial Of Surgery Followed By Chemoradiotherapy Plus Cetuximab For Advanced Squamous Cell Carcinoma Of The Head and Neck|Completed||Phase 2|238|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:08:45.808081|2018-06-01 05:08:45.808081
NCT00084279|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09|||2009-07-01|2004-06-10|2004-06-11|Estimate|||||||2009-07-01|2009-07-03|Estimate|April 2004||2004-04-30|July 2009|2009-07-31|April 2006|Actual|2006-04-30|||||Interventional|||CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)|Safety and Tolerability of Consensus Interferon-Alpha (CIFN) Plus Interferon Gamma-1b (IFN-γ 1b) With or Without Ribavirin (RBV) in the Treatment of Patients With Chronic Hepatitis C Who Are Non-Responders to PEG-IFN-a (2a or 2b) Plus RBV|Completed||Phase 2|81|Actual|InterMune|||||f||||||||||||||2018-06-01 05:08:48.245095|2018-06-01 05:08:48.245095
NCT00084266|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09|2011-03-10||2012-01-30|2004-06-10|2004-06-11|Estimate|2011-04-15|2011-05-09|Estimate||||2012-01-30|2012-02-01|Estimate|October 2004||2004-10-31|January 2012|2012-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|ZEPHYR||Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)|Linezolid In The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus|Completed||Phase 4|1225|Actual|Pfizer|EOS visit window of 15-21 days after last dose as specified in protocol was expanded during blinded evaluability assessments and prior to database lock and unblinding to 7-30 days after last dose in order to better fit the actual study visit days.|2|||f||||f||||||||||2018-06-01 05:08:48.481719|2018-06-01 05:08:48.481719
NCT00084253|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09||2010-03-04|2010-03-04|2004-06-10|2004-06-11|Estimate||||2010-03-04|2010-03-05|Estimate|2010-03-04|2010-03-05|Estimate|June 2004||2004-06-30|June 2008|2008-06-30||||August 2006|Actual|2006-08-31||Interventional|||Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients|Phase IV Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients|Completed||Phase 4|200|Anticipated|Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 05:08:51.802912|2018-06-01 05:08:51.802912
NCT00084240|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09|||2008-10-30|2004-06-10|2004-06-11|Estimate|||||||2008-10-30|2008-11-03|Estimate|March 2004||2004-03-31|October 2008|2008-10-31|April 2005|Actual|2005-04-30|||||Interventional|||Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia|A Phase 2/3, Randomized, Comparative, Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia|Terminated||Phase 2/Phase 3|32|Actual|Pfizer||||See Detailed Description|||||||||||||||2018-06-01 05:08:51.964991|2018-06-01 05:08:51.964991
NCT00084227|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09|||2011-05-10|2004-06-10|2004-06-11|Estimate|||||||2011-05-10|2011-05-11|Estimate|July 2004||2004-07-31|May 2011|2011-05-31|July 2005|Actual|2005-07-31|||||Interventional|||Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America|A Phase Ii/Iii, Randomized, Double Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America|Completed||Phase 2/Phase 3|244|Actual|Pfizer|||||||||||||||||||2018-06-01 05:08:52.050578|2018-06-01 05:08:52.050578
NCT00084305|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09|||2018-05-26|2004-06-09|2004-06-10|Estimate|||||||2018-05-26|2018-05-30|Actual|June 9, 2004||2004-06-09|May 21, 2018|2018-05-21||||||||Observational|||Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis|Procurement and Analysis of Specimens From Individuals With Pulmonary Fibrosis|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:08:52.167805|2018-06-01 05:08:52.167805
NCT00084292|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09|||2017-06-22|2004-06-09|2004-06-10|Estimate|||||||2017-06-22|2017-06-26|Actual|January 2003||2003-01-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|12 Months|Observational [Patient Registry]|||Database for Stroke in Infants and Children|International Pediatric Stroke Study|Recruiting|||12000|Anticipated|The Hospital for Sick Children|||||f||||f||||||||||2018-06-01 05:08:52.404023|2018-06-01 05:08:52.404023
NCT00084214|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-09|||2014-03-05|2004-06-09|2004-06-10|Estimate|||||||2014-03-05|2014-03-06|Estimate|May 2004||2004-05-31|December 2008|2008-12-31||||||||Interventional|||STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma|A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|103||Synta Pharmaceuticals Corp.|||||f||||||||||||||2018-06-01 05:08:52.595294|2018-06-01 05:08:52.595294
NCT00002682|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-06-09|2004-06-10|Estimate|||||||2012-07-27|2012-07-31|Estimate|August 1995||1995-08-31|July 2012|2012-07-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach|CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA|Completed||Phase 2|5|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:08:52.787507|2018-06-01 05:08:52.787507
NCT00002676|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-06-09|2004-06-10|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 1995||1995-07-31|July 2016|2016-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma|PHASE II TRIAL OF CHEMOTHERAPY PLUS RADIOTHERAPY FOR MANAGEMENT OF PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN'S LYMPHOMA (PCNSL)|Completed||Phase 2|36|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:08:52.929649|2018-06-01 05:08:52.929649
NCT00002670|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-23|2004-06-09|2004-06-10|Estimate|||||||2014-01-23|2014-01-24|Estimate|September 1995||1995-09-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|July 2002|Actual|2002-07-31||Interventional|||Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery|Phase III Intergroup Trial of Surgery Followed by (1) Radiotherapy vs. (2) Radiochemotherapy For Resectable High Risk Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|459|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:08:53.145148|2018-06-01 05:08:53.145148
NCT00002656|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-25|2004-06-09|2004-06-10|Estimate|||||||2013-04-25|2013-04-29|Estimate|October 1995||1995-10-31|April 2013|2013-04-30|February 2008|Actual|2008-02-29|December 2001|Actual|2001-12-31||Interventional|||Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer|PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA|Completed||Phase 2|20|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||f||||||||||2018-06-01 05:08:53.338947|2018-06-01 05:08:53.338947
NCT00002646|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-01-04|2004-06-09|2004-06-10|Estimate|||||||2012-01-04|2012-01-05|Estimate|October 1995||1995-10-31|October 2010|2010-10-31||||February 2004|Actual|2004-02-29||Interventional|||Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer|PHASE III DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE RANDOMIZED COMPARISON OF ADJUVANT THERAPY WITH TAMOXIFEN VS. TAMOXIFEN AND FENRETINIDE IN POSTMENOPAUSAL WOMEN WITH INVOLVED AXILLARY LYMPH NODES AND POSITIVE RECEPTORS|Completed||Phase 3|1500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:53.457423|2018-06-01 05:08:53.457423
NCT00002637|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-06-09|2004-06-10|Estimate|||||||2013-06-24|2013-06-25|Estimate|January 1995||1995-01-31|June 2013|2013-06-30|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Biological Therapy in Treating Patients With Prostate Cancer|PHASE I/II STUDY OF IMMUNIZATION WITH MHC CLASS I MATCHED ALLOGENEIC HUMAN PROSTATIC CARCINOMA CELLS ENGINEERED TO SECRETE INTERLEUKIN-2 AND INTERFERON-GAMMA|Completed||Phase 1/Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:08:53.84365|2018-06-01 05:08:53.84365
NCT00002632|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-28|2004-06-09|2004-06-10|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 1995||1995-03-31|August 2013|2013-08-31||||May 2002|Actual|2002-05-31||Interventional|||Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer|PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES|Completed||Phase 2|32|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:08:54.136281|2018-06-01 05:08:54.136281
NCT00002625|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-06-09|2004-06-10|Estimate|||||||2013-02-08|2013-02-11|Estimate|March 1995||1995-03-31|January 2013|2013-01-31|September 2000|Actual|2000-09-30|April 2000|Actual|2000-04-30||Interventional|||Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma|PHASE I STUDY OF TOPOTECAN AND THORACIC RADIATION|Completed||Phase 1|5|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:08:54.512275|2018-06-01 05:08:54.512275
NCT00002551|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-06-09|2004-06-10|Estimate|||||||2013-04-03|2013-04-05|Estimate|March 1994||1994-03-31|April 2013|2013-04-30|October 2008|Actual|2008-10-31|August 2006|Actual|2006-08-31||Interventional|||SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed|Postoperative Evaluation of 5-FU by Bolus Injection vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT Plus Bolus 5-FU Plus Leucovorin in Patients With Rectal Cancer, Phase III|Completed||Phase 3|1917|Actual|Southwest Oncology Group||3|||f||||t||||||||||2018-06-01 05:08:55.002495|2018-06-01 05:08:55.002495
NCT00002538|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-19|2004-06-09|2004-06-10|Estimate|||||||2013-08-19|2013-08-20|Estimate|September 1993||1993-09-30|August 2013|2013-08-31||||March 2010|Actual|2010-03-31||Interventional|||Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers|LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||t||||||||||2018-06-01 05:08:55.421721|2018-06-01 05:08:55.421721
NCT00084201|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-08|||2006-11-28|2004-06-08|2004-06-09|Estimate|||||||2006-11-28|2006-11-30|Estimate|July 2006||2006-07-31|November 2006|2006-11-30|June 2007||2007-06-30|||||Interventional|||Interactions Between Cranberry Juice and Antibiotics Used to Treat Urinary Tract Infections|Cranberry: Interactions With Anti-Infectious Agents|Completed||N/A|18||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:08:55.793136|2018-06-01 05:08:55.793136
NCT00084188|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-08|||2017-01-11|2004-06-08|2004-06-09|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2004||2004-05-31|October 2016|2016-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||HIV/STD Safer Sex Skills Groups for Women in Drug Treatment Programs - 1|HIV/STD Safer Sex Skills Groups for Women in Drug Treatment Programs|Completed||Phase 3|541||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:08:56.177732|2018-06-01 05:08:56.177732
NCT00084175|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-08|||2017-01-11|2004-06-08|2004-06-09|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2004||2004-04-30|October 2016|2016-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs - 1|HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs|Completed||Phase 3|630||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:08:56.653199|2018-06-01 05:08:56.653199
NCT00006451|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2017-11-27|2004-06-08|2004-06-09|Estimate|||||||2017-11-27|2017-11-29|Actual|April 1996||1996-04-30|November 2017|2017-11-30|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Bone Marrow Transplantation in Treating Patients With Leukemia|T-cell Depletion In Unrelated Donor Marrow Transplantation|Withdrawn||Phase 3|0|Actual|Masonic Cancer Center, University of Minnesota||||Withdrawn due to no accrual|f||||t||||||||||2018-06-01 05:08:57.045343|2018-06-01 05:08:57.045343
NCT00006387|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-07-10|2004-06-08|2004-06-09|Estimate|||||||2013-07-10|2013-07-11|Estimate|October 2000||2000-10-31|July 2013|2013-07-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer|A Phase I Study of RAS Peptide Vaccination in Patients With Advanced Pancreatic or Colorectal Adenocarcinoma|Completed||Phase 1|7|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:08:57.381284|2018-06-01 05:08:57.381284
NCT00006382|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2015-05-01|2004-06-08|2004-06-09|Estimate|||||||2015-05-01|2015-05-05|Estimate|August 2000||2000-08-31|June 2010|2010-06-30|December 2002|Actual|2002-12-31|||||Interventional|||Lung Screening Study|Lung Screening Study|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:57.705202|2018-06-01 05:08:57.705202
NCT00006380|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-06-17|2004-06-08|2004-06-09|Estimate|||||||2013-06-17|2013-06-18|Estimate|September 2000||2000-09-30|June 2013|2013-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer|Phase I Evaluation of 131I-J591 Murine Monoclonal Antibody in Patients With Progressive Androgen-Independent Prostate Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:08:57.967845|2018-06-01 05:08:57.967845
NCT00006378|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2014-01-08|2004-06-08|2004-06-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|December 1999||1999-12-31|January 2014|2014-01-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|Phase II Randomized Study of Taxol (PACLITAXEL), Paraplatin (Carboplatin), and Radiation Therapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer|Completed||Phase 2|5|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:08:58.243651|2018-06-01 05:08:58.243651
NCT00006374|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2014-01-14|2004-06-08|2004-06-09|Estimate|||||||2014-01-14|2014-01-15|Estimate|October 1999||1999-10-31|January 2014|2014-01-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized, Phase II Study of Topotecan/Paclitaxel vs Etoposide/Cisplatin as First-Line Therapy for Patients With Extensive Disease Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center||||Slow accrual|f||||t||||||||||2018-06-01 05:08:58.525252|2018-06-01 05:08:58.525252
NCT00006251|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2017-08-09|2004-06-08|2004-06-09|Estimate|||||||2017-08-09|2017-08-10|Actual|May 2000||2000-05-31|August 2017|2017-08-31||||September 2005|Actual|2005-09-30||Interventional|||Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer|Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil|Active, not recruiting||Phase 1/Phase 2|21|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:08:58.816745|2018-06-01 05:08:58.816745
NCT00005994|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-03-04|2004-06-08|2004-06-09|Estimate|||||||2013-03-04|2013-03-05|Estimate|August 2000||2000-08-31|March 2013|2013-03-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy|Patient Information and Antiemetic Drug Efficacy|Completed||N/A|||University of Rochester|||||f||||||||||||||2018-06-01 05:08:59.210954|2018-06-01 05:08:59.210954
NCT00005790|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-06-08|2004-06-08|2004-06-09|Estimate|||||||2012-06-08|2012-06-11|Estimate|April 1996||1996-04-30|June 2012|2012-06-30|May 1999||1999-05-31|May 1999||1999-05-31||Interventional|||Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors|Perfusion Magnetic Resonance Imaging of Brain Tumors: Correlation With Indicators of Angiogenesis|Withdrawn||N/A|0|Actual|Northwestern University||||Unable to accrue subjects.|f||||||||||||||2018-06-01 05:08:59.485666|2018-06-01 05:08:59.485666
NCT00005084|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-12-17|2004-06-08|2004-06-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 1999||1999-02-28|February 2008|2008-02-29||||||||Interventional|||Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma|Pediatric Low Grade Astrocytoma: Treatment Guidance|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:08:59.751369|2018-06-01 05:08:59.751369
NCT00005045|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-06-20|2004-06-08|2004-06-09|Estimate|||||||2013-06-20|2013-06-21|Estimate|March 2000||2000-03-31|December 2005|2005-12-31|June 2004|Actual|2004-06-30|||||Interventional|||Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer|Phase II Study of Carboxyamidotriazole (CAI, NSC #609974) in Patients With Advanced Renal Cell Carcinoma Refractory to Immunotherapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:00.031925|2018-06-01 05:09:00.031925
NCT00004236|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2014-06-23|2004-06-08|2004-06-09|Estimate|||||||2014-06-23|2014-06-24|Estimate|August 1998||1998-08-31|December 2000|2000-12-31||||||||Interventional|||Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer|A Phase II Study of Caelyx in the Treatment of Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:00.631398|2018-06-01 05:09:00.631398
NCT00003992|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-31|2004-06-08|2004-06-09|Estimate|||||||2013-05-31|2013-06-03|Estimate|August 1999||1999-08-31|March 2013|2013-03-31|March 2009|Actual|2009-03-31|January 2007|Actual|2007-01-31||Interventional|||Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2|Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer|Completed||Phase 2|200|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:09:00.900913|2018-06-01 05:09:00.900913
NCT00003859|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-06-08|2004-06-09|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 1992||1992-04-30|April 2009|2009-04-30|April 2003|Actual|2003-04-30|||||Interventional|||Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS|Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood|Completed||Phase 3|230|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:01.27944|2018-06-01 05:09:01.27944
NCT00003733|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-06-08|2004-06-09|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 1997||1997-12-31|December 2000|2000-12-31||||||||Interventional|||Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer|A Phase II Study of Sequential Carboplatin, Paclitaxel and Hycamtin in Patients With Previously Untreated Advanced Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:01.531099|2018-06-01 05:09:01.531099
NCT00003584|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-05-10|2004-06-08|2004-06-09|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 1998||1998-07-31|May 2016|2016-05-31|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer|A Phase II Trial of Combination Vinorelbine-Estramustine With or Without Prednisone for High Risk and Recurrent, Advanced and Metastatic Renal Cell Carcinoma|Completed||Phase 2|35|Anticipated|University of New Mexico|||||f||||||||||||||2018-06-01 05:09:01.790178|2018-06-01 05:09:01.790178
NCT00003435|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-06|2004-06-08|2004-06-09|Estimate|||||||2013-03-06|2013-03-07|Estimate|May 1998||1998-05-31|December 2000|2000-12-31||||||||Interventional|||Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer|A Pilot Study Involving Administration of Combination Anti-Retroviral Therapy and Transplantation of HLA-Matched Sibling Peripheral Blood Stem Cells or Partially HLA-Matched Unrelated Umbilical Cord Blood In Adults With HIV Infection and Hematologic Malignancies|Withdrawn||Phase 1|0|Actual|Duke University|||||f||||||||||||||2018-06-01 05:09:02.180208|2018-06-01 05:09:02.180208
NCT00003410|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-06-08|2004-06-09|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 1998||1998-07-31|May 2006|2006-05-31|June 2004|Actual|2004-06-30|||||Interventional|||Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas|Pilot Trial of Gadolium Texaphyrin for Magnetic Resonance Imaging-Guided Resection of High Grade Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:02.425176|2018-06-01 05:09:02.425176
NCT00003372|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-07|2004-06-08|2004-06-09|Estimate|||||||2010-11-07|2010-11-09|Estimate|December 1997||1997-12-31|November 2010|2010-11-30|December 2009||2009-12-31|||||Interventional|||Topotecan in Treating Patients With Recurrent Brain Tumors|A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma|Completed||Phase 2|30|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:09:02.677484|2018-06-01 05:09:02.677484
NCT00003236|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-06-08|2004-06-09|Estimate|||||||2013-08-22|2013-08-23|Estimate|May 1998||1998-05-31|August 2013|2013-08-31||||June 2002|Actual|2002-06-30||Interventional|||Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer|Randomized Phase II Study of Human C-raf Kinase Antisense Oligonucleotide Isis 5132 (CGP 69846A) or Human Pkc-Alpha Antisence Oligonucleotide ISIS 3521 (CGP 64128A) in Women With Previously Treated Matastatic Breast Cancer|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:09:02.962477|2018-06-01 05:09:02.962477
NCT00002905|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-06-08|2004-06-09|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 1995||1995-06-30|September 2011|2011-09-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|PROSPECTIVE NON-RANDOMIZED STUDY WITH CHEMOTHERAPY FOR RELAPSED OR REFRACTORY HIV-RELATED NON-HODGKIN'S LYMPHOMA: VMP REGIMEN FOR RELAPSED PATIENTS, CDE REGIMEN FOR REFRACTORY PATIENTS|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:03.191713|2018-06-01 05:09:03.191713
NCT00002496|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-23|2004-06-08|2004-06-09|Estimate|||||||2014-01-23|2014-01-24|Estimate|August 1992||1992-08-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|August 2002|Actual|2002-08-31||Interventional|||Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx|PHASE III TRIAL TO PRESERVE THE LARYNX: INDUCTION CHEMOTHERAPY AND RADIATION THERAPY VERSUS CONCOMITANT CHEMOTHERAPY AND RADIATION THERAPY VERSUS RADIATION THERAPY|Completed||Phase 3|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:09:03.269504|2018-06-01 05:09:03.269504
NCT00002478|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-07|2004-06-08|2004-06-09|Estimate|||||||2013-06-07|2013-06-10|Estimate|June 1993||1993-06-30|November 2000|2000-11-30||||October 2003|Actual|2003-10-31||Interventional|||Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer|Phase II Study of Prolonged Oral VP-16 for Advanced Ovarian Epithelial and Cervical Cancer|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:09:03.414529|2018-06-01 05:09:03.414529
NCT00002476|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-01|2004-06-08|2004-06-09|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 1990||1990-01-31|March 2010|2010-03-31|January 2010|Actual|2010-01-31|||||Interventional|||Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer|Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:03.571823|2018-06-01 05:09:03.571823
NCT00002460|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2004-06-08|2004-06-09|Estimate|||||||2013-08-06|2013-08-07|Estimate|September 1987||1987-09-30|December 2006|2006-12-31||||||||Interventional|||Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer|Phase III Randomized Study of Adjuvant Therapy With Tamoxifen vs Endocrine Ablation vs Tamoxifen Plus Endocrine Ablation vs No Adjuvant Therapy in Patients Under Age 50 With Operable Breast Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:03.680197|2018-06-01 05:09:03.680197
NCT00084162|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-08|||2017-06-30|2004-06-07|2004-06-08|Estimate|||||||2017-06-30|2017-07-02|Actual|March 30, 2004||2004-03-30|March 17, 2010|2010-03-17|March 17, 2010||2010-03-17|||||Observational|||Neurocardiac Control in Major Depression|Neurocardiac Control in Major Depression|Completed|||41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:03.787113|2018-06-01 05:09:03.787113
NCT00084149|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-07|||2013-07-26|2004-06-07|2004-06-08|Estimate|||||||2013-07-26|2013-07-29|Estimate|February 2004||2004-02-29|July 2013|2013-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety of and Immune Response to Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in Adults With Acute HIV Infection|A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection|Completed||Phase 2|16|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:09:03.86981|2018-06-01 05:09:03.86981
NCT00084136|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-07|2011-07-13||2015-06-01|2004-06-07|2004-06-08|Estimate|2011-07-13|2011-08-09|Estimate||||2015-06-01|2015-06-26|Estimate|May 2005||2005-05-31|June 2015|2015-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|PEARLS||Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings|Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial|Completed||Phase 4|1571|Actual|AIDS Clinical Trials Group||3|||f||||t||||||||||2018-06-01 05:09:04.032701|2018-06-01 05:09:04.032701
NCT00084123|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-07|||2009-07-09|2004-06-07|2004-06-08|Estimate|||||||2009-07-09|2009-07-10|Estimate|September 2002||2002-09-30|July 2009|2009-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Healing Touch and Relaxation Therapies in Cervical Cancer Patients|Healing Touch in Advanced Cervical Cancer Patients: Immune Effects and Mechanisms|Completed||Phase 2|60|Actual|National Center for Complementary and Integrative Health (NCCIH)||3|||f||||t||||||||||2018-06-01 05:09:05.829154|2018-06-01 05:09:05.829154
NCT00084110|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-07|||2006-08-17|2004-06-07|2004-06-08|Estimate|||||||2006-08-17|2006-08-18|Estimate|August 1993||1993-08-31|August 2006|2006-08-31|September 2000||2000-09-30|||||Observational|||Use of Complementary and Alternative Medicine Among Older Mexican Americans|Complementary Alternative Medicine|Terminated|||3000||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:09:05.926652|2018-06-01 05:09:05.926652
NCT00084071|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-04|||2012-07-12|2004-06-07|2004-06-08|Estimate|||||||2012-07-12|2012-07-13|Estimate|May 2004||2004-05-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia|Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) for the Treatment of Patients With Severe Community-Acquired Pneumonia|Completed||Phase 3|2136|Actual|Novartis|||||f||||||||||||||2018-06-01 05:09:06.004937|2018-06-01 05:09:06.004937
NCT00083993|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-04|||2011-11-07|2004-06-07|2004-06-08|Estimate|||||||2011-11-07|2011-11-08|Estimate|May 2004||2004-05-31|November 2011|2011-11-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer|A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|Terminated||Phase 3|1236||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:09:06.46303|2018-06-01 05:09:06.46303
NCT00005960|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-12-03|2004-06-07|2004-06-08|Estimate|||||||2013-12-03|2013-12-04|Estimate|October 1999||1999-10-31|January 2001|2001-01-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of Doxorubicin and Cyclophosphamide With Sequential Docetaxel in Patients With Hormone-Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:06.752005|2018-06-01 05:09:06.752005
NCT00005641|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-12-10|2004-06-07|2004-06-08|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 1997||1997-09-30|December 2012|2012-12-31|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation|T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation|Terminated||Phase 2|||H. Lee Moffitt Cancer Center and Research Institute||||low study accrual|f||||f||||||||||2018-06-01 05:09:06.826014|2018-06-01 05:09:06.826014
NCT00005091|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-07-09|2004-06-07|2004-06-08|Estimate|||||||2013-07-09|2013-07-10|Estimate|February 1999||1999-02-28|January 2008|2008-01-31|August 2003|Actual|2003-08-31|||||Interventional|||DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer as First Line Therapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:06.922729|2018-06-01 05:09:06.922729
NCT00005054|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-09-19|2004-06-07|2004-06-08|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 1998||1998-05-31|January 2001|2001-01-31||||||||Interventional|||Temozolomide in Treating Women With Advanced Breast Cancer|Phase II Trial of Temodal 4 Hourly in Progressive Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:07.159495|2018-06-01 05:09:07.159495
NCT00005050|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2011-03-25|2004-06-07|2004-06-08|Estimate|||||||2011-03-25|2011-03-28|Estimate|August 1999||1999-08-31|March 2011|2011-03-31||||June 2001|Actual|2001-06-30||Interventional|||Eniluracil, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Colorectal Cancer|A Phase I/II Study of Eniluracil Plus Oral 5-Fluorouracil Combined With Oxaliplatin (FOX-E) in Patients With Previously-Treated Colorectal Cancer|Completed||Phase 1/Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:09:07.38714|2018-06-01 05:09:07.38714
NCT00084097|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-05|||2017-06-30|2004-06-04|2004-06-07|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2, 2004||2004-06-02|December 23, 2008|2008-12-23|February 5, 2007||2007-02-05|||||Interventional|||Omalizumab to Treat Eosinophilic Gastroenteritis|Pilot Study of Omalizumab in Eosinophilic Gastroenteritis|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:07.640835|2018-06-01 05:09:07.640835
NCT00084084|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-05|2013-08-01||2014-03-25|2004-06-04|2004-06-07|Estimate|2013-08-01|2013-10-10|Estimate||||2014-03-25|2014-04-16|Estimate|June 2004||2004-06-30|March 2014|2014-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Replagal Enzyme Replacement Therapy for Children With Fabry Disease|An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy|Completed||Phase 2|17|Actual|Shire||2|||f||||f||||||||||2018-06-01 05:09:07.971012|2018-06-01 05:09:07.971012
NCT00084058|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-04|||2012-05-17|2004-06-04|2004-06-07|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV|A Phase I/II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir With or Without Saquinavir in HIV-Infected Pediatric Subjects Previously Treated With Protease Inhibitors|Completed||Phase 1/Phase 2|26|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:09:09.462828|2018-06-01 05:09:09.462828
NCT00084045|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-04|||2012-10-26|2004-06-04|2004-06-07|Estimate|||||||2012-10-26|2012-10-30|Estimate|November 2004||2004-11-30|October 2012|2012-10-31|December 2006|Actual|2006-12-31|||||Interventional|||Voluntary HIV Counseling, Testing, and Medication for Pregnant Women to Prevent Mother-to-Child HIV Transmission|Mother Infant Rapid Intervention at Delivery (MIRIAD)|Completed||N/A|283|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:09:09.780874|2018-06-01 05:09:09.780874
NCT00084032|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-04|||2012-10-26|2004-06-04|2004-06-07|Estimate|||||||2012-10-26|2012-10-29|Estimate||||October 2012|2012-10-31||||||||Interventional|||Anti-HIV Medications and Structured Treatment Interruptions for People Recently Infected With HIV|A Randomized, Multicenter Trial to Determine Whether Induction Therapy Followed by Treatment Interruption is Superior to Induction Therapy Alone in the Treatment of Primary HIV Infection (PHI): The Structured Treatment Interruption (STI) Study|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:09:09.952045|2018-06-01 05:09:09.952045
NCT00084019|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-04|||2014-06-02|2004-06-04|2004-06-07|Estimate|||||||2014-06-02|2014-06-03|Estimate|July 2004||2004-07-31|June 2014|2014-06-30|May 2006|Actual|2006-05-31|||||Interventional|||Atazanavir/Ritonavir Maintenance Therapy|A Prospective, Open-Label, Pilot Trial of Regimen Simplification to Atazanavir/Ritonavir Alone as Maintenance Antiretroviral Therapy After Sustained Virologic Suppression|Completed||N/A|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:09:10.128081|2018-06-01 05:09:10.128081
NCT00083980|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-04|||2012-10-18|2004-06-04|2004-06-07|Estimate|||||||2012-10-18|2012-10-19|Estimate|June 2002||2002-06-30|August 2006|2006-08-31|August 2004|Actual|2004-08-31|June 2004|Actual|2004-06-30||Interventional|||Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)|KAVA KAVA in Generalized Anxiety: A Double-Blind Trial|Terminated||Phase 2|16|Actual|National Center for Complementary and Integrative Health (NCCIH)||3||European reports of liver toxicity from kava meant that the study had to stop|f||||f||||||||||2018-06-01 05:09:10.416927|2018-06-01 05:09:10.416927
NCT00083967|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-03|||2015-04-09|2004-06-04|2004-06-07|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2004||2004-06-30|April 2015|2015-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment|A Randomized, Double-Masked, Placebo Controlled, Parallel Group, Multi-Center, Dose-Ranging Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Rhegmatogenous Retinal Detachment|Terminated||Phase 2|23|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:09:10.582722|2018-06-01 05:09:10.582722
NCT00083954|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-03|||2013-01-03|2004-06-04|2004-06-07|Estimate|||||||2013-01-03|2013-01-04|Estimate|June 2004||2004-06-30|January 2013|2013-01-31|August 2005|Actual|2005-08-31|||||Interventional|||Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression|A Confirmatory Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression|Completed||Phase 3|530||AstraZeneca|||||||||||||||||||2018-06-01 05:09:10.803321|2018-06-01 05:09:10.803321
NCT00083941|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-03|||2011-06-28|2004-06-04|2004-06-07|Estimate|||||||2011-06-28|2011-06-29|Estimate|August 2004||2004-08-31|June 2011|2011-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer|Clinical Trial Phase II (Single Centre Study) : A Preliminary Study of the Safety, Immunogenicity, and Clinical Efficacy of TroVax Given in Conjunction With Interleukin 2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer|Completed||Phase 2|25|Anticipated|Oxford BioMedica|||||f||||||||||||||2018-06-01 05:09:11.022467|2018-06-01 05:09:11.022467
NCT00083928|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-03|||2013-01-22|2004-06-04|2004-06-07|Estimate|||||||2013-01-22|2013-01-24|Estimate|May 2004||2004-05-31|January 2013|2013-01-31|December 2006|Actual|2006-12-31|February 2006|Actual|2006-02-28||Interventional|||Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels|A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy|Completed||Phase 2|60|Anticipated|Ångstrom Pharmaceuticals|||||||||||||||||||2018-06-01 05:09:11.151841|2018-06-01 05:09:11.151841
NCT00083915|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-03|2011-07-07||2017-10-17|2004-06-03|2004-06-04|Estimate|2011-07-07|2011-08-03|Estimate||||2017-10-17|2017-11-20|Actual|June 2001||2001-06-30|October 2017|2017-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation|University of Arkansas (UARK 2001-12), A Phase III Study of DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation in Patients With Active Multiple Myeloma|Completed||Phase 3|97|Actual|University of Arkansas||2|||f||||f||||||||||2018-06-01 05:09:13.227704|2018-06-01 05:09:13.227704
NCT00083902|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-03|||2010-07-01|2004-06-03|2004-06-04|Estimate|||||||2010-07-01|2010-07-02|Estimate|June 1998||1998-06-30|July 2010|2010-07-31|May 2005||2005-05-31|||||Interventional|||Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy|UARK 98-025, A Randomized Phase II Trial of Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy for Low-Risk Post Transplantation Relapse in Patients With Multiple Myeloma|Completed||Phase 2|190||University of Arkansas|||||||||||||||||||2018-06-01 05:09:13.778422|2018-06-01 05:09:13.778422
NCT00083889|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-03|2009-09-16||2010-01-19|2004-06-03|2004-06-04|Estimate|2009-11-06|2009-12-10|Estimate||||2010-01-19|2010-01-26|Estimate|August 2004||2004-08-31|January 2010|2010-01-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma|A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 3|750|Actual|Pfizer||2|||f||||t||||||||||2018-06-01 05:09:14.304695|2018-06-01 05:09:14.304695
NCT00083876|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2010-07-01|2004-06-03|2004-06-04|Estimate|||||||2010-07-01|2010-07-02|Estimate|September 1998||1998-09-30|July 2010|2010-07-31|November 2007|Actual|2007-11-30|||||Interventional|||D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma|UARK 98-035, A Phase III Study of D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma|Completed||Phase 3|500||University of Arkansas|||||f||||||||||||||2018-06-01 05:09:19.908678|2018-06-01 05:09:19.908678
NCT00083863|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2013-08-08|2004-06-03|2004-06-04|Estimate|||||||2013-08-08|2013-08-12|Estimate|June 2004||2004-06-30|August 2013|2013-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Framingham: Inflammation, Genes & Cardiovascular Disease||Completed|||7374|Actual|Boston University|||2||f||||||||||||||2018-06-01 05:09:20.033318|2018-06-01 05:09:20.033318
NCT00083850|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2016-07-28|2004-06-03|2004-06-04|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2004||2004-06-30|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Genetics and Cardiovascular Reactivity in Young Twins||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:09:20.109458|2018-06-01 05:09:20.109458
NCT00083837|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2016-07-11|2004-06-03|2004-06-04|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2004||2004-05-31|April 2008|2008-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Gene-Specific Responses to Exercise in Discordant Twins||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:09:20.16032|2018-06-01 05:09:20.16032
NCT00083824|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2016-04-19|2004-06-03|2004-06-04|Estimate|||||||2016-04-19|2016-04-21|Estimate|March 2004||2004-03-31|April 2016|2016-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Estrogen, HDL, and Coronary Heart Disease in Women|Estrogen, HDL, and Coronary Heart Disease in Women|Completed||Phase 2/Phase 3|309|Actual|Tufts University||3|||f||||f||||||||||2018-06-01 05:09:20.247881|2018-06-01 05:09:20.247881
NCT00083811|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2016-08-05|2004-06-03|2004-06-04|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2004||2004-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||HYPGENE-Genetics Fitness Obesity & Risk of Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:09:20.37602|2018-06-01 05:09:20.37602
NCT00083798|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2016-08-18|2004-06-03|2004-06-04|Estimate|||||||2016-08-18|2016-08-22|Estimate|September 2003||2003-09-30|August 2016|2016-08-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Family Linkage Study of Obstructive Sleep Apnea (OSA) in Iceland||Completed|||2843|Actual|University of Pennsylvania|||||f||||||||||Samples With DNA|"~     Samples with DNA~   "|||2018-06-01 05:09:20.477111|2018-06-01 05:09:20.477111
NCT00005032|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-02-08|2004-06-03|2004-06-04|Estimate|||||||2013-02-08|2013-02-11|Estimate|April 2000||2000-04-30|February 2013|2013-02-28|September 2001|Actual|2001-09-30|January 2001|Actual|2001-01-31||Interventional|||Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer|A Phase I/II Study of G3139, a BCL-2 Antisense Oligonucleotide, Combined With Paclitaxel for the Treatment of Recurrent Small Cell Lung Cancer|Completed||Phase 1/Phase 2|12|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:09:20.624836|2018-06-01 05:09:20.624836
NCT00005030|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-10-05|2004-06-03|2004-06-04|Estimate|||||||2012-10-05|2012-10-08|Estimate|June 2000||2000-06-30|October 2012|2012-10-31|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver|A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Colorectal Carcinoma Metastatic to the Liver Scheduled for Exploratory Laparotomy and/or Resection|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||2||No enrollment.|f||||f||||||||||2018-06-01 05:09:20.713613|2018-06-01 05:09:20.713613
NCT00004979|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2014-01-03|2004-06-03|2004-06-04|Estimate|||||||2014-01-03|2014-01-06|Estimate||||January 2001|2001-01-31|September 2000|Actual|2000-09-30|||||Interventional|||Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors|Phase I/II Study of Oral Topotecan and Intravenous Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (Phases I and II) and Other Advanced Solid Tumors (Phase I Only)|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:20.883781|2018-06-01 05:09:20.883781
NCT00004927|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2017-01-27|2004-06-03|2004-06-04|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 1999||1999-07-31|January 2017|2017-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy|Phase I Study of BMS-247550 Given Every Three Weeks in Patients With Advanced Malignancies|Completed||Phase 1|||R-Pharm|||||f||||||||||||||2018-06-01 05:09:20.947449|2018-06-01 05:09:20.947449
NCT00004877|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2009-12-02|2004-06-03|2004-06-04|Estimate|||||||2009-12-02|2009-12-03|Estimate|July 1999||1999-07-31|December 2009|2009-12-31||||April 2001|Actual|2001-04-30||Interventional|||BMS-214662 in Treating Patients With Advanced Solid Tumors|Phase I Study of BMS-214662 Oral Dosing in Patients With Advanced Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:21.01955|2018-06-01 05:09:21.01955
NCT00004122|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-01-31|2004-05-20|2004-05-21|Estimate|||||||2013-01-31|2013-02-01|Estimate|July 1999||1999-07-31|January 2013|2013-01-31||||April 2001|Actual|2001-04-30||Interventional|||BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer|A National Phase II Trial of Intron (Interferon-alfa 2b) Plus BCG for Treatment of Superficial Bladder Cancer|Completed||Phase 2|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:10:07.579967|2018-06-01 05:10:07.579967
NCT00004161|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-04-10|2004-06-03|2004-06-04|Estimate|||||||2013-04-10|2013-04-12|Estimate|June 1997||1997-06-30|April 2013|2013-04-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Fenretinide in Treating Patients With Leukoplakia of the Mouth|A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia|Completed||Phase 2|30|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 05:09:21.083681|2018-06-01 05:09:21.083681
NCT00004146|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|2015-03-13||2015-05-05|2004-06-03|2004-06-04|Estimate|2015-05-05|2015-05-08|Estimate||||2015-05-05|2015-05-08|Estimate|March 2000||2000-03-31|April 2015|2015-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM|Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:09:21.166574|2018-06-01 05:09:21.166574
NCT00004071|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-09-10|2004-06-03|2004-06-04|Estimate|||||||2012-09-10|2012-09-11|Estimate|August 1999||1999-08-31|September 2012|2012-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer|A Randomized, Open-Label Phase II/III Study of SU101 Plus Mitoxantrone/Prednisone Compared to Mitoxantrone/Prednisone Alone in Patients With Hormone-Refractory Prostate Cancer|Completed||Phase 2/Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 05:09:21.483517|2018-06-01 05:09:21.483517
NCT00004070|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2017-04-19|2004-06-03|2004-06-04|Estimate|||||||2017-04-19|2017-04-20|Actual|July 1999|Actual|1999-07-31|April 2017|2017-04-30|December 2000|Actual|2000-12-31|November 2000|Actual|2000-11-30||Interventional|||Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer|A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 1/Phase 2|7|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||No||2018-06-01 05:09:21.556335|2018-06-01 05:09:21.556335
NCT00004062|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-12-18|2004-06-03|2004-06-04|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 1999||1999-07-31|May 2004|2004-05-31|August 2006|Actual|2006-08-31|||||Interventional|||Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer|Restoration of Radioiodine Uptake in Thyroid Carcinoma: A Clinical Trial|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:21.676147|2018-06-01 05:09:21.676147
NCT00083785|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2007-04-10|2004-06-02|2004-06-03|Estimate|||||||2007-04-10|2007-04-11|Estimate|May 2004||2004-05-31|April 2007|2007-04-30||||||||Interventional|||Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases|Safety and Effectiveness of Treating Cancers With the Litx™ System and Chemotherapy. Section A: Phase II Safety and Effectiveness Study in Patients With Liver Metastases From Colorectal Cancer|Completed||Phase 2|25||Light Sciences LLC|||||||||||||||||||2018-06-01 05:09:21.755679|2018-06-01 05:09:21.755679
NCT00083772|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-02|||2012-07-27|2004-06-02|2004-06-03|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 2004||2004-05-31|July 2012|2012-07-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Use of Nesiritide in the Management of Acute Diastolic Heart Failure|The Use of Nesiritide in the Management of Acute Diastolic Heart Failure|Terminated||Phase 4|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:09:21.842588|2018-06-01 05:09:21.842588
NCT00083759|ClinicalTrials.gov processed this data on May 31, 2018|2004-06-01|2009-01-27||2016-07-14|2004-06-02|2004-06-03|Estimate|2009-06-01|2009-06-02|Estimate||||2016-07-14|2016-07-18|Estimate|May 2004||2004-05-31|April 2009|2009-04-30||||February 2005|Actual|2005-02-28||Interventional|||Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate|A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)|Terminated||Phase 2|299|Actual|Biogen|The study was terminated prematurely on 28 February 2005. The biological effect seen with natalizumab was not sufficient to warrant further development in RA.|2||"The biological effect seen with natalizumab was not sufficient to warrant further development~   in RA."|||||||||||||||2018-06-01 05:09:21.944369|2018-06-01 05:09:21.944369
NCT00004055|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2016-07-12|2004-06-02|2004-06-03|Estimate|||||||2016-07-12|2016-07-13|Estimate|November 1999||1999-11-30|July 2016|2016-07-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Oral Topotecan and Paclitaxel With G-CSF (Filgrastim) Support in Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer|Completed||Phase 2|38|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:09:22.275149|2018-06-01 05:09:22.275149
NCT00003998|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-06-02|2004-06-03|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1998||1998-10-31|October 2007|2007-10-31|December 2004|Actual|2004-12-31|||||Interventional|||Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer|A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer|Completed||Phase 3|1050|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:22.39657|2018-06-01 05:09:22.39657
NCT00003997|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-06-02|2004-06-03|Estimate|||||||2013-02-07|2013-02-08|Estimate|July 1999||1999-07-31|January 2001|2001-01-31||||October 2000|Actual|2000-10-31||Interventional|||6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia|Phase I Study of MGI-114 (NSC#683863) in Patients With Refractory Myelodysplastic Syndromes, Acute Leukemia and Chronic Myelogenous Leukemia in Blastic Phase (CML-BP)|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:09:22.477315|2018-06-01 05:09:22.477315
NCT00003991|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-06-02|2004-06-03|Estimate|||||||2013-11-05|2013-11-06|Estimate|July 1998||1998-07-31|December 2011|2011-12-31|August 2011|Actual|2011-08-31|||||Interventional|||Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia|Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission (CR)|Completed||Phase 3|360|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:22.57981|2018-06-01 05:09:22.57981
NCT00003939|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-06-02|2004-06-03|Estimate|||||||2012-09-20|2012-09-24|Estimate||||September 2012|2012-09-30||||November 2000|Actual|2000-11-30||Interventional|||Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma|Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult|Completed||Phase 2|132|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:09:22.95215|2018-06-01 05:09:22.95215
NCT00003856|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-06-02|2004-06-03|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1998||1998-10-31|January 2001|2001-01-31||||||||Interventional|||Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy|A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy|Unknown status|Active, not recruiting|Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:23.031678|2018-06-01 05:09:23.031678
NCT00003850|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-06-02|2004-06-03|Estimate|||||||2013-02-07|2013-02-08|Estimate|April 1999||1999-04-30|January 2001|2001-01-31||||June 2003|Actual|2003-06-30||Interventional|||Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of Thalidomide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|47|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:09:23.106079|2018-06-01 05:09:23.106079
NCT00003787|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-05-02|2004-06-02|2004-06-03|Estimate|||||||2017-05-02|2017-05-03|Actual|March 1995||1995-03-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|March 2007|Actual|2007-03-31||Observational|||Women's Healthy Eating and Living Study|Dietary Intervention in Women Who Have Been Treated For Stage I, Stage II, or Stage III Breast Cancer: Women's Healthy Eating and Living (WHEL) Study|Active, not recruiting|||3000|Anticipated|University of California, San Diego|||2||f||||t||||||Samples With DNA|"~     Serum, plasma, buffy coat, RBC, DNA at five time periods~   "|||2018-06-01 05:09:23.189659|2018-06-01 05:09:23.189659
NCT00003773|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-06-02|2004-06-03|Estimate|||||||2014-05-20|2014-05-22|Estimate|February 1999||1999-02-28|May 2014|2014-05-31|August 2001|Actual|2001-08-31|July 2000|Actual|2000-07-31||Interventional|||IM-862 in Treating Patients With Recurrent Ovarian Cancer|Phase I Study of Escalating Doses of IM-862 in Patients With Ovarian Cancer|Completed||Phase 1|43|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:09:23.355344|2018-06-01 05:09:23.355344
NCT00003758|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-06-02|2004-06-03|Estimate|||||||2009-02-06|2009-02-09|Estimate|December 1998||1998-12-31|January 2001|2001-01-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia|Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:23.425158|2018-06-01 05:09:23.425158
NCT00003755|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-06-02|2004-06-03|Estimate|||||||2013-06-24|2013-06-25|Estimate|October 1998||1998-10-31|June 2013|2013-06-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor|Phase I Study of R031-7453, a Novell Cell Cycle Inhibitor, Administered as Escalating Oral Doses in Adults With Solid Tumors: 4-Day Schedule|Completed||Phase 1|40|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:09:23.525053|2018-06-01 05:09:23.525053
NCT00003740|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-06-02|2004-06-03|Estimate|||||||2013-06-20|2013-06-21|Estimate|October 1998||1998-10-31|June 2013|2013-06-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Trastuzumab in Treating Patients With Prostate Cancer|Phase II Study of Herceptin (Recombinant Humanized Anti-p185HER2 Monoclonal Antibody) for the Treatment of Androgen Independent Prostate Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:09:23.582415|2018-06-01 05:09:23.582415
NCT00003443|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-06-02|2004-06-03|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 1998||1998-07-31|June 2013|2013-06-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|A Phase II Trial of Bryostatin-1 In Patients With Metastatic or Recurrent Squamos Cell Carcinoma of the Head and Neck|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:09:23.652142|2018-06-01 05:09:23.652142
NCT00003401|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-28|2004-06-02|2004-06-03|Estimate|||||||2017-03-28|2017-03-30|Actual|January 1999|Actual|1999-01-31|March 2017|2017-03-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma|Autologous Transplantation With Gemcitabine and High Dose BCNU Plus Melphalan Followed by Consolidation With DCEP Plus Gemcitabine and Taxol/Cisplatin in Patients With Multiple Myeloma and >12 Months of Standard Therapy|Completed||Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:09:23.732664|2018-06-01 05:09:23.732664
NCT00003399|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-28|2004-06-02|2004-06-03|Estimate|||||||2017-03-28|2017-03-30|Actual|September 1998|Actual|1998-09-30|March 2017|2017-03-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma|Autologous Transplantation With High Dose BCNU and Melphalan Followed by Consolidation With DCEP and Taxol/Cisplatin in Patients With Multiple Myeloma and < or = 12 Months of Standard Therapy|Completed||Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:09:23.83483|2018-06-01 05:09:23.83483
NCT00003396|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-09-23|2004-06-02|2004-06-03|Estimate|||||||2009-09-23|2009-09-24|Estimate|September 1998||1998-09-30|September 2009|2009-09-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Evaluation of Allogeneic Peripheral Blood Stem Cell Transplants From a Related Donor Without Graft-Versus-Host Prophylaxis in Patients With High Risk of Relapse|Completed||Phase 2|42|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 05:09:23.941385|2018-06-01 05:09:23.941385
NCT00003293|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-10|2004-06-02|2004-06-03|Estimate|||||||2012-09-10|2012-09-11|Estimate|February 1998||1998-02-28|September 2012|2012-09-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme|A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 05:09:24.062774|2018-06-01 05:09:24.062774
NCT00003249|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-06|2004-06-02|2004-06-03|Estimate|||||||2013-02-06|2013-02-07|Estimate|May 1998||1998-05-31|February 2013|2013-02-28||||December 2001|Actual|2001-12-31||Interventional|||Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers|A Phase I Investigation of Carboxyamido-triazole (CAI) Modulated by Ketoconozole In Patients With Advanced Malignancies|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:09:24.225084|2018-06-01 05:09:24.225084
NCT00004113|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-18|2004-05-20|2004-05-21|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 1999||1999-06-30|June 2013|2013-06-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Temozolomide in Treating Patients With Recurrent Malignant Glioma|A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:07.725592|2018-06-01 05:10:07.725592
NCT00003231|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2004-06-02|2004-06-03|Estimate|||||||2012-05-14|2012-05-15|Estimate|April 1997||1997-04-30|May 2012|2012-05-31|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer|Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2)|Completed||Phase 2|40|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:09:24.371941|2018-06-01 05:09:24.371941
NCT00083720|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-28|2009-04-16||2011-05-19|2004-06-01|2004-06-02|Estimate|2009-09-23|2009-10-23|Estimate||||2011-05-19|2011-05-25|Estimate|October 2004||2004-10-31|May 2011|2011-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy|A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Refractory, EGFR-Negative Metastatic Colorectal Carcinoma|Completed||Phase 2|87|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 05:09:24.488378|2018-06-01 05:09:24.488378
NCT00083733|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-29|||2017-06-30|2004-05-28|2004-05-31|Estimate|||||||2017-06-30|2017-07-02|Actual|May 27, 2004||2004-05-27|November 17, 2010|2010-11-17|November 17, 2010||2010-11-17|||||Observational|||Genetic and Protein Profiling in Normal and Cancerous Breast Tissue|Procurement of Normal Breast Tissue and Metastatic Breast Cancer Tissue for Molecular Profiling|Completed|||216|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:24.849348|2018-06-01 05:09:24.849348
NCT00083707|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-27|||2010-07-01|2004-05-28|2004-05-31|Estimate|||||||2010-07-01|2010-07-05|Estimate|January 1999||1999-01-31|July 2010|2010-07-31|February 2003||2003-02-28|||||Interventional|||Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia|UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia|Completed||Phase 2|40||University of Arkansas|||||||||||||||||||2018-06-01 05:09:24.915687|2018-06-01 05:09:24.915687
NCT00083694|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-27|||2010-07-01|2004-05-28|2004-05-31|Estimate|||||||2010-07-01|2010-07-02|Estimate|August 1998||1998-08-31|July 2010|2010-07-31|May 2005||2005-05-31|||||Interventional|||Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia|UARK, 98-032, Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia|Completed||Phase 2|25||University of Arkansas|||||||||||||||||||2018-06-01 05:09:24.981441|2018-06-01 05:09:24.981441
NCT00083681|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-27|||2010-07-01|2004-05-27|2004-05-28|Estimate|||||||2010-07-01|2010-07-02|Estimate|June 1998||1998-06-30|July 2010|2010-07-31|May 2005||2005-05-31|||||Interventional|||DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse|UARK 98-018, A Randomized Phase II Trial of DCEP or DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse in Patients With Multiple Myeloma|Completed||Phase 2|180||University of Arkansas|||||||||||||||||||2018-06-01 05:09:25.139629|2018-06-01 05:09:25.139629
NCT00083668|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-27|||2011-06-06|2004-05-27|2004-05-28|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2004||2004-04-30|March 2010|2010-03-31|May 2005|Actual|2005-05-31|||||Interventional|||Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (ER) Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia|Completed||Phase 3|619|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:09:25.315681|2018-06-01 05:09:25.315681
NCT00083616|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-26|2010-08-06||2013-12-10|2004-05-27|2004-05-28|Estimate|2011-06-30|2011-07-29|Estimate||||2013-12-10|2014-01-10|Estimate|March 2004||2004-03-31|December 2013|2013-12-31|December 2008|Actual|2008-12-31|May 2007|Actual|2007-05-31||Interventional|||Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy|A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy|Completed||Phase 2|185|Actual|Amgen||1|||f||||t||||||||||2018-06-01 05:09:25.637337|2018-06-01 05:09:25.637337
NCT00083564|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-25|||2009-03-30|2004-05-27|2004-05-28|Estimate|||||||2009-03-30|2009-03-31|Estimate|March 2004||2004-03-31|March 2009|2009-03-31||||||||Interventional|||Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma|A Randomized Multicenter Study to Compare the Safety and Efficacy of 166Ho-DOTMP Plus Melphalan to Melphalan Alone as Conditioning for Autologous Peripheral Blood Stem Cell Transplant in Subjects With Primary Refractory Multiple Myeloma|Terminated||Phase 3|240||Poniard Pharmaceuticals||||For business reasons|||||||||||||||2018-06-01 05:09:26.058048|2018-06-01 05:09:26.058048
NCT00083642|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-27|||2017-06-30|2004-05-26|2004-05-27|Estimate|||||||2017-06-30|2017-07-02|Actual|May 25, 2004||2004-05-25|June 13, 2008|2008-06-13|June 13, 2008||2008-06-13|||||Observational|||Observational Learning in Stroke Patients|Neural Correlates of Observational Motor Learning in Chronic Stroke Patients|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:26.187677|2018-06-01 05:09:26.187677
NCT00083629|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-27|||2008-03-03|2004-05-26|2004-05-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2004||2004-05-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Use of [18F]FECNT in Positron Emission Tomography|PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Dopamine Transporter Ligand [18F]FECNT|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:26.369086|2018-06-01 05:09:26.369086
NCT00083603|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-26|||2013-08-21|2004-05-26|2004-05-27|Estimate|||||||2013-08-21|2013-08-22|Estimate|September 2004||2004-09-30|August 2013|2013-08-31|August 2007|Actual|2007-08-31|||||Interventional|||Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults|A Phase I Trial to Evaluate the Safety and Immunogenicity of rMVA-HIV (rMVA-HIV Env/Gag + rMVA-HIV Tat/Rev/Nef-RT) and rFPV-HIV (rFPV-HIV Env/Gag + rFPV-HIV Tat/Rev/Nef-RT) Vaccines, Alone or in Combination, in Healthy, Vaccinia Naive HIV-1 Negative Participants|Completed||Phase 1|150|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||16|||f||||||||||||||2018-06-01 05:09:26.602867|2018-06-01 05:09:26.602867
NCT00083590|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-26|||2008-02-19|2004-05-26|2004-05-27|Estimate|||||||2008-02-19|2008-02-21|Estimate|April 2004||2004-04-30|February 2008|2008-02-29|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Huperzine A in Alzheimer's Disease|A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function|Completed||Phase 2|150|Anticipated|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:09:26.992679|2018-06-01 05:09:26.992679
NCT00083577|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-25|||2010-07-01|2004-05-26|2004-05-27|Estimate|||||||2010-07-01|2010-07-02|Estimate|February 1998||1998-02-28|July 2010|2010-07-31|May 2005||2005-05-31|||||Interventional|||Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma|UARK 98-003, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Multiple Myeloma|Completed||Phase 2|250||University of Arkansas|||||||||||||||||||2018-06-01 05:09:27.216691|2018-06-01 05:09:27.216691
NCT00083551|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-25|2015-08-24||2015-10-21|2004-05-26|2004-05-27|Estimate|2015-08-24|2015-09-22|Estimate||||2015-10-21|2015-11-23|Estimate|August 1998||1998-08-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy|UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy|Completed||Phase 3|668|Actual|University of Arkansas||2|||f||||t||||||||||2018-06-01 05:09:27.379525|2018-06-01 05:09:27.379525
NCT00083538|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-25|||2010-07-06|2004-05-26|2004-05-27|Estimate|||||||2010-07-06|2010-07-07|Estimate|February 2001||2001-02-28|July 2010|2010-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally|UARK 2000-46, A Phase II Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally in Multiple Myeloma Patients|Completed||Phase 2|40|Actual|University of Arkansas|||||f||||f||||||||||2018-06-01 05:09:30.167037|2018-06-01 05:09:30.167037
NCT00083486|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-24|||2011-04-25|2004-05-26|2004-05-27|Estimate|||||||2011-04-25|2011-04-27|Estimate|February 2004||2004-02-29|April 2011|2011-04-30|October 2004|Actual|2004-10-31|||||Interventional|||Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy||Terminated||Phase 3|||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:09:30.482681|2018-06-01 05:09:30.482681
NCT00003160|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-04-19|2004-05-26|2004-05-27|Estimate|||||||2011-04-19|2011-04-20|Estimate|September 1997||1997-09-30|January 2001|2001-01-31||||||||Interventional|||Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum|A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Patients With Taxol/Platinum-Refractory Stage III and IV Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:30.743614|2018-06-01 05:09:30.743614
NCT00003079|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-02-15|2004-05-26|2004-05-27|Estimate|||||||2010-02-15|2010-02-17|Estimate|September 1997||1997-09-30|February 2010|2010-02-28|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma|Phase I Study of Bryostatin 1 (NSC 339555) and High-Dose 1-Beta-D-Arabinofuranosylcytosine (HiDAC) in Patients With Refractory Leukemia|Completed||Phase 1|30|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 05:09:31.045688|2018-06-01 05:09:31.045688
NCT00003075|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-05-26|2004-05-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 1992||1992-09-30|July 2012|2012-07-31|May 2001|Actual|2001-05-31|September 2000|Actual|2000-09-30||Interventional|||Fenretinide in Treating Patients With Cervical Neoplasia|A Randomized Double-Blind Study of N-(4-hydroxyphenyl) Retinamide (4-HPR) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3|Completed||Phase 3|39|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:09:31.287557|2018-06-01 05:09:31.287557
NCT00003031|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-05-26|2004-05-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|June 1997||1997-06-30|June 2012|2012-06-30||||October 2000|Actual|2000-10-31||Interventional|||Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis|An Open Randomised Comparative Multicentre Study of the Efficacy, Safety and Toleration of Voriconazole Versus Amphotericin-B in the Treatment of Acute Invasive Aspergillosis in Immunocompromised Patients|Completed||Phase 3|212|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:09:31.674554|2018-06-01 05:09:31.674554
NCT00003015|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-05-26|2004-05-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1997||1997-01-31|January 2001|2001-01-31||||||||Interventional|||Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma|Ultimate Low Grade Glioma Study|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:32.413797|2018-06-01 05:09:32.413797
NCT00083525|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-25|||2008-01-21|2004-05-25|2004-05-26|Estimate|||||||2008-01-21|2008-01-24|Estimate|May 2004||2004-05-31|January 2008|2008-01-31||||||||Interventional|||Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies||Completed||Phase 1|33|Anticipated|Wilex|||||||||||||||||||2018-06-01 05:09:32.697946|2018-06-01 05:09:32.697946
NCT00083473|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-24|||2005-08-26|2004-05-25|2004-05-26|Estimate|||||||2005-08-26|2005-08-30|Estimate|May 2004||2004-05-31|August 2005|2005-08-31|April 2005||2005-04-30|||||Interventional|||A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia|A Pilot Study of Pivanex, a Histone Deacetylase Inhibitor, in Patients With Chronic Lymphocytic Leukemia|Terminated||Phase 2|28||Titan Pharmaceuticals|||||||||||||||||||2018-06-01 05:09:32.973757|2018-06-01 05:09:32.973757
NCT00083460|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-24|||2010-07-30|2004-05-25|2004-05-26|Estimate|||||||2010-07-30|2010-08-02|Estimate|December 2001||2001-12-31|July 2010|2010-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Study of Combination PS-341 and Thalidomide in Multiple Myeloma|UARK 2001-37, A Phase I Exploratory Study of Combination PS-341 and Thalidomide in Refractory Multiple Myeloma|Completed||Phase 1|86|Actual|University of Arkansas||2|||f||||t||||||||||2018-06-01 05:09:33.258757|2018-06-01 05:09:33.258757
NCT00083447|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-24|||2009-01-06|2004-05-25|2004-05-26|Estimate|||||||2009-01-06|2009-01-07|Estimate|May 2004||2004-05-31|January 2008|2008-01-31|June 2007|Anticipated|2007-06-30|March 2006|Actual|2006-03-31||Interventional|||Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme|A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme|Withdrawn||Phase 3|323||Xenova Biomedix||||This study has been withdrawn because the drug would not meet trial criteria for efficacy|f||||||||||||||2018-06-01 05:09:36.421051|2018-06-01 05:09:36.421051
NCT00083434|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-24|||2011-04-25|2004-05-25|2004-05-26|Estimate|||||||2011-04-25|2011-04-27|Estimate|February 2004||2004-02-29|April 2011|2011-04-30|October 2004|Actual|2004-10-31|||||Interventional|||Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy||Terminated||Phase 3|||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||This study was stopped because of an inadequate rate of enrollment.|||||t||||||||||2018-06-01 05:09:36.866628|2018-06-01 05:09:36.866628
NCT00006877|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2014-01-06|2004-05-25|2004-05-26|Estimate|||||||2014-01-06|2014-01-08|Estimate|July 2000||2000-07-31|February 2001|2001-02-28|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer|A Phase II Study Of Temozolomide In The Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|30|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:09:37.178947|2018-06-01 05:09:37.178947
NCT00006358|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2008-07-23|2004-05-25|2004-05-26|Estimate|||||||2008-07-23|2008-07-24|Estimate|May 2000||2000-05-31|October 2006|2006-10-31||||||||Interventional|||Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor|Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:37.529798|2018-06-01 05:09:37.529798
NCT00006343|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-12-30|2004-05-25|2004-05-26|Estimate|||||||2012-12-30|2013-01-03|Estimate|June 2000||2000-06-30|December 2012|2012-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia|A Phase III Study of STI571 Versus Interferon-a (IFN-a) Combined With Cytarabine (Ara-C) in Patients With Newly Diagnosed Previously Untreated Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Completed||Phase 3|||Novartis|||||f||||f||||||||||2018-06-01 05:09:37.846371|2018-06-01 05:09:37.846371
NCT00006222|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-05-31|2004-05-25|2004-05-26|Estimate|||||||2013-05-31|2013-06-03|Estimate|September 2000||2000-09-30|April 2001|2001-04-30|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase I Trial of EMD 121974 in Patients With HIV Related Kaposi's Sarcoma|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:09:38.302761|2018-06-01 05:09:38.302761
NCT00006212|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-09-16|2004-05-25|2004-05-26|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 1999||1999-11-30|February 2001|2001-02-28||||||||Interventional|||Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer|Phase I Study of Interstitial Colloidal 32P Integrated With External Radiation Therapy and Chemotherapy in the Treatment of Non-Resectable or Medically Inoperable Non-Small Cell Carcinoma of the Lung|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:38.874644|2018-06-01 05:09:38.874644
NCT00006083|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2015-10-01|2004-05-25|2004-05-26|Estimate|||||||2015-10-01|2015-10-02|Estimate|April 2000||2000-04-30|July 2012|2012-07-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter|A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters|Completed||Phase 3|||Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:09:39.108957|2018-06-01 05:09:39.108957
NCT00006079|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-07-27|2004-05-25|2004-05-26|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 2000||2000-06-30|July 2012|2012-07-31|April 2004|Actual|2004-04-30|February 2003|Actual|2003-02-28||Interventional|||Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia|A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3|Completed||Phase 2|150|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:09:39.360205|2018-06-01 05:09:39.360205
NCT00006001|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-31|2004-05-25|2004-05-26|Estimate|||||||2013-05-31|2013-06-03|Estimate|August 2000||2000-08-31|February 2009|2009-02-28|August 2009|Actual|2009-08-31|February 2007|Actual|2007-02-28||Interventional|||SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer|Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced Colorectal Cancer|Terminated||Phase 2|37|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:09:39.52559|2018-06-01 05:09:39.52559
NCT00005942|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-22|2004-05-25|2004-05-26|Estimate|||||||2013-01-22|2013-01-23|Estimate|March 2000||2000-03-31|January 2013|2013-01-31||||December 2000|Actual|2000-12-31||Interventional|||Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy|Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy|Completed||Phase 1/Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:09:39.779538|2018-06-01 05:09:39.779538
NCT00005939|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-11-05|2004-05-25|2004-05-26|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 1999||1999-11-30|February 2001|2001-02-28||||||||Interventional|||Brachytherapy in Treating Patients With Recurrent Prostate Cancer|Phase I/II Study of Interstitial Colloidal 32P for Locally Recurrent Prostate Cancer Failing Radiation|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:40.083723|2018-06-01 05:09:40.083723
NCT00005841|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2014-05-20|2004-05-25|2004-05-26|Estimate|||||||2014-05-20|2014-05-22|Estimate|June 2000||2000-06-30|May 2014|2014-05-31|October 2002|Actual|2002-10-31|December 2000|Actual|2000-12-31||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase I Trial of a Vaccine Combining Tyrosinase/GP100/Mart-1 Peptides Emulsified With Montanide ISA 51 With ProGP for Patients With Resected Stages III and IV Melanoma|Terminated||Phase 1|15|Actual|University of Southern California||||Toxicity/Side Effects|f||||t||||||||||2018-06-01 05:09:40.25302|2018-06-01 05:09:40.25302
NCT00005645|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2014-01-03|2004-05-25|2004-05-26|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 1999||1999-05-31|February 2001|2001-02-28||||||||Interventional|||ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment|Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:40.404461|2018-06-01 05:09:40.404461
NCT00005640|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-09-24|2004-05-25|2004-05-26|Estimate|||||||2012-09-24|2012-09-25|Estimate|June 1999||1999-06-30|September 2012|2012-09-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer|Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer: A Feasibility Study|Completed||N/A|17|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:09:40.567302|2018-06-01 05:09:40.567302
NCT00005636|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-17|2004-05-25|2004-05-26|Estimate|||||||2013-06-17|2013-06-19|Estimate|November 1999||1999-11-30|June 2013|2013-06-30|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery|A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma|Completed||Phase 3|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:09:40.759932|2018-06-01 05:09:40.759932
NCT00005578|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2014-07-23|2004-05-25|2004-05-26|Estimate|||||||2014-07-23|2014-07-24|Estimate|March 1997||1997-03-31|July 2014|2014-07-31|June 2008|Actual|2008-06-30|October 2004|Actual|2004-10-31||Interventional|||Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease|Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study|Completed||Phase 3|219|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:09:40.966974|2018-06-01 05:09:40.966974
NCT00005088|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-11-18|2004-05-25|2004-05-26|Estimate|||||||2013-11-18|2013-11-19|Estimate|April 2000||2000-04-30|November 2013|2013-11-30||||January 2002|Actual|2002-01-31||Interventional|||Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer|A Phase II Trial of Concomitant Boost Radiation and Concurrent Cisplatin for Advanced Head and Neck Carcinomas|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:09:41.535232|2018-06-01 05:09:41.535232
NCT00005059|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2016-07-12|2004-05-25|2004-05-26|Estimate|||||||2016-07-12|2016-07-14|Estimate|January 2000||2000-01-31|July 2016|2016-07-31|April 2006|Actual|2006-04-30|July 2003|Actual|2003-07-31||Interventional|||Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer|A Phase II Study of Carboplatin and Paclitaxel in Elderly Patients With Metastatic or Recurrent Unresectable Non-Small Cell Lung Cancer|Completed||Phase 2|51|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:09:43.98338|2018-06-01 05:09:43.98338
NCT00002923|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-04-24|2004-05-25|2004-05-26|Estimate|||||||2014-04-24|2014-04-25|Estimate|May 1997||1997-05-31|April 2014|2014-04-30|October 2000|Actual|2000-10-31|January 2000|Actual|2000-01-31||Interventional|||KRN5500 in Treating Patients With Metastatic Solid Tumors|Phase I Evaluation of KRN5500 (NSC650426)|Completed||Phase 1|27|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 05:09:44.322624|2018-06-01 05:09:44.322624
NCT00002917|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-14|2004-05-25|2004-05-26|Estimate|||||||2013-05-14|2013-05-15|Estimate|November 1996||1996-11-30|January 2001|2001-01-31|May 2004|Actual|2004-05-31|||||Interventional|||Paclitaxel in Treating Patients With Early-Stage Bladder Cancer|A PHASE I/II INSTITUTIONAL STUDY OF INTRAVESICAL TAXOL (PACLITAXEL) INSTILLATION FOR THE TREATMENT OF SUPERFICIAL BLADDER CANCER|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:44.488972|2018-06-01 05:09:44.488972
NCT00002911|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-05-25|2004-05-26|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 1996||1996-12-31|May 2007|2007-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Marimastat in Treating Patients With Stage III Non-small Cell Lung Cancer|A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MARIMASTAT IN PATIENTS WITH MINIMAL DISEASE STAGE III NON-SMALL CELL LUNG CANCER|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:44.669938|2018-06-01 05:09:44.669938
NCT00002829|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-26|2004-05-25|2004-05-26|Estimate|||||||2012-07-26|2012-07-30|Estimate|February 1994||1994-02-28|July 2012|2012-07-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Bone Marrow Transplantation in Treating Patients With Lymphoma|Autologous and Allogeneic Bone Marrow Transplantation for Low Grade Lymphoma|Completed||Phase 2|45|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:09:45.12517|2018-06-01 05:09:45.12517
NCT00002827|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-05-25|2004-05-26|Estimate|||||||2013-08-22|2013-08-26|Estimate|October 1996||1996-10-31|August 2013|2013-08-31|June 2008|Actual|2008-06-30|October 2004|Actual|2004-10-31||Interventional|||Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease|RESPONSE DEPENDENT TREATMENT OF STAGES IA, IIA AND IIIA HODGKIN'S DISEASE WITH DBVE AND LOW DOSE INVOLVED FIELD IRRADIATION WITH OR WITHOUT ZINECARD: A PEDIATRIC ONCOLOGY GROUP PHASE III STUDY|Completed||Phase 3|294|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:09:45.369758|2018-06-01 05:09:45.369758
NCT00002819|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-10|2004-05-25|2004-05-26|Estimate|||||||2013-04-10|2013-04-11|Estimate|November 1996||1996-11-30|May 2007|2007-05-31||||February 2000|Actual|2000-02-29||Interventional|||Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer|A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY|Terminated||Phase 3|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:09:45.760148|2018-06-01 05:09:45.760148
NCT00002806|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-05-25|2004-05-26|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 1996||1996-07-31|July 2016|2016-07-31|July 2004|Actual|2004-07-31|January 2003|Actual|2003-01-31||Interventional|||Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma|PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS|Completed||Phase 2|43|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:09:46.160087|2018-06-01 05:09:46.160087
NCT00002721|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-05-25|2004-05-26|Estimate|||||||2014-05-20|2014-05-21|Estimate|March 1995||1995-03-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|A PHASE I TRIAL OF ESTRAMUSTINE PHOSPHATE AND DOXORUBICIN IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER|Completed||Phase 1|18|Actual|University of New Mexico||1|||f||||f||||||||||2018-06-01 05:09:46.37538|2018-06-01 05:09:46.37538
NCT00002639|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-05-25|2004-05-26|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 1995||1995-07-31|February 2001|2001-02-28|May 2004|Actual|2004-05-31|||||Interventional|||Suramin in Treating Patients With Recurrent Primary Brain Tumors|ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:46.546414|2018-06-01 05:09:46.546414
NCT00002602|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-03-26|2004-05-25|2004-05-26|Estimate|||||||2015-03-26|2015-03-30|Estimate|May 1994||1994-05-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|March 2004|Actual|2004-03-31||Interventional|||Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer|A PHASE I/II DOSE ESCALATION STUDY USING THREE DIMENSIONAL CONFORMAL RADIATION THERAPY FOR ADENOCARCINOMA OF THE PROSTATE|Completed||Phase 1/Phase 2|1084|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-06-01 05:09:46.747727|2018-06-01 05:09:46.747727
NCT00002555|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-05-25|2004-05-26|Estimate|||||||2012-06-29|2012-07-02|Estimate|February 1994||1994-02-28|June 2012|2012-06-30||||October 2000|Actual|2000-10-31||Interventional|||High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer|A PHASE III RANDOMIZED STUDY ON POSTOPERATIVE RADIO- AND CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED HEAD AND NECK CARCINOMAS|Completed||Phase 3|338|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:09:47.487463|2018-06-01 05:09:47.487463
NCT00002477|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-05-25|2004-05-26|Estimate|||||||2013-12-17|2013-12-18|Estimate|April 1991||1991-04-30|July 2007|2007-07-31||||||||Interventional|||Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer|Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:47.713093|2018-06-01 05:09:47.713093
NCT00083512|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-25|||2017-10-18|2004-05-24|2004-05-25|Estimate|||||||2017-10-18|2017-10-19|Actual|May 24, 2004||2004-05-24|August 25, 2017|2017-08-25||||||||Observational|||Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme|Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:47.885559|2018-06-01 05:09:47.885559
NCT00083499|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-25|||2018-03-27|2004-05-24|2004-05-25|Estimate|||||||2018-03-27|2018-03-29|Actual|May 24, 2004||2004-05-24|February 15, 2018|2018-02-15||||||||Observational|||Mutations in Genes Associated With Pentalogy of Cantrell|Mutations in Genes Associated With Pentalogy of Cantrell|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:48.046042|2018-06-01 05:09:48.046042
NCT00083408|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-24|||2010-07-01|2004-05-24|2004-05-25|Estimate|||||||2010-07-01|2010-07-05|Estimate|March 1998||1998-03-31|July 2010|2010-07-31|May 2005||2005-05-31|||||Interventional|||Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide|UARK 99-016, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Multiple Myeloma and Poor Hematopoietic Stem Cell Reserve|Completed||Phase 2|20||University of Arkansas|||||||||||||||||||2018-06-01 05:09:48.249408|2018-06-01 05:09:48.249408
NCT00004881|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-06-25|2004-05-24|2004-05-25|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2000||2000-04-30|February 2001|2001-02-28|May 2004|Actual|2004-05-31|||||Interventional|||Vaccine Therapy in Treating Patients With Advanced Cancer|Phase I Bridging Trial of TG4010 as Antigen-Specific Immunotherapy in Patients With MUC-1 Positive Advanced Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:48.406972|2018-06-01 05:09:48.406972
NCT00004200|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2012-08-07|2004-05-24|2004-05-25|Estimate|||||||2012-08-07|2012-08-08|Estimate|October 1999||1999-10-31|August 2012|2012-08-31||||January 2002|Actual|2002-01-31||Interventional|||Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in Combination With Temozolomide Following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|||Pfizer|||||f||||||||||||||2018-06-01 05:09:48.515036|2018-06-01 05:09:48.515036
NCT00004190|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2016-07-12|2004-05-24|2004-05-25|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 1999||1999-10-31|July 2016|2016-07-31|June 2003|Actual|2003-06-30|April 2003|Actual|2003-04-30||Interventional|||Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer|A Phase I(Limited)/Phase II Study of Oxaliplatin (OXAL) and Gemcitabine (GEMZAR) in Patients With Metastatic Pancreatic Carcinoma|Completed||Phase 2|59|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:09:48.630765|2018-06-01 05:09:48.630765
NCT00004176|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-05-14|2004-05-24|2004-05-25|Estimate|||||||2013-05-14|2013-05-16|Estimate|October 1998||1998-10-31|May 2013|2013-05-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|A Phase II Evaluation of Ethyol as an Esophageal Mucosal Protectant in the Treatment of Limited Disease Small Cell Lung Cancer With Chemotherapy and Twice-Daily Radiation|Completed||Phase 2|34|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-06-01 05:09:48.850866|2018-06-01 05:09:48.850866
NCT00004139|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2016-07-19|2004-05-24|2004-05-25|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 1999||1999-09-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|July 2004|Actual|2004-07-31||Interventional|||Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Phase II Randomized Trial of Gemcitabine/Docetaxel and Gemcitabine/Irinotecan in Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 2|80|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:09:49.113347|2018-06-01 05:09:49.113347
NCT00004112|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2018-01-13|2004-05-24|2004-05-25|Estimate|||||||2018-01-13|2018-01-17|Actual|September 1999||1999-09-30|January 2018|2018-01-31|March 2003|Actual|2003-03-31|December 2000|Actual|2000-12-31||Interventional|||Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma|A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 3|||University of Nebraska|||||f||||f||||||||||2018-06-01 05:09:49.449908|2018-06-01 05:09:49.449908
NCT00004105|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-03-25|2004-05-24|2004-05-25|Estimate|||||||2011-03-25|2011-03-28|Estimate|September 1998||1998-09-30|March 2011|2011-03-31||||April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I/II Study of Paclitaxel, Estramustine Phosphate, and Vinorelbine (PaclEVin)|Completed||Phase 1/Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:09:49.74696|2018-06-01 05:09:49.74696
NCT00004061|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-25|2004-05-24|2004-05-25|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 1999||1999-05-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|May 2003|Actual|2003-05-31||Interventional|||Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer|A Randomized Double-Blind, Placebo-Controlled Trial of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Patients With Hematologic Malignancies Undergoing Total Body Irradiation (TBI) and High-Dose Chemotherapy With Autologous Peripheral Blood|Completed||Phase 2|111|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:50.004515|2018-06-01 05:09:50.004515
NCT00004030|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-03-22|2004-05-24|2004-05-25|Estimate|||||||2011-03-22|2011-03-24|Estimate|March 1996||1996-03-31|January 2001|2001-01-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin|A Phase I/II Study of the Pharmacokinetics, Tolerability and Safety of Administration of VX-853 to Patients Receiving Single Agent Therapy With Doxorubicin HCI|Completed||Phase 1/Phase 2|45|Anticipated|Georgetown University|||||f||||f||||||||||2018-06-01 05:09:50.273922|2018-06-01 05:09:50.273922
NCT00004012|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-05-24|2004-05-25|Estimate|||||||2013-06-20|2013-06-24|Estimate|December 1998||1998-12-31|June 2013|2013-06-30|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Oral Capecitabine in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:09:50.506048|2018-06-01 05:09:50.506048
NCT00003985|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-05-24|2004-05-25|Estimate|||||||2012-07-10|2012-07-11|Estimate|September 1998||1998-09-30|July 2012|2012-07-31||||||||Interventional|||KRN7000 in Treating Patients With Solid Tumors|Phase I Study of KRN7000 in Patients With Solid Tumor Treated With a Weekly Intravenous Administration Schedule|Withdrawn||Phase 1|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:09:50.72108|2018-06-01 05:09:50.72108
NCT00003984|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-05-24|2004-05-25|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 1999||1999-02-28|July 2012|2012-07-31||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome|Phase II Trial With a Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients With High Risk Primary Myelodysplastic Syndromes|Withdrawn||Phase 2|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:09:51.022017|2018-06-01 05:09:51.022017
NCT00003982|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-05-24|2004-05-25|Estimate|||||||2012-07-10|2012-07-11|Estimate|June 1997||1997-06-30|July 2012|2012-07-31||||||||Interventional|||MEN-10755 in Treating Patients With Solid Tumors|Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every Week for 3 Consecutive Weeks, Followed by One Week's Rest|Completed||Phase 1|30|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:09:51.341424|2018-06-01 05:09:51.341424
NCT00003980|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-05-24|2004-05-25|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 1999||1999-02-28|July 2012|2012-07-31||||||||Interventional|||BIBX 1382 in Treating Patients With Solid Tumors|Phase I and Pharmacokinetics Study to Determine the Safety of BIBX 1382 in Patients With a Solid Tumor on a Continuous Daily Oral Administration Schedule and After Single Oral and Intravenous Doses|Suspended||Phase 1|80|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:09:51.848715|2018-06-01 05:09:51.848715
NCT00003944|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-16|2004-05-24|2004-05-25|Estimate|||||||2013-04-16|2013-04-17|Estimate|August 1998||1998-08-31|April 2013|2013-04-30|February 2003|Actual|2003-02-28|December 1999|Actual|1999-12-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Completed||Phase 2|3|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:09:52.120854|2018-06-01 05:09:52.120854
NCT00003846|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-25|2004-05-24|2004-05-25|Estimate|||||||2014-07-25|2014-07-28|Estimate|July 1999||1999-07-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|October 2004|Actual|2004-10-31||Interventional|||Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors|Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support|Completed||Phase 2|25|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:09:52.38459|2018-06-01 05:09:52.38459
NCT00003752|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-29|2004-05-24|2004-05-25|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 1998||1998-10-31|May 2007|2007-05-31|March 2003|Actual|2003-03-31|||||Interventional|||Bexarotene in Treating Patients With Metastatic Breast Cancer|A Multicenter Phase II Evaluation of Targretin (Bexarotene) Capsules in Patients With Advanced Breast Cancer|Completed||Phase 2|180|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:52.770275|2018-06-01 05:09:52.770275
NCT00003669|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-06|2004-05-24|2004-05-25|Estimate|||||||2012-06-06|2012-06-07|Estimate|November 1998||1998-11-30|April 2008|2008-04-30|April 2001|Actual|2001-04-30|||||Interventional|||Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer|Phase II Nonrandomized Study of LY353381-HC1 in Patients With Recurrent or Advanced Endometrial Cancer|Completed||Phase 2|||Eli Lilly and Company|||||f||||||||||||||2018-06-01 05:09:52.96811|2018-06-01 05:09:52.96811
NCT00003580|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-05-24|2004-05-25|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 1998||1998-06-30|May 2006|2006-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer|Phase II Study - Efficacy of Amifostine in Alleviating Toxicity Associated With Targeted Supradose Cisplatin and Concomitant Radiation Therapy (RADPLAT) in Head and Neck Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:53.119259|2018-06-01 05:09:53.119259
NCT00083395|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-22|||2008-03-03|2004-05-21|2004-05-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2004||2004-05-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Observational|||Isoproterenol Challenge to Detect Arrhythmogenic Right Ventricular Cardiomyopathy|Utility of Isoproterenol Challenge Test to Detect Disease in Patients With Incomplete Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy|Completed|||160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:09:53.265675|2018-06-01 05:09:53.265675
NCT00083382|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-21|2015-06-05||2015-06-05|2004-05-21|2004-05-24|Estimate|2015-06-05|2015-06-24|Estimate||||2015-06-05|2015-06-24|Estimate|December 1998||1998-12-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide|UARK 98-036, A Phase II Trial of Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide in Patients With Smoldering/Indolent Myeloma|Completed||Phase 2|83|Actual|University of Arkansas||1|||f||||f||||||||||2018-06-01 05:09:53.488717|2018-06-01 05:09:53.488717
NCT00083369|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-21|||2013-11-16|2004-05-21|2004-05-24|Estimate|||||||2013-11-16|2013-11-19|Estimate|September 2002||2002-09-30|November 2013|2013-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Genetic and Environmental Determinants of Triglycerides (GOLDN)||Completed|||1327|Actual|University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 05:09:54.46033|2018-06-01 05:09:54.46033
NCT00083343|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-20|||2017-02-20|2004-05-21|2004-05-24|Estimate|||||||2017-02-20|2017-02-23|Actual|May 2004||2004-05-31|February 2017|2017-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)|A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults With Invasive Candida Infections (Excluding Patients With Candidemia as the Sole Site of Infection)|Completed||Phase 2|48|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:09:54.669687|2018-06-01 05:09:54.669687
NCT00008229|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2010-09-17|2004-05-21|2004-05-24|Estimate|||||||2010-09-17|2010-09-21|Estimate|August 2000||2000-08-31|September 2010|2010-09-30|September 2001|Actual|2001-09-30|||||Interventional|||Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma|Completed||Phase 3|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:09:54.940172|2018-06-01 05:09:54.940172
NCT00008073|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-12-18|2004-05-21|2004-05-24|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1996||1996-01-31|December 2013|2013-12-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Octreotide and Doxorubicin in Treating Patients With Advanced Cancer|Phase I Study Of Octreotide Acetate (Sandostatin) (SMS) As A Biomodulator Of Doxorubicin (DOX)|Completed||Phase 1|||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:09:55.223415|2018-06-01 05:09:55.223415
NCT00006344|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2015-05-15|2004-05-21|2004-05-24|Estimate|||||||2015-05-15|2015-05-19|Estimate|May 2000||2000-05-31|May 2015|2015-05-31|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer|A Randomized, Phase III Dose Response Study of Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Lung|Withdrawn||Phase 3|0|Actual|Virginia Commonwealth University||||PI left institution|f||||f||||||||||2018-06-01 05:09:55.475275|2018-06-01 05:09:55.475275
NCT00006269|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2012-05-24|2004-05-21|2004-05-24|Estimate|||||||2012-05-24|2012-05-25|Estimate|December 1999||1999-12-31|May 2012|2012-05-31||||December 1999|Actual|1999-12-31||Interventional|||Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer|A Prospective, Randomized Trial of Sandostatin LAR Depot for the Prevention of Irinotecan-Induced Diarrhea in Patients With Metastatic Colorectal Cancer|Terminated||Phase 3|89|Actual|Novartis|||||f||||||||||||||2018-06-01 05:09:55.720721|2018-06-01 05:09:55.720721
NCT00003523|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-06-20|2004-05-21|2004-05-24|Estimate|||||||2013-06-20|2013-06-21|Estimate|January 1999||1999-01-31|June 2005|2005-06-30|October 2007|Actual|2007-10-31|||||Interventional|||Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum|Evaluation of Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:56.339367|2018-06-01 05:09:56.339367
NCT00003518|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-05-21|2004-05-24|Estimate|||||||2010-01-26|2010-01-27|Estimate|January 1999||1999-01-31|January 2010|2010-01-31||||July 2002|Actual|2002-07-31||Interventional|||Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors|Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors|Completed||Phase 2|44|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:09:56.71572|2018-06-01 05:09:56.71572
NCT00003444|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-05-21|2004-05-24|Estimate|||||||2010-01-26|2010-01-27|Estimate|October 1998||1998-10-31|January 2010|2010-01-31||||September 2003|Actual|2003-09-30||Interventional|||Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin|A Prospective Randomized Phase III Clinical Trial Assessing the Role of Post-Operative Radiotherapy Plus Adjuvant Interferon Alpha-2b in Patients With Cervical, Axillary, and Inguinal Nodal Metastasis From Cutaneous Melanoma|Completed||Phase 3|167|Anticipated|Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:09:56.958682|2018-06-01 05:09:56.958682
NCT00003405|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-05-21|2004-05-24|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 1998||1998-04-30|February 2001|2001-02-28||||||||Interventional|||Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia|Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:09:57.128687|2018-06-01 05:09:57.128687
NCT00003403|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-22|2004-05-21|2004-05-24|Estimate|||||||2013-04-22|2013-04-23|Estimate|August 1999||1999-08-31|February 2001|2001-02-28||||||||Interventional|||GPX-100 in Treating Patients With Solid Tumors|Phase I Safety and Efficacy Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer|Completed||Phase 1|||Gem Pharmaceuticals|||||f||||||||||||||2018-06-01 05:09:57.578188|2018-06-01 05:09:57.578188
NCT00003269|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-01-06|2004-05-21|2004-05-24|Estimate|||||||2011-01-06|2011-01-10|Estimate|February 1998||1998-02-28|January 2011|2011-01-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors|A Phase II, Open-Label, Trial Evaluating the Efficacy of Amifostine in Patients With Cancers Receiving Outpatient Dose-intensive Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Chemotherapy|Completed||Phase 2|20|Actual|Scripps Health|||||f||||f||||||||||2018-06-01 05:09:57.851767|2018-06-01 05:09:57.851767
NCT00003195|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-11-15|2004-05-21|2004-05-24|Estimate|||||||2011-11-15|2011-11-17|Estimate|December 1997||1997-12-31|November 2011|2011-11-30|November 2000|Actual|2000-11-30|||||Interventional|||Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma|A Phase II Study of Total Marrow Irradiation, Busulfan, and Alpha-Interferon Followed by Allogeneic Peripheral Blood Stem Cell or Marrow Transplantation for Treatment of Patients With Advanced Multiple Myeloma.|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:09:58.258085|2018-06-01 05:09:58.258085
NCT00003187|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-02-23|2004-05-21|2004-05-24|Estimate|||||||2010-02-23|2010-02-24|Estimate|May 1995||1995-05-31|February 2010|2010-02-28|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma|The Unrelated Donor Marrow Transplantation Trial|Completed||Phase 2/Phase 3|19|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 05:09:58.574559|2018-06-01 05:09:58.574559
NCT00003098|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-01-29|2004-05-21|2004-05-24|Estimate|||||||2016-01-29|2016-02-01|Estimate|August 1997||1997-08-31|January 2016|2016-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Diet and Estrogen Metabolism in Postmenopausal Women|Diet and Estrogen Metabolism in Postmenopausal Women|Completed||N/A|12|Actual|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-06-01 05:09:58.941614|2018-06-01 05:09:58.941614
NCT00003084|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-05-21|2004-05-24|Estimate|||||||2012-07-27|2012-07-30|Estimate|December 1997||1997-12-31|July 2012|2012-07-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer|A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer|Completed||Phase 2|75|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:09:59.314192|2018-06-01 05:09:59.314192
NCT00003056|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-03-12|2004-05-21|2004-05-24|Estimate|||||||2018-03-12|2018-03-14|Actual|April 1, 1997||1997-04-01|March 2018|2018-03-31|June 1, 2003|Actual|2003-06-01|June 1, 2003|Actual|2003-06-01||Interventional|||Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation|Peripheral Blood Stem Cell Transplantation in Patients With Advanced Malignancies Eligible for Allogeneic Transplantation From Matched Related Donors: A Randomized Study of Cyclosporine/Methotrexate or Cyclosporine/T-Cell Depletion (CD34 Cell Selection) for GVHD Prophylaxis|Terminated||Phase 3|105|Actual|Shire||2||Interim analysis indicated study should be terminated|||||t||||||||||2018-06-01 05:09:59.851572|2018-06-01 05:09:59.851572
NCT00003004|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-05-21|2004-05-24|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 1997||1997-07-31|June 2013|2013-06-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors|An Open-Label, Non-Randomized Phase I Study of the Protein Kinase C Inhibitor Flavopiridol Administered in Combination With Paclitaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|73|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:00.219743|2018-06-01 05:10:00.219743
NCT00002924|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-05-21|2004-05-24|Estimate|||||||2016-07-12|2016-07-14|Estimate|January 1997||1997-01-31|July 2016|2016-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy|Androgen Receptor Mutations in Hormone Refractory Prostate Cancer|Completed|||184|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20~     patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).~   "|||2018-06-01 05:10:00.523171|2018-06-01 05:10:00.523171
NCT00002875|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-31|2004-05-21|2004-05-24|Estimate|||||||2014-07-31|2014-08-01|Estimate|December 1996||1996-12-31|July 2014|2014-07-31|January 2011|Actual|2011-01-31|February 2006|Actual|2006-02-28||Interventional|||Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma|Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA|Completed||Phase 3|421|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:10:01.320506|2018-06-01 05:10:01.320506
NCT00002780|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-21|2004-05-24|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 1996||1996-05-31|February 2001|2001-02-28||||||||Interventional|||Biological Therapy in Treating Women With Metastatic Breast Cancer|INFUSION OF ACTIVATED T CELLS AND LOW DOSE INTERLEUKIN 2 COMBINED WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR THE TREATMENT OF WOMEN WITH METASTATIC BREAST CANCER: PHASE I/II|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:01.857507|2018-06-01 05:10:01.857507
NCT00002750|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2004-05-21|2004-05-24|Estimate|||||||2013-02-15|2013-02-20|Estimate|December 1992||1992-12-31|February 2013|2013-02-28|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Melphalan in Patients With Neoplastic Meningitis|Phase I of Intrathecal Melphalan in Patients With Recurrent Neoplastic Meningitis|Completed||Phase 1|6|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:10:02.47429|2018-06-01 05:10:02.47429
NCT00002734|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-05-21|2004-05-24|Estimate|||||||2013-02-04|2013-02-05|Estimate|March 1996||1996-03-31|February 2001|2001-02-28||||April 2001|Actual|2001-04-30||Interventional|||Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer|PHASE I STUDY OF INTERFERON ENHANCED INTRAPERITONEAL RADIOIMMUNO-CHEMOTHERAPY FOR OVARIAN CANCER|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:02.765379|2018-06-01 05:10:02.765379
NCT00002671|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-08|2004-05-21|2004-05-24|Estimate|||||||2012-11-08|2012-11-09|Estimate|December 1995||1995-12-31|May 2006|2006-05-31||||February 2001|Actual|2001-02-28||Interventional|||Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer|PHASE II STUDY OF 9-20-S-AMINO-CAMPTOTHECIN (9-AC) AS SECOND LINE THERAPY IN ADVANCED OVARIAN CARCINOMA|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:10:03.341105|2018-06-01 05:10:03.341105
NCT00002664|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-07-10|2004-05-21|2004-05-24|Estimate|||||||2017-07-10|2017-07-13|Actual|July 1995||1995-07-31|July 2017|2017-07-31|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|||Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer|PHASE II STUDY OF MONOCLONAL ANTIBODY 17-1A WITH GM-CSF IN TREATMENT OF 5-FU RESISTANT COLORECTAL CANCER|Withdrawn||Phase 2|0|Actual|George Washington University||1||No recruitment|f||||||||||||||2018-06-01 05:10:03.687986|2018-06-01 05:10:03.687986
NCT00002576|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2004-05-21|2004-05-24|Estimate|||||||2013-08-06|2013-08-07|Estimate|November 1992||1992-11-30|May 2007|2007-05-31|January 2001|Actual|2001-01-31|||||Interventional|||Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma|A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER)|Completed||Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:04.024002|2018-06-01 05:10:04.024002
NCT00002571|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-22|2004-05-21|2004-05-24|Estimate|||||||2013-01-22|2013-01-24|Estimate|June 1994||1994-06-30|January 2013|2013-01-31|July 2011|Actual|2011-07-31|November 2003|Actual|2003-11-30||Interventional|||SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma|Study of Promace-Cytabom With Trimethoprim Sulfamethoxazole, Zidovudine (AZT), and Granulocyte Colony Stimulating Factor (G-CSF) in Patients With AIDS-Related Lymphoma, Phase II|Completed||Phase 2|52|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:10:04.419828|2018-06-01 05:10:04.419828
NCT00002567|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-05-21|2004-05-24|Estimate|||||||2013-06-25|2013-06-27|Estimate|March 1994||1994-03-31|June 2013|2013-06-30|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission|PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS|Completed||Phase 2|45|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:04.987739|2018-06-01 05:10:04.987739
NCT00002552|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-05|2004-05-21|2004-05-24|Estimate|||||||2013-04-05|2013-04-09|Estimate|October 1993||1993-10-31|April 2013|2013-04-30|October 2003|Actual|2003-10-31|September 2001|Actual|2001-09-30||Interventional|||Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma|AUTOLOGOUS, ALLOGENEIC, OR SYNGENEIC BONE MARROW TRANSPLANTATION IN HODGKIN'S DISEASE, NON-HODGKIN'S LYMPHOMA, AND MULTIPLE MYELOMA|Completed||Phase 2|40|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:10:05.234719|2018-06-01 05:10:05.234719
NCT00002547|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-06|2004-05-21|2004-05-24|Estimate|||||||2012-08-06|2012-08-07|Estimate|August 1987||1987-08-31|August 2012|2012-08-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome|ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA|Completed||Phase 2|280|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||||||||||||2018-06-01 05:10:07.074378|2018-06-01 05:10:07.074378
NCT00083356|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-21|||2008-03-03|2004-05-20|2004-05-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2004||2004-05-31|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Bradykinin Receptors and Pain|Bradykinin-1 Receptor and Kinin Induction in a Clinical Model of Tissue Injury|Completed||Phase 2|90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:07.178383|2018-06-01 05:10:07.178383
NCT00005648|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2011-05-17|2004-05-20|2004-05-21|Estimate|||||||2011-05-17|2011-05-19|Estimate|November 1999||1999-11-30|October 2010|2010-10-31|November 2003|Actual|2003-11-30|||||Interventional|||Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer|A Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 in Patients With Advanced Pancreatic Cancer|Completed||Phase 3|688|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 05:10:07.268685|2018-06-01 05:10:07.268685
NCT00004198|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2018-01-13|2004-05-20|2004-05-21|Estimate|||||||2018-01-13|2018-01-17|Actual|June 1999||1999-06-30|January 2018|2018-01-31|November 2003|Actual|2003-11-30|January 2002|Actual|2002-01-31||Interventional|||Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma|A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Indolent B Cell Lymphoma|Completed||Phase 2|||University of Nebraska|||||f||||f||||||||||2018-06-01 05:10:07.377983|2018-06-01 05:10:07.377983
NCT00003976|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-05-20|2004-05-21|Estimate|||||||2012-07-10|2012-07-11|Estimate|March 1998||1998-03-31|July 2012|2012-07-31||||||||Interventional|||E7070 in Treating Patients With Solid Tumors|Phase I Study to Determine the Safety of E7070 in Patients With a Solid Tumor on a Single IV Infusion Repeated Every 3 Weeks|Completed||Phase 1|30|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:07.825989|2018-06-01 05:10:07.825989
NCT00003908|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-17|2004-05-20|2004-05-21|Estimate|||||||2013-04-17|2013-04-18|Estimate|November 1999||1999-11-30|April 2013|2013-04-30|January 2007|Actual|2007-01-31|June 2004|Actual|2004-06-30||Interventional|||S9902 Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Evaluation of the Combination of Docetaxel (Taxotere)/ Carboplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|68|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 05:10:08.126677|2018-06-01 05:10:08.126677
NCT00003822|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-05-20|2004-05-21|Estimate|||||||2008-07-23|2008-07-24|Estimate|August 1998||1998-08-31|March 2001|2001-03-31||||||||Interventional|||SR-45023A in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacokinetic Study of SR-45023A During a 14-Day Treatment Schedule|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:08.404247|2018-06-01 05:10:08.404247
NCT00003747|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-05-20|2004-05-21|Estimate|||||||2013-09-19|2013-09-20|Estimate|October 1998||1998-10-31|March 2001|2001-03-31||||||||Interventional|||Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma|Phase I (Tumour Site Specific) Study of Carboplatin and Temozolomide in Patients With Advanced Melanoma|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:08.481087|2018-06-01 05:10:08.481087
NCT00003724|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-11|2004-05-20|2004-05-21|Estimate|||||||2016-07-11|2016-07-12|Estimate|February 1999||1999-02-28|July 2016|2016-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases|Phase III Randomized Prospective Trial of Open Versus Minimally Invasive, Video-Assisted Resection of Pulmonary Metastases|Completed||Phase 3|530|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:10:08.578365|2018-06-01 05:10:08.578365
NCT00003670|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-06|2004-05-20|2004-05-21|Estimate|||||||2012-06-06|2012-06-07|Estimate|October 1998||1998-10-31|April 2008|2008-04-30|January 2001|Actual|2001-01-31|||||Interventional|||Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer|Phase II Study of LY353381-HC1 Administered to Women With Refractory Ovarian Cancer|Completed||Phase 2|||Eli Lilly and Company|||||f||||||||||||||2018-06-01 05:10:08.756166|2018-06-01 05:10:08.756166
NCT00003606|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-05-20|2004-05-21|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1998||1998-03-31|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer|Phase III Randomized Study of Cisplatin and Etoposide With or Without Epirubicin and Cyclophosphamide for Extensive Stage Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|216|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:08.838371|2018-06-01 05:10:08.838371
NCT00003562|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-05-20|2004-05-21|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 1998||1998-07-31|March 2001|2001-03-31||||||||Interventional|||Docetaxel Plus Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin|Unknown status|Active, not recruiting|Phase 2|38|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:09.022277|2018-06-01 05:10:09.022277
NCT00003490|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-05-20|2004-05-21|Estimate|||||||2013-12-03|2013-12-04|Estimate|October 1998||1998-10-31|March 2001|2001-03-31|August 2003|Actual|2003-08-31|||||Interventional|||Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma|Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:09.197976|2018-06-01 05:10:09.197976
NCT00003447|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-20|2004-05-21|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 1998||1998-07-31|September 2007|2007-09-30||||||||Interventional|||Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Vinorelbine Versus Gemcitabine Versus Gemcitabine and Vinorelbine in Elderly Patients With Stage IIIB-IV Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|630|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:09.306585|2018-06-01 05:10:09.306585
NCT00003365|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-01-26|2004-05-20|2004-05-21|Estimate|||||||2011-01-26|2011-01-27|Estimate|August 1996||1996-08-31|January 2011|2011-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Sulindac and Plant Compounds in Preventing Colon Cancer|The Effect of Plant Phenolic Compounds on Human Colon Epithelial Cells|Terminated||N/A|||Rutgers, The State University of New Jersey||||Study completed|f||||f||||||||||2018-06-01 05:10:09.402618|2018-06-01 05:10:09.402618
NCT00003322|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2004-05-20|2004-05-21|Estimate|||||||2013-05-24|2013-05-27|Estimate|March 1998||1998-03-31|August 2012|2012-08-31||||January 2006|Actual|2006-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer|A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma|Completed||Phase 3|384|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:10:09.565912|2018-06-01 05:10:09.565912
NCT00003289|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-08-05|2004-05-20|2004-05-21|Estimate|||||||2010-08-05|2010-08-09|Estimate|June 1998||1998-06-30|August 2010|2010-08-31||||||||Interventional|||UCN-01 in Treating Patients With Advanced Cancer|A Phase I and Pharmacologic Study of UCN-01 (NSC638850)|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:10:09.98805|2018-06-01 05:10:09.98805
NCT00003250|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-04-09|2004-05-20|2004-05-21|Estimate|||||||2014-04-09|2014-04-11|Estimate|May 1998||1998-05-31|April 2014|2014-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Fenretinide in Treating Patients With Solid Tumors|Phase I Evaluation of Fenretinide (NSC# 374551)|Completed||Phase 1|31|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:10:10.41321|2018-06-01 05:10:10.41321
NCT00003101|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-05-20|2004-05-21|Estimate|||||||2013-06-24|2013-06-25|Estimate|August 1997||1997-08-31|June 2013|2013-06-30|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma|A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma|Completed||Phase 2|60|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:10.74744|2018-06-01 05:10:10.74744
NCT00002880|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-27|2004-05-20|2004-05-21|Estimate|||||||2016-06-27|2016-06-28|Estimate|November 1996||1996-11-30|June 2016|2016-06-30|January 2008|Actual|2008-01-31|January 2001|Actual|2001-01-31||Interventional|||Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|PHASE II STUDY OF ORAL ETOPOSIDE WITH PHARMACODYNAMIC MODELING IN RELAPSED NON-HODGKIN'S LYMPHOMA (IWF GRADES A-H)|Completed||Phase 2|53|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:10:10.930269|2018-06-01 05:10:10.930269
NCT00002876|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-05-20|2004-05-21|Estimate|||||||2011-05-10|2011-05-11|Estimate|October 1991||1991-10-31|May 2011|2011-05-31|January 2005|Actual|2005-01-31|April 1998|Actual|1998-04-30||Interventional|||Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas|A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS|Completed||Phase 2|35|Anticipated|Mayo Clinic|||||f||||||||||||||2018-06-01 05:10:11.050185|2018-06-01 05:10:11.050185
NCT00002813|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2004-05-20|2004-05-21|Estimate|||||||2013-05-24|2013-05-27|Estimate|August 1997||1997-08-31|March 2008|2008-03-31||||October 2004|Actual|2004-10-31||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer|A LIMITED ACCESS PHASE II TRIAL OF CISPLATIN AND NAVELBINE (VINORELBINE) IN ADVANCED AND RECURRENT SQUAMOUS CELL CARCINOMA OF THE CERVIX|Completed||Phase 2|62|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:10:11.148836|2018-06-01 05:10:11.148836
NCT00002787|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-05-01|2004-05-20|2004-05-21|Estimate|||||||2018-05-01|2018-05-02|Actual|March 1996||1996-03-31|May 2018|2018-05-31||||December 2002|Actual|2002-12-31||Interventional|||Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation|Phase I Trial of Post Transplant Immunization With Autologous Myeloma Idiotype-KLH/GM-CSF In Myeloma Patients Following Autologous or Allogeneic Marrow or Stem Cell Transplantation|Active, not recruiting||Phase 1|40|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||||||||||||2018-06-01 05:10:11.251764|2018-06-01 05:10:11.251764
NCT00002707|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-02-02|2004-05-20|2004-05-21|Estimate|||||||2010-02-02|2010-02-03|Estimate|December 1995||1995-12-31|February 2010|2010-02-28|February 2010|Actual|2010-02-28|June 2002|Actual|2002-06-30||Interventional|||Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed|A RANDOMIZED TRIAL COMPARING PREOPERATIVE DOXORUBICIN (ADRIAMYCIN)/CYCLOPHOSPHAMIDE (AC) TO PREOPERATIVE AC FOLLOWED BY PREOPERATIVE DOCETAXEL (TAXOTERE) AND TO PREOPERATIVE AC FOLLOWED BY POSTOPERATIVE DOCETAXEL IN PATIENTS WITH OPERABLE CARCINOMA OF THE BREAST|Completed||Phase 3|2411|Actual|NSABP Foundation Inc||3|||f||||t||||||||||2018-06-01 05:10:11.671652|2018-06-01 05:10:11.671652
NCT00002692|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-20|2004-05-21|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 1994||1994-12-31|May 2007|2007-05-31||||||||Interventional|||Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver|A RANDOMISED TRIAL OF INTRAVENOUS VERSUS INTRAHEPATIC ARTERIAL 5-FU AND LEUCOVORIN FOR COLORECTAL LIVER METASTASES|Unknown status|Active, not recruiting|Phase 3|312|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:12.189579|2018-06-01 05:10:12.189579
NCT00002673|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-15|2004-05-20|2004-05-21|Estimate|||||||2010-06-15|2010-06-17|Estimate|June 1995||1995-06-30|June 2010|2010-06-30|February 2002|Actual|2002-02-28|||||Interventional|||Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation|A PHASE II STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY AS PROPHYLAXIS FOR CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION|Completed||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:10:12.341427|2018-06-01 05:10:12.341427
NCT00002599|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-20|2004-05-21|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 1994||1994-09-30|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma|MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL|Unknown status|Active, not recruiting|Phase 3|750|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:12.448323|2018-06-01 05:10:12.448323
NCT00083330|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-20|||2017-06-30|2004-05-19|2004-05-20|Estimate|||||||2017-06-30|2017-07-02|Actual|May 18, 2004||2004-05-18|October 1, 2009|2009-10-01|October 1, 2009|Actual|2009-10-01|October 1, 2009|Actual|2009-10-01||Interventional|||Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Multiclade HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP, in Uninfected Adult Volunteers|Completed||Phase 1|36||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:12.533144|2018-06-01 05:10:12.533144
NCT00083278|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-17|||2012-04-26|2004-05-19|2004-05-20|Estimate|||||||2012-04-26|2012-04-27|Estimate|May 2003||2003-05-31|April 2012|2012-04-30|February 2006|Actual|2006-02-28|||||Interventional|||Study of MDX-010 in Stage IV Breast Cancer|A Phase II Study of MDX-010 in Patients With Stage IV Adenocarcinoma of the Breast|Completed||Phase 2|33|Actual|Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:10:12.614941|2018-06-01 05:10:12.614941
NCT00012350|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2012-10-22|2004-05-19|2004-05-20|Estimate|||||||2012-10-22|2012-10-23|Estimate|January 2001||2001-01-31|October 2012|2012-10-31|January 2010|Actual|2010-01-31|September 2003|Actual|2003-09-30||Interventional|||Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma|Phase II Evaluation of FTI (R115777) (NSC 702818) in Treatment of Advanced Multiple Myeloma|Completed||Phase 2|44|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:10:12.732422|2018-06-01 05:10:12.732422
NCT00010088|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2009-02-06|2004-05-19|2004-05-20|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 1999||1999-01-31|April 2007|2007-04-30||||||||Interventional|||Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct|Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:12.871556|2018-06-01 05:10:12.871556
NCT00006220|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-02-04|2004-05-19|2004-05-20|Estimate|||||||2013-02-04|2013-02-06|Estimate|June 1999||1999-06-30|February 2013|2013-02-28|February 2002|Actual|2002-02-28|November 2000|Actual|2000-11-30||Interventional|||Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy|Arsenic Trioxide Alone or With ATRA (Vesanoid) for Resistant Hematologic Malignancy|Terminated||Phase 1/Phase 2|5|Actual|Washington University School of Medicine||3||Study drug became commercially available.|f||||||||||||||2018-06-01 05:10:13.052753|2018-06-01 05:10:13.052753
NCT00005814|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-17|2004-05-19|2004-05-20|Estimate|||||||2013-06-17|2013-06-19|Estimate|December 1999||1999-12-31|June 2013|2013-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer|Phase II Study of C225 in Combination With Cisplatin and Standard/Delayed Accelerated Hyperfractionated Radiation Therapy in Patients With Advanced Head & Neck Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:13.175522|2018-06-01 05:10:13.175522
NCT00005581|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-12-17|2004-05-19|2004-05-20|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 2000||2000-06-30|June 2007|2007-06-30||||||||Interventional|||Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer|Epirubicin Plus Paclitaxel Versus Cyclophosphamide, Epirubicin and 5-Fluorouracil as Adjuvant Treatment of Node Positive Breast Cancer Patients: A Controlled Randomized Phase III Study|Unknown status|Active, not recruiting|Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:13.270906|2018-06-01 05:10:13.270906
NCT00004880|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2015-10-01|2004-05-19|2004-05-20|Estimate|||||||2015-10-01|2015-10-02|Estimate|June 1997||1997-06-30|July 2012|2012-07-31||||April 2001|Actual|2001-04-30||Interventional|||Vaccine Therapy in Treating Patients With Advanced Kidney Cancer|A Phase I Pilot Trial of a Multi-Antigen Loaded Dendritic Cell Vaccine for the Treatment of Advanced Renal Cell Carcinoma|Completed||Phase 1|14|Actual|Jonsson Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 05:10:13.439931|2018-06-01 05:10:13.439931
NCT00004211|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-03-19|2004-05-19|2004-05-20|Estimate|||||||2013-03-19|2013-03-21|Estimate|July 1999||1999-07-31|January 2005|2005-01-31|January 2002|Actual|2002-01-31|||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer|A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With RNA Encoding Prostate Specific Antigen, PSA|Completed||Phase 1/Phase 2|17|Actual|Duke University|||||f||||||||||||||2018-06-01 05:10:13.512341|2018-06-01 05:10:13.512341
NCT00004156|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-10-29|2004-05-19|2004-05-20|Estimate|||||||2013-10-29|2013-10-30|Estimate|May 1999||1999-05-31|October 2013|2013-10-31||||June 2008|Actual|2008-06-30||Interventional|||Vaccine Therapy in Treating Patients With Breast Cancer|Vaccination of High Risk Breast Cancer Patients With MUC-1 (Glycosylated) Keyhole Limpet Hemocyanin Conjugates Plus the Immunological Adjuvant QS21|Completed||Phase 1|45|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:10:13.734454|2018-06-01 05:10:13.734454
NCT00004132|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-25|2004-05-19|2004-05-20|Estimate|||||||2013-06-25|2013-06-26|Estimate|January 2000||2000-01-31|June 2007|2007-06-30|May 2004|Actual|2004-05-31|||||Interventional|||Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Patients With Hematologic Malignancies Undergoing Total Body Irradiation (TBI) and High-Dose Chemotherapy With Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:13.819984|2018-06-01 05:10:13.819984
NCT00004073|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-05-01|2004-05-19|2004-05-20|Estimate|||||||2012-05-01|2012-05-03|Estimate|December 1999||1999-12-31|May 2012|2012-05-31|June 2004|Actual|2004-06-30|May 2003|Actual|2003-05-31||Interventional|||Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|54|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:10:13.955004|2018-06-01 05:10:13.955004
NCT00004056|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2014-07-24|2004-05-19|2004-05-20|Estimate|||||||2014-07-24|2014-07-28|Estimate|October 1999||1999-10-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|October 2002|Actual|2002-10-31||Interventional|||Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia|Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequential Remission Induction and Consolidation Followed by Single Dose Melphalan With Peripheral Stem Cell Rescue: A POG Pilot Study|Completed||Phase 1|35|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:10:14.061384|2018-06-01 05:10:14.061384
NCT00004051|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-12-18|2004-05-19|2004-05-20|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 1998||1998-08-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|July 2001|Actual|2001-07-31||Interventional|||Irinotecan in Treating Patients With Advanced Solid Tumors|A Phase I Study to Evaluate Orally Administered Irinotecan HCL (CPT-11) Given as a Powder-Filled Capsule Formulation Daily for 14 Days Every Three Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:14.208246|2018-06-01 05:10:14.208246
NCT00004038|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-06|2004-05-19|2004-05-20|Estimate|||||||2013-02-06|2013-02-07|Estimate|January 1999||1999-01-31|June 2001|2001-06-30||||May 2001|Actual|2001-05-31||Interventional|||Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer|Pilot Study of p53 Intralesional Gene Therapy With Chemotherapy in Breast Cancer|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:14.355614|2018-06-01 05:10:14.355614
NCT00003924|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2004-05-19|2004-05-20|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 1995||1995-10-31|May 2007|2007-05-31||||||||Interventional|||Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma|A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease)|Unknown status|Active, not recruiting|Phase 3|360|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:14.441104|2018-06-01 05:10:14.441104
NCT00003876|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-05-19|2004-05-20|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 1999||1999-04-30|May 2001|2001-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma|A Phase I Study of Concurrent Multi-modality Treatment for Patients With Relapsed Malignant Glioma Using Permanent I-125 Interstitial Seeds and Dose Escalation of Gliadel 3.85% Carmustine (BCNU) Polymer Wafers|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:14.550131|2018-06-01 05:10:14.550131
NCT00003801|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-08-19|2004-05-19|2004-05-20|Estimate|||||||2009-08-19|2009-08-20|Estimate||||February 2000|2000-02-29||||||||Interventional|||Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma|Intergroup Rhabdomyosarcoma Study Group: Late Effects After Treatment for Rhabdomyosarcoma|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:14.645022|2018-06-01 05:10:14.645022
NCT00003731|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-05-19|2004-05-20|Estimate|||||||2012-09-20|2012-09-24|Estimate|December 1998||1998-12-31|September 2012|2012-09-30||||January 2001|Actual|2001-01-31||Interventional|||Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors|First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial|Completed||Phase 2|39|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:14.754166|2018-06-01 05:10:14.754166
NCT00003700|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-05-19|2004-05-20|Estimate|||||||2016-07-01|2016-07-06|Estimate|January 1999||1999-01-31|July 2016|2016-07-31|January 2010|Actual|2010-01-31|February 2004|Actual|2004-02-29||Interventional|||Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia|Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradiation|Completed||Phase 2|163|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:10:14.874651|2018-06-01 05:10:14.874651
NCT00003698|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-19|2004-05-20|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 1998||1998-07-31|February 2008|2008-02-29|December 2003|Actual|2003-12-31|||||Interventional|||Chemotherapy in Treating Patients With Solid Tumors|A Phase I Trial of Combretastatin A4 Phosphate in Patients With Solid Tumours Given by Weekly Intravenous Infusion|Completed||Phase 1|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:15.128742|2018-06-01 05:10:15.128742
NCT00003697|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-19|2004-05-20|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1995||1995-10-31|June 2009|2009-06-30|December 1998|Actual|1998-12-31|||||Interventional|||Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors|A Phase I Trial of 5, 6 Dimethyl Xanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors|Completed||Phase 1|3|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:15.210023|2018-06-01 05:10:15.210023
NCT00003685|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-07|2004-05-19|2004-05-20|Estimate|||||||2010-11-07|2010-11-09|Estimate|December 1998||1998-12-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|||||Interventional|||Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer|A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer|Completed||Phase 3|210|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:10:15.297946|2018-06-01 05:10:15.297946
NCT00003640|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-05|2004-05-19|2004-05-20|Estimate|||||||2012-03-05|2012-03-06|Estimate|September 1998||1998-09-30|March 2012|2012-03-31||||November 2000|Actual|2000-11-30||Interventional|||Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer|A Feasibility Study of Thorough Transurethral Resection (TURB) and Escalated Dose M-VAC Chemotherapy as Primary Treatment of T2-T3a, N0-Nx, M0 Transitional Cell Carcinoma of the Bladder, With the Intention of Bladder Preservation|Terminated||Phase 2|73|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:10:15.423284|2018-06-01 05:10:15.423284
NCT00003575|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-05-19|2004-05-20|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 1999||1999-01-31|October 2002|2002-10-31||||April 2002|Actual|2002-04-30||Interventional|||Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma|A Randomized Pre-Phase II Trial of Interleukin-2, Interleukin-12, or No Additional Therapy Following Response to Ifosfamide/Etoposide Chemotherapy for Refractory HIV-Associated Non-Hodgkin's Lymphoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:15.516898|2018-06-01 05:10:15.516898
NCT00003439|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-06|2004-05-19|2004-05-20|Estimate|||||||2013-02-06|2013-02-07|Estimate|August 1998||1998-08-31|April 2007|2007-04-30||||May 2001|Actual|2001-05-31||Interventional|||Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer|A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:15.640618|2018-06-01 05:10:15.640618
NCT00003423|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-19|2004-05-20|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 1995||1995-05-31|April 2001|2001-04-30||||||||Interventional|||Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma T Cell Protocol|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:15.787808|2018-06-01 05:10:15.787808
NCT00003330|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-05-19|2004-05-20|Estimate|||||||2013-02-08|2013-02-11|Estimate|July 1998||1998-07-31|May 2001|2001-05-31||||April 2002|Actual|2002-04-30||Interventional|||Interleukin-12 in Treating Patients With Advanced Cancer|Phase I Clinical Trials of IV rhIL-12 With or Without a Test-Dose in Patients With Advanced Malignancies (rhIL-12 NSC# 672423)|Completed||Phase 1|54|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:15.914856|2018-06-01 05:10:15.914856
NCT00003326|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-05-19|2004-05-20|Estimate|||||||2008-07-23|2008-07-24|Estimate|September 1997||1997-09-30|April 2001|2001-04-30||||||||Interventional|||Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus|A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Patients With Advanced Esophageal Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:16.02327|2018-06-01 05:10:16.02327
NCT00003255|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-11|2004-05-19|2004-05-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 1999||1999-11-30|July 2016|2016-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia|Phase II Study of Continuous Infusion Carboplatin and Topotecan in the Treamtment of Relapsed Acute Myelogenous Leukemia (AML)|Completed||Phase 2|38|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:10:16.147131|2018-06-01 05:10:16.147131
NCT00002578|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-05|2004-05-19|2004-05-20|Estimate|||||||2015-10-05|2015-10-06|Estimate|August 1994||1994-08-31|October 2015|2015-10-31||||January 2007|Actual|2007-01-31||Interventional|||Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma|Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome|Completed||Phase 2|35|Anticipated|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:10:16.213661|2018-06-01 05:10:16.213661
NCT00002503|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-05-19|2004-05-20|Estimate|||||||2012-09-20|2012-09-24|Estimate|October 1992||1992-10-31|September 2012|2012-09-30||||November 2000|Actual|2000-11-30||Interventional|||Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases|A PROSPECTIVE MULTICENTER RANDOMIZED STUDY COMPARING STRONTIUM-89 CHLORIDE AND PALLIATIVE LOCAL FIELD RADIOTHERAPY IN PATIENTS WITH HORMONAL ESCAPED ADVANCED PROSTATIC CANCER|Completed||Phase 3|204|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:16.337232|2018-06-01 05:10:16.337232
NCT00083317|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-19|||2017-06-30|2004-05-18|2004-05-19|Estimate|||||||2017-06-30|2017-07-02|Actual|May 15, 2004||2004-05-15|January 4, 2012|2012-01-04|January 4, 2012||2012-01-04|||||Observational|||Role of the Brain in Making Economic Decisions|The Role of the Prefrontal Cortex in Economic Decision-Making in Reciprocal Trust Games Using Functional Hyperscanning Neuroimaging|Completed|||127|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:16.462163|2018-06-01 05:10:16.462163
NCT00083304|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-18|||2013-05-08|2004-05-18|2004-05-19|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2004||2004-02-29|May 2013|2013-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|ENRICH||Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer|A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Women With Brain Metastases From Breast Cancer|Completed||Phase 3|368|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||t||||||||||2018-06-01 05:10:16.533026|2018-06-01 05:10:16.533026
NCT00083213|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2016-06-01|2004-05-18|2004-05-19|Estimate|||||||2016-06-01|2016-06-03|Estimate|January 2004||2004-01-31|June 2016|2016-06-30||||May 2008|Actual|2008-05-31||Interventional|||Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma|An Open Label, Sequential Cohort Dose-Escalation Safety, Tolerability and Pharmacokinetic Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|25|Actual|Regeneron Pharmaceuticals|||||f||||||||||||||2018-06-01 05:10:16.94411|2018-06-01 05:10:16.94411
NCT00082940|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2017-01-17|2004-05-18|2004-05-19|Estimate|||||||2017-01-17|2017-01-19|Estimate|August 2002||2002-08-31|June 2013|2013-06-30|June 2005|Actual|2005-06-30|January 2005|Actual|2005-01-31||Interventional|||Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia|A Phase II Study of ONTAK® (Denileukin Diftitox, DABIL-2) in Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:10:17.227273|2018-06-01 05:10:17.227273
NCT00082927|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-06-25|2004-05-18|2004-05-19|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2003||2003-04-30|June 2009|2009-06-30|July 2011|Actual|2011-07-31|||||Interventional|||Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain|A Multicentre Randomised Trial Of Single Dose Radiotherapy Compared To Ibandronate For Localised Metastatic Bone Pain|Completed||Phase 3|580|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:17.683358|2018-06-01 05:10:17.683358
NCT00082914|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-06-18|2004-05-18|2004-05-19|Estimate|||||||2013-06-18|2013-06-20|Estimate|March 2004||2004-03-31|December 2005|2005-12-31|July 2006|Actual|2006-07-31|||||Interventional|||Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer|Phase II Evaluation of Denileukin Diftitox in Patients With Metastatic Melanoma or Metastatic Kidney Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:17.982145|2018-06-01 05:10:17.982145
NCT00082888|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|2011-11-02||2018-05-24|2004-05-18|2004-05-19|Estimate|2011-11-02|2011-12-07|Estimate||||2018-05-24|2018-05-25|Actual|March 24, 2004|Actual|2004-03-24|May 2018|2018-05-31||||May 20, 2009|Actual|2009-05-20||Interventional|||Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma|Phase II Evaluation of FTI (R115777) in Treatment of Relapsed and Refractory Lymphoma|Active, not recruiting||Phase 2|93|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:18.169212|2018-06-01 05:10:18.169212
NCT00082875|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-06-04|2004-05-18|2004-05-19|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2004||2004-03-31|June 2013|2013-06-30||||July 2006|Actual|2006-07-31||Interventional|||Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma|A Phase 2 Study of EMD 121974 (Cilengitide, NSC 707544) in Patients With Metastatic Melanoma|Terminated||Phase 2|56|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:10:18.772233|2018-06-01 05:10:18.772233
NCT00082862|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2012-02-10|2004-05-18|2004-05-19|Estimate|||||||2012-02-10|2012-02-13|Estimate|July 2002||2002-07-31|December 2008|2008-12-31||||November 2012|Anticipated|2012-11-30||Interventional|||Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer|A Phase II Clinical Trial of a Timing/Schedule Optimized Combined-Modality Regimen: Cisplatin + Metronomic Low-Dose Interferon-α (IFN-α) Followed by Gemcitabine HCl (GEMZAR) in Combination With Mild, Fever-Range Whole-Body Hyperthermia (FR-WBH) in Patients With Advanced, Inoperable Pancreatic Cancer|Unknown status|Recruiting|Phase 2|48|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:18.920688|2018-06-01 05:10:18.920688
NCT00082836|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-01-15|2004-05-18|2004-05-19|Estimate|||||||2013-01-15|2013-01-17|Estimate|December 2004||2004-12-31|January 2013|2013-01-31||||May 2007|Actual|2007-05-31||Interventional|||Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma|A Pilot Study of Radiolabeled Indium-111 and Yttrium-90 Ibritumomab Tiuxetan in Primary CNS Lymphoma|Completed||N/A|10|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:19.00442|2018-06-01 05:10:19.00442
NCT00082823|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2016-06-01|2004-05-18|2004-05-19|Estimate|||||||2016-06-01|2016-06-03|Estimate|January 2004||2004-01-31|June 2016|2016-06-30||||May 2008|Actual|2008-05-31||Interventional|||Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma|An Open-Label, Long-Term, Safety and Tolerability Study of VEGF Trap Administered Intravenously in Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|25|Actual|Regeneron Pharmaceuticals|||||f||||||||||||||2018-06-01 05:10:19.130237|2018-06-01 05:10:19.130237
NCT00082810|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|2015-05-04||2015-08-03|2004-05-18|2004-05-19|Estimate|2015-08-03|2015-08-10|Estimate||||2015-08-03|2015-08-10|Estimate|March 2004||2004-03-31|October 2013|2013-10-31|September 2008|Actual|2008-09-30|July 2008|Actual|2008-07-31||Interventional|||Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer|A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer|Completed||Phase 2|33|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:10:19.282508|2018-06-01 05:10:19.282508
NCT00082797|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2010-01-28|2004-05-18|2004-05-19|Estimate|||||||2010-01-28|2010-01-29|Estimate|February 2005||2005-02-28|January 2010|2010-01-31||||May 2007|Actual|2007-05-31||Interventional|||High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II Study Of Systemic High-Dose Methotrexate For The Treatment Of Glioblastoma Multiforme In Newly Diagnosed Patients With Measurable Disease|Completed||Phase 2|36|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:10:19.555401|2018-06-01 05:10:19.555401
NCT00082784|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2014-12-22|2004-05-18|2004-05-19|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2004||2004-03-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|October 2012|Actual|2012-10-31||Interventional|||Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms|Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms|Completed||Phase 1|93|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:19.771348|2018-06-01 05:10:19.771348
NCT00082758|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|2013-12-02||2015-01-27|2004-05-18|2004-05-19|Estimate|2013-12-02|2014-01-16|Estimate||||2015-01-27|2015-02-12|Estimate|August 2005||2005-08-31|January 2015|2015-01-31|May 2012|Actual|2012-05-31|February 2008|Actual|2008-02-29||Interventional|||hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma|A Phase II Study Of hu14.18-IL2 In Children With Recurrent Or Refractory Neuroblastoma|Completed||Phase 2|39|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 05:10:19.900984|2018-06-01 05:10:19.900984
NCT00082745|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2017-08-16|2004-05-18|2004-05-19|Estimate|||||||2017-08-16|2017-08-21|Actual|March 2004||2004-03-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors|Key Adverse Events After Childhood Cancer|Recruiting|||8100|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     peripheral blood or buccal sample~   "|||2018-06-01 05:10:21.727013|2018-06-01 05:10:21.727013
NCT00082732|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2012-10-18|2004-05-18|2004-05-19|Estimate|||||||2012-10-18|2012-10-22|Estimate|July 2002||2002-07-31|October 2012|2012-10-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer|Impact of Dietary Intervention in Men With Hormone Refractory Prostate Cancer|Completed||Phase 1|56|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:10:22.432363|2018-06-01 05:10:22.432363
NCT00082719|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2015-05-12|2004-05-18|2004-05-19|Estimate|||||||2015-05-12|2015-05-14|Estimate|December 2003||2003-12-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium|Modulation of Death Effector Expression By Short-Term Exposure to Low-Dose Interferon|Completed||Phase 1|33|Actual|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-06-01 05:10:22.542095|2018-06-01 05:10:22.542095
NCT00082706|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2017-11-03|2004-05-18|2004-05-19|Estimate|||||||2017-11-03|2017-11-07|Actual|April 2003|Actual|2003-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant|Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant|Active, not recruiting||Phase 2|46|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 05:10:22.657191|2018-06-01 05:10:22.657191
NCT00082667|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-02-22|2004-05-18|2004-05-19|Estimate|||||||2013-02-22|2013-02-25|Estimate|October 2002||2002-10-31|February 2013|2013-02-28|June 2005|Actual|2005-06-30|July 2004|Actual|2004-07-31||Interventional|||Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast|EGFR Pathway Modulation In Patients With Ductal Carcinoma In Situ Of The Breast|Terminated||Phase 2|1|Actual|Vanderbilt-Ingram Cancer Center||||PI left VICC|f||||t||||||||||2018-06-01 05:10:22.787565|2018-06-01 05:10:22.787565
NCT00082654|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2010-09-17|2004-05-18|2004-05-19|Estimate|||||||2010-09-17|2010-09-21|Estimate|March 2002||2002-03-31|September 2010|2010-09-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients|Emotional Needs of Caregivers and Patient/Spouse Couples During Hematopoietic Stem Cell Transplantation (HSCT)|Completed||N/A|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:10:22.886055|2018-06-01 05:10:22.886055
NCT00082641|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2017-10-24|2004-05-18|2004-05-19|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2004||2004-01-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer|1) Adenovirus p53 Infected DC Vaccine For Breast Cancer, 2) Translation of Biotechnology Into the Clinic|Active, not recruiting||Phase 1/Phase 2|24|Actual|University of Nebraska||2|||f||||t||||||||||2018-06-01 05:10:23.096537|2018-06-01 05:10:23.096537
NCT00003186|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-05-18|2004-05-19|Estimate|||||||2013-02-04|2013-02-05|Estimate|April 1997||1997-04-30|February 2013|2013-02-28||||March 2005|Actual|2005-03-31||Interventional|||Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer|Dynamic In Vivo Lymphography and Sentinel Node Biopsy in Colorectal Cancer: A Feasibility Study|Completed||N/A|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:10:23.195942|2018-06-01 05:10:23.195942
NCT00003183|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-05-18|2004-05-19|Estimate|||||||2013-12-03|2013-12-04|Estimate|March 1997||1997-03-31|April 2001|2001-04-30||||||||Interventional|||Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer|A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|64|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:23.326946|2018-06-01 05:10:23.326946
NCT00003154|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-09|2004-05-18|2004-05-19|Estimate|||||||2010-06-09|2010-06-10|Estimate|January 1998||1998-01-31|June 2010|2010-06-30|June 2001|Actual|2001-06-30|April 2001|Actual|2001-04-30||Interventional|||Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase II Trial of 9-Aminocamptothecin (9-AC) Colloidal Dispersion (CD) 120-Hour Continuous Intravenous Infusion in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|19|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:10:23.410656|2018-06-01 05:10:23.410656
NCT00003118|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-05-18|2004-05-19|Estimate|||||||2016-07-01|2016-07-04|Estimate|October 1997||1997-10-31|June 2016|2016-06-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus|A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer|Completed||Phase 3|56|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:10:23.515354|2018-06-01 05:10:23.515354
NCT00003117|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-28|2004-05-18|2004-05-19|Estimate|||||||2016-06-28|2016-06-30|Estimate|October 1997||1997-10-31|June 2016|2016-06-30|January 2006|Actual|2006-01-31|December 2004|Actual|2004-12-31||Interventional|||Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer|Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness|Completed||Phase 3|584|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:10:23.665192|2018-06-01 05:10:23.665192
NCT00003095|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-23|2004-05-18|2004-05-19|Estimate|||||||2015-10-23|2015-10-26|Estimate|November 1997||1997-11-30|October 2015|2015-10-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Observational|||S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer|S9719: Clonal Hematopoiesis as a Marker of Genetic Damage Following Adjuvant Chemotherapy for Breast Cancer: Pilot Study to Evaluate Incidence. Ancillary to S9623|Completed|||26|Actual|Southwest Oncology Group|||2||f||||f||||||Samples With DNA|"~     tissue and blood~   "|||2018-06-01 05:10:23.844748|2018-06-01 05:10:23.844748
NCT00003020|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2004-05-18|2004-05-19|Estimate|||||||2013-02-15|2013-02-20|Estimate|September 1997||1997-09-30|February 2013|2013-02-28|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases|Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms|Completed||Phase 1|24|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:10:24.122444|2018-06-01 05:10:24.122444
NCT00002988|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2004-05-18|2004-05-19|Estimate|||||||2013-06-19|2013-06-20|Estimate|April 1997||1997-04-30|February 2013|2013-02-28|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma|Phase I Treatment of Adults With Primary Malignant Glioma With Irinotecan (CPT-11) (NSC #6616348) Plus BCNU (NSC #409962)|Completed||Phase 1|36|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:10:24.199864|2018-06-01 05:10:24.199864
NCT00002985|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-01|2004-05-18|2004-05-19|Estimate|||||||2013-02-01|2013-02-04|Estimate|November 1996||1996-11-30|February 2013|2013-02-28||||January 2007|Actual|2007-01-31||Interventional|||Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma|Double-Blind Randomized Evaluation of Clinical Benefits of DOXIL in Patients With AIDS-Related Kaposi's Sarcoma Treated With DOXIL or DaunoXome|Completed||Phase 3|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:10:24.279044|2018-06-01 05:10:24.279044
NCT00002961|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-10-14|2004-05-18|2004-05-19|Estimate|||||||2013-10-14|2013-10-16|Estimate|October 1995||1995-10-31|October 2013|2013-10-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia|Randomized Trial of Busulfan or Total Body Irradiation Conditioning Regimens for Children With Acute Lymphoblastic Leukemia|Terminated||Phase 3|43|Actual|Children's Hospital of Philadelphia||2||poor accrual|f||||f||||||||||2018-06-01 05:10:24.340463|2018-06-01 05:10:24.340463
NCT00083291|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-18|||2008-03-03|2004-05-17|2004-05-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2004||2004-05-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||Helicobacter Pylori and Dry Eye|Pilot Study of Helicobacter Pylori and Ocular Surface Disease|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:24.448707|2018-06-01 05:10:24.448707
NCT00083252|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2007-06-07|2004-05-17|2004-05-18|Estimate|||||||2007-06-07|2007-06-08|Estimate||||June 2007|2007-06-30||||||||Interventional|||Study of Talabostat and Cisplatin in Advanced Melanoma||Completed||Phase 2|||Point Therapeutics|||||||||||||||||||2018-06-01 05:10:24.606337|2018-06-01 05:10:24.606337
NCT00083239|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2007-06-07|2004-05-17|2004-05-18|Estimate|||||||2007-06-07|2007-06-08|Estimate||||June 2007|2007-06-30||||||||Interventional|||Study of Talabostat in Advanced Melanoma||Completed||Phase 2|||Point Therapeutics|||||||||||||||||||2018-06-01 05:10:24.716205|2018-06-01 05:10:24.716205
NCT00083265|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-15|||2018-02-15|2004-05-14|2004-05-17|Estimate|||||||2018-02-15|2018-02-16|Estimate|May 13, 2004||2004-05-13|February 14, 2018|2018-02-14|February 14, 2018||2018-02-14|||||Observational|||Genetic Causes of Panic Disorder|Association Between Adenosine Receptor Gene Polymorphisms and Physiological Responses to Caffeine in Subjects With Panic Disorder and Healthy Controls|Completed|||117|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:24.775036|2018-06-01 05:10:24.775036
NCT00083226|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|2014-10-24||2014-10-24|2004-05-14|2004-05-17|Estimate|2014-10-24|2014-10-30|Estimate||||2014-10-24|2014-10-30|Estimate|March 2004||2004-03-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|February 2011|Actual|2011-02-28||Interventional||The primary population was the 38 eligible and treated patients|Doxorubicin and Bortezomib in Treating Patients With Liver Cancer|A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma|Completed||Phase 2|42|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 05:10:24.880513|2018-06-01 05:10:24.880513
NCT00083187|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-07-17|2004-05-14|2004-05-17|Estimate|||||||2013-07-17|2013-07-18|Estimate|November 2005||2005-11-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|January 2007|Actual|2007-01-31||Interventional|||VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia|A Phase II Study of VNP40101M For Patients With Acute Myelogenous Leukemia Or High-Risk Myelodysplasia|Completed||Phase 2|230|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:10:25.165849|2018-06-01 05:10:25.165849
NCT00083174|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|2012-11-07||2018-03-27|2004-05-14|2004-05-17|Estimate|2013-05-16|2013-05-20|Estimate||||2018-03-27|2018-04-25|Actual|February 11, 2004|Actual|2004-02-11|March 2018|2018-03-31|January 22, 2018|Actual|2018-01-22|March 25, 2011|Actual|2011-03-25||Interventional|||Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer|A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer|Completed||Phase 3|4560|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-06-01 05:10:25.383137|2018-06-01 05:10:25.383137
NCT00083161|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2012-09-01|2004-05-14|2004-05-17|Estimate|||||||2012-09-01|2012-09-05|Estimate|June 2003||2003-06-30|September 2012|2012-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Pilot Study of a Combination of Standard Etoposide/Cisplatin and Metronomic Cyclophosphamide in Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|8|Actual|Gundersen Lutheran Health System||1|||f||||f||||||||||2018-06-01 05:10:26.271082|2018-06-01 05:10:26.271082
NCT00083148|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2011-03-07|2004-05-14|2004-05-17|Estimate|||||||2011-03-07|2011-03-09|Estimate|November 2002||2002-11-30|March 2011|2011-03-31|September 2006|Actual|2006-09-30|March 2005|Actual|2005-03-31||Interventional|||Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer|Phase I Study of Irinotecan Followed by Capecitabine in Patients With Advanced Breast Carcinoma|Completed||Phase 1|12|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:10:26.342504|2018-06-01 05:10:26.342504
NCT00083135|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2010-10-14|2004-05-14|2004-05-17|Estimate|||||||2010-10-14|2010-10-15|Estimate|March 2004||2004-03-31|May 2009|2009-05-31||||February 2006|Actual|2006-02-28||Interventional|||N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation|I-MIBG Escalating Dose Rapid Sequence Double Infusion Followed By Autologous Stem Cell Infusion For Refractory Neuroblastoma|Completed||Phase 1|18|Anticipated|Children's Hospital Los Angeles|||||f||||t||||||||||2018-06-01 05:10:26.410945|2018-06-01 05:10:26.410945
NCT00083122|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|2013-03-22||2014-05-06|2004-05-14|2004-05-17|Estimate|2013-03-22|2013-05-14|Estimate||||2014-05-06|2014-05-21|Estimate|April 2004||2004-04-30|April 2013|2013-04-30|May 2012|Actual|2012-05-31|July 2010|Actual|2010-07-31||Interventional|||Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Phase II Trial of Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinomas|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:10:26.516101|2018-06-01 05:10:26.516101
NCT00083109|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2015-05-22|2004-05-14|2004-05-17|Estimate|||||||2015-05-22|2015-05-25|Estimate|March 2004||2004-03-31|January 2013|2013-01-31|March 2008|Actual|2008-03-31|December 2005|Actual|2005-12-31||Interventional|||Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer|Phase I/II Trial Of Low Dose Suramin (CI-1003, NSC#34936) And 5-Fluorouracil In Patients With Metastatic Renal Cell Carcinoma (RCC)|Completed||Phase 1/Phase 2|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:27.001544|2018-06-01 05:10:27.001544
NCT00083096|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2015-02-09|2004-05-14|2004-05-17|Estimate|||||||2015-02-09|2015-02-10|Estimate|March 2004||2004-03-31|February 2015|2015-02-28||||June 2009|Actual|2009-06-30||Interventional|||Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas|Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:27.10145|2018-06-01 05:10:27.10145
NCT00083083|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2011-02-26|2004-05-14|2004-05-17|Estimate|||||||2011-02-26|2011-03-01|Estimate|March 2005||2005-03-31|October 2007|2007-10-31||||June 2006|Anticipated|2006-06-30||Interventional|||Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer|Positron Emission Tomography Pre- and Post-treatment Assessment For Locally Advanced Non-Small Cell Lung Carcinoma|Unknown status|Active, not recruiting|Phase 2|250|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:27.197635|2018-06-01 05:10:27.197635
NCT00083070|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2014-02-18|2004-05-14|2004-05-17|Estimate|||||||2014-02-18|2014-02-20|Estimate|March 2004||2004-03-31|February 2014|2014-02-28|June 2008|Actual|2008-06-30|September 2004|Actual|2004-09-30||Interventional|||Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia|A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias|Completed||Phase 1|16|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:10:27.374017|2018-06-01 05:10:27.374017
NCT00083057|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2012-03-14|2004-05-14|2004-05-17|Estimate|||||||2012-03-14|2012-03-15|Estimate|May 2004||2004-05-31|March 2012|2012-03-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck|A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN)|Completed||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:10:27.506158|2018-06-01 05:10:27.506158
NCT00083044|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2012-04-24|2004-05-14|2004-05-17|Estimate|||||||2012-04-24|2012-04-25|Estimate|October 2003||2003-10-31|April 2012|2012-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy|Surrogate Endpoints in Prevention Studies and Ductal Lavage|Withdrawn|||0|Actual|Northwestern University||||Funding ended and will not be renewed|f||||f||||||||||2018-06-01 05:10:27.588075|2018-06-01 05:10:27.588075
NCT00083031|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2009-02-06|2004-05-14|2004-05-17|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2002||2002-11-30|September 2005|2005-09-30||||||||Interventional|||Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer|Metronomic Chemotherapy in Combination With Bevacizumab for Advanced Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:27.689588|2018-06-01 05:10:27.689588
NCT00083018|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-08-23|2004-05-14|2004-05-17|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2003||2003-09-30|December 2005|2005-12-31||||||||Interventional|||Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer|Evaluation Of The Role Of Nipple Aspiration, Ductal Lavage And Duct Endoscopy At The Time Of Surgery In Patients With Breast Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:27.779399|2018-06-01 05:10:27.779399
NCT00083005|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2012-03-14|2004-05-14|2004-05-17|Estimate|||||||2012-03-14|2012-03-15|Estimate|March 2004||2004-03-31|March 2012|2012-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate|A Phase II Trial Combining Estramustine, Docetaxel And Thalidomide In Patients With Androgen-Independent Metastatic Prostate Cancer|Completed||Phase 2|60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:27.876977|2018-06-01 05:10:27.876977
NCT00082979|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2013-08-23|2004-05-14|2004-05-17|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2003||2003-10-31|December 2005|2005-12-31||||||||Interventional|||Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer|Evaluation of the Role of Duct Endoscopy in the Assessment of Cellular Atypia Within Breast Duct Fluid in High-Risk Women Carrying BRCA1/2 or p53 Gene Mutations|Unknown status|Recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:28.040054|2018-06-01 05:10:28.040054
NCT00082966|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-14|||2015-12-03|2004-05-14|2004-05-17|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2004||2004-03-31|June 2013|2013-06-30||||March 2007|Actual|2007-03-31||Interventional|||Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma|Completed||Phase 2|43|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:28.171526|2018-06-01 05:10:28.171526
NCT00082628|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-13|||2014-06-16|2004-05-14|2004-05-17|Estimate|||||||2014-06-16|2014-06-17|Estimate|May 2004||2004-05-31|June 2014|2014-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS|Completed||Phase 3|569|Actual|EMD Serono|||||f||||||||||||||2018-06-01 05:10:28.269668|2018-06-01 05:10:28.269668
NCT00082602|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-12|||2011-05-19|2004-05-14|2004-05-17|Estimate|||||||2011-05-19|2011-05-20|Estimate|May 2004||2004-05-31|April 2009|2009-04-30|April 2005|Actual|2005-04-30|||||Interventional|||Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease|Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease|Completed||Phase 3|83|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:10:28.390671|2018-06-01 05:10:28.390671
NCT00082589|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-12|||2008-05-22|2004-05-13|2004-05-14|Estimate|||||||2008-05-22|2008-05-28|Estimate|April 2004||2004-04-30|April 2007|2007-04-30|March 2006||2006-03-31|||||Interventional|REMODEL||The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure|A Randomized, Double-Blind, Multi-Center,Study Evaluating the Effects of Eplerenone Versus Placebo on Ventricular Remodeling in Patient's With Left Ventricular Systolic Dysfunction (EF Less Than or Equal to 35%) and Mild to Moderate Heart Failure|Completed||Phase 4|250||Pfizer|||||||||||||||||||2018-06-01 05:10:28.470934|2018-06-01 05:10:28.470934
NCT00082576|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-12|||2011-05-10|2004-05-13|2004-05-14|Estimate|||||||2011-05-10|2011-05-11|Estimate|June 2004||2004-06-30|May 2011|2011-05-31|May 2006|Actual|2006-05-31|||||Interventional|||Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa|A Phase II/III, Randomized, Double-Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa|Completed||Phase 2/Phase 3|238|Actual|Pfizer|||||||||||||||||||2018-06-01 05:10:28.69407|2018-06-01 05:10:28.69407
NCT00082420|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-06|||2010-01-12|2004-05-11|2004-05-12|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2004||2004-09-30|January 2010|2010-01-31|November 2005|Actual|2005-11-30|||||Observational|||Retinol Equivalence of Plant Carotenoids in Children||Completed|||32|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:10:30.533401|2018-06-01 05:10:30.533401
NCT00082563|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-12|||2011-04-25|2004-05-13|2004-05-14|Estimate|||||||2011-04-25|2011-04-26|Estimate|August 2004||2004-08-31|April 2011|2011-04-30|November 2004|Actual|2004-11-30|||||Interventional|||Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum|A Phase II, Randomized, Comparative Trial Of Azithromycin In Combination With Chloroquine Versus Chloroquine In The Eradication Of Asymptomatic Plasmodium Falciparum Infection In Semi-Immune Adults|Terminated||Phase 2|14|Actual|Pfizer|||||||||||||||||||2018-06-01 05:10:28.789429|2018-06-01 05:10:28.789429
NCT00082615|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-13|||2017-06-30|2004-05-12|2004-05-13|Estimate|||||||2017-06-30|2017-07-02|Actual|May 11, 2004||2004-05-11|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives|Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives|Completed|||210||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:28.969813|2018-06-01 05:10:28.969813
NCT00082537|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-11|||2017-02-20|2004-05-12|2004-05-13|Estimate|||||||2017-02-20|2017-02-23|Actual|April 2004||2004-04-30|February 2017|2017-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)|A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in Pediatric Patients With Persistent Fever and Neutropenia|Completed||Phase 2|100|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:10:29.057173|2018-06-01 05:10:29.057173
NCT00082524|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-11|||2017-02-20|2004-05-12|2004-05-13|Estimate|||||||2017-02-20|2017-02-23|Actual|April 2004||2004-04-30|February 2017|2017-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)|A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections|Completed||Phase 2|50|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:10:29.131582|2018-06-01 05:10:29.131582
NCT00002936|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-01|2004-05-12|2004-05-13|Estimate|||||||2013-02-01|2013-02-04|Estimate|July 1996||1996-07-31|February 2013|2013-02-28||||January 2007|Actual|2007-01-31||Interventional|||Altretamine and Etoposide in Treating Patients With HIV-Related Cancer|Hexamethylamine and VP-16 an Oral Regimin for HIV Malignancies: A Phase I/II Trial|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:10:29.201733|2018-06-01 05:10:29.201733
NCT00002903|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-05-12|2004-05-13|Estimate|||||||2012-06-29|2012-07-02|Estimate|July 1995||1995-07-31|June 2012|2012-06-30||||||||Interventional|||Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer|PHASE II TRIAL WITH DOCETAXEL IN PATIENTS WITH RELAPSING GERM CELL CANCER|Completed||Phase 2|25|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:29.2661|2018-06-01 05:10:29.2661
NCT00002896|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-05-12|2004-05-13|Estimate|||||||2013-09-19|2013-09-20|Estimate|September 1993||1993-09-30|February 2008|2008-02-29||||||||Interventional|||Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer|RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA|Unknown status|Active, not recruiting|Phase 3|774|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:29.456957|2018-06-01 05:10:29.456957
NCT00002893|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-12|2004-05-13|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 1995||1995-06-30|May 2007|2007-05-31||||||||Interventional|||Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer|CHEMOTHERAPY CHOICES IN ADVANCED COLORECTAL CANCER: A RANDOMISED TRIAL COMPARING 2 DURATIONS AND 3 SYSTEMIC CHEMOTHERAPY REGIMENS IN THE PALLIATIVE TREATMENT OF ADVANCED COLORECTAL CANCER|Unknown status|Active, not recruiting|Phase 3|900|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:29.55381|2018-06-01 05:10:29.55381
NCT00002892|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-12|2004-05-13|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1995||1995-10-31|May 2007|2007-05-31|December 2001|Actual|2001-12-31|||||Interventional|||Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma|A RANDOMISED STUDY OF OBSERVATION VERSUS ADJUVANT LOW DOSE EXTENDED DURATION INTERFERON ALPHA-2A IN COMPLETELY RESECTED HIGH RISK MALIGNANT MELANOMA|Completed||Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:29.671772|2018-06-01 05:10:29.671772
NCT00082550|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-12|||2017-06-30|2004-05-11|2004-05-12|Estimate|||||||2017-06-30|2017-07-02|Actual|May 10, 2004||2004-05-10|April 9, 2007|2007-04-09|April 9, 2007||2007-04-09|||||Observational|||Serotonin Transporters in Obsessive-Compulsive-Related Disorders|PET Imaging of Monoamine Transporters in OCD-related Disorders|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:29.890707|2018-06-01 05:10:29.890707
NCT00082498|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-11|||2014-07-22|2004-05-11|2004-05-12|Estimate|||||||2014-07-22|2014-07-23|Estimate|May 2004||2004-05-31|July 2014|2014-07-31|January 2011|Actual|2011-01-31|December 2005|Actual|2005-12-31||Interventional|||Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients|Phase II, Randomized, Double-Blind Study of the Safety and Efficacy of Vicriviroc (An Orally Administered HIV-1 Entry Inhibitor) in HIV-Infected, Treatment-Experienced Subjects|Completed||Phase 2|119|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 05:10:30.014442|2018-06-01 05:10:30.014442
NCT00082485|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-11|||2017-01-11|2004-05-11|2004-05-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2004||2004-06-30|August 2016|2016-08-31||||July 2006|Actual|2006-07-31||Interventional|||Baclofen for the Treatment of Cocaine Dependence - 1|Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence|Completed||Phase 2|160|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||||||||||||2018-06-01 05:10:30.252117|2018-06-01 05:10:30.252117
NCT00082472|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-11|||2006-04-14|2004-05-11|2004-05-12|Estimate|||||||2006-04-14|2006-04-18|Estimate|January 2004||2004-01-31|April 2006|2006-04-30||||||||Interventional|||Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)|Phase I/II Study of Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Locally Advanced or Metastatic Unresectable Non Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|30||Zivena|||||||||||||||||||2018-06-01 05:10:30.36178|2018-06-01 05:10:30.36178
NCT00082459|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-10|||2012-09-06|2004-05-11|2004-05-12|Estimate|||||||2012-09-06|2012-09-07|Estimate|July 2002||2002-07-31|September 2012|2012-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma|A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|40||Agenus Inc.||||Lack of enrollment|||||||||||||||2018-06-01 05:10:30.44761|2018-06-01 05:10:30.44761
NCT00002870|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-12-14|2004-05-11|2004-05-12|Estimate|||||||2014-12-14|2014-12-16|Estimate|December 1994||1994-12-31|December 2014|2014-12-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer|A RANDOMIZED, MULTI-CENTRE PHASE III TRIAL TO EVALUATE THE ROLE OF INTENSIFIED THERAPY WITH AUTOLOGOUS TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN ADVANCED OR METASTATIC BREAST CANCER RESPONDING TO INDUCTION CHEMOTHERAPY|Completed||Phase 3|180|Anticipated|UNICANCER|||||f||||t||||||||||2018-06-01 05:10:30.59163|2018-06-01 05:10:30.59163
NCT00002826|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-28|2004-05-11|2004-05-12|Estimate|||||||2013-08-28|2013-08-29|Estimate|June 1997||1997-06-30|August 2013|2013-08-31||||November 2003|Actual|2003-11-30||Interventional|||Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer|A PILOT PHASE II TRIAL OF PSC 833 MODULATION OF MULTIDRUG RESISTANCE TO PACLITAXEL IN THE TREATMENT OF METASTATIC CARCINOMA OF THE BREAST|Completed||Phase 2|36|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:10:30.70976|2018-06-01 05:10:30.70976
NCT00002803|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-11|2004-05-12|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 1995||1995-07-31|April 2008|2008-04-30|February 2002|Actual|2002-02-28|||||Interventional|||Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma|COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA|Completed||Phase 2|44|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:30.806158|2018-06-01 05:10:30.806158
NCT00002802|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-05-11|2004-05-12|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 1990||1990-07-31|May 2007|2007-05-31|September 2003|Actual|2003-09-30|||||Interventional|||Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma|PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS|Completed||Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:30.881669|2018-06-01 05:10:30.881669
NCT00082446|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-10|||2014-12-18|2004-05-10|2004-05-11|Estimate|||||||2014-12-18|2014-12-19|Estimate|May 2004||2004-05-31|September 2008|2008-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Combination Study With MVA BN and Dryvax|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of MVA-BN in a Dose Response Regimen Followed by Administration of Dryvax in Healthy Adult Volunteers|Completed||Phase 1|91|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-06-01 05:10:31.001161|2018-06-01 05:10:31.001161
NCT00082433|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-07|2009-05-01||2016-02-09|2004-05-10|2004-05-11|Estimate|2009-07-02|2009-08-17|Estimate||||2016-02-09|2016-03-10|Estimate|November 2003||2003-11-30|February 2016|2016-02-29|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer|A Phase III Study of Novel Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane|Completed||Phase 3|1221|Actual|R-Pharm||2|||f||||t||||||||||2018-06-01 05:10:31.168869|2018-06-01 05:10:31.168869
NCT00082381|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-06|2009-07-16||2015-03-19|2004-05-10|2004-05-11|Estimate|2013-06-25|2013-07-31|Estimate||||2015-03-19|2015-04-07|Estimate|June 2003||2003-06-30|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin|Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin|Completed||Phase 3|551|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 05:10:33.212697|2018-06-01 05:10:33.212697
NCT00002788|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2010-09-13|2004-05-10|2004-05-11|Estimate|||||||2010-09-13|2010-09-15|Estimate|October 1995||1995-10-31|September 2010|2010-09-30|September 2002||2002-09-30|||||Interventional|||High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia|A PILOT STUDY OF TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS TRANSPLANTATION WITH CD34 SELECTED PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA|Completed||Phase 1|15|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:10:33.792168|2018-06-01 05:10:33.792168
NCT00002737|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-05-10|2004-05-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|March 1996||1996-03-31|July 2012|2012-07-31||||January 2001|Actual|2001-01-31||Interventional|||Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer|A RANDOMIZED PHASE II TRIAL OF INTERFERON ALPHA-2A WITH AND WITHOUT 13-CIS RETINOIC ACID IN PATIENTS WITH PROGRESSIVE MEASURABLE METASTATIC RENAL CELL CARCINOMA. Amendment Protocol: Extension to a Randomized Phase III Trial|Completed||Phase 3|320|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:33.865258|2018-06-01 05:10:33.865258
NCT00002677|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-28|2004-05-10|2004-05-11|Estimate|||||||2017-03-28|2017-03-30|Actual|August 1995|Actual|1995-08-31|March 2017|2017-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors|PHASE I STUDY OF THE ORALLY ADMINISTERED BUTYRATE PRODRUG, TRIBUTYRIN, IN PATIENTS WITH SOLID TUMORS|Completed||Phase 1|24|Actual|University of Maryland||1|||f||||||||||||||2018-06-01 05:10:33.995214|2018-06-01 05:10:33.995214
NCT00002644|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-05-10|2004-05-11|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 1994||1994-01-31|July 2011|2011-07-31|May 2011|Actual|2011-05-31|||||Interventional|||Tamoxifen for the Prevention of Breast Cancer in High-Risk Women|INTERNATIONAL BREAST CANCER INTERVENTION STUDY: A MULTICENTRE TRIAL OF TAMOXIFEN TO PREVENT BREAST CANCER|Completed||Phase 3|7000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:34.132378|2018-06-01 05:10:34.132378
NCT00002587|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-31|2004-05-10|2004-05-11|Estimate|||||||2013-05-31|2013-06-03|Estimate|September 1994||1994-09-30|April 2001|2001-04-30|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors|A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH PACLITAXEL (TAXOL)|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:34.245|2018-06-01 05:10:34.245
NCT00082407|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-06|2009-07-16||2015-03-19|2004-05-07|2004-05-10|Estimate|2013-06-25|2013-07-31|Estimate||||2015-03-19|2015-04-07|Estimate|November 2003||2003-11-30|March 2015|2015-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||IIT population|Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin|Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin|Completed||Phase 3|505|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 05:10:34.335379|2018-06-01 05:10:34.335379
NCT00082082|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-28|||2008-01-08|2004-04-29|2004-04-30|Estimate|||||||2008-01-08|2008-01-15|Estimate||||January 2008|2008-01-31||||||||Interventional|||A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma|A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial|Completed||Phase 2|||SciClone Pharmaceuticals|||||||||||||||||||2018-06-01 05:10:47.145905|2018-06-01 05:10:47.145905
NCT00082394|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-06|||2017-05-23|2004-05-07|2004-05-10|Estimate|||||||2017-05-23|2017-05-24|Actual|April 26, 2004|Actual|2004-04-26|May 2017|2017-05-31|March 1, 2006|Actual|2006-03-01|March 1, 2006|Actual|2006-03-01||Interventional|||A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV|A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (Abacavir 300mg, Lamivudine 150mg, and Zidovudine 300mg) BID vs Combivir (Lamivudine 150mg and Zidovudine 300mg) BID Plus Atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects Over 48 Weeks|Completed||Phase 4|||GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:10:35.923675|2018-06-01 05:10:35.923675
NCT00082316|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-05|||2008-01-03|2004-05-06|2004-05-07|Estimate|||||||2008-01-03|2008-01-11|Estimate||||January 2008|2008-01-31||||||||Interventional|||Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain|A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain|Completed||Phase 2|||NeurogesX|||||||||||||||||||2018-06-01 05:10:36.122505|2018-06-01 05:10:36.122505
NCT00082368|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|2015-04-15||2017-08-16|2004-05-05|2004-05-06|Estimate|2015-04-15|2015-05-04|Estimate||||2017-08-16|2017-08-17|Actual|May 16, 2004|Actual|2004-05-16|August 2017|2017-08-31|April 14, 2014|Actual|2014-04-14|April 14, 2014|Actual|2014-04-14||Interventional|||PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy|A Pilot Study of Tc-94m Sestamibi PET MDR Imaging|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)|The lack of flexibility around patient chemotherapy schedules made the protocol difficult to conduct. Future studies should make imaging integral to the treatment protocol .|1|||f||||f|t|f||||||No||2018-06-01 05:10:36.331567|2018-06-01 05:10:36.331567
NCT00082355|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-06|2011-02-08||2014-10-31|2004-05-05|2004-05-06|Estimate|2012-11-16|2012-12-19|Estimate||||2014-10-31|2014-11-06|Estimate|May 2004||2004-05-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|March 2010|Actual|2010-03-31||Interventional|||Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins|"The Treatment of Deep Vein Thrombosis (DVT) of the Lower Extremities With Low-Dose Alteplase: a Pilot Study"|Completed||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)|Small trial of 30 patients does not have statistical power to prove clinical safety (expected to be <1 %)|1|||f||||f||||||||||2018-06-01 05:10:36.742704|2018-06-01 05:10:36.742704
NCT00082342|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-06|2012-08-31||2012-11-22|2004-05-05|2004-05-06|Estimate|2012-11-22|2012-12-27|Estimate||||2012-11-22|2012-12-27|Estimate|March 2003||2003-03-31|November 2012|2012-11-30||||February 2009|Actual|2009-02-28||Interventional|||Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease|Transcranial Direct Current Stimulation for the Treatment of Parkinson's Disease|Completed||Phase 2|25|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:10:36.982411|2018-06-01 05:10:36.982411
NCT00082329|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-06|2014-04-01||2014-04-01|2004-05-05|2004-05-06|Estimate|2014-04-01|2014-05-02|Estimate||||2014-04-01|2014-05-02|Estimate|May 2004||2004-05-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers|Peripheral Blood Hematopoietic Progenitor Cell Mobilization Using Granulocyte Colony Stimulating Factor (G-CSF) Combined With AMD3100 Mozobil (Plerixafor) in Healthy Volunteers|Completed||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:10:37.526125|2018-06-01 05:10:37.526125
NCT00082303|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-05|||2006-08-16|2004-05-05|2004-05-06|Estimate|||||||2006-08-16|2006-08-18|Estimate|July 2002||2002-07-31|August 2006|2006-08-31||||||||Interventional|||Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin’s Lymphoma|Music Imagery for Patients in Protected Environments|Completed||Phase 1/Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:10:37.81586|2018-06-01 05:10:37.81586
NCT00082290|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-05|||2015-12-17|2004-05-05|2004-05-06|Estimate|||||||2015-12-17|2015-12-18|Estimate|May 2003||2003-05-31|December 2015|2015-12-31||||February 2011|Actual|2011-02-28||Interventional|||Massage Therapy in Treating Patients With Cancer Pain|Massage for the Treatment of Pain in Cancer: A Randomized Phase II Study|Completed||Phase 2|92|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 05:10:37.883864|2018-06-01 05:10:37.883864
NCT00082277|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-05|||2011-01-25|2004-05-05|2004-05-06|Estimate|||||||2011-01-25|2011-01-26|Estimate|April 2004||2004-04-30|January 2011|2011-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|SABRE||Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer|A Multicentre Phase III/IV Study, of the Effects of Risedronate Sodium (ACTONEL™, 35mg/Week, Oral) on Bone, in Postmenopausal Women, With Hormone-receptor-positive Early Breast Cancer, Treated With Anastrozole (ARIMIDEX™, 1mg/Day Oral) With Risk of Fragility Fracture (High-risk Fragility Fracture-open-label, Non-comparative Stratum; Moderate-risk of Fragility Fracture-randomised, Double-blind Stratum; Low-risk of Fragility Fracture - Open-label, Non-comparative Stratum)Abbreviated|Completed||Phase 4|237|Actual|AstraZeneca||3|||f||||||||||||||2018-06-01 05:10:37.975698|2018-06-01 05:10:37.975698
NCT00082251|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-03|||2006-10-31|2004-05-04|2004-05-05|Estimate|||||||2006-10-31|2006-11-01|Estimate||||October 2006|2006-10-31||||||||Interventional|||Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST|Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST|Completed||Phase 3|||Kos Pharmaceuticals|||||||||||||||||||2018-06-01 05:10:38.237977|2018-06-01 05:10:38.237977
NCT00082238|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-03|||2018-03-12|2004-05-04|2004-05-05|Estimate|||||||2018-03-12|2018-03-14|Actual|March 2003|Actual|2003-03-31|March 2018|2018-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)|Increased Gluconeogenesis is One Cause of CFRD|Completed||N/A|42|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f|||||f|f||||||||2018-06-01 05:10:38.399815|2018-06-01 05:10:38.399815
NCT00082225|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-03|||2017-02-03|2004-05-04|2004-05-05|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2003||2003-10-31|February 2017|2017-02-28|January 2008|Actual|2008-01-31|February 2006|Actual|2006-02-28||Interventional|ACDAL||LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)|Administration of LMP2a-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody to Patients With Relapsed EBV-Positive Hodgkin's or Non-Hodgkin's Lymphoma|Terminated||Phase 1|4|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 05:10:38.493293|2018-06-01 05:10:38.493293
NCT00082212|ClinicalTrials.gov processed this data on May 31, 2018|2004-05-03|||2010-04-08|2004-05-04|2004-05-05|Estimate|||||||2010-04-08|2010-04-09|Estimate|November 2004||2004-11-30|April 2010|2010-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Terminated||Phase 2|25|Actual|ImClone LLC||1||Due to lack of sufficient efficacy.|f||||f||||||||||2018-06-01 05:10:38.599276|2018-06-01 05:10:38.599276
NCT00014651|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2010-08-06|2004-05-04|2004-05-05|Estimate|||||||2010-08-06|2010-08-10|Estimate|March 2001||2001-03-31|August 2010|2010-08-31|April 2002|Actual|2002-04-30|March 2001|Actual|2001-03-31||Interventional|||Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection|Vapreotide in Pancreas Surgery: A Double-Blind, Placebo-Controlled, Randomized Study of Vapreotide to Prevent Post-Surgical Complications in Patients Undergoing Elective Pancreatic Resection Grant Application Title: Vapreotide to Prevent Complications of Pancreatic Resection|Terminated||Phase 3|||Mayo Clinic||||"Teminated by the DSMB because there are no differences between the control group and the~   Vapreotide group"|f||||||||||||||2018-06-01 05:10:38.692375|2018-06-01 05:10:38.692375
NCT00010322|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2014-03-24|2004-05-04|2004-05-05|Estimate|||||||2014-03-24|2014-03-26|Estimate|October 2000||2000-10-31|March 2014|2014-03-31|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer|Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer|Terminated||Phase 3|||Intarcia Therapeutics||||Withdrawn due to change in standard of care - new protocol required|f||||f||||||||||2018-06-01 05:10:38.851473|2018-06-01 05:10:38.851473
NCT00008255|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-06-25|2004-05-04|2004-05-05|Estimate|||||||2013-06-25|2013-06-26|Estimate|August 2000||2000-08-31|May 2001|2001-05-31|May 2004|Actual|2004-05-31|||||Interventional|||INS316 in Diagnosing Lung Cancer in Patients With Untreated Lung Cancer|Evaluation Of Uridine 5-Triphosphate Solution For Inhalation (UTP) As An Adjunct In The Diagnosis Of Lung Cancer By Sputum Cytology|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:38.97286|2018-06-01 05:10:38.97286
NCT00002568|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-08|2004-05-04|2004-05-05|Estimate|||||||2013-07-08|2013-07-09|Estimate|June 1994||1994-06-30|May 2010|2010-05-31||||December 2004|Actual|2004-12-31||Interventional|||Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer|A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA|Completed||Phase 3|470|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:10:39.076367|2018-06-01 05:10:39.076367
NCT00002516|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-05-04|2004-05-05|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1992||1992-07-31|January 2010|2010-01-31||||||||Interventional|||Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma|EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92]|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:39.217036|2018-06-01 05:10:39.217036
NCT00082199|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-30|||2013-11-07|2004-05-03|2004-05-04|Estimate|||||||2013-11-07|2013-11-11|Estimate|April 2004||2004-04-30|July 2008|2008-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study of Aripiprazole in Subjects With Alcoholism|A Randomized, Multicenter, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence From Alcohol in Subjects With Alcoholism|Completed||Phase 4|400||Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 05:10:39.336975|2018-06-01 05:10:39.336975
NCT00082186|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-30|||2010-02-11|2004-05-03|2004-05-04|Estimate|||||||2010-02-11|2010-02-12|Estimate|July 2003||2003-07-31|February 2010|2010-02-28|November 2007|Actual|2007-11-30|February 2007|Actual|2007-02-28||Interventional|||The Effect of Tracleer® on Male Fertility|TRACLEER® (Bosentan) Pulmonary Arterial Hypertension A Multicenter, Open-label, Single-arm Safety Study to Investigate the Effects of Chronic TRACLEER® Treatment on Testicular Function in Male Patients With Pulmonary Arterial Hypertension|Completed||Phase 4|22|Actual|Actelion||1|||f||||||||||||||2018-06-01 05:10:39.43747|2018-06-01 05:10:39.43747
NCT00082173|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-30|2013-03-26||2013-03-26|2004-05-03|2004-05-04|Estimate|2013-03-26|2013-05-22|Estimate||||2013-03-26|2013-05-22|Estimate|October 2004||2004-10-31|March 2013|2013-03-31|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Interventional||125 had 8-week data (moxifloxacin n=64, ethambutol n=61)|Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis|Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection|Completed||Phase 2|170|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 05:10:39.591836|2018-06-01 05:10:39.591836
NCT00082160|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-30|||2006-08-03|2004-05-03|2004-05-04|Estimate|||||||2006-08-03|2006-08-04|Estimate|July 2001||2001-07-31|August 2006|2006-08-31|June 2005||2005-06-30|||||Observational|||Brain Imaging Technology to Examine the Effects of Meditation|fMRI Investigation of Meditation|Completed|||60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:10:39.975389|2018-06-01 05:10:39.975389
NCT00082134|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-29|||2015-03-04|2004-05-03|2004-05-04|Estimate|||||||2015-03-04|2015-03-05|Estimate||||March 2015|2015-03-31|December 2005|Actual|2005-12-31|||||Interventional|||Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel|A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel|Completed||Phase 2|40||Sanofi|||||||||||||||||||2018-06-01 05:10:40.059063|2018-06-01 05:10:40.059063
NCT00082121|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-29|||2007-07-19|2004-05-03|2004-05-04|Estimate|||||||2007-07-19|2007-07-20|Estimate|April 2004||2004-04-30|July 2007|2007-07-31|December 2005||2005-12-31|||||Interventional|||Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery||Completed||Phase 2|300||Avant Immunotherapeutics|||||||||||||||||||2018-06-01 05:10:40.142859|2018-06-01 05:10:40.142859
NCT00011934|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2014-04-16|2004-05-03|2004-05-04|Estimate|||||||2014-04-16|2014-04-17|Estimate|May 1998||1998-05-31|April 2014|2014-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Bone Marrow Transplantation Plus Biological Therapy in Treating Patients With Chronic Myeloid Leukemia|Granulocyte-Macrophage Colony Stimulating Factor (Rhu-GM-CSF) and Autologous Bone Marrow Transplantation for Chronic Myeloid Leukemia|Completed||Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:10:40.322104|2018-06-01 05:10:40.322104
NCT00008242|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-03-06|2004-05-03|2004-05-04|Estimate|||||||2013-03-06|2013-03-07|Estimate|August 2000||2000-08-31|March 2013|2013-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma|A Phase II Clinical Trial Of Thalidomide, Adramycin And Dexamethasone (TAD) As Initial Therapy For The Treatment Of Multiple Myeloma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:40.43922|2018-06-01 05:10:40.43922
NCT00008125|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2016-01-14|2004-05-03|2004-05-04|Estimate|||||||2016-01-14|2016-01-15|Estimate|March 1998||1998-03-31|January 2016|2016-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors|Phase I Study Of Gemcitabine, Docetaxel And Carboplatin, With And Without Filrastim Support, Combination Chemotherapy In Patients With Advanced Non-Hematological Malignancies|Completed||Phase 1|25|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:10:40.507993|2018-06-01 05:10:40.507993
NCT00008099|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2016-01-19|2004-05-03|2004-05-04|Estimate|||||||2016-01-19|2016-01-20|Estimate|May 1998||1998-05-31|January 2016|2016-01-31|February 2004|Actual|2004-02-29|March 2001|Actual|2001-03-31||Interventional|||Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer|Phase I Dose Escalation Trial of a 100 aa Synthetic Mucin Peptide Admixed With SB-AS2 as Adjuvant in Locally Advanced and Resected Pancreatic Cancer|Completed||Phase 1|25|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 05:10:40.644656|2018-06-01 05:10:40.644656
NCT00006682|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2008-07-23|2004-05-03|2004-05-04|Estimate|||||||2008-07-23|2008-07-24|Estimate|February 2000||2000-02-29|May 2001|2001-05-31||||||||Interventional|||Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer|An Open-Label Phase II Study of Navelbine (Vinorelbine Tartrate) and Taxotere (Docetaxel) as First-Line Therapy for Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:40.767338|2018-06-01 05:10:40.767338
NCT00006669|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2009-02-06|2004-05-03|2004-05-04|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 1999||1999-09-30|May 2001|2001-05-31||||||||Interventional|||Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma|Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-Cell Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:40.883474|2018-06-01 05:10:40.883474
NCT00006342|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2015-10-13|2004-05-03|2004-05-04|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 1997||1997-01-31|June 2013|2013-06-30|January 2001|Actual|2001-01-31|September 2000|Actual|2000-09-30||Observational|||Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor|Analyses of Mutations Associated With Secondary Leukemia or Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease or Childhood Brain Tumors|Completed|||19|Actual|Duke University|||||f||||||||||||||2018-06-01 05:10:40.991427|2018-06-01 05:10:40.991427
NCT00006112|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2011-04-23|2004-05-03|2004-05-04|Estimate|||||||2011-04-23|2011-04-26|Estimate|January 1996||1996-01-31|May 2001|2001-05-31||||||||Interventional|||Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer|Randomized Therapeutic Study Comparing Tumor Resection Followed Immediately by Intraperitoneal Chemotherapy and Systemic Chemotherapy VS Systemic Chemotherapy Alone for the Treatment of Colorectal Cancer Metastatic to the Peritoneum|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:41.068202|2018-06-01 05:10:41.068202
NCT00006097|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2010-09-21|2004-05-03|2004-05-04|Estimate|||||||2010-09-21|2010-09-22|Estimate|August 1999||1999-08-31|May 2001|2001-05-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia|CC-1088 Therapy for Chronic Lymphocytic Leukemia: A Phase I/II Trial|Completed||Phase 1/Phase 2|||Boston Medical Center|||||f||||t||||||||||2018-06-01 05:10:41.16152|2018-06-01 05:10:41.16152
NCT00006053|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-16|2004-05-03|2004-05-04|Estimate|||||||2013-01-16|2013-01-18|Estimate|June 2000||2000-06-30|January 2013|2013-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa|A Study to Determine the Safety and Efficacy of STI571 in Patients With Chronic Myeloid Leukemia Who Are Hematologically or Cytogenetically Resistant or Refractory to Interferon-Alpha, or Intolerant of, Interferon-Alpha|Completed||Phase 2|||Novartis|||||f||||f||||||||||2018-06-01 05:10:41.226121|2018-06-01 05:10:41.226121
NCT00006039|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-17|2004-04-30|2004-05-03|Estimate|||||||2013-06-17|2013-06-19|Estimate|December 1999||1999-12-31|June 2013|2013-06-30|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma|Phase II Study of Weekly Administered High-Dose Pegylated Interferon Alfa-2B (PEGIntron) in Advanced Stage Low Grade Non-Hodgkin's Lymphoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:41.295587|2018-06-01 05:10:41.295587
NCT00005988|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-03-30|2004-04-30|2004-05-03|Estimate|||||||2017-03-30|2017-04-04|Actual|February 2000|Actual|2000-02-29|March 2017|2017-03-31|March 8, 2002|Actual|2002-03-08|June 16, 2001|Actual|2001-06-16||Interventional|||Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy|A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies|Completed||Phase 1|5|Actual|Dana-Farber Cancer Institute||1|||f||||t|f|f||||||No||2018-06-01 05:10:41.415221|2018-06-01 05:10:41.415221
NCT00005974|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2011-09-27|2004-04-30|2004-05-03|Estimate|||||||2011-09-27|2011-09-28|Estimate|July 2000||2000-07-31|September 2011|2011-09-30|September 2008|Actual|2008-09-30|November 2002|Actual|2002-11-30||Interventional|||Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma|A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Previously Untreated Metastatic or Locally Advanced Soft Tissue Sarcoma|Completed||Phase 2|18|Actual|Canadian Cancer Trials Group|||||f||||f||||||||||2018-06-01 05:10:41.575567|2018-06-01 05:10:41.575567
NCT00005871|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-04-30|2004-05-03|Estimate|||||||2013-12-03|2013-12-04|Estimate|November 1998||1998-11-30|June 2007|2007-06-30||||||||Interventional|||Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer|Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:41.721598|2018-06-01 05:10:41.721598
NCT00005612|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-09-24|2004-04-30|2004-05-03|Estimate|||||||2012-09-24|2012-09-26|Estimate|August 1999||1999-08-31|September 2012|2012-09-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|ETC||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer|A Phase I/II Study of Intensive-Dose Etoposide, Topotecan and Carboplatin (ETC) Followed by Autologous Stem Cell Rescue in Chemosensitive Ovarian Cancer Patients With Either Minimal Residual Disease or at First Relapse|Terminated||Phase 1/Phase 2|3|Actual|H. Lee Moffitt Cancer Center and Research Institute||||Low accrual|f||||f||||||||||2018-06-01 05:10:41.806864|2018-06-01 05:10:41.806864
NCT00005594|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-12-30|2004-04-30|2004-05-03|Estimate|||||||2010-12-30|2011-01-04|Estimate|July 2000||2000-07-31|December 2010|2010-12-31||||December 2000|Actual|2000-12-31||Interventional|||ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas|Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-Ras, in Patients With Advanced Pancreatic Cancer|Completed||Phase 2|4|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:10:41.893958|2018-06-01 05:10:41.893958
NCT00005081|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-08-20|2004-04-30|2004-05-03|Estimate|||||||2014-08-20|2014-08-21|Estimate|August 2000||2000-08-31|February 2013|2013-02-28|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma|Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas|Completed||Phase 2|||Duke University|||||f||||||||||||||2018-06-01 05:10:41.972965|2018-06-01 05:10:41.972965
NCT00005055|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-09-20|2004-04-30|2004-05-03|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2000||2000-01-31|September 2012|2012-09-30||||March 2001|Actual|2001-03-31||Interventional|||Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer|Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer|Completed||Phase 2|39|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:42.037135|2018-06-01 05:10:42.037135
NCT00005053|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-09-20|2004-04-30|2004-05-03|Estimate|||||||2012-09-20|2012-09-24|Estimate|December 1999||1999-12-31|September 2012|2012-09-30||||March 2001|Actual|2001-03-31||Interventional|||Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer|Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Pancreatic Cancer|Completed||Phase 2|35|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:42.138561|2018-06-01 05:10:42.138561
NCT00005021|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-07-10|2004-04-30|2004-05-03|Estimate|||||||2013-07-10|2013-07-11|Estimate|July 1996||1996-07-31|July 2013|2013-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma|Phase I Evaluation of Topotecan in Combination With Paclitaxel and Carboplatin|Completed||Phase 1|17|Actual|Fox Chase Cancer Center|||||f||||t||||||||||2018-06-01 05:10:42.224203|2018-06-01 05:10:42.224203
NCT00004893|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2016-07-15|2004-04-30|2004-05-03|Estimate|||||||2016-07-15|2016-07-19|Estimate|December 1999||1999-12-31|July 2016|2016-07-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Interleukin-12 in Treating Patients With Metastatic or Recurrent Breast Cancer|Evaluation of Novel Therapeutic Agents Against Breast Cancer: An Innovative Randomized Phase II Trial Design|Completed||Phase 2|5|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:10:42.358718|2018-06-01 05:10:42.358718
NCT00004892|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2009-02-06|2004-04-30|2004-05-03|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 2000||2000-04-30|February 2007|2007-02-28||||||||Interventional|||O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma|Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:42.563509|2018-06-01 05:10:42.563509
NCT00004884|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-09-20|2004-04-30|2004-05-03|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 1999||1999-07-31|September 2012|2012-09-30||||March 2001|Actual|2001-03-31||Interventional|||Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer|Randomized Phase II Study of Docetaxel/Gemcitabine vs. Docetaxel/Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma|Completed||Phase 2|96|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:42.692652|2018-06-01 05:10:42.692652
NCT00004246|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2012-07-27|2004-04-30|2004-05-03|Estimate|||||||2012-07-27|2012-07-30|Estimate|May 2000||2000-05-31|July 2012|2012-07-31|December 2002|Actual|2002-12-31|February 2001|Actual|2001-02-28||Interventional|||Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx|A Phase I Study of Fludarabine With Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|16|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:10:42.871972|2018-06-01 05:10:42.871972
NCT00004230|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28||2011-02-16|2012-05-31|2004-04-30|2004-05-03|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-31|2012-06-06|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation|Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation|Completed||Phase 3|35|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 05:10:43.00264|2018-06-01 05:10:43.00264
NCT00004213|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-07-17|2004-04-30|2004-05-03|Estimate|||||||2013-07-17|2013-07-18|Estimate|May 1998||1998-05-31|December 2007|2007-12-31|January 2008|Actual|2008-01-31|||||Interventional|||3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors|An Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP) in Cancer Patients Using a Single Daily Dose for Five Days|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:43.135077|2018-06-01 05:10:43.135077
NCT00004101|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-08|2004-04-30|2004-05-03|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 1999||1999-11-30|May 2001|2001-05-31||||June 2005|Actual|2005-06-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|Phase I Trial of Humanized 1D10 Monoclonal Antibody (Hu1D10) In Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:43.241247|2018-06-01 05:10:43.241247
NCT00004049|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2008-07-23|2004-04-30|2004-05-03|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 1999||1999-04-30|May 2001|2001-05-31||||||||Interventional|||SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I and Pharmacokinetic Study of SR-45023A Administered Once Every 7 Days|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:43.368262|2018-06-01 05:10:43.368262
NCT00003972|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-31|2004-04-30|2004-05-03|Estimate|||||||2010-03-31|2010-04-02|Estimate|July 1998||1998-07-31|March 2010|2010-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer|A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast Cancer|Completed||Phase 3|280|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:10:43.431941|2018-06-01 05:10:43.431941
NCT00003968|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2004-04-30|2004-05-03|Estimate|||||||2013-02-07|2013-02-08|Estimate|June 1999||1999-06-30|January 2004|2004-01-31||||December 2003|Actual|2003-12-31||Interventional|||Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer|Phase II Study of Bryostatin-1 in Metastatic Renal Cell Carcinoma(Summary Last Modified 8/1999)|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:43.521917|2018-06-01 05:10:43.521917
NCT00003943|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-16|2004-04-30|2004-05-03|Estimate|||||||2013-04-16|2013-04-17|Estimate|September 1998||1998-09-30|April 2013|2013-04-30|February 2003|Actual|2003-02-28|November 2000|Actual|2000-11-30||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.|A Phase II Trial of High Dose Paclitaxel, Carboplatin and Topotecan With Peripheral Blood Stem Cell Support in Extensive Stage Small Cell Cancer|Completed||Phase 2|3|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:10:43.64048|2018-06-01 05:10:43.64048
NCT00003900|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-04-30|2004-05-03|Estimate|||||||2016-07-01|2016-07-06|Estimate|October 1999||1999-10-31|July 2016|2016-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer|A Phase II Study of Irinotecan (CPT-11) and Docetaxel (Taxotere) in Patients With Recurrent Non-Small Cell Lung Cancer|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:10:43.777651|2018-06-01 05:10:43.777651
NCT00003849|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-04-30|2004-05-03|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 1999||1999-07-31|July 2016|2016-07-31|February 2008|Actual|2008-02-29|February 2005|Actual|2005-02-28||Interventional|||Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Phase II Trial of C2B8 in Patients With Asymptomatic CD20+ B-Cell Follicular Small Cleaved Low-Grade Non-Hodgkin's Lymphoma or Relapsed CD20+ Hodgkin's Disease|Completed||Phase 2|39|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:10:43.917846|2018-06-01 05:10:43.917846
NCT00003825|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-09|2004-04-30|2004-05-03|Estimate|||||||2013-08-09|2013-08-13|Estimate|June 1999||1999-06-30|August 2013|2013-08-31||||April 2006|Actual|2006-04-30||Interventional|||Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy|Phase III Study of Pentosanpolysulfate (PPS) in Treatment of GI Tract Sequelae of Radiotherapy|Completed||Phase 3|174|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:10:44.106216|2018-06-01 05:10:44.106216
NCT00003768|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-01-06|2004-04-30|2004-05-03|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 1998||1998-09-30|January 2014|2014-01-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Combretastatin A4 Phosphate in Treating Patients With Advanced Solid Tumors|A Phase I Pharmacokinetic Study of Single Dose Intravenous CA4P in Patients With Advanced Cancer|Completed||Phase 1|25|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:10:44.708418|2018-06-01 05:10:44.708418
NCT00003726|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-05-16||2016-06-27|2004-04-30|2004-05-03|Estimate|2016-06-27|2016-08-08|Estimate||||2016-06-27|2016-08-08|Estimate|November 1998||1998-11-30|June 2016|2016-06-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer|A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy|Terminated||Phase 1/Phase 2|1|Actual|Dartmouth-Hitchcock Medical Center|The funding of the trial was discontinued and therefore only one participant was enrolled to the trial and experienced no adverse events.|1||Study funding was dropped.|f||||t||||||||||2018-06-01 05:10:45.008609|2018-06-01 05:10:45.008609
NCT00003713|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-04-30|2004-05-03|Estimate|||||||2008-07-23|2008-07-24|Estimate|August 1997||1997-08-31|May 2001|2001-05-31||||||||Interventional|||Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I, Pharmacokinetic, and Treatment Duration and Escalation Study of Intravenous Intoplicine Administered as a 5 to 21-Day Continuous Infusion Every 4 Weeks|Unknown status|Active, not recruiting|Phase 1|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:45.257337|2018-06-01 05:10:45.257337
NCT00003680|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-04-30|2004-05-03|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 1998||1998-11-30|May 2007|2007-05-31||||||||Interventional|||Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer|A Randomised Comparative Trial of Highly Intensive Chemotherapy With Stem Cell Support vs. Relatively Intensive Chemotherapy (CMF 8 Cycles) in Breast Cancer Patients Node Positive Surgery, Having Received Primary Medical Therapy With an Anthracycline Regimen|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:45.357129|2018-06-01 05:10:45.357129
NCT00003646|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-07-05|2004-04-30|2004-05-03|Estimate|||||||2011-07-05|2011-07-07|Estimate|August 1998||1998-08-31|July 2011|2011-07-31|May 2002|Actual|2002-05-31|March 2002|Actual|2002-03-31||Interventional|||Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma|Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma|Completed||Phase 2|78|Actual|Vical|||||f||||t||||||||||2018-06-01 05:10:45.766343|2018-06-01 05:10:45.766343
NCT00003638|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-25|2004-04-30|2004-05-03|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 1999||1999-01-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|January 2007|Actual|2007-01-31||Interventional|||Vaccine Therapy in Treating Women With Metastatic Breast Cancer|A Multi-Center Phase III Randomized, Controlled Study of Theratope Vaccine for Metastatic Breast Cancer|Completed||Phase 3|950|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:45.907178|2018-06-01 05:10:45.907178
NCT00003622|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-07-10|2004-04-30|2004-05-03|Estimate|||||||2017-07-10|2017-07-13|Actual|January 1999||1999-01-31|July 2017|2017-07-31|February 22, 2017|Actual|2017-02-22|May 2008|Actual|2008-05-31||Interventional|||Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy|Phase II Study of Vinorelbine With Paclitaxel in the Treatment of Hormone-Refractory Prostate Cancer|Withdrawn||Phase 2|0|Actual|George Washington University||1||No recruitment|f||||||||||||||2018-06-01 05:10:46.082978|2018-06-01 05:10:46.082978
NCT00082147|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-30|||2018-04-14|2004-04-29|2004-04-30|Estimate|||||||2018-04-14|2018-04-17|Actual|April 29, 2004||2004-04-29|July 5, 2017|2017-07-05|February 21, 2007|Actual|2007-02-21|||||Interventional|||Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer|A Prospective Histopathologic Study of Dynamic Contrast Enhanced MRI for Prostate Cancer Delineation and Characterization With the APT-MRI System|Completed||N/A|20|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:10:46.30528|2018-06-01 05:10:46.30528
NCT00082108|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-29|||2017-08-11|2004-04-29|2004-04-30|Estimate|||||||2017-08-11|2017-08-15|Actual|September 2000||2000-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry|National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members|Recruiting|||3000|Anticipated|University of Rochester|||||f||||f||||||||||2018-06-01 05:10:46.554224|2018-06-01 05:10:46.554224
NCT00082095|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-29|||2014-10-08|2004-04-29|2004-04-30|Estimate|||||||2014-10-08|2014-10-09|Estimate|April 2004||2004-04-30|October 2014|2014-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older|A Randomized, Open-Label Trial Comparing Treatment With Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older|Terminated||Phase 3|62|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||"The study was terminated due to poor recruitment (after enrolling 62 of planned 300 patients in~   20 months"|f||||f||||||||||2018-06-01 05:10:46.754634|2018-06-01 05:10:46.754634
NCT00080041|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-22|||2007-05-11|2004-03-22|2004-03-23|Estimate|||||||2007-05-11|2007-05-15|Estimate||||May 2007|2007-05-31||||||||Interventional|||Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors|Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors|Completed||Phase 1|20||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 05:12:04.776991|2018-06-01 05:12:04.776991
NCT00082069|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-28|||2015-04-28|2004-04-29|2004-04-30|Estimate|||||||2015-04-28|2015-04-30|Estimate|April 2004||2004-04-30|April 2015|2015-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Invaplex 50 Vaccine Dose-Ranging|Safety and Immunogenicity Study of an Intranasal Shigella Flexneri 2a Invaplex 50 Vaccine|Completed||Phase 1|32|Actual|U.S. Army Medical Research and Materiel Command|||||f||||||||||||||2018-06-01 05:10:47.302649|2018-06-01 05:10:47.302649
NCT00081978|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-28|||2010-04-26|2004-04-29|2004-04-30|Estimate|||||||2010-04-26|2010-04-28|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|October 2005|Actual|2005-10-31|||||Interventional|||TMC125-C223: TMC125 in HIV-1 Infected Subjects|A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125 in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations|Completed||Phase 2|211|Actual|Tibotec Pharmaceuticals, Ireland|||||||||||||||||||2018-06-01 05:10:47.424686|2018-06-01 05:10:47.424686
NCT00003583|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-04-29|2004-04-30|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 1997||1997-06-30|May 2006|2006-05-31||||||||Interventional|||Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer|A Phase II Trial Using Amifostine as a Chemo/Radio Protective Agent in the Treatment of Limited Stage Small-Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:47.645465|2018-06-01 05:10:47.645465
NCT00003563|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-10-29|2004-04-29|2004-04-30|Estimate|||||||2013-10-29|2013-10-31|Estimate|August 1998||1998-08-31|June 2008|2008-06-30|June 2005|Actual|2005-06-30|September 2001|Actual|2001-09-30||Interventional|||Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases|Phase III Randomized Trial of Gadolinium Texaphyrin (PCI-0120) Injection as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases|Completed||Phase 3|430|Anticipated|Pharmacyclics LLC.||2|||||||||||||||||2018-06-01 05:10:47.800135|2018-06-01 05:10:47.800135
NCT00003554|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2004-04-29|2004-04-30|Estimate|||||||2013-07-17|2013-07-18|Estimate|November 1998||1998-11-30|March 2008|2008-03-31|April 2004|Actual|2004-04-30|||||Interventional|||Rituximab in Treating Patients With Multiple Myeloma|Rituxan in the Management of Multiple Myeloma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:48.094015|2018-06-01 05:10:48.094015
NCT00003397|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-09-23|2004-04-29|2004-04-30|Estimate|||||||2009-09-23|2009-09-24|Estimate|September 1998||1998-09-30|September 2009|2009-09-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Autologous Stem Cell Transplantation for Poor Prognosis, Relapsed, or Refractory Intermediate-High Grade B-Cell Lymphoma Using Gemcitabine Plus High Dose BCNU and Melphalan Followed by Anti-CD20 Moab (IDEC C2B8, Rituximab, Rituxan) and Consolidative Chemotherapy|Completed||Phase 2|25|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 05:10:48.200594|2018-06-01 05:10:48.200594
NCT00003394|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-04-29|2004-04-30|Estimate|||||||2013-06-20|2013-06-24|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer|Phase I/II Study of Weekly Intravenous Estramustine Phosphate in Combination With Paclitaxel and Carboplatin in Patients With Advanced Prostate Cancer|Completed||Phase 1/Phase 2|18|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:48.333027|2018-06-01 05:10:48.333027
NCT00003276|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-04-29|2004-04-30|Estimate|||||||2016-07-01|2016-07-06|Estimate|March 1998||1998-03-31|July 2016|2016-07-31|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer|A Phase II Study of CPT-11 in Patients With Advanced Gallbladder or Bile Duct Tumors|Completed||Phase 2|40|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:10:48.463429|2018-06-01 05:10:48.463429
NCT00003239|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-04-29|2004-04-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|March 1998||1998-03-31|July 2012|2012-07-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Alpha Interferon (IFN-A), Low-Dose Cytosine Arabinoside (ARA-C), and Homoharringtonine (HHT)|Completed||Phase 2|90|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:10:48.64515|2018-06-01 05:10:48.64515
NCT00003181|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-04-29|2004-04-30|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 1997||1997-05-31|May 2001|2001-05-31||||||||Interventional|||Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Using Low Dose Subcutaneous IL-2, Vinblastine and GM-CSF in the Treatment of Metastatic Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:48.765682|2018-06-01 05:10:48.765682
NCT00003175|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-04-29|2004-04-30|Estimate|||||||2013-12-03|2013-12-04|Estimate|December 1997||1997-12-31|February 2010|2010-02-28|March 2009|Actual|2009-03-31|||||Interventional|||Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer|A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract|Completed||Phase 2|45|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:48.83361|2018-06-01 05:10:48.83361
NCT00003165|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-04-29|2004-04-30|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 1997||1997-12-31|April 2010|2010-04-30||||||||Interventional|||Doxorubicin in Treating Women With Advanced Breast Cancer|A Phase II Trial of PK1 in Women With Advanced Breast Cancer|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:48.970857|2018-06-01 05:10:48.970857
NCT00003133|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-26|2004-04-29|2004-04-30|Estimate|||||||2013-06-26|2013-06-28|Estimate|September 1997||1997-09-30|June 2013|2013-06-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer|Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy After Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium|Completed||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:49.035512|2018-06-01 05:10:49.035512
NCT00003038|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-08-02|2004-04-29|2004-04-30|Estimate|||||||2011-08-02|2011-08-03|Estimate|October 1997||1997-10-31|August 2011|2011-08-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Suramin With Sequential Doxorubicin in Patients With Advanced Solid Tumors|Completed||Phase 1|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:10:49.092043|2018-06-01 05:10:49.092043
NCT00003019|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2014-07-24|2004-04-29|2004-04-30|Estimate|||||||2014-07-24|2014-07-25|Estimate|August 1997||1997-08-31|July 2014|2014-07-31|September 2006|Actual|2006-09-30|July 2003|Actual|2003-07-31||Interventional|||Vinblastine and Methotrexate in Treating Children With Desmoid Tumors|Vinblastine and Methotrexate in Children With Desmoid Tumor (Aggressive Fibromatosis) Which is Recurrent or Not Amenable to Surgical Resection or Irradiation - A Pediatric Oncology Group Phase II Study|Completed||Phase 2|28|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:10:49.14918|2018-06-01 05:10:49.14918
NCT00081939|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-27|2015-09-18||2017-09-13|2004-04-28|2004-04-29|Estimate|2015-09-18|2015-10-21|Estimate||||2017-09-13|2017-10-17|Actual|January 2004||2004-01-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||UARK 2003-33, Total Therapy III|A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance|Completed||Phase 2|303|Actual|University of Arkansas||1|||f||||t||||||||||2018-06-01 05:10:50.163359|2018-06-01 05:10:50.163359
NCT00081926|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-26|||2009-11-20|2004-04-28|2004-04-29|Estimate|||||||2009-11-20|2009-11-23|Estimate|October 2003||2003-10-31|November 2009|2009-11-30|March 2007||2007-03-31|||||Interventional|||Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia||Completed||Phase 4|112||Novartis|||||||||||||||||||2018-06-01 05:10:51.079719|2018-06-01 05:10:51.079719
NCT00014365|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-06-17|2004-04-28|2004-04-29|Estimate|||||||2013-06-17|2013-06-18|Estimate|October 2000||2000-10-31|June 2013|2013-06-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Ro 31-7453 in Treating Patients With Metastatic Solid Tumors|The Food-Effect Bioavailability Study of Ro 31-7453, a Novel Cell Cycle Inhibitor, in Stable Patient Volunteers With Solid Tumors|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:51.192091|2018-06-01 05:10:51.192091
NCT00006483|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2016-07-12|2004-04-28|2004-04-29|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 2000||2000-10-31|July 2016|2016-07-31|January 2013|Actual|2013-01-31|January 2003|Actual|2003-01-31||Interventional|||Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung|A Phase II Study Of Aerosolized GM-CSF In The Treatment Of Metastatic Renal Cell Carcinoma To The Lung|Completed||Phase 2|27|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:10:51.267678|2018-06-01 05:10:51.267678
NCT00006261|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2010-06-09|2004-04-28|2004-04-29|Estimate|||||||2010-06-09|2010-06-10|Estimate|May 2000||2000-05-31|June 2010|2010-06-30||||||||Interventional|||Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer|Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:10:51.504651|2018-06-01 05:10:51.504651
NCT00006106|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-07-09|2004-04-28|2004-04-29|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 1999||1999-07-31|December 2006|2006-12-31||||||||Interventional|||ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer|Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck|Withdrawn||Phase 1|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:51.600961|2018-06-01 05:10:51.600961
NCT00003001|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-04-28|2004-04-29|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 1997||1997-04-30|April 2002|2002-04-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer|Phase I/II Study of 5-Fluorouracil/Folinic Acid/Gemcitabine in Patients With Advanced Colorectal Carcinoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|63|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:51.767726|2018-06-01 05:10:51.767726
NCT00002977|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-13|2004-04-28|2004-04-29|Estimate|||||||2010-09-13|2010-09-15|Estimate|January 1997||1997-01-31|September 2010|2010-09-30||||November 2001|Actual|2001-11-30||Interventional|||Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission|A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer|Completed||Phase 1|45|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:10:51.897351|2018-06-01 05:10:51.897351
NCT00002939|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-04|2004-04-28|2004-04-29|Estimate|||||||2013-09-04|2013-09-05|Estimate|November 1996||1996-11-30|September 2013|2013-09-30|April 2002|Actual|2002-04-30|February 2001|Actual|2001-02-28||Interventional|||Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer|A Phase I Trial of Dose Escalated Irinotecan (CPT-11) With Paclitaxel in Patients With Metastatic or Recurrent Malignancies|Completed||Phase 1|21|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:10:52.021854|2018-06-01 05:10:52.021854
NCT00002912|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-31|2004-04-28|2004-04-29|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 1997||1997-01-31|August 2010|2010-08-31||||March 2006|Actual|2006-03-31||Interventional|||Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia|A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA|Completed||Phase 1|3|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:10:52.224723|2018-06-01 05:10:52.224723
NCT00002884|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2004-04-28|2004-04-29|Estimate|||||||2013-08-06|2013-08-07|Estimate|March 1996||1996-03-31|May 2007|2007-05-31||||||||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus|A PROSPECTIVE RANDOMISED NON SURGICAL TREATMENT OF OESOPHAGEAL CANCER WITH COMBINED CHEMOTHERAPY AND EXTERNAL BEAM IRRADIATION WITH VS WITHOUT HIGH-DOSE BRACHYTHERAPY|Unknown status|Active, not recruiting|Phase 3|326|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:52.451634|2018-06-01 05:10:52.451634
NCT00002773|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2004-04-28|2004-04-29|Estimate|||||||2013-07-09|2013-07-10|Estimate|May 1996||1996-05-31|April 2007|2007-04-30|April 2004|Actual|2004-04-30|||||Interventional|||Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer|A CLINICAL TRIAL FOR PANCREAS CANCER USING ACTIVE INTRALYMPHATIC IMMUNOTHERAPY WITH INTERFERON-TREATED PANCREAS CANCER TISSUE CULTURE CELLS, GMCSF, AND LOW-DOSE CYCLOPHOSPHAMIDE|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:52.571014|2018-06-01 05:10:52.571014
NCT00002719|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-04-28|2004-04-29|Estimate|||||||2012-06-29|2012-07-02|Estimate|December 1995||1995-12-31|June 2012|2012-06-30||||November 2001|Actual|2001-11-30||Interventional|||Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia|RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL)|Completed||Phase 3|500|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:10:52.688212|2018-06-01 05:10:52.688212
NCT00002680|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-23|2004-04-28|2004-04-29|Estimate|||||||2013-07-23|2013-07-24|Estimate|February 1994||1994-02-28|August 2009|2009-08-31|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer|Phase II Trial of Sequential High-Dose Alkylating Agents in Metastatic Breast Cancer|Completed||Phase 2|40|Actual|Yale University|||||f||||f||||||||||2018-06-01 05:10:52.831614|2018-06-01 05:10:52.831614
NCT00002590|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2004-04-28|2004-04-29|Estimate|||||||2014-07-23|2014-07-24|Estimate|July 1994||1994-07-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|March 2001|Actual|2001-03-31||Interventional|||Combination Chemotherapy in Treating Children With Lymphoma|A Pilot Study For The Treatment of Newly-Diagnosed Disseminated Anaplastic Large Cell Ki-1 Lymphoma and T-Large Cell Lymphoma|Completed||Phase 2|221|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:10:52.944247|2018-06-01 05:10:52.944247
NCT00002564|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-04-28|2004-04-29|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 1994||1994-04-30|February 2010|2010-02-28|December 2006|Actual|2006-12-31|||||Interventional|||Nutrition Intervention in Treating Women With Breast Cancer|A CLINICAL TRIAL TO DETERMINE THE EFFICACY OF A DIETARY FAT REDUCTION PROGRAM PROVIDED IN ADDITION TO SYSTEMIC ADJUVANT THERAPY IN THE MANAGEMENT OF PATIENTS WITH PRIMARY INVASIVE BREAST CANCER|Completed||Phase 3|2500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:53.252559|2018-06-01 05:10:53.252559
NCT00002481|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-04-28|2004-04-29|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 1990||1990-03-31|May 2001|2001-05-31||||||||Interventional|||Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase II Study of High-Dose Cytarabine, Cisplatin, and Dexamethasone Followed By Cyclophosphamide, Etoposide, Total Body Irradiation, and Autologous Bone Marrow Rescue in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:53.444275|2018-06-01 05:10:53.444275
NCT00082043|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-28|||2018-05-22|2004-04-27|2004-04-28|Estimate|||||||2018-05-22|2018-05-23|Actual|March 31, 2004||2004-03-31|February 5, 2016|2016-02-05|March 6, 2014|Actual|2014-03-06|March 6, 2014|Actual|2014-03-06||Interventional|||Dutasteride to Treat Women With Menstrually Related Mood Disorders|The Effects of Dutasteride on Mood, HPA Axis, and Serum Allopregnanolone Levels in Women With Menstrual-Related Mood Disorders and Controls|Completed||Phase 1|34|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:10:53.616348|2018-06-01 05:10:53.616348
NCT00082030|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-28|||2017-06-30|2004-04-27|2004-04-28|Estimate|||||||2017-06-30|2017-07-02|Actual|April 19, 2004||2004-04-19|November 18, 2011|2011-11-18|November 18, 2011||2011-11-18|||||Observational|||Function of Catecholamines in the Brain During Depression|Neural Correlates of Depressive Symptoms and Reward Related Mechanisms Following AMPT Depletion in Remitted Depressed Patients Off Treatment and Healthy Controls|Completed|||71|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:53.867279|2018-06-01 05:10:53.867279
NCT00082017|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-28|2012-06-06||2017-05-01|2004-04-27|2004-04-28|Estimate|2012-07-26|2012-08-29|Estimate||||2017-05-01|2017-05-15|Actual|April 5, 2004|Actual|2004-04-05|May 2017|2017-05-31|September 27, 2011|Actual|2011-09-27|September 27, 2011|Actual|2011-09-27||Interventional|||UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas|Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas|Terminated||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)||2||IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.|f||||f|t|f|||t|||No||2018-06-01 05:10:54.096275|2018-06-01 05:10:54.096275
NCT00081991|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-28|||2008-03-03|2004-04-27|2004-04-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2004||2004-04-30|April 2005|2005-04-30|April 2005||2005-04-30|||||Observational|||Dynamic Light Scattering for Studying Lens Aging and Cataract Formation|A Cross Sectional Clinical Study of Human Lens Aging and Cataract Formation, in Vivo, Using Dynamic Light Scattering (DLS)|Completed|||267||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:10:55.099135|2018-06-01 05:10:55.099135
NCT00081965|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-27|||2012-12-11|2004-04-27|2004-04-28|Estimate|||||||2012-12-11|2012-12-13|Estimate||||December 2012|2012-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Acupuncture in Treating Hot Flashes in Women With Breast Cancer|Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients: A Randomized Controlled Trial|Completed||N/A|80|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:55.211986|2018-06-01 05:10:55.211986
NCT00081952|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-27|||2013-03-21|2004-04-27|2004-04-28|Estimate|||||||2013-03-21|2013-03-22|Estimate|October 2003||2003-10-31|March 2013|2013-03-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Amino Acid Therapy for Hot Flashes in Postmenopausal Women|Amino Acid Therapy for Hot Flashes/Postmenopausal Women|Completed||Phase 1/Phase 2|15||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:10:55.355459|2018-06-01 05:10:55.355459
NCT00081913|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-26|||2008-01-23|2004-04-27|2004-04-28|Estimate|||||||2008-01-23|2008-01-29|Estimate|January 2004||2004-01-31|January 2008|2008-01-31|June 2006|Actual|2006-06-30|March 2006|Actual|2006-03-31||Interventional|||Stem Cell Study for Patients With Heart Disease|Injection of Autologous CD34-Positive Cells for Neovascularization and Symptom Relief in Patients With Myocardial Ischemia|Completed||Phase 1|24||Losordo, Douglas, M.D.|||||||||||||||||||2018-06-01 05:10:55.50166|2018-06-01 05:10:55.50166
NCT00081900|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-26|||2015-04-09|2004-04-27|2004-04-28|Estimate|||||||2015-04-09|2015-04-13|Estimate|March 2004||2004-03-31|April 2015|2015-04-30|November 2007|Actual|2007-11-30|July 2007|Actual|2007-07-31||Interventional|||A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care|A Phase 1/2 Study of DENSPM (N1, N11-diethylnorspermine) in Patients With Unresectable Hepatocellular Carcinoma|Terminated||Phase 1/Phase 2|38|Actual|Sanofi||1||"This study was terminated early by Genzyme because there were insufficient data to support~   clinical benefit to HCC patients on the study."|f||||t||||||||||2018-06-01 05:10:55.612123|2018-06-01 05:10:55.612123
NCT00005969|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-02-17|2004-04-27|2004-04-28|Estimate|||||||2012-02-17|2012-02-20|Estimate|September 1999||1999-09-30|February 2012|2012-02-29||||January 2001|Actual|2001-01-31||Interventional|||Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease|Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients With Relapsed or Refractory Hodgkin's Disease|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Study withdrawn.|f||||f||||||||||2018-06-01 05:10:55.857451|2018-06-01 05:10:55.857451
NCT00005883|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2011-03-25|2004-04-27|2004-04-28|Estimate|||||||2011-03-25|2011-03-28|Estimate||||March 2011|2011-03-31||||April 2001|Actual|2001-04-30||Interventional|||Phenethyl Isothiocyanate in Preventing Lung Cancer in People Who Smoke|A Phase I - Part B Multiple Dose Trial of Phenethyl Isothiocyanate|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:10:56.005955|2018-06-01 05:10:56.005955
NCT00071591|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-06-13|2003-10-29|2003-10-30|Estimate|||||||2013-06-13|2013-06-14|Estimate|July 2001||2001-07-31|June 2013|2013-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Rehabilitative Training for Older People With Schizophrenia|Functional Skills Training for Late Life Schizophrenia|Completed||Phase 2|240||University of California, San Diego|||||f||||||||||||||2018-06-01 05:16:10.29693|2018-06-01 05:16:10.29693
NCT00005796|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2015-03-23|2004-04-27|2004-04-28|Estimate|||||||2015-03-23|2015-03-25|Estimate|February 2000||2000-02-29|March 2015|2015-03-31|December 2011|Actual|2011-12-31|June 2003|Actual|2003-06-30||Interventional|||Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors|A Pilot Study of Dose-Intensified Procarbazine, CCNU, Vincristine (PCV) for Poor Prognosis Pediatric and Adult Brain Tumors Utilizing Fibronectin-Assisted, Retroviral-Mediated Modification of CD34+ Peripheral Blood Cells With O6-Methylguanine DNA Methyltransferase|Completed||Phase 1|10|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 05:10:56.136945|2018-06-01 05:10:56.136945
NCT00005649|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2017-08-15|2004-04-27|2004-04-28|Estimate|||||||2017-08-15|2017-08-16|Actual|July 1998||1998-07-31|August 2017|2017-08-31|July 4, 2002||2002-07-04|July 4, 2002|Actual|2002-07-04||Interventional|||Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer|An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma|Completed||Phase 2|||Hoffmann-La Roche|||||f||||||||||||||2018-06-01 05:10:56.36377|2018-06-01 05:10:56.36377
NCT00004933|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2016-07-01|2004-04-27|2004-04-28|Estimate|||||||2016-07-01|2016-07-04|Estimate|January 2000||2000-01-31|July 2016|2016-07-31|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa|A Phase III Study of Interferon-Refractory Patients With BCR/ABL(+) Chronic Myelogenous Leukemia (CML) Treated With Homoharringtonine (NSC #141633) vs. Hydroxyurea|Terminated||Phase 3|5|Actual|Alliance for Clinical Trials in Oncology||2||Poor accrual|f||||t||||||||||2018-06-01 05:10:56.469517|2018-06-01 05:10:56.469517
NCT00004923|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2009-08-21|2004-04-27|2004-04-28|Estimate|||||||2009-08-21|2009-08-25|Estimate|April 1999||1999-04-30|August 2009|2009-08-31|May 2006|Actual|2006-05-31|||||Interventional|||Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors|Dose Escalation Trial of Docetaxel Plus Irinotecan in Patients With Advanced Cancer|Completed||Phase 1/Phase 2|47|Actual|Yale University|||||f||||f||||||||||2018-06-01 05:10:56.778139|2018-06-01 05:10:56.778139
NCT00004903|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2014-01-03|2004-04-27|2004-04-28|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 1999||1999-10-31|June 2001|2001-06-30||||||||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase II Study of High Dose Late Intensification Therapy in Patients With Chemotherapy Sensitive Multiple Myeloma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:56.89983|2018-06-01 05:10:56.89983
NCT00004878|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-07-27|2004-04-27|2004-04-28|Estimate|||||||2012-07-27|2012-07-31|Estimate||||July 2012|2012-07-31||||||||Interventional|||Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia|A Study to Determine the Safety and Efficacy of Using CD8-High Density Microparticles (CD8-HDM) to Deplete CD8+ Cells From Donor Lymphocyte Infusion in Order to Reduce Graft-versus-Host Disease (GvHD) Without Compromising an Anti-Leukemia Effect in Patients With Chronic Myeloid Leukemia Given HLA-Identical Sibling Peripheral Blood Stem Cell Transplants After Non-Myeloablative Conditioning|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||||study never opened|f||||||||||||||2018-06-01 05:10:56.995505|2018-06-01 05:10:56.995505
NCT00004872|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2015-09-30|2004-04-27|2004-04-28|Estimate|||||||2015-09-30|2015-10-02|Estimate|March 2000||2000-03-31|September 2015|2015-09-30||||||||Interventional|||Endostatin in Treating Patients With Advanced Refractory Solid Tumors|Phase I Study of Endostatin in Advanced Cancer Patients|Completed||Phase 1|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:10:57.097705|2018-06-01 05:10:57.097705
NCT00004858|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-09-19|2004-04-27|2004-04-28|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2000||2000-03-31|July 2007|2007-07-31||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|A Phase I Study of B43-Genistein Immunoconjugate in Recurrent B-Lineage Acute Lymphoblastic Leukemia and Non Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:10:57.210161|2018-06-01 05:10:57.210161
NCT00004604|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-02-21|2004-04-27|2004-04-28|Estimate|||||||2013-02-21|2013-02-22|Estimate|February 1997||1997-02-28|February 2013|2013-02-28|July 2002|Actual|2002-07-31|June 2001|Actual|2001-06-30||Interventional|||Biological Therapy in Treating Patients With Metastatic Cancer|A Phase I Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Metastatic Malignancies Expressing Carcinoembryonic Antigen|Completed||Phase 1|24|Actual|Duke University||1|||f||||f||||||||||2018-06-01 05:10:57.408649|2018-06-01 05:10:57.408649
NCT00004249|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-06-18|2004-04-27|2004-04-28|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 1998||1998-08-31|June 2013|2013-06-30|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy|Immunization Using Polysialic Acid-KLH or N-Propionylated Polysialic Acid-KLH Conjugate Plus the Immunological Adjuvant QS-21 in Patients With Small Cell Lung Cancer Who Have Achieved a Major Response to Initial Therapy|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:10:57.626039|2018-06-01 05:10:57.626039
NCT00004174|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-07-09|2004-04-27|2004-04-28|Estimate|||||||2013-07-09|2013-07-10|Estimate|October 1999||1999-10-31|July 2013|2013-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer|High Dose Paclitaxel Added to Cyclophosphamide and Thiotepa Followed by Autologous Stem Cell Rescue: A Phase I Trial in Advanced Breast Cancer|Completed||Phase 1|30|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 05:10:57.769922|2018-06-01 05:10:57.769922
NCT00003960|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-01|2004-04-27|2004-04-28|Estimate|||||||2014-05-01|2014-05-02|Estimate|April 1998||1998-04-30|May 2014|2014-05-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies|Completed||Phase 2|36|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:10:57.946234|2018-06-01 05:10:57.946234
NCT00003953|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-25|2004-04-27|2004-04-28|Estimate|||||||2013-01-25|2013-01-28|Estimate|February 1999||1999-02-28|January 2013|2013-01-31|January 2013|Actual|2013-01-31|November 2001|Actual|2001-11-30||Interventional|||Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer|A Phase II Study of Preoperative Dose-Dense Chemotherapy With Sequential Doxorubicin and Docetaxel for Initial Treatment of Operable and Inoperable Stage II-IIIB Breast Cancer|Completed||Phase 2|39|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:10:58.140987|2018-06-01 05:10:58.140987
NCT00081887|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-23|||2012-07-31|2004-04-26|2004-04-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2004||2004-05-31|July 2012|2012-07-31|June 2007|Actual|2007-06-30|May 2007|Actual|2007-05-31||Interventional|||Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia|Phase I Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia|Terminated||Phase 1|8|Actual|M.D. Anderson Cancer Center||1||low accrual|f||||f||||||||||2018-06-01 05:10:58.342009|2018-06-01 05:10:58.342009
NCT00081874|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-23|||2012-03-20|2004-04-26|2004-04-27|Estimate|||||||2012-03-20|2012-03-21|Estimate|April 2004||2004-04-30|March 2012|2012-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma|Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma|Completed||Phase 1/Phase 2|29|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:10:58.548875|2018-06-01 05:10:58.548875
NCT00081861|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-23|2009-03-05||2012-04-02|2004-04-26|2004-04-27|Estimate|2009-07-17|2009-08-26|Estimate||||2012-04-02|2012-04-05|Estimate|March 2004||2004-03-31|April 2012|2012-04-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma|A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|13|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:10:58.80194|2018-06-01 05:10:58.80194
NCT00003950|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-03-06|2004-04-26|2004-04-27|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2000||2000-01-31|March 2014|2014-03-31|January 2005|Actual|2005-01-31|December 2001|Actual|2001-12-31||Interventional|||Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer|A Phase II Trial of Irinotecan (CPT-11) and Cyclosporine in Patients With 5-FU Refractory Advanced Colorectal Cancer|Completed||Phase 2|16|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:10:59.161941|2018-06-01 05:10:59.161941
NCT00003914|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-05-10|2004-04-26|2004-04-27|Estimate|||||||2011-05-10|2011-05-11|Estimate|August 1999||1999-08-31|May 2011|2011-05-31|May 2009|Actual|2009-05-31|August 2002|Actual|2002-08-31||Interventional|||Dolastatin 10 in Treating Patients With Advanced Kidney Cancer|Phase II Study of Dolastatin-10 in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|30|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 05:10:59.44463|2018-06-01 05:10:59.44463
NCT00003887|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-11-28|2004-04-26|2004-04-27|Estimate|||||||2011-11-28|2011-11-30|Estimate|August 1998||1998-08-31|November 2011|2011-11-30|February 2003|Actual|2003-02-28|||||Interventional|||Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation|Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:10:59.567509|2018-06-01 05:10:59.567509
NCT00003835|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-10-07|2004-04-26|2004-04-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|May 1999||1999-05-31|October 2013|2013-10-31||||August 2007|Actual|2007-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Stage III Colon Cancer|Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer|Completed||Phase 3|1260|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:10:59.718254|2018-06-01 05:10:59.718254
NCT00003819|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-18|2004-04-26|2004-04-27|Estimate|||||||2013-03-18|2013-03-19|Estimate|June 1998||1998-06-30|March 2013|2013-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer|Vaccination of Prostate Cancer Patients With Thompson-Friedenreich [TF(c)]-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Comparing TF(c)-KLH Doses|Completed||Phase 1|21|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:10:59.916939|2018-06-01 05:10:59.916939
NCT00003783|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-24|2004-04-26|2004-04-27|Estimate|||||||2014-07-24|2014-07-28|Estimate|March 1999||1999-03-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|November 2002|Actual|2002-11-30||Interventional|||Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia|ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study|Completed||Phase 2|36|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:11:00.119841|2018-06-01 05:11:00.119841
NCT00003765|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-04-26|2004-04-27|Estimate|||||||2013-02-04|2013-02-05|Estimate|May 1999||1999-05-31|October 2007|2007-10-31||||March 2006|Actual|2006-03-31||Interventional|||O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors|A Trial of 06-BG and BCNU in Children With CNS Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:00.479062|2018-06-01 05:11:00.479062
NCT00003619|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-04-26|2004-04-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|February 1998||1998-02-28|February 2008|2008-02-29|April 2004|Actual|2004-04-30|||||Interventional|||Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia|A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:00.726953|2018-06-01 05:11:00.726953
NCT00003544|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-04-26|2004-04-27|Estimate|||||||2013-06-24|2013-06-26|Estimate|June 1998||1998-06-30|June 2013|2013-06-30|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Irinotecan in Treating Patients With Metastatic Colorectal Cancer|A Phase II Trial of Preoperative Irinotecan (CPT-11) in Patients With High-Risk Resectable Metastatic Colorectal Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:00.839685|2018-06-01 05:11:00.839685
NCT00003434|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-07|2004-04-26|2004-04-27|Estimate|||||||2014-02-07|2014-02-10|Estimate|June 1998||1998-06-30|February 2014|2014-02-28|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer|A Pilot Study of Active Immunotherapy With Carcinoembryonic Antigen Peptide-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Resected, Stage I, II and III Pancreatic Adenocarcinoma Expressing Carcinoembryonic Antigen|Terminated||Phase 1|8|Actual|Duke University|||||f||||f||||||||||2018-06-01 05:11:00.935516|2018-06-01 05:11:00.935516
NCT00003427|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-04-26|2004-04-27|Estimate|||||||2013-06-24|2013-06-26|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer|Phase I Study to Evaluate the Combination Chemotherapy Regimen of Oxaliplatin Plus Irinotecan in Previously Treated Patients With Metastatic Gastrointestinal Cancer|Completed||Phase 1|36|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:01.051175|2018-06-01 05:11:01.051175
NCT00002492|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-14|2004-04-21|2004-04-22|Estimate|||||||2016-12-14|2016-12-15|Estimate|November 1991||1991-11-30|December 2016|2016-12-31|February 2000|Actual|2000-02-29|February 2000|Actual|2000-02-29||Interventional|||Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma|CLINICAL AND PHARMACOLOGICAL STUDY OF CHEMOTHERAPY IN SOFT TISSUE SARCOMA|Completed||Phase 2|||University of Miami|||||f||||||||||||||2018-06-01 05:11:14.076088|2018-06-01 05:11:14.076088
NCT00003407|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-05-09|2004-04-26|2004-04-27|Estimate|||||||2009-05-09|2009-05-12|Estimate|April 1998||1998-04-30|May 2006|2006-05-31||||||||Interventional|||Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia|Protocol for Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantron Followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin and Decadron|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:01.158846|2018-06-01 05:11:01.158846
NCT00003398|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-09-23|2004-04-26|2004-04-27|Estimate|||||||2009-09-23|2009-09-24|Estimate|September 1998||1998-09-30|September 2009|2009-09-30|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor|Completed||Phase 4|45|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 05:11:01.232045|2018-06-01 05:11:01.232045
NCT00003270|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-10-24|2004-04-26|2004-04-27|Estimate|||||||2017-10-24|2017-10-26|Actual|September 4, 1997|Actual|1997-09-04|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|||Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer|Cord Blood Transplantation for Hematologic Malignancies and Bone Marrow Failure Syndromes|Completed||Phase 2|20|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-06-01 05:11:01.518601|2018-06-01 05:11:01.518601
NCT00003144|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-25|2004-04-26|2004-04-27|Estimate|||||||2011-03-25|2011-03-28|Estimate|August 1997||1997-08-31|March 2011|2011-03-31||||April 2001|Actual|2001-04-30||Interventional|||Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors|Phase I Study of Amifostine (Ethyol) as a Cytoprotector of Gemcitabine/Cisplatin Combination|Completed||Phase 1|44|Anticipated|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:11:01.707359|2018-06-01 05:11:01.707359
NCT00003094|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-19|2004-04-26|2004-04-27|Estimate|||||||2014-05-19|2014-05-20|Estimate|October 1997||1997-10-31|August 2007|2007-08-31||||||||Interventional|||Carotenoid Rich Diet in Treating Cervical Dysplasia|Carotenoid-Rich Diet Trial to Reverse CIN II|Withdrawn||Phase 2|0|Actual|University of California, San Diego||||Study was halted prematurely, prior to enrollment of first participant|f||||||||||||||2018-06-01 05:11:01.947151|2018-06-01 05:11:01.947151
NCT00003081|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-16|2004-04-26|2004-04-27|Estimate|||||||2010-09-16|2010-09-20|Estimate|March 1998||1998-03-31|September 2010|2010-09-30|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma|A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarcoma|Completed||Phase 1|16|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:02.096617|2018-06-01 05:11:02.096617
NCT00002964|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-04-26|2004-04-27|Estimate|||||||2013-02-04|2013-02-05|Estimate|February 1995||1995-02-28|February 2013|2013-02-28||||April 2004|Actual|2004-04-30||Interventional|||Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer|Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light|Completed||Phase 2|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:11:02.209763|2018-06-01 05:11:02.209763
NCT00002866|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-07|2004-04-26|2004-04-27|Estimate|||||||2010-11-07|2010-11-09|Estimate|August 1996||1996-08-31|November 2010|2010-11-30|December 2009|Actual|2009-12-31|||||Interventional|||Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer|A PHASE I/II STUDY OF DOCETAXEL AND EPIRUBICIN AS FIRST LINE THERAPY FOR METASTATIC BREAST CANCER|Completed||Phase 1|50|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:11:02.323388|2018-06-01 05:11:02.323388
NCT00006475|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-02-20|2004-04-23|2004-04-26|Estimate|||||||2013-02-20|2013-02-21|Estimate|September 2000||2000-09-30|February 2013|2013-02-28|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis|An Open-Label Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Blast Crisis|Completed||Phase 2|||Novartis|||||f||||||||||||||2018-06-01 05:11:02.46406|2018-06-01 05:11:02.46406
NCT00006463|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2014-02-19|2004-04-23|2004-04-26|Estimate|||||||2014-02-19|2014-02-21|Estimate|October 2000||2000-10-31|February 2014|2014-02-28|September 2005|Actual|2005-09-30|January 2005|Actual|2005-01-31||Interventional|||Ecteinascidin 743 in Treating Children With Refractory Solid Tumors|Phase I Study of ET-743 in Pediatric Refractory Solid Tumors|Completed||Phase 1|13|Actual|Children's Oncology Group||2|||f||||f||||||||||2018-06-01 05:11:02.609594|2018-06-01 05:11:02.609594
NCT00006357|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-09-20|2004-04-23|2004-04-26|Estimate|||||||2012-09-20|2012-09-24|Estimate|August 2000||2000-08-31|September 2012|2012-09-30||||April 2001|Actual|2001-04-30||Interventional|||STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma|Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma|Completed||Phase 1/Phase 2|91|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:02.80565|2018-06-01 05:11:02.80565
NCT00006216|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-09-19|2004-04-23|2004-04-26|Estimate|||||||2013-09-19|2013-09-20|Estimate|August 1997||1997-08-31|July 2001|2001-07-31||||||||Interventional|||Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma|Treatment of Malignant Pleural Mesothelioma With Gene Modified Cancer Cell Lines|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:02.956408|2018-06-01 05:11:02.956408
NCT00006049|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-12-18|2004-04-23|2004-04-26|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2000||2000-05-31|July 2001|2001-07-31||||||||Interventional|||ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer|A Randomized, Double-Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Paclitaxel and Carboplatin Versus Placebo in Combination With Paclitaxel and Carboplatin in Chemotherapy-Naive Patients With Advanced (Stage III or IV) Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:03.148188|2018-06-01 05:11:03.148188
NCT00006048|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-12-18|2004-04-23|2004-04-26|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2000||2000-05-31|July 2001|2001-07-31||||||||Interventional|||ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer|A Randomized, Double Blind, Phase III Comparative Trial of 2 Doses of ZD1839 (IRESSA) in Combination With Gemcitabine and Cisplatin Versus Placebo in Combination With Gemcitabine and Cisplatin in Chemotherapy Naive Patients With Advanced (Stage III or IV) Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:03.265389|2018-06-01 05:11:03.265389
NCT00005870|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-04-23|2004-04-26|Estimate|||||||2013-12-03|2013-12-04|Estimate|March 1999||1999-03-31|June 2007|2007-06-30||||||||Interventional|||Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas|Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:03.383962|2018-06-01 05:11:03.383962
NCT00005849|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-02-08|2004-04-23|2004-04-26|Estimate|||||||2013-02-08|2013-02-11|Estimate|April 2000||2000-04-30|February 2013|2013-02-28|November 2003|Actual|2003-11-30|September 2002|Actual|2002-09-30||Interventional|||Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer|Phase II Study of Bryostatin-1 in Combination With Paclitaxel for Non-Small Cell Lung Cancer|Completed||Phase 2|15|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:11:03.473662|2018-06-01 05:11:03.473662
NCT00005842|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-02-08|2004-04-23|2004-04-26|Estimate|||||||2013-02-08|2013-02-11|Estimate|June 2000||2000-06-30|April 2007|2007-04-30||||February 2004|Actual|2004-02-29||Interventional|||Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer|A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:03.605696|2018-06-01 05:11:03.605696
NCT00005832|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2015-11-16|2004-04-23|2004-04-26|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2000||2000-06-30|November 2015|2015-11-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer|Completed||Phase 2|58|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:11:03.814156|2018-06-01 05:11:03.814156
NCT00002794|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-10-03|2004-04-23|2004-04-26|Estimate|||||||2011-10-03|2011-10-04|Estimate|February 1996||1996-02-29|October 2011|2011-10-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Carboplatin Plus Vincristine in Treating Children With Retinoblastoma|Evaluation of Chemotherapy as Initial Treatment for Retinoblastoma|Completed||Phase 2|25|Actual|St. Jude Children's Research Hospital|||||f||||||||||||||2018-06-01 05:11:04.112599|2018-06-01 05:11:04.112599
NCT00002553|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-11-28|2004-04-23|2004-04-26|Estimate|||||||2011-11-28|2011-11-30|Estimate|August 1990||1990-08-31|November 2011|2011-11-30|June 2003|Actual|2003-06-30|||||Interventional|||Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer|TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MARROW TRANSPLANTATION FROM UNRELATED DONORS MATCHED FOR HLA OR INCOMPATIBLE FOR ONE HLA LOCUS ANTIGEN|Completed||Phase 2|50|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:04.209096|2018-06-01 05:11:04.209096
NCT00002485|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-12|2004-04-23|2004-04-26|Estimate|||||||2014-02-12|2014-02-14|Estimate|February 1992||1992-02-29|February 2014|2014-02-28|September 2005|Actual|2005-09-30|July 2003|Actual|2003-07-31||Observational|||Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer|Barriers to Patient Enrollment Onto Frontline Therapeutic Clinical Trials and Development of Intervention Strategies to Increase the Proportion of Enrollment|Completed|||359|Actual|Children's Oncology Group|||2||f||||||||||||||2018-06-01 05:11:04.334465|2018-06-01 05:11:04.334465
NCT00002466|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2004-04-23|2004-04-26|Estimate|||||||2013-06-19|2013-06-20|Estimate|May 1990||1990-05-31|June 2013|2013-06-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer|Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:04.479919|2018-06-01 05:11:04.479919
NCT00002456|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-11-28|2004-04-23|2004-04-26|Estimate|||||||2011-11-28|2011-11-30|Estimate|May 1986||1986-05-31|November 2011|2011-11-30|April 2002|Actual|2002-04-30|||||Interventional|||Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation|Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease|Completed||Phase 3|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:04.601237|2018-06-01 05:11:04.601237
NCT00081822|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-21|||2012-04-18|2004-04-22|2004-04-23|Estimate|||||||2012-04-18|2012-04-20|Estimate|January 2004||2004-01-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|April 2009|Actual|2009-04-30||Interventional|||Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia|A Phase I Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia|Completed||Phase 1|23|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:11:04.71914|2018-06-01 05:11:04.71914
NCT00081809|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-20|||2012-09-06|2004-04-22|2004-04-23|Estimate|||||||2012-09-06|2012-09-07|Estimate|March 2000||2000-03-31|September 2012|2012-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma|A Phase II Trial of Active Specific Immunotherapy in Patients With Indolent Lymphoma Using Autologous Lymphoma-Derived Heat Shock Protein-Peptide Complex (HSPPC-96)|Completed||Phase 2|35||Agenus Inc.|||||f||||||||||||||2018-06-01 05:11:04.845298|2018-06-01 05:11:04.845298
NCT00005092|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-07-27|2004-04-22|2004-04-23|Estimate|||||||2012-07-27|2012-07-31|Estimate|March 1999||1999-03-31|July 2012|2012-07-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation|Completed||Phase 1|7|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:11:04.946744|2018-06-01 05:11:04.946744
NCT00005082|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-01-07|2004-04-22|2004-04-23|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 1998||1998-11-30|January 2013|2013-01-31||||November 2000|Actual|2000-11-30||Interventional|||Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma|Magnetic Resonance Correlates of Glioma Tumor Burden|Completed||N/A|1|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:11:05.079014|2018-06-01 05:11:05.079014
NCT00005023|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2017-11-28|2004-04-22|2004-04-23|Estimate|||||||2017-11-28|2017-11-30|Actual|March 1999||1999-03-31|November 2017|2017-11-30|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer|A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers|Completed||Phase 1|||University of Washington|||||f||||||||||||||2018-06-01 05:11:05.284487|2018-06-01 05:11:05.284487
NCT00071084|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-10|||2012-12-05|2003-10-14|2003-10-15|Estimate|||||||2012-12-05|2012-12-07|Estimate|May 2003||2003-05-31|November 2012|2012-11-30||||June 2004|Actual|2004-06-30||Interventional|||Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.||Completed||Phase 2|22|Actual|Emergent Product Development Seattle LLC||1|||f||||||||||||||2018-06-01 05:16:23.555114|2018-06-01 05:16:23.555114
NCT00004870|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-02-19|2004-04-22|2004-04-23|Estimate|||||||2013-02-19|2013-02-21|Estimate|June 2000||2000-06-30|February 2013|2013-02-28|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase I/II, Pharmacokinetic, and Biologic Correlative Study of G3139, NSC # 683428 (Phosphorothioate Antisense Oligonucleotide Directed to Bcl-2) and Irinotecan in Patients With Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 05:11:05.355338|2018-06-01 05:11:05.355338
NCT00004254|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2012-07-17|2004-04-22|2004-04-23|Estimate|||||||2012-07-17|2012-07-18|Estimate|November 1999||1999-11-30|July 2012|2012-07-31||||June 2001|Actual|2001-06-30||Interventional|||Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed|Phase II Study on Tomusex in Malignant Mesothelioma|Completed||Phase 2|25|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:05.462221|2018-06-01 05:11:05.462221
NCT00004013|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-31|2004-04-22|2004-04-23|Estimate|||||||2010-03-31|2010-04-02|Estimate|January 1999||1999-01-31|March 2010|2010-03-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer|Treatment of Refractory Stage IV Metastatic Breast Cancer With Weekly Paclitaxel or Weekly Paclitaxel and Herceptin Following Autologous/Syngeneic Stem Cell Transplant|Completed||Phase 2|60|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:05.570748|2018-06-01 05:11:05.570748
NCT00003899|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-10-03|2004-04-22|2004-04-23|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 1999||1999-01-31|September 2010|2010-09-30|November 2001|Actual|2001-11-30|||||Interventional|||Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors|High-Dose Consolidation With Escalating Doses of Melphalan and Thiotepa for Stage IV Breast Cancer|Completed||Phase 1|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:05.748472|2018-06-01 05:11:05.748472
NCT00003880|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-04-15|2004-04-22|2004-04-23|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 1999||1999-02-28|April 2015|2015-04-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer|A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery|Terminated||Phase 2/Phase 3|132|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:11:05.832827|2018-06-01 05:11:05.832827
NCT00003790|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-05|2004-04-22|2004-04-23|Estimate|||||||2014-08-05|2014-08-06|Estimate|February 1995||1995-02-28|August 2014|2014-08-31|September 2006|Actual|2006-09-30|April 2002|Actual|2002-04-30||Observational|||Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome|Detection of Minimal Residual Disease in Children Receiving Therapy for AML or MDS|Completed|||496|Actual|Children's Oncology Group|||||f||||f||||||||||2018-06-01 05:11:05.95618|2018-06-01 05:11:05.95618
NCT00003735|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2004-04-22|2004-04-23|Estimate|||||||2014-07-23|2014-07-24|Estimate|December 1998||1998-12-31|July 2014|2014-07-31|September 2006|Actual|2006-09-30|November 2002|Actual|2002-11-30||Interventional|||Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia|A Phase II Study of Oral Topotecan in Children With Relapsed Acute Leukemia|Completed||Phase 2|11|Actual|Children's Oncology Group||2|||f||||||||||||||2018-06-01 05:11:06.193175|2018-06-01 05:11:06.193175
NCT00003715|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-12-02|2004-04-22|2004-04-23|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 1998||1998-12-31|December 2015|2015-12-31||||||||Interventional|||Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma|A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b|Terminated||Phase 2|425|Anticipated|AVAX Technologies||||"Terminated: recruiting or enrolling participants has halted prematurely and will not resume;~   participants are no longer being examined or treated"|f||||||||||||||2018-06-01 05:11:06.414248|2018-06-01 05:11:06.414248
NCT00003701|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-02|2004-04-22|2004-04-23|Estimate|||||||2010-11-02|2010-11-03|Estimate|March 1999||1999-03-31|February 2009|2009-02-28||||August 2001|Actual|2001-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Bladder Cancer|A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse|Completed||Phase 3|490|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:06.568504|2018-06-01 05:11:06.568504
NCT00003621|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-04-22|2004-04-23|Estimate|||||||2016-07-12|2016-07-14|Estimate|February 1999||1999-02-28|July 2016|2016-07-31|July 2005|Actual|2005-07-31|February 2005|Actual|2005-02-28||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma|Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma)|Completed||Phase 2|29|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:06.685268|2018-06-01 05:11:06.685268
NCT00003445|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-04-22|2004-04-23|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 1997||1997-12-31|September 2001|2001-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Docetaxel in Treating Patients With Advanced Cancer of the Cervix|Neoadjuvant Chemotherapy With Docetaxel in Advanced Cervical Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:06.838681|2018-06-01 05:11:06.838681
NCT00003386|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-10|2004-04-22|2004-04-23|Estimate|||||||2013-04-10|2013-04-11|Estimate|July 1999||1999-07-31|December 2008|2008-12-31||||April 2001|Actual|2001-04-30||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer|Treatment of Ovarian Carcinoma With DNP-Modified Autologous Tumor Vaccine|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:11:06.919864|2018-06-01 05:11:06.919864
NCT00003148|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-04-22|2004-04-23|Estimate|||||||2012-06-29|2012-07-02|Estimate|October 1997||1997-10-31|June 2012|2012-06-30||||April 2001|Actual|2001-04-30||Interventional|||Interleukin-2 in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia|Phase II Study of the Efficacy of rH Interleukin-2 in Patients With Slowly Progressing Acute Myelogenous Leukemia (AML) and With Limited Bone Marrow Blastosis After Autologous Stem Cell Transplantation or Chemotherapy|Completed||Phase 2|86|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:07.084711|2018-06-01 05:11:07.084711
NCT00071071|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-10|||2012-12-05|2003-10-14|2003-10-15|Estimate|||||||2012-12-05|2012-12-07|Estimate|April 2003||2003-04-30|December 2012|2012-12-31||||May 2004|Actual|2004-05-31||Interventional|||Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.||Completed||Phase 2|25|Actual|Emergent Product Development Seattle LLC||1|||f||||||||||||||2018-06-01 05:16:23.632686|2018-06-01 05:16:23.632686
NCT00003146|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-06-21|2004-04-22|2004-04-23|Estimate|||||||2011-06-21|2011-06-23|Estimate|November 1997||1997-11-30|June 2011|2011-06-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase II Trial of Thiotepa, Busulfan, and Melphalan Followed by Autologous or Syngeneic Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:07.216562|2018-06-01 05:11:07.216562
NCT00003076|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-12-18|2004-04-22|2004-04-23|Estimate|||||||2012-12-18|2012-12-19|Estimate|October 1995||1995-10-31|December 2012|2012-12-31|October 2005|Actual|2005-10-31|June 2002|Actual|2002-06-30||Interventional|||Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus|Phase IIb Chemoprevention Trial of Difluoromethylornithine (DFMO) in Human Subjects With Intestinal-type Barrett's Esophagus|Completed||Phase 2|152|Anticipated|University of Michigan Cancer Center|||||f||||||||||||||2018-06-01 05:11:07.324285|2018-06-01 05:11:07.324285
NCT00003041|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2004-04-22|2004-04-23|Estimate|||||||2013-01-30|2013-01-31|Estimate|July 1997||1997-07-31|January 2002|2002-01-31|January 2002|Actual|2002-01-31|||||Interventional|||Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer|Phase II Evaluation of Pyrazoloacridine (NSC #366140) in Patients With Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:07.420727|2018-06-01 05:11:07.420727
NCT00081848|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-22|||2017-06-30|2004-04-21|2004-04-22|Estimate|||||||2017-06-30|2017-07-02|Actual|April 20, 2004||2004-04-20|January 25, 2012|2012-01-25|August 23, 2007|Actual|2007-08-23|August 23, 2007|Actual|2007-08-23||Interventional|||Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors|A Pilot Trial of a CEA-TRICOM Based Vaccine and Radiation to Liver Metastasis in Adults With CEA Positive Solid Tumors|Completed||Phase 1|12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:07.507543|2018-06-01 05:11:07.507543
NCT00081835|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-22|||2017-06-30|2004-04-21|2004-04-22|Estimate|||||||2017-06-30|2017-07-02|Actual|April 19, 2004||2004-04-19|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||Evaluation and Treatment of Eye Complications of Vaccinia Vaccination|Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31]|Completed||Phase 2|400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:07.619062|2018-06-01 05:11:07.619062
NCT00081796|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-20|||2008-08-20|2004-04-21|2004-04-22|Estimate|||||||2008-08-20|2008-08-21|Estimate|April 2004||2004-04-30|August 2008|2008-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer|A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy|Completed||Phase 3|438|Actual|Sanofi|||||||||||||||||||2018-06-01 05:11:07.722992|2018-06-01 05:11:07.722992
NCT00081783|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-20|||2005-06-23|2004-04-21|2004-04-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2004||2004-03-31|March 2005|2005-03-31||||||||Interventional|||Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients|A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL)|Unknown status|Recruiting|Phase 2|40||Xcyte Therapies|||||||||||||||||||2018-06-01 05:11:08.10509|2018-06-01 05:11:08.10509
NCT00081770|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-20|2008-11-03||2017-03-07|2004-04-21|2004-04-22|Estimate|2009-09-24|2009-10-30|Estimate||||2017-03-07|2017-04-04|Actual|March 2004||2004-03-31|March 2017|2017-03-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)|Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1|Completed||Phase 3|4469|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:11:09.234025|2018-06-01 05:11:09.234025
NCT00081757|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|||2010-07-01|2004-04-21|2004-04-22|Estimate|||||||2010-07-01|2010-07-02|Estimate|September 1998||1998-09-30|July 2010|2010-07-31|May 2005||2005-05-31|||||Interventional|||An Open Protocol for the Compassionate Use of Thalidomide|An Open Protocol For The Compassionate Use of Thalidomide For Patients With Advanced Or Refractory Malignancies|Completed||Phase 1/Phase 2|250||University of Arkansas|||||||||||||||||||2018-06-01 05:11:10.883799|2018-06-01 05:11:10.883799
NCT00021346|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-04-16|2004-04-21|2004-04-22|Estimate|||||||2013-04-16|2013-04-17|Estimate|November 1997||1997-11-30|April 2013|2013-04-30|March 2002|Actual|2002-03-31|July 2001|Actual|2001-07-31||Interventional|||Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors|Phase I Evaluation Of Carboplatin And Gemcitabine|Completed||Phase 1|8|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:11:11.003838|2018-06-01 05:11:11.003838
NCT00019357|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2004-04-21|2004-04-22|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 1998||1998-06-30|August 2001|2001-08-31||||||||Interventional|||Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy|Cellular Immunotherapy With Autologous T Lymphocytes Stimulated With the Patient's Tumor-Specific Mutated Ras Peptides|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:11.090845|2018-06-01 05:11:11.090845
NCT00003018|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-02|2004-04-21|2004-04-22|Estimate|||||||2013-01-02|2013-01-03|Estimate|September 1997||1997-09-30|January 2013|2013-01-31|January 2007|Actual|2007-01-31|January 2002|Actual|2002-01-31||Interventional|||S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer|A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma|Completed||Phase 2|54|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:11:11.212734|2018-06-01 05:11:11.212734
NCT00003017|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-04-21|2004-04-22|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 1997||1997-07-31|July 2004|2004-07-31|August 2005|Actual|2005-08-31|||||Interventional|||Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix|Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:11.536218|2018-06-01 05:11:11.536218
NCT00002952|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-04|2004-04-21|2004-04-22|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 1997||1997-01-31|September 2013|2013-09-30|November 2002|Actual|2002-11-30|August 2002|Actual|2002-08-31||Interventional|||Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma|Phase I/II Study of Immunization With MAGE-3 Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|20|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:11:11.687748|2018-06-01 05:11:11.687748
NCT00002889|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-27|2004-04-21|2004-04-22|Estimate|||||||2016-06-27|2016-06-28|Estimate|May 1997||1997-05-31|June 2016|2016-06-30|June 2009|Actual|2009-06-30|January 2004|Actual|2004-01-31||Interventional|||Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer|PROGNOSTIC SIGNIFICANCE OF ENDORECTAL MRI IN PREDICTING OUTCOME AFTER COMBINED RADIATION AND ANDROGEN SUPPRESSION FOR PROSTATE CANCER: A PROSPECTIVE PHASE II STUDY|Completed||Phase 2|180|Actual|Alliance for Clinical Trials in Oncology|||||f||||f||||||||||2018-06-01 05:11:11.830239|2018-06-01 05:11:11.830239
NCT00002818|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2015-12-10|2004-04-21|2004-04-22|Estimate|||||||2015-12-10|2015-12-14|Estimate|February 1995||1995-02-28|December 2015|2015-12-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies|Phase I and Clinical Pharmacokinetic De-Escalation Study of 2'-Deoxycitidine Administered as a Continuous Infusion in Conjunction With a Continuous Infusion of High-Dose ARA-C in Patients With Refractory Acute Myelogenous Leukemia|Completed||Phase 1|15|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 05:11:11.98707|2018-06-01 05:11:11.98707
NCT00002800|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2004-04-21|2004-04-22|Estimate|||||||2013-07-01|2013-07-03|Estimate|July 1996||1996-07-31|July 2013|2013-07-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome|PHASE II STUDY OF HIGH DOSE CYTARABINE COMBINED WITH A SINGLE HIGH DOSE OF IDARUBICIN FOR NEWLY DIAGNOSED PATIENTS WITH AML: THE AML-3 PROTOCOL|Completed||Phase 2|60|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:12.112033|2018-06-01 05:11:12.112033
NCT00002772|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-22|2004-04-21|2004-04-22|Estimate|||||||2013-01-22|2013-01-24|Estimate|July 1996||1996-07-31|January 2013|2013-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer|A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin Plus Paclitaxel Plus Cyclophosphamide With High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women With 4-9 Involved Axillary Lymph Nodes|Terminated||Phase 3|602|Actual|Southwest Oncology Group||2||poor accrual|f||||t||||||||||2018-06-01 05:11:12.244359|2018-06-01 05:11:12.244359
NCT00002768|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-27|2004-04-21|2004-04-22|Estimate|||||||2016-06-27|2016-06-28|Estimate|June 1996||1996-06-30|June 2016|2016-06-30|March 2009|Actual|2009-03-31|February 2003|Actual|2003-02-28||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission|AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY|Completed||Phase 2|51|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:12.388718|2018-06-01 05:11:12.388718
NCT00002764|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-04-21|2004-04-22|Estimate|||||||2012-07-10|2012-07-11|Estimate|April 1996||1996-04-30|July 2012|2012-07-31||||November 2000|Actual|2000-11-30||Interventional|||Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma|METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP)|Completed||Phase 3|340|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:12.519517|2018-06-01 05:11:12.519517
NCT00002745|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-04-21|2004-04-22|Estimate|||||||2013-02-08|2013-02-11|Estimate|April 1996||1996-04-30|January 2013|2013-01-31|January 2008|Actual|2008-01-31|April 2003|Actual|2003-04-30||Interventional|||Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma|PHASE II STUDY OF 9-AMINOCAMPTOTHECIN (9-AC/DMA, NSC# 603071) IN PREVIOUSLY TREATED HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA: IWF GRADES A-H|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 05:11:12.651052|2018-06-01 05:11:12.651052
NCT00002722|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-02|2004-04-21|2004-04-22|Estimate|||||||2012-03-02|2012-03-05|Estimate|January 1996||1996-01-31|March 2012|2012-03-31||||August 1999|Actual|1999-08-31||Interventional|||High-Dose Chemotherapy in Treating Patients With Advanced Stomach Cancer|RANDOMIZED PHASE II STUDY OF A WEEKLY 24H-INFUSION OF HIGH-DOSE 5-FU PLUS OR MINUS FOLINIC ACID (HD-FU/FA) VERSUS HD-FU/FA PLUS BIWEEKLY CISPLATIN VERSUS FAMTX (5-FU/ADRIAMYCIN/METHOTREXATE) IN ADVANCED GASTRIC CANCER, AN EORTC/AIO INTERGROUP TRIAL|Completed||Phase 2|135|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:12.830378|2018-06-01 05:11:12.830378
NCT00002595|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2004-04-21|2004-04-22|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 1991||1991-07-31|August 2010|2010-08-31|September 2010|Actual|2010-09-30|May 2003|Actual|2003-05-31||Interventional|||Toremifene in Treating Patients With Desmoid Tumors|PHASE II STUDY OF THE SAFETY AND EFFICACY OF TOREMIFENE IN THE THERAPY OF DESMOID TUMORS|Completed||Phase 2|72|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:12.955359|2018-06-01 05:11:12.955359
NCT00002583|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-04-21|2004-04-22|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 1994||1994-07-31|March 2012|2012-03-31|December 2009|Actual|2009-12-31|December 2003|Actual|2003-12-31||Interventional|||Vinorelbine Plus Cisplatin or No Further Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Surgically Removed|A PHASE III PROSPECTIVE RANDOMIZED STUDY OF ADJUVANT CHEMOTHERAPY WITH VINORELBINE AND CISPLATIN IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER WITH COMPANION TUMOUR MARKER EVALUATION|Completed||Phase 3|482|Actual|Canadian Cancer Trials Group||2|||f||||||||||||||2018-06-01 05:11:13.230706|2018-06-01 05:11:13.230706
NCT00002534|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-04-21|2004-04-22|Estimate|||||||2013-06-24|2013-06-26|Estimate|May 1993||1993-05-31|June 2013|2013-06-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission|A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS|Completed||Phase 3|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:13.667322|2018-06-01 05:11:13.667322
NCT00002519|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-01|2004-04-21|2004-04-22|Estimate|||||||2013-05-01|2013-05-03|Estimate|January 1997||1997-01-31|April 2011|2011-04-30|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer|PH I Continuous Infusion Taxol in Combination With Thoracic Radiation Therapy in Untreated Locally Advanced Non-Small Cell Lung Cancer|Completed||Phase 1|6|Actual|National Cancer Institute (NCI)|||||f||||t||||||||||2018-06-01 05:11:13.811418|2018-06-01 05:11:13.811418
NCT00002501|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-30|2004-04-21|2004-04-22|Estimate|||||||2016-06-30|2016-07-01|Estimate|October 1992||1992-10-31|June 2016|2016-06-30|January 2006|Actual|2006-01-31|July 2001|Actual|2001-07-31||Interventional|||Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma|PHASE II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE PLUS RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR (rhG-CSF) IN THE TREATMENT OF FOLLICULAR LOW-GRADE NON-HODGKIN'S LYMPHOMA|Completed||Phase 2|29|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:13.932757|2018-06-01 05:11:13.932757
NCT00002463|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-14|2004-04-21|2004-04-22|Estimate|||||||2013-02-14|2013-02-18|Estimate|February 1989||1989-02-28|February 2013|2013-02-28|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors|Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma|Completed||Phase 2|4|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:11:14.160524|2018-06-01 05:11:14.160524
NCT00081744|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|||2013-02-07|2004-04-20|2004-04-21|Estimate|||||||2013-02-07|2013-02-08|Estimate|November 2002||2002-11-30|February 2013|2013-02-28|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects|A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects|Completed||Phase 3|850|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:11:14.251353|2018-06-01 05:11:14.251353
NCT00081731|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|2013-12-09||2015-09-18|2004-04-20|2004-04-21|Estimate|2013-12-09|2014-01-29|Estimate||||2015-09-18|2015-10-05|Estimate|April 2004||2004-04-30|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CORAL||Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions|Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)|Completed||Phase 3|947|Actual|Baim Institute for Clinical Research|Patients could be enrolled in the trial with renal artery stenosis > = 60%. Didn't include patients with fibromuscular dysplasia. Some screened and deemed to be eligible were not enrolled because of physician preference.|2|||f||||t||||||||||2018-06-01 05:11:14.350437|2018-06-01 05:11:14.350437
NCT00081705|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|||2016-07-28|2004-04-20|2004-04-21|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2004||2004-03-31|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Estrogen Receptor Variants, HDL, and Atherosclerosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:11:14.846466|2018-06-01 05:11:14.846466
NCT00081692|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|||2013-08-05|2004-04-20|2004-04-21|Estimate|||||||2013-08-05|2013-08-07|Estimate|January 2004||2004-01-31|August 2013|2013-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Longitudinal Cardiac Outcomes and Body Composition|Longitudinal Cardiac Outcomes and Body Composition|Completed|||715|Actual|Virginia Commonwealth University|||||f||||f||||||None Retained|"~     Only receiving data~   "|||2018-06-01 05:11:14.914814|2018-06-01 05:11:14.914814
NCT00081679|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|||2014-04-15|2004-04-20|2004-04-21|Estimate|||||||2014-04-15|2014-04-16|Estimate|June 2004||2004-06-30|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||SES, Health Behaviors and CVD Among Vietnam-Era Twins||Completed|||||The Miriam Hospital|||||f||||||||||||||2018-06-01 05:11:14.987666|2018-06-01 05:11:14.987666
NCT00081666|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|||2016-07-28|2004-04-20|2004-04-21|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Logical Analysis of Data and Cardiac Surgery Risk||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:11:15.048414|2018-06-01 05:11:15.048414
NCT00081653|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-19|2008-12-22||2017-07-13|2004-04-20|2004-04-21|Estimate|2009-06-02|2009-07-21|Estimate||||2017-07-13|2017-07-14|Actual|May 2004||2004-05-31|July 2017|2017-07-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional||Intent -To - Treat (ITT) population: All participants who were randomized into this study, received at least one dose of the trial medication, and had at least one follow-up efficacy data point (BMD or serum C-terminal peptide cross-links of Collagen Type I [CTX]).|A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva|Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549|Completed||Phase 4|719|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:11:15.147477|2018-06-01 05:11:15.147477
NCT00019344|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2004-04-20|2004-04-21|Estimate|||||||2015-04-28|2015-04-29|Estimate|August 1997||1997-08-31|May 2002|2002-05-31||||||||Interventional|||Flavopiridol in Treating Patients With Refractory Cancer|A Phase I Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Refractory Neoplasms|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:15.923503|2018-06-01 05:11:15.923503
NCT00019240|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2004-04-20|2004-04-21|Estimate|||||||2013-06-19|2013-06-20|Estimate|November 1996||1996-11-30|November 2007|2007-11-30|April 2004|Actual|2004-04-30|||||Interventional|||Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection|PHASE II PROTOCOL WITH LABORATORY CORRELATES OF 1-[(S)-3-HYDROXY-2-(PHOSPHOMETHOXY)PROPYL]CYTOSINE DIHYDRATE(CIDOFOVIR) IN PATIENTS WITH KAPOSI'S SARCOMA (KS)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:16.03844|2018-06-01 05:11:16.03844
NCT00016900|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-17|2004-04-20|2004-04-21|Estimate|||||||2013-06-17|2013-06-18|Estimate|December 2000||2000-12-31|June 2013|2013-06-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus|A Phase II Multicenter Study of the Efficacy and Safety Study of PNU-93914 (Liposome Encapsulated Paclitaxel) in Patients With Advanced Esophageal Cancer Previously Exposed to Chemotherapy|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:16.096549|2018-06-01 05:11:16.096549
NCT00010010|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2016-03-10|2004-04-20|2004-04-21|Estimate|||||||2016-03-10|2016-03-11|Estimate|June 2000||2000-06-30|March 2016|2016-03-31||||May 2001|Actual|2001-05-31||Interventional|||Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer|A Phase II Study of the Combination of Exemestane and Goserelin in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:11:16.156857|2018-06-01 05:11:16.156857
NCT00009828|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-12-18|2004-04-20|2004-04-21|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 1999||1999-12-31|December 2013|2013-12-31||||||||Interventional|||Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors|Phase I Study Of Weekly Paclitaxel In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies|Withdrawn||Phase 1|0|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:11:16.213933|2018-06-01 05:11:16.213933
NCT00081614|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2014-05-14|2004-04-19|2004-04-20|Estimate|||||||2014-05-14|2014-05-16|Estimate|March 2004||2004-03-31|May 2014|2014-05-31|July 2005|Actual|2005-07-31|||||Interventional|||A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma|A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma|Completed||Phase 2|100||Genentech, Inc.|||||||||||||||||||2018-06-01 05:11:16.281975|2018-06-01 05:11:16.281975
NCT00081549|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2005-06-23|2004-04-19|2004-04-20|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2004|2004-04-30||||||||Interventional|||Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies|A Phase I/II Study of Aroplatin and Gemcitabine In Subjects With Unresectable, Locally Advanced And/Or Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|111||Aronex Pharmaceuticals|||||||||||||||||||2018-06-01 05:11:16.367849|2018-06-01 05:11:16.367849
NCT00081536|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2005-06-23|2004-04-19|2004-04-20|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2004|2004-04-30||||||||Interventional|||Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies|A Phase I/II Study of Aroplatin and Capecitabine in Subjects With Unresectable Local Recurrence or Distant Metastases of Colorectal Cancer Refractory to 5-FU/Leucovorin and Irinotecan|Unknown status|Active, not recruiting|Phase 1/Phase 2|105||Aronex Pharmaceuticals|||||||||||||||||||2018-06-01 05:11:16.420804|2018-06-01 05:11:16.420804
NCT00012129|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2016-03-10|2004-04-19|2004-04-20|Estimate|||||||2016-03-10|2016-03-11|Estimate|September 1998||1998-09-30|March 2016|2016-03-31||||May 2001|Actual|2001-05-31||Interventional|||Chemotherapy in Treating Patients With Breast Cancer|Phase I/II Clinical and Pharmacological Study of Liposomal Annamycin in Anthracycline-Resistant Breast Cancer|Completed||Phase 1/Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:11:16.469321|2018-06-01 05:11:16.469321
NCT00009815|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-12-18|2004-04-19|2004-04-20|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 1999||1999-12-31|December 2013|2013-12-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I Study Of Oral Etoposide In Combination With ORZEL (UFT + Leucovorin) For Advanced Non-Hematological Malignancies|Withdrawn||Phase 1|0|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:11:16.528931|2018-06-01 05:11:16.528931
NCT00005989|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2011-08-02|2004-04-19|2004-04-20|Estimate|||||||2011-08-02|2011-08-04|Estimate|November 2002||2002-11-30|August 2011|2011-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer|A Phase II Study of Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:11:16.583061|2018-06-01 05:11:16.583061
NCT00005958|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-12-03|2004-04-19|2004-04-20|Estimate|||||||2013-12-03|2013-12-04|Estimate|October 1999||1999-10-31|October 2001|2001-10-31||||||||Interventional|||Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer|Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:16.667777|2018-06-01 05:11:16.667777
NCT00005950|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-22|2004-04-19|2004-04-20|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2000||2000-04-30|January 2013|2013-01-31||||October 2004|Actual|2004-10-31||Interventional|||506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma|Phase II Study of 506U78 (NSC #686673) for Patients With Relapsed or Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma|Terminated||Phase 2|111|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:11:16.7477|2018-06-01 05:11:16.7477
NCT00005938|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-05-15|2004-04-19|2004-04-20|Estimate|||||||2012-05-15|2012-05-16|Estimate|March 2000||2000-03-31|May 2012|2012-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||DX-8951f in Treating Patients With Biliary Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer)|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:11:16.8103|2018-06-01 05:11:16.8103
NCT00005828|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-07-12|2004-04-19|2004-04-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 2000||2000-12-31|July 2016|2016-07-31|June 2008|Actual|2008-06-30|March 2003|Actual|2003-03-31||Interventional|||Green Tea Extract in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Green Tea Extract in the Treatment of Androgen-Independent Metastatic Prostate Cancer|Completed||Phase 2|54|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:16.87643|2018-06-01 05:11:16.87643
NCT00005827|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-04-20|2004-04-19|2004-04-20|Estimate|||||||2012-04-20|2012-04-24|Estimate|December 1999||1999-12-31|April 2012|2012-04-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer|Phase I Single and Multiple-Dose Safety and Pharmacokinetic Clinical Study of Genistein in Normal Volunteers and in Prostate Neoplasia (Multiple Dose Safety and Pharmacokinetic Clinical Study of Genistein in Prostate Neoplasia)|Withdrawn||Phase 1|0|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:11:16.961658|2018-06-01 05:11:16.961658
NCT00081640|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-16|||2009-12-22|2004-04-16|2004-04-19|Estimate|||||||2009-12-22|2009-12-23|Estimate||||November 2006|2006-11-30||||||||Interventional|||Safety and Acceptability of PRO 2000 Vaginal Gel in HIV Uninfected Women in India|Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P)|Completed||Phase 1|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:11:17.022529|2018-06-01 05:11:17.022529
NCT00081601|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2012-08-22|2004-04-16|2004-04-19|Estimate|||||||2012-08-22|2012-08-24|Estimate|March 2004||2004-03-31|August 2012|2012-08-31|June 2005|Actual|2005-06-30|May 2005|Actual|2005-05-31||Interventional|||Study of CEP-701 in Treatment of Prostate Cancer|An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen|Completed||Phase 2|30||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 05:11:17.073815|2018-06-01 05:11:17.073815
NCT00081588|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2014-06-19|2004-04-16|2004-04-19|Estimate|||||||2014-06-19|2014-06-20|Estimate|November 2003||2003-11-30|June 2014|2014-06-30|December 2008|Actual|2008-12-31|September 2005|Actual|2005-09-30||Interventional|||An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.|An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.|Completed||Phase 2|555|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||t||||||||||2018-06-01 05:11:17.130194|2018-06-01 05:11:17.130194
NCT00081575|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2013-02-07|2004-04-16|2004-04-19|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia|Completed||Phase 3|434|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:11:17.273856|2018-06-01 05:11:17.273856
NCT00081562|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2008-02-19|2004-04-16|2004-04-19|Estimate|||||||2008-02-19|2008-02-21|Estimate|September 1999||1999-09-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Genetics of Ankylosing Spondylitis|Family Studies of the Genetics of Ankylosing Spondylitis|Completed|||1600||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:11:17.334329|2018-06-01 05:11:17.334329
NCT00081380|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-09|||2008-12-19|2004-04-16|2004-04-19|Estimate|||||||2008-12-19|2008-12-22|Estimate|March 2004||2004-03-31|December 2008|2008-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder|Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated)|Completed||Phase 3|710||AstraZeneca|||||||||||||||||||2018-06-01 05:11:17.427763|2018-06-01 05:11:17.427763
NCT00005810|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-07-12|2004-04-16|2004-04-19|Estimate|||||||2016-07-12|2016-07-14|Estimate|March 2000||2000-03-31|July 2016|2016-07-31|June 2006|Actual|2006-06-30|December 2003|Actual|2003-12-31||Interventional|||Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of Estramustine, Docetaxel, and Carboplatin With G-CSF Support in Men With Hormone Refractory Prostate Cancer|Completed||Phase 2|40|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:17.700338|2018-06-01 05:11:17.700338
NCT00005809|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-02-01|2004-04-16|2004-04-19|Estimate|||||||2013-02-01|2013-02-04|Estimate|July 2000||2000-07-31|February 2013|2013-02-28|January 2003|Actual|2003-01-31|October 2000|Actual|2000-10-31||Interventional|ACRIN 6656||Computerized Tomographic Colonography Compared With Standard Diagnostic Procedures in Detecting Colorectal Neoplasia|Computerized Tomographic Colonography: Performance Evaluation in a Multicenter Setting|Completed||N/A|||American College of Radiology Imaging Network|||||f||||t||||||||||2018-06-01 05:11:17.812578|2018-06-01 05:11:17.812578
NCT00005643|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-07|2004-04-16|2004-04-19|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 2000||2000-05-31|November 2005|2005-11-30||||March 2005|Actual|2005-03-31||Interventional|||Chemotherapy in Treating Patients With Sarcoma of the Uterus|Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:11:17.90136|2018-06-01 05:11:17.90136
NCT00005625|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-18|2004-04-16|2004-04-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|December 1999||1999-12-31|June 2013|2013-06-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma|Phase II Study of ET-743 Therapy in Metastatic Osteosarcoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:18.142274|2018-06-01 05:11:18.142274
NCT00005608|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02||2011-02-18|2012-05-31|2004-04-16|2004-04-19|Estimate||||2011-02-18|2011-02-25|Estimate|2012-05-31|2012-06-06|Estimate|February 2000||2000-02-29|May 2012|2012-05-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Fluorouracil-Uracil and Leucovorin in Treating Women With Metastatic Breast Cancer|Orzel (UFT+Leucovorin) as First-Line Therapy for Metastatic Breast Cancer|Terminated||Phase 2|||Northwestern University||||Drug was pulled from the market.|f||||||||||||||2018-06-01 05:11:18.215533|2018-06-01 05:11:18.215533
NCT00005080|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-01-15|2004-04-16|2004-04-19|Estimate|||||||2013-01-15|2013-01-16|Estimate|May 2000||2000-05-31|January 2013|2013-01-31||||January 2006|Actual|2006-01-31||Interventional|||506U78 in Treating Patients With Lymphoma|A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL)|Completed||Phase 2|74|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:18.298965|2018-06-01 05:11:18.298965
NCT00005071|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-11-05|2004-04-16|2004-04-19|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 1998||1998-10-31|June 2007|2007-06-30||||||||Interventional|||Diagnosis and Treatment Planning in Patients Suspected of Having Lung Cancer|A Pilot Study Leading to a Randomized Trial Comparing Outcomes in Patients With Suspected Lung Cancer Investigated in the Conventional Locally (LO) Based (BA) Chest Clinic Compared With a Centralized 2 Stop Pathway (LOBA 2STOP)|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:18.393353|2018-06-01 05:11:18.393353
NCT00004252|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2012-09-10|2004-04-16|2004-04-19|Estimate|||||||2012-09-10|2012-09-11|Estimate|November 1999||1999-11-30|September 2012|2012-09-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer|A Randomized, Open-Label, Multicenter Phase III Study of 5-FU/Leucovorin With or Without Concomitant SU5416 in Patients With Metastatic Colorectal Cancer|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 05:11:18.48699|2018-06-01 05:11:18.48699
NCT00004229|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-02-08|2004-04-16|2004-04-19|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 1999||1999-10-31|December 2002|2002-12-31||||October 2002|Actual|2002-10-31||Interventional|||Endostatin in Treating Patients With Advanced Solid Tumors|A Phase I Surrogate Endpoint Trial of Human Recombinant Endostatin in Patients With Advanced Solid Tumors Amenable to Biopsy|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:18.602989|2018-06-01 05:11:18.602989
NCT00004178|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2011-06-09|2004-04-16|2004-04-19|Estimate|||||||2011-06-09|2011-06-10|Estimate|April 1998||1998-04-30|May 2006|2006-05-31|December 2001|Actual|2001-12-31|December 2000|Actual|2000-12-31||Interventional|||Gene Therapy in Treating Patients With Cancer|Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma|Completed||Phase 1|||Roger Williams Medical Center|||||f||||||||||||||2018-06-01 05:11:18.679709|2018-06-01 05:11:18.679709
NCT00081510|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-14||2009-04-17|2015-03-26|2004-04-15|2004-04-16|Estimate||||2009-10-01|2009-10-05|Estimate|2015-03-26|2015-04-15|Estimate|December 2003||2003-12-31|March 2015|2015-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)|A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer|Completed||Phase 2|110|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-06-01 05:11:18.779656|2018-06-01 05:11:18.779656
NCT00081497|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-14|2008-12-17||2015-03-13|2004-04-15|2004-04-16|Estimate|2010-07-21|2010-08-18|Estimate||||2015-03-13|2015-04-02|Estimate|January 2004||2004-01-31|March 2015|2015-03-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease|Multi-Center, Open-Label Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease That Previously Participated in the AGAL-008-00 Study|Completed||Phase 4|67|Actual|Sanofi|No valid conclusions can be made from the predefined primary efficacy analysis. The sponsor believes that it is more statistically appropriate to compare placebo patients with Fabrazyme patients as they were randomized in the original Phase 4 trial.|1|||f||||||||||||||2018-06-01 05:11:18.943391|2018-06-01 05:11:18.943391
NCT00081484|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-13|||2016-11-01|2004-04-15|2004-04-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2004||2004-06-30|November 2016|2016-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients|A Randomized, Open-label Study of the Effect of Maintenance Mircera Administered With Pre-filled Syringes on Hemoglobin Levels in Anemic Dialysis Patients With Chronic Kidney Disease|Completed||Phase 3|336|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:11:20.458565|2018-06-01 05:11:20.458565
NCT00081471|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-13|||2016-11-01|2004-04-15|2004-04-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2004||2004-06-30|November 2016|2016-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis|A Randomized, Open-label Study of the Effect of Subcutaneous Mircera on Hemoglobin Level/Correction in Non-dialysis Patients With Chronic Kidney Disease|Completed||Phase 3|324|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:11:20.641546|2018-06-01 05:11:20.641546
NCT00004177|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2011-06-21|2004-04-15|2004-04-16|Estimate|||||||2011-06-21|2011-06-22|Estimate|August 1999||1999-08-31|June 2011|2011-06-30||||May 2002|Actual|2002-05-31||Interventional|||Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer|Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 in Advanced Ovarian Cancer Using Autologous Peripheral Blood Stem Cell Rescue (PBSCR) to Control Myelotoxicity|Completed||Phase 1/Phase 2|15|Anticipated|Garden State Cancer Center at the Center for Molecular Medicine and Immunology|||||f||||||||||||||2018-06-01 05:11:21.770809|2018-06-01 05:11:21.770809
NCT00004108|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-05-15|2004-04-15|2004-04-16|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 1999||1999-09-30|May 2012|2012-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||DX-8951f in Treating Patients With Liver Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hepatocellular Carcinoma|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:11:21.853616|2018-06-01 05:11:21.853616
NCT00004107|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-06-21|2004-04-15|2004-04-16|Estimate|||||||2011-06-21|2011-06-22|Estimate|February 1998||1998-02-28|June 2011|2011-06-30||||May 2001|Actual|2001-05-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With High-Dose 90Y-Labeled Humanized LL2 Anti-CD-22 Antibody and Peripheral Blood Stem Cell Rescue|Completed||Phase 1/Phase 2|18|Anticipated|Garden State Cancer Center at the Center for Molecular Medicine and Immunology|||||f||||||||||||||2018-06-01 05:11:21.954396|2018-06-01 05:11:21.954396
NCT00004100|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-12-17|2004-04-15|2004-04-16|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 1998||1998-11-30|June 2008|2008-06-30||||||||Interventional|||Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Gemcitabine and Vinorelbine vs Standard Chemotherapy Containing Cisplatin for Stage IIIB/IV Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:22.057696|2018-06-01 05:11:22.057696
NCT00004087|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-06-21|2004-04-15|2004-04-16|Estimate|||||||2011-06-21|2011-06-22|Estimate|March 1997||1997-03-31|June 2011|2011-06-30||||May 2001|Actual|2001-05-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer|Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 in Advanced Metastatic Colorectal Cancer and Pancreatic Cancers Using Autologous Peripheral Blood Stem Cell Rescue (PBSCR) to Control Myelotoxicity|Completed||Phase 1/Phase 2|15|Anticipated|Garden State Cancer Center at the Center for Molecular Medicine and Immunology|||||f||||f||||||||||2018-06-01 05:11:22.249445|2018-06-01 05:11:22.249445
NCT00081523|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-15|||2018-05-05|2004-04-14|2004-04-15|Estimate|||||||2018-05-05|2018-05-08|Actual|April 14, 2004||2004-04-14|May 4, 2018|2018-05-04||||||||Observational|||Natural History of Sickle Cell Disease|Studies of the Natural History of Sickle Cell Disease|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:22.333412|2018-06-01 05:11:22.333412
NCT00004086|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2009-06-06|2004-04-14|2004-04-15|Estimate|||||||2009-06-06|2009-06-09|Estimate|June 1997||1997-06-30|December 2001|2001-12-31||||||||Interventional|||Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer|A Phase I Trial of a Combined Regimen of Chemotherapy and 90Y-Labeled, Humanized LL2 (Anti-CD22) Antibody With Peripheral Stem Cell Rescue for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:22.434628|2018-06-01 05:11:22.434628
NCT00004085|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-06-21|2004-04-14|2004-04-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|May 1998||1998-05-31|June 2011|2011-06-30||||May 2002|Actual|2002-05-31||Interventional|||Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer|Phase I/II Trial of High-Dose Radioimmunotherapy With a 90Y-Humanized MN-14 Anti-Carcinoembryonic Antigen (CEA) Antibody for the Treatment of Stage IV Breast Cancer|Completed||Phase 1/Phase 2|15|Anticipated|Garden State Cancer Center at the Center for Molecular Medicine and Immunology|||||f||||||||||||||2018-06-01 05:11:22.531486|2018-06-01 05:11:22.531486
NCT00004084|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-06-21|2004-04-14|2004-04-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|April 1998||1998-04-30|June 2011|2011-06-30||||May 2002|Actual|2002-05-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immu-LL2: Treatment With 90Y-hLL2 IgG|Completed||Phase 1/Phase 2|21|Anticipated|Garden State Cancer Center at the Center for Molecular Medicine and Immunology|||||f||||||||||||||2018-06-01 05:11:22.619992|2018-06-01 05:11:22.619992
NCT00004048|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-06-21|2004-04-14|2004-04-15|Estimate|||||||2011-06-21|2011-06-22|Estimate|September 1998||1998-09-30|June 2011|2011-06-30|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer|Phase I/II Radioimmunotherapy With High-Dose 90Y-Labeled Humanized MN-14 Alone or Combined With Doxorubicin and Peripheral Blood Stem Cell Rescue (PBSCR) in Medullary Thyroid Cancer (MTC) Grant Application Title: Radioimmunotherapy of MTC With Y-90 Humanized MN14 Anti-CEA Mab and Doxorubicin|Completed||Phase 1/Phase 2|30|Anticipated|Garden State Cancer Center at the Center for Molecular Medicine and Immunology|||||f||||||||||||||2018-06-01 05:11:22.733015|2018-06-01 05:11:22.733015
NCT00004046|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-05-15|2004-04-14|2004-04-15|Estimate|||||||2012-05-15|2012-05-16|Estimate|June 1999||1999-06-30|May 2012|2012-05-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Chemotherapy in Treating Women With Metastatic Breast Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Adenocarcinoma of the Breast|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:11:22.832107|2018-06-01 05:11:22.832107
NCT00004045|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-05-15|2004-04-14|2004-04-15|Estimate|||||||2012-05-15|2012-05-16|Estimate|June 1999||1999-06-30|May 2012|2012-05-31|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Chemotherapy in Treating Patients With Prostate Cancer|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Hormone-Refractory Prostate Cancer|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:11:22.916075|2018-06-01 05:11:22.916075
NCT00004033|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-03-25|2004-04-14|2004-04-15|Estimate|||||||2011-03-25|2011-03-28|Estimate|September 1998||1998-09-30|March 2011|2011-03-31||||May 2001|Actual|2001-05-31||Interventional|||Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma|Phase II Clinical Study of a Liposome Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally in Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|30|Anticipated|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:11:22.987799|2018-06-01 05:11:22.987799
NCT00004016|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-05|2004-04-14|2004-04-15|Estimate|||||||2013-06-05|2013-06-06|Estimate|April 1999||1999-04-30|June 2013|2013-06-30||||||||Interventional|||Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors|Phase I Trial of Immunotherapy With Adenovirus-Interferon- Gamma (TG1041) in Patients With Malignant Melanoma|Completed||Phase 1|||University of Rochester|||||f||||||||||||||2018-06-01 05:11:23.080216|2018-06-01 05:11:23.080216
NCT00004010|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-25|2004-04-14|2004-04-15|Estimate|||||||2014-02-25|2014-02-26|Estimate|October 1999||1999-10-31|February 2014|2014-02-28|June 2008|Actual|2008-06-30|October 2003|Actual|2003-10-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease|Pilot Study for the Treatment of Children With Newly Diagnosed Advanced Stage Hodgkin's Disease: Upfront Dose Intensive Chemotherapy|Completed||Phase 2|99|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:11:23.171913|2018-06-01 05:11:23.171913
NCT00003954|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-05-14|2004-04-14|2004-04-15|Estimate|||||||2018-05-14|2018-05-15|Actual|March 1999||1999-03-31|May 2018|2018-05-31||||December 2002|Actual|2002-12-31||Interventional|||Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma|Allogeneic Stem Cell Transplantation For Multiple Myeloma: A Two Step Approach To Reduce Toxicity Involving High Dose Melphalan and Autologous Stem Cell Transplant Followed By PBSC Allografting After Low Dose TBI|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||||||||||||2018-06-01 05:11:23.370787|2018-06-01 05:11:23.370787
NCT00081458|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-13|2010-09-24||2015-11-10|2004-04-13|2004-04-14|Estimate|2013-07-11|2013-07-15|Estimate||||2015-11-10|2015-12-08|Estimate|April 2004||2004-04-30|September 2014|2014-09-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional||84 subjects were initially randomized; however, one subject never received study therapy. As a result, the total participant who started flow period is 83.|Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome|A Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome|Completed||Phase 3|84|Actual|Shire||3|||f||||t||||||||||2018-06-01 05:11:23.635556|2018-06-01 05:11:23.635556
NCT00003917|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-08|2004-04-13|2004-04-14|Estimate|||||||2014-01-08|2014-01-09|Estimate|March 1999||1999-03-31|January 2014|2014-01-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer|An Open Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan Versus Intravenous Topotecan for Second Line Therapy in Patients With Small Cell Lung Cancer Who Have Relapsed Greater Than or Equal to 90 Days After Completion of First Line Therapy|Completed||Phase 3|4|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:11:24.599162|2018-06-01 05:11:24.599162
NCT00003870|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-31|2004-04-13|2004-04-14|Estimate|||||||2010-03-31|2010-04-02|Estimate|February 1999||1999-02-28|March 2010|2010-03-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia|Radiolabeled BC8 (Anti-CD45) Antibody Combined With Cyclophosphamide and Total Body Irradiation Followed by HLA-matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Lymphocytic Leukemia|Completed||Phase 2|40|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:24.809934|2018-06-01 05:11:24.809934
NCT00003834|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-04-13|2004-04-14|Estimate|||||||2016-07-01|2016-07-06|Estimate|March 1999||1999-03-31|July 2016|2016-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer|A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver|Completed||Phase 2|44|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:11:24.947995|2018-06-01 05:11:24.947995
NCT00003824|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-07|2004-04-13|2004-04-14|Estimate|||||||2012-03-07|2012-03-09|Estimate|April 1999||1999-04-30|March 2012|2012-03-31|January 2007|Actual|2007-01-31|July 2001|Actual|2001-07-31||Interventional|||S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer|The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder|Terminated||Phase 3|114|Actual|Southwest Oncology Group||2||Permanently Closed Due to Poor Accrual|f||||t||||||||||2018-06-01 05:11:25.120998|2018-06-01 05:11:25.120998
NCT00003809|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-04-13|2004-04-14|Estimate|||||||2013-08-22|2013-08-23|Estimate|June 1999||1999-06-30|August 2013|2013-08-31||||September 2004|Actual|2004-09-30||Interventional|||Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Randomized, Double Blind, Placebo Controlled Phase III Evaluation of Cisplatin + Placebo Versus Cisplatin + C225 a Mouse/Human Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Patients With Metastatic and/or Recurrent Squamous Cell Cancer of the Head and Neck|Completed||Phase 3|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:11:25.496143|2018-06-01 05:11:25.496143
NCT00003719|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-04-13|2004-04-14|Estimate|||||||2014-01-03|2014-01-06|Estimate|July 1997||1997-07-31|August 2001|2001-08-31||||||||Interventional|||Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma|Phase II Evaluation of Irinotecan (CPT-11) in Previously Treated Advanced Sarcomas|Unknown status|Active, not recruiting|Phase 2|27|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:25.757842|2018-06-01 05:11:25.757842
NCT00003718|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-04-13|2004-04-14|Estimate|||||||2014-01-03|2014-01-06|Estimate|September 1998||1998-09-30|August 2001|2001-08-31||||||||Interventional|||Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma|Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:25.824762|2018-06-01 05:11:25.824762
NCT00003717|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-04-13|2004-04-14|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1998||1998-10-31|August 2001|2001-08-31||||||||Interventional|||Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer|A Phase II Trial of Weekly Paclitaxel Plus Oral Estramustine in Patients With Hormone Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|17|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:25.92444|2018-06-01 05:11:25.92444
NCT00003674|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-04-13|2004-04-14|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 1998||1998-12-31|July 2016|2016-07-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer|Phase III Double-Blind Trial Comparing Low-Molecular Weight Heparin (LMWH) Versus Placebo in Patients With Advanced Cancer|Completed||Phase 3|141|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:11:26.00078|2018-06-01 05:11:26.00078
NCT00003493|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2004-04-13|2004-04-14|Estimate|||||||2013-07-17|2013-07-18|Estimate|November 1998||1998-11-30|August 2001|2001-08-31|April 2004|Actual|2004-04-30|||||Interventional|||Combination Chemotherapy in Treating Patients With Multiple Myeloma|Phase II Trial of Doxil, Vincristine and Decadron in Multiple Myeloma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:26.129249|2018-06-01 05:11:26.129249
NCT00003307|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-12|2004-04-13|2004-04-14|Estimate|||||||2010-03-12|2010-03-16|Estimate|March 1998||1998-03-31|May 2006|2006-05-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer|A Phase II Open Label Trial of Amifostine Plus Fractionated Radiotherapy for Primary Prostate Adenocarcinoma (T1a-T3b, NoMo, PSA>10 ng/ml) to Estimate Acute Grade 2 Genitourinary and Gastrointestinal Toxicity|Completed||Phase 2|25|Anticipated|University of Arizona|||||f||||||||||||||2018-06-01 05:11:26.335346|2018-06-01 05:11:26.335346
NCT00003283|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-04-13|2004-04-14|Estimate|||||||2010-01-26|2010-01-27|Estimate|July 1998||1998-07-31|January 2010|2010-01-31||||September 2003|Actual|2003-09-30||Interventional|||Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma|Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma|Completed||Phase 2|38|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:11:26.425313|2018-06-01 05:11:26.425313
NCT00003235|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-04-13|2004-04-14|Estimate|||||||2010-01-26|2010-01-28|Estimate|April 1998||1998-04-30|January 2010|2010-01-31||||August 2006|Actual|2006-08-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed|A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer|Completed||Phase 3|294|Anticipated|Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:11:26.522814|2018-06-01 05:11:26.522814
NCT00003209|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2004-04-13|2004-04-14|Estimate|||||||2012-07-10|2012-07-11|Estimate|December 1997||1997-12-31|July 2012|2012-07-31||||December 1999|Actual|1999-12-31||Interventional|||Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer|A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer|Completed||Phase 3|700|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:26.609478|2018-06-01 05:11:26.609478
NCT00003125|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-22|2004-04-13|2004-04-14|Estimate|||||||2011-03-22|2011-03-24|Estimate|January 1998||1998-01-31|May 2007|2007-05-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors|A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 and GM-CSF in Patients With CEA Expressing Tumors|Completed||Phase 2|24|Anticipated|Georgetown University|||||f||||f||||||||||2018-06-01 05:11:26.700549|2018-06-01 05:11:26.700549
NCT00003080|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-13|2004-04-13|2004-04-14|Estimate|||||||2010-09-13|2010-09-15|Estimate|September 1996||1996-09-30|September 2010|2010-09-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer|A Phase I Trial of Sequential High Dose Chemotherapy Regimens Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With Persistent Stage III/IV Ovarian Cancer|Completed||Phase 1|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:26.784612|2018-06-01 05:11:26.784612
NCT00003061|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-04-13|2004-04-14|Estimate|||||||2012-06-29|2012-07-02|Estimate|July 1997||1997-07-31|June 2012|2012-06-30||||March 2002|Actual|2002-03-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma|Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)|Completed||Phase 2|50|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:26.90722|2018-06-01 05:11:26.90722
NCT00003032|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-07|2004-04-13|2004-04-14|Estimate|||||||2010-11-07|2010-11-09|Estimate|April 1997||1997-04-30|November 2010|2010-11-30|December 2008|Actual|2008-12-31|||||Interventional|||High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer|A Randomized Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy Versus Standard Therapy in Women With Metastatic Breast Cancer Who Have Responded to Anthracycline or Taxane-Based Induction Chemotherapy|Completed||Phase 3|192|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:11:27.028554|2018-06-01 05:11:27.028554
NCT00003010|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-04-13|2004-04-14|Estimate|||||||2010-01-26|2010-01-27|Estimate|September 1997||1997-09-30|January 2010|2010-01-31||||December 2004|Actual|2004-12-31||Interventional|||Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy|A Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After Induction Chemotherapy|Completed||Phase 3|334|Anticipated|Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:11:27.13541|2018-06-01 05:11:27.13541
NCT00021398|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2016-11-22|2004-04-12|2004-04-13|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 1996||1996-07-31|November 2016|2016-11-30||||July 2001|Actual|2001-07-31||Interventional|||Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer|Phase II Study: Hyperfractionated Pre-Op Chemo-Radiation for Locally Advanced Rectal Cancer|Active, not recruiting||Phase 2|23|Actual|Fox Chase Cancer Center||1|||f||||f||||||||||2018-06-01 05:11:27.243731|2018-06-01 05:11:27.243731
NCT00021281|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-12-18|2004-04-12|2004-04-13|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2000||2000-12-31|September 2001|2001-09-30||||||||Interventional|||Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer|A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:27.358296|2018-06-01 05:11:27.358296
NCT00021151|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2014-01-07|2004-04-12|2004-04-13|Estimate|||||||2014-01-07|2014-01-09|Estimate|January 2000||2000-01-31|January 2014|2014-01-31|May 2002|Actual|2002-05-31|April 2001|Actual|2001-04-30||Interventional|||Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia|CAMPATH-1H Compassionate Treatment In Patients With PLL Who Have Failed At Least One Prior Regimen And CLL Patients Who Have Failed Fludarabine Therapy|Completed||N/A|2|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:11:27.421523|2018-06-01 05:11:27.421523
NCT00021008|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-12-18|2004-04-12|2004-04-13|Estimate|||||||2013-12-18|2013-12-19|Estimate||||September 2001|2001-09-30||||||||Interventional|||ZD0473 in Treating Patients With Progressive or Relapsed Non-Small Lung Cancer|A Phase II Open, Multicenter Trial to Assess the Activity and Tolerability of ZD0473 Given Intravenously as Second-line Therapy to Patients With Non-Small Lung Cancer Who Have Failed One Prior Platinum Based Chemotherapy Regimen|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:27.488675|2018-06-01 05:11:27.488675
NCT00020774|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-10-28|2004-04-12|2004-04-13|Estimate|||||||2015-10-28|2015-10-30|Estimate|October 1998||1998-10-31|July 2012|2012-07-31||||January 2003|Actual|2003-01-31||Interventional|||SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer|A Phase IB Clinical Study Of The Farnesyltransferase Inhibitor SCH 66336 And Gemcitabine In Patients With Resectable Primary Liver Neoplasms|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:11:27.539006|2018-06-01 05:11:27.539006
NCT00019552|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2004-04-12|2004-04-13|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 1998||1998-09-30|January 2002|2002-01-31|April 2004|Actual|2004-04-30|||||Interventional|||Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase II Study of MGI-114 in Patients With Recurrent or Persistent Epithelial Ovarian Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:27.604111|2018-06-01 05:11:27.604111
NCT00019474|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2009-02-06|2004-04-12|2004-04-13|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1998||1998-03-31|April 2007|2007-04-30||||||||Interventional|||Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer|Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filigrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:27.669801|2018-06-01 05:11:27.669801
NCT00019318|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2004-04-12|2004-04-13|Estimate|||||||2015-04-28|2015-04-29|Estimate|August 1997||1997-08-31|October 2001|2001-10-31||||||||Interventional|||Depsipeptide in Treating Patients With Solid Tumors|Phase I Trial of a Four Hour Infusion of Depsipeptide (NSC630176) Given on Days 1 and 5 of a 21 Day Cycle in Patients With Refractory Neoplasms|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:27.739647|2018-06-01 05:11:27.739647
NCT00019123|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-08-14|2004-04-12|2004-04-13|Estimate|||||||2013-08-14|2013-08-16|Estimate|April 1996||1996-04-30|November 2007|2007-11-30|April 2004|Actual|2004-04-30|||||Interventional|||Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma|A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:27.791047|2018-06-01 05:11:27.791047
NCT00014391|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2010-03-31|2004-04-12|2004-04-13|Estimate|||||||2010-03-31|2010-04-02|Estimate|February 1999||1999-02-28|March 2010|2010-03-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation|A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT)|Completed||Phase 3|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:27.856254|2018-06-01 05:11:27.856254
NCT00012311|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2014-01-03|2004-04-12|2004-04-13|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2000||2000-01-31|September 2001|2001-09-30||||||||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer|Multi-Cycle High-Dose Chemotherapy Versus Optimized Conventionally-Dosed Chemotherapy in Patients With Metastatic Breast Cancer: A Phase II Prospective Randomized Trial|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:27.943454|2018-06-01 05:11:27.943454
NCT00010283|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2010-03-31|2004-04-12|2004-04-13|Estimate|||||||2010-03-31|2010-04-02|Estimate|July 2000||2000-07-31|March 2010|2010-03-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon|Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:28.008493|2018-06-01 05:11:28.008493
NCT00007943|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2017-04-17|2004-04-12|2004-04-13|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2000|Actual|2000-09-30|August 2009|2009-08-31|February 27, 2001|Actual|2001-02-27|February 27, 2001|Actual|2001-02-27||Interventional|||Gemcitabine in Treating Patients With Advanced Colorectal Cancer|A Phase II Study Of Twenty-Four Hour Infusion Gemcitabine For Advanced Colorectal Cancer|Completed||Phase 2|15|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:11:28.103147|2018-06-01 05:11:28.103147
NCT00006045|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-11-05|2004-04-12|2004-04-13|Estimate|||||||2013-11-05|2013-11-06|Estimate|March 2000||2000-03-31|February 2010|2010-02-28||||||||Interventional|||Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia|Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML)|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:28.165159|2018-06-01 05:11:28.165159
NCT00005875|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-04-12|2004-04-13|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1999||1999-01-31|September 2001|2001-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Nitrocamptothecin in Treating Patients With Metastatic Melanoma|Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:28.418661|2018-06-01 05:11:28.418661
NCT00005874|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-04-12|2004-04-13|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 1999||1999-06-30|September 2001|2001-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas|Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:28.478972|2018-06-01 05:11:28.478972
NCT00005873|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-04-12|2004-04-13|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 1999||1999-09-30|September 2001|2001-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Relapsed Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:28.544726|2018-06-01 05:11:28.544726
NCT00002708|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-18|2004-04-12|2004-04-13|Estimate|||||||2013-11-18|2013-11-19|Estimate|January 1996||1996-01-31|November 2013|2013-11-30|December 2004|Actual|2004-12-31|January 2002|Actual|2002-01-31||Interventional|||Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases|A PHASE III TRIAL COMPARING WHOLE BRAIN IRRADIATION WITH VERSUS WITHOUT STEREOTACTIC RADIOSURGERY BOOST FOR PATIENTS WITH ONE TO THREE UNRESECTED BRAIN METASTASES|Completed||Phase 3|333|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:11:28.678096|2018-06-01 05:11:28.678096
NCT00081432|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-10|||2017-06-30|2004-04-09|2004-04-12|Estimate|||||||2017-06-30|2017-07-02|Actual|April 9, 2004||2004-04-09|April 27, 2010|2010-04-27|April 27, 2010||2010-04-27|||||Observational|||Language and Emotional Function in Patients With Temporal Lobe Epilepsy|Functional MRI (fMRI) and Diffusion Tensor Imaging (DTI) in Temporal Lobe Epilepsy|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:29.200273|2018-06-01 05:11:29.200273
NCT00081419|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-10|||2017-06-30|2004-04-09|2004-04-12|Estimate|||||||2017-06-30|2017-07-02|Actual|April 8, 2004||2004-04-08|January 12, 2009|2009-01-12|January 12, 2009||2009-01-12|||||Observational|||Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder|Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder Using EEG and Surface EMG|Completed|||42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:29.259221|2018-06-01 05:11:29.259221
NCT00081406|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-09|||2014-03-05|2004-04-09|2004-04-12|Estimate|||||||2014-03-05|2014-03-06|Estimate|July 2000||2000-07-31|March 2005|2005-03-31||||||||Interventional|||Individual and Family Therapy for Children With Anxiety Disorders|Child and Family Therapy for Anxiety-Disordered Youth|Completed||Phase 2/Phase 3|150||Temple University|||||f||||||||||||||2018-06-01 05:11:29.312429|2018-06-01 05:11:29.312429
NCT00081367|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-09|||2014-06-09|2004-04-09|2004-04-12|Estimate|||||||2014-06-09|2014-06-10|Estimate|February 2004||2004-02-29|June 2014|2014-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Community-Based Cognitive Therapy for Suicide Attempters|Community-Based Cognitive Therapy for Suicide Attempters|Completed||Phase 3|140|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 05:11:29.371406|2018-06-01 05:11:29.371406
NCT00081341|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-08|||2010-02-12|2004-04-09|2004-04-12|Estimate|||||||2010-02-12|2010-02-15|Estimate||||February 2010|2010-02-28|December 2002|Actual|2002-12-31|||||Observational|||Cognition, Steroids, and Imaging in Cushings Disease|Cognition, Steroids, and Imaging in Cushings Disease|Completed|||||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:11:29.436011|2018-06-01 05:11:29.436011
NCT00081328|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-08|2014-09-26||2017-03-27|2004-04-09|2004-04-12|Estimate|2014-12-08|2014-12-16|Estimate||||2017-03-27|2017-05-01|Actual|May 2004||2004-05-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2011|Actual|2011-02-28||Interventional|TODAY|Age 10–17 years with T2D according to American Diabetes Association criteria for less than 2 years, body mass index (BMI) >=85th percentile, negative diabetes autoantibodies, fasting c-peptide >0.6 ng/mL, and an adult caregiver willing to actively support study participation.|Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)|Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial|Completed||Phase 3|699|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 05:11:29.508223|2018-06-01 05:11:29.508223
NCT00005872|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-04-09|2004-04-12|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 1999||1999-05-31|September 2001|2001-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer|Phase II Study of RFS 2000 in Relapsed NSCLC|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:30.278326|2018-06-01 05:11:30.278326
NCT00005833|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-06-12|2004-04-09|2004-04-12|Estimate|||||||2012-06-12|2012-06-14|Estimate|June 2000||2000-06-30|June 2012|2012-06-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||S9923 R115777 in Treating Patients With Advanced Colorectal Cancer|A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Colorectal Cancer|Completed||Phase 2|62|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:11:30.334847|2018-06-01 05:11:30.334847
NCT00005820|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-07-12|2004-04-09|2004-04-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2000||2000-05-31|July 2016|2016-07-31|September 2006|Actual|2006-09-30|September 2004|Actual|2004-09-30||Interventional|||Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study of 9 Nitrocamptothecin for Hormone Refractory Prostate Cancer|Completed||Phase 2|35|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:30.417496|2018-06-01 05:11:30.417496
NCT00005801|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-11-14|2004-04-09|2004-04-12|Estimate|||||||2013-11-14|2013-11-18|Estimate|November 1999||1999-11-30|September 2001|2001-09-30|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil|Completed||Phase 2|||University of Colorado, Denver|||||f||||||||||||||2018-06-01 05:11:30.63705|2018-06-01 05:11:30.63705
NCT00005077|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2010-01-04|2004-04-09|2004-04-12|Estimate|||||||2010-01-04|2010-01-06|Estimate|February 2000||2000-02-29|January 2010|2010-01-31||||||||Interventional|||Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction|Phase I Study of Oxaliplatin in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction (Summary Last Modified 04/2000)|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:11:30.69968|2018-06-01 05:11:30.69968
NCT00005066|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-09-04|2004-04-09|2004-04-12|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2000||2000-06-30|September 2013|2013-09-30|October 2002|Actual|2002-10-31|September 2001|Actual|2001-09-30||Interventional|||O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma|A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Advanced Soft Tissue Sarcoma|Completed||Phase 2|12|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:11:30.76978|2018-06-01 05:11:30.76978
NCT00081042|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-12-18|2004-04-07|2004-04-08|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2004||2004-02-29|May 2005|2005-05-31|January 2010|Actual|2010-01-31|||||Interventional|||ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma|An Open-Label, Multicenter, Phase II Trial of ABI-007 (A Cremophor® -Free, Protein Stabilized, Nanoparticle Paclitaxel) in Previously Treated Patients With Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:39.764971|2018-06-01 05:11:39.764971
NCT00005061|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-07-17|2004-04-09|2004-04-12|Estimate|||||||2012-07-17|2012-07-18|Estimate|December 1999||1999-12-31|July 2012|2012-07-31||||June 2001|Actual|2001-06-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase I, Open Label Multiple Dose, Safety and Pharmacokinetic Study of Intravenously Administered Humanized Anti-VEGF Monoclonal Antibody (HuMV833) to Patients With Relapsed or Refractory Solid Tumors|Completed||Phase 1|20|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:30.848719|2018-06-01 05:11:30.848719
NCT00005058|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-11-05|2004-04-09|2004-04-12|Estimate|||||||2013-11-05|2013-11-06|Estimate|August 1997||1997-08-31|April 2005|2005-04-30||||||||Interventional|||Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer|A Direct Comparison of Contrast Enhanced Power Doppler Ultrasound in Primary Breast Cancer and Axillary Nodal Status With Histopathological Variables and Clinical Outcome|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:30.905145|2018-06-01 05:11:30.905145
NCT00005040|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-06-18|2004-04-09|2004-04-12|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma|Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:31.052478|2018-06-01 05:11:31.052478
NCT00004885|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-09-20|2004-04-09|2004-04-12|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 1999||1999-07-31|September 2012|2012-09-30||||July 2001|Actual|2001-07-31||Interventional|||Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer|CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer|Completed||Phase 3|430|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:31.137057|2018-06-01 05:11:31.137057
NCT00004860|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-08-22|2004-04-09|2004-04-12|Estimate|||||||2013-08-22|2013-08-23|Estimate|June 2000||2000-06-30|August 2013|2013-08-31||||October 2005|Actual|2005-10-31||Interventional|||Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer|A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:11:31.31693|2018-06-01 05:11:31.31693
NCT00004238|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-06-18|2004-04-09|2004-04-12|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 1999||1999-07-31|June 2013|2013-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:31.478053|2018-06-01 05:11:31.478053
NCT00004166|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-02-18|2012-05-31|2004-04-09|2004-04-12|Estimate||||2011-02-18|2011-02-25|Estimate|2012-05-31|2012-06-06|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy|Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial|Completed||Phase 3|||Northwestern University|||||f||||t||||||||||2018-06-01 05:11:31.535408|2018-06-01 05:11:31.535408
NCT00004137|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-12|2004-04-09|2004-04-12|Estimate|||||||2013-02-12|2013-02-15|Estimate|October 1999||1999-10-31|February 2013|2013-02-28|November 2008|Actual|2008-11-30|March 2004|Actual|2004-03-31||Interventional|||S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Paclitaxel, Carboplatin and Topotecan With G-CSF in Untreated Patients With Extensive Small Cell Lung Cancer|Completed||Phase 2|88|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 05:11:31.61827|2018-06-01 05:11:31.61827
NCT00004102|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-03-25|2004-04-09|2004-04-12|Estimate|||||||2011-03-25|2011-03-28|Estimate|January 1999||1999-01-31|March 2011|2011-03-31||||November 2001|Actual|2001-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:11:31.789738|2018-06-01 05:11:31.789738
NCT00004082|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-25|2004-04-09|2004-04-12|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 1999||1999-07-31|November 2010|2010-11-30|December 2010|Actual|2010-12-31|September 2003|Actual|2003-09-30||Interventional|||Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors|A Phase I Study of Docetaxel (Taxotere), Carboplatin, and Gemcitabine (DoCaGem) as First-Line Therapy for Patients With High-Risk Epithelial Tumors of Mullerian Origin|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:31.854331|2018-06-01 05:11:31.854331
NCT00004002|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-08|2004-04-09|2004-04-12|Estimate|||||||2012-11-08|2012-11-09|Estimate|July 1999||1999-07-31|September 2005|2005-09-30||||October 2001|Actual|2001-10-31||Interventional|||PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma|Phase I Trial of PS-341 in Advanced Cancers|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:11:31.912311|2018-06-01 05:11:31.912311
NCT00003911|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2004-04-09|2004-04-12|Estimate|||||||2013-01-30|2013-01-31|Estimate|July 1999||1999-07-31|January 2013|2013-01-31|August 2007|Actual|2007-08-31|August 2002|Actual|2002-08-31||Interventional|||S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases|A Phase II Pilot Study of Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases|Terminated||Phase 2|2|Actual|Southwest Oncology Group||||Poor accrual|f||||f||||||||||2018-06-01 05:11:31.985189|2018-06-01 05:11:31.985189
NCT00003840|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-17|2004-04-09|2004-04-12|Estimate|||||||2017-01-17|2017-01-19|Estimate|October 2000||2000-10-31|June 2013|2013-06-30|July 2005|Actual|2005-07-31|September 2002|Actual|2002-09-30||Interventional|||DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia|A Phase I Study of DTGM Fusion Protein (IND BB#8153) in Relapsed and Refractory Adult Acute Myeloid Leukemia (AML)|Completed||Phase 1/Phase 2|||Wake Forest University Health Sciences|||||||||||||||||||2018-06-01 05:11:32.109633|2018-06-01 05:11:32.109633
NCT00081354|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-09|||2018-04-04|2004-04-08|2004-04-09|Estimate|||||||2018-04-04|2018-04-05|Actual|April 6, 2004||2004-04-06|January 18, 2018|2018-01-18||||||||Observational|||Early Detection of Barrett's Esophagus|Barrett's Esophagus Early Detection Study|Completed|||737|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:32.257712|2018-06-01 05:11:32.257712
NCT00080587|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2008-03-03|2004-04-06|2004-04-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2004||2004-04-30|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Atherosclerosis in the Coronary and Carotid Arteries|Atherosclerosis in the Coronary and Carotid Arteries: Correlations Between Coronary IVUS, Carotid Ultrasound, and Carotid MRI|Completed|||125||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:42.894449|2018-06-01 05:11:42.894449
NCT00081315|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2007-08-20|2004-04-08|2004-04-09|Estimate|||||||2007-08-20|2007-08-21|Estimate|November 2003||2003-11-30|August 2007|2007-08-31|August 2006|Actual|2006-08-31|||||Interventional|||Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer|Phase II, Randomized, Double-Blind, Multicenter Trial of Subcutaneous Amifostine (Ethyol®) Versus Placebo in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer|Completed||Phase 2|130||MedImmune LLC|||||||||||||||||||2018-06-01 05:11:32.333226|2018-06-01 05:11:32.333226
NCT00005943|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-28|2004-04-08|2004-04-09|Estimate|||||||2013-05-28|2013-05-30|Estimate|February 2000||2000-02-29|October 2001|2001-10-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Gene Therapy in Treating Patients With Metastatic Melanoma|A Phase I Study Using Direct Combination DNA Injections for the Immunotherapy of Metastatic Melanoma|Completed||Phase 1|||University of Colorado, Denver|||||f||||t||||||||||2018-06-01 05:11:32.419129|2018-06-01 05:11:32.419129
NCT00003754|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-04-08|2004-04-09|Estimate|||||||2013-06-24|2013-06-26|Estimate|September 1998||1998-09-30|June 2013|2013-06-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers|A Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent or Refractory Malignancies|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:32.480613|2018-06-01 05:11:32.480613
NCT00003710|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-07|2004-04-08|2004-04-09|Estimate|||||||2012-08-07|2012-08-09|Estimate|August 1998||1998-08-31|June 2012|2012-06-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetic Study of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:11:32.538491|2018-06-01 05:11:32.538491
NCT00003692|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2004-04-08|2004-04-09|Estimate|||||||2016-07-19|2016-07-20|Estimate|December 1998||1998-12-31|July 2016|2016-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer|Video-Assisted Lobectomy for Peripheral (no Greater Than 3 cm), N0, Non-Small Cell Lung Cancer: A Phase II Feasibility Study|Completed||Phase 2|128|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:32.627738|2018-06-01 05:11:32.627738
NCT00003642|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-05|2004-04-08|2004-04-09|Estimate|||||||2012-03-05|2012-03-06|Estimate|October 1998||1998-10-31|March 2012|2012-03-31||||July 2001|Actual|2001-07-31||Interventional|||Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer|A Phase II Feasibility Study of Combined Accelerated External Radiation and Chemotherapy With 5FU and CDDP Following Transurethral Resection in Patients With Muscle Invasive Transitional Carcinoma of the Bladder - T2-T3, N0, M0 (UICC 1992)|Terminated||Phase 2|43|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:11:32.801443|2018-06-01 05:11:32.801443
NCT00003446|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-04-08|2004-04-09|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 1997||1997-12-31|September 2001|2001-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer|Phase II Trial of Trimetrexate (Neutrexin), 5-Fluorouracil and Leucovorin in Metastatic Colorectal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:32.854777|2018-06-01 05:11:32.854777
NCT00003376|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-04-08|2004-04-09|Estimate|||||||2010-01-26|2010-01-27|Estimate|September 1998||1998-09-30|January 2010|2010-01-31||||September 2005|Actual|2005-09-30||Interventional|||Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium|Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium|Completed||Phase 3|330|Anticipated|Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:11:32.908827|2018-06-01 05:11:32.908827
NCT00003316|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-04-10|2004-04-08|2004-04-09|Estimate|||||||2013-04-10|2013-04-11|Estimate|August 1998||1998-08-31|May 2004|2004-05-31||||April 2004|Actual|2004-04-30||Interventional|||Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus|Evaluation of Gemcitabine in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:11:33.927917|2018-06-01 05:11:33.927917
NCT00003301|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-04-08|2004-04-09|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 1998||1998-07-31|September 2005|2005-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Irinotecan in Treating Patients With Recurrent Malignant Glioma|A Dose Finding and Safety/Efficacy Trial of CPT-11 (Irinotecan) in Patients With Recurrent Malignant Gliomas|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:34.047223|2018-06-01 05:11:34.047223
NCT00003232|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-07|2004-04-08|2004-04-09|Estimate|||||||2010-11-07|2010-11-09|Estimate|November 1997||1997-11-30|November 2010|2010-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer|Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain|Completed||Phase 3|204|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:11:34.121857|2018-06-01 05:11:34.121857
NCT00081302|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2015-11-14|2004-04-07|2004-04-08|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 2004||2004-03-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|December 2005|Actual|2005-12-31||Interventional|||Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer|A Phase II Study Of Cetuximab (C225) In Combination With Chemoradiation In Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:11:34.941018|2018-06-01 05:11:34.941018
NCT00081289|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|2013-05-23||2016-12-30|2004-04-07|2004-04-08|Estimate|2013-09-26|2013-11-25|Estimate||||2016-12-30|2017-02-17|Actual|March 2004||2004-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|May 2011|Actual|2011-05-31||Interventional||All eligible patients enrolled after the protocol ammendment.|Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer|Randomized Phase II Trial Of Neoadjuvant Combined Modality Therapy For Locally Advanced Rectal Cancer|Completed||Phase 2|146|Actual|Radiation Therapy Oncology Group|The study was temporarily closed to accrual due to excessive GI AEs in the first 35 pts. The protocol was amended to adjust the chemotherapy and the study reopened (treatment descriptions reflect the revision).|2|||f||||t||||||||||2018-06-01 05:11:35.064614|2018-06-01 05:11:35.064614
NCT00081276|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-01-23|2004-04-07|2004-04-08|Estimate|||||||2013-01-23|2013-01-24|Estimate|July 2005||2005-07-31|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338) In Combination With Cisplatin (Commercially Available: NSC # 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma|Completed||Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:35.99337|2018-06-01 05:11:35.99337
NCT00081263|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|2016-11-29||2017-09-13|2004-04-07|2004-04-08|Estimate|2017-09-13|2017-09-15|Actual||||2017-09-13|2017-09-15|Actual|June 2005||2005-06-30|August 2017|2017-08-31||||September 2012|Actual|2012-09-30||Interventional|||Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia|A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3)|Completed||Phase 2|130|Actual|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 05:11:36.096081|2018-06-01 05:11:36.096081
NCT00081250|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2017-08-04|2004-04-07|2004-04-08|Estimate|||||||2017-08-04|2017-08-08|Actual|December 2004|Actual|2004-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|December 2007|Actual|2007-12-31||Interventional|||Creatine in Treating Patients With Cancer-Associated Weight Loss|Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss|Completed||Phase 3|300|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:11:36.660207|2018-06-01 05:11:36.660207
NCT00081237|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-06-11|2004-04-07|2004-04-08|Estimate|||||||2013-06-11|2013-06-12|Estimate|February 2004||2004-02-29|June 2013|2013-06-30||||August 2005|Actual|2005-08-31||Interventional|||OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer|A Phase I Study of OSI-7904L In Combination With Oxaliplatin In Patients With Advanced Colo-Rectal Cancer|Completed||Phase 1|15|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:11:37.76575|2018-06-01 05:11:37.76575
NCT00081224|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2016-12-14|2004-04-07|2004-04-08|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2004||2004-12-31|December 2016|2016-12-31|November 2010|Actual|2010-11-30|February 2006|Actual|2006-02-28||Interventional|||Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum|A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum|Terminated||Phase 2|3|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:11:38.070971|2018-06-01 05:11:38.070971
NCT00081211|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-01-23|2004-04-07|2004-04-08|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2004||2004-04-30|January 2013|2013-01-31||||July 2004|Actual|2004-07-31||Interventional|||Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck|A Phase I Study Of PV701 In Patients With Head And Neck Squamous Cell Carcinoma|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:11:38.3619|2018-06-01 05:11:38.3619
NCT00081172|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-07-09|2004-04-07|2004-04-08|Estimate|||||||2013-07-09|2013-07-10|Estimate|January 2004||2004-01-31|April 2006|2006-04-30|May 2006|Actual|2006-05-31|||||Interventional|||Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate|A Phase II Trial Of Lu Radiolabeled Monoclonal Antibody HuJ591-GS (Lu-J591) In Patients With Metastatic Androgen-Independent Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:38.638271|2018-06-01 05:11:38.638271
NCT00081159|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|2016-09-22||2016-09-22|2004-04-07|2004-04-08|Estimate|2016-09-22|2016-11-10|Estimate||||2016-09-22|2016-11-10|Estimate|July 2004||2004-07-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases|A Randomized Phase II Study Of Bone-Targeted Therapy In Advanced Androgen-Dependent Prostate Cancer|Completed||Phase 2|80|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:11:38.931819|2018-06-01 05:11:38.931819
NCT00081133|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-06-04|2004-04-07|2004-04-08|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2003||2003-12-31|June 2013|2013-06-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous Leukemia in Accelerated or Blastic Phase Disease or Ph+ Acute Lymphoblastic Leukemia|Completed||Phase 1/Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:39.344698|2018-06-01 05:11:39.344698
NCT00081107|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-06-04|2004-04-07|2004-04-08|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2003||2003-12-31|June 2013|2013-06-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy|A Phase II Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:39.412964|2018-06-01 05:11:39.412964
NCT00081094|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-04-22|2004-04-07|2004-04-08|Estimate|||||||2013-04-22|2013-04-23|Estimate|September 2003||2003-09-30|April 2013|2013-04-30|September 2005|Actual|2005-09-30|June 2005|Actual|2005-06-30||Interventional|||Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer|Detection of Hepatocellular Carcinoma by Positron Emission Tomography With C-Acetate-11 and F-fluorodeoxyglucose-18|Completed||N/A|31|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 05:11:39.509879|2018-06-01 05:11:39.509879
NCT00081068|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-01-07|2004-04-07|2004-04-08|Estimate|||||||2013-01-07|2013-01-08|Estimate|January 2004||2004-01-31|January 2013|2013-01-31||||||||Interventional|||Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:11:39.581452|2018-06-01 05:11:39.581452
NCT00081055|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2014-12-03|2004-04-07|2004-04-08|Estimate|||||||2014-12-03|2014-12-04|Estimate||||December 2014|2014-12-31||||||||Interventional|||OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of OTI-010 in Subjects Who Receive HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies|Withdrawn||Phase 2|0|Actual|Mesoblast, Ltd.|||||f||||||||||||||2018-06-01 05:11:39.680468|2018-06-01 05:11:39.680468
NCT00081029|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2011-03-22|2004-04-07|2004-04-08|Estimate|||||||2011-03-22|2011-03-23|Estimate|January 2004||2004-01-31|March 2008|2008-03-31||||January 2013|Anticipated|2013-01-31||Interventional|||Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia|A Multicentre Randomised Study Of Parotid Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Head And Neck Cancer|Unknown status|Active, not recruiting|Phase 3|84|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:39.841494|2018-06-01 05:11:39.841494
NCT00081003|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2014-07-22|2004-04-07|2004-04-08|Estimate|||||||2014-07-22|2014-07-23|Estimate|November 2003||2003-11-30|December 2005|2005-12-31||||||||Interventional|||Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer|The Intraduct Environment: A Novel Approach to Risk Assessment of Women With a Family History of Breast Cancer|Completed||N/A|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:39.919155|2018-06-01 05:11:39.919155
NCT00080990|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-12-13|2004-04-07|2004-04-08|Estimate|||||||2013-12-13|2013-12-16|Estimate|February 2004||2004-02-29|December 2013|2013-12-31||||April 2009|Actual|2009-04-30||Interventional|||Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Oxaliplatin and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors|Completed||Phase 1|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:39.992254|2018-06-01 05:11:39.992254
NCT00080977|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-12-18|2004-04-07|2004-04-08|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 1998||1998-06-30|June 2005|2005-06-30||||||||Interventional|||High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2|Treatment of Patients With Metastatic Renal Cell Carcinoma Who Have Failed Low Dose Intensity Interleukin-2 With High-Dose Intravenous Recombinant Interleukin-2|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:40.062344|2018-06-01 05:11:40.062344
NCT00080951|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2016-12-05|2004-04-07|2004-04-08|Estimate|||||||2016-12-05|2016-12-07|Estimate|March 2004||2004-03-31|December 2016|2016-12-31|February 2008|Actual|2008-02-29|April 2005|Actual|2005-04-30||Interventional|||Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Trial Of Irinotecan + 5-Fluorouracil + Leucovorin + Oxaliplatin As First-Line Treatment For Metastatic Colorectal Cancer|Completed||Phase 2|14|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:11:40.118044|2018-06-01 05:11:40.118044
NCT00080938|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|2010-12-30||2013-02-12|2004-04-07|2004-04-08|Estimate|2011-08-22|2011-09-27|Estimate||||2013-02-12|2013-02-15|Estimate|October 2005||2005-10-31|February 2013|2013-02-28|February 2009|Actual|2009-02-28|August 2008|Actual|2008-08-31||Interventional|||Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer|A Phase II Study of Temozolomide and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|26|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:11:40.22609|2018-06-01 05:11:40.22609
NCT00080925|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2012-03-07|2004-04-07|2004-04-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2004||2004-02-29|March 2012|2012-03-31|December 2010|Actual|2010-12-31|||||Interventional|||T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies|T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies|Completed||Phase 1|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:11:40.592668|2018-06-01 05:11:40.592668
NCT00080912|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|2015-02-11||2015-02-11|2004-04-07|2004-04-08|Estimate|2015-02-11|2015-02-26|Estimate||||2015-02-11|2015-02-26|Estimate|January 2004||2004-01-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|September 2012|Actual|2012-09-30||Interventional|||Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases|A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases|Completed||Phase 3|850|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:11:40.697125|2018-06-01 05:11:40.697125
NCT00080899|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|2015-02-19||2015-02-19|2004-04-07|2004-04-08|Estimate|2015-02-19|2015-03-06|Estimate||||2015-02-19|2015-03-06|Estimate|June 2004||2004-06-30|February 2013|2013-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer|A Phase II Trial of Fenretinide (4-HPR) in Biochemically Recurrent, Hormone Naive Prostate Cancer|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:40.93695|2018-06-01 05:11:40.93695
NCT00080886|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2018-01-22|2004-04-07|2004-04-08|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2002||2002-05-31|January 2018|2018-01-31|March 2015|Actual|2015-03-31|November 2005|Actual|2005-11-30||Interventional|||Rituximab and Carmustine, Cytarabine, Etoposide, and Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma|Completed||Phase 2|68|Actual|University of Nebraska||1|||f||||t||||||||||2018-06-01 05:11:41.209299|2018-06-01 05:11:41.209299
NCT00080873|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2016-01-05|2004-04-07|2004-04-08|Estimate|||||||2016-01-05|2016-01-07|Estimate|April 2004||2004-04-30|February 2014|2014-02-28|January 2011|Actual|2011-01-31|November 2006|Actual|2006-11-30||Interventional|||Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation|A Randomized Double Blind Placebo Controlled Clinical Trial to Assess the Efficacy of Traumeel® S (IND#66649) for the Prevention and Treatment of Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation|Completed||N/A|195|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:11:41.32423|2018-06-01 05:11:41.32423
NCT00080860|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2012-03-07|2004-04-07|2004-04-08|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2004||2004-02-29|March 2012|2012-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer|Efficacy Of Sentinel Lymph Node Biopsy And Primary Tumor Gene Expression Profiling To Detect Axillary Lymph Node Metastases After Neoadjuvant Chemotherapy For Breast Cancer|Completed||N/A|60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:41.527672|2018-06-01 05:11:41.527672
NCT00068003|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-04|||2018-05-23|2003-09-03|2003-09-04|Estimate|||||||2018-05-23|2018-05-24|Actual|August 22, 2003||2003-08-22|May 3, 2018|2018-05-03||||||||Observational|||Harvesting Cells for Experimental Cancer Treatments|Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols|Enrolling by invitation|||1914|Actual|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-06-01 05:17:42.274417|2018-06-01 05:17:42.274417
NCT00080847|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-01-04|2004-04-07|2004-04-08|Estimate|||||||2013-01-04|2013-01-07|Estimate|March 2004||2004-03-31|January 2013|2013-01-31||||June 2007|Actual|2007-06-30||Interventional|||S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense - NSC-683428) Therapy for Young Patients (< Age 60) With Advanced Stage Diffuse Large B-Cell NHL of Low and Low-Intermediate IPI Risk|Terminated||Phase 2|160|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:11:41.60191|2018-06-01 05:11:41.60191
NCT00080834|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2012-05-15|2004-04-07|2004-04-08|Estimate|||||||2012-05-15|2012-05-16|Estimate|February 2004||2004-02-29|May 2012|2012-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma|A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:11:41.73286|2018-06-01 05:11:41.73286
NCT00080808|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2012-07-27|2004-04-07|2004-04-08|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 2001||2001-08-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|July 2006|Actual|2006-07-31||Interventional|||Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer|A Randomized Phase II Trial Evaluating the Importance of Early Erectile Dysfunction Rehabilitation and Unilateral Autologous Sural Nerve Sparing Radical Prostatectomy Clinically Localized Prostate Cancer|Completed||Phase 2|111|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:11:41.797682|2018-06-01 05:11:41.797682
NCT00080795|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2012-10-18|2004-04-07|2004-04-08|Estimate|||||||2012-10-18|2012-10-22|Estimate|July 2001||2001-07-31|October 2012|2012-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium|Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer|Completed||Phase 2|65|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:11:41.929565|2018-06-01 05:11:41.929565
NCT00080782|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2012-07-27|2004-04-07|2004-04-08|Estimate|||||||2012-07-27|2012-07-30|Estimate|February 2002||2002-02-28|August 2010|2010-08-31|January 2005|Actual|2005-01-31|April 2004|Actual|2004-04-30||Interventional|||Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases|A Randomized Phase II Trial of Bone-Targeted Therapy Consisting of Strontium-89 and Doxorubicin With or Without Celecoxib in Androgen-Independent Prostate Cancer|Terminated||Phase 2|14|Actual|M.D. Anderson Cancer Center||2||Low accrual due to competing trial.|f||||f||||||||||2018-06-01 05:11:42.019879|2018-06-01 05:11:42.019879
NCT00080756|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2017-07-13|2004-04-07|2004-04-08|Estimate|||||||2017-07-13|2017-07-14|Actual|March 11, 2004|Actual|2004-03-11|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease|Biomarkers, Breast Density And Risk Reduction Perspectives In BRCA Carriers|Active, not recruiting||Phase 2|11|Actual|City of Hope Medical Center||2|||f||||f||||||||||2018-06-01 05:11:42.102417|2018-06-01 05:11:42.102417
NCT00080743|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2009-08-04|2004-04-07|2004-04-08|Estimate|||||||2009-08-04|2009-08-06|Estimate|January 2004||2004-01-31|August 2009|2009-08-31|November 2005|Actual|2005-11-30|April 2005|Actual|2005-04-30||Interventional|||Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer|ZD1839 (IRESSA) In Tamoxifen-Resistant Metastatic Breast Cancer|Completed||Phase 2|2|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 05:11:42.225671|2018-06-01 05:11:42.225671
NCT00080678|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2012-10-10|2004-04-07|2004-04-08|Estimate|||||||2012-10-10|2012-10-12|Estimate|May 2003||2003-05-31|October 2012|2012-10-31|March 2008|Actual|2008-03-31|August 2005|Actual|2005-08-31||Interventional|||Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases|Randomized Double-Blind Phase II Trial of Docetaxel and Imatinib Versus Docetaxel and Placebo in Metastatic Androgen-Independent Prostate Cancer (AIPC) With Bone Metastases|Completed||Phase 2|116|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:11:42.301028|2018-06-01 05:11:42.301028
NCT00080665|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2018-04-22|2004-04-07|2004-04-08|Estimate|||||||2018-04-22|2018-04-24|Actual|December 2003||2003-12-31|April 2018|2018-04-30|January 2011|Actual|2011-01-31|January 2007|Actual|2007-01-31||Interventional|||Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer|Completed||Phase 1|12|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-06-01 05:11:42.407119|2018-06-01 05:11:42.407119
NCT00080639|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-08-01|2004-04-07|2004-04-08|Estimate|||||||2013-08-01|2013-08-05|Estimate|June 2003||2003-06-30|August 2013|2013-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||CA-125 in Screening Patients at High Risk for Ovarian Cancer|Specialized Program Of Research Excellence (SPORE) In Ovarian Cancer/Cancer Genetics Network Collaborative Ovarian Cancer Screening Pilot Trial In High Risk Women|Withdrawn|||0|Actual|University of Alabama at Birmingham||||Terminated for administrative reasons and becuase there were no enrollments|f||||t||||||||||2018-06-01 05:11:42.482242|2018-06-01 05:11:42.482242
NCT00080626|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2018-01-31|2004-04-07|2004-04-08|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2003||2003-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2006|Actual|2006-04-30||Interventional|||Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer|A Pilot Study Assessing Patterns of Response or Resistance to Preoperative Dose Dense Docetaxel in Women With Newly Diagnosed Breast Cancer|Active, not recruiting||Phase 2|19|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-06-01 05:11:42.548305|2018-06-01 05:11:42.548305
NCT00080613|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2013-07-09|2004-04-07|2004-04-08|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer|Phase II Study of Neoadjuvant and Adjuvant Exemestane in Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer|Withdrawn||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:42.645979|2018-06-01 05:11:42.645979
NCT00080600|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2017-06-30|2004-04-06|2004-04-07|Estimate|||||||2017-06-30|2017-07-02|Actual|April 6, 2004||2004-04-06|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Brain Physiology in Polio Survivors|Central Motor Physiology in Polio Survivors|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:42.69907|2018-06-01 05:11:42.69907
NCT00080574|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2008-03-03|2004-04-06|2004-04-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2004||2004-04-30|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients|The Effects of Thyroid Hormone on Cytochrome P450 and P-Glycoprotein Activity in Thyroid Cancer Patients|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:42.994328|2018-06-01 05:11:42.994328
NCT00080548|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|||2017-06-30|2004-04-06|2004-04-07|Estimate|||||||2017-06-30|2017-07-02|Actual|April 6, 2004||2004-04-06|January 6, 2009|2009-01-06|January 6, 2009||2009-01-06|||||Observational|||Timing of Voluntary Movement in Patients With Schizophrenia|Timing of Voluntary Movement in Patients With Schizophrenia Using EEG and Surface EMG|Completed|||42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:43.089122|2018-06-01 05:11:43.089122
NCT00080535|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-07|2012-09-24||2018-01-02|2004-04-06|2004-04-07|Estimate|2012-09-24|2012-10-24|Estimate||||2018-01-02|2018-01-29|Actual|April 30, 2004|Actual|2004-04-30|January 2018|2018-01-31|December 31, 2011|Actual|2011-12-31|December 31, 2011|Actual|2011-12-31||Interventional|||Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas|A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||No||2018-06-01 05:11:43.253592|2018-06-01 05:11:43.253592
NCT00080522|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-06|||2007-09-17|2004-04-06|2004-04-07|Estimate|||||||2007-09-17|2007-09-18|Estimate|February 2005||2005-02-28|August 2007|2007-08-31|January 2007|Actual|2007-01-31|||||Interventional|||Strategies for Delivering Anti-HIV Therapy in South Africa|Safeguard the Household: A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country|Completed||N/A|813||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:11:43.653964|2018-06-01 05:11:43.653964
NCT00080509|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-05|||2010-02-02|2004-04-06|2004-04-07|Estimate|||||||2010-02-02|2010-02-03|Estimate|December 2003||2003-12-31|November 2009|2009-11-30|November 2004||2004-11-30|||||Interventional|||Effectiveness of KOS-862 in the Treatment of Lung Cancer|A Phase 2 Study of KOS-862, Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease|Terminated||Phase 2|85||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:11:43.843145|2018-06-01 05:11:43.843145
NCT00080496|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-05|||2008-07-31|2004-04-06|2004-04-07|Estimate|||||||2008-07-31|2008-08-04|Estimate|July 2003||2003-07-31|July 2008|2008-07-31|December 2006|Actual|2006-12-31|||||Interventional|||Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia|Completed||Phase 3|430||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:11:43.948488|2018-06-01 05:11:43.948488
NCT00003176|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-12-13|2004-04-06|2004-04-07|Estimate|||||||2008-12-13|2008-12-16|Estimate|January 1998||1998-01-31|January 2007|2007-01-31||||||||Interventional|||Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma|A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas|Unknown status|Active, not recruiting|Phase 2|82|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:44.103516|2018-06-01 05:11:44.103516
NCT00003156|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-04-10|2004-04-06|2004-04-07|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 1998||1998-06-30|January 2006|2006-01-31||||October 2005|Actual|2005-10-31||Interventional|||Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus|Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:11:44.215575|2018-06-01 05:11:44.215575
NCT00003132|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-08|2004-04-06|2004-04-07|Estimate|||||||2012-11-08|2012-11-09|Estimate|January 1998||1998-01-31|November 2009|2009-11-30||||November 2001|Actual|2001-11-30||Interventional|||Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer|Phase I Study of Bryostatin-1 (NSC 339555) and Cisplatin in Advanced Malignancies|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:11:44.350514|2018-06-01 05:11:44.350514
NCT00003110|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-10|2004-04-06|2004-04-07|Estimate|||||||2010-06-10|2010-06-11|Estimate|July 1997||1997-07-31|June 2010|2010-06-30|December 2002|Actual|2002-12-31|August 2001|Actual|2001-08-31||Interventional|||Bleomycin in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Trial of 72-Hour Continuous Infusion Bleomycin as Salvage Therapy in AIDS-Related and Immunocompetent Non-Hodgkin's Lymphoma|Completed||Phase 2|5|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:11:44.431056|2018-06-01 05:11:44.431056
NCT00002997|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-04-06|2004-04-07|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 1997||1997-08-31|March 2004|2004-03-31||||||||Interventional|||Cryosurgery in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer|Phase II Trial of Cryoablation for Treatment of Unresectable Colorectal Hepatic Metastases|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:44.521154|2018-06-01 05:11:44.521154
NCT00080483|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-05|2013-12-12||2014-06-12|2004-04-05|2004-04-06|Estimate|2014-06-12|2014-06-13|Estimate||||2014-06-12|2014-06-13|Estimate|March 2004||2004-03-31|December 2013|2013-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Testosterone and Growth Hormone for Bone Loss in Men|Will Testosterone and Growth Hormone Improve Bone Structure?|Completed||Phase 2|35|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 05:11:44.588103|2018-06-01 05:11:44.588103
NCT00024063|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-12-18|2004-04-05|2004-04-06|Estimate|||||||2013-12-18|2013-12-19|Estimate||||April 2007|2007-04-30||||||||Interventional|||SU006668 in Treating Patients With Advanced Solid Tumors|A Phase I Study Of SU006668 Via Twice Daily Oral Administration Under Fed Conditions In Patients With Advanced Malignancies|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:44.886241|2018-06-01 05:11:44.886241
NCT00003107|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-09-09|2004-04-05|2004-04-06|Estimate|||||||2014-09-09|2014-09-10|Estimate|October 1997||1997-10-31|September 2014|2014-09-30||||||||Interventional|||Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors|A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support|Completed||Phase 1|||Indiana University|||||f||||||||||||||2018-06-01 05:11:44.964567|2018-06-01 05:11:44.964567
NCT00003103|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2004-04-05|2004-04-06|Estimate|||||||2013-07-01|2013-07-03|Estimate|August 1997||1997-08-31|July 2013|2013-07-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Chemotherapy in Treating Patients With Solid Tumors|A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies|Completed||Phase 1/Phase 2|57|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:45.086159|2018-06-01 05:11:45.086159
NCT00005618|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-20|2004-04-01|2004-04-02|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2000||2000-02-29|October 2001|2001-10-31|March 2004|Actual|2004-03-31|||||Interventional|||Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia|Phase II Study of Arsenic Trioxide, NSC 706363, in Relapsed of Refractory Chronic Myelogenous Leukemia|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:50.627862|2018-06-01 05:11:50.627862
NCT00003012|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-04-05|2004-04-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 1996||1996-10-31|November 2008|2008-11-30||||||||Interventional|||Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer|A Prospective Randomized Comparison of CMF Versus Sequential Epirubicin Followed by SMF as Adjuvant Chemotherapy for Women With Early Breast Cancer|Completed||Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:45.218008|2018-06-01 05:11:45.218008
NCT00002987|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-04-05|2004-04-06|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1997||1997-01-31|March 2005|2005-03-31||||||||Interventional|||Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease|"Minimal Initial Therapy (MIT) for Early Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy"|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:45.336541|2018-06-01 05:11:45.336541
NCT00002814|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-10-26|2004-04-05|2004-04-06|Estimate|||||||2011-10-26|2011-10-27|Estimate|August 1996||1996-08-31|October 2011|2011-10-31|December 2001|Actual|2001-12-31|April 2001|Actual|2001-04-30||Interventional|||Combination Chemotherapy for Patients With Brain Cancer|A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma|Completed||Phase 2|20|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 05:11:45.528421|2018-06-01 05:11:45.528421
NCT00002774|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-06-19|2004-04-05|2004-04-06|Estimate|||||||2014-06-19|2014-06-20|Estimate|June 1996||1996-06-30|June 2014|2014-06-30|June 2005|Actual|2005-06-30|June 2000|Actual|2000-06-30||Interventional|||Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer|Completed||Phase 2|63|Actual|Stanford University||2|||f||||||||||||||2018-06-01 05:11:45.664425|2018-06-01 05:11:45.664425
NCT00002714|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-14|2004-04-05|2004-04-06|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 1995||1995-04-30|September 2001|2001-09-30|September 2001|Actual|2001-09-30|||||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease|A PHASE II TRIAL OF EIGHT-WEEK STANFORD V CHEMOTHERAPY PLUS MODIFIED INVOLVED FIELD RADIOTHERAPY IN FAVORABLE, LIMITED STAGE HODGKIN'S DISEASE|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:45.812722|2018-06-01 05:11:45.812722
NCT00002600|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-04-23|2004-04-05|2004-04-06|Estimate|||||||2011-04-23|2011-04-26|Estimate|September 1994||1994-09-30|September 2001|2001-09-30||||||||Interventional|||Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer|A PHASE I TRIAL OF HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE IN PATIENTS WITH PLATINUM-SENSITIVE, CHEMOTHERAPY-RESPONSIVE EPITHELIAL OVARIAN CARCINOMA|Completed||Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:45.933876|2018-06-01 05:11:45.933876
NCT00002525|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-04-08||2016-07-19|2004-04-05|2004-04-06|Estimate|2016-06-08|2016-07-20|Estimate||||2016-07-19|2016-08-29|Estimate|August 1993||1993-08-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional||The primary analysis population for the study was all randomized patients with Duke's B3 and C disease.|Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed|Phase III Intergroup Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection, Followed by 5-FU/Leucovorin for Patients With Colon Cancer|Terminated||Phase 3|859|Actual|Eastern Cooperative Oncology Group||2||The study was stopped before reaching its accrual goal due to slow accrual|f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 05:11:46.082163|2018-06-01 05:11:46.082163
NCT00002494|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-30|2004-04-05|2004-04-06|Estimate|||||||2016-06-30|2016-07-04|Estimate|May 1992||1992-05-31|June 2016|2016-06-30|January 2006|Actual|2006-01-31|March 2004|Actual|2004-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia|HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN|Completed||Phase 2|134|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:46.865808|2018-06-01 05:11:46.865808
NCT00080470|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-01|2013-04-11||2013-10-25|2004-04-02|2004-04-05|Estimate|2013-08-02|2013-10-10|Estimate||||2013-10-25|2013-11-19|Estimate|June 2003||2003-06-30|October 2013|2013-10-31|December 2012|Actual|2012-12-31|July 2008|Actual|2008-07-31||Interventional|||An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence|Battery Powered Bion Clinical Investigation: An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence|Completed||Phase 3|148|Actual|Boston Scientific Corporation|This study was limited by poor adherence to the clinical protocol and by incomplete data recovery. Analysis of efficacy-related endpoints was not possible.|2|||f||||f||||||||||2018-06-01 05:11:47.110216|2018-06-01 05:11:47.110216
NCT00080457|ClinicalTrials.gov processed this data on May 31, 2018|2004-04-01|||2007-11-08|2004-04-02|2004-04-05|Estimate|||||||2007-11-08|2007-11-09|Estimate|May 2003||2003-05-31|November 2007|2007-11-30|January 2005|Actual|2005-01-31|||||Interventional|||Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 3|240||Encysive Pharmaceuticals|||||||||||||||||||2018-06-01 05:11:47.571407|2018-06-01 05:11:47.571407
NCT00023816|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-09-19|2004-04-02|2004-04-05|Estimate|||||||2013-09-19|2013-09-20|Estimate||||December 2001|2001-12-31||||||||Interventional|||Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma|Third Phase I and Pharmacokinetic Study Of FB-642 Administered Orally To Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:47.667183|2018-06-01 05:11:47.667183
NCT00022386|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-07-17|2004-04-02|2004-04-05|Estimate|||||||2013-07-17|2013-07-18|Estimate||||May 2002|2002-05-31|April 2004|Actual|2004-04-30|||||Interventional|||Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer|An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer|Completed||Phase 4|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:47.862659|2018-06-01 05:11:47.862659
NCT00022256|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-06-17|2004-04-02|2004-04-05|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2001||2001-04-30|June 2013|2013-06-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|An Open-Label Phase II Trial to Evaluate the Safety and Pharmacokinetics of Motexafin Gadolinium and Cranial Irradiation in the Treatment of Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:47.96124|2018-06-01 05:11:47.96124
NCT00020605|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2009-05-09|2004-04-02|2004-04-05|Estimate|||||||2009-05-09|2009-05-12|Estimate|May 2000||2000-05-31|October 2001|2001-10-31||||||||Interventional|||Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-Malignant Pain or Malignant Pain|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:48.111485|2018-06-01 05:11:48.111485
NCT00020540|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-29|2004-04-02|2004-04-05|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2001||2001-03-31|April 2002|2002-04-30||||||||Interventional|||Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer|Treatment Of Patients With Metastatic Melanoma And Renal Cancer With A Combination Of Flt3L And CD40L|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:48.214711|2018-06-01 05:11:48.214711
NCT00019071|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2004-04-02|2004-04-05|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 1995||1995-03-31|May 2002|2002-05-31||||||||Interventional|||Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma|A PHASE I STUDY OF 2-CHLORODEOXYADENOSINE AND RADIATION FOR THE TREATMENT OF HIGH GRADE GLIOMA (CDX)|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:48.313228|2018-06-01 05:11:48.313228
NCT00019058|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2004-04-02|2004-04-05|Estimate|||||||2015-04-28|2015-04-29|Estimate|April 1995||1995-04-30|December 2001|2001-12-31||||||||Interventional|||Radiation Therapy in Treating Patients With Glioblastoma|A PHASE I STUDY OF COMBINED RADIATION RESPONSE MODIFIERS EMPLOYING HYDROXYUREA AND PENTOXIFYLLINE FOR TREATMENT OF GLIOBLASTOMA|Completed||Phase 1|34|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:48.421706|2018-06-01 05:11:48.421706
NCT00016042|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-09-19|2004-04-02|2004-04-05|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2001||2001-01-31|October 2001|2001-10-31||||||||Interventional|||Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer|Interleukin 12-Primed Activated T Cells For Patients With Metastatic Renal Cell Carcinoma Or Colorectal Carcinoma (Phase I)|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:48.544472|2018-06-01 05:11:48.544472
NCT00014573|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-04-05|2004-04-02|2004-04-05|Estimate|||||||2013-04-05|2013-04-08|Estimate|August 1998||1998-08-31|April 2013|2013-04-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer|Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||f||||||||||2018-06-01 05:11:48.620537|2018-06-01 05:11:48.620537
NCT00080444|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-31|||2014-08-04|2004-04-01|2004-04-02|Estimate|||||||2014-08-04|2014-08-05|Estimate|April 2004||2004-04-30|August 2014|2014-08-31|March 2007|Actual|2007-03-31|September 2006|Actual|2006-09-30||Interventional|||Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Emetogenic Chemotherapy in Adolescent Patients|Completed||Phase 3|50|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-06-01 05:11:48.726672|2018-06-01 05:11:48.726672
NCT00080418|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-30|||2011-06-30|2004-04-01|2004-04-02|Estimate|||||||2011-06-30|2011-07-04|Estimate|July 2003||2003-07-31|June 2011|2011-06-30|June 2010|Actual|2010-06-30|July 2005|Actual|2005-07-31||Interventional|||Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer|Phase I Study of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) Formulation in Patients With Advanced Cancer|Completed||Phase 1|40||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:11:48.829394|2018-06-01 05:11:48.829394
NCT00080405|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-30|||2009-03-26|2004-04-01|2004-04-02|Estimate|||||||2009-03-26|2009-03-27|Estimate|March 2004||2004-03-31|March 2009|2009-03-31||||June 2005|Actual|2005-06-30||Interventional|||Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma|Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma|Completed||Phase 1|40||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:11:48.925541|2018-06-01 05:11:48.925541
NCT00009841|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2016-02-11|2004-04-01|2004-04-02|Estimate|||||||2016-02-11|2016-02-12|Estimate|March 1999||1999-03-31|June 2002|2002-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Gene Therapy in Treating Patients With Advanced Head and Neck Cancer|Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma|Completed||Phase 1|13|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:11:48.981803|2018-06-01 05:11:48.981803
NCT00007813|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2009-02-06|2004-04-01|2004-04-02|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 1995||1995-05-31|December 2007|2007-12-31||||||||Interventional|||Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors|TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY|Unknown status|Active, not recruiting|Phase 1|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:49.067873|2018-06-01 05:11:49.067873
NCT00006487|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2012-10-03|2004-04-01|2004-04-02|Estimate|||||||2012-10-03|2012-10-04|Estimate|October 2000||2000-10-31|October 2012|2012-10-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer|A Phase I Study Of Tirapazamine/Cisplatin/Etoposide And Concurrent Thoracic Radiotherapy For Limited Stage Small Cell Lung Cancer|Completed||Phase 1|30|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:11:49.16362|2018-06-01 05:11:49.16362
NCT00006458|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2009-02-28|2004-04-01|2004-04-02|Estimate|||||||2009-02-28|2009-03-03|Estimate|August 2000||2000-08-31|October 2001|2001-10-31||||||||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer|Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:49.335364|2018-06-01 05:11:49.335364
NCT00006376|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-12-03|2004-04-01|2004-04-02|Estimate|||||||2013-12-03|2013-12-04|Estimate|March 2000||2000-03-31|June 2005|2005-06-30|May 2005|Actual|2005-05-31|||||Interventional|||R115777 in Treating Patients With Advanced Bladder Cancer|A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:49.403081|2018-06-01 05:11:49.403081
NCT00006371|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-09-25|2004-04-01|2004-04-02|Estimate|||||||2012-09-25|2012-09-27|Estimate|May 2000||2000-05-31|September 2012|2012-09-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||"A Phase II Trial of Early Medical Adrenalectomy for D0.5 Prostate Cancer"|"A Phase II Trial of Early Medical Adrenalectomy for D0.5 Prostate Cancer"|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute||2||low accrual|f||||f||||||||||2018-06-01 05:11:49.457708|2018-06-01 05:11:49.457708
NCT00006370|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-04-30|2004-04-01|2004-04-02|Estimate|||||||2013-04-30|2013-05-01|Estimate|July 2000||2000-07-31|April 2013|2013-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer|A Phase II, Open-label, Multi-Center Study to Evaluate the Efficacy of 90Y-SMT 487 Administered Intravenously to Patients With Refractory Small Cell Lung or Advanced Metastatic Breast Cancer Expressing Somatostatin Receptors as Determined by OctreoScan Scintigraphy|Completed||Phase 2|275|Actual|Novartis|||||f||||||||||||||2018-06-01 05:11:49.545035|2018-06-01 05:11:49.545035
NCT00006369|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-11-05|2004-04-01|2004-04-02|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2000||2000-06-30|October 2001|2001-10-31||||||||Interventional|||ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase II, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the Treatment of Metastatic Breast Cancer in Postmenopausal Women Who Have Failed Tamoxifen Therapy|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:49.601766|2018-06-01 05:11:49.601766
NCT00006368|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-04-30|2004-04-01|2004-04-02|Estimate|||||||2013-04-30|2013-05-01|Estimate|January 1998||1998-01-31|April 2013|2013-04-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer|A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors|Completed||Phase 1|60|Actual|Novartis|||||f||||||||||||||2018-06-01 05:11:49.669636|2018-06-01 05:11:49.669636
NCT00006052|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2014-01-30|2004-04-01|2004-04-02|Estimate|||||||2014-01-30|2014-01-31|Estimate|June 2000||2000-06-30|January 2014|2014-01-31||||June 2003|Actual|2003-06-30||Interventional|||STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia|A Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Accelerated Phase|Completed||Phase 2|||Novartis|||||f||||f||||||||||2018-06-01 05:11:49.885906|2018-06-01 05:11:49.885906
NCT00006043|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-04|2004-04-01|2004-04-02|Estimate|||||||2013-06-04|2013-06-05|Estimate|February 2000||2000-02-29|June 2013|2013-06-30|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin|Phase II Trial of Temozolomide in Patients With Cisplatin-Refractory Germ Cell Tumors|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:49.952428|2018-06-01 05:11:49.952428
NCT00006032|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-12-10|2004-04-01|2004-04-02|Estimate|||||||2012-12-10|2012-12-11|Estimate|March 2000||2000-03-31|December 2012|2012-12-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer|A Phase II Study of Intensive-Dose Topotecan, Ifosfamide/Mesna and Etoposide (TIME) Followed by Autologous Stem Cell Rescue in Metastatic Breast Cancer|Terminated||Phase 2|||H. Lee Moffitt Cancer Center and Research Institute||||low accrual|f||||f||||||||||2018-06-01 05:11:50.029744|2018-06-01 05:11:50.029744
NCT00006031|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-09-24|2004-04-01|2004-04-02|Estimate|||||||2012-09-24|2012-09-26|Estimate|November 1999||1999-11-30|September 2012|2012-09-30|July 2006|Actual|2006-07-31|July 2001|Actual|2001-07-31||Interventional|||Comparison of Two Types of Biopsy in Patients With Breast Lesions|Randomized Prospective Trial Comparing Radioactive Seed Localized Breast Biopsy to Needle Localized Breast Biopsy|Completed||N/A|117|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 05:11:50.095847|2018-06-01 05:11:50.095847
NCT00005948|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-03-31|2004-04-01|2004-04-02|Estimate|||||||2010-03-31|2010-04-02|Estimate|January 2000||2000-01-31|March 2010|2010-03-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous Leukemia|A Pilot Study of High Dose Busulfan Combined With IL2/GM-CSF Activated Autologous/Syngeneic PBSC, Sequential IL2/GM-CSF Therapy and Alpha Interferon Maintenance Therapy as Treatment of CML|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:50.193623|2018-06-01 05:11:50.193623
NCT00005860|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2011-04-23|2004-04-01|2004-04-02|Estimate|||||||2011-04-23|2011-04-26|Estimate|April 2000||2000-04-30|May 2002|2002-05-31||||||||Interventional|||Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum|A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:50.257905|2018-06-01 05:11:50.257905
NCT00005799|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2017-10-09|2004-04-01|2004-04-02|Estimate|||||||2017-10-09|2017-10-11|Actual|November 1999||1999-11-30|October 2017|2017-10-31||||July 2002|Actual|2002-07-31||Interventional|||Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer|Low-Dose TBI and Fludarabine Followed by Unrelated Donor Stem Cell Transplantation for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial|Active, not recruiting||N/A|55|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:11:50.349937|2018-06-01 05:11:50.349937
NCT00005798|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-10-24|2004-04-01|2004-04-02|Estimate|||||||2012-10-24|2012-10-26|Estimate|July 1995||1995-07-31|October 2012|2012-10-31|July 2007|Actual|2007-07-31|August 2001|Actual|2001-08-31||Interventional|CTC||Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer|A Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin (CTC) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Breast Cancer|Completed||Phase 2|209|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:11:50.475096|2018-06-01 05:11:50.475096
NCT00005628|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-18|2004-04-01|2004-04-02|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 1999||1999-11-30|June 2013|2013-06-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma|A Phase II Trial of Active Specific Immunotherapy in Patients With Recurrent Soft Tissue Sarcoma Using Autologous Tumor-derived Heat Shock Protein-Peptide Complex (HSPPC-96)|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:50.566847|2018-06-01 05:11:50.566847
NCT00005615|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-09-21|2004-04-01|2004-04-02|Estimate|||||||2012-09-21|2012-09-25|Estimate|July 1997||1997-07-31|September 2012|2012-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa|The Florida Melanoma Trial: A Phase I/II Trial of Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa in the Treatment of Advanced Stage III Melanoma: Study Site & Coordinating Center|Completed||Phase 1/Phase 2|24|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:11:50.719223|2018-06-01 05:11:50.719223
NCT00005577|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-02-04|2004-04-01|2004-04-02|Estimate|||||||2013-02-04|2013-02-05|Estimate|August 1996||1996-08-31|December 2002|2002-12-31||||September 2002|Actual|2002-09-30||Interventional|||Gemcitabine in Treating Children With Refractory Solid Tumors|A PEDIATRIC PHASE I STUDY OF GEMCITABINE (NSC# 613327) IN SOLID TUMORS|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:50.82463|2018-06-01 05:11:50.82463
NCT00005097|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2018-04-03|2004-04-01|2004-04-02|Estimate|||||||2018-04-03|2018-04-05|Actual|August 1999||1999-08-31|April 2018|2018-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Green Tea Extract in Treating Patients With Actinic Keratosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology|Terminated||Phase 2|88|Actual|University of California, Irvine||1||terminated due to the low conditional power for a positive study|f||||t||||||||||2018-06-01 05:11:50.896642|2018-06-01 05:11:50.896642
NCT00005068|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2011-08-02|2004-04-01|2004-04-02|Estimate|||||||2011-08-02|2011-08-03|Estimate|January 2000||2000-01-31|August 2011|2011-08-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of Oxaliplatin, CPT-11, 5-FU and Leucovorin in Patients With Solid Tumors|Completed||Phase 1|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:11:51.864475|2018-06-01 05:11:51.864475
NCT00003864|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2004-04-01|2004-04-02|Estimate|||||||2013-08-22|2013-08-23|Estimate|July 1999||1999-07-31|August 2013|2013-08-31||||January 2004|Actual|2004-01-31||Interventional|||Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus|A Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:11:51.979181|2018-06-01 05:11:51.979181
NCT00080431|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-30|||2017-06-30|2004-03-30|2004-03-31|Estimate|||||||2017-06-30|2017-07-02|Actual|March 26, 2004||2004-03-26|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Interventional|||Daclizumab to Treat HIV-Infected Patients|An Open Label Trial to Assess Safety and Tolerability of Daclizumab in HIV-Infected Individuals|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:52.204512|2018-06-01 05:11:52.204512
NCT00005031|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-05-24|2004-03-30|2004-03-31|Estimate|||||||2013-05-24|2013-05-27|Estimate|August 2000||2000-08-31|March 2008|2008-03-31||||October 2004|Actual|2004-10-31||Interventional|||Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer|A Phase II Evaluation of MGI-114 in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:11:52.315248|2018-06-01 05:11:52.315248
NCT00004248|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2011-03-03|2004-03-30|2004-03-31|Estimate|||||||2011-03-03|2011-03-07|Estimate|July 1999||1999-07-31|March 2011|2011-03-31|May 2001|Actual|2001-05-31|June 2000|Actual|2000-06-30||Interventional|||Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Low Dose Schedule of Adriamycin and Protracted Infusion of Recombinant Interleukin-2: A Phase II Study of Immunotherapy in Unresectable Hepatocellular Carcinoma|Completed||Phase 2|24|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:11:53.211016|2018-06-01 05:11:53.211016
NCT00004097|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-09-19|2004-03-30|2004-03-31|Estimate|||||||2013-09-19|2013-09-20|Estimate|August 1999||1999-08-31|October 2001|2001-10-31||||||||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer|A Phase I Study of Concomitant Chemoradiotherapy With Gemcitabine, Paclitaxel, and 5-FU for Patients With Advanced and/or Recurrent Cancer of the Head and Neck|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:53.288093|2018-06-01 05:11:53.288093
NCT00003967|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2004-03-30|2004-03-31|Estimate|||||||2013-05-24|2013-05-27|Estimate|September 1999||1999-09-30|March 2008|2008-03-31||||April 2006|Actual|2006-04-30||Interventional|||Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I Study of Sequential Prolonged Oral Topotecan (IND# 58,131) and Prolonged Oral Etoposide as Second Line Therapy in Ovarian, Peritoneal or Tubal Carcinoma|Completed||Phase 1|24|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:11:53.387588|2018-06-01 05:11:53.387588
NCT00003883|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-31|2004-03-30|2004-03-31|Estimate|||||||2010-03-31|2010-04-02|Estimate|October 1998||1998-10-31|March 2010|2010-03-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation|A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients|Completed||Phase 3|578|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:11:53.480873|2018-06-01 05:11:53.480873
NCT00003769|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-09-09|2004-03-30|2004-03-31|Estimate|||||||2014-09-09|2014-09-10|Estimate|February 1999||1999-02-28|September 2014|2014-09-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer|A Phase II Trial of Perillyl Alcohol in Patients With Resectable Pancreatic Cancer|Completed||Phase 2|||Indiana University|||||f||||||||||||||2018-06-01 05:11:53.586382|2018-06-01 05:11:53.586382
NCT00003657|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-19|2004-03-30|2004-03-31|Estimate|||||||2017-01-19|2017-01-20|Estimate|July 1998||1998-07-31|January 2017|2017-01-31|June 2002|Actual|2002-06-30|November 2000|Actual|2000-11-30||Interventional|||High-dose ICE With Amifostine|High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection|Completed||Phase 2|24|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 05:11:53.686158|2018-06-01 05:11:53.686158
NCT00003635|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2004-03-30|2004-03-31|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 1999||1999-01-31|January 2002|2002-01-31|March 2004|Actual|2004-03-31|||||Interventional|||506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents|A Multicenter Study to Assess the Efficacy of 506U78 in Patients With Chronic Lymphocytic Leukemia Who Are Refractory to Fludarabine and Alkylator Therapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:53.955299|2018-06-01 05:11:53.955299
NCT00080028|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-22|||2007-05-04|2004-03-22|2004-03-23|Estimate|||||||2007-05-04|2007-05-08|Estimate||||May 2007|2007-05-31||||||||Interventional|||Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer|Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 1|18||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 05:12:04.904252|2018-06-01 05:12:04.904252
NCT00003412|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-03-30|2004-03-31|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 1998||1998-06-30|October 2001|2001-10-31||||||||Interventional|||Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation|Phase I Study of Post Transplant rhIL-12 High Dose Cyclophosphamide, Thiotepa, and Carboplatin in the Treatment of Metastatic Breast Carcinoma|Unknown status|Active, not recruiting|Phase 1|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:54.090923|2018-06-01 05:11:54.090923
NCT00003402|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-09-23|2004-03-30|2004-03-31|Estimate|||||||2009-09-23|2009-09-24|Estimate|January 1999||1999-01-31|September 2009|2009-09-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Autologous Transplantation With and High Dose BCNU and Melphalan Followed by Consolidation With DCEP Plus Taxol/Cisplatin in Patients With Poor Prognosis Low Grade Non-Hodgkin's Lymphoma and Chronic Lymphocyte Leukemia, Who Have Received < or = 12 Months of Standard Therapy|Completed||Phase 2|35|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 05:11:54.222033|2018-06-01 05:11:54.222033
NCT00080392|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-30|||2017-06-30|2004-03-29|2004-03-30|Estimate|||||||2017-06-30|2017-07-02|Actual|March 27, 2004||2004-03-27|December 29, 2011|2011-12-29|December 29, 2011|Actual|2011-12-29|||||Interventional|||EW-A-401 to Treat Intermittent Claudication|Modulation of Vascular Endothelial Growth Factor (VEGF) Using an Engineered Zinc-Finger Transcription Factor to Treat Lower Limb Intermittent Claudication|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:54.424474|2018-06-01 05:11:54.424474
NCT00080340|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-26|||2008-01-10|2004-03-29|2004-03-30|Estimate|||||||2008-01-10|2008-01-15|Estimate||||March 2006|2006-03-31|May 2005||2005-05-31|||||Interventional|||Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase 3 Randomized Study of TLK286 (Telcyta) Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|520||Telik|||||||||||||||||||2018-06-01 05:11:54.593375|2018-06-01 05:11:54.593375
NCT00080327|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-26|||2013-11-07|2004-03-29|2004-03-30|Estimate|||||||2013-11-07|2013-11-11|Estimate|November 2003||2003-11-30|August 2008|2008-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia|A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia|Completed||Phase 4|370||Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||||||||||||2018-06-01 05:11:55.227178|2018-06-01 05:11:55.227178
NCT00080314|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-26|||2013-11-07|2004-03-29|2004-03-30|Estimate|||||||2013-11-07|2013-11-11|Estimate|January 2004||2004-01-31|June 2008|2008-06-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode|Completed||Phase 3|400||Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||||||||||||2018-06-01 05:11:55.315099|2018-06-01 05:11:55.315099
NCT00080301|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-26|2009-05-01||2016-02-09|2004-03-29|2004-03-30|Estimate|2009-07-02|2009-08-17|Estimate||||2016-02-09|2016-03-10|Estimate|September 2003||2003-09-30|February 2016|2016-02-29|March 2008|Actual|2008-03-31|November 2006|Actual|2006-11-30||Interventional|||Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer|A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant|Completed||Phase 3|752|Actual|R-Pharm||2|||f||||t||||||||||2018-06-01 05:11:55.51177|2018-06-01 05:11:55.51177
NCT00003345|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-03-29|2004-03-30|Estimate|||||||2013-06-20|2013-06-21|Estimate|October 1997||1997-10-31|June 2013|2013-06-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer|Phase II Trial of Cisplatin and Irinotecan in Patients With Suboptimally Debulked, Incompletely Responding Ovarian Cancer|Completed||Phase 2|35|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:11:57.056344|2018-06-01 05:11:57.056344
NCT00003192|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-04|2004-03-29|2004-03-30|Estimate|||||||2013-09-04|2013-09-05|Estimate|March 1998||1998-03-31|September 2013|2013-09-30|August 2003|Actual|2003-08-31|February 2002|Actual|2002-02-28||Interventional|||Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus|A Phase II Trial of 9-Aminocamptothecin (NSC 603071) Administered as a 120-Hour Continuous Infusion in Patients With Previously Untreated Gastric Cancer|Completed||Phase 2|15|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:11:57.111257|2018-06-01 05:11:57.111257
NCT00003157|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-03-29|2004-03-30|Estimate|||||||2016-07-12|2016-07-14|Estimate|February 1998||1998-02-28|July 2016|2016-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas or Stomach|A Phase I Study of Gemcitabine, Cisplatin, and Radiation Therapy in Patients With Locally Advanced Pancreatic and Gastric Cancer|Completed||Phase 1|26|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:11:57.183042|2018-06-01 05:11:57.183042
NCT00003149|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-03-29|2004-03-30|Estimate|||||||2013-06-20|2013-06-21|Estimate|December 1997||1997-12-31|March 2009|2009-03-31|September 2006|Actual|2006-09-30|||||Interventional|||Interleukin-12 in Treating Patients With Multiple Myeloma|Phase II of Interleukin-12 for Plateau Phase Multiple Myeloma|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:57.262947|2018-06-01 05:11:57.262947
NCT00002974|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-09-30|2004-03-29|2004-03-30|Estimate|||||||2015-09-30|2015-10-02|Estimate|July 1996||1996-07-31|May 2011|2011-05-31|April 2003|Actual|2003-04-30|July 2001|Actual|2001-07-31||Interventional|||Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma|A Phase II Study of Whole Blood Hyperthermia and Ice Chemotherapy in Sarcoma Patients|Completed||Phase 2|34|Anticipated|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 05:11:57.324783|2018-06-01 05:11:57.324783
NCT00080366|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-27|||2007-04-03|2004-03-26|2004-03-29|Estimate|||||||2007-04-03|2007-04-04|Estimate|March 2004||2004-03-31|March 2007|2007-03-31|March 2007||2007-03-31|||||Interventional|||Octanol to Treat Essential Tremor|Treatment Efficacy of 1-Octanol Compared to Placebo in Adults With Essential Tremor|Completed||Phase 2|14||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:57.37965|2018-06-01 05:11:57.37965
NCT00080353|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-27|||2012-06-12|2004-03-26|2004-03-29|Estimate|||||||2012-06-12|2012-06-14|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma|Phase II Study in Metastatic Melanoma Using Lymphocytes Reactive With the gp100 Antigen and Immunization Using a Recombinant rF-gp100P209 Virus Encoding a gp100 Peptide Following a Nonmyeloablative Lymphocyte Depleting Regimen|Completed||Phase 2|58|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:11:57.515143|2018-06-01 05:11:57.515143
NCT00080288|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-25|2009-06-01||2013-07-12|2004-03-26|2004-03-29|Estimate|2009-08-14|2009-09-23|Estimate||||2013-07-12|2013-07-19|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|December 2004||2004-12-31|||||Interventional|||Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD|A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder|Completed||Phase 3|254|Actual|Teva Pharmaceutical Industries||2|||||||||||||||||2018-06-01 05:11:57.598167|2018-06-01 05:11:57.598167
NCT00080275|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-25|||2006-10-31|2004-03-26|2004-03-29|Estimate|||||||2006-10-31|2006-11-01|Estimate|March 2004||2004-03-31|October 2006|2006-10-31||||||||Interventional|||Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)|An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS)|Completed||Phase 3|600||Kos Pharmaceuticals|||||||||||||||||||2018-06-01 05:11:57.942406|2018-06-01 05:11:57.942406
NCT00080262|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-25|||2017-01-27|2004-03-25|2004-03-26|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 2004||2004-02-29|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)|Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine|Completed||Phase 2|125||R-Pharm||1|||f||||||||||||||2018-06-01 05:11:58.011207|2018-06-01 05:11:58.011207
NCT00080236|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|||2012-08-08|2004-03-25|2004-03-26|Estimate|||||||2012-08-08|2012-08-10|Estimate|November 2003||2003-11-30|August 2012|2012-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation|Safety, Tolerability and Efficacy Study of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation (OLT)|Completed||Phase 2|99|Actual|Conatus Pharmaceuticals Inc.||4|||f||||t||||||||||2018-06-01 05:11:58.145306|2018-06-01 05:11:58.145306
NCT00080223|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|2016-02-10||2017-03-20|2004-03-25|2004-03-26|Estimate|2016-02-10|2016-03-09|Estimate||||2017-03-20|2017-04-17|Actual|August 31, 2003|Actual|2003-08-31|March 2017|2017-03-31|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional||All treated participants|Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis|An Open-Label, Phase 2 Study of the Safety of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis|Completed||Phase 2|83|Actual|Genentech, Inc.||1|||f||||f||||||||||2018-06-01 05:11:58.253862|2018-06-01 05:11:58.253862
NCT00080158|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|||2013-11-01|2004-03-25|2004-03-26|Estimate|||||||2013-11-01|2013-11-04|Estimate|March 2004||2004-03-31|July 2008|2008-07-31|June 2007|Actual|2007-06-30|||||Interventional|||Treatment of Adolescent Suicide Attempters (TASA)||Completed||Phase 2/Phase 3|120||New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 05:11:58.671109|2018-06-01 05:11:58.671109
NCT00012142|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-06-20|2004-03-25|2004-03-26|Estimate|||||||2013-06-20|2013-06-24|Estimate|September 2000||2000-09-30|May 2002|2002-05-31|March 2004|Actual|2004-03-31|||||Interventional|||CCI-779 in Treating Patients With Prostate Cancer|Randomized, Double-Blind, Placebo-Controlled, Phase II Study Of Intravenous CCI-779 Administered Weekly To Patients With Androgen-Independent Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:58.81797|2018-06-01 05:11:58.81797
NCT00002950|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-03-25|2004-03-26|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 1996||1996-09-30|October 2001|2001-10-31||||||||Interventional|||Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer|Phase I/II Study of Topotecan (SKF 104864) With Recombinant GM-CSF (Sargramostim) Used as a Priming Agent in Advanced Malignancies|Unknown status|Active, not recruiting|Phase 1/Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:58.881605|2018-06-01 05:11:58.881605
NCT00002947|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-01|2004-03-25|2004-03-26|Estimate|||||||2014-07-01|2014-07-02|Estimate|October 1996||1996-10-31|July 2014|2014-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer|A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors|Terminated||Phase 1|35|Anticipated|Yale University|||||f||||f||||||||||2018-06-01 05:11:59.111758|2018-06-01 05:11:59.111758
NCT00002887|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-03-25|2004-03-26|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1995||1995-07-31|October 2001|2001-10-31||||||||Interventional|||Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer|PHASE I TRIAL OF HYDROXYUREA FOR SALVAGE OF INCURABLE NON-SMALL CELL LUNG CANCER|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:11:59.35117|2018-06-01 05:11:59.35117
NCT00002759|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-03-25|2004-03-26|Estimate|||||||2013-02-04|2013-02-05|Estimate|June 1996||1996-06-30|May 2006|2006-05-31||||April 2002|Actual|2002-04-30||Interventional|||Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma|A PHASE I STUDY OF IRINOTECAN (CPT-11) WITH PHARMACOKINETIC MODULATION BY CYCLOSPORINE A AND PHENOBARBITAL|Completed||Phase 1|3|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:11:59.612665|2018-06-01 05:11:59.612665
NCT00002592|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-01-13|2004-03-25|2004-03-26|Estimate|||||||2015-01-13|2015-01-14|Estimate|June 1993||1993-06-30|January 2015|2015-01-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia|AUTOLOGOUS BONE MARROW TRANSPLANTATION USING C-MYB (LR-3001) ANTISENSE OLIGODEOXYNUCLEOTIDE TREATED BONE MARROW IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC OR ACCELERATED PHASE|Completed||Phase 2|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||||||||||||2018-06-01 05:11:59.891049|2018-06-01 05:11:59.891049
NCT00002540|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-08-30||2018-02-02|2004-03-25|2004-03-26|Estimate|2014-06-19|2014-06-26|Estimate||||2018-02-02|2018-03-05|Actual|November 16, 1993|Actual|1993-11-16|February 2018|2018-02-28||||May 21, 2012|Actual|2012-05-21||Interventional|||Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial|Active, not recruiting||N/A|76685|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:12:00.231835|2018-06-01 05:12:00.231835
NCT00002536|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-08|2004-03-25|2004-03-26|Estimate|||||||2013-07-08|2013-07-09|Estimate|December 1996||1996-12-31|March 2008|2008-03-31||||August 2007|Actual|2007-08-31||Interventional|||Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer|TREATMENT OF PATIENTS WITH SUBOPTIMAL ('BULKY') STAGE IB CARCINOMA OF THE CERVIX: A RANDOMIZED COMPARISON OF RADICAL HYSTERECTOMY AND PELVIC AND PARA-AORTIC LYMPHADENECTOMY WITH OR WITHOUT NEOADJUVANT VINCRISTINE AND CISPLATIN CHEMOTHERAPY, PHASE III|Completed||Phase 3|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:12:01.029297|2018-06-01 05:12:01.029297
NCT00003356|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-10-14|2004-03-19|2004-03-22|Estimate|||||||2013-10-14|2013-10-16|Estimate|November 1997||1997-11-30|October 2013|2013-10-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma|A Phase II Study of Rituxan and IL-2 in Patients With Low Grade or Follicular B-Cell Lymphoma|Completed||Phase 1/Phase 2|58|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 05:12:07.202133|2018-06-01 05:12:07.202133
NCT00002461|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-03-25|2004-03-26|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 1988||1988-04-30|October 2006|2006-10-31||||||||Interventional|||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma|Phase II Study of Intensive Carmustine and Etoposide With Cisplatin or Cyclophosphamide, Followed By Rescue With Autologous Bone Marrow Treated In Vitro With Etoposide and/or Peripheral Blood Stem Cells Mobilized With Filgrastim (G-CSF) or Sargramostim (GM-CSF) With or Without Radiotherapy in Patients With Resistant Hodgkin's Disease or Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:01.154132|2018-06-01 05:12:01.154132
NCT00080210|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|||2013-05-31|2004-03-24|2004-03-25|Estimate|||||||2013-05-31|2013-06-03|Estimate|March 2004||2004-03-31|May 2013|2013-05-31|February 2005||2005-02-28|||||Interventional|||A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy|A Phase II Study of Multiple Doses of Intravenous Puricase in Subjects With Hyperuricemia and Refractory Gout|Completed||Phase 2|40||Savient Pharmaceuticals|||||||||||||||||||2018-06-01 05:12:01.23014|2018-06-01 05:12:01.23014
NCT00080197|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|||2006-10-10|2004-03-24|2004-03-25|Estimate|||||||2006-10-10|2006-10-11|Estimate|February 2004||2004-02-29|October 2006|2006-10-31|May 2005||2005-05-31|||||Interventional|||Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients|An Open-Label Phase II Study of E7070 in Metastatic Breast Cancer Patients Previously Treated With an Anthracycline, a Taxane, and Capecitabine|Completed||Phase 2|250||Eisai Inc.|||||||||||||||||||2018-06-01 05:12:01.297966|2018-06-01 05:12:01.297966
NCT00080184|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|||2006-08-16|2004-03-24|2004-03-25|Estimate|||||||2006-08-16|2006-08-18|Estimate|December 2003||2003-12-31|August 2006|2006-08-31|May 2006||2006-05-31|||||Interventional|||Effectiveness of Brainwave Biofeedback in the Treatment of Fibromyalgia|Effectiveness of EEG Biofeedback in the Treatment of Fibromyalgia|Completed||Phase 1/Phase 2|40||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:12:01.399953|2018-06-01 05:12:01.399953
NCT00080171|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|||2009-03-31|2004-03-24|2004-03-25|Estimate|||||||2009-03-31|2009-04-02|Estimate|February 2004||2004-02-29|March 2009|2009-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Osteoarthritis Initiative (OAI): A Knee Health Study|Osteoarthritis Initiative (OAI): A Knee Health Study|Unknown status|Active, not recruiting||5000|Anticipated|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||Samples With DNA|"~     Blood, urine~   "|||2018-06-01 05:12:01.462657|2018-06-01 05:12:01.462657
NCT00080145|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-24|||2013-08-15|2004-03-24|2004-03-25|Estimate|||||||2013-08-15|2013-08-16|Estimate|February 2004||2004-02-29|August 2013|2013-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders|Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder|Completed||N/A|124|Actual|Yale University||2|||f||||t||||||||||2018-06-01 05:12:01.523648|2018-06-01 05:12:01.523648
NCT00080132|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-23|||2005-06-23|2004-03-24|2004-03-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2004||2004-10-31|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy|An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy|Terminated||Phase 2|50||Medical Research Laboratories International|||||||||||||||||||2018-06-01 05:12:01.606659|2018-06-01 05:12:01.606659
NCT00080119|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-23|2010-07-01||2011-02-10|2004-03-24|2004-03-25|Estimate|2010-10-01|2010-10-19|Estimate||||2011-02-10|2011-02-14|Estimate|February 2004||2004-02-29|February 2011|2011-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV|A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV|Terminated||Phase 2/Phase 3|1354|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|"DSMB recommended stopping study due to futility: no compelling reason to enroll additional infants or to continue to treat participants with the blinded study medication. Week 192 analyses not done as <4% (26%) of HIVpos (HIVneg) reached wk 192"|4||Data Safety Monitoring Board (DSMB) recommended stopping study due to futility|f||||t||||||||||2018-06-01 05:12:01.704366|2018-06-01 05:12:01.704366
NCT00080106|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-23||2009-08-12|2013-07-01|2004-03-24|2004-03-25|Estimate||||2009-08-12|2009-08-14|Estimate|2013-07-01|2013-07-09|Estimate|June 2004||2004-06-30|July 2013|2013-07-31|May 2011|Actual|2011-05-31|September 2007|Actual|2007-09-30||Interventional|||Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients|A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Antiretroviral Effect of Immunization With the MRK Ad5 HIV-1 Gag Vaccine in HIV-1 Infected Individuals Who Interrupt Antiretroviral Therapy|Completed||Phase 2|114|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:12:02.987966|2018-06-01 05:12:02.987966
NCT00010647|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-16|2004-03-24|2004-03-25|Estimate|||||||2006-08-16|2006-08-18|Estimate|August 1999||1999-08-31|August 2006|2006-08-31|July 2004||2004-07-31|||||Interventional|||Cost-Effectiveness of and Long-Term Outcomes Following Acupuncture Treatment for Osteoarthritis of the Knee|Cost-Effectiveness of and Long-Term Outcomes Following Acupuncture Treatment for Osteoarthritis of the Knee|Completed||N/A|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:12:03.095606|2018-06-01 05:12:03.095606
NCT00008320|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2016-12-02|2004-03-24|2004-03-25|Estimate|||||||2016-12-02|2016-12-06|Estimate|January 2001||2001-01-31|December 2016|2016-12-31|October 2009|Actual|2009-10-31|April 2002|Actual|2002-04-30||Interventional|||Ceramide Cream in Treating Women With Cutaneous Breast Cancer|A Phase II Study Of Topical Ceramide Lipids As Treatment For Cutaneous Breast Cancer|Completed||Phase 2|26|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:12:03.151082|2018-06-01 05:12:03.151082
NCT00008151|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2010-03-31|2004-03-24|2004-03-25|Estimate|||||||2010-03-31|2010-04-02|Estimate|October 2000||2000-10-31|March 2010|2010-03-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome|Gemtuzumab Ozogamicin (GO), Fludarabine, And Low-Dose TBI Followed By Donor Stem Cell Transplantation For Patients With Advanced Acute Myeloid Leukemia Or Myelodysplastic Syndrome|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:12:03.230665|2018-06-01 05:12:03.230665
NCT00005865|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2014-01-03|2004-03-23|2004-03-24|Estimate|||||||2014-01-03|2014-01-06|Estimate|April 2000||2000-04-30|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Research Study Evaluating Oral and Intravenous NAVELBINE as a Single Agent for the Treatment of Chemotherapy-Naive Subjects With Inoperable Stage IIIb or Stage IV Non-Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:04.521062|2018-06-01 05:12:04.521062
NCT00006348|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2016-07-01|2004-03-24|2004-03-25|Estimate|||||||2016-07-01|2016-07-06|Estimate|October 2000||2000-10-31|July 2016|2016-07-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment|Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer|Completed||Phase 3|100|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:12:03.291607|2018-06-01 05:12:03.291607
NCT00006345|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-05-29|2004-03-24|2004-03-25|Estimate|||||||2013-05-29|2013-05-30|Estimate|November 1999||1999-11-30|November 2001|2001-11-30|March 2004|Actual|2004-03-31|||||Interventional|||Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma|An Evaluation of Corticosteroid Pretreatment in Cutaneous T-Cell Lymphoma Patients Receiving Ontak (Denileukin Difitox)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:03.44394|2018-06-01 05:12:03.44394
NCT00006262|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11||2011-02-16|2012-06-07|2004-03-24|2004-03-25|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-07|2012-06-11|Estimate|July 2000||2000-07-31|June 2012|2012-06-30|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer|A Phase 2 Study of BMY-27557-14 (a Rebeccamycin Analog) in Patients With Ovarian Cancer|Terminated||Phase 2|||Northwestern University||||Unable to accrue patients to the study.|f||||t||||||||||2018-06-01 05:12:03.534998|2018-06-01 05:12:03.534998
NCT00006090|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-10-05|2004-03-24|2004-03-25|Estimate|||||||2012-10-05|2012-10-10|Estimate|June 2000||2000-06-30|October 2012|2012-10-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia|Phase II Study of Arsenic Trioxide (NSC #706363) Therapy for Fludarabine Refractory or Relapsed Chronic Lymphocytic Leukemia|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||||No enrollment.|f||||f||||||||||2018-06-01 05:12:03.59984|2018-06-01 05:12:03.59984
NCT00006084|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-12-18|2004-03-24|2004-03-25|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2001||2001-02-28|November 2001|2001-11-30||||||||Interventional|||Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia|Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:03.688569|2018-06-01 05:12:03.688569
NCT00006051|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2009-02-06|2004-03-24|2004-03-25|Estimate|||||||2009-02-06|2009-02-09|Estimate|February 1999||1999-02-28|November 2001|2001-11-30||||||||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer|Combination Chemotherapy Concurrent With Postoperative Radiotherapy Epidermoid Carcinoma of the Head and Neck at High Risk of Recurrence - Study of Feasibility|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:03.760309|2018-06-01 05:12:03.760309
NCT00006036|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-11-07|2004-03-24|2004-03-25|Estimate|||||||2010-11-07|2010-11-09|Estimate|April 2000||2000-04-30|March 2010|2010-03-31|December 2009||2009-12-31|||||Interventional|||Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Study of NX 211 in Combination With Cisplatin Given as an IV Infusion Days 1, 2, and 3 Every 3 Weeks in Patients With Solid Tumors|Completed||Phase 1|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:12:03.84585|2018-06-01 05:12:03.84585
NCT00006030|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-08-06|2004-03-24|2004-03-25|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 1992||1992-01-31|December 2006|2006-12-31||||||||Interventional|||Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer|Protocol of a Randomized Trial for the Management of Small Well-Differentiated and Special Type Carcinomas of the Breast|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:03.946162|2018-06-01 05:12:03.946162
NCT00080093|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-23|||2008-09-25|2004-03-23|2004-03-24|Estimate|||||||2008-09-25|2008-09-26|Estimate|January 2006||2006-01-31|September 2008|2008-09-30|December 2008|Anticipated|2008-12-31|October 2007|Actual|2007-10-31||Interventional|||Increasing Condom Use in People at Risk for HIV Infection|Increasing Condom Use With a Stage-Matched Intervention|Unknown status|Active, not recruiting|N/A|534|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:12:04.018976|2018-06-01 05:12:04.018976
NCT00080080|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-23|||2007-06-07|2004-03-23|2004-03-24|Estimate|||||||2007-06-07|2007-06-08|Estimate||||June 2007|2007-06-30||||||||Interventional|||Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer|Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|||Point Therapeutics|||||||||||||||||||2018-06-01 05:12:04.1043|2018-06-01 05:12:04.1043
NCT00006023|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-05-14|2004-03-23|2004-03-24|Estimate|||||||2012-05-14|2012-05-15|Estimate|March 2000||2000-03-31|May 2012|2012-05-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma - Phase II Trials - Protocol 5: Capecitabine|Completed||Phase 2|||Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 05:12:04.175039|2018-06-01 05:12:04.175039
NCT00005992|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-08-06|2004-03-23|2004-03-24|Estimate|||||||2013-08-06|2013-08-07|Estimate|December 2000||2000-12-31|May 2002|2002-05-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Phase I Clinical Trial of Recombinant Prostate Specific Membrane Antigen (rPSMA)-Loaded Mature Autologous Dendritic Cells (CapPVax) for the Treatment of Metastatic Horomone Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:04.234374|2018-06-01 05:12:04.234374
NCT00005972|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-07-12|2004-03-23|2004-03-24|Estimate|||||||2016-07-12|2016-07-14|Estimate|May 2000||2000-05-31|July 2016|2016-07-31|February 2008|Actual|2008-02-29|October 2006|Actual|2006-10-31||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer|Phase II Trial of Gemcitabine/Irinotecan as Second Line Therapy for Small Cell Lung Cancer|Completed||Phase 2|73|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:12:04.310802|2018-06-01 05:12:04.310802
NCT00005944|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2011-04-23|2004-03-23|2004-03-24|Estimate|||||||2011-04-23|2011-04-26|Estimate|November 1999||1999-11-30|June 2007|2007-06-30||||||||Interventional|||Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer|Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:04.439648|2018-06-01 05:12:04.439648
NCT00080067|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-23|||2017-06-30|2004-03-22|2004-03-23|Estimate|||||||2017-06-30|2017-07-02|Actual|March 22, 2004||2004-03-22|February 23, 2009|2009-02-23|February 23, 2009||2009-02-23|||||Observational|||Rhythm Perception and Generation|fMRI Study on Mechanism of Rhythm Perception and Generation|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:04.643915|2018-06-01 05:12:04.643915
NCT00080015|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-19|||2009-07-23|2004-03-22|2004-03-23|Estimate|||||||2009-07-23|2009-07-24|Estimate|March 2004||2004-03-31|July 2009|2009-07-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)|A Phase II Open Label Study Investigating the Activity of Diflomotecan (BN80915) Administered at the Fixed Dose of 7mg as a 20 Minute Intravenous Infusion Once Every 3 Weeks in Patients With Sensitive Small Cell Lung Cancer (SCLC) Who Have Failed First-line Treatment With a Platinum Based Regimen.|Completed||Phase 2|40||Ipsen|||||f||||||||||||||2018-06-01 05:12:04.962466|2018-06-01 05:12:04.962466
NCT00080002|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-19|||2012-09-05|2004-03-22|2004-03-23|Estimate|||||||2012-09-05|2012-09-06|Estimate|December 2003||2003-12-31|March 2005|2005-03-31||||||||Interventional|||Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction|Effectiveness and Safety Study of Pegamotecan (PEG-Camptothecin) in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastroesophageal Junction Who Have Relapsed or Progressed Following a Previous Chemotherapy Treatment|Terminated||Phase 2|||Enzon Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:12:05.014552|2018-06-01 05:12:05.014552
NCT00079989|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-19|||2013-02-07|2004-03-22|2004-03-23|Estimate|||||||2013-02-07|2013-02-08|Estimate|December 2003||2003-12-31|February 2013|2013-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms|A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae|Completed||Phase 3|115|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:12:05.060013|2018-06-01 05:12:05.060013
NCT00005816|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-03-19|2004-03-22|2004-03-23|Estimate|||||||2013-03-19|2013-03-20|Estimate|February 2000||2000-02-29|December 2008|2008-12-31|August 2002|Actual|2002-08-31|||||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer|Active Immunotherapy of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA|Completed||Phase 1|15|Actual|Duke University|||||f||||||||||||||2018-06-01 05:12:05.110696|2018-06-01 05:12:05.110696
NCT00004123|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-07-27|2004-03-22|2004-03-23|Estimate|||||||2012-07-27|2012-07-30|Estimate|July 1997||1997-07-31|July 2012|2012-07-31|October 2009|Actual|2009-10-31|July 2001|Actual|2001-07-31||Interventional|||Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma|A Phase I Study of Preoperative Chemoradiation and Intraoperative Radiation Therapy in the Treatment of Retroperitoneal Sarcoma|Completed||Phase 1|36|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:12:05.167775|2018-06-01 05:12:05.167775
NCT00003817|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-13|2004-03-22|2004-03-23|Estimate|||||||2015-10-13|2015-10-15|Estimate|October 1999||1999-10-31|October 2015|2015-10-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy|A Randomized Phase II Trial of Acupressure and Acustimulation Wrist Bands for the Prevention of Chemotherapy-Induced Nausea and Vomiting|Completed||Phase 2|700|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 05:12:05.24468|2018-06-01 05:12:05.24468
NCT00003693|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-01|2004-03-22|2004-03-23|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 1999||1999-03-31|August 2012|2012-08-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia|Phase I Study of Dolastatin-10 in Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase|Completed||Phase 1|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:12:05.305517|2018-06-01 05:12:05.305517
NCT00003647|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-03-22|2004-03-23|Estimate|||||||2008-07-23|2008-07-25|Estimate|July 1998||1998-07-31|July 2008|2008-07-31|September 2002|Actual|2002-09-30|||||Interventional|||Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma|Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma|Completed||Phase 3|||Vical|||||f||||t||||||||||2018-06-01 05:12:05.376422|2018-06-01 05:12:05.376422
NCT00079976|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-19|||2013-02-07|2004-03-19|2004-03-22|Estimate|||||||2013-02-07|2013-02-08|Estimate|October 2003||2003-10-31|February 2013|2013-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)|A Clinical Research Study to Evaluate the Safety and Efficacy of Tigecycline in the Treatment of Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)|Completed||Phase 3|174|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:12:05.469746|2018-06-01 05:12:05.469746
NCT00079963|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-18|||2017-09-25|2004-03-19|2004-03-22|Estimate|||||||2017-09-25|2017-09-27|Actual|April 2004||2004-04-30|September 2017|2017-09-30|March 24, 2008|Actual|2008-03-24|March 24, 2008|Actual|2008-03-24||Interventional|||Gender, Obesity, C-Reactive Protein, and Oxidative Stress|Gender, Obesity, C-Reactive Protein, and Oxidative Stress|Completed||N/A|396|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 05:12:05.519477|2018-06-01 05:12:05.519477
NCT00079950|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-18|||2012-09-05|2004-03-19|2004-03-22|Estimate|||||||2012-09-05|2012-09-06|Estimate|August 2003||2003-08-31|September 2012|2012-09-30||||||||Interventional|||Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma||Suspended||Phase 2|||Enzon Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 05:12:05.633138|2018-06-01 05:12:05.633138
NCT00079937|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-18|2010-12-03||2012-04-09|2004-03-19|2004-03-22|Estimate|2011-07-07|2011-08-03|Estimate||||2012-04-09|2012-04-11|Estimate|April 2004||2004-04-30|April 2012|2012-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma|A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma|Completed||Phase 3|628|Actual|Novartis||2|||f||||||||||||||2018-06-01 05:12:05.699596|2018-06-01 05:12:05.699596
NCT00003561|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-07-19|2004-03-19|2004-03-22|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 1998||1998-02-28|April 2011|2011-04-30|August 2010|Actual|2010-08-31|October 2001|Actual|2001-10-31||Interventional|||Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|Granulocyte-Macrophage Colony Stimulating Factor (Rhu-GM-CSF) With Interferon-Alpha (IFN-alpha) for Chronic Myeloid Leukemia|Terminated||Phase 2|48|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:12:07.117939|2018-06-01 05:12:07.117939
NCT00003327|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-03-19|2004-03-22|Estimate|||||||2008-07-23|2008-07-24|Estimate|September 1997||1997-09-30|November 2001|2001-11-30||||||||Interventional|||Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer|A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:08.083936|2018-06-01 05:12:08.083936
NCT00003321|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-11|2004-03-19|2004-03-22|Estimate|||||||2013-06-11|2013-06-12|Estimate|February 1998||1998-02-28|June 2013|2013-06-30||||August 2001|Actual|2001-08-31||Observational|||Quality-of-Life Assessment of Patients Who Have Cancer of the Esophagus|An International Field Study of the Reliability and Validity of the EORTC-QLQ-C30 and a Disease Specific Questionnaire Module (the EORTC OES-24) in Assessing the Quality of Life of Patients With Oesophageal Cancer|Completed|||370|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:12:08.211025|2018-06-01 05:12:08.211025
NCT00003274|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2004-03-19|2004-03-22|Estimate|||||||2014-05-20|2014-05-22|Estimate|March 1998||1998-03-31|May 2014|2014-05-31|November 2002|Actual|2002-11-30|September 2001|Actual|2001-09-30||Interventional|||Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery|A Randomized Phase II Trial of a Vaccine Combining Tyrosinase /gp100 Peptides Emulsified With Montanide ISA 51 Alone or With a Block Co-Polymer CRL 1005 or With GM-CSF for Patients With Resected Stages IIA and IIB Melanoma Grant Application Title: MART-1/gp100 Immune Responses to a Melanoma Vaccine|Completed||Phase 2|48|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:12:08.289608|2018-06-01 05:12:08.289608
NCT00079924|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-18|||2007-05-23|2004-03-18|2004-03-19|Estimate|||||||2007-05-23|2007-05-25|Estimate|November 2004||2004-11-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Effects of Teriparatide in Postmenopausal Women With Osteoporosis|Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene|Completed||Phase 4|200||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:12:08.361072|2018-06-01 05:12:08.361072
NCT00079911|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-18|||2017-08-03|2004-03-18|2004-03-19|Estimate|||||||2017-08-03|2017-08-07|Actual|March 14, 2004|Actual|2004-03-14|August 2017|2017-08-31|October 15, 2004|Actual|2004-10-15|October 15, 2004|Actual|2004-10-15||Interventional|||A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons|An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons With CD4+ Lymphocyte Count <100 Cells/mm3.|Terminated||Phase 4|7|Actual|GlaxoSmithKline||2||Terminated|f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:12:08.439506|2018-06-01 05:12:08.439506
NCT00079898|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-18|||2008-01-23|2004-03-18|2004-03-19|Estimate|||||||2008-01-23|2008-01-25|Estimate|July 2002||2002-07-31|January 2008|2008-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Effect of Acupuncture on Human Brain Activity|Modulatory Effect of Acupuncture on Human Brain Activity|Completed||N/A|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:12:08.530193|2018-06-01 05:12:08.530193
NCT00079885|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-18|||2013-02-07|2004-03-18|2004-03-19|Estimate|||||||2013-02-07|2013-02-08|Estimate|November 2003||2003-11-30|February 2013|2013-02-28|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia|Completed||Phase 3|430|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:12:08.676868|2018-06-01 05:12:08.676868
NCT00079872|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-17|||2007-11-05|2004-03-18|2004-03-19|Estimate|||||||2007-11-05|2007-11-06|Estimate|February 2004||2004-02-29|November 2007|2007-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer|A Randomized Phase 2 Trial of ALIMTA Plus a Comparator Versus Leucovorin Modulated Fluorouracil Plus a Comparator in First Line Treatment of Locally Advanced or Metastatic Colorectal Cancer|Completed||Phase 2|120||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:12:08.746261|2018-06-01 05:12:08.746261
NCT00022360|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-06-17|2004-03-18|2004-03-19|Estimate|||||||2013-06-17|2013-06-18|Estimate|May 2001||2001-05-31|June 2013|2013-06-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Taurolidine in Treating Patients With Recurrent or Progressive Glioma|An Open-Label Dose-Ranging Study of the Safety of Taurolidine 2% Solution Administered Intravenously to Patients With Recurrent or Progressive High Grade Glioma|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:08.839836|2018-06-01 05:12:08.839836
NCT00022165|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2015-08-10|2004-03-18|2004-03-19|Estimate|||||||2015-08-10|2015-08-11|Estimate|October 1999||1999-10-31|August 2015|2015-08-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Selenium in the Prevention of Cancer|Prevention Of Cancer By Intervention With Selenium|Completed||N/A|501|Actual|University of Surrey||4|||f||||f||||||||||2018-06-01 05:12:08.923556|2018-06-01 05:12:08.923556
NCT00021138|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-05-14|2004-03-18|2004-03-19|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 2001||2001-04-30|March 2011|2011-03-31|March 2004|Actual|2004-03-31|||||Interventional|||Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking|Computerized Scheduling of Nicotine Inhaler Use|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:09.004085|2018-06-01 05:12:09.004085
NCT00003166|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-10|2004-03-18|2004-03-19|Estimate|||||||2013-01-10|2013-01-11|Estimate|May 1998||1998-05-31|January 2013|2013-01-31||||July 2001|Actual|2001-07-31||Interventional|||Bryostatin and Vincristine in B-Cell Malignancies|A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies|Completed||Phase 1|18|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:09.094183|2018-06-01 05:12:09.094183
NCT00002789|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-29|2004-03-18|2004-03-19|Estimate|||||||2010-03-29|2010-03-30|Estimate|May 1996||1996-05-31|March 2010|2010-03-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia|A PHASE III RANDOMIZED STUDY COMPARING G-CSF MOBILIZED PERIPHERAL BLOOD STEM CELLS WITH MARROW AS THE SOURCE OF STEM CELLS FOR ALLOGENEIC TRANSPLANTS FROM HLA IDENTICAL, RELATED DONORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA|Completed||Phase 3|100|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:12:09.198165|2018-06-01 05:12:09.198165
NCT00079859|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-17|||2005-06-23|2004-03-17|2004-03-18|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2003||2003-10-31|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy|Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy|Terminated||Phase 2|120||Medical Research Laboratories International|||||||||||||||||||2018-06-01 05:12:09.293085|2018-06-01 05:12:09.293085
NCT00079846|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-17|||2005-06-23|2004-03-17|2004-03-18|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2003||2003-09-30|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy|Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy|Terminated||Phase 2|60||Medical Research Laboratories International|||||||||||||||||||2018-06-01 05:12:09.356505|2018-06-01 05:12:09.356505
NCT00079833|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-16|||2010-11-18|2004-03-16|2004-03-17|Estimate|||||||2010-11-18|2010-11-19|Estimate|November 2003||2003-11-30|November 2010|2010-11-30|July 2005|Actual|2005-07-31|||||Interventional|||Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome|A Phase III, Multicenter, Open-Label Study To Evaluate the Control of Gastric Acid Secretion With Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome For 12 Months|Completed||Phase 3|25||AstraZeneca|||||||||||||||||||2018-06-01 05:12:09.412293|2018-06-01 05:12:09.412293
NCT00079820|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-15|||2014-01-09|2004-03-16|2004-03-17|Estimate|||||||2014-01-09|2014-01-13|Estimate|April 2004||2004-04-30|January 2014|2014-01-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults|The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination|Completed||Phase 1|110|Actual|Sanofi||5|||f||||t||||||||||2018-06-01 05:12:09.473581|2018-06-01 05:12:09.473581
NCT00020930|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2009-12-03|2004-03-16|2004-03-17|Estimate|||||||2009-12-03|2009-12-04|Estimate|March 2001||2001-03-31|December 2009|2009-12-31||||August 2002|Actual|2002-08-31||Interventional|||Cetuximab in Treating Patients With Stage IV Colorectal Cancer|Phase II Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Patients With Irinotecan-Refractory, Stage IV Colorectal Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:09.555242|2018-06-01 05:12:09.555242
NCT00020865|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-12-18|2004-03-16|2004-03-17|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2001||2001-09-30|May 2007|2007-05-31||||||||Interventional|||Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia|Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:09.61257|2018-06-01 05:12:09.61257
NCT00014300|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2012-09-20|2004-03-16|2004-03-17|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2001||2001-01-31|September 2012|2012-09-30||||September 2001|Actual|2001-09-30||Interventional|||Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme|Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme|Completed||Phase 2|32|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:12:09.775049|2018-06-01 05:12:09.775049
NCT00012337|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-06-20|2004-03-16|2004-03-17|Estimate|||||||2013-06-20|2013-06-24|Estimate|January 2001||2001-01-31|March 2002|2002-03-31|March 2004|Actual|2004-03-31|||||Interventional|||ZD 1839 in Treating Patients With Metastatic Kidney Cancer|A Trial of ZD1839 (Iressa) in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:09.866493|2018-06-01 05:12:09.866493
NCT00009737|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|2016-05-16||2016-05-16|2004-03-16|2004-03-17|Estimate|2016-05-16|2016-06-22|Estimate||||2016-05-16|2016-06-22|Estimate|November 1998||1998-11-30|May 2016|2016-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional||All randomized population included all participants who were randomized to one of the two treatment arms, regardless of whether they received any study medication.|A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer|An Open-Label Randomized Phase III Study Comparing Xeloda (Capecitabine) With IV Bolus 5-Fluorouracil in Combination With Low-Dose Leucovorin as Adjuvant Chemotherapy in Patients Who Underwent Surgery for Dukes C Colon Cancer|Completed||Phase 3|1987|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:12:10.012903|2018-06-01 05:12:10.012903
NCT00006812|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-04-10|2004-03-16|2004-03-17|Estimate|||||||2013-04-10|2013-04-11|Estimate|March 2001||2001-03-31|November 2005|2005-11-30||||July 2005|Actual|2005-07-31||Interventional|||Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer|Phase II Evaluation Of Capecitabine In Recurrent Platinum-Sensitive Ovarian Or Primary Peritoneal Cancer|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:12:11.006006|2018-06-01 05:12:11.006006
NCT00006708|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-04-08|2004-03-16|2004-03-17|Estimate|||||||2013-04-08|2013-04-10|Estimate|October 2000||2000-10-31|April 2013|2013-04-30|November 2006|Actual|2006-11-30|November 2002|Actual|2002-11-30||Interventional|||S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT|Terminated||Phase 3|7|Actual|Southwest Oncology Group||2||lack of accrual|f||||t||||||||||2018-06-01 05:12:11.197158|2018-06-01 05:12:11.197158
NCT00006218|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-07-17|2004-03-16|2004-03-17|Estimate|||||||2013-07-17|2013-07-18|Estimate|May 2000||2000-05-31|December 2007|2007-12-31|January 2008|Actual|2008-01-31|||||Interventional|||3-AP in Treating Patients With Advanced Cancer|A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:11.405738|2018-06-01 05:12:11.405738
NCT00006215|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-12-18|2004-03-16|2004-03-17|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1999||1999-10-31|December 2001|2001-12-31||||||||Interventional|||Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:11.478707|2018-06-01 05:12:11.478707
NCT00006098|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-06-17|2004-03-16|2004-03-17|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2000||2000-04-30|June 2013|2013-06-30|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||PS-341 in Treating Patients With Hematologic Cancer|A Phase I Study of PS-341 in Patients With Hematologic Malignancies|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:11.592927|2018-06-01 05:12:11.592927
NCT00079807|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-15|||2008-04-21|2004-03-15|2004-03-16|Estimate|||||||2008-04-21|2008-04-22|Estimate|September 2003||2003-09-30|April 2008|2008-04-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Painful HIV Neuropathy and Alpha-Lipoic Acid|Painful HIV Neuropathy: Treatment With Alpha-Lipoic Acid|Completed||Phase 1/Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:12:11.667247|2018-06-01 05:12:11.667247
NCT00079794|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-15|||2008-01-23|2004-03-15|2004-03-16|Estimate|||||||2008-01-23|2008-01-25|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Iscar for Supplemental Care in Stage IV Lung Cancer|Iscar for Supplemental Care in Stage IV Lung Cancer|Completed||Phase 2|36||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:12:11.726464|2018-06-01 05:12:11.726464
NCT00079781|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-12|2013-11-06|2012-01-23|2013-12-23|2004-03-15|2004-03-16|Estimate|2013-11-06|2013-12-24|Estimate|2012-01-23|2012-01-27|Estimate|2013-12-23|2014-01-29|Estimate|January 2004||2004-01-31|December 2013|2013-12-31|December 2007|Actual|2007-12-31|May 2006|Actual|2006-05-31||Interventional||Date of birth was not provided for 5 subjects (4 in the Open Label Group and 1 in the Treatment Group), therefore baseline characteristics calculations requiring age/DOB were derived using an N = 60.|RNS® System Feasibility Study|RNS® System Feasibility Clinical Investigation|Completed||Phase 2|70|Actual|NeuroPace||3|||f||||t||||||||||2018-06-01 05:12:11.823573|2018-06-01 05:12:11.823573
NCT00079755|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-12|||2014-12-17|2004-03-15|2004-03-16|Estimate|||||||2014-12-17|2014-12-18|Estimate|February 2004||2004-02-29|December 2014|2014-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma|A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma|Completed||Phase 2|80||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 05:12:12.562953|2018-06-01 05:12:12.562953
NCT00079742|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-11|||2008-06-05|2004-03-15|2004-03-16|Estimate|||||||2008-06-05|2008-06-09|Estimate|September 2003||2003-09-30|June 2008|2008-06-30|May 2007|Actual|2007-05-31|||||Interventional|||A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis|A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic Fibrosis|Completed||Phase 2|68|Actual|Genentech, Inc.|||||||||||||||||||2018-06-01 05:12:12.637327|2018-06-01 05:12:12.637327
NCT00079716|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-11|||2014-12-17|2004-03-15|2004-03-16|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2004||2004-03-31|December 2014|2014-12-31|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma|A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Refractory or Recurrent Multiple Myeloma|Completed||Phase 1|44|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-06-01 05:12:12.688273|2018-06-01 05:12:12.688273
NCT00006091|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-10-05|2004-03-15|2004-03-16|Estimate|||||||2012-10-05|2012-10-10|Estimate|June 2000||2000-06-30|October 2012|2012-10-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment|Arsenic Trioxide Therapy for Interferon Alpha Refractory or Intolerant Chronic Phase Chronic Myelogenous Leukemia|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||||No enrollment.|f||||f||||||||||2018-06-01 05:12:12.762796|2018-06-01 05:12:12.762796
NCT00006085|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-12-18|2004-03-15|2004-03-16|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 2000||2000-06-30|December 2001|2001-12-31||||||||Interventional|||CP-609,754 in Treating Patients With Advanced Solid Tumors|Phase I Open-Label Study of the Safety, Toleration and Pharmacokinetics of CP-609,754, a Farnesyl Transferase Inhibitor, in Subjects With Advanced Malignant Tumors|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:12.818081|2018-06-01 05:12:12.818081
NCT00006026|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-09-20|2004-03-15|2004-03-16|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2000||2000-05-31|September 2012|2012-09-30||||October 2001|Actual|2001-10-31||Interventional|||Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract|"Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a 5 Days On-2 Days Off Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors"|Completed||Phase 2|21|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:12:12.866752|2018-06-01 05:12:12.866752
NCT00005866|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2015-03-05|2004-03-15|2004-03-16|Estimate|||||||2015-03-05|2015-03-06|Estimate|February 2000||2000-02-29|March 2015|2015-03-31|March 2006|Actual|2006-03-31|March 2004|Actual|2004-03-31||Interventional|||S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia|A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study)|Completed||Phase 3|240|Anticipated|Southwest Oncology Group||1|||f||||||||||||||2018-06-01 05:12:12.938703|2018-06-01 05:12:12.938703
NCT00005848|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-07-10|2004-03-15|2004-03-16|Estimate|||||||2013-07-10|2013-07-11|Estimate|April 2000||2000-04-30|July 2013|2013-07-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Phase II Trial of R115777 (NSC 702818) an Inhibitor of Farnesyl Protein Transferase, in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|7|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:12:13.185601|2018-06-01 05:12:13.185601
NCT00005834|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2015-03-05|2004-03-15|2004-03-16|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2000||2000-04-30|March 2015|2015-03-31|November 2007|Actual|2007-11-30|November 2003|Actual|2003-11-30||Interventional|||S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma|A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients With Refractory Multiple Myeloma|Terminated||Phase 3|19|Actual|Southwest Oncology Group||2||poor accrual|f||||t||||||||||2018-06-01 05:12:13.277462|2018-06-01 05:12:13.277462
NCT00005635|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-08-16|2004-03-15|2004-03-16|Estimate|||||||2013-08-16|2013-08-20|Estimate|January 2000||2000-01-31|August 2013|2013-08-31||||November 2001|Actual|2001-11-30||Interventional|||Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2|A Phase II Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of Herceptin Administered Subcutaneously in Combination With Paclitaxel in Women With HER2 Overexpressing Metastatic Breast Cancer|Completed||Phase 2|||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:12:13.505334|2018-06-01 05:12:13.505334
NCT00005085|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-02-08|2004-03-15|2004-03-16|Estimate|||||||2013-02-08|2013-02-11|Estimate|February 2000||2000-02-29|December 2002|2002-12-31||||June 2002|Actual|2002-06-30||Interventional|||Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer|A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:13.580465|2018-06-01 05:12:13.580465
NCT00005037|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-05-05|2004-03-15|2004-03-16|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2000||2000-01-31|May 2014|2014-05-31|April 2008|Actual|2008-04-30|October 2002|Actual|2002-10-31||Interventional|||Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer|Temozolomide in the Treatment of Advanced Non-Small Cell Lung Carcinoma: Phase II Evaluation in Previously Treated and Chemo-Naive Patients|Completed||Phase 2|51|Actual|Fox Chase Cancer Center||1|||f||||||||||||||2018-06-01 05:12:13.655178|2018-06-01 05:12:13.655178
NCT00004926|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-05-29|2004-03-15|2004-03-16|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 1999||1999-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|August 2002|Actual|2002-08-31||Interventional|||ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy|A Phase I Study of Oral ILX23-7553 in Patients With Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:13.724123|2018-06-01 05:12:13.724123
NCT00004913|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-05-31|2004-03-15|2004-03-16|Estimate|||||||2012-05-31|2012-06-01|Estimate|January 2000||2000-01-31|May 2012|2012-05-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Study of Docetaxel Plus 5-FU, Cisplatin and Leucovorin in Patients With Advanced Solid Tumors|Completed||Phase 1|||Northwestern University|||||f||||||||||||||2018-06-01 05:12:13.779756|2018-06-01 05:12:13.779756
NCT00004909|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2011-02-18|2004-03-15|2004-03-16|Estimate|||||||2011-02-18|2011-02-21|Estimate|November 1999||1999-11-30|February 2011|2011-02-28|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Observational|||Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer|The Impact of Oral Chemotherapy on Quality of Life in Patients With Recurrent Epithelial Ovarian Cancer|Completed|||40|Actual|Northwestern University|||2||f||||t||||||||||2018-06-01 05:12:13.838787|2018-06-01 05:12:13.838787
NCT00004865|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2009-03-06|2004-03-15|2004-03-16|Estimate|||||||2009-03-06|2009-03-09|Estimate|November 1999||1999-11-30|March 2009|2009-03-31||||January 2002|Actual|2002-01-31||Interventional|||Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy|Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Combination With Chemotherapy in Patients With Metastatic or Recurrent Squamous Cell Head and Neck Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:13.901934|2018-06-01 05:12:13.901934
NCT00079703|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-10|||2016-07-28|2004-03-12|2004-03-15|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2002||2002-09-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Diet, Genetics, and CVD Risk Factor Response in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:12:13.976447|2018-06-01 05:12:13.976447
NCT00079690|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-10|||2016-07-28|2004-03-12|2004-03-15|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2002||2002-09-30|May 2009|2009-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Genetic Epidemiology of Blood Pressure Intervention||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:12:14.019439|2018-06-01 05:12:14.019439
NCT00004864|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2011-12-29|2004-03-12|2004-03-15|Estimate|||||||2011-12-29|2012-01-02|Estimate|July 1999||1999-07-31|July 2008|2008-07-31||||||||Interventional|||Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Open-Label Safety Study of Escalating Doses of Taxotere in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors|Completed||Phase 1|||Montefiore Medical Center|||||f||||||||||||||2018-06-01 05:12:14.064475|2018-06-01 05:12:14.064475
NCT00004863|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2010-10-25|2004-03-12|2004-03-15|Estimate|||||||2010-10-25|2010-10-26|Estimate|July 1999||1999-07-31|October 2010|2010-10-31||||||||Interventional|||Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Open-Label Safety Study of Escalating Doses of Taxol in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors|Completed||Phase 1|||Montefiore Medical Center|||||f||||||||||||||2018-06-01 05:12:14.115152|2018-06-01 05:12:14.115152
NCT00004163|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2017-04-14|2004-03-12|2004-03-15|Estimate|||||||2017-04-14|2017-04-18|Actual|October 1999|Actual|1999-10-31|April 2017|2017-04-30|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer|Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas|Completed||Phase 2|14|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-06-01 05:12:14.169531|2018-06-01 05:12:14.169531
NCT00004151|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-09-20|2004-03-12|2004-03-15|Estimate|||||||2012-09-20|2012-09-24|Estimate|September 1999||1999-09-30|September 2012|2012-09-30||||November 2000|Actual|2000-11-30||Interventional|||Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer|Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Advanced Non Small Cell Lung Cancer|Completed||Phase 2|15|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:12:14.247478|2018-06-01 05:12:14.247478
NCT00004142|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-07-27|2004-03-12|2004-03-15|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 1999||1999-09-30|July 2012|2012-07-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver|Phase II Study of Radiofrequency Ablation of Colorectal Cancer Liver Metastases Combined With Post-Ablation Hepatic Arterial Infusion of Floxuridine Alternating With 5-Fluorouracil|Completed||Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:12:14.325471|2018-06-01 05:12:14.325471
NCT00004109|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-08-01|2004-03-12|2004-03-15|Estimate|||||||2012-08-01|2012-08-02|Estimate|March 1998||1998-03-31|August 2012|2012-08-31|April 2011|Actual|2011-04-30|September 2001|Actual|2001-09-30||Interventional|||Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma|A Phase I Study of Preoperative Concurrent Chemoradiation for High-Risk Extremity and Trunk Soft Tissue Sarcomas|Completed||Phase 1|30|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:12:14.492376|2018-06-01 05:12:14.492376
NCT00003959|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-15|2004-03-12|2004-03-15|Estimate|||||||2013-01-15|2013-01-16|Estimate|June 1999||1999-06-30|January 2013|2013-01-31||||December 2001|Actual|2001-12-31||Interventional|||Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome|Vaccination of Patients With Myelodysplastic Syndrome Against Mutated RAS Proteins: A Pilot Trial|Completed||Phase 1|1|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:14.57495|2018-06-01 05:12:14.57495
NCT00003779|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-16|2004-03-12|2004-03-15|Estimate|||||||2013-05-16|2013-05-17|Estimate|November 1998||1998-11-30|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2001|Actual|2001-06-30||Interventional|||Biological Therapy in Treating Patients With Bladder Cancer|A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ|Completed||Phase 3|40|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:12:14.635613|2018-06-01 05:12:14.635613
NCT00003772|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-24|2004-03-12|2004-03-15|Estimate|||||||2012-08-24|2012-08-27|Estimate|January 1999||1999-01-31|August 2012|2012-08-31|February 2003|Actual|2003-02-28|August 2001|Actual|2001-08-31||Observational|||Quality-of-Life Assessment in Patients With Ovarian Cancer|An International Field Study of the Reliability and Validity of a Disease-Specific Questionnaire Module (the QLQ-OV28) in Assessing the Quality of Life of Patients With Ovarian Cancer|Completed|||372|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||f||||||||||2018-06-01 05:12:14.704229|2018-06-01 05:12:14.704229
NCT00003742|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-03-12|2004-03-15|Estimate|||||||2013-06-20|2013-06-21|Estimate|October 1998||1998-10-31|June 2013|2013-06-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Trial of Paclitaxel, Cisplatin, and Irinotecan in Patients With Advanced Solid Tumor Malignancies|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:14.762148|2018-06-01 05:12:14.762148
NCT00003706|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-26|2004-03-12|2004-03-15|Estimate|||||||2012-06-26|2012-06-28|Estimate|April 1998||1998-04-30|June 2012|2012-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function|A Phase I Pharmacokinetic Trial of LY231514 Administered Intravenously Every 3 Weeks in Advanced Cancer Patients With Varying Degrees of Renal Function|Completed||Phase 1|50|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:12:14.814008|2018-06-01 05:12:14.814008
NCT00003705|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-03-12|2004-03-15|Estimate|||||||2008-07-23|2008-07-24|Estimate|November 1997||1997-11-30|August 2007|2007-08-31||||||||Interventional|||BMS-184476 in Treating Patients With Advanced Solid Tumors|Phase I Study of BMS-184476 in Patients With Advanced Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:14.865565|2018-06-01 05:12:14.865565
NCT00003704|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2004-03-12|2004-03-15|Estimate|||||||2016-07-01|2016-07-06|Estimate|April 1999||1999-04-30|July 2016|2016-07-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer|Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis|Completed||Phase 1|51|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:12:14.929015|2018-06-01 05:12:14.929015
NCT00003703|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-25|2004-03-12|2004-03-15|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 1999||1999-01-31|September 2002|2002-09-30|March 2004|Actual|2004-03-31|||||Interventional|||Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetics Study of SarCNU in Patients With Advanced Cancers|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:15.103377|2018-06-01 05:12:15.103377
NCT00003695|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-03-12|2004-03-15|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 1998||1998-05-31|May 2007|2007-05-31|January 2001|Actual|2001-01-31|||||Interventional|||Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer|A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery|Completed||Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:15.17663|2018-06-01 05:12:15.17663
NCT00079768|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-12|||2010-06-16|2004-03-11|2004-03-12|Estimate|||||||2010-06-16|2010-06-17|Estimate|March 2004||2004-03-31|January 2009|2009-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Alemtuzumab to Treat Sporadic Inclusion Body Myositis|Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:15.250738|2018-06-01 05:12:15.250738
NCT00079729|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-11|||2012-10-26|2004-03-11|2004-03-12|Estimate|||||||2012-10-26|2012-10-29|Estimate|April 2004||2004-04-30|October 2012|2012-10-31|July 2004|Actual|2004-07-31|||||Observational|||Directly Observed Therapy in HIV Infected Adolescent Focus Groups|Directly Observed Therapy (DOT) in HIV-Infected Adolescents: Part A-Focus Groups|Completed|||30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:12:15.330911|2018-06-01 05:12:15.330911
NCT00079677|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-10|2009-06-01||2013-07-12|2004-03-11|2004-03-12|Estimate|2010-01-08|2010-02-03|Estimate||||2013-07-12|2013-07-19|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|October 2004||2004-10-31|||||Interventional|||Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome|Completed||Phase 3|263|Actual|Teva Pharmaceutical Industries||2|||||||||||||||||2018-06-01 05:12:15.418159|2018-06-01 05:12:15.418159
NCT00079664|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-10|||2013-09-30|2004-03-11|2004-03-12|Estimate|||||||2013-09-30|2013-10-01|Estimate|September 2001||2001-09-30|September 2013|2013-09-30|July 2003|Actual|2003-07-31|March 2002|Actual|2002-03-31||Interventional|||Comparing Tai Chi Training to a Low-Stress Physical Activity to Enhance Sleep in Older Adults|Tai Chi Training and Sleep Enhancement in the Elderly|Completed||Phase 1|100||Oregon Research Institute|||||f||||f||||||||||2018-06-01 05:12:15.73517|2018-06-01 05:12:15.73517
NCT00079651|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-10|||2013-11-21|2004-03-11|2004-03-12|Estimate|||||||2013-11-21|2013-11-25|Estimate|December 2002||2002-12-31|November 2013|2013-11-30|July 2005|Actual|2005-07-31|April 2005|Actual|2005-04-30||Interventional|||Montessori-Based Activities for Elderly Persons With Dementia|Programming for Dementia: Maximizing Abilities|Completed||Phase 2/Phase 3|300||Menorah Park|||||f||||t||||||||||2018-06-01 05:12:15.795614|2018-06-01 05:12:15.795614
NCT00079638|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-10|||2006-10-31|2004-03-11|2004-03-12|Estimate|||||||2006-10-31|2006-11-01|Estimate|April 2004||2004-04-30|October 2006|2006-10-31|May 2005||2005-05-31|||||Interventional|||Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL|Comparative Efficacy Evaluation of Lipid Levels When Treated With Niaspan and Statin or Other Lipid-Modifying Therapies|Completed||Phase 4|300||Kos Pharmaceuticals|||||||||||||||||||2018-06-01 05:12:15.863037|2018-06-01 05:12:15.863037
NCT00078039|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-17|||2011-06-06|2004-03-11|2004-03-12|Estimate|||||||2011-06-06|2011-06-08|Estimate|March 2004||2004-03-31|April 2010|2010-04-30|January 2005|Actual|2005-01-31|||||Interventional|||Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia|Randomized, Double-blind, Placebo- and Active-controlled Parallel Group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Paliperidone Extended Release (6, 9, and 12 mg/Day) and Olanzapine (10 mg/Day) With Open-label Extension in Treatment of Schizophrenia|Completed||Phase 3|630|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:12:15.92793|2018-06-01 05:12:15.92793
NCT00067847|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-28|||2010-01-12|2003-08-29|2003-09-01|Estimate|||||||2010-01-12|2010-01-13|Estimate|July 2003||2003-07-31|January 2010|2010-01-31|May 2004||2004-05-31|||||Interventional|||Evaluation of California's SB 19 Pupil Nutrition Act||Completed||N/A|5020||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:17:45.524145|2018-06-01 05:17:45.524145
NCT00003617|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-03-11|2004-03-12|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 1995||1995-03-31|April 2009|2009-04-30||||||||Interventional|||Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach|Protocol for a Randomised Trial of Observation Versus Chlorambucil After Anti-Helicobacter Therapy in Low Grade Gastric Lymphoma|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:15.989287|2018-06-01 05:12:15.989287
NCT00003465|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2004-03-11|2004-03-12|Estimate|||||||2013-06-19|2013-06-20|Estimate|March 1998||1998-03-31|October 2009|2009-10-31|February 2001|Actual|2001-02-28|||||Interventional|||Temozolomide in Treating Patients With Anaplastic Oligodendroglioma|Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal|Completed||Phase 2|60|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:12:16.080323|2018-06-01 05:12:16.080323
NCT00003421|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-03-11|2004-03-12|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 1998||1998-06-30|May 2007|2007-05-31|November 2005|Actual|2005-11-30|||||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease|A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease|Completed||Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:16.133487|2018-06-01 05:12:16.133487
NCT00003368|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-19|2004-03-11|2004-03-12|Estimate|||||||2013-03-19|2013-03-21|Estimate|June 1998||1998-06-30|July 2006|2006-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis|Phase I Study of Irinotecan for Patients With Abnormal Liver or Renal Function or With Prior Pelvic Radiation Therapy|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:16.206808|2018-06-01 05:12:16.206808
NCT00003361|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-03-11|2004-03-12|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 1998||1998-04-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|September 2003|Actual|2003-09-30||Interventional|||Decitabine in Treating Patients With Myelodysplastic Syndrome|Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes|Completed||Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:16.390847|2018-06-01 05:12:16.390847
NCT00003338|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-03-11|2004-03-12|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1997||1997-03-31|December 2001|2001-12-31||||||||Interventional|||Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma|The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:16.446139|2018-06-01 05:12:16.446139
NCT00003337|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-03-11|2004-03-12|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1997||1997-03-31|December 2001|2001-12-31||||||||Interventional|||Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma|The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:16.512354|2018-06-01 05:12:16.512354
NCT00003212|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-01-19|2004-03-11|2004-03-12|Estimate|||||||2012-01-19|2012-01-20|Estimate|January 1998||1998-01-31|January 2012|2012-01-31||||November 2001|Actual|2001-11-30||Interventional|||Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma|Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma|Completed||Phase 3|780|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:12:16.578823|2018-06-01 05:12:16.578823
NCT00003021|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-02|2004-03-11|2004-03-12|Estimate|||||||2012-11-02|2012-11-06|Estimate|August 1997||1997-08-31|November 2012|2012-11-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Bizelesin in Treating Patients With Advanced Cancer|A Phase I Trial of Bizelesin (NSC 615291) Using a Single Bolus Infusion Given Every Twenty-eight (28) Days in Patients With Advanced Cancer|Completed||Phase 1|||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 05:12:16.658827|2018-06-01 05:12:16.658827
NCT00003014|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-03-11|2004-03-12|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 1998||1998-04-30|March 2011|2011-03-31|July 2005|Actual|2005-07-31|||||Interventional|||Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer|Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy|Completed||Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:16.716083|2018-06-01 05:12:16.716083
NCT00002930|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-17|2004-03-11|2004-03-12|Estimate|||||||2013-01-17|2013-01-18|Estimate|December 1996||1996-12-31|January 2013|2013-01-31||||October 2002|Actual|2002-10-31||Interventional|||PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery|Whole-Body 18F-Fluorodeoxyglucose Positron Emission Tomography to Measure the Response to Induction Chemotherapy of Potentially Resectable Lung and Esophageal Carcinomas|Completed||Phase 2/Phase 3|75|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:16.825848|2018-06-01 05:12:16.825848
NCT00002928|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-03-11|2004-03-12|Estimate|||||||2013-06-24|2013-06-26|Estimate|January 1997||1997-01-31|June 2013|2013-06-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer|A Phase II Trial of Paclitaxel Administered Weekly in Patients With Advanced Ovarian Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:16.910122|2018-06-01 05:12:16.910122
NCT00002919|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2004-03-11|2004-03-12|Estimate|||||||2013-07-01|2013-07-03|Estimate|November 1996||1996-11-30|July 2013|2013-07-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer|PHASE II TRIAL OF THE COMBINATION OF TRANSURETHRAL RESECTION AND NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH INVASIVE UROTHELIAL TRACT TUMORS SELECTED BY STAGE AND P53 NUCLEAR EXPRESSION|Completed||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:16.958831|2018-06-01 05:12:16.958831
NCT00002901|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-11|2004-03-11|2004-03-12|Estimate|||||||2010-01-11|2010-01-13|Estimate|December 1996||1996-12-31|January 2010|2010-01-31||||||||Interventional|||Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function|PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:12:17.949582|2018-06-01 05:12:17.949582
NCT00002858|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-03-11|2004-03-12|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1993||1993-03-31|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer|PHASE III STUDY COMPARING TWO DOSES OF INDUCTION CHEMOTHERAPY FOLLOWED BY ALTERNATION OF CHEMOTHERAPY AND RADIOTHERAPY IN LIMITED SMALL CELL LUNG CANCER|Unknown status|Active, not recruiting|Phase 3|280|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:18.091061|2018-06-01 05:12:18.091061
NCT00079612|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2014-12-18|2004-03-10|2004-03-11|Estimate|||||||2014-12-18|2014-12-19|Estimate|September 2002||2002-09-30|December 2014|2014-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer|Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer.|Completed||Phase 2|501|Actual|Bayer||2|||f||||||||||||||2018-06-01 05:12:18.193774|2018-06-01 05:12:18.193774
NCT00079586|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2012-01-04|2004-03-10|2004-03-11|Estimate|||||||2012-01-04|2012-01-05|Estimate|April 2004||2004-04-30|January 2012|2012-01-31|November 2004|Actual|2004-11-30|||||Interventional|||Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)|A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)|Completed||Phase 3|150|Actual|The Medicines Company||2|||f||||||||||||||2018-06-01 05:12:18.27702|2018-06-01 05:12:18.27702
NCT00079508|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2011-11-08|2004-03-10|2004-03-11|Estimate|||||||2011-11-08|2011-11-10|Estimate|April 2004||2004-04-30|November 2011|2011-11-30||||October 2005|Actual|2005-10-31||Interventional|HIT/TS||Angiomax in Patients With HIT/HITTS Type II Undergoing CPB|A Phase III Study of Angiomax (Bivalirudin) in Patients With HIT/HITTS Type II Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)|Completed||Phase 3|125|Actual|The Medicines Company|||||f||||||||||||||2018-06-01 05:12:18.362064|2018-06-01 05:12:18.362064
NCT00021359|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-07-09|2004-03-10|2004-03-11|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 1999||1999-08-31|July 2013|2013-07-31|October 2005|Actual|2005-10-31|July 2000|Actual|2000-07-31||Interventional|||Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma|A Phase II Trial of Dexamethasone and 13-cis-Retinoic Acid as First-Line Treatment for Multiple Myeloma|Completed||Phase 2|17|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:12:18.519921|2018-06-01 05:12:18.519921
NCT00017030|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-25|2004-03-10|2004-03-11|Estimate|||||||2013-06-25|2013-06-26|Estimate|February 2001||2001-02-28|December 2009|2009-12-31|December 2009|Actual|2009-12-31|January 2003|Actual|2003-01-31||Interventional|||Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma|Phase II Study of ET-743 Given as a Three Hour Intravenous Infusion in Patients With Advanced and/or Metastatic Soft Tissue Sarcoma Previously Treated With Chemotherapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:18.807782|2018-06-01 05:12:18.807782
NCT00016978|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-02-04|2004-03-10|2004-03-11|Estimate|||||||2013-02-04|2013-02-05|Estimate|April 2001||2001-04-30|August 2007|2007-08-31||||June 2007|Actual|2007-06-30||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan|A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients With Metastatic Colorectal Carcinoma Previously Treated With Irinotecan (CPT-11)|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:18.915049|2018-06-01 05:12:18.915049
NCT00014547|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2008-07-23|2004-03-10|2004-03-11|Estimate|||||||2008-07-23|2008-07-24|Estimate|November 2000||2000-11-30|January 2002|2002-01-31||||||||Interventional|||BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment|Phase II Study Of BBR 3464 As Treatment In Patients With Sensitive Or Refractory Small Cell Lung Cancer After One Prior Chemotherapy Regimen|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:19.083138|2018-06-01 05:12:19.083138
NCT00007969|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-11-05|2004-03-10|2004-03-11|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 2000||2000-10-31|August 2008|2008-08-31||||||||Interventional|||Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase 1/2 Uncontrolled, Open Label Study Of Photodynamic Vaccination In Patients With Stage III/IV Malignant Melanoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:19.188383|2018-06-01 05:12:19.188383
NCT00002823|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-26|2004-03-10|2004-03-11|Estimate|||||||2013-03-26|2013-03-28|Estimate|February 1995||1995-02-28|April 2011|2011-04-30||||January 2001|Actual|2001-01-31||Interventional|||Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer|A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER|Completed||Phase 3|3300|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 05:12:19.459988|2018-06-01 05:12:19.459988
NCT00002650|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-06|2004-03-10|2004-03-11|Estimate|||||||2010-11-06|2010-11-09|Estimate|April 1995||1995-04-30|May 2007|2007-05-31||||||||Interventional|||High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed|PHASE II DOUBLE-BLIND CHEMOPREVENTION TRIAL OF HIGH DOSE FOLIC ACID VERSUS PLACEBO IN PATIENTS WITH RESECTED COLORECTAL POLYPS|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:19.795497|2018-06-01 05:12:19.795497
NCT00002601|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-11-21||2017-01-18|2004-03-10|2004-03-11|Estimate|2016-11-21|2017-01-19|Estimate||||2017-01-18|2017-03-03|Actual|September 1994||1994-09-30|January 2017|2017-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma|High-Dose Doxorubicin and Ifosfamide Followed by Melphalan and Cisplatin for Patients With High-Risk and Recurrent Sarcoma|Completed||Phase 2|13|Actual|City of Hope Medical Center||1|||f||||f||||||||||2018-06-01 05:12:19.900282|2018-06-01 05:12:19.900282
NCT00002581|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-03-10|2004-03-11|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 1993||1993-06-30|May 2007|2007-05-31||||||||Interventional|||Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer|PROTOCOL FOR THE SCOTTISH POSTMENOPAUSAL CHEMO-ENDOCRINE TRIAL|Completed||Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:20.231025|2018-06-01 05:12:20.231025
NCT00002580|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2004-03-10|2004-03-11|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 1993||1993-06-30|May 2007|2007-05-31||||||||Interventional|||Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer|PROTOCOL FOR THE SCOTTISH PREMENOPAUSAL CHEMO-ENDOCRINE TRIAL|Completed||Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:20.313273|2018-06-01 05:12:20.313273
NCT00002537|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2004-03-10|2004-03-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|September 1993||1993-09-30|May 2006|2006-05-31||||March 2006|Actual|2006-03-31||Interventional|||Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer|A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH CHEST IRRADIATION|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:20.386462|2018-06-01 05:12:20.386462
NCT00002526|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2004-03-10|2004-03-11|Estimate|||||||2012-05-14|2012-05-15|Estimate|January 1993||1993-01-31|May 2012|2012-05-31|September 1995|Actual|1995-09-30|September 1995|Actual|1995-09-30||Interventional|||Chemotherapy in Treating Patients With Advanced Sarcoma|Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma|Completed||Phase 2|20|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 05:12:20.448721|2018-06-01 05:12:20.448721
NCT00002508|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-30|2004-03-10|2004-03-11|Estimate|||||||2010-09-30|2010-10-01|Estimate|November 1990||1990-11-30|September 2010|2010-09-30|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors|INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY GERM CELL TUMORS EMPLOYING HIGH-DOSE CARBOPLATIN, ETOPOSIDE, AND THIOTEPA WITH AUTOLOGOUS BONE MARROW RESCUE FOR PATIENTS 15 TO 60 YEARS OF AGE|Completed||Phase 1/Phase 2|||Temple University|||||f||||||||||||||2018-06-01 05:12:20.507022|2018-06-01 05:12:20.507022
NCT00002480|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-03-10|2004-03-11|Estimate|||||||2013-06-24|2013-06-25|Estimate|February 1991||1991-02-28|June 2013|2013-06-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Radiation Therapy in Treating Patients With Prostate Cancer|Phase I Study of 3-Dimensional Conformal Radiotherapy in Patients With Locally Advanced (Stage T2c and T3) Adenocarcinoma of the Prostate|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:12:20.682497|2018-06-01 05:12:20.682497
NCT00002459|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-03-10|2004-03-11|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 1988||1988-04-30|September 2012|2012-09-30||||August 2001|Actual|2001-08-31||Interventional|||Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus|Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma|Completed||Phase 3|224|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:12:20.789713|2018-06-01 05:12:20.789713
NCT00079625|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2017-10-05|2004-03-09|2004-03-10|Estimate|||||||2017-10-05|2017-10-06|Actual|March 5, 2004||2004-03-05|August 9, 2013|2013-08-09|August 9, 2013|Actual|2013-08-09|August 9, 2013|Actual|2013-08-09||Interventional|||Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer|Allogeneic Breast Protocol 2: Phase I Trial of T Cell Exchange With Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning for Metastatic Breast Cancer|Completed||Phase 1|22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:20.925194|2018-06-01 05:12:20.925194
NCT00079599|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2008-09-02|2004-03-09|2004-03-10|Estimate|||||||2008-09-02|2008-09-04|Estimate|November 2002||2002-11-30|September 2008|2008-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||L-Carnitine to Treat Fatigue in AIDS Patients|Phase II Developmental Study on Fatigue in AIDS Patients|Completed||Phase 2|44|Actual|National Institute of Nursing Research (NINR)||2|||f||||t||||||||||2018-06-01 05:12:21.025323|2018-06-01 05:12:21.025323
NCT00079573|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2006-08-16|2004-03-09|2004-03-10|Estimate|||||||2006-08-16|2006-08-18|Estimate|July 2002||2002-07-31|August 2006|2006-08-31|June 2004||2004-06-30|||||Interventional|||Comparison of Popular Weight Loss Diets|Benefits & Risks of Popular Weight Loss Diets|Completed||Phase 2|300||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:12:21.144413|2018-06-01 05:12:21.144413
NCT00079560|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2017-01-10|2004-03-09|2004-03-10|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2001||2001-12-31|October 2008|2008-10-31|August 2005|Actual|2005-08-31|August 2004|Actual|2004-08-31||Interventional|||Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDS|THC and Marijuana--Effects in Individuals With HIV/AIDS|Completed||Phase 1/Phase 2|30|Actual|National Institute on Drug Abuse (NIDA)|||||t||||f||||||||||2018-06-01 05:12:21.268522|2018-06-01 05:12:21.268522
NCT00079547|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2013-06-28|2004-03-09|2004-03-10|Estimate|||||||2013-06-28|2013-07-01|Estimate|April 2003||2003-04-30|January 2008|2008-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||The Safety and Effectiveness of Low and High Carbohydrate Diets|The Safety and Efficacy of Low and High Carbohydrate Diets|Completed||Phase 4|307|Actual|Temple University||2|||f||||t||||||||||2018-06-01 05:12:21.35126|2018-06-01 05:12:21.35126
NCT00079534|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2006-08-16|2004-03-09|2004-03-10|Estimate|||||||2006-08-16|2006-08-18|Estimate|December 2000||2000-12-31|August 2006|2006-08-31|December 2003||2003-12-31|||||Interventional|||Distant Healing for HIV/AIDS|"Distant Healing Efforts for AIDS by Nurses and Healers"|Completed||N/A|150||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:12:21.45904|2018-06-01 05:12:21.45904
NCT00079521|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-09|||2006-08-16|2004-03-09|2004-03-10|Estimate|||||||2006-08-16|2006-08-17|Estimate|March 2003||2003-03-31|August 2006|2006-08-31|April 2006||2006-04-30|||||Interventional|||Therapeutic Touch for Wrist Fractures in Postmenopausal Women|The Effect of Therapeutic Touch on Bone Formation in Postmenopausal Women After Wrist Fracture|Completed||Phase 2|125||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:12:21.523391|2018-06-01 05:12:21.523391
NCT00079495|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2008-03-20|2004-03-09|2004-03-10|Estimate|||||||2008-03-20|2008-03-21|Estimate|July 2003||2003-07-31|September 2007|2007-09-30|April 2005||2005-04-30|||||Interventional|||Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis|Completed||Phase 2|150||Neurocrine Biosciences|||||||||||||||||||2018-06-01 05:12:21.580599|2018-06-01 05:12:21.580599
NCT00079482|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08||2013-08-27|2016-07-19|2004-03-09|2004-03-10|Estimate||||2013-08-27|2013-09-04|Estimate|2016-07-19|2016-07-21|Estimate|October 2003||2003-10-31|July 2016|2016-07-31|January 2010|Actual|2010-01-31|March 2009|Actual|2009-03-31||Interventional|||Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)|A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations|Completed||Phase 2|224|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 05:12:21.673342|2018-06-01 05:12:21.673342
NCT00079469|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2012-03-07|2004-03-09|2004-03-10|Estimate|||||||2012-03-07|2012-03-08|Estimate|February 2004||2004-02-29|March 2012|2012-03-31|August 2004|Actual|2004-08-31|||||Interventional|||Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke|Contingency Management to Enhance Smoking Cessation for Cancer Survivors: A Proof of Concept Trial|Completed||N/A|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:21.961849|2018-06-01 05:12:21.961849
NCT00079456|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-10-10|2004-03-09|2004-03-10|Estimate|||||||2013-10-10|2013-10-11|Estimate|February 2004||2004-02-29|October 2013|2013-10-31||||February 2007|Actual|2007-02-28||Interventional|||Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Trial of CCI-779 in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|25|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:22.035723|2018-06-01 05:12:22.035723
NCT00079443|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-06-28|2004-03-09|2004-03-10|Estimate|||||||2013-06-28|2013-07-01|Estimate|January 2004||2004-01-31|June 2013|2013-06-30||||September 2005|Actual|2005-09-30||Interventional|||FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma|A Phase II Study of Single Agent Depsipeptide (NSC 630176) Followed by a Phase I Study of Rituximab/Fludarabine Combination With an Escalating Dose of Depsipeptide in Relapsed or Refractory Low Grade B Cell Lymphomas|Terminated||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:22.133086|2018-06-01 05:12:22.133086
NCT00079430|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2014-06-18|2004-03-09|2004-03-10|Estimate|||||||2014-06-18|2014-06-19|Estimate|June 2004||2004-06-30|June 2014|2014-06-30||||May 2011|Actual|2011-05-31||Interventional|||Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (NSC #704865) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma|Completed||Phase 1|113|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:22.215467|2018-06-01 05:12:22.215467
NCT00079417|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2013-12-23||2017-02-07|2004-03-09|2004-03-10|Estimate|2013-12-23|2014-02-14|Estimate||||2017-02-07|2017-03-15|Actual|December 2005||2005-12-31|February 2017|2017-02-28|January 2010||2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma|Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma|Completed||Phase 3|28|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:12:22.382194|2018-06-01 05:12:22.382194
NCT00079404|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-06-03|2004-03-09|2004-03-10|Estimate|||||||2013-06-03|2013-06-05|Estimate|March 2004||2004-03-31|June 2013|2013-06-30||||May 2006|Actual|2006-05-31||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia|A Phase I Study of 17-AAG in Relapsed/Refractory Pediatric Patients With Solid Tumors or Leukemia|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:22.697592|2018-06-01 05:12:22.697592
NCT00079391|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2011-04-20||2015-10-05|2004-03-09|2004-03-10|Estimate|2012-04-26|2012-05-28|Estimate||||2015-10-05|2015-10-26|Estimate|January 2004||2004-01-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|December 2008|Actual|2008-12-31||Interventional|||Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Peri-transplant Cyclosporine on Chimerism|Completed||Phase 2|50|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 05:12:22.794331|2018-06-01 05:12:22.794331
NCT00079378|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-09-27|2004-03-09|2004-03-10|Estimate|||||||2013-09-27|2013-09-30|Estimate|February 2004||2004-02-29|September 2013|2013-09-30||||May 2011|Actual|2011-05-31||Interventional|||Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies|Completed||Phase 1|84|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:23.072795|2018-06-01 05:12:23.072795
NCT00079365|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-12-03|2004-03-09|2004-03-10|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2001||2001-05-31|May 2005|2005-05-31||||||||Interventional|||Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas|A Randomized Trial Comparing 5-Fluorouracil, External Beam Radiation, and Gemcitabine With or Without P Radiopharmaceutical Therapy As A First Line Therapy in Patients With Locally/Regionally Advanced Non-Resectable Adenocarcinoma of the Pancreas|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:23.175423|2018-06-01 05:12:23.175423
NCT00079352|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-01-24|2004-03-09|2004-03-10|Estimate|||||||2013-01-24|2013-01-25|Estimate|April 2004||2004-04-30|January 2013|2013-01-31||||October 2007|Actual|2007-10-31||Interventional|||Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors|A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:23.256288|2018-06-01 05:12:23.256288
NCT00079339|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2010-04-30||2014-04-29|2004-03-09|2004-03-10|Estimate|2010-08-31|2010-09-24|Estimate||||2014-04-29|2014-05-15|Estimate|January 2004||2004-01-31|December 2012|2012-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma|Phase I/II Trial of R115777 and XRT in Pediatric Patients With Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas|Completed||Phase 1/Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:23.368946|2018-06-01 05:12:23.368946
NCT00079326|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2013-11-04||2014-05-29|2004-03-09|2004-03-10|Estimate|2014-01-08|2014-02-06|Estimate||||2014-05-29|2014-06-02|Estimate|January 2004||2004-01-31|January 2013|2013-01-31|October 2010|Actual|2010-10-31|July 2008|Actual|2008-07-31||Interventional|||Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer|A Phase 2 Study of Trastuzumab in Combination With BMS-247550 in Women With Metastatic Breast Cancer|Terminated||Phase 2|39|Actual|National Cancer Institute (NCI)||1||Slow accrual.|f||||||||||||||2018-06-01 05:12:24.145844|2018-06-01 05:12:24.145844
NCT00079313|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2017-06-30|2004-03-09|2004-03-10|Estimate|||||||2017-06-30|2017-07-02|Actual|January 14, 2004||2004-01-14|September 23, 2011|2011-09-23|October 25, 2010|Actual|2010-10-25|December 30, 2006|Actual|2006-12-30||Interventional|||Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia|A Pilot Study of the Safety and Efficacy of Imatinib in Reducing Monocytosis or Leukocytosis in Patients With Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia, Respectively|Completed||Phase 2|7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:24.421626|2018-06-01 05:12:24.421626
NCT00079300|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-04-25|2004-03-09|2004-03-10|Estimate|||||||2013-04-25|2013-04-26|Estimate|January 2004||2004-01-31|April 2013|2013-04-30|August 2005|Actual|2005-08-31|||||Interventional|||Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer|Double-Blind, Vehicle-Controlled Study to Evaluate Apoptosis in Basal Cell Carcinoma Treated With Aldara™ (Imiquimod) Cream, 5% Applied Once or Twice a Day|Completed||Phase 1|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:24.485185|2018-06-01 05:12:24.485185
NCT00078156|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2017-01-11|2004-02-20|2004-02-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2004||2004-01-31|October 2016|2016-10-31|October 2005||2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Women's Treatment for Trauma and Substance Use Disorders - 1|Women's Treatment for Trauma and Substance Use Disorders|Completed||Phase 3|409||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:13:00.117806|2018-06-01 05:13:00.117806
NCT00079287|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-09-16|2004-03-09|2004-03-10|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2001||2001-03-31|April 2005|2005-04-30|November 2008|Actual|2008-11-30|||||Interventional|||Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:24.543774|2018-06-01 05:12:24.543774
NCT00079274|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2013-12-05||2015-01-23|2004-03-09|2004-03-10|Estimate|2015-01-23|2015-02-09|Estimate||||2015-01-23|2015-02-09|Estimate|February 2004||2004-02-29|October 2014|2014-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer|A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer|Completed||Phase 3|3397|Actual|National Cancer Institute (NCI)|Accrual to arms A and D terminated early based on the results of the planned 2nd interim analysis. Sample sizes limit statistical conclusions for data from the irinotecan treated patients as those treatment arms were discontinued early in the study.|7|||f||||t||||||||||2018-06-01 05:12:24.893253|2018-06-01 05:12:24.893253
NCT00079261|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2012-09-20|2004-03-09|2004-03-10|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2004||2004-01-31|September 2012|2012-09-30||||March 2007|Actual|2007-03-31||Interventional|||Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma|Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|25|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:12:30.797143|2018-06-01 05:12:30.797143
NCT00079248|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2009-05-09|2004-03-09|2004-03-10|Estimate|||||||2009-05-09|2009-05-12|Estimate|March 2002||2002-03-31|June 2005|2005-06-30||||||||Interventional|||Hormone Replacement Therapy in Relieving Menopausal Symptoms in Postmenopausal Women With Previous Stage I or Stage II Breast Cancer|UK Trial Of Hormone Replacement Therapy (HRT) In Women With A History Of Early Stage Breast Cancer|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:30.880076|2018-06-01 05:12:30.880076
NCT00079235|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-07-15|2004-03-09|2004-03-10|Estimate|||||||2013-07-15|2013-07-16|Estimate|February 2004||2004-02-29|June 2013|2013-06-30||||June 2007|Actual|2007-06-30||Interventional|||CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer|A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:30.941695|2018-06-01 05:12:30.941695
NCT00079222|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-01-07|2004-03-09|2004-03-10|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 2003||2003-11-30|January 2013|2013-01-31||||April 2005|Actual|2005-04-30||Interventional|||Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Randomized Trial Of Safety And Tolerability Of Intravenous/Oral Voriconazole Versus Intravenous/Oral Itraconazole For Long-Term Antifungal Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplant Recipients|Completed||N/A|||Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:12:31.016426|2018-06-01 05:12:31.016426
NCT00079183|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2017-03-30||2017-05-23|2004-03-09|2004-03-10|Estimate|2017-03-30|2017-05-12|Actual||||2017-05-23|2017-06-20|Actual|April 2002||2002-04-30|May 2017|2017-05-31|June 10, 2010|Actual|2010-06-10|July 2009|Actual|2009-07-31||Interventional||This includes all 44 consented subjects.|Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment|A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Sirolimus for Secondary Treatment of Chronic Graft-versus-Host Disease|Completed||Phase 2|44|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||No||2018-06-01 05:12:31.122306|2018-06-01 05:12:31.122306
NCT00079170|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-06-18|2004-03-09|2004-03-10|Estimate|||||||2013-06-18|2013-06-20|Estimate|January 2004||2004-01-31|October 2006|2006-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Pilot Study to Evaluate the Influence of Garlic on the Pharmacokinetics of Docetaxel in Patients With Metastatic Breast Cancer|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:31.682237|2018-06-01 05:12:31.682237
NCT00079157|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2009-07-29|2004-03-09|2004-03-10|Estimate|||||||2009-07-29|2009-07-30|Estimate|February 2004||2004-02-29|July 2009|2009-07-31||||May 2008|Anticipated|2008-05-31||Interventional|||Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer|Phase I Study Of Telomerase Peptide Vaccination For Patients With Advanced Breast Cancer|Unknown status|Active, not recruiting|Phase 1|28|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:31.779928|2018-06-01 05:12:31.779928
NCT00079144|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-06-18|2004-03-09|2004-03-10|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2004||2004-01-31|May 2005|2005-05-31|August 2005|Actual|2005-08-31|||||Interventional|||Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment Of Patients With Metastatic Melanoma Using Nonmyeloablative But Lymphocyte Depleting Regimen Followed By The Administration Of In Vitro Sensitized Lymphocytes Reactive With ESO-1 Antigen|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:31.890487|2018-06-01 05:12:31.890487
NCT00079131|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-06-03|2004-03-08|2004-03-09|Estimate|||||||2013-06-03|2013-06-04|Estimate|January 2004||2004-01-31|June 2013|2013-06-30||||January 2007|Actual|2007-01-31||Interventional|||Oblimersen in Treating Patients With Merkel Cell Carcinoma|A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:31.952646|2018-06-01 05:12:31.952646
NCT00079118|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2016-12-09|2004-03-08|2004-03-09|Estimate|||||||2016-12-09|2016-12-13|Estimate|April 2004||2004-04-30|December 2016|2016-12-31|December 2010|Actual|2010-12-31|February 2007|Actual|2007-02-28||Interventional|||Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer|Phase II Trial of Weekly Irinotecan and Docetaxel in Refractory Metastatic Breast Cancer|Completed||Phase 2|70|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:12:32.102047|2018-06-01 05:12:32.102047
NCT00079105|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2017-03-29|2004-03-08|2004-03-09|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2004||2004-01-31|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years|A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years; Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma|Completed||Phase 2|175|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||No|No IPD were shared, nor will be, for this trial.|2018-06-01 05:12:32.644184|2018-06-01 05:12:32.644184
NCT00079092|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2017-04-17|2004-03-08|2004-03-09|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2004|Actual|2004-01-31|August 2009|2009-08-31|March 21, 2006|Actual|2006-03-21|March 21, 2006|Actual|2006-03-21||Interventional|||Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma|A Phase II Trial Of Thalidomide And Procarbazine In Adults With Recurrent/Progressive Gliomas|Completed||Phase 2|18|Anticipated|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:12:32.850966|2018-06-01 05:12:32.850966
NCT00079079|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2016-11-25|2004-03-08|2004-03-09|Estimate|||||||2016-11-25|2016-11-28|Estimate|October 2003||2003-10-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|September 2008|Actual|2008-09-30||Interventional|||Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor|A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors|Completed||Phase 2|34|Anticipated|Canadian Cancer Trials Group|||||f||||t||||||||Undecided||2018-06-01 05:12:32.9494|2018-06-01 05:12:32.9494
NCT00079066|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-10-31|2004-03-08|2004-03-09|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2003||2003-08-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|March 2006|Actual|2006-03-31||Interventional|||Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer|A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Positive Colorectal Carcinoma|Completed||Phase 3|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:12:33.087332|2018-06-01 05:12:33.087332
NCT00079053|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2016-11-25|2004-03-08|2004-03-09|Estimate|||||||2016-11-25|2016-11-28|Estimate|November 2003||2003-11-30|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Adjuvant Erlotinib After Completing Chemoradiotherapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase I Study of Adjuvant OSI-774 (Tarceva®) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|20|Anticipated|Canadian Cancer Trials Group|||||f||||t||||||||Undecided||2018-06-01 05:12:33.272895|2018-06-01 05:12:33.272895
NCT00079040|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2009-11-19||2014-04-28|2004-03-08|2004-03-09|Estimate|2010-01-11|2010-02-02|Estimate||||2014-04-28|2014-05-14|Estimate|January 2006||2006-01-31|December 2012|2012-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer|A Phase II Study of Cisplatin Plus Etoposide (PE) Plus Bevacizumab (NSC #704865) for Previously Untreated Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|65|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:33.417169|2018-06-01 05:12:33.417169
NCT00079027|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-12-17|2004-03-08|2004-03-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|April 2004||2004-04-30|May 2007|2007-05-31||||||||Interventional|||Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)|A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 3|280|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:33.79478|2018-06-01 05:12:33.79478
NCT00079014|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-05-15|2004-03-08|2004-03-09|Estimate|||||||2013-05-15|2013-05-16|Estimate|January 2004||2004-01-31|May 2013|2013-05-31||||July 2008|Actual|2008-07-31||Interventional|||3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors|A Phase I Study of Triapine® in Combination With Doxorubicin in Refractory Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:33.897023|2018-06-01 05:12:33.897023
NCT00079001|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2014-10-27||2016-10-27|2004-03-08|2004-03-09|Estimate|2014-10-27|2014-10-30|Estimate||||2016-10-27|2016-12-20|Estimate|January 2004||2004-01-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|July 2012|Actual|2012-07-31||Interventional|||Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases|A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone|Completed||Phase 3|645|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:12:34.155425|2018-06-01 05:12:34.155425
NCT00078988|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2015-05-06|2004-03-08|2004-03-09|Estimate|||||||2015-05-06|2015-05-07|Estimate|October 2004||2004-10-31|May 2015|2015-05-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas|A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support|Completed||Phase 3|1|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:12:35.784306|2018-06-01 05:12:35.784306
NCT00078975|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2017-11-06|2004-03-08|2004-03-09|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2004||2004-04-30|November 2017|2017-11-30|January 7, 2009|Actual|2009-01-07|January 2009|Actual|2009-01-31||Interventional|||3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Recurrent/Unresectable/Metastatic Pancreatic Carcinoma|Completed||Phase 2|26|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 05:12:36.156462|2018-06-01 05:12:36.156462
NCT00078962|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-01-23|2004-03-08|2004-03-09|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2004||2004-01-31|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Pharmacokinetics and Pharmacodynamic Study of GTI2040 in Combination With Gemcitabine in Patients With Solid Tumors|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:36.281709|2018-06-01 05:12:36.281709
NCT00078949|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|2014-09-17||2018-02-13|2004-03-08|2004-03-09|Estimate|2014-10-15|2014-10-21|Estimate||||2018-02-13|2018-03-12|Actual|August 2003||2003-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2013|Actual|2013-05-31||Interventional||ITT population|Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation|Active, not recruiting||Phase 3|619|Actual|Canadian Cancer Trials Group||4|||f||||t||||||||||2018-06-01 05:12:36.541754|2018-06-01 05:12:36.541754
NCT00078923|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2014-03-04|2004-03-08|2004-03-09|Estimate|||||||2014-03-04|2014-03-05|Estimate|November 2001||2001-11-30|March 2014|2014-03-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate|Phase II Clinical Trial of Soy Isoflavones Prior to Radical Prostatectomy|Completed||Phase 2|32|Actual|Barbara Ann Karmanos Cancer Institute||4|||f||||t||||||||||2018-06-01 05:12:37.417467|2018-06-01 05:12:37.417467
NCT00078910|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2013-06-21|2004-03-08|2004-03-09|Estimate|||||||2013-06-21|2013-06-24|Estimate|August 2003||2003-08-31|September 2006|2006-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer|A Prospective Phase II Study of Preoperative, Controlled Exisulind Therapy Initiated Prior to Radical Prostatectomy: Effect on Apoptosis|Completed||Phase 2|130|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:37.513241|2018-06-01 05:12:37.513241
NCT00078897|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2016-05-18|2004-03-08|2004-03-09|Estimate|||||||2016-05-18|2016-05-19|Estimate|January 2001||2001-01-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|October 2015|Actual|2015-10-31||Interventional|||Selenium for Prevention of Adenomatous Colorectal Polyps|Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence|Unknown status|Active, not recruiting|Phase 3|1800|Anticipated|University of Arizona||2|||f||||t||||||||||2018-06-01 05:12:37.59163|2018-06-01 05:12:37.59163
NCT00078858|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2018-02-26|2004-03-08|2004-03-09|Estimate|||||||2018-02-26|2018-02-27|Actual|September 2003||2003-09-30|February 2018|2018-02-28||||January 2006|Actual|2006-01-31||Interventional|||Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant|Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial|Active, not recruiting||Phase 1/Phase 2|37|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:12:37.701837|2018-06-01 05:12:37.701837
NCT00078845|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2012-10-16|2004-03-08|2004-03-09|Estimate|||||||2012-10-16|2012-10-17|Estimate|May 2004||2004-05-31|October 2012|2012-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors|Phase II Trial Of Subcutaneous Amifostine For Reversal Of Persistent Paclitaxel-Induced Peripheral Neuropathy|Completed||Phase 2|24|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:12:37.860996|2018-06-01 05:12:37.860996
NCT00078832|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-08|||2018-04-17|2004-03-08|2004-03-09|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2003||2003-09-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|December 2013|Actual|2013-12-31||Interventional|IBIS II||Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer|International Breast Cancer Intervention Study|Active, not recruiting||Phase 3|3864|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-06-01 05:12:37.991277|2018-06-01 05:12:37.991277
NCT00078819|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-05|||2013-07-26|2004-03-08|2004-03-09|Estimate|||||||2013-07-26|2013-07-30|Estimate|August 2004||2004-08-31|July 2013|2013-07-31|June 2007|Actual|2007-06-30|February 2006|Actual|2006-02-28||Interventional|||Etanercept (Enbrel®) in Psoriasis - Pediatrics|Placebo-controlled Multicenter Study With Etanercept to Determine Safety and Efficacy in Pediatric Subjects With Plaque Psoriasis (PEDS)|Completed||Phase 3|211|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:12:38.204345|2018-06-01 05:12:38.204345
NCT00078806|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-05|||2009-04-30|2004-03-08|2004-03-09|Estimate|||||||2009-04-30|2009-05-01|Estimate|June 2001||2001-06-30|April 2009|2009-04-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis|Phase 3 Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis|Terminated||Phase 3|75|Anticipated|Amgen||2||the study was terminated because of slow enrollment|f||||||||||||||2018-06-01 05:12:38.275983|2018-06-01 05:12:38.275983
NCT00078793|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-05|||2013-05-10|2004-03-08|2004-03-09|Estimate|||||||2013-05-10|2013-05-14|Estimate|June 2000||2000-06-30|May 2013|2013-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis|Phase IV Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis|Completed|||600|Actual|Amgen|||1||f||||||||||||||2018-06-01 05:12:38.493379|2018-06-01 05:12:38.493379
NCT00078767|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-05|2017-02-08||2017-04-03|2004-03-05|2004-03-08|Estimate|2017-02-08|2017-03-28|Actual||||2017-04-03|2017-04-05|Actual|April 2001||2001-04-30|April 2017|2017-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Pharmacologic Treatment of PTSD in Sexually Abused Children|Pharmacologic Treatment of PTSD in Sexually Abused Children|Completed||Phase 3|24|Actual|Allegheny Singer Research Institute||2|||f||||t||||||||||2018-06-01 05:12:38.639419|2018-06-01 05:12:38.639419
NCT00078754|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-05|2014-02-19||2018-05-14|2004-03-05|2004-03-08|Estimate|2014-12-29|2014-12-31|Estimate||||2018-05-14|2018-05-16|Actual|May 2003||2003-05-31|May 2018|2018-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder|Fluoxetine and Divalproex: Treatment Correlates in IED|Completed||Phase 2|90|Actual|University of Chicago||3|||f||||t||||||||||2018-06-01 05:12:38.9713|2018-06-01 05:12:38.9713
NCT00078741|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-05|||2015-08-07|2004-03-05|2004-03-08|Estimate|||||||2015-08-07|2015-08-10|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|September 2007|Actual|2007-09-30|March 2006|Actual|2006-03-31||Interventional|||Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals With Severe Mental Illness|CBT for PTSD and SMI in Community Mental Health Centers|Completed||Phase 2|60||Medical University of South Carolina|||||f||||||||||||||2018-06-01 05:12:39.301828|2018-06-01 05:12:39.301828
NCT00078728|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-05|2013-10-24||2018-01-29|2004-03-05|2004-03-08|Estimate|2013-10-24|2013-12-16|Estimate||||2018-01-29|2018-02-07|Actual|September 2003||2003-09-30|January 2018|2018-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Family-Based Prevention Program for Childhood Anxiety|Family-Based Prevention for Childhood Anxiety|Completed||N/A|40|Actual|Johns Hopkins University|Of the 40 participants in the study, no adverse events occured or were reported.|2|||f||||t||||||||||2018-06-01 05:12:39.400554|2018-06-01 05:12:39.400554
NCT00078611|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2016-06-14|2004-03-05|2004-03-08|Estimate|||||||2016-06-14|2016-06-16|Estimate|March 2004||2004-03-31|March 2012|2012-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease|A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn's Disease With Elevated C-Reactive Protein|Completed||Phase 3|462||Biogen|||||||||||||||||||2018-06-01 05:12:39.863054|2018-06-01 05:12:39.863054
NCT00007007|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2015-03-26|2004-03-05|2004-03-08|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2000||2000-11-30|March 2015|2015-03-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases|A Feasibility Study of Neurocognitive Evaluation in Patients Treated for Brain Metastases|Completed||N/A|59|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:12:40.099383|2018-06-01 05:12:40.099383
NCT00006890|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2011-09-27|2004-03-05|2004-03-08|Estimate|||||||2011-09-27|2011-09-28|Estimate|July 2000||2000-07-31|September 2011|2011-09-30|December 2008|Actual|2008-12-31|May 2002|Actual|2002-05-31||Interventional|||Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Randomized Phase II Dose Finding Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant In Patients With Multiple Myeloma|Completed||Phase 2|67|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-06-01 05:12:40.67464|2018-06-01 05:12:40.67464
NCT00006467|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2016-07-01|2004-03-05|2004-03-08|Estimate|||||||2016-07-01|2016-07-06|Estimate|February 2001||2001-02-28|July 2016|2016-07-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas|Phase II Trial of Gemcitabine and ISIS 2503 in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:12:40.880644|2018-06-01 05:12:40.880644
NCT00006452|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2011-06-27|2004-03-05|2004-03-08|Estimate|||||||2011-06-27|2011-06-28|Estimate|April 1999||1999-04-30|June 2011|2011-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme|A Phase I Trial to Evaluate Repetitive Intravenous Doses of Gadolinium-Texaphyrin as a Radiosensitizer in Patients With Glioblastoma Multiforme|Completed||Phase 1|18|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:12:40.985388|2018-06-01 05:12:40.985388
NCT00006350|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2017-03-28|2004-03-05|2004-03-08|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2000|Actual|2000-01-31|March 2017|2017-03-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies After a Non-Myeloablative Conditioning Regimen From HLA-Matched Sibling Donors|Completed||Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:12:41.053744|2018-06-01 05:12:41.053744
NCT00006259|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2010-06-09|2004-03-05|2004-03-08|Estimate|||||||2010-06-09|2010-06-11|Estimate|January 2000||2000-01-31|June 2010|2010-06-30|February 2005|Actual|2005-02-28|November 2001|Actual|2001-11-30||Interventional|||Stereotactic Radiation Therapy in Treating Patients With Brain Metastases|A Phase II Trial of Radiosurgery Alone for Brain Metastases in Elderly Patients or Patients With Poor Performance Status|Completed||Phase 2|10|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:12:41.141593|2018-06-01 05:12:41.141593
NCT00006253|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2011-12-06|2004-03-05|2004-03-08|Estimate|||||||2011-12-06|2011-12-07|Estimate|March 2003||2003-03-31|December 2011|2011-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Pain and Fatigue Study|Family Home Care for Cancer - A Community-Based Model|Completed||N/A|350|Actual|Michigan State University||2|||f||||f||||||||||2018-06-01 05:12:41.252775|2018-06-01 05:12:41.252775
NCT00006126|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2015-11-10|2004-03-05|2004-03-08|Estimate|||||||2015-11-10|2015-11-13|Estimate|September 1999||1999-09-30|November 2015|2015-11-30|April 2001||2001-04-30|April 2001||2001-04-30||Interventional|||Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery|Allogeneic Peripheral Blood Progenitor Cell Transplantation in Patients With Incurable Solid Tumors: A Phase I Study|Withdrawn||Phase 1|0|Actual|Northwestern University||||Unable to accrue subjects.|f||||||||||||||2018-06-01 05:12:41.388675|2018-06-01 05:12:41.388675
NCT00006115|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2009-01-10|2004-03-05|2004-03-08|Estimate|||||||2009-01-10|2009-01-13|Estimate|April 1999||1999-04-30|January 2002|2002-01-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|Alternation of FOLFOX6 (Oxaliplatin - Leucovorin - Fluorouracil) and FOLFIRI (Irinotecan - Leucovorin - Fluorouracil) as Second Line Treatment of Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:41.510168|2018-06-01 05:12:41.510168
NCT00006018|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-06-10|2004-03-05|2004-03-08|Estimate|||||||2010-06-10|2010-06-11|Estimate|July 2000||2000-07-31|June 2010|2010-06-30|April 2002|Actual|2002-04-30|December 2001|Actual|2001-12-31||Interventional|||Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors|Phase I Study of BMS-214662 and Paclitaxel in Patients With Advanced Malignancies|Completed||Phase 1|5|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:12:41.602471|2018-06-01 05:12:41.602471
NCT00078715|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-04|2012-06-07||2012-08-16|2004-03-04|2004-03-05|Estimate|2012-07-11|2012-08-16|Estimate||||2012-08-16|2012-08-20|Estimate|March 2004||2004-03-31|August 2012|2012-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Rapid Antidepressant Effects of Yohimbine in Major Depression|An Investigation of a Pharmacologic Strategy to Bring About Rapid (Next Day) Antidepressant Effects|Completed||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:12:41.680916|2018-06-01 05:12:41.680916
NCT00078689|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-04|||2017-06-30|2004-03-04|2004-03-05|Estimate|||||||2017-06-30|2017-07-02|Actual|March 3, 2004||2004-03-03|July 18, 2008|2008-07-18|July 18, 2008||2008-07-18|||||Interventional|||Daclizumab and Sirolimus to Treat Uveitis|Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis|Completed||Phase 1|6||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:41.937128|2018-06-01 05:12:41.937128
NCT00078637|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-03|||2014-12-19|2004-03-04|2004-03-05|Estimate|||||||2014-12-19|2014-12-23|Estimate|January 2004||2004-01-31|December 2014|2014-12-31|February 2007|Actual|2007-02-28|August 2006|Actual|2006-08-31||Interventional|||Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma|Phase I and Pharmacokinetic Study of E7820 After Oral Administration to Patients With Malignancy|Completed||Phase 1|37|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 05:12:42.061686|2018-06-01 05:12:42.061686
NCT00006000|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-30|2004-03-04|2004-03-05|Estimate|||||||2013-01-30|2013-01-31|Estimate|August 2000||2000-08-31|January 2002|2002-01-31|March 2004|Actual|2004-03-31|||||Interventional|||SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of SU5416 in Combination With CPT-11 and Cisplatin in Patients With Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:42.141813|2018-06-01 05:12:42.141813
NCT00003370|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-02-06|2004-02-09|Estimate|||||||2013-02-04|2013-02-05|Estimate|August 1998||1998-08-31|May 2006|2006-05-31||||March 2006|Actual|2006-03-31||Interventional|||Irofulven in Treating Children With Recurrent or Refractory Solid Tumors|A Trial of MGI 114 in Children With Solid Tumors: A Pediatric Oncology Group Phase I Cooperative Agreement Study|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:40.824672|2018-06-01 05:13:40.824672
NCT00005965|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-07-09|2004-03-04|2004-03-05|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 2000||2000-08-31|July 2004|2004-07-31|April 2004|Actual|2004-04-30|||||Interventional|||Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix|Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:42.255634|2018-06-01 05:12:42.255634
NCT00005947|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|2010-05-28||2010-10-08|2004-03-04|2004-03-05|Estimate|2010-10-08|2010-11-01|Estimate||||2010-10-08|2010-11-01|Estimate|November 1999||1999-11-30|October 2010|2010-10-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge) for Asymptomatic Metastatic Hormome-Refractory Prostate Cancer|Completed||Phase 3|127|Actual|Dendreon||2|||f||||||||||||||2018-06-01 05:12:42.515161|2018-06-01 05:12:42.515161
NCT00005946|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-03-28|2004-03-04|2004-03-05|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2000|Actual|2000-10-31|March 2017|2017-03-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation|A Pilot Study of Combined Chemotherapy and Donor Lymphocyte Infusion for Hematologic Malignancies in Relapse After Allogeneic Bone Marrow Transplantation|Completed||Phase 1|||University of Maryland|||||f||||||||||||||2018-06-01 05:12:42.924271|2018-06-01 05:12:42.924271
NCT00005843|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-02-08|2004-03-04|2004-03-05|Estimate|||||||2013-02-08|2013-02-11|Estimate|May 2000||2000-05-31|April 2007|2007-04-30||||September 2004|Actual|2004-09-30||Interventional|||R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer|Phase II Trial of R115777 (NSC-702818), an Inhibitor of Farnesyl Protein Transferase, in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:42.985982|2018-06-01 05:12:42.985982
NCT00078663|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-03|||2017-06-30|2004-03-03|2004-03-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2, 2004||2004-03-02|August 16, 2011|2011-08-16|August 16, 2011|Actual|2011-08-16|December 28, 2007|Actual|2007-12-28||Interventional|||Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients|The Effect of a Systemic Oral Care Program on Reducing Exposure to Oropharyngeal Pathogens in Critically III Patients|Completed||Phase 3|800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:43.120829|2018-06-01 05:12:43.120829
NCT00078624|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-03|||2013-01-23|2004-03-03|2004-03-04|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2004||2004-04-30|January 2013|2013-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Knee Stability Training for Knee Osteoarthritis (OA)|Knee Stability Training in Individuals With Knee Osteoarthritis|Completed||Phase 2|231|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-06-01 05:12:43.179367|2018-06-01 05:12:43.179367
NCT00005595|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02||2011-02-18|2012-06-07|2004-03-03|2004-03-04|Estimate||||2011-02-18|2011-02-25|Estimate|2012-06-07|2012-06-11|Estimate|June 2000||2000-06-30|June 2012|2012-06-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease|Multicenter Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Hodgkin's Disease|Terminated||Phase 2|2|Actual|Northwestern University||||Unable to accrue subjects in a timely fashion.|f||||t||||||||||2018-06-01 05:12:43.256505|2018-06-01 05:12:43.256505
NCT00005096|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2017-07-12|2004-03-03|2004-03-04|Estimate|||||||2017-07-12|2017-07-14|Actual|December 1999|Actual|1999-12-31|July 2017|2017-07-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer|Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer|Completed||Phase 2|19|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 05:12:43.316871|2018-06-01 05:12:43.316871
NCT00005035|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-01-30|2004-03-03|2004-03-04|Estimate|||||||2013-01-30|2013-01-31|Estimate|December 1999||1999-12-31|February 2002|2002-02-28|March 2004|Actual|2004-03-31|||||Interventional|||Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer|A Phase II Study of Oxaliplatin in Patients With Advanced Carcinoma of the Head and Neck|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:43.411637|2018-06-01 05:12:43.411637
NCT00004914|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-04-08|2012-05-31|2004-03-03|2004-03-04|Estimate||||2011-04-08|2011-04-14|Estimate|2012-05-31|2012-06-06|Estimate|January 2000||2000-01-31|May 2012|2012-05-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue|A Phase II Trial of Progressive Resistance Training (PRT) Plus Procrit for the Treatment of Anemia-Related Fatigue in Cancer Patients|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:12:43.479309|2018-06-01 05:12:43.479309
NCT00078598|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2005-11-08|2004-03-02|2004-03-03|Estimate|||||||2005-11-08|2005-11-09|Estimate|April 2004||2004-04-30|October 2004|2004-10-31||||||||Interventional|||A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma|A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 3|506||Corixa Corporation|||||||||||||||||||2018-06-01 05:12:43.543484|2018-06-01 05:12:43.543484
NCT00078585|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2017-09-07|2004-03-02|2004-03-03|Estimate|||||||2017-09-07|2017-09-11|Actual|November 2003||2003-11-30|September 2017|2017-09-30|January 2009|Actual|2009-01-31|January 4, 2006|Actual|2006-01-04||Interventional|||PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy|A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate|Completed||Phase 2|120||Bavarian Nordic|||||f||||||||||||||2018-06-01 05:12:43.640998|2018-06-01 05:12:43.640998
NCT00078572|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2010-12-09|2004-03-02|2004-03-03|Estimate|||||||2010-12-09|2010-12-13|Estimate|March 2004||2004-03-31|December 2010|2010-12-31|February 2010|Actual|2010-02-28|April 2006|Actual|2006-04-30||Interventional|||Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer|A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer|Completed||Phase 3|408|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-06-01 05:12:43.762039|2018-06-01 05:12:43.762039
NCT00078507|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2010-02-02|2004-03-02|2004-03-03|Estimate|||||||2010-02-02|2010-02-03|Estimate|December 2001||2001-12-31|February 2010|2010-02-28|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Sensory Re-Training Following Facial Surgery for Correction of Facial Skeletal Disharmony|Sensory Re-Training Following Orthognathic Surgery|Completed||Phase 3|186|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 05:12:43.859826|2018-06-01 05:12:43.859826
NCT00004912|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-18|2012-05-17|2004-03-02|2004-03-03|Estimate||||2011-02-18|2011-02-25|Estimate|2012-05-17|2012-05-30|Estimate|January 2000||2000-01-31|May 2012|2012-05-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss|Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:12:43.930704|2018-06-01 05:12:43.930704
NCT00004908|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-08-23|2011-08-25|2004-03-02|2004-03-03|Estimate||||2011-08-25|2011-08-26|Estimate|2011-08-25|2011-08-26|Estimate|November 1999||1999-11-30|August 2011|2011-08-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma|Autologous Blood Stem Cell Transplantation in Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma With High-Dose Cyclophosphamide, Total Body Irradiation and Involved-Field Radiation Therapy|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:12:43.996206|2018-06-01 05:12:43.996206
NCT00004904|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-05-31|2004-03-02|2004-03-03|Estimate|||||||2012-05-31|2012-06-04|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Stem Cell Transplantation in Treating Patients With Hematologic Cancer|"Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 Veto Cells"|Completed||Phase 1|||Northwestern University|||||f||||t||||||||||2018-06-01 05:12:44.060089|2018-06-01 05:12:44.060089
NCT00004898|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-16|2012-06-08|2004-03-02|2004-03-03|Estimate||||2011-02-18|2011-02-25|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia|Dose Escalation of VP-16 With Cyclophosphamide and Total Body Irradiation as Preparative Regimen for Autologous Transplantation for High-Grade Lymphoma and Acute Lymphoblastic Leukemia|Completed||Phase 1/Phase 2|6|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 05:12:44.142131|2018-06-01 05:12:44.142131
NCT00004235|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2016-07-12|2004-03-02|2004-03-03|Estimate|||||||2016-07-12|2016-07-14|Estimate|January 2000||2000-01-31|July 2016|2016-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach|A Phase II Study of Taxotere and Irinotecan (CPT-11) in Patients With Advanced Adenocarcinoma of the Lower Esophagus, Esophagogastric Junction, and Gastric Cardia|Completed||Phase 2|47|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:12:44.212461|2018-06-01 05:12:44.212461
NCT00004175|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-07-01|2012-05-31|2004-03-02|2004-03-03|Estimate||||2011-07-01|2011-07-14|Estimate|2012-05-31|2012-06-06|Estimate|November 1998||1998-11-30|May 2012|2012-05-31|June 2005|Actual|2005-06-30|September 2004|Actual|2004-09-30||Interventional|||Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer|Phase II Study of Taxotere, Doxorubicin and Cyclophosphamide (TAC) Primary Therapy in Stage III Breast Cancer|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:12:44.33023|2018-06-01 05:12:44.33023
NCT00078559|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|2012-04-13||2012-07-25|2004-03-01|2004-03-02|Estimate|2012-06-01|2012-07-09|Estimate||||2012-07-25|2012-08-01|Estimate|November 2003||2003-11-30|July 2012|2012-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults|Campath-1H/Tacrolimus/Sirolimus Withdrawal in Renal Transplantation (ITN013ST)|Completed||Phase 1/Phase 2|10|Actual|University of Wisconsin, Madison|The absence of a control group in this pilot trial precludes any comparison between alemtuzumab-induced patients with further minimization and patients with more conventional immunosuppressive approaches, and is a limitation of the current study|1|||f||||t||||||||||2018-06-01 05:12:44.413246|2018-06-01 05:12:44.413246
NCT00078546|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2012-07-27|2004-03-01|2004-03-02|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 2003||2003-09-30|July 2012|2012-07-31|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|CLANC||EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)|Administration of EBV-Specific Cytotoxic T Lymphocytes Following CD45 Antibody to Patients With EBV Positive Nasopharyngeal Carcinoma|Completed||Phase 1|12|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 05:12:45.945968|2018-06-01 05:12:45.945968
NCT00078533|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2014-10-06|2004-03-01|2004-03-02|Estimate|||||||2014-10-06|2014-10-08|Estimate|April 2004||2004-04-30|June 2014|2014-06-30|June 2011|Actual|2011-06-30|July 2010|Actual|2010-07-31||Interventional|VICTA||Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant|Virus Specific Cytotoxic T-Lymphocytes for the Treatment of CMV After Allogeneic Stem Cell Transplant: A Dose-Finding Trial|Completed||Phase 1|26|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 05:12:46.109905|2018-06-01 05:12:46.109905
NCT00078520|ClinicalTrials.gov processed this data on May 31, 2018|2004-03-01|||2010-04-21|2004-03-01|2004-03-02|Estimate|||||||2010-04-21|2010-04-22|Estimate|January 2003||2003-01-31|March 2010|2010-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|CLIPA||Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells|Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA)|Completed||Phase 1|21|Anticipated|Baylor College of Medicine|||||t||||t||||||||||2018-06-01 05:12:46.453117|2018-06-01 05:12:46.453117
NCT00078468|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-27|||2006-11-08|2004-03-01|2004-03-02|Estimate|||||||2006-11-08|2006-11-09|Estimate|December 2003||2003-12-31|August 2006|2006-08-31|September 2004||2004-09-30|||||Interventional|||Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment|A Phase 2 Open-Label Multicenter Study Of The Garft Inhibitor AG2037 In Patients With Metastatic Colorectal Cancer Who Failed Treatment With A 5-Fluorouracil/Leucovorin Regimen.|Completed||Phase 2|56||Pfizer|||||f||||||||||||||2018-06-01 05:12:46.665015|2018-06-01 05:12:46.665015
NCT00078494|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-27|||2008-03-03|2004-02-27|2004-03-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2004||2004-02-29|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer|Phase I/II Trial of Latent Membrane Protein (LMP) - 2 Immunization for the Assessment of the Natural History and the Immunization-Induced Immunological Response in Patients at High Risk for Recurrence of Anaplastic Nasopharyngeal Cancer|Completed||Phase 1|99||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:47.216671|2018-06-01 05:12:47.216671
NCT00078481|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-27|||2008-03-03|2004-02-27|2004-03-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2004||2004-02-29|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia|Phase 1B Clinical Trial to Establish the Safety and Tolerability of a Multiple-Dose Regimen of Idebenone Administered to Patients With Friedreich's Ataxia|Completed||Phase 1|16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:47.472665|2018-06-01 05:12:47.472665
NCT00078455|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-25|||2015-03-04|2004-02-27|2004-03-01|Estimate|||||||2015-03-04|2015-03-05|Estimate|December 2003||2003-12-31|March 2015|2015-03-31|August 2005|Actual|2005-08-31|||||Interventional|||Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma|A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma|Completed||Phase 2|||Sanofi|||||||||||||||||||2018-06-01 05:12:47.565084|2018-06-01 05:12:47.565084
NCT00078429|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-25|||2008-07-23|2004-02-27|2004-03-01|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2003||2003-07-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Molecular Epidemiology of Myocardial Infarction and Stroke in Older Adults - Ancillary to CHS||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:12:47.684434|2018-06-01 05:12:47.684434
NCT00078221|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-20|||2008-05-08|2004-02-27|2004-03-01|Estimate|||||||2008-05-08|2008-05-09|Estimate|August 1999||1999-08-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)||Unknown status|Active, not recruiting|Phase 3|180||OccuLogix|||||||||||||||||||2018-06-01 05:12:47.744776|2018-06-01 05:12:47.744776
NCT00004171|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-02-16|2012-06-08|2004-02-27|2004-03-01|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma|Autologous Blood Stem Cell Transplantation in Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma Who Have Had Prior Radiation Therapy|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:12:47.961562|2018-06-01 05:12:47.961562
NCT00004091|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-01-27|2004-02-27|2004-03-01|Estimate|||||||2011-01-27|2011-01-31|Estimate|August 1999||1999-08-31|January 2011|2011-01-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Observational|||Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results|Development of Antibody-Based Diagnostic Markers for Abnormal Cervical Cells|Completed|||100|Anticipated|Northwestern University|||||f||||||||||||||2018-06-01 05:12:48.062523|2018-06-01 05:12:48.062523
NCT00003528|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-15|2004-02-27|2004-03-01|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 1998||1998-09-30|January 2013|2013-01-31||||June 2002|Actual|2002-06-30||Interventional|||Raltitrexed in Treating Children With Refractory Acute Leukemia|A Phase I Trial of Tomudex in Children With Leukemia|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:48.184198|2018-06-01 05:12:48.184198
NCT00003351|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-02-27|2004-03-01|Estimate|||||||2016-07-12|2016-07-14|Estimate|August 1998||1998-08-31|July 2016|2016-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer|Randomized Phase II Trial of Irinotecan (CPT-11) In Patients With Refractory Metastatic Breast Cancer|Completed||Phase 2|104|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:12:48.323836|2018-06-01 05:12:48.323836
NCT00003302|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-05-09|2004-02-27|2004-03-01|Estimate|||||||2009-05-09|2009-05-12|Estimate|May 1998||1998-05-31|February 2006|2006-02-28||||||||Interventional|||MRI to Detect Breast Tumors in Women|Breast MRI Protocol|Unknown status|Active, not recruiting|N/A|1500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:48.432414|2018-06-01 05:12:48.432414
NCT00003264|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-16|2004-02-27|2004-03-01|Estimate|||||||2013-04-16|2013-04-17|Estimate|October 1997||1997-10-31|April 2013|2013-04-30|June 2002|Actual|2002-06-30|February 2002|Actual|2002-02-28||Interventional|||Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer|Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck|Completed||Phase 2|22|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:12:48.531541|2018-06-01 05:12:48.531541
NCT00003070|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-04|2004-02-27|2004-03-01|Estimate|||||||2014-08-04|2014-08-05|Estimate|September 2000||2000-09-30|August 2014|2014-08-31|March 2007|Actual|2007-03-31|July 2003|Actual|2003-07-31||Interventional|||Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer|Afterload Reduction Therapy for Late Anthracycline Cardiotoxicity: A Pediatric Oncology Group Cancer Control Study|Completed||Phase 3|13|Actual|Children's Oncology Group||8|||f||||t||||||||||2018-06-01 05:12:48.854818|2018-06-01 05:12:48.854818
NCT00003040|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-13|2004-02-27|2004-03-01|Estimate|||||||2012-06-13|2012-06-15|Estimate|September 1997||1997-09-30|June 2012|2012-06-30|December 2007|Actual|2007-12-31|February 2007|Actual|2007-02-28||Interventional|||S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx|A Phase II Study to Evaluate Transoral CO2 Laser Supraglottic Laryngectomy and Irradiation in Stage I, II and III Squamous Cell Carcinoma of the Supraglottic Larynx|Terminated||Phase 2|42|Actual|Southwest Oncology Group||1||Poor accrual|f||||f||||||||||2018-06-01 05:12:49.041349|2018-06-01 05:12:49.041349
NCT00002825|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-02-27|2004-03-01|Estimate|||||||2013-02-04|2013-02-05|Estimate|January 1997||1997-01-31|May 2006|2006-05-31||||December 2004|Actual|2004-12-31||Interventional|||Docetaxel in Treating Children With Recurrent Solid Tumors|A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS|Completed||Phase 2|20|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:49.123709|2018-06-01 05:12:49.123709
NCT00002652|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-01|2004-02-27|2004-03-01|Estimate|||||||2013-02-01|2013-02-04|Estimate|May 1995||1995-05-31|April 2002|2002-04-30|February 2004|Actual|2004-02-29|||||Interventional|||Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease|A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:49.36309|2018-06-01 05:12:49.36309
NCT00026429|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-12-17|2004-02-26|2004-02-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 2001||2001-01-31|February 2002|2002-02-28||||||||Interventional|||Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma|A Multicenter Phase II Evaluation Of ONTAK (DENILEUKINDIFTITOX) In Patients With Low Or Intermediate Grade-B-Cell Non-Hodgkin's Lymphoma Who Have Been Treated Previously With A Monoclonal Antibody Or Who Are Not Candidates For Monoclonal Antibody Therapy|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:49.420638|2018-06-01 05:12:49.420638
NCT00025012|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-06-17|2004-02-26|2004-02-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 1991||1991-06-30|November 2007|2007-11-30|February 2004|Actual|2004-02-29|||||Interventional|||Isotretinoin in Preventing Skin Cancer|Use Of Isotretinion For Prevention Of Skin Cancer In Patients With Xeroderma Pigmentosum Or Nevoid Basal Cell Carcinoma Syndrome|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:49.527232|2018-06-01 05:12:49.527232
NCT00075140|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-02|||2009-01-15|2004-01-02|2004-01-05|Estimate|||||||2009-01-15|2009-01-16|Estimate|September 2001||2001-09-30|January 2009|2009-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Family Health After Predictive Huntington Disease (HD) Testing|Family Health After Predictive Huntington Disease Testing|Completed|||422|Actual|National Institute of Nursing Research (NINR)|||1||f||||f||||||||||2018-06-01 05:14:40.865729|2018-06-01 05:14:40.865729
NCT00024037|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2010-06-15|2004-02-26|2004-02-27|Estimate|||||||2010-06-15|2010-06-17|Estimate|April 1995||1995-04-30|June 2010|2010-06-30|December 2002|Actual|2002-12-31|||||Interventional|||Laser Therapy in Preventing Oral Mucositis in Patients Undergoing Bone Marrow Transplantation|A Phase II/III Blinded Randomized Trial to Determine the Efficacy of Low Energy Diode Laser Therapy (650 nm or 780 nm) to Prevent Oral Mucositis Following Bone Marrow Transplantation|Completed||Phase 2/Phase 3|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:12:49.593225|2018-06-01 05:12:49.593225
NCT00022542|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2015-04-14|2004-02-26|2004-02-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2001||2001-06-30|December 2012|2012-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma|A Phase II Study of Epothilone B Analog (BMS-247550) in Advanced Soft Tissue Sarcomas|Terminated||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:49.698137|2018-06-01 05:12:49.698137
NCT00022308|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-08-30|2004-02-26|2004-02-27|Estimate|||||||2013-08-30|2013-09-02|Estimate|January 1999||1999-01-31|August 2013|2013-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Phase I Trial of Radical Thoracic Radiation, Weekly CPT-11 (Irinotecan) and Cisplatin in Locally Advanced Non-Small Cell Lung Carcinoma|Completed||Phase 1|||Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:12:49.957853|2018-06-01 05:12:49.957853
NCT00022217|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-12-17|2004-02-26|2004-02-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2000||2000-11-30|February 2002|2002-02-28||||||||Interventional|||Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer|A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:50.02334|2018-06-01 05:12:50.02334
NCT00022178|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-09-19|2004-02-26|2004-02-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 1998||1998-12-31|February 2002|2002-02-28||||||||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin|An Open Label Prospective Randomised Study Comparing The Use Of Vincristine, Adriamycin And Cyclophosphamide (VAC) Versus Epirubicin, Cisplatin And Continuous 5-Flourouracil (ECF) In Patients With Unknown Primary Carcinoma (UPC)|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:50.096401|2018-06-01 05:12:50.096401
NCT00021996|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-07-17|2004-02-26|2004-02-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2001||2001-01-31|February 2002|2002-02-28|February 2004|Actual|2004-02-29|||||Interventional|||Valdecoxib in Treating Chronic Pain in Cancer Patients|Clinical Protocol for a Randomized Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib (SC-65872) 40mg BID as Add-On Therapy to Opioid Medication in Patients With Chronic Cancer Pain|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:50.152205|2018-06-01 05:12:50.152205
NCT00021372|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-07-09|2004-02-26|2004-02-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|February 1996||1996-02-29|July 2013|2013-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase II Study of Paclitaxel and Estramustine Phosphate in Patients With Relapsed Non-Hodgkin's Lymphoma|Completed||Phase 2|25|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:12:50.199249|2018-06-01 05:12:50.199249
NCT00020618|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-07-17|2004-02-26|2004-02-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2001||2001-03-31|February 2002|2002-02-28|February 2004|Actual|2004-02-29|||||Interventional|||Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain|An Open Label, Randomized, Multicenter, Crossover, Phase II Study to Compare Pain Relief Following Morphine Administration Via AERxPMS vs Orally in Cancer Patients Experiencing Opioid-Sensitive Breakthrough Pain|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:50.279985|2018-06-01 05:12:50.279985
NCT00020098|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-28|2004-02-26|2004-02-27|Estimate|||||||2012-03-28|2012-03-29|Estimate|June 2000||2000-06-30|March 2012|2012-03-31|September 2001|Actual|2001-09-30|||||Interventional|||Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast Cancer|Use of Complementary or Alternative Medicine Practices by Women at Increased Risk for Breast Cancer|Completed||N/A|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:50.339084|2018-06-01 05:12:50.339084
NCT00019409|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-21|2004-02-26|2004-02-27|Estimate|||||||2012-03-21|2012-03-23|Estimate|October 1999||1999-10-31|March 2012|2012-03-31|July 2001|Actual|2001-07-31|||||Interventional|||Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia|A Randomized Study of Two Methods of CNS Prophylaxis in Patients With Acute Lymphoblastic Leukemia|Withdrawn||Phase 3|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:50.418992|2018-06-01 05:12:50.418992
NCT00017303|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-11-05|2004-02-26|2004-02-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 2001||2001-01-31|February 2002|2002-02-28||||||||Interventional|||Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer|A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:51.384641|2018-06-01 05:12:51.384641
NCT00016367|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2012-07-27|2004-02-26|2004-02-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|May 2001||2001-05-31|July 2012|2012-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:12:51.464209|2018-06-01 05:12:51.464209
NCT00015990|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-23|2004-02-26|2004-02-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2001||2001-04-30|January 2013|2013-01-31||||February 2007|Actual|2007-02-28||Interventional|||Thalidomide in Treating Patients With Myelodysplastic Syndrome|Phase II Study of Thalidomide in the Treatment of Myelodysplastic Syndromes in Adults: A Clinical and Biologic Study|Completed||Phase 2|29|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:51.562183|2018-06-01 05:12:51.562183
NCT00075114|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-02|||2015-01-14|2004-01-02|2004-01-05|Estimate|||||||2015-01-14|2015-01-15|Estimate|September 2000||2000-09-30|January 2015|2015-01-31|April 2006|Actual|2006-04-30|February 2002|Actual|2002-02-28||Interventional|||Prevent Inability To Control Urination|Promoting Self -Care to Prevent Urinary Incontinence|Completed||Phase 3|417|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 05:14:40.952253|2018-06-01 05:14:40.952253
NCT00015964|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-09-04|2004-02-26|2004-02-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|March 2001||2001-03-31|September 2013|2013-09-30|July 2005|Actual|2005-07-31|September 2001|Actual|2001-09-30||Interventional|||ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck|A Phase II Stdy of ZD 1839 in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|51|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:12:51.642466|2018-06-01 05:12:51.642466
NCT00002597|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-05-08||2017-05-08|2004-02-26|2004-02-27|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|October 1994||1994-10-31|May 2017|2017-05-31||||July 2011|Actual|2011-07-31||Interventional||All eligible patients.|Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer|A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE|Completed||Phase 3|2028|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:12:51.840553|2018-06-01 05:12:51.840553
NCT00002577|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-18|2004-02-26|2004-02-27|Estimate|||||||2013-11-18|2013-11-19|Estimate|July 1995||1995-07-31|November 2013|2013-11-30||||January 2003|Actual|2003-01-31||Interventional|||Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer|A PHASE I/II DOSE ESCALATION STUDY USING THREE DIMENSIONAL CONFORMAL RADIATION THERAPY POST INDUCTION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE, NON-SMALL CELL LUNG CANCER|Completed||Phase 1/Phase 2|36|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:12:53.41034|2018-06-01 05:12:53.41034
NCT00002454|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-07-23|2004-02-26|2004-02-27|Estimate|||||||2011-07-23|2011-07-26|Estimate|December 1971||1971-12-31|January 2002|2002-01-31||||||||Interventional|||Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx|Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:53.845148|2018-06-01 05:12:53.845148
NCT00078442|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-25|||2009-08-06|2004-02-25|2004-02-26|Estimate|||||||2009-08-06|2009-08-07|Estimate|May 2006||2006-05-31|August 2009|2009-08-31||||January 2007|Actual|2007-01-31||Interventional|||Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People|A Phase II Open-Label Pilot Trial of the Antiretroviral Activity, Safety, and Tolerability of Pegylated Interferon Alfa-2A (40KD) [PegasysTM] in HIV-1 Infected Subjects|Completed||Phase 2|12|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:12:53.989862|2018-06-01 05:12:53.989862
NCT00078390|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-24|||2018-04-30|2004-02-25|2004-02-26|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2003|Actual|2003-02-28|April 2018|2018-04-30|October 26, 2006|Actual|2006-10-26|September 28, 2006|Actual|2006-09-28||Interventional|||Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer|A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer.|Completed||Phase 1/Phase 2|9|Actual|Shionogi Inc.||2|||f||||||||||||||2018-06-01 05:12:54.107725|2018-06-01 05:12:54.107725
NCT00078377|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-24|2009-06-01||2013-07-12|2004-02-25|2004-02-26|Estimate|2009-12-17|2010-01-21|Estimate||||2013-07-12|2013-07-19|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy|Completed||Phase 3|196|Actual|Teva Pharmaceutical Industries||3|||||||||||||||||2018-06-01 05:12:54.242371|2018-06-01 05:12:54.242371
NCT00078338|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-23|||2014-08-05|2004-02-25|2004-02-26|Estimate|||||||2014-08-05|2014-08-06|Estimate|March 2004||2004-03-31|April 2011|2011-04-30|September 2007|Actual|2007-09-30|||||Interventional|||Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis|Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis|Completed||Phase 4|764|Actual|EMD Serono|||||f||||||||||||||2018-06-01 05:12:54.676098|2018-06-01 05:12:54.676098
NCT00076687|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-29|2011-07-28||2011-08-30|2004-02-25|2004-02-26|Estimate|2011-08-30|2011-10-03|Estimate||||2011-08-30|2011-10-03|Estimate|October 2003||2003-10-31|August 2011|2011-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function||Completed||Phase 2|155|Actual|Allergan||3|||f||||||||||||||2018-06-01 05:12:55.023786|2018-06-01 05:12:55.023786
NCT00014690|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-08-01|2004-02-25|2004-02-26|Estimate|||||||2013-08-01|2013-08-02|Estimate|March 2001||2001-03-31|December 2004|2004-12-31|February 2004|Actual|2004-02-29|||||Interventional|||ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II, Open, Randomized Multicenter Trial to Assess the Efficacy and Tolerability of Intravenous ZD9331 Given as Monotherapy (at Two Doses) or in Combination With Topotecan, in Patients With Ovarian Cancer Refractory or Recurrent After Failing Platinum and Paclitaxel in Combination|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:55.458993|2018-06-01 05:12:55.458993
NCT00014339|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-12-17|2004-02-25|2004-02-26|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2000||2000-03-31|November 2007|2007-11-30||||||||Interventional|||Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma|A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:55.526556|2018-06-01 05:12:55.526556
NCT00012259|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-05-30|2004-02-25|2004-02-26|Estimate|||||||2013-05-30|2013-05-31|Estimate|October 2000||2000-10-31|May 2013|2013-05-31||||February 2002|Actual|2002-02-28||Interventional|||Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Study Of Troxatyl In Patients With CML Blastic Phase Disease|Completed||Phase 2|31|Actual|Shire||1|||f||||||||||||||2018-06-01 05:12:55.617|2018-06-01 05:12:55.617
NCT00010179|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2010-11-07|2004-02-25|2004-02-26|Estimate|||||||2010-11-07|2010-11-09|Estimate|June 2000||2000-06-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer|Randomized Phase II Study Of NX 211 Given By Two Different Intravenous Schedules In Advanced And/Or Recurrent Epithelial Ovarian Cancer|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:12:55.711325|2018-06-01 05:12:55.711325
NCT00065858|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2016-08-17|2003-08-04|2003-08-05|Estimate|||||||2016-08-17|2016-08-19|Estimate|September 2001||2001-09-30|August 2016|2016-08-31|April 2005||2005-04-30|||||Interventional|||Effectiveness of BufferGel as a Vaginal Contraceptive|A Randomized, Controlled Trial of the Efficacy, Safety, and Acceptability of BufferGel|Completed||Phase 2/Phase 3|975||Health Decisions|||||||||||||||||||2018-06-01 05:18:24.961989|2018-06-01 05:18:24.961989
NCT00006472|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2009-02-06|2004-02-25|2004-02-26|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2000||2000-01-31|February 2002|2002-02-28||||||||Interventional|||Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer|Esophageal Cancer: A Phase II Study of Paclitaxel, Carboplatin and 5-Fluorouracil With Simultaneous Radiotherapy Followed by Surgical Resection|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:55.785695|2018-06-01 05:12:55.785695
NCT00006365|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2014-01-23|2004-02-25|2004-02-26|Estimate|||||||2014-01-23|2014-01-24|Estimate|November 2000||2000-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|December 2006|Actual|2006-12-31||Interventional|||External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer|A Phase II Study of External Beam Radiation Therapy Combined With Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate|Completed||Phase 2|138|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:12:55.9238|2018-06-01 05:12:55.9238
NCT00006108|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-02-03|2004-02-25|2004-02-26|Estimate|||||||2012-02-03|2012-02-07|Estimate|August 1999||1999-08-31|February 2012|2012-02-29|July 2002|Actual|2002-07-31|September 2001|Actual|2001-09-30||Interventional|||Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer|A Phase II Trial of Xeloda, Every Three Week Taxol and Herceptin in Metastatic Breast Cancer|Completed||Phase 1/Phase 2|||UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:12:56.377996|2018-06-01 05:12:56.377996
NCT00006037|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2014-05-20|2004-02-25|2004-02-26|Estimate|||||||2014-05-20|2014-05-22|Estimate|November 1999||1999-11-30|May 2014|2014-05-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer|Phase II Randomized Placebo-Controlled Double-Blinded Study With 5-FU vs. 5-FU With IM862 With Cross-Over to CPT-11 vs. CPT-11 With IM862|Terminated||Phase 2|18|Actual|University of Southern California||||Drug not available|f||||t||||||||||2018-06-01 05:12:56.445346|2018-06-01 05:12:56.445346
NCT00006014|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-31|2004-02-25|2004-02-26|Estimate|||||||2013-05-31|2013-06-03|Estimate|August 2000||2000-08-31|February 2009|2009-02-28|February 2009|Actual|2009-02-28|February 2007|Actual|2007-02-28||Interventional|||SU5416 in Treating Patients With Malignant Mesothelioma|A Phase II Trial of SU5416 (NSC# 696819) in Patients With Malignant Mesothelioma|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:12:56.519311|2018-06-01 05:12:56.519311
NCT00078403|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-24|2010-11-05||2016-11-30|2004-02-24|2004-02-25|Estimate|2011-03-30|2011-04-27|Estimate||||2016-11-30|2017-01-27|Estimate|July 2004||2004-07-31|November 2016|2016-11-30|February 2009|Actual|2009-02-28|May 2007|Actual|2007-05-31||Interventional||All Arm A, B and C participants.|Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)|Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C)|Completed||Phase 2|333|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 05:12:56.639508|2018-06-01 05:12:56.639508
NCT00078325|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-23|2009-06-01||2013-07-12|2004-02-24|2004-02-25|Estimate|2010-07-06|2010-07-29|Estimate||||2013-07-12|2013-07-19|Estimate|February 2004||2004-02-29|July 2013|2013-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)|A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome|Completed||Phase 3|395|Actual|Teva Pharmaceutical Industries||3|||||||f||||||||||2018-06-01 05:12:57.686289|2018-06-01 05:12:57.686289
NCT00078312|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-23|2009-06-01||2013-07-12|2004-02-24|2004-02-25|Estimate|2010-01-27|2010-02-22|Estimate||||2013-07-12|2013-07-19|Estimate|January 2004||2004-01-31|July 2013|2013-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder|A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)|Completed||Phase 3|328|Actual|Teva Pharmaceutical Industries|||||||||f||||||||||2018-06-01 05:12:57.99955|2018-06-01 05:12:57.99955
NCT00005991|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-10-05|2004-02-24|2004-02-25|Estimate|||||||2012-10-05|2012-10-10|Estimate|April 2000||2000-04-30|October 2012|2012-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer|Phase I/II Study of Gemcitabine and Doxil Combination Chemotherapy in Patients With Advanced Solid Tumors (Phase I)/Breast Cancer (Phase II)|Completed||Phase 2|76|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:12:58.326532|2018-06-01 05:12:58.326532
NCT00005880|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2008-07-23|2004-02-24|2004-02-25|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2000||2000-07-31|July 2007|2007-07-31||||||||Interventional|||Budesonide in Treating Former and Current Smokers With Bronchial Dysplasia|A Phase II Trial of Inhaled Budesonide (Pulmicort Turbuhaler) in Persons With Dysplasia of the Bronchial Epithelium|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:58.38184|2018-06-01 05:12:58.38184
NCT00005869|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-02-24|2004-02-25|Estimate|||||||2013-12-03|2013-12-04|Estimate|November 1998||1998-11-30|June 2007|2007-06-30||||||||Interventional|||Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer|Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:58.428675|2018-06-01 05:12:58.428675
NCT00005864|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-30|2004-02-24|2004-02-25|Estimate|||||||2013-01-30|2013-01-31|Estimate|April 2000||2000-04-30|September 2002|2002-09-30|February 2004|Actual|2004-02-29|||||Interventional|||Chloroquinoxaline Sulfonamide in Treating Patients With Stage IV Colorectal Cancer|A Phase II Study of Chloroquinoxaline Sulfonamide (CQS) in Colorectal Cancer Stage IV|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:58.487192|2018-06-01 05:12:58.487192
NCT00005593|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-06-09|2004-02-24|2004-02-25|Estimate|||||||2010-06-09|2010-06-11|Estimate|September 1998||1998-09-30|June 2010|2010-06-30|March 2003|Actual|2003-03-31|April 2002|Actual|2002-04-30||Interventional|||Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome|Phase I Study of Fludarabine, Carboplatin, and Topotecan for Patients With Relapsed/Refractory Acute Leukemia and Advanced Myelodysplastic Syndromes|Completed||Phase 1|31|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:12:58.550119|2018-06-01 05:12:58.550119
NCT00005075|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-11-05|2004-02-24|2004-02-25|Estimate|||||||2013-11-05|2013-11-06|Estimate|July 1999||1999-07-31|May 2009|2009-05-31||||||||Interventional|||Ultrasound in Treating Patients With Recurrent Stage I or Stage II Prostate Cancer|Evaluation of the Ablatherm High Intensity Focused Ultrasound Device After Failed Radiation Therapy for Localized Prostate Cancer|Terminated||Phase 3|||National Cancer Institute (NCI)||||Withdrawn because Ablatherm devices were not available anymore at trial centers|f||||||||||||||2018-06-01 05:12:58.626648|2018-06-01 05:12:58.626648
NCT00005026|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-05-24|2004-02-24|2004-02-25|Estimate|||||||2013-05-24|2013-05-27|Estimate|February 2000||2000-02-29|July 2008|2008-07-31||||January 2007|Actual|2007-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer|A Phase I Feasibility Trial of Carboplatin and Topotecan Followed by Carboplatin and Paclitaxel (Sequential Doublets) in Patients With Previously Untreated Epithelial Ovarian Carcinoma and Primary Peritoneal Carcinoma|Completed||Phase 1|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:12:58.697122|2018-06-01 05:12:58.697122
NCT00004223|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2010-01-26|2004-02-24|2004-02-25|Estimate|||||||2010-01-26|2010-01-27|Estimate|December 1999||1999-12-31|January 2010|2010-01-31||||October 2002|Actual|2002-10-31||Interventional|||Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer|Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:12:58.820204|2018-06-01 05:12:58.820204
NCT00004216|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-07-17|2004-02-24|2004-02-25|Estimate|||||||2013-07-17|2013-07-18|Estimate|August 1999||1999-08-31|December 2007|2007-12-31|January 2008|Actual|2008-01-31|||||Interventional|||VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy|A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intratumoral Injection|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:12:58.987844|2018-06-01 05:12:58.987844
NCT00004183|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2016-07-12|2004-02-24|2004-02-25|Estimate|||||||2016-07-12|2016-07-14|Estimate|November 2000||2000-11-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|December 2003|Actual|2003-12-31||Interventional|||Capecitabine in Treating Patients With Malignant Mesothelioma|Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study|Completed||Phase 2|27|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:12:59.056109|2018-06-01 05:12:59.056109
NCT00078364|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-23|||2008-03-03|2004-02-23|2004-02-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2004||2004-02-29|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Pain Pathways in the Brain|Imaging Neural Mechanisms Underlying Pain Modulation|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:59.183155|2018-06-01 05:12:59.183155
NCT00078351|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-23|||2008-03-03|2004-02-23|2004-02-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2004||2004-02-29|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Synvisc to Treat Osteoarthritis of the Temporomandibular Joint|The Effects of Viscosupplementation Using Synvisc in Symptomatic Osteoarthritis of the Temporomandibular Joint|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:59.318786|2018-06-01 05:12:59.318786
NCT00078286|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-20|2009-05-11||2013-01-23|2004-02-23|2004-02-24|Estimate|2013-01-23|2013-02-27|Estimate||||2013-01-23|2013-02-27|Estimate|November 2003||2003-11-30|January 2013|2013-01-31|September 2008|Actual|2008-09-30|March 2008|Actual|2008-03-31||Interventional|SADHART-CHF||Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure|Safety and Efficacy of Sertraline for Depression CHF|Completed||Phase 2/Phase 3|469|Actual|Duke University|NFS may have limited our ability to detect effect of sertraline on depression scores. Dropout rate was higher than expected. A 12-week duration of therapy may have been insufficient to show potential effects of sertraline on clinical outcomes.|2|||f||||t||||||||||2018-06-01 05:12:59.395969|2018-06-01 05:12:59.395969
NCT00078273|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-20|||2013-12-10|2004-02-23|2004-02-24|Estimate|||||||2013-12-10|2013-12-11|Estimate|July 2003||2003-07-31|December 2013|2013-12-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Indicated Prevention With At-Risk Gamblers|Indicated Prevention With At-Risk Gamblers|Completed||Phase 2|225|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 05:12:59.626048|2018-06-01 05:12:59.626048
NCT00078260|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-20|||2016-11-21|2004-02-23|2004-02-24|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2003||2003-12-31|November 2016|2016-11-30|April 2008|Actual|2008-04-30|October 2006|Actual|2006-10-31||Interventional|||A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer|A Randomized Phase 3 Study of Two Doses of Alimta in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy|Completed||Phase 3|589|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-06-01 05:12:59.708859|2018-06-01 05:12:59.708859
NCT00078299|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-20|||2008-03-03|2004-02-20|2004-02-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2004||2004-02-29|April 2005|2005-04-30|April 2005||2005-04-30|||||Observational|||Evaluation of the Age-Related Eye Disease Study (AREDS) Clinical Lens Grading System|Evaluation of the Age-Related Eye Disease Study (AREDS) Clinical Lens Grading System|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:12:59.772053|2018-06-01 05:12:59.772053
NCT00078247|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-20|||2010-08-10|2004-02-20|2004-02-23|Estimate|||||||2010-08-10|2010-08-12|Estimate|October 2004||2004-10-31|August 2010|2010-08-31||||||||Interventional|||Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis|Delaying HIV Disease Progression With Punctuated Antiretroviral Therapy in HIV-Associated Tuberculosis|Completed||Phase 3|350|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:12:59.818092|2018-06-01 05:12:59.818092
NCT00078234|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-20|||2011-11-04|2004-02-20|2004-02-23|Estimate|||||||2011-11-04|2011-11-07|Estimate|November 2003||2003-11-30|May 2009|2009-05-31|September 2010|Actual|2010-09-30|September 2008|Actual|2008-09-30||Interventional|||Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia|A Pilot Study of Genasense® (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|25|Actual|Genta Incorporated|||||f||||||||||||||2018-06-01 05:12:59.955357|2018-06-01 05:12:59.955357
NCT00078169|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2017-01-11|2004-02-20|2004-02-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2003||2003-11-30|October 2016|2016-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Motivational Enhancement for Spanish Speaking Individuals - 1|Motivational Enhancement for Spanish Speaking Individuals|Completed||Phase 3|463||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:13:00.041658|2018-06-01 05:13:00.041658
NCT00078143|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2017-01-11|2004-02-20|2004-02-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2003||2003-10-31|October 2016|2016-10-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Motivational Enhancement Therapy to Improve Treatment Utilization in Pregnant Substance Users - 1|Motivational Enhancement Therapy (MET) to Improve Treatment Utilization in Pregnant Substance Users|Completed||Phase 3|200||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:13:00.207755|2018-06-01 05:13:00.207755
NCT00078208|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2017-06-30|2004-02-19|2004-02-20|Estimate|||||||2017-06-30|2017-07-02|Actual|February 18, 2004||2004-02-18|August 19, 2010|2010-08-19|August 19, 2010||2010-08-19|||||Observational|||Exhaled Breath Condensate as a Measure of Airway Inflammation in Children With Asthma|Exhaled Breath Condensate as a Measurement of Airway Inflammation in Children With Asthma|Completed|||128|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:00.292362|2018-06-01 05:13:00.292362
NCT00078195|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2016-10-14|2004-02-19|2004-02-20|Estimate|||||||2016-10-14|2016-10-18|Estimate|April 2003||2003-04-30|October 2016|2016-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies|Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD)|Completed||Phase 2|168||National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research data sharing portal.|2018-06-01 05:13:00.365114|2018-06-01 05:13:00.365114
NCT00078182|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2016-12-13|2004-02-19|2004-02-20|Estimate|||||||2016-12-13|2016-12-14|Estimate||||May 2005|2005-05-31||||||||Interventional|||Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia|Study of Daily Oral Tenofovir (Tenofovir Disoproxil Fumarate) to Prevent HIV-1 Infection Among Sex Workers in Cambodia|Withdrawn||Phase 2/Phase 3|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:13:00.526404|2018-06-01 05:13:00.526404
NCT00078130|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2017-01-11|2004-02-19|2004-02-20|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2003||2003-07-31|October 2016|2016-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1|Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents|Completed||Phase 3|223||National Institute on Drug Abuse (NIDA)|||||||||t||||||||||2018-06-01 05:13:00.595838|2018-06-01 05:13:00.595838
NCT00078117|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-19|||2017-01-11|2004-02-19|2004-02-20|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2003||2003-06-30|April 2010|2010-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1|Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules|Completed||Phase 3|516||National Institute on Drug Abuse (NIDA)|||||||||t||||||||||2018-06-01 05:13:00.677514|2018-06-01 05:13:00.677514
NCT00078065|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-18|||2005-11-10|2004-02-19|2004-02-20|Estimate|||||||2005-11-10|2005-11-11|Estimate|November 2003||2003-11-30|March 2005|2005-03-31|June 2004||2004-06-30|||||Interventional|||Xcellerated T CellsTM in Patients With Multiple Myeloma|A Randomized Phase II Study of Xcellerated T CellsTM With or Without Prior Fludarabine Therapy in Patients With Multiple Myeloma|Completed||Phase 2|30||Xcyte Therapies|||||||||||||||||||2018-06-01 05:13:00.755847|2018-06-01 05:13:00.755847
NCT00004148|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-08|2004-02-19|2004-02-20|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 1999||1999-10-31|June 2006|2006-06-30||||April 2006|Actual|2006-04-30||Interventional|||Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma|A Phase I Trial of Intra Lesional RV-B7.1 Vaccine in the Treatment of Malignant Melanoma|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:00.826395|2018-06-01 05:13:00.826395
NCT00003935|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-25|2004-02-19|2004-02-20|Estimate|||||||2014-07-25|2014-07-28|Estimate|September 1999||1999-09-30|July 2014|2014-07-31|March 2007|Actual|2007-03-31|October 2003|Actual|2003-10-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma|Treatment of Children With Diffuse Intrinsic Brain Stem Glioma With Standard Dose Irradiation and Vincristine Plus Oral VP-16, A POG Pilot Study|Completed||Phase 1|31|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:13:00.910439|2018-06-01 05:13:00.910439
NCT00003814|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-02-19|2004-02-20|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 1999||1999-02-28|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Eflornithine in Treating Patients With Bladder Cancer|Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer|Completed||Phase 3|450|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:01.179784|2018-06-01 05:13:01.179784
NCT00003766|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-03-05|2004-02-19|2004-02-20|Estimate|||||||2014-03-05|2014-03-06|Estimate|October 1999||1999-10-31|March 2014|2014-03-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery|Determination of Optimal O6-Benzylguanine Dose to Achieve O6-Alkylguanine-DNA Alkyltransferase Depletion in Patients With Surgically Resectable Solid Tumors|Completed||Phase 1|25|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:13:01.29531|2018-06-01 05:13:01.29531
NCT00003623|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-02-19|2004-02-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 1999||1999-10-31|July 2016|2016-07-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer|Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder|Completed||Phase 3|21|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:13:01.353692|2018-06-01 05:13:01.353692
NCT00003615|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2004-02-19|2004-02-20|Estimate|||||||2010-01-26|2010-01-28|Estimate|March 1999||1999-03-31|January 2010|2010-01-31||||August 2006|Actual|2006-08-31||Interventional|||Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study of DAB 389 IL-2, an Interleukin-2 Fusion Toxin, for Previously Treated Stage II, III, and IV Follicular Low-Grade Non-Hodgkin's Lymphoma|Completed||Phase 2|77|Anticipated|Eastern Cooperative Oncology Group|||||||||f||||||||||2018-06-01 05:13:01.427608|2018-06-01 05:13:01.427608
NCT00003600|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-02-19|2004-02-20|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 1998||1998-12-31|July 2016|2016-07-31|January 2010|Actual|2010-01-31|December 2001|Actual|2001-12-31||Interventional|||Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy|A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy|Completed||Phase 3|344|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:13:01.501491|2018-06-01 05:13:01.501491
NCT00075101|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-02|||2008-08-14|2004-01-02|2004-01-05|Estimate|||||||2008-08-14|2008-08-18|Estimate|September 2000||2000-09-30|August 2008|2008-08-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Sleep, Fatigue, and Dexamethosone in Children With Leukemia|Sleep, Fatigue, and Dexamethosone in Childhood Cancer|Completed||Phase 3|134|Anticipated|National Institute of Nursing Research (NINR)||1|||f||||f||||||||||2018-06-01 05:14:41.019349|2018-06-01 05:14:41.019349
NCT00003573|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-24|2004-02-19|2004-02-20|Estimate|||||||2014-07-24|2014-07-25|Estimate|November 1998||1998-11-30|July 2014|2014-07-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma|A Phase I/II Feasibility Study of Oral Etoposide Given Concurrently With Radiotherapy Followed With Dose Intensive Adjuvant Chemotherapy for Children With Newly Diagnosed High Stage Medulloblastoma|Completed||Phase 2|53|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:13:01.591615|2018-06-01 05:13:01.591615
NCT00003572|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-01|2004-02-19|2004-02-20|Estimate|||||||2014-05-01|2014-05-02|Estimate|August 1998||1998-08-31|May 2014|2014-05-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers|Non-Myeloablative Allogeneic Bone Marrow Transplant for Hematologic Malignancies|Completed||Phase 2|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:13:02.686125|2018-06-01 05:13:02.686125
NCT00003548|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2011-03-25|2004-02-19|2004-02-20|Estimate|||||||2011-03-25|2011-03-28|Estimate|August 1998||1998-08-31|March 2011|2011-03-31||||December 2001|Actual|2001-12-31||Interventional|||Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity|Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity|Completed||Phase 1|20|Anticipated|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:13:02.760245|2018-06-01 05:13:02.760245
NCT00003425|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-25|2004-02-19|2004-02-20|Estimate|||||||2013-04-25|2013-04-26|Estimate|December 1997||1997-12-31|April 2013|2013-04-30||||July 2002|Actual|2002-07-31||Interventional|||Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect|Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients|Completed||Phase 1/Phase 2|25|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-06-01 05:13:02.836298|2018-06-01 05:13:02.836298
NCT00003411|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-01-15|2004-02-19|2004-02-20|Estimate|||||||2016-01-15|2016-01-18|Estimate|November 1998||1998-11-30|January 2016|2016-01-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer|Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers|Completed||Phase 1|||University of Pittsburgh|||||f||||t||||||||||2018-06-01 05:13:02.929024|2018-06-01 05:13:02.929024
NCT00003299|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2004-02-19|2004-02-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 1998||1998-04-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|June 2005|Actual|2005-06-30||Interventional|||Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Phase III Study Comparing Etoposide and Cisplatin With Etoposide, Cisplatin and Paclitaxel in Patients With Extensive Small Cell Lung Cancer|Completed||Phase 3|587|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:13:03.000101|2018-06-01 05:13:03.000101
NCT00003240|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2004-02-19|2004-02-20|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 1995||1995-10-31|May 2007|2007-05-31||||||||Interventional|||Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|A Major Randomised Trial to Determine the Value of Cisplatin-Based Chemotherapy For All Patients With Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|1800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:03.210707|2018-06-01 05:13:03.210707
NCT00003120|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-10-07|2004-02-19|2004-02-20|Estimate|||||||2014-10-07|2014-10-09|Estimate|November 1997||1997-11-30|October 2014|2014-10-31|November 2012|Actual|2012-11-30|June 2003|Actual|2003-06-30||Interventional|||S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission|Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy|Completed||Phase 3|308|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:13:03.319603|2018-06-01 05:13:03.319603
NCT00078104|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-18|||2008-03-03|2004-02-18|2004-02-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2004||2004-02-29|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction|Proinflammatory Gene Expression and Prostanoid Levels in a Clinical Model of Tissue Injury|Completed||Phase 2|148||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:03.549667|2018-06-01 05:13:03.549667
NCT00078091|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-18|||2018-05-24|2004-02-18|2004-02-19|Estimate|||||||2018-05-24|2018-05-25|Actual|February 17, 2004||2004-02-17|February 5, 2016|2016-02-05|February 5, 2016||2016-02-05|||||Observational|||Genetics and Clinical Characteristics of Bardet-Biedl Syndrome|Bardet-Biedl Syndrome: Phenotype and Metabolic Characteristics|Terminated|||194|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:03.615153|2018-06-01 05:13:03.615153
NCT00078078|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-18|||2018-03-27|2004-02-18|2004-02-19|Estimate|||||||2018-03-27|2018-03-29|Actual|February 17, 2004||2004-02-17|January 17, 2018|2018-01-17||||||||Observational|||Clinical and Laboratory Study of Methylmalonic Acidemia|Clinical and Basic Investigations of Methylmalonic Acidemia (MMA) and Related Disorders|Recruiting|||1250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:03.68516|2018-06-01 05:13:03.68516
NCT00078052|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-17|||2013-03-18|2004-02-18|2004-02-19|Estimate|||||||2013-03-18|2013-03-20|Estimate|September 2003||2003-09-30|March 2013|2013-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Genetic Markers of Coronary Heart Disease in Type 2 Diabetes||Completed|||120000|Actual|Harvard School of Public Health|||||f||||||||||Samples With DNA|"~     Plasma and buffy coat~   "|||2018-06-01 05:13:03.763344|2018-06-01 05:13:03.763344
NCT00078026|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-16|||2014-02-04|2004-02-18|2004-02-19|Estimate|||||||2014-02-04|2014-02-05|Estimate|August 2003||2003-08-31|February 2014|2014-02-28|December 2004||2004-12-31|||||Interventional|||An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass|A Phase I/II Randomized Study of the Short-Term Effects of APOMINE vs Placebo in Postmenopausal Women With Osteoporosis or Low Bone Mass|Terminated||Phase 1/Phase 2|60||Sanofi|||||||||||||||||||2018-06-01 05:13:03.819588|2018-06-01 05:13:03.819588
NCT00030602|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2017-03-28|2004-02-18|2004-02-19|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2000|Actual|2000-01-31|March 2017|2017-03-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer|A Phase 2 Study Of Prostate Specific Antigen-3 (PSA-3) (NSC # 694155) With Montanide (NSC #675756) Vaccination In Patients With Prostate Cancer Recurrent|Completed||Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:13:03.883882|2018-06-01 05:13:03.883882
NCT00003089|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2004-02-18|2004-02-19|Estimate|||||||2013-07-09|2013-07-10|Estimate|July 1997||1997-07-31|May 2006|2006-05-31|February 2004|Actual|2004-02-29|||||Interventional|||Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer|A Phase II Trial of Induction Paclitaxel Plus Carboplatin Followed by Thoracic Radiation Therapy With Concurrent Weekly Low-Dose Paclitaxel and Twice Weekly Amifostine for Patients With Unresectable Locally Advanced or Partially Resected Non-Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:03.937712|2018-06-01 05:13:03.937712
NCT00003046|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2004-02-18|2004-02-19|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 1997||1997-08-31|July 2012|2012-07-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Interleukin-12 in Treating Patients With Cancer in the Abdomen|Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas|Completed||Phase 1|29|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:13:04.00033|2018-06-01 05:13:04.00033
NCT00003035|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-22|2004-02-18|2004-02-19|Estimate|||||||2011-03-22|2011-03-24|Estimate|March 1997||1997-03-31|December 2006|2006-12-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer|A Pilot Trial Comparing Doxorubicin and Paclitaxel Induced Apoptosis in Locally Advanced Breast Cancer|Completed||Phase 2|40|Anticipated|Georgetown University|||||f||||f||||||||||2018-06-01 05:13:04.18329|2018-06-01 05:13:04.18329
NCT00078013|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-13|||2005-06-23|2004-02-17|2004-02-18|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2003||2003-04-30|March 2005|2005-03-31|August 2004||2004-08-31|||||Interventional|||MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Examine the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Standard Therapy With Primary PCI in Patients Diagnosed as Having an ST Elevation Acute Myocardial Infarction|Completed||Phase 2|414||Mitsubishi Tanabe Pharma Corporation|||||||||||||||||||2018-06-01 05:13:04.253761|2018-06-01 05:13:04.253761
NCT00078000|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-13|||2008-11-24|2004-02-17|2004-02-18|Estimate|||||||2008-11-24|2008-11-26|Estimate|March 2004||2004-03-31|November 2008|2008-11-30|November 2005|Actual|2005-11-30|||||Interventional|||A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.|A Phase 2 Study Of The Efficacy And Safety Of SU011248 In Patients With Metastatic Breast Cancer|Completed||Phase 2|64|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:13:04.314664|2018-06-01 05:13:04.314664
NCT00077987|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-13|||2007-01-09|2004-02-17|2004-02-18|Estimate|||||||2007-01-09|2007-01-11|Estimate|December 2003||2003-12-31|October 2005|2005-10-31|April 2005||2005-04-30|||||Interventional|||Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.|A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab|Completed||Phase 2|84||Pfizer|||||f||||||||||||||2018-06-01 05:13:04.391584|2018-06-01 05:13:04.391584
NCT00077974|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-13|2009-09-25||2010-10-08|2004-02-17|2004-02-18|Estimate|2009-09-25|2009-11-03|Estimate||||2010-10-08|2010-10-13|Estimate|February 2004||2004-02-29|October 2010|2010-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.|A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma|Completed||Phase 2|106|Actual|Pfizer||1|||f||||t||||||||||2018-06-01 05:13:04.526512|2018-06-01 05:13:04.526512
NCT00077961|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-13|||2015-03-25|2004-02-17|2004-02-18|Estimate|||||||2015-03-25|2015-03-26|Estimate|December 2003||2003-12-31|March 2015|2015-03-31||||February 2006|Actual|2006-02-28||Interventional|||Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL|Phase I/II Study of Rituximab Plus CAMPATH in Patients With Previously Treated Relapsed or Refractory Low-Grade Follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|49||Sanofi|||||||||||||||||||2018-06-01 05:13:05.343239|2018-06-01 05:13:05.343239
NCT00077948|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-13|||2014-01-08|2004-02-17|2004-02-18|Estimate|||||||2014-01-08|2014-01-10|Estimate|July 2003||2003-07-31|January 2014|2014-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure|A Phase III, Randomized, Double-Blind, Double Placebo-Controlled, Multicenter, Three Parallel Group Study of Enoximone Plus Extended-Release Metoprolol Succinate in Advanced CHF Subjects Previously Intolerant to Beta-Blocker Treatment|Terminated||Phase 3|175||Gilead Sciences||3|||f||||||||||||||2018-06-01 05:13:05.413348|2018-06-01 05:13:05.413348
NCT00077935|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-13|||2011-06-06|2004-02-17|2004-02-18|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2003||2003-11-30|February 2004|2004-02-29|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Civamide in OA of the Knee(s)|An Open-Label Multicenter Study Evaluating the Safety of Civamide Cream 0.075% as a Treatment in Subjects With Osteoarthritis of the Knee(s)|Completed||Phase 3|351|Actual|Winston Laboratories|||||f||||f||||||||||2018-06-01 05:13:05.49923|2018-06-01 05:13:05.49923
NCT00077844|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2011-01-10|2004-02-17|2004-02-18|Estimate|||||||2011-01-10|2011-01-11|Estimate|January 2004||2004-01-31|January 2011|2011-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)|An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Percutaneous Coronary Intervention|Completed||Phase 2/Phase 3|3532|Anticipated|Sanofi|||||f||||||||||||||2018-06-01 05:13:05.702526|2018-06-01 05:13:05.702526
NCT00077883|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2011-07-21|2004-02-13|2004-02-16|Estimate|||||||2011-07-21|2011-07-25|Estimate|February 2004||2004-02-29|June 2005|2005-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Cisplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|50|Anticipated|Telik|||||f||||||||||||||2018-06-01 05:13:05.766148|2018-06-01 05:13:05.766148
NCT00077870|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2009-09-01|2004-02-13|2004-02-16|Estimate|||||||2009-09-01|2009-09-03|Estimate|February 2004||2004-02-29|September 2009|2009-09-30|December 2006|Actual|2006-12-31|||||Interventional|||A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid Arthritis|A Randomized, Placebo-Controlled, Multicenter, Blinded Phase I/II Study of the Safety of Escalating Doses of Ocrelizumab (PRO70769) in Subjects With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate|Completed||Phase 1/Phase 2|237||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:13:05.835747|2018-06-01 05:13:05.835747
NCT00077857|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|2013-02-13||2013-03-27|2004-02-13|2004-02-16|Estimate|2013-03-27|2013-05-10|Estimate||||2013-03-27|2013-05-10|Estimate|July 2003||2003-07-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer|A Randomized, Open-label Study of the Effect of Different Dosing Regimens of Xeloda® in Combination With Taxotere® on Disease Progression in Patients With Locally Advanced and/or Metastatic Breast Cancer|Completed||Phase 2|470|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:13:05.952316|2018-06-01 05:13:05.952316
NCT00077831|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2015-07-19|2004-02-13|2004-02-16|Estimate|||||||2015-07-19|2015-07-21|Estimate|September 2001||2001-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Observational|CILP||Child and Infant Learning Project|Neurobehavioral Correlates of Craniosynostosis|Completed|||535|Actual|Seattle Children's Hospital|||||f||||f||||||||||2018-06-01 05:13:06.612819|2018-06-01 05:13:06.612819
NCT00077818|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2009-10-14|2004-02-13|2004-02-16|Estimate|||||||2009-10-14|2009-10-15|Estimate|June 2002||2002-06-30|October 2009|2009-10-31||||February 2005|Actual|2005-02-28||Interventional|||Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)|A Prospective, Open-label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome|Completed||Phase 4|||Sanofi|||||t||||||||||||||2018-06-01 05:13:06.693513|2018-06-01 05:13:06.693513
NCT00077805|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2011-01-10|2004-02-13|2004-02-16|Estimate|||||||2011-01-10|2011-01-11|Estimate|August 2003||2003-08-31|January 2011|2011-01-31||||July 2006|Actual|2006-07-31||Interventional|||PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)|An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke|Completed||Phase 4|||Sanofi|||||f||||||||||||||2018-06-01 05:13:06.755124|2018-06-01 05:13:06.755124
NCT00077792|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2009-04-17|2004-02-13|2004-02-16|Estimate|||||||2009-04-17|2009-04-20|Estimate|October 2002||2002-10-31|April 2009|2009-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)|A Randomized, Double-Blind, Double-Dummy , Parallel Group, Multinational, Clinical Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Patients With Acute ST-Segment Elevation Myocardial Infarction Receiving Fibrinolytic Therapy|Completed||Phase 3|20506|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:13:06.855702|2018-06-01 05:13:06.855702
NCT00077779|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2007-09-23|2004-02-13|2004-02-16|Estimate|||||||2007-09-23|2007-09-26|Estimate|July 2003||2003-07-31|September 2007|2007-09-30||||||||Interventional|CHARM||Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease|A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease|Completed||Phase 3|854|Actual|Abbott|||||||||||||||||||2018-06-01 05:13:06.996331|2018-06-01 05:13:06.996331
NCT00077766|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|2016-07-27||2016-09-16|2004-02-13|2004-02-16|Estimate|2016-07-27|2016-09-14|Estimate||||2016-09-16|2016-10-26|Estimate|March 2004||2004-03-31|November 2015|2015-11-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional||The safety population was defined as all participants who received at least one dose of RO0503821 or darbepoetin alfa and had a safety follow-up, whether withdrawn prematurely or not. There were 4 participants who were excluded from the safety population as they did not receive the study medication.|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.|A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.|Completed||Phase 3|313|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:13:07.123833|2018-06-01 05:13:07.123833
NCT00077753|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2011-01-10|2004-02-13|2004-02-16|Estimate|||||||2011-01-10|2011-01-11|Estimate|February 2002||2002-02-28|January 2011|2011-01-31|February 2007|Actual|2007-02-28|October 2006|Actual|2006-10-31||Interventional|||EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization|A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization|Completed||Phase 4|4726||Sanofi|||||||||||||||||||2018-06-01 05:13:08.260777|2018-06-01 05:13:08.260777
NCT00077727|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-11|||2011-05-20|2004-02-13|2004-02-16|Estimate|||||||2011-05-20|2011-05-24|Estimate|March 2003||2003-03-31|April 2010|2010-04-30|February 2005|Actual|2005-02-28|||||Interventional|||A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.|A Study of Galantamine HBr as an Adjunctive Treatment to Atypical Antipsychotic Medications in Outpatients With Schizophrenia and Associated Cognitive Deficits.|Completed||Phase 3|107|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:13:08.355427|2018-06-01 05:13:08.355427
NCT00077714|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-11|||2011-06-06|2004-02-13|2004-02-16|Estimate|||||||2011-06-06|2011-06-08|Estimate|January 2004||2004-01-31|April 2010|2010-04-30|January 2005|Actual|2005-01-31|||||Interventional|||Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia|A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Paliperidone Extended Release Tablets and Olanzapine, With Open-label Extension, in the Treatment of Patients With Schizophrenia|Completed||Phase 3|12|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:13:08.413882|2018-06-01 05:13:08.413882
NCT00077688|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2009-06-02|2004-02-13|2004-02-16|Estimate|||||||2009-06-02|2009-06-04|Estimate|November 2003||2003-11-30|June 2009|2009-06-30|September 2007|Actual|2007-09-30|||||Interventional|||TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium|A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|44||Achieve Life Sciences|||||f||||||||||||||2018-06-01 05:13:08.478338|2018-06-01 05:13:08.478338
NCT00076973|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-06|||2017-03-03|2004-02-13|2004-02-16|Estimate|||||||2017-03-03|2017-03-06|Actual|August 2003||2003-08-31|March 2017|2017-03-31|October 2006|Actual|2006-10-31|June 2006|Actual|2006-06-30||Interventional|||An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)|A Randomized, 2-Period, Multicenter, Dble-Blind, Parallel-Group Study Comparing Effects of 2 Doses of MK0476 and Placebo in the Tx of Respiratory Symptoms Associated w/ Respiratory Syncytial Virus-Induced Bronchiolitis in Children 3 to 24 Mths|Completed||Phase 3|1125|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:13:08.545411|2018-06-01 05:13:08.545411
NCT00027924|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2010-03-31|2004-02-13|2004-02-16|Estimate|||||||2010-03-31|2010-04-02|Estimate|October 2001||2001-10-31|March 2010|2010-03-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome|Fludarabine And Busulfan As Conditioning For Patients With Chronic Myeloid Leukemia Or Myelodysplastic Syndrome Transplanted With Hematopoietic Stem Cells From HLA-Compatible Related Or Unrelated Donors|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:13:08.617289|2018-06-01 05:13:08.617289
NCT00023647|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2012-07-09|2004-02-13|2004-02-16|Estimate|||||||2012-07-09|2012-07-10|Estimate|July 2000||2000-07-31|July 2012|2012-07-31|November 2002|Actual|2002-11-30|April 2002|Actual|2002-04-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients|Completed||Phase 1|26|Actual|Mannkind Corporation||3|||f||||f||||||||||2018-06-01 05:13:08.689325|2018-06-01 05:13:08.689325
NCT00021294|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2010-03-23|2004-02-13|2004-02-16|Estimate|||||||2010-03-23|2010-03-24|Estimate|May 2001||2001-05-31|June 2002|2002-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis|Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms|Completed||Phase 2|||University of Arizona|||||f||||||||||||||2018-06-01 05:13:08.762921|2018-06-01 05:13:08.762921
NCT00021034|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2004-02-13|2004-02-16|Estimate|||||||2013-06-17|2013-06-18|Estimate|March 2001||2001-03-31|June 2013|2013-06-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Phase I Trial of Taurolidine After Positive Second Look Surgery for Recurrent Ovarian Epithelial, Fallopian Tube and Primary Peritoneal Cancers|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:08.818406|2018-06-01 05:13:08.818406
NCT00021021|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-03-25|2004-02-13|2004-02-16|Estimate|||||||2013-03-25|2013-03-26|Estimate|September 2001||2001-09-30|May 2002|2002-05-31|February 2004|Actual|2004-02-29|||||Interventional|||RPI.4610 in Treating Patients With Metastatic Kidney Cancer|A Phase II, Open-Label, Multicenter Trial of Angiozyme in Subjects With Metastatic Renal Cell Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:08.870429|2018-06-01 05:13:08.870429
NCT00020917|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2004-02-13|2004-02-16|Estimate|||||||2013-06-17|2013-06-18|Estimate|February 2001||2001-02-28|June 2013|2013-06-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer|Pilot Study of an Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, Cetuximab, in Combination With Irinotecan, Fluorouracil, and Leucovorin, and in Patients With Newly Diagnosed Stage IV Colorectal Carcinoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:08.921939|2018-06-01 05:13:08.921939
NCT00020553|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-09-19|2004-02-13|2004-02-16|Estimate|||||||2013-09-19|2013-09-20|Estimate|August 2000||2000-08-31|October 2006|2006-10-31||||||||Interventional|||Video Support Program For Families With a Parent Newly Diagnosed With Cancer|We Can Cope: Family Support When A Parent Has Cancer|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:08.973845|2018-06-01 05:13:08.973845
NCT00017459|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-08-01|2004-02-13|2004-02-16|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2000||2000-07-31|February 2010|2010-02-28|February 2004|Actual|2004-02-29|||||Interventional|||Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|The International Tirazone Triple Trial (i3T): A Phase III, Randomized Efficacy And Safety Study Of The Combination Chemotherapy With Tirapazamine+Cisplatin+Vinorelbine Versus Cisplatin+Vinorelbine In Subjects With Inoperable, Previously Untreated, Non-Small Cell Lung Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:09.030324|2018-06-01 05:13:09.030324
NCT00017199|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-01-30|2004-02-13|2004-02-16|Estimate|||||||2013-01-30|2013-01-31|Estimate|April 2001||2001-04-30|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors|Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:09.232701|2018-06-01 05:13:09.232701
NCT00017056|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-17|2004-02-13|2004-02-16|Estimate|||||||2013-06-17|2013-06-18|Estimate|February 2001||2001-02-28|June 2013|2013-06-30|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy|A Phase II Study Of Epothilone Analog BMS-247550 In Patients With Metastatic Gastric Adenocarcinoma Previously Treated With A Fluoropyrimidine And/Or Platinum|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:09.429969|2018-06-01 05:13:09.429969
NCT00016172|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-06-17|2004-02-13|2004-02-16|Estimate|||||||2013-06-17|2013-06-18|Estimate|November 2000||2000-11-30|June 2013|2013-06-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of ZD0473 and Doxil in Patients With Advanced Refractory Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:09.514726|2018-06-01 05:13:09.514726
NCT00014625|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2012-07-23|2004-02-13|2004-02-16|Estimate|||||||2012-07-23|2012-07-24|Estimate|February 2001||2001-02-28|July 2012|2012-07-31||||November 2001|Actual|2001-11-30||Interventional|||E7070 in Treating Patients With Stage IV Melanoma|Open Label Phase II Study Of E7070 In Patients With Metastatic Melanoma (Stage IV)|Completed||Phase 2|28|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:09.630338|2018-06-01 05:13:09.630338
NCT00014430|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-03-12|2004-02-13|2004-02-16|Estimate|||||||2013-03-12|2013-03-14|Estimate|November 1999||1999-11-30|November 2002|2002-11-30||||September 2002|Actual|2002-09-30||Interventional|||Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer|Phase I Clinical Trial Of Vinorelbine (Navelbine) And Trastuzumab (Herceptin) In Patients With Carcinoma Of The Breast Or Non-Small Cell Lung Cancer And HER-2/NEU Overexpression|Completed||Phase 1|13|Actual|Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:13:09.745724|2018-06-01 05:13:09.745724
NCT00008281|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2014-01-03|2004-02-13|2004-02-16|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2000||2000-10-31|April 2002|2002-04-30||||||||Interventional|||Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer|A Multicenter, Open-Label, Randomized, Three-Arm Study Of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) Or Oxaliplatin Or A Combination Of (5-Fu) LV + Oxaliplatin As Second-Line Treatment Of Metastatic Colorectal Carcinoma|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:09.829787|2018-06-01 05:13:09.829787
NCT00007878|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-12-10|2004-02-13|2004-02-16|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2000||2000-09-30|December 2013|2013-12-31||||January 2008|Actual|2008-01-31||Interventional|||Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Phase I Study of PS-341 in Combination With 5-FU/LV in Solid Tumors|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:10.068188|2018-06-01 05:13:10.068188
NCT00006122|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-07-13|2004-02-13|2004-02-16|Estimate|||||||2012-07-13|2012-07-16|Estimate|June 2000||2000-06-30|July 2012|2012-07-31||||January 2002|Actual|2002-01-31||Interventional|||Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia|Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study|Completed||Phase 2|106|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:10.165834|2018-06-01 05:13:10.165834
NCT00005795|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02||2011-02-16|2012-06-07|2004-02-13|2004-02-16|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-07|2012-06-11|Estimate|February 2000||2000-02-29|June 2012|2012-06-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia|Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old|Completed||Phase 2|11|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 05:13:10.435801|2018-06-01 05:13:10.435801
NCT00005791|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-18|2004-02-13|2004-02-16|Estimate|||||||2013-12-18|2013-12-19|Estimate|October 1999||1999-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|July 2002|Actual|2002-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:10.499488|2018-06-01 05:13:10.499488
NCT00005631|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-18|2004-02-13|2004-02-16|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 1999||1999-11-30|June 2013|2013-06-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma|Cytoreduction and Stem Cell Mobilization With Rituximab and ICE for Patients With Refractory or Relapsed CD20+ B-Cell IGL Eligible for ASCT: The RICE Protocol|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:10.588133|2018-06-01 05:13:10.588133
NCT00005609|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-08-14|2004-02-13|2004-02-16|Estimate|||||||2013-08-14|2013-08-16|Estimate|April 2000||2000-04-30|September 2009|2009-09-30|February 2004|Actual|2004-02-29|||||Interventional|||Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia|Rituximab for Waldenstrom's Macroglobulinemia (WM): A Phase II Pilot Study for Untreated or Previously Treated Patients|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:10.667765|2018-06-01 05:13:10.667765
NCT00005089|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2017-01-12|2004-02-13|2004-02-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|April 2000||2000-04-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|November 2004|Actual|2004-11-30||Interventional|||S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma|Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized Aggressive Histologies of Non-Hodgkin's Lymphoma|Completed||Phase 2|71|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:13:10.881775|2018-06-01 05:13:10.881775
NCT00004152|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-01-15|2004-02-13|2004-02-16|Estimate|||||||2013-01-15|2013-01-16|Estimate|February 1999||1999-02-28|January 2013|2013-01-31||||December 2002|Actual|2002-12-31||Interventional|||PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma|A Pilot Study to Compare 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) Scanning in Addition to CT Scanning With CT Scanning Alone in the Pre-Operative Evaluation of Patients With Stage III and IV Melanoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:11.088076|2018-06-01 05:13:11.088076
NCT00004145|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2014-03-06|2004-02-13|2004-02-16|Estimate|||||||2014-03-06|2014-03-07|Estimate|November 1998||1998-11-30|March 2014|2014-03-31|August 2011|Actual|2011-08-31|November 2003|Actual|2003-11-30||Interventional|||Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Allogeneic Peripheral Blood Stem Cell Transplantation Using a Non-Myeloablative Preparative Regimen for Patients With Hematologic Malignancies|Completed||Phase 2|16|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:13:11.147737|2018-06-01 05:13:11.147737
NCT00004114|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2015-09-30|2004-02-13|2004-02-16|Estimate|||||||2015-09-30|2015-10-02|Estimate||||July 2012|2012-07-31||||||||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer|Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study|Withdrawn||Phase 1|0|Actual|Jonsson Comprehensive Cancer Center||||Study never opened|f||||||||||||||2018-06-01 05:13:11.254193|2018-06-01 05:13:11.254193
NCT00003916|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2004-02-13|2004-02-16|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 1999||1999-04-30|September 2012|2012-09-30||||December 2001|Actual|2001-12-31||Interventional|||Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma|Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study|Completed||Phase 3|25|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:11.328333|2018-06-01 05:13:11.328333
NCT00003867|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-02-13|2004-02-16|Estimate|||||||2008-07-23|2008-07-24|Estimate|March 1999||1999-03-31|April 2007|2007-04-30||||||||Interventional|||Irinotecan and Capecitabine in Treating Patients With Solid Tumors|Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:11.399017|2018-06-01 05:13:11.399017
NCT00003632|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-15|2004-02-13|2004-02-16|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 1998||1998-09-30|January 2013|2013-01-31||||July 2005|Actual|2005-07-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma|A Phase II Study of Intensive Methotrexate and Cytarabine Followed by High Dose Beam Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma|Completed||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:11.458374|2018-06-01 05:13:11.458374
NCT00003582|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-14|2004-02-13|2004-02-16|Estimate|||||||2016-12-14|2016-12-15|Estimate|May 1988||1988-05-31|December 2016|2016-12-31|December 1996|Actual|1996-12-31|December 1996|Actual|1996-12-31||Interventional|||Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer|Phase I/II Study to Evaluate Combined Hyperfractionated Radiation Therapy and 5-Fluorouracil, Cisplatin and Paclitaxel (Taxol) and Amifostine (WR 2721, Ethyol) in Stage III and IV Inoperable Head and Neck Carcinomas|Completed||Phase 1/Phase 2|36|Anticipated|University of Miami|||||f||||||||||||||2018-06-01 05:13:11.522532|2018-06-01 05:13:11.522532
NCT00003545|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2004-02-13|2004-02-16|Estimate|||||||2013-02-04|2013-02-05|Estimate|August 1998||1998-08-31|April 2007|2007-04-30||||March 2007|Actual|2007-03-31||Interventional|||506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|A Phase II Study of 506U78 in Patients With Refractory or Relapsed T-Lineage Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphomas (LBL)|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:11.611518|2018-06-01 05:13:11.611518
NCT00003207|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-11|2004-02-13|2004-02-16|Estimate|||||||2013-04-11|2013-04-12|Estimate|March 1998||1998-03-31|April 2013|2013-04-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers|Phase I Study on Doxil and SDZ PSC 833 in the Treatment of AIDS-Associated Kaposi's Sarcoma and Other Advanced Malignancies|Completed||Phase 1|14|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-06-01 05:13:11.768687|2018-06-01 05:13:11.768687
NCT00003150|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-02-13|2004-02-16|Estimate|||||||2013-06-20|2013-06-21|Estimate|December 1997||1997-12-31|August 2010|2010-08-31|September 2006|Actual|2006-09-30|||||Interventional|||Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma|Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma|Completed||Phase 3|630|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:11.943261|2018-06-01 05:13:11.943261
NCT00003066|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2004-02-13|2004-02-16|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 1997||1997-02-28|December 2006|2006-12-31||||||||Interventional|||Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer|Phase II Evaluation of Docetaxel Combined With Estramustine Phosphate in Patients With Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:12.115449|2018-06-01 05:13:12.115449
NCT00003062|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-02-13|2004-02-16|Estimate|||||||2012-06-29|2012-07-02|Estimate|July 1997||1997-07-31|June 2012|2012-06-30||||January 2002|Actual|2002-01-31||Interventional|||Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer|A Phase II Study of TEMOZOLOMIDE in Advanced Non-Small Cell Lung Cancer With and Without Brain Metastases|Completed||Phase 2|70|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:12.169676|2018-06-01 05:13:12.169676
NCT00003011|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-30|2004-02-13|2004-02-16|Estimate|||||||2013-05-30|2013-06-03|Estimate|March 1997||1997-03-31|January 2012|2012-01-31|December 2008|Actual|2008-12-31|January 2001|Actual|2001-01-31||Interventional|||Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer|A Phase III Study of Marimastat in Patients With Small Cell Lung Cancer Following a Response to First Line Chemotherapy|Completed||Phase 3|555|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:13:12.309941|2018-06-01 05:13:12.309941
NCT00002869|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-02-13|2004-02-16|Estimate|||||||2013-12-18|2013-12-19|Estimate|April 1995||1995-04-30|February 2008|2008-02-29||||||||Interventional|||Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia|PROSPECTIVE RANDOMISED STUDY TO COMPARE LOW-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA VS HIGH-DOSE INTERFERON-ALPHA-n1 (WELLFERON) +/- HYDROXYUREA IN PATIENTS WITH NEWLY DIAGONISED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA|Unknown status|Active, not recruiting|Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:12.438836|2018-06-01 05:13:12.438836
NCT00002868|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-02-09|2004-02-13|2004-02-16|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 1996||1996-01-31|June 2005|2005-06-30||||March 2004|Actual|2004-03-31||Interventional|||Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia|PROSPECTIVE RANDOMISED STUDY TO COMPARE INTERFERON-ALPHA-n1 (WELLFERON) VS 'IDAC' CHEMOTHERAPY AND AUTOGRAFTING FOLLOWED BY INTERFERON ALPHA-n1 (WELLFERON) IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA|Completed||Phase 3|744|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:13:12.505398|2018-06-01 05:13:12.505398
NCT00002532|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2004-02-13|2004-02-16|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 1993||1993-01-31|March 2002|2002-03-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia|TREATMENT OF ADULT PATIENTS WITH RELAPSING ACUTE LYMPHOCYTIC LEUKEMIA, A MULTICENTER TRIAL|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:12.575075|2018-06-01 05:13:12.575075
NCT00002531|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2004-02-13|2004-02-16|Estimate|||||||2013-09-16|2013-09-17|Estimate|January 1993||1993-01-31|December 2006|2006-12-31||||||||Interventional|||Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia|MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93)|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:12.654253|2018-06-01 05:13:12.654253
NCT00077922|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|2012-10-17||2017-12-27|2004-02-12|2004-02-13|Estimate|2012-10-17|2012-11-15|Estimate||||2017-12-27|2018-01-23|Actual|February 29, 2004|Actual|2004-02-29|December 2017|2017-12-31|December 31, 2011|Actual|2011-12-31|December 31, 2011|Actual|2011-12-31||Interventional|||Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia|A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia|Completed||Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||No||2018-06-01 05:13:12.758245|2018-06-01 05:13:12.758245
NCT00077909|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2018-04-03|2004-02-12|2004-02-13|Estimate|||||||2018-04-03|2018-04-04|Actual|February 12, 2004||2004-02-12|March 21, 2018|2018-03-21||||||||Observational|||Study of Lung Proteins in Patients With Pneumonia|Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:13.151303|2018-06-01 05:13:13.151303
NCT00077896|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-12|||2008-03-03|2004-02-12|2004-02-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2004||2004-02-29|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Direct Current Brain Polarization in Frontotemporal Dementia|Direct Current Brain Polarization in Frontotemporal Dementia|Completed||Phase 1|6||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:13.257396|2018-06-01 05:13:13.257396
NCT00077675|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2009-12-02||2010-05-13|2004-02-12|2004-02-13|Estimate|2009-12-02|2010-01-11|Estimate||||2010-05-13|2010-05-18|Estimate|February 2004||2004-02-29|May 2010|2010-05-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|FAST2||Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|Completed||Phase 2|201|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||t||||||||||2018-06-01 05:13:13.341933|2018-06-01 05:13:13.341933
NCT00077649|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2016-02-03||2016-03-21|2004-02-12|2004-02-13|Estimate|2016-03-21|2016-04-18|Estimate||||2016-03-21|2016-04-18|Estimate|January 2004||2004-01-31|March 2016|2016-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional||The ITT [intent to treat] population which consisted of all participants who were randomized and received at least one dose of either of the study medication|A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).|Randomized, Multicenter, Double-blind, Phase IV Pilot Study Evaluating the Effect of PEGASYS Doses of 180 ug or 270 ug in Combination With Copegus Doses of 1200 mg or 1600 mg on Viral Kinetics, Virological Response, Pharmacokinetics, and Safety in Interferon-naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Body Weight Greater Than 85 kg|Completed||Phase 4|188|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 05:13:14.022924|2018-06-01 05:13:14.022924
NCT00077636|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2015-12-15||2016-01-22|2004-02-12|2004-02-13|Estimate|2015-12-15|2016-01-21|Estimate||||2016-01-22|2016-02-23|Estimate|December 2003||2003-12-31|January 2016|2016-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.|A Randomized, Open-label Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection|Completed||Phase 4|1469|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:13:15.368681|2018-06-01 05:13:15.368681
NCT00077623|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2016-03-24||2016-04-26|2004-02-12|2004-02-13|Estimate|2016-03-24|2016-04-26|Estimate||||2016-04-26|2016-05-25|Estimate|March 2004||2004-03-31|April 2016|2016-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional||The analysis was done on safety population which included all participants who received at least one dose of study drug.|A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.|A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis|Completed||Phase 3|572|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 05:13:17.078608|2018-06-01 05:13:17.078608
NCT00077610|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2016-01-29||2016-11-23|2004-02-12|2004-02-13|Estimate|2016-01-29|2016-02-29|Estimate||||2016-11-23|2017-01-13|Estimate|February 2004||2004-02-29|September 2016|2016-09-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional||The safety population included all participants who received at least one dose of RO0503821 or Epoetin, and a safety follow-up, whether withdrawn prematurely or not.|A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients|A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis.|Completed||Phase 3|673|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 05:13:20.662764|2018-06-01 05:13:20.662764
NCT00077662|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2015-05-04|2004-02-11|2004-02-12|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2004||2004-03-31|May 2015|2015-05-31|January 2006|Actual|2006-01-31|May 2005|Actual|2005-05-31||Observational|||A Prospective, Observational Study in Patients With Late-Onset Pompe Disease|A Prospective, Observational Study in Patients With Late-Onset Pompe Disease|Completed|||61|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:13:23.416014|2018-06-01 05:13:23.416014
NCT00077597|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2016-11-01|2004-02-11|2004-02-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2004||2004-02-29|November 2016|2016-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study of Mircera for the Treatment of Anemia in Dialysis Patients|A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease|Completed||Phase 3|182|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:13:23.663817|2018-06-01 05:13:23.663817
NCT00077558|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2010-03-09|2004-02-11|2004-02-12|Estimate|||||||2010-03-09|2010-03-10|Estimate|January 2004||2004-01-31|March 2010|2010-03-31||||||||Interventional|||3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome|A Phase I Trial Of Sequential Administration Of Triapine (3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone) Followed By Fludarabine In Adults With Relapsed And Refractory Leukemias And Myelodysplasias|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:13:24.064184|2018-06-01 05:13:24.064184
NCT00077545|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-10-07|2004-02-11|2004-02-12|Estimate|||||||2013-10-07|2013-10-08|Estimate|January 2004||2004-01-31|October 2013|2013-10-31||||March 2007|Actual|2007-03-31||Interventional|||3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction|A Phase II Study Of Triapine In Combination With Cisplatin Esophageal Carcinoma|Completed||Phase 2|39|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:24.307588|2018-06-01 05:13:24.307588
NCT00077532|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2012-06-21|2004-02-11|2004-02-12|Estimate|||||||2012-06-21|2012-06-22|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|February 2008|Actual|2008-02-29|January 2007|Actual|2007-01-31||Interventional|||Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma|A Study of Intra-Patient Escalating Doses of MDX-010 Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 in the Treatment of Patients With Stage IV Melanoma|Completed||Phase 2|179|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:24.787008|2018-06-01 05:13:24.787008
NCT00077519|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2009-02-06|2004-02-11|2004-02-12|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2004||2004-01-31|April 2007|2007-04-30||||||||Interventional|||Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer|A Phase I Trial of the Farnesyltransferase Inhibitor, R115777 (NSC# 702818) and Radiotherapy in Patients With Locally Advanced Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:13:25.053721|2018-06-01 05:13:25.053721
NCT00074516|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-12|||2017-10-05|2003-12-12|2003-12-15|Estimate|||||||2017-10-05|2017-10-06|Actual|December 10, 2003||2003-12-10|June 11, 2014|2014-06-11|June 11, 2014||2014-06-11|||||Observational|||Kidney Transplantation in Patients With Cystinosis|Renal Transplantation in Recipients With Nephropathic Cystinosis|Completed|||11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:04.258359|2018-06-01 05:15:04.258359
NCT00077493|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2007-12-21|2004-02-11|2004-02-12|Estimate|||||||2007-12-21|2007-12-28|Estimate|January 2004||2004-01-31|December 2007|2007-12-31|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma|Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas|Suspended||Phase 1|95|Anticipated|MedImmune LLC||4||protocol development and Amended protocol revision|f||||f||||||||||2018-06-01 05:13:25.29597|2018-06-01 05:13:25.29597
NCT00077467|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-06-04|2004-02-11|2004-02-12|Estimate|||||||2013-06-04|2013-06-05|Estimate|January 2004||2004-01-31|June 2013|2013-06-30||||March 2006|Actual|2006-03-31||Interventional|||Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia|A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients With Refractory/Recurrent Leukemias|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:25.603484|2018-06-01 05:13:25.603484
NCT00077454|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-06-04|2004-02-11|2004-02-12|Estimate|||||||2013-06-04|2013-06-05|Estimate|February 2004||2004-02-29|June 2013|2013-06-30||||September 2007|Actual|2007-09-30||Interventional|||Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors|Completed||Phase 1|95|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:25.899098|2018-06-01 05:13:25.899098
NCT00077441|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-06-03|2004-02-11|2004-02-12|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2005||2005-04-30|June 2013|2013-06-30||||June 2006|Actual|2006-06-30||Interventional|||Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)|Phase II Trial of PS-341 in Patients With Hepatocellular Carcinoma|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:26.200672|2018-06-01 05:13:26.200672
NCT00077428|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-01-23|2004-02-11|2004-02-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|June 2004||2004-06-30|January 2013|2013-01-31||||June 2007|Actual|2007-06-30||Interventional|||Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck|Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:26.486683|2018-06-01 05:13:26.486683
NCT00077415|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-05-14|2004-02-11|2004-02-12|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 2004||2004-04-30|August 2006|2006-08-31|February 2008|Actual|2008-02-29|January 2008|Actual|2008-01-31||Interventional|||3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer|A Randomized Phase II Study Of Triapine® Alone Versus Triapine and Gemcitabine As Second-Line Treatment Of Advanced Non-Small-Cell-Lung Cancer In Patients Who Had Prior Gemcitabine With Evaluation Of The Effect Of Triapine® On Gemcitabine Pharmacokinetics and Cellular Uptake In Peripheral Mononuclear Cells|Completed||Phase 2|31|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:13:26.794353|2018-06-01 05:13:26.794353
NCT00077402|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-05-14|2004-02-11|2004-02-12|Estimate|||||||2013-05-14|2013-05-15|Estimate|November 2003||2003-11-30|December 2006|2006-12-31|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer|A Phase 2 Study Of Fenretinide In Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:27.051559|2018-06-01 05:13:27.051559
NCT00077389|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2014-06-23|2004-02-11|2004-02-12|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2004||2004-01-31|December 2009|2009-12-31||||||||Interventional|||Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma|Intensified Pre-Operative Chemotherapy And Radical Surgery For High Risk Hepatoblastoma|Unknown status|Active, not recruiting|Phase 2|57|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:27.352943|2018-06-01 05:13:27.352943
NCT00077376|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2011-03-04||2014-05-02|2004-02-11|2004-02-12|Estimate|2011-03-04|2011-04-04|Estimate||||2014-05-02|2014-05-21|Estimate|March 2005||2005-03-31|December 2012|2012-12-31|March 2011|Actual|2011-03-31|March 2009|Actual|2009-03-31||Interventional|||Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer|A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone(BMS-247550) and Carboplatin in Patients With HER2/Neu-Positive Metastatic Breast Cancer|Completed||Phase 2|61|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:27.992867|2018-06-01 05:13:27.992867
NCT00077363|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-02-26|2004-02-11|2004-02-12|Estimate|||||||2013-02-26|2013-02-27|Estimate|May 2004||2004-05-31|February 2013|2013-02-28||||February 2007|Actual|2007-02-28||Interventional|||Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer|A Phase II Trial of Capecitabine in Combination With the Farnesyltransferase Inhibitor, R115777 (Tipifarnib, Zarnestra) in Patients With Metastatic Breast Cancer|Completed||Phase 2|70|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:28.91073|2018-06-01 05:13:28.91073
NCT00077350|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-02-26|2004-02-11|2004-02-12|Estimate|||||||2013-02-26|2013-02-27|Estimate|July 2004||2004-07-31|February 2013|2013-02-28||||April 2005|Actual|2005-04-30||Interventional|||A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer|A Phase II Trial of Triapine® (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer|Completed||Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:29.210185|2018-06-01 05:13:29.210185
NCT00077337|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-06-21|2004-02-11|2004-02-12|Estimate|||||||2013-06-21|2013-06-24|Estimate|April 2004||2004-04-30|November 2005|2005-11-30|April 2006|Actual|2006-04-30|||||Interventional|||FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer|Phase II Trial of Depsipeptide (NSC-630176) in Colorectal Cancer Patients Who Have Received Either One or Two Prior Chemotherapy Regimens for Metastatic or Locally Advanced, Unresectable Disease|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:13:29.544052|2018-06-01 05:13:29.544052
NCT00077324|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2016-07-01|2004-02-11|2004-02-12|Estimate|||||||2016-07-01|2016-07-06|Estimate|February 2004||2004-02-29|July 2016|2016-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions|Use Of Proteomic Analysis Of Serum Samples For Detection Of Non-Small Cell Lung Cancer|Completed|||1000|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 05:13:30.164792|2018-06-01 05:13:30.164792
NCT00076427|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-21|||2017-10-05|2004-01-21|2004-01-22|Estimate|||||||2017-10-05|2017-10-06|Actual|January 14, 2004||2004-01-14|June 9, 2015|2015-06-09|June 9, 2015||2015-06-09|||||Observational|||Leukapheresis for Research on HCV-Coinfected Patients|Evaluation of Clinical, Virologic and Immunologic Factors That Contribute to the Pathogenesis of Chronic Hepatitis C and Its Complications|Completed|||327|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:55.399303|2018-06-01 05:13:55.399303
NCT00077311|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2016-06-28|2004-02-11|2004-02-12|Estimate|||||||2016-06-28|2016-06-30|Estimate|August 2004||2004-08-31|June 2016|2016-06-30|April 2009|Actual|2009-04-30|July 2006|Actual|2006-07-31||Interventional|||Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|160|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:13:30.624231|2018-06-01 05:13:30.624231
NCT00007852|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2012-03-23|2004-02-11|2004-02-12|Estimate|||||||2012-03-23|2012-03-26|Estimate|September 2000||2000-09-30|March 2012|2012-03-31|January 2011|Actual|2011-01-31|January 2002|Actual|2002-01-31||Interventional|||Rituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Lymphoma|Completed||Phase 2|44|Actual|University of Nebraska||1|||f||||f||||||||||2018-06-01 05:13:30.801611|2018-06-01 05:13:30.801611
NCT00006786|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-06-20|2004-02-11|2004-02-12|Estimate|||||||2013-06-20|2013-06-24|Estimate|November 2000||2000-11-30|September 2006|2006-09-30|September 2006|Actual|2006-09-30|||||Interventional|||Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer|Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:30.89881|2018-06-01 05:13:30.89881
NCT00006459|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2012-06-06|2004-02-11|2004-02-12|Estimate|||||||2012-06-06|2012-06-07|Estimate|July 2000||2000-07-31|April 2002|2002-04-30|October 2005|Actual|2005-10-31|||||Interventional|||Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer|Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 3|||Eli Lilly and Company|||||f||||||||||||||2018-06-01 05:13:31.037053|2018-06-01 05:13:31.037053
NCT00006388|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2015-11-14|2004-02-11|2004-02-12|Estimate|||||||2015-11-14|2015-11-17|Estimate|December 2000||2000-12-31|November 2015|2015-11-30||||October 2003|Actual|2003-10-31||Interventional|||Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme|A Phase II Trial of High Dose Tamoxifen For The Treatment of Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM)|Completed||Phase 2|77|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:13:31.310104|2018-06-01 05:13:31.310104
NCT00006375|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-06-17|2004-02-11|2004-02-12|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2000||2000-06-30|June 2013|2013-06-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||LY293111 in Treating Patients With Advanced Solid Tumors|A Phase I Clinical and Pharmacokinetic Evaluation of LY293111 in Patients With Solid Tumors (Protocol H6H-MC-JEAI)|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:31.767945|2018-06-01 05:13:31.767945
NCT00006123|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2018-05-10|2004-02-11|2004-02-12|Estimate|||||||2018-05-10|2018-05-16|Actual|July 2000||2000-07-31|May 2018|2018-05-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer|Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Dana-Farber Cancer Institute||||Never started|f||||||||||||||2018-06-01 05:13:31.830022|2018-06-01 05:13:31.830022
NCT00006047|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-09-25|2004-02-11|2004-02-12|Estimate|||||||2012-09-25|2012-09-26|Estimate|June 2000||2000-06-30|September 2012|2012-09-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide|Phase I Study of Combination Therapy With Oral 9-Nitrocamptothecin and Oral Etoposide|Completed||Phase 1|44|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:13:31.906468|2018-06-01 05:13:31.906468
NCT00006038|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-17|2004-02-11|2004-02-12|Estimate|||||||2013-06-17|2013-06-19|Estimate|February 2000||2000-02-29|June 2013|2013-06-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer|A Phase II Trial of Neoadjuvant Cisplatin-Fluorouracil-Docetaxel Chemotherapy, Surgery, and Intraperitoneal (IP) Floxuridine (FUdR) Plus Leucovorin in Patients With Locally Advanced Gastric Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:31.984307|2018-06-01 05:13:31.984307
NCT00005995|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-03-04|2004-02-11|2004-02-12|Estimate|||||||2013-03-04|2013-03-05|Estimate|October 2000||2000-10-31|February 2008|2008-02-29||||March 2007|Actual|2007-03-31||Interventional|||AE-941 in Treating Patients With Metastatic Kidney Cancer|AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy|Completed||Phase 3|||AEterna Zentaris|||||f||||||||||||||2018-06-01 05:13:32.053522|2018-06-01 05:13:32.053522
NCT00005986|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-11-27|2004-02-11|2004-02-12|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2000||2000-08-31|November 2017|2017-11-30||||September 2004|Actual|2004-09-30||Interventional|||Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia|Autologous Transplantation for Chronic Myelogenous Leukemia Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming|Terminated||Phase 2|||Masonic Cancer Center, University of Minnesota||||Principal investigator left the university.|f||||||||||||||2018-06-01 05:13:32.112497|2018-06-01 05:13:32.112497
NCT00005877|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2004-02-11|2004-02-12|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 1999||1999-09-30|April 2002|2002-04-30||||||||Interventional|||Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer|Phase II and Pharmacokinetic Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Colorectal Cancer Who Have Failed Previous 5-FU Based Chemotherapy|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:32.211801|2018-06-01 05:13:32.211801
NCT00005862|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-02-08|2004-02-11|2004-02-12|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 2000||2000-10-31|April 2002|2002-04-30||||July 2004|Actual|2004-07-31||Interventional|||SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas|A Phase II Trial of SU5416 (NSC #696819) in Previously Treated Patients With Advanced, Metastatic and/or Locally Recurrent Soft Tissue Sarcomas|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:32.273226|2018-06-01 05:13:32.273226
NCT00005610|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2016-07-12|2004-02-11|2004-02-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2000||2000-09-30|July 2016|2016-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung|Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung|Completed||Phase 2|28|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:13:32.364288|2018-06-01 05:13:32.364288
NCT00004919|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-07-01|2004-02-11|2004-02-12|Estimate|||||||2013-07-01|2013-07-02|Estimate|December 1999||1999-12-31|July 2013|2013-07-31||||March 2003|Actual|2003-03-31||Interventional|||Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy|A Trial of Irinotecan and Cisplatin in Children With Refractory Solid Tumors|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:32.458673|2018-06-01 05:13:32.458673
NCT00004889|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2015-09-30|2004-02-11|2004-02-12|Estimate|||||||2015-09-30|2015-10-02|Estimate|December 1999||1999-12-31|July 2012|2012-07-31|July 2005|Actual|2005-07-31|January 2002|Actual|2002-01-31||Interventional|||Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia|Completed||Phase 2|8|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 05:13:32.528606|2018-06-01 05:13:32.528606
NCT00004203|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-09-04|2004-02-11|2004-02-12|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2000||2000-02-29|September 2013|2013-09-30|April 2005|Actual|2005-04-30|February 2002|Actual|2002-02-28||Interventional|||Oxaliplatin in Treating Patients With Metastatic Bladder Cancer|A Phase II Study of Oxaliplatin in Urothelial Cancer|Completed||Phase 2|20|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:13:32.603009|2018-06-01 05:13:32.603009
NCT00004157|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2010-03-31|2004-02-11|2004-02-12|Estimate|||||||2010-03-31|2010-04-02|Estimate|August 2000||2000-08-31|March 2010|2010-03-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors|Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC)|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:13:32.68929|2018-06-01 05:13:32.68929
NCT00004003|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2004-02-11|2004-02-12|Estimate|||||||2013-04-03|2013-04-05|Estimate|April 1999||1999-04-30|April 2013|2013-04-30|August 2003|Actual|2003-08-31|November 2001|Actual|2001-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery|A Study of Gemcitabine, Cisplatin, and 5-Fluorouracil in the Treatment of Advanced Pancreatic Cancer|Completed||Phase 2|30|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:13:32.761755|2018-06-01 05:13:32.761755
NCT00077584|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2016-10-26|2004-02-10|2004-02-11|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2003||2003-10-31|October 2016|2016-10-31|May 2005|Actual|2005-05-31|March 2005|Actual|2005-03-31||Interventional|RAPIDS-2||Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis|Completed||Phase 3|188|Actual|Actelion||2|||f||||||||||||||2018-06-01 05:13:32.820591|2018-06-01 05:13:32.820591
NCT00077298|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2015-04-14|2004-02-10|2004-02-11|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2003||2003-12-31|December 2012|2012-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer|A Randomized Phase II Study of Bevacizumab in Combination With Cetuximab Plus Irinotecan, or in Combination With Cetuximab Alone, in Irinotecan-Refractory Colorectal Cancer|Completed||Phase 2|70|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:13:33.047186|2018-06-01 05:13:33.047186
NCT00077285|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2018-01-29|2004-02-10|2004-02-11|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2003||2003-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma|A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma|Active, not recruiting||Phase 2|65|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:13:33.143335|2018-06-01 05:13:33.143335
NCT00077259|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-01-15|2004-02-10|2004-02-11|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2003||2003-10-31|January 2013|2013-01-31||||September 2004|Actual|2004-09-30||Interventional|||Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer|A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic Colorectal Carcinoma (CRC)|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:33.250545|2018-06-01 05:13:33.250545
NCT00077246|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-11-05|2004-02-10|2004-02-11|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2003||2003-09-30|December 2009|2009-12-31||||October 2008|Actual|2008-10-31||Interventional|||ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer|An Open-Label, Phase I/II Trial Of ABI-007 (A CREMOPHOR® El-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly In Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|64|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:33.304464|2018-06-01 05:13:33.304464
NCT00077233|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2018-05-11|2004-02-10|2004-02-11|Estimate|||||||2018-05-11|2018-05-16|Actual|December 2003||2003-12-31|May 2018|2018-05-31|June 2010|Actual|2010-06-30|December 2006|Actual|2006-12-31||Interventional|||FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum|A Phase II Trial Of Irinotecan /5-FU/ Leucovorin Or Oxaliplatin /5-FU / Leucovorin With And Without Cetuximab (C225) For Patients With Untreated Metastatic Adenocarcinoma Of The Colon or Rectum|Terminated||Phase 3|238|Actual|Alliance for Clinical Trials in Oncology||4||Poor accrual|f||||f||||||||||2018-06-01 05:13:33.387129|2018-06-01 05:13:33.387129
NCT00077220|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2009-02-06|2004-02-10|2004-02-11|Estimate|||||||2009-02-06|2009-02-09|Estimate|June 2002||2002-06-30|May 2007|2007-05-31||||||||Interventional|||Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung Cancer|Phase III Randomised Study Of Adjuvant Paclitaxel And Carboplatin (TAXOL-PARAPLATINE) With Concomittant Radiotherapy In Patients With Stage II or III Non-Metastatic Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:33.694387|2018-06-01 05:13:33.694387
NCT00077207|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2014-01-08||2018-04-16|2004-02-10|2004-02-11|Estimate|2014-06-30|2014-07-02|Estimate||||2018-04-16|2018-05-16|Actual|July 2004||2004-07-31|April 2018|2018-04-30|December 2013|Actual|2013-12-31|March 2010|Actual|2010-03-31||Interventional|||Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma|A Pilot Study Using Carboplatin, Vincristine And Temozolomide For Children ≤ 10 Years With Progressive/Symptomatic Low-Grade Gliomas|Completed||N/A|66|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:13:33.927258|2018-06-01 05:13:33.927258
NCT00077194|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-02-08|2004-02-10|2004-02-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|January 2004||2004-01-31|February 2005|2005-02-28||||December 2005|Actual|2005-12-31||Interventional|||FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study Of Depsipeptide, A Histone Deacetylase Inhibitor, In Relapsed Or Refractory Mantle Cell Or Diffuse Large Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:34.303684|2018-06-01 05:13:34.303684
NCT00077181|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-01-23|2004-02-10|2004-02-11|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2004||2004-01-31|January 2013|2013-01-31||||July 2008|Actual|2008-07-31||Interventional|||3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies|A Phase I Study of Triapine in Combination With High Dose Ara-C (Hi-DAC) in Patients With Advanced Hematologic Malignancies|Completed||Phase 1|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:34.363688|2018-06-01 05:13:34.363688
NCT00077168|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2009-02-06|2004-02-10|2004-02-11|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 2004||2004-04-30|October 2007|2007-10-31||||September 2017|Anticipated|2017-09-30||Interventional|||Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole|Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy|Unknown status|Active, not recruiting|Phase 2|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:34.432283|2018-06-01 05:13:34.432283
NCT00077155|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-01-23|2004-02-10|2004-02-11|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 2003||2003-12-31|January 2013|2013-01-31||||June 2010|Actual|2010-06-30||Interventional|||Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study Of Continuous Infusion EMD 121974 In Patients With Solid Tumors|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:34.516249|2018-06-01 05:13:34.516249
NCT00077142|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2012-07-27|2004-02-10|2004-02-11|Estimate|||||||2012-07-27|2012-07-30|Estimate|April 2001||2001-04-30|July 2012|2012-07-31|August 2005|Actual|2005-08-31|July 2005|Actual|2005-07-31||Interventional|||TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)|Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|37|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:13:34.589654|2018-06-01 05:13:34.589654
NCT00077129|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2010-01-26|2004-02-10|2004-02-11|Estimate|||||||2010-01-26|2010-01-28|Estimate|September 2004||2004-09-30|January 2010|2010-01-31||||August 2006|Actual|2006-08-31||Interventional|||Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer|Phase II Trial Of Paclitaxel Plus Carboplatin In Patients With Metastatic Or Locally Advanced Collecting Duct Renal Cell Cancer|Completed||Phase 2|22|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:13:34.662386|2018-06-01 05:13:34.662386
NCT00077116|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2012-07-13|2004-02-10|2004-02-11|Estimate|||||||2012-07-13|2012-07-16|Estimate|November 2003||2003-11-30|July 2012|2012-07-31||||November 2006|Actual|2006-11-30||Interventional|||Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome|Idarubicin and Ara-C in Combination With Gemtuzumab-Ozogamicin (IAGO) for Young Untreated Patients, Without an HLA Identical Sibling, With High Risk MDS or AML Developing After a Preceding Period With MDS During 6 Months Duration: A Phase II Study|Completed||Phase 2|31|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:34.893832|2018-06-01 05:13:34.893832
NCT00077103|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2010-06-09|2004-02-10|2004-02-11|Estimate|||||||2010-06-09|2010-06-11|Estimate|November 2003||2003-11-30|June 2010|2010-06-30|December 2007|Actual|2007-12-31|February 2007|Actual|2007-02-28||Interventional|||Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer|Phase II Trial of Combined Modality Combretastatin A-4 Phosphate (CA4P)-Based Therapy for Patients With Newly Diagnosed Anaplastic Thyroid Cancer [Induction Chemotherapy With Doxorubicin/Cisplatin; Combined Modality Therapy With CA4P and Radiation; Followed by 2 Cycles of CA4P Consolidation]|Terminated||Phase 1/Phase 2|4|Actual|Case Comprehensive Cancer Center||||slow accrual|f||||t||||||||||2018-06-01 05:13:34.99661|2018-06-01 05:13:34.99661
NCT00077090|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2013-12-17|2004-02-10|2004-02-11|Estimate|||||||2013-12-17|2013-12-18|Estimate|April 2004||2004-04-30|September 2007|2007-09-30||||||||Interventional|||Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Patients Who Have Undergone Radiation Therapy for Cancer|Randomized Phase II Trial Of Hyperbaric Oxygen Therapy In Patients With Chronic Arm Lymphoedema After Radiotherapy For Cancer|Unknown status|Active, not recruiting|Phase 2|63|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:35.078341|2018-06-01 05:13:35.078341
NCT00077077|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2012-05-15|2004-02-10|2004-02-11|Estimate|||||||2012-05-15|2012-05-16|Estimate|February 2004||2004-02-29|May 2012|2012-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Study Of The Combination Of Oral DJ-927 And Capecitabine In Patients With Advanced Solid Tumors|Completed||Phase 1|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:13:35.210017|2018-06-01 05:13:35.210017
NCT00077064|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|2016-06-16||2018-02-06|2004-02-10|2004-02-11|Estimate|2018-02-06|2018-03-08|Actual||||2018-02-06|2018-03-08|Actual|June 2003||2003-06-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|November 2008|Actual|2008-11-30||Interventional||Randomized eligible patients.|Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy|A Phase II Randomized Trial With Captopril In Patients Who Have Received Radiation Therapy +/- Chemotherapy For Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, Or Limited-Stage Small-Cell Lung Cancer|Terminated||Phase 2|81|Actual|Radiation Therapy Oncology Group|The study stopped accrual early due to unmet accrual/randomization goals: 81 accrued of 205 planned, 33 randomized of 168 planned. Statistical testing of primary outcome measure not done due to low power.|2||Due to unmet accrual/randomization goals|f||||t||||||||||2018-06-01 05:13:35.400605|2018-06-01 05:13:35.400605
NCT00077051|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-10|||2016-12-14|2004-02-10|2004-02-11|Estimate|||||||2016-12-14|2016-12-15|Estimate|April 2004||2004-04-30|December 2016|2016-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)|Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With a Fixed Dose of Cisplatin Concomitant With Definitive Radiation in Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity and Oropharynx|Completed||Phase 1|1|Actual|University of Miami||1|||f||||||||||||||2018-06-01 05:13:36.716627|2018-06-01 05:13:36.716627
NCT00077025|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-09|||2014-07-15|2004-02-10|2004-02-11|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2004||2004-01-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer|Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer|Completed||Phase 2|174|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-06-01 05:13:36.802612|2018-06-01 05:13:36.802612
NCT00077012|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-09|||2012-05-22|2004-02-10|2004-02-11|Estimate|||||||2012-05-22|2012-05-23|Estimate|March 2003||2003-03-31|May 2012|2012-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia|A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Transurethral Photodynamic Therapy With QLT0074 for Benign Prostatic Hyperplasia|Completed||Phase 1/Phase 2|||QLT Inc.|||||f||||||||||||||2018-06-01 05:13:36.926202|2018-06-01 05:13:36.926202
NCT00077038|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-09|||2017-06-30|2004-02-09|2004-02-10|Estimate|||||||2017-06-30|2017-07-02|Actual|February 6, 2004||2004-02-06|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Observational|||Brain Activity in Visual-Motor Behavior|Modulation of the Visual Information Processing in the Human Parieto-Frontal Network as Studied by a Frequency Tagging Technique During Visuomotor Tracking|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:36.983039|2018-06-01 05:13:36.983039
NCT00076999|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-09|2011-06-27||2014-04-25|2004-02-09|2004-02-10|Estimate|2011-06-27|2011-07-25|Estimate||||2014-04-25|2014-05-12|Estimate|November 2003||2003-11-30|April 2014|2014-04-30||||June 2010|Actual|2010-06-30||Interventional|||Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children|Multiple-dose, Open-label, Randomized, Safety and Pharmacokinetic Study of Tipranavir in Combination With Low-dose Ritonavir in HIV-infected Pediatric Patients|Completed||Phase 1|115|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 05:13:37.149175|2018-06-01 05:13:37.149175
NCT00076986|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-06|||2011-06-02|2004-02-09|2004-02-10|Estimate|||||||2011-06-02|2011-06-06|Estimate|February 2004||2004-02-29|June 2011|2011-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme|PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence|Completed||Phase 3|300||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:13:39.57019|2018-06-01 05:13:39.57019
NCT00076960|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-06|||2016-12-12|2004-02-09|2004-02-10|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2003||2003-10-31|January 2016|2016-01-31||||July 2017|Anticipated|2017-07-31||Expanded Access|||Compassionate Use of Stanate (TM) [Stannsoporfin]|Compassionate Use of Stannsoporfin as an Adjuvant to Phototherapy to Reduce the Need for Exchange Transfusions|No longer available|||||InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company|||||||||||||||||||2018-06-01 05:13:39.745522|2018-06-01 05:13:39.745522
NCT00076947|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-06|||2008-03-20|2004-02-06|2004-02-09|Estimate|||||||2008-03-20|2008-03-21|Estimate|August 2003||2003-08-31|March 2005|2005-03-31||||||||Interventional|||Safety of the EnvPro HIV Vaccine in Healthy Volunteers|Evaluation of Tolerability and Safety of a Recombinant Purified HIV Envelope Vaccine|Completed||Phase 1|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:13:39.807027|2018-06-01 05:13:39.807027
NCT00076934|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-06|||2017-03-23|2004-02-06|2004-02-09|Estimate|||||||2017-03-23|2017-03-27|Actual|January 2003||2003-01-31|March 2017|2017-03-31|February 2006|Actual|2006-02-28|||||Interventional|||Safety of RG2077 in Patients With Multiple Sclerosis|A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in: 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal.|2018-06-01 05:13:39.863405|2018-06-01 05:13:39.863405
NCT00076921|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-06|||2013-04-08|2004-02-06|2004-02-09|Estimate|||||||2013-04-08|2013-04-10|Estimate|September 2002||2002-09-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Epidemiology & Intervention Research for Tobacco Control|Research on China Tobacco Control Epidemiology and Intervention|Completed|||15705|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||None Retained|"~     No bio-specimens collected. Sampled nicotine from buildings only.~   "|||2018-06-01 05:13:40.031165|2018-06-01 05:13:40.031165
NCT00003937|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-04|2004-02-06|2004-02-09|Estimate|||||||2014-08-04|2014-08-05|Estimate|September 1999||1999-09-30|August 2014|2014-08-31|June 2008|Actual|2008-06-30|March 2004|Actual|2004-03-31||Interventional|||Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma|Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study|Completed||Phase 3|253|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 05:13:40.113281|2018-06-01 05:13:40.113281
NCT00003923|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-01|2004-02-06|2004-02-09|Estimate|||||||2013-03-01|2013-03-04|Estimate|March 1999||1999-03-31|March 2013|2013-03-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas|Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction|Completed||Phase 2|4|Actual|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:40.388389|2018-06-01 05:13:40.388389
NCT00003721|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-27|2004-02-06|2004-02-09|Estimate|||||||2012-06-27|2012-06-29|Estimate|November 1998||1998-11-30|June 2012|2012-06-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I, Pharmacologic and Biologic Study of Col-3 (NSC683551) Administered on a 28-Day Oral Dosing Schedule in Patients With Advanced Solid Tumors|Completed||Phase 1|33|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:13:40.450528|2018-06-01 05:13:40.450528
NCT00003665|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-27|2004-02-06|2004-02-09|Estimate|||||||2013-02-27|2013-02-28|Estimate|April 1999||1999-04-30|February 2013|2013-02-28|November 2002|Actual|2002-11-30|October 2002|Actual|2002-10-31||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Melanoma|Phase I Trial of a Dendritic Cell Vaccine for Melanoma|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:13:40.659874|2018-06-01 05:13:40.659874
NCT00003616|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-12-13|2004-02-06|2004-02-09|Estimate|||||||2008-12-13|2008-12-16|Estimate|September 1998||1998-09-30|May 2006|2006-05-31||||||||Interventional|||Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma|Phase I/II Trial of Irinotecan (CPT-11) in Patients With Recurrent Malignant Glioma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:40.734826|2018-06-01 05:13:40.734826
NCT00003367|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2004-02-06|2004-02-09|Estimate|||||||2013-06-24|2013-06-26|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Diet and PSA Levels in Patients With Prostate Cancer|The Effect of a Low Fat Diet, High in Soy, Fruits, Vegetables, Green Tea, Vitamin E and Fiber on the PSA in Patients With Prostate Cancer|Completed||Phase 3|154|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:40.960088|2018-06-01 05:13:40.960088
NCT00003334|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-03-10|2004-02-06|2004-02-09|Estimate|||||||2016-03-10|2016-03-11|Estimate|March 1997||1997-03-31|March 2016|2016-03-31||||December 2001|Actual|2001-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract|Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:13:41.031075|2018-06-01 05:13:41.031075
NCT00003222|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-01-22||2014-12-18|2004-02-06|2004-02-09|Estimate|2014-12-18|2014-12-19|Estimate||||2014-12-18|2014-12-19|Estimate|April 1998||1998-04-30|December 2014|2014-12-31||||September 2003|Actual|2003-09-30||Interventional|||Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma|Phase II Trial for the Evaluation of the Efficacy of Vaccination With Synthetic Melanoma Peptides Either Pulsed on Dendritic Cells, or Administered With GM-CSF-in-Adjuvant, Plus Administration of Sustemic IL-2, in Patients With Advanced Melanoma.|Completed||Phase 2|40|Actual|University of Virginia||2|||f||||t||||||||||2018-06-01 05:13:41.251881|2018-06-01 05:13:41.251881
NCT00003185|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2004-02-06|2004-02-09|Estimate|||||||2013-12-03|2013-12-04|Estimate|August 1997||1997-08-31|December 2008|2008-12-31|July 1998|Actual|1998-07-31|||||Interventional|||Biological Therapy in Treating Patients With Glioblastoma Multiforme|Adoptive Immunotherapy of Glioblastoma Multiforme With Tumor-Sensitized, Ex Vivo Activated T Lymphocytes|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:43.034597|2018-06-01 05:13:43.034597
NCT00003108|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2004-02-06|2004-02-09|Estimate|||||||2013-07-17|2013-07-18|Estimate|October 1997||1997-10-31|July 2004|2004-07-31|October 2007|Actual|2007-10-31|||||Interventional|||Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer|A Phase I Study of Bryostatin and Cisplatin in Patients With Advanced Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:43.560545|2018-06-01 05:13:43.560545
NCT00003086|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2004-02-06|2004-02-09|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1997||1997-03-31|December 2006|2006-12-31||||||||Interventional|||Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer|Phase I/II Study of Samarium 153 as Part of a Double (Sequential) Autologous Bone Marrow Transplant (ABMT) for Patients With Stage IV Breast Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:43.669457|2018-06-01 05:13:43.669457
NCT00076869|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-05|||2015-01-12|2004-02-05|2004-02-06|Estimate|||||||2015-01-12|2015-01-13|Estimate|January 2003||2003-01-31|January 2015|2015-01-31|August 2005|Actual|2005-08-31|September 2004|Actual|2004-09-30||Interventional|||MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)|A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of MK0991 in Combination With Amphotericin B, Lipid Formulations of Amphotericin B, or Azoles in the Treatment of Invasive Aspergillus Infection in Adults Who Are Refractory to or Intolerant of Standard Therapy|Completed||Phase 2|55|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:13:43.757429|2018-06-01 05:13:43.757429
NCT00076856|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-04|||2017-05-08|2004-02-05|2004-02-06|Estimate|||||||2017-05-08|2017-05-09|Actual|March 31, 2004|Actual|2004-03-31|May 2017|2017-05-31|March 31, 2006|Actual|2006-03-31|March 31, 2006|Actual|2006-03-31||Interventional|||Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)|A Randomized, Open-Label Phase 2 Study of Temozolomide Added to Whole Brain Radiation Therapy Versus Whole Brain Radiation Therapy Alone for the Treatment of Brain Metastasis From Non-Small Cell Lung Cancer|Completed||Phase 2|95|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:13:43.959408|2018-06-01 05:13:43.959408
NCT00076817|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-03|||2012-10-26|2004-02-05|2004-02-06|Estimate|||||||2012-10-26|2012-10-29|Estimate|June 2006||2006-06-30|October 2012|2012-10-31|September 2008|Actual|2008-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm|A Phase I Double Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of the Aventis Pasteur ALVAC-HIV (vCP205) Administered to the Groin Area Versus the Deltoid Area|Completed||Phase 1|18|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:13:44.049367|2018-06-01 05:13:44.049367
NCT00076804|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-03|2010-06-01||2015-03-09|2004-02-05|2004-02-06|Estimate|2010-06-01|2010-07-02|Estimate||||2015-03-09|2015-03-27|Estimate|February 2005||2005-02-28|March 2015|2015-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Helping HIV Infected Patients in South Africa Adhere to Drug Regimens|DOT-HAART for HIV-Infected South African Adults|Terminated||Phase 2|274|Actual|Johns Hopkins University|Intervention was stopped at 12 months, transition phase did not ensure that participants developed a set of adherence strategies to replace DOT-ART. Low incidence of AIDS-defining illness and death limit our ability to make final conclusions|2||DSMB stopped trial for futility|f||||t||||||||||2018-06-01 05:13:44.128338|2018-06-01 05:13:44.128338
NCT00076791|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-03|||2013-07-05|2004-02-05|2004-02-06|Estimate|||||||2013-07-05|2013-07-09|Estimate|March 2004||2004-03-31|July 2013|2013-07-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants|A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants|Completed||Phase 1|66|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:13:44.595559|2018-06-01 05:13:44.595559
NCT00033592|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2016-07-12|2004-02-05|2004-02-06|Estimate|||||||2016-07-12|2016-07-13|Estimate|February 2002||2002-02-28|July 2016|2016-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking|Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention|Completed||Phase 3|1708|Actual|Alliance for Clinical Trials in Oncology||15|||f||||f||||||||||2018-06-01 05:13:45.004053|2018-06-01 05:13:45.004053
NCT00026377|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-09-04|2004-02-05|2004-02-06|Estimate|||||||2013-09-04|2013-09-05|Estimate|November 2001||2001-11-30|September 2013|2013-09-30|April 2003|Actual|2003-04-30|March 2002|Actual|2002-03-31||Interventional|||SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer|A Phase I Study Of SU5416 With Androgen Ablation And Radiation In Patients With Intermediate and Advanced Stage Prostate Cancer|Completed||Phase 1|3|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:13:45.187275|2018-06-01 05:13:45.187275
NCT00024362|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2008-07-23|2004-02-05|2004-02-06|Estimate|||||||2008-07-23|2008-07-24|Estimate|May 2001||2001-05-31|April 2007|2007-04-30||||||||Interventional|||BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery|A Phase II Trial of BBR 3464 as First Line Treatment in Patients With Inoperable, Locally Advanced or Metastatic Adenocarcinoma of the Pancreas|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:45.262259|2018-06-01 05:13:45.262259
NCT00024011|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-01-15|2004-02-05|2004-02-06|Estimate|||||||2013-01-15|2013-01-16|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||September 2006|Actual|2006-09-30||Interventional|||PS-341 in Treating Patients With Metastatic Malignant Melanoma|A Phase II Study of PS-341 in the Treatment of Metastatic Malignant Melanoma|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:45.397064|2018-06-01 05:13:45.397064
NCT00003320|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-28|2004-02-05|2004-02-06|Estimate|||||||2015-10-28|2015-10-30|Estimate|March 1997||1997-03-31|July 2012|2012-07-31||||August 2006|Actual|2006-08-31||Interventional|||Radiation Therapy Following Surgery to Remove Brain Metastases|Pilot Study of Adjuvant Fractionated Stereotactic Radiotherapy Following Surgical Removal of Cerebral Metastases|Completed||N/A|20|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:13:45.469044|2018-06-01 05:13:45.469044
NCT00003073|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-22|2004-02-05|2004-02-06|Estimate|||||||2010-03-22|2010-03-23|Estimate|February 1997||1997-02-28|April 2002|2002-04-30||||||||Interventional|||Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors|A Phase I Dose Escalation Study of Intrathecal DepoFoam Encapsulated Cytarabine (DTC 101) in Pediatric Patients With Advanced Meningeal Malignancies|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:45.601131|2018-06-01 05:13:45.601131
NCT00002801|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-02-05|2004-02-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|April 1996||1996-04-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2003|Actual|2003-12-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Colorectal Cancer|PHASE I TRIAL OF POST-OPERATIVE COMBINED ORAL UFT PLUS LEUCOVORIN AND RADIATION THERAPY FOR RECTAL CANCER|Completed||Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:45.682299|2018-06-01 05:13:45.682299
NCT00002679|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-08-24|2004-02-05|2004-02-06|Estimate|||||||2009-08-24|2009-08-26|Estimate|February 1994||1994-02-28|August 2009|2009-08-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer|Sequential Adjuvant Chemotherapy With Doxorubicin, Taxol, and Cyclophosphamide for Stage II or III Resectable Breast Cancer With Four or More Involved Axillary Lymph Nodes|Completed||Phase 2|89|Actual|Yale University|||||f||||f||||||||||2018-06-01 05:13:45.741487|2018-06-01 05:13:45.741487
NCT00076843|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2018-03-27|2004-02-03|2004-02-04|Estimate|||||||2018-03-27|2018-03-29|Actual|February 3, 2004||2004-02-03|February 9, 2018|2018-02-09|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis|Phase I/II Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:45.883854|2018-06-01 05:13:45.883854
NCT00076830|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2018-05-22|2004-02-03|2004-02-04|Estimate|||||||2018-05-22|2018-05-23|Actual|February 3, 2004||2004-02-03|May 12, 2018|2018-05-12||||||||Observational|||Evaluation and Treatment of Patients With Connective Tissue Disease|Screening and Diagnosis of Patients With Connective Tissue Disorders|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:45.956482|2018-06-01 05:13:45.956482
NCT00076726|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-02|||2011-05-16|2004-02-03|2004-02-04|Estimate|||||||2011-05-16|2011-05-17|Estimate|November 2003||2003-11-30|April 2010|2010-04-30|July 2005|Actual|2005-07-31|||||Interventional|||A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis|A Randomized, Double-Masked, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Infliximab in Subjects With Giant Cell Arteritis|Terminated||Phase 2|44|Actual|Centocor, Inc.||||"Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative~   glucocorticosteroid dosage"|||||t||||||||||2018-06-01 05:13:46.046449|2018-06-01 05:13:46.046449
NCT00076544|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-26|||2015-12-10|2004-02-03|2004-02-04|Estimate|||||||2015-12-10|2015-12-14|Estimate|February 2004||2004-02-29|December 2015|2015-12-31||||March 2005|Actual|2005-03-31||Interventional|||Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain|An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain|Completed||Phase 3|300||Elan Pharmaceuticals|||||||||||||||||||2018-06-01 05:13:46.118574|2018-06-01 05:13:46.118574
NCT00076518|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-26|||2012-05-17|2004-02-03|2004-02-04|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|September 2005|Actual|2005-09-30|||||Interventional|||The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)|A Phase II Trial of the Effect of Combination Therapy With Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) Who Are Not Responding to Either Fish Oil or Fenofibrate Alone|Completed||Phase 2|100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:13:46.278213|2018-06-01 05:13:46.278213
NCT00022373|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2014-10-14|2004-02-03|2004-02-04|Estimate|||||||2014-10-14|2014-10-15|Estimate|December 2000||2000-12-31|November 2001|2001-11-30||||||||Interventional|||Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer|A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:46.361927|2018-06-01 05:13:46.361927
NCT00022243|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2014-01-03|2004-02-03|2004-02-04|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2000||2000-10-31|May 2002|2002-05-31||||||||Interventional|||T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy|A Phase II, Open Label Study Of T138067-Sodium In A Second-Line Setting In Non-Small-Cell Lung Cancer Patients With Locally Advanced Or Metastatic Disease Who Have Failed First-Line Therapy With a Taxane|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:46.418497|2018-06-01 05:13:46.418497
NCT00022204|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-11-05|2004-02-03|2004-02-04|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 2000||2000-01-31|May 2007|2007-05-31||||||||Interventional|||Vitamin E and Pentoxifylline in Treating Women With Lymphedema After Radiation Therapy for Breast Cancer|Double-Blind, Placebo-Controlled, Randomised Trial Of Alpha-Tocopherol And Oxpentifylline In Patients With Radiation Fibrosis|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:46.470735|2018-06-01 05:13:46.470735
NCT00021385|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-12-17|2004-02-03|2004-02-04|Estimate|||||||2013-12-17|2013-12-18|Estimate|May 2001||2001-05-31|May 2002|2002-05-31||||||||Interventional|||Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer|A Phase IIA Trial of Continuous Five Day Infusions of MSI-1256F (Squalamine Lactate) Plus Carboplatin for Therapy of Refractory and Resistant Stage III and IV Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:46.529269|2018-06-01 05:13:46.529269
NCT00020696|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-01-07|2004-02-03|2004-02-04|Estimate|||||||2012-01-07|2012-01-10|Estimate|June 2001||2001-06-30|March 2008|2008-03-31||||April 2006|Actual|2006-04-30||Interventional|||Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation of Tirapazamine (NSC #130181, IND #46,525) in Combination With Cisplatin in Recurrent Platinum Sensitive Ovarian or Primary Peritoneal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:46.589749|2018-06-01 05:13:46.589749
NCT00017407|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2009-02-06|2004-02-03|2004-02-04|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 2000||2000-10-31|December 2006|2006-12-31||||||||Interventional|||Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer|A Prospective, Randomized, Open-Label, Phase III Trial of Chemotherapy With Carboplatin And Paclitaxel, Versus Carboplatin And Paclitaxel In Combination With ISIS-3521, An Antisense Inhibitor Of Protein Kinase C Alpha In Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:46.723319|2018-06-01 05:13:46.723319
NCT00014105|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-12-03|2004-02-03|2004-02-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|December 2000||2000-12-31|May 2002|2002-05-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I/II Trial of Temozolomide and Carboplatin in Recurrent Glioblastoma Multiforme|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:46.781816|2018-06-01 05:13:46.781816
NCT00014066|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-02-04|2004-02-03|2004-02-04|Estimate|||||||2013-02-04|2013-02-05|Estimate|March 1993||1993-03-31|February 2013|2013-02-28||||February 2004|Actual|2004-02-29||Interventional|||Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer|A Phase I Study of Photodynamic Therapy (PDT) Combined With High Dose Rate (HDR) Brachytherapy for Patients With Obstructive Bronchogenic Carcinoma|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:13:46.833641|2018-06-01 05:13:46.833641
NCT00010244|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2011-02-18|2004-02-03|2004-02-04|Estimate|||||||2011-02-18|2011-02-21|Estimate|September 1999||1999-09-30|January 2011|2011-01-31||||||||Interventional|||Comparison of Radiation Therapy Regimens in Treating Patients With Localized Prostate Cancer|Conformational, Curative Ratiotherapy For Prostate Cancer (NO, N-): Phase III Multicenter Study Of The Contribution To Survival Without Clinical Or Biological Change With A Dose Variation Of 15% (80 Gy VS 70 Gy)|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:47.111697|2018-06-01 05:13:47.111697
NCT00076752|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-02|2014-03-25||2017-04-09|2004-02-02|2004-02-03|Estimate|2014-05-09|2014-06-10|Estimate||||2017-04-09|2017-05-02|Actual|January 30, 2004||2004-01-30|April 2017|2017-04-30|October 15, 2013|Actual|2013-10-15|October 15, 2013|Actual|2013-10-15||Interventional|||Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus|A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus|Completed||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||No||2018-06-01 05:13:47.247788|2018-06-01 05:13:47.247788
NCT00076739|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-02|||2017-06-30|2004-02-02|2004-02-03|Estimate|||||||2017-06-30|2017-07-02|Actual|February 2, 2004||2004-02-02|December 12, 2011|2011-12-12|December 12, 2011||2011-12-12|||||Observational|||Study of Brain Function During Cognitive Tasks|Examining Associative Relations in Structured Event Complexes Using Functional Neuroimaging|Completed|||452|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:47.911178|2018-06-01 05:13:47.911178
NCT00076713|ClinicalTrials.gov processed this data on May 31, 2018|2004-02-02|||2013-02-11|2004-02-02|2004-02-03|Estimate|||||||2013-02-11|2013-02-12|Estimate|April 2000||2000-04-30|February 2013|2013-02-28|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|APSCORE||Antiphospholipid Syndrome Collaborative Registry (APSCORE)|Antiphospholipid Syndrome Collaborative Registry (APSCORE)|Completed|||860|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     Serum, plasma, genomic DNA~   "|||2018-06-01 05:13:47.979532|2018-06-01 05:13:47.979532
NCT00009997|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2011-03-25|2004-02-02|2004-02-03|Estimate|||||||2011-03-25|2011-03-28|Estimate|March 1999||1999-03-31|March 2011|2011-03-31||||January 2004|Actual|2004-01-31||Interventional|||Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer|Herceptin and Paclitaxel in Locally Advanced Breast Cancer With Her-2 Overexpression|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:13:48.058672|2018-06-01 05:13:48.058672
NCT00009958|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-05-15|2004-02-02|2004-02-03|Estimate|||||||2013-05-15|2013-05-16|Estimate|November 2000||2000-11-30|May 2013|2013-05-31||||April 2010|Actual|2010-04-30||Interventional|||Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer|A Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM (B7.1/ICAM/LFA-3) Alone, and in Combination With Vaccinia-CEA(6D)-TRICOM, and the Role of GM-CSF, in Patients With CEA Expressing Carcinomas|Terminated||Phase 1|42|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:13:48.123871|2018-06-01 05:13:48.123871
NCT00009906|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2014-12-19|2004-02-02|2004-02-03|Estimate|||||||2014-12-19|2014-12-23|Estimate|December 2000||2000-12-31|June 2014|2014-06-30|November 2014|Actual|2014-11-30|May 2007|Actual|2007-05-31||Interventional|||Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor|Phase III Randomized, Intergroup Trial Assessing the Clinical Activity Of STI-571 at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the Kit Receptor Tyrosine Kinase (CD117)|Terminated||Phase 3|748|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:13:48.23766|2018-06-01 05:13:48.23766
NCT00008333|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2016-07-12|2004-02-02|2004-02-03|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2001||2001-04-30|July 2016|2016-07-31|July 2007|Actual|2007-07-31|March 2004|Actual|2004-03-31||Interventional|||Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Oral Vinorelbine For The Treatment Of Metastatic Non-Small Cell Lung Cancer In Patients More Than Or Equal To 65 Years Of Age: A Phase II Trial of Efficacy and Patients Perceived Preference for Oral Therapy|Completed||Phase 2|59|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:13:48.473359|2018-06-01 05:13:48.473359
NCT00076414|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-21|||2008-03-03|2004-01-21|2004-01-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2004||2004-01-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||The Effect of Lopinavir/Ritonavir on Endothelial Function|The Effect of Lopinavir/Ritonavir on Endothelial Function in Normal Volunteers|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:55.465987|2018-06-01 05:13:55.465987
NCT00008034|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2012-07-17|2004-02-02|2004-02-03|Estimate|||||||2012-07-17|2012-07-18|Estimate|February 2000||2000-02-29|July 2012|2012-07-31||||December 2000|Actual|2000-12-31||Interventional|||Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer|A Phase I Study Of Cyclophoshamide And Epirubicin In Combination With Capecitabine (XELODA) (CEX) As Primary Treatment Of Locally Advanced/Inflammatory Or Large Operable Breast Cancer|Completed||Phase 1|15|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:48.549242|2018-06-01 05:13:48.549242
NCT00006460|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-12-03|2004-02-02|2004-02-03|Estimate|||||||2013-12-03|2013-12-04|Estimate|August 2000||2000-08-31|May 2002|2002-05-31||||||||Interventional|||Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:48.597808|2018-06-01 05:13:48.597808
NCT00006454|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2015-12-22|2004-02-02|2004-02-03|Estimate|||||||2015-12-22|2015-12-23|Estimate|December 1999||1999-12-31|December 2015|2015-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer|Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan|Completed||Phase 3|||AGO Study Group|||||f||||t||||||||||2018-06-01 05:13:48.645089|2018-06-01 05:13:48.645089
NCT00006111|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2009-02-06|2004-02-02|2004-02-03|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 1999||1999-04-30|May 2002|2002-05-31||||||||Interventional|||Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract|Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:48.750367|2018-06-01 05:13:48.750367
NCT00076700|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-31|||2008-03-03|2004-01-31|2004-02-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2004||2004-01-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Enhanced Tactile Memory in the Blind|Enhanced Tactile Memory in the Blind|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:48.823796|2018-06-01 05:13:48.823796
NCT00006050|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2009-02-06|2004-01-30|2004-02-02|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 1999||1999-01-31|September 2005|2005-09-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver|Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:48.876419|2018-06-01 05:13:48.876419
NCT00005881|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-08-22|2004-01-30|2004-02-02|Estimate|||||||2013-08-22|2013-08-23|Estimate|April 2000||2000-04-30|August 2013|2013-08-31|September 2006|Actual|2006-09-30|March 2003|Actual|2003-03-31||Observational|||Quality of Life in Children Treated for Cancer|Assessment of Health/Quality of Life in Survivors of Childhood Cancer|Completed|||538|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-06-01 05:13:49.060421|2018-06-01 05:13:49.060421
NCT00005792|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2018-03-27|2004-01-30|2004-02-02|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2, 1998|Actual|1998-06-02|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|July 1, 2006|Actual|2006-07-01||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Study of Intensive-Dose Melphalan, Topotecan, and VP-16 Phosphate (MTV) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma|Active, not recruiting||Phase 1|131|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:13:49.158912|2018-06-01 05:13:49.158912
NCT00005064|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-01-22|2004-01-30|2004-02-02|Estimate|||||||2013-01-22|2013-01-23|Estimate|February 2000||2000-02-29|January 2013|2013-01-31||||October 2002|Actual|2002-10-31||Interventional|||PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome|Phase I Study of PS-341 in Acute Myeloid Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:49.240031|2018-06-01 05:13:49.240031
NCT00076648|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-28|||2006-07-31|2004-01-29|2004-01-30|Estimate|||||||2006-07-31|2006-08-02|Estimate||||July 2006|2006-07-31||||||||Interventional|||Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting|A Phase III, Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception From Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection [Polymerized Human Hemoglobin (Pyridoxylated), PolyHeme(R)] When Used to Treat Patients in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Prehospital Setting|Unknown status|Active, not recruiting|Phase 3|||Northfield Laboratories|||||||||||||||||||2018-06-01 05:13:49.350171|2018-06-01 05:13:49.350171
NCT00076635|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-28|||2007-11-02|2004-01-29|2004-01-30|Estimate|||||||2007-11-02|2007-11-06|Estimate|November 2003||2003-11-30|November 2007|2007-11-30|April 2007|Actual|2007-04-30|||||Interventional|||An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF|An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis|Terminated||Phase 3|91|Actual|InterMune||||program discontinued based on GIPF-007 results|f||||f||||||||||2018-06-01 05:13:49.435857|2018-06-01 05:13:49.435857
NCT00076674|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-28|||2016-09-21|2004-01-28|2004-01-29|Estimate|||||||2016-09-21|2016-09-22|Estimate|January 2004||2004-01-31|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Levetiracetam Treatment of L-dopa Induced Dyskinesias|Levetiracetam Treatment of L-dopa Induced Dyskinesias|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:49.559387|2018-06-01 05:13:49.559387
NCT00076622|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-28|2017-03-28||2018-01-02|2004-01-28|2004-01-29|Estimate|2018-01-02|2018-01-31|Actual||||2018-01-02|2018-01-31|Actual|November 2003||2003-11-30|January 2018|2018-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Medication Treatment for Depression in Nursing Home Residents|Drug Treatment of Depression in the Nursing Home Aged|Completed|||94|Actual|University of Pennsylvania|Based on an a priori sample size calculation of 160 subjects needed, it is likely that the final sample (N=94) was insufficient to detect a significant difference on the primary outcome measures in the intent-to-treat analyses.||4||f||||f||||||||||2018-06-01 05:13:49.639954|2018-06-01 05:13:49.639954
NCT00005022|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-10-31|2004-01-28|2004-01-29|Estimate|||||||2013-10-31|2013-11-04|Estimate|February 1998||1998-02-28|October 2013|2013-10-31|June 2010|Actual|2010-06-30|October 2002|Actual|2002-10-31||Interventional|||Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer|A Phase I/II Escalation Study of Thoracic Irradiation With Concurrent Chemotherapy for Patients With Limited Small Cell Lung Cancer|Completed||Phase 1|64|Actual|Radiation Therapy Oncology Group||6|||f||||t||||||||||2018-06-01 05:13:50.50783|2018-06-01 05:13:50.50783
NCT00004862|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-01-31|2004-01-28|2004-01-29|Estimate|||||||2013-01-31|2013-02-01|Estimate|October 1999||1999-10-31|May 2002|2002-05-31||||December 2001|Actual|2001-12-31||Interventional|||Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I Study of G3139 (NSC 683428) in Combination With Salvage Chemotherapy for Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:13:50.983743|2018-06-01 05:13:50.983743
NCT00004239|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2016-07-01|2004-01-28|2004-01-29|Estimate|||||||2016-07-01|2016-07-04|Estimate|December 1999||1999-12-31|July 2016|2016-07-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment|A Phase I Study of Compound 506U78 (NSC #686673) in Patients With Hematologic Malignancies and Renal or Hepatic Impairment|Terminated||Phase 1|10|Actual|Alliance for Clinical Trials in Oncology||1||poor accrual|f||||f||||||||||2018-06-01 05:13:51.085304|2018-06-01 05:13:51.085304
NCT00003888|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-07-16|2004-01-28|2004-01-29|Estimate|||||||2015-07-16|2015-07-17|Estimate|April 1999||1999-04-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2002|Actual|2002-03-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer|A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere) Plus Cisplatin Plus 5-Fluorouracil Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 3|359|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:51.157158|2018-06-01 05:13:51.157158
NCT00076609|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-27|||2007-03-27|2004-01-27|2004-01-28|Estimate|||||||2007-03-27|2007-03-28|Estimate|October 2003||2003-10-31|March 2007|2007-03-31||||||||Interventional|||Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma|A Phase I/II Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|31||PhytoCeutica|||||||||||||||||||2018-06-01 05:13:51.257364|2018-06-01 05:13:51.257364
NCT00076557|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-26|||2007-04-02|2004-01-27|2004-01-28|Estimate|||||||2007-04-02|2007-04-04|Estimate|January 2004||2004-01-31|January 2004|2004-01-31||||||||Interventional|||Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B|A Phase I Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using Adeno-Associated Viral Vector to Deliver the Gene for Human Factor IX Into the Liver|Terminated||Phase 1/Phase 2|15||Avigen|||||||||||||||||||2018-06-01 05:13:51.310194|2018-06-01 05:13:51.310194
NCT00076596|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-26|||2017-06-30|2004-01-26|2004-01-27|Estimate|||||||2017-06-30|2017-07-02|Actual|January 23, 2004||2004-01-23|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Brain Control of Movements in Cerebral Palsy|Brain Reorganization in Cerebral Palsy|Completed|||130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:51.35691|2018-06-01 05:13:51.35691
NCT00076583|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-26|||2008-03-03|2004-01-26|2004-01-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2004||2004-01-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Spinal Reflexes in Motor Skill Learning|Motor Skill Learning: Spinal Reflexes|Completed|||22||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:52.283645|2018-06-01 05:13:52.283645
NCT00076570|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-26|2013-08-07||2013-08-12|2004-01-26|2004-01-27|Estimate|2013-08-12|2013-10-16|Estimate||||2013-08-12|2013-10-16|Estimate|January 2004||2004-01-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Baseline analysis was performed using the patients who finished study.|Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation|Depletion Induction With Rabbit Anti-Thymocyte Globulin, Followed by Two Approaches Toward Monotherapy Immunosuppression in Kidney Transplant Recipients|Completed||Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:13:52.353002|2018-06-01 05:13:52.353002
NCT00076531|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-26|||2008-01-24|2004-01-26|2004-01-27|Estimate|||||||2008-01-24|2008-01-28|Estimate|December 2003||2003-12-31|January 2008|2008-01-31||||November 2004|Actual|2004-11-30||Interventional|||Clinical Trial for Prostate Cancer||Completed||Phase 3|||Oakwood Laboratories, LLC|||||||||||||||||||2018-06-01 05:13:52.589996|2018-06-01 05:13:52.589996
NCT00076492|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-23|||2012-10-31|2004-01-26|2004-01-27|Estimate|||||||2012-10-31|2012-11-02|Estimate|January 2004||2004-01-31|October 2012|2012-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485|A Multi-center, Double-blind, Pilot Study of CoQ10 and GPI 1485 in Subjects With Early Untreated Parkinson's Disease|Completed||Phase 2|195||University of Rochester|||||f||||||||||||||2018-06-01 05:13:52.640258|2018-06-01 05:13:52.640258
NCT00003882|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-03|2004-01-26|2004-01-27|Estimate|||||||2011-03-03|2011-03-07|Estimate|March 1999||1999-03-31|March 2011|2011-03-31|September 2000|Actual|2000-09-30|April 2000|Actual|2000-04-30||Interventional|||Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors|Phase I Dose Finding Study of Anhydrovinblastine Administered as a 1-Hour Infusion Every 3 Weeks to Patients With Advanced Solid Tumors|Completed||Phase 1|10|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:13:52.715005|2018-06-01 05:13:52.715005
NCT00003852|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-22|2004-01-26|2004-01-27|Estimate|||||||2016-06-22|2016-06-23|Estimate|March 1998||1998-03-31|June 2016|2016-06-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors|Phase II Study of Intensive Chemotherapy With Autologous Peripheral Blood Stem Cell Support in Patients With Cisplatin Resistant Germ Cell Tumors|Terminated||Phase 2|45|Anticipated|UNICANCER||||lack of patient inclusion|f||||||||||||||2018-06-01 05:13:52.775693|2018-06-01 05:13:52.775693
NCT00003683|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-07-23|2004-01-26|2004-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|March 1998||1998-03-31|May 2002|2002-05-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer|Treatment of Sarcomatous Kidney Cancer That is Metastatic in Adults With Doxorubicin and Ifosfamide. Phase II Study|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:52.960035|2018-06-01 05:13:52.960035
NCT00003682|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-22|2004-01-26|2004-01-27|Estimate|||||||2016-06-22|2016-06-23|Estimate|October 1998||1998-10-31|June 2016|2016-06-30|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer|Treatment of Metastatic Prostate Cancer That is Hormone-Independent: Evaluation of the Role of Chemotherapy on the Quality of Life of Patients. Phase II Study|Terminated||Phase 3|160|Anticipated|UNICANCER||||lack of inclusions|f||||||||||||||2018-06-01 05:13:53.058159|2018-06-01 05:13:53.058159
NCT00075777|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2014-08-27|2004-01-12|2004-01-13|Estimate|||||||2014-08-27|2014-08-29|Estimate|February 2005||2005-02-28|August 2014|2014-08-31|February 2008|Actual|2008-02-29|July 2007|Actual|2007-07-31||Interventional|||Valproic Acid in Treating Patients With Kaposi's Sarcoma|A Pilot Trial Of Valproic Acid In Patients With Kaposi's Sarcoma|Completed||N/A|19|Actual|AIDS Malignancy Consortium|||||f||||||||||||||2018-06-01 05:14:10.725959|2018-06-01 05:14:10.725959
NCT00003578|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2004-01-26|2004-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 1993||1993-01-31|May 2007|2007-05-31||||||||Interventional|||High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma|A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:53.155357|2018-06-01 05:13:53.155357
NCT00076505|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-23|||2017-06-30|2004-01-23|2004-01-26|Estimate|||||||2017-06-30|2017-07-02|Actual|January 14, 2004||2004-01-14|November 30, 2006|2006-11-30|November 30, 2006||2006-11-30|||||Observational|||Cell Studies of Parkinson's Disease|Bioenergetic Function in Parkinson's Disease|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:53.323449|2018-06-01 05:13:53.323449
NCT00076453|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-22|||2011-09-26|2004-01-23|2004-01-26|Estimate|||||||2011-09-26|2011-09-27|Estimate|June 2003||2003-06-30|September 2011|2011-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study of Orthotic Shoe Inserts for Controlling Osteoarthritic Knee Pain|Clinical Effects of Altered Biomechanics in Knee Osteoarthritis|Completed||N/A|100|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-06-01 05:13:53.408612|2018-06-01 05:13:53.408612
NCT00076440|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-22|||2009-12-10|2004-01-23|2004-01-26|Estimate|||||||2009-12-10|2009-12-11|Estimate|December 2003||2003-12-31|March 2007|2007-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study|Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study|Completed||Phase 2|90||National Institute on Aging (NIA)|||||||||||||||||||2018-06-01 05:13:53.485824|2018-06-01 05:13:53.485824
NCT00076401|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-21|||2014-06-25|2004-01-23|2004-01-26|Estimate|||||||2014-06-25|2014-06-26|Estimate||||June 2014|2014-06-30||||||||Interventional|||A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)|Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 2|27||Pharmacyclics LLC.|||||f||||||||||||||2018-06-01 05:13:53.555194|2018-06-01 05:13:53.555194
NCT00076479|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-22|||2008-03-03|2004-01-22|2004-01-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2004||2004-01-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Role of the Right Brain in Recovery of Language Function in Chronic Stroke||Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:53.611387|2018-06-01 05:13:53.611387
NCT00076466|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-22|||2017-06-30|2004-01-22|2004-01-23|Estimate|||||||2017-06-30|2017-07-02|Actual|January 22, 2004||2004-01-22|January 14, 2009|2009-01-14|January 14, 2009||2009-01-14|||||Observational|||Brain Changes Associated With Learning a Motor Task|Changes in Intracortical Inhibitory Processes Are Associated With the Development of Implicit Learning of a Motor Task|Completed|||72||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:53.673937|2018-06-01 05:13:53.673937
NCT00076388|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-21|||2011-05-12|2004-01-22|2004-01-23|Estimate|||||||2011-05-12|2011-05-13|Estimate|February 2004||2004-02-29|May 2011|2011-05-31|October 2007|Actual|2007-10-31|March 2007|Actual|2007-03-31||Interventional|||Iressa Versus Docetaxel (Taxotere)|A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy|Completed||Phase 3|1440||AstraZeneca|||||||||||||||||||2018-06-01 05:13:53.758693|2018-06-01 05:13:53.758693
NCT00076375|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-21|||2005-06-23|2004-01-22|2004-01-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 2003||2003-11-30|April 2004|2004-04-30|April 2004||2004-04-30|||||Interventional|||Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Two Concentrations of Nanocrystalline Silver Cream (NPI) Applied Twice Daily in Adults With Mild to Moderate Atopic Dermatitis|Completed||Phase 2|180||Nucryst Pharmaceuticals|||||||||||||||||||2018-06-01 05:13:54.17443|2018-06-01 05:13:54.17443
NCT00076362|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-21|||2011-09-08|2004-01-22|2004-01-23|Estimate|||||||2011-09-08|2011-09-12|Estimate|March 2004||2004-03-31|September 2011|2011-09-30||||July 2005|Actual|2005-07-31||Interventional|||Pediatric Hypothalamic Obesity||Completed||Phase 4|60|Actual|Novartis|||||f||||||||||||||2018-06-01 05:13:54.330296|2018-06-01 05:13:54.330296
NCT00003541|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2004-01-22|2004-01-23|Estimate|||||||2013-06-20|2013-06-24|Estimate|June 1998||1998-06-30|June 2013|2013-06-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma|High Dose Combined Modality Therapy With Peripheral Blood Progenitor Cell Transplantation as Primary Treatment for Patients With Mantle Cell Lymphoma|Completed||Phase 1/Phase 2|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:13:54.45484|2018-06-01 05:13:54.45484
NCT00003418|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-01-22|2004-01-23|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 1998||1998-02-28|March 2008|2008-03-31||||||||Interventional|||Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer|Randomized Double-Blind Trial in Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen|Unknown status|Active, not recruiting|Phase 3|4400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:54.574615|2018-06-01 05:13:54.574615
NCT00003364|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2004-01-22|2004-01-23|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1993||1993-01-31|May 2007|2007-05-31|August 2006|Actual|2006-08-31|||||Interventional|||Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer|A Randomised Study of Timing of Thoracic Irradiation in Small Cell Lung Cancer (Study 8)|Completed||Phase 3|398|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:54.657174|2018-06-01 05:13:54.657174
NCT00003298|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2015-06-02||2015-06-22|2004-01-22|2004-01-23|Estimate|2015-06-02|2015-06-23|Estimate||||2015-06-22|2015-07-16|Estimate|February 1999||1999-02-28|June 2015|2015-06-30|May 2011|Actual|2011-05-31|February 2010|Actual|2010-02-28||Interventional||Eligible and treated in step 1|Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer|A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer|Completed||Phase 2|39|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:13:54.788013|2018-06-01 05:13:54.788013
NCT00003287|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2004-01-22|2004-01-23|Estimate|||||||2012-06-29|2012-07-02|Estimate|March 1998||1998-03-31|June 2012|2012-06-30||||March 2002|Actual|2002-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer|First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial|Completed||Phase 3|554|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:55.191065|2018-06-01 05:13:55.191065
NCT00076349|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-20|||2014-05-08|2004-01-21|2004-01-22|Estimate|||||||2014-05-08|2014-05-09|Estimate|April 2004||2004-04-30|May 2014|2014-05-31|March 2008|Actual|2008-03-31|December 2005|Actual|2005-12-31||Interventional|||SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)|A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Combination With Rituximab in Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 2|66|Actual|Teva Pharmaceutical Industries||1|||f||||||||||||||2018-06-01 05:13:55.546524|2018-06-01 05:13:55.546524
NCT00076336|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-20|2011-01-03||2011-08-04|2004-01-21|2004-01-22|Estimate|2011-08-04|2011-09-05|Estimate||||2011-08-04|2011-09-05|Estimate|December 2003||2003-12-31|August 2011|2011-08-31||||December 2009|Actual|2009-12-31||Interventional|||Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis|Randomized, Double-Blind Trial of Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis|Completed||Phase 3|232|Actual|Novartis||2|||f||||||||||||||2018-06-01 05:13:55.688594|2018-06-01 05:13:55.688594
NCT00003137|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2004-01-21|2004-01-22|Estimate|||||||2016-07-12|2016-07-14|Estimate|December 1997||1997-12-31|July 2016|2016-07-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Irinotecan in Treating Patients With Advanced Cancer of the Stomach|A Phase II Trial of CPT-11 in Patients With Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Incorporating Pretreatment and Posttreatment Biopsies for Evaluation of Tumor Thymidylate Synthase, MIB-1, Topoisomerase I, and p53|Completed||Phase 2|70|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:13:56.392205|2018-06-01 05:13:56.392205
NCT00003007|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2004-01-21|2004-01-22|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 1996||1996-07-31|September 2002|2002-09-30|January 2004|Actual|2004-01-31|||||Interventional|||Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma|Interferon Maintenance in Advanced Multiple Myeloma After Using High-Dose Melphalan as Myeloablative Chemotherapy: A Pilot Study|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:56.483408|2018-06-01 05:13:56.483408
NCT00002840|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-06|2004-01-21|2004-01-22|Estimate|||||||2012-07-06|2012-07-10|Estimate|August 1996||1996-08-31|July 2012|2012-07-31||||March 2002|Actual|2002-03-31||Interventional|||Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma|PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA|Completed||Phase 3|350|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:13:56.555294|2018-06-01 05:13:56.555294
NCT00002817|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-09|2004-01-21|2004-01-22|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 1996||1996-04-30|May 2002|2002-05-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:56.666836|2018-06-01 05:13:56.666836
NCT00002748|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-10-03|2004-01-21|2004-01-22|Estimate|||||||2011-10-03|2011-10-04|Estimate|December 1991||1991-12-31|October 2011|2011-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma|Phase I Study of Cytokine-Gene Modified Autologous or Partially Matched Allogeneic Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma|Completed||Phase 1|38|Actual|St. Jude Children's Research Hospital|||||f||||||||||||||2018-06-01 05:13:56.717432|2018-06-01 05:13:56.717432
NCT00076323|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-20|||2010-07-26|2004-01-20|2004-01-21|Estimate|||||||2010-07-26|2010-07-27|Estimate|December 2003||2003-12-31|July 2010|2010-07-31|November 2006|Actual|2006-11-30|||||Interventional|||A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency|A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency|Completed||N/A|14||Walter Reed Army Institute of Research (WRAIR)|||||f||||||||||||||2018-06-01 05:13:56.772842|2018-06-01 05:13:56.772842
NCT00076310|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-20|||2018-04-26|2004-01-20|2004-01-21|Estimate|||||||2018-04-26|2018-04-30|Actual|January 2004|Actual|2004-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer|A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer|Active, not recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-06-01 05:13:56.943031|2018-06-01 05:13:56.943031
NCT00076284|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-16|||2008-03-03|2004-01-16|2004-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2004||2004-01-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||GW873140 to Treat HIV-1 Infected Adults|A Phase II, Double-Blind RAndomized, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of GW873130 for 10 Days in HIV-1 Infected Adults|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:57.03303|2018-06-01 05:13:57.03303
NCT00076271|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-16|||2017-06-30|2004-01-16|2004-01-19|Estimate|||||||2017-06-30|2017-07-02|Actual|January 14, 2004||2004-01-14|October 28, 2008|2008-10-28|October 28, 2008||2008-10-28|||||Observational|||Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases|Evaluation and Treatment of Pediatric, Developmental and Genetic Eye Diseases|Completed|||350||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:13:57.095857|2018-06-01 05:13:57.095857
NCT00076258|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-16|2015-11-17||2016-10-14|2004-01-16|2004-01-19|Estimate|2016-10-14|2016-12-07|Estimate||||2016-10-14|2016-12-07|Estimate|April 2003||2003-04-30|October 2016|2016-10-31|August 2007|Actual|2007-08-31|October 2006|Actual|2006-10-31||Interventional|TREAD||Adding Exercise to Antidepressant Medication Treatment for Depression|Treatment With Exercise Augmentation for Depression (TREAD)|Completed||N/A|126|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-06-01 05:13:57.185332|2018-06-01 05:13:57.185332
NCT00076245|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-16|2014-02-24||2014-06-24|2004-01-16|2004-01-19|Estimate|2014-06-24|2014-06-25|Estimate||||2014-06-24|2014-06-25|Estimate|November 2002||2002-11-30|June 2014|2014-06-30|November 2005|Actual|2005-11-30|February 2004|Actual|2004-02-29||Interventional|||Cognitive Behavioral Therapy for the Treatment of Seasonal Affective Disorder (SAD)|Cognitive Behavioral Approaches to Seasonal Depression|Completed||Phase 1|61|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||4|||f||||f||||||||||2018-06-01 05:13:57.506776|2018-06-01 05:13:57.506776
NCT00076219|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-15|2013-06-12||2013-08-16|2004-01-16|2004-01-19|Estimate|2013-06-12|2013-08-16|Estimate||||2013-08-16|2013-08-23|Estimate|October 2003||2003-10-31|August 2013|2013-08-31|July 2008|Actual|2008-07-31|September 2007|Actual|2007-09-30||Interventional|ATN||Acute Renal Failure Trial Network (ATN) Study|CSP #530 - Intensive vs. Conventional Renal Support in Acute Renal Failure|Completed||Phase 3|1124|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:13:57.94349|2018-06-01 05:13:57.94349
NCT00076206|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-15|||2015-12-07|2004-01-16|2004-01-19|Estimate|||||||2015-12-07|2015-12-09|Estimate|December 2003||2003-12-31|December 2015|2015-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy|A Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Oral Dose Levels (1, 2, And 4 Mg) of CCI-779 in Subjects With Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy|Terminated||Phase 2|||Wyeth is now a wholly owned subsidiary of Pfizer||4|||||||||||||||||2018-06-01 05:13:58.661785|2018-06-01 05:13:58.661785
NCT00076232|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-15|||2010-12-29|2004-01-15|2004-01-16|Estimate|||||||2010-12-29|2010-12-30|Estimate|April 2005||2005-04-30|August 2009|2009-08-31|November 2007|Actual|2007-11-30|June 2007|Actual|2007-06-30||Interventional|||A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes|A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir for the Reduction of HIV Acquisition Among High-Risk HSV-2 Seropositive, HIV Seronegative Individuals|Completed||Phase 3|3682|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:13:58.721098|2018-06-01 05:13:58.721098
NCT00076154|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-14|||2014-04-18|2004-01-15|2004-01-16|Estimate|||||||2014-04-18|2014-04-21|Estimate|January 2003||2003-01-31|April 2014|2014-04-30|September 2009|Actual|2009-09-30|September 2007|Actual|2007-09-30||Observational|ALS Registry||National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank|CSP #500A - National Registry of Veterans With Amyotrophic Lateral Sclerosis|Completed|||2121|Actual|VA Office of Research and Development|||1||f||||f||||||Samples With DNA|"~     DNA samples or blood or mouthwash were collected in veterans' homes by nurses.~   "|||2018-06-01 05:13:58.799813|2018-06-01 05:13:58.799813
NCT00076141|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-14|||2018-03-01|2004-01-15|2004-01-16|Estimate|||||||2018-03-01|2018-03-05|Actual|January 1, 2002|Actual|2002-01-01|February 2018|2018-02-28|January 1, 2021|Anticipated|2021-01-01|January 1, 2014|Actual|2014-01-01||Observational|ACTIVE Health||Relatively Healthy Male Veterans Observed Over Time to See What Types of Diseases Develop|CSP #499A - Selenium and Vitamin E Cancer Prevention Trial - COHORT|Active, not recruiting|||991|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|Samples With DNA|"~     PE and buffy coat~   "|No||2018-06-01 05:13:58.857981|2018-06-01 05:13:58.857981
NCT00076115|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-14|||2011-06-06|2004-01-15|2004-01-16|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 2003||2003-12-31|April 2010|2010-04-30|December 2005|Actual|2005-12-31|||||Interventional|||Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents|Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Risperidone for the Treatment of Acute Mania in Bipolar I Disorder|Completed||Phase 3|13|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:13:58.962901|2018-06-01 05:13:58.962901
NCT00076180|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-14|||2018-03-01|2004-01-14|2004-01-15|Estimate|||||||2018-03-01|2018-03-02|Actual|March 1, 2004||2004-03-01|February 9, 2018|2018-02-09|November 12, 2010|Actual|2010-11-12|November 12, 2010|Actual|2010-11-12||Interventional|||Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia|Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:13:59.045623|2018-06-01 05:13:59.045623
NCT00076089|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-13|||2016-12-01|2004-01-14|2004-01-15|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)|Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.|Completed||Phase 3|1100||AstraZeneca|||||f||||||||||||||2018-06-01 05:13:59.106293|2018-06-01 05:13:59.106293
NCT00076076|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-13|||2016-12-01|2004-01-14|2004-01-15|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2003||2003-12-31|September 2016|2016-09-30|June 2005|Actual|2005-06-30|||||Interventional|||The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)|The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 mcg and 500 mcg Versus Placebo in Patients With Asthma|Completed||Phase 3|822||AstraZeneca|||||f||||||||||||||2018-06-01 05:13:59.315031|2018-06-01 05:13:59.315031
NCT00033735|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2012-12-20|2004-01-14|2004-01-15|Estimate|||||||2012-12-20|2012-12-24|Estimate|January 2000||2000-01-31|December 2012|2012-12-31||||June 2003|Actual|2003-06-30||Interventional|||Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer|Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma|Completed||Phase 3|158|Actual|Eisai Inc.||2|||f||||t||||||||||2018-06-01 05:13:59.438705|2018-06-01 05:13:59.438705
NCT00027508|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2015-02-23|2004-01-14|2004-01-15|Estimate|||||||2015-02-23|2015-02-24|Estimate|July 2001||2001-07-31|June 2013|2013-06-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma|Phase II Study Of ET-743 In Patients With Unresectable Malignant Pleural Mesothelioma|Terminated||Phase 2|||PharmaMar||||Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained.|f||||||||||||||2018-06-01 05:13:59.633129|2018-06-01 05:13:59.633129
NCT00024401|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2008-07-23|2004-01-14|2004-01-15|Estimate|||||||2008-07-23|2008-07-24|Estimate|May 2001||2001-05-31|June 2002|2002-06-30||||||||Interventional|||DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer|Phase II Open-Label Study of Taxoperxin (DHA-Paclitacel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Cancer of the Colon/Rectum|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:59.699073|2018-06-01 05:13:59.699073
NCT00002566|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-11-02|2004-01-14|2004-01-15|Estimate|||||||2010-11-02|2010-11-03|Estimate|February 1994||1994-02-28|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors|INTERNATIONAL RANDOMIZED STUDY FOR THE SALVAGE TREATMENT OF GERM CELL TUMOURS|Unknown status|Active, not recruiting|Phase 3|280|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:13:59.763627|2018-06-01 05:13:59.763627
NCT00076102|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-13|2012-01-04||2018-04-19|2004-01-13|2004-01-14|Estimate|2012-06-06|2012-07-12|Estimate||||2018-04-19|2018-04-23|Actual|July 21, 2004|Actual|2004-07-21|April 2018|2018-04-30|April 1, 2010|Actual|2010-04-01|April 1, 2010|Actual|2010-04-01||Interventional|||Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas|Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas|Completed||Phase 2|36|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||No||2018-06-01 05:13:59.877898|2018-06-01 05:13:59.877898
NCT00076063|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-13|||2015-03-12|2004-01-13|2004-01-14|Estimate|||||||2015-03-12|2015-03-13|Estimate|March 2004||2004-03-31|March 2015|2015-03-31|March 2007|Actual|2007-03-31|||||Interventional|||A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines|A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC Prime/LIPO-5 Boost in Healthy, HIV-1 Uninfected Adult Participants|Completed||Phase 1/Phase 2|174|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 05:14:00.416538|2018-06-01 05:14:00.416538
NCT00076050|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-13|2013-06-26||2016-10-12|2004-01-13|2004-01-14|Estimate|2016-10-12|2016-12-06|Estimate||||2016-10-12|2016-12-06|Estimate|September 2003||2003-09-30|October 2016|2016-10-31|June 2009|Actual|2009-06-30|March 2009|Actual|2009-03-31||Interventional|SPARE||Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms|Bone Sparing Effects of Soy Phytoestrogens in Menopause|Completed||Phase 3|248|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 05:14:00.536496|2018-06-01 05:14:00.536496
NCT00076037|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-13|||2015-03-03|2004-01-13|2004-01-14|Estimate|||||||2015-03-03|2015-03-05|Estimate|April 2004||2004-04-30|March 2015|2015-03-31|June 2006|Actual|2006-06-30|||||Interventional|||Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a CTL Multi-Epitope Peptide HIV Vaccine Formulated With RC529-SE, With or Without GM-CSF, in Healthy, HIV-1 Uninfected Adult Participants|Completed||Phase 1|96|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:14:00.813515|2018-06-01 05:14:00.813515
NCT00076024|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|2012-02-25|2009-03-20|2012-06-21|2004-01-13|2004-01-14|Estimate|2012-02-25|2012-03-16|Estimate|2009-09-24|2009-09-28|Estimate|2012-06-21|2012-06-26|Estimate|February 2004||2004-02-29|June 2012|2012-06-30|November 2008|Actual|2008-11-30|January 2007|Actual|2007-01-31||Interventional|||AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer|Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination|Completed||Phase 1/Phase 2|174|Actual|Pfizer|Analysis of TTP (Phase 2, Double-blind) was performed with both discontinuation due to lack of efficacy (LOE) considered a progression and not considered a progression event. Latter was considered primary analysis and former a sensitivity analysis.|2|||f||||t||||||||||2018-06-01 05:14:00.951471|2018-06-01 05:14:00.951471
NCT00076011|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|2012-02-25||2012-06-20|2004-01-13|2004-01-14|Estimate|2012-02-25|2012-03-19|Estimate||||2012-06-20|2012-06-26|Estimate|October 2003||2003-10-31|June 2012|2012-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma|Phase 2 Study of AG 013736 as Second-Line Treatment in Patients With Metastatic Renal Cell Cancer|Completed||Phase 2|52|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:14:02.469324|2018-06-01 05:14:02.469324
NCT00075998|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|||2009-07-01|2004-01-13|2004-01-14|Estimate|||||||2009-07-01|2009-07-02|Estimate|December 2003||2003-12-31|July 2009|2009-07-31|May 2007|Actual|2007-05-31|||||Interventional|||The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)|Terminated||Phase 3|826|Actual|InterMune||||test drug showed lack of benefit at interim analysis|f||||t||||||||||2018-06-01 05:14:03.254929|2018-06-01 05:14:03.254929
NCT00075985|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|||2009-01-20|2004-01-13|2004-01-14|Estimate|||||||2009-01-20|2009-01-21|Estimate|May 2000||2000-05-31|April 2007|2007-04-30|April 2006||2006-04-30|||||Observational|||Following Patients on Warfarin Therapy to See if Differences in Hemorrhagic Complications Exist|CSP #716B - The 80+ Hemorrhagic Cohort Study|Completed|||700||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:14:03.318337|2018-06-01 05:14:03.318337
NCT00075972|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|||2015-06-25|2004-01-13|2004-01-14|Estimate|||||||2015-06-25|2015-06-26|Estimate|March 2003||2003-03-31|June 2015|2015-06-30|March 2006||2006-03-31|||||Interventional|||Mood and Smoking: A Comparison of Smoking Cessation Treatments|CSP #725 - Mood and Smoking: A Comparison of Smoking Cessation Treatments|Completed||N/A|128||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:14:03.381246|2018-06-01 05:14:03.381246
NCT00075959|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|||2013-01-03|2004-01-13|2004-01-14|Estimate|||||||2013-01-03|2013-01-04|Estimate|August 2004||2004-08-31|January 2013|2013-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke|CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage (ICH)|Completed||Phase 2|600||AstraZeneca|||||||||||||||||||2018-06-01 05:14:03.443182|2018-06-01 05:14:03.443182
NCT00075946|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|2015-02-09||2015-06-03|2004-01-13|2004-01-14|Estimate|2015-06-03|2015-06-22|Estimate||||2015-06-03|2015-06-22|Estimate|November 2003||2003-11-30|June 2015|2015-06-30|September 2023|Anticipated|2023-09-30|September 2013|Actual|2013-09-30||Interventional||As the primary analysis only includes randomized patients, the baseline characteristics were provided among patients who were correctly randomized to one of the two arms for maintenance therapy.|Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 3|545|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 05:14:04.537703|2018-06-01 05:14:04.537703
NCT00024388|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2008-07-23|2004-01-13|2004-01-14|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 2001||2001-04-30|June 2002|2002-06-30||||||||Interventional|||Chemotherapy in Treating Patients With Metastatic Kidney Cancer|Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion In Patients With Metastatic, Locally Advanced, or Unresectable Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:05.841398|2018-06-01 05:14:05.841398
NCT00022347|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-06-25|2004-01-13|2004-01-14|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2001||2001-05-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|April 2004|Actual|2004-04-30||Interventional|||TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:05.904382|2018-06-01 05:14:05.904382
NCT00022321|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-12-18|2004-01-13|2004-01-14|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2001||2001-09-30|June 2002|2002-06-30||||||||Interventional|||Gemtuzumab in Treating Patients With Myelodysplastic Syndrome|A Randomized Study Of The Safety And Efficacy Of Two Dose Schedules Of Gemcituzumab Ozogamicin In Patients With Intermediate-2 Or High-Risk Myelodysplastic Syndromes|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:05.968624|2018-06-01 05:14:05.968624
NCT00021333|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-04-16|2004-01-13|2004-01-14|Estimate|||||||2013-04-16|2013-04-17|Estimate|September 1999||1999-09-30|April 2013|2013-04-30|May 2008|Actual|2008-05-31|April 2006|Actual|2006-04-30||Interventional|||Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer|Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung|Completed||Phase 2|29|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:14:06.029281|2018-06-01 05:14:06.029281
NCT00021307|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-07-10|2004-01-13|2004-01-14|Estimate|||||||2013-07-10|2013-07-11|Estimate||||July 2013|2013-07-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I/II Trial Of Temozolomide And Carboplatin In Recurrent Glioblastoma Multiforme|Withdrawn||Phase 1/Phase 2|0|Actual|Fox Chase Cancer Center||||Study not activated.|f||||f||||||||||2018-06-01 05:14:06.10382|2018-06-01 05:14:06.10382
NCT00075933|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-12|||2009-04-27|2004-01-12|2004-01-13|Estimate|||||||2009-04-27|2009-04-28|Estimate|September 2003||2003-09-30|April 2009|2009-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||ARQ 501 in Subjects With Cancer|A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects With Advanced Solid Tumors|Completed||Phase 1|80||ArQule|||||f||||||||||||||2018-06-01 05:14:06.239103|2018-06-01 05:14:06.239103
NCT00075907|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-10-04|2004-01-12|2004-01-13|Estimate|||||||2013-10-04|2013-10-07|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|September 2006|Actual|2006-09-30|||||Interventional|||Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents|A Comparative Trial of Protease-Containing and Protease-Sparing HAART Regimens in HIV-Infected Adolescents With an Evaluation of Therapeutic Drug Monitoring|Completed||Phase 3|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:14:06.30302|2018-06-01 05:14:06.30302
NCT00075894|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2009-01-10|2004-01-12|2004-01-13|Estimate|||||||2009-01-10|2009-01-13|Estimate|March 2004||2004-03-31|August 2006|2006-08-31||||||||Interventional|||Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas|A Phase I/II, Open-Label, Non-Randomized, Multicenter, Single Agent Study Of Intravenous SDX-102 For The Treatment Of Patients With MTAP-Deficient High Grade Recurrent Malignant Gliomas|Completed||Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:06.406354|2018-06-01 05:14:06.406354
NCT00075881|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2012-03-08||2014-05-29|2004-01-12|2004-01-13|Estimate|2012-08-28|2012-09-28|Estimate||||2014-05-29|2014-06-02|Estimate|January 2004||2004-01-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma|Phase II Study of PS-341 for Patients With High-Risk, Newly Diagnosed Multiple Myeloma|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:14:06.487509|2018-06-01 05:14:06.487509
NCT00075868|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2015-11-14|2004-01-12|2004-01-13|Estimate|||||||2015-11-14|2015-11-17|Estimate|December 2003||2003-12-31|November 2015|2015-11-30||||August 2006|Actual|2006-08-31||Interventional|||Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer|A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer|Completed||Phase 3|233|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:14:06.761944|2018-06-01 05:14:06.761944
NCT00075855|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2016-07-12|2004-01-12|2004-01-13|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2004||2004-04-30|July 2016|2016-07-31|October 2007|Actual|2007-10-31|May 2007|Actual|2007-05-31||Interventional|||Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors|The Use of Low Dose Testosterone To Enhance Libido In Female Cancer Survivors: A Phase III Randomized, Placebo-Controlled, Double-Blind Crossover Study|Completed||Phase 3|150|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:14:07.104154|2018-06-01 05:14:07.104154
NCT00075842|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2016-12-02|2004-01-12|2004-01-13|Estimate|||||||2016-12-02|2016-12-06|Estimate|August 2003||2003-08-31|December 2016|2016-12-31|January 2010|Actual|2010-01-31|March 2007|Actual|2007-03-31||Interventional|||(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy|"The Use Of Valeriana Officinalis (Valerian) In Improving Sleep In Patients Who Are Undergoing Adjuvant Treatment For Cancer A Phase III Randomized, Placebo-Controlled, Double-Blind Study"|Completed||Phase 3|227|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:14:07.204507|2018-06-01 05:14:07.204507
NCT00075829|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2014-12-17||2017-08-24|2004-01-12|2004-01-13|Estimate|2016-06-20|2016-08-04|Estimate||||2017-08-24|2017-09-25|Actual|December 2003||2003-12-31|August 2017|2017-08-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional||Analysis is based on intention-to-treat data. Primary analysis of the clinical trial focused on patients meeting protocol criteria of standard risk multiple myeloma.|Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)|A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy vs Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients With Multiple Myeloma (BMT CTN #0102)|Completed||Phase 3|710|Actual|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||f||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-06-01 05:14:07.427206|2018-06-01 05:14:07.427206
NCT00075816|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2015-01-22||2017-10-24|2004-01-12|2004-01-13|Estimate|2015-12-28|2016-02-01|Estimate||||2017-10-24|2017-11-28|Actual|January 2004||2004-01-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional||All randomized patients were included in primary, intention-to-treat analysis.|Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)|A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)|Completed||Phase 3|551|Actual|Medical College of Wisconsin||2|||f||||t||||||||Yes|Results will be published in a manuscript|2018-06-01 05:14:08.401738|2018-06-01 05:14:08.401738
NCT00075803|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2013-02-22||2016-08-01|2004-01-12|2004-01-13|Estimate|2015-08-05|2015-09-04|Estimate||||2016-08-01|2016-09-12|Estimate|November 2003||2003-11-30|August 2016|2016-08-31|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Interventional|||Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)|A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)|Completed||Phase 3|600|Actual|Medical College of Wisconsin||2|||f||||t||||||||Yes||2018-06-01 05:14:09.836879|2018-06-01 05:14:09.836879
NCT00075764|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2016-10-26||2017-12-06|2004-01-12|2004-01-13|Estimate|2017-02-15|2017-04-04|Actual||||2017-12-06|2018-01-02|Actual|April 2004||2004-04-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|December 2012|Actual|2012-12-31||Interventional|||S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer|Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer|Active, not recruiting||Phase 3|695|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:14:10.900634|2018-06-01 05:14:10.900634
NCT00075751|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-02-27|2004-01-12|2004-01-13|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2004||2004-01-31|February 2013|2013-02-28||||July 2007|Actual|2007-07-31||Interventional|||Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer|A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|99|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:14:17.590111|2018-06-01 05:14:17.590111
NCT00075738|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2008-07-23|2004-01-12|2004-01-13|Estimate|||||||2008-07-23|2008-07-24|Estimate|October 2003||2003-10-31|July 2007|2007-07-31||||||||Interventional|||Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer|Phase II Study Of 5FU-Irinotecan-Cisplatin As First-Line Treatment In Patients With Metastatic Carcinoma Of The Esophagus|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:17.703721|2018-06-01 05:14:17.703721
NCT00075725|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2015-07-10||2017-02-14|2004-01-12|2004-01-13|Estimate|2015-07-10|2015-08-06|Estimate||||2017-02-14|2017-03-21|Actual|December 2003||2003-12-31|February 2017|2017-02-28||||December 2010|Actual|2010-12-31||Interventional|||Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia|High Risk B-Precursor Acute Lymphoblastic Leukemia|Completed||Phase 3|3154|Actual|Children's Oncology Group|The COG SDC reviewed the NLM notification related to ct.gov AE/SAE reporting. The information in ‘Additional Description’ is accurate with respect to data supplied to ct.gov.COG plans to submit data AE/SAE data consistent with the text in this field.|12|||f||||t||||||||||2018-06-01 05:14:18.244196|2018-06-01 05:14:18.244196
NCT00075712|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-08-09|2004-01-12|2004-01-13|Estimate|||||||2013-08-09|2013-08-12|Estimate|September 2003||2003-09-30|May 2007|2007-05-31||||||||Interventional|||Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma|Completed||Phase 2/Phase 3|150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:25.743825|2018-06-01 05:14:25.743825
NCT00075699|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-08-06|2004-01-12|2004-01-13|Estimate|||||||2013-08-06|2013-08-07|Estimate|September 2003||2003-09-30|June 2008|2008-06-30||||||||Interventional|||Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma|A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma|Completed||Phase 3|840|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:25.979163|2018-06-01 05:14:25.979163
NCT00075686|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2015-11-16|2004-01-12|2004-01-13|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2004||2004-01-31|November 2015|2015-11-30|April 2009|Actual|2009-04-30|May 2007|Actual|2007-05-31||Interventional|||S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer|A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer|Completed||Phase 3|766|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:14:26.119609|2018-06-01 05:14:26.119609
NCT00075920|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-11|||2017-06-30|2004-01-10|2004-01-12|Estimate|||||||2017-06-30|2017-07-02|Actual|January 8, 2004||2004-01-08|October 17, 2007|2007-10-17|October 17, 2007||2007-10-17|||||Observational|||Technical Development of Strain Rate Echocardiography|Technical Development of Strain Rate Echocardiography|Completed|||125||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:27.105584|2018-06-01 05:14:27.105584
NCT00075673|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2011-07-21|2004-01-11|2004-01-12|Estimate|||||||2011-07-21|2011-07-22|Estimate|November 2003||2003-11-30|July 2011|2011-07-31|February 2005|Actual|2005-02-28|September 2004|Actual|2004-09-30||Interventional|||Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer|A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer|Terminated||Phase 1|6|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:14:27.160353|2018-06-01 05:14:27.160353
NCT00075660|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2010-11-07|2004-01-11|2004-01-12|Estimate|||||||2010-11-07|2010-11-09|Estimate|January 2004||2004-01-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma|A Phase II Study of Triapine (NSC 663249) in Previously Untreated Patients With Recurrent Renal Cell Carcinoma|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:14:27.228715|2018-06-01 05:14:27.228715
NCT00075647|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-01-16|2004-01-11|2004-01-12|Estimate|||||||2013-01-16|2013-01-17|Estimate|December 2003||2003-12-31|January 2013|2013-01-31||||March 2005|Actual|2005-03-31||Interventional|||CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase II Trial of CCI-779 in Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:14:27.289974|2018-06-01 05:14:27.289974
NCT00075634|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-09-27|2004-01-11|2004-01-12|Estimate|||||||2013-09-27|2013-09-30|Estimate|December 2003||2003-12-31|September 2013|2013-09-30||||September 2007|Actual|2007-09-30||Interventional|||Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma|A Phase I Study of Decitabine (NSC# 127716, IND# 50733) in Combination With Doxorubicin and Cyclophosphamide in the Treatment of Relapsed or Refractory Solid Tumors|Completed||Phase 1|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:14:27.354542|2018-06-01 05:14:27.354542
NCT00075621|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2018-04-09|2004-01-11|2004-01-12|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2000||2000-08-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|June 2005|Actual|2005-06-30||Interventional|||Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis|A Phase II Trial of Tandem Transplantation in AL Amyloidosis|Active, not recruiting||Phase 2|62|Actual|Boston Medical Center||1|||f||||f|||||f|||No||2018-06-01 05:14:27.442593|2018-06-01 05:14:27.442593
NCT00075608|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2014-08-20||2016-12-02|2004-01-11|2004-01-12|Estimate|2016-12-02|2017-01-27|Estimate||||2016-12-02|2017-01-27|Estimate|August 2001||2001-08-31|December 2016|2016-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis|Phase II Trial of Second Autologous Transplantation in AL Amyloidosis|Terminated||Phase 2|12|Actual|Boston Medical Center||1||poor accrual|f||||t||||||||No||2018-06-01 05:14:27.523216|2018-06-01 05:14:27.523216
NCT00075595|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2009-01-03|2004-01-11|2004-01-12|Estimate|||||||2009-01-03|2009-01-06|Estimate|June 2002||2002-06-30|August 2007|2007-08-31||||||||Interventional|||Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer|Phase II Study of 5FU/Folinic Acid and Irinotecan as Second or Third Line Treatment in Patients With Metastatic, Unresectable, Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:27.799229|2018-06-01 05:14:27.799229
NCT00075582|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2013-12-16||2016-11-02|2004-01-11|2004-01-12|Estimate|2014-03-06|2014-04-11|Estimate||||2016-11-02|2016-11-04|Estimate|September 2004||2004-09-30|October 2016|2016-10-31||||September 2012|Actual|2012-09-30||Interventional|||Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma|Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma|Active, not recruiting||Phase 3|390|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:14:27.926363|2018-06-01 05:14:27.926363
NCT00075569|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2018-05-17|2004-01-11|2004-01-12|Estimate|||||||2018-05-17|2018-05-21|Actual|March 2004|Actual|2004-03-31|January 2006|2006-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia|SGN-00101 (HspE7) Immunotherapy Of CIN III|Completed||Phase 2|64|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||||||||||||2018-06-01 05:14:28.689307|2018-06-01 05:14:28.689307
NCT00075556|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2009-02-06|2004-01-11|2004-01-12|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2002||2002-01-31|May 2008|2008-05-31||||||||Interventional|||Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma|Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:28.772156|2018-06-01 05:14:28.772156
NCT00075543|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2008-07-23|2004-01-11|2004-01-12|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2003||2003-07-31|July 2007|2007-07-31||||||||Interventional|||Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer|Phase I-II Study Of Docetaxel And Oxaliplatine In Patients With Stage III-IV Ovarian Epithelial Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:28.851961|2018-06-01 05:14:28.851961
NCT00075517|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2008-07-23|2004-01-11|2004-01-12|Estimate|||||||2008-07-23|2008-07-24|Estimate|September 2003||2003-09-30|July 2007|2007-07-31||||||||Interventional|||Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:28.922542|2018-06-01 05:14:28.922542
NCT00075504|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2015-05-19||2015-08-31|2004-01-11|2004-01-12|Estimate|2015-08-31|2015-09-28|Estimate||||2015-08-31|2015-09-28|Estimate|November 2003||2003-11-30|May 2013|2013-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder|Completed||Phase 2|33|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:14:29.012007|2018-06-01 05:14:29.012007
NCT00075491|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-01-23|2004-01-11|2004-01-12|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 2003||2003-12-31|January 2013|2013-01-31||||March 2005|Actual|2005-03-31||Interventional|||Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme|A Phase II Evaluation With Correlative Studies Of Fenretinide (NSC 374551-4HPR) As A Single Agent In The Treatment Of Adult Patients With Recurrent Glioblastoma Multiforme|Terminated||Phase 2|42|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:14:29.262517|2018-06-01 05:14:29.262517
NCT00075478|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2014-04-16||2017-04-07|2004-01-11|2004-01-12|Estimate|2014-04-18|2014-05-19|Estimate||||2017-04-07|2017-05-15|Actual|October 2003||2003-10-31|April 2017|2017-04-30|February 2, 2014|Actual|2014-02-02|February 2014|Actual|2014-02-28||Interventional||The randomization will be stratified on institution, disease risk (indolent vs. aggressive), and prior conventional HCT and will be balanced (blocked) over time.|Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies|Completed||Phase 3|87|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 05:14:29.342715|2018-06-01 05:14:29.342715
NCT00075465|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2008-07-23|2004-01-11|2004-01-12|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 2001||2001-04-30|July 2007|2007-07-31||||||||Interventional|||Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach|Phase II Study of Docetaxel and Epirubicine as First-Line Treatment in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:29.852337|2018-06-01 05:14:29.852337
NCT00075452|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2008-07-23|2004-01-11|2004-01-12|Estimate|||||||2008-07-23|2008-07-24|Estimate|November 2003||2003-11-30|May 2007|2007-05-31||||||||Interventional|||Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma|Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:29.955965|2018-06-01 05:14:29.955965
NCT00075439|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-06-03|2004-01-11|2004-01-12|Estimate|||||||2013-06-03|2013-06-04|Estimate|December 2003||2003-12-31|June 2013|2013-06-30||||May 2007|Actual|2007-05-31||Interventional|||Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors|A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors|Completed||Phase 2|90|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:14:30.060775|2018-06-01 05:14:30.060775
NCT00075426|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2013-02-11|2004-01-11|2004-01-12|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2002||2002-11-30|February 2013|2013-02-28|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Pilot Phase II Protocol Of Arsenic Trioxide (Trisenox) In Subjects With Advanced Non-Small Cell Carcinoma Of The Lung|Completed||Phase 2|30|Anticipated|The University of Texas Medical Branch, Galveston|||||f||||||||||||||2018-06-01 05:14:30.201798|2018-06-01 05:14:30.201798
NCT00003191|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-06|2003-11-25|2003-11-26|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 1998||1998-03-31|August 2006|2006-08-31||||March 2005|Actual|2005-03-31||Interventional|||Fenretinide in Treating Children With Solid Tumors|A Phase I Study of Fenretinide (NSC #374551) in Children With High Risk Solid Tumors|Completed||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:20.96088|2018-06-01 05:15:20.96088
NCT00075413|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2015-09-30|2004-01-11|2004-01-12|Estimate|||||||2015-09-30|2015-10-02|Estimate|November 2002||2002-11-30|September 2015|2015-09-30||||July 2005|Actual|2005-07-31||Interventional|||Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer|A Pilot Phase II Protocol Of Arsenic Trioxide (TRISENOX) In Subjects With Advanced Carcinoma Of The Breast|Withdrawn||Phase 2|0|Actual|The University of Texas Medical Branch, Galveston||||Unable to identify qualified subjects willing to participate in this study|f||||||||||||||2018-06-01 05:14:30.281539|2018-06-01 05:14:30.281539
NCT00075400|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|2015-05-06||2017-10-27|2004-01-11|2004-01-12|Estimate|2015-05-06|2015-05-22|Estimate||||2017-10-27|2017-12-04|Actual|January 2004||2004-01-31|October 2017|2017-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||Eligible and treated patients.|Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer|A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus|Completed||Phase 2|26|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:14:30.379834|2018-06-01 05:14:30.379834
NCT00075387|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2018-05-02|2004-01-11|2004-01-12|Estimate|||||||2018-05-02|2018-05-07|Actual|March 7, 2003|Actual|2003-03-07|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors|Phase II Clinical Trial of Patients With High-Grade Glioma Treated With Intra-arterial Carboplatin-Based Chemotherapy, Randomized to Treatment With or Without Delayed Intravenous Sodium Thiosulfate as a Potential Chemoprotectant Against Severe Thrombocytopenia|Recruiting||Phase 2|60|Anticipated|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-06-01 05:14:30.859514|2018-06-01 05:14:30.859514
NCT00075374|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2014-01-15|2004-01-11|2004-01-12|Estimate|||||||2014-01-15|2014-01-16|Estimate|October 2003||2003-10-31|January 2014|2014-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Multicenter, Randomized Phase II Study of Two Schedules of Taxotere (Weekly Versus Every 3 Weeks) in Elderly or Poor Performance (ECOG PS 2), Chemotherapy-Naive Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|6|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:14:30.994883|2018-06-01 05:14:30.994883
NCT00075348|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-09|||2012-03-14|2004-01-11|2004-01-12|Estimate|||||||2012-03-14|2012-03-15|Estimate|December 2003||2003-12-31|March 2012|2012-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome|Genetic Mutation Analysis In A VHL Population|Completed|||260|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:31.059272|2018-06-01 05:14:31.059272
NCT00075335|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-08|2014-04-01||2018-02-05|2004-01-08|2004-01-09|Estimate|2018-02-05|2018-02-07|Actual||||2018-02-05|2018-02-07|Actual|January 2004||2004-01-31|February 2018|2018-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation|Peripheral Blood Hematopoietic Progenitor Cell Mobilization With AMD 3100 (Mozobil) in Healthy Volunteers Previously Mobilized With G-CSF|Completed||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:14:31.119615|2018-06-01 05:14:31.119615
NCT00075296|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-08|||2017-06-30|2004-01-08|2004-01-09|Estimate|||||||2017-06-30|2017-07-02|Actual|January 5, 2004||2004-01-05|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression|FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:31.261897|2018-06-01 05:14:31.261897
NCT00075283|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-08|||2005-06-23|2004-01-08|2004-01-09|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 2002||2002-11-30|January 2004|2004-01-31||||||||Interventional|||Walking Therapy In Hemiparetic Stroke Patients Using Robotic-Assisted Treadmill Training|Gait Restoration In Hemiparetic Stroke Patients Using Goal-Directed, Robotic-Assisted, Treadmill Training|Unknown status|Recruiting|Phase 1|50||U.S. Department of Education|||||f||||||||||||||2018-06-01 05:14:31.311131|2018-06-01 05:14:31.311131
NCT00075270|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-07|2013-03-14||2015-04-16|2004-01-08|2004-01-09|Estimate|2014-02-13|2014-03-31|Estimate||||2015-04-16|2015-05-06|Estimate|January 2004||2004-01-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|October 2006|Actual|2006-10-31||Interventional|||Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination With Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer|Completed||Phase 3|580|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-06-01 05:14:31.482698|2018-06-01 05:14:31.482698
NCT00075257|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-07|||2009-08-18|2004-01-08|2004-01-09|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of DVS-233 SR For Prevention Of Depressive Relapse In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|603|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:14:35.4645|2018-06-01 05:14:35.4645
NCT00075231|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-06|||2006-09-28|2004-01-07|2004-01-08|Estimate|||||||2006-09-28|2006-10-02|Estimate|December 2003||2003-12-31|September 2006|2006-09-30||||||||Interventional|||A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects|A Randomized, Open-Label Study Exploring a Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects|Completed||Phase 2|150||Abbott|||||||||||||||||||2018-06-01 05:14:35.655493|2018-06-01 05:14:35.655493
NCT00075218|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-06|2009-05-06||2009-08-31|2004-01-07|2004-01-08|Estimate|2009-08-31|2009-09-28|Estimate||||2009-08-31|2009-09-28|Estimate|December 2003||2003-12-31|August 2009|2009-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor|Completed||Phase 3|361|Actual|Pfizer|Duration of Tumor Response could not be reliably estimated at the time of analysis.|2|||f||||t||||||||||2018-06-01 05:14:36.040042|2018-06-01 05:14:36.040042
NCT00075153|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-02|||2014-04-21|2004-01-07|2004-01-08|Estimate|||||||2014-04-21|2014-04-22|Estimate|September 2001||2001-09-30|April 2014|2014-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Quality of Life in Children With HIV Infection|Quality of Life in Children With HIV Infection|Completed|||1993|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-06-01 05:14:39.490814|2018-06-01 05:14:39.490814
NCT00020787|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-09-30|2004-01-07|2004-01-08|Estimate|||||||2015-09-30|2015-10-02|Estimate|July 2001||2001-07-31|July 2012|2012-07-31|December 2002|Actual|2002-12-31|January 2002|Actual|2002-01-31||Interventional|||Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer|An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV)|Completed||Phase 3|8|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:14:39.544968|2018-06-01 05:14:39.544968
NCT00017576|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2017-04-26|2004-01-07|2004-01-08|Estimate|||||||2017-04-26|2017-04-28|Actual|December 2000||2000-12-31|April 2017|2017-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy|Phase II Study of Calcitrol Enhanced Carboplatin in Hormone Refractory Prostate Cancer|Completed||Phase 2|19|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 05:14:39.642119|2018-06-01 05:14:39.642119
NCT00017537|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-08-02|2004-01-07|2004-01-08|Estimate|||||||2013-08-02|2013-08-05|Estimate|March 2000||2000-03-31|November 2012|2012-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer|Phase IB Trial of Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer Adjuvant in Patients With Metastatic Cancer|Withdrawn||Phase 1|0|Actual|University of Alabama at Birmingham||5|||f||||t||||||||||2018-06-01 05:14:39.727364|2018-06-01 05:14:39.727364
NCT00017433|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2008-11-16|2004-01-07|2004-01-08|Estimate|||||||2008-11-16|2008-11-18|Estimate|January 2001||2001-01-31|June 2002|2002-06-30||||||||Interventional|||Arsenic Trioxide in Treating Patients With Multiple Myeloma|Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:39.796996|2018-06-01 05:14:39.796996
NCT00075244|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-06|||2008-03-03|2004-01-06|2004-01-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2004||2004-01-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Alternative Dosing and Regimen of Replagal to Treat Fabry Disease|A Phase I-II Pharmacokinetic/Pharmacodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients With Fabry Disease|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:39.853042|2018-06-01 05:14:39.853042
NCT00075192|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-05|||2012-06-05|2004-01-06|2004-01-07|Estimate|||||||2012-06-05|2012-06-06|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|March 2006|Actual|2006-03-31|||||Interventional|||CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer|A Phase 1, Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and a Phase 2, Open Label, Randomized Study to Evaluate the Efficacy of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and Androgen Ablation Alone in Patients With High Risk Prostate Cancer|Completed||Phase 1/Phase 2|8|Actual|AstraZeneca|||||f||||||||||||||2018-06-01 05:14:39.993325|2018-06-01 05:14:39.993325
NCT00017082|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-25|2004-01-06|2004-01-07|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2001||2001-04-30|December 2010|2010-12-31|December 2010|Actual|2010-12-31|June 2003|Actual|2003-06-30||Interventional|||Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer|A Multicenter, Phase II Study Of Oxaliplatin Single Agent As Third-Line Treatment Of Metastatic Colorectal Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:40.076724|2018-06-01 05:14:40.076724
NCT00016237|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-10-22|2004-01-06|2004-01-07|Estimate|||||||2013-10-22|2013-10-23|Estimate|December 2000||2000-12-31|June 2002|2002-06-30||||||||Interventional|||Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment|Phase I Dose-Escalation Study of the Pharmacokinetic, Safety, Tolerability, and Biologic Activity of huKS-IL-2 Administered Daily as a 1-Hour Intravenous Infusion for Five Consecutive Days for Treatment of Refractory Epithelial Cancer|Completed||Phase 1|||EMD Serono|||||f||||||||||||||2018-06-01 05:14:40.140423|2018-06-01 05:14:40.140423
NCT00016198|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-06-25|2004-01-06|2004-01-07|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2001||2001-05-31|December 2010|2010-12-31|December 2010|Actual|2010-12-31|April 2003|Actual|2003-04-30||Interventional|||Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer|A Randomized, Multicenter, Phase II Study Of Bolus/Infusion 5-FU/LV (de Gramont Regimen) Versus Oxaliplatin And Bolus/Infusion 5-FU/LV (de Gramont Regimen) As Third-Line Treatment Of Patients With Metastatic Colorectal Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:40.206239|2018-06-01 05:14:40.206239
NCT00014404|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-01-15|2004-01-06|2004-01-07|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2000||2000-10-31|January 2013|2013-01-31||||January 2006|Actual|2006-01-31||Interventional|||Celecoxib in Treating Patients With Precancerous Lesions of the Mouth|Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:14:40.364818|2018-06-01 05:14:40.364818
NCT00014287|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-12-18|2004-01-06|2004-01-07|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2000||2000-09-30|December 2013|2013-12-31||||||||Interventional|||Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer|Intravesical Gemcitabine Therapy for BCG-Refractory Superficial Bladder Cancer: A Phase I and Pharmacokinetic Study|Withdrawn||Phase 1|0|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:14:40.418013|2018-06-01 05:14:40.418013
NCT00075205|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-05|||2017-06-30|2004-01-05|2004-01-06|Estimate|||||||2017-06-30|2017-07-02|Actual|December 31, 2003||2003-12-31|June 2, 2010|2010-06-02|March 15, 2007|Actual|2007-03-15|March 15, 2007|Actual|2007-03-15||Interventional|||Rimonabant to Reduce Alcohol Consumption|Clinical Trial of the Cannabinoid CB1 Receptor Antagonist, SR141716 (Rimonabant), to Reduce Voluntary Ethanol Drinking in Healthy, Non-Treatment Seeking Individuals Who Consume Between 20 and 50 Drinks Per Week|Completed||Phase 2|54|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:40.469838|2018-06-01 05:14:40.469838
NCT00075179|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-05|||2012-07-31|2004-01-05|2004-01-06|Estimate|||||||2012-07-31|2012-08-01|Estimate|January 2004||2004-01-31|July 2012|2012-07-31|March 2006|Actual|2006-03-31|May 2005|Actual|2005-05-31||Interventional|||Natrecor in Pulmonary Hypertension|Phase IV, Open Labeled Study to Test the Effectiveness of Nesiritide in Reversing Pulmonary Hypertension in Patients Who Will be Undergoing CardioThoracic Surgery|Terminated||Phase 4|7|Actual|M.D. Anderson Cancer Center||1||Low accrual.|f||||f||||||||||2018-06-01 05:14:40.549758|2018-06-01 05:14:40.549758
NCT00075166|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-02|||2008-03-03|2004-01-02|2004-01-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2003||2003-12-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors|A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors|Completed||Phase 4|130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:40.800336|2018-06-01 05:14:40.800336
NCT00075088|ClinicalTrials.gov processed this data on May 31, 2018|2004-01-02|2013-06-08||2015-05-15|2004-01-02|2004-01-05|Estimate|2013-08-16|2013-08-19|Estimate||||2015-05-15|2015-06-17|Estimate|September 2003||2003-09-30|May 2015|2015-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Tele-Electrocardiography in Emergency Cardiac Care|Tele-electrocardiography in Emergency Cardiac Care|Completed||Phase 3|794|Actual|University of California, San Francisco|Sample size was not powered to detect a statistically significant difference in survival between patients with and without a prehospital ECG|2|||f||||t||||||||||2018-06-01 05:14:41.098864|2018-06-01 05:14:41.098864
NCT00075075|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-31|||2017-06-30|2003-12-31|2004-01-01|Estimate|||||||2017-06-30|2017-07-02|Actual|December 23, 2003||2003-12-23|September 6, 2007|2007-09-06|September 6, 2007||2007-09-06|||||Interventional|||Infliximab to Treat Non-Infectious Scleritis|Pilot Study of the Evaluation of Infliximab in the Treatment of Non-Infectious Scleritis|Completed||Phase 1|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:41.335595|2018-06-01 05:14:41.335595
NCT00075062|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-31|||2008-08-20|2003-12-31|2004-01-01|Estimate|||||||2008-08-20|2008-08-21|Estimate||||May 2006|2006-05-31||||||||Observational|||A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials|Characteristics of Baseline Mucosal Indices of Injury and Inflammation in Men For Use in Rectal Microbicide Trials|Completed|||16||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:14:41.394754|2018-06-01 05:14:41.394754
NCT00075049|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-31|||2014-08-20|2003-12-31|2004-01-01|Estimate|||||||2014-08-20|2014-08-21|Estimate|December 2003||2003-12-31|August 2014|2014-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria|Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactogenicity, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S|Completed||Phase 1/Phase 2|104||U.S. Army Medical Research and Materiel Command|||||f||||||||||||||2018-06-01 05:14:41.522991|2018-06-01 05:14:41.522991
NCT00014183|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2009-09-23|2003-12-31|2004-01-01|Estimate|||||||2009-09-23|2009-09-24|Estimate|January 2001||2001-01-31|September 2009|2009-09-30|August 2005|Actual|2005-08-31|May 2002|Actual|2002-05-31||Interventional|||ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer|A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent|Completed||Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:14:41.587064|2018-06-01 05:14:41.587064
NCT00012116|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2015-10-28|2003-12-31|2004-01-01|Estimate|||||||2015-10-28|2015-10-30|Estimate|October 2000||2000-10-31|July 2012|2012-07-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain|Temozolomide For Patients With Cerebral Metastases Who Have Failed Radiation Therapy|Completed||Phase 2|4|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 05:14:41.654945|2018-06-01 05:14:41.654945
NCT00009919|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-01-22|2003-12-31|2004-01-01|Estimate|||||||2013-01-22|2013-01-23|Estimate|December 2000||2000-12-31|January 2013|2013-01-31||||June 2003|Actual|2003-06-30||Interventional|||SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment|Phase II Study of SU5416 (NSC 696819) for Patients With Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or 5-Fluorouracil Containing Regimens|Terminated||Phase 2|50|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:14:41.729251|2018-06-01 05:14:41.729251
NCT00009893|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2016-12-05|2003-12-31|2004-01-01|Estimate|||||||2016-12-05|2016-12-07|Estimate|May 2001||2001-05-31|December 2016|2016-12-31|October 2009|Actual|2009-10-31|January 2005|Actual|2005-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer|Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma|Completed||Phase 2|42|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:14:41.825366|2018-06-01 05:14:41.825366
NCT00075036|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-30|||2018-04-04|2003-12-30|2003-12-31|Estimate|||||||2018-04-04|2018-04-05|Actual|December 30, 2003||2003-12-30|July 24, 2017|2017-07-24||||||||Observational|||Patient-Provider Trust Among Individuals With End-Stage Kidney Disease|Exploring Patient-Provider Trust Among Individuals With End-Stage Renal Disease|Completed|||113|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:41.945484|2018-06-01 05:14:41.945484
NCT00075023|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-30|2015-10-29||2015-10-29|2003-12-30|2003-12-31|Estimate|2015-10-29|2015-11-04|Estimate||||2015-10-29|2015-11-04|Estimate|December 2003||2003-12-31|October 2015|2015-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||The sample size for the proof of concept study was calculated by using the data for aphthous ulcer percentage healing (personal communication with investigator) with topical thalidomide gel at 0 mg and 20 mg. This gave a total sample size of 60 using an alpha level = .05, beta = -.20 and a 2-tailed test. Assuming drop out rate of 10%, total is 66.|Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis|Evaluation of Efficacy and Mechanisms of Topical Thalidomide for Chronic Graft-Versus-Host-Disease Related Stomatitis|Terminated||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)|Small sample size due to difficult enrollment|2||unable to enroll adequate subjects|f||||t||||||||||2018-06-01 05:14:42.015959|2018-06-01 05:14:42.015959
NCT00075010|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-29|||2012-06-08|2003-12-30|2003-12-31|Estimate|||||||2012-06-08|2012-06-11|Estimate|January 2004||2004-01-31|June 2012|2012-06-30|November 2006|Actual|2006-11-30|March 2005|Actual|2005-03-31||Interventional|||Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes|Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes|Completed||Phase 1/Phase 2|54|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:14:42.25338|2018-06-01 05:14:42.25338
NCT00074997|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-28||2013-03-15|2016-06-17|2003-12-30|2003-12-31|Estimate||||2013-03-15|2013-03-21|Estimate|2016-06-17|2016-06-20|Estimate|December 2002||2002-12-31|June 2016|2016-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection|A Randomized Phase II, Double-Blind, Controlled Trial to Evaluate the Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced With Placebo or an Anti-HIV-1 Ribozyme (OZ1) in Patients With HIV-1 Infection|Completed||Phase 2|1|Actual|Janssen-Cilag Pty Ltd||2|||f||||t||||||||||2018-06-01 05:14:42.333611|2018-06-01 05:14:42.333611
NCT00009867|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-06-03|2003-12-30|2003-12-31|Estimate|||||||2013-06-03|2013-06-04|Estimate|December 2000||2000-12-31|June 2013|2013-06-30||||June 2004|Actual|2004-06-30||Interventional|||Arsenic Trioxide in Treating Patients With Urothelial Cancer|A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:14:42.400148|2018-06-01 05:14:42.400148
NCT00009698|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-06-27|2003-12-30|2003-12-31|Estimate|||||||2013-06-27|2013-06-28|Estimate|March 1998||1998-03-31|June 2013|2013-06-30|September 2005|Actual|2005-09-30|June 2001|Actual|2001-06-30||Interventional|||Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia|IL-2 Infusion in AML Patients After Autologous Bone Marrow Transplant: A Pediatric Oncology Group Wide Phase I Trial|Completed||Phase 1|1|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:14:42.473688|2018-06-01 05:14:42.473688
NCT00006481|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-11-18|2003-12-30|2003-12-31|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2000||2000-10-31|November 2013|2013-11-30||||August 2002|Actual|2002-08-31||Interventional|||Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer|A Phase III Comparison of Biafine to Declared Institutional Preference for Radiation Induced Skin Toxicity in Patients Undergoing Radiation Therapy for Advanced Squamous Cell Carcinomas of the Head and Neck|Completed||Phase 3|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:14:42.85198|2018-06-01 05:14:42.85198
NCT00006480|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2010-09-17|2003-12-30|2003-12-31|Estimate|||||||2010-09-17|2010-09-21|Estimate|May 2000||2000-05-31|September 2010|2010-09-30|March 2005|Actual|2005-03-31|||||Interventional|||Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma|Phase I Study to Evaluate the Safety of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Genetically-Modified Autologous CD8+ T Cell Clones|Completed||Phase 1|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:14:43.309215|2018-06-01 05:14:43.309215
NCT00074984|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-24|2010-07-21||2013-12-02|2003-12-24|2003-12-25|Estimate|2010-11-18|2010-12-15|Estimate||||2013-12-02|2013-12-27|Estimate|February 2001||2001-02-28|December 2013|2013-12-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease|Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Fabrazyme on Progression of Renal Disease and Significant Clinical Events in Patients With Fabry Disease|Completed||Phase 4|82|Actual|Sanofi||2|||f||||t||||||||||2018-06-01 05:14:43.430034|2018-06-01 05:14:43.430034
NCT00074971|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-24|||2013-12-02|2003-12-24|2003-12-25|Estimate|||||||2013-12-02|2013-12-04|Estimate|October 1999||1999-10-31|December 2013|2013-12-31|December 2004||2004-12-31|||||Interventional|||A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease|A Multi-center, Open-Label Extension Study of the Safety and Efficacy of Recombinant Human a-Galactosidase A (r-haGAL) Replacement in Patients With Fabry Disease|Completed||Phase 3|58||Sanofi|||||||||||||||||||2018-06-01 05:14:44.803858|2018-06-01 05:14:44.803858
NCT00074958|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-24|2009-03-03||2015-03-13|2003-12-24|2003-12-25|Estimate|2009-04-28|2009-06-16|Estimate||||2015-03-13|2015-04-02|Estimate|October 2002||2002-10-31|March 2015|2015-03-31|July 2005|Actual|2005-07-31|May 2005|Actual|2005-05-31||Interventional|||A Study of Fabrazyme in Pediatric Patients With Fabry Disease|A Multi-center, Phase 2, Open-Label Study of Fabrazyme (Recombinant Human a-Galactosidase A) Replacement Therapy in Pediatric Patients With Fabry Disease|Completed||Phase 2|16|Actual|Sanofi|The trial was not powered to demonstrate clinical benefit.|1|||f||||||||||||||2018-06-01 05:14:44.968567|2018-06-01 05:14:44.968567
NCT00074932|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-23|||2014-02-04|2003-12-24|2003-12-25|Estimate|||||||2014-02-04|2014-02-06|Estimate|November 2004||2004-11-30|February 2014|2014-02-28|December 2006|Actual|2006-12-31|August 2006|Actual|2006-08-31||Interventional|||Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease|Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease|Completed||N/A|9|Actual|Sanofi||1|||t||||||||||||||2018-06-01 05:14:45.253252|2018-06-01 05:14:45.253252
NCT00074919|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-23|||2014-02-04|2003-12-24|2003-12-25|Estimate|||||||2014-02-04|2014-02-05|Estimate|December 2003||2003-12-31|February 2014|2014-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Expanded Access|||Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease|Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease|Approved for marketing|||||Sanofi|||||||||||||||||||2018-06-01 05:14:45.540183|2018-06-01 05:14:45.540183
NCT00074906|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-23|||2012-05-04|2003-12-24|2003-12-25|Estimate|||||||2012-05-04|2012-05-07|Estimate|November 2003||2003-11-30|January 2012|2012-01-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)|Venticute in Patients With Pneumonia or Aspiration of Gastric Contents Leading to Intubation, Ventilation, and Severe Oxygenation Impairment: A Randomized, Multinational, Multicenter, Parallel Group, Double Blind, Control Group Study|Completed||Phase 3|1200|Anticipated|Takeda|||||f||||t||||||||||2018-06-01 05:14:45.670937|2018-06-01 05:14:45.670937
NCT00074945|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-23|||2017-10-05|2003-12-23|2003-12-24|Estimate|||||||2017-10-05|2017-10-06|Actual|December 19, 2003||2003-12-19|February 28, 2013|2013-02-28|February 28, 2013||2013-02-28|||||Observational|||Obesity and Fatty Acid Flux Comparison Trials|A Comparison of Free Fatty Acid Flux in African Americans and Caucasians|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:46.449057|2018-06-01 05:14:46.449057
NCT00074893|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-23|||2006-03-06|2003-12-23|2003-12-24|Estimate|||||||2006-03-06|2006-03-08|Estimate|November 2003||2003-11-30|March 2006|2006-03-31|February 2004||2004-02-29|||||Interventional|||Protective Brace to Prevent Hand and Arm Injuries|Shock Absorbing Brace for Study of Upper Extremity Musculoskeletal Disorders|Completed||N/A|15||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:14:46.560673|2018-06-01 05:14:46.560673
NCT00074867|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-22|||2006-11-06|2003-12-23|2003-12-24|Estimate|||||||2006-11-06|2006-11-07|Estimate|October 2003||2003-10-31|July 2006|2006-07-31|September 2004||2004-09-30|||||Interventional|||Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer|A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube Cancer|Completed||Phase 2|29||Pfizer|||||f||||||||||||||2018-06-01 05:14:46.749349|2018-06-01 05:14:46.749349
NCT00074854|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-22|||2006-11-08|2003-12-23|2003-12-24|Estimate|||||||2006-11-08|2006-11-09|Estimate|May 2002||2002-05-31|July 2006|2006-07-31|March 2005||2005-03-31|||||Interventional|||A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy|A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy (Paclitaxel And Carboplatin) Vs. Chemotherapy Alone For The Treatment Of Advanced Stage Non-Small Cell Lung Cancer.|Completed||Phase 1/Phase 2|87||Pfizer|||||f||||||||||||||2018-06-01 05:14:46.963423|2018-06-01 05:14:46.963423
NCT00074841|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-22|||2011-05-09|2003-12-23|2003-12-24|Estimate|||||||2011-05-09|2011-05-10|Estimate|September 2003||2003-09-30|May 2011|2011-05-31|January 2005|Actual|2005-01-31|||||Interventional|||Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India|A Phase II/III, Randomized, Comparative Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in India|Completed||Phase 2/Phase 3|230|Actual|Pfizer|||||||||||||||||||2018-06-01 05:14:47.129255|2018-06-01 05:14:47.129255
NCT00006384|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2011-10-18|2003-12-23|2003-12-24|Estimate|||||||2011-10-18|2011-10-20|Estimate|November 2000||2000-11-30|October 2011|2011-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer|Phase II Trial of SU5416 and Interferon Alfa 2B in Unresectable or Metastatic Renal Cell Carcinoma|Completed||Phase 2|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:14:47.366453|2018-06-01 05:14:47.366453
NCT00006353|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-09-20|2003-12-23|2003-12-24|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 2000||2000-07-31|September 2012|2012-09-30||||March 2002|Actual|2002-03-31||Interventional|||Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study|Completed||Phase 3|575|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:14:47.967541|2018-06-01 05:14:47.967541
NCT00006247|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2009-10-13|2003-12-23|2003-12-24|Estimate|||||||2009-10-13|2009-10-14|Estimate|August 2000||2000-08-31|October 2009|2009-10-31|March 2006|Actual|2006-03-31|July 2003|Actual|2003-07-31||Interventional|||SU5416 in Treating Children With Recurrent or Progressive Brain Tumors|A Phase I Study of SU5416 in Pediatric Patients With Recurrent or Progressive Poor Prognosis Brain Tumors|Terminated||Phase 1|33|Actual|Pediatric Brain Tumor Consortium||||The pharmaceutical company discontinued further development of SU5416.|f||||t||||||||||2018-06-01 05:14:48.322101|2018-06-01 05:14:48.322101
NCT00006213|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-01-22|2003-12-23|2003-12-24|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2000||2000-04-30|January 2013|2013-01-31||||October 2002|Actual|2002-10-31||Interventional|||BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia|Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086) in Acute Leukemias, Myelodysplastic Syndromes (RAEB and RAEB-T) and Chronic Myeloid Leukemia in Blast Phase|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:14:48.630957|2018-06-01 05:14:48.630957
NCT00006104|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-08-10|2003-12-23|2003-12-24|Estimate|||||||2012-08-10|2012-08-14|Estimate|September 1998||1998-09-30|August 2012|2012-08-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer|A Multi-Institutional Phase II Pilot Trial With Weekly Docetaxel and Herceptin as First or Second Line Therapy for HER2/Neu Overexpressing Metastatic Breast Cancer|Completed||Phase 2|46|Actual|Vanderbilt-Ingram Cancer Center|||||f||||t||||||||||2018-06-01 05:14:49.192653|2018-06-01 05:14:49.192653
NCT00074880|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-22|||2008-03-03|2003-12-22|2003-12-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2003||2003-12-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy|The Role of Atrio-Ventricular Coupling in Exercise Tolerance in Non-Obstructive Hypertrophic Cardiomyopathy|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:49.66208|2018-06-01 05:14:49.66208
NCT00074828|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|||2008-03-27|2003-12-22|2003-12-23|Estimate|||||||2008-03-27|2008-03-31|Estimate|December 2003||2003-12-31|March 2008|2008-03-31|May 2005|Actual|2005-05-31|||||Interventional|||New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery|A Comparison of the Oral Anticoagulant LY517717 Difumarate to Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolic Events (VTE) Post-Total Hip Replacement (THR) and Post-Total Knee Replacement (TKR) Surgery|Completed||Phase 2|511|Actual|Eli Lilly and Company||2|||||||||||||||||2018-06-01 05:14:49.85074|2018-06-01 05:14:49.85074
NCT00074763|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|||2012-08-01|2003-12-22|2003-12-23|Estimate|||||||2012-08-01|2012-08-02|Estimate|July 2003||2003-07-31|August 2012|2012-08-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets|Randomized Crossover Study Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets|Terminated||Phase 3|4|Actual|M.D. Anderson Cancer Center||1||Terminated due to low recruitment.|f||||f||||||||||2018-06-01 05:14:50.07077|2018-06-01 05:14:50.07077
NCT00074750|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|||2012-02-20|2003-12-22|2003-12-23|Estimate|||||||2012-02-20|2012-02-22|Estimate|December 2003||2003-12-31|February 2012|2012-02-29|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)|A Phase I Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)|Terminated||Phase 1|7|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||t||||||||||2018-06-01 05:14:50.715182|2018-06-01 05:14:50.715182
NCT00074737|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|||2014-09-16|2003-12-22|2003-12-23|Estimate|||||||2014-09-16|2014-09-18|Estimate|April 2004||2004-04-30|September 2014|2014-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML|Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)|Completed||Phase 2|53|Actual|Eleos, Inc.||3|||f||||f||||||||||2018-06-01 05:14:50.871621|2018-06-01 05:14:50.871621
NCT00074724|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|||2013-04-16|2003-12-22|2003-12-23|Estimate|||||||2013-04-16|2013-04-18|Estimate|May 2003||2003-05-31|April 2013|2013-04-30|April 2016|Anticipated|2016-04-30|December 2008|Actual|2008-12-31||Interventional|DECIPHER||Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization|Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization|Unknown status|Active, not recruiting|N/A|319|Actual|Medstar Health Research Institute||2|||f||||t||||||||||2018-06-01 05:14:51.22573|2018-06-01 05:14:51.22573
NCT00006099|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2009-02-06|2003-12-22|2003-12-23|Estimate|||||||2009-02-06|2009-02-09|Estimate|May 2000||2000-05-31|June 2002|2002-06-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer|Pilot Trial of Humanized 3S193 Monoclonal Antibody (hu3S193) in Presurgical Patients With Ovarian Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:51.310432|2018-06-01 05:14:51.310432
NCT00006087|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2009-02-06|2003-12-22|2003-12-23|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 1999||1999-11-30|December 2007|2007-12-31||||||||Interventional|||Chest X-Ray or Chest CT Scan in Patients at High Risk of Developing Lung Cancer|A Randomized Prospective Study Comparing Annual Chest X-Rays to Annual Spiral Chest CT Scanning in Patients at High-Risk for the Development of Lung Cancer|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:51.40928|2018-06-01 05:14:51.40928
NCT00006080|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2008-11-22|2003-12-22|2003-12-23|Estimate|||||||2008-11-22|2008-11-25|Estimate|November 2000||2000-11-30|September 2005|2005-09-30||||||||Interventional|||Fenretinide in Treating Patients With Recurrent Malignant Glioma|Phase II Evaluation of Fenretinide NSC (374551) as a Single Agent in the Treatment of Adult Patients With Recurrent Malignant Glioma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:14:51.522908|2018-06-01 05:14:51.522908
NCT00005978|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-10-14|2003-12-22|2003-12-23|Estimate|||||||2010-10-14|2010-10-15|Estimate|May 2000||2000-05-31|May 2009|2009-05-31||||December 2004|Actual|2004-12-31||Interventional|||N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma|Dose Escalation Study of 131 I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma - A Phase I Study|Completed||Phase 1|||New Approaches to Neuroblastoma Therapy Consortium|||||f||||t||||||||||2018-06-01 05:14:51.645464|2018-06-01 05:14:51.645464
NCT00005963|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-12-05|2003-12-22|2003-12-23|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2000||2000-11-30|December 2016|2016-12-31|January 2009|Actual|2009-01-31|October 2002|Actual|2002-10-31||Interventional|||Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer|Phase II Trial of Docetaxel and Carboplatin as First-Line Therapy for Metastatic Breast Cancer|Completed||Phase 2|53|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:14:51.771561|2018-06-01 05:14:51.771561
NCT00074815|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|2012-11-15||2014-07-23|2003-12-19|2003-12-22|Estimate|2013-01-08|2013-02-11|Estimate||||2014-07-23|2014-07-29|Estimate|September 2003||2003-09-30|November 2012|2012-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Treatment of Obsessive Compulsive Disorder in Children|Treatment of Pediatric OCD for SRI Partial Responders|Completed||Phase 3|124|Actual|Duke University||3|||f||||t||||||||||2018-06-01 05:14:51.896415|2018-06-01 05:14:51.896415
NCT00074802|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|2017-02-24||2017-05-16|2003-12-19|2003-12-22|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|December 2003||2003-12-31|May 2017|2017-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Patients included here were the subset of enrollees completing the open trial as partial responders.|Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder|CBT Augmentation of Paroxetine for Social Anxiety|Completed||Phase 3|150|Actual|Temple University|Limitations include the small size of the randomized sample and the lack of a placebo arm in the randomization phase of the study.|2|||f||||t|t|f||||||No||2018-06-01 05:14:52.320049|2018-06-01 05:14:52.320049
NCT00074789|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|||2013-06-20|2003-12-19|2003-12-22|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 2003||2003-06-30|June 2013|2013-06-30|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Interventional|||Reducing Symptoms of Depression in Low-Income Mothers|Reducing Depressive Symptoms in Low-Income Mothers|Completed||Phase 2|226|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 05:14:53.90401|2018-06-01 05:14:53.90401
NCT00074776|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|||2012-07-19|2003-12-19|2003-12-22|Estimate|||||||2012-07-19|2012-07-23|Estimate|May 2003||2003-05-31|July 2012|2012-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Acute Treatment of Bipolar II Depression|Acute Treatment of Bipolar II Depression|Completed||Phase 3|102|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 05:14:54.117033|2018-06-01 05:14:54.117033
NCT00074711|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-19|2012-07-03||2016-07-05|2003-12-19|2003-12-22|Estimate|2016-07-05|2016-07-06|Estimate||||2016-07-05|2016-07-06|Estimate|August 2004||2004-08-31|July 2016|2016-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Adding Phosphorus to Osteoporosis Drug Treatment|Bone Sparing by Calcium Salts With and Without Extra Phosphorus|Completed||Phase 2|241|Actual|Creighton University||2|||f||||f||||||||||2018-06-01 05:14:54.316155|2018-06-01 05:14:54.316155
NCT00074698|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-18|||2007-12-10|2003-12-19|2003-12-22|Estimate|||||||2007-12-10|2007-12-12|Estimate||||December 2007|2007-12-31|May 2004||2004-05-31|||||Interventional|||Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis|A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis|Completed||Phase 1|27||FibroGen|||||f||||||||||||||2018-06-01 05:14:54.738629|2018-06-01 05:14:54.738629
NCT00074685|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-18|||2009-04-28|2003-12-18|2003-12-19|Estimate|||||||2009-04-28|2009-04-30|Estimate|September 1994||1994-09-30|April 2009|2009-04-30||||||||Observational|||National Registry for Ichthyosis and Related Disorders|Research Registry for Inherited Disorders of Keratinization|Unknown status|Active, not recruiting||610|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||f||||||Samples With DNA|"~     Histology, DNA from participating enrollees~   "|||2018-06-01 05:14:55.707679|2018-06-01 05:14:55.707679
NCT00074646|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-17|||2007-01-02|2003-12-18|2003-12-19|Estimate|||||||2007-01-02|2007-01-04|Estimate|December 2003||2003-12-31|January 2007|2007-01-31|June 2005||2005-06-30|||||Interventional|||Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas|Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas|Completed||Phase 1|36||Celgene|||||||||||||||||||2018-06-01 05:14:55.805896|2018-06-01 05:14:55.805896
NCT00074633|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-17|||2010-01-12|2003-12-18|2003-12-19|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2000||2000-01-31|January 2010|2010-01-31||||||||Interventional|||"Evaluating Health at Every Size(HAES) as an Alternative Obesity Treatment Model"|"Evaluating Health at Every Size(HAES) as an Alternative Obesity Treatment Model"|Completed||N/A|79||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:14:55.885772|2018-06-01 05:14:55.885772
NCT00074620|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-17|||2007-10-04|2003-12-18|2003-12-19|Estimate|||||||2007-10-04|2007-10-05|Estimate|November 2003||2003-11-30|October 2007|2007-10-31|January 2006||2006-01-31|||||Interventional|||A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis|A Randomised, Multicenter, Open-Label, Parallel Group Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Unfractionated Heparin as Anticoagulant Treatment in Patients Undergoing Haemodialysis Via an Arteriovenous Graft|Completed||Phase 2|260||Speedel Pharma Ltd.|||||||||f||||||||||2018-06-01 05:14:55.981088|2018-06-01 05:14:55.981088
NCT00074672|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-17|||2017-06-30|2003-12-17|2003-12-18|Estimate|||||||2017-06-30|2017-07-02|Actual|December 12, 2003||2003-12-12|April 14, 2009|2009-04-14|April 14, 2009||2009-04-14|||||Observational|||Relationship Between Sensory and Motor Systems in Restless Leg Syndrome|Sensorimotor Gating Studies in Restless Legs Syndrome|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:14:56.055924|2018-06-01 05:14:56.055924
NCT00074607|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-16|||2012-11-09|2003-12-17|2003-12-18|Estimate|||||||2012-11-09|2012-11-12|Estimate|December 2001||2001-12-31|November 2012|2012-11-30|April 2007|Actual|2007-04-30|July 2005|Actual|2005-07-31||Interventional|||Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine|Intrathecal Gemcitabine Therapy for Neoplastic Meningitis: A Phase I and Pharmacokinetic Study|Terminated||Phase 1|10|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 05:14:56.173724|2018-06-01 05:14:56.173724
NCT00074581|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-16|2016-09-09||2016-11-03|2003-12-16|2003-12-17|Estimate|2016-09-09|2016-10-31|Estimate||||2016-11-03|2016-11-07|Estimate|February 2005||2005-02-28|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Preventing Sexual Transmission of HIV With Anti-HIV Drugs|A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples|Completed||Phase 3|3526|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:14:56.351523|2018-06-01 05:14:56.351523
NCT00074568|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-16|||2016-01-04|2003-12-16|2003-12-17|Estimate|||||||2016-01-04|2016-01-06|Estimate|September 2000||2000-09-30|January 2016|2016-01-31||||January 2022|Anticipated|2022-01-31||Observational|Registry||Scleroderma Registry|Scleroderma Family Registry and DNA Repository|Recruiting|||5000|Anticipated|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||2||f||||f||||||Samples With DNA|"~     Serum, Plasma, DNA~   "|||2018-06-01 05:14:58.205731|2018-06-01 05:14:58.205731
NCT00074555|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-16|||2016-01-05|2003-12-16|2003-12-17|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2001||2001-01-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Observational|CLEAR||Registry for African Americans With Early Rheumatoid Arthritis|Consortium for the Longitudinal Evaluation of African Americans With Early Rheumatoid Arthritis (CLEAR)|Completed|||357|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||f||||||Samples With DNA|"~     serum, DNA~   "|||2018-06-01 05:15:01.82873|2018-06-01 05:15:01.82873
NCT00005959|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-12-03|2003-12-16|2003-12-17|Estimate|||||||2013-12-03|2013-12-04|Estimate|December 1999||1999-12-31|June 2002|2002-06-30||||||||Interventional|||Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma|Phase II Trial of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated Intermediate or High Grade Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:02.108952|2018-06-01 05:15:02.108952
NCT00005876|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-03|2003-12-16|2003-12-17|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 2000||2000-04-30|June 2002|2002-06-30||||||||Interventional|||Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery|A Phase II Study of RFS 2000 (Rubitecan, 9-Nitro-Camptothecin, 9-NC) in Patients With Advanced Gastric Carcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:02.473655|2018-06-01 05:15:02.473655
NCT00005646|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2016-07-12|2003-12-16|2003-12-17|Estimate|||||||2016-07-12|2016-07-14|Estimate|April 2000||2000-04-30|July 2016|2016-07-31|February 2008|Actual|2008-02-29|January 2004|Actual|2004-01-31||Interventional|||Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|36|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:15:02.626772|2018-06-01 05:15:02.626772
NCT00005642|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-06-09|2003-12-16|2003-12-17|Estimate|||||||2010-06-09|2010-06-11|Estimate|May 2000||2000-05-31|June 2010|2010-06-30|November 2005|Actual|2005-11-30|December 2002|Actual|2002-12-31||Interventional|||SU5416 in Treating Patients With Advanced Solid Tumors|A Phase I Pharmacodynamic Trial of SU5416 (NSC 696819)|Completed||Phase 1|19|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:15:02.924615|2018-06-01 05:15:02.924615
NCT00005634|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-18|2003-12-16|2003-12-17|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy|Phase I Clinical and Pharmacological Study of Suberoylanilide Hydroxamic Acid- SAHA (MSK390) in Patients With Advanced Solid Tumors|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:03.208587|2018-06-01 05:15:03.208587
NCT00074542|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-15|||2007-02-20|2003-12-15|2003-12-16|Estimate|||||||2007-02-20|2007-02-21|Estimate|September 2002||2002-09-30|October 2005|2005-10-31|January 2005||2005-01-31|||||Interventional|||An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease|A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease|Completed||Phase 3|364||Tillotts Pharma AG|||||||||||||||||||2018-06-01 05:15:03.417704|2018-06-01 05:15:03.417704
NCT00074529|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-15|||2015-07-23|2003-12-15|2003-12-16|Estimate|||||||2015-07-23|2015-07-24|Estimate|October 2003||2003-10-31|July 2015|2015-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease|Completed||Phase 2|512|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:15:03.568838|2018-06-01 05:15:03.568838
NCT00005598|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-12-19|2003-12-15|2003-12-16|Estimate|||||||2012-12-19|2012-12-21|Estimate|October 2000||2000-10-31|December 2012|2012-12-31|March 2002|Actual|2002-03-31|December 2001|Actual|2001-12-31||Interventional|||Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome|A Phase II Trial of 5-Azacytidine (NSC #102816) and Ethyol (Amifostine) in the Treatment of Adults With Myelodysplastic Syndromes|Completed||Phase 2|||University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 05:15:03.656617|2018-06-01 05:15:03.656617
NCT00005592|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2015-10-20|2003-12-15|2003-12-16|Estimate|||||||2015-10-20|2015-10-21|Estimate|November 1999||1999-11-30|October 2015|2015-10-31|November 2005|Actual|2005-11-30|March 2002|Actual|2002-03-31||Interventional|||Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multicenter, Open-Label, Trial to Evaluate the Efficacy and Safety of IDEC-Y2B8 Radioimmunotherapy of Relapsed or Refractory Low-Grade or Follicular Transformed B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|23|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:15:03.738603|2018-06-01 05:15:03.738603
NCT00005083|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-10-02|2003-12-15|2003-12-16|Estimate|||||||2012-10-02|2012-10-04|Estimate|March 1998||1998-03-31|October 2012|2012-10-31||||||||Interventional|||Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors|Defining Functional Tissue in Brain Tumors With Integrated Neuroimaging (Pilot Study)|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||||no participants enrolled|f||||||||||||||2018-06-01 05:15:03.87074|2018-06-01 05:15:03.87074
NCT00004890|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-03-25|2003-12-15|2003-12-16|Estimate|||||||2013-03-25|2013-03-26|Estimate|December 2000||2000-12-31|January 2008|2008-01-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer|Phase IB Open-Label Rising-Dose Study of Biomed 101 in Patients Treated With Interleukin-2 for Malignancy|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:03.95294|2018-06-01 05:15:03.95294
NCT00004874|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2018-01-13|2003-12-15|2003-12-16|Estimate|||||||2018-01-13|2018-01-17|Actual|November 1998||1998-11-30|January 2018|2018-01-31|November 2012|Actual|2012-11-30|April 2002|Actual|2002-04-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma|Terminated||Phase 3|31|Actual|University of Nebraska||||lack of FDA approval|f||||||||||||||2018-06-01 05:15:04.09838|2018-06-01 05:15:04.09838
NCT00074503|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-12|||2017-06-30|2003-12-12|2003-12-15|Estimate|||||||2017-06-30|2017-07-02|Actual|December 12, 2003||2003-12-12|July 13, 2010|2010-07-13|July 13, 2010||2010-07-13|||||Observational|||PET Imaging of DHA Metabolism|Positron Emission Tomography Imaging of Incorporation of Docosahexaenoic Acid (DHA) From Plasma Into Human Brain|Completed|||85|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:04.428903|2018-06-01 05:15:04.428903
NCT00074490|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-03-09|2003-12-12|2003-12-15|Estimate|||||||2018-03-09|2018-03-12|Actual|January 1, 2004||2004-01-01|November 15, 2017|2017-11-15|August 16, 2017|Actual|2017-08-16|July 20, 2017|Actual|2017-07-20||Interventional|||Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers|Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome|Completed||Phase 2|380|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-06-01 05:15:04.519497|2018-06-01 05:15:04.519497
NCT00074477|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-12|||2011-05-20|2003-12-12|2003-12-15|Estimate|||||||2011-05-20|2011-05-24|Estimate|October 2003||2003-10-31|April 2010|2010-04-30|July 2004|Actual|2004-07-31|||||Interventional|||Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 Mg-eq of Paliperidone Palmitate in Patients With Schizophrenia|Completed||Phase 2|250|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:15:04.770562|2018-06-01 05:15:04.770562
NCT00074464|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-12|||2013-05-03|2003-12-12|2003-12-15|Estimate|||||||2013-05-03|2013-05-06|Estimate|August 2003||2003-08-31|May 2013|2013-05-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Cholesterol Homeostasis in Framingham Offspring Study||Completed|||3378|Actual|Tufts University|||||f||||f||||||||||2018-06-01 05:15:04.876667|2018-06-01 05:15:04.876667
NCT00074451|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-12|||2008-08-20|2003-12-12|2003-12-15|Estimate|||||||2008-08-20|2008-08-21|Estimate|September 2003||2003-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Genomewide Search for Loci Underlying Metabolic Syndrome||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:15:04.957657|2018-06-01 05:15:04.957657
NCT00074438|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-12|||2013-05-07|2003-12-12|2003-12-15|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2003||2003-06-30|May 2013|2013-05-31|July 2011|Actual|2011-07-31|September 2004|Actual|2004-09-30||Interventional|||Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis|Randomized, Multifactorial, Double-blind, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Rituximab (MabThera®/Rituxan®) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis|Completed||Phase 2|465|Actual|Genentech, Inc.||9|||f||||||||||||||2018-06-01 05:15:05.021285|2018-06-01 05:15:05.021285
NCT00074425|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-11||2009-08-24|2013-07-05|2003-12-12|2003-12-15|Estimate||||2009-08-24|2009-08-26|Estimate|2013-07-05|2013-07-11|Estimate|January 2005||2005-01-31|July 2013|2013-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women|Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women|Completed||Phase 2|3101|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 05:15:05.162559|2018-06-01 05:15:05.162559
NCT00074412|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-11|2013-05-30||2013-07-05|2003-12-12|2003-12-15|Estimate|2013-07-05|2013-09-16|Estimate||||2013-07-05|2013-09-16|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding|A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding|Completed||Phase 3|2026|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The rate of maternal highly active antiretroviral therapy use was higher than expected in our study. Thus there were fewer infant infections which decreased the power to detect differences in HIV transmission risks between study groups.|2|||f||||||||||||||2018-06-01 05:15:05.298431|2018-06-01 05:15:05.298431
NCT00074399|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-11|||2009-08-06|2003-12-12|2003-12-15|Estimate|||||||2009-08-06|2009-08-07|Estimate|February 2001||2001-02-28|August 2009|2009-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV|Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant|Completed||Phase 3|775|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:15:06.146788|2018-06-01 05:15:06.146788
NCT00074386|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-11|||2014-01-16|2003-12-12|2003-12-15|Estimate|||||||2014-01-16|2014-01-17|Estimate|October 2003||2003-10-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Kidney and Liver Transplantation in People With HIV|Solid Organ Transplantation in HIV: Multi-Site Study|Completed|||275|Actual|University of California, San Francisco|||||f||||t||||||Samples Without DNA|"~     Whole Blood, serum, PBMC, kidney and liver biopsy slides, saliva, spleen tissue~   "|||2018-06-01 05:15:06.250652|2018-06-01 05:15:06.250652
NCT00074373|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-11|||2017-10-12|2003-12-11|2003-12-12|Estimate|||||||2017-10-12|2017-10-13|Actual|September 1994||1994-09-30|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||The Research Registry for Neonatal Lupus|The Research Registry for Neonatal Lupus|Recruiting|||500|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||Samples With DNA|"~     Blood~   "|||2018-06-01 05:15:06.355663|2018-06-01 05:15:06.355663
NCT00021983|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2015-04-28|2003-12-11|2003-12-12|Estimate|||||||2015-04-28|2015-04-29|Estimate|December 1998||1998-12-31|January 2006|2006-01-31||||||||Interventional|||Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia|Phase I Study of BL22, a Recombinant Immunotoxin for Treatment of CD22+ Leukemias and Lymphomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:06.461999|2018-06-01 05:15:06.461999
NCT00008177|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2017-11-06|2003-12-11|2003-12-12|Estimate|||||||2017-11-06|2017-11-08|Actual|July 27, 1999|Actual|1999-07-27|November 2017|2017-11-30||||March 21, 2009|Actual|2009-03-21||Interventional|||Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|A Phase I Study Combining Escalating Doses of Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to Establish Mixed or Full Donor Chimerism for Elderly Patients With Advanced Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome|Active, not recruiting||Phase 1|79|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:15:06.519503|2018-06-01 05:15:06.519503
NCT00074360|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2018-04-13|2003-12-10|2003-12-11|Estimate|||||||2018-04-13|2018-04-17|Actual|December 9, 2003||2003-12-09|December 17, 2012|2012-12-17|December 17, 2012||2012-12-17|||||Observational|||The Effect of Ethanol on Brain Activity|The Effect of Ethanol on Cerebral Blood Flow as Measured by Functional Magnetic Resonance Imaging and the Development of Conditioned Response to Ethanol Administration|Completed|||107|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:06.651592|2018-06-01 05:15:06.651592
NCT00074334|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2009-10-20|2003-12-10|2003-12-11|Estimate|||||||2009-10-20|2009-10-21|Estimate|May 2004||2004-05-31|October 2009|2009-10-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma|A Phase I/II Study Of A Recombinant Chimeric Protein Composed Of Transforming Growth Factor (TGF)-a And A Mutated Pseudomonas Exotoxin Termed PE38 (TP-38) In Pediatric Patients With Recurrent Or Progressive Supratentorial High Grade Gliomas|Terminated||Phase 1/Phase 2|3|Actual|Pediatric Brain Tumor Consortium||||Drug company withdrawal of support for investigational agent in this indication.|f||||t||||||||||2018-06-01 05:15:06.778548|2018-06-01 05:15:06.778548
NCT00074321|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2013-06-05|2003-12-10|2003-12-11|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2003||2003-11-30|June 2013|2013-06-30||||July 2010|Actual|2010-07-31||Interventional|||Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors|A Phase I And Pharmacogenetic Study Of CPT-11, Oxaliplatin, And Capecitabine In Patients With Solid Tumors|Completed||Phase 1|84|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:06.880775|2018-06-01 05:15:06.880775
NCT00074308|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2017-08-21||2017-12-14|2003-12-10|2003-12-11|Estimate|2017-12-14|2018-01-16|Actual||||2017-12-14|2018-01-16|Actual|October 2003||2003-10-31|December 2017|2017-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Total of 40 patients were enrolled (Phase 1= 17; Phase 2 = 23)|Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers|A Phase I/II Study Of Imatinib Mesylate And Bevacizumab In Patients With Advanced Melanoma And Other Advanced Cancers|Completed||Phase 1/Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:06.990207|2018-06-01 05:15:06.990207
NCT00074295|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2012-07-20|2003-12-10|2003-12-11|Estimate|||||||2012-07-20|2012-07-24|Estimate|March 2004||2004-03-31|July 2012|2012-07-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer|Phase II Trial of CG8123, an Autologous Cancer Vaccine (GVAX), in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)|Terminated||Phase 2|19|Actual|Southwest Oncology Group||1||closed due to lack of availability of vaccine|f||||t||||||||||2018-06-01 05:15:07.441967|2018-06-01 05:15:07.441967
NCT00074282|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2012-11-09|2003-12-10|2003-12-11|Estimate|||||||2012-11-09|2012-11-12|Estimate|December 2004||2004-12-31|November 2012|2012-11-30||||October 2014|Anticipated|2014-10-31||Interventional|||Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia|Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Lenalidomide for Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia|Unknown status|Recruiting|Phase 2|110|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:07.590207|2018-06-01 05:15:07.590207
NCT00074269|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2014-05-29||2018-04-30|2003-12-10|2003-12-11|Estimate|2014-11-20|2014-11-24|Estimate||||2018-04-30|2018-05-31|Estimate|July 2003||2003-07-31|April 2018|2018-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||This is a pilot study. The original planned target accrual was 15 male or female patients age 18-60 but due to poor enrollment the study was closed to accrual early after 5 patients had been enrolled.|Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer|Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer|Terminated||Phase 2|5|Actual|University of California, San Diego|Terminated early due to small numbers of subjects enrolled on study|1||Terminated early due to poor enrollment|f||||t||||||||||2018-06-01 05:15:08.073686|2018-06-01 05:15:08.073686
NCT00074243|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2015-04-29|2003-12-10|2003-12-11|Estimate|||||||2015-04-29|2015-04-30|Estimate|December 2003||2003-12-31|November 2006|2006-11-30||||||||Interventional|||CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas|A Phase I Trial Of CC-8490 For The Treatment Of Patients With Recurrent/Refractory High-Grade Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:15:08.312084|2018-06-01 05:15:08.312084
NCT00074230|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2015-05-11|2003-12-10|2003-12-11|Estimate|||||||2015-05-11|2015-05-12|Estimate|July 2003||2003-07-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma|Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding for Mage-3, MelanA, and Survivin Antigens|Completed||Phase 1/Phase 2|82|Actual|University Hospital Erlangen|||||f||||||||||||||2018-06-01 05:15:08.376458|2018-06-01 05:15:08.376458
NCT00074204|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2010-08-13|2003-12-10|2003-12-11|Estimate|||||||2010-08-13|2010-08-16|Estimate|October 2003||2003-10-31|August 2010|2010-08-31|April 2008|Actual|2008-04-30|August 2005|Actual|2005-08-31||Interventional|||Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase III Study of Delayed vs. Immediate Second-Line Therapy With Docetaxel After Gemcitabine + Carboplatin in Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|17|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:15:08.451782|2018-06-01 05:15:08.451782
NCT00074191|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2017-04-19|2003-12-10|2003-12-11|Estimate|||||||2017-04-19|2017-04-21|Actual|January 2000||2000-01-31|April 2017|2017-04-30|October 2000|Actual|2000-10-31|October 2000|Actual|2000-10-31||Interventional|Protocol-A||Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma|Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma|Completed||Phase 2|1|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 05:15:08.547394|2018-06-01 05:15:08.547394
NCT00074178|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2017-04-19|2003-12-10|2003-12-11|Estimate|||||||2017-04-19|2017-04-21|Actual|January 2000||2000-01-31|April 2017|2017-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|Protocol-B||Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma|Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma|Completed||Phase 2|22|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 05:15:08.612196|2018-06-01 05:15:08.612196
NCT00074165|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2011-10-10||2017-04-19|2003-12-10|2003-12-11|Estimate|2011-10-10|2011-11-16|Estimate||||2017-04-19|2017-04-21|Actual|January 2003||2003-01-31|April 2017|2017-04-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen|A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen|Terminated||Phase 2|17|Actual|OHSU Knight Cancer Institute||1||Lack of accrual|f||||t||||||||||2018-06-01 05:15:08.695487|2018-06-01 05:15:08.695487
NCT00074152|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2015-04-07||2017-05-23|2003-12-10|2003-12-11|Estimate|2015-04-24|2015-05-12|Estimate||||2017-05-23|2017-06-16|Actual|July 2002||2002-07-31|May 2017|2017-05-31|August 22, 2016|Actual|2016-08-22|February 2014|Actual|2014-02-28||Interventional|CALOR||Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer|A Randomized Clinical Trial Of Adjuvant Chemotherapy For Radically Resected Loco-Regional Relapse Of Breast Cancer|Completed||Phase 3|162|Actual|International Breast Cancer Study Group|Small sample size|2|||f||||t||||||||||2018-06-01 05:15:09.036604|2018-06-01 05:15:09.036604
NCT00074139|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2014-03-04|2003-12-10|2003-12-11|Estimate|||||||2014-03-04|2014-03-05|Estimate|September 2003||2003-09-30|March 2014|2014-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer|A Pharmacokinetic Interaction Study Of Docetaxel (Taxotere) 75 mg/mIV On The Combination Therapy Doxorubicin (50 mg/m) And Cyclophosphamide (50 mg/m) In The Treatment Of Advanced Breast Cancer|Withdrawn||Phase 1|0|Actual|Case Comprehensive Cancer Center||||No patients were enrolled|f||||t||||||||||2018-06-01 05:15:09.885481|2018-06-01 05:15:09.885481
NCT00074100|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2013-05-29|2003-12-10|2003-12-11|Estimate|||||||2013-05-29|2013-05-30|Estimate|August 2003||2003-08-31|August 2004|2004-08-31|September 2004|Actual|2004-09-30|||||Interventional|||Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy|Amonafide: Individual Phenotype-Adjusted Chemotherapy for Women With Metastatic Breast Cancer Who Have Progressed Despite Prior Chemotherapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:09.952688|2018-06-01 05:15:09.952688
NCT00074087|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2015-07-16|2003-12-10|2003-12-11|Estimate|||||||2015-07-16|2015-07-17|Estimate|October 2003||2003-10-31|July 2015|2015-07-31|September 2010|Actual|2010-09-30|July 2009|Actual|2009-07-31||Interventional|||Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides|Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy|Completed||Phase 2|49|Actual|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||||||||||||2018-06-01 05:15:10.023764|2018-06-01 05:15:10.023764
NCT00074074|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2012-07-13|2003-12-10|2003-12-11|Estimate|||||||2012-07-13|2012-07-16|Estimate|October 2003||2003-10-31|July 2012|2012-07-31||||December 2006|Actual|2006-12-31||Interventional|||Infliximab in Treating Patients With Myelodysplastic Syndrome|Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia|Completed||Phase 2|46|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:15:10.119452|2018-06-01 05:15:10.119452
NCT00074048|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2010-06-17|2003-12-10|2003-12-11|Estimate|||||||2010-06-17|2010-06-22|Estimate|October 2003||2003-10-31|June 2010|2010-06-30|July 2008|Actual|2008-07-31|April 2007|Actual|2007-04-30||Interventional|||BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia|Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia|Completed||Phase 2|36|Actual|MedImmune LLC||1|||f||||f||||||||||2018-06-01 05:15:10.21258|2018-06-01 05:15:10.21258
NCT00074035|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2017-01-26||2018-04-06|2003-12-10|2003-12-11|Estimate|2017-01-26|2017-03-15|Actual||||2018-04-06|2018-05-08|Actual|December 2003|Actual|2003-12-31|April 2018|2018-04-30|November 1, 2014|Actual|2014-11-01|August 2008|Actual|2008-08-31||Interventional||1 participant cancelled prior to receiving treatment and is excluded from all analyses.|Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease|A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease|Completed||Phase 2|39|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:15:10.311087|2018-06-01 05:15:10.311087
NCT00074022|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2013-01-23|2003-12-10|2003-12-11|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2003||2003-10-31|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors|A Phase I/2 Study of GTI-2040 Combined With Docetaxel In Metastatic Or Unresectable Locally Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:10.745645|2018-06-01 05:15:10.745645
NCT00074009|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2012-02-11|2003-12-10|2003-12-11|Estimate|||||||2012-02-11|2012-02-14|Estimate|October 2003||2003-10-31|December 2009|2009-12-31||||April 2005|Actual|2005-04-30||Interventional|||Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma|A Multicenter, Open-Label, Two-Stage, Phase II Study Of PS-341 (LDP-341, NSC # 681239) In Patients With Unresectable Or Metastatic Gastric Adenocarcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:10.82546|2018-06-01 05:15:10.82546
NCT00073983|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2011-03-15||2012-02-08|2003-12-10|2003-12-11|Estimate|2012-02-08|2012-03-12|Estimate||||2012-02-08|2012-03-12|Estimate|October 2006||2006-10-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|January 2010|Actual|2010-01-31||Interventional|||Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma|Phase II Study Of Sequential Gemcitabine Followed By Docetaxel For Recurrent Ewing's Sarcoma, Osteosarcoma, Or Unresectable Or Locally Recurrent Chondrosarcoma [SARC Study]|Completed||Phase 2|54|Actual|Sarcoma Alliance for Research through Collaboration|Since this design did not specify a rule for declaring the treatment as “active” a direct comparison to a standard 2 stage phase 2 design is not appropriate.||||f||||t||||||||||2018-06-01 05:15:10.891049|2018-06-01 05:15:10.891049
NCT00073970|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2012-05-21|2003-12-10|2003-12-11|Estimate|||||||2012-05-21|2012-05-23|Estimate|April 2003||2003-04-30|May 2012|2012-05-31|January 2006|Actual|2006-01-31|June 2005|Actual|2005-06-30||Interventional|||Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy|A Trial Of COX-2 Inhibitors In PSA Recurrence After Definitive Radiation Or Radical Prostatectomy For Prostate Cancer|Terminated||Phase 2|37|Actual|UNC Lineberger Comprehensive Cancer Center||||Study stopped due to increased cardiovascular risks associated with Celebrex|f||||t||||||||||2018-06-01 05:15:11.180916|2018-06-01 05:15:11.180916
NCT00063700|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-02|||2010-01-12|2003-07-02|2003-07-03|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2002||2002-09-30|January 2010|2010-01-31|July 2005||2005-07-31|||||Interventional|||Impact of Non-Commercialism Policy in Seattle Schools|Impact of Non-Commercialism Policy in Seattle Schools|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:13.91872|2018-06-01 05:19:13.91872
NCT00073957|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2017-04-12||2017-12-21|2003-12-10|2003-12-11|Estimate|2017-12-21|2018-01-23|Actual||||2017-12-21|2018-01-23|Actual|December 2003|Actual|2003-12-31|December 2017|2017-12-31|January 1, 2012|Actual|2012-01-01|January 1, 2012|Actual|2012-01-01||Interventional|||Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Zevalin And Rituxan For The Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|25|Actual|Beth Israel Deaconess Medical Center||1|||f|||||t|f|||f|||No||2018-06-01 05:15:11.272987|2018-06-01 05:15:11.272987
NCT00073944|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2013-05-29|2003-12-10|2003-12-11|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2003||2003-04-30|July 2004|2004-07-31||||January 2005|Actual|2005-01-31||Interventional|||BCX-1777 in Treating Patients With Refractory Cancer|Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:11.486701|2018-06-01 05:15:11.486701
NCT00073931|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2015-02-03|2003-12-10|2003-12-11|Estimate|||||||2015-02-03|2015-02-05|Estimate|October 1999||1999-10-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|May 2007|Actual|2007-05-31||Interventional|||Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial Evaluating: Radioiodinated Anti-B1 (Anti-CD20) Antibody With Autologous Stem Cell Transplantation For Relapsed Or Refractory Non-Hodgkin's Lymphoma In Patients 60 Years Of Age And Older|Completed||Phase 2|25|Actual|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:15:11.590824|2018-06-01 05:15:11.590824
NCT00073918|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|2016-12-02||2017-07-21|2003-12-10|2003-12-11|Estimate|2016-12-02|2017-01-27|Estimate||||2017-07-21|2017-08-18|Actual|February 1999||1999-02-28|July 2017|2017-07-31|October 2, 2011|Actual|2011-10-02|October 2, 2011|Actual|2011-10-02||Interventional|||Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|111|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:15:11.728565|2018-06-01 05:15:11.728565
NCT00073905|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2012-06-02|2003-12-10|2003-12-11|Estimate|||||||2012-06-02|2012-06-05|Estimate|April 2003||2003-04-30|June 2012|2012-06-30|January 2009|Actual|2009-01-31|June 2006|Actual|2006-06-30||Interventional|||Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer|Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial|Completed||Phase 2|44|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||||2018-06-01 05:15:12.042452|2018-06-01 05:15:12.042452
NCT00073892|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2016-08-29|2003-12-10|2003-12-11|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2004||2004-01-31|August 2016|2016-08-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma|A Phase I/II Study Of PI-88 In Advanced Malignancies (Phase I), And In Advanced Melanoma(Phase II)|Completed||Phase 1/Phase 2|44|Actual|Medigen Biotechnology Corporation||1|||f||||||||||||Undecided||2018-06-01 05:15:12.149678|2018-06-01 05:15:12.149678
NCT00073879|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2015-01-27|2003-12-10|2003-12-11|Estimate|||||||2015-01-27|2015-01-29|Estimate|April 2003||2003-04-30|January 2015|2015-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation|Allogeneic Adoptive Immunochemotherapy For Treatment Of Renal Cell Carcinoma|Completed||N/A|||Baylor College of Medicine|||||f||||||||||||||2018-06-01 05:15:12.260534|2018-06-01 05:15:12.260534
NCT00073866|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10||2011-02-16|2012-07-10|2003-12-10|2003-12-11|Estimate||||2011-02-16|2011-02-18|Estimate|2012-07-10|2012-07-19|Estimate|June 2003||2003-06-30|July 2012|2012-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase I/II Trial Of Weekly Irinotecan And Docetaxel With The Addition Of Celecoxib In Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:15:12.338842|2018-06-01 05:15:12.338842
NCT00073853|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-10|||2009-08-27|2003-12-10|2003-12-11|Estimate|||||||2009-08-27|2009-08-28|Estimate|September 2003||2003-09-30|March 2006|2006-03-31||||||||Interventional|||Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries|A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries|Suspended||Phase 2|61||Proneuron Biotechnologies|||||||||||||||||||2018-06-01 05:15:12.419414|2018-06-01 05:15:12.419414
NCT00073840|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-09|||2012-02-21|2003-12-10|2003-12-11|Estimate|||||||2012-02-21|2012-02-22|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma|An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma|Completed||Phase 3|386|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 05:15:12.520608|2018-06-01 05:15:12.520608
NCT00073827|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-09|||2012-02-21|2003-12-10|2003-12-11|Estimate|||||||2012-02-21|2012-02-22|Estimate|May 2002||2002-05-31|February 2012|2012-02-29|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma|An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma|Completed||Phase 3|445|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 05:15:12.704274|2018-06-01 05:15:12.704274
NCT00004857|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2016-07-01|2003-12-10|2003-12-11|Estimate|||||||2016-07-01|2016-07-06|Estimate|January 2000||2000-01-31|July 2016|2016-07-31|February 2010|Actual|2010-02-28|March 2003|Actual|2003-03-31||Interventional|||Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Fludarabine Induction Followed by CAMPATH-1H Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|86|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:15:12.855693|2018-06-01 05:15:12.855693
NCT00004261|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2018-02-20|2003-12-10|2003-12-11|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 1999||1999-12-31|February 2018|2018-02-28||||June 2002|Actual|2002-06-30||Interventional|||EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma|A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas|Terminated||Phase 1|||University Health Network, Toronto||||Lack of patient accrual|f||||||||||||||2018-06-01 05:15:12.978681|2018-06-01 05:15:12.978681
NCT00063323|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2017-01-11|2003-06-30|2003-07-01|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2000||2000-08-31|January 2010|2010-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Maintenance Treatment for Abstinent Smokers|Maintenance Treatment for Prevention of Smoking Relapse|Completed||Phase 3|589|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||t||||||||||2018-06-01 05:19:16.831478|2018-06-01 05:19:16.831478
NCT00004242|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-02-08|2003-12-10|2003-12-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 1999||1999-10-31|July 2002|2002-07-31||||December 2003|Actual|2003-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors|Phase I Study of Oxaliplatin in Combination With 5-Fluorouracil and Gemcitabine in Patients With Solid Tumors|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:13.079995|2018-06-01 05:15:13.079995
NCT00003927|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-03-08|2003-12-10|2003-12-11|Estimate|||||||2018-03-08|2018-03-12|Actual|April 22, 1999||1999-04-22|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer|High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer|Active, not recruiting||Phase 1|15|Anticipated|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 05:15:13.148459|2018-06-01 05:15:13.148459
NCT00073814|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-09|||2012-02-21|2003-12-09|2003-12-10|Estimate|||||||2012-02-21|2012-02-22|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma|An Efficacy, Safety, and Tolerability Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma|Completed||Phase 3|80|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 05:15:13.227127|2018-06-01 05:15:13.227127
NCT00073788|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-08|||2014-05-30|2003-12-09|2003-12-10|Estimate|||||||2014-05-30|2014-06-02|Estimate|September 2003||2003-09-30|May 2014|2014-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Wounded Spirits, Ailing Hearts: Post-Traumatic Stress Disorder and Cardiovascular Disease in Indians|Wounded Spirits, Ailing Hearts: Post-Traumatic Stress Disorder and Cardiovascular Disease in Indians|Completed|||267|Actual|University of Colorado, Denver|||2||f||||f||||||||||2018-06-01 05:15:13.3792|2018-06-01 05:15:13.3792
NCT00073775|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-08|||2013-08-08|2003-12-09|2003-12-10|Estimate|||||||2013-08-08|2013-08-12|Estimate|September 2003||2003-09-30|August 2013|2013-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Epidemiology of Stress and the Metabolic Syndrome|Epidemiology of Stress and the Metabolic Syndrome|Completed|||3075|Actual|University of Florida|||||f||||f||||||Samples With DNA|"~     DNA, blood~   "|||2018-06-01 05:15:13.436836|2018-06-01 05:15:13.436836
NCT00003811|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-03|2003-12-09|2003-12-10|Estimate|||||||2013-07-03|2013-07-04|Estimate|April 2000||2000-04-30|July 2013|2013-07-31|September 2007|Actual|2007-09-30|October 2004|Actual|2004-10-31||Interventional|||Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors|High-Dose Cisplatin, Etoposide and Bleomycin (HD-PEB) Combined With Amifostine in Children With High-Risk Malignant Germ Cell Tumors - A POG Pilot Study|Completed||Phase 2|27|Actual|Children's Oncology Group|||||f||||||||||||||2018-06-01 05:15:13.506144|2018-06-01 05:15:13.506144
NCT00003777|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-12-09|2003-12-10|Estimate|||||||2009-02-06|2009-02-09|Estimate|December 1998||1998-12-31|November 2002|2002-11-30||||||||Interventional|||Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer|A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:14.794301|2018-06-01 05:15:14.794301
NCT00003761|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-02-13|2003-12-09|2003-12-10|Estimate|||||||2017-02-13|2017-02-15|Actual|March 3, 1999|Actual|1999-03-03|February 2017|2017-02-28|October 19, 2001|Actual|2001-10-19|April 20, 2001|Actual|2001-04-20||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Breast Cancer|A Phase I Trial of Recombinant Vaccinia Virus That Expresses DF3/MUC1 in Patients With Metastatic Adenocarcinoma of the Breast|Completed||Phase 1|20|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-06-01 05:15:14.929063|2018-06-01 05:15:14.929063
NCT00003729|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2003-12-09|2003-12-10|Estimate|||||||2012-09-20|2012-09-24|Estimate|December 1998||1998-12-31|September 2012|2012-09-30||||April 2002|Actual|2002-04-30||Interventional|||Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia|Phase II Study of Fludarabine + Idarubicin + Aracytine in Refractory or Relapsed ALL in Children|Terminated||Phase 2|13|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:15:15.162443|2018-06-01 05:15:15.162443
NCT00073801|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-08|||2018-03-27|2003-12-08|2003-12-09|Estimate|||||||2018-03-27|2018-03-29|Actual|December 8, 2003||2003-12-08|January 25, 2018|2018-01-25||||||||Observational|||Pelvic Pain in Women With Endometriosis|The Neural Immune Mechanisms and Genetic Influences on Chronic Pelvic Pain in Women With Endometriosis|Completed|||78|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:15.340697|2018-06-01 05:15:15.340697
NCT00003734|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-20|2003-12-08|2003-12-09|Estimate|||||||2016-07-20|2016-07-21|Estimate|December 1998||1998-12-31|December 2011|2011-12-31||||||||Interventional|||Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer|A Randomised Comparison of Short and Protracted Neoadjuvant Hormonal Therapy Prior to Radiation Therapy of High Risk Localized Prostate Cancer|Unknown status|Active, not recruiting|Phase 3|276|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:15.459059|2018-06-01 05:15:15.459059
NCT00073762|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-04|||2009-08-18|2003-12-07|2003-12-08|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Fixed Doses (200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|375|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:15:15.572277|2018-06-01 05:15:15.572277
NCT00073749|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-04|||2013-02-14|2003-12-04|2003-12-05|Estimate|||||||2013-02-14|2013-02-15|Estimate|August 2003||2003-08-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma|A Phase 1 Study Of CMC-544 Administered As A Single Agent In Subjects With B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 1|80|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 05:15:15.662748|2018-06-01 05:15:15.662748
NCT00073736|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-03|||2011-08-10|2003-12-04|2003-12-05|Estimate|||||||2011-08-10|2011-08-12|Estimate|September 2003||2003-09-30|August 2011|2011-08-31||||July 2007|Actual|2007-07-31||Interventional|||Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma|A Phase 1/2 Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous Infusion of MB07133 in Subjects With Unresectable Hepatocellular Carcinoma and Child-Pugh Class A Liver Function|Completed||Phase 1/Phase 2|28|Actual|Ligand Pharmaceuticals||5|||f||||f||||||||||2018-06-01 05:15:15.812214|2018-06-01 05:15:15.812214
NCT00073723|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-03|||2016-12-14|2003-12-04|2003-12-05|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2003||2003-12-31|December 2016|2016-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer|An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|75||Celgene Corporation|||||f||||||||||||||2018-06-01 05:15:15.921174|2018-06-01 05:15:15.921174
NCT00003716|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-17|2003-12-04|2003-12-05|Estimate|||||||2012-03-17|2012-03-20|Estimate|March 1998||1998-03-31|June 2002|2002-06-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy|Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression|Unknown status|Active, not recruiting|Phase 2|15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:15.991898|2018-06-01 05:15:15.991898
NCT00003694|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-04|2003-12-04|2003-12-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 1999||1999-03-31|June 2013|2013-06-30||||August 2003|Actual|2003-08-31||Interventional|||Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase|A Phase II Study of Newly Diagnosed Patients With BCR/ABL (+) Chronic Myelogenous Leukemia Treated With Combined Homoharringtonine (NSC #141633) and Low-Dose Cytarabine|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:16.07311|2018-06-01 05:15:16.07311
NCT00003679|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2003-12-04|2003-12-05|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 1998||1998-11-30|May 2007|2007-05-31||||||||Interventional|||Combination Chemotherapy in Treating Women With Breast Cancer|A Randomised Comparative Trial of Adriamycin + Taxotere vs. Adriamycin + Cyclophosphamide as Primary Medical Therapy for Patients With Potentially Operable Breast Cancer Greater Than or Equal to 3 cm Diameter, Locally Advanced, or Inflammatory Disease|Unknown status|Active, not recruiting|Phase 3|350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:16.153103|2018-06-01 05:15:16.153103
NCT00003598|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-20|2003-12-04|2003-12-05|Estimate|||||||2010-09-20|2010-09-22|Estimate|January 1999||1999-01-31|September 2010|2010-09-30|November 2009|Actual|2009-11-30|March 2001|Actual|2001-03-31||Interventional|IRB 1996-0189||UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia|Retinoids and Intermediate Biomarkers for CIN II and III: Pilot Trial|Completed||N/A|180|Anticipated|University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 05:15:16.213432|2018-06-01 05:15:16.213432
NCT00003450|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-12-04|2003-12-05|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 1998||1998-09-30|June 2002|2002-06-30||||||||Interventional|||Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer|Phase I Trial of Intraperitoneal Adenoviral p53 Gene Therapy in Patients With Advanced Recurrent or Persistent Ovarian Cancer|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:16.366849|2018-06-01 05:15:16.366849
NCT00073710|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-03|||2006-07-31|2003-12-03|2003-12-04|Estimate|||||||2006-07-31|2006-08-02|Estimate|September 2004||2004-09-30|July 2006|2006-07-31||||||||Interventional|||Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium|A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium|Completed||Phase 4|30||Abbott|||||||||||||||||||2018-06-01 05:15:16.435661|2018-06-01 05:15:16.435661
NCT00073697|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-02|||2012-01-10|2003-12-02|2003-12-03|Estimate|||||||2012-01-10|2012-01-11|Estimate|May 2003||2003-05-31|January 2012|2012-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Treatment of Depression in Adults|Depression: The Search for Treatment-Relevant Phenotypes|Completed||Phase 4|290|Actual|University of Pittsburgh||3|||f||||||||||||||2018-06-01 05:15:16.518917|2018-06-01 05:15:16.518917
NCT00073684|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-02|||2014-05-06|2003-12-02|2003-12-03|Estimate|||||||2014-05-06|2014-05-08|Estimate|August 2003||2003-08-31|May 2014|2014-05-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Optimal Treatment Strategies for Sexually Abused Children|Young Sexually Abused Children: Optimal CBT Strategies|Completed||Phase 3|210|Actual|Rowan University||4|||f||||t||||||||||2018-06-01 05:15:16.634831|2018-06-01 05:15:16.634831
NCT00073671|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-02|||2017-04-07|2003-12-02|2003-12-03|Estimate|||||||2017-04-07|2017-04-10|Actual|March 2003||2003-03-31|April 2017|2017-04-30|January 2009|Actual|2009-01-31|March 2006|Actual|2006-03-31||Interventional|||Prevention of Depression in At-Risk Adolescents|Prevention of Depression in At-Risk Adolescents|Completed||N/A|316|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 05:15:16.744758|2018-06-01 05:15:16.744758
NCT00073658|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-02|||2014-03-07|2003-12-02|2003-12-03|Estimate|||||||2014-03-07|2014-03-10|Estimate|January 2000||2000-01-31|March 2014|2014-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Treating Behavioral Disturbances in Individuals With Dementia|Continuation Pharmacotherapy for Agitation of Dementia|Completed||Phase 2|137||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:15:16.842558|2018-06-01 05:15:16.842558
NCT00073645|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-02|||2013-08-19|2003-12-02|2003-12-03|Estimate|||||||2013-08-19|2013-08-20|Estimate|July 2002||2002-07-31|August 2013|2013-08-31|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Family and Peer Involvement in the Treatment of Anxiety Disorders in Children|Therapy Specificity and Mediation in Family and Group CBT|Completed||Phase 1|241|Actual|Florida International University||2|||f||||t||||||||||2018-06-01 05:15:16.933301|2018-06-01 05:15:16.933301
NCT00073632|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-02|||2013-11-05|2003-12-02|2003-12-03|Estimate|||||||2013-11-05|2013-11-06|Estimate|May 2002||2002-05-31|September 2008|2008-09-30|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Acceptance-Based Treatment for Generalized Anxiety Disorder|Developing a New Therapy for GAD: Acceptance-Based CBT|Completed||Phase 1|50|Actual|University of Massachusetts, Boston|||||f||||f||||||||||2018-06-01 05:15:17.022213|2018-06-01 05:15:17.022213
NCT00073619|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-02|||2016-06-22|2003-12-02|2003-12-03|Estimate|||||||2016-06-22|2016-06-23|Estimate|December 2001||2001-12-31|June 2016|2016-06-30|July 2011|Actual|2011-07-31|July 2007|Actual|2007-07-31||Interventional|||Preventing Anxiety Disorders in Urban Youth|Community Violence and Youth: Preventing Anxiety Disorders|Completed||N/A|200|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||No|There is no plan to make individual participant data available.|2018-06-01 05:15:17.096976|2018-06-01 05:15:17.096976
NCT00073606|ClinicalTrials.gov processed this data on May 31, 2018|2003-12-01|||2017-06-30|2003-12-01|2003-12-02|Estimate|||||||2017-06-30|2017-07-02|Actual|December 1, 2003||2003-12-01|May 20, 2008|2008-05-20|May 20, 2008||2008-05-20|||||Observational|||Spinal Cord Plasticity|Intraspinal Plasticity Associated With Locomotor Learning|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:17.175734|2018-06-01 05:15:17.175734
NCT00003426|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2003-12-01|2003-12-02|Estimate|||||||2013-06-20|2013-06-21|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer|A Phase I Trial of Combined Modality Gemcitabine Plus Radiation Therapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:17.231303|2018-06-01 05:15:17.231303
NCT00003414|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-07-16|2003-12-01|2003-12-02|Estimate|||||||2015-07-16|2015-07-20|Estimate|October 1997||1997-10-31|July 2015|2015-07-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease|Randomized Trial of Autologous GVHD for Refractory Lymphoma|Completed||Phase 3|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:15:17.29506|2018-06-01 05:15:17.29506
NCT00003409|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-12-01|2003-12-02|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 1998||1998-07-31|June 2007|2007-06-30||||||||Interventional|||Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I Dose Escalating Study of the Safety and Tolerability of Gadolinium Texaphyrin as a Radiation Sensitizer in Patients With Primary Glioblastoma Multiforme|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:17.365222|2018-06-01 05:15:17.365222
NCT00003388|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2003-12-01|2003-12-02|Estimate|||||||2010-01-26|2010-01-27|Estimate|February 1999||1999-02-28|January 2010|2010-01-31||||April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma|A Phase II Study of Doxil (Liposomal Doxorubicin), Cyclophosphamide, Vincristine and Prednisone for AIDS-Related Systemic Lymphoma|Completed||Phase 2|38|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:15:17.427626|2018-06-01 05:15:17.427626
NCT00073593|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-26|||2011-11-08|2003-11-26|2003-11-27|Estimate|||||||2011-11-08|2011-11-10|Estimate|August 2003||2003-08-31|November 2011|2011-11-30||||May 2004|Actual|2004-05-31||Interventional|OPCAB||Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB|A Study Comparing Angiomax (Bivalirudin) to Heparin With Protamine Reversal in Patients Undergoing Coronary Artery Bypass (OPCAB) Surgery|Completed||Phase 3|150|Actual|The Medicines Company||2|||f||||||||||||||2018-06-01 05:15:17.497744|2018-06-01 05:15:17.497744
NCT00073580|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-26|||2011-11-08|2003-11-26|2003-11-27|Estimate|||||||2011-11-08|2011-11-10|Estimate|October 2003||2003-10-31|November 2011|2011-11-30||||September 2005|Actual|2005-09-30||Interventional|||Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)|Angiomax in Patients With HIT/HITTS Type II Undergoing Off-PUMP CABG|Unknown status|Active, not recruiting|Phase 3|88|Actual|The Medicines Company|||||f||||||||||||||2018-06-01 05:15:17.566376|2018-06-01 05:15:17.566376
NCT00073554|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-24|||2009-12-16|2003-11-25|2003-11-26|Estimate|||||||2009-12-16|2009-12-17|Estimate|June 2003||2003-06-30|November 2006|2006-11-30||||||||Interventional|||Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion|A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion|Completed||Phase 2|100||ARCA Biopharma, Inc.|||||||||||||||||||2018-06-01 05:15:17.629795|2018-06-01 05:15:17.629795
NCT00073541|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-24|||2017-01-19|2003-11-25|2003-11-26|Estimate|||||||2017-01-19|2017-01-20|Estimate|April 2003||2003-04-30|January 2017|2017-01-31|August 2004|Actual|2004-08-31|March 2004|Actual|2004-03-31||Interventional|||A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer|An Open-Label Phase II Study in Subjects With Recurrent EGFR-Positive Ovarian Cancer to Investigate the Safety and Efficacy of EMD 72000 Administered as a Single Agent|Completed||Phase 2|38|Actual|EMD Serono|||||||||||||||||||2018-06-01 05:15:17.709675|2018-06-01 05:15:17.709675
NCT00073528|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-24|2012-04-19||2018-01-10|2003-11-25|2003-11-26|Estimate|2012-04-19|2012-05-17|Estimate||||2018-01-10|2018-02-06|Actual|December 9, 2003|Actual|2003-12-09|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|June 3, 2008|Actual|2008-06-03||Interventional|||Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 3|1285|Actual|Novartis||2|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-06-01 05:15:17.894215|2018-06-01 05:15:17.894215
NCT00003387|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-19|2003-11-25|2003-11-26|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 1998||1998-07-31|July 2016|2016-07-31|April 2009|Actual|2009-04-30|May 2007|Actual|2007-05-31||Interventional|||Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery|Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial|Completed||Phase 3|366|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:15:20.020414|2018-06-01 05:15:20.020414
NCT00003313|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-11-19|2003-11-25|2003-11-26|Estimate|||||||2014-11-19|2014-11-21|Estimate|September 1998||1998-09-30|November 2014|2014-11-30|June 2010|Actual|2010-06-30|July 2002|Actual|2002-07-31||Interventional|||Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer|A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitaxel and Carboplatin|Completed||Phase 3|243|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:15:20.248474|2018-06-01 05:15:20.248474
NCT00003253|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-11-25|2003-11-26|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 1997||1997-07-31|May 2006|2006-05-31||||||||Interventional|||Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer|Assessment of the Predictive Value of the Extreme Drug Resistance (EDR) Assay in Patients Receiving Paclitaxel for Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:20.762579|2018-06-01 05:15:20.762579
NCT00003202|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-18|2003-11-25|2003-11-26|Estimate|||||||2017-01-18|2017-01-19|Estimate|January 1998||1998-01-31|July 2012|2012-07-31|July 2006|Actual|2006-07-31|April 2002|Actual|2002-04-30||Interventional|||Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|Alternating Phase I/II Trials of Twice-Weekly Infusion Gemcitabine (2'2'-Difluoro-2'-Deoxycytidine) and Concurrent Thoracic Radiation Alone - Or Following 2 Cycles of Cisplatin/Gemcitabine Induction Chemotherapy for the Treatment of Stage IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|40|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 05:15:20.888874|2018-06-01 05:15:20.888874
NCT00063375|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2013-10-24|2003-06-26|2003-06-27|Estimate|||||||2013-10-24|2013-10-25|Estimate|January 2002||2002-01-31|October 2013|2013-10-31||||February 2007|Actual|2007-02-28||Interventional|||Interactive Computer Treatment for Panic Disorder|Interactive Computer Treatment for Panic Disorder|Completed||Phase 1|60|Anticipated|Florida State University|||||f||||||||||||||2018-06-01 05:19:18.023009|2018-06-01 05:19:18.023009
NCT00073515|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-21|||2010-02-02|2003-11-24|2003-11-25|Estimate|||||||2010-02-02|2010-02-03|Estimate||||June 2005|2005-06-30||||||||Interventional|||Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices|A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters|Completed||Phase 2|115||ARCA Biopharma, Inc.|||||||||||||||||||2018-06-01 05:15:21.060334|2018-06-01 05:15:21.060334
NCT00073502|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-21|||2006-02-17|2003-11-24|2003-11-25|Estimate|||||||2006-02-17|2006-02-22|Estimate|October 2003||2003-10-31|October 2003|2003-10-31|October 2003||2003-10-31|||||Interventional|||Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer|A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction|Completed||Phase 2|43||OSI Pharmaceuticals|||||||||||||||||||2018-06-01 05:15:21.110258|2018-06-01 05:15:21.110258
NCT00073489|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-21|||2011-10-14|2003-11-24|2003-11-25|Estimate|||||||2011-10-14|2011-10-17|Estimate|May 2001||2001-05-31|October 2011|2011-10-31|December 2003|Actual|2003-12-31|||||Interventional|||A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)|A Pilot Trial of OSI-461 in Patients With Chronic Lymphocytic Leukemia|Completed||Phase 2|23||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:15:21.1724|2018-06-01 05:15:21.1724
NCT00073463|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-21|||2008-01-24|2003-11-24|2003-11-25|Estimate|||||||2008-01-24|2008-01-28|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|October 2005||2005-10-31|||||Interventional|||Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis|A Multicenter, Double-Blind, Placebo Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis|Terminated||Phase 2/Phase 3|100||Targeted Genetics Corporation|||||f||||||||||||||2018-06-01 05:15:21.260063|2018-06-01 05:15:21.260063
NCT00003167|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-22|2003-11-24|2003-11-25|Estimate|||||||2013-01-22|2013-01-23|Estimate|May 1998||1998-05-31|January 2013|2013-01-31||||December 2002|Actual|2002-12-31||Interventional|||Gene Therapy in Treating Patients With Advanced Bladder Cancer|A Phase I Trial of Intravesical Ad-p53 Treatment in Locally Advanced and Metastatic Bladder Cancer|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:21.315471|2018-06-01 05:15:21.315471
NCT00003130|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-15|2003-11-24|2003-11-25|Estimate|||||||2016-07-15|2016-07-19|Estimate|November 1997||1997-11-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|January 2002|Actual|2002-01-31||Interventional|||Paclitaxel in Treating Women With Recurrent Solid Tumors|Prospective Evaluation of Body Surface Area (BSA) as a Determinant of Paclitaxel Pharmacokinetics/Pharmacodynamics in Women With Solid Tumors|Completed||Phase 2|32|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:15:21.377146|2018-06-01 05:15:21.377146
NCT00003060|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-11-24|2003-11-25|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1995||1995-03-31|June 2002|2002-06-30||||||||Interventional|||Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma|Pilot Study for Matched-Related Allogeneic Bone Marrow Transplantation for Metastatic Malignant Melanoma|Unknown status|Active, not recruiting|Phase 1|6|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:21.696973|2018-06-01 05:15:21.696973
NCT00003037|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2003-11-24|2003-11-25|Estimate|||||||2013-06-25|2013-06-27|Estimate|April 1997||1997-04-30|June 2013|2013-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|Phase I/II Trial of the Combination of Docetaxel, Gemcitabine and Cisplatin (DGP) as Induction Chemotherapy in Patients With Stage III Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:21.763677|2018-06-01 05:15:21.763677
NCT00002989|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-11-24|2003-11-25|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 1997||1997-03-31|July 2007|2007-07-31||||||||Interventional|||Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome|A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse|Unknown status|Active, not recruiting|Phase 3|207|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:21.833902|2018-06-01 05:15:21.833902
NCT00073476|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-21|||2006-06-20|2003-11-21|2003-11-24|Estimate|||||||2006-06-20|2006-06-22|Estimate|September 2003||2003-09-30|June 2006|2006-06-30|February 2005||2005-02-28|||||Interventional|||A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke|A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.|Terminated||Phase 2|300||Pfizer|||||||||||||||||||2018-06-01 05:15:21.939334|2018-06-01 05:15:21.939334
NCT00073450|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-20|||2015-04-20|2003-11-21|2003-11-24|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2003||2003-09-30|April 2015|2015-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)|An Open-Label Phase 2 Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|15|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:15:22.031502|2018-06-01 05:15:22.031502
NCT00073437|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-20|||2011-05-16|2003-11-21|2003-11-24|Estimate|||||||2011-05-16|2011-05-17|Estimate|October 2003||2003-10-31|April 2010|2010-04-30|February 2005|Actual|2005-02-28|||||Interventional|||A Study of Infliximab in Patients With Sarcoidosis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade�) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement.|Completed||Phase 3|139|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:15:22.16034|2018-06-01 05:15:22.16034
NCT00002940|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-18|2003-11-21|2003-11-24|Estimate|||||||2012-10-18|2012-10-19|Estimate|October 1996||1996-10-31|June 2002|2002-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS|Hydroxyurea Treatment of EBV-Associated Primary CNS Lymphoma in Children and Adults With AIDS|Completed||Phase 2|||St. Jude Children's Research Hospital|||||f||||f||||||||||2018-06-01 05:15:22.226474|2018-06-01 05:15:22.226474
NCT00002836|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2003-11-21|2003-11-24|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 1995||1995-05-31|July 2012|2012-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer|A Phase III Randomized Comparison of High Dose Chemotherapy G-CSF To G-CSF For Mobilization of Peripheral Blood Stem Cells For Autologous Transplantation For Patients With Responsive Metastatic Breast Cancer Or High Risk Stage II-III Patients|Completed||Phase 3|184|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:15:22.325638|2018-06-01 05:15:22.325638
NCT00002828|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2003-11-21|2003-11-24|Estimate|||||||2013-06-20|2013-06-21|Estimate|April 1995||1995-04-30|June 2013|2013-06-30|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer|PHASE I TRIAL OF SEQUENTIAL TOMUDEX AND 5-FLUOROURACIL IN SUBJECTS WITH ADVANCED COLORECTAL CARCINOMA|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:22.428295|2018-06-01 05:15:22.428295
NCT00002812|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-23|2003-11-21|2003-11-24|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 1996||1996-09-30|August 2013|2013-08-31||||March 2006|Actual|2006-03-31||Interventional|||Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia|Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study|Completed||Phase 3|2078|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:15:22.506868|2018-06-01 05:15:22.506868
NCT00002761|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-16|2003-11-21|2003-11-24|Estimate|||||||2012-11-16|2012-11-19|Estimate|February 1996||1996-02-29|November 2012|2012-11-30|October 2007|Actual|2007-10-31|February 2007|Actual|2007-02-28||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia|CAMP-010: PHASE I/II STUDY OF IN VIVO PURGING FOLLOWED BY HIGH DOSE CHEMOTHERAPY, AUTOLOGOUS HEMATOPOIETIC STEM CELL INFUSION AND IMMUNOTHERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA|Withdrawn||Phase 1/Phase 2|0|Actual|Columbia University||||PI left institution|f||||||||||||||2018-06-01 05:15:22.692151|2018-06-01 05:15:22.692151
NCT00073424|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-20|||2013-05-31|2003-11-20|2003-11-21|Estimate|||||||2013-05-31|2013-06-03|Estimate|January 2004||2004-01-31|May 2013|2013-05-31|October 2006|Actual|2006-10-31|||||Observational|||Factors Affecting Adherence to Anti-HIV Drug Regimens in Children and Adolescents|Cognitive, Behavioral, and Psychosocial Correlates of Medication Adherence in Children and Adolescents With HIV-1 Infection|Completed|||200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:15:22.767521|2018-06-01 05:15:22.767521
NCT00073411|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-20|||2007-07-30|2003-11-20|2003-11-21|Estimate|||||||2007-07-30|2007-07-31|Estimate|November 2003||2003-11-30|July 2007|2007-07-31|May 2005|Actual|2005-05-31|||||Interventional|||Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression|Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression|Completed||Phase 3|675||Eli Lilly and Company|||||f||||f||||||||||2018-06-01 05:15:22.853175|2018-06-01 05:15:22.853175
NCT00073385|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19|||2005-08-26|2003-11-20|2003-11-21|Estimate|||||||2005-08-26|2005-08-30|Estimate|September 2003||2003-09-30|August 2005|2005-08-31|October 2004||2004-10-31|||||Interventional|||Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients With Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)|Completed||Phase 2|225||Titan Pharmaceuticals|||||||||||||||||||2018-06-01 05:15:22.914145|2018-06-01 05:15:22.914145
NCT00073372|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19|||2011-05-16|2003-11-20|2003-11-21|Estimate|||||||2011-05-16|2011-05-17|Estimate|October 2003||2003-10-31|June 2010|2010-06-30|December 2005|Actual|2005-12-31|||||Interventional|||A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)|Abciximab (ReoPro) in Acute Ischemic Stroke: A Phase III, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Trial.|Terminated||Phase 3|808|Actual|Centocor, Inc.||||"Based on the data and observed benefit-risk profile, the trial's independent oversight~   committee recommended that enrollment not resume."|||||t||||||||||2018-06-01 05:15:22.968244|2018-06-01 05:15:22.968244
NCT00073359|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19|||2014-05-19|2003-11-20|2003-11-21|Estimate|||||||2014-05-19|2014-05-20|Estimate|February 2003||2003-02-28|November 2005|2005-11-30|June 2005||2005-06-30|||||Interventional|||Effects of Therapist Behavior on the Treatment of Depressed Adolescents|Engagement and Alliance in CBT for Depressed Adolescents|Unknown status|Active, not recruiting|Phase 1/Phase 2|40||University of Denver|||||f||||||||||||||2018-06-01 05:15:23.037861|2018-06-01 05:15:23.037861
NCT00073346|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19|||2013-06-19|2003-11-20|2003-11-21|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 2003||2003-09-30|June 2013|2013-06-30|August 2006||2006-08-31|||||Interventional|||Treatment of Compulsive Hoarding|Treatment of Compulsive Hoarding|Completed||Phase 1|52||Boston University|||||f||||||||||||||2018-06-01 05:15:23.087388|2018-06-01 05:15:23.087388
NCT00073333|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19|2013-05-14||2013-07-01|2003-11-20|2003-11-21|Estimate|2013-05-14|2013-07-02|Estimate||||2013-07-01|2013-07-18|Estimate|December 2002||2002-12-31|July 2013|2013-07-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Assessment and Treatment of Social Skills Deficits in Individuals With Social Phobia|Social Phobia: Assessment and Treatment of Social Skills|Completed||N/A|379|Actual|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-06-01 05:15:23.28138|2018-06-01 05:15:23.28138
NCT00073320|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19|||2010-04-26|2003-11-20|2003-11-21|Estimate|||||||2010-04-26|2010-04-27|Estimate|August 2003||2003-08-31|April 2010|2010-04-30|May 2004|Actual|2004-05-31|||||Interventional|||Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia|Pharmacokinetics, Tolerability, and Safety of Paliperidone After Repeated Intramuscular Injection of Paliperidone Palmitate in the Arm or the Buttock of Subjects With Schizophrenia|Completed||Phase 3|88|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:15:23.516206|2018-06-01 05:15:23.516206
NCT00073307|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19|2011-08-02||2014-01-08|2003-11-20|2003-11-21|Estimate|2011-11-09|2011-12-14|Estimate||||2014-01-08|2014-02-06|Estimate|November 2003||2003-11-30|January 2014|2014-01-31|April 2010|Actual|2010-04-30|September 2006|Actual|2006-09-30||Interventional|||Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer|A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.|Completed||Phase 3|903|Actual|Bayer|Per final PFS data (N=769) study unblinded; placebo-randomized subjects switched to sorafenib ~31May2005 (N=216) that diluted final OS, sorafenib treatment effect. Final ITT, N=903, reported safety data include additional data and cleaning.|2|||f||||t||||||||||2018-06-01 05:15:23.658564|2018-06-01 05:15:23.658564
NCT00036920|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-06-25|2003-11-20|2003-11-21|Estimate|||||||2013-06-25|2013-06-26|Estimate|January 2002||2002-01-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|August 2002|Actual|2002-08-31||Interventional|||TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:25.458861|2018-06-01 05:15:25.458861
NCT00027521|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2012-09-17|2003-11-20|2003-11-21|Estimate|||||||2012-09-17|2012-09-19|Estimate|December 2000||2000-12-31|September 2012|2012-09-30||||||||Interventional|||Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer|Phase I Study: Electroporation Therapy With Bleomycin For The Treatment Of Pancreatic Cancer|Withdrawn||Phase 1|0|Actual|Ichor Medical Systems Incorporated||||Program terminated|f||||||||||||||2018-06-01 05:15:25.511371|2018-06-01 05:15:25.511371
NCT00025532|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2012-09-13|2003-11-20|2003-11-21|Estimate|||||||2012-09-13|2012-09-14|Estimate|April 2001||2001-04-30|September 2012|2012-09-30||||||||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer|A Pre-Phase I Biodistribution Study Of hCC^CH2 Labeled With 131 Iodine In Patients With Gastrointestinal Adenocarcinomas|Withdrawn||Phase 1|0|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 05:15:25.68484|2018-06-01 05:15:25.68484
NCT00002561|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-11-25|2003-11-20|2003-11-21|Estimate|||||||2016-11-25|2016-11-28|Estimate|January 1994||1994-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease|A PHASE III STUDY OF RADIOTHERAPY OR ABVD PLUS RADIOTHERAPY VERSUS ABVD ALONE IN THE TREATMENT OF EARLY STAGE HODGKIN'S DISEASE|Completed||Phase 3|405|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||Undecided||2018-06-01 05:15:25.762136|2018-06-01 05:15:25.762136
NCT00073398|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-19||2015-04-07|2015-06-25|2003-11-19|2003-11-20|Estimate||||2015-04-07|2015-04-29|Estimate|2015-06-25|2015-07-20|Estimate|November 2003||2003-11-30|June 2015|2015-06-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Vaccine Treatment for Advanced Non-Small Cell Lung Cancer|A Phase I/II Study of Tergenpumatucel-L (HyperAcute Lung) an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|54|Actual|NewLink Genetics Corporation||1|||f||||f||||||||||2018-06-01 05:15:25.894016|2018-06-01 05:15:25.894016
NCT00073294|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-18|||2018-02-28|2003-11-19|2003-11-20|Estimate|||||||2018-02-28|2018-03-02|Actual||||January 2010|2010-01-31||||||||Interventional|||Insulin Resistance and Insulin Secretion|Phenotypic Assessment of Insulin Resistance and Insulin Secretory Capacity|Withdrawn||N/A|0|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||||Trial was not funded|f||||||||||||||2018-06-01 05:15:25.977561|2018-06-01 05:15:25.977561
NCT00073281|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-18|||2010-01-14|2003-11-19|2003-11-20|Estimate|||||||2010-01-14|2010-01-15|Estimate|August 2003||2003-08-31|January 2010|2010-01-31|December 2004||2004-12-31|||||Interventional|||Islet Transplantation for Patients With Type 1 Diabetes|Islet Transplantation for Patients With Type 1 Diabetes and Stable Renal Allografts Using Steroid Sparing Immunosuppression|Completed||Phase 1|10||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:15:26.030361|2018-06-01 05:15:26.030361
NCT00073255|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-18|||2010-01-14|2003-11-19|2003-11-20|Estimate|||||||2010-01-14|2010-01-15|Estimate|June 2003||2003-06-30|January 2010|2010-01-31|December 2005||2005-12-31|||||Interventional|||Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)|Evaluation of Tolerability, Safety, and Pharmacokinetics of hOKT3g1 (Ala-Ala)|Completed||Phase 1|12||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 05:15:26.078869|2018-06-01 05:15:26.078869
NCT00073268|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-18|||2010-01-14|2003-11-18|2003-11-19|Estimate|||||||2010-01-14|2010-01-15|Estimate|December 2002||2002-12-31|January 2010|2010-01-31|June 2007||2007-06-30|||||Interventional|||Prevention of Type 2 Diabetes Mellitus in Children|Prevention of Type 2 Diabetes Mellitus in Children|Completed||Phase 1|300|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:15:26.209993|2018-06-01 05:15:26.209993
NCT00073242|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-18|||2015-06-03|2003-11-18|2003-11-19|Estimate|||||||2015-06-03|2015-06-04|Estimate|July 2000||2000-07-31|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Low-Dose Leptin and the Formerly-Obese|Effects of Low-Dose Leptin on the Metabolic/Behavioral Phenotypes of the Formerly-Obese|Unknown status|Recruiting|Phase 3|25|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-06-01 05:15:26.279839|2018-06-01 05:15:26.279839
NCT00073229|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-18|||2008-09-25|2003-11-18|2003-11-19|Estimate|||||||2008-09-25|2008-09-26|Estimate|July 2000||2000-07-31|September 2008|2008-09-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Observational|||Immune Function of Infants With HIV|Killer Cells and Viral Load in Vertical HIV Infection|Completed|||80|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||f||||||||||2018-06-01 05:15:26.390948|2018-06-01 05:15:26.390948
NCT00073216|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-18|||2012-05-03|2003-11-18|2003-11-19|Estimate|||||||2012-05-03|2012-05-04|Estimate||||May 2012|2012-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine and a Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine in Healthy, HIV-1 Uninfected Adult Participants|Completed||Phase 1|96|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:15:26.458139|2018-06-01 05:15:26.458139
NCT00073203|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2009-08-27|2003-11-18|2003-11-19|Estimate|||||||2009-08-27|2009-08-28|Estimate||||May 2004|2004-05-31|May 2004||2004-05-31|||||Interventional|||A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder|A 6- Week, Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD)|Completed||Phase 2|488||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:15:26.537131|2018-06-01 05:15:26.537131
NCT00073177|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2016-10-24|2003-11-18|2003-11-19|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2003||2003-11-30|September 2016|2016-09-30||||||||Interventional|||Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)|A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Roflumilast (250 mcg or 500 mcg) Daily in Patients With Asthma|Completed||Phase 3|819||AstraZeneca|||||f||||||||||||||2018-06-01 05:15:26.601156|2018-06-01 05:15:26.601156
NCT00073190|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2013-12-13|2003-11-17|2003-11-18|Estimate|||||||2013-12-13|2013-12-16|Estimate|September 2003||2003-09-30|December 2013|2013-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Patient- and Physician-Based Osteoporosis Education|Randomized Controlled Testing of Osteoporosis Education|Completed||Phase 1|30000||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:15:26.720836|2018-06-01 05:15:26.720836
NCT00073164|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2006-08-02|2003-11-17|2003-11-18|Estimate|||||||2006-08-02|2006-08-04|Estimate|July 2003||2003-07-31|August 2006|2006-08-31||||||||Interventional|||Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia|A Study of the Safety and Efficacy of Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia|Completed||Phase 2|400||Abbott|||||||||||||||||||2018-06-01 05:15:26.788597|2018-06-01 05:15:26.788597
NCT00073151|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2007-11-28|2003-11-17|2003-11-18|Estimate|||||||2007-11-28|2007-11-29|Estimate|September 2003||2003-09-30|November 2007|2007-11-30|January 2006|Actual|2006-01-31|||||Interventional|||A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer|A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens|Completed||Phase 2|30|Anticipated|Abbott|||||f||||f||||||||||2018-06-01 05:15:26.886983|2018-06-01 05:15:26.886983
NCT00073138|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2007-11-28|2003-11-17|2003-11-18|Estimate|||||||2007-11-28|2007-11-29|Estimate|August 2003||2003-08-31|November 2007|2007-11-30|February 2005|Actual|2005-02-28|||||Interventional|||A Study of ABT-751 in Patients With Colorectal Cancer|A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma|Completed||Phase 2|40||Abbott|||||f||||f||||||||||2018-06-01 05:15:27.187928|2018-06-01 05:15:27.187928
NCT00073125|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2007-08-13|2003-11-17|2003-11-18|Estimate|||||||2007-08-13|2007-08-15|Estimate|May 2003||2003-05-31|August 2007|2007-08-31||||||||Interventional|||Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma|A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma|Completed||Phase 2|103|Actual|Abbott|||||f||||f||||||||||2018-06-01 05:15:27.258254|2018-06-01 05:15:27.258254
NCT00073112|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-17|||2007-11-28|2003-11-17|2003-11-18|Estimate|||||||2007-11-28|2007-11-29|Estimate|August 2003||2003-08-31|November 2007|2007-11-30|September 2006|Actual|2006-09-30|||||Interventional|||A Study of ABT-751 in Patients With Renal Cell Cancer|A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma|Completed||Phase 2|60||Abbott|||||f||||f||||||||||2018-06-01 05:15:27.359047|2018-06-01 05:15:27.359047
NCT00073047|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-14|||2009-07-17|2003-11-17|2003-11-18|Estimate|||||||2009-07-17|2009-07-20|Estimate|April 2003||2003-04-30|July 2009|2009-07-31|July 2006|Actual|2006-07-31|||||Interventional|||Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis|A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study of Intravenous Daclizumab in Patients With Moderate-to-severe Ulcerative Colitis|Completed||Phase 2|150||Facet Biotech|||||||||||||||||||2018-06-01 05:15:27.458297|2018-06-01 05:15:27.458297
NCT00073034|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-14|||2013-02-20|2003-11-17|2003-11-18|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of 3 Fixed Doses of EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy|Terminated||Phase 2|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:15:27.66206|2018-06-01 05:15:27.66206
NCT00073099|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-14|||2017-06-30|2003-11-14|2003-11-17|Estimate|||||||2017-06-30|2017-07-02|Actual|November 14, 2003||2003-11-14|September 6, 2007|2007-09-06|September 6, 2007||2007-09-06|||||Observational|||Digital Photography to Evaluate Dry Eye|Digital Image Based Determination of Ocular Surface Vital Dye Staining|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:27.725082|2018-06-01 05:15:27.725082
NCT00073086|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-14|||2017-06-30|2003-11-14|2003-11-17|Estimate|||||||2017-06-30|2017-07-02|Actual|November 5, 2003||2003-11-05|December 27, 2010|2010-12-27|December 27, 2010||2010-12-27|||||Observational|||Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)|Clinical Evaluation and Management of Persons With Severe Acute Respiratory Syndrome (SARS)|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:27.79765|2018-06-01 05:15:27.79765
NCT00073073|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-14|2016-04-11||2016-04-11|2003-11-14|2003-11-17|Estimate|2016-04-11|2016-05-17|Estimate||||2016-04-11|2016-05-17|Estimate|November 2003||2003-11-30|October 2015|2015-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Patients who were treated|Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer|A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer|Completed||Phase 2|46|Actual|Georgetown University||1|||f||||f||||||||||2018-06-01 05:15:27.876627|2018-06-01 05:15:27.876627
NCT00073060|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-14|||2018-04-03|2003-11-14|2003-11-17|Estimate|||||||2018-04-03|2018-04-04|Actual|November 14, 2003||2003-11-14|March 19, 2018|2018-03-19||||||||Observational|||Citrate Effects and Bone Density in Long-Term Apheresis Donors|Citrate Effects and Bone Density Studies in Long-Term Apheresis Donors|Completed|||273|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:28.137186|2018-06-01 05:15:28.137186
NCT00073021|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-13|2011-03-25||2015-06-01|2003-11-14|2003-11-17|Estimate|2011-06-29|2011-07-28|Estimate||||2015-06-01|2015-06-29|Estimate|September 2000||2000-09-30|June 2015|2015-06-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis|A Double-Blind, Randomized, 6-Week, Parallel-Group Design Clinical Trial to Assess Safety and Efficacy of Asacol 4.8 g/Day (800 mg Tablet) Versus Asacol 2.4 g/Day (400 mg Tablet) for the Treatment of Moderately Active Ulcerative Colitis|Completed||Phase 3|386|Actual|Warner Chilcott||2|||f||||f||||||||||2018-06-01 05:15:28.251404|2018-06-01 05:15:28.251404
NCT00073008|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-13|2009-06-15||2017-01-16|2003-11-14|2003-11-17|Estimate|2009-11-30|2010-01-06|Estimate||||2017-01-16|2017-02-28|Actual|November 2003||2003-11-30|January 2017|2017-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer|A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History|Terminated||Phase 2|131|Actual|GlaxoSmithKline|Based on interim analysis and predefined stopping rules for futility, the study was discontinued due to lack of efficacy. At that time, no additional participants were added; enrolled participants could continue on treatment, following the protocol.|1||"Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,~   further enrollment was stopped due to lack of efficacy"|f||||t||||||||||2018-06-01 05:15:29.072947|2018-06-01 05:15:29.072947
NCT00072995|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-13|||2013-01-29|2003-11-14|2003-11-17|Estimate|||||||2013-01-29|2013-01-30|Estimate|September 2003||2003-09-30|January 2013|2013-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Preventing Obesity Using Novel Dietary Strategies|Preventing Overweight Using Novel Dietary Strategies (Pounds Lost)|Completed||N/A|811||Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 05:15:29.905931|2018-06-01 05:15:29.905931
NCT00072982|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-13|||2008-08-22|2003-11-14|2003-11-17|Estimate|||||||2008-08-22|2008-08-25|Estimate|November 2006||2006-11-30|August 2008|2008-08-31|November 2008|Anticipated|2008-11-30|May 2008|Actual|2008-05-31||Interventional|||Treatment of Rheumatoid Arthritis With Marine and Botanical Oils|Treatment of Rheumatoid Arthritis With Marine and Botanical Oils|Unknown status|Active, not recruiting|Phase 3|156|Actual|National Center for Complementary and Integrative Health (NCCIH)||3|||f||||t||||||||||2018-06-01 05:15:30.067205|2018-06-01 05:15:30.067205
NCT00072943|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2012-03-09|2003-11-14|2003-11-17|Estimate|||||||2012-03-09|2012-03-13|Estimate|March 2002||2002-03-31|March 2012|2012-03-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease|A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease|Completed||Phase 2|175||Facet Biotech|||||f||||||||||||||2018-06-01 05:15:30.21421|2018-06-01 05:15:30.21421
NCT00072930|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2008-01-11|2003-11-14|2003-11-17|Estimate|||||||2008-01-11|2008-01-15|Estimate|December 2003||2003-12-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|April 2007|Anticipated|2007-04-30||Interventional|||MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer|Phase II, Randomized, Open-Label, Two-Arm, Multicenter Study of MEDI-522, a HuMA Directed Against the Human Alpha V Beta 3 Integrin, in Combination With Docetaxel, Prednisone, and Zoledronic Acid in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer|Completed||Phase 2|150||MedImmune LLC||2|||f||||||||||||||2018-06-01 05:15:30.439404|2018-06-01 05:15:30.439404
NCT00072917|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2010-01-15|2003-11-13|2003-11-14|Estimate|||||||2010-01-15|2010-01-18|Estimate|October 2003||2003-10-31|January 2010|2010-01-31|June 2008||2008-06-30|||||Observational|||The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women|The Effects of Overfeeding on Obesity-Prone (OP) and Obesity-Resistant (OR) Women|Completed|||100|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||Samples With DNA|"~     Blood and urine~   "|||2018-06-01 05:15:30.624241|2018-06-01 05:15:30.624241
NCT00072904|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2012-02-27|2003-11-13|2003-11-14|Estimate|||||||2012-02-27|2012-02-28|Estimate|June 2001||2001-06-30|February 2012|2012-02-29|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Diabetes Therapy to Improve BMI and Lung Function in CF|Diabetes Therapy to Improve BMI and Lung Function in CF|Completed||Phase 3|108|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||||||||||||2018-06-01 05:15:30.679522|2018-06-01 05:15:30.679522
NCT00072891|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2010-02-12|2003-11-13|2003-11-14|Estimate|||||||2010-02-12|2010-02-15|Estimate||||February 2010|2010-02-28|December 2005|Actual|2005-12-31|||||Interventional|||Improving Medication Adherence in Comorbid Conditions||Completed||N/A|400||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:15:30.82769|2018-06-01 05:15:30.82769
NCT00072969|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2008-03-03|2003-11-12|2003-11-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2003||2003-11-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)|A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)|Completed||Phase 2|132||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:30.889086|2018-06-01 05:15:30.889086
NCT00072956|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2008-03-03|2003-11-12|2003-11-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2003||2003-11-30|October 2005|2005-10-31|October 2005||2005-10-31|||||Observational|||The Physiology of Tricks|The Physiology of Tricks|Completed|||49||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:30.997129|2018-06-01 05:15:30.997129
NCT00072865|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-12|||2007-01-24|2003-11-12|2003-11-13|Estimate|||||||2007-01-24|2007-01-26|Estimate|June 2003||2003-06-30|January 2007|2007-01-31|September 2005||2005-09-30|||||Interventional|||Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer|A Phase II Study of Alimta and Carboplatin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|50||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:15:31.055298|2018-06-01 05:15:31.055298
NCT00072852|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-11|||2008-10-15|2003-11-12|2003-11-13|Estimate|||||||2008-10-15|2008-10-16|Estimate|November 2003||2003-11-30|October 2008|2008-10-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine|Phase II Trial of Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine|Completed||Phase 2|134|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:15:31.152778|2018-06-01 05:15:31.152778
NCT00072839|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-11|||2015-11-10|2003-11-12|2003-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|October 2003||2003-10-31|January 2015|2015-01-31|September 2005|Actual|2005-09-30|July 2005|Actual|2005-07-31||Interventional|||Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease|A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects With Moderately Active Crohn's Disease|Completed||Phase 2|100|Actual|Shire||4|||f||||f||||||||||2018-06-01 05:15:31.336456|2018-06-01 05:15:31.336456
NCT00072787|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-10|||2009-08-06|2003-11-12|2003-11-13|Estimate|||||||2009-08-06|2009-08-07|Estimate|October 2003||2003-10-31|August 2009|2009-08-31|May 2006|Actual|2006-05-31|March 2006|Actual|2006-03-31||Interventional|||Phase 1/2 Study of S-1 and Cisplatin in Advanced Gastric Cancer|A Phase I/II, Open-Label, Nonrandomized, Dose-Finding Safety, Tolerance, Pharmacokinetic, and Efficacy Study of Orally Administered S-1 in Combination With Cisplatin in Patients With Advanced Gastric Cancer|Completed||Phase 1/Phase 2|41||Taiho Oncology, Inc.|||||||||||||||||||2018-06-01 05:15:31.472204|2018-06-01 05:15:31.472204
NCT00072774|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-10|||2009-08-18|2003-11-12|2003-11-13|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Three Fixed Doses (100 Mg, 200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|480|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:15:31.602636|2018-06-01 05:15:31.602636
NCT00072761|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-10|2015-05-04||2016-01-07|2003-11-12|2003-11-13|Estimate|2016-01-07|2016-02-08|Estimate||||2016-01-07|2016-02-08|Estimate|December 2004||2004-12-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SIT||Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial|Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial|Completed||Phase 3|196|Actual|Washington University School of Medicine|The SIT Trial results are not directly applicable to all children with SCA. Those who were on hydroxyurea therapy for severe disease, had abnormally elevated TCDs, were receiving blood transfusion for stroke prevention or had epilepsy were excluded.|2|||f||||t||||||||||2018-06-01 05:15:31.67568|2018-06-01 05:15:31.67568
NCT00072748|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-10|||2009-08-20|2003-11-12|2003-11-13|Estimate|||||||2009-08-20|2009-08-21|Estimate||||August 2009|2009-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Study Evaluating EKB-569 in Advanced Colorectal Cancer||Completed||Phase 2|63|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:15:32.116168|2018-06-01 05:15:32.116168
NCT00072722|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-07|||2006-12-18|2003-11-12|2003-11-13|Estimate|||||||2006-12-18|2006-12-19|Estimate|September 2003||2003-09-30|December 2006|2006-12-31|April 2005||2005-04-30|||||Interventional|||Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)|Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)|Completed||Phase 2|36||Celgene|||||||||||||||||||2018-06-01 05:15:32.239207|2018-06-01 05:15:32.239207
NCT00017017|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-05-29|2003-11-12|2003-11-13|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 2001||2001-02-28|December 2009|2009-12-31|December 2009|Actual|2009-12-31|February 2003|Actual|2003-02-28||Interventional|||CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer|A Phase I/II Trial fo Intravenous CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:32.319607|2018-06-01 05:15:32.319607
NCT00072657|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-07|||2013-04-01|2003-11-07|2003-11-10|Estimate|||||||2013-04-01|2013-04-04|Estimate|February 2004||2004-02-29|April 2013|2013-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Cognitive-Behavioral Therapy and Tai Chi Chih for Patients With Rheumatoid Arthritis|Behavioral Treatments for Rheumatoid Arthritis|Completed||N/A|106|Actual|University of California, Los Angeles||3|||f||||||||||||||2018-06-01 05:15:35.11495|2018-06-01 05:15:35.11495
NCT00014677|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-07-17|2003-11-12|2003-11-13|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2001||2001-03-31|June 2002|2002-06-30|July 2008|Actual|2008-07-31|September 2002|Actual|2002-09-30||Interventional|||NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme|A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:32.394473|2018-06-01 05:15:32.394473
NCT00014638|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-02-20|2003-11-12|2003-11-13|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2001||2001-01-31|February 2013|2013-02-28|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer|Open Label, Multicenter Trial Of Femera (Letrozole) 2.5 mg As First-line Therapy In Postmenopausal Women With Metastatic Breast Cancer Relapsing Following Adjuvant Tamoxifen Therapy|Completed||Phase 4|||Novartis|||||f||||||||||||||2018-06-01 05:15:32.487716|2018-06-01 05:15:32.487716
NCT00014352|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-01-15|2003-11-12|2003-11-13|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2000||2000-09-30|January 2013|2013-01-31||||March 2003|Actual|2003-03-31||Interventional|||Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer|Phase II Trial Of Sequential Estramustine/Paclitaxel Followed By Doxorubicin/Ketoconazole In Patients With Androgen-Independent Prostate Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:32.73629|2018-06-01 05:15:32.73629
NCT00072826|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-10|||2018-05-15|2003-11-10|2003-11-11|Estimate|||||||2018-05-15|2018-05-16|Actual|November 4, 2003||2003-11-04|December 7, 2015|2015-12-07|August 24, 2007|Actual|2007-08-24|August 24, 2007|Actual|2007-08-24||Interventional|||Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease|Atorvastatin Therapy To Improve Endothelial Function in Sickle Cell Disease|Completed||Phase 1|44|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:32.881497|2018-06-01 05:15:32.881497
NCT00072813|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-10|||2017-06-30|2003-11-10|2003-11-11|Estimate|||||||2017-06-30|2017-07-02|Actual|November 10, 2003||2003-11-10|November 12, 2009|2009-11-12||||November 12, 2009|Actual|2009-11-12||Observational|||MRI in Autosomal Dominant Partial Epilepsy With Auditory Features|MRI in Autosomal Dominant Partial Epilepsy With Auditory Features|Completed|||72||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:32.974544|2018-06-01 05:15:32.974544
NCT00072800|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-10|||2008-03-03|2003-11-10|2003-11-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2003||2003-11-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Classification of Cerebral Palsy Subtypes|Classification of Cerebral Palsy Subtypes|Completed|||115||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:33.092814|2018-06-01 05:15:33.092814
NCT00072709|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-07|||2011-11-22|2003-11-10|2003-11-11|Estimate|||||||2011-11-22|2011-11-24|Estimate|September 2003||2003-09-30|November 2011|2011-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating Four Oral Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis|Completed||Phase 2|551|Actual|Novartis|||||f||||||||||||||2018-06-01 05:15:33.190413|2018-06-01 05:15:33.190413
NCT00072683|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-07|||2007-01-24|2003-11-10|2003-11-11|Estimate|||||||2007-01-24|2007-01-26|Estimate|April 2003||2003-04-30|January 2007|2007-01-31|February 2006||2006-02-28|||||Interventional|||“SALT Trial” Study of Ascending Levels of Tolvaptan in Hyponatremia|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia|Completed||Phase 3|240||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:15:33.296677|2018-06-01 05:15:33.296677
NCT00072670|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-07|||2014-04-07|2003-11-10|2003-11-11|Estimate|||||||2014-04-07|2014-04-08|Estimate|January 2004||2004-01-31|April 2014|2014-04-30|November 2008|Actual|2008-11-30|September 2008|Actual|2008-09-30||Interventional|||A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer|Phase 2 Study of Yondelis in Men With Advanced Prostate Carcinoma|Completed||Phase 2|59|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||t||||||||||2018-06-01 05:15:33.613551|2018-06-01 05:15:33.613551
NCT00012090|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-06-17|2003-11-10|2003-11-11|Estimate|||||||2013-06-17|2013-06-18|Estimate|September 2000||2000-09-30|June 2013|2013-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum|A Phase II Trial Of Oral Bicalutamide With Subcutaneous Goserelin In Patients With Epithelial Ovarian, Fallopian Tube, Or Peritoneal Carcinoma In Second Or Greater Remission|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:33.836979|2018-06-01 05:15:33.836979
NCT00010309|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2014-01-03|2003-11-10|2003-11-11|Estimate|||||||2014-01-03|2014-01-06|Estimate|November 2000||2000-11-30|July 2002|2002-07-31||||||||Interventional|||Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma|Phase I/II Trial Investigating The Safety And Immunogenicity Of Adenoviruses Encoding The Melan-A/MART-1 And gp 100 Melanoma Antigens Administered Intradermally To Patients With Stage II-IV Melanoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:34.001034|2018-06-01 05:15:34.001034
NCT00008372|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2011-10-18|2003-11-10|2003-11-11|Estimate|||||||2011-10-18|2011-10-20|Estimate|December 2000||2000-12-31|October 2011|2011-10-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer|Phase II Trial Of CQS (NSC 339004) In Platinum-Refractory Small Cell Lung Cancer|Completed||Phase 2|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:15:34.265027|2018-06-01 05:15:34.265027
NCT00006367|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2010-06-15|2003-11-10|2003-11-11|Estimate|||||||2010-06-15|2010-06-17|Estimate|May 2000||2000-05-31|June 2010|2010-06-30|January 2004|Actual|2004-01-31|||||Interventional|||Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis|Autologous Peripheral Blood Stem Cell Mobilization and Transplantation for Myelofibrosis|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:15:34.601571|2018-06-01 05:15:34.601571
NCT00006224|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-04-10|2003-11-10|2003-11-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|September 2000||2000-09-30|June 2005|2005-06-30||||April 2005|Actual|2005-04-30||Interventional|||Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix|Evaluation of Gemcitabine in Persistent or Recurrent Non-Squamous Cell Carcinoma of the Cervix|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:15:34.824292|2018-06-01 05:15:34.824292
NCT00072735|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-07|||2017-06-30|2003-11-07|2003-11-10|Estimate|||||||2017-06-30|2017-07-02|Actual|November 6, 2003||2003-11-06|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||Improvement of Use Dependent Plasticity in Chronic Stroke Patients|Improvement of Use Dependent Plasticity in Chronic Stroke Patients|Completed||Phase 1|48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:34.983743|2018-06-01 05:15:34.983743
NCT00072644|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-06|||2017-06-30|2003-11-06|2003-11-07|Estimate|||||||2017-06-30|2017-07-02|Actual|October 30, 2003||2003-10-30|June 17, 2008|2008-06-17|June 17, 2008||2008-06-17|||||Observational|||Pharmacokinetic Interactions With Prednisolone in Healthy Volunteers and HIV-infected Patients Receiving Single-Dose Prednisone|Pharmacokinetic Interactions With Prednisolone in Healthy Volunteers and HIV-infected Patients Receiving Single-Dose Prednisone|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:35.367137|2018-06-01 05:15:35.367137
NCT00072631|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-05|||2018-02-06|2003-11-06|2003-11-07|Estimate|||||||2018-02-06|2018-02-08|Actual|November 5, 2003|Actual|2003-11-05|June 2015|2015-06-30|March 14, 2007|Actual|2007-03-14|March 14, 2007|Actual|2007-03-14||Interventional|||Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy|Completed||Phase 2|43|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-06-01 05:15:35.522457|2018-06-01 05:15:35.522457
NCT00072618|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-05|||2011-10-18|2003-11-06|2003-11-07|Estimate|||||||2011-10-18|2011-10-20|Estimate|October 2001||2001-10-31|October 2011|2011-10-31|August 2003|Actual|2003-08-31|||||Interventional|||Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients|A Phase I/II Multi-Center Study of Weekly Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed a Prior Platinum-Containing Regimen|Completed||Phase 1/Phase 2|52||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:15:35.718106|2018-06-01 05:15:35.718106
NCT00072501|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2012-10-27|2003-11-05|2003-11-06|Estimate|||||||2012-10-27|2012-10-30|Estimate|April 2004||2004-04-30|February 2006|2006-02-28||||April 2012|Actual|2012-04-30||Interventional|||Breast Ultrasound and Mammography in Screening Women at High Risk for Breast Cancer|Screening Breast Ultrasound in High-Risk Women|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:35.781769|2018-06-01 05:15:35.781769
NCT00072488|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2010-06-05|2003-11-05|2003-11-06|Estimate|||||||2010-06-05|2010-06-08|Estimate|October 2004||2004-10-31|October 2007|2007-10-31||||December 2005|Anticipated|2005-12-31||Interventional|||Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma|Whole-Body MRI in the Evaluation of Pediatric Malignancies|Unknown status|Active, not recruiting|N/A|226|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:35.963778|2018-06-01 05:15:35.963778
NCT00072475|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2014-05-22||2016-07-01|2003-11-05|2003-11-06|Estimate|2014-05-22|2014-06-24|Estimate||||2016-07-01|2016-08-01|Estimate|December 2003||2003-12-31|July 2016|2016-07-31|June 2014|Actual|2014-06-30|November 2008|Actual|2008-11-30||Interventional||Of the 155 participants recruited, 2 participants cancelled prior to starting treatment; 7 were determined to have AML at registration and 4 had diagnosis other than MDS. Thus 142 participants were evaluable for response|Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes|A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS)|Completed||Phase 2|155|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:15:36.098414|2018-06-01 05:15:36.098414
NCT00072462|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2018-04-17|2003-11-05|2003-11-06|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2003||2003-09-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|December 2015|Actual|2015-12-31||Interventional|IBIS-II DCIS||Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ|International Breast Cancer Intervention Study II (IBIS-II) (DCIS)|Active, not recruiting||Phase 3|2980|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-06-01 05:15:37.064195|2018-06-01 05:15:37.064195
NCT00072449|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2013-06-14||2013-06-14|2003-11-05|2003-11-06|Estimate|2013-06-14|2013-08-28|Estimate||||2013-06-14|2013-08-28|Estimate|May 2004||2004-05-31|June 2013|2013-06-30|June 2010|Actual|2010-06-30|March 2009|Actual|2009-03-31||Interventional|||Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma|A Phase II Study Of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy For Patients With Refractory Or Relapsed Primary CNS Lymphoma (PCNSL)|Terminated||Phase 2|12|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Study terminated early due to slow accrual and lack of resources and priority due to NCI mandate of combining two consortia. Unable to fully analyze the data, or objectives, not enough patients. Not able to do statistics|1||slow accrual and lack of resources and priority due to combining 2 consortia|f||||||||||||||2018-06-01 05:15:38.317385|2018-06-01 05:15:38.317385
NCT00072436|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-07-01|2003-11-05|2003-11-06|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2003||2003-09-30|July 2013|2013-07-31||||March 2009|Actual|2009-03-31||Interventional|||Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors|A Phase I Trial of Gemcitabine Followed by a Short Infusion of Flavopiridol in Patients With Solid Tumors|Completed||Phase 1|58|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:15:38.704538|2018-06-01 05:15:38.704538
NCT00072410|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2009-02-06|2003-11-05|2003-11-06|Estimate|||||||2009-02-06|2009-02-09|Estimate|June 2003||2003-06-30|August 2005|2005-08-31||||||||Interventional|||Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer|Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized Monoclonal Antibody 3S193 (90Y-hu3S193) in Patients With Advanced Ovarian Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:38.785439|2018-06-01 05:15:38.785439
NCT00072384|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-06-18|2003-11-05|2003-11-06|Estimate|||||||2013-06-18|2013-06-19|Estimate|April 2007||2007-04-30|June 2013|2013-06-30||||February 2013|Actual|2013-02-28||Interventional|||Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma|A Single Arm Trial of Systemic And Subtenon Chemotherapy For Groups C And D Intraocular Retinoblastoma|Completed||Phase 3|30|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:15:38.849517|2018-06-01 05:15:38.849517
NCT00072358|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2017-10-03|2003-11-05|2003-11-06|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2003||2003-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma|Phase II Study of Anti-GD2 3F8 Antibody and GM-CSF for High-Risk Neuroblastoma|Active, not recruiting||Phase 2|340|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 05:15:39.067408|2018-06-01 05:15:39.067408
NCT00072345|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-01-17|2003-11-05|2003-11-06|Estimate|||||||2013-01-17|2013-01-18|Estimate|July 2003||2003-07-31|January 2013|2013-01-31||||August 2004|Actual|2004-08-31||Interventional|||Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma|A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:39.173126|2018-06-01 05:15:39.173126
NCT00071604|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-05-03|2003-10-29|2003-10-30|Estimate|||||||2013-05-03|2013-05-06|Estimate|September 2002||2002-09-30|April 2008|2008-04-30|May 2007||2007-05-31|||||Interventional|||Medication Adherence in Older People With Psychosis|Medication Adherence in Older Psychotic People|Unknown status|Active, not recruiting|N/A|240|Anticipated|Veterans Medical Research Foundation|||||f||||||||||||||2018-06-01 05:16:10.20266|2018-06-01 05:16:10.20266
NCT00072332|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-12-18|2003-11-05|2003-11-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 2003||2003-08-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2005|Actual|2005-12-31||Interventional|||Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Dose Escalation Study of Edotecarin (PHA-782615) and Cisplatin in Adult Patients With Advanced/Metastatic Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:39.25564|2018-06-01 05:15:39.25564
NCT00072319|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-03-01|2003-11-05|2003-11-06|Estimate|||||||2013-03-01|2013-03-04|Estimate|August 2003||2003-08-31|March 2013|2013-03-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer|Pilot Study of Epirubicin and Cyclophosphamide Followed by Paclitaxel at 10-11 Days Interval for Women With Early Breast Carcinoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:15:39.322013|2018-06-01 05:15:39.322013
NCT00072293|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2016-02-26||2017-12-22|2003-11-05|2003-11-06|Estimate|2016-04-12|2016-05-18|Estimate||||2017-12-22|2018-01-23|Actual|December 2001||2001-12-31|December 2017|2017-12-31|March 31, 2017|Actual|2017-03-31|September 2012|Actual|2012-09-30||Interventional|23-01|Intention-to-treat|Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases|A Randomized Trial Of Axillary Dissection Versus No Axillary Dissection For Patients With Clinically Node Negative Breast Cancer And Micrometastases In The Sentinel Node|Completed||N/A|931|Actual|International Breast Cancer Study Group||2|||f||||t||||||||||2018-06-01 05:15:39.415188|2018-06-01 05:15:39.415188
NCT00072280|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2013-09-23||2014-09-16|2003-11-05|2003-11-06|Estimate|2013-09-23|2013-11-26|Estimate||||2014-09-16|2014-09-30|Estimate|November 2004||2004-11-30|September 2014|2014-09-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma|A Pilot Phase II Study for Children With Infantile Fibrosarcoma|Terminated||Phase 2|7|Actual|Children's Oncology Group|Study closed early due to slow accrual. Analysis plans were not carried out (lack of statistical precision compromised the ability to draw appropriate conclusions). Reported Primary Outcome Measure data reflects data collection through March 2008.|2||Due to poor accrual|f||||t||||||||||2018-06-01 05:15:39.76653|2018-06-01 05:15:39.76653
NCT00072267|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2015-07-22|2003-11-05|2003-11-06|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2004||2004-01-31|July 2015|2015-07-31||||April 2005|Actual|2005-04-30||Interventional|||UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase II Study of UCN-01 in Combination With Topotecan in Patients With Advanced Ovarian Cancer|Completed||Phase 2|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 05:15:40.411176|2018-06-01 05:15:40.411176
NCT00072228|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-07-09|2003-11-05|2003-11-06|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Study of Soblidotin and Gemcitabine in Patients With Locally Advanced or Metastatic Solid Tumors|Withdrawn||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:40.647863|2018-06-01 05:15:40.647863
NCT00072215|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2016-07-01|2003-11-05|2003-11-06|Estimate|||||||2016-07-01|2016-07-04|Estimate|April 2004||2004-04-30|July 2016|2016-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors|A Randomized Phase III Study of Paclitaxel, Ifosfamide and Cisplatin Versus Vinblastine, Ifosfamide and Cisplatin as Second-Line Therapy for Patients With Relapsed/Resistant Germ Cell Tumors|Terminated||Phase 3|1|Actual|Alliance for Clinical Trials in Oncology||2||poor accrual|f||||t||||||||||2018-06-01 05:15:40.776095|2018-06-01 05:15:40.776095
NCT00072189|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2015-02-17||2015-02-17|2003-11-05|2003-11-06|Estimate|2015-02-17|2015-03-02|Estimate||||2015-02-17|2015-03-02|Estimate|November 2003||2003-11-30|October 2013|2013-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase II Study of UCN-01 in Metastatic Melanoma|A Phase II Study of UCN-01 in Metastatic Melanoma|Terminated||Phase 2|17|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results|1||Early termination for discouraging results|f||||||||||||||2018-06-01 05:15:41.484127|2018-06-01 05:15:41.484127
NCT00072176|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2015-02-05||2015-02-05|2003-11-05|2003-11-06|Estimate|2015-02-05|2015-02-23|Estimate||||2015-02-05|2015-02-23|Estimate|May 2004||2004-05-31|March 2014|2014-03-31|August 2009|Actual|2009-08-31|May 2009|Actual|2009-05-31||Interventional||All patients received treatment|Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer|A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer|Completed||Phase 2|62|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:41.894445|2018-06-01 05:15:41.894445
NCT00072163|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-01-15|2003-11-05|2003-11-06|Estimate|||||||2013-01-15|2013-01-17|Estimate|October 2003||2003-10-31|January 2013|2013-01-31||||September 2006|Actual|2006-09-30||Interventional|||Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma|A Phase II Study Of Temozolomide And Thalidomide In Patients With Metastatic Melanoma In The Brain|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:42.714281|2018-06-01 05:15:42.714281
NCT00072150|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-06-04|2003-11-05|2003-11-06|Estimate|||||||2013-06-04|2013-06-05|Estimate|October 2003||2003-10-31|June 2013|2013-06-30||||March 2006|Actual|2006-03-31||Interventional|||Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma|Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:42.853182|2018-06-01 05:15:42.853182
NCT00072137|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2014-12-22|2003-11-05|2003-11-06|Estimate|||||||2014-12-22|2014-12-23|Estimate|October 2003||2003-10-31|August 2013|2013-08-31|November 2010|Actual|2010-11-30|December 2009|Actual|2009-12-31||Interventional|||Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy|Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy|Terminated||Phase 1|21|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:15:43.134242|2018-06-01 05:15:43.134242
NCT00072124|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-06-18|2003-11-05|2003-11-06|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2003||2003-09-30|January 2005|2005-01-31|May 2005|Actual|2005-05-31|||||Interventional|||Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma|A Prospective Random Assignment Trial Comparing Complete Metastasectomy to Chemotherapy for Selected Patients With Stage IV Melanoma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:43.341367|2018-06-01 05:15:43.341367
NCT00072111|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2015-04-29|2003-11-05|2003-11-06|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2003||2003-09-30|April 2006|2006-04-30||||||||Interventional|||Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene|Phase I Study of Anakinra Mediated Tumor Regression and Angiogenesis Inhibition in Subjects With Cancers Producing Interleukin-1|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:43.417257|2018-06-01 05:15:43.417257
NCT00072098|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2017-01-10|2003-11-05|2003-11-06|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2003||2003-09-30|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer|Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver|Terminated||Phase 1|22|Actual|Icahn School of Medicine at Mount Sinai||1||limited funding|f||||t||||||||||2018-06-01 05:15:43.571438|2018-06-01 05:15:43.571438
NCT00072085|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-06-18|2003-11-05|2003-11-06|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2003||2003-09-30|May 2005|2005-05-31|July 2006|Actual|2006-07-31|||||Interventional|||Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma|Immunization Of Patients With Metastatic Melanoma Using A Recombinant GP100 Protein (184V) And A Class I Restricted Peptide From The GP100 Antigen|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:43.763781|2018-06-01 05:15:43.763781
NCT00072072|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-09-19|2003-11-05|2003-11-06|Estimate|||||||2013-09-19|2013-09-20|Estimate|August 2003||2003-08-31|January 2006|2006-01-31|January 2006|Actual|2006-01-31|||||Interventional|||Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase I Trial Of A COX-2 Inhibitor (Celecoxib) In Combination With An EGFR Inhibitor (OSI-774) In Metastatic Non-Small Cell Lung Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:43.918131|2018-06-01 05:15:43.918131
NCT00072059|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-07-17|2003-11-05|2003-11-06|Estimate|||||||2013-07-17|2013-07-18|Estimate|July 2003||2003-07-31|January 2005|2005-01-31|February 2005|Actual|2005-02-28|||||Interventional|||Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer|An Open Label, Randomized, Multicenter, Phase II Study To Determine Hemoglobin Dose Response, Safety And Pharmacokinetic Profile Of Ro 50-3821 Given Subcutaneously Once Weekly Or Once Every 3 Weeks To Anemic Patients With Stage IIIB or IV Non-Small Cell Lung Carcinoma Receiving Antineoplastic Therapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:44.222341|2018-06-01 05:15:44.222341
NCT00072046|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2016-07-01|2003-11-05|2003-11-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|October 2003||2003-10-31|July 2016|2016-07-31|November 2012|Actual|2012-11-30|January 2004|Actual|2004-01-31||Interventional|||Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)|A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma|Completed||Phase 3|732|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:15:44.402359|2018-06-01 05:15:44.402359
NCT00072033|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2012-06-02|2003-11-05|2003-11-06|Estimate|||||||2012-06-02|2012-06-05|Estimate|March 2003||2003-03-31|June 2012|2012-06-30|May 2010|Actual|2010-05-31|March 2003|Actual|2003-03-31||Interventional|||Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer|Docetaxel and Cisplatin Chemo- and Radiochemotherapy Followed by Surgery in Patients With Locally Advanced Esophageal Cancer - A Multicenter Phase II Trial|Completed||Phase 2|66|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||||2018-06-01 05:15:46.461946|2018-06-01 05:15:46.461946
NCT00072020|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-08-01|2003-11-05|2003-11-06|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 2003||2003-08-31|January 2006|2006-01-31||||||||Interventional|||Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer|Does Adjuvant Zoledronic Acid Reduce Recurrence in Patients With High Risk Localized Breast Cancer?|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:46.628951|2018-06-01 05:15:46.628951
NCT00072007|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2012-05-14|2003-11-05|2003-11-06|Estimate|||||||2012-05-14|2012-05-15|Estimate|June 2002||2002-06-30|May 2012|2012-05-31|October 2010|Actual|2010-10-31|March 2003|Actual|2003-03-31||Interventional|||Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL|2-CDA and Rituximab as Remission Induction and Rituximab as In Vivo Purging Prior to Peripheral Stem Cell Mobilization in Patients With Chronic Lymphocytic Leukemia (CLL) - A Prospective Multicenter Phase II Trial|Completed||Phase 2|43|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 05:15:46.956439|2018-06-01 05:15:46.956439
NCT00071994|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-02-26|2003-11-05|2003-11-06|Estimate|||||||2013-02-26|2013-02-27|Estimate|February 2004||2004-02-29|February 2013|2013-02-28||||May 2005|Actual|2005-05-31||Interventional|||Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)|A Phase II Study of ZD1839 (Iressa, Gefitinib, NSC 715055) in Advanced Unresectable Hepatocellular Carcinoma|Completed||Phase 2|59|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:47.082618|2018-06-01 05:15:47.082618
NCT00071981|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2012-11-24||2015-10-06|2003-11-05|2003-11-06|Estimate|2012-11-30|2013-01-03|Estimate||||2015-10-06|2015-10-28|Estimate|March 2005||2005-03-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|August 2011|Actual|2011-08-31||Interventional|||Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma|A Randomized Phase II Trial of Multi-Epitope Vaccination With Melanoma Peptides For Cytotoxic T Cells And Helper T Cells For Patients With Metastatic Melanoma|Completed||Phase 2|175|Actual|Eastern Cooperative Oncology Group||4|||f||||f||||||||||2018-06-01 05:15:47.465971|2018-06-01 05:15:47.465971
NCT00071968|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-01-07|2003-11-05|2003-11-06|Estimate|||||||2013-01-07|2013-01-08|Estimate|August 2003||2003-08-31|January 2013|2013-01-31||||May 2006|Actual|2006-05-31||Interventional|||Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse|An Open-Label Study Of Exploratory Pharmacogenomics And Pharmacologic Effects Of Neoadjuvant Oral CCI-779 In Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have A High Risk Of Relapse|Completed||Phase 2|15|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:15:49.11565|2018-06-01 05:15:49.11565
NCT00071955|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-12-18|2003-11-05|2003-11-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2003||2003-03-31|January 2006|2006-01-31|January 2009|Actual|2009-01-31|||||Interventional|||Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma|A Phase II Study to Evaluate Safety and Efficacy of Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH and GM-CSF Following the Anti-CD20 Antibody, Rituximab, in Previously Treated Patients With Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:49.206154|2018-06-01 05:15:49.206154
NCT00071942|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-12-10|2003-11-05|2003-11-06|Estimate|||||||2013-12-10|2013-12-11|Estimate|October 2003||2003-10-31|December 2013|2013-12-31||||November 2007|Actual|2007-11-30||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Breast Cancer|A Phase I Trial of An Admixture of Recombinant Vaccinia Virus That Express DF3/MUC1 and rV-TRICOM (B7.ICAM-1, and LFA-3) in Patients With Metastatic Adenocarcinoma of The Breast|Terminated||Phase 1|22|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:49.421461|2018-06-01 05:15:49.421461
NCT00071929|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-06-20|2003-11-05|2003-11-06|Estimate|||||||2013-06-20|2013-06-24|Estimate|November 1999||1999-11-30|September 2004|2004-09-30|September 2007|Actual|2007-09-30|||||Interventional|||Oxaliplatin in Treating Patients With Persistent or Recurrent Endometrial Cancer|Phase II Evaluation of Oxaliplatin in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:49.59981|2018-06-01 05:15:49.59981
NCT00003141|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-03-27|2003-11-05|2003-11-06|Estimate|||||||2014-03-27|2014-03-28|Estimate|March 1998||1998-03-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|December 2007|Actual|2007-12-31||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors|A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors|Completed||Phase 1|94|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:15:49.78172|2018-06-01 05:15:49.78172
NCT00072605|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2017-06-30|2003-11-04|2003-11-05|Estimate|||||||2017-06-30|2017-07-02|Actual|October 30, 2003||2003-10-30|August 22, 2007|2007-08-22|August 22, 2007||2007-08-22|||||Interventional|||Experimental Ebola Vaccine Trial|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiple Strain Ebola DNA Plasmid Vaccine, VRC-EBODNA012-00-VP, in Adult Volunteers|Completed||Phase 1|27||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:50.29846|2018-06-01 05:15:50.29846
NCT00072592|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2008-03-03|2003-11-04|2003-11-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies|An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:15:50.380366|2018-06-01 05:15:50.380366
NCT00072579|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2017-01-17|2003-11-04|2003-11-05|Estimate|||||||2017-01-17|2017-01-19|Estimate|May 2003||2003-05-31|June 2013|2013-06-30|December 2007|Actual|2007-12-31|April 2006|Actual|2006-04-30||Interventional|||Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment|Phase II Study of GM-CSF in Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) Who Are Not in Complete Cytogenetic Remission After Initial Therapy|Completed||Phase 2|||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:15:50.531393|2018-06-01 05:15:50.531393
NCT00072566|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2015-04-14||2015-05-08|2003-11-04|2003-11-05|Estimate|2015-05-08|2015-05-12|Estimate||||2015-05-08|2015-05-12|Estimate|December 2003||2003-12-31|December 2012|2012-12-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Clinical Trial of Bevacizumab (NSC 704865) and Low Dose Oral Cyclophosphamide in Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma|Completed||Phase 2|70|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:15:50.716146|2018-06-01 05:15:50.716146
NCT00072553|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2009-02-06|2003-11-04|2003-11-05|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 2003||2003-09-30|May 2007|2007-05-31||||||||Interventional|||Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer|A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:15:51.463619|2018-06-01 05:15:51.463619
NCT00072540|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2013-11-07|2003-11-04|2003-11-05|Estimate|||||||2013-11-07|2013-11-08|Estimate||||November 2013|2013-11-30||||||||Interventional|||S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix|S0212: Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||||drug issues|f||||t||||||||||2018-06-01 05:15:51.588386|2018-06-01 05:15:51.588386
NCT00072527|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2016-07-01|2003-11-04|2003-11-05|Estimate|||||||2016-07-01|2016-07-06|Estimate|November 2003||2003-11-30|July 2016|2016-07-31|January 2013|Actual|2013-01-31|June 2007|Actual|2007-06-30||Interventional|||Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Induction Cisplatin/Irinotecan Followed By Combination Carboplatin, Etoposide And Chest Radiotherapy In Limited Stage Small Cell Lung Cancer: A Phase II Study|Completed||Phase 2|78|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:15:51.689434|2018-06-01 05:15:51.689434
NCT00072514|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|2017-04-14||2017-05-28|2003-11-04|2003-11-05|Estimate|2017-05-28|2017-06-29|Actual||||2017-05-28|2017-06-29|Actual|August 2003||2003-08-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|July 2008|Actual|2008-07-31||Interventional|||Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies|A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies|Completed||Phase 2|55|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:15:51.942556|2018-06-01 05:15:51.942556
NCT00071916|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-04|||2010-10-28|2003-11-04|2003-11-05|Estimate|||||||2010-10-28|2010-10-29|Estimate|March 2001||2001-03-31|March 2010|2010-03-31|June 2010|Anticipated|2010-06-30|||||Observational|||Racial Difference in HCV/Host Interactions|African American Response to Therapy for Hepatitis C|Unknown status|Recruiting||260|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Blood. No liver biopsies will be performed specifically for inclusion into the tissue~     repository. Only slides or paraffin tissue blocks of previously performed liver biopsies will~     be included in the tissue repository.~   "|||2018-06-01 05:15:52.189702|2018-06-01 05:15:52.189702
NCT00071851|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-03|||2015-04-09|2003-11-04|2003-11-05|Estimate|||||||2015-04-09|2015-04-10|Estimate|December 2003||2003-12-31|April 2015|2015-04-30|October 2005|Actual|2005-10-31|||||Interventional|||Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults|A Phase IB Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, Administered at 2 Different Dosing Schedules, in HIV-1-Uninfected Adult Participants|Completed||Phase 1/Phase 2|180||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:15:52.332682|2018-06-01 05:15:52.332682
NCT00071812|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-31|2012-02-27||2013-08-01|2003-11-04|2003-11-05|Estimate|2012-05-22|2012-06-25|Estimate||||2013-08-01|2013-08-14|Estimate|December 2003||2003-12-31|August 2013|2013-08-31|December 2005|Actual|2005-12-31|January 2005|Actual|2005-01-31||Interventional|||A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)|A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)|Completed||Phase 2|283|Actual|Human Genome Sciences Inc.||4|||f||||t||||||||||2018-06-01 05:15:52.550471|2018-06-01 05:15:52.550471
NCT00071799|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-31|2010-03-02||2010-08-24|2003-11-04|2003-11-05|Estimate|2010-06-01|2010-07-05|Estimate||||2010-08-24|2010-08-31|Estimate|November 2003||2003-11-30|August 2010|2010-08-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care|A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)|Completed||Phase 3|358|Actual|Celgene||2|||f||||t||||||||||2018-06-01 05:15:54.323431|2018-06-01 05:15:54.323431
NCT00006008|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-20|2003-11-04|2003-11-05|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 2000||2000-06-30|August 2002|2002-08-31|September 2006|Actual|2006-09-30|||||Interventional|||Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase II Trial of Arsenic Trioxide (NSC #706363) for Relapsed or Refractory Acute Lymphoblastic Leukemia|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:02.733583|2018-06-01 05:16:02.733583
NCT00005964|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-07-12|2003-11-04|2003-11-05|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2000||2000-05-31|July 2016|2016-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|Randomized Phase II Study of Dose-Adjusted EPOCH vs. NHL-15 Chemotherapy for Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 2|59|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:16:03.023127|2018-06-01 05:16:03.023127
NCT00005962|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-08-16|2003-11-04|2003-11-05|Estimate|||||||2013-08-16|2013-08-20|Estimate|July 2000||2000-07-31|August 2013|2013-08-31|June 2007|Actual|2007-06-30|October 2005|Actual|2005-10-31||Interventional|||Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia|A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:16:03.40917|2018-06-01 05:16:03.40917
NCT00005576|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-01-15|2003-11-04|2003-11-05|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2001||2001-01-31|January 2013|2013-01-31||||March 2002|Actual|2002-03-31||Interventional|||Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma|A PHASE I STUDY OF CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY (ch14.18) WITH GM-CSF AND INTERLEUKIN-2 (IL-2) IN CHILDREN WITH NEUROBLASTOMA IMMEDIATELY POST AUTOLOGOUS BMT OR PBSC RESCUE|Completed||Phase 1|6|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:03.667024|2018-06-01 05:16:03.667024
NCT00005094|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-04-11|2003-11-04|2003-11-05|Estimate|||||||2013-04-11|2013-04-12|Estimate|March 2000||2000-03-31|April 2013|2013-04-30||||April 2006|Actual|2006-04-30||Interventional|||Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps|Prevention of Sporadic Colorectal Adenomas With Celecoxib|Completed||Phase 3|1170|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:16:03.887522|2018-06-01 05:16:03.887522
NCT00071903|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-03|||2017-06-30|2003-11-03|2003-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|October 30, 2003||2003-10-30|July 18, 2008|2008-07-18|July 18, 2008||2008-07-18|||||Observational|||The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study|The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study|Completed|||18||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:04.038003|2018-06-01 05:16:04.038003
NCT00071890|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-03|2010-09-13||2010-09-13|2003-11-03|2003-11-04|Estimate|2010-09-13|2010-10-05|Estimate||||2010-09-13|2010-10-05|Estimate|October 2003||2003-10-31|September 2010|2010-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|ILIADE||Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx|Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Anti-Retroviral TX in HIV Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm(3) Who Have Received Anti-Retroviral TX|Completed||Phase 2|148|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:16:04.214197|2018-06-01 05:16:04.214197
NCT00071877|ClinicalTrials.gov processed this data on May 31, 2018|2003-11-03|||2008-03-03|2003-11-03|2003-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease|A Clinical Trial of Replagal Enzyme Replacement Therapy in Children Ages 7 - 17 Years With Fabry Disease|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:04.810557|2018-06-01 05:16:04.810557
NCT00005072|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-07-25|2003-11-03|2003-11-04|Estimate|||||||2014-07-25|2014-07-29|Estimate|November 2000||2000-11-30|July 2014|2014-07-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer|Phase I/II Study Evaluating the Safety and Efficacy of Leuvectin Immunotherapy for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy (Summary Last Updated: 02/2001)|Terminated||Phase 1/Phase 2|25|Actual|Vical||1||Development in prostate cancer indication halted|f||||f||||||||||2018-06-01 05:16:04.937137|2018-06-01 05:16:04.937137
NCT00005046|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-05-24|2003-11-03|2003-11-04|Estimate|||||||2013-05-24|2013-05-27|Estimate|April 2000||2000-04-30|July 2008|2008-07-31||||January 2007|Actual|2007-01-31||Interventional|||Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer|A Phase I Open Label Assessment of the Safety and Pharmacokinetics of Intraperitoneal PACLIMER Microspheres (Polilactofate/Paclitaxel) in Patients With Ovarian Cancer|Completed||Phase 1|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:16:05.176193|2018-06-01 05:16:05.176193
NCT00004206|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2014-06-23|2003-11-03|2003-11-04|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 1999||1999-09-30|July 2002|2002-07-31||||||||Interventional|||Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer|Phase II Study of Oxaliplatin and 5 Fluorouracil in the Treatment of Advanced Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:05.354775|2018-06-01 05:16:05.354775
NCT00004093|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-05-25|2012-05-31|2003-11-03|2003-11-04|Estimate||||2011-05-25|2011-06-02|Estimate|2012-05-31|2012-06-06|Estimate|August 1999||1999-08-31|May 2012|2012-05-31|March 2002|Actual|2002-03-31|February 2002|Actual|2002-02-28||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|A Phase I-II Study of Induction Chemotherapy With Carboplatin and Gemcitabine, Followed by Chemoradiotherapy With Paclitaxel and Vinorelbine for Patients With Locally Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|36|Actual|Northwestern University||||Original Principal Investigator left the institution.|f||||||||||||||2018-06-01 05:16:05.492597|2018-06-01 05:16:05.492597
NCT00071838|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-31|||2017-06-30|2003-10-31|2003-11-03|Estimate|||||||2017-06-30|2017-07-02|Actual|October 30, 2003||2003-10-30|August 16, 2011|2011-08-16|August 16, 2011|Actual|2011-08-16|October 4, 2007|Actual|2007-10-04||Interventional|||Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis|Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System|Completed||Phase 2|16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:05.733593|2018-06-01 05:16:05.733593
NCT00071773|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-30|||2016-08-25|2003-10-31|2003-11-03|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2003||2003-07-31|August 2016|2016-08-31|February 2008|Actual|2008-02-29|November 2005|Actual|2005-11-30||Interventional|Laser||A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema|A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema|Completed||Phase 2|263|Actual|Jaeb Center for Health Research||2|||f||||f||||||||||2018-06-01 05:16:05.897256|2018-06-01 05:16:05.897256
NCT00071786|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-30|||2018-04-24|2003-10-30|2003-10-31|Estimate|||||||2018-04-24|2018-04-25|Actual|October 30, 2003||2003-10-30|April 9, 2018|2018-04-09||||||||Observational|||Family Study of Affective and Anxiety Spectrum Disorders|Family Study of Affective and Anxiety Spectrum Disorders|Recruiting|||3975|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:06.050491|2018-06-01 05:16:06.050491
NCT00071760|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-30|2012-03-02||2016-11-28|2003-10-30|2003-10-31|Estimate|2012-07-19|2012-08-23|Estimate||||2016-11-28|2017-01-13|Estimate|October 2003||2003-10-31|November 2016|2016-11-30|June 2021|Anticipated|2021-06-30|July 2011|Actual|2011-07-31||Interventional|||Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects|A 48 Week, Phase II, Open-label, 2-cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-experienced Pediatric Subjects Aged 4 Weeks to <2 Years.|Active, not recruiting||Phase 2|75|Actual|ViiV Healthcare||2|||f||||t||||||||||2018-06-01 05:16:06.29303|2018-06-01 05:16:06.29303
NCT00071747|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-30|||2016-08-30|2003-10-30|2003-10-31|Estimate|||||||2016-08-30|2016-09-01|Estimate|August 2003||2003-08-31|August 2016|2016-08-31|January 2005|Actual|2005-01-31|||||Interventional|||Clinical Study Of Schizophrenia in Both Men and Women|A Multi-Center, Double Blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine Versus Placebo As Add-On Therapy In Schizophrenia|Completed||Phase 3|176||GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:16:07.870517|2018-06-01 05:16:07.870517
NCT00071721|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|2010-07-06||2014-09-15|2003-10-30|2003-10-31|Estimate|2010-09-24|2010-10-20|Estimate||||2014-09-15|2014-09-25|Estimate|October 2003||2003-10-31|September 2014|2014-09-30|December 2009|Actual|2009-12-31|February 2009|Actual|2009-02-28||Interventional|||Valproate in Dementia (VALID)|A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)|Completed||Phase 3|313|Actual|Alzheimer's Disease Cooperative Study (ADCS)||2|||f||||t||||||||||2018-06-01 05:16:08.218241|2018-06-01 05:16:08.218241
NCT00071708|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2008-07-30|2003-10-29|2003-10-30|Estimate|||||||2008-07-30|2008-08-01|Estimate||||July 2008|2008-07-31||||||||Expanded Access|||Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial|Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial|No longer available|||||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:16:09.362768|2018-06-01 05:16:09.362768
NCT00071695|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2007-05-17|2003-10-29|2003-10-30|Estimate|||||||2007-05-17|2007-05-21|Estimate|July 2003||2003-07-31|May 2007|2007-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Duloxetine vs. Active Comparator in the Treatment of Patients With Depression|Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder|Completed||Phase 4|320||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:16:09.575277|2018-06-01 05:16:09.575277
NCT00071682|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-05-13|2003-10-29|2003-10-30|Estimate|||||||2013-05-13|2013-05-15|Estimate|October 2007||2007-10-31|May 2013|2013-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Evaulation of Interaction Between Herbal Products and Anticoagulants|Early Identification of Adverse Reactions to Herbs|Withdrawn|||0|Actual|University of California, San Francisco|||||f||||f||||||||||2018-06-01 05:16:09.707567|2018-06-01 05:16:09.707567
NCT00071669|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-04-12|2003-10-29|2003-10-30|Estimate|||||||2013-04-12|2013-04-15|Estimate|November 2001||2001-11-30|November 2005|2005-11-30||||||||Interventional|||Acupuncture as a Supplemental Treatment for Bipolar Depression|Adjunctive Acupuncture as a Treatment for Bipolar Depression|Completed||Phase 2|30||University of Texas Southwestern Medical Center|||||f||||||||||||||2018-06-01 05:16:09.768612|2018-06-01 05:16:09.768612
NCT00071656|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-08-06|2003-10-29|2003-10-30|Estimate|||||||2013-08-06|2013-08-09|Estimate|September 2002||2002-09-30|August 2013|2013-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I|Psychosocial Treatment for ADHD Inattentive Type I|Completed||N/A|60||University of California, San Francisco|||||f||||||||||||||2018-06-01 05:16:09.868384|2018-06-01 05:16:09.868384
NCT00071643|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2017-08-31|2003-10-29|2003-10-30|Estimate|||||||2017-08-31|2017-09-05|Actual|September 2002||2002-09-30|August 2017|2017-08-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Preventing Post-Stroke Depression|Prevention of Post-Stroke Depression - Treatment Strategy|Completed||N/A|201|Actual|University of Iowa||3|||f||||f|f|f||||||||2018-06-01 05:16:09.924106|2018-06-01 05:16:09.924106
NCT00071630|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-11-06|2003-10-29|2003-10-30|Estimate|||||||2013-11-06|2013-11-07|Estimate|September 2002||2002-09-30|September 2008|2008-09-30|August 2005||2005-08-31|||||Interventional|||Therapeutic Processes and Treatment Outcome in Adolescents With Anxiety Disorders|Process as a Predictor of Outcomes in CBT for Youth|Completed||Phase 4|130||Temple University|||||f||||||||||||||2018-06-01 05:16:10.039578|2018-06-01 05:16:10.039578
NCT00071617|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-11-08|2003-10-29|2003-10-30|Estimate|||||||2013-11-08|2013-11-11|Estimate|November 2002||2002-11-30|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Youth-Nominated Support Team Intervention for Suicidal Adolescents|Youth Support Team Intervention for Suicidal Adolescents|Completed||Phase 2|448|Actual|University of Michigan||2|||f||||t||||||||||2018-06-01 05:16:10.107596|2018-06-01 05:16:10.107596
NCT00071578|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2013-06-26|2003-10-29|2003-10-30|Estimate|||||||2013-06-26|2013-06-27|Estimate|October 2003||2003-10-31|June 2013|2013-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Comparing Two Group Therapy Treatments for Binge Eating Disorder|Comparison of Dialectical Behavior Therapy and Supportive Therapy for Binge Eating Disorder|Completed||N/A|101|Actual|Stanford University||2|||f||||t||||||||||2018-06-01 05:16:10.386974|2018-06-01 05:16:10.386974
NCT00071734|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-29|||2008-03-03|2003-10-28|2003-10-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Brain Activation During Simple Vocal Behaviors|Brain Activation During Simple Vocal Behaviors|Completed|||37||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:10.469565|2018-06-01 05:16:10.469565
NCT00071565|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-28|||2015-08-17|2003-10-28|2003-10-29|Estimate|||||||2015-08-17|2015-08-18|Estimate|September 2002||2002-09-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Familial Intracranial Aneurysm Study II|Familial Intracranial Aneurysm Study II|Completed|||5875|Actual|University of Cincinnati|||1||f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-06-01 05:16:10.564636|2018-06-01 05:16:10.564636
NCT00071552|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-28|||2014-05-09|2003-10-28|2003-10-29|Estimate|||||||2014-05-09|2014-05-12|Estimate|January 2004||2004-01-31|May 2014|2014-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients|Evaluation of Clinical Efficacy of HFA-Propelled Beclomethasone Dipropionate Metered-Dose Inhaler Versus Fluticasone Propionate Multidose Dry Powder Inhaler on Small Airways in Poorly Controlled Asthmatic Adolescent and Adult Patients|Terminated||Phase 4|49|Actual|Teva Pharmaceutical Industries||2||Very poor enrollment|f||||f||||||||||2018-06-01 05:16:10.739458|2018-06-01 05:16:10.739458
NCT00071539|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-28|||2012-01-18|2003-10-28|2003-10-29|Estimate|||||||2012-01-18|2012-01-20|Estimate|October 2003||2003-10-31|January 2012|2012-01-31|July 2006|Actual|2006-07-31|January 2006|Actual|2006-01-31||Interventional|||Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors||Completed||Phase 2|56|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 05:16:10.852094|2018-06-01 05:16:10.852094
NCT00004074|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-27|2003-10-28|2003-10-29|Estimate|||||||2013-02-27|2013-02-28|Estimate|August 1999||1999-08-31|February 2013|2013-02-28||||February 2009|Actual|2009-02-28||Interventional|||Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu|A Phase I Trial of Herceptin and Interleukin-12|Completed||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:11.014402|2018-06-01 05:16:11.014402
NCT00004050|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2014-07-25|2003-10-28|2003-10-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|June 1999||1999-06-30|July 2014|2014-07-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer|Phase II Study Evaluating the Safety and Efficacy of Neoadjuvant Leuvectin Immunotherapy for the Treatment of Prostate Cancer|Terminated||Phase 2|13|Actual|Vical||1||Development in prostate cancer indication halted|f||||f||||||||||2018-06-01 05:16:11.155205|2018-06-01 05:16:11.155205
NCT00004025|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2003-10-28|2003-10-29|Estimate|||||||2014-01-03|2014-01-06|Estimate|March 1999||1999-03-31|July 2002|2002-07-31||||||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma|Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of Autologous Dendritic Cells Transduced With Adenoviruses Encoding the MART-1 and gp100 Melanoma Antigens Administered With or Without Low Dose Recombinant Interleukin-2 (rIL-2) in Patients With Stage IV Melanoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:11.302361|2018-06-01 05:16:11.302361
NCT00003794|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-07|2003-10-28|2003-10-29|Estimate|||||||2013-06-07|2013-06-10|Estimate|April 1999||1999-04-30|November 2005|2005-11-30||||July 2005|Actual|2005-07-31||Observational|||Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer|Quality of Life in Ovarian Germ Cell Cancer Survivors|Terminated|||||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:16:11.386849|2018-06-01 05:16:11.386849
NCT00003648|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-10-28|2003-10-29|Estimate|||||||2016-07-01|2016-07-04|Estimate|July 1998||1998-07-31|July 2016|2016-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Genetic Study of Patients and Families With a History of Colorectal Cancer|The Familial Colorectal Neoplasia Collaborative Group|Completed|||1500|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     blood and tumor samples~   "|||2018-06-01 05:16:11.476448|2018-06-01 05:16:11.476448
NCT00071526|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-27|||2018-03-27|2003-10-27|2003-10-28|Estimate|||||||2018-03-27|2018-03-29|Actual|October 27, 2003||2003-10-27|September 26, 2017|2017-09-26||||||||Observational|||Urinary Vitamin C Loss in Diabetic Subjects|Urinary Vitamin C Loss in Subjects With and Without Diabetes|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:11.622976|2018-06-01 05:16:11.622976
NCT00071513|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-24|2015-12-06||2016-07-07|2003-10-27|2003-10-28|Estimate|2016-07-07|2016-08-17|Estimate||||2016-07-07|2016-08-17|Estimate|March 2003||2003-03-31|July 2016|2016-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|CAST-T/HSTS|All participants.|Middle School to High School Transition Project: Depression and Substance Abuse Prevention|Middle School to High School Transition Project|Completed||Phase 1|497|Actual|University of Washington|"A significant limitation of this trial was the brief nature of the comparison condition, the Brief Intervention group; findings might reflect dose rather than content of the CAST-T/HSTS intervention."|2|||f||||f||||||||No|Add data has been de-identified. De-identified data is available to share.|2018-06-01 05:16:11.727839|2018-06-01 05:16:11.727839
NCT00071500|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-24|||2008-09-25|2003-10-27|2003-10-28|Estimate|||||||2008-09-25|2008-09-26|Estimate|October 2003||2003-10-31|September 2008|2008-09-30|June 2009|Anticipated|2009-06-30|June 2007|Actual|2007-06-30||Interventional|||An Electronic Pillbox for People With HIV|A Novel Technology to Improve HIV Medication Compliance|Unknown status|Active, not recruiting|Phase 1|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 05:16:12.173267|2018-06-01 05:16:12.173267
NCT00071487|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-24|2012-02-27||2013-08-01|2003-10-27|2003-10-28|Estimate|2012-07-25|2012-08-28|Estimate||||2013-08-01|2013-08-07|Estimate|October 2003||2003-10-31|August 2013|2013-08-31|June 2006|Actual|2006-06-30|August 2005|Actual|2005-08-31||Interventional|||Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|449|Actual|Human Genome Sciences Inc.||4|||f||||t||||||||||2018-06-01 05:16:12.349901|2018-06-01 05:16:12.349901
NCT00003595|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-07|2003-10-27|2003-10-28|Estimate|||||||2013-02-07|2013-02-08|Estimate|January 1999||1999-01-31|May 2007|2007-05-31||||April 2006|Actual|2006-04-30||Interventional|||Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma|Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma|Completed||Phase 3|120|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:16:14.382802|2018-06-01 05:16:14.382802
NCT00003266|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-06|2003-10-27|2003-10-28|Estimate|||||||2012-05-06|2012-05-08|Estimate|June 1999||1999-06-30|March 2008|2008-03-31||||May 2002|Actual|2002-05-31||Interventional|||Methylphenidate in Treating Patients With Melanoma|Double-Blind Randomized Trial of Methylphenidate for Alleviation of Fatigue and Lethargy Associated With Interferon Alpha 2b|Completed||Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:14.589139|2018-06-01 05:16:14.589139
NCT00003234|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-25|2003-10-27|2003-10-28|Estimate|||||||2014-07-25|2014-07-28|Estimate|May 1998||1998-05-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|March 2006|Actual|2006-03-31||Interventional|||Vinorelbine in Treating Children With Recurrent or Refractory Cancers|A Phase II Study of Navelbine (Vinorelbine) In Children With Recurrent Or Refractory Malignancies|Completed||Phase 2|50|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 05:16:14.784835|2018-06-01 05:16:14.784835
NCT00003190|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-03|2003-10-27|2003-10-28|Estimate|||||||2013-06-03|2013-06-04|Estimate|January 1998||1998-01-31|June 2013|2013-06-30||||August 2002|Actual|2002-08-31||Interventional|||Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia|Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML &gt;60 Years|Completed||Phase 3|640|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:16:15.226176|2018-06-01 05:16:15.226176
NCT00003126|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-02|2003-10-27|2003-10-28|Estimate|||||||2017-01-02|2017-01-04|Estimate|June 1997||1997-06-30|January 2017|2017-01-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer|A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma|Completed||Phase 3|69|Actual|Loyola University||2|||f||||t||||||||No|There is no plan to share individual participant data|2018-06-01 05:16:15.475177|2018-06-01 05:16:15.475177
NCT00071474|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-23|||2007-01-22|2003-10-23|2003-10-24|Estimate|||||||2007-01-22|2007-01-24|Estimate|August 2003||2003-08-31|January 2007|2007-01-31|May 2005||2005-05-31|||||Interventional|||Shamanic Healing for Women With Temporomandibular Joint Disorders (TMDs)||Completed||Phase 1|25||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:15.615103|2018-06-01 05:16:15.615103
NCT00071461|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-23||2010-02-11|2012-02-22|2003-10-23|2003-10-24|Estimate||||2010-02-11|2010-02-15|Estimate|2012-02-22|2012-02-24|Estimate|August 2003||2003-08-31|February 2012|2012-02-29|May 2010|Actual|2010-05-31|September 2005|Actual|2005-09-30||Interventional|BUILD 1||Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension|Completed||Phase 2/Phase 3|158|Actual|Actelion||2|||f||||t||||||||||2018-06-01 05:16:15.696812|2018-06-01 05:16:15.696812
NCT00071448|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-23|||2016-12-21|2003-10-23|2003-10-24|Estimate|||||||2016-12-21|2016-12-22|Estimate|June 2002||2002-06-30|December 2016|2016-12-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population|Basal/Bolus Therapy With Insulin Aspart (NovoLog®) Versus Regular Human Insulin (Novolin® R) or Insulin Lispro (Humalog®) in Combination With NPH: An Open-Label, Randomized, Parallel Group, Multicenter Study in Children and Adolescents With Type 1 Diabetes|Completed||Phase 3|378|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:16:15.851706|2018-06-01 05:16:15.851706
NCT00071435|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-22|||2008-03-03|2003-10-22|2003-10-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|February 2006|2006-02-28|February 2006||2006-02-28|||||Observational|||Brain Function in Primary Lateral Sclerosis|Movement Related Cortical Potentials in Primary Lateral Sclerosis|Completed|||36||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:16.186987|2018-06-01 05:16:16.186987
NCT00071422|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-22|||2014-07-10|2003-10-22|2003-10-23|Estimate|||||||2014-07-10|2014-07-11|Estimate|October 2003||2003-10-31|August 2011|2011-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Rising-dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Insulin-using Type 2 Diabetes Mellitus Patients|Completed||Phase 2|126|Actual|Exsulin Corporation||3|||f||||||||||||||2018-06-01 05:16:16.2643|2018-06-01 05:16:16.2643
NCT00071409|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-22|||2014-07-10|2003-10-22|2003-10-23|Estimate|||||||2014-07-10|2014-07-11|Estimate|October 2003||2003-10-31|August 2011|2011-08-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes|A Randomized, Double-blind, Placebo-controlled, Rising Dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Type I Diabetes Mellitus Patients|Completed||Phase 2|63|Actual|Exsulin Corporation||3|||f||||f||||||||||2018-06-01 05:16:16.39524|2018-06-01 05:16:16.39524
NCT00071396|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-21|2009-09-25||2012-08-01|2003-10-21|2003-10-22|Estimate|2011-01-31|2011-02-25|Estimate||||2012-08-01|2012-08-07|Estimate|October 2002||2002-10-31|August 2012|2012-08-31|August 2007|Actual|2007-08-31|September 2006|Actual|2006-09-30||Interventional|||Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders|Continuous Infusion Followed by Subcutaneous Injection of Campath-1H Plus Rituximab in the Treatment of CD52- and CD20-Positive Refractory or Relapsed Chronic Lymphoid Disorders|Completed||Phase 2|48|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:16:16.490739|2018-06-01 05:16:16.490739
NCT00033527|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-11-05|2003-10-21|2003-10-22|Estimate|||||||2013-11-05|2013-11-06|Estimate||||September 2002|2002-09-30||||||||Interventional|||INS316 Compared With Saline for Sputum Collection in Diagnosing Lung Cancer|A Double-Blinded, Placebo-Controlled, Parallel Group Study Of Uridine 5'-Triphosphate (UTP) Solution For Inhalation As An Adjunct In The Diagnosis Of Lung Cancer By Sputum Cytology|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:16.687022|2018-06-01 05:16:16.687022
NCT00025350|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-06-20|2003-10-21|2003-10-22|Estimate|||||||2013-06-20|2013-06-24|Estimate|October 2001||2001-10-31|January 2006|2006-01-31|June 2006|Actual|2006-06-30|||||Interventional|||Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer|A Randomized Phase II Trial of Two Dose Levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in Patients With Recurrent Colorectal Adenocarcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:16.848115|2018-06-01 05:16:16.848115
NCT00003077|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-10-21|2003-10-22|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 1995||1995-10-31|July 2016|2016-07-31|November 2004|Actual|2004-11-30|July 2004|Actual|2004-07-31||Interventional|||Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss|Phase I/II Trial of Omega-3 Fatty Acids for Cancer Cachexia|Completed||Phase 1/Phase 2|63|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:16:17.02033|2018-06-01 05:16:17.02033
NCT00002935|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-12-22|2003-10-21|2003-10-22|Estimate|||||||2011-12-22|2011-12-23|Estimate|October 1995||1995-10-31|December 2011|2011-12-31|September 2007|Actual|2007-09-30|August 2006|Actual|2006-08-31||Interventional|||Photodynamic Therapy in Treating Patients With Early Esophageal Cancer|A Phase II Study of the Safety and Efficacy of Photodynamic Therapy in Carcinoma in Situ of the Esophagus|Completed||Phase 2|30|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:16:17.178506|2018-06-01 05:16:17.178506
NCT00002723|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-27|2003-10-21|2003-10-22|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 1996||1996-01-31|February 2013|2013-02-28|March 2008|Actual|2008-03-31|August 2002|Actual|2002-08-31||Interventional|||Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer|A PHASE III STUDY OF THREE DIFFERENT DOSES OF SURAMIN (NSC #34936) ADMINISTERED WITH A FIXED DOSING SCHEDULE IN PATIENTS WITH ADVANCED PROSTATE CANCER|Completed||Phase 3|390|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 05:16:17.369374|2018-06-01 05:16:17.369374
NCT00071331|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-20|||2012-05-02|2003-10-20|2003-10-21|Estimate|||||||2012-05-02|2012-05-03|Estimate|September 2003||2003-09-30|May 2012|2012-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan|Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure|Completed||Phase 3|3600||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:16:17.718136|2018-06-01 05:16:17.718136
NCT00071292|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-17|||2008-03-05|2003-10-20|2003-10-21|Estimate|||||||2008-03-05|2008-03-07|Estimate|July 2003||2003-07-31|March 2008|2008-03-31|March 2005||2005-03-31|||||Interventional|||Meditation-Based Stress Reduction in Rheumatoid Arthritis|Mindfulness Meditation-Based Stress Reduction in Relieving Symptoms Associated With Rheumatoid Arthritis|Completed||Phase 2|80||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:18.44779|2018-06-01 05:16:18.44779
NCT00030420|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-04-25|2003-10-20|2003-10-21|Estimate|||||||2013-04-25|2013-04-29|Estimate|October 2001||2001-10-31|April 2013|2013-04-30|February 2008|Actual|2008-02-29|May 2004|Actual|2004-05-31||Interventional|||Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer|Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy|Completed||Phase 2|24|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 05:16:18.55714|2018-06-01 05:16:18.55714
NCT00026260|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-06-20|2003-10-20|2003-10-21|Estimate|||||||2013-06-20|2013-06-24|Estimate||||June 2007|2007-06-30|October 2003|Actual|2003-10-31|||||Interventional|||SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation of SU5416 (NSC 696819) in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:18.667904|2018-06-01 05:16:18.667904
NCT00024206|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-01-22|2003-10-20|2003-10-21|Estimate|||||||2013-01-22|2013-01-23|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||July 2003|Actual|2003-07-31||Interventional|||SU6668 in Treating Patients With Advanced Solid Tumors|A Phase I Surrogate Endpoint Trial of SU6668 in Patients With Incurable Solid Tumors|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:18.729416|2018-06-01 05:16:18.729416
NCT00024128|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2016-02-01|2003-10-20|2003-10-21|Estimate|||||||2016-02-01|2016-02-03|Estimate|August 2001||2001-08-31|February 2016|2016-02-29|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma|Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD)|Withdrawn||Phase 2|0|Actual|AIDS Malignancy Consortium||||Withdrawn prior to initiation.|f||||||||||||||2018-06-01 05:16:18.816327|2018-06-01 05:16:18.816327
NCT00023738|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-06-20|2003-10-20|2003-10-21|Estimate|||||||2013-06-20|2013-06-24|Estimate|August 2001||2001-08-31|December 2010|2010-12-31|October 2003|Actual|2003-10-31|||||Interventional|||Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma|A Phase I/II Study Of Neoadjuvant Chemotherapy, Angiogenesis Inhibitor SU5416 (NSC # 696819; A TK Inhibitor Anti-Angionesises Compound), And Radiation Therapy In The Management Of High Risk, High-Grade, Soft Tissue Sarcomas Of The Extremities And Body Wall|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:18.917562|2018-06-01 05:16:18.917562
NCT00071370|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-20|||2008-03-03|2003-10-17|2003-10-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Activating Effects of Sleep Deprivation on Synchronized MEG-EEG Recordings of Epilepsy Patients With Non-Diagnostic EEG|Activating Effects of Sleep Deprivation On Synchronized MEG-EEG Recordings Of Epilepsy Patients With Non-Diagnostic EEG|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:20.336852|2018-06-01 05:16:20.336852
NCT00071305|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-17|||2017-06-30|2003-10-17|2003-10-20|Estimate|||||||2017-06-30|2017-07-02|Actual|October 17, 2003||2003-10-17|October 6, 2009|2009-10-06||||October 6, 2009|Actual|2009-10-06||Observational|||Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings|Non-Invasive Seizure Localization in Patients With Medically Refractory Localization Related Epilepsy: Synchronized MEG-EEG Recordings|Completed|||35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:20.580906|2018-06-01 05:16:20.580906
NCT00071279|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-16|||2011-04-05|2003-10-17|2003-10-20|Estimate|||||||2011-04-05|2011-04-06|Estimate|November 2003||2003-11-30|April 2011|2011-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis|The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006|Completed||Phase 3|1215|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:16:20.726731|2018-06-01 05:16:20.726731
NCT00071266|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-16|||2006-10-31|2003-10-17|2003-10-20|Estimate|||||||2006-10-31|2006-11-02|Estimate|October 2003||2003-10-31|October 2006|2006-10-31||||||||Interventional|||The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC|The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - a Matrix Design|Completed||Phase 3|870||Kos Pharmaceuticals|||||||||||||||||||2018-06-01 05:16:21.126732|2018-06-01 05:16:21.126732
NCT00003832|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-24|2003-09-29|2003-09-30|Estimate|||||||2013-01-24|2013-01-25|Estimate|July 1999||1999-07-31|January 2013|2013-01-31||||June 2002|Actual|2002-06-30||Interventional|||Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer|Cell Kinetic Study of Bromodeoxyuridine (BrdU) in Prostate Cancer|Completed||Phase 2|75|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:01.820669|2018-06-01 05:17:01.820669
NCT00071253|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-16|||2006-08-02|2003-10-17|2003-10-20|Estimate|||||||2006-08-02|2006-08-04|Estimate|July 2003||2003-07-31|August 2006|2006-08-31||||||||Interventional|||Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness|A Randomized, Double-Blind Study of Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness|Terminated||Phase 4|180||Abbott|||||||||||||||||||2018-06-01 05:16:21.323035|2018-06-01 05:16:21.323035
NCT00071240|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-16|||2009-08-14|2003-10-16|2003-10-17|Estimate|||||||2009-08-14|2009-08-17|Estimate|October 2002||2002-10-31|August 2009|2009-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Growth Hormone to Increase Immune Function in People With HIV|The Use of Recombinant Growth Hormone to Enhance T-Cell Production in Adults Infected With HIV-1|Completed||Phase 2|22|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 05:16:21.481441|2018-06-01 05:16:21.481441
NCT00071214|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-15|||2006-07-07|2003-10-16|2003-10-17|Estimate|||||||2006-07-07|2006-07-11|Estimate|September 2003||2003-09-30|July 2006|2006-07-31|September 2005||2005-09-30|||||Interventional|||Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis|A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Efficacy of StaphVAX, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adults on Hemodialysis|Completed||Phase 3|3600||Nabi Biopharmaceuticals|||||||||||||||||||2018-06-01 05:16:21.639361|2018-06-01 05:16:21.639361
NCT00071201|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-15|||2013-10-14|2003-10-16|2003-10-17|Estimate|||||||2013-10-14|2013-10-16|Estimate|June 2003||2003-06-30|October 2013|2013-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B|A Multi-Center Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Varying Degrees of Renal Impairment|Completed||Phase 3|48||Gilead Sciences|||||||||||||||||||2018-06-01 05:16:21.773044|2018-06-01 05:16:21.773044
NCT00064428|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2016-09-22|2003-10-16|2003-10-17|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2003||2003-08-31|September 2016|2016-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction|An International Randomized Study Evaluating the Efficacy and Safety of Fondaparinux Versus Control Therapy in a Broad Range of Patients With ST Segment Elevation Acute Myocardial Infarction.|Completed||Phase 3|12092|Actual|GlaxoSmithKline||4|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:16:21.891293|2018-06-01 05:16:21.891293
NCT00071227|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-15|||2017-06-30|2003-10-15|2003-10-16|Estimate|||||||2017-06-30|2017-07-02|Actual|October 15, 2003||2003-10-15|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders|Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders|Completed||Phase 1|16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:22.113456|2018-06-01 05:16:22.113456
NCT00071188|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-14|||2016-08-24|2003-10-15|2003-10-16|Estimate|||||||2016-08-24|2016-08-25|Estimate|February 2004||2004-02-29|August 2016|2016-08-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|||Sanofi|||||f||||||||||||||2018-06-01 05:16:22.259275|2018-06-01 05:16:22.259275
NCT00071136|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-13|||2007-01-24|2003-10-15|2003-10-16|Estimate|||||||2007-01-24|2007-01-26|Estimate|December 2003||2003-12-31|January 2007|2007-01-31|August 2006||2006-08-31|||||Interventional|||Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer|Completed||Phase 1/Phase 2|48||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:16:22.528969|2018-06-01 05:16:22.528969
NCT00071175|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-14|||2017-09-15|2003-10-14|2003-10-15|Estimate|||||||2017-09-15|2017-09-18|Actual|October 1995||1995-10-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|September 2012|Actual|2012-09-30||Observational|LFRR||Lupus Genetics Studies|Lupus Genetic Studies; Lupus Family Registry & Repository|Completed|||3460|Actual|Oklahoma Medical Research Foundation|||||f||||f||||||Samples With DNA|"~     DNA, sera, plasma, cell lines~   "|||2018-06-01 05:16:22.641347|2018-06-01 05:16:22.641347
NCT00071162|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-14|||2009-03-31|2003-10-14|2003-10-15|Estimate|||||||2009-03-31|2009-04-01|Estimate|September 1999||1999-09-30|March 2009|2009-03-31||||||||Observational|||Genetics of Fibromyalgia|Fibromyalgia Family Study Registry|Unknown status|Active, not recruiting||560|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||f||||||Samples With DNA|"~     DNA, whole blood~   "|||2018-06-01 05:16:22.756487|2018-06-01 05:16:22.756487
NCT00071149|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-14|||2006-08-17|2003-10-14|2003-10-15|Estimate|||||||2006-08-17|2006-08-18|Estimate|November 2001||2001-11-30|July 2006|2006-07-31|April 2004||2004-04-30|||||Observational|||Consistency of Traditional Chinese Medicine Diagnoses and Herbal Prescriptions for Rheumatoid Arthritis|Consistency of Traditional Chinese Medicine Rheumatoid Arthritis Diagnosis and Herbal Prescriptions|Completed|||120||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:22.886017|2018-06-01 05:16:22.886017
NCT00071110|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-10|2009-03-27||2009-12-04|2003-10-14|2003-10-15|Estimate|2009-12-04|2010-01-11|Estimate||||2009-12-04|2010-01-11|Estimate|March 2004||2004-03-31|December 2009|2009-12-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Electroacupuncture for Major Depression|Electroacupuncture for Major Depression: A Pilot Study|Completed||Phase 2|57|Actual|National Center for Complementary and Integrative Health (NCCIH)|Four participants were excluded from the analyses because of a protocol violation. In the Sham Acupuncture group, the acupuncturist placed unelectrified needles in GV-20 and Yin tang points instead of placing them laterally.|2|||f||||||||||||||2018-06-01 05:16:22.989187|2018-06-01 05:16:22.989187
NCT00071097|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-10|||2016-09-19|2003-10-14|2003-10-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2003||2003-10-31|September 2016|2016-09-30|November 2007|Actual|2007-11-30|February 2005|Actual|2005-02-28||Interventional|||TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients|A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.|Completed||Phase 2|330|Actual|Tibotec Pharmaceuticals, Ireland||5|||f||||t||||||||||2018-06-01 05:16:23.376828|2018-06-01 05:16:23.376828
NCT00025467|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-01-23|2003-10-14|2003-10-15|Estimate|||||||2013-01-23|2013-01-24|Estimate|September 2001||2001-09-30|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:23.719144|2018-06-01 05:16:23.719144
NCT00023725|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-06-20|2003-10-14|2003-10-15|Estimate|||||||2013-06-20|2013-06-24|Estimate|August 2001||2001-08-31|August 2007|2007-08-31|October 2003|Actual|2003-10-31|||||Interventional|||Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma|A Randomized Phase I/II Study Of Preoperative Radiotherapy With/Without SUGEN 5416 (NSC # 696819; A TK Inhibitor Anti-Angiogenesis Compound) In The Management Of Low To Intermediate Grade Soft Tissue Sarcoma Of The Trunk or Extremity|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:23.874294|2018-06-01 05:16:23.874294
NCT00023699|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-06-20|2003-10-14|2003-10-15|Estimate|||||||2013-06-20|2013-06-24|Estimate|August 2001||2001-08-31|August 2003|2003-08-31|May 2006|Actual|2006-05-31|||||Interventional|||Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:24.422012|2018-06-01 05:16:24.422012
NCT00022282|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-02-27|2003-10-14|2003-10-15|Estimate|||||||2013-02-27|2013-02-28|Estimate|April 2001||2001-04-30|February 2008|2008-02-29||||March 2007|Actual|2007-03-31||Interventional|||AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma|Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients|Completed||Phase 2|||AEterna Zentaris|||||f||||||||||||||2018-06-01 05:16:24.578607|2018-06-01 05:16:24.578607
NCT00016250|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-06-17|2003-10-14|2003-10-15|Estimate|||||||2013-06-17|2013-06-18|Estimate|December 2000||2000-12-31|June 2013|2013-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer|A Randomized Phase II Study of Two Shcedules of Ro 31-7453 in Patients With Metastatic (Dukes' D) Colorectal Carcinoma (CRC) Who Have Failed Both Fluoropyrimidine and Irinotecan Chemotherapy|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:16:24.674099|2018-06-01 05:16:24.674099
NCT00015912|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-24|2003-10-14|2003-10-15|Estimate|||||||2013-01-24|2013-01-25|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||September 2003|Actual|2003-09-30||Interventional|||Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Clinical And Biologic Study Of The Combination Of Low Dose Interferon-Alpha And Thalidomide (NSC #66847) For Patients With Relapsed Or Refractory Low-Grade Follicular Lymphoma|Terminated||Phase 2|35|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:16:24.772361|2018-06-01 05:16:24.772361
NCT00015886|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2017-05-25|2003-10-14|2003-10-15|Estimate|||||||2017-05-25|2017-05-30|Actual|January 1997||1997-01-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|May 2002|Actual|2002-05-31||Interventional|||Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery|Docetaxel (Taxotere) and 5-Fluorouracil As Second- Or Third-Line Chemotherapy In Women With Metastatic Breast Cancer|Completed||Phase 2|25|Actual|Wake Forest University Health Sciences|||||f||||t|t|f||||||||2018-06-01 05:16:24.872751|2018-06-01 05:16:24.872751
NCT00014144|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2012-10-05|2003-10-14|2003-10-15|Estimate|||||||2012-10-05|2012-10-08|Estimate|February 2001||2001-02-28|October 2012|2012-10-31|December 2007|Actual|2007-12-31|May 2003|Actual|2003-05-31||Interventional|||S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract|Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II|Completed||Phase 2|31|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:16:25.049982|2018-06-01 05:16:25.049982
NCT00007917|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-02-27|2003-10-14|2003-10-15|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2001||2001-01-31|February 2013|2013-02-28|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of Gemcitabine Followed By Flavopiridol In Patients With Solid Tumors|Completed||Phase 1|58|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:25.300012|2018-06-01 05:16:25.300012
NCT00071383|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-20|||2008-03-03|2003-10-10|2003-10-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|November 2004|2004-11-30|November 2004||2004-11-30|||||Observational|||Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2|Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2|Completed|||78||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:25.386029|2018-06-01 05:16:25.386029
NCT00071357|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-20|||2008-03-03|2003-10-10|2003-10-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer|Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast Cancer|Completed|||78||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:25.45682|2018-06-01 05:16:25.45682
NCT00071344|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-20|||2008-03-03|2003-10-10|2003-10-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2003||2003-10-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Analysis of Brain Metastasis in Patients With Lung Cancer|Analysis of Brain Metastasis in Patients With Lung Cancer|Completed|||78||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:25.513183|2018-06-01 05:16:25.513183
NCT00071123|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-10|||2017-06-30|2003-10-10|2003-10-13|Estimate|||||||2017-06-30|2017-07-02|Actual|October 9, 2003||2003-10-09|November 15, 2010|2010-11-15|November 15, 2010||2010-11-15|||||Observational|||Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder|The Functional Neuroanatomy of Emotion Regulation in Major Depressive Disorder (MDD)|Completed|||172|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:25.618402|2018-06-01 05:16:25.618402
NCT00071032|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|2014-08-14||2014-08-14|2003-10-10|2003-10-13|Estimate|2014-08-14|2014-08-28|Estimate||||2014-08-14|2014-08-28|Estimate|July 2003||2003-07-31|August 2014|2014-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|FOCUS|Randomized subjects|Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease|Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)|Completed||Phase 3|2016|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-06-01 05:16:25.77258|2018-06-01 05:16:25.77258
NCT00071019|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2017-04-18|2003-10-10|2003-10-13|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2003||2003-09-30|April 2017|2017-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Dietary Fatty Acids, PPAR Activated Genes, and CHD|Dietary Fatty Acids, PPAR Activated Genes, and CHD|Completed|||4547|Actual|Harvard School of Public Health|||||f||||f|f|f||||Samples With DNA|"~     Whole blood~   "|No||2018-06-01 05:16:26.300055|2018-06-01 05:16:26.300055
NCT00071006|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|2012-02-25||2012-05-31|2003-10-10|2003-10-13|Estimate|2012-02-25|2012-03-19|Estimate||||2012-05-31|2012-06-08|Estimate|September 2003||2003-09-30|May 2012|2012-05-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)|Phase 2 Study Of AG-013736 In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)|Completed||Phase 2|12|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 05:16:26.703044|2018-06-01 05:16:26.703044
NCT00070993|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2006-08-03|2003-10-10|2003-10-13|Estimate|||||||2006-08-03|2006-08-04|Estimate|December 2002||2002-12-31|August 2006|2006-08-31|May 2006||2006-05-31|||||Interventional|||Creatine for the Treatment of Amyotrophic Lateral Sclerosis|Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis|Completed||Phase 2|110||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:16:27.494352|2018-06-01 05:16:27.494352
NCT00070980|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2006-08-17|2003-10-10|2003-10-13|Estimate|||||||2006-08-17|2006-08-18|Estimate|March 2003||2003-03-31|July 2006|2006-07-31|November 2004||2004-11-30|||||Interventional|||Massage to Increase Well-Being and Immune Function in Dominican Children Infected With HIV|Massage to Enhance Well-Being in HIV-Positive Dominican Children|Completed||N/A|54||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:27.576748|2018-06-01 05:16:27.576748
NCT00070967|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2006-08-17|2003-10-10|2003-10-13|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2001||2001-09-30|July 2006|2006-07-31|February 2005||2005-02-28|||||Interventional|||Acupuncture to Improve Quality of Life in Patients With Advanced Cancer|Effects of Acupuncture on Pain, Nausea, Quality of Life|Completed||Phase 2|40||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:27.703149|2018-06-01 05:16:27.703149
NCT00070954|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2011-06-27|2003-10-10|2003-10-13|Estimate|||||||2011-06-27|2011-06-28|Estimate|February 2003||2003-02-28|August 2008|2008-08-31|March 2005|Actual|2005-03-31|January 2005|Actual|2005-01-31||Interventional|||Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT)|Ginkgo Biloba for ECT-induced Memory Deficits|Terminated||Phase 1/Phase 2|50|Anticipated|Medical University of South Carolina||2|||f||||||||||||||2018-06-01 05:16:27.77732|2018-06-01 05:16:27.77732
NCT00070941|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|2013-05-03||2016-06-02|2003-10-10|2003-10-13|Estimate|2016-06-02|2016-07-13|Estimate||||2016-06-02|2016-07-13|Estimate|July 2003||2003-07-31|June 2016|2016-06-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||SAM-e for the Treatment of Depression in Patients With Parkinson's Disease|SAM-e Treatment of Depression in Parkinson's Disease.|Completed||Phase 2/Phase 3|29|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-06-01 05:16:27.920574|2018-06-01 05:16:27.920574
NCT00070928|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2006-07-25|2003-10-10|2003-10-13|Estimate|||||||2006-07-25|2006-07-26|Estimate|September 2000||2000-09-30|July 2006|2006-07-31|June 2006||2006-06-30|||||Interventional|||Valerian to Improve Sleep in Patients With Parkinson's Disease|Polysomnographic Assessment of Alternative Treatments for Sleep Disturbance in Parkinson's Disease|Completed||Phase 2|80||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:28.382381|2018-06-01 05:16:28.382381
NCT00070915|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2017-10-11|2003-10-10|2003-10-13|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2000||2000-09-30|October 2017|2017-10-31|June 2003||2003-06-30|||||Interventional|||Massage, Meditation, and Tai Chi for Chronic Lower Back Pain|Relaxation-Related CAM Therapies for Chronic Back Pain|Completed||N/A|120||Kaiser Permanente|||||f||||||||||||||2018-06-01 05:16:28.455581|2018-06-01 05:16:28.455581
NCT00070902|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2006-08-16|2003-10-10|2003-10-13|Estimate|||||||2006-08-16|2006-08-18|Estimate|June 2000||2000-06-30|August 2006|2006-08-31|October 2002||2002-10-31|||||Interventional|||Using MRI Scans to Evaluate Spinal Manipulation|The Effects of Positioning and Adjusting on the Z Joint|Completed||Phase 1|64||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:28.588066|2018-06-01 05:16:28.588066
NCT00070889|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2006-08-17|2003-10-10|2003-10-13|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|July 2006|2006-07-31|August 2004||2004-08-31|||||Observational|||Brain Cell Injury in Patients With A First Episode of Psychosis|Oxidative Cell Injury: First Episode Psychotic Patients|Completed|||30||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:16:28.694573|2018-06-01 05:16:28.694573
NCT00070850|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-08|||2007-06-28|2003-10-10|2003-10-13|Estimate|||||||2007-06-28|2007-07-02|Estimate|April 2001||2001-04-30|August 2005|2005-08-31|July 2005||2005-07-31|||||Observational|||Prenatal Screening For Smith-Lemli-Opitz Syndrome|The Feasibility of Screening for Smith-Lemli-Opitz Syndrome|Completed|||1800||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:16:28.770187|2018-06-01 05:16:28.770187
NCT00070837|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-08|||2007-07-12|2003-10-10|2003-10-13|Estimate|||||||2007-07-12|2007-07-13|Estimate|October 2003||2003-10-31|July 2007|2007-07-31|October 2004||2004-10-31|||||Interventional|||MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer|A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer|Completed||Phase 1/Phase 2|46||Millennium Pharmaceuticals, Inc.|||||t||||||||||||||2018-06-01 05:16:28.854107|2018-06-01 05:16:28.854107
NCT00070824|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-08|||2007-09-06|2003-10-10|2003-10-13|Estimate|||||||2007-09-06|2007-09-10|Estimate|January 2004||2004-01-31|September 2007|2007-09-30|April 2007|Actual|2007-04-30|||||Interventional|||Functional Brain Imaging - Acupuncture and Osteoarthritis|Functional Brain Imaging - Acupuncture and Osteoarthritis|Completed||Phase 2/Phase 3|16|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 05:16:28.929554|2018-06-01 05:16:28.929554
NCT00070811|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-08|||2013-07-02|2003-10-10|2003-10-13|Estimate|||||||2013-07-02|2013-07-04|Estimate|August 2001||2001-08-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Assessing the Results of Lip Surgery in Patients With Cleft Lip and Palate|Functional Outcomes of Cleft Lip and Lip Revision Surgery|Completed|||127|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-06-01 05:16:29.039452|2018-06-01 05:16:29.039452
NCT00070720|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-07|||2013-12-16|2003-10-10|2003-10-13|Estimate|||||||2013-12-16|2013-12-17|Estimate|September 2003||2003-09-30|December 2013|2013-12-31|December 2006|Actual|2006-12-31|||||Interventional|||Improving Perinatal Care in Latin America|Clustered Trial for Improving Perinatal Care in Uruguay/Argentina|Completed||Phase 4|21780||NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 05:16:29.140727|2018-06-01 05:16:29.140727
NCT00071058|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|2012-08-13||2012-09-12|2003-10-09|2003-10-10|Estimate|2012-08-13|2012-09-12|Estimate||||2012-09-12|2012-09-18|Estimate|October 2003||2003-10-31|September 2012|2012-09-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer|A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection|Completed||Phase 2|50|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:16:29.422717|2018-06-01 05:16:29.422717
NCT00071045|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-09|||2018-05-22|2003-10-09|2003-10-10|Estimate|||||||2018-05-22|2018-05-23|Actual|October 8, 2003||2003-10-08|May 11, 2018|2018-05-11||||||||Observational|||Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members|Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members|Recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:29.836623|2018-06-01 05:16:29.836623
NCT00070746|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-07|||2014-07-29|2003-10-09|2003-10-10|Estimate|||||||2014-07-29|2014-07-31|Estimate|June 2003||2003-06-30|July 2014|2014-07-31|July 2005||2005-07-31|||||Observational|||Perinatal Infections in Pakistan|Perinatal Infections and Pregnancy Outcomes in Pakistan: A Collaborative Research Project in Partnership With the University of Alabama, USA|Completed|||1500||NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-06-01 05:16:29.962457|2018-06-01 05:16:29.962457
NCT00070733|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-07|||2005-11-04|2003-10-09|2003-10-10|Estimate|||||||2005-11-04|2005-11-07|Estimate|August 2003||2003-08-31|October 2003|2003-10-31|June 2005||2005-06-30|||||Interventional|||The Effect of 5-Alpha Reductase on Testosterone in Men|The Role of 5-Alpha Reductase in Mediating Testosterone Actions|Unknown status|Recruiting|Phase 3|184||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:16:30.074066|2018-06-01 05:16:30.074066
NCT00070707|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-07|||2017-03-27|2003-10-09|2003-10-10|Estimate|||||||2017-03-27|2017-03-28|Actual|April 3, 2003|Actual|2003-04-03|March 2017|2017-03-31|November 26, 2003|Actual|2003-11-26|November 26, 2003|Actual|2003-11-26||Interventional|||Efficacy and Safety of Nasonex vs. Placebo in Subjects With SAR and Concomitant Asthma (Study P03280)||Terminated||Phase 4|188|Actual|Merck Sharp & Dohme Corp.||||Recruitment challenges.|||||||||||||||2018-06-01 05:16:30.166406|2018-06-01 05:16:30.166406
NCT00070876|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-08|||2013-04-01|2003-10-08|2003-10-09|Estimate|||||||2013-04-01|2013-04-04|Estimate|August 2002||2002-08-31|April 2013|2013-04-30|August 2008|Actual|2008-08-31|August 2005|Actual|2005-08-31||Interventional|||Psychosocial Training for Pediatric Health Care Providers|Trial of Psychosocial Training for Pediatric Generalists|Completed||N/A|350||Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||||||2018-06-01 05:16:30.275757|2018-06-01 05:16:30.275757
NCT00070863|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-08|||2017-10-30|2003-10-08|2003-10-09|Estimate|||||||2017-10-30|2017-11-01|Actual|June 2002||2002-06-30|October 2017|2017-10-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Treatment for Men Who Are Abusive to Their Partners|Behavior Therapy for Partner Violent Men|Completed||Phase 1|60||University of Maryland, Baltimore County|||||f||||||||||||||2018-06-01 05:16:30.385046|2018-06-01 05:16:30.385046
NCT00070681|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06|||2016-07-28|2003-10-08|2003-10-09|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2003||2003-09-30|April 2009|2009-04-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Outcomes of Sleep Disorders in Older Men||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:16:30.476767|2018-06-01 05:16:30.476767
NCT00070668|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06|||2008-08-20|2003-10-08|2003-10-09|Estimate|||||||2008-08-20|2008-08-21|Estimate|September 2003||2003-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Inflammatory Genomics in Human Carotid Artery Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:16:30.554443|2018-06-01 05:16:30.554443
NCT00070655|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06|||2011-04-05|2003-10-08|2003-10-09|Estimate|||||||2011-04-05|2011-04-06|Estimate|September 2003||2003-09-30|April 2011|2011-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)|The AMADEUS Trial, A Multicenter, Randomized, Open-label, Assessor Blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Idraparinux (SR34006) With Adjusted-dose Oral Vitamin-K Antagonists in the Prevention of Thromboembolic Events in Patients With Atrial Fibrillation|Completed||Phase 3|4673|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:16:30.662338|2018-06-01 05:16:30.662338
NCT00069433|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-24|||2013-09-23|2003-10-08|2003-10-09|Estimate|||||||2013-09-23|2013-09-24|Estimate|April 2001||2001-04-30|September 2013|2013-09-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Enhancing the Outcome of Skills Training for People With Schizophrenia|Skills Training for Schizophrenia: Enhancing Outcomes|Completed||N/A|60||New York State Psychiatric Institute|||||f||||f||||||||||2018-06-01 05:16:30.834299|2018-06-01 05:16:30.834299
NCT00021099|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-01-23|2003-10-08|2003-10-09|Estimate|||||||2013-01-23|2013-01-24|Estimate|June 2001||2001-06-30|January 2013|2013-01-31||||August 2007|Actual|2007-08-31||Interventional|||Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer|A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:30.942356|2018-06-01 05:16:30.942356
NCT00017368|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2014-02-12|2003-10-08|2003-10-09|Estimate|||||||2014-02-12|2014-02-13|Estimate|April 2001||2001-04-30|February 2014|2014-02-28|January 2012|Actual|2012-01-31|September 2005|Actual|2005-09-30||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma|A Pilot Study Of Tandem High Dose Chemotherapy With Stem Cell Rescue Following Induction Therapy In Children With High Risk Neuroblastoma|Completed||Phase 2|42|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:16:31.052579|2018-06-01 05:16:31.052579
NCT00003907|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-01-07||2013-02-12|2003-10-08|2003-10-09|Estimate|2013-01-07|2013-02-08|Estimate||||2013-02-12|2013-02-15|Estimate|August 1999||1999-08-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|May 2011|Actual|2011-05-31||Interventional|||Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver|Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial|Completed||Phase 2|50|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 05:16:31.207518|2018-06-01 05:16:31.207518
NCT00070785|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-07|||2017-06-30|2003-10-07|2003-10-08|Estimate|||||||2017-06-30|2017-07-02|Actual|October 6, 2003||2003-10-06|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations|Comprehensive Epitope Mapping of the Epstein-Barr Virus Latent Membrane Protein-2 in Ethnically Diverse Populations|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:31.771782|2018-06-01 05:16:31.771782
NCT00070759|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-07|||2017-06-30|2003-10-07|2003-10-08|Estimate|||||||2017-06-30|2017-07-02|Actual|October 6, 2003||2003-10-06|October 2, 2006|2006-10-02|October 2, 2006||2006-10-02|||||Interventional|||Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis|Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study|Completed||Phase 2|6||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:31.822133|2018-06-01 05:16:31.822133
NCT00070642|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06|||2009-02-09|2003-10-07|2003-10-08|Estimate|||||||2009-02-09|2009-02-10|Estimate|December 2003||2003-12-31|February 2009|2009-02-28|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||CPG 7909 Injection in Melanoma|ProMune™ (CPG 7909 Injection) With or Without Chemotherapy for the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open Label, Parallel Group, Active-Controlled, Phase II/III Study|Completed||Phase 2|184|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 05:16:31.88851|2018-06-01 05:16:31.88851
NCT00070629|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06|||2009-02-09|2003-10-07|2003-10-08|Estimate|||||||2009-02-09|2009-02-10|Estimate|May 2003||2003-05-31|February 2009|2009-02-28|July 2007|Actual|2007-07-31|||||Interventional|||CPG 7909 Injection in Non-Small Cell Lung Cancer|Promune™ (CPG 7909 Injection) In Combination With Chemotherapy In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer, A Randomized, Multi-Center, Controlled, Phase 2 Study|Completed||Phase 2|116|Actual|Pfizer||2|||f||||||||||||||2018-06-01 05:16:31.981105|2018-06-01 05:16:31.981105
NCT00070616|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06|||2014-10-23|2003-10-07|2003-10-08|Estimate|||||||2014-10-23|2014-10-24|Estimate|December 2001||2001-12-31|October 2014|2014-10-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support|An Open-label Study of the Pharmacokinetics (PK) of Recombinant Human Keratinocyte Growth Factor (Palifermin; rHuKGF) in Subjects With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy Followed by Peripheral Blood Progenitor Cell (PBPC) Transplantation|Completed||Phase 1|25|Actual|Swedish Orphan Biovitrum||2|||||||||||||||||2018-06-01 05:16:32.585118|2018-06-01 05:16:32.585118
NCT00070590|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06||2010-02-11|2010-02-11|2003-10-07|2003-10-08|Estimate||||2010-02-11|2010-02-15|Estimate|2010-02-11|2010-02-15|Estimate|July 2003||2003-07-31|February 2010|2010-02-28|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis|Completed||Phase 2/Phase 3|132||Actelion|||||||||||||||||||2018-06-01 05:16:32.763823|2018-06-01 05:16:32.763823
NCT00007839|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-12-17|2003-10-07|2003-10-08|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2000||2000-08-31|April 2010|2010-04-30||||||||Interventional|||Beta Alethine in Treating Patients With Low-Grade Lymphoma|Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:32.916722|2018-06-01 05:16:32.916722
NCT00006482|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-04-10|2003-10-07|2003-10-08|Estimate|||||||2013-04-10|2013-04-11|Estimate|October 2000||2000-10-31|May 2004|2004-05-31||||April 2006|Actual|2006-04-30||Interventional|||Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix|A Phase II Evaluation Of Gemcitabine And Cisplatin In Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:16:33.020439|2018-06-01 05:16:33.020439
NCT00006466|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-12-17|2003-10-07|2003-10-08|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2000||2000-08-31|September 2002|2002-09-30||||||||Interventional|||Beta Alethine in Treating Patients With Myeloma|Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:33.485074|2018-06-01 05:16:33.485074
NCT00006257|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2010-01-11|2003-10-07|2003-10-08|Estimate|||||||2010-01-11|2010-01-13|Estimate|November 2000||2000-11-30|January 2010|2010-01-31||||||||Interventional|||SU5416 and Paclitaxel in Treating Patients With Advanced Cancer|Phase I Trial of SU5416 in Combination With Weekly Paclitaxel in Patients With Advanced Malignancies|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:16:33.632117|2018-06-01 05:16:33.632117
NCT00006121|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-07-23|2003-10-07|2003-10-08|Estimate|||||||2012-07-23|2012-07-24|Estimate|May 2000||2000-05-31|July 2012|2012-07-31||||May 2002|Actual|2002-05-31||Interventional|||Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy|Phase II Study of Oxaliplatin Single Agent in Patients With Metastatic Breast Cancer After Failure of Anthracycline/Taxane Based Chemotherapy|Terminated||Phase 2|18|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:16:33.805732|2018-06-01 05:16:33.805732
NCT00006012|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-07-01|2003-10-07|2003-10-08|Estimate|||||||2016-07-01|2016-07-06|Estimate|February 2001||2001-02-28|July 2016|2016-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase I-II Study of Topotecan and Paclitaxel Followed by High-Dose Thoracic Radiation Therapy With Concomitant Cisplatin/Etoposide and Amifostine in Limited-Stage Small Cell Lung Cancer|Completed||Phase 1/Phase 2|73|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:16:33.974985|2018-06-01 05:16:33.974985
NCT00006009|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-14|2003-10-07|2003-10-08|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 2001||2001-04-30|April 2003|2003-04-30|October 2003|Actual|2003-10-31|||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma|A Phase I, Multiple Dose Escalation Trial of Intravenous Humanized Anti-CD3 Antibody (HuM291) in Patients With CD3+ T-cell Lymphomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:34.442514|2018-06-01 05:16:34.442514
NCT00005998|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-11-27|2003-10-07|2003-10-08|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2000||2000-01-31|November 2017|2017-11-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease|Autologous Transplantation for Non-Hodgkin's Lymphoma and Hodgkin's Disease Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Mobilization Using Hematopoietic Cytokines Plus Chemotherapy|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||||Withdrawn because study never enrolled patients|f||||t||||||||||2018-06-01 05:16:34.605565|2018-06-01 05:16:34.605565
NCT00005800|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-09-24|2003-10-07|2003-10-08|Estimate|||||||2012-09-24|2012-09-25|Estimate|April 1999||1999-04-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|January 2006|Actual|2006-01-31||Interventional|||Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer|A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy|Completed||Phase 2|45|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:16:34.726894|2018-06-01 05:16:34.726894
NCT00005794|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2015-10-15|2003-10-07|2003-10-08|Estimate|||||||2015-10-15|2015-10-19|Estimate|February 2000||2000-02-29|October 2015|2015-10-31|July 2003|Actual|2003-07-31|||||Interventional|||Perifosine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Perifosine on a Loading Dose/Maintenance Dose Schedule in Patients With Advanced Cancer|Completed||Phase 1|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:16:34.826935|2018-06-01 05:16:34.826935
NCT00070694|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-06|||2008-03-03|2003-10-06|2003-10-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2003||2003-09-30|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression|An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907 in Combination With Escitalopram in Treatment Resistant Depression|Completed||Phase 2|96||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:35.172583|2018-06-01 05:16:35.172583
NCT00070564|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2017-01-09||2017-12-21|2003-10-06|2003-10-07|Estimate|2017-03-03|2017-04-17|Actual||||2017-12-21|2018-01-19|Actual|November 2003||2003-11-30|December 2017|2017-12-31|January 2027|Anticipated|2027-01-31|January 2015|Actual|2015-01-31||Interventional||Only eligible and analyzable patients were included in the analysis.|S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer|Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer|Active, not recruiting||Phase 3|3294|Actual|Southwest Oncology Group||6|||f||||t||||||||||2018-06-01 05:16:35.47061|2018-06-01 05:16:35.47061
NCT00070551|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-06-03|2003-10-06|2003-10-07|Estimate|||||||2013-06-03|2013-06-04|Estimate|September 2003||2003-09-30|June 2013|2013-06-30||||February 2009|Actual|2009-02-28||Interventional|||GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia|A Phase I Study of GTI2040 (NSC 722929; IND 67368) in Combination With High-dose Cytarabine in Refractory or Relapsed Acute Myeloid Leukemia (AML)|Completed||Phase 1|51|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:16:41.148746|2018-06-01 05:16:41.148746
NCT00070538|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-07-17|2003-10-06|2003-10-07|Estimate|||||||2013-07-17|2013-07-18|Estimate|June 2003||2003-06-30|August 2008|2008-08-31|January 2008|Actual|2008-01-31|September 2004|Actual|2004-09-30||Interventional|||VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies|A Phase I Study Of VNP40101M And Cytarabine For Patients With Hematologic Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:41.285446|2018-06-01 05:16:41.285446
NCT00070525|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-10-07|2003-10-06|2003-10-07|Estimate|||||||2013-10-07|2013-10-08|Estimate|November 2003||2003-11-30|October 2013|2013-10-31||||September 2006|Actual|2006-09-30||Interventional|||Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma|A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma|Completed||Phase 2|90|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:41.372487|2018-06-01 05:16:41.372487
NCT00070499|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2012-06-05||2018-04-20|2003-10-06|2003-10-07|Estimate|2012-06-05|2012-07-10|Estimate||||2018-04-20|2018-04-24|Actual|August 15, 2004|Actual|2004-08-15|April 2018|2018-04-30||||November 1, 2010|Actual|2010-11-01||Interventional|||Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia|A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase|Active, not recruiting||Phase 2|406|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 05:16:41.578037|2018-06-01 05:16:41.578037
NCT00070486|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2016-06-28|2003-10-06|2003-10-07|Estimate|||||||2016-06-28|2016-06-30|Estimate|December 2003||2003-12-31|June 2016|2016-06-30|May 2011|Actual|2011-05-31|December 2006|Actual|2006-12-31||Interventional|||Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer|Randomized Phase II Study of Eicosanoid Pathway Modulators and Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|140|Actual|Alliance for Clinical Trials in Oncology||3|||f||||f||||||||||2018-06-01 05:16:43.671729|2018-06-01 05:16:43.671729
NCT00070473|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2014-02-19|2003-10-06|2003-10-07|Estimate|||||||2014-02-19|2014-02-20|Estimate|October 2003||2003-10-31|February 2014|2014-02-28|June 2008|Actual|2008-06-30|March 2006|Actual|2006-03-31||Interventional|||Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors|A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors|Completed||Phase 1|33|Actual|Children's Oncology Group|||||||||t||||||||||2018-06-01 05:16:43.967011|2018-06-01 05:16:43.967011
NCT00070447|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2014-01-27|2003-10-06|2003-10-07|Estimate|||||||2014-01-27|2014-01-28|Estimate|November 2003||2003-11-30|October 2004|2004-10-31|June 2006|Actual|2006-06-30|||||Interventional|||Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma|Phase II Study of Rituximab (NSC 687451) + CHOP Followed by 90Y-Ibritumomab Tiuxetan (NSC 710085) in Patients With Previously Untreated Mantle Cell Lymphoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:44.13198|2018-06-01 05:16:44.13198
NCT00070434|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2012-06-05|2003-10-06|2003-10-07|Estimate|||||||2012-06-05|2012-06-07|Estimate|August 2004||2004-08-31|June 2012|2012-06-30||||February 2006|Actual|2006-02-28||Interventional|||S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum|A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients With Clinical T4 Rectal Cancer|Withdrawn||Phase 2|0|Actual|Southwest Oncology Group||3||poor accrual|f||||t||||||||||2018-06-01 05:16:44.41034|2018-06-01 05:16:44.41034
NCT00070421|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-05-14|2003-10-06|2003-10-07|Estimate|||||||2013-05-14|2013-05-15|Estimate|April 2003||2003-04-30|December 2004|2004-12-31|January 2005|Actual|2005-01-31|||||Interventional|||Study of @neWorld: A Virtual Community for Children With Cancer|@neWorld: A Virtual Community For Kids With Cancer|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:44.517274|2018-06-01 05:16:44.517274
NCT00070382|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2015-10-01|2003-10-06|2003-10-07|Estimate|||||||2015-10-01|2015-10-02|Estimate|August 2003||2003-08-31|August 2012|2012-08-31||||November 2003|Actual|2003-11-30||Interventional|||Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer|A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy|Completed||Phase 3|14|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:16:44.592086|2018-06-01 05:16:44.592086
NCT00070343|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2014-01-03|2003-10-06|2003-10-07|Estimate|||||||2014-01-03|2014-01-06|Estimate|August 2003||2003-08-31|November 2004|2004-11-30||||||||Interventional|||Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301|Continuation Protocol For G3139 (Bcl-2 Antisense Oligonucleotide) And Dacarbazine In Patients With Malignant Melanoma Who Responded To This Combination In Protocol GM301|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:44.755486|2018-06-01 05:16:44.755486
NCT00070317|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2017-09-08||2017-10-03|2003-10-06|2003-10-07|Estimate|2017-09-08|2017-10-03|Actual||||2017-10-03|2017-11-06|Actual|June 2004||2004-06-30|June 2015|2015-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Eligible and evaluable patients|Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer|Lymphatic Mapping and Sentinel Node Identification in Patients With Stage1B1 Cervical Carcinoma|Terminated||N/A|102|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:16:44.836465|2018-06-01 05:16:44.836465
NCT00070304|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-07-25|2003-10-06|2003-10-07|Estimate|||||||2013-07-25|2013-07-26|Estimate|July 2004||2004-07-31|July 2013|2013-07-31||||September 2007|Actual|2007-09-30||Interventional|||Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma|A Phase II Study Of Weekly Gemcitabine And Vinorelbine In Children With Recurrent Or Refractory Hodgkin's Disease|Completed||Phase 2|33|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:16:47.149025|2018-06-01 05:16:47.149025
NCT00070291|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2013-01-07||2013-02-12|2003-10-06|2003-10-07|Estimate|2013-01-07|2013-02-08|Estimate||||2013-02-12|2013-02-15|Estimate|September 2005||2005-09-30|February 2013|2013-02-28|May 2011|Actual|2011-05-31|March 2009|Actual|2009-03-31||Interventional|||Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma|A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma|Terminated||Phase 2|4|Actual|Eastern Cooperative Oncology Group||1||Slow accrual.|f||||f||||||||||2018-06-01 05:16:48.390692|2018-06-01 05:16:48.390692
NCT00070278|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-08-06|2003-10-06|2003-10-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2005||2005-01-31|January 2009|2009-01-31||||September 2007|Actual|2007-09-30||Interventional|||Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer|A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphamide and Paclitaxel + - Gemcitabine in Poor Risk Early Breast Cancer|Unknown status|Active, not recruiting|Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:48.60672|2018-06-01 05:16:48.60672
NCT00070265|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-01-23|2003-10-06|2003-10-07|Estimate|||||||2013-01-23|2013-01-24|Estimate|August 2003||2003-08-31|January 2013|2013-01-31||||September 2004|Actual|2004-09-30||Interventional|||Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer|A Multi-Institutional Phase II Trial Of Neoadjuvant Capecitabine (XELODA) And Oxaliplatin (ELOXATIN) For Resectable Colorectal Metastases In The Liver|Terminated||Phase 2|80|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:16:48.677045|2018-06-01 05:16:48.677045
NCT00070252|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2015-05-01|2003-10-06|2003-10-07|Estimate|||||||2015-05-01|2015-05-04|Estimate|September 2003||2003-09-30|December 2012|2012-12-31|June 2010|Actual|2010-06-30|February 2006|Actual|2006-02-28||Interventional|||Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer|Phase Ib/II Neoadjuvant Trial of the Farnesyltransferase Inhibitor, R115777 With Docetaxel and Capecitabine for Patients With Stage IIIA or IIIB Breast Cancer|Completed||Phase 1/Phase 2|53|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:48.849134|2018-06-01 05:16:48.849134
NCT00070239|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-12-13|2003-10-06|2003-10-07|Estimate|||||||2013-12-13|2013-12-16|Estimate|August 2003||2003-08-31|December 2013|2013-12-31||||June 2006|Actual|2006-06-30||Interventional|||Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies|A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies|Terminated||Phase 1|100|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:16:48.940724|2018-06-01 05:16:48.940724
NCT00070213|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-09-16|2003-10-06|2003-10-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2003||2003-09-30|June 2011|2011-06-30||||||||Interventional|||Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer|Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed|Unknown status|Active, not recruiting|Phase 3|460|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:49.060442|2018-06-01 05:16:49.060442
NCT00070200|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2014-02-12|2003-10-06|2003-10-07|Estimate|||||||2014-02-12|2014-02-13|Estimate|March 2004||2004-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|September 2006|Actual|2006-09-30||Interventional|||Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma|A Pilot Induction Regimen Incorporating Topotecan for Treatment of Newly Diagnosed High Risk Neuroblastoma|Completed||Phase 1|31|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:16:49.299284|2018-06-01 05:16:49.299284
NCT00070187|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-10-16|2003-10-06|2003-10-07|Estimate|||||||2013-10-16|2013-10-17|Estimate|November 2003||2003-11-30|October 2013|2013-10-31||||June 2005|Actual|2005-06-30||Interventional|||Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma|A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease|Completed||Phase 2/Phase 3|24|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:16:49.421601|2018-06-01 05:16:49.421601
NCT00070174|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2014-02-19|2003-10-06|2003-10-07|Estimate|||||||2014-02-19|2014-02-20|Estimate|December 2003||2003-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|September 2006|Actual|2006-09-30||Interventional|||Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy|Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study|Completed||Phase 2|350|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:16:49.632843|2018-06-01 05:16:49.632843
NCT00070161|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2017-11-27|2003-10-06|2003-10-07|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2001||2001-07-31|November 2017|2017-11-30|August 2012|Actual|2012-08-31|May 2005|Actual|2005-05-31||Interventional|||Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor|Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases|Completed||Phase 2|68|Actual|Wake Forest University Health Sciences|||||f||||t|t|f||||||No||2018-06-01 05:16:49.888763|2018-06-01 05:16:49.888763
NCT00070148|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2016-12-20|2003-10-06|2003-10-07|Estimate|||||||2016-12-20|2016-12-21|Estimate|March 2004||2004-03-31|April 2013|2013-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer|A Phase III Randomized Study Comparing The Effects Of Oxandrolone (Oxandrin) And Megestrol Acetate (Megace) On Lean Body Mass, Weight, Body Fat, And Quality Of Life In Patients With Solid Tumors And Weight Loss Receiving Chemotherapy|Completed||Phase 3|155|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||Undecided||2018-06-01 05:16:50.106139|2018-06-01 05:16:50.106139
NCT00069719|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-30|||2008-08-04|2003-10-03|2003-10-06|Estimate|||||||2008-08-04|2008-08-05|Estimate|February 1999||1999-02-28|August 2008|2008-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients|Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients|Completed||Phase 2|||Alcon Research|||||||||||||||||||2018-06-01 05:16:56.81697|2018-06-01 05:16:56.81697
NCT00070135|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2017-03-20||2017-03-20|2003-10-06|2003-10-07|Estimate|2017-03-20|2017-04-28|Actual||||2017-03-20|2017-04-28|Actual|January 2004||2004-01-31|March 2017|2017-03-31||||December 2013|Actual|2013-12-31||Interventional||Seven (7) participants were excluded from the all analyses after they were deemed ineligible.|Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission|A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen|Active, not recruiting||Phase 2|121|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:16:50.284878|2018-06-01 05:16:50.284878
NCT00070122|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-01-24|2003-10-06|2003-10-07|Estimate|||||||2013-01-24|2013-01-25|Estimate|April 2004||2004-04-30|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer|A Phase III Trial of Modified FOLFOX6 Versus CAPOX, With Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients With Previously Untreated Advanced Colorectal Cancer|Terminated||Phase 3|2200|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:16:51.245257|2018-06-01 05:16:51.245257
NCT00070109|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2013-12-09||2014-09-16|2003-10-06|2003-10-07|Estimate|2013-12-09|2014-01-27|Estimate||||2014-09-16|2014-09-29|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|||Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors|A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas|Completed||Phase 2|50|Actual|Children's Oncology Group||5|||f||||t||||||||||2018-06-01 05:16:51.411521|2018-06-01 05:16:51.411521
NCT00070096|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-06-21|2003-10-06|2003-10-07|Estimate|||||||2013-06-21|2013-06-24|Estimate|August 2003||2003-08-31|April 2006|2006-04-30|June 2007|Actual|2007-06-30|||||Interventional|||Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors|A Phase II Study of BMS-247550 In Advanced Germ Cell Tumor Patients - THERAPEUTIC/DIAGNOSTIC PROTOCOL|Completed||Phase 2|29|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:16:52.276297|2018-06-01 05:16:52.276297
NCT00070083|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2009-04-04|2003-10-06|2003-10-07|Estimate|||||||2009-04-04|2009-04-07|Estimate|July 2003||2003-07-31|June 2005|2005-06-30||||||||Interventional|||Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma|A Phase I Study Of G3139 Antisense Oligonucleotide (Oblimersen) In Combination With CHOP And Rituximab In Untreated Advanced Stage Diffuse Large B Cell Lymphoma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:52.336249|2018-06-01 05:16:52.336249
NCT00070070|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-07-18|2003-10-06|2003-10-07|Estimate|||||||2013-07-18|2013-07-22|Estimate|May 2003||2003-05-31|July 2013|2013-07-31||||April 2006|Actual|2006-04-30||Interventional|||Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder|NY-ESO-1 Protein Immunization of Post-Cystectomy Patients With Transitional Cell Carcinomas Expressing NY-ESO-1 or LAGE-1 Antigen|Completed||Phase 1|||Ludwig Institute for Cancer Research|||||f||||||||||||||2018-06-01 05:16:52.415125|2018-06-01 05:16:52.415125
NCT00070057|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2016-12-28|2003-10-06|2003-10-07|Estimate|||||||2016-12-28|2016-12-29|Estimate|April 2003||2003-04-30|December 2016|2016-12-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer|An Exploratory, Open-Label Phase I Pharmacodynamic Study of COX-2 Inhibition With Celecoxib (Celebrex) and Aromatase Activity in Breast Cancer|Completed||Phase 1|75|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:16:52.470755|2018-06-01 05:16:52.470755
NCT00070031|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-12-18|2003-10-06|2003-10-07|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 2003||2003-06-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|April 2006|Actual|2006-04-30||Interventional|||Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy|A Phase II Study of Intravenous Edotecarin (PHA-782615) in Patients With Anthracycline- and Taxane-Refractory or Chemoresistant Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:52.569513|2018-06-01 05:16:52.569513
NCT00070018|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2012-03-05||2017-04-20|2003-10-06|2003-10-07|Estimate|2012-03-05|2012-04-03|Estimate||||2017-04-20|2017-05-18|Actual|February 2004||2004-02-29|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|November 2010|Actual|2010-11-30||Interventional|||S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma|Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin Lymphoma, Phase II|Active, not recruiting||Phase 2|46|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:16:52.790613|2018-06-01 05:16:52.790613
NCT00070005|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2013-08-06|2003-10-06|2003-10-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2002||2002-06-30|April 2007|2007-04-30||||||||Interventional|||J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma|A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:53.142156|2018-06-01 05:16:53.142156
NCT00069992|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2012-10-05|2003-10-06|2003-10-07|Estimate|||||||2012-10-05|2012-10-10|Estimate|December 2001||2001-12-31|October 2012|2012-10-31|April 2007|Actual|2007-04-30|September 2006|Actual|2006-09-30||Interventional|MPDMDSBMT||Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML|Safety And Efficacy of Sub-Myeloablative Allogeneic Stem Cell Transplantation For Patients With Myeloproliferative Disorder (MPD), Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia|Terminated||Phase 2|7|Actual|Baylor College of Medicine||1||Closed due to competing protocols|f||||t||||||||||2018-06-01 05:16:53.243726|2018-06-01 05:16:53.243726
NCT00069966|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2009-07-04|2003-10-06|2003-10-07|Estimate|||||||2009-07-04|2009-07-07|Estimate|April 2003||2003-04-30|November 2004|2004-11-30||||||||Interventional|||Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse|A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:16:53.419005|2018-06-01 05:16:53.419005
NCT00069953|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|2014-10-14||2016-12-30|2003-10-06|2003-10-07|Estimate|2014-10-14|2014-10-20|Estimate||||2016-12-30|2017-02-17|Actual|September 2003||2003-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2007|Actual|2007-03-31||Interventional||All eligible patients.|Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus|Completed||Phase 2|43|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:16:53.57164|2018-06-01 05:16:53.57164
NCT00069940|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2010-12-26|2003-10-06|2003-10-07|Estimate|||||||2010-12-26|2010-12-28|Estimate|December 2000||2000-12-31|December 2010|2010-12-31|August 2008|Actual|2008-08-31|August 2006|Actual|2006-08-31||Interventional|||Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor|A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF|Completed||Phase 1|||Dana-Farber Cancer Institute|||||f||||t||||||||||2018-06-01 05:16:53.955085|2018-06-01 05:16:53.955085
NCT00069927|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2014-01-31|2003-10-06|2003-10-07|Estimate|||||||2014-01-31|2014-02-03|Estimate|August 2003||2003-08-31|January 2014|2014-01-31|September 2006|Actual|2006-09-30|June 2006|Actual|2006-06-30||Interventional|||Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression|Adderall-XR Versus Concerta For Cancer Treatment-Related Neurocognitive Sequelae And Depression In Pediatric Patients: A Randomized Phase II Study|Terminated||Phase 2|12|Actual|University of South Florida||2||Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility|f||||t||||||||||2018-06-01 05:16:54.100465|2018-06-01 05:16:54.100465
NCT00006034|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-14|2003-10-06|2003-10-07|Estimate|||||||2013-05-14|2013-05-15|Estimate|June 1998||1998-06-30|January 2006|2006-01-31|March 2004|Actual|2004-03-31|||||Interventional|||Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer|A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer|Completed||Phase 3|||National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:16:54.233936|2018-06-01 05:16:54.233936
NCT00003868|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-08-20|2003-10-06|2003-10-07|Estimate|||||||2010-08-20|2010-08-24|Estimate|February 1999||1999-02-28|August 2010|2010-08-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia|Radiolabeled BC8 (Anti-CD45) Antibody Combined With Cyclophosphamide and Total Body Irradiation Followed by HLA-matched Related or Unrelated Stem Cell Transplantation as Treatment for Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome|Completed||Phase 2|40|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:16:54.451704|2018-06-01 05:16:54.451704
NCT00070577|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-03|||2017-06-30|2003-10-03|2003-10-06|Estimate|||||||2017-06-30|2017-07-02|Actual|September 29, 2003||2003-09-29|May 3, 2011|2011-05-03|May 3, 2011||2011-05-03|||||Observational|||Influence of Age and Sex on Alcohol Metabolism and Acute Responses|Influence of Age and Sex on Alcohol Metabolism and Acute Responses|Completed|||65|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:54.522021|2018-06-01 05:16:54.522021
NCT00069901|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-02|||2008-09-18|2003-10-03|2003-10-06|Estimate|||||||2008-09-18|2008-09-22|Estimate|February 2003||2003-02-28|September 2008|2008-09-30|September 2006|Actual|2006-09-30|November 2005|Actual|2005-11-30||Interventional|||Phase II CT-2103/Carboplatin in Ovarian Cancer|CT-2103/Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer: A Phase 2 Study|Completed||Phase 2|82|Actual|CTI BioPharma|||||||||||||||||||2018-06-01 05:16:54.758291|2018-06-01 05:16:54.758291
NCT00069888|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-02|||2011-06-07|2003-10-03|2003-10-06|Estimate|||||||2011-06-07|2011-06-08|Estimate|November 2001||2001-11-30|June 2011|2011-06-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy|A Multicenter, Open-Label, Phase II Trial of Adjuvant Taxotere in Patients At High Risk of Relapse Following Prostatectomy|Completed||Phase 2|83|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:16:54.841711|2018-06-01 05:16:54.841711
NCT00069875|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-02|||2007-12-17|2003-10-03|2003-10-06|Estimate|||||||2007-12-17|2007-12-21|Estimate|September 2003||2003-09-30|December 2007|2007-12-31|December 2005||2005-12-31|||||Interventional|||A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer|Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined With Two Different Doses of LY293111 or Placebo in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer|Completed||Phase 2|195||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:16:54.903751|2018-06-01 05:16:54.903751
NCT00069810|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-01|||2017-04-04|2003-10-03|2003-10-06|Estimate|||||||2017-04-04|2017-04-06|Actual|August 2003||2003-08-31|April 2017|2017-04-30|December 2010|Anticipated|2010-12-31|December 2010|Anticipated|2010-12-31||Observational|||Role of Chronic Kidney Disease in Cardiovascular Disease|Oxidative Stress in Chronic Kidney Disease|Withdrawn|||0|Actual|University of Washington||||The study is not a clinical trial.|f||||f||||||Samples With DNA|"~     EDTA tube of whole blood~   "|||2018-06-01 05:16:54.983389|2018-06-01 05:16:54.983389
NCT00069797|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-01|||2013-01-14|2003-10-03|2003-10-06|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2003||2003-09-30|January 2013|2013-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Epidemiology of Coronary Heart Disease in Men Aged 40 and Over|Epidemiology of Coronary Heart Disease in Men Aged 40 and Over|Completed|||1027|Actual|University of Pittsburgh|||||f||||||||||Samples With DNA|"~     Blood samples (serum and plasma), buffy coat for DNA~   "|||2018-06-01 05:16:55.037745|2018-06-01 05:16:55.037745
NCT00069784|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-01|2012-12-18||2013-01-24|2003-10-03|2003-10-06|Estimate|2012-12-18|2013-01-25|Estimate||||2013-01-24|2013-01-31|Estimate|August 2003||2003-08-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|ORIGIN||The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)|A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)|Completed||Phase 3|12537|Actual|Sanofi||4|||f||||t||||||||||2018-06-01 05:16:55.209513|2018-06-01 05:16:55.209513
NCT00069745|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-30||2012-03-22|2012-08-01|2003-10-03|2003-10-06|Estimate||||2012-04-27|2012-05-01|Estimate|2012-08-01|2012-08-07|Estimate|September 2003||2003-09-30|August 2012|2012-08-31|March 2007|Actual|2007-03-31|January 2006|Actual|2006-01-31||Interventional|||Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen|A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen|Completed||Phase 3|||Agennix|||||f||||||||||||||2018-06-01 05:16:56.341792|2018-06-01 05:16:56.341792
NCT00069706|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-30|||2012-02-11|2003-10-03|2003-10-06|Estimate|||||||2012-02-11|2012-02-14|Estimate|July 2003||2003-07-31|February 2012|2012-02-29|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients|Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients|Completed||Phase 2|118|Actual|Alcon Research||5|||f||||||||||||||2018-06-01 05:16:56.873381|2018-06-01 05:16:56.873381
NCT00069914|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-02|||2008-03-03|2003-10-02|2003-10-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Immune Response to Influenza Vaccine in HIV-Infected Individuals|Immune Response to Influenza Vaccination in HIV-Infected Individuals|Completed|||165||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:56.970148|2018-06-01 05:16:56.970148
NCT00069862|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-02|||2015-03-04|2003-10-02|2003-10-03|Estimate|||||||2015-03-04|2015-03-05|Estimate|September 2003||2003-09-30|March 2015|2015-03-31|November 2005|Actual|2005-11-30|||||Interventional|||Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia|Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia|Completed||Phase 1/Phase 2|25||Sanofi|||||||||||||||||||2018-06-01 05:16:57.030935|2018-06-01 05:16:57.030935
NCT00069836|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-01|||2016-08-31|2003-10-02|2003-10-03|Estimate|||||||2016-08-31|2016-09-01|Estimate|October 2003||2003-10-31|August 2016|2016-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.|A 24 Week, Randomised, Double Blind, Parallel Study to Compare the Change in HbA1c With AVANDAMET® (8.0mg / 2.0g) Plus Insulin to Placebo Plus Insulin, in Subjects With Type 2 Diabetes Starting Insulin Therapy|Completed||Phase 3|272|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:16:57.102757|2018-06-01 05:16:57.102757
NCT00069823|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-01|2010-05-14||2012-12-17|2003-10-02|2003-10-03|Estimate|2012-09-18|2012-10-19|Estimate||||2012-12-17|2012-12-19|Estimate|September 2003||2003-09-30|December 2012|2012-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study of Acid Reflux in Asthma|The Study of Acid Reflux in Asthma|Completed||Phase 3|403|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-06-01 05:16:57.326875|2018-06-01 05:16:57.326875
NCT00069732|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-30|||2010-02-11|2003-10-02|2003-10-03|Estimate|||||||2010-02-11|2010-02-12|Estimate||||February 2010|2010-02-28||||||||Interventional|||Study of Two Complementary and Alternative Medical Treatments for Maintenance of Weight Loss|Pilot of Two CAM Treatments for Maintenance of Weight Loss|Terminated||Phase 2|90||Kaiser Permanente|||||f||||||||||||||2018-06-01 05:16:58.071019|2018-06-01 05:16:58.071019
NCT00069849|ClinicalTrials.gov processed this data on May 31, 2018|2003-10-01|||2006-08-31|2003-10-01|2003-10-02|Estimate|||||||2006-08-31|2006-09-04|Estimate|July 2003||2003-07-31|August 2006|2006-08-31||||||||Interventional|||A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease|A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease|Terminated||Phase 2|64||Abbott|||||||||||||||||||2018-06-01 05:16:58.261304|2018-06-01 05:16:58.261304
NCT00069758|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-30|||2014-05-08|2003-10-01|2003-10-02|Estimate|||||||2014-05-08|2014-05-09|Estimate|September 2003||2003-09-30|May 2014|2014-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Safety and Activity of SDX-105 (Bendamustine) in Patients With Rituximab Refractory Non-Hodgkin's Lymphoma|A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab|Completed||Phase 2|72||Teva Pharmaceutical Industries|||||||||||||||||||2018-06-01 05:16:58.32419|2018-06-01 05:16:58.32419
NCT00069641|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|2014-01-16||2015-04-27|2003-09-30|2003-10-01|Estimate|2015-04-27|2015-05-13|Estimate||||2015-04-27|2015-05-13|Estimate|September 2003||2003-09-30|January 2014|2014-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional||Intent-to-treat (ITT) population included all randomized participants.|Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)|A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II|Completed||Phase 2/Phase 3|96|Actual|Shire||3|||f||||t||||||||||2018-06-01 05:16:58.437002|2018-06-01 05:16:58.437002
NCT00069524|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2007-09-25|2003-09-30|2003-10-01|Estimate|||||||2007-09-25|2007-09-26|Estimate|June 2004||2004-06-30|September 2007|2007-09-30|May 2006|Actual|2006-05-31|||||Interventional|||Antihyperlipidemic Effects of Oyster Mushrooms|Antihyperlipidemic Effects of Oyster Mushrooms|Completed||Phase 1/Phase 2|20||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:16:59.460533|2018-06-01 05:16:59.460533
NCT00005630|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-18|2003-09-30|2003-10-01|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 1999||1999-07-31|June 2013|2013-06-30|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer|Vaccination of Non-Small Cell Lung Cancer Patients Against Mutated K-Ras: A Pilot Trial|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:16:59.524821|2018-06-01 05:16:59.524821
NCT00005629|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2015-09-30|2003-09-30|2003-10-01|Estimate|||||||2015-09-30|2015-10-02|Estimate|July 1999||1999-07-31|July 2012|2012-07-31|June 2002|Actual|2002-06-30|May 2002|Actual|2002-05-31||Interventional|||Vaccine Therapy in Treating Patients With Liver Cancer|Phase I/II Trial Testing Alpha Fetoprotein (AFP) Peptide Immunization in Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|6|Actual|Jonsson Comprehensive Cancer Center||3|||f||||t||||||||||2018-06-01 05:16:59.594317|2018-06-01 05:16:59.594317
NCT00004922|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-06-18|2003-09-30|2003-10-01|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 1999||1999-06-30|June 2013|2013-06-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors|A Phase II Clinical Trial of Irinotecan (CPT-11) in Patients With Advanced High Grade Neuroendocrine Tumors|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:16:59.680431|2018-06-01 05:16:59.680431
NCT00004886|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-09-20|2003-09-30|2003-10-01|Estimate|||||||2012-09-20|2012-09-24|Estimate|December 1999||1999-12-31|September 2012|2012-09-30||||June 2002|Actual|2002-06-30||Interventional|||MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Study to Determine the Safety of MS-209 in Combination With Docetaxel in Patients With a Solid Progressive Tumor|Completed||Phase 1|30|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:16:59.751467|2018-06-01 05:16:59.751467
NCT00069693|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2017-06-30|2003-09-29|2003-09-30|Estimate|||||||2017-06-30|2017-07-02|Actual|September 26, 2003||2003-09-26|August 5, 2008|2008-08-05|August 5, 2008||2008-08-05|||||Observational|||Evaluation of Chronic Orthostatic Intolerance|Clinical Laboratory Evaluation of Chronic Orthostatic Intolerance|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:59.813794|2018-06-01 05:16:59.813794
NCT00069654|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2017-06-30|2003-09-29|2003-09-30|Estimate|||||||2017-06-30|2017-07-02|Actual|September 25, 2003||2003-09-25|May 18, 2009|2009-05-18||||May 18, 2009|Actual|2009-05-18||Interventional|||Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease|Dietary Nitrate/Nitrite as Sources of Bioactive Nitric Oxide in Patients With Coronary Artery Disease|Completed||Phase 2|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:16:59.963149|2018-06-01 05:16:59.963149
NCT00069628|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2016-09-02|2003-09-29|2003-09-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|July 2003||2003-07-31|September 2016|2016-09-30|November 2004||2004-11-30|||||Interventional|||Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer|DirecNet Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer in the Management of Type 1 Diabetes in Children|Completed||Phase 4|200||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 05:17:00.046952|2018-06-01 05:17:00.046952
NCT00069615|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2016-09-02|2003-09-29|2003-09-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|February 2003||2003-02-28|September 2016|2016-09-30|June 2003||2003-06-30|||||Interventional|||Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children|DirecNet Pilot Study to Evaluate the GlucoWatch G2 Biographer in the Management of Type 1 Diabetes in Children|Completed||Phase 4|15||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 05:17:00.127235|2018-06-01 05:17:00.127235
NCT00069602|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2016-09-02|2003-09-29|2003-09-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|August 2002||2002-08-31|September 2016|2016-09-30|November 2002||2002-11-30|||||Interventional|||Assessing Continuous Glucose Monitors in Healthy Children|DirecNet Pilot Study to Assess the Accuracy of Continuous Glucose Monitors in Normal Children|Completed||Phase 4|20||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 05:17:00.208259|2018-06-01 05:17:00.208259
NCT00069589|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2018-02-15|2003-09-29|2003-09-30|Estimate|||||||2018-02-15|2018-02-19|Actual|November 2001||2001-11-30|February 2018|2018-02-28|November 2099|Anticipated|2099-11-30|November 2099|Anticipated|2099-11-30||Observational|NAAR||Alopecia Areata Registry|Alopecia Areata Registry and Immunogenetic Mechanisms|Active, not recruiting|||3100|Anticipated|M.D. Anderson Cancer Center|||||f||||f|f|f||||Samples With DNA|"~     DNA will be analyzed to learn the link between gene markers of traites of alopecia areata.~     Sera will be used to analyse cytokins. Lymphocytes will be used for the creation of B-cell~     lines.~   "|||2018-06-01 05:17:00.284217|2018-06-01 05:17:00.284217
NCT00069576|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2018-03-19|2003-09-29|2003-09-30|Estimate|||||||2018-03-19|2018-03-21|Actual|October 2002||2002-10-31|March 2018|2018-03-31|October 2013|Actual|2013-10-31|November 2007|Actual|2007-11-30||Interventional|GDM||Gestational Diabetes Mellitus Trial (GDM)|A Randomized Clinical Trial of Treatment for Mild Gestational Diabetes Mellitus|Completed||N/A|1889|Actual|The George Washington University Biostatistics Center||2|||f||||t||||||||||2018-06-01 05:17:00.360421|2018-06-01 05:17:00.360421
NCT00069563|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2005-06-23|2003-09-29|2003-09-30|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|October 2003|2003-10-31|September 2000||2000-09-30|||||Interventional|||Improving Mental Health Services for Economically Disadvantaged Children: Training Teachers|John F. Kennedy Center for Mental Retardation: Parent Vs. Teacher-Training in Children's Mental Health Services|Completed||N/A|93||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:00.453767|2018-06-01 05:17:00.453767
NCT00069550|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2005-06-23|2003-09-29|2003-09-30|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2004||2004-09-30|December 2004|2004-12-31|June 2008||2008-06-30|||||Interventional|||Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome|Pathogenesis of Rett Syndrome: Natural History and Treatment|Unknown status|Recruiting|Phase 3|90||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||||||||||||||||2018-06-01 05:17:00.649521|2018-06-01 05:17:00.649521
NCT00069537|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2016-09-02|2003-09-29|2003-09-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|May 2002||2002-05-31|September 2016|2016-09-30|November 2002||2002-11-30|||||Interventional|||Continuous Glucose Monitors for Children With Diabetes Mellitus|DirecNet Inpatient Study to Test the Accuracy of Continuous Blood Glucose Monitoring Devices in Children With Type 1 Diabetes|Completed||Phase 4|90||Jaeb Center for Health Research|||||f||||||||||||||2018-06-01 05:17:00.736088|2018-06-01 05:17:00.736088
NCT00069511|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-29|||2005-06-23|2003-09-29|2003-09-30|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2003||2003-07-31|June 2004|2004-06-30|December 2004||2004-12-31|||||Interventional|||12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.||Unknown status|Active, not recruiting|Phase 2|72||Unither Pharmaceuticals|||||||||||||||||||2018-06-01 05:17:00.826773|2018-06-01 05:17:00.826773
NCT00069498|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-26|||2007-05-24|2003-09-29|2003-09-30|Estimate|||||||2007-05-24|2007-05-25|Estimate|October 1999||1999-10-31|July 2006|2006-07-31||||||||Interventional|||Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients|Impact of Co-Receptor and HIV Viral Burden on Gut Mucosa|Completed||Phase 1|14||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:17:00.901056|2018-06-01 05:17:00.901056
NCT00069485|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-26|||2007-09-17|2003-09-29|2003-09-30|Estimate|||||||2007-09-17|2007-09-18|Estimate|December 1995||1995-12-31|July 2007|2007-07-31||||||||Observational|||Resistance to HIV Infection|Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals|Unknown status|Recruiting||100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:17:00.964156|2018-06-01 05:17:00.964156
NCT00004883|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-01-15|2003-09-29|2003-09-30|Estimate|||||||2013-01-15|2013-01-16|Estimate|February 2000||2000-02-29|January 2013|2013-01-31||||August 2005|Actual|2005-08-31||Interventional|||Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2|A Phase II Trial of Trastuzumab (Herceptin) for Advanced Stage (IIIB, IV), HER2 Overexpressing, Non-Small Cell Lung Cancer|Completed||Phase 2|84|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:01.0165|2018-06-01 05:17:01.0165
NCT00004856|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-05-01|2003-09-29|2003-09-30|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2002||2002-07-31|May 2013|2013-05-31||||July 2002|Actual|2002-07-31||Interventional|||Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium|A Phase II Trial of Trastuzumab (Herceptin; NSC #688097, IND #6667) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma|Terminated||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:17:01.082296|2018-06-01 05:17:01.082296
NCT00003930|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-13|2003-09-29|2003-09-30|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 1999||1999-09-30|October 2015|2015-10-31|November 2013|Actual|2013-11-30|July 2003|Actual|2003-07-31||Interventional|||Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer|A Phase I/II Trial in Patients With Muscle-Invading Bladder Cancer of Transurethral Surgery Plus Taxol, Cisplatin and Bid Irradiation Followed by Either Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy|Completed||Phase 1/Phase 2|84|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:17:01.252827|2018-06-01 05:17:01.252827
NCT00069472|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-25|||2015-09-09|2003-09-26|2003-09-29|Estimate|||||||2015-09-09|2015-09-10|Estimate|October 2002||2002-10-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|NARAC||Genetic Registry for Rheumatoid Arthritis|Genetics of Rheumatoid Arthritis Registry|Completed|||1062|Actual|Northwell Health|||||f||||f||||||Samples With DNA|"~     DNA, plasma, serum and cells~   "|||2018-06-01 05:17:01.894592|2018-06-01 05:17:01.894592
NCT00069459|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-25|||2017-09-21|2003-09-25|2003-09-26|Estimate|||||||2017-09-21|2017-09-25|Actual|September 23, 2003|Actual|2003-09-23|September 2017|2017-09-30|June 3, 2004|Actual|2004-06-03|June 3, 2004|Actual|2004-06-03||Interventional|||Seasonal Affective Depression (SAD) Study|A 7 Month, Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/Day of Extended-Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase|Completed||Phase 1|250|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 05:17:01.971182|2018-06-01 05:17:01.971182
NCT00069446|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-25|||2017-05-09|2003-09-25|2003-09-26|Estimate|||||||2017-05-09|2017-05-11|Actual|August 2003|Actual|2003-08-31|May 2017|2017-05-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers|An Exploratory, Double-Blind, Randomized, Placebo Controlled Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers|Completed||Phase 1|50||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:17:02.16136|2018-06-01 05:17:02.16136
NCT00069368|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-24|||2014-09-25|2003-09-25|2003-09-26|Estimate|||||||2014-09-25|2014-09-29|Estimate|July 2003||2003-07-31|September 2014|2014-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||ORWH:SCOR on Sex and Gender Factors Affecting Women's Incontinence|ORWH:SCOR on Sex and Gender Factors Affecting Women's Incontinence|Completed|||2161|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||||2018-06-01 05:17:02.228294|2018-06-01 05:17:02.228294
NCT00069420|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-24|||2013-12-30|2003-09-24|2003-09-25|Estimate|||||||2013-12-30|2014-01-01|Estimate|September 2003||2003-09-30|December 2013|2013-12-31|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Interventional|||Cognitive Motivational Behavior Therapy for Gamblers|Cognitive-Motivational Behavior Therapy for Gamblers|Completed||Phase 1|40||University at Albany|||||f||||f||||||||||2018-06-01 05:17:02.291863|2018-06-01 05:17:02.291863
NCT00069407|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-24|||2014-12-12|2003-09-24|2003-09-25|Estimate|||||||2014-12-12|2014-12-16|Estimate|February 2003||2003-02-28|December 2014|2014-12-31|December 2006|Actual|2006-12-31|May 2006|Actual|2006-05-31||Interventional|||Comparison of Three Electroconvulsive Therapy (ECT) Techniques for the Treatment of Major Depression|Comparing Three Electrode Placements to Optimize ECT|Completed||N/A|230|Actual|Rutgers, The State University of New Jersey||3|||f||||t||||||||||2018-06-01 05:17:02.353325|2018-06-01 05:17:02.353325
NCT00069381|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-24|||2013-03-27|2003-09-24|2003-09-25|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2002||2002-04-30|March 2013|2013-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Treatment for Women With Post-Traumatic Stress Disorder Related to Childhood Abuse|Skills Training, Exposure, and Their Combination in Childhood Abuse PTSD|Completed||N/A|144|Actual|New York University School of Medicine||1|||f||||||||||||||2018-06-01 05:17:02.45296|2018-06-01 05:17:02.45296
NCT00003827|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-09-24|2003-09-25|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1999||1999-01-31|July 2007|2007-07-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome|Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:02.721195|2018-06-01 05:17:02.721195
NCT00003620|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-16|2003-09-24|2003-09-25|Estimate|||||||2013-01-16|2013-01-17|Estimate|June 1999||1999-06-30|January 2013|2013-01-31||||June 2006|Actual|2006-06-30||Interventional|||Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia|A PHASE II STUDY OF FLAVOPIRIDOL (NSC # 649890) IN PATIENTS WITH PREVIOUSLY TREATED BCELL CHRONIC LYMPHOCYTIC LEUKEMIA|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:02.962902|2018-06-01 05:17:02.962902
NCT00003594|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-09-24|2003-09-25|Estimate|||||||2016-07-01|2016-07-06|Estimate|October 1998||1998-10-31|July 2016|2016-07-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum|Completed||Phase 3|1691|Actual|Alliance for Clinical Trials in Oncology||3|||f||||f||||||||||2018-06-01 05:17:03.148781|2018-06-01 05:17:03.148781
NCT00003540|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2003-09-24|2003-09-25|Estimate|||||||2013-06-24|2013-06-26|Estimate|June 1998||1998-06-30|June 2013|2013-06-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel|Phase II Study of Gemcitabine in the Treatment of Patients With Metastatic Breast Cancer Previously Treated With Adriamycin and Taxol|Completed||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:17:04.007054|2018-06-01 05:17:04.007054
NCT00003463|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2003-09-24|2003-09-25|Estimate|||||||2013-02-15|2013-02-18|Estimate|July 1998||1998-07-31|February 2013|2013-02-28|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas|Phase I Treatment of Adults With Recurrent Supratentorial High Grade Glioma With Gliadel Wafers Plus Irinotecan (CPT-11)|Completed||Phase 1|||Duke University|||||f||||||||||||||2018-06-01 05:17:04.082164|2018-06-01 05:17:04.082164
NCT00069355|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-23|||2008-03-03|2003-09-23|2003-09-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2003||2003-09-30|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||Propranolol for the Treatment of Acute Stress Disorder|Propranolol For the Treatment of Acute Stress Disorder|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:04.141788|2018-06-01 05:17:04.141788
NCT00069342|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-23|||2018-04-13|2003-09-23|2003-09-24|Estimate|||||||2018-04-13|2018-04-17|Actual|September 22, 2003||2003-09-22|April 12, 2018|2018-04-12|April 12, 2018||2018-04-12|||||Observational|||Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases|Health Beliefs and Health Behavior Practices Among Minorities With Rheumatic Diseases|Completed|||140|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:04.207055|2018-06-01 05:17:04.207055
NCT00069277|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-19|2012-01-09||2012-04-06|2003-09-23|2003-09-24|Estimate|2012-01-09|2012-02-09|Estimate||||2012-04-06|2012-04-11|Estimate|August 2003||2003-08-31|April 2012|2012-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors|A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|21|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 05:17:04.268215|2018-06-01 05:17:04.268215
NCT00069264|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-19|2011-11-16||2011-11-16|2003-09-23|2003-09-24|Estimate|2011-11-16|2011-12-20|Estimate||||2011-11-16|2011-12-20|Estimate|September 2003||2003-09-30|November 2011|2011-11-30|July 2005|Actual|2005-07-31|March 2005|Actual|2005-03-31||Interventional|||Study of E7389 in Patients With Advanced Solid Tumors|A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) in Patients With Advanced Solid Tumors|Completed||Phase 1|33|Actual|Eisai Inc.||1|||f||||||||||||||2018-06-01 05:17:04.460832|2018-06-01 05:17:04.460832
NCT00069251|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-18|||2017-01-11|2003-09-23|2003-09-24|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2003||2003-07-31|July 2008|2008-07-31|June 2005||2005-06-30|||||Interventional|||Bupropion for the Treatment of Methamphetamine Dependence - 1|Bupropion for the Treatment of Methamphetamine Dependence|Completed||Phase 2|150||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:17:04.762317|2018-06-01 05:17:04.762317
NCT00003449|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-20|2003-09-23|2003-09-24|Estimate|||||||2014-05-20|2014-05-22|Estimate|May 1998||1998-05-31|May 2014|2014-05-31|February 2004|Actual|2004-02-29|June 2002|Actual|2002-06-30||Interventional|||Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer|Phase II Study of Weekly Paclitaxel and Gemcitabine in Platinum-Resistant Ovarian Cancer|Completed||Phase 2|35|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:17:04.822576|2018-06-01 05:17:04.822576
NCT00003281|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-09-23|2003-09-24|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 1998||1998-04-30|July 2016|2016-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer|Phase II Trial of Topotecan and Paclitaxel in Previously Treated Patients With Relapsed Small Cell Lung Cancer|Completed||Phase 2|84|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:17:04.878872|2018-06-01 05:17:04.878872
NCT00003280|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2003-09-23|2003-09-24|Estimate|||||||2012-05-14|2012-05-15|Estimate|January 1998||1998-01-31|May 2012|2012-05-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma|A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4|Completed||Phase 3|240|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:17:04.982216|2018-06-01 05:17:04.982216
NCT00003245|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-05|2003-09-23|2003-09-24|Estimate|||||||2012-10-05|2012-10-08|Estimate|February 1998||1998-02-28|October 2012|2012-10-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma|Phase II Study of Irinotecan for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|50|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:17:05.116132|2018-06-01 05:17:05.116132
NCT00003113|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-01-13|2003-09-23|2003-09-24|Estimate|||||||2011-01-13|2011-01-17|Estimate|July 1997||1997-07-31|January 2011|2011-01-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas|Oral Combination Chemotherapy in Conjunction With G-CSF in the Treatment of Elderly Patients With Intermediate and High Grade Non-Hodgkin's Lymphoma|Terminated||Phase 2|6|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:17:05.219805|2018-06-01 05:17:05.219805
NCT00069329|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-22|2016-05-06||2016-10-07|2003-09-22|2003-09-23|Estimate|2016-10-07|2016-12-01|Estimate||||2016-10-07|2016-12-01|Estimate|September 2003||2003-09-30|October 2016|2016-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease|A Long-Term Outcome Study With the IL-1 Receptor Antagonist Anakinra/Kineret in Patients With Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) A Therapeutic Approach to Study the Pathogenesis of This Disease|Terminated||Phase 1/Phase 2|43|Actual|National Institutes of Health Clinical Center (CC)|Data reported is on 26 patients who completed their 3 year assessment and 20 of these patients also completed their 5 year assessment.|1||data submitted for Food and Drug Administration (FDA) approval|f||||f||||||||Yes|with Swedish Orphan Biovitrum Inc (SOBI)|2018-06-01 05:17:05.335871|2018-06-01 05:17:05.335871
NCT00069316|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-22|||2017-06-30|2003-09-22|2003-09-23|Estimate|||||||2017-06-30|2017-07-02|Actual|September 22, 2003||2003-09-22|February 18, 2011|2011-02-18|June 27, 2007|Actual|2007-06-27|June 27, 2007|Actual|2007-06-27||Interventional|||Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease|A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV)|Completed||Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:05.94815|2018-06-01 05:17:05.94815
NCT00069303|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-22|||2017-06-30|2003-09-22|2003-09-23|Estimate|||||||2017-06-30|2017-07-02|Actual|September 16, 2003||2003-09-16|February 18, 2011|2011-02-18|February 18, 2011||2011-02-18|||||Observational|||Natural History of West Nile Virus Infection|Investigation of the Natural History of West Nile Virus Infection in Patients With Recently Acquired West Nile Fever or Neuroinvasive Disease|Completed|||110|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:06.160315|2018-06-01 05:17:06.160315
NCT00069186|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-17|||2005-06-23|2003-09-22|2003-09-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2003||2003-06-30|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis|A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis|Unknown status|Active, not recruiting|Phase 3|107||The Avicena Group|||||||||||||||||||2018-06-01 05:17:06.488907|2018-06-01 05:17:06.488907
NCT00069238|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-17|2015-10-07||2018-04-16|2003-09-17|2003-09-18|Estimate|2015-12-15|2016-01-21|Estimate||||2018-04-16|2018-05-16|Actual|September 19, 2003|Actual|2003-09-19|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|June 11, 2009|Actual|2009-06-11||Interventional|||Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas|Phase 2 Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas|Active, not recruiting||Phase 2|31|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f|t|f||||||No||2018-06-01 05:17:09.010546|2018-06-01 05:17:09.010546
NCT00069225|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-17|||2008-03-03|2003-09-17|2003-09-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2003||2003-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder|Cerebral Structure and Function Before and After Pharmacological and Psychological Treatment for PTSD|Completed|||95||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:09.828066|2018-06-01 05:17:09.828066
NCT00069212|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-17|||2018-04-21|2003-09-17|2003-09-18|Estimate|||||||2018-04-21|2018-04-24|Actual|September 16, 2003||2003-09-16|September 17, 2012|2012-09-17|September 17, 2012||2012-09-17|||||Observational|||Psychobiological Mechanisms of Resilience to Trauma|Psychobiological Mechanisms of Resilience to Trauma|Completed|||210|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:09.874667|2018-06-01 05:17:09.874667
NCT00069121|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-15|2011-03-31||2013-08-13|2003-09-17|2003-09-18|Estimate|2011-07-05|2011-07-29|Estimate||||2013-08-13|2013-08-22|Estimate|January 2003||2003-01-31|August 2013|2013-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer|A Randomized, Open-label Study of the Effect of Intermittent Xeloda in Combination With Eloxatin, Versus Fluorouracil/Leucovorin, on Disease-free Survival in Patients Who Have Undergone Surgery for Colon Cancer.|Completed||Phase 3|1886|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:17:10.270522|2018-06-01 05:17:10.270522
NCT00069108|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-15|2016-01-27||2016-03-03|2003-09-17|2003-09-18|Estimate|2016-01-27|2016-02-24|Estimate||||2016-03-03|2016-04-01|Estimate|July 2003||2003-07-31|March 2016|2016-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional||All participants with written informed consent who were randomized to one of the two study arms were included in the Intent-to-treat (ITT) population. Participants in this population were analyzed according to the arm to which they were randomized|A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer|"An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (XELOX) Versus Bolus and Continuous Infusion Fluorouracil/ Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) (FOLFOX4) as Treatment for Patients With Metastatic Colorectal Cancer Who Have Received Prior Treatment With CPT-11 in Combination With 5-FU/LV as First Line Therapy"|Completed||Phase 3|627|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:17:12.349694|2018-06-01 05:17:12.349694
NCT00069095|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-15|2015-12-11||2016-08-26|2003-09-17|2003-09-18|Estimate|2015-12-11|2016-01-22|Estimate||||2016-08-26|2016-10-06|Estimate|July 2003||2003-07-31|August 2016|2016-08-31|April 2009|Actual|2009-04-30|January 2006|Actual|2006-01-31||Interventional||Baseline characteristics were described for the Intent-to-treat (ITT) population.This population included all randomized participants who provided written informed consent.|A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer|"A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) (XELOX) With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) (FOLFOX-4) With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer"|Completed||Phase 3|2035|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 05:17:13.420597|2018-06-01 05:17:13.420597
NCT00002638|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-09-17|2003-09-18|Estimate|||||||2013-07-09|2013-07-10|Estimate|March 1995||1995-03-31|September 2002|2002-09-30|March 2005|Actual|2005-03-31|||||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia|HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR CHILDREN WITH RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:18.906897|2018-06-01 05:17:18.906897
NCT00002559|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2003-09-17|2003-09-18|Estimate|||||||2013-07-01|2013-07-02|Estimate|January 1994||1994-01-31|July 2013|2013-07-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin|PHASE I/II TRIAL OF TAXOL, IFOSFAMIDE, AND CISPLATIN FOR CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH FAVORABLE PROGNOSTIC FEATURES|Completed||Phase 1/Phase 2|43|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:17:18.996145|2018-06-01 05:17:18.996145
NCT00002533|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-14|2003-09-17|2003-09-18|Estimate|||||||2016-12-14|2016-12-15|Estimate|February 1993||1993-02-28|December 2016|2016-12-31|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional|||Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer|A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER|Completed||Phase 2/Phase 3|||University of Miami|||||f||||t||||||||||2018-06-01 05:17:19.064618|2018-06-01 05:17:19.064618
NCT00069173|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-16|||2005-06-23|2003-09-16|2003-09-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2000||2000-07-31|June 2003|2003-06-30||||||||Interventional|||Preventing Osteoporosis in Adolescent Girls|Prevention of Osteoporosis Among Sedentary Adolescent Females|Unknown status|Recruiting|Phase 1|250||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:19.144223|2018-06-01 05:17:19.144223
NCT00069134|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-15|||2017-07-31|2003-09-16|2003-09-17|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2003||2003-06-30|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study of Antioxidants and Oxidants in Malnourished Children|Glutathione Homeostasis and Oxidant Damage in Kwashiorkor|Completed||N/A|86|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 05:17:19.244552|2018-06-01 05:17:19.244552
NCT00069017|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-12|||2007-11-26|2003-09-16|2003-09-17|Estimate|||||||2007-11-26|2007-11-27|Estimate|September 2003||2003-09-30|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate|A Phase II, Randomized, Double-Blind Study to Evaluate the Effects of MEDI-522, a Humanized MAb to Integrin Alpha V Beta 3, On Disease Activity and Progression of Joint Damage in Pts With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate|Completed||Phase 2|300|Actual|MedImmune LLC||2|||f||||||||||||||2018-06-01 05:17:19.335187|2018-06-01 05:17:19.335187
NCT00030381|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-01-15|2003-09-16|2003-09-17|Estimate|||||||2013-01-15|2013-01-16|Estimate|December 2001||2001-12-31|January 2013|2013-01-31||||January 2003|Actual|2003-01-31||Interventional|||Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis|Phase I Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL)|Terminated||Phase 1|22|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:17:19.455858|2018-06-01 05:17:19.455858
NCT00026286|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2009-05-09|2003-09-16|2003-09-17|Estimate|||||||2009-05-09|2009-05-12|Estimate|September 2000||2000-09-30|March 2008|2008-03-31||||August 2002|Actual|2002-08-31||Interventional|||Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer|A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:19.554567|2018-06-01 05:17:19.554567
NCT00025116|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2010-11-07|2003-09-16|2003-09-17|Estimate|||||||2010-11-07|2010-11-09|Estimate|April 2001||2001-04-30|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Randomized Phase II Study Of ZD1839 (IRESSA) In Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:17:19.761143|2018-06-01 05:17:19.761143
NCT00069160|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-15|2011-06-30||2012-09-12|2003-09-15|2003-09-16|Estimate|2012-09-12|2012-10-12|Estimate||||2012-09-12|2012-10-12|Estimate|September 2003||2003-09-30|September 2012|2012-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer|A Clinical Trial of the P-Glycoprotein Antagonist, Tariquidar (XR9576), in Combination With Docetaxel in Patients With Lung, Ovarian, Renal and Cervical Cancer: Analysis of the Interaction Between Tariquidar and Docetaxel|Completed||Phase 2|48|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:17:19.920437|2018-06-01 05:17:19.920437
NCT00069082|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-15|||2011-06-08|2003-09-15|2003-09-16|Estimate|||||||2011-06-08|2011-06-10|Estimate|August 2003||2003-08-31|June 2011|2011-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Intranasal Civamide for Episodic Cluster Headache|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache|Completed||Phase 3|2|Actual|Winston Laboratories||2|||f||||||||||||||2018-06-01 05:17:20.651083|2018-06-01 05:17:20.651083
NCT00069030|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-12|||2012-11-07|2003-09-15|2003-09-16|Estimate|||||||2012-11-07|2012-11-08|Estimate|December 2003||2003-12-31|November 2012|2012-11-30|December 2006|Actual|2006-12-31|||||Interventional|||Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) With the Plasmid Cytokine Adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig)|Completed||Phase 1|70|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:17:20.721143|2018-06-01 05:17:20.721143
NCT00069004|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-12|||2014-01-06|2003-09-15|2003-09-16|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2003||2003-10-31|January 2014|2014-01-31|August 2005|Actual|2005-08-31|||||Observational|||A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth|Prevalence of Morphologic and Metabolic Abnormalities in Vertically HIV-Infected and Uninfected Children and Youth|Completed|||450||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:17:20.804762|2018-06-01 05:17:20.804762
NCT00068991|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-12|||2015-05-29|2003-09-15|2003-09-16|Estimate|||||||2015-05-29|2015-06-01|Estimate||||September 2008|2008-09-30|June 2007||2007-06-30|||||Interventional|||HIV Educational Programs for Villagers of Funan County or Yingzhou District, Anhui Province, China|A Cluster-Randomized Trial to Evaluate the Efficacy of a Combined Individual- and Community-Based Behavioral Intervention to Improve Quality of Life for HIV-Positive Villagers in Rural China (China CIPRA Project 2)|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||f||||||||||2018-06-01 05:17:20.956703|2018-06-01 05:17:20.956703
NCT00068978|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-12|||2007-09-17|2003-09-15|2003-09-16|Estimate|||||||2007-09-17|2007-09-18|Estimate|April 2003||2003-04-30|August 2007|2007-08-31||||||||Observational|||Analysis of Immune Responses to HIV Vaccines|Flow Cytometry Study of T Cell Responses to HIV Vaccines|Completed|||200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:17:21.034236|2018-06-01 05:17:21.034236
NCT00068952|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-12|||2008-03-27|2003-09-15|2003-09-16|Estimate|||||||2008-03-27|2008-04-01|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|March 2006||2006-03-31|||||Interventional|||Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme|A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy|Completed||Phase 3|118||Pfizer|||||f||||||||||||||2018-06-01 05:17:21.147897|2018-06-01 05:17:21.147897
NCT00069069|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2018-05-10|2003-09-12|2003-09-15|Estimate|||||||2018-05-10|2018-05-11|Actual|October 1, 2003||2003-10-01|May 9, 2018|2018-05-09|May 9, 2018|Actual|2018-05-09|May 9, 2018|Actual|2018-05-09||Interventional|||E-Selectin Nasal Instillation to Prevent Secondary Stroke|Induction of Mucosal Tolerance to Human E-Selectin for the Secondary Prevention of Stroke|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:17:21.283322|2018-06-01 05:17:21.283322
NCT00069056|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-13|||2017-06-30|2003-09-12|2003-09-15|Estimate|||||||2017-06-30|2017-07-02|Actual|September 10, 2003||2003-09-10|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema|A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema|Completed||Phase 1|4||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:21.369163|2018-06-01 05:17:21.369163
NCT00068900|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2015-04-29|2003-09-11|2003-09-12|Estimate|||||||2015-04-29|2015-04-30|Estimate|November 2003||2003-11-30|April 2015|2015-04-30|February 2004|Actual|2004-02-29|January 2004|Actual|2004-01-31||Observational|||FFA Metabolism in Different Types of Human Obesity|FFA Metabolism in Different Types of Human Obesity|Withdrawn|||0|Actual|Mayo Clinic||||NOT A CLINICAL TRIAL|f||||||||||||||2018-06-01 05:17:21.453525|2018-06-01 05:17:21.453525
NCT00068887|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2015-04-29|2003-09-11|2003-09-12|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 1999||1999-09-30|April 2015|2015-04-30|December 2005||2005-12-31|||||Observational|||Regional Fatty Acid Metabolism in Humans|Regional Fatty Acid Metabolism in Humans|Withdrawn|||0|Actual|Mayo Clinic||||NOT A CLINICAL TRIAL|f||||||||||||||2018-06-01 05:17:21.50072|2018-06-01 05:17:21.50072
NCT00068926|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-11|||2017-06-30|2003-09-10|2003-09-11|Estimate|||||||2017-06-30|2017-07-02|Actual|September 3, 2003||2003-09-03|June 29, 2011|2011-06-29|June 29, 2011||2011-06-29|||||Observational|||VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases|VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases|Completed|||958|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:21.575694|2018-06-01 05:17:21.575694
NCT00068913|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2005-06-23|2003-09-10|2003-09-11|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2000||2000-03-31|September 2004|2004-09-30||||||||Interventional|||Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome|Investigation of Clinical Syndromes Associated With mtDNA Point Mutations: MELAS/DCA Clinical Trial|Unknown status|Active, not recruiting|Phase 2|35||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||||||||||||||||2018-06-01 05:17:21.642162|2018-06-01 05:17:21.642162
NCT00068874|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2018-05-03|2003-09-10|2003-09-11|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2004||2004-04-30|May 2018|2018-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Improving Quality of Life for African American Female Adolescents With Lupus|Predictors of Adaptation and a Cognitive Behavioral Intervention for African American Adolescents With Lupus|Completed||Phase 2|120|Anticipated|Medical University of South Carolina||3|||f||||t||||||||||2018-06-01 05:17:21.852127|2018-06-01 05:17:21.852127
NCT00068094|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-05|||2006-08-16|2003-09-08|2003-09-09|Estimate|||||||2006-08-16|2006-08-18|Estimate|July 2005||2005-07-31|August 2006|2006-08-31|February 2006||2006-02-28|||||Interventional|||The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics|The Effect of a Probiotic on Hepatic Steatosis|Terminated||Phase 1/Phase 2|30||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:17:38.15384|2018-06-01 05:17:38.15384
NCT00068861|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2007-09-28|2003-09-10|2003-09-11|Estimate|||||||2007-09-28|2007-10-01|Estimate|November 2002||2002-11-30|September 2005|2005-09-30|February 2006|Actual|2006-02-28|||||Interventional|||Treatment of Infertility in Women With Polycystic Ovary Syndrome|Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome|Completed||Phase 3|678||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||||||||||||||||2018-06-01 05:17:21.947531|2018-06-01 05:17:21.947531
NCT00068848|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2007-04-09|2003-09-10|2003-09-11|Estimate|||||||2007-04-09|2007-04-10|Estimate|February 2003||2003-02-28|April 2007|2007-04-30|March 2005||2005-03-31|||||Interventional|||Quick Start Approach to Birth Control Pills|RCT of a Novel Oral Contraceptive Initiation Method|Completed||Phase 4|2000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:22.060561|2018-06-01 05:17:22.060561
NCT00068835|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2005-06-23|2003-09-10|2003-09-11|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2000||2000-06-30|November 2004|2004-11-30|May 2005||2005-05-31|||||Interventional|||Using fMRI to Evaluate Instructional Programs for Children With Developmental Dyslexia|Remediation in Developmental Dyslexia|Unknown status|Active, not recruiting|N/A|160||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:22.156329|2018-06-01 05:17:22.156329
NCT00068822|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2012-08-07||2012-09-24|2003-09-10|2003-09-11|Estimate|2012-09-24|2012-09-27|Estimate||||2012-09-24|2012-09-27|Estimate|April 2003||2003-04-30|September 2012|2012-09-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Interventional|||Vertebroplasty for the Treatment of Fractures Due to Osteoporosis|Investigational Vertebroplasty Efficacy and Safety Trial (INVEST)|Completed||Phase 3|131|Actual|Mayo Clinic|The possible role of the placebo effect on outcomes remains unclear. Crossover at 1 month was allowed, which complicated the interpretation of between-group outcome differences. Other medical treatments received were not compared to study groups.|2|||f||||t||||||||||2018-06-01 05:17:22.244784|2018-06-01 05:17:22.244784
NCT00068809|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2017-02-27|2003-09-10|2003-09-11|Estimate|||||||2017-02-27|2017-03-01|Actual|July 2003||2003-07-31|February 2016|2016-02-29|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||4-Day-A-Week Treatment Plan for HIV Infected Adolescents|Short-Cycle Therapy in Adolescents Following Continuous Therapy With Established Viral Suppression: The Impact on Viral Load Suppression|Completed||Phase 4|31|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-06-01 05:17:22.809539|2018-06-01 05:17:22.809539
NCT00068783|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-02-27|2003-09-10|2003-09-11|Estimate|||||||2013-02-27|2013-02-28|Estimate|October 2003||2003-10-31|February 2013|2013-02-28||||June 2007|Actual|2007-06-30||Interventional|||S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer|A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:22.948652|2018-06-01 05:17:22.948652
NCT00068770|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2012-11-19||2015-03-17|2003-09-10|2003-09-11|Estimate|2015-03-17|2015-03-18|Estimate||||2015-03-17|2015-03-18|Estimate|October 2003||2003-10-31|March 2015|2015-03-31|May 2006|Actual|2006-05-31|May 2005|Actual|2005-05-31||Interventional|||Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT|A Pharmacokinetic Study of the Interaction Between Celecoxib and Anticonvulsant Drugs in Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Radiation Therapy|Terminated||Phase 2|35|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Study ended early when results from another study became available documenting Temozolomide (TMZ) and radiation improved survival, we felt it was unethical to continue this study, our study did not include TMZ.|2||EORTC trail showed TMZ & RT conferred significant survivial in this population|f||||t||||||||||2018-06-01 05:17:23.056751|2018-06-01 05:17:23.056751
NCT00068757|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2012-09-11|2003-09-10|2003-09-11|Estimate|||||||2012-09-11|2012-09-12|Estimate|August 2003||2003-08-31|September 2012|2012-09-30||||November 2007|Actual|2007-11-30||Interventional|||Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer|Phase I Study of Lonafarnib (SCH66336) in Combination With Herceptin Plus Paclitaxel in HER 2 NEU Overexpressing Breast Cancer|Completed||Phase 1|23|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:17:23.716994|2018-06-01 05:17:23.716994
NCT00068744|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2012-09-20|2003-09-10|2003-09-11|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 2003||2003-07-31|September 2012|2012-09-30||||November 2007|Actual|2007-11-30||Interventional|||Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer|Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study|Terminated||Phase 2/Phase 3|88|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:17:23.819725|2018-06-01 05:17:23.819725
NCT00068731|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2016-07-12|2003-09-10|2003-09-11|Estimate|||||||2016-07-12|2016-07-13|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|October 2009|Actual|2009-10-31|February 2007|Actual|2007-02-28||Interventional|||Lycopene in Treating Patients With Metastatic Prostate Cancer|A Phase II Trial Of Lycopene For Patients With Asymptomatic Androgen-Independent Metastatic Prostate Cancer With PSA Elevation|Completed||Phase 2|47|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:17:24.060925|2018-06-01 05:17:24.060925
NCT00068718|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2017-01-20||2017-03-10|2003-09-10|2003-09-11|Estimate|2017-01-20|2017-03-10|Actual||||2017-03-10|2017-04-10|Actual|May 2003||2003-05-31|March 2017|2017-03-31||||May 2013|Actual|2013-05-31||Interventional|||Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant|Donor Lymphocyte Infusion for the Treatment of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-center Trial|Active, not recruiting||Phase 1/Phase 2|35|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:17:24.330189|2018-06-01 05:17:24.330189
NCT00068692|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-02-26|2003-09-10|2003-09-11|Estimate|||||||2013-02-26|2013-02-27|Estimate|October 2003||2003-10-31|February 2013|2013-02-28||||January 2100|Anticipated|2100-01-31||Interventional|||Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery|Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil|Terminated||Phase 3|3000|Actual|National Cancer Institute (NCI)||6||Administratively complete.|f||||||||||||||2018-06-01 05:17:24.845462|2018-06-01 05:17:24.845462
NCT00068666|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2016-12-14|2003-09-10|2003-09-11|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2004||2004-01-31|December 2016|2016-12-31|March 2010|Actual|2010-03-31|March 2005|Actual|2005-03-31||Interventional|||Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System|A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System|Terminated||Phase 2|41|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:17:25.094609|2018-06-01 05:17:25.094609
NCT00068653|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-04-25|2003-09-10|2003-09-11|Estimate|||||||2013-04-25|2013-04-29|Estimate|June 2003||2003-06-30|April 2013|2013-04-30|May 2008|Actual|2008-05-31|October 2007|Actual|2007-10-31||Interventional|||Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer|Phase II Study of the Combination of ZD1839 (Iressa) and Celecoxib in Patients With Platinum Refractory Non-Small Cell Lung Cance|Completed||Phase 2|27|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 05:17:25.280443|2018-06-01 05:17:25.280443
NCT00068614|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2014-02-04|2003-09-10|2003-09-11|Estimate|||||||2014-02-04|2014-02-05|Estimate|July 2003||2003-07-31|February 2014|2014-02-28||||October 2005|Actual|2005-10-31||Interventional|||HER-2 Protein Vaccine in Treating Women With Breast Cancer|A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer|Completed||Phase 1|||Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:17:25.42081|2018-06-01 05:17:25.42081
NCT00068601|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2016-12-16||2017-02-15|2003-09-10|2003-09-11|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|October 2003||2003-10-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|January 2014|Actual|2014-01-31||Interventional||Patients who are both eligible and evaluable|S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer|Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer|Completed||Phase 3|257|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:17:25.529467|2018-06-01 05:17:25.529467
NCT00068588|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2014-09-25||2014-10-24|2003-09-10|2003-09-11|Estimate|2014-10-24|2014-10-31|Estimate||||2014-10-24|2014-10-31|Estimate|October 2003||2003-10-31|January 2013|2013-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer|A Phase 2 Study of GTI-2040 (NSC 722929) in Combination With Capecitabine in Metastatic Breast Cancer|Completed||Phase 2|24|Actual|National Cancer Institute (NCI)|In the first stage of the two stage Optimum design, following the dose escalation step, 3 of 15 patients responded for a response rate of 20%. A response rate of less than 25% would not warrant further study.|1|||f||||||||||||||2018-06-01 05:17:26.058077|2018-06-01 05:17:26.058077
NCT00068575|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2012-01-23||2012-02-13|2003-09-10|2003-09-11|Estimate|2012-01-23|2012-02-14|Estimate||||2012-02-13|2012-02-15|Estimate|May 2002||2002-05-31|February 2012|2012-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer|A Phase II Trial of Pancreaticoduodenectomy Plus Postoperative Cisplatin, Interferon Alfa-2b, and 5-FU Combined With Radiation Treatment for Patients With Resected Pancreatic Adenocarcinoma|Completed||Phase 2|29|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:17:26.526279|2018-06-01 05:17:26.526279
NCT00068549|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2014-12-23|2003-09-10|2003-09-11|Estimate|||||||2014-12-23|2014-12-25|Estimate|October 2003||2003-10-31|December 2014|2014-12-31||||January 2008|Actual|2008-01-31||Interventional|||Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer|A Phase I Study of Whole Pelvic Radiation Therapy With Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis|Completed||Phase 1|13|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:17:26.857753|2018-06-01 05:17:26.857753
NCT00068523|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2010-06-10|2003-09-10|2003-09-11|Estimate|||||||2010-06-10|2010-06-11|Estimate|June 2003||2003-06-30|June 2010|2010-06-30||||March 2004|Actual|2004-03-31||Interventional|||Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies|Immunomodulation by Ultraviolet B-Irradiation (UVB) to Facilitate Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies|Completed||N/A|10|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:17:27.070949|2018-06-01 05:17:27.070949
NCT00068510|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2015-09-30|2003-09-10|2003-09-11|Estimate|||||||2015-09-30|2015-10-02|Estimate|June 2003||2003-06-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Vaccine Therapy in Treating Patients With Malignant Glioma|Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas|Completed||Phase 1|28|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:17:27.294033|2018-06-01 05:17:27.294033
NCT00068497|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-01-11|2003-09-10|2003-09-11|Estimate|||||||2013-01-11|2013-01-14|Estimate|August 2003||2003-08-31|January 2013|2013-01-31||||December 2007|Actual|2007-12-31||Interventional|||Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer|Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger)|Completed||N/A|40|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:27.51566|2018-06-01 05:17:27.51566
NCT00068484|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-01-31|2003-09-10|2003-09-11|Estimate|||||||2013-01-31|2013-02-01|Estimate|July 2003||2003-07-31|January 2013|2013-01-31||||February 2006|Actual|2006-02-28||Interventional|||A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies|A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:27.770334|2018-06-01 05:17:27.770334
NCT00068471|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-06-18|2003-09-10|2003-09-11|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2003||2003-07-31|April 2004|2004-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Anidulafungin in Treating Immunocompromised Children With Neutropenia|Phase I-II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Neutropenia|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:27.987836|2018-06-01 05:17:27.987836
NCT00068458|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2017-12-15|2003-09-10|2003-09-11|Estimate|||||||2017-12-15|2017-12-19|Actual|September 2003||2003-09-30|April 2013|2013-04-30|January 2005|Actual|2005-01-31|January 2004|Actual|2004-01-31||Interventional|||Survival TRaining for ENhancing Total Health (STRENGTH)|A Phase II Randomized Study to Assess the Feasibility of Distance Medicine Based Exercise and Dietary Approaches to Prevent Body Composition Change Occurring During Adjuvant Chemotherapy for Early Stage Breast Cancer|Completed||Phase 2|39|Actual|Duke University||3|||f||||t||||||||||2018-06-01 05:17:28.130899|2018-06-01 05:17:28.130899
NCT00068445|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2018-02-06||2018-04-03|2003-09-10|2003-09-11|Estimate|2018-04-03|2018-05-04|Actual||||2018-04-03|2018-05-04|Actual|February 2004||2004-02-29|April 2018|2018-04-30|November 2013|Actual|2013-11-30|May 2006|Actual|2006-05-31||Interventional|||Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer|The Efficacy of Lamotrigine in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double Blind, Placebo-Controlled Trial|Completed||Phase 3|131|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:17:28.315265|2018-06-01 05:17:28.315265
NCT00068432|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2012-01-09|2003-09-10|2003-09-11|Estimate|||||||2012-01-09|2012-01-11|Estimate|December 2003||2003-12-31|January 2012|2012-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer|A Phase II Trial of Gemcitabine and Celecoxib as First-Line Treatment for Patients With Advanced Metastatic Pancreatic Cancer|Completed||Phase 2|28|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:17:29.22381|2018-06-01 05:17:29.22381
NCT00068419|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2013-10-07||2017-03-23|2003-09-10|2003-09-11|Estimate|2013-10-07|2013-12-04|Estimate||||2017-03-23|2017-04-21|Actual|February 2004||2004-02-29|March 2017|2017-03-31||||August 2010|Actual|2010-08-31||Interventional|||Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor|A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy|Active, not recruiting||Phase 2|70|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:17:29.361776|2018-06-01 05:17:29.361776
NCT00068406|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2017-09-15||2017-10-17|2003-09-10|2003-09-11|Estimate|2017-09-15|2017-10-17|Actual||||2017-10-17|2017-11-20|Actual|January 2005||2005-01-31|October 2011|2011-10-31|January 20, 2012|Actual|2012-01-20|December 2010|Actual|2010-12-31||Interventional||Eligible and treated patients|Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva|A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva|Completed||Phase 2|61|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:17:29.741948|2018-06-01 05:17:29.741948
NCT00068393|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2012-11-30||2013-01-04|2003-09-10|2003-09-11|Estimate|2012-12-03|2013-01-04|Estimate||||2013-01-04|2013-01-10|Estimate|December 2003||2003-12-31|January 2013|2013-01-31|May 2011|Actual|2011-05-31|June 2009|Actual|2009-06-30||Interventional|||Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma|Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma With Sarcomatoid Features|Completed||Phase 2|39|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:17:30.35258|2018-06-01 05:17:30.35258
NCT00068380|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2014-07-21||2018-03-27|2003-09-10|2003-09-11|Estimate|2014-07-21|2014-08-12|Estimate||||2018-03-27|2018-04-25|Actual|March 2004||2004-03-31|March 2018|2018-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer|A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer|Completed||Phase 2|17|Actual|National Cancer Institute (NCI)|In the first stage none of the 17 patients responded (CR/PR) to treatment. Due to budget constraints and recent reprioritizations, CTEP closed the study to accrual.|1|||f||||||||||||||2018-06-01 05:17:31.894768|2018-06-01 05:17:31.894768
NCT00068367|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2017-04-20||2017-10-03|2003-09-10|2003-09-11|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|December 2003||2003-12-31|October 2017|2017-10-31|August 2009|Actual|2009-08-31|July 2007|Actual|2007-07-31||Interventional|||S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor|U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II|Completed||Phase 2|24|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:17:32.389288|2018-06-01 05:17:32.389288
NCT00068341|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2016-02-11||2017-02-03|2003-09-10|2003-09-11|Estimate|2017-02-03|2017-03-27|Actual||||2017-02-03|2017-03-27|Actual|July 2003||2003-07-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer|Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer|Completed||Phase 2|74|Actual|Jonsson Comprehensive Cancer Center||3|||f||||t||||||||||2018-06-01 05:17:33.141774|2018-06-01 05:17:33.141774
NCT00068328|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2017-08-07|2003-09-10|2003-09-11|Estimate|||||||2017-08-07|2017-08-08|Actual|August 2003||2003-08-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2006|Actual|2006-12-31||Observational|||Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer|Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer|Completed|||1706|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 05:17:34.167714|2018-06-01 05:17:34.167714
NCT00068315|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-09-27|2003-09-10|2003-09-11|Estimate|||||||2013-09-27|2013-09-30|Estimate|July 2003||2003-07-31|September 2013|2013-09-30||||December 2008|Actual|2008-12-31||Interventional|||Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia|Completed||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:34.521357|2018-06-01 05:17:34.521357
NCT00068302|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2015-03-11|2003-09-10|2003-09-11|Estimate|||||||2015-03-11|2015-03-12|Estimate|January 2003||2003-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|April 2009|Actual|2009-04-30||Interventional|||Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma|A Phase I Trial Of Sirolimus In Relapsed/Refractory Leukemia And Non-Hodgkin's Lymphoma|Terminated||Phase 1|10|Actual|Children's Hospital of Philadelphia||1||Recruiting/enrolling participants halted prematurely but potentially will resume|f||||t||||||||||2018-06-01 05:17:34.674642|2018-06-01 05:17:34.674642
NCT00068289|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2013-06-21|2003-09-10|2003-09-11|Estimate|||||||2013-06-21|2013-06-24|Estimate|September 2003||2003-09-30|August 2004|2004-08-31|July 2007|Actual|2007-07-31|||||Interventional|||Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy|A Phase II Trial of PS-341 (NSC-681239) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:34.840037|2018-06-01 05:17:34.840037
NCT00068276|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2017-01-17|2003-09-10|2003-09-11|Estimate|||||||2017-01-17|2017-01-19|Estimate|July 2003||2003-07-31|June 2013|2013-06-30|September 2006|Actual|2006-09-30|June 2005|Actual|2005-06-30||Interventional|||Cholecalciferol in Treating Patients With Myelodysplastic Syndrome|Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial|Completed||Phase 2|||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:17:35.16198|2018-06-01 05:17:35.16198
NCT00068081|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-05|||2008-03-04|2003-09-08|2003-09-09|Estimate|||||||2008-03-04|2008-03-06|Estimate||||September 2007|2007-09-30||||||||Interventional|||Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|Completed||Phase 3|150||NeurogesX|||||||||||||||||||2018-06-01 05:17:38.247574|2018-06-01 05:17:38.247574
NCT00068263|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2016-12-30|2003-09-10|2003-09-11|Estimate|||||||2016-12-30|2017-01-04|Estimate|August 2003||2003-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2005|Actual|2005-06-30||Interventional|||3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection|A Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma|Completed||Phase 1/Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:17:35.355829|2018-06-01 05:17:35.355829
NCT00068250|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2017-12-14||2018-02-01|2003-09-10|2003-09-11|Estimate|2018-02-01|2018-02-07|Actual||||2018-02-01|2018-02-07|Actual|July 2003||2003-07-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||Eligible patients who started study treatment|Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma|Completed||Phase 1/Phase 2|60|Actual|Radiation Therapy Oncology Group|The 200 mg/m^2 treatment arm in the phase I component of the study did not open. Outcome measures are categorized as the phase I or phase II study component, but phase I patients at corresponding dose level are included in the phase II analyses.|4|||f||||t||||||||||2018-06-01 05:17:35.500354|2018-06-01 05:17:35.500354
NCT00068237|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|2013-10-29||2016-12-30|2003-09-10|2003-09-11|Estimate|2013-12-27|2014-01-31|Estimate||||2016-12-30|2017-02-17|Actual|August 2003||2003-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|January 2008|Actual|2008-01-31||Interventional||All eligible patients who started study treatment.|Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer|A Phase II Study Of Submandibular Salivary Gland Transfer To The Submental Space Prior To Start Of Radiation Treatment For Prevention Of Radiation-Induced Xerostomia In Head And Neck Cancer Patients|Completed||Phase 2|49|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:17:36.348027|2018-06-01 05:17:36.348027
NCT00068211|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-09|||2015-03-04|2003-09-10|2003-09-11|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2003||2003-08-31|March 2015|2015-03-31|January 2006|Actual|2006-01-31|||||Interventional|||Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma|A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma.|Completed||Phase 2|||Sanofi|||||||||||||||||||2018-06-01 05:17:36.785569|2018-06-01 05:17:36.785569
NCT00068224|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-10|||2018-03-27|2003-09-09|2003-09-10|Estimate|||||||2018-03-27|2018-03-29|Actual|September 8, 2003||2003-09-08|November 13, 2017|2017-11-13||||||||Observational|||Clinical and Molecular Investigations Into Ciliopathies|Clinical and Molecular Investigations Into Ciliopathies|Active, not recruiting|||326|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:36.92563|2018-06-01 05:17:36.92563
NCT00068198|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-09|||2010-08-26|2003-09-09|2003-09-10|Estimate|||||||2010-08-26|2010-08-27|Estimate||||May 2006|2006-05-31|November 2004||2004-11-30|||||Interventional|||Human Immune Responses Smallpox|Evaluation of Human Immune Response to Smallpox Vaccine (Vaccinia Virus)|Completed||Phase 1|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:17:37.070632|2018-06-01 05:17:37.070632
NCT00068185|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-09|||2009-12-09|2003-09-09|2003-09-10|Estimate|||||||2009-12-09|2009-12-11|Estimate|August 2003||2003-08-31|December 2009|2009-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Study of the Pharmacokinetics of Black Cohosh|Interactions Between SERMs, Soy and Black Cohosh|Terminated||Phase 1|12|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||||PI left institution, study did not continue, funding stopped|f||||t||||||||||2018-06-01 05:17:37.177835|2018-06-01 05:17:37.177835
NCT00068172|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-09|||2016-03-30|2003-09-09|2003-09-10|Estimate|||||||2016-03-30|2016-03-31|Estimate|July 2001||2001-07-31|March 2016|2016-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study of PI-88 in Patients With Advanced Melanoma|A Phase I/II Study of PI-88 in Advanced Malignancies (Phase I), and in Advanced Melanoma (Phase II)|Completed||Phase 1/Phase 2|88||Medigen Biotechnology Corporation|||||f||||||||||||||2018-06-01 05:17:37.299426|2018-06-01 05:17:37.299426
NCT00068133|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-08|||2005-06-23|2003-09-09|2003-09-10|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2003||2003-06-30|May 2005|2005-05-31|June 2005||2005-06-30|||||Interventional|||Trial of VLTS-589 in Subjects With Intermittent Claudication|A Phase II Multicenter, Double-Blind, Placebo-Controlled, Trial of VLTS-589 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease|Completed||Phase 2|100||Valentis|||||||||||||||||||2018-06-01 05:17:37.38723|2018-06-01 05:17:37.38723
NCT00025207|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-01-15|2003-09-09|2003-09-10|Estimate|||||||2013-01-15|2013-01-17|Estimate|September 2001||2001-09-30|January 2013|2013-01-31||||February 2006|Actual|2006-02-28||Interventional|||Gefitinib in Treating Patients With Malignant Mesothelioma|A Phase II Study Of ZD 1839 (NSC 715055, IND 61187) In Patients With Malignant Mesothelioma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:37.497409|2018-06-01 05:17:37.497409
NCT00021268|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-08-01|2003-09-09|2003-09-10|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2001||2001-04-30|October 2002|2002-10-31||||||||Interventional|||Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer|Phase I Study Of Tocladesine In Patients With Colorectal Carcinoma Following Therapy With 5-FU And Irinotecan|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:37.685533|2018-06-01 05:17:37.685533
NCT00020904|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2003-09-09|2003-09-10|Estimate|||||||2013-06-17|2013-06-18|Estimate|February 2001||2001-02-28|June 2013|2013-06-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||BMS-247550 in Treating Women With Metastatic Breast Cancer|A Phase II Study of Epothilone B Analog BMS-247550 in Patients With Taxane-Resistant Metastatic Breast Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:17:37.780863|2018-06-01 05:17:37.780863
NCT00068159|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-09|||2018-03-27|2003-09-08|2003-09-09|Estimate|||||||2018-03-27|2018-03-29|Actual|September 8, 2003||2003-09-08|February 1, 2018|2018-02-01||||||||Observational|||Cardiac Function in Patients With Hereditary Hemochromatosis|Characterization of Cardiac Function in Subjects With Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I|Active, not recruiting|||66|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:37.876029|2018-06-01 05:17:37.876029
NCT00068146|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-09|||2017-10-05|2003-09-08|2003-09-09|Estimate|||||||2017-10-05|2017-10-06|Actual|September 19, 2002||2002-09-19|November 26, 2012|2012-11-26|November 26, 2012||2012-11-26|||||Observational|||Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma|Study of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Evaluation of the Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-Associated Lymphoma|Completed|||77|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:37.986095|2018-06-01 05:17:37.986095
NCT00017043|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-04-03|2003-09-08|2003-09-09|Estimate|||||||2013-04-03|2013-04-05|Estimate|February 2001||2001-02-28|April 2013|2013-04-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy|A Phase II Study of Epothilone Analog BMS-247550 in Patients With Metastatic Gastric Adenocarcinoma Previously Treated With a Taxane|Completed||Phase 2|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:17:38.332217|2018-06-01 05:17:38.332217
NCT00016939|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-20|2003-09-08|2003-09-09|Estimate|||||||2013-06-20|2013-06-24|Estimate|May 2001||2001-05-31|January 2008|2008-01-31|April 2006|Actual|2006-04-30|||||Interventional|||Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer|A Phase II Study of Flavopiridol 1 Hour Bolus Days 1-3 Q 21 Days in Patients With Advanced Renal Cell Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:38.446052|2018-06-01 05:17:38.446052
NCT00016874|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-07-17|2003-09-08|2003-09-09|Estimate|||||||2013-07-17|2013-07-18|Estimate|December 2000||2000-12-31|December 2007|2007-12-31|January 2008|Actual|2008-01-31|||||Interventional|||3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer|A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:38.697696|2018-06-01 05:17:38.697696
NCT00016341|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-04-10|2003-09-08|2003-09-09|Estimate|||||||2013-04-10|2013-04-11|Estimate|May 2001||2001-05-31|June 2007|2007-06-30||||October 2003|Actual|2003-10-31||Interventional|||Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer|Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients With Stage III & IV or Recurrent Endometrial Cancer|Terminated||Phase 3|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:17:38.800449|2018-06-01 05:17:38.800449
NCT00068107|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-06|2015-03-12||2015-03-19|2003-09-05|2003-09-08|Estimate|2015-03-19|2015-03-31|Estimate||||2015-03-19|2015-03-31|Estimate|September 2003||2003-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Dosing Study of Replagal in Patients With Fabry Disease|Study of Weekly Dosing Regimens of Replagal in Patients With Fabry Disease With Incomplete Clinical Response to Long-Term Therapy|Completed||Phase 2|13|Actual|Baylor Research Institute|Small number of subjects. Single group with comparison to baseline data.|1|||f||||f||||||||||2018-06-01 05:17:39.019245|2018-06-01 05:17:39.019245
NCT00068068|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-04|||2006-09-18|2003-09-05|2003-09-08|Estimate|||||||2006-09-18|2006-09-19|Estimate|October 2003||2003-10-31|September 2006|2006-09-30||||||||Interventional|||Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases|Safety and Efficacy of Treating Refractory Cancers With the Litx™ System: Phase II Safety and Efficacy Study in Patients With Liver Metastases From Colorectal Cancer That Have Failed Chemotherapy|Completed||Phase 2|25||Light Sciences LLC|||||||||||||||||||2018-06-01 05:17:39.629091|2018-06-01 05:17:39.629091
NCT00068055|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-04|||2011-02-03|2003-09-05|2003-09-08|Estimate|||||||2011-02-03|2011-02-07|Estimate|September 2003||2003-09-30|July 2009|2009-07-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||IVIG - West Nile Encephalitis: Safety and Efficacy|A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (OMR-IGG-AM) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus (WNV) Encephalitis and/or Myelitis|Completed||Phase 1/Phase 2|62|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 05:17:39.825378|2018-06-01 05:17:39.825378
NCT00068042|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-04|||2008-04-03|2003-09-05|2003-09-08|Estimate|||||||2008-04-03|2008-04-07|Estimate|April 2003||2003-04-30|April 2008|2008-04-30|May 2006|Actual|2006-05-31|||||Interventional|||A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly|A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly|Completed||Phase 4|100||Pfizer|||||||||||||||||||2018-06-01 05:17:40.086328|2018-06-01 05:17:40.086328
NCT00067899|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-29|||2013-06-17|2003-09-05|2003-09-08|Estimate|||||||2013-06-17|2013-06-19|Estimate|September 2000||2000-09-30|June 2013|2013-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Oxidative Stress and Vitamin E Requirements|Oxidative Stress and Vitamin E Requirements|Completed||Phase 2|99||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||||2018-06-01 05:17:40.258554|2018-06-01 05:17:40.258554
NCT00068029|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-04|||2008-04-03|2003-09-04|2003-09-05|Estimate|||||||2008-04-03|2008-04-07|Estimate|October 2003||2003-10-31|April 2008|2008-04-30|May 2006|Actual|2006-05-31|||||Interventional|||Pegvisomant And Sandostatin LAR Combination Study|A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly|Completed||Phase 4|75||Pfizer|||||||||||||||||||2018-06-01 05:17:40.383617|2018-06-01 05:17:40.383617
NCT00067990|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-03|2017-03-13||2017-09-13|2003-09-04|2003-09-05|Estimate|2017-09-13|2017-09-18|Actual||||2017-09-13|2017-09-18|Actual|December 2002||2002-12-31|September 2017|2017-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Angiotensin II Blockade for Chronic Allograft Nephropathy|Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients|Completed||Phase 4|153|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No|There are no plans to share individual participant data.|2018-06-01 05:17:40.579857|2018-06-01 05:17:40.579857
NCT00067964|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-03|||2010-01-12|2003-09-04|2003-09-05|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31||||||||Interventional|||Diet and Physical Activity Interactions in Obesity||Completed||N/A|90||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:17:41.1296|2018-06-01 05:17:41.1296
NCT00067951|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-03|||2018-03-19|2003-09-04|2003-09-05|Estimate|||||||2018-03-19|2018-03-21|Actual|October 17, 2003||2003-10-17|March 2018|2018-03-31|November 30, 2004|Actual|2004-11-30|November 1, 2004|Actual|2004-11-01||Interventional|||A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics|An Open-label Trial to Evaluate the Safety and Efficacy of Fixed Dose Rosiglitazone/Metformin Combination Therapy in Poorly-controlled Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|190|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:17:41.227217|2018-06-01 05:17:41.227217
NCT00067938|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-03|||2016-08-31|2003-09-04|2003-09-05|Estimate|||||||2016-08-31|2016-09-01|Estimate|August 2003||2003-08-31|August 2016|2016-08-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bipolar Study in Adults at Least 18 Years of Age|Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.|Completed||Phase 4|1200|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:17:41.554768|2018-06-01 05:17:41.554768
NCT00067925|ClinicalTrials.gov processed this data on May 31, 2018|2003-09-03|||2010-10-18|2003-09-03|2003-09-04|Estimate|||||||2010-10-18|2010-10-19|Estimate|September 2000||2000-09-30|August 2003|2003-08-31|June 2002||2002-06-30|||||Interventional|||A School-Based Osteoporosis Prevention Program for Adolescent Girls|Incorporating More Physical Activity and Calcium in Teens (IMPACT): A School-Based Osteoporosis Prevention Program for Adolescent Girls|Completed||Phase 1|718||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:42.440483|2018-06-01 05:17:42.440483
NCT00016276|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-15|2003-09-03|2003-09-04|Estimate|||||||2013-01-15|2013-01-16|Estimate|May 2001||2001-05-31|January 2013|2013-01-31||||March 2005|Actual|2005-03-31||Interventional|||Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer|A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ STAGE IIIA, IIIB OR REGIONAL STAGE IV BREAST CANCER|Terminated||Phase 3|396|Actual|National Cancer Institute (NCI)||8||Administratively complete.|f||||||||||||||2018-06-01 05:17:42.587101|2018-06-01 05:17:42.587101
NCT00010036|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2011-03-25|2003-09-03|2003-09-04|Estimate|||||||2011-03-25|2011-03-28|Estimate|May 1999||1999-05-31|March 2011|2011-03-31||||October 2001|Actual|2001-10-31||Interventional|||Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme|A Phase I/II Trial of CPT-11 With Carboplatin in Patients With Glioblastoma Multiforme Prior to Radiation Therapy|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:17:42.791507|2018-06-01 05:17:42.791507
NCT00008359|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-01-17|2003-09-03|2003-09-04|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2000||2000-08-31|January 2013|2013-01-31||||March 2003|Actual|2003-03-31||Interventional|||Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment|A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia|Completed||Phase 3|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:17:42.881616|2018-06-01 05:17:42.881616
NCT00008086|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-12-18|2003-09-03|2003-09-04|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1996||1996-01-31|December 2013|2013-12-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carboplatin in Advanced Solid Tumors|Completed||Phase 1|||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:17:43.038342|2018-06-01 05:17:43.038342
NCT00006346|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-07-09|2003-09-03|2003-09-04|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 2000||2000-08-31|March 2010|2010-03-31|September 2003|Actual|2003-09-30|||||Interventional|||Stress Reduction in Older Women With Stage II, Stage III, or Stage IV Breast Cancer|Stress Reduction For Breast Cancer in Women 55 Years of Age or Older: Enhancing Quality of Life and Survival|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:43.13065|2018-06-01 05:17:43.13065
NCT00067912|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-29|||2007-05-17|2003-09-02|2003-09-03|Estimate|||||||2007-05-17|2007-05-21|Estimate|April 2003||2003-04-30|May 2007|2007-05-31|March 2004|Actual|2004-03-31|||||Interventional|||Duloxetine vs. Active Comparator for the Treatment of Depression|Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder|Completed||Phase 4|480||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:17:43.298247|2018-06-01 05:17:43.298247
NCT00006265|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2016-07-12|2003-09-02|2003-09-03|Estimate|||||||2016-07-12|2016-07-14|Estimate|March 2001||2001-03-31|July 2016|2016-07-31|May 2005|Actual|2005-05-31|December 2004|Actual|2004-12-31||Interventional|||Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Dose Escalation And Phase II Study Of Gemtuzumab Ozogamicin (CMA-676; Mylotarg) With High-Dose Cytarabine For Patients With Refractory Or Relapsed Acute Myeloid Leukemia (AML)|Completed||Phase 2|60|Actual|Alliance for Clinical Trials in Oncology||4|||f||||f||||||||||2018-06-01 05:17:43.420241|2018-06-01 05:17:43.420241
NCT00006254|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-07-17|2003-09-02|2003-09-03|Estimate|||||||2013-07-17|2013-07-18|Estimate|May 2000||2000-05-31|December 2007|2007-12-31|January 2008|Actual|2008-01-31|||||Interventional|||VNP20009 in Treating Patients With Advanced Solid Tumors|A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:43.755825|2018-06-01 05:17:43.755825
NCT00006223|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-06-20|2003-09-02|2003-09-03|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 2000||2000-07-31|September 2006|2006-09-30|January 2007|Actual|2007-01-31|||||Interventional|||flt3L in Treating Patients With Acute Myeloid Leukemia|A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:43.848515|2018-06-01 05:17:43.848515
NCT00006103|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2016-07-01|2003-09-02|2003-09-03|Estimate|||||||2016-07-01|2016-07-06|Estimate|July 2000||2000-07-31|July 2016|2016-07-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Colorectal Cancer|Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11|Completed||Phase 3|400|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:17:43.986227|2018-06-01 05:17:43.986227
NCT00006096|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-06-07|2003-09-02|2003-09-03|Estimate|||||||2013-06-07|2013-06-10|Estimate|March 2001||2001-03-31|June 2007|2007-06-30||||January 2003|Actual|2003-01-31||Interventional|||Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva|A Randomized Study of Adjuvant Radiation Treatment Versus Radiation and Chemotherapy in Patients With Vulvar Cancer and Involved Nodes|Terminated||Phase 3|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:17:44.09053|2018-06-01 05:17:44.09053
NCT00067886|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-29|||2016-04-12|2003-08-29|2003-09-01|Estimate|||||||2016-04-12|2016-04-13|Estimate|March 2003||2003-03-31|April 2016|2016-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Matrix Metalloproteinases and Diabetic Nephropathy|Matrix Metalloproteinases and Diabetic Nephropathy|Completed|||330|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-06-01 05:17:45.202483|2018-06-01 05:17:45.202483
NCT00067873|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-29|||2017-11-16|2003-08-29|2003-09-01|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2000|Actual|2000-12-31|October 2017|2017-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Exercise Training in Obesity-prone Black and White Women|Exercise Training in Obesity-prone Black and White Women|Completed||N/A|231|Actual|University of Alabama at Birmingham||3|||f||||t|f|f||||||||2018-06-01 05:17:45.290318|2018-06-01 05:17:45.290318
NCT00067860|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-29|||2016-05-12|2003-08-29|2003-09-01|Estimate|||||||2016-05-12|2016-05-16|Estimate|October 1996||1996-10-31|May 2016|2016-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Diet/Growth Factor Mechanisms of Gut Adaptation|Diet/Growth Factor Mechanisms of Gut Adaptation|Completed||Phase 2|27|Actual|Emory University|||||||||||||||||||2018-06-01 05:17:45.398148|2018-06-01 05:17:45.398148
NCT00067834|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-28|||2015-12-22|2003-08-29|2003-09-01|Estimate|||||||2015-12-22|2015-12-23|Estimate|November 2003||2003-11-30|December 2015|2015-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Electromagnetic Treatment For Bone Loss After Forearm Fracture|Feasibility and Dosing Study of Bone Density Changes With and Without PEMF Following Immobilization of the Forearm|Completed||Phase 1/Phase 2|80||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:17:45.622745|2018-06-01 05:17:45.622745
NCT00006019|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-20|2003-08-28|2003-08-29|Estimate|||||||2013-06-20|2013-06-24|Estimate|May 2000||2000-05-31|October 2002|2002-10-31|August 2003|Actual|2003-08-31|||||Interventional|||Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer|Pilot Study of Sodium Phenylbutyrate Plus Azacytidine|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:45.77072|2018-06-01 05:17:45.77072
NCT00006002|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-09-04|2003-08-28|2003-08-29|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2000||2000-06-30|September 2013|2013-09-30|January 2006|Actual|2006-01-31|September 2002|Actual|2002-09-30||Interventional|||SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of SU5416 (NSC# 686819) in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|36|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 05:17:45.91998|2018-06-01 05:17:45.91998
NCT00005887|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-05-08|2003-08-28|2003-08-29|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2000||2000-02-29|May 2013|2013-05-31||||||||Interventional|||Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases|A Phase III, Randomized, Open-Label, Comparative Study of Standard Whole Brain Radiation Therapy With or Without RSR13 in Patients With Brain Metastases|Completed||Phase 3|||Spectrum Pharmaceuticals, Inc|||||f||||||||||||||2018-06-01 05:17:46.20758|2018-06-01 05:17:46.20758
NCT00005886|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2017-01-12|2003-08-28|2003-08-29|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2000||2000-07-31|January 2017|2017-01-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer|A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer|Completed||Phase 1|||University of Kansas Medical Center|||||f||||||||||||||2018-06-01 05:17:46.479792|2018-06-01 05:17:46.479792
NCT00005857|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2011-10-18|2003-08-28|2003-08-29|Estimate|||||||2011-10-18|2011-10-20|Estimate|August 2000||2000-08-31|October 2011|2011-10-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy|Randomized Phase II Trial of Herceptin (NSC 688097) and Weekly Docetaxel (NSC 628503) in Androgen-Independent (Horomone Refractory) Adenocarcinoma of the Prostate (CaP)|Completed||Phase 2|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:17:46.656215|2018-06-01 05:17:46.656215
NCT00005845|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-13|2003-08-28|2003-08-29|Estimate|||||||2013-12-13|2013-12-16|Estimate|June 2002||2002-06-30|December 2013|2013-12-31||||September 2009|Actual|2009-09-30||Interventional|||Tipifarnib in Treating Patients With Myelodysplastic Syndromes|Phase I Study of the Farnesyl Transferase Inhibitor R115777 (NSC #702818) in Patients With Myelodysplastic Syndrome|Completed||Phase 1|65|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:46.84332|2018-06-01 05:17:46.84332
NCT00067821|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-28|||2018-05-22|2003-08-27|2003-08-28|Estimate|||||||2018-05-22|2018-05-23|Actual|August 27, 2003||2003-08-27|May 4, 2018|2018-05-04||||||||Observational|||Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity|A Comparative Study of Pediatric CNS Tumor Activity as Assessed by [18]F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging ([1]H-MRSI)|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:46.980182|2018-06-01 05:17:46.980182
NCT00067808|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-27|2009-09-25||2012-08-01|2003-08-27|2003-08-28|Estimate|2011-04-28|2011-05-26|Estimate||||2012-08-01|2012-08-07|Estimate|October 2003||2003-10-31|August 2012|2012-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)|Phase II Randomized Study of Three Different Schedules of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) in Myelodysplastic Syndrome (MDS)|Completed||Phase 2|128|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:17:47.116229|2018-06-01 05:17:47.116229
NCT00067795|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-27|||2010-11-19|2003-08-27|2003-08-28|Estimate|||||||2010-11-19|2010-11-22|Estimate||||November 2010|2010-11-30||||||||Observational|||Evaluating Immune Function Tests in People With HIV|"HIV Antigen-Specific Immune Responses - A Comparison of Alternative In Vitro Assays From Subjects Characterized as Either Stable HAART or Efficient Immune Control"|Completed|||54||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:17:47.686964|2018-06-01 05:17:47.686964
NCT00067782|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-27||2010-01-28|2011-04-07|2003-08-27|2003-08-28|Estimate||||2010-01-28|2010-02-01|Estimate|2011-04-07|2011-04-14|Estimate|December 2002||2002-12-31|January 2010|2010-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy||Completed||Phase 3|||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 05:17:47.781599|2018-06-01 05:17:47.781599
NCT00067769|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-27|||2015-12-04|2003-08-27|2003-08-28|Estimate|||||||2015-12-04|2015-12-07|Estimate|October 2003||2003-10-31|June 2014|2014-06-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Internet-based Treatment of Early Childhood Fecal Incontinence|Treatment of Early Childhood Constipation/Encopresis|Completed||N/A|91|Actual|University of Virginia||2|||f||||f||||||||||2018-06-01 05:17:48.048623|2018-06-01 05:17:48.048623
NCT00005804|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-03-31|2003-08-27|2003-08-28|Estimate|||||||2010-03-31|2010-04-02|Estimate|October 1999||1999-10-31|March 2010|2010-03-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:17:48.225191|2018-06-01 05:17:48.225191
NCT00005090|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-01-22|2003-08-27|2003-08-28|Estimate|||||||2013-01-22|2013-01-24|Estimate|April 2000||2000-04-30|January 2013|2013-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease|A Randomized Phase III Trial Comparing Early High Dose Chemotherapy and an Autologous Stem Cell Transplant to Conventional Dose ABVD Chemotherapy for Patients With Advanced Stage Poor Prognosis Hodgkin's Disease as Defined by the International Prognostic Factors Project on Advanced Hodgkin's Disease|Terminated||Phase 3|11|Actual|Southwest Oncology Group||2||poor accrual|f||||t||||||||||2018-06-01 05:17:48.389436|2018-06-01 05:17:48.389436
NCT00062673|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-10|||2007-05-17|2003-06-11|2003-06-12|Estimate|||||||2007-05-17|2007-05-21|Estimate|March 2003||2003-03-31|May 2007|2007-05-31|July 2004|Actual|2004-07-31|||||Interventional|||Study of Duloxetine in Elderly Patients With Major Depressive Disorder|Duloxetine Versus Placebo in the Treatment of Elderly Patients With Major Depressive Disorder|Completed||Phase 3|311||Eli Lilly and Company|||||f||||f||||||||||2018-06-01 05:19:29.326432|2018-06-01 05:19:29.326432
NCT00067756|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-26|||2014-01-02|2003-08-26|2003-08-27|Estimate|||||||2014-01-02|2014-01-03|Estimate|November 2001||2001-11-30|April 2013|2013-04-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?|"4 Phenyl Butyrate Mediated Secretion Rescue in Alpha 1-Antitrypsin Deficient Individuals"|Completed||Phase 2|12|Actual|University of Florida||1|||f||||t||||||||||2018-06-01 05:17:48.602641|2018-06-01 05:17:48.602641
NCT00067743|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-26|||2007-12-28|2003-08-26|2003-08-27|Estimate|||||||2007-12-28|2008-01-03|Estimate|August 2003||2003-08-31|December 2006|2006-12-31|August 2007|Actual|2007-08-31|October 2004|Actual|2004-10-31||Interventional|CRPS||A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)|A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)|Completed||Phase 2|40|Actual|Celgene||1|||f||||t||||||||||2018-06-01 05:17:48.729846|2018-06-01 05:17:48.729846
NCT00067730|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2007-12-03|2003-08-26|2003-08-27|Estimate|||||||2007-12-03|2007-12-07|Estimate|March 2003||2003-03-31|December 2007|2007-12-31|October 2003|Actual|2003-10-31|||||Interventional|||A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation|A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis|Completed||Phase 4|7|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-06-01 05:17:48.834509|2018-06-01 05:17:48.834509
NCT00067717|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2014-10-17|2003-08-26|2003-08-27|Estimate|||||||2014-10-17|2014-10-20|Estimate|November 2003||2003-11-30|October 2014|2014-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Distance Healing in Wound Healing|Placebo Effects in Distance Healing of Wounds|Completed||Phase 1/Phase 2|72|Actual|California Pacific Medical Center Research Institute||3|||f||||t||||||||||2018-06-01 05:17:48.930915|2018-06-01 05:17:48.930915
NCT00067704|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2015-10-09|2003-08-26|2003-08-27|Estimate|||||||2015-10-09|2015-10-14|Estimate|February 2004||2004-02-29|October 2015|2015-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Emotional Disclosure in HIV|Efficacy of an Emotional Disclosure Intervention in HIV|Completed||N/A|283|Actual|University of Miami||2|||f||||f||||||||||2018-06-01 05:17:49.039903|2018-06-01 05:17:49.039903
NCT00067691|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2006-08-16|2003-08-26|2003-08-27|Estimate|||||||2006-08-16|2006-08-18|Estimate|November 2001||2001-11-30|August 2006|2006-08-31|November 2003||2003-11-30|||||Interventional|||Acupuncture for Shortness of Breath in Cancer Patients|Acupuncture for Shortness of Breath in Cancer Patients|Completed||N/A|40||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:17:49.163537|2018-06-01 05:17:49.163537
NCT00067678|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2006-08-16|2003-08-26|2003-08-27|Estimate|||||||2006-08-16|2006-08-18|Estimate|July 2001||2001-07-31|August 2006|2006-08-31|June 2003||2003-06-30|||||Interventional|||Soy Protein in Early Diabetic Nephropathy|Soy Protein in Early Diabetic Nephropathy|Completed||Phase 1/Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:17:49.236414|2018-06-01 05:17:49.236414
NCT00067665|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2011-03-25|2003-08-26|2003-08-27|Estimate|||||||2011-03-25|2011-03-28|Estimate|August 2003||2003-08-31|January 2011|2011-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Hypertension in Hemodialysis|Hypertension in Hemodialysis|Completed||N/A|150|Anticipated|Indiana University||2|||f||||f||||||||||2018-06-01 05:17:49.30259|2018-06-01 05:17:49.30259
NCT00067652|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2010-01-12|2003-08-26|2003-08-27|Estimate|||||||2010-01-12|2010-01-14|Estimate|April 2003||2003-04-30|January 2010|2010-01-31|November 2003||2003-11-30|||||Interventional|||Improving Body Image in Middle Schoolers||Completed||Phase 1|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:17:49.372557|2018-06-01 05:17:49.372557
NCT00067639|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2012-07-31|2003-08-25|2003-08-26|Estimate|||||||2012-07-31|2012-08-01|Estimate|December 2003||2003-12-31|July 2012|2012-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma|Pegfilgrastim (Neulasta) for Mobilization of Peripheral Blood Progenitor Cells (PBPC) in Patients With Multiple Myeloma|Completed||Phase 2|50|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:17:49.483762|2018-06-01 05:17:49.483762
NCT00067626|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2010-10-14|2003-08-25|2003-08-26|Estimate|||||||2010-10-14|2010-10-15|Estimate|April 2005||2005-04-30|October 2010|2010-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes|Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes|Completed||Phase 2|60|Anticipated|Griffin Hospital||2|||f||||t||||||||||2018-06-01 05:17:49.575369|2018-06-01 05:17:49.575369
NCT00067613|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2015-06-03|2003-08-25|2003-08-26|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2001||2001-03-31|June 2015|2015-06-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|Benchmarking||Benchmarking Initiative to Reduce Bronchopulmonary Dysplasia|Randomized Controlled Trial of Benchmarking to Reduce Bronchopulmonary Dysplasia to Reduce Bronchopulmonary Dysplasia|Completed||N/A|4095|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 05:17:49.697104|2018-06-01 05:17:49.697104
NCT00067600|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2014-10-28|2003-08-25|2003-08-26|Estimate|||||||2014-10-28|2014-10-29|Estimate|August 2000||2000-08-31|October 2014|2014-10-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study|Lifestyle Changes to Increase Bone Density in Teen Girls|Completed||Phase 1|228||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:49.817936|2018-06-01 05:17:49.817936
NCT00067587|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2017-02-27|2003-08-25|2003-08-26|Estimate|||||||2017-02-27|2017-03-01|Actual|July 2003||2003-07-31|February 2016|2016-02-29|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Observational|||Metabolic Abnormalities in HIV Infected and Uninfected Young Women|Prevalence of Morphologic and Metabolic Abnormalities in HIV Infected and Uninfected Young Women|Completed|||300|Actual|University of North Carolina, Chapel Hill|||5||f||||t||||||||||2018-06-01 05:17:49.913248|2018-06-01 05:17:49.913248
NCT00067574|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-25|||2017-03-02|2003-08-25|2003-08-26|Estimate|||||||2017-03-02|2017-03-06|Actual|July 2003||2003-07-31|July 2016|2016-07-31||||||||Interventional|||Treatment Plan to Decrease Drug Exposure in HIV Infected Adolescents|Structured Treatment Interruption as an Autovaccination Approach to Enhance Immune Based HIV-1 Control in an Adolescent/Young Adult Population|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||||"The study was never opened for enrollment; concept became irrelevant as other study results~   became available."|f||||||||||||||2018-06-01 05:17:50.129613|2018-06-01 05:17:50.129613
NCT00067561|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-21|||2015-04-15|2003-08-22|2003-08-25|Estimate|||||||2015-04-15|2015-04-16|Estimate|June 2003||2003-06-30|April 2015|2015-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy|A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects With Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy|Completed||Phase 3|702|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:17:50.2631|2018-06-01 05:17:50.2631
NCT00067548|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-21|||2009-08-20|2003-08-22|2003-08-25|Estimate|||||||2009-08-20|2009-08-21|Estimate||||August 2009|2009-08-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of EKB-569 in Subjects With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|44|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:17:50.581483|2018-06-01 05:17:50.581483
NCT00067535|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-21|||2017-01-11|2003-08-22|2003-08-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2003||2003-06-30|February 2009|2009-02-28|June 2005|Actual|2005-06-30|January 2005|Actual|2005-01-31||Interventional|||Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1|Potential Interactions Between IV Cocaine and RPR 102681|Completed||Phase 1|16|Actual|National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:17:50.693615|2018-06-01 05:17:50.693615
NCT00067522|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-21|||2007-06-28|2003-08-22|2003-08-25|Estimate|||||||2007-06-28|2007-06-29|Estimate|January 2002||2002-01-31|September 2005|2005-09-30||||||||Interventional|||Preventing Unplanned Pregnancies in HIV Infected Zambian Couples|Family Planning Promotion to Prevent Unplanned Pregnancies in HIV Infected Zambian Couples|Unknown status|Active, not recruiting|N/A|5000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:50.782384|2018-06-01 05:17:50.782384
NCT00067509|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-21|||2005-06-23|2003-08-22|2003-08-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2001||2001-06-30|July 2003|2003-07-31|May 2004||2004-05-31|||||Interventional|||Emergency Contraception (ECP): Reducing Unintended Pregnancies|A Second Chance With Emergency Contraception (ECP): Reducing Unintended Pregnancy|Completed||Phase 4|1100||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:17:50.911751|2018-06-01 05:17:50.911751
NCT00067470|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-20|2009-02-04||2009-12-18|2003-08-22|2003-08-25|Estimate|2009-07-06|2009-08-17|Estimate||||2009-12-18|2009-12-24|Estimate|September 2003||2003-09-30|December 2009|2009-12-31|March 2004||2004-03-31|||||Interventional|||Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI||Completed||Phase 3|39|Actual|BioMarin Pharmaceutical||2|||||||||||||||||2018-06-01 05:17:51.055127|2018-06-01 05:17:51.055127
NCT00004256|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-11-05|2003-08-22|2003-08-25|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 1997||1997-10-31|August 2006|2006-08-31|July 2006|Actual|2006-07-31|||||Interventional|||Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer|Randomised Phase II Study of GM-CSF to Reduce Severity of Mucositis Caused by Accelerated Radiotherapy of Laryngeal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:51.764945|2018-06-01 05:17:51.764945
NCT00004233|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2011-07-21|2003-08-22|2003-08-25|Estimate|||||||2011-07-21|2011-07-25|Estimate|February 2001||2001-02-28|May 2010|2010-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach|A Phase II Study of PN-401, 5-FU and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach|Completed||Phase 2|65|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:17:51.840445|2018-06-01 05:17:51.840445
NCT00004221|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2017-08-08|2003-08-22|2003-08-25|Estimate|||||||2017-08-08|2017-08-09|Actual|November 1999||1999-11-30|August 2017|2017-08-31||||February 6, 2002|Actual|2002-02-06||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer|A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma|Terminated||Phase 2|12|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:17:52.138923|2018-06-01 05:17:52.138923
NCT00004125|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2010-01-28|2003-08-22|2003-08-25|Estimate|||||||2010-01-28|2010-01-29|Estimate|October 1999||1999-10-31|January 2010|2010-01-31||||May 2007|Actual|2007-05-31||Interventional|||Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes|A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer|Completed||Phase 3|||Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:17:52.309971|2018-06-01 05:17:52.309971
NCT00004032|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-01-22|2003-08-22|2003-08-25|Estimate|||||||2013-01-22|2013-01-23|Estimate|October 1997||1997-10-31|January 2013|2013-01-31||||April 2004|Actual|2004-04-30||Interventional|||Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer|Intraperitoneal (IP) Autologous Therapeutic Tumor Vaccine AUT-OV-ALVAC-h.B7.1 Plus IP rIFN-gamma for Patients With Ovarian Cancer. A Pilot Study|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:52.549008|2018-06-01 05:17:52.549008
NCT00067496|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-20|||2008-08-26|2003-08-20|2003-08-21|Estimate|||||||2008-08-26|2008-08-27|Estimate|August 2003||2003-08-31|May 2005|2005-05-31|August 2006||2006-08-31|||||Interventional|||Modafinil to Treat Fatigue in Post-Polio Syndrome|Modafinil in the Treatment of Fatigue in Post-Polio Syndrome|Terminated||Phase 3|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:52.716561|2018-06-01 05:17:52.716561
NCT00067483|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-20|||2017-06-30|2003-08-20|2003-08-21|Estimate|||||||2017-06-30|2017-07-02|Actual|August 15, 2003||2003-08-15|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Pilot Study: Dynamic Light Scattering Device for Studying Early Changes in Cataract|Pilot Study on the Use of the NASA-NEI Dynamic Light Scattering (DLS) Device in Detecting Lens Changes in the Other Eye of Patients With Pre-Senile Cataracts|Completed|||15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:52.802389|2018-06-01 05:17:52.802389
NCT00067457|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-20|||2015-04-15|2003-08-20|2003-08-21|Estimate|||||||2015-04-15|2015-04-16|Estimate|June 2003||2003-06-30|April 2015|2015-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy|A 12-Week, Randomized, Double-Blind, Placebo- Controlled Study of PRN BID and Fixed Dosing Regimens of Alosetron in Female Subjects With Severe Diarrhea-Predominant Irritable Bowel Syndrome Who Have Failed Conventional Therapy|Completed||Phase 3|700|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:17:52.934269|2018-06-01 05:17:52.934269
NCT00067444|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-19|||2016-08-30|2003-08-20|2003-08-21|Estimate|||||||2016-08-30|2016-09-01|Estimate|June 2003||2003-06-30|August 2016|2016-08-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Depression Study In Elderly Patients|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed With Major Depressive Disorder|Completed||Phase 3|560|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:17:53.277316|2018-06-01 05:17:53.277316
NCT00067431|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-19|||2006-08-02|2003-08-19|2003-08-20|Estimate|||||||2006-08-02|2006-08-04|Estimate|July 2003||2003-07-31|August 2006|2006-08-31||||||||Interventional|||A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children|A Study of the Safety and Efficacy of Depakote Sprinkle Capsules in the Treatment of Partial Seizures in Children|Terminated||Phase 3|300||Abbott|||||||||||||||||||2018-06-01 05:17:53.554805|2018-06-01 05:17:53.554805
NCT00067405|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-18|||2008-04-21|2003-08-19|2003-08-20|Estimate|||||||2008-04-21|2008-04-22|Estimate|June 2004||2004-06-30|April 2008|2008-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia|Intravenous Micronutrient Therapy (IVMT) for Fibromyalgia|Completed||Phase 1/Phase 2|40||National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:17:53.645349|2018-06-01 05:17:53.645349
NCT00067392|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-15|||2010-11-08|2003-08-19|2003-08-20|Estimate|||||||2010-11-08|2010-11-09|Estimate|November 2003||2003-11-30|July 2008|2008-07-31|May 2009|Anticipated|2009-05-31|April 2008|Anticipated|2008-04-30||Interventional|||Evaluation of Implants Placed Immediately or Delayed Into Extraction Sites|Prospective Evaluation of Immediate Temporized Implants|Unknown status|Active, not recruiting|Phase 3|90|Anticipated|Louisiana State University Health Sciences Center in New Orleans|||||f||||||||||||||2018-06-01 05:17:53.712153|2018-06-01 05:17:53.712153
NCT00067340|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-15|||2015-05-29|2003-08-19|2003-08-20|Estimate|||||||2015-05-29|2015-06-02|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Caries Transmission Prevention in Alaska Native Infants|Northwest Alaska Center to Reduce Oral Health Disparity Project 2: Caries Transmission Prevention in Alaska Native Infants|Terminated||Phase 3|250|Anticipated|University of Washington||2||Unable to recruit sufficient number of subjects|f||||t||||||||||2018-06-01 05:17:53.787807|2018-06-01 05:17:53.787807
NCT00004004|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2003-08-19|2003-08-20|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 1999||1999-07-31|May 2007|2007-05-31|August 2003|Actual|2003-08-31|||||Interventional|||Procarbazine in Treating Patients With Recurrent Brain Tumor|A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:53.909216|2018-06-01 05:17:53.909216
NCT00003931|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-08-19|2003-08-20|Estimate|||||||2016-07-01|2016-07-04|Estimate|February 1999||1999-02-28|July 2016|2016-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Diagnostic Study of Gene Alterations in Patients With Acute Myeloid Leukemia|Assessment of the Partial Tandem Duplication of ALL1 (MLL) in Patients With Acute Myeloid Leukemia- A CALGB Leukemia Tissue Bank Project|Completed|||9769|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     blood or bone marrow samples~   "|||2018-06-01 05:17:54.12054|2018-06-01 05:17:54.12054
NCT00003890|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-11-07|2003-08-19|2003-08-20|Estimate|||||||2010-11-07|2010-11-09|Estimate|February 1999||1999-02-28|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||MG98 in Treating Patients With Advanced Solid Tumors|A Phase I Study of MG98 Given as a 2 Hour Twice Weekly IV Infusion in Patients With Advanced Cancer|Completed||Phase 1|20|Anticipated|Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:17:54.392057|2018-06-01 05:17:54.392057
NCT00003736|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-08-19|2003-08-20|Estimate|||||||2009-02-06|2009-02-09|Estimate|June 1999||1999-06-30|June 2007|2007-06-30||||||||Interventional|||MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer|Pilot Study: High Risk Breast Cancer Screening Pilot Study|Unknown status|Active, not recruiting|N/A|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:54.55502|2018-06-01 05:17:54.55502
NCT00003464|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2003-08-19|2003-08-20|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 1997||1997-09-30|October 2009|2009-10-31|August 2003|Actual|2003-08-31|||||Interventional|||Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme|Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal|Completed||Phase 2|50|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:17:54.68786|2018-06-01 05:17:54.68786
NCT00067418|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-18|||2008-03-03|2003-08-18|2003-08-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2003||2003-08-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Light Scattering Spectroscopy to Determine Brain Tumors|Spectroscopic Determination of Brain Tumor Cells|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:54.81264|2018-06-01 05:17:54.81264
NCT00067379|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-15|||2010-06-09|2003-08-18|2003-08-19|Estimate|||||||2010-06-09|2010-06-10|Estimate|April 2003||2003-04-30|June 2010|2010-06-30|June 2009|Anticipated|2009-06-30|June 2009|Anticipated|2009-06-30||Interventional|||Early Orthodontic Intervention Under Medicaid|Early Orthodontic Intervention Under Medicaid|Unknown status|Active, not recruiting|Phase 1|150|Anticipated|University of Washington||1|||f||||t||||||||||2018-06-01 05:17:54.881978|2018-06-01 05:17:54.881978
NCT00067366|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-15|||2017-07-27|2003-08-18|2003-08-19|Estimate|||||||2017-07-27|2017-08-01|Actual|October 2003||2003-10-31|July 2017|2017-07-31|September 2011|Actual|2011-09-30|October 2008|Actual|2008-10-31||Interventional|||Brief Treatment for Temporomandibular Pain|Brief Focused Treatment for TMD: Mechanisms of Action|Completed||N/A|116|Actual|UConn Health||2|||f||||||||||||||2018-06-01 05:17:55.007526|2018-06-01 05:17:55.007526
NCT00067353|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-15|||2010-05-06|2003-08-18|2003-08-19|Estimate|||||||2010-05-06|2010-05-10|Estimate|November 2003||2003-11-30|May 2010|2010-05-31|August 2005|Actual|2005-08-31|July 2005|Actual|2005-07-31||Interventional|||Yakima Head Start Fluoride Varnish Study|Fluoride Varnish Trial in High Caries Preschoolers|Completed||Phase 3|500||University of Washington|||||f||||t||||||||||2018-06-01 05:17:55.205631|2018-06-01 05:17:55.205631
NCT00067327|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-15|||2006-03-16|2003-08-18|2003-08-19|Estimate|||||||2006-03-16|2006-03-17|Estimate|February 2002||2002-02-28|March 2006|2006-03-31|September 2005||2005-09-30|||||Interventional|||Treatment of Multiple Sclerosis Using Over the Counter Inosine|Treatment of Multiple Sclerosis Using Over the Counter Inosine|Completed||Phase 2|30||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:17:55.398163|2018-06-01 05:17:55.398163
NCT00067314|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-15|||2012-01-13|2003-08-15|2003-08-18|Estimate|||||||2012-01-13|2012-01-18|Estimate|June 2003||2003-06-30|January 2012|2012-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy|A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer|Completed||Phase 2|65||Pfizer|||||f||||||||||||||2018-06-01 05:17:55.513626|2018-06-01 05:17:55.513626
NCT00067301|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-14|||2008-01-23|2003-08-14|2003-08-15|Estimate|||||||2008-01-23|2008-01-25|Estimate|September 2003||2003-09-30|January 2008|2008-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||PUFA Augmentation in Treatment of Major Depression|PUFA Augmentation in Treatment of Major Depression|Completed||Phase 3|60||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:17:55.668949|2018-06-01 05:17:55.668949
NCT00067288|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-14|||2006-08-16|2003-08-14|2003-08-15|Estimate|||||||2006-08-16|2006-08-18|Estimate|May 2002||2002-05-31|August 2006|2006-08-31|March 2006||2006-03-31|||||Interventional|||Meaning-Centered Psychotherapy in Advanced Cancer|Meaning-Centered Psychotherapy in Advanced Cancer|Completed||Phase 2|118||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:17:55.735412|2018-06-01 05:17:55.735412
NCT00067262|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-13|||2006-08-02|2003-08-14|2003-08-15|Estimate|||||||2006-08-02|2006-08-04|Estimate|March 2003||2003-03-31|August 2006|2006-08-31||||||||Interventional|||An Outpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder in Children and Adolescents|A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Depakote ER for the Treatment of Bipolar Disorder in Children and Adolescents|Completed||Phase 3|150||Abbott|||||||||||||||||||2018-06-01 05:17:55.832835|2018-06-01 05:17:55.832835
NCT00067249|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-13|||2007-02-26|2003-08-14|2003-08-15|Estimate|||||||2007-02-26|2007-02-27|Estimate|April 2001||2001-04-30|February 2007|2007-02-28|September 2001||2001-09-30|||||Observational|||Women's Use of Alternative Medicine: A Multiethnic Study||Completed|||3200||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:17:55.977546|2018-06-01 05:17:55.977546
NCT00067275|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-13|||2017-06-30|2003-08-13|2003-08-14|Estimate|||||||2017-06-30|2017-07-02|Actual|August 8, 2003||2003-08-08|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Observational|||The Effect of Dopamine on Motor Skills Training|Dopamine Release in Use-Dependent Plasticity in Health and Disease|Completed|||98||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:56.055557|2018-06-01 05:17:56.055557
NCT00067236|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-13|2011-08-03||2011-09-27|2003-08-13|2003-08-14|Estimate|2011-09-27|2011-11-04|Estimate||||2011-09-27|2011-11-04|Estimate|September 2003||2003-09-30|September 2011|2011-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Study of Oral PG-116800 Following a Heart Attack|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Oral PG-116800 Following a Heart Attack|Completed||Phase 2|253|Actual|Procter and Gamble||2|||f||||f||||||||||2018-06-01 05:17:56.142396|2018-06-01 05:17:56.142396
NCT00067223|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-12|||2017-06-30|2003-08-12|2003-08-13|Estimate|||||||2017-06-30|2017-07-02|Actual|August 5, 2003||2003-08-05|June 25, 2007|2007-06-25|June 25, 2007||2007-06-25|||||Observational|||Studying Use-Dependent Plasticity|Bi-hemispheric Plasticity Elicited By Unilateral Finger Motor Training|Completed|||28||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:56.676468|2018-06-01 05:17:56.676468
NCT00067210|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-12|||2017-06-30|2003-08-12|2003-08-13|Estimate|||||||2017-06-30|2017-07-02|Actual|August 11, 2003||2003-08-11|June 13, 2008|2008-06-13|May 22, 2007||2007-05-22|||||Interventional|||Reducing Seizure Frequency Using Cooling of the Head and Neck|Cooling of the Head and Neck to Reduce Seizure Frequency: A Pilot Study|Completed||Phase 2|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:56.782362|2018-06-01 05:17:56.782362
NCT00067197|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-12|||2017-06-30|2003-08-12|2003-08-13|Estimate|||||||2017-06-30|2017-07-02|Actual|August 11, 2003||2003-08-11|July 17, 2008|2008-07-17|July 17, 2008||2008-07-17|||||Observational|||Improving Motor Learning in Stroke Patients|Modulation of Motor Learning in Chronic Stroke Patients by Transcranial DC Stimulation|Completed|||76||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:56.877715|2018-06-01 05:17:56.877715
NCT00067184|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-12|||2018-04-24|2003-08-12|2003-08-13|Estimate|||||||2018-04-24|2018-04-25|Actual|September 2002||2002-09-30|April 2018|2018-04-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|||Fetal Neurobehavioral Development in Methadone Maintained Pregnancies|Methadone, Buprenorphine and Fetal Development|Completed|||157|Actual|Johns Hopkins University|||||f||||f||||||||||2018-06-01 05:17:56.974232|2018-06-01 05:17:56.974232
NCT00067171|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-12|||2017-01-11|2003-08-12|2003-08-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2003||2003-01-31|October 2016|2016-10-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Telephone Enhancement Procedure for Continuing Care - 1|Telephone Enhancement Procedure (TELE) for Continuing Care|Completed||Phase 3|339||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:17:57.082077|2018-06-01 05:17:57.082077
NCT00067158|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-12|||2017-01-11|2003-08-12|2003-08-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1|Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy|Completed||Phase 3|585||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:17:57.221127|2018-06-01 05:17:57.221127
NCT00067145|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-11|||2010-01-12|2003-08-12|2003-08-13|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31||||||||Interventional|||Computer Intervention for Prevention of Weight Regain||Completed||Phase 3|300||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:17:57.311131|2018-06-01 05:17:57.311131
NCT00067132|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-11|||2010-01-12|2003-08-12|2003-08-13|Estimate|||||||2010-01-12|2010-01-14|Estimate|March 2003||2003-03-31|January 2010|2010-01-31||||||||Interventional|||Adjuvant Nutrition for Critically Ill Trauma Patients||Completed||Phase 1|100|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:17:57.38658|2018-06-01 05:17:57.38658
NCT00067119|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-11|||2017-09-18|2003-08-12|2003-08-13|Estimate|||||||2017-09-18|2017-09-19|Actual|January 1, 2003|Actual|2003-01-01|September 2017|2017-09-30|January 31, 2008|Actual|2008-01-31|January 31, 2008|Actual|2008-01-31||Interventional|GRAFT||Aggrenox Prevention of Access Stenosis|Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency|Completed||Phase 3|649|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||Yes|Data will be available at the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK) Central Repository|2018-06-01 05:17:57.459345|2018-06-01 05:17:57.459345
NCT00067106|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-11|||2015-05-15|2003-08-12|2003-08-13|Estimate|||||||2015-05-15|2015-05-19|Estimate|July 2003||2003-07-31|September 2014|2014-09-30|March 2009|Actual|2009-03-31|March 2007|Actual|2007-03-31||Observational|||Antiviral Therapy and HIV in the Female Genital Tract|Antiviral Therapy and HIV in the Genital Tract of Women|Completed|||130|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||f||||||Samples With DNA|"~     Blood and genital tract collection~   "|||2018-06-01 05:17:57.560033|2018-06-01 05:17:57.560033
NCT00067093|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-11|||2011-04-05|2003-08-12|2003-08-13|Estimate|||||||2011-04-05|2011-04-06|Estimate|May 2003||2003-05-31|April 2011|2011-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)||Completed||Phase 3|1452|Actual|Sanofi|||||||||||||||||||2018-06-01 05:17:57.669282|2018-06-01 05:17:57.669282
NCT00067080|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-11|||2017-08-18|2003-08-12|2003-08-13|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2003||2003-05-31|August 2017|2017-08-31||||July 2007|Actual|2007-07-31||Interventional|||Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions|A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis|Completed||Phase 2|195|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:17:57.858221|2018-06-01 05:17:57.858221
NCT00067041|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-08|||2013-03-05|2003-08-12|2003-08-13|Estimate|||||||2013-03-05|2013-03-07|Estimate|March 2003||2003-03-31|March 2013|2013-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft|A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft|Terminated||Phase 2/Phase 3|30||United Therapeutics|||||f||||||||||||||2018-06-01 05:17:58.060318|2018-06-01 05:17:58.060318
NCT00067028|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-08|||2013-06-17|2003-08-12|2003-08-13|Estimate|||||||2013-06-17|2013-06-18|Estimate|December 2003||2003-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML|A Prospective Randomized Phase I/II Study of Clofarabine (Clo) and Ara-C vs Clo and Ida vs Clo Plus Ida and Ara-C in Patients With First Relapse or First Salvage of Primary Refractory AML; and High-Grade MDS(>/= 10% Blasts); or CML in Myeloid Blasts Phase as Front Line Therapy or in First Salvage.|Completed||Phase 2|166|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:17:58.152131|2018-06-01 05:17:58.152131
NCT00003433|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2003-08-12|2003-08-13|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 1998||1998-06-30|November 2002|2002-11-30|August 2003|Actual|2003-08-31|||||Interventional|||Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer|A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous, Cultured Dendritic Cells After Complete Resection of Hepatic Metastases of Colorectal Carcinoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:17:58.292031|2018-06-01 05:17:58.292031
NCT00003323|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-08-12|2003-08-13|Estimate|||||||2016-07-01|2016-07-04|Estimate|May 1998||1998-05-31|July 2016|2016-07-31|March 2010|Actual|2010-03-31|May 2002|Actual|2002-05-31||Interventional|||Hormone Therapy in Treating Patients With Prostate Cancer|A Phase II Trial of Potency-Sparing Hormonal Therapy in Patients With Elevated Serum PSA After Radiation Therapy or Radical Prostatectomy for Prostate Cancer|Completed||Phase 2|101|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:17:58.417918|2018-06-01 05:17:58.417918
NCT00003210|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-04-14|2003-08-12|2003-08-13|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 1998||1998-02-28|January 2013|2013-01-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease|A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease|Completed||Phase 2|105|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:58.603393|2018-06-01 05:17:58.603393
NCT00003114|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-09|2003-08-12|2003-08-13|Estimate|||||||2010-06-09|2010-06-11|Estimate|July 1997||1997-07-31|June 2010|2010-06-30|February 2003|Actual|2003-02-28|June 2002|Actual|2002-06-30||Interventional|||Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease|Oral Combination Chemotherapy in the Treatment of AIDS-Associated Hodgkin's Disease|Completed||Phase 2|5|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:17:58.720728|2018-06-01 05:17:58.720728
NCT00003006|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-28|2003-08-12|2003-08-13|Estimate|||||||2016-06-28|2016-06-29|Estimate|May 1997||1997-05-31|June 2016|2016-06-30|June 2010|Actual|2010-06-30|March 2002|Actual|2002-03-31||Observational|||Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer|Detection of Occult Micrometastases in Patients With Clinical Stage I NSCLC: A Prospective Analysis|Completed|||501|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Patients enrolled onto CALGB 9761 will have, at the time of thoracotomy (or video assisted~     lobectomy) and pulmonary resection, samples of bone marrow, primary tumor, and intrathoracic~     lymph nodes harvested.~   "|||2018-06-01 05:17:58.827291|2018-06-01 05:17:58.827291
NCT00067067|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-08|||2008-03-03|2003-08-08|2003-08-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2003||2003-08-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Investigating Endothelial Precursor Cells (EPCs)|Circulating Endothelial Progenitor Cells in Gliomas|Completed|||84||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:58.95552|2018-06-01 05:17:58.95552
NCT00067054|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-08|||2018-05-23|2003-08-08|2003-08-11|Estimate|||||||2018-05-23|2018-05-24|Actual|August 8, 2003||2003-08-08|February 8, 2018|2018-02-08||||||||Observational|||Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies|VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:17:59.034076|2018-06-01 05:17:59.034076
NCT00067015|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-08|||2015-12-21|2003-08-08|2003-08-11|Estimate|||||||2015-12-21|2015-12-22|Estimate|May 2003||2003-05-31|December 2015|2015-12-31|September 2008|Actual|2008-09-30|October 2004|Actual|2004-10-31||Interventional|||Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer|Phase III Randomized Trial Study Comparing the Outcome of High-Dose IMRT (86.4 GY) Alone With IMRT to 75.6 GY Plus Neoadjuvant/Adjuvant Androgen Deprivation in Patients With High Grade Intermediate Risk and Unfavorable Risk Prostate Cancer|Completed||Phase 3|3|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 05:17:59.129878|2018-06-01 05:17:59.129878
NCT00067002|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-08|||2016-07-15|2003-08-08|2003-08-11|Estimate|||||||2016-07-15|2016-07-18|Estimate|April 2003||2003-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Randomized Double Cord Blood Transplant Study|Randomized Trial of Unmanipulated Versus Expanded Cord Blood|Completed||Phase 2|110|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 05:17:59.223955|2018-06-01 05:17:59.223955
NCT00066989|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-08|||2012-05-10|2003-08-08|2003-08-11|Estimate|||||||2012-05-10|2012-05-14|Estimate|July 2003||2003-07-31|May 2012|2012-05-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates|A Double Blind, Randomized, Multicenter Stratified Study to Assess the Safety of an Intravenous Staphylococcus Aureus Immune Globulin (Human) [Altastaph] in Low-Birth-Weight-Neonates|Completed||Phase 2|200||Nabi Biopharmaceuticals|||||f||||||||||||||2018-06-01 05:17:59.383301|2018-06-01 05:17:59.383301
NCT00046878|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-03-26|2003-08-08|2003-08-11|Estimate|||||||2013-03-26|2013-03-28|Estimate||||March 2013|2013-03-31|August 2002|Actual|2002-08-31|||||Interventional|||Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme|Phase 2 Trial of BCNU Plus O6-Benzylguanine (NSC 637037) in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme|Withdrawn||Phase 2|0|Actual|Duke University|||||f||||||||||||||2018-06-01 05:17:59.472802|2018-06-01 05:17:59.472802
NCT00002970|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2003-08-08|2003-08-11|Estimate|||||||2013-07-01|2013-07-02|Estimate|June 1997||1997-06-30|July 2013|2013-07-31||||January 2005|Actual|2005-01-31||Interventional|||506U78 in Treating Patients With Refractory Hematologic Cancer|A Phase II Study of Compound 506U78 in Patients With Refractory T-Cell Malignancies-POG/CCG Intergroup Study|Completed||Phase 2|148|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:17:59.585671|2018-06-01 05:17:59.585671
NCT00002621|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2003-08-08|2003-08-11|Estimate|||||||2014-07-23|2014-07-24|Estimate|December 1994||1994-12-31|July 2014|2014-07-31|September 2005|Actual|2005-09-30|July 2002|Actual|2002-07-31||Interventional|||Interferon Alfa in Treating Children With HIV-Related Cancer|A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study|Completed||Phase 2|8|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:17:59.781761|2018-06-01 05:17:59.781761
NCT00002548|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-03-05|2003-08-08|2003-08-11|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 1994||1994-01-31|March 2015|2015-03-31|November 2006|Actual|2006-11-30|October 2003|Actual|2003-10-31||Interventional|||SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma|Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study|Completed||Phase 3|899|Actual|Southwest Oncology Group||4|||f||||t||||||||||2018-06-01 05:17:59.896234|2018-06-01 05:17:59.896234
NCT00002520|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-06|2003-08-08|2003-08-11|Estimate|||||||2015-10-06|2015-10-07|Estimate|June 1992||1992-06-30|October 2015|2015-10-31||||February 2002|Actual|2002-02-28||Interventional|||Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer|Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings|Completed||N/A|434|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 05:18:00.144934|2018-06-01 05:18:00.144934
NCT00066976|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-07|||2017-06-30|2003-08-07|2003-08-08|Estimate|||||||2017-06-30|2017-07-02|Actual|August 5, 2003||2003-08-05|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||Studying Fetal Breathing Patterns|Classification of Fetal Breathing Patterns in the Maturing Upper Airway: Spectral Waveform Analysis of Amniotic Fluid Flow Dynamics in Normal Development, Polyhydramnios, and Oligohydramnios|Completed|||0||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:00.272042|2018-06-01 05:18:00.272042
NCT00066963|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-07|2011-04-05||2014-04-30|2003-08-07|2003-08-08|Estimate|2012-04-10|2012-05-08|Estimate||||2014-04-30|2014-05-15|Estimate|October 2002||2002-10-31|April 2014|2014-04-30|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Fluoride Varnish Randomized Clinical Trial|Comprehensive Oral Health Center for Discovery: New Strategies for Enhancing Tissue Integrity and Repair Early Childhood Caries: Prevention and Treatment Outcomes|Completed||Phase 3|376|Actual|University of California, San Francisco|In a protocol deviation, children received placebo varnish for 10 months; this would be expected to bias the study toward the null of no difference among groups. The study did not address FV efficacy for children with extant or past caries.|3|||f||||t||||||||||2018-06-01 05:18:00.386184|2018-06-01 05:18:00.386184
NCT00066950|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-07|||2014-04-30|2003-08-07|2003-08-08|Estimate|||||||2014-04-30|2014-05-02|Estimate|March 2003||2003-03-31|April 2014|2014-04-30|August 2005|Actual|2005-08-31|July 2005|Actual|2005-07-31||Interventional|||Prevention Management Model for Early Childhood Caries (MAYA Project)|Prevention Management Model for Early Childhood Caries|Completed||Phase 3|361|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-06-01 05:18:00.728586|2018-06-01 05:18:00.728586
NCT00066937|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-07|2017-04-17||2017-07-21|2003-08-07|2003-08-08|Estimate|2017-07-21|2017-07-24|Actual||||2017-07-21|2017-07-24|Actual|November 2002||2002-11-30|July 2017|2017-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Comparison of Psychological and Pharmacological Treatments for Pain Due to Temporomandibular Joint Disorder (TMD)|Pain Management in Temporomandibular Joint Disorders|Completed||Phase 2|140|Actual|Johns Hopkins University||4|||f||||t|t|f|||f|||No||2018-06-01 05:18:00.894335|2018-06-01 05:18:00.894335
NCT00066924|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-07|||2005-06-23|2003-08-07|2003-08-08|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2003||2003-09-30|May 2005|2005-05-31|June 2004||2004-06-30|||||Observational|||Spirituality, Religiosity, and Immune Functioning||Completed|||120||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:01.439412|2018-06-01 05:18:01.439412
NCT00066898|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2006-09-29|2003-08-07|2003-08-08|Estimate|||||||2006-09-29|2006-10-03|Estimate|June 2003||2003-06-30|September 2006|2006-09-30|December 2006||2006-12-31|||||Interventional|||ARISE – Aggressive Reduction of Inflammation Stops Events|“Reduction of Vascular Inflammation and Coronary Atherosclerosis With AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease”|Unknown status|Active, not recruiting|Phase 3|6000||AtheroGenics|||||||||||||||||||2018-06-01 05:18:01.513496|2018-06-01 05:18:01.513496
NCT00066885|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2007-05-03|2003-08-07|2003-08-08|Estimate|||||||2007-05-03|2007-05-07|Estimate|June 2003||2003-06-30|May 2007|2007-05-31|December 2005||2005-12-31|||||Interventional|||Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer|A Phase 1/2 Multicenter, Open Label, Dose Ranging Study of DN-101 and Taxotere® in Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Previous Therapy With Platinum-Based Chemotherapy|Completed||Phase 1/Phase 2|80||Novacea|||||||||||||||||||2018-06-01 05:18:03.554034|2018-06-01 05:18:03.554034
NCT00011973|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-04-03|2003-08-07|2003-08-08|Estimate|||||||2013-04-03|2013-04-05|Estimate|December 2000||2000-12-31|April 2013|2013-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Chemotherapy in Treating Patients With Advanced Kidney Cancer|A Phase Two Study Of Fenretinide In Renal Cell Cancer|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:18:03.681368|2018-06-01 05:18:03.681368
NCT00005027|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-04-03|2003-08-07|2003-08-08|Estimate|||||||2013-04-03|2013-04-05|Estimate|June 2000||2000-06-30|April 2013|2013-04-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer|A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer|Completed||Phase 2|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:18:03.776729|2018-06-01 05:18:03.776729
NCT00066911|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2017-06-30|2003-08-06|2003-08-07|Estimate|||||||2017-06-30|2017-07-02|Actual|August 2, 2003||2003-08-02|November 5, 2009|2009-11-05||||November 5, 2009|Actual|2009-11-05||Observational|||Brain Mapping of Voice Control|Functional Brain Mapping of Laryngeal Sensorimotor Control in Voice Disorders|Completed|||174||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:03.855976|2018-06-01 05:18:03.855976
NCT00066872|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-09-16|2003-08-06|2003-08-07|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 2002||2002-10-31|September 2009|2009-09-30|April 2010|Actual|2010-04-30|||||Interventional|||Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer|A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma|Completed||Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:03.909068|2018-06-01 05:18:03.909068
NCT00066859|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2017-11-27|2003-08-06|2003-08-07|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2004||2004-03-31|November 2017|2017-11-30|November 2005|Actual|2005-11-30|April 2005|Actual|2005-04-30||Interventional|||Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression|A Phase III Double-Blind Randomized Trial Comparing Sertraline (Zoloft) And Hypericum Perforatum (St. John's Wort) In Cancer Patients With Mild To Moderate Depression|Completed||Phase 3|2|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-06-01 05:18:04.009052|2018-06-01 05:18:04.009052
NCT00066846|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-06-18|2003-08-06|2003-08-07|Estimate|||||||2013-06-18|2013-06-20|Estimate|August 2003||2003-08-31|April 2004|2004-04-30|July 2007|Actual|2007-07-31|||||Interventional|||Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy|A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancers That Have Progressed After Standard Chemotherapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:04.112632|2018-06-01 05:18:04.112632
NCT00066807|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2016-03-11||2016-09-26|2003-08-06|2003-08-07|Estimate|2016-03-11|2016-04-11|Estimate||||2016-09-26|2016-10-28|Estimate|August 2003||2003-08-31|September 2016|2016-09-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|PERCHE||Premenopausal Endocrine Responsive Chemotherapy Trial|A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy|Terminated||Phase 3|29|Actual|International Breast Cancer Study Group|Trial terminated early due to poor accrual. Adverse event data is available ONLY for selected Grade 3-5 AEs for chemotherapy arm. 25 of 29 patients were co-enrolled in TEXT (IBCSG 25-02), which reports AEs and outcomes of endocrine therapy.|2||Poor accrual, patients were followed until completion of 5 yrs treatment|f||||t||||||||||2018-06-01 05:18:04.333678|2018-06-01 05:18:04.333678
NCT00066794|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2015-03-05|2003-08-06|2003-08-07|Estimate|||||||2015-03-05|2015-03-06|Estimate|July 2004||2004-07-31|March 2015|2015-03-31|January 2010|Actual|2010-01-31|February 2007|Actual|2007-02-28||Interventional|||S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older|Completed||Phase 2|69|Actual|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:18:04.631223|2018-06-01 05:18:04.631223
NCT00066781|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2017-02-17||2017-02-17|2003-08-06|2003-08-07|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|February 2004||2004-02-29|February 2017|2017-02-28|March 2009|Actual|2009-03-31|April 2008|Actual|2008-04-30||Interventional|||Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary|A Phase II Study Of Gemcitabine (GEMZAR) And Irinotecan (CPT-11) In Previously Untreated Patients With Measurable Disease With Unknown Primary Carcinoma|Completed||Phase 2|31|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:18:04.903735|2018-06-01 05:18:04.903735
NCT00066768|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-06-03|2003-08-06|2003-08-07|Estimate|||||||2013-06-03|2013-06-04|Estimate|July 2003||2003-07-31|June 2013|2013-06-30||||March 2008|Actual|2008-03-31||Interventional|||Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer|A Pilot Study of Low Dose Suramin as Modulator of Docetaxel and Gemcitabine in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:18:05.292115|2018-06-01 05:18:05.292115
NCT00066742|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2012-06-14||2014-04-29|2003-08-06|2003-08-07|Estimate|2012-06-14|2012-07-19|Estimate||||2014-04-29|2014-05-15|Estimate|September 2003||2003-09-30|December 2012|2012-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer|A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer|Completed||Phase 2|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:18:05.510876|2018-06-01 05:18:05.510876
NCT00066729|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2011-04-23|2003-08-06|2003-08-07|Estimate|||||||2011-04-23|2011-04-26|Estimate|May 2003||2003-05-31|December 2009|2009-12-31||||July 2006|Actual|2006-07-31||Interventional|||Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer Expressing NY-ESO-1 or LAGE-1|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:06.034027|2018-06-01 05:18:06.034027
NCT00066716|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2009-12-07|2003-08-06|2003-08-07|Estimate|||||||2009-12-07|2009-12-08|Estimate|June 2003||2003-06-30|December 2009|2009-12-31||||May 2007|Actual|2007-05-31||Interventional|||Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus|A Phase II Study Of Preoperative Celecoxib/Paclitaxel/Carboplatin For Squamous Cell And Adenocarcinoma Of The Esophagus|Completed||Phase 2|39|Actual|Weill Medical College of Cornell University|||||f||||f||||||||||2018-06-01 05:18:06.116469|2018-06-01 05:18:06.116469
NCT00066703|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2015-07-14||2017-12-22|2003-08-06|2003-08-07|Estimate|2016-03-07|2016-04-05|Estimate||||2017-12-22|2018-01-23|Actual|August 2003||2003-08-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2014|Actual|2014-06-30||Interventional|TEXT|Intention-to-treat population excludes 12 patients who immediately withdrew consent, were at a non-adherent center, or had inadequate documentation of informed consent.|Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer|A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer|Active, not recruiting||Phase 3|2672|Actual|International Breast Cancer Study Group||2|||f||||t||||||||||2018-06-01 05:18:06.348393|2018-06-01 05:18:06.348393
NCT00066690|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2015-07-14||2016-07-29|2003-08-06|2003-08-07|Estimate|2016-07-29|2016-09-22|Estimate||||2016-07-29|2016-09-22|Estimate|August 2003||2003-08-31|July 2016|2016-07-31||||December 2031|Anticipated|2031-12-31||Interventional|SOFT|Intention-to-treat population, excludes 19 patients who immediately withdrew consent.|Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer|A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer|Active, not recruiting||Phase 3|3066|Actual|International Breast Cancer Study Group||3|||f||||t||||||||||2018-06-01 05:18:08.002944|2018-06-01 05:18:08.002944
NCT00066677|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-06-18|2003-08-06|2003-08-07|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 2003||2003-10-31|May 2013|2013-05-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|||Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer|Phase II and Coagulation Study of rhuMAb-VEGF With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|46|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:18:10.858622|2018-06-01 05:18:10.858622
NCT00066664|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2012-03-14|2003-08-06|2003-08-07|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2003||2003-06-30|March 2012|2012-03-31|March 2010|Actual|2010-03-31|December 2007|Actual|2007-12-31||Interventional|||Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin|Characterization of Serum Proteomic Patterns in Neoplastic and Inflammatory Skin Disease|Completed||N/A|423|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:11.602503|2018-06-01 05:18:11.602503
NCT00066651|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2015-04-29|2003-08-06|2003-08-07|Estimate|||||||2015-04-29|2015-04-30|Estimate|July 2003||2003-07-31|February 2006|2006-02-28||||||||Interventional|||Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors|Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:18:11.692803|2018-06-01 05:18:11.692803
NCT00066638|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2015-03-16|2003-08-06|2003-08-07|Estimate|||||||2015-03-16|2015-03-17|Estimate|June 2003||2003-06-30|December 2012|2012-12-31|March 2011|Actual|2011-03-31|May 2007|Actual|2007-05-31||Interventional|||FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 2 Study of Depsipeptide in Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:18:11.818975|2018-06-01 05:18:11.818975
NCT00066625|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-01-31|2003-08-06|2003-08-07|Estimate|||||||2013-01-31|2013-02-01|Estimate|July 2003||2003-07-31|January 2013|2013-01-31||||April 2007|Actual|2007-04-30||Interventional|||Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer|A Phase I and Pharmacokinetic Study of Oxaliplatin (Eloxatin™) in Combination With Bortezomib (PS-341, Velcade™) in Patients With Advanced Malignancy|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:18:12.48418|2018-06-01 05:18:12.48418
NCT00066612|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2012-10-31|2003-08-06|2003-08-07|Estimate|||||||2012-10-31|2012-11-02|Estimate|July 2003||2003-07-31|October 2012|2012-10-31|May 2010|Actual|2010-05-31|August 2007|Actual|2007-08-31||Interventional|||S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy|Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium|Completed||Phase 2|45|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:18:12.643496|2018-06-01 05:18:12.643496
NCT00066599|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-06-18|2003-08-06|2003-08-07|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 2003||2003-06-30|July 2004|2004-07-31|June 2004|Actual|2004-06-30|||||Interventional|||Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy|An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - <12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:12.890951|2018-06-01 05:18:12.890951
NCT00066586|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-05-30|2003-08-06|2003-08-07|Estimate|||||||2013-05-30|2013-06-03|Estimate|August 2001||2001-08-31|September 2011|2011-09-30|February 2009|Actual|2009-02-28|April 2006|Actual|2006-04-30||Interventional|||Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer|A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer|Completed||N/A|98|Actual|Canadian Cancer Trials Group||2|||f||||||||||||||2018-06-01 05:18:13.385941|2018-06-01 05:18:13.385941
NCT00066573|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2014-04-16||2018-03-21|2003-08-06|2003-08-07|Estimate|2014-04-16|2014-05-15|Estimate||||2018-03-21|2018-04-19|Actual|June 2003||2003-06-30|March 2018|2018-03-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer|A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer|Completed||Phase 3|7576|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:18:14.942079|2018-06-01 05:18:14.942079
NCT00066547|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-12-03|2003-08-06|2003-08-07|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2003||2003-05-31|August 2004|2004-08-31||||||||Interventional|||Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy|An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and Taxane Therapy|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:15.582835|2018-06-01 05:18:15.582835
NCT00066508|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-01-07|2003-08-06|2003-08-07|Estimate|||||||2013-01-07|2013-01-08|Estimate|May 2003||2003-05-31|January 2013|2013-01-31||||July 2005|Actual|2005-07-31||Interventional|||Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy|A Phase II Study Of PS-341 (VELCADE) In Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 2|7|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:18:15.681934|2018-06-01 05:18:15.681934
NCT00066482|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-10-15|2003-08-06|2003-08-07|Estimate|||||||2013-10-15|2013-10-17|Estimate|July 2004||2004-07-31|October 2013|2013-10-31||||April 2007|Actual|2007-04-30||Interventional|||Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors|Pilot Study of Cisplatin, Etoposide, Bleomycin and Escalating Dose Cyclophosphamide Therapy for Children With High Risk Malignant Germ Cell Tumors|Completed||N/A|19|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:18:15.909274|2018-06-01 05:18:15.909274
NCT00066469|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2013-09-17||2016-09-14|2003-08-06|2003-08-07|Estimate|2013-12-03|2014-01-17|Estimate||||2016-09-14|2016-09-16|Estimate|April 2004||2004-04-30|September 2016|2016-09-30||||October 2009|Actual|2009-10-31||Interventional|||Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation|Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT)|Active, not recruiting||Phase 2|55|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:18:16.213478|2018-06-01 05:18:16.213478
NCT00066456|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2016-02-10|2003-08-06|2003-08-07|Estimate|||||||2016-02-10|2016-02-11|Estimate|September 2003||2003-09-30|February 2016|2016-02-29||||July 2010|Actual|2010-07-31||Interventional|||Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I Study Using Low Dose Abdominal Radiotherapy as A Docetaxel Chemosensitizer for Recurrent , Persistent Or Advanced Ovarian, Peritoneal Or Fallopian Tube Cancer|Completed||Phase 1|13|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:18:16.974391|2018-06-01 05:18:16.974391
NCT00066443|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2015-11-02|2003-08-06|2003-08-07|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2003||2003-02-28|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer|A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer|Completed||Phase 1/Phase 2|93|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-06-01 05:18:17.077384|2018-06-01 05:18:17.077384
NCT00066430|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2014-09-16|2003-08-06|2003-08-07|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2003||2003-09-30|September 2014|2014-09-30|April 2006|Actual|2006-04-30|September 2004|Actual|2004-09-30||Interventional|||Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia|Infrared Coagulator For Treatment Of High Grade Squamous Intraepithelial Neoplasia (HSIL) in the Anal Canal In HIV Infected Individuals: A Pilot Study|Completed||Phase 1|18|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-06-01 05:18:17.242207|2018-06-01 05:18:17.242207
NCT00066417|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-04-30|2003-08-06|2003-08-07|Estimate|||||||2013-04-30|2013-05-01|Estimate||||November 2006|2006-11-30|January 2007|Actual|2007-01-31|||||Interventional|||Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia|Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia|Terminated||Phase 2|51|Anticipated|National Cancer Institute (NCI)||||Trial was withdrawn for drug availability issues.|f||||||||||||||2018-06-01 05:18:17.333556|2018-06-01 05:18:17.333556
NCT00066404|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2010-08-07|2003-08-06|2003-08-07|Estimate|||||||2010-08-07|2010-08-10|Estimate|April 2003||2003-04-30|December 2005|2005-12-31||||||||Interventional|||Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions|A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:17.42026|2018-06-01 05:18:17.42026
NCT00066391|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2012-09-20|2003-08-06|2003-08-07|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2003||2003-06-30|September 2012|2012-09-30||||January 2006|Actual|2006-01-31||Interventional|||Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer|Phase II Study of Irinotecan (CPT 11) and Cisplatin (CDDP) in Metastatic or Locally Advanced Penile Carcinoma|Completed||Phase 2|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:18:17.524033|2018-06-01 05:18:17.524033
NCT00066378|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-10-23|2003-08-06|2003-08-07|Estimate|||||||2013-10-23|2013-10-24|Estimate|May 2003||2003-05-31|October 2013|2013-10-31||||August 2007|Actual|2007-08-31||Interventional|||Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer|An EORTC Randomized, Double Blind, Placebo-Controlled, Phase II Multi-Center Trial Of Anastrozole (Arimidex) In Combination With ZD 1839 (Iressa) Or Placebo In Patients With Advanced Breast Cancer|Completed||Phase 2|71|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 05:18:17.693309|2018-06-01 05:18:17.693309
NCT00066365|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2015-02-11||2015-03-17|2003-08-06|2003-08-07|Estimate|2015-03-17|2015-03-30|Estimate||||2015-03-17|2015-03-30|Estimate|July 2004||2004-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|July 2010|Actual|2010-07-31||Interventional|||Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma|A Phase II Study of Aerosolized GM-CSF (NSC# 613795, IND# 11042) in Patients With First Pulmonary Recurrence of Osteosarcoma|Completed||Phase 2|49|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:18:17.86728|2018-06-01 05:18:17.86728
NCT00066352|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2015-07-22|2003-08-06|2003-08-07|Estimate|||||||2015-07-22|2015-07-23|Estimate|September 2003||2003-09-30|July 2015|2015-07-31||||September 2003|Actual|2003-09-30||Interventional|||Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter|A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)|Completed||Phase 2|||University Health Network, Toronto|||||||||||||||||||2018-06-01 05:18:18.669253|2018-06-01 05:18:18.669253
NCT00066339|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2012-07-17|2003-08-06|2003-08-07|Estimate|||||||2012-07-17|2012-07-18|Estimate|May 2003||2003-05-31|July 2012|2012-07-31||||January 2004|Actual|2004-01-31||Interventional|||Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy|An IDBBC Single Arm Phase II Trial Evaluating The Activity Of Iressa (ZD1839) In Metastatic Breast Cancer Patients Pretreated With An Antiestrogen And A Non-Steroidal Aromatase Inhibitor (Anastrozole Or Letrozole)|Completed||Phase 2|44|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:18:18.765704|2018-06-01 05:18:18.765704
NCT00066326|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2013-04-03|2003-08-06|2003-08-07|Estimate|||||||2013-04-03|2013-04-05|Estimate|June 2003||2003-06-30|April 2013|2013-04-30|September 2005|Actual|2005-09-30|October 2004|Actual|2004-10-31||Interventional|||Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia|Phase I Study Of The Combination Of 17-AAG And Imatinib Mesylate (Gleevec) In Patients With Blastic Phase, Accelerated Phase Of Chronic Mesylate Leukemia (CML) Or Patients With Chronic Phase CML Who Have Not Achieved A Cytogenetic Response With Imatinib Mesylate|Completed||Phase 1|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:18:18.861542|2018-06-01 05:18:18.861542
NCT00066313|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2016-08-23|2003-08-06|2003-08-07|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2003||2003-05-31|August 2016|2016-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||ZD6474 in Treating Patients With Small Cell Lung Cancer|A Phase II Study Of ZD6474 Or Placebo In Small Cell Lung Cancer Patients Who Have Complete Or Partial Response To Induction Chemotherapy +/- Radiation Therapy|Completed||Phase 2|||Sanofi|||||||||||||||||||2018-06-01 05:18:18.941964|2018-06-01 05:18:18.941964
NCT00066274|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2009-01-10|2003-08-06|2003-08-07|Estimate|||||||2009-01-10|2009-01-13|Estimate|May 2002||2002-05-31|May 2005|2005-05-31||||||||Interventional|||Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer|Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:19.149066|2018-06-01 05:18:19.149066
NCT00066248|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|||2014-01-31|2003-08-06|2003-08-07|Estimate|||||||2014-01-31|2014-02-03|Estimate|June 2003||2003-06-30|January 2014|2014-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment|The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia|Completed||Phase 2|70|Actual|University of South Florida||2|||f||||t||||||||||2018-06-01 05:18:19.261937|2018-06-01 05:18:19.261937
NCT00066222|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-06|2014-12-10||2017-11-27|2003-08-06|2003-08-07|Estimate|2014-12-10|2014-12-18|Estimate||||2017-11-27|2017-12-22|Actual|June 2003||2003-06-30|November 2017|2017-11-30|November 2013|Actual|2013-11-30|May 2012|Actual|2012-05-31||Interventional||Eligible patients who started protocol treatment.|Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|A Phase II Study Of Accelerated High Dose Thoracic Irradiation With Concurrent Chemotherapy For Patients With Limited Small Cell Lung Cancer|Completed||Phase 2|72|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:18:19.499836|2018-06-01 05:18:19.499836
NCT00066196|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-05|||2008-01-14|2003-08-06|2003-08-07|Estimate|||||||2008-01-14|2008-01-15|Estimate|August 2003||2003-08-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|April 2007|Anticipated|2007-04-30||Interventional|||Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma|A Phase II, Randomized, Open-Label Study Evaluating The Antitumor Activity Of MEDI-522, A Humanized Monoclonal Antibody Directed Against The Human Alpha V Beta 3 Integrin, ± Dacarbazine In Patients With Metastatic Melanoma|Completed||Phase 2|110||MedImmune LLC||2|||f||||f||||||||||2018-06-01 05:18:20.217272|2018-06-01 05:18:20.217272
NCT00020462|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-29|2003-08-06|2003-08-07|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2001||2001-02-28|December 2008|2008-12-31||||||||Interventional|||Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma|Active Specific Immunotherapy for Follicular Lymphomas With Liposomes Containing Tumor-Derived Antigen and IL-2|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:20.349559|2018-06-01 05:18:20.349559
NCT00019721|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2003-08-06|2003-08-07|Estimate|||||||2013-06-18|2013-06-20|Estimate|April 1999||1999-04-30|August 2002|2002-08-31|June 2003|Actual|2003-06-30|||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using MART-1 and GP100 Peptides Modified to Increase Binding to HLA-0201|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:20.451965|2018-06-01 05:18:20.451965
NCT00019383|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-08-06|2003-08-07|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 1998||1998-01-31|June 2003|2003-06-30|June 2003|Actual|2003-06-30|||||Interventional|||Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using Immunodominant Peptides From the Tyrosinase Protein or Tyrosinase Related Protein-1 (TRP1)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:20.507119|2018-06-01 05:18:20.507119
NCT00066209|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-05|||2017-06-30|2003-08-05|2003-08-06|Estimate|||||||2017-06-30|2017-07-02|Actual|August 4, 2003||2003-08-04|May 24, 2007|2007-05-24|May 24, 2007||2007-05-24|||||Observational|||Investigating Severe Acute Respiratory Syndrome (SARS)|An Investigation of the Inflammatory Response in Severe Acute Respiratory Syndrome (SARS)|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:20.574337|2018-06-01 05:18:20.574337
NCT00066170|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-04|2011-10-21||2011-12-21|2003-08-05|2003-08-06|Estimate|2011-10-21|2011-11-30|Estimate||||2011-12-21|2011-12-29|Estimate|April 2003||2003-04-30|December 2011|2011-12-31|November 2004|Actual|2004-11-30|July 2004|Actual|2004-07-31||Interventional|||Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy|Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) and Modafinil With Placebo in Treatment of Daytime Sleepiness in Narcolepsy|Completed||Phase 3|231|Actual|Jazz Pharmaceuticals||4|||f||||f||||||||||2018-06-01 05:18:20.662628|2018-06-01 05:18:20.662628
NCT00033722|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2014-01-03|2003-08-05|2003-08-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 2002||2002-02-28|November 2002|2002-11-30||||||||Interventional|||Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:21.672011|2018-06-01 05:18:21.672011
NCT00033306|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-08-01|2003-08-05|2003-08-06|Estimate|||||||2013-08-01|2013-08-05|Estimate|February 2002||2002-02-28|August 2013|2013-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||BMS-247550 in Treating Patients With Metastatic Colorectal Cancer|A Phase II Study Of Epothilone Analog BMS-247550 In Patients With Metastatic Colorectal Cancer Previously Treated With A Fluoropyrimidine And Irinotecan|Terminated||Phase 2|2|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-06-01 05:18:21.76118|2018-06-01 05:18:21.76118
NCT00031811|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2012-05-24|2003-08-05|2003-08-06|Estimate|||||||2012-05-24|2012-05-28|Estimate|March 2001||2001-03-31|June 2010|2010-06-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer|Breast Cancer Survivors: Exercise and Raloxifene|Completed||N/A|80|Actual|OHSU Knight Cancer Institute|||||f||||||||||||||2018-06-01 05:18:21.848519|2018-06-01 05:18:21.848519
NCT00031785|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2017-04-17|2003-08-05|2003-08-06|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2000|Actual|2000-09-30|August 2009|2009-08-31|September 11, 2002|Actual|2002-09-11|September 11, 2002|Actual|2002-09-11||Interventional|||Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer|A Phase III, Double-Blind, Randomized Study of the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer Patients Receiving Thoracic Radiation Therapy|Completed||Phase 3|25|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:18:21.942187|2018-06-01 05:18:21.942187
NCT00066183|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-04|||2008-03-03|2003-08-04|2003-08-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2003||2003-08-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Studying Phosphorus Metabolism|Studies in Phosphorus Metabolism|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:22.202313|2018-06-01 05:18:22.202313
NCT00066157|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-04|||2015-10-01|2003-08-04|2003-08-05|Estimate|||||||2015-10-01|2015-10-05|Estimate|September 2001||2001-09-30|September 2010|2010-09-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Alzheimer's Disease: Therapeutic Potential of Estrogen|Alzheimer's Disease: Therapeutic Potential of Estrogen|Completed||Phase 2/Phase 3|42|Actual|University of Wisconsin, Madison||4|||f||||t||||||||||2018-06-01 05:18:22.296293|2018-06-01 05:18:22.296293
NCT00066144|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-04|||2007-10-11|2003-08-04|2003-08-05|Estimate|||||||2007-10-11|2007-10-12|Estimate|April 2003||2003-04-30|October 2007|2007-10-31|April 2006|Actual|2006-04-30|||||Interventional|||Use of Black Cohosh and Red Clover for the Relief of Menopausal Symptoms|Black Cohosh and Red Clover Efficacy for the Relief of Menopausal Symptoms|Completed||Phase 2|112|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:18:22.409119|2018-06-01 05:18:22.409119
NCT00066131|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-04|||2015-07-24|2003-08-04|2003-08-05|Estimate|||||||2015-07-24|2015-07-27|Estimate|March 2003||2003-03-31|July 2015|2015-07-31|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|OPT||Obstetrics and Periodontal Therapy (OPT) Study|Effects of Periodontal Therapy on Preterm Birth|Completed||Phase 3|823|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 05:18:22.473419|2018-06-01 05:18:22.473419
NCT00066118|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-04|||2017-03-20|2003-08-04|2003-08-05|Estimate|||||||2017-03-20|2017-03-22|Actual|August 1996||1996-08-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|July 2005|Actual|2005-07-31||Interventional|||Health Effects of Silver-Mercury Dental Fillings|The Casa Pia Study of the Health Effects of Dental Amalgam in Children.|Completed||Phase 3|507||University of Washington|||||f||||||||||||||2018-06-01 05:18:22.583081|2018-06-01 05:18:22.583081
NCT00066092|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-04|||2008-02-20|2003-08-04|2003-08-05|Estimate|||||||2008-02-20|2008-02-28|Estimate|April 2003||2003-04-30|February 2008|2008-02-29|October 2004|Actual|2004-10-31|March 2004|Actual|2004-03-31||Interventional|||Pegfilgrastim PBPC Mobilization Study|Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.|Completed||Phase 2|41|Actual|Amgen||3|||f||||||||||||||2018-06-01 05:18:22.704767|2018-06-01 05:18:22.704767
NCT00066079|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2008-08-04|2003-08-04|2003-08-05|Estimate|||||||2008-08-04|2008-08-06|Estimate|August 2003||2003-08-31|August 2008|2008-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Home Based Massage and Relaxation for Sickle Cell Pain|Home Based Massage and Relaxation for Sickle Cell Pain|Completed||Phase 2|30||National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:18:22.788054|2018-06-01 05:18:22.788054
NCT00066066|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|2012-12-11||2013-03-06|2003-08-04|2003-08-05|Estimate|2013-03-06|2013-04-22|Estimate||||2013-03-06|2013-04-22|Estimate|July 2003||2003-07-31|March 2013|2013-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers|Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers|Completed||Phase 2|146|Actual|The Forsyth Institute||3|||f||||f||||||||||2018-06-01 05:18:22.943076|2018-06-01 05:18:22.943076
NCT00066053|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2011-08-04|2003-08-04|2003-08-05|Estimate|||||||2011-08-04|2011-08-05|Estimate|January 2003||2003-01-31|May 2007|2007-05-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||"Periodontitis and Cardiovascular Events or PAVE"|Periodontal Intervention for Cardiac Events: A Pilot Trial|Completed||N/A|303|Actual|University at Buffalo||2|||f||||t||||||||||2018-06-01 05:18:23.496086|2018-06-01 05:18:23.496086
NCT00066040|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2012-07-16|2003-08-04|2003-08-05|Estimate|||||||2012-07-16|2012-07-17|Estimate|January 2001||2001-01-31|July 2012|2012-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Prevention of Transmission of Bacteria That Cause Cavities From Mothers to Their Children|Prevention of Transmission of Mutans Streptococci From Mother to Child|Completed||N/A|280||New York University|||||f||||t||||||||||2018-06-01 05:18:23.635767|2018-06-01 05:18:23.635767
NCT00066027|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2015-12-01|2003-08-04|2003-08-05|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2002||2002-06-30|December 2015|2015-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effects of Low-Dose Doxycycline on Oral Bone Loss|Low-Dose Doxycycline Effects on Osteopenic Bone Loss|Completed||Phase 3|128|Actual|University of Nebraska||2|||f||||t||||||||||2018-06-01 05:18:23.732341|2018-06-01 05:18:23.732341
NCT00066014|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2012-02-21|2003-08-04|2003-08-05|Estimate|||||||2012-02-21|2012-02-22|Estimate|November 1998||1998-11-30|January 2010|2010-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Clinical Investigation of Mandibular Implant Overdenture|Clinical Investigation of Mandibular Implant Overdenture|Completed||Phase 2|30|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-06-01 05:18:23.83736|2018-06-01 05:18:23.83736
NCT00066001|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2010-11-08|2003-08-04|2003-08-05|Estimate|||||||2010-11-08|2010-11-09|Estimate|December 2002||2002-12-31|November 2010|2010-11-30|December 2009|Actual|2009-12-31|December 2007|Actual|2007-12-31||Interventional|||Microbial Associations in Periodontal Health and Disease|The Effect of Systemically Administered Metronidazole Alone and in Combination With Professional Supragingival Plaque Removal on Plaque Composition|Completed||Phase 2|154|Actual|The Forsyth Institute||1|||f||||f||||||||||2018-06-01 05:18:23.962736|2018-06-01 05:18:23.962736
NCT00065988|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2010-04-27|2003-08-04|2003-08-05|Estimate|||||||2010-04-27|2010-04-28|Estimate|September 1997||1997-09-30|August 2005|2005-08-31|March 2005||2005-03-31|||||Interventional|||The Children's Amalgam Trial|Health Effects of Dental Amalgams in Children|Completed||Phase 3|534||New England Research Institutes|||||f||||||||||||||2018-06-01 05:18:24.092535|2018-06-01 05:18:24.092535
NCT00065975|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2006-08-16|2003-08-04|2003-08-05|Estimate|||||||2006-08-16|2006-08-18|Estimate|April 2002||2002-04-30|August 2006|2006-08-31|December 2002||2002-12-31|||||Interventional|||Physical CAM Therapies for Chronic Low Back Pain|Physical CAM Therapies for Chronic Low Back Pain|Completed||Phase 2|120||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:24.193215|2018-06-01 05:18:24.193215
NCT00065962|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2005-06-23|2003-08-04|2003-08-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|June 2003|2003-06-30|May 2000||2000-05-31|||||Interventional|||Secretin for the Treatment of Autism|Multisite Controlled Secretin Trial in Autism|Completed||Phase 3|85||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.269945|2018-06-01 05:18:24.269945
NCT00065949|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2005-06-23|2003-08-04|2003-08-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1987||1987-08-31|May 2003|2003-05-31|February 2003||2003-02-28|||||Interventional|||Magnesium Sulfate to Prevent Brain Injury in Premature Infants|Magnesium Prevention of Brain Injury in Preterm Infants|Unknown status|Active, not recruiting|Phase 3|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.348311|2018-06-01 05:18:24.348311
NCT00065936|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2005-06-23|2003-08-04|2003-08-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1997||1997-07-31|May 2003|2003-05-31|June 2002||2002-06-30|||||Interventional|||Self-Injury: Diagnosis and Treatment|Behavioral and Biochemical Mechanisms of Self-Injury|Unknown status|Active, not recruiting|Phase 3|37||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.442174|2018-06-01 05:18:24.442174
NCT00065923|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2013-04-30|2003-08-04|2003-08-05|Estimate|||||||2013-04-30|2013-05-01|Estimate|July 2002||2002-07-31|August 2010|2010-08-31||||December 2005|Actual|2005-12-31||Interventional|||Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome|Topiramate Effects on SIB in Prader-Willi Syndrome|Completed||N/A|10|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.573076|2018-06-01 05:18:24.573076
NCT00065910|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2007-06-28|2003-08-04|2003-08-05|Estimate|||||||2007-06-28|2007-07-02|Estimate|September 2001||2001-09-30|June 2003|2003-06-30|January 2006||2006-01-31|||||Interventional|||Improving Attention Skills of Children With Autism|A Joint Attention Intervention With Caregivers and Their Children With Autism|Completed||Phase 1/Phase 2|30||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.648734|2018-06-01 05:18:24.648734
NCT00065897|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2005-06-23|2003-08-04|2003-08-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1996||1996-09-30|June 2003|2003-06-30|August 2000||2000-08-31|||||Interventional|||Prenatal Testing: Amniocentesis Versus Transabdominal Chorionic Villus Sampling (TA CVS)|Randomized Trial of 11-14 Week Amniocentesis and Transabdominal Chorionic Villus Sampling (TA CVS)|Completed||N/A|6400||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.712321|2018-06-01 05:18:24.712321
NCT00065884|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2005-06-23|2003-08-04|2003-08-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2003|2003-06-30||||||||Interventional|||Valproate Response in Aggressive Autistic Adolescents|Valproate Response in Aggressive Autistic Adolescents|Unknown status|Recruiting|Phase 3|30||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.795366|2018-06-01 05:18:24.795366
NCT00065871|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2007-04-05|2003-08-04|2003-08-05|Estimate|||||||2007-04-05|2007-04-06|Estimate|June 2003||2003-06-30|November 2004|2004-11-30|February 2006||2006-02-28|||||Interventional|||The Direct Access Study: Access to Hormonal Birth Control Through Community Pharmacies|Improving Contraceptive Practice and Delivery Through Community Pharmacists: The Direct Access Study|Unknown status|Active, not recruiting|N/A|250||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:24.878784|2018-06-01 05:18:24.878784
NCT00065845|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2011-01-09|2003-08-04|2003-08-05|Estimate|||||||2011-01-09|2011-01-11|Estimate|April 2002||2002-04-30|October 2010|2010-10-31|April 2007|Actual|2007-04-30|March 2007|Actual|2007-03-31||Interventional|CARE||Colpopexy and Urinary Reduction Efforts (CARE) Protocol|CARE: A Randomized Trial of Colpopexy and Urinary Reduction Efforts|Completed||Phase 3|322|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 05:18:25.043964|2018-06-01 05:18:25.043964
NCT00031707|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-07-12|2003-08-04|2003-08-05|Estimate|||||||2016-07-12|2016-07-14|Estimate|March 2000||2000-03-31|July 2016|2016-07-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite|Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Megestrol Acetate (Megace) Versus an N-3 Fatty Acid (EPA) Enriched Nutritional Supplement Versus Both for the Treatment of Cancer Cachexia and Anorexia|Completed||Phase 3|429|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-06-01 05:18:25.293039|2018-06-01 05:18:25.293039
NCT00026273|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2012-08-06|2003-08-04|2003-08-05|Estimate|||||||2012-08-06|2012-08-07|Estimate|January 2001||2001-01-31|August 2012|2012-08-31||||September 2004|Actual|2004-09-30||Interventional|||Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer|Multicenter Phase III Open Label Randomized Trial Comparing CPT-11 In Combination With A 5-FU/FA Infusional Regimen To The Same 5-FU/FA Infusional Regimen Alone As Adjuvant Treatment Of Stage III Colon Cancer|Completed||Phase 3|||Pfizer|||||f||||||||||||||2018-06-01 05:18:25.596067|2018-06-01 05:18:25.596067
NCT00025688|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2008-07-23|2003-08-04|2003-08-05|Estimate|||||||2008-07-23|2008-07-24|Estimate|January 2001||2001-01-31|September 2006|2006-09-30||||||||Interventional|||Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer|A Randomized, Phase II Trial of Weekly Taxol (Paclitaxel) Versus Weekly Taxol Plus Paraplatin (Carboplatin) as First-Line Chemotherapy in Patients Age 65 Years or Older With Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:25.747007|2018-06-01 05:18:25.747007
NCT00024024|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-02-08|2003-08-04|2003-08-05|Estimate|||||||2013-02-08|2013-02-11|Estimate|August 2001||2001-08-31|April 2008|2008-04-30||||August 2003|Actual|2003-08-31||Interventional|||BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma|Completed||Phase 1/Phase 2|59|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:18:25.849117|2018-06-01 05:18:25.849117
NCT00022477|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-09-04|2003-08-04|2003-08-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2001||2001-09-30|September 2013|2013-09-30|December 2004|Actual|2004-12-31|October 2002|Actual|2002-10-31||Interventional|||BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Study Of Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Advanced Colorectal Carcinoma|Completed||Phase 2|24|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:18:25.961389|2018-06-01 05:18:25.961389
NCT00065832|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2015-06-02|2003-08-01|2003-08-04|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 1993||1993-07-31|October 2004|2004-10-31|June 2002||2002-06-30|||||Interventional|||Reading Problems in Children Living in Urban Areas|Early Interventions for Children With Reading Problems|Completed||Phase 3|1400||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:26.09319|2018-06-01 05:18:26.09319
NCT00065819|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|||2005-06-23|2003-08-01|2003-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1996||1996-09-30|June 2003|2003-06-30|August 1999||1999-08-31|||||Interventional|||HIV Symptom Management Program for African American Mothers|HIV Symptom Management With African American Mothers|Completed||Phase 3|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:26.155387|2018-06-01 05:18:26.155387
NCT00065806|ClinicalTrials.gov processed this data on May 31, 2018|2003-08-01|2013-02-11||2013-07-15|2003-08-01|2003-08-04|Estimate|2013-07-15|2013-08-15|Estimate||||2013-07-15|2013-08-15|Estimate|September 2003||2003-09-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Efficacy of Lipitor (Atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE|Completed||Phase 3|221|Actual|Duke University||2|||f||||t||||||||||2018-06-01 05:18:26.272363|2018-06-01 05:18:26.272363
NCT00065793|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2015-01-30|2003-08-01|2003-08-04|Estimate|||||||2015-01-30|2015-02-03|Estimate|July 2003||2003-07-31|January 2015|2015-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||VLDL and LDL Particle Types as Coronary Heart Disease Risk Factors||Completed|||1478|Actual|Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:18:27.812316|2018-06-01 05:18:27.812316
NCT00065780|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2013-10-25|2003-08-01|2003-08-04|Estimate|||||||2013-10-25|2013-10-28|Estimate|August 2003||2003-08-31|October 2013|2013-10-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Ventricular Size and Value Calcification Measures by Computed Tomography - Ancillary to MESA||Completed|||6814|Actual|Los Angeles Biomedical Research Institute|||||f||||||||||||||2018-06-01 05:18:27.89328|2018-06-01 05:18:27.89328
NCT00065767|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2015-10-01|2003-08-01|2003-08-04|Estimate|||||||2015-10-01|2015-10-05|Estimate|September 2001||2001-09-30|September 2010|2010-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease|Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease|Completed||Phase 2/Phase 3|20||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:18:27.979208|2018-06-01 05:18:27.979208
NCT00065754|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2011-09-16|2003-07-31|2003-08-01|Estimate|||||||2011-09-16|2011-09-20|Estimate|September 2003||2003-09-30|August 2011|2011-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Brain Imaging and Pain in Irritable Bowel Syndrome|Brain Imaging and Pain: Analysis of Placebo Analgesia|Completed||N/A|50||University of Florida|||||f||||f||||||||||2018-06-01 05:18:28.091749|2018-06-01 05:18:28.091749
NCT00065741|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2007-03-21|2003-07-31|2003-08-01|Estimate|||||||2007-03-21|2007-03-23|Estimate|September 2003||2003-09-30|March 2007|2007-03-31|March 2006||2006-03-31|||||Interventional|||Botanical/Drug Interactions in HIV: Glucuronidation|Botanical/Drug Interactions in HIV: Glucuronidation|Completed||Phase 1|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:28.177376|2018-06-01 05:18:28.177376
NCT00065728|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31||2012-11-27|2013-09-04|2003-07-31|2003-08-01|Estimate||||2012-11-27|2012-11-28|Estimate|2013-09-04|2013-09-16|Estimate|June 2003||2003-06-30|May 2009|2009-05-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD|An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients With Subfoveal Exudative Age-Related Macular Degeneration (AMD)|Terminated||Phase 3|111|Actual|Alcon Research||1||Management decision|f||||||||||||||2018-06-01 05:18:28.300986|2018-06-01 05:18:28.300986
NCT00065715|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2014-12-03|2003-07-31|2003-08-01|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2003||2003-09-30|December 2014|2014-12-31|April 2013|Actual|2013-04-30|August 2008|Actual|2008-08-31||Interventional|PEP||Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)|"Placebo: Physician or Pill? A Randomized Trial in a Common Cold Model Funded by NIH NCCAM Under RFA The Placebo Effect in Clinical Practice"|Completed||Phase 3|719|Actual|University of Wisconsin, Madison||4|||f||||t||||||||||2018-06-01 05:18:28.388951|2018-06-01 05:18:28.388951
NCT00065702|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2006-08-17|2003-07-31|2003-08-01|Estimate|||||||2006-08-17|2006-08-18|Estimate|October 2000||2000-10-31|August 2006|2006-08-31|September 2002||2002-09-30|||||Interventional|||Biomarkers of Homeopathy in Fibromyalgia||Completed||Phase 1/Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:29.260746|2018-06-01 05:18:29.260746
NCT00065689|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-31|||2006-07-24|2003-07-31|2003-08-01|Estimate|||||||2006-07-24|2006-07-26|Estimate|March 2003||2003-03-31|July 2006|2006-07-31|September 2005||2005-09-30|||||Interventional|||High Intensity Light Therapy in Alzheimer's Disease|High Intensity Light Therapy in Alzheimer's Disease|Completed||Phase 3|107||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:29.327534|2018-06-01 05:18:29.327534
NCT00065676|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-30|||2018-05-26|2003-07-30|2003-07-31|Estimate|||||||2018-05-26|2018-05-30|Actual|July 29, 2003||2003-07-29|May 21, 2018|2018-05-21|December 17, 2025|Anticipated|2025-12-17|December 17, 2020|Anticipated|2020-12-17||Interventional|||Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes|Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics|Recruiting||Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:29.418197|2018-06-01 05:18:29.418197
NCT00065663|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-30|||2007-11-16|2003-07-30|2003-07-31|Estimate|||||||2007-11-16|2007-11-20|Estimate|August 2002||2002-08-31|November 2007|2007-11-30|December 2004||2004-12-31|||||Interventional|||Gene Therapy to Improve Wound Healing in Patients With Diabetes|Growth Factor Gene Therapy for Wound Healing|Completed||Phase 1|21||Tissue Repair Company|||||||||||||||||||2018-06-01 05:18:29.526453|2018-06-01 05:18:29.526453
NCT00065650|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-30|||2015-04-14|2003-07-30|2003-07-31|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2003||2003-07-31|April 2015|2015-04-30|January 2004||2004-01-31|||||Interventional|||Pilot Study of Vedic Medicine for Type 2 Diabetes||Completed||Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:29.614332|2018-06-01 05:18:29.614332
NCT00065624|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-29|||2007-09-28|2003-07-30|2003-07-31|Estimate|||||||2007-09-28|2007-10-02|Estimate|November 2003||2003-11-30|September 2007|2007-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Antioxidant Functions of Lipoic Acid|Antioxidant Functions of Lipoic Acid|Completed||Phase 2|16||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:29.713364|2018-06-01 05:18:29.713364
NCT00065585|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-28|||2014-02-25|2003-07-30|2003-07-31|Estimate|||||||2014-02-25|2014-02-26|Estimate|April 2004||2004-04-30|February 2014|2014-02-28|June 2007|Actual|2007-06-30|September 2006|Actual|2006-09-30||Interventional|||Efficacy of Acupuncture for Chronic Low Back Pain|Efficacy of Acupuncture for Chronic Low Back Pain|Completed||Phase 3|640||Kaiser Permanente||4|||f||||t||||||||||2018-06-01 05:18:29.80245|2018-06-01 05:18:29.80245
NCT00065572|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-28|||2011-01-25|2003-07-30|2003-07-31|Estimate|||||||2011-01-25|2011-01-26|Estimate|August 2003||2003-08-31|January 2011|2011-01-31|February 2004|Anticipated|2004-02-29|February 2004|Anticipated|2004-02-29||Interventional|||Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)||Suspended||Phase 2|||AstraZeneca|||||||||||||||||||2018-06-01 05:18:29.905538|2018-06-01 05:18:29.905538
NCT00065559|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-28|||2010-01-12|2003-07-30|2003-07-31|Estimate|||||||2010-01-12|2010-01-14|Estimate|April 2003||2003-04-30|January 2010|2010-01-31|December 2004||2004-12-31|||||Interventional|||Treatment of Diabetic Nephropathy||Terminated||N/A|30||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:18:30.117079|2018-06-01 05:18:30.117079
NCT00065546|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-28|||2012-01-05|2003-07-30|2003-07-31|Estimate|||||||2012-01-05|2012-01-06|Estimate|June 2007||2007-06-30|January 2012|2012-01-31|January 2012|Actual|2012-01-31|September 2009|Actual|2009-09-30||Interventional|||Human Requirements for the Nutrient Choline|Human Requirements for the Nutrient Choline|Completed||N/A|43|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-06-01 05:18:30.220023|2018-06-01 05:18:30.220023
NCT00065637|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-29|||2013-02-04|2003-07-29|2003-07-30|Estimate|||||||2013-02-04|2013-02-05|Estimate|December 2003||2003-12-31|February 2013|2013-02-28|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Once Weekly Parathyroid Hormone for Osteoporosis|PTH Once Weekly Research (POWR)|Completed||Phase 3|50||University of California, San Francisco||2|||f||||||||||||||2018-06-01 05:18:30.334699|2018-06-01 05:18:30.334699
NCT00014560|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|2013-04-02||2018-04-02|2003-07-29|2003-07-30|Estimate|2013-08-01|2013-08-05|Estimate||||2018-04-02|2018-05-03|Actual|September 28, 2000|Actual|2000-09-28|April 2018|2018-04-30|February 14, 2003|Actual|2003-02-14|February 14, 2003|Actual|2003-02-14||Interventional|||Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)|Terminated||Phase 1|3|Actual|Dartmouth-Hitchcock Medical Center|This study was prematurely ended by the sponsor Medarex (supplier of BsAb) due to toxicities experienced at other sites on unrelated trials leading to the decision that Medarex would not be manufacturing the investigational product (BsAb).|1||"Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on~   unrelated trials halting manufacturing of BsAb"|f||||||||||||||2018-06-01 05:18:30.498584|2018-06-01 05:18:30.498584
NCT00014261|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2018-03-28|2003-07-29|2003-07-30|Estimate|||||||2018-03-28|2018-03-30|Actual|October 2000|Actual|2000-10-31|March 2018|2018-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors|A Phase-I Study Of Cyclical Oral Administration Of Temozolomide In Combination With PEG12000-Interferon Alfa-2B In Patients With Refractory And/Or Advanced Solid Tumors|Completed||Phase 1|||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:18:30.737882|2018-06-01 05:18:30.737882
NCT00014248|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-03-15|2003-07-29|2003-07-30|Estimate|||||||2013-03-15|2013-03-18|Estimate|October 2000||2000-10-31|March 2013|2013-03-31||||November 2002|Actual|2002-11-30||Interventional|||Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors|A Phase I Study And Pharmacokinetics Of Adenosine 5'- Triphosphate (ATP) When Administered By Intravenous Infusion On A Multiple Weekly Dose Schedule To Patients With Advanced Malignancies (Solid Tumors)|Completed||Phase 1|||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:18:30.833955|2018-06-01 05:18:30.833955
NCT00065455|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-23|||2017-06-30|2003-07-23|2003-07-24|Estimate|||||||2017-06-30|2017-07-02|Actual|July 17, 2003||2003-07-17|May 6, 2009|2009-05-06|May 6, 2009||2009-05-06|||||Interventional|||Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa|Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa|Completed||Phase 1|11||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:41.075872|2018-06-01 05:18:41.075872
NCT00014209|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2016-11-25|2003-07-29|2003-07-30|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 2000||2000-12-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|July 2002|Actual|2002-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma That Has Not Responded to Previous Treatment|A Phase II Study Of Gemcitabine, Dexamethasone, And Cisplatin (GDP) In Patients With Either Hodgkin's Disease Or Aggressive Histology Non-Hodgkin's Lymphoma Which Is Relapsed Or Refractory|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||t||||||||Undecided||2018-06-01 05:18:30.939931|2018-06-01 05:18:30.939931
NCT00010127|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-03-19|2003-07-29|2003-07-30|Estimate|||||||2013-03-19|2013-03-21|Estimate|November 2000||2000-11-30|December 2008|2008-12-31|March 2003|Actual|2003-03-31|||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer|A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA|Terminated||Phase 1|3|Actual|Duke University|||||||||||||||||||2018-06-01 05:18:31.055014|2018-06-01 05:18:31.055014
NCT00065611|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-28|2011-09-20||2011-09-20|2003-07-28|2003-07-29|Estimate|2011-09-20|2011-10-28|Estimate||||2011-09-20|2011-10-28|Estimate|July 2003||2003-07-31|September 2011|2011-09-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Steroid Treatment for Kidney Disease|Pulse Dexamethasone Over 48 Weeks for Podocyte Disease|Completed||Phase 3|8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:31.136701|2018-06-01 05:18:31.136701
NCT00065533|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-28|||2007-06-21|2003-07-28|2003-07-29|Estimate|||||||2007-06-21|2007-06-22|Estimate|May 2003||2003-05-31|June 2007|2007-06-30|June 2005|Actual|2005-06-30|||||Interventional|||Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer|Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer|Completed||Phase 2|92|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 05:18:31.571228|2018-06-01 05:18:31.571228
NCT00065507|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-28|2010-02-25||2013-06-17|2003-07-28|2003-07-29|Estimate|2010-06-01|2010-07-02|Estimate||||2013-06-17|2013-06-24|Estimate|August 2003||2003-08-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|October 2008|Actual|2008-10-31||Interventional|||Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation|Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation|Completed||Phase 3|195|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-06-01 05:18:31.96771|2018-06-01 05:18:31.96771
NCT00006799|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2017-04-17|2003-07-25|2003-07-28|Estimate|||||||2017-04-17|2017-04-19|Actual|October 2000|Actual|2000-10-31|August 2009|2009-08-31|September 6, 2002|Actual|2002-09-06|September 6, 2002|Actual|2002-09-06||Interventional|||Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer|A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy|Completed||Phase 3|13|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:18:38.493117|2018-06-01 05:18:38.493117
NCT00006486|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-01-15|2003-07-25|2003-07-28|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2000||2000-10-31|January 2013|2013-01-31||||October 2005|Actual|2005-10-31||Interventional|||Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer|A Phase II Randomized Discontinuation Trial Of Carboxyaminoimidazole (CAI, NSC 609974) In Metastatic Renal Carcinoma|Completed||Phase 2|335|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:18:38.607452|2018-06-01 05:18:38.607452
NCT00006453|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2015-12-22|2003-07-25|2003-07-28|Estimate|||||||2015-12-22|2015-12-23|Estimate|September 1999||1999-09-30|December 2015|2015-12-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy|A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy|Completed||Phase 3|||AGO Study Group|||||f||||t||||||||||2018-06-01 05:18:38.729416|2018-06-01 05:18:38.729416
NCT00006352|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-07-17|2003-07-25|2003-07-28|Estimate|||||||2012-07-17|2012-07-18|Estimate|September 1999||1999-09-30|July 2012|2012-07-31||||October 2002|Actual|2002-10-31||Interventional|||Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer|The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG|Completed||Phase 3|453|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:18:38.880769|2018-06-01 05:18:38.880769
NCT00006240|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2015-04-27|2003-07-25|2003-07-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|October 2000||2000-10-31|November 2002|2002-11-30|August 2001|Actual|2001-08-31|||||Interventional|||Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia|A Pilot Study of Phenylbutyrate, Dexamethasone and GM-CSF in Refractory or Relapsed t(8;21) Acute Myeloid Leukemia|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:38.946454|2018-06-01 05:18:38.946454
NCT00065468|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-24|2012-03-22||2012-09-24|2003-07-24|2003-07-25|Estimate|2012-09-24|2012-10-25|Estimate||||2012-09-24|2012-10-25|Estimate|July 2003||2003-07-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|June 2006|Actual|2006-06-30||Interventional|ARCC||Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma|A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.|Completed||Phase 3|626|Actual|Pfizer|Efficacy data was not collected or analyzed after the primary analysis was completed.|3|||f||||t||||||||||2018-06-01 05:18:39.086087|2018-06-01 05:18:39.086087
NCT00006229|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-11-11|2003-07-24|2003-07-25|Estimate|||||||2013-11-11|2013-11-13|Estimate|April 2000||2000-04-30|August 2011|2011-08-31|February 2009|Actual|2009-02-28|December 2003|Actual|2003-12-31||Interventional|||Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer|A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer|Completed||Phase 2/Phase 3|774|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:18:40.784615|2018-06-01 05:18:40.784615
NCT00006081|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-07-27|2003-07-24|2003-07-25|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 2000||2000-06-30|July 2012|2012-07-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer|A Phase II Study of Bryostatin-1 (NSC 339555) Plus Paclitaxel in Patients With Metastatic or Unresectable Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction|Completed||Phase 2|37|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:18:41.002214|2018-06-01 05:18:41.002214
NCT00065442|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-23|2010-05-28||2010-09-02|2003-07-23|2003-07-24|Estimate|2010-09-02|2010-09-06|Estimate||||2010-09-02|2010-09-06|Estimate|July 2003||2003-07-31|September 2010|2010-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy|A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loading With PA2024 (Provenge(R), APC8015) in Men With Metastatic Androgen Independent Prostatic Adenocarcinoma|Completed||Phase 3|512|Actual|Dendreon||2|||f||||||||||||||2018-06-01 05:18:41.243317|2018-06-01 05:18:41.243317
NCT00065429|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-23|2011-08-03||2012-07-09|2003-07-23|2003-07-24|Estimate|2012-05-17|2012-06-20|Estimate||||2012-07-09|2012-07-18|Estimate|April 2003||2003-04-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer|A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion|Completed||Phase 1/Phase 2|64|Actual|ImmunoGen, Inc.||7|||f||||f||||||||||2018-06-01 05:18:42.087648|2018-06-01 05:18:42.087648
NCT00005604|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-01-31|2003-07-23|2003-07-24|Estimate|||||||2013-01-31|2013-02-01|Estimate|March 2000||2000-03-31|January 2013|2013-01-31||||July 2003|Actual|2003-07-31||Interventional|||Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors|Phase I Trial of Twice Weekly IV IL-12 Plus Low-Dose Subcutaneous IL-2 in Patients With Advanced Malignancies|Completed||Phase 1|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:18:42.685441|2018-06-01 05:18:42.685441
NCT00004887|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-09-19|2003-07-23|2003-07-24|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 1999||1999-01-31|March 2000|2000-03-31||||||||Interventional|||Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery|A Randomized Phase III Comparative Study of Paclitaxel With Carboplatin Versus Mitomycin, Ifosfamide, Cisplatin (MIC) Chemotherapy in Inoperable Advanced Stage Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:42.764297|2018-06-01 05:18:42.764297
NCT00065416|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-22|||2005-06-23|2003-07-22|2003-07-23|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 2004|2004-10-31||||||||Interventional|||Evaluating Therapeutic Massage for Chronic Neck Pain||Completed||Phase 1/Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:42.832421|2018-06-01 05:18:42.832421
NCT00065403|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-22|||2006-08-16|2003-07-22|2003-07-23|Estimate|||||||2006-08-16|2006-08-18|Estimate|February 2004||2004-02-29|August 2006|2006-08-31|September 2005||2005-09-30|||||Interventional|||Acupuncture for Irritable Bowel Syndrome||Completed||Phase 1/Phase 2|260||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:42.893908|2018-06-01 05:18:42.893908
NCT00065364|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2005-06-23|2003-07-22|2003-07-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2000||2000-05-31|October 2004|2004-10-31||||||||Interventional|||Improving Brain Development in Medically Healthy Premature Infants|Neurodevelopment and Experience: Behavior, Quantitative EEG and MRI|Completed||N/A|90||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:42.95758|2018-06-01 05:18:42.95758
NCT00065351|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2016-11-21|2003-07-22|2003-07-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|July 2003||2003-07-31|November 2016|2016-11-30|March 2007|Actual|2007-03-31|October 2006|Actual|2006-10-31||Interventional|||Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma|A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma|Completed||Phase 2|222|Actual|Celgene Corporation||1|||f||||f||||||||||2018-06-01 05:18:43.039392|2018-06-01 05:18:43.039392
NCT00065338|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2011-04-01|2003-07-22|2003-07-23|Estimate|||||||2011-04-01|2011-04-05|Estimate|June 2003||2003-06-30|April 2011|2011-04-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Nutritional Restriction and Activity Thermogenesis|Nutritional Restriction and Activity Thermogenesis|Completed||Phase 1|90|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 05:18:43.128343|2018-06-01 05:18:43.128343
NCT00065325|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2015-02-23|2003-07-22|2003-07-23|Estimate|||||||2015-02-23|2015-02-24|Estimate|August 2003||2003-08-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|June 2006|Actual|2006-06-30||Interventional|EFECT||The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer|A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy|Completed||Phase 3|694|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 05:18:43.18976|2018-06-01 05:18:43.18976
NCT00004253|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-12-17|2003-07-22|2003-07-23|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2000||2000-03-31|November 2002|2002-11-30||||||||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase II Study of 3-Dimensional Conformal Hyperfractionation Radiation Therapy (3D-CHRT) With Dose Escalation and Amifostine Mucosal Protection for Patients With Favorable Prognosis Inoperable Stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC) Receiving Paclitaxel and Carboplatin|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:43.507939|2018-06-01 05:18:43.507939
NCT00065390|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2008-03-03|2003-07-21|2003-07-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2003||2003-07-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome|Pilot (Phase I-II) Study of Pyrimethamine (Daraprim) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)|Completed||Phase 1|8||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:43.567594|2018-06-01 05:18:43.567594
NCT00065377|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2006-06-23|2003-07-21|2003-07-22|Estimate|||||||2006-06-23|2006-06-26|Estimate|July 2003||2003-07-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Interventional|||Effects of Oral Glucosamine on Insulin and Blood Vessel Activity in Normal and Obese People|An Exploratory Study of the Effects of Oral Glucosamine Administration on Insulin Sensitivity and Capillary Recruitment in Normal and Obese Subjects|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:43.650399|2018-06-01 05:18:43.650399
NCT00065312|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2006-07-18|2003-07-21|2003-07-22|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes||Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:18:43.740699|2018-06-01 05:18:43.740699
NCT00065299|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2005-06-23|2003-07-21|2003-07-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1984||1984-05-31|May 2000|2000-05-31|April 2000||2000-04-30|||||Interventional|||Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)|Effects of Maternal Phenylketonuria (PKU) on Pregnancy Outcome|Completed||N/A|572||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:43.831688|2018-06-01 05:18:43.831688
NCT00065286|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2005-06-23|2003-07-21|2003-07-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1996||1996-12-31|June 2003|2003-06-30|November 1999||1999-11-30|||||Observational|||Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation|Movement Dynamic Analyses of Akathisia|Completed|||||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:43.886045|2018-06-01 05:18:43.886045
NCT00065273|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-21|||2005-06-23|2003-07-21|2003-07-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1998||1998-07-31|June 2003|2003-06-30|June 2001||2001-06-30|||||Interventional|||Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay|Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors|Completed||Phase 3|50||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:43.939481|2018-06-01 05:18:43.939481
NCT00065247|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-18|||2005-06-23|2003-07-21|2003-07-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|June 2003|2003-06-30|May 2004||2004-05-31|||||Interventional|||The BONES Project: Building Healthy Bones in Children|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES)|Unknown status|Active, not recruiting|N/A|1500||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:44.000273|2018-06-01 05:18:44.000273
NCT00065234|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-18|||2017-03-27|2003-07-21|2003-07-22|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2003||2003-09-30|March 2017|2017-03-31|May 2006||2006-05-31|||||Interventional|||Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus)|Acupuncture to Prevent Postoperative Paralytic Ileus|Terminated||Phase 2|100||National Center for Complementary and Integrative Health (NCCIH)||||Not available|f||||||||||||||2018-06-01 05:18:44.051827|2018-06-01 05:18:44.051827
NCT00065221|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-18|||2008-01-24|2003-07-21|2003-07-22|Estimate|||||||2008-01-24|2008-01-25|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Ginger Control of Chemotherapy Induced Nausea and Vomiting|Trial of Encapsulated Ginger as a Treatment for Chemotherapy-Induced Nausea and Vomiting|Completed||Phase 2|180|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:44.102215|2018-06-01 05:18:44.102215
NCT00065208|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-18|||2012-09-20|2003-07-21|2003-07-22|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 2005||2005-04-30|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Reiki/Energy Healing in Prostate Cancer|Effects of Energy Healing on Prostate Cancer|Completed||Phase 1/Phase 2|79|Actual|The Cleveland Clinic||3|||f||||t||||||||||2018-06-01 05:18:44.166445|2018-06-01 05:18:44.166445
NCT00065260|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-18|2016-02-03||2016-02-03|2003-07-18|2003-07-21|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|July 2003||2003-07-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia|A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment|Completed||Phase 2|54|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:18:44.467118|2018-06-01 05:18:44.467118
NCT00065195|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-18|||2008-01-23|2003-07-18|2003-07-21|Estimate|||||||2008-01-23|2008-01-25|Estimate|November 2003||2003-11-30|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||REST: Reducing End-of-Life Symptoms With Touch|Efficacy of Massage at the End of Life|Completed||Phase 2|440||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:44.705947|2018-06-01 05:18:44.705947
NCT00065182|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-17|||2015-04-13|2003-07-17|2003-07-18|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2003||2003-08-31|April 2015|2015-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized, Phase III Study Comparing Combination IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Advanced (IIIB/IV) Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|408||GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:18:44.794552|2018-06-01 05:18:44.794552
NCT00065169|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-17|||2017-05-03|2003-07-17|2003-07-18|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2000||2000-11-30|May 2017|2017-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs|Anti-Inflammation in AD: PET Imaging Supplement|Completed||N/A|138||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:18:45.077547|2018-06-01 05:18:45.077547
NCT00065156|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-17|2009-08-31||2011-10-05|2003-07-17|2003-07-18|Estimate|2010-05-10|2010-06-09|Estimate||||2011-10-05|2011-10-10|Estimate|June 2003||2003-06-30|October 2011|2011-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality|A Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion-dependent Subjects With Myelodysplastic Syndromes Associated With a Del(5q) Cytogenetic Abnormality.|Completed||Phase 2|148|Actual|Celgene||1|||f||||f||||||||||2018-06-01 05:18:45.318531|2018-06-01 05:18:45.318531
NCT00065143|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-17|||2012-01-20|2003-07-17|2003-07-18|Estimate|||||||2012-01-20|2012-01-24|Estimate|June 2003||2003-06-30|January 2012|2012-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome|A Phase II Study of Clofarabine in Combination With Cytarabine (Ara-C) in Patients >/= 50 Years With Newly Diagnosed and Previously Untreated Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) (>/= 10% Bone Marrow Blasts)|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:18:46.349849|2018-06-01 05:18:46.349849
NCT00065130|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-17|||2016-12-21|2003-07-17|2003-07-18|Estimate|||||||2016-12-21|2016-12-22|Estimate|April 2000||2000-04-30|December 2016|2016-12-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes|Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Basal/Bolus Therapy for Patients With Gestational Diabetes|Completed||Phase 3|27|Actual|Novo Nordisk A/S|||||f||||f||||||||||2018-06-01 05:18:46.409443|2018-06-01 05:18:46.409443
NCT00065117|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-17|||2011-01-25|2003-07-17|2003-07-18|Estimate|||||||2011-01-25|2011-01-26|Estimate|September 2003||2003-09-30|January 2011|2011-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.||Terminated||Phase 2|180||AstraZeneca|||||||||||||||||||2018-06-01 05:18:46.47144|2018-06-01 05:18:46.47144
NCT00065104|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-17|||2006-08-16|2003-07-17|2003-07-18|Estimate|||||||2006-08-16|2006-08-18|Estimate|October 2000||2000-10-31|August 2006|2006-08-31|April 2003||2003-04-30|||||Interventional|||Dehydroepiandrosterone Effects on HIV-1 Replication|Dehydroepiandrosterone Effects on HIV-1 Replication|Completed||Phase 2|40||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:18:46.527121|2018-06-01 05:18:46.527121
NCT00065078|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2005-09-09|2003-07-17|2003-07-18|Estimate|||||||2005-09-09|2005-09-13|Estimate|June 2003||2003-06-30|September 2005|2005-09-30|July 2005||2005-07-31|||||Interventional|||Providing Birth Control Through Home Health Visits|Effectiveness of Nurse Home Contraceptive Dispensing|Unknown status|Active, not recruiting|N/A|600||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:46.569194|2018-06-01 05:18:46.569194
NCT00065065|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|2014-07-10||2017-12-14|2003-07-17|2003-07-18|Estimate|2014-12-01|2014-12-02|Estimate||||2017-12-14|2018-01-16|Actual|September 2002||2002-09-30|December 2017|2017-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Trial of Rosiglitazone for Ulcerative Colitis|A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis|Completed||Phase 2|105|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 05:18:46.634774|2018-06-01 05:18:46.634774
NCT00065052|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2010-01-12|2003-07-17|2003-07-18|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2002||2002-09-30|January 2010|2010-01-31|May 2007|Actual|2007-05-31|||||Interventional|||Modifying the Home Television Watching Environment|Modifying the Home Television Watching Environment|Completed||N/A|70|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||||2018-06-01 05:18:47.081031|2018-06-01 05:18:47.081031
NCT00065039|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2010-01-12|2003-07-17|2003-07-18|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2003||2003-04-30|January 2010|2010-01-31||||||||Interventional|||Wise Mind: Environmental Approach for Obesity Prevention||Completed||Phase 1|1000|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:18:47.134702|2018-06-01 05:18:47.134702
NCT00065026|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2010-01-12|2003-07-17|2003-07-18|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2003||2003-04-30|January 2010|2010-01-31||||||||Interventional|||Increasing Physical Activity Levels in Low-Income Women|Environmental Approaches to Reducing Obesity: Increasing Physical Activity Levels in Low-Income Women|Completed||N/A|150|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:18:47.178989|2018-06-01 05:18:47.178989
NCT00065013|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2010-06-23|2003-07-17|2003-07-18|Estimate|||||||2010-06-23|2010-06-24|Estimate|March 2003||2003-03-31|January 2010|2010-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Strength Training Following Gastric Bypass for Obesity|Strength Training Following Gastric Bypass for Obesity|Completed||Phase 2|24|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||f||||||||||2018-06-01 05:18:47.219947|2018-06-01 05:18:47.219947
NCT00065000|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2010-01-12|2003-07-17|2003-07-18|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31|August 2003||2003-08-31|||||Interventional|||Impact of Non-Commercialism Policy in Seattle Schools||Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:18:47.267326|2018-06-01 05:18:47.267326
NCT00004204|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2014-01-03|2003-07-17|2003-07-18|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 2000||2000-02-29|April 2006|2006-04-30||||||||Interventional|||Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma|A Phase II Study of Temozolomide in the Treatment of Recurrent Malignant Gliomas|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:47.376366|2018-06-01 05:18:47.376366
NCT00004006|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-10-03|2003-07-17|2003-07-18|Estimate|||||||2011-10-03|2011-10-04|Estimate|November 1997||1997-11-30|October 2011|2011-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma|Treatment for Extrachoroidal or Metastatic Retinoblastoma|Completed||Phase 2|4|Actual|St. Jude Children's Research Hospital|||||f||||||||||||||2018-06-01 05:18:47.443488|2018-06-01 05:18:47.443488
NCT00003895|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2015-04-28||2016-12-28|2003-07-17|2003-07-18|Estimate|2016-12-28|2017-02-20|Actual||||2016-12-28|2017-02-20|Actual|April 1999||1999-04-30|December 2016|2016-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma|A Randomized Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2 Positive Patients With a &gt;1mm Melanoma on Initial Biopsy|Completed||Phase 2|36|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:18:47.527834|2018-06-01 05:18:47.527834
NCT00003795|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2003-07-17|2003-07-18|Estimate|||||||2013-05-24|2013-05-27|Estimate|April 1999||1999-04-30|March 2009|2009-03-31||||March 2002|Actual|2002-03-31||Observational|||Quality of Life in Survivors of Gynecologic Cancer|Quality of Life of Gynecologic Cancer Survivors|Completed|||311|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:18:47.81568|2018-06-01 05:18:47.81568
NCT00003759|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2003-07-17|2003-07-18|Estimate|||||||2013-01-30|2013-01-31|Estimate|November 1998||1998-11-30|November 2002|2002-11-30|November 2002|Actual|2002-11-30|||||Interventional|||AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer|Intravesical Treatment of Superficial Bladder Cancer Characterized on the Basis of the Tumor Markers p53 and pRb|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:47.926177|2018-06-01 05:18:47.926177
NCT00064987|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|2017-04-03||2017-07-05|2003-07-16|2003-07-17|Estimate|2017-07-05|2017-07-07|Actual||||2017-07-05|2017-07-07|Actual|April 2001||2001-04-30|July 2017|2017-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism|Role of FSH in Human Gonadal Development|Terminated||Phase 2|19|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2||Recruitment was at a standstill. We are currently preparing our results for publication.|f||||t||||||||||2018-06-01 05:18:48.004372|2018-06-01 05:18:48.004372
NCT00064974|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2013-04-03|2003-07-16|2003-07-17|Estimate|||||||2013-04-03|2013-04-04|Estimate|June 2003||2003-06-30|April 2013|2013-04-30|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes|A Multicenter, Single-Arm, Open-Label Study of the Efficacy and Safety of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes|Completed||Phase 2|215|Actual|Celgene||1|||f||||t||||||||||2018-06-01 05:18:48.388532|2018-06-01 05:18:48.388532
NCT00064961|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-16|||2009-12-09|2003-07-16|2003-07-17|Estimate|||||||2009-12-09|2009-12-11|Estimate|March 2000||2000-03-31|December 2009|2009-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Obesity Prevention After Smoking Cessation in Menopause||Completed||N/A|100||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:18:48.58216|2018-06-01 05:18:48.58216
NCT00064935|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-15|||2005-06-23|2003-07-15|2003-07-16|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1999||1999-04-30|May 2003|2003-05-31|February 2002||2002-02-28|||||Interventional|||Endometrial Biopsy in Infertile Patients|Utility of the Endometrial Biopsy in the Evaluation of the Luteal Phase|Completed||Phase 3|880||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:48.629141|2018-06-01 05:18:48.629141
NCT00064532|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2014-12-02|2003-07-09|2003-07-10|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2003||2003-07-31|November 2013|2013-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Serum Sex Hormone Levels and Subclinical Atherosclerosis - Ancillary to MESA||Completed|||6173|Actual|Northwestern University|||||f||||||||||||||2018-06-01 05:18:57.306765|2018-06-01 05:18:57.306765
NCT00064922|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-15|||2017-01-11|2003-07-15|2003-07-16|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2002||2002-01-31|May 2008|2008-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Incentive Programs for Female Substance Abusers Who Smoke - 3|Incentive Programs for Female Substance Abusers Who Smoke|Completed||Phase 2/Phase 3|90||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:18:48.682713|2018-06-01 05:18:48.682713
NCT00064870|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2017-11-29|2003-07-15|2003-07-16|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2002||2002-06-30|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|NCRAD||Alzheimer's Disease Genetics Study|National Cell Repository for Alzheimer's Disease (NCRAD)|Recruiting|||3000|Anticipated|Indiana University|||||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-06-01 05:18:48.738326|2018-06-01 05:18:48.738326
NCT00064857|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2008-04-21|2003-07-15|2003-07-16|Estimate|||||||2008-04-21|2008-04-22|Estimate|August 2003||2003-08-31|April 2008|2008-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors|Pycnogenol for the Treatment of Lymphedema of the Arm in Breast Cancer Survivors|Completed||Phase 2|26||National Center for Complementary and Integrative Health (NCCIH)|||||||||t||||||||||2018-06-01 05:18:48.792583|2018-06-01 05:18:48.792583
NCT00064909|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2008-03-03|2003-07-14|2003-07-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2003||2003-07-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Observational|||MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis|Using MR Perfusion Imaging and Hypercapnia to Study Angiogenesis in Multiple Sclerosis Patients|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:48.875501|2018-06-01 05:18:48.875501
NCT00064896|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2017-10-27|2003-07-14|2003-07-15|Estimate|||||||2017-10-27|2017-10-30|Actual|July 14, 2003||2003-07-14|October 26, 2017|2017-10-26|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Technical Development of Cardiovascular Magnetic Resonance Imaging|Technical Development of Interventional Cardiovascular Magnetic Resonance Imaging|Completed||Phase 1|37|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:49.042176|2018-06-01 05:18:49.042176
NCT00064883|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2017-10-18|2003-07-14|2003-07-15|Estimate|||||||2017-10-18|2017-10-19|Actual|July 14, 2003||2003-07-14|August 25, 2017|2017-08-25||||||||Observational|||Radiation Therapy and the Natural History of Childhood Cancers|The Natural History of Childhood Malignancies Treated With Radiation Therapy|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:49.11021|2018-06-01 05:18:49.11021
NCT00064844|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|2013-01-31||2013-03-08|2003-07-14|2003-07-15|Estimate|2013-03-08|2013-04-16|Estimate||||2013-03-08|2013-04-16|Estimate|August 2002||2002-08-31|March 2013|2013-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Combination Nicotine Replacement for Alcoholic Smokers|Combination Nicotine Replacement for Alcoholic Smokers|Completed||Phase 4|96|Actual|Yale University||2|||f||||f||||||||||2018-06-01 05:18:49.180404|2018-06-01 05:18:49.180404
NCT00064831|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2007-12-06|2003-07-14|2003-07-15|Estimate|||||||2007-12-06|2007-12-07|Estimate|July 2003||2003-07-31|December 2007|2007-12-31|February 2007|Actual|2007-02-28|||||Interventional|||Black Cohosh Extract in Postmenopausal Breast Health|The Effect of Black Cohosh Extract on the Human Breast|Completed||Phase 1/Phase 2|73||National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:18:49.373072|2018-06-01 05:18:49.373072
NCT00064818|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2006-08-17|2003-07-14|2003-07-15|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2000||2000-09-30|July 2006|2006-07-31|September 2003||2003-09-30|||||Observational|||Acupuncture Needling on Connective Tissue by Ultrasound|Acupuncture Needling on Connective Tissue by Ultrasound|Completed|||46||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:49.426787|2018-06-01 05:18:49.426787
NCT00064805|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-14|||2014-08-13|2003-07-14|2003-07-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|August 2002||2002-08-31|April 2014|2014-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Therapy for Reading Problems in Adults After Brain Injury|Cognitively-based Treatments of Acquired Dyslexias|Completed||N/A|58|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:49.472369|2018-06-01 05:18:49.472369
NCT00064779|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-11|||2011-06-02|2003-07-14|2003-07-15|Estimate|||||||2011-06-02|2011-06-06|Estimate|July 2003||2003-07-31|June 2011|2011-06-30|July 2007|Actual|2007-07-31|June 2006|Actual|2006-06-30||Interventional|||Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma|Pilot Imaging Study to Assess the Distribution of IL13-PE38QQR Cytotoxin Infusions in Patients With Recurrent, Resectable, Supratentorial Malignant Glioma|Completed||Phase 1|18||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:18:49.535934|2018-06-01 05:18:49.535934
NCT00064766|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-11|||2005-06-23|2003-07-14|2003-07-15|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2003||2003-02-28|May 2003|2003-05-31|February 2005||2005-02-28|||||Interventional|||Norplant and Irregular Bleeding/Spotting|A Prospective Randomized Clinical Trial of Doxycycline 20mg Twice a Day Versus Placebo on the Bleeding and Spotting in Women After Insertion of a Levonorgestrel Implant (Norplant) Protocol #2002-1|Unknown status|Recruiting|Phase 4|50||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||||||||||||||||2018-06-01 05:18:49.654838|2018-06-01 05:18:49.654838
NCT00064753|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-11|2015-10-26||2017-09-17|2003-07-14|2003-07-15|Estimate|2015-10-26|2015-11-26|Estimate||||2017-09-17|2017-10-18|Actual|May 2002||2002-05-31|October 2015|2015-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|FAVORIT|7273 patients were screened, of whom 2056 and 2054 were randomized to high-dose and low-dose multivitamins, respectively; 34% did not meet eligibility cutpoints for tHey and Cer, and 9% were not enrolled for other reasons. Baseline characteristics were well balanced between treatment groups overall and within country.|Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)|Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)|Completed||Phase 2/Phase 3|4110|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The B-vitamin pathway for reducing total homocysteine (tHcy) may not be the optimal one for reducing CVD risk. Also, the duration of follow-up may not have been sufficient to identify a lagged impact on modification of CVD risk.|2|||f||||t|t|f||||||Yes|Individual patient data and samples are available at the NIDDK Central repository|2018-06-01 05:18:49.765009|2018-06-01 05:18:49.765009
NCT00003712|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-08-07|2003-07-14|2003-07-15|Estimate|||||||2012-08-07|2012-08-09|Estimate|January 2001||2001-01-31|August 2012|2012-08-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||CCI-779 in Treating Patients With Advanced Solid Tumors|A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous CCI-779 Given Once Daily for 5 Days Every 2 Weeks to Patients With Advanced Solid Tumors|Completed||Phase 1|15|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:18:50.371029|2018-06-01 05:18:50.371029
NCT00003707|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-26|2003-07-14|2003-07-15|Estimate|||||||2012-06-26|2012-06-28|Estimate|October 1998||1998-10-31|June 2012|2012-06-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer|Completed||Phase 1|22|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:18:50.441287|2018-06-01 05:18:50.441287
NCT00003645|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-21|2003-07-14|2003-07-15|Estimate|||||||2017-03-21|2017-03-23|Actual|June 14, 1999|Actual|1999-06-14|March 2017|2017-03-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence|A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence|Completed||Phase 3|64|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-06-01 05:18:50.503906|2018-06-01 05:18:50.503906
NCT00003571|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-07-14|2003-07-15|Estimate|||||||2016-07-01|2016-07-06|Estimate|August 1998||1998-08-31|July 2016|2016-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Gene Testing in Patients With Colon Cancer|Tumor Replication Error (RER) Status and Outcome in a Colon Cancer Adjuvant Chemotherapy Trial|Completed|||300|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Samples of tumor and normal tissue~   "|||2018-06-01 05:18:50.582376|2018-06-01 05:18:50.582376
NCT00003382|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-07|2003-07-14|2003-07-15|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 1998||1998-05-31|May 2006|2006-05-31||||April 2006|Actual|2006-04-30||Interventional|||Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer|A Phase I Study of Gemcitabine/Topotecan in Combination in Refractory Ovarian Cancer or Cancer of the Fallopian Tube|Terminated||Phase 1|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:18:50.701278|2018-06-01 05:18:50.701278
NCT00064792|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-11|2012-07-30||2014-06-04|2003-07-11|2003-07-14|Estimate|2014-06-04|2014-06-06|Estimate||||2014-06-04|2014-06-06|Estimate|July 2003||2003-07-31|June 2014|2014-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Simvastatin Therapy in Smith-Lemli-Opitz Syndrome|Investigation of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome|Completed||Phase 2|23|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:18:50.766528|2018-06-01 05:18:50.766528
NCT00064740|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-11|||2006-08-16|2003-07-11|2003-07-14|Estimate|||||||2006-08-16|2006-08-18|Estimate|July 2003||2003-07-31|August 2006|2006-08-31|March 2006||2006-03-31|||||Interventional|||Relaxation Response With Acupuncture for HIV Patients|Relaxation Response With Acupuncture for HIV Patients|Completed||Phase 2|100||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:18:51.116145|2018-06-01 05:18:51.116145
NCT00064701|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|2013-07-25|2010-09-22|2013-11-12|2003-07-11|2003-07-14|Estimate|2013-07-25|2013-09-26|Estimate|2011-11-10|2011-11-16|Estimate|2013-11-12|2013-12-05|Estimate|June 2003||2003-06-30|November 2013|2013-11-30|March 2009|Actual|2009-03-31|March 2005|Actual|2005-03-31||Interventional||Full analysis set; all randomized patients who received at least one dose of study drug.|Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients|A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (Cyclosporine)/MMF in de Novo Kidney Transplant Recipients|Completed||Phase 3|668|Actual|Astellas Pharma Inc|Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.|3|||f||||t||||||||||2018-06-01 05:18:51.284797|2018-06-01 05:18:51.284797
NCT00064688|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2015-09-08|2003-07-11|2003-07-14|Estimate|||||||2015-09-08|2015-09-10|Estimate|July 2003||2003-07-31|September 2015|2015-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Genomic Dissection of a QTL Affecting the Lipid Profile|Genomic Dissection of a QTL Affecting the Lipid Profile|Withdrawn|||0|Actual|Medical College of Wisconsin||||This protocol was created to support work as part of an NIH-funded study.|f||||f||||||Samples With DNA|"~     DNA~   "|||2018-06-01 05:18:55.281153|2018-06-01 05:18:55.281153
NCT00064675|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2013-04-04|2003-07-11|2003-07-14|Estimate|||||||2013-04-04|2013-04-08|Estimate|July 2003||2003-07-31|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Genetics of Cardiovascular Reactivity in Black Youth|Genetics of Cardiovascular Reactivity in Black Youth|Completed|||500|Actual|University of Tennessee|||||f||||||||||Samples With DNA|"~     buccal specimens stored at Med Coll Wisconsin~   "|||2018-06-01 05:18:55.325868|2018-06-01 05:18:55.325868
NCT00006073|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-25|||2017-10-05|2003-07-11|2003-07-14|Estimate|||||||2017-10-05|2017-10-06|Actual|July 19, 2000||2000-07-19|August 31, 2016|2016-08-31|August 31, 2016||2016-08-31|||||Observational|||Endocrine Studies in Health and Disease|Endocrine Studies in Health and Disease|Terminated|||3090|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:55.371927|2018-06-01 05:18:55.371927
NCT00064727|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2017-06-30|2003-07-10|2003-07-11|Estimate|||||||2017-06-30|2017-07-02|Actual|July 9, 2003||2003-07-09|April 11, 2007|2007-04-11|April 11, 2007||2007-04-11|||||Interventional|||Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes|Attenuating Insulin Resistance as a Therapeutic Target in the Management of Heart Failure|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:18:55.421903|2018-06-01 05:18:55.421903
NCT00064714|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10||2010-08-13|2015-02-23|2003-07-10|2003-07-11|Estimate||||2010-08-13|2010-08-18|Estimate|2015-02-23|2015-03-11|Estimate|July 2003||2003-07-31|January 2015|2015-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes|Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes|Completed||Phase 2|47|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 05:18:55.479587|2018-06-01 05:18:55.479587
NCT00064662|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|2012-03-26||2013-05-08|2003-07-10|2003-07-11|Estimate|2012-08-27|2012-09-28|Estimate||||2013-05-08|2013-05-10|Estimate|February 2002||2002-02-28|May 2013|2013-05-31|March 2010|Actual|2010-03-31|June 2006|Actual|2006-06-30||Interventional|SISTEr||Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence|Randomized Clinical Trial of the Burch Modified Tanagho and Autologous Fascia Sling Procedures for Women With Predominantly Stress Urinary Incontinence|Completed||Phase 2/Phase 3|655|Actual|New England Research Institutes|Patients received care at tertiary care centers which could limit the generalizability of the findings. Patients and providers were aware of treatment assignment which could lead to assessment bias.|2|||f||||f||||||||||2018-06-01 05:18:55.570587|2018-06-01 05:18:55.570587
NCT00064649|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2010-01-12|2003-07-10|2003-07-11|Estimate|||||||2010-01-12|2010-01-14|Estimate|April 2004||2004-04-30|January 2010|2010-01-31|June 2006|Actual|2006-06-30|||||Interventional|MIST||Minimally Invasive Surgical Therapy for BPH|Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia|Terminated||Phase 3|49|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3||Inability to recruit required sample size.|f||||t||||||||||2018-06-01 05:18:55.988916|2018-06-01 05:18:55.988916
NCT00064636|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2005-06-23|2003-07-10|2003-07-11|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2002||2002-12-31|September 2003|2003-09-30||||||||Interventional|||Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|A Phase I, Open Label, Dose Escalation Study of PS-341 Plus Docetaxel in Treatment-Naive or Previously Treated Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors|Terminated||Phase 1|46||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:18:56.073243|2018-06-01 05:18:56.073243
NCT00064623|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2008-03-04|2003-07-10|2003-07-11|Estimate|||||||2008-03-04|2008-03-06|Estimate|August 2003||2003-08-31|March 2008|2008-03-31|November 2005||2005-11-30|||||Interventional|||Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy|A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Painful HIV-Associated Distal Symmetrical Polyneuropathy|Completed||Phase 3|300||NeurogesX|||||||||||||||||||2018-06-01 05:18:56.137629|2018-06-01 05:18:56.137629
NCT00064610|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2008-02-07|2003-07-10|2003-07-11|Estimate|||||||2008-02-07|2008-02-11|Estimate|December 2002||2002-12-31|February 2008|2008-02-29||||December 2004|Actual|2004-12-31||Interventional|||Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer|A Phase I/II, Open Label, Dose Escalation Study to Determine the Tolerance and Preliminary Activity of PS-341 Plus Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer Requiring Chemotherapy|Completed||Phase 1/Phase 2|102||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:18:56.245051|2018-06-01 05:18:56.245051
NCT00064597|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-10|||2005-06-23|2003-07-10|2003-07-11|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1987||1987-12-31|June 2003|2003-06-30|December 2003||2003-12-31|||||Observational|||Noninvasive Prenatal Diagnosis: Using Fetal Cells From Maternal Blood|National Institute of Child Health and Human Development Fetal Cell Isolation Study (NIFTY)|Unknown status|Active, not recruiting||3500||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:18:56.299191|2018-06-01 05:18:56.299191
NCT00063726|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-02|||2012-01-12|2003-07-10|2003-07-11|Estimate|||||||2012-01-12|2012-01-13|Estimate|April 2002||2002-04-30|January 2012|2012-01-31|July 2005|Actual|2005-07-31|May 2005|Actual|2005-05-31||Interventional|||A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039|An International, Non-Comparative, Open-Label Study of PS-341 Administered to Patients With Multiple Myeloma Who Experienced Relapsed or Progressive Disease After Receiving at Least Four Previous Treatment Regimens or Experienced Progressive Disease After Receiving Dexamethasone in Millennium Protocol M34101-039|Completed||Phase 3|600||Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 05:18:56.369187|2018-06-01 05:18:56.369187
NCT00003350|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-09|2003-07-10|2003-07-11|Estimate|||||||2013-01-09|2013-01-10|Estimate|March 1999||1999-03-31|January 2013|2013-01-31||||March 2007|Actual|2007-03-31||Interventional|||Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma|Phase III Study of Paclitaxel Versus Liposomal Doxorubicin for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma|Completed||Phase 3|240|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:18:56.640559|2018-06-01 05:18:56.640559
NCT00003184|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-02|2003-07-10|2003-07-11|Estimate|||||||2013-04-02|2013-04-04|Estimate|August 1996||1996-08-31|November 2000|2000-11-30|July 2003|Actual|2003-07-31|||||Interventional|||Vaccine Therapy in Treating Women With Metastatic Breast Cancer|Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:18:56.71924|2018-06-01 05:18:56.71924
NCT00003045|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-04-25|2003-07-10|2003-07-11|Estimate|||||||2017-04-25|2017-04-26|Actual|April 1997||1997-04-30|April 2017|2017-04-30|December 31, 2003|Actual|2003-12-31|December 31, 2001|Actual|2001-12-31||Interventional|||Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer|A Phase II Trial of Hyperthermia and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate|Completed||N/A|38|Actual|Dana-Farber Cancer Institute||1|||f||||t|f|t|f|f||||No||2018-06-01 05:18:56.779836|2018-06-01 05:18:56.779836
NCT00003008|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2003-07-10|2003-07-11|Estimate|||||||2010-01-26|2010-01-28|Estimate|June 1997||1997-06-30|January 2010|2010-01-31||||June 2006|Actual|2006-06-30||Interventional|||Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma|Pilot Study to Evaluate the Potential Interactions Between Paclitaxel and Protease Inhibitors in Patients With AIDS-Related Kaposi's Sarcoma|Completed||Phase 2|33|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:18:56.84813|2018-06-01 05:18:56.84813
NCT00002965|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2003-07-10|2003-07-11|Estimate|||||||2012-07-27|2012-07-30|Estimate|January 1997||1997-01-31|July 2012|2012-07-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas|Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas|Completed||Phase 2|16|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:18:56.907353|2018-06-01 05:18:56.907353
NCT00064584|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-09|||2009-03-23|2003-07-09|2003-07-10|Estimate|||||||2009-03-23|2009-03-24|Estimate|May 2002||2002-05-31|March 2009|2009-03-31|July 2005|Actual|2005-07-31|January 2005|Actual|2005-01-31||Interventional|||Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)|Tolerability and PK/PD of Multiple Oral Doses of CT53518 in Patients With Acute Myelogenous Leukemia|Completed||Phase 1|60||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:18:57.047953|2018-06-01 05:18:57.047953
NCT00064571|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-09|||2006-04-21|2003-07-09|2003-07-10|Estimate|||||||2006-04-21|2006-04-24|Estimate|October 2002||2002-10-31|April 2006|2006-04-30|October 2005||2005-10-31|||||Interventional|||Surgery for Vocal Cord Paralysis|Medialization Vs Reinnervation for Vocal Cord Paralysis|Terminated||Phase 3|300||National Institute on Deafness and Other Communication Disorders (NIDCD)|||||f||||||||||||||2018-06-01 05:18:57.116168|2018-06-01 05:18:57.116168
NCT00064558|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2018-05-16|2003-07-09|2003-07-10|Estimate|||||||2018-05-16|2018-05-17|Actual|July 2003||2003-07-31|May 2018|2018-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Genetic Determinants of Sudden Cardiac Death|Genetic Determinants of Sudden Cardiac Death|Completed|||2500|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 05:18:57.202212|2018-06-01 05:18:57.202212
NCT00064545|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-12-11|2003-07-09|2003-07-10|Estimate|||||||2012-12-11|2012-12-13|Estimate|July 2003||2003-07-31|December 2012|2012-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC||Completed|||1500|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 05:18:57.253194|2018-06-01 05:18:57.253194
NCT00064519|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2015-09-22|2003-07-09|2003-07-10|Estimate|||||||2015-09-22|2015-09-24|Estimate|July 2003||2003-07-31|September 2015|2015-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Genetics of CRP in Families With Myocardial Infarction||Completed|||1406|Actual|Medical College of Wisconsin|||1||f||||f||||||Samples With DNA|"~     i.) Blood: A blood sample (30 cc, ~2 tablespoons) will be drawn. This will take place in the~     catheterization lab at the end of the catheterization procedure or by using standard~     venipuncture technique during a clinic visit or at community outreach events when feasible.~      ii.) Buccal Swab: The participant uses specially prepared cotton swabs (called buccal swabs)~     to rub in a circular motion on the inside of both cheeks. The swabs collect cheek cells that~     can be processed to obtain DNA.~      iii.) Saliva: A saliva sample is obtained by having the participant spit in a special vial~     specifically designed for genetic testing. The participant will continue to spit into the~     vial until it contains 2 ml (about 1 teaspoon) of saliva.~   "|||2018-06-01 05:18:57.360785|2018-06-01 05:18:57.360785
NCT00064506|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2015-01-13|2003-07-09|2003-07-10|Estimate|||||||2015-01-13|2015-01-15|Estimate|July 2003||2003-07-31|January 2015|2015-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Gene-Environment Interactions in Complex Disease|Gene-Environment Interactions in Complex Disease|Completed|||15792|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-06-01 05:18:57.415581|2018-06-01 05:18:57.415581
NCT00064493|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2008-07-01|2003-07-09|2003-07-10|Estimate|||||||2008-07-01|2008-07-02|Estimate|June 2003||2003-06-30|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Modeling DNA Diversity in Reverse Cholesterol Transport||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:18:57.464832|2018-06-01 05:18:57.464832
NCT00064480|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2018-05-14|2003-07-09|2003-07-10|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2003||2003-07-31|April 2008|2008-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Black Pooling Project||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:18:57.510442|2018-06-01 05:18:57.510442
NCT00064467|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2017-05-24|2003-07-09|2003-07-10|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2003||2003-06-30|May 2017|2017-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Lethargic Depression Study|An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms|Completed||Phase 3|268||GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:18:57.557741|2018-06-01 05:18:57.557741
NCT00064454|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-05-09|2003-07-09|2003-07-10|Estimate|||||||2012-05-09|2012-05-10|Estimate|May 2003||2003-05-31|May 2012|2012-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis|FACTS II: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects With Active Ulcerative Colitis|Completed||Phase 3|375||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:18:57.659655|2018-06-01 05:18:57.659655
NCT00064441|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-05-09|2003-07-09|2003-07-10|Estimate|||||||2012-05-09|2012-05-10|Estimate|May 2003||2003-05-31|May 2012|2012-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis|FACTS I: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects With Active Ulcerative Colitis|Completed||Phase 3|375||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:18:57.738637|2018-06-01 05:18:57.738637
NCT00064415|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-02-21|2003-07-08|2003-07-09|Estimate|||||||2012-02-21|2012-02-22|Estimate|June 2002||2002-06-30|February 2012|2012-02-29|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD|A Multicenter, Open-Label, Randomized, Active-Controlled, Parallel Group Chronic Safety Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|799|Actual|Sunovion||2|||f||||t||||||||||2018-06-01 05:18:57.821694|2018-06-01 05:18:57.821694
NCT00064402|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-02-21|2003-07-08|2003-07-09|Estimate|||||||2012-02-21|2012-02-22|Estimate|April 2002||2002-04-30|February 2012|2012-02-29|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD|A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|741|Actual|Sunovion||5|||f||||t||||||||||2018-06-01 05:18:58.181116|2018-06-01 05:18:58.181116
NCT00064389|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-02-21|2003-07-08|2003-07-09|Estimate|||||||2012-02-21|2012-02-22|Estimate|January 2003||2003-01-31|February 2012|2012-02-29|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma|Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma|Completed||Phase 3|746|Actual|Sunovion||2|||f||||f||||||||||2018-06-01 05:18:58.380026|2018-06-01 05:18:58.380026
NCT00064376|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2018-01-25|2003-07-08|2003-07-09|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2003|Actual|2003-05-31|January 2018|2018-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Paricalcitol in Treating Patients With Myelodysplastic Syndrome|A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes|Completed||Phase 2|||Cedars-Sinai Medical Center|||||f|||||t|f||||||||2018-06-01 05:18:58.643016|2018-06-01 05:18:58.643016
NCT00064363|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-03-07|2003-07-08|2003-07-09|Estimate|||||||2012-03-07|2012-03-08|Estimate|June 2003||2003-06-30|March 2012|2012-03-31|February 2007|Actual|2007-02-28|||||Interventional|||Talampanel in Treating Patients With Recurrent High-Grade Glioma|A Phase II Trial Of Talampanel In Patients With Recurrent High-Grade Gliomas|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:18:58.768655|2018-06-01 05:18:58.768655
NCT00064350|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2012-03-08||2015-11-25|2003-07-08|2003-07-09|Estimate|2012-11-26|2012-11-28|Estimate||||2015-11-25|2015-11-30|Estimate|May 2004||2004-05-31|November 2015|2015-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer|A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens|Completed||Phase 2|342|Actual|Eastern Cooperative Oncology Group||3|||f||||t||||||||||2018-06-01 05:18:59.16517|2018-06-01 05:18:59.16517
NCT00064181|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-09-20|2003-07-08|2003-07-09|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2003||2003-05-31|September 2012|2012-09-30||||January 2005|Actual|2005-01-31||Interventional|||Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer|Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer|Completed||Phase 3|86|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:19:03.22828|2018-06-01 05:19:03.22828
NCT00064337|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2016-10-26||2017-10-03|2003-07-08|2003-07-09|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|January 2004||2004-01-31|October 2017|2017-10-31|November 2015|Actual|2015-11-30|May 2012|Actual|2012-05-31||Interventional|||S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis|S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study)|Completed||Phase 2|104|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:19:00.703693|2018-06-01 05:19:00.703693
NCT00064324|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-06-03|2003-07-08|2003-07-09|Estimate|||||||2013-06-03|2013-06-04|Estimate|June 2003||2003-06-30|June 2013|2013-06-30||||November 2005|Actual|2005-11-30||Interventional|||Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma|A Phase II Study of Perifosine in Soft Tissue Sarcoma|Completed||Phase 2|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:01.262603|2018-06-01 05:19:01.262603
NCT00064311|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-03-07|2003-07-08|2003-07-09|Estimate|||||||2012-03-07|2012-03-08|Estimate|June 2003||2003-06-30|March 2012|2012-03-31|September 2004|Actual|2004-09-30|||||Interventional|||Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation|A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 1/Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:01.337757|2018-06-01 05:19:01.337757
NCT00064298|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2017-05-08||2017-12-20|2003-07-08|2003-07-09|Estimate|2017-05-08|2017-07-24|Actual||||2017-12-20|2018-01-19|Actual|January 2004||2004-01-31|December 2017|2017-12-31|April 2009|Actual|2009-04-30|October 2008|Actual|2008-10-31||Interventional||All randomized participants|Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer|A Phase II Randomized Placebo Controlled, Double Blinded Trial To Evaluate The Effects Of Fruit And Vegetable Extracts On Intermediate Biomarkers In Head And Neck Cancer Patients|Completed||N/A|134|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-06-01 05:19:01.481655|2018-06-01 05:19:01.481655
NCT00064285|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2010-04-30|2003-07-08|2003-07-09|Estimate|||||||2010-04-30|2010-05-03|Estimate|June 2003||2003-06-30|April 2010|2010-04-30||||||||Interventional|||Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer|Phase I Study Of Flavopiridol In Combination With Imatinib Mesylate (STI571, Gleevec) In Bcr/Abl+ Hematological Malignancies|Completed||Phase 1|22|Actual|Virginia Commonwealth University|||||||||f||||||||||2018-06-01 05:19:02.266731|2018-06-01 05:19:02.266731
NCT00064272|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2016-10-20|2003-07-08|2003-07-09|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2003||2003-05-31|October 2016|2016-10-31||||May 2007|Actual|2007-05-31||Interventional|IRB 2003-551||UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer|Phase II Trial Of Encapsulized Ginger As A Treatment For Chemotherapy-Induced Nausea and Vomiting AKA IRB 2003-213|Completed||Phase 2|180|Anticipated|University of Michigan Cancer Center||3|||f||||||||||||||2018-06-01 05:19:02.374796|2018-06-01 05:19:02.374796
NCT00064259|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2015-06-10||2015-06-10|2003-07-08|2003-07-09|Estimate|2015-06-10|2015-06-29|Estimate||||2015-06-10|2015-06-29|Estimate|June 2003||2003-06-30|May 2013|2013-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional||Total number of participants at different dose levels of Oblimersen (3, 5, or 7 mg/kg/d) in combination with 5-FU (1000 mg/m2/d or 750 mg/m2/d) and Cisplatin (100 mg/m2 or 75 mg/m2)|A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer|A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer|Terminated||Phase 1/Phase 2|15|Actual|National Cancer Institute (NCI)||1||Discontinued development of G3139 (oblimersen)|f||||t||||||||||2018-06-01 05:19:02.462395|2018-06-01 05:19:02.462395
NCT00064246|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-01-24|2003-07-08|2003-07-09|Estimate|||||||2013-01-24|2013-01-25|Estimate|July 2003||2003-07-31|January 2013|2013-01-31||||September 2004|Actual|2004-09-30||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder|A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation|Completed||Phase 1/Phase 2|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:02.699686|2018-06-01 05:19:02.699686
NCT00064233|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2015-10-01|2003-07-08|2003-07-09|Estimate|||||||2015-10-01|2015-10-02|Estimate|November 2003||2003-11-30|August 2012|2012-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate|A Phase I Dose-Escalation Study To Determine The Safety, Pharmacokinetics, And Pharmacodynamics Of BMS-354825 In The Treatment Of Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Hematologic Resistance To Imatinib Mesylate (Gleevec|Completed||Phase 1|42|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:19:02.803707|2018-06-01 05:19:02.803707
NCT00064220|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-05-15|2003-07-08|2003-07-09|Estimate|||||||2012-05-15|2012-05-16|Estimate|April 2003||2003-04-30|May 2012|2012-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma|A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:19:02.870718|2018-06-01 05:19:02.870718
NCT00064207|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2012-09-20|2003-07-08|2003-07-09|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2003||2003-05-31|September 2012|2012-09-30||||January 2007|Actual|2007-01-31||Interventional|||Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer|Randomized Phase II/III Study Comparing Gemcitabine Followed by Gemcitabine Plus Concomitant Radiation (50.4 Gy) Versus Control After Curative Pancreaticoduodenectomy for Pancreatic Head Cancer|Completed||Phase 2/Phase 3|97|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:19:02.954913|2018-06-01 05:19:02.954913
NCT00064194|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2016-11-25|2003-07-08|2003-07-09|Estimate|||||||2016-11-25|2016-11-28|Estimate|November 2001||2001-11-30|March 2010|2010-03-31|April 2008|Actual|2008-04-30|||||Interventional|||Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia|A Double-Blind, Placebo-Controlled, Randomized Study Of Combination Vitamin E, Selenium And Soy Protein Product In Subjects With High Grade Prostatic Intraepithelial Neoplasia|Completed||Phase 3|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:19:03.135359|2018-06-01 05:19:03.135359
NCT00064142|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-06-04|2003-07-08|2003-07-09|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 2003||2003-05-31|June 2013|2013-06-30||||December 2006|Actual|2006-12-31||Interventional|||Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma|A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:19:03.365083|2018-06-01 05:19:03.365083
NCT00064129|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2018-04-09|2003-07-08|2003-07-09|Estimate|||||||2018-04-09|2018-04-10|Actual|May 13, 2003|Actual|2003-05-13|April 2018|2018-04-30|February 9, 2011|Actual|2011-02-09|January 5, 2011|Actual|2011-01-05||Interventional|||Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer|A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (Ipilimumab) in Combination With GM-CSF in Patients With Metastatic, Androgen-Independent Prostate Cancer|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1||||||||t|f|||f|||||2018-06-01 05:19:03.439145|2018-06-01 05:19:03.439145
NCT00064116|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2014-06-23|2003-07-08|2003-07-09|Estimate|||||||2014-06-23|2014-06-24|Estimate|May 2001||2001-05-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|December 2010|Actual|2010-12-31||Interventional|||Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8)|Completed||Phase 3|824|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:19:03.669239|2018-06-01 05:19:03.669239
NCT00064103|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-01-22|2003-07-08|2003-07-09|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2003||2003-06-30|January 2013|2013-01-31||||August 2007|Actual|2007-08-31||Interventional|||Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx|Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135]|Completed||Phase 1/Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:03.817337|2018-06-01 05:19:03.817337
NCT00064090|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-07-17|2003-07-08|2003-07-09|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2003||2003-03-31|August 2008|2008-08-31|January 2008|Actual|2008-01-31|September 2004|Actual|2004-09-30||Interventional|||3-AP and Cytarabine in Treating Patients With Hematologic Cancer|A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:03.907943|2018-06-01 05:19:03.907943
NCT00064077|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2015-05-27|2003-07-08|2003-07-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2003||2003-05-31|May 2015|2015-05-31||||January 2011|Actual|2011-01-31||Interventional|||Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix|A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix|Completed||Phase 3|513|Actual|Gynecologic Oncology Group||4|||f||||||||||||||2018-06-01 05:19:04.011843|2018-06-01 05:19:04.011843
NCT00064064|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-11-05|2003-07-08|2003-07-09|Estimate|||||||2013-11-05|2013-11-06|Estimate|January 2003||2003-01-31|August 2004|2004-08-31|August 2008|Actual|2008-08-31|||||Interventional|||3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Patients With Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:04.149696|2018-06-01 05:19:04.149696
NCT00064051|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-08-01|2003-07-08|2003-07-09|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 2003||2003-01-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2006|Actual|2006-08-31||Interventional|||3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer|A Phase II Study of Triapine in Combination With Gemcitabine in Patients With Pancreatic Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:04.227692|2018-06-01 05:19:04.227692
NCT00064038|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2012-11-19||2015-03-05|2003-07-08|2003-07-09|Estimate|2013-06-12|2013-07-17|Estimate||||2015-03-05|2015-03-25|Estimate|November 2004||2004-11-30|March 2015|2015-03-31|May 2012|Actual|2012-05-31|October 2008|Actual|2008-10-31||Interventional|||S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma|Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients With Previously Untreated Multiple Myeloma|Completed||Phase 3|198|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:19:04.334735|2018-06-01 05:19:04.334735
NCT00064025|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2014-01-31||2016-03-17|2003-07-08|2003-07-09|Estimate|2014-07-24|2014-08-15|Estimate||||2016-03-17|2016-04-11|Estimate|April 2004||2004-04-30|March 2016|2016-03-31||||September 2010|Actual|2010-09-30||Interventional|||Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus|A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus|Completed||Phase 2|75|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:19:06.461883|2018-06-01 05:19:06.461883
NCT00064012|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-03-18|2003-07-08|2003-07-09|Estimate|||||||2013-03-18|2013-03-19|Estimate|May 2003||2003-05-31|March 2013|2013-03-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-Label, Phase II Study Of VELCADE Alone Or VELCADE Plus Docetaxel In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|4|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-06-01 05:19:06.796566|2018-06-01 05:19:06.796566
NCT00063999|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2018-01-24||2018-03-23|2003-07-08|2003-07-09|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|August 2003||2003-08-31|October 2016|2016-10-31||||June 2013|Actual|2013-06-30||Interventional||Eligible and treated patients|Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer|Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer|Active, not recruiting||Phase 3|1381|Actual|Gynecologic Oncology Group|Eligibility for this study was expanded from measurable, stage 3 or stage 4 or recurrent disease to include non-measurable, stage 4 or recurrent disease and then to include non-measurable stage 3 disease.|2|||f||||||||||||||2018-06-01 05:19:07.048768|2018-06-01 05:19:07.048768
NCT00063986|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2012-11-29||2013-02-07|2003-07-08|2003-07-09|Estimate|2013-01-04|2013-02-11|Estimate||||2013-02-07|2013-02-12|Estimate|March 2004||2004-03-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|December 2010|Actual|2010-12-31||Interventional|||Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer|Minimally Invasive Esophagectomy (MIE): A Multicenter Feasibility Study|Completed||Phase 2|110|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:19:08.646514|2018-06-01 05:19:08.646514
NCT00063973|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-09-27|2003-07-08|2003-07-09|Estimate|||||||2013-09-27|2013-09-30|Estimate|July 2003||2003-07-31|September 2013|2013-09-30||||March 2008|Actual|2008-03-31||Interventional|||Cilengitide in Treating Children With Refractory Primary Brain Tumors|Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:09.401192|2018-06-01 05:19:09.401192
NCT00063960|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2016-07-01|2003-07-08|2003-07-09|Estimate|||||||2016-07-01|2016-07-06|Estimate|August 2003||2003-08-31|July 2016|2016-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer|A Phase II Trial Of Toxicity Assessment In Two Cohorts Of Patients (Resection Alone Or Ablation With Or Without Resection Of Hepatic Metastases From Colorectal Cancer) Treated With Adjuvant Hepatic Arterial Infusion (HAI) FUDR Plus Systemic CPT-11|Completed||Phase 2|94|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:19:09.564405|2018-06-01 05:19:09.564405
NCT00063947|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-06-03|2003-07-08|2003-07-09|Estimate|||||||2013-06-03|2013-06-04|Estimate|May 2003||2003-05-31|June 2013|2013-06-30||||February 2009|Actual|2009-02-28||Interventional|||Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer|A Phase I Study of OSI-774 in Combination With Gemcitabine and Radiation in Locally Advanced, Non-Operable Pancreatic Cancer|Completed||Phase 1|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:09.711249|2018-06-01 05:19:09.711249
NCT00063934|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|2012-07-10||2014-05-06|2003-07-08|2003-07-09|Estimate|2012-07-10|2012-08-16|Estimate||||2014-05-06|2014-05-21|Estimate|May 2003||2003-05-31|December 2012|2012-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer|A Phase 1/2 Study of Bcl-2 Antisense Oligonucleotide G3139 in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer|Terminated||Phase 1/Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:09.890555|2018-06-01 05:19:09.890555
NCT00063895|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2013-01-08|2003-07-08|2003-07-09|Estimate|||||||2013-01-08|2013-01-09|Estimate|April 2003||2003-04-30|January 2013|2013-01-31||||October 2005|Actual|2005-10-31||Interventional|||Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck|A Pharmacogenetic and Pharmacodynamic Study of Erlotinib (OSI-774) Toxicity in Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|80|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:10.206019|2018-06-01 05:19:10.206019
NCT00063882|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-08|||2017-05-18|2003-07-08|2003-07-09|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2003||2003-06-30|May 2017|2017-05-31||||May 2017|Actual|2017-05-31||Interventional|||Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer|A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma|Active, not recruiting||Phase 3|588|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:19:10.421252|2018-06-01 05:19:10.421252
NCT00063869|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2009-09-03|2003-07-08|2003-07-09|Estimate|||||||2009-09-03|2009-09-04|Estimate||||September 2009|2009-09-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis|A Double-blind, Parallel, Placebo-controlled, Randomized Study of the Efficacy and Safety of Etanercept in Patients With Idiopathic Pulmonary Fibrosis.|Completed||Phase 2|88|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:19:10.969762|2018-06-01 05:19:10.969762
NCT00023907|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-04-10|2003-07-08|2003-07-09|Estimate|||||||2013-04-10|2013-04-11|Estimate|July 2001||2001-07-31|May 2004|2004-05-31||||April 2006|Actual|2006-04-30||Interventional|||Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum and Paclitaxel-Resistant Ovarian or Primary Peritoneal Cancer|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:19:11.131758|2018-06-01 05:19:11.131758
NCT00005940|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-08-28|2003-07-08|2003-07-09|Estimate|||||||2017-08-28|2017-08-30|Actual|October 1999||1999-10-31|August 2017|2017-08-31||||January 2006|Actual|2006-01-31||Interventional|||Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission|Phase II Study of Radiolabeled BC8 (Anti-CD45) Antibody Combined With Busulfan and Cyclophosphamide as Treatment for Acute Myelogenous Leukemia in First Remission Followed by HLA-Identical Related Peripheral Blood Stem Cell Transplantation|Completed||Phase 2|18|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:19:11.355167|2018-06-01 05:19:11.355167
NCT00003211|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-06|2003-07-08|2003-07-09|Estimate|||||||2012-11-06|2012-11-07|Estimate|October 1996||1996-10-31|November 2012|2012-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor|Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support|Completed||Phase 2|94|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-06-01 05:19:11.580084|2018-06-01 05:19:11.580084
NCT00002878|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-28|2003-07-08|2003-07-09|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 1997||1997-03-31|August 2013|2013-08-31||||April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma|A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA|Completed||Phase 3|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:19:11.763615|2018-06-01 05:19:11.763615
NCT00063856|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2012-02-09|2003-07-07|2003-07-08|Estimate|||||||2012-02-09|2012-02-13|Estimate|July 2003||2003-07-31|May 2007|2007-05-31|June 2004||2004-06-30|||||Interventional|||Dressing Preparations for Smallpox|A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus|Completed||Phase 1/Phase 2|102|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:19:11.940424|2018-06-01 05:19:11.940424
NCT00063843|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2010-08-26|2003-07-07|2003-07-08|Estimate|||||||2010-08-26|2010-08-27|Estimate|July 2003||2003-07-31|May 2006|2006-05-31|August 2005||2005-08-31|||||Interventional|||Anthrax-rPA: Safety, Tolerability, Immunogenicity|A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two Intramuscular Doses to Healthy Adults|Completed||Phase 1|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:19:12.020536|2018-06-01 05:19:12.020536
NCT00063765|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-03|||2008-03-03|2003-07-03|2003-07-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2003||2003-06-30|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye|A Phase I Study of NT-501-10 and NT-501-6A.02, Implants of Encapsulated Human NTC-210 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Patients With Retinitis Pigmentosa|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:13.622965|2018-06-01 05:19:13.622965
NCT00063830|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2007-10-15|2003-07-07|2003-07-08|Estimate|||||||2007-10-15|2007-10-17|Estimate||||October 2007|2007-10-31||||||||Interventional|||ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.|ISIS 2302-CS27, Phase 2, Double-Blinded, Controlled Study of Four Dosing Regimens of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis|Completed||Phase 2|||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:19:12.111498|2018-06-01 05:19:12.111498
NCT00063817|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2017-12-22|2003-07-07|2003-07-08|Estimate|||||||2017-12-22|2017-12-27|Actual|June 2003||2003-06-30|December 2017|2017-12-31|July 2009|Actual|2009-07-31|January 2009|Actual|2009-01-31||Interventional|||Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant|Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)|Completed||Phase 1|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 05:19:12.204134|2018-06-01 05:19:12.204134
NCT00063804|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2012-05-17|2003-07-07|2003-07-08|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|October 2006|Actual|2006-10-31|||||Interventional|||Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men|A Phase 1, Dose-Rising Study of AMD11070 in HIV-Seronegative Men to Assess the Safety and Pharmacokinetics After Single or Multiple Doses|Completed||Phase 1|44|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||||||||||||||||2018-06-01 05:19:12.356703|2018-06-01 05:19:12.356703
NCT00063791|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2007-02-13|2003-07-07|2003-07-08|Estimate|||||||2007-02-13|2007-02-14|Estimate||||July 2003|2003-07-31||||||||Expanded Access|||A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE|An Open-Labeled, Randomized Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE in Patients With Relapsed Multiple Myeloma Who Have Failed Four or More Lines of Therapy|No longer available|||1000||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:19:12.477032|2018-06-01 05:19:12.477032
NCT00063778|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-07|||2012-06-27|2003-07-07|2003-07-08|Estimate|||||||2012-06-27|2012-07-02|Estimate|July 2003||2003-07-31|June 2012|2012-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa|A Phase I Safety and Immunogenicity Trial of an Alphavirus Replicon HIV Subtype C Gag Vaccine (AVX101, Alphavax, Inc.) in Healthy HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|48|Actual|AlphaVax, Inc.||3|||f||||||||||||||2018-06-01 05:19:12.567873|2018-06-01 05:19:12.567873
NCT00063752|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-03|||2005-06-23|2003-07-07|2003-07-08|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2003||2003-07-31|April 2005|2005-04-30|March 2005||2005-03-31|||||Interventional|||Safety Study of PI-0824 to Treat Pemphigus Vulgaris|An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy|Completed||Phase 1|15||Peptimmune|||||||||||||||||||2018-06-01 05:19:12.768825|2018-06-01 05:19:12.768825
NCT00045357|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2010-09-20|2003-07-07|2003-07-08|Estimate|||||||2010-09-20|2010-09-21|Estimate|November 2001||2001-11-30|September 2010|2010-09-30|August 2008|Actual|2008-08-31|||||Interventional|||Biological Therapy in Treating Patients With Metastatic Melanoma|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD4+ Antigen-Specific T Cell Clones for Patients With Metastatic Melanoma|Completed||Phase 1|18|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:19:12.841174|2018-06-01 05:19:12.841174
NCT00042900|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-06-04|2003-07-07|2003-07-08|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2002||2002-04-30|June 2013|2013-06-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Pyroxamide in Treating Patients With Advanced Cancer|A Phase I Clinical And Pharmacological Study Of Pyroxamide (NSC 696085) In Patients With Advanced Malignancies|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:19:12.892651|2018-06-01 05:19:12.892651
NCT00040820|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2011-03-03|2003-07-07|2003-07-08|Estimate|||||||2011-03-03|2011-03-07|Estimate|January 2002||2002-01-31|March 2011|2011-03-31|March 2004|Actual|2004-03-31|August 2003|Actual|2003-08-31||Interventional|||Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer|A Treatment Access Program With Oxaliplatin for Previously Treated Colorectal Cancer Patients|Completed||N/A|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:19:13.046207|2018-06-01 05:19:13.046207
NCT00039169|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2008-07-23|2003-07-07|2003-07-08|Estimate|||||||2008-07-23|2008-07-24|Estimate|December 2001||2001-12-31|January 2008|2008-01-31||||||||Interventional|||BAY 59-8862 in Treating Patients With Advanced Kidney Cancer|An Uncontrolled Phase II Multi-Center Trial Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Advanced Renal Cell Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:13.119377|2018-06-01 05:19:13.119377
NCT00036660|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2010-11-07|2003-07-07|2003-07-08|Estimate|||||||2010-11-07|2010-11-09|Estimate|August 2001||2001-08-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||SarCNU in Treating Patients With Recurrent Malignant Glioma|A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:19:13.200273|2018-06-01 05:19:13.200273
NCT00033384|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-04-10|2003-07-07|2003-07-08|Estimate|||||||2013-04-10|2013-04-12|Estimate|February 2002||2002-02-28|December 2002|2002-12-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer|A Multicenter Phase 2 Study of CI-1040 In Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer Or Pancreatic Cancer|Completed||Phase 2|||University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 05:19:13.338411|2018-06-01 05:19:13.338411
NCT00002752|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-15|2003-07-07|2003-07-08|Estimate|||||||2014-07-15|2014-07-16|Estimate|February 1993||1993-02-28|February 2013|2013-02-28|March 2010|Actual|2010-03-31|January 2003|Actual|2003-01-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers|PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS|Completed||Phase 1/Phase 2|||Duke University|||||f||||||||||||||2018-06-01 05:19:13.410392|2018-06-01 05:19:13.410392
NCT00002582|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-01|2003-07-07|2003-07-08|Estimate|||||||2013-08-01|2013-08-02|Estimate|June 1993||1993-06-30|May 2007|2007-05-31|April 2007|Actual|2007-04-30|||||Interventional|||Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer|UKCCCR RANDOMISED TRIAL OF ADJUVANT ENDOCRINE THERAPY AND CHEMOTHERAPY IN WOMEN WITH EARLY BREAST CANCER, THE ADJUVANT BREAST CANCER (ABC) TRIAL|Completed||Phase 3|6000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:13.507919|2018-06-01 05:19:13.507919
NCT00063713|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-02|||2008-02-07|2003-07-03|2003-07-04|Estimate|||||||2008-02-07|2008-02-11|Estimate|June 2003||2003-06-30|February 2008|2008-02-29||||December 2005|Actual|2005-12-31||Interventional|||VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma|A Phase 2 Study of VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma|Completed||Phase 2|152||Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 05:19:13.778994|2018-06-01 05:19:13.778994
NCT00063687|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-02|||2005-08-03|2003-07-02|2003-07-03|Estimate|||||||2005-08-03|2005-08-05|Estimate|March 2003||2003-03-31|July 2003|2003-07-31|June 2005||2005-06-30|||||Interventional|||Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure|A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure|Completed||Phase 2/Phase 3|400||Cardiome Pharma|||||||||||||||||||2018-06-01 05:19:14.017093|2018-06-01 05:19:14.017093
NCT00063674|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-02|||2010-01-12|2003-07-02|2003-07-03|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2003||2003-04-30|January 2010|2010-01-31||||||||Interventional|||Type 2 Diabetes Primary Prevention for At Risk Girls||Completed||Phase 2/Phase 3|240|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:14.098155|2018-06-01 05:19:14.098155
NCT00063648|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-01|||2010-01-12|2003-07-02|2003-07-03|Estimate|||||||2010-01-12|2010-01-13|Estimate|May 2002||2002-05-31|January 2010|2010-01-31|December 2007||2007-12-31|||||Interventional|||Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant||Completed||Phase 1|50||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:14.169049|2018-06-01 05:19:14.169049
NCT00063635|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-01|2012-06-26||2012-08-27|2003-07-02|2003-07-03|Estimate|2012-08-27|2012-09-27|Estimate||||2012-08-27|2012-09-27|Estimate|September 2005||2005-09-30|August 2012|2012-08-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|TONIC||Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)|Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)|Completed||Phase 3|173|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 05:19:14.258952|2018-06-01 05:19:14.258952
NCT00063622|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-01|2012-06-14||2018-03-12|2003-07-02|2003-07-03|Estimate|2012-06-26|2012-08-01|Estimate||||2018-03-12|2018-04-06|Actual|January 2005||2005-01-31|August 2012|2012-08-31|September 2009|Actual|2009-09-30|June 2009|Actual|2009-06-30||Interventional|PIVENS||Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)|Clinical Research Network in Nonalcoholic Steatohepatitis: Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)|Completed||Phase 3|247|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-06-01 05:19:15.057375|2018-06-01 05:19:15.057375
NCT00063609|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-01|||2017-09-11|2003-07-02|2003-07-03|Estimate|||||||2017-09-11|2017-09-13|Actual|April 2003||2003-04-30|September 2017|2017-09-30|April 2005||2005-04-30|||||Interventional|||The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy|The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy|Completed||Phase 4|200||Novartis|||||||||||||||||||2018-06-01 05:19:15.465381|2018-06-01 05:19:15.465381
NCT00063661|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-02|||2008-03-03|2003-07-01|2003-07-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2003||2003-06-30|May 2005|2005-05-31|May 2005||2005-05-31|||||Observational|||Studying Automatic Movements in Patients With Parkinson's Disease|A Neuroimaging Study of Automatic Movements in Patients With Parkinson's Disease|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:15.566195|2018-06-01 05:19:15.566195
NCT00063596|ClinicalTrials.gov processed this data on May 31, 2018|2003-07-01|||2005-06-23|2003-07-01|2003-07-02|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|November 2004|2004-11-30|May 2004||2004-05-31|||||Interventional|||Vitamin A Supplementation in Preterm Infants|Vitamin A Therapy in Preterm Infants: Vaccine Response|Unknown status|Active, not recruiting|N/A|220||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:15.608826|2018-06-01 05:19:15.608826
NCT00063583|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|||2009-11-03|2003-07-01|2003-07-02|Estimate|||||||2009-11-03|2009-11-04|Estimate|June 2003||2003-06-30|November 2009|2009-11-30|March 2009|Actual|2009-03-31|November 2007|Actual|2007-11-30||Interventional|||Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes|Pirfenidone: A Novel Anti-Scarring Therapy for Diabetic Nephropathy|Completed||Phase 1/Phase 2|77|Actual|Sharma, Kumar, M.D.||3|||f||||t||||||||||2018-06-01 05:19:15.682719|2018-06-01 05:19:15.682719
NCT00063570|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|2009-01-27||2009-05-12|2003-06-30|2003-07-01|Estimate|2009-03-26|2009-05-13|Estimate||||2009-05-12|2009-05-29|Estimate|July 2003||2003-07-31|May 2009|2009-05-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy|Phase II Trial of Alimta (Pemetrexed) and Gemzar (Gemcitabine) in Metastatic Breast Cancer Patients Who Have Received Prior Taxane Therapy|Completed||Phase 2|73|Actual|Eli Lilly and Company||2|||f||||||||||||||2018-06-01 05:19:15.773552|2018-06-01 05:19:15.773552
NCT00063557|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|||2016-04-08|2003-06-30|2003-07-01|Estimate|||||||2016-04-08|2016-04-11|Estimate|June 2003||2003-06-30|January 2008|2008-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Neighborhoods and CVD Risk in a Multiethnic Cohort - Ancillary to MESA||Completed|||||University of Michigan|||||f||||||||||||||2018-06-01 05:19:16.444772|2018-06-01 05:19:16.444772
NCT00063544|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|||2016-05-24|2003-06-30|2003-07-01|Estimate|||||||2016-05-24|2016-05-26|Estimate|May 2003||2003-05-31|May 2016|2016-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Physical Activity and Childhood Obesity|Physical Activity and Childhood Obesity|Withdrawn|||0|Actual|University of Bristol||||CI left institution|f||||f||||||||||2018-06-01 05:19:16.480718|2018-06-01 05:19:16.480718
NCT00063531|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|||2018-04-16|2003-06-30|2003-07-01|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2003||2003-06-30|April 2018|2018-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Comparison of Two Methods to Diagnose Coronary Artery Disease|Coronary Disease Detection by Thallium SPECT and Fast CT|Completed|||650|Actual|Johns Hopkins University|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-06-01 05:19:16.589473|2018-06-01 05:19:16.589473
NCT00063518|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|||2013-09-09|2003-06-30|2003-07-01|Estimate|||||||2013-09-09|2013-09-10|Estimate|April 2003||2003-04-30|September 2013|2013-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Monitoring Trends in Venous Thromboembolism|Incidence Rates, Clinical Profile, and Outcomes of Patients With Venous Thromboembolism|Completed|||||University of Massachusetts, Worcester|||||f||||f||||||||||2018-06-01 05:19:16.650956|2018-06-01 05:19:16.650956
NCT00063505|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|||2014-04-22|2003-06-30|2003-07-01|Estimate|||||||2014-04-22|2014-04-24|Estimate|December 2002||2002-12-31|April 2014|2014-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Genes of Hypertension in African Americans|Genes of Hypertension in African Americans|Completed|||5000|Actual|Medical College of Wisconsin|||||f||||f||||||Samples With DNA|"~     Blood cells and DNA~   "|||2018-06-01 05:19:16.709627|2018-06-01 05:19:16.709627
NCT00063492|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-30|||2013-07-23|2003-06-30|2003-07-01|Estimate|||||||2013-07-23|2013-07-24|Estimate|January 2003||2003-01-31|July 2013|2013-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Angiotensinogen Gene and Human Hypertension||Completed|||||University of Utah|||||f||||||||||||||2018-06-01 05:19:16.774758|2018-06-01 05:19:16.774758
NCT00033319|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-09-16|2003-06-30|2003-07-01|Estimate|||||||2013-09-16|2013-09-17|Estimate|May 1997||1997-05-31|December 2002|2002-12-31||||||||Interventional|||Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps|UKCAP Trial: A Multi-Center Double Blind Randomised Controlled Trial Of Aspirin And/Or Folate Supplementation For the Prevention Of Recurrent Colorectal Adenomas|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:16.931338|2018-06-01 05:19:16.931338
NCT00031954|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2015-12-22|2003-06-30|2003-07-01|Estimate|||||||2015-12-22|2015-12-23|Estimate|August 2001||2001-08-31|December 2015|2015-12-31||||April 2004|Actual|2004-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|A Phase II Study Of Paclitaxel, Carboplatin And Gemcitabine In Previously Untreated Patients With Epithelial Ovarian Carcinoma FIGO Stage IIB-IV|Completed||Phase 2|105|Actual|AGO Study Group|||||f||||||||||||||2018-06-01 05:19:17.066487|2018-06-01 05:19:17.066487
NCT00031889|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2012-05-14|2003-06-30|2003-07-01|Estimate|||||||2012-05-14|2012-05-15|Estimate|August 2001||2001-08-31|May 2012|2012-05-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer|A Randomized Phase II Trial of Exemestane With and Without Bicalutamide as Second Line Therapy After Failure of Androgen Suppression in Advanced Prostate Cancer|Completed||Phase 2|5|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:19:17.165996|2018-06-01 05:19:17.165996
NCT00031668|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-11-11|2003-06-30|2003-07-01|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2001||2001-01-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|||||Interventional|||Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation|A Phase III Study of Involved Field Radiation Therapy (IFRT) in Patients With Histologically Aggressive Non-Hodgkin's Lymphoma Following High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT)|Completed||Phase 3|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:19:17.25336|2018-06-01 05:19:17.25336
NCT00028938|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2017-04-17|2003-06-30|2003-07-01|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2002|Actual|2002-01-31|August 2009|2009-08-31|November 10, 2002|Actual|2002-11-10|November 10, 2002|Actual|2002-11-10||Interventional|||Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer|A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer|Completed||Phase 3|1|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:19:17.320962|2018-06-01 05:19:17.320962
NCT00063479|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-27|||2017-05-31|2003-06-27|2003-06-30|Estimate|||||||2017-05-31|2017-06-01|Actual|June 2003||2003-06-30|May 2017|2017-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Bisphosphonate Treatment of Osteogenesis Imperfecta|Bisphosphonate Treatment of Osteogenesis Imperfecta|Completed||Phase 2|158||Novartis|||||||||||||||||||2018-06-01 05:19:17.389719|2018-06-01 05:19:17.389719
NCT00063453|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-26|||2017-12-08|2003-06-27|2003-06-30|Estimate|||||||2017-12-08|2017-12-12|Actual|August 2003||2003-08-31|December 2017|2017-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Supplemental Selenium and Vitamin E and Pulmonary Function|The Respiratory Ancillary Study (RAS) to SELECT|Completed||Phase 3|2920|Actual|Cornell University||4|||f||||t||||||||||2018-06-01 05:19:17.465459|2018-06-01 05:19:17.465459
NCT00063440|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-26|||2013-02-06|2003-06-27|2003-06-30|Estimate|||||||2013-02-06|2013-02-08|Estimate|June 2003||2003-06-30|February 2013|2013-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Epidemiology of Carotid IMT Progression in MESA - Ancillary Study||Completed|||5610|Actual|Tufts Medical Center|||||f||||||||||||||2018-06-01 05:19:17.557799|2018-06-01 05:19:17.557799
NCT00028925|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2016-12-05|2003-06-27|2003-06-30|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2001||2001-11-30|December 2016|2016-12-31|August 2008|Actual|2008-08-31|November 2005|Actual|2005-11-30||Interventional|||Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF (Filgrastim) Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|27|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:19:17.622322|2018-06-01 05:19:17.622322
NCT00028613|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2014-01-08|2003-06-27|2003-06-30|Estimate|||||||2014-01-08|2014-01-09|Estimate|March 2001||2001-03-31|January 2014|2014-01-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma|Phase I Safety Study Of 131I-Lym-1 For The Treatment Of Previously Treated Diffuse Large B-Cell Lymphoma|Completed||Phase 1|2|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:19:17.731756|2018-06-01 05:19:17.731756
NCT00063427|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-26|||2009-08-20|2003-06-26|2003-06-27|Estimate|||||||2009-08-20|2009-08-21|Estimate||||August 2009|2009-08-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Study Evaluating MAC-321 in Colorectal Cancer|A Phase 2, Open-Label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Advanced Colorectal Cancer|Completed||Phase 2|45|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:19:17.784796|2018-06-01 05:19:17.784796
NCT00063414|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2007-10-15|2003-06-26|2003-06-27|Estimate|||||||2007-10-15|2007-10-17|Estimate||||October 2007|2007-10-31||||||||Interventional|||ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis|ISIS 2302-CS22, Phase II, Double-Blinded, Active-Controlled Study of Alicaforsen (ISIS 2302) Enema, an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Mild to Moderate Active Ulcerative Colitis (Left-Sided Colitis or Pancolitis With Left Sided Disease Flare)|Completed||Phase 2|||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:19:17.825057|2018-06-01 05:19:17.825057
NCT00063401|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2010-04-07|2003-06-26|2003-06-27|Estimate|||||||2010-04-07|2010-04-08|Estimate|September 2003||2003-09-30|April 2010|2010-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer|A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|Completed||Phase 2|39|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 05:19:17.874758|2018-06-01 05:19:17.874758
NCT00063388|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2010-04-08|2003-06-26|2003-06-27|Estimate|||||||2010-04-08|2010-04-12|Estimate|May 2003||2003-05-31|April 2010|2010-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer|A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|66|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 05:19:17.944776|2018-06-01 05:19:17.944776
NCT00063362|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|2013-11-04||2016-10-03|2003-06-26|2003-06-27|Estimate|2013-12-23|2014-01-30|Estimate||||2016-10-03|2016-11-07|Estimate|February 2002||2002-02-28|October 2016|2016-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Combination Therapy for the Treatment of Bipolar Disorders|Combination Therapy in Bipolar Rapid Cycling|Terminated||Phase 3|49|Actual|University Hospitals Cleveland Medical Center||2||Funding Expiration|f||||t||||||||||2018-06-01 05:19:18.068823|2018-06-01 05:19:18.068823
NCT00063336|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2013-11-07|2003-06-26|2003-06-27|Estimate|||||||2013-11-07|2013-11-08|Estimate|December 2001||2001-12-31|May 2009|2009-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Treatment Response to Rehabilitation in Patients With Schizophrenia|Treatment Response to Rehabilitation in Schizophrenia|Completed||N/A|46|Actual|Hartford Hospital||2|||f||||||||||||||2018-06-01 05:19:18.361789|2018-06-01 05:19:18.361789
NCT00030446|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2010-11-07|2003-06-26|2003-06-27|Estimate|||||||2010-11-07|2010-11-09|Estimate|January 2002||2002-01-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|||||Interventional|||Erlotinib and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Study Of OSI-774 (NSC 718781) Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:19:18.428132|2018-06-01 05:19:18.428132
NCT00028483|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2011-10-21|2003-06-26|2003-06-27|Estimate|||||||2011-10-21|2011-10-24|Estimate|October 2000||2000-10-31|October 2011|2011-10-31|April 2003|Actual|2003-04-30|||||Interventional|||Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer|A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma|Terminated||Phase 2|||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 05:19:18.502113|2018-06-01 05:19:18.502113
NCT00006968|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-01-07|2003-06-26|2003-06-27|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2000||2000-09-30|January 2013|2013-01-31||||September 2004|Actual|2004-09-30||Interventional|||Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer|Non-Myeloablative Chemotherapy Followed By Related Allogeneic Stem Cell Rescue In Patients With Advanced Renal Cell Carcinoma|Completed||Phase 1/Phase 2|4|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:19:18.570214|2018-06-01 05:19:18.570214
NCT00003352|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-12-10|2003-06-26|2003-06-27|Estimate|||||||2012-12-10|2012-12-11|Estimate|June 1998||1998-06-30|December 2012|2012-12-31|December 2002|Actual|2002-12-31|September 2000|Actual|2000-09-30||Interventional|||Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer|A Phase II Study in Patients With Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)|Completed||Phase 2|89|Actual|NSABP Foundation Inc|||||f||||t||||||||||2018-06-01 05:19:18.645286|2018-06-01 05:19:18.645286
NCT00063310|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2009-12-10|2003-06-25|2003-06-26|Estimate|||||||2009-12-10|2009-12-11|Estimate|March 2003||2003-03-31|February 2006|2006-02-28|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation|Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN)|Completed||Phase 2|90||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:19:19.886121|2018-06-01 05:19:19.886121
NCT00063297|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-25|||2009-08-27|2003-06-25|2003-06-26|Estimate|||||||2009-08-27|2009-08-28|Estimate|May 2003||2003-05-31|December 2003|2003-12-31|October 2003||2003-10-31|||||Interventional|||Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia||Completed||Phase 2|180||Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:19:19.963474|2018-06-01 05:19:19.963474
NCT00040729|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2015-04-24|2003-06-25|2003-06-26|Estimate|||||||2015-04-24|2015-04-28|Estimate|March 2002||2002-03-31|May 2003|2003-05-31||||||||Observational|||Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C|Retrospective Analysis Of Promoter Polymorphism Of UGT1A1 Gene In Cancer Patients Enrolled On Clinical Trials With Flavopiridol At National Cancer Institute To Assess The Pharmacokinetics And Pharmacodynamics Of Flavopiridol|Completed|||||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:20.045805|2018-06-01 05:19:20.045805
NCT00063284|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-24|||2017-06-30|2003-06-24|2003-06-25|Estimate|||||||2017-06-30|2017-07-02|Actual|June 18, 2003||2003-06-18|April 15, 2009|2009-04-15|April 15, 2009||2009-04-15|||||Interventional|||Investigating the Safety of srTMS in the Treatment of Parkinson's Disease|Safety Study of the Super Rapid Transcranial Magnetic Stimulation in Patients With Parkinson's Disease|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:20.097788|2018-06-01 05:19:20.097788
NCT00063258|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-24|2010-08-25||2016-04-05|2003-06-24|2003-06-25|Estimate|2011-05-05|2011-06-03|Estimate||||2016-04-05|2016-05-09|Estimate|June 2003||2003-06-30|April 2016|2016-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer|Phase II Randomized Open-Label Trial of the EGFR Tyrosine Kinase Inhibitor OSI-774 (Tarceva™) in Combination With Paclitaxel and Carboplatin Prior to Surgery in Resectable Stage IIIA (N2) and IIIB (T4 N2) NSCLC: A Clinical Outcome and Biological Endpoint Trial|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center|Despite active study recruitment and screening for this study, only 5 subjects were enrolled out of the planned 40 subjects. Of the 5 subjects enrolled, only 1 patient was evaluable for response assessment. The study was subsequently terminated.|2||Low accrual rate|f||||t||||||||||2018-06-01 05:19:20.25914|2018-06-01 05:19:20.25914
NCT00063219|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-23|||2009-08-20|2003-06-24|2003-06-25|Estimate|||||||2009-08-20|2009-08-21|Estimate||||August 2009|2009-08-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy|A Phase 2, Open-label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Non-small Cell Lung Cancer Refractory to Platinum-based Therapy|Completed||Phase 2|48|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:19:20.513433|2018-06-01 05:19:20.513433
NCT00063206|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-23|||2009-08-18|2003-06-24|2003-06-25|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder|Completed||Phase 3|247|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:19:20.597778|2018-06-01 05:19:20.597778
NCT00063193|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-23|||2016-01-19|2003-06-24|2003-06-25|Estimate|||||||2016-01-19|2016-01-20|Estimate|May 2003||2003-05-31|January 2016|2016-01-31|July 2005|Actual|2005-07-31|May 2005|Actual|2005-05-31||Interventional|||National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial|A Multi-center, Double-blind, Pilot Study of Minocycline and Creatine in Subjects With Early Untreated Parkinson's Disease|Completed||Phase 2|195||University of Rochester|||||f||||t||||||||||2018-06-01 05:19:20.659905|2018-06-01 05:19:20.659905
NCT00063154|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-20|2015-05-26||2015-06-08|2003-06-24|2003-06-25|Estimate|2015-05-26|2015-06-08|Estimate||||2015-06-08|2015-07-07|Estimate|July 2003||2003-07-31|June 2015|2015-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional||Safety population: All participants who received any amount of pertuzumab.|Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy|A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer|Completed||Phase 2|51|Actual|Genentech, Inc.||1|||f||||f||||||||||2018-06-01 05:19:20.754717|2018-06-01 05:19:20.754717
NCT00063141|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-20|||2010-04-08|2003-06-24|2003-06-25|Estimate|||||||2010-04-08|2010-04-12|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|October 2007|Actual|2007-10-31|June 2006|Actual|2006-06-30||Interventional|||Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer|Revised Protocol 07 to Protocol CA225006 - A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Carcinoma|Completed||Phase 3|1302|Actual|ImClone LLC||2|||f||||||||||||||2018-06-01 05:19:21.020732|2018-06-01 05:19:21.020732
NCT00063128|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-20|||2007-12-20|2003-06-24|2003-06-25|Estimate|||||||2007-12-20|2007-12-21|Estimate|April 2003||2003-04-30|December 2007|2007-12-31|April 2004|Actual|2004-04-30|||||Interventional|||Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.|Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus|Completed||Phase 2|119|Actual|Eli Lilly and Company||2|||||||f||||||||||2018-06-01 05:19:21.431202|2018-06-01 05:19:21.431202
NCT00030797|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2012-05-14|2003-06-24|2003-06-25|Estimate|||||||2012-05-14|2012-05-15|Estimate|February 2001||2001-02-28|May 2012|2012-05-31|December 2003|Actual|2003-12-31|May 2002|Actual|2002-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer|A Randomized Phase II Trial Of Capecitabine And Different Schedules Of Irinotecan As First Line Treatment For Advanced Or Metastatic Colorectal Cancer|Completed||Phase 2|75|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:19:21.562083|2018-06-01 05:19:21.562083
NCT00026520|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-06-20|2003-06-24|2003-06-25|Estimate|||||||2013-06-20|2013-06-24|Estimate|November 2001||2001-11-30|April 2003|2003-04-30|April 2006|Actual|2006-04-30|||||Interventional|||Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma|Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:21.66611|2018-06-01 05:19:21.66611
NCT00026364|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-03-19|2003-06-24|2003-06-25|Estimate|||||||2013-03-19|2013-03-21|Estimate|November 2001||2001-11-30|September 2002|2002-09-30||||December 2006|Actual|2006-12-31||Interventional|||ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer|A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer|Completed||Phase 1|22|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:21.858926|2018-06-01 05:19:21.858926
NCT00026351|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-02-01|2003-06-24|2003-06-25|Estimate|||||||2013-02-01|2013-02-04|Estimate|December 2000||2000-12-31|July 2002|2002-07-31|June 2003|Actual|2003-06-30|||||Interventional|||Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase II Multicenter Trial Of Pentostatin and Rituximab In Patients With Previously Treated and Untreated Low Grade B-Cell Non-Hodgkin's Lymphoma (NHL) Including Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:21.935963|2018-06-01 05:19:21.935963
NCT00025571|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2011-03-03|2003-06-24|2003-06-25|Estimate|||||||2011-03-03|2011-03-07|Estimate|June 2001||2001-06-30|March 2011|2011-03-31|October 2004|Actual|2004-10-31|October 2002|Actual|2002-10-31||Interventional|||Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer|A Phase I Study of Photodynamic Therapy (PDT) Using 2-(1-hexyloxyethyl)-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Early Stage Lung Cancer - A Dose Ranging Study|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:19:21.997854|2018-06-01 05:19:21.997854
NCT00006013|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-07-10|2003-06-24|2003-06-25|Estimate|||||||2013-07-10|2013-07-11|Estimate|June 2000||2000-06-30|July 2013|2013-07-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma|Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma|Completed||Phase 2|21|Actual|Fox Chase Cancer Center|||||f||||t||||||||||2018-06-01 05:19:22.052896|2018-06-01 05:19:22.052896
NCT00004037|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-04-10|2003-06-24|2003-06-25|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 1998||1998-06-30|May 2003|2003-05-31||||April 2003|Actual|2003-04-30||Interventional|||Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer|Evaluation of Docetaxel in Recurrent, Platinum Resistant, Refractory and Paclitaxel Refractory Ovarian Cancer and Primary Peritoneal Carcinoma|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:19:22.121002|2018-06-01 05:19:22.121002
NCT00003054|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-04-11|2003-06-24|2003-06-25|Estimate|||||||2018-04-11|2018-04-12|Actual|August 1997||1997-08-31|April 2018|2018-04-30||||July 2002|Actual|2002-07-31||Interventional|||Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus|Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:19:22.361523|2018-06-01 05:19:22.361523
NCT00063245|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-23|||2008-03-03|2003-06-23|2003-06-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2003||2003-06-30|April 2005|2005-04-30|April 2005||2005-04-30|||||Observational|||Stimulating Deep Brain Regions With a Magnetic Stimulator|Noninvasive Stimulation of Human Deep Brain Regions With a Magnetic Stimulator|Completed|||18||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:22.506578|2018-06-01 05:19:22.506578
NCT00063232|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-23|2011-03-14||2011-06-21|2003-06-23|2003-06-24|Estimate|2011-06-21|2011-07-20|Estimate||||2011-06-21|2011-07-20|Estimate|June 2003||2003-06-30|June 2011|2011-06-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Treating Nonalcoholic Steatohepatitis (NASH) With Metformin|Treatment of Nonalcoholic Steatohepatitis With Metformin|Completed||Phase 2|28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:22.575813|2018-06-01 05:19:22.575813
NCT00063180|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-20|||2017-06-30|2003-06-20|2003-06-23|Estimate|||||||2017-06-30|2017-07-02|Actual|June 19, 2003||2003-06-19|April 20, 2009|2009-04-20|April 20, 2009||2009-04-20|||||Observational|||Evaluating the Remote Effects of Stroke With MRI and PET Scans|Remote Effects of Stroke on Cerebral Metabolism. Evaluation With Positron Emission Tomography and Proton Magnetic Resonance Spectroscopy|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:22.798526|2018-06-01 05:19:22.798526
NCT00063102|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2007-11-28|2003-06-20|2003-06-23|Estimate|||||||2007-11-28|2007-11-29|Estimate|November 2002||2002-11-30|November 2007|2007-11-30|August 2004|Actual|2004-08-31|||||Interventional|||A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.|A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens|Completed||Phase 2|40||Abbott|||||f||||f||||||||||2018-06-01 05:19:22.869923|2018-06-01 05:19:22.869923
NCT00063115|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2017-06-30|2003-06-19|2003-06-20|Estimate|||||||2017-06-30|2017-07-02|Actual|June 16, 2003||2003-06-16|July 2, 2008|2008-07-02|July 2, 2008||2008-07-02|||||Observational|||Using fMRI to Understand the Roles of Brain Areas for Fine Hand Movements|Event-Related fMRI Analysis of Patients With Ideomotor Apraxia During Transitive and Intransitive Hand Gesturing|Completed|||35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:22.939321|2018-06-01 05:19:22.939321
NCT00063089|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2012-05-10|2003-06-19|2003-06-20|Estimate|||||||2012-05-10|2012-05-14|Estimate|September 2002||2002-09-30|May 2012|2012-05-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever|Initial Safety and Pharmacokinetics Trial of Immune Globulin to Staphylococcus Aureus Capsule Polysaccharide (Altastaph) in Subjects With S. Aureus Bacteremia and Persistent Fever|Completed||Phase 1/Phase 2|40|Actual|Nabi Biopharmaceuticals||2|||f||||||||||||||2018-06-01 05:19:22.991588|2018-06-01 05:19:22.991588
NCT00063076|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2012-08-01|2003-06-19|2003-06-20|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2003||2003-05-31|August 2012|2012-08-31|May 2007|Actual|2007-05-31|October 2006|Actual|2006-10-31||Interventional|||Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata|A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata|Completed||Phase 2/Phase 3|46|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 05:19:23.06527|2018-06-01 05:19:23.06527
NCT00063063|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2017-08-11|2003-06-19|2003-06-20|Estimate|||||||2017-08-11|2017-08-15|Actual|January 1987||1987-01-31|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|GDB||Generic Database of Very Low Birth Weight Infants|Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants|Recruiting|||80000|Anticipated|NICHD Neonatal Research Network|||||f||||f||||||||||2018-06-01 05:19:23.153816|2018-06-01 05:19:23.153816
NCT00063050|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2011-11-14|2003-06-19|2003-06-20|Estimate|||||||2011-11-14|2011-11-16|Estimate|April 2000||2000-04-30|November 2011|2011-11-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Osteoporosis Prevention: Changes to Exercise and Diet in Children|Healthy Children Healthy Families|Completed||Phase 2|155|Actual|San Diego State University|||||f||||f||||||||||2018-06-01 05:19:23.31859|2018-06-01 05:19:23.31859
NCT00063037|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2005-06-23|2003-06-19|2003-06-20|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|May 2003|2003-05-31|May 2005||2005-05-31|||||Interventional|||Building Better Bones in Children|Building Better Bones in Children|Unknown status|Active, not recruiting|N/A|139||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:23.376593|2018-06-01 05:19:23.376593
NCT00063024|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2005-06-23|2003-06-19|2003-06-20|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|May 2003|2003-05-31|May 2004||2004-05-31|||||Interventional|||Program to Prevent Osteoporosis in Girls|Behavioral Strategies to Prevent Osteoporosis in Girls|Unknown status|Active, not recruiting|Phase 3|322||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:23.419358|2018-06-01 05:19:23.419358
NCT00063011|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-19|||2005-06-23|2003-06-19|2003-06-20|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1998||1998-05-31|May 2003|2003-05-31||||||||Interventional|||Bone Development in Adolescent Girls: Effects of Calcium and Exercise|Calcium and Exercise Effect on Pubertal Bone Gain|Unknown status|Active, not recruiting|Phase 1/Phase 2|107||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:23.461034|2018-06-01 05:19:23.461034
NCT00025545|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2010-05-12|2003-06-19|2003-06-20|Estimate|||||||2010-05-12|2010-05-13|Estimate|March 1996||1996-03-31|May 2010|2010-05-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>|A Phase II Trial to Evaluate the Use of G-CSF-Mobilized Peripheral Blood Progenitor Cells as Hematopoietic Rescue in Patients With Acute Leukemia Undergoing Allografting From an Unrelated Donor|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:19:23.50792|2018-06-01 05:19:23.50792
NCT00024323|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-07-17|2003-06-19|2003-06-20|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2001||2001-03-31|November 2002|2002-11-30|June 2003|Actual|2003-06-30|||||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer|A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:23.554381|2018-06-01 05:19:23.554381
NCT00024310|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-09-16|2003-06-19|2003-06-20|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2001||2001-09-30|November 2002|2002-11-30||||||||Interventional|||Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Trial of Lometrexol Sodium and Paclitaxel Adminsitered Intravenously Every 21 Days in Conjunction With Oral Folic Acid in Patients With Solid Tumors|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:23.607422|2018-06-01 05:19:23.607422
NCT00024141|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2011-03-03|2003-06-19|2003-06-20|Estimate|||||||2011-03-03|2011-03-07|Estimate|May 2001||2001-05-31|March 2011|2011-03-31|January 2003|Actual|2003-01-31|September 2002|Actual|2002-09-30||Interventional|||Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors|5-Flourouracil Preceded by Irinotecan In Patients With Advanced Solid Tumors: A Pilot Study|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:19:23.650994|2018-06-01 05:19:23.650994
NCT00023933|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-01-24|2003-06-19|2003-06-20|Estimate|||||||2013-01-24|2013-01-25|Estimate|October 2001||2001-10-31|January 2013|2013-01-31||||July 2005|Actual|2005-07-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer|Phase I Trial of 131I-HuCC49^CH2 for Colon Cancer|Completed||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:23.708867|2018-06-01 05:19:23.708867
NCT00062998|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-18|||2010-03-17|2003-06-18|2003-06-19|Estimate|||||||2010-03-17|2010-03-18|Estimate||||March 2010|2010-03-31||||||||Observational|||Free-Living Physical Activity and Energy Expenditure||Completed|||15||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:23.763636|2018-06-01 05:19:23.763636
NCT00062985|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-18|||2017-10-20|2003-06-18|2003-06-19|Estimate|||||||2017-10-20|2017-10-24|Actual|March 1999|Actual|1999-03-31|October 2017|2017-10-31|February 2005|Actual|2005-02-28|October 2003|Actual|2003-10-31||Interventional|||Obesity Treatment in a Managed Care Setting||Completed||N/A|1801|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f|f|f||||||||2018-06-01 05:19:23.881696|2018-06-01 05:19:23.881696
NCT00062972|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-18|||2017-04-21|2003-06-18|2003-06-19|Estimate|||||||2017-04-21|2017-04-25|Actual|September 1999||1999-09-30|May 2011|2011-05-31|August 2002||2002-08-31|||||Interventional|||Improving Memory in Patients With Multiple Sclerosis|Interventions to Improve Memory in Patients With Multiple Sclerosis|Withdrawn||Phase 3|0|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||||Study terminated/withdrawn|f||||||||||||||2018-06-01 05:19:23.947093|2018-06-01 05:19:23.947093
NCT00062959|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-18|||2005-06-23|2003-06-18|2003-06-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1994||1994-06-30|May 2003|2003-05-31|June 2000||2000-06-30|||||Interventional|||Preventing Problem Behavior Among Middle School Students|Preventing Problem Behaviors Among Middle School Students|Completed||N/A|2768||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:24.028092|2018-06-01 05:19:24.028092
NCT00062907|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2006-12-05|2003-06-18|2003-06-19|Estimate|||||||2006-12-05|2006-12-06|Estimate|May 2003||2003-05-31|November 2004|2004-11-30||||||||Interventional|||Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer|Phase I Open-Label Dose Escalation Trial Evaluating The Safety And Immunogenicity Of Sequential Administration Of Recombinant DNA And Adenovirus Expressing L523S Protein In Patients With Early Stage Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 1|9||Corixa Corporation|||||||||||||||||||2018-06-01 05:19:24.082562|2018-06-01 05:19:24.082562
NCT00062894|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2007-09-13|2003-06-18|2003-06-19|Estimate|||||||2007-09-13|2007-09-17|Estimate|April 2003||2003-04-30|September 2007|2007-09-30|April 2007||2007-04-30|||||Interventional|||Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab|A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|12|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:19:24.142056|2018-06-01 05:19:24.142056
NCT00062946|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2017-06-30|2003-06-17|2003-06-18|Estimate|||||||2017-06-30|2017-07-02|Actual|June 17, 2003||2003-06-17|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Interventional|||PET Imaging of Dopamine in Healthy Study Participants|PET Imaging of Dopamine D2 Receptors and Extracellular Dopamine With (18F)Fallypride, D-amphetamine, and Alpha-Methyl-Para-Tyrosine in Healthy Subjects|Completed||Phase 2|45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:24.205559|2018-06-01 05:19:24.205559
NCT00062933|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2012-08-17|2003-06-17|2003-06-18|Estimate|||||||2012-08-17|2012-08-20|Estimate|June 2003||2003-06-30|August 2012|2012-08-31|March 2008|Actual|2008-03-31|September 2007|Actual|2007-09-30||Interventional|||A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma|A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:24.259439|2018-06-01 05:19:24.259439
NCT00062881|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2006-08-21|2003-06-17|2003-06-18|Estimate|||||||2006-08-21|2006-08-22|Estimate|June 1990||1990-06-30|April 2005|2005-04-30|September 2005||2005-09-30|||||Interventional|||Intrathecal Mafosfamide|Phase I Study of Intrathecal Mafosfamide|Completed||Phase 1|65||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:19:24.316649|2018-06-01 05:19:24.316649
NCT00062868|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2017-08-29|2003-06-17|2003-06-18|Estimate|||||||2017-08-29|2017-08-31|Actual|April 2007|Actual|2007-04-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2014|Actual|2014-04-30||Interventional|ALCI||LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma|Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI)|Active, not recruiting||Phase 1|89|Anticipated|Baylor College of Medicine||3|||f||||t|t|f||||||||2018-06-01 05:19:24.384643|2018-06-01 05:19:24.384643
NCT00062855|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2012-10-26|2003-06-17|2003-06-18|Estimate|||||||2012-10-26|2012-10-29|Estimate|November 1997||1997-11-30|October 2012|2012-10-31|March 2006|Actual|2006-03-31|August 2001|Actual|2001-08-31||Interventional|CYCHE||Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma|Phase I Study of Chemokine and Cytokine Gene Modified Autologous Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma Using an Adenoviral Vector (CYCHE)|Completed||Phase 1|9|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 05:19:24.468811|2018-06-01 05:19:24.468811
NCT00062842|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2007-04-09|2003-06-17|2003-06-18|Estimate|||||||2007-04-09|2007-04-11|Estimate|November 1998||1998-11-30|April 2007|2007-04-30|May 2005||2005-05-31|||||Interventional|||Study of Irinotecan in Children|Pediatric Phase I and Pharmacokinetic Study of Irinotecan|Completed||Phase 1|25||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:19:24.545712|2018-06-01 05:19:24.545712
NCT00062829|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-17|||2014-09-24|2003-06-17|2003-06-18|Estimate|||||||2014-09-24|2014-09-25|Estimate|September 1998||1998-09-30|September 2014|2014-09-30|September 2005|Actual|2005-09-30|September 2000|Actual|2000-09-30||Interventional|||Young Driver Intervention Study: Preventing Motor Vehicle Crashes|Young Driver Intervention Study: Preventing Motor Vehicle Crashes Among Young Drivers|Completed||N/A|3743|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||f||||||||||2018-06-01 05:19:24.599506|2018-06-01 05:19:24.599506
NCT00062816|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-16|||2007-10-15|2003-06-17|2003-06-18|Estimate|||||||2007-10-15|2007-10-17|Estimate|May 2004||2004-05-31|October 2007|2007-10-31||||||||Interventional|||Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs||Completed||Phase 1/Phase 2|22||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:19:24.675546|2018-06-01 05:19:24.675546
NCT00002643|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-31|2003-06-17|2003-06-18|Estimate|||||||2013-01-31|2013-02-01|Estimate|April 1995||1995-04-30|March 2007|2007-03-31||||June 2003|Actual|2003-06-30||Interventional|||Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor|INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY|Completed||Phase 2|130|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:24.77948|2018-06-01 05:19:24.77948
NCT00062803|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-16|||2009-04-28|2003-06-16|2003-06-17|Estimate|||||||2009-04-28|2009-04-29|Estimate|June 2003||2003-06-30|April 2009|2009-04-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism|The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism|Completed||Phase 3|||Sanofi|||||||||||||||||||2018-06-01 05:19:24.938843|2018-06-01 05:19:24.938843
NCT00017446|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2014-01-03|2003-06-11|2003-06-12|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2000||2000-10-31|September 2002|2002-09-30||||||||Interventional|||CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma|Phase II Evaluation Of CP4071 In Previously Treated Advanced Sarcomas|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:31.102605|2018-06-01 05:19:31.102605
NCT00062790|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-16|||2016-09-13|2003-06-16|2003-06-17|Estimate|||||||2016-09-13|2016-09-15|Estimate|October 2003||2003-10-31|September 2016|2016-09-30|July 2005|Actual|2005-07-31|||||Interventional|||Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels|Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels|Completed||Phase 4|50||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:19:25.120663|2018-06-01 05:19:25.120663
NCT00027612|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2016-12-05|2003-06-16|2003-06-17|Estimate|||||||2016-12-05|2016-12-07|Estimate|July 2002||2002-07-31|December 2016|2016-12-31|July 2009|Actual|2009-07-31|October 2006|Actual|2006-10-31||Interventional|||Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme|Pilot And Phase II Trial Of Irinotecan And Radiation Followed By Irinotecan And BCNU In Glioblastoma Multiforme Patients|Completed||Phase 1/Phase 2|58|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:19:25.206871|2018-06-01 05:19:25.206871
NCT00025376|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-09-04|2003-06-16|2003-06-17|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2001||2001-10-31|September 2013|2013-09-30|March 2006|Actual|2006-03-31|September 2002|Actual|2002-09-30||Interventional|||PS-341 in Treating Patients With Metastatic Kidney Cancer|A Phase II Trial of PS-341 in Patients With Renal Cell Cancer|Completed||Phase 2|23|Actual|University of Chicago||2|||f||||f||||||||||2018-06-01 05:19:25.269818|2018-06-01 05:19:25.269818
NCT00023868|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2009-01-03|2003-06-16|2003-06-17|Estimate|||||||2009-01-03|2009-01-06|Estimate|November 2001||2001-11-30|December 2003|2003-12-31||||||||Interventional|||Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver|A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:25.343987|2018-06-01 05:19:25.343987
NCT00022594|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2012-07-23|2003-06-16|2003-06-17|Estimate|||||||2012-07-23|2012-07-24|Estimate|May 2001||2001-05-31|July 2012|2012-07-31||||August 2002|Actual|2002-08-31||Interventional|||Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer|Phase II Study Of NX 211 (Liposomal Lurtotecan) Given As An IV Bolus Injection On Days 1 and 8 Every 3 Weeks In Patients With Metastatic Or Loco-Regional Recurrent Squamous Cell Carcinoma Of The Head and Neck With Target Lesions Within Previously Irradiated Fields Or Outside Previously Irradiated Fields|Completed||Phase 2|50|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:19:25.4054|2018-06-01 05:19:25.4054
NCT00022529|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-01-24|2003-06-16|2003-06-17|Estimate|||||||2013-01-24|2013-01-25|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||January 2004|Actual|2004-01-31||Interventional|||BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors|Phase I Study of Intravenous BMS-214662 FTI (NSC# 710086) and Herceptin (NSC# 688097) Weekly in Patients With Advanced Malignancies|Completed||Phase 1|28|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:25.47634|2018-06-01 05:19:25.47634
NCT00062777|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-13|||2017-06-30|2003-06-13|2003-06-16|Estimate|||||||2017-06-30|2017-07-02|Actual|June 12, 2003||2003-06-12|June 16, 2011|2011-06-16|June 16, 2011||2011-06-16|||||Observational|||The Framingham Study: Examining DNA Markers and Links to Diseases|A Genome-Wide Scan for Quantitative Trait Loci of Hematocrit - A Framingham Study|Completed|||330|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:25.537498|2018-06-01 05:19:25.537498
NCT00062764|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-12|2011-03-01||2012-12-14|2003-06-12|2003-06-13|Estimate|2011-03-01|2011-04-05|Estimate||||2012-12-14|2012-12-19|Estimate|June 2003||2003-06-30|December 2012|2012-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Treating Nonalcoholic Steatohepatitis With Pioglitazone|Long-Term Treatment of Nonalcoholic Steatohepatitis With Pioglitazone|Completed||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)|"A major limitation of this study was the lack of a concurrently followed control group.~Another important shortcoming of this study was that patients were treated for 48 weeks only."|1|||f||||f||||||||||2018-06-01 05:19:25.670776|2018-06-01 05:19:25.670776
NCT00062751|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-12|2010-10-27||2011-04-13|2003-06-12|2003-06-13|Estimate|2010-10-27|2010-11-25|Estimate||||2011-04-13|2011-04-15|Estimate|December 2002||2002-12-31|April 2011|2011-04-30|October 2009|Actual|2009-10-31|April 2005|Actual|2005-04-30||Interventional|||Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms|A Phase 2 Randomized Open-Label Study Of Letrozole In Combination With Two Dose Levels And Schedules Of Oral Temsirolimus (CCI-779), Or Letrozole Alone, In Postmenopausal Women With Locally Advanced Or Metastatic Breast Cancer|Completed||Phase 2|108|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|Clinical development of oral temsirolimus for treatment of locally advanced or metastatic breast cancer was terminated by Wyeth based on the results of a phase 3 clinical study with the combination temsirolimus and letrozole.|3|||f||||f||||||||||2018-06-01 05:19:26.001014|2018-06-01 05:19:26.001014
NCT00062738|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-12|2012-12-05||2015-10-27|2003-06-12|2003-06-13|Estimate|2013-01-24|2013-03-05|Estimate||||2015-10-27|2015-11-24|Estimate|June 2003||2003-06-30|October 2015|2015-10-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Treatment of Depression in Parkinson's Disease Trial|Treatment of Depression in Patients With Parkinson's Disease|Completed||Phase 2|52|Actual|Rutgers, The State University of New Jersey|This was only an eight week trial with relatively few participants.|3|||f||||t||||||||||2018-06-01 05:19:27.961402|2018-06-01 05:19:27.961402
NCT00062699|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-11|||2006-07-31|2003-06-12|2003-06-13|Estimate|||||||2006-07-31|2006-08-02|Estimate|April 2003||2003-04-30|July 2006|2006-07-31||||||||Interventional|||Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis|A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects With Stage V Chronic Kidney Disease on Hemodialysis|Terminated||Phase 4|2200||Abbott|||||||||||||||||||2018-06-01 05:19:28.211162|2018-06-01 05:19:28.211162
NCT00062712|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-11|||2017-06-30|2003-06-11|2003-06-12|Estimate|||||||2017-06-30|2017-07-02|Actual|June 9, 2003||2003-06-09|March 22, 2007|2007-03-22|March 22, 2007||2007-03-22|||||Interventional|||Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients|Induction of Donor Specific Immunologic Hyporesponsiveness With Thymoglobulin, Sirolimus and Donor Bone Marrow Infusion|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:28.311478|2018-06-01 05:19:28.311478
NCT00062686|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-11|||2015-04-14|2003-06-11|2003-06-12|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2003||2003-11-30|April 2015|2015-04-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||GW572016 For Treatment Of Refractory Metastatic Breast Cancer|An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens|Completed||Phase 2|200||GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:19:29.260936|2018-06-01 05:19:29.260936
NCT00062660|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-10|||2016-11-29|2003-06-11|2003-06-12|Estimate|||||||2016-11-29|2016-11-30|Estimate|May 2003||2003-05-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Expanded Access|||Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection|An Open Label Safety Study to Evaluate the Safety of Tipranavir Plus Ritonavir When Used in Combination With Other Agents for the Treatment of Patients With HIV Infection Who Have Failed and/or Are Intolerant to Combination Antiretroviral Therapy and Have Limited Treatment Options|Approved for marketing|||||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 05:19:29.413231|2018-06-01 05:19:29.413231
NCT00062647|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|2009-12-02||2011-03-30|2003-06-11|2003-06-12|Estimate|2011-02-22|2011-03-22|Estimate||||2011-03-30|2011-04-04|Estimate|August 2003||2003-08-31|March 2011|2011-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|ASSURE||Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia|A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia|Completed||Phase 2|60|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||f||||||||||2018-06-01 05:19:29.764744|2018-06-01 05:19:29.764744
NCT00062634|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2005-06-23|2003-06-11|2003-06-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2003||2003-06-30|October 2004|2004-10-31|August 2005||2005-08-31|||||Interventional|||Education Program to Promote Female Condom Use|Female Condom Intervention Trial|Unknown status|Recruiting|N/A|400||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:30.205671|2018-06-01 05:19:30.205671
NCT00062621|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2013-02-01|2003-06-11|2003-06-12|Estimate|||||||2013-02-01|2013-02-05|Estimate|June 2003||2003-06-30|February 2013|2013-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure|Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure|Completed||Phase 1|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:19:30.270228|2018-06-01 05:19:30.270228
NCT00062608|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2010-01-12|2003-06-11|2003-06-12|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31||||||||Interventional|||Written Self-disclosure for Youth Abdominal Pain|RCT of Written Self-disclosure for Youth Abdominal Pain|Completed||Phase 2/Phase 3|160|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:30.332248|2018-06-01 05:19:30.332248
NCT00062595|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2016-05-16|2003-06-11|2003-06-12|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 2000||2000-09-30|May 2016|2016-05-31|October 2004||2004-10-31|||||Interventional|||Vitamin K and Bone Turnover in Postmenopausal Women|Vitamin K and Bone Turnover in Postmenopausal Women|Completed||Phase 3|375||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 05:19:30.376197|2018-06-01 05:19:30.376197
NCT00062569|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2009-03-10|2003-06-11|2003-06-12|Estimate|||||||2009-03-10|2009-03-12|Estimate|September 2002||2002-09-30|March 2009|2009-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Bathing Persons With Alzheimer's Disease aT Home (The BATH Study)|Reminiscence During Bathing Persons With Alzheimer's Disease at Home|Completed||N/A|90|Actual|National Institute of Nursing Research (NINR)||2|||f||||f||||||||||2018-06-01 05:19:30.423799|2018-06-01 05:19:30.423799
NCT00062556|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2006-10-31|2003-06-11|2003-06-12|Estimate|||||||2006-10-31|2006-11-01|Estimate|January 2003||2003-01-31|October 2006|2006-10-31|March 2006||2006-03-31|||||Interventional|||Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication|Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication|Completed||Phase 3|366||Kos Pharmaceuticals|||||||||||||||||||2018-06-01 05:19:30.485582|2018-06-01 05:19:30.485582
NCT00062543|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2012-08-01|2003-06-11|2003-06-12|Estimate|||||||2012-08-01|2012-08-03|Estimate|May 2002||2002-05-31|August 2012|2012-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Hepatic Artery Infusion of CD34+ Cells|Hepatic Artery Infusion of CD34+ Cells, Isolated by the Isolex 300i Device, in Stem Cell Transplant Recipients With Hepatic Failure Due to Veno-occlusive Disease|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:19:30.580422|2018-06-01 05:19:30.580422
NCT00062530|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2008-09-25|2003-06-11|2003-06-12|Estimate|||||||2008-09-25|2008-09-26|Estimate||||September 2008|2008-09-30||||||||Interventional|||Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers|Development of an Oral Prime-Boost AIDS Vaccine to Elicit Broadly Neutralizing Antibodies Against HIV-1|Unknown status|Not yet recruiting|Phase 1|38|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:19:30.708401|2018-06-01 05:19:30.708401
NCT00062504|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-06|||2011-05-20|2003-06-11|2003-06-12|Estimate|||||||2011-05-20|2011-05-23|Estimate|July 2003||2003-07-31|May 2011|2011-05-31|April 2006|Actual|2006-04-30|January 2006|Actual|2006-01-31||Interventional|||Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas|A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.|Terminated||Phase 2|30|Actual|Teva Pharmaceutical Industries||3|||f||||||||||||||2018-06-01 05:19:30.781091|2018-06-01 05:19:30.781091
NCT00062491|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-06|||2017-09-20|2003-06-11|2003-06-12|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2002||2002-05-31|September 2017|2017-09-30|November 2005|Actual|2005-11-30|June 2003|Actual|2003-06-30||Interventional|||Study of Karenitecin (BNP1350) to Treat Malignant Melanoma|Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma|Completed||Phase 2|46|Actual|BioNumerik Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 05:19:30.835556|2018-06-01 05:19:30.835556
NCT00062478|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-06|||2017-09-20|2003-06-11|2003-06-12|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2001||2001-10-31|September 2017|2017-09-30||||August 2002|Actual|2002-08-31||Interventional|||Study of Karenitecin (BNP1350) in Patients With Brain Tumors|Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin|Completed||Phase 2|40|Actual|BioNumerik Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-06-01 05:19:30.901832|2018-06-01 05:19:30.901832
NCT00022009|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-09-19|2003-06-11|2003-06-12|Estimate|||||||2013-09-19|2013-09-20|Estimate|July 2001||2001-07-31|October 2002|2002-10-31||||||||Interventional|||Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase I/II Randomized Trial Comparing Two Treatment Schedules Of Gemcitabine In Poor Prognosis Status Patients With Advanced Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2/Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:30.963579|2018-06-01 05:19:30.963579
NCT00018954|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-02-16|2003-06-11|2003-06-12|Estimate|||||||2012-02-16|2012-02-20|Estimate|October 1992||1992-10-31|February 2012|2012-02-29|October 2002|Actual|2002-10-31|||||Interventional|||Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma|PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:31.02197|2018-06-01 05:19:31.02197
NCT00017394|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-01-16|2003-06-11|2003-06-12|Estimate|||||||2013-01-16|2013-01-17|Estimate|March 2001||2001-03-31|January 2013|2013-01-31||||September 2007|Actual|2007-09-30||Interventional|||Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer|A Phase II Study of Bevacizumab in Combination With Vinorelbine in Stage IV Breast Cancer|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:31.158032|2018-06-01 05:19:31.158032
NCT00017316|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-02-08|2003-06-11|2003-06-12|Estimate|||||||2013-02-08|2013-02-11|Estimate|March 2001||2001-03-31|August 2002|2002-08-31||||September 2003|Actual|2003-09-30||Interventional|||Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma|A Phase II, Pharmacologic and Biologic Study of Escalating Doses of Thalidomide (NSC #66847) Administered Orally Once a Day in Combination With a Fixed Dose of SU5416 (NSC #696819) in Patients With Metastatic Melanoma|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:31.228842|2018-06-01 05:19:31.228842
NCT00062582|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-09|||2016-11-22|2003-06-09|2003-06-10|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2003||2003-06-30|September 2016|2016-09-30||||||||Interventional|||Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)|A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1000||AstraZeneca|||||f||||||||||||||2018-06-01 05:19:31.296542|2018-06-01 05:19:31.296542
NCT00016107|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-06-04|2003-06-09|2003-06-10|Estimate|||||||2013-06-04|2013-06-05|Estimate|June 2001||2001-06-30|June 2013|2013-06-30||||February 2007|Actual|2007-02-28||Interventional|||Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer|A Phase II Study Of Estramustine, Docetaxel, And Bevacizumab (IND # 7921, NSC # 704865) In Men With Hormone Refractory Prostate Cancer|Completed||Phase 2|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:31.404829|2018-06-01 05:19:31.404829
NCT00014664|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-12-17|2003-06-09|2003-06-10|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2000||2000-10-31|September 2002|2002-09-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II, Open-Label, Randomized, Multicenter Trial To Evaluate The Preliminary Safety And Efficacy of Hu1D10 In Patients With Relapsed Or Refractory Grades I, II, or III B-Cell Non-Hodgkin's Lymphoma (Including Follicular, Small Lymphocytic And Marginal Zone/MALT)|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:31.490472|2018-06-01 05:19:31.490472
NCT00014534|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2016-07-12|2003-06-09|2003-06-10|Estimate|||||||2016-07-12|2016-07-14|Estimate|March 2004||2004-03-31|July 2016|2016-07-31|April 2009|Actual|2009-04-30|July 2005|Actual|2005-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Bladder Cancer|Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder|Completed||Phase 3|42|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:19:31.610714|2018-06-01 05:19:31.610714
NCT00014170|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-07-15|2003-06-09|2003-06-10|Estimate|||||||2013-07-15|2013-07-16|Estimate|March 2001||2001-03-31|June 2013|2013-06-30||||July 2003|Actual|2003-07-31||Interventional|||Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma)|Completed||Phase 2|92|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:32.114247|2018-06-01 05:19:32.114247
NCT00062517|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-06|||2017-10-05|2003-06-06|2003-06-09|Estimate|||||||2017-10-05|2017-10-06|Actual|June 5, 2003||2003-06-05|September 21, 2016|2016-09-21|September 21, 2016||2016-09-21|||||Observational|||Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning|Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Social Emotional Information and Instrumental Learning|Completed|||497|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:32.190631|2018-06-01 05:19:32.190631
NCT00012155|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-06-25|2003-06-06|2003-06-09|Estimate|||||||2013-06-25|2013-06-26|Estimate|October 2000||2000-10-31|November 2002|2002-11-30|December 2009|Actual|2009-12-31|November 2002|Actual|2002-11-30||Interventional|||Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver|A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:32.247508|2018-06-01 05:19:32.247508
NCT00062465|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2008-03-03|2003-06-05|2003-06-06|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2003||2003-06-30|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine|A 24-Week, Double Blind, Randomized Study to Determine the Effects of 24 Weeks of Dosing With Tripterygium Wilfordii Hook F (TwHF) or Sulfasalazine, in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|157||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:32.301491|2018-06-01 05:19:32.301491
NCT00062452|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2017-10-05|2003-06-05|2003-06-06|Estimate|||||||2017-10-05|2017-10-06|Actual|May 2002||2002-05-31|January 2010|2010-01-31|July 2005|Actual|2005-07-31|April 2005|Actual|2005-04-30||Observational|||Esophageal Motility and Airway Defenses Among Infants|Esophageal Motility and Airway Defenses Among Infants|Completed|||65|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||1||f||||t|f|f||||||||2018-06-01 05:19:32.359434|2018-06-01 05:19:32.359434
NCT00062439|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|2012-11-15||2013-10-30|2003-06-05|2003-06-06|Estimate|2013-10-30|2013-11-25|Estimate||||2013-10-30|2013-11-25|Estimate|July 2003||2003-07-31|October 2013|2013-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors|A Phase II Trial of Induction Chemoradiotherapy With Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)|Completed||Phase 2|46|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:19:32.479243|2018-06-01 05:19:32.479243
NCT00062426|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-11-05|2003-06-05|2003-06-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|May 2003||2003-05-31|April 2004|2004-04-30|February 2011|Actual|2011-02-28|||||Interventional|||Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer|A Randomized, Prospective Study Comparing Three Regimens Of Eloxatin ™ Plus Fluoropyrimidine For Evaluation Of Safety And Tolerability In First Line Treatment Of Patients With Advanced Colorectal Cancer (Tree Study)|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:33.270192|2018-06-01 05:19:33.270192
NCT00062400|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-10-23|2003-06-05|2003-06-06|Estimate|||||||2013-10-23|2013-10-24|Estimate|May 2003||2003-05-31|October 2013|2013-10-31||||June 2008|Actual|2008-06-30||Interventional|||Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer|A Survey of the Breast International Group (B.I.G.) to Assess the Attitude of Patients Aged Less Than 35 Years, With Early Breast Cancer, Toward the Risk of Loss of Fertility Related to Adjuvant Therapies|Completed||N/A|385|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:19:33.425198|2018-06-01 05:19:33.425198
NCT00062387|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-05-31|2003-06-05|2003-06-06|Estimate|||||||2013-05-31|2013-06-03|Estimate|May 2003||2003-05-31|October 2004|2004-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study Of Perifosine In Patients With Recurrent Or Metastatic Head And Neck Cancer|Terminated||Phase 2|46|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:19:33.52816|2018-06-01 05:19:33.52816
NCT00062374|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|2014-09-22||2017-06-07|2003-06-05|2003-06-06|Estimate|2017-06-07|2017-07-06|Actual||||2017-06-07|2017-07-06|Actual|June 2003||2003-06-30|June 2017|2017-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction|An Evaluation of Preoperative Chemotherapy With Irinotecan and Cisplatin for Advanced, But Resectable Gastric Cancer: A Coordinated Multidisciplinary, Multicenter Study Linking Functional Imaging, Genomic Expression Profiles and Histopathology|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)|Technical problems with measurement leading to unreliable or uninterpretable data. Data adjudication was invalid, and needs to be re-adjudicated.|1|||f||||||||||||||2018-06-01 05:19:33.635259|2018-06-01 05:19:33.635259
NCT00062348|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2012-01-19|2003-06-05|2003-06-06|Estimate|||||||2012-01-19|2012-01-20|Estimate|April 2003||2003-04-30|January 2012|2012-01-31||||December 2007|Actual|2007-12-31||Interventional|||Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases|B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA|Completed||Phase 1|27|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:19:33.996754|2018-06-01 05:19:33.996754
NCT00062335|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2012-09-20|2003-06-05|2003-06-06|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 2003||2003-04-30|September 2012|2012-09-30||||February 2006|Actual|2006-02-28||Interventional|||High-Dose 3-Dimensional Conformal Radiation Therapy in Treating Patients With Inoperable Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|A Phase I Study On The Feasibility Of High Dose Three Dimensional Conformal Radiotherapy In Patients With Inoperable And Locally Advanced Non Small Cell Lung Cancer|Terminated||Phase 1|14|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:19:34.080694|2018-06-01 05:19:34.080694
NCT00062322|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2010-02-11|2003-06-05|2003-06-06|Estimate|||||||2010-02-11|2010-02-12|Estimate|February 2003||2003-02-28|February 2010|2010-02-28|October 2009|Actual|2009-10-31|||||Interventional|||Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase I Study of Preoperative Chemo/Radiation (Concurrent Irinotecan/Cisplatin/RT) Followed by Surgery in Limited Stage Small Cell Lung Cancer (SCLC-LS)|Completed||Phase 1|||Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:19:34.158334|2018-06-01 05:19:34.158334
NCT00062309|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2016-03-01|2003-06-05|2003-06-06|Estimate|||||||2016-03-01|2016-03-03|Estimate|June 2002||2002-06-30|March 2016|2016-03-31||||May 2006|Actual|2006-05-31||Interventional|||Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer|A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation|Completed||Phase 3|307|Actual|Fox Chase Cancer Center||2|||f||||f||||||||||2018-06-01 05:19:34.218461|2018-06-01 05:19:34.218461
NCT00062296|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-07-10|2003-06-05|2003-06-06|Estimate|||||||2013-07-10|2013-07-11|Estimate|March 2003||2003-03-31|July 2013|2013-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase II Study of Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL|Completed||Phase 2|5|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:19:34.301347|2018-06-01 05:19:34.301347
NCT00062283|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-06-25|2003-06-05|2003-06-06|Estimate|||||||2013-06-25|2013-06-26|Estimate|March 2003||2003-03-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|December 2005|Actual|2005-12-31||Interventional|||Alanosine in Treating Patients With Cancer|A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:34.385064|2018-06-01 05:19:34.385064
NCT00062270|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2015-10-06|2003-06-05|2003-06-06|Estimate|||||||2015-10-06|2015-10-08|Estimate|May 2003||2003-05-31|September 2015|2015-09-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer|Neoadjuvant Chemoradiotherapy (Gemcitabine/Cisplatin and Taxotere) With or Without Co-Administration of ZD 1839 (Iressa) for Stage IIIA (N2) and Selective Stage IIIB Non-Small Cell Lung Cancer: Phase I-II Study|Completed||Phase 1/Phase 2|||University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 05:19:34.481|2018-06-01 05:19:34.481
NCT00062257|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-05-14|2003-06-05|2003-06-06|Estimate|||||||2013-05-14|2013-05-15|Estimate|June 2003||2003-06-30|March 2005|2005-03-31|September 2006|Actual|2006-09-30|||||Interventional|||Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer|A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:34.544604|2018-06-01 05:19:34.544604
NCT00062244|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-06-03|2003-06-05|2003-06-06|Estimate|||||||2013-06-03|2013-06-04|Estimate|May 2003||2003-05-31|June 2013|2013-06-30||||June 2007|Actual|2007-06-30||Interventional|||Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia|Phase I/II Study of G3139 (Genasense) in Patients With Waldenstrom's Macroglobulinemia|Completed||Phase 1/Phase 2|58|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:34.601844|2018-06-01 05:19:34.601844
NCT00062231|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2012-09-20|2003-06-05|2003-06-06|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 2002||2002-04-30|September 2012|2012-09-30||||October 2006|Actual|2006-10-31||Interventional|||Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer|Oral Empirical Therapy of Fever in Low-Risk Neutropenic Cancer Patients: A Prospective, Double-Blind, Randomized, Multicenter Trial Comparing Monotherapy (Single Daily Dose Moxifloxacin) With Combination Therapy (Ciprofloxacin Plus Amoxicillin/Clavulanic Acid)|Terminated||N/A|351|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:19:34.686418|2018-06-01 05:19:34.686418
NCT00062205|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2010-02-05|2003-06-05|2003-06-06|Estimate|||||||2010-02-05|2010-02-09|Estimate|June 2002||2002-06-30|February 2010|2010-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor|Phase II Trial of Gleevec (STI571) in Therapy of Ewing's Family of Tumors and Desmoplastic Small Round Cell Tumors|Completed||Phase 2|40|Anticipated|City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:19:34.793594|2018-06-01 05:19:34.793594
NCT00062179|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2015-10-01|2003-06-05|2003-06-06|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2003||2003-03-31|August 2012|2012-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer|A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer|Completed||Phase 2|7|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:19:34.843533|2018-06-01 05:19:34.843533
NCT00062166|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2017-11-30|2003-06-05|2003-06-06|Estimate|||||||2017-11-30|2017-12-02|Actual|April 11, 2003||2003-04-11|November 29, 2017|2017-11-29|November 29, 2017||2017-11-29|||||Observational|||Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease|Evaluation of the Natural History and Management of Pancreatic Lesions Associated With Von Hippel-Lindau|Completed|||340|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:34.904842|2018-06-01 05:19:34.904842
NCT00062140|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2010-09-20|2003-06-05|2003-06-06|Estimate|||||||2010-09-20|2010-09-21|Estimate|April 2003||2003-04-30|September 2010|2010-09-30|July 2004|Actual|2004-07-31|||||Interventional|||Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer|A Phase I Trial Of Total Body Irradiation, Cyclophosphamide Dose-Adjustment Based On Its Metabolism, And Hematopoietic Stem Cell Transplantation For Patients With Hematological Malignancy|Completed||Phase 1|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:19:35.000073|2018-06-01 05:19:35.000073
NCT00062127|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-01-23|2003-06-05|2003-06-06|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2003||2003-04-30|January 2013|2013-01-31||||May 2006|Actual|2006-05-31||Interventional|||Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors|A Phase I Pharmacokinetic Interaction Study of Irinotecan (NSC616348) and Thalidomide (NSC66847) in Patients With Advanced Solid Tumors|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:19:35.125252|2018-06-01 05:19:35.125252
NCT00062114|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2016-07-01|2003-06-05|2003-06-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|April 2004||2004-04-30|July 2016|2016-07-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase II Study To Evaluate The Safety And Efficacy Of Zevalin (IND # BB IND 4850) Therapeutic Regimen In Patients With Transformed CD20 + B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|84|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:19:35.202718|2018-06-01 05:19:35.202718
NCT00062101|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-06-05|2003-06-05|2003-06-06|Estimate|||||||2013-06-05|2013-06-06|Estimate|January 2004||2004-01-31|June 2013|2013-06-30||||January 2006|Actual|2006-01-31||Interventional|||Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer|A Phase II Study of OSI 774 (IND Number 63383) in Combination With Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:19:35.392297|2018-06-01 05:19:35.392297
NCT00062075|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2015-12-03|2003-06-05|2003-06-06|Estimate|||||||2015-12-03|2015-12-04|Estimate|May 2003||2003-05-31|April 2013|2013-04-30||||March 2007|Actual|2007-03-31||Interventional|||Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML|Completed||Phase 2|47|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:35.467068|2018-06-01 05:19:35.467068
NCT00062062|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2016-12-12|2003-06-05|2003-06-06|Estimate|||||||2016-12-12|2016-12-14|Estimate|October 2004||2004-10-31|December 2016|2016-12-31|November 2010|Actual|2010-11-30|August 2006|Actual|2006-08-31||Interventional|||Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer|Parallel Phase II Trials of ZD1839 (Iressa) Alone or Weekly Carboplatin and Paclitaxel Followed by ZD1839 (Iressa) (Oncologists Must Choose) for Metastatic Non-Small Cell Lung Cancer in Patients > or = 65 Years of Age|Completed||Phase 2|65|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:19:35.56819|2018-06-01 05:19:35.56819
NCT00062049|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2012-03-07|2003-06-05|2003-06-06|Estimate|||||||2012-03-07|2012-03-08|Estimate|April 2003||2003-04-30|March 2012|2012-03-31|May 2011|Actual|2011-05-31|||||Interventional|||Interleukin-7 in Treating Patients With Refractory Solid Tumors|"A Phase I Study of Subcutaneous CYT 99 007 (Interleukin-7) in Patients With Refractory Non Hematologic Malignancy"|Completed||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:19:35.839415|2018-06-01 05:19:35.839415
NCT00062036|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2017-06-30|2003-06-05|2003-06-06|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2003||2003-06-30|March 2012|2012-03-31|September 2008|Actual|2008-09-30|February 2007|Actual|2007-02-28||Interventional|||Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma|Tumor Infiltrating Lymphocytes (TIL Cells) Transduced With An Interleukin-2 (SBIL-2) Gene Following The Administration Of A Nonmyeloablative But Lymphocyte Depleting Regimen in Metastatic Melanoma|Completed||Phase 1/Phase 2|33|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:19:35.908115|2018-06-01 05:19:35.908115
NCT00062023|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2012-07-27|2003-06-05|2003-06-06|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 2003||2003-06-30|July 2012|2012-07-31|May 2006|Actual|2006-05-31|April 2005|Actual|2005-04-30||Interventional|||Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer|Phase II Study Of Colorectal ACF Screening, Regression And Prevention In High Risk Participants|Terminated||Phase 2|12|Actual|M.D. Anderson Cancer Center||4||Study closed by the NCI.|f||||t||||||||||2018-06-01 05:19:35.992503|2018-06-01 05:19:35.992503
NCT00062010|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|2012-12-01||2015-10-06|2003-06-05|2003-06-06|Estimate|2012-12-01|2013-01-04|Estimate||||2015-10-06|2015-10-08|Estimate|February 2004||2004-02-29|December 2012|2012-12-31|August 2012|Actual|2012-08-31|May 2011|Actual|2011-05-31||Interventional|||Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer|Interferon Alpha (NSC# 377523) Plus 13-Cis-Retinoic Acid Modulation Of BCL-2 Plus Paclitaxel For Recurrent Small Cell Lung Cancer|Completed||Phase 2|37|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:19:36.110617|2018-06-01 05:19:36.110617
NCT00061997|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2010-02-01|2003-06-05|2003-06-06|Estimate|||||||2010-02-01|2010-02-02|Estimate|May 2003||2003-05-31|November 2005|2005-11-30||||||||Interventional|||Inositol in Preventing Lung Cancer in Patients With Bronchial Epithelial Dysplasia Who Are Current or Former Smokers|A Phase I Study Of The Safety Of Myo-Inositol As A Chemopreventive Agent|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:36.441706|2018-06-01 05:19:36.441706
NCT00061984|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2014-10-24|2003-06-05|2003-06-06|Estimate|||||||2014-10-24|2014-10-27|Estimate|April 2003||2003-04-30|October 2014|2014-10-31|July 2012|Actual|2012-07-31|May 2010|Actual|2010-05-31||Interventional|||Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma|Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma|Completed||Phase 3|455|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:19:36.499014|2018-06-01 05:19:36.499014
NCT00061958|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-01-22|2003-06-05|2003-06-06|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2003||2003-06-30|January 2013|2013-01-31||||April 2005|Actual|2005-04-30||Interventional|||Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Study of Arsenic Trioxide (NSC 706363) in Patients With Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction|Terminated||Phase 2|50|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:19:36.610373|2018-06-01 05:19:36.610373
NCT00061945|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|2013-12-05||2014-03-20|2003-06-05|2003-06-06|Estimate|2014-03-20|2014-04-16|Estimate||||2014-03-20|2014-04-16|Estimate|June 2003||2003-06-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|December 2007|Actual|2007-12-31||Interventional|||Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia|A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 1/Phase 2|302|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:36.73058|2018-06-01 05:19:36.73058
NCT00061932|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|2015-05-15||2015-05-15|2003-06-05|2003-06-06|Estimate|2015-05-15|2015-06-03|Estimate||||2015-05-15|2015-06-03|Estimate|April 2003||2003-04-30|June 2013|2013-06-30|November 2013|Actual|2013-11-30|December 2009|Actual|2009-12-31||Interventional|||Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach|A Phase II Study of PS-341 Alone or in Combination With Irinotecan in Patients With Adenocarcinoma of the Gastroesophageal Junction (GEJ) or Stomach|Completed||Phase 2|41|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 05:19:38.829618|2018-06-01 05:19:38.829618
NCT00061919|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2012-03-15|2003-06-05|2003-06-06|Estimate|||||||2012-03-15|2012-03-16|Estimate|April 2003||2003-04-30|March 2012|2012-03-31|July 2007|Actual|2007-07-31|February 2007|Actual|2007-02-28||Interventional|||Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer|A Phase III Randomized, Double Blind, Placebo Controlled Trial Of Carboplatin/Etoposide With Or Without Thalidomide In Small Cell Lung Cancer (Study 12)|Completed||Phase 3|724|Actual|University College, London||2|||f||||t||||||||||2018-06-01 05:19:39.290395|2018-06-01 05:19:39.290395
NCT00061906|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2014-02-10|2003-06-05|2003-06-06|Estimate|||||||2014-02-10|2014-02-11|Estimate|January 2003||2003-01-31|February 2014|2014-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer|Phase II Study Of Celecoxib In Metastatic Differentiated Thyroid Carcinoma|Completed||Phase 2|25|Actual|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:19:39.43429|2018-06-01 05:19:39.43429
NCT00061893|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|2013-01-17||2014-09-16|2003-06-05|2003-06-06|Estimate|2013-02-07|2013-03-12|Estimate||||2014-09-16|2014-09-29|Estimate|April 2004||2004-04-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|April 2008|Actual|2008-04-30||Interventional|||Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors|A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors|Completed||Phase 2|38|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:19:39.582323|2018-06-01 05:19:39.582323
NCT00061880|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-05-29|2003-06-05|2003-06-06|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 2003||2003-02-28|July 2004|2004-07-31|January 2008|Actual|2008-01-31|January 2005|Actual|2005-01-31||Interventional|||BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma|Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL)|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:41.21744|2018-06-01 05:19:41.21744
NCT00061867|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2013-05-29|2003-06-05|2003-06-06|Estimate|||||||2013-05-29|2013-05-30|Estimate|March 2003||2003-03-31|July 2005|2005-07-31|August 2005|Actual|2005-08-31|||||Interventional|||Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer|A Dose Escalation, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:41.429727|2018-06-01 05:19:41.429727
NCT00061854|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2012-05-15|2003-06-05|2003-06-06|Estimate|||||||2012-05-15|2012-05-16|Estimate|April 2003||2003-04-30|May 2012|2012-05-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Study Of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, To Patients With Progressive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) Following Treatment With Platinum-Based Chemotherapy|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:19:41.53736|2018-06-01 05:19:41.53736
NCT00061841|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2010-01-12|2003-06-05|2003-06-06|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31||||||||Interventional|||Medical College of Georgia FitKid Project||Completed||Phase 2|685|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:41.658076|2018-06-01 05:19:41.658076
NCT00061828|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-05|||2018-02-15|2003-06-05|2003-06-06|Estimate|||||||2018-02-15|2018-02-19|Actual|May 2004||2004-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|PROBE||PROBE: A Prospective Database of Infants With Cholestasis|Childhood Liver Disease Research and Education Network (CHILDREN): A Prospective Database of Infants With Cholestasis|Recruiting|||1000|Anticipated|Arbor Research Collaborative for Health|||2||f||||t||||||Samples With DNA|"~     Samples of blood, urine and liver tissue samples will be collected for research purposes.~   "|Yes|The data will be transferred to NIDDK at the end of the study.|2018-06-01 05:19:41.852587|2018-06-01 05:19:41.852587
NCT00061815|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-04|||2010-04-08|2003-06-05|2003-06-06|Estimate|||||||2010-04-08|2010-04-12|Estimate|March 2003||2003-03-31|April 2010|2010-04-30|November 2005|Actual|2005-11-30|December 2004|Actual|2004-12-31||Interventional|||Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer|A Phase 3 Randomized Multicenter Study of Cetuximab, Oxaliplatin, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and Leucovorin in Subjects With Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma|Completed||Phase 3|102|Actual|ImClone LLC||2|||f||||f||||||||||2018-06-01 05:19:42.098713|2018-06-01 05:19:42.098713
NCT00033462|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-06-03|2003-06-05|2003-06-06|Estimate|||||||2013-06-03|2013-06-04|Estimate|March 2002||2002-03-31|June 2013|2013-06-30||||November 2006|Actual|2006-11-30||Interventional|||Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer|A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma|Completed||Phase 2|78|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:42.345059|2018-06-01 05:19:42.345059
NCT00010231|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2015-03-27|2003-06-05|2003-06-06|Estimate|||||||2015-03-27|2015-03-30|Estimate|June 1999||1999-06-30|March 2015|2015-03-31|November 2002|Actual|2002-11-30|August 2002|Actual|2002-08-31||Interventional|||Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Phase I Study Of Oral, 1,25 Dihydroxycholecalciferol (Calcitriol) + Dexamethasone In Hormone-refractory Prostate Cancer|Completed||Phase 1|22|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 05:19:42.493129|2018-06-01 05:19:42.493129
NCT00010114|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2011-07-19|2003-06-05|2003-06-06|Estimate|||||||2011-07-19|2011-07-20|Estimate|March 2001||2001-03-31|July 2011|2011-07-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Observational|||Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children|Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis|Completed|||83|Actual|Pediatric Brain Tumor Consortium|||1||f||||f||||||||||2018-06-01 05:19:42.614894|2018-06-01 05:19:42.614894
NCT00009932|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-05-14|2003-06-05|2003-06-06|Estimate|||||||2013-05-14|2013-05-15|Estimate|January 2001||2001-01-31|October 2002|2002-10-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Solid Tumors|A Phase I Study Of Fenretinide Combined With Paclitaxel And Cisplatin For The Treatment Of Refractory Solid Tumors|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:42.785948|2018-06-01 05:19:42.785948
NCT00009802|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-12-18|2003-06-05|2003-06-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 1998||1998-06-30|December 2013|2013-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of Oral Calcitriol [1,25-(OH)2D3] And Paclitaxel In Advanced Solid Tumors|Completed||Phase 1|45|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:19:42.926576|2018-06-01 05:19:42.926576
NCT00061802|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-04|||2012-02-06|2003-06-04|2003-06-05|Estimate|||||||2012-02-06|2012-02-07|Estimate|June 2003||2003-06-30|February 2012|2012-02-29|February 2004|Actual|2004-02-29|||||Interventional|||Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder|A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder|Completed||Phase 4|225|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:19:43.02657|2018-06-01 05:19:43.02657
NCT00009789|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2016-07-12|2003-06-04|2003-06-05|Estimate|||||||2016-07-12|2016-07-14|Estimate|December 2000||2000-12-31|July 2016|2016-07-31|June 2010|Actual|2010-06-30|June 2007|Actual|2007-06-30||Interventional|||Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction|Accelerated Conformal Radiotherapy for Stage I Non-Small Cell Lung Cancer in Patients With Pulmonary Dysfunction: A Phase I Study|Completed||Phase 1|39|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:19:43.233498|2018-06-01 05:19:43.233498
NCT00008424|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2014-05-02|2003-06-04|2003-06-05|Estimate|||||||2014-05-02|2014-05-05|Estimate|October 2000||2000-10-31|May 2014|2014-05-31|September 2006|Actual|2006-09-30|September 2005|Actual|2005-09-30||Interventional|||Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants|A Phase I Study of Irinotecan in Patients With Refractory Solid Tumors Who Are Concomitantly Receiving Anticonvulsants|Completed||Phase 1|7|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:19:43.474687|2018-06-01 05:19:43.474687
NCT00008398|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-11-18|2003-06-04|2003-06-05|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2000||2000-10-31|November 2013|2013-11-30||||March 2004|Actual|2004-03-31||Interventional|||Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer|A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients|Completed||Phase 3|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:19:43.828862|2018-06-01 05:19:43.828862
NCT00008203|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-02-01|2003-06-04|2003-06-05|Estimate|||||||2013-02-01|2013-02-04|Estimate|May 1996||1996-05-31|May 2003|2003-05-31|May 2008|Actual|2008-05-31|December 2005|Actual|2005-12-31||Interventional|||Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer|High-Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support And One Of Two Regimens Aimed At Modifying Immune Reconstitution In Women With High Risk Stage 2 And Stage 3 Breast Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:44.271592|2018-06-01 05:19:44.271592
NCT00008112|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-08-06|2003-06-04|2003-06-05|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2000||2000-06-30|October 2002|2002-10-31||||||||Interventional|||Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer|Feasibility Study of the Combination of Radiotherapy, Chemotherapy and Hyperthermia for the Treatment of Stage IIB-III-IVA Cervical Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:44.370387|2018-06-01 05:19:44.370387
NCT00061789|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-04|||2008-03-03|2003-06-03|2003-06-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2003||2003-02-28|August 2004|2004-08-31|August 2004||2004-08-31|||||Interventional|||Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia|SPECT Imaging of Alpha 4 Beta 2 Nicotinic Acetylcholine Receptors Using [(123)I]5-I-A-85380 in Schizophrenia|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:44.561286|2018-06-01 05:19:44.561286
NCT00061776|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-03|||2008-03-04|2003-06-03|2003-06-04|Estimate|||||||2008-03-04|2008-03-06|Estimate||||March 2008|2008-03-31||||||||Interventional|||NGX-4010 for the Treatment of Postherpetic Neuralgia|A Randomized, Double-Blind, Controlled Dose Finding Study of NGX-4010 for the Treatment of Postherpetic Neuralgia|Completed||Phase 2/Phase 3|300||NeurogesX|||||||||||||||||||2018-06-01 05:19:44.687137|2018-06-01 05:19:44.687137
NCT00061763|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-03|||2017-08-17|2003-06-03|2003-06-04|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2003||2003-05-31|August 2017|2017-08-31||||November 2004|Actual|2004-11-30||Interventional|||Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias|Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine|Completed||Phase 2|175|Actual|Novartis|||||||||||||||||||2018-06-01 05:19:44.828107|2018-06-01 05:19:44.828107
NCT00061750|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-03|||2012-04-18|2003-06-03|2003-06-04|Estimate|||||||2012-04-18|2012-04-19|Estimate|May 2003||2003-05-31|April 2012|2012-04-30||||November 2004|Actual|2004-11-30||Interventional|||Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions|A Randomized, Comparative, Open Label Phase III Trial on Efficacy & Safety of Long-term Treatment With ICL670 Compared to Deferoxamine in Beta-thalassemia Patients With Transfusional Hemosiderosis|Completed||Phase 3|595|Actual|Novartis||2|||f||||||||||||||2018-06-01 05:19:44.915062|2018-06-01 05:19:44.915062
NCT00061737|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-03|||2010-01-12|2003-06-03|2003-06-04|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 2003||2003-01-31|January 2010|2010-01-31||||||||Observational|||Quality of Life in Pediatric Inflammatory Bowel Disease||Completed|||350|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:45.145239|2018-06-01 05:19:45.145239
NCT00061724|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-03|||2010-01-12|2003-06-03|2003-06-04|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31||||||||Observational|||Medical and Surgical Treatment of Esophageal Reflux||Completed|||175|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:45.264367|2018-06-01 05:19:45.264367
NCT00061711|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-03|||2009-12-09|2003-06-03|2003-06-04|Estimate|||||||2009-12-09|2009-12-11|Estimate|July 2000||2000-07-31|December 2009|2009-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Alternative Therapies for Menopause: A Randomized Trial||Completed||N/A|355||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:19:45.356406|2018-06-01 05:19:45.356406
NCT00061698|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-03|||2015-06-11|2003-06-03|2003-06-04|Estimate|||||||2015-06-11|2015-06-12|Estimate|April 2002||2002-04-30|June 2015|2015-06-30|December 2008|Actual|2008-12-31|August 2008|Actual|2008-08-31||Interventional|||Treatment for Depressed Preadolescent Girls|CBT vs CBT Plus Parent Training for Girls With Depression|Completed||Phase 1|153|Actual|University of Texas at Austin||3|||f||||f||||||||||2018-06-01 05:19:45.465025|2018-06-01 05:19:45.465025
NCT00061672|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-02|||2007-08-13|2003-06-03|2003-06-04|Estimate|||||||2007-08-13|2007-08-15|Estimate|April 2003||2003-04-30|August 2007|2007-08-31||||||||Interventional|||Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma|A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma|Completed||Phase 2|67|Actual|Abbott|||||f||||f||||||||||2018-06-01 05:19:45.627877|2018-06-01 05:19:45.627877
NCT00061659|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-02|||2007-11-28|2003-06-03|2003-06-04|Estimate|||||||2007-11-28|2007-11-29|Estimate|May 2003||2003-05-31|November 2007|2007-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma|A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma|Completed||Phase 2|88|Actual|Abbott|||||f||||f||||||||||2018-06-01 05:19:45.814801|2018-06-01 05:19:45.814801
NCT00061646|ClinicalTrials.gov processed this data on May 31, 2018|2003-06-02|||2007-08-10|2003-06-03|2003-06-04|Estimate|||||||2007-08-10|2007-08-14|Estimate|March 2003||2003-03-31|August 2007|2007-08-31||||||||Interventional|||Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)|A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|25|Actual|Abbott||||"Enrollment suspended based upon interim analysis; subjects allowed to stay on study until~   disease progression."|f||||f||||||||||2018-06-01 05:19:45.956649|2018-06-01 05:19:45.956649
NCT00051714|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-15|||2013-07-12|2003-06-03|2003-06-04|Estimate|||||||2013-07-12|2013-07-16|Estimate|March 1997||1997-03-31|July 2013|2013-07-31||||December 2012|Actual|2012-12-31||Interventional|||Early Prevention of Conduct Problems|Early Primary Prevention of Conduct Problems|Completed||Phase 4|1050|Actual|New York University School of Medicine||1|||f||||||||||||||2018-06-01 05:19:46.102687|2018-06-01 05:19:46.102687
NCT00061633|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-30|2009-12-02||2010-01-27|2003-05-30|2003-06-02|Estimate|2009-12-02|2010-01-11|Estimate||||2010-01-27|2010-02-02|Estimate|June 2003||2003-06-30|January 2010|2010-01-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|FAST||Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)|Completed||Phase 2|169|Actual|Theravance Biopharma Antibiotics, Inc.||2|||||||t||||||||||2018-06-01 05:19:46.269136|2018-06-01 05:19:46.269136
NCT00061620|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-30|||2012-07-27|2003-05-30|2003-06-02|Estimate|||||||2012-07-27|2012-07-31|Estimate|September 2001||2001-09-30|July 2012|2012-07-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies|Phase I Study of Continuous Infusion Schedule of (E)-2'-Deoxy-2'-(Fluoromethylene) Cytidine (Tezacitabine, FMdC) in Hematologic Malignancies|Completed||Phase 1|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:19:47.134859|2018-06-01 05:19:47.134859
NCT00059462|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-25|||2014-12-18|2003-05-30|2003-06-02|Estimate|||||||2014-12-18|2014-12-23|Estimate|December 2002||2002-12-31|December 2014|2014-12-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection|Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone.|Completed||Phase 1/Phase 2|56|Actual|Bayer||2|||f||||||||||||||2018-06-01 05:19:47.288578|2018-06-01 05:19:47.288578
NCT00008021|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-08-06|2003-05-30|2003-06-02|Estimate|||||||2013-08-06|2013-08-07|Estimate|February 2001||2001-02-28|December 2002|2002-12-31||||||||Interventional|||Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma|A Phase I Study of 90Y-DOTA-Peptide-Lym-1 With Peripheral Blood Stem Cell Support, Paclitaxel And Cyclosporin A In Patients With Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:47.428546|2018-06-01 05:19:47.428546
NCT00006864|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2014-01-08|2003-05-30|2003-06-02|Estimate|||||||2014-01-08|2014-01-09|Estimate|July 2000||2000-07-31|January 2014|2014-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin|Completed||Phase 4|||Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:19:47.495606|2018-06-01 05:19:47.495606
NCT00006484|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-06-20|2003-05-30|2003-06-02|Estimate|||||||2013-06-20|2013-06-24|Estimate|November 2000||2000-11-30|January 2002|2002-01-31|April 2006|Actual|2006-04-30|||||Interventional|||Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:47.98078|2018-06-01 05:19:47.98078
NCT00061607|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-29|||2017-10-05|2003-05-29|2003-05-30|Estimate|||||||2017-10-05|2017-10-06|Actual|May 19, 2003||2003-05-19|April 4, 2017|2017-04-04|April 4, 2017||2017-04-04|||||Observational|||Measuring Levels of SMN in Blood Samples of SMA Patients|SMN Levels in Peripheral Blood Samples of SMA Patients and the Effects of Pharmacological Compounds In Vitro|Completed|||73|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:48.539081|2018-06-01 05:19:48.539081
NCT00061594|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-29|||2014-03-18|2003-05-29|2003-05-30|Estimate|||||||2014-03-18|2014-03-19|Estimate|May 2003||2003-05-31|March 2014|2014-03-31|September 2006|Actual|2006-09-30|||||Interventional|||A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration|A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration|Completed||Phase 3|426||Genentech, Inc.|||||f||||||||||||||2018-06-01 05:19:48.830841|2018-06-01 05:19:48.830841
NCT00061542|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2016-11-16|2003-05-29|2003-05-30|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2003||2003-01-31|August 2008|2008-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension|Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension|Completed||Phase 3|105|Actual|Alcon Research||3|||||||||||||||||2018-06-01 05:19:49.102861|2018-06-01 05:19:49.102861
NCT00061529|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2008-08-04|2003-05-29|2003-05-30|Estimate|||||||2008-08-04|2008-08-05|Estimate|January 2003||2003-01-31|August 2008|2008-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:19:49.219343|2018-06-01 05:19:49.219343
NCT00061516|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2016-11-16|2003-05-29|2003-05-30|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2003||2003-01-31|August 2008|2008-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension|Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension|Completed||Phase 3|78|Actual|Alcon Research||2|||||||||||||||||2018-06-01 05:19:49.33393|2018-06-01 05:19:49.33393
NCT00061503|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2008-08-04|2003-05-29|2003-05-30|Estimate|||||||2008-08-04|2008-08-05|Estimate|April 2003||2003-04-30|August 2008|2008-08-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension|A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension|Completed||Phase 4|||Alcon Research|||||||||||||||||||2018-06-01 05:19:49.418231|2018-06-01 05:19:49.418231
NCT00006464|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2010-01-13|2003-05-29|2003-05-30|Estimate|||||||2010-01-13|2010-01-15|Estimate|March 2001||2001-03-31|January 2010|2010-01-31|June 2008|Actual|2008-06-30|January 2005|Actual|2005-01-31||Interventional|||UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors|Phase I Dose Escalation Study of UCN-01 (NSC 638850) Plus Cisplatin in Advanced Malignant Solid Tumors|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:19:49.539839|2018-06-01 05:19:49.539839
NCT00006457|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2012-06-07|2003-05-29|2003-05-30|Estimate|||||||2012-06-07|2012-06-11|Estimate|August 2000||2000-08-31|June 2012|2012-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Oltipraz in the Prevention of Lung Cancer in People Who Smoke|Clinical Phase I Multiple-Dose Safety Research Study of Oltipraz in Smokers|Completed||Phase 1|||Northwestern University|||||f||||||||||||||2018-06-01 05:19:49.666494|2018-06-01 05:19:49.666494
NCT00006383|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-11-05|2003-05-29|2003-05-30|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2000||2000-06-30|December 2002|2002-12-31|August 2009|Actual|2009-08-31|||||Interventional|||Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma|Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Diffuse Large B-Cell Non-Hodgkin's Lymphoma That is Refractory or Relapsed After Second-Line Combination Chemotherapy Revised Title Per 03/01 SR Pivotal Phase II Multicenter Study of Vincristine Sulfate Liposomes Injection in Aggressive Non-Hodgkin's Lymphoma That is Refractory to or Relapsed After Second-Line Combination Chemotherapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:49.777258|2018-06-01 05:19:49.777258
NCT00006377|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-06-17|2003-05-29|2003-05-30|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2000||2000-06-30|June 2013|2013-06-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer|Phase II Study of Sequential Administration of Doxorubicin, Paclitaxel, and Carboplatin in Patients With Advanced and Recurrent Endometrial Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:19:49.870755|2018-06-01 05:19:49.870755
NCT00006361|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2009-12-03|2003-05-29|2003-05-30|Estimate|||||||2009-12-03|2009-12-04|Estimate|December 2000||2000-12-31|December 2002|2002-12-31||||January 2003|Actual|2003-01-31||Interventional|||SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck|A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:49.972639|2018-06-01 05:19:49.972639
NCT00061581|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-29|||2018-02-13|2003-05-28|2003-05-29|Estimate|||||||2018-02-13|2018-02-14|Actual|May 19, 2003||2003-05-19|June 14, 2017|2017-06-14|June 14, 2017|Actual|2017-06-14|December 28, 2007|Actual|2007-12-28||Interventional|||Experimental Bone Marrow Transplant Protocol|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies - Effect of Irradiated Donor Lymphocytes on Chimerism|Completed||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:50.225103|2018-06-01 05:19:50.225103
NCT00061568|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-29|||2018-05-15|2003-05-28|2003-05-29|Estimate|||||||2018-05-15|2018-05-16|Actual|May 23, 2003||2003-05-23|May 14, 2018|2018-05-14|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias|Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-Thalassemia|Recruiting||Phase 2|150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:50.336035|2018-06-01 05:19:50.336035
NCT00061490|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2017-09-22|2003-05-28|2003-05-29|Estimate|||||||2017-09-22|2017-09-26|Actual|September 2002|Actual|2002-09-30|September 2017|2017-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||The Effect of Weight Loss and Exercise on Knee Osteoarthritis|The Impact of Weight Loss and Exercise on Knee Osteoarthritis|Completed||N/A|160|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-06-01 05:19:50.478472|2018-06-01 05:19:50.478472
NCT00061477|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2007-01-24|2003-05-28|2003-05-29|Estimate|||||||2007-01-24|2007-01-26|Estimate|December 2002||2002-12-31|January 2007|2007-01-31|September 2006||2006-09-30|||||Interventional|||Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma|ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial|Completed||Phase 2|48||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:19:50.624237|2018-06-01 05:19:50.624237
NCT00061464|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2007-01-24|2003-05-28|2003-05-29|Estimate|||||||2007-01-24|2007-01-26|Estimate|February 2003||2003-02-28|January 2007|2007-01-31|February 2006||2006-02-28|||||Interventional|||Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.|ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial|Completed||Phase 2|48||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:19:50.698405|2018-06-01 05:19:50.698405
NCT00061451|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-28|||2010-12-20|2003-05-28|2003-05-29|Estimate|||||||2010-12-20|2010-12-22|Estimate|December 2002||2002-12-31|December 2010|2010-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial|ALIMTA Plus Gemcitabine as Front-line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase II Clinical Trial|Completed||Phase 2|48||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:19:50.807506|2018-06-01 05:19:50.807506
NCT00006349|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2016-07-12|2003-05-28|2003-05-29|Estimate|||||||2016-07-12|2016-07-13|Estimate|February 2001||2001-02-28|July 2016|2016-07-31|January 2007|Actual|2007-01-31|January 2005|Actual|2005-01-31||Interventional|||Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer|An Exploratory Trial of Donepezil and Vitamin E to Prevent Cognitive Dysfunction in Patients With Small Cell Lung Cancer (SCLC) After Cancer Treatment Which Includes Prophylatic Cranial Irradiation (PCI)|Completed||Phase 3|9|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:19:50.933776|2018-06-01 05:19:50.933776
NCT00006341|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2016-01-29|2003-05-28|2003-05-29|Estimate|||||||2016-01-29|2016-02-02|Estimate|June 1997||1997-06-30|January 2016|2016-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer|Efficacy of Implant-Supported Maxillofacial Prostheses|Completed||Phase 2|46|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||No||2018-06-01 05:19:51.044752|2018-06-01 05:19:51.044752
NCT00061438|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-27|||2017-08-31|2003-05-27|2003-05-28|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2003||2003-02-28|August 2017|2017-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died|A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis|Completed||Phase 4|240||Pfizer|||||||||||||||||||2018-06-01 05:19:51.128009|2018-06-01 05:19:51.128009
NCT00061425|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-27|||2009-01-08|2003-05-27|2003-05-28|Estimate|||||||2009-01-08|2009-01-09|Estimate|August 2000||2000-08-31|January 2009|2009-01-31||||November 2007|Actual|2007-11-30||Interventional|||Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG|Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG|Completed||Phase 1/Phase 2|||Immunomedics, Inc.|||||f||||f||||||||||2018-06-01 05:19:51.265368|2018-06-01 05:19:51.265368
NCT00061412|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-27|||2006-09-27|2003-05-27|2003-05-28|Estimate|||||||2006-09-27|2006-09-28|Estimate|December 1995||1995-12-31|September 2006|2006-09-30|November 2005||2005-11-30|||||Interventional|||Comprehensive Program to Improve Reading and Writing Skills in At-Risk and Dyslexic Children|Learning Disabilities: Links to Schools and Biology|Completed||N/A|2500||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:51.336289|2018-06-01 05:19:51.336289
NCT00061399|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-27|||2014-10-28|2003-05-27|2003-05-28|Estimate|||||||2014-10-28|2014-10-29|Estimate|July 2002||2002-07-31|April 2007|2007-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Prospective Memory in Children With Traumatic Brain Injury|Prospective Memory in Normal and Head-Injured Children|Completed|||178||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:51.415451|2018-06-01 05:19:51.415451
NCT00061386|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-27|||2005-09-09|2003-05-27|2003-05-28|Estimate|||||||2005-09-09|2005-09-13|Estimate|March 2001||2001-03-31|September 2005|2005-09-30|March 2004||2004-03-31|||||Interventional|||Improving Health in Low Income Women Following the Birth of a Child|Reducing Disease Risk in Low Income Postpartum Women|Completed||N/A|680||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:51.491869|2018-06-01 05:19:51.491869
NCT00061321|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|||2008-07-30|2003-05-27|2003-05-28|Estimate|||||||2008-07-30|2008-07-31|Estimate|August 2002||2002-08-31|August 2007|2007-08-31|September 2007|Actual|2007-09-30|April 2007|Actual|2007-04-30||Interventional|SWEN||Daily Nevirapine to Prevent Mother to Infant Transmission of HIV|Prevention of Maternal to Infant HIV Transmission in India|Completed||Phase 3|770|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 05:19:51.595427|2018-06-01 05:19:51.595427
NCT00061308|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|||2017-06-08|2003-05-27|2003-05-28|Estimate|||||||2017-06-08|2017-06-09|Actual|December 2002||2002-12-31|March 2013|2013-03-31||||September 2004|Actual|2004-09-30||Interventional|||Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer|An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer|Completed||Phase 2|75||GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:19:51.731281|2018-06-01 05:19:51.731281
NCT00061295|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|||2005-06-23|2003-05-27|2003-05-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1999||1999-03-31|March 2003|2003-03-31|February 2004||2004-02-29|||||Interventional|||Treadmill Training With Body Weight Support in Patients With Spinal Cord Injury|Body Weight Supported Ambulation Training After Spinal Cord Injury|Unknown status|Recruiting|Phase 1|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:51.890452|2018-06-01 05:19:51.890452
NCT00045149|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2010-05-05|2003-05-27|2003-05-28|Estimate|||||||2010-05-05|2010-05-07|Estimate|October 2002||2002-10-31|May 2010|2010-05-31|June 2005|Actual|2005-06-30|||||Interventional|||Biological Therapy in Treating Patients With Metastatic Melanoma|Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen Specific T Cell Clones Targeting Cancer Testis Antigens for Patients With Metastatic Melanoma|Completed||Phase 1|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:19:51.980485|2018-06-01 05:19:51.980485
NCT00060723|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-09|||2016-12-03|2003-05-12|2003-05-13|Estimate|||||||2016-12-03|2016-12-06|Estimate|August 1999||1999-08-31|December 2016|2016-12-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Observational|||Behavioral Effects of Obstructive Sleep Apnea in Children|Behavioral Effect of Obstructive Sleep Apnea in Children|Completed|||106|Actual|University of Michigan|||2||f||||f||||||||||2018-06-01 05:20:07.725754|2018-06-01 05:20:07.725754
NCT00019734|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-05-27|2003-05-28|Estimate|||||||2013-06-19|2013-06-20|Estimate|July 1999||1999-07-31|May 2007|2007-05-31|May 2003|Actual|2003-05-31|||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:52.042776|2018-06-01 05:19:52.042776
NCT00061373|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|2012-12-27||2012-12-27|2003-05-23|2003-05-26|Estimate|2012-12-27|2013-02-04|Estimate||||2012-12-27|2013-02-04|Estimate|May 2003||2003-05-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|December 2009|Actual|2009-12-31||Interventional|CATALIST||Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)|Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)|Completed||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)|All patients enrolled were dosed with aspirin and tinzaparin. None of the patients received iv eptifibatide. The study was closed prior to dosing with eptifibatide due to slow recruitment over the 5-year trial period.|2|||f||||t||||||||||2018-06-01 05:19:52.155826|2018-06-01 05:19:52.155826
NCT00061360|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|||2018-03-27|2003-05-23|2003-05-26|Estimate|||||||2018-03-27|2018-03-29|Actual|May 23, 2003||2003-05-23|August 16, 2017|2017-08-16|September 8, 2015|Actual|2015-09-08|May 31, 2006|Actual|2006-05-31||Interventional|||Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia|A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia|Completed||Phase 2|77|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:52.693271|2018-06-01 05:19:52.693271
NCT00061347|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|||2018-04-20|2003-05-23|2003-05-26|Estimate|||||||2018-04-20|2018-04-23|Actual|May 23, 2003||2003-05-23|April 19, 2018|2018-04-19|April 19, 2018|Actual|2018-04-19|May 31, 2004|Actual|2004-05-31||Interventional|||Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment|Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study|Completed||Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:19:52.825827|2018-06-01 05:19:52.825827
NCT00061334|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|||2017-06-30|2003-05-23|2003-05-26|Estimate|||||||2017-06-30|2017-07-02|Actual|May 7, 2003||2003-05-07|December 29, 2011|2011-12-29|December 29, 2011||2011-12-29|||||Observational|||Investigating the Cognitive Processes That Underlie Social Knowledge and Behavior|Social Knowledge Representation in the Human Prefrontal Cortex|Completed|||222|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:52.933671|2018-06-01 05:19:52.933671
NCT00061282|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-23|||2017-07-18|2003-05-23|2003-05-26|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2002||2002-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CAPTURE||Clotrimazole Enemas for Pouchitis in Children and Adults|Clotrimazole Enemas for Pouchitis in Children and Adults|Suspended||Phase 1/Phase 2|40|Anticipated|Boston Children’s Hospital||3||Funding Horizon|f||||t||||||||||2018-06-01 05:19:52.995398|2018-06-01 05:19:52.995398
NCT00041353|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-07-10|2003-05-23|2003-05-26|Estimate|||||||2013-07-10|2013-07-11|Estimate||||July 2013|2013-07-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Comparison of Biomarkers Based on Fine-Needle Aspiration in Women at Increased or Normal Risk of Breast Cancer|Breast Cancer Biomarkers Based on Fine Needle Aspirates|Withdrawn||N/A|0|Actual|Fox Chase Cancer Center||||Study was not activated at Fox Chase Cancer Center|f||||f||||||||||2018-06-01 05:19:53.143347|2018-06-01 05:19:53.143347
NCT00019175|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-05-23|2003-05-26|Estimate|||||||2015-04-28|2015-04-29|Estimate|August 1996||1996-08-31|April 2003|2003-04-30||||||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma|PHASE I TRIAL IN PATIENTS WITH METASTATIC MELANOMA OF IMMUNIZATION WITH A RECOMBINANT FOWLPOX VIRUS ENCODING THE GP100 MELANOMA ANTIGEN|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:53.207196|2018-06-01 05:19:53.207196
NCT00002786|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-05-06|2003-05-23|2003-05-26|Estimate|||||||2010-05-06|2010-05-10|Estimate|October 1995||1995-10-31|May 2010|2010-05-31|March 2006|Actual|2006-03-31|||||Interventional|||Biological Therapy in Treating Patients With Metastatic Melanoma|PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY USING GENETICALLY MODIFIED AND UNMODIFIED AUTOLOGOUS CD8+ TYROSINASE-SPECIFIC T CELLS FOR PATIENTS WITH METASTATIC MELANOMA|Completed||Phase 1/Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:19:53.347941|2018-06-01 05:19:53.347941
NCT00061269|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-22|||2010-01-12|2003-05-22|2003-05-23|Estimate|||||||2010-01-12|2010-01-13|Estimate|September 2003||2003-09-30|January 2010|2010-01-31||||||||Interventional|||Videoendoscopic Drainage of Infected Pancreatic Collections||Completed||Phase 2|40|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:53.433259|2018-06-01 05:19:53.433259
NCT00061256|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-22|||2009-08-06|2003-05-22|2003-05-23|Estimate|||||||2009-08-06|2009-08-07|Estimate||||August 2009|2009-08-31|September 2006|Actual|2006-09-30|||||Interventional|||The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Once-Weekly Alendronate in HIV-Infected Subjects With Decreased Bone Mineral Density Receiving Calcium and Vitamin D|Completed||Phase 2|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:19:53.518713|2018-06-01 05:19:53.518713
NCT00061243|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-22|||2008-09-25|2003-05-22|2003-05-23|Estimate|||||||2008-09-25|2008-09-26|Estimate|April 2004||2004-04-30|December 2005|2005-12-31|April 2010|Anticipated|2010-04-30|April 2005|Actual|2005-04-30||Interventional|||Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Multi-Gene, Polyvalent HIV-1 DNA Plasmid Prime/Env Protein Boost Vaccine Formulation, DP6-001 in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 05:19:53.629658|2018-06-01 05:19:53.629658
NCT00061230|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-22|||2005-06-23|2003-05-22|2003-05-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2003||2003-03-31|April 2003|2003-04-30|March 2006||2006-03-31|||||Interventional|||Relaxation Training to Decrease Pain and Improve Function in Adolescents With Cerebral Palsy|Efficacy of Relaxation Training|Unknown status|Recruiting|N/A|60||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:53.759432|2018-06-01 05:19:53.759432
NCT00061217|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-22|||2005-06-23|2003-05-22|2003-05-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2001||2001-04-30|October 2004|2004-10-31|March 2005||2005-03-31|||||Interventional|||Prosthetic Limbs After Leg Amputation: Alternative Method of Socket Design|Comparison of Rectified and Unrectified Amputee Sockets|Unknown status|Active, not recruiting|Phase 2|59||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:53.899174|2018-06-01 05:19:53.899174
NCT00061178|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2016-10-18|2003-05-22|2003-05-23|Estimate|||||||2016-10-18|2016-10-19|Estimate||||October 2016|2016-10-31||||||||Interventional|||Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma|Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy & Safety of rhuMAb VEGF in Previously Treated Metastatic Renal Cell Carcinoma|Withdrawn||Phase 3|0|Actual|Genentech, Inc.||||No patients were enrolled, study cancelled before start|||||||||||||||2018-06-01 05:19:54.13336|2018-06-01 05:19:54.13336
NCT00061165|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2010-01-12|2003-05-22|2003-05-23|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2003||2003-02-28|January 2010|2010-01-31||||||||Interventional|||Obesity Prevention in African American School Children||Completed||N/A|900|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:19:54.236701|2018-06-01 05:19:54.236701
NCT00019084|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-05-22|2003-05-23|Estimate|||||||2013-06-19|2013-06-20|Estimate|February 1996||1996-02-29|April 2007|2007-04-30|May 2003|Actual|2003-05-31|||||Interventional|||Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer|VACCINE THERAPY WITH TUMOR SPECIFIC MUTATED P53 OR RAS PEPTIDES ALONE OR IN COMBINATION WITH CELLULAR IMMUNOTHERAPY WITH PEPTIDE ACTIVATED LYMPHOCYTES (PAL CELLS) ALONG WITH SUBCUTANEOUS IL-2|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:54.295897|2018-06-01 05:19:54.295897
NCT00015821|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-10-07|2003-05-22|2003-05-23|Estimate|||||||2013-10-07|2013-10-08|Estimate|May 2000||2000-05-31|October 2013|2013-10-31||||December 2007|Actual|2007-12-31||Interventional|||Thalidomide in Treating Patients With Myelofibrosis|A Pilot Study of Thalidomide as an Inhibitor of Angiogenesis in the Treatment of Myelofibrosis With Myeloid Metaplasia (MMM)|Completed||Phase 2|43|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:54.429038|2018-06-01 05:19:54.429038
NCT00004868|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2008-11-22|2003-05-22|2003-05-23|Estimate|||||||2008-11-22|2008-11-25|Estimate|February 2000||2000-02-29|March 2003|2003-03-31||||||||Interventional|||SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy|A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:54.563209|2018-06-01 05:19:54.563209
NCT00003408|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-25|2003-05-22|2003-05-23|Estimate|||||||2013-03-25|2013-03-26|Estimate|April 1998||1998-04-30|April 2003|2003-04-30|March 2000|Actual|2000-03-31|||||Interventional|||Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer|Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:54.708828|2018-06-01 05:19:54.708828
NCT00061204|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2008-03-03|2003-05-21|2003-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Observational|||Magnetic Resonance Imaging of the Brain in Emotional Processing|Functional Neuroimaging of Social Cognitive and Emotional Processing: Technical and Cognitive Issues|Completed|||38||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:19:54.901815|2018-06-01 05:19:54.901815
NCT00061152|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2007-09-12|2003-05-21|2003-05-22|Estimate|||||||2007-09-12|2007-09-14|Estimate||||September 2007|2007-09-30||||||||Interventional|||Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy|An Open-Label Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy|Unknown status|Active, not recruiting|Phase 2|||NeurogesX|||||||||||||||||||2018-06-01 05:19:55.039748|2018-06-01 05:19:55.039748
NCT00061139|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2005-06-23|2003-05-21|2003-05-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2002||2002-09-30|April 2003|2003-04-30|September 2006||2006-09-30|||||Interventional|||Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy|Randomized Controlled Trial of Pediatric CI Therapy|Unknown status|Recruiting|Phase 2|52||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:19:55.222506|2018-06-01 05:19:55.222506
NCT00061126|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2005-06-23|2003-05-21|2003-05-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2003||2003-04-30|September 2004|2004-09-30||||||||Interventional|||ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body|A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis|Completed||Phase 2|50||Abgenix|||||||||||||||||||2018-06-01 05:19:55.378858|2018-06-01 05:19:55.378858
NCT00061113|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2017-01-11|2003-05-21|2003-05-22|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2001||2001-02-28|September 2008|2008-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Substance Dependent Teens - Impact of Treating Depression Study 1 - 1|Substance Dependent Teens - Impact of Treating Depression Study 1|Completed||Phase 4|126|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 05:19:55.588063|2018-06-01 05:19:55.588063
NCT00061100|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2018-05-10|2003-05-21|2003-05-22|Estimate|||||||2018-05-10|2018-05-16|Actual|October 1999||1999-10-31|May 2018|2018-05-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||HIV Counseling Intervention for Methadone-Maintained Patients - 2|HIV Counseling Intervention for Methadone-Maintained Patients|Completed||Phase 1|50|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 05:19:55.890381|2018-06-01 05:19:55.890381
NCT00061087|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2018-05-10|2003-05-21|2003-05-22|Estimate|||||||2018-05-10|2018-05-16|Actual|February 1998||1998-02-28|May 2018|2018-05-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1|Treatment of Adult ADHD in Methadone Patients|Completed||Phase 2/Phase 3|115|Actual|New York State Psychiatric Institute||3|||f||||t||||||||||2018-06-01 05:19:56.064846|2018-06-01 05:19:56.064846
NCT00061074|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2015-12-01|2003-05-21|2003-05-22|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 1993||1993-03-31|December 2015|2015-12-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||Tobacco Cessation in Postmenopausal Women (Part II) - 2|The Effects of ERT on Appetitive Behavior and Withdrawal in Short-term Smoking Cessation in Postmenopausal Females on Transdermal Nicotine Replacement|Completed||Phase 1|1|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 05:19:56.23064|2018-06-01 05:19:56.23064
NCT00061061|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-21|||2015-12-01|2003-05-21|2003-05-22|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 1997||1997-03-31|December 2015|2015-12-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Tobacco Cessation in Postmenopausal Women (Part I) - 1|The Effects of ERT on Appetitive Behavior and Withdrawal in Short-term Smoking Cessation Compared to Smoking ad Lib in Postmenopausal Female Smokers.|Completed||Phase 4|0||University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-06-01 05:19:56.318157|2018-06-01 05:19:56.318157
NCT00061035|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-20|||2008-08-26|2003-05-21|2003-05-22|Estimate|||||||2008-08-26|2008-08-28|Estimate|April 2003||2003-04-30|August 2008|2008-08-31||||||||Interventional|||Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma|A Phase 1, Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma|Completed||Phase 1|18|Anticipated|Cosmo Bioscience|||||||||||||||||||2018-06-01 05:19:56.408731|2018-06-01 05:19:56.408731
NCT00006243|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-01-24|2003-05-21|2003-05-22|Estimate|||||||2013-01-24|2013-01-25|Estimate|October 2000||2000-10-31|January 2013|2013-01-31||||May 2006|Actual|2006-05-31||Interventional|||Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma|Melanoma Vaccines: Differentiation Antigen Peptides (MART-1:27-35, Tyrosinase and Gp-100) as Immune Targets|Completed||N/A|30|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:19:56.51465|2018-06-01 05:19:56.51465
NCT00006242|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-01-31|2003-05-21|2003-05-22|Estimate|||||||2013-01-31|2013-02-01|Estimate|July 2000||2000-07-31|January 2013|2013-01-31||||September 2005|Actual|2005-09-30||Interventional|||BMS-214662 in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Farnesyltransferase Inhibitor BMS-214662 (NSC 710086) Escalating to a 24 Hour Continuous Intravenous Infusion in Patients With Solid Tumors|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:19:56.649373|2018-06-01 05:19:56.649373
NCT00006095|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2014-02-20|2003-05-21|2003-05-22|Estimate|||||||2014-02-20|2014-02-21|Estimate|July 2000||2000-07-31|February 2014|2014-02-28|September 2005|Actual|2005-09-30|January 2005|Actual|2005-01-31||Interventional|||Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy|A Trial of Irinotecan (NSC# 616348) Plus Vincristine in Children With Solid Tumors|Completed||Phase 1|20|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:19:56.849341|2018-06-01 05:19:56.849341
NCT00006086|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2010-09-08|2003-05-21|2003-05-22|Estimate|||||||2010-09-08|2010-09-09|Estimate|June 2000||2000-06-30|September 2002|2002-09-30||||February 2003|Actual|2003-02-28||Interventional|||BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer|Phase I Study of BMS-188797 in Combination With Carboplatin in Patients With Advanced Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:57.028446|2018-06-01 05:19:57.028446
NCT00006082|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-09-20|2003-05-21|2003-05-22|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2000||2000-05-31|September 2012|2012-09-30||||August 2002|Actual|2002-08-31||Interventional|||Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer|"Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a 5 Days On - 2 Days Off Oral Treatment in Advanced Small Cell Lung Cancer"|Completed||Phase 2|38|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:19:57.18776|2018-06-01 05:19:57.18776
NCT00061048|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-20|2011-05-17||2012-10-26|2003-05-20|2003-05-21|Estimate|2011-05-17|2011-06-08|Estimate||||2012-10-26|2012-10-31|Estimate|May 2003||2003-05-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2009|Actual|2009-07-31||Interventional|||Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma|Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia|Completed||Phase 2|29|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:19:57.31868|2018-06-01 05:19:57.31868
NCT00061022|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-20|||2010-11-10|2003-05-20|2003-05-21|Estimate|||||||2010-11-10|2010-11-15|Estimate|May 2003||2003-05-31|November 2010|2010-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke|SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke|Completed||Phase 3|3200||AstraZeneca|||||||||||||||||||2018-06-01 05:19:57.860829|2018-06-01 05:19:57.860829
NCT00006046|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2009-02-06|2003-05-20|2003-05-21|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 2000||2000-01-31|March 2003|2003-03-31||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer|Phase I Study of Humanized 3S193 (Anti-Lewis-Y) Antibody in Patients With Advanced Colorectal Carcinoma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:58.237197|2018-06-01 05:19:58.237197
NCT00005999|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-20|2003-05-20|2003-05-21|Estimate|||||||2013-06-20|2013-06-21|Estimate|April 2000||2000-04-30|March 2002|2002-03-31|May 2003|Actual|2003-05-31|||||Interventional|||Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer|A Phase II Study of Arsenic Trioxide (NSC #706363) in Patients With Advanced Cervical Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:19:58.299859|2018-06-01 05:19:58.299859
NCT00005977|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-08-19|2003-05-20|2003-05-21|Estimate|||||||2013-08-19|2013-08-21|Estimate|September 2000||2000-09-30|August 2013|2013-08-31|September 2006|Actual|2006-09-30|March 2004|Actual|2004-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia|A Pilot Study of Dose Intensification of Methotrexate in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Cell Non-Hodgkins Lymphoma and B-Cell All|Completed||Phase 3|83|Actual|Children's Oncology Group||5|||f||||t||||||||||2018-06-01 05:19:59.36415|2018-06-01 05:19:59.36415
NCT00005971|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-11-07|2003-05-20|2003-05-21|Estimate|||||||2010-11-07|2010-11-09|Estimate|July 2000||2000-07-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|||||Interventional|||Flavopiridol in Treating Patients With Metastatic Malignant Melanoma|A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Previously Untreated Metastatic Malignant Melanoma|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:20:01.061412|2018-06-01 05:20:01.061412
NCT00005956|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2014-07-07|2003-05-20|2003-05-21|Estimate|||||||2014-07-07|2014-07-09|Estimate|February 2000||2000-02-29|March 2013|2013-03-31|July 2002|Actual|2002-07-31|August 2001|Actual|2001-08-31||Interventional|||Biological Therapy in Treating Patients With Advanced Cancer|A Pilot Study of Active Immunotherapy With HER2/Neu Intracellular Domain (ICD) Protein-Pulsed, Autologous, Cultured Dendritic Cells in Patients With No Evidence of Disease After Standard Treatment for HER2/Neu Expressing Malignancies|Completed||N/A|3|Actual|Duke University|||||f||||f||||||||||2018-06-01 05:20:01.560638|2018-06-01 05:20:01.560638
NCT00005868|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-07-17|2003-05-20|2003-05-21|Estimate|||||||2012-07-17|2012-07-18|Estimate|March 2000||2000-03-31|July 2012|2012-07-31||||August 2002|Actual|2002-08-31||Interventional|||Docetaxel and Cisplatin in Treating Patients With Untreated Stage IIIA Non-small Cell Lung Cancer|Taxotere and Cisplatin as Induction Chemotherapy in Patients With Stage IIIa N2 Non Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|47|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:20:01.772424|2018-06-01 05:20:01.772424
NCT00061009|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-19|||2008-03-03|2003-05-19|2003-05-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Hypnosis in Autonomic Function|Relationship of Autonomic Function to Hypnotic Susceptibility|Completed|||93||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:01.963342|2018-06-01 05:20:01.963342
NCT00060996|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-19|||2013-03-05|2003-05-19|2003-05-20|Estimate|||||||2013-03-05|2013-03-07|Estimate|February 2003||2003-02-28|March 2013|2013-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures|A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures|Terminated||Phase 3|30||United Therapeutics|||||f||||||||||||||2018-06-01 05:20:02.035307|2018-06-01 05:20:02.035307
NCT00005813|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2011-10-26|2003-05-19|2003-05-20|Estimate|||||||2011-10-26|2011-10-27|Estimate|March 1997||1997-03-31|October 2011|2011-10-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme|A Phase I Trial of Intratumoral Bispecific Antibody and Activated Monocytes in Patients With Recurrent or Refractory Glioblastoma Multiforme|Completed||Phase 1|||Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 05:20:02.164513|2018-06-01 05:20:02.164513
NCT00060983|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-16|||2005-06-23|2003-05-16|2003-05-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1998||1998-05-31|May 2003|2003-05-31|April 2002||2002-04-30|||||Interventional|||Improving Gait in Patients With Spinal Cord Injuries|Effects of Sensory Motor Input on Gait in SCI (Spinal Cord Injured) Subjects|Completed||Phase 2|36||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:02.238253|2018-06-01 05:20:02.238253
NCT00060970|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-16|||2005-06-23|2003-05-16|2003-05-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|March 2003|2003-03-31|August 2000||2000-08-31|||||Observational|||Evaluating Muscle Function After Ankle Surgery|Restoration of Muscle Function During Rehabilitation|Completed|||30||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:02.305497|2018-06-01 05:20:02.305497
NCT00060957|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-16|||2016-09-23|2003-05-16|2003-05-19|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 1997||1997-07-31|May 2011|2011-05-31||||June 2002|Actual|2002-06-30||Interventional|||Botulinum Toxin (BOTOX) for Cerebral Palsy|Botulinum Toxin for Spasticity in Cerebral Palsy|Completed||Phase 2|40||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:02.416773|2018-06-01 05:20:02.416773
NCT00060944|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-16|2014-01-14|2011-08-12|2014-08-28|2003-05-16|2003-05-19|Estimate|2014-08-28|2014-09-08|Estimate|2011-08-12|2011-08-15|Estimate|2014-08-28|2014-09-08|Estimate|May 2003||2003-05-31|August 2014|2014-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer|A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide|Completed||Phase 2|271|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-06-01 05:20:02.522014|2018-06-01 05:20:02.522014
NCT00005861|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-07|2003-05-16|2003-05-19|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 2000||2000-05-31|August 2002|2002-08-31||||August 2005|Actual|2005-08-31||Interventional|||Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer|Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:20:03.69629|2018-06-01 05:20:03.69629
NCT00005588|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-12-18|2003-05-16|2003-05-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1999||1999-01-31|June 2000|2000-06-30|December 2004|Actual|2004-12-31|||||Interventional|||Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer|Standardization of Breast Radiotherapy: Trial A - A Randomized Comparison of Fractionation Regimens After Local Excision or Mastectomy in Women With Early Stage Breast Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:03.886938|2018-06-01 05:20:03.886938
NCT00005587|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-12-18|2003-05-16|2003-05-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1999||1999-01-31|July 2001|2001-07-31|June 2004|Actual|2004-06-30|||||Interventional|||Radiation Therapy After Surgery in Treating Women With Early Stage Breast Cancer|Standardization of Breast Radiotherapy: Trial B - A Randomized Comparison of Fractionation Regimens After Local Excision or Mastectomy in Women With Early Stage Breast Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:04.199041|2018-06-01 05:20:04.199041
NCT00003203|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2003-05-16|2003-05-19|Estimate|||||||2013-08-22|2013-08-23|Estimate|March 1998||1998-03-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|October 2007|Actual|2007-10-31||Interventional|||Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors|An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed by Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors|Completed||Phase 2|168|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:20:04.564198|2018-06-01 05:20:04.564198
NCT00060931|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-15|||2015-04-13|2003-05-15|2003-05-16|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2001||2001-06-30|April 2015|2015-04-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension|A Randomized, Double-Blind, Multicenter Study Comparing the Effects of Carvedilol and Metoprolol on Glycemic Control in Hypertensive Patients With Type II Diabetes Mellitus.|Completed||Phase 4|501|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:20:04.998924|2018-06-01 05:20:04.998924
NCT00060918|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-15|||2015-04-14|2003-05-15|2003-05-16|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2001||2001-06-30|June 2012|2012-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension|A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients With Type II Diabetes Mellitus.|Completed||Phase 4|1210||GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:20:05.300862|2018-06-01 05:20:05.300862
NCT00060905|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-15|||2006-08-02|2003-05-15|2003-05-16|Estimate|||||||2006-08-02|2006-08-04|Estimate|January 2003||2003-01-31|August 2006|2006-08-31||||||||Interventional|||An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder|An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder|Completed||Phase 3|370||Abbott|||||||||||||||||||2018-06-01 05:20:05.447476|2018-06-01 05:20:05.447476
NCT00060892|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-15|||2008-01-09|2003-05-15|2003-05-16|Estimate|||||||2008-01-09|2008-01-11|Estimate|April 2003||2003-04-30|January 2008|2008-01-31|January 2007|Actual|2007-01-31|May 2006|Actual|2006-05-31||Interventional|||Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia|A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia|Completed||Phase 2|104|Actual|AnGes USA, Inc.||4|||f||||t||||||||||2018-06-01 05:20:05.573305|2018-06-01 05:20:05.573305
NCT00005086|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-09-04|2003-05-15|2003-05-16|Estimate|||||||2013-09-04|2013-09-05|Estimate|August 1999||1999-08-31|September 2013|2013-09-30|April 2005|Actual|2005-04-30|August 2002|Actual|2002-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer|"A Phase II Trial of Sequential Doublets Chemotherapy in Patients With Locally Advanced or Metastatic Bladder Cancer"|Completed||Phase 2|6|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:20:05.885161|2018-06-01 05:20:05.885161
NCT00005078|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2015-06-03|2003-05-15|2003-05-16|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2000||2000-03-31|June 2015|2015-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors|Phase I Dose Escalation Study of Tirapazamine (NSC 130181) in Combination With Carboplatin and Paclitaxel in Advanced Malignant Solid Tumors|Completed||Phase 1|44|Actual|City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:20:05.98016|2018-06-01 05:20:05.98016
NCT00060866|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-14|||2008-03-03|2003-05-14|2003-05-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance|Propranolol for Syncope With Sympathoadrenal Imbalance|Completed||Phase 4|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:06.108759|2018-06-01 05:20:06.108759
NCT00060840|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-14|2010-08-25||2016-07-22|2003-05-14|2003-05-15|Estimate|2010-08-25|2010-09-17|Estimate||||2016-07-22|2016-08-22|Estimate|July 2003||2003-07-31|July 2016|2016-07-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation|The Effects of Nitric Oxide for Inhalation During Left Ventricular Assist Device (LVAD) Implantation|Completed||Phase 2|150|Actual|Mallinckrodt||2|||f||||t||||||||||2018-06-01 05:20:06.215435|2018-06-01 05:20:06.215435
NCT00060827|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-14|||2014-10-28|2003-05-14|2003-05-15|Estimate|||||||2014-10-28|2014-10-30|Estimate||||March 2004|2004-03-31||||||||Observational|||Measuring Head Impacts in Sports|Head Impact Recording Technology for Field Applications|Withdrawn|||0|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 05:20:06.659601|2018-06-01 05:20:06.659601
NCT00060814|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-14|||2017-01-11|2003-05-14|2003-05-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2002||2002-06-30|October 2016|2016-10-31|December 2002|Actual|2002-12-31|September 2002|Actual|2002-09-30||Interventional|||Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients|Pilot Study Examining the Effects of Combined Pharmacotherapy (Zyban/NRT)/Behavioral Treatment on Smoking Cessation Among MMT Patients.|Completed||Phase 2|28|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||f||||||||||2018-06-01 05:20:06.726736|2018-06-01 05:20:06.726736
NCT00060853|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-14|||2008-03-03|2003-05-13|2003-05-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Observational|||Magnetic Resonance Imaging of the Brain in Social and Emotional Reasoning|Reasoning About Social and Economic Knowledge: Identifying the Role of the Human Prefrontal Cortex Using Functional Neuroimaging|Completed|||330||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:06.832658|2018-06-01 05:20:06.832658
NCT00060801|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-13|||2013-10-30|2003-05-13|2003-05-14|Estimate|||||||2013-10-30|2013-10-31|Estimate|May 2003||2003-05-31|October 2013|2013-10-31||||July 2004|Actual|2004-07-31||Interventional|||Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult (75 mg, 150 mg) and Pediatric (75 mg) Cystic Fibrosis Patients|Terminated||Phase 2|420||Boehringer Ingelheim|||||||||||||||||||2018-06-01 05:20:06.935967|2018-06-01 05:20:06.935967
NCT00060788|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-13|||2006-03-06|2003-05-13|2003-05-14|Estimate|||||||2006-03-06|2006-03-07|Estimate|September 2001||2001-09-30|March 2006|2006-03-31|December 2005||2005-12-31|||||Observational|||Antisocial Behavior: Passing From Parent to Child to Grandchild|Intergenerational Transmission of Antisocial Behavior|Unknown status|Recruiting||663||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:07.052764|2018-06-01 05:20:07.052764
NCT00004931|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-01-10|2003-05-13|2003-05-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|February 2000||2000-02-29|January 2013|2013-01-31||||September 2005|Actual|2005-09-30||Interventional|||Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer|A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon|Completed||Phase 3|2472|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:20:07.132217|2018-06-01 05:20:07.132217
NCT00004928|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-06-18|2003-05-13|2003-05-14|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 1999||1999-10-31|June 2013|2013-06-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer|A Phase I Study of 1,25 Dihydroxy-Vitamin D3 (Calcitriol) in Patients With Prostate Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:07.25126|2018-06-01 05:20:07.25126
NCT00004925|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-06-18|2003-05-13|2003-05-14|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 1999||1999-08-31|June 2013|2013-06-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer|Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:07.352854|2018-06-01 05:20:07.352854
NCT00004916|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-07-01|2012-05-31|2003-05-13|2003-05-14|Estimate||||2011-07-01|2011-07-14|Estimate|2012-05-31|2012-06-06|Estimate|February 1999||1999-02-28|May 2012|2012-05-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|Phase I/II Study of Mesna, Ifosfamide, Teniposide and Weekly Taxol (MITTen) in Relapsed Lymphoma|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:20:07.427494|2018-06-01 05:20:07.427494
NCT00004911|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-18|2012-05-31|2003-05-13|2003-05-14|Estimate||||2011-02-18|2011-02-25|Estimate|2012-05-31|2012-06-06|Estimate|January 2000||2000-01-31|May 2012|2012-05-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction|A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:20:07.507238|2018-06-01 05:20:07.507238
NCT00060775|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-12|||2018-05-23|2003-05-12|2003-05-13|Estimate|||||||2018-05-23|2018-05-24|Actual|May 12, 2003||2003-05-12|March 23, 2018|2018-03-23||||||||Observational|||The Psychobiology of Childhood Temperament|The Psychobiology of Temperament: An fMRI Study|Recruiting|||1010|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:07.585584|2018-06-01 05:20:07.585584
NCT00060762|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-12|||2014-05-14|2003-05-12|2003-05-13|Estimate|||||||2014-05-14|2014-05-15|Estimate|April 2002||2002-04-30|May 2014|2014-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Effectiveness of Binge Eating Disorder Treatments|Effectiveness of Psychological Treatments for BED|Completed||Phase 4|205|Actual|Stanford University||3|||f||||t||||||||||2018-06-01 05:20:07.654259|2018-06-01 05:20:07.654259
NCT00060710|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-09|||2011-10-14|2003-05-12|2003-05-13|Estimate|||||||2011-10-14|2011-10-17|Estimate|January 2003||2003-01-31|October 2011|2011-10-31|December 2004|Actual|2004-12-31|||||Interventional|||CP-461 in the Treatment of Patients With Advanced Melanoma|Phase II Study of CP-461 in the Treatment of Patients With Advanced Melanoma|Terminated||Phase 2|35||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:20:07.779704|2018-06-01 05:20:07.779704
NCT00060749|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-09|||2017-06-30|2003-05-09|2003-05-12|Estimate|||||||2017-06-30|2017-07-02|Actual|May 5, 2003||2003-05-05|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Interventional|||Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy|Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy|Completed||Phase 1|22||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:07.862981|2018-06-01 05:20:07.862981
NCT00060736|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-09|||2018-05-19|2003-05-09|2003-05-12|Estimate|||||||2018-05-19|2018-05-22|Actual|May 5, 2003||2003-05-05|April 27, 2016|2016-04-27|April 27, 2016||2016-04-27|||||Observational|||The Effects of Estrogen Withdrawal on Mood Symptoms in Women|The Effects of Acute Withdrawal of Estradiol on Mood Symptoms in Women With Perimenopausal Depression|Completed|||60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:07.924915|2018-06-01 05:20:07.924915
NCT00060697|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-09|||2005-06-23|2003-05-09|2003-05-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2000||2000-12-31|May 2003|2003-05-31|May 2005||2005-05-31|||||Interventional|||A Mother's Role in Delaying Onset of Sexual Activity in Her Children|Family Intervention to Promote Health in Children|Unknown status|Recruiting|Phase 2|1300||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:08.039208|2018-06-01 05:20:08.039208
NCT00060684|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-09|||2015-01-15|2003-05-09|2003-05-12|Estimate|||||||2015-01-15|2015-01-19|Estimate|December 2001||2001-12-31|September 2008|2008-09-30|May 2007|Actual|2007-05-31|January 2005|Actual|2005-01-31||Interventional|||Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma|A Phase I Trial of BBR 2778 in Combination With Fludarabine, Dexamethasone and Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma|Completed||Phase 1|30||CTI BioPharma|||||||||||||||||||2018-06-01 05:20:08.288755|2018-06-01 05:20:08.288755
NCT00060671|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-09|||2015-01-15|2003-05-09|2003-05-12|Estimate|||||||2015-01-15|2015-01-19|Estimate|January 2005||2005-01-31|May 2013|2013-05-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma|An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)|Terminated||Phase 3|800||CTI BioPharma|||||f||||||||||||||2018-06-01 05:20:08.503285|2018-06-01 05:20:08.503285
NCT00060645|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-08|||2015-08-26|2003-05-09|2003-05-12|Estimate|||||||2015-08-26|2015-08-27|Estimate|May 2003||2003-05-31|August 2015|2015-08-31|February 2009|Actual|2009-02-28|May 2006|Actual|2006-05-31||Interventional|||Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily x 5 Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies|Completed||Phase 1|33|Actual|Merck Sharp & Dohme Corp.||1|||f||||||||||||||2018-06-01 05:20:08.716312|2018-06-01 05:20:08.716312
NCT00060632|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-08|||2015-08-26|2003-05-09|2003-05-12|Estimate|||||||2015-08-26|2015-08-27|Estimate|April 2003||2003-04-30|August 2015|2015-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)|A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients With Refractory or Advanced Malignancies|Completed||Phase 1|46|Actual|Merck Sharp & Dohme Corp.||6|||f||||||||||||||2018-06-01 05:20:08.872196|2018-06-01 05:20:08.872196
NCT00060619|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-08|||2005-06-23|2003-05-09|2003-05-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1999||1999-05-31|March 2003|2003-03-31|June 2004||2004-06-30|||||Interventional|||Migraine and Recurrent Abdominal Pain in Children|Treatment of Recurrent Pain Syndromes in Children|Unknown status|Recruiting|N/A|180|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:09.033139|2018-06-01 05:20:09.033139
NCT00060658|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-08|||2008-03-03|2003-05-08|2003-05-09|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||Magnetic Resonance Imaging of Calculus Problem Solving|Functional Neuroimaging of Calculus Problem Solving|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:09.161041|2018-06-01 05:20:09.161041
NCT00060606|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-08|||2017-06-20|2003-05-08|2003-05-09|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2003||2003-02-28|June 2017|2017-06-30|June 2017|Actual|2017-06-30|February 2014|Actual|2014-02-28||Interventional|MOMS||Management of Myelomeningocele Study (MOMS)|Myelomeningocele Repair Randomized Trial|Completed||N/A|183|Actual|The George Washington University Biostatistics Center||2|||f||||t|f|f||||||Yes|The dataset will be shared per NIH policy after the completion and publication of the main analyses.|2018-06-01 05:20:09.212745|2018-06-01 05:20:09.212745
NCT00060567|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|||2013-06-05|2003-05-08|2003-05-09|Estimate|||||||2013-06-05|2013-06-06|Estimate|March 2003||2003-03-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Dose-Finding Study of E7070 in Combination With Irinotecan|Phase I Dose-Finding Study of E7070 in Combination With Irinotecan|Completed||Phase 1|88|Actual|Eisai Inc.||3|||f||||||||||||||2018-06-01 05:20:09.344569|2018-06-01 05:20:09.344569
NCT00004910|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-18|2012-05-31|2003-05-08|2003-05-09|Estimate||||2011-02-18|2011-02-25|Estimate|2012-05-31|2012-06-06|Estimate|January 2000||2000-01-31|May 2012|2012-05-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction|A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:20:09.428865|2018-06-01 05:20:09.428865
NCT00004895|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-16|2012-05-31|2003-05-08|2003-05-09|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-31|2012-06-06|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery|Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:20:09.544276|2018-06-01 05:20:09.544276
NCT00060320|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2016-07-12|2003-05-06|2003-05-07|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 2003||2003-10-31|July 2016|2016-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer|A Phase III Double-Blind, Randomized, Placebo-Controlled Crossover Trial Of Black Cohosh In The Management Of Hot Flashes|Completed||Phase 3|132|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:20:14.862043|2018-06-01 05:20:14.862043
NCT00004255|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-07-09|2003-05-08|2003-05-09|Estimate|||||||2013-07-09|2013-07-10|Estimate|March 2000||2000-03-31|February 2002|2002-02-28|May 2003|Actual|2003-05-31|||||Interventional|||Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation|A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia|Completed||Phase 2/Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:09.622337|2018-06-01 05:20:09.622337
NCT00004232|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2012-05-31|2003-05-08|2003-05-09|Estimate|||||||2012-05-31|2012-06-01|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies|Completed||Phase 1|||Northwestern University|||||f||||t||||||||||2018-06-01 05:20:09.776687|2018-06-01 05:20:09.776687
NCT00004180|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2017-02-09|2003-05-08|2003-05-09|Estimate|||||||2017-02-09|2017-02-13|Actual|October 1999||1999-10-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|March 2006|Actual|2006-03-31||Interventional|||Rosiglitazone in Treating Patients With Liposarcoma|Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma|Completed||Phase 2|32|Actual|Dana-Farber Cancer Institute||4|||f||||f||||||||No||2018-06-01 05:20:09.913959|2018-06-01 05:20:09.913959
NCT00060593|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|||2008-03-03|2003-05-07|2003-05-08|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|May 2005|2005-05-31|May 2005||2005-05-31|||||Observational|||MRI Study of Self-Perception of Postural Stability|Self-Perception of Postural Stability: Event-Related fMRI Study|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:10.000077|2018-06-01 05:20:10.000077
NCT00060580|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|||2008-03-03|2003-05-07|2003-05-08|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2003||2003-05-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Raman Scattering Spectroscopy to Measure Macular Pigment|Measurement of Macular Pigment With Resonant Raman Backscattering Spectroscopy|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:10.075013|2018-06-01 05:20:10.075013
NCT00060554|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|||2009-11-02|2003-05-07|2003-05-08|Estimate|||||||2009-11-02|2009-11-03|Estimate|April 2003||2003-04-30|November 2009|2009-11-30||||||||Interventional|||A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)||Withdrawn||Phase 2|300||Schering-Plough||||"Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have~   data."|||||||||||||||2018-06-01 05:20:10.140079|2018-06-01 05:20:10.140079
NCT00060515|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|||2005-08-04|2003-05-07|2003-05-08|Estimate|||||||2005-08-04|2005-08-05|Estimate||||August 2005|2005-08-31||||||||Interventional|||RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease|An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases|Terminated||Phase 1|12||Repligen Corporation|||||||||||||||||||2018-06-01 05:20:10.227733|2018-06-01 05:20:10.227733
NCT00060502|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|||2011-05-16|2003-05-07|2003-05-08|Estimate|||||||2011-05-16|2011-05-17|Estimate|April 2003||2003-04-30|April 2010|2010-04-30|February 2006|Actual|2006-02-28|||||Interventional|||A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia|A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer.|Completed||Phase 2|73|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:20:10.265633|2018-06-01 05:20:10.265633
NCT00060489|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2011-01-25|2003-05-07|2003-05-08|Estimate|||||||2011-01-25|2011-01-26|Estimate|September 2002||2002-09-30|January 2011|2011-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression||Completed||Phase 3|||AstraZeneca|||||||||||||||||||2018-06-01 05:20:10.325733|2018-06-01 05:20:10.325733
NCT00004094|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2014-01-03|2003-05-07|2003-05-08|Estimate|||||||2014-01-03|2014-01-06|Estimate|August 1999||1999-08-31|December 2002|2002-12-31||||||||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx|A Phase II Study of Induction Chemotherapy Followed by Concomitant Paclitaxel (1 Hour Infusion), Fluorouracil, Hydroxyurea and Hyperfractionated Radiotherapy for Advanced Oral, Pharynx and Larynx Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:10.439066|2018-06-01 05:20:10.439066
NCT00004068|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-10-03|2003-05-07|2003-05-08|Estimate|||||||2011-10-03|2011-10-04|Estimate|March 1999||1999-03-31|October 2011|2011-10-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor|Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide|Completed||Phase 2|53|Actual|St. Jude Children's Research Hospital|||||f||||||||||||||2018-06-01 05:20:10.572797|2018-06-01 05:20:10.572797
NCT00004059|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-20|2003-05-07|2003-05-08|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 1999||1999-07-31|June 2013|2013-06-30|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors|A Phase I Study of the Cyclin-Dependent Kinase (CDK)/Protein Kinase C (PKC) Inhibitor UCN-01 (NSC 638850) in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:10.687957|2018-06-01 05:20:10.687957
NCT00004052|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-24|2003-05-07|2003-05-08|Estimate|||||||2013-06-24|2013-06-25|Estimate|March 1999||1999-03-31|June 2013|2013-06-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia|Phase II, Multicenter Vaccination of Patients With Chronic Myelogenous Leukemia With a Multivalent Tumor Specific Breakpoint Peptide Vaccine|Completed||Phase 2|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:10.779781|2018-06-01 05:20:10.779781
NCT00004008|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2003-05-07|2003-05-08|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 1999||1999-07-31|November 1999|1999-11-30|May 2003|Actual|2003-05-31|||||Interventional|||Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer|A Phase II Trial of Bryostatin 1 in Ovarian Cancer Administered by Weekly 24 Hour Intravenous Infusion|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:10.872532|2018-06-01 05:20:10.872532
NCT00060541|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|||2018-05-30|2003-05-06|2003-05-07|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 6, 2003||2003-05-06|November 13, 2017|2017-11-13||||||||Observational|||Evaluation and Treatment of Neurosurgical Disorders|Evaluation and Treatment of Neurosurgical Disorders|Recruiting|||2500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:10.969683|2018-06-01 05:20:10.969683
NCT00060528|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-07|2011-11-30||2017-09-25|2003-05-06|2003-05-07|Estimate|2012-01-18|2012-02-23|Estimate||||2017-09-25|2017-10-26|Actual|May 22, 2003|Actual|2003-05-22|September 2017|2017-09-30|June 8, 2009|Actual|2009-06-08|March 7, 2006|Actual|2006-03-07||Interventional|||Sequential Vaccinations in Prostate Cancer Patients|A Phase I/II Pilot Study of Sequential Vaccinations With rFowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM) Alone, or in Combination With rVaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), and the Role of GM-CSF, in Men With Prostate Cancer|Completed||Phase 1/Phase 2|32|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||f|t|f|||f|||No||2018-06-01 05:20:11.070175|2018-06-01 05:20:11.070175
NCT00060476|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2017-05-05|2003-05-06|2003-05-07|Estimate|||||||2017-05-05|2017-05-09|Actual|January 8, 2003|Actual|2003-01-08|May 2017|2017-05-31|December 8, 2004|Actual|2004-12-08|December 8, 2004|Actual|2004-12-08||Interventional|||Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)|Completed||Phase 3|15000|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:20:11.967928|2018-06-01 05:20:11.967928
NCT00060463|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2005-06-23|2003-05-06|2003-05-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2002||2002-10-31|October 2004|2004-10-31|October 2005||2005-10-31|||||Interventional|||Increased Access to Emergency Contraceptive Pills|Increased Access to Emergency Contraceptive Pills|Unknown status|Active, not recruiting|N/A|1490||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:12.083266|2018-06-01 05:20:12.083266
NCT00060450|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2016-09-08|2003-05-06|2003-05-07|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2001||2001-08-31|September 2016|2016-09-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation|Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation|Terminated||Phase 3|84|Actual|Mallinckrodt||2||Slow Enrollment|f||||f||||||||||2018-06-01 05:20:12.181602|2018-06-01 05:20:12.181602
NCT00060437|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-06-18|2003-05-06|2003-05-07|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 2003||2003-10-31|April 2004|2004-04-30|April 2004|Actual|2004-04-30|||||Interventional|||Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer|A Phase II Trial Of Oral Perifosine In Patients With Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:12.294503|2018-06-01 05:20:12.294503
NCT00060424|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|2017-04-14||2017-12-05|2003-05-06|2003-05-07|Estimate|2017-12-05|2017-12-08|Actual||||2017-12-05|2017-12-08|Actual|March 2003||2003-03-31|December 2017|2017-12-31|September 22, 2010|Actual|2010-09-22|September 2010|Actual|2010-09-30||Interventional|||Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial|Completed||Phase 2|21|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:20:12.477398|2018-06-01 05:20:12.477398
NCT00060411|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-09-27|2003-05-06|2003-05-07|Estimate|||||||2013-09-27|2013-09-30|Estimate|June 2003||2003-06-30|September 2013|2013-09-30||||July 2007|Actual|2007-07-31||Interventional|||A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer|A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:12.947433|2018-06-01 05:20:12.947433
NCT00060398|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2009-05-09|2003-05-06|2003-05-07|Estimate|||||||2009-05-09|2009-05-12|Estimate|June 2004||2004-06-30|July 2006|2006-07-31||||June 2006|Actual|2006-06-30||Interventional|||Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer|Study Of Epoetin Alfa Vs Epoetin Alfa With Dexamethasone In Hormone Refractory Prostate Cancer Patients: Impact On Fatigue, Anemia, Functional Status And Quality Of Life|Completed||Phase 3|282|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:13.162753|2018-06-01 05:20:13.162753
NCT00060385|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2012-09-20|2003-05-06|2003-05-07|Estimate|||||||2012-09-20|2012-09-24|Estimate|March 2003||2003-03-31|September 2012|2012-09-30||||August 2004|Actual|2004-08-31||Interventional|||Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma|Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life|Terminated||Phase 2/Phase 3|3|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:20:13.484502|2018-06-01 05:20:13.484502
NCT00060372|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-03-26|2003-05-06|2003-05-07|Estimate|||||||2013-03-26|2013-03-27|Estimate|April 2003||2003-04-30|March 2013|2013-03-31||||April 2008|Actual|2008-04-30||Interventional|||Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer|CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 1|21|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:13.592231|2018-06-01 05:20:13.592231
NCT00060359|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2015-05-07|2003-05-06|2003-05-07|Estimate|||||||2015-05-07|2015-05-08|Estimate|April 2003||2003-04-30|May 2015|2015-05-31||||January 2009|Actual|2009-01-31||Interventional|||Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer|A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of CT-2103 and Carboplatin (NSC #214240) in Patients With Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma|Completed||Phase 1|32|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:20:13.746345|2018-06-01 05:20:13.746345
NCT00060346|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|2013-01-10||2013-02-11|2003-05-06|2003-05-07|Estimate|2013-01-10|2013-02-12|Estimate||||2013-02-11|2013-02-13|Estimate|June 2004||2004-06-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia|Phase II Pilot Study Of Rituximab Plus CHOP In Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia|Terminated||Phase 2|16|Actual|Eastern Cooperative Oncology Group||1||slow accrual|f||||f||||||||||2018-06-01 05:20:13.968515|2018-06-01 05:20:13.968515
NCT00060333|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|2017-01-30||2017-01-30|2003-05-06|2003-05-07|Estimate|2017-01-30|2017-03-17|Actual||||2017-01-30|2017-03-17|Actual|July 2003||2003-07-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|June 2011|Actual|2011-06-30||Interventional|||Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma|Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma|Completed||Phase 2|20|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:20:14.494482|2018-06-01 05:20:14.494482
NCT00060307|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-02-27|2003-05-06|2003-05-07|Estimate|||||||2013-02-27|2013-02-28|Estimate|May 2003||2003-05-31|February 2013|2013-02-28||||May 2007|Actual|2007-05-31||Interventional|||Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer|A Phase II Study of OSI-774 (NSC-718781) in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:14.969453|2018-06-01 05:20:14.969453
NCT00060294|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-01-07|2003-05-06|2003-05-07|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2003||2003-04-30|January 2013|2013-01-31||||June 2004|Actual|2004-06-30||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia|Phase I Study of Zevalin (90Y-Ibritumomab Tiuxetan) in Waldenstrom's Macroglobulinemia (Lymphoplasmacytic Lymphoma)|Terminated||Phase 1|||Jonsson Comprehensive Cancer Center||||no accrual|f||||t||||||||||2018-06-01 05:20:15.073921|2018-06-01 05:20:15.073921
NCT00060268|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2011-03-07|2003-05-06|2003-05-07|Estimate|||||||2011-03-07|2011-03-09|Estimate|January 1997||1997-01-31|March 2011|2011-03-31|June 2004|Actual|2004-06-30|September 2003|Actual|2003-09-30||Interventional|||Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors|A Phase I/II Trial for Treatment of Obstructive Esophageal Tumors by Photodynamic Therapy (PDT) Using 2-(1-Hydroxyethyl)-2-Devinylpyropheophorbide-a (HPPH)|Completed||Phase 1/Phase 2|11|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:20:16.276138|2018-06-01 05:20:16.276138
NCT00060255|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-05-07|2003-05-06|2003-05-07|Estimate|||||||2013-05-07|2013-05-09|Estimate|December 1991||1991-12-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|August 2006|Actual|2006-08-31||Interventional|||High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors|Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors|Completed||Phase 2|451|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:20:16.421088|2018-06-01 05:20:16.421088
NCT00060242|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2010-06-10|2003-05-06|2003-05-07|Estimate|||||||2010-06-10|2010-06-11|Estimate|February 2003||2003-02-28|June 2010|2010-06-30|January 2008|Actual|2008-01-31|February 2007|Actual|2007-02-28||Interventional|||Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer|Phase II Trial Of Combretastatin A-4 Phosphate (CA4P) In Advanced Anaplastic Carcinoma Of The Thyroid|Completed||Phase 2|26|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:20:16.596783|2018-06-01 05:20:16.596783
NCT00060203|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2014-01-14|2003-05-06|2003-05-07|Estimate|||||||2014-01-14|2014-01-16|Estimate|December 2002||2002-12-31|January 2014|2014-01-31|April 2004|Actual|2004-04-30|March 2003|Actual|2003-03-31||Interventional|||Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma|A Phase I/II Study of the Safety and Efficacy of Brostallicin (PNU-166196A) in Adult Patients With Multiple Myeloma That Has Progressed on Prior Chemotherapy|Completed||Phase 1/Phase 2|3|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:20:16.713168|2018-06-01 05:20:16.713168
NCT00060151|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-09-19|2003-05-06|2003-05-07|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 2002||2002-12-31|April 2006|2006-04-30|June 2009|Actual|2009-06-30|||||Interventional|||GW786034 in Treating Patients With Advanced Solid Tumors|A Phase I, Open Label, Multiple Dose, Dose Escalation Study OF GW786034 In Patients With Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:16.818924|2018-06-01 05:20:16.818924
NCT00060138|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-05-13|2003-05-06|2003-05-07|Estimate|||||||2013-05-13|2013-05-15|Estimate|November 2002||2002-11-30|May 2013|2013-05-31||||September 2004|Actual|2004-09-30||Interventional|||Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases|A Phase I-II, 24-Week, Multi-Center, Double-Blind, Randomized, Dose-Ranging Study To Evaluate The Safety And Efficacy Of A Humanized Monoclonal Antibody To PTHrP Versus Zoledronic Acid In Patients With Breast Cancer Metastatic To Bone|Completed||Phase 1/Phase 2|||Chugai Pharmaceutical|||||f||||||||||||||2018-06-01 05:20:16.89231|2018-06-01 05:20:16.89231
NCT00060125|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-06-04|2003-05-06|2003-05-07|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 2003||2003-05-31|June 2013|2013-06-30||||June 2006|Actual|2006-06-30||Interventional|||Tipifarnib in Treating Patients With Metastatic Malignant Melanoma|PHASE II TRIAL OF R115777 IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:16.99439|2018-06-01 05:20:16.99439
NCT00060112|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-01-24|2003-05-06|2003-05-07|Estimate|||||||2013-01-24|2013-01-25|Estimate|March 2003||2003-03-31|January 2013|2013-01-31||||December 2009|Actual|2009-12-31||Interventional|||Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma|A Phase I Study of Oblimersen (Genasense™, G3139) in Combination With Gemcitabine in Advanced Malignancies|Terminated||Phase 1|15|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:20:17.207326|2018-06-01 05:20:17.207326
NCT00060099|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-11-05|2003-05-06|2003-05-07|Estimate|||||||2013-11-05|2013-11-06|Estimate|May 2003||2003-05-31|March 2005|2005-03-31||||||||Interventional|||SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia|Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:17.364674|2018-06-01 05:20:17.364674
NCT00060086|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2017-10-11|2003-05-06|2003-05-07|Estimate|||||||2017-10-11|2017-10-13|Actual|March 2003|Actual|2003-03-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer|Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate|Active, not recruiting||N/A|40|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-06-01 05:20:17.456835|2018-06-01 05:20:17.456835
NCT00060021|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2015-04-29|2003-05-06|2003-05-07|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2003||2003-03-31|April 2004|2004-04-30||||||||Interventional|||Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation|A Randomized, Placebo-Controlled, Blinded Study Of Acupuncture Therapy In Mucositis-Related Pain In Patients Undergoing Hematopoietic Stem Cell Transplantation|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:17.584842|2018-06-01 05:20:17.584842
NCT00060008|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|2014-04-01||2014-04-03|2003-05-06|2003-05-07|Estimate|2014-04-03|2014-04-04|Estimate||||2014-04-03|2014-04-04|Estimate|April 2002||2002-04-30|April 2014|2014-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma|Novel Imaging Modalities For Plexiform Neurofibromas|Terminated||N/A|18|Actual|Children's Hospital of Philadelphia|The sample size was modest. It is possible that with increased sample size, if the correlation estimate holds, it will become statistically significant.|1||Study was closed early due to poor accrual.|f||||f||||||||||2018-06-01 05:20:17.715921|2018-06-01 05:20:17.715921
NCT00059995|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-05-29|2003-05-06|2003-05-07|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2003||2003-01-31|November 2009|2009-11-30|November 2009|Actual|2009-11-30|October 2007|Actual|2007-10-31||Interventional|||MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma|Phase I/II Open Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Patients With Refractory/Relapsed CD30 Lymphoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:17.954559|2018-06-01 05:20:17.954559
NCT00059982|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-06-21|2003-05-06|2003-05-07|Estimate|||||||2013-06-21|2013-06-24|Estimate|July 2003||2003-07-31|August 2004|2004-08-31|August 2005|Actual|2005-08-31|||||Interventional|||Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer|Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:18.088976|2018-06-01 05:20:18.088976
NCT00059943|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-01-15|2003-05-06|2003-05-07|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2002||2002-09-30|January 2013|2013-01-31||||September 2005|Actual|2005-09-30||Interventional|||Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer|Pharmacokinetics of Weekly Docetaxel in Patients Age 65 and Older With Metastatic Breast or Lung Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:18.229388|2018-06-01 05:20:18.229388
NCT00059930|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2017-07-05|2003-05-06|2003-05-07|Estimate|||||||2017-07-05|2017-07-06|Actual|January 2003|Actual|2003-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer|A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin As Adjuvant Treatment After Resection Of Hepatic Metastases From Colorectal Cancer|Active, not recruiting||Phase 1|38|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:20:18.380374|2018-06-01 05:20:18.380374
NCT00059917|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-05-29|2003-05-06|2003-05-07|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2003||2003-01-31|April 2005|2005-04-30|May 2005|Actual|2005-05-31|||||Interventional|||Polyglutamate Camptothecin in Treating Patients With Advanced Cancer|Phase I Study of CT-2106 in Patients With Advanced Malignancy|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:18.461353|2018-06-01 05:20:18.461353
NCT00059904|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-07-17|2003-05-06|2003-05-07|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2003||2003-01-31|July 2004|2004-07-31|June 2004|Actual|2004-06-30|||||Interventional|||Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma|An Open-Labeled, Phase II Study of Rituximab in Combination With Recombinant IL-2 for Relapsed or Refractory Non-Hodgkin's Lymphoma of Intermediate- or High-Grade Histology|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:18.513969|2018-06-01 05:20:18.513969
NCT00059891|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-02-26|2003-05-06|2003-05-07|Estimate|||||||2013-02-26|2013-02-27|Estimate|January 2003||2003-01-31|February 2013|2013-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer|Total Anorectal Reconstruction With The American Medical Systems, Inc. Acticon Neosphincter Prosthesis After Abdominoperineal Resection|Completed||N/A|4|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:20:18.590162|2018-06-01 05:20:18.590162
NCT00059878|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-06-17|2003-05-06|2003-05-07|Estimate|||||||2013-06-17|2013-06-19|Estimate|August 2003||2003-08-31|July 2004|2004-07-31|January 2005|Actual|2005-01-31|||||Interventional|||Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections|A Prospective, Randomized, Double-Blind, Multicenter Pilot Study Of The Safety And Efficacy Of Interferon Gamma- 1b (IFN-y 1b) Plus Voriconazole Versus Placebo Plus Voriconazole In The Treatment Of Invasive Aspergillosis And Other Filamentous Fungal Infections|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:18.657825|2018-06-01 05:20:18.657825
NCT00059865|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2016-12-05|2003-05-06|2003-05-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|January 2004||2004-01-31|December 2016|2016-12-31|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Interventional|||Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer|Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma|Completed||Phase 1/Phase 2|68|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:20:18.810004|2018-06-01 05:20:18.810004
NCT00059852|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2016-12-05|2003-05-06|2003-05-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|June 2003||2003-06-30|December 2016|2016-12-31|January 2009|Actual|2009-01-31|August 2006|Actual|2006-08-31||Interventional|||Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane|A Phase II Study of OSI-774 (Tarceva) and Gemcitabine for Patients With Metastatic Breast Cancer|Completed||Phase 2|61|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:20:18.952181|2018-06-01 05:20:18.952181
NCT00059839|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|2013-06-28||2014-09-10|2003-05-06|2003-05-07|Estimate|2013-07-25|2013-10-08|Estimate||||2014-09-10|2014-09-22|Estimate|November 2003||2003-11-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|December 2009|Actual|2009-12-31||Interventional|||Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma|A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine|Completed||Phase 3|129|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:20:19.176671|2018-06-01 05:20:19.176671
NCT00059826|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2016-12-05|2003-05-06|2003-05-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|March 2003||2003-03-31|December 2016|2016-12-31|February 2011|Actual|2011-02-28|July 2007|Actual|2007-07-31||Interventional|||Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer|A Phase II Study of Interferon-Based Adjuvant Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma|Completed||Phase 2|89|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:20:20.000647|2018-06-01 05:20:20.000647
NCT00059813|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-08-23|2003-05-06|2003-05-07|Estimate|||||||2013-08-23|2013-08-26|Estimate|August 2003||2003-08-31|August 2013|2013-08-31||||June 2005|Actual|2005-06-30||Interventional|||Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer|A Phase II Trial of G3139 (Genasense) Anti-Bcl-2 Antisense Oligonucleotide Plus Alpha-Interferon in Metastatic Renal Cancer|Completed||Phase 2|41|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:20.148086|2018-06-01 05:20:20.148086
NCT00059800|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2013-06-25|2003-05-06|2003-05-07|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2002||2002-05-31|December 2005|2005-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Boron Neutron Capture Therapy in Treating Patients With Melanoma|A Phase II Trial For Neutron Capture Therapy In Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:20.335804|2018-06-01 05:20:20.335804
NCT00059787|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|2015-04-29||2015-10-29|2003-05-06|2003-05-07|Estimate|2015-10-29|2015-12-01|Estimate||||2015-10-29|2015-12-01|Estimate|April 2003||2003-04-30|May 2013|2013-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma|Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:20:22.182785|2018-06-01 05:20:22.182785
NCT00059761|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-06|||2015-11-14|2003-05-06|2003-05-07|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 2003||2003-03-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|March 2009|Actual|2009-03-31||Interventional|||Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Phase I Study of Irinotecan and Cisplatin in Combination With Twice Daily Thoracic Radiotherapy (45 Gy) or Once Daily Thoracic Radiotherapy (70 Gy) for Patients With Limited Stage Small Cell Lung Cancer|Completed||Phase 1|36|Actual|Radiation Therapy Oncology Group||6|||f||||t||||||||||2018-06-01 05:20:23.892159|2018-06-01 05:20:23.892159
NCT00059735|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-05|||2008-02-29|2003-05-06|2003-05-07|Estimate|||||||2008-02-29|2008-03-05|Estimate|May 2002||2002-05-31|February 2008|2008-02-29|December 2003|Actual|2003-12-31|||||Interventional|||A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma|A Phase II Study of E7070 in Patients With Progressive Inoperable and/or Metastatic Renal Cell Carcinoma (RCC)|Completed||Phase 2|30|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 05:20:24.139446|2018-06-01 05:20:24.139446
NCT00043108|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2018-02-23|2003-05-06|2003-05-07|Estimate|||||||2018-02-23|2018-02-26|Actual|July 2002||2002-07-31|February 2018|2018-02-28||||December 2006|Actual|2006-12-31||Interventional|||Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Trimodality Protocol for the Treatment of Locally Advanced, Potentially Resectable Non-Small Cell Lung Cancer Targeting|Active, not recruiting||Phase 2|57|Anticipated|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:20:24.333164|2018-06-01 05:20:24.333164
NCT00030667|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2015-04-14|2003-05-06|2003-05-07|Estimate|||||||2015-04-14|2015-04-15|Estimate|May 2002||2002-05-31|December 2013|2013-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood|A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors|Completed||Phase 2|100|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:24.56861|2018-06-01 05:20:24.56861
NCT00030524|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2012-10-26|2003-05-06|2003-05-07|Estimate|||||||2012-10-26|2012-10-30|Estimate|January 2002||2002-01-31|October 2012|2012-10-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients With Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy|Completed||Phase 2|||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 05:20:24.830143|2018-06-01 05:20:24.830143
NCT00027599|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-02-08|2003-05-06|2003-05-07|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2001||2001-12-31|December 2003|2003-12-31||||July 2007|Actual|2007-07-31||Interventional|||APC8015 and Bevacizumab in Treating Patients With Prostate Cancer|A Phase II Study Of Prostatic Acid Phosphatase-Pulsed Dendritic Cells (Provenge) In Combination With Bevacizumab In Patients With Serologic Progression Of Prostate Cancer After Definitive Local Therapy|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:24.959141|2018-06-01 05:20:24.959141
NCT00017134|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-07|2003-05-06|2003-05-07|Estimate|||||||2013-06-07|2013-06-10|Estimate|September 2002||2002-09-30|November 2006|2006-11-30||||December 2006|Actual|2006-12-31||Interventional|||Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk|An Exploratory Evaluation of Fenretinide (4-HPR) as a Chemopreventive Agent for Ovarian Carcinoma|Terminated||N/A|71|Anticipated|Gynecologic Oncology Group||||Withdrawn due to poor accrual|||||||||||||||2018-06-01 05:20:25.050432|2018-06-01 05:20:25.050432
NCT00016315|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2015-11-14|2003-05-06|2003-05-07|Estimate|||||||2015-11-14|2015-11-17|Estimate|May 2001||2001-05-31|November 2015|2015-11-30|June 2010|Actual|2010-06-30|January 2009|Actual|2009-01-31||Interventional|||Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer|A Phase I Study of Gemcitabine, Carboplatin or Gemcitabine, Paclitaxel and Radiation Therapy Followed by Adjuvant Chemotherapy for Patients With Favorable Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|35|Actual|Radiation Therapy Oncology Group||13|||f||||t||||||||||2018-06-01 05:20:25.227084|2018-06-01 05:20:25.227084
NCT00006225|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11||2011-02-18|2012-05-31|2003-05-06|2003-05-07|Estimate||||2011-02-18|2011-02-25|Estimate|2012-05-31|2012-06-06|Estimate|November 1999||1999-11-30|May 2012|2012-05-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer|Ex Vivo Expanded Megakaryocytes for Supportive Care of Breast Cancer Patients: A Phase I/II Study|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||||||||||||2018-06-01 05:20:25.386493|2018-06-01 05:20:25.386493
NCT00005793|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-09-24|2003-05-06|2003-05-07|Estimate|||||||2012-09-24|2012-09-25|Estimate|July 1999||1999-07-31|September 2012|2012-09-30|November 2006|Actual|2006-11-30|July 2006|Actual|2006-07-31||Interventional|||A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide|A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59|Completed||Phase 1/Phase 2|41|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:20:25.470407|2018-06-01 05:20:25.470407
NCT00005065|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-06-03|2003-05-06|2003-05-07|Estimate|||||||2013-06-03|2013-06-04|Estimate|January 2000||2000-01-31|June 2013|2013-06-30||||December 2003|Actual|2003-12-31||Interventional|||Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|A Phase I Study of Induction Carboplatin / Paclitaxel Chemotherapy, Pre-operative Radiotherapy With Gadolinium Texaphyrin (Gd-Tex), and Surgical Resection in Stage IIIA (N2) Non-small Cell Lung Carcinoma.|Completed||Phase 1|12|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:25.694177|2018-06-01 05:20:25.694177
NCT00004127|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-02-08|2003-05-06|2003-05-07|Estimate|||||||2013-02-08|2013-02-11|Estimate|February 2000||2000-02-29|February 2013|2013-02-28|August 2003|Actual|2003-08-31|October 2002|Actual|2002-10-31||Interventional|||Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach|A Phase II Study of Oxaliplatin in Combination With Fluorouracil and Leucovorin in Carcinoma of the Esophagus and Gastric Cardia|Completed||Phase 2|35|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:20:25.807329|2018-06-01 05:20:25.807329
NCT00059098|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-17|||2016-07-11|2003-04-17|2003-04-18|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2003||2003-03-31|April 2008|2008-04-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Identification of Genes Predisposing to Atherosclerosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:20:40.188291|2018-06-01 05:20:40.188291
NCT00004095|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2017-04-14|2003-05-06|2003-05-07|Estimate|||||||2017-04-14|2017-04-18|Actual|August 1999||1999-08-31|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors|Phase I Trial of Irinotecan (CPT-11) and Gemcitabine in Patients With Solid Tumors|Completed||Phase 1|38|Actual|Northwestern University||1|||f||||||||||||||2018-06-01 05:20:25.944222|2018-06-01 05:20:25.944222
NCT00059748|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-05|||2018-03-30|2003-05-05|2003-05-06|Estimate|||||||2018-03-30|2018-04-02|Actual|April 30, 2003||2003-04-30|January 9, 2018|2018-01-09||||||||Observational|||Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still's Disease, Behcet's Disease, and Other Undifferentiated Autoinflammatory Diseases)|Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, CRMO, Still s Disease, Behcet s Disease, and Other Undifferentiated Autoinflammatory Diseases)|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:26.063846|2018-06-01 05:20:26.063846
NCT00019435|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-05-05|2003-05-06|Estimate|||||||2015-04-28|2015-04-29|Estimate|May 1998||1998-05-31|April 2007|2007-04-30||||||||Interventional|||LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors|Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Immunotoxin for Advanced Carcinomas That Express Lewis Y Antigen|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:26.153076|2018-06-01 05:20:26.153076
NCT00002765|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-04-28|2003-05-05|2003-05-06|Estimate|||||||2015-04-28|2015-04-29|Estimate|April 1996||1996-04-30|March 2003|2003-03-31||||||||Interventional|||Immunotoxin in Treating Patients With Leukemia or Lymphoma|PHASE I STUDY OF ANTI-TAC(Fv)-PE38 (LMB-2), A RECOMBINANT SINGLE-CHAIN IMMUNOTOXIN FOR TREATMENT OF TAC-EXPRESSING MALIGNANCIES|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:26.239951|2018-06-01 05:20:26.239951
NCT00059722|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-02|||2016-08-22|2003-05-02|2003-05-05|Estimate|||||||2016-08-22|2016-08-24|Estimate|May 2003||2003-05-31|August 2016|2016-08-31|June 2007|Actual|2007-06-30|||||Interventional|||This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.|A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.|Completed||Phase 2|160||Sanofi|||||||||||||||||||2018-06-01 05:20:26.408419|2018-06-01 05:20:26.408419
NCT00059709|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-02|||2007-04-02|2003-05-02|2003-05-05|Estimate|||||||2007-04-02|2007-04-03|Estimate|August 2000||2000-08-31|January 2006|2006-01-31||||||||Interventional|||Learning to Resolve Family Conflict|Understanding and Learning How to Resolve Family Conflict|Completed||N/A|360||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:26.706114|2018-06-01 05:20:26.706114
NCT00059696|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-01|||2016-09-23|2003-05-02|2003-05-05|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 1999||1999-12-31|May 2011|2011-05-31||||November 2004|Actual|2004-11-30||Interventional|||Treatment for Movement Problems in Elderly Stroke Patients|A Treatment for Excess Motor Disability in the Aged|Completed||Phase 2|80|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:26.792981|2018-06-01 05:20:26.792981
NCT00059683|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-01|||2014-09-29|2003-05-02|2003-05-05|Estimate|||||||2014-09-29|2014-09-30|Estimate|January 2003||2003-01-31|September 2014|2014-09-30|October 2009|Actual|2009-10-31|November 2007|Actual|2007-11-30||Interventional|||Ultrasound-indicated Cerclage to Prevent Premature Birth in High-risk Women|Vaginal Ultrasound Cerclage Trial|Completed||N/A|300|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-06-01 05:20:26.880145|2018-06-01 05:20:26.880145
NCT00018941|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-14|2003-05-02|2003-05-05|Estimate|||||||2013-06-14|2013-06-17|Estimate|April 1991||1991-04-30|March 2003|2003-03-31|May 2003|Actual|2003-05-31|||||Interventional|||Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:26.993393|2018-06-01 05:20:26.993393
NCT00005837|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-20|2003-05-02|2003-05-05|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2000||2000-02-29|July 2004|2004-07-31|June 2004|Actual|2004-06-30|||||Interventional|||Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer|Phase II Evaluation of Oxaliplatin in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:27.110541|2018-06-01 05:20:27.110541
NCT00005818|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-22|2003-05-02|2003-05-05|Estimate|||||||2013-01-22|2013-01-23|Estimate|March 2000||2000-03-31|January 2013|2013-01-31||||March 2003|Actual|2003-03-31||Interventional|||SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer|A Phase I/II Study of Escalating Doses of SU5416 (NSC 696819) in Combination With CPT-11 in Patients With Advanced Colorectal Carcinoma|Completed||Phase 1/Phase 2|68|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:27.625596|2018-06-01 05:20:27.625596
NCT00005025|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-11-05|2003-05-02|2003-05-05|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2000||2000-06-30|March 2003|2003-03-31||||||||Interventional|||Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:27.806544|2018-06-01 05:20:27.806544
NCT00002971|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2008-12-13|2003-05-02|2003-05-05|Estimate|||||||2008-12-13|2008-12-16|Estimate|April 1997||1997-04-30|March 2003|2003-03-31||||||||Interventional|||O(6)-Benzylguanine in Treating Patients With Malignant Glioma|A Phase I Trial of Pre-Surgical O6-Benzylguanine in the Treatment of Patients With Malignant Glioma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:27.878415|2018-06-01 05:20:27.878415
NCT00059670|ClinicalTrials.gov processed this data on May 31, 2018|2003-05-01|||2010-01-12|2003-05-01|2003-05-02|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Comparison of Two Therapies for Upper Esophageal Sphincter (UES) Dysphagia|Comparison of Two Therapies for UES Dysphagia|Completed||N/A|204||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:20:28.028657|2018-06-01 05:20:28.028657
NCT00059657|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-29|||2006-05-17|2003-05-01|2003-05-02|Estimate|||||||2006-05-17|2006-05-19|Estimate|August 2001||2001-08-31|May 2006|2006-05-31|November 2005||2005-11-30|||||Interventional|||Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM in Conjunction With Peripheral Revascularization for the Treatment of Critical Leg Ischemia|Completed||Phase 3|280||Mitsubishi Tanabe Pharma Corporation|||||||||||||||||||2018-06-01 05:20:28.15748|2018-06-01 05:20:28.15748
NCT00059644|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-29|||2005-06-23|2003-05-01|2003-05-02|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2001||2001-07-31|June 2005|2005-06-30|June 2004||2004-06-30|||||Interventional|||Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM for the Treatment of Critical Leg Ischemia|Terminated||Phase 3|560||Mitsubishi Tanabe Pharma Corporation|||||||||||||||||||2018-06-01 05:20:28.312475|2018-06-01 05:20:28.312475
NCT00003933|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-06|2003-05-01|2003-05-02|Estimate|||||||2014-08-06|2014-08-07|Estimate|April 1999||1999-04-30|August 2014|2014-08-31||||April 2006|Actual|2006-04-30||Interventional|||Diagnostic Study of Gene Alterations in Children Who Have Been Treated for Relapsed Acute Lymphocytic Leukemia|The Incidence and Prognostic Significance of P16 INK4A/ P15 INK4B Gene Alterations in Children With Relapsed ALL Treated on CCG-1941|Completed||N/A|||Children's Oncology Group|||||f||||f||||||||||2018-06-01 05:20:28.496243|2018-06-01 05:20:28.496243
NCT00003926|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-11-27|2003-05-01|2003-05-02|Estimate|||||||2017-11-27|2017-11-29|Actual|November 1998||1998-11-30|November 2017|2017-11-30|August 2003|Actual|2003-08-31|August 2002|Actual|2002-08-31||Interventional|||Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors|A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors|Terminated||Phase 1|13|Actual|Masonic Cancer Center, University of Minnesota||2||Withdrawn due to slow accrual|f||||t||||||||||2018-06-01 05:20:28.642508|2018-06-01 05:20:28.642508
NCT00003925|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-05|2003-05-01|2003-05-02|Estimate|||||||2013-04-05|2013-04-08|Estimate|May 1998||1998-05-31|April 2013|2013-04-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Combination Chemotherapy In Treating Patients With Advanced Cancer|Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin|Completed||Phase 1|36|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:20:28.832205|2018-06-01 05:20:28.832205
NCT00003802|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-12-12|2003-05-01|2003-05-02|Estimate|||||||2012-12-12|2012-12-17|Estimate|February 1999||1999-02-28|December 2012|2012-12-31|October 2002|Actual|2002-10-31|||||Interventional|||Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma|A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma|Completed||Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:20:28.932633|2018-06-01 05:20:28.932633
NCT00003797|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-05-01|2003-05-02|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 1999||1999-03-31|December 2002|2002-12-31||||||||Interventional|||Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas|Herceptin (NSC #688097) and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/NEU|Unknown status|Active, not recruiting|Phase 2|41|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:29.082403|2018-06-01 05:20:29.082403
NCT00059631|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-29|||2015-06-19|2003-04-29|2003-04-30|Estimate|||||||2015-06-19|2015-06-23|Estimate|March 2003||2003-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone|Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone in Patients With Advanced Androgen-Independent Prostate Cancer (AI-PCa)|Completed||Phase 1|42|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:20:29.214637|2018-06-01 05:20:29.214637
NCT00059618|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-29|||2012-08-01|2003-04-29|2003-04-30|Estimate|||||||2012-08-01|2012-08-02|Estimate|April 2003||2003-04-30|August 2012|2012-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer|A Phase I Study Evaluating the Safety and Tolerability of PS-341(Bortezomib)and Carboplatin in Patients With Platinum- and Taxane-Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer|Completed||Phase 1|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:20:29.3359|2018-06-01 05:20:29.3359
NCT00059605|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-29|||2012-02-21|2003-04-29|2003-04-30|Estimate|||||||2012-02-21|2012-02-23|Estimate|March 2003||2003-03-31|February 2012|2012-02-29|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Phase I Study of IV DOTAP: Cholesterol-Fus1 in Non-Small-Cell Lung Cancer|Phase I Study Of Intravenous DOTAP:Cholesterol-Fus1 Liposome Complex (DOTAP:Chol-fus1) In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy|Completed||Phase 1|32|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:20:29.467138|2018-06-01 05:20:29.467138
NCT00059592|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-29|||2005-06-23|2003-04-29|2003-04-30|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1998||1998-05-31|May 2005|2005-05-31||||||||Interventional|||Valacyclovir in Immunocompromised Children|Valacyclovir in Immunocompromised Children|Completed||Phase 1|30||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:20:29.593157|2018-06-01 05:20:29.593157
NCT00003757|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2003-04-29|2003-04-30|Estimate|||||||2012-05-14|2012-05-15|Estimate|February 1998||1998-02-28|May 2012|2012-05-31|July 2007|Actual|2007-07-31|July 2002|Actual|2002-07-31||Interventional|||Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy|Rituximab (IDEC-C2B8, Mabthera) in Patients With Hairy Cell Leukemia Relapsing After Treatment With 2-Chlorodeoxyadenosine (CDA)|Completed||Phase 2|25|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:20:29.73579|2018-06-01 05:20:29.73579
NCT00003649|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-04-29|2003-04-30|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 1998||1998-11-30|February 2002|2002-02-28||||||||Interventional|||Gene Therapy in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Surgically Removed|Phase I Pilot Trial of Adenovirus p53 in Bronchioloalveolar Cell Lung Carcinoma (BAC) Administered by Bronchoalveolar Lavage|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:29.860219|2018-06-01 05:20:29.860219
NCT00003627|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-04-29|2003-04-30|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 1998||1998-10-31|January 2001|2001-01-31||||||||Interventional|||Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx|Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx|Unknown status|Active, not recruiting|Phase 3|160|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:29.959163|2018-06-01 05:20:29.959163
NCT00003484|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-04-22|2003-04-29|2003-04-30|Estimate|||||||2015-04-22|2015-04-23|Estimate|September 1997||1997-09-30|April 2015|2015-04-30|March 2010|Actual|2010-03-31|November 2003|Actual|2003-11-30||Interventional|||Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors|Phase I Study of Anti-Tenascin Monoclonal Antibody I-Labeled 81C6 Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary Brain Tumors After External Beam Radiotherapy|Completed||Phase 1|21|Actual|Duke University|||||f||||||||||||||2018-06-01 05:20:30.06499|2018-06-01 05:20:30.06499
NCT00003436|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-04-29|2003-04-30|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 1998||1998-07-31|December 2000|2000-12-31|December 2005|Actual|2005-12-31|||||Interventional|||Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia|Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12|Completed||Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:30.318166|2018-06-01 05:20:30.318166
NCT00059579|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-29|||2017-06-30|2003-04-28|2003-04-29|Estimate|||||||2017-06-30|2017-07-02|Actual|April 24, 2003||2003-04-24|November 12, 2010|2010-11-12|November 12, 2010||2010-11-12|||||Observational|||Brain Regulation of Emotions in People With Depression and Anhedonia|Functional MRI Study of Brain Mechanism Mediating Anhedonia in Major Depression|Completed|||163|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:30.459051|2018-06-01 05:20:30.459051
NCT00059553|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-28|||2009-06-17|2003-04-28|2003-04-29|Estimate|||||||2009-06-17|2009-06-18|Estimate|May 2000||2000-05-31|August 2005|2005-08-31|January 2005||2005-01-31|||||Interventional|||Retraining Walking After Spinal Cord Injury|Activity-Dependent Plasticity After Spinal Cord Injury|Unknown status|Active, not recruiting|Phase 2/Phase 3|16||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:30.534081|2018-06-01 05:20:30.534081
NCT00059540|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-28|||2016-09-20|2003-04-28|2003-04-29|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 1993||1993-05-31|September 2016|2016-09-30|March 2011|Actual|2011-03-31|March 1995|Actual|1995-03-31||Observational|MLS||The Maternal Lifestyle Study (MLS)|The Maternal Lifestyle Study|Completed|||11811|Actual|NICHD Neonatal Research Network|||||f||||t||||||||||2018-06-01 05:20:30.643353|2018-06-01 05:20:30.643353
NCT00059527|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-28|||2014-10-28|2003-04-28|2003-04-29|Estimate|||||||2014-10-28|2014-10-30|Estimate|March 1999||1999-03-31|August 2005|2005-08-31|May 2003||2003-05-31|||||Interventional|||Healthy Youth Places: A Program to Promote Nutrition and Physical Activity in Adolescents|Youth Environments Promoting Nutrition and Activity|Completed||Phase 4|2000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:30.793435|2018-06-01 05:20:30.793435
NCT00059514|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-28|||2017-04-03|2003-04-28|2003-04-29|Estimate|||||||2017-04-03|2017-04-05|Actual|May 2000|Actual|2000-05-31|April 2017|2017-04-30|May 2006|Actual|2006-05-31|April 2005|Actual|2005-04-30||Observational|||Tobacco Use Among Arab American Youth|Arab American Youth: Tobacco Use and Intervention|Completed|||2300|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t|f|f||||||No||2018-06-01 05:20:30.869712|2018-06-01 05:20:30.869712
NCT00059449|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-25|||2010-01-12|2003-04-28|2003-04-29|Estimate|||||||2010-01-12|2010-01-13|Estimate||||January 2010|2010-01-31||||||||Observational|||Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis|Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis|Completed|||372|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:20:31.001531|2018-06-01 05:20:31.001531
NCT00005836|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-20|2003-04-28|2003-04-29|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2000||2000-02-29|March 2003|2003-03-31|July 2004|Actual|2004-07-31|||||Interventional|||Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy|Phase II Evaluation of Oxaliplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:31.206846|2018-06-01 05:20:31.206846
NCT00059501|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-26|||2008-03-03|2003-04-25|2003-04-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||Postural Control in the Elderly|Cortical Control of Postural Stability in the Elderly|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:31.514263|2018-06-01 05:20:31.514263
NCT00059475|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-26|2012-03-30||2012-10-17|2003-04-25|2003-04-28|Estimate|2012-07-06|2012-08-14|Estimate||||2012-10-17|2012-10-23|Estimate|April 2003||2003-04-30|October 2012|2012-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Peptide Vaccination for Patients at High Risk for Recurrent Melanoma|Randomized Comparison of Peptide Immunization in Patients at High Risk for Recurrence of Melanoma|Completed||Phase 2|138|Actual|National Institutes of Health Clinical Center (CC)||8|||f||||f||||||||||2018-06-01 05:20:31.70876|2018-06-01 05:20:31.70876
NCT00059436|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-25|||2016-09-23|2003-04-25|2003-04-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 1999||1999-10-31|May 2011|2011-05-31||||September 2004|Actual|2004-09-30||Interventional|||Mental Effort and Muscle Strength|Mental-effort Effect on Large Muscle Strengthening|Completed||Phase 1|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:33.184863|2018-06-01 05:20:33.184863
NCT00059410|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-24|||2009-12-10|2003-04-25|2003-04-28|Estimate|||||||2009-12-10|2009-12-11|Estimate|January 2003||2003-01-31|February 2008|2008-02-29|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Observational|||Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II|Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II|Completed|||210||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:20:33.349527|2018-06-01 05:20:33.349527
NCT00059423|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-25|||2018-03-27|2003-04-24|2003-04-25|Estimate|||||||2018-03-27|2018-03-29|Actual|April 23, 2003||2003-04-23|November 22, 2017|2017-11-22||||||||Observational|||Natural History Study for BEN|Natural History and Molecular Characterization of Benign Ethnic Neutropenia in Individuals of African Descent|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:33.480627|2018-06-01 05:20:33.480627
NCT00059397|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-24|||2010-03-17|2003-04-24|2003-04-25|Estimate|||||||2010-03-17|2010-03-18|Estimate|April 2003||2003-04-30|March 2010|2010-03-31||||||||Observational|||Hepatitis C: Grading and Staging by MR|Hepatitis C: Grading and Staging by MR|Completed|||80|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:20:33.563835|2018-06-01 05:20:33.563835
NCT00003432|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2003-04-24|2003-04-25|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 1998||1998-06-30|November 2013|2013-11-30|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Immunotherapy in Treating Patients With Metastatic Breast Cancer|A Phase I/II Study of Active Immunotherapy With Carcinoembryonic Antigen RNA-Pulsed, Autologous Cultured Dendritic Cells for Patients With Breast Cancer Who Achieve a Complete Response After High Dose Chemotherapy and Stem Cell Support|Terminated||Phase 1/Phase 2|4|Actual|Duke University||1||low accrual|f||||f||||||||||2018-06-01 05:20:33.655338|2018-06-01 05:20:33.655338
NCT00003346|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2003-04-24|2003-04-25|Estimate|||||||2013-06-24|2013-06-25|Estimate|November 1997||1997-11-30|June 2013|2013-06-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma|Phase I-II Trial of High-Dose Acetaminophen With Carmustine in Patients With Metastatic Melanoma|Completed||Phase 2|80|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:33.87292|2018-06-01 05:20:33.87292
NCT00003341|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2003-04-24|2003-04-25|Estimate|||||||2013-07-01|2013-07-03|Estimate|December 1997||1997-12-31|July 2013|2013-07-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy|The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial|Completed||Phase 3|275|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:33.984378|2018-06-01 05:20:33.984378
NCT00003324|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-09-30|2003-04-24|2003-04-25|Estimate|||||||2015-09-30|2015-10-02|Estimate|December 1997||1997-12-31|July 2012|2012-07-31||||July 2006|Actual|2006-07-31||Interventional|||Radiation Therapy With or Without Surgery in Treating Patients Who Have Brain Metastases|Prognostic Factors Associated With Successful Omission of Whole Brain Radiotherapy in Patients With 4 or Less Cerebral Metastases Treated With Focal Radiation or Surgery|Completed||N/A|61|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:20:34.159854|2018-06-01 05:20:34.159854
NCT00003311|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-05|2003-04-24|2003-04-25|Estimate|||||||2012-10-05|2012-10-08|Estimate|March 1999||1999-03-31|October 2012|2012-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma|Phase II CCOP Trial of High Dose Methotrexate/ARA-C and HCVAD for Newly Diagnosed Nodular and Diffuse Mantle Cell Lymphoma and Their Blastic Variants|Completed||Phase 2|19|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:20:34.286678|2018-06-01 05:20:34.286678
NCT00059384|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-23|||2008-09-16|2003-04-23|2003-04-24|Estimate|||||||2008-09-16|2008-09-17|Estimate|January 2003||2003-01-31|July 2007|2007-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Alternative Dosing Strategy for Anti-HIV Drugs|Concentration-Controlled Antiretroviral Therapy in Persons Experiencing Persistent Viremia|Completed||Phase 4|66||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:20:34.430028|2018-06-01 05:20:34.430028
NCT00059371|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-23|||2008-05-28|2003-04-23|2003-04-24|Estimate|||||||2008-05-28|2008-05-30|Estimate|February 2002||2002-02-28|September 2007|2007-09-30|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Male Circumcision and HIV Rates in Kenya|Trial of Male Circumcision to Reduce HIV Incidence|Completed||Phase 3|2887|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-06-01 05:20:34.535146|2018-06-01 05:20:34.535146
NCT00059358|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-23|||2009-08-06|2003-04-23|2003-04-24|Estimate|||||||2009-08-06|2009-08-07|Estimate|September 2001||2001-09-30|August 2009|2009-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Zidovudine Levels in HIV Infected Patients Being Treated for HCV|Pharmacological Interactions Between Zidovudine and Ribavirin in HCV-HIV Co-Infected Patients Treated With Rebetron or Peg-Intron Plus Ribavirin|Completed||Phase 1/Phase 2|16|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:20:34.65826|2018-06-01 05:20:34.65826
NCT00059345|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-23|||2013-11-15|2003-04-23|2003-04-24|Estimate|||||||2013-11-15|2013-11-18|Estimate|September 2002||2002-09-30|November 2013|2013-11-30|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Interaction Between Patient and Healthcare Provider: Response to Acupuncture in Knee Osteoarthritis|The Impact of Patient-Provider Interaction on Response to Acupuncture|Completed||N/A|639|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:20:34.76146|2018-06-01 05:20:34.76146
NCT00059332|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-23|2015-06-09||2015-07-24|2003-04-23|2003-04-24|Estimate|2015-07-24|2015-08-21|Estimate||||2015-07-24|2015-08-21|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|FAST-MAG||Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial|Field Administration of Stroke Therapy-Magnesium Trial: A Randomized, Double-Blind, Placebo Controlled Trial of Neuroprotective Magnesium Sulfate Therapy for Acute Stroke Initiated Within 2 Hours of Onset by Paramedics in the Field|Completed||Phase 3|1700|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 05:20:34.875511|2018-06-01 05:20:34.875511
NCT00059319|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-23|||2007-05-18|2003-04-23|2003-04-24|Estimate|||||||2007-05-18|2007-05-21|Estimate|January 1999||1999-01-31|May 2007|2007-05-31||||||||Interventional|||Reduced Manipulation of the Aorta and Neurobehavioral Outcome Trial||Completed||Phase 3|300||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:20:37.14455|2018-06-01 05:20:37.14455
NCT00059306|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-23|||2013-04-02|2003-04-23|2003-04-24|Estimate|||||||2013-04-02|2013-04-04|Estimate|February 2003||2003-02-28|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SPS3||Secondary Prevention of Small Subcortical Strokes Trial|Secondary Prevention of Small Subcortical Strokes (SPS3) Trial|Completed||Phase 3|3020|Actual|University of British Columbia||2|||f||||t||||||||||2018-06-01 05:20:37.23943|2018-06-01 05:20:37.23943
NCT00059293|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-22|||2018-05-03|2003-04-23|2003-04-24|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2002||2002-09-30|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG|TCD Ultrasound of Subjects Enrolled in Baby Hug (Baby TCD)|Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||f||||||||||2018-06-01 05:20:37.547626|2018-06-01 05:20:37.547626
NCT00058981|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-15|||2009-03-18|2003-04-23|2003-04-24|Estimate|||||||2009-03-18|2009-03-19|Estimate|October 2002||2002-10-31|March 2009|2009-03-31|May 2007|Actual|2007-05-31|March 2007|Actual|2007-03-31||Interventional|||Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Tolerability as Well as the Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in LADA Subjects|Terminated||Phase 2|100||DeveloGen Israel, Ltd.|||||||||||||||||||2018-06-01 05:20:37.650924|2018-06-01 05:20:37.650924
NCT00059280|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-22|||2014-02-04|2003-04-22|2003-04-23|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2003||2003-04-30|July 2006|2006-07-31|September 2005|Actual|2005-09-30|June 2005|Actual|2005-06-30||Interventional|||A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease|An Open-label, Multicenter, Multinational Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid Alpha-glucosidase Treatment in Patients Less Than 6 Months Old With Infantile-onset Pompe Disease|Completed||Phase 2/Phase 3|16|Actual|Sanofi||1|||f||||||||||||||2018-06-01 05:20:37.789985|2018-06-01 05:20:37.789985
NCT00059267|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-22|||2017-10-16|2003-04-22|2003-04-23|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2001|Actual|2001-03-31|October 2017|2017-10-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Prevention of Recurrent Hepatitis B After Liver Transplantation|Prevention of Recurrent Hepatitis B After Liver Transplantation|Completed|||317|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:20:37.884986|2018-06-01 05:20:37.884986
NCT00059254|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-22|||2017-10-11|2003-04-22|2003-04-23|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2000|Actual|2000-09-30|October 2017|2017-10-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Differential Metabolism of Dietary Fatty Acids|Differential Metabolism of Dietary Fatty Acids|Completed||N/A|19|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f|||||f|f||||||||2018-06-01 05:20:37.979445|2018-06-01 05:20:37.979445
NCT00059241|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-22|||2005-06-23|2003-04-22|2003-04-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2000||2000-07-31|April 2003|2003-04-30||||||||Interventional|||"The Reach For Health Program: Delaying Sexual Activity in Children"|Reach For Health--Middle Childhood Risk Prevention Study|Unknown status|Recruiting|Phase 2|1200||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:38.134875|2018-06-01 05:20:38.134875
NCT00059215|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-21|2010-04-19||2010-05-21|2003-04-22|2003-04-23|Estimate|2010-04-19|2010-05-21|Estimate||||2010-05-21|2010-05-25|Estimate|April 2003||2003-04-30|May 2010|2010-05-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)|A Double-Blind, Randomized, Multicenter, Dose-Ranging Trial of CS-747 Compared With Clopidogrel in Subjects Undergoing Percutaneous Coronary Intervention|Completed||Phase 2|905|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-06-01 05:20:38.268023|2018-06-01 05:20:38.268023
NCT00003290|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-04-22|2003-04-23|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1998||1998-01-31|July 2001|2001-07-31|August 2004|Actual|2004-08-31|||||Interventional|||Radiation Therapy in Treating Patients With Prostate Cancer|A Randomised Trial of High Dose Therapy in Localised Cancer of the Prostate Using Conformal Radiotherapy Techniques|Completed||Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:39.124148|2018-06-01 05:20:39.124148
NCT00003262|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-04-22|2003-04-23|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 1997||1997-05-31|October 2002|2002-10-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection|"Prospective Non Randomized Study With Chemotherapy in Patients With Hodgkin's Disease and HIV Infection: Stanford V Regimen For Low Risk Patients, EBVP Regimen For High Risk Patients"|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:39.308253|2018-06-01 05:20:39.308253
NCT00003205|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-28|2003-04-22|2003-04-23|Estimate|||||||2013-05-28|2013-05-30|Estimate|April 1998||1998-04-30|December 2002|2002-12-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Bryostatin 1 in Treating Patients With Stage IV Breast Cancer|A Phase II Trial of Bryostatin-1 for the Treatment of Stage IV Breast Cancer|Completed||Phase 2|||University of Colorado, Denver|||||f||||t||||||||||2018-06-01 05:20:39.377244|2018-06-01 05:20:39.377244
NCT00003193|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-12-05|2003-04-22|2003-04-23|Estimate|||||||2012-12-05|2012-12-06|Estimate|January 1998||1998-01-31|December 2012|2012-12-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Phase I/II Study of Escalating Doses of Taxol Used Concurrently With Ethyol and Accelerated Hyperfractionated Radiotherapy in the Treatment of Stage III and IV Carcinoma of the Head and Neck|Completed||Phase 1/Phase 2|37|Anticipated|Massachusetts General Hospital||1|||f||||||||||||||2018-06-01 05:20:39.439782|2018-06-01 05:20:39.439782
NCT00003173|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-06|2003-04-22|2003-04-23|Estimate|||||||2013-03-06|2013-03-07|Estimate|September 1997||1997-09-30|March 2013|2013-03-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors|High-Dose Thiotepa With Autologous Stem Cell Rescue in Patients With Malignancies Refractory to Conventional Chemotherapy|Completed||Phase 2|36|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:39.523848|2018-06-01 05:20:39.523848
NCT00059228|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-22|||2017-10-05|2003-04-21|2003-04-22|Estimate|||||||2017-10-05|2017-10-06|Actual|April 17, 2003||2003-04-17|November 15, 2016|2016-11-15|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||Clinical Trial of Estrogen for Postpartum Depression|The Efficacy of 17Beta-Estradiol in Postpartum-Related Depressive Illness|Terminated||Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:20:39.600247|2018-06-01 05:20:39.600247
NCT00059202|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-21|||2013-10-31|2003-04-21|2003-04-22|Estimate|||||||2013-10-31|2013-11-01|Estimate||||October 2013|2013-10-31||||||||Interventional|||Trial of High-dose Urso in Primary Sclerosing Cholangitis|Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis|Completed||Phase 2/Phase 3|150||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:20:39.735091|2018-06-01 05:20:39.735091
NCT00059189|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-19|||2008-03-03|2003-04-18|2003-04-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|April 2005|2005-04-30|April 2005||2005-04-30|||||Observational|||Brain Plasticity of Verbal Memory in the Blind|Cross-Modal Plasticity of Verbal Memory in the Blind|Completed|||85||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:39.848594|2018-06-01 05:20:39.848594
NCT00005839|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2015-06-03|2003-04-18|2003-04-21|Estimate|||||||2015-06-03|2015-06-08|Estimate|August 2000||2000-08-31|June 2015|2015-06-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor|A Phase I Study of Oxaliplatin in Combination With Capecitabine in Metastatic/Recurrent Solid Tumors|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:20:39.922568|2018-06-01 05:20:39.922568
NCT00004220|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2010-01-11|2003-04-18|2003-04-21|Estimate|||||||2010-01-11|2010-01-13|Estimate|October 1999||1999-10-31|January 2010|2010-01-31||||||||Interventional|||Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer|A Phase I Study of Oxaliplatin in Combination With Gemcitabine|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:20:39.981726|2018-06-01 05:20:39.981726
NCT00059137|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-18|||2008-03-03|2003-04-17|2003-04-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|March 2006|2006-03-31|March 2006||2006-03-31|||||Observational|||Breathing Cycle Biofeedback During Computed Tomography Procedures|Respiratory Cycle Biofeedback During CT Guided Procedures|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:40.041806|2018-06-01 05:20:40.041806
NCT00059124|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-17|||2013-07-10|2003-04-17|2003-04-18|Estimate|||||||2013-07-10|2013-07-12|Estimate|March 2003||2003-03-31|July 2013|2013-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||Aortic Calcium: Epidemiology and Progression -- Ancillary to MESA|Aortic Calcium: Epidemiology and Progression|Completed|||1980|Actual|University of California, San Diego|||||f||||f||||||||||2018-06-01 05:20:40.092032|2018-06-01 05:20:40.092032
NCT00059111|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-17|||2017-05-02|2003-04-17|2003-04-18|Estimate|||||||2017-05-02|2017-05-04|Actual|April 2003||2003-04-30|May 2017|2017-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Mechanisms Mediating Cardiovascular Disease in Children With Obstructive Sleep Apnea||Completed|||||Children's Hospital Medical Center, Cincinnati|||||f||||||||||||||2018-06-01 05:20:40.139963|2018-06-01 05:20:40.139963
NCT00004257|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-03-25|2003-04-17|2003-04-18|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 2000||2000-01-31|December 2007|2007-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Oxaliplatin and Fluorouracil Plus Radiation Therapy in Treating Patients With Primary Esophageal or Stomach Cancer|A Phase I Study of Oxaliplatin in Combination With Continuous Infusion 5-Fluorouracil and Radiation in Esophageal Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:40.240835|2018-06-01 05:20:40.240835
NCT00004243|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2010-01-11|2003-04-17|2003-04-18|Estimate|||||||2010-01-11|2010-01-13|Estimate|March 2000||2000-03-31|January 2010|2010-01-31||||||||Interventional|||Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor|A Phase I Study of Oxaliplatin in Combination With Docetaxel (Taxotere) Metastatic/Recurrent Solid Tumors|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:20:40.321332|2018-06-01 05:20:40.321332
NCT00003597|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2003-04-17|2003-04-18|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 1998||1998-11-30|July 2014|2014-07-31|September 2005|Actual|2005-09-30|October 2004|Actual|2004-10-31||Interventional|||Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors|A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors|Completed||Phase 1|16|Actual|Children's Oncology Group||2|||f||||||||||||||2018-06-01 05:20:40.408511|2018-06-01 05:20:40.408511
NCT00003163|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2003-04-17|2003-04-18|Estimate|||||||2014-01-03|2014-01-06|Estimate|September 1997||1997-09-30|October 2002|2002-10-31||||||||Interventional|||Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers|Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:40.530213|2018-06-01 05:20:40.530213
NCT00003162|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-11-14|2003-04-17|2003-04-18|Estimate|||||||2015-11-14|2015-11-17|Estimate|February 1998||1998-02-28|November 2015|2015-11-30||||July 2003|Actual|2003-07-31||Interventional|||Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer|Randomized Trial of Palliative Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life|Completed||Phase 3|949|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:20:40.644788|2018-06-01 05:20:40.644788
NCT00003129|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-06-06|2003-04-17|2003-04-18|Estimate|||||||2009-06-06|2009-06-09|Estimate|July 1998||1998-07-31|January 2002|2002-01-31||||November 2002|Actual|2002-11-30||Interventional|||Chemotherapy in Treating Patients With Early-Stage Bladder Cancer|Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin|Completed||Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:41.165029|2018-06-01 05:20:41.165029
NCT00003124|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2003-04-17|2003-04-18|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 1997||1997-05-31|December 2002|2002-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer|Phase II Trial of Maximal Androgen Deprivation Followed by Conformal External Beam Radiotherapy With Continued Androgen Deprivation for Clinically Localized Prostate Cancer|Completed||Phase 2|105|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:41.243435|2018-06-01 05:20:41.243435
NCT00003064|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2003-04-17|2003-04-18|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 1997||1997-01-31|December 2002|2002-12-31||||||||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer|Phase I-II Study of Tandem Cycles of High Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Support in Women With Persistent, Refractory or Recurrent Advanced (Stage III or IV), Epithelial Ovarian Cancer|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:41.311174|2018-06-01 05:20:41.311174
NCT00002972|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-04-16|2003-04-17|Estimate|||||||2012-06-29|2012-07-02|Estimate|January 1997||1997-01-31|June 2012|2012-06-30||||August 2002|Actual|2002-08-31||Interventional|||Paclitaxel in Treating Patients With Lung Cancer|Phase II Study on TAXOL in Bronchioalveolar Carcinoma|Completed||Phase 2|25|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:20:41.383696|2018-06-01 05:20:41.383696
NCT00059046|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-16|||2008-03-03|2003-04-15|2003-04-16|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Brain Imaging of Serotonin Transporters in the Brain|Kinetic Studies in Whole Body and Brain of [11C]DASB PET Imaging of Serotonin Transporters|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:41.451832|2018-06-01 05:20:41.451832
NCT00059033|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-16|||2018-03-30|2003-04-15|2003-04-16|Estimate|||||||2018-03-30|2018-04-02|Actual|April 10, 2003||2003-04-10|January 8, 2018|2018-01-08||||||||Observational|||Evaluation of Primary Chronic Autonomic Failure|Clinical Laboratory Evaluation of Primary Chronic Autonomic Failure|Recruiting|||435|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:41.51714|2018-06-01 05:20:41.51714
NCT00059020|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-16|||2008-03-03|2003-04-15|2003-04-16|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|November 2004|2004-11-30|November 2004||2004-11-30|||||Observational|||The Role of Gene Changes in Brain Tumor Formation and Growth|EGF Polymorphisms and Gliomagenesis|Completed|||344||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:41.584655|2018-06-01 05:20:41.584655
NCT00058994|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-15|||2012-11-28|2003-04-15|2003-04-16|Estimate|||||||2012-11-28|2012-11-29|Estimate|March 2003||2003-03-31|August 2008|2008-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD|An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-related Macular Degeneration|Completed||Phase 3|||Alcon Research|||||f||||f||||||||||2018-06-01 05:20:41.640043|2018-06-01 05:20:41.640043
NCT00058968|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-15|||2007-05-16|2003-04-15|2003-04-16|Estimate|||||||2007-05-16|2007-05-17|Estimate|October 2002||2002-10-31|May 2007|2007-05-31|March 2005|Actual|2005-03-31|||||Interventional|||A Study for the Treatment of Painful Diabetic Neuropathy|Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy|Completed||Phase 3|660||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:20:41.708701|2018-06-01 05:20:41.708701
NCT00058955|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-15|||2008-09-09|2003-04-15|2003-04-16|Estimate|||||||2008-09-09|2008-09-10|Estimate|August 2003||2003-08-31|September 2008|2008-09-30|March 2005||2005-03-31|||||Interventional|||Physiological, Behavioral and Subjective Effects of Drugs (GHB)|Physiological, Behavioral and Subjective Effects of Drugs (GHB)|Completed||Phase 1|20|Anticipated|Orphan Medical||4|||f||||f||||||||||2018-06-01 05:20:41.779242|2018-06-01 05:20:41.779242
NCT00058942|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-15|||2009-12-09|2003-04-15|2003-04-16|Estimate|||||||2009-12-09|2009-12-11|Estimate|January 2000||2000-01-31|November 2006|2006-11-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Trial of Tap Water Treatment in the Elderly|A Randomized Trial of Tap Water Treatment in the Elderly|Completed||N/A|810||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:20:41.849829|2018-06-01 05:20:41.849829
NCT00058929|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-14|||2013-03-05|2003-04-15|2003-04-16|Estimate|||||||2013-03-05|2013-03-07|Estimate|October 2002||2002-10-31|March 2013|2013-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension|A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutaneous Remodulin® Therapy After Transition From Flolan® in Patients With Pulmonary Arterial Hypertension|Completed||Phase 4|39||United Therapeutics|||||f||||f||||||||||2018-06-01 05:20:41.904012|2018-06-01 05:20:41.904012
NCT00058903|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-14|||2010-01-12|2003-04-15|2003-04-16|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2003||2003-04-30|January 2010|2010-01-31|March 2005||2005-03-31|||||Interventional|||Treatment of Cholestatic Pruritus With Sertraline|Treatment of Cholestatic Pruritus With Sertraline|Completed||Phase 2|40|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 05:20:41.955378|2018-06-01 05:20:41.955378
NCT00058890|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-14|||2017-10-12|2003-04-15|2003-04-16|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2000|Actual|2000-11-30|October 2017|2017-10-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Gabapentin to Treat Itch in Patients With Liver Disease|Study of Gabapentin for the Pruritus of Cholestasis|Completed||Phase 3|15|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f|||||t|f||||||||2018-06-01 05:20:42.00014|2018-06-01 05:20:42.00014
NCT00002945|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-04-12|2003-04-15|2003-04-16|Estimate|||||||2012-04-12|2012-04-13|Estimate|December 1996||1996-12-31|April 2012|2012-04-30|August 2011|Actual|2011-08-31|August 2001|Actual|2001-08-31||Interventional|||High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia|High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia|Completed||Phase 3|61|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:20:42.073859|2018-06-01 05:20:42.073859
NCT00002934|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-06|2003-04-15|2003-04-16|Estimate|||||||2015-10-06|2015-10-08|Estimate|April 1997||1997-04-30|October 2015|2015-10-31|October 2012|Actual|2012-10-31|December 2007|Actual|2007-12-31||Interventional|||Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ|Local Excision Alone for Selected Patients With DCIS of the Breast|Terminated||Phase 2|711|Actual|Eastern Cooperative Oncology Group||1||"This study was terminated when the accrual goal for the low/intermediate grade stratum was~   reached. The high grade stratum was closed due to slow accrual."|f||||f||||||||||2018-06-01 05:20:42.150879|2018-06-01 05:20:42.150879
NCT00002835|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2003-04-15|2003-04-16|Estimate|||||||2012-07-27|2012-07-30|Estimate|July 1995||1995-07-31|July 2012|2012-07-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Combination Chemotherapy in Treating Patients With Lymphoma|A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma|Completed||Phase 3|116|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:20:42.333371|2018-06-01 05:20:42.333371
NCT00002822|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-04-15|2003-04-16|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 1996||1996-03-31|December 2000|2000-12-31|November 2005|Actual|2005-11-30|||||Interventional|||Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer|RANDOMISED CLINICAL TRIAL OF IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE WITH MID-CYCLE VINCRISTINE (VICE) VERSUS STANDARD PRACTICE CHEMOTHERAPY IN PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER (SCLC) AND GOOD PERFORMANCE STATUS|Completed||Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:42.485344|2018-06-01 05:20:42.485344
NCT00058864|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-14|||2009-02-26|2003-04-14|2003-04-15|Estimate|||||||2009-02-26|2009-02-27|Estimate|September 2001||2001-09-30|February 2009|2009-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||The HIP Impact Protection Program (HIP PRO)|Trochanteric Padding to Prevent Hip Fractures|Completed||N/A|546||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:20:42.574291|2018-06-01 05:20:42.574291
NCT00058851|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-14|||2009-08-17|2003-04-14|2003-04-15|Estimate|||||||2009-08-17|2009-08-19|Estimate|January 2003||2003-01-31|August 2009|2009-08-31|November 2007|Actual|2007-11-30|||||Interventional|||Massage Therapy for Breast Cancer Treatment-Related Swelling of the Arms|Massage Therapy for Breast Cancer-Related Lymphedema|Completed||Phase 2|88|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:20:42.640456|2018-06-01 05:20:42.640456
NCT00058838|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-14|||2006-06-06|2003-04-14|2003-04-15|Estimate|||||||2006-06-06|2006-06-07|Estimate|April 2003||2003-04-30|June 2006|2006-06-30|September 2004||2004-09-30|||||Interventional|||Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease|A Phase III, Double-Blind, Placebo-Controlled, Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinson's Disease.|Completed||Phase 3|854||Pfizer|||||||||||||||||||2018-06-01 05:20:42.734636|2018-06-01 05:20:42.734636
NCT00058825|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|2015-09-23||2016-09-20|2003-04-14|2003-04-15|Estimate|2015-09-23|2015-10-22|Estimate||||2016-09-20|2016-11-07|Estimate|August 2000||2000-08-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|HIMSUM||Stem Cell Transplant for Hematologic Diseases|Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H|Terminated||Phase 1/Phase 2|27|Actual|Baylor College of Medicine||1||Slow accrual due to practice changes meant study would take too long to finish|f||||t||||||||||2018-06-01 05:20:43.004827|2018-06-01 05:20:43.004827
NCT00058812|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2015-01-27|2003-04-14|2003-04-15|Estimate|||||||2015-01-27|2015-01-29|Estimate|May 1993||1993-05-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ETNA||Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts|Administration of EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts|Completed||Phase 1|69|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 05:20:44.178921|2018-06-01 05:20:44.178921
NCT00058799|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2010-07-27|2003-04-14|2003-04-15|Estimate|||||||2010-07-27|2010-07-29|Estimate|June 1999||1999-06-30|July 2010|2010-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine|Treatment of High Risk Acute Leukemia With CD40 Ligand and IL-2 Gene Modified Autologous Skin Fibroblasts and Tumor Cells|Completed||Phase 1|11|Actual|Baylor College of Medicine|||||t||||f||||||||||2018-06-01 05:20:44.277313|2018-06-01 05:20:44.277313
NCT00058786|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2012-05-21|2003-04-14|2003-04-15|Estimate|||||||2012-05-21|2012-05-23|Estimate|December 2002||2002-12-31|May 2012|2012-05-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|CLIMAT||Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells|Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells|Completed||Phase 1|9|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 05:20:44.368751|2018-06-01 05:20:44.368751
NCT00058773|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2012-11-05|2003-04-14|2003-04-15|Estimate|||||||2012-11-05|2012-11-06|Estimate|January 1996||1996-01-31|November 2012|2012-11-30|August 2006|Actual|2006-08-31|April 2002|Actual|2002-04-30||Interventional|ANGELA||Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease|Administration of Autologous Neomycin Resistant Gene Marked EBV Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving Autologous Bone Marrow Transplant for Relapsed EBV-Positive Lymphoma.|Terminated||Phase 1|5|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-06-01 05:20:44.447598|2018-06-01 05:20:44.447598
NCT00058760|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2005-06-23|2003-04-14|2003-04-15|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2001||2001-02-28|March 2003|2003-03-31|January 2006||2006-01-31|||||Interventional|||Delaying Sexual Activity in African American Adolescent Girls|A Randomized Controlled Trial of the NIA Intervention|Unknown status|Recruiting|Phase 1|240||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:20:44.562516|2018-06-01 05:20:44.562516
NCT00058747|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2012-09-06|2003-04-14|2003-04-15|Estimate|||||||2012-09-06|2012-09-07|Estimate|March 2003||2003-03-31|September 2012|2012-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™|Phase II Exploratory Study Of AG-858 Plus Gleevec™ In Patients With Chronic Myelogenous Leukemia (CML) In Chronic Phase Who Are Cytogenetically Positive After Treatment With Gleevec™|Terminated||Phase 2|40||Agenus Inc.||||Business decision of the sponsor|||||||||||||||2018-06-01 05:20:44.63847|2018-06-01 05:20:44.63847
NCT00058734|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2007-08-23|2003-04-11|2003-04-14|Estimate|||||||2007-08-23|2007-08-27|Estimate|November 2000||2000-11-30|August 2007|2007-08-31||||||||Interventional|||Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients|Immune Responses to Antigen-Bearing Dendritic Cells in HIV-Infected Individuals|Completed||Phase 1|5|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:20:44.771518|2018-06-01 05:20:44.771518
NCT00058721|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2008-03-03|2003-04-10|2003-04-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease|SPECT Evaluation of Nicotinic Cholinergic Receptors in Parkinson's Disease|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:44.853919|2018-06-01 05:20:44.853919
NCT00058695|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2018-02-13|2003-04-10|2003-04-11|Estimate|||||||2018-02-13|2018-02-14|Actual|April 4, 2003||2003-04-04|October 21, 2015|2015-10-21|October 21, 2015||2015-10-21|||||Observational|||Genetic Factors in Age-Related Macular Degeneration|Evaluation of Single Nucleotide Polymorphism (SNP) in Patients With and Subjects Without Age-Related Macular Degeneration (AMD)|Terminated|||477|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:44.908434|2018-06-01 05:20:44.908434
NCT00058682|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-11|||2008-03-03|2003-04-10|2003-04-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|January 2005|2005-01-31|January 2005||2005-01-31|||||Interventional|||Anidulafungin Versus Fluconazole in the Treatment of Candidemia|A Phase III, Double Blind, Randomized, Multi-Center Study of the Safety and Efficacy of Anidulafungin VS. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications|Completed||Phase 3|248||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:45.03257|2018-06-01 05:20:45.03257
NCT00058669|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-10|||2016-01-04|2003-04-10|2003-04-11|Estimate|||||||2016-01-04|2016-01-05|Estimate|March 2003||2003-03-31|January 2016|2016-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|||CVD Risk Factors and Sexual Identity in Women|CVD Risk Factors and Sexual Identity in Women|Completed|||1174|Actual|University of Pittsburgh|||||f||||f||||||Samples Without DNA|"~     urine, plasma,~   "|||2018-06-01 05:20:45.112515|2018-06-01 05:20:45.112515
NCT00002777|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-04-10|2003-04-11|Estimate|||||||2012-06-29|2012-07-02|Estimate|May 1996||1996-05-31|June 2012|2012-06-30||||December 2002|Actual|2002-12-31||Interventional|||Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer|RANDOMIZED PHASE II STUDY IN FIRST LINE HORMONAL TREATMENT FOR METASTATIC BREAST CANCER WITH EXEMESTANE OR TAMOXIFEN IN POSTMENOPAUSAL PATIENTS|Completed||Phase 3|342|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:20:45.169873|2018-06-01 05:20:45.169873
NCT00002701|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-04-10|2003-04-11|Estimate|||||||2013-09-19|2013-09-20|Estimate|October 1995||1995-10-31|November 2006|2006-11-30||||||||Interventional|||Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia|INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LEUKEMIA|Unknown status|Active, not recruiting|Phase 3|750|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:45.296338|2018-06-01 05:20:45.296338
NCT00002695|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-05-18|2003-04-10|2003-04-11|Estimate|||||||2017-05-18|2017-05-19|Actual|January 17, 1996|Actual|1996-01-17|May 2017|2017-05-31|May 27, 2011|Actual|2011-05-27|October 18, 2002|Actual|2002-10-18||Observational|||Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck|CLINICAL EFFICACY OF MOLECULAR ANALYSIS OF SURGICAL MARGINS AND REGIONAL LYMPH NODES IN MANAGEMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA|Completed|||530|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:20:45.587344|2018-06-01 05:20:45.587344
NCT00002693|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-08-02|2003-04-10|2003-04-11|Estimate|||||||2011-08-02|2011-08-03|Estimate|October 1995||1995-10-31|August 2011|2011-08-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Recurrent Acute Leukemia|PHASE I STUDY OF CONTINUOUS INFUSION CARBOPLATIN AND TOPOTECAN IN THE TREATMENT OF RELAPSED ACUTE LEUKEMIA AND BLAST CRISIS CHRONIC MYELOGENOUS LEUKEMIA|Completed||Phase 1|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:20:45.704545|2018-06-01 05:20:45.704545
NCT00002669|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-06-29|2003-04-10|2003-04-11|Estimate|||||||2012-06-29|2012-07-02|Estimate|June 1995||1995-06-30|June 2012|2012-06-30||||August 2002|Actual|2002-08-31||Interventional|||Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma|TREATMENT OF METASTATIC MELANOMA WITH DTIC, CDDP AND IFN ALPHA WITH OR WITHOUT IL-2: A RANDOMIZED PHASE III TRIAL|Completed||Phase 2|90|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:20:45.850157|2018-06-01 05:20:45.850157
NCT00058656|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-08|||2006-11-20|2003-04-09|2003-04-10|Estimate|||||||2006-11-20|2006-11-22|Estimate|March 2003||2003-03-31|January 2005|2005-01-31||||||||Interventional|||Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients|A Phase I/II Study of Xcellerated T Cells(tm) in Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 1/Phase 2|18||Xcyte Therapies|||||||||||||||||||2018-06-01 05:20:45.963788|2018-06-01 05:20:45.963788
NCT00002658|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-04-09|2003-04-10|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1994||1994-01-31|October 2002|2002-10-31||||||||Interventional|||Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia|ACUTE MYELOID LEUKAEMIA TRIAL 12|Unknown status|Active, not recruiting|Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:46.051231|2018-06-01 05:20:46.051231
NCT00002653|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-04-09|2003-04-10|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 1993||1993-09-30|October 2002|2002-10-31||||||||Interventional|||Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma|VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE|Unknown status|Active, not recruiting|Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:46.141292|2018-06-01 05:20:46.141292
NCT00002575|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-15|2003-04-09|2003-04-10|Estimate|||||||2016-07-15|2016-07-18|Estimate|August 1994||1994-08-31|July 2016|2016-07-31|November 2009|Actual|2009-11-30|May 2004|Actual|2004-05-31||Interventional|||Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer|A PHASE III PROSPECTIVE RANDOMIZED TRIAL COMPARING LAPAROSCOPIC-ASSISTED COLECTOMY VERSUS OPEN COLECTOMY FOR COLON CANCER|Completed||Phase 3|810|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:20:46.253813|2018-06-01 05:20:46.253813
NCT00002550|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-11-14|2003-04-09|2003-04-10|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 1994||1994-03-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|June 2004|Actual|2004-06-30||Interventional|||Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer|Completed||Phase 3|429|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:20:46.552518|2018-06-01 05:20:46.552518
NCT00002539|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2003-04-09|2003-04-10|Estimate|||||||2012-09-20|2012-09-24|Estimate|August 1993||1993-08-31|September 2012|2012-09-30||||October 2002|Actual|2002-10-31||Interventional|||Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma|A RANDOMISED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT GRANULOCYTE COLONY-STIMULATING FACTOR IN OPERABLE OSTEOSARCOMA|Completed||Phase 3|214|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:20:46.647553|2018-06-01 05:20:46.647553
NCT00058617|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-08|||2017-02-13|2003-04-08|2003-04-09|Estimate|||||||2017-02-13|2017-02-15|Actual|January 1996||1996-01-31|February 2017|2017-02-28|July 2014|Actual|2014-07-31|August 2011|Actual|2011-08-31||Interventional|||Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL|Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma|Completed||Phase 1|13|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-06-01 05:20:46.729515|2018-06-01 05:20:46.729515
NCT00058604|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-08|||2009-04-09|2003-04-08|2003-04-09|Estimate|||||||2009-04-09|2009-04-10|Estimate|January 2001||2001-01-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|EUCLID||Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).|Autologous EBV Specific CTLs for Prophylaxis and Therapy of EBV Lymphoma Post Solid Organ Transplant|Completed||Phase 1|14|Anticipated|Baylor College of Medicine|||||t||||t||||||||||2018-06-01 05:20:46.793917|2018-06-01 05:20:46.793917
NCT00058591|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-08|||2009-04-09|2003-04-08|2003-04-09|Estimate|||||||2009-04-09|2009-04-10|Estimate|January 2000||2000-01-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|SCAEBV||Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)|Autologous EBV Specific CTLs for Therapy of Severe Chronic EBV Infection|Completed||Phase 1|18|Anticipated|Baylor College of Medicine|||||t||||t||||||||||2018-06-01 05:20:46.849378|2018-06-01 05:20:46.849378
NCT00058578|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-08|||2007-04-09|2003-04-08|2003-04-09|Estimate|||||||2007-04-09|2007-04-11|Estimate|June 1999||1999-06-30|April 2007|2007-04-30|June 2004||2004-06-30|||||Interventional|||Stem Cell Transplant to Treat Patients With Systemic Sclerosis|Autologous T-Cell Depleted Peripheral Blood Stem Cell Transplantation for the Treatment of Selected Patients With Systemic Sclerosis|Completed||Phase 1|24||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:20:46.931487|2018-06-01 05:20:46.931487
NCT00058552|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-08|2015-06-02||2017-01-25|2003-04-08|2003-04-09|Estimate|2015-06-02|2015-06-23|Estimate||||2017-01-25|2017-03-08|Actual|May 2003|Actual|2003-05-31|January 2017|2017-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional||All the participants who received at least 1 dose of study drug were included in the analysis.|A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer|A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer|Completed||Phase 2|129|Actual|Genentech, Inc.|||||||||||||||||||2018-06-01 05:20:47.001537|2018-06-01 05:20:47.001537
NCT00058539|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-08|2015-06-02||2015-06-02|2003-04-08|2003-04-09|Estimate|2015-06-02|2015-06-23|Estimate||||2015-06-02|2015-06-23|Estimate|April 2003||2003-04-30|June 2015|2015-06-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional||All the participants who received at least 1 dose of study drug were included in the analysis.|Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer|A Phase II, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Omnitarg (Pertuzumab) in Subjects With Castration-Resistant Prostate Cancer|Completed||Phase 2|42|Actual|Genentech, Inc.|||||||||||||||||||2018-06-01 05:20:47.357203|2018-06-01 05:20:47.357203
NCT00058526|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2017-05-12|2003-04-08|2003-04-09|Estimate|||||||2017-05-12|2017-05-15|Actual|March 20, 2003|Actual|2003-03-20|May 2017|2017-05-31|September 6, 2006|Actual|2006-09-06|September 6, 2006|Actual|2006-09-06||Interventional|||A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer|A Multicenter Phase I Open-label Dose-escalation Vaccine Trial of dHER2 Protein With AS15 Adjuvant in HER2-overexpressing Patients With High-risk Breast Cancer|Completed||Phase 1|61|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-06-01 05:20:48.467071|2018-06-01 05:20:48.467071
NCT00058487|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-07-17|2003-04-08|2003-04-09|Estimate|||||||2013-07-17|2013-07-18|Estimate|December 2001||2001-12-31|October 2006|2006-10-31|January 2007|Actual|2007-01-31|||||Interventional|||Epirubicin and Thalidomide in Treating Patients With Liver Cancer|A Phase II Study Of Epirubicin And Thalidomide In Unresectable Or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|12|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:48.555487|2018-06-01 05:20:48.555487
NCT00058474|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2016-03-22|2003-04-08|2003-04-09|Estimate|||||||2016-03-22|2016-03-23|Estimate|July 2004||2004-07-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|August 2013|Actual|2013-08-31||Interventional|||Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer|A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum|Unknown status|Active, not recruiting|Phase 3|1608|Actual|NSABP Foundation Inc||4|||f||||t||||||||||2018-06-01 05:20:48.617936|2018-06-01 05:20:48.617936
NCT00058461|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-10-07|2003-04-08|2003-04-09|Estimate|||||||2013-10-07|2013-10-08|Estimate|November 2003||2003-11-30|October 2013|2013-10-31||||March 2007|Actual|2007-03-31||Interventional|||Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia|A Phase II Study of Rituximab (IND #7028) and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy in Children With Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia|Terminated||Phase 2|82|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:48.700265|2018-06-01 05:20:48.700265
NCT00058448|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-04-16|2003-04-08|2003-04-09|Estimate|||||||2013-04-16|2013-04-17|Estimate|October 2004||2004-10-31|April 2013|2013-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)|Phase II Study Of Weekly Docetaxel In Patients With Advanced Epidermoid Carcinoma Of The Penis|Terminated||Phase 2|1|Actual|Southwest Oncology Group||||Study terminated due to poor patient recruitment.|f||||f||||||||||2018-06-01 05:20:48.786058|2018-06-01 05:20:48.786058
NCT00058435|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-06-04|2003-04-08|2003-04-09|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2002||2002-12-31|June 2013|2013-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|Phase I Trial of the Monoclonal Anti-Idiotype Antibody ACA125 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:20:48.993783|2018-06-01 05:20:48.993783
NCT00058422|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2018-03-01|2003-04-08|2003-04-09|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2003|Actual|2003-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma|A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 2|65|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:20:49.064264|2018-06-01 05:20:49.064264
NCT00058396|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-05-29|2003-04-08|2003-04-09|Estimate|||||||2013-05-29|2013-05-30|Estimate|October 2002||2002-10-31|December 2009|2009-12-31||||October 2004|Actual|2004-10-31||Interventional|||Monoclonal Antibody in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Phase I Study Of IDEC-152 (Anti-CD23 Monoclonal Antibody) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:49.15654|2018-06-01 05:20:49.15654
NCT00058370|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2018-02-23|2003-04-08|2003-04-09|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2003|Actual|2003-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma|A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma|Active, not recruiting||N/A|6|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:20:49.219826|2018-06-01 05:20:49.219826
NCT00058357|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2016-06-27|2003-04-08|2003-04-09|Estimate|||||||2016-06-27|2016-06-28|Estimate|May 2004||2004-05-31|June 2016|2016-06-30|July 2007|Actual|2007-07-31|July 2006|Actual|2006-07-31||Interventional|||Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery|The Efficacy Of Lidocaine Patch In The Management Of Postsurgical Neuropathic Pain In Patients With Cancer: A Phase III Double-Blind, Crossover Study|Completed||Phase 3|30|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:20:49.344081|2018-06-01 05:20:49.344081
NCT00058331|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2016-07-15|2003-04-08|2003-04-09|Estimate|||||||2016-07-15|2016-07-18|Estimate|June 2003||2003-06-30|July 2016|2016-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Epoetin Alfa in Treating Anemia in Patients With Solid Tumors|A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer|Completed||Phase 3|365|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:20:49.679921|2018-06-01 05:20:49.679921
NCT00058318|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2012-10-31|2003-04-08|2003-04-09|Estimate|||||||2012-10-31|2012-11-02|Estimate|December 2004||2004-12-31|October 2012|2012-10-31|November 2008|Actual|2008-11-30|May 2007|Actual|2007-05-31||Interventional|||S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer|A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients With Advanced Renal Cell Cancer|Completed||Phase 2|43|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:20:49.785202|2018-06-01 05:20:49.785202
NCT00058305|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-01-09|2003-04-08|2003-04-09|Estimate|||||||2013-01-09|2013-01-10|Estimate|March 2003||2003-03-31|January 2013|2013-01-31||||December 2007|Actual|2007-12-31||Interventional|||Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation|A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant|Completed||Phase 2|28|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:49.85447|2018-06-01 05:20:49.85447
NCT00058292|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2012-05-31|2003-04-08|2003-04-09|Estimate|||||||2012-05-31|2012-06-01|Estimate|April 2000||2000-04-30|May 2012|2012-05-31|March 2009|Actual|2009-03-31|June 2006|Actual|2006-06-30||Interventional|||Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 1|44|Actual|Northwestern University||1|||f||||||||||||||2018-06-01 05:20:49.943972|2018-06-01 05:20:49.943972
NCT00058279|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-06-18|2003-04-08|2003-04-09|Estimate|||||||2013-06-18|2013-06-20|Estimate|February 2003||2003-02-28|August 2006|2006-08-31|August 2006|Actual|2006-08-31|||||Interventional|||Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma|MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:20:50.050848|2018-06-01 05:20:50.050848
NCT00058266|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07||2011-05-19|2012-07-10|2003-04-08|2003-04-09|Estimate||||2011-05-19|2011-05-23|Estimate|2012-07-10|2012-07-19|Estimate|December 2002||2002-12-31|July 2012|2012-07-31|September 2009|Actual|2009-09-30|November 2006|Actual|2006-11-30||Interventional|||Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy|A Phase II Study Of Genistein In Patients With Localized Prostate Cancer (Molecular Correlates of Soy In Humans)|Terminated||Phase 2|36|Actual|Northwestern University||2||Data Monitoring Committee cited poor accrual.|f||||t||||||||||2018-06-01 05:20:50.118745|2018-06-01 05:20:50.118745
NCT00058253|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2014-06-16|2003-04-08|2003-04-09|Estimate|||||||2014-06-16|2014-06-17|Estimate|February 2003||2003-02-28|December 2012|2012-12-31|March 2010|Actual|2010-03-31|January 2008|Actual|2008-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Study of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC# 330507) in Combination With Docetaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|80|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:20:50.208541|2018-06-01 05:20:50.208541
NCT00058240|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2015-04-07||2017-06-02|2003-04-08|2003-04-09|Estimate|2017-05-02|2017-06-02|Actual||||2017-06-02|2017-07-02|Actual|April 2003|Actual|2003-04-30|June 2017|2017-06-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||52 unique patients due to 6 patients being|Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma|A Dose-Escalation Study of Flavopiridol (NSC 649890) Administered as a 30 Minute Loading Dose Followed by a 4-Hour Infusion in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Completed||Phase 1/Phase 2|52|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:50.304499|2018-06-01 05:20:50.304499
NCT00058227|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-06-03|2003-04-08|2003-04-09|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2003||2003-04-30|June 2013|2013-06-30||||February 2009|Actual|2009-02-28||Interventional|||Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma|A Phase I Study of Flavopiridol, Fludarabine and Rituximab in Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma|Completed||Phase 1|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:50.589917|2018-06-01 05:20:50.589917
NCT00058214|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2015-02-09||2015-02-09|2003-04-08|2003-04-09|Estimate|2015-02-09|2015-02-23|Estimate||||2015-02-09|2015-02-23|Estimate|March 2003||2003-03-31|February 2013|2013-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Perifosine in Treating Patients With Recurrent Prostate Cancer|A Phase II Trial of Perifosine (IND 58,156; NSC# 639966) in Biochemically Recurrent, Hormone Sensitive Prostate Cancer|Terminated||Phase 2|25|Actual|National Cancer Institute (NCI)|Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.|1||Did not meet interim stopping criteria for continuation to the second stage.|f||||||||||||||2018-06-01 05:20:50.682091|2018-06-01 05:20:50.682091
NCT00058201|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-12-17|2003-04-08|2003-04-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 2001||2001-07-31|May 2008|2008-05-31|September 2010|Actual|2010-09-30|April 2008|Actual|2008-04-30||Interventional|||Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer|European Study Group For Pancreatic Cancer - Trial 3|Completed||Phase 3|1030|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:20:50.871491|2018-06-01 05:20:50.871491
NCT00058188|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2018-04-11|2003-04-08|2003-04-09|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2003||2003-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation|A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation|Active, not recruiting||Phase 3|70|Anticipated|Northwestern University||2|||f||||t||||||||||2018-06-01 05:20:50.973426|2018-06-01 05:20:50.973426
NCT00058149|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2011-09-20|2003-04-08|2003-04-09|Estimate|||||||2011-09-20|2011-09-21|Estimate|March 2003||2003-03-31|April 2004|2004-04-30||||July 2006|Actual|2006-07-31||Interventional|||Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:51.150072|2018-06-01 05:20:51.150072
NCT00058123|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2014-08-11|2003-04-08|2003-04-09|Estimate|||||||2014-08-11|2014-08-12|Estimate|March 2003||2003-03-31|August 2014|2014-08-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma|A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma|Completed||Phase 2|46|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:20:51.298074|2018-06-01 05:20:51.298074
NCT00058097|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-04-08|2003-04-08|2003-04-09|Estimate|||||||2013-04-08|2013-04-09|Estimate|August 2003||2003-08-31|April 2013|2013-04-30||||January 2007|Actual|2007-01-31||Interventional|||Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study of R115777 for the Treatment of Adults With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|54|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:51.39619|2018-06-01 05:20:51.39619
NCT00058084|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2017-02-21|2003-04-08|2003-04-09|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2003||2003-03-31|February 2017|2017-02-28||||October 1, 2007|Actual|2007-10-01||Interventional|||Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer|A Randomized Phase II Study Of BMS 247550 Or Mitoxantrone And Prednisone In Patients With Taxane Resistant Hormone Refractory Prostate Cancer|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:20:51.472008|2018-06-01 05:20:51.472008
NCT00058071|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-07-08|2003-04-08|2003-04-09|Estimate|||||||2013-07-08|2013-07-09|Estimate|March 2003||2003-03-31|July 2007|2007-07-31||||December 2007|Actual|2007-12-31||Interventional|||Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer|A Randomized Phase III Trial of Amifostine vs. No Treatment for Platinum Induced Peripheral Neuropathy|Completed||Phase 3|100|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:20:51.567497|2018-06-01 05:20:51.567497
NCT00058058|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2012-10-23|2003-04-08|2003-04-09|Estimate|||||||2012-10-23|2012-10-24|Estimate|February 2001||2001-02-28|April 2004|2004-04-30||||March 2007|Actual|2007-03-31||Interventional|||Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer|MRI Evaluation Of The Contralateral Breast In Women With Recent Diagnosis Of Breast Cancer|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:51.702245|2018-06-01 05:20:51.702245
NCT00057161|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|June 2004|Actual|2004-06-30|||||Interventional|||Homelessness Prevention: Psychiatric Care With Representative Payeeship|Homelessness Prevention: Psychiatric Care With Representative Payeeship|Completed||N/A|240|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:07.647481|2018-06-01 05:21:07.647481
NCT00058045|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-01-30|2003-04-08|2003-04-09|Estimate|||||||2013-01-30|2013-01-31|Estimate|August 2002||2002-08-31|January 2013|2013-01-31||||November 2003|Actual|2003-11-30||Interventional|||Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer|A Phase I Study Of Low-Dose Subcutaneous Interleukin 2 (IL-2) And Stem Cell Factor (r-metHuSCF) For Patients With AIDS And AIDS-Associated Malignancy|Completed||Phase 1|1|Actual|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:20:51.794764|2018-06-01 05:20:51.794764
NCT00058032|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-12-03|2003-04-08|2003-04-09|Estimate|||||||2013-12-03|2013-12-04|Estimate|February 2003||2003-02-28|September 2005|2005-09-30|March 2009|Actual|2009-03-31|||||Interventional|||CA 125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women|United Kingdom Collaborative Trial Of Ovarian Cancer Screening|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:51.880101|2018-06-01 05:20:51.880101
NCT00058019|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2013-08-19||2014-05-07|2003-04-08|2003-04-09|Estimate|2014-01-10|2014-02-27|Estimate||||2014-05-07|2014-05-23|Estimate|February 2003||2003-02-28|October 2011|2011-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas|Completed||Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:20:51.961111|2018-06-01 05:20:51.961111
NCT00058006|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2012-06-07|2003-04-08|2003-04-09|Estimate|||||||2012-06-07|2012-06-11|Estimate|September 2002||2002-09-30|June 2012|2012-06-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer|Pilot Randomized Trial Of Adjuvant Celecoxib In Patients With Early Stage Head And Neck And Non-Small Cell Lung Cancers|Completed||Phase 2|||Northwestern University|||||f||||||||||||||2018-06-01 05:20:52.336586|2018-06-01 05:20:52.336586
NCT00057993|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07||2011-02-16|2012-06-07|2003-04-08|2003-04-09|Estimate||||2011-02-16|2011-02-23|Estimate|2012-06-07|2012-06-11|Estimate|July 2002||2002-07-31|June 2012|2012-06-30|August 2004||2004-08-31|August 2004||2004-08-31||Interventional|||Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer|Phase II Study Of Herceptin And Exemestane For Treatment Of Postmenopausal Women With Metastatic Hormone-Responsive, HER2/NEU Positive Breast Cancer|Withdrawn||Phase 2|0|Actual|Northwestern University||||"Unable to accrue subjects to the study after 2 years - closed per request by Data Monitoring~   Committee."|f||||t||||||||||2018-06-01 05:20:52.406501|2018-06-01 05:20:52.406501
NCT00057980|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07||2011-02-18|2012-06-07|2003-04-08|2003-04-09|Estimate||||2011-02-18|2011-02-25|Estimate|2012-06-07|2012-06-11|Estimate|October 2002||2002-10-31|June 2012|2012-06-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma|Phase I/II Study of Epirubicin and Celecoxib for Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|8|Actual|Northwestern University|||||f||||t||||||||||2018-06-01 05:20:52.460969|2018-06-01 05:20:52.460969
NCT00057967|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2017-09-06|2003-04-08|2003-04-09|Estimate|||||||2017-09-06|2017-09-11|Actual|July 2000||2000-07-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 18, 2019|Anticipated|2019-08-18||Interventional|||Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome|Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome|Active, not recruiting||Phase 2|37|Anticipated|Northwestern University||1|||f||||t||||||||||2018-06-01 05:20:52.525349|2018-06-01 05:20:52.525349
NCT00057954|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2013-01-07||2013-02-11|2003-04-08|2003-04-09|Estimate|2013-01-07|2013-02-08|Estimate||||2013-02-11|2013-02-13|Estimate|June 2005||2005-06-30|February 2013|2013-02-28|May 2011|Actual|2011-05-31|April 2008|Actual|2008-04-30||Interventional|||Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma|A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplantation for the Treatment of Relapsed Non-Hodgkin and Hodgkin Lymphoma|Terminated||Phase 2|6|Actual|Eastern Cooperative Oncology Group||1||Slow accrual|f||||f||||||||||2018-06-01 05:20:52.596715|2018-06-01 05:20:52.596715
NCT00057941|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2011-04-11||2014-04-22|2003-04-08|2003-04-09|Estimate|2011-04-11|2011-05-06|Estimate||||2014-04-22|2014-05-12|Estimate|September 2003||2003-09-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer|A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer|Completed||Phase 2|148|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:20:52.94538|2018-06-01 05:20:52.94538
NCT00057928|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2012-06-11|2003-04-08|2003-04-09|Estimate|||||||2012-06-11|2012-06-13|Estimate|April 2003||2003-04-30|June 2012|2012-06-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer|Phase III Randomized Trial of Cisplatin/Paclitaxel Versus Cisplatin/Gemcitabine in Recurrent, Persistent or Metastatic Carcinoma of the Cervix|Withdrawn||Phase 3|0|Actual|Southwest Oncology Group||||lack of accrual|f||||t||||||||||2018-06-01 05:20:53.435977|2018-06-01 05:20:53.435977
NCT00057915|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2014-09-04|2003-04-08|2003-04-09|Estimate|||||||2014-09-04|2014-09-08|Estimate|September 2003||2003-09-30|September 2014|2014-09-30|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer|A Phase I Study of Active Immunotherapy With CAP-1 (6D) and CMVpp65 Peptide-Pulsed, Autologous Dendritic Cells Produced in the Aastromreplicell Cell Production System in Patients With Stage IV CEA Expressing Malignancies|Completed||Phase 1|4|Actual|Duke University||1|||f||||f||||||||||2018-06-01 05:20:53.638714|2018-06-01 05:20:53.638714
NCT00057889|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2012-03-14|2003-04-08|2003-04-09|Estimate|||||||2012-03-14|2012-03-15|Estimate|February 2003||2003-02-28|March 2012|2012-03-31|February 2008|Actual|2008-02-29|October 2007|Actual|2007-10-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer|A Phase II Open-Label Study of Single Agent MDX-010 for the Treatment of IL-2 Refractory or IL-2 Ineligible Patients With Stage IV Renal Cancer|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:20:53.699899|2018-06-01 05:20:53.699899
NCT00057876|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2011-02-28||2013-02-11|2003-04-08|2003-04-09|Estimate|2011-02-28|2011-03-25|Estimate||||2013-02-11|2013-02-13|Estimate|April 2003||2003-04-30|February 2013|2013-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer|A Randomized Phase III Study Of Gemcitabine In Combination With Radiation Therapy Versus Gemcitabine Alone In Patients With Localized, Unresectable Pancreatic Cancer|Completed||Phase 3|74|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 05:20:53.82484|2018-06-01 05:20:53.82484
NCT00057148|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2003||2003-02-28|March 2006|2006-03-31|June 2005|Actual|2005-06-30|||||Interventional|||Massage After Surgery To Help Treat Post-Operative Pain|Acute Post-Operative Pain Management Using Massage As Adjuvant Therapy|Completed||N/A|300|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:07.710734|2018-06-01 05:21:07.710734
NCT00057863|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2015-10-16||2015-10-16|2003-04-08|2003-04-09|Estimate|2015-10-16|2015-11-17|Estimate||||2015-10-16|2015-11-17|Estimate|January 2003||2003-01-31|December 2012|2012-12-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer|A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:54.649956|2018-06-01 05:20:54.649956
NCT00057850|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-02-08|2003-04-08|2003-04-09|Estimate|||||||2013-02-08|2013-02-11|Estimate|January 2002||2002-01-31|April 2003|2003-04-30||||July 2003|Actual|2003-07-31||Interventional|||BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1/Phase 2|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:54.937655|2018-06-01 05:20:54.937655
NCT00057837|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2013-01-11||2013-01-11|2003-04-08|2003-04-09|Estimate|2013-01-11|2013-02-13|Estimate||||2013-01-11|2013-02-13|Estimate|March 2004||2004-03-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC): Topotecan Sequenced With Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced With Etoposide|Completed||Phase 2|140|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 05:20:55.028286|2018-06-01 05:20:55.028286
NCT00057811|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2014-01-21||2014-09-10|2003-04-08|2003-04-09|Estimate|2014-08-06|2014-08-22|Estimate||||2014-09-10|2014-09-19|Estimate|June 2004||2004-06-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|October 2009|Actual|2009-10-31||Interventional|||Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma|A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy|Completed||Phase 2|97|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:20:55.669232|2018-06-01 05:20:55.669232
NCT00057798|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2011-03-07|2003-04-08|2003-04-09|Estimate|||||||2011-03-07|2011-03-08|Estimate|March 2000||2000-03-31|March 2011|2011-03-31|June 2008|Actual|2008-06-30|May 2003|Actual|2003-05-31||Interventional|||Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery|Molecular And Genetic Changes In Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Vinorelbine And Gemcitabine - Phase II Study|Completed||Phase 2|21|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:20:56.538281|2018-06-01 05:20:56.538281
NCT00057785|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2014-10-08||2016-12-30|2003-04-08|2003-04-09|Estimate|2014-10-08|2014-10-13|Estimate||||2016-12-30|2017-02-17|Actual|February 2003||2003-02-28|December 2016|2016-12-31|December 2016|Actual|2016-12-31|February 2007|Actual|2007-02-28||Interventional||All eligible patients|Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer|A Phase II Study Of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy For Nasopharyngeal Cancer|Completed||Phase 2|68|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:20:56.603957|2018-06-01 05:20:56.603957
NCT00057759|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2015-11-14|2003-04-08|2003-04-09|Estimate|||||||2015-11-14|2015-11-17|Estimate|January 2003||2003-01-31|November 2015|2015-11-30||||December 2006|Actual|2006-12-31||Interventional|||Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer|Treatment Of Erectile Dysfunction In Patients Treated On RTOG-9910 For Prostate Cancer: Impact On Patient And Partner Quality Of Life|Completed||N/A|115|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:20:57.056742|2018-06-01 05:20:57.056742
NCT00057746|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|2016-04-18||2016-04-18|2003-04-08|2003-04-09|Estimate|2016-04-18|2016-05-25|Estimate||||2016-04-18|2016-05-25|Estimate|February 2003||2003-02-28|April 2016|2016-04-30|November 2013|Actual|2013-11-30|May 2009|Actual|2009-05-31||Interventional|||Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer|A Phase II Randomized Trial Of Two Dose Schedules For Delivering Prophylactic Cranial Irradiation For Patients With Limited Disease Small Cell Lung Cancer|Completed||Phase 2|265|Actual|Radiation Therapy Oncology Group|The number of inevaluable patients at one year (e.g., patients dying prior to 1 year, patients not completing the neurocognitive battery at 1 year) was greater than anticipated.|3|||f||||t||||||||||2018-06-01 05:20:57.295543|2018-06-01 05:20:57.295543
NCT00057733|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2013-05-29|2003-04-08|2003-04-09|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 2003||2003-02-28|April 2005|2005-04-30|June 2006|Actual|2006-06-30|April 2005|Actual|2005-04-30||Interventional|||Stress Management Training in Patients Undergoing Radiation Therapy for Cancer|Stress Management Training For Patients Undergoing Radiotherapy|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:20:57.921536|2018-06-01 05:20:57.921536
NCT00030368|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-06-03|2003-04-08|2003-04-09|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 2001||2001-11-30|June 2013|2013-06-30||||February 2009|Actual|2009-02-28||Interventional|||Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Study of PS-341 in Combination With Paclitaxel in Metastatic Solid Tumors|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:57.992684|2018-06-01 05:20:57.992684
NCT00023673|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|2014-02-12||2017-11-27|2003-04-08|2003-04-09|Estimate|2014-02-12|2014-03-27|Estimate||||2017-11-27|2017-12-22|Actual|July 2001||2001-07-31|November 2017|2017-11-30|November 2013|Actual|2013-11-30|January 2009|Actual|2009-01-31||Interventional||Eligible patients who started protocol treatment.|Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|63|Actual|Radiation Therapy Oncology Group|This study was originally designed to escalate 3DRT via increasing doses per fraction. However, due to excessive toxicity at dose level 1 (75.25 Gy, 2.15 Gy/fraction), the protocol was amended in January 2003 to de-escalate 3DRT dose.|4|||f||||||||||||||2018-06-01 05:20:58.135662|2018-06-01 05:20:58.135662
NCT00004079|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-01-31|2003-04-08|2003-04-09|Estimate|||||||2013-01-31|2013-02-01|Estimate|August 1999||1999-08-31|January 2013|2013-01-31||||September 2005|Actual|2005-09-30||Interventional|||Sarcosinamide Nitrosourea in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Trial of Sarcosinamide Nitrosourea (SarCNU) in Patients With Solid Tumors|Completed||Phase 1|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:20:58.813301|2018-06-01 05:20:58.813301
NCT00057135|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2002||2002-11-30|April 2007|2007-04-30|September 2006|Actual|2006-09-30|||||Interventional|||Improving Antipsychotic Adherence Among Patients With Serious Mental Illness|Improving Antipsychotic Adherence Among Patients With Schizophrenia|Completed||N/A|150|Anticipated|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 05:21:07.779504|2018-06-01 05:21:07.779504
NCT00057720|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-07|||2011-07-21|2003-04-07|2003-04-08|Estimate|||||||2011-07-21|2011-07-25|Estimate|June 2003||2003-06-30|May 2006|2006-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer|Phase 3 Randomized Study of TLK286 (Telcyta) Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-1 (Assessment of Survival In Solid Tumors-1)]|Completed||Phase 3|440||Telik|||||f||||||||||||||2018-06-01 05:20:58.965543|2018-06-01 05:20:58.965543
NCT00057707|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-05|||2017-06-30|2003-04-04|2003-04-07|Estimate|||||||2017-06-30|2017-07-02|Actual|March 26, 2003||2003-03-26|June 16, 2017|2017-06-16|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||Effects of Modafinil on Brain Function in Patients With Schizophrenia|Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype|Completed||Phase 1|176|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:59.532577|2018-06-01 05:20:59.532577
NCT00057694|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-05|||2008-03-03|2003-04-04|2003-04-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|January 2004|2004-01-31|January 2004||2004-01-31|||||Observational|||The Value of Genetic Information to Adult Adopted Individuals|Genetic Information: Exploring the Value to Adult Adoptees|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:20:59.618903|2018-06-01 05:20:59.618903
NCT00057681|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|2012-05-29||2013-03-27|2003-04-04|2003-04-07|Estimate|2013-02-13|2013-03-27|Estimate||||2013-03-27|2013-04-04|Estimate|February 2003||2003-02-28|March 2013|2013-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|TEAM||Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents|Treatment of Early Age Mania (TEAM) Study|Completed||Phase 3|379|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 05:20:59.683425|2018-06-01 05:20:59.683425
NCT00057668|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2013-11-18|2003-04-04|2003-04-07|Estimate|||||||2013-11-18|2013-11-19|Estimate|September 2001||2001-09-30|August 2006|2006-08-31|August 2006||2006-08-31|||||Interventional|||Preventing Behavior Problems in Children With ADHD|Prevention of Behavioral Deficits in Young ADHD Children|Unknown status|Active, not recruiting|Phase 2|200||Lehigh University|||||f||||||||||||||2018-06-01 05:20:59.960211|2018-06-01 05:20:59.960211
NCT00057655|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2015-12-01|2003-04-04|2003-04-07|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2002||2002-01-31|December 2015|2015-12-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Observational|||Behavioral Health Services for Women Receiving Public Assistance|Access to Behavioral Health Services for Women on TANF|Withdrawn|||0|Actual|University of Pennsylvania||||lack of funding|f||||f||||||||||2018-06-01 05:21:00.006732|2018-06-01 05:21:00.006732
NCT00057642|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2013-08-16|2003-04-04|2003-04-07|Estimate|||||||2013-08-16|2013-08-20|Estimate|September 2002||2002-09-30|September 2008|2008-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Improving Retention of Hispanics Receiving Antidepressant Therapy|Improving Hispanic Retention in Antidepressant Therapy|Completed||N/A|50|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-06-01 05:21:00.0556|2018-06-01 05:21:00.0556
NCT00057629|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2015-11-12|2003-04-04|2003-04-07|Estimate|||||||2015-11-12|2015-11-13|Estimate|January 2002||2002-01-31|November 2015|2015-11-30|August 2009|Actual|2009-08-31|August 2008|Actual|2008-08-31||Interventional|||Prolonged Exposure Therapy for Post Traumatic Stress Disorder Following Sexual Assault|Effectiveness of Treatment for PTSD in Community Agencies|Completed||Phase 2/Phase 3|187|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-06-01 05:21:00.119926|2018-06-01 05:21:00.119926
NCT00057616|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2017-04-25|2003-04-04|2003-04-07|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2002||2002-10-31|April 2017|2017-04-30|December 2004||2004-12-31|||||Interventional|||Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.|Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy|Completed||Phase 3|274||Celgene|||||||||||||||||||2018-06-01 05:21:00.262691|2018-06-01 05:21:00.262691
NCT00057603|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2011-11-08|2003-04-04|2003-04-07|Estimate|||||||2011-11-08|2011-11-09|Estimate|January 2001||2001-01-31|November 2011|2011-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Deep Brain Stimulation for Treatment-Resistant Obsessive Compulsive Disorder|Pilot Study of DBS for Treatment-Refractory OCD|Completed||N/A|6|Actual|University of Florida||1|||f||||f||||||||||2018-06-01 05:21:00.366094|2018-06-01 05:21:00.366094
NCT00057590|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2013-05-03|2003-04-04|2003-04-07|Estimate|||||||2013-05-03|2013-05-06|Estimate|March 2003||2003-03-31|May 2013|2013-05-31||||||||Interventional|||Outreach and Treatment for Depression in the Labor Force|Outreach and Treatment for Depression in the Labor Force|Completed||N/A|590||Harvard Medical School|||||f||||||||||||||2018-06-01 05:21:00.422732|2018-06-01 05:21:00.422732
NCT00057577|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|2013-12-18||2017-05-22|2003-04-04|2003-04-07|Estimate|2015-04-01|2015-04-02|Estimate||||2017-05-22|2017-05-30|Actual|October 2002||2002-10-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|July 2012|Actual|2012-07-31||Interventional|CPT3|All participants met criteria for Major Depressive Disorder (MDD) with exclusions only for psychosis and selected personality disorders|Prevention of Recurrence in Depression With Drugs and CT|Prevention of Recurrence in Depression With Drugs and CT|Completed||Phase 4|452|Actual|Vanderbilt University||2|||f||||t||||||||||2018-06-01 05:21:00.474258|2018-06-01 05:21:00.474258
NCT00057564|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2015-09-09|2003-04-04|2003-04-07|Estimate|||||||2015-09-09|2015-09-11|Estimate|February 2003||2003-02-28|September 2015|2015-09-30|August 2013|Actual|2013-08-31|April 2006|Actual|2006-04-30||Interventional|||A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma|A Multicenter, Randomized, Parallel-group , Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma|Completed||Phase 3|470|Actual|Celgene||2|||f||||t||||||||||2018-06-01 05:21:00.809655|2018-06-01 05:21:00.809655
NCT00057551|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|2015-04-07||2017-11-01|2003-04-04|2003-04-07|Estimate|2016-05-03|2016-06-10|Estimate||||2017-11-01|2017-12-06|Actual|April 2003||2003-04-30|November 2017|2017-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|REVAMP||Research Evaluating the Value of Augmenting Medication With Psychotherapy|CBASP Augmentation for Treatment of Chronic Depression|Completed||Phase 4|491|Actual|Weill Medical College of Cornell University||3|||f||||t||||||||No||2018-06-01 05:21:00.964688|2018-06-01 05:21:00.964688
NCT00057538|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-04|||2006-08-16|2003-04-04|2003-04-07|Estimate|||||||2006-08-16|2006-08-18|Estimate|May 2003||2003-05-31|August 2006|2006-08-31|May 2003||2003-05-31|||||Interventional|||Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIV|Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIV|Completed||Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:21:02.019305|2018-06-01 05:21:02.019305
NCT00057525|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-03|||2011-06-29|2003-04-04|2003-04-07|Estimate|||||||2011-06-29|2011-06-30|Estimate|April 2003||2003-04-30|June 2011|2011-06-30|August 2004|Actual|2004-08-31|April 2004|Actual|2004-04-30||Interventional|||A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults|A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults|Completed||Phase 1|70|Actual|DynPort Vaccine Company LLC, A CSC Company||2|||f||||t||||||||||2018-06-01 05:21:02.080118|2018-06-01 05:21:02.080118
NCT00057512|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-03|||2016-02-20|2003-04-03|2003-04-04|Estimate|||||||2016-02-20|2016-02-23|Estimate|January 2003||2003-01-31|January 2006|2006-01-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck|Open-Label Phase 1 Dose Escalation Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck|Completed||Phase 1|9|Actual|Erimos Pharmaceuticals||1|||f||||f||||||||No||2018-06-01 05:21:02.146874|2018-06-01 05:21:02.146874
NCT00057499|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-03|||2017-02-06|2003-04-03|2003-04-04|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2003||2003-03-31|February 2017|2017-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Evaluation of a Diabetes Vaccine in Newly Diagnosed Diabetics|Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus|Completed||Phase 1|12|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Data access is provided to the public in : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) portal.|2018-06-01 05:21:02.237513|2018-06-01 05:21:02.237513
NCT00057486|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-02|||2016-12-13|2003-04-02|2003-04-03|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 1997||1997-09-30|March 2003|2003-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients|A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS|Terminated||Phase 1/Phase 2|2||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:21:02.352135|2018-06-01 05:21:02.352135
NCT00057473|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-02||2010-02-03|2011-04-07|2003-04-02|2003-04-03|Estimate||||2010-02-03|2010-02-05|Estimate|2011-04-07|2011-04-14|Estimate|February 2003||2003-02-28|April 2011|2011-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors||Completed||Phase 2|||Bristol-Myers Squibb||2|||f||||||||||||||2018-06-01 05:21:02.426212|2018-06-01 05:21:02.426212
NCT00057447|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-01|||2007-10-30|2003-04-02|2003-04-03|Estimate|||||||2007-10-30|2007-11-01|Estimate|March 2003||2003-03-31|October 2007|2007-10-31|June 2004|Actual|2004-06-30|||||Interventional|||Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients|Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|24|Actual|InterMune||||administrative reasons|f||||||||||||||2018-06-01 05:21:03.210676|2018-06-01 05:21:03.210676
NCT00057434|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-01|||2007-09-17|2003-04-02|2003-04-03|Estimate|||||||2007-09-17|2007-09-18|Estimate|September 1998||1998-09-30|August 2007|2007-08-31||||||||Interventional|||Vitamin A Therapy for Tuberculosis|Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS|Completed||Phase 3|1140||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:21:03.315562|2018-06-01 05:21:03.315562
NCT00057421|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-01|||2007-09-17|2003-04-02|2003-04-03|Estimate|||||||2007-09-17|2007-09-18|Estimate|November 1998||1998-11-30|August 2007|2007-08-31|September 2002||2002-09-30|||||Interventional|||Tuberculosis in HIV Infected Patients in Uganda|Impact of Tuberculosis on HIV Infection in Uganda|Completed||Phase 2|190||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:21:03.419744|2018-06-01 05:21:03.419744
NCT00057460|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-02|||2008-03-03|2003-04-01|2003-04-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2003||2003-04-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Effect of Talampanel (an AMPA Receptor Blocker) on Brain Activity|Effects of AMPA Receptor Blockade on Human Cortical Excitability - A Pilot Study|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:03.479812|2018-06-01 05:21:03.479812
NCT00057408|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-01|||2015-03-24|2003-04-01|2003-04-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2003||2003-05-31|September 2011|2011-09-30|September 2005||2005-09-30|||||Interventional|||A Controlled Study of Olanzapine in Children With Autism|A Controlled Study of Olanzapine in Children With Autism|Completed||Phase 2|78|Anticipated|FDA Office of Orphan Products Development||2|||f||||t||||||||||2018-06-01 05:21:03.548308|2018-06-01 05:21:03.548308
NCT00057395|ClinicalTrials.gov processed this data on May 31, 2018|2003-04-01|||2005-06-23|2003-04-01|2003-04-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2004|2004-04-30||||||||Interventional|||A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies|A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies|Unknown status|Active, not recruiting|Phase 1/Phase 2|40||Aronex Pharmaceuticals|||||||||||||||||||2018-06-01 05:21:03.617094|2018-06-01 05:21:03.617094
NCT00057382|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|||2005-06-23|2003-04-01|2003-04-02|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2003||2003-03-31|September 2004|2004-09-30||||||||Interventional|||T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients||Terminated||Phase 2/Phase 3|750||Tularik|||||||||||||||||||2018-06-01 05:21:03.723227|2018-06-01 05:21:03.723227
NCT00057369|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|||2005-06-23|2003-04-01|2003-04-02|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2001||2001-02-28|June 2003|2003-06-30|June 2003||2003-06-30|||||Interventional|||Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections|Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens|Unknown status|Active, not recruiting|Phase 2|88||Vicuron Pharmaceuticals|||||||||||||||||||2018-06-01 05:21:03.977467|2018-06-01 05:21:03.977467
NCT00057356|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|||2014-04-30|2003-03-31|2003-04-01|Estimate|||||||2014-04-30|2014-05-02|Estimate|November 2002||2002-11-30|April 2014|2014-04-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients With Decompensated Chronic Heart Failure|Completed||Phase 2|170|Actual|Cumberland Pharmaceuticals||4|||f||||f||||||||||2018-06-01 05:21:04.064271|2018-06-01 05:21:04.064271
NCT00057343|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|||2006-09-08|2003-03-31|2003-04-01|Estimate|||||||2006-09-08|2006-09-12|Estimate|March 2003||2003-03-31|September 2006|2006-09-30||||||||Interventional|||Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma|A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL|Terminated||Phase 3|400||Biogen|||||||||||||||||||2018-06-01 05:21:04.269619|2018-06-01 05:21:04.269619
NCT00057330|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|2011-09-29||2016-09-29|2003-03-31|2003-04-01|Estimate|2011-09-29|2011-11-03|Estimate||||2016-09-29|2016-09-30|Estimate|January 2003||2003-01-31|March 2013|2013-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||HerpeVac Trial for Young Women|A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative|Completed||Phase 3|8323|Actual|GlaxoSmithKline|Out of the 8323 subjects enrolled and vaccinated, 7850 subjects were followed throughout the study, e. a. for safety and adverse event assessment (4488 in the Herpes Simplex Virus Group and 3662 in the Havrix Group).|2|||f||||||||||||||2018-06-01 05:21:04.482366|2018-06-01 05:21:04.482366
NCT00057317|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|||2016-08-23|2003-03-31|2003-04-01|Estimate|||||||2016-08-23|2016-08-24|Estimate|December 2001||2001-12-31|August 2016|2016-08-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus|A Phase II, Randomized, Double-blind, Placebo-controlled Dose-ranging Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|||Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:21:05.729506|2018-06-01 05:21:05.729506
NCT00057304|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|||2017-02-28|2003-03-31|2003-04-01|Estimate|||||||2017-02-28|2017-03-03|Actual|April 22, 2003|Actual|2003-04-22|February 2017|2017-02-28|March 18, 2004|Actual|2004-03-18|March 18, 2004|Actual|2004-03-18||Interventional|||Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus|A Phase II Randomized, Double-Blind, Dose-Ranging Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|||Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:21:05.96335|2018-06-01 05:21:05.96335
NCT00057291|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-31|||2014-10-28|2003-03-31|2003-04-01|Estimate|||||||2014-10-28|2014-10-29|Estimate|April 2000||2000-04-30|December 2004|2004-12-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Effect of Improving Caregiving on Early Mental Health|Effect of Improving Caregiving on Early Mental Health|Completed||N/A|1521|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||1|||f||||f||||||||||2018-06-01 05:21:06.173206|2018-06-01 05:21:06.173206
NCT00057031|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2006-10-31|2003-03-31|2003-04-01|Estimate|||||||2006-10-31|2006-11-01|Estimate|November 2002||2002-11-30|February 2005|2005-02-28|March 2004||2004-03-31|||||Interventional|||Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)|A Phase 2, Multicenter, Open Label Study of the Safety and Efficacy of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome|Unknown status|Active, not recruiting|Phase 2|46||Novacea|||||||||||||||||||2018-06-01 05:21:06.276897|2018-06-01 05:21:06.276897
NCT00057278|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-28|||2007-12-14|2003-03-28|2003-03-31|Estimate|||||||2007-12-14|2007-12-19|Estimate|March 2003||2003-03-31|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|||Gabapentin in Fibromyalgia Trial (GIFT)|Gabapentin in Fibromyalgia Trial (GIFT)|Completed||Phase 2/Phase 3|150||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||||||||||||||||2018-06-01 05:21:06.386074|2018-06-01 05:21:06.386074
NCT00057265|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-28|||2015-03-19|2003-03-28|2003-03-31|Estimate|||||||2015-03-19|2015-03-20|Estimate|February 2003||2003-02-28|March 2015|2015-03-31||||April 2006|Actual|2006-04-30||Interventional|||A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B|A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B|Completed||Phase 3|||Novartis|||||||||||||||||||2018-06-01 05:21:06.51659|2018-06-01 05:21:06.51659
NCT00057200|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-28|2003-03-31|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|January 2005|Actual|2005-01-31|||||Interventional|||Evaluating Telehealth Home Care for Elderly Veterans With Congestive Heart Failure|Evaluating Telehealth Home Care for Elderly Veterans With Congestive Heart Failure|Completed||N/A|198|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:06.623041|2018-06-01 05:21:06.623041
NCT00057187|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-28|2003-03-31|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|January 2005|Actual|2005-01-31|||||Interventional|||Improving Substance Abuse Treatment Aftercare Adherence and Outcome|Improving Substance Abuse Treatment Aftercare Adherence and Outcome|Completed||N/A|157|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:06.699994|2018-06-01 05:21:06.699994
NCT00057252|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2018-04-03|2003-03-27|2003-03-28|Estimate|||||||2018-04-03|2018-04-04|Actual|March 20, 2003||2003-03-20|March 23, 2018|2018-03-23||||||||Observational|||Development of Computer-aided Detection and Diagnosis From Imaging Techniques|Development and Evaluation of Techniques for Computer Aided Detection and Diagnosis From Radiologic Images|Enrolling by invitation|||121491|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:06.795843|2018-06-01 05:21:06.795843
NCT00057239|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2010-10-01|2003-03-27|2003-03-28|Estimate|||||||2010-10-01|2010-10-04|Estimate|March 2003||2003-03-31|October 2010|2010-10-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20mg and 60mg) of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks|Completed||Phase 2|546||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:21:06.936618|2018-06-01 05:21:06.936618
NCT00057226|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-15|2003-03-27|2003-03-28|Estimate|||||||2015-04-15|2015-04-16|Estimate|March 2003||2003-03-31|April 2015|2015-04-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.|Completed||Phase 2|365|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:21:07.218574|2018-06-01 05:21:07.218574
NCT00057213|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-15|2003-03-27|2003-03-28|Estimate|||||||2015-04-15|2015-04-16|Estimate|March 2003||2003-03-31|April 2015|2015-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.|Completed||Phase 2|367|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:21:07.363052|2018-06-01 05:21:07.363052
NCT00057174|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|June 2004|Actual|2004-06-30|||||Interventional|||Economic Impact of Guidelines for Gastroesophageal Reflux Disease|Economic Impact of Guidelines for Gastroesophageal Reflux Disease|Completed||N/A|484|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:07.501371|2018-06-01 05:21:07.501371
NCT00057122|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2012-10-19|2003-03-27|2003-03-28|Estimate|||||||2012-10-19|2012-10-22|Estimate|September 2002||2002-09-30|October 2012|2012-10-31|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Tuberculosis Prevention for HIV Infected Adults|Novel TB Prevention Regimens for HIV-Infected Adults|Completed||Phase 3|1148|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 05:21:07.994358|2018-06-01 05:21:07.994358
NCT00057109|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate||||December 2005|2005-12-31|June 2005|Actual|2005-06-30|||||Observational|||Health Values and Spirituality in Veterans With HIV/AIDS|Health Values and Spirituality in Veterans With HIV/AIDS|Completed|||100|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:21:08.097815|2018-06-01 05:21:08.097815
NCT00057096|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2004|Actual|2004-03-31|||||Interventional|||Onsite Versus Referral Models of Primary Care for Substance Abusing Patients|Onsite Versus Referral Models of Primary Care for Substance Abusing Patients|Completed||N/A|800|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:08.185146|2018-06-01 05:21:08.185146
NCT00057083|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2003||2003-03-31|February 2008|2008-02-29|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Effect of Telemedicine on Physician-Patient Communication|Effect of Telemedicine on Physician-Patient Communication|Completed||N/A|221|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:08.273453|2018-06-01 05:21:08.273453
NCT00057070|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2001||2001-10-31|February 2007|2007-02-28|September 2003|Actual|2003-09-30|||||Interventional|||Facilitating Implementation of the PHS Smoking Cessation Guidelines - RESET|Facilitating Implementation of the PHS Smoking Cessation Guidelines - RESET|Completed||N/A|1900|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:08.428623|2018-06-01 05:21:08.428623
NCT00057057|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2005|Actual|2005-03-31|||||Interventional|||Telephone Intervention in Heart Failure Patients|Randomized Trial of a Telephone Intervention in Heart Failure Patients|Completed||N/A|438|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:08.542445|2018-06-01 05:21:08.542445
NCT00057044|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-27|||2015-04-06|2003-03-27|2003-03-28|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2001||2001-10-31|February 2007|2007-02-28|September 2003|Actual|2003-09-30|||||Interventional|||From Research to Practice - Lipid Management for Low HDL-Cholesterol|From Research to Practice - Lipid Management for Low HDL-Cholesterol|Completed||N/A|11700|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:21:08.645287|2018-06-01 05:21:08.645287
NCT00057018|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2016-09-23|2003-03-27|2003-03-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2000||2000-04-30|May 2011|2011-05-31|January 2006||2006-01-31|March 2005|Actual|2005-03-31||Interventional|||Improving Arm Mobility and Use After Stroke|The Extremity Constraint Induced Therapy Evaluation (EXCITE) Trial|Completed||Phase 3|229||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:21:08.758653|2018-06-01 05:21:08.758653
NCT00057005|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2010-01-19|2003-03-27|2003-03-28|Estimate|||||||2010-01-19|2010-01-21|Estimate|February 2003||2003-02-28|November 2009|2009-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|ADVL||Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation|Phase I Study of Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation (ADVL)|Completed||Phase 1|24|Anticipated|Baylor College of Medicine||1|||t||||t||||||||||2018-06-01 05:21:08.901748|2018-06-01 05:21:08.901748
NCT00056992|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2015-03-24|2003-03-26|2003-03-27|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2002||2002-09-30|September 2002|2002-09-30|October 2003||2003-10-31|||||Interventional|||Testing of ADI-PEG in Hepatocellular Carcinoma|Phase II Testing of ADI-PEG in Hepatocellular Carcinoma|Completed||Phase 2|34||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:21:08.9909|2018-06-01 05:21:08.9909
NCT00056979|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2015-09-21|2003-03-26|2003-03-27|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2002||2002-06-30|September 2015|2015-09-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases|Anti-CD45 (YTH-24 & YTH 54) and ANTI-CD52 (CAMPATH-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases|Terminated||Phase 1/Phase 2|2|Actual|Baylor College of Medicine||1|||f||||||||||||||2018-06-01 05:21:09.047912|2018-06-01 05:21:09.047912
NCT00056966|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2012-06-27|2003-03-26|2003-03-27|Estimate|||||||2012-06-27|2012-06-29|Estimate|November 2002||2002-11-30|June 2012|2012-06-30|December 2006|Actual|2006-12-31|May 2005|Actual|2005-05-31||Interventional|||Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases|Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases|Completed||Phase 1/Phase 2|24|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-06-01 05:21:09.122067|2018-06-01 05:21:09.122067
NCT00056953|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2005-07-27|2003-03-26|2003-03-27|Estimate|||||||2005-07-27|2005-07-29|Estimate|September 1999||1999-09-30|July 2005|2005-07-31|November 2004||2004-11-30|||||Interventional|||Peer Mentors for Adolescents in HIV Affected Families|Peer Mentors for Early Adolescents in HIV-Affected Families|Completed||Phase 2|160||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:21:09.20032|2018-06-01 05:21:09.20032
NCT00056940|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2007-04-23|2003-03-26|2003-03-27|Estimate|||||||2007-04-23|2007-04-24|Estimate|September 2001||2001-09-30|April 2007|2007-04-30|July 2006|Actual|2006-07-31|||||Interventional|||Prevention of Violent Behavior Among Children|Randomized Controlled Trial to Prevent Child Violence|Completed||N/A|6600||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||t||||||||||2018-06-01 05:21:09.249724|2018-06-01 05:21:09.249724
NCT00056927|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2006-09-29|2003-03-26|2003-03-27|Estimate|||||||2006-09-29|2006-10-02|Estimate|September 1997||1997-09-30|July 2005|2005-07-31|August 2002||2002-08-31|||||Interventional|||Anti-Smoking Program for Parents: Effects on Child Smoking|Preventing Initiation of Smoking by Children|Completed||N/A|1007||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:21:09.298932|2018-06-01 05:21:09.298932
NCT00056875|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-25|||2015-03-24|2003-03-26|2003-03-27|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2002||2002-09-30|February 2006|2006-02-28|June 2005||2005-06-30|||||Interventional|||Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants|Safety and Efficacy of Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants|Completed||Phase 1/Phase 2|50||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:21:09.3481|2018-06-01 05:21:09.3481
NCT00056914|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2017-06-30|2003-03-25|2003-03-26|Estimate|||||||2017-06-30|2017-07-02|Actual|March 21, 2003||2003-03-21|January 5, 2010|2010-01-05|January 5, 2010||2010-01-05|||||Observational|||Development of Techniques for Use in MRI With a Magnetic Field of 7 Tesla|Development of 7 Tesla MRI Methodology for Anatomical Functional and Spectroscopic Imaging of the Brain|Completed|||102|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:09.39785|2018-06-01 05:21:09.39785
NCT00056901|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2018-02-13|2003-03-25|2003-03-26|Estimate|||||||2018-02-13|2018-02-14|Actual|March 25, 2003||2003-03-25|December 24, 2017|2017-12-24|December 24, 2017||2017-12-24|||||Observational|||Screening Evaluation for Women With Postpartum Depression|A Screening Protocol to Evaluate Women With Postpartum-Related Mood and Behavioral Disorders|Terminated|||68|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:09.440444|2018-06-01 05:21:09.440444
NCT00056888|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-26|||2017-06-30|2003-03-25|2003-03-26|Estimate|||||||2017-06-30|2017-07-02|Actual|March 21, 2003||2003-03-21|February 17, 2009|2009-02-17|February 17, 2009||2009-02-17|||||Observational|||Neurophysiological Studies in Patients With Paroxysmal Hyperkinetic Movement Disorders|Neurophysiological Studies in Patients With Psychogenic Movement Disorders|Completed|||115||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:09.489952|2018-06-01 05:21:09.489952
NCT00056836|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-24|||2014-05-14|2003-03-25|2003-03-26|Estimate|||||||2014-05-14|2014-05-16|Estimate|March 2003||2003-03-31|May 2014|2014-05-31|December 2005|Actual|2005-12-31|||||Interventional|||A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration|A Phase III, Multicenter, Randomized, Double Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects With Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration|Completed||Phase 3|720||Genentech, Inc.|||||||||||||||||||2018-06-01 05:21:09.629573|2018-06-01 05:21:09.629573
NCT00056823|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-24|||2013-06-19|2003-03-25|2003-03-26|Estimate|||||||2013-06-19|2013-06-21|Estimate|March 2003||2003-03-31|June 2013|2013-06-30|December 2005|Actual|2005-12-31|||||Interventional|||Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)|A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration|Completed||Phase 1/Phase 2|168||Genentech, Inc.|||||||||||||||||||2018-06-01 05:21:09.679815|2018-06-01 05:21:09.679815
NCT00056862|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-25|2010-11-12||2013-11-13|2003-03-24|2003-03-25|Estimate|2011-05-26|2011-06-27|Estimate||||2013-11-13|2013-12-06|Estimate|March 2003||2003-03-31|November 2013|2013-11-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3|Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3|Completed||Phase 4|58|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:21:09.741483|2018-06-01 05:21:09.741483
NCT00056849|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-25|||2018-03-27|2003-03-24|2003-03-25|Estimate|||||||2018-03-27|2018-03-29|Actual|March 24, 2003||2003-03-24|January 29, 2018|2018-01-29||||||||Observational|||Genetic Determinants of Ankylosing Spondylitis Severity|Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study|Completed|||134|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:10.482143|2018-06-01 05:21:10.482143
NCT00056810|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-24|||2015-03-24|2003-03-24|2003-03-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2002||2002-09-30|May 2006|2006-05-31|May 2005||2005-05-31|||||Interventional|||Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine|Assessment of Chronic GBS Improvement With Use of 4-AP|Completed||Phase 2|30||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:21:10.636925|2018-06-01 05:21:10.636925
NCT00056797|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-24|||2016-12-13|2003-03-24|2003-03-25|Estimate|||||||2016-12-13|2016-12-14|Estimate|March 2002||2002-03-31|July 2007|2007-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV|A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy (HAART).|Completed||Phase 2|92||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:21:10.917746|2018-06-01 05:21:10.917746
NCT00056784|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-22|||2017-10-05|2003-03-21|2003-03-24|Estimate|||||||2017-10-05|2017-10-06|Actual|March 20, 2003||2003-03-20|June 17, 2014|2014-06-17|June 17, 2014||2014-06-17|||||Observational|||The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation|The Pathogenesis of Chronic Graft Failure After Kidney Transplantation|Completed|||134|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:11.119231|2018-06-01 05:21:11.119231
NCT00056771|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-22|||2018-04-04|2003-03-21|2003-03-24|Estimate|||||||2018-04-04|2018-04-05|Actual|March 18, 2003||2003-03-18|May 25, 2016|2016-05-25|May 25, 2016||2016-05-25|||||Observational|||Clinical and Genetic Studies of Families With Congenital or Hereditary Cataracts|Clinical and Molecular Studies in Families With Congenital or Hereditary Cataracts|Completed|||3432|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:11.322107|2018-06-01 05:21:11.322107
NCT00056758|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-21|||2007-08-23|2003-03-21|2003-03-24|Estimate|||||||2007-08-23|2007-08-27|Estimate|February 2003||2003-02-28|August 2007|2007-08-31||||||||Interventional|||HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs|Randomized Phase I Evaluation of Immunization With Highly Conserved HIV-1 Derived Peptides and Influenza Matrix Peptide in HIV-1-Infected Subjects on Highly Active Antiretroviral Therapy (HAART) Using Autologous Dendritic Cells Derived From Adherent Monocytic Precursors|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:21:11.428988|2018-06-01 05:21:11.428988
NCT00056745|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-21|||2007-09-17|2003-03-21|2003-03-24|Estimate|||||||2007-09-17|2007-09-18|Estimate||||July 2007|2007-07-31||||||||Interventional|||Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines|The Role of Immunization Site in Eliciting Mucosal Immunity|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:21:11.551097|2018-06-01 05:21:11.551097
NCT00056693|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-20|||2008-07-18|2003-03-21|2003-03-24|Estimate|||||||2008-07-18|2008-07-21|Estimate|April 2003||2003-04-30|July 2008|2008-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Treatment With SU11248 in Patients With Neuroendocrine Tumors|A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor|Completed||Phase 2|107|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 05:21:11.711096|2018-06-01 05:21:11.711096
NCT00056680|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-20|||2007-06-19|2003-03-21|2003-03-24|Estimate|||||||2007-06-19|2007-06-20|Estimate|July 2001||2001-07-31|May 2007|2007-05-31|December 2006|Actual|2006-12-31|||||Interventional|||Three-Part Program for Parents With Premature Infants|Adult Attachment and Intervention Efficacy With Preterms|Completed||N/A|173|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||||||2018-06-01 05:21:11.881283|2018-06-01 05:21:11.881283
NCT00056667|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-20|||2014-01-15|2003-03-21|2003-03-24|Estimate|||||||2014-01-15|2014-01-17|Estimate|July 2001||2001-07-31|January 2014|2014-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Relaxation Response Training for the Treatment of Rheumatoid Arthritis|Relaxation Response, Somatic Style and Rheumatoid Arthritis|Completed||Phase 4|168|Actual|Brigham and Women's Hospital||3|||f||||f||||||||||2018-06-01 05:21:12.047481|2018-06-01 05:21:12.047481
NCT00056654|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-20|||2008-09-16|2003-03-20|2003-03-21|Estimate|||||||2008-09-16|2008-09-17|Estimate|March 2003||2003-03-31|September 2008|2008-09-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer|Pharmacokinetic, Safety and Efficacy Study of a Six-Month Depot Formulation of Leuprolide in Subjects With Prostatic Carcinoma|Completed||N/A|164|Actual|Abbott||1|||f||||f||||||||||2018-06-01 05:21:12.347878|2018-06-01 05:21:12.347878
NCT00056641|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-19|||2013-11-13|2003-03-20|2003-03-21|Estimate|||||||2013-11-13|2013-11-14|Estimate|January 2003||2003-01-31|November 2013|2013-11-30||||January 2004|Actual|2004-01-31||Interventional|||Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients|An Open Label, Randomized, Parallel-group Pharmacokinetics Trial of Tipranavir / Ritonavir (TPV/RTV), Alone or in Combination With RTV-boosted Saquinavir (SQV), Amprenavir (APV), or Lopinavir (LPV), Plus an Optimized Background Regimen, in Multiple Antiretroviral (ARV) Experienced Patients.|Completed||Phase 2|328||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 05:21:12.611845|2018-06-01 05:21:12.611845
NCT00056719|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-21|||2018-04-24|2003-03-19|2003-03-20|Estimate|||||||2018-04-24|2018-04-25|Actual|March 19, 2003||2003-03-19|April 16, 2018|2018-04-16||||||||Observational|||Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study|Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study|Active, not recruiting|||299|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:12.834708|2018-06-01 05:21:12.834708
NCT00056706|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-21|||2008-03-03|2003-03-19|2003-03-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2003||2003-03-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Ischemic Nerve Block to Improve Hand Function in Stroke Patients|Improved Function in the Paretic Hand of Chronic Stroke Patients by Transient Deafferentation of the Intact Upper Extremity|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:13.010579|2018-06-01 05:21:13.010579
NCT00056628|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-19|||2006-09-11|2003-03-19|2003-03-20|Estimate|||||||2006-09-11|2006-09-12|Estimate|January 2001||2001-01-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||COGNIShunt® System for Alzheimer's Disease|Study to Evaluate the Effect of Flow-Regulated Ventriculoperitoneal Shunting on Progression of Alzheimer's Disease: An Investigation of the Safety and Effectiveness of the COGNIShunt® CNS Shunt System|Completed||Phase 3|250||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:21:13.096896|2018-06-01 05:21:13.096896
NCT00056589|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-18|||2017-01-10|2003-03-19|2003-03-20|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2003||2003-03-31|January 2017|2017-01-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency|A Phase 1 Escalating Dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor XIII Deficiency|Completed||Phase 1|11|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-06-01 05:21:13.181647|2018-06-01 05:21:13.181647
NCT00056602|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-19|||2018-03-27|2003-03-18|2003-03-19|Estimate|||||||2018-03-27|2018-03-29|Actual|March 18, 2003||2003-03-18|January 23, 2018|2018-01-23||||||||Observational|||Clinically Important Changes in Rheumatoid Arthritis|Clinically Important Changes in Rheumatoid Arthritis|Completed|||192|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:13.337871|2018-06-01 05:21:13.337871
NCT00056576|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-18|||2011-07-14|2003-03-18|2003-03-19|Estimate|||||||2011-07-14|2011-07-18|Estimate|February 2002||2002-02-28|July 2011|2011-07-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy|A Double-Blind, Randomized, Multicenter, Parallel Group Study to Establish Dose-Response, Safety, and Efficacy of Zonegran (Zonisamide) as Monotherapy in Patients With Newly Diagnosed Epilepsy|Completed||Phase 3|165||Eisai Inc.|||||||||||||||||||2018-06-01 05:21:13.506559|2018-06-01 05:21:13.506559
NCT00056563|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-18|2013-05-20||2014-04-24|2003-03-18|2003-03-19|Estimate|2013-07-24|2013-07-30|Estimate||||2014-04-24|2014-05-09|Estimate|April 2002||2002-04-30|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial|CSP #468 Phase I - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease|Completed||Phase 3|255|Actual|VA Office of Research and Development|A limitation of this study is that the STN and GPi cases are pooled into a single DBS group. When the study was planned, it was thought that differences between STN and GPi at six months would be small, which was tested during the study analysis.|2|||f||||t||||||||||2018-06-01 05:21:13.6778|2018-06-01 05:21:13.6778
NCT00056550|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-17|2012-03-19||2012-09-17|2003-03-17|2003-03-18|Estimate|2012-09-17|2012-10-16|Estimate||||2012-09-17|2012-10-16|Estimate|December 2002||2002-12-31|August 2012|2012-08-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|rhAT||Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.|A Study to Assess the Incidence of Deep Vein Thrombosis (DVT) Following Prophylactic Intravenous Administration of Recombinant Human Antithrombin(rhAT) to Hereditary Antithrombin (AT) Deficient Patients in High Risk Situations.|Completed||Phase 3|14|Actual|rEVO Biologics||1|||f||||f||||||||||2018-06-01 05:21:14.381639|2018-06-01 05:21:14.381639
NCT00056537|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-16|||2014-08-26|2003-03-17|2003-03-18|Estimate|||||||2014-08-26|2014-08-27|Estimate|April 2003||2003-04-30|August 2014|2014-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer|An Open-Label, Phase I, Repeat Dose-Escalation Study of ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer|Completed||Phase 1|44|Actual|Active Biotech AB||1|||f||||f||||||||||2018-06-01 05:21:14.668578|2018-06-01 05:21:14.668578
NCT00056524|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-15|||2016-07-13|2003-03-17|2003-03-18|Estimate|||||||2016-07-13|2016-07-14|Estimate|February 2003||2003-02-28|July 2016|2016-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)|An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.|Completed||Phase 3|600|Anticipated|Avanir Pharmaceuticals|||||||||||||||||||2018-06-01 05:21:14.873482|2018-06-01 05:21:14.873482
NCT00055328|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-25|||2013-09-06|2003-02-25|2003-02-26|Estimate|||||||2013-09-06|2013-09-10|Estimate|December 2002||2002-12-31|August 2008|2008-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Treatment for Depression in the Primary Care Setting|Problem-Solving Treatment for Primary Care Depression|Completed||Phase 4|300||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:21:45.456066|2018-06-01 05:21:45.456066
NCT00056511|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-14|||2006-08-16|2003-03-17|2003-03-18|Estimate|||||||2006-08-16|2006-08-18|Estimate|May 2002||2002-05-31|August 2006|2006-08-31|April 2005||2005-04-30|||||Interventional|||Comparing Effects of 3 Sources of Garlic on Cholesterol Levels|Comparing Effects of 3 Sources of Garlic on Serum Lipids|Completed||Phase 2/Phase 3|220||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:21:15.118744|2018-06-01 05:21:15.118744
NCT00056498|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-14|2009-03-23||2018-02-14|2003-03-14|2003-03-17|Estimate|2012-06-12|2012-07-16|Estimate||||2018-02-14|2018-02-15|Actual|December 2001||2001-12-31|February 2018|2018-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine|Clozapine Treatment of Schizophrenic Patients|Completed||Phase 4|65|Actual|University of Maryland||2|||f||||t||||||||||2018-06-01 05:21:15.262342|2018-06-01 05:21:15.262342
NCT00056485|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-14|||2017-04-11|2003-03-14|2003-03-17|Estimate|||||||2017-04-11|2017-04-13|Actual|April 2002||2002-04-30|April 2017|2017-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Treatment of Depression in Nursing Homes|Behavioral Intervention for Depression in Nursing Homes|Completed||N/A|25|Actual|University of Louisville|||||f||||f|f|f||||||No||2018-06-01 05:21:15.878374|2018-06-01 05:21:15.878374
NCT00056472|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-14|2009-06-16||2013-06-26|2003-03-14|2003-03-17|Estimate|2013-06-26|2013-08-02|Estimate||||2013-06-26|2013-08-02|Estimate|January 2003||2003-01-31|June 2013|2013-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|STOP-PD||Study of Pharmacotherapy of Psychotic Depression|Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression|Completed||Phase 3|259|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-06-01 05:21:16.003233|2018-06-01 05:21:16.003233
NCT00012454|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-09|||2010-05-03|2003-03-14|2003-03-17|Estimate|||||||2010-05-03|2010-05-04|Estimate|March 2001||2001-03-31|May 2010|2010-05-31|February 2004||2004-02-29|||||Interventional|||E-Selectin Nasal Spray to Prevent Stroke Recurrence|Induction of Mucosal Tolerance to E-Selectin for the Secondary Prevention of Stroke|Terminated||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:16.513833|2018-06-01 05:21:16.513833
NCT00056459|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-13|||2009-11-18|2003-03-13|2003-03-14|Estimate|||||||2009-11-18|2009-11-19|Estimate|February 2003||2003-02-28|November 2009|2009-11-30||||January 2007|Actual|2007-01-31||Interventional|||Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.|A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo|Completed||Phase 3|1168|Actual|Novartis||2|||f||||||||||||||2018-06-01 05:21:16.616289|2018-06-01 05:21:16.616289
NCT00056446|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-13|||2017-03-02|2003-03-13|2003-03-14|Estimate|||||||2017-03-02|2017-03-06|Actual|January 2003||2003-01-31|January 2016|2016-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer|A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum|Completed||Phase 3|855|Actual|Novartis||2|||f||||f||||||||||2018-06-01 05:21:17.21056|2018-06-01 05:21:17.21056
NCT00056433|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-12|||2018-05-16|2003-03-12|2003-03-13|Estimate|||||||2018-05-16|2018-05-17|Actual|March 10, 2003||2003-03-10|December 7, 2015|2015-12-07|December 27, 2006|Actual|2006-12-27|December 27, 2006|Actual|2006-12-27||Interventional|||Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia|Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia|Completed||Phase 1|39|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:21.516015|2018-06-01 05:21:21.516015
NCT00056420|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-12|||2017-06-30|2003-03-12|2003-03-13|Estimate|||||||2017-06-30|2017-07-02|Actual|March 10, 2003||2003-03-10|January 22, 2009|2009-01-22|January 22, 2009||2009-01-22|||||Observational|||Brain Dynamics Involved in Generating Tics and Controlling Voluntary Movement|Spatiotemporal Dynamics of Cortical Connectivity Involved in Tics and Voluntary Movements in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder: An EEG Study|Completed|||54||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:21.673194|2018-06-01 05:21:21.673194
NCT00056407|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-11|2010-02-01||2016-08-17|2003-03-12|2003-03-13|Estimate|2010-02-01|2010-03-05|Estimate||||2016-08-17|2016-09-23|Estimate|March 2003||2003-03-31|August 2016|2016-08-31|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|REDUCE||"REDUCE - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk"|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer|Completed||Phase 3|8231|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:21:22.253849|2018-06-01 05:21:22.253849
NCT00056394|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-11|||2014-07-11|2003-03-11|2003-03-12|Estimate|||||||2014-07-11|2014-07-14|Estimate|February 2003||2003-02-28|November 2013|2013-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Coping Skills Training for Early Rheumatoid Arthritis|Coping Skills Training for Early Rheumatoid Arthritis|Completed||N/A|105|Actual|Duke University||3|||f||||t||||||||||2018-06-01 05:21:26.977583|2018-06-01 05:21:26.977583
NCT00056381|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-11|||2008-10-17|2003-03-11|2003-03-12|Estimate|||||||2008-10-17|2008-10-21|Estimate|July 2003||2003-07-31|October 2008|2008-10-31|June 2004|Actual|2004-06-30|||||Interventional|||Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17|Phase I/II Study of the Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children With Fever and Neutropenia|Completed||Phase 1/Phase 2|25|Actual|Pfizer|||||||||||||||||||2018-06-01 05:21:27.102612|2018-06-01 05:21:27.102612
NCT00056368|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-11|||2008-10-17|2003-03-11|2003-03-12|Estimate|||||||2008-10-17|2008-10-21|Estimate|March 2003||2003-03-31|October 2008|2008-10-31|October 2004|Actual|2004-10-31|||||Interventional|||The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis|A Phase III, Double-Blind, Randomized, Multi-Center, Study of the Safety and Efficacy of Anidulafungin vs. Fluconazole in the Treatment of Patients With Candidemia and Other Forms of Invasive Candidiasis and Prevention of Complications.|Completed||Phase 3|256|Actual|Pfizer|||||||||||||||||||2018-06-01 05:21:27.160265|2018-06-01 05:21:27.160265
NCT00056329|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-10|||2012-05-02|2003-03-11|2003-03-12|Estimate|||||||2012-05-02|2012-05-04|Estimate|April 2002||2002-04-30|May 2012|2012-05-31|May 2012|Anticipated|2012-05-31|May 2012|Anticipated|2012-05-31||Interventional|||Vitamin E in Aging Persons With Down Syndrome|Multicenter Vitamin E Trial in Aging Persons With Down Syndrome|Unknown status|Active, not recruiting|Phase 3|350|Actual|New York State Institute for Basic Research||2|||f||||t||||||||||2018-06-01 05:21:27.364808|2018-06-01 05:21:27.364808
NCT00056355|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-10|||2008-03-03|2003-03-10|2003-03-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2003||2003-03-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease|A Single Arm Study of Extracorporeal Photoimmune Therapy With Uvadex For Corticosteroid Sparing in Patients With Corticosteroid-Dependent Crohn's Disease Who May Also Be Refractory or Intolerant to Immunosuppressants and/or Anti-Tumor Necrosis Factor Agen|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:27.535709|2018-06-01 05:21:27.535709
NCT00056316|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-10|2008-10-23||2014-06-04|2003-03-10|2003-03-11|Estimate|2008-11-17|2008-11-19|Estimate||||2014-06-04|2014-06-23|Estimate|January 2002||2002-01-31|June 2014|2014-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Reducing Depression in Dementia Caregivers|Reducing Depression in Dementia Caregivers|Completed||Phase 1/Phase 2|74|Actual|University of Missouri, St. Louis||2|||f||||t||||||||||2018-06-01 05:21:27.591651|2018-06-01 05:21:27.591651
NCT00056303|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-10|||2016-12-19|2003-03-10|2003-03-11|Estimate|||||||2016-12-19|2016-12-20|Estimate|December 2002||2002-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mental Health Services for Foster and Adopted Children|Specialized Mental Health Services for Foster Infants|Completed||Phase 1|220|Actual|University of Delaware||2|||f||||t||||||||No||2018-06-01 05:21:27.9993|2018-06-01 05:21:27.9993
NCT00056290|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-10|||2010-11-10|2003-03-10|2003-03-11|Estimate|||||||2010-11-10|2010-11-11|Estimate|December 2002||2002-12-31|November 2010|2010-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||VEGF Gene Transfer for Diabetic Neuropathy|p.VGI.1 (VEGF2) Gene Transfer for Diabetic Neuropathy|Completed||Phase 1/Phase 2|60|Anticipated|Losordo, Douglas, M.D.||2|||t||||t||||||||||2018-06-01 05:21:28.077961|2018-06-01 05:21:28.077961
NCT00056277|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-10|||2017-04-06|2003-03-10|2003-03-11|Estimate|||||||2017-04-06|2017-04-07|Actual|February 27, 2003||2003-02-27|April 2017|2017-04-30|December 14, 2005|Actual|2005-12-14|August 1, 2005|Actual|2005-08-01||Interventional|||Bipolar Disorder Study for Men and Women|Double Blind Placebo Controlled Study of Lamictal in Acute Bipolar Depression|Completed||Phase 3|150|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:21:28.155728|2018-06-01 05:21:28.155728
NCT00056264|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-07|||2011-05-16|2003-03-08|2003-03-10|Estimate|||||||2011-05-16|2011-05-17|Estimate|December 2002||2002-12-31|April 2010|2010-04-30|December 2004|Actual|2004-12-31|||||Interventional|||A Study of Safety and Efficacy of Infliximab (Remicade) in Patients With COPD|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group, Dose Finding Study Evaluating the Safety and Efficacy of Infliximab Administration in Symptomatic Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|234|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:21:28.256455|2018-06-01 05:21:28.256455
NCT00056251|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-07|||2005-06-23|2003-03-08|2003-03-10|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2003||2003-01-31|January 2004|2004-01-31|August 2003||2003-08-31|||||Interventional|||Interstitial Cystitis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of RTX Topical Solution in Patients With Interstitial Cystitis|Completed||Phase 2|150||ICOS Corporation|||||||||||||||||||2018-06-01 05:21:28.316704|2018-06-01 05:21:28.316704
NCT00056238|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-07|||2005-06-23|2003-03-08|2003-03-10|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2003||2003-02-28|March 2003|2003-03-31||||||||Interventional|||Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy|A Phase II Pilot Study of the Safety, Tolerability and Pharmacokinetics of Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy|Completed||Phase 2|30||Bellus Health Inc|||||||||||||||||||2018-06-01 05:21:28.562251|2018-06-01 05:21:28.562251
NCT00056225|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-07|||2009-06-10|2003-03-08|2003-03-10|Estimate|||||||2009-06-10|2009-06-12|Estimate|January 2003||2003-01-31|June 2009|2009-06-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study)|High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL)|Completed||Phase 3|340|Actual|National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:21:28.636155|2018-06-01 05:21:28.636155
NCT00056212|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-07|||2006-08-17|2003-03-08|2003-03-10|Estimate|||||||2006-08-17|2006-08-18|Estimate|July 2002||2002-07-31|July 2006|2006-07-31|October 2004||2004-10-31|||||Interventional|||Evaluating Yoga for Chronic Low Back Pain|Evaluating Yoga for Chronic Low Back Pain|Completed||N/A|100||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:21:28.748058|2018-06-01 05:21:28.748058
NCT00056173|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2008-01-04|2003-03-08|2003-03-10|Estimate|||||||2008-01-04|2008-01-07|Estimate|March 2002||2002-03-31|January 2008|2008-01-31||||December 2004|Actual|2004-12-31||Interventional|||Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma|A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)|Completed||Phase 1/Phase 2|43|Anticipated|Aptose Biosciences Inc.|||||||||||||||||||2018-06-01 05:21:28.802603|2018-06-01 05:21:28.802603
NCT00056199|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-07|||2008-03-03|2003-03-06|2003-03-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2003||2003-03-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome|Pilot Study of Intravitreal Injection of EYE001 (Anti-VEGF Pegylated Aptamer) for Advanced Ocular Disease of Von Hippel-Lindau (VHL) Disease|Completed||Phase 1|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:28.862572|2018-06-01 05:21:28.862572
NCT00056186|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-07|||2008-03-03|2003-03-06|2003-03-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2003||2003-03-31|January 2004|2004-01-31|January 2004||2004-01-31|||||Observational|||Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling|Exploration of Transitional Life Events in Individuals With Friedreich's Ataxia: Implications for Genetic Counseling|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:28.913924|2018-06-01 05:21:28.913924
NCT00056160|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|2009-12-24||2017-09-18|2003-03-06|2003-03-07|Estimate|2010-02-02|2010-03-03|Estimate||||2017-09-18|2017-10-19|Actual|January 1, 2003|Actual|2003-01-01|September 2017|2017-09-30|October 1, 2008|Actual|2008-10-01|November 1, 2005|Actual|2005-11-01||Interventional|||CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma|A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma|Completed||Phase 3|353|Actual|Celgene|Analyses for efficacy had data cutoff dates of 07 Jun 2005 and a data cutoff date of 23 Jul 2008 for overall survival. Only safety data were collected for 6 subjects ongoing beyond the 23 Jul 2008 data cutoff date.|2|||f||||t||||||||||2018-06-01 05:21:29.076708|2018-06-01 05:21:29.076708
NCT00054873|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-12|||2006-07-10|2003-02-12|2003-02-13|Estimate|||||||2006-07-10|2006-07-11|Estimate|November 2003||2003-11-30|June 2006|2006-06-30|December 2004||2004-12-31|||||Interventional|||Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer||Completed||Phase 2|||Chiron Corporation|||||||||||||||||||2018-06-01 05:21:53.384785|2018-06-01 05:21:53.384785
NCT00056147|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2015-01-28|2003-03-06|2003-03-07|Estimate|||||||2015-01-28|2015-01-29|Estimate|April 2003||2003-04-30|January 2015|2015-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease|Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects With Mild to Moderate Cystic Fibrosis Lung Disease|Completed||Phase 2|90|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:21:30.221203|2018-06-01 05:21:30.221203
NCT00056134|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2018-02-16|2003-03-06|2003-03-07|Estimate|||||||2018-02-16|2018-02-19|Actual|October 2002||2002-10-31|February 2018|2018-02-28|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Vaccination of HLA-A1 and/or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide-Loaded Autologous Dendritic Cells With Prior Depletion of CD25-Positive Cells Using Denileukin Difitox (ONTAK)|Completed||Phase 1/Phase 2|23|Actual|University Hospital Erlangen|||||f||||f||||||||||2018-06-01 05:21:30.305926|2018-06-01 05:21:30.305926
NCT00056095|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2009-02-06|2003-03-06|2003-03-07|Estimate|||||||2009-02-06|2009-02-09|Estimate|December 2002||2002-12-31|December 2006|2006-12-31||||||||Interventional|||Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer|Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer|Unknown status|Recruiting|Phase 2|170|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:21:30.437604|2018-06-01 05:21:30.437604
NCT00056082|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2017-02-13|2003-03-06|2003-03-07|Estimate|||||||2017-02-13|2017-02-15|Actual|January 2003||2003-01-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2008|Actual|2008-07-31||Interventional|||Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women|A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer|Completed||Phase 2|110|Actual|University of Kansas Medical Center||1|||f||||f||||||||No|Global results will be published|2018-06-01 05:21:30.744165|2018-06-01 05:21:30.744165
NCT00056069|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2015-05-06|2003-03-06|2003-03-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|December 2002||2002-12-31|May 2015|2015-05-31|March 2010|Actual|2010-03-31|January 2010|Actual|2010-01-31||Interventional|||Study of the Physical and Emotional Needs of Parents Caring for Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia|Differences in Parental Caregiving Demands in Childhood Acute Lymphoblastic Leukemia by Length of Infusion Therapy|Completed||N/A|172|Actual|Children's Oncology Group||1|||f||||f||||||||||2018-06-01 05:21:30.905992|2018-06-01 05:21:30.905992
NCT00056056|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2012-06-19|2003-03-06|2003-03-07|Estimate|||||||2012-06-19|2012-06-20|Estimate|January 2003||2003-01-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides|A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides|Terminated||Phase 3|93|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||poor accrual|f||||t||||||||||2018-06-01 05:21:31.280752|2018-06-01 05:21:31.280752
NCT00056030|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2017-01-20|2003-03-06|2003-03-07|Estimate|||||||2017-01-20|2017-01-24|Estimate|December 2004|Actual|2004-12-31|January 2017|2017-01-31||||October 2007|Actual|2007-10-31||Interventional|||Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer|A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum|Completed||Phase 2|73|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:21:31.582661|2018-06-01 05:21:31.582661
NCT00056004|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-04-25|2003-03-06|2003-03-07|Estimate|||||||2013-04-25|2013-04-29|Estimate|June 2003||2003-06-30|April 2013|2013-04-30|March 2009|Actual|2009-03-31|September 2006|Actual|2006-09-30||Interventional|||Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia|Phase II Trial Of Zileuton In Persons With Bronchial Dysplasia|Completed||Phase 2|38|Actual|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:21:31.95817|2018-06-01 05:21:31.95817
NCT00055991|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-02-04|2003-03-06|2003-03-07|Estimate|||||||2013-02-04|2013-02-05|Estimate|September 2001||2001-09-30|February 2013|2013-02-28|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Bexarotene in Preventing Breast Cancer in Women at Genetic Risk|A Multicenter Randomized Double-Blind Trial Of Targretin Capsules Modifying Immunophenotypic Markers Related To Breast Cancer Progression In Breast Tissue From Genetically Identified High Risk Patients|Completed||Phase 1|87|Actual|Baylor Breast Care Center||2|||f||||t||||||||||2018-06-01 05:21:32.08388|2018-06-01 05:21:32.08388
NCT00055978|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2011-06-16|2003-03-06|2003-03-07|Estimate|||||||2011-06-16|2011-06-20|Estimate|October 2002||2002-10-31|June 2011|2011-06-30|May 2009|Actual|2009-05-31|March 2008|Actual|2008-03-31||Interventional|||Celecoxib in Preventing Lung Cancer in Former Heavy Smokers|Lung Cancer Chemoprevention With Celecoxib In Ex-Smokers|Completed||Phase 2|112|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 05:21:32.24516|2018-06-01 05:21:32.24516
NCT00055965|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-09-19|2003-03-06|2003-03-07|Estimate|||||||2013-09-19|2013-09-20|Estimate|November 2002||2002-11-30|January 2009|2009-01-31||||August 2006|Actual|2006-08-31||Interventional|||Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin|A Pragmatic, Randomised Study To Compare The Hospitalisation Rates Of Two Platinum-Based Outpatient Regimens (Gemcitabine/Cisplatin vs. Gemcitabine/Carboplatin) In Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:21:32.395999|2018-06-01 05:21:32.395999
NCT00055952|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2012-05-15|2003-03-06|2003-03-07|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2003||2003-01-31|May 2012|2012-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor|A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT)|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:21:32.85387|2018-06-01 05:21:32.85387
NCT00055939|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2012-05-15|2003-03-06|2003-03-07|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2003||2003-01-31|May 2012|2012-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma|A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:21:34.307692|2018-06-01 05:21:34.307692
NCT00055926|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2015-10-28|2003-03-06|2003-03-07|Estimate|||||||2015-10-28|2015-10-30|Estimate|January 2003||2003-01-31|August 2012|2012-08-31|May 2005|Actual|2005-05-31|December 2004|Actual|2004-12-31||Interventional|||CP-724,714 in Treating Patients With Metastatic Breast Cancer|A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer|Completed||Phase 1|9|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:21:34.579061|2018-06-01 05:21:34.579061
NCT00055913|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2014-02-11|2003-03-06|2003-03-07|Estimate|||||||2014-02-11|2014-02-12|Estimate|March 2003||2003-03-31|December 2012|2012-12-31||||September 2007|Actual|2007-09-30||Interventional|||Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck|Completed||Phase 1/Phase 2|58|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:21:34.807576|2018-06-01 05:21:34.807576
NCT00055887|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-05-08|2003-03-06|2003-03-07|Estimate|||||||2013-05-08|2013-05-10|Estimate|November 2002||2002-11-30|May 2013|2013-05-31||||||||Interventional|||Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer|Withdrawn||Phase 3|0|Actual|Spectrum Pharmaceuticals, Inc||||Study never started. No patients were enrolled.|f||||||||||||||2018-06-01 05:21:35.177379|2018-06-01 05:21:35.177379
NCT00055874|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2018-05-02|2003-03-06|2003-03-07|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2002||2002-06-30|November 2011|2011-11-30|March 31, 2017|Actual|2017-03-31|March 31, 2012|Actual|2012-03-31||Interventional|||Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase|Completed||Phase 3|1551|Actual|Heidelberg University|||||f|||||f|f||||||||2018-06-01 05:21:35.318513|2018-06-01 05:21:35.318513
NCT00055861|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-06-03|2003-03-06|2003-03-07|Estimate|||||||2013-06-03|2013-06-04|Estimate|July 2002||2002-07-31|June 2013|2013-06-30||||August 2006|Actual|2006-08-31||Interventional|||Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer|PHASE 2 STUDY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH ADVANCED BREAST CANCER|Completed||Phase 2|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:21:35.875131|2018-06-01 05:21:35.875131
NCT00055848|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2016-07-12|2003-03-06|2003-03-07|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 2001||2001-12-31|July 2015|2015-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Genetic Study of Familial Factors in Patients With Colon Cancer|Familial Factors in the Development of Colon Cancer|Completed|||600|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 05:21:36.074095|2018-06-01 05:21:36.074095
NCT00055835|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-01-30|2003-03-06|2003-03-07|Estimate|||||||2013-01-30|2013-01-31|Estimate|November 2002||2002-11-30|January 2013|2013-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium|Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients With Locally Advanced or Recurrent Urothelial Malignancy|Completed||Phase 2|7|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 05:21:36.226865|2018-06-01 05:21:36.226865
NCT00055822|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2012-07-03|2003-03-06|2003-03-07|Estimate|||||||2012-07-03|2012-07-04|Estimate|October 2002||2002-10-31|July 2012|2012-07-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer|A Phase I/II Study of Oblimersen Sodium (G3139, Genasense) in Combination With Oxaliplatin, 5FU and Leucovorin (FOLFOX4) Regimen in Advanced Colorectal Cancer|Completed||Phase 1/Phase 2|16|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:21:36.593189|2018-06-01 05:21:36.593189
NCT00055809|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-01-22|2003-03-06|2003-03-07|Estimate|||||||2013-01-22|2013-01-23|Estimate|January 2003||2003-01-31|January 2013|2013-01-31||||June 2007|Actual|2007-06-30||Interventional|||Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors|Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:21:36.661792|2018-06-01 05:21:36.661792
NCT00055783|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-05-14|2003-03-06|2003-03-07|Estimate|||||||2013-05-14|2013-05-15|Estimate|July 2002||2002-07-31|April 2003|2003-04-30|April 2003|Actual|2003-04-30|||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma|A Phase II Study of Hu1D10 in Recurrent Hodgkin's Disease|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:21:36.787633|2018-06-01 05:21:36.787633
NCT00055770|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-11-21|2003-03-06|2003-03-07|Estimate|||||||2013-11-21|2013-11-25|Estimate|October 2002||2002-10-31|November 2013|2013-11-30||||December 2006|Actual|2006-12-31||Interventional|||Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer|A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1/Phase 2|45|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:21:36.904443|2018-06-01 05:21:36.904443
NCT00055757|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-06-03|2003-03-06|2003-03-07|Estimate|||||||2013-06-03|2013-06-04|Estimate|October 2003||2003-10-31|June 2013|2013-06-30||||April 2004|Actual|2004-04-30||Interventional|||Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Phase II Trial of R115777, a Farnesyl Transferase Inhibitor, in Combination With Gemcitabine and Cisplatin in Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:21:37.102369|2018-06-01 05:21:37.102369
NCT00055731|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2018-05-14|2003-03-06|2003-03-07|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2002|Actual|2002-11-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2010|Actual|2010-12-31||Interventional|||Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse|Phase III Randomized Study Of Adjuvant Hormonal Therapy With And Without Docetaxel And Estramustine In Patients With Advanced Prostate Cancer Or With A High Risk Of Relapse|Active, not recruiting||Phase 3|250|Anticipated|UNICANCER|||||f||||t||||||||||2018-06-01 05:21:37.256071|2018-06-01 05:21:37.256071
NCT00055718|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-12-17|2003-03-06|2003-03-07|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2001||2001-11-30|May 2006|2006-05-31|January 2010|Actual|2010-01-31|||||Interventional|||Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy|A Pilot Study of Silymarin During Maintenance Therapy in Children With Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:21:37.396266|2018-06-01 05:21:37.396266
NCT00055705|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2011-04-23|2003-03-06|2003-03-07|Estimate|||||||2011-04-23|2011-04-26|Estimate|January 2003||2003-01-31|August 2004|2004-08-31||||||||Interventional|||PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer|A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:21:37.574007|2018-06-01 05:21:37.574007
NCT00055692|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|2015-08-25||2016-01-29|2003-03-06|2003-03-07|Estimate|2016-01-29|2016-02-29|Estimate||||2016-01-29|2016-02-29|Estimate|February 2003||2003-02-28|December 2012|2012-12-31|December 2009|Actual|2009-12-31|January 2008|Actual|2008-01-31||Interventional|||Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer|Bevacizumab (RhuMAB-VEGF) In Hepatocellular Cancer For Patients With Unresectable Tumor (Without Invasion Of The Main Portal Vein Or Metastatic Disease) A Phase II Study|Completed||Phase 2|46|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:21:37.721814|2018-06-01 05:21:37.721814
NCT00055679|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-06-17|2003-03-06|2003-03-07|Estimate|||||||2013-06-17|2013-06-18|Estimate|August 2002||2002-08-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Combination Chemotherapy in Treating Women With Stage I Breast Cancer|Phase III Randomized Study Of Adjuvant Fluourouracil, Epirubicin And Cyclophosphamide, In Women With Stage I Breast Cancer|Completed||Phase 3|1512|Actual|UNICANCER||2|||f||||t||||||||||2018-06-01 05:21:38.353488|2018-06-01 05:21:38.353488
NCT00055666|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2011-03-07|2003-03-06|2003-03-07|Estimate|||||||2011-03-07|2011-03-08|Estimate|March 2001||2001-03-31|March 2011|2011-03-31|April 2006|Actual|2006-04-30|February 2005|Actual|2005-02-28||Interventional|||Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract|Compassionate Use Of Oral Beclomethasone Dipropionate For Treatment Of Gastrointestinal Graft Versus Host Disease|Completed||N/A|51|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:21:38.603159|2018-06-01 05:21:38.603159
NCT00055653|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2011-03-03|2003-03-06|2003-03-07|Estimate|||||||2011-03-03|2011-03-07|Estimate|January 2003||2003-01-31|March 2011|2011-03-31|September 2005|Actual|2005-09-30|September 2003|Actual|2003-09-30||Interventional|||Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders|Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation|Completed||Phase 2|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:21:38.732754|2018-06-01 05:21:38.732754
NCT00055640|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2010-06-09|2003-03-06|2003-03-07|Estimate|||||||2010-06-09|2010-06-10|Estimate|October 2002||2002-10-31|June 2010|2010-06-30|March 2006|Actual|2006-03-31|April 2005|Actual|2005-04-30||Interventional|||Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma|Molecular Risk Guided Treatment Of Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|9|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:21:38.966511|2018-06-01 05:21:38.966511
NCT00055614|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2013-06-25|2003-03-06|2003-03-07|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2002||2002-05-31|April 2007|2007-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Phase I Study of Oral Topotecan as Consolidation for Patients With Mullerian Origin Tumors (Ovary, Tube, Peritoneum)|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:21:39.123665|2018-06-01 05:21:39.123665
NCT00055601|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|2016-06-30||2017-05-03|2003-03-06|2003-03-07|Estimate|2016-06-30|2016-08-10|Estimate||||2017-05-03|2017-06-01|Actual|December 2002||2002-12-31|May 2017|2017-05-31||||October 2010|Actual|2010-10-31||Interventional||All eligible patients who started protocol treatment.|Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer|A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy|Active, not recruiting||Phase 2|97|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:21:39.307834|2018-06-01 05:21:39.307834
NCT00022139|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-12-05|2003-03-06|2003-03-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|January 2002||2002-01-31|December 2016|2016-12-31|January 2009|Actual|2009-01-31|July 2005|Actual|2005-07-31||Interventional|||Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction|A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer|Completed||Phase 2|56|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:21:40.01167|2018-06-01 05:21:40.01167
NCT00005028|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2017-03-28|2003-03-06|2003-03-07|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2000|Actual|2000-05-31|March 2017|2017-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer|Phase II Study of Weekly Paclitaxel and Bryostatin-1 in Hormone Refractory Prostate Cancer|Completed||Phase 2|46|Actual|University of Maryland||1|||f||||||||||||||2018-06-01 05:21:40.173264|2018-06-01 05:21:40.173264
NCT00055588|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2017-06-30|2003-03-05|2003-03-06|Estimate|||||||2017-06-30|2017-07-02|Actual|March 4, 2003||2003-03-04|May 20, 2008|2008-05-20|May 20, 2008||2008-05-20|||||Interventional|||Nervous System Function in Normal Volunteers During Cycling Training|Spinal Substrates of Training-Dependent Improvements in Locomotor Function|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:40.305801|2018-06-01 05:21:40.305801
NCT00055575|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-06|||2018-05-23|2003-03-05|2003-03-06|Estimate|||||||2018-05-23|2018-05-24|Actual|February 27, 2003||2003-02-27|February 2, 2015|2015-02-02|February 2, 2015|Actual|2015-02-02|February 2, 2015|Actual|2015-02-02||Interventional|||Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies|Cholinergic Modulation of Cognition and Emotion in Mood Disorders: Functional Neuroimaging Studies|Terminated||N/A|197|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:40.407815|2018-06-01 05:21:40.407815
NCT00055562|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-05|||2005-06-23|2003-03-05|2003-03-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2003||2003-01-31|May 2004|2004-05-31|December 2004||2004-12-31|||||Interventional|||Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma|Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy|Completed||Phase 2/Phase 3|274||Celgene|||||||||||||||||||2018-06-01 05:21:40.509266|2018-06-01 05:21:40.509266
NCT00055536|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-04|||2016-06-14|2003-03-05|2003-03-06|Estimate|||||||2016-06-14|2016-06-16|Estimate|April 2002||2002-04-30|March 2012|2012-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease|A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission|Completed||Phase 2|60||Biogen|||||||||||||||||||2018-06-01 05:21:40.725168|2018-06-01 05:21:40.725168
NCT00055523|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-04|||2006-08-11|2003-03-05|2003-03-06|Estimate|||||||2006-08-11|2006-08-15|Estimate|April 2002||2002-04-30|August 2006|2006-08-31||||||||Interventional|||A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease|A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease|Completed||Phase 2|300||Abbott|||||||||||||||||||2018-06-01 05:21:40.831858|2018-06-01 05:21:40.831858
NCT00055549|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-05|||2017-06-30|2003-03-04|2003-03-05|Estimate|||||||2017-06-30|2017-07-02|Actual|March 4, 2003||2003-03-04|November 13, 2009|2009-11-13|November 13, 2009|Actual|2009-11-13|November 13, 2009|Actual|2009-11-13||Interventional|||Dextromethorphan to Treat Patients With Voice Spasms|The Effects of an NMDA-Receptor Antagonist in Idiopathic Voice Disorders|Completed||Phase 1|65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:40.966656|2018-06-01 05:21:40.966656
NCT00055510|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-04|||2005-06-23|2003-03-04|2003-03-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2004|2004-02-29||||||||Interventional|||A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.||Completed||Phase 2/Phase 3|||Chugai Pharma USA|||||||||||||||||||2018-06-01 05:21:41.088054|2018-06-01 05:21:41.088054
NCT00055497|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-03|2009-12-15||2011-04-07|2003-03-04|2003-03-05|Estimate|2010-04-15|2010-05-18|Estimate||||2011-04-07|2011-04-11|Estimate|August 2002||2002-08-31|April 2011|2011-04-30|December 2008|Actual|2008-12-31|January 2005|Actual|2005-01-31||Interventional|CLASSICII||Remission in Subjects With Crohn's Disease, 1 Year Phase|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease|Completed||Phase 3|276|Actual|Abbott||4|||f||||f||||||||||2018-06-01 05:21:41.346693|2018-06-01 05:21:41.346693
NCT00055484|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-03|||2015-12-10|2003-03-04|2003-03-05|Estimate|||||||2015-12-10|2015-12-14|Estimate|March 2002||2002-03-31|December 2015|2015-12-31|May 2003|Actual|2003-05-31|||||Interventional|||A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache|A Double-Blind, Randomized, Multicenter, Parallel Dose Study to Evaluate the Safety and Efficacy of Zonisamide 150 mg and 300 mg Per Day and Placebo in Subjects With Migraine Headache|Completed||Phase 2|204||Elan Pharmaceuticals|||||||||||||||||||2018-06-01 05:21:43.774633|2018-06-01 05:21:43.774633
NCT00055471|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-03|2011-03-29||2012-10-23|2003-03-03|2003-03-04|Estimate|2012-07-31|2012-08-31|Estimate||||2012-10-23|2012-10-31|Estimate|June 2003||2003-06-30|October 2012|2012-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer||Completed||Phase 2|22|Actual|AstraZeneca|One patient received one dose of 22.5 mg and was dose reduced to 15 mg thereafter. This patient was classified into the 15 mg dose group, except for the single dose pharmacokinetic results (not posted).|3|||f||||||||||||||2018-06-01 05:21:43.891396|2018-06-01 05:21:43.891396
NCT00055445|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-03|||2006-08-17|2003-03-03|2003-03-04|Estimate|||||||2006-08-17|2006-08-18|Estimate|November 2003||2003-11-30|July 2006|2006-07-31|April 2006||2006-04-30|||||Interventional|||IdB 1016 Treatment for Hepatitis C Disease|IdB 1016 in Hepatitis C|Completed||Phase 1/Phase 2|45||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:21:44.641874|2018-06-01 05:21:44.641874
NCT00055432|ClinicalTrials.gov processed this data on May 31, 2018|2003-03-03|||2006-09-13|2003-03-03|2003-03-04|Estimate|||||||2006-09-13|2006-09-15|Estimate||||September 2006|2006-09-30||||||||Interventional|||Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer||Terminated||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:21:44.706358|2018-06-01 05:21:44.706358
NCT00055419|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-28|||2010-04-08|2003-03-03|2003-03-04|Estimate|||||||2010-04-08|2010-04-09|Estimate|February 2003||2003-02-28|April 2010|2010-04-30|August 2004|Actual|2004-08-31|July 2004|Actual|2004-07-31||Interventional|||A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer|A Phase II Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer|Completed||Phase 2|744|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 05:21:44.775905|2018-06-01 05:21:44.775905
NCT00055393|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-28|||2017-03-10|2003-02-28|2003-03-03|Estimate|||||||2017-03-10|2017-03-14|Actual|July 2002||2002-07-31|March 2017|2017-03-31|April 2006|Actual|2006-04-30|May 2005|Actual|2005-05-31||Interventional|||Bupropion in the Treatment of Pathological Gambling|Bupropion Versus Placebo in the Treatment of Pathological Gambling|Completed||N/A|80|Actual|University of Iowa||2|||f||||f|f|||||||No|There is no plan to share individual participant data.|2018-06-01 05:21:44.888706|2018-06-01 05:21:44.888706
NCT00055380|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-28|||2008-03-03|2003-02-27|2003-02-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2003||2003-02-28|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients|Molecular, Genetic, and Biochemical Effects Of Novel Therapies In Buccal Mucosal Cells|Completed||Phase 1|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:44.992282|2018-06-01 05:21:44.992282
NCT00055367|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-26|||2016-06-14|2003-02-27|2003-02-28|Estimate|||||||2016-06-14|2016-06-16|Estimate|April 2002||2002-04-30|March 2012|2012-03-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease|A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease|Completed||Phase 2|30||Biogen|||||||||||||||||||2018-06-01 05:21:45.104416|2018-06-01 05:21:45.104416
NCT00055354|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-26|||2006-08-17|2003-02-26|2003-02-27|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2002||2002-09-30|July 2006|2006-07-31|May 2004||2004-05-31|||||Interventional|||Acupuncture for the Treatment of Post-Traumatic Stress Disorder (PTSD)|Acupuncture Diagnosis and Treatment of DSM-IV PTSD|Completed||N/A|90||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:21:45.212102|2018-06-01 05:21:45.212102
NCT00055341|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-25|||2008-07-29|2003-02-26|2003-02-27|Estimate|||||||2008-07-29|2008-07-30|Estimate|March 2002||2002-03-31|December 2006|2006-12-31|June 2005||2005-06-30|||||Interventional|||Treatment of Hepatitis C in Hemophilic Patients With HIV|A Prospective Multicenter, Phase II, Open Label, Controlled Trial Evaluating the Response of Hepatitis C Virus (HCV) to Pegylated Interferon Alpha-2A and Ribavirin in Hemophilic Patients With and Without Coinfection With the Human Immunodeficiency Virus (HIV)|Completed||Phase 2|22||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:21:45.288381|2018-06-01 05:21:45.288381
NCT00055315|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-25|||2017-03-15|2003-02-25|2003-02-26|Estimate|||||||2017-03-15|2017-03-16|Actual|July 2002||2002-07-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|December 2007|Actual|2007-12-31||Interventional|||Treatment for Borderline Personality Disorder|A Cognitive Group Treatment for Borderline Outpatients|Completed||N/A|383|Actual|University of Iowa||2|||f||||f||||||||No|There is no plan to share individual participant data.|2018-06-01 05:21:45.55893|2018-06-01 05:21:45.55893
NCT00055302|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-25|||2015-08-31|2003-02-25|2003-02-26|Estimate|||||||2015-08-31|2015-09-01|Estimate|August 2002||2002-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|February 2006|Actual|2006-02-28||Interventional|||Arimidex in McCune Albright Syndrome|An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome|Completed||Phase 2|40|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 05:21:45.671169|2018-06-01 05:21:45.671169
NCT00055263|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-21|||2009-07-24|2003-02-24|2003-02-25|Estimate|||||||2009-07-24|2009-07-28|Estimate|March 2002||2002-03-31|February 2003|2003-02-28||||||||Interventional|||A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies|A Phase I, Open Label, Dose Escalation Study of a New Formulation of Calcitriol (DN-101) for Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies|Completed||Phase 1|60||Novacea|||||||||||||||||||2018-06-01 05:21:45.818509|2018-06-01 05:21:45.818509
NCT00055289|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-22|||2008-03-03|2003-02-21|2003-02-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2003||2003-02-28|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Brain Use of Sensory Information to Generate Movement|Role of Multimodal Areas for Sensory-To-Motor Processing|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:45.960413|2018-06-01 05:21:45.960413
NCT00055250|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-21|||2007-01-24|2003-02-21|2003-02-24|Estimate|||||||2007-01-24|2007-01-26|Estimate|January 2003||2003-01-31|January 2007|2007-01-31|October 2005||2005-10-31|||||Interventional|||A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer|A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|130||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:21:46.046824|2018-06-01 05:21:46.046824
NCT00055237|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-21|2012-06-19||2017-08-07|2003-02-20|2003-02-21|Estimate|2012-06-19|2012-07-26|Estimate||||2017-08-07|2017-09-06|Actual|February 26, 2003|Actual|2003-02-26|August 2017|2017-08-31|March 15, 2010|Actual|2010-03-15|March 15, 2010|Actual|2010-03-15||Interventional|||Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients|Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma|Completed||Phase 2|19|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f||||||No||2018-06-01 05:21:46.171079|2018-06-01 05:21:46.171079
NCT00055224|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-21|||2018-05-08|2003-02-20|2003-02-21|Estimate|||||||2018-05-08|2018-05-09|Actual|February 20, 2003||2003-02-20|April 26, 2018|2018-04-26||||||||Observational|||Expectation of Unpleasant Events in Anxiety Disorders|Predictability and Aversive Expectancies in Anxiety and Depressive Disorders|Recruiting|||1271|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:46.781999|2018-06-01 05:21:46.781999
NCT00055198|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-20|||2017-06-12|2003-02-20|2003-02-21|Estimate|||||||2017-06-12|2017-06-14|Actual|December 19, 2002|Actual|2002-12-19|June 2017|2017-06-30|January 26, 2004|Actual|2004-01-26|January 26, 2004|Actual|2004-01-26||Interventional|||Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria|A Compassionate Use Protocol for Intravenous Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria That Cannot be Adequately Treated With Currently Available Therapy|Terminated||Phase 3|75||Cubist Pharmaceuticals LLC||||Study terminated due to low enrollment|||||||||||||||2018-06-01 05:21:46.955235|2018-06-01 05:21:46.955235
NCT00055185|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-20|||2008-10-02|2003-02-20|2003-02-21|Estimate|||||||2008-10-02|2008-10-03|Estimate|April 2003||2003-04-30|October 2008|2008-10-31|June 2005|Actual|2005-06-30|||||Interventional|||Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients||Completed||Phase 2|24||Progenics Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 05:21:47.082456|2018-06-01 05:21:47.082456
NCT00055146|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-19|||2009-04-16|2003-02-20|2003-02-21|Estimate|||||||2009-04-16|2009-04-17|Estimate|March 2003||2003-03-31|April 2009|2009-04-30|May 2006|Actual|2006-05-31|March 2006|Actual|2006-03-31||Interventional|||Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)|A Multicenter, Phase II Study of ONTAK (Denileukin Diftitox) in Patients With Previously-Treated Chronic Lymphocytic Leukemia|Completed||Phase 2|41|Anticipated|Eisai Inc.|||||f||||||||||||||2018-06-01 05:21:47.169739|2018-06-01 05:21:47.169739
NCT00055133|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-19|||2008-07-26|2003-02-20|2003-02-21|Estimate|||||||2008-07-26|2008-07-29|Estimate|September 2002||2002-09-30|July 2008|2008-07-31|December 2004||2004-12-31|||||Interventional|||A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis|A Phase 2 Open-Label Clinical Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis|Completed||Phase 2|50||Angiotech Pharmaceuticals|||||||||||||||||||2018-06-01 05:21:47.304519|2018-06-01 05:21:47.304519
NCT00055172|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-20|||2018-05-26|2003-02-19|2003-02-20|Estimate|||||||2018-05-26|2018-05-30|Actual|February 19, 2003||2003-02-19|May 23, 2018|2018-05-23||||||||Observational|||Genetic Basis of Immunodeficiency|The Determination of Genetic Basis Of Immunodeficiency|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:47.419215|2018-06-01 05:21:47.419215
NCT00055159|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-20|||2017-06-30|2003-02-19|2003-02-20|Estimate|||||||2017-06-30|2017-07-02|Actual|February 19, 2003||2003-02-19|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Interventional|||Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins|Treatment of Jugular, Subclavian, and/or Innominate Vein Thrombosis With Low Dose Recombinant Tissue Plasminogen Activator Plus Anticoagulation|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:47.619853|2018-06-01 05:21:47.619853
NCT00055120|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-19|||2014-10-14|2003-02-19|2003-02-20|Estimate|||||||2014-10-14|2014-10-15|Estimate|March 2003||2003-03-31|October 2014|2014-10-31|August 2007|Actual|2007-08-31|September 2006|Actual|2006-09-30||Interventional|||When to Start Anti-HIV Drugs in Patients With Opportunistic Infections|A Phase IV Study of Antiretroviral Therapy for HIV Infected Adults Presenting With Acute Opportunistic Infections: Immediate Versus Deferred Initiation of Antiretroviral Therapy|Completed||Phase 4|283|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:21:47.737734|2018-06-01 05:21:47.737734
NCT00055107|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-19|||2012-02-14|2003-02-19|2003-02-20|Estimate|||||||2012-02-14|2012-02-16|Estimate||||February 2012|2012-02-29|May 2006|Actual|2006-05-31|||||Interventional|||Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children|A Phase I/II Open Label Study of Nitazoxanide (NTZ) for the Treatment of Cryptosporidium Parvum in HIV Infected Infants, Children, and Adolescents|Completed||Phase 1/Phase 2|6|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:21:47.917878|2018-06-01 05:21:47.917878
NCT00055094|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-19|||2005-06-23|2003-02-19|2003-02-20|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1999||1999-07-31|April 2004|2004-04-30||||||||Observational|||Treatment of Acute HIV Infection to Preserve Immune Function|Immune Control of HIV Replication|Completed|||500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:21:48.123072|2018-06-01 05:21:48.123072
NCT00055081|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-19|||2013-12-05|2003-02-19|2003-02-20|Estimate|||||||2013-12-05|2013-12-06|Estimate|July 2002||2002-07-31|December 2013|2013-12-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||The Impact of Family CTI on Homeless Children|The Impact of Family CTI on Homeless Children|Completed||N/A|320|Actual|Nathan Kline Institute for Psychiatric Research|||||f||||f||||||||||2018-06-01 05:21:48.189696|2018-06-01 05:21:48.189696
NCT00055068|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-19|||2014-05-06|2003-02-19|2003-02-20|Estimate|||||||2014-05-06|2014-05-07|Estimate|March 2002||2002-03-31|February 2008|2008-02-29|February 2006||2006-02-28|||||Interventional|||Family Based Treatment of Early Childhood Obsessive Compulsive Disorder|Family Based Treatment of Early Childhood OCD|Completed||Phase 3|38|Anticipated|Rhode Island Hospital|||||f||||||||||||||2018-06-01 05:21:48.347341|2018-06-01 05:21:48.347341
NCT00055055|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-15|||2018-04-03|2003-02-14|2003-02-17|Estimate|||||||2018-04-03|2018-04-04|Actual|February 14, 2003||2003-02-14|March 22, 2018|2018-03-22||||||||Observational|||Study of Families With Twins or Siblings Discordant for Rheumatic Disorders|Pathogenic Studies In Families With Twins Or Siblings Discordant For Systemic Rheumatic Disorders|Recruiting|||1550|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:50.860259|2018-06-01 05:21:50.860259
NCT00055042|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-15|||2008-03-03|2003-02-14|2003-02-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2003||2003-02-28|January 2004|2004-01-31|January 2004||2004-01-31|||||Interventional|||Laser and Antioxidant Treatment of Diabetic Macular Edema|Laser and Antioxidant Treatment of Diabetic Macular Edema|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:51.280421|2018-06-01 05:21:51.280421
NCT00055029|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-15|||2018-03-27|2003-02-14|2003-02-17|Estimate|||||||2018-03-27|2018-03-29|Actual|February 12, 2003||2003-02-12|February 5, 2018|2018-02-05||||||||Observational|||Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis|X-Linked Juvenile Retinoschisis - Clinical and Molecular Studies|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:51.471337|2018-06-01 05:21:51.471337
NCT00055016|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-15|||2017-06-30|2003-02-14|2003-02-17|Estimate|||||||2017-06-30|2017-07-02|Actual|February 13, 2003||2003-02-13|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||Registry of Fabry Disease - A Multicenter Observational Study|Registry of Fabry Disease: A Multicenter, Longitudinal Observational Study|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:51.572421|2018-06-01 05:21:51.572421
NCT00055003|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-15|||2017-06-30|2003-02-14|2003-02-17|Estimate|||||||2017-06-30|2017-07-02|Actual|February 13, 2003||2003-02-13|November 18, 2010|2010-11-18|November 18, 2010||2010-11-18|||||Observational|||Effect of Hydrocortisone on the Brain|Effects of Hydrocortisone Infusion on Processing of Facially Expressed Emotion During Functional Magnetic Resonance Imaging|Completed|||80|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:51.674318|2018-06-01 05:21:51.674318
NCT00054990|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-15|||2008-03-03|2003-02-14|2003-02-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2003||2003-02-28|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Effects of Antiepileptic Drugs on Brain Excitability|The Effects Of Antiepileptic Drugs On Cortical Excitability|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:51.784867|2018-06-01 05:21:51.784867
NCT00054977|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-14|||2012-03-09|2003-02-14|2003-02-17|Estimate|||||||2012-03-09|2012-03-12|Estimate|February 2003||2003-02-28|March 2012|2012-03-31|September 2006|Actual|2006-09-30|April 2005|Actual|2005-04-30||Interventional|||Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors|A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors|Completed||Phase 1|40|Actual|Galectin Therapeutics Inc.|||||f||||f||||||||||2018-06-01 05:21:51.837535|2018-06-01 05:21:51.837535
NCT00054964|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-14|||2017-02-03|2003-02-14|2003-02-17|Estimate|||||||2017-02-03|2017-02-06|Estimate|March 2003||2003-03-31|February 2017|2017-02-28|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Comparative Effectiveness of a Breath-operated Albuterol Inhaler in Asthma Patients With Poor Inhaler Technique|Comparison of Single-dose Efficacy of Albuterol-HFA-BOI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability|Completed||Phase 2|14|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-06-01 05:21:51.937272|2018-06-01 05:21:51.937272
NCT00054951|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-13|||2005-06-23|2003-02-14|2003-02-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2001||2001-06-30|September 2003|2003-09-30||||||||Interventional|||Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads|A Phase I/II, Open Label, Multicenter, Single-Arm, Safety and Efficacy Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery (Via Hepatic Artery Catheterization) for the Treatment of Patients With Unresectable Hepatocellular Carcinoma.|Unknown status|Active, not recruiting|Phase 1/Phase 2|30||FeRx|||||||||||||||||||2018-06-01 05:21:52.026138|2018-06-01 05:21:52.026138
NCT00054938|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-13|||2013-12-23|2003-02-13|2003-02-14|Estimate|||||||2013-12-23|2013-12-24|Estimate|March 2003||2003-03-31|December 2013|2013-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)|A Randomized Controlled Trial of Strategies for the Prevention of Accelerated Atherosclerosis in Systemic Lupus Erythematosus - A Pilot Study|Completed||Phase 2|150||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:21:52.207262|2018-06-01 05:21:52.207262
NCT00054925|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-13|||2012-03-06|2003-02-13|2003-02-14|Estimate|||||||2012-03-06|2012-03-07|Estimate|January 2003||2003-01-31|March 2012|2012-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|WLM||Weight Loss Maintenance (WLM)|Weight Loss Maintenance (WLM)|Completed||N/A|1685|Actual|Duke University||2|||f||||t||||||||||2018-06-01 05:21:52.331535|2018-06-01 05:21:52.331535
NCT00054912|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-12|||2008-04-07|2003-02-13|2003-02-14|Estimate|||||||2008-04-07|2008-04-09|Estimate|February 2003||2003-02-28|April 2004|2004-04-30||||||||Interventional|||An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer|An Open Label, Multi-Center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage III Colon Cancer|Completed||Phase 1|18||Epimmune|||||||||||||||||||2018-06-01 05:21:52.508132|2018-06-01 05:21:52.508132
NCT00054899|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-12|||2010-03-23|2003-02-13|2003-02-14|Estimate|||||||2010-03-23|2010-03-24|Estimate|January 2003||2003-01-31|April 2004|2004-04-30||||||||Interventional|||An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer|An Open Label, Multi-center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|18||Epimmune|||||||||||||||||||2018-06-01 05:21:53.076382|2018-06-01 05:21:53.076382
NCT00054886|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-12|||2007-05-04|2003-02-12|2003-02-13|Estimate|||||||2007-05-04|2007-05-07|Estimate|January 2003||2003-01-31|July 2006|2006-07-31|August 2004|Actual|2004-08-31|||||Interventional|||Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer|Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma|Completed||Phase 2|63||Pfizer|||||f||||||||||||||2018-06-01 05:21:53.206605|2018-06-01 05:21:53.206605
NCT00054860|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-11|||2015-04-13|2003-02-12|2003-02-13|Estimate|||||||2015-04-13|2015-04-14|Estimate||||April 2015|2015-04-30|September 2005|Actual|2005-09-30|||||Interventional|||Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults|A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of the EP HIV-1090 DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants|Completed||Phase 1|42||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:21:53.537594|2018-06-01 05:21:53.537594
NCT00054847|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-11|2014-01-31||2014-04-18|2003-02-12|2003-02-13|Estimate|2014-01-31|2014-03-14|Estimate||||2014-04-18|2014-05-05|Estimate|February 2003||2003-02-28|April 2014|2014-04-30|February 2010|Actual|2010-02-28|February 2009|Actual|2009-02-28||Interventional|||Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery|CSP #474 - Radial Artery vs. Saphenous Vein Grafts in Coronary Artery Bypass Surgery (Radial Artery)|Completed||N/A|733|Actual|VA Office of Research and Development|There was more disease in the radial artery grafts at 1 week and at 1 year. There is more spasm or string sign in radial artery grafts. Study was conducted predominantly in men. Data show lower vein graft patency when endoscopic harvesting was used.|2|||f||||t||||||||||2018-06-01 05:21:53.768272|2018-06-01 05:21:53.768272
NCT00054834|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-11|||2008-01-08|2003-02-12|2003-02-13|Estimate|||||||2008-01-08|2008-01-09|Estimate|March 2003||2003-03-31|January 2008|2008-01-31||||||||Interventional|||Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma|A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma|Terminated||Phase 1|27||Immunomedics, Inc.||||lack of accrual|||||||||||||||2018-06-01 05:21:56.191625|2018-06-01 05:21:56.191625
NCT00054821|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-11|||2017-03-16|2003-02-12|2003-02-13|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2002||2002-11-30|March 2017|2017-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Prevention of Post-Traumatic Osteoarthritis (OA)|Pathogenesis-Prevention of Post-Traumatic Osteoarthritis (OA): Effects of Distraction and Motion on OA|Completed||N/A|40|Actual|University of Iowa||2|||f||||t||||||||||2018-06-01 05:21:56.325068|2018-06-01 05:21:56.325068
NCT00054808|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-10|||2006-02-07|2003-02-12|2003-02-13|Estimate|||||||2006-02-07|2006-02-08|Estimate|June 2002||2002-06-30|February 2006|2006-02-28||||||||Interventional|||Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Multicenter Study of Gallium Nitrate in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|40||Genta Incorporated|||||||||||||||||||2018-06-01 05:21:56.445153|2018-06-01 05:21:56.445153
NCT00054795|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-10|||2007-05-04|2003-02-12|2003-02-13|Estimate|||||||2007-05-04|2007-05-08|Estimate||||May 2007|2007-05-31||||||||Interventional|||Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)|Randomized Phase III Trial of Xcytrin® (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy|Completed||Phase 3|550||Pharmacyclics LLC.|||||||||||||||||||2018-06-01 05:21:56.580575|2018-06-01 05:21:56.580575
NCT00054769|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-10|||2008-09-16|2003-02-10|2003-02-11|Estimate|||||||2008-09-16|2008-09-17|Estimate|March 2002||2002-03-31|July 2007|2007-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Diagnosing Tuberculosis in HIV Infected Children in Peru|Diagnostics For AIDS-Related Pediatric TB, Peru|Completed|||760||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:21:56.827354|2018-06-01 05:21:56.827354
NCT00054730|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-07|||2005-06-23|2003-02-10|2003-02-11|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2002||2002-06-30|February 2005|2005-02-28||||||||Interventional|||Effects of CX516 on Functioning in Fragile X Syndrome and Autism|Effects of Ampakine CX516 (Ampalex®) on Functioning in Fragile X Syndrome and Autism|Completed||Phase 2|||RespireRx|||||||||||||||||||2018-06-01 05:21:56.894686|2018-06-01 05:21:56.894686
NCT00054756|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-07|||2017-10-18|2003-02-07|2003-02-10|Estimate|||||||2017-10-18|2017-10-19|Actual|February 7, 2003||2003-02-07|April 25, 2017|2017-04-25|February 3, 2017|Actual|2017-02-03|February 3, 2017|Actual|2017-02-03||Interventional|||Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities|Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities|Completed||Phase 2|157|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:57.047731|2018-06-01 05:21:57.047731
NCT00054743|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-07|||2017-06-30|2003-02-07|2003-02-10|Estimate|||||||2017-06-30|2017-07-02|Actual|February 6, 2003||2003-02-06|April 28, 2011|2011-04-28|April 28, 2011|Actual|2011-04-28|||||Interventional|||Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United States|Global Initiative to Characterize Differences in Antiretroviral Pharmacokinetics in HIV-Infected Populations|Completed||Phase 4|24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:21:57.162231|2018-06-01 05:21:57.162231
NCT00054717|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-07|2009-09-09||2014-06-23|2003-02-07|2003-02-10|Estimate|2009-11-02|2009-11-19|Estimate||||2014-06-23|2014-07-02|Estimate|January 2003||2003-01-31|April 2014|2014-04-30||||September 2008|Actual|2008-09-30||Interventional||Safety Set, all patients treated with at least one dose of study drug|Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)|Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.|Completed||Phase 3|630|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-06-01 05:21:57.446621|2018-06-01 05:21:57.446621
NCT00054704|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-06|2015-12-10||2016-05-17|2003-02-06|2003-02-07|Estimate|2016-04-22|2016-05-02|Estimate||||2016-05-17|2016-05-19|Estimate|February 2003||2003-02-28|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All participants randomized.|Riluzole to Treat Depression in Bipolar Disorder|An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression|Terminated||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)|The study was terminated due to results suggesting the active drug was leading to worse outcomes than placebo.|2||Placebo was better than active drug.|f||||t||||||||No||2018-06-01 05:22:00.899295|2018-06-01 05:22:00.899295
NCT00054691|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-06|2015-01-28||2015-02-24|2003-02-06|2003-02-07|Estimate|2015-01-28|2015-02-12|Estimate||||2015-02-24|2015-03-13|Estimate|May 2004||2004-05-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Out of 40 participants, 2 participants had unmeasurable disease and 1 participant was noncompliant.|ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin|A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin|Completed||Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:22:02.185582|2018-06-01 05:22:02.185582
NCT00054522|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2011-03-07|2003-02-05|2003-02-06|Estimate|||||||2011-03-07|2011-03-08|Estimate|April 2002||2002-04-30|March 2011|2011-03-31|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy|Calcitriol + Dexamethasone in Early, Recurrent Prostate Cancer Following Local Therapy, A Phase I/II Trial|Completed||Phase 2|15|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:05.551256|2018-06-01 05:22:05.551256
NCT00054678|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-06|||2007-10-11|2003-02-06|2003-02-07|Estimate|||||||2007-10-11|2007-10-15|Estimate|February 2003||2003-02-28|October 2007|2007-10-31|October 2007|Anticipated|2007-10-31|||||Interventional|||MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)|A Phase I, Open-Label, Non-Randomized, Dose Escalation, Multi Center Study to Assess the Safety and Cardiovascular Effects of Autologous Skeletal Myoblast Implantation by a Transendocardial Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s) With Previous Placement of ICD|Unknown status|Active, not recruiting|Phase 1|20||Bioheart, Inc.|||||f||||||||||||||2018-06-01 05:22:02.65393|2018-06-01 05:22:02.65393
NCT00050531|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-12|||2016-05-09|2003-02-06|2003-02-07|Estimate|||||||2016-05-09|2016-05-11|Estimate|April 2003||2003-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|April 2007|Actual|2007-04-30||Interventional|||High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)|Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia With High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination With Peg-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF)|Completed||Phase 3|94|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 05:22:02.76168|2018-06-01 05:22:02.76168
NCT00054665|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2012-06-25||2012-08-10|2003-02-05|2003-02-06|Estimate|2012-08-10|2012-09-11|Estimate||||2012-08-10|2012-09-11|Estimate|February 2003||2003-02-28|August 2012|2012-08-31|July 2009|Actual|2009-07-31|September 2008|Actual|2008-09-30||Interventional|||PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma|PS-341 and PS-341 + Epoch Chemotherapy and Molecular Profiling in Relapsed or Refractory Diffuse Large B-Cell Lymphomas|Completed||Phase 2|50|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:22:03.052653|2018-06-01 05:22:03.052653
NCT00054652|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2008-03-03|2003-02-05|2003-02-06|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2003||2003-02-28|February 2005|2005-02-28|February 2005||2005-02-28|||||Observational|||Survey of Sensory and Motor Tricks in Focal Dystonia|Survey of Sensory and Motor Tricks in Focal Dystonia|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:22:03.879984|2018-06-01 05:22:03.879984
NCT00054639|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2011-01-24||2014-05-13|2003-02-05|2003-02-06|Estimate|2011-01-24|2011-02-21|Estimate||||2014-05-13|2014-05-28|Estimate|January 2003||2003-01-31|March 2013|2013-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma|A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas|Completed||Phase 2|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:03.998466|2018-06-01 05:22:03.998466
NCT00054626|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-12-17|2003-02-05|2003-02-06|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2001||2001-09-30|November 2008|2008-11-30||||June 2008|Anticipated|2008-06-30||Interventional|||Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer|Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer|Unknown status|Active, not recruiting|Phase 3|700|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:04.241378|2018-06-01 05:22:04.241378
NCT00054613|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2017-08-14|2003-02-05|2003-02-06|Estimate|||||||2017-08-14|2017-08-16|Actual|June 2002||2002-06-30|August 2017|2017-08-31|March 2004||2004-03-31|||||Interventional|||Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease|A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft-versus-Host Disease|Completed||Phase 2|72||Mallinckrodt|||||||||||||||||||2018-06-01 05:22:04.538924|2018-06-01 05:22:04.538924
NCT00054600|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2017-08-14|2003-02-05|2003-02-06|Estimate|||||||2017-08-14|2017-08-16|Actual|June 2002||2002-06-30|August 2017|2017-08-31|June 2004||2004-06-30|||||Interventional|||Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease|A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant|Completed||Phase 2|60||Mallinckrodt|||||||||||||||||||2018-06-01 05:22:04.819908|2018-06-01 05:22:04.819908
NCT00054587|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-07-18|2003-02-05|2003-02-06|Estimate|||||||2013-07-18|2013-07-19|Estimate|June 2001||2001-06-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer|Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And FISH+) Subjects|Completed||Phase 3|3010|Actual|UNICANCER||2|||f||||t||||||||||2018-06-01 05:22:04.950173|2018-06-01 05:22:04.950173
NCT00054574|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2012-08-02|2003-02-05|2003-02-06|Estimate|||||||2012-08-02|2012-08-06|Estimate|November 2002||2002-11-30|August 2012|2012-08-31|February 2004|Actual|2004-02-29|September 2003|Actual|2003-09-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer|A Clinical Trial Evaluating The Safety And Efficacy Of ABX-EGF In Patients With Hormone Resistant Prostate Cancer With Elevated PSA Without Metastasis|Completed||Phase 2|||Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:05.070983|2018-06-01 05:22:05.070983
NCT00054561|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2009-02-06|2003-02-05|2003-02-06|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2003||2003-08-31|May 2004|2004-05-31||||December 2004|Actual|2004-12-31||Interventional|||Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With Stages III/IV Head and Neck Squamous Cell Carcinoma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:05.157563|2018-06-01 05:22:05.157563
NCT00054548|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-05-15|2003-02-05|2003-02-06|Estimate|||||||2013-05-15|2013-05-16|Estimate|October 2002||2002-10-31|May 2013|2013-05-31||||May 2008|Actual|2008-05-31||Interventional|||Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors|A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors|Completed||Phase 1|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:05.410079|2018-06-01 05:22:05.410079
NCT00054535|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-06-18|2003-02-05|2003-02-06|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2003||2003-01-31|July 2004|2004-07-31|September 2004|Actual|2004-09-30|||||Interventional|||Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:05.496832|2018-06-01 05:22:05.496832
NCT00054496|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2014-01-09|2003-02-05|2003-02-06|Estimate|||||||2014-01-09|2014-01-10|Estimate|August 2002||2002-08-31|December 2006|2006-12-31||||||||Interventional|||Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme|Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme|Unknown status|Recruiting|Phase 2|73|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:05.620815|2018-06-01 05:22:05.620815
NCT00054483|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-05-15|2003-02-05|2003-02-06|Estimate|||||||2013-05-15|2013-05-16|Estimate|January 2003||2003-01-31|May 2013|2013-05-31||||September 2009|Actual|2009-09-30||Interventional|||Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction|A Phase I Pharmacokinetic Study of PS341 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group|Completed||Phase 1|69|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:05.695898|2018-06-01 05:22:05.695898
NCT00054470|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2012-06-27|2003-02-05|2003-02-06|Estimate|||||||2012-06-27|2012-06-29|Estimate|December 2002||2002-12-31|June 2012|2012-06-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer|A Phase II Evaluation Of The Efficacy And Safety Of R115777 (NSC702818) A Non-Peptidomimetic Farnesyl Transferase Inhibitor, And Trastuzumab In Patients With Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|The University of Texas Health Science Center at San Antonio|||||f||||t||||||||||2018-06-01 05:22:05.803252|2018-06-01 05:22:05.803252
NCT00054457|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2016-12-09|2003-02-05|2003-02-06|Estimate|||||||2016-12-09|2016-12-13|Estimate|September 2003||2003-09-30|December 2016|2016-12-31|February 2008|Actual|2008-02-29|February 2007|Actual|2007-02-28||Interventional|||Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction|A Phase II Study Of Docetaxel And Capecitabine In Patients With Measurable Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction|Completed||Phase 2|46|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:22:05.894318|2018-06-01 05:22:05.894318
NCT00054444|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2014-12-29|2003-02-05|2003-02-06|Estimate|||||||2014-12-29|2014-12-31|Estimate|September 2007||2007-09-30|December 2014|2014-12-31||||January 2012|Actual|2012-01-31||Interventional|||Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer|A PHASE I STUDY OF PELVIC RADIATION THERAPY WITH CONCOMITANT WEEKLY CISPLATIN AND TOPOTECAN CHEMOTHERAPY IN PATIENTS WITH CERVICAL CARCINOMA WITHOUT EXTRA-PELVIC METASTASIS|Completed||Phase 1|11|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:22:06.033192|2018-06-01 05:22:06.033192
NCT00054431|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-01-22|2003-02-05|2003-02-06|Estimate|||||||2013-01-22|2013-01-23|Estimate|January 2003||2003-01-31|January 2013|2013-01-31||||May 2007|Actual|2007-05-31||Interventional|||Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia|Phase II Study of Imatinib Mesylate (Gleevec, STI-571) (NSC#716051) and Decitabine (5-AZA-2'-Deoxycitidine) (NSC#127716), in Chronic Myelogenous Leukemia in Accelerated and Blastic Phases|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:06.145743|2018-06-01 05:22:06.145743
NCT00054418|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2016-07-12|2003-02-05|2003-02-06|Estimate|||||||2016-07-12|2016-07-13|Estimate|March 2003||2003-03-31|July 2016|2016-07-31|May 2008|Actual|2008-05-31|April 2007|Actual|2007-04-30||Interventional|||Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer|A Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of Risedronate (Actonel) For Prevention Of Bone Loss In Premenopausal Women Undergoing Chemotherapy For Primary Breast Carcinoma|Completed||Phase 3|216|Actual|Alliance for Clinical Trials in Oncology||2|||f||||||||||||||2018-06-01 05:22:06.292311|2018-06-01 05:22:06.292311
NCT00054405|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-04-08|2003-02-05|2003-02-06|Estimate|||||||2013-04-08|2013-04-09|Estimate|December 2002||2002-12-31|April 2013|2013-04-30||||May 2009|Actual|2009-05-31||Interventional|||Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma|A Phase I Investigation of IL-12 (NSC 672423)/Pulse IL-2 (Aldesleukin) in Children With Persistent and/or Refractory Neuroblastoma (13623)|Terminated||Phase 1|40|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:22:06.74264|2018-06-01 05:22:06.74264
NCT00054392|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-07-10|2003-02-05|2003-02-06|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2001||2001-09-30|July 2013|2013-07-31|September 2001|Actual|2001-09-30|September 2001|Actual|2001-09-30||Interventional|||Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer|Withdrawn||Phase 3|0|Actual|Fox Chase Cancer Center||||Not opened at Fox Chase Cancer Center|f||||||||||||||2018-06-01 05:22:06.862023|2018-06-01 05:22:06.862023
NCT00054353|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2017-04-11||2017-09-14|2003-02-05|2003-02-06|Estimate|2017-09-14|2017-10-16|Actual||||2017-09-14|2017-10-16|Actual|October 2002||2002-10-31|September 2017|2017-09-30|October 14, 2012|Actual|2012-10-14|October 2009|Actual|2009-10-31||Interventional|||Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma|Reduced-Intensity Allogeneic HSC Transplantation From HLA-Matched Related and Unrelated Donors for Patients With Multiple Myeloma - A Multi-Center Trial|Completed||Phase 1/Phase 2|16|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-06-01 05:22:07.075913|2018-06-01 05:22:07.075913
NCT00054340|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2010-05-12|2003-02-05|2003-02-06|Estimate|||||||2010-05-12|2010-05-14|Estimate|October 2002||2002-10-31|May 2010|2010-05-31|September 2006|Actual|2006-09-30|||||Interventional|||Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder|Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:22:07.608539|2018-06-01 05:22:07.608539
NCT00054327|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2013-04-30||2013-06-19|2003-02-05|2003-02-06|Estimate|2013-06-19|2013-07-24|Estimate||||2013-06-19|2013-07-24|Estimate|November 2000||2000-11-30|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer|Hematopoietic Stem Cell Transplantation Using Bone Marrow Or Peripheral Blood Stem Cells From Matched, Unrelated, Volunteer Donors|Completed||Phase 2|34|Actual|Case Comprehensive Cancer Center||6|||f||||t||||||||||2018-06-01 05:22:07.75324|2018-06-01 05:22:07.75324
NCT00054314|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-01-30|2003-02-05|2003-02-06|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 2002||2002-03-31|January 2013|2013-01-31||||April 2003|Actual|2003-04-30||Interventional|||BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer|An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC)|Completed||Phase 2|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:22:08.659106|2018-06-01 05:22:08.659106
NCT00054301|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2010-06-10|2003-02-05|2003-02-06|Estimate|||||||2010-06-10|2010-06-11|Estimate|November 2002||2002-11-30|June 2010|2010-06-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer|Intraoperative Radiation Therapy to the Tumor Bed for Boost Treatment After Lumpectomy Prior to Whole Breast Radiation in Breast Conservation Candidates|Completed||Phase 2|2|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:08.712364|2018-06-01 05:22:08.712364
NCT00054288|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2014-01-10|2003-02-05|2003-02-06|Estimate|||||||2014-01-10|2014-01-13|Estimate|August 2001||2001-08-31|January 2014|2014-01-31|June 2009|Actual|2009-06-30|May 2003|Actual|2003-05-31||Interventional|||Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors|Escalating Irinotecan (CPT-11) Administered 24 Hours Prior To Gemcitabine In Patients With Refractory Solid Tumors|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:08.768802|2018-06-01 05:22:08.768802
NCT00054275|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2012-02-21||2016-02-15|2003-02-05|2003-02-06|Estimate|2012-02-21|2012-03-13|Estimate||||2016-02-15|2016-02-17|Estimate|December 2002||2002-12-31|February 2016|2016-02-29|November 2012|Actual|2012-11-30|April 2010|Actual|2010-04-30||Interventional|||Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer|A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With The Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer|Completed||Phase 2|39|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:22:08.83461|2018-06-01 05:22:08.83461
NCT00054262|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-07-17|2003-02-05|2003-02-06|Estimate|||||||2013-07-17|2013-07-18|Estimate|November 2002||2002-11-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|March 2004|Actual|2004-03-31||Interventional|||T900607 in Treating Patients With Unresectable Liver Cancer|A Phase II Study Of Intravenous T900607-Sodium In Subjects With Chemotherapy-Naive Unresectable Hepatocellular Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:09.218447|2018-06-01 05:22:09.218447
NCT00054249|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-07-17|2003-02-05|2003-02-06|Estimate|||||||2013-07-17|2013-07-18|Estimate|September 2002||2002-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|October 2004|Actual|2004-10-31||Interventional|||T900607 in Treating Patients With Gastroesophageal Junction Cancer|A Phase II Study Of Intravenous T900607-Sodium In Subjects With Previously Treated Gastric Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:09.269232|2018-06-01 05:22:09.269232
NCT00054236|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2012-09-11|2003-02-05|2003-02-06|Estimate|||||||2012-09-11|2012-09-12|Estimate|May 2002||2002-05-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia|Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia|Completed||Phase 1|55|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:22:09.322128|2018-06-01 05:22:09.322128
NCT00054223|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2012-03-14|2003-02-05|2003-02-06|Estimate|||||||2012-03-14|2012-03-16|Estimate|January 2003||2003-01-31|March 2012|2012-03-31|November 2005|Actual|2005-11-30|||||Interventional|||Study of Decision Making in Patients Participating in Phase I Clinical Trials|Ethics Study To Understand The Decision Making Process Of Phase I Cancer Patients|Completed||N/A|250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:22:09.402274|2018-06-01 05:22:09.402274
NCT00054210|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2008-07-23|2003-02-05|2003-02-06|Estimate|||||||2008-07-23|2008-07-24|Estimate|January 2003||2003-01-31|July 2004|2004-07-31||||||||Interventional|||Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|CT-2103/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:09.471756|2018-06-01 05:22:09.471756
NCT00054197|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2011-02-23|2003-02-05|2003-02-06|Estimate|||||||2011-02-23|2011-02-24|Estimate|January 2003||2003-01-31|July 2004|2004-07-31||||||||Interventional|||Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|CT-2103 vs Gemcitabine or Vinorelbine for the Treatment of PS = 2 Patients With Chemotherapy Naive Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Study|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:09.580482|2018-06-01 05:22:09.580482
NCT00054184|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-07-29|2003-02-05|2003-02-06|Estimate|||||||2013-07-29|2013-07-30|Estimate|January 2003||2003-01-31|July 2013|2013-07-31||||December 2013|Anticipated|2013-12-31||Interventional|||Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer|CT-2103 vs Docetaxel for the Second-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): A Phase III Study|Unknown status|Active, not recruiting|Phase 3|350|Anticipated|CTI BioPharma||1|||f||||||||||||||2018-06-01 05:22:09.644588|2018-06-01 05:22:09.644588
NCT00054171|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-01-30|2003-02-05|2003-02-06|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 1999||1999-02-28|January 2013|2013-01-31||||July 2005|Actual|2005-07-31||Interventional|||Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia|A Pilot Study of Short (1-2.5 h), Medium (4-6 h) and Long (18-24 h) Applications of 20% Topical ALA-PDT for Photodynamic Therapy of Cutaneous T and B Cell Lymphomas and Cutaneous Infiltrates of Early CLL|Completed||Phase 2|1|Actual|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:22:09.738834|2018-06-01 05:22:09.738834
NCT00054158|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-01-30|2003-02-05|2003-02-06|Estimate|||||||2013-01-30|2013-01-31|Estimate|August 2004||2004-08-31|January 2013|2013-01-31||||April 2006|Actual|2006-04-30||Interventional|||Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma|A Phase II Study of VAD (Vincristine, Adriamycin, Dexamethasone) Plus Thalidomide (Low Dose) as Frontline Therapy for Newly Diagnosed Patients With Multiple Myeloma (MM)|Completed||Phase 2|24|Actual|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:22:09.794684|2018-06-01 05:22:09.794684
NCT00054145|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2015-07-22|2003-02-05|2003-02-06|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2003||2003-06-30|July 2015|2015-07-31||||April 2007|Actual|2007-04-30||Interventional|||Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer|A Phase 2 Study Of Perifosine In Metastatic Or Advanced Breast Cancer|Completed||Phase 2|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 05:22:10.752146|2018-06-01 05:22:10.752146
NCT00054132|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2016-03-09||2017-06-23|2003-02-05|2003-02-06|Estimate|2017-06-23|2017-07-24|Actual||||2017-06-23|2017-07-24|Actual|December 2002||2002-12-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer|A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer|Completed||Phase 2|38|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:22:10.834543|2018-06-01 05:22:10.834543
NCT00054119|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2017-07-12|2003-02-05|2003-02-06|Estimate|||||||2017-07-12|2017-07-13|Actual|January 2003||2003-01-31|July 2017|2017-07-31||||September 30, 2005|Actual|2005-09-30||Interventional|||Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Karenitecin in the Third-Line Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|27|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:22:11.069325|2018-06-01 05:22:11.069325
NCT00054106|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2010-11-07|2003-02-05|2003-02-06|Estimate|||||||2010-11-07|2010-11-09|Estimate|December 2002||2002-12-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer|A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer|Completed||Phase 1|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:22:11.132822|2018-06-01 05:22:11.132822
NCT00054067|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-04-10|2003-02-05|2003-02-06|Estimate|||||||2013-04-10|2013-04-11|Estimate|February 2003||2003-02-28|April 2013|2013-04-30||||April 2005|Actual|2005-04-30||Interventional|||Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix|Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation|Terminated||Phase 3|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:22:11.299997|2018-06-01 05:22:11.299997
NCT00054054|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2011-07-21|2003-02-05|2003-02-06|Estimate|||||||2011-07-21|2011-07-25|Estimate|April 2003||2003-04-30|July 2011|2011-07-31||||November 2007|Actual|2007-11-30||Interventional|||S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Docetaxel (NSC-628503), Cisplatin (NSC-119875), And 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed By Accelerated Fractionation/Concomitant Boost Radiation And Concurrent Single Agent Cisplatin (NSC-119875), In Patients With Advanced Squamous Cell Head And Neck Cancer|Completed||Phase 2|||Southwest Oncology Group|||||f||||f||||||||||2018-06-01 05:22:11.463257|2018-06-01 05:22:11.463257
NCT00054041|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-01-23|2003-02-05|2003-02-06|Estimate|||||||2013-01-23|2013-01-24|Estimate|June 2004||2004-06-30|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia|Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3|Completed||Phase 2|84|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:22:11.668354|2018-06-01 05:22:11.668354
NCT00054028|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2014-11-17||2015-03-03|2003-02-05|2003-02-06|Estimate|2015-03-03|2015-03-17|Estimate||||2015-03-03|2015-03-17|Estimate|December 2002||2002-12-31|February 2015|2015-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer|A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer|Completed||Phase 1/Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:11.76547|2018-06-01 05:22:11.76547
NCT00054015|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-11-05|2003-02-05|2003-02-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|December 2002||2002-12-31|April 2004|2004-04-30|January 2008|Actual|2008-01-31|||||Interventional|||3-AP in Treating Patients With Advanced Prostate Cancer|A Phase II Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Patients With Advanced Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:12.223545|2018-06-01 05:22:12.223545
NCT00054002|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2011-02-25|2003-02-05|2003-02-06|Estimate|||||||2011-02-25|2011-03-01|Estimate|March 1999||1999-03-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|June 2006|Actual|2006-06-30||Interventional|||Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma|Surgery and Intracavitary Photodynamic Therapy (PDT) for the Treatment of Malignant Pleural Mesothelioma; The Use of Light Delivery Fibers With Large Diffusers|Completed||Phase 2|12|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:12.36084|2018-06-01 05:22:12.36084
NCT00053989|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2018-05-08|2003-02-05|2003-02-06|Estimate|||||||2018-05-08|2018-05-14|Actual|January 29, 2002|Actual|2002-01-29|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia|Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Aplastic Anemia|Active, not recruiting||Phase 2|41|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:12.437162|2018-06-01 05:22:12.437162
NCT00053976|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2017-01-19|2003-02-05|2003-02-06|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2001||2001-01-31|January 2017|2017-01-31|November 2004|Actual|2004-11-30|November 2003|Actual|2003-11-30||Interventional|||Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease|Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo|Completed||Phase 3|105|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 05:22:12.545085|2018-06-01 05:22:12.545085
NCT00053963|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-01-15|2003-02-05|2003-02-06|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2002||2002-09-30|January 2013|2013-01-31||||February 2006|Actual|2006-02-28||Interventional|||FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia|A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:12.655597|2018-06-01 05:22:12.655597
NCT00053950|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-04-08|2003-02-05|2003-02-06|Estimate|||||||2013-04-08|2013-04-09|Estimate|December 2002||2002-12-31|April 2013|2013-04-30||||March 2007|Actual|2007-03-31||Interventional|||Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma|A Phase I Study of High-dose Pyrazoloacridine (PZA) (NSC 366140) Supported With Autologous Hematopoietic Stem Cell Rescue in Children With Recurrent or Resistant Neuroblastoma (IND # 36325)|Terminated||Phase 1|42|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:22:12.747399|2018-06-01 05:22:12.747399
NCT00053937|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2015-04-29|2003-02-05|2003-02-06|Estimate|||||||2015-04-29|2015-04-30|Estimate|December 2002||2002-12-31|April 2004|2004-04-30||||||||Interventional|||Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas|Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:22:12.837585|2018-06-01 05:22:12.837585
NCT00053924|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2015-07-22|2003-02-05|2003-02-06|Estimate|||||||2015-07-22|2015-07-23|Estimate|May 2003||2003-05-31|July 2015|2015-07-31||||May 2006|Actual|2006-05-31||Interventional|||Perifosine in Treating Patients With Advanced Pancreatic Cancer|A Phase 2 Study Of Perifosine As Second Line Therapy For Advanced Pancreatic Carcinoma|Completed||Phase 2|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 05:22:12.924323|2018-06-01 05:22:12.924323
NCT00053911|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2014-12-14|2003-02-05|2003-02-06|Estimate|||||||2014-12-14|2014-12-16|Estimate|November 2002||2002-11-30|December 2014|2014-12-31||||April 2004|Actual|2004-04-30||Interventional|||Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer|Randomized And Multicentric Phase III Study Evaluating The Benefit By Using A Chemotherapy With FEC 100 And Docetaxel In Non Metastatic Breast Cancer Which Has Relapsed After A Conservative Surgery|Terminated||Phase 3|||UNICANCER|||||f||||||||||||||2018-06-01 05:22:13.004768|2018-06-01 05:22:13.004768
NCT00053898|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2017-11-20||2018-03-09|2003-02-05|2003-02-06|Estimate|2018-03-09|2018-03-12|Actual||||2018-03-09|2018-03-12|Actual|January 2003||2003-01-31|March 2018|2018-03-31|May 2016|Actual|2016-05-31|March 2015|Actual|2015-03-31||Interventional|||Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy|A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy|Completed||Phase 3|3104|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 05:22:13.321547|2018-06-01 05:22:13.321547
NCT00053885|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2016-06-30|2003-02-05|2003-02-06|Estimate|||||||2016-06-30|2016-07-01|Estimate|July 2003||2003-07-31|June 2016|2016-06-30|June 2006|Actual|2006-06-30|July 2005|Actual|2005-07-31||Interventional|||PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma|A Phase II Study of PTK787/ZK222584 (NSC#719335) in Patients With Unresectable Malignant Mesothelioma|Completed||Phase 2|47|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:22:15.097726|2018-06-01 05:22:15.097726
NCT00053872|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2014-06-23|2003-02-05|2003-02-06|Estimate|||||||2014-06-23|2014-06-24|Estimate|February 2003||2003-02-28|February 2007|2007-02-28||||||||Interventional|||Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma|A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma|Unknown status|Active, not recruiting|Phase 3|316|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:15.326647|2018-06-01 05:22:15.326647
NCT00053846|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|2014-08-20||2015-10-27|2003-02-05|2003-02-06|Estimate|2015-03-12|2015-03-20|Estimate||||2015-10-27|2015-11-24|Estimate|November 2002||2002-11-30|October 2015|2015-10-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Buspirone in Reducing Shortness of Breath in Patients With Cancer|Buspirone in Reducing Shortness of Breath in Patients With Cancer|Completed||Phase 2/Phase 3|432|Actual|University of Rochester||2|||f||||t||||||||||2018-06-01 05:22:15.419224|2018-06-01 05:22:15.419224
NCT00053833|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-11-07|2003-02-05|2003-02-06|Estimate|||||||2013-11-07|2013-11-08|Estimate|April 2003||2003-04-30|November 2013|2013-11-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|S0025: Phase II Trial Of Irinotecan (CAMPTOSAR) For Patients With Platinum And Taxane Refractory Ovarian, Peritoneal Or Fallopian Tube Cancer|Terminated||Phase 2|2|Actual|Southwest Oncology Group||1||lack of accrual|f||||t||||||||||2018-06-01 05:22:15.935929|2018-06-01 05:22:15.935929
NCT00053820|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2013-12-18|2003-02-05|2003-02-06|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2002||2002-07-31|August 2006|2006-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer|A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 3|670|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:16.122009|2018-06-01 05:22:16.122009
NCT00053807|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2012-09-20|2003-02-05|2003-02-06|Estimate|||||||2012-09-20|2012-09-24|Estimate|February 1998||1998-02-28|September 2012|2012-09-30||||January 2004|Actual|2004-01-31||Interventional|||Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer|Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma|Completed||Phase 3|96|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:22:16.20115|2018-06-01 05:22:16.20115
NCT00053794|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2010-11-07|2003-02-05|2003-02-06|Estimate|||||||2010-11-07|2010-11-09|Estimate|May 2003||2003-05-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma|A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:22:16.274138|2018-06-01 05:22:16.274138
NCT00053781|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2010-11-07|2003-02-05|2003-02-06|Estimate|||||||2010-11-07|2010-11-09|Estimate|June 2003||2003-06-30|March 2010|2010-03-31|December 2009|Actual|2009-12-31|||||Interventional|||Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma|A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:22:16.329702|2018-06-01 05:22:16.329702
NCT00053768|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-05|||2009-02-06|2003-02-05|2003-02-06|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 2002||2002-04-30|June 2007|2007-06-30||||||||Interventional|||Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma|Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses|Unknown status|Active, not recruiting|Phase 3|552|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:16.575691|2018-06-01 05:22:16.575691
NCT00053716|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|||2007-03-06|2003-02-05|2003-02-06|Estimate|||||||2007-03-06|2007-03-07|Estimate|February 2003||2003-02-28|March 2004|2004-03-31|August 2003||2003-08-31|||||Interventional|||Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease|Phase II, Single Center, Non-Controlled, Open-Label Study of Liposomal Prostaglandin E1 (Liprostin) as Adjunct Therapy With Lower Limb Angioplasty in Patients With Ischemic and Non-Ischemic Peripheral Arterial Occlusive Disease|Unknown status|Recruiting|Phase 2|12||Endovasc|||||||||||||||||||2018-06-01 05:22:16.925048|2018-06-01 05:22:16.925048
NCT00045123|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-12-17|2003-02-05|2003-02-06|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2002||2002-02-28|February 2004|2004-02-29||||||||Interventional|||R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence|Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence With Rising PSA Levels After Prostatectomy, Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:17.0004|2018-06-01 05:22:17.0004
NCT00028678|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2010-01-26|2003-02-05|2003-02-06|Estimate|||||||2010-01-26|2010-01-28|Estimate|May 2002||2002-05-31|January 2010|2010-01-31||||July 2006|Actual|2006-07-31||Interventional|||Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme|A Phase II Study to Evaluate the Effect of Dalteparin and Radiation Therapy on Survival Compared to the RTOG RPA Database and on Thromboembolic Events in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||||||f||||||||||2018-06-01 05:22:17.138652|2018-06-01 05:22:17.138652
NCT00017342|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2010-02-26|2003-02-05|2003-02-06|Estimate|||||||2010-02-26|2010-03-01|Estimate|July 2001||2001-07-31|February 2010|2010-02-28|June 2005|Actual|2005-06-30|September 2004|Actual|2004-09-30||Interventional|||Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia|Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia|Completed||Phase 2|||Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 05:22:17.227815|2018-06-01 05:22:17.227815
NCT00053742|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|||2008-03-03|2003-02-04|2003-02-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2003||2003-02-28|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox|A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Immunogenicity and Protective Efficacy Against Dryvax® (Registered Trademark) Challenge in Vaccinia-Immune Individuals|Completed||Phase 1|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:22:17.294853|2018-06-01 05:22:17.294853
NCT00053703|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|2013-09-16||2014-02-07|2003-02-04|2003-02-05|Estimate|2014-02-07|2014-03-26|Estimate||||2014-02-07|2014-03-26|Estimate|February 2002||2002-02-28|February 2014|2014-02-28|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|TEOSS|We are referring to the population of participants who had baseline assessment, took at least one dose of trial medication, and had at least one post-baseline assessment. There were 3 randomized subjects, on in each treatment group, who did not take at least one dose of study medication and are not included.|Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)|Treatment of Schizophrenia and Related Disorders in Children and Adolescents|Completed||Phase 4|116|Actual|University of North Carolina, Chapel Hill|The most significant weakness of this study was the sample size, which was sufficient only to detect large differences across the three treatments and limited our ability to identify predictors of response or adverse effects.|3|||f||||t||||||||||2018-06-01 05:22:17.371898|2018-06-01 05:22:17.371898
NCT00053690|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|||2013-09-09|2003-02-04|2003-02-05|Estimate|||||||2013-09-09|2013-09-10|Estimate|January 2002||2002-01-31|February 2009|2009-02-28|December 2004||2004-12-31|||||Interventional|||Treatment of Post Traumatic Stress Disorder in Patients With Other Mental Illnesses|Cognitive-Behavioral Treatment of PTSD in SMI Clients|Completed||N/A|88||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:22:17.988291|2018-06-01 05:22:17.988291
NCT00053677|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|2017-04-03||2017-07-31|2003-02-04|2003-02-05|Estimate|2017-07-31|2017-10-03|Actual||||2017-07-31|2017-10-03|Actual|December 2002||2002-12-31|July 2017|2017-07-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Drug Treatment for Pathologic Gambling Disorder|Naltrexone Treatment in Pathologic Gambling Disorder|Completed||Phase 3|83|Actual|University of Chicago|Pathological gambling is a chronic disease that may require long-term therapy. Although this study is one of the longest medication trials for PG, the study did not assess treatment effects beyond the acute 18-week treatment period.|2|||f||||||||||||||2018-06-01 05:22:19.814718|2018-06-01 05:22:19.814718
NCT00053651|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|||2013-08-20|2003-02-04|2003-02-05|Estimate|||||||2013-08-20|2013-08-22|Estimate|September 2001||2001-09-30|August 2013|2013-08-31||||||||Interventional|||Prevention of Postpartum Depression in Low-Income Women|Depression Intervention for Poor Pregnant Women|Completed||Phase 1|250||Butler Hospital|||||f||||t||||||||||2018-06-01 05:22:20.877239|2018-06-01 05:22:20.877239
NCT00053638|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|||2010-10-01|2003-02-04|2003-02-05|Estimate|||||||2010-10-01|2010-10-04|Estimate|February 2003||2003-02-28|October 2010|2010-10-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy|A Phase III, Randomized, Open-label, Multicenter Study of the Safety and Efficacy of Efavirenz Versus Tenofovir When Administered in Combination With the Abacavir/Lamivudine Fixed-dose Combination Tablet as a Once-daily Regimen in Antiretroviral-naive HIV-1 Infected Subjects.|Completed||Phase 3|345||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:22:21.043267|2018-06-01 05:22:21.043267
NCT00053625|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-04|||2015-04-02|2003-02-04|2003-02-05|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 1999||1999-06-30|April 2015|2015-04-30|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Deep Brain Stimulation for Parkinson's Disease Trial|Deep Brain Stimulation for Parkinson's Disease Trial|Completed||Phase 3|123|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t||||||||||2018-06-01 05:22:21.447303|2018-06-01 05:22:21.447303
NCT00053612|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-03|||2016-12-13|2003-02-04|2003-02-05|Estimate|||||||2016-12-13|2016-12-14|Estimate||||August 2007|2007-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission|Prevention of HIV Shedding in Women - Trial of Vitamin A|Completed||Phase 2|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:22:21.556071|2018-06-01 05:22:21.556071
NCT00053599|ClinicalTrials.gov processed this data on May 31, 2018|2003-02-03|||2009-07-24|2003-02-03|2003-02-04|Estimate|||||||2009-07-24|2009-07-28|Estimate|December 2002||2002-12-31|June 2009|2009-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease|Completed||Phase 3|400||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:22:21.669863|2018-06-01 05:22:21.669863
NCT00053573|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-31|||2014-02-04|2003-02-01|2003-02-03|Estimate|||||||2014-02-04|2014-02-05|Estimate|February 2003||2003-02-28|February 2014|2014-02-28|November 2006|Actual|2006-11-30|July 2006|Actual|2006-07-31||Interventional|||rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)|An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of rhGAA Treatment in Patients Greater Than 6 Months and Less Than or Equal to 36 Months Old With Infantile-Onset GSD-II|Completed||Phase 1/Phase 2|20|Actual|Sanofi||1|||f||||||||||||||2018-06-01 05:22:21.881006|2018-06-01 05:22:21.881006
NCT00053560|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|||2007-12-26|2003-02-01|2003-02-03|Estimate|||||||2007-12-26|2008-01-07|Estimate|December 2002||2002-12-31|November 2004|2004-11-30|August 2004||2004-08-31|||||Interventional|||To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids|A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids|Unknown status|Active, not recruiting|Phase 3|155||Genelabs Technologies|||||f||||||||||||||2018-06-01 05:22:21.965249|2018-06-01 05:22:21.965249
NCT00053547|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|||2006-07-31|2003-02-01|2003-02-03|Estimate|||||||2006-07-31|2006-08-02|Estimate|January 2002||2002-01-31|July 2006|2006-07-31||||||||Interventional|||Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis|Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis|Completed||Phase 4|28||Abbott|||||||||||||||||||2018-06-01 05:22:22.128407|2018-06-01 05:22:22.128407
NCT00053534|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|||2014-02-19|2003-01-30|2003-01-31|Estimate|||||||2014-02-19|2014-02-20|Estimate|January 2003||2003-01-31|February 2014|2014-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Heart Failure in the Community||Completed|||||Mayo Clinic|||||f||||||||||||||2018-06-01 05:22:22.5087|2018-06-01 05:22:22.5087
NCT00053521|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|||2016-11-04|2003-01-30|2003-01-31|Estimate|||||||2016-11-04|2016-11-07|Estimate|January 2003||2003-01-31|January 2008|2008-01-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Observational|||Genetic Epidemiology of CVD Risk Factors||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:22:22.640322|2018-06-01 05:22:22.640322
NCT00053508|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|||2014-01-17|2003-01-30|2003-01-31|Estimate|||||||2014-01-17|2014-01-22|Estimate|September 2002||2002-09-30|January 2014|2014-01-31|September 2003|Actual|2003-09-30|March 2003|Actual|2003-03-31||Interventional|||Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination|The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study|Terminated||Phase 2|274|Actual|Sanofi||4||CDC's decision to down-select vaccine development to single candidate, ACAM2000|f||||t||||||||||2018-06-01 05:22:22.725178|2018-06-01 05:22:22.725178
NCT00053495|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|2011-01-03||2018-01-26|2003-01-30|2003-01-31|Estimate|2011-01-14|2011-02-11|Estimate||||2018-01-26|2018-02-23|Actual|January 2003||2003-01-31|January 2018|2018-01-31|November 2003|Actual|2003-11-30|June 2003|Actual|2003-06-30||Interventional|||Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination|The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination|Completed||Phase 2|353|Actual|Emergent BioSolutions||5|||f||||t||||||||||2018-06-01 05:22:22.915947|2018-06-01 05:22:22.915947
NCT00053482|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|2011-01-03||2018-01-26|2003-01-30|2003-01-31|Estimate|2011-01-14|2011-02-11|Estimate||||2018-01-26|2018-02-23|Actual|January 2003||2003-01-31|January 2018|2018-01-31|October 2003|Actual|2003-10-31|April 2003|Actual|2003-04-30||Interventional|||Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults|The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination|Completed||Phase 2|357|Actual|Emergent BioSolutions||5|||f||||t||||||||||2018-06-01 05:22:24.091479|2018-06-01 05:22:24.091479
NCT00053469|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|||2018-05-19|2003-01-29|2003-01-30|Estimate|||||||2018-05-19|2018-05-22|Actual|January 28, 2003||2003-01-28|March 30, 2015|2015-03-30|March 30, 2015||2015-03-30|||||Observational|||Infant s Examination and Manipulation of Objects|Early Learning and Development Project|Completed|||350|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:22:25.131034|2018-06-01 05:22:25.131034
NCT00053456|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-30|||2008-03-03|2003-01-29|2003-01-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2003||2003-01-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||The Effect of Exercise on Stem Cell Mobilization and Heart Function in Patients Undergoing Cardiac Rehabilitation|Stem Cell Mobilization For Improvement in Vascular Function and Myocardial Perfusion in Patients Undergoing Cardiac Rehabilitation|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:22:25.315633|2018-06-01 05:22:25.315633
NCT00053443|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-29|||2016-12-13|2003-01-29|2003-01-30|Estimate|||||||2016-12-13|2016-12-14|Estimate||||December 2005|2005-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens|Compliance Enhancement In HIV/AIDS Patients|Completed||Phase 2|156||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:22:25.413553|2018-06-01 05:22:25.413553
NCT00053430|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-29|||2009-08-06|2003-01-29|2003-01-30|Estimate|||||||2009-08-06|2009-08-07|Estimate|April 2001||2001-04-30|August 2009|2009-08-31|February 2006|Actual|2006-02-28|August 2005|Actual|2005-08-31||Interventional|||Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People|Pharmacologic T Cell Costimulation In HIV Disease|Completed||Phase 2|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:22:25.47734|2018-06-01 05:22:25.47734
NCT00053417|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-29|2011-05-16||2011-08-03|2003-01-29|2003-01-30|Estimate|2011-08-03|2011-08-04|Estimate||||2011-08-03|2011-08-04|Estimate|February 2003||2003-02-28|August 2011|2011-08-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis|Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis|Completed||Phase 2|206|Actual|Acorda Therapeutics||4|||||||||||||||||2018-06-01 05:22:25.597551|2018-06-01 05:22:25.597551
NCT00053404|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-28|||2008-09-25|2003-01-28|2003-01-29|Estimate|||||||2008-09-25|2008-09-26|Estimate|March 2003||2003-03-31|September 2008|2008-09-30|December 2008|Anticipated|2008-12-31|December 2006|Actual|2006-12-31||Observational|||Immunologic Control of Drug Resistant HIV|Observational Study of HIV Infected Adults With Detectable Plasma HIV-1 RNA Levels Between 200 and 10,000 Copies/mL While Receiving Stable Antiretroviral Therapy|Unknown status|Active, not recruiting||50|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||Samples With DNA|"~     Blood collection~   "|||2018-06-01 05:22:26.209854|2018-06-01 05:22:26.209854
NCT00053391|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2015-05-11|2003-01-27|2003-01-28|Estimate|||||||2015-05-11|2015-05-12|Estimate|October 2002||2002-10-31|May 2015|2015-05-31|June 2007|Actual|2007-06-30|June 2005|Actual|2005-06-30||Interventional|||Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma|Vaccination Of HLA-A1 And/Or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide - Loaded Autologous Dendritic Cells That Are Generated In The Absence Or Presence Of CD40 Ligand|Completed||Phase 1/Phase 2|62|Actual|University Hospital Erlangen|||||f||||f||||||||||2018-06-01 05:22:26.285174|2018-06-01 05:22:26.285174
NCT00053378|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2006-07-31|2003-01-27|2003-01-28|Estimate|||||||2006-07-31|2006-08-02|Estimate|January 2002||2002-01-31|July 2006|2006-07-31||||||||Interventional|||A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects|A Placebo-Controlled, Double-Blind Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects|Completed||Phase 2|45||Abbott|||||||||||||||||||2018-06-01 05:22:26.404869|2018-06-01 05:22:26.404869
NCT00053365|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|2013-08-12||2017-10-23|2003-01-27|2003-01-28|Estimate|2013-10-29|2013-12-19|Estimate||||2017-10-23|2017-11-28|Actual|June 2003||2003-06-30|October 2017|2017-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional||This is the number of eligible and evaluable participants.|Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of Irofulven (IND #55804, NSC #683863) In The Treatment Of Recurrent Or Persistent Platinium-Sensitive Ovarian Or Primary Peritoneal Cancer|Completed||Phase 2|61|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:26.525126|2018-06-01 05:22:26.525126
NCT00053352|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|2016-07-11||2017-12-07|2003-01-27|2003-01-28|Estimate|2017-12-07|2017-12-08|Actual||||2017-12-07|2017-12-08|Actual|November 2003||2003-11-30|December 2017|2017-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors|A Phase III Study Of Reduced Therapy In The Treatment Of Children With Low And Intermediate Risk Extracranial Germ Cell Tumors|Completed||Phase 3|302|Actual|Children's Oncology Group|Only patients considered eligible contribute to the tabulation of AEs. Arm 1: 182 eligible as described in Participant Flow as 190 enrolled, -8 ineligible. Arm 2: 104 eligible as described in Participant Flow as 112 enrolled, -8 ineligible.|2|||f||||t||||||||||2018-06-01 05:22:27.101739|2018-06-01 05:22:27.101739
NCT00053339|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2016-07-11|2003-01-27|2003-01-28|Estimate|||||||2016-07-11|2016-07-12|Estimate||||July 2016|2016-07-31||||||||Interventional|||Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer|Phase III Randomized Study of Trastuzumab (Herceptin) With or Without Tamoxifen in Women With Progressive, Stage IV, Estrogen or Progesterone Receptor- and HER2/Neu-Positive Breast Cancer|Withdrawn||Phase 3|0|Actual|Alliance for Clinical Trials in Oncology||2||The study was not activated.|f||||f||||||||||2018-06-01 05:22:28.339257|2018-06-01 05:22:28.339257
NCT00053326|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2013-10-07|2003-01-27|2003-01-28|Estimate|||||||2013-10-07|2013-10-08|Estimate|May 2003||2003-05-31|October 2013|2013-10-31||||March 2006|Actual|2006-03-31||Interventional|||Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma|A Phase II Study of Fenretinide (NSC# 374551, IND# 40294) in Children With Recurrent/Resistant High Risk Neuroblastoma|Completed||Phase 2|70|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:28.453166|2018-06-01 05:22:28.453166
NCT00053300|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2010-06-09|2003-01-27|2003-01-28|Estimate|||||||2010-06-09|2010-06-10|Estimate|August 2002||2002-08-31|June 2010|2010-06-30|April 2010|Actual|2010-04-30|November 2005|Actual|2005-11-30||Interventional|||Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial of Daily Thalidomide in Extensive Stage Small Cell Lung Cancer Patients Achieving a Complete or Partial Response to Induction Chemotherapy|Completed||Phase 2|30|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:28.541117|2018-06-01 05:22:28.541117
NCT00053287|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2010-06-09|2003-01-27|2003-01-28|Estimate|||||||2010-06-09|2010-06-10|Estimate|September 2002||2002-09-30|June 2010|2010-06-30|March 2007|Actual|2007-03-31|January 2007|Actual|2007-01-31||Interventional|||Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS|Phase II Study of Fludarabine, Carboplatin, and Topotecan With Thalidomide for Patients With Relapsed/Refractory or High Risk Acute Myelogenous Leukemia, Chronic Myeloid Leukemia and Advanced Myelodysplastic Syndromes|Completed||Phase 2|42|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:28.59546|2018-06-01 05:22:28.59546
NCT00053261|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2013-05-24|2003-01-27|2003-01-28|Estimate|||||||2013-05-24|2013-05-27|Estimate|July 2003||2003-07-31|June 2005|2005-06-30||||January 2007|Actual|2007-01-31||Observational|||Vaginal Changes and Sexual Function in Patients With Cervical Cancer|Vaginal Length, Elasticity, Lubrication And Sexual Function In Women With Stage IB2 Cervix Carcinoma|Completed|||||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:22:28.682299|2018-06-01 05:22:28.682299
NCT00053248|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2012-05-24|2003-01-27|2003-01-28|Estimate|||||||2012-05-24|2012-05-28|Estimate|October 2002||2002-10-31|June 2010|2010-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase I/II Study To Determine The Safety, Tolerability, And Anti-Leukemic Effects of Trisenox (Arsenic Trioxide) In Combination With Gleevec (STI571) In Patients With Resistant Chronic Myelogenous Leukemia In Chronic Phase|Completed||Phase 1/Phase 2|16|Actual|OHSU Knight Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:28.88428|2018-06-01 05:22:28.88428
NCT00053235|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2015-05-29|2003-01-27|2003-01-28|Estimate|||||||2015-05-29|2015-06-01|Estimate|November 2002||2002-11-30|May 2015|2015-05-31||||August 2010|Actual|2010-08-31||Observational|||Research Study in Patients With Advanced Ovarian Epithelial Cancer|A Pilot Study to Correlate DNA Sequence Copy Number Abnormalities With Outcome in Patients With Advanced Epithelial Ovarian Cancer|Withdrawn|||0|Actual|Gynecologic Oncology Group|||1||f||||||||||||||2018-06-01 05:22:29.048605|2018-06-01 05:22:29.048605
NCT00053222|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2013-09-04|2003-01-27|2003-01-28|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2003||2003-02-28|September 2013|2013-09-30|July 2007|Actual|2007-07-31|January 2005|Actual|2005-01-31||Interventional|||Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine|A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine|Completed||Phase 2|13|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:22:29.132089|2018-06-01 05:22:29.132089
NCT00053209|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2012-11-30|2003-01-27|2003-01-28|Estimate|||||||2012-11-30|2012-12-04|Estimate|April 2004||2004-04-30|November 2012|2012-11-30|May 2009|Actual|2009-05-31|September 2007|Actual|2007-09-30||Interventional|||Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium|Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer|Completed||Phase 2|46|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:22:29.25691|2018-06-01 05:22:29.25691
NCT00053196|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2016-06-30|2003-01-27|2003-01-28|Estimate|||||||2016-06-30|2016-07-01|Estimate|December 2002||2002-12-31|June 2016|2016-06-30|August 2010|Actual|2010-08-31|November 2006|Actual|2006-11-30||Interventional|||Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer|Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation|Completed||Phase 2|82|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:22:29.487457|2018-06-01 05:22:29.487457
NCT00053183|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2009-02-06|2003-01-27|2003-01-28|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 2003||2003-10-31|July 2004|2004-07-31||||||||Interventional|||Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I Brachytherapy Dose Escalation Using The GliaSite RTS In Newly Diagnosed Glioblastoma Multiforme In Conjunction With External Beam Radiation Therapy|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:29.68253|2018-06-01 05:22:29.68253
NCT00053157|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2013-01-30|2003-01-27|2003-01-28|Estimate|||||||2013-01-30|2013-01-31|Estimate|June 2002||2002-06-30|January 2013|2013-01-31||||August 2004|Actual|2004-08-31||Interventional|||Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia|Use Of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) To Mobilize Donor Peripheral Blood Stem Cells Along With GM-CSF Administration Post Allogeneic Transplant - A Pilot Study|Completed||N/A|10|Actual|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:22:29.767766|2018-06-01 05:22:29.767766
NCT00052689|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|December 2002||2002-12-31|October 2013|2013-10-31||||October 2007|Actual|2007-10-31||Interventional|||Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer|A Randomized Phase II Trial of PS-341 and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|88|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:22:36.766426|2018-06-01 05:22:36.766426
NCT00053144|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2011-03-07|2003-01-27|2003-01-28|Estimate|||||||2011-03-07|2011-03-08|Estimate|November 1999||1999-11-30|March 2011|2011-03-31|March 2003|Actual|2003-03-31|February 2003|Actual|2003-02-28||Interventional|||Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia|Irinotecan And Cytarabine In Refractory or Relapsed Acute Myeloid Leukemia And In Chronic Myelogenous Leukemia In Myeloid Blast Transformation: Efficacy And In Vitro Correlates|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:30.763127|2018-06-01 05:22:30.763127
NCT00053131|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2011-03-07|2003-01-27|2003-01-28|Estimate|||||||2011-03-07|2011-03-08|Estimate|January 1999||1999-01-31|March 2011|2011-03-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|High Dose Cytarabine And Mitoxantrone Therapy For Relapsed And Refractory Acute Myeloid And Lymphocytic Leukemia: Effects Of GM-CSF Versus G-CSF On Dendritic Cells And Leukemia Associated Antigen-Specific T-Lymphocytes|Completed||Phase 2|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:30.89568|2018-06-01 05:22:30.89568
NCT00053118|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2011-02-25|2003-01-27|2003-01-28|Estimate|||||||2011-02-25|2011-03-01|Estimate|March 2002||2002-03-31|February 2011|2011-02-28|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer|High Dose Carboplatin Combined With Oral VP-16 In The Treatment Of Pediatric CNS Malignancies|Completed||Phase 1|1|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:22:30.979288|2018-06-01 05:22:30.979288
NCT00053105|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2009-07-04|2003-01-27|2003-01-28|Estimate|||||||2009-07-04|2009-07-07|Estimate|February 2002||2002-02-28|March 2003|2003-03-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase I Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:31.283338|2018-06-01 05:22:31.283338
NCT00053092|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2013-12-17|2003-01-27|2003-01-28|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2002||2002-10-31|June 2007|2007-06-30|February 2009|Actual|2009-02-28|||||Interventional|||Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma|National Mantle Cell Lymphoma Trial - Phase II Randomized Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma|Completed||Phase 2|82|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:31.487092|2018-06-01 05:22:31.487092
NCT00053053|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2016-12-06|2003-01-27|2003-01-28|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2002||2002-12-31|October 2013|2013-10-31|February 2009|Actual|2009-02-28|March 2005|Actual|2005-03-31||Interventional|||Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer|A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement|Completed||Phase 3|472|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:22:31.679463|2018-06-01 05:22:31.679463
NCT00053040|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2010-09-23|2003-01-27|2003-01-28|Estimate|||||||2010-09-23|2010-09-24|Estimate|October 2005||2005-10-31|September 2010|2010-09-30||||||||Interventional|||Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas|Phase I/II Trial Of Intracerebral IL13-PE38QQR Infusions In Pediatric Patients With Recurrent Malignant Glioma|Withdrawn||Phase 1/Phase 2|0|Actual|Pediatric Brain Tumor Consortium||1||Withdrawal of pharmaceutical company support for the investigational drug|f||||t||||||||||2018-06-01 05:22:32.280585|2018-06-01 05:22:32.280585
NCT00053027|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2016-12-05|2003-01-27|2003-01-28|Estimate|||||||2016-12-05|2016-12-07|Estimate|February 2003||2003-02-28|December 2016|2016-12-31|November 2009|Actual|2009-11-30|January 2006|Actual|2006-01-31||Interventional|||Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma|Phase II Trial of Rituximab and 2-Chlorodeoxyadenosine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL)|Completed||Phase 2|30|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:22:32.380341|2018-06-01 05:22:32.380341
NCT00053014|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|2013-01-02||2015-03-05|2003-01-27|2003-01-28|Estimate|2013-02-15|2013-03-22|Estimate||||2015-03-05|2015-03-25|Estimate|April 2003||2003-04-30|March 2015|2015-03-31|June 2006|Actual|2006-06-30|June 2005|Actual|2005-06-30||Interventional|||S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia|S0125, A Phase II Study Of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation In Older Patients With Acute Myeloid Leukemia (AML) In First Complete Remission (A BMT Study)|Terminated||Phase 2|5|Actual|Southwest Oncology Group||1||Poor accrual|f||||t||||||||||2018-06-01 05:22:32.579972|2018-06-01 05:22:32.579972
NCT00053001|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-27|||2013-06-25|2003-01-27|2003-01-28|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 2001||2001-06-30|October 2007|2007-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome|A Phase II Study on the Effectiveness of Thalomid (Thalidomide) Combined With Procrit (Erythropoietin) for the Treatment of Anemia in Patients With Low and Intermediate Risk-1 (IPSS Score Less Than or Equal to 1.5) Myelodysplastic Syndromes|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:32.998654|2018-06-01 05:22:32.998654
NCT00041275|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-09-19|2003-01-27|2003-01-28|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 2002||2002-05-31|September 2002|2002-09-30|August 2011|Actual|2011-08-31|June 2007|Actual|2007-06-30||Interventional|||Megestrol in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery|Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma|Completed||Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:33.104195|2018-06-01 05:22:33.104195
NCT00004078|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-13|2003-01-27|2003-01-28|Estimate|||||||2013-06-13|2013-06-14|Estimate|October 1999||1999-10-31|June 2013|2013-06-30||||October 2007|Actual|2007-10-31||Interventional|||Irinotecan in Treating Children With Refractory Solid Tumors|Phase II Trial of Irinotecan in Children With Refractory Solid Tumors|Completed||Phase 2|181|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:22:33.218794|2018-06-01 05:22:33.218794
NCT00003830|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-05-04||2017-11-14|2003-01-27|2003-01-28|Estimate|2017-11-14|2017-12-13|Actual||||2017-11-14|2017-12-13|Actual|May 1999||1999-05-31|November 2017|2017-11-30|February 2014|Actual|2014-02-28|September 2010|Actual|2010-09-30||Interventional|||Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer|A Randomized, Phase III Clinical Trial to Compare Sentinel Node Resection to Conventional Axillary Dissection in Clinically Node-Negative Breast Cancer Patients|Completed||Phase 3|5611|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 05:22:33.357342|2018-06-01 05:22:33.357342
NCT00052962|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-26|2012-09-04||2012-11-16|2003-01-25|2003-01-27|Estimate|2012-10-16|2012-11-19|Estimate||||2012-11-16|2012-11-22|Estimate|January 2003||2003-01-31|November 2012|2012-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis|A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma|Completed||Phase 3|30|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:22:33.862981|2018-06-01 05:22:33.862981
NCT00052949|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|May 2003||2003-05-31|October 2013|2013-10-31||||October 2007|Actual|2007-10-31||Interventional|||Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer|Phase II Trial of STI571 in Patients With Relapsed Small Cell Lung Cancer|Completed||Phase 2|91|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:34.2084|2018-06-01 05:22:34.2084
NCT00052936|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2010-03-11|2003-01-26|2003-01-27|Estimate|||||||2010-03-11|2010-03-12|Estimate|January 2001||2001-01-31|June 2007|2007-06-30||||||||Interventional|||Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma|Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 3|1580|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:34.388938|2018-06-01 05:22:34.388938
NCT00052923|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 2003||2003-03-31|June 2006|2006-06-30||||June 2006|Actual|2006-06-30||Interventional|||Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma|Randomized Phase III Trial Of Rituximab (NSC #687451) And Autologous Stem Cell Transplantation For B Cell Diffuse Large Cell Lymphoma|Completed||Phase 3|427|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:22:34.696338|2018-06-01 05:22:34.696338
NCT00052910|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2016-06-17|2003-01-26|2003-01-27|Estimate|||||||2016-06-17|2016-06-20|Estimate|December 2002||2002-12-31|June 2016|2016-06-30||||June 2012|Actual|2012-06-30||Interventional|||Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer|Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma|Active, not recruiting||Phase 3|546|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:22:34.882769|2018-06-01 05:22:34.882769
NCT00052897|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2002||2002-12-31|April 2004|2004-04-30||||July 2005|Actual|2005-07-31||Interventional|||SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia|A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals|Completed||Phase 1/Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:35.756474|2018-06-01 05:22:35.756474
NCT00052884|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2012-11-30|2003-01-26|2003-01-27|Estimate|||||||2012-11-30|2012-12-03|Estimate|October 2003||2003-10-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|September 2007|Actual|2007-09-30||Interventional|||Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation|A Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic Amyloidosis|Terminated||Phase 1|8|Actual|Eastern Cooperative Oncology Group||1||Slow accrual and changes in clinical practice|f||||f||||||||||2018-06-01 05:22:35.826665|2018-06-01 05:22:35.826665
NCT00052845|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2016-06-30|2003-01-26|2003-01-27|Estimate|||||||2016-06-30|2016-07-01|Estimate|November 2002||2002-11-30|June 2016|2016-06-30|April 2009|Actual|2009-04-30|January 2006|Actual|2006-01-31||Interventional|||Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer|Completed||Phase 2|80|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:22:35.94687|2018-06-01 05:22:35.94687
NCT00052832|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2015-09-30|2003-01-26|2003-01-27|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2002||2002-09-30|September 2015|2015-09-30||||July 2005|Actual|2005-07-31||Interventional|||Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes|Completed||Phase 2|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:22:36.101464|2018-06-01 05:22:36.101464
NCT00052780|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-09-27|2003-01-26|2003-01-27|Estimate|||||||2013-09-27|2013-09-30|Estimate|October 2002||2002-10-31|September 2013|2013-09-30||||November 2007|Actual|2007-11-30||Interventional|||Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors|Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Patients With Recurrent Brain Tumors|Completed||Phase 1|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:36.162712|2018-06-01 05:22:36.162712
NCT00052754|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|October 2002||2002-10-31|September 2012|2012-09-30||||October 2005|Actual|2005-10-31||Interventional|||Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma|Phase II Study Of Iressa (ZD 1839) In Locally Advanced And/Or Metastatic Synovial Sarcoma Expressing HER1/EGFR1|Completed||Phase 2|48|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:22:36.282389|2018-06-01 05:22:36.282389
NCT00052728|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|December 2002||2002-12-31|May 2005|2005-05-31|July 2006|Actual|2006-07-31|||||Interventional|||Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer|A Phase II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:36.358094|2018-06-01 05:22:36.358094
NCT00052715|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|2017-01-26||2017-01-26|2003-01-26|2003-01-27|Estimate|2017-01-26|2017-03-16|Actual||||2017-01-26|2017-03-16|Actual|November 2002||2002-11-30|January 2017|2017-01-31|December 2009|Actual|2009-12-31|April 2008|Actual|2008-04-30||Interventional|Poly-ICLC||Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Trial Of Poly-ICLC For Glioblastoma|Terminated||Phase 2|31|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Enrollment was prematurely discontinued after the results of the EORTC phase-3 study defined the standard of care for newly diagnosed glioblastoma patients as radiotherapy plus concomitant and adjuvant temozolomide|1||"prematurely discontinued after results of the EORTC phase-3 study defined the SOC for newly~   diagnosed GMB pts as RT plus concomitant and adjuvant TMZ"|f||||t||||||||No||2018-06-01 05:22:36.484735|2018-06-01 05:22:36.484735
NCT00052676|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 2002||2002-10-31|September 2007|2007-09-30|May 2007|Actual|2007-05-31|||||Interventional|||Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer|French Randomized Sentinel Node Multicentric Study|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:36.861379|2018-06-01 05:22:36.861379
NCT00052637|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-10-22|2003-01-26|2003-01-27|Estimate|||||||2013-10-22|2013-10-23|Estimate|September 2001||2001-09-30|October 2013|2013-10-31||||May 2002|Actual|2002-05-31||Interventional|||Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer|An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer|Completed||Phase 3|||Photocure|||||f||||f||||||||||2018-06-01 05:22:36.956067|2018-06-01 05:22:36.956067
NCT00052624|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2018-05-14|2003-01-26|2003-01-27|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2002||2002-07-31|April 2004|2004-04-30||||||||Interventional|||Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma|A Phase I Multicenter Trial Of Intratumoral/Interstitial Therapy With HN66000, NC66000 (TransMID) In Patients Between 5 and 18 Years Of Age With Progressive Or Recurrent Glioblastoma Multiforme Or Anaplastic Astrocytoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:37.018052|2018-06-01 05:22:37.018052
NCT00052611|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2018-03-28|2003-01-26|2003-01-27|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2002|Actual|2002-06-30|March 2018|2018-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia|Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study|Completed||Phase 2|23|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-06-01 05:22:37.074095|2018-06-01 05:22:37.074095
NCT00052598|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24||2017-02-13|2017-02-13|2003-01-26|2003-01-27|Estimate||||2017-02-13|2017-02-15|Actual|2017-02-13|2017-02-15|Actual|September 2002||2002-09-30|February 2017|2017-02-28|June 2011|Actual|2011-06-30|November 2009|Actual|2009-11-30||Interventional|||Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant|Phase I/II Study of Adoptive Immunotherapy With CD8+ Proteinase 3 (Myeloblastin)-Specific CTL Clones for HLA-A2+ Patients With Relapse or Progression of Disease After Allogeneic Hematopoietic Stem Cell Transplant for High Risk Myeloid Leukemias|Terminated||Phase 1/Phase 2|7|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:22:37.156038|2018-06-01 05:22:37.156038
NCT00052585|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2002||2002-10-31|January 2013|2013-01-31||||November 2004|Actual|2004-11-30||Interventional|||Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer|A Phase II Trial Of IRESSA (NSC 715055, IND 61187) In Combination With 5-FU/LV/ CPT-11 In Patients With Advanced Or Recurrent Colorectal Cancer|Terminated||Phase 2|50|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:22:37.234382|2018-06-01 05:22:37.234382
NCT00052572|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|October 2002||2002-10-31|April 2006|2006-04-30|July 2007|Actual|2007-07-31|||||Interventional|||Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders|A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders|Completed||Phase 2|35|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:22:37.316248|2018-06-01 05:22:37.316248
NCT00052559|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2002||2002-08-31|June 2013|2013-06-30||||April 2003|Actual|2003-04-30||Interventional|||Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer|A Phase I Study Of The Antiangiogenic Agent Bevacizumab In Combination With 5-Fluourouracil And External Beam Radiation Therapy In Rectal Cancer|Completed||Phase 1|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:37.392662|2018-06-01 05:22:37.392662
NCT00052520|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24||2017-03-27|2017-03-27|2003-01-26|2003-01-27|Estimate||||2017-03-27|2017-03-29|Actual|2017-03-27|2017-03-29|Actual|September 2002||2002-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|April 2011|Actual|2011-04-30||Interventional|||Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation|Phase I/II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant|Completed||Phase 1/Phase 2|37|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:22:37.483404|2018-06-01 05:22:37.483404
NCT00052507|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2015-07-22|2003-01-26|2003-01-27|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2003||2003-01-31|July 2015|2015-07-31||||August 2005|Actual|2005-08-31||Interventional|||Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase II Study Of PS-341 In Patients With Metastatic Colorectal Cancer|Completed||Phase 2|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 05:22:37.602695|2018-06-01 05:22:37.602695
NCT00052494|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2015-07-22|2003-01-26|2003-01-27|Estimate|||||||2015-07-22|2015-07-23|Estimate|April 2003||2003-04-30|July 2015|2015-07-31||||February 2009|Actual|2009-02-28||Interventional|||Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I Study Of STI 571 (Gleevec) In Combination With Cisplatin/Irinotecan In Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 1|9|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 05:22:37.713553|2018-06-01 05:22:37.713553
NCT00052481|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|September 2002||2002-09-30|July 2016|2016-07-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Observational|||Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer|Health-Related Quality Of Life In Patients With Low Risk, Localized Prostate Cancer Randomized To Radical Prostatectomy Or Brachytherapy|Completed|||500|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 05:22:37.798796|2018-06-01 05:22:37.798796
NCT00052468|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2014-06-24|2003-01-26|2003-01-27|Estimate|||||||2014-06-24|2014-06-25|Estimate|August 2002||2002-08-31|June 2014|2014-06-30|January 2011|Actual|2011-01-31|July 2009|Actual|2009-07-31||Interventional|AGO-OVAR9||Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer|A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV|Completed||Phase 3|1742|Actual|AGO Study Group||2|||f||||t||||||||||2018-06-01 05:22:37.898048|2018-06-01 05:22:37.898048
NCT00052455|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2002||2002-10-31|May 2007|2007-05-31|September 2010|Actual|2010-09-30|||||Interventional|||Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma|A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV|Completed||Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:37.994222|2018-06-01 05:22:37.994222
NCT00052442|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|August 2002||2002-08-31|December 2009|2009-12-31||||March 2009|Actual|2009-03-31||Interventional|||10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomas and Hodgkin's Disease|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:38.078305|2018-06-01 05:22:38.078305
NCT00052429|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|2015-12-15||2017-12-11|2003-01-26|2003-01-27|Estimate|2016-01-22|2016-02-22|Estimate||||2017-12-11|2018-01-09|Actual|September 2002||2002-09-30|December 2017|2017-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer|Phase I/II Study of Dose-Painting Using Intensity Modulated Radiation Therapy Plus Chemotherapy in Patients With Stage II-IVB Nasopharyngeal Carcinoma|Completed||Phase 1/Phase 2|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:22:38.154035|2018-06-01 05:22:38.154035
NCT00052416|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|October 2002||2002-10-31|April 2003|2003-04-30|January 2003|Actual|2003-01-31|||||Interventional|||Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Thalidomide in Indolent Non-Hodgkin's Lymphoma: A Feasibility Study|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:38.327397|2018-06-01 05:22:38.327397
NCT00052403|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2014-01-15|2003-01-26|2003-01-27|Estimate|||||||2014-01-15|2014-01-16|Estimate|February 2002||2002-02-28|January 2014|2014-01-31||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors|Phase I Study of Monoclonal Antibody Anti-Anb3 Integrin in Patients With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|Barbara Ann Karmanos Cancer Institute||||Study was not successful at recruiting particpants|f||||t||||||||||2018-06-01 05:22:38.438498|2018-06-01 05:22:38.438498
NCT00052390|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|October 2002||2002-10-31|February 2004|2004-02-29|October 2005|Actual|2005-10-31|||||Interventional|||Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma|A Multi-Institutional, Open-Label, Phase II Study Of Doxorubicin And Bevacizumab (Anti-VEFG Monoclonal Antibody, NSC 704865) For Patients With Advanced Or Metastatic Soft-Tissue Sarcoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:38.4914|2018-06-01 05:22:38.4914
NCT00052377|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2002||2002-09-30|January 2013|2013-01-31||||June 2005|Actual|2005-06-30||Interventional|||Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides|A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12|Terminated||Phase 1/Phase 2|46|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:22:38.615077|2018-06-01 05:22:38.615077
NCT00052364|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-18|Estimate|September 2002||2002-09-30|June 2013|2013-06-30||||January 2006|Actual|2006-01-31||Interventional|||Oxaliplatin in Treating Patients With Liver Cancer|A Phase II Study of Oxaliplatin in Hepatocellular Cancer|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:38.698175|2018-06-01 05:22:38.698175
NCT00052351|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|September 2002||2002-09-30|May 2003|2003-05-31|October 2007|Actual|2007-10-31|||||Interventional|||Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer|A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:38.770446|2018-06-01 05:22:38.770446
NCT00052338|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|September 2002||2002-09-30|January 2013|2013-01-31||||May 2004|Actual|2004-05-31||Interventional|||Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|A Phase I Study Of PS-341 In Combination With Gemcitabine And Carbloplatin In Selected Stage IIIB Or IV Non-Small Cell Lung Cancer|Completed||Phase 1|34|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:38.828463|2018-06-01 05:22:38.828463
NCT00052325|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2002||2002-10-31|July 2005|2005-07-31||||||||Interventional|||Mistletoe in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Are Receiving Palliative Chemotherapy|Iscar For Supplemental Care In Advanced Non-Small Cell Lung Carcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:38.912065|2018-06-01 05:22:38.912065
NCT00052312|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|September 2002||2002-09-30|September 2012|2012-09-30||||September 2006|Actual|2006-09-30||Interventional|||Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer|Randomized Trial Of Adriamycin (A) Cisplatin (P) Chemotherapy Versus Paclitaxel (T) Adriamycin (A) And Cisplatin (P) In Patients With Metastatic/Relapsed Or Locally Advanced Inoperable Endometrial Cancer|Completed||Phase 2|141|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:22:38.973994|2018-06-01 05:22:38.973994
NCT00052299|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2012-08-24|2003-01-26|2003-01-27|Estimate|||||||2012-08-24|2012-08-27|Estimate|September 2002||2002-09-30|August 2012|2012-08-31|February 2012|Actual|2012-02-29|January 2008|Actual|2008-01-31||Interventional|AML-17||Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia|Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP|Completed||Phase 3|472|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 05:22:39.106413|2018-06-01 05:22:39.106413
NCT00052286|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2016-02-05|2003-01-26|2003-01-27|Estimate|||||||2016-02-05|2016-02-08|Estimate|September 2002||2002-09-30|February 2016|2016-02-29|August 2010|Actual|2010-08-31|July 2006|Actual|2006-07-31||Interventional|||Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer|A Pilot Study of Modafinil for Treatment of Fatigue and Neurobehavioral Dysfunction in Adult Brain Tumor Patients|Completed||N/A|29|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:22:39.243733|2018-06-01 05:22:39.243733
NCT00052273|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2015-10-28|2003-01-26|2003-01-27|Estimate|||||||2015-10-28|2015-10-30|Estimate|December 2002||2002-12-31|August 2012|2012-08-31|October 2005|Actual|2005-10-31|November 2004|Actual|2004-11-30||Interventional|||LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients|Completed||Phase 1|16|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:39.319711|2018-06-01 05:22:39.319711
NCT00052221|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2016-04-05|2003-01-26|2003-01-27|Estimate|||||||2016-04-05|2016-04-06|Estimate|May 2003||2003-05-31|October 2012|2012-10-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy|A Placebo Controlled Trial Of Short-Term, High-Dose Epoetin Alfa In Advanced Cancer Outpatients With Mild Fatigue|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:22:39.37696|2018-06-01 05:22:39.37696
NCT00052208|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2013-06-11|2003-01-26|2003-01-27|Estimate|||||||2013-06-11|2013-06-13|Estimate|March 2002||2002-03-31|May 2013|2013-05-31||||June 2005|Actual|2005-06-30||Interventional|||Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme|A Phase I/II Study of an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), ZD 1839 (Iressa), [NSC #715055] With Radiation Therapy in Glioblastoma Multiforme|Completed||Phase 1/Phase 2|158|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:39.444032|2018-06-01 05:22:39.444032
NCT00052195|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2016-02-17|2003-01-26|2003-01-27|Estimate|||||||2016-02-17|2016-02-19|Estimate|September 2001||2001-09-30|February 2016|2016-02-29|May 2009|Actual|2009-05-31|December 2008|Actual|2008-12-31||Interventional|||Investigational Vaccine for the Prevention of Disseminated Tuberculosis in HIV Infected People|DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)|Completed||Phase 2/Phase 3|1975|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 05:22:39.516276|2018-06-01 05:22:39.516276
NCT00052182|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2007-10-22|2003-01-26|2003-01-27|Estimate|||||||2007-10-22|2007-10-23|Estimate|October 2002||2002-10-31|September 2007|2007-09-30||||||||Interventional|||Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients|A Single Center Phase I Safety and Immunogenicity Study of Epimmune HIV-1 CTL Epitope-Based DNA Vaccine (EP HIV-1090) for Immunotherapy of HIV-1 Infected Individuals Receiving Highly Active Antiretroviral Therapy (HAART)|Completed||Phase 1|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:22:39.583872|2018-06-01 05:22:39.583872
NCT00052169|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-24|||2007-12-13|2003-01-26|2003-01-27|Estimate|||||||2007-12-13|2007-12-18|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|September 2006|Actual|2006-09-30|||||Interventional|||Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer|A Phase 2, Multi-Center Trial of ZD1839 (IRESSA) in Combination With Docetaxel as First-Line Treatment in Patients With Advanced Breast Cancer|Completed||Phase 2|33|Actual|NSABP Foundation Inc|||||f||||f||||||||||2018-06-01 05:22:39.664372|2018-06-01 05:22:39.664372
NCT00049712|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2015-07-22|2003-01-26|2003-01-27|Estimate|||||||2015-07-22|2015-07-23|Estimate|October 2002||2002-10-31|July 2015|2015-07-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma|A Phase I Study Of Medi 522 In Patients With Advanced Tumors|Completed||Phase 1|||University of Wisconsin, Madison|||||||||||||||||||2018-06-01 05:22:39.735164|2018-06-01 05:22:39.735164
NCT00049699|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|October 2002||2002-10-31|March 2004|2004-03-31|January 2008|Actual|2008-01-31|||||Interventional|||VNP40101M in Treating Patients With Advanced or Metastatic Cancer|A Phase I Trial of VNP40101M, a Novel Alkylating Agent, Administered Weekly for Patients With Advanced or Metastatic Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:39.821526|2018-06-01 05:22:39.821526
NCT00049686|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|April 2002||2002-04-30|September 2003|2003-09-30|January 2008|Actual|2008-01-31|||||Interventional|||VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome|A Phase I Trial Of VNP40101M, A Novel Alkylating Agent, For Patients With Hematologic Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:39.881294|2018-06-01 05:22:39.881294
NCT00049673|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2015-10-05|2003-01-26|2003-01-27|Estimate|||||||2015-10-05|2015-10-06|Estimate|September 2002||2002-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|February 2010|Actual|2010-02-28||Interventional|||Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma|Completed||Phase 3|332|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:22:39.949484|2018-06-01 05:22:39.949484
NCT00049660|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|September 2002||2002-09-30|July 2012|2012-07-31||||December 2004|Actual|2004-12-31||Interventional|||Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer|A Randomized Phase II-III Trial Evaluating the Efficacy of Capecitabine and Vinorelbine in Anthracycline and Taxane Pre-Treated Metastatic Breast Cancer|Terminated||Phase 2/Phase 3|47|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:22:40.051757|2018-06-01 05:22:40.051757
NCT00049634|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2010-09-14|2003-01-26|2003-01-27|Estimate|||||||2010-09-14|2010-09-16|Estimate|January 2002||2002-01-31|September 2010|2010-09-30||||February 2007|Actual|2007-02-28||Interventional|||Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder|A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies|Completed||Phase 1/Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:22:40.154047|2018-06-01 05:22:40.154047
NCT00049608|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|July 2002||2002-07-31|April 2007|2007-04-30|August 2011|Actual|2011-08-31|||||Interventional|||Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors|A Phase I Study Of The Effect Of Mistletoe Extract, A Complementary Medicine Botanical, On Pharmacokinetics, Pharmacodynamics And Safety Of Gemcitabine In Patients With Advanced Solid Tumors|Terminated||Phase 1|51|Anticipated|National Cancer Institute (NCI)||||Principal investigator [PI] has left institution.|f||||||||||||||2018-06-01 05:22:40.214877|2018-06-01 05:22:40.214877
NCT00049595|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2017-07-26|2003-01-26|2003-01-27|Estimate|||||||2017-07-26|2017-07-27|Actual|August 2002||2002-08-31|July 2017|2017-07-31||||January 2010|Actual|2010-01-31||Interventional|||Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma|BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma|Active, not recruiting||Phase 3|552|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 05:22:40.286278|2018-06-01 05:22:40.286278
NCT00049582|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-09-27|2003-01-26|2003-01-27|Estimate|||||||2013-09-27|2013-09-30|Estimate|September 2002||2002-09-30|September 2013|2013-09-30||||June 2010|Actual|2010-06-30||Interventional|||Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia|Phase I Study of 5-Aza-2'-Deoxycytidine (Decitabine) as a Biologic Modifier of Retinoid Responsive Genes in Patients With High-Risk Myelodysplastic Syndromes and Acute Myelogenous Leukemia (De-novo, Relapsed or Secondary)|Terminated||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:40.614063|2018-06-01 05:22:40.614063
NCT00049569|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|January 2003||2003-01-31|October 2013|2013-10-31||||March 2006|Actual|2006-03-31||Interventional|||Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia|Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse|Completed||N/A|126|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:22:40.718972|2018-06-01 05:22:40.718972
NCT00049556|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|October 2002||2002-10-31|January 2006|2006-01-31|August 2006|Actual|2006-08-31|||||Interventional|||Gefitinib in Treating Patients With Cervical Cancer|Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or Cervical Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:22:40.839453|2018-06-01 05:22:40.839453
NCT00049543|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2014-12-19||2014-12-19|2003-01-26|2003-01-27|Estimate|2014-12-19|2015-01-01|Estimate||||2014-12-19|2015-01-01|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery|A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer|Completed||Phase 3|503|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 05:22:40.956854|2018-06-01 05:22:40.956854
NCT00049530|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2014-01-30||2015-10-06|2003-01-26|2003-01-27|Estimate|2014-05-01|2014-06-03|Estimate||||2015-10-06|2015-10-28|Estimate|September 2003||2003-09-30|May 2014|2014-05-31|June 2014|Actual|2014-06-30|August 2012|Actual|2012-08-31||Interventional||The primary analysis population was all eligible (meeting all eligibility criteria listed in protocol) and treated patients (receiving at least one dose of the protocol therapy). All baseline analysis and efficacy endpoints are based on the primary population (n=29).|PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma|Phase II Study of Low Dose Peginterferon Alfa-2b in Patients With Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor|Completed||Phase 2|32|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:22:41.650197|2018-06-01 05:22:41.650197
NCT00049517|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2013-01-10||2016-12-01|2003-01-26|2003-01-27|Estimate|2013-01-10|2013-02-12|Estimate||||2016-12-01|2017-01-30|Estimate|December 2002||2002-12-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|March 2009|Actual|2009-03-31||Interventional|||Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia|A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation|Active, not recruiting||Phase 3|657|Actual|Eastern Cooperative Oncology Group||6|||f||||t||||||||||2018-06-01 05:22:41.934542|2018-06-01 05:22:41.934542
NCT00049504|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2017-04-10||2017-04-10|2003-01-26|2003-01-27|Estimate|2017-04-10|2017-05-17|Actual||||2017-04-10|2017-05-17|Actual|January 2002|Actual|2002-01-31|April 2017|2017-04-30|February 2014|Actual|2014-02-28|March 2011|Actual|2011-03-31||Interventional|||Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer|Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation|Completed||Phase 2|53|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||f||||||No|Individual patient data is protected by HIPAA at each participant organization.|2018-06-01 05:22:42.631433|2018-06-01 05:22:42.631433
NCT00049465|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2010-09-17|2003-01-26|2003-01-27|Estimate|||||||2010-09-17|2010-09-21|Estimate|August 1998||1998-08-31|September 2010|2010-09-30||||February 2005|Actual|2005-02-28||Interventional|||Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer|Multi-Site Randomized Clinical Trial Comparing Standard Recovery Preparation to Extended Recovery Preparation to Enhance Long Term Function After Marrow or Stem Cell Transplant|Completed||N/A|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:22:43.764092|2018-06-01 05:22:43.764092
NCT00049452|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2001||2001-12-31|April 2007|2007-04-30|August 2008|Actual|2008-08-31|||||Interventional|||Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer|A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer|Completed||Phase 3|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:43.851533|2018-06-01 05:22:43.851533
NCT00049439|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|March 1998||1998-03-31|June 2010|2010-06-30|February 2008|Actual|2008-02-29|October 2005|Actual|2005-10-31||Interventional|||Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma|Dose-Modified Oral Combination Chemotherapy In Patients With Aids-Related Non-Hodgkin's Lymphoma In The United States And Africa|Completed||Phase 2|54|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:43.923761|2018-06-01 05:22:43.923761
NCT00049413|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2011-05-10|2003-01-26|2003-01-27|Estimate|||||||2011-05-10|2011-05-12|Estimate|June 2002||2002-06-30|May 2011|2011-05-31|December 2005|Actual|2005-12-31|December 2004|Actual|2004-12-31||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma|Pentostatin, Cyclophosphamide And Rituximab (PCR) For B-Cell Chronic Lymphocytic Leukemia (CLL) And Small B-Cell Lymphocytic Lymphoma (SLL): Four Phase II Trials With Patient Stratification Based On Prior Therapy|Completed||Phase 2|||Hoag Memorial Hospital Presbyterian|||||f||||f||||||||||2018-06-01 05:22:44.008802|2018-06-01 05:22:44.008802
NCT00049400|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2015-04-01|2003-01-26|2003-01-27|Estimate|||||||2015-04-01|2015-04-03|Estimate|October 2003||2003-10-31|April 2015|2015-04-30|December 2007|Actual|2007-12-31|September 2006|Actual|2006-09-30||Interventional|||S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction|A Phase I Pharmacokinetic Study Of Epothilone B Analogue BMS-247550 (NSC 710428D) In Patients With Advanced Malignancies And Varying Levels Of Liver Dysfunction|Completed||Phase 1|78|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:22:44.08037|2018-06-01 05:22:44.08037
NCT00049387|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2015-04-14|2003-01-26|2003-01-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2002||2002-09-30|December 2013|2013-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma|Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 1|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:44.316654|2018-06-01 05:22:44.316654
NCT00049374|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2009-09-23|2003-01-26|2003-01-27|Estimate|||||||2009-09-23|2009-09-24|Estimate|September 2002||2002-09-30|September 2009|2009-09-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma|Completed||Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:22:44.405858|2018-06-01 05:22:44.405858
NCT00049361|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2017-04-17|2003-01-26|2003-01-27|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2004|Actual|2004-01-31|April 2017|2017-04-30|December 7, 2004|Actual|2004-12-07|December 7, 2004|Actual|2004-12-07||Interventional|||Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases|A Phase II Study Of Whole-Brain Radiation Therapy With Thalidomide And Temozolomide In Patients With Newly Diagnosed Brain Metastases|Completed||Phase 2|||Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:22:44.48525|2018-06-01 05:22:44.48525
NCT00049348|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2010-11-12|2003-01-26|2003-01-27|Estimate|||||||2010-11-12|2010-11-15|Estimate|May 2003||2003-05-31|June 2005|2005-06-30||||October 2005|Actual|2005-10-31||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer|A Randomized Phase II Study Of Gemcitabine Plus Radiotherapy Vs. Gemcitabine, 5-Fluorouracil And Cisplatin Followed By Radiotherapy And 5-Fluoraracil For Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:22:44.601465|2018-06-01 05:22:44.601465
NCT00049335|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-01-02|2003-01-26|2003-01-27|Estimate|||||||2013-01-02|2013-01-03|Estimate|February 2003||2003-02-28|January 2013|2013-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed|Protocol For Assessment Of Capecitabine For Advanced Colorectal Cancer In Patients Aged 70 Years And Older (And In A Cohort Of Patients Younger Than 60 Years)|Completed||Phase 2|29|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:22:44.907487|2018-06-01 05:22:44.907487
NCT00049322|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2016-01-20||2016-02-17|2003-01-26|2003-01-27|Estimate|2016-02-17|2016-03-15|Estimate||||2016-02-17|2016-03-15|Estimate|June 2003||2003-06-30|February 2016|2016-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery|A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization|Completed||Phase 2|30|Actual|Jonsson Comprehensive Cancer Center|Size of study limits any strong conclusions regarding efficacy.Since this study was first designed and implemented, there have been many advances in the field, including confirmation of proof of principal for anti-angiogenic agents in advanced HCC.|2|||f||||t||||||||||2018-06-01 05:22:45.19065|2018-06-01 05:22:45.19065
NCT00049309|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2017-02-21|2003-01-26|2003-01-27|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2003||2003-01-31|February 2013|2013-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer|Prostate Cancer: Impact Of Fat And Flaxseed - Modified Diets|Completed||Phase 2|161|Actual|Duke University||4|||f||||t||||||||||2018-06-01 05:22:45.547285|2018-06-01 05:22:45.547285
NCT00049296|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2010-06-10|2003-01-26|2003-01-27|Estimate|||||||2010-06-10|2010-06-11|Estimate|July 2002||2002-07-31|June 2010|2010-06-30|January 2006|Actual|2006-01-31|December 2004|Actual|2004-12-31||Interventional|||Thalidomide and Docetaxel in Treating Patients With Advanced Cancer|Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles|Completed||Phase 1|26|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:45.62865|2018-06-01 05:22:45.62865
NCT00049283|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2014-06-05|2003-01-26|2003-01-27|Estimate|||||||2014-06-05|2014-06-06|Estimate|September 2002||2002-09-30|January 2013|2013-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer|A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:45.755528|2018-06-01 05:22:45.755528
NCT00049257|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2011-04-28||2015-10-01|2003-01-26|2003-01-27|Estimate|2012-02-10|2012-03-15|Estimate||||2015-10-01|2015-10-05|Estimate|October 2002||2002-10-31|August 2012|2012-08-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Paclitaxel and Carboplatin in the Treatment of Hormone-Refractory Prostate Cancer (HRPC)|Completed||Phase 2|58|Actual|Jonsson Comprehensive Cancer Center|The major weakness of the study is, it is a single-arm non-comparative study. With the small sample size of 58 participants who received treatment, the study does not have the statistical power to make categorical assessments or statements.|1|||f||||t||||||||||2018-06-01 05:22:45.863682|2018-06-01 05:22:45.863682
NCT00049244|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2017-01-27|2003-01-26|2003-01-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|September 2002||2002-09-30|January 2017|2017-01-31||||||||Interventional|||BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer|A Phase I Study of BMS-247550 in Combination With Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With a Taxane and an Anthracycline|Active, not recruiting||Phase 1|||R-Pharm|||||f||||||||||||||2018-06-01 05:22:46.132827|2018-06-01 05:22:46.132827
NCT00049231|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|June 2003||2003-06-30|June 2005|2005-06-30|August 2005|Actual|2005-08-31|||||Interventional|||EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer|Evaluation of Hypoxia by EF5 (NSC#684681) Binding in Cervix Cancer|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:46.185286|2018-06-01 05:22:46.185286
NCT00049218|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2014-05-08|2003-01-26|2003-01-27|Estimate|||||||2014-05-08|2014-05-09|Estimate|April 2003||2003-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|June 2007|Actual|2007-06-30||Interventional|||Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I-II Trial Using Dendritic Cells Transduced With An Adenoviral Vector Containing The p53 Gene To Immunize Patients With Extensive Stage Small Cell Lung Cancer After Standard Chemotherapy|Completed||Phase 1/Phase 2|56|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:22:46.23949|2018-06-01 05:22:46.23949
NCT00049192|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 2002||2002-11-30|June 2013|2013-06-30||||November 2005|Actual|2005-11-30||Interventional|||Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A PHASE II STUDY OF G3139 (GENASENSE™, NSC # 683428 IND # 58842) + IMATINIB MESYLATE (GLEEVEC®, STI571) IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA|Completed||Phase 2|43|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:46.384651|2018-06-01 05:22:46.384651
NCT00049179|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2015-03-05|2003-01-26|2003-01-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2003||2003-04-30|March 2015|2015-03-31|October 2010|Actual|2010-10-31|December 2005|Actual|2005-12-31||Interventional|||S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia|A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML)|Completed||Phase 2|33|Actual|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:22:46.490067|2018-06-01 05:22:46.490067
NCT00049166|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-09-27|2003-01-26|2003-01-27|Estimate|||||||2013-09-27|2013-09-30|Estimate|October 2002||2002-10-31|September 2013|2013-09-30||||July 2007|Actual|2007-07-31||Interventional|||Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer|A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV|Completed||Phase 1|48|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:22:46.738097|2018-06-01 05:22:46.738097
NCT00049140|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2014-07-24|2003-01-26|2003-01-27|Estimate|||||||2014-07-24|2014-07-25|Estimate|August 2002||2002-08-31|February 2013|2013-02-28||||October 2004|Actual|2004-10-31||Interventional|||EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer|Pilot Study of the Relationship Between EF5 Uptake and Concentration of Oxygen-Related Metabolites in Head and Neck Cancer|Completed||Phase 2|8|Actual|Duke University||1|||f||||||||||||||2018-06-01 05:22:46.826643|2018-06-01 05:22:46.826643
NCT00049127|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2013-11-25||2017-08-07|2003-01-26|2003-01-27|Estimate|2014-10-01|2014-10-06|Estimate||||2017-08-07|2017-09-06|Actual|June 2003|Actual|2003-06-30|August 2017|2017-08-31||||August 2011|Actual|2011-08-31||Interventional|||Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor|Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma|Active, not recruiting||Phase 1/Phase 2|64|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:22:46.975025|2018-06-01 05:22:46.975025
NCT00049114|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-06-05|2003-01-26|2003-01-27|Estimate|||||||2013-06-05|2013-06-06|Estimate|February 2003||2003-02-28|June 2013|2013-06-30||||January 2007|Actual|2007-01-31||Interventional|||Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer|A Phase I-II Study of R115777 (ZARNESTRA) Plus Doxorubicin and Cyclophosphamide in Patients With Locally Advanced Breast Cancer and Metastatic Breast Cancer|Completed||Phase 2|62|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:48.344473|2018-06-01 05:22:48.344473
NCT00049101|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|August 2002||2002-08-31|April 2004|2004-04-30|August 2004|Actual|2004-08-31|||||Interventional|||Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|A Phase I/II Study Of OSI-774 In Combination With Oxaliplatin, And 5-Fluourouracil In Patients With Metastatic Colorectal Carcinoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:48.433505|2018-06-01 05:22:48.433505
NCT00049088|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|August 2002||2002-08-31|January 2013|2013-01-31||||February 2009|Actual|2009-02-28||Interventional|||Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of PS-341 in Combination With Docetaxel in Patients With Advanced Solid Tumors|Terminated||Phase 1|24|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:22:48.498682|2018-06-01 05:22:48.498682
NCT00049075|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2016-11-25|2003-01-26|2003-01-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|August 2002||2002-08-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|July 2005|Actual|2005-07-31||Interventional|||Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Oral Fludarabine Phosphate in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 2|128|Actual|Canadian Cancer Trials Group|||||f||||t||||||||Undecided||2018-06-01 05:22:48.587232|2018-06-01 05:22:48.587232
NCT00049062|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-02-19|2003-01-26|2003-01-27|Estimate|||||||2013-02-19|2013-02-21|Estimate|September 2002||2002-09-30|February 2013|2013-02-28|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer|A Phase II And Biologic Correlative Study Investigating ARIMIDEX In Combination With IRESSA (ZD1839) In Post-Menopausal Patients With Estrogen Receptor-Positive Metastatic Breast Carcinoma Who Have Previously Failed Hormonal Therapy|Completed||Phase 2|||The University of Texas Health Science Center at San Antonio|||||f||||||||||||||2018-06-01 05:22:48.685283|2018-06-01 05:22:48.685283
NCT00049036|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2011-05-23||2014-04-28|2003-01-26|2003-01-27|Estimate|2011-05-23|2011-06-22|Estimate||||2014-04-28|2014-05-14|Estimate|March 2003||2003-03-31|December 2012|2012-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma|A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma|Completed||Phase 2|106|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:22:48.837969|2018-06-01 05:22:48.837969
NCT00049023|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2016-06-17|2003-01-26|2003-01-27|Estimate|||||||2016-06-17|2016-06-21|Estimate|January 2002||2002-01-31|June 2016|2016-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors|A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors|Completed||Phase 1|27|Actual|University of Iowa||1|||f||||t||||||||||2018-06-01 05:22:49.392006|2018-06-01 05:22:49.392006
NCT00049010|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2016-06-30|2003-01-26|2003-01-27|Estimate|||||||2016-06-30|2016-07-01|Estimate|September 2002||2002-09-30|June 2016|2016-06-30|October 2009|Actual|2009-10-31|March 2006|Actual|2006-03-31||Interventional|||Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma|Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma|Completed||N/A|314|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:22:49.491697|2018-06-01 05:22:49.491697
NCT00048997|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|2014-09-30||2016-12-30|2003-01-26|2003-01-27|Estimate|2014-09-30|2014-10-06|Estimate||||2016-12-30|2017-02-17|Actual|September 2002||2002-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2008|Actual|2008-12-31||Interventional||All eligible patients with consent.|Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer|A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|356|Actual|Radiation Therapy Oncology Group|This study stopped accrual early due to unmet accrual goals.|2|||f||||t||||||||||2018-06-01 05:22:49.602638|2018-06-01 05:22:49.602638
NCT00048984|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|January 2003||2003-01-31|June 2013|2013-06-30||||February 2013|Actual|2013-02-28||Observational|||Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma|A Groupwide Biology and Banking Study for Ewing Sarcoma|Completed|||637|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens~   "|||2018-06-01 05:22:49.829544|2018-06-01 05:22:49.829544
NCT00048971|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy|A Pharmacogenetic Case-Control Study of Severe Diarrhea and Life-Threatening Neutropenia in Patients Treated With Irinotecan, 5-Fluorouracil and Leucovorin|Completed|||308|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     blood specimens~   "|||2018-06-01 05:22:49.908996|2018-06-01 05:22:49.908996
NCT00048958|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2017-08-07|2003-01-26|2003-01-27|Estimate|||||||2017-08-07|2017-08-08|Actual|June 1984||1984-06-30|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Cytogenetic Studies in Acute Leukemia and Multiple Myeloma|Cytogenetic Studies in Acute Leukemia and Multiple Myeloma: Companion to CALGB Treatment Studies For Previously Untreated Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) or Multiple Myeloma (MM) Patients|Active, not recruiting|||9000|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Institutions must submit patient samples (eg, bone marrow and peripheral blood) at diagnosis,~     at complete remission, and at the time of relapse to the Alliance-Approved Institutional~     Cytogeneticist.~   "|||2018-06-01 05:22:50.267698|2018-06-01 05:22:50.267698
NCT00047385|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|2012-05-30||2014-05-02|2003-01-26|2003-01-27|Estimate|2012-05-30|2012-07-06|Estimate||||2014-05-02|2014-05-20|Estimate|August 2002||2002-08-31|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|NLST||National Lung Screening Trial (NLST) Screening|National Lung Screening Trial A Randomized Trial Comparing Low-dose Helical CT With Chest Xray for Lung Cancer|Completed||Phase 3|53454|Actual|National Cancer Institute (NCI)|"NLST utilized institutions with special expertise. The healthy volunteer effect may apply. Scanners are now more technologically advanced. Ongoing LDCT screening may reduce the rate of lung cancer deaths more than three rounds done in NLST."|2|||f||||t||||||||||2018-06-01 05:22:50.623442|2018-06-01 05:22:50.623442
NCT00047346|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2002||2002-08-31|January 2013|2013-01-31||||December 2005|Actual|2005-12-31||Interventional|||Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction|A Dose-Finding, Safety, And Pharmacokinetic Study Of The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor OSI-774 (NSC 718781) In Patients With Unresectable Hepatocellular Carcinoma And Moderate Hepatic Dysfunction|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:51.179288|2018-06-01 05:22:51.179288
NCT00047333|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2002||2002-08-31|January 2013|2013-01-31||||January 2006|Actual|2006-01-31||Interventional|||Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed|A Phase 2 Open-Label Study Of OSI-774 (NSC 718781) In Unresectable Hepatocellular Carcinoma|Terminated||Phase 2|80|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:22:51.282439|2018-06-01 05:22:51.282439
NCT00047320|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|2014-01-15||2018-01-17|2003-01-26|2003-01-27|Estimate|2014-01-15|2014-02-27|Estimate||||2018-01-17|2018-02-14|Actual|January 2004||2004-01-31|January 2018|2018-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors|A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT|Completed||Phase 2|104|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:22:51.435971|2018-06-01 05:22:51.435971
NCT00047307|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|August 2002||2002-08-31|June 2013|2013-06-30||||August 2008|Actual|2008-08-31||Interventional|||Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer|A Phase 1 Study of Alvocidib (Flavopiridol) in Combination With Radiation in Locally Advanced, Non-Operable Pancreatic and Extrahepatic Bile Duct Cancers|Completed||Phase 1|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:52.006814|2018-06-01 05:22:52.006814
NCT00047294|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2017-07-06|2003-01-26|2003-01-27|Estimate|||||||2017-07-06|2017-07-11|Actual|April 2001|Actual|2001-04-30|May 2005|2005-05-31|September 2007|Actual|2007-09-30|March 2005|Actual|2005-03-31||Interventional|||Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting|Completed||Phase 2|||Dana-Farber Cancer Institute|||||f||||t|t|f||||||||2018-06-01 05:22:52.136335|2018-06-01 05:22:52.136335
NCT00047281|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2017-07-06|2003-01-26|2003-01-27|Estimate|||||||2017-07-06|2017-07-11|Actual|March 2004|Actual|2004-03-31|July 2017|2017-07-31|February 2006|Actual|2006-02-28|August 2005|Actual|2005-08-31||Interventional|||Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma|Trial Of Oral Thalidomide, Celecoxib, Etoposide And Cyclophosphamide In Adult Patients With Relapsed Or Progressive Malignant Gliomas|Completed||Phase 2|||Dana-Farber Cancer Institute|||||f||||t|t|f||||||No||2018-06-01 05:22:52.255729|2018-06-01 05:22:52.255729
NCT00047268|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1998||1998-07-31|July 2007|2007-07-31||||||||Interventional|||Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome|Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:52.349351|2018-06-01 05:22:52.349351
NCT00047255|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2016-02-11|2003-01-26|2003-01-27|Estimate|||||||2016-02-11|2016-02-12|Estimate|May 2002||2002-05-31|February 2016|2016-02-29|April 2010|Actual|2010-04-30|January 2006|Actual|2006-01-31||Interventional|||Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer|A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification|Completed||Phase 3|263|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:22:52.489109|2018-06-01 05:22:52.489109
NCT00047242|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2010-08-05|2003-01-26|2003-01-27|Estimate|||||||2010-08-05|2010-08-09|Estimate|August 2002||2002-08-31|August 2010|2010-08-31||||February 2006|Actual|2006-02-28||Interventional|||UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors|The Pharmacokinetic and Safety Profile of UCN-01 in Combination With Irinotecan in Solid Tumors (Primarily Lung, Ovarian and GI Cancers)|Completed||Phase 1|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||||||||||||||||2018-06-01 05:22:52.872359|2018-06-01 05:22:52.872359
NCT00047229|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2017-11-06|2003-01-26|2003-01-27|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2002||2002-10-31|November 2017|2017-11-30|April 2009|Actual|2009-04-30|January 2009|Actual|2009-01-31||Interventional|||Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)|A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma|Completed||Phase 2|27|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 05:22:52.980077|2018-06-01 05:22:52.980077
NCT00047216|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2015-07-22|2003-01-26|2003-01-27|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2002||2002-11-30|July 2015|2015-07-31||||March 2006|Actual|2006-03-31||Interventional|||Tipifarnib in Treating Patients With Recurrent Bladder Cancer|A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder|Completed||Phase 2|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 05:22:53.438255|2018-06-01 05:22:53.438255
NCT00047203|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|September 2002||2002-09-30|January 2013|2013-01-31||||September 2006|Actual|2006-09-30||Interventional|||Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase II Study of Flavopiridol in Patients With Relapsed and Refractory Multiple Myeloma|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:54.084818|2018-06-01 05:22:54.084818
NCT00047190|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|August 2002||2002-08-31|June 2013|2013-06-30||||April 2007|Actual|2007-04-30||Interventional|||Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia|A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM)|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:54.211084|2018-06-01 05:22:54.211084
NCT00047177|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2009-10-14|2003-01-26|2003-01-27|Estimate|||||||2009-10-14|2009-10-15|Estimate|October 2002||2002-10-31|October 2009|2009-10-31|July 2007|Actual|2007-07-31|August 2004|Actual|2004-08-31||Interventional|||Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor|A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors|Completed||Phase 2|43|Actual|Pediatric Brain Tumor Consortium|||||f||||t||||||||||2018-06-01 05:22:54.58642|2018-06-01 05:22:54.58642
NCT00047164|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2016-09-23|2003-01-26|2003-01-27|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2002||2002-09-30|March 2012|2012-03-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy|A Pilot Study of Ipilimumab (MDX-CTLA4, MDX-010) in Lymphoma|Completed||Phase 1|89|Actual|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:22:54.707524|2018-06-01 05:22:54.707524
NCT00047138|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2014-06-23|2003-01-26|2003-01-27|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2001||2001-01-31|June 2009|2009-06-30||||||||Interventional|||Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor|Nephroblastoma (Wilms Tumour) Clinical Trial And Study|Unknown status|Recruiting|Phase 3|350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:54.880281|2018-06-01 05:22:54.880281
NCT00047125|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2012-06-19|2003-01-26|2003-01-27|Estimate|||||||2012-06-19|2012-06-20|Estimate|July 2002||2002-07-31|June 2012|2012-06-30||||July 2004|Actual|2004-07-31||Interventional|||Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor|Randomized Phase III Study On The Selection Of The Target Volume In Postoperative Radiotherapy For Cervical Lymph Node Metastases Of Squamous Cell Carcinoma From And Unknown Primary (CUP)|Completed||Phase 3|600|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-06-01 05:22:55.395167|2018-06-01 05:22:55.395167
NCT00047112|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2016-05-27|2003-01-26|2003-01-27|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2002||2002-05-31|May 2016|2016-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer|Randomized Study of Pre-Operative Radio-Chemotherapy Versus Surgery Alone in Thoracic Esophageal Cancer Deemed to be Resectable|Completed||Phase 3|195|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||||||||||||2018-06-01 05:22:56.076083|2018-06-01 05:22:56.076083
NCT00047099|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|August 2001||2001-08-31|December 2002|2002-12-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Combination Chemotherapy in Treating Women With Breast Cancer|A Randomized Phase III Trial Comparing FEC-Chemotherapy vs. EC-Doc-Chemotherapy in Patients With Primary Breast Cancer|Completed||Phase 3|446|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:56.496713|2018-06-01 05:22:56.496713
NCT00047073|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2012-07-27|2003-01-26|2003-01-27|Estimate|||||||2012-07-27|2012-07-31|Estimate|July 2002||2002-07-31|July 2012|2012-07-31|October 2007|Actual|2007-10-31|June 2005|Actual|2005-06-30||Interventional|||Sirolimus in Treating Patients With Glioblastoma Multiforme|A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme|Completed||Phase 1/Phase 2|13|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:22:56.654024|2018-06-01 05:22:56.654024
NCT00045604|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2002||2002-07-31|April 2004|2004-04-30||||||||Interventional|||Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase I Study of Imatinib (Gleevec) in Combination With Irinotecan and Cisplatin in Extensive Stage Small Cell Lung Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:09.049174|2018-06-01 05:23:09.049174
NCT00047060|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2018-03-27|2003-01-26|2003-01-27|Estimate|||||||2018-03-27|2018-03-29|Actual|July 30, 2002||2002-07-30|March 1, 2018|2018-03-01|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome|A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H|Active, not recruiting||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:22:56.825911|2018-06-01 05:22:56.825911
NCT00047047|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|August 2002||2002-08-31|June 2013|2013-06-30||||September 2007|Actual|2007-09-30||Interventional|||Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of Gemcitabine, 17-Allylaminogeldanamycin (17-AAG) And Cisplatin In Advanced Solid Tumor Patients|Completed||Phase 1|78|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:56.975674|2018-06-01 05:22:56.975674
NCT00047034|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-01-04|2003-01-26|2003-01-27|Estimate|||||||2013-01-04|2013-01-07|Estimate|August 2002||2002-08-31|January 2013|2013-01-31||||October 2007|Actual|2007-10-31||Interventional|||E7389 in Treating Patients With Advanced Solid Tumors|Phase I Trial of E7389 (Halichondrin B Analog) (NSC# 707389) in Patients With Advanced Solid Tumors|Completed||Phase 1|31|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:22:57.070988|2018-06-01 05:22:57.070988
NCT00047021|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2010-06-10|2003-01-26|2003-01-27|Estimate|||||||2010-06-10|2010-06-11|Estimate|November 2001||2001-11-30|June 2010|2010-06-30|September 2005|Actual|2005-09-30|August 2005|Actual|2005-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma|A Pilot Study Of Cytarabine And High-Dose Mitoxantrone For Relapsed Or Refractory Hematologic Malignancies|Completed||Phase 2|3|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:22:57.184911|2018-06-01 05:22:57.184911
NCT00047008|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|2014-07-28||2017-05-18|2003-01-26|2003-01-27|Estimate|2014-07-28|2014-08-15|Estimate||||2017-05-18|2017-06-14|Actual|July 2002|Actual|2002-07-31|May 2017|2017-05-31||||June 2010|Actual|2010-06-30||Interventional||Eligible patients who did not withdraw consent.|Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer|A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas|Active, not recruiting||Phase 3|743|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||No||2018-06-01 05:22:57.4408|2018-06-01 05:22:57.4408
NCT00046995|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 2001||2001-05-31|November 2002|2002-11-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Colon Cancer|5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03).|Unknown status|Active, not recruiting|Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:58.53626|2018-06-01 05:22:58.53626
NCT00046969|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|July 2002||2002-07-31|March 2007|2007-03-31|June 2007|Actual|2007-06-30|||||Interventional|||Epoetin Beta in Treating Anemia in Patients With Cervical Cancer|Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin)|Completed||Phase 4|450|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:58.737175|2018-06-01 05:22:58.737175
NCT00046943|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2011-02-18|2003-01-26|2003-01-27|Estimate|||||||2011-02-18|2011-02-21|Estimate|September 2002||2002-09-30|September 2003|2003-09-30||||June 2007|Actual|2007-06-30||Interventional|||Atrasentan in Treating Patients With Prostate Cancer|A Phase III Extension Study to Evaluate the Safety of 10 mg Atrasentan in Men With Hormone-Refractory Prostate Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:22:58.938335|2018-06-01 05:22:58.938335
NCT00046930|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|2010-08-17||2015-06-01|2003-01-26|2003-01-27|Estimate|2010-08-17|2010-09-06|Estimate||||2015-06-01|2015-06-26|Estimate|July 2002||2002-07-31|June 2015|2015-06-30||||June 2009|Actual|2009-06-30||Interventional|||Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia|A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts|Completed||Phase 3|449|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 05:22:59.105559|2018-06-01 05:22:59.105559
NCT00046917|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2014-02-21|2003-01-26|2003-01-27|Estimate|||||||2014-02-21|2014-02-24|Estimate|July 2002||2002-07-31|October 2011|2011-10-31||||March 2010|Actual|2010-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Irinotecan (CPT-11) and Cisplatin in Patients With Advanced Solid Tumors|Completed||Phase 1|13|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:02.582156|2018-06-01 05:23:02.582156
NCT00046904|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2011-05-04|2003-01-26|2003-01-27|Estimate|||||||2011-05-04|2011-05-05|Estimate|May 2003||2003-05-31|May 2011|2011-05-31||||September 2007|Actual|2007-09-30||Interventional|||Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer|Phase III Placebo-Controlled, Randomized, Double-Blind Comparison Of Etanercept (Enbrel) Versus Placebo For The Treatment Of Cancer-Associated Weight Loss And Anorexia|Completed||Phase 3|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:23:03.731052|2018-06-01 05:23:03.731052
NCT00046891|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|2015-02-25||2016-07-01|2003-01-26|2003-01-27|Estimate|2015-03-31|2015-04-15|Estimate||||2016-07-01|2016-07-06|Estimate|December 2002||2002-12-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|October 2006|Actual|2006-10-31||Interventional|||EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer|The Use of Ginkgo Biloba For The Prevention Of Chemotherapy-Related Cognitive Dysfunction|Completed||Phase 3|226|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:23:04.125857|2018-06-01 05:23:04.125857
NCT00046865|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2012-10-05|2003-01-26|2003-01-27|Estimate|||||||2012-10-05|2012-10-10|Estimate|October 2002||2002-10-31|October 2012|2012-10-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer|Treatment of Chemotherapy-Induced Nausea With Acupressure: A Phase III Trial|Completed||Phase 3|57|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:23:05.156564|2018-06-01 05:23:05.156564
NCT00045097|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|May 2002||2002-05-31|January 2007|2007-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase II Clinical Trial Of BMS-247550 (NSC 710428), An Epothilone B Analog, In Patients With Breast Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:23:14.276874|2018-06-01 05:23:14.276874
NCT00046852|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2009-09-23|2003-01-26|2003-01-27|Estimate|||||||2009-09-23|2009-09-24|Estimate|December 2001||2001-12-31|September 2009|2009-09-30|February 2008|Actual|2008-02-29|November 2004|Actual|2004-11-30||Interventional|||Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma|High-Dose Therapy and Autologous Blood Stem Cell Transplantation (ASCT) Followed by Post-Transplant Immunotherapy With Costimulated Autologous T-Cells in Conjunction With Pneumococcal Conjugate Vaccine Immunization for Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:23:05.237231|2018-06-01 05:23:05.237231
NCT00046839|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|2014-01-28||2015-11-14|2003-01-26|2003-01-27|Estimate|2014-01-28|2014-03-17|Estimate||||2015-11-14|2015-11-17|Estimate|July 2002||2002-07-31|November 2015|2015-11-30||||September 2011|Actual|2011-09-30||Interventional||Eligible patients who started protocol treatment.|Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer|A Phase I/II Trial of a COX-2 Inhibitor, Celebrex (Celecoxib), [National Screening Committee# 719627] With Limited Field Radiation for Intermediate Prognosis Patients With Locally Advanced Non-Small Cell Lung Cancer, With Analysis of Prognostic Factors|Completed||Phase 1/Phase 2|21|Actual|Radiation Therapy Oncology Group|This study stopped accrual early with 21 subjects accrued out of 128 planned, therefore only the phase I and phase II primary outcomes were reported.|3|||f||||t||||||||||2018-06-01 05:23:06.270154|2018-06-01 05:23:06.270154
NCT00046826|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-04-02|2003-01-26|2003-01-27|Estimate|||||||2013-04-02|2013-04-04|Estimate|September 2001||2001-09-30|January 2006|2006-01-31|October 2009|Actual|2009-10-31|June 2007|Actual|2007-06-30||Interventional|||Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy|A Phase II Clinical Trial of Taxotere, Emcyt and Thalidomide (TET) for the Treatment of Hormone-Refractory Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:06.565434|2018-06-01 05:23:06.565434
NCT00045747|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|July 2002||2002-07-31|August 2004|2004-08-31|September 2004|Actual|2004-09-30|||||Interventional|||UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer|Phase II Study of UCN-01 in Combination With Fluorouracil in Advanced Pancreatic Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:06.625141|2018-06-01 05:23:06.625141
NCT00045734|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2017-03-10||2017-05-02|2003-01-26|2003-01-27|Estimate|2017-05-02|2017-05-15|Actual||||2017-05-02|2017-05-15|Actual|February 2003||2003-02-28|May 2017|2017-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||23 patients were enrolled and evaluated however 1 patient was found to be ineligible as patient had a second malignancy within 3 years of registration. Demographics for this patient are reported.|Imatinib Mesylate in Treating Patients With Recurrent Meningioma|Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)|The study was closed prematurely due to limited activity and slow accrual. Study was designed to enroll (statistically powered) for 30 patients into each group (30 benign; 30 Atypical and 30 Anaplastic) meningioma's. Study enroll only 23 patients.|1|||f||||t||||||||No||2018-06-01 05:23:06.79913|2018-06-01 05:23:06.79913
NCT00045721|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2009-10-15|2003-01-26|2003-01-27|Estimate|||||||2009-10-15|2009-10-16|Estimate|March 2003||2003-03-31|October 2009|2009-10-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma|Phase I Trial of GLIADEL and O(6)-Benzylguanine in Pediatric Patients With Recurrent Malignant Gliomas|Terminated||Phase 1|3|Actual|Pediatric Brain Tumor Consortium||||Poor accrual|f||||t||||||||||2018-06-01 05:23:07.098725|2018-06-01 05:23:07.098725
NCT00045708|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2016-10-14||2017-09-15|2003-01-26|2003-01-27|Estimate|2017-03-28|2017-05-09|Actual||||2017-09-15|2017-10-18|Actual|October 2002||2002-10-31|September 2017|2017-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas|A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-grade Gliomas|Completed||Phase 1/Phase 2|57|Actual|National Cancer Institute (NCI)|Phase 2 was completed using only nonP450 MTD (6.8mg/m21) as the MTD for P450 was not determined until the Phase 2 accrual had completed.|3|||f||||t||||||||No||2018-06-01 05:23:07.226059|2018-06-01 05:23:07.226059
NCT00045695|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-05-16|2003-01-26|2003-01-27|Estimate|||||||2013-05-16|2013-05-17|Estimate|August 2002||2002-08-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|March 2006|Actual|2006-03-31||Interventional|||Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia|A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Waldenstrom's Macroglobulinemia|Completed||Phase 2|27|Actual|National Cancer Institute (NCI)|||||f||||f||||||||||2018-06-01 05:23:07.896053|2018-06-01 05:23:07.896053
NCT00045682|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2017-07-12|2003-01-26|2003-01-27|Estimate|||||||2017-07-12|2017-07-13|Actual|September 2002||2002-09-30|July 2017|2017-07-31||||July 15, 2006|Actual|2006-07-15||Interventional|||CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of CT-2103 in the Third-Line Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Cancer|Completed||Phase 2|78|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:23:07.978354|2018-06-01 05:23:07.978354
NCT00045669|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2012-06-11|2003-01-26|2003-01-27|Estimate|||||||2012-06-11|2012-06-12|Estimate|July 2002||2002-07-31|June 2012|2012-06-30|January 2005|Actual|2005-01-31|January 2004|Actual|2004-01-31||Interventional|||Imatinib Mesylate in Treating Patients With Salivary Gland Cancer|A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas|Completed||Phase 2|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 05:23:08.0862|2018-06-01 05:23:08.0862
NCT00045630|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2012-11-15||2013-04-16|2003-01-26|2003-01-27|Estimate|2013-04-16|2013-05-27|Estimate||||2013-04-16|2013-05-27|Estimate|January 2003||2003-01-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|May 2008|Actual|2008-05-31||Interventional|||S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium|A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates|Completed||Phase 2|77|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:23:08.309805|2018-06-01 05:23:08.309805
NCT00045617|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2012-06-11|2003-01-26|2003-01-27|Estimate|||||||2012-06-11|2012-06-13|Estimate|January 2003||2003-01-31|June 2012|2012-06-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer|A Phase II Trial of Patients With Limited Stage Small Cell Lung Cancer Treated With Thoracic Radiation Therapy and Chemotherapy With Cisplatin/Etoposide Followed by Cisplatin/Etoposide and Anti-Idiotype Monoclonal Antibody Vaccines|Terminated||Phase 2|9|Actual|Southwest Oncology Group||1||Closed due to lack of drug availability.|f||||t||||||||||2018-06-01 05:23:08.850237|2018-06-01 05:23:08.850237
NCT00045591|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2017-01-09|2003-01-26|2003-01-27|Estimate|||||||2017-01-09|2017-01-11|Estimate|February 2003||2003-02-28|January 2017|2017-01-31|January 2010|Actual|2010-01-31|August 2005|Actual|2005-08-31||Interventional|||Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer|Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design|Terminated||Phase 2|39|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:23:09.127283|2018-06-01 05:23:09.127283
NCT00045565|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-04-08|2003-01-26|2003-01-27|Estimate|||||||2013-04-08|2013-04-09|Estimate|October 2002||2002-10-31|April 2013|2013-04-30||||November 2008|Actual|2008-11-30||Interventional|||Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma|Phase I Study of Combined Radiotherapy and Arsenic Trioxide for the Treatment of Newly Diagnosed Malignant Glioma|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:23:09.392505|2018-06-01 05:23:09.392505
NCT00045539|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|October 2002||2002-10-31|December 2005|2005-12-31|January 2006|Actual|2006-01-31|||||Interventional|||Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma|A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:09.467835|2018-06-01 05:23:09.467835
NCT00045526|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|June 2002||2002-06-30|June 2013|2013-06-30||||February 2007|Actual|2007-02-28||Interventional|||Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer|Phase II Study Of OSI-774 In Advanced Esophageal Cancer|Completed||Phase 2|48|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:09.55345|2018-06-01 05:23:09.55345
NCT00045513|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2015-07-22|2003-01-26|2003-01-27|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2002||2002-06-30|July 2015|2015-07-31||||December 2003|Actual|2003-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma|Phase I/II Study Of UCN-01 In Combination With Fludarabine In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma|Completed||Phase 1/Phase 2|||University Health Network, Toronto|||||f||||||||||||||2018-06-01 05:23:09.63867|2018-06-01 05:23:09.63867
NCT00045500|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2002||2002-06-30|August 2005|2005-08-31||||January 2010|Actual|2010-01-31||Interventional|||UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma|A Phase I Trial Of UCN-01 And Prednisone In Patients With Refractory Solid Tumors And Lymphomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:23:09.723733|2018-06-01 05:23:09.723733
NCT00045487|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2013-05-07||2013-12-09|2003-01-26|2003-01-27|Estimate|2013-12-09|2014-01-27|Estimate||||2013-12-09|2014-01-27|Estimate|June 2002||2002-06-30|December 2013|2013-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|OSI-774||Erlotinib in Treating Patients With Advanced Kidney Cancer|A Phase II, Pharmacokinetic And Biologic Correlative Study of OSI-774, An EGFR Tyrosine Kinase Inhibitor, In Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|41|Actual|The University of Texas Health Science Center at San Antonio|The PI/responsible party left this institution. Additional records for completion of results entries is not available at our institution. NCI transferred the PRS record to this institution >4.5 years after the PIs left employment.|1|||f||||f||||||||||2018-06-01 05:23:09.810168|2018-06-01 05:23:09.810168
NCT00045474|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 2002||2002-10-31|April 2003|2003-04-30||||||||Interventional|||Brachytherapy in Treating Patients With Recurrent Malignant Glioma|Phase I Brachytherapy Dose Escalating Study Using the Proxima Therapeutics, Inc. GliaSite RTS in Patients With Recurrent Malignant Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:09.975921|2018-06-01 05:23:09.975921
NCT00045461|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2000||2000-06-30|October 2002|2002-10-31||||||||Interventional|||Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY|Unknown status|Recruiting|Phase 2/Phase 3|241|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:10.066629|2018-06-01 05:23:10.066629
NCT00045448|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2002||2002-04-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|January 2006|Actual|2006-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Single Center Open-Label Non-Comparative Phase I Dose Finding Study Of Weekly Flavopiridol In Combination With Weekly Docetaxel In Patients With Advanced Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:10.157588|2018-06-01 05:23:10.157588
NCT00045435|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2017-01-25||2017-04-11|2003-01-26|2003-01-27|Estimate|2017-01-25|2017-03-16|Actual||||2017-04-11|2017-05-19|Actual|April 2002||2002-04-30|April 2017|2017-04-30||||June 2009|Actual|2009-06-30||Interventional|||Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission|Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission|Active, not recruiting||Phase 2|17|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:23:10.246684|2018-06-01 05:23:10.246684
NCT00045422|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2002||2002-04-30|June 2013|2013-06-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Open Label Study to Determine Safety and Efficacy of Interferon-alpha in Combination With Imantinib Mesylate (Gleevec) in Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Not Achieved a Complete Cytogenetic Response to Gleevec as a Single Agent|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:23:10.475566|2018-06-01 05:23:10.475566
NCT00045396|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-01-08|2003-01-26|2003-01-27|Estimate|||||||2013-01-08|2013-01-09|Estimate|June 2002||2002-06-30|January 2013|2013-01-31||||October 2007|Actual|2007-10-31||Interventional|||A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)|A Phase II Study of the Farnesyltransferase Inhibitor ZARNESTRA (Tipifarnib, R115777, NSC #702818, IND #58,359) in Complete Remission Following Induction and/or Consolidation Chemotherapy in Adults With Poor-Risk Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplasia (MDS).|Completed||Phase 2|44|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:10.534784|2018-06-01 05:23:10.534784
NCT00045370|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2002||2002-04-30|June 2013|2013-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer|A Phase I Study of the Safety, Tolerability, and Antitumor Activity of Escalating Doses of Intravenous CCI-779 Given in Combination With Escalating Doses of Interferon-Alpha to Patients With Advanced Renal Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:23:10.595974|2018-06-01 05:23:10.595974
NCT00045331|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 2002||2002-08-31|October 2004|2004-10-31|October 2007|Actual|2007-10-31|||||Interventional|||Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer|Are the Proteomic Profiles of Serum and Urine Predictivefor Clinical Outcome After Definitive Radiotherapy for Localized Prostate Cancer? A Preliminary Cohort Study|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:10.653226|2018-06-01 05:23:10.653226
NCT00045318|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|May 2002||2002-05-31|April 2003|2003-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction|A Phase I Study of DX-8951f (Exatecan Mesylate for Injection) in Patients With Renal Dysfunction|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:10.701792|2018-06-01 05:23:10.701792
NCT00045305|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2015-01-09||2015-01-15|2003-01-26|2003-01-27|Estimate|2015-01-15|2015-01-19|Estimate||||2015-01-15|2015-01-19|Estimate|May 2005||2005-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional||eligible and treated patients|Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes|A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes|Completed||Phase 2|17|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:23:10.76994|2018-06-01 05:23:10.76994
NCT00045292|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2010-09-17|2003-01-26|2003-01-27|Estimate|||||||2010-09-17|2010-09-21|Estimate|April 2002||2002-04-30|September 2010|2010-09-30|October 2004|Actual|2004-10-31|||||Interventional|||Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation|A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants|Completed||Phase 3|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:23:11.11761|2018-06-01 05:23:11.11761
NCT00045279|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2002||2002-04-30|June 2013|2013-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of PEG-Intron in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:23:11.257941|2018-06-01 05:23:11.257941
NCT00045266|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2016-06-01|2003-01-26|2003-01-27|Estimate|||||||2016-06-01|2016-06-03|Estimate|April 2002||2002-04-30|June 2016|2016-06-30||||February 2007|Actual|2007-02-28||Interventional|||VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma|An Open-Label, Long Term, Safety, and Tolerability Study of VEGF Trap in Patients With Incurable, Relapsed or Refractory Solid Tumors or Lymphoma|Completed||Phase 1|||Regeneron Pharmaceuticals|||||f||||||||||||||2018-06-01 05:23:11.325291|2018-06-01 05:23:11.325291
NCT00045227|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 2002||2002-08-31|December 2003|2003-12-31|October 2007|Actual|2007-10-31|||||Interventional|||Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer|A Pilot Trial of Pox Vector PSA Vaccine With Concurrent Docetaxel Versus Pox Vector Vaccine Followed by Docetaxel in Metastatic Androgen Independent Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:11.396412|2018-06-01 05:23:11.396412
NCT00045201|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2018-04-20|2003-01-26|2003-01-27|Estimate|||||||2018-04-20|2018-04-23|Actual|June 13, 2002|Actual|2002-06-13|April 2018|2018-04-30||||June 1, 2009|Actual|2009-06-01||Interventional|||Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors|Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:11.473712|2018-06-01 05:23:11.473712
NCT00045188|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2002||2002-08-31|January 2013|2013-01-31||||July 2004|Actual|2004-07-31||Interventional|||Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer|Phase II Trial of STI571 in Metastatic Breast Cancer|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:11.562434|2018-06-01 05:23:11.562434
NCT00045175|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2016-06-21|2003-01-26|2003-01-27|Estimate|||||||2016-06-21|2016-06-23|Estimate|June 2002||2002-06-30|June 2016|2016-06-30||||June 2013|Actual|2013-06-30||Interventional|||UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer|A Phase I Study of UCN-01 in Combination With Topotecan in Patients With Solid Tumors|Completed||Phase 1|33|Actual|University Health Network, Toronto||1|||f||||||||||||||2018-06-01 05:23:11.646274|2018-06-01 05:23:11.646274
NCT00045162|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2013-04-16||2013-07-03|2003-01-26|2003-01-27|Estimate|2013-07-03|2013-07-09|Estimate||||2013-07-03|2013-07-09|Estimate|November 2002||2002-11-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|March 2008|Actual|2008-03-31||Interventional||Eleven ineligible patients on the cisplatin + irinotecan arm, and eight ineligible patients on the cisplatin + etoposide arm were excluded from the analysis.|S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer|Randomized Phase III Trial of Cisplatin and Irinotecan (NSC-616348) Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (E-SCLC)|Completed||Phase 3|671|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:23:11.897339|2018-06-01 05:23:11.897339
NCT00045136|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2009-04-02|2003-01-26|2003-01-27|Estimate|||||||2009-04-02|2009-04-03|Estimate|January 2002||2002-01-31|April 2009|2009-04-30||||January 2003|Actual|2003-01-31||Interventional|||Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:13.518446|2018-06-01 05:23:13.518446
NCT00045110|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2017-05-04||2017-07-14|2003-01-26|2003-01-27|Estimate|2017-06-14|2017-07-13|Actual||||2017-07-14|2017-08-17|Actual|August 2002||2002-08-31|July 2017|2017-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||enrolled between 8/2002 and 8/2005. All recruited from outpatient setting.|Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma|A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy|Completed||Phase 1/Phase 2|136|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||No||2018-06-01 05:23:13.642664|2018-06-01 05:23:13.642664
NCT00045045|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|May 2002||2002-05-31|September 2002|2002-09-30|July 2007|Actual|2007-07-31|||||Interventional|||Positron Emission Tomography in Detecting Testicle Cancer|A Study Of 18 FDG PET In The Prediction Of Relapse In Patients With A Clinical Stage I Non-Seminomatous Germ Cell Tumor|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:14.429571|2018-06-01 05:23:14.429571
NCT00045032|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|2016-10-19||2017-03-17|2003-01-26|2003-01-27|Estimate|2017-03-17|2017-04-27|Actual||||2017-03-17|2017-04-27|Actual|November 2001||2001-11-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|March 2005|Actual|2005-03-31||Interventional|HERA|Full Analysis Set (FAS) Population: All enrolled/randomized participants who had an available signed Informed Consent Form.|Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer|A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy|Completed||Phase 3|5099|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 05:23:14.659248|2018-06-01 05:23:14.659248
NCT00045019|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2012-08-24|2003-01-26|2003-01-27|Estimate|||||||2012-08-24|2012-08-27|Estimate|May 2002||2002-05-31|August 2012|2012-08-31|March 2005|Actual|2005-03-31|June 2004|Actual|2004-06-30||Observational|||Study to Assess Cancer Patients' Satisfaction With Hospital Quality of Care|An International Field-Testing Study Of The Reliability And Validity Of A Patient Satisfaction Module (QLQ-SAT32) Assessing Cancer Patients' Perception Of The Quality Of Care Received Within The Hospital|Completed|||795|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||1||f||||f||||||||||2018-06-01 05:23:18.696155|2018-06-01 05:23:18.696155
NCT00045006|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|July 2001||2001-07-31|October 2003|2003-10-31|July 2008|Actual|2008-07-31|December 2005|Actual|2005-12-31||Interventional|||Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer|Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:18.780543|2018-06-01 05:23:18.780543
NCT00044993|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 2002||2002-02-28|July 2004|2004-07-31|August 2004|Actual|2004-08-31|||||Interventional|||Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer|Phase II, Single Arm, Single Institution Clinical Trial of Docetaxel and Doxorubicin in Combination With Local Administration of INGN 201 (Ad5CMV-p53) in Locally Advanced Breast Cancer (LABC)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:18.873709|2018-06-01 05:23:18.873709
NCT00044980|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2017-02-21|2003-01-26|2003-01-27|Estimate|||||||2017-02-21|2017-02-23|Actual|July 2002||2002-07-31|November 2012|2012-11-30|December 2006|Actual|2006-12-31|September 2005|Actual|2005-09-30||Interventional|||Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer|Fresh Start: Promoting Health in Prostate Cancer Survivors|Completed||N/A|||Duke University|||||f||||t||||||||||2018-06-01 05:23:18.933583|2018-06-01 05:23:18.933583
NCT00044967|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|May 2002||2002-05-31|July 2016|2016-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||Genetic Study of Young Patients With Colorectal Cancer|A Prospective Study Of The Prognostic Significance Of Microsatellite Instability In Patients With Early Age-Of-Onset Colorectal Cancer|Completed|||651|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 05:23:19.016825|2018-06-01 05:23:19.016825
NCT00044954|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 2001||2001-11-30|February 2005|2005-02-28||||||||Interventional|||Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:19.244528|2018-06-01 05:23:19.244528
NCT00043147|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2002||2002-04-30|December 2004|2004-12-31|January 2005|Actual|2005-01-31|||||Interventional|||Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease|A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:19.328754|2018-06-01 05:23:19.328754
NCT00043134|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2010-04-10|2003-01-26|2003-01-27|Estimate|||||||2010-04-10|2010-04-13|Estimate|May 2002||2002-05-31|April 2008|2008-04-30||||May 2008|Anticipated|2008-05-31||Interventional|||Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome|Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study|Unknown status|Active, not recruiting|Phase 3|220|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:19.390632|2018-06-01 05:23:19.390632
NCT00043121|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-12-10|2003-01-26|2003-01-27|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2002||2002-06-30|December 2013|2013-12-31||||August 2008|Actual|2008-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery|A Phase I Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Advanced Malignancy|Completed||Phase 1|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:19.508977|2018-06-01 05:23:19.508977
NCT00043095|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|June 2002||2002-06-30|April 2005|2005-04-30||||||||Interventional|||BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of BMS 247550 (NSC# 710428) and Gemcitabine in Patients With Advanced Solid Tumor Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:19.582732|2018-06-01 05:23:19.582732
NCT00043082|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2015-10-23|2003-01-26|2003-01-27|Estimate|||||||2015-10-23|2015-10-26|Estimate|August 2002||2002-08-31|October 2015|2015-10-31|July 2011|Actual|2011-07-31|June 2007|Actual|2007-06-30||Interventional|||S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer|A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy|Completed||Phase 3|61|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:23:19.654814|2018-06-01 05:23:19.654814
NCT00043069|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2002||2002-11-30|December 2016|2016-12-31|January 2010|Actual|2010-01-31|June 2006|Actual|2006-06-30||Interventional|||Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer|Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study|Completed||Phase 3|71|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-06-01 05:23:20.017239|2018-06-01 05:23:20.017239
NCT00043043|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|May 2003||2003-05-31|November 2004|2004-11-30|October 2007|Actual|2007-10-31|||||Interventional|||Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia|Rectal Abberant Crypt Foci And Other Intermediate Biomarkers For Sporadic Colorectal Neoplasia: Cross-Sectional Prevelance And Modulation By Celecoxib|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:20.334295|2018-06-01 05:23:20.334295
NCT00043030|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2002||2002-06-30|March 2012|2012-03-31|May 2009|Actual|2009-05-31|December 2006|Actual|2006-12-31||Interventional|||Evaluating Patient Participation in Phase I Clinical Trials|Survey Of Patient's Motivations, Perceptions, And Expectations In Phase I Clinical Trials|Completed||N/A|120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:23:20.432719|2018-06-01 05:23:20.432719
NCT00043017|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-09|Estimate|May 2002||2002-05-31|October 2013|2013-10-31|March 2011|Actual|2011-03-31|May 2005|Actual|2005-05-31||Interventional|ACRIN 6657||Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer|Contrast-Enhanced Breast MRI For Evaluation Of Patients Undergoing Neoadjuvant Treatment For Locally-Advanced Breast Cancer (I-SPY 1/ACRIN 6657)|Completed||Phase 2|356|Actual|American College of Radiology Imaging Network||1|||f||||t||||||||||2018-06-01 05:23:20.532299|2018-06-01 05:23:20.532299
NCT00043004|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2002||2002-05-31|September 2012|2012-09-30||||June 2007|Actual|2007-06-30||Interventional|||Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer|CLOCC Trial (Chemotherapy + Local Ablation Versus Chemotherapy) Randomized Phase II Study Of Local Treatment Of Liver Metastases By Radiofrequency Combined With Chemotherapy Versus Chemotherapy Alone In Patients With Unresectable Colorectal Liver Metastases|Terminated||Phase 2|119|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:23:20.712525|2018-06-01 05:23:20.712525
NCT00042991|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|2011-02-09||2014-05-15|2003-01-26|2003-01-27|Estimate|2011-06-13|2011-07-11|Estimate||||2014-05-15|2014-05-28|Estimate|July 2002||2002-07-31|December 2012|2012-12-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Interventional|||Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas|Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors|Completed||Phase 1/Phase 2|69|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:20.959693|2018-06-01 05:23:20.959693
NCT00042978|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-01-11|2003-01-26|2003-01-27|Estimate|||||||2013-01-11|2013-01-14|Estimate|April 2003||2003-04-30|January 2013|2013-01-31||||May 2005|Actual|2005-05-31||Interventional|||Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer|A Randomized Phase II Study Of Carboplatin And Etoposide With Or Without G3139 (NSC #683428, IND #58842) In Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:23:27.168941|2018-06-01 05:23:27.168941
NCT00042965|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 2002||2002-10-31|July 2016|2016-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma|Completed||Phase 2|60|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:23:29.510173|2018-06-01 05:23:29.510173
NCT00042952|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-17|Estimate|June 2002||2002-06-30|January 2013|2013-01-31||||October 2003|Actual|2003-10-31||Interventional|||Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer|A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma|Terminated||Phase 2|32|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:23:30.068342|2018-06-01 05:23:30.068342
NCT00042939|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|2011-06-21||2013-04-02|2003-01-26|2003-01-27|Estimate|2011-06-21|2011-07-19|Estimate||||2013-04-02|2013-04-09|Estimate|July 2003||2003-07-31|December 2012|2012-12-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer|Phase II Trial of Irinotecan/Docetaxel for Advanced Pancreatic Cancer, With Randomization Between Irinotecan/Docetaxel and Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor (EGF-r)|Completed||Phase 2|94|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 05:23:30.471178|2018-06-01 05:23:30.471178
NCT00042926|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|May 2002||2002-05-31|December 2016|2016-12-31|November 2010|Actual|2010-11-30|May 2007|Actual|2007-05-31||Interventional|||Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer|A Trial Of Lymphatic Mapping And Sentinel Node Lymphadenectomy For Patients With T1 or T2 Clinically N0 Oral Cavity Squamous Cell Carcinoma|Completed||N/A|161|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:23:32.007899|2018-06-01 05:23:32.007899
NCT00042913|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2002||2002-05-31|September 2003|2003-09-30||||||||Interventional|||Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase 2 Open Label, Randomized, Dose And Schedule Finding, Clinical Trial Of Immunotherapy With AMG 412 In Subjects With Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:32.138961|2018-06-01 05:23:32.138961
NCT00042887|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2002||2002-05-31|September 2012|2012-09-30||||May 2004|Actual|2004-05-31||Interventional|||Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer|Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial|Terminated||Phase 3|58|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:23:32.238932|2018-06-01 05:23:32.238932
NCT00042874|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|May 2002||2002-05-31|June 2013|2013-06-30||||January 2009|Actual|2009-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study of Alvocidib (Flavopiridol) Administered With Irinotecan (CPT-11) and Fluorouracil/Leucovorin in Patients With Advanced Solid Tumors|Completed||Phase 1|77|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:32.357685|2018-06-01 05:23:32.357685
NCT00042861|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|August 2002||2002-08-31|April 2003|2003-04-30||||||||Interventional|||UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors|A Phase I Pharmacologic Trial Of Infusional UCN-01 Given With A Weekly Schedule Of 5-Fluorouracil And Leucovorin|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:32.503138|2018-06-01 05:23:32.503138
NCT00042848|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2015-10-13|2003-01-26|2003-01-27|Estimate|||||||2015-10-13|2015-10-15|Estimate|August 2002||2002-08-31|October 2015|2015-10-31|October 2007|Actual|2007-10-31|April 2007|Actual|2007-04-30||Interventional|||Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer|Phase III Randomized, Placebo-Controlled, Double-Blind Trial Of The Effect Of Modafinil On Fatigue In Cancer Patients Receiving Chemotherapy|Completed||Phase 3|837|Anticipated|University of Rochester|||||f||||t||||||||||2018-06-01 05:23:32.620324|2018-06-01 05:23:32.620324
NCT00042835|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-01-31|2003-01-26|2003-01-27|Estimate|||||||2013-01-31|2013-02-01|Estimate|May 2002||2002-05-31|January 2013|2013-01-31||||December 2008|Actual|2008-12-31||Interventional|||Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer|A Phase I Study Of OSI-774 (NSC #718781)-Based Multimodality Therapy For Inoperable Stage III Non Small Cell Lung Cancer|Terminated||Phase 1|48|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:23:32.747993|2018-06-01 05:23:32.747993
NCT00042822|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2011-05-14|2003-01-26|2003-01-27|Estimate|||||||2011-05-14|2011-05-17|Estimate|May 2002||2002-05-31|December 2009|2009-12-31||||March 2005|Actual|2005-03-31||Interventional|||FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma|A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:32.901049|2018-06-01 05:23:32.901049
NCT00042809|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2002||2002-05-31|January 2013|2013-01-31||||December 2007|Actual|2007-12-31||Interventional|||Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors|Phase I Study To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Combined EGFR (erbB1) And HER2 (erbB2) Blockade, With OSI-774 And Trastuzumab, In Combination With Weekly Paclitaxel|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:32.968839|2018-06-01 05:23:32.968839
NCT00042796|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|December 2002||2002-12-31|January 2013|2013-01-31||||October 2005|Actual|2005-10-31||Interventional|||Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|A Phase I Study Of Decitabine (DAC) (IND # 50733) In Children With Relapsed Or Refractory Acute Leukemia|Terminated||Phase 1|21|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:23:33.083302|2018-06-01 05:23:33.083302
NCT00042783|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|September 2002||2002-09-30|April 2004|2004-04-30|March 2006|Actual|2006-03-31|||||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Phase II Trial Of A D1/3-MAGE3-HIS Fusion Protein (NSC-719274) With Adjuvant SBAS02B (NSC-719275) For Patients With Stage IV, M1a or M1b Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:33.208563|2018-06-01 05:23:33.208563
NCT00042770|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-04|Estimate|May 2002||2002-05-31|July 2016|2016-07-31|February 2008|Actual|2008-02-29|February 2005|Actual|2005-02-28||Interventional|||Standard Chest Tube Compared With a Small Catheter in Treating Malignant Pleural Effusion in Patients With Cancer|Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control, OPEC)|Completed||Phase 3|67|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:23:33.464883|2018-06-01 05:23:33.464883
NCT00042731|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2012-09-21|2003-01-26|2003-01-27|Estimate|||||||2012-09-21|2012-09-24|Estimate|July 2002||2002-07-31|September 2012|2012-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical Prostatectomy|A Randomized Pilot Clinical Trial Of The Action Of Isoflavones And Lycopene In Localized Prostate Cancer: Administration Prior To Radical Prostatectomy|Completed||N/A|79|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f||||||||||2018-06-01 05:23:33.577857|2018-06-01 05:23:33.577857
NCT00041379|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 2002||2002-03-31|December 2005|2005-12-31||||||||Interventional|||Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia|Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:33.763953|2018-06-01 05:23:33.763953
NCT00041340|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|May 2002||2002-05-31|January 2013|2013-01-31||||July 2006|Actual|2006-07-31||Interventional|||Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer|Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known As(STI571) (NSC #716051) In Patients With Colorectal Cancer Stage IV|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:33.906838|2018-06-01 05:23:33.906838
NCT00041327|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-02-01|2003-01-26|2003-01-27|Estimate|||||||2016-02-01|2016-02-03|Estimate|October 2002||2002-10-31|February 2016|2016-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma|Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|19|Actual|AIDS Malignancy Consortium|||||f||||||||||||||2018-06-01 05:23:34.022715|2018-06-01 05:23:34.022715
NCT00041314|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2009-06-06|2003-01-26|2003-01-27|Estimate|||||||2009-06-06|2009-06-09|Estimate|August 2002||2002-08-31|August 2002|2002-08-31||||July 2005|Actual|2005-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer|A Phase II Trial Of Carboplatin And Gemcitabine With Exisulind In Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:34.183665|2018-06-01 05:23:34.183665
NCT00041301|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2012-08-24|2003-01-26|2003-01-27|Estimate|||||||2012-08-24|2012-08-27|Estimate|March 2002||2002-03-31|August 2012|2012-08-31|November 2005|Actual|2005-11-30|December 2004|Actual|2004-12-31||Observational|||Assessing Quality of Life of Patients With Prostate Cancer|An International Field Study Of The Reliability And Validity Of The EORTC QLQ-C30 And A Disease-Specific Questionnaire Module (QLQ-PR25) For Assessing Quality Of Life Of Patients With Prostate Cancer|Completed|||625|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||1||f||||f||||||||||2018-06-01 05:23:34.412928|2018-06-01 05:23:34.412928
NCT00041288|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 2001||2001-10-31|March 2003|2003-03-31||||||||Interventional|||Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|A Phase II Multicenter Randomized Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:34.569569|2018-06-01 05:23:34.569569
NCT00041262|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-08-09|2003-01-26|2003-01-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|November 2004||2004-11-30|March 2007|2007-03-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Esophageal Cancer|A Prospective Randomized Trial Comparing Standard Chemotherapy Followed By Resection Versus Infusional Chemotherapy In Patients With Resectable Adenocarcinoma Of The Oesophagus|Unknown status|Recruiting|Phase 3|1300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:34.773853|2018-06-01 05:23:34.773853
NCT00041249|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|May 2002||2002-05-31|July 2012|2012-07-31||||January 2004|Actual|2004-01-31||Interventional|||Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma|Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment|Completed||Phase 2|64|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:23:34.916331|2018-06-01 05:23:34.916331
NCT00041236|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|May 2002||2002-05-31|July 2012|2012-07-31||||December 2004|Actual|2004-12-31||Interventional|||Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma|Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group|Completed||Phase 2|39|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:23:35.169526|2018-06-01 05:23:35.169526
NCT00041223|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2002||2002-09-30|September 2002|2002-09-30||||||||Interventional|||IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer|Double-Blind, Placebo-Controlled, Randomized Phase II Trial of IH636 Grape Seed Proanthocyanidin Extract (GSPE) in Patients With Adverse Effects of High Dose Breast Radiotherapy|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:35.332315|2018-06-01 05:23:35.332315
NCT00041210|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|October 2001||2001-10-31|April 2009|2009-04-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma|Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease|Unknown status|Active, not recruiting|Phase 3|850|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:35.438657|2018-06-01 05:23:35.438657
NCT00041197|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-07-15|2003-01-26|2003-01-27|Estimate|||||||2013-07-15|2013-07-16|Estimate|June 2002||2002-06-30|June 2013|2013-06-30||||April 2007|Actual|2007-04-30||Interventional|||Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery|A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec™) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)|Completed||Phase 3|732|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:23:35.590405|2018-06-01 05:23:35.590405
NCT00041171|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-07-11|2003-01-26|2003-01-27|Estimate|||||||2016-07-11|2016-07-12|Estimate||||July 2016|2016-07-31||||||||Interventional|||Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery|Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors|Withdrawn||Phase 3|0|Actual|Alliance for Clinical Trials in Oncology||3||The study was not activated.|f||||||||||||||2018-06-01 05:23:35.669787|2018-06-01 05:23:35.669787
NCT00041132|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2012-03-05||2012-10-03|2003-01-26|2003-01-27|Estimate|2012-10-03|2012-11-01|Estimate||||2012-10-03|2012-11-01|Estimate|September 2002||2002-09-30|October 2012|2012-10-31|June 2011|Actual|2011-06-30|November 2007|Actual|2007-11-30||Interventional|||S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma|Pilot Trial of Hyper-CVAD and Methotrexate/ARA C Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma|Completed||Phase 2|56|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:23:35.764259|2018-06-01 05:23:35.764259
NCT00041119|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2017-01-09||2017-04-12|2003-01-26|2003-01-27|Estimate|2017-04-12|2017-05-18|Actual||||2017-04-12|2017-05-18|Actual|May 2002||2002-05-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|April 2012|Actual|2012-04-30||Interventional||All patients that were eligible and treated for the study were evaluated|Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer|Cyclophosphamide And Doxorubicin (CA) (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes:A 2X2 Factorial Phase III Randomized Study|Completed||Phase 3|3871|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-06-01 05:23:36.185628|2018-06-01 05:23:36.185628
NCT00041106|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 2002||2002-05-31|June 2013|2013-06-30||||July 2007|Actual|2007-07-31||Interventional|||Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer|Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND #61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:38.675133|2018-06-01 05:23:38.675133
NCT00041093|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2018-01-09|2003-01-26|2003-01-27|Estimate|||||||2018-01-09|2018-01-10|Actual|June 2002||2002-06-30|January 2018|2018-01-31||||October 23, 2006|Actual|2006-10-23||Interventional|||Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix|Completed||Phase 2|27|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:23:38.855984|2018-06-01 05:23:38.855984
NCT00041080|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2013-07-09||2014-04-29|2003-01-26|2003-01-27|Estimate|2013-07-09|2013-09-16|Estimate||||2014-04-29|2014-05-15|Estimate|February 2003||2003-02-28|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||"Description of population is based on eligible patients.~1 patient not included in characteristics due to ineligible primary tumor site."|Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy|Completed||Phase 3|139|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:23:38.995089|2018-06-01 05:23:38.995089
NCT00041067|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2012-11-15||2013-05-20|2003-01-26|2003-01-27|Estimate|2013-05-20|2013-06-06|Estimate||||2013-05-20|2013-06-06|Estimate|September 2002||2002-09-30|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2008|Actual|2008-01-31||Interventional|||S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer|Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer|Completed||Phase 2|76|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:23:39.687199|2018-06-01 05:23:39.687199
NCT00041054|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|June 2002||2002-06-30|December 2016|2016-12-31|February 2008|Actual|2008-02-29|August 2004|Actual|2004-08-31||Interventional|||Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients With Extensive Small Cell Lung Cancer|Completed||Phase 2|41|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:23:41.340032|2018-06-01 05:23:41.340032
NCT00041041|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-02-19|2003-01-26|2003-01-27|Estimate|||||||2013-02-19|2013-02-20|Estimate|June 2002||2002-06-30|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of Gleevec (Imatinib Mesylate) (IND #61135, NSC #716051) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:42.524788|2018-06-01 05:23:42.524788
NCT00041028|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2015-04-30|2003-01-26|2003-01-27|Estimate|||||||2015-04-30|2015-05-01|Estimate|May 2002||2002-05-31|September 2006|2006-09-30|April 2014|Actual|2014-04-30|September 2007|Actual|2007-09-30||Interventional|||EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer|Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients With Non-Small Cell Lung Cancer|Completed||Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:23:44.248689|2018-06-01 05:23:44.248689
NCT00041015|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2014-01-08|2003-01-26|2003-01-27|Estimate|||||||2014-01-08|2014-01-09|Estimate|September 2001||2001-09-30|January 2014|2014-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment For Chemotherapy-Naive Patients With Extensive Disease - Small Cell Lung|Completed||Phase 3|4|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:23:45.835291|2018-06-01 05:23:45.835291
NCT00040989|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer|Phase II Study of BAY 56-3722 in Patients With Recurrent, Unresectable, or Metastatic Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:46.091339|2018-06-01 05:23:46.091339
NCT00040950|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2002||2002-03-31|July 2003|2003-07-31|October 2007|Actual|2007-10-31|||||Interventional|||Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:46.39103|2018-06-01 05:23:46.39103
NCT00040937|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2012-10-31||2016-10-26|2003-01-26|2003-01-27|Estimate|2013-06-12|2013-07-17|Estimate||||2016-10-26|2016-12-08|Estimate|June 2002||2002-06-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2008|Actual|2008-10-31||Interventional|||S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase II Trial Of Thalidomide/Dexamethasone Induction Followed By Tandem Melphalan Transplant And Prednisone/Thalidomide Maintenance (A BMT Study)|Completed||Phase 2|147|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:23:46.993562|2018-06-01 05:23:46.993562
NCT00040911|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-31|Estimate|April 2005||2005-04-30|May 2013|2013-05-31|January 2011|Actual|2011-01-31|October 2009|Actual|2009-10-31||Interventional|||Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma|A Randomized Study Of Electroacupuncture Treatment For Delayed Chemotherapy-Induced Nausea And Vomiting In Patients With Pediatric Solid Tumors|Completed||N/A|17|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:23:47.908019|2018-06-01 05:23:47.908019
NCT00040898|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-01-17|2003-01-26|2003-01-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|January 2001||2001-01-31|January 2013|2013-01-31||||January 2006|Actual|2006-01-31||Interventional|||Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed|Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:23:48.049101|2018-06-01 05:23:48.049101
NCT00040885|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2002||2002-10-31|December 2016|2016-12-31|October 2008|Actual|2008-10-31|February 2006|Actual|2006-02-28||Interventional|||Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)|Docetaxel And Infliximab/Placebo In Non-Small Cell Lung Cancer (NSCLC) Patients Greater Than Or Equal To 65 Years Of Age Or In NSCLC Patients With Poor Performance Status: A Double-Blind Randomized, Placebo-Controlled Trial To Prevent And Treat Wasting, Anorexia, And Asthenia In Chemotherapy-Naive And Previously-Treated Patients|Completed||Phase 3|67|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:23:48.284317|2018-06-01 05:23:48.284317
NCT00040872|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-03-06|2003-01-26|2003-01-27|Estimate|||||||2013-03-06|2013-03-07|Estimate|June 2000||2000-06-30|March 2013|2013-03-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Multiple Therapies in Treating Patients With Advanced Neuroblastoma|N8: Dose-Intensive Chemotherapy Plus Biologics in the Treatment of Neuroblastoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:23:48.861793|2018-06-01 05:23:48.861793
NCT00040859|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|September 2002||2002-09-30|December 2016|2016-12-31|April 2008|Actual|2008-04-30|January 2005|Actual|2005-01-31||Interventional|||Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer|A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:23:48.973839|2018-06-01 05:23:48.973839
NCT00040846|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2017-01-26||2017-03-24|2003-01-26|2003-01-27|Estimate|2017-01-26|2017-03-16|Actual||||2017-03-24|2017-04-24|Actual|November 2001||2001-11-30|March 2017|2017-03-31||||December 2009|Actual|2009-12-31||Interventional|||Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies|Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial|Active, not recruiting||Phase 2|60|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:23:49.152258|2018-06-01 05:23:49.152258
NCT00040833|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|February 2002||2002-02-28|June 2013|2013-06-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer|Acupuncture for the Treatment of Pancreatic Cancer Pain: A Single Arm Phase II Study|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:23:50.05569|2018-06-01 05:23:50.05569
NCT00040807|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2009-07-29|2003-01-26|2003-01-27|Estimate|||||||2009-07-29|2009-07-30|Estimate|October 2002||2002-10-31|November 2004|2004-11-30||||April 2005|Actual|2005-04-30||Interventional|||Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer|Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:50.207051|2018-06-01 05:23:50.207051
NCT00040794|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 2002||2002-05-31|June 2013|2013-06-30||||March 2006|Actual|2006-03-31||Interventional|||Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer|ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study|Completed||Phase 2|144|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:23:50.502853|2018-06-01 05:23:50.502853
NCT00040781|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2002||2002-06-30|January 2013|2013-01-31||||October 2004|Actual|2004-10-31||Interventional|||Gefitinib in Treating Children With Refractory Solid Tumors|A Phase I Study Of ZD1839 (Iressa TM), An Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, In Children With Refractory Solid Tumors|Completed||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:50.683065|2018-06-01 05:23:50.683065
NCT00040768|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|April 2002||2002-04-30|January 2013|2013-01-31||||March 2006|Actual|2006-03-31||Interventional|||Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer|A Phase II Study Of PS-341 In Metastatic Non-Small Cell Lung Cancer|Terminated||Phase 2|35|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:23:50.836114|2018-06-01 05:23:50.836114
NCT00040755|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-01-31|2003-01-26|2003-01-27|Estimate|||||||2013-01-31|2013-02-01|Estimate|May 2002||2002-05-31|January 2013|2013-01-31||||July 2006|Actual|2006-07-31||Interventional|||BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer|Completed||Phase 2|68|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:23:51.00871|2018-06-01 05:23:51.00871
NCT00040742|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2014-07-10||2015-10-13|2003-01-26|2003-01-27|Estimate|2015-02-24|2015-03-10|Estimate||||2015-10-13|2015-11-09|Estimate|March 2003||2003-03-31|October 2015|2015-10-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer|A Phase II/III Randomized, Controlled Clinical Trial Of Ginger (Zingiber Officinale) For Nausea Caused By Chemotherapy For Cancer|Completed||Phase 2/Phase 3|745|Actual|University of Rochester|Two main weaknesses of the study, which should be controlled for in future studies, were not controlling for chemotherapy regimens (i.e., high versus low emetogenic regimens) or the severity level of nausea before enrollment.|4|||f||||t||||||||||2018-06-01 05:23:51.26964|2018-06-01 05:23:51.26964
NCT00040690|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|November 2008||2008-11-30|May 2007|2007-05-31|December 2008|Actual|2008-12-31|||||Interventional|||Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia|A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma|Completed||Phase 2|120|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:52.817618|2018-06-01 05:23:52.817618
NCT00039611|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|May 2002||2002-05-31|July 2002|2002-07-31|October 2007|Actual|2007-10-31|||||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|Oxaliplatin (NSC 266046) in Combination With 5-Fluorouracil and Leucovorin (FOLFOX4) for Patients Who Have Not Received Prior Chemotherapy for Advanced Colorectal Cancer|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:52.943434|2018-06-01 05:23:52.943434
NCT00039585|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|May 2002||2002-05-31|February 2007|2007-02-28||||February 2006|Actual|2006-02-28||Interventional|||Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor|Phase II Clinical Trial With Proteomic Profiling Of Imatinib Mesylate (Gleevec; STI571), A PDGFR And C-Kit Inhibitor, In Patients With Refractory Or Relapsed Epithelial Ovarian Cancer, Fallopian Tube And Primary Peritoneal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:23:53.075372|2018-06-01 05:23:53.075372
NCT00039572|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2002||2002-05-31|July 2002|2002-07-31|January 2005|Actual|2005-01-31|||||Interventional|||Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain|A Phase I/II Trial For Neutron Capture Therapy In Glioblastoma Multiforme And Intracranial Melanoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:53.172108|2018-06-01 05:23:53.172108
NCT00039559|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-06-07|2003-01-26|2003-01-27|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 2002||2002-05-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer|Ovarian Cancer Screening Pilot Trial in High Risk Women|Unknown status|Active, not recruiting|N/A|2430|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-06-01 05:23:53.285682|2018-06-01 05:23:53.285682
NCT00039546|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2001||2001-08-31|May 2005|2005-05-31||||||||Interventional|||Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery|'tAnGo', A Phase III Randomised Trial Of Gemcitabine In Paclitaxel-Containing, Epirubicin-Based, Adjuvant Chemotherapy For ER/PgR-Poor, Early Stage, Breast Cancer|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:53.502748|2018-06-01 05:23:53.502748
NCT00039520|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2014-05-05|2003-01-26|2003-01-27|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2002||2002-01-31|May 2014|2014-05-31|July 2008|Actual|2008-07-31|June 2004|Actual|2004-06-30||Interventional|||Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer|A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenocarcinoma Of The Breast|Completed||Phase 2|10|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:23:53.696159|2018-06-01 05:23:53.696159
NCT00039507|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2010-02-11|2003-01-26|2003-01-27|Estimate|||||||2010-02-11|2010-02-12|Estimate|June 2002||2002-06-30|February 2010|2010-02-28|February 2004|Actual|2004-02-29|||||Interventional|||Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer|Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer|Completed||Phase 2|||Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:23:53.796781|2018-06-01 05:23:53.796781
NCT00039494|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|December 2002||2002-12-31|August 2013|2013-08-31||||July 2007|Actual|2007-07-31||Interventional|||Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors|A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme|Completed||Phase 2|171|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:53.95696|2018-06-01 05:23:53.95696
NCT00039481|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-01-16|2003-01-26|2003-01-27|Estimate|||||||2013-01-16|2013-01-17|Estimate|November 2002||2002-11-30|January 2013|2013-01-31||||October 2005|Actual|2005-10-31||Interventional|||Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors|A Phase I Trial Of G3139 (BCL-2 Antisense, NSC# 683428, IND# 58842) Combined With Cytotoxic Chemotherapy In Relapsed Childhood Solid Tumors|Completed||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:54.463544|2018-06-01 05:23:54.463544
NCT00039468|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2011-10-26|2003-01-26|2003-01-27|Estimate|||||||2011-10-26|2011-10-27|Estimate|March 2002||2002-03-31|October 2011|2011-10-31|February 2008|Actual|2008-02-29|September 2007|Actual|2007-09-30||Interventional|||Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy|A Phase II Study Of Thalidomide And CPT-11 (IRINOTECAN) Following Radiotherapy For Glioblastoma Multiforme|Completed||Phase 2|26|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 05:23:54.690311|2018-06-01 05:23:54.690311
NCT00039455|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-01-31|2003-01-26|2003-01-27|Estimate|||||||2013-01-31|2013-02-01|Estimate|April 2002||2002-04-30|January 2013|2013-01-31||||December 2004|Actual|2004-12-31||Interventional|||Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer|A Phase I Study of Herceptin/Flavopiridol in HER-2 Positive Metastatic Breast Cancer|Terminated||Phase 1|50|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:23:54.868258|2018-06-01 05:23:54.868258
NCT00039442|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2017-08-23|2003-01-26|2003-01-27|Estimate|||||||2017-08-23|2017-08-24|Actual|April 29, 2002|Actual|2002-04-29|August 2017|2017-08-31||||December 7, 2005|Actual|2005-12-07||Interventional|||Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer|A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix|Completed||Phase 2|21|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:23:54.989214|2018-06-01 05:23:54.989214
NCT00039429|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2010-01-26|2003-01-26|2003-01-27|Estimate|||||||2010-01-26|2010-01-28|Estimate|May 2003||2003-05-31|January 2010|2010-01-31||||April 2006|Actual|2006-04-30||Interventional|||Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer|A Phase II Trial Evaluating Atrasentan In Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|180|Anticipated|Eastern Cooperative Oncology Group|||||||||f||||||||||2018-06-01 05:23:55.189454|2018-06-01 05:23:55.189454
NCT00039416|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2014-02-24|2003-01-26|2003-01-27|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2002||2002-04-30|December 2012|2012-12-31||||August 2007|Actual|2007-08-31||Interventional|||Imatinib Mesylate in Treating Patients With Myelofibrosis|A Phase II Study Of Gleevec (Imatinib Mesylate Formerly Known as STI-571) In Patients With Myelofibrosis|Completed||Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:55.692803|2018-06-01 05:23:55.692803
NCT00039403|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2002||2002-04-30|January 2013|2013-01-31||||May 2006|Actual|2006-05-31||Interventional|||UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer|A Phase I Study Of UCN-01 In Combination With Gemcitabine In Unresectable Or Metastatic Pancreatic Carcinoma|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:55.826815|2018-06-01 05:23:55.826815
NCT00039390|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-01-24|2003-01-26|2003-01-27|Estimate|||||||2013-01-24|2013-01-25|Estimate|April 2002||2002-04-30|January 2013|2013-01-31||||May 2007|Actual|2007-05-31||Interventional|||Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors|A Phase I Trial of ZD1839 With Capecitabine in Patients With Advanced Solid Tumors (Formerly a Phase I Trial of ZD1839 With Capecitabine and Celecoxib)|Completed||Phase 1|41|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:23:56.111876|2018-06-01 05:23:56.111876
NCT00039377|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|2013-11-27||2014-11-13|2003-01-26|2003-01-27|Estimate|2014-03-06|2014-03-18|Estimate||||2014-11-13|2014-11-24|Estimate|April 2002||2002-04-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|April 2012|Actual|2012-04-30||Interventional|||Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC # 716051), and Transplantation for Adults With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG|Completed||Phase 2|58|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-06-01 05:23:56.465736|2018-06-01 05:23:56.465736
NCT00039364|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2012-07-23|2003-01-26|2003-01-27|Estimate|||||||2012-07-23|2012-07-24|Estimate|March 2002||2002-03-31|July 2012|2012-07-31||||August 2004|Actual|2004-08-31||Interventional|||Imatinib Mesylate in Treating Patients With Gliomas|Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas|Completed||Phase 2|112|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:23:58.030204|2018-06-01 05:23:58.030204
NCT00039351|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|March 2002||2002-03-31|September 2012|2012-09-30||||January 2005|Actual|2005-01-31||Interventional|||Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma|Diffuse Large B Cell And Peripheral T-Cell Non-Hodgkin's Lymphoma In The Frail Elderly. Progressive And Cautious Treatment Strategy In Poor Status Patients. A Phase II Trial With Emphasis On Geriatric Assessment And Quality Of Life|Completed||Phase 2|32|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:23:58.244591|2018-06-01 05:23:58.244591
NCT00039338|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2016-12-02|2003-01-26|2003-01-27|Estimate|||||||2016-12-02|2016-12-05|Estimate|March 2002||2002-03-31|December 2016|2016-12-31||||July 2019|Anticipated|2019-07-31||Interventional|||Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer|Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer|Active, not recruiting||Phase 3|686|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-06-01 05:23:58.505266|2018-06-01 05:23:58.505266
NCT00039325|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2015-10-01|2003-01-26|2003-01-27|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2002||2002-03-31|July 2012|2012-07-31|June 2009|Actual|2009-06-30|September 2005|Actual|2005-09-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma|A Phase I/II Trial Testing Mart-1 Genetic Immunization In Malignant Melanoma|Completed||Phase 1/Phase 2|28|Actual|Jonsson Comprehensive Cancer Center||5|||f||||t||||||||||2018-06-01 05:23:58.700681|2018-06-01 05:23:58.700681
NCT00039312|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2012-07-27|2003-01-26|2003-01-27|Estimate|||||||2012-07-27|2012-07-31|Estimate|December 1999||1999-12-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|August 2003|Actual|2003-08-31||Interventional|||Comparison of Screening Tests in Detecting Cervical Neoplasia|Multi-Institutional Prospective Cohort Study For The Comparison Of Different Primary Screening Strategies For The Detection Of Cervical Neoplasia|Completed||N/A|15|Actual|Jonsson Comprehensive Cancer Center|||||f||||f||||||||||2018-06-01 05:23:58.862447|2018-06-01 05:23:58.862447
NCT00039299|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-04-02|2003-01-26|2003-01-27|Estimate|||||||2013-04-02|2013-04-04|Estimate|March 2002||2002-03-31|June 2003|2003-06-30|June 2003|Actual|2003-06-30|||||Interventional|||Biological Therapy in Treating Patients With Prostate Cancer|A Phase I Safety Study Of Xcellerate In Patients With Hormone Refractory Prostate Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:58.958782|2018-06-01 05:23:58.958782
NCT00039286|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2015-12-23|2003-01-26|2003-01-27|Estimate|||||||2015-12-23|2015-12-24|Estimate|October 2001||2001-10-31|December 2015|2015-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer|A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma|Completed||Phase 1|118|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:23:59.067803|2018-06-01 05:23:59.067803
NCT00039273|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-01-07|2003-01-26|2003-01-27|Estimate|||||||2013-01-07|2013-01-08|Estimate|July 2002||2002-07-31|January 2013|2013-01-31||||May 2003|Actual|2003-05-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer|An Open Label Phase II Clinical Trial To Evaluate The Safety And Efficacy Of ABX-EGF In Patients With Metastatic Colorectal Carcinoma|Completed||Phase 2|44|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:23:59.446654|2018-06-01 05:23:59.446654
NCT00039234|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2002||2002-09-30|December 2003|2003-12-31||||||||Interventional|||Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver|A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:23:59.799441|2018-06-01 05:23:59.799441
NCT00039208|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2012-07-12|2003-01-26|2003-01-27|Estimate|||||||2012-07-12|2012-07-13|Estimate|February 2002||2002-02-28|July 2012|2012-07-31||||August 2005|Actual|2005-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Colorectal Cancer|Time Finding Study of Chronomodulated Irinotecan, 5 Fluorouracil, Leucovorin and Oxaliplatin as First or Second Chemotherapy Line Against Metastatic Colorectal Cancer|Completed||Phase 2|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:24:00.323814|2018-06-01 05:24:00.323814
NCT00039195|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|2015-12-15||2016-06-29|2003-01-26|2003-01-27|Estimate|2016-06-29|2016-08-10|Estimate||||2016-06-29|2016-08-10|Estimate|November 2006||2006-11-30|June 2016|2016-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma|Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index II or III Diffuse Large B Cell Lymphoma|Completed||Phase 2|98|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:24:00.511105|2018-06-01 05:24:00.511105
NCT00039182|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2002||2002-05-31|January 2013|2013-01-31||||June 2007|Actual|2007-06-30||Interventional|||Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung|A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:01.087037|2018-06-01 05:24:01.087037
NCT00039156|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|January 2002||2002-01-31|January 2004|2004-01-31||||||||Interventional|||BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma|An Open Phase II Multi-Center Trial of BAY 59-8862 in Patients With Aggressive Refractory Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:01.222164|2018-06-01 05:24:01.222164
NCT00039130|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|2014-10-16||2016-07-01|2003-01-26|2003-01-27|Estimate|2014-10-16|2014-10-22|Estimate||||2016-07-01|2016-08-01|Estimate|May 2002||2002-05-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|September 2010|Actual|2010-09-30||Interventional|||Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia|Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia|Completed||Phase 2|105|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:01.528761|2018-06-01 05:24:01.528761
NCT00039117|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2015-12-03|2003-01-26|2003-01-27|Estimate|||||||2015-12-03|2015-12-04|Estimate|April 2002||2002-04-30|June 2013|2013-06-30||||September 2003|Actual|2003-09-30||Interventional|||Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia|A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)&gt;= 60 Years of Age|Completed||Phase 1|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:02.962835|2018-06-01 05:24:02.962835
NCT00039104|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2002||2002-04-30|June 2013|2013-06-30||||January 2005|Actual|2005-01-31||Interventional|||Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer|A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:03.14348|2018-06-01 05:24:03.14348
NCT00039091|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-01-09|2003-01-26|2003-01-27|Estimate|||||||2013-01-09|2013-01-10|Estimate|March 2002||2002-03-31|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer|Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 (Anti-CTLA-4) Humanized Monoclonal Antibody (MDX-CTLA-4 NSC# 732442, Previously 720801) in Patients Previously Vaccinated With GM-CSF-Based Autologous Tumor Vaccines (CTEP Protocol Number P-5708) and Patients With Acute Myelogenous Leukemia/ Myelodysplasia, and Non-Small Cell Lung Cancer Who Have Not Received a Prior Vaccine|Terminated||Phase 1|48|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:03.252512|2018-06-01 05:24:03.252512
NCT00039078|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2017-06-22|2003-01-26|2003-01-27|Estimate|||||||2017-06-22|2017-06-26|Actual|August 2000||2000-08-31|June 2017|2017-06-30|August 2000||2000-08-31|August 2000||2000-08-31||Interventional|||Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery|The Use of TheraSphere® for the Treatment of Unresectable Hepatocellular Carcinoma|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||||Record created in error - not a research study|f|||||f|t|f|f|f|||||2018-06-01 05:24:03.375935|2018-06-01 05:24:03.375935
NCT00039052|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2002||2002-01-31|March 2003|2003-03-31|July 2008|Actual|2008-07-31|May 2003|Actual|2003-05-31||Interventional|||Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer|An Open Label, Multiple-Dose, Sequential Dose-Escalation Study of NBI-3001 in Patients With Recurrent or Unresponsive Solid Tumors Known to Over-Express IL-4 Receptors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:03.470843|2018-06-01 05:24:03.470843
NCT00039039|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2000||2000-02-29|August 2006|2006-08-31||||||||Interventional|||Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer|Phase III Randomized Study of Paclitaxel and Carboplatin or Cisplatin Followed by Radiotherapy With or Without Concurrent Paclitaxel in Patients With Unresectable Stage III Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:03.577127|2018-06-01 05:24:03.577127
NCT00037037|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 2001||2001-10-31|May 2004|2004-05-31||||||||Interventional|||Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma|A Phase I Study of Peptide Based Vaccine Therapy in Patients With High-Risk or Metastatic Melanoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:03.797222|2018-06-01 05:24:03.797222
NCT00037024|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2017-02-21|2003-01-26|2003-01-27|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2002||2002-04-30|November 2012|2012-11-30|October 2004|Actual|2004-10-31|February 2004|Actual|2004-02-29||Interventional|||Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer|Project LEAD: Promoting Health Among Populations With Early Stage Cancers|Completed||N/A|||Duke University|||||f||||t||||||||||2018-06-01 05:24:03.933204|2018-06-01 05:24:03.933204
NCT00037011|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-01-17|2003-01-26|2003-01-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|November 2001||2001-11-30|January 2013|2013-01-31||||January 2005|Actual|2005-01-31||Interventional|||Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma|Phase I Study of Oral Beta-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:24:04.061841|2018-06-01 05:24:04.061841
NCT00036998|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|August 2001||2001-08-31|July 2004|2004-07-31||||||||Interventional|||Microwave Thermotherapy in Treating Women With Stage I or Stage II Breast Cancer|A Randomized Pivotal Clinical Trial In Breast Cancer Patients Of Pre-Operative Focal Microwave Thermotherapy Treatment For Early-Stage Breast Disease In Intact Breast|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:04.162866|2018-06-01 05:24:04.162866
NCT00036985|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 2001||2001-08-31|July 2004|2004-07-31||||||||Interventional|||Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer|A Randomized Pivotal Clinical Trial To Assess The Efficacy Of Pre-operative Focused Microwave Thermotherapy Treatment Combined With Pre-operative Chemotherapy For Cytoreduction Of Advanced Breast Cacer In Intact Breast|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:04.276468|2018-06-01 05:24:04.276468
NCT00036972|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|November 2001||2001-11-30|December 2009|2009-12-31|December 2009|Actual|2009-12-31|January 2005|Actual|2005-01-31||Interventional|||Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma|Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:04.402649|2018-06-01 05:24:04.402649
NCT00036959|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|March 2002||2002-03-31|March 2012|2012-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||ABT-751 in Treating Young Patients With Refractory Solid Tumors|Phase I Trial and Pharmacokinetic Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, on a 7 Day and 21 Day Dosing Schedule in Pediatric Patients With Refractory Solid Tumors|Completed||Phase 1|90|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:24:04.476945|2018-06-01 05:24:04.476945
NCT00036946|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2016-06-01|2003-01-26|2003-01-27|Estimate|||||||2016-06-01|2016-06-03|Estimate|November 2001||2001-11-30|June 2016|2016-06-30||||March 2002|Actual|2002-03-31||Interventional|||VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma|An Open-Label, Sequential Cohort Dose-Escalation Safety, Tolerability And Pharmacokinetic Study Of VEGF Trap In Patients With Incurable, Relapsed Or Refractory Solid Tumors Or Lymphoma|Completed||Phase 1|||Regeneron Pharmaceuticals|||||f||||||||||||||2018-06-01 05:24:04.670105|2018-06-01 05:24:04.670105
NCT00036933|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-03-22|2003-01-26|2003-01-27|Estimate|||||||2013-03-22|2013-03-25|Estimate|March 2002||2002-03-31|March 2013|2013-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer|Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates Plus The Immunological Adjuvant QS21|Completed||Phase 1|9|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:24:04.775817|2018-06-01 05:24:04.775817
NCT00036894|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2002||2002-03-31|November 2003|2003-11-30||||||||Interventional|||CC-5013 in Treating Patients With Recurrent Glioma|A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:04.928776|2018-06-01 05:24:04.928776
NCT00036881|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|May 2002||2002-05-31|July 2016|2016-07-31|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer|Phase III Double-Blind, Placebo-Controlled Randomized Comparison Of Zinc Sulfate Versus Placebo For The Prevention Of Altered Taste In Patients With Head And Neck Cancer During Radiation|Completed||Phase 3|173|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:24:05.098701|2018-06-01 05:24:05.098701
NCT00036868|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-06-06|2003-01-26|2003-01-27|Estimate|||||||2013-06-06|2013-06-07|Estimate|February 2002||2002-02-28|June 2013|2013-06-30||||June 2009|Actual|2009-06-30||Interventional|||Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer|A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|90|Actual|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||||||||||||2018-06-01 05:24:05.229307|2018-06-01 05:24:05.229307
NCT00036855|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-01-16|2003-01-26|2003-01-27|Estimate|||||||2013-01-16|2013-01-17|Estimate|June 2002||2002-06-30|January 2013|2013-01-31||||March 2005|Actual|2005-03-31||Interventional|||Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma|A Phase I Study Of Yttrium-Ibritumomab Tiuxetan (90Y Zevalin, Yttrium (90)-Anti-CD20, NSC # 710085) Preceded By Rituximab In Children With Recurrent/Refractory CD20 Positive Lymphoma|Terminated||Phase 1|36|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:24:05.629629|2018-06-01 05:24:05.629629
NCT00036842|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|April 2002||2002-04-30|August 2004|2004-08-31|June 2007|Actual|2007-06-30|||||Interventional|||Arsenic Trioxide in Treating Men With Germ Cell Cancer|Phase II Study Of Arsenic Trioxide In Patients With Refractory Germ Cell Malignancies|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:06.004625|2018-06-01 05:24:06.004625
NCT00036829|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2002||2002-03-31|March 2003|2003-03-31|April 2003|Actual|2003-04-30|||||Interventional|||Improving Pain Management in Patients With Nonhematologic Cancer|Improving Pain Management in Cancer Care|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:06.209408|2018-06-01 05:24:06.209408
NCT00036816|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|February 2002||2002-02-28|September 2012|2012-09-30||||February 2003|Actual|2003-02-28||Interventional|||Vaccine Therapy in Treating Patients With Melanoma of the Eye|Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse|Terminated||Phase 3|13|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:24:06.280962|2018-06-01 05:24:06.280962
NCT00036790|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2015-09-30|2003-01-26|2003-01-27|Estimate|||||||2015-09-30|2015-10-02|Estimate|February 2002||2002-02-28|September 2015|2015-09-30||||October 2005|Actual|2005-10-31||Interventional|||Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer|An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies|Completed||Phase 1|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:24:06.356378|2018-06-01 05:24:06.356378
NCT00036777|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-06-28|2003-01-26|2003-01-27|Estimate|||||||2013-06-28|2013-07-01|Estimate|March 2002||2002-03-31|June 2013|2013-06-30||||October 2004|Actual|2004-10-31||Interventional|||UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors|A Phase 1 Study of UCN-01 in Combination With Carboplatin in Advanced Solid Tumors|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:06.45154|2018-06-01 05:24:06.45154
NCT00036764|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-01-24|2003-01-26|2003-01-27|Estimate|||||||2013-01-24|2013-01-25|Estimate|February 2002||2002-02-28|January 2013|2013-01-31||||August 2004|Actual|2004-08-31||Interventional|||BMS-247550 in Treating Patients With Stage IV Melanoma|A Phase II Study Of Epothilone B Analog BMS 247550 (NSC # 710428) In Stage IV Malignant Melanoma|Completed||Phase 2|88|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:06.642921|2018-06-01 05:24:06.642921
NCT00036751|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2002||2002-04-30|January 2013|2013-01-31||||August 2007|Actual|2007-08-31||Interventional|||Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Trial Of STI571 For The Treatment Of Platinum And Taxane Refractory Stage III And IV Epithelial Ovarian Cancer And Primary Peritoneal Cancer|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:06.805637|2018-06-01 05:24:06.805637
NCT00036738|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|2017-07-24||2018-03-26|2003-01-26|2003-01-27|Estimate|2017-07-24|2017-08-22|Actual||||2018-03-26|2018-04-24|Actual|July 13, 2001|Actual|2001-07-13|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 14, 2014|Actual|2014-07-14||Interventional|||Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib|Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? A Multi-center Trial|Active, not recruiting||Phase 2|28|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:24:07.026653|2018-06-01 05:24:07.026653
NCT00036712|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2002||2002-01-31|June 2009|2009-06-30||||August 2009|Anticipated|2009-08-31||Interventional|||Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation|A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients|Unknown status|Recruiting|Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:07.328235|2018-06-01 05:24:07.328235
NCT00036686|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2012-09-21|2003-01-26|2003-01-27|Estimate|||||||2012-09-21|2012-09-24|Estimate|December 2002||2002-12-31|September 2012|2012-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Isoflavones in Treating Women Who Have Breast Cancer and Are Planning to Undergo Mastectomy or Lumpectomy|A Clinical Trial of the Action of Isoflavones in Breast Neoplasia: Administration Prior to Mastectomy or Lumpectomy-A Pilot Study|Terminated||N/A|1|Actual|H. Lee Moffitt Cancer Center and Research Institute||2||low accrual|f||||f||||||||||2018-06-01 05:24:07.40316|2018-06-01 05:24:07.40316
NCT00033748|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|December 2001||2001-12-31|July 2016|2016-07-31|June 2010|Actual|2010-06-30|March 2007|Actual|2007-03-31||Interventional|||Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver|Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer|Completed||Phase 2|56|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:07.520147|2018-06-01 05:24:07.520147
NCT00033709|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|March 2002||2002-03-31|May 2005|2005-05-31||||||||Interventional|||Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma|A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:07.817662|2018-06-01 05:24:07.817662
NCT00033696|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|September 2001||2001-09-30|July 2016|2016-07-31|April 2009|Actual|2009-04-30|January 2007|Actual|2007-01-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Paclitaxel/Topotecan/Etoposide (EtopoTax) Induction Followed by Consolidation Chemoradiotherapy for Limited Stage Small Cell Lung Cancer: A Phase II Study|Completed||Phase 2|65|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:08.044535|2018-06-01 05:24:08.044535
NCT00033683|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|February 2001||2001-02-28|June 2005|2005-06-30||||||||Interventional|||Combination Chemotherapy in Treating Women With Resected Breast Cancer|A Randomised Trial Of Standard Anthracycline-Based Chemotherapy With Fluorouracil, Epirubicin And Cyclophosphamide (FEC) Or Epirubicin And CMF (Epi-CMF) Versus FEC Followed By Sequential Docetaxel As Adjuvant Treatment For Women With Early Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:08.367968|2018-06-01 05:24:08.367968
NCT00033657|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|2011-06-21||2012-11-30|2003-01-26|2003-01-27|Estimate|2011-06-21|2011-07-19|Estimate||||2012-11-30|2012-12-03|Estimate|May 2002||2002-05-31|November 2012|2012-11-30|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer|Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus|Completed||Phase 2|97|Actual|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-06-01 05:24:08.617253|2018-06-01 05:24:08.617253
NCT00033644|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-04-10|2003-01-26|2003-01-27|Estimate|||||||2013-04-10|2013-04-11|Estimate|March 2002||2002-03-31|September 2004|2004-09-30||||October 2005|Actual|2005-10-31||Interventional|||Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus|A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:24:09.275832|2018-06-01 05:24:09.275832
NCT00033631|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|2016-12-16||2018-03-21|2003-01-26|2003-01-27|Estimate|2016-12-16|2017-02-08|Estimate||||2018-03-21|2018-04-23|Actual|March 2002||2002-03-31|March 2018|2018-03-31||||April 2014|Actual|2014-04-30||Interventional||All eligible patients who did not withdraw consent|Radiation Therapy in Treating Patients With Stage II Prostate Cancer|A Phase III Randomized Study Of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT In Patients Treated For Localized Prostate Cancer|Active, not recruiting||Phase 3|1532|Actual|Radiation Therapy Oncology Group|The data monitoring committee (DMC) recommended early reporting of the trial when the third interim analysis futility boundary was crossed.|2|||f||||t||||||||||2018-06-01 05:24:09.391664|2018-06-01 05:24:09.391664
NCT00033618|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-02-26|2003-01-26|2003-01-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|November 2002||2002-11-30|February 2013|2013-02-28||||January 2007|Actual|2007-01-31||Interventional|||Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck|A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|144|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:10.001045|2018-06-01 05:24:10.001045
NCT00033605|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis|Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy|Completed||Phase 3|130|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:24:10.182053|2018-06-01 05:24:10.182053
NCT00033566|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2011-03-03|2003-01-26|2003-01-27|Estimate|||||||2011-03-03|2011-03-07|Estimate|October 2001||2001-10-31|March 2011|2011-03-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||S-3304 in Treating Patients With Advanced Solid Tumors|A Phase I Study of S-3304 in Patients With Solid Tumors|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:24:10.311533|2018-06-01 05:24:10.311533
NCT00033553|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|March 2002||2002-03-31|July 2016|2016-07-31|June 2010|Actual|2010-06-30|September 2006|Actual|2006-09-30||Interventional|||Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer|Induction/Concurrent Chemotherapy and Dose-Escalated Three Dimensional Thoracic Radiation for Patients With Stage III Non Small Cell Lung Cancer: A Randomized Phase II Study|Completed||Phase 2|69|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:24:10.39039|2018-06-01 05:24:10.39039
NCT00033540|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|2012-06-14||2017-08-14|2003-01-26|2003-01-27|Estimate|2012-07-20|2012-08-28|Estimate||||2017-08-14|2017-09-12|Actual|September 2003||2003-09-30|August 2017|2017-08-31|July 2011|Actual|2011-07-31|April 2008|Actual|2008-04-30||Interventional|||S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma|A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma|Completed||Phase 2|57|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:24:10.586869|2018-06-01 05:24:10.586869
NCT00033514|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|2016-02-11||2016-03-11|2003-01-26|2003-01-27|Estimate|2016-03-11|2016-04-11|Estimate||||2016-03-11|2016-04-11|Estimate|August 2001||2001-08-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||enrolled subjects|Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression|Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression|Completed||Phase 1/Phase 2|27|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:24:14.859414|2018-06-01 05:24:14.859414
NCT00033488|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2000||2000-09-30|June 2007|2007-06-30|March 2010|Actual|2010-03-31|||||Interventional|||Screening Women at High Genetic Risk for Ovarian Cancer|The UK Familial Ovarian Cancer Screening Study|Completed||N/A|5000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:15.632503|2018-06-01 05:24:15.632503
NCT00033475|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2001||2001-03-31|June 2002|2002-06-30||||||||Interventional|||Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation|Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients|Unknown status|Active, not recruiting|Phase 3|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:15.747549|2018-06-01 05:24:15.747549
NCT00033449|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-01-24|2003-01-26|2003-01-27|Estimate|||||||2013-01-24|2013-01-25|Estimate|February 2002||2002-02-28|January 2013|2013-01-31||||April 2010|Actual|2010-04-30||Interventional|||Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer|A Phase I Study Of ZD 1839 In Combination With Radiation And Chemotherapy In Locally Advanced Squamous Cell Carcinoma Of The Head And Neck|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:24:15.89835|2018-06-01 05:24:15.89835
NCT00033436|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|October 2000||2000-10-31|December 2002|2002-12-31|November 2008|Actual|2008-11-30|||||Interventional|||Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer|A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer|Completed||Phase 3|330|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:16.095857|2018-06-01 05:24:16.095857
NCT00033423|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-12-12|2003-01-26|2003-01-27|Estimate|||||||2013-12-12|2013-12-13|Estimate|August 2001||2001-08-31|December 2013|2013-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase I, Multicenter, Open Label, Dose Escalation Of 90Y-Zevalin Radioimmunotherapy Using A Modified Treatment Regimen For Relapsed Or Refractory CD20+ B-Cell (Follicular/Transformed) Non-Hodgkin's Lymphoma|Terminated||Phase 1|18|Actual|University of Alabama at Birmingham||5|||f||||t||||||||||2018-06-01 05:24:16.201521|2018-06-01 05:24:16.201521
NCT00033410|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|March 2002||2002-03-31|September 2006|2006-09-30||||||||Interventional|||Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|A Phase I Study Of Tirapazamine (NSC 130181) Paclitaxel And Carboplatin With Concurrent Radiation Followed By Tirapazamine/Paclitaxel/Carboplatin Consolidation For Stage III Non-Small Cell Lung Cancer|Completed||Phase 1|30|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:24:16.49253|2018-06-01 05:24:16.49253
NCT00033397|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2017-07-11|2003-01-26|2003-01-27|Estimate|||||||2017-07-11|2017-07-13|Actual|February 2002||2002-02-28|July 2017|2017-07-31|May 1, 2012|Actual|2012-05-01|May 2012|Actual|2012-05-31||Observational|||Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery|Contrast-Enhanced Breast MRI, MRS, And Correlative Science Studies To Characterize Tumor Response In Patients Undergoing Neoadjuvant Treatment For Locally Advanced Breast Cancer|Completed|||360|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 05:24:16.56331|2018-06-01 05:24:16.56331
NCT00033371|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|2015-01-26||2016-12-28|2003-01-26|2003-01-27|Estimate|2015-01-26|2015-02-04|Estimate||||2016-12-28|2017-02-15|Actual|December 2001||2001-12-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|April 2009|Actual|2009-04-30||Interventional||According to the protocol, a patient needed to receive at least 80% of intended overall dose AND at least 80% dose during the final 60 days of the study to qualify as evaluable. One participant was randomized to Arm II but withdrew prior to receiving any treatment.|Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis|A Two-Arm Phase II Chemoprevention Trial in Adenomatous Polyposis Coli Patients|Terminated||Phase 2|112|Actual|National Cancer Institute (NCI)|Following reports of COX-2 inhibitor-associated cardiovascular toxicities, trial suspended from December 17, 2004 to March 18, 2005 pending reevaluation of cardiovascular risks, only two sites resumed the trial.|2||Slow recruitment.|f||||t||||||||||2018-06-01 05:24:16.718864|2018-06-01 05:24:16.718864
NCT00033358|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-05-02|2003-01-26|2003-01-27|Estimate|||||||2013-05-02|2013-05-03|Estimate|February 2002||2002-02-28|April 2013|2013-04-30||||October 2007|Actual|2007-10-31||Interventional|||Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer|Modulation Of Putative Surrogate Endpoint Biomarkers In Endometrial Biopsies From Women With HNPCC|Completed||Phase 2|52|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:17.876331|2018-06-01 05:24:17.876331
NCT00033345|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2016-08-17|2003-01-26|2003-01-27|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2002||2002-01-31|August 2016|2016-08-31||||July 2008|Actual|2008-07-31||Interventional|||Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer|Multiple Daily Dose Phase I Safety And Pharmacokinetic Clinical Study Of Indole-3-Carbinol|Completed||Phase 1|17|Actual|University of Kansas Medical Center||1|||f||||||||||||||2018-06-01 05:24:17.968132|2018-06-01 05:24:17.968132
NCT00033332|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2014-04-02|2003-01-26|2003-01-27|Estimate|||||||2014-04-02|2014-04-04|Estimate|April 2002||2002-04-30|November 2005|2005-11-30|June 2006|Actual|2006-06-30|March 2006|Actual|2006-03-31||Interventional|||Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma|A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:18.076639|2018-06-01 05:24:18.076639
NCT00033293|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|2016-01-28||2017-04-18|2003-01-26|2003-01-27|Estimate|2016-08-09|2016-10-03|Estimate||||2017-04-18|2017-05-22|Actual|March 2004||2004-03-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma|A Pilot Study Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone|Completed||Phase 3|53|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:24:18.368312|2018-06-01 05:24:18.368312
NCT00033280|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2018-05-15|2003-01-26|2003-01-27|Estimate|||||||2018-05-15|2018-05-17|Actual|July 2002||2002-07-31|May 2018|2018-05-31|May 14, 2018|Actual|2018-05-14|April 2005|Actual|2005-04-30||Interventional|||Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas|A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas|Completed||Phase 2|42|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||No||2018-06-01 05:24:19.094473|2018-06-01 05:24:19.094473
NCT00033267|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2014-04-02|2003-01-26|2003-01-27|Estimate|||||||2014-04-02|2014-04-03|Estimate|April 2002||2002-04-30|December 2012|2012-12-31|February 2008|Actual|2008-02-29|February 2006|Actual|2006-02-28||Interventional|||CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma|A Phase II Study of CCI-779 in Previously Treated Patients With Mantle Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:19.226944|2018-06-01 05:24:19.226944
NCT00033254|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2013-06-05|2003-01-26|2003-01-27|Estimate|||||||2013-06-05|2013-06-06|Estimate|March 2002||2002-03-31|June 2013|2013-06-30||||May 2006|Actual|2006-05-31||Interventional|||Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases|A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC#66847) Versus Conventional Radiation Therapy for Multiple Brain Metastases|Completed||Phase 3|332|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:19.294159|2018-06-01 05:24:19.294159
NCT00033241|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2018-01-08|2003-01-26|2003-01-27|Estimate|||||||2018-01-08|2018-01-10|Actual|July 23, 2001|Actual|2001-07-23|June 2015|2015-06-30|April 22, 2004|Actual|2004-04-22|April 22, 2004|Actual|2004-04-22||Interventional|||Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors|A Phase Ib Multicenter Trial To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Gemcitabine Administered In Combination With Escalating Oral Doses Of OSI-774 To Patient Cohorts With Recently Diagnosed, Gemcitabine-Naive, Advanced Pancreatic Carcinoma Or Other Potentially Responsive Malignancies|Completed||Phase 1|||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:24:19.450907|2018-06-01 05:24:19.450907
NCT00033228|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2011-05-11|2003-01-26|2003-01-27|Estimate|||||||2011-05-11|2011-05-12|Estimate|January 2002||2002-01-31|May 2011|2011-05-31|April 2003|Actual|2003-04-30|March 2003|Actual|2003-03-31||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Melanoma|A Phase I/II Pilot Study Of Intranodal Delivery Of A Plasmid DNA (Synchrovax SEM Vaccine) In Stage IV Melanoma Patients|Completed||Phase 1/Phase 2|19|Actual|Mannkind Corporation||3|||||||f||||||||||2018-06-01 05:24:19.629709|2018-06-01 05:24:19.629709
NCT00032188|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2002||2002-01-31|January 2013|2013-01-31||||June 2006|Actual|2006-06-30||Interventional|||Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer|A Randomized Phase II Study Of Interluekin-2 In Combination With Three Different Doses Of Bryostatin In Patients With Renal Cell Carcinoma|Completed||Phase 2|65|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:24:19.751913|2018-06-01 05:24:19.751913
NCT00032175|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2002||2002-04-30|April 2007|2007-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer|Completed||Phase 3|508|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:19.855197|2018-06-01 05:24:19.855197
NCT00032162|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2012-05-29|2003-01-26|2003-01-27|Estimate|||||||2012-05-29|2012-05-31|Estimate|August 2001||2001-08-31|May 2012|2012-05-31||||May 2005|Actual|2005-05-31||Interventional|||Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer|Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors|Completed||Phase 1/Phase 2|63|Actual|AGO Study Group||1|||f||||t||||||||||2018-06-01 05:24:19.973391|2018-06-01 05:24:19.973391
NCT00032149|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|October 2001||2001-10-31|March 2007|2007-03-31||||||||Interventional|||Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:20.1692|2018-06-01 05:24:20.1692
NCT00032136|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|December 2001||2001-12-31|March 2007|2007-03-31|April 2009|Actual|2009-04-30|||||Interventional|||Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer|An Open Label, Randomized Multicenter Comparative Trial Of 5 Years Adjuvant Exemestane Treatment Versus 5 Years Adjuvant Tamoxifen Treatment In Postmenopausal Women With Early Breast Cancer|Completed||Phase 3|4400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:20.282661|2018-06-01 05:24:20.282661
NCT00032123|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-06-21|2003-01-26|2003-01-27|Estimate|||||||2013-06-21|2013-06-24|Estimate|June 2002||2002-06-30|October 2003|2003-10-31|May 2006|Actual|2006-05-31|||||Interventional|||Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer|A Phase II Study Of OSI-774 (NSC 718781) In Unresectable Or Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:20.398671|2018-06-01 05:24:20.398671
NCT00032110|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2015-04-14|2003-01-26|2003-01-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2002||2002-01-31|January 2013|2013-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Study of OSI-774 in Metastatic Colorectal Cancer|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:20.737311|2018-06-01 05:24:20.737311
NCT00032097|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|April 2002||2002-04-30|January 2004|2004-01-31||||||||Interventional|||Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain|A Phase I Trial To Evaluate Repetitive Intravenous Doses Of Gadolinium-Texaphyrin As A Radiosensitizer In Patients With Glioblastoma Multi Forme|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:20.881625|2018-06-01 05:24:20.881625
NCT00032084|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-03-08|2003-01-26|2003-01-27|Estimate|||||||2013-03-08|2013-03-11|Estimate|January 2002||2002-01-31|March 2013|2013-03-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery|Smoking Cessation Intervention (Including Bupropion-Zyban Versus Placebo) for Completely Resected Stage I and II Non-Small Cell Lung Cancer Survivors Who Are Current Smokers|Terminated||Phase 3|10|Actual|Southwest Oncology Group||2||This study was closed early due to poor accrual|f||||t||||||||||2018-06-01 05:24:21.128105|2018-06-01 05:24:21.128105
NCT00032058|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2011-02-18|2003-01-26|2003-01-27|Estimate|||||||2011-02-18|2011-02-21|Estimate|June 2003||2003-06-30|April 2005|2005-04-30||||June 2006|Actual|2006-06-30||Interventional|||Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer|MR Imaging And MR Spectroscopic Imaging Of Prostate Cancer Prior To Radical Prostatectomy: A Prospective Multi-Institutional Clinicopathological Study|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:21.63064|2018-06-01 05:24:21.63064
NCT00032045|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|January 2002||2002-01-31|March 2003|2003-03-31|August 2006|Actual|2006-08-31|||||Interventional|||Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma|An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:24:21.710791|2018-06-01 05:24:21.710791
NCT00032032|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-11-30|2003-01-26|2003-01-27|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2002||2002-05-31|November 2016|2016-11-30|January 2010|Actual|2010-01-31|January 2008|Actual|2008-01-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm|Completed||Phase 1|69|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:24:21.811856|2018-06-01 05:24:21.811856
NCT00032019|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|February 2002||2002-02-28|July 2016|2016-07-31|April 2009|Actual|2009-04-30|December 2004|Actual|2004-12-31||Interventional|||Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Phase II Study Of Dose-Adjusted Epoch-Rituximab (EPOCH-R) Chemotherapy For Patients With Previously Untreated Aggressive CD20+ B-Cell Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 2|78|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:22.044231|2018-06-01 05:24:22.044231
NCT00032006|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|February 2002||2002-02-28|July 2016|2016-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer|A Trial Of Neoadjuvant Androgen Supression And Dose Escalation Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:22.307169|2018-06-01 05:24:22.307169
NCT00031993|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-01-16|2003-01-26|2003-01-27|Estimate|||||||2013-01-16|2013-01-17|Estimate|March 2002||2002-03-31|January 2013|2013-01-31||||November 2005|Actual|2005-11-30||Interventional|||Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix|A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix|Completed||Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:22.424091|2018-06-01 05:24:22.424091
NCT00031980|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|March 2002||2002-03-31|July 2016|2016-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer|Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia|Completed||Phase 2|30|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:22.530284|2018-06-01 05:24:22.530284
NCT00031967|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-11-18|2003-01-26|2003-01-27|Estimate|||||||2013-11-18|2013-11-19|Estimate|May 2002||2002-05-31|November 2013|2013-11-30||||March 2004|Actual|2004-03-31||Interventional|||Melatonin and Radiation Therapy in Treating Patients With Brain Metastases|A Randomized Phase II Study of A.M. and P.M. Melatonin for Brain Metastasis in RPA Class II Patients|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:24:22.671684|2018-06-01 05:24:22.671684
NCT00031941|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|April 2002||2002-04-30|March 2012|2012-03-31|April 2009|Actual|2009-04-30|September 2007|Actual|2007-09-30||Interventional|||CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy|A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer|Completed||Phase 1|||National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:24:23.037602|2018-06-01 05:24:23.037602
NCT00031928|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|January 2002||2002-01-31|November 2003|2003-11-30||||||||Interventional|||Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors|Phase I Study of Intrathecal Mafosfamide|Completed||Phase 1|3000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:23.102291|2018-06-01 05:24:23.102291
NCT00031915|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2002||2002-06-30|October 2003|2003-10-31|May 2007|Actual|2007-05-31|||||Interventional|||Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma|Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:23.166947|2018-06-01 05:24:23.166947
NCT00031902|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|October 2001||2001-10-31|February 2003|2003-02-28||||||||Interventional|||Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma|Rituxumab Combined With Chemotherapy (PVB) For Poor Prognosis HIV-Related Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:23.253976|2018-06-01 05:24:23.253976
NCT00031876|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|May 2000||2000-05-31|May 2012|2012-05-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer|Phase I/II Trial of Capecitabine With Weekly Paclitaxel for Advanced Breast Cancer|Completed||Phase 1/Phase 2|34|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 05:24:23.314518|2018-06-01 05:24:23.314518
NCT00031863|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2001||2001-02-28|June 2002|2002-06-30|September 2007|Actual|2007-09-30|||||Interventional|||Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer|Phase III, Randomized, Double Blind, Placebo Controlled Study of Rofecoxib in Colorectal Cancer Patients Following Adjuvant Chemotherapy|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:23.476701|2018-06-01 05:24:23.476701
NCT00031850|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|March 2000||2000-03-31|May 2007|2007-05-31|May 2007|Actual|2007-05-31|||||Interventional|||Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer|A Randomized Trial Of Raloxifene Plus Zoladex For Prevention Of Breast Cancer|Completed||N/A|150|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:23.567554|2018-06-01 05:24:23.567554
NCT00031837|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2015-10-13|2003-01-26|2003-01-27|Estimate|||||||2015-10-13|2015-10-14|Estimate|October 2002||2002-10-31|October 2015|2015-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer|A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer|Terminated||Phase 3|400|Anticipated|University of Rochester||1|||f||||||||||||||2018-06-01 05:24:23.661674|2018-06-01 05:24:23.661674
NCT00031824|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2014-02-12|2003-01-26|2003-01-27|Estimate|||||||2014-02-12|2014-02-14|Estimate|April 2002||2002-04-30|February 2014|2014-02-28|January 2011|Actual|2011-01-31|May 2005|Actual|2005-05-31||Interventional|||Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease|Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease|Completed||Phase 3|82|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:24:23.870029|2018-06-01 05:24:23.870029
NCT00031798|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2017-01-18|2003-01-26|2003-01-27|Estimate|||||||2017-01-18|2017-01-20|Estimate|April 2002||2002-04-30|August 2009|2009-08-31|May 2006|Actual|2006-05-31|March 2005|Actual|2005-03-31||Interventional|||Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors|A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy|Terminated||Phase 3|||Wake Forest University Health Sciences||||low accrual; loss of funding|f||||||||||||||2018-06-01 05:24:24.283719|2018-06-01 05:24:24.283719
NCT00031772|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-02-12|2003-01-26|2003-01-27|Estimate|||||||2013-02-12|2013-02-15|Estimate|July 1998||1998-07-31|February 2013|2013-02-28|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer|Enhancing Well-Being During Breast Cancer Recurrence. SWOG Study S9832.|Completed||N/A|322|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:24:24.446062|2018-06-01 05:24:24.446062
NCT00031759|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|June 1999||1999-06-30|July 2016|2016-07-31|February 2010|Actual|2010-02-28|July 2004|Actual|2004-07-31||Interventional|||Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia|Phase II Topical Immunomodulatory Therapy With Imiquimod for the Chemoprevention of Recurrent and High-Grade Cervical Intraepithelial Neoplasia (CIN)|Completed||Phase 2|57|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:24:24.788234|2018-06-01 05:24:24.788234
NCT00031746|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|February 2000||2000-02-29|July 2016|2016-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels|Effects of Dietary Soy on Biomarkers of Prostate Cancer: A Prospective Phase II Study|Completed||Phase 2|26|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:24:24.907719|2018-06-01 05:24:24.907719
NCT00031733|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2014-05-20|2003-01-26|2003-01-27|Estimate|||||||2014-05-20|2014-05-22|Estimate|February 2002||2002-02-28|May 2014|2014-05-31|November 2007|Actual|2007-11-30|December 2004|Actual|2004-12-31||Interventional|||Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma|A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma|Completed||Phase 2|60|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:24:25.035032|2018-06-01 05:24:25.035032
NCT00031720|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|March 2002||2002-03-31|July 2016|2016-07-31|November 2013|Actual|2013-11-30|April 2006|Actual|2006-04-30||Interventional|||Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease|Phase II Study of Soy Protein to Treat Vasomotor Symptoms in Postmenopausal Women Taking Tamoxifen|Completed||Phase 2|112|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:24:25.125659|2018-06-01 05:24:25.125659
NCT00031694|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|2015-04-08||2015-04-08|2003-01-26|2003-01-27|Estimate|2015-04-08|2015-04-21|Estimate||||2015-04-08|2015-04-21|Estimate|January 2002||2002-01-31|May 2013|2013-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer|A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients With Advanced Pancreatic Cancer|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:24:25.247379|2018-06-01 05:24:25.247379
NCT00031681|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-09-27|2003-01-26|2003-01-27|Estimate|||||||2013-09-27|2013-09-30|Estimate|December 2001||2001-12-31|September 2013|2013-09-30||||January 2011|Actual|2011-01-31||Interventional|||7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)|A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)|Completed||Phase 1|41|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:25.530317|2018-06-01 05:24:25.530317
NCT00031655|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2012-12-05|2003-01-26|2003-01-27|Estimate|||||||2012-12-05|2012-12-07|Estimate|September 2001||2001-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|August 2006|Actual|2006-08-31||Interventional|||Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission|Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Unrelated Donors for Treatment of Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission - A Multicenter Trial|Completed||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:24:25.68092|2018-06-01 05:24:25.68092
NCT00031642|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-12-13|2003-01-26|2003-01-27|Estimate|||||||2013-12-13|2013-12-17|Estimate|January 2002||2002-01-31|December 2013|2013-12-31|March 2008|Actual|2008-03-31|November 2005|Actual|2005-11-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation|Phase I/II Study of IDEC-Y2B8 (Zevalin) for Post Transplant Relapses of B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|26|Actual|University of Nebraska|||||f||||f||||||||||2018-06-01 05:24:25.867985|2018-06-01 05:24:25.867985
NCT00031629|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2016-12-07|2003-01-26|2003-01-27|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2005||2005-01-31|December 2016|2016-12-31||||July 2007|Actual|2007-07-31||Interventional|||Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus|A Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Completed||Phase 2|51|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:24:25.991132|2018-06-01 05:24:25.991132
NCT00031616|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 2001||2001-12-31|April 2004|2004-04-30||||||||Interventional|||NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer|A Phase I/II Study Of NB1011 Administered Intravenously Daily For 5 Days Every 4 Weeks In Fluoropyrimidine-Resistant Metastatic Or Relapsed Colorectal Cancers|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:26.079234|2018-06-01 05:24:26.079234
NCT00031590|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2015-09-30|2003-01-26|2003-01-27|Estimate|||||||2015-09-30|2015-10-01|Estimate|April 2001||2001-04-30|September 2015|2015-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma|Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)|Terminated||Phase 2|30|Actual|Children's Hospital of Philadelphia||1||The study was terminated prematurely due to slow accrual.|f||||t||||||||||2018-06-01 05:24:26.294122|2018-06-01 05:24:26.294122
NCT00031577|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2015-03-17|2003-01-26|2003-01-27|Estimate|||||||2015-03-17|2015-03-19|Estimate|August 1999||1999-08-31|January 2014|2014-01-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma|A Phase I Study Of Taxol And Involved Field Radiation Therapy For Newly Diagnosed Intrinsic Gliomas Of Childhood|Terminated||Phase 1|11|Actual|Children's Hospital of Philadelphia||||"Administrative closure 9/22/2006. Decline in enrollment at CHOP. due to competing protocols~   with new agents."|f||||||||||||||2018-06-01 05:24:26.400581|2018-06-01 05:24:26.400581
NCT00031564|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-08|||2012-09-26|2003-01-26|2003-01-27|Estimate|||||||2012-09-26|2012-09-27|Estimate|May 2000||2000-05-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2005|Actual|2005-06-30||Interventional|||Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2|Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2 for Patients With Stage IV Renal Cell Carcinoma|Completed||Phase 2|49|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:24:26.480155|2018-06-01 05:24:26.480155
NCT00030914|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|September 2006|Actual|2006-09-30|February 2006|Actual|2006-02-28||Interventional|||Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women|Phase III Comparison of Depomedroxyprogesterone Acetate (DPROV) to Venlafaxine for Managing Hot Flashes|Completed||Phase 3|227|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-06-01 05:24:26.558038|2018-06-01 05:24:26.558038
NCT00030901|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|2012-11-19||2013-01-02|2003-01-26|2003-01-27|Estimate|2013-01-02|2013-02-06|Estimate||||2013-01-02|2013-02-06|Estimate|February 2000||2000-02-29|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate|L-Selenium-Based Chemoprevention Of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia|Completed||Phase 3|619|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:24:26.684218|2018-06-01 05:24:26.684218
NCT00030888|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2002||2002-12-31|December 2003|2003-12-31||||||||Interventional|||UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer|A Phase 2 Study Of UCN-01 In Advanced Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:27.201101|2018-06-01 05:24:27.201101
NCT00030875|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2010-11-07|2003-01-26|2003-01-27|Estimate|||||||2010-11-07|2010-11-09|Estimate|July 2002||2002-07-31|March 2010|2010-03-31|December 2009|Actual|2009-12-31|||||Interventional|||Bortezomib in Treating Patients With Mantle Cell Lymphoma|A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Mantle Cell Lymphoma|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:24:27.258583|2018-06-01 05:24:27.258583
NCT00030862|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|October 2001||2001-10-31|June 2013|2013-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus|Phase II Single-Arm Trial Of CPT-11 (Irinotecan HC1; Camptosar Injection)/Cisplatin In Patients With Advanced Esophageal Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:24:27.32933|2018-06-01 05:24:27.32933
NCT00030849|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-04-02|2003-01-26|2003-01-27|Estimate|||||||2013-04-02|2013-04-04|Estimate|October 2001||2001-10-31|December 2009|2009-12-31|December 2009|Actual|2009-12-31|September 2004|Actual|2004-09-30||Interventional|||Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma|Phase II Trial Of Oral Bexarotene (Targretin) Combined With Interferon Alfa-2b (Intron-A) For Patients With Cutaneous T-Cell Lymphoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:28.379348|2018-06-01 05:24:28.379348
NCT00030823|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|2015-10-23||2015-11-24|2003-01-26|2003-01-27|Estimate|2015-11-24|2015-12-30|Estimate||||2015-11-24|2015-12-30|Estimate|March 2001||2001-03-31|November 2015|2015-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence|Vaccination Of High Risk Breast Cancer Patients With Heptavalent Antigen - Keyhole Limpet Hemocyanin Conjugate Plus The Immunological Adjuvant QS21|Completed||N/A|14|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:24:28.499259|2018-06-01 05:24:28.499259
NCT00030810|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|September 2001||2001-09-30|May 2012|2012-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC|Preoperative Chemoradiotherapy In Non-Small Cell Lung Cancer (NSCLC) Patients With Operable Stage IIIB Disease: A Prospective Phase II Trial|Completed||Phase 2|46|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 05:24:28.715727|2018-06-01 05:24:28.715727
NCT00030784|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|November 2001||2001-11-30|September 2012|2012-09-30||||March 2005|Actual|2005-03-31||Interventional|||Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma|Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas|Completed||Phase 1|28|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:24:28.867406|2018-06-01 05:24:28.867406
NCT00030290|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|October 2001||2001-10-31|December 2008|2008-12-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Ultrasound in Treating Patients With Prostate Cancer Confined to the Prostate|Feasibility Study for Organ Confined Prostate Cancer Treatment With HIFU Using SONABLATE System|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:32.56827|2018-06-01 05:24:32.56827
NCT00030771|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2018-05-25|2003-01-26|2003-01-27|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 4, 2001|Actual|2001-04-04|May 2018|2018-05-31|December 2037|Anticipated|2037-12-31|April 9, 2014|Actual|2014-04-09||Interventional|||Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients|Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial|Active, not recruiting||Phase 3|232|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||No||2018-06-01 05:24:28.96367|2018-06-01 05:24:28.96367
NCT00030758|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2001||2001-10-31|June 2007|2007-06-30||||||||Interventional|||Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer|G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer|Unknown status|Active, not recruiting|Phase 4|816|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:29.218942|2018-06-01 05:24:29.218942
NCT00030745|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|June 2000||2000-06-30|May 2012|2012-05-31|August 2003|Actual|2003-08-31|May 2003|Actual|2003-05-31||Interventional|||Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung|Preoperative Chemotherapy Of Potentially Resectable Mesothelioma Of The Pleura|Completed||Phase 2|61|Actual|Swiss Group for Clinical Cancer Research|||||f||||t||||||||||2018-06-01 05:24:29.367245|2018-06-01 05:24:29.367245
NCT00030732|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|June 2001||2001-06-30|May 2012|2012-05-31|April 2008|Actual|2008-04-30|June 2004|Actual|2004-06-30||Interventional|||Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer|Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial|Completed||Phase 3|319|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:24:29.46143|2018-06-01 05:24:29.46143
NCT00030719|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2014-06-23|2003-01-26|2003-01-27|Estimate|||||||2014-06-23|2014-06-24|Estimate|December 2001||2001-12-31|August 2010|2010-08-31||||||||Interventional|||Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma|High Risk Neuroblastoma Study 1 Of Siop-Europe|Unknown status|Recruiting|Phase 3|175|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:29.588067|2018-06-01 05:24:29.588067
NCT00030706|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|November 2004||2004-11-30|February 2006|2006-02-28||||||||Interventional|||Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Study Of Epothilone B Analogue BMS-247550 In Relapse And/Or Refractory Stage III Or IV Ovarian Epithelial Cancer, Following Front-Line Treatment With Platinum Plus Taxane-Based Chemotherapy|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:29.797608|2018-06-01 05:24:29.797608
NCT00030693|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 2001||2001-12-31|January 2013|2013-01-31||||April 2010|Actual|2010-04-30||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Solid Tumors|Intra-Lesional rF-B7.1 Versus rF-Tricom Vaccine In The Treatment Of Metastatic Cancer|Terminated||Phase 1|42|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:24:29.869614|2018-06-01 05:24:29.869614
NCT00030680|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-08-26|2003-01-26|2003-01-27|Estimate|||||||2013-08-26|2013-08-27|Estimate|November 2001||2001-11-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Radiation Therapy in Treating Patients With Aggressive Fibromatoses|Phase II Pilot Study Of Moderate Dose Radiotherapy For Inoperable Aggressive Fibromatoses|Completed||Phase 2|44|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:24:29.962451|2018-06-01 05:24:29.962451
NCT00030654|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2017-03-09|2003-01-26|2003-01-27|Estimate|||||||2017-03-09|2017-03-10|Actual|October 2002||2002-10-31|March 2017|2017-03-31|February 4, 2005|Actual|2005-02-04|February 4, 2005|Actual|2005-02-04||Interventional|||Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer|A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy|Completed||Phase 3|21|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:24:30.077005|2018-06-01 05:24:30.077005
NCT00030641|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2001||2001-10-31|September 2003|2003-09-30||||||||Interventional|||Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer|Randomized Study of Docetaxel Versus Docetaxel Plus Genasense™ (G3139; Bcl-2 Antisense Oligonucleotide) in Patients With Previously Treated Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2/Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:30.394024|2018-06-01 05:24:30.394024
NCT00030628|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2016-07-06|2003-01-26|2003-01-27|Estimate|||||||2016-07-06|2016-07-07|Estimate|December 2001||2001-12-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|March 2005|Actual|2005-03-31||Interventional|||Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase III Randomized Trial Of The Role Of Whole Brain Radiation Therapy In Addition To Radiosurgery In The Management Of Patients With One To Three Cerebral Metastases|Completed||Phase 3|480|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:24:30.567549|2018-06-01 05:24:30.567549
NCT00030615|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-02-06|2003-01-26|2003-01-27|Estimate|||||||2013-02-06|2013-02-07|Estimate|December 2001||2001-12-31|February 2013|2013-02-28||||September 2008|Actual|2008-09-30||Interventional|||Decitabine in Treating Patients With Advanced Solid Tumors|A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:30.694794|2018-06-01 05:24:30.694794
NCT00030589|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|February 2001||2001-02-28|October 2003|2003-10-31||||||||Interventional|||Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma|A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:30.789599|2018-06-01 05:24:30.789599
NCT00030576|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2017-10-30|2003-01-26|2003-01-27|Estimate|||||||2017-10-30|2017-10-31|Actual|November 2001||2001-11-30|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase I/II Study Of OSI-774 In Combination With Cisplatin In Patients With Recurrent Or Metastatic Squamous Cell Cancer Of The Head And Neck|Completed||Phase 1/Phase 2|51|Actual|University Health Network, Toronto||1|||f||||t||||||||No||2018-06-01 05:24:30.91813|2018-06-01 05:24:30.91813
NCT00030563|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2017-04-13|2003-01-26|2003-01-27|Estimate|||||||2017-04-13|2017-04-17|Actual|May 2001||2001-05-31|April 2017|2017-04-30|October 2005|Actual|2005-10-31|October 2004|Actual|2004-10-31||Interventional|||Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver|A Phase II Study Of Adjuvant Intravenous Irinotecan Following Resection With Or Without Radiofrequency Ablation (RFA), Of Hepatic Metastases From Colorectal Carcinoma|Completed||Phase 2|||University of Washington|||||f||||||||||||||2018-06-01 05:24:31.023514|2018-06-01 05:24:31.023514
NCT00030550|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-01-30|2003-01-26|2003-01-27|Estimate|||||||2013-01-30|2013-01-31|Estimate|September 2001||2001-09-30|January 2013|2013-01-31||||June 2003|Actual|2003-06-30||Interventional|||Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing The Safety And Efficacy Of Thalidomide (THALOMID) For The Treatment Of Anemia In Red Blood Cell Transfusion-Dependent Patients With Myelodysplastic Syndromes|Completed||Phase 2|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:24:31.100431|2018-06-01 05:24:31.100431
NCT00030537|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|November 2001||2001-11-30|October 2002|2002-10-31|March 2003|Actual|2003-03-31|||||Interventional|||Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Pilot Study to Evaluate Epidermal Growth Factor Receptor Signaling After Treatment With Oral OSI-774 in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:31.179623|2018-06-01 05:24:31.179623
NCT00030511|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2012-07-13|2003-01-26|2003-01-27|Estimate|||||||2012-07-13|2012-07-16|Estimate|October 2001||2001-10-31|July 2012|2012-07-31||||July 2003|Actual|2003-07-31||Interventional|||Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer|A Phase II Study of Chronomodulated Preoperative Infusional Chemoradiation for Biliary Tract Cancer|Terminated||Phase 2|||European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:24:31.241848|2018-06-01 05:24:31.241848
NCT00030498|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|December 2001||2001-12-31|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction|Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction|Completed||Phase 1|75|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:31.336791|2018-06-01 05:24:31.336791
NCT00030485|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2014-01-24|2003-01-26|2003-01-27|Estimate|||||||2014-01-24|2014-01-27|Estimate|January 2002||2002-01-31|January 2011|2011-01-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer|A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:31.454389|2018-06-01 05:24:31.454389
NCT00030472|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-04-10|2003-01-26|2003-01-27|Estimate|||||||2013-04-10|2013-04-11|Estimate|December 2001||2001-12-31|September 2004|2004-09-30||||October 2006|Actual|2006-10-31||Interventional|||Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix|A Phase II Evaluation of Liposomal Doxorubicin (Doxil) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix|Terminated||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:24:31.518611|2018-06-01 05:24:31.518611
NCT00030459|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|November 2000||2000-11-30|May 2003|2003-05-31||||||||Interventional|||Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma|Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:31.59087|2018-06-01 05:24:31.59087
NCT00030433|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-02-12|2003-01-26|2003-01-27|Estimate|||||||2013-02-12|2013-02-15|Estimate|January 2002||2002-01-31|February 2013|2013-02-28|November 2008|Actual|2008-11-30|February 2007|Actual|2007-02-28||Interventional|||S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Trial Of Gemcitabine (NSC-613327) And Irinotecan (NSC-616348) In Patients With Untreated Extensive Stage Small Cell Lung Cancer (SCLC)|Completed||Phase 2|85|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 05:24:31.793712|2018-06-01 05:24:31.793712
NCT00030407|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-04-25|2003-01-26|2003-01-27|Estimate|||||||2013-04-25|2013-04-29|Estimate|October 2001||2001-10-31|April 2013|2013-04-30|April 2009|Actual|2009-04-30|September 2005|Actual|2005-09-30||Interventional|||Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer|Evaluation Of Celecoxib In Combination With Weekly Docetaxel In Elderly (70 Years) Or Poor Performance Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|34|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||f||||||||||2018-06-01 05:24:32.039857|2018-06-01 05:24:32.039857
NCT00030394|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-01-16|2003-01-26|2003-01-27|Estimate|||||||2013-01-16|2013-01-17|Estimate|September 2002||2002-09-30|January 2013|2013-01-31||||October 2007|Actual|2007-10-31||Interventional|||Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia|Completed||Phase 2|64|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:32.162243|2018-06-01 05:24:32.162243
NCT00030355|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-03-21|2003-01-26|2003-01-27|Estimate|||||||2013-03-21|2013-03-22|Estimate||||September 2007|2007-09-30||||||||Interventional|||Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia|A Phase I/II Open-Label Study Of The Intravenous Administration Of Homoharringtonine (CGX-635) Salvage Therapy For The Treatment Of Refractory Acute Promyelocytic Leukemia|Withdrawn||Phase 1/Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:32.282043|2018-06-01 05:24:32.282043
NCT00030342|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|November 2001||2001-11-30|October 2008|2008-10-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|||Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer|A Phase I/II Study Of Interleukin-12-Primed Activated T Cells In Combination With 5FU, GM-CSF And Interferon Alfa-2b In Metastatic Renal Cell Carcinoma Or Colorectal Carcinoma|Completed||Phase 1/Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:32.375011|2018-06-01 05:24:32.375011
NCT00030303|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2017-04-26|2003-01-26|2003-01-27|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2001|Actual|2001-01-31|April 2017|2017-04-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia|A Feasibility And Toxicity Study Of Vaccination With HSP70 For The Treatment Of Chronic Myelogenous Leukemia In Chronic Phase|Completed||Phase 1|20|Actual|UConn Health||1|||f|||||t|f|||f|||||2018-06-01 05:24:32.456107|2018-06-01 05:24:32.456107
NCT00030277|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|October 2001||2001-10-31|December 2008|2008-12-31|December 2008|Actual|2008-12-31|October 2007|Actual|2007-10-31||Interventional|||High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer|Feasibility Study for Locally Recurrent Prostate Cancer Treatment With HIFU Using the SONABLATE System|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:32.628439|2018-06-01 05:24:32.628439
NCT00030264|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2016-06-01|2003-01-26|2003-01-27|Estimate|||||||2016-06-01|2016-06-02|Estimate|February 2001||2001-02-28|June 2016|2016-06-30|March 2016|Actual|2016-03-31|December 2013|Actual|2013-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas|Vinblastine/Methotrexate For Severe Progressive Plexiform Neurofibromas: A Phase II Study|Completed||Phase 2|25|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-06-01 05:24:32.722019|2018-06-01 05:24:32.722019
NCT00030108|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-30|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|November 2001||2001-11-30|March 2012|2012-03-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy|Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias|Completed||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:24:32.843189|2018-06-01 05:24:32.843189
NCT00030095|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-30|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2001||2001-09-30|July 2006|2006-07-31||||||||Interventional|||2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors|A Phase I Trial Of 2-Methoxyestradiol (2ME2), (NSC-659853) An Angiogenesis Inhibitor, In Patients With Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:24:32.940688|2018-06-01 05:24:32.940688
NCT00030082|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-30|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|July 2001||2001-07-31|July 2004|2004-07-31||||||||Interventional|||Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer|A Phase I Study of Hepatic Arterial Infusion of Escalating Dose Melphalan With Venous Filtration for Metastatic Unresectable Cancers of the Liver|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:33.052356|2018-06-01 05:24:33.052356
NCT00029029|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2017-05-23|2003-01-26|2003-01-27|Estimate|||||||2017-05-23|2017-05-25|Actual|October 2000||2000-10-31|January 2016|2016-01-31||||October 2002|Actual|2002-10-31||Interventional|||Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases|RF Ablation of Painful Metastases Involving Bone|Unknown status|Active, not recruiting|Phase 2|||Mayo Clinic|||||f||||f|f|f||||||No||2018-06-01 05:24:33.131137|2018-06-01 05:24:33.131137
NCT00029003|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-02-27|2003-01-26|2003-01-27|Estimate|||||||2013-02-27|2013-02-28|Estimate|December 2001||2001-12-31|February 2013|2013-02-28||||December 2004|Actual|2004-12-31||Interventional|||Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)|Completed||Phase 2|90|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:33.22064|2018-06-01 05:24:33.22064
NCT00028990|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2012-03-08|2003-01-26|2003-01-27|Estimate|||||||2012-03-08|2012-03-09|Estimate|December 2001||2001-12-31|January 2010|2010-01-31|May 2009|Actual|2009-05-31|November 2006|Actual|2006-11-30||Interventional|||Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer|A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 3|722|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 05:24:33.338808|2018-06-01 05:24:33.338808
NCT00028977|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2012-09-13|2003-01-26|2003-01-27|Estimate|||||||2012-09-13|2012-09-17|Estimate|August 2001||2001-08-31|September 2012|2012-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Herbal Therapy in Treating Women With Metastatic Breast Cancer|A Pilot Safety, Feasibility, Efficacy And Correlative (Phase I/II) Study Assessing Herba Scutellaria Barbatae (HSB) For Metastatic Breast Cancer|Completed||Phase 1/Phase 2|21|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 05:24:33.464601|2018-06-01 05:24:33.464601
NCT00028964|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2011-02-20|2003-01-26|2003-01-27|Estimate|||||||2011-02-20|2011-02-23|Estimate|February 2001||2001-02-28|February 2011|2011-02-28|February 2005|Actual|2005-02-28|||||Interventional|||Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer|A Randomized, Double Blind, Pacebo-Controlled Study to Assess The Feasibility, Toxicity And Efficacy (Phase I/II) Of A Chinese Herbal Therapy (CHT) For Symptom Management In Women Undergoing Chemotherapy For Stage I/II/III Breast Cancer|Completed||Phase 1/Phase 2|||University of California, San Francisco|||||f||||||||||||||2018-06-01 05:24:33.528637|2018-06-01 05:24:33.528637
NCT00028951|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-07-08|2003-01-26|2003-01-27|Estimate|||||||2013-07-08|2013-07-09|Estimate|January 2003||2003-01-31|December 2005|2005-12-31||||December 2005|Actual|2005-12-31||Interventional|||Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva|A Phase III Clinical Trial Use of TISSEEL VH Fibrin Sealant to Reduce Lymphedema Incidence After Inguinal Lymph Node Dissection Performed in the Management of Vulvar Malignancies|Completed||Phase 3|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:24:33.652446|2018-06-01 05:24:33.652446
NCT00028912|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2011-04-23|2003-01-26|2003-01-27|Estimate|||||||2011-04-23|2011-04-26|Estimate|November 2001||2001-11-30|April 2004|2004-04-30||||||||Interventional|||Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|Phase I Trial of Bortezomib (NSC 681239, IND#58443) and Carboplatin in Recurrent or Progressive Epithelial Ovarian Cancer or Primary Peritoneal Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:33.758926|2018-06-01 05:24:33.758926
NCT00028899|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2014-02-18|2003-01-26|2003-01-27|Estimate|||||||2014-02-18|2014-02-20|Estimate|July 2002||2002-07-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|September 2006|Actual|2006-09-30||Interventional|||Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes|A Dose Finding Study of the Safety of Gemtuzumab Ozogamicin Combined With Conventional Chemotherapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 1|47|Actual|Children's Oncology Group|||||||||t||||||||||2018-06-01 05:24:33.823148|2018-06-01 05:24:33.823148
NCT00028886|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2001||2001-03-31|October 2012|2012-10-31||||||||Interventional|||Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma|A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma|Unknown status|Active, not recruiting|Phase 3|450|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:34.088474|2018-06-01 05:24:34.088474
NCT00028873|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|September 2001||2001-09-30|July 2012|2012-07-31||||June 2002|Actual|2002-06-30||Interventional|||R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy|An EORTC-IDBBC/ECSG Phase II Study Evaluating The Role Of The Multi-Drug Resistance (MDR) Reversor, R101933, In Patients With Taxane Refractory Metastatic Breast Cancer|Completed||Phase 2|35|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:24:34.203121|2018-06-01 05:24:34.203121
NCT00028860|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|October 2001||2001-10-31|August 2004|2004-08-31|October 2004|Actual|2004-10-31|||||Interventional|||Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer|A Phase II Trial Of Adjuvant Chemotherapy For High Risk Transitional Cell Carcinoma Of The Urothelium|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:34.269325|2018-06-01 05:24:34.269325
NCT00028847|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2001||2001-04-30|August 2011|2011-08-31||||||||Interventional|||Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia|A Dose-ranging Phase I/II Study of STI571 in Combination With Cytarabin in Patients With First Chronic Phase Chronic Myeloid Leukemia|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:34.358836|2018-06-01 05:24:34.358836
NCT00028834|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|February 2002||2002-02-28|January 2013|2013-01-31||||December 2004|Actual|2004-12-31||Interventional|||Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer|A Phase II Trial Of Bevacizumab (NSC#704865) Plus Gemcitabine In Patients With Advanced Pancreatic Cancer|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:34.463788|2018-06-01 05:24:34.463788
NCT00028821|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2002||2002-01-31|January 2013|2013-01-31||||April 2006|Actual|2006-04-30||Interventional|||2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacologic Study of 2-Methoxyestradiol in Patients With Advanced Solid Tumors|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:34.556577|2018-06-01 05:24:34.556577
NCT00028795|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2014-02-19|2003-01-26|2003-01-27|Estimate|||||||2014-02-19|2014-02-21|Estimate|December 2002||2002-12-31|February 2014|2014-02-28|March 2012|Actual|2012-03-31|September 2007|Actual|2007-09-30||Interventional|||Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma|A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma|Completed||Phase 2|170|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:24:34.759564|2018-06-01 05:24:34.759564
NCT00028782|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2001||2001-10-31|January 2013|2013-01-31||||September 2007|Actual|2007-09-30||Interventional|||EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer|The Detection of Tumor Hypoxia and Vascularity in Patients Undergoing Intraperitoneal Photodynamic Therapy|Terminated||N/A|80|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:24:35.112582|2018-06-01 05:24:35.112582
NCT00028769|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|2012-11-15||2013-06-12|2003-01-26|2003-01-27|Estimate|2013-06-12|2013-07-16|Estimate||||2013-06-12|2013-07-16|Estimate|December 2001||2001-12-31|June 2013|2013-06-30|July 2011|Actual|2011-07-31|June 2010|Actual|2010-06-30||Interventional|||S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer|Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination With Hormone Therapy in Patients With High-Risk Metastatic Adenocarinoma of the Prostate|Completed||Phase 2|41|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:24:35.242426|2018-06-01 05:24:35.242426
NCT00028756|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2016-08-01|2003-01-26|2003-01-27|Estimate|||||||2016-08-01|2016-08-02|Estimate|October 2001||2001-10-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium|Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder|Completed||Phase 3|285|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 05:24:35.694786|2018-06-01 05:24:35.694786
NCT00028743|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-10-31|2003-01-26|2003-01-27|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2001||2001-08-31|December 2012|2012-12-31|January 2013|Actual|2013-01-31|October 2007|Actual|2007-10-31||Interventional|||Comparison of Combination Chemotherapy Regimens in Treating Newly Diagnosed Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer|Completed||Phase 3|819|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:24:35.889983|2018-06-01 05:24:35.889983
NCT00028730|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2015-12-21|2003-01-26|2003-01-27|Estimate|||||||2015-12-21|2015-12-22|Estimate|August 2001||2001-08-31|December 2015|2015-12-31|June 2008|Actual|2008-06-30|July 2006|Actual|2006-07-31||Interventional|||Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer|Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders|Completed||Phase 2|25|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:24:36.062585|2018-06-01 05:24:36.062585
NCT00028717|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|February 2001||2001-02-28|November 2007|2007-11-30||||||||Interventional|||Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma|A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:36.210121|2018-06-01 05:24:36.210121
NCT00028028|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-02-27|2003-01-26|2003-01-27|Estimate|||||||2013-02-27|2013-02-28|Estimate|February 2002||2002-02-28|February 2013|2013-02-28||||January 2007|Actual|2007-01-31||Interventional|||CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer|A Randomized, Phase II ECOG Trial of Two Dose Levels of CCI-779 in Patients With Extensive-Stage Small Cell Lung Cancer Who Have Responding or Stable Disease After Induction Chemotherapy|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:39.19396|2018-06-01 05:24:39.19396
NCT00028704|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|October 2001||2001-10-31|July 2012|2012-07-31||||December 2003|Actual|2003-12-31||Interventional|||Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy|Conservative Local Treatment Versus Mastectomy After Induction Chemotherapy In Locally Advanced Breast Cancer: A Randomized Phase III Study|Terminated||Phase 3|26|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:24:36.347804|2018-06-01 05:24:36.347804
NCT00028691|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|December 2002||2002-12-31|January 2002|2002-01-31||||||||Interventional|||Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma|Chlorambucil Versus 2x2 Gy Involved Field Radiotherapy in Stage III/IV Previously Untreated Follicular Lymphoma Patients. A Prospective, Randomized Phase III Clinical Trial|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:36.4946|2018-06-01 05:24:36.4946
NCT00028665|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-10|Estimate|June 2000||2000-06-30|June 2010|2010-06-30||||March 2005|Actual|2005-03-31||Interventional|||Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma|Randomized Phase II Trial of B-Lymphocyte Purging of Autologous Peripheral Blood Progenitor Cells in Patients With B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|37|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:24:36.611868|2018-06-01 05:24:36.611868
NCT00028652|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2015-09-30|2003-01-26|2003-01-27|Estimate|||||||2015-09-30|2015-10-02|Estimate|January 2002||2002-01-31|September 2015|2015-09-30||||||||Interventional|||Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases|Treament of Spontaneous Tumor Metastases With IL-12 DNA (NSC #709933): A Phase IB Trial|Terminated||Phase 1|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:24:36.771374|2018-06-01 05:24:36.771374
NCT00028639|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04||2011-07-01|2011-07-01|2003-01-26|2003-01-27|Estimate||||2011-07-01|2011-07-29|Estimate|2011-07-01|2011-07-29|Estimate|August 2001||2001-08-31|July 2011|2011-07-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||PS-341 in Treating Women With Metastatic Breast Cancer|A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:24:36.862736|2018-06-01 05:24:36.862736
NCT00028626|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2001||2001-08-31|June 2013|2013-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer|Clinical Efficacy And Biologic Effects Of Preoperative Portal Vein Embolization In Patients With Colorectal Liver Metastases|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:24:36.939559|2018-06-01 05:24:36.939559
NCT00028600|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-04|Estimate|November 2001||2001-11-30|July 2016|2016-07-31|February 2010|Actual|2010-02-28|June 2006|Actual|2006-06-30||Interventional|||Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma|Autologous Followed By Non-Myeloablative Allogeneic Transplant For Multiple Myeloma|Completed||Phase 2|60|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:37.01251|2018-06-01 05:24:37.01251
NCT00028587|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|December 2001||2001-12-31|January 2013|2013-01-31||||April 2006|Actual|2006-04-30||Interventional|||PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Malignancies|Completed||Phase 1|96|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:37.151811|2018-06-01 05:24:37.151811
NCT00028574|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2016-06-27|2003-01-26|2003-01-27|Estimate|||||||2016-06-27|2016-06-28|Estimate|December 2001||2001-12-31|June 2016|2016-06-30|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer|A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Management of Hot Flashes in Men|Completed||Phase 3|223|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-06-01 05:24:37.284097|2018-06-01 05:24:37.284097
NCT00028561|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-01-16|2003-01-26|2003-01-27|Estimate|||||||2013-01-16|2013-01-17|Estimate|October 2001||2001-10-31|January 2013|2013-01-31||||February 2007|Actual|2007-02-28||Interventional|||BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of Epothilone B Analog BMS 247550 in Combination With Carboplatin in Recurrent and/or Refractory Solid Tumors|Terminated||Phase 1|45|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:24:37.585144|2018-06-01 05:24:37.585144
NCT00028548|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2014-04-24|2003-01-26|2003-01-27|Estimate|||||||2014-04-24|2014-04-25|Estimate|January 2002||2002-01-31|April 2014|2014-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||XK469 in Treating Patients With Advanced Solid Tumors|Phase I Study of R(+)-XK469 (NSC 698215) Given Daily, Days 1-5, Repeated Every Three Weeks in Patients With Advanced Malignancies|Completed||Phase 1|22|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 05:24:37.665685|2018-06-01 05:24:37.665685
NCT00028535|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 2001||2001-11-30|June 2013|2013-06-30||||February 2009|Actual|2009-02-28||Interventional|||Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors|Phase I Trial of Interleukin-12 in Combination With Paclitaxel Plus Herceptin in Patients With Her2-positive Malignancies|Completed||Phase 1|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:37.751905|2018-06-01 05:24:37.751905
NCT00028522|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-12-13|2003-01-26|2003-01-27|Estimate|||||||2013-12-13|2013-12-16|Estimate|December 2001||2001-12-31|December 2013|2013-12-31||||September 2009|Actual|2009-09-30||Interventional|||R(+)XK469 in Treating Patients With Advanced Neuroblastoma|Phase I Study Of R(+)XK469 In Patients With Advanced Neuroblastoma|Completed||Phase 1|85|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:37.880279|2018-06-01 05:24:37.880279
NCT00028509|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2014-02-11|2003-01-26|2003-01-27|Estimate|||||||2014-02-11|2014-02-13|Estimate|July 2002||2002-07-31|February 2014|2014-02-28||||July 2011|Actual|2011-07-31||Observational|||Brain Function in Children Previously Treated on Clinical Trials POG-9605 and POG-9201|Assessment of Clinical and Neuroradiologic Evidence of Methotrexate Leukoencephalopathy in Children Treated on POG 9605 and 9201|Completed|||66|Actual|Children's Oncology Group|||||f||||f||||||||||2018-06-01 05:24:37.96061|2018-06-01 05:24:37.96061
NCT00028496|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2013-01-24|2003-01-26|2003-01-27|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2001||2001-11-30|January 2013|2013-01-31||||November 2005|Actual|2005-11-30||Interventional|||Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer|Phase I Study of a Recombinant Fowl Pox Vaccine rF-CEA (6D)/TRICOM Alone or With GM-CSF in Patients With Advanced CEA Expressing Adenocarinomas|Completed||Phase 1|48|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:38.106164|2018-06-01 05:24:38.106164
NCT00028015|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2010-11-07|2003-01-26|2003-01-27|Estimate|||||||2010-11-07|2010-11-09|Estimate|October 2001||2001-10-31|March 2010|2010-03-31||||||||Interventional|||SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:24:39.279839|2018-06-01 05:24:39.279839
NCT00028002|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|2012-11-29||2014-05-07|2003-01-26|2003-01-27|Estimate|2013-05-15|2013-07-10|Estimate||||2014-05-07|2014-05-23|Estimate|February 2002||2002-02-28|November 2012|2012-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor|A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051) for Primary and Recurrent Operable Malignant GIST Expressing the KIT Receptor Tyrosine Kinase (CD117)|Completed||Phase 2|63|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:39.370852|2018-06-01 05:24:39.370852
NCT00027989|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 2001||2001-12-31|April 2004|2004-04-30||||||||Interventional|||Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer|An Open-Label, Single-Arm, Phase II Study of Liposomal Doxorubicin (Doxil) and Gemcitabine in the Treatment of Women With Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:39.671328|2018-06-01 05:24:39.671328
NCT00027976|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-05|Estimate|December 2001||2001-12-31|November 2012|2012-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses|A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Celecoxib In Subjects With Actinic Keratoses|Withdrawn||Phase 2/Phase 3|0|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-06-01 05:24:39.830494|2018-06-01 05:24:39.830494
NCT00027963|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-04|Estimate|February 2002||2002-02-28|July 2016|2016-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy|The Efficacy Of Gabapentin In The Management Of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial|Completed||Phase 3|100|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:24:39.936282|2018-06-01 05:24:39.936282
NCT00027937|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2010-05-12|2003-01-26|2003-01-27|Estimate|||||||2010-05-12|2010-05-14|Estimate|August 2001||2001-08-31|May 2010|2010-05-31|November 2007|Actual|2007-11-30|||||Interventional|||Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma|A Phase II Study Of Mobilization Chemotherapy With GMCSF And GCSF Followed By High Dose Therapy Combined With IL2 Activated Autologous Peripheral Blood Stem Cells Followed By Sequential IL2 Therapy As Treatment For Solid Tumors And Lymphoma|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:24:40.062684|2018-06-01 05:24:40.062684
NCT00027911|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-02-13|2003-01-26|2003-01-27|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2001||2001-04-30|February 2013|2013-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma|A Pilot Study of NY-ESO-1 Immunization in Patients With NY-ESO-1/LAGE Antigen Expressing Cancer|Terminated||Phase 1|||Columbia University||||Departure of PI|f||||||||||||||2018-06-01 05:24:40.166843|2018-06-01 05:24:40.166843
NCT00027898|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-02-06|2003-01-26|2003-01-27|Estimate|||||||2013-02-06|2013-02-07|Estimate|January 2002||2002-01-31|February 2013|2013-02-28||||January 2006|Actual|2006-01-31||Interventional|||Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Study of PS-341 (NSC 681239), Carboplatin, and Etoposide in Patients With Advanced Solid Tumors Refractory to Standard Therapy|Completed||Phase 1|27|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:40.238116|2018-06-01 05:24:40.238116
NCT00027885|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-06-14|2003-01-26|2003-01-27|Estimate|||||||2013-06-14|2013-06-17|Estimate|November 2001||2001-11-30|June 2013|2013-06-30|August 2010|Actual|2010-08-31|December 2005|Actual|2005-12-31||Interventional|||Phase II Bevacizumab + Tax In Advanced Breast Cancer|A Randomized Phase II Study of Bevacizumab in Combination With Docetaxel in Locally Advanced Breast Cancer|Completed||Phase 2|49|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:24:40.341605|2018-06-01 05:24:40.341605
NCT00027872|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-03-22|2003-01-26|2003-01-27|Estimate|||||||2013-03-22|2013-03-25|Estimate|October 2001||2001-10-31|March 2013|2013-03-31|January 2009|Actual|2009-01-31|July 2007|Actual|2007-07-31||Interventional|||Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia|A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC #702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia|Completed||Phase 2|125|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:40.458209|2018-06-01 05:24:40.458209
NCT00027859|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2010-01-26|2003-01-26|2003-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|May 2003||2003-05-31|January 2010|2010-01-31||||December 2004|Actual|2004-12-31||Interventional|||Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer|A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy for Prostate Cancer|Completed||Phase 3|||Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:24:40.570278|2018-06-01 05:24:40.570278
NCT00027846|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|2016-05-27||2017-01-11|2003-01-26|2003-01-27|Estimate|2017-01-11|2017-03-01|Actual||||2017-01-11|2017-03-01|Actual|August 2003||2003-08-31|January 2017|2017-01-31||||January 2010|Actual|2010-01-31||Interventional|||Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma|A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma|Active, not recruiting||Phase 2|378|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 05:24:40.914171|2018-06-01 05:24:40.914171
NCT00027833|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2001||2001-12-31|September 2003|2003-09-30||||||||Interventional|||Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer|Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:41.871084|2018-06-01 05:24:41.871084
NCT00027820|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2017-12-11|2003-01-26|2003-01-27|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2001||2001-08-31|December 2017|2017-12-31||||September 2004|Actual|2004-09-30||Interventional|||Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer|Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial|Active, not recruiting||Phase 1/Phase 2|106|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:24:41.958535|2018-06-01 05:24:41.958535
NCT00027807|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2016-02-15|2003-01-26|2003-01-27|Estimate|||||||2016-02-15|2016-02-17|Estimate|October 2001||2001-10-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|September 2010|Actual|2010-09-30||Interventional|||Biological Therapy in Treating Women With Stage IV Breast Cancer|Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date)|Completed||Phase 1|6|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 05:24:42.052513|2018-06-01 05:24:42.052513
NCT00027794|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|September 2001||2001-09-30|September 2012|2012-09-30||||January 2005|Actual|2005-01-31||Interventional|||Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer|Radical Prostatectomy for Locally Advanced Prostate Cancer. A Feasibility Study|Completed||Phase 2|40|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:24:42.131275|2018-06-01 05:24:42.131275
NCT00027781|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2012-07-23|2003-01-26|2003-01-27|Estimate|||||||2012-07-23|2012-07-24|Estimate|August 2001||2001-08-31|July 2012|2012-07-31||||March 2003|Actual|2003-03-31||Interventional|||MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy|Open Label Phase II Study of MEN-10755 Administered Every 3 Weeks in Patients With Progressive Hormone Refractory Prostate Cancer|Completed||Phase 2|37|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:24:42.288699|2018-06-01 05:24:42.288699
NCT00027768|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 2001||2001-06-30|June 2007|2007-06-30||||||||Interventional|||Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer|Randomised Trial of Adjuvant Hepatic Intra-Arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:42.356307|2018-06-01 05:24:42.356307
NCT00027742|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 2001||2001-05-31|June 2013|2013-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma|A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:24:42.412221|2018-06-01 05:24:42.412221
NCT00027729|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|June 2001||2001-06-30|June 2013|2013-06-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer|Phase I/II Study of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer|Completed||Phase 1/Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:24:42.797793|2018-06-01 05:24:42.797793
NCT00027716|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-06|Estimate|October 2001||2001-10-31|June 2013|2013-06-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma|A Multi-Institutional, Open-Label, Two-Group, Phase II Study of PS-341 (LDP-341, NSC #681239) in Patients With Advanced or Metastatic Sarcoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:24:42.858023|2018-06-01 05:24:42.858023
NCT00027703|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2014-02-10|2003-01-26|2003-01-27|Estimate|||||||2014-02-10|2014-02-11|Estimate|October 2001||2001-10-31|December 2012|2012-12-31||||May 2006|Actual|2006-05-31||Interventional|||Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma|A Double Blind, Placebo Controlled Randomized Phase II Trial Of Gemcitabine And Cisplatin With Or Without The VEGF Inhibitor Bevacizumab (NSC #704865) In Patients With Malignant Mesotheloma|Completed||Phase 2|106|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:42.92405|2018-06-01 05:24:42.92405
NCT00027690|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2015-03-13|2003-01-26|2003-01-27|Estimate|||||||2015-03-13|2015-03-17|Estimate|June 2002||2002-06-30|December 2012|2012-12-31|July 2013|Actual|2013-07-31|September 2004|Actual|2004-09-30||Interventional|||Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer|A Phase II Trial of ZD 1839 (IRESSA) (NSC #715055) in the Treatment of Persistent or Recurrent Endometrial Carcinoma|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:43.007627|2018-06-01 05:24:43.007627
NCT00027677|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2012-07-23|2003-01-26|2003-01-27|Estimate|||||||2012-07-23|2012-07-24|Estimate|August 2001||2001-08-31|July 2012|2012-07-31||||February 2004|Actual|2004-02-29||Interventional|||Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors|Phase I Study To Determine The Safety Of Halofuginone In Patients With A Solid Progressive Tumor|Completed||Phase 1|25|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:24:43.085533|2018-06-01 05:24:43.085533
NCT00027664|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|February 2001||2001-02-28|March 2002|2002-03-31||||||||Interventional|||Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer|Interferon Alpha In Combination With Thalidomide In The Treatment Of Metastatic Renal Cell Carcinoma A Randomized Phase II Study|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:43.148285|2018-06-01 05:24:43.148285
NCT00027638|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-18|Estimate|March 2001||2001-03-31|June 2013|2013-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors|Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers)|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:24:43.208763|2018-06-01 05:24:43.208763
NCT00027625|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2008-12-13|2003-01-26|2003-01-27|Estimate|||||||2008-12-13|2008-12-16|Estimate|January 2002||2002-01-31|September 2003|2003-09-30||||||||Interventional|||Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma|A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:43.326221|2018-06-01 05:24:43.326221
NCT00027586|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2012-07-27|2003-01-26|2003-01-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 2001||2001-09-30|July 2012|2012-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Imatinib Mesylate in Treating Patients With Metastatic Melanoma|Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:24:43.404578|2018-06-01 05:24:43.404578
NCT00027573|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 2001||2001-10-31|July 2016|2016-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer|Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A Phase II Study|Completed||Phase 2|36|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:43.482489|2018-06-01 05:24:43.482489
NCT00027560|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|2012-11-27||2012-12-03|2003-01-26|2003-01-27|Estimate|2012-12-03|2013-01-07|Estimate||||2012-12-03|2013-01-07|Estimate|July 2001||2001-07-31|December 2012|2012-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer|Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphohematopoietic Malignancies|Completed||Phase 2|51|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:24:43.580131|2018-06-01 05:24:43.580131
NCT00027547|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2011-11-28|2003-01-26|2003-01-27|Estimate|||||||2011-11-28|2011-11-30|Estimate|July 2001||2001-07-31|November 2011|2011-11-30|July 2004|Actual|2004-07-31|||||Interventional|||Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia|Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Sibling Donors For Treatment Of Patients With High Risk Acute Lymphocytic Leukemia In Complete Remission|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:24:43.764167|2018-06-01 05:24:43.764167
NCT00027534|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2014-09-04|2003-01-26|2003-01-27|Estimate|||||||2014-09-04|2014-09-08|Estimate|January 2002||2002-01-31|September 2014|2014-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer|A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA|Completed||Phase 1|14|Actual|Duke University||1|||f||||f||||||||||2018-06-01 05:24:43.823495|2018-06-01 05:24:43.823495
NCT00027495|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2012-12-19|2003-01-26|2003-01-27|Estimate|||||||2012-12-19|2012-12-21|Estimate|December 2001||2001-12-31|December 2012|2012-12-31|September 2007|Actual|2007-09-30|February 2004|Actual|2004-02-29||Interventional|||Curcumin for the Prevention of Colon Cancer|Phase I Pharmacokinetic Trial of Curcuminoids Administered in a Capsule Formulation|Completed||Phase 1|||University of Michigan Cancer Center|||||f||||t||||||||||2018-06-01 05:24:43.893509|2018-06-01 05:24:43.893509
NCT00026533|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2017-06-04|2003-01-26|2003-01-27|Estimate|||||||2017-06-04|2017-06-06|Actual|June 2001||2001-06-30|June 2017|2017-06-30|December 2005|Actual|2005-12-31|November 2003|Actual|2003-11-30||Interventional|||Thalidomide in Treating Patients With Thyroid Cancer|Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas|Completed||Phase 2|||University of Kentucky|||||f||||f||||||||||2018-06-01 05:24:43.943829|2018-06-01 05:24:43.943829
NCT00026494|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|2015-12-15||2015-12-15|2003-01-26|2003-01-27|Estimate|2015-12-15|2016-01-18|Estimate||||2015-12-15|2016-01-18|Estimate|July 2001||2001-07-31|December 2015|2015-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases|A Phase I/II Trial Of Temozolomide And Vinorelbine For Patients With Recurrent Brain Metastases|Completed||Phase 1/Phase 2|49|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:24:44.155375|2018-06-01 05:24:44.155375
NCT00026468|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-07-23|2003-01-26|2003-01-27|Estimate|||||||2013-07-23|2013-07-24|Estimate|July 1999||1999-07-31|July 2013|2013-07-31|July 1999|Actual|1999-07-31|July 1999|Actual|1999-07-31||Interventional|||Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis|Chemoprevention of Duodenal Polyps in Familial Adenomatous Polyposis|Withdrawn||Phase 2/Phase 3|0|Actual|University of Utah||||Principle Investigator has left the University.|f||||||||||||||2018-06-01 05:24:44.68447|2018-06-01 05:24:44.68447
NCT00026442|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2001||2001-11-30|April 2004|2004-04-30||||||||Interventional|||Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer|A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:44.756595|2018-06-01 05:24:44.756595
NCT00026416|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2001||2001-10-31|October 2003|2003-10-31||||||||Interventional|||Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma|Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:44.816705|2018-06-01 05:24:44.816705
NCT00026403|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|September 2001||2001-09-30|July 2016|2016-07-31|July 2009|Actual|2009-07-31|June 2007|Actual|2007-06-30||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer|A Phase II Study of Gemcitabine, Cisplatin and Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 2|48|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:44.93008|2018-06-01 05:24:44.93008
NCT00026338|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2011-09-28|2003-01-26|2003-01-27|Estimate|||||||2011-09-28|2011-09-30|Estimate|August 2001||2001-08-31|September 2011|2011-09-30|February 2009|Actual|2009-02-28|September 2004|Actual|2004-09-30||Interventional|||Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer|A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer|Completed||Phase 3|569|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:24:45.059175|2018-06-01 05:24:45.059175
NCT00026312|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|2017-02-09||2017-04-03|2003-01-26|2003-01-27|Estimate|2017-02-09|2017-03-29|Actual||||2017-04-03|2017-05-10|Actual|October 2001||2001-10-31|April 2017|2017-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma|Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue|Completed||Phase 3|1449|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 05:24:45.418448|2018-06-01 05:24:45.418448
NCT00026299|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-09-04|2003-01-26|2003-01-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2001||2001-09-30|September 2013|2013-09-30|February 2005|Actual|2005-02-28|December 2002|Actual|2002-12-31||Interventional|||Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer|A Phase I/ Randomized Phase II Trial Of Oxaliplatin (NSC #266046) With Or Without ZD 1839 (NSC # 715055) In Patients With Advanced Colorectal Carcinoma|Completed||Phase 1/Phase 2|14|Actual|University of Chicago||3|||f||||f||||||||||2018-06-01 05:24:47.295168|2018-06-01 05:24:47.295168
NCT00026247|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2011-04-07|2003-01-26|2003-01-27|Estimate|||||||2011-04-07|2011-04-08|Estimate|November 2001||2001-11-30|March 2006|2006-03-31||||February 2011|Actual|2011-02-28||Interventional|||Radiofrequency Ablation in Treating Patients With Bone Metastases|A Phase I/II Study of Percutaneous Radiofrequency Ablation of Bone Metastases Using CT Guidance|Completed||Phase 1/Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:47.500135|2018-06-01 05:24:47.500135
NCT00026234|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-07-15|2003-01-26|2003-01-27|Estimate|||||||2013-07-15|2013-07-16|Estimate|February 2002||2002-02-28|June 2013|2013-06-30||||January 2006|Actual|2006-01-31||Interventional|||Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver|A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Liver|Completed||Phase 2|75|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:47.567997|2018-06-01 05:24:47.567997
NCT00026221|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|2015-12-16||2016-02-18|2003-01-26|2003-01-27|Estimate|2016-02-18|2016-03-17|Estimate||||2016-02-18|2016-03-17|Estimate|November 2001||2001-11-30|February 2016|2016-02-29|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma|A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma|Completed||Phase 2|57|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:24:47.669336|2018-06-01 05:24:47.669336
NCT00026208|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|2018-03-16||2018-04-16|2003-01-26|2003-01-27|Estimate|2018-04-16|2018-05-15|Actual||||2018-04-16|2018-05-15|Actual|June 2001||2001-06-30|April 2018|2018-04-30|February 13, 2017|Actual|2017-02-13|April 26, 2013|Actual|2013-04-26||Interventional||Prior to amendment, participants with tumor size < 5 cm received Stanford V-C only. Subsequent to amendment, all participants received Stanford V-C + low-dose radiotherapy (RT)|Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma|Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study|Completed||Phase 2|76|Actual|Stanford University||2|||f||||t|t|f|||f|||No||2018-06-01 05:24:47.975522|2018-06-01 05:24:47.975522
NCT00026195|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|September 2001||2001-09-30|July 2016|2016-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Irinotecan in Treating Aging Patients With Solid Tumors|Clinical Pharmacology In The Elderly: Prospective Evaluation Of The Pharmacokinetics, Pharmacogenetics And Pharmacodynamics Of CPT-11 And Aging|Completed||Phase 1|140|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:48.35122|2018-06-01 05:24:48.35122
NCT00026182|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2001||2001-10-31|August 2013|2013-08-31||||February 2005|Actual|2005-02-28||Interventional|||Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma|Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma|Completed||Phase 2|99|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:48.446939|2018-06-01 05:24:48.446939
NCT00026169|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-01-09|2003-01-26|2003-01-27|Estimate|||||||2013-01-09|2013-01-10|Estimate|September 2001||2001-09-30|January 2013|2013-01-31||||April 2005|Actual|2005-04-30||Interventional|||Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure|A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group|Completed||Phase 1|69|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:49.444808|2018-06-01 05:24:49.444808
NCT00026156|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-02-12|2003-01-26|2003-01-27|Estimate|||||||2013-02-12|2013-02-15|Estimate|November 2001||2001-11-30|February 2013|2013-02-28|November 2008|Actual|2008-11-30|July 2004|Actual|2004-07-31||Interventional|||S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer|Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or With Performance Status 2|Completed||Phase 2|125|Actual|Southwest Oncology Group|||||f||||f||||||||||2018-06-01 05:24:49.683213|2018-06-01 05:24:49.683213
NCT00026143|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|October 2001||2001-10-31|June 2013|2013-06-30||||July 2004|Actual|2004-07-31||Interventional|||Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma|Phase II Trial of Interleukin-12 (NSC #672423, IND #6798) Followed by Interferon Alfa-2B in Patients With Metastatic Malignant Melanoma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:50.126|2018-06-01 05:24:50.126
NCT00026130|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|September 2001||2001-09-30|July 2016|2016-07-31|June 2010|Actual|2010-06-30|December 2005|Actual|2005-12-31||Interventional|||Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer|A Phase II Trial of Gemcitabine, 5-Fluorouracil and Radiation Therapy in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|81|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:24:50.963752|2018-06-01 05:24:50.963752
NCT00026117|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|August 2001||2001-08-31|July 2016|2016-07-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer|Phase III Evaluation Of Benefin Shark Cartilage In Patients With Advanced Cancer|Completed||Phase 3|88|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:24:51.501661|2018-06-01 05:24:51.501661
NCT00026104|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-06-05|2003-01-26|2003-01-27|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2001||2001-11-30|June 2013|2013-06-30||||August 2006|Actual|2006-08-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer|A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC #702818) for Locally Advanced Pancreatic Cancer|Completed||Phase 2|154|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:51.65737|2018-06-01 05:24:51.65737
NCT00020995|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|August 2001||2001-08-31|May 2004|2004-05-31|January 2010|Actual|2010-01-31|||||Interventional|||Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer|Effects of a Low Fat Diet on Serum Factors and Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:41.995933|2018-06-01 05:25:41.995933
NCT00026091|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-03-22|2003-01-26|2003-01-27|Estimate|||||||2013-03-22|2013-03-25|Estimate|September 2001||2001-09-30|February 2013|2013-02-28||||March 2004|Actual|2004-03-31||Interventional|||Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer|Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:51.799926|2018-06-01 05:24:51.799926
NCT00026078|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|March 2001||2001-03-31|November 2006|2006-11-30||||||||Interventional|||Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer|Docetaxel (DTX) - Ifosfamide (IFX) As First Line Chemotherapy In Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|42|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:52.052435|2018-06-01 05:24:52.052435
NCT00025675|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2012-05-18|2003-01-26|2003-01-27|Estimate|||||||2012-05-18|2012-05-21|Estimate|January 2002||2002-01-31|May 2012|2012-05-31||||June 2009|Actual|2009-06-30||Interventional|||Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors|ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs|Completed||Phase 2|105|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-06-01 05:24:52.206511|2018-06-01 05:24:52.206511
NCT00025662|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|2011-04-20||2016-09-21|2003-01-26|2003-01-27|Estimate|2011-12-09|2012-01-13|Estimate||||2016-09-21|2016-10-28|Estimate|May 2001||2001-05-31|September 2016|2016-09-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS|"Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using RFT5-SMPT-dgA: Reducing GVHD Risk Associated With Matched, Nonmyeloablative, Stem Cell Transplant for Hematologic Malignancies in Older Adults"|Completed||Phase 2|23|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 05:24:52.360664|2018-06-01 05:24:52.360664
NCT00025649|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1999||1999-07-31|December 2001|2001-12-31|March 2009|Actual|2009-03-31|||||Interventional|||Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma|European Infant Neuroblastoma Study - Stage 2, 3, 4, and 4S; MYCN Amplified Tumors|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:52.743347|2018-06-01 05:24:52.743347
NCT00025636|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 2001||2001-07-31|June 2007|2007-06-30||||||||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma|A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease|Unknown status|Active, not recruiting|Phase 3|220|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:52.90778|2018-06-01 05:24:52.90778
NCT00025623|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1999||1999-07-31|December 2002|2002-12-31|March 2009|Actual|2009-03-31|||||Interventional|||Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma|European Infant Neuroblastoma Study - Stage 4 With Bone, Lung, Pleura or CNS Involvement; MYCN Not Amplified|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:53.071862|2018-06-01 05:24:53.071862
NCT00025610|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1999||1999-07-31|November 2001|2001-11-30|March 2009|Actual|2009-03-31|||||Interventional|||Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma|European Infant Neuroblastoma Study - Stage 4S and Stage 4 (No Bone, Lung, Pleura or CNS); MYCN Not Amplified|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:53.17463|2018-06-01 05:24:53.17463
NCT00025597|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1999||1999-07-31|November 2001|2001-11-30|February 2011|Actual|2011-02-28|||||Interventional|||Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.|European Infant Neuroblastoma Study - Unresectable Tumors (MYCN Not Amplified)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:53.304253|2018-06-01 05:24:53.304253
NCT00025584|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2001||2001-08-31|January 2013|2013-01-31||||August 2004|Actual|2004-08-31||Interventional|||PS-341 in Treating Women With Metastatic Breast Cancer|Phase II Trial Of PS-341 In Metastatic Breast Cancer|Completed||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:53.413054|2018-06-01 05:24:53.413054
NCT00025558|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2011-03-25|2003-01-26|2003-01-27|Estimate|||||||2011-03-25|2011-03-28|Estimate|October 2000||2000-10-31|March 2011|2011-03-31||||May 2007|Actual|2007-05-31||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer|Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:24:53.544763|2018-06-01 05:24:53.544763
NCT00025519|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-07-10|2003-01-26|2003-01-27|Estimate|||||||2013-07-10|2013-07-11|Estimate|June 2001||2001-06-30|July 2013|2013-07-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer|Submyeloablative Allogeneic Blood Stem Cell Transplantation With HLA Identical Donor Lymphocyte Infusions From Matched Related and Matched Unrelated Donors for Treatment of Metastatic Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|Fox Chase Cancer Center|||||f||||f||||||||||2018-06-01 05:24:53.640574|2018-06-01 05:24:53.640574
NCT00025506|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|2015-05-07||2017-12-20|2003-01-26|2003-01-27|Estimate|2015-05-07|2015-05-27|Estimate||||2017-12-20|2018-01-19|Actual|September 2001||2001-09-30|December 2017|2017-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Eligible and treated patients.|Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus|A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-06-01 05:24:53.7661|2018-06-01 05:24:53.7661
NCT00025493|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-24|Estimate|October 2001||2001-10-31|January 2013|2013-01-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer|Single Agent Docetaxel for Metastatic Breast Cancer in Patients Aged 70 Years and Older (and in a Cohort of Patients Younger Than 60 Years)|Terminated||Phase 2|27|Actual|Southwest Oncology Group||1||poor accrual|f||||t||||||||||2018-06-01 05:24:54.487943|2018-06-01 05:24:54.487943
NCT00025480|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2001||2001-08-31|April 2007|2007-04-30||||||||Interventional|||Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer|Completed||Phase 1|12|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:24:54.699099|2018-06-01 05:24:54.699099
NCT00025454|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2010-02-05|2003-01-26|2003-01-27|Estimate|||||||2010-02-05|2010-02-08|Estimate|August 2001||2001-08-31|February 2010|2010-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||R115777 in Treating Patients With Advanced Solid Tumors|Phase I Trial of R115777 (NSA 702818) in Advanced Malignant Solid Tumors|Completed||Phase 1|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:24:54.881806|2018-06-01 05:24:54.881806
NCT00025441|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|November 1998||1998-11-30|November 2001|2001-11-30|March 2010|Actual|2010-03-31|||||Interventional|||Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors|MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:55.081512|2018-06-01 05:24:55.081512
NCT00025428|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|December 2000||2000-12-31|November 2006|2006-11-30|November 2013|Actual|2013-11-30|||||Interventional|||Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma|Treatment Of Children Over The Age Of 1 Year With Unresectable Localized Neuroblastoma Without MYCN Amplification|Completed||Phase 3|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:55.487564|2018-06-01 05:24:55.487564
NCT00025415|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-02-06|2003-01-26|2003-01-27|Estimate|||||||2013-02-06|2013-02-07|Estimate|August 2001||2001-08-31|February 2013|2013-02-28||||January 2005|Actual|2005-01-31||Interventional|||Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction|A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:24:55.65497|2018-06-01 05:24:55.65497
NCT00025402|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 1997||1997-07-31|July 2002|2002-07-31||||||||Interventional|||Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia|Randomized Multicenter Treatment Optimization Study In Chronic Myeloid Leukemia (CML) Interferon-a Vs. Allogeneic Stem Cell Transplantation Vs. High-Dose Chemotherapy Followed By Autografting And Interferon-a Maintainance In Early Chronic Phase|Unknown status|Active, not recruiting|Phase 3|1000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:55.938114|2018-06-01 05:24:55.938114
NCT00025389|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 2001||2001-11-30|February 2013|2013-02-28|August 2007|Actual|2007-08-31|December 2005|Actual|2005-12-31||Interventional|||Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer|A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer|Completed||Phase 2|8|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:24:56.305577|2018-06-01 05:24:56.305577
NCT00025363|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-01-16|2003-01-26|2003-01-27|Estimate|||||||2013-01-16|2013-01-17|Estimate|November 2001||2001-11-30|January 2013|2013-01-31||||October 2007|Actual|2007-10-31||Interventional|||Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma|A Groupwide Randomized Phase II Window Study of Two Different Schedules of Irinotecan in Combination With Vincristine And Pilot Assessment of Safety and Efficacy of Tirapazamine Combined With Multiagent Chemotherapy for First Relapse or Progressive Disease in Rhabdomyosarcoma and Related Tumors|Completed||Phase 2|150|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:24:56.456004|2018-06-01 05:24:56.456004
NCT00025337|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|September 2001||2001-09-30|January 2013|2013-01-31||||April 2007|Actual|2007-04-30||Interventional|||Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated|Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer|Completed||Phase 3|880|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:24:56.645614|2018-06-01 05:24:56.645614
NCT00025324|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 2000||2000-12-31|December 2004|2004-12-31||||||||Interventional|||Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors|Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:24:56.757042|2018-06-01 05:24:56.757042
NCT00025311|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2012-11-08|2003-01-26|2003-01-27|Estimate|||||||2012-11-08|2012-11-09|Estimate|May 2001||2001-05-31|March 2003|2003-03-31||||October 2003|Actual|2003-10-31||Interventional|||Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain|A Phase I Study Of Seven Day Continuous Intrathecal/Intraventricular Infusion Of Topotecan For Patients With Recurrent, Progressive Or Refractory Leptomingeal Disease|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:24:56.850337|2018-06-01 05:24:56.850337
NCT00025298|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 2001||2001-07-31|September 2012|2012-09-30||||October 2002|Actual|2002-10-31||Interventional|||Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx|A Feasibility Study Of Primary Chemotherapy Followed By Concomitant Chemoradiation With And Without Amifostine In Patients With Locally Advanced Undifferentiated Nasopharyngeal Cancer (UNPC)|Terminated||Phase 2|5|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:24:57.010368|2018-06-01 05:24:57.010368
NCT00025285|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2017-04-17|2003-01-26|2003-01-27|Estimate|||||||2017-04-17|2017-04-19|Actual|November 2001|Actual|2001-11-30|August 2009|2009-08-31|September 29, 2004|Actual|2004-09-29|September 29, 2004|Actual|2004-09-29||Interventional|||Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer|Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|46|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:24:57.168252|2018-06-01 05:24:57.168252
NCT00025272|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2017-04-17|2003-01-26|2003-01-27|Estimate|||||||2017-04-17|2017-04-19|Actual|November 2001|Actual|2001-11-30|August 2009|2009-08-31|January 18, 2005|Actual|2005-01-18|January 18, 2005|Actual|2005-01-18||Interventional|||Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer|Phase II Study of Sequential Topotecan-Carboplatin-Etoposide in Patients With Extensive Stage Small Cell Lung Cancer|Completed||Phase 2|14|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:24:57.313708|2018-06-01 05:24:57.313708
NCT00025259|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|2016-10-19||2017-03-15|2003-01-26|2003-01-27|Estimate|2017-01-13|2017-03-07|Actual||||2017-03-15|2017-04-12|Actual|September 2002||2002-09-30|May 2016|2016-05-31||||August 2012|Actual|2012-08-31||Interventional|||Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease|A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease|Completed||Phase 3|1734|Actual|Children's Oncology Group||7|||f||||||||||||||2018-06-01 05:24:57.599478|2018-06-01 05:24:57.599478
NCT00025246|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-02-19|2003-01-26|2003-01-27|Estimate|||||||2013-02-19|2013-02-20|Estimate|September 2001||2001-09-30|January 2013|2013-01-31||||November 2007|Actual|2007-11-30||Interventional|||Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery|A Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST)|Completed||Phase 2|89|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:00.495365|2018-06-01 05:25:00.495365
NCT00025233|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|2015-06-10||2017-12-27|2003-01-26|2003-01-27|Estimate|2015-06-10|2015-06-29|Estimate||||2017-12-27|2018-01-23|Actual|April 2002||2002-04-30|December 2017|2017-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||Eligible and treated patients.|Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix|A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:00.598984|2018-06-01 05:25:00.598984
NCT00025220|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2015-03-13|2003-01-26|2003-01-27|Estimate|||||||2015-03-13|2015-03-17|Estimate|September 2001||2001-09-30|December 2012|2012-12-31|July 2008|Actual|2008-07-31|April 2003|Actual|2003-04-30||Interventional|||Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus|A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:01.426855|2018-06-01 05:25:01.426855
NCT00025194|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 2001||2001-07-31|November 2005|2005-11-30|July 2006|Actual|2006-07-31|||||Interventional|||Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer|A Phase I And Randomized Phase 2 Trial Of Epothilone B Analogue BMS 247550 (NSC # 710428) Administered Every 21 Days With Or Without Oral Estramustine Phosphate In Patients With Androgen Independent Prostate Cancer|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:03.645503|2018-06-01 05:25:03.645503
NCT00025181|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2014-05-20|2003-01-26|2003-01-27|Estimate|||||||2014-05-20|2014-05-22|Estimate|October 2001||2001-10-31|May 2014|2014-05-31|June 2005|Actual|2005-06-30|January 2003|Actual|2003-01-31||Interventional|||Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery|An Open-label Study Of MDX-CTLA4 In Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Resected Stage III Or Stage IV Melanoma|Completed||Phase 1|19|Actual|University of Southern California|||||f||||t||||||||||2018-06-01 05:25:07.599673|2018-06-01 05:25:07.599673
NCT00025168|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2017-04-17|2003-01-26|2003-01-27|Estimate|||||||2017-04-17|2017-04-19|Actual|November 2001|Actual|2001-11-30|April 2017|2017-04-30|August 29, 2003|Actual|2003-08-29|August 29, 2003|Actual|2003-08-29||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer|Phase II Trial Of Induction Gemcitabine/CPT-11 Followed By Twice-Weekly Infusion Gemcitabine And Concurrent External Beam Radiation For The Treatment Of Locally Advanced Pancreatic Cancer|Completed||Phase 2|20|Actual|Wake Forest University Health Sciences|||||f||||||||||||||2018-06-01 05:25:08.445373|2018-06-01 05:25:08.445373
NCT00025155|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|2015-04-29||2018-01-03|2003-01-26|2003-01-27|Estimate|2015-06-17|2015-07-13|Estimate||||2018-01-03|2018-01-29|Actual|July 2002||2002-07-31|January 2018|2018-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Patients who were eligible and received any study treatment.|Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy|A Phase II Evaluation of Epothilone-B BMS 247550 (NSC # 710428) in the Treatment of Recurrent or Persistent Platinum and Paclitaxel Refractory Ovarian or Primary Peritoneal Cancer|Completed||Phase 2|51|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:08.576276|2018-06-01 05:25:08.576276
NCT00025142|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|July 2001||2001-07-31|February 2005|2005-02-28|November 2006|Actual|2006-11-30|||||Interventional|||Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer|A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:10.288339|2018-06-01 05:25:10.288339
NCT00025129|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 2001||2001-03-31|March 2004|2004-03-31|May 2004|Actual|2004-05-31|||||Interventional|||VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial of VNP4010M, A Novel Alkylating Agent for Patients With Advanced or Metastatic Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:10.367013|2018-06-01 05:25:10.367013
NCT00025103|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2001||2001-05-31|June 2009|2009-06-30||||November 2008|Anticipated|2008-11-30||Interventional|||Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney|Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK)|Unknown status|Active, not recruiting|Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:10.464394|2018-06-01 05:25:10.464394
NCT00025090|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|March 2001||2001-03-31|March 2007|2007-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer|Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer|Completed||Phase 3|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:10.636579|2018-06-01 05:25:10.636579
NCT00025077|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 2000||2000-01-31|June 2007|2007-06-30|April 2011|Actual|2011-04-30|||||Interventional|||Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors|Treatment Of Recurrent Central Nervous System Primitive Neuroectodermal Tumors (PNETs) In Children And Adolescents A Strategy Including The Use Of High Dose Thiotepa And High Dose Carboplatin|Completed||Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:10.768038|2018-06-01 05:25:10.768038
NCT00025064|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2000||2000-01-31|December 2002|2002-12-31||||||||Interventional|||Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma|Protocol For The Treatment Of Children And Adolescents With Hodgkin's Disease|Unknown status|Active, not recruiting|Phase 2|260|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:10.88425|2018-06-01 05:25:10.88425
NCT00025051|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-03-21|2003-01-26|2003-01-27|Estimate|||||||2013-03-21|2013-03-22|Estimate||||December 2006|2006-12-31||||||||Interventional|||Celecoxib in Preventing Skin Cancer|A Phase II, Double-Blind, Placebo-Controlled Clinical Trial To Assess Celecoxib As A Chemopreventive Agent Inhibiting UV-Induced Erythema And Cutaneous Carcinogenesis As Assessed Through Surrogate Biological Markers In Biopsied Skin After Exposure Of Skin In Normal Volunteers Ages 20-60 Years Old With Fitzpatrick Type I, II, III And IV Skin To UV-Radiation From Artificial Light Sources|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:11.05267|2018-06-01 05:25:11.05267
NCT00025038|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2013-04-10|2003-01-26|2003-01-27|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 2001||2001-06-30|January 2013|2013-01-31||||October 2007|Actual|2007-10-31||Interventional|||Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia|Phase II Window Evaluation of the Farnesyl Transferase Inhibitor (R115777) Followed by 13-CIS Retinoic Acid, Cytosine Arabinoside and Fludarabine Plus Hematopoietic Stem Cell Transplantation in Children With Juvenile Myelomonocytic Leukemia|Completed||Phase 2|100|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:11.139312|2018-06-01 05:25:11.139312
NCT00025025|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-04|Estimate|October 2001||2001-10-31|July 2016|2016-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Screening Tests in Detecting Colorectal Cancer|Colorectal Cancer Screening: Fecal Blood vs. DNA|Completed|||4482|Actual|Alliance for Clinical Trials in Oncology|||2||f||||f||||||||||2018-06-01 05:25:11.409052|2018-06-01 05:25:11.409052
NCT00024466|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2014-05-01|2003-01-26|2003-01-27|Estimate|||||||2014-05-01|2014-05-02|Estimate|March 2001||2001-03-31|May 2014|2014-05-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Chemotherapy, Vaccine Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Multiple Myeloma|Vaccination In Peripheral Stem Cell Transplant Setting For Multiple Myeloma: The Use Of Autologous Tumor Cells/An Allo PSCT|Completed||Phase 1/Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:25:11.597542|2018-06-01 05:25:11.597542
NCT00024453|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|February 1999||1999-02-28|June 2009|2009-06-30||||December 2009|Anticipated|2009-12-31||Interventional|||Teicoplanin in Treating Septicemia in Patients Who Are Receiving Chemotherapy Through a Central Venous Catheter|The Use of Teicoplanin in the Treatment of Septicaemia Caused by Coagulase-Negative Staphylococci - A Randomized Study Comparing Bolus Injection With Infused and/or Line-Locked Teicoplanin|Unknown status|Active, not recruiting|N/A|1360|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:11.701955|2018-06-01 05:25:11.701955
NCT00024440|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|July 2001||2001-07-31|October 2003|2003-10-31|February 2007|Actual|2007-02-28|||||Interventional|||Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:11.802491|2018-06-01 05:25:11.802491
NCT00024427|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2012-06-27|2003-01-26|2003-01-27|Estimate|||||||2012-06-27|2012-06-28|Estimate|February 2001||2001-02-28|May 2010|2010-05-31||||February 2006|Actual|2006-02-28||Interventional|||Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer|An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer|Completed||Phase 3|250|Actual|Wellstat Therapeutics|||||f||||f||||||||||2018-06-01 05:25:11.915871|2018-06-01 05:25:11.915871
NCT00024414|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|April 2001||2001-04-30|March 2003|2003-03-31||||||||Interventional|||DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer|Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:12.24977|2018-06-01 05:25:12.24977
NCT00024375|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2009-02-17|2003-01-26|2003-01-27|Estimate|||||||2009-02-17|2009-02-18|Estimate|June 2001||2001-06-30|March 2003|2003-03-31||||||||Interventional|||DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer|Phase II Open-Label Study of Taxoperxin (DHA-Paclitaxel) Injection by 2 Hour Intravenous Infusion in Patients With Metastatic Cancer of the Pancreas|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:12.345222|2018-06-01 05:25:12.345222
NCT00024349|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 2001||2001-06-30|May 2007|2007-05-31|April 2012|Actual|2012-04-30|||||Interventional|||Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer|2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer|Completed||Phase 3|350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:12.515097|2018-06-01 05:25:12.515097
NCT00024336|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 1999||1999-08-31|December 2006|2006-12-31||||||||Interventional|||Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma|Treatment of Children With Newly Diagnosed Diffuse Pontine Gliomas Using Conventional Radiotherapy and High Dose Tamoxifen|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:12.752588|2018-06-01 05:25:12.752588
NCT00024297|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 1999||1999-10-31|December 2002|2002-12-31|February 2009|Actual|2009-02-28|||||Interventional|||Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters|A Multicenter Prospective Randomized Controlled Trial of Thrombosis Prophylaxis With Warfarin in Cancer Patients With Central Venous Catheters|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:12.996147|2018-06-01 05:25:12.996147
NCT00024284|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-04-03|2003-01-26|2003-01-27|Estimate|||||||2013-04-03|2013-04-05|Estimate|June 2001||2001-06-30|April 2013|2013-04-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors|A Phase I Study Of Carboplatin And Irinotecan In Patients 1-21 Years Of Age With Refractory Solid Tumors|Completed||Phase 1|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:25:13.302565|2018-06-01 05:25:13.302565
NCT00024271|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 2001||2001-05-31|January 2004|2004-01-31||||||||Interventional|||Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer|Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:13.417913|2018-06-01 05:25:13.417913
NCT00024258|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|2015-10-22||2015-10-22|2003-01-26|2003-01-27|Estimate|2015-10-22|2015-11-25|Estimate||||2015-10-22|2015-11-25|Estimate|March 2001||2001-03-31|October 2015|2015-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors|Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors|Completed||Phase 2|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:25:13.507607|2018-06-01 05:25:13.507607
NCT00024245|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2001||2001-05-31|March 2003|2003-03-31|April 2003|Actual|2003-04-30|||||Interventional|||10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors|Phase I and Clinical Pharamcologic Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Combination With Probenecid in Adults With Advanced Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:13.825909|2018-06-01 05:25:13.825909
NCT00024232|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2001||2001-06-30|June 2013|2013-06-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer|Pilot Trial of Humanized Monoclonal Antibody J591 in Patients With Progressive Androgen-Independent Prostate Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:25:13.935935|2018-06-01 05:25:13.935935
NCT00024193|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 1999||1999-04-30|November 2001|2001-11-30||||||||Interventional|||Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma|A Study Of The Treatment Of Metastatic Neuroblastoma In Children More Than One Year Of Age At Diagnosis|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:14.039115|2018-06-01 05:25:14.039115
NCT00024180|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-01-30|2003-01-26|2003-01-27|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2002||2002-01-31|November 2002|2002-11-30|August 2006|Actual|2006-08-31|||||Interventional|||FR901228 in Treating Patients With Hematologic Cancer|A Phase I Study of Depsipeptide in Selected Hematologic Malignancies (NSC 630176)|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:14.140388|2018-06-01 05:25:14.140388
NCT00024167|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|2016-01-22||2016-02-19|2003-01-26|2003-01-27|Estimate|2016-02-19|2016-03-22|Estimate||||2016-02-19|2016-03-22|Estimate|April 2002||2002-04-30|February 2016|2016-02-29||||September 2014|Actual|2014-09-30||Interventional||Of the 265 participants enrolled - 133 participants received only induction treatment and 127 were randomized to either the Sr-89 treatment arm or the no Sr-89 treatment arm. 5 participants never received any treatment.|Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer|A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer|Terminated||Phase 3|265|Actual|M.D. Anderson Cancer Center||4||Terminated due to slow accrual|f||||t||||||||||2018-06-01 05:25:14.298578|2018-06-01 05:25:14.298578
NCT00024154|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|February 2002||2002-02-28|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer|A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2)|Completed||Phase 2|132|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:15.323601|2018-06-01 05:25:15.323601
NCT00024115|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2015-04-27|2003-01-26|2003-01-27|Estimate|||||||2015-04-27|2015-04-28|Estimate||||December 2006|2006-12-31||||||||Interventional|||BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Withdrawn||Phase 1|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:15.42677|2018-06-01 05:25:15.42677
NCT00024102|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|2012-11-20||2016-07-12|2003-01-26|2003-01-27|Estimate|2012-12-21|2013-01-31|Estimate||||2016-07-12|2016-08-12|Estimate|September 2001||2001-09-30|July 2016|2016-07-31|November 2012|Actual|2012-11-30|May 2008|Actual|2008-05-31||Interventional|||Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer|A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer|Completed||Phase 3|633|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:25:15.722333|2018-06-01 05:25:15.722333
NCT00024089|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|July 2001||2001-07-31|November 2005|2005-11-30||||March 2006|Actual|2006-03-31||Interventional|||Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer|A Phase II Study of ZD 1839 (Iressa) in Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:17.333009|2018-06-01 05:25:17.333009
NCT00024076|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2015-10-28|2003-01-26|2003-01-27|Estimate|||||||2015-10-28|2015-10-30|Estimate|May 2000||2000-05-31|July 2012|2012-07-31||||December 2006|Actual|2006-12-31||Interventional|||Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer|Radiofrequency Ablation of Pulmonary Malignancy|Completed||Phase 2|30|Actual|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:25:17.467412|2018-06-01 05:25:17.467412
NCT00024050|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2010-05-12|2003-01-26|2003-01-27|Estimate|||||||2010-05-12|2010-05-13|Estimate|February 2001||2001-02-28|May 2010|2010-05-31|August 2007|Actual|2007-08-31|||||Interventional|||Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome|"Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for the Treatment of Less Advanced Myelodysplasi"|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:25:17.559269|2018-06-01 05:25:17.559269
NCT00023998|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-02-01|2003-01-26|2003-01-27|Estimate|||||||2013-02-01|2013-02-04|Estimate|July 2001||2001-07-31|January 2013|2013-01-31|May 2007||2007-05-31|November 2005|Actual|2005-11-30||Interventional|||Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma|A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2|Completed||Phase 2|80|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:17.628161|2018-06-01 05:25:17.628161
NCT00023985|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2011-03-03|2003-01-26|2003-01-27|Estimate|||||||2011-03-03|2011-03-07|Estimate|January 2001||2001-01-31|March 2011|2011-03-31|August 2003|Actual|2003-08-31|July 2003|Actual|2003-07-31||Interventional|||Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer|Vaccination With Autologous Tumor Lysate-Pulsed Dendritic Cells - Phase I|Completed||Phase 1|||Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:25:17.919263|2018-06-01 05:25:17.919263
NCT00023972|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2012-05-15|2003-01-26|2003-01-27|Estimate|||||||2012-05-15|2012-05-16|Estimate|July 2001||2001-07-31|May 2012|2012-05-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Randomized, Open-Label, Multicenter Phase III Study Comparing the Efficacy and Safety of a Combination of Intravenous DX-8951f (Exatecan Mesylate) Plus Gemcitabine to Gemcitabine Alone in Patients With Locally Advanced or Metastatic Cancer of the Exocrine Pancreas Who Have Not Received Prior Chemotherapy|Completed||Phase 3|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:25:18.050101|2018-06-01 05:25:18.050101
NCT00023959|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-02-06|2003-01-26|2003-01-27|Estimate|||||||2013-02-06|2013-02-07|Estimate|July 2001||2001-07-31|February 2013|2013-02-28||||March 2010|Actual|2010-03-31||Interventional|||Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer|A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer|Completed||Phase 1|39|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:18.257035|2018-06-01 05:25:18.257035
NCT00023946|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2014-05-13|2003-01-26|2003-01-27|Estimate|||||||2014-05-13|2014-05-14|Estimate|August 2001||2001-08-31|December 2012|2012-12-31|November 2009|Actual|2009-11-30|July 2005|Actual|2005-07-31||Interventional|||BMS-247550 in Treating Patients With Liver or Gallbladder Cancer|A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer|Terminated||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:18.430577|2018-06-01 05:25:18.430577
NCT00023920|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||September 2004|Actual|2004-09-30||Interventional|||Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia|A Phase II Study of Bevacizumab (rhuMab VEGF, NSC 704865), Idarubicin and Cytarabine in Patients With Chronic Myeloid Leukemia in Blast Phase|Terminated||Phase 2|60|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:25:18.64641|2018-06-01 05:25:18.64641
NCT00023894|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 2001||2001-07-31|May 2004|2004-05-31|February 2006|Actual|2006-02-28|||||Interventional|||Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Flavopiridol (NSC# 649890) in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:18.773949|2018-06-01 05:25:18.773949
NCT00023881|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2012-10-05|2003-01-26|2003-01-27|Estimate|||||||2012-10-05|2012-10-10|Estimate|July 2001||2001-07-31|October 2012|2012-10-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Bortezomib in Treating Patients With Chronic Myelogenous Leukemia|Phase II Study of a Proteasome Inhibitor, PS-341 (NSC 681239) in Chronic Myelogenous Leukemia (CML) in Chronic or Accelerated Phase|Completed||Phase 2|7|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:25:18.935647|2018-06-01 05:25:18.935647
NCT00023855|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2015-09-30|2003-01-26|2003-01-27|Estimate|||||||2015-09-30|2015-10-02|Estimate|June 2001||2001-06-30|September 2015|2015-09-30||||October 2003|Actual|2003-10-31||Interventional|||PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors|A Phase I and Pharmacodynamic Study of Proteasome Inhibitor, PS-341, in Combination With Doxorubicin in Patients With Advanced Solid Tumors|Completed||Phase 1|||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:25:19.072994|2018-06-01 05:25:19.072994
NCT00023842|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2001||2001-06-30|September 2012|2012-09-30||||February 2005|Actual|2005-02-28||Interventional|||BCG With or Without Mitomycin in Treating Patients With Bladder Cancer|A Randomized Phase II Trial of Sequential Chemo-Immunotherapy Versus Immunotherapy Alone in Carcinoma in Situ of the Urinary Bladder|Completed||Phase 2|97|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:25:19.1881|2018-06-01 05:25:19.1881
NCT00023829|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-11-12|2003-01-26|2003-01-27|Estimate|||||||2013-11-12|2013-11-13|Estimate|August 2001||2001-08-31|November 2013|2013-11-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer|Phase III Randomized Study of Adjuvant Therapy for High Risk pT3N0 Prostate Cancer|Completed||Phase 3|67|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-06-01 05:25:20.261181|2018-06-01 05:25:20.261181
NCT00023790|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2011-08-23|2003-01-26|2003-01-27|Estimate|||||||2011-08-23|2011-08-24|Estimate|August 2001||2001-08-31|August 2011|2011-08-31|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin|Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies|Terminated||Phase 1|3|Actual|Case Comprehensive Cancer Center||||slow accrual|f||||t||||||||||2018-06-01 05:25:20.408994|2018-06-01 05:25:20.408994
NCT00023777|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2015-03-05|2003-01-26|2003-01-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2001||2001-08-31|March 2015|2015-03-31|April 2008|Actual|2008-04-30|June 2003|Actual|2003-06-30||Interventional|||S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia|A Phase II Study Of Daunomycin And ARA-C, Both Given By Continous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older|Completed||Phase 2|71|Actual|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:25:20.58774|2018-06-01 05:25:20.58774
NCT00023764|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|2013-10-23||2015-11-02|2003-01-26|2003-01-27|Estimate|2014-02-17|2014-04-01|Estimate||||2015-11-02|2015-12-08|Estimate|June 2001||2001-06-30|December 2012|2012-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Bortezomib in Treating Patients With Lymphoproliferative Disorders|Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders|Completed||Phase 2|103|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:20.972926|2018-06-01 05:25:20.972926
NCT00023751|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|July 2001||2001-07-31|July 2016|2016-07-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer|A Phase II Study of Local Excision Alone or Local Excision Plus Adjuvant Chemoradiation Therapy for Small Distal Rectal Cancers|Completed||Phase 2|320|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:25:21.452164|2018-06-01 05:25:21.452164
NCT00023712|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|2013-09-17||2017-10-25|2003-01-26|2003-01-27|Estimate|2013-09-17|2013-11-20|Estimate||||2017-10-25|2017-12-02|Actual|November 5, 2001|Actual|2001-11-05|October 2017|2017-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Cohort 1: 2 participants were not eligible/evaluable after enrollment. Cohort 2: 1 participant was not eligible/evaluable after enrollment.|Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Bortezomib (Velcade™, PS-341, NSC #681239, IND #58443) in the Treatment of Persistent or Recurrent Platinum-Sensitive Epithelial Ovarian or Primary Peritoneal Cancer|Completed||Phase 2|58|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:21.928137|2018-06-01 05:25:21.928137
NCT00023686|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|October 2001||2001-10-31|July 2016|2016-07-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer|A Randomized Trial of Radical Prostatectomy Versus Brachytherapy for Patients With T1c or T2a N0 M0 Prostate Cancer|Completed||Phase 3|190|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:25:22.887683|2018-06-01 05:25:22.887683
NCT00023660|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-11-18|2003-01-26|2003-01-27|Estimate|||||||2013-11-18|2013-11-19|Estimate|August 2001||2001-08-31|November 2013|2013-11-30||||January 2005|Actual|2005-01-31||Interventional|||Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer|A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer|Completed||Phase 1/Phase 2|84|Actual|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:25:23.185922|2018-06-01 05:25:23.185922
NCT00023634|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2015-03-05|2003-01-26|2003-01-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2001||2001-06-30|March 2015|2015-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer|An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers|Terminated||Phase 1|14|Actual|Southwest Oncology Group||2||lack of accrual|f||||t||||||||||2018-06-01 05:25:23.420662|2018-06-01 05:25:23.420662
NCT00023621|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-13|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|February 2001||2001-02-28|July 2007|2007-07-31|July 2007|Actual|2007-07-31|||||Interventional|||Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome|Completed||Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:23.585454|2018-06-01 05:25:23.585454
NCT00022737|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2014-02-26|2003-01-26|2003-01-27|Estimate|||||||2014-02-26|2014-02-27|Estimate|October 2002||2002-10-31|November 2012|2012-11-30||||October 2006|Actual|2006-10-31||Interventional|||Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia|A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051)|Completed||Phase 3|220|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:23.681941|2018-06-01 05:25:23.681941
NCT00022724|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2008-11-22|2003-01-26|2003-01-27|Estimate|||||||2008-11-22|2008-11-25|Estimate|December 2001||2001-12-31|January 2005|2005-01-31||||||||Interventional|||CCI-779 in Treating Patients With Malignant Glioma|Phase I/II Trial Of CCI-779 In Patients With Malignant Glioma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:23.895435|2018-06-01 05:25:23.895435
NCT00022711|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-07-10|2003-01-26|2003-01-27|Estimate|||||||2013-07-10|2013-07-11|Estimate|January 2002||2002-01-31|July 2013|2013-07-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer|A Phase II Study of Temozolomide (SCH 52365) in the Treatment of Patients With Relapsed Small Cell Lung Cancer|Completed||Phase 2|7|Actual|Fox Chase Cancer Center||1|||f||||f||||||||||2018-06-01 05:25:24.071806|2018-06-01 05:25:24.071806
NCT00022698|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|2016-03-16||2016-03-16|2003-01-26|2003-01-27|Estimate|2016-03-16|2016-04-15|Estimate||||2016-03-16|2016-04-15|Estimate|May 2001||2001-05-31|February 2005|2005-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional||The All Patients Population included participants who received at least one dose of study drug in Cohort 1 or Cohort 2.|Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer|A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer|Completed||Phase 2|67|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:25:24.368557|2018-06-01 05:25:24.368557
NCT00022685|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2001||2001-09-30|April 2003|2003-04-30||||||||Interventional|||Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma|A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab)|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:25.190089|2018-06-01 05:25:25.190089
NCT00022672|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|2013-04-02||2013-06-07|2003-01-26|2003-01-27|Estimate|2013-06-07|2013-06-13|Estimate||||2013-06-07|2013-06-13|Estimate|January 2001||2001-01-31|June 2013|2013-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer|A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer|Completed||Phase 3|208|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:25:25.349109|2018-06-01 05:25:25.349109
NCT00022659|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|2015-04-23||2018-01-10|2003-01-26|2003-01-27|Estimate|2015-04-23|2015-05-12|Estimate||||2018-01-10|2018-02-06|Actual|April 2002||2002-04-30|January 2018|2018-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||Eligible and treated patients.|Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase II Evaluation of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 2|64|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:27.196279|2018-06-01 05:25:27.196279
NCT00022646|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|August 2001||2001-08-31|December 2016|2016-12-31|October 2008|Actual|2008-10-31|November 2003|Actual|2003-11-30||Interventional|||Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Clinical Trial Evaluating Three Schedules Of ALIMTA Plus Gemcitabine As Frontline Chemotherapy For Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|157|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-06-01 05:25:30.356641|2018-06-01 05:25:30.356641
NCT00022633|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|2012-11-26||2016-07-08|2003-01-26|2003-01-27|Estimate|2016-01-26|2016-02-24|Estimate||||2016-07-08|2016-08-11|Estimate|July 2001||2001-07-31|July 2016|2016-07-31|July 2011|Actual|2011-07-31|June 2008|Actual|2008-06-30||Interventional||All eligible patients who started treatment were included in the analysis|S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract|Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years)|Terminated||Phase 2|65|Actual|Southwest Oncology Group||1||Permanently Closed Due to Poor Accrual|f||||f||||||||||2018-06-01 05:25:30.514666|2018-06-01 05:25:30.514666
NCT00022620|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2001||2001-06-30|September 2012|2012-09-30||||October 2002|Actual|2002-10-31||Interventional|||Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer|Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC)|Completed||Phase 2|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:25:31.538752|2018-06-01 05:25:31.538752
NCT00022607|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|January 2002||2002-01-31|October 2004|2004-10-31|May 2006|Actual|2006-05-31|||||Interventional|||Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:31.670542|2018-06-01 05:25:31.670542
NCT00022581|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-01-04|2003-01-26|2003-01-27|Estimate|||||||2013-01-04|2013-01-07|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||December 2004|Actual|2004-12-31||Interventional|||Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial of Thalidomide (NSC #66847, IND #48832) for Patients With Relapsed or Refractory Low Grade Non-Hodgkin's Lymphoma|Completed||Phase 2|45|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:31.753169|2018-06-01 05:25:31.753169
NCT00022568|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2001||2001-08-31|December 2003|2003-12-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:31.946257|2018-06-01 05:25:31.946257
NCT00022555|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-01-24|2003-01-26|2003-01-27|Estimate|||||||2013-01-24|2013-01-25|Estimate|November 2001||2001-11-30|January 2013|2013-01-31||||July 2003|Actual|2003-07-31||Interventional|||Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma|A Phase I Trial of Combination Bryostatin-1 and Vincristine in HIV-Related B-cell Neoplasms|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:32.048709|2018-06-01 05:25:32.048709
NCT00022516|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|2015-11-06||2016-08-05|2003-01-26|2003-01-27|Estimate|2015-11-06|2015-12-11|Estimate||||2016-08-05|2016-09-16|Estimate|November 2000||2000-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|January 2015|Actual|2015-01-31||Interventional|22-00|Patients who started overall study|Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer|"Low-dose Cytotoxics as Anti-angiogenesis Treatment Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer"|Completed||Phase 3|1086|Actual|International Breast Cancer Study Group|This trial collected only Grade 3 or higher Adverse Events.|2|||f||||t||||||||||2018-06-01 05:25:32.181025|2018-06-01 05:25:32.181025
NCT00022490|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|2012-06-06||2015-12-08|2003-01-26|2003-01-27|Estimate|2012-06-06|2012-07-11|Estimate||||2015-12-08|2016-01-07|Estimate|June 2001||2001-06-30|December 2015|2015-12-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia|A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase|Terminated||Phase 2|24|Actual|OHSU Knight Cancer Institute|Study was terminated, therefore the 12 month response data was not analyzed.|1|||f||||t||||||||||2018-06-01 05:25:32.815476|2018-06-01 05:25:32.815476
NCT00022464|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2015-06-03|2003-01-26|2003-01-27|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2001||2001-06-30|June 2015|2015-06-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||CCI-779 in Treating Patients With Metastatic Melanoma|A Phase II Study Of CCI-779 (NSC 683864) In Metastatic Melanoma|Completed||Phase 2|||City of Hope Medical Center|||||f||||||||||||||2018-06-01 05:25:33.019413|2018-06-01 05:25:33.019413
NCT00022451|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2001||2001-06-30|March 2012|2012-03-31|March 2005|Actual|2005-03-31|||||Interventional|||Tipifarnib in Treating Young Patients With Refractory Leukemia|A Phase I Trial and Pharmacokinetic Study of R115777 in Pediatric Patients With Refractory Leukemia|Completed||Phase 1|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:33.257832|2018-06-01 05:25:33.257832
NCT00022438|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2001||2001-06-30|July 2004|2004-07-31|August 2004|Actual|2004-08-31|||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment|Immunization of HLA-0201 Positive Patients With Metastatic Melanoma Using a Peptide From Tyrosinase-related Protein 2 (TRP-2)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:33.470624|2018-06-01 05:25:33.470624
NCT00022425|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 2001||2001-06-30|September 2003|2003-09-30||||||||Interventional|||Perillyl Alcohol in Preventing Recurrent Breast Cancer in Women Who Have Been Treated With Surgery With or Without Adjuvant Therapy|Multiple-Dose Phase I and Pharmacokinetic Trial of Perillyl Alcohol|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:33.607925|2018-06-01 05:25:33.607925
NCT00022412|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-10-10|2003-01-26|2003-01-27|Estimate|||||||2016-10-10|2016-10-11|Estimate|August 2001||2001-08-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|February 2006|Actual|2006-02-28||Interventional|||Doxercalciferol Before Surgery in Treating Localized Prostate Cancer|Phase II Open Label, Multi-Center Clinical Trial Of Modulation Of Intermediate Endpoint Biomarkers By 1x-Hydroxyvitamin D2 In Patients With Clinically Localized Prostate Cancer And High Grade PIN|Completed||Phase 2|60|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-06-01 05:25:33.680731|2018-06-01 05:25:33.680731
NCT00022399|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2011-02-18|2003-01-26|2003-01-27|Estimate|||||||2011-02-18|2011-02-21|Estimate|September 2001||2001-09-30|October 2004|2004-10-31||||||||Interventional|||Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer|A Randomized, Placebo-Controlled Trial Of Celecoxib In Men Pre-Prostatectomy For Clinically Localized Adenocarcinoma Of The Prostate: Evaluation Of Drug-Specific Biomarker Modulation|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:33.8912|2018-06-01 05:25:33.8912
NCT00022334|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2015-10-28|2003-01-26|2003-01-27|Estimate|||||||2015-10-28|2015-10-30|Estimate|January 2001||2001-01-31|July 2012|2012-07-31|October 2008|Actual|2008-10-31|December 2004|Actual|2004-12-31||Interventional|||Vaccine Therapy in Treating Patients With Liver Cancer|A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|33|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:25:34.082416|2018-06-01 05:25:34.082416
NCT00022295|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-03-25|2003-01-26|2003-01-27|Estimate|||||||2013-03-25|2013-03-26|Estimate|August 2001||2001-08-31|March 2007|2007-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Phenoxodiol in Treating Patients With Refractory Solid Tumors|Phase IB Study of Phenoxodiol Given by Constant Intravenous Infusion in Patients With Solid Neoplasms (With the Exception of Breast Cancer) Whose Tumors Are Refractory to Standard Therapy|Completed||Phase 1|36|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:34.245239|2018-06-01 05:25:34.245239
NCT00022230|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2015-05-04|2003-01-26|2003-01-27|Estimate|||||||2015-05-04|2015-05-05|Estimate|January 2000||2000-01-31|May 2015|2015-05-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer|Combination of Chemotherapy With Taxol, Adriamycin, and Cytoxan (TAC), Multiple Infusions of Activated T Cells (ATC), Interleukin-2 (IL-2) and GM-CSF for High Risk Breast Cancer With and Without Her2/Neu Overexpression. (Phase I/II)|Withdrawn||Phase 1/Phase 2|0|Actual|Roger Williams Medical Center||||PI left Institution|f||||t||||||||||2018-06-01 05:25:34.362659|2018-06-01 05:25:34.362659
NCT00022191|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-06-11|2003-01-26|2003-01-27|Estimate|||||||2013-06-11|2013-06-12|Estimate|May 2001||2001-05-31|June 2013|2013-06-30||||June 2004|Actual|2004-06-30||Interventional|||Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer|Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy|Completed||Phase 3|608|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:25:34.586876|2018-06-01 05:25:34.586876
NCT00022152|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|November 2001||2001-11-30|July 2016|2016-07-31|August 2007|Actual|2007-08-31|March 2006|Actual|2006-03-31||Interventional|||Vinorelbine in Treating Older Women With Stage IV Breast Cancer|Phase II Trial of Oral Vinorelbine for the Treatment of Metastatic Breast Cancer in Patients >65 Years of Age: A Trial of Efficacy, Toxicity, and Patients' Perceived Preference for Oral Therapy|Completed||Phase 2|25|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:25:35.017105|2018-06-01 05:25:35.017105
NCT00022126|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2014-02-18|2003-01-26|2003-01-27|Estimate|||||||2014-02-18|2014-02-20|Estimate|November 2002||2002-11-30|February 2014|2014-02-28|April 2006|Actual|2006-04-30|January 2005|Actual|2005-01-31||Interventional|||Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia|A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia|Completed||Phase 2|6|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:25:35.191752|2018-06-01 05:25:35.191752
NCT00022113|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-01-24|2003-01-26|2003-01-27|Estimate|||||||2013-01-24|2013-01-25|Estimate|May 2001||2001-05-31|January 2013|2013-01-31||||May 2005|Actual|2005-05-31||Interventional|||EMD 121974 in Treating Patients With Advanced Solid Tumors|A Phase I Study of EMD 121974 in Patients With Advanced Solid Tumors|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:35.398833|2018-06-01 05:25:35.398833
NCT00022087|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|December 2001||2001-12-31|July 2016|2016-07-31|February 2009|Actual|2009-02-28|March 2007|Actual|2007-03-31||Interventional|||Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer|Phase III Trial of Intravenous Zoledronic Acid (Zometa) in the Prevention of Bone Loss in Localized Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure|Completed||Phase 3|439|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:25:35.51954|2018-06-01 05:25:35.51954
NCT00022074|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2015-10-13|2003-01-26|2003-01-27|Estimate|||||||2015-10-13|2015-10-15|Estimate|July 2001||2001-07-31|October 2015|2015-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Gabapentin For the Control of Hot Flashes in Women With Breast Cancer|Control of Vasomotor Symptoms in Women Treated for Breast Cancer|Completed||N/A|||University of Rochester|||||f||||||||||||||2018-06-01 05:25:35.871865|2018-06-01 05:25:35.871865
NCT00022048|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|August 2001||2001-08-31|October 2004|2004-10-31|November 2004|Actual|2004-11-30|||||Interventional|||Bevacizumab in Treating Patients With Myelodysplastic Syndrome|Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS)|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:35.974346|2018-06-01 05:25:35.974346
NCT00022035|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-01-30|2003-01-26|2003-01-27|Estimate|||||||2013-01-30|2013-01-31|Estimate|August 2000||2000-08-31|January 2013|2013-01-31||||November 2002|Actual|2002-11-30||Interventional|||Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia|Influenza Vaccine Immunogenicity in Children During and After Therapy for Acute Lymphoblastic Leukemia|Completed||N/A|||Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:25:36.044665|2018-06-01 05:25:36.044665
NCT00022022|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 2000||2000-12-31|April 2006|2006-04-30||||||||Interventional|||Docetaxel in Treating Patients With Non-Small Cell Lung Cancer|Docetaxel In Second-Line Treatment Of Advanced Non-Small-Cell Lung Cancer - The Distal Study|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:36.139781|2018-06-01 05:25:36.139781
NCT00021450|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-13|||2016-09-01|2003-01-26|2003-01-27|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2001||2001-04-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|April 2008|Actual|2008-04-30||Interventional|||Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer|Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy Alone Vs Three Dimensional Conformal Therapy / Intensity Modulated Radiotherapy Plus Adjuvant Hormonal Therapy In Localized T1b-c, T2a, N0, M0 Prostatic Carcinoma. A Phase III Randomized Study|Completed||Phase 3|819|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:25:36.397112|2018-06-01 05:25:36.397112
NCT00021424|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2001||2001-06-30|August 2002|2002-08-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer|Phase I/Pilot Study of Intralesional Immunotherapy With A Recombinant Avipox Virus Engineered To Express A Triad Of Co-Stimulatory Molecules In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:36.590565|2018-06-01 05:25:36.590565
NCT00021320|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2014-05-07|2003-01-26|2003-01-27|Estimate|||||||2014-05-07|2014-05-09|Estimate|May 2000||2000-05-31|May 2014|2014-05-31|April 2009|Actual|2009-04-30|January 2004|Actual|2004-01-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer|Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer|Completed||Phase 2|21|Actual|Fox Chase Cancer Center|||||f||||||||||||||2018-06-01 05:25:36.68799|2018-06-01 05:25:36.68799
NCT00021255|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|2016-06-15||2016-09-26|2003-01-26|2003-01-27|Estimate|2016-09-26|2016-11-15|Estimate||||2016-09-26|2016-11-15|Estimate|April 2001||2001-04-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Intent-To-Treat (ITT) population included all randomized participants.|Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer|Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration|Completed||Phase 3|3222|Actual|Sanofi||3|||f||||||||||||||2018-06-01 05:25:36.852116|2018-06-01 05:25:36.852116
NCT00021242|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2014-08-07|2003-01-26|2003-01-27|Estimate|||||||2014-08-07|2014-08-08|Estimate|August 2002||2002-08-31|August 2014|2014-08-31|September 2006|Actual|2006-09-30|March 2006|Actual|2006-03-31||Interventional|||Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia|A Phase II Study of Docetaxel (Taxotere) (NSC# 628503, IND# 59,761) in Children With Refractory Leukemias|Completed||Phase 2|12|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:25:38.048193|2018-06-01 05:25:38.048193
NCT00021229|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|2010-02-09||2014-07-25|2003-01-26|2003-01-27|Estimate|2010-03-25|2010-04-09|Estimate||||2014-07-25|2014-07-31|Estimate|May 2001||2001-05-31|February 2013|2013-02-28|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma|A Phase I/II Trial Of STI571 In Children With Newly Diagnosed Poor Prognosis Brainstem Gliomas And Recurrent Intracranial Malignant Gliomas|Terminated||Phase 1/Phase 2|85|Actual|National Cancer Institute (NCI)|The phase II component of the trial was terminated because of poor accrual. Only one patient enrolled to the phase II component and did not receive the investigational drug.|1||Poor accrual|f||||t||||||||||2018-06-01 05:25:38.530466|2018-06-01 05:25:38.530466
NCT00021216|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-14|2003-01-26|2003-01-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|November 2001||2001-11-30|December 2013|2013-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Bortezomib in Treating Children With Advanced Solid Tumors|A Phase I Study Of PS-341 In Pediatric Patients With Refractory Solid Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:40.687143|2018-06-01 05:25:40.687143
NCT00021164|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|May 2001||2001-05-31|April 2004|2004-04-30|May 2004|Actual|2004-05-31|||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Cancer|Immunization of HLA-A*0201 Patients With Metastatic Cancer Using a Peptide Epitope From the Telomerase Antigen|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:40.873487|2018-06-01 05:25:40.873487
NCT00021125|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 2000||2000-07-31|December 2002|2002-12-31|June 2007|Actual|2007-06-30|||||Interventional|||Radiation Therapy in Treating Patients With Head and Neck Cancer|A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients|Completed||Phase 3|460|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:41.049517|2018-06-01 05:25:41.049517
NCT00021112|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|April 2001||2001-04-30|July 2012|2012-07-31||||October 2002|Actual|2002-10-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer|Surgical Treatment Of Stage IIIB Non-Small Cell Lung Cancer After Induction-Chemoradiotherapy|Terminated||Phase 2|5|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:25:41.176031|2018-06-01 05:25:41.176031
NCT00021073|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-12-10|2003-01-26|2003-01-27|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2001||2001-05-31|December 2013|2013-12-31||||April 2006|Actual|2006-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer|Phase I Study of Flavopiridol in Combination With 5-Fluorouracil, Leucovorin and Irinotecan in Patients With Advanced Malignancies|Completed||Phase 1|90|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:41.361047|2018-06-01 05:25:41.361047
NCT00021060|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-02-26|2003-01-26|2003-01-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|August 2002||2002-08-31|February 2013|2013-02-28||||September 2006|Actual|2006-09-30||Interventional|||Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer|Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC|Completed||Phase 2/Phase 3|842|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:25:41.615247|2018-06-01 05:25:41.615247
NCT00021047|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-07|2003-01-26|2003-01-27|Estimate|||||||2012-03-07|2012-03-08|Estimate|July 2001||2001-07-31|March 2012|2012-03-31|June 2004|Actual|2004-06-30|||||Interventional|||Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor|A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients|Completed||Phase 1/Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:41.87448|2018-06-01 05:25:41.87448
NCT00020969|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2011-05-12|2003-01-26|2003-01-27|Estimate|||||||2011-05-12|2011-05-13|Estimate|March 2001||2001-03-31|September 2004|2004-09-30||||||||Interventional|||Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes|Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:42.089679|2018-06-01 05:25:42.089679
NCT00020943|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|June 2001||2001-06-30|July 2016|2016-07-31|September 2009|Actual|2009-09-30|December 2006|Actual|2006-12-31||Interventional|||Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma|A Phase II Study Of Intensive Induction Chemotherapy Followed By Autologous Stem Cell Transplantation Plus Immunotherapy For Mantle Cell Lymphoma|Completed||Phase 2|79|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:25:42.225069|2018-06-01 05:25:42.225069
NCT00020891|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-01-17|2003-01-26|2003-01-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|March 2001||2001-03-31|January 2013|2013-01-31||||June 2006|Actual|2006-06-30||Interventional|||CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy|The Use Of Multiple CT Scans To Reduce Target Positioning Errors In Patients Undergoing External Beam Radiotherapy Treatment For Prostate Cancer|Completed||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:25:42.492096|2018-06-01 05:25:42.492096
NCT00020878|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2016-03-02|2003-01-26|2003-01-27|Estimate|||||||2016-03-02|2016-03-04|Estimate|March 2001||2001-03-31|March 2016|2016-03-31|May 2009|Actual|2009-05-31|November 2002|Actual|2002-11-30||Interventional|||Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers|Celecoxib for Chemoprevention of Primary Lung Cancer|Completed||Phase 2|21|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:25:42.590396|2018-06-01 05:25:42.590396
NCT00020852|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|May 2001||2001-05-31|May 2004|2004-05-31|July 2004|Actual|2004-07-31|||||Interventional|||Cryosurgery in Treating Women With Breast Lesions|Evaluation of Freezing Tumors in the Treatment of Breast Cancer Safety Study - 1-Probe CRYOcare Surgical System for Breast Tumor Ablation|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:42.68268|2018-06-01 05:25:42.68268
NCT00020839|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 2001||2001-04-30|September 2012|2012-09-30||||May 2003|Actual|2003-05-31||Interventional|||Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain|Temozolomide Versus Temozolomide + Whole Brain Radiation In Stage IV Melanoma Patients With Asymptomatic Brain Metastases|Terminated||Phase 3|23|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:25:42.795613|2018-06-01 05:25:42.795613
NCT00020826|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-08-24|2003-01-26|2003-01-27|Estimate|||||||2012-08-24|2012-08-27|Estimate|April 2001||2001-04-30|August 2012|2012-08-31|January 2004|Actual|2004-01-31|May 2003|Actual|2003-05-31||Observational|||Assessing Quality of Life of Patients With Stomach Cancer|An International Field Study Of The Reliability And Validity Of The EORTC QLQ-C30 And A Disease-Specific Questionnaire Module (The QLQ-STO22) In Assessing The Quality Of Life Of Patients With Gastric Cancer|Completed|||267|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||1||f||||f||||||||||2018-06-01 05:25:43.058185|2018-06-01 05:25:43.058185
NCT00020800|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-01-07|2003-01-26|2003-01-27|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2001||2001-09-30|January 2013|2013-01-31||||April 2003|Actual|2003-04-30||Interventional|||Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia|Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)|Completed||Phase 2|7|Actual|Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:25:43.185874|2018-06-01 05:25:43.185874
NCT00020761|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-10-28|2003-01-26|2003-01-27|Estimate|||||||2015-10-28|2015-10-30|Estimate|April 2000||2000-04-30|July 2012|2012-07-31|August 2005|Actual|2005-08-31|December 2002|Actual|2002-12-31||Interventional|||Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach|A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract|Completed||Phase 2|51|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:25:43.273418|2018-06-01 05:25:43.273418
NCT00020748|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2011-03-23|2003-01-26|2003-01-27|Estimate|||||||2011-03-23|2011-03-24|Estimate|August 2000||2000-08-31|January 2005|2005-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer|A Phase I Study of Epirubicin in Combination With Irinotecan in Patients With Advanced Cancer|Completed||Phase 1|||Georgetown University|||||f||||f||||||||||2018-06-01 05:25:43.385296|2018-06-01 05:25:43.385296
NCT00020735|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-12-01|2003-01-26|2003-01-27|Estimate|||||||2015-12-01|2015-12-02|Estimate|April 2001||2001-04-30|December 2015|2015-12-31|June 2009|Actual|2009-06-30|January 2005|Actual|2005-01-31||Interventional|||Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer|A Phase II Randomized Controlled Clinical Trial Of The Antiestrogen GTx-006 In Subjects With Prostate Cancer|Completed||Phase 2|45|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 05:25:43.47505|2018-06-01 05:25:43.47505
NCT00020722|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|2015-02-09||2016-02-15|2003-01-26|2003-01-27|Estimate|2015-03-17|2015-03-30|Estimate||||2016-02-15|2016-02-17|Estimate|August 2007||2007-08-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer|Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II)|Terminated||Phase 2|7|Actual|Barbara Ann Karmanos Cancer Institute|Not enough funding to finish study, cost of immunotherapy infusions for the stem cell transplant portion & of infusions for targeted T cell therapy were limited due to lack of funding, trial was converted into a proof-of-principle or concept trial.|1||Lack of funding to continue study.|f||||t||||||||||2018-06-01 05:25:43.602028|2018-06-01 05:25:43.602028
NCT00020709|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-02-26|2003-01-26|2003-01-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|June 2001||2001-06-30|February 2013|2013-02-28||||February 2007|Actual|2007-02-28||Interventional|||Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery|A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer|Completed||Phase 3|840|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:25:43.789323|2018-06-01 05:25:43.789323
NCT00020683|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|March 2003||2003-03-31|October 2013|2013-10-31||||November 2005|Actual|2005-11-30||Interventional|||A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma|A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma|Terminated||Phase 2|70|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:25:43.943124|2018-06-01 05:25:43.943124
NCT00020670|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2017-06-19|2003-01-26|2003-01-27|Estimate|||||||2017-06-19|2017-06-20|Actual|February 20, 2001|Actual|2001-02-20|June 2017|2017-06-30|July 1, 2003|Actual|2003-07-01|April 1, 2003|Actual|2003-04-01||Interventional|||Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia|A Phase I Study of Vaccination With Autologous CD40-Activated Acute Lymphoblastic Leukemia Cells|Terminated||Early Phase 1|9|Actual|Dana-Farber Cancer Institute||1||Slow accrual|f||||t||||||||No||2018-06-01 05:25:44.111658|2018-06-01 05:25:44.111658
NCT00020657|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-10-13|2003-01-26|2003-01-27|Estimate|||||||2015-10-13|2015-10-15|Estimate|July 2001||2001-07-31|October 2015|2015-10-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer|Treatment of Delayed Nausea: What Works Best?|Completed||Phase 3|||University of Rochester|||||f||||||||||||||2018-06-01 05:25:44.355|2018-06-01 05:25:44.355
NCT00020644|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|March 2000||2000-03-31|April 2004|2004-04-30||||||||Interventional|||Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer|Phase I Study of Continuous Infusion Gemcitabine|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:44.556975|2018-06-01 05:25:44.556975
NCT00020631|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|October 2001||2001-10-31|April 2004|2004-04-30|October 2007|Actual|2007-10-31|||||Interventional|||Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer|A Pilot Study Of Pirfenidone For The Treatment Of Radiation-Induced Fibrosis|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:44.654458|2018-06-01 05:25:44.654458
NCT00020579|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|March 2001||2001-03-31|March 2012|2012-03-31|October 2008|Actual|2008-10-31|April 2008|Actual|2008-04-30||Interventional|||MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas|Completed||Phase 1|75|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:25:44.776852|2018-06-01 05:25:44.776852
NCT00020566|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2014-06-23|2003-01-26|2003-01-27|Estimate|||||||2014-06-23|2014-06-24|Estimate|February 2001||2001-02-28|June 2012|2012-06-30||||December 2011|Anticipated|2011-12-31||Interventional|||Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma|European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)|Unknown status|Recruiting|Phase 3|1200|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:25:44.943949|2018-06-01 05:25:44.943949
NCT00020527|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2001||2001-03-31|March 2003|2003-03-31|June 2003|Actual|2003-06-30|||||Interventional|||Caspofungin Acetate in Treating Children With Fever and Neutropenia|A Multicenter, Open, Non-Comparative, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Separate Doses of MK-0991 in Children With New Onset Fever and Neutropenia|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:45.494371|2018-06-01 05:25:45.494371
NCT00020501|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-07|2003-01-26|2003-01-27|Estimate|||||||2012-03-07|2012-03-08|Estimate|March 2001||2001-03-31|March 2012|2012-03-31|January 2005|Actual|2005-01-31|||||Interventional|||Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver|A Phase III Prospective Random Assignment Trial of Regional and Systemic Chemotherapy With or Without Initial Isolated Hepatic Perfusion for Patients With Metastatic Unresectable Colorectal Cancers of the Liver|Completed||Phase 3|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:45.628141|2018-06-01 05:25:45.628141
NCT00020488|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2001||2001-02-28|September 2003|2003-09-30||||||||Interventional|||Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors|A Phase I & Pharmacologic Trial Of Sequential Irinotecan As A 24-Hour IV Infusion, Leucovorin, & Flurouracil As A 48-Hour IV Infusion In Adult Cancer Patients|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:45.743467|2018-06-01 05:25:45.743467
NCT00020449|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2001||2001-01-31|March 2004|2004-03-31|May 2004|Actual|2004-05-31|||||Interventional|||Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma|A Phase II Study of Liposomal Doxorubicin and Interleukin-12 in AIDS-Associated Kaposi's Sarcoma Followed by Chronic Administration of Interleukin-12|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:45.854504|2018-06-01 05:25:45.854504
NCT00020410|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2001||2001-02-28|September 2003|2003-09-30||||||||Interventional|||Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer|Phase I Study Of Yttrium 90-labeled Monoclonal Antibody B3 With Autologous Stem Cell Support For Metastatic Breast Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:45.926377|2018-06-01 05:25:45.926377
NCT00020397|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 2000||2000-11-30|January 2005|2005-01-31|July 2005|Actual|2005-07-31|||||Interventional|||Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma|Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:46.043821|2018-06-01 05:25:46.043821
NCT00020358|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2000||2000-09-30|March 2003|2003-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Vaccine Therapy in Treating Patients With Melanoma|Randomized Comparison of Three Schedules of Peptide Immunization in Patients With Stage II or III, or Completely Resected Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:46.145549|2018-06-01 05:25:46.145549
NCT00020332|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-14|2003-01-26|2003-01-27|Estimate|||||||2013-06-14|2013-06-17|Estimate|October 2000||2000-10-31|July 2002|2002-07-31|March 2003|Actual|2003-03-31|||||Interventional|||Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer|A Phase I/II Trial of Docetaxel Followed by Infusional Flavopiridol Over 72 Hours in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:46.275437|2018-06-01 05:25:46.275437
NCT00020254|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2000||2000-06-30|April 2003|2003-04-30||||October 2004|Actual|2004-10-31||Interventional|||Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer|A Randomized Phase II Study of Either Immunotherapy With a Regimen of Recombinant Pox Viruses That Express PSA/B7.1 Plus Adjuvant GM-CSF and IL2 or Hormone Therapy With Nilutamide in Patients With Hormone Refractory Prostate Cancer and No Radiographic Evidence of Disease|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:46.400877|2018-06-01 05:25:46.400877
NCT00020189|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2000||2000-06-30|August 2004|2004-08-31|August 2004|Actual|2004-08-31|||||Interventional|||Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:46.527237|2018-06-01 05:25:46.527237
NCT00020176|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|June 2000||2000-06-30|November 2004|2004-11-30|August 2007|Actual|2007-08-31|||||Interventional|||Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer|Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:25:46.717516|2018-06-01 05:25:46.717516
NCT00020150|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2000||2000-06-30|August 2004|2004-08-31||||||||Interventional|||Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors|Phase I Trial and Pharmacokinetic Study of Temozolomide and O6-Benzylguanine in Childhood Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:46.843077|2018-06-01 05:25:46.843077
NCT00020124|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|June 2000||2000-06-30|March 2012|2012-03-31|December 2002|Actual|2002-12-31|||||Interventional|||Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs|Phase I and Clinical Pharmacologic Study of Inhaled Doxorubicin in Adults With Advanced Solid Tumors Affecting the Lungs|Completed||Phase 1|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:46.95137|2018-06-01 05:25:46.95137
NCT00020111|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2000||2000-03-31|February 2005|2005-02-28||||||||Interventional|||Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma|Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients With Refractory Leukemia or Lymphoma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:47.050899|2018-06-01 05:25:47.050899
NCT00020072|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2000||2000-03-31|March 2003|2003-03-31||||||||Interventional|||Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells|Gene Expression Analysis in Cutaneous T-Cell Lymphoma|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:47.20081|2018-06-01 05:25:47.20081
NCT00020007|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|December 1999||1999-12-31|January 2006|2006-01-31||||||||Interventional|||Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery|A Phase I Study of Isolated Lung Perfusion With Paclitaxel and Moderate Hyperthermia in Patients With Unresectable Pulmonary Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:47.308047|2018-06-01 05:25:47.308047
NCT00019994|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|October 1999||1999-10-31|March 2003|2003-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using a Class II Restricted Peptide From the GP100 Antigen and Class I Restricted Peptides From the GP100 and MART-1 Antigens|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:47.430145|2018-06-01 05:25:47.430145
NCT00019955|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2000||2000-03-31|September 2005|2005-09-30||||||||Interventional|||Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)|A Phase II Study to Evaluate Radiofrequency Ablation of Renal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:47.53162|2018-06-01 05:25:47.53162
NCT00019929|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|August 2000||2000-08-31|November 2005|2005-11-30|December 2005|Actual|2005-12-31|||||Interventional|||Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer|Phase II Trial of Individualized Mutant p53 Peptide-Pulsed Cultured Autologous Dendritic Cells in the Adjuvant Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer After Standard Therapy|Completed||Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:25:47.642148|2018-06-01 05:25:47.642148
NCT00019916|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|June 2000||2000-06-30|December 2005|2005-12-31|July 2006|Actual|2006-07-31|||||Interventional|||Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer|Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Adenocarcinoma of the Breast or Ovary|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:25:47.759552|2018-06-01 05:25:47.759552
NCT00019864|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-06-04|2003-01-26|2003-01-27|Estimate|||||||2015-06-04|2015-06-08|Estimate|March 2000||2000-03-31|October 2007|2007-10-31|October 2011|Actual|2011-10-31|December 2006|Actual|2006-12-31||Interventional|||Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma|Osteosarcoma: Outcome of Therapy Based on Histologic Response. A Collaborative Effort of the POB/NCI, Texas Children's Hospital and University of Oklahoma.|Terminated||Phase 2|100|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:47.914469|2018-06-01 05:25:47.914469
NCT00019838|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|July 1999||1999-07-31|February 2005|2005-02-28||||||||Interventional|||UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia|Phase I and Pharmacokinetic Study of UCN-01 and Fludarabine in Relapsed or Refractory Low-Grade Lymphoid Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:25:47.996545|2018-06-01 05:25:47.996545
NCT00019825|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|October 1999||1999-10-31|July 2004|2004-07-31||||||||Interventional|||Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura|Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Lung Cancer Patients|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:48.12773|2018-06-01 05:25:48.12773
NCT00019812|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-21|2003-01-26|2003-01-27|Estimate|||||||2012-03-21|2012-03-23|Estimate|August 1999||1999-08-31|April 2003|2003-04-30|February 2004|Actual|2004-02-29|||||Interventional|||Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2|Study of Trastuzumab (Herceptin) and Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer|Completed||Phase 2|55|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:48.278447|2018-06-01 05:25:48.278447
NCT00019786|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-21|2003-01-26|2003-01-27|Estimate|||||||2012-03-21|2012-03-23|Estimate|August 1999||1999-08-31|March 2012|2012-03-31|January 2006|Actual|2006-01-31|||||Interventional|||Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases|A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver|Completed||Phase 2|67|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:48.377241|2018-06-01 05:25:48.377241
NCT00019773|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|July 1999||1999-07-31|April 2003|2003-04-30||||||||Interventional|||Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer|Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:48.492696|2018-06-01 05:25:48.492696
NCT00019747|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|2012-09-25||2015-10-06|2003-01-26|2003-01-27|Estimate|2012-09-25|2012-10-25|Estimate||||2015-10-06|2015-10-28|Estimate|August 1999||1999-08-31|September 2015|2015-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer|A Phase II Trial of Oral Thalidomide as an Adjuvant Agent Following Metastasectomy in Patients With Recurrent Colorectal Cancer|Terminated||Phase 2|39|Actual|National Institutes of Health Clinical Center (CC)||2||DSMB recommended closure of the protocol due to slow accrual.|f||||t||||||||||2018-06-01 05:25:48.638764|2018-06-01 05:25:48.638764
NCT00019708|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-12-13|2003-01-26|2003-01-27|Estimate|||||||2013-12-13|2013-12-16|Estimate|June 1999||1999-06-30|December 2013|2013-12-31||||April 2010|Actual|2010-04-30||Interventional|||Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|A Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (AAG, NSC 330507) in Adult Patients With Solid Tumors|Terminated||Phase 1|45|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:49.321139|2018-06-01 05:25:49.321139
NCT00019682|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|2016-12-02||2017-11-16|2003-01-26|2003-01-27|Estimate|2017-11-16|2017-11-20|Actual||||2017-11-16|2017-11-20|Actual|December 1999||1999-12-31|November 2017|2017-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma|A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma|Completed||Phase 3|185|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-06-01 05:25:49.500026|2018-06-01 05:25:49.500026
NCT00019669|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|October 1999||1999-10-31|August 2004|2004-08-31|October 2007|Actual|2007-10-31|||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Immunization of Patients With Metastatic Melanoma Using a Recombinant Fowlpox Virus Encoding a GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:50.13568|2018-06-01 05:25:50.13568
NCT00019656|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|August 1999||1999-08-31|August 2004|2004-08-31||||||||Interventional|||Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer|A Phase I Trial of Oral Perifosine With Different Loading Schedules in Patients With Refractory Neoplasms|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:50.262917|2018-06-01 05:25:50.262917
NCT00019604|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|2014-04-01||2016-12-07|2003-01-26|2003-01-27|Estimate|2014-05-13|2014-06-12|Estimate||||2016-12-07|2017-02-03|Estimate|August 1998||1998-08-31|December 2016|2016-12-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer|The Use of Radiofrequency Ablation to Treat Hepatic Neoplasms|Terminated||Phase 2|44|Actual|National Institutes of Health Clinical Center (CC)|Adverse event data is available but the format is uninterpretable.|1||Principal investigator left the institution.|f||||f||||||||No||2018-06-01 05:25:50.385052|2018-06-01 05:25:50.385052
NCT00019591|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|March 1999||1999-03-31|November 2005|2005-11-30|November 2005|Actual|2005-11-30|||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase I/II Trial of Vaccination With Mutant Ras Peptide-Pulsed Dendritic Cells in the Treatment of HLA A2.1 Positive Patients With Colorectal Cancer|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:25:50.782155|2018-06-01 05:25:50.782155
NCT00019565|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2016-09-23|2003-01-26|2003-01-27|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 1998||1998-10-31|September 2016|2016-09-30||||August 2008|Actual|2008-08-31||Interventional|||PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy|The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature|Completed||Phase 1|53|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:50.894362|2018-06-01 05:25:50.894362
NCT00019513|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-21|2003-01-26|2003-01-27|Estimate|||||||2012-03-21|2012-03-23|Estimate|August 1998||1998-08-31|March 2012|2012-03-31|June 2004|Actual|2004-06-30|||||Interventional|||Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas|A Phase I Study of Weekly Gemcitabine in Combination With Infusional 5-Fluorouracil and Oral Calcium Leucovorin in Adult Cancer Patients|Completed||Phase 1|108|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:25:51.049898|2018-06-01 05:25:51.049898
NCT00019487|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|November 1998||1998-11-30|March 2003|2003-03-31|May 2003|Actual|2003-05-31|||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma Using Cloned Peripheral Blood Lymphocytes Sensitized In Vitro to the gp209-2M Immunodominant Peptide|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:51.206623|2018-06-01 05:25:51.206623
NCT00019461|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|April 1998||1998-04-30|June 2003|2003-06-30|October 2007|Actual|2007-10-31|||||Interventional|||Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:51.321073|2018-06-01 05:25:51.321073
NCT00019422|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-08-14|2003-01-26|2003-01-27|Estimate|||||||2013-08-14|2013-08-16|Estimate|March 1998||1998-03-31|April 2003|2003-04-30|April 2003|Actual|2003-04-30|||||Interventional|||Lobradimil and Carboplatin in Treating Children With Brain Tumors|A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:51.452821|2018-06-01 05:25:51.452821
NCT00019331|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|October 1997||1997-10-31|April 2004|2004-04-30|May 2007|Actual|2007-05-31|||||Interventional|||Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors|Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:52.24592|2018-06-01 05:25:52.24592
NCT00019227|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|October 1996||1996-10-31|March 2003|2003-03-31|July 2006|Actual|2006-07-31|||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Leukemia|PHASE I/II STUDY OF TAC-EXPRESSING ADULT T-CELL LEUKEMIA (ATL) WITH YTTRIUM-90 (90Y)-RADIOLABELED HUMANIZED ANTI-TAC AND CALCIUM-DTPA|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:52.883992|2018-06-01 05:25:52.883992
NCT00019214|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|April 1997||1997-04-30|January 2005|2005-01-31|July 2006|Actual|2006-07-31|||||Interventional|||Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma|Phase I/II Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From The Melanoma Associated Antigens MART-1 and gp 100|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:53.290621|2018-06-01 05:25:53.290621
NCT00019201|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|August 1996||1996-08-31|February 2000|2000-02-29||||||||Interventional|||Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer|PILOT STUDY OF THE CORRELATION BETWEEN THE FINDINGS OF ATYPICAL/MALIGNANT CELLS IN SPUTUM AND FLUORESCENCE BRONCHOSCOPY IN PATIENTS AT RISK FOR LUNG CANCER OF THE LIFE IMAGING SYSTEM AND WHITE LIGHT BRONCHOSCOPY|Completed||N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:53.446742|2018-06-01 05:25:53.446742
NCT00019136|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|February 1997||1997-02-28|December 2003|2003-12-31||||||||Interventional|||Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer|TREATMENT OF PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER USING ANTI-CD3 STIMULATED PERIPHERAL BLOOD LYMPHOCYTES TRANSDUCED WITH A GENE ENCODING A CHIMERIC T-CELL RECEPTOR REACTIVE WITH FOLATE BINDING PROTEIN|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:53.656882|2018-06-01 05:25:53.656882
NCT00019110|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|November 1995||1995-11-30|November 1999|1999-11-30||||||||Interventional|||Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer|VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:53.935046|2018-06-01 05:25:53.935046
NCT00019032|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-27|2003-01-26|2003-01-27|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 1996||1996-03-31|April 2004|2004-04-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia|PHASE I STUDY OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA USING THE MIK-BETA 1 MONOCLONAL ANTIBODY DIRECTED TOWARD THE IL-2R BETA SUBUNIT|Completed||Phase 1|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:54.108328|2018-06-01 05:25:54.108328
NCT00019019|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|October 1994||1994-10-31|March 2012|2012-03-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas|A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA|Completed||Phase 1|70|Anticipated|National Institutes of Health Clinical Center (CC)|||||||||||||||||||2018-06-01 05:25:54.20743|2018-06-01 05:25:54.20743
NCT00018967|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|November 1993||1993-11-30|April 2007|2007-04-30||||April 2007|Actual|2007-04-30||Interventional|||Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate|A Trial of Carboxypeptidase-G2 (CPDG2) For The Management of Patients With Intrathecal Methotrexate Overdose|Completed||N/A|10|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:25:54.469226|2018-06-01 05:25:54.469226
NCT00017602|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2000||2000-12-31|August 2003|2003-08-31|April 2009|Actual|2009-04-30|||||Interventional|||Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma|Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:54.869862|2018-06-01 05:25:54.869862
NCT00017589|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2000||2000-12-31|April 2003|2003-04-30|May 2006|Actual|2006-05-31|||||Interventional|||Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia|Phase II Study of Genasense (Bcl-2 Antisense) Combined With Mylotarg (Gemtuzumab Ozogamicin) in Elderly Patients With Relapsed Acute Myeloid Leukemia|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:54.975902|2018-06-01 05:25:54.975902
NCT00017563|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|2011-05-31||2017-04-26|2003-01-26|2003-01-27|Estimate|2011-08-01|2011-08-31|Estimate||||2017-04-26|2017-04-28|Actual|September 2000||2000-09-30|April 2017|2017-04-30||||May 2010|Actual|2010-05-31||Interventional|||Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer|Phase I/II Study of Neoadjuvant Weekly Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients With High Risk Localized Prostate Cancer|Completed||Phase 2|57|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-06-01 05:25:55.1776|2018-06-01 05:25:55.1776
NCT00017550|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 2001||2001-08-31|March 2003|2003-03-31||||||||Interventional|||Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome|An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS)|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:55.539638|2018-06-01 05:25:55.539638
NCT00017524|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-12-12|2003-01-26|2003-01-27|Estimate|||||||2013-12-12|2013-12-16|Estimate|March 2001||2001-03-31|November 2012|2012-11-30|November 2004|Actual|2004-11-30|||||Interventional|||AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors|A Phase I Dose-Escalation Study of AG2037 Administered Once Weekly for Three Weeks to Patients With Advanced Cancer|Completed||Phase 1|22|Actual|University of Alabama at Birmingham|||||f||||t||||||||||2018-06-01 05:25:55.769799|2018-06-01 05:25:55.769799
NCT00001816|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|May 2000|2000-05-31|February 2001||2001-02-28|||||Observational|||The Impact of Starbright World on Children Being Treated at the NIH|The Impact of Starbright World on Children Being Treated at the NIH|Completed|||35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.324178|2018-06-01 05:29:40.324178
NCT00017511|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2012-05-15|2003-01-26|2003-01-27|Estimate|||||||2012-05-15|2012-05-16|Estimate|June 2001||2001-06-30|May 2012|2012-05-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region|Completed||Phase 3|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:25:55.924155|2018-06-01 05:25:55.924155
NCT00017498|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|February 2001||2001-02-28|September 2012|2012-09-30||||April 2003|Actual|2003-04-30||Interventional|||Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck|Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck|Completed||Phase 2|21|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:25:56.207344|2018-06-01 05:25:56.207344
NCT00017485|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2011-03-03|2003-01-26|2003-01-27|Estimate|||||||2011-03-03|2011-03-07|Estimate|January 2000||2000-01-31|March 2011|2011-03-31|January 2007|Actual|2007-01-31|December 2006|Actual|2006-12-31||Interventional|||Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer|A Phase I Study Of Photodynamic Therapy (PDT) For The Treatment Of Basal Cell Carcinoma (BCC): A Drug/Light Dose Finding Study Utilizing 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A (HPPH-PHOTOCLOR)|Completed||Phase 1|6|Actual|Roswell Park Cancer Institute|||||f||||t||||||||||2018-06-01 05:25:56.323904|2018-06-01 05:25:56.323904
NCT00017472|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 2001||2001-04-30|June 2013|2013-06-30||||April 2006|Actual|2006-04-30||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia|Phase I Study of Thrice Weekly Hu1D10*in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Acute Leukemia|Completed||Phase 1|35|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:56.509571|2018-06-01 05:25:56.509571
NCT00017381|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-01-08|2003-01-26|2003-01-27|Estimate|||||||2013-01-08|2013-01-09|Estimate|April 2001||2001-04-30|January 2013|2013-01-31||||December 2007|Actual|2007-12-31||Interventional|||Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma|Dose Finding Study of IDEC-Y2B8 With Autologous Stem Cell Support|Completed||Early Phase 1|30|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:56.688123|2018-06-01 05:25:56.688123
NCT00017355|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2001||2001-04-30|March 2003|2003-03-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Metastatic Melanoma|Mature Dendritic Cell Immunotherapy Of Metastatic Melanoma- A Phase I Trial|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:56.933206|2018-06-01 05:25:56.933206
NCT00017329|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2009-12-13|2003-01-26|2003-01-27|Estimate|||||||2009-12-13|2009-12-15|Estimate|April 2001||2001-04-30|December 2009|2009-12-31||||April 2004|Actual|2004-04-30||Interventional|||PS-341 in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of PS341 (NSC 681239) in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:57.117048|2018-06-01 05:25:57.117048
NCT00017290|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|November 2000||2000-11-30|August 2002|2002-08-31||||||||Interventional|||Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma|A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:57.399959|2018-06-01 05:25:57.399959
NCT00017277|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|March 2001||2001-03-31|September 2012|2012-09-30||||April 2003|Actual|2003-04-30||Interventional|||Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer|A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma|Terminated||Phase 3|47|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:25:57.711339|2018-06-01 05:25:57.711339
NCT00017264|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2009-01-10|2003-01-26|2003-01-27|Estimate|||||||2009-01-10|2009-01-13|Estimate|June 2002||2002-06-30|August 2004|2004-08-31||||||||Interventional|||Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma|A Phase I Evaluation of the Safety and Pharmacokinetics of ABT-627 in Adults With Recurrent Malignant Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:57.994005|2018-06-01 05:25:57.994005
NCT00017251|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2001||2001-04-30|January 2013|2013-01-31||||January 2004|Actual|2004-01-31||Interventional|||Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer|A Phase I Study Of Genasense, A Bcl-2 Antisense Oligonucleotide, Combined With Carboplatin And Etoposide In Patients With Small Cell Lung Cancer|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:58.248486|2018-06-01 05:25:58.248486
NCT00017238|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-01-10|2003-01-26|2003-01-27|Estimate|||||||2013-01-10|2013-01-11|Estimate|February 2002||2002-02-28|January 2013|2013-01-31||||November 2008|Actual|2008-11-30||Interventional|||KRN5500 in Treating Patients With Solid Tumors|A Phase I Trial of KRN5500 (NSC 650426) Given as a 72 Hour Continuous IV Infusion Every 21 Days in Patients With Solid Tumors|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:25:58.433876|2018-06-01 05:25:58.433876
NCT00017225|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 1997||1997-05-31|August 2002|2002-08-31|February 2002|Actual|2002-02-28|||||Interventional|||Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma|Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:25:58.68256|2018-06-01 05:25:58.68256
NCT00017212|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2012-05-15|2003-01-26|2003-01-27|Estimate|||||||2012-05-15|2012-05-16|Estimate|April 2001||2001-04-30|May 2012|2012-05-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||DX-8951f in Treating Patients With Metastatic Stomach Cancer|A Phase II Study Of Intravenous Exatecan Mesylate (DX-891F) Administered Daily For Five Days Every Three Weeks To Patients With Previously Untreated Metastatic Gastric Cancer|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:25:59.031144|2018-06-01 05:25:59.031144
NCT00001584|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|May 2000|2000-05-31|April 2001||2001-04-30|||||Observational|||Determination of HIV-1 Production by the Prostate|Determination of HIV-1 Production by the Prostate|Completed|||35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.926466|2018-06-01 05:29:44.926466
NCT00017186|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|July 2001||2001-07-31|December 2016|2016-12-31|May 2008|Actual|2008-05-31|August 2004|Actual|2004-08-31||Interventional|||Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma|Phase II Study of Gemcitabine and Epirubicin for the Treatment of Mesothelioma|Completed||Phase 2|69|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:25:59.18722|2018-06-01 05:25:59.18722
NCT00017173|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2012-06-12|2003-01-26|2003-01-27|Estimate|||||||2012-06-12|2012-06-14|Estimate|February 2003||2003-02-28|June 2012|2012-06-30|July 2011|Actual|2011-07-31|May 2007|Actual|2007-05-31||Interventional|||S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat|Phase II Trial Of Surgery With Perioperative RPR/INGN 201 (Ad5CMV-p53) Gene Therapy Followed By Chemoradiotherapy For Advanced, Resectable Squamous Cell Carcinoma Of The Oral Cavity, Oropharynx, Larynx, and Pharynx|Terminated||Phase 2|13|Actual|Southwest Oncology Group||1||Terminated for poor accrual.|f||||f||||||||||2018-06-01 05:25:59.505|2018-06-01 05:25:59.505
NCT00017160|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-27|Estimate||||June 2013|2013-06-30||||||||Interventional|||Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma|Phase II Study of Neoadjuvant Doxorubicin and Ifosfamide, Radiotherapy, and Surgical Resection in Patients With Primary or Recurrent Retroperitoneal Sarcoma|Withdrawn||Phase 2|0|Actual|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:25:59.680908|2018-06-01 05:25:59.680908
NCT00017147|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-01-28|2003-01-26|2003-01-27|Estimate|||||||2013-01-28|2013-01-30|Estimate|September 2001||2001-09-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|May 2006|Actual|2006-05-31||Interventional|||S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma|A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma|Completed||Phase 3|183|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:26:00.740767|2018-06-01 05:26:00.740767
NCT00017121|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|May 2002||2002-05-31|July 2016|2016-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung|Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung|Completed||Phase 1|40|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:03.59955|2018-06-01 05:26:03.59955
NCT00017108|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|March 2001||2001-03-31|June 2004|2004-06-30||||||||Interventional|||Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia|Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3)|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:04.373047|2018-06-01 05:26:04.373047
NCT00017095|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-10-23|2003-01-26|2003-01-27|Estimate|||||||2013-10-23|2013-10-24|Estimate|March 2001||2001-03-31|October 2013|2013-10-31||||November 2006|Actual|2006-11-30||Interventional|||Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer|First Prospective Intergroup Translational Research Trial Assessing the Potential Predictive Value of p53 Using a Functional Assay in Yeast in Patients With Locally Advanced/Inflammatory or Large Operable Breast Cancer Prospectively Randomised to a Taxane Versus a Non Taxane Regimen|Completed||Phase 3|1856|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 05:26:04.72661|2018-06-01 05:26:04.72661
NCT00017069|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2008-11-16|2003-01-26|2003-01-27|Estimate|||||||2008-11-16|2008-11-18|Estimate|February 2001||2001-02-28|April 2004|2004-04-30||||||||Interventional|||Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma|CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:05.433529|2018-06-01 05:26:05.433529
NCT00017004|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2017-08-08|2003-01-26|2003-01-27|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2001||2001-08-31|August 2017|2017-08-31||||May 15, 2004|Actual|2004-05-15||Interventional|||Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia|Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer|Completed||Phase 3|114|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 05:26:05.705568|2018-06-01 05:26:05.705568
NCT00016991|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|June 2001||2001-06-30|October 2009|2009-10-31|April 2005|Actual|2005-04-30|||||Interventional|||ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse|A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme|Completed||Phase 2|||Duke University|||||f||||||||||||||2018-06-01 05:26:06.076716|2018-06-01 05:26:06.076716
NCT00016965|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 2001||2001-07-31|April 2003|2003-04-30|April 2006|Actual|2006-04-30|||||Interventional|||BMS-247550 in Treating Patients With Advanced Pancreatic Cancer|A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:06.43116|2018-06-01 05:26:06.43116
NCT00016952|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|April 2001||2001-04-30|December 2016|2016-12-31|October 2009|Actual|2009-10-31|April 2004|Actual|2004-04-30||Interventional|||Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer|Phase II Study in Patients With Metastatic Colorectal Carcinoma Previously Treated With Oxaliplatin (OXAL) or a Combination of Irinotecan (CPT-11) and OXAL|Completed||Phase 2|19|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:26:07.107357|2018-06-01 05:26:07.107357
NCT00016926|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-05-24|2003-01-26|2003-01-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|April 2001||2001-04-30|May 2004|2004-05-31||||July 2007|Actual|2007-07-31||Interventional|||Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer|A Limited Access Phase II Trial Of Capecitabine In Advanced, Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:26:07.486078|2018-06-01 05:26:07.486078
NCT00016224|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-18|Estimate|January 2001||2001-01-31|June 2013|2013-06-30|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer|Phase II Trial of Thalidomide in Patients With Ovarian Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:14.355807|2018-06-01 05:26:14.355807
NCT00016913|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|2015-07-31||2016-07-01|2003-01-26|2003-01-27|Estimate|2015-12-28|2016-01-29|Estimate||||2016-07-01|2016-07-06|Estimate|May 2001||2001-05-31|July 2016|2016-07-31|May 2008|Actual|2008-05-31|July 2007|Actual|2007-07-31||Interventional|||Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer|Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer|Completed||Phase 2|34|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:07.826276|2018-06-01 05:26:07.826276
NCT00016887|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|December 2000||2000-12-31|August 2003|2003-08-31||||||||Interventional|||Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma|Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:08.910849|2018-06-01 05:26:08.910849
NCT00016861|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 1998||1998-09-30|November 2004|2004-11-30|January 2005|Actual|2005-01-31|||||Interventional|||Irinotecan in Treating Children With Refractory or Progressive Solid Tumors|Pediatric Phase I and Pharmacokinetic Study of Irinotecan|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:09.152387|2018-06-01 05:26:09.152387
NCT00016432|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2011-04-18|2003-01-26|2003-01-27|Estimate|||||||2011-04-18|2011-04-19|Estimate|May 2001||2001-05-31|April 2011|2011-04-30|February 2011|Actual|2011-02-28|October 2003|Actual|2003-10-31||Interventional|||Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen|A Randomized Trial Evaluating The Effect Of Exemestane In Clinical Stage T1-3 N0-1 M0 Postmenopausal Breast Cancer Patients Completing At Least Five Years Of Tamoxifen Therapy|Completed||Phase 3|1598|Actual|NSABP Foundation Inc||2|||f||||||||||||||2018-06-01 05:26:09.450728|2018-06-01 05:26:09.450728
NCT00016419|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2015-03-05|2003-01-26|2003-01-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2001||2001-08-31|March 2015|2015-03-31|January 2007|Actual|2007-01-31|July 2003|Actual|2003-07-31||Interventional|||S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome|A Phase II Study of Anti-Thymocyte Globulin and Cyclosporine for Patients With Myelodysplastic Syndrome (MDS)|Completed||Phase 2|130|Anticipated|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:26:10.341219|2018-06-01 05:26:10.341219
NCT00016406|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2001||2001-05-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|September 2006|Actual|2006-09-30||Interventional|||S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer|A Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory and Locally Advanced Breast Cancer|Completed||Phase 3|399|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:26:11.016182|2018-06-01 05:26:11.016182
NCT00016393|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|June 2001||2001-06-30|February 2004|2004-02-29|April 2006|Actual|2006-04-30|||||Interventional|||BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:12.203601|2018-06-01 05:26:12.203601
NCT00016380|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2016-11-25|2003-01-26|2003-01-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|February 2001||2001-02-28|March 2010|2010-03-31|February 2009|Actual|2009-02-28|April 2004|Actual|2004-04-30||Interventional|||Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen|A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis|Completed||Phase 3|||Canadian Cancer Trials Group|||||f||||t||||||||Undecided||2018-06-01 05:26:12.489731|2018-06-01 05:26:12.489731
NCT00016354|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|2012-06-11||2013-03-18|2003-01-26|2003-01-27|Estimate|2012-07-27|2012-08-31|Estimate||||2013-03-18|2013-03-25|Estimate|March 2001||2001-03-31|March 2013|2013-03-31|September 2006|Actual|2006-09-30|August 2004|Actual|2004-08-31||Interventional|||Benzoylphenylurea in Treating Patients With Advanced Solid Tumors|Phase I Study of Continuous Weekly Dosing of Dimethyl Benzoylphenylurea (BPU) in Patients With Solid Tumors Not Responding to Conventional Therapy|Completed||Phase 1|19|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-06-01 05:26:12.607246|2018-06-01 05:26:12.607246
NCT00016328|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|May 2001||2001-05-31|June 2013|2013-06-30||||August 2005|Actual|2005-08-31||Interventional|||CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 2|33|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:12.978712|2018-06-01 05:26:12.978712
NCT00016302|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|April 2001||2001-04-30|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia|The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia|Completed||N/A|100|Actual|National Cancer Institute (NCI)||6|||f||||||||||||||2018-06-01 05:26:13.180562|2018-06-01 05:26:13.180562
NCT00016289|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|July 2001||2001-07-31|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer|Phase II Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis (Residual Disease < 1cm) Associated With Ovarian Epithelial Cancer or Primary Peritoneal Carcinoma|Completed||Phase 2|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:13.738126|2018-06-01 05:26:13.738126
NCT00016263|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|July 2000||2000-07-31|October 2002|2002-10-31|December 2004|Actual|2004-12-31|||||Interventional|||Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma|Randomized Study Of Dacarbazine Versus Dacarbazine Plus G3139 (Bcl-2 Antisense Oligonucleotide) In Patients With Advanced Malignant Melanoma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:14.092651|2018-06-01 05:26:14.092651
NCT00016211|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|February 2001||2001-02-28|September 2012|2012-09-30||||March 2006|Actual|2006-03-31||Interventional|||Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer|Prophylactic Cranial Irradiation In Extensive Disease Small Cell Lung Cancer|Completed||Phase 3|287|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:26:14.628913|2018-06-01 05:26:14.628913
NCT00016185|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-04-03|2003-01-26|2003-01-27|Estimate|||||||2013-04-03|2013-04-05|Estimate|March 2001||2001-03-31|April 2013|2013-04-30|December 2005|Actual|2005-12-31|February 2003|Actual|2003-02-28||Interventional|||Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors|Phase I Study Of Flavopiridol And Docetaxel (Taxotere) In Patients With Advanced Cancers|Completed||Phase 1|||Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:26:14.920394|2018-06-01 05:26:14.920394
NCT00016159|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|November 2000||2000-11-30|January 2013|2013-01-31||||March 2007|Actual|2007-03-31||Interventional|||Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia|Phase II Study Of Combined Modality Postremission Therapy As Determined By Molecular Response (Adaptive Regulation) In The Treatment Of Acute Promyelocytic Leukemia (APL)|Completed||Phase 2|35|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:15.041819|2018-06-01 05:26:15.041819
NCT00016146|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-03-18|2003-01-26|2003-01-27|Estimate|||||||2013-03-18|2013-03-19|Estimate|July 2000||2000-07-31|March 2013|2013-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer|Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates: A Dose-Escalating Trial Studying The Immunogenicity And Safety Of The Immunological Adjuvant GPI-0100|Completed||Phase 1|34|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:26:15.132561|2018-06-01 05:26:15.132561
NCT00016133|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|March 2001||2001-03-31|July 2004|2004-07-31|August 2004|Actual|2004-08-31|||||Interventional|||Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery|A Non-Randomized Multicenter Phase I/II Study Of Active Specific Immunotherapy In Patients With Stage II and Stage III Colon Cancer|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:15.246594|2018-06-01 05:26:15.246594
NCT00016094|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-28|2003-01-26|2003-01-27|Estimate|||||||2013-01-28|2013-01-29|Estimate|April 2001||2001-04-30|January 2013|2013-01-31|September 2008|Actual|2008-09-30|August 2005|Actual|2005-08-31||Interventional|||S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma|Bevacizumab (rhuMab VEGF) (NSC-704865) Therapy for Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:15.37144|2018-06-01 05:26:15.37144
NCT00016081|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2010-03-26|2003-01-26|2003-01-27|Estimate|||||||2010-03-26|2010-03-30|Estimate|March 1998||1998-03-31|March 2010|2010-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation|A Randomized Phase III Study To Evaluate The Safety And Efficacy Or Ribavirin Inhaled Solution In Preventing Progression Of Upper Respiratory Tract Respiratory Syncytial Virus (RSV) Infection To RSV Pneumonia In Blood And Bone Marrow Transplant (BMT) Recipients|Completed||Phase 3|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:26:15.445807|2018-06-01 05:26:15.445807
NCT00016068|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2010-05-14|2003-01-26|2003-01-27|Estimate|||||||2010-05-14|2010-05-17|Estimate|January 2001||2001-01-31|May 2010|2010-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation|A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 3|184|Anticipated|Fred Hutchinson Cancer Research Center|||||||||||||||||||2018-06-01 05:26:15.536016|2018-06-01 05:26:15.536016
NCT00016055|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|November 2000||2000-11-30|November 2006|2006-11-30||||||||Interventional|||Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma|Interleukin 12-Primed Activated T Cells As Therapy For Patients With Metastatic Melanoma (Phase I)|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:15.650929|2018-06-01 05:26:15.650929
NCT00016029|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-03-20|2003-01-26|2003-01-27|Estimate|||||||2013-03-20|2013-03-22|Estimate|August 2000||2000-08-31|September 2003|2003-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer|Prospective Comparison of Air Contrast Barium Enema (ACBE), Computed Tomographic Colonography (Virtual Colonoscopy) and Colonoscopy for Evaluation of the Colon in Patients With Fecal Occult Blood|Terminated||N/A|775|Actual|Duke University|||||f||||||||||||||2018-06-01 05:26:15.729417|2018-06-01 05:26:15.729417
NCT00016016|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|February 2001||2001-02-28|October 2013|2013-10-31||||November 2006|Actual|2006-11-30||Interventional|||Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia|A Phase I/II Study of Flavopiridol (NSC 649890, IND 46,211) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Poor-Risk Acute Leukemias|Completed||Phase 1/Phase 2|53|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:15.913594|2018-06-01 05:26:15.913594
NCT00015977|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2014-03-06|2003-01-26|2003-01-27|Estimate|||||||2014-03-06|2014-03-07|Estimate|November 2001||2001-11-30|March 2014|2014-03-31|January 2005|Actual|2005-01-31|March 2003|Actual|2003-03-31||Interventional|||Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Phase II Study of Immunization With PSMA Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients With Metastatic Prostate Cancer|Completed||Phase 2|13|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:26:16.044513|2018-06-01 05:26:16.044513
NCT00015951|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2009-09-23|2003-01-26|2003-01-27|Estimate|||||||2009-09-23|2009-09-24|Estimate|April 2001||2001-04-30|September 2009|2009-09-30|March 2004|Actual|2004-03-31|April 2003|Actual|2003-04-30||Interventional|||Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers|A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Refractory and Relapsed Acute Myelogenous Leukemias (AMLs)|Completed||Phase 2|||University of Maryland|||||f||||||||||||||2018-06-01 05:26:16.166527|2018-06-01 05:26:16.166527
NCT00014079|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 1997||1997-09-30|July 2016|2016-07-31|May 2005|Actual|2005-05-31|July 2003|Actual|2003-07-31||Observational|||Genetic Markers in Patients With Colorectal Cancer|Clinical Significance of Genetic Markers in Colon Cancer|Completed|||675|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||||||2018-06-01 05:26:21.020195|2018-06-01 05:26:21.020195
NCT00015938|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2001||2001-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|February 2005|Actual|2005-02-28||Interventional|||S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer|Docetaxel And Vinorelbine Plus Filgrastim For HER-2 Negative, Stage IV Breast Cancer|Completed||Phase 2|95|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:16.304848|2018-06-01 05:26:16.304848
NCT00015925|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2010-03-09|2003-01-26|2003-01-27|Estimate|||||||2010-03-09|2010-03-10|Estimate|February 2001||2001-02-28|March 2010|2010-03-31||||||||Interventional|||MS-275 in Treating Patients With Hematologic Cancer|Phase I Clinical-Labratory Study of the Histone Deacetylase (HDA) Inhibitor MS-275 in Adults With Refractory and Relapsed Hematologic Malignancies|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:26:16.563046|2018-06-01 05:26:16.563046
NCT00015899|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2009-10-13|2003-01-26|2003-01-27|Estimate|||||||2009-10-13|2009-10-14|Estimate|January 2002||2002-01-31|October 2009|2009-10-31|March 2007|Actual|2007-03-31|September 2005|Actual|2005-09-30||Interventional|||SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors|Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors|Completed||Phase 1|53|Actual|Pediatric Brain Tumor Consortium|||||f||||t||||||||||2018-06-01 05:26:16.655449|2018-06-01 05:26:16.655449
NCT00015873|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2014-02-14|2003-01-26|2003-01-27|Estimate|||||||2014-02-14|2014-02-17|Estimate|May 1999||1999-05-31|February 2014|2014-02-28|December 2009|Actual|2009-12-31|February 2006|Actual|2006-02-28||Interventional|||Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia|International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia|Completed||Phase 3|350|Anticipated|Dutch Childhood Oncology Group||2|||f||||t||||||||||2018-06-01 05:26:16.791224|2018-06-01 05:26:16.791224
NCT00015860|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|May 2001||2001-05-31|September 2003|2003-09-30|October 2003|Actual|2003-10-31|||||Interventional|||STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia|A Phase I/II Trial of STI-571 and Chemotherapy in Lymphoid Blast Crisis of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoid Leukemia|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:17.008951|2018-06-01 05:26:17.008951
NCT00015847|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|2012-06-06||2012-07-12|2003-01-26|2003-01-27|Estimate|2012-07-12|2012-08-20|Estimate||||2012-07-12|2012-08-20|Estimate|April 2001||2001-04-30|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia|A Phase I/II Dose-Finding Study to Determine the Safety, Tolerability, and Anti-Leukemic Effects of STI571 (NSC 716051) in Combination With Interferon-alpha in Patients With Chronic Myelogenous Leukemia in Chronic Phase|Terminated||Phase 2|25|Actual|OHSU Knight Cancer Institute|Early termination; 12 month follow-up was not carried out.||||f||||t||||||||||2018-06-01 05:26:17.175448|2018-06-01 05:26:17.175448
NCT00015834|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2001||2001-05-31|January 2013|2013-01-31||||April 2003|Actual|2003-04-30||Interventional|||STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia|A Phase I/II Trial of STI571 and High-Dose Cytarabine in Myeloid Blast Crisis of Chronic Myeloid Leukemia|Completed||Phase 1/Phase 2|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:17.499177|2018-06-01 05:26:17.499177
NCT00014612|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-10-28|2003-01-26|2003-01-27|Estimate|||||||2013-10-28|2013-10-29|Estimate|February 2001||2001-02-28|October 2013|2013-10-31|March 2013|Actual|2013-03-31|November 2010|Actual|2010-11-30||Interventional|AMAROS||Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer|After Mapping Of The Axilla: Radiotherapy Or Surgery|Completed||Phase 3|4813|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 05:26:17.614206|2018-06-01 05:26:17.614206
NCT00014599|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|February 2001||2001-02-28|September 2012|2012-09-30||||February 2005|Actual|2005-02-28||Interventional|||Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva|Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy|Completed||Phase 2|31|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:26:17.777829|2018-06-01 05:26:17.777829
NCT00014586|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2001||2001-01-31|September 2012|2012-09-30||||February 2003|Actual|2003-02-28||Interventional|||Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer|Randomized Phase III Step-Up Study On Initial Antiandrogen Monotherapy In Comparison With Watchful Waiting In Asymptomatic T1-3 Any G (Any Gleason) NO or Nx M0 Prostate Cancer Patients Without Local Treatment With Curative Intent|Terminated||Phase 3|110|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:26:17.864876|2018-06-01 05:26:17.864876
NCT00014521|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|January 2002||2002-01-31|February 2005|2005-02-28||||||||Interventional|||Karenitecin in Treating Patients With Recurrent Malignant Glioma|Phase I Evaluation Of The Safety Of Karenitecin In The Treatment Of Recurrent Malignant Gliomas|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:17.951185|2018-06-01 05:26:17.951185
NCT00014508|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2009-02-25|2003-01-26|2003-01-27|Estimate|||||||2009-02-25|2009-02-26|Estimate|April 2001||2001-04-30|November 2005|2005-11-30||||February 2007|Actual|2007-02-28||Interventional|||Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:18.031404|2018-06-01 05:26:18.031404
NCT00014495|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|2015-12-17||2015-12-17|2003-01-26|2003-01-27|Estimate|2015-12-17|2016-01-22|Estimate||||2015-12-17|2016-01-22|Estimate|November 2000||2000-11-30|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer|Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies|Completed||Phase 1/Phase 2|32|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:26:18.13755|2018-06-01 05:26:18.13755
NCT00014482|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-18|Estimate|December 2000||2000-12-31|June 2013|2013-06-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation|Music Therapy for Distress During Autologous Stem Cell Transplantation: A Randomized Trial|Completed||N/A|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:18.598528|2018-06-01 05:26:18.598528
NCT00014469|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-03-06|2003-01-26|2003-01-27|Estimate|||||||2013-03-06|2013-03-07|Estimate|December 2000||2000-12-31|March 2013|2013-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer|A Phase II Trial of IV Busulfan (Busulfex) and Melphalan as a Preparatory Regimen Prior to Allogeneic Bone Marrow Transplantation for the Treatment of Advanced and High Risk Hematologic Malignancies|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:18.685911|2018-06-01 05:26:18.685911
NCT00014456|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-08-27|2003-01-26|2003-01-27|Estimate|||||||2013-08-27|2013-08-28|Estimate|March 2000||2000-03-31|August 2013|2013-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors|A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors|Completed||Phase 1|35|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-06-01 05:26:18.868911|2018-06-01 05:26:18.868911
NCT00014443|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|August 2000||2000-08-31|January 2006|2006-01-31||||||||Interventional|||Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma|A Pilot Study Of Hycamtin (Topotecan) And Thalomid (Thalidomide) In Patients With Recurrent Malignant Gliomas|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:18.979503|2018-06-01 05:26:18.979503
NCT00014378|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2015-12-17|2003-01-26|2003-01-27|Estimate|||||||2015-12-17|2015-12-18|Estimate|October 2000||2000-10-31|December 2015|2015-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors|A Phase I Study Of The Chinese Herb Huanglian (Coptis Chinesis) In Patients With Advanced Solid Tumors|Completed||Phase 1|34|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:26:19.124474|2018-06-01 05:26:19.124474
NCT00014326|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2012-07-13|2003-01-26|2003-01-27|Estimate|||||||2012-07-13|2012-07-16|Estimate|January 2001||2001-01-31|July 2012|2012-07-31||||March 2009|Actual|2009-03-31||Interventional|||Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma|A Phase III Randomized Study On Low-Dose Total Body Irradiation And Involved Field Radiotherapy In Patients With Localized, Stages I and II, Low Grade Non-Hodgkin's Lymphoma|Terminated||Phase 3|204|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:26:19.236262|2018-06-01 05:26:19.236262
NCT00014313|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2001||2001-01-31|September 2012|2012-09-30||||December 2002|Actual|2002-12-31||Interventional|||Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor|A Phase II Study to Evaluate the Role of Weekly Cisplatin With Oral Etoposide in Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) With Bone and/or Bone Marrow Metatstatic Disease|Terminated||Phase 2|3|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:26:19.411486|2018-06-01 05:26:19.411486
NCT00014274|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-06-11|2003-01-26|2003-01-27|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2001||2001-01-31|June 2013|2013-06-30||||March 2008|Actual|2008-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium|Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy|Completed||Phase 2/Phase 3|238|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:26:19.544065|2018-06-01 05:26:19.544065
NCT00014235|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2017-11-20|2003-01-26|2003-01-27|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2000||2000-12-31|November 2017|2017-11-30||||February 2005|Actual|2005-02-28||Interventional|||Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies|Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine and/or Low Dose TBI With Disease-Risk Based Immunosuppression|Active, not recruiting||N/A|160|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||||||||||||2018-06-01 05:26:19.734733|2018-06-01 05:26:19.734733
NCT00014222|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2014-03-17|2003-01-26|2003-01-27|Estimate|||||||2014-03-17|2014-03-18|Estimate|December 2000||2000-12-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|October 2006|Actual|2006-10-31||Interventional|||Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer|A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery For Node Positive Or High Risk Node Negative Breast Cancer|Completed||Phase 3|2104|Actual|Canadian Cancer Trials Group||3|||f||||t||||||||||2018-06-01 05:26:19.999618|2018-06-01 05:26:19.999618
NCT00014196|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-02-12|2003-01-26|2003-01-27|Estimate|||||||2013-02-12|2013-02-15|Estimate|March 2001||2001-03-31|February 2013|2013-02-28|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer|Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer|Terminated||Phase 2|33|Actual|Southwest Oncology Group||1||This study was closed early due to poor accrual.|f||||f||||||||||2018-06-01 05:26:20.29938|2018-06-01 05:26:20.29938
NCT00014131|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2016-05-25|2003-01-26|2003-01-27|Estimate|||||||2016-05-25|2016-05-27|Estimate|November 2001||2001-11-30|June 2014|2014-06-30||||December 2009|Actual|2009-12-31||Interventional|||Vaccine Therapy in Treating Patients With Kidney Cancer|Vaccine Biotherapy Of Cancer: Autologous Tumor Cells And Dendritic Cells As Active Specific Immunotherapy In Patients With Stage IV Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|9|Actual|Caladrius Biosciences, Inc.||1|||f||||f||||||||||2018-06-01 05:26:20.529516|2018-06-01 05:26:20.529516
NCT00014118|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2015-10-06|2003-01-26|2003-01-27|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2001||2001-03-31|October 2015|2015-10-31|May 2009|Actual|2009-05-31|March 2007|Actual|2007-03-31||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer|A Phase II Trial OF Chemoradiation For Organ Preservation In Resectable Stage III or IV Squamous Cell Carcinomas Of The Larynx Or Oropharynx|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:26:20.695056|2018-06-01 05:26:20.695056
NCT00014092|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2013-03-25|2003-01-26|2003-01-27|Estimate|||||||2013-03-25|2013-03-26|Estimate|December 1999||1999-12-31|March 2004|2004-03-31|December 2003|Actual|2003-12-31|||||Interventional|||Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery|Treatment of Patients With Metastatic Malignant Melanoma With Chemobiotherapy With Temozolomide, GM-CSF, IL2, and Interferon Alfa-2b Phase II Trial|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:20.910443|2018-06-01 05:26:20.910443
NCT00012389|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2000||2000-12-31|October 2002|2002-10-31|October 2008|Actual|2008-10-31|||||Interventional|||Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer|A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:21.184569|2018-06-01 05:26:21.184569
NCT00012376|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-01-08|2003-01-26|2003-01-27|Estimate|||||||2013-01-08|2013-01-09|Estimate|March 2001||2001-03-31|January 2013|2013-01-31||||January 2010|Actual|2010-01-31||Interventional|||Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer|Dose Finding Study of Bryostatin-1 and GM-CSF in Refractory Myeloid Malignancies|Completed||Phase 1|35|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:22.30546|2018-06-01 05:26:22.30546
NCT00012363|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2012-06-12|2003-01-26|2003-01-27|Estimate|||||||2012-06-12|2012-06-14|Estimate|April 2001||2001-04-30|June 2012|2012-06-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus|Gemcitabine Plus Irinotecan in Patients With Esophageal Cancer, Phase II|Completed||Phase 2|61|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:22.427998|2018-06-01 05:26:22.427998
NCT00012324|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2000||2000-09-30|October 2005|2005-10-31|November 2005|Actual|2005-11-30|||||Interventional|||Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer|A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:22.832183|2018-06-01 05:26:22.832183
NCT00012298|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|2015-11-04||2015-11-04|2003-01-26|2003-01-27|Estimate|2015-11-04|2015-12-17|Estimate||||2015-11-04|2015-12-17|Estimate|April 2001||2001-04-30|December 2012|2012-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of Two Sequential Doses of IDEC-Y2B8 in Patients With Relapsed Low-Grade and Follicular Non-Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|81|Actual|National Cancer Institute (NCI)||1||Trial completed prematurely.|f||||||||||||||2018-06-01 05:26:23.063076|2018-06-01 05:26:23.063076
NCT00012246|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-05-15|2003-01-26|2003-01-27|Estimate|||||||2013-05-15|2013-05-16|Estimate|July 2002||2002-07-31|May 2013|2013-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract|A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin|Terminated||Phase 2|7|Actual|The University of Texas Medical Branch, Galveston||||Administratively Terminated|f||||||||||||||2018-06-01 05:26:24.561918|2018-06-01 05:26:24.561918
NCT00012220|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|January 2001||2001-01-31|July 2016|2016-07-31|April 2009|Actual|2009-04-30|June 2004|Actual|2004-06-30||Interventional|||Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas|A Randomized Phase II Study Of Gemcitabine/Cisplatin, Gemcitabine/Docetaxel, Gemcitabine/Irinotecan, Or Fixed Dose Rate Infusion Gemcitabine In Patients With Metastic Pancreatic Cancer|Completed||Phase 2|259|Actual|Alliance for Clinical Trials in Oncology||4|||f||||t||||||||||2018-06-01 05:26:24.712316|2018-06-01 05:26:24.712316
NCT00012207|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2010-08-20|2003-01-26|2003-01-27|Estimate|||||||2010-08-20|2010-08-24|Estimate|September 2000||2000-09-30|August 2010|2010-08-31|July 2010|Actual|2010-07-31|||||Interventional|||Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase I Study To Evaluate The Safety Of Cellular Immunotherapy Using Genetically Modified Autologous Cd20-Specific Cd8+ T Cell Clones For Patients With Relapsed Cd20+ Indolent Lymphomas|Completed||Phase 1|12|Anticipated|Fred Hutchinson Cancer Research Center|||||||||t||||||||||2018-06-01 05:26:24.954254|2018-06-01 05:26:24.954254
NCT00012194|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-07-08|2003-01-26|2003-01-27|Estimate|||||||2013-07-08|2013-07-09|Estimate|March 2001||2001-03-31|July 2013|2013-07-31||||January 2007|Actual|2007-01-31||Interventional|||7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors|Phase I Dose Escalation Study of UCN-01 (NSC 638850) Plus Cisplatin in Advanced Malignant Solid Tumors|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:25.055958|2018-06-01 05:26:25.055958
NCT00012181|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-07-01|2003-01-26|2003-01-27|Estimate|||||||2013-07-01|2013-07-02|Estimate|April 2001||2001-04-30|July 2013|2013-07-31||||January 2005|Actual|2005-01-31||Interventional|||Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas|A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:25.180236|2018-06-01 05:26:25.180236
NCT00012168|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2016-03-10|2003-01-26|2003-01-27|Estimate|||||||2016-03-10|2016-03-11|Estimate|May 1999||1999-05-31|March 2016|2016-03-31||||July 2003|Actual|2003-07-31||Interventional|||Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat|Lymphoscintigraphy Assisted Molecular Staging of Head and Neck Cancer|Completed||N/A|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:26:25.342609|2018-06-01 05:26:25.342609
NCT00012103|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2011-03-25|2003-01-26|2003-01-27|Estimate|||||||2011-03-25|2011-03-28|Estimate|September 1999||1999-09-30|March 2011|2011-03-31||||December 2001|Actual|2001-12-31||Interventional|||Computed Tomography for Early Detection of Cancer in Women Who Are at Risk for Lung Cancer|Prevention and Early Detection of Lung Cancer in Women|Completed||N/A|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:26:25.444463|2018-06-01 05:26:25.444463
NCT00012064|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2014-01-27|2003-01-26|2003-01-27|Estimate|||||||2014-01-27|2014-01-29|Estimate|July 2000||2000-07-31|August 2013|2013-08-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma|Vaccine Biotherapy of Cancer: Tumor Cells and Dendritic Cells as Active Specific Immunotherapy of Patients With Metastatic Melanoma|Completed||Phase 1/Phase 2|56|Actual|Caladrius Biosciences, Inc.||1|||f||||f||||||||||2018-06-01 05:26:25.574585|2018-06-01 05:26:25.574585
NCT00012051|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-08-09|2003-01-26|2003-01-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|September 2000||2000-09-30|March 2007|2007-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma|A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma(HOVON 44 STUDY)|Completed||Phase 3|340|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:25.720164|2018-06-01 05:26:25.720164
NCT00012038|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 2001||2001-07-31|September 2003|2003-09-30|October 2003|Actual|2003-10-31|||||Interventional|||Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors|A Phase I/II Trial Of MGI114 For Treatment Of Patients With Recurrent Malignant Gliomas|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:25.847876|2018-06-01 05:26:25.847876
NCT00012025|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|May 2001||2001-05-31|July 2016|2016-07-31|August 2008|Actual|2008-08-31|March 2006|Actual|2006-03-31||Interventional|||ICI 182780 in Treating Women With Metastatic Breast Cancer|Phase II Trial Of Fulvestrant (Faslodex) In Women With Metastatic Breast Cancer And Failure on Aromatase Inhibitor Therapy|Completed||Phase 2|80|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:25.990692|2018-06-01 05:26:25.990692
NCT00012012|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|2014-12-24||2014-12-24|2003-01-26|2003-01-27|Estimate|2014-12-24|2015-01-07|Estimate||||2014-12-24|2015-01-07|Estimate|August 2001||2001-08-31|December 2014|2014-12-31|June 2010|Actual|2010-06-30|September 2007|Actual|2007-09-30||Interventional||All eligible patients.|Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer|A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes|Completed||Phase 1/Phase 2|45|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:26:26.244849|2018-06-01 05:26:26.244849
NCT00011999|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2015-11-14|2003-01-26|2003-01-27|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 2001||2001-03-31|November 2015|2015-11-30|June 2010|Actual|2010-06-30|February 2004|Actual|2004-02-29||Interventional|||Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer|Phase II Early Postoperative Paclitaxel Followed By Paclitaxel And Cisplatin Concurrent With Radiation Therapy For Resected, High Risk Squamous Carcinoma Of The Head And Neck|Completed||Phase 2|70|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:27.109533|2018-06-01 05:26:27.109533
NCT00011986|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|2014-02-18||2016-03-17|2003-01-26|2003-01-27|Estimate|2016-03-17|2016-04-19|Estimate||||2016-03-17|2016-04-19|Estimate|January 2001||2001-01-31|March 2016|2016-03-31||||March 2010|Actual|2010-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer|A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma|Completed||Phase 3|3882|Actual|Gynecologic Oncology Group||5|||f||||||||||||||2018-06-01 05:26:27.585482|2018-06-01 05:26:27.585482
NCT00011960|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2015-11-14|2003-01-26|2003-01-27|Estimate|||||||2015-11-14|2015-11-17|Estimate|May 2001||2001-05-31|November 2015|2015-11-30||||May 2006|Actual|2006-05-31||Interventional|||Chemotherapy and Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Stomach Who Have Undergone Surgery|A Randomized Phase II Comparison Of Two Cisplatin-Paclitaxel Containing Chemoradiation Regimens In Resected Gastric Cancers|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:26:28.768409|2018-06-01 05:26:28.768409
NCT00011921|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 1997||1997-09-30|March 2003|2003-03-31||||||||Interventional|||Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer|Phase III Randomized Trial of Sequential High-Dose Chemotherapy Versus Standard Chemotherapy for the Treatment of Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|430|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:29.052989|2018-06-01 05:26:29.052989
NCT00010270|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|April 2001||2001-04-30|January 2007|2007-01-31||||||||Interventional|||LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer|A Phase I Study Of LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin Administered By 5-Days Continuous Infusion For Patients With Colorectal Adenocarcinoma|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:29.151164|2018-06-01 05:26:29.151164
NCT00010257|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|2012-09-17||2015-10-07|2003-01-26|2003-01-27|Estimate|2012-09-17|2012-10-18|Estimate||||2015-10-07|2015-10-09|Estimate|February 2001||2001-02-28|June 2013|2013-06-30|August 2012|Actual|2012-08-31|November 2008|Actual|2008-11-30||Interventional|||Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma|Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma|Completed||Phase 2|46|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:26:29.249284|2018-06-01 05:26:29.249284
NCT00010218|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|April 2001||2001-04-30|July 2016|2016-07-31|January 2006|Actual|2006-01-31|April 2003|Actual|2003-04-30||Interventional|||Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer|Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer|Completed||Phase 2|55|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:29.834721|2018-06-01 05:26:29.834721
NCT00010205|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-01-24|2003-01-26|2003-01-27|Estimate|||||||2013-01-24|2013-01-25|Estimate|December 2000||2000-12-31|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Benzoylphenylurea in Treating Patients With Advanced Cancer|Phase I Trial Of Benzoylphenylurea (NSC#639829) In Advanced Malignancy|Terminated||Phase 1|30|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:26:30.008535|2018-06-01 05:26:30.008535
NCT00010192|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-06-05|2003-01-26|2003-01-27|Estimate|||||||2013-06-05|2013-06-06|Estimate|December 2000||2000-12-31|June 2013|2013-06-30||||January 2003|Actual|2003-01-31||Interventional|||Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer|A Phase I Trial Of Rituximab And Interleukin-2|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:30.135515|2018-06-01 05:26:30.135515
NCT00010166|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2017-05-25|2003-01-26|2003-01-27|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2000|Actual|2000-12-31|August 2009|2009-08-31|October 3, 2003|Actual|2003-10-03|October 3, 2003|Actual|2003-10-03||Interventional|||Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas|Phase II Trial Of Adjuvant 2'2'-Difluoro-2'-Deoxycytidine (Gemcitabine) And External Beam Radiation For The Treatment Of Resectable Pancreatic Cancer|Completed||Phase 2|26|Actual|Wake Forest University Health Sciences|||||f|||||t|f||||||||2018-06-01 05:26:30.280242|2018-06-01 05:26:30.280242
NCT00010153|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2012-07-18|2003-01-26|2003-01-27|Estimate|||||||2012-07-18|2012-07-19|Estimate|November 2000||2000-11-30|July 2012|2012-07-31||||October 2001|Actual|2001-10-31||Interventional|||ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer|"A Double-Blind Phase III Clinical Trial to Compare the Effects of a Pre-Operatively Administered Single Dose of Faslodex (Long-Acting ICI 182.780) With Placebo on Tumor Recurrence in Pre- and Postmenopausal Women Treated for Operable First Primary Breast Cancer"|Terminated||Phase 3|||European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:26:30.414489|2018-06-01 05:26:30.414489
NCT00010140|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 1997||1997-08-31|September 2005|2005-09-30||||||||Interventional|||Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer|A Multicenter Randomized Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin in Node Positive Postmenopausal Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:30.490563|2018-06-01 05:26:30.490563
NCT00010101|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2011-07-19|2003-01-26|2003-01-27|Estimate|||||||2011-07-19|2011-07-20|Estimate|March 2001||2001-03-31|July 2011|2011-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Observational|||Genetic Study of Brain Tumors in Young Children|INI1 Mutation Analysis and Expression Profiling of Embryonal CNS Tumors|Terminated|||38|Actual|Pediatric Brain Tumor Consortium||||Poor accrual|f||||f||||||Samples With DNA|"~     Tumor samples~   "|||2018-06-01 05:26:30.595421|2018-06-01 05:26:30.595421
NCT00010075|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|January 2000||2000-01-31|June 2003|2003-06-30||||||||Interventional|||Combination Chemotherapy in Treating Older Women With Metastatic Breast Cancer|Study Of The Survival Without Degradation To The Quality Of Life During Chemotherapy For Metastatic Breast Cancer In Women|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:30.701294|2018-06-01 05:26:30.701294
NCT00010062|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 2000||2000-10-31|April 2007|2007-04-30||||||||Interventional|||Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer|Study Of Post-Operative Concomitant Radio-Chemotherapy With A Continuous Infusion Of Flourouracil For Adjuvant Treatment Of Resected Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:30.795606|2018-06-01 05:26:30.795606
NCT00010049|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2010-07-31|2003-01-26|2003-01-27|Estimate|||||||2010-07-31|2010-08-03|Estimate|November 2002||2002-11-30|December 2003|2003-12-31||||||||Interventional|||Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma|Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:31.026156|2018-06-01 05:26:31.026156
NCT00010023|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2011-04-04|2003-01-26|2003-01-27|Estimate|||||||2011-04-04|2011-04-05|Estimate|August 2000||2000-08-31|April 2011|2011-04-30||||August 2007|Actual|2007-08-31||Interventional|||Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors|A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:26:31.123398|2018-06-01 05:26:31.123398
NCT00009984|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-06-05|2003-01-26|2003-01-27|Estimate|||||||2013-06-05|2013-06-06|Estimate|March 2002||2002-03-31|June 2013|2013-06-30||||November 2006|Actual|2006-11-30||Interventional|||Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer|Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine|Terminated||Phase 2|70|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:26:31.241834|2018-06-01 05:26:31.241834
NCT00009971|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 2000||2000-11-30|October 2003|2003-10-31||||September 2005|Actual|2005-09-30||Interventional|||Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer|Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:31.384848|2018-06-01 05:26:31.384848
NCT00009945|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|2017-10-17||2017-11-17|2003-01-26|2003-01-27|Estimate|2017-10-17|2017-11-20|Actual||||2017-11-17|2017-12-13|Actual|January 2001||2001-01-31|November 2017|2017-11-30|December 2012|Actual|2012-12-31|March 2011|Actual|2011-03-31||Interventional|||Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer|A Clinical Trial Comparing Adjuvant Clodronate Therapy vs Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Hormonal Therapy or No Therapy|Completed||Phase 3|3323|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 05:26:31.54573|2018-06-01 05:26:31.54573
NCT00009880|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-19|Estimate|April 2001||2001-04-30|July 2004|2004-07-31||||July 2006|Actual|2006-07-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach|Non-Operative Therapy Of Local-Regional Carcinoma Of The Esophagus: A Randomizd Phase II Study Of Two Paclitaxel-Based Chemoradiotherapy Regimens|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:26:32.359538|2018-06-01 05:26:32.359538
NCT00009854|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2000||2000-06-30|March 2003|2003-03-31||||||||Interventional|||Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm|Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:32.538345|2018-06-01 05:26:32.538345
NCT00009776|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2001||2001-03-31|October 2001|2001-10-31||||||||Interventional|||Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma|Combined Modality Radioimmunotherapy For Non-Hodgkin's Lymphoma With Three Cycles Of 90Y-DOTA-peptide-Lym-1, Paclitaxel and Cyclosporin A|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:32.607133|2018-06-01 05:26:32.607133
NCT00009763|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2001||2001-03-31|November 2003|2003-11-30||||||||Interventional|||Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer|Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:32.691941|2018-06-01 05:26:32.691941
NCT00009750|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2001||2001-03-31|November 2003|2003-11-30||||||||Interventional|||Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|Combined Modality Radioimmunotherapy For Hormone Refractory Metastatic Prostate Cancer With Two Cycles Of Escalating Dose 90Y-DOTA-Peptide-m170 And Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:32.756748|2018-06-01 05:26:32.756748
NCT00009711|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-04-29|2003-01-26|2003-01-27|Estimate|||||||2013-04-29|2013-05-01|Estimate|March 1996||1996-03-31|April 2013|2013-04-30|August 2005|Actual|2005-08-31|August 2004|Actual|2004-08-31||Observational|||Study of Lung Function in Children Who Have Undergone Bone Marrow Transplantation|The Impact of Pediatric Marrow Transplantation on Late Pulmonary Function|Completed|||280|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:26:32.830834|2018-06-01 05:26:32.830834
NCT00008697|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-13|||2013-04-11|2003-01-26|2003-01-27|Estimate|||||||2013-04-11|2013-04-12|Estimate|November 1998||1998-11-30|April 2013|2013-04-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia|A Phase I/II Trial of Infusional Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia|Completed||Phase 1/Phase 2|13|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-06-01 05:26:32.886771|2018-06-01 05:26:32.886771
NCT00008437|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2012-06-29|2003-01-26|2003-01-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|December 2000||2000-12-31|June 2012|2012-06-30|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||MRI-Guided Ultrasound Energy in Treating Patients With Stage I, Stage II, or Stage IIIA Breast Cancer|Pilot Study of MR-Guided Focused Ultrasound for Tissue Coagulation in Women With Breast Cancer: MR Imaging and Histopathic Correlation, An Assessment or Target Accuracy and Patient Acceptance|Completed||Phase 2|||InSightec|||||f||||f||||||||||2018-06-01 05:26:32.985278|2018-06-01 05:26:32.985278
NCT00008411|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2012-07-27|2003-01-26|2003-01-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|December 1999||1999-12-31|July 2012|2012-07-31|January 2007|Actual|2007-01-31|March 2006|Actual|2006-03-31||Interventional|||Docetaxel in Treating Patients With Metastatic Breast Cancer|Phase III Study Comparing the Use of Docetaxel on a Every Three-Week vs. Weekly Schedule in the Treatment of Patients With Metastatic Breast Cancer|Completed||Phase 3|90|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:26:33.062744|2018-06-01 05:26:33.062744
NCT00008385|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|2016-02-02||2016-03-31|2003-01-26|2003-01-27|Estimate|2016-03-31|2016-05-04|Estimate||||2016-03-31|2016-05-04|Estimate|October 2000||2000-10-31|March 2016|2016-03-31|November 2019|Anticipated|2019-11-30|June 2011|Actual|2011-06-30||Interventional||All randomized patients|Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer|Phase III Chemoprevention Trial Of Selenium Supplementation In Persons With Resected Stage I Non-Small Cell Lung Cancer|Terminated||Phase 3|1772|Actual|Eastern Cooperative Oncology Group||2||The trial was stopped based on futility analysis results in November 2009.|f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-06-01 05:26:33.265054|2018-06-01 05:26:33.265054
NCT00008346|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2017-07-07|2003-01-26|2003-01-27|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2001|Actual|2001-10-31|July 2017|2017-07-31|June 30, 2005|Actual|2005-06-30|February 2005|Actual|2005-02-28||Interventional|DMIST||Digital Mammography Screening Trial (ACRIN6652)|Screening and Diagnostic Trial to Compare the Effectiveness of Two Types of Mammography in Detecting Breast Cancer in Women|Completed||N/A|49528|Actual|American College of Radiology Imaging Network||2|||f||||||||||||||2018-06-01 05:26:34.45822|2018-06-01 05:26:34.45822
NCT00008307|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|April 1998||1998-04-30|April 2006|2006-04-30||||||||Interventional|||Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders|Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation|Unknown status|Active, not recruiting|Phase 2|52|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:34.588451|2018-06-01 05:26:34.588451
NCT00008294|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-01-17|2003-01-26|2003-01-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2000||2000-08-31|January 2013|2013-01-31||||May 2006|Actual|2006-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer|A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:34.69788|2018-06-01 05:26:34.69788
NCT00008268|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-18|Estimate|August 2000||2000-08-31|June 2013|2013-06-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma|A Phase II Study Of Blood Stem Cell Mobilization With Intravenous Melphalan (60 MG/M2) + G-CSF In Patients With Multiple Myeloma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:34.778456|2018-06-01 05:26:34.778456
NCT00008216|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2014-06-05|2003-01-26|2003-01-27|Estimate|||||||2014-06-05|2014-06-06|Estimate|July 1996||1996-07-31|June 2014|2014-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31|36 Months|Observational [Patient Registry]|||Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer|The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation|Terminated|||48|Actual|Columbia University|||1|Poor enrollment|f||||f||||||Samples Without DNA|"~     Standard bloodwork that would be required for transplantation patients~   "|||2018-06-01 05:26:34.885426|2018-06-01 05:26:34.885426
NCT00008190|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-02-01|2003-01-26|2003-01-27|Estimate|||||||2013-02-01|2013-02-04|Estimate|March 1999||1999-03-31|April 2004|2004-04-30|May 2008|Actual|2008-05-31|November 2005|Actual|2005-11-30||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia|High Dose Chemotherapy And Autologous Peripheral Blood Stem Cell Rescue For High Risk Acute Leukemia|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:34.981737|2018-06-01 05:26:34.981737
NCT00008164|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 1997||1997-01-31|January 2007|2007-01-31||||||||Interventional|||Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia|Transplantation Using Umbilical Cord And Placental Blood|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:35.041407|2018-06-01 05:26:35.041407
NCT00008138|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|2012-06-13||2015-12-08|2003-01-26|2003-01-27|Estimate|2012-07-20|2012-08-24|Estimate||||2015-12-08|2016-01-08|Estimate|March 2001||2001-03-31|December 2015|2015-12-31|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|S0009||S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer|Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer|Completed||Phase 2|62|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:26:35.152772|2018-06-01 05:26:35.152772
NCT00006260|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|May 1997||1997-05-31|June 2010|2010-06-30||||January 2005|Actual|2005-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer|A Phase II Study Of An OutPatient Three Day VIP Regimen With Oral Mesna For Metastatic Breast Cancer|Completed||Phase 2|36|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:26:49.950679|2018-06-01 05:26:49.950679
NCT00008060|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2000||2000-05-31|March 2002|2002-03-31|December 2003|Actual|2003-12-31|||||Interventional|||Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer|Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:35.467111|2018-06-01 05:26:35.467111
NCT00008047|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 1999||1999-08-31|February 2001|2001-02-28||||||||Interventional|||Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus|Multicentre Phase II Study Of Concomitant Radio-Chemotherapy Associating Continuous Infusion 5-FU With Hydroxyuree Via Bone Marrow With Or Without Paclitaxel In Treatment Of Inoperable Epidermoid Carcinoma Of Esophagus|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:35.56763|2018-06-01 05:26:35.56763
NCT00008008|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-02-01|2003-01-26|2003-01-27|Estimate|||||||2013-02-01|2013-02-04|Estimate|September 1997||1997-09-30|July 2007|2007-07-31|May 2008|Actual|2008-05-31|June 2005|Actual|2005-06-30||Interventional|||Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma|CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:35.664027|2018-06-01 05:26:35.664027
NCT00007995|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-02-01|2003-01-26|2003-01-27|Estimate|||||||2013-02-01|2013-02-04|Estimate|July 1999||1999-07-31|July 2007|2007-07-31|May 2008|Actual|2008-05-31|November 2007|Actual|2007-11-30||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis|Phase 2 Study Of High Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support In Patients With Multiple Myeloma And Primary Light Chain Amyloidosis|Completed||Phase 2|75|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:35.744967|2018-06-01 05:26:35.744967
NCT00007982|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-02-01|2003-01-26|2003-01-27|Estimate|||||||2013-02-01|2013-02-04|Estimate|April 1999||1999-04-30|July 2007|2007-07-31|May 2008|Actual|2008-05-31|February 2005|Actual|2005-02-28||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer|CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:35.814799|2018-06-01 05:26:35.814799
NCT00007956|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|November 2000||2000-11-30|February 2002|2002-02-28||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma|A Phase I Study Of Therapy With Mono-dgA-RFB4 In Patients With Relapsed And Refractory CD22+ B-Cell Lymphoma|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:36.895713|2018-06-01 05:26:36.895713
NCT00007930|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|August 1999||1999-08-31|December 2006|2006-12-31||||||||Interventional|||Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer|Randomized Trial of Wide Mesorectal Excision Versus Total Mesorectal Excision for Mid Rectal Cancer|Unknown status|Recruiting|Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:36.959643|2018-06-01 05:26:36.959643
NCT00007904|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2012-09-28|2003-01-26|2003-01-27|Estimate|||||||2012-09-28|2012-10-02|Estimate|July 2000||2000-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|June 2006|Actual|2006-06-30||Interventional|||Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes|A Phase II Study Of Safety And Tolerability Of Adjuvant Chemotherapy With Continuous Infusion Paclitaxel And Dose Intense Cyclophosphamide And Hematopoietic Growth Factor Support Followed By Doxorubicin For Stage II-IIIA Breast Cancer Involving Greater Than or Equal to 10 Lymph Nodes|Completed||Phase 2|16|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:26:37.07302|2018-06-01 05:26:37.07302
NCT00007891|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|June 1997||1997-06-30|September 2004|2004-09-30|October 2004|Actual|2004-10-31|||||Interventional|||Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer|Phase I Study of 90-Y-Humanized-BrE-3 Followed by Autologous Hematopoietic Progenitor Cell Support in Patients With Metastatic Breast Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:37.192018|2018-06-01 05:26:37.192018
NCT00007865|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2018-01-13|2003-01-26|2003-01-27|Estimate|||||||2018-01-13|2018-01-17|Actual|September 2000||2000-09-30|January 2018|2018-01-31|April 2008|Actual|2008-04-30|March 2004|Actual|2004-03-31||Interventional|||Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma|A Phase II Trial of Ifosfamide, Carboplatin, and Etoposide (ICE) Chemotherapy in Combination With Rituximab as Salvage Therapy|Completed||Phase 2|||University of Nebraska|||||f||||f||||||||||2018-06-01 05:26:37.27508|2018-06-01 05:26:37.27508
NCT00007826|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|April 2000||2000-04-30|February 2005|2005-02-28||||||||Interventional|||Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer|A Phase I/II Trial of an Allogeneic Cell Based Vaccine and an Anti-Idiotypic Antibody Vaccine Approach for Metastatic Adenocarcinoma of the Colon or Rectum|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:37.355522|2018-06-01 05:26:37.355522
NCT00006994|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2015-11-17|2003-01-26|2003-01-27|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2001||2001-11-30|November 2015|2015-11-30|April 2006|Actual|2006-04-30|April 2005|Actual|2005-04-30||Interventional|||S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat|S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III|Terminated||Phase 3|23|Actual|Southwest Oncology Group||2||Withdrawn due to drug availability and funding|f||||t||||||||||2018-06-01 05:26:37.457041|2018-06-01 05:26:37.457041
NCT00006981|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2015-04-29|2003-01-26|2003-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|December 2000||2000-12-31|May 2005|2005-05-31||||||||Interventional|||Immunotoxin Therapy in Treating Patients With Advanced Cancer|Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:37.791926|2018-06-01 05:26:37.791926
NCT00006942|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|October 2000||2000-10-31|August 2013|2013-08-31||||March 2004|Actual|2004-03-31||Interventional|||Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Bryostatin in Combination With Cisplatin in Patients With Recurrent or Persistent Epithelial Ovarian Cancer|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:37.886867|2018-06-01 05:26:37.886867
NCT00006929|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|September 2000||2000-09-30|June 2013|2013-06-30||||November 2007|Actual|2007-11-30||Interventional|||Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|A Phase I/II Study of Carboplatin / Paclitaxel / Suramin Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|82|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:38.038542|2018-06-01 05:26:38.038542
NCT00006916|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|2013-06-12||2015-11-14|2003-01-26|2003-01-27|Estimate|2013-12-10|2014-02-03|Estimate||||2015-11-14|2015-12-11|Estimate|June 2001||2001-06-30|November 2015|2015-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme|A Phase II Trial Of Conventional Radiation Therapy Followed By Intratumoral Bleomycin Delivered Using A Refillable, Sustained Release Device (IND# 46,592) For The Treatment Of Supratentorial Glioblastoma|Terminated||Phase 2|19|Actual|Radiation Therapy Oncology Group|This study stopped accrual early due unmet targeted accrual goals with 19 subjects accrued out of 72 planned. No efficacy analyses were performed since the small number of patients would not have provided meaningful results.|1||Low accrual|f||||t||||||||||2018-06-01 05:26:38.176948|2018-06-01 05:26:38.176948
NCT00006903|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|2014-05-20||2018-03-16|2003-01-26|2003-01-27|Estimate|2014-05-20|2014-06-24|Estimate||||2018-03-16|2018-03-20|Actual|August 2004||2004-08-31|May 2017|2017-05-31||||March 2008|Actual|2008-03-31||Interventional||Total number of eligible and treated participants by estrogen receptor status in metastatic tumor|Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer|Phase II Study of Faslodex ® in Recurrent/Metastatic Endometrial Carcinoma|Active, not recruiting||Phase 2|67|Actual|Gynecologic Oncology Group|Accrual was discontinued after completion of the first stage of accrual due to lack of study drug activity.|1|||f||||||||||||||2018-06-01 05:26:38.418537|2018-06-01 05:26:38.418537
NCT00006825|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2011-03-25|2003-01-26|2003-01-27|Estimate|||||||2011-03-25|2011-03-28|Estimate|July 2000||2000-07-31|March 2011|2011-03-31||||July 2004|Actual|2004-07-31||Interventional|||Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer|A Safety Study Of Doxil And Herceptin In Patients With Advanced Her-2 Overexpressing Breast Cancer|Completed||Phase 1/Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:26:38.903973|2018-06-01 05:26:38.903973
NCT00006773|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2001||2001-05-31|January 2013|2013-01-31||||June 2007|Actual|2007-06-30||Interventional|||Bortezomib in Treating Patients With Recurrent Glioma|Phase I Evaluation of the Safety of PS 341 in the Treatment of Recurrent Gliomas|Terminated||Phase 1|42|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:26:38.96966|2018-06-01 05:26:38.96966
NCT00006760|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-07-25|2003-01-26|2003-01-27|Estimate|||||||2013-07-25|2013-07-26|Estimate|May 2001||2001-05-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|July 2005|Actual|2005-07-31||Interventional|||Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma|A Pilot Study of Re-Induction Chemotherapy With Ifosfamide, and Vinorelbine (IV) in Children With Refractory/Relapsed Hodgkin's Disease|Completed||Phase 2|66|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:39.116004|2018-06-01 05:26:39.116004
NCT00006747|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-19|Estimate|November 2000||2000-11-30|July 2016|2016-07-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma|Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma|Completed||Phase 2|4|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:39.395188|2018-06-01 05:26:39.395188
NCT00006734|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-05-16|2003-01-26|2003-01-27|Estimate|||||||2013-05-16|2013-05-17|Estimate|May 2001||2001-05-31|May 2013|2013-05-31||||August 2006|Actual|2006-08-31||Interventional|||Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor|Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors|Completed||Phase 3|587|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:26:39.690805|2018-06-01 05:26:39.690805
NCT00006721|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|2012-11-02||2017-07-13|2003-01-26|2003-01-27|Estimate|2013-01-22|2013-02-26|Estimate||||2017-07-13|2017-08-11|Actual|March 2001||2001-03-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|September 2011|Actual|2011-09-30||Interventional|||S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma|A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas|Active, not recruiting||Phase 3|571|Actual|Southwest Oncology Group||3|||f||||t|t|f||||||Yes|https://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-06-01 05:26:40.331244|2018-06-01 05:26:40.331244
NCT00006695|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2015-05-26|2003-01-26|2003-01-27|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2000||2000-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|September 2005|Actual|2005-09-30||Interventional|||Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|BEAM Plus Iodine-131 Anti-B1 Antibody and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|50|Actual|University of Nebraska||1|||f||||||||||||||2018-06-01 05:26:41.774095|2018-06-01 05:26:41.774095
NCT00006656|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2000||2000-06-30|August 2003|2003-08-31||||||||Interventional|||Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme|A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:41.869031|2018-06-01 05:26:41.869031
NCT00006485|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2009-12-13|2003-01-26|2003-01-27|Estimate|||||||2009-12-13|2009-12-15|Estimate|September 2000||2000-09-30|June 2003|2003-06-30||||December 2003|Actual|2003-12-31||Interventional|||Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors|An Open-Labeled, Non-Randomized Phase I Study Of Flavopiridol Administered With Irinotecan (CPT-11) In Patients With Advanced Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:41.947742|2018-06-01 05:26:41.947742
NCT00006479|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2011-04-15|2003-01-26|2003-01-27|Estimate|||||||2011-04-15|2011-04-18|Estimate|September 2000||2000-09-30|December 2000|2000-12-31||||||||Interventional|||Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer|Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:42.030326|2018-06-01 05:26:42.030326
NCT00006478|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|2010-10-19||2018-01-13|2003-01-26|2003-01-27|Estimate|2010-10-19|2010-11-17|Estimate||||2018-01-13|2018-02-09|Actual|September 2000||2000-09-30|January 2018|2018-01-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Vaccine Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|Pilot Trial to Evaluate Immune Response Using Idiotype Vaccines Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Follicular Lymphoma|Terminated||Phase 2|19|Actual|University of Nebraska|The Sponsor Genitope suspend development of MyVax in light of the decision made by the FDA March 6, 2008, therefore this trial was halted prematurely leaving insufficient data to analyze.|||"Genitope suspend development of MyVax in light of the decision made by the Food and Drug~   Administration (FDA) March 6, 2008"|f||||||||||||||2018-06-01 05:26:42.27304|2018-06-01 05:26:42.27304
NCT00006477|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|September 2000||2000-09-30|July 2012|2012-07-31||||June 2004|Actual|2004-06-30||Interventional|||Mistletoe Lectin in Treating Patients With Refractory Advanced Solid Tumors|Phase I Clinical Trial of Recombinant Viscumin (rVISCUMIN, rMISTLETOE LECTIN, rML) Administered Twice Weekly by the Subcutanous Route in Patients With Solid Tumors After Failure of Standard Therapy|Completed||Phase 1|26|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:26:42.434129|2018-06-01 05:26:42.434129
NCT00006476|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|October 2000||2000-10-31|March 2007|2007-03-31|October 2007|Actual|2007-10-31|||||Interventional|||Suramin in Treating Patients With Recurrent Bladder Cancer|A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer|Completed||Phase 1|15|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:42.494739|2018-06-01 05:26:42.494739
NCT00006474|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|March 2001||2001-03-31|February 2013|2013-02-28|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma|Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas|Completed||Phase 1|||Duke University|||||f||||f||||||||||2018-06-01 05:26:42.555274|2018-06-01 05:26:42.555274
NCT00006473|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|September 2000||2000-09-30|January 2013|2013-01-31||||February 2006|Actual|2006-02-28||Interventional|||Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma|A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:42.627572|2018-06-01 05:26:42.627572
NCT00006471|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2012-07-27|2003-01-26|2003-01-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|September 2000||2000-09-30|July 2012|2012-07-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Phase II Study of Fenretinide in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|11|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:26:42.697596|2018-06-01 05:26:42.697596
NCT00006470|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-08-09|2003-01-26|2003-01-27|Estimate|||||||2013-08-09|2013-08-13|Estimate|March 2001||2001-03-31|August 2013|2013-08-31||||December 2004|Actual|2004-12-31||Interventional|||Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery|Phase II Study of Postoperative Adjuvant Immunotherapy and Radiation in Patients With Completely Resected Stage II and Stage IIIA Non-Small Cell Lung Cancer|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:26:42.799434|2018-06-01 05:26:42.799434
NCT00006469|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|August 1999||1999-08-31|May 2006|2006-05-31||||||||Interventional|||Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer|Phase II Trial of Concurrent Paclitaxel, Carboplatin and External Beam Radiotherapy Followed by Surgical Resection in Stage IIIA (N2) Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:43.226307|2018-06-01 05:26:43.226307
NCT00006468|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2009-01-10|2003-01-26|2003-01-27|Estimate|||||||2009-01-10|2009-01-13|Estimate|January 2000||2000-01-31|December 2000|2000-12-31||||||||Interventional|||Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer|Phase III Study of An Optimized LV-5FU-Oxaliplatin Regimen in Metastatic Colorectal Cancer. C99-1.|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:43.293019|2018-06-01 05:26:43.293019
NCT00006465|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2010-06-10|2003-01-26|2003-01-27|Estimate|||||||2010-06-10|2010-06-11|Estimate|December 2000||2000-12-31|June 2010|2010-06-30|April 2005|Actual|2005-04-30|November 2003|Actual|2003-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I Study of Oxaliplatin (NSC# 266046), Irinotecan, and Capecitabine in Patients With Solid Tumors|Completed||Phase 1|22|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:26:43.356477|2018-06-01 05:26:43.356477
NCT00006462|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2014-02-18|2003-01-26|2003-01-27|Estimate|||||||2014-02-18|2014-02-20|Estimate|April 2001||2001-04-30|February 2014|2014-02-28|September 2006|Actual|2006-09-30|August 2003|Actual|2003-08-31||Interventional|||Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia|A Phase II Study of Gemcitabine (NSC #613327) in Children With Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia|Completed||Phase 2|32|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:43.474781|2018-06-01 05:26:43.474781
NCT00006461|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2013-08-07|2003-01-26|2003-01-27|Estimate|||||||2013-08-07|2013-08-09|Estimate|October 2000||2000-10-31|August 2013|2013-08-31||||September 2007|Actual|2007-09-30||Interventional|||Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor|Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children &gt;/= to 8 Months and &lt;3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study|Completed||Phase 3|82|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:43.832621|2018-06-01 05:26:43.832621
NCT00006456|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2010-02-23|2003-01-26|2003-01-27|Estimate|||||||2010-02-23|2010-02-24|Estimate|February 1999||1999-02-28|February 2010|2010-02-28|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors|Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors|Completed||Phase 2|26|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 05:26:43.957769|2018-06-01 05:26:43.957769
NCT00006455|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2011-08-25|2003-01-26|2003-01-27|Estimate|||||||2011-08-25|2011-08-26|Estimate|December 1999||1999-12-31|August 2011|2011-08-31||||||||Interventional|||Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma|International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:44.018472|2018-06-01 05:26:44.018472
NCT00006392|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|2012-06-12||2015-10-23|2003-01-26|2003-01-27|Estimate|2012-10-05|2012-11-06|Estimate||||2015-10-23|2015-11-20|Estimate|July 2001||2001-07-31|October 2015|2015-10-31|September 2012|Actual|2012-09-30|May 2011|Actual|2011-05-31||Interventional|SELECT||S0000 Selenium and Vitamin E in Preventing Prostate Cancer|Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer|Completed||Phase 3|35533|Actual|Southwest Oncology Group||4|||f||||t||||||||||2018-06-01 05:26:44.154038|2018-06-01 05:26:44.154038
NCT00006391|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2011-04-04|2003-01-26|2003-01-27|Estimate|||||||2011-04-04|2011-04-05|Estimate|August 2000||2000-08-31|April 2011|2011-04-30||||November 2004|Actual|2004-11-30||Interventional|||Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I Dose-Finding Study of Oxaliplatin (NSC #266046) Combined With Continuous Infusion Topotecan Hydrochloride as Chemotherapy for Patients With Previously Treated Ovarian Cancer|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:26:45.271831|2018-06-01 05:26:45.271831
NCT00006390|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2010-01-26|2003-01-26|2003-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|February 2001||2001-02-28|January 2010|2010-01-31||||December 2004|Actual|2004-12-31||Interventional|||Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia|Phase II Study of Campath-1H (NSC #950010) and Peripheral Blood Stem Cell Transplant for Patients With Chronic Lymphocytic Leukemia|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||||||f||||||||||2018-06-01 05:26:45.364128|2018-06-01 05:26:45.364128
NCT00006389|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|2014-09-26||2014-09-26|2003-01-26|2003-01-27|Estimate|2014-09-26|2014-10-01|Estimate||||2014-09-26|2014-10-01|Estimate|October 2000||2000-10-31|October 2013|2013-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer|A Phase II Combination Trial of Bryostatin-1 and Cisplatin in the Treatment of Metastatic Gastric Cancer|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)|Of 12 pts accrued\treated, none responded. The initial phase accrual goal was 15, but given the 12 non-responders, we determined the probability of 3 future pts all responding (stochastic curtailed sampling) at 2.7%. Decided to terminate the trial.|1|||f||||||||||||||2018-06-01 05:26:45.44639|2018-06-01 05:26:45.44639
NCT00006386|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2015-11-14|2003-01-26|2003-01-27|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 2001||2001-03-31|November 2015|2015-11-30|February 2009|Actual|2009-02-28|November 2004|Actual|2004-11-30||Interventional|||Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme|A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boosts For Supratentorial Glioblastoma Multiforme|Completed||Phase 2|80|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:45.902722|2018-06-01 05:26:45.902722
NCT00006385|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2011-11-05|2003-01-26|2003-01-27|Estimate|||||||2011-11-05|2011-11-08|Estimate|September 2000||2000-09-30|December 2002|2002-12-31||||October 2006|Actual|2006-10-31||Interventional|||Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma|Phase II Evaluation of Immunization With an HLA-A2 Multi-Epitope Peptide Vaccine Containing MART-1 (NSC #672643), gp100 (NSC #683472), and Tyrosinase (NSC #699048) Peptides Alone or in Combination With GM-CSF, IFN Alpha-2b, or GM-CSF + IFN Alpha-2b in Patients With Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:46.340598|2018-06-01 05:26:46.340598
NCT00006381|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 2000||2000-06-30|December 2003|2003-12-31|February 2004|Actual|2004-02-29|||||Interventional|||Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer|Phase II Study of Celecoxib in HER-2/Neu Overexpressing Metastatic Breast Cancer Patients Who Have Failed Recombinant Humanized Anti-p 185HER Monoclonal Antibody Trastuzumab (HERCEPTIN)|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:46.45266|2018-06-01 05:26:46.45266
NCT00006379|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2011-12-07|2003-01-26|2003-01-27|Estimate|||||||2011-12-07|2011-12-08|Estimate|June 2000||2000-06-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|January 2004|Actual|2004-01-31||Interventional|||Non-Ablative Allo HSCT For Hematologic Malignancies or SAA|Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia|Completed||Phase 2|58|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:26:46.513409|2018-06-01 05:26:46.513409
NCT00006373|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|February 2000||2000-02-29|June 2013|2013-06-30|December 2011|Actual|2011-12-31|October 2006|Actual|2006-10-31||Interventional|||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma|A Phase II Study of Intensive-Dose Topotecan, Ifosfamide/Mesna and Etoposide (Vepesid)(TIME) Followed by Autologous Stem Cell Rescue in High Risk Lymphoma|Completed||Phase 2|27|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:26:46.603153|2018-06-01 05:26:46.603153
NCT00006372|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|February 2000||2000-02-29|June 2010|2010-06-30|February 2005|Actual|2005-02-28|April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|Phase I Trial of Combination Pegylated Liposomal Doxorubicin (Doxil), Vinorelbine, and Gemcitabine|Completed||Phase 1|10|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:26:46.705989|2018-06-01 05:26:46.705989
NCT00006366|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-19|Estimate|February 2001||2001-02-28|December 2002|2002-12-31||||December 2003|Actual|2003-12-31||Interventional|||Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum|Randomized Phase II Trial of Preoperative Combined Modality Chemoradiation for Distal Rectal Cancer|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:26:46.81062|2018-06-01 05:26:46.81062
NCT00006364|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|November 1999||1999-11-30|January 2013|2013-01-31||||September 2005|Actual|2005-09-30||Interventional|||Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia|Phase I and Pilot Study of Subcutaneous Homoharringtonine in Chronic Myelogenous Leukemia|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:47.153345|2018-06-01 05:26:47.153345
NCT00006363|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 2000||2000-11-30|June 2013|2013-06-30||||June 2005|Actual|2005-06-30||Interventional|||Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia|Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML &lt; 60 Years|Completed||Phase 3|720|Actual|National Cancer Institute (NCI)||7|||f||||||||||||||2018-06-01 05:26:47.225668|2018-06-01 05:26:47.225668
NCT00006362|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2011-08-01|2003-01-26|2003-01-27|Estimate|||||||2011-08-01|2011-08-03|Estimate|November 1999||1999-11-30|August 2011|2011-08-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||PS-341 in Treating Patients With Advanced Cancer|A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Patients With Advanced Solid Tumors and B-cell Lymphoproliferative Disorders|Completed||Phase 1|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:26:47.32391|2018-06-01 05:26:47.32391
NCT00006360|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2016-12-30|2003-01-26|2003-01-27|Estimate|||||||2016-12-30|2017-01-04|Estimate|February 2001||2001-02-28|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2005|Actual|2005-11-30||Interventional|||Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer|Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer|Completed||Phase 1/Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:26:47.394832|2018-06-01 05:26:47.394832
NCT00006359|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-18|Estimate|September 2000||2000-09-30|July 2016|2016-07-31|March 2012|Actual|2012-03-31|October 2007|Actual|2007-10-31||Interventional|||Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer|Phase II Trial of Androgen Suppression for 6 Months Combined With External Beam Radiotherapy (EBRT) With Brachytherapy (BT) Boost for Intermediate Risk Prostate Cancer|Completed||Phase 2|63|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:48.424355|2018-06-01 05:26:48.424355
NCT00006356|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|August 2000||2000-08-31|September 2012|2012-09-30||||October 2002|Actual|2002-10-31||Interventional|||Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer|A Randomized Phase III Study for the Treatment of Recurrent Epithelial Ovarian Cancer: Chemotherapy Alone Versus Chemotherapy Followed by Secondary Cytoreductive Surgery in Patients With a Treatment-Free Interval of More Than 12 Months|Terminated||Phase 3|38|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:26:48.532432|2018-06-01 05:26:48.532432
NCT00006355|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-05-01|2003-01-26|2003-01-27|Estimate|||||||2012-05-01|2012-05-03|Estimate|May 2000||2000-05-31|May 2012|2012-05-31|October 2006|Actual|2006-10-31|October 2004|Actual|2004-10-31||Interventional|||Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme|Phase I/II Study of Pyrazoloacridine (PZA) in Adults With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 1/Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:26:48.59065|2018-06-01 05:26:48.59065
NCT00006354|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-07-23|2003-01-26|2003-01-27|Estimate|||||||2012-07-23|2012-07-24|Estimate|August 2000||2000-08-31|July 2012|2012-07-31||||March 2003|Actual|2003-03-31||Interventional|||Mistletoe Lectin in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy|Phase I Clinical Trial of Recombinant Viscumin (rViscumin, rMistletoe Lectin, rML) Administered Twice Weekly By The Intravenous Route In Patients With Solid Tumors After Failure of Standard Therapy|Completed||Phase 1|41|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:26:48.661486|2018-06-01 05:26:48.661486
NCT00006351|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 2000||2000-06-30|September 2012|2012-09-30||||December 2001|Actual|2001-12-31||Interventional|||SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract|Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997|Completed||Phase 2|34|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:26:48.718641|2018-06-01 05:26:48.718641
NCT00006347|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2009-02-28|2003-01-26|2003-01-27|Estimate|||||||2009-02-28|2009-03-03|Estimate|August 2000||2000-08-31|April 2003|2003-04-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Small Cell Lung Cancer (SCLC)|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:49.531296|2018-06-01 05:26:49.531296
NCT00006340|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2013-07-25|2003-01-26|2003-01-27|Estimate|||||||2013-07-25|2013-07-26|Estimate|December 1994||1994-12-31|July 2013|2013-07-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus|A PHASE I TRIAL OF BUTYRATE AND GANCICLOVIR IN EBV-ASSOCIATED MALIGNANCIES|Completed||Phase 1|||Boston Medical Center|||||f||||||||||||||2018-06-01 05:26:49.609533|2018-06-01 05:26:49.609533
NCT00006268|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|October 2000||2000-10-31|March 2005|2005-03-31|March 2005|Actual|2005-03-31|||||Interventional|||Immunotoxin Therapy in Treating Patients With Malignant Glioma|Interstitial Infusion of IL 13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:49.702489|2018-06-01 05:26:49.702489
NCT00006267|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-07-08|2003-01-26|2003-01-27|Estimate|||||||2013-07-08|2013-07-09|Estimate||||May 2004|2004-05-31||||May 2006|Actual|2006-05-31||Interventional|||Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Evaluation Of 9-Nitro-Camptothecin In The Third-Line Treatment Of Recurrent Ovarian Or Primary Peritoneal Cancer|Withdrawn||Phase 2|0|Actual|Gynecologic Oncology Group||||Never activated.|f||||||||||||||2018-06-01 05:26:49.770342|2018-06-01 05:26:49.770342
NCT00006264|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2016-02-01|2003-01-26|2003-01-27|Estimate|||||||2016-02-01|2016-02-03|Estimate|July 2000||2000-07-31|February 2016|2016-02-29|July 2003|Actual|2003-07-31|March 2003|Actual|2003-03-31||Interventional|||Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma|A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma|Completed||Phase 2|||AIDS Malignancy Consortium|||||f||||||||||||||2018-06-01 05:26:49.820378|2018-06-01 05:26:49.820378
NCT00006263|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2015-08-03|2003-01-26|2003-01-27|Estimate|||||||2015-08-03|2015-08-05|Estimate|November 1997||1997-11-30|August 2015|2015-08-31||||||||Interventional|||Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma|Phase II Trial of Temozolomide, Carboplatin and Neupogen in High-Grade Gliomas, Both Newly-Diagnosed and Recurrent|Withdrawn||Phase 2|0|Actual|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:26:49.880428|2018-06-01 05:26:49.880428
NCT00006258|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|November 1997||1997-11-30|December 2004|2004-12-31|January 2005|Actual|2005-01-31|||||Interventional|||Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma|Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:50.110847|2018-06-01 05:26:50.110847
NCT00006256|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2018-01-29|2003-01-26|2003-01-27|Estimate|||||||2018-01-29|2018-01-31|Actual|June 8, 2000||2000-06-08|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|November 30, 2005|Actual|2005-11-30||Interventional|||Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer|Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy|Active, not recruiting||Phase 2|44|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:26:50.201025|2018-06-01 05:26:50.201025
NCT00006255|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|April 2000||2000-04-30|June 2010|2010-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases|A Phase II Study of Magnetic Resonance Guided and Monitored Interstitial Thermal Radiofrequency Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases|Completed||Phase 2|17|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:26:50.279074|2018-06-01 05:26:50.279074
NCT00006252|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2016-07-15|2003-01-26|2003-01-27|Estimate|||||||2016-07-15|2016-07-18|Estimate|February 2001||2001-02-28|July 2016|2016-07-31|October 2011|Actual|2011-10-31|January 2007|Actual|2007-01-31||Interventional|||Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma|Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells|Completed||Phase 2|47|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:50.351568|2018-06-01 05:26:50.351568
NCT00006250|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 2000||2000-05-31|March 2007|2007-03-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma|Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:50.496283|2018-06-01 05:26:50.496283
NCT00006249|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2015-02-09|2003-01-26|2003-01-27|Estimate|||||||2015-02-09|2015-02-10|Estimate|June 2000||2000-06-30|February 2015|2015-02-28||||August 2003|Actual|2003-08-31||Interventional|||Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma|PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial|Unknown status|Active, not recruiting|Phase 3|1258|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-06-01 05:26:50.667259|2018-06-01 05:26:50.667259
NCT00006248|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-04-08|2003-01-26|2003-01-27|Estimate|||||||2013-04-08|2013-04-10|Estimate|November 2000||2000-11-30|April 2013|2013-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer|Evaluation of Three Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 2|78|Actual|Southwest Oncology Group|||||f||||t||||||||||2018-06-01 05:26:50.976205|2018-06-01 05:26:50.976205
NCT00006246|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2009-10-06|2003-01-26|2003-01-27|Estimate|||||||2009-10-06|2009-10-07|Estimate|November 2000||2000-11-30|October 2009|2009-10-31||||May 2003|Actual|2003-05-31||Interventional|||Busulfan in Treating Children and Adolescents With Refractory CNS Cancer|Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis|Completed||Phase 1|28|Actual|Pediatric Brain Tumor Consortium|||||||||t||||||||||2018-06-01 05:26:51.20112|2018-06-01 05:26:51.20112
NCT00006245|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 2000||2000-07-31|April 2004|2004-04-30|August 2007|Actual|2007-08-31|||||Interventional|||Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel|Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:51.291726|2018-06-01 05:26:51.291726
NCT00006244|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|2017-04-12||2017-06-16|2003-01-26|2003-01-27|Estimate|2017-04-12|2017-05-16|Actual||||2017-06-16|2017-07-12|Actual|February 2000||2000-02-29|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma|Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma|Completed||Phase 2|36|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:26:51.375246|2018-06-01 05:26:51.375246
NCT00006239|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|December 2000||2000-12-31|September 2017|2017-09-30|March 2005|Actual|2005-03-31|February 2005|Actual|2005-02-28||Interventional|||Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer|A Phase I, Dose-Finding Trial of Sodium Phenylbutrate (NSC 657802) in Combination With All Trans-retinoic Acid (ATRA, NSC 122758) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:26:51.618315|2018-06-01 05:26:51.618315
NCT00006237|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|2012-08-20||2015-03-05|2003-01-26|2003-01-27|Estimate|2012-08-20|2012-09-19|Estimate||||2015-03-05|2015-03-25|Estimate|August 2000||2000-08-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma|Phase III Trial of High Dose Interferon Alfa 2-b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma|Completed||Phase 3|432|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:26:51.81733|2018-06-01 05:26:51.81733
NCT00006234|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2011-11-30|2003-01-26|2003-01-27|Estimate|||||||2011-11-30|2011-12-01|Estimate|November 2001||2001-11-30|November 2011|2011-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone|A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:26:52.863507|2018-06-01 05:26:52.863507
NCT00006233|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2011-11-28|2003-01-26|2003-01-27|Estimate|||||||2011-11-28|2011-11-30|Estimate|January 2000||2000-01-31|November 2011|2011-11-30|December 2003|Actual|2003-12-31|||||Interventional|||Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma|Phase II Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low-Dose TBI, and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil (MMF) Followed by Donor Lymphocyte Infusion in Selected Patients With Metastatic Melanoma|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:26:52.918765|2018-06-01 05:26:52.918765
NCT00006232|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 1996||1996-10-31|March 2007|2007-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma|A Randomized Trial Comparing Z-Dex With VAD as Induction Therapy for Patients With Multiple Myeloma|Completed||Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:52.985287|2018-06-01 05:26:52.985287
NCT00006231|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 1998||1998-02-28|October 2000|2000-10-31|December 2002|Actual|2002-12-31|||||Interventional|||Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma|A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma|Completed||Phase 3|44|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:53.068973|2018-06-01 05:26:53.068973
NCT00006230|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 2000||2000-05-31|September 2012|2012-09-30||||April 2003|Actual|2003-04-30||Interventional|||Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer|"Open Label Phase II Study on RFS 2000 (9-Nitro-camptothecin, 9-NC) Administered as a 5 Days On-2 Days Off Oral Treatment in Advanced Ovarian Cancer"|Completed||Phase 2|51|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:26:53.126941|2018-06-01 05:26:53.126941
NCT00006228|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|July 2000||2000-07-31|October 2013|2013-10-31||||July 2003|Actual|2003-07-31||Interventional|||Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer|Phase II Trial of Anti-HER-2 Monoclonal Antibody Trastuzumab (Herceptin) in Combination With Low Dose Interleukin-2 (Proleukin) in Metastatic Breast Cancer Patients Who Have Previously Failed Trastuzumab|Completed||Phase 2|37|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:53.1922|2018-06-01 05:26:53.1922
NCT00006227|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2017-08-23|2003-01-26|2003-01-27|Estimate|||||||2017-08-23|2017-08-24|Actual|November 20, 2000|Actual|2000-11-20|August 2017|2017-08-31|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Interventional|||Paclitaxel in Treating Patients With Ovarian Stromal Cancer|Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy|Completed||Phase 2|31|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:26:53.357916|2018-06-01 05:26:53.357916
NCT00006226|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-10-07|2003-01-26|2003-01-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|September 2000||2000-09-30|October 2013|2013-10-31||||December 2007|Actual|2007-12-31||Interventional|||Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|A Phase II Trial of Thalidomide in Patients With Relapsed Chronic Lymphocytic Leukemia|Completed||Phase 2|41|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:53.57434|2018-06-01 05:26:53.57434
NCT00006221|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|November 2000||2000-11-30|July 2004|2004-07-31||||June 2005|Actual|2005-06-30||Interventional|||BMS-247550 in Treating Patients With Advanced Cancers|A Phase I Study of BMS-247550 (NSC 710428) Given Weekly X 3 Every 4 Weeks in Patients With Advanced Malignancies|Completed||Phase 1|54|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:53.668732|2018-06-01 05:26:53.668732
NCT00006219|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2011-08-02|2003-01-26|2003-01-27|Estimate|||||||2011-08-02|2011-08-04|Estimate|August 2000||2000-08-31|August 2011|2011-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma|A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance|Completed||Phase 2|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:26:53.753025|2018-06-01 05:26:53.753025
NCT00006125|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 2000||2000-07-31|July 2016|2016-07-31||||August 2006|Actual|2006-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma|A Phase II Study of Sequential Doxorubicin and Topotecan (Dox/Topo) in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 2|||Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:53.837878|2018-06-01 05:26:53.837878
NCT00006124|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-02-12|2003-01-26|2003-01-27|Estimate|||||||2013-02-12|2013-02-13|Estimate|June 2000||2000-06-30|January 2013|2013-01-31|April 2008|Actual|2008-04-30|March 2006|Actual|2006-03-31||Interventional|||Celecoxib in Treating Patients With Bladder Cancer|Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer|Completed||Phase 2/Phase 3|152|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-06-01 05:26:54.017275|2018-06-01 05:26:54.017275
NCT00006120|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|May 2000||2000-05-31|March 2006|2006-03-31||||||||Interventional|||Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer|Phase II Randomized Study of Two Different Schedules of Docetaxel or Paclitaxel for Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:54.244443|2018-06-01 05:26:54.244443
NCT00006119|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 1999||1999-07-31|December 2004|2004-12-31||||||||Interventional|||Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma|Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:54.354686|2018-06-01 05:26:54.354686
NCT00006118|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 1999||1999-07-31|November 2001|2001-11-30||||||||Interventional|||Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer|First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:54.533083|2018-06-01 05:26:54.533083
NCT00006114|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2011-02-26|2003-01-26|2003-01-27|Estimate|||||||2011-02-26|2011-03-01|Estimate|May 1999||1999-05-31|September 2000|2000-09-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:54.604357|2018-06-01 05:26:54.604357
NCT00006113|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2014-05-20|2003-01-26|2003-01-27|Estimate|||||||2014-05-20|2014-05-22|Estimate|June 1999||1999-06-30|May 2014|2014-05-31|April 2006|Actual|2006-04-30|May 2003|Actual|2003-05-31||Interventional|||Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma|A Phase II Trial of a MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Treated With CD40 Ligand/Gamma Interferon With Subcutaneous IL-2 for Patients With Metastatic Melanoma|Terminated||Phase 2|25|Actual|University of Southern California||||Lack of efficacy|f||||t||||||||||2018-06-01 05:26:54.667103|2018-06-01 05:26:54.667103
NCT00006110|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|2017-04-05||2017-06-30|2003-01-26|2003-01-27|Estimate|2017-06-30|2017-07-31|Actual||||2017-06-30|2017-07-31|Actual|December 1998||1998-12-31|June 2017|2017-06-30|April 2013|Actual|2013-04-30|March 2012|Actual|2012-03-31||Interventional|NRR||Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer|Nonrandomized Ph II Study of Multimodality Therapy for Stg IIB, IIIA/B, or Stg IV Breast Cancer w/4 Cycles of Adriamycin and Cytoxan (AC),Followed by 12 Weeks of Paclitaxel w/ or w/o Herceptin Followed by Local Therapy Followed by Wkly Herceptin or no Additional Therapy|Completed||Phase 2|82|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||No||2018-06-01 05:26:54.76864|2018-06-01 05:26:54.76864
NCT00006107|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2017-06-15|2003-01-26|2003-01-27|Estimate|||||||2017-06-15|2017-06-16|Actual|July 14, 2000|Actual|2000-07-14|June 2017|2017-06-30|July 3, 2004|Actual|2004-07-03|July 17, 2003|Actual|2003-07-17||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer|Taxotere Plus Concurrent Concomitant Boost Radiotherapy For Squamous Cell Cancer of the Head and Neck (TAXT-XRT)|Completed||Phase 1|31|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-06-01 05:26:55.406901|2018-06-01 05:26:55.406901
NCT00006105|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-09-04|2003-01-26|2003-01-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2000||2000-06-30|September 2013|2013-09-30|September 2006|Actual|2006-09-30|November 2004|Actual|2004-11-30||Interventional|||Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer|Phase II Trial of Adjuvant Gemcitabine Plus Cisplatin With Amifostine Cytoprotection in Patients With Locally Advanced Bladder Cancer|Completed||Phase 2|37|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:26:55.51424|2018-06-01 05:26:55.51424
NCT00006102|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-02-04|2003-01-26|2003-01-27|Estimate|||||||2013-02-04|2013-02-05|Estimate|July 2000||2000-07-31|November 2010|2010-11-30||||June 2006|Actual|2006-06-30||Interventional|||Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma|A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors|Completed||Phase 2|200|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:55.63455|2018-06-01 05:26:55.63455
NCT00006101|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|2018-02-07||2018-04-11|2003-01-26|2003-01-27|Estimate|2018-03-13|2018-04-12|Actual||||2018-04-11|2018-05-14|Actual|October 1998||1998-10-31|April 2018|2018-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer|Randomized Placebo-Controlled, Double-Blind Phase IIb Chemoprevention Trial of Difluoromethylornithine in Brothers and First Cousin Males of Familial Prostate Cancer Probands|Completed||Phase 2|76|Actual|University of California, Irvine||2|||f||||t||||||||No||2018-06-01 05:26:55.996856|2018-06-01 05:26:55.996856
NCT00006100|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|April 2000||2000-04-30|May 2005|2005-05-31||||||||Interventional|||Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma|A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:56.194002|2018-06-01 05:26:56.194002
NCT00006094|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|July 2000||2000-07-31|January 2013|2013-01-31||||October 2006|Actual|2006-10-31||Interventional|||Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum|A Phase I/II Study of Preoperative Oxaliplatin (NSC# 266046), 5-Fluorouracil, and External Beam Radiation Therapy in Locally Advanced Rectal Cancer|Completed||Phase 1/Phase 2|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:56.280661|2018-06-01 05:26:56.280661
NCT00006093|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|September 2000||2000-09-30|April 2003|2003-04-30|October 2006|Actual|2006-10-31|||||Interventional|||EMD 121974 in Treating Patients With Progressive or Recurrent Glioma|A Phase I/II Trial of EMD 121974 for Treatment of Patients With Recurrent Anaplastic Gliomas|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:56.345955|2018-06-01 05:26:56.345955
NCT00006092|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2012-09-25|2003-01-26|2003-01-27|Estimate|||||||2012-09-25|2012-09-26|Estimate|August 2000||2000-08-31|September 2012|2012-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia|A Phase II Study of Arsenic Trioxide for Induction Therapy of Adult Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Previously Untreated Chronic Myeloid Leukemia With Blast Crisis|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||low accrual|f||||f||||||||||2018-06-01 05:26:56.496813|2018-06-01 05:26:56.496813
NCT00006089|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2014-01-10|2003-01-26|2003-01-27|Estimate|||||||2014-01-10|2014-01-13|Estimate|March 2001||2001-03-31|January 2014|2014-01-31||||September 2007|Actual|2007-09-30||Interventional|||Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer|A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy|Completed||Phase 2|42|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:56.580834|2018-06-01 05:26:56.580834
NCT00006078|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 2000||2000-06-30|December 2004|2004-12-31|January 2005|Actual|2005-01-31|||||Interventional|||Lycopene In Preventing of Prostate Cancer|Single Dose Pharmacokinetic Study of Lycopene Delivered in a Well Defined Food-Based Lycopene Delivery System (Tomato Paste-oil Mixture) in Healthy Male Volunteers Between 18 and 45 Years of Age|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:56.649115|2018-06-01 05:26:56.649115
NCT00048022|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2017-06-15|2002-10-24|2002-10-25|Estimate|||||||2017-06-15|2017-06-19|Actual|October 25, 2002|Actual|2002-10-25|February 2017|2017-02-28|February 2, 2004|Actual|2004-02-02|February 2, 2004|Actual|2004-02-02||Interventional|||Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma||Completed||Phase 2|||Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:30:55.180763|2018-06-01 05:30:55.180763
NCT00006044|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-17|2003-01-26|2003-01-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|February 2000||2000-02-29|January 2013|2013-01-31||||February 2005|Actual|2005-02-28||Interventional|||Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy|A Phase I Trial of Testosterone in Patients With Progressive Androgen-Independent Prostate Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:56.702725|2018-06-01 05:26:56.702725
NCT00006042|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-03-09|2003-01-26|2003-01-27|Estimate|||||||2010-03-09|2010-03-10|Estimate|December 1999||1999-12-31|March 2010|2010-03-31||||||||Interventional|||Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer|Non-Myeloablative Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Using Haploidentical Donors: A Phase I Trial of Pre-Transplant Cyclophosphamide|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:26:56.759209|2018-06-01 05:26:56.759209
NCT00006040|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|April 2000||2000-04-30|June 2013|2013-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia|Phase I Study of Yttrium-90 Labeled HuM195 Combined With Etoposide as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients With Advanced Myelodysplastic Syndrome and Refractory Leukemia|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:26:56.834206|2018-06-01 05:26:56.834206
NCT00006029|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 2000||2000-07-31|July 2016|2016-07-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|A Phase I/II Study of Gemcitabine (GEMZAR)/Vinorelbine (NAVELBINE)/Liposomal Doxorubicin (DOXIL) in Relapsed/Refractory Hodgkin's Disease|Completed||Phase 1/Phase 2|91|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:26:56.904176|2018-06-01 05:26:56.904176
NCT00006028|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-24|2003-01-26|2003-01-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|January 2001||2001-01-31|March 2003|2003-03-31||||January 2007|Actual|2007-01-31||Interventional|||Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy|Evaluation of Gemcitabine and Cisplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:26:57.126182|2018-06-01 05:26:57.126182
NCT00006027|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-08-09|2003-01-26|2003-01-27|Estimate|||||||2013-08-09|2013-08-13|Estimate|August 2000||2000-08-31|August 2013|2013-08-31||||June 2004|Actual|2004-06-30||Interventional|||Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer|A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer|Completed||Phase 3|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:26:57.253135|2018-06-01 05:26:57.253135
NCT00006025|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2008-11-22|2003-01-26|2003-01-27|Estimate|||||||2008-11-22|2008-11-25|Estimate|November 2000||2000-11-30|August 2004|2004-08-31||||May 2008|Actual|2008-05-31||Interventional|||Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma|Phase I-II Trial of CPT-11 and Temozolomide (Temodar) in Patients With Recurrent Malignant Glioma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:57.406433|2018-06-01 05:26:57.406433
NCT00006024|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2014-02-11|2003-01-26|2003-01-27|Estimate|||||||2014-02-11|2014-02-13|Estimate|November 2000||2000-11-30|February 2014|2014-02-28|September 2006|Actual|2006-09-30|January 2005|Actual|2005-01-31||Interventional|||Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma|A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas|Completed||Phase 1|32|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:26:57.537564|2018-06-01 05:26:57.537564
NCT00006022|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2015-12-10|2003-01-26|2003-01-27|Estimate|||||||2015-12-10|2015-12-14|Estimate|September 2000||2000-09-30|December 2015|2015-12-31|January 2004|Actual|2004-01-31|October 2003|Actual|2003-10-31||Interventional|||Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer|Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)|Completed||Phase 1|17|Actual|Virginia Commonwealth University|||||f||||t||||||||||2018-06-01 05:26:57.91633|2018-06-01 05:26:57.91633
NCT00006021|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-12-14|2003-01-26|2003-01-27|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2000||2000-06-30|December 2016|2016-12-31|March 2007|Actual|2007-03-31|May 2006|Actual|2006-05-31||Interventional|||Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma|Phase I/II Trial of Arsenic Trioxide (As2O3) With Ascorbic Acid in the Treatment of Relapsed/Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|22|Actual|University of Miami|||||||||t||||||||||2018-06-01 05:26:57.973174|2018-06-01 05:26:57.973174
NCT00006020|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2015-03-05|2003-01-26|2003-01-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|July 2000||2000-07-31|March 2015|2015-03-31|July 2004|Actual|2004-07-31|June 2004|Actual|2004-06-30||Interventional|||S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia|A Phase II Trial of 506U78 (IND 52611) in Patients With Relapsed or Refractory Non T-cell Acute Lymphoblastic Leukemia (ALL)|Completed||Phase 2|35|Anticipated|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:26:58.071467|2018-06-01 05:26:58.071467
NCT00006017|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-10|Estimate|May 2000||2000-05-31|June 2010|2010-06-30|January 2005|Actual|2005-01-31|July 2003|Actual|2003-07-31||Interventional|||Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer|A Randomized Phase II Trial of Two Different Schedules of Administration of Rebeccamycin Analog in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|42|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-06-01 05:26:58.332183|2018-06-01 05:26:58.332183
NCT00006016|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2015-04-14|2003-01-26|2003-01-27|Estimate|||||||2015-04-14|2015-04-15|Estimate|May 2000||2000-05-31|January 2013|2013-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery|An Evaluation of Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer|Completed||Phase 2|75|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:58.410982|2018-06-01 05:26:58.410982
NCT00005983|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-24|Estimate|June 2000||2000-06-30|January 2013|2013-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer|Randomized Trial of Post-Mastectomy Radiotherapy in Stage II Breast Cancer in Women With One to Three Positive Axillary Nodes Phase III|Terminated||Phase 3|98|Actual|Southwest Oncology Group||2||due to lack of accrual|f||||t||||||||||2018-06-01 05:27:00.341683|2018-06-01 05:27:00.341683
NCT00006015|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-01|2003-01-26|2003-01-27|Estimate|||||||2013-05-01|2013-05-03|Estimate|May 2000||2000-05-31|June 2011|2011-06-30|February 2003|Actual|2003-02-28|December 2002|Actual|2002-12-31||Interventional|||Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer|Phase II Study Evaluating the Combination of 5-Fluorouracil, Leucovorin, Oxaliplatin, and Herceptin in the Treatment of Patients With Metastatic Colorectal Cancer Who Have Progressed After 5-FU and/or Irinotecan-Containing Therapy|Terminated||Phase 2|26|Actual|National Cancer Institute (NCI)||1||lack of sufficient accrual|f||||t||||||||||2018-06-01 05:26:58.491657|2018-06-01 05:26:58.491657
NCT00006011|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|2014-05-20||2015-04-30|2003-01-26|2003-01-27|Estimate|2014-05-27|2014-06-26|Estimate||||2015-04-30|2015-05-19|Estimate|July 2000||2000-07-31|April 2015|2015-04-30||||March 2010|Actual|2010-03-31||Interventional||Total number of eligible participants.|Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer|A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma|Completed||Phase 3|659|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 05:26:58.619585|2018-06-01 05:26:58.619585
NCT00006010|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|September 2001||2001-09-30|December 2016|2016-12-31|April 2008|Actual|2008-04-30|May 2004|Actual|2004-05-31||Interventional|||Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer|Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|25|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:26:59.123726|2018-06-01 05:26:59.123726
NCT00006007|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2000||2000-12-31|December 2016|2016-12-31|May 2008|Actual|2008-05-31|March 2004|Actual|2004-03-31||Interventional|||LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer|A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer|Completed||Phase 2|59|Actual|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-06-01 05:26:59.270521|2018-06-01 05:26:59.270521
NCT00006006|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|August 2000||2000-08-31|September 2003|2003-09-30||||March 2005|Actual|2005-03-31||Interventional|||Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed|Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression|Completed||Phase 2|38|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:26:59.422654|2018-06-01 05:26:59.422654
NCT00006005|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-21|Estimate|September 2000||2000-09-30|August 2004|2004-08-31|August 2006|Actual|2006-08-31|||||Interventional|||Thalidomide in Treating Patients With Gynecologic Sarcomas|Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:26:59.52947|2018-06-01 05:26:59.52947
NCT00006004|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-08-16|2003-01-26|2003-01-27|Estimate|||||||2013-08-16|2013-08-20|Estimate|May 2000||2000-05-31|August 2013|2013-08-31||||January 2005|Actual|2005-01-31||Interventional|||Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer|A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:26:59.623571|2018-06-01 05:26:59.623571
NCT00006003|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|July 2000||2000-07-31|January 2013|2013-01-31||||July 2003|Actual|2003-07-31||Interventional|||SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated|A Phase II Trial of SU5416 (NSC #696819) in Patients With Metastatic Melanoma|Terminated||Phase 2|35|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:26:59.725847|2018-06-01 05:26:59.725847
NCT00005997|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|April 1999||1999-04-30|June 2010|2010-06-30|November 2005|Actual|2005-11-30|April 2005|Actual|2005-04-30||Interventional|||Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer|Phase II and Pharmacokinetic Trial of Rebeccamycin Analog in Hepatobiliary Cancers|Terminated||Phase 2|72|Actual|Case Comprehensive Cancer Center||||slow accrual for Cohort II|f||||t||||||||||2018-06-01 05:26:59.847238|2018-06-01 05:26:59.847238
NCT00005990|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-11-08|2003-01-26|2003-01-27|Estimate|||||||2012-11-08|2012-11-09|Estimate|August 2000||2000-08-31|January 2006|2006-01-31||||September 2006|Actual|2006-09-30||Interventional|||R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors|Phase I and Pharmacokinetic Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan|Completed||Phase 1|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:26:59.934985|2018-06-01 05:26:59.934985
NCT00005987|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-11-27|2003-01-26|2003-01-27|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2000||2000-08-31|November 2017|2017-11-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma|Autologous Transplantation for Multiple Myeloma: A Research Study of Multiple Myeloma Using Chemotherapy Plus Growth Factor Primed Peripheral Blood Stem Cells Followed by Autologous Transplantation and Post-Transplant Immunotherapy|Terminated||Phase 2|87|Actual|Masonic Cancer Center, University of Minnesota||||Withdrawn because treatment guidelines changed|f||||t||||||||||2018-06-01 05:27:00.000141|2018-06-01 05:27:00.000141
NCT00005985|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-11-27|2003-01-26|2003-01-27|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2000||2000-08-31|November 2017|2017-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma|Primed Peripheral Blood Stem Cell Autologous Transplantation for Lymphoma and Hodgkin's Disease|Completed||Phase 2|213|Actual|Masonic Cancer Center, University of Minnesota|||||f||||t||||||||||2018-06-01 05:27:00.089013|2018-06-01 05:27:00.089013
NCT00005984|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-11-27|2003-01-26|2003-01-27|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2000||2000-08-31|September 2017|2017-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia|Autologous Marrow Transplantation for Chronic Myelogenous Leukemia Using Stem Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming|Terminated||Phase 2|22|Actual|Masonic Cancer Center, University of Minnesota||1||Study terminated as principal investigator [PI] left the university.|f||||t||||||||||2018-06-01 05:27:00.217655|2018-06-01 05:27:00.217655
NCT00003466|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-07|2003-01-26|2003-01-27|Estimate|||||||2014-07-07|2014-07-09|Estimate|March 1998||1998-03-31|February 2013|2013-02-28|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Temozolomide in Treating Patients With Progressive Low-Grade Glioma|Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal|Completed||Phase 2|100|Anticipated|Duke University|||||f||||f||||||||||2018-06-01 05:28:21.642936|2018-06-01 05:28:21.642936
NCT00005982|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2000||2000-04-30|January 2013|2013-01-31||||July 2004|Actual|2004-07-31||Interventional|||506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma|Phase II Study of 506U78 (NSC #686673) in Patients With Previously Treated Cutaneous T-Cell Lymphoma|Terminated||Phase 2|35|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:27:00.512575|2018-06-01 05:27:00.512575
NCT00005981|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-10|Estimate|June 2000||2000-06-30|June 2010|2010-06-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer|Phase II Trial of O6Benzylguanine and BCNU in Patients With Colon and Rectal Carcinoma|Completed||Phase 2|13|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:27:00.624868|2018-06-01 05:27:00.624868
NCT00005980|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|April 2000||2000-04-30|July 2012|2012-07-31||||July 2002|Actual|2002-07-31||Interventional|||Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer|A Randomized Phase II Study of Two Different Schedules of Caelyx in Metastatic Breast Cancer|Completed||Phase 2|116|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:00.719575|2018-06-01 05:27:00.719575
NCT00005979|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2009-02-03|2003-01-26|2003-01-27|Estimate|||||||2009-02-03|2009-02-04|Estimate|February 1998||1998-02-28|September 2000|2000-09-30||||||||Interventional|||Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer|Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:00.827225|2018-06-01 05:27:00.827225
NCT00005976|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-05-31|2003-01-26|2003-01-27|Estimate|||||||2013-05-31|2013-06-03|Estimate|May 2000||2000-05-31|September 2003|2003-09-30|April 2007|Actual|2007-04-30|December 2006|Actual|2006-12-31||Interventional|||Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma|Phase I/II Trial of Pyrazoloacridine and Carboplatin in Patients With Recurrent Glioma|Completed||Phase 2|60|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:27:01.013711|2018-06-01 05:27:01.013711
NCT00005973|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|April 2000||2000-04-30|January 2013|2013-01-31||||July 2004|Actual|2004-07-31||Interventional|||BMS-214662 in Treating Patients With Solid Tumors|Phase I Study of Farnesyl Transferase Inhibitor BMS-214662 (NSC 710086D) in Solid Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:01.164458|2018-06-01 05:27:01.164458
NCT00005970|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2017-08-21|2003-01-26|2003-01-27|Estimate|||||||2017-08-21|2017-08-22|Actual|May 19, 2000|Actual|2000-05-19|August 2017|2017-08-31||||November 15, 2009|Actual|2009-11-15||Interventional|||Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer|Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer|Active, not recruiting||Phase 3|3441|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-06-01 05:27:01.25606|2018-06-01 05:27:01.25606
NCT00005967|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|August 2000||2000-08-31|October 2004|2004-10-31||||April 2004|Actual|2004-04-30||Interventional|||Tipifarnib in Treating Patients With Advanced Hematologic Cancer|A Dose Finding Study of R115777 (NSC 702818) in Patients With Advanced Hematologic Malignancies|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:02.48167|2018-06-01 05:27:02.48167
NCT00005966|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2009-02-04|2003-01-26|2003-01-27|Estimate|||||||2009-02-04|2009-02-05|Estimate|October 2000||2000-10-31|September 2002|2002-09-30||||March 2006|Actual|2006-03-31||Interventional|||Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer|Phase III Randomized Trial of Interferon-Alfa2b Alone Versus Interferon-Alfa2b Plus Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:02.667132|2018-06-01 05:27:02.667132
NCT00005961|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|June 2000||2000-06-30|April 2003|2003-04-30||||December 2005|Actual|2005-12-31||Interventional|||O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma|A Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU (Carmustine) in Patients With Metatstatic Melanoma|Completed||Phase 2|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:03.080556|2018-06-01 05:27:03.080556
NCT00005957|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|2016-04-05||2017-04-19|2003-01-26|2003-01-27|Estimate|2016-05-09|2016-06-15|Estimate||||2017-04-19|2017-05-18|Actual|April 2000||2000-04-30|May 2016|2016-05-31|April 19, 2017|Actual|2017-04-19|October 2014|Actual|2014-10-31||Interventional||Intention-to-treat|Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer|A Phase III Study of Regional Radiation Therapy in Early Breast Cancer|Completed||Phase 3|1832|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:27:03.318173|2018-06-01 05:27:03.318173
NCT00005955|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|August 2000||2000-08-31|October 2009|2009-10-31|September 2002|Actual|2002-09-30|||||Interventional|||Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors|Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy|Completed||Phase 2|||Duke University|||||f||||||||||||||2018-06-01 05:27:03.719743|2018-06-01 05:27:03.719743
NCT00005954|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|August 2000||2000-08-31|October 2009|2009-10-31|June 2003|Actual|2003-06-30|||||Interventional|||Temozolomide in Treating Patients With Brain Metastases|Phase II Treatment of Adults With Brain Metastases With Temodar|Completed||Phase 2|||Duke University|||||f||||||||||||||2018-06-01 05:27:03.877967|2018-06-01 05:27:03.877967
NCT00005952|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|August 2000||2000-08-31|February 2013|2013-02-28|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors|A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors|Completed||Phase 1/Phase 2|30|Anticipated|Duke University|||||f||||f||||||||||2018-06-01 05:27:03.990322|2018-06-01 05:27:03.990322
NCT00005951|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2014-08-20|2003-01-26|2003-01-27|Estimate|||||||2014-08-20|2014-08-22|Estimate|August 2000||2000-08-31|February 2013|2013-02-28|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma|Phase I Treatment of Adults With Primary Malignant Glioma With Irinotecan (CPT-11) (NSC- #6616348) Plus Temodar (NSC #362856)|Completed||Phase 1|||Duke University|||||f||||||||||||||2018-06-01 05:27:04.176317|2018-06-01 05:27:04.176317
NCT00005949|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|March 2001||2001-03-31|January 2013|2013-01-31||||March 2006|Actual|2006-03-31||Interventional|||Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma|Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma|Completed||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:04.28683|2018-06-01 05:27:04.28683
NCT00005945|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2016-02-19|2003-01-26|2003-01-27|Estimate|||||||2016-02-19|2016-02-23|Estimate|June 2000||2000-06-30|February 2016|2016-02-29|June 2008|Actual|2008-06-30|November 2007|Actual|2007-11-30||Interventional|||Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia|Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia|Completed||Phase 3|3054|Actual|Children's Oncology Group||7|||f||||t||||||||||2018-06-01 05:27:04.54801|2018-06-01 05:27:04.54801
NCT00005941|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2010-03-31|2003-01-26|2003-01-27|Estimate|||||||2010-03-31|2010-04-02|Estimate|November 1999||1999-11-30|March 2010|2010-03-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer|Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced or Metastatic Human Papilloma Virus (HPV) - Associated Cervical Carcinoma Refractory to Standard Therapy|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:27:04.97303|2018-06-01 05:27:04.97303
NCT00005879|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|2017-01-23||2017-04-19|2003-01-26|2003-01-27|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|August 2000||2000-08-31|April 2017|2017-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||LY353381 in Preventing Breast Cancer in Women With Hyperplasia|A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia|Completed||Phase 2|199|Actual|University of Kansas Medical Center||2|||f||||f||||||||No|Global results will be published.|2018-06-01 05:27:05.143081|2018-06-01 05:27:05.143081
NCT00005878|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-10-12|2003-01-26|2003-01-27|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2000||2000-07-31|October 2016|2016-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus|Chemoprevention for Barrett's Esophagus Trial (CBET)|Completed||Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:27:06.073923|2018-06-01 05:27:06.073923
NCT00005867|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|January 1998||1998-01-31|March 2007|2007-03-31|August 2007|Actual|2007-08-31|||||Interventional|||Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma|Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma|Completed||Phase 3|310|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:06.274973|2018-06-01 05:27:06.274973
NCT00005863|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 1998||1998-08-31|January 2006|2006-01-31|December 2004|Actual|2004-12-31|||||Interventional|||Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia|Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:06.473359|2018-06-01 05:27:06.473359
NCT00005859|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|August 2000||2000-08-31|April 2004|2004-04-30||||||||Interventional|||Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma|Phase I/II Trial of R115777 in Patients With Recurrent Malignant Glioma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:06.5706|2018-06-01 05:27:06.5706
NCT00005858|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2017-03-28|2003-01-26|2003-01-27|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2000|Actual|2000-04-30|March 2017|2017-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer|Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin Admistered by Continuous Infusion|Completed||Phase 1|25|Actual|University of Maryland||1|||f||||||||||||||2018-06-01 05:27:06.643313|2018-06-01 05:27:06.643313
NCT00005856|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 2000||2000-12-31|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults With Newly Diagnosed Glioblastoma Multiforme|Terminated||Phase 1/Phase 2|59|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:27:06.733576|2018-06-01 05:27:06.733576
NCT00005855|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 2000||2000-07-31|December 2003|2003-12-31|October 2006|Actual|2006-10-31|||||Interventional|||Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma|A Phase I/II Study to Evaluate the Safety and Tolerance of Escalating Doses of RSR13 Administered With a Fixed Dose of BCNU Every Six Weeks in Patients With Recurrent Malignant Glioma|Completed||Phase 1/Phase 2|48|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:06.831432|2018-06-01 05:27:06.831432
NCT00005853|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-03-31|2003-01-26|2003-01-27|Estimate|||||||2010-03-31|2010-04-02|Estimate|December 1999||1999-12-31|March 2010|2010-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Biological Therapy in Treating Patients With Myelodysplastic Syndrome|Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc|Completed||Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:27:06.92386|2018-06-01 05:27:06.92386
NCT00005851|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2017-07-03|2003-01-26|2003-01-27|Estimate|||||||2017-07-03|2017-07-05|Actual|February 2000||2000-02-29|July 2017|2017-07-31||||July 2004|Actual|2004-07-31||Interventional|||Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer|Phase I/II Study of HLA-Matched Non-Myeloablative Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation as Treatment for Patients With Metastatic Renal Cell Carcinoma. A Multi-Center Trial.|Active, not recruiting||Phase 1/Phase 2|11|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:27:07.021802|2018-06-01 05:27:07.021802
NCT00005850|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-04|Estimate|August 2001||2001-08-31|July 2016|2016-07-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer|Fluoxetine in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A Phase II Pilot Study to Improve Quality of Life During Chemotherapy|Completed||Phase 2|21|Actual|Alliance for Clinical Trials in Oncology||1|||f||||||||||||||2018-06-01 05:27:07.29339|2018-06-01 05:27:07.29339
NCT00005847|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-01-26|2003-01-26|2003-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|January 2001||2001-01-31|January 2010|2010-01-31||||July 2004|Actual|2004-07-31||Interventional|||Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy|A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients With Metatstatic Hormone Refractory Prostate Cancer|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:27:07.498745|2018-06-01 05:27:07.498745
NCT00005844|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-10-22|2003-01-26|2003-01-27|Estimate|||||||2012-10-22|2012-10-23|Estimate|April 2000||2000-04-30|October 2012|2012-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Oxaliplatin in Treating Children With Advanced Solid Tumors|A Phase I Study of Oxaliplatin in Children With Solid Tumors|Completed||Phase 1|26|Actual|St. Jude Children's Research Hospital|||||f||||f||||||||||2018-06-01 05:27:07.73986|2018-06-01 05:27:07.73986
NCT00005840|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2014-12-29|2003-01-26|2003-01-27|Estimate|||||||2014-12-29|2014-12-31|Estimate|July 2000||2000-07-31|December 2014|2014-12-31||||July 2009|Actual|2009-07-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer|Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy|Completed||Phase 1|35|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:27:07.823963|2018-06-01 05:27:07.823963
NCT00005838|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-22|2003-01-26|2003-01-27|Estimate|||||||2013-01-22|2013-01-23|Estimate|March 2000||2000-03-31|January 2013|2013-01-31||||February 2007|Actual|2007-02-28||Interventional|||Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery|Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer|Completed||Phase 3|756|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:07.945736|2018-06-01 05:27:07.945736
NCT00005835|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-08-27|2003-01-26|2003-01-27|Estimate|||||||2016-08-27|2016-08-30|Estimate|August 2001||2001-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|BSO||N99-02: Melphalan and Buthionine Sulfoximine|Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112)|Completed||Phase 1|30|Anticipated|New Approaches to Neuroblastoma Therapy Consortium|||||f||||t||||||||||2018-06-01 05:27:08.179606|2018-06-01 05:27:08.179606
NCT00005831|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-11|2003-01-26|2003-01-27|Estimate|||||||2013-01-11|2013-01-14|Estimate|March 2000||2000-03-31|January 2013|2013-01-31||||August 2004|Actual|2004-08-31||Interventional|||Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer|Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:08.322697|2018-06-01 05:27:08.322697
NCT00005830|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2014-12-29|2003-01-26|2003-01-27|Estimate|||||||2014-12-29|2014-12-31|Estimate|July 2000||2000-07-31|December 2014|2014-12-31||||July 2009|Actual|2009-07-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer|Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma|Completed||Phase 1|31|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:27:08.540602|2018-06-01 05:27:08.540602
NCT00005825|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 1998||1998-09-30|July 2003|2003-07-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer|Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:08.660221|2018-06-01 05:27:08.660221
NCT00005824|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2016-02-01|2003-01-26|2003-01-27|Estimate|||||||2016-02-01|2016-02-03|Estimate|November 2000||2000-11-30|February 2016|2016-02-29|April 2006|Actual|2006-04-30|July 2004|Actual|2004-07-31||Interventional|||Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma|Pilot Study of the Safety and Feasibility of Autologous Peripheral Blood Stem Cell Transplantation for Patients With Relapsed AIDS-Related Lymphoma|Completed||Phase 2|||AIDS Malignancy Consortium|||||f||||||||||||||2018-06-01 05:27:08.78008|2018-06-01 05:27:08.78008
NCT00005823|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 1998||1998-12-31|September 2006|2006-09-30|December 2007|Actual|2007-12-31|||||Interventional|||Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over|Completed||Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:08.89539|2018-06-01 05:27:08.89539
NCT00005822|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-06-10|2003-01-26|2003-01-27|Estimate|||||||2010-06-10|2010-06-11|Estimate|April 2000||2000-04-30|June 2010|2010-06-30|October 2003|Actual|2003-10-31|December 2002|Actual|2002-12-31||Interventional|||SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer|A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer|Completed||Phase 1|21|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:27:09.010551|2018-06-01 05:27:09.010551
NCT00005821|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|December 1998||1998-12-31|March 2003|2003-03-31||||||||Interventional|||Sentinel Lymph Node Biopsy to Assess Axillary Lymph Nodes in Women With Stage I or Stage II Breast Cancer|Sentinel Lymph Node Biopsy in the Assessment of Axillary Nodal Status in Operable Breast Cancer|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:09.07647|2018-06-01 05:27:09.07647
NCT00005819|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|April 2000||2000-04-30|June 2010|2010-06-30|August 2006|Actual|2006-08-31|May 2005|Actual|2005-05-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Solid Tumors|A Phase I Trial of Fenretinide in Combination With Paclitaxel and Cisplatin|Completed||Phase 1|21|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:27:09.185159|2018-06-01 05:27:09.185159
NCT00005817|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-31|2003-01-26|2003-01-27|Estimate|||||||2013-01-31|2013-02-01|Estimate|March 2000||2000-03-31|January 2013|2013-01-31||||May 2006|Actual|2006-05-31||Interventional|||Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer|A Randomized Phase 2 Study of Rebeccamycin Analog in Advanced Breast Cancer|Completed||Phase 2|42|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:09.304724|2018-06-01 05:27:09.304724
NCT00005815|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|December 1999||1999-12-31|June 2013|2013-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma|A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma|Completed||Phase 1/Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:09.381354|2018-06-01 05:27:09.381354
NCT00005812|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-05-13|2003-01-26|2003-01-27|Estimate|||||||2013-05-13|2013-05-14|Estimate|January 2000||2000-01-31|May 2013|2013-05-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma|A Pilot Phase II Trial of Temozolomide in Leptomeningeal Metastases|Terminated||Phase 2|12|Actual|Dartmouth-Hitchcock Medical Center||1||No objective response documented, protocol terminated after 12 patients.|f||||t||||||||||2018-06-01 05:27:09.467035|2018-06-01 05:27:09.467035
NCT00005811|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-02-20|2003-01-26|2003-01-27|Estimate|||||||2013-02-20|2013-02-21|Estimate|April 2000||2000-04-30|February 2013|2013-02-28|February 2009|Actual|2009-02-28|April 2006|Actual|2006-04-30||Interventional|||Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment|A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies|Completed||Phase 2|77|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:09.629375|2018-06-01 05:27:09.629375
NCT00005808|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-02-06|2003-01-26|2003-01-27|Estimate|||||||2013-02-06|2013-02-07|Estimate|December 2000||2000-12-31|February 2013|2013-02-28||||April 2004|Actual|2004-04-30||Interventional|||Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia|Phase I Study Photodynamic Therapy Using Lutrin (Lutetium Texaphyrin) in the Treatment of Patients With Cervical Intraepithelial Neoplasia|Terminated||Phase 1|54|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:27:09.734773|2018-06-01 05:27:09.734773
NCT00005807|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2008-07-23|2003-01-26|2003-01-27|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2000||2000-07-31|September 2003|2003-09-30||||||||Interventional|||BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer|A Phase I Scientific Exploratory Study of Epothilone B Analog (BMS-247550; NSC #710428) in Patients With Solid Tumors and Gynecological Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:09.841739|2018-06-01 05:27:09.841739
NCT00005803|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|2017-04-14||2018-02-12|2003-01-26|2003-01-27|Estimate|2017-12-05|2017-12-07|Actual||||2018-02-12|2018-03-12|Actual|September 1999||1999-09-30|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|January 2016|Actual|2016-01-31||Interventional|||Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma|A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial|Active, not recruiting||Phase 1/Phase 2|76|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:27:10.06801|2018-06-01 05:27:10.06801
NCT00005802|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2010-03-31|2003-01-26|2003-01-27|Estimate|||||||2010-03-31|2010-04-02|Estimate|June 1999||1999-06-30|March 2010|2010-03-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia|Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant|Completed||Phase 1/Phase 2|||Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:27:10.622716|2018-06-01 05:27:10.622716
NCT00005797|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-10-24|2003-01-26|2003-01-27|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 1993||1993-03-31|October 2012|2012-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Bone Marrow Transplant in Treating Patients With Hematologic Cancers|Allogeneic Bone Marrow Transplantation for Hematologic Malignancies: A Treatment Approach Based on Risk of Relapse and Toxicity|Completed||Phase 2|125|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-06-01 05:27:10.748412|2018-06-01 05:27:10.748412
NCT00005788|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02||2011-07-01|2012-05-31|2003-01-26|2003-01-27|Estimate||||2011-07-01|2011-07-14|Estimate|2012-05-31|2012-06-06|Estimate|April 1997||1997-04-30|May 2012|2012-05-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome|Phase II Trial of Subcutaneous Injections of Interleukin-2 for the Treatment of Mycosis Fungoides or the Sezary Syndrome|Terminated||Phase 2|||Northwestern University||||Low/inadequate rate of accrual.|f||||t||||||||||2018-06-01 05:27:10.853344|2018-06-01 05:27:10.853344
NCT00005787|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2012-05-31|2003-01-26|2003-01-27|Estimate|||||||2012-05-31|2012-06-01|Estimate|September 1999||1999-09-30|May 2012|2012-05-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma|Ex Vivo Expanded Peripheral Blood Mononuclear Cells for the Elimination of Neutropenia Associated With High Dose Chemotherapy|Terminated||Phase 1|3|Actual|Northwestern University||||Per PI due to poor/inadequate accrual.|f||||t||||||||||2018-06-01 05:27:11.006606|2018-06-01 05:27:11.006606
NCT00005786|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2013-01-31|2003-01-26|2003-01-27|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2001||2001-01-31|January 2013|2013-01-31||||November 2004|Actual|2004-11-30||Interventional|||Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia|A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas|Terminated||N/A|25|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:27:11.113446|2018-06-01 05:27:11.113446
NCT00005647|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-10|Estimate|May 2000||2000-05-31|June 2010|2010-06-30|October 2003|Actual|2003-10-31|December 2002|Actual|2002-12-31||Interventional|||SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck|A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck|Completed||Phase 1|12|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:27:11.260389|2018-06-01 05:27:11.260389
NCT00005644|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-09-29|2003-01-26|2003-01-27|Estimate|||||||2012-09-29|2012-10-02|Estimate|May 2000||2000-05-31|July 2002|2002-07-31||||February 2003|Actual|2003-02-28||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function|Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:11.43637|2018-06-01 05:27:11.43637
NCT00004241|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-02-06|2003-01-26|2003-01-27|Estimate|||||||2013-02-06|2013-02-07|Estimate|October 1999||1999-10-31|February 2013|2013-02-28||||May 2006|Actual|2006-05-31||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma|A Phase I Trial of Weekly 17-Allylamino-17 Demethoxygeldanamycin|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:33.857175|2018-06-01 05:27:33.857175
NCT00005639|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-03-13|2003-01-26|2003-01-27|Estimate|||||||2010-03-13|2010-03-16|Estimate|June 2000||2000-06-30|December 2005|2005-12-31||||||||Interventional|||Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment|A Phase I Dose Escalation to Maximally Tolerated Dose Trial of 5-Azacytidine (5 AC, NSC 102816) in Combination With Sodium Phenylbutyrate (PB, NSC 657802) in Patients With Refractory Solid Tumors|Completed||Phase 1|||National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:27:11.591813|2018-06-01 05:27:11.591813
NCT00005638|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-17|2003-01-26|2003-01-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|October 1999||1999-10-31|June 2013|2013-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer|Phase I Trial of Combined Modality Irinotecan, Cisplatin, and Concurrent Radiation Therapy for Patients With Locally Advanced Esophageal Cancer|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:11.726007|2018-06-01 05:27:11.726007
NCT00005637|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-04-02|2003-01-26|2003-01-27|Estimate|||||||2013-04-02|2013-04-04|Estimate|December 1999||1999-12-31|March 2003|2003-03-31|December 2009|Actual|2009-12-31|June 2003|Actual|2003-06-30||Interventional|||Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma|A Phase I Study of Extended Low Dose Temozolomide (SCH 52365, Temodar (R)) and Carmustine (BCNU) in the Treatment of Malignant Gliomas After Radiation Therapy|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:11.847455|2018-06-01 05:27:11.847455
NCT00005627|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|March 1999||1999-03-31|April 2003|2003-04-30|April 2003|Actual|2003-04-30|||||Interventional|||Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy|A Phase I Study of Estramustine, Taxotere and Carboplatin (ETP) in Patients With Horomone Refractory Prostate Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:11.91816|2018-06-01 05:27:11.91816
NCT00005623|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-03-25|2003-01-26|2003-01-27|Estimate|||||||2013-03-25|2013-03-26|Estimate|December 1999||1999-12-31|December 2003|2003-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer|A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:11.992946|2018-06-01 05:27:11.992946
NCT00005622|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2012-10-24|2003-01-26|2003-01-27|Estimate|||||||2012-10-24|2012-10-25|Estimate|May 1996||1996-05-31|October 2012|2012-10-31|July 2009|Actual|2009-07-31|September 2005|Actual|2005-09-30||Interventional|||Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders|Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors|Completed||Phase 2|72|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-06-01 05:27:12.126552|2018-06-01 05:27:12.126552
NCT00005617|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2015-10-28|2003-01-26|2003-01-27|Estimate|||||||2015-10-28|2015-10-30|Estimate|July 1997||1997-07-31|July 2012|2012-07-31||||June 2002|Actual|2002-06-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma|A Phase I Trial Testing Mart-1 Peptide Immunization in Malignant Melanoma|Completed||Phase 1|||Jonsson Comprehensive Cancer Center||6|||f||||t||||||||||2018-06-01 05:27:12.263304|2018-06-01 05:27:12.263304
NCT00005606|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02||2011-02-16|2012-05-31|2003-01-26|2003-01-27|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-31|2012-06-06|Estimate|February 2000||2000-02-29|May 2012|2012-05-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation|Adoptive Immunotherapy of Epstein Barr Virus Induced Lymhoproliferative Disease. A Comparison of Allogeneic and Autologous Lymphocyte Responses ex Vivo and Use of Highly Selected Reactive Cells as an Alternative to Chemotherapy in Vivo.|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:27:12.394225|2018-06-01 05:27:12.394225
NCT00005605|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2011-02-18|2003-01-26|2003-01-27|Estimate|||||||2011-02-18|2011-02-21|Estimate|February 2000||2000-02-29|February 2011|2011-02-28|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Observational|||Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer|Does Tamoxifen Prevent the Skeletal and Cardiovascular Morbidity of Chemotherapy in Premenopausal Women?|Completed|||79|Actual|Northwestern University|||2||f||||||||||||||2018-06-01 05:27:12.513864|2018-06-01 05:27:12.513864
NCT00005603|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2014-02-18|2003-01-26|2003-01-27|Estimate|||||||2014-02-18|2014-02-20|Estimate|March 2000||2000-03-31|February 2014|2014-02-28||||September 2005|Actual|2005-09-30||Interventional|||Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia|ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study|Completed||Phase 3|276|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:27:12.633803|2018-06-01 05:27:12.633803
NCT00005602|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2014-02-19|2003-01-26|2003-01-27|Estimate|||||||2014-02-19|2014-02-21|Estimate|February 2001||2001-02-28|February 2014|2014-02-28|September 2005|Actual|2005-09-30|January 2005|Actual|2005-01-31||Interventional|||Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas|Phase I Study of Concurrent Cereport and Carboplatin With Radiation Therapy for Children With Newly-Diagnosed Brain Stem Gliomas|Completed||Phase 1|13|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:27:12.780174|2018-06-01 05:27:12.780174
NCT00005601|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2016-12-05|2003-01-26|2003-01-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2000||2000-10-31|December 2016|2016-12-31|February 2008|Actual|2008-02-29|July 2003|Actual|2003-07-31||Interventional|||Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|A Phase II Trial of Cisplatinum, Cytosine Arabinoside, Dexamethasone (DHAP) With Rituxan in Patients With Relapsed CD20+ B-Cell Non-Hodgkin's Lymphoma|Completed||Phase 2|58|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:27:12.948444|2018-06-01 05:27:12.948444
NCT00005600|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 1997||1997-11-30|December 2005|2005-12-31||||||||Interventional|||Axillary Drainage Following Lymph Node Dissection in Women With Stage I or Stage II Breast Cancer|Optimum Drainage of the Axilla After Lymph Node Dissection: A Randomized Prospective Study|Unknown status|Active, not recruiting|N/A|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:13.087312|2018-06-01 05:27:13.087312
NCT00005599|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2000||2000-02-29|August 2004|2004-08-31|August 2004|Actual|2004-08-31|||||Interventional|||Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer|Phase II Trail of Bryostatin-1 and Paclitaxel in Patients With Advanced Esophageal Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:13.175181|2018-06-01 05:27:13.175181
NCT00005597|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-01-02|2003-01-26|2003-01-27|Estimate|||||||2013-01-02|2013-01-03|Estimate|April 2000||2000-04-30|January 2013|2013-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors|Phase II Study of Temozolomide in Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)|Completed||Phase 2|25|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:27:13.37214|2018-06-01 05:27:13.37214
NCT00005596|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2016-05-11|2003-01-26|2003-01-27|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2000||2000-04-30|May 2016|2016-05-31|July 2007|Actual|2007-07-31|July 2005|Actual|2005-07-31||Interventional|||Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia|ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study|Completed||Phase 3|1076|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:27:13.593546|2018-06-01 05:27:13.593546
NCT00005590|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 1999||1999-08-31|July 2002|2002-07-31|September 2005|Actual|2005-09-30|||||Interventional|||Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma|A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:13.898073|2018-06-01 05:27:13.898073
NCT00005589|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 1999||1999-10-31|March 2007|2007-03-31|April 2013|Actual|2013-04-30|||||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|Randomized Study of Rituximab (Mabthera) in Patients With Relapsed Follicular Lymphoma Prior to High-Dose Therapy as In Vivo Purging and to Maintain Remission Following High-Dose Therapy|Completed||Phase 3|460|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:14.037671|2018-06-01 05:27:14.037671
NCT00005586|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 1997||1997-10-31|March 2007|2007-03-31||||||||Interventional|||Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed|A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer|Completed||Phase 3|2500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:14.414219|2018-06-01 05:27:14.414219
NCT00005585|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-07|2003-01-26|2003-01-27|Estimate|||||||2013-06-07|2013-06-10|Estimate|April 2000||2000-04-30|June 2013|2013-06-30||||July 2007|Actual|2007-07-31||Interventional|||Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia|ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study|Completed||Phase 3|838|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:27:14.510917|2018-06-01 05:27:14.510917
NCT00005584|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2017-07-26|2003-01-26|2003-01-27|Estimate|||||||2017-07-26|2017-07-27|Actual|October 1998||1998-10-31|July 2017|2017-07-31||||May 2004|Actual|2004-05-31||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma|Prospective Controlled Trial in Clinical Stages I-II Supradiaphragmatic Hodgkin's Disease: Evaluation of Treatment Efficacy, (Long Term) Toxicity and Quality of Life in Two Different Prognostic Subgroups|Active, not recruiting||Phase 3|1649|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:14.93633|2018-06-01 05:27:14.93633
NCT00005583|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 2000||2000-01-31|November 2006|2006-11-30|July 2010|Actual|2010-07-31|||||Interventional|||Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer|A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma|Completed||Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:15.211743|2018-06-01 05:27:15.211743
NCT00005580|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2010-02-23|2003-01-26|2003-01-27|Estimate|||||||2010-02-23|2010-02-24|Estimate|September 1998||1998-09-30|February 2010|2010-02-28|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma|Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma|Completed||Phase 1|54|Actual|Virginia Commonwealth University|||||f||||f||||||||||2018-06-01 05:27:15.354995|2018-06-01 05:27:15.354995
NCT00005579|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 1998||1998-06-30|November 2002|2002-11-30|February 2003|Actual|2003-02-28|||||Interventional|||Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia|Phase II Trial of Dolastin 10 in Indolent Lymphoma and Chronic Lymphocytic Leukemia|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:15.464769|2018-06-01 05:27:15.464769
NCT00005095|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2016-09-29|2003-01-26|2003-01-27|Estimate|||||||2016-09-29|2016-09-30|Estimate|March 2000||2000-03-31|September 2016|2016-09-30||||December 2020|Anticipated|2020-12-31||Observational|||Specimen and Data Study for Ovarian Cancer Early Detection and Prevention|Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study|Recruiting|||6000|Anticipated|Northwestern University|||1||f||||t||||||Samples With DNA|"~     Subjects blood and other specimens are collected their follow-up clinic appointments.~   "|||2018-06-01 05:27:15.538352|2018-06-01 05:27:15.538352
NCT00005087|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2015-11-14|2003-01-26|2003-01-27|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 2000||2000-03-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|November 2004|Actual|2004-11-30||Interventional|||Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer|Phase II Study of Paclitaxel and Cisplatin in Combination With Split Course Concomitant Hyperfractionated Re-Irradiation in Patients With Recurrent Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|105|Actual|Radiation Therapy Oncology Group||1|||f||||t||||||||||2018-06-01 05:27:15.703276|2018-06-01 05:27:15.703276
NCT00005079|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|January 1999||1999-01-31|April 2003|2003-04-30|October 2004|Actual|2004-10-31|||||Interventional|||Timing of Menstrual Cycle and Surgery in Treating Premenopausal Women With Stage I, Stage II, or Stage III Breast Cancer|Timing of Breast Cancer Surgery, Menstrual Cycle and Prognosis|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:16.212486|2018-06-01 05:27:16.212486
NCT00005074|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2010-11-07|2003-01-26|2003-01-27|Estimate|||||||2010-11-07|2010-11-09|Estimate|January 2000||2000-01-31|March 2010|2010-03-31|September 2008|Actual|2008-09-30|||||Interventional|||Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma|A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Untreated or Relapsed Mantle Cell Lymphoma|Completed||Phase 2|||Canadian Cancer Trials Group|||||f||||||||||||||2018-06-01 05:27:16.325949|2018-06-01 05:27:16.325949
NCT00005067|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|February 2000||2000-02-29|January 2013|2013-01-31||||January 2007|Actual|2007-01-31||Interventional|||Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer|A Phase I Trial of Photodynamic Therapy With Lutetium Texaphyrin in Patients With Locally Recurrent Prostate Carcinoma|Terminated||Phase 1|24|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:27:16.421151|2018-06-01 05:27:16.421151
NCT00005062|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2014-03-12|2003-01-26|2003-01-27|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 1999||1999-09-30|March 2014|2014-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission|A Phase III Trial Comparing High Versus Standard Dose of Prophylactic Cranial Irradiation (PCI) in Limited Small Cell Lung Cancer Complete Responders|Completed||Phase 3|||Gustave Roussy, Cancer Campus, Grand Paris|||||f||||||||||||||2018-06-01 05:27:16.528701|2018-06-01 05:27:16.528701
NCT00005060|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|November 1999||1999-11-30|May 2012|2012-05-31|March 2006|Actual|2006-03-31|November 2005|Actual|2005-11-30||Interventional|||Combination Chemotherapy and Surgery in Treating Patients With Locally Advanced Stomach Cancer|A Phase III Trial of Preoperative vs. Postoperative Chemotherapy With Taxotere-Cisplatin-5FU (TCF) in Patients With Locally Advanced Operable Gastric Carcinoma|Completed||Phase 3|240|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:27:16.825869|2018-06-01 05:27:16.825869
NCT00005052|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|December 1999||1999-12-31|January 2006|2006-01-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Primary Stage II Melanoma|Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:16.970951|2018-06-01 05:27:16.970951
NCT00005051|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2012-11-08|2003-01-26|2003-01-27|Estimate|||||||2012-11-08|2012-11-09|Estimate|August 1999||1999-08-31|December 2003|2003-12-31||||March 2003|Actual|2003-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer|Phase II Study of First-Line Therapy of Ovarian Cancer With Sequential Regimens: Cisplatin-Prolonged Oral Topotecan (C-PORT) Followed by Paclitaxel/Carboplatin (PC)|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:27:17.306934|2018-06-01 05:27:17.306934
NCT00005049|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2011-04-04|2003-01-26|2003-01-27|Estimate|||||||2011-04-04|2011-04-06|Estimate|May 1997||1997-05-31|April 2011|2011-04-30||||November 2006|Actual|2006-11-30||Interventional|||Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer|Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies|Completed||Phase 2|45|Actual|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:27:17.418378|2018-06-01 05:27:17.418378
NCT00005047|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|2017-03-23||2017-05-10|2003-01-26|2003-01-27|Estimate|2017-05-10|2017-06-08|Actual||||2017-05-10|2017-06-08|Actual|August 1997|Actual|1997-08-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|March 2011|Actual|2011-03-31||Interventional|||4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer|MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) in Organ-Confined Bladder Cancer Based on p53 Status|Terminated||Phase 3|521|Actual|Southwest Oncology Group||4||"Accrual was halted on the basis of the Data and Safety Monitoring Board review of a futility~   analysis."|f||||t||||||||||2018-06-01 05:27:17.567153|2018-06-01 05:27:17.567153
NCT00005044|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|2017-10-02||2017-10-02|2003-01-26|2003-01-27|Estimate|2017-10-02|2017-10-31|Actual||||2017-10-02|2017-10-31|Actual|February 2000|Actual|2000-02-29|October 2017|2017-10-31||||September 2012|Actual|2012-09-30||Interventional||Eligible patients with follow-up data|Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer|A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer|Active, not recruiting||Phase 3|1579|Actual|Radiation Therapy Oncology Group|The data monitoring committee decided in June 2012 after the first interim analysis that the trial should be reported early due to the low number of events.|2|||f||||t||||||||||2018-06-01 05:27:18.632091|2018-06-01 05:27:18.632091
NCT00005039|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2000||2000-01-31|January 2013|2013-01-31||||March 2007|Actual|2007-03-31||Interventional|||Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)|A Phase II Randomized Trial of Recombinant Fowlpox and Recombinant Vaccinia Virus Expressing PSA in Patients With Adenocarcinoma of the Prostate|Terminated||Phase 2|86|Actual|National Cancer Institute (NCI)||2||Administratively complete.|f||||||||||||||2018-06-01 05:27:20.429188|2018-06-01 05:27:20.429188
NCT00005038|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 1999||1999-06-30|June 2001|2001-06-30||||||||Interventional|||Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer|A Randomized Phase II Study to Evaluate the Efficacy of Combined Immunotherapy With Subcutaneous Interleukin-2 and Maxamine in Patients With Metastatic Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:20.555692|2018-06-01 05:27:20.555692
NCT00005036|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-05-01|2003-01-26|2003-01-27|Estimate|||||||2013-05-01|2013-05-03|Estimate|November 1999||1999-11-30|May 2013|2013-05-31||||December 2006|Actual|2006-12-31||Interventional|||Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer|A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU|Completed||Phase 3|560|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:20.641005|2018-06-01 05:27:20.641005
NCT00005033|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-21|Estimate|December 1999||1999-12-31|August 2004|2004-08-31|August 2004|Actual|2004-08-31|||||Interventional|||Trastuzumab in Treating Patients With Recurrent Osteosarcoma|Phase II Study of Recombinant Humanized Monoclonal Antibody Against HER2 for the Treatment of Recurrent Osteosarcoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:20.757336|2018-06-01 05:27:20.757336
NCT00004936|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-01-25|2003-01-26|2003-01-27|Estimate|||||||2013-01-25|2013-01-28|Estimate|April 2000||2000-04-30|January 2013|2013-01-31|October 2002|Actual|2002-10-31|May 2001|Actual|2001-05-31||Interventional|ACRIN 6651||MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients|Role of Radiology in the Pretreatment Evaluation of Invasive Cervical Cancer|Completed||N/A|||American College of Radiology Imaging Network|||||f||||t||||||||||2018-06-01 05:27:20.842092|2018-06-01 05:27:20.842092
NCT00004935|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2017-11-02|2003-01-26|2003-01-27|Estimate|||||||2017-11-02|2017-11-06|Actual|August 30, 1999|Actual|1999-08-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|November 6, 2014|Actual|2014-11-06||Interventional|||Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2|Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.|Active, not recruiting||Phase 3|175|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:27:20.987634|2018-06-01 05:27:20.987634
NCT00004934|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-02-01|2003-01-26|2003-01-27|Estimate|||||||2013-02-01|2013-02-04|Estimate|August 1999||1999-08-31|May 2003|2003-05-31|May 2003|Actual|2003-05-31|||||Interventional|||Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer|A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:21.363178|2018-06-01 05:27:21.363178
NCT00004932|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2014-02-20|2003-01-26|2003-01-27|Estimate|||||||2014-02-20|2014-02-21|Estimate|January 2002||2002-01-31|February 2014|2014-02-28|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||STI571 in Treating Patients With Recurrent Leukemia|A Phase I Study of STI571 in Ph+ Leukemia|Completed||Phase 1|31|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:27:23.076924|2018-06-01 05:27:23.076924
NCT00004930|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 1999||1999-07-31|June 2013|2013-06-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases|Phase I and Clinical Pharmacologic Study of Inhaled Doxorubicin in Adults With Advanced Solid Tumors Affecting the Lungs|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:24.149084|2018-06-01 05:27:24.149084
NCT00004924|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2009-08-21|2003-01-26|2003-01-27|Estimate|||||||2009-08-21|2009-08-25|Estimate|March 1999||1999-03-31|August 2009|2009-08-31|February 2006|Actual|2006-02-28|||||Interventional|||Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer|Phase II Trial of Irinotecan Plus Paclitaxel in Patients With Advanced Nonsmall Cell Lung Cancer|Completed||Phase 2|28|Actual|Yale University|||||f||||f||||||||||2018-06-01 05:27:24.256375|2018-06-01 05:27:24.256375
NCT00004921|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 1998||1998-09-30|July 2002|2002-07-31|September 2007|Actual|2007-09-30|||||Interventional|||High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery|A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:24.346756|2018-06-01 05:27:24.346756
NCT00004920|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|November 1999||1999-11-30|July 2012|2012-07-31||||January 2003|Actual|2003-01-31||Interventional|||Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura|Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma|Completed||Phase 3|256|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:24.650742|2018-06-01 05:27:24.650742
NCT00004918|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-01-04|2003-01-26|2003-01-27|Estimate|||||||2013-01-04|2013-01-07|Estimate|December 1999||1999-12-31|January 2013|2013-01-31||||December 2007|Actual|2007-12-31||Interventional|||Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome|A Phase I/II Study of PR1 (NSC 698102) Human Leukemia Peptide Vaccine With Montanide ISA 51 (NSC 675756) or Montanide ISA 51 VG (NSC 737063) Adjuvant|Completed||Phase 1/Phase 2|69|Anticipated|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:27:25.057207|2018-06-01 05:27:25.057207
NCT00004917|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2016-12-30|2003-01-26|2003-01-27|Estimate|||||||2016-12-30|2017-01-04|Estimate|June 2000||2000-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2007|Actual|2007-11-30||Interventional|||Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer|A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiotherapy for Carcinoma of the Head and Neck|Completed||Phase 3|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:27:26.562821|2018-06-01 05:27:26.562821
NCT00004907|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-16|2012-06-08|2003-01-26|2003-01-27|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma|High-Dose Chemoradiotherapy With Stem Cell Allogeneic Cellular Rescue in Patients With Relapsed or Refractory Hematologic Malignancy - A Phase I/II Study|Completed||Phase 1/Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:27:28.834128|2018-06-01 05:27:28.834128
NCT00004899|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-16|2012-06-08|2003-01-26|2003-01-27|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:27:29.0011|2018-06-01 05:27:29.0011
NCT00004896|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07||2011-02-16|2012-06-08|2003-01-26|2003-01-27|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:27:29.091734|2018-06-01 05:27:29.091734
NCT00004891|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2015-12-21|2003-01-26|2003-01-27|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 1999||1999-09-30|December 2015|2015-12-31||||March 2007|Actual|2007-03-31||Interventional|||PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery|Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer|Completed||N/A|149|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:27:29.348596|2018-06-01 05:27:29.348596
NCT00004888|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|2011-06-21||2014-05-07|2003-01-26|2003-01-27|Estimate|2011-10-18|2011-11-23|Estimate||||2014-05-07|2014-05-23|Estimate|January 2001||2001-01-31|December 2012|2012-12-31|May 2009|Actual|2009-05-31|April 2008|Actual|2008-04-30||Interventional|||Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer|A Safety and Efficacy Study of Doxil and Taxotere ± Herceptin in Advanced Breast Cancer|Completed||Phase 2|84|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:29.53997|2018-06-01 05:27:29.53997
NCT00004879|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-01-07|2003-01-26|2003-01-27|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2000||2000-04-30|January 2013|2013-01-31||||July 2005|Actual|2005-07-31||Interventional|||Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer|An Open Label, Multiple Dose, Dose-Rising Clinical Trial of the Safety of ABX-EGF in Patients With Renal, Prostate, Pancreatic, Non-Small-Cell Lung, Colorectal, or Esophageal Cancer|Completed||Phase 1|||Jonsson Comprehensive Cancer Center|||||f||||||||||||||2018-06-01 05:27:30.205811|2018-06-01 05:27:30.205811
NCT00004876|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|August 1999||1999-08-31|November 2011|2011-11-30||||||||Interventional|||Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer|A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:30.335089|2018-06-01 05:27:30.335089
NCT00004873|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|August 1999||1999-08-31|May 2012|2012-05-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer|Taxotere-Cisplatin-5FU (TCF) Versus Taxotere-Cisplatin (TC) Versus Epirubicin-Cisplatin-5FU (ECF) as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial|Completed||Phase 2|||Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:27:30.448749|2018-06-01 05:27:30.448749
NCT00004871|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2010-03-09|2003-01-26|2003-01-27|Estimate|||||||2010-03-09|2010-03-10|Estimate|May 2000||2000-05-31|March 2010|2010-03-31||||||||Interventional|||Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|Phase I, Dose De-Escalation to Minimal Effective Pharmacologic Dose Trial of Sodium Phenylbutyrate (PB, NSC 657802) in Combination With 5-Azacytidine (5-AZA, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:27:30.543656|2018-06-01 05:27:30.543656
NCT00004867|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2017-01-20|2003-01-26|2003-01-27|Estimate|||||||2017-01-20|2017-01-24|Estimate|November 1999||1999-11-30|January 2017|2017-01-31|January 2009|Actual|2009-01-31|July 2005|Actual|2005-07-31||Interventional|||Positron Emission Tomography in Determining Stage of Esophageal Cancer|The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Carcinoma of the Thoracic Esophagus|Completed||N/A|235|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:27:30.720194|2018-06-01 05:27:30.720194
NCT00004866|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|||2012-05-15|2003-01-26|2003-01-27|Estimate|||||||2012-05-15|2012-05-16|Estimate|January 2000||2000-01-31|May 2012|2012-05-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix|A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix|Completed||Phase 2|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:27:30.991539|2018-06-01 05:27:30.991539
NCT00004859|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-07|2012-02-16||2014-05-29|2003-01-26|2003-01-27|Estimate|2012-02-16|2012-03-22|Estimate||||2014-05-29|2014-06-02|Estimate|January 2000||2000-01-31|February 2013|2013-02-28|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer|A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|589|Actual|National Cancer Institute (NCI)||2||Trial was stopped early for futility|f||||t||||||||||2018-06-01 05:27:31.202377|2018-06-01 05:27:31.202377
NCT00004262|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|November 1999||1999-11-30|June 2013|2013-06-30||||May 2005|Actual|2005-05-31||Interventional|||Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme|PHASE I TRIAL OF GADOLINIUM TEXAPHYRIN (PCI -0120) AS A RADIOSENSITIZER DURING STEREOTACTIC RADIOSURGERY BOOST FOR GLIOBLASTOMA MULTIFORME|Completed||Phase 1|12|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:32.20172|2018-06-01 05:27:32.20172
NCT00004259|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|2017-05-25||2017-12-21|2003-01-26|2003-01-27|Estimate|2017-10-11|2017-11-13|Actual||||2017-12-21|2018-01-23|Actual|June 2000||2000-06-30|December 2017|2017-12-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2015|Actual|2015-02-01||Interventional||Eligible patients|Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas|A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)|Active, not recruiting||Phase 3|230|Actual|Radiation Therapy Oncology Group|Accrual to the TMZ BCNU arm required an acceptable toxicity profile from a pilot arm. Treatment cessation/reduction for toxicity caused the combination arm to be dropped. Per the protocol, the pilot arms were not included in the Phase III analyses.|4|||f||||t||||||||||2018-06-01 05:27:32.338986|2018-06-01 05:27:32.338986
NCT00004250|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|August 1999||1999-08-31|January 2013|2013-01-31||||June 2007|Actual|2007-06-30||Interventional|||Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery|A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity|Completed||Phase 2|35|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:33.577276|2018-06-01 05:27:33.577276
NCT00004245|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-01-17|2003-01-26|2003-01-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 1999||1999-08-31|January 2013|2013-01-31||||September 2004|Actual|2004-09-30||Interventional|||Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia|A Phase I Study of Salicylate for Adult Patients With Advanced Myelodysplastic Disorders or Acute Myelogenous Leukemia|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:33.668875|2018-06-01 05:27:33.668875
NCT00004244|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-03-19|2003-01-26|2003-01-27|Estimate|||||||2013-03-19|2013-03-21|Estimate|March 2000||2000-03-31|June 2005|2005-06-30|September 2008|Actual|2008-09-30|July 2005|Actual|2005-07-31||Interventional|||Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma|Phase I Trial of rhIL-12 and rHuIFN-a2b in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||3|||f||||||||||||||2018-06-01 05:27:33.764173|2018-06-01 05:27:33.764173
NCT00004237|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 1998||1998-10-31|May 2005|2005-05-31|September 2005|Actual|2005-09-30|||||Interventional|||Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer|A Randomized Phase II Trial of Navelbine/Epirubicin Versus Navelbine/Mitozantrone Versus Cyclophosphamide/Adriamycin as Preoperative Chemotherapy in Patients With > or = 3cm Diameter Early Breast Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:33.964867|2018-06-01 05:27:33.964867
NCT00004234|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2016-11-25|2003-01-26|2003-01-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|August 1999||1999-08-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|March 2005|Actual|2005-03-31||Interventional|||Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx|A Comparison of Acute Oral Mucositis Between Morning and Afternoon Radiotherapy in Patients Receiving Radiation Treatment for Cancer of the Head and Neck|Completed||Phase 3|||Canadian Cancer Trials Group|||||f||||t||||||||Undecided||2018-06-01 05:27:34.078731|2018-06-01 05:27:34.078731
NCT00004231|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28||2011-02-16|2012-05-31|2003-01-26|2003-01-27|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-31|2012-06-06|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma|Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:27:34.25095|2018-06-01 05:27:34.25095
NCT00004228|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|2013-10-08||2016-12-01|2003-01-26|2003-01-27|Estimate|2013-10-08|2013-12-05|Estimate||||2016-12-01|2017-01-30|Estimate|June 2000||2000-06-30|November 2016|2016-11-30||||August 2008|Actual|2008-08-31||Interventional|||Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma|Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma|Active, not recruiting||Phase 3|393|Actual|Children's Oncology Group||7|||f||||t||||||||||2018-06-01 05:27:34.428274|2018-06-01 05:27:34.428274
NCT00004227|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2014-02-05|2003-01-26|2003-01-27|Estimate|||||||2014-02-05|2014-02-06|Estimate|April 1999||1999-04-30|November 2012|2012-11-30|May 2008|Actual|2008-05-31|March 2007|Actual|2007-03-31||Interventional|||Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx|Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck|Terminated||Phase 3|32|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-06-01 05:27:37.258011|2018-06-01 05:27:37.258011
NCT00004226|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2000||2000-05-31|July 2004|2004-07-31||||||||Interventional|||Radiation Therapy Following Surgery in Treating Patients With Recurrent or Second Primary Cancer of the Head and Neck Following Previous Radiation Therapy|Phase I/II Study of High Dose Limited Volume Postoperative Reirradiation in Recurrent or Second Primary Carcinoma of the Head and Neck|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:37.396406|2018-06-01 05:27:37.396406
NCT00004225|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2010-07-03|2003-01-26|2003-01-27|Estimate|||||||2010-07-03|2010-07-07|Estimate|January 2000||2000-01-31|April 2004|2004-04-30||||||||Interventional|||Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer|Phase I Pilot Trial of Adenovirus p53 and Radiotherapy on Nonsmall Cell Lung Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:37.472989|2018-06-01 05:27:37.472989
NCT00004224|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 1999||1999-01-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|||||Interventional|||Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma|SIOP Study of Combined Modality Treatment in Childhood Ependymoma|Completed||Phase 2|65|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:37.547236|2018-06-01 05:27:37.547236
NCT00004218|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|October 1999||1999-10-31|January 2006|2006-01-31|July 2007|Actual|2007-07-31|||||Interventional|||Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:37.628075|2018-06-01 05:27:37.628075
NCT00004212|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2012-05-15|2003-01-26|2003-01-27|Estimate|||||||2012-05-15|2012-05-16|Estimate|September 1999||1999-09-30|May 2012|2012-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas|A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas|Completed||Phase 1|||Daiichi Sankyo, Inc.|||||f||||||||||||||2018-06-01 05:27:37.949431|2018-06-01 05:27:37.949431
NCT00004210|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2014-10-23|2003-01-26|2003-01-27|Estimate|||||||2014-10-23|2014-10-24|Estimate|February 2000||2000-02-29|July 2009|2009-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study of the Results of Education and Counseling for Persons Undergoing Genetic Testing for Hereditary Nonpolyposis Colon Cancer|Outcomes in Education and Counseling for HNPCC Testing|Completed||N/A|900|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:38.043779|2018-06-01 05:27:38.043779
NCT00004208|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2015-03-10|2003-01-26|2003-01-27|Estimate|||||||2015-03-10|2015-03-11|Estimate|August 2000||2000-08-31|March 2015|2015-03-31|October 2011|Actual|2011-10-31|October 2006|Actual|2006-10-31||Interventional|||Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome|Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care|Completed||Phase 3|86|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:27:38.139607|2018-06-01 05:27:38.139607
NCT00004205|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2017-12-08|2003-01-26|2003-01-27|Estimate|||||||2017-12-08|2017-12-12|Actual|March 1998||1998-03-31|December 2017|2017-12-31|June 30, 2016|Actual|2016-06-30|December 2008|Actual|2008-12-31||Interventional|BIG 1-98||Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer|A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors|Completed||Phase 3|8028|Actual|International Breast Cancer Study Group||4|||f||||t||||||||||2018-06-01 05:27:38.277423|2018-06-01 05:27:38.277423
NCT00004196|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2014-01-16|2003-01-26|2003-01-27|Estimate|||||||2014-01-16|2014-01-20|Estimate|October 1999||1999-10-31|April 2013|2013-04-30|November 2007|Actual|2007-11-30|October 2004|Actual|2004-10-31||Interventional|||Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis|A Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients With Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy|Completed||Phase 3|3000|Anticipated|University of Alabama at Birmingham||5|||f||||t||||||||||2018-06-01 05:27:38.416617|2018-06-01 05:27:38.416617
NCT00004189|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|October 1999||1999-10-31|September 2003|2003-09-30||||July 2003|Actual|2003-07-31||Interventional|||Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer|A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin Without and With Granulocyte Colony-Stimulating Factor Support Every 21 Days|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:38.518071|2018-06-01 05:27:38.518071
NCT00004188|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2013-05-16|2003-01-26|2003-01-27|Estimate|||||||2013-05-16|2013-05-17|Estimate|February 2001||2001-02-28|May 2013|2013-05-31||||October 2007|Actual|2007-10-31||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma|A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma|Completed||Phase 3|495|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:38.67848|2018-06-01 05:27:38.67848
NCT00004181|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21||2011-02-16|2012-06-08|2003-01-26|2003-01-27|Estimate||||2011-02-16|2011-02-18|Estimate|2012-06-08|2012-06-12|Estimate|October 1999||1999-10-31|June 2012|2012-06-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia|Allogeneic Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in the Chronic Phase or Multiple Myeloma|Completed||Phase 2|||Northwestern University|||||f||||t||||||||||2018-06-01 05:27:39.171646|2018-06-01 05:27:39.171646
NCT00004179|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2017-07-26|2003-01-26|2003-01-27|Estimate|||||||2017-07-26|2017-07-27|Actual|May 1999||1999-05-31|July 2017|2017-07-31|July 19, 2017|Actual|2017-07-19|April 2004|Actual|2004-04-30||Interventional|||Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma|Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkin's Lymphoma: A Phase III Randomized Clinical Trial - Intergroup Collaborative Study|Completed||Phase 3|475|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:39.324528|2018-06-01 05:27:39.324528
NCT00004173|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|October 1999||1999-10-31|July 2003|2003-07-31||||||||Interventional|||Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer|A Phase I Study of Oxaliplatin in Combination With Paclitaxel|Unknown status|Active, not recruiting|Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:39.840417|2018-06-01 05:27:39.840417
NCT00004165|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-02-16|2012-05-31|2003-01-26|2003-01-27|Estimate||||2011-02-16|2011-02-18|Estimate|2012-05-31|2012-06-06|Estimate|October 1999||1999-10-31|May 2012|2012-05-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma|Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma|Completed||Phase 3|||Northwestern University|||||f||||t||||||||||2018-06-01 05:27:39.918439|2018-06-01 05:27:39.918439
NCT00004154|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2016-06-16|2003-01-26|2003-01-27|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2000||2000-06-30|October 2012|2012-10-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer|Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer|Completed||Phase 3|111|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 05:27:40.013129|2018-06-01 05:27:40.013129
NCT00004153|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-09-04|2003-01-26|2003-01-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 1998||1998-06-30|September 2013|2013-09-30|January 2005|Actual|2005-01-31|March 2004|Actual|2004-03-31||Interventional|||Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma|Sensitive RT-PCR Analysis for Melanoma Markers From Lymph Nodes and Peripheral Blood in Patients With Melanoma|Completed||N/A|106|Actual|University of Chicago|||||f||||f||||||||||2018-06-01 05:27:40.106527|2018-06-01 05:27:40.106527
NCT00004150|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|March 1999||1999-03-31|February 2001|2001-02-28|April 2007|Actual|2007-04-30|||||Interventional|||High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer|Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:40.234173|2018-06-01 05:27:40.234173
NCT00004149|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-07-07|2003-01-26|2003-01-27|Estimate|||||||2011-07-07|2011-07-08|Estimate|September 1999||1999-09-30|July 2004|2004-07-31||||||||Interventional|||Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy|A Phase II Trial of Arsenic Trioxide in Advanced Hormone-Refractory Prostate Cancer|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:40.430426|2018-06-01 05:27:40.430426
NCT00004147|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 2000||2000-07-31|May 2003|2003-05-31|November 2006|Actual|2006-11-30|||||Interventional|||COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors|A Phase I/II Study of Col-3 Administered on a Continuous Daily Oral Schedule in Patients With Recurrent High-Grade Astrocytoma|Completed||Phase 1/Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:40.481631|2018-06-01 05:27:40.481631
NCT00004144|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2014-04-22|2003-01-26|2003-01-27|Estimate|||||||2014-04-22|2014-04-24|Estimate|May 2000||2000-05-31|April 2014|2014-04-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer|Phase I Study of Bryostatin 1 and Gemcitabine (Gemzar)|Completed||Phase 1|36|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-06-01 05:27:40.592775|2018-06-01 05:27:40.592775
NCT00004143|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|2013-09-06||2014-11-19|2003-01-26|2003-01-27|Estimate|2013-09-06|2013-11-11|Estimate||||2014-11-19|2014-12-05|Estimate|September 1999||1999-09-30|November 2014|2014-11-30|June 2009|Actual|2009-06-30|May 2008|Actual|2008-05-31||Interventional|||Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes|Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes|Completed||Phase 2|2|Actual|Duke University|Small number of subjects analyzed|2|||f||||t||||||||||2018-06-01 05:27:40.781535|2018-06-01 05:27:40.781535
NCT00004141|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-09-04|2003-01-26|2003-01-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|August 1998||1998-08-31|September 2013|2013-09-30|April 2006|Actual|2006-04-30|January 2003|Actual|2003-01-31||Interventional|||Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma|Phase II Study of Outpatient CDDP and DTIC Followed by GM-CSF, IFN-a2b, and IL-2 in Patients With Advanced Melanoma|Completed||Phase 2|46|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:27:41.039582|2018-06-01 05:27:41.039582
NCT00004138|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 1999||1999-09-30|July 2016|2016-07-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Positron Emission Tomography for Detecting Non-small Cell Lung Cancer|The Utility of Positron Emission Tomography (PET) in Staging of Patients With Potentially Operable Non-Small Cell Lung Carcinoma|Completed||N/A|303|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:27:41.14983|2018-06-01 05:27:41.14983
NCT00004135|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2014-03-06|2003-01-26|2003-01-27|Estimate|||||||2014-03-06|2014-03-07|Estimate|February 1999||1999-02-28|March 2014|2014-03-31|August 2007|Actual|2007-08-31|October 2004|Actual|2004-10-31||Interventional|||Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer|Allogeneic Stem Cell Transplantation of Renal Cell Cancer and Metastatic Melanoma After Non-Myeloablative Chemotherapy|Completed||Phase 2|19|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:27:41.278812|2018-06-01 05:27:41.278812
NCT00004129|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 1999||1999-09-30|April 2008|2008-04-30||||||||Interventional|||Phosphorus 32 in Treating Patients With Glioblastoma Multiforme|Phase I/II Study of Interstitial Colloidal 32P for the Treatment of Recurrent Malignant Central Nervous System Tumors and Primary Central Nervous System Tumors With Poor Prognostic Factors|Unknown status|Recruiting|Phase 1|12|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:41.390032|2018-06-01 05:27:41.390032
NCT00004128|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2009-12-22|2003-01-26|2003-01-27|Estimate|||||||2009-12-22|2009-12-23|Estimate|September 1999||1999-09-30|April 2008|2008-04-30||||January 2008|Anticipated|2008-01-31||Interventional|||Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia|The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP|Unknown status|Active, not recruiting|Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:41.550945|2018-06-01 05:27:41.550945
NCT00004124|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2017-12-01|2003-01-26|2003-01-27|Estimate|||||||2017-12-01|2017-12-05|Actual|October 1999||1999-10-31|December 2017|2017-12-31|June 1, 2022|Anticipated|2022-06-01|June 2017|Actual|2017-06-30||Interventional|||S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer|Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High-Risk Prostate Cancer Patients Following Radical Prostatectomy|Active, not recruiting||Phase 3|983|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:41.760356|2018-06-01 05:27:41.760356
NCT00004115|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|December 1998||1998-12-31|April 2003|2003-04-30||||||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy|Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:42.245034|2018-06-01 05:27:42.245034
NCT00004110|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-10-30|2003-01-26|2003-01-27|Estimate|||||||2013-10-30|2013-10-31|Estimate|August 1999||1999-08-31|October 2013|2013-10-31||||September 2004|Actual|2004-09-30||Interventional|||Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma|Monoclonal Antibody 3F8 and Oral Etoposide for the Treatment of Neuroblastoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:42.303136|2018-06-01 05:27:42.303136
NCT00004106|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10||2011-07-01|2012-05-31|2003-01-26|2003-01-27|Estimate||||2011-07-01|2011-07-14|Estimate|2012-05-31|2012-06-06|Estimate|May 1998||1998-05-31|May 2012|2012-05-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome|Phase II Trial of Temozolomide for the Treatment of Mycosis Fungoides and the Sezary Syndrome|Terminated||Phase 2|29|Actual|Northwestern University||||Per Data Monitoring Committee given the poor/inadequate accrual.|f||||||||||||||2018-06-01 05:27:42.395944|2018-06-01 05:27:42.395944
NCT00004103|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-04-05|2003-01-26|2003-01-27|Estimate|||||||2011-04-05|2011-04-06|Estimate|July 1998||1998-07-31|April 2011|2011-04-30|June 2009|Actual|2009-06-30|March 2007|Actual|2007-03-31||Interventional|||Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer|A Phase II Study of Systemic Therapy With CPT-11 (Camptosar HCl) and Cisplatin in Patients With Advanced Gastric Cancer to be Followed by Surgical Resection and Postoperative Intraperitoneal Chemotherapy|Completed||Phase 2|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:27:42.474149|2018-06-01 05:27:42.474149
NCT00004099|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 1999||1999-07-31|September 2012|2012-09-30||||February 2004|Actual|2004-02-29||Interventional|||Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer|Randomized Phase III Study of Preoperative Chemotherapy Followed by Surgery Versus Surgery Alone in Locally Advanced Gastric Cancer (cT3 and cT4NxM0)|Terminated||Phase 3|144|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:27:42.589828|2018-06-01 05:27:42.589828
NCT00004092|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|2015-07-07||2015-07-07|2003-01-26|2003-01-27|Estimate|2015-07-07|2015-08-04|Estimate||||2015-07-07|2015-08-04|Estimate|May 1999||1999-05-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer|Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer|Completed||Phase 2|72|Actual|City of Hope Medical Center||2|||f||||||||||||||2018-06-01 05:27:42.710112|2018-06-01 05:27:42.710112
NCT00004088|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2018-01-10|2003-01-26|2003-01-27|Estimate|||||||2018-01-10|2018-01-12|Actual|April 13, 1999||1999-04-13|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma|Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma|Completed||Phase 2|77|Actual|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 05:27:43.370502|2018-06-01 05:27:43.370502
NCT00004081|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2012-08-09|2003-01-26|2003-01-27|Estimate|||||||2012-08-09|2012-08-13|Estimate|July 1999||1999-07-31|August 2012|2012-08-31|March 2003|Actual|2003-03-31|January 2002|Actual|2002-01-31||Interventional|||Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer|A Phase II Trial of Weekly, Low-Dose Docetaxel (Taxotere) in Patients With Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Serous Cancer|Completed||Phase 2|30|Actual|Dana-Farber Cancer Institute|||||f||||f||||||||||2018-06-01 05:27:43.465169|2018-06-01 05:27:43.465169
NCT00004077|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 1996||1996-05-31|January 2001|2001-01-31|July 2005|Actual|2005-07-31|||||Interventional|||Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer|A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors|Completed||Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:43.535258|2018-06-01 05:27:43.535258
NCT00004075|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2011-08-02|2003-01-26|2003-01-27|Estimate|||||||2011-08-02|2011-08-03|Estimate|August 1999||1999-08-31|August 2011|2011-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery|A Phase I Trial of 17-Allylaminogeldanamycin (17-AAG) in Solid Tumor and Lymphoma Patients|Completed||Phase 1|||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:27:43.634608|2018-06-01 05:27:43.634608
NCT00004072|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|September 1999||1999-09-30|June 2010|2010-06-30|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma|Phase II Trial of O6-Benzylguanine (NSC 637037) and BCNU in Patients With Multiple Myeloma|Completed||Phase 2|17|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:27:43.719977|2018-06-01 05:27:43.719977
NCT00004067|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2016-03-22|2003-01-26|2003-01-27|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2000||2000-02-29|March 2016|2016-03-31|March 2020|Anticipated|2020-03-31|March 2005|Actual|2005-03-31||Interventional|||Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2|A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2|Active, not recruiting||Phase 3|2130|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 05:27:43.806414|2018-06-01 05:27:43.806414
NCT00004066|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-03-06|2003-01-26|2003-01-27|Estimate|||||||2013-03-06|2013-03-07|Estimate|June 1999||1999-06-30|March 2013|2013-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma|A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma|Completed||Phase 2|82|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:45.052817|2018-06-01 05:27:45.052817
NCT00004065|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|July 1999||1999-07-31|June 2013|2013-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer|A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:27:45.127746|2018-06-01 05:27:45.127746
NCT00004063|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2009-04-29|2003-01-26|2003-01-27|Estimate|||||||2009-04-29|2009-04-30|Estimate|August 1999||1999-08-31|December 2008|2008-12-31||||November 2011|Anticipated|2011-11-30||Interventional|||Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer|A Phase I-II Clinical Trial of Cisplatin (Platinol) Followed by Gemcitabine HCl (Gemzar) in Combination With Mild, Fever-Range Whole Body Hyperthermia (LL-WBH) at 40C in Patients With Advanced Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:45.251357|2018-06-01 05:27:45.251357
NCT00004058|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2010-01-25|2003-01-26|2003-01-27|Estimate|||||||2010-01-25|2010-01-26|Estimate|December 1998||1998-12-31|January 2010|2010-01-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder|Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders|Terminated||Phase 1|||Rutgers, The State University of New Jersey||||At this time it is felt that we will not gain further information from an additional patients.|f||||t||||||||||2018-06-01 05:27:45.353433|2018-06-01 05:27:45.353433
NCT00004054|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|2014-12-24||2017-11-13|2003-01-26|2003-01-27|Estimate|2014-12-24|2015-01-07|Estimate||||2017-11-13|2017-12-12|Actual|January 2000||2000-01-31|November 2017|2017-11-30|November 2013|Actual|2013-11-30|April 2010|Actual|2010-04-30||Interventional||All eligible patients|Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer|A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer|Completed||Phase 3|397|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:45.492006|2018-06-01 05:27:45.492006
NCT00004031|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2013-05-22|2003-01-26|2003-01-27|Estimate|||||||2013-05-22|2013-05-23|Estimate|July 1997||1997-07-31|May 2013|2013-05-31||||July 2010|Actual|2010-07-31||Interventional|||SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma|SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups|Completed||Phase 3|397|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:46.192647|2018-06-01 05:27:46.192647
NCT00004028|ClinicalTrials.gov processed this data on May 31, 2018|1999-12-10|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|September 1996||1996-09-30|January 1999|1999-01-31||||||||Interventional|||Carmustine in Treating Patients With Recurrent Malignant Glioma|PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:46.304442|2018-06-01 05:27:46.304442
NCT00004024|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2003-01-26|2003-01-27|Estimate|||||||2013-04-03|2013-04-05|Estimate|June 1997||1997-06-30|April 2013|2013-04-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma|Immunotherapy for Malignant Glioma - Phase II Trial of Autologous Cancer Antigen Specific Immunotherapy|Completed||Phase 2|60|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:27:46.373326|2018-06-01 05:27:46.373326
NCT00004017|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|February 2000||2000-02-29|March 2003|2003-03-31||||||||Interventional|||Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma|Phase II Open-Label, Non-Randomized, Multicenter Study of Interstitial 131I-chTNT-1/B for the Treatment of Newly Diagnosed or Recurrent Malignant Glioma|Completed||Phase 2|60|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:46.436408|2018-06-01 05:27:46.436408
NCT00004015|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|June 2002||2002-06-30|July 2012|2012-07-31||||July 2003|Actual|2003-07-31||Interventional|||Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery|Postoperative Treatment of Glioblastoma With BNCT at the Petten Irradiation Facility|Completed||Phase 1|36|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:46.498949|2018-06-01 05:27:46.498949
NCT00004011|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2003-01-26|2003-01-27|Estimate|||||||2013-01-30|2013-01-31|Estimate|October 1999||1999-10-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|May 2005|Actual|2005-05-31||Interventional|||S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer|A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB (T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|354|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:46.7375|2018-06-01 05:27:46.7375
NCT00004005|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-04-24|2003-01-26|2003-01-27|Estimate|||||||2017-04-24|2017-04-26|Actual|September 1998||1998-09-30|October 2011|2011-10-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin|Irinotecan and 5-Fluorouracil/Leucovorin for Patients With Colorectal Carcinoma and Other Refractory Tumors|Completed||Phase 2|12|Actual|St. Jude Children's Research Hospital|||||f||||f|t|f||||||||2018-06-01 05:27:47.29478|2018-06-01 05:27:47.29478
NCT00004001|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-21|2003-01-26|2003-01-27|Estimate|||||||2014-02-21|2014-02-25|Estimate|October 1999||1999-10-31|February 2014|2014-02-28|January 2007|Actual|2007-01-31|July 2006|Actual|2006-07-31||Interventional|||S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy|Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer|Completed||Phase 3|770|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:47.374974|2018-06-01 05:27:47.374974
NCT00003994|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-13|2003-01-26|2003-01-27|Estimate|||||||2013-06-13|2013-06-14|Estimate|March 1999||1999-03-31|June 2013|2013-06-30||||October 2007|Actual|2007-10-31||Interventional|||Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer|Intergroup Protocol for Treatment of Children With Hepatoblastoma|Completed||Phase 3|277|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:27:47.491896|2018-06-01 05:27:47.491896
NCT00003993|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-04-28|2003-01-26|2003-01-27|Estimate|||||||2015-04-28|2015-04-29|Estimate|September 1999||1999-09-30|May 2006|2006-05-31||||July 2008|Actual|2008-07-31||Interventional|||Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma|A Phase lb Trial of the Combination of Bryostatin-1 and Low Dose Interleukin-2: Evaluation of the Functional and Molecular Status of Human Monocytes as Antigen Presenting Cells|Completed||Phase 1|24|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:27:47.598229|2018-06-01 05:27:47.598229
NCT00003981|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2003-01-26|2003-01-27|Estimate|||||||2012-07-10|2012-07-11|Estimate|April 1998||1998-04-30|July 2012|2012-07-31||||||||Interventional|||E7070 in Treating Patients With Solid Tumors|Phase I Study to Determine the Safety of E7070 in Patients With a Solid Tumor as a Single IV Infusion Weekly X 4, Repeated Every 6 Weeks|Completed||Phase 1|30|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:47.686837|2018-06-01 05:27:47.686837
NCT00003979|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-10|2003-01-26|2003-01-27|Estimate|||||||2012-07-10|2012-07-11|Estimate|April 1999||1999-04-30|July 2012|2012-07-31||||||||Interventional|||CHS 828 in Treating Patients With Solid Tumors|Phase I and Pharmacokinetics Study to Determine the Safety of CHS 828 in Patients With a Solid Tumor on a Single Oral Dose Repeated Every 3 Weeks|Withdrawn||Phase 1|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:47.876769|2018-06-01 05:27:47.876769
NCT00003977|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|November 1999||1999-11-30|December 2003|2003-12-31||||||||Interventional|||Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer|A Phase I Study of Immunization With Alternating Human Papillomavirus E7 Lipopeptide Epitope Vaccine and Dendritic Cells Presenting the E7 Epitope for the Treatment of Recurrent or Persistent Cervical Cancer|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:48.009714|2018-06-01 05:27:48.009714
NCT00003970|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 1999||1999-01-31|January 2013|2013-01-31||||October 2003|Actual|2003-10-31||Interventional|||Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma|A Phase I Clinical Trial to Investigate the Correlation Between UGT1A1 Genotype and Irinotecan (CPT-11) Pharmacokinetics and Toxicity in Cancer Patients|Completed||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:48.098961|2018-06-01 05:27:48.098961
NCT00003969|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|August 1998||1998-08-31|December 2000|2000-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Geldanamycin Analogue in Treating Patients With Advanced Cancer|A Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino-17-Demethoxygeldanamycin (17-AAG) (NSC 330507) Via Intravenous Administration in Patients With Advanced Malignancies|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:48.195234|2018-06-01 05:27:48.195234
NCT00003966|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-19|2003-01-26|2003-01-27|Estimate|||||||2017-01-19|2017-01-20|Estimate|April 2000||2000-04-30|January 2017|2017-01-31|April 2006|Actual|2006-04-30|February 2006|Actual|2006-02-28||Interventional|||Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation|Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose|Completed||Phase 2|151|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 05:27:48.264555|2018-06-01 05:27:48.264555
NCT00003963|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-09-30|2003-01-26|2003-01-27|Estimate|||||||2015-09-30|2015-10-02|Estimate|May 1999||1999-05-31|July 2012|2012-07-31|February 2005|Actual|2005-02-28|September 2003|Actual|2003-09-30||Interventional|||Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation|Treatment of B-Cell NHL Relapsing After Transplant With a Rituxan Vinorelbine Combination|Completed||Phase 2|14|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-06-01 05:27:48.37831|2018-06-01 05:27:48.37831
NCT00003961|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-04-16|2003-01-26|2003-01-27|Estimate|||||||2014-04-16|2014-04-17|Estimate|April 1999||1999-04-30|April 2014|2014-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes|Completed||Phase 2|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:27:48.456259|2018-06-01 05:27:48.456259
NCT00003958|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-13|2003-01-26|2003-01-27|Estimate|||||||2013-06-13|2013-06-17|Estimate|September 2002||2002-09-30|June 2013|2013-06-30||||October 2007|Actual|2007-10-31||Interventional|||Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma|Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma|Completed||Phase 3|702|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:48.512006|2018-06-01 05:27:48.512006
NCT00003955|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-12|2003-01-26|2003-01-27|Estimate|||||||2014-02-12|2014-02-14|Estimate|September 1999||1999-09-30|February 2014|2014-02-28|October 2009|Actual|2009-10-31|January 2005|Actual|2005-01-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma|"A Phase II Up-Front Window Study of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study"|Completed||Phase 2|77|Actual|Children's Oncology Group|||||f||||||||||||||2018-06-01 05:27:48.642438|2018-06-01 05:27:48.642438
NCT00003945|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2003-01-26|2003-01-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|June 1999||1999-06-30|September 2004|2004-09-30||||January 2007|Actual|2007-01-31||Interventional|||Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer|A Randomized Phase III Study of Cisplatin Versus Cisplatin Plus Topotecan Versus MVAC in Stage IVB, Recurrent or Persistent Squamous Cell Carcinoma of the Cervix|Completed||Phase 3|400|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:27:49.159513|2018-06-01 05:27:49.159513
NCT00003941|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|April 1999||1999-04-30|September 2012|2012-09-30||||June 2007|Actual|2007-06-30||Interventional|||Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer|A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer|Completed||Phase 3|222|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:49.265766|2018-06-01 05:27:49.265766
NCT00003938|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|June 1999||1999-06-30|September 2012|2012-09-30||||May 2003|Actual|2003-05-31||Interventional|||Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients|A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials|Completed||Phase 3|115|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:27:49.438934|2018-06-01 05:27:49.438934
NCT00003934|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|June 1999||1999-06-30|June 2013|2013-06-30||||November 2006|Actual|2006-11-30||Interventional|||Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia|Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia|Completed||Phase 3|420|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:49.598309|2018-06-01 05:27:49.598309
NCT00003928|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|January 1999||1999-01-31|June 2010|2010-06-30|April 2006|Actual|2006-04-30|February 2005|Actual|2005-02-28||Interventional|||Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer|A Phase II Study Utilizing Gemcitabine and Cisplatinum in Patients With Renal Cell Carcinoma|Completed||Phase 2|32|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:27:49.712325|2018-06-01 05:27:49.712325
NCT00003915|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-01|2003-01-26|2003-01-27|Estimate|||||||2017-03-01|2017-03-03|Actual|May 1999||1999-05-31|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer|Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment|Active, not recruiting||Phase 2|63|Actual|University of Massachusetts, Worcester||1|||f||||t||||||||||2018-06-01 05:27:49.779592|2018-06-01 05:27:49.779592
NCT00003913|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-31|2003-01-26|2003-01-27|Estimate|||||||2010-03-31|2010-04-02|Estimate|December 1998||1998-12-31|March 2010|2010-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease|A Multicenter Study of Unrelated Umbilical Cord Blood as an Alternate Source of Stem Cells for Transplantation|Completed||Phase 2|390|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:27:49.867212|2018-06-01 05:27:49.867212
NCT00003912|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 1998||1998-06-30|December 2000|2000-12-31|October 2009|Actual|2009-10-31|||||Interventional|||Chemotherapy in Treating Children With Liver Cancer|Liver Tumour Studies - Hepatoblastoma and Hepatocellular Carcinoma|Completed||Phase 3|260|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:49.968743|2018-06-01 05:27:49.968743
NCT00003910|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2012-10-16||2017-10-20|2003-01-26|2003-01-27|Estimate|2013-04-02|2013-05-27|Estimate||||2017-10-20|2017-11-24|Actual|July 16, 1999|Actual|1999-07-16|October 2012|2012-10-31|March 2012|Actual|2012-03-31|December 1, 2010|Actual|2010-12-01||Interventional|||Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia|A Phase II Study of Initial Treatment With Methotrexate in Large Granular Lymphocytic (LGL) Leukemia|Terminated||Phase 2|59|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:27:50.059013|2018-06-01 05:27:50.059013
NCT00003909|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|August 1999||1999-08-31|January 2013|2013-01-31||||March 2007|Actual|2007-03-31||Interventional|||Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma|A Phase I Study of Motexafin Gadolinium (Xcytrin, NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood|Completed||Phase 1|24|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:50.348407|2018-06-01 05:27:50.348407
NCT00003906|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-05|2003-01-26|2003-01-27|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 1999||1999-05-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|December 2005|Actual|2005-12-31||Interventional|||Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women|Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer|Completed||Phase 3|19747|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-06-01 05:27:50.617384|2018-06-01 05:27:50.617384
NCT00003903|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-10-14|2003-01-26|2003-01-27|Estimate|||||||2013-10-14|2013-10-16|Estimate|July 1999||1999-07-31|October 2013|2013-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer|An Evaluation of the Effect of Androgen Ablation on Bone Resorption in Prostate Cancer Patients|Completed||N/A|150|Anticipated|University of Rochester|||||f||||||||||||||2018-06-01 05:27:51.503512|2018-06-01 05:27:51.503512
NCT00003902|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|March 1999||1999-03-31|May 2012|2012-05-31|September 2005|Actual|2005-09-30|December 2004|Actual|2004-12-31||Interventional|||Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement|Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement|Completed||Phase 1/Phase 2|110|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:27:51.56353|2018-06-01 05:27:51.56353
NCT00003901|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-12-22||2016-12-22|2003-01-26|2003-01-27|Estimate|2016-12-22|2017-02-16|Actual||||2016-12-22|2017-02-16|Actual|July 1999||1999-07-31|December 2016|2016-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery|A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma|Completed||Phase 3|1310|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:27:51.652048|2018-06-01 05:27:51.652048
NCT00003896|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2012-10-30||2013-01-02|2003-01-26|2003-01-27|Estimate|2012-10-30|2012-11-29|Estimate||||2013-01-02|2013-01-04|Estimate|September 1999||1999-09-30|January 2013|2013-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||S9912 Combination Chemo in Stage III Ovarian Cancer,|Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women With Optimally-Debulked Stage III Epithelial Ovarian Cancer|Completed||Phase 2|68|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:27:52.249702|2018-06-01 05:27:52.249702
NCT00003893|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 1998||1998-07-31|November 2001|2001-11-30|April 2006|Actual|2006-04-30|||||Interventional|||Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer|Sequencing of Chemotherapy and Radiotherapy in Adjuvant Breast Cancer|Completed||Phase 3|2250|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:52.662526|2018-06-01 05:27:52.662526
NCT00003878|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-21|Estimate|April 2002||2002-04-30|July 2003|2003-07-31|April 2003|Actual|2003-04-30|||||Interventional|||Carmustine Implants in Treating Patients With Brain Metastases|The Treatment of One or Two Supratentorial Brain Metastases With Surgical Resection and BCNU-Polymer Wafers|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:52.800069|2018-06-01 05:27:52.800069
NCT00003875|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-03-18||2017-05-03|2003-01-26|2003-01-27|Estimate|2017-05-03|2017-06-05|Actual||||2017-05-03|2017-06-05|Actual|October 13, 1998|Actual|1998-10-13|May 2017|2017-05-31|June 11, 2015|Actual|2015-06-11|June 11, 2015|Actual|2015-06-11||Interventional|||Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia|Treatment of Acute Myelogenous Leukemia With Busulfan and Etoposide Followed by Autologous or Syngeneic Stem Cell Rescue and Low-Dose Interleukin 2 (IL-2) Immunotherapy|Completed||Phase 2|30|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f|t|f||||||No||2018-06-01 05:27:53.022418|2018-06-01 05:27:53.022418
NCT00003869|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2010-11-24||2014-05-02|2003-01-26|2003-01-27|Estimate|2010-11-24|2010-12-22|Estimate||||2014-05-02|2014-05-20|Estimate|April 1999||1999-04-30|December 2012|2012-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer|Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 3|186|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:53.24517|2018-06-01 05:27:53.24517
NCT00003865|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-07-11|2003-01-26|2003-01-27|Estimate|||||||2017-07-11|2017-07-13|Actual|July 22, 1999|Actual|1999-07-22|July 2017|2017-07-31|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|||Toremifene in Treating Patients With Ovarian Cancer|Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary|Withdrawn||Phase 2|0|Actual|George Washington University||1|||f||||f|f|f|||f|||No||2018-06-01 05:27:54.160838|2018-06-01 05:27:54.160838
NCT00003863|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|June 1999||1999-06-30|July 2016|2016-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Observational|||Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma|Genetic Changes in Diffuse Aggressive Non-Hodgkin's Lymphoma|Completed|||391|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Tissue samples~   "|||2018-06-01 05:27:54.308531|2018-06-01 05:27:54.308531
NCT00003862|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-19|Estimate|November 1999||1999-11-30|September 2003|2003-09-30||||November 2004|Actual|2004-11-30||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer|A Phase II Trial of Preoperative Chemotherapy and Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Stomach|Completed||Phase 2|||Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:27:54.608377|2018-06-01 05:27:54.608377
NCT00003861|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-08-07|2003-01-26|2003-01-27|Estimate|||||||2017-08-07|2017-08-08|Actual|April 1999||1999-04-30|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia|Molecular Genetic Features of Acute Leukemia|Active, not recruiting|||840|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||||||||Samples With DNA|"~     Tissue, Blood~   "|||2018-06-01 05:27:54.765634|2018-06-01 05:27:54.765634
NCT00003857|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-05-18|2003-01-26|2003-01-27|Estimate|||||||2017-05-18|2017-05-19|Actual|December 1999|Actual|1999-12-31|May 2017|2017-05-31||||February 2004|Actual|2004-02-29||Interventional|||Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ|Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast|Active, not recruiting||Phase 3|636|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:27:55.007988|2018-06-01 05:27:55.007988
NCT00003855|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|April 1999||1999-04-30|July 2016|2016-07-31|February 2011|Actual|2011-02-28|August 2007|Actual|2007-08-31||Interventional|||Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer|A Randomized Trial of Axillary Node Dissection in Women With Clinical T1-2 N0-1 M0 Breast Cancer Who Have a Positive Sentinel Node|Completed||Phase 3|605|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:27:55.866387|2018-06-01 05:27:55.866387
NCT00003854|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 1999||1999-04-30|July 2016|2016-07-31|July 2011|Actual|2011-07-31|August 2006|Actual|2006-08-31||Interventional|||Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer|A Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Clinical T1-2 N0 Breast Cancer|Completed||Phase 3|4590|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:27:56.214099|2018-06-01 05:27:56.214099
NCT00003851|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-13|2003-01-26|2003-01-27|Estimate|||||||2013-02-13|2013-02-15|Estimate|March 1999||1999-03-31|February 2013|2013-02-28|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer|Evaluation of Intensive Pancreatic Proteolytic Enzyme Therapy With Ancillary Nutritional Support Versus Gemcitabine Chemotherapy in the Treatment of Inoperable Pancreatic Adenocarcinoma|Terminated||N/A|90|Anticipated|Columbia University||2||Approval lapse|f||||f||||||||||2018-06-01 05:27:56.448047|2018-06-01 05:27:56.448047
NCT00003843|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-02-13|2003-01-26|2003-01-27|Estimate|||||||2015-02-13|2015-02-16|Estimate|October 1998||1998-10-31|September 2013|2013-09-30|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Observational|||Irinotecan in Treating Patients With Colorectal Cancer|UGT1A1 Polymorphism in Patients With Colorectal Cancer Treated With CPT-11 (Irinotecan)|Terminated|||28|Anticipated|California Cancer Consortium||||Study terminated due to poor accrual|||||||||||||||2018-06-01 05:27:56.519085|2018-06-01 05:27:56.519085
NCT00003838|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-05-17|2003-01-26|2003-01-27|Estimate|||||||2018-05-17|2018-05-18|Actual|February 23, 1999||1999-02-23|November 27, 2017|2017-11-27|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow|Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases|Recruiting||Phase 2|214|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:27:56.577292|2018-06-01 05:27:56.577292
NCT00003837|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-18|2003-01-26|2003-01-27|Estimate|||||||2013-06-18|2013-06-20|Estimate|September 1999||1999-09-30|December 2005|2005-12-31|November 2007|Actual|2007-11-30|||||Interventional|||506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma|Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma|Completed||N/A|25|Anticipated|National Cancer Institute (NCI)|||||||||||||||||||2018-06-01 05:27:56.651092|2018-06-01 05:27:56.651092
NCT00003833|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|February 1999||1999-02-28|July 2016|2016-07-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Genetic Study in Patients With Stage II or Stage III Colon Cancer|The Clinical and Pathological Significance of Allelic Imbalance of 8p in Patients With Colorectal Cancer|Completed|||598|Actual|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     Normal and tumor tissue~   "|||2018-06-01 05:27:56.712839|2018-06-01 05:27:56.712839
NCT00003831|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 1999||1999-07-31|July 2016|2016-07-31|January 2011|Actual|2011-01-31|March 2006|Actual|2006-03-31||Interventional|||Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer|Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma|Completed||Phase 3|1023|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-06-01 05:27:56.964391|2018-06-01 05:27:56.964391
NCT00003820|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-05-29||2017-03-08|2003-01-26|2003-01-27|Estimate|2017-03-08|2017-04-20|Actual||||2017-03-08|2017-04-20|Actual|January 1999||1999-01-31|March 2017|2017-03-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional||This was a single-arm study with multiple treatment periods added by amendment (ie, Secondary Group), with results reported by treatment period. As this was always considered a single-arm study, there was no intent to report the results for the initial treatment period separately as the Initial Group vs the Secondary Group.|Rituximab in Treating Patients With Hodgkin's Lymphoma|Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease|Completed||Phase 2|39|Actual|Stanford University||1|||f||||f|t|f||||||No||2018-06-01 05:27:57.197603|2018-06-01 05:27:57.197603
NCT00003816|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-01-30|2003-01-26|2003-01-27|Estimate|||||||2018-01-30|2018-01-31|Actual|October 19, 1998|Actual|1998-10-19|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer|Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia|Active, not recruiting||Phase 2/Phase 3|362|Actual|Roswell Park Cancer Institute||9|||f||||t||||||||||2018-06-01 05:27:57.573168|2018-06-01 05:27:57.573168
NCT00003815|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 1994||1994-06-30|July 2001|2001-07-31||||||||Interventional|||Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma|A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:57.714292|2018-06-01 05:27:57.714292
NCT00003803|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-17|2003-01-26|2003-01-27|Estimate|||||||2012-07-17|2012-07-18|Estimate|February 1999||1999-02-28|July 2012|2012-07-31||||March 2003|Actual|2003-03-31||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed|A Randomized Phase III Study Comparing Induction Chemotherapy to Daily Low Dose Cisplatin Both Combined With High Dose Radiotherapy Using Concomitant Boost Technique in Patients With Inoperable Non-Small Cell Lung Cancer Stage I, II, and Low Volume Stage III|Terminated||Phase 3|158|Actual|European Organisation for Research and Treatment of Cancer - EORTC||||low accrual|f||||||||||||||2018-06-01 05:27:57.807118|2018-06-01 05:27:57.807118
NCT00003800|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-10-19|2003-01-26|2003-01-27|Estimate|||||||2017-10-19|2017-10-23|Actual|May 1999||1999-05-31|October 2017|2017-10-31||||December 2004|Actual|2004-12-31||Interventional|||Diagnostic Study of Patients With Stage I Testicular Cancer|Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor|Completed||N/A|76|Actual|Eastern Cooperative Oncology Group||1|||f||||f||||||||||2018-06-01 05:27:57.904757|2018-06-01 05:27:57.904757
NCT00003741|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|February 1999||1999-02-28|March 2005|2005-03-31|December 2007|Actual|2007-12-31|||||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma|HeFi-1 Antibody Therapy in Ki-1 and Hodgkin's Lymphomas, a Phase I Study|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:01.92654|2018-06-01 05:28:01.92654
NCT00003799|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-09|2003-01-26|2003-01-27|Estimate|||||||2013-01-09|2013-01-10|Estimate|May 1999||1999-05-31|January 2013|2013-01-31||||September 2003|Actual|2003-09-30||Interventional|||Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer|Phase I Study of Preoperative Radiation Therapy With Concurrent Protracted Continuous Infusion 5-FU and Dose Escalating Oxaliplatin Followed by Surgery, 5-FU, and Leucovorin for Locally Advanced (T3 and T4) Rectal Adenocarcinoma|Completed||Phase 1|20|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:58.006111|2018-06-01 05:27:58.006111
NCT00003796|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-08|2003-01-26|2003-01-27|Estimate|||||||2013-02-08|2013-02-11|Estimate|May 1999||1999-05-31|March 2003|2003-03-31||||December 2003|Actual|2003-12-31||Interventional|||Irofulven in Treating Patients With Metastatic Breast Cancer|Phase II Study of MGI-114 in Patients With Metastatic Breast Cancer|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:27:58.096754|2018-06-01 05:27:58.096754
NCT00003793|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-04|2003-01-26|2003-01-27|Estimate|||||||2014-08-04|2014-08-05|Estimate|December 1998||1998-12-31|August 2014|2014-08-31|March 2007|Actual|2007-03-31|December 2005|Actual|2005-12-31||Observational|||Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma|Clinical and Biological Predictors of Therapy-Related Leukemia|Completed|||294|Actual|Children's Oncology Group|||2||f||||f||||||Samples With DNA|"~     blood~   "|||2018-06-01 05:27:58.176582|2018-06-01 05:27:58.176582
NCT00003789|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-15|2003-01-26|2003-01-27|Estimate|||||||2013-07-15|2013-07-16|Estimate|March 1999||1999-03-31|June 2013|2013-06-30||||January 2004|Actual|2004-01-31||Interventional|||Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg|A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion and Melphalan With and Without Tumor Necrosis Factor in Patients With Localized Advanced Extremity Melanoma|Completed||Phase 3|216|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:27:58.338527|2018-06-01 05:27:58.338527
NCT00003788|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|April 1998||1998-04-30|September 2003|2003-09-30||||||||Interventional|||Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas|Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors|Unknown status|Active, not recruiting|Phase 3|270|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:58.509875|2018-06-01 05:27:58.509875
NCT00003782|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2012-08-24||2013-01-11|2003-01-26|2003-01-27|Estimate|2012-10-02|2012-10-31|Estimate||||2013-01-11|2013-01-18|Estimate|March 1999||1999-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2008|Actual|2008-12-31||Interventional|||Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes|A Three-Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere (AC-T); Adriamycin and Taxotere (AT); and Adriamycin, Taxotere, and Cyclophosphamide (ATC) in Breast Cancer Patients With Positive Axillary Lymph Nodes|Completed||Phase 3|5351|Actual|NSABP Foundation Inc||3|||f||||t||||||||||2018-06-01 05:27:58.627712|2018-06-01 05:27:58.627712
NCT00003771|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|September 1997||1997-09-30|July 2001|2001-07-31|February 2004|Actual|2004-02-29|||||Interventional|||Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer|Protocol for Randomized Clinical Study Concerning Hormonal Replacement Therapy (HRT) After Previous Radical Breast Cancer Treatment|Completed||Phase 3|1300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:27:59.220174|2018-06-01 05:27:59.220174
NCT00003764|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2003-01-26|2003-01-27|Estimate|||||||2010-01-26|2010-01-28|Estimate|December 1999||1999-12-31|January 2010|2010-01-31||||November 2005|Actual|2005-11-30||Interventional|||Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia|Phase III Randomized Trial of Fludarabine and Cyclophosphamide Versus Fludarabine for Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 3|280|Anticipated|Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:28:00.298905|2018-06-01 05:28:00.298905
NCT00003753|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|September 1998||1998-09-30|June 2013|2013-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer|A Phase I-II Study of Hepatic Arterial Therapy Via Pump (Protocol D97-063) With Floxuridine (FUDR) and Dexamethasone (DEX) in Combination With Intravenous Irinotecan as Adjuvant Treatment After Resection of Hepatic Metastases From Colorectal Cancer|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:00.779581|2018-06-01 05:28:00.779581
NCT00003750|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-06|2003-01-26|2003-01-27|Estimate|||||||2014-08-06|2014-08-08|Estimate|October 2001||2001-10-31|August 2014|2014-08-31|September 2005|Actual|2005-09-30|January 2005|Actual|2005-01-31||Interventional|||Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors|A Phase I/IB Intergroup Trial of the HU14.18-IL2 Fusion Protein in Children With Refractory Neuroblastoma and Other GD2 Positive Tumors|Completed||Phase 1|28|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:28:00.886235|2018-06-01 05:28:00.886235
NCT00003749|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|April 1998||1998-04-30|April 1999|1999-04-30|December 2008|Actual|2008-12-31|||||Interventional|||Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer|A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer|Completed||Phase 3|2300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:01.048612|2018-06-01 05:28:01.048612
NCT00003746|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|September 1998||1998-09-30|May 2012|2012-05-31|November 2010|Actual|2010-11-30|November 2005|Actual|2005-11-30||Interventional|||Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia|Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia|Completed||Phase 3|100|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-06-01 05:28:01.11997|2018-06-01 05:28:01.11997
NCT00003745|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-04|2003-01-26|2003-01-27|Estimate|||||||2013-02-04|2013-02-05|Estimate|May 1999||1999-05-31|April 2003|2003-04-30||||June 2003|Actual|2003-06-30||Interventional|||Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas|A Phase II Study of Continuous 21 Day Infusion of Topotecan (NSC # 609699) in Children With Relapsed Solid Tumors|Completed||Phase 2|125|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:28:01.359128|2018-06-01 05:28:01.359128
NCT00003744|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-17|2003-01-26|2003-01-27|Estimate|||||||2017-01-17|2017-01-19|Estimate|November 1998||1998-11-30|January 2017|2017-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery|Gemcitabine for Advanced Salivary Cancer: A Phase II Study|Completed||Phase 2|16|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-06-01 05:28:01.813305|2018-06-01 05:28:01.813305
NCT00003739|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-12|2003-01-26|2003-01-27|Estimate|||||||2014-02-12|2014-02-14|Estimate|March 1999||1999-03-31|February 2014|2014-02-28|September 2006|Actual|2006-09-30|December 2002|Actual|2002-12-31||Interventional|||Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy|Randomized Comparison Between Antibiotics Alone and Antibiotics Plus Granulocyte-Colony Stimulating Factor in Pediatric Patients With Chemotherapy Induced Febrile Neutropenia|Completed||Phase 3|67|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:28:02.062667|2018-06-01 05:28:02.062667
NCT00003737|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2003-01-26|2003-01-27|Estimate|||||||2013-06-24|2013-06-25|Estimate|January 1999||1999-01-31|June 2013|2013-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma|A Pharmacokinetic-Guided Phase II Trial of the Rebeccamycin Analog NSC# 655649 in Pediatric Patients With Relapsed/Refractory Neuroblastoma|Completed||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:03.146328|2018-06-01 05:28:03.146328
NCT00003732|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-09|2003-01-26|2003-01-27|Estimate|||||||2013-08-09|2013-08-12|Estimate|September 1998||1998-09-30|July 2002|2002-07-31|September 2005|Actual|2005-09-30|||||Interventional|||Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer|A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered Every 21 Days to Patients With Epithelial Ovarian Cancer Stages IIb, IIc, III and IV|Completed||Phase 2|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:03.285259|2018-06-01 05:28:03.285259
NCT00003730|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-01-26|2003-01-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|December 1998||1998-12-31|June 2012|2012-06-30||||November 2004|Actual|2004-11-30||Interventional|||Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer|A Multicenter Randomized Trial, With Direct Individual Benefit, to Determine the Optimal Circadian Time of Vinorelbine Administration Combined With Chronomodulated Infusion of 5-Fluorouracil in Previously Treated Patients With Metastatic Breast Cancer|Completed||N/A|80|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:28:03.357558|2018-06-01 05:28:03.357558
NCT00003728|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-01-20|2003-01-26|2003-01-27|Estimate|||||||2011-01-20|2011-01-21|Estimate|December 1998||1998-12-31|June 2009|2009-06-30||||May 2008|Anticipated|2008-05-31||Interventional|||Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma|The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood|Unknown status|Active, not recruiting|Phase 3|1500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:03.454996|2018-06-01 05:28:03.454996
NCT00003727|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-09-23|2003-01-26|2003-01-27|Estimate|||||||2009-09-23|2009-09-24|Estimate|March 1999||1999-03-31|September 2009|2009-09-30|February 2008|Actual|2008-02-29|March 2005|Actual|2005-03-31||Interventional|||Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia|Autotransplantation for Chronic Myelogenous Leukemia (CML) Followed by Immunotherapy With Ex-Vivo Expanded Autologous T Cells|Completed||Phase 2|22|Anticipated|University of Maryland|||||f||||||||||||||2018-06-01 05:28:03.586602|2018-06-01 05:28:03.586602
NCT00003702|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-11-02||2018-04-12|2003-01-26|2003-01-27|Estimate|2018-04-12|2018-05-15|Actual||||2018-04-12|2018-05-15|Actual|June 1999||1999-06-30|February 2016|2016-02-29||||July 2010|Actual|2010-07-31||Interventional||Eligible participants|Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia|"A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus Pulsed Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia"|Completed||Phase 3|240|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 05:28:03.681008|2018-06-01 05:28:03.681008
NCT00003696|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 1998||1998-10-31|November 2001|2001-11-30||||||||Interventional|||Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer|Phase III Study of Cyclophosphamide, Doxorubicin and Etoposide Compared to Carboplatin and Taxol in Patients With Extensive Disease Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|250|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:03.953155|2018-06-01 05:28:03.953155
NCT00003690|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-08-02|2003-01-26|2003-01-27|Estimate|||||||2011-08-02|2011-08-03|Estimate|December 1998||1998-12-31|August 2011|2011-08-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors|Phase I Study of Flavopiridol in Combination With Cisplatin in Patients With Advanced Malignancies|Completed||Phase 1|48|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 05:28:04.010944|2018-06-01 05:28:04.010944
NCT00003688|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-07|2003-01-26|2003-01-27|Estimate|||||||2013-06-07|2013-06-10|Estimate|October 1999||1999-10-31|December 2003|2003-12-31||||September 2006|Actual|2006-09-30||Interventional|||Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia|Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia|Completed||Phase 2|||Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:28:04.08628|2018-06-01 05:28:04.08628
NCT00003687|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-11-25|2003-01-26|2003-01-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 1998||1998-12-31|March 2010|2010-03-31|February 2009|Actual|2009-02-28|September 2001|Actual|2001-09-30||Interventional|||Treatment for Chronic Pain in Patients With Advanced Cancer|A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients|Completed||Phase 3|||Canadian Cancer Trials Group|||||f||||t||||||||Undecided||2018-06-01 05:28:04.254453|2018-06-01 05:28:04.254453
NCT00003678|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 1991||1991-05-31|March 2007|2007-03-31||||||||Interventional|||Tamoxifen in Treating Women With Breast Cancer|A Large, Uniquely Simple, Randomised Study to Assess Much More Reliably the Balance of Benefits and Risks of Prolonging Adjuvant Tamoxifen Treatment in Early Breast Cancer|Unknown status|Active, not recruiting|Phase 3|20000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:04.36208|2018-06-01 05:28:04.36208
NCT00003659|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2012-11-28||2017-09-22|2003-01-26|2003-01-27|Estimate|2012-11-28|2012-12-31|Estimate||||2017-09-22|2017-10-24|Actual|September 1998||1998-09-30|September 2017|2017-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia|A Phase II Study of Fludarabine Induction With Sequential High Dose Cyclophosphamide and Rituximab as Consolidation Therapy for Previously Untreated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia|Completed||Phase 2|39|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:28:04.438238|2018-06-01 05:28:04.438238
NCT00003658|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2003-01-26|2003-01-27|Estimate|||||||2013-06-24|2013-06-25|Estimate|September 1998||1998-09-30|June 2013|2013-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers|A Phase I-II Study of Pentostatin With Cyclophosphamide for Previously Treated Patients With Intermediate and High-Risk Chronic Lymphocytic Leukemia|Completed||Phase 2|60|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:04.623075|2018-06-01 05:28:04.623075
NCT00003656|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-11-06|2003-01-26|2003-01-27|Estimate|||||||2017-11-06|2017-11-08|Actual|January 1999|Actual|1999-01-31|November 2017|2017-11-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer|Phase II Trial of Atragen and Interferon Alfa-2b in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|26|Actual|Weill Medical College of Cornell University||1|||f||||||||||||||2018-06-01 05:28:04.696379|2018-06-01 05:28:04.696379
NCT00003653|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-11-25|2003-01-26|2003-01-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|January 1999||1999-01-31|August 2012|2012-08-31|January 2013|Actual|2013-01-31|May 2010|Actual|2010-05-31||Interventional|||Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer|A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer|Completed||Phase 3|1386|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:28:04.800273|2018-06-01 05:28:04.800273
NCT00003652|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|January 1999||1999-01-31|May 2005|2005-05-31||||||||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer|Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study|Unknown status|Active, not recruiting|Phase 3|350|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:04.964734|2018-06-01 05:28:04.964734
NCT00003650|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-01-20|2003-01-26|2003-01-27|Estimate|||||||2011-01-20|2011-01-21|Estimate|June 1998||1998-06-30|March 2001|2001-03-31||||||||Interventional|||Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma|Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:05.100422|2018-06-01 05:28:05.100422
NCT00003644|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-03-17|2003-01-26|2003-01-27|Estimate|||||||2016-03-17|2016-03-21|Estimate|October 1998||1998-10-31|March 2016|2016-03-31||||March 2010|Actual|2010-03-31||Interventional|||Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer|A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma|Completed||Phase 3|571|Actual|Gynecologic Oncology Group||2|||f||||t||||||||||2018-06-01 05:28:05.233367|2018-06-01 05:28:05.233367
NCT00003643|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-05|2003-01-26|2003-01-27|Estimate|||||||2012-03-05|2012-03-06|Estimate|October 1998||1998-10-31|March 2012|2012-03-31||||||||Interventional|||Combination Chemotherapy in Treating Men With Germ Cell Cancer|Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer|Unknown status|Active, not recruiting|Phase 2/Phase 3|498|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:28:05.50999|2018-06-01 05:28:05.50999
NCT00003641|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-02-02||2016-03-31|2003-01-26|2003-01-27|Estimate|2016-03-31|2016-05-04|Estimate||||2016-03-31|2016-05-04|Estimate|December 1998||1998-12-31|March 2016|2016-03-31|October 2025|Anticipated|2025-10-31|January 2015|Actual|2015-01-31||Interventional||All randomized patients|High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma|Phase III Randomized Study of Four Weeks of High Dose Interferon Alfa-2b in Stage T2bN0, T3a-bN0, T4a-bN0, and T1-4, N1a,2a (Microscopic) Melanoma|Terminated||Phase 3|1150|Actual|Eastern Cooperative Oncology Group||2||"The third interim analysis showed that there was no evidence of benefit from treatment with~   interferon."|f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy|2018-06-01 05:28:05.843599|2018-06-01 05:28:05.843599
NCT00003637|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 1998||1998-09-30|January 2006|2006-01-31||||||||Interventional|||Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx|Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:07.270148|2018-06-01 05:28:07.270148
NCT00003636|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-08-04|2003-01-26|2003-01-27|Estimate|||||||2015-08-04|2015-08-05|Estimate|September 1998||1998-09-30|August 2013|2013-08-31||||January 2009|Actual|2009-01-31||Interventional|||Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer|A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma|Completed||Phase 3|704|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:28:07.355093|2018-06-01 05:28:07.355093
NCT00003633|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 1998||1998-08-31|March 2005|2005-03-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer|Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:07.591197|2018-06-01 05:28:07.591197
NCT00003631|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2015-12-17||2015-12-17|2003-01-26|2003-01-27|Estimate|2015-12-17|2016-01-25|Estimate||||2015-12-17|2016-01-25|Estimate|August 1998||1998-08-31|December 2015|2015-12-31||||April 2010|Actual|2010-04-30||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma|High-Dose Chemo-Radiotherapy for Patients With Primary Refractory and Relapsed Hodgkin's Disease|Completed||Phase 2|118|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-06-01 05:28:07.686643|2018-06-01 05:28:07.686643
NCT00003613|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-10|2003-01-26|2003-01-27|Estimate|||||||2013-01-10|2013-01-11|Estimate|April 1999||1999-04-30|January 2013|2013-01-31||||May 2006|Actual|2006-05-31||Interventional|||O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma|Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma|Terminated||Phase 1|20|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:28:08.070697|2018-06-01 05:28:08.070697
NCT00003612|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-08-04|2003-01-26|2003-01-27|Estimate|||||||2017-08-04|2017-08-08|Actual|April 1999||1999-04-30|August 2017|2017-08-31||||December 2005|Actual|2005-12-31||Interventional|||Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer|Randomized Phase II Trial of Paclitaxel, Carboplatin and rhuMAb Her-2 (Herceptin) as First-Line Chemotherapy in Patients With Metastatic Breast Cancer Who Overexpress Her-2|Active, not recruiting||Phase 2|92|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:28:08.155157|2018-06-01 05:28:08.155157
NCT00003611|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2000||2000-05-31|July 2016|2016-07-31|June 2003|Actual|2003-06-30|February 2003|Actual|2003-02-28||Interventional|||Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation|Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers|Completed||N/A|129|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:28:08.259811|2018-06-01 05:28:08.259811
NCT00003607|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-06-22|2003-01-26|2003-01-27|Estimate|||||||2016-06-22|2016-06-23|Estimate|December 1997||1997-12-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|December 2002|Actual|2002-12-31||Interventional|||Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer|Phase III Randomized Study of Radiotherapy to the Prostate With or Without Radiotherapy to the Pelvis in Patients With Stage I, II, or III Adenocarcinoma of the Prostate|Completed||Phase 3|450|Anticipated|UNICANCER|||||f||||||||||||||2018-06-01 05:28:08.433294|2018-06-01 05:28:08.433294
NCT00003603|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 1998||1998-03-31|February 2001|2001-02-28||||||||Interventional|||Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma|A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma|Unknown status|Active, not recruiting|Phase 3|660|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:08.527978|2018-06-01 05:28:08.527978
NCT00003602|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 1998||1998-03-31|January 2001|2001-01-31||||||||Interventional|||Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia|A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission|Unknown status|Active, not recruiting|Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:08.627351|2018-06-01 05:28:08.627351
NCT00003596|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-30|2003-01-26|2003-01-27|Estimate|||||||2016-12-30|2017-01-04|Estimate|October 1998||1998-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2005|Actual|2005-10-31||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer|A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal|Completed||Phase 3|682|Actual|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:28:08.789389|2018-06-01 05:28:08.789389
NCT00003593|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-26|2003-01-26|2003-01-27|Estimate|||||||2013-06-26|2013-06-27|Estimate|June 1999||1999-06-30|June 2013|2013-06-30|April 2012|Actual|2012-04-30|March 2007|Actual|2007-03-31||Interventional|||Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome|Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study|Completed||Phase 3|254|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:28:09.83401|2018-06-01 05:28:09.83401
NCT00003590|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2011-11-07||2016-04-20|2003-01-26|2003-01-27|Estimate|2012-01-12|2012-02-16|Estimate||||2016-04-20|2016-05-20|Estimate|November 1998||1998-11-30|April 2016|2016-04-30|July 2011|Actual|2011-07-31|December 2008|Actual|2008-12-31||Interventional|||S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma|Phase II Study of Hydroxyurea for Unresectable Meningioma|Completed||Phase 2|29|Actual|Southwest Oncology Group|Early termination leading to fewer than expected subjects analyzed. With 28 eligible patients estimate of response probability can be estimated to within +/- 19%.|1|||f||||f||||||||||2018-06-01 05:28:10.43737|2018-06-01 05:28:10.43737
NCT00003577|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 1996||1996-03-31|February 2001|2001-02-28|September 2008|Actual|2008-09-30|||||Interventional|||Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer|National Breast Cancer Study of Epirubicin + CMF v Classical CMF Adjuvant Therapy|Completed||Phase 3|2000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:10.816246|2018-06-01 05:28:10.816246
NCT00003576|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 1997||1997-01-31|April 2007|2007-04-30|August 2005|Actual|2005-08-31|||||Interventional|||Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery|Surgery and Adjuvant Radiotherapy Versus Concurrent Chemo-Radiotherapy for Resectable (Non-Metastatic) Stage III/IV Head and Neck Squamous Cell Cancer|Completed||Phase 3|200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:10.885745|2018-06-01 05:28:10.885745
NCT00003569|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2003-01-26|2003-01-27|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 1998||1998-03-31|January 2013|2013-01-31||||June 2003|Actual|2003-06-30||Observational|||Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel|Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol|Completed|||2|Actual|Roswell Park Cancer Institute|||||f||||||||||||||2018-06-01 05:28:10.961423|2018-06-01 05:28:10.961423
NCT00003568|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|November 1998||1998-11-30|November 2005|2005-11-30|December 2005|Actual|2005-12-31|||||Interventional|||Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma|A Randomized Phase II Trial of a Mutated gp100 Melanoma Peptide (g209-217(210M) With Hight Dose Interleukin-2 (IL-2) in HLA-A2.1+Patients With Metastatic Melanoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:11.028921|2018-06-01 05:28:11.028921
NCT00003567|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|May 1999||1999-05-31|June 2010|2010-06-30|February 2007|Actual|2007-02-28|January 2007|Actual|2007-01-31||Interventional|||Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Mutant MGMT Gene Transfer Into Human Hematopoietic Progenitors to Protect Hematopoiesis During O6-Benzylguanine (BG, NSC 637037) and Carmustine Followed by Temozolomide Therapy of Advanced Solid Tumors|Terminated||Phase 1|8|Actual|Case Comprehensive Cancer Center||||slow accrual|f||||t||||||||||2018-06-01 05:28:11.089072|2018-06-01 05:28:11.089072
NCT00003566|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|September 1998||1998-09-30|July 2016|2016-07-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer|Pre-Resection Minimally Invasive Surgical Restaging of Stage III (Mediastinal Node Positive) Non-Small Cell Lung Cancer (NSCLC)|Completed||N/A|75|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:28:11.168695|2018-06-01 05:28:11.168695
NCT00003565|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|September 1998||1998-09-30|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2006|Actual|2006-01-31||Interventional|||Docetaxel in Treating Patients With Solid Tumors|A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients|Completed||Phase 2|109|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:28:11.440757|2018-06-01 05:28:11.440757
NCT00003560|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|May 1998||1998-05-31|September 2003|2003-09-30||||||||Interventional|||Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:11.66632|2018-06-01 05:28:11.66632
NCT00003558|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 1998||1998-08-31|February 2003|2003-02-28||||||||Interventional|||Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin|A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site|Unknown status|Active, not recruiting|Phase 3|140|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:11.727087|2018-06-01 05:28:11.727087
NCT00003553|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-06-23|2003-01-26|2003-01-27|Estimate|||||||2009-06-23|2009-06-24|Estimate|January 1999||1999-01-31|June 2009|2009-06-30||||December 2009|Anticipated|2009-12-31||Interventional|||Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of HLA-Matched Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation for Metastatic Renal Cell Carcinoma Followed by Allogeneic T-Cell Infusion as Adoptive Immunotherapy|Unknown status|Recruiting|Phase 2|80|Anticipated|National Cancer Institute (NCI)||6|||f||||||||||||||2018-06-01 05:28:11.798557|2018-06-01 05:28:11.798557
NCT00003538|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-01|2003-01-26|2003-01-27|Estimate|||||||2014-05-01|2014-05-02|Estimate|March 1997||1997-03-31|May 2014|2014-05-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation|Stem Cell Augmented, Elutriated Grafts for Allogeneic Bone Marrow Transplantation|Completed||N/A|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:28:11.883083|2018-06-01 05:28:11.883083
NCT00003537|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-10-25||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-12-28|2017-02-20|Actual||||2017-07-24|2017-08-24|Actual|April 1995||1995-04-30|July 2017|2017-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|AA||Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma|Completed||Phase 2|19|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:12.000257|2018-06-01 05:28:12.000257
NCT00003536|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer|Phase II Randomized Study of Methotrexate With or Without Antineoplaston A10 Capsules in Women With Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:12.30065|2018-06-01 05:28:12.30065
NCT00003535|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-08-01||2018-03-07|2003-01-26|2003-01-27|Estimate|2017-08-01|2017-12-13|Actual||||2018-03-07|2018-03-21|Actual|April 1994||1994-04-30|March 2018|2018-03-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma|Phase II Study of Antineoplastons A10 and AS2-1 in Children With High Grade Glioma|Terminated||Phase 2|9|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-06-01 05:28:12.376273|2018-06-01 05:28:12.376273
NCT00003534|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-01-29|2003-01-26|2003-01-27|Estimate|||||||2018-01-29|2018-01-31|Actual|October 11, 1996|Actual|1996-10-11|January 2018|2018-01-31|February 20, 1997|Actual|1997-02-20|February 20, 1997|Actual|1997-02-20||Interventional|||Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate|Withdrawn||Phase 2|0|Actual|Burzynski Research Institute||1||No participants enrolled.|f||||f|t|f||||||No||2018-06-01 05:28:12.572236|2018-06-01 05:28:12.572236
NCT00003533|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-12-11|2003-01-26|2003-01-27|Estimate|||||||2017-12-11|2017-12-12|Actual|February 27, 1996|Actual|1996-02-27|December 2017|2017-12-31|December 31, 1999|Actual|1999-12-31|December 31, 1999|Actual|1999-12-31||Interventional|||Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate|Terminated||Phase 2|12|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:12.647862|2018-06-01 05:28:12.647862
NCT00003532|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-12-11|2003-01-26|2003-01-27|Estimate|||||||2017-12-11|2017-12-12|Actual|March 5, 1996|Actual|1996-03-05|December 2017|2017-12-31|October 18, 2002|Actual|2002-10-18|October 18, 2002|Actual|2002-10-18||Interventional|||Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary|Terminated||Phase 2|7|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:12.711874|2018-06-01 05:28:12.711874
NCT00003531|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-11-19|2003-01-26|2003-01-27|Estimate|||||||2017-11-19|2017-11-21|Actual|March 10, 1996|Actual|1996-03-10|November 2017|2017-11-30|July 18, 2005|Actual|2005-07-18|July 18, 2005|Actual|2005-07-18||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Pancreas|Terminated||Phase 2|15|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:12.783237|2018-06-01 05:28:12.783237
NCT00003530|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-11-19|2003-01-26|2003-01-27|Estimate|||||||2017-11-19|2017-11-21|Actual|March 21, 1977|Actual|1977-03-21|November 2017|2017-11-30|October 17, 1999|Actual|1999-10-17|October 17, 1999|Actual|1999-10-17||Interventional|||Antineoplaston Therapy in Treating Patients With Primary Liver Cancer|Phase II Study of Antineoplaston A10 in Patients With Primary Liver Cancer|Terminated||Phase 2|3|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:12.845737|2018-06-01 05:28:12.845737
NCT00003486|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Antineoplaston Therapy in Treating Patients With Colon Cancer|Phase II Study of Antineoplastons A10 and AS2-1 Capsules in Patients With Adenocarcinoma of the Colon|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:15.195681|2018-06-01 05:28:15.195681
NCT00003526|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-12-11|2003-01-26|2003-01-27|Estimate|||||||2017-12-11|2017-12-12|Actual|March 18, 1996|Actual|1996-03-18|December 2017|2017-12-31|February 2, 2005|Actual|2005-02-02|February 2, 2005|Actual|2005-02-02||Interventional|||Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of Unknown Primary|Terminated||Phase 2|8|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:12.912305|2018-06-01 05:28:12.912305
NCT00003525|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|June 3, 1996|Actual|1996-06-03|September 2017|2017-09-30|January 22, 1998|Actual|1998-01-22|January 22, 1998|Actual|1998-01-22||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Uterine Cervix and/or Vulva|Terminated||Phase 2|8|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||||2018-06-01 05:28:12.972842|2018-06-01 05:28:12.972842
NCT00003524|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|October 4, 1996|Actual|1996-10-04|September 2017|2017-09-30|August 24, 1998|Actual|1998-08-24|August 24, 1998|Actual|1998-08-24||Interventional|||Antineoplaston Therapy in Treating Patients With Stomach Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Stomach|Terminated||Phase 2|1|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.0571|2018-06-01 05:28:13.0571
NCT00003522|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|August 13, 1997|Actual|1997-08-13|September 2017|2017-09-30|December 14, 1997|Actual|1997-12-14|December 14, 1997|Actual|1997-12-14||Interventional|||Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Small Intestine|Terminated||Phase 2|1|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.137254|2018-06-01 05:28:13.137254
NCT00003521|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|June 14, 1996|Actual|1996-06-14|August 2017|2017-08-31|August 30, 2003|Actual|2003-08-30|August 30, 2003|Actual|2003-08-30||Interventional|||Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Soft Tissue Sarcoma|Terminated||Phase 2|14|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.209715|2018-06-01 05:28:13.209715
NCT00003520|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|March 27, 1996|Actual|1996-03-27|September 2017|2017-09-30|January 23, 2005|Actual|2005-01-23|January 23, 2005|Actual|2005-01-23||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Kidney|Terminated||Phase 2|15|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.267484|2018-06-01 05:28:13.267484
NCT00003517|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer|Phase II Study of Antineoplastons A10 and AS2-1 Capsules With Total Androgen Blockade in Patients With Stage III or IV Adenocarcinoma of the Prostate|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:13.32343|2018-06-01 05:28:13.32343
NCT00003516|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-01|2003-01-26|2003-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 27, 1996|Actual|1996-03-27|February 2018|2018-02-28|March 18, 2004|Actual|2004-03-18|March 18, 2004|Actual|2004-03-18||Interventional|||Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer|Phase II Study of Antineoplaston A10 and AS2-1 Capsules In Patients With Incurable, Stage C or D Adenocarcinoma of the Prostate|Terminated||Phase 2|16|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.379938|2018-06-01 05:28:13.379938
NCT00003515|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|December 12, 1996|Actual|1996-12-12|September 2017|2017-09-30|January 3, 1997|Actual|1997-01-03|January 3, 1997|Actual|1997-01-03||Interventional|||Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Primitive Neuroectodermal Tumor Outside the Central Nervous System|Terminated||Phase 2|1|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.562693|2018-06-01 05:28:13.562693
NCT00003514|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:13.625076|2018-06-01 05:28:13.625076
NCT00003513|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-26|2003-01-26|2003-01-27|Estimate|||||||2017-09-26|2017-09-28|Actual|December 16, 1996|Actual|1996-12-16|September 2017|2017-09-30|March 29, 1999|Actual|1999-03-29|March 29, 1999|Actual|1999-03-29||Interventional|||Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Neuroblastoma|Terminated||Phase 2|3|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.696863|2018-06-01 05:28:13.696863
NCT00003512|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-01|2003-01-26|2003-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 18, 1999|Actual|1999-02-18|February 2018|2018-02-28|April 26, 2000|Actual|2000-04-26|April 26, 2000|Actual|2000-04-26||Interventional|||Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Macroglobulinemia of Waldenstrom|Withdrawn||Phase 2|0|Actual|Burzynski Research Institute||1||No participants enrolled|f||||f|t|f||||||No||2018-06-01 05:28:13.760451|2018-06-01 05:28:13.760451
NCT00003511|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-01|2003-01-26|2003-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 4, 1996|Actual|1996-04-04|February 2018|2018-02-28|October 21, 1999|Actual|1999-10-21|October 21, 1999|Actual|1999-10-21||Interventional|||Antineoplaston Therapy in Treating Patients With Multiple Myeloma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Multiple Myeloma|Terminated||Phase 2|5|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.823274|2018-06-01 05:28:13.823274
NCT00003509|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-01-30|2003-01-26|2003-01-27|Estimate|||||||2018-01-30|2018-01-31|Actual|March 27, 1996|Actual|1996-03-27|January 2018|2018-01-31|February 14, 2005|Actual|2005-02-14|February 14, 2005|Actual|2005-02-14||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Melanoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Malignant Melanoma|Terminated||Phase 2|13|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:13.885919|2018-06-01 05:28:13.885919
NCT00003508|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|March 1996||1996-03-31|June 2009|2009-06-30||||December 2011|Anticipated|2011-12-31||Interventional|||Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Mesothelioma|Terminated||Phase 2|40|Anticipated|National Cancer Institute (NCI)||||Withdrawn due to slow enrollment|f||||||||||||||2018-06-01 05:28:13.944455|2018-06-01 05:28:13.944455
NCT00003505|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||October 2006|2006-10-31||||||||Interventional|||Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Primary Central Nervous System Lymphoma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:14.067046|2018-06-01 05:28:14.067046
NCT00003502|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Stage II, III, or IV Mantle Cell Lymphoma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:14.137689|2018-06-01 05:28:14.137689
NCT00003501|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-01|2003-01-26|2003-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 10, 1996|Actual|1996-04-10|February 2018|2018-02-28|July 2, 2003|Actual|2003-07-02|July 2, 2003|Actual|2003-07-02||Interventional|||Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma, High Grade|Terminated||Phase 2|2|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||||2018-06-01 05:28:14.204768|2018-06-01 05:28:14.204768
NCT00003500|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-01|2003-01-26|2003-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 11, 1996|Actual|1996-03-11|February 2018|2018-02-28|June 16, 2000|Actual|2000-06-16|June 16, 2000|Actual|2000-06-16||Interventional|||Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma, Intermediate Grade|Terminated||Phase 2|12|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||||2018-06-01 05:28:14.276051|2018-06-01 05:28:14.276051
NCT00003499|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-12-11|2003-01-26|2003-01-27|Estimate|||||||2017-12-11|2017-12-12|Actual|March 6, 1996|Actual|1996-03-06|December 2017|2017-12-31|September 13, 2003|Actual|2003-09-13|September 13, 2003|Actual|2003-09-13||Interventional|||Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma|Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma Low Grade|Terminated||Phase 2|31|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.352559|2018-06-01 05:28:14.352559
NCT00003498|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-01|2003-01-26|2003-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 5, 1996|Actual|1996-12-05|February 2018|2018-02-28|November 28, 2000|Actual|2000-11-28|November 28, 2000|Actual|2000-11-28||Interventional|||Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma|Terminated||Phase 2|5|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.426277|2018-06-01 05:28:14.426277
NCT00003497|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-01|2003-01-26|2003-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|August 21, 1996|Actual|1996-08-21|February 2018|2018-02-28|February 2, 1998|Actual|1998-02-02|February 2, 1998|Actual|1998-02-02||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 Capsules In Patients With Non Small Cell Lung Cancer|Terminated||Phase 2|9|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.511453|2018-06-01 05:28:14.511453
NCT00003496|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-26|2003-01-26|2003-01-27|Estimate|||||||2017-09-26|2017-09-28|Actual|March 7, 1996|Actual|1996-03-07|September 2017|2017-09-30|February 5, 2004|Actual|2004-02-05|February 5, 2004|Actual|2004-02-05||Interventional|||Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Small Cell Carcinoma of the Lung|Terminated||Phase 2|4|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.597787|2018-06-01 05:28:14.597787
NCT00003495|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-26|2003-01-26|2003-01-27|Estimate|||||||2017-09-26|2017-09-28|Actual|March 27, 1996|Actual|1996-03-27|September 2017|2017-09-30|November 4, 2003|Actual|2003-11-04|November 4, 2003|Actual|2003-11-04||Interventional|||Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Squamos Cell Carcinoma of the Lung|Terminated||Phase 2|7|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.730876|2018-06-01 05:28:14.730876
NCT00003494|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-01-30|2003-01-26|2003-01-27|Estimate|||||||2018-01-30|2018-01-31|Actual|March 26, 1996|Actual|1996-03-26|January 2018|2018-01-31|May 26, 2002|Actual|2002-05-26|May 26, 2002|Actual|2002-05-26||Interventional|||Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Bronchial Alveolar Carcinoma of the Lung|Terminated||Phase 2|4|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.816785|2018-06-01 05:28:14.816785
NCT00003492|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-12-10|2003-01-26|2003-01-27|Estimate|||||||2017-12-10|2017-12-12|Actual|April 10, 1996|Actual|1996-04-10|December 2017|2017-12-31|December 1, 2000|Actual|2000-12-01|December 1, 2000|Actual|2000-12-01||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung|Terminated||Phase 2|9|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.892389|2018-06-01 05:28:14.892389
NCT00003491|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-27|2003-01-26|2003-01-27|Estimate|||||||2017-09-27|2017-09-29|Actual|March 20, 1996|Actual|1996-03-20|September 2017|2017-09-30|July 31, 1998|Actual|1998-07-31|July 31, 1998|Actual|1998-07-31||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Lung|Terminated||Phase 2|17|Actual|Burzynski Research Institute||1||Slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:14.982216|2018-06-01 05:28:14.982216
NCT00003489|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-11-19|2003-01-26|2003-01-27|Estimate|||||||2017-11-19|2017-11-21|Actual|May 6, 1996|Actual|1996-05-06|November 2017|2017-11-30|April 3, 1998|Actual|1998-04-03|April 3, 1998|Actual|1998-04-03||Interventional|||Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck|Terminated||Phase 2|7|Actual|Burzynski Research Institute||1||slow accrual|f|||||t|f||||||No||2018-06-01 05:28:15.05815|2018-06-01 05:28:15.05815
NCT00003487|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|May 1996||1996-05-31|June 2009|2009-06-30||||December 2011|Anticipated|2011-12-31||Interventional|||Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of the Esophagus|Terminated||Phase 2|40|Anticipated|National Cancer Institute (NCI)||||Withdrawn due to slow enrollment|f||||||||||||||2018-06-01 05:28:15.135453|2018-06-01 05:28:15.135453
NCT00003485|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-26|2003-01-26|2003-01-27|Estimate|||||||2017-09-26|2017-09-28|Actual|April 10, 1996|Actual|1996-04-10|September 2017|2017-09-30|May 11, 2003|Actual|2003-05-11|May 11, 2003|Actual|2003-05-11||Interventional|||Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Colon|Terminated||Phase 2|15|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||||2018-06-01 05:28:15.243348|2018-06-01 05:28:15.243348
NCT00003483|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-12-28||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-12-28|2017-02-17|Actual||||2017-07-24|2017-08-24|Actual|June 1998||1998-06-30|July 2017|2017-07-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Antineoplaston Therapy in Treating Patients With Meningioma|Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Meningioma|Terminated||Phase 2|3|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-06-01 05:28:15.322811|2018-06-01 05:28:15.322811
NCT00003479|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-12-28||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-12-28|2017-02-17|Actual||||2017-07-24|2017-08-24|Actual|July 1966||1966-07-31|July 2017|2017-07-31|October 2000|Actual|2000-10-31|October 2000|Actual|2000-10-31||Interventional|||Antineoplaston Therapy in Treating Patients With Ependymoma|Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Patients With Ependymoma|Terminated||Phase 2|9|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-06-01 05:28:15.511517|2018-06-01 05:28:15.511517
NCT00003478|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2003-01-26|2003-01-27|Estimate|||||||2013-02-15|2013-02-20|Estimate|October 1997||1997-10-31|February 2013|2013-02-28|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors|Phase I Study of Intra-Tumoral, Radiolabeled, Anti-Tenascin Monoclonal Antibody 81C6 in the Treatment of Patients With Malignant Primary Brain Tumors|Completed||Phase 1/Phase 2|10|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:28:15.718596|2018-06-01 05:28:15.718596
NCT00003477|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-08-04||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-10-25|2016-12-16|Estimate||||2017-07-24|2017-08-24|Actual|June 1996||1996-06-30|July 2017|2017-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|VPG||Antineoplaston Therapy in Treating Children With Visual Pathway Glioma|Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Children With Visual Pathway Glioma|Completed||Phase 2|12|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:15.951675|2018-06-01 05:28:15.951675
NCT00003476|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-12-28||2017-07-24|2003-01-26|2003-01-27|Estimate|2017-02-26|2017-04-10|Actual||||2017-07-24|2017-08-24|Actual|March 1996||1996-03-31|July 2017|2017-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Children With Primary Malignant Brain Tumors|Terminated||Phase 2|8|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-06-01 05:28:16.248607|2018-06-01 05:28:16.248607
NCT00003475|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-10-26||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-10-26|2016-12-19|Estimate||||2017-07-24|2017-08-24|Actual|February 1996||1996-02-29|July 2017|2017-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Primary Malignant Brain Tumors|Completed||Phase 2|40|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:16.79347|2018-06-01 05:28:16.79347
NCT00003474|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-07-27||2018-03-07|2003-01-26|2003-01-27|Estimate|2017-07-31|2017-12-13|Actual||||2018-03-07|2018-03-22|Actual|March 14, 1996|Actual|1996-03-14|March 2018|2018-03-31|June 21, 2003|Actual|2003-06-21|June 21, 2003|Actual|2003-06-21||Interventional|||Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Glioblastoma Multiforme|Completed||Phase 2|40|Actual|Burzynski Research Institute||1|||f||||f|t|||||||No||2018-06-01 05:28:17.209633|2018-06-01 05:28:17.209633
NCT00003473|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-08-24||2017-12-18|2003-01-26|2003-01-27|Estimate|2016-09-12|2016-11-01|Estimate||||2017-12-18|2018-01-17|Actual|March 1996||1996-03-31|December 2017|2017-12-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Mixed Glioma|Completed||Phase 2|20|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:17.491676|2018-06-01 05:28:17.491676
NCT00003472|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-08-01||2018-03-07|2003-01-26|2003-01-27|Estimate|2017-08-01|2017-12-13|Actual||||2018-03-07|2018-03-21|Actual|May 1996||1996-05-31|March 2018|2018-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Oligodendroglioma|Terminated||Phase 2|13|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-06-01 05:28:18.764983|2018-06-01 05:28:18.764983
NCT00003471|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-07-31||2018-03-07|2003-01-26|2003-01-27|Estimate|2017-08-01|2017-12-13|Actual||||2018-03-07|2018-03-22|Actual|March 1996||1996-03-31|March 2018|2018-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Low Grade Astrocytoma|Terminated||Phase 2|7|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-06-01 05:28:19.231071|2018-06-01 05:28:19.231071
NCT00003470|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-10-25||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-10-25|2016-12-16|Estimate||||2017-07-24|2017-08-24|Actual|March 1996||1996-03-31|December 2016|2016-12-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|AA||Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Anaplastic Astrocytoma|Completed||Phase 2|27|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:20.213917|2018-06-01 05:28:20.213917
NCT00003469|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-01-17||2017-07-24|2003-01-26|2003-01-27|Estimate|2017-01-17|2017-03-07|Actual||||2017-07-24|2017-08-24|Actual|February 1996||1996-02-29|July 2017|2017-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System|Phase II Study of Antineoplastons A10 and AS2-1 in Children With Rhabdoid Tumor of the Central Nervous System|Terminated||Phase 2|4|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-06-01 05:28:20.503687|2018-06-01 05:28:20.503687
NCT00003468|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-09-22||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-09-22|2016-11-10|Estimate||||2017-07-24|2017-08-24|Actual|July 1996||1996-07-31|July 2017|2017-07-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma|Phase II Study of Antineoplastons A10 and AS2-1 in Children With Low Grade Astrocytoma|Completed||Phase 2|11|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:20.762445|2018-06-01 05:28:20.762445
NCT00003467|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-19|2003-01-26|2003-01-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 1998||1998-01-31|October 2009|2009-10-31|February 2004|Actual|2004-02-29|||||Interventional|||Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma|Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers|Completed||Phase 2|68|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:28:21.15945|2018-06-01 05:28:21.15945
NCT00003462|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2003-01-26|2003-01-27|Estimate|||||||2013-02-15|2013-02-20|Estimate|April 1998||1998-04-30|February 2013|2013-02-28|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors|Phase I Study of Intrathecal Spartaject-Busulfan in Patients With Neoplastic Meningitis|Completed||Phase 1|20|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:28:21.704765|2018-06-01 05:28:21.704765
NCT00003461|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-20|2003-01-26|2003-01-27|Estimate|||||||2014-08-20|2014-08-21|Estimate|February 1998||1998-02-28|February 2013|2013-02-28|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors|Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors|Completed||Phase 1/Phase 2|||Duke University|||||f||||||||||||||2018-06-01 05:28:21.881107|2018-06-01 05:28:21.881107
NCT00003460|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-09-22||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-09-22|2016-11-10|Estimate||||2017-07-24|2017-08-24|Actual|April 1996||1996-04-30|July 2017|2017-07-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|PNET||Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors|Phase II Study of Antineoplastons A10 and AS2-1 In Children With Primitive Neuroectodermal Tumors|Completed||Phase 2|13|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:22.016351|2018-06-01 05:28:22.016351
NCT00003459|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-05-25||2018-03-11|2003-01-26|2003-01-27|Estimate|2016-08-18|2016-10-12|Estimate||||2018-03-11|2018-03-14|Actual|March 1996||1996-03-31|March 2018|2018-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Antineoplaston Therapy in Treating Patients With Brain Stem Glioma|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Brain Stem Glioma|Completed||Phase 2|40|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:22.477923|2018-06-01 05:28:22.477923
NCT00003458|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-09-22||2018-02-01|2003-01-26|2003-01-27|Estimate|2016-11-22|2017-01-19|Estimate||||2018-02-01|2018-02-02|Estimate|September 1996||1996-09-30|February 2018|2018-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Antineoplaston Therapy in Treating Children With Brain Tumors|Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors|Completed||Phase 2|34|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:22.904075|2018-06-01 05:28:22.904075
NCT00003457|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-10-25||2017-07-24|2003-01-26|2003-01-27|Estimate|2016-10-25|2016-12-16|Estimate||||2017-07-24|2017-08-22|Actual|July 1996||1996-07-31|July 2017|2017-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Antineoplaston Therapy in Treating Patients With Brain Tumors|Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors.|Completed||Phase 2|40|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-06-01 05:28:23.405441|2018-06-01 05:28:23.405441
NCT00003456|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-07-24||2018-03-07|2003-01-26|2003-01-27|Estimate|2017-07-31|2017-12-13|Actual||||2018-03-07|2018-03-22|Actual|March 14, 1995|Actual|1995-03-14|March 2018|2018-03-31|December 7, 2004|Actual|2004-12-07|December 7, 2004|Actual|2004-12-07||Interventional|||Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Glioblastoma Multiforme|Completed||Phase 2|40|Actual|Burzynski Research Institute||1|||f||||f|t|||||||No||2018-06-01 05:28:23.837487|2018-06-01 05:28:23.837487
NCT00003455|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate||||December 2006|2006-12-31||||||||Interventional|||Antineoplaston Therapy in Treating Women With Advanced Breast Cancer|Phase II Study of Oral Antineoplastons A10 and AS2-1 in Women With Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:24.303014|2018-06-01 05:28:24.303014
NCT00003454|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-26|2003-01-26|2003-01-27|Estimate|||||||2017-09-26|2017-09-28|Actual|March 18, 1996|Actual|1996-03-18|September 2017|2017-09-30|December 28, 2002|Actual|2002-12-28|December 28, 2002|Actual|2002-12-28||Interventional|||Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Breast|Terminated||Phase 2|19|Actual|Burzynski Research Institute||1||slow accrual|f||||f|t|f||||||No||2018-06-01 05:28:24.436657|2018-06-01 05:28:24.436657
NCT00003453|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2018-03-11||2018-04-09|2003-01-26|2003-01-27|Estimate|2018-04-09|2018-05-09|Actual||||2018-04-09|2018-05-09|Actual|August 21, 1996||1996-08-21|April 2018|2018-04-30|July 5, 2011|Actual|2011-07-05|July 5, 2011|Actual|2011-07-05||Interventional|||Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland|Terminated||Phase 2|6|Actual|Burzynski Research Institute||1||Slow enrollment|f||||f|t|f||||||No||2018-06-01 05:28:24.642045|2018-06-01 05:28:24.642045
NCT00003452|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-26|2003-01-26|2003-01-27|Estimate|||||||2017-09-26|2017-09-28|Actual|May 6, 1996|Actual|1996-05-06|September 2017|2017-09-30|May 4, 1998|Actual|1998-05-04|May 4, 1998|Actual|1998-05-04||Interventional|||Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder|Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder|Terminated||Phase 2|4|Actual|Burzynski Research Institute||1||slow enrollment|f||||f|t|f||||||No||2018-06-01 05:28:25.458431|2018-06-01 05:28:25.458431
NCT00003440|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-03|2003-01-26|2003-01-27|Estimate|||||||2013-06-03|2013-06-04|Estimate|July 1998||1998-07-31|June 2013|2013-06-30||||July 2004|Actual|2004-07-31||Interventional|||Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic|A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hour Infusion Every 3 Weeks With Herceptin (Trastuzumab) (NSC #688097) in the Treatment of Patients With/Without HER-2/Neu-Overexpressing Metastatic Breast Cancer|Completed||Phase 3|580|Actual|National Cancer Institute (NCI)||6|||f||||||||||||||2018-06-01 05:28:27.304305|2018-06-01 05:28:27.304305
NCT00003437|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1997||1997-01-31|February 2003|2003-02-28||||||||Interventional|||Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia|Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial|Unknown status|Active, not recruiting|Phase 3|1800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:29.810662|2018-06-01 05:28:29.810662
NCT00003429|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-12-17|2003-01-26|2003-01-27|Estimate|||||||2015-12-17|2015-12-18|Estimate|May 1998||1998-05-31|December 2015|2015-12-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||PET Scans in Diagnosing Primary or Recurrent Cervical Cancer in Patients Who Are Undergoing Surgery|A Pilot Study of 18F-Flourodeoxyglucose Positron Emission Tomography in the Diagnosis of Primary and Recurrent Cervical Cancer|Completed||N/A|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:30.218225|2018-06-01 05:28:30.218225
NCT00051792|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2006-08-16|2003-01-16|2003-01-17|Estimate|||||||2006-08-16|2006-08-18|Estimate|January 2003||2003-01-31|August 2006|2006-08-31|July 2004||2004-07-31|||||Interventional|||Yoga for Treating Shortness of Breath in Chronic Obstructive Pulmonary Disease (COPD)|Efficacy of Yoga for Self-Management of Dyspnea in COPD|Completed||Phase 1/Phase 2|36||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:29:21.061606|2018-06-01 05:29:21.061606
NCT00003422|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1998||1998-01-31|March 2007|2007-03-31|June 2010|Actual|2010-06-30|||||Interventional|||Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed|A Randomised Trial Comparing Pre-Operative Radiotherapy and Selective Post-Operative Chemoradiotherapy in Rectal Cancer|Completed||Phase 3|1800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:30.340596|2018-06-01 05:28:30.340596
NCT00003420|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 1997||1997-07-31|December 2002|2002-12-31|April 2010|Actual|2010-04-30|||||Interventional|||CT Scans in Treating Patients With Stage I Testicular Cancer After Undergoing Orchiectomy|A Study of CT Scan Frequency in Patients With Stage I Testicular Teratoma|Completed||N/A|900|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:30.964434|2018-06-01 05:28:30.964434
NCT00003419|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 1998||1998-06-30|November 2001|2001-11-30||||||||Interventional|||Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma|Treatment of HIV-Related Kaposi's Sarcoma and Stage I-III Slow-Proliferative Disease With Highly Active Antiretroviral Therapy (HAART)|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:31.092789|2018-06-01 05:28:31.092789
NCT00003417|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-11-14|2003-01-26|2003-01-27|Estimate|||||||2015-11-14|2015-11-17|Estimate|September 1998||1998-09-30|November 2015|2015-11-30||||May 2004|Actual|2004-05-31||Interventional|||Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme|Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial Glioblastoma Multiforme|Completed||Phase 1/Phase 2|40|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:28:31.29598|2018-06-01 05:28:31.29598
NCT00003404|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-11-25|2003-01-26|2003-01-27|Estimate|||||||2015-11-25|2015-11-30|Estimate|January 1998||1998-01-31|October 2015|2015-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Radiation Therapy After Surgery in Treating Women With Phyllodes Tumor of the Breast|A Prospective Study of Adjuvant Radiation Therapy After Resection of Borderline and Malignant Phyllodes Tumors|Active, not recruiting||Phase 2|50|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-06-01 05:28:32.117005|2018-06-01 05:28:32.117005
NCT00003389|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2015-08-05||2017-10-18|2003-01-26|2003-01-27|Estimate|2015-08-05|2015-09-03|Estimate||||2017-10-18|2017-11-20|Actual|April 1999||1999-04-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|September 2011|Actual|2011-09-30||Interventional||Eligible patients are included in the primary analysis.|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma|A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease|Completed||Phase 3|854|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 05:28:32.501538|2018-06-01 05:28:32.501538
NCT00003385|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2003-01-26|2003-01-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|March 1999||1999-03-31|September 2003|2003-09-30||||January 2007|Actual|2007-01-31||Interventional|||Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer|A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma|Completed||Phase 1|48|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:28:34.382174|2018-06-01 05:28:34.382174
NCT00003384|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-05-27|2003-01-26|2003-01-27|Estimate|||||||2015-05-27|2015-05-29|Estimate|September 1998||1998-09-30|May 2015|2015-05-31||||January 2011|Actual|2011-01-31||Interventional|||Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer|Expression of the MN Protein in Atypical Glandular Cells of Undetermined Significance (Agus or Agcus) As a Potential Diagnostic Biomarker of Cervical Dysplasia/Neoplasia|Completed||N/A|684|Actual|Gynecologic Oncology Group||1|||f||||||||||||||2018-06-01 05:28:34.486644|2018-06-01 05:28:34.486644
NCT00003379|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-24|2003-01-26|2003-01-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|November 1999||1999-11-30|November 2004|2004-11-30||||January 2007|Actual|2007-01-31||Interventional|||Radiation Therapy Plus Paclitaxel and Cisplatin in Treating Patients With Cervical Cancer|A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis|Completed||Phase 1/Phase 2|40|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:28:34.662089|2018-06-01 05:28:34.662089
NCT00003377|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2012-11-23||2012-12-27|2003-01-26|2003-01-27|Estimate|2012-12-27|2013-02-04|Estimate||||2012-12-27|2013-02-04|Estimate|November 1999||1999-11-30|December 2012|2012-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix|A Phase I Study of Extended Field Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes|Completed||Phase 1|29|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-06-01 05:28:34.902266|2018-06-01 05:28:34.902266
NCT00003375|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-05-15|2003-01-26|2003-01-27|Estimate|||||||2018-05-15|2018-05-17|Actual|October 1998||1998-10-31|May 2018|2018-05-31|May 14, 2018|Actual|2018-05-14|August 2005|Actual|2005-08-31||Interventional|||Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma|A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma|Completed||Phase 2/Phase 3|370|Actual|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-06-01 05:28:37.581909|2018-06-01 05:28:37.581909
NCT00003354|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 1996||1996-07-31|January 2001|2001-01-31|December 2009|Actual|2009-12-31|||||Interventional|||Conventional Surgery Compared With Laparoscopic-Assisted Surgery in Treating Patients With Colorectal Cancer|Conventional Versus Laparoscopic-Assisted Surgery in Colorectal Cancer|Completed||Phase 3|1200|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:37.826168|2018-06-01 05:28:37.826168
NCT00003342|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-02|2003-01-26|2003-01-27|Estimate|||||||2013-07-02|2013-07-03|Estimate|December 1997||1997-12-31|July 2013|2013-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer|Phase I Trial of Dose-Dense Gemcitabine, Doxorubicin, Then Paclitaxel Plus Carboplatin In Patients With Transitional Cell Carcinoma of the Urothelium and Impaired Renal Function|Completed||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:37.955894|2018-06-01 05:28:37.955894
NCT00003336|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-10|2003-01-26|2003-01-27|Estimate|||||||2010-06-10|2010-06-11|Estimate|January 1998||1998-01-31|June 2010|2010-06-30|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders|Completed||Phase 2|6|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:28:38.05227|2018-06-01 05:28:38.05227
NCT00003335|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-03-14|2003-01-26|2003-01-27|Estimate|||||||2012-03-14|2012-03-15|Estimate|January 1998||1998-01-31|March 2012|2012-03-31|January 2012|Actual|2012-01-31|November 2007|Actual|2007-11-30||Interventional|||Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer|A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies|Completed||Phase 2|44|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:28:38.210427|2018-06-01 05:28:38.210427
NCT00003332|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-25|2003-01-26|2003-01-27|Estimate|||||||2011-03-25|2011-03-28|Estimate|July 1997||1997-07-31|March 2011|2011-03-31||||October 2004|Actual|2004-10-31||Interventional|||Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer|Phase I/II Study of Induction Chemotherapy With Gemcitabine and Cisplatin Followed by Combined Chemo-radiation and/or Surgical Resection for Locally Advanced Pancreatic Cancer|Completed||Phase 1/Phase 2|36|Anticipated|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:28:38.372898|2018-06-01 05:28:38.372898
NCT00003329|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-02|2003-01-26|2003-01-27|Estimate|||||||2013-04-02|2013-04-04|Estimate|January 1998||1998-01-31|March 2008|2008-03-31||||December 2007|Actual|2007-12-31||Observational|||Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer|ECOG Laboratory Study: Mapping Interactive Cancer Susceptibility Loci|Completed|||4000|Anticipated|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:28:38.595219|2018-06-01 05:28:38.595219
NCT00003325|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-05-27|2003-01-26|2003-01-27|Estimate|||||||2015-05-27|2015-05-29|Estimate|December 1999||1999-12-31|May 2015|2015-05-31||||July 2013|Actual|2013-07-31||Interventional|||Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva|Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva|Completed||Phase 3|515|Actual|Gynecologic Oncology Group||1|||f||||f||||||||||2018-06-01 05:28:38.716869|2018-06-01 05:28:38.716869
NCT00003309|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2003-01-26|2003-01-27|Estimate|||||||2010-01-26|2010-01-27|Estimate|July 1998||1998-07-31|January 2010|2010-01-31||||March 2004|Actual|2004-03-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer|"A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With Poor Risk Medulloblastoma, PNET, and Disseminated Ependymoma"|Completed||Phase 2|33|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:28:38.94949|2018-06-01 05:28:38.94949
NCT00003308|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-22|2003-01-26|2003-01-27|Estimate|||||||2013-08-22|2013-08-23|Estimate|July 1998||1998-07-31|August 2013|2013-08-31||||September 2004|Actual|2004-09-30||Interventional|||Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma|A Phase II Trial of Radiosurgery for 1 to 3 Newly Diagnosed Brain Metastases From Renal Cell, Melanoma and Sarcoma|Completed||Phase 2|||Eastern Cooperative Oncology Group|||||f||||||||||||||2018-06-01 05:28:39.041527|2018-06-01 05:28:39.041527
NCT00003292|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-07|2003-01-26|2003-01-27|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 1998||1998-07-31|November 2013|2013-11-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||S9624 Ifosfamide in Treating Patients With Meningeal Tumors|S9624: Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors|Terminated||Phase 2|7|Actual|Southwest Oncology Group||1||lack of accrual|f||||t||||||||||2018-06-01 05:28:39.150899|2018-06-01 05:28:39.150899
NCT00003291|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-07|2003-01-26|2003-01-27|Estimate|||||||2014-08-07|2014-08-08|Estimate|March 1998||1998-03-31|August 2014|2014-08-31||||March 2006|Actual|2006-03-31||Observational|||Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia|Molecular Genetic Lesions and Clinical Outcome in Pediatric ALL Patients|Completed|||200|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-06-01 05:28:39.348783|2018-06-01 05:28:39.348783
NCT00003282|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|March 1998||1998-03-31|January 2013|2013-01-31||||May 2005|Actual|2005-05-31||Interventional|||EF5 in Treating Patients With Solid Tumors|Phase I Trial of EF5, an Agent for the Detection of Hypoxia|Completed||Phase 1|50|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:28:39.445296|2018-06-01 05:28:39.445296
NCT00003278|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|March 1998||1998-03-31|July 2016|2016-07-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Radiation Therapy and High-Dose Corticosteroids in Treating Older Patients With Primary CNS Non-Hodgkin's Lymphoma|Primary Central Nervous System Non-Hodgkins's Lymphoma (PCNSL): A Phase II Clinical Trial of Radiation Therapy and High Dose Corticosteroids for Elderly Patients (70 Years of Age and Older)|Completed||Phase 2|28|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:28:39.577774|2018-06-01 05:28:39.577774
NCT00003273|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-11-30|2003-01-26|2003-01-27|Estimate|||||||2015-11-30|2015-12-03|Estimate|November 1997||1997-11-30|November 2015|2015-11-30||||||||Interventional|||Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor|Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue|Withdrawn||Phase 2|0|Actual|New York University School of Medicine|||||f||||||||||||||2018-06-01 05:28:40.597428|2018-06-01 05:28:40.597428
NCT00003268|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 1998||1998-01-31|October 2003|2003-10-31|December 2003|Actual|2003-12-31|||||Interventional|||Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I Study of Cytosine Arabinoside, Idarubicin, and Amifostine as Induction Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 1|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:40.744083|2018-06-01 05:28:40.744083
NCT00003261|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 1997||1997-05-31|October 2001|2001-10-31||||||||Interventional|||Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma|Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy|Unknown status|Active, not recruiting|Phase 2|14|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:40.844365|2018-06-01 05:28:40.844365
NCT00003243|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-09|2003-01-26|2003-01-27|Estimate|||||||2010-03-09|2010-03-10|Estimate|January 1998||1998-01-31|March 2010|2010-03-31||||||||Interventional|||Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer|A Phase I Trial of Combined Chemotherapy and Donor Lymphocyte Infusion for Aggressive Hematologic Malignancies in Relapse After Allogeneic Bone Marrow Transplantation|Completed||Phase 1|||Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||||||||||||2018-06-01 05:28:40.955243|2018-06-01 05:28:40.955243
NCT00051350|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|||2008-04-22|2003-01-10|2003-01-13|Estimate|||||||2008-04-22|2008-04-23|Estimate|May 2002||2002-05-31|April 2008|2008-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||OmniHeart Trial: Macronutrients and Cardiovascular Risk||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:29:25.889879|2018-06-01 05:29:25.889879
NCT00003216|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-18|2003-01-26|2003-01-27|Estimate|||||||2013-11-18|2013-11-19|Estimate|July 1998||1998-07-31|November 2013|2013-11-30||||October 2005|Actual|2005-10-31||Interventional|||Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas|A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma|Completed||Phase 3|518|Anticipated|Radiation Therapy Oncology Group|||||f||||t||||||||||2018-06-01 05:28:41.124414|2018-06-01 05:28:41.124414
NCT00003215|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-05-14|2003-01-26|2003-01-27|Estimate|||||||2012-05-14|2012-05-15|Estimate|April 1997||1997-04-30|May 2012|2012-05-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma|Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL)|Completed||Phase 3|400|Anticipated|Swiss Group for Clinical Cancer Research|||||f||||||||||||||2018-06-01 05:28:41.515976|2018-06-01 05:28:41.515976
NCT00003204|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2013-02-26|2003-01-26|2003-01-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|March 1998||1998-03-31|February 2013|2013-02-28||||May 2006|Actual|2006-05-31||Interventional|||Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma|Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy|Completed||Phase 3|515|Actual|National Cancer Institute (NCI)||4|||f||||||||||||||2018-06-01 05:28:41.716796|2018-06-01 05:28:41.716796
NCT00003199|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-04-10||2017-06-16|2003-01-26|2003-01-27|Estimate|2017-04-10|2017-05-17|Actual||||2017-06-16|2017-07-12|Actual|November 1997|Actual|1997-11-30|June 2017|2017-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer|A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF|Completed||Phase 2|50|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-06-01 05:28:41.867063|2018-06-01 05:28:41.867063
NCT00003194|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 1997||1997-07-31|March 2003|2003-03-31||||||||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors|A Phase I Study of Thiotepa in Combination With Carboplatin and Topotecan With Peripheral Blood Progenitor Cell Support for the Treatment of Children With Recurrent or Refractory Solid Tumors.|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:42.266109|2018-06-01 05:28:42.266109
NCT00003179|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-07|2003-01-26|2003-01-27|Estimate|||||||2013-06-07|2013-06-10|Estimate|November 1998||1998-11-30|July 2006|2006-07-31||||February 2006|Actual|2006-02-28||Interventional|||Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer|A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera|Terminated||Phase 2|360|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:28:42.40274|2018-06-01 05:28:42.40274
NCT00003178|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2014-07-24|2003-01-26|2003-01-27|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 1998||1998-03-31|July 2014|2014-07-31|March 2007|Actual|2007-03-31|December 2004|Actual|2004-12-31||Interventional|||Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia|Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study|Completed||Phase 2|120|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 05:28:42.746921|2018-06-01 05:28:42.746921
NCT00003174|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-04-22|2003-01-26|2003-01-27|Estimate|||||||2014-04-22|2014-04-24|Estimate|May 1998||1998-05-31|April 2014|2014-04-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia|Phase I Clinical Evaluation of Bryostatin 1 in Combination With 2-CdA in Patients With Relapsed CLL|Completed||Phase 1|80|Anticipated|Barbara Ann Karmanos Cancer Institute|||||f||||t||||||||||2018-06-01 05:28:43.316287|2018-06-01 05:28:43.316287
NCT00003159|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|August 1997||1997-08-31|May 2005|2005-05-31|June 2007|Actual|2007-06-30|||||Interventional|||Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer|Randomized Trial of Surgical Resection With or Without Pre-Operative Chemotherapy in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) of Any Stage|Completed||Phase 3|600|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:43.422576|2018-06-01 05:28:43.422576
NCT00003153|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-25|2003-01-26|2003-01-27|Estimate|||||||2009-02-25|2009-02-26|Estimate|February 1998||1998-02-28|July 2004|2004-07-31||||February 2007|Actual|2007-02-28||Interventional|||Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation|Phase II Study of Salvage Cellular Immunotherapy for Patients With Persistent or Recurrent Multiple Myeloma After Allogeneic Bone Marrow Transplantation From an HLA-Matched Sibling Donor|Completed||Phase 2|22|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:43.530203|2018-06-01 05:28:43.530203
NCT00003145|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-01-03|2003-01-26|2003-01-27|Estimate|||||||2018-01-03|2018-01-05|Actual|August 1997||1997-08-31|January 2018|2018-01-31||||March 2005|Actual|2005-03-31||Interventional|||Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia|Induction of Mixed Hematopoietic Chimerism Using Fludarabine, Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion In Patients With Chronic Myeloid Leukemia in Chronic and Accelerated Phases: A Multi-center Study|Active, not recruiting||Phase 2|18|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:28:43.637869|2018-06-01 05:28:43.637869
NCT00003140|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-09-18|2003-01-26|2003-01-27|Estimate|||||||2014-09-18|2014-09-19|Estimate|August 1998||1998-08-31|March 2012|2012-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Letrozole After Tamoxifen in Treating Women With Breast Cancer|A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen|Completed||Phase 3|5187|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:28:43.829866|2018-06-01 05:28:43.829866
NCT00003138|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-09-11||2015-10-06|2003-01-26|2003-01-27|Estimate|2013-11-13|2013-12-06|Estimate||||2015-10-06|2015-10-28|Estimate|December 1997||1997-12-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|August 2008|Actual|2008-08-31||Interventional||All patients with complete data are included.|Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes|Phase III Evaluation of EPO With or Without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes|Completed||Phase 3|118|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 05:28:44.042718|2018-06-01 05:28:44.042718
NCT00003135|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-04-29|2003-01-26|2003-01-27|Estimate|||||||2009-04-29|2009-04-30|Estimate|November 1997||1997-11-30|December 2008|2008-12-31||||September 2009|Anticipated|2009-09-30||Interventional|||Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer|A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy|Unknown status|Recruiting|Phase 2|34|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:45.221507|2018-06-01 05:28:45.221507
NCT00003128|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-08|2003-01-26|2003-01-27|Estimate|||||||2013-07-08|2013-07-09|Estimate|November 1997||1997-11-30|May 2004|2004-05-31||||February 2007|Actual|2007-02-28||Interventional|||Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus|A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus|Completed||Phase 3|166|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:28:45.317118|2018-06-01 05:28:45.317118
NCT00003122|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|December 1994||1994-12-31|July 2007|2007-07-31||||||||Interventional|||Surgery in Treating Patients With Neuroblastoma|Phase II Trial of Surgery as the Only Treatment for INSS Stage 2A & 2B Neuroblastoma|Unknown status|Recruiting|Phase 2|210|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:45.472304|2018-06-01 05:28:45.472304
NCT00003119|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-03-09|2003-01-26|2003-01-27|Estimate|||||||2017-03-09|2017-03-13|Actual|March 1998||1998-03-31|March 2017|2017-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Surgery in Treating Children With Neuroblastoma|Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study|Completed||Phase 3|968|Actual|Children's Oncology Group||2|||f||||f||||||||||2018-06-01 05:28:45.865116|2018-06-01 05:28:45.865116
NCT00003116|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-09|2003-01-26|2003-01-27|Estimate|||||||2010-06-09|2010-06-11|Estimate|May 1997||1997-05-31|June 2010|2010-06-30|June 2009|Actual|2009-06-30|March 2006|Actual|2006-03-31||Interventional|||High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer|Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies|Completed||Phase 2|66|Actual|Case Comprehensive Cancer Center|||||f||||t||||||||||2018-06-01 05:28:46.333944|2018-06-01 05:28:46.333944
NCT00003111|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-23|2003-01-26|2003-01-27|Estimate|||||||2013-07-23|2013-07-25|Estimate|April 1997||1997-04-30|August 2009|2009-08-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer|Phase II Clinical and Laboratory Study of Irinotecan/Cisplatin Chemotherapy Followed by Surgery in Stage III NSCLC|Completed||Phase 2|10|Actual|Yale University|||||f||||f||||||||||2018-06-01 05:28:46.445503|2018-06-01 05:28:46.445503
NCT00003105|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-02|2003-01-26|2003-01-27|Estimate|||||||2013-07-02|2013-07-03|Estimate|September 1997||1997-09-30|July 2013|2013-07-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer|Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium|Completed||Phase 1/Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:46.533657|2018-06-01 05:28:46.533657
NCT00003104|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2003-01-26|2003-01-27|Estimate|||||||2013-06-24|2013-06-26|Estimate|June 1997||1997-06-30|June 2013|2013-06-30|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Computer Planned Radiation Therapy in Treating Patients With Prostate Cancer|A Phase II Study Using High Dose Three Dimensional Conformal Radiation Therapy in Intermediate Prognostic Risk Patients With Adenocarcinoma of the Prostate|Completed||Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:46.638811|2018-06-01 05:28:46.638811
NCT00003096|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-05|2003-01-26|2003-01-27|Estimate|||||||2014-08-05|2014-08-06|Estimate|December 1996||1996-12-31|August 2014|2014-08-31|March 2007|Actual|2007-03-31|March 2006|Actual|2006-03-31||Observational|||Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors|Molecular Biology of Pediatric Brain Tumors|Completed|||88|Actual|Children's Oncology Group|||||f||||f||||||||||2018-06-01 05:28:46.783386|2018-06-01 05:28:46.783386
NCT00003093|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-31|2003-01-26|2003-01-27|Estimate|||||||2014-07-31|2014-08-01|Estimate|March 1988||1988-03-31|July 2014|2014-07-31|January 2011|Actual|2011-01-31|September 2006|Actual|2006-09-30||Interventional|||Combination Chemotherapy in Treating Children With Neuroblastoma|Treatment for Infants and Children With Intermediate Risk Neuroblastoma: A Phase III Intergroup CCG/POG Study|Completed||Phase 3|573|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:28:47.023672|2018-06-01 05:28:47.023672
NCT00003092|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|September 1997||1997-09-30|July 2016|2016-07-31|June 2006|Actual|2006-06-30|March 2006|Actual|2006-03-31||Interventional|||Paclitaxel in Treating Older Patients With Solid Tumors|Clinical Pharmacology of Paclitaxel in Relation to Patient Age|Completed||Phase 3|120|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:28:47.479353|2018-06-01 05:28:47.479353
NCT00003067|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|July 1997||1997-07-31|October 2008|2008-10-31||||||||Interventional|||Biological Therapy in Treating Patients With Primary or Advanced Glioma|Intracavitary Interleukin-2 (IL-2) and Lymphokine-Activated Killer (LAK) Cell Therapy for Malignant Gliomas|Suspended||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:47.729342|2018-06-01 05:28:47.729342
NCT00003065|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-03|2003-01-26|2003-01-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 1997||1997-01-31|September 2003|2003-09-30|February 2004|Actual|2004-02-29|||||Interventional|||Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix|Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix|Completed||Phase 2|25|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:47.824101|2018-06-01 05:28:47.824101
NCT00003063|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|November 1991||1991-11-30|November 2005|2005-11-30||||||||Interventional|||Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer|Adjuvant Chemoimmunotherapy for Colorectal Cancer|Unknown status|Active, not recruiting|Phase 3|1050|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:47.935461|2018-06-01 05:28:47.935461
NCT00003053|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 1994||1994-01-31|January 2008|2008-01-31||||||||Interventional|||Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed|Adjuvant Treatment of Non Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 3|750|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:48.143878|2018-06-01 05:28:48.143878
NCT00003052|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 1997||1997-07-31|November 2006|2006-11-30|June 2010|Actual|2010-06-30|||||Interventional|||Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma|Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults|Completed||Phase 3|340|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:48.343431|2018-06-01 05:28:48.343431
NCT00003049|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-20|2003-01-26|2003-01-27|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 1997||1997-05-31|May 2011|2011-05-31|July 2007|Actual|2007-07-31|August 2005|Actual|2005-08-31||Interventional|||Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas|A Prospective, Randomized Trial of Extended Lymphadenectomy in the Management of Resectable Pancreatic Cancer|Completed||Phase 3|100|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-06-01 05:28:48.460242|2018-06-01 05:28:48.460242
NCT00003042|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-09-26|2003-01-26|2003-01-27|Estimate|||||||2017-09-26|2017-09-27|Actual|May 1997||1997-05-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer|Dose-Intense Chemotherapy and Stem Cell Rescue in the Treatment of Inflammatory Breast Carcinoma|Active, not recruiting||Phase 2|60|Anticipated|City of Hope Medical Center||2|||f||||||||||||||2018-06-01 05:28:48.576558|2018-06-01 05:28:48.576558
NCT00003034|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-11-05|2003-01-26|2003-01-27|Estimate|||||||2013-11-05|2013-11-06|Estimate|May 1997||1997-05-31|October 2007|2007-10-31||||February 2008|Anticipated|2008-02-29||Interventional|||ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen|ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:28:48.705426|2018-06-01 05:28:48.705426
NCT00003029|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-01-26|2003-01-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|May 1997||1997-05-31|June 2012|2012-06-30||||July 2003|Actual|2003-07-31||Interventional|||Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas|Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial.|Completed||Phase 3|200|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:28:48.839751|2018-06-01 05:28:48.839751
NCT00003027|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-28|2003-01-26|2003-01-27|Estimate|||||||2010-01-28|2010-01-29|Estimate|October 1997||1997-10-31|January 2010|2010-01-31||||July 2007|Actual|2007-07-31||Interventional|||Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma|A Randomized Phase III Trial of Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, IL-2 and Interferon A-2B Versus Cisplatin, Vinblastine, Dacarbazine Alone in Patients With Metastatic Malignant Melanoma|Completed||Phase 3|482|Anticipated|Eastern Cooperative Oncology Group|||||f||||t||||||||||2018-06-01 05:28:49.038813|2018-06-01 05:28:49.038813
NCT00003026|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-01-26|2003-01-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|April 1997||1997-04-30|June 2012|2012-06-30||||September 2001|Actual|2001-09-30||Interventional|||Hormone Therapy in Treating Patients With Advanced Prostate Cancer|Long Term Adjuvant Hormonal Treatment With LHRH Analogue Versus No Further Treatment in Locally Advanced Prostatic Carcinoma Treated by External Irradiation and a Six Months Combined Androgen Blockade - A Phase III Study|Completed||Phase 3|966|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:28:49.227529|2018-06-01 05:28:49.227529
NCT00003023|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-17|2003-01-26|2003-01-27|Estimate|||||||2013-01-17|2013-01-18|Estimate|March 1997||1997-03-31|January 2013|2013-01-31||||January 2005|Actual|2005-01-31||Interventional|||Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer|Phase I Trial of A1G4 Anti-Idiotypic Monoclonal Antibody With Bacille-Calmette-Guerin (BCG) Adjuvant in High Risk Patients With GD2 Positive Tumors|Completed||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:49.438462|2018-06-01 05:28:49.438462
NCT00003022|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2003-01-26|2003-01-27|Estimate|||||||2013-07-01|2013-07-03|Estimate|April 1997||1997-04-30|July 2013|2013-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer|Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms|Completed||Phase 1|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:49.541306|2018-06-01 05:28:49.541306
NCT00003016|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 1995||1995-10-31|October 2002|2002-10-31||||||||Interventional|||Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer|Reliable Assessment of the Efficacy and Safety of Prolonging the Use of Adjuvant Tamoxifen: A Large, Simple, Randomised Study|Unknown status|Active, not recruiting|Phase 3|20000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:49.677238|2018-06-01 05:28:49.677238
NCT00003013|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-16|2003-01-26|2003-01-27|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 1996||1996-10-31|June 2000|2000-06-30|March 2009|Actual|2009-03-31|||||Interventional|||Chemotherapy Plus Surgery in Treating Women With Breast Cancer|European Cooperative Study of Chemotherapy and Surgery Comparing Adjuvant Doxorubicin Followed by CMF vs. Adjuvant Doxorubicin/Paclitaxel Followed by CMF vs. Primary Doxorubicin/Paclitaxel Followed by CMF in Women With Operable Breast Cancer and T>2 cm|Completed||Phase 3|450|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:49.791637|2018-06-01 05:28:49.791637
NCT00002996|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-26|2003-01-26|2003-01-27|Estimate|||||||2010-01-26|2010-01-28|Estimate|February 1998||1998-02-28|January 2010|2010-01-31||||April 2006|Actual|2006-04-30||Interventional|||Flecainide in Treating Patients With Chronic Neuropathic Pain|Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial|Completed||Phase 2|20|Anticipated|Eastern Cooperative Oncology Group|||||f||||f||||||||||2018-06-01 05:28:50.124707|2018-06-01 05:28:50.124707
NCT00002746|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-12-12|2003-01-26|2003-01-27|Estimate|||||||2012-12-12|2012-12-13|Estimate|January 1996||1996-01-31|December 2012|2012-12-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Interleukin-2 in Treating Patients With Myelodysplastic Syndrome|A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)|Completed||Phase 1|24|Actual|University of Washington|||||f||||||||||||||2018-06-01 05:29:06.110474|2018-06-01 05:29:06.110474
NCT00002995|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-12|2003-01-26|2003-01-27|Estimate|||||||2014-02-12|2014-02-14|Estimate|August 1997||1997-08-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|September 2006|Actual|2006-09-30||Interventional|||Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma|Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol|Completed||Phase 3|483|Actual|Children's Oncology Group|||||f||||t||||||||||2018-06-01 05:28:50.363515|2018-06-01 05:28:50.363515
NCT00002990|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-11|2003-01-26|2003-01-27|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 1997||1997-03-31|June 2013|2013-06-30||||April 2005|Actual|2005-04-30||Interventional|||Surgery and BCG in Treating Patients With Bladder Cancer|Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder|Completed||Phase 3|1288|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:28:51.123207|2018-06-01 05:28:51.123207
NCT00002986|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-15|2003-01-26|2003-01-27|Estimate|||||||2013-02-15|2013-02-20|Estimate|February 1997||1997-02-28|February 2013|2013-02-28|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Chemotherapy in Treating Patients With Recurrent Malignant Glioma|Phase I Treatment of Adults With Primary Malignant Glioma With Topotecan (NSC #609699) Plus BCNU (NSC #409962)|Completed||Phase 1|36|Anticipated|Duke University|||||f||||||||||||||2018-06-01 05:28:51.50376|2018-06-01 05:28:51.50376
NCT00002982|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2003-01-26|2003-01-27|Estimate|||||||2013-07-01|2013-07-03|Estimate|January 1997||1997-01-31|July 2013|2013-07-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma|A Phase II Trial of ICE Chemotherapy Followed by High Dose BEAM Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients >= 60 Years Old With Refractory or Relapsed Intermediate Grade Non-Hodgkin's Lymphoma|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:28:52.033959|2018-06-01 05:28:52.033959
NCT00002981|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-01-19|2003-01-26|2003-01-27|Estimate|||||||2018-01-19|2018-01-23|Actual|January 1997||1997-01-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||PET Scan in Treating Patients With Metastatic Prostate Cancer|11C-Methionine and 2-18F-Fluoro-2-Deoxy-D-Glucose PET Imaging in Patients With Progressive Prostate Cancer|Active, not recruiting||N/A|173|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:28:52.160787|2018-06-01 05:28:52.160787
NCT00002976|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-10|2003-01-26|2003-01-27|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 1997||1997-06-30|April 2003|2003-04-30||||July 2006|Actual|2006-07-31||Interventional|||Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer|A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma|Terminated||Phase 3|2108|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:28:52.634119|2018-06-01 05:28:52.634119
NCT00002975|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2013-06-28||2013-08-02|2003-01-26|2003-01-27|Estimate|2013-08-02|2013-10-10|Estimate||||2013-08-02|2013-10-10|Estimate|February 1997||1997-02-28|August 2013|2013-08-31|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional||Treated Patients|Photodynamic Therapy in Treating Patients With Skin Cancer|A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses|Completed||Phase 2|180|Actual|Roswell Park Cancer Institute|Study was activated prior to RPCI putting a system in place to centralize data entry and data management. Data entry was done by PI's staff. PI died and left incomplete data. Efficay and safety data were not analyzed.|1|||f||||t||||||||||2018-06-01 05:28:53.138387|2018-06-01 05:28:53.138387
NCT00002968|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-04|2003-01-26|2003-01-27|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 1997||1997-05-31|June 2013|2013-06-30||||July 2003|Actual|2003-07-31||Interventional|||Edrecolomab in Treating Patients With Stage II Colon Cancer|Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon|Completed||Phase 3|2100|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:28:53.427539|2018-06-01 05:28:53.427539
NCT00002963|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-30|2003-01-26|2003-01-27|Estimate|||||||2013-01-30|2013-01-31|Estimate|November 1993||1993-11-30|January 2013|2013-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Photodynamic Therapy in Treating Patients With Skin Cancer|Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy|Completed||Phase 2|||Roswell Park Cancer Institute|||||||||t||||||||||2018-06-01 05:28:53.515431|2018-06-01 05:28:53.515431
NCT00002951|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-04|2003-01-26|2003-01-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 1996||1996-06-30|September 2013|2013-09-30|July 2006|Actual|2006-07-31|June 2004|Actual|2004-06-30||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer|Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck|Completed||Phase 2|53|Actual|University of Chicago||1|||f||||f||||||||||2018-06-01 05:28:53.601608|2018-06-01 05:28:53.601608
NCT00002948|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-01|2003-01-26|2003-01-27|Estimate|||||||2014-07-01|2014-07-02|Estimate|October 1996||1996-10-31|July 2014|2014-07-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer|A Phase I Study of High Dose Topotecan With Filgrastim and Peripheral Blood Stem Cell Support for Patients With Refractory Malignancies|Terminated||Phase 1|||Yale University|||||f||||f||||||||||2018-06-01 05:28:53.823908|2018-06-01 05:28:53.823908
NCT00002944|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-06|2003-01-26|2003-01-27|Estimate|||||||2013-09-06|2013-09-09|Estimate|April 1997||1997-04-30|September 2013|2013-09-30|April 2012|Actual|2012-04-30|February 2006|Actual|2006-02-28||Interventional|||Combination Chemotherapy in Treating Children With Progressive Brain Tumors|Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old|Completed||Phase 3|428|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-06-01 05:28:53.957279|2018-06-01 05:28:53.957279
NCT00002943|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2017-01-18|2003-01-26|2003-01-27|Estimate|||||||2017-01-18|2017-01-19|Estimate|February 1993||1993-02-28|July 2012|2012-07-31|August 2007|Actual|2007-08-31|October 2003|Actual|2003-10-31||Interventional|||Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer|High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study|Completed||Phase 2|11|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-06-01 05:28:55.595697|2018-06-01 05:28:55.595697
NCT00002941|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-31|2003-01-26|2003-01-27|Estimate|||||||2014-07-31|2014-08-01|Estimate|April 1998||1998-04-30|July 2014|2014-07-31|March 2007|Actual|2007-03-31|November 2002|Actual|2002-11-30||Interventional|||Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma|A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, BCNU, and Etoposide (CBV) for Recurrent and Primarily Refractory Hodgkin's and Non-Hodgkin's Lymphoma|Completed||Phase 2|69|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:28:55.841672|2018-06-01 05:28:55.841672
NCT00002938|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-01|2003-01-26|2003-01-27|Estimate|||||||2016-07-01|2016-07-06|Estimate|May 1997||1997-05-31|July 2016|2016-07-31|January 2010|Actual|2010-01-31|February 2005|Actual|2005-02-28||Interventional|||Surgery in Treating Patients With Prostate Cancer|The Role of Salvage Prostatectomy for Radiation Failure in Prostate Carcinoma: A Phase II Trial|Completed||Phase 2|49|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:28:56.461838|2018-06-01 05:28:56.461838
NCT00002931|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-11-04||2017-01-06|2003-01-26|2003-01-27|Estimate|2016-11-04|2017-01-04|Estimate||||2017-01-06|2017-02-23|Actual|February 1997||1997-02-28|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer|Tandem High-Dose Chemotherapy With Autologous Stem Cell Rescue for Poor-Prognosis Germ Cell Cancer|Completed||Phase 2|48|Actual|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 05:28:56.709819|2018-06-01 05:28:56.709819
NCT00002926|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-05-26|2003-01-26|2003-01-27|Estimate|||||||2010-05-26|2010-05-27|Estimate|December 1996||1996-12-31|May 2001|2001-05-31||||||||Interventional|||Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia|Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration|Unknown status|Active, not recruiting|Phase 3|80|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:57.125343|2018-06-01 05:28:57.125343
NCT00002920|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-30|2003-01-26|2003-01-27|Estimate|||||||2012-10-30|2012-10-31|Estimate|March 1997||1997-03-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2006|Actual|2006-12-31||Interventional|||S9630, Medroxyprogesterone in Treating Women With Breast Cancer|A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III|Completed||Phase 3|313|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:28:57.353713|2018-06-01 05:28:57.353713
NCT00002916|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-01-26|2003-01-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|November 1996||1996-11-30|June 2012|2012-06-30||||||||Interventional|||Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer|A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins|Completed||Phase 2|44|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:28:57.705977|2018-06-01 05:28:57.705977
NCT00002913|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-23|2003-01-26|2003-01-27|Estimate|||||||2013-01-23|2013-01-24|Estimate|December 1996||1996-12-31|January 2013|2013-01-31||||July 2007|Actual|2007-07-31||Interventional|||Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer|PHASE I STUDY OF PACLITAXEL COMBINED WITH TOPOTECAN AND CISPLATIN AND G-CSF IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN EPITHELIAL MALIGNANCIES|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-06-01 05:28:57.841457|2018-06-01 05:28:57.841457
NCT00002900|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-10-15|2003-01-26|2003-01-27|Estimate|||||||2015-10-15|2015-10-19|Estimate|February 1997||1997-02-28|October 2015|2015-10-31||||March 2008|Actual|2008-03-31||Observational|||SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial|A STUDY OF THE LATE CARDIAC EFFECTS OF TWO DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENTS IN WOMEN WITH NODE NEGATIVE BREAST CANCER TREATED ON SWOG-8897|Completed|||180|Actual|Southwest Oncology Group|||||f||||||||||||||2018-06-01 05:28:58.020053|2018-06-01 05:28:58.020053
NCT00002899|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-01-26|2003-01-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|November 1996||1996-11-30|June 2012|2012-06-30||||November 2007|Actual|2007-11-30||Interventional|||Adjuvant Radiation Therapy in Treating Patients With Brain Metastases|Phase III Trial on Convergent Beam Irradiation of Cerebral Metastases|Terminated||Phase 3|340|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||||Low accrual|f||||||||||||||2018-06-01 05:28:58.313835|2018-06-01 05:28:58.313835
NCT00002898|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 1995||1995-01-31|May 1999|1999-05-31|December 2009|Actual|2009-12-31|||||Interventional|||Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma|MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood|Completed||Phase 3|400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:58.484126|2018-06-01 05:28:58.484126
NCT00002895|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-03|2003-01-26|2003-01-27|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 1996||1996-06-30|September 2005|2005-09-30|October 2010|Actual|2010-10-31|||||Interventional|||Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer|A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators|Completed||Phase 3|1400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:58.607317|2018-06-01 05:28:58.607317
NCT00002894|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 1996||1996-03-31|February 2001|2001-02-28|June 2003|Actual|2003-06-30|||||Interventional|||Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer|A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER|Completed||Phase 3|800|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:58.716205|2018-06-01 05:28:58.716205
NCT00002883|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-02-06|2003-01-26|2003-01-27|Estimate|||||||2009-02-06|2009-02-09|Estimate|October 1996||1996-10-31|April 2001|2001-04-30||||||||Interventional|||Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus|A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION|Unknown status|Active, not recruiting|Phase 3|250|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:28:58.919109|2018-06-01 05:28:58.919109
NCT00002882|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-12-12|2003-01-26|2003-01-27|Estimate|||||||2011-12-12|2011-12-13|Estimate|November 1995||1995-11-30|December 2011|2011-12-31|April 2006|Actual|2006-04-30|August 2003|Actual|2003-08-31||Interventional|||Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma|Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2|Completed||Phase 3|140|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-06-01 05:28:59.033839|2018-06-01 05:28:59.033839
NCT00002874|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-06-06||2017-07-18|2003-01-26|2003-01-27|Estimate|2017-07-18|2017-08-18|Actual||||2017-07-18|2017-08-18|Actual|February 1998||1998-02-28|July 2017|2017-07-31||||August 2015|Actual|2015-08-31||Interventional||Eligible patients who have not withdrawn|Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy|A PHASE III TRIAL OF RADIATION THERAPY WITH OR WITHOUT CASODEX IN PATIENTS WITH PSA ELEVATION FOLLOWING RADICAL PROSTATECTOMY FOR pT3N0 CARCINOMA OF THE PROSTATE|Active, not recruiting||Phase 3|840|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:28:59.237069|2018-06-01 05:28:59.237069
NCT00002860|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-01-11|2003-01-26|2003-01-27|Estimate|||||||2012-01-11|2012-01-13|Estimate|November 1996||1996-11-30|January 2012|2012-01-31|December 2010|Actual|2010-12-31|December 2006|Actual|2006-12-31||Interventional|||SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma|A Phase II Trial of Complete Surgical Resection For Stage IV Melanoma -- Surgical Resection With Biological Evaluation and Clinical Follow-Up|Completed||Phase 2|77|Actual|Southwest Oncology Group||1|||f||||f||||||||||2018-06-01 05:29:00.254009|2018-06-01 05:29:00.254009
NCT00002855|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-07-27|2003-01-26|2003-01-27|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 1996||1996-08-31|July 2012|2012-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer|A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate|Completed||Phase 3|306|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:29:00.487257|2018-06-01 05:29:00.487257
NCT00002854|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-08-24|2003-01-26|2003-01-27|Estimate|||||||2015-08-24|2015-08-26|Estimate|December 1994||1994-12-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer|PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT|Completed||Phase 1|33|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-06-01 05:29:00.759966|2018-06-01 05:29:00.759966
NCT00002852|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-02|2003-01-26|2003-01-27|Estimate|||||||2013-07-02|2013-07-03|Estimate|October 1996||1996-10-31|July 2013|2013-07-31||||July 2004|Actual|2004-07-31||Interventional|||Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer|A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG|Completed||Phase 3|500|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:29:00.903804|2018-06-01 05:29:00.903804
NCT00002851|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-01-28|2003-01-26|2003-01-27|Estimate|||||||2010-01-28|2010-01-29|Estimate|July 1996||1996-07-31|December 2004|2004-12-31||||||||Interventional|||Lymph Node Radiation Therapy in Patients With Stage I, Stage II, or Stage III Breast Cancer That Has Been Surgically Removed|PHASE III RANDOMISED TRIAL INVESTIGATING THE ROLE OF INTERNAL MAMMARY AND MEDIAL SUPRACLAVICULAR (IM-MS) LYMPH NODE CHAIN IRRADIATION IN STAGE I-III BREAST CANCER|Unknown status|Active, not recruiting|Phase 3|4000|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:01.050731|2018-06-01 05:29:01.050731
NCT00002850|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2014-07-10||2015-10-13|2003-01-26|2003-01-27|Estimate|2015-02-11|2015-02-13|Estimate||||2015-10-13|2015-11-11|Estimate|March 1997||1997-03-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional||Patients with symptomatic and untreated MM receiving chemotherapy without an active infection during the 7 days prior to initiation of chemotherapy and off antibiotics for the prior 7 days were eligable for this study. They were required to receive myelosuppressive and/or immunosuppressive chemotherapy, and were randomized on a 1:1 basis.|Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy|Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma|Completed||Phase 3|212|Actual|University of Rochester||3|||f||||t||||||||||2018-06-01 05:29:01.294771|2018-06-01 05:29:01.294771
NCT00002849|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-03-05|2003-01-26|2003-01-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 1996||1996-11-30|March 2015|2015-03-31|July 2000|Actual|2000-07-31|December 1998|Actual|1998-12-31||Interventional|||S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis|Phase II Study of Dexamethasone/Alpha-Interferon in AL Amyloidosis|Completed||Phase 2|93|Actual|Southwest Oncology Group||1|||f||||t||||||||||2018-06-01 05:29:02.076462|2018-06-01 05:29:02.076462
NCT00002848|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-04|2003-01-26|2003-01-27|Estimate|||||||2013-03-04|2013-03-05|Estimate|April 1997||1997-04-30|March 2013|2013-03-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Group Therapy Compared With Educational Materials in Patients With Prostate Cancer|SUPPORTIVE-EXPRESSIVE GROUP THERAPY FOR MEN WITH PRIMARY PROSTATE CANCER|Completed||N/A|480|Anticipated|University of Rochester|||||f||||f||||||||||2018-06-01 05:29:02.357968|2018-06-01 05:29:02.357968
NCT00002847|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 1995||1995-09-30|December 2003|2003-12-31||||||||Interventional|||Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 AND INTERFERON ALPHA|Unknown status|Active, not recruiting|Phase 2|14|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:02.490147|2018-06-01 05:29:02.490147
NCT00002846|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 1995||1995-09-30|December 2003|2003-12-31||||||||Interventional|||Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer|TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH LOW-DOSE INTRAVENOUS RECOMBINANT INTERLEUKIN-2|Unknown status|Active, not recruiting|Phase 2|14|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:02.617664|2018-06-01 05:29:02.617664
NCT00002842|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2017-02-28||2017-02-28|2003-01-26|2003-01-27|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|September 1994||1994-09-30|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer|Hepatic Resection Followed by Concurrent Adjuvant Portal Vein Infusion of Fluorodeoxyuridine and Systemic 5-Fluorouracil and Folinic Acid for Metastatic Colorectal Carcinoma|Completed||Phase 2|49|Actual|City of Hope Medical Center||1|||f||||||||||||||2018-06-01 05:29:02.756207|2018-06-01 05:29:02.756207
NCT00002839|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-07|2003-01-26|2003-01-27|Estimate|||||||2013-01-07|2013-01-08|Estimate|July 1996||1996-07-31|January 2013|2013-01-31||||May 2004|Actual|2004-05-31||Interventional|||Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx|PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS|Completed||Phase 3|564|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:29:03.123041|2018-06-01 05:29:03.123041
NCT00002810|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-30|2003-01-26|2003-01-27|Estimate|||||||2010-09-30|2010-10-01|Estimate|May 1996||1996-05-31|September 2010|2010-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis|Autologous Peripheral Blood Stem Cell Transplantation With High Dose Melphalan For Treatment Of Primary Amyloidosis (AL)|Completed||Phase 2|||Temple University|||||f||||||||||||||2018-06-01 05:29:03.259358|2018-06-01 05:29:03.259358
NCT00002809|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-30|2003-01-26|2003-01-27|Estimate|||||||2010-09-30|2010-10-01|Estimate|August 1996||1996-08-31|September 2010|2010-09-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer|Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States|Completed||Phase 2|10|Anticipated|Temple University|||||f||||||||||||||2018-06-01 05:29:03.331147|2018-06-01 05:29:03.331147
NCT00002807|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-11-25|2003-01-26|2003-01-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 1996||1996-07-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|March 2007|Actual|2007-03-31||Interventional|||Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery|A Phase III Randomized Trial Comparing TAH BSO Versus TAH BSO Plus Adjuvant Pelvic Irradiation in Intermediate Risk Carcinoma of the Endometrium|Completed||Phase 3|116|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:29:03.42777|2018-06-01 05:29:03.42777
NCT00002798|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-24|||2013-01-15|2003-01-26|2003-01-27|Estimate|||||||2013-01-15|2013-01-16|Estimate|August 1996||1996-08-31|January 2013|2013-01-31||||September 2006|Actual|2006-09-30||Interventional|||Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)|Completed||Phase 3|880|Actual|National Cancer Institute (NCI)||5|||f||||||||||||||2018-06-01 05:29:03.593117|2018-06-01 05:29:03.593117
NCT00002796|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-01-31|2003-01-26|2003-01-27|Estimate|||||||2013-01-31|2013-02-01|Estimate|May 1997||1997-05-31|January 2013|2013-01-31||||December 2004|Actual|2004-12-31||Interventional|||Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer|Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate, Indomethacin and Recombinant Human Interferon-Gamma in Advanced Colorectal Cancer|Terminated||Phase 1/Phase 2|46|Actual|National Cancer Institute (NCI)||1||Administratively complete.|f||||||||||||||2018-06-01 05:29:03.731369|2018-06-01 05:29:03.731369
NCT00002792|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-03-31|2003-01-26|2003-01-27|Estimate|||||||2010-03-31|2010-04-02|Estimate|June 1996||1996-06-30|March 2010|2010-03-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders|ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS|Completed||Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||||||||||||2018-06-01 05:29:03.879709|2018-06-01 05:29:03.879709
NCT00002778|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-07-19|2003-01-26|2003-01-27|Estimate|||||||2011-07-19|2011-07-20|Estimate|February 1995||1995-02-28|April 2011|2011-04-30|July 2010|Actual|2010-07-31|February 2005|Actual|2005-02-28||Interventional|||Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia|GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (Rhu-GM-CSF) FOR REDUCTION OF LEUKEMIC RELAPSE AFTER T-LYMPHOCYTE DEPLETED ALLOGENEIC BMT FOR CHRONIC MYELOID LEUKEMIA|Terminated||Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||subject accrual and data analysis is completed.|f||||||||||||||2018-06-01 05:29:04.067695|2018-06-01 05:29:04.067695
NCT00002771|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|January 1995||1995-01-31|July 2000|2000-07-31||||||||Interventional|||Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia|PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML|Unknown status|Active, not recruiting|Phase 3|750|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:04.225601|2018-06-01 05:29:04.225601
NCT00002766|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2015-12-17||2016-01-25|2003-01-26|2003-01-27|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|March 1996||1996-03-31|January 2016|2016-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma|"A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol"|Completed||Phase 3|170|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-06-01 05:29:04.402054|2018-06-01 05:29:04.402054
NCT00002762|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-11|2003-01-26|2003-01-27|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 1996||1996-06-30|July 2016|2016-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer|MENSTRUAL CYCLE AND SURGICAL TREATMENT OF BREAST CANCER|Completed|||1118|Actual|Alliance for Clinical Trials in Oncology|||1||f||||t||||||||||2018-06-01 05:29:05.32221|2018-06-01 05:29:05.32221
NCT00002757|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2003-01-26|2003-01-27|Estimate|||||||2014-07-23|2014-07-24|Estimate|June 2001||2001-06-30|July 2014|2014-07-31|October 2009|Actual|2009-10-31|October 2003|Actual|2003-10-31||Interventional|||TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma|FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study|Completed||Phase 3|1148|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-06-01 05:29:05.521037|2018-06-01 05:29:05.521037
NCT00002756|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-02-12|2003-01-26|2003-01-27|Estimate|||||||2014-02-12|2014-02-14|Estimate|June 1996||1996-06-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|September 2007|Actual|2007-09-30||Interventional|||Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia|Induction Intensification in Infant ALL: A Children's Oncology Group Study|Completed||Phase 2|221|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:29:05.762622|2018-06-01 05:29:05.762622
NCT00002738|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-03-06|2003-01-26|2003-01-27|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 1996||1996-01-31|March 2013|2013-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma|Phase II Trial of Trimetrexate and Leucovorin in The Treatment of Recurrent Childhood Acute Lymphoblastic Leukemia|Completed||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:29:06.217963|2018-06-01 05:29:06.217963
NCT00002727|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-12-30|2003-01-26|2003-01-27|Estimate|||||||2016-12-30|2017-01-04|Estimate|April 1996||1996-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2005|Actual|2005-10-31||Interventional|||Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord|A RANDOMIZED STUDY OF HYPERFRACTIONATION VERSUS CONVENTIONAL FRACTIONATION IN T2 SQUAMOUS CELL CARCINOMA OF THE VOCAL CORD|Completed||Phase 3|250|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:29:06.388032|2018-06-01 05:29:06.388032
NCT00002720|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 1995||1995-12-31|August 2000|2000-08-31|December 2012|Actual|2012-12-31|||||Interventional|||Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer|QUADRANTECTOMY PLUS AXILLARY DISSECTION VERSUS QUADRANTECTOMY ALONE IN MAMMOGRAPHIC STAGE T1N0 BREAST CANCER PATIENTS AGED OVER 65 YEARS|Completed||Phase 3|642|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:06.879138|2018-06-01 05:29:06.879138
NCT00002718|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-12-21|2003-01-26|2003-01-27|Estimate|||||||2015-12-21|2015-12-23|Estimate|November 1995||1995-11-30|December 2015|2015-12-31|October 2008|Actual|2008-10-31|January 2004|Actual|2004-01-31||Interventional|||T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia|A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor|Completed||Phase 2|31|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:29:07|2018-06-01 05:29:07
NCT00002716|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|January 1996||1996-01-31|July 2016|2016-07-31|August 2006|Actual|2006-08-31|March 2006|Actual|2006-03-31||Interventional|||Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer|PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER|Completed||Phase 3|135|Actual|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-06-01 05:29:07.143167|2018-06-01 05:29:07.143167
NCT00002715|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2009-07-01|2003-01-26|2003-01-27|Estimate|||||||2009-07-01|2009-07-02|Estimate|April 1989||1989-04-30|June 2009|2009-06-30||||||||Interventional|||Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma|A PHASE II PILOT STUDY OF SHORT TERM (12 WEEK) COMBINATION CHEMOTHERAPY (STANFORD V) IN UNFAVORABLE HODGKIN'S DISEASE|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:07.608655|2018-06-01 05:29:07.608655
NCT00002706|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-05-27|2003-01-26|2003-01-27|Estimate|||||||2015-05-27|2015-05-29|Estimate|April 1996||1996-04-30|May 2015|2015-05-31||||March 2010|Actual|2010-03-31||Interventional|||Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus|A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III|Completed||Phase 3|2616|Actual|Gynecologic Oncology Group||2|||f||||||||||||||2018-06-01 05:29:07.738467|2018-06-01 05:29:07.738467
NCT00002702|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-23|2003-01-26|2003-01-27|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 1992||1992-09-30|February 2011|2011-02-28||||||||Interventional|||Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx|Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx|Unknown status|Recruiting|Phase 3|260|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:07.902853|2018-06-01 05:29:07.902853
NCT00002700|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-11|2003-01-26|2003-01-27|Estimate|||||||2013-06-11|2013-06-12|Estimate|August 1995||1995-08-31|June 2013|2013-06-30||||March 2004|Actual|2004-03-31||Interventional|||Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia|A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4)|Completed||Phase 3|392|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:29:08.014996|2018-06-01 05:29:08.014996
NCT00002697|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-01|2003-01-26|2003-01-27|Estimate|||||||2013-07-01|2013-07-03|Estimate|September 1995||1995-09-30|July 2013|2013-07-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|HIGH DOSE CHEMORADIOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR PATIENTS WITH PRIMARY REFRACTORY, RELAPSED AND POOR PROGNOSIS NON-HODGKIN'S LYMPHOMA|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:29:08.261294|2018-06-01 05:29:08.261294
NCT00002696|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|October 1995||1995-10-31|April 2008|2008-04-30||||||||Interventional|||Combination Chemotherapy in Treating Women With Stage III Breast Cancer|MULTIMODALITY TREATMENT STRATEGY FOR STAGE III BREAST CANCER|Suspended||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:08.353554|2018-06-01 05:29:08.353554
NCT00002689|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-17|2003-01-26|2003-01-27|Estimate|||||||2013-07-17|2013-07-18|Estimate|September 1995||1995-09-30|June 2007|2007-06-30|June 2007|Actual|2007-06-30|||||Interventional|||Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer|Phase II Interstitial Colloidal 32P Integrated in The Treatment of Non-Resectable Pancreatic Cancer|Completed||Phase 2|48|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:08.53747|2018-06-01 05:29:08.53747
NCT00002687|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-30|2003-01-26|2003-01-27|Estimate|||||||2012-11-30|2012-12-04|Estimate|February 1995||1995-02-28|November 2012|2012-11-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Interleukin-2 in Treating Patients With Mycosis Fungoides|Phase 1 Trial of Subcutaneous [SC]; Outpatient Interleukin-2 for Patients With Advanced Mycosis Fungoides [Stage IIb, III, IV]|Completed||Phase 1|30|Anticipated|University of Washington|||||f||||||||||||||2018-06-01 05:29:08.706535|2018-06-01 05:29:08.706535
NCT00002684|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-02|2003-01-26|2003-01-27|Estimate|||||||2013-07-02|2013-07-03|Estimate|May 1995||1995-05-31|July 2013|2013-07-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer|Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors|Completed||Phase 2|40|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:29:08.801827|2018-06-01 05:29:08.801827
NCT00002681|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-06-09|2003-01-26|2003-01-27|Estimate|||||||2011-06-09|2011-06-10|Estimate|July 1995||1995-07-31|June 2011|2011-06-30|December 2003|Actual|2003-12-31|September 2003|Actual|2003-09-30||Interventional|||Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma|Humanized Anti-Tac Antibody Therapy In Hodgkin's Disease, A Phase Ib/II Trial|Completed||Phase 1/Phase 2|25|Anticipated|Roger Williams Medical Center|||||f||||||||||||||2018-06-01 05:29:08.924863|2018-06-01 05:29:08.924863
NCT00002678|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-09-20|2003-01-26|2003-01-27|Estimate|||||||2012-09-20|2012-09-24|Estimate|May 1995||1995-05-31|September 2011|2011-09-30|December 2009|Actual|2009-12-31|December 2003|Actual|2003-12-31||Interventional|||Combination Chemotherapy in Treating Patients With Multiple Myeloma|A COMPARATIVE STUDY OF DEXAMETHASONE VERSUS PREDNISONE (BOTH IN COMBINATION WITH MELPHALAN) AS INDUCTION THERAPY IN UNTREATED SYMPTOMATIC MYELOMA WITH AN ADDITIONAL ASSESSMENT OF DEXAMETHASONE VERSUS NO ADDITIONAL TREATMENT AS MAINTENANCE THERAPY IN NON-PROGRESSING PATIENTS|Completed||Phase 3|595|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:29:09.092012|2018-06-01 05:29:09.092012
NCT00002668|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-30|2003-01-26|2003-01-27|Estimate|||||||2012-11-30|2012-12-03|Estimate|October 1995||1995-10-31|November 2012|2012-11-30|September 1998|Actual|1998-09-30|September 1998|Actual|1998-09-30||Interventional|||Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer|PATIENT SKILLS FOR CANCER PAIN CONTROL IN PATIENTS WITH METASTATIC BREAST OR PROSTATE CANCER|Terminated||N/A|13|Actual|Eastern Cooperative Oncology Group||2||Slow accrual|f||||f||||||||||2018-06-01 05:29:09.24252|2018-06-01 05:29:09.24252
NCT00002663|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2018-02-26|2003-01-26|2003-01-27|Estimate|||||||2018-02-26|2018-02-28|Actual|March 1995|Actual|1995-03-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies|An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases|Recruiting||Phase 1/Phase 2|84|Anticipated|Atara Biotherapeutics||1|||t||||||||||||||2018-06-01 05:29:09.440341|2018-06-01 05:29:09.440341
NCT00002662|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 1994||1994-08-31|April 2004|2004-04-30|June 2004|Actual|2004-06-30|||||Interventional|||Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer|PHASE III COMPARISON OF TAXOTERE (DOCETAXEL) AND TAXOL (PACLITAXEL) IN PATIENTS WITH ADVANCED BREAST CANCER|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:09.592717|2018-06-01 05:29:09.592717
NCT00002651|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2016-11-15||2017-03-03|2003-01-26|2003-01-27|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|May 1995||1995-05-31|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Randomized and eligible patients (After induction, Patients with stable or declining PSA levels of 4.0 ng per milliliter or lower at months 6 and 7 were eligible for randomization).|SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer|Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III|Completed||Phase 3|3040|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-06-01 05:29:09.78569|2018-06-01 05:29:09.78569
NCT00002649|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-02-27|2003-01-26|2003-01-27|Estimate|||||||2013-02-27|2013-02-28|Estimate|May 1995||1995-05-31|February 2013|2013-02-28||||November 2006|Actual|2006-11-30||Interventional|||Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma|Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma|Completed||Phase 3|206|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:29:11.370368|2018-06-01 05:29:11.370368
NCT00002647|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-09-19|2003-01-26|2003-01-27|Estimate|||||||2013-09-19|2013-09-20|Estimate|May 1994||1994-05-31|June 2009|2009-06-30||||||||Interventional|||Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors|Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study|Unknown status|Recruiting|Phase 1|24|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:11.563911|2018-06-01 05:29:11.563911
NCT00002641|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-08-07|2003-01-26|2003-01-27|Estimate|||||||2014-08-07|2014-08-08|Estimate|February 1995||1995-02-28|July 2002|2002-07-31|June 2012|Actual|2012-06-30|February 2006|Actual|2006-02-28||Interventional|||Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma|RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA|Completed||Phase 3|350|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:29:11.715951|2018-06-01 05:29:11.715951
NCT00002633|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-01-31|2003-01-26|2003-01-27|Estimate|||||||2014-01-31|2014-02-03|Estimate|March 1995||1995-03-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer|Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate|Completed||Phase 3|361|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-06-01 05:29:12.011923|2018-06-01 05:29:12.011923
NCT00002624|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-07-12|2003-01-26|2003-01-27|Estimate|||||||2016-07-12|2016-07-14|Estimate|December 1994||1994-12-31|July 2016|2016-07-31|August 2005|Actual|2005-08-31|April 2005|Actual|2005-04-30||Interventional|||Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function|VIDEO ASSISTED WEDGE RESECTION (VAR) AND RADIOTHERAPY FOR HIGH RISK T1 NON-SMALL CELL LUNG CANCER: A PHASE II STUDY|Completed||Phase 2|66|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-06-01 05:29:12.171028|2018-06-01 05:29:12.171028
NCT00002623|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-06-29|2003-01-26|2003-01-27|Estimate|||||||2012-06-29|2012-07-02|Estimate|December 1994||1994-12-31|June 2012|2012-06-30||||December 2002|Actual|2002-12-31||Interventional|||Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY|Completed||Phase 3|640|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:29:12.370919|2018-06-01 05:29:12.370919
NCT00002615|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-18|2003-01-26|2003-01-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 1994||1994-06-30|August 2001|2001-08-31|December 2003|Actual|2003-12-31|||||Interventional|||Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer|A RANDOMISED, CONTROLLED TRIAL OF PRE- AND POST-OPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER|Completed||Phase 3|500|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:12.570177|2018-06-01 05:29:12.570177
NCT00002611|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2003-01-26|2003-01-27|Estimate|||||||2014-07-23|2014-07-24|Estimate|July 1995||1995-07-31|July 2014|2014-07-31|August 2003|Actual|2003-08-31|June 2002|Actual|2002-06-30||Interventional|||Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer|NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY|Completed||Phase 3|3031|Actual|Children's Oncology Group||9|||f||||t||||||||||2018-06-01 05:29:12.756738|2018-06-01 05:29:12.756738
NCT00002610|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2003-01-26|2003-01-27|Estimate|||||||2014-07-23|2014-07-25|Estimate|January 1996||1996-01-31|July 2014|2014-07-31|February 2006|Actual|2006-02-28|June 2002|Actual|2002-06-30||Interventional|||Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors|National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study|Completed||Phase 3|203|Actual|Children's Oncology Group||4|||f||||t||||||||||2018-06-01 05:29:13.452787|2018-06-01 05:29:13.452787
NCT00002608|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|May 1994||1994-05-31|May 2005|2005-05-31|April 2005|Actual|2005-04-30|||||Interventional|||Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors|Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies|Completed||Phase 2|30|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:13.875962|2018-06-01 05:29:13.875962
NCT00002598|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-24|2003-01-26|2003-01-27|Estimate|||||||2013-06-24|2013-06-25|Estimate|June 1994||1994-06-30|June 2013|2013-06-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia|A PHASE II STUDY OF MITOXANTRONE AND HIGH-DOSE ARA-C FOLLOWED BY INTENSIVE CONSOLIDATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE FOR MYELOID BLAST CRISIS OF CHRONIC MYELOGENOUS LEUKEMIA (CML)|Completed||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:29:13.944357|2018-06-01 05:29:13.944357
NCT00002596|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-25|2003-01-26|2003-01-27|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 1994||1994-09-30|October 2003|2003-10-31|July 2006|Actual|2006-07-31|||||Interventional|||Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors|RANDOMIZED MULTIINSTITUTIONAL PHASE III TRIAL OF BEP AND HIGH DOSE CHEMOTHERAPY VERSUS BEP ALONE IN PREVIOUSLY UNTREATED PATIENTS WITH POOR RISK GERM CELL TUMORS|Completed||Phase 3|270|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:14.110828|2018-06-01 05:29:14.110828
NCT00002594|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-07-23|2003-01-26|2003-01-27|Estimate|||||||2014-07-23|2014-07-24|Estimate|September 1994||1994-09-30|July 2014|2014-07-31|March 2007|Actual|2007-03-31|September 2003|Actual|2003-09-30||Interventional|||Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors|Dose-Intensive Melphalan and Cyclophosphamide With Autologous Bone Marrow Rescue for Recurrent Medulloblastoma and Germ Cell Tumors|Completed||Phase 2|31|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-06-01 05:29:14.420027|2018-06-01 05:29:14.420027
NCT00002589|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|July 1994||1994-07-31|December 2005|2005-12-31||||||||Interventional|||Lymphocyte Therapy in Treating Patients With Kidney Cancer|Adjuvant Autolymphocyte Therapy (ALT) For Patients With Non-Metastatic Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:14.697931|2018-06-01 05:29:14.697931
NCT00002586|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2014-05-05|2003-01-26|2003-01-27|Estimate|||||||2014-05-05|2014-05-07|Estimate|January 1993||1993-01-31|May 2014|2014-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|13-Cis||13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer|ASSESSMENT OF INTERMEDIATE ENDPOINT BIOMARKERS TO 13-CIS RETINOIC ACID WITH OR WITHOUT ALPHA TOCOPHEROL OR OBSERVATION|Completed||Phase 2|96|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-06-01 05:29:14.763689|2018-06-01 05:29:14.763689
NCT00002569|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2015-11-14|2003-01-26|2003-01-27|Estimate|||||||2015-11-14|2015-11-17|Estimate|July 1994||1994-07-31|November 2015|2015-11-30||||February 2005|Actual|2005-02-28||Interventional|||Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma|Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas|Completed||Phase 3|299|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-06-01 05:29:14.88588|2018-06-01 05:29:14.88588
NCT00002560|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-27|2003-01-26|2003-01-27|Estimate|||||||2013-06-27|2013-06-28|Estimate|February 1994||1994-02-28|June 2013|2013-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma|PHASE II TRIAL OF MONOCLONAL ANTIBODY 3F8 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) FOR NEUROBLASTOMA|Completed||Phase 2|40|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:29:15.093327|2018-06-01 05:29:15.093327
NCT00002558|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|2015-12-21||2016-04-11|2003-01-26|2003-01-27|Estimate|2016-04-11|2016-05-23|Estimate||||2016-04-11|2016-05-23|Estimate|January 1994||1994-01-31|April 2016|2016-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors|PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES|Completed||Phase 1/Phase 2|108|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:29:15.163425|2018-06-01 05:29:15.163425
NCT00002556|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-30|2003-01-26|2003-01-27|Estimate|||||||2013-05-30|2013-05-31|Estimate|July 1994||1994-07-31|May 2013|2013-05-31||||January 2006|Actual|2006-01-31||Interventional|||Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma|The Treatment of Multiple Myeloma Utilizing VBMCP Chemotherapy Alternating With High-Dose Cyclophosphamide and Alpha2b-Interferon Versus VBMCP: A Phase III Study for Previously Untreated Multiple Myeloma|Completed||Phase 3|312|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-06-01 05:29:15.424951|2018-06-01 05:29:15.424951
NCT00002474|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-29|2003-01-26|2003-01-27|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 1991||1991-02-28|March 2003|2003-03-31|October 2005|Actual|2005-10-31|||||Interventional|||Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer|Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:16.946539|2018-06-01 05:29:16.946539
NCT00002546|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-02-10|2003-01-26|2003-01-27|Estimate|||||||2016-02-10|2016-02-11|Estimate|December 1993||1993-12-31|February 2016|2016-02-29||||September 2007|Actual|2007-09-30||Interventional|||Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus|A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus|Completed||Phase 3|216|Anticipated|Gynecologic Oncology Group|||||f||||||||||||||2018-06-01 05:29:15.613787|2018-06-01 05:29:15.613787
NCT00002544|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-01|2003-01-26|2003-01-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 1993||1993-05-31|April 2001|2001-04-30|November 2002|Actual|2002-11-30|||||Interventional|||Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer|MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS|Completed||Phase 3|300|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:15.763371|2018-06-01 05:29:15.763371
NCT00002528|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-04-03|2003-01-26|2003-01-27|Estimate|||||||2013-04-03|2013-04-04|Estimate|May 1993||1993-05-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|December 2002|Actual|2002-12-31||Interventional|10-93||Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I or Stage IIA Breast Cancer|Surgical Therapy With or Without Axillary Node Clearance for Breast Cancer in the Elderly Who Receive Adjuvant Therapy With Tamoxifen.|Completed||Phase 3|473|Actual|International Breast Cancer Study Group||2|||f||||t||||||||||2018-06-01 05:29:15.824682|2018-06-01 05:29:15.824682
NCT00002523|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2016-09-01|2003-01-26|2003-01-27|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 1993||1993-04-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|March 2003|Actual|2003-03-31||Interventional|||Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed|FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY|Completed||Phase 3|1011|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:29:15.955497|2018-06-01 05:29:15.955497
NCT00002522|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-30|2003-01-26|2003-01-27|Estimate|||||||2010-09-30|2010-10-01|Estimate|February 1993||1993-02-28|September 2010|2010-09-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma|HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (CEP) WITH RESCUE BY AUTOLOGOUS BONE MARROW OR AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN'S DISEASE|Completed||Phase 2|||Temple University|||||f||||||||||||||2018-06-01 05:29:16.111929|2018-06-01 05:29:16.111929
NCT00002521|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-09-30|2003-01-26|2003-01-27|Estimate|||||||2010-09-30|2010-10-01|Estimate|February 1993||1993-02-28|September 2010|2010-09-30|February 2000|Actual|2000-02-29|February 2000|Actual|2000-02-29||Interventional|||Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma|HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (CEP) WITH RESCUE BY AUTOLOGOUS BONE MARROW OR AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA (INTERMEDIATE AND HIGH-GRADE HISTOLOGIES)|Completed||Phase 2|||Temple University|||||f||||||||||||||2018-06-01 05:29:16.189928|2018-06-01 05:29:16.189928
NCT00002517|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2010-06-19|2003-01-26|2003-01-27|Estimate|||||||2010-06-19|2010-06-22|Estimate|March 1993||1993-03-31|December 2002|2002-12-31||||May 2010|Actual|2010-05-31||Interventional|||Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome|IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:16.263227|2018-06-01 05:29:16.263227
NCT00002515|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-20|2003-01-26|2003-01-27|Estimate|||||||2013-06-20|2013-06-24|Estimate|October 1992||1992-10-31|June 2013|2013-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer|Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers|Completed||Phase 2|||Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-06-01 05:29:16.359937|2018-06-01 05:29:16.359937
NCT00002514|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-11-21|2003-01-26|2003-01-27|Estimate|||||||2012-11-21|2012-11-22|Estimate|April 1993||1993-04-30|August 2007|2007-08-31||||December 2006|Actual|2006-12-31||Interventional|||Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission|Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission|Completed||Phase 3|1929|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-06-01 05:29:16.470611|2018-06-01 05:29:16.470611
NCT00002511|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2012-10-15|2003-01-26|2003-01-27|Estimate|||||||2012-10-15|2012-10-16|Estimate|December 1992||1992-12-31|October 2012|2012-10-31||||December 2001|Actual|2001-12-31||Interventional|||Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer|PHASE III STUDY OF POST-OPERATIVE EXTERNAL RADIOTHERAPY IN PATHOLOGICAL STAGE T3 N0 PROSTATIC CARCINOMA|Completed||Phase 3|1005|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:29:16.709654|2018-06-01 05:29:16.709654
NCT00002490|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-12-17|2003-01-26|2003-01-27|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 1991||1991-09-30|June 2001|2001-06-30||||||||Interventional|||Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer|A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER|Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:16.763746|2018-06-01 05:29:16.763746
NCT00002484|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-10-31|2003-01-26|2003-01-27|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 1991||1991-10-31|October 2013|2013-10-31||||July 2008|Actual|2008-07-31||Interventional|||Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer|A PHASE I TRIAL OF DOSE ESCALATION OF EXTERNAL BEAM RADIATION THERAPY USING CONFORMAL 3-DIMENSIONAL TREATMENT PLANNING FOR NON-SMALL CELL LUNG CANCER|Completed||Phase 1|104|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-06-01 05:29:16.818139|2018-06-01 05:29:16.818139
NCT00002475|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-07-09|2003-01-26|2003-01-27|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 1991||1991-04-30|November 2008|2008-11-30|June 2009|Actual|2009-06-30|December 2007|Actual|2007-12-31||Interventional|||Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer|A Trial of Active Intralymphatic Immunotherapy With Interferon-Treated Cells and Cyclophosphamide|Completed||Phase 2|40|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:16.878051|2018-06-01 05:29:16.878051
NCT00051870|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2008-03-03|2003-01-16|2003-01-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2003||2003-01-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Brain Encoding for Memory|Role of the Prefrontal Cortex in Successful Memory Encoding|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:20.818226|2018-06-01 05:29:20.818226
NCT00002473|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-06-11|2003-01-26|2003-01-27|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 1992||1992-03-31|June 2013|2013-06-30||||February 2011|Actual|2011-02-28||Interventional|||Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer|A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma|Completed||Phase 3|||European Organisation for Research and Treatment of Cancer - EORTC|||||f||||||||||||||2018-06-01 05:29:17.004414|2018-06-01 05:29:17.004414
NCT00002472|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2011-03-14|2003-01-26|2003-01-27|Estimate|||||||2011-03-14|2011-03-15|Estimate|March 1991||1991-03-31|March 2011|2011-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors|Phase II Pre-Irradiation Chemotherapy for Central Nervous System Germ Cell Malignancies|Completed||Phase 2|||Mayo Clinic|||||f||||||||||||||2018-06-01 05:29:17.061444|2018-06-01 05:29:17.061444
NCT00002470|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-05-14|2003-01-26|2003-01-27|Estimate|||||||2013-05-14|2013-05-15|Estimate|September 1990||1990-09-30|December 2003|2003-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors|A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid|Completed||Phase 2|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:17.123747|2018-06-01 05:29:17.123747
NCT00002455|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-01|||2013-08-06|2003-01-26|2003-01-27|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 1971||1971-04-30|November 1998|1998-11-30||||||||Interventional|||Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma|Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts|Unknown status|Active, not recruiting|Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:29:17.175926|2018-06-01 05:29:17.175926
NCT00052156|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-23|||2005-06-23|2003-01-23|2003-01-24|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2005|2005-04-30||||||||Interventional|||Vaccine Therapy for Patients With Stage IV Melanoma|A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma|Unknown status|Active, not recruiting|Phase 3|670||CancerVax Corporation|||||||||||||||||||2018-06-01 05:29:17.237106|2018-06-01 05:29:17.237106
NCT00052143|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-23|||2009-04-15|2003-01-23|2003-01-24|Estimate|||||||2009-04-15|2009-04-16|Estimate|July 1999||1999-07-31|February 2008|2008-02-29|July 2010|Anticipated|2010-07-31|July 2010|Anticipated|2010-07-31||Observational|PHAROS||Prospective Huntington At Risk Observational Study|Prospective Huntington At Risk Observational Study (PHAROS)|Unknown status|Active, not recruiting||1001|Actual|Huntington Study Group|||||f||||t||||||Samples With DNA|"~     Blood sample~   "|||2018-06-01 05:29:17.523335|2018-06-01 05:29:17.523335
NCT00052130|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-22|||2005-06-23|2003-01-23|2003-01-24|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 2004|2004-09-30||||||||Interventional|||Vaccine Therapy for Patients With Stage III Melanoma|Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma|Unknown status|Active, not recruiting|Phase 3|1118||CancerVax Corporation|||||||||||||||||||2018-06-01 05:29:17.710563|2018-06-01 05:29:17.710563
NCT00051818|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2016-02-08|2003-01-23|2003-01-24|Estimate|||||||2016-02-08|2016-02-09|Estimate|September 2000||2000-09-30|December 2005|2005-12-31|July 2003|Actual|2003-07-31|May 2003|Actual|2003-05-31||Interventional|||Immune and Viral Outcomes of HIV-1 Therapy Interruption|Immune and Viral Outcomes of HIV-1 Therapy Interruption|Completed||Phase 1|20|Actual|The Wistar Institute|||||f||||t||||||||||2018-06-01 05:29:17.909098|2018-06-01 05:29:17.909098
NCT00052117|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-22|||2007-10-05|2003-01-22|2003-01-23|Estimate|||||||2007-10-05|2007-10-10|Estimate|January 2003||2003-01-31|October 2007|2007-10-31|May 2005||2005-05-31|||||Interventional|||Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens|A Phase 2, Randomized, Double-Blind, Dose-Ranging Study Of Capravirine (AG1549) In Combination With Kaletra (Trademark) and At Least 2 Nucleoside Reverse Transcriptase Inhibitors in Hiv-Infected Subjects Who Have Failed Antiretroviral Regimens Containing Protease Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Nucleoside Reverse Transcriptase Inhibitors|Completed||Phase 2|300||Pfizer|||||||||||||||||||2018-06-01 05:29:17.983052|2018-06-01 05:29:17.983052
NCT00052104|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-22|||2013-08-07|2003-01-22|2003-01-23|Estimate|||||||2013-08-07|2013-08-09|Estimate|December 2001||2001-12-31|March 2008|2008-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Telephone-Based Support for Caregivers of Patients With Dementia|A Telephone Intervention for Dementia Caregivers|Completed||Phase 2/Phase 3|85||Rhode Island Hospital|||||f||||||||||||||2018-06-01 05:29:18.059177|2018-06-01 05:29:18.059177
NCT00052091|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-22|||2018-01-25|2003-01-22|2003-01-23|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2002||2002-09-30|January 2018|2018-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Therapy for Depressed Elders With Thought Problems|PST in Geriatric Depression With Executive Dysfunction|Completed||Phase 3|221|Actual|University of Washington||2|||f||||t||||||||Yes||2018-06-01 05:29:18.113405|2018-06-01 05:29:18.113405
NCT00052078|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-22|2016-07-29||2017-08-21|2003-01-22|2003-01-23|Estimate|2017-03-14|2017-04-25|Actual||||2017-08-21|2017-09-19|Actual|January 2003||2003-01-31|August 2017|2017-08-31|March 2008|Actual|2008-03-31|October 2007|Actual|2007-10-31||Interventional|||Child and Adolescent Anxiety Disorders (CAMS)|Child/Adolescent Anxiety Multimodal Treatment Study|Completed||Phase 3|488|Actual|Johns Hopkins University||4|||f||||||||||||Yes||2018-06-01 05:29:18.203382|2018-06-01 05:29:18.203382
NCT00052065|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2011-07-21|2003-01-22|2003-01-23|Estimate|||||||2011-07-21|2011-07-25|Estimate|February 2003||2003-02-28|June 2011|2011-06-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer|Completed||Phase 1/Phase 2|28||Telik|||||f||||||||||||||2018-06-01 05:29:18.569575|2018-06-01 05:29:18.569575
NCT00052052|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2007-11-02|2003-01-22|2003-01-23|Estimate|||||||2007-11-02|2007-11-06|Estimate|September 2002||2002-09-30|November 2007|2007-11-30|September 2004|Actual|2004-09-30|||||Interventional|||An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)|An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.|Completed||Phase 2|210|Actual|InterMune|||||f||||||||||||||2018-06-01 05:29:18.617539|2018-06-01 05:29:18.617539
NCT00052026|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2008-12-24|2003-01-22|2003-01-23|Estimate|||||||2008-12-24|2008-12-25|Estimate|May 2000||2000-05-31|December 2008|2008-12-31|July 2006|Actual|2006-07-31|June 2005|Actual|2005-06-30||Interventional|||Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure|A Multicenter, Placebo-Controlled, 8-Month Study of the Effect of Twice Daily Carvedilol in Children With Congestive Heart Failure Due to Systemic Ventricular Systolic Dysfunction|Completed||Phase 3|161|Actual|Shaddy, Robert, M.D.||3|||f||||t||||||||||2018-06-01 05:29:18.684282|2018-06-01 05:29:18.684282
NCT00052039|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2007-11-02|2003-01-21|2003-01-22|Estimate|||||||2007-11-02|2007-11-06|Estimate|April 2002||2002-04-30|November 2007|2007-11-30|June 2002|Actual|2002-06-30|||||Interventional|||A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone|A Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving Prednisone|Terminated||Phase 3|0|Actual|InterMune||||Study design changes were needed based on GIPF-001 results|f||||||||||||||2018-06-01 05:29:18.781107|2018-06-01 05:29:18.781107
NCT00052013|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2017-03-02|2003-01-21|2003-01-22|Estimate|||||||2017-03-02|2017-03-06|Actual|February 2003||2003-02-28|February 2011|2011-02-28||||June 2006|Actual|2006-06-30||Interventional|||Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584|A Phase II Open-Label Study of Oral, Continuous, Once Daily PTK787/ZK 222584 in Patients With Von Hippel-Lindau Disease (VHL) and Hemangioblastoma (HB)|Completed||Phase 2|11|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:29:18.832926|2018-06-01 05:29:18.832926
NCT00052000|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2007-02-28|2003-01-21|2003-01-22|Estimate|||||||2007-02-28|2007-03-01|Estimate|November 2002||2002-11-30|February 2007|2007-02-28||||||||Interventional|||A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer|A Phase 1 Single Ascending Dose Trial of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen Independent Prostate Cancer|Completed||Phase 1|29||Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 05:29:18.918314|2018-06-01 05:29:18.918314
NCT00051987|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2008-02-07|2003-01-21|2003-01-22|Estimate|||||||2008-02-07|2008-02-11|Estimate|December 2002||2002-12-31|February 2008|2008-02-29||||March 2004|Actual|2004-03-31||Interventional|||Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma|A Randomized, Multicenter, Open-Label, Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma|Completed||Phase 2|175||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:29:18.975004|2018-06-01 05:29:18.975004
NCT00051974|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-21|||2008-02-07|2003-01-21|2003-01-22|Estimate|||||||2008-02-07|2008-02-11|Estimate|December 2002||2002-12-31|February 2008|2008-02-29||||September 2004|Actual|2004-09-30||Interventional|||Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|155||Millennium Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:29:19.043432|2018-06-01 05:29:19.043432
NCT00051948|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-17|||2011-07-21|2003-01-21|2003-01-22|Estimate|||||||2011-07-21|2011-07-25|Estimate|January 2003||2003-01-31|February 2007|2007-02-28|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer|Completed||Phase 1/Phase 2|28||Telik|||||f||||||||||||||2018-06-01 05:29:19.107201|2018-06-01 05:29:19.107201
NCT00051935|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-17|||2014-02-04|2003-01-21|2003-01-22|Estimate|||||||2014-02-04|2014-02-05|Estimate|January 2003||2003-01-31|February 2014|2014-02-28|October 2003|Actual|2003-10-31|April 2003|Actual|2003-04-30||Interventional|||A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II|Open-Label, Pilot Study of the Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Human Acid Alpha-Glucosidase (rhGAA) as Enzyme Replacement Therapy in Siblings With Glycogen Storage Disease Type II (GSD-II).|Completed||Phase 2|2|Actual|Sanofi||1|||f||||||||||||||2018-06-01 05:29:19.156007|2018-06-01 05:29:19.156007
NCT00051922|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-17|||2011-06-06|2003-01-21|2003-01-22|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 1997||1997-10-31|June 2011|2011-06-30|June 2009|Actual|2009-06-30|July 2006|Actual|2006-07-31||Interventional|||Development of a New HIV Vaccine|Evaluation of the Safety of a Polyvalent Vaccinia Virus HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults|Completed||Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:29:19.211911|2018-06-01 05:29:19.211911
NCT00051961|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-17|||2017-06-30|2003-01-17|2003-01-20|Estimate|||||||2017-06-30|2017-07-02|Actual|January 14, 2003||2003-01-14|October 18, 2007|2007-10-18|October 18, 2007||2007-10-18|||||Observational|||Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome|Effects of Dopaminergic Agonist Treatment on Spinal Cord Excitability in Restless Legs Syndrome|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:20.241839|2018-06-01 05:29:20.241839
NCT00051909|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-17|||2006-07-18|2003-01-17|2003-01-20|Estimate|||||||2006-07-18|2006-07-19|Estimate|November 2002||2002-11-30|July 2006|2006-07-31|June 2003||2003-06-30|||||Interventional|||Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease|Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease|Completed||Phase 2|200||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:29:20.297801|2018-06-01 05:29:20.297801
NCT00051896|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-17|||2017-01-10|2003-01-17|2003-01-20|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2002||2002-08-31|March 2005|2005-03-31||||||||Interventional|||Assessment of the Potential Interactions Between Cocaine and GBR 12909 - 1|Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers|Unknown status|Active, not recruiting|Phase 1|24||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:29:20.366077|2018-06-01 05:29:20.366077
NCT00051883|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-17|||2017-01-11|2003-01-17|2003-01-20|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 1999||1999-12-31|October 2016|2016-10-31|February 2005|Actual|2005-02-28|||||Observational|||Chemical Dependency and Smoking Cessation: Patient's Views - 1|Chemical Dependency and Smoking Cessation: Patient's Views|Completed|||125|Actual|National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 05:29:20.422774|2018-06-01 05:29:20.422774
NCT00051844|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2011-05-09|2003-01-17|2003-01-20|Estimate|||||||2011-05-09|2011-05-10|Estimate|August 2002||2002-08-31|May 2011|2011-05-31|November 2004|Actual|2004-11-30|||||Interventional|||Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen|A Double Blind- Randomized, Placebo-controlled Study of Two Doses of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Patients Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen|Completed||Phase 2|179|Actual|Pfizer|||||||||||||||||||2018-06-01 05:29:20.488546|2018-06-01 05:29:20.488546
NCT00051831|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2015-05-29|2003-01-17|2003-01-20|Estimate|||||||2015-05-29|2015-06-02|Estimate|October 2003||2003-10-31|May 2015|2015-05-31|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults|A Pilot Study to Measure the Clearance of Replication-Competent HIV-1 in Resting Memory CD4+ Cells in HIV-1-Infected Subjects Who Receive Enfuvirtide Plus Oral Combination Antiretroviral Therapy|Completed||N/A|19|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:29:20.699685|2018-06-01 05:29:20.699685
NCT00051779|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2005-06-23|2003-01-16|2003-01-17|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2004|2004-02-29||||||||Interventional|||An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer|A 24-Week Blinded Study Conducted at Multiple Centers, Evaluating the Safety and Effectiveness of Various Doses of the Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) When Randomly Assigned to Patients With Breast Cancer That Has Metastasized to Bone|Completed||Phase 1|||Chugai Pharma USA|||||||||||||||||||2018-06-01 05:29:21.128953|2018-06-01 05:29:21.128953
NCT00051766|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2005-06-23|2003-01-16|2003-01-17|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 2005|2005-05-31||||||||Interventional|||Computer-Assisted Adherence Program for Patients Taking Anti-HIV Drugs|A Computer-Based HIV Medication Adherence Intervention|Terminated||N/A|200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:29:21.223949|2018-06-01 05:29:21.223949
NCT00051753|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-16|||2011-01-07|2003-01-16|2003-01-17|Estimate|||||||2011-01-07|2011-01-10|Estimate|November 2002||2002-11-30|January 2011|2011-01-31|May 2005|Actual|2005-05-31|||||Interventional|||Levofloxacin In The Treatment Of Children With Recurrent And/or Persistent Acute Otitis Media|A Multicenter, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Levofloxacin in the Treatment of Children Who Have Recurrent and/or Persistent Acute Otitis Media|Completed||Phase 3|1643|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:29:21.27322|2018-06-01 05:29:21.27322
NCT00051740|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-15|||2013-04-05|2003-01-16|2003-01-17|Estimate|||||||2013-04-05|2013-04-09|Estimate|February 2002||2002-02-28|April 2013|2013-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Treating Thought Problems in Patients With Schizophrenia|Compensating for Cognitive Deficits in Schizophrenia|Completed||N/A|120|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||||||||||||2018-06-01 05:29:21.327146|2018-06-01 05:29:21.327146
NCT00051727|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-15|||2012-01-06|2003-01-16|2003-01-17|Estimate|||||||2012-01-06|2012-01-10|Estimate|October 2002||2002-10-31|January 2012|2012-01-31||||||||Interventional|||Prevention of School Dropout for Mexican American Adolescents|Preventive Intervention for Mexican American Adolescents|Completed||Phase 2|480||Arizona State University|||||f||||||||||||||2018-06-01 05:29:21.400467|2018-06-01 05:29:21.400467
NCT00051701|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-15|||2015-03-04|2003-01-16|2003-01-17|Estimate|||||||2015-03-04|2015-03-05|Estimate|December 2002||2002-12-31|March 2015|2015-03-31|August 2005|Actual|2005-08-31|||||Interventional|||Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma|Terminated||Phase 1/Phase 2|61||Sanofi|||||||||||||||||||2018-06-01 05:29:21.456246|2018-06-01 05:29:21.456246
NCT00051688|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-15|||2006-07-10|2003-01-15|2003-01-16|Estimate|||||||2006-07-10|2006-07-11|Estimate|June 2003||2003-06-30|July 2006|2006-07-31|August 2004||2004-08-31|||||Interventional|||Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer||Terminated||Phase 2|||Chiron Corporation|||||||||||||||||||2018-06-01 05:29:21.610809|2018-06-01 05:29:21.610809
NCT00051675|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-14|||2005-06-23|2003-01-15|2003-01-16|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2002||2002-07-31|September 2004|2004-09-30|September 2003||2003-09-30|||||Interventional|||Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas|An Open-Label, Multi-Dose, Phase I, Dose-Escalating Study of a Subcutaneously Administered Human-Engineered Monoclonal Antibody, ING-1(heMAb), in Subjects With Advanced Adenocarcinomas|Completed||Phase 1|30||XOMA (US) LLC|||||||||||||||||||2018-06-01 05:29:21.671443|2018-06-01 05:29:21.671443
NCT00051662|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-14|||2005-06-23|2003-01-15|2003-01-16|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 2004|2004-09-30|February 2004||2004-02-29|||||Interventional|||Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis|Completed||Phase 1|45||XOMA (US) LLC|||||||||||||||||||2018-06-01 05:29:21.727457|2018-06-01 05:29:21.727457
NCT00051636|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-14|2012-04-05||2012-05-09|2003-01-14|2003-01-15|Estimate|2012-04-05|2012-05-07|Estimate||||2012-05-09|2012-05-15|Estimate|January 2001||2001-01-31|May 2012|2012-05-31|April 2011|Actual|2011-04-30|March 2004|Actual|2004-03-31||Interventional|||Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period|Randomized, Double-blind, Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Paget's Disease of Bone Using Risedronate as a Comparator, Including an Extended Observational Period|Completed||Phase 3|172|Actual|Novartis||2|||f||||||||||||||2018-06-01 05:29:21.814284|2018-06-01 05:29:21.814284
NCT00051623|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-14|||2011-05-16|2003-01-14|2003-01-15|Estimate|||||||2011-05-16|2011-05-17|Estimate|May 2003||2003-05-31|March 2010|2010-03-31|June 2004|Actual|2004-06-30|||||Interventional|||A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis|A Multicenter, Randomized, Double-blind Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Patients With Psoriatic Arthritis|Completed||Phase 3|70|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:29:22.291069|2018-06-01 05:29:22.291069
NCT00051597|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-13|||2011-10-07|2003-01-14|2003-01-15|Estimate|||||||2011-10-07|2011-10-12|Estimate||||October 2011|2011-10-31|August 2003|Actual|2003-08-31|||||Interventional|||A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies|A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies|Completed||Phase 1/Phase 2|70||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 05:29:22.347525|2018-06-01 05:29:22.347525
NCT00051584|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-13|||2011-10-21|2003-01-14|2003-01-15|Estimate|||||||2011-10-21|2011-10-24|Estimate||||October 2011|2011-10-31|May 2003|Actual|2003-05-31|||||Interventional|||Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer|A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer|Terminated||Phase 2|60||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 05:29:22.414461|2018-06-01 05:29:22.414461
NCT00051571|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-13|||2011-10-21|2003-01-14|2003-01-15|Estimate|||||||2011-10-21|2011-10-24|Estimate||||October 2011|2011-10-31|October 2003|Actual|2003-10-31|||||Interventional|||Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma|A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma|Completed||Phase 2|60||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 05:29:22.468833|2018-06-01 05:29:22.468833
NCT00051428|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|||2006-08-16|2003-01-14|2003-01-15|Estimate|||||||2006-08-16|2006-08-18|Estimate|January 2003||2003-01-31|August 2006|2006-08-31|February 2005||2005-02-28|||||Interventional|||The Efficacy of Reiki in the Treatment of Fibromyalgia|The Efficacy of Reiki in the Treatment of Fibromyalgia|Completed||Phase 1|100||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:29:22.534071|2018-06-01 05:29:22.534071
NCT00004576|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-17|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2000||2000-02-29|February 2000|2000-02-29|August 2000||2000-08-31|||||Interventional|||Study of LY300164 for the Treatment of Parkinson's Disease|AMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's Disease|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.386027|2018-06-01 05:29:38.386027
NCT00051415|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|||2006-08-17|2003-01-14|2003-01-15|Estimate|||||||2006-08-17|2006-08-18|Estimate|January 2003||2003-01-31|July 2006|2006-07-31|January 2005||2005-01-31|||||Interventional|||Safety and Effectiveness of Flaxseed for Reducing High Cholesterol|A Double Blind, Randomized, Placebo Controlled Trial of Flaxseed in Patients With Hypercholesterolemia|Completed||Phase 2/Phase 3|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:29:22.58019|2018-06-01 05:29:22.58019
NCT00051402|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|||2007-10-24|2003-01-14|2003-01-15|Estimate|||||||2007-10-24|2007-10-26|Estimate|December 2002||2002-12-31|October 2007|2007-10-31|August 2007|Actual|2007-08-31|||||Interventional|||Phytoestrogens and Memory Decline in Menopause|Phytoestrogens and Cognition in Menopause|Completed||Phase 2|96||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:29:22.630188|2018-06-01 05:29:22.630188
NCT00051558|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-13|2009-01-14||2009-02-13|2003-01-13|2003-01-14|Estimate|2009-01-14|2009-02-13|Estimate||||2009-02-13|2009-03-12|Estimate|November 2002||2002-11-30|February 2009|2009-02-28|January 2008|Actual|2008-01-31|July 2006|Actual|2006-07-31||Interventional|||Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis|Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis|Completed||Phase 3|428|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-06-01 05:29:22.822118|2018-06-01 05:29:22.822118
NCT00051545|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-13|||2007-02-21|2003-01-13|2003-01-14|Estimate|||||||2007-02-21|2007-02-22|Estimate|November 1999||1999-11-30|April 2005|2005-04-30|June 2004||2004-06-30|||||Interventional|||Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma|Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5 ug) or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Treatment for Hepatocellular Carcinoma|Terminated||Phase 3|608||LEO Pharma|||||||||||||||||||2018-06-01 05:29:24.18758|2018-06-01 05:29:24.18758
NCT00051532|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-13|||2007-03-05|2003-01-13|2003-01-14|Estimate|||||||2007-03-05|2007-03-06|Estimate|September 1999||1999-09-30|April 2005|2005-04-30|May 2004||2004-05-31|||||Interventional|||Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma|Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5ug) or Placebo in the Treatment of Patients With Hepatocellular Carcinoma Not Amenable to Curative Treatment|Terminated||N/A|700||LEO Pharma|||||||||||||||||||2018-06-01 05:29:24.248657|2018-06-01 05:29:24.248657
NCT00051506|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-10|||2006-07-18|2003-01-13|2003-01-14|Estimate|||||||2006-07-18|2006-07-20|Estimate||||July 2006|2006-07-31||||||||Interventional|||ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.||Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:29:24.406675|2018-06-01 05:29:24.406675
NCT00051493|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-10|||2006-07-18|2003-01-13|2003-01-14|Estimate|||||||2006-07-18|2006-07-19|Estimate|April 2002||2002-04-30|July 2006|2006-07-31|December 2002||2002-12-31|||||Interventional|||ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.|ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.|Completed||Phase 2|50||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:29:24.46271|2018-06-01 05:29:24.46271
NCT00051519|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-10|||2017-06-30|2003-01-10|2003-01-13|Estimate|||||||2017-06-30|2017-07-02|Actual|January 9, 2003||2003-01-09|June 25, 2009|2009-06-25|December 1, 2007|Actual|2007-12-01|December 1, 2007|Actual|2007-12-01||Observational|||Screening HIV-Infected Patients for Vaccine Studies|Screening HIV-Infected Subjects for Vaccine Research Studies|Completed|||1000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:24.511008|2018-06-01 05:29:24.511008
NCT00051480|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-10|||2011-05-11|2003-01-10|2003-01-13|Estimate|||||||2011-05-11|2011-05-12|Estimate||||May 2011|2011-05-31||||||||Interventional|||Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer|A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer|Completed||Phase 2|||GenVec|||||||||||||||||||2018-06-01 05:29:24.556902|2018-06-01 05:29:24.556902
NCT00051467|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-10|||2012-02-22|2003-01-10|2003-01-13|Estimate|||||||2012-02-22|2012-02-23|Estimate||||May 2011|2011-05-31||||||||Interventional|||A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer|A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer|Completed||Phase 3|||GenVec|||||||||||||||||||2018-06-01 05:29:24.619618|2018-06-01 05:29:24.619618
NCT00051454|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-10|||2007-08-23|2003-01-10|2003-01-13|Estimate|||||||2007-08-23|2007-08-27|Estimate|March 2003||2003-03-31|August 2007|2007-08-31|February 2005||2005-02-28|||||Interventional|||Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults|A Randomised, Placebo-Controlled, Double-Blind, Phase I/IIa Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic DNA Prime-rFPV Boost HIV Vaccination Strategy|Completed||Phase 1/Phase 2|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:29:24.700208|2018-06-01 05:29:24.700208
NCT00051441|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|||2011-05-17|2003-01-10|2003-01-13|Estimate|||||||2011-05-17|2011-05-19|Estimate||||April 2010|2010-04-30|February 2005|Actual|2005-02-28|||||Interventional|||Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx|A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine HCl 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Mucositis|Completed||Phase 3|605|Actual|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|||||||||||||||||||2018-06-01 05:29:24.765427|2018-06-01 05:29:24.765427
NCT00051389|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|||2016-02-17|2003-01-10|2003-01-13|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 2002||2002-02-28|January 2008|2008-01-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||ACE Inhibition and Novel Cardiovascular Risk Factors||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:29:24.822614|2018-06-01 05:29:24.822614
NCT00051376|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|||2016-02-17|2003-01-10|2003-01-13|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2001||2001-09-30|November 2005|2005-11-30|August 2006|Actual|2006-08-31|||||Interventional|||Vascular Interaction With Age in Myocardial Infarction||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:29:24.873468|2018-06-01 05:29:24.873468
NCT00051363|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-09|2016-02-29|2009-07-23|2016-10-06|2003-01-10|2003-01-13|Estimate|2016-10-06|2016-11-30|Estimate|2010-02-23|2010-02-24|Estimate|2016-10-06|2016-11-30|Estimate|September 2002||2002-09-30|October 2016|2016-10-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|APPLES||Apnea Positive Pressure Long-Term Efficacy Study|APPLES: Apnea Positive Pressure Long-Term Efficacy Study|Completed||Phase 3|1105|Actual|Stanford University|There are study sample limitations because although participants with severe OSA were included, those who had the lowest oxygen saturation, a history of sleepiness-related accidents, or major cardiovascular comorbidities were excluded.|2|||f||||t||||||||Yes|Only in de-identified format to researchers|2018-06-01 05:29:24.964363|2018-06-01 05:29:24.964363
NCT00051337|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-08|||2008-03-03|2003-01-08|2003-01-09|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2003||2003-01-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Single Photon Emission Computed Tomography (SPECT) to Study Paroxysmal Hyperkinetic Movement Disorders|The Physiology of Paroxysmal Hyperkinetic Movement Disorders: A SPECT Study|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:25.931136|2018-06-01 05:29:25.931136
NCT00051324|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-08|||2017-11-27|2003-01-08|2003-01-09|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2002||2002-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 31, 2017|Actual|2017-08-31||Observational|PREDICT-HD||Neurobiological Predictors of Huntington's Disease (PREDICT-HD)|Neurobiological Predictors of Huntington's Disease Trial|Active, not recruiting|||1500|Actual|University of Iowa|||||f||||f|f|f||||Samples With DNA|"~     Cerebral spinal fluid acquired and retained since 2012.~      Urine, plasma and cell lines to be acquired and retained since study initiation 2002.~   "|Yes|All data have been de-identified and anonymized with the best possible methods to allow and facilitate data sharing with other investigators. Data has been shared to CHDI and dbGaP.|2018-06-01 05:29:25.975959|2018-06-01 05:29:25.975959
NCT00051298|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2007-06-11|2003-01-08|2003-01-09|Estimate|||||||2007-06-11|2007-06-12|Estimate|November 2002||2002-11-30|June 2007|2007-06-30|April 2005|Actual|2005-04-30|||||Interventional|||Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia|Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia|Completed||Phase 3|107|Actual|Eli Lilly and Company|||||||||||||||||||2018-06-01 05:29:26.101004|2018-06-01 05:29:26.101004
NCT00051285|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2014-01-08|2003-01-08|2003-01-09|Estimate|||||||2014-01-08|2014-01-10|Estimate|February 2002||2002-02-28|January 2014|2014-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||"ESSENTIAL-The Studies of Oral Enoximone Therapy in Advanced Heart Failure"|ESSENTIAL Protocol No. My-021 and Protocol No. My-026, Each Titled: A Phase III, Randomized, Double-Blind, Multicenter, Parallel Group, Placebo-Controlled Study of Oral Enoximone vs. Placebo in Advanced Chronic Heart Failure Subjects|Terminated||Phase 3|1800||Gilead Sciences||2|||f||||||||||||||2018-06-01 05:29:26.193555|2018-06-01 05:29:26.193555
NCT00051311|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-08|||2018-04-18|2003-01-07|2003-01-08|Estimate|||||||2018-04-18|2018-04-19|Actual|January 3, 2003||2003-01-03|September 25, 2014|2014-09-25|September 25, 2014|Actual|2014-09-25|September 25, 2014|Actual|2014-09-25||Interventional|||Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers|A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies|Completed||Phase 2|62|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:26.25061|2018-06-01 05:29:26.25061
NCT00051272|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2011-03-28|2003-01-07|2003-01-08|Estimate|||||||2011-03-28|2011-03-29|Estimate|January 2003||2003-01-31|March 2011|2011-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Effects Of Antidepressants On Sexual Functioning In Adults|A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period|Completed||Phase 3|425|Actual|GlaxoSmithKline|||||||||||||||||||2018-06-01 05:29:26.305628|2018-06-01 05:29:26.305628
NCT00051259|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2010-10-01|2003-01-07|2003-01-08|Estimate|||||||2010-10-01|2010-10-04|Estimate|January 2003||2003-01-31|October 2010|2010-10-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Effects of Antidepressants on Sexual Functioning|A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period|Completed||Phase 3|420||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:29:26.399914|2018-06-01 05:29:26.399914
NCT00051246|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2014-01-23|2003-01-07|2003-01-08|Estimate|||||||2014-01-23|2014-01-24|Estimate|January 2002||2002-01-31|January 2014|2014-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Group Therapy for Postpartum Depression|Relational Group Intervention for Postpartum Depression|Completed||N/A|147|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-06-01 05:29:26.489254|2018-06-01 05:29:26.489254
NCT00051233|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2014-06-26|2003-01-07|2003-01-08|Estimate|||||||2014-06-26|2014-06-30|Estimate|January 2003||2003-01-31|June 2014|2014-06-30|January 2005||2005-01-31|||||Interventional|||Treatment of Schizophrenia Through Internet-Based Psychoeducation|Schizophrenia Patient and Family Continuity of Care|Completed||Phase 2|40||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:29:26.562791|2018-06-01 05:29:26.562791
NCT00051220|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2013-06-06|2003-01-07|2003-01-08|Estimate|||||||2013-06-06|2013-06-07|Estimate|October 2001||2001-10-31|June 2013|2013-06-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||Treatment for Specific Phobias in Children|One-Session Treatment for Specific Phobias in Children|Completed||Phase 1/Phase 2|150|Actual|Virginia Polytechnic Institute and State University|||||f||||||||||||||2018-06-01 05:29:26.62055|2018-06-01 05:29:26.62055
NCT00051207|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-07|||2013-06-21|2003-01-07|2003-01-08|Estimate|||||||2013-06-21|2013-06-25|Estimate|November 2002||2002-11-30|December 2007|2007-12-31|August 2005|Actual|2005-08-31|||||Interventional|||Therapy for Depression With Co-occurring Panic or Anxiety Symptoms|Interpersonal Psychotherapy for Depression With Co-occurring Panic and Anxiety Symptoms (IPT-PS)|Completed||Phase 1/Phase 2|36||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:29:26.675408|2018-06-01 05:29:26.675408
NCT00051194|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2012-04-12|2003-01-06|2003-01-07|Estimate|||||||2012-04-12|2012-04-16|Estimate|September 2002||2002-09-30|March 2006|2006-03-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension|A 6-week Safety and Efficacy Study of Combination IOP-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension.|Completed||Phase 2|||Alcon Research|||||||||||||||||||2018-06-01 05:29:26.727309|2018-06-01 05:29:26.727309
NCT00051181|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2008-08-04|2003-01-06|2003-01-07|Estimate|||||||2008-08-04|2008-08-05|Estimate|January 2000||2000-01-31|August 2008|2008-08-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma|A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma.|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:29:26.78255|2018-06-01 05:29:26.78255
NCT00051168|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|2010-03-22||2011-10-02|2003-01-06|2003-01-07|Estimate|2010-03-22|2010-04-12|Estimate||||2011-10-02|2011-10-07|Estimate|January 2006||2006-01-31|April 2010|2010-04-30||||March 2009|Actual|2009-03-31||Interventional|||A Long-term Safety Study of Once-daily Travatan|A Long-term Safety Study of Once-daily TRAVATAN|Completed||Phase 3|502|Actual|Alcon Research||1|||f||||||||||||||2018-06-01 05:29:26.851652|2018-06-01 05:29:26.851652
NCT00051155|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2008-08-04|2003-01-06|2003-01-07|Estimate|||||||2008-08-04|2008-08-05|Estimate|January 2001||2001-01-31|August 2008|2008-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)|A 6-Week Safety and Efficacy Study of TRAVATAN Compared to XALCOM in Subjects With Open-Angle Glaucoma or Ocular Hypertension.|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:29:27.244489|2018-06-01 05:29:27.244489
NCT00051142|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2008-08-04|2003-01-06|2003-01-07|Estimate|||||||2008-08-04|2008-08-05|Estimate|February 2001||2001-02-28|August 2008|2008-08-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)|A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:29:27.295744|2018-06-01 05:29:27.295744
NCT00051129|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03||2012-11-27|2012-11-27|2003-01-06|2003-01-07|Estimate||||2012-11-27|2012-11-28|Estimate|2012-11-27|2012-11-28|Estimate|January 2007||2007-01-31|August 2008|2008-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)|An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration.|Completed||Phase 3|291|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 05:29:27.37412|2018-06-01 05:29:27.37412
NCT00051116|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2009-09-22|2003-01-06|2003-01-07|Estimate|||||||2009-09-22|2009-09-23|Estimate|May 2002||2002-05-31|September 2009|2009-09-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma|A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma|Completed||Phase 2|100|Actual|Celgene|||||f||||f||||||||||2018-06-01 05:29:27.634041|2018-06-01 05:29:27.634041
NCT00051103|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2015-04-14|2003-01-03|2003-01-06|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2002||2002-10-31|April 2015|2015-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.|An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens|Completed||Phase 2|||GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:29:27.728379|2018-06-01 05:29:27.728379
NCT00051090|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2012-05-17|2003-01-03|2003-01-06|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31||||||||Interventional|||Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV|Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:29:27.99683|2018-06-01 05:29:27.99683
NCT00051077|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-03|||2012-05-16|2003-01-03|2003-01-06|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31||||||||Interventional|||Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)|A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:29:28.242302|2018-06-01 05:29:28.242302
NCT00051051|ClinicalTrials.gov processed this data on May 31, 2018|2003-01-02|||2007-05-03|2003-01-02|2003-01-03|Estimate|||||||2007-05-03|2007-05-04|Estimate|December 2002||2002-12-31|September 2006|2006-09-30|May 2005|Actual|2005-05-31|||||Interventional|||A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer|A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer|Completed||Phase 2|168||Pfizer|||||f||||||||||||||2018-06-01 05:29:28.349145|2018-06-01 05:29:28.349145
NCT00051038|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-31||2010-01-29|2011-04-07|2003-01-02|2003-01-03|Estimate||||2010-01-29|2010-02-02|Estimate|2011-04-07|2011-04-14|Estimate|September 2002||2002-09-30|August 2007|2007-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients|A Phase II Study of the Safety and Efficacy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Who Have Hepatitis B Viremia While Being Treated With Lamivudine|Completed||Phase 2/Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:29:28.486301|2018-06-01 05:29:28.486301
NCT00051025|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-31|2011-07-07||2012-07-07|2003-01-02|2003-01-03|Estimate|2011-07-07|2011-08-03|Estimate||||2012-07-07|2012-07-13|Estimate|May 2000||2000-05-31|July 2012|2012-07-31|September 2006|Actual|2006-09-30|January 2001|Actual|2001-01-31||Interventional|||Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)|A Randomized, Multicenter, Phase II Evaluation of ONTAK (Denileukin Diftitox) in Patients With Previously Treated, Indolent, B-Cell, Non-Hodgkin's Lymphoma|Completed||Phase 2|9|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 05:29:28.548572|2018-06-01 05:29:28.548572
NCT00051012|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-31|||2008-02-29|2003-01-02|2003-01-03|Estimate|||||||2008-02-29|2008-03-05|Estimate|September 1995||1995-09-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients|A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25|Completed||Phase 4|86||Eisai Inc.|||||f||||||||||||||2018-06-01 05:29:29.131636|2018-06-01 05:29:29.131636
NCT00050999|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-31|||2008-02-29|2003-01-02|2003-01-03|Estimate|||||||2008-02-29|2008-03-05|Estimate|June 1995||1995-06-30|February 2008|2008-02-29|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients|A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25|Completed||Phase 4|195||Eisai Inc.|||||f||||||||||||||2018-06-01 05:29:29.324351|2018-06-01 05:29:29.324351
NCT00050986|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-31|2009-09-25||2012-07-27|2003-01-02|2003-01-03|Estimate|2010-08-25|2010-09-16|Estimate||||2012-07-27|2012-08-01|Estimate|December 2002||2002-12-31|July 2012|2012-07-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme|Phase I/II Evaluation Temozolomide and Farnesyl Transferase Inhibitor ZARNESTRA (R115777) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme|Completed||Phase 1/Phase 2|55|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:29:29.472275|2018-06-01 05:29:29.472275
NCT00050973|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-31|||2013-05-13|2003-01-02|2003-01-03|Estimate|||||||2013-05-13|2013-05-14|Estimate||||July 2008|2008-07-31|March 2005|Actual|2005-03-31|November 2004|Actual|2004-11-30||Interventional|||Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|Randomized Phase III Trial Comparing Targretin Capsules/Cisplatin/Vinorelbine Versus Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|623|Actual|Eisai Inc.|||||f||||||||||||||2018-06-01 05:29:29.756113|2018-06-01 05:29:29.756113
NCT00050960|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-31|2010-07-23||2012-07-07|2003-01-02|2003-01-03|Estimate|2010-07-23|2010-08-24|Estimate||||2012-07-07|2012-07-13|Estimate|May 2002||2002-05-31|July 2012|2012-07-31|March 2005|Actual|2005-03-31|July 2004|Actual|2004-07-31||Interventional|||Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 3|612|Actual|Eisai Inc.||2|||f||||||||||||||2018-06-01 05:29:30.040429|2018-06-01 05:29:30.040429
NCT00050947|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-30|||2011-11-22|2002-12-31|2003-01-01|Estimate|||||||2011-11-22|2011-11-23|Estimate|July 2002||2002-07-31|November 2011|2011-11-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Pediatric Epilepsy Study|A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Monotherapy in Pediatric Patients With Inadequately-controlled Partial Seizures.|Completed||Phase 3|94|Actual|Novartis|||||f||||||||||||||2018-06-01 05:29:30.783252|2018-06-01 05:29:30.783252
NCT00050934|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-30|||2011-11-22|2002-12-31|2003-01-01|Estimate|||||||2011-11-22|2011-11-23|Estimate|June 2002||2002-06-30|November 2011|2011-11-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Pediatric Epilepsy Study|A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.|Completed||Phase 3|132|Actual|Novartis|||||f||||||||||||||2018-06-01 05:29:30.865616|2018-06-01 05:29:30.865616
NCT00050921|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-30|||2012-05-16|2002-12-31|2003-01-01|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|March 2005|Actual|2005-03-31|||||Interventional|||Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs|Improving Immune Reconstitution With Growth Hormone in HIV-infected Subjects With Incomplete CD4+ Lymphocyte Restoration on Highly Active Antiretroviral Therapy (HAART)|Completed||N/A|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:29:30.94507|2018-06-01 05:29:30.94507
NCT00050908|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-30|||2013-07-26|2002-12-31|2003-01-01|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|May 2007|Actual|2007-05-31|||||Observational|||Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs|Endothelial Function in HIV-Infected Subjects Prior To and After Starting a Potent Antiretroviral Regimen|Completed|||75||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:29:31.936442|2018-06-01 05:29:31.936442
NCT00050895|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-30|||2012-05-17|2002-12-31|2003-01-01|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|March 2006|Actual|2006-03-31|||||Interventional|||Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients|A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection|Completed||Phase 3|775||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:29:32.029578|2018-06-01 05:29:32.029578
NCT00050882|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-29|||2005-06-23|2002-12-30|2002-12-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2004|2004-02-29||||||||Interventional|||Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis|A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis|Completed||Phase 2|||Chugai Pharma USA|||||||||||||||||||2018-06-01 05:29:32.196284|2018-06-01 05:29:32.196284
NCT00050869|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-27|||2017-06-30|2002-12-27|2002-12-30|Estimate|||||||2017-06-30|2017-07-02|Actual|December 23, 2002||2002-12-23|November 15, 2007|2007-11-15|November 15, 2007||2007-11-15|||||Observational|||Learning a Motor Task Through Observation|Encoding a Motor Memory by Action Observation|Completed|||56||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:32.456964|2018-06-01 05:29:32.456964
NCT00050856|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-23|||2008-03-03|2002-12-23|2002-12-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2002||2002-11-30|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection|Multicenter, Open-Label, Early Acces Program of Fuzeon (Enfuvirtide T-20/Ro 29,9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiretroviral Regimen to Assess Serious Adverse Events, Serious AIDS-Defining Events, and Tolerability in Patient|Completed||Phase 3|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:32.532389|2018-06-01 05:29:32.532389
NCT00050843|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-23|||2005-06-23|2002-12-23|2002-12-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2001||2001-08-31|May 2004|2004-05-31|February 2004||2004-02-29|||||Interventional|||A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes||Completed||Phase 3|220||Celgene|||||||||||||||||||2018-06-01 05:29:32.608625|2018-06-01 05:29:32.608625
NCT00050830|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-20|||2006-11-06|2002-12-23|2002-12-24|Estimate|||||||2006-11-06|2006-11-08|Estimate|January 2003||2003-01-31|January 2006|2006-01-31|November 2005||2005-11-30|||||Interventional|||A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer|A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|163||Pfizer|||||f||||||||||||||2018-06-01 05:29:32.728941|2018-06-01 05:29:32.728941
NCT00050817|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-20|||2012-04-20|2002-12-20|2002-12-23|Estimate|||||||2012-04-20|2012-04-23|Estimate|October 2002||2002-10-31|April 2012|2012-04-30|August 2005|Actual|2005-08-31|||||Interventional|||Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)|A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-dose ASA.|Completed||Phase 3|15603|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:29:32.853537|2018-06-01 05:29:32.853537
NCT00050791|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-19|||2010-10-18|2002-12-20|2002-12-23|Estimate|||||||2010-10-18|2010-10-19|Estimate|March 2001||2001-03-31|October 2010|2010-10-31|June 2009|Actual|2009-06-30|November 2006|Actual|2006-11-30||Interventional|||Effects of Leptin Treatment on Weight Loss|Leptin Treatment for Prevention of the Metabolic and Endocrine Sequelae of a Decreased Caloric Intake: Studies of Patients on a Very Low Calorie Diet|Completed||Phase 2|40|Anticipated|Rockefeller University||2|||f||||f||||||||||2018-06-01 05:29:32.95214|2018-06-01 05:29:32.95214
NCT00050778|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-19|2008-11-03||2015-01-06|2002-12-20|2002-12-23|Estimate|2009-07-13|2009-08-25|Estimate||||2015-01-06|2015-01-08|Estimate|December 2002||2002-12-31|January 2015|2015-01-31|January 2010|Actual|2010-01-31|September 2007|Actual|2007-09-30||Interventional||FAS population included all randomized participants who had correct diagnosis of MS at entry. One participant was included in safety but excluded from efficacy analysis as initial multiple sclerosis diagnosis was incorrect.|A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis|A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|334|Actual|Sanofi||3|||f||||t||||||||||2018-06-01 05:29:33.201451|2018-06-01 05:29:33.201451
NCT00050804|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-19|||2008-03-03|2002-12-19|2002-12-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2002||2002-12-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Evaluation of Stress Disorders|Efficacy of an SSRI in Acute Stress Disorder and PTSD|Completed||Phase 4|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:34.640153|2018-06-01 05:29:34.640153
NCT00050765|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-18|||2006-03-06|2002-12-18|2002-12-19|Estimate|||||||2006-03-06|2006-03-08|Estimate|August 2006||2006-08-31|March 2006|2006-03-31|August 2006||2006-08-31|||||Interventional|||Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection|A Phase I Multi-Center Study to Assess the Safety and Cardiovascular Effects of MyoCell™ Implantation in Patients With a Previous MI and Placement of an ICD Requiring De Novo Coronary Artery Bypass Graft Therapy|Unknown status|Not yet recruiting|Phase 1|15||Bioheart, Inc.|||||||||||||||||||2018-06-01 05:29:34.794728|2018-06-01 05:29:34.794728
NCT00050687|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17||2011-01-11|2011-01-21|2002-12-18|2002-12-19|Estimate||||2011-01-21|2011-01-28|Estimate|2011-01-21|2011-01-28|Estimate|June 2001||2001-06-30|November 2006|2006-11-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies|A Randomized, Serum Level-targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Patients With Various Refractory Malignancies|Terminated||Phase 1/Phase 2|||Titan Pharmaceuticals|||||||||||||||||||2018-06-01 05:29:34.865771|2018-06-01 05:29:34.865771
NCT00050752|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2017-10-05|2002-12-17|2002-12-18|Estimate|||||||2017-10-05|2017-10-06|Actual|December 17, 2002||2002-12-17|July 25, 2017|2017-07-25||||||||Observational|||Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer|Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer|Recruiting|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:34.934174|2018-06-01 05:29:34.934174
NCT00050726|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2013-11-19|2002-12-17|2002-12-18|Estimate|||||||2013-11-19|2013-11-21|Estimate|May 2001||2001-05-31|November 2013|2013-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2|Substudies of ESPRIT: ESPRIT Influenza Vaccine Substudy (FLUVAC) and ESPRIT Tetanus-Pneumococcal Vaccine Substudy (TEPVAC)|Completed||Phase 2|620||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:29:34.997243|2018-06-01 05:29:34.997243
NCT00050713|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2017-10-05|2002-12-17|2002-12-18|Estimate|||||||2017-10-05|2017-10-06|Actual|December 17, 2002||2002-12-17|July 7, 2015|2015-07-07|August 27, 2007|Actual|2007-08-27|August 27, 2007|Actual|2007-08-27||Interventional|||Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy|Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:35.075134|2018-06-01 05:29:35.075134
NCT00050700|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2017-06-30|2002-12-17|2002-12-18|Estimate|||||||2017-06-30|2017-07-02|Actual|December 16, 2002||2002-12-16|May 14, 2010|2010-05-14|May 14, 2010||2010-05-14|||||Observational|||Brain Imaging in Depression|Muscarinic Cholinergic Receptor Imaging in Depression|Completed|||107|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:35.140259|2018-06-01 05:29:35.140259
NCT00050674|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2012-12-26|2002-12-17|2002-12-18|Estimate|||||||2012-12-26|2012-12-27|Estimate|November 2001||2001-11-30|December 2012|2012-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma|Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma|Completed||Phase 2|40|Actual|Schwartzberg, Lee, M.D.||1|||f||||f||||||||||2018-06-01 05:29:35.197363|2018-06-01 05:29:35.197363
NCT00050661|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2009-03-24|2002-12-17|2002-12-18|Estimate|||||||2009-03-24|2009-03-25|Estimate|October 1997||1997-10-31|March 2009|2009-03-31|April 2008|Actual|2008-04-30|April 2004|Actual|2004-04-30||Interventional|||To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris|Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody/ Placebo to Prevent Relapse of Psoriasis Vulgaris Following NBUVB Therapy|Completed||Phase 1/Phase 2|6|Actual|Rockefeller University||2|||f||||f||||||||||2018-06-01 05:29:35.273307|2018-06-01 05:29:35.273307
NCT00050648|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2009-03-12|2002-12-17|2002-12-18|Estimate|||||||2009-03-12|2009-03-13|Estimate|October 1997||1997-10-31|March 2009|2009-03-31|April 2008|Actual|2008-04-30|September 2004|Actual|2004-09-30||Interventional|||To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris|Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody and Cyclosporine for the Treatment of Active Psoriasis.|Completed||Phase 1/Phase 2|20|Actual|Rockefeller University||3|||f||||f||||||||||2018-06-01 05:29:35.354603|2018-06-01 05:29:35.354603
NCT00050635|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-17|||2009-11-18|2002-12-17|2002-12-18|Estimate|||||||2009-11-18|2009-11-19|Estimate|December 2002||2002-12-31|November 2009|2009-11-30|July 2003||2003-07-31|||||Interventional|||STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea||Completed||Phase 4|150||Novartis|||||f||||||||||||||2018-06-01 05:29:35.438808|2018-06-01 05:29:35.438808
NCT00050609|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-16|||2007-11-16|2002-12-17|2002-12-18|Estimate|||||||2007-11-16|2007-11-20|Estimate|February 2003||2003-02-28|November 2007|2007-11-30|September 2003|Actual|2003-09-30|||||Interventional|||Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of IC351 (LY450190) in Patients With Diabetic Gastroparesis|Completed||Phase 2|2|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-06-01 05:29:35.536749|2018-06-01 05:29:35.536749
NCT00050427|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-09|||2011-04-26|2002-12-17|2002-12-18|Estimate|||||||2011-04-26|2011-04-28|Estimate|December 2002||2002-12-31|April 2011|2011-04-30|December 2006|Actual|2006-12-31|||||Interventional|||A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer|A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer|Completed||Phase 2|53|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 05:29:35.622832|2018-06-01 05:29:35.622832
NCT00004574|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-17|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2000||2000-02-29|December 1999|1999-12-31|May 2001||2001-05-31|||||Observational|||Vitamin Replacement in Abetalipoproteinemia|Vitamin Replacement in Abetalipoproteinemia|Completed|||1||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.443182|2018-06-01 05:29:38.443182
NCT00050622|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-16|2016-05-31||2016-08-08|2002-12-16|2002-12-17|Estimate|2016-08-08|2016-09-30|Estimate||||2016-08-08|2016-09-30|Estimate|September 2001||2001-09-30|August 2016|2016-08-31|June 2005|Actual|2005-06-30|August 2004|Actual|2004-08-31||Interventional|||Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)|ADHD Treatment: Comparative and Combined Dosage Effects|Completed||N/A|154|Actual|Florida International University|Highly structured environment and direct observational measures were used. Additional study in natural school and home settings will be necessary.|12|||f||||f||||||||Yes||2018-06-01 05:29:35.844397|2018-06-01 05:29:35.844397
NCT00050596|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-16|||2011-06-23|2002-12-16|2002-12-17|Estimate|||||||2011-06-23|2011-06-27|Estimate|November 2002||2002-11-30|June 2011|2011-06-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer|A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose of Docetaxel in Patients With Hormone-Refractory Prostate Cancer|Completed||Phase 2|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:29:36.255814|2018-06-01 05:29:36.255814
NCT00050583|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-16|||2014-01-10|2002-12-16|2002-12-17|Estimate|||||||2014-01-10|2014-01-14|Estimate|February 2001||2001-02-28|January 2014|2014-01-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Treatment of Medically Unexplained Physical Ailments (Somatization Disorder)|Treatment of Somatization in Primary Care|Completed||Phase 3|172|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-06-01 05:29:36.327561|2018-06-01 05:29:36.327561
NCT00050570|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-16|||2015-04-02|2002-12-16|2002-12-17|Estimate|||||||2015-04-02|2015-04-06|Estimate|February 2001||2001-02-28|April 2015|2015-04-30||||April 2012|Actual|2012-04-30||Interventional|||Reducing Eating Disorder Risk Factors|Interventions to Reduce Eating Disorder Risk Factors|Completed||N/A|206|Actual|Stanford University|||||f||||||||||||||2018-06-01 05:29:36.390567|2018-06-01 05:29:36.390567
NCT00050557|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-13|||2012-05-02|2002-12-13|2002-12-16|Estimate|||||||2012-05-02|2012-05-03|Estimate|July 2001||2001-07-31|May 2012|2012-05-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|||Family Psychoeducation for Children With Mood Disorders|Family Psychoeducation: Efficacy in Child Mood Disorders|Completed||Phase 1|165|Actual|Ohio State University||2|||f||||f||||||||||2018-06-01 05:29:36.454528|2018-06-01 05:29:36.454528
NCT00050518|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-11|||2010-08-26|2002-12-12|2002-12-13|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2010|2010-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||APSV in Vaccinia Naive Adults|A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults.|Completed||Phase 2|444||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:29:36.597263|2018-06-01 05:29:36.597263
NCT00050505|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-10|||2014-12-04|2002-12-10|2002-12-11|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2002||2002-10-31|July 2009|2009-07-31|December 2003|Actual|2003-12-31|||||Interventional|||Expanded Dryvax Dilution Study in Previously Vaccinated Adults|A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults|Completed||Phase 2|927|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 05:29:36.662081|2018-06-01 05:29:36.662081
NCT00050492|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-09|||2017-06-30|2002-12-09|2002-12-10|Estimate|||||||2017-06-30|2017-07-02|Actual|December 6, 2002||2002-12-06|September 19, 2006|2006-09-19|September 19, 2006||2006-09-19|||||Observational|||Biological Markers in Retinal Vasculitis|Identification of Biological Markers in Retinal Vasculitis|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:36.733546|2018-06-01 05:29:36.733546
NCT00050479|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-09|||2006-07-18|2002-12-09|2002-12-10|Estimate|||||||2006-07-18|2006-07-19|Estimate|December 2002||2002-12-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||Laser and Medical Treatment of Diabetic Macular Edema|Preliminary Multi-Center Assessment of Laser and Medical Treatment of Diabetic Macular Edema|Completed||Phase 3|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:36.785579|2018-06-01 05:29:36.785579
NCT00050466|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-09|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2002||2002-12-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Dynamic Light Scattering and Keratoscopy for Corneal Examination|A Pilot Study Using the Dynamic Light Scattering Device (DLS) Combined With Keratoscopy on the Cornea in Vivo|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:36.849116|2018-06-01 05:29:36.849116
NCT00050440|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-09|||2013-01-07|2002-12-09|2002-12-10|Estimate|||||||2013-01-07|2013-01-08|Estimate|July 2002||2002-07-31|January 2013|2013-01-31|July 2004|Actual|2004-07-31|||||Interventional|||Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma|A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma|Completed||Phase 2|50|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 05:29:36.907902|2018-06-01 05:29:36.907902
NCT00050414|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-09|||2013-01-09|2002-12-09|2002-12-10|Estimate|||||||2013-01-09|2013-01-10|Estimate|October 2002||2002-10-31|January 2013|2013-01-31|September 2005|Actual|2005-09-30|||||Interventional|||A Study of Trabectedin in Patients With Advanced Ovarian Cancer|Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer|Completed||Phase 2|147|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-06-01 05:29:37.01875|2018-06-01 05:29:37.01875
NCT00050401|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-08|||2017-08-31|2002-12-09|2002-12-10|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2002||2002-07-31|August 2017|2017-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support|Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia|Completed||Phase 3|500||Pfizer|||||||||||||||||||2018-06-01 05:29:37.103332|2018-06-01 05:29:37.103332
NCT00011635|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-24|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|December 2000|2000-12-31|June 2001||2001-06-30|||||Interventional|||The Effect of Milk Thistle on the Pharmacokinetics of Indinavir|The Effect of Milk Thistle on the Pharmacokinetics of Indinavir|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.171687|2018-06-01 05:29:37.171687
NCT00011063|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-09|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|January 2001|2001-01-31|April 2001||2001-04-30|||||Interventional|||Effect of Ginkgo Biloba on Phenytoin Elimination|Evaluation of the Effect of Ginkgo Biloba on Phenytoin Pharmacokinetics|Completed||Phase 1|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.232851|2018-06-01 05:29:37.232851
NCT00009542|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-27|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|January 2001|2001-01-31|April 2001||2001-04-30|||||Interventional|||Effects of Kava on the Body's Elimination of Caffeine and Dextromethorphan|Evaluation of the Effect of Kava on Drug Metabolism Enzymes and EEG Measured Beta Amplitude|Completed||Phase 4|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.293124|2018-06-01 05:29:37.293124
NCT00006395|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-07|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2000||2000-10-31|September 2000|2000-09-30|April 2001||2001-04-30|||||Interventional|||Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers|Evaluation of the Effect of St. John's Wort on Single Dose Carbamazepine Pharmacokinetics in Normal Healthy Volunteers|Completed||Phase 4|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.369701|2018-06-01 05:29:37.369701
NCT00006191|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-29|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2000||2000-08-31|August 2000|2000-08-31|June 2001||2001-06-30|||||Observational|||Effect of Levetiracetam on Brain Excitability|Effects of Levetiracetam on Cortical Excitability in Humans|Completed|||14||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.428446|2018-06-01 05:29:37.428446
NCT00006155|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-09|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2000||2000-08-31|June 2000|2000-06-30|April 2001||2001-04-30|||||Interventional|||SU5416 and Carboplatin to Treat Ovarian Cancer|A Phase I Study of SU5416, an Antiangiogenesis Agent, in Combination With Carboplatin in Patients With Platinum-Refractory Ovarian Cancer|Completed||Phase 1|33||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.481507|2018-06-01 05:29:37.481507
NCT00006071|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-21|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2000||2000-07-31|July 2000|2000-07-31|March 2001||2001-03-31|||||Observational|||Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol|Effects of Rosiglitazone on Endothelium-Dependent Vasodilation and on Endothelin Activity in Patients With Essential Hypertension and in Patients With Hypercholesterolemia|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.55324|2018-06-01 05:29:37.55324
NCT00006062|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-11|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2000||2000-07-31|June 2000|2000-06-30|May 2001||2001-05-31|||||Interventional|||Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction|Phase I Study of Oxaliplatin in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.599898|2018-06-01 05:29:37.599898
NCT00005926|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-28|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|June 2000|2000-06-30|December 2000||2000-12-31|||||Interventional|||Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas|A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.668382|2018-06-01 05:29:37.668382
NCT00005912|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-14|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|June 2000|2000-06-30|January 2001||2001-01-31|||||Interventional|||Voriconazole to Prevent Systemic Fungal Infections in Children|An Open Intravenous Multiple Dose, Multi-Center Study to Investigate the Pharmacokinetics, Safety and Toleration of Voriconazole in Children Aged 2-12 Years Who Require Treatment for the Prevention of Systemic Fungal Infection|Completed||Phase 1|48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.725787|2018-06-01 05:29:37.725787
NCT00005783|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2000||2000-03-31|February 2000|2000-02-29|October 2000||2000-10-31|||||Interventional|||A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders|A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.782461|2018-06-01 05:29:37.782461
NCT00005781|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2000||2000-05-31|May 2000|2000-05-31|September 2000||2000-09-30|||||Observational|||Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles|Digital Imaging as a Tool for Assessing the Prevalence of Atypical Nevi, Psoriasis and Hand Dermatitis: A Validation Study in Preparation for NHANES IV, Dermatology Section|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.833422|2018-06-01 05:29:37.833422
NCT00005574|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2000||2000-02-29|January 2000|2000-01-31|January 2001||2001-01-31|||||Interventional|||Gentamicin Treatment of Muscular Dystrophy|Gentamicin Treatment of Patients With Muscular Dystrophy Due to Nonsense Mutations in Dystrophin|Completed||Phase 1|4||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.891916|2018-06-01 05:29:37.891916
NCT00005570|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-22|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2000||2000-04-30|April 2000|2000-04-30|July 2000||2000-07-31|||||Observational|||An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers|An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:37.939362|2018-06-01 05:29:37.939362
NCT00005111|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-13|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2000||2000-04-30|March 2000|2000-03-31|March 2001||2001-03-31|||||Observational|||PET Scans in Normal Volunteers and Patients With Fabry Disease|(18)Fluorodeoxyglucose Positron Emission Tomography in Patients With Fabry Disease|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.097814|2018-06-01 05:29:38.097814
NCT00005016|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-04|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2000||2000-03-31|March 2000|2000-03-31|February 2001||2001-02-28|||||Observational|||Study of the Experiences and Needs of Parents Continuing a Pregnancy Following a Prenatal Diagnosis of Holopresencephaly|The Experiences and Needs of Parents Continuing a Pregnancy Following Abnormal Prenatal Results: The Case of Holoprosencephaly|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.23838|2018-06-01 05:29:38.23838
NCT00004851|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-02|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|March 2000|2000-03-31|May 2001||2001-05-31|||||Observational|||Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies|Generation of Anti-HCV Antibodies From Bone Marrow: Defining the Repertoire of Immune Response to HCV Quasispecies|Completed|||1||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.284593|2018-06-01 05:29:38.284593
NCT00004848|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-02|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1981||1981-07-31|July 1999|1999-07-31|May 2000||2000-05-31|||||Observational|||A Controlled Prospective Study of Transfusion-Associated Hepatitis|A Controlled Prospective Study of Transfusion-Associated Hepatitis|Completed|||2000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.334363|2018-06-01 05:29:38.334363
NCT00004557|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-08|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1992||1992-01-31|February 1999|1999-02-28|April 2000||2000-04-30|||||Observational|||Models of Disordered Knowledge and Memory Systems in Dementia and Related Disorders|Models of Disordered Knowledge and Memory Systems in Dementia and Related Disorders|Completed|||650||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.505429|2018-06-01 05:29:38.505429
NCT00001986|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|January 2000|2000-01-31|January 2001||2001-01-31|||||Interventional|||1-Octanol to Treat Essential Tremor|Double-Blind, Placebo-Controlled, Single-Dose Trial of 1-Octanol in Essential Tremor|Completed||Phase 1|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.555165|2018-06-01 05:29:38.555165
NCT00001982|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1993||1993-06-30|May 1999|1999-05-31|April 2000||2000-04-30|||||Observational|||History of Hepatitis C in Volunteer Blood Donors|Natural History of Chronic Hepatitis C Among Volunteer Blood Donors|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.669735|2018-06-01 05:29:38.669735
NCT00001977|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-20|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|January 2000|2000-01-31|April 2001||2001-04-30|||||Observational|||The Effect of Acetylcholine on Memory and Attention|Cholinergic Modulation of Human Memory and Attention: Functional Neuroimaging Studies|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.72878|2018-06-01 05:29:38.72878
NCT00001968|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|December 1999|1999-12-31|November 2000||2000-11-30|||||Interventional|||Once-Daily Drug Regimen for HIV-Infected Patients|A Pilot Study of Once-Daily Therapy With Amprenavir, Ritonavir, Lamivudine and Abacavir in HIV-Infected, Antiretroviral-Naive Patients|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.782924|2018-06-01 05:29:38.782924
NCT00001966|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|January 2000|2000-01-31|January 2001||2001-01-31|||||Interventional|||Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome|A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.839476|2018-06-01 05:29:38.839476
NCT00001965|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|November 1999|1999-11-30|February 2001||2001-02-28|||||Interventional|||Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)|Double Blind Placebo Controlled Study of Cyclosporin A in Patients With Left Ventricular Hypertrophy Caused by Sarcomeric Gene Mutations|Completed||Phase 2|32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.893624|2018-06-01 05:29:38.893624
NCT00001963|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|November 1999|1999-11-30|October 2000||2000-10-31|||||Interventional|||Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects|Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects|Completed||Phase 1|28||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:38.954316|2018-06-01 05:29:38.954316
NCT00001944|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|December 2000|2000-12-31|June 2001||2001-06-30|||||Interventional|||Vinorelbine and XR9576 to Treat Cancer|A Clinical Trial of the P-Glycoprotein Antagonist, XR9576, in Combination With Vinorelbine in Patients With Cancer: Analysis of the Interaction Between XR9576 and Vinorelbine|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.016865|2018-06-01 05:29:39.016865
NCT00001940|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|November 2000|2000-11-30|July 2001||2001-07-31|||||Interventional|||Voriconazole to Treat Fungal Infections|An Open Label, Non-Comparative, Multi-Center Phase III Trial of the Efficacy, Safety, and Toleration of Extended Voriconazole in the Treatment of Invasive Fungal Infections|Completed||Phase 3|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.077147|2018-06-01 05:29:39.077147
NCT00001937|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1999||1999-11-30|November 1999|1999-11-30|December 2000||2000-12-31|||||Interventional|||Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients|A Phase III, Randomized, Double-Blind, Comparative Trial of FK463 Versus Fluconazole for Prophylaxis of Fungal Infections in Patients Undergoing a Hematopoetic Stem Cell Transplant|Completed||Phase 3|800||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.13929|2018-06-01 05:29:39.13929
NCT00001931|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|June 2000|2000-06-30|January 2001||2001-01-31|||||Interventional|||Treatment of Parkinson's Disease With a Transdermal Skin Patch|Transdermal Application of Dopamine Agonist N-0923 in Parkinson's Disease|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.200559|2018-06-01 05:29:39.200559
NCT00001930|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|April 2000|2000-04-30|February 2001||2001-02-28|||||Interventional|||Treatment of Huntington's Chorea With Amantadine|NMDA-Receptor Blockade in Huntington's Chorea|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.277683|2018-06-01 05:29:39.277683
NCT00001929|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|January 2000|2000-01-31|January 2001||2001-01-31|||||Interventional|||Treatment of Parkinson's Disease With Eliprodil|NMDA-Receptor Blockade With Eliprodil in Parkinson's Disease|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.338673|2018-06-01 05:29:39.338673
NCT00001928|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|March 1999|1999-03-31|July 2000||2000-07-31|||||Observational|||Intravenous Levodopa for the Diagnosis of Parkinson's Disease|Intravenous Levodopa in Parkinsonism|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.392709|2018-06-01 05:29:39.392709
NCT00001918|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1999||1999-07-31|June 1999|1999-06-30|August 2000||2000-08-31|||||Observational|||L-5-HTP-Related EMS|L-5-Hydroxy-Tryptophan-Related Eosinophilia-Myalgia Syndrome (EMS): Clinical Patient Evaluation|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.444163|2018-06-01 05:29:39.444163
NCT00001839|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1998||1998-12-31|December 1998|1998-12-31|May 2000||2000-05-31|||||Interventional|||A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome|A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome|Completed||Phase 2|182||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.281819|2018-06-01 05:29:40.281819
NCT00001916|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|February 1999|1999-02-28|August 2000||2000-08-31|||||Observational|||Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression|Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression|Completed|||17||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.495439|2018-06-01 05:29:39.495439
NCT00001909|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|May 1999|1999-05-31|May 2000||2000-05-31|||||Interventional|||Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma|Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.551364|2018-06-01 05:29:39.551364
NCT00001906|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|April 2000|2000-04-30|May 2001||2001-05-31|||||Interventional|||Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants|Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.602549|2018-06-01 05:29:39.602549
NCT00001904|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|January 2000|2000-01-31|September 2000||2000-09-30|||||Observational|||Assessment of a B-Mode Ultrasound Technique for the Measurement of Carotid Artery Intima-Media Thickness|Assessment of a B-Mode Ultrasound Technique for the Measurement of Carotid Artery Intima-Media Thickness|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.657563|2018-06-01 05:29:39.657563
NCT00001903|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|March 2000|2000-03-31|May 2001||2001-05-31|||||Interventional|||Prevention of RSV Infections in Bone Marrow Transplant Recipients|Prevention of RSV Infections in Bone Marrow Transplant Recipients|Completed||Phase 4|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.702346|2018-06-01 05:29:39.702346
NCT00001891|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|March 2000|2000-03-31|March 2001||2001-03-31|||||Interventional|||Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle|Assessment of Myocardial Viability Utilizing Myocardial Contrast Echocardiography|Completed||Phase 3|200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.762969|2018-06-01 05:29:39.762969
NCT00001890|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|May 2000|2000-05-31|March 2001||2001-03-31|||||Interventional|||Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections|Immunomodulatory Effects of Hormone Therapy in Postmenopausal Women With Chronic Chlamydia Pneumoniae or Cytomegalovirus Infection|Completed||Phase 2|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.817812|2018-06-01 05:29:39.817812
NCT00001889|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|February 2000|2000-02-29|March 2001||2001-03-31|||||Interventional|||Comparison of Echocardiographic Techniques in Diagnosis of Coronary Artery Disease|Comparison of Myocardial Contrast Echo With Dobutamine Echo in Diagnosis of Coronary Artery Disease|Completed||Phase 2|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.872514|2018-06-01 05:29:39.872514
NCT00001887|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|February 2000|2000-02-29|February 2001||2001-02-28|||||Observational|||Factors Involved in Asthma and Airway Inflammation|The Role of a Novel Aminopeptidase-Like Protein in Asthma|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.927709|2018-06-01 05:29:39.927709
NCT00001886|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|February 2000|2000-02-29|March 2001||2001-03-31|||||Interventional|||Real Time 3-Dimensional Stress Echocardiography|Real Time 3-Dimensional Stress Echocardiography|Completed||Phase 2|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:39.975582|2018-06-01 05:29:39.975582
NCT00001881|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|February 2000|2000-02-29|April 2001||2001-04-30|||||Observational|||Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease|Clinical Manifestations of Mutations in Genes Linked to Familial Cardiomyopathy|Completed|||9999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.02975|2018-06-01 05:29:40.02975
NCT00001879|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|February 2000|2000-02-29|March 2001||2001-03-31|||||Observational|||Collections of Blood and Stool Samples in Patients With Acute Hepatitis|Collection of Blood and Stool Samples in Patients With Acute Hepatitis|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.072061|2018-06-01 05:29:40.072061
NCT00001871|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1999||1999-01-31|December 1999|1999-12-31|March 2001||2001-03-31|||||Observational|||Study of Muscle Abnormalities in Patients With Specific Genetic Mutations|An Exploratory Study of Skeletal Muscle Abnormalities in Patients With Mutations in Alpha-Tropomyosin and PABP2 Genes|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.117217|2018-06-01 05:29:40.117217
NCT00001867|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1999||1999-09-30|September 1999|1999-09-30|September 2000||2000-09-30|||||Observational|||Effect of Pregnancy on Uveitis|Effect of Pregnancy on Uveitis|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.157477|2018-06-01 05:29:40.157477
NCT00001857|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|May 1999|1999-05-31|April 2000||2000-04-30|||||Interventional|||Study Comparing the Safety of BG9588 (Anti-CD40L Antibody) Against Standard Treatment in Kidney Transplantation|A Multicenter, Open-Label, Study to Determine the Safety of BG9588 (Anti-CD40L Antibody) Therapy Compared to Standard Treatment in Renal Allograft Transplantation|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.198869|2018-06-01 05:29:40.198869
NCT00001840|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1999||1999-02-28|January 2001|2001-01-31|July 2001||2001-07-31|||||Observational|||Evaluation of Treated and Untreated Stroke|Evaluation of Treated and Untreated Stroke|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.239762|2018-06-01 05:29:40.239762
NCT00001814|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|February 2000|2000-02-29|January 2001||2001-01-31|||||Observational|||Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples|Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.361195|2018-06-01 05:29:40.361195
NCT00001812|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|April 2000|2000-04-30|August 2000||2000-08-31|||||Interventional|||A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2|A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2|Completed||Phase 3|84||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.481348|2018-06-01 05:29:40.481348
NCT00001810|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|April 2000|2000-04-30|October 2000||2000-10-31|||||Interventional|||An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections|An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections|Completed||Phase 3|300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.534635|2018-06-01 05:29:40.534635
NCT00001805|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|March 2000|2000-03-31|June 2000||2000-06-30|||||Interventional|||A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab|A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.583584|2018-06-01 05:29:40.583584
NCT00001797|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1999||1999-01-31|December 1999|1999-12-31|September 2000||2000-09-30|||||Interventional|||Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis|Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis|Completed||Phase 2|36||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.64898|2018-06-01 05:29:40.64898
NCT00001790|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1998||1998-10-31|October 1999|1999-10-31|September 2000||2000-09-30|||||Interventional|||Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia|Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia|Completed||Phase 1|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.7003|2018-06-01 05:29:40.7003
NCT00001789|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1999||1999-06-30|June 1999|1999-06-30|May 2000||2000-05-31|||||Interventional|||BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis|An Open-Label, Multiple-Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BG9588 (Anti-CD40L Antibody) in Subjects With Proliferative Lupus Glomerulonephritis (SLE-GN)|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.748198|2018-06-01 05:29:40.748198
NCT00001782|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1998||1998-03-31|November 1999|1999-11-30|December 2000||2000-12-31|||||Observational|||Areas of Brain Responsible for Understanding American Sign Language|Hemispheric Lateralization of Language Receptive Function in the Deaf and in Hearing Individuals Who Learned ASL as First Language|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.797659|2018-06-01 05:29:40.797659
NCT00001777|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1997||1997-12-31|November 1998|1998-11-30|May 2000||2000-05-31|||||Interventional|||Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)|A Controlled, Randomized, Double-Blind Trial of Sertraline in Patients With Frontal Lobe Dementia (FLD)|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.838822|2018-06-01 05:29:40.838822
NCT00001774|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|November 1999|1999-11-30|October 2000||2000-10-31|||||Observational|||Vasodilation in Patients With Fabry's Disease|An Investigation of Endothelium-Derived Vasodilation in Patients With Fabry's Disease|Completed|||48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:40.943936|2018-06-01 05:29:40.943936
NCT00001772|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1998||1998-09-30|August 2000|2000-08-31|July 2001||2001-07-31|||||Observational|||Evaluation of Patients With Rapid Cycling Bipolar Disorder (RCBD)|Evaluation of Patients With Rapid Cycling Bipolar Disorder|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.0016|2018-06-01 05:29:41.0016
NCT00001768|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|December 1999|1999-12-31|June 2000||2000-06-30|||||Interventional|||Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)|Childhood Onset Psychiatric Disorders: A Placebo Controlled Double-Blind Crossover Trial of Intravenous Immunoglobulin (IVIg)|Completed||Phase 3|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.055519|2018-06-01 05:29:41.055519
NCT00001763|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|April 1999|1999-04-30|March 2000||2000-03-31|||||Interventional|||Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection|Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.123616|2018-06-01 05:29:41.123616
NCT00001761|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1998||1998-02-28|January 1999|1999-01-31|April 2000||2000-04-30|||||Interventional|||Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis|Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.206707|2018-06-01 05:29:41.206707
NCT00001759|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1997||1997-12-31|February 2000|2000-02-29|January 2001||2001-01-31|||||Observational|||Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography|Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography|Completed|||95||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.269488|2018-06-01 05:29:41.269488
NCT00001757|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1997||1997-11-30|December 1999|1999-12-31|July 2000||2000-07-31|||||Interventional|||An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections|An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections|Completed||Phase 3|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.336053|2018-06-01 05:29:41.336053
NCT00001754|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1998||1998-06-30|June 2000|2000-06-30|May 2001||2001-05-31|||||Observational|||Study of Skeletal Disorders and Short Stature|Clinical and Molecular Manifestations of Human Skeletal Dysplasias and Short Stature|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.40945|2018-06-01 05:29:41.40945
NCT00001753|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1998||1998-09-30|August 1999|1999-08-31|November 2000||2000-11-30|||||Interventional|||Study of the Effects of Temperature on Metabolism in Human Muscle|Study of Temperature Effects on Skeletal Muscle Aerobic Energy Metabolism|Completed||Phase 1|17||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.473847|2018-06-01 05:29:41.473847
NCT00001752|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1998||1998-09-30|August 1999|1999-08-31|July 2000||2000-07-31|||||Interventional|||Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women|Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.529563|2018-06-01 05:29:41.529563
NCT00001748|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1998||1998-06-30|August 1999|1999-08-31|May 2000||2000-05-31|||||Interventional|||HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies|HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies|Completed||Phase 1|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.59469|2018-06-01 05:29:41.59469
NCT00001747|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1998||1998-05-31|May 2000|2000-05-31|March 2001||2001-03-31|||||Observational|||Racial Differences in Control of Blood Vessel Tone and Blood Flow|Racial Differences in Flow Mediated Vasodilator Function|Completed|||108||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.656969|2018-06-01 05:29:41.656969
NCT00001742|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1998||1998-02-28|January 2000|2000-01-31|January 2001||2001-01-31|||||Observational|||The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients|The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.708997|2018-06-01 05:29:41.708997
NCT00001740|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|November 1999|1999-11-30|October 2000||2000-10-31|||||Observational|||Evaluation of Left Ventricular Volumes by Real-Time 3-Dimensional Echocardiography|Evaluation of Left Ventricular Volumes by Real-Time 3-Dimensional Echocardiography|Completed|||240||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.76109|2018-06-01 05:29:41.76109
NCT00001738|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1998||1998-08-31|August 1999|1999-08-31|June 2000||2000-06-30|||||Observational|||Vascular Endothelial Growth Factor (VEGF) in Uveitis|A Pilot Study to Demonstrate the Presence of Vascular Endothelial Growth Factor (VEGF) in Uveitic Cystoid Macular Edema|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.813483|2018-06-01 05:29:41.813483
NCT00001736|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1998||1998-05-31|April 2000|2000-04-30|March 2001||2001-03-31|||||Interventional|||New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis|Safety and Efficacy Trial of a Proposed NDA Formulation of Topical Cysteamine in the Treatment of Corneal Cystine Crystal Accumulation in Cystinosis|Completed||Phase 1|51||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.864541|2018-06-01 05:29:41.864541
NCT00001735|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|March 2000|2000-03-31|October 2000||2000-10-31|||||Interventional|||Gene Therapy for Gyrate Atrophy|Phase I Study in the Safety and Efficacy of Transduced Keratinocytes for Possible Treatment of Gyrate Atrophy|Completed||Phase 1|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.921423|2018-06-01 05:29:41.921423
NCT00001731|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1997||1997-11-30|October 1999|1999-10-31|October 2000||2000-10-31|||||Interventional|||Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops|A Double-Masked, Randomized, Vehicle-Controlled Pilot Study of the Treatment of Keratoconjunctivitis Sicca With Topical Cyclosporin A 0.1% Emulsion|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:41.969865|2018-06-01 05:29:41.969865
NCT00001730|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1997||1997-12-31|November 1999|1999-11-30|April 2000||2000-04-30|||||Interventional|||Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.|A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal|Completed||Phase 4|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.020204|2018-06-01 05:29:42.020204
NCT00001718|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1998||1998-07-31|July 1999|1999-07-31|June 2000||2000-06-30|||||Interventional|||Facilitation of Oral Bolus Propulsion Using Electropalatography in Patients With Dysphagia|Facilitation of Oral Bolus Propulsion Using Electropalatography in Patients With Dysphagia|Completed||N/A|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.068175|2018-06-01 05:29:42.068175
NCT00001717|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1998||1998-07-31|June 1999|1999-06-30|July 2000||2000-07-31|||||Observational|||Influences on HIV Infected Subjects' Willingness to Participate in Research and Ability to Give Informed Consent|Influences on HIV Infected Subjects' Willingness to Participate in Research and Ability to Give Informed Consent|Completed|||225||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.110873|2018-06-01 05:29:42.110873
NCT00001714|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1998||1998-03-31|February 2001|2001-02-28|July 2001||2001-07-31|||||Observational|||Magnetization Transfer Quantitation and Characterization for Clinical Scanners|Magnetization Transfer Quantitation and Characterization for Clinical Scanners|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.153509|2018-06-01 05:29:42.153509
NCT00001705|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1998||1998-07-31|July 2000|2000-07-31|June 2001||2001-06-30|||||Interventional|||Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence|Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence|Completed||Phase 2|141||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.219846|2018-06-01 05:29:42.219846
NCT00001699|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1998||1998-06-30|June 1999|1999-06-30|March 2000||2000-03-31|||||Observational|||A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers|A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.26719|2018-06-01 05:29:42.26719
NCT00001696|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|April 2000|2000-04-30|March 2001||2001-03-31|||||Interventional|||A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor|A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.311166|2018-06-01 05:29:42.311166
NCT00001685|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1997||1997-11-30|October 1999|1999-10-31|September 2000||2000-09-30|||||Interventional|||Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase|Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase|Completed||Phase 2|114||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.47058|2018-06-01 05:29:42.47058
NCT00001681|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|October 1999|1999-10-31|September 2000||2000-09-30|||||Observational|||A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations|A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.53486|2018-06-01 05:29:42.53486
NCT00001680|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|September 2000|2000-09-30|July 2001||2001-07-31|||||Interventional|||A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus|A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus|Completed||Phase 2|17||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.585691|2018-06-01 05:29:42.585691
NCT00001679|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1998||1998-08-31|August 1999|1999-08-31|June 2000||2000-06-30|||||Observational|||Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients|Prognostic Indicators and Determinants of the 2-5 Year Outcome in a Cohort of Early Synovitis Patients|Completed|||250||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.662806|2018-06-01 05:29:42.662806
NCT00001677|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1998||1998-06-30|May 1999|1999-05-31|April 2000||2000-04-30|||||Interventional|||Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy|Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.71161|2018-06-01 05:29:42.71161
NCT00001672|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1997||1997-09-30|August 1999|1999-08-31|March 2000||2000-03-31|||||Observational|||Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy|Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.783054|2018-06-01 05:29:42.783054
NCT00001669|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|April 1999|1999-04-30|April 2000||2000-04-30|||||Interventional|||A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients|A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients|Completed||Phase 2|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.830471|2018-06-01 05:29:42.830471
NCT00001668|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1997||1997-04-30|May 1999|1999-05-31|April 2000||2000-04-30|||||Observational|||Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors|Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.887012|2018-06-01 05:29:42.887012
NCT00001667|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1997||1997-03-31|February 1999|1999-02-28|April 2000||2000-04-30|||||Observational|||Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases|Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.932985|2018-06-01 05:29:42.932985
NCT00001665|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1997||1997-01-31|December 1999|1999-12-31|September 2000||2000-09-30|||||Observational|||Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease|Can Subthreshold Transcranial Magnetic Stimulation (rTMS) to Motor Cortex and/or to Supplementary Motor Area (SMA) Improve Performance of Complex Motor Sequences in Parkinson's Disease?|Completed|||12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:42.980871|2018-06-01 05:29:42.980871
NCT00001527|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1995||1995-11-30|November 1999|1999-11-30|September 2000||2000-09-30|||||Observational|||Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension|Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.94847|2018-06-01 05:29:45.94847
NCT00001658|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|August 2000|2000-08-31|June 2001||2001-06-30|||||Interventional|||Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections|A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections|Completed||Phase 4|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:43.038762|2018-06-01 05:29:43.038762
NCT00001657|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1997||1997-06-30|August 1999|1999-08-31|May 2000||2000-05-31|||||Observational|||Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Chronic Posttraumatic Stress Disorder (PTSD)|Controlled Studies of Repetitive Transcranial Magnetic Stimulation (rTMS) in Chronic Posttraumatic Stress Disorder (PTSD)|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:43.087068|2018-06-01 05:29:43.087068
NCT00001646|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1997||1997-08-31|September 1999|1999-09-30|August 2000||2000-08-31|||||Interventional|||Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis|Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis|Completed||Phase 3|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:43.133205|2018-06-01 05:29:43.133205
NCT00001642|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1997||1997-05-31|May 1999|1999-05-31|March 2000||2000-03-31|||||Observational|||Positional Cloning of the Gene(s) Responsible for Alagille Syndrome|Positional Cloning of the Gene(s) Responsible for Alagille Syndrome|Completed|||225||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:43.182793|2018-06-01 05:29:43.182793
NCT00001639|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1996||1996-12-31|October 1999|1999-10-31|October 2000||2000-10-31|||||Observational|||Evaluation of Patients With Unresolved Chromosome Abnormalities|Evaluation of Patients With Unresolved Chromosome Aberrations|Completed|||263||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:43.228077|2018-06-01 05:29:43.228077
NCT00001633|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1997||1997-09-30|December 1999|1999-12-31|December 2000||2000-12-31|||||Interventional|||Safety and Effectiveness of Coronary Magnetic Resonance Angiography (CMRA) Imaging|A Phase II Feasibility Study of the Safety and Efficacy of Coronary Magnetic Resonance Angiography (CMRA) Imaging|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:43.270165|2018-06-01 05:29:43.270165
NCT00001629|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|June 1999|1999-06-30|September 2000||2000-09-30|||||Interventional|||The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function|The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function|Completed||Phase 3|49||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.213104|2018-06-01 05:29:44.213104
NCT00001628|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|June 1999|1999-06-30|September 2000||2000-09-30|||||Interventional|||The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function|The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function|Completed||Phase 3|36||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.295223|2018-06-01 05:29:44.295223
NCT00001624|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1997||1997-03-31|February 1999|1999-02-28|March 2000||2000-03-31|||||Interventional|||Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation|Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation|Completed||Phase 1|16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.352918|2018-06-01 05:29:44.352918
NCT00001622|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1997||1997-03-31|January 2000|2000-01-31|March 2001||2001-03-31|||||Interventional|||Study of the Response of Human Small Blood Vessels|Study of the Relation Between In Vivo and In Vitro Response of Human Small Vessels|Completed||Phase 1|87||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.410454|2018-06-01 05:29:44.410454
NCT00001617|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1997||1997-09-30|November 1999|1999-11-30|August 2000||2000-08-31|||||Observational|||Test of QLS Device to Detect Early Cataracts|Feasibility Study - Use of Quasielastic Light Scattering (QLS) Device in a Study of the Human Lens and Lens Opacities|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.469257|2018-06-01 05:29:44.469257
NCT00001615|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|May 1999|1999-05-31|May 2000||2000-05-31|||||Interventional|||Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration|Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration|Completed||Phase 1|180||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.519084|2018-06-01 05:29:44.519084
NCT00001614|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|June 1999|1999-06-30|May 2000||2000-05-31|||||Interventional|||The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis|The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis|Completed||Phase 1|13||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.578386|2018-06-01 05:29:44.578386
NCT00001612|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1997||1997-05-31|May 1999|1999-05-31|August 2000||2000-08-31|||||Observational|||Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)|Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)|Completed|||170||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.63732|2018-06-01 05:29:44.63732
NCT00001605|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1997||1997-05-31|April 2000|2000-04-30|April 2001||2001-04-30|||||Interventional|||Vaccination for Middle Ear Infection|Phase I Study to Evaluate the Safety and Immunogenicity of a Nontypeable Haemophilus Influenzae Vaccine for Otitis Media|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.707154|2018-06-01 05:29:44.707154
NCT00001587|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1997||1997-09-30|April 2000|2000-04-30|March 2001||2001-03-31|||||Interventional|||A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver|A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.853924|2018-06-01 05:29:44.853924
NCT00001579|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-07-14|2002-12-09|2002-12-10|Estimate|||||||2006-07-14|2006-07-17|Estimate|June 1997||1997-06-30|May 2000|2000-05-31|March 2001||2001-03-31|||||Interventional|||A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors|A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:44.986719|2018-06-01 05:29:44.986719
NCT00001577|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1997||1997-06-30|April 1999|1999-04-30|March 2000||2000-03-31|||||Interventional|||Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity|Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.052145|2018-06-01 05:29:45.052145
NCT00001573|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1997||1997-03-31|February 2000|2000-02-29|May 2000||2000-05-31|||||Interventional|||A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy|A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.118569|2018-06-01 05:29:45.118569
NCT00001571|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1997||1997-02-28|January 2000|2000-01-31|December 2000||2000-12-31|||||Observational|||A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines|A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.18466|2018-06-01 05:29:45.18466
NCT00001570|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1997||1997-02-28|January 2000|2000-01-31|January 2001||2001-01-31|||||Interventional|||A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer|A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer|Completed||Phase 1|46||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.246877|2018-06-01 05:29:45.246877
NCT00001565|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1996||1996-12-31|November 1999|1999-11-30|October 2000||2000-10-31|||||Interventional|||Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy|Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy|Completed||Phase 1|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.314348|2018-06-01 05:29:45.314348
NCT00001554|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1996||1996-06-30|May 1999|1999-05-31|June 2000||2000-06-30|||||Interventional|||Infrared Camera for Brain Mapping During Surgery|Intraoperative Infrared Functional Brain Mapping|Completed||Phase 1|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.373465|2018-06-01 05:29:45.373465
NCT00001553|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1996||1996-05-31|April 2000|2000-04-30|March 2001||2001-03-31|||||Observational|||Motor Changes Associated With Recovery From Stroke After Therapy|Functional Changes Associated With Recovery of Motor Function in Chronic Ischemic Subcortical Stroke After a Therapeutic Intervention|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.421776|2018-06-01 05:29:45.421776
NCT00001546|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1996||1996-05-31|April 1999|1999-04-30|June 2000||2000-06-30|||||Observational|||Circadian Regulation of Sleep in Habitual Short Sleepers and Long Sleepers|Circadian Regulation of Sleep in Habitual Short Sleepers and Long Sleepers|Completed|||38||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.470849|2018-06-01 05:29:45.470849
NCT00001540|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-01|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1996||1996-04-30|February 1999|1999-02-28|March 2000||2000-03-31|||||Observational|||The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo|The Use of Bacteriophage Phi X174 to Assess the Immune Competence of HIV-Infected Patients In Vivo|Completed|||52||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.521135|2018-06-01 05:29:45.521135
NCT00001538|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1996||1996-03-31|February 2000|2000-02-29|April 2001||2001-04-30|||||Interventional|||Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers|Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers|Completed||Phase 1|41||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.565659|2018-06-01 05:29:45.565659
NCT00001536|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1996||1996-08-31|August 1999|1999-08-31|July 2000||2000-07-31|||||Observational|||Issues Surrounding Prenatal Genetic Testing for Achondroplasia|Issues Surrounding Prenatal Genetic Testing for Achondroplasia|Completed|||2000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.615108|2018-06-01 05:29:45.615108
NCT00001533|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-07-14|2002-12-09|2002-12-10|Estimate|||||||2006-07-14|2006-07-17|Estimate|September 1996||1996-09-30|October 1999|1999-10-31|September 2000||2000-09-30|||||Interventional|||Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine|Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.667979|2018-06-01 05:29:45.667979
NCT00001531|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1996||1996-06-30|August 1999|1999-08-31|September 2000||2000-09-30|||||Observational|||Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction|Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction|Completed|||355||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.72017|2018-06-01 05:29:45.72017
NCT00001530|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1996||1996-04-30|April 1999|1999-04-30|May 2000||2000-05-31|||||Observational|||Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy|Long-Term Results of DDD Pacing in Obstructive Hypertrophic Cardiomyopathy|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.765407|2018-06-01 05:29:45.765407
NCT00001528|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1996||1996-02-29|April 2000|2000-04-30|March 2001||2001-03-31|||||Observational|||Analysis of Heart Muscle Function Following Exercise in Patients With Heart Disease|Post-Stress Left Ventricular Contractile Dysfunction: Does It Represent Persistent Myocardial Ischemia or Stunning?|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:45.896785|2018-06-01 05:29:45.896785
NCT00001523|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1996||1996-05-31|June 1999|1999-06-30|March 2000||2000-03-31|||||Observational|||Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation|Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.004445|2018-06-01 05:29:46.004445
NCT00001520|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1996||1996-09-30|September 1999|1999-09-30|August 2000||2000-08-31|||||Interventional|||The Early Reversibility of Rocuronium After Different Doses of Neostigmine|The Early Reversibility of Rocuronium After Different Doses of Neostigmine|Completed||Phase 4|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.053187|2018-06-01 05:29:46.053187
NCT00001519|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1996||1996-06-30|May 2000|2000-05-31|April 2001||2001-04-30|||||Observational|||Oxygen Uptake Kinetics During Recovery From Maximal and Submaximal Exercise|Oxygen Uptake Kinetics During Recovery From Maximal and Submaximal Exercise|Completed|||5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.120077|2018-06-01 05:29:46.120077
NCT00001518|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1996||1996-01-31|December 1999|1999-12-31|November 2000||2000-11-30|||||Observational|||A Randomized Evaluation of the Effect of Routine Normal Saline Flush Versus Heparinized Saline Solution in Groshong and Groshong PICC Catheters|A Randomized Evaluation of the Effect of Routine Normal Saline Flush Versus Heparinized Saline Solution in Groshong and Groshong PICC Catheters|Completed|||132||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.175491|2018-06-01 05:29:46.175491
NCT00001509|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1996||1996-07-31|June 1999|1999-06-30|May 2000||2000-05-31|||||Interventional|||A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor|A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.233084|2018-06-01 05:29:46.233084
NCT00001502|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1996||1996-04-30|February 2000|2000-02-29|March 2000||2000-03-31|||||Interventional|||A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors|Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.29397|2018-06-01 05:29:46.29397
NCT00001499|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1996||1996-03-31|March 2000|2000-03-31|June 2000||2000-06-30|||||Interventional|||Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer|Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.355962|2018-06-01 05:29:46.355962
NCT00001498|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1996||1996-02-29|January 2000|2000-01-31|December 2000||2000-12-31|||||Interventional|||A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer|A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer|Completed||Phase 2|55||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.419844|2018-06-01 05:29:46.419844
NCT00001497|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1995||1995-12-31|November 1999|1999-11-30|October 2000||2000-10-31|||||Observational|||Assessment of Attentional Functioning in Children With HIV-1 Infection|Assessment of Attentional Functioning in Children With HIV-1 Infection|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.483013|2018-06-01 05:29:46.483013
NCT00001495|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1995||1995-11-30|September 1999|1999-09-30|October 2000||2000-10-31|||||Interventional|||A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors|A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.533046|2018-06-01 05:29:46.533046
NCT00001493|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1995||1995-10-31|August 1999|1999-08-31|June 2000||2000-06-30|||||Interventional|||Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer|Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cance|Completed||Phase 2|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.589449|2018-06-01 05:29:46.589449
NCT00001489|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1994||1994-10-31|August 1999|1999-08-31|August 2000||2000-08-31|||||Observational|||Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism|The Effect of Vigabatrin on Cerebral Blood Flow and Glucose Metabolism|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.643782|2018-06-01 05:29:46.643782
NCT00001485|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|August 1999|1999-08-31|April 2000||2000-04-30|||||Observational|||Effects of Season on Melatonin Secretion in Healthy Men and Women and Patients With Seasonal Affective Disorder|Gender Differences in the Effects of Season on Patterns of Nocturnal Melatonin Secretion in Healthy Volunteers and Patients With Seasonal Affective Disorder (SAD)|Completed|||116||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.699918|2018-06-01 05:29:46.699918
NCT00001482|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1995||1995-05-31|June 2000|2000-06-30|May 2001||2001-05-31|||||Interventional|||New Drugs in the Treatment of Mood Disorders|Evaluation of Lamotrigine (Lamictal® (Registered Trademark)) Monotherapy and Gabapentin (Neurontin® (Registered Trademark)) Monotherapy in the Treatment of Mood Disorders|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.752637|2018-06-01 05:29:46.752637
NCT00001479|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1995||1995-01-31|June 1999|1999-06-30|May 2000||2000-05-31|||||Observational|||Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression|Intensively Sampled Dynamics of ACTH and Cortisol Affective Disorders|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.809879|2018-06-01 05:29:46.809879
NCT00001478|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1994||1994-10-31|January 2000|2000-01-31|January 2001||2001-01-31|||||Observational|||Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders|Regional Cerebral Blood Flow Correlates of Spontaneous and Drug-Induced Clinical Changes in Mood Disorders|Completed|||170||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.856106|2018-06-01 05:29:46.856106
NCT00001477|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1995||1995-08-31|February 2000|2000-02-29|October 2000||2000-10-31|||||Observational|||Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy|Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.899443|2018-06-01 05:29:46.899443
NCT00001468|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1995||1995-03-31|February 2000|2000-02-29|February 2001||2001-02-28|||||Observational|||Outcomes of Education and Counseling for BRCA1 Testing|Outcomes of Education and Counseling for BRCA1 or BRCA2 Testing|Completed|||1500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:46.945697|2018-06-01 05:29:46.945697
NCT00001466|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1994||1994-10-31|September 1999|1999-09-30|October 2000||2000-10-31|||||Observational|||Study of Clinical and Molecular Manifestations of Genetic Disorders|Clinical and Molecular Manifestations of Six Categories of Genetic Disorders|Completed|||1200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:47.004728|2018-06-01 05:29:47.004728
NCT00001462|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1995||1995-05-31|August 1999|1999-08-31|April 2000||2000-04-30|||||Observational|||Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals|Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:47.068413|2018-06-01 05:29:47.068413
NCT00001461|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1995||1995-03-31|April 2000|2000-04-30|April 2001||2001-04-30|||||Observational|||Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme|Investigation of the Interaction Between the Vascular Endothelium and Angiotensin-Converting Enzyme|Completed|||209||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:50.097358|2018-06-01 05:29:50.097358
NCT00001459|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1995||1995-01-31|January 2000|2000-01-31|March 2001||2001-03-31|||||Observational|||Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers|Tomographic Myocardial Wall Motion Analysis in Patients With Myocardial Ischemia and in Normal Subjects|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:51.389964|2018-06-01 05:29:51.389964
NCT00001455|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|June 1999|1999-06-30|June 2000||2000-06-30|||||Observational|||Iron Overload in African Americans|Iron Overload in African Americans|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:51.442393|2018-06-01 05:29:51.442393
NCT00001450|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1995||1995-09-30|July 1999|1999-07-31|June 2000||2000-06-30|||||Interventional|||Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC|Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC|Completed||Phase 2|58||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:51.650323|2018-06-01 05:29:51.650323
NCT00001449|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1995||1995-09-30|September 1999|1999-09-30|April 2000||2000-04-30|||||Interventional|||A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients|A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:51.90228|2018-06-01 05:29:51.90228
NCT00001448|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1995||1995-08-31|July 1999|1999-07-31|June 2000||2000-06-30|||||Observational|||The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection|The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:52.008481|2018-06-01 05:29:52.008481
NCT00001446|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1995||1995-09-30|August 2000|2000-08-31|July 2001||2001-07-31|||||Interventional|||A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer|A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer|Completed||Phase 2|64||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:52.103844|2018-06-01 05:29:52.103844
NCT00001445|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1995||1995-08-31|August 2000|2000-08-31|July 2001||2001-07-31|||||Interventional|||Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection|Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection|Completed||Phase 1|32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:52.187064|2018-06-01 05:29:52.187064
NCT00001443|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1995||1995-07-31|March 2000|2000-03-31|October 2000||2000-10-31|||||Interventional|||A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection|A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection|Completed||Phase 1|63||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:52.335085|2018-06-01 05:29:52.335085
NCT00001439|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|May 1999|1999-05-31|April 2000||2000-04-30|||||Interventional|||A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant|A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant|Completed||Phase 1|255||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:52.498817|2018-06-01 05:29:52.498817
NCT00001438|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|January 2000|2000-01-31|December 2000||2000-12-31|||||Interventional|||A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes|A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:52.652939|2018-06-01 05:29:52.652939
NCT00001437|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|May 1999|1999-05-31|March 2000||2000-03-31|||||Interventional|||Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis|Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:52.886169|2018-06-01 05:29:52.886169
NCT00001436|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1995||1995-05-31|April 2000|2000-04-30|September 2000||2000-09-30|||||Interventional|||A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma|A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma|Completed||Phase 1|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:53.07453|2018-06-01 05:29:53.07453
NCT00001435|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1995||1995-04-30|February 2000|2000-02-29|December 2000||2000-12-31|||||Observational|||Psychosocial Correlates and Coping Strategies Associated With Long-Term Survival of HIV-Infected Children|Psychosocial Correlates and Coping Strategies Associated With Long-Term Survival of HIV-Infected Children|Completed|||110||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:53.283876|2018-06-01 05:29:53.283876
NCT00001431|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1995||1995-02-28|November 2000|2000-11-30|November 2000||2000-11-30|||||Interventional|||A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas|A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:53.43842|2018-06-01 05:29:53.43842
NCT00001428|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1995||1995-02-28|January 2000|2000-01-31|December 2000||2000-12-31|||||Interventional|||A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer|A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer|Completed||Phase 2|65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:53.613039|2018-06-01 05:29:53.613039
NCT00001427|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1995||1995-01-31|January 2000|2000-01-31|April 2000||2000-04-30|||||Interventional|||A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin|A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:53.753592|2018-06-01 05:29:53.753592
NCT00001424|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1994||1994-11-30|October 1999|1999-10-31|August 2000||2000-08-31|||||Observational|||Evaluation and Natural History of Children With Cancer and AIDS|Evaluation and Natural History of Children With Cancer and AIDS|Completed|||110||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:53.880215|2018-06-01 05:29:53.880215
NCT00001422|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|May 1999|1999-05-31|April 2000||2000-04-30|||||Interventional|||A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis|A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:53.93318|2018-06-01 05:29:53.93318
NCT00001421|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|May 2000|2000-05-31|April 2001||2001-04-30|||||Interventional|||Methimazole to Treat Polymyositis and Dermatomyositis|A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.04394|2018-06-01 05:29:54.04394
NCT00001416|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2016-09-21|2002-12-09|2002-12-10|Estimate|||||||2016-09-21|2016-09-22|Estimate|December 1993||1993-12-31|September 2016|2016-09-30|November 2000||2000-11-30|||||Interventional|||Bone Response to Enzyme Replacement in Gaucher's Disease|Skeletal Responses to Macrophage-Targeted Glucocerebrosidase in Patients With Type 1 Gaucher's Disease|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.175853|2018-06-01 05:29:54.175853
NCT00001415|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1994||1994-05-31|April 1999|1999-04-30|July 2000||2000-07-31|||||Observational|||Glucocorticoid Effects on Cellular Cytokine Release|Glucocorticoid Effects on Cellular Cytokine Release|Completed|||130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.386472|2018-06-01 05:29:54.386472
NCT00001402|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1994||1994-01-31|December 1999|1999-12-31|March 2001||2001-03-31|||||Interventional|||PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers|Assessment of Metabolic Function and Perfusion Using Positron Emission Tomography: An Analysis of Patients With Congestive Cardiomyopathy Before and After Beta-Blockers|Completed||Phase 2|130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.518813|2018-06-01 05:29:54.518813
NCT00001395|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1994||1994-03-31|March 1999|1999-03-31|August 2000||2000-08-31|||||Observational|||Long Term Follow-Up of Diabetic Retinopathy|Long Term Follow-Up of Diabetic Retinopathy|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.6596|2018-06-01 05:29:54.6596
NCT00001387|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1994||1994-09-30|August 1999|1999-08-31|July 2000||2000-07-31|||||Interventional|||Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy|Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.757419|2018-06-01 05:29:54.757419
NCT00001384|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1994||1994-05-31|April 2000|2000-04-30|February 2001||2001-02-28|||||Interventional|||A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients|A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients|Completed||Phase 2|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:54.960105|2018-06-01 05:29:54.960105
NCT00001383|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1994||1994-03-31|March 2000|2000-03-31|January 2001||2001-01-31|||||Interventional|||A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833|A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833|Completed||Phase 1|52||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.060451|2018-06-01 05:29:55.060451
NCT00001382|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1994||1994-03-31|March 2000|2000-03-31|March 2000||2000-03-31|||||Interventional|||A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate|A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate|Completed||Phase 1|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.151789|2018-06-01 05:29:55.151789
NCT00001381|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1994||1994-03-31|January 2000|2000-01-31|December 2000||2000-12-31|||||Interventional|||A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder|A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder|Completed||Phase 1|18||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.21143|2018-06-01 05:29:55.21143
NCT00001378|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1994||1994-01-31|November 1999|1999-11-30|November 2000||2000-11-30|||||Interventional|||A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer|A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer|Completed||Phase 1|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.34724|2018-06-01 05:29:55.34724
NCT00001377|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1993||1993-12-31|December 1999|1999-12-31|December 2000||2000-12-31|||||Observational|||Familial Prostate Cancer|Familial Prostate Cancer|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.45688|2018-06-01 05:29:55.45688
NCT00001376|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1994||1994-08-31|July 1999|1999-07-31|June 2000||2000-06-30|||||Observational|||Steroid Hormones, TH1/TH2 Cytokines and Reproductive Status|Steroid Hormones, TH1/TH2 Cytokines and Reproductive Status|Completed|||209||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.589936|2018-06-01 05:29:55.589936
NCT00001375|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1994||1994-08-31|August 1999|1999-08-31|June 2000||2000-06-30|||||Observational|||The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis|The Pathogenesis of Inflammatory Synovitis: A Study of Early Arthritis|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.71244|2018-06-01 05:29:55.71244
NCT00001371|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1993||1993-12-31|December 1999|1999-12-31|December 2000||2000-12-31|||||Observational|||A Pilot Study of Topical Antiflammin-2 for Psoriasis|A Pilot Study of Topical Antiflammin-2 for Psoriasis|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:55.823128|2018-06-01 05:29:55.823128
NCT00001365|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-07-12|2002-12-09|2002-12-10|Estimate|||||||2006-07-12|2006-07-13|Estimate|July 1993||1993-07-31|July 2000|2000-07-31|June 2001||2001-06-30|||||Interventional|||Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System|NMDA Receptor Antagonist Treatment of Neurodegenerative Disease|Completed||Phase 2|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:56.015736|2018-06-01 05:29:56.015736
NCT00001363|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1993||1993-01-31|May 2000|2000-05-31|March 2001||2001-03-31|||||Observational|||PET Scan to Map the Areas of the Brain Involved in Planning|Functional Brain Mapping of Planning Activities With [015] Water PET Blood Flow Technique|Completed|||230||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:56.281993|2018-06-01 05:29:56.281993
NCT00001346|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1992||1992-11-30|February 2000|2000-02-29|October 2000||2000-10-31|||||Observational|||Diabetic Retinopathy and Visual Function Study|Diabetic Retinopathy and Visual Function Study|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:56.394206|2018-06-01 05:29:56.394206
NCT00001344|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1993||1993-03-31|March 2000|2000-03-31|February 2001||2001-02-28|||||Interventional|||Dextromethorphan Versus Placebo for Neuropathic Pain|Dextromethorphan Versus Placebo for Neuropathic Pain|Completed||Phase 2|129||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:56.520562|2018-06-01 05:29:56.520562
NCT00001342|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1992||1992-11-30|October 1999|1999-10-31|April 2001||2001-04-30|||||Observational|||Study of Glycogen Storage Disease and Associated Disorders|A Study of Collateral Disorders of Glycogen Storage Disease|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:56.644149|2018-06-01 05:29:56.644149
NCT00001341|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1993||1993-09-30|August 2000|2000-08-31|June 2001||2001-06-30|||||Interventional|||A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease|A Phase I Trial of ZD1694 (TOMUDEX® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:56.792436|2018-06-01 05:29:56.792436
NCT00001338|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1993||1993-06-30|April 2000|2000-04-30|January 2001||2001-01-31|||||Interventional|||A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer|A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer|Completed||Phase 3|65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:56.906204|2018-06-01 05:29:56.906204
NCT00001332|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1992||1992-12-31|November 1999|1999-11-30|October 2000||2000-10-31|||||Interventional|||Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis|Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.16157|2018-06-01 05:29:57.16157
NCT00001330|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1992||1992-11-30|November 1999|1999-11-30|October 2000||2000-10-31|||||Observational|||Study of Silicone-Associated Connective Tissue Diseases|Epidemiologic, Immunologic, and Immunogenetic Factors in Silicone-Associated Connective Tissue Diseases|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.246246|2018-06-01 05:29:57.246246
NCT00001324|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1992||1992-03-31|March 2000|2000-03-31|July 2001||2001-07-31|||||Observational|||PET Scan to Study Brain Control of Human Movement|CNS Control of Human Movement: H215O PET Studies|Completed|||510||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.315318|2018-06-01 05:29:57.315318
NCT00001318|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1992||1992-08-31|August 1999|1999-08-31|November 2000||2000-11-30|||||Interventional|||Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma|Treatment of Non-Tuberculous Mycobacterial Infections With Interferon Gamma|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.375143|2018-06-01 05:29:57.375143
NCT00001317|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1992||1992-05-31|May 2000|2000-05-31|July 2001||2001-07-31|||||Interventional|||A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood|A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood|Completed||Phase 4|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.432533|2018-06-01 05:29:57.432533
NCT00001314|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1992||1992-05-31|April 2000|2000-04-30|March 2001||2001-03-31|||||Observational|||Investigation of Heart Function in Patients With Heart Valve Defects|Investigation of Myocardial Contractile Reserve by Dobutamine Stress Transesophageal Echocardiography in Aortic and Mitral Regurgitation|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.498083|2018-06-01 05:29:57.498083
NCT00001311|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1992||1992-04-30|March 2000|2000-03-31|February 2001||2001-02-28|||||Interventional|||Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients|Evaluation of the Efficacy of a Surface Modified Intraocular Lens in Reducing Post-Operative Inflammatory Signs Following Extracapsular Surgery in Uveitis Patients With Cataracts|Completed||Phase 2|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.556425|2018-06-01 05:29:57.556425
NCT00001301|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1992||1992-08-31|June 1999|1999-06-30|April 2000||2000-04-30|||||Observational|||Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors|Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors|Completed|||107||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.638|2018-06-01 05:29:57.638
NCT00001300|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1992||1992-06-30|April 2000|2000-04-30|March 2001||2001-03-31|||||Interventional|||A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma|A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma|Completed||Phase 3|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.693546|2018-06-01 05:29:57.693546
NCT00001298|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1992||1992-03-31|February 2000|2000-02-29|January 2001||2001-01-31|||||Interventional|||A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction|A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.761738|2018-06-01 05:29:57.761738
NCT00001296|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1992||1992-02-29|November 1999|1999-11-30|October 2000||2000-10-31|||||Interventional|||A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma|A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma|Completed||Phase 3|122||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.845733|2018-06-01 05:29:57.845733
NCT00001292|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|2002-12-09|2002-12-10|Estimate|||||||2008-03-04|2008-03-05|Estimate|February 1992||1992-02-29|April 2000|2000-04-30|April 2001||2001-04-30|||||Observational|||Study of Scaling Disorders and Other Inherited Skin Diseases|Clinical and Genetic Studies of the Scaling Disorders and Other Selected Genodermatoses|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.920419|2018-06-01 05:29:57.920419
NCT00001291|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|2002-12-09|2002-12-10|Estimate|||||||2008-03-04|2008-03-05|Estimate|December 1991||1991-12-31|December 1999|1999-12-31|January 2001||2001-01-31|||||Observational|||Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions|Investigations of Blood, Synovial Tissue and Synovial Fluids From Patients With Rheumatoid Arthritis and Related Conditions|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:57.98022|2018-06-01 05:29:57.98022
NCT00001287|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1990||1990-12-31|February 2000|2000-02-29|January 2001||2001-01-31|||||Interventional|||Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.063627|2018-06-01 05:29:58.063627
NCT00001285|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1991||1991-08-31|October 1999|1999-10-31|June 2000||2000-06-30|||||Observational|||Effects of Sex Hormones on Circadian Rhythm in Men and Women|Chronobiologic Effects of Gonadal Steroid Manipulations in Volunteer Subjects|Completed|||73||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.118874|2018-06-01 05:29:58.118874
NCT00001280|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1991||1991-01-31|February 2000|2000-02-29|March 2001||2001-03-31|||||Interventional|||Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease|Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.1868|2018-06-01 05:29:58.1868
NCT00001278|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1991||1991-05-31|May 2000|2000-05-31|April 2001||2001-04-30|||||Observational|||Study of Eye Tissue for Sarcoidosis|Immunologic Assay of Conjunctiva and Lacrimal Gland for Sarcoidosis|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.238908|2018-06-01 05:29:58.238908
NCT00001272|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1991||1991-09-30|June 1999|1999-06-30|May 2000||2000-05-31|||||Interventional|||A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients|A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.288437|2018-06-01 05:29:58.288437
NCT00001271|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1991||1991-07-31|June 2000|2000-06-30|April 2001||2001-04-30|||||Interventional|||A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma|A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma|Completed||Phase 1|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.34405|2018-06-01 05:29:58.34405
NCT00001270|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1991||1991-06-30|May 1999|1999-05-31|March 2000||2000-03-31|||||Interventional|||Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma|Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma|Completed||Phase 1|85||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.395919|2018-06-01 05:29:58.395919
NCT00001269|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1991||1991-05-31|April 2000|2000-04-30|February 2001||2001-02-28|||||Interventional|||Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer|Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer|Completed||Phase 1|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.454356|2018-06-01 05:29:58.454356
NCT00001267|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1990||1990-10-31|August 1999|1999-08-31|April 2000||2000-04-30|||||Interventional|||A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine|A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine|Completed||Phase 3|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.521343|2018-06-01 05:29:58.521343
NCT00001249|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1989||1989-12-31|November 1999|1999-11-30|October 2000||2000-10-31|||||Interventional|||Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac|Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.574557|2018-06-01 05:29:58.574557
NCT00001239|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1989||1989-07-31|April 2000|2000-04-30|January 2001||2001-01-31|||||Interventional|||Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer|Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.65161|2018-06-01 05:29:58.65161
NCT00001237|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1989||1989-03-31|January 2000|2000-01-31|April 2000||2000-04-30|||||Interventional|||Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas|Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas|Completed||Phase 2|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.71846|2018-06-01 05:29:58.71846
NCT00001233|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1988||1988-12-31|January 2000|2000-01-31|December 2000||2000-12-31|||||Observational|||Study of Children at Risk for Disruptive Behavior Disorders|A Longitudinal Study of Children at Risk for Disruptive Behavior Disorders: Transitions From Early Childhood to Middle Childhood and Adolescence|Completed|||900||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.796023|2018-06-01 05:29:58.796023
NCT00001232|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1988||1988-07-31|July 1999|1999-07-31|June 2000||2000-06-30|||||Observational|||The Effect of GnRH on Pitutitary Hormones in Menstrual-Cycle Mood Related Disorders|Pituitary Gonadotropin Response to GnRH Stimulation in Menstrual, Climacteric and, Menopause-Related Mood and Behavioral Disorders|Completed|||140||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.851383|2018-06-01 05:29:58.851383
NCT00001229|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1988||1988-10-31|November 1999|1999-11-30|January 2001||2001-01-31|||||Observational|||Diagnosis and Treatment of Pheochromocytoma|Diagnosis and Treatment of Pheochromocytoma|Completed|||240||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.89424|2018-06-01 05:29:58.89424
NCT00001218|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1987||1987-02-28|January 2000|2000-01-31|January 2001||2001-01-31|||||Observational|||Development of Normative Ultrasound Databases of Tongue Surface Configuration|Development of Normative Ultrasound Databases of Tongue Surface Configuration|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.947217|2018-06-01 05:29:58.947217
NCT00048009|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2017-06-16|2002-10-24|2002-10-25|Estimate|||||||2017-06-16|2017-06-19|Actual|October 25, 2002|Actual|2002-10-25|February 2017|2017-02-28|February 2, 2004|Actual|2004-02-02|February 2, 2004|Actual|2004-02-02||Interventional|||Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids||Completed||Phase 2|||Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:30:55.377192|2018-06-01 05:30:55.377192
NCT00001217|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1987||1987-05-31|January 2000|2000-01-31|December 2000||2000-12-31|||||Interventional|||Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study|Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study|Completed||Phase 3|260||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:58.997354|2018-06-01 05:29:58.997354
NCT00001216|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1986||1986-02-28|December 1999|1999-12-31|February 2001||2001-02-28|||||Observational|||Non-Invasive Electrical Stimulation of the Human Brain|Non-Invasive Stimulation of the Human Central Nervous System (Digitimer)|Completed|||175||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.054416|2018-06-01 05:29:59.054416
NCT00001211|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1986||1986-01-31|February 2000|2000-02-29|December 2000||2000-12-31|||||Observational|||Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects|Clinical Study of Oral Endosseous Titanium Implants in Edentulous Subjects|Completed|||160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.099353|2018-06-01 05:29:59.099353
NCT00001210|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1986||1986-11-30|October 1999|1999-10-31|September 2000||2000-09-30|||||Observational|||Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines|Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.154547|2018-06-01 05:29:59.154547
NCT00001209|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1986||1986-10-31|September 1999|1999-09-30|August 2000||2000-08-31|||||Interventional|||A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors|A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors|Completed||Phase 1|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.196523|2018-06-01 05:29:59.196523
NCT00001194|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1984||1984-04-30|March 2000|2000-03-31|February 2001||2001-02-28|||||Observational|||NMR Scanning on Patients|NMR Scanning on Patients|Completed|||99999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.325022|2018-06-01 05:29:59.325022
NCT00001193|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1984||1984-11-30|August 1999|1999-08-31|September 2000||2000-09-30|||||Interventional|||A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer|A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer|Completed||Phase 2|200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.382863|2018-06-01 05:29:59.382863
NCT00001189|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1983||1983-12-31|May 2000|2000-05-31|April 2001||2001-04-30|||||Interventional|||The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors|The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors|Completed||Phase 2|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.451224|2018-06-01 05:29:59.451224
NCT00001188|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1983||1983-12-31|November 1999|1999-11-30|September 2000||2000-09-30|||||Interventional|||The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities|The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.528276|2018-06-01 05:29:59.528276
NCT00001173|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1980||1980-06-30|June 1999|1999-06-30|June 2000||2000-06-30|||||Observational|||Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization|Studies of In Vitro B Lymphocyte Responses in Subjects Receiving Tetanus Toxoid Booster Immunization|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.599636|2018-06-01 05:29:59.599636
NCT00001169|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1979||1979-12-31|February 2000|2000-02-29|February 2001||2001-02-28|||||Observational|||Clinical Investigation of Infections Due to Leishmanial Parasites|Clinical Investigation of Infections Due to Leishmanial Parasites|Completed|||250||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.694698|2018-06-01 05:29:59.694698
NCT00001164|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|2002-12-09|2002-12-10|Estimate|||||||2008-03-04|2008-03-05|Estimate|July 1978||1978-07-31|June 2000|2000-06-30|June 2000||2000-06-30|||||Observational|||Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers|Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.792413|2018-06-01 05:29:59.792413
NCT00001158|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|2002-12-09|2002-12-10|Estimate|||||||2008-03-04|2008-03-05|Estimate|April 1977||1977-04-30|April 1999|1999-04-30|March 2000||2000-03-31|||||Observational|||Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System|Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.857647|2018-06-01 05:29:59.857647
NCT00001153|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1976||1976-06-30|May 1999|1999-05-31|May 2000||2000-05-31|||||Observational|||Visual Function and Ocular Pigmentation in Albinism|Visual Function and Ocular Pigmentation in Albinism|Completed|||130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.92322|2018-06-01 05:29:59.92322
NCT00001152|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1976||1976-06-30|May 1998|1998-05-31|June 2000||2000-06-30|||||Observational|||Pigment Dispersion Syndrome With and Without Glaucoma|Pigment Dispersion Syndrome With and Without Glaucoma|Completed|||175||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:29:59.996313|2018-06-01 05:29:59.996313
NCT00001142|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-12-09|2002-12-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1999||1999-10-31|October 2000|2000-10-31|December 2000||2000-12-31|||||Observational|||Metabolism and Body Shape of Healthy Children and Children With Chronic Infections|Metabolism and Body Composition of Healthy Children and Children With Chronic Infections|Completed|||185||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:00.176936|2018-06-01 05:30:00.176936
NCT00050388|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-06|||2008-06-20|2002-12-06|2002-12-09|Estimate|||||||2008-06-20|2008-06-24|Estimate||||June 2008|2008-06-30|June 2002||2002-06-30|||||Interventional|||Phase II Trial of Allovectin-7® for Head and Neck Cancer|Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx|Completed||Phase 3|||Vical|||||||||||||||||||2018-06-01 05:30:00.418075|2018-06-01 05:30:00.418075
NCT00050375|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-05|||2007-12-13|2002-12-05|2002-12-06|Estimate|||||||2007-12-13|2007-12-18|Estimate|December 2002||2002-12-31|June 2006|2006-06-30|December 2007|Actual|2007-12-31|||||Interventional|||Clinical Trial for Ovarian Cancer (OvaRex®)|A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex® MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin|Terminated||Phase 3|354||Unither Pharmaceuticals||||Study closed by sponser|||||||||||||||2018-06-01 05:30:00.624425|2018-06-01 05:30:00.624425
NCT00050362|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-04|||2008-03-03|2002-12-04|2002-12-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2002||2002-12-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||Rofecoxib and Bupivacaine to Prevent Pain After Third Molar (Wisdom Tooth) Extraction|Evaluation of a Long-Acting Local Anesthesia (Bupivacaine) and a Selective COX-2 Inhibitor (Rofecoxib) in Suppression of Central Sensitization|Completed||Phase 2|136||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:00.804237|2018-06-01 05:30:00.804237
NCT00050349|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-04|||2017-02-28|2002-12-04|2002-12-05|Estimate|||||||2017-02-28|2017-03-01|Actual|July 2002||2002-07-31|March 2013|2013-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||EPO906 in Carcinoid and Other Neuroendocrine Tumors|EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors|Completed||Phase 2|33|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:30:00.921537|2018-06-01 05:30:00.921537
NCT00050336|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-04|||2015-08-26|2002-12-04|2002-12-05|Estimate|||||||2015-08-26|2015-08-27|Estimate|December 2002||2002-12-31|August 2015|2015-08-31|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|||Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)|A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer|Terminated||Phase 3|702|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:30:01.039357|2018-06-01 05:30:01.039357
NCT00050323|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-04|||2015-03-04|2002-12-04|2002-12-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|November 2002||2002-11-30|March 2015|2015-03-31|March 2004|Actual|2004-03-31|||||Interventional|||Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer|Phase 1/2 Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusion in Patients With AJCC Stage IV Renal Cell Carcinoma|Completed||Phase 1/Phase 2|30||Sanofi|||||||||||||||||||2018-06-01 05:30:01.137153|2018-06-01 05:30:01.137153
NCT00050310|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-03|||2018-03-27|2002-12-03|2002-12-04|Estimate|||||||2018-03-27|2018-03-29|Actual|March 4, 2002||2002-03-04|October 18, 2017|2017-10-18||||||||Observational|||Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients|Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:01.212917|2018-06-01 05:30:01.212917
NCT00050297|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-03|||2012-06-06|2002-12-03|2002-12-04|Estimate|||||||2012-06-06|2012-06-07|Estimate||||June 2012|2012-06-30|February 2004|Actual|2004-02-29|||||Interventional|||YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer||Terminated||Phase 2|||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:30:01.277237|2018-06-01 05:30:01.277237
NCT00050284|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-03|||2010-11-05|2002-12-03|2002-12-04|Estimate|||||||2010-11-05|2010-11-09|Estimate||||November 2010|2010-11-30||||||||Observational|||Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection|Predictors of Immunologic and Clinical Progression in Subjects With CD4+ Cell Counts Greater Than 350 Cells/mm3 Who Discontinue Antiretroviral Therapy|Completed|||158||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:30:01.363635|2018-06-01 05:30:01.363635
NCT00050271|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-03|||2012-05-17|2002-12-03|2002-12-04|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|January 2007|Actual|2007-01-31|||||Interventional|||Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy|An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy|Completed||N/A|27|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:30:01.460433|2018-06-01 05:30:01.460433
NCT00050245|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-02|||2017-06-30|2002-12-02|2002-12-03|Estimate|||||||2017-06-30|2017-07-02|Actual|November 27, 2002||2002-11-27|October 17, 2007|2007-10-17|October 17, 2007||2007-10-17|||||Interventional|||Rituximab to Treat Neuropathy With Anti-MAG Antibodies|Safety, Tolerability, and Efficacy of Rituximab in Patients With Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy: A Double-Blind Placebo-Controlled Randomized Trial|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:01.612381|2018-06-01 05:30:01.612381
NCT00050232|ClinicalTrials.gov processed this data on May 31, 2018|2002-12-02|||2016-07-13|2002-12-02|2002-12-03|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2002||2002-12-31|July 2016|2016-07-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients||Completed||Phase 3|96||Avanir Pharmaceuticals|||||f||||f||||||||||2018-06-01 05:30:01.832015|2018-06-01 05:30:01.832015
NCT00050219|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-29|||2008-03-03|2002-11-29|2002-12-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2002||2002-11-30|September 2004|2004-09-30|September 2004||2004-09-30|||||Observational|||Role of Dopamine in Response to Alcohol|Striatal Dopamine and Alcohol Risk|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:01.95151|2018-06-01 05:30:01.95151
NCT00050141|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-22|||2013-01-31|2002-11-27|2002-11-28|Estimate|||||||2013-01-31|2013-02-01|Estimate|September 2002||2002-09-30|January 2013|2013-01-31|January 2008|Actual|2008-01-31|October 2005|Actual|2005-10-31||Interventional|||Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer|A Randomised, Blinded, Phase 2 Study of Letrozole Plus the Farnesyl Transferase Inhibitor ZARNESTRA TM (R115777) and Letrozole Plus Placebo in the Treatment of Advanced Breast Cancer After Antiestrogen Therapy.|Completed||Phase 2|121|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:30:02.095294|2018-06-01 05:30:02.095294
NCT00050206|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-26|||2007-06-11|2002-11-26|2002-11-27|Estimate|||||||2007-06-11|2007-06-12|Estimate|November 2002||2002-11-30|June 2007|2007-06-30|May 2005|Actual|2005-05-31|||||Interventional|||Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder|Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder|Completed||Phase 4|130||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:30:02.263778|2018-06-01 05:30:02.263778
NCT00050167|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-25|2011-07-07||2011-08-25|2002-11-26|2002-11-27|Estimate|2011-07-07|2011-08-05|Estimate||||2011-08-25|2011-08-29|Estimate|November 2002||2002-11-30|August 2011|2011-08-31|August 2011|Actual|2011-08-31|July 2008|Actual|2008-07-31||Interventional|||Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer|Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer|Completed||Phase 1|603|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-06-01 05:30:02.391485|2018-06-01 05:30:02.391485
NCT00050193|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-25|||2018-05-18|2002-11-25|2002-11-26|Estimate|||||||2018-05-18|2018-05-21|Actual|November 22, 2002||2002-11-22|March 10, 2014|2014-03-10|March 10, 2014||2014-03-10|||||Observational|||Cause and Natural Course of Pediatric-Onset Mastocytosis|Determining the Pathogenesis of Systemic Pediatric-Onset Mastocytosis|Completed|||103|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:03.798273|2018-06-01 05:30:03.798273
NCT00050180|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-25|||2017-06-30|2002-11-25|2002-11-26|Estimate|||||||2017-06-30|2017-07-02|Actual|November 22, 2002||2002-11-22|May 3, 2012|2012-05-03|August 24, 2007|Actual|2007-08-24|August 24, 2007|Actual|2007-08-24||Interventional|||Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers|Influence of MDR1 Genotype on Indinavir and Saquinavir Pharmacokinetics in Healthy Volunteers|Completed||Phase 4|81|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:03.877246|2018-06-01 05:30:03.877246
NCT00050154|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-22|||2010-04-23|2002-11-22|2002-11-25|Estimate|||||||2010-04-23|2010-04-27|Estimate|July 2002||2002-07-31|April 2010|2010-04-30|May 2006|Actual|2006-05-31|||||Interventional|||Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)|An Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of the Farnesyl-Transferase Inhibitor ZARNESTRA(tm) (R115777) in Subjects With High-Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 2|82|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:30:03.976131|2018-06-01 05:30:03.976131
NCT00050128|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-21|||2017-06-30|2002-11-21|2002-11-22|Estimate|||||||2017-06-30|2017-07-02|Actual|November 18, 2002||2002-11-18|October 24, 2007|2007-10-24|October 24, 2007||2007-10-24|||||Interventional|||Preliminary Study of Transcranial Magnetic Stimulation for Stroke Rehabilitation|Repetitive Transcranial Magnetic Stimulation in Chronic Stroke Patients. Dose Effect on Motor Cortex Excitability, Motor Performance, and Safety Using Different Stimulation Parameters|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:04.097342|2018-06-01 05:30:04.097342
NCT00050102|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-21||2011-01-12|2011-01-20|2002-11-21|2002-11-22|Estimate||||2011-01-20|2011-01-28|Estimate|2011-01-20|2011-01-28|Estimate|October 2002||2002-10-31|January 2011|2011-01-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma|A Randomized Study Comparing MDX-010 (CTLA-4) Alone or in Combination With DTIC in the Treatment of Patients With Chemotherapy Naїve Metastatic Melanoma.|Completed||Phase 2|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:30:04.200536|2018-06-01 05:30:04.200536
NCT00050089|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-20|2013-09-11||2015-04-03|2002-11-21|2002-11-22|Estimate|2014-01-17|2014-02-13|Estimate||||2015-04-03|2015-04-23|Estimate|January 2001||2001-01-31|April 2015|2015-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|OPTIMA|HIV-positive patients with a CD4 count <=300 cells/ul who had prior anti-retroviral treatment failure requiring retreatment|CSP #512 - Options in Management With Anti-Retrovirals|CSP #512 - Options in Management With Anti-Retrovirals (OPTIMA), Management of Patients With HIV Infection for Whom First and Second-line Highly Active Anti-Retroviral Therapy Has Failed|Completed||N/A|368|Actual|VA Office of Research and Development||4|||f||||f||||||||||2018-06-01 05:30:04.492004|2018-06-01 05:30:04.492004
NCT00050076|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-20|||2012-01-31|2002-11-20|2002-11-21|Estimate|||||||2012-01-31|2012-02-02|Estimate|August 2002||2002-08-31|January 2012|2012-01-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.|A Phase II, Double-Blind, Randomized, Exploratory, Placebo-Controlled Study of Efficacy, Safety, and Tolerability of MCC-135 Comparing QD vs BID Doses in Subjects With Congestive Heart Failure, NYHA Class II/III|Completed||Phase 2|204|Actual|Takeda||4|||f||||f||||||||||2018-06-01 05:30:07.420618|2018-06-01 05:30:07.420618
NCT00050063|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-20|||2012-05-17|2002-11-20|2002-11-21|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|May 2004|Actual|2004-05-31|||||Observational|||Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs|A Rollover Study of A5058s: A Phase II Trial to Evaluate the Ability of Vaccine-Induced Helper and CTL Responses to Control Viremia in the Absence of Antiretroviral Therapy|Completed|||78||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:30:07.587126|2018-06-01 05:30:07.587126
NCT00050050|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-20|||2014-05-23|2002-11-20|2002-11-21|Estimate|||||||2014-05-23|2014-05-26|Estimate|September 2001||2001-09-30|May 2014|2014-05-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder|CBT for Residual ADHD Symptoms in Adults|Completed||Phase 1|40|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-06-01 05:30:07.699506|2018-06-01 05:30:07.699506
NCT00050037|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-20|||2013-04-10|2002-11-20|2002-11-21|Estimate|||||||2013-04-10|2013-04-11|Estimate|April 2001||2001-04-30|April 2013|2013-04-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Cognitive Therapy for Binge-Eating Disorder|Cognitive Therapy Via CD-Rom for Binge-Eating Disorder|Completed||N/A|60|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-06-01 05:30:07.843678|2018-06-01 05:30:07.843678
NCT00050115|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-21|||2018-04-03|2002-11-19|2002-11-20|Estimate|||||||2018-04-03|2018-04-04|Actual|November 18, 2002||2002-11-18|March 21, 2018|2018-03-21||||||||Observational|||Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia|Collection of Blood, Stool, Bone Marrow and/or Tissue Samples From Subjects With Hepatitis-Associated Aplastic Anemia|Completed|||9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:07.939147|2018-06-01 05:30:07.939147
NCT00050024|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-19|||2017-06-30|2002-11-19|2002-11-20|Estimate|||||||2017-06-30|2017-07-02|Actual|November 13, 2002||2002-11-13|September 17, 2008|2008-09-17|September 17, 2008||2008-09-17|||||Observational|||Transcranial Magnetic Stimulation and Electrical Stimulation of Nerves to Study Focal Dystonia|The Effect of Peripheral Heterotopic Stimulation on Cortical Excitability in Dystonia|Completed|||38||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:08.041477|2018-06-01 05:30:08.041477
NCT00050011|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-18|2013-12-04||2014-02-21|2002-11-19|2002-11-20|Estimate|2013-12-04|2014-01-28|Estimate||||2014-02-21|2014-03-21|Estimate|September 2002||2002-09-30|February 2014|2014-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy|An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy|Completed||Phase 3|602|Actual|Novartis||2|||f||||f||||||||||2018-06-01 05:30:08.179614|2018-06-01 05:30:08.179614
NCT00049998|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-18|||2013-03-01|2002-11-19|2002-11-20|Estimate|||||||2013-03-01|2013-03-04|Estimate|October 2001||2001-10-31|March 2013|2013-03-31||||April 2004|Actual|2004-04-30||Interventional|||Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer|An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non Small Cell Lung Cancer|Completed||Phase 3|760||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:30:09.254203|2018-06-01 05:30:09.254203
NCT00049985|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-18|||2009-08-06|2002-11-18|2002-11-19|Estimate|||||||2009-08-06|2009-08-07|Estimate|July 2002||2002-07-31|August 2009|2009-08-31||||||||Interventional|||Heart Failure and Anemia|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects With Symptomatic Heart Failure (CHF) and Anemia.|Completed||Phase 2|300||Amgen|||||||||||||||||||2018-06-01 05:30:09.521978|2018-06-01 05:30:09.521978
NCT00049972|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-18|||2017-09-08|2002-11-18|2002-11-19|Estimate|||||||2017-09-08|2017-09-11|Actual|September 2002||2002-09-30|September 2017|2017-09-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Major Depressive Disorder Study In Adults|An Open Label Study Assessing Paxil CR (Paroxetine CR) in Patients With Major Depressive Disorder Who Discontinued Treatment With Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor Due to Intolerability|Completed||Phase 4|646||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:30:09.630355|2018-06-01 05:30:09.630355
NCT00049959|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-15||2011-03-01|2011-03-01|2002-11-18|2002-11-19|Estimate||||2011-03-01|2011-03-16|Estimate|2011-03-01|2011-03-16|Estimate||||March 2011|2011-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.|A Randomized, Placebo-Controlled, Masked, Multicenter Phase III Study Of Photodynamic Therapy With Verteporfin For Injection (VFI) For The Treatment Of Multiple Basal Cell Carcinoma|Terminated||Phase 3|||QLT Inc.|||||||||||||||||||2018-06-01 05:30:09.89212|2018-06-01 05:30:09.89212
NCT00049946|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-15|||2017-08-14|2002-11-15|2002-11-18|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2002||2002-10-31|August 2017|2017-08-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Schizophrenia Study In Adults|A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia|Completed||Phase 2|231||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:30:09.96598|2018-06-01 05:30:09.96598
NCT00049933|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2018-05-01|2002-11-14|2002-11-15|Estimate|||||||2018-05-01|2018-05-07|Actual|September 2002||2002-09-30|May 2018|2018-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Hormone Replacement Therapy and Prothrombotic Variants||Completed|||1000|Actual|University of Washington|||||f||||||||||||||2018-06-01 05:30:10.082449|2018-06-01 05:30:10.082449
NCT00049920|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2016-07-28|2002-11-14|2002-11-15|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2002||2002-09-30|October 2008|2008-10-31|September 2008|Actual|2008-09-30|May 2006|Actual|2006-05-31||Observational|||The ARIC MRI Study|The ARIC Neurocognitive Longitudinal Study|Completed|||1134|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t||||||Samples With DNA|"~     Plasma and DNA~   "|||2018-06-01 05:30:10.169055|2018-06-01 05:30:10.169055
NCT00049907|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2016-02-17|2002-11-14|2002-11-15|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2002||2002-09-30|January 2006|2006-01-31|August 2004|Actual|2004-08-31|||||Observational|||Cardiac and Renal Disease Study (CARDS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:30:10.228532|2018-06-01 05:30:10.228532
NCT00049894|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2016-02-17|2002-11-14|2002-11-15|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2002||2002-09-30|October 2005|2005-10-31|August 2004|Actual|2004-08-31|||||Observational|||Predictors of Recurrent Stroke in the PROGRESS Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:30:10.306911|2018-06-01 05:30:10.306911
NCT00049881|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2016-02-17|2002-11-14|2002-11-15|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2002||2002-04-30|January 2005|2005-01-31|March 2004|Actual|2004-03-31|||||Observational|||Genetic Determinants:Low HDL, High Triglycerides, Obesity||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:30:10.358689|2018-06-01 05:30:10.358689
NCT00049868|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2016-01-11|2002-11-14|2002-11-15|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2002||2002-09-30|January 2006|2006-01-31|August 2005||2005-08-31|||||Observational|||Enhanced Linkage Maps From Family-Based Genetics Studies||Completed|||||Rutgers University|||||f||||||||||||||2018-06-01 05:30:10.423566|2018-06-01 05:30:10.423566
NCT00049855|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2014-04-15|2002-11-14|2002-11-15|Estimate|||||||2014-04-15|2014-04-17|Estimate|September 2002||2002-09-30|April 2014|2014-04-30|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Observational|||Novel Approaches in Linkage Analysis for Complex Traits||Completed|||||Mayo Clinic|||||f||||||||||||||2018-06-01 05:30:10.484086|2018-06-01 05:30:10.484086
NCT00049842|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|2010-10-07||2017-03-07|2002-11-14|2002-11-15|Estimate|2010-12-17|2011-01-20|Estimate||||2017-03-07|2017-04-04|Actual|October 2002||2002-10-31|March 2017|2017-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)|PEG-Intron(TM) Maintenance Therapy vs. an Untreated Control Group for Prevention of Progression of Fibrosis in Adult Subjects With Chronic Hepatitis C With Hepatic Fibrosis (METAVIR Fibrosis Score of F2 or F3), Who Failed Therapy With PEG-Intron Plus REBETOL(R) (in Protocol No. P02370)|Completed||Phase 3|540|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:30:10.566347|2018-06-01 05:30:10.566347
NCT00049829|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2011-11-01|2002-11-14|2002-11-15|Estimate|||||||2011-11-01|2011-11-02|Estimate|January 2002||2002-01-31|November 2011|2011-11-30||||June 2006|Actual|2006-06-30||Interventional|||HORIZON-PFT: Pivotal Fracture Trial|HORIZON-PFT: Pivotal Fracture Trial|Completed||Phase 3|7700||Novartis|||||||||||||||||||2018-06-01 05:30:11.387968|2018-06-01 05:30:11.387968
NCT00049816|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-14|||2013-05-16|2002-11-14|2002-11-15|Estimate|||||||2013-05-16|2013-05-17|Estimate|October 2002||2002-10-31|May 2013|2013-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Aerobic Exercise Intervention for Knee Osteoarthritis|Aerobic Exercise Intervention for Knee Osteoarthritis|Completed||N/A|306|Actual|Mayo Clinic||3|||f||||||||||||||2018-06-01 05:30:11.680052|2018-06-01 05:30:11.680052
NCT00049803|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-13|||2005-06-23|2002-11-14|2002-11-15|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2000||2000-12-31|July 2004|2004-07-31|April 2004||2004-04-30|||||Interventional|||Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem (Sodium Oxybate) With Placebo for the Treatment of Narcolepsy|Completed||Phase 3|200||Orphan Medical|||||||||||||||||||2018-06-01 05:30:11.794854|2018-06-01 05:30:11.794854
NCT00049790|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-13|||2009-01-08|2002-11-14|2002-11-15|Estimate|||||||2009-01-08|2009-01-09|Estimate||||January 2009|2009-01-31|December 2004||2004-12-31|||||Interventional|||Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer||Completed||Phase 2|||CASI Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:30:11.97051|2018-06-01 05:30:11.97051
NCT00049777|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-13|||2007-01-24|2002-11-14|2002-11-15|Estimate|||||||2007-01-24|2007-01-26|Estimate|December 2002||2002-12-31|January 2007|2007-01-31|August 2005||2005-08-31|||||Interventional|||A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)|A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Heparin in Patients With Severe Sepsis and Higher Disease Severity Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)|Completed||Phase 4|2000||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:30:12.121361|2018-06-01 05:30:12.121361
NCT00049764|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-13|||2007-11-15|2002-11-13|2002-11-14|Estimate|||||||2007-11-15|2007-11-20|Estimate|November 2002||2002-11-30|November 2007|2007-11-30|April 2005|Actual|2005-04-30|||||Interventional|||Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis|Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis|Completed||Phase 3|474|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-06-01 05:30:12.234972|2018-06-01 05:30:12.234972
NCT00049751|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-13|||2006-08-13|2002-11-13|2002-11-14|Estimate|||||||2006-08-13|2006-08-15|Estimate|September 2002||2002-09-30|August 2006|2006-08-31||||||||Interventional|||Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis|A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis|Completed||Phase 3|3000||Abbott|||||||||||||||||||2018-06-01 05:30:12.435783|2018-06-01 05:30:12.435783
NCT00048945|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2017-02-16|2002-11-13|2002-11-14|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2002|Actual|2002-01-31|February 2017|2017-02-28|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B||Completed||Phase 3|820|Actual|Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:30:12.630934|2018-06-01 05:30:12.630934
NCT00049738|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2017-10-06|2002-11-12|2002-11-13|Estimate|||||||2017-10-06|2017-10-09|Actual|October 29, 2002||2002-10-29|October 5, 2017|2017-10-05|October 5, 2017||2017-10-05|||||Observational|||Screening for Childhood-Onset Psychotic Disorders|Screening, Evaluation, Diagnosis, Treatment Optimization and Follow-up for Childhood Onset Psychotic Disorders|Terminated|||123|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:12.805257|2018-06-01 05:30:12.805257
NCT00049725|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-12|||2008-03-03|2002-11-12|2002-11-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2002||2002-11-30|December 2004|2004-12-31|December 2004||2004-12-31|||||Interventional|||Daclizumab to Treat Chronic Immune Thrombocytopenia|A Study of Daclizumab in Chronic Immune Thrombocytopenia (ITP)|Completed||Phase 2|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:12.984333|2018-06-01 05:30:12.984333
NCT00048932|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-11|2011-04-01||2011-11-15|2002-11-12|2002-11-13|Estimate|2011-04-01|2011-05-03|Estimate||||2011-11-15|2011-11-24|Estimate|December 2002||2002-12-31|November 2011|2011-11-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis||Completed||Phase 3|1795|Actual|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:30:13.202919|2018-06-01 05:30:13.202919
NCT00048854|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|||2016-01-11|2002-11-12|2002-11-13|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2001||2001-09-30|January 2016|2016-01-31|January 2008|Actual|2008-01-31|June 2007|Actual|2007-06-30||Interventional|||Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder|Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder|Completed||Phase 1/Phase 2|66|Actual|Yale University||2|||f||||t||||||||||2018-06-01 05:30:18.845436|2018-06-01 05:30:18.845436
NCT00048841|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|||2010-03-01|2002-11-12|2002-11-13|Estimate|||||||2010-03-01|2010-03-02|Estimate|May 2002||2002-05-31|March 2010|2010-03-31|December 2005|Actual|2005-12-31|||||Interventional|||Prevention of Osteoporosis in Men With Prostate Cancer|Prevention of Osteoporosis in Men With Prostate Cancer|Completed||Phase 3|112||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:30:19.138393|2018-06-01 05:30:19.138393
NCT00048828|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|||2013-07-01|2002-11-12|2002-11-13|Estimate|||||||2013-07-01|2013-07-02|Estimate|October 2001||2001-10-31|July 2013|2013-07-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Treating Drug-Resistant Childhood Schizophrenia|Treating Refractory Childhood Schizophrenia|Completed||Phase 4|41|Actual|Northwell Health||2|||f||||||||||||||2018-06-01 05:30:19.416483|2018-06-01 05:30:19.416483
NCT00048815|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|2014-06-17||2018-05-09|2002-11-12|2002-11-13|Estimate|2018-05-09|2018-05-10|Estimate||||2018-05-09|2018-05-10|Estimate|February 2003||2003-02-28|May 2018|2018-05-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Drug Therapy to Treat Minor Depression|Pharmacotherapy for Minor Depression|Completed||N/A|73|Actual|Massachusetts General Hospital|Stringent inclusion criteria may have yielded a sample who depression was too mild to show added benefit for either active treatment beyond general therapeutic effects of study participation|3|||f||||t||||||||||2018-06-01 05:30:20.700188|2018-06-01 05:30:20.700188
NCT00048802|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|||2014-01-21|2002-11-12|2002-11-13|Estimate|||||||2014-01-21|2014-01-22|Estimate|August 2002||2002-08-31|January 2014|2014-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Treatment and Outcome of Early Onset Bipolar Disorder|Treatment and Outcome of Early Onset Bipolar Disorder|Completed||Phase 4|40||Northwell Health|||||f||||||||||||||2018-06-01 05:30:21.689905|2018-06-01 05:30:21.689905
NCT00048581|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-02|2011-04-07||2011-11-14|2002-11-12|2002-11-13|Estimate|2011-05-26|2011-06-23|Estimate||||2011-11-14|2011-11-21|Estimate|December 2002||2002-12-31|November 2011|2011-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.|A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy|Completed||Phase 3|738|Actual|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:30:22.27582|2018-06-01 05:30:22.27582
NCT00048568|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-02|2011-03-28||2011-10-26|2002-11-12|2002-11-13|Estimate|2011-10-26|2011-12-05|Estimate||||2011-10-26|2011-12-05|Estimate|December 2002||2002-12-31|October 2011|2011-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|Completed||Phase 3|1250|Actual|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:30:29.055826|2018-06-01 05:30:29.055826
NCT00048906|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|||2008-03-03|2002-11-08|2002-11-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2002||2002-11-30|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||Alpha-Galactosidase A Replacement Therapy for Fabry Disease|A Safety and Pharmacokinetic Study of Replagal Enzyme Replacement Therapy in Patients With Fabry Disease|Completed||Phase 2|3||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:38.745467|2018-06-01 05:30:38.745467
NCT00048893|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|2011-10-25||2012-03-20|2002-11-08|2002-11-11|Estimate|2012-03-20|2012-04-13|Estimate||||2012-03-20|2012-04-13|Estimate|November 2002||2002-11-30|March 2012|2012-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer|A Multicenter Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion|Terminated||Phase 1/Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)|The study was closed to accrual due to very poor enrollment. No meaningful data analysis was possible on the small number of accrued subjects, so none was done.|||The study was closed to accrual due to very poor enrollment.|f||||t||||||||||2018-06-01 05:30:38.858802|2018-06-01 05:30:38.858802
NCT00048880|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-08|||2017-06-30|2002-11-08|2002-11-11|Estimate|||||||2017-06-30|2017-07-02|Actual|November 5, 2002||2002-11-05|March 5, 2010|2010-03-05|July 2, 2008|Actual|2008-07-02|July 2, 2008|Actual|2008-07-02||Interventional|||Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein|Phase I Study of HeFi-1 in Refractory CD30-Positive Malignancy|Completed||Phase 1|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:39.327736|2018-06-01 05:30:39.327736
NCT00048776|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-07|||2005-07-14|2002-11-08|2002-11-11|Estimate|||||||2005-07-14|2005-07-19|Estimate|October 2001||2001-10-31|July 2005|2005-07-31|June 2003||2003-06-30|||||Interventional|||Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon||Completed||Phase 4|75||Otsuka America Pharmaceutical|||||||||||||||||||2018-06-01 05:30:39.389377|2018-06-01 05:30:39.389377
NCT00048763|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-07|||2005-07-14|2002-11-08|2002-11-11|Estimate|||||||2005-07-14|2005-07-19|Estimate|October 2001||2001-10-31|July 2005|2005-07-31|June 2003||2003-06-30|||||Interventional|||Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon||Completed||Phase 4|75||Otsuka America Pharmaceutical|||||||||||||||||||2018-06-01 05:30:39.462921|2018-06-01 05:30:39.462921
NCT00048789|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-07|||2017-06-30|2002-11-07|2002-11-08|Estimate|||||||2017-06-30|2017-07-02|Actual|November 4, 2002||2002-11-04|January 29, 2009|2009-01-29|January 29, 2009||2009-01-29|||||Interventional|||Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease|Treatment of Chronic Graft Versus Host Disease With Extracorporeal Photopheresis|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:39.552461|2018-06-01 05:30:39.552461
NCT00048750|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-06|||2012-03-26|2002-11-07|2002-11-08|Estimate|||||||2012-03-26|2012-03-27|Estimate|January 2003||2003-01-31|March 2008|2008-03-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU|A Phase 3, Randomized,Double-Blind, Comparative Study of Micafungin (FK463) Versus Placebo as Preemptive Prophylactic Antifungal Therapy in Patients in the Intensive Care Unit|Terminated||Phase 3|104|Actual|Astellas Pharma Inc||2||Inadequate enrollment|f||||t||||||||||2018-06-01 05:30:39.620293|2018-06-01 05:30:39.620293
NCT00048737|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-06|2013-04-22||2013-06-11|2002-11-07|2002-11-08|Estimate|2013-06-11|2013-06-13|Estimate||||2013-06-11|2013-06-13|Estimate|October 2002||2002-10-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies|Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies|Completed||Phase 1/Phase 2|70|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:30:39.782967|2018-06-01 05:30:39.782967
NCT00048724|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-06|2009-04-23||2017-03-07|2002-11-07|2002-11-08|Estimate|2009-04-23|2009-06-11|Estimate||||2017-03-07|2017-04-04|Actual|June 2002||2002-06-30|March 2017|2017-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)|PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin|Completed||Phase 3|631|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:30:40.217509|2018-06-01 05:30:40.217509
NCT00048711|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-06|||2009-08-24|2002-11-07|2002-11-08|Estimate|||||||2009-08-24|2009-08-25|Estimate|March 2002||2002-03-31|August 2009|2009-08-31|June 2006|Actual|2006-06-30|||||Interventional|||Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI|Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI|Completed||Phase 2|||BioMarin Pharmaceutical|||||||||||||||||||2018-06-01 05:30:41.121922|2018-06-01 05:30:41.121922
NCT00048698|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-05|||2008-03-03|2002-11-05|2002-11-06|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2002||2002-11-30|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Effects of Direct Current Brain Stimulation on Cognition|A Phase I Trial of Focal DC Brain Polarization|Completed||Phase 1|170||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:41.176228|2018-06-01 05:30:41.176228
NCT00048685|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-05|||2008-03-03|2002-11-05|2002-11-06|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2002||2002-11-30|August 2004|2004-08-31|August 2004||2004-08-31|||||Observational|||Study of Oral Bacteria in Patients With Dry Mouth|Incidence and Frequency of Cariogenic Microflora in Patients With Clinical Xerostomia and Autoimmune Disease|Completed|||44||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:41.233866|2018-06-01 05:30:41.233866
NCT00048672|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-05|||2016-01-19|2002-11-05|2002-11-06|Estimate|||||||2016-01-19|2016-01-20|Estimate|March 2001||2001-03-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|November 2002|Actual|2002-11-30||Interventional|||Therapy of Early Chronic Phase CML With Gleevec|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Gleevec (STI571)|Completed||Phase 2|50|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:30:41.283185|2018-06-01 05:30:41.283185
NCT00048659|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-04|||2012-06-06|2002-11-05|2002-11-06|Estimate|||||||2012-06-06|2012-06-07|Estimate||||June 2012|2012-06-30|June 2004|Actual|2004-06-30|||||Interventional|||YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy||Terminated||Phase 2|||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:30:41.357849|2018-06-01 05:30:41.357849
NCT00048646|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-04|||2014-09-17|2002-11-05|2002-11-06|Estimate|||||||2014-09-17|2014-09-19|Estimate|May 2002||2002-05-31|September 2014|2014-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Progesterone Treatment of Blunt Traumatic Brain Injury|ProTECT: Single Center, Phase II (Pilot), Double Blind, 4:1 Randomized, Placebo Controlled Clinical Trial for Progesterone Treatment of Moderate and Severe Blunt TBI|Completed||Phase 1/Phase 2|100|Actual|Emory University||2|||f||||t||||||||||2018-06-01 05:30:41.539628|2018-06-01 05:30:41.539628
NCT00048633|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-04|||2012-05-22|2002-11-05|2002-11-06|Estimate|||||||2012-05-22|2012-05-23|Estimate|November 2001||2001-11-30|May 2012|2012-05-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer||Completed||Phase 2|30||QLT Inc.||1|||f||||||||||||||2018-06-01 05:30:41.633577|2018-06-01 05:30:41.633577
NCT00048620|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-04|||2006-11-02|2002-11-05|2002-11-06|Estimate|||||||2006-11-02|2006-11-03|Estimate|September 2000||2000-09-30|November 2006|2006-11-30|November 2005||2005-11-30|||||Interventional|||Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI|Double-Blind,2 Dose Group Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI|Completed||Phase 1|||BioMarin Pharmaceutical|||||||||||||||||||2018-06-01 05:30:41.768974|2018-06-01 05:30:41.768974
NCT00048607|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-04|||2017-05-02|2002-11-04|2002-11-05|Estimate|||||||2017-05-02|2017-05-05|Actual|July 30, 2002|Actual|2002-07-30|May 2017|2017-05-31|December 31, 2003|Actual|2003-12-31|December 31, 2003|Actual|2003-12-31||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)|A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder|Completed||Phase 3|600|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:30:41.829455|2018-06-01 05:30:41.829455
NCT00048594|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-04|||2017-05-02|2002-11-04|2002-11-05|Estimate|||||||2017-05-02|2017-05-05|Actual|January 3, 2002|Actual|2002-01-03|May 2017|2017-05-31|December 22, 2003|Actual|2003-12-22|December 18, 2003|Actual|2003-12-18||Interventional|||Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Patients With Major Depressive Disorder|Completed||Phase 3|800|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:30:41.898966|2018-06-01 05:30:41.898966
NCT00048555|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-01|||2013-09-12|2002-11-04|2002-11-05|Estimate|||||||2013-09-12|2013-09-16|Estimate|November 2002||2002-11-30|January 2011|2011-01-31|November 2010|Actual|2010-11-30|March 2004|Actual|2004-03-31||Interventional|||Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma|A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan® for Patients With Relapsed or Refractory, Follicular Lymphoma|Completed||Phase 1/Phase 2|90|Actual|Biogen||1|||f||||f||||||||||2018-06-01 05:30:41.972086|2018-06-01 05:30:41.972086
NCT00048542|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-01|2009-12-07||2011-08-18|2002-11-04|2002-11-05|Estimate|2009-12-07|2010-01-11|Estimate||||2011-08-18|2011-08-22|Estimate|September 2002||2002-09-30|August 2011|2011-08-31|June 2010|Actual|2010-06-30|January 2005|Actual|2005-01-31||Interventional|||Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis|Completed||Phase 3|171|Actual|Abbott||8|||f||||t||||||||||2018-06-01 05:30:42.132394|2018-06-01 05:30:42.132394
NCT00048529|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-01|||2005-06-23|2002-11-01|2002-11-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2002||2002-09-30|April 2004|2004-04-30||||||||Interventional|||Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus||Suspended||Phase 2|70||Tularik|||||||||||||||||||2018-06-01 05:30:43.59927|2018-06-01 05:30:43.59927
NCT00048516|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-01|||2006-07-31|2002-11-01|2002-11-04|Estimate|||||||2006-07-31|2006-08-02|Estimate|February 2002||2002-02-28|July 2006|2006-07-31||||||||Interventional|||Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)|Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)|Completed||Phase 3|68||Abbott|||||||||||||||||||2018-06-01 05:30:43.649063|2018-06-01 05:30:43.649063
NCT00048503|ClinicalTrials.gov processed this data on May 31, 2018|2002-11-01|||2010-04-23|2002-11-01|2002-11-04|Estimate|||||||2010-04-23|2010-04-27|Estimate|June 2002||2002-06-30|April 2010|2010-04-30|November 2005|Actual|2005-11-30|||||Interventional|||Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older|An Open-label, Phase 2 Study of the Farnesyl Transferase Inhibitor ZARNESTRA (R115777) as Post-consolidation Therapy for Acute Myeloid Leukemia (AML) in Patients Age 60 Years and Older.|Completed||Phase 2|88|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:30:43.770907|2018-06-01 05:30:43.770907
NCT00048464|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-31|||2006-11-06|2002-11-01|2002-11-04|Estimate|||||||2006-11-06|2006-11-07|Estimate|October 2002||2002-10-31|March 2005|2005-03-31||||||||Interventional|||T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant|A Phase I/II Study of Xcellerated T Cells After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma|Unknown status|Active, not recruiting|Phase 1/Phase 2|35||Xcyte Therapies|||||||||||||||||||2018-06-01 05:30:43.836114|2018-06-01 05:30:43.836114
NCT00048451|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-31|||2006-07-31|2002-11-01|2002-11-04|Estimate|||||||2006-07-31|2006-08-02|Estimate|February 2002||2002-02-28|July 2006|2006-07-31||||||||Interventional|||Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)|Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)|Completed||Phase 3|68||Abbott|||||||||||||||||||2018-06-01 05:30:43.973161|2018-06-01 05:30:43.973161
NCT00048438|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-31|||2006-08-10|2002-11-01|2002-11-04|Estimate|||||||2006-08-10|2006-08-15|Estimate|February 2002||2002-02-28|August 2006|2006-08-31||||||||Interventional|||Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)|Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)|Completed||Phase 3|68||Abbott|||||||||||||||||||2018-06-01 05:30:44.054442|2018-06-01 05:30:44.054442
NCT00048425|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-31|||2006-12-14|2002-11-01|2002-11-04|Estimate|||||||2006-12-14|2006-12-15|Estimate|September 2002||2002-09-30|December 2006|2006-12-31|December 2004||2004-12-31|||||Interventional|||Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.|Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.|Completed||Phase 3|600||Abbott|||||||||||||||||||2018-06-01 05:30:44.171307|2018-06-01 05:30:44.171307
NCT00048490|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-31|||2008-03-03|2002-10-31|2002-11-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2002||2002-10-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||Transcranial Magnetic Stimulation to Treat Epilepsy|Drug-Refractory Neocortical Epilepsy: rTMS Treatment|Completed||Phase 2|70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:44.438709|2018-06-01 05:30:44.438709
NCT00048477|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-31|||2008-03-03|2002-10-31|2002-11-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2002||2002-10-31|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers|Determination of Nitrite as a Source of Bioactive Nitric Oxide in Human Subjects|Completed||Phase 2|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:44.488132|2018-06-01 05:30:44.488132
NCT00048412|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-30|||2007-04-09|2002-10-31|2002-11-01|Estimate|||||||2007-04-09|2007-04-11|Estimate|June 2000||2000-06-30|April 2007|2007-04-30||||||||Interventional|||Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H|Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancy, Using MHC Identical or Near Identical Donors and Sub-Myeloablative Conditioning With CAMPATH 1H (DIMSUM)|Completed||Phase 1/Phase 2|40||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:30:44.543106|2018-06-01 05:30:44.543106
NCT00048399|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-30|||2007-04-09|2002-10-31|2002-11-01|Estimate|||||||2007-04-09|2007-04-11|Estimate|December 2000||2000-12-31|April 2007|2007-04-30||||||||Interventional|||Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H|Phase I/II Study of Allogeneic Stem Cell Transplantation For Patients With Graft Failure Following Allogeneic Transplantation Using MHC Identical or Near Identical Donors and Submyeloablative Conditioning With CAMPATH 1H (CAMGRAFT)|Terminated||Phase 1/Phase 2|40||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:30:44.613199|2018-06-01 05:30:44.613199
NCT00048386|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-30|||2012-07-26|2002-10-31|2002-11-01|Estimate|||||||2012-07-26|2012-07-27|Estimate|November 1999||1999-11-30|July 2012|2012-07-31|October 2009|Actual|2009-10-31|December 2004|Actual|2004-12-31||Interventional|CYCHE2||Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy|A Pilot Study of Gene Modified Autologous Neuroblastoma Vaccine for the Post-Chemotherapy Treatment of High-Risk Neuroblastoma|Completed||Phase 1|13|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 05:30:44.684148|2018-06-01 05:30:44.684148
NCT00048373|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-30|||2006-08-22|2002-10-31|2002-11-01|Estimate|||||||2006-08-22|2006-08-24|Estimate|October 2001||2001-10-31|August 2006|2006-08-31|April 2004||2004-04-30|||||Interventional|||Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL|Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE)|Completed||Phase 2|20||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:30:44.749316|2018-06-01 05:30:44.749316
NCT00048360|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-30|||2013-02-11|2002-10-30|2002-10-31|Estimate|||||||2013-02-11|2013-02-12|Estimate|October 2002||2002-10-31|February 2013|2013-02-28|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults|An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 3|162||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:30:44.818319|2018-06-01 05:30:44.818319
NCT00048321|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-29|||2007-10-15|2002-10-30|2002-10-31|Estimate|||||||2007-10-15|2007-10-17|Estimate|January 2002||2002-01-31|October 2007|2007-10-31||||||||Interventional|||ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis|ISIS 104838-CS7, A Double-Blind, Placebo-Controlled, Randomized Trial of the Safety, Efficacy and Pharmacokinetic Profile of ISIS 104838 (TNF-Alpha Antisense Oligonucleotide) Subcutaneous Injections in Active Rheumatoid Arthritis Patients|Completed||Phase 2|160||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:30:44.908069|2018-06-01 05:30:44.908069
NCT00048308|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-29|||2017-02-21|2002-10-30|2002-10-31|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2002|Actual|2002-01-31|February 2017|2017-02-28||||March 2003|Actual|2003-03-31||Interventional|||Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass||Completed||Phase 3|3000||Alexion Pharmaceuticals|||||||||||||||||||2018-06-01 05:30:45.215238|2018-06-01 05:30:45.215238
NCT00048347|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-29|2010-07-06||2010-08-30|2002-10-29|2002-10-30|Estimate|2010-08-11|2010-08-31|Estimate||||2010-08-30|2010-09-08|Estimate|October 2002||2002-10-31|August 2010|2010-08-31|May 2010|Actual|2010-05-31|June 2008|Actual|2008-06-30||Interventional|||Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis|An Open-Label, Pilot Study of Type I Interferon (AVONEX) Treatment of Ulcerative Colitis|Completed||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)|While this study was designed as a proof-of-concept pilot trial to correlate changes in IL-13 and other cytokines with clinical response, efficacy was measured. The efficacy estimate is limited by the open-label design.|1|||f||||f||||||||||2018-06-01 05:30:45.581169|2018-06-01 05:30:45.581169
NCT00048334|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-29|||2018-05-23|2002-10-29|2002-10-30|Estimate|||||||2018-05-23|2018-05-24|Actual|October 26, 2002||2002-10-26|January 7, 2014|2014-01-07|April 1, 2010|Actual|2010-04-01|April 1, 2010|Actual|2010-04-01||Interventional|||Depsipeptide to Treat Thyroid and Other Advanced Cancers|Phase I Trial of Romidepsin Given on Days One, Three, and Five in Patients With Thyroid and Other Advanced Cancers|Completed||Phase 1|28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:45.76452|2018-06-01 05:30:45.76452
NCT00048295|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-29|||2005-06-23|2002-10-29|2002-10-30|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2002||2002-05-31|April 2004|2004-04-30||||||||Interventional|||Alicaforsen (ISIS 2302) in Patients With Active Crohn’s Disease|ISIS 2302-CS21, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn’s Disease|Unknown status|Active, not recruiting|Phase 3|150||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:30:45.853462|2018-06-01 05:30:45.853462
NCT00048282|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-29|||2010-05-13|2002-10-29|2002-10-30|Estimate|||||||2010-05-13|2010-05-14|Estimate||||January 2006|2006-01-31||||||||Observational|||HIV Prevention Preparedness Study|HIV Prevention Preparedness Study|Completed|||1200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:30:45.931741|2018-06-01 05:30:45.931741
NCT00048230|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-28|||2012-01-12|2002-10-29|2002-10-30|Estimate|||||||2012-01-12|2012-01-13|Estimate|June 2002||2002-06-30|January 2012|2012-01-31|December 2004|Actual|2004-12-31|July 2004|Actual|2004-07-31||Interventional|||PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 3|620|Actual|Millennium Pharmaceuticals, Inc.|||||f||||||||||||||2018-06-01 05:30:46.022086|2018-06-01 05:30:46.022086
NCT00048217|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-28|||2005-06-23|2002-10-29|2002-10-30|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2004|2004-07-31||||||||Interventional|||A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102||Unknown status|Active, not recruiting|Phase 1/Phase 2|||Trimeris|||||||||||||||||||2018-06-01 05:30:46.202408|2018-06-01 05:30:46.202408
NCT00048204|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-28|||2017-10-05|2002-10-29|2002-10-30|Estimate|||||||2017-10-05|2017-10-09|Actual|November 4, 2002|Actual|2002-11-04|October 2017|2017-10-31|September 30, 2003||2003-09-30|September 30, 2003|Actual|2003-09-30||Interventional|||A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder|An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of GW597599B or Paroxetine to Placebo in Moderately to Severely Depressed Patients With Major Depressive Disorder|Completed||Phase 2|372|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:30:46.254655|2018-06-01 05:30:46.254655
NCT00048256|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-28|||2008-03-03|2002-10-28|2002-10-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates|Exploring the Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates|Completed|||57||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:46.342719|2018-06-01 05:30:46.342719
NCT00048165|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|2016-05-04||2016-05-04|2002-10-24|2002-10-25|Estimate|2016-05-04|2016-06-13|Estimate||||2016-05-04|2016-06-13|Estimate|August 1999||1999-08-31|May 2016|2016-05-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional||The randomized population included all participants who were randomized into the study, whether they received the study drug or not.|A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation|A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation.|Completed||Phase 4|434|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-06-01 05:30:46.460505|2018-06-01 05:30:46.460505
NCT00048152|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2016-11-01|2002-10-24|2002-10-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2000||2000-12-31|November 2016|2016-11-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients|A Randomized, Open-label Study Comparing the Effects of Low-dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab|Completed||Phase 3|539|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 05:30:47.690819|2018-06-01 05:30:47.690819
NCT00048139|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2016-11-01|2002-10-24|2002-10-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2001||2001-10-31|November 2016|2016-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer|An Open-label Study of the Effect of Intermittent Xeloda in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer|Completed||Phase 2|52|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 05:30:47.836349|2018-06-01 05:30:47.836349
NCT00048126|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2016-11-01|2002-10-24|2002-10-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2001||2001-07-31|November 2016|2016-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer|An Open-label Study of the Effect of Continuous Xeloda Therapy in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer|Completed||Phase 2|57|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-06-01 05:30:47.984738|2018-06-01 05:30:47.984738
NCT00048113|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2007-10-15|2002-10-24|2002-10-25|Estimate|||||||2007-10-15|2007-10-17|Estimate|September 2001||2001-09-30|October 2007|2007-10-31||||||||Interventional|||Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease|ISIS 2302-CS20, Phase 3 Double-Masked, Placebo-Controlled Study of Alicaforsen (ISIS 2302), an Antisense Inhibitor of ICAM-1, for the Treatment of Patients With Active Crohn's Disease|Completed||Phase 3|150||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:30:48.116711|2018-06-01 05:30:48.116711
NCT00048100|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2012-08-22|2002-10-24|2002-10-25|Estimate|||||||2012-08-22|2012-08-23|Estimate|February 2001||2001-02-28|August 2012|2012-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes|Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy|Terminated||Phase 1|2|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||t||||||||||2018-06-01 05:30:48.233989|2018-06-01 05:30:48.233989
NCT00048087|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|||2012-07-27|2002-10-24|2002-10-25|Estimate|||||||2012-07-27|2012-07-31|Estimate|August 2002||2002-08-31|July 2012|2012-07-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Iressa/Docetaxel in Non-Small-Cell Lung Cancer|A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Combination With Docetaxel in Patients With Recurrent or Metastatic Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||t||||||||||2018-06-01 05:30:48.323378|2018-06-01 05:30:48.323378
NCT00048074|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|2016-01-04||2016-01-04|2002-10-24|2002-10-25|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|June 2002||2002-06-30|January 2016|2016-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional||Safety Population: All participants who were randomized and had at least one dose of study drug, whether withdrawn prematurely or not, and who had at least one follow-up data point were included.|DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis|A Randomized, Double-blind Study Comparing the Effect of Different Treatment Regimens of Intravenous Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis|Completed||Phase 3|1395|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-06-01 05:30:48.477218|2018-06-01 05:30:48.477218
NCT00048061|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|2016-02-05||2018-02-28|2002-10-24|2002-10-25|Estimate|2016-04-22|2016-05-30|Estimate||||2018-02-28|2018-03-29|Actual|April 2002||2002-04-30|February 2018|2018-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional||The safety population consisted of all participants who were randomized and received at least one dose of the study medication, and who have at least one follow-up data point.|MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis|Randomized, Double-blind, Double Dummy, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of Monthly Oral Administration of 100 mg and 150 mg Ibandronate With 2.5 mg Daily Oral Ibandronate in Postmenopausal Osteoporosis|Completed||Phase 3|1609|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-06-01 05:30:49.880333|2018-06-01 05:30:49.880333
NCT00048048|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|2016-10-26||2017-05-29|2002-10-24|2002-10-25|Estimate|2017-05-29|2018-01-02|Actual||||2017-05-29|2018-01-02|Actual|March 2002||2002-03-31|May 2017|2017-05-31|November 2004|Actual|2004-11-30|October 2003|Actual|2003-10-31||Interventional||The safety population was considered for analysis which included all participants who received at least one dose of study drug.|A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.|An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy|Completed||Phase 2|65|Actual|Hoffmann-La Roche||9|||f||||||||||||||2018-06-01 05:30:52.520185|2018-06-01 05:30:52.520185
NCT00048035|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-24|2016-05-03||2016-10-26|2002-10-24|2002-10-25|Estimate|2016-10-26|2016-12-20|Estimate||||2016-10-26|2016-12-20|Estimate|March 2002||2002-03-31|October 2016|2016-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional||The Intent-to-Treat (ITT) population was used for the analysis. It was defined as all randomized participants.|A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia|An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Intravenous Epoetin Alfa to Maintenance Treatment With Intravenous RO0503821 in Hemodialysis Patients With Chronic Renal Anemia.|Completed||Phase 2|91|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-06-01 05:30:54.194963|2018-06-01 05:30:54.194963
NCT00047775|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-18|||2005-06-23|2002-10-18|2002-10-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2001||2001-05-31|October 2004|2004-10-31|August 2004||2004-08-31|||||Interventional|||African-American Heart Failure Trial||Completed||Phase 4|1100||Nitromed|||||||||||||||||||2018-06-01 05:30:57.104491|2018-06-01 05:30:57.104491
NCT00047983|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-23|||2017-01-10|2002-10-23|2002-10-24|Estimate|||||||2017-01-10|2017-01-11|Estimate||||January 2017|2017-01-31|April 2004|Actual|2004-04-30|||||Interventional|||Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients|A Randomized Trial of Immunomodulating Diets With Arginine and Omega-3 Fatty Acids in Renal Transplant Recipients|Completed||Early Phase 1|75|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:30:55.536192|2018-06-01 05:30:55.536192
NCT00047970|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-23|||2015-04-14|2002-10-23|2002-10-24|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2003||2003-08-31|November 2012|2012-11-30|April 2015|Actual|2015-04-30|August 2009|Actual|2009-08-31||Observational|||The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer|The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer|Completed|||50884|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||f||||||||||2018-06-01 05:30:55.629957|2018-06-01 05:30:55.629957
NCT00047840|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-18|||2016-08-24|2002-10-23|2002-10-24|Estimate|||||||2016-08-24|2016-08-25|Estimate|October 2002||2002-10-31|August 2016|2016-08-31|September 2006|Actual|2006-09-30|||||Interventional|||This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.|A Randomized, Double-blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxel (TAXOTERE™) in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-based Chemotherapy.|Completed||Phase 2|129||Sanofi|||||f||||||||||||||2018-06-01 05:30:55.838019|2018-06-01 05:30:55.838019
NCT00047827|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-18|||2014-08-19|2002-10-23|2002-10-24|Estimate|||||||2014-08-19|2014-08-20|Estimate|December 2002||2002-12-31|August 2014|2014-08-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis|A Phase 2, Open-Label, Non-Comparative Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) as First-Line Therapy in the Treatment of Invasive Aspergillosis|Terminated||Phase 2|2|Actual|Astellas Pharma Inc||1||Inadequate enrollment|f||||f||||||||||2018-06-01 05:30:55.947307|2018-06-01 05:30:55.947307
NCT00047814|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-18|||2011-12-08|2002-10-23|2002-10-24|Estimate|||||||2011-12-08|2011-12-09|Estimate|October 2002||2002-10-31|December 2011|2011-12-31|March 2006|Actual|2006-03-31|||||Interventional|||Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection|A Multiple Rising-Dose Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 2|48||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:30:56.035834|2018-06-01 05:30:56.035834
NCT00047957|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-22|||2008-03-03|2002-10-22|2002-10-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2002||2002-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Brain Inhibition of Muscle Movement in Normal Volunteers|The Effect of Peripheral Homotopic and Heterotopic Stimulation on Cortical Excitability|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:56.102115|2018-06-01 05:30:56.102115
NCT00047944|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-22|||2017-10-05|2002-10-22|2002-10-23|Estimate|||||||2017-10-05|2017-10-06|Actual|October 12, 2002||2002-10-12|October 27, 2016|2016-10-27|October 27, 2016||2016-10-27|||||Observational|||MRI Study of Brain Activity and Risk for Depression in Adolescents|Neural Circuitry and Risk for Depression in Adolescents: A Study Using Functional Magnetic Resonance Imaging|Completed|||88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:56.16212|2018-06-01 05:30:56.16212
NCT00047931|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-22|||2017-06-30|2002-10-22|2002-10-23|Estimate|||||||2017-06-30|2017-07-02|Actual|October 17, 2002||2002-10-17|May 5, 2009|2009-05-05|May 5, 2009||2009-05-05|||||Interventional|||HIV-1 Vaccine Test in Uninfected Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP in Uninfected Adult Volunteers|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:56.216015|2018-06-01 05:30:56.216015
NCT00047918|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-22|||2008-03-03|2002-10-22|2002-10-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2002||2002-10-31|August 2004|2004-08-31|August 2004||2004-08-31|||||Observational|||Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing|Investigation of Hematologic Parameters in Mastocytosis and Idiopathic Anaphylaxis|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:56.327571|2018-06-01 05:30:56.327571
NCT00047905|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-22|||2008-03-03|2002-10-22|2002-10-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2002||2002-10-31|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Pilot Study of the Process of Prenatal Genetic Counseling|The Process of Prenatal Genetic Counseling Using a Simulated Client - A Pilot Study|Completed||N/A|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:56.392819|2018-06-01 05:30:56.392819
NCT00047879|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2011-05-24||2011-09-19|2002-10-22|2002-10-23|Estimate|2011-09-19|2011-10-26|Estimate||||2011-09-19|2011-10-26|Estimate|October 2002||2002-10-31|September 2011|2011-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas|A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas|Completed||Phase 2|7|Actual|National Institutes of Health Clinical Center (CC)|Registered 7 out of 64 participants and they came off study for progressive disease around 3-4 months after starting the study.|2|||f||||f||||||||||2018-06-01 05:30:56.486186|2018-06-01 05:30:56.486186
NCT00047866|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-22|||2017-06-30|2002-10-22|2002-10-23|Estimate|||||||2017-06-30|2017-07-02|Actual|October 12, 2002||2002-10-12|June 25, 2010|2010-06-25|June 25, 2010||2010-06-25|||||Observational|||Brain Function in Response to Motivational Stimuli|Brain Activation in Response to Motivational and Affective Stimuli: Pharmacological Manipulations|Completed|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:56.848052|2018-06-01 05:30:56.848052
NCT00047853|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-22|||2018-04-03|2002-10-22|2002-10-23|Estimate|||||||2018-04-03|2018-04-04|Actual|October 15, 2002||2002-10-15|March 23, 2018|2018-03-23||||||||Observational|||Brain Changes in Fear|fMRI Investigation of Explicit Cue and Contextual Fear|Recruiting|||1600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:30:56.909581|2018-06-01 05:30:56.909581
NCT00047801|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-18|||2011-07-21|2002-10-18|2002-10-21|Estimate|||||||2011-07-21|2011-07-25|Estimate|October 2002||2002-10-31|June 2011|2011-06-30|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer|Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|28||Telik|||||f||||||||||||||2018-06-01 05:30:56.982738|2018-06-01 05:30:56.982738
NCT00047788|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-18|||2016-08-22|2002-10-18|2002-10-21|Estimate|||||||2016-08-22|2016-08-24|Estimate|October 2002||2002-10-31|August 2016|2016-08-31|May 2004|Actual|2004-05-31|||||Interventional|||Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer|A Phase Two Study of ZD6474 in Patients With Relapsed Multiple Myeloma|Completed||Phase 2|30||Sanofi|||||||||||||||||||2018-06-01 05:30:57.043257|2018-06-01 05:30:57.043257
NCT00047762|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-16|||2005-06-23|2002-10-17|2002-10-18|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2002||2002-10-31|November 2004|2004-11-30||||||||Interventional|||Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer|Open-Label, Multicenter, Dose-Escalation Study in Subjects w/Advanced Colorectal Cancer to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tarceva in Combination w/5-Fluorouracil, Leucovorin, and Irinotecan and of Bevacizumab in Combination w/Tarceva, 5-Fluorouracil, Leucovorin, and Irinotecan|Completed||Phase 1|||Genentech, Inc.|||||||||||||||||||2018-06-01 05:30:57.161372|2018-06-01 05:30:57.161372
NCT00047554|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2013-05-13|2002-10-17|2002-10-18|Estimate|||||||2013-05-13|2013-05-15|Estimate|May 2003||2003-05-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Study of TRAVATAN in Subjects With Iris Pigmentation Changes|A Five-Year, Multicenter, Commercial Label Safety Study of TRAVATAN® 0.004% in Patients With TRAVATAN-Induced Iris Pigmentation Changes|Terminated|||336|Actual|Alcon Research|||1|Study objectives met|f||||||||||||||2018-06-01 05:30:57.226937|2018-06-01 05:30:57.226937
NCT00047541|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2008-08-04|2002-10-17|2002-10-18|Estimate|||||||2008-08-04|2008-08-05|Estimate|February 2001||2001-02-28|August 2008|2008-08-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70|Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients C-01-70.|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:30:57.303264|2018-06-01 05:30:57.303264
NCT00047528|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2008-08-04|2002-10-17|2002-10-18|Estimate|||||||2008-08-04|2008-08-05|Estimate|January 2001||2001-01-31|August 2008|2008-08-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41|Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients (C-02-41).|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:30:57.360702|2018-06-01 05:30:57.360702
NCT00047515|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2008-08-04|2002-10-17|2002-10-18|Estimate|||||||2008-08-04|2008-08-05|Estimate|January 2001||2001-01-31|August 2008|2008-08-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69|Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients C-01-69.|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:30:57.468056|2018-06-01 05:30:57.468056
NCT00047749|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-16|||2015-12-10|2002-10-16|2002-10-17|Estimate|||||||2015-12-10|2015-12-14|Estimate|August 2002||2002-08-31|December 2015|2015-12-31|June 2003||2003-06-30|||||Interventional|||Prialt (Ziconotide) In Severe Chronic Pain|A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults With Severe Chronic Pain|Completed||Phase 3|220||Elan Pharmaceuticals|||||||||||||||||||2018-06-01 05:30:57.642153|2018-06-01 05:30:57.642153
NCT00047736|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-16|||2013-06-19|2002-10-16|2002-10-17|Estimate|||||||2013-06-19|2013-06-21|Estimate|July 2001||2001-07-31|June 2013|2013-06-30|July 2003|Actual|2003-07-31|||||Interventional|||A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer|A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy|Completed||Phase 3|||Genentech, Inc.|||||||||||||||||||2018-06-01 05:30:57.776905|2018-06-01 05:30:57.776905
NCT00047723|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-16|||2007-12-18|2002-10-16|2002-10-17|Estimate|||||||2007-12-18|2007-12-21|Estimate|January 2003||2003-01-31|December 2007|2007-12-31|January 2007|Actual|2007-01-31|||||Interventional|||Minocycline to Treat Amyotrophic Lateral Sclerosis||Completed||Phase 3|400||National Institute of Neurological Disorders and Stroke (NINDS)|||||||||||||||||||2018-06-01 05:30:57.873758|2018-06-01 05:30:57.873758
NCT00047710|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-14|||2012-07-31|2002-10-15|2002-10-16|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2002||2002-09-30|July 2012|2012-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer|A Phase I Trial of Concurrent RHUMAB VEGF (BEVACIZUMAB) and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer|Completed||Phase 1|48|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:30:57.997659|2018-06-01 05:30:57.997659
NCT00047697|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-11|2015-03-30||2017-09-07|2002-10-15|2002-10-16|Estimate|2017-09-07|2017-10-05|Actual||||2017-09-07|2017-10-05|Actual|October 2002||2002-10-31|September 2017|2017-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Donepezil HCl & Cognitive Deficits in Autism|Donepezil HCl: Treating Cognitive Deficits in Autism|Completed||Phase 2|34|Actual|University of Pittsburgh|The trial may not have been long enough to obtain clinically significant effects|2|||f||||t||||||||No|We have no specific plan to share data at this time.|2018-06-01 05:30:58.096942|2018-06-01 05:30:58.096942
NCT00047684|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-11|||2013-09-09|2002-10-15|2002-10-16|Estimate|||||||2013-09-09|2013-09-10|Estimate|November 2001||2001-11-30|September 2008|2008-09-30|November 2002||2002-11-30|||||Interventional|||Brief Integrative Therapy for Post-Traumatic Stress Disorder|Development and Initial Evaluation of Brief Integrative Therapy for PTSD|Completed||N/A|20||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:30:58.378907|2018-06-01 05:30:58.378907
NCT00047671|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-11|||2009-08-03|2002-10-15|2002-10-16|Estimate|||||||2009-08-03|2009-08-04|Estimate|June 2002||2002-06-30|August 2009|2009-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Ethnic Variations in Antidepressant Response|Ethnic Variations in Antidepressant Response|Completed||Phase 4|400|Anticipated|National Institute of Mental Health (NIMH)||1|||f||||t||||||||||2018-06-01 05:30:58.447154|2018-06-01 05:30:58.447154
NCT00047658|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-09|||2007-11-02|2002-10-10|2002-10-11|Estimate|||||||2007-11-02|2007-11-06|Estimate|November 2001||2001-11-30|November 2007|2007-11-30|May 2003|Actual|2003-05-31|||||Interventional|||A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label Extension|Completed||Phase 2|32|Actual|InterMune|||||f||||||||||||||2018-06-01 05:30:58.568266|2018-06-01 05:30:58.568266
NCT00047645|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-09|||2007-11-01|2002-10-10|2002-10-11|Estimate|||||||2007-11-01|2007-11-02|Estimate|April 2000||2000-04-30|November 2007|2007-11-30|December 2002|Actual|2002-12-31|||||Interventional|||A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 3|330|Actual|InterMune|||||f||||||||||||||2018-06-01 05:30:58.648177|2018-06-01 05:30:58.648177
NCT00046800|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2011-10-18|2002-10-03|2002-10-04|Estimate|||||||2011-10-18|2011-10-20|Estimate|September 2002||2002-09-30|October 2011|2011-10-31|March 2003|Actual|2003-03-31|||||Interventional|||Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer|A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer|Completed||Phase 2|80||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:31:00.657266|2018-06-01 05:31:00.657266
NCT00047632|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-09|||2007-10-30|2002-10-10|2002-10-11|Estimate|||||||2007-10-30|2007-11-01|Estimate|October 2001||2001-10-31|October 2007|2007-10-31|February 2006|Actual|2006-02-28|||||Interventional|||Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer|Interferon Gamma-1b in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First Line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma.|Terminated||Phase 3|847|Actual|InterMune||||futility|f||||||||||||||2018-06-01 05:30:58.706653|2018-06-01 05:30:58.706653
NCT00047606|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2012-08-16|2002-10-10|2002-10-11|Estimate|||||||2012-08-16|2012-08-17|Estimate|August 2002||2002-08-31|August 2008|2008-08-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32|Phase 4 Study to Compare Two Different IOP Lowering Medications for the Treatment of Open Angle Glaucoma or Ocular Hypertension in Caucasian and Japanese Subjects C-02-32.|Terminated||Phase 4|84|Actual|Alcon Research||||Management Decision|||||||||||||||2018-06-01 05:30:58.803704|2018-06-01 05:30:58.803704
NCT00047593|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2008-08-04|2002-10-10|2002-10-11|Estimate|||||||2008-08-04|2008-08-05|Estimate|January 2000||2000-01-31|August 2008|2008-08-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98|Phase 3 Study to Compare Two Different IOP Lowering Medications for the Treatment of Open Angle Glaucoma or Ocular Hypertension in Japanese Subjects C-01-98.|Completed||Phase 3|||Alcon Research|||||||||||||||||||2018-06-01 05:30:58.85738|2018-06-01 05:30:58.85738
NCT00047619|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-09|2015-07-08||2015-09-10|2002-10-09|2002-10-10|Estimate|2015-09-10|2015-10-05|Estimate||||2015-09-10|2015-10-05|Estimate|June 2002||2002-06-30|September 2015|2015-09-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Enhancement of Pressure Healing With Pulsatile Lavage|Enhancement of Pressure Healing With Pulsatile Lavage|Completed||Phase 2|28|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:30:58.924665|2018-06-01 05:30:58.924665
NCT00047580|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2015-12-10|2002-10-09|2002-10-10|Estimate|||||||2015-12-10|2015-12-14|Estimate|June 2002||2002-06-30|December 2015|2015-12-31|September 2002||2002-09-30|||||Interventional|||Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.|A Multicenter, Open-Label, Randomized, 4-Way Crossover Trial of the Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex (Tizanidine Hydrochloride) Tablets Taken Under Fed and Fasted Conditions in Patients With Moderate to Severe Spasticity|Completed||Phase 3|120||Elan Pharmaceuticals|||||||||||||||||||2018-06-01 05:30:59.18382|2018-06-01 05:30:59.18382
NCT00047567|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2015-12-10|2002-10-09|2002-10-10|Estimate|||||||2015-12-10|2015-12-14|Estimate|July 2002||2002-07-31|December 2015|2015-12-31|July 2002||2002-07-31|||||Interventional|||Open-label Adjunctive Zonisamide for Bipolar Disorder||Terminated||Phase 4|20||Elan Pharmaceuticals|||||||||||||||||||2018-06-01 05:30:59.273137|2018-06-01 05:30:59.273137
NCT00046371|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-27|||2008-01-22|2002-10-09|2002-10-10|Estimate|||||||2008-01-22|2008-01-23|Estimate|August 2002||2002-08-31|January 2008|2008-01-31|August 2005|Actual|2005-08-31|||||Interventional|||Safety and Immunological Response Rate Study of THERATOPE® Vaccine in Metastatic Breast Cancer Patients|Open-Label, Phase II Trial of Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects With Metastatic Breast Cancer Undergoing Treatment With Aromatase Inhibitors or Faslodex®|Completed||Phase 2|||Oncothyreon Canada Inc.|||||f||||||||||||||2018-06-01 05:30:59.325148|2018-06-01 05:30:59.325148
NCT00047502|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2012-02-20|2002-10-08|2002-10-09|Estimate|||||||2012-02-20|2012-02-22|Estimate|November 2002||2002-11-30|February 2012|2012-02-29|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia|Phase I Study of Lonafarnib (SCH66336) and Gleevec (Imatinib Mesylate) in Chronic Myelogenous Leukemia (CML)|Completed||Phase 1|23|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:30:59.486057|2018-06-01 05:30:59.486057
NCT00047489|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2012-02-20|2002-10-08|2002-10-09|Estimate|||||||2012-02-20|2012-02-22|Estimate|December 2002||2002-12-31|February 2012|2012-02-29|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Study of ABT-751 in Patients With Refractory Hematologic Malignancies|A Phase I Study of ABT-751 in Patients With Refractory Hematologic Malignancies|Completed||Phase 1|32|Actual|M.D. Anderson Cancer Center|||||||||||||||||||2018-06-01 05:30:59.5702|2018-06-01 05:30:59.5702
NCT00047476|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-08|||2005-06-23|2002-10-08|2002-10-09|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2002||2002-06-30|May 2004|2004-05-31|March 2004||2004-03-31|||||Interventional|||D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients|Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of d-MPH in the Treatment of Fatigue and Neurobehavioral Impairment Related to Chemotherapy in Adult Cancer Patients|Completed||Phase 2|160||Celgene|||||||||||||||||||2018-06-01 05:30:59.634858|2018-06-01 05:30:59.634858
NCT00047463|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-07|2009-11-18||2016-07-20|2002-10-07|2002-10-08|Estimate|2011-03-31|2011-05-03|Estimate||||2016-07-20|2016-07-21|Estimate|September 2002||2002-09-30|July 2016|2016-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Effects of Treating Obstructive Sleep Apnea in Epilepsy|Effects of Treating Obstructive Sleep Apnea in Epilepsy|Completed||Phase 2|68|Actual|Vanderbilt University|Being a pilot study with a relatively small sample size, we were unable to isolate the effects of specific medications or seizure types on the presence of sleep apnea.|2|||f||||t||||||||||2018-06-01 05:30:59.748813|2018-06-01 05:30:59.748813
NCT00047450|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-04|||2013-08-06|2002-10-04|2002-10-07|Estimate|||||||2013-08-06|2013-08-09|Estimate|September 2001||2001-09-30|August 2013|2013-08-31|September 2007|Actual|2007-09-30|September 2006|Actual|2006-09-30||Interventional|||Antidepressant Treatment in Older Adults With Schizophrenia|Citalopram Augmentation in Older Patients With Schizophrenia|Completed||N/A|212|Actual|Veterans Medical Research Foundation||2|||f||||t||||||||||2018-06-01 05:31:00.174475|2018-06-01 05:31:00.174475
NCT00047437|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2013-03-20|2002-10-03|2002-10-04|Estimate|||||||2013-03-20|2013-03-21|Estimate|April 2003||2003-04-30|March 2013|2013-03-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure|Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)|Completed||Phase 3|2331|Actual|Duke University||2|||f||||t||||||||||2018-06-01 05:31:00.3023|2018-06-01 05:31:00.3023
NCT00047424|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2009-02-04|2002-10-03|2002-10-04|Estimate|||||||2009-02-04|2009-02-05|Estimate|September 2002||2002-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Stop Atherosclerosis in Native Diabetics Study (SANDS)|Stop Atherosclerosis in Native Diabetics Study (SANDS)|Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:31:00.476809|2018-06-01 05:31:00.476809
NCT00047411|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2008-03-06|2002-10-03|2002-10-04|Estimate|||||||2008-03-06|2008-03-10|Estimate|September 2002||2002-09-30|March 2008|2008-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|HAT||Home Use of Automatic External Defibrillators to Treat Sudden Cardiac Arrest|Home Automatic External Defibrillator Trial -- HAT|Completed||Phase 3|7001|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 05:31:00.527805|2018-06-01 05:31:00.527805
NCT00046787|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2011-10-18|2002-10-03|2002-10-04|Estimate|||||||2011-10-18|2011-10-20|Estimate|September 2002||2002-09-30|October 2011|2011-10-31|February 2003|Actual|2003-02-28|||||Interventional|||Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer|Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer|Completed||Phase 2|47||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:31:00.719752|2018-06-01 05:31:00.719752
NCT00046761|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-02|||2012-10-10|2002-10-03|2002-10-04|Estimate|||||||2012-10-10|2012-10-11|Estimate|November 2002||2002-11-30|October 2012|2012-10-31||||May 2005|Actual|2005-05-31||Interventional|||A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke|A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke|Terminated||Phase 2/Phase 3|1320||Ono Pharmaceutical Co. Ltd|||||f||||||||||||||2018-06-01 05:31:00.798807|2018-06-01 05:31:00.798807
NCT00046748|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-02|||2017-07-31|2002-10-03|2002-10-04|Estimate|||||||2017-07-31|2017-08-02|Actual|December 2001||2001-12-31|July 2017|2017-07-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma|Ph III, 28-wk, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess Efficacy, Safety, Tolerability of SC Omalizumab in Adults and Adolescents w/ Severe Persist. Allergic Asthma & Are Inadequately Controlled Despite GINA (2002) Step 4 Tx|Completed||Phase 3|484|Actual|Novartis|||||||||||||||||||2018-06-01 05:31:01.049182|2018-06-01 05:31:01.049182
NCT00046813|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-03|||2017-01-11|2002-10-02|2002-10-03|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 2001||2001-08-31|August 2008|2008-08-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1|High-Dose Versus Regular-Dose Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder|Terminated||Phase 4|100||National Institute on Drug Abuse (NIDA)||||Interim data analysis showed no effect between treatment groups|f||||||||||||||2018-06-01 05:31:01.124578|2018-06-01 05:31:01.124578
NCT00046774|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-02|||2018-05-24|2002-10-02|2002-10-03|Estimate|||||||2018-05-24|2018-05-25|Actual|September 2, 2002||2002-09-02|September 7, 2017|2017-09-07|September 7, 2017|Actual|2017-09-07|January 1, 2007|Actual|2007-01-01||Interventional|||Monoclonal Antibody Treatment for Systemic Lupus Erythematosus|A Phase I, Open-Labeled, Dose-Ascending Clinical Trial of Immunotherapy of MRA, A Humanized Anti-IL 6 Receptor Monoclonal Antibody, In Patients With Systemic Lupus Erythematosus|Completed||Phase 1|23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:01.192573|2018-06-01 05:31:01.192573
NCT00046735|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-02|||2016-11-22|2002-10-02|2002-10-03|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2002||2002-06-30|November 2016|2016-11-30|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||Phase 1 Study OF CDC-501 in Patients With Solid Tumors|A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors|Completed||Phase 1|24|Actual|Celgene Corporation||1|||f||||||||||||||2018-06-01 05:31:01.325448|2018-06-01 05:31:01.325448
NCT00046722|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-01|||2007-06-12|2002-10-02|2002-10-03|Estimate|||||||2007-06-12|2007-06-14|Estimate|January 2003||2003-01-31|June 2007|2007-06-30|April 2005||2005-04-30|||||Interventional|||Marijuana for HIV-Related Peripheral Neuropathy|Effects of Marijuana on Neuropathic Pain in HIV-Related Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study.|Completed||Phase 1/Phase 2|50||Center for Medicinal Cannabis Research|||||||||||||||||||2018-06-01 05:31:01.3986|2018-06-01 05:31:01.3986
NCT00046527|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2006-07-12|2002-10-02|2002-10-03|Estimate|||||||2006-07-12|2006-07-13|Estimate|June 2001||2001-06-30|October 2004|2004-10-31||||||||Interventional|||Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer|A Controlled, Randomized, Phase III, Multicenter, Open Label Study of ABI-007(a Cremophor Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol in Patients With Metastatic Breast Cancer|Completed||Phase 3|460||Celgene Corporation|||||||||||||||||||2018-06-01 05:31:01.466292|2018-06-01 05:31:01.466292
NCT00046514|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2016-12-14|2002-10-02|2002-10-03|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2001||2001-06-30|December 2016|2016-12-31||||||||Interventional|||ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer|A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer|Completed||Phase 2|100||Celgene Corporation|||||||||||||||||||2018-06-01 05:31:01.529845|2018-06-01 05:31:01.529845
NCT00046423|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2016-11-23|2002-10-02|2002-10-03|Estimate|||||||2016-11-23|2016-11-25|Estimate|April 2000||2000-04-30|November 2016|2016-11-30||||||||Interventional|||A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies|A Phase I Trial of ABI-007 Administered Weekly for Three Doses Every 4 Weeks in Patients With Advanced Non-hematologic Malignancies|Completed||Phase 1|20||Celgene Corporation|||||||||||||||||||2018-06-01 05:31:01.587722|2018-06-01 05:31:01.587722
NCT00046709|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-01|||2013-10-09|2002-10-01|2002-10-02|Estimate|||||||2013-10-09|2013-10-10|Estimate|September 2002||2002-09-30|October 2013|2013-10-31|October 2004|Actual|2004-10-31|||||Interventional|||Marijuana for Cancer Pain|Marijuana in Combination With Opioids for Cancer Pain: A Pilot Study|Terminated||Phase 1/Phase 2|16||Center for Medicinal Cannabis Research||||Discontinued due to non-enrollment.|||||||||||||||2018-06-01 05:31:01.648535|2018-06-01 05:31:01.648535
NCT00046696|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-01|||2015-05-19|2002-10-01|2002-10-02|Estimate|||||||2015-05-19|2015-05-20|Estimate|May 2001||2001-05-31|May 2015|2015-05-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.|A Phase I and Pharmacokinetic Study of NM-3 Administered Orally Once or Twice Daily on Five Consecutive Days and Repeated Weekly for Six Weeks Every Eight Weeks in Patients With Advanced Solid Tumors.|Completed||Phase 1|32||Sanofi|||||||||||||||||||2018-06-01 05:31:01.711844|2018-06-01 05:31:01.711844
NCT00046683|ClinicalTrials.gov processed this data on May 31, 2018|2002-10-01|||2016-07-27|2002-10-01|2002-10-02|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2001||2001-07-31|July 2016|2016-07-31|June 2006|Actual|2006-06-30|||||Interventional|||Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia|A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia|Completed||Phase 3|284||Sanofi|||||||||||||||||||2018-06-01 05:31:01.777307|2018-06-01 05:31:01.777307
NCT00046540|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2011-06-30|2002-10-01|2002-10-02|Estimate|||||||2011-06-30|2011-07-04|Estimate|October 2002||2002-10-31|June 2011|2011-06-30|November 2010|Actual|2010-11-30|August 2007|Actual|2007-08-31||Interventional|||Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer||Completed||Phase 1|40||INSYS Therapeutics Inc|||||f||||||||||||||2018-06-01 05:31:01.861571|2018-06-01 05:31:01.861571
NCT00046410|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-27|||2017-06-30|2002-09-27|2002-09-30|Estimate|||||||2017-06-30|2017-07-02|Actual|September 25, 2002||2002-09-25|November 15, 2007|2007-11-15|November 15, 2007||2007-11-15|||||Observational|||Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting|Assessing the Risk of New Ischemic Brain Lesions With On- Versus Off-Pump Coronary Artery Bypass Grafting|Completed|||340||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:07.819031|2018-06-01 05:31:07.819031
NCT00046501|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2011-01-10|2002-10-01|2002-10-02|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2002||2002-11-30|January 2011|2011-01-31||||February 2005|Actual|2005-02-28||Interventional|||Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents|Morning LANTUS v. Intermediate-acting Insulin 2x/Day as Basal Insulin in a Multiple Daily Inj. w/ Humalog in Adolescents w/ Type 1 Diabetes Mellitus: an Active-controlled, Open, Randomized, Gender-stratified, Two-arm, Parallel-group Study|Completed||Phase 3|250||Sanofi|||||f||||||||||||||2018-06-01 05:31:01.9192|2018-06-01 05:31:01.9192
NCT00046488|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2013-09-12|2002-10-01|2002-10-02|Estimate|||||||2013-09-12|2013-09-16|Estimate|September 2002||2002-09-30|May 2010|2010-05-31|March 2010|Actual|2010-03-31|April 2004|Actual|2004-04-30||Interventional|||Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)|A Phase I Multicenter, Dose-Escalation Study of IDEC-152 (Anti-CD23 Monoclonal Antibody) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 1|70|Actual|Biogen|||||f||||t||||||||||2018-06-01 05:31:01.977351|2018-06-01 05:31:01.977351
NCT00046475|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|2015-04-24||2015-05-13|2002-10-01|2002-10-02|Estimate|2015-04-24|2015-05-12|Estimate||||2015-05-13|2015-06-08|Estimate|January 2002||2002-01-31|November 2007|2007-11-30|October 2004|Actual|2004-10-31|||||Interventional||The intent-to-treat (ITT) population, defined as all patients who were randomly assigned to treatment in the study and have at least one post-randomization Orthostatic Hypotension Questionnaire (OHQ) measurement.|A Study for Patients With Neurogenic Orthostatic Hypotension|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Assess the Clinical Benefit of Midodrine Hydrochloride in Patients With Neurogenic Orthostatic Hypotension|Completed||Phase 4|140|Actual|Shire|||||||||||||||||||2018-06-01 05:31:02.098606|2018-06-01 05:31:02.098606
NCT00046462|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2011-01-10|2002-10-01|2002-10-02|Estimate|||||||2011-01-10|2011-01-11|Estimate|November 2001||2001-11-30|January 2011|2011-01-31|December 2004|Actual|2004-12-31|November 2004|Actual|2004-11-30||Interventional|||Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment|Substituting Lantus®(Insulin Glargine[rDNAorigin]Inj) for a Thiazolidinedione vs. a 3rd Oral Agent as add-on Therapy in Patients Failing a Thiazolidinedione & Sulfonylurea or Metformin Combination|Completed||Phase 3|240||Sanofi|||||f||||||||||||||2018-06-01 05:31:03.552748|2018-06-01 05:31:03.552748
NCT00046449|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2015-06-02|2002-10-01|2002-10-02|Estimate|||||||2015-06-02|2015-06-04|Estimate|September 2002||2002-09-30|June 2015|2015-06-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Prevention of Seasonal Affective Disorder||Completed||Phase 3|||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:31:05.872529|2018-06-01 05:31:05.872529
NCT00046670|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2014-03-04|2002-09-30|2002-10-01|Estimate|||||||2014-03-04|2014-03-05|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Sleep Disordered Breathing, APOE, and Lipid Metabolism||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:31:06.085466|2018-06-01 05:31:06.085466
NCT00046657|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2016-07-28|2002-09-30|2002-10-01|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2002||2002-09-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Longitudinal Study of Neighborhood Predictors of CVD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:31:06.369086|2018-06-01 05:31:06.369086
NCT00046644|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2014-04-16|2002-09-30|2002-10-01|Estimate|||||||2014-04-16|2014-04-17|Estimate|June 2002||2002-06-30|April 2014|2014-04-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Observational|||Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial||Completed|||||Nemours Children's Clinic|||||f||||||||||||||2018-06-01 05:31:06.603115|2018-06-01 05:31:06.603115
NCT00046631|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2014-03-11|2002-09-30|2002-10-01|Estimate|||||||2014-03-11|2014-03-13|Estimate|August 2002||2002-08-31|March 2014|2014-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|TAAG2||Community Characteristics and Physical Activity Among Adolescent Girls - Ancillary to TAAG|Community Characteristics and Physical Activity Among Adolescent Girls|Completed|||1556|Actual|RAND|||1||f||||f||||||||||2018-06-01 05:31:06.702608|2018-06-01 05:31:06.702608
NCT00046618|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2014-02-19|2002-09-30|2002-10-01|Estimate|||||||2014-02-19|2014-02-20|Estimate|July 2002||2002-07-31|February 2014|2014-02-28|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Mapping Novel Disease Genes for Dilated Cardiomyopathy||Completed|||||Mayo Clinic|||||f||||||||||||||2018-06-01 05:31:06.830178|2018-06-01 05:31:06.830178
NCT00046605|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2017-11-03|2002-09-30|2002-10-01|Estimate|||||||2017-11-03|2017-11-07|Actual|August 2002||2002-08-31|November 2017|2017-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Inflammation Genomics and Atherosclerosis - Ancillary to CARDIA||Completed|||3600|Actual|University of Washington|||||f||||||||||||||2018-06-01 05:31:06.92323|2018-06-01 05:31:06.92323
NCT00046592|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2016-02-17|2002-09-30|2002-10-01|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 2002||2002-08-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Mechanisms of Disability in Peripheral Arterial Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:31:07.100213|2018-06-01 05:31:07.100213
NCT00046579|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2016-07-28|2002-09-30|2002-10-01|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 2002||2002-08-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Psychosocial Determinants of Nutrient Intake in Girls||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:31:07.172138|2018-06-01 05:31:07.172138
NCT00046566|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|2016-11-30||2017-04-27|2002-09-30|2002-10-01|Estimate|2017-04-27|2017-07-24|Actual||||2017-04-27|2017-07-24|Actual|July 2002||2002-07-31|April 2017|2017-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|ProBP||Clinical Trial of Dietary Protein and Blood Pressure|Clinical Trial of Dietary Protein on Blood Pressure|Completed||N/A|352|Actual|Tulane University||3|||f||||t||||||||No||2018-06-01 05:31:07.240517|2018-06-01 05:31:07.240517
NCT00046553|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2008-03-03|2002-09-30|2002-10-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2002||2002-09-30|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Brain Receptor Function in Post-Traumatic Stress Disorder|Glucocorticoid and Mineralocorticoid Receptor Function in Post Traumatic Stress Disorder|Completed|||97||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:07.564637|2018-06-01 05:31:07.564637
NCT00046436|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-30|||2013-05-31|2002-09-30|2002-10-01|Estimate|||||||2013-05-31|2013-06-03|Estimate||||May 2013|2013-05-31|March 2004|Actual|2004-03-31|||||Observational|||Rapid HIV Tests for Women Late in Pregnancy and During Labor|Mother-Infant Rapid Intervention at Delivery (MIRIAD)|Terminated|||7500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:31:07.698462|2018-06-01 05:31:07.698462
NCT00046384|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-27|||2013-11-07|2002-09-30|2002-10-01|Estimate|||||||2013-11-07|2013-11-11|Estimate|June 2002||2002-06-30|September 2007|2007-09-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder||Completed||Phase 3|||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:31:07.745834|2018-06-01 05:31:07.745834
NCT00046397|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-27|||2008-03-03|2002-09-27|2002-09-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2002||2002-09-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||Phase I Trial of Smallpox Vaccine|A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Dosing Schedule, Immunogenicity and Protective Efficacy Against Dryvax Challenge in Vaccinia-Naive Individuals|Completed||Phase 1|195||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:07.875216|2018-06-01 05:31:07.875216
NCT00046345|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-26|||2011-04-13|2002-09-27|2002-09-30|Estimate|||||||2011-04-13|2011-04-14|Estimate|May 2002||2002-05-31|April 2011|2011-04-30|July 2003||2003-07-31|||||Expanded Access|||Atazanavir for HIV Infected Individuals: An Early Access Program||No longer available|||||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:31:07.957089|2018-06-01 05:31:07.957089
NCT00046332|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-26|||2013-02-20|2002-09-27|2002-09-30|Estimate|||||||2013-02-20|2013-02-21|Estimate|June 2002||2002-06-30|February 2013|2013-02-28|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients|A Phase II, Randomized, Placebo-controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Doses of S-1360 Versus Placebo Over 10 Days in ART-naive HIV-1 Infected Adults.|Completed||Phase 2|100||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:31:08.333672|2018-06-01 05:31:08.333672
NCT00046319|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-26|||2009-04-15|2002-09-27|2002-09-30|Estimate|||||||2009-04-15|2009-04-16|Estimate|September 2002||2002-09-30|April 2009|2009-04-30|June 2003||2003-06-30|||||Interventional|||Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension|A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging, Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Patients With Moderate to Severe Pulmonary Arterial Hypertension|Completed||Phase 2|60||Gilead Sciences|||||||||||||||||||2018-06-01 05:31:08.419682|2018-06-01 05:31:08.419682
NCT00046306|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-26|||2013-01-11|2002-09-27|2002-09-30|Estimate|||||||2013-01-11|2013-01-14|Estimate||||January 2013|2013-01-31|August 2005|Actual|2005-08-31|||||Interventional|||Nevada Environmental Tobacco Smoke and Health Study||Completed||Phase 3|375||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:08.519586|2018-06-01 05:31:08.519586
NCT00046358|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-26|||2008-03-03|2002-09-26|2002-09-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2002||2002-09-30|August 2005|2005-08-31|August 2005||2005-08-31|||||Interventional|||The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease|The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-Amyloid|Completed||Phase 4|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:08.572613|2018-06-01 05:31:08.572613
NCT00046293|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-25|||2017-06-30|2002-09-25|2002-09-26|Estimate|||||||2017-06-30|2017-07-02|Actual|September 24, 2002||2002-09-24|April 8, 2011|2011-04-08|July 20, 2007|Actual|2007-07-20|July 20, 2007|Actual|2007-07-20||Interventional|||ReoPro and Retavase to Treat Acute Stroke|ReoPro Retavase Reperfusion of Stroke Safety Study-Imaging Evaluation With Computed Tomography (ROSIE-CT)|Completed||Phase 2|72|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:08.635721|2018-06-01 05:31:08.635721
NCT00046280|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-24|||2018-05-01|2002-09-25|2002-09-26|Estimate|||||||2018-05-01|2018-05-02|Actual|April 1984||1984-04-30|May 2018|2018-05-31||||April 2019|Anticipated|2019-04-30||Observational|||Multicenter AIDS Cohort Study (MACS)|Multicenter AIDS Cohort Study (MACS)|Active, not recruiting|||7087|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||f|f|f||||Samples With DNA|"~     Blood serum, plasma, and cells~   "|||2018-06-01 05:31:08.692297|2018-06-01 05:31:08.692297
NCT00046267|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-24|||2011-02-28|2002-09-24|2002-09-25|Estimate|||||||2011-02-28|2011-03-02|Estimate||||May 2006|2006-05-31||||December 2006|Actual|2006-12-31||Interventional|||Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients|A Pilot Study of the Safety, Efficacy, and Tolerability of Extended-Release Niacin (Niaspan) for the Treatment of Elevated Non-HDL Cholesterol and Elevated Triglycerides in HIV-Infected Subjects|Completed||N/A|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:31:08.753981|2018-06-01 05:31:08.753981
NCT00046254|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-24|||2012-05-01|2002-09-24|2002-09-25|Estimate|||||||2012-05-01|2012-05-02|Estimate|February 2002||2002-02-28|May 2012|2012-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture||Completed||Phase 3|2127||Novartis|||||||||||||||||||2018-06-01 05:31:09.778384|2018-06-01 05:31:09.778384
NCT00046241|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-24|||2017-01-20|2002-09-24|2002-09-25|Estimate|||||||2017-01-20|2017-01-23|Estimate|September 2002|Actual|2002-09-30|January 2017|2017-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Prevention of Seasonal Affective Disorder|A 7 Month, Multicenter, Randomized, Double-blind, Placebo-controlled Comparison of 150-300mg/Day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase|Completed||Phase 3|300||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:31:09.892861|2018-06-01 05:31:09.892861
NCT00046228|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-24|2009-03-26||2014-07-25|2002-09-24|2002-09-25|Estimate|2009-03-27|2009-05-15|Estimate||||2014-07-25|2014-07-31|Estimate|August 2002||2002-08-31|July 2014|2014-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)|A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.|Completed||Phase 3|2461|Actual|Centocor, Inc.|Some AEs were collected separately per protocol and are reported as “Other Pre-Specified Outcomes Measures”.|3|||f||||||||||||||2018-06-01 05:31:10.162656|2018-06-01 05:31:10.162656
NCT00046215|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-21|||2008-03-03|2002-09-21|2002-09-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2002||2002-09-30|November 2003|2003-11-30|November 2003||2003-11-30|||||Observational|||Transcranial Magnetic Stimulation to Study Imagination of Movement|Effect of Transcranial Magnetic Stimulation to Dorsal Premotor Cortex on Motor Imagination|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:11.986508|2018-06-01 05:31:11.986508
NCT00046202|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-21|||2018-03-27|2002-09-21|2002-09-23|Estimate|||||||2018-03-27|2018-03-29|Actual|September 19, 2002||2002-09-19|March 13, 2018|2018-03-13||||||||Observational|||Study of Inborn Errors of Cholesterol Synthesis and Related Disorders|Investigations Into Inborn Errors of Cholesterol Synthesis and Related Disorders|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:12.030797|2018-06-01 05:31:12.030797
NCT00046189|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-21|||2017-10-18|2002-09-21|2002-09-23|Estimate|||||||2017-10-18|2017-10-19|Actual|September 20, 2002||2002-09-20|August 29, 2017|2017-08-29||||||||Observational|||Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum|Cancer Risk in Xeroderma Pigmentosum Heterozygotes|Recruiting|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:12.087084|2018-06-01 05:31:12.087084
NCT00046176|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-20|||2011-06-02|2002-09-20|2002-09-23|Estimate|||||||2011-06-02|2011-06-06|Estimate|August 2002||2002-08-31|May 2011|2011-05-31||||||||Interventional|||A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients|A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients.|Completed||Phase 3|240||GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:31:12.161041|2018-06-01 05:31:12.161041
NCT00046163|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-20|||2007-11-02|2002-09-20|2002-09-23|Estimate|||||||2007-11-02|2007-11-06|Estimate|September 2002||2002-09-30|November 2007|2007-11-30|August 2003|Actual|2003-08-31|||||Interventional|||A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension|A Phase IV, Multi-Center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled Study to Assess the Clinical Benefit of Three Doses of Midodrine Hydrochloride (ProAmatine®) in Subjects With Neurogenic Orthostatic Hypotension|Terminated||Phase 4|150||Shire||||Study was terminated due to poor enrollment|||||||||||||||2018-06-01 05:31:12.378517|2018-06-01 05:31:12.378517
NCT00046150|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-20|||2008-06-18|2002-09-20|2002-09-23|Estimate|||||||2008-06-18|2008-06-19|Estimate|May 2002||2002-05-31|June 2008|2008-06-30|December 2002|Actual|2002-12-31|||||Interventional|||12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.|12-Week, Multinational, Multicenter, Controlled, Open, 1:1 Randomized, Parallel Clinical Trial Comparing the Safety of HMR1964 and Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion (CSII) in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 3|59|Actual|Sanofi|||||||||||||||||||2018-06-01 05:31:12.430626|2018-06-01 05:31:12.430626
NCT00046137|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-20|||2006-07-19|2002-09-20|2002-09-23|Estimate|||||||2006-07-19|2006-07-20|Estimate||||July 2006|2006-07-31||||||||Interventional|||Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis||Completed||Phase 3|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:12.508033|2018-06-01 05:31:12.508033
NCT00046124|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-20|||2006-09-01|2002-09-20|2002-09-23|Estimate|||||||2006-09-01|2006-09-04|Estimate||||September 2006|2006-09-30||||||||Observational|||Organophosphate Pesticides and Human Reproductive Health||Completed|||||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:12.569549|2018-06-01 05:31:12.569549
NCT00046111|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-19|||2017-05-24|2002-09-20|2002-09-23|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2001||2001-09-30|May 2017|2017-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors|A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients With Advanced Solid Tumors|Completed||Phase 1|1|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-06-01 05:31:12.611927|2018-06-01 05:31:12.611927
NCT00046085|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-19|||2016-09-08|2002-09-20|2002-09-23|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2001||2001-03-31|September 2016|2016-09-30|November 2006|Actual|2006-11-30|December 2005|Actual|2005-12-31||Interventional|||Online Family Support and Education for Schizophrenia|Online Family Support and Education for Schizophrenia|Completed||N/A|42|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-06-01 05:31:12.682437|2018-06-01 05:31:12.682437
NCT00046072|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-19|||2005-12-08|2002-09-19|2002-09-20|Estimate|||||||2005-12-08|2005-12-12|Estimate|October 2001||2001-10-31|December 2005|2005-12-31|April 2005||2005-04-30|||||Interventional|||A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis|A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis|Completed||Phase 2|300||Eisai Inc.|||||||||||||||||||2018-06-01 05:31:12.752043|2018-06-01 05:31:12.752043
NCT00046059|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-18|||2018-05-23|2002-09-18|2002-09-19|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2, 2000||2000-02-02|January 17, 2018|2018-01-17||||||||Observational|||Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)|Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)|Active, not recruiting|||3481|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:12.823589|2018-06-01 05:31:12.823589
NCT00046033|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-18|||2011-02-28|2002-09-18|2002-09-19|Estimate|||||||2011-02-28|2011-03-01|Estimate||||May 2005|2005-05-31||||March 2003|Actual|2003-03-31||Interventional|||Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance|A Phase II, Randomized, Open-Label Study Comparing Fixed-Dose Versus Concentration-Adjusted Lopinavir/Ritonavir Therapy in HIV-Infected Subjects on Salvage Therapy|Completed||Phase 2|118||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:31:13.016598|2018-06-01 05:31:13.016598
NCT00046020|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-18|||2009-08-13|2002-09-18|2002-09-19|Estimate|||||||2009-08-13|2009-08-14|Estimate|August 2000||2000-08-31|August 2009|2009-08-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Study Evaluating Venlafaxine ER in Recurrent Depression|An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER|Completed||Phase 4|1096|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:31:13.101843|2018-06-01 05:31:13.101843
NCT00045994|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-17|||2009-07-28|2002-09-18|2002-09-19|Estimate|||||||2009-07-28|2009-07-29|Estimate|August 2001||2001-08-31|August 2007|2007-08-31|June 2003|Actual|2003-06-30|January 2002|Actual|2002-01-31||Interventional|||The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling|Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SILVER Study|Completed||Phase 2|180||Synvista Therapeutics, Inc|||||||||||||||||||2018-06-01 05:31:13.156037|2018-06-01 05:31:13.156037
NCT00045981|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-17|||2010-03-25|2002-09-18|2002-09-19|Estimate|||||||2010-03-25|2010-03-26|Estimate|October 2001||2001-10-31|August 2007|2007-08-31|August 2006|Actual|2006-08-31|May 2003|Actual|2003-05-31||Interventional|||The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)|Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SAPPHIRE Study|Completed||Phase 2|450||Synvista Therapeutics, Inc|||||||||||||||||||2018-06-01 05:31:13.212094|2018-06-01 05:31:13.212094
NCT00045968|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-17|||2016-10-12|2002-09-18|2002-09-19|Estimate|||||||2016-10-12|2016-10-14|Estimate|December 2006||2006-12-31|October 2016|2016-10-31||||November 2016|Anticipated|2016-11-30||Interventional|GBM||Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer|A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)|Active, not recruiting||Phase 3|348|Anticipated|Northwest Biotherapeutics||2|||f||||t||||||||||2018-06-01 05:31:13.289629|2018-06-01 05:31:13.289629
NCT00045955|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-17|||2008-08-20|2002-09-18|2002-09-19|Estimate|||||||2008-08-20|2008-08-21|Estimate|February 2002||2002-02-28|August 2008|2008-08-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Long-Term Safety Performance of Fexofenadine in Asthma|A Multicenter, Open-Label, Randomized, Parallel Groups Study to Assess the Long-Term Safety Performance of Fexofenadine Compared to Montelukast in Subjects With Asthma|Completed||Phase 3|1200|Anticipated|Sanofi|||||||||||||||||||2018-06-01 05:31:13.538209|2018-06-01 05:31:13.538209
NCT00045942|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-16|2017-05-03||2017-08-07|2002-09-17|2002-09-18|Estimate|2017-06-15|2017-07-17|Actual||||2017-08-07|2017-08-11|Actual|January 30, 2002|Actual|2002-01-30|August 2017|2017-08-31|March 27, 2008|Actual|2008-03-27|March 27, 2008|Actual|2008-03-27||Interventional||The baseline characteristics for PKC412A2104E2 do not include data for the 2 patients who transferred from CPKC412A2104E1 since the data for these 2 patients are included under CPKC412A2104E1.|PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)|An Open-label Phase II (Proof of Concept (POC)) Trial of PKC412 Monotherapy in Participants With Acute Myeloid Leukemia (AML) and Participants With High Risk Myelodysplastic Syndrome (MDS) (CPKC412A2104 Core); An Open-label, Randomized Phase II POC Trial in PKC412 in Participants With AML and Participants With High Risk MDS With Either Wild Type or Mutated FLT3 (CPKC412A2104E1); and An Open-label, Randomized Phase 1/II POC Trial in PKC412 in Participants With AML and Participants With High Risk MDS With Either Wild Type or Mutated FLT3 (CPKC412A2104E2)|Completed||Phase 1/Phase 2|144|Actual|Novartis||9|||f||||f|t|f||||||Undecided||2018-06-01 05:31:13.809982|2018-06-01 05:31:13.809982
NCT00045916|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-13|||2013-08-09|2002-09-16|2002-09-17|Estimate|||||||2013-08-09|2013-08-13|Estimate|February 2001||2001-02-28|October 2008|2008-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Optimizing Electroconvulsive Therapy for Depression|Optimization of Electroconvulsive Therapy|Completed||Phase 4|340|Actual|New York State Psychiatric Institute||6|||f||||||||||||||2018-06-01 05:31:19.196675|2018-06-01 05:31:19.196675
NCT00045903|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-13|||2014-04-22|2002-09-16|2002-09-17|Estimate|||||||2014-04-22|2014-04-23|Estimate|August 2000||2000-08-31|October 2012|2012-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|Aug1||Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder|CBT Augmentation for SRI Pharmacotherapy in OCD|Completed||N/A|136|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-06-01 05:31:19.282333|2018-06-01 05:31:19.282333
NCT00044824|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-05|||2008-08-20|2002-09-16|2002-09-17|Estimate|||||||2008-08-20|2008-08-21|Estimate|February 2002||2002-02-28|August 2008|2008-08-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma|A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma|Completed||Phase 3|1000|Anticipated|Sanofi|||||||||||||||||||2018-06-01 05:31:19.346479|2018-06-01 05:31:19.346479
NCT00044811|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-05|||2008-08-20|2002-09-16|2002-09-17|Estimate|||||||2008-08-20|2008-08-21|Estimate|March 2002||2002-03-31|August 2008|2008-08-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma|A Multicenter, Double-Blind, Randomized, Parallel Groups Placebo-Controlled Study to Assess the Efficacy and Safety of Fexofenadine 120mg BID in Subjects With Mild to Moderate Persistent Asthma|Completed||Phase 3|1000|Anticipated|Sanofi|||||||||||||||||||2018-06-01 05:31:19.483875|2018-06-01 05:31:19.483875
NCT00045877|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-12|||2006-02-02|2002-09-13|2002-09-16|Estimate|||||||2006-02-02|2006-02-06|Estimate||||February 2006|2006-02-28||||||||Interventional|||Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments||Completed||Phase 2/Phase 3|||Chiron Corporation|||||||||||||||||||2018-06-01 05:31:19.567244|2018-06-01 05:31:19.567244
NCT00045864|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-12|||2006-02-02|2002-09-13|2002-09-16|Estimate|||||||2006-02-02|2006-02-06|Estimate||||February 2006|2006-02-28||||||||Interventional|||Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.||Completed||Phase 2|||Chiron Corporation|||||||||||||||||||2018-06-01 05:31:19.692508|2018-06-01 05:31:19.692508
NCT00045838|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-10|||2015-09-30|2002-09-10|2002-09-11|Estimate|||||||2015-09-30|2015-10-02|Estimate|August 2002||2002-08-31|September 2015|2015-09-30|April 2003|Actual|2003-04-30|April 2003|Anticipated|2003-04-30||Interventional|||HIV-1 Vaccine Test in Uninfected Adult Volunteers|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA006-00-VP, In Uninfected Adult Volunteers|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)||||The study product was revised. PI withdrew the study without enrolling participants..|f||||||||||||||2018-06-01 05:31:19.772179|2018-06-01 05:31:19.772179
NCT00045812|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-10|||2008-03-03|2002-09-10|2002-09-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|April 2004|2004-04-30|April 2004||2004-04-30|||||Interventional|||SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia|Completed||Phase 2|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:19.824839|2018-06-01 05:31:19.824839
NCT00045799|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-09|||2014-04-24|2002-09-10|2002-09-11|Estimate|||||||2014-04-24|2014-04-28|Estimate|May 2002||2002-05-31|April 2014|2014-04-30|May 2003|Actual|2003-05-31|||||Interventional|||Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill|Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill|Completed||Phase 3|354|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-06-01 05:31:20.224506|2018-06-01 05:31:20.224506
NCT00045786|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-09|||2017-04-24|2002-09-10|2002-09-11|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2001||2001-10-31|April 2017|2017-04-30|November 2003|Actual|2003-11-30|December 2001|Actual|2001-12-31||Interventional|||Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes|A Multi-center, An Open Label, Dose-Escalation Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment for Myelodysplastic Syndromes|Completed||Phase 2|18|Actual|Celgene||4|||||||||||||||||2018-06-01 05:31:20.380719|2018-06-01 05:31:20.380719
NCT00045773|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-09|||2017-10-27|2002-09-10|2002-09-11|Estimate|||||||2017-10-27|2017-10-31|Actual|April 2001||2001-04-30|October 2017|2017-10-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Observational|||Treatment Outcome of Vascular Depression|Treatment Outcome of Vascular Depression|Completed|||208|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-06-01 05:31:20.443262|2018-06-01 05:31:20.443262
NCT00045760|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-09|||2006-07-18|2002-09-09|2002-09-10|Estimate|||||||2006-07-18|2006-07-20|Estimate|September 2002||2002-09-30|July 2006|2006-07-31||||||||Interventional|||The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis||Completed||Phase 4|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:20.615385|2018-06-01 05:31:20.615385
NCT00044928|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2013-02-07|2002-09-09|2002-09-10|Estimate|||||||2013-02-07|2013-02-08|Estimate|July 2002||2002-07-31|February 2013|2013-02-28|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection|Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection|Completed||Phase 4|262|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:31:21.528367|2018-06-01 05:31:21.528367
NCT00044915|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2009-06-09|2002-09-06|2002-09-09|Estimate|||||||2009-06-09|2009-06-12|Estimate|December 2000||2000-12-31|June 2009|2009-06-30|September 2004|Actual|2004-09-30|||||Interventional|||Repinotan in Patients With Acute Ischemic Stroke|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic / Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients With Acute Ischemic Stroke|Completed||Phase 2|782|Actual|Bayer||2|||f||||||||||||||2018-06-01 05:31:21.676645|2018-06-01 05:31:21.676645
NCT00044902|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2007-12-20|2002-09-06|2002-09-09|Estimate|||||||2007-12-20|2007-12-28|Estimate||||December 2007|2007-12-31||||||||Interventional|||Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)||Completed||Phase 2|||Amgen|||||||||||||||||||2018-06-01 05:31:21.982718|2018-06-01 05:31:21.982718
NCT00044889|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-06|||2014-03-17|2002-09-06|2002-09-09|Estimate|||||||2014-03-17|2014-03-19|Estimate|May 2002||2002-05-31|March 2014|2014-03-31|March 2003|Actual|2003-03-31|||||Interventional|||Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia|A Phase II, Open-Label Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia|Completed||Phase 2|40||Sanofi|||||||||||||||||||2018-06-01 05:31:22.132722|2018-06-01 05:31:22.132722
NCT00044863|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-05|||2011-02-21|2002-09-06|2002-09-09|Estimate|||||||2011-02-21|2011-02-23|Estimate|August 2002||2002-08-31|February 2011|2011-02-28|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma|A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma|Completed||Phase 2|250|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 05:31:22.576688|2018-06-01 05:31:22.576688
NCT00044837|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-05|||2015-06-03|2002-09-06|2002-09-09|Estimate|||||||2015-06-03|2015-06-04|Estimate||||June 2003|2003-06-30||||||||Interventional|||Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women|A Phase I, Pharmacokinetic Study of Hormone Replacement Therapy in HIV-1-Infected, Postmenopausal Women on Nelfinavir, Lopinavir/Ritonavir, or Efavirenz|Terminated||Phase 1|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:31:22.809594|2018-06-01 05:31:22.809594
NCT00044876|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-05|||2018-05-24|2002-09-05|2002-09-06|Estimate|||||||2018-05-24|2018-05-25|Actual|September 2, 2002||2002-09-02|October 1, 2015|2015-10-01|October 1, 2015|Actual|2015-10-01|June 16, 2007|Actual|2007-06-16||Interventional|||Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist|Treatment of Leiomyomata With the Selective Progesterone Receptor Modulator CDB-2914|Completed||Phase 2|56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:22.946497|2018-06-01 05:31:22.946497
NCT00044798|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-04|||2013-09-26|2002-09-05|2002-09-06|Estimate|||||||2013-09-26|2013-09-27|Estimate|September 2001||2001-09-30|September 2013|2013-09-30|August 2008|Actual|2008-08-31|March 2007|Actual|2007-03-31||Interventional|rtms||Magnetic Stimulation Therapy for Treating Vascular Depression|Vascular Depression and Magnetic Stimulation Therapy|Completed||Phase 3|132|Anticipated|University of Iowa||2|||f||||t||||||||||2018-06-01 05:31:23.069326|2018-06-01 05:31:23.069326
NCT00044785|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-04|||2005-06-23|2002-09-05|2002-09-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2002||2002-08-31|May 2005|2005-05-31|March 2004||2004-03-31|||||Interventional|||Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors|A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.|Terminated||Phase 1|24||Wellstat Therapeutics|||||||||||||||||||2018-06-01 05:31:23.187537|2018-06-01 05:31:23.187537
NCT00044772|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-04|||2009-08-13|2002-09-05|2002-09-06|Estimate|||||||2009-08-13|2009-08-14|Estimate|November 2001||2001-11-30|August 2009|2009-08-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Study Evaluating Venlafaxine ER in Patients With Panic Disorder|A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder|Completed||Phase 3|653|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:31:23.242675|2018-06-01 05:31:23.242675
NCT00044759|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-04|||2007-10-08|2002-09-05|2002-09-06|Estimate|||||||2007-10-08|2007-10-10|Estimate||||October 2007|2007-10-31|January 2003|Actual|2003-01-31|||||Interventional|||Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma|A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma|Completed||Phase 3|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:31:23.33421|2018-06-01 05:31:23.33421
NCT00044746|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-04|||2013-02-07|2002-09-05|2002-09-06|Estimate|||||||2013-02-07|2013-02-08|Estimate|October 2000||2000-10-31|February 2013|2013-02-28|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections|An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients|Completed||Phase 4|314|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:31:23.417164|2018-06-01 05:31:23.417164
NCT00044733|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-04|||2006-05-17|2002-09-05|2002-09-06|Estimate|||||||2006-05-17|2006-05-18|Estimate|March 2000||2000-03-31|May 2006|2006-05-31|September 2004||2004-09-30|||||Interventional|||Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant|A Dose-Finding Study of the Safety of Gemtuzumab Ozogamicin as Single Agent Treatment of Patients With Relapsed Acute Myelogenous Leukemia After Autologous or Allogenic Hematopoietic Stem Cell Transplant (HSCT)|Completed||Phase 2|38||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:31:23.513314|2018-06-01 05:31:23.513314
NCT00044720|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-04|||2009-08-17|2002-09-05|2002-09-06|Estimate|||||||2009-08-17|2009-08-18|Estimate||||August 2009|2009-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients|An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor|Completed||Phase 4|484|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:31:23.577227|2018-06-01 05:31:23.577227
NCT00044707|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2015-05-20|2002-09-04|2002-09-05|Estimate|||||||2015-05-20|2015-05-21|Estimate|August 2002||2002-08-31|May 2015|2015-05-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide||Completed||Phase 2|24|Actual|AstraZeneca||2|||f||||||||||||||2018-06-01 05:31:23.623737|2018-06-01 05:31:23.623737
NCT00044694|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2015-02-19|2002-09-04|2002-09-05|Estimate|||||||2015-02-19|2015-02-20|Estimate|August 2002||2002-08-31|January 2015|2015-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|156|Actual|AstraZeneca||8|||f||||f||||||||||2018-06-01 05:31:23.819025|2018-06-01 05:31:23.819025
NCT00044681|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2011-05-17|2002-09-04|2002-09-05|Estimate|||||||2011-05-17|2011-05-18|Estimate|October 2002||2002-10-31|November 2010|2010-11-30|March 2004|Actual|2004-03-31|||||Interventional|||A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression|A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression|Completed||Phase 3|258|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:31:24.027572|2018-06-01 05:31:24.027572
NCT00044668|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2015-02-19|2002-09-04|2002-09-05|Estimate|||||||2015-02-19|2015-02-20|Estimate|August 2002||2002-08-31|January 2015|2015-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination|An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination|Completed||Phase 3|155|Actual|AstraZeneca||1|||f||||f||||||||||2018-06-01 05:31:24.372195|2018-06-01 05:31:24.372195
NCT00044655|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|2013-09-27||2016-03-28|2002-09-04|2002-09-05|Estimate|2013-09-30|2013-12-05|Estimate||||2016-03-28|2016-04-28|Estimate|July 2001||2001-07-31|March 2016|2016-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Switching Medication to Treat Schizophrenia|Effectiveness of Switching Antipsychotic Medications|Completed||Phase 4|219|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-06-01 05:31:24.445459|2018-06-01 05:31:24.445459
NCT00044642|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2013-12-05|2002-09-04|2002-09-05|Estimate|||||||2013-12-05|2013-12-06|Estimate|December 2000||2000-12-31|December 2013|2013-12-31|July 2007|Actual|2007-07-31|||||Interventional|||Lorazepam-Induced Toxicity in the Aged|Long-Term Lorazepam Use and Acute Toxicity in the Aged|Completed||Phase 4|90|Anticipated|Nathan Kline Institute for Psychiatric Research|||||f||||||||||||||2018-06-01 05:31:24.851171|2018-06-01 05:31:24.851171
NCT00044629|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2013-09-12|2002-09-04|2002-09-05|Estimate|||||||2013-09-12|2013-09-16|Estimate|September 2001||2001-09-30|September 2013|2013-09-30|August 2006||2006-08-31|||||Interventional|||Combined Behavioral/Pharmacological Therapy for Insomnia|Combined Behavioral/Pharmacological Therapy for Insomnia|Completed||Phase 2|162|Actual|Duke University||3|||f||||||||||||||2018-06-01 05:31:25.02833|2018-06-01 05:31:25.02833
NCT00044616|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2015-10-02|2002-09-04|2002-09-05|Estimate|||||||2015-10-02|2015-10-06|Estimate|February 2001||2001-02-28|December 2013|2013-12-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Relapse Prevention for Bipolar Type-II Disorder|Relapse Prevention of Bipolar Type-II Disorder|Completed||Phase 4|180||University of Pennsylvania|||||f||||||||||||||2018-06-01 05:31:25.167281|2018-06-01 05:31:25.167281
NCT00044603|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2014-10-14|2002-09-04|2002-09-05|Estimate|||||||2014-10-14|2014-10-15|Estimate|February 2000||2000-02-29|October 2014|2014-10-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Vulnerability of the Fetus/Infant to PAH, PM2.5 AND ETS.|Vulnerability of the Fetus/Infant to PAH, PM2.5 AND ETS|Completed|||505|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||f||||||Samples With DNA|"~     Biologic samples were collected from the mothers and their children as follows: maternal~     blood (30-35 ml) within 1 day postpartum and umbilical cord blood (30 - 60 ml) collected by~     delivery room staff immediately after the cord was cut. Members of the research staff~     transported the samples to the laboratory immediately. The buffy coat, packed red blood~     cells, and plasma samples were separated and stored at -70°C and then shipped to Columbia~     University. Placental tissue and meconium were also collected. The placental tissue and~     meconium were sent to Columbia and stored for future analysis under separate funding.~   "|||2018-06-01 05:31:25.217807|2018-06-01 05:31:25.217807
NCT00044590|ClinicalTrials.gov processed this data on May 31, 2018|2002-09-03|||2017-05-12|2002-09-04|2002-09-05|Estimate|||||||2017-05-12|2017-05-16|Actual|September 1, 2000|Actual|2000-09-01|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||Parkinson's Diseases Susceptibility Genes and Pesticides|Parkinson's Diseases Susceptibility Genes and Pesticides|Completed|||1870|Actual|National Institute of Environmental Health Sciences (NIEHS)|||2||f||||f||||||Samples With DNA|"~     Blood, saliva, urine, and stool samples~   "|Undecided||2018-06-01 05:31:25.279215|2018-06-01 05:31:25.279215
NCT00044577|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-30|||2011-03-17|2002-09-03|2002-09-04|Estimate|||||||2011-03-17|2011-03-21|Estimate|July 2002||2002-07-31|March 2011|2011-03-31||||||||Interventional|||New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects|See Detailed Description|Completed||Phase 3|166||GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:31:25.372746|2018-06-01 05:31:25.372746
NCT00044564|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-30|||2014-12-18|2002-09-03|2002-09-04|Estimate|||||||2014-12-18|2014-12-19|Estimate|December 2001||2001-12-31|December 2014|2014-12-31|January 2003|Actual|2003-01-31|||||Interventional|||Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma|An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma|Completed||Phase 2|54|Actual|Bayer||1|||||||||||||||||2018-06-01 05:31:25.56319|2018-06-01 05:31:25.56319
NCT00044551|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-30|||2013-10-10|2002-09-03|2002-09-04|Estimate|||||||2013-10-10|2013-10-14|Estimate|February 2002||2002-02-28|October 2013|2013-10-31|July 2003|Actual|2003-07-31|||||Interventional|||Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma|An Open Phase II, Multi Center Trial of BAY 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|29|Actual|Bayer||1|||f||||||||||||||2018-06-01 05:31:25.679206|2018-06-01 05:31:25.679206
NCT00044538|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-30|||2009-06-19|2002-09-03|2002-09-04|Estimate|||||||2009-06-19|2009-06-22|Estimate|December 2001||2001-12-31|June 2009|2009-06-30|June 2004|Actual|2004-06-30|||||Interventional|||Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients|An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC)|Completed||Phase 2|102|Actual|Bayer||1|||f||||||||||||||2018-06-01 05:31:25.781006|2018-06-01 05:31:25.781006
NCT00044525|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-30|||2014-12-18|2002-09-03|2002-09-04|Estimate|||||||2014-12-18|2014-12-23|Estimate|April 2002||2002-04-30|December 2014|2014-12-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients|An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer|Completed||Phase 2|82|Actual|Bayer||1|||f||||||||||||||2018-06-01 05:31:25.896143|2018-06-01 05:31:25.896143
NCT00044291|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-23|||2015-07-29|2002-08-26|2002-08-27|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2002||2002-06-30|July 2015|2015-07-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer||Completed||Phase 3|865|Actual|Intarcia Therapeutics||2|||f||||||||||||||2018-06-01 05:31:27.971784|2018-06-01 05:31:27.971784
NCT00044512|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-30|2009-02-20||2014-03-26|2002-09-03|2002-09-04|Estimate|2009-06-19|2009-08-06|Estimate||||2014-03-26|2014-04-16|Estimate|August 2002||2002-08-31|March 2014|2014-03-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma|A Phase II Multicenter Uncontrolled Trial of Sorafenib (BAY43-9006) in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 2|137|Actual|Bayer|Subjects had advanced disease and were heavily pretreated. National Cancer Institute-Common Toxicity Criteria (NCI-CTC) was translated to Medical Dictionary for Regulatory Activities (MedDRA) for System Organ Class (SOC) only.|1|||f||||f||||||||||2018-06-01 05:31:26.023733|2018-06-01 05:31:26.023733
NCT00044486|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-29|||2017-03-07|2002-09-03|2002-09-04|Estimate|||||||2017-03-07|2017-03-10|Actual|July 2002||2002-07-31|March 2017|2017-03-31|April 2005|Actual|2005-04-30|December 2004|Actual|2004-12-31||Interventional|||Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)|A Randomized Controlled Trial of Posaconazole (SCH 56592) vs. Standard Azole Therapy for the Prevention of Invasive Fungal Infections Among High-Risk Neutropenic Patients|Completed||Phase 3|602|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:31:26.528987|2018-06-01 05:31:26.528987
NCT00044473|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-29|||2011-06-06|2002-09-03|2002-09-04|Estimate|||||||2011-06-06|2011-06-08|Estimate|November 2002||2002-11-30|January 2011|2011-01-31|July 2003|Actual|2003-07-31|||||Interventional|||A Study of the Effectiness and Safety of Levofloxacin in Treating Children With a Rapid and Severe Onset of Infection and Inflammation of the Middle Ear That is Difficult to Treat|An Open-Label Study of Levofloxacin to Evaluate Bacteriologic Outcome in the Treatment of Children Who Are at Risk for Acute Otitis Media That is Difficult to Treat|Completed||Phase 3|206|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:31:26.605182|2018-06-01 05:31:26.605182
NCT00044460|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-29|||2017-10-05|2002-08-29|2002-08-30|Estimate|||||||2017-10-05|2017-10-09|Actual|May 2002|Actual|2002-05-31|October 2017|2017-10-31|April 10, 2003|Actual|2003-04-10|April 10, 2003|Actual|2003-04-10||Interventional|||Efficacy and Safety In Poorly Controlled Type 2 Diabetics|A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|142||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:31:26.671336|2018-06-01 05:31:26.671336
NCT00044447|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-28|||2008-06-18|2002-08-29|2002-08-30|Estimate|||||||2008-06-18|2008-06-19|Estimate|May 2001||2001-05-31|June 2008|2008-06-30|September 2002|Actual|2002-09-30|||||Interventional|||Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione|A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy|Completed||Phase 3|170|Actual|Sanofi|||||||||||||||||||2018-06-01 05:31:26.764739|2018-06-01 05:31:26.764739
NCT00044434|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-28|||2008-01-25|2002-08-29|2002-08-30|Estimate|||||||2008-01-25|2008-01-29|Estimate|May 2002||2002-05-31|January 2008|2008-01-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Bupropion as a Smoking Cessation Aid in Alcoholics|Bupropion as a Smoking Cessation Aid in Alcoholics|Completed||Phase 4|200||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:31:26.875876|2018-06-01 05:31:26.875876
NCT00044421|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-28|||2007-11-05|2002-08-29|2002-08-30|Estimate|||||||2007-11-05|2007-11-06|Estimate|July 2002||2002-07-31|November 2007|2007-11-30|October 2006|Actual|2006-10-31|||||Interventional|||Treatment of Peripheral Neuropathy in Patients With Diabetes|LY333531 Treatment of Peripheral Neuropathy in Patients With Diabetes|Completed||Phase 3|400||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:26.940669|2018-06-01 05:31:26.940669
NCT00044408|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-28|||2016-07-25|2002-08-29|2002-08-30|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2002||2002-07-31|July 2016|2016-07-31|October 2005|Actual|2005-10-31|||||Interventional|||Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes|LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes|Completed||Phase 3|200||Chromaderm, Inc.|||||||||||||||||||2018-06-01 05:31:27.205606|2018-06-01 05:31:27.205606
NCT00044395|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-28|||2007-11-05|2002-08-29|2002-08-30|Estimate|||||||2007-11-05|2007-11-06|Estimate|July 2002||2002-07-31|November 2007|2007-11-30|October 2005|Actual|2005-10-31|||||Interventional|||Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes|LY333531 Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes|Completed||Phase 3|200||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:27.345498|2018-06-01 05:31:27.345498
NCT00044382|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-27|||2009-06-16|2002-08-28|2002-08-29|Estimate|||||||2009-06-16|2009-06-17|Estimate|February 2002||2002-02-28|June 2009|2009-06-30||||January 2007|Actual|2007-01-31||Interventional|||Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome|A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome|Completed||Phase 2|25||Celgene|||||f||||t||||||||||2018-06-01 05:31:27.463906|2018-06-01 05:31:27.463906
NCT00044369|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-27|||2006-09-01|2002-08-27|2002-08-28|Estimate|||||||2006-09-01|2006-09-04|Estimate|May 2000||2000-05-31|September 2006|2006-09-30|April 2005||2005-04-30|||||Observational|||Role of the Toxic Metal Cadmium in the Mechanism Producing Infertility With a Varicocele|Increased Testicular Cd2+ & Infertility With Varicocele ( a Varicose Vein in the Scrotum)|Completed|||400||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:27.535629|2018-06-01 05:31:27.535629
NCT00044356|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-26|||2011-07-05|2002-08-27|2002-08-28|Estimate|||||||2011-07-05|2011-07-07|Estimate|February 2001||2001-02-28|July 2011|2011-07-31|September 2004|Actual|2004-09-30|August 2004|Actual|2004-08-31||Interventional|||Phase II Trial of Allovectin-7® for Metastatic Melanoma|A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma|Completed||Phase 2|133|Actual|Vical|||||f||||f||||||||||2018-06-01 05:31:27.618786|2018-06-01 05:31:27.618786
NCT00044343|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-26|||2014-07-09|2002-08-27|2002-08-28|Estimate|||||||2014-07-09|2014-07-10|Estimate|September 2002||2002-09-30|July 2014|2014-07-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin|An Open-Label, Multicenter, Phase II Study of Oral Lapatinib (GW572016) as Single Agent, Second-Line Therapy in Subjects With Metastatic Colorectal Cancer Who Have Progressed on First-Line Therapy With 5-Fluorouracil in Combination With Irinotecan or Oxaliplatin|Completed||Phase 2|80|Actual|GlaxoSmithKline|||||f||||||||||||||2018-06-01 05:31:27.740063|2018-06-01 05:31:27.740063
NCT00044317|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-26|||2005-06-23|2002-08-26|2002-08-27|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Observational|||Health Effects of Particulate Acids in Late Adolescence||Completed|||1500||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:27.903222|2018-06-01 05:31:27.903222
NCT00044304|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-24|||2018-04-03|2002-08-24|2002-08-26|Estimate|||||||2018-04-03|2018-04-04|Actual|August 23, 2002||2002-08-23|March 21, 2018|2018-03-21|January 1, 2026|Anticipated|2026-01-01|January 1, 2026|Anticipated|2026-01-01||Interventional|||Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome|Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome|Recruiting||Phase 2|60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:28.109894|2018-06-01 05:31:28.109894
NCT00044278|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-23|||2017-01-16|2002-08-23|2002-08-26|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2000||2000-09-30|January 2017|2017-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Pediatric Epilepsy Study in Subjects 1-24 Months|An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)|Completed||Phase 2|197|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:31:28.311846|2018-06-01 05:31:28.311846
NCT00044265|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-23|||2012-06-06|2002-08-23|2002-08-26|Estimate|||||||2012-06-06|2012-06-07|Estimate|July 2002||2002-07-31|June 2012|2012-06-30|November 2004||2004-11-30|||||Interventional|||Treatment of Pediatric Hypertension With Altace Trial|A Dose Escalation, Randomized, Double-blind Withdrawal Study of the Efficacy, Dose-response, and Safety of Ramipril for the Treatment of Hypertension in Children and Adolescents|Completed||Phase 4|310||Pfizer|||||||||||||||||||2018-06-01 05:31:28.492365|2018-06-01 05:31:28.492365
NCT00044252|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-22|||2017-06-30|2002-08-22|2002-08-23|Estimate|||||||2017-06-30|2017-07-02|Actual|July 26, 2002||2002-07-26|January 22, 2008|2008-01-22|January 22, 2008||2008-01-22|||||Observational|||Role of Hormones in Susceptibility to Seizures in Women With Epilepsy|Role of Serum Gonadal and Neuroactive Steroids in the Seizure Susceptibility of Women With Catamenial Epilepsy|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:28.574173|2018-06-01 05:31:28.574173
NCT00044239|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-22|||2017-06-30|2002-08-22|2002-08-23|Estimate|||||||2017-06-30|2017-07-02|Actual|August 20, 2002||2002-08-20|May 18, 2010|2010-05-18|May 18, 2010||2010-05-18|||||Observational|||Characterization of Childhood-Onset Obsessive-Compulsive Disorder|The Characterization of Childhood Onset Obsessive Compulsive Disorder and the PANDAS Subgroup|Completed|||49|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:28.624472|2018-06-01 05:31:28.624472
NCT00044226|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-22|||2005-06-23|2002-08-22|2002-08-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2002||2002-04-30|August 2002|2002-08-31|October 2002||2002-10-31|||||Interventional|||A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Dosing Regimens of ML-04A in Subjects With Symptomatic Benign Prostatic Hyperplasia|Unknown status|Recruiting|Phase 2|350||Milkhaus Laboratory|||||||||||||||||||2018-06-01 05:31:28.705391|2018-06-01 05:31:28.705391
NCT00044213|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-22|2013-08-30|2013-05-03|2013-08-30|2002-08-22|2002-08-23|Estimate|2013-08-30|2013-11-05|Estimate|2013-05-03|2013-05-13|Estimate|2013-08-30|2013-11-05|Estimate|September 2003||2003-09-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|||Trial to Assess Chelation Therapy (TACT)|Trial to Assess Chelation Therapy (TACT)|Completed||Phase 3|1708|Actual|Mt. Sinai Medical Center, Miami||4|||f||||t||||||||||2018-06-01 05:31:28.804995|2018-06-01 05:31:28.804995
NCT00044187|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-21|||2006-07-18|2002-08-22|2002-08-23|Estimate|||||||2006-07-18|2006-07-19|Estimate|April 2001||2001-04-30|July 2006|2006-07-31|September 2003||2003-09-30|||||Interventional|||The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder|The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder|Completed||Phase 4|130||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:30.143705|2018-06-01 05:31:30.143705
NCT00044200|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-21|||2017-10-05|2002-08-21|2002-08-22|Estimate|||||||2017-10-05|2017-10-06|Actual|January 10, 2000||2000-01-10|June 12, 2015|2015-06-12|June 12, 2015||2015-06-12|||||Observational|||Positron Emission Tomography (PET) to Study Brain Signaling|Positron Emission Tomography Imaging of Activation-Induced Signal Transduction in Human Brain|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:30.215206|2018-06-01 05:31:30.215206
NCT00044174|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-20|||2018-04-04|2002-08-20|2002-08-21|Estimate|||||||2018-04-04|2018-04-05|Actual|August 17, 2002||2002-08-17|March 8, 2018|2018-03-08||||||||Observational|||Dyadic Interactions in Depressed and Non-Depressed Mothers and Their Infants|Dyadic Interactions in Depressed and Non-Depressed Mothers and Their Infants|Completed|||701|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:30.295574|2018-06-01 05:31:30.295574
NCT00044148|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-20|||2017-01-30|2002-08-20|2002-08-21|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 16, 2002|Actual|2002-07-16|January 2017|2017-01-31|April 28, 2004|Actual|2004-04-28|April 28, 2004|Actual|2004-04-28||Interventional|||The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes|The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial|Completed||Phase 2|||Chromaderm, Inc.|||||f|||||t|f||||||||2018-06-01 05:31:30.353839|2018-06-01 05:31:30.353839
NCT00044135|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-20|||2005-06-23|2002-08-20|2002-08-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2002||2002-08-31|November 2002|2002-11-30||||||||Interventional|||A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.|A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus.|Unknown status|Active, not recruiting|Phase 2|30||Triangle Pharmaceuticals|||||f||||||||||||||2018-06-01 05:31:30.540678|2018-06-01 05:31:30.540678
NCT00044070|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|||2006-03-31|2002-08-19|2002-08-20|Estimate|||||||2006-03-31|2006-04-03|Estimate|December 2000||2000-12-31|March 2006|2006-03-31|January 2003||2003-01-31|||||Interventional|||A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion, and FLAIR Magnetic Resonance Imaging in Patients With Acute Ischemic Stroke|Completed||Phase 2|||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:31:30.631339|2018-06-01 05:31:30.631339
NCT00044057|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|||2006-03-31|2002-08-19|2002-08-20|Estimate|||||||2006-03-31|2006-04-03|Estimate|December 2000||2000-12-31|March 2006|2006-03-31|January 2003||2003-01-31|||||Interventional|||A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)|A Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients With Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo|Completed||Phase 2|||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:31:30.86019|2018-06-01 05:31:30.86019
NCT00044044|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|2011-02-01||2014-03-31|2002-08-19|2002-08-20|Estimate|2011-03-11|2011-04-12|Estimate||||2014-03-31|2014-04-17|Estimate|July 2002||2002-07-31|March 2014|2014-03-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia|A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol in Patients With Schizophrenia Who Are Experiencing an Acute Exacerbation of Symptoms|Completed||Phase 2|356|Actual|Sunovion||5|||f||||f||||||||||2018-06-01 05:31:31.441504|2018-06-01 05:31:31.441504
NCT00044031|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|||2014-04-16|2002-08-19|2002-08-20|Estimate|||||||2014-04-16|2014-04-17|Estimate|February 2001||2001-02-28|April 2014|2014-04-30|October 2007|Actual|2007-10-31|April 2004|Actual|2004-04-30||Interventional|||Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma|Prospective, Randomized, Controlled, Double-Blind, Multi-National, Multi-Center Study of G17DT Immunogen in Combination With Gemcitabine Versus Placebo in Combination With Gemcitabine in Previously Untreated Subjects With Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Protocol No. PC4)|Completed||Phase 3|394|Actual|Cancer Advances Inc.||2|||t||||f||||||||||2018-06-01 05:31:32.674633|2018-06-01 05:31:32.674633
NCT00044018|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|||2009-09-22|2002-08-19|2002-08-20|Estimate|||||||2009-09-22|2009-09-23|Estimate|April 2002||2002-04-30|September 2009|2009-09-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma|An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|102|Actual|Celgene|||||f||||f||||||||||2018-06-01 05:31:32.744584|2018-06-01 05:31:32.744584
NCT00044005|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|2011-02-16||2014-03-31|2002-08-19|2002-08-20|Estimate|2011-04-19|2011-05-19|Estimate||||2014-03-31|2014-04-17|Estimate|September 2002||2002-09-30|March 2014|2014-03-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Safety and Tolerability Study of Drug to Treat Schizophrenia|A Randomized, Open-Label, Dose-Blinded, Multicenter, 6-Month Study of Safety and Tolerability of 3 Dose Levels of SM-13496 (Lurasidone) in Patients With Schizophrenia|Completed||Phase 2|98|Actual|Sunovion||3|||f||||f||||||||||2018-06-01 05:31:32.851799|2018-06-01 05:31:32.851799
NCT00043329|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2007-10-30|2002-08-19|2002-08-20|Estimate|||||||2007-10-30|2007-11-01|Estimate|January 2002||2002-01-31|October 2007|2007-10-31|September 2005|Actual|2005-09-30|||||Observational|||Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis|Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis|Completed|||6|Actual|InterMune|||||f||||||||||||||2018-06-01 05:31:33.201593|2018-06-01 05:31:33.201593
NCT00044122|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-17|||2018-03-27|2002-08-17|2002-08-19|Estimate|||||||2018-03-27|2018-03-29|Actual|August 16, 2002||2002-08-16|September 12, 2017|2017-09-12||||||||Observational|||Study of Factors Regulating Mast Cell Proliferation|Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells|Recruiting|||550|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:33.275495|2018-06-01 05:31:33.275495
NCT00044109|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-17|||2006-06-23|2002-08-17|2002-08-19|Estimate|||||||2006-06-23|2006-06-26|Estimate|August 2002||2002-08-31|June 2006|2006-06-30|June 2006||2006-06-30|||||Interventional|||Magnets in the Treatment of Sciatica|Static Magnets In The Treatment of Sciatica|Completed||Phase 2|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:33.44061|2018-06-01 05:31:33.44061
NCT00044096|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|||2017-10-05|2002-08-16|2002-08-19|Estimate|||||||2017-10-05|2017-10-06|Actual|August 15, 2002||2002-08-15|September 17, 2013|2013-09-17|September 17, 2013||2013-09-17|||||Observational|||Psychopharmacology of Fear-Potentiated Startle in Humans|Psychopharmacology of Fear-Potentiated Startle in Humans|Completed|||225|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:33.498283|2018-06-01 05:31:33.498283
NCT00044083|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|||2016-08-31|2002-08-16|2002-08-19|Estimate|||||||2016-08-31|2016-09-01|Estimate|August 2002||2002-08-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Trial of Tolcapone for Cognition in Schizophrenia|Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype|Completed||Phase 2|213|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:33.57213|2018-06-01 05:31:33.57213
NCT00043992|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-16|||2006-09-01|2002-08-16|2002-08-19|Estimate|||||||2006-09-01|2006-09-04|Estimate|July 2001||2001-07-31|September 2006|2006-09-30||||||||Observational|||Outdoor Allergen Exposure, Sensitivity, and Acute Asthma||Completed|||1000||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:33.679092|2018-06-01 05:31:33.679092
NCT00043966|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-15|||2006-07-26|2002-08-16|2002-08-19|Estimate|||||||2006-07-26|2006-07-27|Estimate|July 2002||2002-07-31|July 2006|2006-07-31||||||||Interventional|||Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects|A Randomized, Open-Label Study of 800 Mg Lopinavir/200 Mg Ritonavir QD in Combination With Tenofovir and Emtricitabine Vs. 400 Mg Lopinavir /100 Mg Ritonavir BID in Combination With Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects|Completed||Phase 3|200||Abbott|||||||||||||||||||2018-06-01 05:31:33.745592|2018-06-01 05:31:33.745592
NCT00043953|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-15|||2007-09-26|2002-08-16|2002-08-19|Estimate|||||||2007-09-26|2007-09-27|Estimate|August 2002||2002-08-31|September 2007|2007-09-30||||||||Interventional|||Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects|A Phase II Study of Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects|Completed||Phase 2|30|Actual|Abbott|||||f||||f||||||||||2018-06-01 05:31:33.903311|2018-06-01 05:31:33.903311
NCT00043888|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2013-02-11|2002-08-16|2002-08-19|Estimate|||||||2013-02-11|2013-02-12|Estimate|January 2002||2002-01-31|February 2013|2013-02-28|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR|A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg Twice Daily or 700mg/100mg Twice Daily) When Used in Combination With a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR Twice Daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects.|Completed||Phase 3|60||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:31:33.995361|2018-06-01 05:31:33.995361
NCT00043979|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-15|2013-04-03||2017-04-11|2002-08-15|2002-08-16|Estimate|2013-09-12|2013-09-13|Estimate||||2017-04-11|2017-05-31|Actual|September 19, 2002|Actual|2002-09-19|April 2017|2017-04-30|December 14, 2011|Actual|2011-12-14|May 1, 2009|Actual|2009-05-01||Interventional|||Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas|Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas|Completed||Phase 2|60|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|f|f||||||No||2018-06-01 05:31:34.162534|2018-06-01 05:31:34.162534
NCT00043940|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2011-09-15|2002-08-15|2002-08-16|Estimate|||||||2011-09-15|2011-09-16|Estimate|April 1999||1999-04-30|September 2011|2011-09-30||||February 2003|Actual|2003-02-28||Interventional|||Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)|Anticoagulant Therapy With Bivalirudin in the Performance of PCI in Patients With Heparin-Induced Thrombocytopenia|Completed||Phase 3|50|Actual|The Medicines Company|||||f||||||||||||||2018-06-01 05:31:35.741622|2018-06-01 05:31:35.741622
NCT00043927|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2013-08-20|2002-08-15|2002-08-16|Estimate|||||||2013-08-20|2013-08-21|Estimate|April 2001||2001-04-30|August 2013|2013-08-31||||January 2004|Actual|2004-01-31||Interventional|||Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults|An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer.|Completed||Phase 3|760||GlaxoSmithKline|||||||||||||||||||2018-06-01 05:31:35.845145|2018-06-01 05:31:35.845145
NCT00043914|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2017-10-06|2002-08-15|2002-08-16|Estimate|||||||2017-10-06|2017-10-09|Actual|January 14, 2002|Actual|2002-01-14|October 2017|2017-10-31|January 29, 2003|Actual|2003-01-29|January 29, 2003|Actual|2003-01-29||Interventional|||Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy|A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients With Epilepsy|Completed||Phase 4|72||GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:31:37.028711|2018-06-01 05:31:37.028711
NCT00043901|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2017-03-31|2002-08-15|2002-08-16|Estimate|||||||2017-03-31|2017-04-04|Actual|December 1, 2000||2000-12-01|March 2017|2017-03-31|March 1, 2005|Actual|2005-03-01|November 1, 2003|Actual|2003-11-01||Interventional|||Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects Wtih Primary Generalized Tonic-Clonic Seizures|Completed||Phase 4|141|Actual|GlaxoSmithKline|||||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:31:39.532309|2018-06-01 05:31:39.532309
NCT00043875|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2016-09-13|2002-08-14|2002-08-15|Estimate|||||||2016-09-13|2016-09-15|Estimate|May 2000||2000-05-31|September 2016|2016-09-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Pediatric Epilepsy Trial in Subjects 1-24 Months|A Double-Blind, Placebo-Controlled, Add-On Clinical Trial of the Safety, Pharmacokinetics and Efficacy of Lamictal in Pediatric Age Subjects (1-24 Months)|Completed||Phase 2|177|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:31:40.251803|2018-06-01 05:31:40.251803
NCT00043862|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2017-05-30|2002-08-14|2002-08-15|Estimate|||||||2017-05-30|2017-05-31|Actual|August 2002||2002-08-31|March 2013|2013-03-31||||November 2005|Actual|2005-11-30||Interventional|(SCLC)||The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)|A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer With Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer|Completed||Phase 2|60|Actual|GlaxoSmithKline|||||||||f||||||||||2018-06-01 05:31:40.445598|2018-06-01 05:31:40.445598
NCT00043849|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2009-12-10|2002-08-14|2002-08-15|Estimate|||||||2009-12-10|2009-12-11|Estimate|July 2002||2002-07-31|August 2006|2006-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)|Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)|Completed||Phase 4|60||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:31:40.580437|2018-06-01 05:31:40.580437
NCT00043836|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2009-09-01|2002-08-14|2002-08-15|Estimate|||||||2009-09-01|2009-09-02|Estimate|July 2002||2002-07-31|August 2007|2007-08-31|October 2005|Actual|2005-10-31|February 2003|Actual|2003-02-28||Interventional|||The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure|A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study|Completed||Phase 2|20||Synvista Therapeutics, Inc|||||||||||||||||||2018-06-01 05:31:40.710052|2018-06-01 05:31:40.710052
NCT00043823|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2012-04-18|2002-08-14|2002-08-15|Estimate|||||||2012-04-18|2012-04-19|Estimate|August 2002||2002-08-31|April 2012|2012-04-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer|Safety and Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMAb VEGF and EGFR Tyrosine Kinase Inhibitor OSI-774 for Locally Advanced or Metastatic Non-Squamous Cell NSCLC in Patients Who Have Been Previously Treated|Completed||Phase 1/Phase 2|41|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:31:40.800251|2018-06-01 05:31:40.800251
NCT00043810|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-14|||2012-07-27|2002-08-14|2002-08-15|Estimate|||||||2012-07-27|2012-07-31|Estimate|July 2002||2002-07-31|July 2012|2012-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Study of Gelonin Purging of Autologous Stem Cells for Transplantation|Dose Finding Study of Gelonin Purging of Autologous Stem Cells for Transplantation of Patients With AML/MDS in First or Subsequent Remission|Terminated||Phase 1/Phase 2|3|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:31:40.999573|2018-06-01 05:31:40.999573
NCT00043797|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-13|||2005-06-23|2002-08-14|2002-08-15|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2002|2002-12-31||||||||Interventional|||Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy||Unknown status|Active, not recruiting|Phase 2|||The Institute for Diabetes Discovery, LLC|||||||||||||||||||2018-06-01 05:31:41.190778|2018-06-01 05:31:41.190778
NCT00043784|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-13|||2008-09-15|2002-08-14|2002-08-15|Estimate|||||||2008-09-15|2008-09-16|Estimate|August 2001||2001-08-31|September 2008|2008-09-30||||February 2005|Actual|2005-02-28||Interventional|||SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes|A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting With Acute Coronary Syndromes (ACS)|Completed||Phase 3|8000||Sanofi|||||f||||||||||||||2018-06-01 05:31:41.280095|2018-06-01 05:31:41.280095
NCT00043693|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-12|||2012-08-07|2002-08-14|2002-08-15|Estimate|||||||2012-08-07|2012-08-08|Estimate|April 2002||2002-04-30|August 2012|2012-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Family Intervention for Mental Illness and Substance Abuse|Family Intervention for SMI and Substance Use Disorder|Completed||N/A|108|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||||||||||||2018-06-01 05:31:41.414478|2018-06-01 05:31:41.414478
NCT00043771|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-13|||2005-06-23|2002-08-13|2002-08-14|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2002||2002-05-31|September 2002|2002-09-30|September 2002||2002-09-30|||||Interventional|||Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients|Multi-Center, Double-Blind Study to Compare the Effects of 30mg Qd Versus 15 Mg Bid of Tolvaptan in Congestive Heart Failure Patients|Completed||Phase 2|40||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:31:41.493356|2018-06-01 05:31:41.493356
NCT00043758|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-13|||2005-06-23|2002-08-13|2002-08-14|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2002||2002-07-31|June 2005|2005-06-30|July 2004||2004-07-31|||||Interventional|||Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients||Completed||Phase 2|170||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:31:41.564765|2018-06-01 05:31:41.564765
NCT00043745|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-13|||2013-02-06|2002-08-13|2002-08-14|Estimate|||||||2013-02-06|2013-02-07|Estimate|March 2003||2003-03-31|February 2013|2013-02-28||||April 2008|Actual|2008-04-30||Interventional|SIRBL||Bone Response to Soy Isoflavones in Women|Bone Response to Soy Isoflavones in Women|Completed||Phase 2|224|Actual|Iowa State University||3|||f||||t||||||||||2018-06-01 05:31:41.652273|2018-06-01 05:31:41.652273
NCT00043732|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-12|||2010-04-26|2002-08-13|2002-08-14|Estimate|||||||2010-04-26|2010-04-27|Estimate||||April 2010|2010-04-30|September 2003|Actual|2003-09-30|||||Interventional|||Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of SCIO-469 in Patients in Active Rheumatoid Arthritis Receiving Methotrexate|Completed||Phase 2|120|Actual|Scios, Inc.|||||||||||||||||||2018-06-01 05:31:41.832909|2018-06-01 05:31:41.832909
NCT00043719|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-12|||2009-01-29|2002-08-13|2002-08-14|Estimate|||||||2009-01-29|2009-02-02|Estimate|July 2002||2002-07-31|January 2009|2009-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Nitroglycerin Ointment for Preventing Bone Loss in Postmenopausal Women|Prevention of Postmenopausal Bone Loss With Nitric Oxide|Completed||Phase 3|200||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||||||||||||||||2018-06-01 05:31:41.890216|2018-06-01 05:31:41.890216
NCT00043706|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-12|||2015-03-04|2002-08-13|2002-08-14|Estimate|||||||2015-03-04|2015-03-05|Estimate||||March 2015|2015-03-31|September 2003|Actual|2003-09-30|||||Interventional|||Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis|A Phase 1/2 Double Blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic Sclerosis|Completed||Phase 1/Phase 2|||Sanofi|||||||||||||||||||2018-06-01 05:31:41.970145|2018-06-01 05:31:41.970145
NCT00043602|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2013-09-25|2002-08-12|2002-08-13|Estimate|||||||2013-09-25|2013-09-26|Estimate|September 2001||2001-09-30|September 2013|2013-09-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Clinician Managed Interpersonal Psychotherapy|Clinician Managed Interpersonal Psychotherapy|Completed||Early Phase 1|140|Actual|University of Iowa||2|||f||||f||||||||||2018-06-01 05:31:42.021782|2018-06-01 05:31:42.021782
NCT00043589|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2013-12-03|2002-08-12|2002-08-13|Estimate|||||||2013-12-03|2013-12-05|Estimate|June 2002||2002-06-30|December 2013|2013-12-31|December 2007|Actual|2007-12-31|December 2006|Actual|2006-12-31||Interventional|||Memory and Mental Health in Aging|Memory and Mental Health in Aging|Completed||N/A|200||Stanford University|||||f||||f||||||||||2018-06-01 05:31:42.088332|2018-06-01 05:31:42.088332
NCT00043576|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2009-03-10|2002-08-12|2002-08-13|Estimate|||||||2009-03-10|2009-03-12|Estimate|August 2002||2002-08-31|February 2005|2005-02-28|December 2005||2005-12-31|||||Interventional|||ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere|A Phase 2/3 Multicenter, Randomized, Double Blind Study of Docetaxel (Taxotere) Plus DN-101 or Placebo in Androgen Independent Prostate Cancer (AIPC)|Unknown status|Active, not recruiting|Phase 2/Phase 3|250||Novacea|||||||||||||||||||2018-06-01 05:31:42.159443|2018-06-01 05:31:42.159443
NCT00043680|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-10|||2008-03-03|2002-08-10|2002-08-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2002||2002-08-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Interventional|||Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy|Multi-Center Randomized Phase I/II Trial to Study the Effects of Cyclooxygenase-2 Inhibition on the Response to Photodynamic Therapy in Patients With Age-Related Macular Degeneration|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:42.365403|2018-06-01 05:31:42.365403
NCT00043667|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-10|||2008-03-03|2002-08-10|2002-08-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2002||2002-08-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis|Evaluation of Subcutaneous Daclizumab Treatments in Patients With Non-Infectious Sight-Threatening Uveitis: A Multicenter, Open-Label, Phase II Study|Completed||Phase 2|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:42.441066|2018-06-01 05:31:42.441066
NCT00043654|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2017-06-30|2002-08-09|2002-08-12|Estimate|||||||2017-06-30|2017-07-02|Actual|August 7, 2002||2002-08-07|June 25, 2007|2007-06-25|June 25, 2007||2007-06-25|||||Interventional|||Clinical Trial of Mifepristone for Bipolar Depression|Antiglucocorticoid Therapy in Bipolar Depression With Mifepristone (RU486)|Completed||Phase 2|110||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:42.50302|2018-06-01 05:31:42.50302
NCT00043641|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2017-10-05|2002-08-09|2002-08-12|Estimate|||||||2017-10-05|2017-10-06|Actual|July 26, 2002||2002-07-26|February 7, 2013|2013-02-07|February 7, 2013||2013-02-07|||||Observational|||HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)|HIV Expression in Patients With Viral Loads Suppressed on HAART|Completed|||73|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:42.573523|2018-06-01 05:31:42.573523
NCT00043628|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2008-03-03|2002-08-09|2002-08-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2002||2002-08-31|February 2005|2005-02-28|February 2005||2005-02-28|||||Interventional|||Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease|Stem Cell Mobilization as Therapy for Chronic Myocardial Ischemia in Patients With Coronary Artery Disease|Completed||Phase 2|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:42.628647|2018-06-01 05:31:42.628647
NCT00043615|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2017-06-30|2002-08-09|2002-08-12|Estimate|||||||2017-06-30|2017-07-02|Actual|July 29, 2002||2002-07-29|April 10, 2012|2012-04-10|April 10, 2012||2012-04-10|||||Observational|||Collection of Blood, Bone Marrow, Tumor or Tissue Samples|Acquisition of Blood, Bone Marrow, Tumor, or Tissue Samples|Completed|||74|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:42.678046|2018-06-01 05:31:42.678046
NCT00043563|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2015-12-15|2002-08-09|2002-08-12|Estimate|||||||2015-12-15|2015-12-16|Estimate|January 2001||2001-01-31|December 2015|2015-12-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Cognitive Behavioral Treatment of Pediatric Trichotillomania|Cognitive Behavioral Treatment of Pediatric Trichotillomania|Completed||N/A|24|Actual|University of Pennsylvania|||||f||||t||||||||||2018-06-01 05:31:42.757793|2018-06-01 05:31:42.757793
NCT00043550|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|2015-08-26||2017-04-28|2002-08-09|2002-08-12|Estimate|2017-04-28|2017-06-02|Actual||||2017-04-28|2017-06-02|Actual|November 2001||2001-11-30|April 2017|2017-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Treatments for Depression: Drug Versus Psychotherapy|Efficacy of Dynamic Therapy Versus Selective Serotonin Reuptake Inhibitor for Depression|Completed||Phase 3|156|Actual|University of Pennsylvania|Two limitations are the relatively high level of attrition and small sample size for specific combinations within our moderation analysis.|3|||f||||t||||||||||2018-06-01 05:31:42.828441|2018-06-01 05:31:42.828441
NCT00043511|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2012-05-03|2002-08-09|2002-08-12|Estimate|||||||2012-05-03|2012-05-04|Estimate||||May 2012|2012-05-31|April 2003|Actual|2003-04-30|||||Interventional|||Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults|A Phase I Trial to Evaluate the Safety and Immunogenicity of the HIV-1 pGA2/JS2 Plasmid DNA Vaccine Given Intramuscularly (IM) in HIV-1 Uninfected Adults|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:31:43.255167|2018-06-01 05:31:43.255167
NCT00043498|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-09|||2014-10-14|2002-08-09|2002-08-12|Estimate|||||||2014-10-14|2014-10-15|Estimate|August 1997||1997-08-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Health Effects of Early-Life Exposure to Urban Pollutants in Minority Children|Health Effects of Early-Life Exposure to Urban Pollutants in Minority Children|Completed|||727|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||t||||||Samples With DNA|"~     We collected maternal urine during the third trimester of pregnancy, maternal blood at~     delivery, umbilical cord blood, meconium, blood and urine from the child at ages 24, 36, and~     60 months.~   "|||2018-06-01 05:31:43.326228|2018-06-01 05:31:43.326228
NCT00043459|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2005-06-23|2002-08-09|2002-08-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2002||2002-07-31|March 2003|2003-03-31|March 2003||2003-03-31|||||Interventional|||Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.||Terminated||Phase 2|35||Tularik|||||||||||||||||||2018-06-01 05:31:43.382984|2018-06-01 05:31:43.382984
NCT00043446|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2005-06-23|2002-08-09|2002-08-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2002||2002-07-31|April 2004|2004-04-30||||||||Interventional|||Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.||Unknown status|Active, not recruiting|Phase 2|35||Tularik|||||||||||||||||||2018-06-01 05:31:43.456365|2018-06-01 05:31:43.456365
NCT00043433|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2005-06-23|2002-08-09|2002-08-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2002||2002-07-31|April 2004|2004-04-30||||||||Interventional|||Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.||Unknown status|Active, not recruiting|Phase 2|35||Tularik|||||||||||||||||||2018-06-01 05:31:43.515581|2018-06-01 05:31:43.515581
NCT00043420|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2009-02-11|2002-08-09|2002-08-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|January 2003||2003-01-31|February 2009|2009-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||CPG 7909 in Patients With Cutaneous T-Cell Lymphoma|A Phase I/II Open Label, Multi-Center Study For The Evaluation Of Pf-3512676 (CPG 7909) In Patients With Stage Ib To Iva Cutaneous T-Cell Lymphoma|Completed||Phase 1/Phase 2|42|Actual|Pfizer||8|||f||||f||||||||||2018-06-01 05:31:43.577517|2018-06-01 05:31:43.577517
NCT00043407|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2009-02-11|2002-08-09|2002-08-12|Estimate|||||||2009-02-11|2009-02-12|Estimate|March 2002||2002-03-31|February 2009|2009-02-28|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||CPG 7909 in Patients Wih Stage IV Renal Cell Cancer|A Phase I/II, Open Label, Multi-Center Study For The Evaluation Of CPG 7909 In Patients With Stage Iv Renal Cell Carcinoma|Completed||Phase 1/Phase 2|42|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 05:31:43.650825|2018-06-01 05:31:43.650825
NCT00043394|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2009-03-11|2002-08-09|2002-08-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|September 2002||2002-09-30|March 2009|2009-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer|A Phase I/II Open Label, Multi-Center, Dose-Escalation Study Of Subcutaneous CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer|Completed||Phase 2|16|Actual|Pfizer||4|||f||||f||||||||||2018-06-01 05:31:43.760695|2018-06-01 05:31:43.760695
NCT00043381|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2013-01-22|2002-08-09|2002-08-12|Estimate|||||||2013-01-22|2013-01-24|Estimate|April 2001||2001-04-30|June 2011|2011-06-30|April 2003|Actual|2003-04-30|November 2002|Actual|2002-11-30||Interventional|||Decitabine Versus Supportive Care in Adults With Advanced-stage MDS|A Randomized, Open-label, Phase III Trial of Decitabine (5-aza-2'Deoxycytidine) Versus Supportive Care in Adults With Advanced-stage Myelodysplastic Syndrome|Completed||Phase 3|160||Astex Pharmaceuticals|||||f||||||||||||||2018-06-01 05:31:43.843757|2018-06-01 05:31:43.843757
NCT00043368|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-08|||2009-03-11|2002-08-09|2002-08-12|Estimate|||||||2009-03-11|2009-03-12|Estimate|September 2002||2002-09-30|March 2009|2009-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)|A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy|Completed||Phase 2|31|Actual|Pfizer||1|||f||||f||||||||||2018-06-01 05:31:43.921054|2018-06-01 05:31:43.921054
NCT00043355|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2007-10-30|2002-08-09|2002-08-12|Estimate|||||||2007-10-30|2007-11-01|Estimate|December 2000||2000-12-31|October 2007|2007-10-31|February 2003|Actual|2003-02-28|||||Interventional|||Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterials in Previously Treated or Mod-to-Sev Pulmonary Mycobacterium Avium Complex Infection|Terminated||Phase 2|100|Actual|InterMune||||Futility|f||||||||||||||2018-06-01 05:31:44.120423|2018-06-01 05:31:44.120423
NCT00043342|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2007-10-29|2002-08-09|2002-08-12|Estimate|||||||2007-10-29|2007-11-01|Estimate|April 2002||2002-04-30|October 2007|2007-10-31|March 2003|Actual|2003-03-31|||||Interventional|||Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis|A Phase I/II Study of Interferon Gamma-1b by Subcutaneous Injection for the Treatment of Patients With Cystic Fibrosis|Completed||Phase 1/Phase 2|51|Actual|InterMune|||||f||||||||||||||2018-06-01 05:31:44.173339|2018-06-01 05:31:44.173339
NCT00043472|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2018-02-13|2002-08-08|2002-08-09|Estimate|||||||2018-02-13|2018-02-14|Actual|August 6, 2002||2002-08-06|November 8, 2017|2017-11-08||||||||Observational|||Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk|Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer|Completed|||40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:44.222991|2018-06-01 05:31:44.222991
NCT00043316|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2007-10-29|2002-08-08|2002-08-09|Estimate|||||||2007-10-29|2007-11-01|Estimate|February 2001||2001-02-28|October 2007|2007-10-31|October 2002|Actual|2002-10-31|||||Interventional|||Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis|A Phase I/II Study of Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis|Completed||Phase 1/Phase 2|66|Actual|InterMune|||||f||||||||||||||2018-06-01 05:31:44.283013|2018-06-01 05:31:44.283013
NCT00043303|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2007-10-29|2002-08-08|2002-08-09|Estimate|||||||2007-10-29|2007-11-01|Estimate|September 2001||2001-09-30|October 2007|2007-10-31|November 2003|Actual|2003-11-30|||||Interventional|||Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis|A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.|Completed||Phase 2|502|Actual|InterMune|||||f||||||||||||||2018-06-01 05:31:44.358184|2018-06-01 05:31:44.358184
NCT00043277|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2006-01-31|2002-08-07|2002-08-08|Estimate|||||||2006-01-31|2006-02-01|Estimate|August 2002||2002-08-31|January 2006|2006-01-31|December 2004||2004-12-31|||||Interventional|||Study Of Angiomax In Infants Under Six Months With Thrombosis|Pilot Dose Finding And Efficacy Study Of Angiomax® (Bivalirudin) As Primary Anticoagulation In Infants Under Six Months With Thrombosis|Completed||Phase 2|25||The Medicines Company|||||||||||||||||||2018-06-01 05:31:44.406553|2018-06-01 05:31:44.406553
NCT00043264|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2005-06-23|2002-08-07|2002-08-08|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis|Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis|Completed||Phase 2|40||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:31:44.523767|2018-06-01 05:31:44.523767
NCT00043238|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-07|||2015-04-13|2002-08-07|2002-08-08|Estimate|||||||2015-04-13|2015-04-14|Estimate||||April 2015|2015-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Observational|||Mohawk Culture, Behavior, Toxicant Exposure and Health|Mohawk Culture, Behavior, Toxicant Exposure and Health|Completed|||220|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:44.583327|2018-06-01 05:31:44.583327
NCT00043212|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-06|||2013-04-30|2002-08-07|2002-08-08|Estimate|||||||2013-04-30|2013-05-01|Estimate||||April 2013|2013-04-30||||||||Interventional|||Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.|A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating DCVax(tm)-Prostate, Autologous Dendritic Cells Loaded With Recombinant PSMA for the Treatment of Metastatic Hormone Refractory Prostate Cancer|Withdrawn||Phase 3|0|Actual|Northwest Biotherapeutics||||Redirection of company goals|f||||||||||||||2018-06-01 05:31:44.664041|2018-06-01 05:31:44.664041
NCT00043199|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-06|||2005-06-23|2002-08-07|2002-08-08|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2004|2004-04-30||||||||Interventional|||A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies|A Phase II Study of Aroplatin in Subjects With Recurrent, Unresectable and Metastatic Colorectal Cancer Refractory to 5-Fluorouracil (5-FU)/Leucovorin or Capecitabine, and Irinotecan|Unknown status|Active, not recruiting|Phase 2|40||Aronex Pharmaceuticals|||||||||||||||||||2018-06-01 05:31:44.759906|2018-06-01 05:31:44.759906
NCT00043225|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2018-03-27|2002-08-06|2002-08-07|Estimate|||||||2018-03-27|2018-03-29|Actual|June 20, 2001||2001-06-20|November 22, 2017|2017-11-22||||||||Observational|||The Role of Bacteria and Genetic Variations in Cystic Fibrosis|Clinical Course in Cystic Fibrosis: The Effects of Pseudomonas Aeruginosa and Potential Modifier Genes|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:44.822048|2018-06-01 05:31:44.822048
NCT00043186|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-06|2009-12-22|2009-11-23|2013-09-06|2002-08-06|2002-08-07|Estimate|2010-06-25|2010-07-28|Estimate|2009-11-23|2009-11-25|Estimate|2013-09-06|2013-09-18|Estimate|May 2002||2002-05-31|September 2013|2013-09-30|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density|A Randomized, Double-Blind, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 162 in the Treatment of Postmenopausal Women With Low Bone Mineral Density|Completed||Phase 2|412|Actual|Amgen||9|||f||||||||||||||2018-06-01 05:31:45.08048|2018-06-01 05:31:45.08048
NCT00042718|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2010-04-26|2002-08-06|2002-08-07|Estimate|||||||2010-04-26|2010-04-28|Estimate|November 2001||2001-11-30|April 2010|2010-04-30|August 2003|Actual|2003-08-31|||||Interventional|||A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.||Completed||Phase 3|659|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:31:50.335971|2018-06-01 05:31:50.335971
NCT00042705|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2015-04-13|2002-08-05|2002-08-06|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2000||2000-05-31|April 2015|2015-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Asthma Severity in Children and Environmental Agents||Completed|||||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:50.394795|2018-06-01 05:31:50.394795
NCT00042692|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-05|||2006-03-22|2002-08-05|2002-08-06|Estimate|||||||2006-03-22|2006-03-23|Estimate|March 2001||2001-03-31|March 2006|2006-03-31|March 2002||2002-03-31|||||Observational|||Catechol Thioethers in Parkinson's Disease||Completed|||20||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:50.526966|2018-06-01 05:31:50.526966
NCT00042679|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-02|||2006-07-18|2002-08-05|2002-08-06|Estimate|||||||2006-07-18|2006-07-19|Estimate|June 2002||2002-06-30|July 2006|2006-07-31||||||||Interventional|||A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.|A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.|Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:50.573539|2018-06-01 05:31:50.573539
NCT00042666|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-02||2009-10-16|2009-10-16|2002-08-05|2002-08-06|Estimate||||2009-10-16|2009-10-19|Estimate|2009-10-16|2009-10-19|Estimate|June 2002||2002-06-30|October 2009|2009-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.|A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Completed||Phase 2|55|Actual|Eli Lilly and Company|||||f||||f||||||||||2018-06-01 05:31:50.644385|2018-06-01 05:31:50.644385
NCT00042653|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-02|||2013-05-06|2002-08-05|2002-08-06|Estimate|||||||2013-05-06|2013-05-08|Estimate|May 2002||2002-05-31|May 2013|2013-05-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis|A Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of Chronic Kidney Disease (Hemodialysis and Peritoneal Dialysis)|Completed||Phase 3|380|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 05:31:50.711033|2018-06-01 05:31:50.711033
NCT00042601|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-01|||2015-10-20|2002-08-02|2002-08-05|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2002||2002-07-31|October 2015|2015-10-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Evaluation of the Effect of Pramlintide on Satiety and Food Intake|A Single Center, Randomized, Double-blind, Placebo-controlled, Two-period, Crossover Study Evaluating the Acute Effect of Pramlintide on Satiety and Food Intake in Normal-weight and Obese Non-diabetic Subjects and in Insulin Treated Subjects With Type 1 and Type 2 Diabetes Mellitus|Completed||Phase 2|51|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 05:31:50.78773|2018-06-01 05:31:50.78773
NCT00042588|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-01|||2005-06-23|2002-08-02|2002-08-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2002||2002-05-31|January 2004|2004-01-31||||||||Interventional|||A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis|Completed||Phase 2|||ICOS Corporation|||||||||||||||||||2018-06-01 05:31:50.848499|2018-06-01 05:31:50.848499
NCT00042575|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-31|||2006-07-18|2002-08-02|2002-08-05|Estimate|||||||2006-07-18|2006-07-19|Estimate|June 2002||2002-06-30|July 2006|2006-07-31|August 2002||2002-08-31|||||Interventional|||Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression|Protocol F1J-US-HMBY Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression|Completed||Phase 3|120||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:50.896112|2018-06-01 05:31:50.896112
NCT00042562|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-31|||2006-07-18|2002-08-02|2002-08-05|Estimate|||||||2006-07-18|2006-07-19|Estimate|December 2002||2002-12-31|July 2006|2006-07-31|December 2003||2003-12-31|||||Interventional|||Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression|Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression|Completed||Phase 3|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:31:50.956415|2018-06-01 05:31:50.956415
NCT00042549|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-31|||2005-06-23|2002-08-02|2002-08-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2002||2002-05-31|June 2003|2003-06-30||||||||Interventional|||Lithotripsy for the Treatment of Gallstones|Biliary Lithotripsy in Combination With Actigall Versus Actigall Monotherapy for the Treatment of Symptomatic Cholesterol Gallstones|Terminated||Phase 4|184||Medstone International|||||||||||||||||||2018-06-01 05:31:51.047036|2018-06-01 05:31:51.047036
NCT00042627|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-01|||2017-06-30|2002-08-01|2002-08-02|Estimate|||||||2017-06-30|2017-07-02|Actual|July 30, 2002||2002-07-30|June 25, 2007|2007-06-25|June 25, 2007||2007-06-25|||||Observational|||Prevalence and Risk of Cataracts in Granulocyte Donors|Prevalence and Risks for Posterior Subcapsular Cataracts in Volunteer Granulocytapheresis Donors|Completed|||252||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:51.328012|2018-06-01 05:31:51.328012
NCT00042614|ClinicalTrials.gov processed this data on May 31, 2018|2002-08-01|||2018-04-03|2002-08-01|2002-08-02|Estimate|||||||2018-04-03|2018-04-04|Actual|September 1, 2002||2002-09-01|March 29, 2018|2018-03-29||||||||Observational|||Study of Heart Transplant Rejection|Acute Cardiac Allograft Cellular Rejection and Cardiac Allograft Vasculopathy: Identification of Diagnostic Biomarkers and Target Pathways for Preventive Therapy|Recruiting|||482|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:51.389303|2018-06-01 05:31:51.389303
NCT00042536|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-31|||2008-03-03|2002-07-31|2002-08-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2002||2002-07-31|April 2004|2004-04-30|April 2004||2004-04-30|||||Observational|||Effects of Yohimbine and Naltrexone on Sexual Function|Effects of Alpha-2 Adrenergic and Opiate Receptor Blockade on Sexual Function in Healthy Male Volunteers|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:51.50883|2018-06-01 05:31:51.50883
NCT00042523|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-31|||2008-03-03|2002-07-31|2002-08-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2002||2002-07-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus|Role of the Antibody Against NR2 Glutamate Receptor in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus|Completed|||61||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:51.64672|2018-06-01 05:31:51.64672
NCT00042510|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-31|||2014-08-27|2002-07-31|2002-08-01|Estimate|||||||2014-08-27|2014-08-28|Estimate|August 2000||2000-08-31|August 2014|2014-08-31|July 2004|Actual|2004-07-31|February 2003|Actual|2003-02-28||Interventional|||Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer|Open-Label,Multicenter Study of G17DT Immunogen in Combination w/ Cisplatin and 5-FU in Subjects w/ Metastatic or Locally Recurrent Gastric or Gastroesophageal Cancer Previously Untreated With Chemotherapy.|Completed||Phase 2|103|Actual|Cancer Advances Inc.||1|||f||||f||||||||||2018-06-01 05:31:51.806286|2018-06-01 05:31:51.806286
NCT00042497|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-30|||2005-06-23|2002-07-31|2002-08-01|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2002||2002-07-31|September 2002|2002-09-30||||||||Interventional|||Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma|A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma|Suspended||Phase 2|60||Anosys|||||||||||||||||||2018-06-01 05:31:52.105782|2018-06-01 05:31:52.105782
NCT00042484|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-30|||2015-04-13|2002-07-31|2002-08-01|Estimate|||||||2015-04-13|2015-04-14|Estimate||||April 2015|2015-04-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Community Organizing Network for Environmental Health||Completed||N/A|||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:52.197519|2018-06-01 05:31:52.197519
NCT00042471|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-30|||2015-09-22|2002-07-31|2002-08-01|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2002||2002-06-30|August 2015|2015-08-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Evaluation of the Bioavailability of Pramlintide||Completed||Phase 2|75|Actual|AstraZeneca||1|||f||||||||||||||2018-06-01 05:31:52.275232|2018-06-01 05:31:52.275232
NCT00042458|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-30|||2015-09-22|2002-07-31|2002-08-01|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2002||2002-04-30|August 2015|2015-08-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control|A Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety of Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by Insulin Dose Optimization in Subjects With Type 1 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Intensive Insulin Therapy|Completed||Phase 3|296|Actual|AstraZeneca||2|||f||||f||||||||||2018-06-01 05:31:52.529998|2018-06-01 05:31:52.529998
NCT00042445|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-30|||2006-09-01|2002-07-31|2002-08-01|Estimate|||||||2006-09-01|2006-09-04|Estimate|August 2000||2000-08-31|September 2006|2006-09-30|July 2005||2005-07-31|||||Observational|||Brain Neoplasms, Leukemia and Petrochemical Exposures||Completed|||1456||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:52.696164|2018-06-01 05:31:52.696164
NCT00042432|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-29|2010-11-04||2013-05-09|2002-07-31|2002-08-01|Estimate|2011-02-04|2011-03-01|Estimate||||2013-05-09|2013-05-13|Estimate|June 2002||2002-06-30|May 2013|2013-05-31|August 2003|Actual|2003-08-31|March 2003|Actual|2003-03-31||Interventional|||Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients|A Study of an Investigational Medication for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients|Completed||Phase 2|54|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:31:52.787296|2018-06-01 05:31:52.787296
NCT00042419|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-29|||2006-09-01|2002-07-31|2002-08-01|Estimate|||||||2006-09-01|2006-09-04|Estimate|March 2002||2002-03-31|September 2006|2006-09-30|July 2003||2003-07-31|||||Observational|||Work and Health Disparities Among Rural Women||Completed|||150||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:53.19014|2018-06-01 05:31:53.19014
NCT00042406|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-29|||2012-12-05|2002-07-31|2002-08-01|Estimate|||||||2012-12-05|2012-12-07|Estimate|September 2002||2002-09-30|December 2012|2012-12-31||||September 2002|Actual|2002-09-30||Interventional|||Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-alpha Blocker|A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active RA Failing Treatment With Methotrexate and TNF-alpha Blocking Agents|Terminated||Phase 2/Phase 3|75|Actual|Emergent Product Development Seattle LLC||3|||f||||||||||||||2018-06-01 05:31:53.268535|2018-06-01 05:31:53.268535
NCT00042393|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-27|||2014-01-03|2002-07-31|2002-08-01|Estimate|||||||2014-01-03|2014-01-07|Estimate||||January 2014|2014-01-31||||||||Expanded Access|||An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options|A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options|Approved for marketing|||||Gilead Sciences|||||||||||||||||||2018-06-01 05:31:53.414314|2018-06-01 05:31:53.414314
NCT00042367|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2012-02-10|2002-07-31|2002-08-01|Estimate|||||||2012-02-10|2012-02-14|Estimate|April 2000||2000-04-30|February 2012|2012-02-29|June 2006|Actual|2006-06-30|December 2005|Actual|2005-12-31||Interventional|BB'98||Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors|Pilot Study of Systemic and Intrathecal Chemotherapy Followed by Conformal Radiation for Infants With Brain Tumors|Completed||N/A|119|Actual|Baylor College of Medicine|||||f||||t||||||||||2018-06-01 05:31:53.469063|2018-06-01 05:31:53.469063
NCT00042354|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2015-03-04|2002-07-31|2002-08-01|Estimate|||||||2015-03-04|2015-03-05|Estimate|May 2002||2002-05-31|March 2015|2015-03-31|August 2004|Actual|2004-08-31|||||Interventional|||Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients|A Phase II, Open Label Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myelogenous Leukemia|Completed||Phase 2|40||Sanofi|||||||||||||||||||2018-06-01 05:31:53.579292|2018-06-01 05:31:53.579292
NCT00042341|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2014-03-17|2002-07-31|2002-08-01|Estimate|||||||2014-03-17|2014-03-19|Estimate|May 2002||2002-05-31|March 2014|2014-03-31|January 2006|Actual|2006-01-31|||||Interventional|||Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)|A Phase II, Open Label Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia|Completed||Phase 2|60||Sanofi|||||||||||||||||||2018-06-01 05:31:53.868764|2018-06-01 05:31:53.868764
NCT00042328|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2015-08-20|2002-07-31|2002-08-01|Estimate|||||||2015-08-20|2015-08-24|Estimate|August 2001||2001-08-31|August 2015|2015-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients|A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients|Completed||Phase 2|30||Baylor College of Medicine|||||f||||t||||||||||2018-06-01 05:31:53.949357|2018-06-01 05:31:53.949357
NCT00042315|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2012-05-22|2002-07-31|2002-08-01|Estimate|||||||2012-05-22|2012-05-23|Estimate|June 2002||2002-06-30|May 2012|2012-05-31|June 2003||2003-06-30|June 2003||2003-06-30||Interventional|||A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)||Terminated||Phase 3|490||QLT Inc.|||||f||||||||||||||2018-06-01 05:31:54.053508|2018-06-01 05:31:54.053508
NCT00042302|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2012-05-22|2002-07-31|2002-08-01|Estimate|||||||2012-05-22|2012-05-23|Estimate|June 2002||2002-06-30|May 2012|2012-05-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)||Terminated||Phase 3|540||QLT Inc.|||||f||||||||||||||2018-06-01 05:31:54.204616|2018-06-01 05:31:54.204616
NCT00042289|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2018-05-01|2002-07-31|2002-08-01|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2003|Actual|2003-03-31|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy|Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum|Recruiting||Phase 4|1786|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||||||||||||2018-06-01 05:31:54.383625|2018-06-01 05:31:54.383625
NCT00041483|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-09|||2014-06-30|2002-07-31|2002-08-01|Estimate|||||||2014-06-30|2014-07-01|Estimate|June 2002||2002-06-30|July 2008|2008-07-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD|Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD|Completed||Phase 3|530|Actual|Alcon Research||2|||f||||||||||||||2018-06-01 05:31:54.821927|2018-06-01 05:31:54.821927
NCT00042380|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2008-03-03|2002-07-26|2002-07-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2002||2002-07-31|April 2005|2005-04-30|April 2005||2005-04-30|||||Interventional|||Examination of a Soy-Based Supplement for Major Depression|A Phase 2A Study of Soy Isoflavones in the Treatment of Major Depression|Completed||Phase 2|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:54.924708|2018-06-01 05:31:54.924708
NCT00042276|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-26|||2017-10-05|2002-07-25|2002-07-26|Estimate|||||||2017-10-05|2017-10-06|Actual|July 14, 2002||2002-07-14|March 15, 2013|2013-03-15|March 15, 2013||2013-03-15|||||Observational|||The Natural History of Upper Trapezius Myofascial Trigger Points: Comparison of Local and Remote Tissue Milieu in Normal Muscle, Latent and Active Myofascial Trigger Points Over Time|The Natural History of Upper Trapezius Myofascial Trigger Points: Comparison of Local and Remote Tissue Milieu in Normal Muscle, Latent and Active Myofascial Trigger Points Over Time|Completed|||88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:54.990503|2018-06-01 05:31:54.990503
NCT00042263|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-25|||2006-09-01|2002-07-25|2002-07-26|Estimate|||||||2006-09-01|2006-09-04|Estimate|April 2002||2002-04-30|September 2006|2006-09-30||||||||Observational|||Healthy Environments Partnership|Social and Physical Environments and Health Disparities|Completed|||1000||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:55.052488|2018-06-01 05:31:55.052488
NCT00042250|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2012-01-20|2002-07-25|2002-07-26|Estimate|||||||2012-01-20|2012-01-24|Estimate|May 1992||1992-05-31|January 2012|2012-01-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||IUdR/BUdR Cell Cycle Labelling|Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling|Completed||N/A|28|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:31:55.150558|2018-06-01 05:31:55.150558
NCT00042237|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2013-08-20|2002-07-25|2002-07-26|Estimate|||||||2013-08-20|2013-08-22|Estimate|September 2001||2001-09-30|August 2013|2013-08-31||||||||Interventional|||Treatment of Depressed Women Who Have Been Sexually Abused|Treatment of Women With Depression and Sexual Abuse|Completed||Phase 1|24||Butler Hospital|||||f||||||||||||||2018-06-01 05:31:55.2429|2018-06-01 05:31:55.2429
NCT00042224|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|2015-04-09||2017-04-10|2002-07-25|2002-07-26|Estimate|2015-09-15|2015-10-15|Estimate||||2017-04-10|2017-05-15|Actual|December 2000||2000-12-31|April 2017|2017-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Electroconvulsive Therapy in Clozapine Refractory Schizophrenia|ECT in Clozapine Refractory Schizophrenia|Completed||Phase 1/Phase 2|39|Actual|Northwell Health||2|||f||||t||||||||||2018-06-01 05:31:55.319501|2018-06-01 05:31:55.319501
NCT00042211|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2014-01-07|2002-07-25|2002-07-26|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2001||2001-02-28|February 2008|2008-02-29|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Preventing Depression in Patients With Macular Degeneration|Preventing Depression in Macular Degeneration|Completed||Phase 3|206|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 05:31:55.517979|2018-06-01 05:31:55.517979
NCT00042198|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2013-07-01|2002-07-25|2002-07-26|Estimate|||||||2013-07-01|2013-07-02|Estimate|December 2001||2001-12-31|July 2013|2013-07-31|August 2006|Actual|2006-08-31|December 2005|Actual|2005-12-31||Interventional|||Treatment of Depression After Coronary Bypass Surgery|Treatment of Depression After Coronary Bypass Surgery|Completed||N/A|123|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-06-01 05:31:55.591209|2018-06-01 05:31:55.591209
NCT00042185|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2013-09-26|2002-07-25|2002-07-26|Estimate|||||||2013-09-26|2013-09-27|Estimate|February 2001||2001-02-28|September 2013|2013-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Eating Disorder Prevention Programs|Austin Body Acceptance Study|Completed||N/A|450||University of Texas at Austin||4|||f||||||||||||||2018-06-01 05:31:55.66256|2018-06-01 05:31:55.66256
NCT00042172|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2014-02-27|2002-07-25|2002-07-26|Estimate|||||||2014-02-27|2014-03-03|Estimate|June 2002||2002-06-30|February 2014|2014-02-28|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Treatment for Early Memory Loss|Cognitive Enhancers Explored With PET Imaging|Completed||Phase 4|40||University of Iowa|||||f||||||||||||||2018-06-01 05:31:55.747172|2018-06-01 05:31:55.747172
NCT00042159|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2013-08-02|2002-07-25|2002-07-26|Estimate|||||||2013-08-02|2013-08-06|Estimate|July 2002||2002-07-31|August 2013|2013-08-31|June 2004|Actual|2004-06-30|July 2003|Actual|2003-07-31||Interventional|||Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations|TMS Intervention Development for Auditory Hallucinations|Completed||N/A|50|Actual|Yale University|||||f||||t||||||||||2018-06-01 05:31:55.802627|2018-06-01 05:31:55.802627
NCT00042146|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2013-05-17|2002-07-25|2002-07-26|Estimate|||||||2013-05-17|2013-05-21|Estimate|December 2001||2001-12-31|May 2013|2013-05-31||||||||Interventional|||Behavioral and Pharmacological Treatment for Insomnia|Behavioral and Pharmacological Treatment for Insomnia|Completed||Phase 4|160||Laval University|||||f||||||||||||||2018-06-01 05:31:55.85758|2018-06-01 05:31:55.85758
NCT00042133|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2015-04-13|2002-07-25|2002-07-26|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2001||2001-04-30|April 2015|2015-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Socio-economic Status and Age-related Disability in a Biracial Community||Completed|||6000|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:55.917574|2018-06-01 05:31:55.917574
NCT00042120|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2014-09-26|2002-07-25|2002-07-26|Estimate|||||||2014-09-26|2014-09-29|Estimate|April 2001||2001-04-30|August 2009|2009-08-31||||July 2011|Actual|2011-07-31||Observational|FAME||Farming and Movement Evaluation Study (FAME)|Pesticides and Risk in the Agricultural Health Study|Completed|||520|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:55.963113|2018-06-01 05:31:55.963113
NCT00042107|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-24|||2014-09-26|2002-07-25|2002-07-26|Estimate|||||||2014-09-26|2014-09-29|Estimate|September 2000||2000-09-30|July 2002|2002-07-31|June 2005||2005-06-30|||||Observational|||Molecular Epidemiology of Parkinson's Disease||Completed|||2022|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:56.022945|2018-06-01 05:31:56.022945
NCT00042094|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-23|||2011-06-29|2002-07-25|2002-07-26|Estimate|||||||2011-06-29|2011-06-30|Estimate|March 2002||2002-03-31|June 2011|2011-06-30|March 2003||2003-03-31|||||Interventional|||Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®|A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®)|Completed||Phase 1|350||DynPort Vaccine Company LLC, A CSC Company|||||||||||||||||||2018-06-01 05:31:56.070572|2018-06-01 05:31:56.070572
NCT00042081|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-22|||2006-05-04|2002-07-23|2002-07-24|Estimate|||||||2006-05-04|2006-05-05|Estimate|July 2002||2002-07-31|July 2005|2005-07-31|February 2005||2005-02-28|||||Interventional|||Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures|A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures|Completed||Phase 3|3000||Anesiva, Inc.|||||||||||||||||||2018-06-01 05:31:56.299073|2018-06-01 05:31:56.299073
NCT00042068|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-22|||2013-10-31|2002-07-23|2002-07-24|Estimate|||||||2013-10-31|2013-11-01|Estimate|June 2002||2002-06-30|October 2013|2013-10-31|July 2003||2003-07-31|||||Interventional|||A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis|A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis|Completed||Phase 3|1000||Boehringer Ingelheim|||||f||||||||||||||2018-06-01 05:31:56.685855|2018-06-01 05:31:56.685855
NCT00042055|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-22|||2011-10-14|2002-07-23|2002-07-24|Estimate|||||||2011-10-14|2011-10-17|Estimate|July 2002||2002-07-31|October 2011|2011-10-31|September 2003|Actual|2003-09-30|||||Interventional|||CP-461 for the Treatment of Crohn's Disease|A Phase II Pilot Study of CP-461 in the Treatment of Moderately to Severely Active Crohn's Disease|Completed||Phase 2|30||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:31:56.970714|2018-06-01 05:31:56.970714
NCT00042042|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-22|||2005-06-23|2002-07-22|2002-07-23|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2002|2002-07-31||||||||Interventional|||Screening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic|Screening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic|Unknown status|Recruiting|N/A|400||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:31:57.033757|2018-06-01 05:31:57.033757
NCT00042029|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-22|||2017-05-02|2002-07-22|2002-07-23|Estimate|||||||2017-05-02|2017-05-05|Actual|June 18, 2002|Actual|2002-06-18|May 2017|2017-05-31|October 3, 2003|Actual|2003-10-03|October 3, 2003|Actual|2003-10-03||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)|A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder|Completed||Phase 3|324|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:31:57.087738|2018-06-01 05:31:57.087738
NCT00042016|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-19|||2009-10-12|2002-07-22|2002-07-23|Estimate|||||||2009-10-12|2009-10-14|Estimate|July 2002||2002-07-31|June 2005|2005-06-30||||||||Interventional|||Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)|A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Chronic Phase Refractory to Imatinib Mesylate (STI 571)|Completed||Phase 2|40||Astex Pharmaceuticals|||||||||||||||||||2018-06-01 05:31:57.150825|2018-06-01 05:31:57.150825
NCT00042003|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-19|||2013-01-22|2002-07-22|2002-07-23|Estimate|||||||2013-01-22|2013-01-23|Estimate|July 2002||2002-07-31|June 2008|2008-06-30||||December 2004|Actual|2004-12-31||Interventional|||Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)|A Phase II, Multicenter Study of Decitabine (5-aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Blast Phase Refractory to Imatinib Mesylate (STI 571)|Completed||Phase 2|40||Astex Pharmaceuticals|||||f||||f||||||||||2018-06-01 05:31:57.20773|2018-06-01 05:31:57.20773
NCT00040261|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-22|||2008-03-03|2002-06-22|2002-06-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Clinical Trial of Memantine for Major Depression|An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression|Completed||Phase 3|112||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:11.339074|2018-06-01 05:32:11.339074
NCT00041990|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-19|||2007-12-12|2002-07-22|2002-07-23|Estimate|||||||2007-12-12|2007-12-17|Estimate|July 2002||2002-07-31|December 2007|2007-12-31||||||||Interventional|||Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)|A Phase II, Multicenter Study of Decitabine (5-Aza-2'Deoxycytidine) in Chronic Myelogenous Leukemia Accelerated Phase Refractory to Imatinib Mesylate (STI 571)|Completed||Phase 2|40||Astex Pharmaceuticals|||||||||||||||||||2018-06-01 05:31:57.268262|2018-06-01 05:31:57.268262
NCT00041977|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-19|||2005-06-23|2002-07-22|2002-07-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2002||2002-06-30|November 2003|2003-11-30||||||||Interventional|||Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea|Completed||Phase 3|150||CollaGenex Pharmaceuticals|||||||||||||||||||2018-06-01 05:31:57.330827|2018-06-01 05:31:57.330827
NCT00041964|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-19|||2012-07-23|2002-07-19|2002-07-22|Estimate|||||||2012-07-23|2012-07-24|Estimate||||July 2012|2012-07-31||||||||Observational|||A Study of HIV Levels During Pregnancy and After Childbirth|A Prospective Observational Study of Virologic and Immunologic Changes in HIV-Infected Women During the Postpartum Period|Completed|||129||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:31:57.38939|2018-06-01 05:31:57.38939
NCT00041951|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-19|||2016-05-31|2002-07-19|2002-07-22|Estimate|||||||2016-05-31|2016-06-01|Estimate|December 1998||1998-12-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study|Search for Genes Influencing Childhood Absence Epilepsy Study|Completed|||185|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-06-01 05:31:57.478192|2018-06-01 05:31:57.478192
NCT00041938|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-19|2013-01-03||2014-08-29|2002-07-19|2002-07-22|Estimate|2013-04-01|2013-05-14|Estimate||||2014-08-29|2014-09-05|Estimate|October 2002||2002-10-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|August 2011|Actual|2011-08-31||Interventional|WARCEF||Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial|Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial|Completed||Phase 3|2305|Actual|Columbia University||2|||f||||t||||||||||2018-06-01 05:31:57.559227|2018-06-01 05:31:57.559227
NCT00041925|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-18|||2005-07-14|2002-07-19|2002-07-22|Estimate|||||||2005-07-14|2005-07-15|Estimate|November 2001||2001-11-30|July 2005|2005-07-31|November 2004||2004-11-30|||||Interventional|||Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures|A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Peripheral Vein Grafts in Patients Undergoing Peripheral Arterial Bypass Graft Procedures|Completed||Phase 2/Phase 3|1400||Anesiva, Inc.|||||||||||||||||||2018-06-01 05:31:58.2827|2018-06-01 05:31:58.2827
NCT00041860|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-18|||2005-06-23|2002-07-19|2002-07-22|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2002|2002-07-31||||||||Interventional|||Modulation of Benzene Metabolism by Exposure to Environment||Completed||N/A|||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:58.559737|2018-06-01 05:31:58.559737
NCT00041847|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-18|||2015-04-14|2002-07-19|2002-07-22|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2001||2001-07-31|April 2015|2015-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Observational|||Gene-Environment Interaction in Prostate Cancer|Gene-Environment Interaction in Prostate Cancer|Completed|||881|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:58.61194|2018-06-01 05:31:58.61194
NCT00041834|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-18|||2005-06-23|2002-07-19|2002-07-22|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2000||2000-09-30|July 2002|2002-07-31|August 2003||2003-08-31|||||Observational|||Geographic Modeling of Traffic and Asthma Rates||Completed|||||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:58.666973|2018-06-01 05:31:58.666973
NCT00041821|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-18|||2006-03-22|2002-07-19|2002-07-22|Estimate|||||||2006-03-22|2006-03-23|Estimate|September 2000||2000-09-30|March 2006|2006-03-31||||||||Interventional|||Nasal Irritation Study: Individual Factors in Nasal Irritant Sensitivity|Individual Factors in Nasal Irritant Sensitivity|Completed||N/A|64||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:31:58.728393|2018-06-01 05:31:58.728393
NCT00041899|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-18|||2008-03-03|2002-07-18|2002-07-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2002||2002-05-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914|Pharmacokinetic Comparison of Two Preparations of the Selective Progesterone Receptor Modular CDB2914|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:58.786097|2018-06-01 05:31:58.786097
NCT00041886|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-18|||2008-03-03|2002-07-18|2002-07-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2002||2002-07-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Radiofrequency Ablation of Painful Soft Tissue Neoplasms|Radiofrequency Ablation of Painful Soft Tissue Neoplasms|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:31:58.847125|2018-06-01 05:31:58.847125
NCT00041808|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-17|||2005-06-23|2002-07-18|2002-07-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2001||2001-07-31|February 2003|2003-02-28|April 2003||2003-04-30|||||Interventional|||Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver|A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the Liver .|Completed||Phase 1/Phase 2|20||FeRx|||||||||||||||||||2018-06-01 05:31:58.901434|2018-06-01 05:31:58.901434
NCT00041795|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-16|||2005-06-23|2002-07-18|2002-07-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2002||2002-01-31|July 2002|2002-07-31||||||||Interventional|||Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer|Completed||Phase 2|50||NeoTherapeutics|||||||||||||||||||2018-06-01 05:31:58.9662|2018-06-01 05:31:58.9662
NCT00041782|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-16|||2012-07-27|2002-07-18|2002-07-19|Estimate|||||||2012-07-27|2012-07-31|Estimate|October 2000||2000-10-31|July 2012|2012-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients|Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients|Terminated||Phase 2|26|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:31:59.020159|2018-06-01 05:31:59.020159
NCT00041769|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-16|||2010-07-12|2002-07-16|2002-07-17|Estimate|||||||2010-07-12|2010-07-13|Estimate|June 2002||2002-06-30|December 2008|2008-12-31|August 2007|Actual|2007-08-31|April 2007|Actual|2007-04-30||Interventional|||Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor|A Phase II Randomized Controlled Trial Evaluating the Impact of Therapeutic Drug Monitoring (TDM) on Virologic Response to a Salvage Regimen in Subjects With a Normalized Inhibitory Quotient (NIQ) Less Than or Equal to 1 to One or More Protease Inhibitors|Completed||Phase 3|360||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:31:59.143907|2018-06-01 05:31:59.143907
NCT00041756|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-16|2011-08-03||2011-11-07|2002-07-16|2002-07-17|Estimate|2011-11-07|2011-11-08|Estimate||||2011-11-07|2011-11-08|Estimate|July 2002||2002-07-31|November 2011|2011-11-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis|Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis|Completed||Phase 2|395|Actual|Procter and Gamble||5|||f||||f||||||||||2018-06-01 05:31:59.319929|2018-06-01 05:31:59.319929
NCT00041743|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-16|||2010-01-12|2002-07-16|2002-07-17|Estimate|||||||2010-01-12|2010-01-13|Estimate|July 2002||2002-07-31|January 2010|2010-01-31|December 2007|Actual|2007-12-31|||||Interventional|||Treatment of Binge Eating Disorder|Treatment of Binge Eating Disorder|Completed||N/A|200||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:32:00.715519|2018-06-01 05:32:00.715519
NCT00041730|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-15|||2009-09-29|2002-07-16|2002-07-17|Estimate|||||||2009-09-29|2009-09-30|Estimate|July 2002||2002-07-31|October 2004|2004-10-31||||||||Interventional|||Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma|Phase II Trial of Rituxan(R) Plus FavId(TM) (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients With Grade 1 or 2 Follicular B-Cell Lymphoma|Unknown status|Active, not recruiting|Phase 2|90||Favrille|||||||||||||||||||2018-06-01 05:32:00.768564|2018-06-01 05:32:00.768564
NCT00041717|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-12|2013-02-26||2013-04-25|2002-07-15|2002-07-16|Estimate|2013-04-25|2013-05-31|Estimate||||2013-04-25|2013-05-31|Estimate|July 2002||2002-07-31|April 2013|2013-04-30|May 2004|Actual|2004-05-31|February 2004|Actual|2004-02-29||Interventional|||Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury|Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury|Completed||Phase 3|213|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-06-01 05:32:00.889417|2018-06-01 05:32:00.889417
NCT00041704|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-12|||2008-10-17|2002-07-15|2002-07-16|Estimate|||||||2008-10-17|2008-10-20|Estimate|August 2002||2002-08-31|October 2008|2008-10-31|August 2004|Actual|2004-08-31|||||Interventional|||The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)|A Phase 2 Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis.|Completed||Phase 2|19|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:32:01.259552|2018-06-01 05:32:01.259552
NCT00041691|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-12|||2005-06-23|2002-07-12|2002-07-15|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2003|2003-01-31||||||||Interventional|||Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery|A Phase I, Single Dose Escalating Study to Investigate the Tolerability, Pharmacokinetics and Dosimetry of 90 Y-Humanized MN-14 IgG in Colorectal Cancer Patients With Limited Residual Disease After Primary or Salvage Surgery|Terminated||Phase 1|30||Immunomedics, Inc.|||||||||||||||||||2018-06-01 05:32:01.324793|2018-06-01 05:32:01.324793
NCT00041678|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-12|||2013-11-07|2002-07-12|2002-07-15|Estimate|||||||2013-11-07|2013-11-11|Estimate|January 2000||2000-01-31|September 2007|2007-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type||Completed||Phase 3|||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:32:01.373052|2018-06-01 05:32:01.373052
NCT00041665|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-11|||2013-05-06|2002-07-12|2002-07-15|Estimate|||||||2013-05-06|2013-05-08|Estimate||||May 2013|2013-05-31||||||||Interventional|||Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy|A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Recombinant Human Keratinocyte Growth Factor for Reduction of Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy With Autologous PBPC Transplantation|Completed||Phase 3|||Amgen|||||||||||||||||||2018-06-01 05:32:01.428989|2018-06-01 05:32:01.428989
NCT00041652|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-11|||2005-10-21|2002-07-12|2002-07-15|Estimate|||||||2005-10-21|2005-10-24|Estimate|February 2000||2000-02-29|October 2005|2005-10-31|June 2003||2003-06-30|||||Interventional|||Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer|A Phase I/II Clinical Trial of Immunotherapy With Humanized MN-14 IgG in Recurrent, Metastatic, Unresectable Colorectal and Breast Carcinomas|Completed||Phase 1/Phase 2|30||Immunomedics, Inc.|||||||||||||||||||2018-06-01 05:32:01.481942|2018-06-01 05:32:01.481942
NCT00041639|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-11|||2005-06-23|2002-07-12|2002-07-15|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|January 2004|2004-01-31|December 2003||2003-12-31|||||Interventional|||Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer|A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma|Completed||Phase 1/Phase 2|75||Immunomedics, Inc.|||||||||||||||||||2018-06-01 05:32:01.554764|2018-06-01 05:32:01.554764
NCT00041626|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-11|||2007-09-10|2002-07-11|2002-07-12|Estimate|||||||2007-09-10|2007-09-11|Estimate||||September 2007|2007-09-30||||||||Interventional|||Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone||Unknown status|Recruiting|Phase 3|||Introgen Therapeutics|||||||||||||||||||2018-06-01 05:32:02.603859|2018-06-01 05:32:02.603859
NCT00041613|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-11|||2008-03-28|2002-07-11|2002-07-12|Estimate|||||||2008-03-28|2008-04-01|Estimate||||March 2008|2008-03-31||||||||Interventional|||Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate||Unknown status|Recruiting|Phase 3|||Introgen Therapeutics|||||||||||||||||||2018-06-01 05:32:02.723874|2018-06-01 05:32:02.723874
NCT00041600|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-11|||2014-06-27|2002-07-11|2002-07-12|Estimate|||||||2014-06-27|2014-06-30|Estimate|April 1996||1996-04-30|June 2014|2014-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Human Epilepsy Genetics--Neuronal Migration Disorders Study|Human Epilepsy Genetics--Neuronal Migration Disorders Study|Recruiting|||3500|Anticipated|Harvard University Faculty of Medicine|||||f||||f||||||Samples With DNA|"~     whole blood, DNA~   "|||2018-06-01 05:32:02.796305|2018-06-01 05:32:02.796305
NCT00041587|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-10|||2011-06-02|2002-07-11|2002-07-12|Estimate|||||||2011-06-02|2011-06-06|Estimate|July 2002||2002-07-31|June 2011|2011-06-30|July 2007|Actual|2007-07-31|June 2006|Actual|2006-06-30||Interventional|||Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma|Pre-operative IL13-PE38QQR Infusion in Patients With Recurrent or Progressive Supratentorial Malignant Glioma: A Phase I/II Study|Completed||Phase 1/Phase 2|80||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:32:02.87344|2018-06-01 05:32:02.87344
NCT00041509|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-09|||2017-05-24|2002-07-11|2002-07-12|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2002||2002-01-31|May 2017|2017-05-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|TEMPEST||ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)|ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty|Completed||Phase 2|343|Actual|GlaxoSmithKline||3|||||||f||||||||||2018-06-01 05:32:02.931952|2018-06-01 05:32:02.931952
NCT00041496|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-09|||2014-08-07|2002-07-11|2002-07-12|Estimate|||||||2014-08-07|2014-08-11|Estimate|November 2001||2001-11-30|August 2014|2014-08-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Prevention Of Recurrence Of Atrial Fibrillation|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)|Completed||Phase 2|520|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-06-01 05:32:02.991349|2018-06-01 05:32:02.991349
NCT00041574|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-10|||2016-09-08|2002-07-10|2002-07-11|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2002||2002-04-30|September 2016|2016-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide|Development of a Hospital-Based Home Program for the Use of Inhaled Nitric Oxide in the Chronic Management of Severe Cardiopulmonary Diseases|Terminated||Phase 2|7|Actual|Mallinckrodt||1||Closed for lack of enrollment|f||||t||||||||||2018-06-01 05:32:03.162319|2018-06-01 05:32:03.162319
NCT00041561|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-10|||2016-07-22|2002-07-10|2002-07-11|Estimate|||||||2016-07-22|2016-07-26|Estimate|January 2002||2002-01-31|July 2016|2016-07-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics|The Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) In Pediatrics|Terminated||Phase 3|55|Actual|Mallinckrodt||2||Study stopped due to poor enrollment|f||||t||||||||||2018-06-01 05:32:03.255802|2018-06-01 05:32:03.255802
NCT00041548|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-10|||2016-10-18|2002-07-10|2002-07-11|Estimate|||||||2016-10-18|2016-10-19|Estimate|May 2002||2002-05-31|October 2016|2016-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation|Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation|Terminated||Phase 1/Phase 2|7|Actual|Mallinckrodt||2||slow enrollment|f||||t||||||||||2018-06-01 05:32:03.360357|2018-06-01 05:32:03.360357
NCT00041535|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-09|||2017-06-30|2002-07-09|2002-07-10|Estimate|||||||2017-06-30|2017-07-02|Actual|July 5, 2002||2002-07-05|March 3, 2008|2008-03-03|March 21, 2007||2007-03-21|||||Interventional|||OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease|A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:03.437181|2018-06-01 05:32:03.437181
NCT00041470|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-09|2017-03-23||2017-06-19|2002-07-09|2002-07-10|Estimate|2017-05-08|2017-06-06|Actual||||2017-06-19|2017-07-17|Actual|March 2001||2001-03-31|June 2017|2017-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial|Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial|Terminated||Phase 1/Phase 2|38|Actual|University of Washington||1||Sponsor withdrew the study|f||||f||||||||No||2018-06-01 05:32:03.51341|2018-06-01 05:32:03.51341
NCT00040677|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08||2011-07-07|2011-07-13|2002-07-09|2002-07-10|Estimate||||2011-07-13|2011-07-18|Estimate|2011-07-13|2011-07-18|Estimate|February 2002||2002-02-28|July 2011|2011-07-31|January 2004|Actual|2004-01-31|November 2003|Actual|2003-11-30||Interventional|||A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.|A Phase II, Multicenter, Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Range-Finding Study of the Efficacy and Safety of ICA-17043 With or Without Hydroxyurea Therapy in Patients With Sickle Cell Anemia|Completed||Phase 2|90|Actual|Icagen||3|||f||||t||||||||||2018-06-01 05:32:03.718364|2018-06-01 05:32:03.718364
NCT00040664|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-05|2009-08-06||2017-01-19|2002-07-09|2002-07-10|Estimate|2010-02-05|2010-02-23|Estimate||||2017-01-19|2017-03-03|Actual|July 2002||2002-07-31|January 2017|2017-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years|A 48 Week, Phase II, Open-Label Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir QD and GW433908/Ritonavir BID When Administered to HIV-1 Infected, Antiretroviral Naive and Experienced, Pediatric Subjects 2-18 Years Old|Completed||Phase 2|69|Actual|ViiV Healthcare||3|||f||||||||||||||2018-06-01 05:32:03.885844|2018-06-01 05:32:03.885844
NCT00040651|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-05|||2007-12-19|2002-07-09|2002-07-10|Estimate|||||||2007-12-19|2007-12-28|Estimate|July 2002||2002-07-31|December 2007|2007-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients|Transplantation With T-Cell Depleted Autologous Peripheral Stem Cells for Severe Systemic Sclerosis: A Phase I Dose Escalation Study|Terminated||Phase 1|15||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||||||||||||||||2018-06-01 05:32:04.710451|2018-06-01 05:32:04.710451
NCT00041457|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2015-08-05|2002-07-08|2002-07-09|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2002||2002-07-31|August 2015|2015-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Epidemiology of Venous Thromboembolism||Completed|||||Brigham and Women's Hospital|||4||f||||||||||||||2018-06-01 05:32:04.847007|2018-06-01 05:32:04.847007
NCT00041444|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-02-05|2002-07-08|2002-07-09|Estimate|||||||2016-02-05|2016-02-08|Estimate|June 2002||2002-06-30|February 2016|2016-02-29|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|MESA-Eye||Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study|Multi-Ethnic Study of Atherosclerosis-Eye Study|Completed|||6176|Actual|University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:32:04.921095|2018-06-01 05:32:04.921095
NCT00041431|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-05-12|2002-07-08|2002-07-09|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 2001||2001-12-31|May 2005|2005-05-31|December 2003|Actual|2003-12-31|||||Interventional|||Estrogen, Cytokines and Heart Failure in Women||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:05.00766|2018-06-01 05:32:05.00766
NCT00041418|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-07-28|2002-07-08|2002-07-09|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Cardiac MR of Subclinical CVD: Impact of Age||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:05.064254|2018-06-01 05:32:05.064254
NCT00041405|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|||2016-05-12|2002-07-08|2002-07-09|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2001||2001-07-31|July 2005|2005-07-31|June 2005|Actual|2005-06-30|||||Observational|||Mechanisms of Pro-Thrombosis in Diabetes Mellitus -- Ancillary to BARI 2D||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:05.113555|2018-06-01 05:32:05.113555
NCT00041392|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-08|2012-08-05||2013-07-25|2002-07-08|2002-07-09|Estimate|2012-09-27|2012-10-30|Estimate||||2013-07-25|2013-07-30|Estimate|December 2001||2001-12-31|April 2012|2012-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|POINT||Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery|PeriOperative Interventional Neuroprotection Trial (POINT)|Completed||Phase 2|389|Actual|Duke University||2|||f||||||||||||||2018-06-01 05:32:05.184573|2018-06-01 05:32:05.184573
NCT00040599|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-01|||2008-01-08|2002-07-02|2002-07-03|Estimate|||||||2008-01-08|2008-01-09|Estimate|January 2000||2000-01-31|January 2008|2008-01-31|January 2004||2004-01-31|||||Interventional|||Safety Study of 90Y-hMN14 to Treat Colorectal Cancer|A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Metastatic/Recurrent Colorectal Carcinomas|Completed||Phase 1/Phase 2|72||Immunomedics, Inc.|||||||||||||||||||2018-06-01 05:32:05.686443|2018-06-01 05:32:05.686443
NCT00040586|ClinicalTrials.gov processed this data on May 31, 2018|2002-07-01|||2007-01-19|2002-07-01|2002-07-02|Estimate|||||||2007-01-19|2007-01-22|Estimate||||July 2002|2002-07-31||||||||Interventional|||Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2|Phase II Trial of Monoclonal Antibody J591 in Combination With Low-Dose Interleukin-2 in Patients With Recurrent Prostate Cancer|Completed||Phase 2|||BZL Biologics|||||||||||||||||||2018-06-01 05:32:05.864795|2018-06-01 05:32:05.864795
NCT00040573|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-29|||2009-03-30|2002-07-01|2002-07-02|Estimate|||||||2009-03-30|2009-03-31|Estimate|June 2002||2002-06-30|March 2009|2009-03-31|August 2003||2003-08-31|||||Interventional|||Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.|A Phase I/II Open Label, Single Dose Study of Intracavitary Administered 131I-TM-601 in Adult Patients With Recurrent High-Grade Glioma.|Completed||Phase 1/Phase 2|18||TransMolecular|||||||||||||||||||2018-06-01 05:32:05.934763|2018-06-01 05:32:05.934763
NCT00040560|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-28|||2005-06-23|2002-07-01|2002-07-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2003|2003-01-31||||||||Interventional|||Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer||Unknown status|Active, not recruiting|Phase 1|||Copharos|||||||||||||||||||2018-06-01 05:32:06.032329|2018-06-01 05:32:06.032329
NCT00040547|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-28|||2015-02-16|2002-06-28|2002-07-01|Estimate|||||||2015-02-16|2015-02-18|Estimate|June 2001||2001-06-30|February 2015|2015-02-28|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)|Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors|Completed||Phase 1|29|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:32:06.109502|2018-06-01 05:32:06.109502
NCT00040534|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-28|||2015-02-13|2002-06-28|2002-07-01|Estimate|||||||2015-02-13|2015-02-16|Estimate|January 2001||2001-01-31|February 2015|2015-02-28|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)||Terminated||Phase 1|22|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:32:06.228202|2018-06-01 05:32:06.228202
NCT00040521|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-27|||2013-02-07|2002-06-27|2002-06-28|Estimate|||||||2013-02-07|2013-02-08|Estimate|April 2002||2002-04-30|September 2005|2005-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Study Evaluating rhIL-11 in Active Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease|Completed||Phase 2|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:06.276009|2018-06-01 05:32:06.276009
NCT00040495|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2013-02-07|2002-06-27|2002-06-28|Estimate|||||||2013-02-07|2013-02-08|Estimate|April 2001||2001-04-30|February 2013|2013-02-28|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage|An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis|Completed||Phase 3|149|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:32:06.52969|2018-06-01 05:32:06.52969
NCT00040482|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2007-04-09|2002-06-27|2002-06-28|Estimate|||||||2007-04-09|2007-04-11|Estimate|April 1999||1999-04-30|April 2007|2007-04-30|August 2005||2005-08-31|||||Interventional|||High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis|Intensive Immunosuppression Followed by Rescue With CD34 Selected, T Cell Depleted, Leukopheresis Products in Patients With Multiple Sclerosis|Completed||Phase 2|10||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:32:07.459697|2018-06-01 05:32:07.459697
NCT00040469|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2007-04-09|2002-06-27|2002-06-28|Estimate|||||||2007-04-09|2007-04-11|Estimate|August 2000||2000-08-31|April 2007|2007-04-30||||||||Interventional|||Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies|Allogeneic Bone Marrow Transplant From HLA Identical Related Donors for Patients With High Risk Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, Hemoglobin SB0/+ Thalassemia, or Homozygous B0/+ Thalassemia or Severe Variants of B0/+ Thalassemia|Terminated||Phase 2|15||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:32:08.125206|2018-06-01 05:32:08.125206
NCT00040456|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2012-11-15|2002-06-27|2002-06-28|Estimate|||||||2012-11-15|2012-11-19|Estimate|January 2001||2001-01-31|November 2012|2012-11-30|May 2006|Actual|2006-05-31|||||Interventional|||Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate|The Effect of Oral Magnesium Pidolate on Incidence of Painful Crises in Patients With Hemoglobin SC Disease|Terminated||Phase 2|12|Actual|Baylor College of Medicine||2||Lack of accrual|f||||t||||||||||2018-06-01 05:32:08.279327|2018-06-01 05:32:08.279327
NCT00040443|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2005-06-23|2002-06-27|2002-06-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2002||2002-04-30|February 2005|2005-02-28|March 2003||2003-03-31|||||Interventional|||Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.|Efficacy And Safety Of CX516 (900 Mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-Week Study.|Completed||Phase 2|160||RespireRx|||||||||||||||||||2018-06-01 05:32:08.396252|2018-06-01 05:32:08.396252
NCT00040430|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2005-06-23|2002-06-27|2002-06-28|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2003|2003-01-31||||||||Interventional|||Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer||Unknown status|Active, not recruiting|Phase 1|||Copharos|||||||||||||||||||2018-06-01 05:32:08.549839|2018-06-01 05:32:08.549839
NCT00040508|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2008-03-03|2002-06-26|2002-06-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|January 2005|2005-01-31|January 2005||2005-01-31|||||Interventional|||Sirolimus for Focal Segmental Glomerulosclerosis|Sirolimus for Focal Segmental Glomerulosclerosis|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:08.617645|2018-06-01 05:32:08.617645
NCT00040417|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2007-04-09|2002-06-26|2002-06-27|Estimate|||||||2007-04-09|2007-04-11|Estimate|August 2000||2000-08-31|April 2007|2007-04-30||||||||Interventional|||Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies|Allo SCT From HLA Haploidentical Related Donors Using Sub-Myeloablative Conditioning For Patients With High Risk Hemoglobinopathies: Hemo SS, Hemo SC, Hemo SB0/+ Thalassemia, Homozygous B0/+ Thalassemia or Severe B0/+ Thalassemia Variants|Terminated||Phase 2|15||Baylor College of Medicine|||||||||||||||||||2018-06-01 05:32:08.76517|2018-06-01 05:32:08.76517
NCT00040248|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-22|||2008-03-03|2002-06-22|2002-06-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Daclizumab to Treat Wegener's Granulomatosis|A Randomized Trial Examining the Use of Daclizumab in Wegener's Granulomatosis|Completed||Phase 2|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:11.402667|2018-06-01 05:32:11.402667
NCT00040404|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26||2012-05-03|2012-05-08|2002-06-26|2002-06-27|Estimate||||2012-05-03|2012-05-08|Estimate|2012-05-08|2012-05-10|Estimate|March 2002||2002-03-31|May 2012|2012-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Parkinson's Disease|Terminated||Phase 2/Phase 3|806|Actual|Teva Pharmaceutical Industries||4||Unlikely to provide evidence of significant effect|f||||t||||||||||2018-06-01 05:32:08.857756|2018-06-01 05:32:08.857756
NCT00040391|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-26|||2016-11-30|2002-06-26|2002-06-27|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2002||2002-06-30|November 2016|2016-11-30||||||||Interventional|||A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer|A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer|Terminated||Phase 2|||Celgene Corporation|||||||||||||||||||2018-06-01 05:32:09.076062|2018-06-01 05:32:09.076062
NCT00040378|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-25|||2018-03-12|2002-06-26|2002-06-27|Estimate|||||||2018-03-12|2018-03-14|Actual|May 2002|Actual|2002-05-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|January 2014|Actual|2014-01-31||Observational|||Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)|Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)|Completed|||4246|Actual|University of Kentucky|||4||f||||t||||||||||2018-06-01 05:32:09.289304|2018-06-01 05:32:09.289304
NCT00040365|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-25|2012-01-13||2012-04-26|2002-06-25|2002-06-26|Estimate|2012-02-28|2012-03-29|Estimate||||2012-04-26|2012-04-30|Estimate|June 2002||2002-06-30|April 2012|2012-04-30|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer|Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study|Completed||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:32:09.756994|2018-06-01 05:32:09.756994
NCT00040352|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-25|||2018-01-25|2002-06-25|2002-06-26|Estimate|||||||2018-01-25|2018-01-26|Actual|June 24, 2002||2002-06-24|January 19, 2018|2018-01-19||||||||Observational|||Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:10.228657|2018-06-01 05:32:10.228657
NCT00040339|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-24|||2007-12-26|2002-06-24|2002-06-25|Estimate|||||||2007-12-26|2008-01-08|Estimate|May 2002||2002-05-31|December 2007|2007-12-31|July 2005|Actual|2005-07-31|||||Interventional|||Hypothermia to Treat Severe Brain Injury|The National Acute Brain Injury Study: Hypothermia II (NABISH II)|Completed||N/A|42||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:32:10.329924|2018-06-01 05:32:10.329924
NCT00040326|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-24|||2010-02-22|2002-06-24|2002-06-25|Estimate|||||||2010-02-22|2010-02-23|Estimate|July 2002||2002-07-31|February 2010|2010-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|ERSET||Early Surgical Intervention to Treat Epilepsy|Early Randomized Surgical Epilepsy Trial|Completed||Phase 3|200|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-06-01 05:32:10.485565|2018-06-01 05:32:10.485565
NCT00040313|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-24|||2006-05-02|2002-06-24|2002-06-25|Estimate|||||||2006-05-02|2006-05-03|Estimate|October 2002||2002-10-31|May 2006|2006-05-31|February 2005||2005-02-28|||||Interventional|||Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula|A Phase II Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center, Comparative Trial, in Parallel Groups, to Establish the Safety and Preliminary Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer), Given Every 6 Weeks for 12 to 30 Weeks to Patients With Clinically Significant Diabetic Macular Edema (CSME) Involving the Center of the Macula|Completed||Phase 2|0||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 05:32:10.58246|2018-06-01 05:32:10.58246
NCT00040300|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-24|||2005-07-18|2002-06-24|2002-06-25|Estimate|||||||2005-07-18|2005-07-21|Estimate|June 2002||2002-06-30|July 2005|2005-07-31|December 2002||2002-12-31|||||Interventional|||A 14-Day Study of Racivir When Used in Combination in HIV-Infected Males||Completed||Phase 1|18||Pharmasset|||||||||||||||||||2018-06-01 05:32:10.637698|2018-06-01 05:32:10.637698
NCT00040287|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-24|||2007-05-16|2002-06-24|2002-06-25|Estimate|||||||2007-05-16|2007-05-17|Estimate|January 1999||1999-01-31|May 2007|2007-05-31||||||||Interventional|||Theory-Based Interventions for Smoking and Obesity (Challenge) Trial||Completed||Phase 3|1778||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:32:10.691923|2018-06-01 05:32:10.691923
NCT00040274|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-24|||2005-07-18|2002-06-24|2002-06-25|Estimate|||||||2005-07-18|2005-07-19|Estimate||||July 2005|2005-07-31||||||||Interventional|||A Study of DPC 817 in HIV-Infected Males|A Placebo-Controlled, Dose-Escalation Study in HIV-1 Infected Subjects to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of DPC 817|Completed||Phase 1|30||Pharmasset|||||||||||||||||||2018-06-01 05:32:10.750026|2018-06-01 05:32:10.750026
NCT00040183|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-21|||2018-01-08|2002-06-24|2002-06-25|Estimate|||||||2018-01-08|2018-01-10|Actual|November 29, 2001|Actual|2001-11-29|June 2015|2015-06-30|January 15, 2004|Actual|2004-01-15|January 15, 2004|Actual|2004-01-15||Interventional|||OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.|A Randomized Placebo Controlled Study of OSI-774 (Tarceva (TM)) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|Completed||Phase 3|569|Actual|Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:32:10.858358|2018-06-01 05:32:10.858358
NCT00040170|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-21|||2006-10-31|2002-06-24|2002-06-25|Estimate|||||||2006-10-31|2006-11-02|Estimate|May 2002||2002-05-31|October 2006|2006-10-31||||||||Interventional|||Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer|Randomized Multicenter Phase II Study Evaluating Two Dosing Schedules of TG4010(MVA-MUC1-IL2) in Patients With Adenocarcinoma of the Prostate|Terminated||Phase 2|50||Transgene|||||||||||||||||||2018-06-01 05:32:11.093497|2018-06-01 05:32:11.093497
NCT00040157|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-21|||2015-12-29|2002-06-24|2002-06-25|Estimate|||||||2015-12-29|2015-12-30|Estimate||||December 2015|2015-12-31|May 2003|Actual|2003-05-31|||||Interventional|||Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.|A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load|Terminated||Phase 2|60||Achillion Pharmaceuticals||||Safety concerns|||||||||||||||2018-06-01 05:32:11.202646|2018-06-01 05:32:11.202646
NCT00040144|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-21|||2009-08-18|2002-06-24|2002-06-25|Estimate|||||||2009-08-18|2009-08-19|Estimate|July 2002||2002-07-31|August 2009|2009-08-31|May 2003|Actual|2003-05-31|||||Interventional|||Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B|A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B|Terminated||Phase 2|85||Achillion Pharmaceuticals||||Safety concerns|||||||||||||||2018-06-01 05:32:11.259339|2018-06-01 05:32:11.259339
NCT00040235|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-22|||2008-03-03|2002-06-22|2002-06-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Magnesium Effects in Apheresis|Citrate Effects and Role of Prophylactic Magnesium Administration During Large-Volume Leukapheresis|Completed||Phase 3|52||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:11.453371|2018-06-01 05:32:11.453371
NCT00040222|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-22|||2018-03-01|2002-06-22|2002-06-24|Estimate|||||||2018-03-01|2018-03-02|Actual|June 21, 2002||2002-06-21|February 12, 2018|2018-02-12||||||||Observational|||Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer|Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer|Completed|||377|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:11.500183|2018-06-01 05:32:11.500183
NCT00040209|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-21|||2008-03-03|2002-06-21|2002-06-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||JP-1730 to Treat Parkinson's Disease|Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:11.569809|2018-06-01 05:32:11.569809
NCT00040196|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-21|||2017-06-30|2002-06-21|2002-06-24|Estimate|||||||2017-06-30|2017-07-02|Actual|June 19, 2002||2002-06-19|July 9, 2009|2009-07-09|July 9, 2009|Actual|2009-07-09|July 9, 2009|Actual|2009-07-09||Observational|||How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance|Dopaminergic Modulation of Cerebral Connectivity During Sequential Finger Movements|Completed|||133||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:11.713716|2018-06-01 05:32:11.713716
NCT00040131|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-20|||2015-10-30|2002-06-20|2002-06-21|Estimate|||||||2015-10-30|2015-11-02|Estimate|January 2002||2002-01-31|October 2015|2015-10-31|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)||Terminated||Phase 2|316|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:32:11.790347|2018-06-01 05:32:11.790347
NCT00040105|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-19|||2012-07-31|2002-06-20|2002-06-21|Estimate|||||||2012-07-31|2012-08-01|Estimate|October 2002||2002-10-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia|Phase I Study of Zarnestra (R115777.USA30) and Gleevec (Imatinib Mesylate) in Chronic Phase Chronic Myelogenous Leukemia (CML)|Completed||Phase 1|26|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:11.857246|2018-06-01 05:32:11.857246
NCT00040092|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-19|||2008-01-04|2002-06-19|2002-06-20|Estimate|||||||2008-01-04|2008-01-07|Estimate|July 2002||2002-07-31|January 2008|2008-01-31||||July 2005|Actual|2005-07-31||Interventional|||A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer||Completed||Phase 3|400||Aptose Biosciences Inc.|||||||||||||||||||2018-06-01 05:32:11.978292|2018-06-01 05:32:11.978292
NCT00040014|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2012-02-14|2002-06-19|2002-06-20|Estimate|||||||2012-02-14|2012-02-16|Estimate|June 2002||2002-06-30|February 2012|2012-02-29|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women|Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen.|Terminated||Phase 2|100||Pfizer|||||f||||||||||||||2018-06-01 05:32:12.034582|2018-06-01 05:32:12.034582
NCT00040001|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2005-06-23|2002-06-19|2002-06-20|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2003|2003-02-28||||||||Interventional|||Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation||Completed||Phase 2|||Aderis Pharmaceuticals|||||||||||||||||||2018-06-01 05:32:12.095241|2018-06-01 05:32:12.095241
NCT00039988|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2016-09-20|2002-06-19|2002-06-20|Estimate|||||||2016-09-20|2016-09-22|Estimate|November 2001||2001-11-30|September 2016|2016-09-30|November 2007|Actual|2007-11-30|March 2006|Actual|2006-03-31||Interventional|||Treatment of Multiple Sclerosis With Copaxone and Albuterol|Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol|Completed||N/A|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||Yes|Data access including but not limited to participant level data, is available to the public in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:32:12.147718|2018-06-01 05:32:12.147718
NCT00039975|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2012-05-17|2002-06-19|2002-06-20|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|April 2004|Actual|2004-04-30|||||Interventional|||Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers|Evaluation of Potential Pharmacokinetic Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers|Completed||Phase 1|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:32:12.241398|2018-06-01 05:32:12.241398
NCT00039962|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-17|||2008-01-08|2002-06-18|2002-06-19|Estimate|||||||2008-01-08|2008-01-15|Estimate|May 2002||2002-05-31|January 2008|2008-01-31||||||||Interventional|||Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin||Completed||Phase 3|500||SciClone Pharmaceuticals|||||||||||||||||||2018-06-01 05:32:12.332318|2018-06-01 05:32:12.332318
NCT00039936|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-17|||2010-01-12|2002-06-18|2002-06-19|Estimate|||||||2010-01-12|2010-01-13|Estimate|February 2002||2002-02-28|January 2010|2010-01-31||||||||Interventional|||Treatment of Binge Eating Disorder||Completed||N/A|180||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:32:12.468399|2018-06-01 05:32:12.468399
NCT00040066|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2017-01-10|2002-06-17|2002-06-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2002||2002-05-31|September 2004|2004-09-30|August 2003||2003-08-31|||||Interventional|||Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1|Development of Human Laboratory Study Model of Cocaine Relapse Prevention|Unknown status|Active, not recruiting|Phase 1|32||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:32:12.523873|2018-06-01 05:32:12.523873
NCT00040053|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2017-01-11|2002-06-17|2002-06-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2002||2002-06-30|July 2008|2008-07-31|February 2004|Actual|2004-02-29|||||Interventional|||Ondansetron for the Treatment of Methamphetamine Dependence - 1|Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence.|Completed||Phase 2|154||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:32:12.598439|2018-06-01 05:32:12.598439
NCT00040040|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-18|||2017-01-10|2002-06-17|2002-06-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2002||2002-06-30|August 2003|2003-08-31|September 2003||2003-09-30|||||Interventional|||Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1|Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion|Unknown status|Active, not recruiting|Phase 1|20||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:32:12.665455|2018-06-01 05:32:12.665455
NCT00039923|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-14|||2008-03-03|2002-06-14|2002-06-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria|A Pilot Study to Determine if Transfer of Gpi-Linked Proteins Occurs Following Transfusion of Red Cells to Patients With Paroxysmal Nocturnal Hemoglobinuria|Completed|||7||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:12.723587|2018-06-01 05:32:12.723587
NCT00039910|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-14|||2007-05-03|2002-06-14|2002-06-17|Estimate|||||||2007-05-03|2007-05-04|Estimate|July 2000||2000-07-31|September 2006|2006-09-30|March 2003|Actual|2003-03-31|||||Interventional|||Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy|Completed||Phase 3|240||Pfizer|||||f||||||||||||||2018-06-01 05:32:12.794281|2018-06-01 05:32:12.794281
NCT00039884|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-13|||2005-06-23|2002-06-14|2002-06-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 2001||2001-09-30|June 2002|2002-06-30|March 2003||2003-03-31|||||Interventional|||Will Radiation/Chemotherapy Treatment of Cervical Cancer Work Better With Medication That May Improve Anemia?|Phase II Study of NESP (Novel Erythropoiesis Stimulating Protein) During Concurrent Chemo-Radiation for the Treatment of Cervical Carcinoma.|Unknown status|Active, not recruiting|Phase 2|64||Mirhashemi, Ramin, M.D.|||||||||||||||||||2018-06-01 05:32:12.916488|2018-06-01 05:32:12.916488
NCT00039871|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-13|2008-09-29||2017-03-07|2002-06-13|2002-06-14|Estimate|2008-12-10|2008-12-11|Estimate||||2017-03-07|2017-04-04|Actual|May 2002||2002-05-31|March 2017|2017-03-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)|PEG-Intron Plus REBETOL for the Treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Alpha Interferon Treatment in Combination With Ribavirin)|Completed||Phase 3|2333|Actual|Merck Sharp & Dohme Corp.||1|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:32:12.998093|2018-06-01 05:32:12.998093
NCT00039858|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-13|||2007-01-10|2002-06-13|2002-06-14|Estimate|||||||2007-01-10|2007-01-11|Estimate|September 2003||2003-09-30|January 2007|2007-01-31|March 2006||2006-03-31|||||Interventional|||Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin|Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin|Completed||Phase 4|24||Encysive Pharmaceuticals|||||||||||||||||||2018-06-01 05:32:13.532034|2018-06-01 05:32:13.532034
NCT00039845|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-12|||2017-06-30|2002-06-12|2002-06-13|Estimate|||||||2017-06-30|2017-07-02|Actual|June 7, 2002||2002-06-07|April 20, 2009|2009-04-20|April 20, 2009||2009-04-20|||||Observational|||MRI Language Studies in Young Children|fMRI Languages Studies In Young Children|Completed|||180||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:13.602952|2018-06-01 05:32:13.602952
NCT00039832|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-12|||2011-09-19|2002-06-12|2002-06-13|Estimate|||||||2011-09-19|2011-09-21|Estimate|March 2002||2002-03-31|September 2011|2011-09-30|May 2008|Actual|2008-05-31|April 2007|Actual|2007-04-30||Interventional|||ReoPro and Retavase to Restore Brain Blood Flow After Stroke|ReoPro Retavase Reperfusion of Stroke Safety Study - Imaging Evaluation|Completed||Phase 2|42|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:32:13.647865|2018-06-01 05:32:13.647865
NCT00039793|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-11|||2006-08-17|2002-06-12|2002-06-13|Estimate|||||||2006-08-17|2006-08-18|Estimate|March 2001||2001-03-31|July 2006|2006-07-31|March 2004||2004-03-31|||||Interventional|||Massage Therapy for Cancer-Related Fatigue|Massage Therapy for Cancer-Related Fatigue|Completed||Phase 2|45||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:32:13.720083|2018-06-01 05:32:13.720083
NCT00039780|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-10|||2017-09-20|2002-06-12|2002-06-13|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2001||2001-09-30|September 2017|2017-09-30|September 2014|Actual|2014-09-30|October 2006|Actual|2006-10-31||Interventional|||Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel|BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer|Completed||Phase 3|764|Actual|BioNumerik Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-06-01 05:32:13.772991|2018-06-01 05:32:13.772991
NCT00039819|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-11|||2008-03-03|2002-06-11|2002-06-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|May 2003|2003-05-31|May 2003||2003-05-31|||||Observational|||Nerve Stimulation to Modify a Spinal Reflex|Plasticity of Reciprocal Inhibition|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:13.842915|2018-06-01 05:32:13.842915
NCT00039754|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-07|||2009-01-19|2002-06-10|2002-06-11|Estimate|||||||2009-01-19|2009-01-21|Estimate|March 2002||2002-03-31|January 2009|2009-01-31||||||||Interventional|||A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma|A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma|Terminated||Phase 1/Phase 2|||Poniard Pharmaceuticals||||business reasons|||||||||||||||2018-06-01 05:32:13.888822|2018-06-01 05:32:13.888822
NCT00039741|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-07|2011-12-19|2010-08-19|2015-10-26|2002-06-10|2002-06-11|Estimate|2012-03-26|2012-04-24|Estimate|2011-05-16|2011-05-17|Estimate|2015-10-26|2015-11-23|Estimate|August 2002||2002-08-31|November 2014|2014-11-30|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children|A Phase II/III Randomized, Open-Label Study of Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV-1-Infected Antiretroviral Naive Children Between 30 Days and 18 Years of Age|Completed||Phase 2/Phase 3|266|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 05:32:14.051043|2018-06-01 05:32:14.051043
NCT00039767|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-07|||2008-03-03|2002-06-07|2002-06-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2002||2002-05-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices|Heparin vs. Lepirudin Flushes in Preventing Withdrawal Occlusion of Tunneled, Open-Ended Venous Access Devices: A Blinded, Randomized, Clinical Trial|Completed||Phase 2|340||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:15.366234|2018-06-01 05:32:15.366234
NCT00039026|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2015-02-23|2002-06-07|2002-06-10|Estimate|||||||2015-02-23|2015-02-24|Estimate|February 2002||2002-02-28|January 2015|2015-01-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea|A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone|Completed||Phase 3|377|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 05:32:15.456528|2018-06-01 05:32:15.456528
NCT00039013|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2015-02-23|2002-06-07|2002-06-10|Estimate|||||||2015-02-23|2015-02-24|Estimate|March 2002||2002-03-31|January 2015|2015-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin|A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone|Completed||Phase 3|336|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 05:32:15.697613|2018-06-01 05:32:15.697613
NCT00039000|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2012-09-06|2002-06-07|2002-06-10|Estimate|||||||2012-09-06|2012-09-07|Estimate|March 2002||2002-03-31|September 2012|2012-09-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma|A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus Physician's Choice Including Interleukin-2 and/or Dacarbazine/Temozolomide-based Therapy and/or Complete Tumor Resection in Stage IV Melanoma|Completed||Phase 3|350||Agenus Inc.|||||f||||||||||||||2018-06-01 05:32:16.769589|2018-06-01 05:32:16.769589
NCT00038987|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2010-08-26|2002-06-07|2002-06-10|Estimate|||||||2010-08-26|2010-08-27|Estimate|May 2002||2002-05-31|December 2003|2003-12-31|August 2002||2002-08-31|||||Interventional|||Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT|A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults|Completed||Phase 1/Phase 2|330||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:32:16.904346|2018-06-01 05:32:16.904346
NCT00038974|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2017-08-02|2002-06-07|2002-06-10|Estimate|||||||2017-08-02|2017-08-03|Actual|August 2002||2002-08-31|August 2017|2017-08-31|November 2005|Actual|2005-11-30|December 2004|Actual|2004-12-31||Interventional|||Hepatitis C Antiviral Resistance in African-Americans|Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)|Completed||Phase 3|401|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t|t|f||||||Yes|Individual participant data are available in the NIDDK Central Repository|2018-06-01 05:32:16.975572|2018-06-01 05:32:16.975572
NCT00038961|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2016-08-31|2002-06-07|2002-06-10|Estimate|||||||2016-08-31|2016-09-01|Estimate|November 2001||2001-11-30|August 2016|2016-08-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).|A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdomi|Completed||Phase 3|1309|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-06-01 05:32:17.156767|2018-06-01 05:32:17.156767
NCT00039715|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2008-03-03|2002-06-06|2002-06-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|September 2004|2004-09-30|September 2004||2004-09-30|||||Observational|||Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder|Effect of Hydrocortisone Infusion on Hippocampal Glucose Metabolism, Neuropsychological Test Performance and Reexperiencing Symptoms in Patients With Post-Traumatic Stress Disorder (PTSD)|Completed|||93||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:17.252869|2018-06-01 05:32:17.252869
NCT00039702|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2008-03-03|2002-06-06|2002-06-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2002||2002-06-30|September 2004|2004-09-30|September 2004||2004-09-30|||||Observational|||Brain Imaging in Alzheimer's Disease|SPECT Imaging of Alpha4beta2 Nicotinic Acetylcholine Receptors Using [123I]5-I-A-85380 in Alzheimer's Disease|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:17.320007|2018-06-01 05:32:17.320007
NCT00039689|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2018-05-24|2002-06-06|2002-06-07|Estimate|||||||2018-05-24|2018-05-25|Actual|May 21, 2002||2002-05-21|May 23, 2018|2018-05-23||||||||Observational|||Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Primary and Chronic HIV-Infected Patients|Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-Infected Patients|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:17.386934|2018-06-01 05:32:17.386934
NCT00039676|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2018-05-08|2002-06-06|2002-06-07|Estimate|||||||2018-05-08|2018-05-09|Actual|June 19, 2002||2002-06-19|April 20, 2018|2018-04-20||||||||Observational|||Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:17.471588|2018-06-01 05:32:17.471588
NCT00039663|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2008-03-03|2002-06-06|2002-06-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2002||2002-05-31|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Endothelial Dysfunction as a Risk Factor in HIV Study|Endothelial Dysfunction as a Risk Factor in HIV Study|Completed||Phase 1|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:17.54778|2018-06-01 05:32:17.54778
NCT00039650|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2008-03-03|2002-06-06|2002-06-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2002||2002-05-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Pilot Study: Effects of G-CSF on T Cell Function|Pilot Study of the Effects of G-CSF on T Cell Function|Completed|||15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:17.630818|2018-06-01 05:32:17.630818
NCT00039624|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-06|||2018-02-13|2002-06-06|2002-06-07|Estimate|||||||2018-02-13|2018-02-14|Actual|June 3, 2002||2002-06-03|September 27, 2017|2017-09-27|June 28, 2010|Actual|2010-06-28|July 29, 2004|Actual|2004-07-29||Interventional|||Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer|A Phase II Study of MR-Guided High Dose Rate Brachytherapy Boosts For Prostate Cancer|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:32:17.68665|2018-06-01 05:32:17.68665
NCT00038948|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|2009-05-29||2010-04-22|2002-06-06|2002-06-07|Estimate|2010-04-22|2010-05-14|Estimate||||2010-04-22|2010-05-14|Estimate|January 2002||2002-01-31|April 2010|2010-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients|A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients|Completed||Phase 3|830|Actual|Wyeth is now a wholly owned subsidiary of Pfizer||2|||f||||t||||||||||2018-06-01 05:32:17.820954|2018-06-01 05:32:17.820954
NCT00038935|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2008-04-18|2002-06-06|2002-06-07|Estimate|||||||2008-04-18|2008-04-22|Estimate||||April 2008|2008-04-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A|A Single Dose, Randomized, Double-Blind, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Factor VIII (BDDrFVIII) Manufactured by the Current Process (ReFacto) and by an Albumin Free Manufacturing Process (ReFacto AF)|Completed||Phase 3|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:19.036925|2018-06-01 05:32:19.036925
NCT00038922|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2006-05-17|2002-06-06|2002-06-07|Estimate|||||||2006-05-17|2006-05-18|Estimate||||May 2006|2006-05-31||||||||Interventional|||Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Safety and Exploratory Pharmacogenomic Study of Orally Administered Recombinant Human Interleukin Eleven (rhIL-11) in Patients With Mild to Moderate Left-Sided Ulcerative Colitis|Terminated||Phase 1|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:19.083512|2018-06-01 05:32:19.083512
NCT00038909|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2013-02-07|2002-06-06|2002-06-07|Estimate|||||||2013-02-07|2013-02-08|Estimate|September 1994||1994-09-30|February 2013|2013-02-28|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|||Study Evaluating ReFacto in Hemophilia A|Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study|Completed||N/A|103|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:32:19.138895|2018-06-01 05:32:19.138895
NCT00038896|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2009-08-13|2002-06-06|2002-06-07|Estimate|||||||2009-08-13|2009-08-14|Estimate|April 2001||2001-04-30|August 2009|2009-08-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Study Evaluating Venlafaxine ER in Adults With Panic Disorder|A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder|Completed||Phase 3|343|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:19.184928|2018-06-01 05:32:19.184928
NCT00038883|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-07-27|2002-06-06|2002-06-07|Estimate|||||||2012-07-27|2012-07-31|Estimate|April 2001||2001-04-30|July 2012|2012-07-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies|Campath-1H Snd Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies|Completed||N/A|19|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:19.229993|2018-06-01 05:32:19.229993
NCT00038870|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-08-02|2002-06-06|2002-06-07|Estimate|||||||2012-08-02|2012-08-06|Estimate|January 2001||2001-01-31|August 2012|2012-08-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes|Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 05:32:19.299524|2018-06-01 05:32:19.299524
NCT00038857|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|2012-06-21||2012-08-07|2002-06-06|2002-06-07|Estimate|2012-06-21|2012-08-07|Estimate||||2012-08-07|2012-08-10|Estimate|September 2001||2001-09-30|August 2012|2012-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases|Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases|Completed||Phase 2|29|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:19.379712|2018-06-01 05:32:19.379712
NCT00038844|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2011-10-31|2002-06-06|2002-06-07|Estimate|||||||2011-10-31|2011-11-02|Estimate|June 2001||2001-06-30|October 2011|2011-10-31|September 2010|Actual|2010-09-30|December 2007|Actual|2007-12-31||Interventional|||Safety and Efficacy of Campath in Nonmyeloablative Transplantation|Safety and Efficacy of Campath in Nonmyeloablative Transplantation|Completed||N/A|65|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:19.574916|2018-06-01 05:32:19.574916
NCT00038831|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-07-31|2002-06-06|2002-06-07|Estimate|||||||2012-07-31|2012-08-01|Estimate|May 2001||2001-05-31|July 2012|2012-07-31|October 2006|Actual|2006-10-31|March 2005|Actual|2005-03-31||Interventional|||Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS|Phase I/II Evaluation of Safety and Activity of Mylotarg Plus Melphalan and Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation|Completed||Phase 1/Phase 2|47|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:19.739729|2018-06-01 05:32:19.739729
NCT00038818|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-08-22|2002-06-06|2002-06-07|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2001||2001-05-31|August 2012|2012-08-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation|CD8 Depleted Donor Lymphocyte Infusions for Patients With Relapse Or Residual Disease Following Allogeneic Stem Cell Transplantation|Terminated||N/A|3|Actual|M.D. Anderson Cancer Center||1||Low accrual.|f||||f||||||||||2018-06-01 05:32:19.831741|2018-06-01 05:32:19.831741
NCT00038805|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-07-27|2002-06-06|2002-06-07|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 2001||2001-05-31|July 2012|2012-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)|Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS)|Terminated||Phase 2/Phase 3|3|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:19.922093|2018-06-01 05:32:19.922093
NCT00038792|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-08-01|2002-06-06|2002-06-07|Estimate|||||||2012-08-01|2012-08-02|Estimate|October 2000||2000-10-31|August 2012|2012-08-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD|A Phase I/II Trial of Recombinant Human Keratinocyte Growth Factor (rHuKFG) for the Treatment of Steroid Refractory Gastrointestinal Acute Graft-versus-host Disease (aGvHD)|Terminated||Phase 1/Phase 2|7|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||t||||||||||2018-06-01 05:32:20.010685|2018-06-01 05:32:20.010685
NCT00038779|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-08-03|2002-06-06|2002-06-07|Estimate|||||||2012-08-03|2012-08-06|Estimate|August 1996||1996-08-31|August 2012|2012-08-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States|Terminated||N/A|7|Actual|M.D. Anderson Cancer Center||1||Lack of Accrual|f||||f||||||||||2018-06-01 05:32:20.082435|2018-06-01 05:32:20.082435
NCT00004575|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-17|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2000||2000-02-29|October 2001|2001-10-31|October 2001||2001-10-31|||||Interventional|||Effects of Miconazole on Blood Flow|Investigation of Miconazole as an Inhibitor of Endothelium-Derived Hyperpolarizing Factor|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.41039|2018-06-01 05:32:33.41039
NCT00038766|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-05|||2012-08-22|2002-06-06|2002-06-07|Estimate|||||||2012-08-22|2012-08-23|Estimate|June 2002||2002-06-30|August 2012|2012-08-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|CD02||CNI-1493 for Treatment of Moderate to Severe Crohn's Disease|A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease|Terminated||Phase 2|33|Actual|Ferring Pharmaceuticals||3||Unable to enroll into study.|f||||f||||||||||2018-06-01 05:32:20.145091|2018-06-01 05:32:20.145091
NCT00038753|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-04|||2009-10-15|2002-06-04|2002-06-05|Estimate|||||||2009-10-15|2009-10-16|Estimate||||October 2009|2009-10-31||||||||Interventional|||Vision In Preschoolers Study (VIP Study)||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:32:20.235347|2018-06-01 05:32:20.235347
NCT00038727|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-04|2017-02-21||2017-09-25|2002-06-04|2002-06-05|Estimate|2017-09-25|2017-10-24|Actual||||2017-09-25|2017-10-24|Actual|September 2002||2002-09-30|September 2017|2017-09-30|January 2025|Anticipated|2025-01-31|October 2024|Anticipated|2024-10-31||Interventional|DPPOS||Diabetes Prevention Program Outcomes Study|Diabetes Prevention Program Outcomes Study|Active, not recruiting||Phase 3|2779|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t|t|f||||||Yes|NIDDK Repository|2018-06-01 05:32:20.309693|2018-06-01 05:32:20.309693
NCT00038714|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-04|||2007-06-26|2002-06-04|2002-06-05|Estimate|||||||2007-06-26|2007-06-27|Estimate|November 2001||2001-11-30|June 2007|2007-06-30|January 2004||2004-01-31|||||Interventional|||A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis|A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis|Completed||Phase 2|27|Anticipated|Nventa Biopharmaceuticals Corporation|||||||||||||||||||2018-06-01 05:32:20.71488|2018-06-01 05:32:20.71488
NCT00038701|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-04|||2012-07-27|2002-06-04|2002-06-05|Estimate|||||||2012-07-27|2012-07-31|Estimate|August 2000||2000-08-31|July 2012|2012-07-31|May 2004|Actual|2004-05-31|July 2002|Actual|2002-07-31||Interventional|||Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas|Phase II Study of Gemcitabine-Based Chemoradiation and TNP-470 for Patients With Locally Advanced, Nonmetastatic Adenocarcinoma of the Pancreas|Terminated||Phase 2|6|Actual|M.D. Anderson Cancer Center||1||Slow accrual.|f||||f||||||||||2018-06-01 05:32:20.904601|2018-06-01 05:32:20.904601
NCT00038688|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-04|||2009-10-29|2002-06-04|2002-06-05|Estimate|||||||2009-10-29|2009-10-30|Estimate||||March 2006|2006-03-31||||||||Interventional|||A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk Contacts|A Phase III Randomized Study to Evaluate the Efficacy of a Network-Oriented Peer Education Intervention for the Prevention of HIV Transmission Among Injection Drug Users and Their Network Members|Completed||Phase 3|2610||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:32:20.971476|2018-06-01 05:32:20.971476
NCT00038675|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-04|||2013-12-10|2002-06-04|2002-06-05|Estimate|||||||2013-12-10|2013-12-12|Estimate|June 2001||2001-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate|Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With Platelet Derived Growth Factor (PDGF-R) Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)|Completed||N/A|125|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:32:21.038869|2018-06-01 05:32:21.038869
NCT00038662|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-03|||2006-08-10|2002-06-03|2002-06-04|Estimate|||||||2006-08-10|2006-08-15|Estimate|May 2002||2002-05-31|August 2006|2006-08-31||||||||Interventional|||Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure|A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure|Completed||Phase 2|200||Abbott|||||||||||||||||||2018-06-01 05:32:21.123333|2018-06-01 05:32:21.123333
NCT00038649|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-03|||2013-12-06|2002-06-03|2002-06-04|Estimate|||||||2013-12-06|2013-12-09|Estimate|June 2001||2001-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Higher-Dose Gleevec (STI571)|Terminated||Phase 2|117|Actual|M.D. Anderson Cancer Center||1||Sponsor discontinued providing study drug.|f||||t||||||||||2018-06-01 05:32:21.227198|2018-06-01 05:32:21.227198
NCT00038636|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-03|||2006-08-13|2002-06-03|2002-06-04|Estimate|||||||2006-08-13|2006-08-15|Estimate|September 2000||2000-09-30|August 2006|2006-08-31||||||||Interventional|||A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors|A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors|Completed||Phase 3|36||Abbott|||||||||||||||||||2018-06-01 05:32:21.297462|2018-06-01 05:32:21.297462
NCT00038623|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-03|||2011-10-31|2002-06-03|2002-06-04|Estimate|||||||2011-10-31|2011-11-02|Estimate|April 2002||2002-04-30|October 2011|2011-10-31|February 2010|Actual|2010-02-28|December 2007|Actual|2007-12-31||Interventional|||Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma|A Phase II Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma|Completed||Phase 2|35|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:21.423434|2018-06-01 05:32:21.423434
NCT00038610|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-03|2015-08-19||2015-08-19|2002-06-03|2002-06-04|Estimate|2015-08-19|2015-09-18|Estimate||||2015-08-19|2015-09-18|Estimate|March 2001||2001-03-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia|Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia|Completed||Phase 2|54|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:21.514754|2018-06-01 05:32:21.514754
NCT00038597|ClinicalTrials.gov processed this data on May 31, 2018|2002-06-03|||2012-01-20|2002-06-03|2002-06-04|Estimate|||||||2012-01-20|2012-01-23|Estimate|April 2001||2001-04-30|January 2012|2012-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)|Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)|Completed||Phase 2|13|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:32:21.765208|2018-06-01 05:32:21.765208
NCT00038584|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2012-07-31|2002-05-31|2002-06-03|Estimate|||||||2012-07-31|2012-08-01|Estimate|June 1999||1999-06-30|July 2012|2012-07-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer|A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy|Completed||Phase 1|37|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:32:21.833489|2018-06-01 05:32:21.833489
NCT00038571|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2012-07-27|2002-05-31|2002-06-03|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 2002||2002-05-31|July 2012|2012-07-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy|Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-06-01 05:32:21.895611|2018-06-01 05:32:21.895611
NCT00038558|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2012-07-27|2002-05-31|2002-06-03|Estimate|||||||2012-07-27|2012-07-31|Estimate|November 2001||2001-11-30|July 2012|2012-07-31|March 2005|Actual|2005-03-31|February 2004|Actual|2004-02-29||Interventional|||Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy|Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy|Completed||Phase 3|25|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:32:21.994639|2018-06-01 05:32:21.994639
NCT00038545|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2012-01-20|2002-05-31|2002-06-03|Estimate|||||||2012-01-20|2012-01-23|Estimate|May 2001||2001-05-31|January 2012|2012-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma|A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Patients With Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma|Completed||Phase 2|25|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:32:22.089433|2018-06-01 05:32:22.089433
NCT00038532|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2008-03-29|2002-05-31|2002-06-03|Estimate|||||||2008-03-29|2008-04-01|Estimate|April 2001||2001-04-30|July 2006|2006-07-31||||||||Interventional|||Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART|An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART|Completed||Phase 2|24||Abbott|||||||||||||||||||2018-06-01 05:32:22.157431|2018-06-01 05:32:22.157431
NCT00038519|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2006-07-27|2002-05-31|2002-06-03|Estimate|||||||2006-07-27|2006-07-28|Estimate|April 2001||2001-04-30|July 2006|2006-07-31||||||||Interventional|||Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor|An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.|Completed||Phase 2/Phase 3|16||Abbott|||||||||||||||||||2018-06-01 05:32:22.269835|2018-06-01 05:32:22.269835
NCT00038506|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2015-04-06|2002-05-31|2002-06-03|Estimate|||||||2015-04-06|2015-04-08|Estimate|March 2002||2002-03-31|October 2010|2010-10-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure|A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)|Completed||Phase 4|100||ViiV Healthcare|||||||||||||||||||2018-06-01 05:32:22.392712|2018-06-01 05:32:22.392712
NCT00038493|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2012-01-20|2002-05-31|2002-06-03|Estimate|||||||2012-01-20|2012-01-23|Estimate|September 2001||2001-09-30|January 2012|2012-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme|Phase II Evaluation Temozolomide and Farnesyl Transferase Inhibitor (SCH66336) for the Treatment of Recurrent and Progressive Glioblastoma Multiforme|Terminated||Phase 2|23|Actual|M.D. Anderson Cancer Center||||Lack of Accrual|f||||f||||||||||2018-06-01 05:32:22.479695|2018-06-01 05:32:22.479695
NCT00038480|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|||2012-05-17|2002-05-31|2002-06-03|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|September 2007|Actual|2007-09-30|||||Interventional|||Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants|A Phase I/II Study of Lopinavir/Ritonavir in HIV-1 Infected Infants Less Than 6 Months of Age|Completed||Phase 1|31|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:32:22.659363|2018-06-01 05:32:22.659363
NCT00038467|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-31|2014-03-05||2014-04-21|2002-05-31|2002-06-03|Estimate|2014-03-05|2014-04-10|Estimate||||2014-04-21|2014-05-07|Estimate|February 1998||1998-02-28|April 2014|2014-04-30|March 2013|Actual|2013-03-31|June 2003|Actual|2003-06-30||Interventional|IES|Intent-to-treat (ITT) population included all participants assigned to the treatment group to which they were randomized, irrespective of the treatment they actually received.|Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer|Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen|Completed||Phase 3|4740|Actual|Pfizer|Other AEs included both SAEs and AEs. Non-SAE could not be presented separately for this study as AEs were collected in clinical database where SAE flags were not collected.|2|||f||||t||||||||||2018-06-01 05:32:22.938345|2018-06-01 05:32:22.938345
NCT00038454|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2005-06-23|2002-05-30|2002-05-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2003|2003-04-30||||||||Interventional|||Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery|A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery|Suspended||Phase 2/Phase 3|180||Hemosol|||||||||||||||||||2018-06-01 05:32:27.109249|2018-06-01 05:32:27.109249
NCT00038441|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2012-07-27|2002-05-30|2002-05-31|Estimate|||||||2012-07-27|2012-07-31|Estimate|September 1995||1995-09-30|July 2012|2012-07-31|August 2005|Actual|2005-08-31|February 2003|Actual|2003-02-28||Interventional|||Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas|Phase I Trial of Intratumoral Injection of DTI-015 for Recurrent Malignant Gliomas|Completed||Phase 1/Phase 2|39|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:27.212534|2018-06-01 05:32:27.212534
NCT00038428|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2011-07-21|2002-05-30|2002-05-31|Estimate|||||||2011-07-21|2011-07-25|Estimate|June 2001||2001-06-30|June 2011|2011-06-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer||Completed||Phase 2|40||Telik|||||f||||||||||||||2018-06-01 05:32:27.334867|2018-06-01 05:32:27.334867
NCT00038415|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2012-08-01|2002-05-30|2002-05-31|Estimate|||||||2012-08-01|2012-08-02|Estimate|December 2001||2001-12-31|August 2012|2012-08-31|January 2005|Actual|2005-01-31|July 2004|Actual|2004-07-31||Interventional|||A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach|A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach|Terminated||Phase 1/Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Vaccine unavailable.|f||||t||||||||||2018-06-01 05:32:27.391014|2018-06-01 05:32:27.391014
NCT00038402|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2012-07-19|2002-05-30|2002-05-31|Estimate|||||||2012-07-19|2012-07-20|Estimate|April 2001||2001-04-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|November 2004|Actual|2004-11-30||Interventional|||Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer|Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer|Completed||Phase 3|74|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:27.473216|2018-06-01 05:32:27.473216
NCT00038389|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2012-07-27|2002-05-30|2002-05-31|Estimate|||||||2012-07-27|2012-07-31|Estimate|January 2002||2002-01-31|July 2012|2012-07-31|January 2005|Actual|2005-01-31|October 2004|Actual|2004-10-31||Interventional|||Study of Vioxx and Radiation Therapy for Brainstem Glioma|Phase I Study of Vioxx and Radiation Therapy for Brainstem Glioma|Terminated||Phase 1|8|Actual|M.D. Anderson Cancer Center||1||Unavailability of study drug.|f||||f||||||||||2018-06-01 05:32:27.599026|2018-06-01 05:32:27.599026
NCT00038376|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2012-07-27|2002-05-30|2002-05-31|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 1990||1990-05-31|July 2012|2012-07-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies|Phase II Study of Interferon Alpha and Isotretinoin in Patients With T-Cell Malignancies|Terminated||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:27.678376|2018-06-01 05:32:27.678376
NCT00038363|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2009-01-20|2002-05-30|2002-05-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2001||2001-04-30|May 2002|2002-05-31|March 2004|Actual|2004-03-31|||||Interventional|||Comparison of Subacute and Hospital Based Rehabilitation Care|Comparison of Subacute and Hospital Based Rehabilitation Care|Completed||Phase 2|260|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:27.750049|2018-06-01 05:32:27.750049
NCT00038350|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2008-05-05|2002-05-30|2002-05-31|Estimate|||||||2008-05-05|2008-05-06|Estimate|January 2002||2002-01-31|May 2008|2008-05-31|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||Effects of Age and Age-Related Diseases on Swallowing|Effects of Age and Age-Related Diseases on Swallowing|Completed||Phase 2|60|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:32:27.833856|2018-06-01 05:32:27.833856
NCT00038337|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2009-01-20|2002-05-30|2002-05-31|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2001||2001-04-30|May 2002|2002-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Improving Functional Health Literacy in Older Veterans|Improving Functional Health Literacy in Older Veterans|Completed||Phase 2|240|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:27.88762|2018-06-01 05:32:27.88762
NCT00038311|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-30|||2015-04-30|2002-05-30|2002-05-31|Estimate|||||||2015-04-30|2015-05-04|Estimate|September 2000||2000-09-30|April 2015|2015-04-30|March 2003|Actual|2003-03-31|||||Interventional|||Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI))|Completed||Phase 3|120||Pfizer|||||f||||||||||||||2018-06-01 05:32:28.804427|2018-06-01 05:32:28.804427
NCT00038298|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2011-01-20|2002-05-30|2002-05-31|Estimate|||||||2011-01-20|2011-01-21|Estimate|April 2002||2002-04-30|January 2011|2011-01-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy, Safety and Tolerability of AMG 719 in Subjects With Rheumatoid Arthritis Receiving Methothrexate|Completed||Phase 2|53|Actual|Amgen||4|||f||||||||||||||2018-06-01 05:32:28.908046|2018-06-01 05:32:28.908046
NCT00038285|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2009-01-20|2002-05-29|2002-05-30|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2002||2002-04-30|May 2002|2002-05-31|March 2005|Actual|2005-03-31|||||Interventional|||Healthy Heart Amputation Rehabilitation Treatment (H.A.R.T)|Healthy Heart Amputation Rehabilitation Treatment (H.A.R.T)|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:29.008591|2018-06-01 05:32:29.008591
NCT00038272|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2012-05-17|2002-05-29|2002-05-30|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|April 2006|Actual|2006-04-30|||||Interventional|||A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Pilot Study of Beta-D-2,6-diaminopurine Dioxolane (DAPD) Versus DAPD Plus Mycophenolate Mofetil (MMF) in Treatment-Experienced Subjects|Completed||Phase 2|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:32:29.072306|2018-06-01 05:32:29.072306
NCT00038259|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2012-05-09|2002-05-29|2002-05-30|Estimate|||||||2012-05-09|2012-05-11|Estimate||||May 2012|2012-05-31|May 2006|Actual|2006-05-31|||||Interventional|||Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy|An Exploratory, Open-Label, Randomized Trial to Evaluate the Ability of Interleukin-2 (IL-2) to Enhance HIV-Specific Immunity and Influence the Time to Virologic Relapse Following Withdrawal of Potent Antiretroviral Therapy|Completed||N/A|21||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:32:29.169708|2018-06-01 05:32:29.169708
NCT00038246|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2013-05-31|2002-05-29|2002-05-30|Estimate|||||||2013-05-31|2013-06-03|Estimate|October 2000||2000-10-31|May 2013|2013-05-31|December 2004|Actual|2004-12-31|February 2004|Actual|2004-02-29||Interventional|||Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma|Phase I/II Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma (AI-PCa)|Completed||Phase 1/Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:32:29.254693|2018-06-01 05:32:29.254693
NCT00038233|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2012-07-27|2002-05-29|2002-05-30|Estimate|||||||2012-07-27|2012-07-31|Estimate|May 1999||1999-05-31|July 2012|2012-07-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Thalidomide for Multiple Myeloma|Thalidomide for Multiple Myeloma|Completed||Phase 3|27|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:32:29.325973|2018-06-01 05:32:29.325973
NCT00038220|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2006-07-26|2002-05-29|2002-05-30|Estimate|||||||2006-07-26|2006-07-27|Estimate|July 2000||2000-07-31|July 2006|2006-07-31||||||||Interventional|||Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients|A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to Completely Suppress Viral Replication in Subjects Infected With HIV-1|Completed||Phase 2|40||Abbott|||||||||||||||||||2018-06-01 05:32:29.497685|2018-06-01 05:32:29.497685
NCT00038207|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2012-07-27|2002-05-29|2002-05-30|Estimate|||||||2012-07-27|2012-07-31|Estimate|June 2000||2000-06-30|July 2012|2012-07-31|September 2005|Actual|2005-09-30|September 2004|Actual|2004-09-30||Interventional|||Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies|Phase II Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies|Completed||Phase 2|29|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:29.566031|2018-06-01 05:32:29.566031
NCT00038194|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2012-07-31|2002-05-29|2002-05-30|Estimate|||||||2012-07-31|2012-08-01|Estimate|October 2001||2001-10-31|July 2012|2012-07-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer|Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer|Completed||Phase 1|28|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:29.68312|2018-06-01 05:32:29.68312
NCT00038181|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2012-07-31|2002-05-29|2002-05-30|Estimate|||||||2012-07-31|2012-08-01|Estimate|October 2000||2000-10-31|July 2012|2012-07-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer|A Tolerance and Efficacy Trial of Preoperative Thalidomide Treatment Followed by Radical Retropubic Prostatectomy (RRP) in Select Patients With Locally Advanced Prostate Cancer|Completed||Phase 2|18|Actual|M.D. Anderson Cancer Center|||||f||||f||||||||||2018-06-01 05:32:29.765865|2018-06-01 05:32:29.765865
NCT00038168|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2012-07-31|2002-05-29|2002-05-30|Estimate|||||||2012-07-31|2012-08-01|Estimate|June 2000||2000-06-30|July 2012|2012-07-31|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma|Phase I/II Study of Intravenous Estramustine Phosphate Combined With Taxol in Patients With Hormone Refractory Adenocarcinoma of the Prostate|Completed||Phase 1/Phase 2|14|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:29.826833|2018-06-01 05:32:29.826833
NCT00038155|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2010-09-22|2002-05-29|2002-05-30|Estimate|||||||2010-09-22|2010-09-24|Estimate|May 2002||2002-05-31|September 2010|2010-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|STAGE||Rehabilitation for Older Adults From Acute Medical Conditions|Rehabilitation for Older Adults From Acute Medical Conditions|Completed||Phase 2|10|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:32:29.932544|2018-06-01 05:32:29.932544
NCT00038142|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2016-03-03|2002-05-29|2002-05-30|Estimate|||||||2016-03-03|2016-03-04|Estimate|November 1997||1997-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients|Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma|Terminated||Phase 2|46|Actual|M.D. Anderson Cancer Center||2||Low Accrual|f||||t||||||||||2018-06-01 05:32:30.036173|2018-06-01 05:32:30.036173
NCT00038129|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2013-06-17|2002-05-29|2002-05-30|Estimate|||||||2013-06-17|2013-06-19|Estimate|May 2002||2002-05-31|June 2013|2013-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||SPRINT - Randomized Trial of Tibial Fracture Fixation|Study to Prospectively Evaluate Reamed Intramedullary Nails in Tibial Shaft Fractures (SPRINT)|Completed||N/A|1200|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-06-01 05:32:30.150967|2018-06-01 05:32:30.150967
NCT00038116|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|||2013-02-04|2002-05-29|2002-05-30|Estimate|||||||2013-02-04|2013-02-05|Estimate|May 1995||1995-05-31|March 2010|2010-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Embryonic Dopamine Cell Implants for Parkinson's Disease|Embryonic Dopamine Cell Implants for Parkinson's Disease: A Double-Blind Study|Completed||Phase 3|40|Actual|University of Colorado, Denver||2|||f||||||||||||||2018-06-01 05:32:30.258112|2018-06-01 05:32:30.258112
NCT00038103|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-29|2009-03-27||2010-02-11|2002-05-29|2002-05-30|Estimate|2010-02-11|2010-02-25|Estimate||||2010-02-11|2010-02-25|Estimate|January 2002||2002-01-31|February 2010|2010-02-28|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen|Open-Label, Multicentre, Controlled Study Of Exemestane (Aromasin®) With Or Without Celecoxib (Celebrex®) In Postmenopausal Women With Advanced Breast Cancer (ABC) Having Progressed On Tamoxifen|Completed||Phase 2|111|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 05:32:30.393736|2018-06-01 05:32:30.393736
NCT00038090|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-28|||2012-07-31|2002-05-28|2002-05-29|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 2001||2001-09-30|July 2012|2012-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Thalidomide-Dexamethasone for Multiple Myeloma|Thalidomide-Dexamethasone for Multiple Myeloma|Completed||Phase 2/Phase 3|83|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:31.210595|2018-06-01 05:32:31.210595
NCT00038077|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-28|||2010-11-17|2002-05-28|2002-05-29|Estimate|||||||2010-11-17|2010-11-19|Estimate|August 2001||2001-08-31|November 2010|2010-11-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Reversal of Ventricular Remodeling With Toprol-XL||Completed||Phase 3|300||AstraZeneca|||||||||||||||||||2018-06-01 05:32:31.303692|2018-06-01 05:32:31.303692
NCT00038064|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-28|||2008-09-11|2002-05-28|2002-05-29|Estimate|||||||2008-09-11|2008-09-15|Estimate|January 2002||2002-01-31|September 2008|2008-09-30|April 2004|Actual|2004-04-30|October 2003|Actual|2003-10-31||Interventional|||Anemia in Patients With a Non-Myeloid Malignancy|A Randomized, Open-Label Study of Darbepoetin Alfa (Novel Erythropoiesis Stimulation Protein, NESP) and rHuEPO for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy|Completed||Phase 3|707|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:32:31.433603|2018-06-01 05:32:31.433603
NCT00038051|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2013-04-01|2002-05-24|2002-05-27|Estimate|||||||2013-04-01|2013-04-04|Estimate|May 1999||1999-05-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies|Phase I Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies|Completed||Phase 1|28|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-06-01 05:32:31.530463|2018-06-01 05:32:31.530463
NCT00038038|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2012-07-31|2002-05-24|2002-05-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|January 1994||1994-01-31|July 2012|2012-07-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole|Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||1||No participants enrolled, study terminated.|f||||f||||||||||2018-06-01 05:32:31.598301|2018-06-01 05:32:31.598301
NCT00038025|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2012-08-01|2002-05-24|2002-05-27|Estimate|||||||2012-08-01|2012-08-02|Estimate|September 1994||1994-09-30|August 2012|2012-08-31|November 2006|Actual|2006-11-30|August 2006|Actual|2006-08-31||Interventional|||A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies|A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies|Completed||Phase 2|60|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:31.66867|2018-06-01 05:32:31.66867
NCT00038012|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2012-07-31|2002-05-24|2002-05-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|September 1999||1999-09-30|July 2012|2012-07-31|June 2004|Actual|2004-06-30|October 2002|Actual|2002-10-31||Interventional|||rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin|A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved With Thrombosol and 2% DMSO in Patients With Gynecologic Malignancy Receiving Carboplatin|Completed||N/A|31|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:31.739298|2018-06-01 05:32:31.739298
NCT00037999|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2009-01-20|2002-05-24|2002-05-27|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2001||2001-04-30|May 2002|2002-05-31|March 2004|Actual|2004-03-31|||||Interventional|||The Effect of Testosterone Supplementation on Rehabilitation Outcomes|The Effect of Testosterone Supplementation on Rehabilitation Outcomes|Completed||Phase 2|60|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:31.806457|2018-06-01 05:32:31.806457
NCT00037986|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2009-02-09|2002-05-24|2002-05-27|Estimate|||||||2009-02-09|2009-02-11|Estimate|July 2001||2001-07-31|February 2009|2009-02-28|June 2004|Actual|2004-06-30|May 2004|Actual|2004-05-31||Interventional|||Functioning, Disability, and Quality of Life in the Adult Hearing Impaired|Functioning, Disability, and Quality of Life in the Adult Hearing Impaired|Completed||Phase 2|330|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:32:31.856766|2018-06-01 05:32:31.856766
NCT00037973|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2010-09-15|2002-05-24|2002-05-27|Estimate|||||||2010-09-15|2010-09-16|Estimate|August 2000||2000-08-31|September 2010|2010-09-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Effect of Ventilation-Feedback Training on Exercise Performance in COPD|Effects of Ventilation-Feedback Training on Exercise Performance in COPD|Completed||Phase 2|108|Anticipated|VA Office of Research and Development||3|||f||||f||||||||||2018-06-01 05:32:31.921554|2018-06-01 05:32:31.921554
NCT00037960|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2009-01-20|2002-05-24|2002-05-27|Estimate|||||||2009-01-20|2009-01-21|Estimate|June 2001||2001-06-30|May 2002|2002-05-31|June 2004|Actual|2004-06-30|||||Interventional|||Automated Constraint-Induced Therapy for Restoring Movement After Stroke|Automated Constraint-Induced Therapy for Restoring Movement After Stroke|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:32.087536|2018-06-01 05:32:32.087536
NCT00037947|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2008-06-02|2002-05-24|2002-05-27|Estimate|||||||2008-06-02|2008-06-04|Estimate|October 2001||2001-10-31|June 2008|2008-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Auditory Function in Patients With and Without Multiple Sclerosis|Auditory Function in Patients With and Without Multiple Sclerosis|Completed||Phase 2|300|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:32.144046|2018-06-01 05:32:32.144046
NCT00037934|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2011-10-06|2002-05-24|2002-05-27|Estimate|||||||2011-10-06|2011-10-07|Estimate|April 2002||2002-04-30|October 2011|2011-10-31|December 2004|Actual|2004-12-31|September 2004|Actual|2004-09-30||Interventional|||Robotic Upper-Limb Neurorehabilitation in Chronic Stroke Patient|Evaluation of Robotic Upper Extremity Neuro-Rehabilitation|Completed||Phase 2|30|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:32:32.194931|2018-06-01 05:32:32.194931
NCT00037921|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2010-05-05|2002-05-24|2002-05-27|Estimate|||||||2010-05-05|2010-05-07|Estimate|January 2001||2001-01-31|May 2010|2010-05-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||UTI Prophylaxis Using Bacterial Interference Following SCI|UTI Prophylaxis Using Bacterial Interference Following SCI|Completed||Phase 2|40|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:32:32.257469|2018-06-01 05:32:32.257469
NCT00037908|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2009-01-20|2002-05-24|2002-05-27|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2000||2000-10-31|May 2002|2002-05-31|September 2003|Actual|2003-09-30|||||Interventional|||Effects of Strength Training on Upper-Limb Function in Post-Stroke Hemiparesis|Effects of Strength Training on Upper-Limb Function in Post-Stroke Hemiparesis|Completed||Phase 2|60|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:32.31346|2018-06-01 05:32:32.31346
NCT00037895|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2009-01-20|2002-05-24|2002-05-27|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2001||2001-01-31|May 2002|2002-05-31|December 2003|Actual|2003-12-31|||||Interventional|||Stroke Rehabilitation Outcomes With Supported Treadmill Ambulation Training|Stroke Rehabilitation Outcomes With Supported Treadmill Ambulation Training|Completed||Phase 2|48|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:32:32.37071|2018-06-01 05:32:32.37071
NCT00037882|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2012-07-31|2002-05-24|2002-05-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|February 2001||2001-02-28|July 2012|2012-07-31|December 2003|Actual|2003-12-31|October 2003|Actual|2003-10-31||Interventional|||PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron|A Phase II Study of SCH 54031 (Peg Interferon Alpha-2B/PEG-Intron) in Subjects With Interferon-Refractory Chronic Myelogenous Leukemia|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:32.42184|2018-06-01 05:32:32.42184
NCT00037869|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-24|||2012-07-31|2002-05-24|2002-05-27|Estimate|||||||2012-07-31|2012-08-01|Estimate|November 2001||2001-11-30|July 2012|2012-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors|High Dose I-131 Metaiodobenzylguanidine (MIBG) Therapy for Metastatic Neuroendocrine Tumors|Completed||Phase 3|15|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:32.487765|2018-06-01 05:32:32.487765
NCT00037843|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-23|||2012-02-20|2002-05-23|2002-05-24|Estimate|||||||2012-02-20|2012-02-22|Estimate|December 1988||1988-12-31|February 2012|2012-02-29|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening|Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening|Completed||Phase 3|114|Actual|M.D. Anderson Cancer Center|||||f||||||||||||||2018-06-01 05:32:32.547444|2018-06-01 05:32:32.547444
NCT00037830|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-22|2011-07-13||2012-12-18|2002-05-22|2002-05-23|Estimate|2012-07-18|2012-08-09|Estimate||||2012-12-18|2012-12-21|Estimate|November 1999||1999-11-30|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||GM1 Ganglioside Effects on Parkinson's Disease|The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication|Completed||Phase 2|94|Actual|Thomas Jefferson University||3|||f||||f||||||||||2018-06-01 05:32:32.617707|2018-06-01 05:32:32.617707
NCT00037817|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-21|||2017-10-05|2002-05-21|2002-05-22|Estimate|||||||2017-10-05|2017-10-06|Actual|May 17, 2002||2002-05-17|November 30, 2016|2016-11-30|November 9, 2009|Actual|2009-11-09|October 8, 2008|Actual|2008-10-08||Interventional|||Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies|Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies|Completed||Phase 1|34|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-06-01 05:32:33.192394|2018-06-01 05:32:33.192394
NCT00037804|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-21|||2009-08-13|2002-05-21|2002-05-22|Estimate|||||||2009-08-13|2009-08-14|Estimate||||August 2009|2009-08-31||||||||Interventional|||Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction||Completed||Phase 1|||Pfizer|||||||||||||||||||2018-06-01 05:32:33.273254|2018-06-01 05:32:33.273254
NCT00037791|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-21|||2006-11-08|2002-05-21|2002-05-22|Estimate|||||||2006-11-08|2006-11-09|Estimate|December 1999||1999-12-31|September 2006|2006-09-30|September 2002||2002-09-30|||||Interventional|||Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia|Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Patients Receiving Myelosuppressive Treatment Regimens Requiring Platelet Transfusion Support.|Completed||Phase 3|180||Pfizer|||||f||||||||||||||2018-06-01 05:32:33.348048|2018-06-01 05:32:33.348048
NCT00001908|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1999||1999-06-30|July 2001|2001-07-31|July 2001||2001-07-31|||||Observational|||T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma|T Cell Cytokine Changes During IL-4 Receptor Treatment for Asthma|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.476816|2018-06-01 05:32:33.476816
NCT00001866|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1999||1999-08-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||Eye Muscle Surgery to Treat Congenital Nystagmus|Horizontal Rectus Tenotomy in the Treatment of Congenital Nystagmus|Completed||Phase 2|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.527843|2018-06-01 05:32:33.527843
NCT00001864|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||Amblyopia (Lazy Eye) Treatment Study|Amblyopia Treatment Study|Completed||Phase 3|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.579017|2018-06-01 05:32:33.579017
NCT00001818|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1999||1999-06-30|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||Combination Drug Treatment of Pediatric HIV Infection|A Pilot Study of Hydroxyurea in Combination With Stavudine, Didanosine and Efavirenz in Pediatric Patients With HIV-1 Infection|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.635864|2018-06-01 05:32:33.635864
NCT00001688|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1998||1998-01-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine|A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.690873|2018-06-01 05:32:33.690873
NCT00001542|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1996||1996-07-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||Fluconazole Prophylaxis of Thrush in AIDS|Fluconazole Prophylaxis of Thrush in AIDS|Completed||Phase 4|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.832915|2018-06-01 05:32:33.832915
NCT00001190|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|2002-05-21|2002-05-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1983||1983-11-30|October 2001|2001-10-31|October 2001||2001-10-31|||||Interventional|||Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature|A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:33.892906|2018-06-01 05:32:33.892906
NCT00037778|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2016-08-29|2002-05-20|2002-05-21|Estimate|||||||2016-08-29|2016-08-31|Estimate|September 2001||2001-09-30|August 2016|2016-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Genetic Modifiers of Cystic Fibrosis: Sibling Study|Genetic Modifiers of Cystic Fibrosis: Sibling Study|Completed|||3459|Actual|Johns Hopkins University|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-06-01 05:32:33.960848|2018-06-01 05:32:33.960848
NCT00037765|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2018-01-24|2002-05-20|2002-05-21|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2001||2001-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Gene Modifiers of Cystic Fibrosis Lung Disease|Gene Modifiers of Cystic Fibrosis Lung Disease|Active, not recruiting|||600|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 05:32:34.019737|2018-06-01 05:32:34.019737
NCT00037752|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2014-05-20|2002-05-20|2002-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2002||2002-09-30|May 2014|2014-05-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|SUCCESS||Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates|Use of Sibutramine in Smoking Cessation|Completed||N/A|436|Actual|University of Tennessee||2|||f||||t||||||||||2018-06-01 05:32:34.103625|2018-06-01 05:32:34.103625
NCT00037739|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2016-01-19|2002-05-20|2002-05-21|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 2001||2001-04-30|January 2016|2016-01-31|March 2004||2004-03-31|||||Observational|||Chronic Obstructive Pulmonary Disease Gene Localization||Completed|||||University of Utah|||||f||||||||||||||2018-06-01 05:32:34.188198|2018-06-01 05:32:34.188198
NCT00037726|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2015-12-21|2002-05-20|2002-05-21|Estimate|||||||2015-12-21|2015-12-23|Estimate|April 2001||2001-04-30|December 2005|2005-12-31|March 2004||2004-03-31|||||Observational|||Antibiotics in Infancy--Risk Factor for Childhood Asthma||Completed|||||Augusta University|||||f||||||||||||||2018-06-01 05:32:34.232878|2018-06-01 05:32:34.232878
NCT00037713|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2010-04-07|2002-05-20|2002-05-21|Estimate|||||||2010-04-07|2010-04-08|Estimate|September 1998||1998-09-30|April 2010|2010-04-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG|The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG|Completed||Phase 3|515|Actual|ImClone LLC||2|||f||||f||||||||||2018-06-01 05:32:34.289196|2018-06-01 05:32:34.289196
NCT00037700|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2009-11-25|2002-05-20|2002-05-21|Estimate|||||||2009-11-25|2009-11-26|Estimate|May 2001||2001-05-31|December 2007|2007-12-31|December 2002||2002-12-31|||||Interventional|||Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis||Completed||Phase 2|||Swedish Orphan Biovitrum|||||||||||||||||||2018-06-01 05:32:34.365958|2018-06-01 05:32:34.365958
NCT00037687|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2005-06-23|2002-05-20|2002-05-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2001||2001-04-30|January 2003|2003-01-31|December 2004||2004-12-31|||||Interventional|||Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis|A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®) for Reducing 28 Day All Cause Mortality in Patients With Severe Sepsis|Terminated||Phase 3|2500||ICOS Corporation|||||||||||||||||||2018-06-01 05:32:34.415309|2018-06-01 05:32:34.415309
NCT00037674|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-20|||2011-05-17|2002-05-20|2002-05-21|Estimate|||||||2011-05-17|2011-05-18|Estimate|January 2001||2001-01-31|January 2011|2011-01-31|May 2003|Actual|2003-05-31|||||Interventional|||A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Two Doses of Topiramate for the Treatment of Acute Manic or Mixed Episodes in Patients With Bipolar I Disorder With an Optional Open-Label Extension|Completed||Phase 3|434|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:32:34.467165|2018-06-01 05:32:34.467165
NCT00037661|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-18|||2015-10-01|2002-05-19|2002-05-20|Estimate|||||||2015-10-01|2015-10-02|Estimate|April 2002||2002-04-30|October 2015|2015-10-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye|Double-Masked, Randomized, Placebo-Controlled Study of Efficacy Parameter Following Administration of INS365 Ophthalmic Solution or Placebo in a Controlled Adverse Environment (CAE) Chamber in Subjects With Non-Sjogren's Associated Dry Eye|Completed||Phase 3|222|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:32:34.541019|2018-06-01 05:32:34.541019
NCT00037648|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2009-11-25|2002-05-17|2002-05-20|Estimate|||||||2009-11-25|2009-11-26|Estimate|July 2000||2000-07-31|February 2008|2008-02-29|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Juvenile Rheumatoid Arthritis|A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Open-label Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-metHuIL-1ra (Anakinra) in Polyarticular-Course Juvenile Rheumatoid Arthritis|Completed||Phase 2|86|Actual|Swedish Orphan Biovitrum||2|||f||||||||||||||2018-06-01 05:32:34.589472|2018-06-01 05:32:34.589472
NCT00037635|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2013-05-06|2002-05-17|2002-05-20|Estimate|||||||2013-05-06|2013-05-08|Estimate|December 2001||2001-12-31|May 2013|2013-05-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients|A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis|Completed||Phase 3|400|Anticipated|Amgen||2|||f||||||||||||||2018-06-01 05:32:34.661269|2018-06-01 05:32:34.661269
NCT00037622|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2009-08-18|2002-05-17|2002-05-20|Estimate|||||||2009-08-18|2009-08-19|Estimate||||August 2009|2009-08-31|May 2003|Actual|2003-05-31|||||Interventional|||Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.|An Open-Label Treatment Protocol to Provide Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection|Terminated||N/A|100||Achillion Pharmaceuticals||||Safety concerns from other studies.|||||||||||||||2018-06-01 05:32:34.739935|2018-06-01 05:32:34.739935
NCT00037609|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2012-10-22|2002-05-17|2002-05-20|Estimate|||||||2012-10-22|2012-10-24|Estimate|January 2001||2001-01-31|October 2012|2012-10-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients|Phase I-II Study to Evaluate Safety, Efficacy and Pharmacokinetic Interactions Between Capecitabine (XELODA) and Exisulind (APTOSYN) in Patients With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|35|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-06-01 05:32:34.789525|2018-06-01 05:32:34.789525
NCT00037596|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2013-02-11|2002-05-17|2002-05-20|Estimate|||||||2013-02-11|2013-02-13|Estimate|August 2000||2000-08-31|February 2013|2013-02-28|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia|A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.|Completed||Phase 2|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:34.880117|2018-06-01 05:32:34.880117
NCT00037583|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2009-08-20|2002-05-17|2002-05-20|Estimate|||||||2009-08-20|2009-08-21|Estimate||||August 2009|2009-08-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia|A Dose-Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (go) Given in Combination With Cytarabine and Daunorubicin in Relapsed or Refractory Patients and in Younger de Novo Patients With Acute Myeloid Leukemia (AML)|Completed||Phase 2|69|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:34.974607|2018-06-01 05:32:34.974607
NCT00037570|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2013-02-07|2002-05-17|2002-05-20|Estimate|||||||2013-02-07|2013-02-08|Estimate|November 2000||2000-11-30|February 2013|2013-02-28|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage|A Randomized Study of the Effect of Intravenous Pantoprazole on Gastric pH After Successful Hemostasis in Patients With Bleeding Peptic Ulcer|Completed||Phase 2|12|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:32:35.027811|2018-06-01 05:32:35.027811
NCT00037557|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2007-12-18|2002-05-17|2002-05-20|Estimate|||||||2007-12-18|2007-12-27|Estimate|September 2002||2002-09-30|December 2007|2007-12-31|November 2007|Actual|2007-11-30|||||Interventional|||Study Evaluating rFIX; BeneFIX in Severe Hemophilia B|An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Children Less Than 6 Years of Age With Severe Hemophilia B|Completed||Phase 3|20||Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||||||||||||2018-06-01 05:32:35.085315|2018-06-01 05:32:35.085315
NCT00037544|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2008-04-18|2002-05-17|2002-05-20|Estimate|||||||2008-04-18|2008-04-22|Estimate||||April 2008|2008-04-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Study Evaluating ReFacto AF in Severe Hemophilia A|An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) With Severe Hemophilia A|Completed||Phase 3|||Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:35.151349|2018-06-01 05:32:35.151349
NCT00037531|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2009-08-17|2002-05-17|2002-05-20|Estimate|||||||2009-08-17|2009-08-18|Estimate||||August 2009|2009-08-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients|An Open-label Extension Study of the Safety of Long-term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients|Completed||Phase 3|769|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||||||||||||||||2018-06-01 05:32:35.210747|2018-06-01 05:32:35.210747
NCT00037518|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2013-05-06|2002-05-17|2002-05-20|Estimate|||||||2013-05-06|2013-05-08|Estimate|April 2001||2001-04-30|May 2013|2013-05-31||||||||Interventional|||A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer|An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.|Completed||Phase 4|46||Amgen|||||||||||||||||||2018-06-01 05:32:35.295528|2018-06-01 05:32:35.295528
NCT00037505|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2005-06-23|2002-05-17|2002-05-20|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Major Depression and Inflammatory Risk Markers for Coronary Heart Disease|Major Depression and Inflammatory Risk Markers for Coronary Heart Disease|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:32:35.368324|2018-06-01 05:32:35.368324
NCT00037492|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2007-05-21|2002-05-17|2002-05-20|Estimate|||||||2007-05-21|2007-05-22|Estimate||||May 2007|2007-05-31||||||||Interventional|||Families In Recovery From Stroke Trial (F.I.R.S.T.)|Psychological Intervention in Stroke Recovery|Completed||Phase 3|291||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:32:35.426043|2018-06-01 05:32:35.426043
NCT00037479|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-17|||2005-12-06|2002-05-17|2002-05-20|Estimate|||||||2005-12-06|2005-12-07|Estimate|December 1999||1999-12-31|December 2005|2005-12-31||||||||Interventional|||Brain Imaging and Retreatment Study of Persistent Lyme Disease|PET and MRI Imaging of Persistent Lyme Encephalopathy|Completed||Phase 2|65||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:32:35.505431|2018-06-01 05:32:35.505431
NCT00037466|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-03-01|2002-05-16|2002-05-17|Estimate|||||||2016-03-01|2016-03-03|Estimate|September 2000||2000-09-30|February 2005|2005-02-28|November 2002|Actual|2002-11-30|August 2001|Actual|2001-08-31||Observational|||Relation of Diet to Serum Homocysteine Level in Youths|Relation of Diet to Serum Homocysteine Level in Youths|Completed|||2445|Actual|Boston Children’s Hospital|||||f||||f||||||||No|Data Sharing was not required at the time the study was conducted.|2018-06-01 05:32:35.576441|2018-06-01 05:32:35.576441
NCT00037453|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-03-15|2002-05-16|2002-05-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 2001||2001-04-30|August 2004|2004-08-31|March 2003|Actual|2003-03-31|||||Observational|||Analysis of Sex Hormones and Lipoproteins in Young Males||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:35.628311|2018-06-01 05:32:35.628311
NCT00037440|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2014-12-01|2002-05-16|2002-05-17|Estimate|||||||2014-12-01|2014-12-03|Estimate|September 2001||2001-09-30|December 2014|2014-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Genetic Epidemiology of Change in CVD Risk Factors|Genetic Epidemiology of Change in CVD Risk Factors (HL70568-1)|Completed|||1735|Actual|The University of Texas Health Science Center, Houston|||2||f||||f||||||||||2018-06-01 05:32:35.680796|2018-06-01 05:32:35.680796
NCT00037427|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-03-15|2002-05-16|2002-05-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2001||2001-09-30|May 2005|2005-05-31|July 2004|Actual|2004-07-31|||||Observational|||Airway Responses Following Chlorine Gas Exposure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:35.740594|2018-06-01 05:32:35.740594
NCT00037414|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-08-19|2002-05-16|2002-05-17|Estimate|||||||2016-08-19|2016-08-23|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Joint Determinants of Bone Density and CVD Calcification||Completed|||||University of Maryland|||||f||||||||||||||2018-06-01 05:32:35.781008|2018-06-01 05:32:35.781008
NCT00037401|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-02-17|2002-05-16|2002-05-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Postprandial Lipemia and Endothelial Function in ACCORD- Ancillary to ACCORD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:35.91229|2018-06-01 05:32:35.91229
NCT00037388|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-07-28|2002-05-16|2002-05-17|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2004||2004-07-31|January 2008|2008-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:35.97925|2018-06-01 05:32:35.97925
NCT00037375|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-02-17|2002-05-16|2002-05-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 2001||2001-07-31|February 2005|2005-02-28|June 2003|Actual|2003-06-30|||||Observational|||Physical Activity, Body Composition, and Prevalent Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.066756|2018-06-01 05:32:36.066756
NCT00037362|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-07-28|2002-05-16|2002-05-17|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Measuring Sensitivity to Nonignorability||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.132678|2018-06-01 05:32:36.132678
NCT00037349|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-02-17|2002-05-16|2002-05-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 2001||2001-03-31|January 2005|2005-01-31|February 2004|Actual|2004-02-29|||||Observational|||Heart Rate Recovery and Mortality||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.19662|2018-06-01 05:32:36.19662
NCT00037336|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2014-03-14|2002-05-16|2002-05-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|September 2001||2001-09-30|March 2014|2014-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Atherosclerosis in Rheumatoid Arthritis||Completed|||||Vanderbilt University|||||f||||||||||||||2018-06-01 05:32:36.261771|2018-06-01 05:32:36.261771
NCT00037323|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-03-15|2002-05-16|2002-05-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 2001||2001-05-31|May 2004|2004-05-31|October 2003|Actual|2003-10-31|||||Observational|||Framingham Offspring Study: Psychosocial Risk Factors||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.316688|2018-06-01 05:32:36.316688
NCT00037310|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-07-28|2002-05-16|2002-05-17|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2001||2001-04-30|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||New CVD Risk Factors for Lowered Cognitive Functioning||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.378222|2018-06-01 05:32:36.378222
NCT00037297|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-07-28|2002-05-16|2002-05-17|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2001||2001-07-31|January 2008|2008-01-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Epidemiology of Cardiovascular Disease in Diabetes||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.446992|2018-06-01 05:32:36.446992
NCT00037284|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-07-11|2002-05-16|2002-05-17|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2001||2001-07-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Behavioral and Immunological Factors in Coronary Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.517679|2018-06-01 05:32:36.517679
NCT00037271|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-02-17|2002-05-16|2002-05-17|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2001||2001-04-30|August 2004|2004-08-31|March 2003|Actual|2003-03-31|||||Observational|||Genome Scan for Obesity in a Multi-Ethnic Sample||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.571591|2018-06-01 05:32:36.571591
NCT00037258|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2014-03-28|2002-05-16|2002-05-17|Estimate|||||||2014-03-28|2014-04-01|Estimate|September 2001||2001-09-30|March 2014|2014-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Dyslipidemia and Risk of Cardiovascular Disease in Diabetic Men and Women||Completed|||||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:32:36.630484|2018-06-01 05:32:36.630484
NCT00037245|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-02-08|2002-05-16|2002-05-17|Estimate|||||||2016-02-08|2016-02-10|Estimate|September 2001||2001-09-30|December 2005|2005-12-31|July 2005||2005-07-31|||||Observational|||Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:32:36.691043|2018-06-01 05:32:36.691043
NCT00037232|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2016-03-15|2002-05-16|2002-05-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 2001||2001-04-30|May 2005|2005-05-31|March 2005|Actual|2005-03-31|||||Observational|||Failure Time Methods for Family Disease Studies||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:36.74375|2018-06-01 05:32:36.74375
NCT00036244|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2005-08-04|2002-05-08|2002-05-09|Estimate|||||||2005-08-04|2005-08-05|Estimate|April 2002||2002-04-30|August 2005|2005-08-31|January 2004||2004-01-31|||||Interventional|||Synthetic Human Secretin in Children With Autism|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism|Completed||Phase 3|||Repligen Corporation|||||||||||||||||||2018-06-01 05:32:46.540434|2018-06-01 05:32:46.540434
NCT00037219|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2008-10-17|2002-05-16|2002-05-17|Estimate|||||||2008-10-17|2008-10-21|Estimate|August 2001||2001-08-31|October 2008|2008-10-31|November 2002|Actual|2002-11-30|||||Interventional|||The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.|A Phase 2, Open-Label, Randomized, Dose-Ranging Study of the Safety and Efficacy of Intravenous Anidulafungin (VER002) in the Treatment of Patients With Invasive Candidiasis|Completed||Phase 2|120|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:32:36.797171|2018-06-01 05:32:36.797171
NCT00037206|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2008-10-17|2002-05-16|2002-05-17|Estimate|||||||2008-10-17|2008-10-21|Estimate|May 2002||2002-05-31|October 2008|2008-10-31|February 2003|Actual|2003-02-28|||||Interventional|||A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).|An Open Label Non-Comparative Study of the Safety and Efficacy of Intravenous Anidulafungin Plus AmBisome® [(Amphotericin B) Liposome for Injection] as a Treatment for Invasive Aspergillosis.|Completed||Phase 2/Phase 3|30|Actual|Pfizer|||||f||||||||||||||2018-06-01 05:32:36.8873|2018-06-01 05:32:36.8873
NCT00037193|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2005-06-23|2002-05-16|2002-05-17|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Acute Regulation of Parathyroid Hormone by Dietary Phosphate|Acute Regulation of Parathyroid Hormone by Dietary Phosphate|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:32:36.946873|2018-06-01 05:32:36.946873
NCT00037180|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2008-09-25|2002-05-16|2002-05-17|Estimate|||||||2008-09-25|2008-09-29|Estimate|April 2002||2002-04-30|September 2008|2008-09-30|January 2003|Actual|2003-01-31|||||Interventional|||For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy|Phase II, Randomized, Double-Blind, Multicenter Trial Of Celecoxib Vs Placebo For The Prevention Of Diarrhea Associated With CPT-11/5fu/LV Chemotherapy In Patients With Previously Untreated Metastatic Colorectal Cancer|Terminated||Phase 2|212||Pfizer|||||f||||||||||||||2018-06-01 05:32:37.019973|2018-06-01 05:32:37.019973
NCT00037167|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2009-04-08|2002-05-16|2002-05-17|Estimate|||||||2009-04-08|2009-04-09|Estimate|September 2001||2001-09-30|April 2009|2009-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Effects of Exercise Poles on Older Adults During Exercise Walking|Impact of Running Poles on Older Adult Exercise Walking|Completed||Phase 1/Phase 2|150||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:32:37.124266|2018-06-01 05:32:37.124266
NCT00037154|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2010-01-12|2002-05-16|2002-05-17|Estimate|||||||2010-01-12|2010-01-14|Estimate|August 1999||1999-08-31|January 2010|2010-01-31|December 2002||2002-12-31|||||Interventional|||Saw Palmetto Extract in Benign Prostatic Hyperplasia|Saw Palmetto Extract In Benign Prostatic Hyperplasia|Completed||Phase 3|224||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 05:32:37.188668|2018-06-01 05:32:37.188668
NCT00037141|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-15|||2007-10-04|2002-05-16|2002-05-17|Estimate|||||||2007-10-04|2007-10-10|Estimate|March 2002||2002-03-31|June 2004|2004-06-30|March 2004||2004-03-31|||||Interventional|||Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)|Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate)|Completed||Phase 1/Phase 2|150||American Medical Systems|||||||||||||||||||2018-06-01 05:32:37.264723|2018-06-01 05:32:37.264723
NCT00037128|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-16|||2005-12-08|2002-05-16|2002-05-17|Estimate|||||||2005-12-08|2005-12-09|Estimate|March 1998||1998-03-31|May 2004|2004-05-31||||||||Interventional|||Study of GL701 in Men With Systemic Lupus Erythematosus||Unknown status|Active, not recruiting|Phase 3|40||Genelabs Technologies|||||||||||||||||||2018-06-01 05:32:37.314523|2018-06-01 05:32:37.314523
NCT00037115|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-15|||2018-04-10|2002-05-16|2002-05-17|Estimate|||||||2018-04-10|2018-04-12|Actual|May 2002|Actual|2002-05-31|April 2018|2018-04-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.|An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results.|Withdrawn||Phase 4|0|Actual|MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute||||Lack of funding|||||||||||||||2018-06-01 05:32:37.37767|2018-06-01 05:32:37.37767
NCT00037102|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-15|||2018-04-10|2002-05-16|2002-05-17|Estimate|||||||2018-04-10|2018-04-12|Actual|July 2001||2001-07-31|April 2018|2018-04-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|MTX01||Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis|An Open Label Study of the Safety and Efficacy of Combination Therapy With AVONEX and Bi-Monthly High Dose Intravenous Methotrexate With Leucovorin Rescue in the Treatment of Multiple Sclerosis|Completed||Phase 4|16|Actual|MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute|||||f||||f||||||||||2018-06-01 05:32:37.470264|2018-06-01 05:32:37.470264
NCT00037089|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-14|||2005-06-23|2002-05-14|2002-05-15|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2005|2005-01-31||||||||Interventional|||A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer||Unknown status|Active, not recruiting|Phase 2|||Edelman, Martin, M.D.|||||||||||||||||||2018-06-01 05:32:37.529433|2018-06-01 05:32:37.529433
NCT00037076|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-14|||2012-10-30|2002-05-14|2002-05-15|Estimate|||||||2012-10-30|2012-10-31|Estimate||||October 2012|2012-10-31|July 2003|Actual|2003-07-31|||||Observational|||Prevalence of Hepatitis C Virus Infection in HIV-Infected Children|Hepatitis C Prevalence in Perinatally Infected HIV-Positive Children Enrolled in PACTG 219C|Completed|||600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:32:37.617078|2018-06-01 05:32:37.617078
NCT00037063|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-14|||2015-06-03|2002-05-14|2002-05-15|Estimate|||||||2015-06-03|2015-06-04|Estimate||||June 2003|2003-06-30||||||||Interventional|||A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs|A Pilot Study of the Efficacy of a Combination of Antioxidants and B Vitamins in Preventing the Recurrence of Hyperlactatemia in Subjects Who Have Limited Antiretroviral Options|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:32:37.72017|2018-06-01 05:32:37.72017
NCT00037050|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-14|||2009-09-11|2002-05-14|2002-05-15|Estimate|||||||2009-09-11|2009-09-14|Estimate|April 2002||2002-04-30|September 2009|2009-09-30|July 2005|Actual|2005-07-31|||||Interventional|||Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria|Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram-Positive Bloodstream Infections|Completed||Phase 3|739|Actual|Pfizer|||||||||||||||||||2018-06-01 05:32:37.790937|2018-06-01 05:32:37.790937
NCT00036647|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2018-01-08|2002-05-13|2002-05-14|Estimate|||||||2018-01-08|2018-01-10|Actual|November 1, 2001|Actual|2001-11-01|June 2015|2015-06-30|January 30, 2004|Actual|2004-01-30|January 30, 2004|Actual|2004-01-30||Interventional|||OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer|A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease|Completed||Phase 3|731|Actual|Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:32:37.873092|2018-06-01 05:32:37.873092
NCT00036634|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-13|||2014-01-13|2002-05-13|2002-05-14|Estimate|||||||2014-01-13|2014-01-15|Estimate|March 2002||2002-03-31|January 2014|2014-01-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients|A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1|Completed||Phase 1/Phase 2|30|Actual|Gilead Sciences||3|||f||||||||||||||2018-06-01 05:32:38.874267|2018-06-01 05:32:38.874267
NCT00036621|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-11||2010-02-27|2010-02-27|2002-05-11|2002-05-13|Estimate||||2010-02-27|2010-03-02|Estimate|2010-02-27|2010-03-02|Estimate||||August 2007|2007-08-31||||September 2002|Actual|2002-09-30||Interventional|||A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy||Terminated||Phase 2|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:32:38.94612|2018-06-01 05:32:38.94612
NCT00036608|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10||2010-01-28|2011-04-07|2002-05-11|2002-05-13|Estimate||||2010-01-28|2010-02-01|Estimate|2011-04-07|2011-04-14|Estimate|January 2002||2002-01-31|January 2010|2010-01-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine||Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:32:39.0073|2018-06-01 05:32:39.0073
NCT00036595|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2008-03-03|2002-05-10|2002-05-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2002||2002-05-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Observational|||Functional Coupling of Cortico-Cortical and Cortico-Muscular Connections During Motor Movements: An Electrocorticographic Study of Ipsilateral Motor Control|Functional Coupling Of Cortico-Cortical and Cortico-Muscular Connections During Motor Movements: An Electrocorticographic Study of Ipsilateral Motor Control|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:39.195597|2018-06-01 05:32:39.195597
NCT00036582|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2008-03-03|2002-05-10|2002-05-13|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2002||2002-05-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents|Clozapine vs Placebo In Treatment-Refractory Bipolar Disorder In Children And Adolescents|Completed||Phase 3|116||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:32:39.252221|2018-06-01 05:32:39.252221
NCT00036569|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|2011-09-20||2012-01-10|2002-05-10|2002-05-13|Estimate|2012-01-10|2012-02-13|Estimate||||2012-01-10|2012-02-13|Estimate|May 2002||2002-05-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Interventional|||A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas|A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) in Children With Diffuse Pontine Gliomas|Completed||Phase 2|32|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:32:39.330259|2018-06-01 05:32:39.330259
NCT00036556|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2007-08-13|2002-05-10|2002-05-13|Estimate|||||||2007-08-13|2007-08-15|Estimate|June 2001||2001-06-30|August 2007|2007-08-31||||||||Interventional|||Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer|A Phase III, Randomized Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer|Completed||Phase 3|941|Actual|Abbott|||||f||||||||||||||2018-06-01 05:32:39.686021|2018-06-01 05:32:39.686021
NCT00036543|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2006-08-10|2002-05-10|2002-05-13|Estimate|||||||2006-08-10|2006-08-15|Estimate|May 2001||2001-05-31|August 2006|2006-08-31||||||||Interventional|||A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer|Completed||Phase 3|1000||Abbott|||||||||||||||||||2018-06-01 05:32:40.342997|2018-06-01 05:32:40.342997
NCT00036517|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2005-06-23|2002-05-10|2002-05-13|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2002||2002-02-28|September 2004|2004-09-30|March 2003||2003-03-31|||||Interventional|||Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer|A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose Escalation, Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer|Terminated||Phase 1/Phase 2|30||PhytoCeutica|||||||||||||||||||2018-06-01 05:32:40.748099|2018-06-01 05:32:40.748099
NCT00036504|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2010-10-12|2002-05-10|2002-05-13|Estimate|||||||2010-10-12|2010-10-13|Estimate|August 2001||2001-08-31|October 2010|2010-10-31|August 2002||2002-08-31|||||Interventional|||Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin|Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients New to Insulin Therapy Who Were Inadequately Controlled on Oral Agents|Completed||Phase 4|100||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:32:40.867845|2018-06-01 05:32:40.867845
NCT00036491|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2017-11-01|2002-05-10|2002-05-13|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2001||2001-01-31|November 2017|2017-11-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Anti-CD20 in Systemic Lupus Erythematosus|An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus|Completed||Phase 1/Phase 2|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-06-01 05:32:40.991946|2018-06-01 05:32:40.991946
NCT00036478|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2017-01-18|2002-05-10|2002-05-13|Estimate|||||||2017-01-18|2017-01-19|Estimate||||October 2004|2004-10-31||||||||Observational|||Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients|Pilot Study to Evaluate the Use of Phosphorus P31 Nuclear Magnetic Resonance Spectroscopy as a Non-Invasive Means to Evaluate Mitochondrial Dysfunction in HIV-Infected Subjects|Withdrawn|||0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:32:41.310607|2018-06-01 05:32:41.310607
NCT00036465|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2013-07-26|2002-05-10|2002-05-13|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|September 2005|Actual|2005-09-30|||||Interventional|||Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads|A Phase II, Randomized, Controlled, Pilot Study of Antiretroviral Switch at Lower Versus Higher HIV-1 RNA Levels in Subjects Experiencing Virologic Relapse on a Current HAART Regimen|Completed||Phase 2|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:32:41.39196|2018-06-01 05:32:41.39196
NCT00036452|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2012-05-17|2002-05-10|2002-05-13|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|January 2006|Actual|2006-01-31|||||Interventional|||A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation|A Randomized, Phase II, Open Label Study to Compare Twice Daily and Once Daily Potent Antiretroviral Therapy and to Compare Self-Administered Therapy and Therapy Administered Under Direct Observation|Completed||Phase 2|402|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:32:41.501614|2018-06-01 05:32:41.501614
NCT00036439|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-10|||2011-05-16|2002-05-10|2002-05-13|Estimate|||||||2011-05-16|2011-05-17|Estimate|February 2002||2002-02-28|March 2010|2010-03-31|January 2007|Actual|2007-01-31|||||Interventional|||A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis|A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis|Completed||Phase 3|364|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:32:41.63302|2018-06-01 05:32:41.63302
NCT00036426|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-09|||2005-06-23|2002-05-09|2002-05-10|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2001||2001-03-31|October 2004|2004-10-31||||||||Interventional|||Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma|Phase II Study of FavId (Tumor-Specific Idiotype-KLH) and Soluble GM-CSF Immunotherapy in Patients With Stable or Progressive Grade 1 and 2 Follicular B-Cell Lymphomas|Unknown status|Active, not recruiting|Phase 2|22||Favrille|||||||||||||||||||2018-06-01 05:32:41.712618|2018-06-01 05:32:41.712618
NCT00036413|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-09|||2011-11-22|2002-05-09|2002-05-10|Estimate|||||||2011-11-22|2011-11-24|Estimate|January 2002||2002-01-31|November 2011|2011-11-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis|A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Safety and Dose-ranging Study of Three Oral Doses (0.5 mg, 2.5 mg and 10 mg Once Daily) of TCH346 in Patients With Amyotrophic Lateral Sclerosis.|Completed||Phase 2|44|Actual|Novartis|||||f||||||||||||||2018-06-01 05:32:41.792615|2018-06-01 05:32:41.792615
NCT00036400|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-09|||2011-06-08|2002-05-09|2002-05-10|Estimate|||||||2011-06-08|2011-06-10|Estimate|December 2001||2001-12-31|April 2010|2010-04-30|December 2003|Actual|2003-12-31|||||Interventional|||Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery|A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery|Completed||Phase 3|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:32:41.862598|2018-06-01 05:32:41.862598
NCT00036387|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-09|||2011-05-18|2002-05-09|2002-05-10|Estimate|||||||2011-05-18|2011-05-19|Estimate||||May 2010|2010-05-31|November 2003|Actual|2003-11-30|||||Interventional|||A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Rheumatoid Arthritis.|A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug Background Therapy.|Completed||Phase 3|347|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:32:41.927684|2018-06-01 05:32:41.927684
NCT00036374|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-09|||2011-05-16|2002-05-09|2002-05-10|Estimate|||||||2011-05-16|2011-05-17|Estimate|October 2001||2001-10-31|April 2010|2010-04-30|December 2006|Actual|2006-12-31|||||Interventional|||A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis|A Randomized, Double-Blind Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate for the Treatment of Patients With Polyarticular Juvenile Rheumatoid Arthritis|Completed||Phase 3|123|Actual|Centocor, Inc.|||||||||||||||||||2018-06-01 05:32:41.99734|2018-06-01 05:32:41.99734
NCT00036361|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2013-11-07|2002-05-09|2002-05-10|Estimate|||||||2013-11-07|2013-11-11|Estimate|July 2002||2002-07-31|September 2007|2007-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Broad Effectiveness: Study With Aripiprazole|Broad Effectiveness: Study With Aripiprazole|Completed||Phase 3|444||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:32:42.060441|2018-06-01 05:32:42.060441
NCT00036348|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2013-11-07|2002-05-09|2002-05-10|Estimate|||||||2013-11-07|2013-11-11|Estimate|March 2000||2000-03-31|September 2007|2007-09-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Study of Aripiprazole in Patients With a History of Bipolar Disorder||Completed||Phase 3|||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:32:42.125109|2018-06-01 05:32:42.125109
NCT00036335|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2006-07-18|2002-05-09|2002-05-10|Estimate|||||||2006-07-18|2006-07-19|Estimate|March 2002||2002-03-31|July 2006|2006-07-31|January 2003||2003-01-31|||||Interventional|||Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain|Duloxetine Hydrochloride (LY248686) Protocol F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain|Completed||Phase 3|286||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:32:42.202035|2018-06-01 05:32:42.202035
NCT00036309|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2006-07-18|2002-05-08|2002-05-09|Estimate|||||||2006-07-18|2006-07-19|Estimate|May 2002||2002-05-31|July 2006|2006-07-31|July 2003||2003-07-31|||||Interventional|||Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder|Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder|Completed||Phase 3|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:32:42.286803|2018-06-01 05:32:42.286803
NCT00036296|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2011-04-11|2002-05-08|2002-05-09|Estimate|||||||2011-04-11|2011-04-13|Estimate|December 2006||2006-12-31|October 2009|2009-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Effects of Talampanel on Patients With Advanced Parkinson's Disease|Effects of Talampanel on Patients With Advanced Parkinson's Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia (Abnormal Involuntary Movements)|Completed||Phase 1/Phase 2|22|Actual|Teva Pharmaceutical Industries||2|||f||||||||||||||2018-06-01 05:32:42.334423|2018-06-01 05:32:42.334423
NCT00036283|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2008-09-25|2002-05-08|2002-05-09|Estimate|||||||2008-09-25|2008-09-29|Estimate|November 2000||2000-11-30|September 2008|2008-09-30|April 2004|Actual|2004-04-30|||||Interventional|||Chemoprevention of Oral Premalignant Lesions|Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND|Completed||Phase 2|42||Pfizer|||||f||||||||||||||2018-06-01 05:32:42.399375|2018-06-01 05:32:42.399375
NCT00036270|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|2009-10-30||2015-10-06|2002-05-08|2002-05-09|Estimate|2009-11-02|2009-12-04|Estimate||||2015-10-06|2015-10-28|Estimate|August 2001||2001-08-31|October 2015|2015-10-31|February 2011|Actual|2011-02-28|October 2008|Actual|2008-10-31||Interventional|TEAM||Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane|Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients|Completed||Phase 3|9779|Actual|Pfizer|Overall Survival was reported as number of events which otherwise reported as time.|2|||f||||t||||||||||2018-06-01 05:32:42.566236|2018-06-01 05:32:42.566236
NCT00036257|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2011-10-14|2002-05-08|2002-05-09|Estimate|||||||2011-10-14|2011-10-17|Estimate|March 2002||2002-03-31|October 2011|2011-10-31|April 2003|Actual|2003-04-30|||||Interventional|||Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia||Completed||Phase 1|15||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:32:46.446535|2018-06-01 05:32:46.446535
NCT00036231|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2005-11-17|2002-05-08|2002-05-09|Estimate|||||||2005-11-17|2005-11-21|Estimate|April 2002||2002-04-30|August 2005|2005-08-31||||||||Interventional|||Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction|Terminated||Phase 3|||Repligen Corporation|||||||||||||||||||2018-06-01 05:32:46.672206|2018-06-01 05:32:46.672206
NCT00036218|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2006-06-06|2002-05-08|2002-05-09|Estimate|||||||2006-06-06|2006-06-07|Estimate|December 2001||2001-12-31|June 2006|2006-06-30|April 2003||2003-04-30|||||Interventional|||Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.|A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.|Completed||Phase 3|600||Pfizer|||||||||||||||||||2018-06-01 05:32:46.768864|2018-06-01 05:32:46.768864
NCT00036205|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2007-01-17|2002-05-08|2002-05-09|Estimate|||||||2007-01-17|2007-01-18|Estimate|August 2000||2000-08-31|January 2007|2007-01-31|December 2004||2004-12-31|||||Interventional|||Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease|Open-Label, Long Term, Flexible Dose Study Of Safety, Tolerability, And Therapeutic Response In Patients With Parkinson's Disease.|Terminated||Phase 3|984||Pfizer|||||||||||||||||||2018-06-01 05:32:47.028098|2018-06-01 05:32:47.028098
NCT00036192|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2011-12-08|2002-05-08|2002-05-09|Estimate|||||||2011-12-08|2011-12-09|Estimate|February 2002||2002-02-28|December 2011|2011-12-31|March 2006|Actual|2006-03-31|||||Interventional|||Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea|A Randomized, Double-Blind, Placebo-Controlled Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea|Completed||Phase 2|200||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:32:47.29724|2018-06-01 05:32:47.29724
NCT00036179|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2018-01-08|2002-05-08|2002-05-09|Estimate|||||||2018-01-08|2018-01-10|Actual|February 27, 1999|Actual|1999-02-27|June 2015|2015-06-30|January 27, 2002|Actual|2002-01-27|January 27, 2002|Actual|2002-01-27||Interventional|||Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis|An Open-Label, Non-Comparative Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis|Completed||Phase 2|75|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 05:32:47.419399|2018-06-01 05:32:47.419399
NCT00036166|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2018-01-08|2002-05-08|2002-05-09|Estimate|||||||2018-01-08|2018-01-10|Actual|January 29, 1999|Actual|1999-01-29|June 2015|2015-06-30|January 31, 2002|Actual|2002-01-31|January 31, 2002|Actual|2002-01-31||Interventional|||Study of FK463 for the Treatment of Invasive Aspergillosis|An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis|Completed||Phase 2|326|Actual|Astellas Pharma Inc|||||f||||||||||||||2018-06-01 05:32:47.511882|2018-06-01 05:32:47.511882
NCT00036153|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2012-03-26|2002-05-08|2002-05-09|Estimate|||||||2012-03-26|2012-03-27|Estimate|March 2002||2002-03-31|December 2011|2011-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis|A Randomized, Double-Blind Study to Assess the Efficacy of Tacrolimus (Prograf®)+ Methotrexate Vs. Placebo + Methotrexate in the Treatment of Rheumatoid Arthritis in Patients With Partial Response to Methotrexate|Completed||Phase 3|210||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:32:47.613869|2018-06-01 05:32:47.613869
NCT00036140|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-08|||2005-06-23|2002-05-08|2002-05-09|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2004|2004-03-31||||||||Interventional|||Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma||Completed||Phase 1|||Pfizer|||||||||||||||||||2018-06-01 05:32:47.915299|2018-06-01 05:32:47.915299
NCT00036127|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2013-11-07|2002-05-08|2002-05-09|Estimate|||||||2013-11-07|2013-11-11|Estimate|April 2002||2002-04-30|September 2007|2007-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders||Completed||Phase 2/Phase 3|||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:32:47.979211|2018-06-01 05:32:47.979211
NCT00036114|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2013-11-07|2002-05-08|2002-05-09|Estimate|||||||2013-11-07|2013-11-11|Estimate|March 2000||2000-03-31|April 2011|2011-04-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type||Completed||Phase 3|||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:32:48.095758|2018-06-01 05:32:48.095758
NCT00036101|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2013-11-07|2002-05-08|2002-05-09|Estimate|||||||2013-11-07|2013-11-11|Estimate|February 2002||2002-02-28|September 2007|2007-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder||Completed||Phase 3|||Otsuka Pharmaceutical Development & Commercialization, Inc.|||||||||||||||||||2018-06-01 05:32:48.228362|2018-06-01 05:32:48.228362
NCT00036088|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2006-07-18|2002-05-07|2002-05-08|Estimate|||||||2006-07-18|2006-07-19|Estimate|August 2001||2001-08-31|July 2006|2006-07-31|July 2002||2002-07-31|||||Interventional|||Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia||Completed||Phase 4|530||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:32:48.409486|2018-06-01 05:32:48.409486
NCT00036075|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2011-10-14|2002-05-07|2002-05-08|Estimate|||||||2011-10-14|2011-10-17|Estimate|August 2001||2001-08-31|October 2011|2011-10-31|December 2005|Actual|2005-12-31|||||Interventional|||Study Using CP-461 to Treat Advanced Prostate Cancer||Completed||Phase 2|25||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:32:48.546028|2018-06-01 05:32:48.546028
NCT00036062|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2006-07-18|2002-05-07|2002-05-08|Estimate|||||||2006-07-18|2006-07-19|Estimate|August 2001||2001-08-31|July 2006|2006-07-31|December 2002||2002-12-31|||||Interventional|||A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury|A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury|Completed||Phase 1/Phase 2|600||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:32:48.634949|2018-06-01 05:32:48.634949
NCT00036036|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2011-10-14|2002-05-07|2002-05-08|Estimate|||||||2011-10-14|2011-10-17|Estimate|July 2001||2001-07-31|October 2011|2011-10-31|July 2003|Actual|2003-07-31|||||Interventional|||Study of CP-461 in Patients With Advanced Renal Cell Cancer|Phase II Study of CP-461 in Patients With Advanced Renal Cell Cancer|Completed||Phase 2|14||Astellas Pharma Inc|||||||||||||||||||2018-06-01 05:32:48.829165|2018-06-01 05:32:48.829165
NCT00036023|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2009-05-07|2002-05-07|2002-05-08|Estimate|||||||2009-05-07|2009-05-11|Estimate||||May 2009|2009-05-31||||||||Interventional|||Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies|A Randomized, Open-Label, Dose-Timing Study of Darbepoetin Alfa Administered Once Every 3 Weeks (Q3W) by Subcutaneous (SC) Injection for Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy|Completed||Phase 2|||Amgen|||||||||||||||||||2018-06-01 05:32:48.886458|2018-06-01 05:32:48.886458
NCT00035568|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03||2010-02-15|2011-04-07|2002-05-03|2002-05-06|Estimate||||2010-02-15|2010-02-17|Estimate|2011-04-07|2011-04-15|Estimate|February 2002||2002-02-28|April 2011|2011-04-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes||Completed||Phase 4|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:32:54.19753|2018-06-01 05:32:54.19753
NCT00035997|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2009-11-20|2002-05-07|2002-05-08|Estimate|||||||2009-11-20|2009-11-23|Estimate|April 2002||2002-04-30|November 2009|2009-11-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis|An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis|Completed||Phase 4|261|Actual|Novartis|||||||||||||||||||2018-06-01 05:32:48.95987|2018-06-01 05:32:48.95987
NCT00035984|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2015-02-23|2002-05-07|2002-05-08|Estimate|||||||2015-02-23|2015-02-24|Estimate|May 2002||2002-05-31|January 2015|2015-01-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus|A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea|Completed||Phase 3|734|Actual|AstraZeneca||4|||f||||f||||||||||2018-06-01 05:32:49.074881|2018-06-01 05:32:49.074881
NCT00035971|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2006-07-18|2002-05-07|2002-05-08|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||EVA: Evista Alendronate Comparison||Completed||Phase 4|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:32:49.432411|2018-06-01 05:32:49.432411
NCT00035958|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-07|||2013-07-31|2002-05-07|2002-05-08|Estimate|||||||2013-07-31|2013-08-01|Estimate|August 2002||2002-08-31|July 2013|2013-07-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis|Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis|Terminated||Phase 2/Phase 3|75||Children's Hospital Medical Center, Cincinnati||||"Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make the~   project budget over the limit for this funding mechanism."|||||||||||||||2018-06-01 05:32:49.657909|2018-06-01 05:32:49.657909
NCT00035945|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2007-10-15|2002-05-07|2002-05-08|Estimate|||||||2007-10-15|2007-10-17|Estimate||||October 2007|2007-10-31||||||||Interventional|||ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections||Completed||Phase 2|||Ionis Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:32:49.750734|2018-06-01 05:32:49.750734
NCT00035932|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|2010-10-14||2010-11-29|2002-05-07|2002-05-08|Estimate|2010-11-29|2010-12-24|Estimate||||2010-11-29|2010-12-24|Estimate|November 2001||2001-11-30|November 2010|2010-11-30|March 2009|Actual|2009-03-31|July 2003|Actual|2003-07-31||Interventional|||Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV|Phase III Open Label Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV|Completed||Phase 3|571|Actual|Bristol-Myers Squibb||3|||t||||f||||||||||2018-06-01 05:32:49.898157|2018-06-01 05:32:49.898157
NCT00035919|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2014-05-20|2002-05-06|2002-05-07|Estimate|||||||2014-05-20|2014-05-22|Estimate|November 2002||2002-11-30|May 2014|2014-05-31|October 2003||2003-10-31|||||Interventional|||Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver|Tumor Site Specific Phase I Evaluation of Safety of Hepatic Arterial Infusion of a Matrix-Targeted Retroviral Vector Bearing a Dominant Negative Cyclin G1 Construct as Intervention for Colorectal Carcinoma Metastatic to Liver|Withdrawn||Phase 1/Phase 2|0|Actual|University of Southern California||||Never received final IRB approval for amendments, so never opened officially|f||||||||||||||2018-06-01 05:32:51.956801|2018-06-01 05:32:51.956801
NCT00035906|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2011-05-27|2002-05-06|2002-05-07|Estimate|||||||2011-05-27|2011-05-30|Estimate|October 2001||2001-10-31|May 2011|2011-05-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Research Study in Patients With Persistent Macular Edema|Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome|Completed||Phase 2|315|Actual|Allergan|||||f||||||||||||||2018-06-01 05:32:52.014345|2018-06-01 05:32:52.014345
NCT00035893|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2013-04-16|2002-05-06|2002-05-07|Estimate|||||||2013-04-16|2013-04-17|Estimate|May 2001||2001-05-31|April 2013|2013-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART|The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval.|Completed||Phase 2|40|Actual|Hemispherx Biopharma||2|||f||||f||||||||||2018-06-01 05:32:52.063162|2018-06-01 05:32:52.063162
NCT00035880|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2005-06-23|2002-05-06|2002-05-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|July 2003|2003-07-31|June 2003||2003-06-30|||||Interventional|||Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease|A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease|Completed||Phase 2/Phase 3|95||Abgenix|||||||||||||||||||2018-06-01 05:32:52.203647|2018-06-01 05:32:52.203647
NCT00035867|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2008-05-30|2002-05-06|2002-05-07|Estimate|||||||2008-05-30|2008-06-03|Estimate|April 2002||2002-04-30|June 2005|2005-06-30|May 2007|Actual|2007-05-31|||||Interventional|||Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome|Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome|Completed||Phase 1/Phase 2|65||Telik|||||||||||||||||||2018-06-01 05:32:52.267388|2018-06-01 05:32:52.267388
NCT00035854|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2009-08-13|2002-05-06|2002-05-07|Estimate|||||||2009-08-13|2009-08-14|Estimate|February 2002||2002-02-28|August 2009|2009-08-31|May 2004|Actual|2004-05-31|||||Interventional|||New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)|Linezolid IV/PO for the Treatment of Vancomycin-Resistant Enterococcus Infections in Children|Completed||Phase 3|13|Actual|Pfizer|||||||||||||||||||2018-06-01 05:32:52.335668|2018-06-01 05:32:52.335668
NCT00035841|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2011-07-21|2002-05-06|2002-05-07|Estimate|||||||2011-07-21|2011-07-25|Estimate|April 2002||2002-04-30|June 2011|2011-06-30|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Phase 2 Study of TLK286 in Metastatic Breast Cancer|Phase 2 Study of TLK286 in Metastatic Breast Cancer|Completed||Phase 2|60||Telik|||||f||||||||||||||2018-06-01 05:32:52.42819|2018-06-01 05:32:52.42819
NCT00035828|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2005-06-23|2002-05-06|2002-05-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2001||2001-12-31|July 2003|2003-07-31|December 2002||2002-12-31|||||Interventional|||A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD||Completed||Phase 2|150||Abgenix|||||||||||||||||||2018-06-01 05:32:52.479531|2018-06-01 05:32:52.479531
NCT00035815|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|2009-11-17||2013-02-13|2002-05-06|2002-05-07|Estimate|2013-02-13|2013-02-15|Estimate||||2013-02-13|2013-02-15|Estimate|June 2003||2003-06-30|February 2013|2013-02-28|December 2007|Actual|2007-12-31|August 2007|Actual|2007-08-31||Interventional|||Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial|Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 3|330|Actual|Mayo Clinic||2|||f||||t||||||||||2018-06-01 05:32:52.573845|2018-06-01 05:32:52.573845
NCT00035802|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-06|||2011-06-23|2002-05-06|2002-05-07|Estimate|||||||2011-06-23|2011-06-27|Estimate|January 2002||2002-01-31|June 2011|2011-06-30|April 2002|Actual|2002-04-30|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 4-Week Study of the Safety and Efficacy of Topiramate in Adolescents With Acute Manic or Mixed Episodes of Bipolar I Disorder, With an Optional 6-Month Open-Label Extension|Completed||Phase 3|13|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||||||||||||2018-06-01 05:32:52.898531|2018-06-01 05:32:52.898531
NCT00035789|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-05||2010-01-28|2011-04-07|2002-05-05|2002-05-06|Estimate||||2010-01-28|2010-02-01|Estimate|2011-04-07|2011-04-14|Estimate|November 2001||2001-11-30|January 2010|2010-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen||Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:32:52.979423|2018-06-01 05:32:52.979423
NCT00035776|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2016-03-15|2002-05-04|2002-05-06|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2001||2001-01-31|January 2006|2006-01-31|December 2005|Actual|2005-12-31|||||Observational|||Blood Factors and Peripheral Arterial Disease Outcomes||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:53.07325|2018-06-01 05:32:53.07325
NCT00035763|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2016-03-23|2002-05-04|2002-05-06|Estimate|||||||2016-03-23|2016-03-24|Estimate|October 2001||2001-10-31|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Pain in Sickle Cell Epidemiologic Study|Pain in Sickle Cell Epidemiologic Study|Completed|||||Virginia Commonwealth University|||||f||||||||||||||2018-06-01 05:32:53.128732|2018-06-01 05:32:53.128732
NCT00035750|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2016-01-28|2002-05-04|2002-05-06|Estimate|||||||2016-01-28|2016-02-01|Estimate|September 2001||2001-09-30|January 2016|2016-01-31|August 2005||2005-08-31|||||Observational|||Risk Factors for Atherogenesis in Type 1 Diabetes||Completed|||||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:32:53.172003|2018-06-01 05:32:53.172003
NCT00035737|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2014-02-20|2002-05-04|2002-05-06|Estimate|||||||2014-02-20|2014-02-21|Estimate|May 2002||2002-05-31|February 2014|2014-02-28|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Vascular Function in the Framingham Third Generation||Completed|||||Boston University|||||f||||||||||||||2018-06-01 05:32:53.215329|2018-06-01 05:32:53.215329
NCT00035724|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2016-07-28|2002-05-04|2002-05-06|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2002||2002-04-30|May 2009|2009-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Monitoring Community Trends in Heart Failure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:53.257868|2018-06-01 05:32:53.257868
NCT00035711|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2016-03-15|2002-05-04|2002-05-06|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2001||2001-09-30|November 2005|2005-11-30|August 2004|Actual|2004-08-31|||||Observational|||VA HDL Intervention Trial (VA-HIT) Ancillary Study Data Analysis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:53.299554|2018-06-01 05:32:53.299554
NCT00035698|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2017-03-16|2002-05-04|2002-05-06|Estimate|||||||2017-03-16|2017-03-17|Actual|December 2001||2001-12-31|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Epidemiological and Genetic Studies of Body Mass Index|Epidemiological and Genetic Studies of Body Mass Index|Completed|||1027|Actual|Boston University|||||f||||f|f|f||||None Retained|"~     This study ended years ago, I do not know why I am being asked to update it as a clinical~     trial. It was never a clinical trial.~   "|No||2018-06-01 05:32:53.343027|2018-06-01 05:32:53.343027
NCT00035685|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2016-02-17|2002-05-04|2002-05-06|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 2001||2001-12-31|January 2008|2008-01-31|November 2006|Actual|2006-11-30|||||Observational|||Exposure of Children With Asthma to Household Environmental Tobacco Smoke||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:32:53.403092|2018-06-01 05:32:53.403092
NCT00035672|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2017-11-16|2002-05-04|2002-05-06|Estimate|||||||2017-11-16|2017-11-20|Actual|March 2002||2002-03-31|November 2017|2017-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Genetic Predictors of Incident Cardiovascular Disease||Withdrawn|||0|Actual|University of Michigan|||||f||||||||||||||2018-06-01 05:32:53.48964|2018-06-01 05:32:53.48964
NCT00035659|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04|||2015-10-26|2002-05-04|2002-05-06|Estimate|||||||2015-10-26|2015-10-27|Estimate|April 2002||2002-04-30|October 2015|2015-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Longitudinal Study of the Menopause and Fat Patterning||Completed|||868|Actual|Rush University Medical Center|||||f||||||||||||||2018-06-01 05:32:53.53507|2018-06-01 05:32:53.53507
NCT00035633|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-04||2010-01-28|2011-04-07|2002-05-05|2002-05-06|Estimate||||2010-01-28|2010-02-01|Estimate|2011-04-07|2011-04-14|Estimate|December 2001||2001-12-31|January 2010|2010-01-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen||Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:32:53.593022|2018-06-01 05:32:53.593022
NCT00035620|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2010-02-25|2002-05-03|2002-05-06|Estimate|||||||2010-02-25|2010-02-26|Estimate|April 2000||2000-04-30|February 2010|2010-02-28|April 2007|Actual|2007-04-30|January 2007|Actual|2007-01-31||Interventional|||Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy|A Study of Single Dose Per Cycle Filgrastim-SD/01 as an Adjunct to VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients|Completed||Phase 2|44|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:32:53.690649|2018-06-01 05:32:53.690649
NCT00035607|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2013-05-09|2002-05-03|2002-05-06|Estimate|||||||2013-05-09|2013-05-13|Estimate|December 2001||2001-12-31|May 2013|2013-05-31|April 2003|Actual|2003-04-30|December 2002|Actual|2002-12-31||Interventional|||Chemotherapy Related Anemia|A Randomized, Open-label, Multicenter Study of Subcutaneous and Intravenous Administration of Darbepoetin Alfa (Novel Erythropoiesis Stimulating Protein, NESP) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy|Completed||Phase 2|120|Actual|Amgen||2|||f||||||||||||||2018-06-01 05:32:53.754954|2018-06-01 05:32:53.754954
NCT00035594|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2013-05-07|2002-05-03|2002-05-06|Estimate|||||||2013-05-07|2013-05-09|Estimate|February 2002||2002-02-28|May 2013|2013-05-31|June 2004|Actual|2004-06-30|February 2004|Actual|2004-02-29||Interventional|||Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy|A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects With Advanced Breast Cancer Treated With Single Agent Docetaxel|Completed||Phase 3|928||Amgen||2|||f||||||||||||||2018-06-01 05:32:54.030909|2018-06-01 05:32:54.030909
NCT00035581|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2013-04-16|2002-05-03|2002-05-06|Estimate|||||||2013-04-16|2013-04-17|Estimate|May 2001||2001-05-31|April 2013|2013-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART|A Multi-Center, Randomized, Controlled Study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease|Terminated||Phase 2|16|Actual|Hemispherx Biopharma||2|||f||||f||||||||||2018-06-01 05:32:54.111347|2018-06-01 05:32:54.111347
NCT00035555|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|2013-09-04||2013-11-27|2002-05-03|2002-05-06|Estimate|2013-11-27|2014-01-13|Estimate||||2013-11-27|2014-01-13|Estimate|March 2001||2001-03-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|January 2004|Actual|2004-01-31||Interventional||Baseline characteristics are provided for all patients who were randomized and received transplants; participant flow is provided for all randomized participants who received treatment.|Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney|Phase II/III, Open-Label, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 (Belatacept) as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients|Completed||Phase 2|230|Actual|Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:32:54.345877|2018-06-01 05:32:54.345877
NCT00035542|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03||2010-02-15|2011-04-07|2002-05-03|2002-05-06|Estimate||||2010-02-15|2010-02-17|Estimate|2011-04-07|2011-04-15|Estimate|December 2001||2001-12-31|April 2011|2011-04-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.||Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:32:56.720488|2018-06-01 05:32:56.720488
NCT00035529|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03||2010-09-03|2010-12-02|2002-05-03|2002-05-06|Estimate||||2010-09-03|2010-09-08|Estimate|2010-12-02|2010-12-06|Estimate|November 2001||2001-11-30|December 2010|2010-12-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis|A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis|Terminated||Phase 2|||Bristol-Myers Squibb||3|||f||||||||||||||2018-06-01 05:32:56.896036|2018-06-01 05:32:56.896036
NCT00035516|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2016-02-09|2002-05-03|2002-05-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2001||2001-02-28|February 2016|2016-02-29|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy||Completed||Phase 2|||R-Pharm|||||||||||||||||||2018-06-01 05:32:57.475959|2018-06-01 05:32:57.475959
NCT00035503|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2013-02-20|2002-05-03|2002-05-06|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2002||2002-01-31|February 2013|2013-02-28|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Multicenter Trial For Patients With Acute Crohn's Disease||Completed||Phase 2|||Teva Pharmaceutical Industries|||||f||||||||||||||2018-06-01 05:32:57.564153|2018-06-01 05:32:57.564153
NCT00035490|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2011-09-30|2002-05-03|2002-05-06|Estimate|||||||2011-09-30|2011-10-03|Estimate|September 2001||2001-09-30|September 2011|2011-09-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators|Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators|Completed||Phase 3|633|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 05:32:57.736754|2018-06-01 05:32:57.736754
NCT00035477|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2011-09-30|2002-05-03|2002-05-06|Estimate|||||||2011-09-30|2011-10-03|Estimate|September 2000||2000-09-30|September 2011|2011-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation|Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation|Completed||Phase 3|446|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 05:32:58.96046|2018-06-01 05:32:58.96046
NCT00035464|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2011-09-30|2002-05-03|2002-05-06|Estimate|||||||2011-09-30|2011-10-03|Estimate|December 2000||2000-12-31|September 2011|2011-09-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.|Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients|Completed||Phase 3|431|Actual|Forest Laboratories||2|||f||||f||||||||||2018-06-01 05:32:59.238015|2018-06-01 05:32:59.238015
NCT00035451|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2011-09-30|2002-05-03|2002-05-06|Estimate|||||||2011-09-30|2011-10-03|Estimate|February 2001||2001-02-28|September 2011|2011-09-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.|Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.|Completed||Phase 3|658|Actual|Forest Laboratories||3|||f||||f||||||||||2018-06-01 05:32:59.60063|2018-06-01 05:32:59.60063
NCT00035438|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2006-08-03|2002-05-03|2002-05-06|Estimate|||||||2006-08-03|2006-08-04|Estimate|May 2002||2002-05-31|August 2006|2006-08-31|September 2003||2003-09-30|||||Interventional|||St. John’s Wort Vs. Placebo in Obsessive-Compulsive Disorder.|St. John’s Wort Vs. Placebo in Obsessive-Compulsive Disorder.|Completed||Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:32:59.955423|2018-06-01 05:32:59.955423
NCT00035425|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2009-11-30|2002-05-03|2002-05-06|Estimate|||||||2009-11-30|2009-12-01|Estimate|November 2001||2001-11-30|November 2009|2009-11-30|November 2002|Actual|2002-11-30|||||Interventional|||Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection|A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections|Completed||Phase 3|120|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 05:33:00.051309|2018-06-01 05:33:00.051309
NCT00035412|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2006-08-17|2002-05-03|2002-05-06|Estimate|||||||2006-08-17|2006-08-18|Estimate|December 2001||2001-12-31|July 2006|2006-07-31|August 2004||2004-08-31|||||Interventional|||St. John's Wort Versus Placebo in Social Phobia|St. John's Wort Versus Placebo in Social Phobia|Completed||Phase 2|40||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:00.30385|2018-06-01 05:33:00.30385
NCT00035399|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-03|||2008-08-11|2002-05-03|2002-05-06|Estimate|||||||2008-08-11|2008-08-12|Estimate|March 2002||2002-03-31|August 2008|2008-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Efficacy of Acupuncture With Physical Therapy for Knee Osteo-Arthritis|Efficacy of Acupuncture With Physical Therapy for Knee Osteo-Arthritis|Completed||Phase 3|300|Anticipated|National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:33:00.368588|2018-06-01 05:33:00.368588
NCT00035360|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-03-07|2002-05-03|2002-05-06|Estimate|||||||2017-03-07|2017-03-10|Actual|March 2002||2002-03-31|March 2017|2017-03-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Phase III PEG-Intron in HIV-infected Patients (Study P00738)|Phase 3 Study of PEG-Intron in Heavily Treatment-experienced, HIV-infected Patients|Completed||Phase 3|49|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:33:00.430865|2018-06-01 05:33:00.430865
NCT00035191|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-06-06|2002-05-02|2002-05-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|October 2001||2001-10-31|November 2010|2010-11-30|September 2003|Actual|2003-09-30|||||Interventional|||A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia|A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia|Completed||Phase 3|254|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:33:02.088126|2018-06-01 05:33:02.088126
NCT00035347|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-03-07|2002-05-03|2002-05-06|Estimate|||||||2017-03-07|2017-03-10|Actual|January 2001||2001-01-31|March 2017|2017-03-31|June 2002|Actual|2002-06-30|||||Interventional|||Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia|A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia|Completed||Phase 4|219|Actual|Pfizer||2|||f||||f||||||||||2018-06-01 05:33:00.504205|2018-06-01 05:33:00.504205
NCT00035386|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2008-03-03|2002-05-02|2002-05-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2002||2002-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study|Trans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility Study|Completed||Phase 2|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:00.684185|2018-06-01 05:33:00.684185
NCT00035373|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2018-05-15|2002-05-02|2002-05-03|Estimate|||||||2018-05-15|2018-05-16|Actual|April 19, 2002||2002-04-19|April 29, 2015|2015-04-29|April 29, 2015||2015-04-29|||||Observational|||Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols|Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute (NCI) Clinical Research Protocols|Terminated|||767|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:00.784186|2018-06-01 05:33:00.784186
NCT00035334|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-02-13|2002-05-02|2002-05-03|Estimate|||||||2006-02-13|2006-02-14|Estimate|October 2001||2001-10-31|February 2006|2006-02-28|December 2004||2004-12-31|||||Interventional|||Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis|A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis|Completed||Phase 2/Phase 3|150||Bellus Health Inc|||||||||||||||||||2018-06-01 05:33:00.953357|2018-06-01 05:33:00.953357
NCT00035321|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-07-21|2002-05-02|2002-05-03|Estimate|||||||2006-07-21|2006-07-24|Estimate|April 2002||2002-04-30|July 2006|2006-07-31|July 2005||2005-07-31|||||Interventional|||The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression|The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features|Completed||Phase 3|600||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:01.077443|2018-06-01 05:33:01.077443
NCT00035308|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-09-22|2002-05-02|2002-05-03|Estimate|||||||2006-09-22|2006-09-25|Estimate||||December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease|Completed||Phase 3|330||La Jolla Pharmaceutical Company|||||||||||||||||||2018-06-01 05:33:01.240156|2018-06-01 05:33:01.240156
NCT00035295|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-04-17|2002-05-02|2002-05-03|Estimate|||||||2017-04-17|2017-04-18|Actual|November 8, 2001|Actual|2001-11-08|April 2017|2017-04-30|December 5, 2003|Actual|2003-12-05|December 5, 2003|Actual|2003-12-05||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)|A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder|Completed||Phase 3|584|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:33:01.36663|2018-06-01 05:33:01.36663
NCT00035282|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2015-02-06|2002-05-02|2002-05-03|Estimate|||||||2015-02-06|2015-02-09|Estimate|September 2001||2001-09-30|February 2015|2015-02-28|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)|A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder|Completed||Phase 3|450|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:33:01.526993|2018-06-01 05:33:01.526993
NCT00035269|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-04-25|2002-05-02|2002-05-03|Estimate|||||||2011-04-25|2011-04-26|Estimate|December 2001||2001-12-31|April 2011|2011-04-30|May 2003|Actual|2003-05-31|||||Interventional|||New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)|Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study|Completed||Phase 3|230|Actual|Pfizer|||||||||||||||||||2018-06-01 05:33:01.595739|2018-06-01 05:33:01.595739
NCT00035256|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2007-05-11|2002-05-02|2002-05-03|Estimate|||||||2007-05-11|2007-05-15|Estimate|October 2001||2001-10-31|May 2007|2007-05-31|July 2005|Actual|2005-07-31|||||Interventional|||Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis|Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 4|330||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:01.743573|2018-06-01 05:33:01.743573
NCT00035243|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2012-04-16|2002-05-02|2002-05-03|Estimate|||||||2012-04-16|2012-04-17|Estimate|April 2002||2002-04-30|April 2012|2012-04-30||||August 2003|Actual|2003-08-31||Interventional|||EPO906 Therapy in Patients With Advanced Kidney Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Renal Cancer|Completed||Phase 2|53|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:33:01.813438|2018-06-01 05:33:01.813438
NCT00035230|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-06-06|2002-05-02|2002-05-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|July 2001||2001-07-31|January 2011|2011-01-31|November 2002|Actual|2002-11-30|||||Interventional|||A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder|A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Topiramate in Patients With Acute Manic or Mixed Episodes of Bipolar I Disorder With an Optional Open-Label Extension|Completed||Phase 3|338|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:33:01.895143|2018-06-01 05:33:01.895143
NCT00035217|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2005-06-23|2002-05-02|2002-05-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program|Follow-Up Study for Men Diagnoses With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:01.964922|2018-06-01 05:33:01.964922
NCT00035204|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-06-06|2002-05-02|2002-05-03|Estimate|||||||2011-06-06|2011-06-08|Estimate||||April 2010|2010-04-30|May 2003|Actual|2003-05-31|||||Interventional|||A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease|A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)|Completed||Phase 4|63|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:33:02.028328|2018-06-01 05:33:02.028328
NCT00035178|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2005-06-23|2002-05-02|2002-05-03|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2002||2002-05-31|December 2003|2003-12-31|November 2002||2002-11-30|||||Interventional|||Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis|Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis|Completed||Phase 4|12||Encysive Pharmaceuticals|||||||||||||||||||2018-06-01 05:33:02.153463|2018-06-01 05:33:02.153463
NCT00035165|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2012-04-24|2002-05-02|2002-05-03|Estimate|||||||2012-04-24|2012-04-25|Estimate|March 2002||2002-03-31|April 2012|2012-04-30||||May 2003|Actual|2003-05-31||Interventional|||EPO906 Therapy in Patients With Advanced Melanoma|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Melanoma|Completed||Phase 2|51|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:33:02.211268|2018-06-01 05:33:02.211268
NCT00035152|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2016-09-16|2002-05-02|2002-05-03|Estimate|||||||2016-09-16|2016-09-19|Estimate|June 2000||2000-06-30|September 2016|2016-09-30|December 2004||2004-12-31|||||Interventional|||Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer|A Multicenter, Randomized Trial for Stage IIIB or IV NSCLC Comparing Weekly Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen Versus Standard Taxol and Carboplatin Administered Every Three Weeks, Followed by Weekly Taxol.|Completed||Phase 3|444||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:33:02.310118|2018-06-01 05:33:02.310118
NCT00035139|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2005-06-23|2002-05-02|2002-05-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery|Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery|Completed||Phase 4|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:02.425558|2018-06-01 05:33:02.425558
NCT00035126|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-02-07|2002-05-02|2002-05-03|Estimate|||||||2017-02-07|2017-02-08|Estimate|January 2002|Actual|2002-01-31|February 2017|2017-02-28|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||EPO906 Therapy in Patients With Advanced Breast Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Breast Cancer|Completed||Phase 2|46|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:33:02.483645|2018-06-01 05:33:02.483645
NCT00035113|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-02-07|2002-05-02|2002-05-03|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2002||2002-01-31|February 2017|2017-02-28|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||EPO906 Therapy in Patients With Prostate Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Androgen-independent Prostate Cancer|Completed||Phase 2|48|Actual|Novartis|||||f||||||||||||||2018-06-01 05:33:02.570861|2018-06-01 05:33:02.570861
NCT00035100|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2012-04-13|2002-05-02|2002-05-03|Estimate|||||||2012-04-13|2012-04-16|Estimate|September 2001||2001-09-30|April 2012|2012-04-30||||June 2003|Actual|2003-06-30||Interventional|||EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer|Completed||Phase 2|54|Actual|Novartis||1|||f||||||||||||||2018-06-01 05:33:02.646484|2018-06-01 05:33:02.646484
NCT00035087|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2013-12-03|2002-05-02|2002-05-03|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2002||2002-05-31|December 2013|2013-12-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||EPO906 Therapy in Patients With Advanced Colorectal Cancer|An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Colorectal Cancer|Completed||Phase 2|62|Actual|Novartis|||||f||||||||||||||2018-06-01 05:33:02.734237|2018-06-01 05:33:02.734237
NCT00035074|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2005-06-23|2002-05-02|2002-05-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease|A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease|Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:02.816368|2018-06-01 05:33:02.816368
NCT00035061|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-07-18|2002-05-02|2002-05-03|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium||Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:02.867595|2018-06-01 05:33:02.867595
NCT00035048|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-05-02|2002-05-02|2002-05-03|Estimate|||||||2017-05-02|2017-05-05|Actual|November 21, 2001|Actual|2001-11-21|May 2017|2017-05-31|December 31, 2003|Actual|2003-12-31|December 29, 2003|Actual|2003-12-29||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)|A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients With Major Depressive Disorder|Completed||Phase 3|540|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:33:02.935521|2018-06-01 05:33:02.935521
NCT00035035|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-07-18|2002-05-02|2002-05-03|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.|A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.|Completed||Phase 3|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:03.00582|2018-06-01 05:33:03.00582
NCT00035022|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-01-12|2002-05-02|2002-05-03|Estimate|||||||2006-01-12|2006-01-13|Estimate|August 2001||2001-08-31|February 2005|2005-02-28|March 2004||2004-03-31|||||Interventional|||Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas|Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies|Completed||Phase 1/Phase 2|71||BioCryst Pharmaceuticals|||||||||||||||||||2018-06-01 05:33:03.283748|2018-06-01 05:33:03.283748
NCT00035009|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-04-17|2002-05-02|2002-05-03|Estimate|||||||2017-04-17|2017-04-18|Actual|September 20, 2001|Actual|2001-09-20|April 2017|2017-04-30|March 24, 2004|Actual|2004-03-24|December 22, 2003|Actual|2003-12-22||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)|A Double-Blind, Multicenter, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder With Melancholic Features|Completed||Phase 3|468|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:33:03.3528|2018-06-01 05:33:03.3528
NCT00034983|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-04-24|2002-05-02|2002-05-03|Estimate|||||||2017-04-24|2017-04-26|Actual|October 29, 2001|Actual|2001-10-29|April 2017|2017-04-30|December 29, 2003|Actual|2003-12-29|December 29, 2003|Actual|2003-12-29||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)|A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder|Completed||Phase 3|900|Actual|Merck Sharp & Dohme Corp.|||||f||||||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-06-01 05:33:03.418824|2018-06-01 05:33:03.418824
NCT00034944|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2017-05-02|2002-05-02|2002-05-03|Estimate|||||||2017-05-02|2017-05-05|Actual|January 24, 2002|Actual|2002-01-24|May 2017|2017-05-31|December 17, 2003|Actual|2003-12-17|December 17, 2003|Actual|2003-12-17||Interventional|||Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)|A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder|Completed||Phase 3|495|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:33:03.697823|2018-06-01 05:33:03.697823
NCT00034918|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2016-08-22|2002-05-02|2002-05-03|Estimate|||||||2016-08-22|2016-08-24|Estimate|May 2002||2002-05-31|August 2016|2016-08-31|November 2003|Actual|2003-11-30|||||Interventional|||This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer|An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).|Completed||Phase 2|44||Sanofi|||||||||||||||||||2018-06-01 05:33:03.769854|2018-06-01 05:33:03.769854
NCT00034905|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2013-01-03|2002-05-02|2002-05-03|Estimate|||||||2013-01-03|2013-01-04|Estimate|July 2001||2001-07-31|January 2013|2013-01-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||A Comparison of Seroquel vs. Risperidone in Schizophrenia||Completed||Phase 4|||AstraZeneca|||||||||||||||||||2018-06-01 05:33:03.840827|2018-06-01 05:33:03.840827
NCT00034892|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2013-01-03|2002-05-02|2002-05-03|Estimate|||||||2013-01-03|2013-01-04|Estimate|March 2002||2002-03-31|January 2013|2013-01-31|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Interventional|||CAFE Comparison of Atypicals in First Episode of Psychosis|Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison|Completed||Phase 3|||AstraZeneca|||||||||||||||||||2018-06-01 05:33:03.990256|2018-06-01 05:33:03.990256
NCT00034879|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2013-01-03|2002-05-02|2002-05-03|Estimate|||||||2013-01-03|2013-01-04|Estimate|August 2000||2000-08-31|January 2013|2013-01-31|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Iressa Expanded Access Program (EAP)|An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 3|||AstraZeneca|||||t||||f||||||||||2018-06-01 05:33:04.188626|2018-06-01 05:33:04.188626
NCT00034866|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2005-09-19|2002-05-02|2002-05-03|Estimate|||||||2005-09-19|2005-09-20|Estimate|April 2002||2002-04-30|September 2005|2005-09-30|October 2002||2002-10-31|||||Interventional|||Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals|Double-Blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-Experienced Subjects.|Completed||Phase 2|165||Boehringer Ingelheim|||||||||||||||||||2018-06-01 05:33:05.189213|2018-06-01 05:33:05.189213
NCT00034853|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2013-10-31|2002-05-02|2002-05-03|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2000||2000-12-31|October 2013|2013-10-31||||June 2003|Actual|2003-06-30||Interventional|||Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)|A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis|Completed||Phase 3|180|Anticipated|Boehringer Ingelheim|||||f||||||||||||||2018-06-01 05:33:05.314931|2018-06-01 05:33:05.314931
NCT00034840|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2013-10-31|2002-05-02|2002-05-03|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2001||2001-10-31|October 2013|2013-10-31|August 2002||2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose|A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDIS® (Telmisartan 80 mg p.o. Once Daily) and Diovan® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Hypertension After Missing One Dose|Completed||Phase 4|490||Boehringer Ingelheim|||||||||||||||||||2018-06-01 05:33:05.41217|2018-06-01 05:33:05.41217
NCT00034827|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2007-05-03|2002-05-02|2002-05-03|Estimate|||||||2007-05-03|2007-05-04|Estimate|January 2002||2002-01-31|July 2006|2006-07-31|May 2003|Actual|2003-05-31|||||Interventional|||A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer|A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer, or Pancreatic Cancer|Completed||Phase 2|172||Pfizer|||||f||||||||||||||2018-06-01 05:33:05.53296|2018-06-01 05:33:05.53296
NCT00034814|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-03-15|2002-05-02|2002-05-03|Estimate|||||||2011-03-15|2011-03-17|Estimate|January 2002||2002-01-31|March 2011|2011-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Multicenter Trial for Adults With Partial Seizures|Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients With Partial Seizures: A Phase II Clinical Trial.|Completed||Phase 2|190|Actual|Teva Pharmaceutical Industries||6|||f||||||||||||||2018-06-01 05:33:05.609477|2018-06-01 05:33:05.609477
NCT00034801|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2006-07-18|2002-05-02|2002-05-03|Estimate|||||||2006-07-18|2006-07-19|Estimate|September 2001||2001-09-30|July 2006|2006-07-31|March 2003||2003-03-31|||||Interventional|||Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia|A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression|Completed||Phase 4|378||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:05.676466|2018-06-01 05:33:05.676466
NCT00034788|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-06-06|2002-05-02|2002-05-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|December 2000||2000-12-31|March 2010|2010-03-31|February 2004|Actual|2004-02-29|||||Interventional|||A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX|A Multicenter Clinical Evaluation of the Efficacy and Safety of REGRANEX Gel in the Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers|Terminated||Phase 3|84|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||||Slow recruitment; Study did not address safety concern raised by European Medicines Agency|||||f||||||||||2018-06-01 05:33:06.66644|2018-06-01 05:33:06.66644
NCT00034775|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-01-07|2002-05-02|2002-05-03|Estimate|||||||2011-01-07|2011-01-10|Estimate|August 2001||2001-08-31|January 2011|2011-01-31|October 2002|Actual|2002-10-31|||||Interventional|||A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.|Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres|Completed||Phase 3|141|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:33:06.73851|2018-06-01 05:33:06.73851
NCT00034762|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-01-31|2002-05-02|2002-05-03|Estimate|||||||2011-01-31|2011-02-01|Estimate|December 2000||2000-12-31|January 2011|2011-01-31|January 2003|Actual|2003-01-31|||||Interventional|||Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease|Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.|Completed||Phase 3|473|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:33:06.799203|2018-06-01 05:33:06.799203
NCT00034749|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-06-06|2002-05-02|2002-05-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|April 2001||2001-04-30|March 2010|2010-03-31|March 2006|Actual|2006-03-31|||||Interventional|||The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia|The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone|Completed||Phase 3|279|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:33:06.86992|2018-06-01 05:33:06.86992
NCT00034736|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-02|||2011-06-06|2002-05-02|2002-05-03|Estimate|||||||2011-06-06|2011-06-08|Estimate|August 2002||2002-08-31|December 2010|2010-12-31|June 2004|Actual|2004-06-30|||||Interventional|||A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting|A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting|Completed||Phase 3|691|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|||||||||||||||||||2018-06-01 05:33:06.930462|2018-06-01 05:33:06.930462
NCT00034723|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2008-03-03|2002-05-01|2002-05-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2002||2002-04-30|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis|MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:06.999207|2018-06-01 05:33:06.999207
NCT00034710|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2006-02-06|2002-05-01|2002-05-02|Estimate|||||||2006-02-06|2006-02-07|Estimate|March 2002||2002-03-31|February 2006|2006-02-28|October 2002||2002-10-31|||||Interventional|||Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain|A Double-Blind Controlled Pilot Study of High-Dose Capsaicin Patches in the Treatment of Pain Associated With Postherpetic Neuralgia|Completed||Phase 2|42||NeurogesX|||||||||||||||||||2018-06-01 05:33:07.055269|2018-06-01 05:33:07.055269
NCT00034697|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2017-05-22|2002-05-01|2002-05-02|Estimate|||||||2017-05-22|2017-05-23|Actual|June 28, 2001|Actual|2001-06-28|May 2017|2017-05-31|January 30, 2003|Actual|2003-01-30|January 30, 2003|Actual|2003-01-30||Interventional|||Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)|A Phase II Study of Temozolomide (SCH 52365) in Subjects With Brain Metastasis From Non-Small-Cell Lung Cancer|Terminated||Phase 2|24|Actual|Merck Sharp & Dohme Corp.||||Slow Enrollment|||||||||||||||2018-06-01 05:33:07.128559|2018-06-01 05:33:07.128559
NCT00034684|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2015-06-16|2002-05-01|2002-05-02|Estimate|||||||2015-06-16|2015-06-17|Estimate|July 2001||2001-07-31|June 2015|2015-06-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)|Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia|Completed||Phase 1/Phase 2|132|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:33:07.181745|2018-06-01 05:33:07.181745
NCT00034671|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2015-12-30|2002-05-01|2002-05-02|Estimate|||||||2015-12-30|2015-12-31|Estimate|January 2001||2001-01-31|December 2015|2015-12-31|March 2002|Actual|2002-03-31|November 2001|Actual|2001-11-30||Interventional|||PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)|Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts|Completed||Phase 2|98|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:33:07.342945|2018-06-01 05:33:07.342945
NCT00034658|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2017-03-07|2002-05-01|2002-05-02|Estimate|||||||2017-03-07|2017-03-10|Actual|December 1998||1998-12-31|March 2017|2017-03-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)|Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections|Completed||Phase 3|336|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:33:07.415616|2018-06-01 05:33:07.415616
NCT00034645|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2017-03-07|2002-05-01|2002-05-02|Estimate|||||||2017-03-07|2017-03-10|Actual|January 1999||1999-01-31|March 2017|2017-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease||Completed||Phase 3|600|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:33:07.486773|2018-06-01 05:33:07.486773
NCT00034632|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2017-03-07|2002-05-01|2002-05-02|Estimate|||||||2017-03-07|2017-03-10|Actual|April 2001||2001-04-30|March 2017|2017-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)|Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections|Completed||Phase 3|||Merck Sharp & Dohme Corp.|||||f||||||||||||||2018-06-01 05:33:07.560868|2018-06-01 05:33:07.560868
NCT00034619|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2006-07-18|2002-05-01|2002-05-02|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.||Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:07.64826|2018-06-01 05:33:07.64826
NCT00034606|ClinicalTrials.gov processed this data on May 31, 2018|2002-05-01|||2006-07-18|2002-05-01|2002-05-02|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||Comparing 3 Schedules of Alimta Plus Gemzar||Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:07.765745|2018-06-01 05:33:07.765745
NCT00034593|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-30|||2006-07-18|2002-04-30|2002-05-01|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium||Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:07.828831|2018-06-01 05:33:07.828831
NCT00034580|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-30|||2006-07-18|2002-04-30|2002-05-01|Estimate|||||||2006-07-18|2006-07-19|Estimate|August 2001||2001-08-31|July 2006|2006-07-31|August 2002||2002-08-31|||||Interventional|||Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder|Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed|Completed||Phase 4|326||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:07.900422|2018-06-01 05:33:07.900422
NCT00034567|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-30|||2007-09-14|2002-04-30|2002-05-01|Estimate|||||||2007-09-14|2007-09-18|Estimate||||September 2007|2007-09-30||||||||Observational|||Healthy Aging and Memory Study|Alzheimer's Disease Prevention Instrument Protocol|Completed|||650||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:33:07.98831|2018-06-01 05:33:07.98831
NCT00034554|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-30|||2010-04-08|2002-04-30|2002-05-01|Estimate|||||||2010-04-08|2010-04-09|Estimate|March 2002||2002-03-31|December 2009|2009-12-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Study of gp75 Vaccine in Patients With Stage III and IV Melanoma|Phase I Study of gp75 DNA Vaccine in Patients With AJCC Stage III and IV Melanoma|Completed||Phase 1|31|Actual|ImClone LLC||5|||f||||f||||||||||2018-06-01 05:33:08.098369|2018-06-01 05:33:08.098369
NCT00034541|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-30|||2010-04-08|2002-04-30|2002-05-01|Estimate|||||||2010-04-08|2010-04-09|Estimate|December 2000||2000-12-31|April 2010|2010-04-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer|Phase Ib/IIa Study of an Anti-Epidermal Growth Factor Receptor (EGFr) Antibody Cetuximab in Combination With Carboplatin-Paclitaxel in Patients With Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|32|Actual|ImClone LLC||1|||f||||f||||||||||2018-06-01 05:33:08.176357|2018-06-01 05:33:08.176357
NCT00034528|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-30|||2013-04-30|2002-04-30|2002-05-01|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2001||2001-09-30|April 2013|2013-04-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia|Allogeneic Stem Cell Transplantation Following Nonmyeloablative Chemotherapy in Patients With Hemoglobinopathies|Terminated||Phase 2|2|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1||Due to slow recruitment|f||||||||||||||2018-06-01 05:33:08.345586|2018-06-01 05:33:08.345586
NCT00034515|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-29|||2015-02-13|2002-04-29|2002-04-30|Estimate|||||||2015-02-13|2015-02-16|Estimate|June 2001||2001-06-30|February 2015|2015-02-28|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||A Study in Adult and Pediatric Patients With Cystic Fibrosis|Ph 1b/2a Study to Assess Levels of INS37217 and Placebo Treatment With Maximum Tolerated Dose Administered by Inhalation Via the Pari LC Star Nebulizer in Adult and Pediatric CF Patients|Completed||Phase 1/Phase 2|63|Actual|Merck Sharp & Dohme Corp.|||||||||||||||||||2018-06-01 05:33:08.447683|2018-06-01 05:33:08.447683
NCT00034502|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-29|||2006-07-18|2002-04-29|2002-04-30|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.||Completed||Phase 1/Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:08.510668|2018-06-01 05:33:08.510668
NCT00034489|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-29|||2006-07-18|2002-04-29|2002-04-30|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.|A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.|Completed||Phase 2|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:08.580893|2018-06-01 05:33:08.580893
NCT00034476|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-29|||2006-07-18|2002-04-29|2002-04-30|Estimate|||||||2006-07-18|2006-07-19|Estimate|October 2001||2001-10-31|July 2006|2006-07-31|October 2002||2002-10-31|||||Interventional|||A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis|A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis|Completed||Phase 1/Phase 2|466||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:08.653756|2018-06-01 05:33:08.653756
NCT00034463|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-29|||2006-07-18|2002-04-29|2002-04-30|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer|A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer|Completed||Phase 1|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:08.820685|2018-06-01 05:33:08.820685
NCT00034450|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-29|||2006-08-17|2002-04-29|2002-04-30|Estimate|||||||2006-08-17|2006-08-18|Estimate|January 2002||2002-01-31|March 2006|2006-03-31|August 2004||2004-08-31|||||Interventional|||Developmental Study on Fatigue in Cancer|Developmental Study on Fatigue in Cancer|Completed||Phase 2|140||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:08.880313|2018-06-01 05:33:08.880313
NCT00034437|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-27|||2008-03-03|2002-04-27|2002-04-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2002||2002-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Immune Response to Cytomegalovirus|Measurement of Cytomegalovirus (CMV)-Specific T Lymphocytes in CMV-Seropositive Normal Volunteers.|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:08.943932|2018-06-01 05:33:08.943932
NCT00034424|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-27|||2017-12-27|2002-04-27|2002-04-29|Estimate|||||||2017-12-27|2017-12-28|Actual|July 1, 2002||2002-07-01|December 17, 2017|2017-12-17||||||||Observational|||Cause of Familial Testicular Cancer|Multidisciplinary Etiologic Study of Familial Testicular Cancer|Recruiting|||1750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:09.000186|2018-06-01 05:33:09.000186
NCT00034398|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-26|||2017-06-30|2002-04-26|2002-04-29|Estimate|||||||2017-06-30|2017-07-02|Actual|April 24, 2002||2002-04-24|March 11, 2010|2010-03-11|March 11, 2010||2010-03-11|||||Observational|||Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome|Evaluation of Density and Pattern of Distribution of GABA A Receptors in Brain of Patients With Tourette's Syndrome Studied With PET Using [11C] Flumazenil|Completed|||26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:09.073463|2018-06-01 05:33:09.073463
NCT00034385|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|||2017-06-30|2002-04-26|2002-04-29|Estimate|||||||2017-06-30|2017-07-02|Actual|April 24, 2002||2002-04-24|August 20, 2008|2008-08-20|October 30, 2009|Actual|2009-10-30|January 30, 2007|Actual|2007-01-30||Interventional|||Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients|Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients|Completed||Phase 4|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:09.127113|2018-06-01 05:33:09.127113
NCT00034372|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-26|||2007-12-13|2002-04-26|2002-04-29|Estimate|||||||2007-12-13|2007-12-18|Estimate|September 2000||2000-09-30|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma||Terminated||Phase 2|102||Unither Pharmaceuticals||||closed by sponser|||||||||||||||2018-06-01 05:33:09.189775|2018-06-01 05:33:09.189775
NCT00034359|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-26|||2014-02-18|2002-04-26|2002-04-29|Estimate|||||||2014-02-18|2014-02-19|Estimate|February 2002||2002-02-28|February 2014|2014-02-28|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection|A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults|Completed||Phase 2|79|Actual|Achillion Pharmaceuticals|||||||||||||||||||2018-06-01 05:33:09.27979|2018-06-01 05:33:09.27979
NCT00017862|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-15|||2008-03-03|2002-04-26|2002-04-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2001||2001-06-30|June 2003|2003-06-30|June 2003||2003-06-30|||||Interventional|||Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome|A Pilot Phase II Study of the Efficacy of Humanized Anti-IL5 Antibody (SCH55700) in Reducing Eosinophilia in Patients With Hypereosinophilic Syndrome or Eosinophilic Gastroenteritis Refractory to or Intolerant of Conventional Therapy|Completed||Phase 2|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:09.342316|2018-06-01 05:33:09.342316
NCT00033917|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-12|2013-01-08||2013-02-20|2002-04-12|2002-04-15|Estimate|2013-02-20|2013-03-28|Estimate||||2013-02-20|2013-03-28|Estimate|September 1989||1989-09-30|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial|Randomized Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial|Completed||Phase 3|630|Actual|Yale University||2|||f||||||||||||||2018-06-01 05:33:14.099493|2018-06-01 05:33:14.099493
NCT00034346|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-25|||2007-12-20|2002-04-25|2002-04-26|Estimate|||||||2007-12-20|2007-12-24|Estimate|January 2002||2002-01-31|December 2007|2007-12-31||||||||Interventional|||ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)|A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|194||Amgen|||||||||||||||||||2018-06-01 05:33:09.413753|2018-06-01 05:33:09.413753
NCT00034333|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-25|||2005-06-23|2002-04-25|2002-04-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2002||2002-03-31|May 2004|2004-05-31||||||||Interventional|||Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer|Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers (MTC-DOX) Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients With Unresectable Hepatocellular Carcinoma|Terminated||Phase 2/Phase 3|240||FeRx|||||||||||||||||||2018-06-01 05:33:09.495491|2018-06-01 05:33:09.495491
NCT00034307|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2005-06-23|2002-04-24|2002-04-25|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 2002|2002-05-31||||||||Interventional|||Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension|A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension|Unknown status|Active, not recruiting|Phase 2/Phase 3|180||ICOS-Texas Biotechnology|||||||||||||||||||2018-06-01 05:33:09.589682|2018-06-01 05:33:09.589682
NCT00034294|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2015-03-04|2002-04-24|2002-04-25|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2002||2002-02-28|March 2015|2015-03-31|July 2003|Actual|2003-07-31|||||Interventional|||A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea|A Randomized, Double-Blind Study of GT160-246 Versus Vancomycin in Patients With C. Difficile-Associated Diarrhea|Completed||Phase 2|300||Sanofi|||||||||||||||||||2018-06-01 05:33:09.80709|2018-06-01 05:33:09.80709
NCT00034281|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2012-01-31|2002-04-24|2002-04-25|Estimate|||||||2012-01-31|2012-02-02|Estimate|June 2002||2002-06-30|January 2012|2012-01-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2|A Phase I, Open-Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose and Pharmacokinetics of Oral TAK-165 Administered Once Daily to Subjects With Tumors Known to Express HER2.|Completed||Phase 1|16|Actual|Takeda||1|||f||||f||||||||||2018-06-01 05:33:10.018986|2018-06-01 05:33:10.018986
NCT00034268|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2006-07-18|2002-04-24|2002-04-25|Estimate|||||||2006-07-18|2006-07-19|Estimate|March 2002||2002-03-31|July 2006|2006-07-31||||||||Interventional|||A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer|A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer|Completed||Phase 3|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:10.394879|2018-06-01 05:33:10.394879
NCT00034255|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2005-06-23|2002-04-24|2002-04-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2001||2001-12-31|June 2003|2003-06-30||||||||Interventional|||Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients|Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients|Completed||Phase 1/Phase 2|62||GMP Endotherapeutics|||||||||||||||||||2018-06-01 05:33:10.726024|2018-06-01 05:33:10.726024
NCT00034203|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-23|||2005-06-23|2002-04-24|2002-04-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2002||2002-04-30|September 2004|2004-09-30|August 2003||2003-08-31|||||Interventional|||Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.||Completed||Phase 2|||XOMA (US) LLC|||||||||||||||||||2018-06-01 05:33:11.438511|2018-06-01 05:33:11.438511
NCT00034190|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-23|||2009-06-02|2002-04-24|2002-04-25|Estimate|||||||2009-06-02|2009-06-04|Estimate|March 2002||2002-03-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma|A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma|Completed||Phase 2|28|Actual|Achieve Life Sciences|||||f||||||||||||||2018-06-01 05:33:11.758378|2018-06-01 05:33:11.758378
NCT00034177|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-23|||2009-06-02|2002-04-24|2002-04-25|Estimate|||||||2009-06-02|2009-06-04|Estimate|April 2002||2002-04-30|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium|Safety And Efficacy Of Weekly Administration Of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment Of Patients With Locally Advanced, Metastatic, Or Recurrent Transitional Cell Carcinoma Of The Urothelium|Completed||Phase 2|27|Actual|Achieve Life Sciences|||||f||||||||||||||2018-06-01 05:33:11.882751|2018-06-01 05:33:11.882751
NCT00034242|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2008-03-03|2002-04-23|2002-04-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2002||2002-04-30|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration|The Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With Cerebellar Degeneration: A Double Blind, Placebo Controlled Trial|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:12.072123|2018-06-01 05:33:12.072123
NCT00034229|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2008-03-03|2002-04-23|2002-04-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2002||2002-04-30|March 2006|2006-03-31|March 2006||2006-03-31|||||Interventional|||Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression|A Double-Blind Randomized Placebo-Controlled Trial of Felbamate in Treatment Resistant Bipolar Depression|Completed||Phase 2|52||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:12.242476|2018-06-01 05:33:12.242476
NCT00034216|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-24|||2018-01-25|2002-04-23|2002-04-24|Estimate|||||||2018-01-25|2018-01-26|Actual|April 19, 2002||2002-04-19|January 12, 2018|2018-01-12||||||||Observational|||Collection of Blood From Patients With Cancer|Biospecimen Acquisition From Human Subjects|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:12.467209|2018-06-01 05:33:12.467209
NCT00034164|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-23|||2009-06-02|2002-04-23|2002-04-24|Estimate|||||||2009-06-02|2009-06-04|Estimate|April 2002||2002-04-30|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer|A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer|Completed||Phase 2|52|Actual|Achieve Life Sciences|||||f||||f||||||||||2018-06-01 05:33:12.567823|2018-06-01 05:33:12.567823
NCT00033137|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2018-02-07|2002-04-05|2002-04-08|Estimate|||||||2018-02-07|2018-02-08|Actual|April 4, 2002||2002-04-04|January 23, 2018|2018-01-23||||||||Observational|||Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer|The Birt Hogg-Dube Syndrome: Identification of the Disease Gene and Characterization of the Predisposition of Renal Cancer|Recruiting|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-06-01 05:33:15.72222|2018-06-01 05:33:15.72222
NCT00034151|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-23|||2009-06-02|2002-04-23|2002-04-24|Estimate|||||||2009-06-02|2009-06-04|Estimate|March 2002||2002-03-31|June 2009|2009-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer|A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma|Completed||Phase 2|52|Actual|Achieve Life Sciences|||||f||||||||||||||2018-06-01 05:33:12.623619|2018-06-01 05:33:12.623619
NCT00034138|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-23|||2007-12-13|2002-04-23|2002-04-24|Estimate|||||||2007-12-13|2007-12-18|Estimate|March 2002||2002-03-31|December 2007|2007-12-31|December 2007|Actual|2007-12-31|||||Interventional|||A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma||Terminated||Phase 1/Phase 2|24||Unither Pharmaceuticals||||closed by sponser|||||||||||||||2018-06-01 05:33:12.747496|2018-06-01 05:33:12.747496
NCT00034125|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-23|||2006-07-18|2002-04-23|2002-04-24|Estimate|||||||2006-07-18|2006-07-19|Estimate||||July 2006|2006-07-31||||||||Interventional|||Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.|a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.|Completed||Phase 3|||Eli Lilly and Company|||||||||||||||||||2018-06-01 05:33:12.813583|2018-06-01 05:33:12.813583
NCT00034112|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-22|||2006-08-17|2002-04-22|2002-04-23|Estimate|||||||2006-08-17|2006-08-18|Estimate|April 2001||2001-04-30|July 2006|2006-07-31|March 2002||2002-03-31|||||Interventional|||Efficacy of Osteopathic Manipulation in Chronic Obstructive Pulmonary Disease|Efficacy of Osteopathic Manipulation in Chronic Obstructive Pulmonary Disease|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:12.891023|2018-06-01 05:33:12.891023
NCT00034086|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-22|||2012-05-17|2002-04-22|2002-04-23|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|June 2006|Actual|2006-06-30|||||Interventional|||Study of Anti-HIV Therapy Intensification|Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375|Completed||N/A|22||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:13.046018|2018-06-01 05:33:13.046018
NCT00034073|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-20|||2017-06-30|2002-04-20|2002-04-22|Estimate|||||||2017-06-30|2017-07-02|Actual|April 18, 2002||2002-04-18|April 16, 2009|2009-04-16|April 16, 2009||2009-04-16|||||Observational|||Magnetic Resonance Imaging in Children and Adults Using Arterial Spin Tagging Techniques|Quantitative fMRI in Children and Adults Using Arterial Spin Tagging Techniques|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:13.159512|2018-06-01 05:33:13.159512
NCT00034060|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-19|||2008-03-03|2002-04-19|2002-04-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2002||2002-04-30|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept|Suppression of the Growth Hormone/ Insulin-Like Growth Factor-1 (GH/IGF-1) Axis in Women With Rheumatoid Arthritis|Completed||Phase 2|36||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:13.242479|2018-06-01 05:33:13.242479
NCT00034047|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-19|||2008-01-23|2002-04-19|2002-04-22|Estimate|||||||2008-01-23|2008-01-25|Estimate|September 2002||2002-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Endometriosis : Traditional Medicine vs Hormone Therapy|Endometriosis : Traditional Medicine vs Hormone Therapy|Completed||Phase 1/Phase 2|50||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:13.336152|2018-06-01 05:33:13.336152
NCT00034034|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-19|||2007-01-04|2002-04-19|2002-04-22|Estimate|||||||2007-01-04|2007-01-05|Estimate|June 2002||2002-06-30|January 2007|2007-01-31|August 2006||2006-08-31|||||Interventional|||Acupuncture to Reduce Symptoms of Advanced Colorectal Cancer|An Intervention to Improve End-of-Life Symptom Distress|Completed||Phase 1|105||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:13.428709|2018-06-01 05:33:13.428709
NCT00034021|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-19|||2006-08-17|2002-04-19|2002-04-22|Estimate|||||||2006-08-17|2006-08-18|Estimate|June 2002||2002-06-30|July 2006|2006-07-31|September 2004||2004-09-30|||||Interventional|||Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction|Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:13.502322|2018-06-01 05:33:13.502322
NCT00034008|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-19|||2006-08-17|2002-04-19|2002-04-22|Estimate|||||||2006-08-17|2006-08-18|Estimate|July 2003||2003-07-31|July 2006|2006-07-31|July 2004||2004-07-31|||||Interventional|||Efficacy of Healing Touch in Stressed Neonates|Efficacy of Healing Touch in Stressed Neonates|Completed||Phase 2|13||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:13.57009|2018-06-01 05:33:13.57009
NCT00033995|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-18|||2017-06-30|2002-04-18|2002-04-19|Estimate|||||||2017-06-30|2017-07-02|Actual|April 17, 2002||2002-04-17|February 17, 2009|2009-02-17|February 17, 2009||2009-02-17|||||Observational|||Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder|Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder With [15O]H2O PET in Awake and in Sleep States|Completed|||46||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:13.650426|2018-06-01 05:33:13.650426
NCT00033982|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-18|||2017-06-30|2002-04-18|2002-04-19|Estimate|||||||2017-06-30|2017-07-02|Actual|April 11, 2002||2002-04-11|February 20, 2007|2007-02-20|February 20, 2007||2007-02-20|||||Interventional|||Posaconazole to Treat Invasive Fungal Infections|Open Label, Limited Access Protocol of Posaconazole in Invasive Fungal Infections|Completed||Phase 3|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:13.729418|2018-06-01 05:33:13.729418
NCT00033969|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-17|||2018-05-23|2002-04-17|2002-04-18|Estimate|||||||2018-05-23|2018-05-24|Actual|April 15, 2002||2002-04-15|October 23, 2014|2014-10-23|October 23, 2014||2014-10-23|||||Observational|||Study of Proteins Associated With Complex Regional Pain Syndrome|Complex Regional Pain Syndrome Proteomics Study|Terminated|||120|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:13.801648|2018-06-01 05:33:13.801648
NCT00033956|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-17|||2005-06-23|2002-04-17|2002-04-18|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2001||2001-12-31|May 2002|2002-05-31||||||||Interventional|||Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2|Phase I/II Open Label Dose Escalation and Double-Blind, Placebo-Controlled Evaluation of M40403, for the Prevention of the Dose Limiting Toxicities of High Dose IV Bolus IL-2 Treatment of Metastatic Melanoma or Renal Cell Carcinoma.|Suspended||Phase 1/Phase 2|48||MetaPhore Pharmaceuticals|||||||||||||||||||2018-06-01 05:33:13.864746|2018-06-01 05:33:13.864746
NCT00033943|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-16|||2005-06-23|2002-04-16|2002-04-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2001||2001-01-31|October 2002|2002-10-31|September 2002||2002-09-30|||||Interventional|||Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis|A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Two Dosage Levels of OP2000 (75 Mg and 125 Mg) Administered Once Daily by Subcutaneous Injection for the Treatment of Active Ulcerative Colitis|Completed||Phase 2/Phase 3|270||Incara Pharmaceuticals|||||||||||||||||||2018-06-01 05:33:13.996618|2018-06-01 05:33:13.996618
NCT00033904|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-12|||2012-09-06|2002-04-12|2002-04-15|Estimate|||||||2012-09-06|2012-09-07|Estimate|June 2000||2000-06-30|September 2012|2012-09-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer|A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma|Completed||Phase 3|650||Agenus Inc.|||||||||||||||||||2018-06-01 05:33:14.371275|2018-06-01 05:33:14.371275
NCT00033891|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-11|||2018-04-03|2002-04-11|2002-04-12|Estimate|||||||2018-04-03|2018-04-04|Actual|April 10, 2002||2002-04-10|March 29, 2018|2018-03-29|May 20, 2010|Actual|2010-05-20|July 31, 2007|Actual|2007-07-31||Interventional|||Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis|A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis|Completed||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:14.56011|2018-06-01 05:33:14.56011
NCT00033878|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-11|||2007-03-27|2002-04-11|2002-04-12|Estimate|||||||2007-03-27|2007-03-28|Estimate|November 2001||2001-11-30|March 2007|2007-03-31|June 2006|Actual|2006-06-30|||||Interventional|||Study of Noni in Cancer Patients|Phase I Study of Noni in Cancer Patients|Completed||Phase 1|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:14.628463|2018-06-01 05:33:14.628463
NCT00033865|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-11|||2015-04-27|2002-04-11|2002-04-12|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2001||2001-04-30|April 2015|2015-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Yoga as a Treatment for Insomnia|Yoga as a Treatment for Insomnia|Completed||Phase 2|48|Anticipated|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||||||||||||2018-06-01 05:33:14.705247|2018-06-01 05:33:14.705247
NCT00033852|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-11|||2008-03-05|2002-04-11|2002-04-12|Estimate|||||||2008-03-05|2008-03-07|Estimate|April 2002||2002-04-30|March 2008|2008-03-31|May 2004||2004-05-31|||||Interventional|||Treatment of Depression With Massage in HIV|Treatment of Depression With Massage in HIV|Completed||Phase 2|90||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:14.780981|2018-06-01 05:33:14.780981
NCT00033839|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-11|||2011-06-08|2002-04-11|2002-04-12|Estimate|||||||2011-06-08|2011-06-10|Estimate|January 2002||2002-01-31|June 2011|2011-06-30|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache|Completed||Phase 3|60||Winston Laboratories|||||f||||||||||||||2018-06-01 05:33:14.861103|2018-06-01 05:33:14.861103
NCT00033826|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-10|||2013-05-23|2002-04-10|2002-04-11|Estimate|||||||2013-05-23|2013-05-24|Estimate|April 2002||2002-04-30|May 2013|2013-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Role of Fat Tissue in Vitamin D Metabolism|The Role of Adipose Tissue in Vitamin D Metabolism|Completed|||41|Actual|Tufts University|||||f||||f||||||||||2018-06-01 05:33:14.941286|2018-06-01 05:33:14.941286
NCT00033813|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-10|||2014-03-07|2002-04-10|2002-04-11|Estimate|||||||2014-03-07|2014-03-10|Estimate|January 2002||2002-01-31|March 2014|2014-03-31||||December 2006|Actual|2006-12-31||Interventional|||KUL0401: An Open-label Pilot Study of Oxatomide in Steroid-Naive Duchenne Muscular Dystrophy||Completed||Phase 2|15||Cooperative International Neuromuscular Research Group|||||f||||||||||||||2018-06-01 05:33:15.003533|2018-06-01 05:33:15.003533
NCT00033787|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2017-06-30|2002-04-09|2002-04-10|Estimate|||||||2017-06-30|2017-07-02|Actual|April 5, 2002||2002-04-05|June 8, 2009|2009-06-08|April 30, 2005|Actual|2005-04-30|April 30, 2005|Actual|2005-04-30||Observational|||Serotonin Function During Depression|Tryptophan Depletion PET Study in Remitted Depressed Subjects and Healthy Controls, and GABA MRS Study in Remitted and Currently Depressed Subjects and Healthy Controls|Completed|||450||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:15.054123|2018-06-01 05:33:15.054123
NCT00033774|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2018-03-27|2002-04-09|2002-04-10|Estimate|||||||2018-03-27|2018-03-29|Actual|April 8, 2002||2002-04-08|November 22, 2017|2017-11-22||||||||Observational|||Stem Cell Collection for Adult Volunteers|Peripheral Blood Stem Cell Collection From Adult Volunteers|Recruiting|||99999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:15.102515|2018-06-01 05:33:15.102515
NCT00033215|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2018-04-24|2002-04-09|2002-04-10|Estimate|||||||2018-04-24|2018-04-26|Actual|November 2001|Actual|2001-11-30|April 2018|2018-04-30|March 12, 2003|Actual|2003-03-12|February 13, 2003|Actual|2003-02-13||Interventional|||A Phase 1 Study of S-3304 in Patients With Solid Tumors|A Phase 1 Study of S-3304 in Patients With Solid Tumors|Completed||Phase 1|32|Actual|Shionogi Inc.|||||f|||||t|f||||||||2018-06-01 05:33:15.177749|2018-06-01 05:33:15.177749
NCT00033202|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-09|||2009-06-02|2002-04-09|2002-04-10|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2002||2002-03-31|June 2009|2009-06-30|February 2005|Actual|2005-02-28|||||Interventional|||This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor|Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.|Completed||Phase 1|30|Anticipated|Sigma-Tau Research, Inc.|||||||||||||||||||2018-06-01 05:33:15.228607|2018-06-01 05:33:15.228607
NCT00033189|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-08|||2010-11-15|2002-04-08|2002-04-09|Estimate|||||||2010-11-15|2010-11-16|Estimate|September 2001||2001-09-30|November 2010|2010-11-30|January 2005||2005-01-31|||||Interventional|||An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy||Completed||Phase 2|15||Cooperative International Neuromuscular Research Group|||||||||||||||||||2018-06-01 05:33:15.272381|2018-06-01 05:33:15.272381
NCT00033176|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-08|||2006-08-17|2002-04-08|2002-04-09|Estimate|||||||2006-08-17|2006-08-18|Estimate|February 2002||2002-02-28|July 2006|2006-07-31|August 2004||2004-08-31|||||Interventional|||Immune Restoration by Lipoic Acid in AIDS|Immune Restoration by Lipoic Acid in AIDS|Completed||Phase 2|33||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:15.3206|2018-06-01 05:33:15.3206
NCT00033163|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-08|||2012-05-17|2002-04-08|2002-04-09|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|May 2005|Actual|2005-05-31|||||Interventional|||A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV|A Randomized, Phase II, Controlled Trial Comparing the Efficacy of Adefovir Dipivoxil and Tenofovir Disoproxil Fumarate for the Treatment of Lamivudine-Resistant Hepatitis B Virus in Subjects Who Are Co-Infected With HIV|Completed||Phase 2|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:15.470753|2018-06-01 05:33:15.470753
NCT00033150|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-08|||2006-04-21|2002-04-08|2002-04-09|Estimate|||||||2006-04-21|2006-04-24|Estimate|June 2002||2002-06-30|April 2006|2006-04-30|January 2005||2005-01-31|||||Interventional|||A Comparison of Language Intervention Programs|A Comparison of Language Intervention Programs|Completed||Phase 3|216||National Institute on Deafness and Other Communication Disorders (NIDCD)|||||f||||||||||||||2018-06-01 05:33:15.642392|2018-06-01 05:33:15.642392
NCT00033124|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-10|2002-04-05|2002-04-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2001||2001-07-31|August 2003|2003-08-31|June 2002||2002-06-30|||||Interventional|||A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1|Behavioral Trial for the Treatment of Methamphetamine Dependence|Unknown status|Active, not recruiting|Phase 2|50||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:15.836569|2018-06-01 05:33:15.836569
NCT00033111|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2001||2001-06-30|October 2016|2016-10-31|April 2004|Actual|2004-04-30|||||Interventional|||A Study of Cabergoline for the Treatment of Cocaine Dependence - 1|Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence|Completed||Phase 2|140|Actual|National Institute on Drug Abuse (NIDA)||2|||||||t||||||||||2018-06-01 05:33:15.924036|2018-06-01 05:33:15.924036
NCT00033098|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-10|2002-04-05|2002-04-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2001||2001-11-30|August 2003|2003-08-31|May 2002||2002-05-31|||||Interventional|||Cocaine-Metyrapone Interaction Study - 1|Cocaine-Metyrapone Interaction Study|Unknown status|Active, not recruiting|Phase 1|12||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:16.027541|2018-06-01 05:33:16.027541
NCT00033085|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2001||2001-05-31|July 2008|2008-07-31|December 2002||2002-12-31|||||Interventional|||Ondansetron for the Treatment of Cocaine Dependence - 1|Double-Blind, Placebo-Controlled Trial of Ondansetron for the Treatment of Cocaine Dependence|Completed||Phase 2|60||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:16.104157|2018-06-01 05:33:16.104157
NCT00033072|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-10|2002-04-05|2002-04-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2001||2001-09-30|November 2003|2003-11-30|October 2002||2002-10-31|||||Interventional|||Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1|Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline|Unknown status|Active, not recruiting|Phase 1|16||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:33:16.170986|2018-06-01 05:33:16.170986
NCT00033059|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-10|2002-04-05|2002-04-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2001||2001-07-31|August 2003|2003-08-31|March 2002||2002-03-31|||||Interventional|||Assessment of Potential Interactions Between Cocaine and Tolcapone - 1|Assessment of Potential Interactions Between Intravenous Cocaine and Tolcapone|Unknown status|Active, not recruiting|Phase 1|16||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:16.254281|2018-06-01 05:33:16.254281
NCT00033046|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-10|2002-04-05|2002-04-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2001||2001-06-30|May 2004|2004-05-31|April 2002||2002-04-30|||||Interventional|||Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1|Safety Evaluation of Cocaine Treatment Medication Modafinil: Interactions With Intravenous Cocaine|Unknown status|Active, not recruiting|Phase 1|12||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:33:16.321915|2018-06-01 05:33:16.321915
NCT00033033|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2001||2001-07-31|August 2008|2008-08-31|May 2003||2003-05-31|||||Interventional|||Reserpine for the Treatment of Cocaine Dependence - 1|Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence|Completed||Phase 2|140||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:16.384019|2018-06-01 05:33:16.384019
NCT00033020|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|April 2010|2010-04-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1|Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics|Completed||Phase 3|390||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:33:16.473288|2018-06-01 05:33:16.473288
NCT00033007|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|April 2010|2010-04-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics - 1|Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics|Completed||Phase 3|440||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:33:16.574209|2018-06-01 05:33:16.574209
NCT00032994|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|April 2010|2010-04-30|October 2002||2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Motivational Interviewing to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1|Motivational Interviewing (MI) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse|Completed||Phase 3|422||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:33:16.656938|2018-06-01 05:33:16.656938
NCT00032981|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2001||2001-05-31|April 2010|2010-04-30|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Interventional|||Motivational Enhancement to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse - 1|Motivational Enhancement Treatment (MET) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse|Completed||Phase 3|561||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:33:16.729696|2018-06-01 05:33:16.729696
NCT00032968|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2001||2001-01-31|April 2010|2010-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1|Buprenorphine/Naloxone Versus Clonidine For Out-patient Opiate Detoxification|Completed||Phase 3|341||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:33:16.842131|2018-06-01 05:33:16.842131
NCT00032955|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2001||2001-02-28|April 2010|2010-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1|Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification|Completed||Phase 3|163||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:33:16.920939|2018-06-01 05:33:16.920939
NCT00032942|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2001||2001-04-30|July 2008|2008-07-31||||October 2004|Actual|2004-10-31||Interventional|||Lofexidine for Opiate Withdrawal - 1|A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal|Completed||Phase 3|66||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:16.989369|2018-06-01 05:33:16.989369
NCT00032929|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-11|2002-04-05|2002-04-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2001||2001-03-31|May 2009|2009-05-31||||December 2002|Actual|2002-12-31||Interventional|||Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1|Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence|Completed||Phase 3|269|Actual|National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:17.049581|2018-06-01 05:33:17.049581
NCT00032916|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2017-01-10|2002-04-05|2002-04-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2001||2001-06-30|April 2004|2004-04-30|December 2002||2002-12-31|||||Interventional|||Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers - 1|Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers|Unknown status|Active, not recruiting|Phase 1|24||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:33:17.158912|2018-06-01 05:33:17.158912
NCT00032903|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2009-06-02|2002-04-05|2002-04-08|Estimate|||||||2009-06-02|2009-06-03|Estimate|March 2002||2002-03-31|June 2009|2009-06-30|October 2005|Actual|2005-10-31|||||Interventional|||This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.|Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial|Completed||Phase 1/Phase 2|59|Anticipated|Sigma-Tau Research, Inc.|||||||||||||||||||2018-06-01 05:33:17.211344|2018-06-01 05:33:17.211344
NCT00032890|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-05|||2009-01-20|2002-04-05|2002-04-08|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2000||2000-04-30|November 2006|2006-11-30|February 2004||2004-02-29|||||Interventional|||Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)|Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)|Completed||Phase 3|1588||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:33:17.291782|2018-06-01 05:33:17.291782
NCT00032877|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-04|||2008-03-03|2002-04-04|2002-04-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2002||2002-04-30|February 2003|2003-02-28|February 2003||2003-02-28|||||Observational|||Genetic Analysis of Fraser Syndrome and Fryns Syndrome|Molecular Genetic Analysis of Fraser Syndrome and Fryns Syndrome|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:17.36498|2018-06-01 05:33:17.36498
NCT00032864|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-04|||2009-01-20|2002-04-04|2002-04-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1997||1997-01-31|February 2003|2003-02-28|September 2000||2000-09-30|||||Observational|||Clinical Trial of Footwear in Patients With Diabetes|Clinical Trial of Footwear in Patients With Diabetes|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:33:17.425556|2018-06-01 05:33:17.425556
NCT00032838|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-03|||2008-03-03|2002-04-03|2002-04-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2002||2002-03-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Effects of Stress Hormones on Emotion and Cognition|The Effects of Cortisol and Norepinephrine Modulation on Emotional and Nonemotional Processing|Completed|||170||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:17.490731|2018-06-01 05:33:17.490731
NCT00032825|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-03|||2018-05-23|2002-04-03|2002-04-04|Estimate|||||||2018-05-23|2018-05-24|Actual|March 19, 2002||2002-03-19|May 4, 2012|2012-05-04|June 13, 2011|Actual|2011-06-13|||||Interventional|||Ketoconazole Plus Docetaxel to Treat Prostate Cancer|A Phase I Trial of High Dose Ketoconazole Plus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer|Completed||Phase 1|674|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:17.560453|2018-06-01 05:33:17.560453
NCT00032799|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-03|||2016-06-14|2002-04-03|2002-04-04|Estimate|||||||2016-06-14|2016-06-16|Estimate|December 2001||2001-12-31|March 2012|2012-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease|A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease|Completed||Phase 3|905|Actual|Biogen|||||||||||||||||||2018-06-01 05:33:17.658194|2018-06-01 05:33:17.658194
NCT00032786|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-03|||2016-06-14|2002-04-03|2002-04-04|Estimate|||||||2016-06-14|2016-06-16|Estimate|March 2002||2002-03-31|March 2012|2012-03-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease|A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease|Completed||Phase 3|||Biogen|||||||||||||||||||2018-06-01 05:33:17.728788|2018-06-01 05:33:17.728788
NCT00032773|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-02|||2009-10-12|2002-04-03|2002-04-04|Estimate|||||||2009-10-12|2009-10-14|Estimate||||June 2005|2005-06-30||||||||Interventional|||Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD|A Sequentially Adaptive, Open Label, Dose-finding, Phase I/II Trial of Pentostatin in the Treatment of Steroid-refractory Acute Graft Versus Host Disease (aGvHD)|Terminated||Phase 1/Phase 2|36||Astex Pharmaceuticals|||||||||||||||||||2018-06-01 05:33:17.774116|2018-06-01 05:33:17.774116
NCT00032812|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-03|||2008-03-03|2002-04-02|2002-04-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2002||2002-03-31|April 2004|2004-04-30|April 2004||2004-04-30|||||Observational|||The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease|Motor Memory: Study of the Role of Dopamine in Healthy Subjects and Patients With Parkinson's Disease Using PET and EEG|Completed|||64||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:18.753295|2018-06-01 05:33:18.753295
NCT00032760|ClinicalTrials.gov processed this data on May 31, 2018|2002-04-01|||2007-09-28|2002-04-01|2002-04-02|Estimate|||||||2007-09-28|2007-10-02|Estimate|March 2002||2002-03-31|September 2007|2007-09-30|March 2004|Actual|2004-03-31|||||Interventional|||Meditation-Based Treatment for Binge Eating Disorder|Meditation-Based Treatment for Binge Eating Disorder|Completed||Phase 2/Phase 3|160||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:18.835917|2018-06-01 05:33:18.835917
NCT00032747|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-29|||2008-06-16|2002-03-29|2002-04-01|Estimate|||||||2008-06-16|2008-06-17|Estimate|August 2001||2001-08-31|June 2008|2008-06-30|February 2003|Actual|2003-02-28|||||Interventional|||Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Effects of Vasopressin V2 Receptor Antagonist on Clinical Improvement in Patients With Severe Chronic Heart Failure|Completed||Phase 2|338|Actual|Sanofi|||||||||||||||||||2018-06-01 05:33:18.907558|2018-06-01 05:33:18.907558
NCT00032734|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-29|||2008-06-16|2002-03-29|2002-04-01|Estimate|||||||2008-06-16|2008-06-17|Estimate|June 2001||2001-06-30|June 2008|2008-06-30|July 2003|Actual|2003-07-31|||||Interventional|||Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion.|Completed||Phase 2|35|Actual|Sanofi|||||||||||||||||||2018-06-01 05:33:19.000057|2018-06-01 05:33:19.000057
NCT00032721|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-29|||2006-08-17|2002-03-29|2002-04-01|Estimate|||||||2006-08-17|2006-08-18|Estimate|March 2002||2002-03-31|July 2006|2006-07-31|September 2003||2003-09-30|||||Interventional|||The Use of Reiki for Patients With Advanced AIDS|The Use of Reiki for Patients With Advanced AIDS|Completed||Phase 2|146||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:19.06911|2018-06-01 05:33:19.06911
NCT00032708|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-28|||2010-08-26|2002-03-28|2002-03-29|Estimate|||||||2010-08-26|2010-08-27|Estimate|April 2004||2004-04-30|May 2006|2006-05-31|November 2004||2004-11-30|||||Interventional|||Dryvax Dilution-Prev Vacc Adults|A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults|Completed||Phase 2|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:19.124534|2018-06-01 05:33:19.124534
NCT00032695|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-28|||2006-05-12|2002-03-28|2002-03-29|Estimate|||||||2006-05-12|2006-05-15|Estimate||||November 2005|2005-11-30||||||||Interventional|||Treatment of AIDS Vacuolar Myelopathy With Methionine||Completed||Phase 3|56||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:33:19.197105|2018-06-01 05:33:19.197105
NCT00032682|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2008-03-03|2002-03-27|2002-03-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2002||2002-03-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Observational|||Constipation in Pediatric Cancer Patients Receiving Vinca Alkaloids or Narcotics|A Pilot Study Evaluating the Assessment Process for Constipation in Pediatric Oncology Patients Who Are Receiving Vinca Alkaloids and/or Narcotics|Completed|||34||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:19.29015|2018-06-01 05:33:19.29015
NCT00032669|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2008-03-03|2002-03-27|2002-03-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2002||2002-03-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children|Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children|Completed||Phase 1|34||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:19.44272|2018-06-01 05:33:19.44272
NCT00032656|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2006-08-17|2002-03-27|2002-03-28|Estimate|||||||2006-08-17|2006-08-18|Estimate|February 2001||2001-02-28|July 2006|2006-07-31|December 2003||2003-12-31|||||Observational|||Adolescents' Use of Complementary and Alternative Medicine|Adolescents' Use of Complementary and Alternative Medicine|Completed|||1400||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:19.505536|2018-06-01 05:33:19.505536
NCT00032643|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2013-11-04|2002-03-27|2002-03-28|Estimate|||||||2013-11-04|2013-11-05|Estimate|June 2004||2004-06-30|November 2013|2013-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)|CSP #526 - A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)|Terminated||Phase 2|150|Anticipated|VA Office of Research and Development||1||Funding support withdrawn (much slower than expected enrollment)|f||||f||||||||||2018-06-01 05:33:19.564169|2018-06-01 05:33:19.564169
NCT00032630|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|2013-08-08||2014-04-18|2002-03-27|2002-03-28|Estimate|2013-11-21|2014-01-10|Estimate||||2014-04-18|2014-05-05|Estimate|April 2002||2002-04-30|April 2014|2014-04-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|ROOBY||Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass|CSP #517 - Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass|Completed||Phase 3|2203|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:33:19.669008|2018-06-01 05:33:19.669008
NCT00032617|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2010-09-22|2002-03-27|2002-03-28|Estimate|||||||2010-09-22|2010-09-24|Estimate|August 2002||2002-08-31|September 2010|2010-09-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Randomized Clinical Trial of Cognitive-Behavioral Treatment for Post-Traumatic Stress Disorders in Women|CSP #494 - A Randomized Clinical Trial of Cognitive-Behavioral Treatment for PTSD in Women (PTSD)|Completed||Phase 3|284|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:33:19.98872|2018-06-01 05:33:19.98872
NCT00032591|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|2013-06-12||2014-03-18|2002-03-27|2002-03-28|Estimate|2013-12-24|2014-02-06|Estimate||||2014-03-18|2014-04-15|Estimate|August 2003||2003-08-31|March 2014|2014-03-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|THINRS|3745 participants were screened for participation|The Home INR Study|CSP #481 - The Home INR Study (THINRS)|Completed||Phase 4|2922|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:33:20.161874|2018-06-01 05:33:20.161874
NCT00032578|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2009-01-20|2002-03-27|2002-03-28|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2000||2000-01-31|June 2006|2006-06-30||||||||Observational|||VA Genetic Tissue Banking|CSP #478 (FeAST-DNA), Genetic Tissue Banking in VA Clinical Research: A Cooperative Studies Program Demonstration Project|Completed|||1000||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:33:21.366491|2018-06-01 05:33:21.366491
NCT00032565|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2010-09-22|2002-03-27|2002-03-28|Estimate|||||||2010-09-22|2010-09-24|Estimate|November 2002||2002-11-30|September 2010|2010-09-30|March 2008|Actual|2008-03-31|July 2007|Actual|2007-07-31||Observational|EQUIC||EQUIC-SM: Enhancing Quality of Informed Consent|CSP #476SM - Enhancing Quality of Informed Consent (EQUIC-SM) Self-Monitoring|Completed|||836|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:33:21.426558|2018-06-01 05:33:21.426558
NCT00032552|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2010-03-23|2002-03-27|2002-03-28|Estimate|||||||2010-03-23|2010-03-25|Estimate|April 1999||1999-04-30|March 2010|2010-03-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||Enhancing Quality of Informed Consent (EQUIC-DP) Developmental Phase|CSP #476DP - Enhancing Quality of Informed Consent (EQUIC-DP) Developmental Phase|Completed|||632|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:33:21.527931|2018-06-01 05:33:21.527931
NCT00032539|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-27|||2012-03-14|2002-03-27|2002-03-28|Estimate|||||||2012-03-14|2012-03-16|Estimate|April 1999||1999-04-30|March 2012|2012-03-31|April 1999|Actual|1999-04-30|April 1999|Actual|1999-04-30||Observational|||EQUIC-CC: Enhancing Quality of Informed Consent - Customized Consent|CSP #476CC - Enhancing Quality of Informed Consent (EQUIC-CC) Customized Consent|Completed|||240|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:33:21.624526|2018-06-01 05:33:21.624526
NCT00032526|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-25|||2005-06-23|2002-03-25|2002-03-26|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Classical Conditioning to Treat Allergic Airway Diseases|Classical Conditioning to Treat Allergic Airway Diseases|Unknown status|Recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:21.716766|2018-06-01 05:33:21.716766
NCT00032513|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-22|||2018-05-26|2002-03-22|2002-03-25|Estimate|||||||2018-05-26|2018-05-30|Actual|March 20, 2002||2002-03-20|May 24, 2018|2018-05-24||||||||Observational|||Genetic Studies of Chronic Active Epstein-Barr Disease|Genetic Studies of Chronic Active Epstein-Barr Virus Infection|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:21.812654|2018-06-01 05:33:21.812654
NCT00032500|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-22|||2006-08-17|2002-03-22|2002-03-25|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2001||2001-09-30|July 2006|2006-07-31|May 2004||2004-05-31|||||Interventional|||Evaluation of Echinacea for the Common Cold|Evaluation of Echinacea in a Human Rhinovirus Challenge|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:22.222765|2018-06-01 05:33:22.222765
NCT00032487|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-21|2013-09-10||2017-02-28|2002-03-21|2002-03-22|Estimate|2013-12-19|2014-02-12|Estimate||||2017-02-28|2017-03-30|Actual|December 1, 2000|Actual|2000-12-01|February 2017|2017-02-28|May 30, 2008|Actual|2008-05-30|May 30, 2008|Actual|2008-05-30||Interventional|VADT||Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)|CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)|Completed||Phase 3|1791|Actual|VA Office of Research and Development|Our study had several limitations. Since we were studying veterans, the patients were predominantly men, and extrapolation of our findings to women must be done with caution.Changes in therapeutic agents have occurred since the design of our protocol|2|||f||||t||||||||No||2018-06-01 05:33:22.715309|2018-06-01 05:33:22.715309
NCT00032474|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-21|||2006-08-17|2002-03-21|2002-03-22|Estimate|||||||2006-08-17|2006-08-18|Estimate|December 2001||2001-12-31|July 2006|2006-07-31|May 2005||2005-05-31|||||Interventional|||Ginkgo Biloba Extract and the Insulin Resistance Syndrome|Ginkgo Biloba Extract and the Insulin Resistance Syndrome|Completed||Phase 1/Phase 2|150||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:23.342677|2018-06-01 05:33:23.342677
NCT00032461|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-20|||2009-01-20|2002-03-21|2002-03-22|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 1998||1998-11-30|March 2007|2007-03-31|April 2001||2001-04-30|||||Observational|||Compare the Medical Conditions of Gulf War Veterans to Non-Deployed Veterans|National Health Survey of Gulf War Era Veterans and Their Families - Phase III Physical Examinations|Completed|||2000||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:33:23.414778|2018-06-01 05:33:23.414778
NCT00032448|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-20|||2011-04-13|2002-03-21|2002-03-22|Estimate|||||||2011-04-13|2011-04-14|Estimate|October 1998||1998-10-31|April 2011|2011-04-30|June 2004|Actual|2004-06-30|December 2003|Actual|2003-12-31||Interventional|||Does Tension-Free Herniorrhaphy or Laparoscopic Herniorrhaphy Achieve Equal or Better Recurrence Rates and Lower Costs While Achieving Equivalent Outcomes for Hernia Patients?|CSP #456 - Tension Free Inguinal Hernia Repair: Comparison of Open and Laparoscopic Surgical Techniques|Completed||Phase 3|2200|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:33:23.527712|2018-06-01 05:33:23.527712
NCT00032435|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-20|||2010-10-14|2002-03-21|2002-03-22|Estimate|||||||2010-10-14|2010-10-15|Estimate|May 2001||2001-05-31|October 2010|2010-10-31|September 2006|Actual|2006-09-30|August 2006|Actual|2006-08-31||Interventional|||Homocysteine Study (HOST)|CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)|Completed||Phase 3|2003|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:33:23.822733|2018-06-01 05:33:23.822733
NCT00032422|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-20|||2006-08-17|2002-03-21|2002-03-22|Estimate|||||||2006-08-17|2006-08-18|Estimate|July 2001||2001-07-31|July 2006|2006-07-31|June 2003||2003-06-30|||||Interventional|||Acupuncture in Cardiovascular Disease|Acupuncture in Cardiovascular Disease|Completed||Phase 2|200||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:23.956992|2018-06-01 05:33:23.956992
NCT00032409|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-20|||2006-08-17|2002-03-21|2002-03-22|Estimate|||||||2006-08-17|2006-08-18|Estimate|August 2001||2001-08-31|July 2006|2006-07-31|June 2004||2004-06-30|||||Interventional|||The Effects of Music Therapy-Based Stress Reduction on Bone Marrow Transplant Recipients|The Effects of Music Therapy-Based Stress Reduction on Bone Marrow Transplant Recipients|Completed||Phase 2|50||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:24.174384|2018-06-01 05:33:24.174384
NCT00032396|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-20|||2006-05-25|2002-03-21|2002-03-22|Estimate|||||||2006-05-25|2006-05-29|Estimate|November 2001||2001-11-30|December 2002|2002-12-31||||||||Interventional|||"A Study to Evaluate Retisert in the Treatment of Patients With the Wet Form of Age-Related Macular Degeneration"||Unknown status|Active, not recruiting|Phase 2|||Control Delivery Systems|||||||||||||||||||2018-06-01 05:33:24.246303|2018-06-01 05:33:24.246303
NCT00032383|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-20|||2007-01-19|2002-03-21|2002-03-22|Estimate|||||||2007-01-19|2007-01-22|Estimate|April 2001||2001-04-30|July 2006|2006-07-31|April 2003||2003-04-30|||||Interventional|||Complementary/Alternative Medicine for Abnormality in the Vestibular (Balance) System|Complementary/Alternative Medicine for Vestibulopathy|Completed||Phase 1/Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:24.29926|2018-06-01 05:33:24.29926
NCT00032370|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-19|||2015-06-25|2002-03-19|2002-03-20|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 1997||1997-08-31|June 2015|2015-06-30|May 2004|Actual|2004-05-31|February 2004|Actual|2004-02-29||Interventional|CARP||Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality|CSP #411 - The Coronary Artery Revascularization Prophylaxis (CARP) Trial|Completed||N/A|510|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:33:24.374767|2018-06-01 05:33:24.374767
NCT00032357|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-19|||2013-01-18|2002-03-19|2002-03-20|Estimate|||||||2013-01-18|2013-01-21|Estimate|May 1999||1999-05-31|January 2013|2013-01-31|September 2005|Actual|2005-09-30|April 2005|Actual|2005-04-30||Interventional|FeAST||Does the Reduction of Total Body Iron Storage (TBIS) Alter Mortality in a Population of Patients With Advanced PVD?|CSP #410 - The Iron (Fe) and Atherosclerosis Study (FeAST)|Completed||Phase 3|1277|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:33:24.533164|2018-06-01 05:33:24.533164
NCT00032344|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-18|||2010-11-19|2002-03-18|2002-03-19|Estimate|||||||2010-11-19|2010-11-23|Estimate|October 1993||1993-10-31|November 2010|2010-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps|CSP #380 - Prospective Evaluation of Risk Factors for Large (> 1 CM) Colonic Adenomas in Asymptomatic Subjects|Completed||Phase 3|3200|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-06-01 05:33:24.731926|2018-06-01 05:33:24.731926
NCT00032331|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-18|||2009-01-20|2002-03-18|2002-03-19|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1999||1999-01-31|January 2004|2004-01-31|June 2003||2003-06-30|||||Interventional|||(PET) Imaging in the Management of Patients With Solitary Pulmonary Nodules|18/F-FLUORODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN THE MANAGEMENT OF PATIENTS WITH SOLITARY PULMONARY NODULES|Completed||Phase 3|500||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:33:24.929119|2018-06-01 05:33:24.929119
NCT00032305|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-14|||2012-03-06|2002-03-15|2002-03-18|Estimate|||||||2012-03-06|2012-03-07|Estimate|March 2002||2002-03-31|March 2012|2012-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Research Study in Patients With Severe Ulcerative Colitis|A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids|Completed||Phase 2/Phase 3|20||Facet Biotech|||||f||||||||||||||2018-06-01 05:33:25.0092|2018-06-01 05:33:25.0092
NCT00032292|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-14|||2012-03-09|2002-03-15|2002-03-18|Estimate|||||||2012-03-09|2012-03-13|Estimate|March 2002||2002-03-31|March 2012|2012-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease|A Phase I/II, Open-Label, Dose-Escalation, Pilot Study to Evaluate Safety and Preliminary Efficacy of Visilizumab as Primary Therapy for Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation|Completed||Phase 1/Phase 2|34||Facet Biotech|||||f||||||||||||||2018-06-01 05:33:25.078335|2018-06-01 05:33:25.078335
NCT00032279|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-15|||2005-06-23|2002-03-15|2002-03-18|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2002||2002-03-31|October 2003|2003-10-31||||||||Interventional|||Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease|A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory, Acute Graft-Versus-Host Disease|Unknown status|Active, not recruiting|Phase 2|80||Facet Biotech|||||||||||||||||||2018-06-01 05:33:25.149528|2018-06-01 05:33:25.149528
NCT00032240|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-12|||2013-06-02|2002-03-12|2002-03-13|Estimate|||||||2013-06-02|2013-06-04|Estimate|February 2002||2002-02-28|June 2013|2013-06-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Shoe Inserts for Treating Osteoarthritis of the Knee|Randomized Trial of a Wedged Insole for Treatment of Osteoarthritis of the Knee|Completed||Phase 3|90||Boston University|||||f||||||||||||||2018-06-01 05:33:25.233985|2018-06-01 05:33:25.233985
NCT00032227|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-12|||2013-05-04|2002-03-12|2002-03-13|Estimate|||||||2013-05-04|2013-05-07|Estimate|August 2002||2002-08-31|May 2013|2013-05-31|April 2008|Actual|2008-04-30|April 2007|Actual|2007-04-30||Interventional|||Carpal Tunnel Syndrome: Diagnosis and Treatment Trial|Carpal Tunnel Syndrome: Diagnosis and Treatment Trial|Completed||N/A|116|Actual|University of Washington||2|||f||||||||||||||2018-06-01 05:33:25.319704|2018-06-01 05:33:25.319704
NCT00032201|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-09|||2018-05-23|2002-03-09|2002-03-11|Estimate|||||||2018-05-23|2018-05-24|Actual|March 6, 2002||2002-03-06|December 3, 2014|2014-12-03|December 3, 2014||2014-12-03|||||Observational|||Cell Lines From High-Risk Breast Tissue|Establishment of Normal High Risk Breast Epithelial Cell Cultures, and A High Risk Cell Line and Tissue Repository From Breast Tissue From Women at High Risk of Breast Cancer|Completed|||43|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:25.450763|2018-06-01 05:33:25.450763
NCT00031551|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-07|2015-11-24||2017-11-01|2002-03-07|2002-03-08|Estimate|2015-11-24|2015-12-30|Estimate||||2017-11-01|2017-12-06|Actual|March 2002||2002-03-31|November 2017|2017-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury|Evaluation of Efficacy and Mechanisms of an Anti-Inflammatory Intervention for Chemotherapy Related Mucosal Injury|Terminated||Phase 2|27|Actual|National Institutes of Health Clinical Center (CC)||3||It was not feasible to recruit required sample size from two clinical sites.|f||||t||||||||||2018-06-01 05:33:25.523466|2018-06-01 05:33:25.523466
NCT00031538|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|||2018-05-11|2002-03-06|2002-03-07|Estimate|||||||2018-05-11|2018-05-14|Actual|March 1, 2002||2002-03-01|April 29, 2015|2015-04-29|April 29, 2015||2015-04-29|||||Observational|||Genetic Analysis of Brain Tumors|A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative|Terminated|||674|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:26.133989|2018-06-01 05:33:26.133989
NCT00031512|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06||2011-07-20|2013-02-28|2002-03-06|2002-03-07|Estimate||||2011-07-20|2011-07-22|Estimate|2013-02-28|2013-03-08|Estimate|June 2001||2001-06-30|August 2012|2012-08-31|September 2012|Actual|2012-09-30|September 2010|Actual|2010-09-30||Interventional|||Pleconaril Enteroviral Sepsis Syndrome|A Double-Blind, Placebo-Controlled, Virologic Efficacy Trial of Pleconaril in the Treatment of Neonates With Enteroviral Sepsis Syndrome|Completed||Phase 2|61|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:33:26.219632|2018-06-01 05:33:26.219632
NCT00031499|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|||2013-04-25|2002-03-06|2002-03-07|Estimate|||||||2013-04-25|2013-04-29|Estimate|June 2000||2000-06-30|April 2013|2013-04-30|March 2009|Actual|2009-03-31|August 2007|Actual|2007-08-31||Interventional|||Azithromycin/Bicillin Syphilis|A Phase III Equivalence Trial of Azithromycin vs. Benzathine Penicillin for the Treatment of Early Syphilis|Completed||Phase 3|593|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:33:26.333878|2018-06-01 05:33:26.333878
NCT00031486|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|2012-03-15|2011-05-05|2012-05-10|2002-03-06|2002-03-07|Estimate|2012-05-10|2012-06-12|Estimate|2011-05-05|2011-05-13|Estimate|2012-05-10|2012-06-12|Estimate|September 2000||2000-09-30|October 2011|2011-10-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Interventional|||Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir|A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)|Completed||Phase 3|91|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:33:26.443957|2018-06-01 05:33:26.443957
NCT00031473|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|||2010-08-26|2002-03-06|2002-03-07|Estimate|||||||2010-08-26|2010-08-27|Estimate|November 1997||1997-11-30|December 2003|2003-12-31|March 2003||2003-03-31|||||Interventional|||Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients|A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient|Terminated||Phase 3|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:27.372614|2018-06-01 05:33:27.372614
NCT00031460|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|2009-04-02||2012-05-10|2002-03-06|2002-03-07|Estimate|2010-03-23|2010-04-09|Estimate||||2012-05-10|2012-05-16|Estimate|December 1997||1997-12-31|October 2009|2009-10-31|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates|A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Involving the Central Nervous System|Completed||Phase 3|46|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:33:27.528208|2018-06-01 05:33:27.528208
NCT00031447|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|2009-04-01||2012-05-10|2002-03-06|2002-03-07|Estimate|2010-03-23|2010-04-09|Estimate||||2012-05-10|2012-05-16|Estimate|August 1999||1999-08-31|November 2009|2009-11-30|April 2008|Actual|2008-04-30|February 2008|Actual|2008-02-29||Interventional|||Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth|A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to the Skin, Eye, and Mouth|Completed||Phase 3|29|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:33:27.970095|2018-06-01 05:33:27.970095
NCT00031434|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|||2011-02-03|2002-03-06|2002-03-07|Estimate|||||||2011-02-03|2011-02-07|Estimate|July 2002||2002-07-31|July 2009|2009-07-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Valganciclovir in Congenital CMV Infants|A Phase I/II Pharmacokinetic and Pharmacodynamic Evaluation of Oral Valganciclovir in Neonates With Symptomatic Congenital Cytomegalovirus (CMV) Infection (CASG 109)|Completed||Phase 1/Phase 2|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:33:28.378237|2018-06-01 05:33:28.378237
NCT00031421|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-06|||2011-08-11|2002-03-06|2002-03-07|Estimate|||||||2011-08-11|2011-08-12|Estimate|September 2001||2001-09-30|July 2008|2008-07-31|November 2005||2005-11-30|||||Observational|||Neonatal CMV-Ganciclovir Follow-up Study|A Follow-up Assessment of Subjects Who Received Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) During the Phase I/II Study to Evaluate the Safety and Efficacy of Ganciclovir Treatment for Congenital Cytomegalovirus (CMV) Infections|Completed|||8||National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||||||2018-06-01 05:33:28.473324|2018-06-01 05:33:28.473324
NCT00031408|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-05|||2018-05-04|2002-03-05|2002-03-06|Estimate|||||||2018-05-04|2018-05-07|Actual|March 2002||2002-03-31|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|||Consent for Use of Stored Patient Specimens for Future Testing|Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses|Recruiting|||30000|Anticipated|AIDS Clinical Trials Group|||||f||||t||||||Samples With DNA|"~     Blood and tissue samples~   "|||2018-06-01 05:33:28.549455|2018-06-01 05:33:28.549455
NCT00031395|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-04|||2009-05-20|2002-03-04|2002-03-05|Estimate|||||||2009-05-20|2009-05-21|Estimate|September 1999||1999-09-30|May 2009|2009-05-31|June 2007|Actual|2007-06-30|||||Interventional|||Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children|Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT)|Completed||Phase 3|122|Actual|University of Cincinnati||4|||f||||t||||||||||2018-06-01 05:33:28.730571|2018-06-01 05:33:28.730571
NCT00031382|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-02|||2008-03-03|2002-03-02|2002-03-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2002||2002-02-28|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||Imaging Study of Automatic Movements|A Neuroimaging Study of Automatic Movements|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:28.801317|2018-06-01 05:33:28.801317
NCT00031369|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-02|||2017-10-05|2002-03-02|2002-03-04|Estimate|||||||2017-10-05|2017-10-06|Actual|February 27, 2002||2002-02-27|March 10, 2015|2015-03-10|March 10, 2015||2015-03-10|||||Observational|||Brain Anatomy in Dystonia|In Vivo Mapping Of Structural and Biochemical Abnormalities In Patients With Primary Focal Dystonia|Terminated|||189|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:28.844989|2018-06-01 05:33:28.844989
NCT00031343|ClinicalTrials.gov processed this data on May 31, 2018|2002-03-02|||2008-03-03|2002-03-02|2002-03-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2002||2002-02-28|April 2004|2004-04-30|April 2004||2004-04-30|||||Interventional|||The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin|A Randomized, Controlled Study to Assess the Impact of Highly Active Antiretroviral Therapy to Hepatitis C Therapy in Patients Coinfected With HIV-1 and Treated With Peginterferon Alpha-2b and Ribavirin|Completed||Phase 2|128||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:28.894188|2018-06-01 05:33:28.894188
NCT00031317|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-28|||2008-03-03|2002-02-28|2002-03-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2002||2002-02-28|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression|Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression|Completed||Phase 4|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:28.945955|2018-06-01 05:33:28.945955
NCT00031304|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-28|||2018-05-23|2002-02-28|2002-03-01|Estimate|||||||2018-05-23|2018-05-24|Actual|February 27, 2002||2002-02-27|April 8, 2013|2013-04-08|April 8, 2013||2013-04-08|||||Observational|||Screening Protocol for HIV Vaccine Studies|Screening Subjects for HIV Vaccine Research Studies|Completed|||1324|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:29.022093|2018-06-01 05:33:29.022093
NCT00031291|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-28|||2008-03-03|2002-02-28|2002-03-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2002||2002-02-28|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin|Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:29.1925|2018-06-01 05:33:29.1925
NCT00031278|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-28|||2011-05-26|2002-02-28|2002-03-01|Estimate|||||||2011-05-26|2011-05-30|Estimate|October 2001||2001-10-31|May 2011|2011-05-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer|A Phase I/II Open Label, Multi-Center Study For The Evaluation Of The Combination Of CpG 7909 And Herceptin® In Patients With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|12|Actual|Pfizer||4|||||||||||||||||2018-06-01 05:33:29.260318|2018-06-01 05:33:29.260318
NCT00031265|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-28|||2005-10-11|2002-02-28|2002-03-01|Estimate|||||||2005-10-11|2005-10-12|Estimate|October 1998||1998-10-31|October 2005|2005-10-31||||||||Interventional|||Efficacy of a Family Telephone Intervention for Stroke||Completed||Phase 2|290||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:33:29.352743|2018-06-01 05:33:29.352743
NCT00031252|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-27|||2013-06-24|2002-02-27|2002-02-28|Estimate|||||||2013-06-24|2013-06-26|Estimate|January 2001||2001-01-31|June 2013|2013-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||Neighborhood-Level Influences on All-Cause Mortality||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:33:29.401862|2018-06-01 05:33:29.401862
NCT00031239|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-27|||2016-07-28|2002-02-27|2002-02-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2001||2001-09-30|May 2009|2009-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Sleep Apnea in Look AHEAD Participants - Ancillary to Look AHEAD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:29.444165|2018-06-01 05:33:29.444165
NCT00031226|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-27|||2014-03-12|2002-02-27|2002-02-28|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 2004||2004-09-30|March 2014|2014-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Biomarkers of Oxidative Stress in LOOK AHEAD - Ancillary to LOOK AHEAD||Completed|||||Arizona State University|||||f||||||||||||||2018-06-01 05:33:29.50346|2018-06-01 05:33:29.50346
NCT00031213|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-27|||2016-07-28|2002-02-27|2002-02-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Heavy Metals, Obesity and Cardiovascular Risk - Ancillary to Look AHEAD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:29.566639|2018-06-01 05:33:29.566639
NCT00031200|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-27|||2016-07-28|2002-02-27|2002-02-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||MRI Derived Organ & Tissue Mass Changes With Weight Loss - Ancillary to Look AHEAD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:29.605551|2018-06-01 05:33:29.605551
NCT00031187|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-27|||2011-10-21|2002-02-27|2002-02-28|Estimate|||||||2011-10-21|2011-10-24|Estimate|October 2000||2000-10-31|October 2011|2011-10-31|July 2003|Actual|2003-07-31|||||Interventional|||Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer|Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma|Completed||Phase 2|160||Seattle Genetics, Inc.|||||||||||||||||||2018-06-01 05:33:29.712163|2018-06-01 05:33:29.712163
NCT00031174|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-26|||2018-03-27|2002-02-26|2002-02-27|Estimate|||||||2018-03-27|2018-03-29|Actual|February 25, 2002||2002-02-25|February 21, 2018|2018-02-21||||||||Observational|||Blood Component Collection From Patients With Rheumatic or Kidney Disease and Healthy Volunteers|Collection Of Blood Components Using Apheresis From Patients With Rheumatic or Kidney Diseases and Healthy Volunteers|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:29.822903|2018-06-01 05:33:29.822903
NCT00031161|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-26|||2015-03-24|2002-02-26|2002-02-27|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|January 2002|2002-01-31|September 2005||2005-09-30|||||Interventional|||Prevention of Dichloroacetate Toxicity|Prevention of Dichloroacetate Toxicity|Completed||N/A|30|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:29.923354|2018-06-01 05:33:29.923354
NCT00031148|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-26|||2015-03-24|2002-02-26|2002-02-27|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|January 2002|2002-01-31|August 2003||2003-08-31|||||Interventional|||Keratinocyte Growth Factor to Prevent Acute GVHD|Phase I/II Trial of Keratinocyte Growth Factor (rHuKGF) to Prevent Acute GVHD in 6/6 HLA=BMT Recipients|Completed||Phase 1/Phase 2|72||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:30.003658|2018-06-01 05:33:30.003658
NCT00031135|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-26|||2015-03-24|2002-02-26|2002-02-27|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|January 2002|2002-01-31|September 2005||2005-09-30|||||Interventional|||Total Parenteral Nutrition-Associated Liver Disease|Prevention of TPN-Associated Hepatic Steatosis: A Placebo Controlled Trial|Terminated||Phase 2|48|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:30.069686|2018-06-01 05:33:30.069686
NCT00031122|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-26|||2010-10-04|2002-02-26|2002-02-27|Estimate|||||||2010-10-04|2010-10-05|Estimate|September 2000||2000-09-30|May 2009|2009-05-31|September 2012|Anticipated|2012-09-30|September 2011|Anticipated|2011-09-30||Observational|SBRR||Study of Genetic Risk Factors for Spina Bifida and Anencephaly|The Spina Bifida Research Resource|Unknown status|Active, not recruiting||1100|Anticipated|Office of Rare Diseases (ORD)|||1||f||||f||||||Samples With DNA|"~     DNA extracted from whole blood, saliva, buccal swab, and/or amniocytes~   "|||2018-06-01 05:33:30.129491|2018-06-01 05:33:30.129491
NCT00031109|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-25|||2012-05-03|2002-02-25|2002-02-26|Estimate|||||||2012-05-03|2012-05-04|Estimate||||May 2012|2012-05-31|May 2005|Actual|2005-05-31|||||Interventional|||The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys|An Open-Label, Passive Antibody Trial to Assess Efficacy in the Pathogenic SHIV-89.6P Macaque Model of Human Antibodies Generated by a Candidate HIV-1 Vaccine in a Phase I Clinical Trial|Completed||N/A|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:30.206008|2018-06-01 05:33:30.206008
NCT00031096|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-21|||2014-02-23|2002-02-21|2002-02-22|Estimate|||||||2014-02-23|2014-02-25|Estimate|January 2002||2002-01-31|February 2014|2014-02-28|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne|A 12-week, Randomized, Double-blind, Multicenter Study Comparing the Clinical Efficacy and Safety of Azelaic Acid 15% Gel (SH H 655 BA) With Its Vehicle (SH H 655 PBA) in Patients With Mild to Moderate Acne.|Completed||Phase 3|879|Actual|Bayer||2|||f||||||||||||||2018-06-01 05:33:30.280135|2018-06-01 05:33:30.280135
NCT00031083|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|||2012-06-07|2002-02-21|2002-02-22|Estimate|||||||2012-06-07|2012-06-08|Estimate|January 2002||2002-01-31|November 2004|2004-11-30|March 2004||2004-03-31|||||Interventional|||Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas|A Multi-center, Open Label, Two Part, Dose Escalation Study to Determine the Tolerability of Interferon-Beta Gene Transfer (BG00001) in the Treatment of Recurrent or Progressive Grade III and Grade IV Gliomas|Suspended||Phase 1|35||Biogen|||||||||||||||||||2018-06-01 05:33:30.383332|2018-06-01 05:33:30.383332
NCT00031070|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|||2015-03-05|2002-02-21|2002-02-22|Estimate|||||||2015-03-05|2015-03-09|Estimate||||August 2006|2006-08-31|December 2006|Actual|2006-12-31|||||Interventional|||Increasing HAART-Induced Immune Restoration With Cyclosporine|Augmenting the Magnitude of HAART-Induced Immune Restoration With the Use of Cyclosporine|Completed||Phase 2|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:30.454307|2018-06-01 05:33:30.454307
NCT00031057|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|||2011-02-25|2002-02-21|2002-02-22|Estimate|||||||2011-02-25|2011-02-28|Estimate||||November 2004|2004-11-30||||March 2003|Actual|2003-03-31||Interventional|||Vitamin B Therapy for Hyperlactatemia|A Pilot Study of Oral B Vitamin Therapy for Asymptomatic or Mildly Symptomatic Hyperlactatemia in Patients on NRTIs|Completed||N/A|225||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:30.543587|2018-06-01 05:33:30.543587
NCT00031044|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|||2012-05-17|2002-02-21|2002-02-22|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|November 2004|Actual|2004-11-30|||||Interventional|||Adding New Drugs for HIV Infected Patients Failing Current Therapy|A Randomized Phase I/II Placebo-controlled Study of Amdoxovir (DAPD) Versus Placebo Together With Enfuvirtide (T-20) Plus Optimized Background Therapy for HIV-Infected Subjects Failing Current Therapy|Completed||Phase 1/Phase 2|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:30.612083|2018-06-01 05:33:30.612083
NCT00031031|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|||2007-11-26|2002-02-21|2002-02-22|Estimate|||||||2007-11-26|2007-11-27|Estimate|June 2001||2001-06-30|November 2007|2007-11-30|November 2002|Actual|2002-11-30|||||Interventional|||Kanglaite Injection Phase I Study|Phase I Study of KLT in Patients With Solid Tumors Refractory to Standard Therapy|Completed||Phase 1|16|Actual|KangLaiTe USA|||||||||||||||||||2018-06-01 05:33:30.756122|2018-06-01 05:33:30.756122
NCT00031018|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|||2008-02-04|2002-02-21|2002-02-22|Estimate|||||||2008-02-04|2008-02-05|Estimate||||February 2008|2008-02-29||||||||Interventional|||Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha|Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha|Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:30.805845|2018-06-01 05:33:30.805845
NCT00031005|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|||2008-03-03|2002-02-20|2002-02-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2002||2002-02-28|February 2003|2003-02-28|February 2003||2003-02-28|||||Interventional|||Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency|Treatment of Leukocyte Adhesion Deficiency With Allogeneic Stem Cell Transplantation|Completed||Phase 2|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:30.874238|2018-06-01 05:33:30.874238
NCT00030992|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-20|2012-06-06||2012-08-13|2002-02-20|2002-02-21|Estimate|2012-06-06|2012-07-20|Estimate||||2012-08-13|2012-08-20|Estimate|February 2002||2002-02-28|June 2012|2012-06-30|June 2012|Actual|2012-06-30|January 2009|Actual|2009-01-31||Interventional|||BMS 247550 to Treat Kidney Cancer|A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma|Completed||Phase 2|102|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:33:30.951787|2018-06-01 05:33:30.951787
NCT00030979|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-15|||2008-03-03|2002-02-15|2002-02-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2002||2002-02-28|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Donepezil to Treat Dementia in Parkinson's Disease|Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial|Completed||Phase 4|28||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:31.492766|2018-06-01 05:33:31.492766
NCT00030966|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-15|||2009-06-17|2002-02-15|2002-02-18|Estimate|||||||2009-06-17|2009-06-18|Estimate|January 2002||2002-01-31|June 2009|2009-06-30|December 2005|Actual|2005-12-31|April 2005|Actual|2005-04-30||Interventional|||Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|1200|Actual|Biogen||2|||f||||t||||||||||2018-06-01 05:33:31.578606|2018-06-01 05:33:31.578606
NCT00030953|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2018-05-15|2002-02-14|2002-02-15|Estimate|||||||2018-05-15|2018-05-16|Actual|February 11, 2002||2002-02-11|February 3, 2015|2015-02-03|February 3, 2015||2015-02-03|||||Observational|||Magnetic Resonance Spectroscopy to Evaluate Tourette s Syndrome|Evaluation of Tourette's Syndrome With Multimetabolite H-Magnetic Resonance Spectroscopy at 3T|Completed|||100|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:31.764914|2018-06-01 05:33:31.764914
NCT00030940|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-14|||2017-06-30|2002-02-14|2002-02-15|Estimate|||||||2017-06-30|2017-07-02|Actual|February 11, 2002||2002-02-11|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Observational|||Cause, Development, and Progression of Stiff-Person Syndrome|Natural History and Immunopathogenesis of Stiff Person Syndrome (SPS)|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:31.822635|2018-06-01 05:33:31.822635
NCT00030238|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-12|||2018-03-14|2002-02-11|2002-02-12|Estimate|||||||2018-03-14|2018-03-15|Actual|February 6, 2002||2002-02-06|October 28, 2014|2014-10-28|December 14, 2007|Actual|2007-12-14|December 14, 2007|Actual|2007-12-14||Interventional|||Supplemental Calcium in Overweight People|Supplemental Calcium in Overweight Out-Patients|Completed||Phase 3|540|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:33:31.902489|2018-06-01 05:33:31.902489
NCT00030225|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-11|||2012-07-24|2002-02-11|2002-02-12|Estimate|||||||2012-07-24|2012-07-26|Estimate|January 2002||2002-01-31|July 2012|2012-07-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure|Phase 2 Evaluation of the Vitagen Extracorporeal Liver Assist Device (ELAD) System in the Management of the Patients With Fulminant Hepatic Failure|Completed||Phase 2|19|Actual|Vital Therapies, Inc.||2|||f||||t||||||||||2018-06-01 05:33:31.968437|2018-06-01 05:33:31.968437
NCT00030212|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-07|||2017-06-30|2002-02-07|2002-02-08|Estimate|||||||2017-06-30|2017-07-02|Actual|February 4, 2002||2002-02-04|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Immune Abnormalities in Sporadic Inclusion Body Myositis|Study of Immune Dysregulation in Patients With Sporadic Inclusion Body Myositis (s-IBM)|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:32.035434|2018-06-01 05:33:32.035434
NCT00030199|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-07|||2008-03-03|2002-02-07|2002-02-08|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2002||2002-02-28|February 2004|2004-02-29|February 2004||2004-02-29|||||Observational|||Brain Control of Blinking|Cortical Control of Voluntary Blinking|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:32.10409|2018-06-01 05:33:32.10409
NCT00030186|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-07||2012-05-03|2012-08-14|2002-02-07|2002-02-08|Estimate||||2012-05-03|2012-05-08|Estimate|2012-08-14|2012-08-23|Estimate|January 2002||2002-01-31|August 2012|2012-08-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation|An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations|Completed||Phase 2|37|Actual|Teva Pharmaceutical Industries||3|||f||||||||||||||2018-06-01 05:33:32.161821|2018-06-01 05:33:32.161821
NCT00030173|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-07|||2009-01-07|2002-02-07|2002-02-08|Estimate|||||||2009-01-07|2009-01-08|Estimate|October 2001||2001-10-31|January 2009|2009-01-31|June 2003|Actual|2003-06-30|||||Interventional|||A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors|A Phase 1, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Epothilone D in Patients With Advanced Solid Tumors|Completed||Phase 1|45||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:33:32.219751|2018-06-01 05:33:32.219751
NCT00030160|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-07|||2010-01-12|2002-02-07|2002-02-08|Estimate|||||||2010-01-12|2010-01-13|Estimate|April 2002||2002-04-30|January 2010|2010-01-31|July 2005||2005-07-31|||||Interventional|||Strength Training for Obesity Prevention|Strength Training for Obesity Prevention|Completed||Phase 2|160||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:33:32.304132|2018-06-01 05:33:32.304132
NCT00030147|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-06|2016-06-02||2016-07-18|2002-02-06|2002-02-07|Estimate|2016-07-18|2016-09-05|Estimate||||2016-07-18|2016-09-05|Estimate|February 2002||2002-02-28|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Raloxifene and Rimostil for Perimenopause-Related Depression|The Efficacy of Phytoestrogens and Selective Estrogen Receptor Modulators in Perimenopause-Related Depression|Completed||Phase 4|65|Actual|National Institutes of Health Clinical Center (CC)|Two participants signed the consent but were not started (did not meet inclusion criteria.) Early termination of Rimostil treatment arm limits the generalizability of treatment response in this arm.|4|||f||||f||||||||No||2018-06-01 05:33:33.341991|2018-06-01 05:33:33.341991
NCT00030134|ClinicalTrials.gov processed this data on May 31, 2018|2002-02-02|||2008-03-03|2002-02-02|2002-02-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|February 2003|2003-02-28|February 2003||2003-02-28|||||Observational|||Data Collection in Women With Fabry Disease|A Study to Collect Normative Data in Female Patients With Fabry Disease|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:34.70364|2018-06-01 05:33:34.70364
NCT00030121|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-31|||2008-02-19|2002-01-31|2002-02-01|Estimate|||||||2008-02-19|2008-02-20|Estimate|December 1999||1999-12-31|February 2008|2008-02-29||||||||Interventional|||Carperitide in Acute Respiratory Distress Syndrome (ARDS)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Evaluation of the Safety and Efficacy of Carperitide Infusion in Patients With ARDS|Completed||Phase 2|||Suntory Pharmaceutical|||||||||||||||||||2018-06-01 05:33:34.782136|2018-06-01 05:33:34.782136
NCT00030069|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-30|||2016-01-14|2002-01-30|2002-01-31|Estimate|||||||2016-01-14|2016-01-15|Estimate|September 2001||2001-09-30|January 2016|2016-01-31|May 2009|Actual|2009-05-31|September 2007|Actual|2007-09-30||Interventional|||Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes|Calcitriol and Dexamethasone for Myelodysplastic Syndromes|Completed||Phase 2|32|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:33:34.849367|2018-06-01 05:33:34.849367
NCT00030056|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-30|||2015-03-24|2002-01-30|2002-01-31|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|January 2002|2002-01-31|December 2005||2005-12-31|||||Interventional|||GM-CSF in Patients With Pulmonary Alveolar Proteinosis|Trial of GM-CSF for Alveolar Proteinosis|Terminated||Phase 2|48|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:34.918622|2018-06-01 05:33:34.918622
NCT00030043|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-30|||2015-03-24|2002-01-30|2002-01-31|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|January 2002|2002-01-31|August 2003||2003-08-31|||||Interventional|||An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors|Penetrating Auditory Brainstem Implant for Neurofibromatosis 2|Completed||Phase 1|10||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:33:34.998507|2018-06-01 05:33:34.998507
NCT00030030|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-30|||2006-08-17|2002-01-30|2002-01-31|Estimate|||||||2006-08-17|2006-08-18|Estimate|July 2000||2000-07-31|July 2006|2006-07-31|June 2002||2002-06-30|||||Interventional|||Evaluating Silymarin for Chronic Hepatitis C|Evaluating Silymarin for Chronic Hepatitis C|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:35.176469|2018-06-01 05:33:35.176469
NCT00030004|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-29|||2006-08-17|2002-01-29|2002-01-30|Estimate|||||||2006-08-17|2006-08-18|Estimate|May 2000||2000-05-31|July 2006|2006-07-31|April 2001||2001-04-30|||||Interventional|||Pilot Study of Spinal Manipulation for Chronic Neck Pain|Pilot Study of Spinal Manipulation for Chronic Neck Pain|Terminated||Phase 1|30||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:35.276472|2018-06-01 05:33:35.276472
NCT00029991|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-29|||2006-08-17|2002-01-29|2002-01-30|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2000||2000-09-30|July 2006|2006-07-31|July 2005||2005-07-31|||||Interventional|||Extract of Ginkgo Biloba (EGB 761) and Vascular Function|Extract of Ginkgo Biloba (Egb 761) and Vascular Function|Completed||Phase 1/Phase 2|100||National Center for Complementary and Integrative Health (NCCIH)|||||||||||||||||||2018-06-01 05:33:35.34088|2018-06-01 05:33:35.34088
NCT00029978|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-29|||2006-08-17|2002-01-29|2002-01-30|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2000||2000-09-30|July 2006|2006-07-31|January 2004||2004-01-31|||||Observational|||Transfer of Neural Energy Between Humans|Transfer of Neural Energy Between Human Subjects|Completed|||60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:35.410054|2018-06-01 05:33:35.410054
NCT00029965|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-27|||2018-04-24|2002-01-26|2002-01-28|Estimate|||||||2018-04-24|2018-04-25|Actual|January 25, 2002||2002-01-25|April 10, 2018|2018-04-10||||||||Observational|||Nervous System Degeneration in Glycosphingolipid Storage Disorders|Investigation of Neurodegeneration in the Glycosphingolipid Storage Disorders|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:35.463161|2018-06-01 05:33:35.463161
NCT00029952|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-26|||2008-03-03|2002-01-25|2002-01-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1993||1993-07-31|September 2004|2004-09-30|September 2004||2004-09-30|||||Observational|||Long Term Post Operative Follow-Up of Cushing Syndrome|Long-Term Post-Operative Follow-Up of Cushing Syndrome|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:35.56883|2018-06-01 05:33:35.56883
NCT00029939|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-26|||2017-06-30|2002-01-25|2002-01-28|Estimate|||||||2017-06-30|2017-07-02|Actual|January 22, 2002||2002-01-22|November 23, 2010|2010-11-23|November 23, 2010||2010-11-23|||||Observational|||Brain Activity During Production of Movement|Real-Time Analysis of Scalp Electroencephalography and Magnetoencephalography During Production of Human Voluntary Movement|Completed|||140|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:35.641348|2018-06-01 05:33:35.641348
NCT00029926|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-26|||2008-03-03|2002-01-25|2002-01-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|November 2002|2002-11-30|November 2002||2002-11-30|||||Observational|||Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity|A Pilot Study of F-18FDG Positron Emission Tomography (PET) to Assess the Distribution of Activated Lymphocytes in Systemic Lupus Erythematosus (SLE)|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:35.722648|2018-06-01 05:33:35.722648
NCT00029913|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-24|||2010-08-31|2002-01-24|2002-01-25|Estimate|||||||2010-08-31|2010-09-02|Estimate|April 2002||2002-04-30|August 2010|2010-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials|A Multi-Site Evaluation of Virologic, Immunologic, and Clinical Natural History of Participants Enrolled in Phase I and Phase II HIV-1 Vaccine Protocols or HIV-1 Vaccine Preparedness Cohorts Who Develop HIV-1 Infection Subsequent to Trial Enrollment|Completed|||54|Anticipated|HIV Vaccine Trials Network|||1||f||||||||||||||2018-06-01 05:33:35.80898|2018-06-01 05:33:35.80898
NCT00029900|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-24|||2015-03-24|2002-01-24|2002-01-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|January 2002|2002-01-31|August 2003||2003-08-31|||||Interventional|||ADI-PEG in Patients With Metastatic Melanoma|Phase I Testing of ADI-PEG in Metastatic Melanoma|Completed||Phase 1|15||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:35.930178|2018-06-01 05:33:35.930178
NCT00029874|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-24|||2015-03-24|2002-01-24|2002-01-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|December 2004|2004-12-31|August 2003||2003-08-31|||||Interventional|||Minocycline in Patients With Huntington's Disease|Minocycline Dosing and Safety in Huntington's Disease|Completed||Phase 1/Phase 2|63||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:36.008528|2018-06-01 05:33:36.008528
NCT00029861|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2009-04-17|2002-01-23|2002-01-24|Estimate|||||||2009-04-17|2009-04-20|Estimate|August 2001||2001-08-31|April 2009|2009-04-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Obese Patients With or Without Comorbidities (RIO-North America)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities|Completed||Phase 3|3045|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:33:36.099161|2018-06-01 05:33:36.099161
NCT00029848|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2009-04-17|2002-01-23|2002-01-24|Estimate|||||||2009-04-17|2009-04-20|Estimate|October 2001||2001-10-31|April 2009|2009-04-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|RIO-Diabetes||Obese Patients With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes|Completed||Phase 3|1045|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:33:36.261694|2018-06-01 05:33:36.261694
NCT00029835|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2009-04-17|2002-01-23|2002-01-24|Estimate|||||||2009-04-17|2009-04-20|Estimate|September 2001||2001-09-30|April 2009|2009-04-30|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|RIO-Lipids||Obese Patients With Untreated Dyslipidemias|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias|Completed||Phase 3|1033|Actual|Sanofi|||||f||||||||||||||2018-06-01 05:33:36.531639|2018-06-01 05:33:36.531639
NCT00029822|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2008-06-06|2002-01-23|2002-01-24|Estimate|||||||2008-06-06|2008-06-09|Estimate|May 2001||2001-05-31|June 2008|2008-06-30|March 2005|Actual|2005-03-31|||||Interventional|||Clinical Trial in Males With BPH (Enlarged Prostate)|Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.|Completed||Phase 3|1522|Actual|Sanofi|||||||||||||||||||2018-06-01 05:33:36.696027|2018-06-01 05:33:36.696027
NCT00029809|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2006-08-17|2002-01-23|2002-01-24|Estimate|||||||2006-08-17|2006-08-18|Estimate||||July 2006|2006-07-31||||||||Interventional|||Chinese Exercise Modalities in Parkinson's Disease|Chinese Exercise Modalities in Parkinson's Disease|Completed||Phase 1/Phase 2|40||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:36.879921|2018-06-01 05:33:36.879921
NCT00029796|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2013-03-21|2002-01-23|2002-01-24|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Isoflavones and Acute-phase Response in Chronic Renal Failure|Isoflavones and Acute-phase Response in Chronic Renal Failure|Completed||Phase 2|52||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:36.952795|2018-06-01 05:33:36.952795
NCT00029783|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2006-08-17|2002-01-23|2002-01-24|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2000||2000-09-30|July 2006|2006-07-31|June 2005||2005-06-30|||||Interventional|||Efficacy of Distant Healing in Glioblastoma Treatment|Efficacy of Distant Healing in Glioblastoma Treatment|Completed||Phase 2|150||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:37.035251|2018-06-01 05:33:37.035251
NCT00029770|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-23|||2008-01-23|2002-01-23|2002-01-24|Estimate|||||||2008-01-23|2008-01-25|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Chiropractic Care, Medication, and Self-Care for Neck Pain|Chiropractic Care, Medication, and Self-Care for Neck Pain|Completed||Phase 2|270||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:37.108657|2018-06-01 05:33:37.108657
NCT00029757|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-22|||2005-11-04|2002-01-22|2002-01-23|Estimate|||||||2005-11-04|2005-11-07|Estimate||||December 2003|2003-12-31||||||||Interventional|||Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women|Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women|Completed||N/A|15||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:37.174227|2018-06-01 05:33:37.174227
NCT00029731|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-21|||2015-03-24|2002-01-21|2002-01-22|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 2001||2001-08-31|January 2002|2002-01-31|July 2005||2005-07-31|||||Interventional|||Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients|Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease|Completed||Phase 2|30|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:37.333299|2018-06-01 05:33:37.333299
NCT00029718|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-14|||2017-06-30|2002-01-18|2002-01-21|Estimate|||||||2017-06-30|2017-07-02|Actual|January 16, 2002||2002-01-16|November 18, 2011|2011-11-18|November 18, 2011||2011-11-18|||||Observational|||Interhemispheric Interactions Associated With Performance of Voluntary Movements in Patients With Stroke Motor Disability|Interhemispheric Interactions Associated With Performance of Voluntary Movements in Patients With Stroke Motor Disability|Completed|||57|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:37.387119|2018-06-01 05:33:37.387119
NCT00029692|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-18|||2006-07-24|2002-01-18|2002-01-21|Estimate|||||||2006-07-24|2006-07-26|Estimate|March 2002||2002-03-31|July 2006|2006-07-31|March 2005||2005-03-31|||||Interventional|||Effects of Ginseng and Ginkgo on Drug Disposition in Man|Effects of Ginseng and Ginkgo on Drug Disposition in Man|Completed||Phase 2|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:37.440729|2018-06-01 05:33:37.440729
NCT00029679|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-18|||2006-08-16|2002-01-18|2002-01-21|Estimate|||||||2006-08-16|2006-08-18|Estimate|September 2000||2000-09-30|August 2006|2006-08-31|July 2005||2005-07-31|||||Interventional|||Borage Oil and Ginkgo Biloba (EGb 761) in Asthma|Borage Oil and Ginkgo Biloba (EGb 761) in Asthma|Completed||Phase 1/Phase 2|280||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:37.482461|2018-06-01 05:33:37.482461
NCT00029666|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-17|||2008-03-03|2002-01-17|2002-01-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Study of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease|Placebo Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:37.54903|2018-06-01 05:33:37.54903
NCT00029653|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-16|||2008-03-03|2002-01-16|2002-01-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Effect of Transcranial Magnetic Stimulation on Free Will|The Effect of Transcranial Magnetic Stimulation on Free Will|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:37.605724|2018-06-01 05:33:37.605724
NCT00029640|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-16|||2008-03-03|2002-01-16|2002-01-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||The Treatment of Children and Adolescents With Treatment-Resistant Depression|Clinical and Neurochemical Effects of Pharmacologic Treatment in Pediatric Depression|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:37.67915|2018-06-01 05:33:37.67915
NCT00029627|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-16|||2008-03-03|2002-01-16|2002-01-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|December 2004|2004-12-31|December 2004||2004-12-31|||||Observational|||Brain Receptors in Sympathetic Nervous System Regulation|Alpha(2)-Adrenoreceptor (AR) Subtype Polymorphisms and Physiological Responses to Alpha(2)-AR Agonist and Antagonist Drugs|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:37.730639|2018-06-01 05:33:37.730639
NCT00029614|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-16|||2010-04-27|2002-01-16|2002-01-17|Estimate|||||||2010-04-27|2010-04-28|Estimate|May 2006||2006-05-31|April 2010|2010-04-30|July 2007|Actual|2007-07-31|||||Interventional|||Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD|Psychopharmacology of Adolescents With AUD and ADHD|Completed||Phase 2|24|Anticipated|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:33:37.78695|2018-06-01 05:33:37.78695
NCT00029601|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-15|||2008-03-03|2002-01-15|2002-01-16|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|July 2002|2002-07-31|July 2002||2002-07-31|||||Observational|||Surround Inhibition in Patients With Dystonia|The Study of Surround Inhibition in Patients With Dystonia|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:37.928141|2018-06-01 05:33:37.928141
NCT00029588|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-15|||2017-10-05|2002-01-15|2002-01-16|Estimate|||||||2017-10-05|2017-10-06|Actual|January 11, 2002||2002-01-11|July 24, 2017|2017-07-24|July 24, 2017||2017-07-24|||||Observational|||Reward-Related Processes and Brain Function|Reward-Related Processes and Brain Function|Completed|||241|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:37.995672|2018-06-01 05:33:37.995672
NCT00029575|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-15|||2008-03-03|2002-01-15|2002-01-16|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Interventional|||Magnetic Resonance Imaging of Narrowed Arteries|Intravascular Narrow Field Magnetic Resonance Arterial Wall Imaging|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:38.074446|2018-06-01 05:33:38.074446
NCT00029536|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-15|2017-03-31||2017-06-02|2002-01-15|2002-01-16|Estimate|2017-06-02|2017-06-05|Actual||||2017-06-02|2017-06-05|Actual|October 2000||2000-10-31|June 2017|2017-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Progesterone vs Placebo Therapy for Women With Epilepsy|Phase 3 Study of Progesterone vs Placebo Therapy|Completed||Phase 3|294|Actual|Beth Israel Deaconess Medical Center||4|||f||||t||||||||||2018-06-01 05:33:38.171308|2018-06-01 05:33:38.171308
NCT00029523|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-15|||2007-02-27|2002-01-15|2002-01-16|Estimate|||||||2007-02-27|2007-02-28|Estimate|April 2001||2001-04-30|February 2007|2007-02-28|November 2004||2004-11-30|||||Interventional|||DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor|A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis|Completed||Phase 4|100||Pacira Pharmaceuticals, Inc|||||||||||||||||||2018-06-01 05:33:38.67276|2018-06-01 05:33:38.67276
NCT00029510|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-14|||2006-08-17|2002-01-14|2002-01-15|Estimate|||||||2006-08-17|2006-08-18|Estimate|May 2002||2002-05-31|July 2006|2006-07-31|June 2006||2006-06-30|||||Interventional|||Magnesium and Asthma - Clinical Trials|Magnesium and Asthma - Clinical Trials|Completed||Phase 2|240||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:38.795811|2018-06-01 05:33:38.795811
NCT00029497|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-14|||2013-03-21|2002-01-14|2002-01-15|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Sham Device, Pill Placebo or Treatment For Arm Pain|Sham Device, Pill Placebo or Treatment For Arm Pain|Completed||Phase 2|240||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:38.852088|2018-06-01 05:33:38.852088
NCT00029484|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-11|||2006-08-17|2002-01-14|2002-01-15|Estimate|||||||2006-08-17|2006-08-18|Estimate||||July 2006|2006-07-31||||||||Interventional|||Tai Chi Chih and Varicella Zoster Immunity|Tai Chi Chih and Varicella Zoster Immunity|Completed||Phase 2|70||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:38.91939|2018-06-01 05:33:38.91939
NCT00029458|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-11|||2008-03-03|2002-01-11|2002-01-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|October 2005|2005-10-31|October 2005||2005-10-31|||||Interventional|||Clozapine for Treatment-Resistant Mania|A Double Blind Study Examining the Efficacy of Clozapine and a Study of the Pathophysiology in Treatment Resistant Mania|Completed||Phase 2|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:38.973705|2018-06-01 05:33:38.973705
NCT00029445|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-11|||2018-03-27|2002-01-11|2002-01-14|Estimate|||||||2018-03-27|2018-03-29|Actual|January 4, 2002||2002-01-04|March 7, 2018|2018-03-07||||||||Observational|||Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors|Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:39.033602|2018-06-01 05:33:39.033602
NCT00029406|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-10|||2015-12-15|2002-01-10|2002-01-11|Estimate|||||||2015-12-15|2015-12-16|Estimate|April 2001||2001-04-30|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|TRIPPS||Transfusion Infections Pediatric Prospective Study (TRIPPS)|Transfusion Infections Pediatric Prospective Study (TRIPPS)|Completed|||600|Actual|Children's Research Institute|||||f||||f||||||Samples Without DNA|"~     Whole blood and plasma samples~   "|||2018-06-01 05:33:39.10654|2018-06-01 05:33:39.10654
NCT00029393|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-10|||2016-07-28|2002-01-10|2002-01-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 2001||2001-08-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Induction of Stable Chimerism for Sickle Cell Anemia||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:39.159378|2018-06-01 05:33:39.159378
NCT00029380|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-10|||2016-07-28|2002-01-10|2002-01-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 1999||1999-01-31|September 2008|2008-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia|Sibling Donor Cord Blood Banking and Transplantation|Completed||Phase 2|30|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:39.235433|2018-06-01 05:33:39.235433
NCT00029341|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-10|||2008-07-29|2002-01-10|2002-01-11|Estimate|||||||2008-07-29|2008-07-30|Estimate||||January 2005|2005-01-31||||||||Interventional|||A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body|A Phase II Study to Demonstrate That Therapy With Efavirenz (EFV) and Other Antiretroviral Drugs Can Be Interrupted Without Selecting for EFV-Resistant Virus, and Relation to Kinetics of Drug Elimination|Completed||Phase 2|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:39.348742|2018-06-01 05:33:39.348742
NCT00029328|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-10|||2015-03-24|2002-01-10|2002-01-11|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|November 2001|2001-11-30|September 2003||2003-09-30|||||Interventional|||Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation|Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation|Completed||Phase 1/Phase 2|15||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:39.405954|2018-06-01 05:33:39.405954
NCT00029315|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-10|||2015-03-24|2002-01-10|2002-01-11|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|December 2001|2001-12-31|September 2004||2004-09-30|||||Interventional|||Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage|Intraventricular Rt-PA Pharmacokinetic and Pharmacodynamic Study|Completed||Phase 2|30|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:39.465615|2018-06-01 05:33:39.465615
NCT00029302|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2017-06-30|2002-01-09|2002-01-10|Estimate|||||||2017-06-30|2017-07-02|Actual|December 10, 2001||2001-12-10|December 24, 2008|2008-12-24|December 24, 2008||2008-12-24|||||Observational|||Brain Control of Bimanual (Both Hands) Movements|Brain Areas Involved in Temporal Linkage of Bilateral Movements|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:39.526948|2018-06-01 05:33:39.526948
NCT00029289|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2006-08-16|2002-01-09|2002-01-10|Estimate|||||||2006-08-16|2006-08-18|Estimate|April 2001||2001-04-30|August 2006|2006-08-31|October 2002||2002-10-31|||||Interventional|||Effects of Lutein in Retinitis Pigmentosa|Effects of Lutein in Retinitis Pigmentosa|Completed||Phase 1/Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:39.587482|2018-06-01 05:33:39.587482
NCT00029276|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2006-08-16|2002-01-09|2002-01-10|Estimate|||||||2006-08-16|2006-08-18|Estimate|August 2000||2000-08-31|August 2006|2006-08-31|April 2005||2005-04-30|||||Interventional|||Magnetic Stimulation for Parkinson Disease|Transcranial Magnetic Stimulation For Treatment Of Depression In Parkinson's Disease|Completed||Phase 1|50||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:39.635123|2018-06-01 05:33:39.635123
NCT00029263|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2006-08-17|2002-01-09|2002-01-10|Estimate|||||||2006-08-17|2006-08-18|Estimate|August 2001||2001-08-31|July 2006|2006-07-31|May 2004||2004-05-31|||||Interventional|||Screening Herbs for Drug Interactions|R-21 Project: Screening Herbs for Drug Interference|Completed||Phase 2|140||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:39.703125|2018-06-01 05:33:39.703125
NCT00029250|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2013-03-21|2002-01-09|2002-01-10|Estimate|||||||2013-03-21|2013-03-22|Estimate|November 2001||2001-11-30|March 2013|2013-03-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Garlic in Hyperlipidemia Caused by HAART|Phase II, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study on the Effects of Garlic on Hyperlipidemia Induced by HAART in HIV-positive Individuals|Withdrawn||Phase 2|0|Actual|National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:39.750816|2018-06-01 05:33:39.750816
NCT00029237|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2006-08-17|2002-01-09|2002-01-10|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2000||2000-09-30|August 2006|2006-08-31|May 2005||2005-05-31|||||Interventional|||Alternative Stress Management Approaches in HIV Disease|Alternative Stress Management Approaches in HIV Disease|Completed||Phase 3|392||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:39.903127|2018-06-01 05:33:39.903127
NCT00029224|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2012-01-30|2002-01-09|2002-01-10|Estimate|||||||2012-01-30|2012-02-01|Estimate|October 2001||2001-10-31|January 2012|2012-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions|A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions|Completed||Phase 4|500||Novartis|||||f||||||||||||||2018-06-01 05:33:39.982767|2018-06-01 05:33:39.982767
NCT00029211|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2006-08-17|2002-01-09|2002-01-10|Estimate|||||||2006-08-17|2006-08-18|Estimate|April 2000||2000-04-30|August 2006|2006-08-31|March 2003||2003-03-31|||||Interventional|||A Trial of Echinacea in Children|A Randomized Controlled Trial of Echinacea in Children|Completed||Phase 3|600||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:40.071989|2018-06-01 05:33:40.071989
NCT00029198|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-09|||2014-04-09|2002-01-09|2002-01-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|April 2003||2003-04-30|April 2014|2014-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Preterm Infants' Weight Gain Following Massage Therapy|Preterm Infants' Weight Gain Following Massage Therapy|Completed||Phase 3|139|Actual|University of Miami||2|||f||||t||||||||||2018-06-01 05:33:40.156627|2018-06-01 05:33:40.156627
NCT00029185|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-08|||2015-03-24|2002-01-08|2002-01-09|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|October 2001|2001-10-31|September 2007||2007-09-30|||||Interventional|||Study of Dehydrex in Patients With Corneal Erosion|Topical Dehydrex in Treating Recurrent Corneal Erosion|Completed||N/A|300|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:40.254737|2018-06-01 05:33:40.254737
NCT00029172|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-08|2009-08-03||2009-12-31|2002-01-08|2002-01-09|Estimate|2009-12-31|2010-01-28|Estimate||||2009-12-31|2010-01-28|Estimate|May 1999||1999-05-31|December 2009|2009-12-31|December 2005|Actual|2005-12-31|||||Interventional|||Treatment for Post-Stroke Depression|Treatment for Post-Stroke Depression|Completed||Phase 4|188|Actual|Indiana University||1|||f||||t||||||||||2018-06-01 05:33:40.370613|2018-06-01 05:33:40.370613
NCT00029159|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-08|||2012-06-04|2002-01-08|2002-01-09|Estimate|||||||2012-06-04|2012-06-05|Estimate|November 1992||1992-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|January 2007|Actual|2007-01-31||Interventional|||The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome|The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome|Completed||Phase 3|200|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-06-01 05:33:40.59103|2018-06-01 05:33:40.59103
NCT00029146|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-08|2012-01-17||2012-03-24|2002-01-08|2002-01-09|Estimate|2012-02-23|2012-03-26|Estimate||||2012-03-24|2012-03-27|Estimate|July 2002||2002-07-31|March 2012|2012-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|COSS||Carotid Occlusion Surgery Study|Carotid Occlusion Surgery Study|Terminated||Phase 3|700|Actual|University of North Carolina, Chapel Hill||2||Pre-specified futility boundary was reached.|f||||t||||||||||2018-06-01 05:33:40.77881|2018-06-01 05:33:40.77881
NCT00029133|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-08|||2005-06-23|2002-01-08|2002-01-09|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2000||2000-02-29|August 2003|2003-08-31||||||||Interventional|||Hypothermia During Intracranial Aneurysm Surgery Trial||Completed||Phase 3|1000||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:33:41.560074|2018-06-01 05:33:41.560074
NCT00028431|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2014-05-20|2002-01-08|2002-01-09|Estimate|||||||2014-05-20|2014-05-22|Estimate|August 2001||2001-08-31|May 2014|2014-05-31|June 2005|Actual|2005-06-30|January 2003|Actual|2003-01-31||Interventional|||Novel Adjuvants for Peptide-Based Melanoma Vaccines|An Open Label Study of MDX-CTLA4 in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 in the Treatment of Patients With Resected Stage III or IV Melanoma|Completed||Phase 1|19|Actual|University of Southern California|||||||||||||||||||2018-06-01 05:33:41.627603|2018-06-01 05:33:41.627603
NCT00028418|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2015-03-24|2002-01-08|2002-01-09|Estimate|||||||2015-03-24|2015-03-25|Estimate|February 1999||1999-02-28|November 2001|2001-11-30|March 2004||2004-03-31|||||Interventional|||Clofarabine in Chronic Lymphocytic Leukemia|Phase I Study of CL-F-ARA-A in Solid and Hematologic Malignancies|Completed||Phase 1|100||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:41.694429|2018-06-01 05:33:41.694429
NCT00028405|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2005-06-23|2002-01-08|2002-01-09|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 2001||2001-11-30|March 2003|2003-03-31|December 2002||2002-12-31|||||Interventional|||Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors|A Multicenter Phase I Safety and Tolerability Study of the Oncolux System for Intratumoral Delivery of Non-Coherent Light for the Photoactivation of LS 11 in Patients With Refractory Solid Tumors|Completed||Phase 1|48||Light Sciences LLC|||||||||||||||||||2018-06-01 05:33:41.763823|2018-06-01 05:33:41.763823
NCT00029120|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-05|||2017-06-30|2002-01-05|2002-01-07|Estimate|||||||2017-06-30|2017-07-02|Actual|December 18, 2001||2001-12-18|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder|MRI Contrast Imaging in the Evaluation and Follow-up of Patients With Memory Disorder and Healthy Controls|Completed|||450||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:41.860151|2018-06-01 05:33:41.860151
NCT00029107|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-05|2011-10-26||2012-04-10|2002-01-05|2002-01-07|Estimate|2012-02-21|2012-04-03|Estimate||||2012-04-10|2012-04-16|Estimate|December 2001||2001-12-31|April 2012|2012-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis|Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis|Completed||Phase 2|47|Actual|National Institutes of Health Clinical Center (CC)|The study was not blinded. In addition, the study was limited to patients who had failed antiviral therapy.|2|||f||||f||||||||||2018-06-01 05:33:41.930471|2018-06-01 05:33:41.930471
NCT00029068|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2008-03-03|2002-01-04|2002-01-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2002||2002-01-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Observational|||Cortical Excitability in Obsessive-Compulsive and Related Disorders|Studies of Cortical Excitability in Obsessive-Compulsive Disorder, Related Disorder and Healthy Volunteers Using Paired-Pulse Transcranial Magnetic Stimulation|Completed|||145||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:42.162518|2018-06-01 05:33:42.162518
NCT00029042|ClinicalTrials.gov processed this data on May 31, 2018|2002-01-04|||2008-08-26|2002-01-04|2002-01-07|Estimate|||||||2008-08-26|2008-08-27|Estimate|January 2002||2002-01-31|August 2008|2008-08-31|October 2005|Actual|2005-10-31|||||Interventional|||Infliximab to Treat Children With Juvenile Rheumatoid Arthritis|A Randomized Double Blind Controlled Intra-Patient Dose Escalation Phase II Trial of Infliximab in Pediatric Patients With Refractory Juvenile Rheumatoid Arthritis|Terminated||Phase 2|48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:42.218036|2018-06-01 05:33:42.218036
NCT00028379|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-27|||2008-03-03|2001-12-27|2001-12-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Enhancement of Use-Dependent Plasticity by Somatosensory Stimulation in Chronic Stroke|Enhancement of Use-Dependent Plasticity by Somatosensory Stimulation in Chronic Stroke|Completed||N/A|52||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:42.292988|2018-06-01 05:33:42.292988
NCT00028366|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-27|||2012-08-15|2001-12-27|2001-12-28|Estimate|||||||2012-08-15|2012-08-16|Estimate||||August 2012|2012-08-31|July 2005|Actual|2005-07-31|||||Interventional|||Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People|A Randomized, Comparative Study of Lopinavir/Ritonavir Versus GW433908 and Ritonavir Versus Lopinavir/Ritonavir and GW433908 (In Combination With Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase Inhibitors) in HIV-1-Infected Subjects With Virologic Treatment Failure|Completed||N/A|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:42.352775|2018-06-01 05:33:42.352775
NCT00028353|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-22|||2013-11-13|2001-12-22|2001-12-24|Estimate|||||||2013-11-13|2013-11-15|Estimate|April 2001||2001-04-30|November 2013|2013-11-30|July 2003||2003-07-31|||||Interventional|||A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)||Completed||Phase 2|500||GTx|||||||||||||||||||2018-06-01 05:33:42.430008|2018-06-01 05:33:42.430008
NCT00028340|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-21|||2017-10-18|2001-12-21|2001-12-24|Estimate|||||||2017-10-18|2017-10-19|Actual|December 13, 2001||2001-12-13|August 25, 2017|2017-08-25||||||||Observational|||High-Risk Breast Duct Epithelium|Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile|Recruiting|||184|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:42.51138|2018-06-01 05:33:42.51138
NCT00028327|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-20|||2011-02-28|2001-12-20|2001-12-21|Estimate|||||||2011-02-28|2011-03-02|Estimate||||July 2004|2004-07-31||||July 2004|Actual|2004-07-31||Interventional|||Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care|Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy for HIV-Infected Subjects With CD4 Cell Counts Less Than 350 Cells/mm3 Admitted to Intensive Care Areas With an AIDS-Defining Illness, Pneumonia, or Sepsis|Completed||Phase 3|250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:42.583243|2018-06-01 05:33:42.583243
NCT00028314|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-20|||2013-07-26|2001-12-20|2001-12-21|Estimate|||||||2013-07-26|2013-07-29|Estimate|March 2002||2002-03-31|July 2013|2013-07-31|March 2005|Actual|2005-03-31|||||Interventional|||Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients|A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting|Completed||N/A|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:42.645264|2018-06-01 05:33:42.645264
NCT00028301|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-20||2010-09-10|2010-09-10|2001-12-20|2001-12-21|Estimate||||2010-09-10|2010-09-13|Estimate|2010-09-10|2010-09-13|Estimate|February 2001||2001-02-28|September 2010|2010-09-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)|A Randomized Open-label Study of the Antiviral Efficacy and Safety of Atazanavir Versus Lopinavir/Ritonavir(LPV/RTV), Each in Combination With Two Nucleosides in Subjects Who Have Experienced Virologic Failure With Prior Protease Inhibitor-Containing HAART Regimen(s)|Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:33:42.836248|2018-06-01 05:33:42.836248
NCT00028288|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-19|||2012-03-09|2001-12-19|2001-12-20|Estimate|||||||2012-03-09|2012-03-13|Estimate|September 2001||2001-09-30|March 2012|2012-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Study of Daclizumab in Patients With Chronic, Persistent Asthma|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma|Completed||Phase 2|120||Facet Biotech|||||f||||||||||||||2018-06-01 05:33:43.108341|2018-06-01 05:33:43.108341
NCT00028275|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-18|||2008-03-03|2001-12-18|2001-12-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||Gamma Interferon Therapy for Chronic Hepatitis C|Pilot Studies of Gamma Interferon Therapy for Chronic Hepatitis C|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:43.235794|2018-06-01 05:33:43.235794
NCT00028262|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|2015-01-09||2016-09-21|2001-12-17|2001-12-18|Estimate|2015-01-16|2015-01-21|Estimate||||2016-09-21|2016-10-27|Estimate|February 2001||2001-02-28|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis|A Combination Therapy With Cystagon and N-Acetylcysteine for INCL Patients|Completed||Phase 4|10|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 05:33:43.323969|2018-06-01 05:33:43.323969
NCT00028249|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|||2008-03-03|2001-12-17|2001-12-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Observational|||Process and Outcomes of Pain Management|A Randomized Study Evaluating the Process and Outcomes of the Pain and Palliative Care Team Intervention|Completed|||298||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:43.535091|2018-06-01 05:33:43.535091
NCT00028236|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|||2017-06-30|2001-12-17|2001-12-18|Estimate|||||||2017-06-30|2017-07-02|Actual|December 10, 2001||2001-12-10|July 25, 2011|2011-07-25|July 25, 2011|Actual|2011-07-25|July 25, 2011|Actual|2011-07-25||Interventional|||Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)|Ex Vivo Retroviral Gene Transfer For Treatment of X-Linked Severe Combined Immunodeficiency (XSCID)|Completed||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:43.591729|2018-06-01 05:33:43.591729
NCT00028210|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|||2008-03-03|2001-12-17|2001-12-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Enhanced Tactile (Touch) Spatial Acuity in Upper Limb Amputees|Enhancement of Tactile Spatial Acuity in Upper Limb Amputees|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:43.675443|2018-06-01 05:33:43.675443
NCT00028197|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|||2008-03-03|2001-12-17|2001-12-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Comparison of Externally and Self-Initiated Movements|Comparison of Externally and Self-Initiated Movements|Completed|||55||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:43.73392|2018-06-01 05:33:43.73392
NCT00028184|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|||2008-03-03|2001-12-17|2001-12-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|December 2004|2004-12-31|December 2004||2004-12-31|||||Observational|||Role of the Intact Hemisphere in Recovery of Motor Function After Stroke|Role of the Intact Hemisphere in Recovery of Motor Function After Stroke|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:43.787295|2018-06-01 05:33:43.787295
NCT00028171|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|||2005-06-23|2001-12-17|2001-12-18|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing|Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Once Daily Versus Twice Daily Dosing|Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:43.846225|2018-06-01 05:33:43.846225
NCT00028158|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-17|||2005-06-23|2001-12-17|2001-12-18|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2001||2001-12-31|December 2001|2001-12-31|October 2003||2003-10-31|||||Interventional|||Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer|An Open-Label Phase Ib/II Study of the Safety, Tolerability and Efficacy of G207, a Genetically Engineered Herpes Simplex Type-1 Virus, Administered Intracerebrally to Patients With Recurrent Malignant Glioma|Completed||Phase 1/Phase 2|65||MediGene|||||||||||||||||||2018-06-01 05:33:43.897581|2018-06-01 05:33:43.897581
NCT00028145|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-13|||2014-10-08|2001-12-13|2001-12-14|Estimate|||||||2014-10-08|2014-10-10|Estimate|October 2002||2002-10-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission|Perinatal Core Protocol|Completed|||3090|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||1||f||||t||||||Samples With DNA|"~     Blood and amniotic fluid~   "|||2018-06-01 05:33:43.978947|2018-06-01 05:33:43.978947
NCT00028132|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-13|||2012-02-16|2001-12-13|2001-12-14|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|December 2005|Actual|2005-12-31|||||Interventional|||Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel|Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel|Completed||Phase 1|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:44.129683|2018-06-01 05:33:44.129683
NCT00028119|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-13|||2014-08-18|2001-12-13|2001-12-14|Estimate|||||||2014-08-18|2014-08-19|Estimate|August 2002||2002-08-31|August 2010|2010-08-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||HIV Incidence and Participation Retention in Pune, India|HPTN HIV Incidence and Participant Retention Protocol, Pune, India|Completed|||1070||HIV Prevention Trials Network|||2||f||||||||||||||2018-06-01 05:33:44.189012|2018-06-01 05:33:44.189012
NCT00028106|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-11|||2017-06-30|2001-12-11|2001-12-12|Estimate|||||||2017-06-30|2017-07-02|Actual|December 5, 2001||2001-12-05|August 21, 2008|2008-08-21|January 8, 2007||2007-01-08|||||Interventional|||131MIBG to Treat Malignant Pheochromocytoma|(131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma|Completed||Phase 2|32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:44.240297|2018-06-01 05:33:44.240297
NCT00028093|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-11|2011-05-26||2013-09-04|2001-12-11|2001-12-12|Estimate|2013-09-04|2013-11-08|Estimate||||2013-09-04|2013-11-08|Estimate|December 2001||2001-12-31|May 2013|2013-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease|Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease|Completed||Phase 4|50|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:33:44.325723|2018-06-01 05:33:44.325723
NCT00028080|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-11|||2018-05-23|2001-12-11|2001-12-12|Estimate|||||||2018-05-23|2018-05-24|Actual|November 21, 2001||2001-11-21|February 15, 2018|2018-02-15||||||||Observational|||Evaluation, Treatment, and Follow-up of Patients With Lyme Disease|Evaluation, Treatment and Follow up of Patients With Lyme Disease|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:44.717526|2018-06-01 05:33:44.717526
NCT00028067|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-10||2011-04-13|2011-04-28|2001-12-10|2001-12-11|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|August 2001||2001-08-31|April 2011|2011-04-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor|A Phase III Study Comparing the Antiviral Efficacy and Safety of Atazanavir With Nelfinavir: Each in Combination With Dual Nucleoside Therapy in HIV-Infected Subjects Who Have Failed a Regimen Not Containing a Protease Inhibitor|Terminated||Phase 3|500||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:33:44.793232|2018-06-01 05:33:44.793232
NCT00027482|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2017-06-30|2001-12-06|2001-12-07|Estimate|||||||2017-06-30|2017-07-02|Actual|December 4, 2001||2001-12-04|August 27, 2008|2008-08-27|August 27, 2008||2008-08-27|||||Observational|||Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers|Studies of Specific Immune Responses in HIV-Infected and HIV-Uninfected Volunteers|Completed|||2000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:44.906462|2018-06-01 05:33:44.906462
NCT00027469|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2008-03-03|2001-12-06|2001-12-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2001||2001-12-31|December 2005|2005-12-31|December 2005||2005-12-31|||||Interventional|||MRI to Detect Embolism Following Angiography and Angioplasty-Stenting of the Renal Artery|Evidence of Procedural Embolism Complicating Renal Artery Stenting|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:44.954735|2018-06-01 05:33:44.954735
NCT00027456|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-07|||2008-03-03|2001-12-06|2001-12-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2001||2001-11-30|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Leptin to Treat Severe Insulin Resistance - Pilot Study|Efficacy of Leptin in Severe Insulin Resistance: A Pilot Study|Completed||Phase 2|2||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:45.977083|2018-06-01 05:33:45.977083
NCT00027443|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-05|||2015-03-24|2001-12-06|2001-12-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 2001||2001-08-31|October 2001|2001-10-31|July 2007||2007-07-31|||||Interventional|||Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis|Giant Cell Myocarditis Treatment Trial Pilot Study|Completed||N/A|40|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:46.034259|2018-06-01 05:33:46.034259
NCT00027430|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-05|||2015-03-24|2001-12-06|2001-12-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|November 2001|2001-11-30|December 2004||2004-12-31|||||Interventional|||Androgen Replacement Therapy in Women With Hypopituitarism|TheraDerm Administration in Women With Hypopituitarism|Completed||N/A|50|Anticipated|FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:46.101027|2018-06-01 05:33:46.101027
NCT00027417|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-05|||2013-08-01|2001-12-06|2001-12-07|Estimate|||||||2013-08-01|2013-08-05|Estimate|April 2001||2001-04-30|August 2013|2013-08-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Study of Triostat in Infants During Heart Surgery|Triostat in Children During CardioPulmonary Bypass (CPB)|Completed||Phase 3|195|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-06-01 05:33:46.172109|2018-06-01 05:33:46.172109
NCT00027404|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-05|||2015-03-24|2001-12-06|2001-12-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|November 2002|2002-11-30|August 2005||2005-08-31|||||Interventional|||Study of Fluoxetine in Adults With Autistic Disorder|Fluoxetine vs Placebo in Adult Autistic Disorder|Completed||N/A|48||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:46.247291|2018-06-01 05:33:46.247291
NCT00027391|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-05|||2015-03-24|2001-12-06|2001-12-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2001||2001-09-30|November 2001|2001-11-30|August 2004||2004-08-31|||||Interventional|||Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)|Clinical Trials of Albuterol and Oxandrolone in FSH Dystrophy|Completed||N/A|160||FDA Office of Orphan Products Development|||||||||||||||||||2018-06-01 05:33:46.332879|2018-06-01 05:33:46.332879
NCT00027378|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-04|2012-02-08||2013-06-17|2001-12-04|2001-12-05|Estimate|2013-06-17|2013-07-18|Estimate||||2013-06-17|2013-07-18|Estimate|July 2001||2001-07-31|June 2013|2013-06-30|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|FIDAA||Pharmacological Intervention Project (Fluoxetine)|Pharmacological Intervention Project (Fluoxetine)|Completed||Phase 2|50|Actual|University of Pittsburgh|Limited sample size; efficacy of CBT/MET Therapy|2|||f||||f||||||||||2018-06-01 05:33:46.399136|2018-06-01 05:33:46.399136
NCT00027365|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-04|||2012-05-03|2001-12-04|2001-12-05|Estimate|||||||2012-05-03|2012-05-04|Estimate||||May 2012|2012-05-31|June 2003|Actual|2003-06-30|||||Interventional|||An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV|A Phase I Safety and Immunogenicity Trial of a Combination Vaccine (NefTat and gp120w61d) Formulated With AS02A (GlaxoSmithKline Biologicals) Given Intramuscularly in HIV-1 Uninfected Adult Participants|Completed||Phase 1|84||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:46.714118|2018-06-01 05:33:46.714118
NCT00027352|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-04|||2009-11-24|2001-12-04|2001-12-05|Estimate|||||||2009-11-24|2009-11-25|Estimate||||December 2008|2008-12-31||||||||Observational|||A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)|A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)|Completed|||6000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:46.852759|2018-06-01 05:33:46.852759
NCT00027339|ClinicalTrials.gov processed this data on May 31, 2018|2001-12-04|||2012-05-17|2001-12-04|2001-12-05|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|June 2005|Actual|2005-06-30|||||Interventional|||Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV|A Phase II Study of the Predictive Value of Pharmacokinetic-Adjusted Phenotypic Susceptibility (C12h/IC50) on Antiretroviral Response to Ritonavir-Enhanced Protease Inhibitors in Subjects With Failure of Previous Protease Inhibitor-Based Regimens|Completed||Phase 2|53|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:47.192935|2018-06-01 05:33:47.192935
NCT00027326|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2018-04-24|2001-11-30|2001-12-03|Estimate|||||||2018-04-24|2018-04-25|Actual|December 6, 2001||2001-12-06|April 18, 2018|2018-04-18||||||||Observational|||Collection of Blood and Urine From Patients Undergoing Radiation Therapy|Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy|Recruiting|||450|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:47.360111|2018-06-01 05:33:47.360111
NCT00027300|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-30|||2017-01-05|2001-11-30|2001-12-03|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2001||2001-11-30|January 2017|2017-01-31|January 2005|Actual|2005-01-31|November 2004|Actual|2004-11-30||Interventional|||Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|900|Actual|Biogen||2|||f||||t||||||||||2018-06-01 05:33:47.443776|2018-06-01 05:33:47.443776
NCT00027287|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-29|||2008-03-03|2001-11-29|2001-11-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2001||2001-11-30|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Laser and Medical Treatment of Diabetic Macular Edema|Preliminary Assessment of Laser and Medical Treatment of Diabetic Macular Edema|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:47.634985|2018-06-01 05:33:47.634985
NCT00027274|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-29|||2018-02-13|2001-11-29|2001-11-30|Estimate|||||||2018-02-13|2018-02-14|Actual|January 1, 2002||2002-01-01|December 17, 2017|2017-12-17||||||||Observational|||Cancer in Inherited Bone Marrow Failure Syndromes|Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study|Recruiting|||4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:47.7039|2018-06-01 05:33:47.7039
NCT00027261|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-29|||2012-05-15|2001-11-29|2001-11-30|Estimate|||||||2012-05-15|2012-05-17|Estimate||||May 2012|2012-05-31|December 2005|Actual|2005-12-31|||||Interventional|||Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults|A Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of High-Dose Live Recombinant Canarypox ALVAC-HIV Vaccine (vCP1452) in Healthy, HIV-1 Uninfected Adult Participants|Completed||Phase 1|110|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:47.78661|2018-06-01 05:33:47.78661
NCT00027248|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-29|||2005-09-12|2001-11-29|2001-11-30|Estimate|||||||2005-09-12|2005-09-14|Estimate|September 2000||2000-09-30|September 2005|2005-09-30|July 2003||2003-07-31|||||Interventional|||Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections|Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization|Completed||Phase 3|1400||BioWest Therapeutics Inc|||||||||||||||||||2018-06-01 05:33:47.867709|2018-06-01 05:33:47.867709
NCT00027235|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-28|||2005-06-23|2001-11-28|2001-11-29|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Popcorn Lung: the Discovery of a New Disease|Popcorn Lung: the Discovery of a New Disease|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:47.93371|2018-06-01 05:33:47.93371
NCT00027209|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-28|||2006-05-12|2001-11-28|2001-11-29|Estimate|||||||2006-05-12|2006-05-15|Estimate||||November 2005|2005-11-30||||||||Interventional|||Hormone Replacement in Menopausal Women With Epilepsy||Completed||Phase 2|125||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:33:47.984467|2018-06-01 05:33:47.984467
NCT00027196|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-27|||2008-03-03|2001-11-27|2001-11-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease|Clinical Correlates of Molecular Defects in Familial Cardiomyopathy|Completed|||9999999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:48.041798|2018-06-01 05:33:48.041798
NCT00027183|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-27|||2018-05-18|2001-11-27|2001-11-28|Estimate|||||||2018-05-18|2018-05-21|Actual|February 5, 1998||1998-02-05|February 20, 2018|2018-02-20||||||||Observational|||Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa|Role of Exotoxins in the Pathogenesis of Pseudomonas Aeruginosa|Recruiting|||225|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:48.090603|2018-06-01 05:33:48.090603
NCT00027170|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-27|||2018-04-24|2001-11-27|2001-11-28|Estimate|||||||2018-04-24|2018-04-25|Actual|November 19, 2001||2001-11-19|April 12, 2018|2018-04-12||||||||Observational|||Technical Development of Cardiovascular Magnetic Resonance Imaging|Technical Development of Cardiovascular Magnetic Resonance Imaging|Suspended|||8522|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:48.149161|2018-06-01 05:33:48.149161
NCT00027157|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-27|||2008-03-03|2001-11-27|2001-11-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2000||2000-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Determination of Variances in Exhaled Nitric Oxide Output in Normal Healthy Male Volunteers Consuming High and Low Nitrate/Nitrite Diets|The Determination of Variances in Exhaled Nitric Oxide Output in Normal Healthy Male Volunteers Consuming High and Low Nitrate/Nitrite Diets|Completed|||18||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:48.20424|2018-06-01 05:33:48.20424
NCT00027144|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-27|||2005-06-23|2001-11-27|2001-11-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 2000||2000-12-31|November 2001|2001-11-30|October 2002||2002-10-31|||||Interventional|||Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase|A Feasibility and Toxicity Study of Vaccination With HSP70 for the Treatment of Chronic Myelogenous Leukemia in the Chronic Phase|Completed||Phase 1|10||UConn Health|||||||||||||||||||2018-06-01 05:33:48.249535|2018-06-01 05:33:48.249535
NCT00027131|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-27|||2008-10-07|2001-11-27|2001-11-28|Estimate|||||||2008-10-07|2008-10-08|Estimate|December 2000||2000-12-31|October 2008|2008-10-31|October 2002||2002-10-31|||||Interventional|||Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70|Vaccination Against High Risk Breast Cancer With Autologous Tumor-Derived Heat Shock Protein 70-Peptide Complexes (HSP70)|Terminated||Phase 1/Phase 2|15||UConn Health||||difficulty with accrual|||||||||||||||2018-06-01 05:33:48.317814|2018-06-01 05:33:48.317814
NCT00027118|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-20|||2018-05-19|2001-11-20|2001-11-21|Estimate|||||||2018-05-19|2018-05-22|Actual|November 16, 2001||2001-11-16|August 17, 2016|2016-08-17|August 17, 2016||2016-08-17|||||Observational|||Morbidity After Diagnosis and Treatment of Breast Cancer Patients|A Prospective (Cohort) Study to Identify Factors Affecting Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center (BCC)|Completed|||326|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:48.377509|2018-06-01 05:33:48.377509
NCT00027105|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-20|||2018-05-19|2001-11-20|2001-11-21|Estimate|||||||2018-05-19|2018-05-22|Actual|November 16, 2001||2001-11-16|August 17, 2016|2016-08-17|August 17, 2016||2016-08-17|||||Observational|||Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer|Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center|Completed|||165|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:48.43693|2018-06-01 05:33:48.43693
NCT00027092|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-20|||2008-08-06|2001-11-20|2001-11-21|Estimate|||||||2008-08-06|2008-08-07|Estimate||||February 2004|2004-02-29||||||||Observational|||Use of a Test That Evaluates How the Body Handles Insulin and Glucose|AACTG Modified Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT) for the Assessment of Insulin Sensitivity: A Substudy of A5079|Completed|||50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:48.725237|2018-06-01 05:33:48.725237
NCT00027079|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-20|||2007-12-07|2001-11-20|2001-11-21|Estimate|||||||2007-12-07|2007-12-10|Estimate|September 2001||2001-09-30|December 2007|2007-12-31|August 2004|Actual|2004-08-31|||||Interventional|||Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)||Completed||Phase 2|360||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:33:48.805234|2018-06-01 05:33:48.805234
NCT00027066|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-20|||2011-06-16|2001-11-20|2001-11-21|Estimate|||||||2011-06-16|2011-06-17|Estimate|June 1993||1993-06-30|June 2011|2011-06-30|November 2001|Actual|2001-11-30|June 2000|Actual|2000-06-30||Interventional|||Warfarin Versus Aspirin Recurrent Stroke Study|A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke|Completed||Phase 3|2206||Columbia University||2|||f||||f||||||||||2018-06-01 05:33:48.885298|2018-06-01 05:33:48.885298
NCT00027053|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-19|||2010-05-11|2001-11-19|2001-11-20|Estimate|||||||2010-05-11|2010-05-13|Estimate|June 2002||2002-06-30|March 2006|2006-03-31|June 2006|Actual|2006-06-30|January 2006|Actual|2006-01-31||Interventional|SIESTA||Trazodone for Sleep Disturbance in Early Alcohol Recovery|Trazodone for Sleep Disturbance - Early Alcohol Recovery|Completed||Phase 2|173|Actual|Rhode Island Hospital||2|||f||||f||||||||||2018-06-01 05:33:49.029704|2018-06-01 05:33:49.029704
NCT00027040|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-16|||2015-01-15|2001-11-16|2001-11-19|Estimate|||||||2015-01-15|2015-01-16|Estimate||||October 2012|2012-10-31|June 2005|Actual|2005-06-30|||||Interventional|||A Study of Decreased Mental Function Associated With HIV|HIV-Associated Cognitive Impairment and Oxidative Stress: An In Vivo Proton Magnetic Resonance Spectroscopy Study of Cerebral Injury|Completed||N/A|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:49.151541|2018-06-01 05:33:49.151541
NCT00027027|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-15|2015-06-26||2015-07-24|2001-11-15|2001-11-16|Estimate|2015-07-24|2015-07-27|Estimate||||2015-07-24|2015-07-27|Estimate|November 2001||2001-11-30|July 2015|2015-07-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional||The baseline analysis population included all participants that were enrolled into one of the 5 treatment groups.|Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors|A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies|Completed||Phase 1|21|Actual|Genentech, Inc.|||||f||||||||||||||2018-06-01 05:33:49.677528|2018-06-01 05:33:49.677528
NCT00027014|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-15|||2007-02-07|2001-11-15|2001-11-16|Estimate|||||||2007-02-07|2007-02-08|Estimate|September 2001||2001-09-30|July 2006|2006-07-31|May 2005||2005-05-31|||||Interventional|||Herb-Opioid Interactions|Herb-Opioid Interactions|Completed||Phase 4|54||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:51.267842|2018-06-01 05:33:51.267842
NCT00027001|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-15|||2006-08-17|2001-11-15|2001-11-16|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2000||2000-09-30|July 2006|2006-07-31|June 2003||2003-06-30|||||Interventional|||Qigong Therapy For Heart Device Patients|Qigong Therapy for Heart Device Patients|Completed||N/A|30||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:51.3231|2018-06-01 05:33:51.3231
NCT00026988|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-15|||2006-08-17|2001-11-15|2001-11-16|Estimate|||||||2006-08-17|2006-08-18|Estimate|October 2001||2001-10-31|July 2006|2006-07-31|June 2006||2006-06-30|||||Interventional|||Creatine Therapy for Huntington's Disease|Creatine Therapy for Huntington's Disease|Completed||Phase 1/Phase 2|64||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:51.368144|2018-06-01 05:33:51.368144
NCT00026975|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-15|||2006-08-17|2001-11-15|2001-11-16|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 2000||2000-09-30|August 2006|2006-08-31|August 2005||2005-08-31|||||Interventional|||Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients|Clinical Outcomes Modeling for Laryngectomy Surgery Patients and Efficacy of Hyperbaric Oxygen Therapy|Completed||Phase 2|150||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:51.418169|2018-06-01 05:33:51.418169
NCT00026962|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1999||1999-09-30|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||Effects of Raloxifene on Hormone Levels|Assessment of the Effects of Raloxifene on Salivary Estradiol and Progesterone Levels|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:51.476655|2018-06-01 05:33:51.476655
NCT00026949|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1999||1999-08-31|August 2004|2004-08-31|August 2004||2004-08-31|||||Observational|||Study of Etoposide in Breast Cancer Patients|Pharmacokinetics of Etoposide in Patients With Breast Cancer Receiving High-Dose Etoposide|Completed|||33||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:51.623315|2018-06-01 05:33:51.623315
NCT00026936|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1999||1999-05-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Interventional|||A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning|A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning|Completed||Phase 2|140||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:51.718001|2018-06-01 05:33:51.718001
NCT00026923|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1999||1999-01-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Interventional|||A Phase II Evaluation of Telesurgery Systems|A Phase II Evaluation of Telesurgery Systems|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:51.783206|2018-06-01 05:33:51.783206
NCT00026910|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1998||1998-07-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma|Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:51.865911|2018-06-01 05:33:51.865911
NCT00026897|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1997||1997-12-31|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer|Trafficking of Indium-111-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:51.930135|2018-06-01 05:33:51.930135
NCT00026884|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-05-16|2001-11-14|2001-11-15|Estimate|||||||2018-05-16|2018-05-17|Actual|July 14, 1997||1997-07-14|February 20, 2018|2018-02-20||||||||Observational|||Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease|Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-06-01 05:33:52.021328|2018-06-01 05:33:52.021328
NCT00026871|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System|Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.148808|2018-06-01 05:33:52.148808
NCT00026858|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1994||1994-10-31|November 2002|2002-11-30|November 2002||2002-11-30|||||Interventional|||Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts|Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.212554|2018-06-01 05:33:52.212554
NCT00026832|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2017-10-05|2001-11-14|2001-11-15|Estimate|||||||2017-10-05|2017-10-06|Actual|October 4, 2001||2001-10-04|November 27, 2012|2012-11-27|November 27, 2012||2012-11-27|||||Observational|||Examination of Brain Serotonin Receptors in Patients With Mood Disorders|Serotonin1A Receptor and Serotonin Transporter Imaging In Mood Disorders|Completed|||214|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.258993|2018-06-01 05:33:52.258993
NCT00026819|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2001||2001-11-30|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction|Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model|Completed||Phase 2|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.327659|2018-06-01 05:33:52.327659
NCT00026806|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2001||2001-07-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Long-Term Survival With HIV: Psychological and Behavioral Factors Associated With the Transition From Adolescence to Young Adulthood|Long-Term Survival With HIV: A Study of the Psychological and Behavioral Factors Associated With the Transition From Adolescence To Young Adulthood|Completed|||55||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.388274|2018-06-01 05:33:52.388274
NCT00026793|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-05-23|2001-11-14|2001-11-15|Estimate|||||||2018-05-23|2018-05-24|Actual|April 23, 2001||2001-04-23|December 22, 2017|2017-12-22||||||||Observational|||Assessment of Blood Vessel Density in Kaposi s Sarcoma Lesions|Protocol to Assess Vascularity in Kaposi's Sarcoma Lesions Utilizing Non-Invasive Imaging Techniques|Completed|||29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.441207|2018-06-01 05:33:52.441207
NCT00026780|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-03-13|2001-11-14|2001-11-15|Estimate|||||||2018-03-13|2018-03-14|Actual|April 18, 2001||2001-04-18|November 21, 2017|2017-11-21||||||||Observational|||Eligibility Screening for a NCI Pediatric Oncology Branch Research Study|Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI), Pediatric Oncology Branch (POB) Clinical Research Protocols|Enrolling by invitation|||1480|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.500468|2018-06-01 05:33:52.500468
NCT00026767|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-05-15|2001-11-14|2001-11-15|Estimate|||||||2018-05-15|2018-05-16|Actual|April 9, 2001||2001-04-09|July 17, 2012|2012-07-17|July 17, 2012||2012-07-17|||||Observational|||Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients|Surveillance of Invasive Fungal Infections in Bone Marrow/Stem Cell and Solid Organ Transplantation Recipients and Other Immunocompromised Patients: A Prospective Study|Completed|||217|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.56942|2018-06-01 05:33:52.56942
NCT00026754|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-02-13|2001-11-14|2001-11-15|Estimate|||||||2018-02-13|2018-02-14|Actual|March 21, 2001||2001-03-21|February 12, 2018|2018-02-12||||||||Observational|||Screening Patients for NCI Protocol Eligibility|Eligibility Screening and Tissue Procurement for the National Cancer Institute Center for Cancer Research Clinical Protocols|Recruiting|||20000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.628544|2018-06-01 05:33:52.628544
NCT00026741|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Observational|||Research in Skin Inflammation|Expression of Chemokine and Chemokine Receptors in Skin in a Model of Delayed-Type Hypersensitivity|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.702239|2018-06-01 05:33:52.702239
NCT00026728|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|December 2005|2005-12-31|December 2005||2005-12-31|||||Observational|||Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States|The Seroprevalence of Kaposi's Sarcoma Herpesvirus in the United States|Completed|||20169||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.771218|2018-06-01 05:33:52.771218
NCT00026715|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Evaluation of New Test Method to Measure Kidney Function|Validation of Fast Methods to Measure Glomerular Filtration Rate|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.833423|2018-06-01 05:33:52.833423
NCT00026702|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-03-27|2001-11-14|2001-11-15|Estimate|||||||2018-03-27|2018-03-29|Actual|April 6, 2000||2000-04-06|June 27, 2017|2017-06-27||||||||Observational|||Search for New Methods to Detect Acute Renal Failure|Search for Novel Methods to Detect Acute Renal Failure|Recruiting|||640|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.923213|2018-06-01 05:33:52.923213
NCT00026689|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-05-18|2001-11-14|2001-11-15|Estimate|||||||2018-05-18|2018-05-21|Actual|July 24, 2000||2000-07-24|November 24, 2017|2017-11-24||||||||Observational|||Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols|Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:52.990606|2018-06-01 05:33:52.990606
NCT00026676|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2008-03-03|2001-11-14|2001-11-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2000||2000-05-31|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Correlation of HIV Levels With Clinical and Immunologic Outcome in Children Treated With Didanosine|Retrospective Analysis of HIV-1 RNA Levels in Pediatric HIV-Infected Patients Treated With Didanosine|Completed|||82||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:53.201488|2018-06-01 05:33:53.201488
NCT00026663|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-05-24|2001-11-14|2001-11-15|Estimate|||||||2018-05-24|2018-05-25|Actual|February 17, 2000||2000-02-17|January 16, 2018|2018-01-16||||||||Observational|||Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance|Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer or Normal Volunteers|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-06-01 05:33:53.262815|2018-06-01 05:33:53.262815
NCT00026650|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2018-05-18|2001-11-14|2001-11-15|Estimate|||||||2018-05-18|2018-05-21|Actual|February 7, 2000||2000-02-07|March 19, 2018|2018-03-19||||||||Observational|||Follow Up of Patients Treated With Radiotherapy|Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:53.345333|2018-06-01 05:33:53.345333
NCT00026637|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-14|||2017-11-02|2001-11-14|2001-11-15|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2001||2001-08-31|November 2017|2017-11-30|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Depression and Health Outcomes in Refractory Epilepsy|Depression and Health Outcomes in Refractory Epilepsy|Completed||Phase 3|140|Actual|Columbia University||2|||f||||t|t|f|||f|||No||2018-06-01 05:33:53.413194|2018-06-01 05:33:53.413194
NCT00026624|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-12|||2012-05-16|2001-11-12|2001-11-13|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|October 2006|Actual|2006-10-31|||||Interventional|||Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC|A Phase I/II Study to Evaluate the Safety and Immunogenicity of the Subcutaneous Administration of ALVAC-HIV vCP1452 Infected Autologous Dendritic Cells Versus the Subcutaneous Administration of ALVAC-HIV vCP1452 To HIV-Infected Subjects|Completed||Phase 1|||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:33:53.487215|2018-06-01 05:33:53.487215
NCT00026611|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-12|||2010-08-26|2001-11-12|2001-11-13|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2010|2010-03-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults|A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults|Completed||Phase 2|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:33:53.546238|2018-06-01 05:33:53.546238
NCT00026598|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-10|||2008-03-03|2001-11-10|2001-11-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|November 2003|2003-11-30|November 2003||2003-11-30|||||Observational|||Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease|Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:53.616408|2018-06-01 05:33:53.616408
NCT00026585|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-10|||2017-06-30|2001-11-10|2001-11-12|Estimate|||||||2017-06-30|2017-07-02|Actual|November 9, 2001||2001-11-09|May 20, 2008|2008-05-20|November 2, 2007||2007-11-02|||||Interventional|||Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder|A Double-Blind Study Examining the Efficacy of the Protein Kinase C Inhibitor Tamoxifen in the Treatment of Acute Mania|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:53.661853|2018-06-01 05:33:53.661853
NCT00026559|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-10|||2018-05-08|2001-11-10|2001-11-12|Estimate|||||||2018-05-08|2018-05-09|Actual|June 27, 2001||2001-06-27|April 25, 2018|2018-04-25||||||||Observational|||Effects of Arousal and Stress in Anxiety|Effects of Arousal and Stress on Classical Conditioning|Recruiting|||1427|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:53.808125|2018-06-01 05:33:53.808125
NCT00026546|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2018-05-22|2001-11-09|2001-11-12|Estimate|||||||2018-05-22|2018-05-23|Actual|November 7, 2001||2001-11-07|June 7, 2017|2017-06-07||||||||Observational|||Behavior in Children With Attention Deficit Hyperactivity Disorder and in Healthy Volunteers|A Behavioral and Functional Neuroimaging Study of Inhibitory Motor Control|Completed|||189|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:53.916059|2018-06-01 05:33:53.916059
NCT00026065|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-09|||2007-09-28|2001-11-09|2001-11-12|Estimate|||||||2007-09-28|2007-10-01|Estimate|February 2000||2000-02-29|August 2006|2006-08-31|March 2006||2006-03-31|||||Interventional|||Hypertension: Prediction of Biofeedback Success|Hypertension: Prediction of Biofeedback Success|Completed||Phase 1|60||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:53.987363|2018-06-01 05:33:53.987363
NCT00026052|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-08|||2008-03-03|2001-11-08|2001-11-09|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2001||2001-11-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Riluzole to Treat Major Depression|An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent With Neurotrophic Properties in Major Depression|Completed||Phase 2|31||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:54.187355|2018-06-01 05:33:54.187355
NCT00026039|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-07|||2006-05-12|2001-11-07|2001-11-08|Estimate|||||||2006-05-12|2006-05-15|Estimate|December 1993||1993-12-31|November 2005|2005-11-30||||||||Interventional|||Women's Estrogen for Stroke Trial (WEST)||Completed||Phase 3|||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:33:54.272679|2018-06-01 05:33:54.272679
NCT00026026|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-06|||2005-06-23|2001-11-06|2001-11-07|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders|Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders|Unknown status|Recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:54.325173|2018-06-01 05:33:54.325173
NCT00026013|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-05|||2006-08-17|2001-11-05|2001-11-06|Estimate|||||||2006-08-17|2006-08-18|Estimate|January 2002||2002-01-31|July 2006|2006-07-31|January 2004||2004-01-31|||||Interventional|||Effects of St. John's Wort on the Effectiveness of Oral Contraceptives|Effects of Hypericum Perforatum on Effectiveness of Oral Contraceptives|Completed||N/A|25||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:33:54.387618|2018-06-01 05:33:54.387618
NCT00024687|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-24|||2014-11-13|2001-09-24|2001-09-25|Estimate|||||||2014-11-13|2014-11-14|Estimate|November 2000||2000-11-30|November 2014|2014-11-30||||||||Interventional|||Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses||Withdrawn||Phase 1|0|Actual|INSYS Therapeutics Inc||||Support withdrawn - Study continued by NCI - see record NCT00006981|||||||||||||||2018-06-01 05:33:57.263189|2018-06-01 05:33:57.263189
NCT00026000|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-02|||2008-03-03|2001-11-02|2001-11-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2001||2001-11-30|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Brain Activation in Vocal and Motor Tics|Brain Activation in Motor and Vocal Tics in Patients With Tourette's Syndrome or Chronic Motor or Vocal Tic Disorder Using Blood Oxygenation Level Dependent Functional MRI|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:54.449117|2018-06-01 05:33:54.449117
NCT00025987|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-02|||2008-03-03|2001-11-02|2001-11-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2001||2001-11-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Temperature Response to a Head-Neck Cooling System|Thermal Responses In Normal Volunteers To Head-Neck Cooling|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:54.526878|2018-06-01 05:33:54.526878
NCT00025974|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-02|||2017-06-30|2001-11-02|2001-11-05|Estimate|||||||2017-06-30|2017-07-02|Actual|October 31, 2001||2001-10-31|July 21, 2008|2008-07-21|July 21, 2008||2008-07-21|||||Observational|||Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder|Serotonin 1A Receptor Imaging and Benzodiazepine Receptor Imaging in Panic Disorder and Posttraumatic Stress Disorder|Completed|||230||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:54.590092|2018-06-01 05:33:54.590092
NCT00025935|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-31|||2018-03-27|2001-10-31|2001-11-01|Estimate|||||||2018-03-27|2018-03-29|Actual|October 29, 2001||2001-10-29|January 11, 2018|2018-01-11||||||||Observational|||Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder|Characterization and Pathophysiology of Severe Mood and Behavioral Dysregulation in Children and Youth|Recruiting|||1850|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:54.650089|2018-06-01 05:33:54.650089
NCT00025922|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-31|||2008-03-03|2001-10-31|2001-11-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|October 2003|2003-10-31|October 2003||2003-10-31|||||Observational|||Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral Load|Influenza Vaccine in HIV Infection: Immunologic Responses and Effect on HIV Viral Load|Completed|||240||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:54.727877|2018-06-01 05:33:54.727877
NCT00025909|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-31|||2008-03-03|2001-10-31|2001-11-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Interventional|||Intermittent vs. Continuous HAART to Treat Chronic HIV Infection|A Randomized, Controlled Trial of Short Cycle Intermittent Versus Continuous HAART for the Treatment of Chronic HIV Infection|Completed||Phase 3|90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:54.780374|2018-06-01 05:33:54.780374
NCT00025896|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-31|||2014-11-12|2001-10-31|2001-11-01|Estimate|||||||2014-11-12|2014-11-13|Estimate|May 2001||2001-05-31|November 2014|2014-11-30|September 2002|Actual|2002-09-30|||||Interventional|||Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease|A Prospective Multinational, Multicenter, Clinical Trial of the Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) in Cross-Reacting Immunologic Material-Positive Patients With Classical Infantile Pompe Disease|Completed||Phase 2|8||Sanofi|||||||||||||||||||2018-06-01 05:33:54.833108|2018-06-01 05:33:54.833108
NCT00027222|ClinicalTrials.gov processed this data on May 31, 2018|2001-11-28|||2005-06-23|2001-10-26|2001-10-29|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 2001||2001-10-31|December 2003|2003-12-31||||||||Interventional|||The Early Treatment for Retinopathy of Prematurity Study (ETROP)|The Early Treatment for Retinopathy of Prematurity Study (ETROP)|Unknown status|Active, not recruiting|Phase 2/Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:33:54.883105|2018-06-01 05:33:54.883105
NCT00025883|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-27|2016-03-01||2016-08-12|2001-10-27|2001-10-29|Estimate|2016-08-12|2016-08-16|Estimate||||2016-08-12|2016-08-16|Estimate|October 2001||2001-10-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Leptin to Treat Lipodystrophy|Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy|Completed||Phase 2|103|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||Yes||2018-06-01 05:33:54.976841|2018-06-01 05:33:54.976841
NCT00025870|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-27|||2017-10-05|2001-10-27|2001-10-29|Estimate|||||||2017-10-05|2017-10-06|Actual|October 25, 2001||2001-10-25|June 23, 2016|2016-06-23|June 23, 2016||2016-06-23|||||Observational|||Studies of Children With Metabolic and Other Genetic Disorders|Studies of Pediatric Patients With Metabolic or Other Genetic Disorders|Completed|||1090|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:55.453959|2018-06-01 05:33:55.453959
NCT00025857|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-26|||2018-05-23|2001-10-26|2001-10-29|Estimate|||||||2018-05-23|2018-05-24|Actual|October 22, 2001||2001-10-22|June 29, 2012|2012-06-29|June 29, 2012||2012-06-29|||||Observational|||Brain Function in Mentally Ill Adolescents|Adolescent Medial Temporal Lobe Function in Health and Illness|Completed|||105|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:55.506332|2018-06-01 05:33:55.506332
NCT00025844|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-26|||2017-06-30|2001-10-26|2001-10-29|Estimate|||||||2017-06-30|2017-07-02|Actual|October 22, 2001||2001-10-22|April 10, 2012|2012-04-10|April 10, 2012||2012-04-10|||||Observational|||Fear Conditioning Using Computer-Generated Virtual Reality|Fear Conditioning Using Computer-Generated Virtual Reality|Completed|||202|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:55.562386|2018-06-01 05:33:55.562386
NCT00025831|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-26|||2008-03-03|2001-10-26|2001-10-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Biological Specimen Collection for Laboratory Methods Development and Training Purposes|Biological Specimen Collection for Laboratory Methods Development and for Training Purposes|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:55.608535|2018-06-01 05:33:55.608535
NCT00025818|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-26|||2011-05-27|2001-10-26|2001-10-29|Estimate|||||||2011-05-27|2011-05-30|Estimate|May 2001||2001-05-31|May 2011|2011-05-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome||Completed||Phase 3|290|Actual|Allergan|||||f||||||||||||||2018-06-01 05:33:55.65149|2018-06-01 05:33:55.65149
NCT00025805|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-25|||2017-06-30|2001-10-25|2001-10-26|Estimate|||||||2017-06-30|2017-07-02|Actual|October 23, 2001||2001-10-23|June 13, 2008|2008-06-13|June 13, 2008||2008-06-13|||||Interventional|||G-CSF to Treat Crohn's Disease|Granulocyte-Colony Stimulating Factor Treatment for Crohn's Disease: A Pilot Study Assessing Immune and Clinical Response|Completed||Phase 1|23||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:55.797333|2018-06-01 05:33:55.797333
NCT00025792|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-24|||2008-03-03|2001-10-24|2001-10-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Clinical Trial of Pramipexole in Bipolar Depression|An Investigation of the Antidepressant Efficacy of a Dopamine Agonist With Neurotrophic Properties in Bipolar Disorder|Completed||Phase 2|200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:55.85309|2018-06-01 05:33:55.85309
NCT00023530|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-07|||2016-02-17|2001-09-06|2001-09-07|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2001||2001-09-30|July 2006|2006-07-31|August 2006|Actual|2006-08-31|||||Interventional|||Blood and Marrow Transplant Clinical Research Network|Blood and Marrow Transplant Clinical Research Network|Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:34:06.122295|2018-06-01 05:34:06.122295
NCT00025779|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-23|||2009-07-24|2001-10-23|2001-10-24|Estimate|||||||2009-07-24|2009-07-28|Estimate|October 2001||2001-10-31|August 2008|2008-08-31||||November 2003|Actual|2003-11-30||Interventional|||Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders|Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders|Completed||N/A|60||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:33:55.910559|2018-06-01 05:33:55.910559
NCT00025766|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-22|||2013-11-25|2001-10-22|2001-10-23|Estimate|||||||2013-11-25|2013-11-27|Estimate|September 2001||2001-09-30|November 2013|2013-11-30|December 2011|Actual|2011-12-31|April 2006|Actual|2006-04-30||Interventional|TOSCA-2||Angioplasty and Heart Stents to Treat Individuals With an Occluded Artery Following a Heart Attack|TOSCA-2: An Angiographic Substudy (Ancillary) of the Occluded Artery Trial (OAT)|Completed||Phase 4|380|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-06-01 05:33:55.990104|2018-06-01 05:33:55.990104
NCT00025753|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-19|||2005-06-23|2001-10-19|2001-10-22|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution|Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution|Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:56.058834|2018-06-01 05:33:56.058834
NCT00025740|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-16|||2008-03-03|2001-10-16|2001-10-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|August 2004|2004-08-31|August 2004||2004-08-31|||||Interventional|||Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder|Combined Treatment With a Benzodiazepine (Clonazepam) and a Selective Serotonin Reuptake Inhibitor (Paroxetine) for Rapid Treatment of Posttraumatic Stress Disorder (PTSD)|Completed||Phase 4|78||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.116233|2018-06-01 05:33:56.116233
NCT00025727|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-15|||2005-06-23|2001-10-15|2001-10-16|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2001||2001-05-31|June 2002|2002-06-30||||||||Interventional|||Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure|A Phase III, Randomized, Multicenter, Parallel Group, Open-Label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/Ritonavir (700mg/100mg Twice Daily or 1400mg/200mg Once Daily) Versus Lopinavir/Ritonavir (400mg/100mg Twice Daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure|Unknown status|Active, not recruiting|Phase 3|330||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:33:56.188158|2018-06-01 05:33:56.188158
NCT00025714|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2018-05-19|2001-10-11|2001-10-12|Estimate|||||||2018-05-19|2018-05-22|Actual|October 10, 2001||2001-10-10|May 18, 2018|2018-05-18||||||||Observational|||Study of Specimens Obtained During Epilepsy Surgery|Research Study of Specimens Obtained During Epilepsy Surgery|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.351479|2018-06-01 05:33:56.351479
NCT00025701|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-11|||2017-06-30|2001-10-11|2001-10-12|Estimate|||||||2017-06-30|2017-07-02|Actual|October 9, 2001||2001-10-09|October 4, 2010|2010-10-04|October 4, 2010||2010-10-04|||||Observational|||EEG and EMG Studies of Hand Dystonia|EEG Study of Movement-Related Center-Surround Organization in Hand Dystonia|Completed|||75|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.436905|2018-06-01 05:33:56.436905
NCT00024999|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-10|||2008-03-03|2001-10-10|2001-10-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||EEG and EMG Analysis of Ideomotor Apraxia|EEG Analysis of Ideomotor Apraxia|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.522244|2018-06-01 05:33:56.522244
NCT00024986|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-10|||2008-03-03|2001-10-10|2001-10-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2001||2001-10-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Tenofovir Disoproxil Fumarate to Treat Pediatric HIV|A Phase I Study of Tenofovir Disoproxil Fumarate (PMPA Prodrug), A Novel Nucleotide Analog Reverse Transcriptase Inhibitor in Children With HIV Infection|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.609085|2018-06-01 05:33:56.609085
NCT00024960|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-09|||2017-06-30|2001-10-09|2001-10-10|Estimate|||||||2017-06-30|2017-07-02|Actual|October 3, 2001||2001-10-03|October 29, 2010|2010-10-29|October 29, 2010||2010-10-29|||||Observational|||Dopamine Function in Developmental Stuttering|Assessment of Pre- and Post-Synaptic Dopamine Function in Developmental Stuttering Using 11C-Raclopride and Positron Emission Tomography|Completed|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.687756|2018-06-01 05:33:56.687756
NCT00024934|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-09|||2016-09-21|2001-10-09|2001-10-10|Estimate|||||||2016-09-21|2016-09-22|Estimate|October 2001||2001-10-31|September 2016|2016-09-30|August 2004||2004-08-31|||||Interventional|||B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency|A Phase I Dose Escalation Study of B-Lymphocyte Stimulator (BLyS) Administered Subcutaneously in Patients With Selective IgA Deficiency|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.755225|2018-06-01 05:33:56.755225
NCT00024921|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-05|||2013-09-05|2001-10-09|2001-10-10|Estimate|||||||2013-09-05|2013-09-06|Estimate||||December 2003|2003-12-31||||||||Observational|||The Genetics of Kidneys in Diabetes (GoKinD) Study|The Genetics of Kidneys in Diabetes (GoKinD) Study|Completed|||2100|Anticipated|National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:33:56.824235|2018-06-01 05:33:56.824235
NCT00024908|ClinicalTrials.gov processed this data on May 31, 2018|2001-10-04|||2017-06-30|2001-10-03|2001-10-04|Estimate|||||||2017-06-30|2017-07-02|Actual|October 1, 2001||2001-10-01|April 7, 2010|2010-04-07|April 7, 2010||2010-04-07|||||Observational|||Test of A Model of Representational Knowledge Stored in the Human Prefrontal Cortex|Testing A Model of the Representational Knowledge Stored in the Human Prefrontal Cortex|Completed|||949|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.878551|2018-06-01 05:33:56.878551
NCT00024804|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-28|||2018-05-24|2001-09-28|2001-10-01|Estimate|||||||2018-05-24|2018-05-25|Actual|September 27, 2001||2001-09-27|April 5, 2018|2018-04-05||||||||Observational|||Evaluation and Treatment of Skeletal Diseases|Evaluation and Treatment of Bone and Mineral Disorders|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:56.949601|2018-06-01 05:33:56.949601
NCT00024843|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-28|||2016-05-12|2001-09-27|2001-09-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1999||1999-09-30|August 2004|2004-08-31|August 2003|Actual|2003-08-31|||||Observational|||Family Based Interventions: Preschool Children and Parent||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:57.022049|2018-06-01 05:33:57.022049
NCT00024830|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-28|||2016-03-15|2001-09-27|2001-09-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1999||1999-09-30|October 2005|2005-10-31|August 2002|Actual|2002-08-31|||||Observational|||Peer-Based Skills Training to Enhance Teen Weight Loss||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:57.073193|2018-06-01 05:33:57.073193
NCT00024674|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-24|||2014-11-13|2001-09-24|2001-09-25|Estimate|||||||2014-11-13|2014-11-14|Estimate|February 2001||2001-02-28|November 2014|2014-11-30||||||||Interventional|||Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days||Withdrawn||Phase 1|0|Actual|INSYS Therapeutics Inc||||Support withdrawn - Study continued by NCI - see record NCT00006981|||||||||||||||2018-06-01 05:33:57.327906|2018-06-01 05:33:57.327906
NCT00024661|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-24|||2011-04-12|2001-09-24|2001-09-25|Estimate|||||||2011-04-12|2011-04-13|Estimate|March 2001||2001-03-31|April 2011|2011-04-30|October 2004||2004-10-31|||||Interventional|||Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors|Study to Determine the Maximum Tolerated Dose of Liposome-Encapsulated C-RAF Antisense Oligodeoxynucleotide (LErafAON) in Patients With Advanced Solid Tumors|Completed||Phase 1|30||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:33:57.38697|2018-06-01 05:33:57.38697
NCT00024648|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-24|||2011-04-12|2001-09-24|2001-09-25|Estimate|||||||2011-04-12|2011-04-13|Estimate|March 2001||2001-03-31|April 2011|2011-04-30|December 2004||2004-12-31|||||Interventional|||Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies|Phase I Study to Determine the Maximum Tolerated Dose of LErafAON in Combination With Radiotherapy in Patients With Advanced Malignancies|Completed||Phase 1|25||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:33:57.446598|2018-06-01 05:33:57.446598
NCT00024622|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-23|||2018-03-27|2001-09-22|2001-09-24|Estimate|||||||2018-03-27|2018-03-29|Actual|September 17, 2001||2001-09-17|September 27, 2017|2017-09-27||||||||Observational|||PET Scanning in Parkinson s Disease|Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia|Recruiting|||460|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:57.501453|2018-06-01 05:33:57.501453
NCT00024596|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-21|||2015-12-21|2001-09-20|2001-09-21|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2001||2001-09-30|December 2015|2015-12-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)||Completed|||3389|Actual|Washington University School of Medicine|||2||f||||||||||Samples With DNA|"~     Stored DNA, lymphoblasts~   "|||2018-06-01 05:33:57.562873|2018-06-01 05:33:57.562873
NCT00024583|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-21|||2016-02-17|2001-09-20|2001-09-21|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2001||2001-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Prenatal Nutrition and Adult Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:33:57.62025|2018-06-01 05:33:57.62025
NCT00024570|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-20|||2014-11-12|2001-09-20|2001-09-21|Estimate|||||||2014-11-12|2014-11-14|Estimate|November 2000||2000-11-30|November 2014|2014-11-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma|Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma: Phase I/II Study|Completed||Phase 1/Phase 2|60||INSYS Therapeutics Inc|||||f||||||||||||||2018-06-01 05:33:57.668184|2018-06-01 05:33:57.668184
NCT00024557|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-20|||2011-06-02|2001-09-20|2001-09-21|Estimate|||||||2011-06-02|2011-06-06|Estimate|June 2001||2001-06-30|June 2011|2011-06-30|July 2007|Actual|2007-07-31|June 2006|Actual|2006-06-30||Interventional|||Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients|Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma|Completed||Phase 1|40||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:33:57.725996|2018-06-01 05:33:57.725996
NCT00024544|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-19|||2012-03-06|2001-09-19|2001-09-20|Estimate|||||||2012-03-06|2012-03-07|Estimate|August 2001||2001-08-31|March 2012|2012-03-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||Pilot Study in Patients With Symptomatic Steroid-Naive Asthma|A Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of SB 240683 in Patients With Symptomatic Steroid-Naive Asthma|Completed||Phase 2|120||Facet Biotech|||||f||||||||||||||2018-06-01 05:33:57.783719|2018-06-01 05:33:57.783719
NCT00024531|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-19|||2006-11-08|2001-09-19|2001-09-20|Estimate|||||||2006-11-08|2006-11-09|Estimate|October 2000||2000-10-31|November 2006|2006-11-30|August 2004||2004-08-31|||||Interventional|||Lipitor as a Treatment for Alzheimer's Disease|Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease|Completed||Phase 2|98||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:33:57.950021|2018-06-01 05:33:57.950021
NCT00024518|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-19|||2013-11-18|2001-09-18|2001-09-19|Estimate|||||||2013-11-18|2013-11-19|Estimate|September 2001||2001-09-30|November 2013|2013-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Interferon-Alpha for Diabetes Mellitus Type 1|"Ingested Interferon-Alpha: Prolongation or Permanence of the Honeymoon Phase in Newly Diagnosed Diabetes Mellitus"|Completed||Phase 2|57|Actual|The University of Texas Health Science Center, Houston||3|||f||||f||||||||||2018-06-01 05:33:58.033746|2018-06-01 05:33:58.033746
NCT00024505|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-18|||2013-01-15|2001-09-17|2001-09-18|Estimate|||||||2013-01-15|2013-01-17|Estimate|September 2001||2001-09-30|January 2013|2013-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Multidisciplinary Study of Right Ventricular Dysplasia|Multidisciplinary Study of Right Ventricular Dysplasia|Completed|||320|Actual|University of Arizona|||||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-06-01 05:33:58.13009|2018-06-01 05:33:58.13009
NCT00024492|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-17|||2011-06-02|2001-09-17|2001-09-18|Estimate|||||||2011-06-02|2011-06-06|Estimate|August 2001||2001-08-31|August 2004|2004-08-31|June 2004||2004-06-30|||||Interventional|||Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer||Completed||Phase 1|40||INSYS Therapeutics Inc|||||||||||||||||||2018-06-01 05:33:58.207625|2018-06-01 05:33:58.207625
NCT00024479|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-14|||2018-03-27|2001-09-13|2001-09-14|Estimate|||||||2018-03-27|2018-03-29|Actual|September 12, 2001||2001-09-12|February 1, 2018|2018-02-01||||||||Observational|||Natural History of Rheumatic Diseases in Minority Communities|Studies of the Natural History of Rheumatic Disease in Minority Communities|Recruiting|||100000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:33:58.260314|2018-06-01 05:33:58.260314
NCT00023595|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-11|2016-12-23||2017-07-20|2001-09-10|2001-09-11|Estimate|2017-07-20|2017-07-24|Actual||||2017-07-20|2017-07-24|Actual|January 2002||2002-01-31|July 2017|2017-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|STICH||Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease|Surgical Treatment for Ischemic Heart Failure (STICH)|Completed||Phase 3|2136|Actual|Duke University||4|||f||||t||||||||||2018-06-01 05:33:58.511189|2018-06-01 05:33:58.511189
NCT00023582|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-10|||2008-08-07|2001-09-10|2001-09-11|Estimate|||||||2008-08-07|2008-08-08|Estimate||||November 2006|2006-11-30||||||||Observational|||HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru|HIV Prevalence, Incidence and HSV-2 Prevalence Among High-Risk MSM in Lima, Peru|Completed|||250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:03.613946|2018-06-01 05:34:03.613946
NCT00023569|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-08|||2008-03-03|2001-09-08|2001-09-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2001||2001-09-30|September 2003|2003-09-30|September 2003||2003-09-30|||||Observational|||Electrical Stimulation to Improve Hand Function in Patients With Chronic Stroke|Cortical Motor Reorganization in Chronic Stroke Following EMG Triggered NMES Therapy|Completed|||16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:34:03.684027|2018-06-01 05:34:03.684027
NCT00023504|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-07|||2018-03-27|2001-09-07|2001-09-10|Estimate|||||||2018-03-27|2018-03-29|Actual|September 5, 2001||2001-09-05|December 11, 2017|2017-12-11||||||||Observational|||Antibody Production in Immune Disorders|Evaluation of Immune Response to Vaccines in Primary Immune Disorders|Recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:34:03.744326|2018-06-01 05:34:03.744326
NCT00023465|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2005-06-23|2001-09-08|2001-09-10|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging|Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging|Unknown status|Recruiting||10||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:34:03.845285|2018-06-01 05:34:03.845285
NCT00023452|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|2012-08-15||2018-03-15|2001-09-08|2001-09-10|Estimate|2012-08-28|2012-09-27|Estimate||||2018-03-15|2018-04-10|Actual|June 2001||2001-06-30|July 2015|2015-07-31|September 2013|Actual|2013-09-30|October 2010|Actual|2010-10-31||Interventional|PREVENT TB||Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection|TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection|Completed||Phase 3|8053|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-06-01 05:34:03.956406|2018-06-01 05:34:03.956406
NCT00023439|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2011-08-02|2001-09-08|2001-09-10|Estimate|||||||2011-08-02|2011-08-03|Estimate|May 2000||2000-05-31|June 2011|2011-06-30||||||||Observational|||TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment|Study of the Performance of Several Nucleic Acid Amplification Methodologies in the Diagnosis and Management of Active TB|Completed|||300|Anticipated|Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 05:34:04.808347|2018-06-01 05:34:04.808347
NCT00023426|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2005-09-09|2001-09-08|2001-09-10|Estimate|||||||2005-09-09|2005-09-13|Estimate|July 1999||1999-07-31|September 2005|2005-09-30|February 2003||2003-02-28|||||Interventional|||TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis|TBTC Study 25:A Prospective, Randomized, Double-Blind Study of the Tolerability of Higher Doses of Rifapentine|Completed||Phase 2|150||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 05:34:04.893872|2018-06-01 05:34:04.893872
NCT00023413|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2012-06-04|2001-09-08|2001-09-10|Estimate|||||||2012-06-04|2012-06-05|Estimate|November 1999||1999-11-30|June 2012|2012-06-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz|TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections|Completed||Phase 2|20||Centers for Disease Control and Prevention|||||f||||||||||||||2018-06-01 05:34:04.990233|2018-06-01 05:34:04.990233
NCT00023400|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2005-09-01|2001-09-08|2001-09-10|Estimate|||||||2005-09-01|2005-09-05|Estimate|February 2000||2000-02-29|September 2005|2005-09-30|February 2002||2002-02-28|||||Interventional|||TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB|TBTC Study 23B:Intensive Pharmacokinetics of the Nelfinavir Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen|Completed||Phase 4|20||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 05:34:05.087483|2018-06-01 05:34:05.087483
NCT00023387|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2005-09-09|2001-09-08|2001-09-10|Estimate|||||||2005-09-09|2005-09-13|Estimate|March 2000||2000-03-31|September 2005|2005-09-30|May 2001||2001-05-31|||||Interventional|||TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine|Intensive Pharmacokinetic Study of Three Doses of Rifapentine (600, 900 and 1200mg) During Continuation Phase Therapy of Tuberculosis in HIV-Negative Adults|Completed||N/A|36||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 05:34:05.177101|2018-06-01 05:34:05.177101
NCT00023374|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2011-08-02|2001-09-08|2001-09-10|Estimate|||||||2011-08-02|2011-08-03|Estimate|August 2000||2000-08-31|June 2011|2011-06-30|December 2010|Actual|2010-12-31|December 2006|Actual|2006-12-31||Interventional|||TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance|TBTC Study 24: A Non-Comparative Study of the Efficacy of a Largely-Intermittent, Six-Month Tuberculosis Treatment Regimen Among Patients Who Will Not Receive Isoniazid Due to Initial Isoniazid Resistance or Intolerance|Completed||N/A|98|Actual|Centers for Disease Control and Prevention||1|||f||||t||||||||||2018-06-01 05:34:05.269427|2018-06-01 05:34:05.269427
NCT00023361|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2005-09-01|2001-09-08|2001-09-10|Estimate|||||||2005-09-01|2005-09-05|Estimate|February 1999||1999-02-28|September 2005|2005-09-30|February 2003||2003-02-28|||||Interventional|||TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen|TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen|Completed||N/A|215||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 05:34:05.603243|2018-06-01 05:34:05.603243
NCT00023348|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2005-09-09|2001-09-08|2001-09-10|Estimate|||||||2005-09-09|2005-09-13|Estimate|July 1999||1999-07-31|September 2005|2005-09-30|November 2002||2002-11-30|||||Interventional|||TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB|TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in USPHS Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen|Completed||Phase 2/Phase 3|150||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 05:34:05.705566|2018-06-01 05:34:05.705566
NCT00023335|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-06|||2005-09-01|2001-09-08|2001-09-10|Estimate|||||||2005-09-01|2005-09-05|Estimate|April 1995||1995-04-30|September 2005|2005-09-30|March 2001||2001-03-31|||||Interventional|||TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis|TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis|Completed||Phase 3|1000||Centers for Disease Control and Prevention|||||||||||||||||||2018-06-01 05:34:05.815658|2018-06-01 05:34:05.815658
NCT00023556|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-07|||2016-07-11|2001-09-06|2001-09-07|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2001||2001-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Genetic Architecture of Heart Disease in Rural Brazil||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:34:05.966118|2018-06-01 05:34:05.966118
NCT00023543|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-07|||2013-06-18|2001-09-06|2001-09-07|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2001||2001-09-30|June 2013|2013-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Reduction of Triglycerides in Women on Hormone Replacement Therapy|Reduction of Triglycerides in Women on HRT|Completed||Phase 2|508|Actual|University of Pittsburgh||1|||f||||||||||||||2018-06-01 05:34:06.03798|2018-06-01 05:34:06.03798
NCT00023491|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-07|||2008-03-03|2001-09-06|2001-09-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2001||2001-09-30|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells|Assessment of the Potential of Hematopoietic Stem Cells to Transdifferentiate Into Salivary Gland and Oral Mucosal Epithelial Cells in Adult Bone Marrow Transplant Patients|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:34:06.212224|2018-06-01 05:34:06.212224
NCT00023322|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-03|2013-04-15||2013-07-09|2001-09-01|2001-09-03|Estimate|2013-07-09|2013-07-10|Estimate||||2013-07-09|2013-07-10|Estimate|August 2001||2001-08-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Pegylated Interferon to Treat Chronic Hepatitis D|Treatment of Chronic Delta Hepatitis With Pegylated Interferon|Completed||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:34:06.277542|2018-06-01 05:34:06.277542
NCT00023309|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-03|2011-07-07||2016-09-22|2001-09-01|2001-09-03|Estimate|2013-02-21|2013-04-04|Estimate||||2016-09-22|2016-09-23|Estimate|August 2001||2001-08-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|April 2010|Actual|2010-04-30||Interventional|||Lamivudine and Adefovir to Treat Chronic Hepatitis B|Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B|Completed||Phase 2|41|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:34:06.526774|2018-06-01 05:34:06.526774
NCT00023296|ClinicalTrials.gov processed this data on May 31, 2018|2001-09-03|||2018-05-22|2001-09-01|2001-09-03|Estimate|||||||2018-05-22|2018-05-23|Actual|July 27, 2001||2001-07-27|November 9, 2015|2015-11-09|November 9, 2015|Actual|2015-11-09|November 2, 2006|Actual|2006-11-02||Interventional|||Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension|Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension|Completed||Phase 1|59|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:34:08.301083|2018-06-01 05:34:08.301083
NCT00023283|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-30|||2008-12-30|2001-08-30|2001-08-31|Estimate|||||||2008-12-30|2009-01-01|Estimate||||December 2008|2008-12-31||||||||Interventional|||Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1|Counseling Conditions for Thrice Weekly Buprenorphine in a Primary Care Clinic|Unknown status|Not yet recruiting|Phase 2|0|Anticipated|National Institute on Drug Abuse (NIDA)||3|||f||||||||||||||2018-06-01 05:34:08.42835|2018-06-01 05:34:08.42835
NCT00023244|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-29|||2016-10-19|2001-08-30|2001-08-31|Estimate|||||||2016-10-19|2016-10-21|Estimate|January 2001||2001-01-31|October 2016|2016-10-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Steroid Withdrawal in Pediatric Kidney Transplant Recipients|A Double-Blind Randomized Trial of Steroid Withdrawal in Sirolimus- and Cyclosporine-Treated Primary Transplant Recipients|Terminated||Phase 2|274|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||"Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferative~   disorder"|f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:34:08.593323|2018-06-01 05:34:08.593323
NCT00023231|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-29|||2016-10-19|2001-08-30|2001-08-31|Estimate|||||||2016-10-19|2016-10-21|Estimate|February 2001||2001-02-28|October 2016|2016-10-31|August 2006|Actual|2006-08-31|August 2004|Actual|2004-08-31||Interventional|||Pediatric Kidney Transplant Without Calcineurin Inhibitors|Calcineurin Inhibitor Sparing Protocol in Living Donor Pediatric Kidney Transplantation|Completed||N/A|35|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:34:08.806868|2018-06-01 05:34:08.806868
NCT00023218|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-29|||2015-03-05|2001-08-30|2001-08-31|Estimate|||||||2015-03-05|2015-03-09|Estimate||||June 2003|2003-06-30||||||||Interventional|||Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis|Effect of Change to a Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimen of Efavirenz (EFV) and Lopinavir/Ritonavir (LPV/r) on Liver Histology in HIV-1-Infected Individuals With Lactic Acidemia and Persistent Alanine Aminotransferase (ALT) Elevations on NRTI-Containing Antiretroviral Therapy|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:09.176981|2018-06-01 05:34:09.176981
NCT00023205|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-29|||2013-12-23|2001-08-30|2001-08-31|Estimate|||||||2013-12-23|2013-12-24|Estimate|November 2002||2002-11-30|December 2013|2013-12-31|December 2006|Actual|2006-12-31|August 2006|Actual|2006-08-31||Interventional|||Impact of Literacy Level on Patient Education and Health Among People With Arthritis|Literacy in Arthritis Management: A Randomized Controlled Clinical Trial of a Novel Education Intervention|Completed||Phase 2|134|Actual|Brigham and Women's Hospital||2|||f||||||||||||||2018-06-01 05:34:09.294326|2018-06-01 05:34:09.294326
NCT00022763|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-11|2015-12-04||2016-01-19|2001-08-30|2001-08-31|Estimate|2016-01-19|2016-02-15|Estimate||||2016-01-19|2016-02-15|Estimate|August 2001||2001-08-31|January 2016|2016-01-31||||December 2004|Actual|2004-12-31||Interventional|||T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents|A Phase I/II Pharmacokinetic and Safety Study of T-20 in Combination With an Optimized Background in HIV Infected Children and Adolescents|Completed||Phase 2|52|Actual|Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:34:09.465644|2018-06-01 05:34:09.465644
NCT00021775|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-04|||2013-12-31|2001-08-30|2001-08-31|Estimate|||||||2013-12-31|2014-01-03|Estimate|April 2002||2002-04-30|December 2013|2013-12-31|February 2004|Actual|2004-02-29|||||Observational|||HIV Prevention Preparedness Study in Russia, China, and India|HIV Prevention Preparedness Study|Completed|||2000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:10.209721|2018-06-01 05:34:10.209721
NCT00021762|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-04|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31||||||||Interventional|||Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV|A Pilot Phase II Evaluation of the Effects on HIV Replication of Immunization With a gp120-Depleted, Inactivated Whole Virus Vaccine Combined With Exposures to Replicating Autologous HIV by Scheduled Treatment Interruptions, a Rollover Study of A5057|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:10.301691|2018-06-01 05:34:10.301691
NCT00021671|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-31|||2012-02-13|2001-08-30|2001-08-31|Estimate|||||||2012-02-13|2012-02-14|Estimate||||February 2012|2012-02-29|November 2004|Actual|2004-11-30|||||Interventional|||Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission|Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission|Completed||Phase 3|3720||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:10.362008|2018-06-01 05:34:10.362008
NCT00021632|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-26|||2015-05-15|2001-08-30|2001-08-31|Estimate|||||||2015-05-15|2015-05-19|Estimate||||July 2013|2013-07-31||||||||Observational|||Effects of Ribavirin on Zidovudine or Stavudine|Pharmacokinetic Evaluation of the Effects of Ribavirin (RBV) on Zidovudine (ZDV) or Stavudine (d4T) Triphosphate (TP) Formation|Completed|||32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:10.445206|2018-06-01 05:34:10.445206
NCT00021554|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-21|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 2002|2002-05-31||||||||Interventional|||T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs|A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Regimen Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each of the Three Classes of Approved Antiretrovirals (Nucleoside Reverse Transcriptase, Non-Nucleoside Reverse Transcriptase and Protease Inhibitors)|Completed||Phase 3|525||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:10.522128|2018-06-01 05:34:10.522128
NCT00021489|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-18|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31||||||||Interventional|||Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment|A Phase I/II Study of the Safety, Tolerability, and Antiretroviral Activity of Mycophenolate Mofetil As an Adjunct to Abacavir Therapy in HIV-Infected Subjects With Treatment Failure and Extensive Prior Antiretroviral Exposure|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:10.628195|2018-06-01 05:34:10.628195
NCT00021463|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-14|||2011-02-24|2001-08-30|2001-08-31|Estimate|||||||2011-02-24|2011-02-28|Estimate||||January 2003|2003-01-31||||February 2002|Actual|2002-02-28||Interventional|||Changing to Nonprotease Inhibitor Treatment to Improve Side Effects|Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities|Completed||Phase 2|342||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:10.714627|2018-06-01 05:34:10.714627
NCT00017992|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-23|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2003|2003-03-31||||||||Interventional|||Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV|An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV-Infected Pediatric Patients|Unknown status|Recruiting|Phase 2|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:10.781773|2018-06-01 05:34:10.781773
NCT00017797|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-12|||2006-08-03|2001-08-30|2001-08-31|Estimate|||||||2006-08-03|2006-08-07|Estimate||||August 2006|2006-08-31||||||||Observational|||Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women|Evaluation of Metabolic Complications Associated With Antiretroviral Medications in HIV-1-Infected Pregnant Women|Completed|||160||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:10.864541|2018-06-01 05:34:10.864541
NCT00017784|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-11|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2001|2001-06-30||||||||Interventional|||Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection|Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment|Unknown status|Active, not recruiting|Phase 3|500||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:10.956248|2018-06-01 05:34:10.956248
NCT00017771|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-11|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate|June 2001||2001-06-30|July 2013|2013-07-31|July 2004|Actual|2004-07-31|||||Observational|||Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV Drugs|A Pathophysiologic Study of Development of Distal Symmetrical Polyneuropathy in Individuals With Advanced HIV-1 Infection and Prior Antiretroviral Exposure|Completed|||100|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||Samples With DNA|"~     Blood collection~   "|||2018-06-01 05:34:11.025871|2018-06-01 05:34:11.025871
NCT00017758|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-11|||2006-03-13|2001-08-30|2001-08-31|Estimate|||||||2006-03-13|2006-03-14|Estimate||||February 2004|2004-02-29||||||||Interventional|||The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs|The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors|Completed||Phase 1|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:11.120029|2018-06-01 05:34:11.120029
NCT00017719|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-08|||2013-11-25|2001-08-30|2001-08-31|Estimate|||||||2013-11-25|2013-11-26|Estimate|May 2002||2002-05-31|November 2013|2013-11-30|March 2006|Actual|2006-03-31|||||Interventional|||Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy|Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy|Completed||Phase 3|440||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:11.199749|2018-06-01 05:34:11.199749
NCT00017693|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-07|||2016-03-03|2001-08-30|2001-08-31|Estimate|||||||2016-03-03|2016-03-07|Estimate|May 1998||1998-05-31|March 2016|2016-03-31|February 2000|Actual|2000-02-29|February 2000|Actual|2000-02-29||Interventional|||Recombinant Human IL-4 Receptor Used in Treatment of Asthma|Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma|Completed||Phase 2|62|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 05:34:11.313113|2018-06-01 05:34:11.313113
NCT00016783|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-02|||2013-10-04|2001-08-30|2001-08-31|Estimate|||||||2013-10-04|2013-10-07|Estimate||||October 2013|2013-10-31|October 2006|Actual|2006-10-31|||||Observational|||Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV|Intensification of HIV-Specific CD4 and CD8 Activity by Cycling Highly Active Antiretroviral Therapy (HAART) in Pediatric/Adolescent Patients With Less Than 50 HIV RNA Copies/ml|Completed|||39||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:11.539548|2018-06-01 05:34:11.539548
NCT00016718|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-31|2017-08-01|2010-01-20|2017-10-16|2001-08-30|2001-08-31|Estimate|2017-10-16|2017-10-17|Actual|2010-01-20|2010-01-22|Estimate|2017-10-16|2017-10-17|Actual|August 2001||2001-08-31|September 2017|2017-09-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs|An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects|Completed||Phase 1/Phase 2|43|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 05:34:11.688882|2018-06-01 05:34:11.688882
NCT00016692|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-24|||2006-04-26|2001-08-30|2001-08-31|Estimate|||||||2006-04-26|2006-04-27|Estimate||||April 2001|2001-04-30||||||||Interventional|||Safety and Tolerability of Z-100 in Patients With Early HIV Infection|A Phase 1b Multicenter Double-Blind, Placebo-Controlled, Randomized Study on the Safety and Tolerability of Z-100 in Early HIV-1 Infected Patients|Terminated||Phase 1|||Zeria Pharmaceutical|||||||||||||||||||2018-06-01 05:34:12.636263|2018-06-01 05:34:12.636263
NCT00006324|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-02|||2008-08-06|2001-08-30|2001-08-31|Estimate|||||||2008-08-06|2008-08-07|Estimate|December 1999||1999-12-31|November 2006|2006-11-30|December 2002||2002-12-31|||||Interventional|||Hormonal Birth Control and the Risk of Acquiring HIV|Hormonal Contraception and the Risk of HIV Acquisition|Completed||N/A|6360||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:25.076528|2018-06-01 05:34:25.076528
NCT00016601|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-18|||2012-10-31|2001-08-30|2001-08-31|Estimate|||||||2012-10-31|2012-11-02|Estimate|June 2001||2001-06-30|October 2012|2012-10-31|May 2004|Actual|2004-05-31|||||Interventional|||Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women|An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) and Selected Protease Inhibitor (PI) and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapies Among HIV-Infected Women|Completed||N/A|76||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:12.713801|2018-06-01 05:34:12.713801
NCT00016588|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-17|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2001||2001-05-31|May 2002|2002-05-31||||||||Interventional|||Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs|An Open-Label Study to Assess the Anti-HIV-1 Activity of Tenofovir Disoproxil Fumarate (TDF) in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:12.857263|2018-06-01 05:34:12.857263
NCT00016536|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-16|||2012-04-03|2001-08-30|2001-08-31|Estimate|||||||2012-04-03|2012-04-04|Estimate||||April 2012|2012-04-30|May 1997|Actual|1997-05-31|||||Interventional|||Effects of BufferGel and PRO 2000/5 Gel in Men|Male Tolerance Study of BufferGel and PRO 2000/5 Gel (P)|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:12.909564|2018-06-01 05:34:12.909564
NCT00015704|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-01|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|November 2004|Actual|2004-11-30|||||Interventional|||Effect of Interleukin-2 on HIV Treatment Interruption|An Open-Label, Pilot Study Utilizing CD4 T-Cell Counts Lower Than 350 Cells/mm3 as the Threshold for Restarting Therapy With Potent Antiretroviral Therapy With or Without Interleukin-2 to Determine the Effect of Pulse Therapy on the Characteristics of Treatment Interruptions|Completed||N/A|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:12.971712|2018-06-01 05:34:12.971712
NCT00015691|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-01|||2013-07-19|2001-08-30|2001-08-31|Estimate|||||||2013-07-19|2013-07-22|Estimate||||July 2013|2013-07-31||||January 2006|Actual|2006-01-31||Interventional|||Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities|A Randomized, Double-Blind, Placebo-Controlled Study of Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Subjects With Hyperinsulinemia and Elevated Waist/Hip Ratio|Completed||N/A|105||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:13.070279|2018-06-01 05:34:13.070279
NCT00015652|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-26|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|March 2005|Actual|2005-03-31|||||Interventional|||Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection|A Pilot Study of Low Dose Interleukin-2 (IL-2) With the Addition of Pegylated Interferon (PEG-IFN Alfa-2b) and Ribavirin (RBV) for the Treatment of Hepatitis C Infection in Subjects With HIV Coinfection|Completed||N/A|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:13.302984|2018-06-01 05:34:13.302984
NCT00014937|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-14|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31||||December 2004|Actual|2004-12-31||Interventional|||Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen|A Randomized, Controlled Trial of Two Potent, Simplified Regimens Utilizing A Protease Inhibitor-Sparing Regimen Versus A Nucleoside-Sparing Regimen for HIV-Infected Subjects Who Participated in ACTG 388 or Who Responded to A First Potent Combination Regimen and Have 200 or Less HIV-1 RNA Copies/ml|Completed||N/A|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:13.444825|2018-06-01 05:34:13.444825
NCT00014911|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-13|2012-09-13||2017-02-06|2001-08-30|2001-08-31|Estimate|2012-09-13|2012-10-17|Estimate||||2017-02-06|2017-03-15|Actual|April 2001||2001-04-30|February 2017|2017-02-28|August 2010|Actual|2010-08-31|June 2005|Actual|2005-06-30||Interventional|||Islet Transplantation for Type 1 Diabetes|Islet Transplantation for Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression (ITN005CT)|Completed||Phase 2|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||Yes|Data access is provided to the public in : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools available to researchers; and 2.) TrialShare, the Immune Tolerance Network (ITN) portal.|2018-06-01 05:34:13.626568|2018-06-01 05:34:13.626568
NCT00014053|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||June 2003|2003-06-30||||||||Observational|||A Study of Immune System Activity in Healthy Adults|A Study of Immune Function in Healthy Adults Aged 18-30 and 45 and Older|Completed|||48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:14.055192|2018-06-01 05:34:14.055192
NCT00014014|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-07|||2013-10-04|2001-08-30|2001-08-31|Estimate|||||||2013-10-04|2013-10-07|Estimate||||October 2013|2013-10-31|August 2002|Actual|2002-08-31|||||Interventional|||Zidovudine and Lamivudine Given Once Versus Twice Daily|A Phase I Pharmacokinetic Study of Once Versus Twice Daily Dosing With Zidovudine and Lamivudine|Completed||Phase 1|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:14.112081|2018-06-01 05:34:14.112081
NCT00013897|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-31||2011-04-13|2011-04-28|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|February 2001||2001-02-28|April 2011|2011-04-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine|A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine|Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:14.19255|2018-06-01 05:34:14.19255
NCT00013871|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-31|||2013-11-25|2001-08-30|2001-08-31|Estimate|||||||2013-11-25|2013-11-26|Estimate||||November 2013|2013-11-30|November 2004|Actual|2004-11-30|||||Interventional|||Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs|Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Treated With Highly Active Antiretroviral Therapy (HAART)|Completed||N/A|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:15.389974|2018-06-01 05:34:15.389974
NCT00013663|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-27|||2012-11-01|2001-08-30|2001-08-31|Estimate|||||||2012-11-01|2012-11-02|Estimate||||June 2006|2006-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load|A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy|Completed||Phase 2|92||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:15.660394|2018-06-01 05:34:15.660394
NCT00013585|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-22|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|December 2005|Actual|2005-12-31|||||Interventional|||"Safety and Effectiveness of the Selegiline Patch for Decreased Mental Function in HIV Patients"|Phase II, Placebo-Controlled, Double-Blind Study of the Selegiline Transdermal System (STS) in the Treatment of HIV-Associated Cognitive Impairment|Completed||Phase 2|127|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:15.975876|2018-06-01 05:34:15.975876
NCT00013572|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-21|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2003|2003-03-31||||||||Interventional|||HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults|A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly|Unknown status|Active, not recruiting|Phase 1|36||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:16.094027|2018-06-01 05:34:16.094027
NCT00013520|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-16|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|June 2005|Actual|2005-06-30|||||Interventional|||Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection|Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection|Completed||Phase 3|1125||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:16.186269|2018-06-01 05:34:16.186269
NCT00012519|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-10|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|July 2005|Actual|2005-07-31|||||Interventional|||Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment|A Phase I/II Trial of Ritonavir and Indinavir in Children Failing Other Antiretroviral Therapy|Completed||Phase 1/Phase 2|29|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:16.44327|2018-06-01 05:34:16.44327
NCT00012467|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-09|||2009-05-29|2001-08-30|2001-08-31|Estimate|||||||2009-05-29|2009-06-03|Estimate|January 2000||2000-01-31|May 2009|2009-05-31|July 2001|Actual|2001-07-31|||||Interventional|||Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis|Completed||Phase 2|60||InterMune|||||f||||||||||||||2018-06-01 05:34:16.543514|2018-06-01 05:34:16.543514
NCT00011895|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2001||2001-02-28|March 2002|2002-03-31||||||||Interventional|||Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without Efavirenz in HIV-1 Infected Antiretroviral Therapy Naive Subjects|Unknown status|Active, not recruiting|Phase 4|400||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:16.691256|2018-06-01 05:34:16.691256
NCT00011479|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|August 2002|Actual|2002-08-31|||||Interventional|||Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents|Single Dose Pharmacokinetic Study of Abacavir in HIV-Infected Children and Adolescents|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:16.909272|2018-06-01 05:34:16.909272
NCT00011128|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-10|||2015-05-15|2001-08-30|2001-08-31|Estimate|||||||2015-05-15|2015-05-18|Estimate||||May 2004|2004-05-31||||||||Interventional|||Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment|Phase III Evaluation of the Role of Temporary Cessation of Antiretroviral Treatment and Resistance Testing-Based Selection of Antiretroviral Drugs in the Virologic Response to Salvage Therapy for Heavily Treatment-Experienced HIV-Infected Individuals Failing Current Antiretroviral Therapy|Withdrawn||Phase 3|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:17.067517|2018-06-01 05:34:17.067517
NCT00011089|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-09|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2001||2001-02-28|November 2001|2001-11-30||||||||Interventional|||Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations|US Expanded Access Program of Tenofovir Disoproxil Fumarate in the Treatment of HIV-1 Infected Patients Who Have Limited Treatment Options|Unknown status|Active, not recruiting|N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:17.215655|2018-06-01 05:34:17.215655
NCT00011050|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-09|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate|January 2001||2001-01-31|November 2004|2004-11-30||||||||Observational|||Effects of Storage on Lactate in Blood Samples|Effects of Storage on Plasma Lactate Determinations|Completed|||13||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:17.527565|2018-06-01 05:34:17.527565
NCT00011037|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-08|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|July 2004|Actual|2004-07-31|||||Interventional|||ALVAC-HIV vCP1452 Alone and Combined With MN rgp120|A Multisite Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of ALVAC-HIV vCP1452 Alone and Combined With MN rgp120|Completed||Phase 2|160|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-06-01 05:34:17.605037|2018-06-01 05:34:17.605037
NCT00011011|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-08|||2013-07-30|2001-08-30|2001-08-31|Estimate|||||||2013-07-30|2013-07-31|Estimate|February 2001||2001-02-28|July 2013|2013-07-31|October 2006|Actual|2006-10-31|||||Interventional|||Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV|A Randomized Phase I/II Pilot Study of Intermittent Withdrawal of Antiretroviral Therapy as an Immunization Strategy and Double-Blinded Immunization With ALVAC-HIV vCP1452 in Subjects With Persistent CD4+ Cell Counts Greater Than 400 Cells/mm3 and Plasma HIV-1 RNA Levels Less Than 50 Copies/ml|Completed||Phase 1/Phase 2|94|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:17.696494|2018-06-01 05:34:17.696494
NCT00009555|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-01|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|March 2006|Actual|2006-03-31|||||Interventional|||Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat|A Prospective, Multicenter, Randomized, Placebo-Controlled Trial of Physiologic Testosterone Supplementation for HIV-Positive Men With Mildly to Moderately Reduced Serum Testosterone Levels and Abdominal Obesity|Completed||Phase 4|86||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:17.830609|2018-06-01 05:34:17.830609
NCT00009061|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 2000||2000-11-30|March 2002|2002-03-31||||||||Interventional|||Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs|A Randomized, Open-Label, Two Arm Trial to Compare the Safety and Antiviral Efficacy of GW433908/Ritonavir QD to Nelfinavir BID When Used in Combination With Abacavir and Lamivudine for 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Subjects|Unknown status|Active, not recruiting|Phase 3|624||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:17.977639|2018-06-01 05:34:17.977639
NCT00008866|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-18|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31||||||||Interventional|||Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy|A Phase II, Double-Blind, Randomized Study to Determine the Effect of Adding Delayed Versus Immediate Hydroxyurea to a Genotypic Based, ddI-Containing, Three-Drug Antiretroviral Regimen on the Recovery of Total CD4+ T-Cell Counts and Suppression of Plasma Viral Load in Advanced HIV-1 Infected Subjects Failing a First or Second Triple Combination Therapy|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:18.091182|2018-06-01 05:34:18.091182
NCT00008853|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-18|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines|Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines|Completed||Phase 1|65||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:18.195508|2018-06-01 05:34:18.195508
NCT00008840|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-18|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia|A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia|Completed|||866||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:18.421799|2018-06-01 05:34:18.421799
NCT00008554|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-13|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 2000||2000-11-30|July 2001|2001-07-31||||||||Interventional|||Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy|A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults|Unknown status|Active, not recruiting|Phase 3|210||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:18.505866|2018-06-01 05:34:18.505866
NCT00008528|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-12|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2001|2001-06-30||||||||Interventional|||T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs|A Phase III Open-Label, Randomized, Active-Controlled Study Assessing the Efficacy and Safety of T-20 (HIV-1 Fusion Inhibitor) in Combination With an Optimized Background Regimen, Versus Optimized Background Therapy Alone, in Patients With Prior Experience and/or Prior Documented Resistance to Each of the Three Classes of Approved Antiretrovirals (Nucleoside Reverse Transcriptase, Non-Nucleoside Reverse Transcriptase and Protease Inhibitors)|Completed||Phase 3|525||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:18.606805|2018-06-01 05:34:18.606805
NCT00008489|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-30|||2005-12-08|2001-08-30|2001-08-31|Estimate|||||||2005-12-08|2005-12-09|Estimate||||January 2002|2002-01-31||||||||Interventional|||Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults|A Randomized Open-Label Trial Comparing the Tolerability of Videx EC Capsules to Videx Tablets in Adults With HIV Infection|Unknown status|Active, not recruiting|Phase 3|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:18.851905|2018-06-01 05:34:18.851905
NCT00008463|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-09|||2013-06-07|2001-08-30|2001-08-31|Estimate|||||||2013-06-07|2013-06-10|Estimate|November 2000||2000-11-30|June 2013|2013-06-30|August 2006||2006-08-31|||||Interventional|||A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)|A Prospective, Multicenter, Phase II/III, Open-Label, Controlled, Randomized Trial Evaluating the Efficacy, Safety, and Tolerability of Interferon-alfa-2a Plus Ribavirin Versus PEG-interferon-alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus (HCV) Infection in Individuals Co-Infected With Human Immunodeficiency Virus-1 (HIV-1)|Completed||Phase 2|132||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:18.983726|2018-06-01 05:34:18.983726
NCT00007787|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-04|||2013-01-18|2001-08-30|2001-08-31|Estimate|||||||2013-01-18|2013-01-23|Estimate|April 2000||2000-04-30|January 2013|2013-01-31|March 2004|Actual|2004-03-31|||||Interventional|||Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants|Evaluation of Antibody Plus Delayed CSA vs CSA in Determining Delayed Graft Function in Cadaver Transplant Recipients|Completed||N/A|350|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:34:19.132337|2018-06-01 05:34:19.132337
NCT00007488|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-23|||2013-11-19|2001-08-30|2001-08-31|Estimate|||||||2013-11-19|2013-11-20|Estimate|November 2000||2000-11-30|November 2013|2013-11-30|August 2004|Actual|2004-08-31|||||Observational|||HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs|Virologic Studies in Compartmental Samples From HIV-Infected Subjects Changing or Initiating Potent Antiretroviral Therapy|Completed|||164||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:19.247695|2018-06-01 05:34:19.247695
NCT00007449|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2002|2002-06-30||||||||Interventional|||Safety and Effectiveness of the Drug DPC 083 in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Patients Who Are Failing Treatment With Nonnucleoside Reverse Transcriptase Inhibitors|A Phase II, Open Label, Multicenter Study to Assess the Safety and Efficacy of 100 Mg DPC 083 Once Daily in Combination With Nucleoside Analogue Reverse Transcriptase Inhibitors in HIV-1-Infected Subjects Who Are Failing Treatment With a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimen|Unknown status|Active, not recruiting|Phase 2|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:19.384471|2018-06-01 05:34:19.384471
NCT00007436|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2001|2001-07-31||||||||Interventional|||The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients|A Phase 3, Open-Label, Multicenter Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients|Unknown status|Active, not recruiting|Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:19.466983|2018-06-01 05:34:19.466983
NCT00007423|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|September 2001|Actual|2001-09-30|||||Interventional|||Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda|A Phase I Study of the Safety and Immunogenicity of Live Recombinant ALVAC-HIV vCP205 in HIV-1 Uninfected Adult Volunteers in Uganda|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:19.553935|2018-06-01 05:34:19.553935
NCT00007332|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|April 2003|Actual|2003-04-30|||||Interventional|||Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B|A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a Combined Regimen Using ALVAC vCP1452 and AIDSVAX B/B|Completed||Phase 2|330||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:19.700217|2018-06-01 05:34:19.700217
NCT00007319|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2008-09-16|2001-08-30|2001-08-31|Estimate|||||||2008-09-16|2008-09-17|Estimate||||May 2006|2006-05-31||||||||Observational|||Carotid Artery Thickness in HIV Infected and Uninfected Adults|Carotid Artery Intima-Media Thickness in HIV-Infected and Uninfected Adults: A Pilot Study|Completed|||132||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:19.816845|2018-06-01 05:34:19.816845
NCT00007202|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-15|||2013-09-20|2001-08-30|2001-08-31|Estimate|||||||2013-09-20|2013-09-23|Estimate||||September 2013|2013-09-30|October 2006|Actual|2006-10-31|||||Interventional|||Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients|A Pilot Open-Label Phase II Clinical Trial to Evaluate the Safety and Efficacy of a Compact Three Drug Antiretroviral Treatment Regimen for Subjects With Acute HIV-1 Infection or Recent HIV-1 Seroconversion|Completed||Phase 2|55|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:19.887325|2018-06-01 05:34:19.887325
NCT00006643|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||June 2003|2003-06-30||||||||Observational|||Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus|Use of Single Photon Emission Computed Tomography (SPECT) as a Noninvasive Alternative to Liver Biopsies in Assessing Liver Involvement in Subjects Coinfected With HIV and Hepatitis C Virus (HCV)|Completed|||44||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:19.991602|2018-06-01 05:34:19.991602
NCT00006630|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2012-05-11|2001-08-30|2001-08-31|Estimate|||||||2012-05-11|2012-05-14|Estimate||||May 2012|2012-05-31||||||||Interventional|||Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection|Open-Label, Multi-Site Study for the Administration of Vaccinia Immune Globulin (Human) To Subjects Who Experience Complications From Vaccinia Virus Vaccinations or To Unprotected Individuals Accidentally Exposed To Vaccinia Virus or Related Orthopox Viruses [During HIV Vaccine Research]|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:20.076408|2018-06-01 05:34:20.076408
NCT00006617|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2015-05-14|2001-08-30|2001-08-31|Estimate|||||||2015-05-14|2015-05-15|Estimate||||December 2004|2004-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients|An Open-Label, Single Center Trial to Evaluate the Efficacy and Safety of Quadruple Chemotherapy (Zidovudine, EPIVIR, 1592U89, and 141W94) in Subjects Infected With HIV-1 (GW QUAD)|Completed||N/A|25||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:20.140415|2018-06-01 05:34:20.140415
NCT00006604|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|2016-01-29||2016-03-07|2001-08-30|2001-08-31|Estimate|2016-03-07|2016-04-05|Estimate||||2016-03-07|2016-04-05|Estimate|November 2000||2000-11-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|October 2011|Actual|2011-10-31||Interventional||"Participants accrued and treated at the dose ultimately selected for their groups.~NOTE: (1) Final Dose not established for Grps 1, 2; (2) Grp 5a started with n=12, but (1) participant inadvertently enrolled,never received ATV, final n=11; (3) Grp 8 started with n=15, but (1) participant inadvertently enrolled, never received ATV, final n=14."|Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents|Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents|Completed||Phase 1/Phase 2|195|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||9|||f||||f||||||||||2018-06-01 05:34:20.315595|2018-06-01 05:34:20.315595
NCT00006591|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-01|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2004|2004-12-31||||||||Interventional|||Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment|The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals|Unknown status|Active, not recruiting|N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:23.004627|2018-06-01 05:34:23.004627
NCT00006578|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-01|||2015-03-05|2001-08-30|2001-08-31|Estimate|||||||2015-03-05|2015-03-09|Estimate||||June 2003|2003-06-30||||||||Interventional|||Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication|Evaluation of the Relationship Between Immunologic Recovery After Highly Active Antiretroviral Therapy and the Ability to Mobilize CD34+ Stem Cells Following G-CSF Administration|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:23.068454|2018-06-01 05:34:23.068454
NCT00006509|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-17|||2015-03-05|2001-08-30|2001-08-31|Estimate|||||||2015-03-05|2015-03-09|Estimate||||March 2015|2015-03-31|June 2007|Actual|2007-06-30|||||Interventional|||A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years|A Phase I/II Safety and Immunogenicity Evaluation of a Prime/Boost Vaccine Using ALVAC-HIV (vCP 1452) With Recombinant gp160 LAI/MN-2 in HIV-Infected Subjects Treated With Antiretroviral Therapy for a Minimum of 2 Years|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:23.12557|2018-06-01 05:34:23.12557
NCT00006495|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-15|||2013-07-19|2001-08-30|2001-08-31|Estimate|||||||2013-07-19|2013-07-22|Estimate||||July 2013|2013-07-31|September 2004|Actual|2004-09-30|||||Interventional|||Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452|Augmentation of HIV-Specific Helper and CTL Responses Through Therapeutic Vaccination in Individuals Receiving Potent Suppressive Antiretroviral Therapies|Completed||Phase 1|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:23.18167|2018-06-01 05:34:23.18167
NCT00006490|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-08|||2008-09-24|2001-08-30|2001-08-31|Estimate|||||||2008-09-24|2008-09-25|Estimate||||July 2004|2004-07-31||||||||Observational|||A Comparison of Two Tests for Anti-HIV Drug Resistance|HIV-1 Resistance Testing During Antiretroviral Failure: Comparison of Sequencing Versus Phenotyping|Completed|||600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:23.33847|2018-06-01 05:34:23.33847
NCT00006444|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2013-11-19|2001-08-30|2001-08-31|Estimate|||||||2013-11-19|2013-11-20|Estimate|November 2000||2000-11-30|November 2013|2013-11-30|August 2005|Actual|2005-08-31|||||Observational|||The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women|Assessment of Prevalence and Persistence of Human Papillomavirus (HPV) DNA in HIV-Infected Women Who Are Antiretroviral Naive and Have Initiated HAART|Completed|||160||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:23.44478|2018-06-01 05:34:23.44478
NCT00006443|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2011-03-01|2001-08-30|2001-08-31|Estimate|||||||2011-03-01|2011-03-02|Estimate||||January 2005|2005-01-31||||October 2003|Actual|2003-10-31||Interventional|||Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection|Evaluating Responses to Antiretroviral Drugs in Cells and Tissues (The ERADICATE Study): Comprehensive Comparisons of Viral and Cellular Dynamics Among Previously-Untreated Subjects With Acute HIV Infection (Seroconversion Syndrome) or Recently Acquired HIV Infection Versus the Early, Middle, and Advanced Stages of Seropositive HIV Infection|Completed||N/A|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:23.547252|2018-06-01 05:34:23.547252
NCT00006442|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||January 2005|2005-01-31||||||||Observational|||The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected Patients|Quantitative Assessment of Viral and Lymphocyte Dynamics in Blood and Lymphoreticular Tissues of HIV-1 Infected Patients Treated With Antiretroviral Agents|Completed|||60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:23.603053|2018-06-01 05:34:23.603053
NCT00006441|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2015-03-05|2001-08-30|2001-08-31|Estimate|||||||2015-03-05|2015-03-09|Estimate|February 2003||2003-02-28|April 2014|2014-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV|A Single Center, Randomized Open Label Study of Initial Interleukin-2 Compared to Delayed Interleukin-2 When Added to Zidovudine, 3TC and Nelfinavir In Order to Modulate Immune Function and to Sustain Suppression of HIV-1 Replication Among Those Persons With Primary or Early HIV Infection|Completed||N/A|398|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:34:23.654948|2018-06-01 05:34:23.654948
NCT00006440|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2016-10-27|2001-08-30|2001-08-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|March 2000||2000-03-31|October 2012|2012-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||A Test of Behavioral Intervention for Women at High Risk for HIV Infection|Feasibility Study of a Behavioral Intervention for Women at Persistent High Risk for HIV Infection|Completed|||180||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:23.748235|2018-06-01 05:34:23.748235
NCT00006415|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-19|||2015-03-05|2001-08-30|2001-08-31|Estimate|||||||2015-03-05|2015-03-09|Estimate||||March 2015|2015-03-31||||||||Observational|||A Study of Patients Who Recently Have Been Infected With HIV|Evaluation of Subjects With Primary or Early Human Immunodeficiency Virus (HIV) Infection|Withdrawn|||0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:24.039283|2018-06-01 05:34:24.039283
NCT00006412|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-13|||2013-07-19|2001-08-30|2001-08-31|Estimate|||||||2013-07-19|2013-07-22|Estimate||||July 2013|2013-07-31|May 2003|Actual|2003-05-31|||||Interventional|||Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids|A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities|Completed||Phase 3|630||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:24.12514|2018-06-01 05:34:24.12514
NCT00006397|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-10|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2000||2000-08-31|June 2001|2001-06-30||||||||Interventional|||Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs|A Study of the Combination of Indinavir, Ritonavir, Enteric-Coated ddI and d4T In Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitor Experienced Patients: An Open-Label Study Investigating Differences Between Women and Men|Unknown status|Active, not recruiting|Phase 3|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:24.282126|2018-06-01 05:34:24.282126
NCT00006396|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-10|||2012-02-13|2001-08-30|2001-08-31|Estimate|||||||2012-02-13|2012-02-14|Estimate||||February 2012|2012-02-29|November 2004|Actual|2004-11-30|||||Interventional|||Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns|A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates|Completed||Phase 3|1500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:24.36441|2018-06-01 05:34:24.36441
NCT00006339|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31||||||||Interventional|||Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection|A Prospective Randomized Open-Label Clinical Trial to Evaluate the Comparative Efficacy and Safety of a Potent Antiretroviral Treatment Regimen With or Without Hydroxyurea for Subjects With Acute HIV-1 Infection or Recent HIV-1 Seroconversion|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:24.455881|2018-06-01 05:34:24.455881
NCT00006327|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1999||1999-03-31|June 2003|2003-06-30|August 2000||2000-08-31|||||Interventional|||Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand|A Phase III Trial to Determine the Efficacy of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand|Completed||Phase 3|2500||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:24.722108|2018-06-01 05:34:24.722108
NCT00006326|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2000||2000-08-31|July 2002|2002-07-31||||||||Interventional|||Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir|A Randomized, Open-Label Study to Evaluate 3 Salvage Regimens in HIV-Infected Subjects Experiencing Virologic Failure on an Initial HAART Regimen Containing Nelfinavir|Terminated||N/A|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:24.892155|2018-06-01 05:34:24.892155
NCT00006325|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-02|||2012-05-18|2001-08-30|2001-08-31|Estimate|||||||2012-05-18|2012-05-22|Estimate||||May 2012|2012-05-31|March 2004|Actual|2004-03-31|||||Interventional|||Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children|Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of PEG-Intron in HIV-1 Infected Children|Completed||Phase 1|54||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:24.955616|2018-06-01 05:34:24.955616
NCT00006316|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2008-07-30|2001-08-30|2001-08-31|Estimate|||||||2008-07-30|2008-08-01|Estimate||||February 2004|2004-02-29||||||||Observational|||Withdrawal of Antifungal Treatment for Histoplasmosis in Patients After Improved Immune Response to Anti-HIV Drugs|Discontinuation of Antifungal Therapy for Histoplasmosis Following Immunologic Response to Antiretroviral Therapy|Completed|||50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:25.147608|2018-06-01 05:34:25.147608
NCT00006304|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-27|||2013-10-04|2001-08-30|2001-08-31|Estimate|||||||2013-10-04|2013-10-07|Estimate||||October 2013|2013-10-31|May 2002|Actual|2002-05-31|||||Observational|||Long-Term Effects of HIV Exposure and Infection in Children|Pediatric Late Outcomes Protocol|Completed|||4150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:25.246152|2018-06-01 05:34:25.246152
NCT00006298|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-26|||2008-09-24|2001-08-30|2001-08-31|Estimate|||||||2008-09-24|2008-09-25|Estimate||||July 2004|2004-07-31||||||||Observational|||Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa|Virological and Immunological Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa|Completed|||125||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:25.438805|2018-06-01 05:34:25.438805
NCT00006291|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-22|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|October 2005|Actual|2005-10-31|||||Interventional|||Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination|A Phase II, Randomized, Partially Blinded Trial of Combinations of Potent Antiretroviral Therapy, HIV-Specific Immunizations, and Cycles of Interleukin-2 to Promote Efficient Control of Viral Replication|Completed||Phase 2|100||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:25.502484|2018-06-01 05:34:25.502484
NCT00006290|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-21|||2008-09-24|2001-08-30|2001-08-31|Estimate|||||||2008-09-24|2008-09-25|Estimate||||June 2003|2003-06-30||||||||Observational|||Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs|Perceived Changes in Body Habitus and Body Image Among HIV+ Persons Currently Receiving or Recently Discontinuing Combination Antiretroviral Therapy|Completed|||60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:25.598545|2018-06-01 05:34:25.598545
NCT00006279|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-14|||2012-02-13|2001-08-30|2001-08-31|Estimate|||||||2012-02-13|2012-02-14|Estimate||||February 2012|2012-02-29|May 2005|Actual|2005-05-31|||||Interventional|||The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months|Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months|Completed||Phase 1|75||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:25.652074|2018-06-01 05:34:25.652074
NCT00006211|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2000||2000-02-29|March 2001|2001-03-31|April 2001||2001-04-30|||||Interventional|||A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments|A Double-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With VIRACEPT and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen|Completed||Phase 2|350||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:25.831107|2018-06-01 05:34:25.831107
NCT00006209|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2000||2000-06-30|June 2001|2001-06-30||||||||Interventional|||A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs|A Phase I Open-Label Dose Escalation Trial of Tucaresol in HIV-1 Infected Subjects Taking Potent Antiretroviral Therapy|Unknown status|Active, not recruiting|Phase 1|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:25.887067|2018-06-01 05:34:25.887067
NCT00006208|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2000||2000-08-31|June 2006|2006-06-30||||||||Interventional|||A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs|A Randomized, Double-Blind, Equivalence Trial Comparing Emtricitabine to Stavudine Within a Triple Drug Combination Containing Didanosine Plus Efavirenz in Antiretroviral-Drug Naive HIV-1 Infected Patients|Unknown status|Active, not recruiting|Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:25.994488|2018-06-01 05:34:25.994488
NCT00006207|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||June 2003|2003-06-30||||||||Interventional|||Safety and Tolerability of the Vaginal Gel PRO 2000/5|A Phase I Multicenter Dose Escalation Safety and Acceptability Study of the Investigational Vaginal Microbicide Agent PRO 2000/5 Gel (P)|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:26.210819|2018-06-01 05:34:26.210819
NCT00006154|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-07|||2013-09-04|2001-08-30|2001-08-31|Estimate|||||||2013-09-04|2013-09-06|Estimate||||September 2013|2013-09-30||||||||Interventional|||A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection|Randomized, Controlled, Open Label, Multi-Center Phase III Trial Comparing the Safety and Antiviral Activity of a Protease-Containing Regimen (d4T/ddI/IDV/RTV) Versus a Protease-Sparing Regimen (d4T/ddI/EFV) and the Ability of Interleukin-2 to Purge HIV From Latent Stores in Patients With Acute/Early HIV Infection|Completed||Phase 3|165|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:34:26.270163|2018-06-01 05:34:26.270163
NCT00006153|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-07|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||June 2003|2003-06-30||||||||Interventional|||Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination|A Multicenter, Double-Blind, Phase I, Adjuvant Controlled Study to Evaluate the Effect of Remune (HIV-1 Immunogen) Compared to IFA, in Combination With Fully Suppressive Antiviral Drug Therapy on HIV-1-Specific Immunogenicity in Subjects With Acute or Primary HIV-1 Infection|Terminated||Phase 1|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:26.429845|2018-06-01 05:34:26.429845
NCT00006152|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-07|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|August 2002|Actual|2002-08-31|||||Interventional|||A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment|A Phase II, Restrictively Randomized, Open-Label, Pilot Study of Treatment Intensification of Early Virologic Failure|Completed||Phase 2|42||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:26.493107|2018-06-01 05:34:26.493107
NCT00006146|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-07|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate|August 2000||2000-08-31|November 2005|2005-11-30|September 2000||2000-09-30|||||Interventional|||Half-Dose Flu Vaccine Study in Healthy Adults|Evaluation of the Immunogenicity of Low Dose Trivalent Inactivated Influenza Vaccine in Healthy Adults|Completed||Phase 2|840||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:26.595705|2018-06-01 05:34:26.595705
NCT00006145|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-07|||2013-07-08|2001-08-30|2001-08-31|Estimate|||||||2013-07-08|2013-07-10|Estimate|August 2000||2000-08-31|July 2013|2013-07-31|February 2006|Actual|2006-02-28|||||Interventional|||Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV|A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay|Completed||Phase 3|350||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:26.676636|2018-06-01 05:34:26.676636
NCT00006144|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-07|||2013-11-06|2001-08-30|2001-08-31|Estimate|||||||2013-11-06|2013-11-07|Estimate|October 2000||2000-10-31|November 2013|2013-11-30|April 2005|Actual|2005-04-30|||||Interventional|||A Study of HIV-Disease Development in Aging|A Phase II Exploratory Study Examining Immunologic and Virologic Indices in Two Age-Differentiated Cohorts of HIV-Infected Subjects to Explore the Basis of Accelerated HIV-Disease Progression Associated With Aging|Completed||Phase 2|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:26.830413|2018-06-01 05:34:26.830413
NCT00006143|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-07|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|July 2002|Actual|2002-07-31|||||Interventional|||Growth Hormone Treatment of Children With HIV-Associated Growth Failure|A Randomized, Open-Label Study of Recombinant Human Growth Hormone (r-hGH) in Children With HIV-Associated Growth Failure|Completed||N/A|102||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:26.985622|2018-06-01 05:34:26.985622
NCT00006075|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-27|||2008-09-26|2001-08-30|2001-08-31|Estimate|||||||2008-09-26|2008-09-30|Estimate||||June 2004|2004-06-30|August 2007|Actual|2007-08-31|||||Interventional|||A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies|Phase IIA Study of Tolerance and Safety of Differing Concentrations of Chlorhexidine, for Peripartum Vaginal and Infant Washes, to Prevent Mother to Infant HIV-1 Transmission|Completed||Phase 2|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:27.259316|2018-06-01 05:34:27.259316
NCT00006066|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-14|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|June 2006|Actual|2006-06-30|||||Interventional|||Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems|Phase I/II Trial of Subcutaneous IL-2 With Highly Active Antiretroviral Therapy in HIV-Infected Children With Immunosuppression|Completed||Phase 1|92||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:27.794988|2018-06-01 05:34:27.794988
NCT00006064|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-16|||2014-10-28|2001-08-30|2001-08-31|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2000||2000-06-30|October 2014|2014-10-31|February 2005|Actual|2005-02-28|||||Observational|||The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children|Effect of Antiretroviral Therapy on Body Composition in HIV-Infected Children|Completed|||100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:27.889479|2018-06-01 05:34:27.889479
NCT00005931|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-30|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2000|2000-12-31||||||||Interventional|||SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment|A Multicenter, Open-Label, Phase II Study of SU5416 in Patients With Therapy-Refractory Cutaneous AIDS-Related Kaposi's Sarcoma|Completed||Phase 2|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:29.570061|2018-06-01 05:34:29.570061
NCT00005921|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-19|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2000|2000-06-30||||||||Interventional|||A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis|An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis|Completed||N/A|18||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:29.962662|2018-06-01 05:34:29.962662
NCT00005920|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-19|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2000|2000-06-30||||||||Interventional|||Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole|A Multiclinic, Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety, Tolerability, and Efficacy of L-743,872 in the Treatment of Fluconazole-Unresponsive Oropharyngeal Candidiasis in Adults|Terminated||Phase 2|70||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:30.114936|2018-06-01 05:34:30.114936
NCT00005918|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-15||2011-04-13|2011-04-28|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|June 2000||2000-06-30|April 2011|2011-04-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients|The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy|Completed||Phase 3|730||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:30.184559|2018-06-01 05:34:30.184559
NCT00005915|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-15|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|June 2004|Actual|2004-06-30|||||Observational|||A Comparison of Two Anti-HIV Treatment Plans|A Randomized Study of a Prescribed 4-Month Structured Treatment Interruption (STI) Followed by Initiation of a New Antiretroviral Regimen Versus Immediate Initiation of a New Antiretroviral Regimen in HIV-Infected Patients With Multidrug Resistant (MDR) Virus|Completed|||480||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:30.568287|2018-06-01 05:34:30.568287
NCT00005779|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy|A Phase I, Limited-Center, Sequential Cohort Trial of HIV Vaccine (Polyvalent Peptide Vaccine C4-V3) in Conjunction With Interleukin-12 in Subjects With Maximal Suppression of HIV Replication and CD4 Count > 400 Cells/mm3|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:30.682979|2018-06-01 05:34:30.682979
NCT00005764|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-30|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2000||2000-05-31|June 2001|2001-06-30||||||||Interventional|||A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients|Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)|Completed||Phase 4|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:30.768136|2018-06-01 05:34:30.768136
NCT00005762|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-07-19|2001-08-30|2001-08-31|Estimate|||||||2013-07-19|2013-07-22|Estimate|March 2001||2001-03-31|July 2013|2013-07-31|May 2004|Actual|2004-05-31|||||Interventional|||Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers|Pharmacokinetic Interaction Studies of Amprenavir (APV), Efavirenz (EFV), and a Second Protease Inhibitor in HIV-Seronegative Volunteers|Completed||N/A|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:34:30.872214|2018-06-01 05:34:30.872214
NCT00005758|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-23|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|September 2005|Actual|2005-09-30|||||Interventional|||Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination|A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of Immunization With an HIV Immunogen on the Time to Virologic Relapse in Individuals Receiving Potent, Suppressive Antiretroviral Therapies|Completed||Phase 3|472||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:30.994319|2018-06-01 05:34:30.994319
NCT00005668|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-18|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma|A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma|Completed||Phase 2|96||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:31.163239|2018-06-01 05:34:31.163239
NCT00005663|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-11|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|July 2001|2001-07-31||||||||Interventional|||A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients|An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects|Unknown status|Active, not recruiting|Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:31.278465|2018-06-01 05:34:31.278465
NCT00005572|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-28|||2008-07-31|2001-08-30|2001-08-31|Estimate|||||||2008-07-31|2008-08-04|Estimate||||June 2003|2003-06-30||||||||Observational|||A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection|Study of Pathogen-Specific Immune Responses and General Immune Competence in Opportunistic Infections|Completed|||90||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:31.405038|2018-06-01 05:34:31.405038
NCT00005120|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-20|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2000||2000-04-30|June 2001|2001-06-30||||||||Interventional|||The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Phase IB Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-Calanolide A on Surrogate Markers in HIV-Positive Patients With No Previous Antiretroviral Therapy|Unknown status|Active, not recruiting|Phase 1|16||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:31.512039|2018-06-01 05:34:31.512039
NCT00005118|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-07|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2001|2001-07-31||||||||Interventional|||The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment|A Multicenter, Open-Label, 24-Week Study to Evaluate the Efficacy and Safety of Indinavir Sulfate 800 Mg and Ritonavir 200 Mg b.i.d. Plus 2 NRTIs b.i.d. in HIV-1 Infected Individuals Who Require Early Treatment Intervention|Unknown status|Active, not recruiting|Phase 2|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:31.59173|2018-06-01 05:34:31.59173
NCT00005113|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-14|||2012-03-12|2001-08-30|2001-08-31|Estimate|||||||2012-03-12|2012-03-13|Estimate|July 1999||1999-07-31|March 2012|2012-03-31|March 2006|Actual|2006-03-31|July 2004|Actual|2004-07-31||Interventional|||A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant|An Open-Label, Comparative Study of the Effect of Sirolimus Versus Standard Treatment on Clinical Outcomes and Histologic Progression of Allograft Nephropathy in High Risk Pediatric Renal Transplant Patients|Terminated||Phase 3|102|Actual|Boston Children’s Hospital||2||Inability to meet the accrual target of 213.|f||||t||||||||||2018-06-01 05:34:31.74487|2018-06-01 05:34:31.74487
NCT00005106|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1999||1999-09-30|November 2000|2000-11-30||||||||Interventional|||A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients|A 96-Week, Randomized, Open-Label, Multicenter Trial to Evaluate the Safety and Tolerability of the Antiretroviral Activity of Stavudine (40mg BID) Plus Lamivudine (150mg BID) Plus Nelfinavir (1250mg BID) Versus Abacavir (300mg BID) Plus Combivir (3TC 150mg/ZDV 300mg BID) Versus Combivir (3TC 150mg/ZDV 300mg BID) Plus Nelfinavir (1250mg BID) in HIV-1 Infected Subjects|Completed||Phase 4|230||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:31.84133|2018-06-01 05:34:31.84133
NCT00005020|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2010-03-24|2001-08-30|2001-08-31|Estimate|||||||2010-03-24|2010-03-25|Estimate||||December 2004|2004-12-31||||||||Observational|||Observing Patients With Early HIV Infection|An Observational Study of Viral and Immune Dynamics in Subjects With Acute HIV Infection: A Study of the UCSD Acute/Early HIV Infection (AEHIV) Clinical Studies Unit|Completed|||10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:31.952696|2018-06-01 05:34:31.952696
NCT00005018|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-04|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1999||1999-07-31|August 2000|2000-08-31|October 2000||2000-10-31|||||Interventional|||Safety and Effectiveness of a Combination Anti-HIV Drug Treatment|A Phase IV 48-Week, Randomized, Open-Label, Multicenter Trial of Abacavir (300mg BID)/Efavirenz (600mg QD)/Didanosine (400mg QD) +/- Hydroxyurea (500mg BID) in HIV-1 Infected Subjects Failing Initial Therapy With 3TC/ZDV (or d4T) +/- Protease Inhibitor(s)|Completed||Phase 4|150||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.015056|2018-06-01 05:34:32.015056
NCT00005017|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-03|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2001|2001-06-30||||||||Interventional|||Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment|A Phase IV, Open-Label, Randomized Study to Compare the Efficacy and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) for 96 Weeks in the Treatment of HIV-1 Infected Subjects Who Are Antiretroviral Therapy Naive|Unknown status|Active, not recruiting|Phase 4|300||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.104238|2018-06-01 05:34:32.104238
NCT00005012|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-29|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2000||2000-03-31|August 2000|2000-08-31|September 2000||2000-09-30|||||Interventional|||Safety and Effectiveness of PEG-Intron in HIV-Infected Patients|Antiviral Activity and Tolerability of PEG-Intron in HIV-Infected Subjects Failing HAART|Completed||Phase 2|250||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.193094|2018-06-01 05:34:32.193094
NCT00005010|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-28|||2013-01-23|2001-08-30|2001-08-31|Estimate|||||||2013-01-23|2013-01-25|Estimate||||January 2013|2013-01-31|March 2004|Actual|2004-03-31|||||Interventional|||Prevention of Kidney Transplant Rejection|An Interventional Trial in Established Chronic Renal Allograft Rejection|Completed||Phase 3|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||||||2018-06-01 05:34:32.413097|2018-06-01 05:34:32.413097
NCT00005009|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-28|||2017-02-14|2001-08-30|2001-08-31|Estimate|||||||2017-02-14|2017-02-16|Actual|February 1998||1998-02-28|February 2017|2017-02-28|June 16, 2001|Actual|2001-06-16|June 16, 2001|Actual|2001-06-16||Interventional|||Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients|Evaluation of the Safety and Immunogenicity of Varivax® (Live-Attenuated Varicella-Zoster Virus Vaccine) in Pediatric Renal Transplant Recipients|Terminated||Phase 1|7|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1||Slow enrollment|f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:34:32.475817|2018-06-01 05:34:32.475817
NCT00005002|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-21|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2001|2001-08-31||||||||Interventional|||Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)|A Randomized, Double-Blind, Adjuvant-Controlled, Multicenter Study to Compare the Virologic and Immunologic Effect of Highly Active Antiretroviral Therapy (HAART) Plus Remune Versus HAART Plus Incomplete Freund's Adjuvant (IFA) in Antiretroviral-Naive Patients Infected With Human Immunodeficiency Virus Type 1 (HIV-1)|Unknown status|Active, not recruiting|Phase 3|688||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.56976|2018-06-01 05:34:32.56976
NCT00005001|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-21|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2001|2001-03-31||||||||Interventional|||Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)|A Pilot, Phase II, Double-Blind Study to Assess the Virologic Effect of Remune Versus Incomplete Freund's Adjuvant (IFA) in Patients Who Are Infected With Human Immunodeficiency Virus Type I (HIV-1), Have a Plasma HIV-1 RNA Level Less Than 50 Copies/Ml, Are Receiving Highly Active Antiretroviral Therapy (HAART), and Who Subsequently Discontinue Their HAART Regimen|Completed||Phase 2|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.634746|2018-06-01 05:34:32.634746
NCT00005000|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-21|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1999||1999-12-31|July 2002|2002-07-31||||||||Interventional|||Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs|A Randomized, Open-Label, Study of Nelfinavir or Efavirenz in HIV-1 Infected, Antiretroviral Naive Patients|Unknown status|Active, not recruiting|Phase 4|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.707702|2018-06-01 05:34:32.707702
NCT00004999|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-21|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1999||1999-08-31|March 2001|2001-03-31||||||||Interventional|||Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients|A Randomized, Double-Blind, Placebo-Controlled Study of AG1549 in Combination With Viracept (Nelfinavir Mesylate) and Combivir (Zidovudine + Lamivudine) in Treatment-Naive HIV-Infected Patients|Suspended||Phase 2|350||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.784008|2018-06-01 05:34:32.784008
NCT00004998|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-21|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1999||1999-11-30|March 2001|2001-03-31||||||||Interventional|||Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients|A Phase II, Open-Label Study of AG1549 in Combination With Other Antiretroviral Agents in Treatment-Naive HIV-Infected Patients|Suspended||Phase 2|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.90822|2018-06-01 05:34:32.90822
NCT00004987|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-16|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|June 2001|2001-06-30||||||||Interventional|||Treatment of Advanced AIDS Patients With Dextrin Sulfate|Intraperitoneal Dextrin Sulfate in Patients With Advanced HIV Disease: A Phase I Trial|Unknown status|Active, not recruiting|Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:32.966247|2018-06-01 05:34:32.966247
NCT00004986|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-16|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2000||2000-02-29|August 2000|2000-08-31||||||||Interventional|||Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients|Open Label, Multi-Center Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in Subjects With AIDS in the United States|Terminated||Phase 3|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:33.030136|2018-06-01 05:34:33.030136
NCT00004985|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-15|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|March 2001|2001-03-31||||||||Interventional|||Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy|A Phase II, Single-Blind, Randomized, Placebo-Controlled Study of Capravirine (AG1549) in Combination With Viracept and Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Subjects Who Failed an Initial Nonnucleoside Reverse Transcriptase Inhibitor Containing Regimen|Completed||Phase 2|75||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:33.078547|2018-06-01 05:34:33.078547
NCT00004981|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-13|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2001|2001-06-30||||||||Interventional|||Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)|A Phase IIIB Randomized, Multicenter Study of the Efficacy and Safety of Combivir 1 Tablet Po Bid Plus Ziagen 300mg Po Bid Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet Po Bid, Administered for 24 Weeks in Subjects With HIV-1 Infection|Unknown status|Active, not recruiting|Phase 3|230||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:33.15832|2018-06-01 05:34:33.15832
NCT00004978|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-10|2011-01-20|2009-10-16|2013-05-01|2001-08-30|2001-08-31|Estimate|2011-03-21|2011-04-25|Estimate|2009-10-16|2009-10-20|Estimate|2013-05-01|2013-05-06|Estimate|March 2000||2000-03-31|October 2012|2012-10-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|ESPRIT||An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy|A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mm^3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial|Completed||Phase 3|4150|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-06-01 05:34:34.319897|2018-06-01 05:34:34.319897
NCT00004855|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-29|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|April 2005|Actual|2005-04-30|||||Interventional|||Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs|A Randomized, Open-Label, Pilot Treatment Trial Evaluating Cellular Dynamics and Immune Restoration in Treatment-Naive HIV-Infected Subjects Receiving Either the Protease Inhibitor LPV/r or the Nucleoside Analogue Reverse Transcriptase Inhibitors d4T/3TC/Abacavir With the Non-Nucleoside Reverse Transcriptase Inhibitor Nevirapine|Completed||N/A|55||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:36.063368|2018-06-01 05:34:36.063368
NCT00004852|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1999||1999-09-30|August 2000|2000-08-31||||||||Interventional|||Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs|A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily Vs. Lamivudine 150mg BID in Combination With Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretroviral-Naive Adults With HIV-1 Infection|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:36.198507|2018-06-01 05:34:36.198507
NCT00004736|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2008-09-10|2001-08-30|2001-08-31|Estimate|||||||2008-09-10|2008-09-11|Estimate||||June 2003|2003-06-30||||||||Interventional|||Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis|Viral and Immune Dynamics in HIV-Infected Patients With Tuberculosis|Completed||Phase 1|44||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:36.389668|2018-06-01 05:34:36.389668
NCT00004735|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2013-10-04|2001-08-30|2001-08-31|Estimate|||||||2013-10-04|2013-10-07|Estimate|February 2000||2000-02-29|October 2013|2013-10-31|September 2006|Actual|2006-09-30|||||Interventional|||The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV|The Effects of Highly Active Antiretroviral Therapy (HAART) on the Recovery of Immune Function in HIV-Infected Children and Young Adults|Completed||N/A|81|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:34:36.482629|2018-06-01 05:34:36.482629
NCT00004585|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-15|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|November 2000|2000-11-30||||||||Interventional|||A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults|A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy With Combivir (Lamivudine 150mg/Zidovudine 300mg) BID, Ziagen (Abacavir) 300mg BID, and Sustiva (Efavirenz) 600mg QD for 24 Weeks, Followed by the Triple Nucleoside Combination Tablet (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) BID Plus Sustiva (Efavirenz) 600mg QD for 24 Weeks in HIV-Infected Adults|Completed||Phase 4|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:36.62|2018-06-01 05:34:36.62
NCT00004584|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-10||2011-04-13|2011-04-28|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|December 1999||1999-12-31|April 2011|2011-04-30|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment|Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, in Combination Regimen(s) as Compared to a Reference Combination Regimen(s) in Antiretroviral-Experienced HIV-Infected Subjects|Completed||Phase 2|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:36.717047|2018-06-01 05:34:36.717047
NCT00004583|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate|March 1999||1999-03-31|February 2009|2009-02-28||||||||Interventional|||A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy|A Randomized, Double-Blind, Phase III Study of ABT-378/Ritonavir Plus Stavudine and Lamivudine vs Nelfinavir Plus Stavudine and Lamivudine in Antiretroviral Naive HIV-Infected Subjects|Completed||Phase 3|660||Abbott|||||f||||||||||||||2018-06-01 05:34:36.873637|2018-06-01 05:34:36.873637
NCT00004582|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2000|2000-08-31||||||||Interventional|||ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past|A Phase II Study of ABT-378/Ritonavir and Efavirenz in Multiple Protease Inhibitor-Experienced Subjects|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:37.09949|2018-06-01 05:34:37.09949
NCT00004581|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment|A Randomized, Open-Label, Phase III Study of ABT-378/Ritonavir in Combination With Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination With Nevirapine and Two NRTIs in Antiretroviral-Experienced HIV-Infected Subjects|Completed||Phase 3|300||Abbott|||||f||||||||||||||2018-06-01 05:34:37.216405|2018-06-01 05:34:37.216405
NCT00004580|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors|Phase I/II Study of ABT-378/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients|Completed||Phase 1|||Abbott|||||f||||||||||||||2018-06-01 05:34:37.415703|2018-06-01 05:34:37.415703
NCT00004579|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1998||1998-04-30|June 2003|2003-06-30||||||||Interventional|||A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection|A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:37.4934|2018-06-01 05:34:37.4934
NCT00004578|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-04-02|2001-08-30|2001-08-31|Estimate|||||||2008-04-02|2008-04-03|Estimate|November 1997||1997-11-30|April 2008|2008-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects|Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naive HIV-Infected Patients|Completed||Phase 1/Phase 2|100|Actual|Abbott||2|||f||||f||||||||||2018-06-01 05:34:37.566146|2018-06-01 05:34:37.566146
NCT00002453|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-24|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1999||1999-12-31|May 2000|2000-05-31||||||||Interventional|||A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection|An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients|Completed||N/A|300||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:37.689084|2018-06-01 05:34:37.689084
NCT00002452|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2000|2000-02-29||||||||Interventional|||A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir|A Multicenter, Open-Label, Pilot Study to Evaluate the Safety and Activity of L-756423/Indinavir Sulfate, 800/400 Mg b.i.d. in Combination With Two nRTIs in HIV-Infected Patients Who Failed an Indinavir Containing Regimen|Completed||Phase 2|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:37.784012|2018-06-01 05:34:37.784012
NCT00002451|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2002|2002-07-31||||||||Interventional|||Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs|A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Activity of Indinavir Sulfate 1200 Mg q.d. and Ritonavir 200 Mg q.d. in Combination With Stavudine and Lamivudine in Treatment Naive HIV-1 Infected Patients|Unknown status|Active, not recruiting|Phase 2|8||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:37.870932|2018-06-01 05:34:37.870932
NCT00002450|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2000|2000-07-31||||||||Interventional|||Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Tenofovir Disoproxil Fumarate in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients|Completed||Phase 3|600||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:37.967774|2018-06-01 05:34:37.967774
NCT00002449|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1999||1999-08-31|July 2001|2001-07-31||||||||Interventional|||Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy|A Bridging Dose-Escalation Study of the Safety, Pharmacokinetic Properties, and Immunologic Effect of Subcutaneous L2-7001 (Recombinant Human Interleukin-2) in Patients Infected With HIV With CD4+ T-Cell Counts of 300 to 500 Cells/mm3 and Viral Burden Under 10,000 Copies/Ml on Active Antiretroviral Therapy (ART)|Unknown status|Active, not recruiting|Phase 1|212||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.117769|2018-06-01 05:34:38.117769
NCT00002448|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|January 2001|2001-01-31||||||||Interventional|||A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients|Evaluation of Immune Reconstitution in HIV Infected Patients Treated With Fortovase (Saquinavir) SGC QD Plus Ritonavir QD Plus 2 NRTIs Vs Efavirenz QD Plus 2 NRTIs|Completed||Phase 3|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.255134|2018-06-01 05:34:38.255134
NCT00002447|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|January 2001|2001-01-31||||||||Interventional|||A Study to Compare Two Anti-HIV Drug Combinations|An Open Label, Randomized, Multicenter Study to Evaluate Fortovase (Saquinavir) SGC QD, Norvir (Ritonavir) QD Plus Two NRTIs Vs Sustiva (Efavirenz) QD Plus Two NRTIs in HIV Infected Patients|Completed||Phase 3|146||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.421295|2018-06-01 05:34:38.421295
NCT00002446|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1998||1998-08-31|February 2000|2000-02-29||||||||Interventional|||Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients|Randomized, Controlled Trial of SCH 56592 Oral Suspension Versus Fluconazole Suspension in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients|Completed||Phase 3|300||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.524109|2018-06-01 05:34:38.524109
NCT00002445|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2001|2001-06-30||||||||Interventional|||Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients|A Phase III Randomized Placebo Controlled and Double Blinded Study of IM862 for Patients With Muco-Cutaneous AIDS Associated Kaposi's Sarcoma|Completed||Phase 3|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.602794|2018-06-01 05:34:38.602794
NCT00002444|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1995||1995-10-31|February 1996|1996-02-29|February 1996||1996-02-29|||||Interventional|||A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea|Phase I/II Open Label Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients|Completed||Phase 1|28||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.749242|2018-06-01 05:34:38.749242
NCT00002443|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1996|1996-09-30|January 1996||1996-01-31|||||Interventional|||The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|Twelve-Month Study in HIV-1 Seropositive Retroviral-Naive Patients to Compare the Safety and Efficacy of MK-639 and Zidovudine (AZT) Administered Concomitantly to MK-639 Alone and Zidovudine (AZT) Alone|Completed||N/A|780||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.817303|2018-06-01 05:34:38.817303
NCT00002442|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|August 2000|2000-08-31||||||||Interventional|||A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs|A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of Epivir 150 Mg BID Versus Epivir 300 Mg Once-Daily When Administered for 24 Weeks in Combination With FDA-Approved Dosage Regimens of Zerit and Either Crixivan or Viracept in Subjects With HIV-1 Infection|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.89934|2018-06-01 05:34:38.89934
NCT00002441|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2000|2000-01-31||||||||Interventional|||Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection|A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1 Infection in North America|Completed||Phase 3|5000||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:38.988263|2018-06-01 05:34:38.988263
NCT00002440|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|An Open-Label, Phase II Trial to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of 1592U89 in Combination With Selected HIV-1 Protease Inhibitors in Antiretroviral-Naive, HIV-1-Infected Patients.|Completed||Phase 2|80||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.145622|2018-06-01 05:34:39.145622
NCT00002439|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma|Randomized Phase III Vehicle Controlled Trial of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.231985|2018-06-01 05:34:39.231985
NCT00002345|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||The Safety and Effectiveness of Megace in HIV-Infected Women|Phase IV Study on the Safety and Efficacy of Megace Oral Suspension in HIV-Positive Females|Completed||Phase 4|40||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:50.192324|2018-06-01 05:34:50.192324
NCT00002438|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients|Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.300815|2018-06-01 05:34:39.300815
NCT00002437|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1994|1994-11-30||||||||Interventional|||The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS|Completed||Phase 2|48||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.383294|2018-06-01 05:34:39.383294
NCT00002436|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1994|1994-05-31||||||||Interventional|||The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT|A Randomized Lamivudine (3TC)/Dideoxycytidine (ddC) Double-Blind Multicenter Trial (With Open-Label AZT) to Evaluate the Safety and Efficacy of Low Dose 3TC Administered Concurrently With AZT Versus High Dose 3TC Administered Concurrently With AZT Versus ddC Administered Concurrently With AZT in the Treatment of HIV-1 Infected, AZT-Experienced (>= 24 Weeks) Patients With CD4 Counts of 100-300 Cells/mm3|Completed||Phase 3|325||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.465014|2018-06-01 05:34:39.465014
NCT00002435|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1998|1998-02-28||||||||Interventional|||A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients|Study of the Activity of Thymic Humoral Factor (THF Gamma 2) on HIV Load in HIV-Positive Individuals With CD4+ Cell Counts in the Range of 200-500 Cells/mm3|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.562108|2018-06-01 05:34:39.562108
NCT00002434|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1994|1994-01-31||||||||Interventional|||A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)|A Study of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.628236|2018-06-01 05:34:39.628236
NCT00002433|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS|Activation of Alveolar Macrophages by Aerosolized r-metHuIFN-Gamma (IFN-Gamma) in Patients With AIDS|Completed||N/A|12||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.68019|2018-06-01 05:34:39.68019
NCT00002432|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1990|1990-07-31||||||||Interventional|||A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|An Open Study of Foscarnet Treatment of CMV-Retinitis in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.735839|2018-06-01 05:34:39.735839
NCT00002431|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1993|1993-11-30||||||||Interventional|||The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients|A Multi-Center Trial to Evaluate the Safety and Effectiveness of Peridex Dosed Twice or Three Times Daily for Preventing or Delaying the Occurrence of Lesions Due to Oral Candidiasis in HIV-Positive Individuals|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.789246|2018-06-01 05:34:39.789246
NCT00002430|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2000|2000-02-29||||||||Interventional|||A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations|A Multicenter, Open-Label, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate/d4T/3TC Versus Indinavir Sulfate/Nelfinavir Mesylate/d4T/3TC in HIV-Infected Individuals|Completed||N/A|220||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:39.868873|2018-06-01 05:34:39.868873
NCT00002429|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02||2011-04-13|2011-04-28|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|July 1999||1999-07-31|April 2011|2011-04-30|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen|Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen|Completed||Phase 3|500||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:39.99294|2018-06-01 05:34:39.99294
NCT00002428|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects|A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.171141|2018-06-01 05:34:40.171141
NCT00002427|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1999||1999-05-31|August 2000|2000-08-31||||||||Interventional|||Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults|A Phase I/II Study of the Safety and Antiretroviral Activity of Nine Hydroxyurea Regimens in Combination With ddI and d4T in Subjects With HIV Infection|Completed||Phase 1|225||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.246063|2018-06-01 05:34:40.246063
NCT00002426|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1999|1999-12-31||||||||Interventional|||A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Adefovir Dipivoxil as Intensification Therapy in Combination With Highly Active Antiretroviral Therapy (HAART) in HIV Infected Patients With HIV-1 RNA > 50 and <= 400 Copies/Ml|Completed||N/A|390||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.378331|2018-06-01 05:34:40.378331
NCT00002425|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1996|1996-12-31||||||||Interventional|||The Safety and Effectiveness of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs|A Multicenter, Open-Label Study of the Safety and Activity of Saquinavir Soft Gelatin Capsule Formulation (Saquinavir SGC) in Combination With Other Antiretroviral Drugs|Completed||Phase 4|400||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.546711|2018-06-01 05:34:40.546711
NCT00002424|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2000|2000-04-30||||||||Interventional|||A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine|A Multicenter, Double-Blind, Randomized Pilot Study to Compare the Safety and Activity of L-756423/Indinavir, 1600/800 Mg Qd or 800/400 Mg Bid Versus Indinavir, 800 Mg q8h, All in Combination With Stavudine and Lamivudine|Suspended||Phase 2|186||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.615978|2018-06-01 05:34:40.615978
NCT00002423|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1999||1999-03-31|December 1999|1999-12-31||||||||Interventional|||A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir|A Phase II, Open-Label Trial for Treatment of HIV Infection in Subjects Who Have Failed Initial Combination Therapy With Regimens Containing Indinavir or Nelfinavir: Combination Therapy With 3TC (150 Mg BID), Abacavir (300 Mg BID) and Amprenavir (1200 Mg BID) Plus Either Nelfinavir (1250 Mg BID) or Indinavir (800 Mg TID) for 48 Weeks|Completed||Phase 2|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.715962|2018-06-01 05:34:40.715962
NCT00002422|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-06-24|2001-08-30|2001-08-31|Estimate|||||||2009-06-24|2009-06-25|Estimate||||April 2002|2002-04-30||||||||Interventional|||A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy|A Phase I/II, Open-Label Study of the Safety, Tolerance, Pharmacokinetics, Drug-Interaction and Anti-HIV Activity of Intramuscularly Administered Alpha-Epi-Br (HE2000) in HIV-Infected Patients on Salvage Therapy|Completed||Phase 1|42||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.790516|2018-06-01 05:34:40.790516
NCT00002420|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-13|2001-08-30|2001-08-31|Estimate|||||||2008-08-13|2008-08-14|Estimate||||August 2008|2008-08-31||||||||Interventional|||The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors|A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Rescriptor (Delavirdine Mesylate), and MKC-442 (With or Without Hydroxyurea) for the Treatment of HIV-1- Infected Patients Who Failed Previous Protease Inhibitor Treatment|Terminated||Phase 2|25||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:40.851524|2018-06-01 05:34:40.851524
NCT00002419|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment|A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of Novel Quadruple-Combination Therapy With Preveon (Adefovir Dipivoxil; Bis-POM PMEA), Abacavir (1592U89), Sustiva (Efavirenz; DMP-266), and Amprenavir (141W94) for the Treatment of HIV-1 Infection in Patients Who Have Failed Previous Protease Inhibitor Treatment|Completed||Phase 2|25||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:40.929386|2018-06-01 05:34:40.929386
NCT00002418|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-13|2001-08-30|2001-08-31|Estimate|||||||2008-08-13|2008-08-14|Estimate||||March 2000|2000-03-31||||||||Interventional|||The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors|A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Transcriptase Inhibitor Naive Patients Who Failed Previous Protease Inhibitor Treatment|Terminated||Phase 2|25||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:40.99459|2018-06-01 05:34:40.99459
NCT00002417|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications|An Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who Are Intolerant (Hyperlipidemia With or Without Lipodystrophy) But Not Failing Their Current Protease Inhibitor Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.058427|2018-06-01 05:34:41.058427
NCT00002416|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2000|2000-03-31||||||||Interventional|||Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination|A Randomized, Open-Label Equivalence Study of FTC Versus Lamivudine in Patients on a Stable Triple Antiretroviral Therapy Regimen Containing Lamivudine, Stavudine or Zidovudine, and a Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor|Completed||Phase 3|390||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.129267|2018-06-01 05:34:41.129267
NCT00002415|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Antiviral Activity of the Addition of PMPA Prodrug to Combination Antiretroviral Regimens in Treatment-Experienced HIV-Infected Patients|Completed||Phase 2|175||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.194861|2018-06-01 05:34:41.194861
NCT00002414|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2000|2000-04-30||||||||Interventional|||Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia|Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment|Unknown status|Active, not recruiting|Phase 2|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.277196|2018-06-01 05:34:41.277196
NCT00002413|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of MKC-442 in HIV-Positive Patients|An Open Label Study of MKC-442 in at Least Triple Drug Combination in Patients Previously Treated With Nucleoside Reverse Transcriptase and Protease Inhibitors and Who Are Naive to Non-Nucleoside Reverse Transcriptase Inhibitors|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.341219|2018-06-01 05:34:41.341219
NCT00002412|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of MKC-442 in Combination With Other Anti-HIV Drugs|A Randomized, Double-Blind Study of MKC-442 Combined With Stavudine, Didanosine, and Hydroxyurea in HIV-Infected Patients Who Are Protease Inhibitor Experienced and Non-Nucleoside Reverse Transcriptase Inhibitor Naive|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.381262|2018-06-01 05:34:41.381262
NCT00002411|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02||2011-04-13|2011-04-13|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-13|2011-04-25|Estimate|March 1998||1998-03-31|April 2011|2011-04-30|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs|A Randomized Study of the Long-Term Suppression of Plasma HIV RNA Levels by Triple Combination Regimens in Treatment Naive Subjects|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:34:41.472815|2018-06-01 05:34:41.472815
NCT00002410|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients|A Phase III, Multicenter, Randomized, Open-Label Study to Compare Antiretroviral Activity and Tolerability of Three Different Combination Regimens (DMP 266 + Indinavir, DMP 266 + Zidovudine + Lamivudine, Indinavir + Zidovudine + Lamivudine) in HIV-Infected Patients|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.605199|2018-06-01 05:34:41.605199
NCT00002409|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||The Effect of Teaching HIV-Infected Patients About HIV and Treatment|A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virological Outcomes, Adherence, Immunological Outcome, and Health Outcomes in HIV-Infected Subjects From Under-Represented Populations Treated With Triple Nucleoside Therapy (Combivir, Lamivudine 150 Mg/Zidovudine 300 Mg PO BID Plus Abacavir 300 Mg PO BID) for Twenty-Four Weeks|Completed||Phase 3|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:41.707299|2018-06-01 05:34:41.707299
NCT00002408|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients|Completed||Phase 3|300||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:42.71041|2018-06-01 05:34:42.71041
NCT00002407|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs|A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:43.400943|2018-06-01 05:34:43.400943
NCT00002406|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients|A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulphate, 800 Mg q 8h Versus 1,200 Mg q 12h in HIV-Infected Individuals Having Plasma Viral RNA Less Than 400 Copies/Ml, on Concomitant Therapy With 2 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI)|Completed||Phase 3|350||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:43.86155|2018-06-01 05:34:43.86155
NCT00002405|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of Amprenavir in HIV-Infected Patients|Amprenavir (141W94) Open Label Protocol for Subjects With HIV-1 Infection Who Have Experienced Treatment Failure or Are Intolerant to Previous Protease Inhibitor Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:44.008375|2018-06-01 05:34:44.008375
NCT00002404|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-01-24|2001-08-30|2001-08-31|Estimate|||||||2008-01-24|2008-01-29|Estimate||||June 1999|1999-06-30||||||||Interventional|||The Effect of Valacyclovir on the Detection of HIV From Genital Herpes Lesions in HIV-Infected Patients|The Effect of Treatment With Valacyclovir 500 mg BID on the Detection of HIV From Genital HSV Lesions in HIV-Infected Patients: A Double-Blind Crossover Study|Completed||N/A|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:44.179415|2018-06-01 05:34:44.179415
NCT00002403|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1999|1999-12-31||||||||Interventional|||Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients|A Phase I/II Multiple Dose Study to Evaluate the Safety, Pharmacokinetic Profile and Virologic/Immunologic Activity of Zintevir (AR177) in HIV-1 Patients|Completed||Phase 1|12||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:44.593996|2018-06-01 05:34:44.593996
NCT00002402|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1998|1998-08-31||||||||Interventional|||A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines|Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAX B/B and B/E Vaccines in the United States|Completed||Phase 1|120||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:44.778143|2018-06-01 05:34:44.778143
NCT00002401|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1999|1999-01-31||||||||Interventional|||A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients|An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) in Triple and Quadruple Combinations With Zidovudine (ZDV), Indinavir (IDV), and Lamivudine (3TC) in HIV-1 Infected Individuals|Completed||N/A|160||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:44.90456|2018-06-01 05:34:44.90456
NCT00002400|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1999|1999-01-31||||||||Interventional|||A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients|An Open-Label Randomized Study of Delavirdine Mesylate (Rescriptor) in Combination With Zidovudine (Retrovir) and Two Doses of Indinavir (Crixivan) Versus Zidovudine, Lamivudine (Epivir), and Indinavir in HIV-1-Infected Individuals|Completed||N/A|45||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:44.980456|2018-06-01 05:34:44.980456
NCT00002399|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1999|1999-01-31||||||||Interventional|||A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients|A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 Versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients|Completed||Phase 2|500||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:45.088049|2018-06-01 05:34:45.088049
NCT00002344|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Azithromycin in HIV-Infected Patients|Double-Blind Crossover Study Assessing the Dose Proportionality of Azithromycin Tablets in HIV-Infected Subjects|Completed||Phase 1|12||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.269446|2018-06-01 05:34:50.269446
NCT00002398|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1999|1999-12-31||||||||Interventional|||Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations|A Randomized, Open-Label Expanded Access Program to Evaluate the Safety of Preveon (Adefovir Dipivoxil) at Two Dose Levels When Used in Combination With Other Antiretroviral Agents for the Treatment of Patients With HIV Infection Who Have Failed Other Antiretroviral Therapy and Have Limited Treatment Options|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:45.390953|2018-06-01 05:34:45.390953
NCT00002397|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease|An Exploratory Study of Fortovase (Saquinavir) Soft Gelatin Capsules (SGC) Plus d4T and 3TC or Fortovase (Saquinavir) SGC Plus Nelfinavir and d4T in Patients With HIV-1 Associated Nephropathy|Completed||Phase 3|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:45.495619|2018-06-01 05:34:45.495619
NCT00002396|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients|A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Activity of 9-[2-(R)-[[Bis[[(Isopropoxycarbonyl)- Oxy]Methoxy]Phosphinoyl]Methoxy]Propyl]Adenine Fumarate (PMPA Prodrug) in HIV-Infected Patients|Unknown status|Active, not recruiting|Phase 1|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:45.597767|2018-06-01 05:34:45.597767
NCT00002395|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2000|2000-07-31||||||||Interventional|||Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)|An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy|Completed||Phase 2|54||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:45.779746|2018-06-01 05:34:45.779746
NCT00002394|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1999|1999-12-31||||||||Interventional|||Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment|A Four-Week, Open-Label, Non-Randomized, Multicenter, Dose-Finding, Pilot Study to Evaluate the Safety and Efficacy of Two Daily Doses of Lamisil (1500 Mg and 2000 Mg), Administered for a Maximum of 4 Weeks in HIV-Positive Subjects With Oral Mucosal Candidiasis Not Having Responded to a Minimum of 200 Mg Fluconazole Monotherapy|Completed||N/A|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:45.888225|2018-06-01 05:34:45.888225
NCT00002393|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Study of Indinavir Taken With or Without DMP 266|A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study to Determine the Effectiveness and Tolerability of the Combination of DMP 266 and Indinavir Versus Indinavir in HIV-Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy|Completed||Phase 3|300||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:45.973365|2018-06-01 05:34:45.973365
NCT00002392|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART|A Study to Investigate the Potential of Thalidomide Treatment to Enhance Immune Responses in HIV-Infected Individuals Who Are Receiving Highly Active Antiretroviral Therapy.|Completed||N/A|12||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.048564|2018-06-01 05:34:46.048564
NCT00002391|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs|A Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of 1592U89/Zidovudine (ZDV)/Lamivudine (3TC) Versus the Combination of Zidovudine (ZDV)/Lamivudine (3TC) in HIV-1 Therapy-Experienced Pediatric Patients.|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.270928|2018-06-01 05:34:46.270928
NCT00002390|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients|A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.387761|2018-06-01 05:34:46.387761
NCT00002389|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs|A Randomized, Double-Blind, Parallel-Group, Multicenter Trial to Evaluate the Safety and Efficacy of 1592U89 in Combination With Lamivudine (3TC) and Zidovudine (ZDV) Versus 3TC/ZDV in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects With CD4+ Counts >= 100 Cells/mm3|Completed||Phase 3|210||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.471363|2018-06-01 05:34:46.471363
NCT00002388|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of 1592U89 in HIV-Infected Patients|A Study to Evaluate the Single-Dose and Steady-State Pharmacokinetics/Dynamics of 1592U89 and Its Active Moiety, 1144U88 5'-Triphosphate (1144U88-TP) Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects|Completed||Phase 1|48||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.578637|2018-06-01 05:34:46.578637
NCT00002387|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz|A Multicenter, Open, Randomized, Forty-Eight-Week, Pilot Study to Evaluate the Activity, Safety, and Pharmacokinetics of Indinavir Sulfate, 1200 Mg q 12h and DMP 266, 300 Mg q 12h Versus Indinavir Sulfate, 1000 Mg q 8h and DMP 266, 600 Mg q.h.s.|Completed||N/A|80||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.663137|2018-06-01 05:34:46.663137
NCT00002317|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1993|1993-07-31||||||||Interventional|||A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia|A Study of Neutrexin (Trimetrexate Glucuronate) With Leucovorin Protection for Pediatric Patients (Ages 2-12) With Pneumocystis Carinii Pneumonia|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.475919|2018-06-01 05:34:52.475919
NCT00002386|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia|A Multiclinic, Open Pilot Study to Investigate the Effect of Combination Antiretroviral Therapy Including Indinavir Sulfate on Coagulation Factors, on Platelet Aggregation, and on Factor VIII/IX Half-Life in HIV-1 Seropositive Patients With Hemophilia A or B|Completed||Phase 4|55||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.748859|2018-06-01 05:34:46.748859
NCT00002385|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients|Multicenter, Rising, Multiple-Dose, Placebo-Controlled, Dose-Response Study to Evaluate the Safety, Tolerability, and Anti-Viral Activity of 4 Weeks of Treatment With 200-800 Mg Fozivudine Tidoxil in Patients With HIV-1 Infection (MF4314).|Completed||N/A|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.843156|2018-06-01 05:34:46.843156
NCT00002384|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|Vistide (Cidofovir Intravenous) Treatment IND Protocol for Relapsing Cytomegalovirus Retinitis in Patients With AIDS|Unknown status|Active, not recruiting|N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.89731|2018-06-01 05:34:46.89731
NCT00002383|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients|A Randomized, Parallel, Open-Label Study Comparing Saquinavir (Hard Gelatin Formulation, 600 Mg Tid) to Saquinavir Soft Gelatin Formulation [(400 Mg, 800 Mg, 1200 Mg) Tid} x 4 Weeks in HIV Infected Patients|Completed||Phase 1|80||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:46.989882|2018-06-01 05:34:46.989882
NCT00002382|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1997|1997-06-30||||||||Interventional|||A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients|An Open Label International Compassionate Treatment Program for the Use of Saquinavir (R0 31-8959) Either As Monotherapy or in Combination With Other Anti-Retroviral Drugs in Patients With Proven HIV Infection|Completed||Phase 3|4000||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.070654|2018-06-01 05:34:47.070654
NCT00002381|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Interventional|||The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1 Infected Adults Treated With Stavudine [d4T] (Zerit)|Completed||Phase 1|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.165316|2018-06-01 05:34:47.165316
NCT00002380|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||The Safety and Effectiveness of Two Forms of Saquinavir Combined With Other Anti-HIV Drugs in HIV-Infected Infants and Children|A Phase I/II Pharmacokinetic and Safety Study of Saquinavir Soft Gelatin Capsules and Pediatric Pellet Formulations in Combination With Nucleoside Antiretroviral Agents With or Without Nelfinavir, in HIV-Infected Infants and Children|Completed||Phase 1|28||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.224917|2018-06-01 05:34:47.224917
NCT00002379|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1998|1998-10-31||||||||Interventional|||The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs|A Phase II, Stratified, Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil and Indinavir in Combination With Zidovudine, Lamivudine, or Stavudine for the Treatment of Therapy Naive HIV-Infected Patients With CD4 Cell Counts >= 100 Cells/mm3 and HIV-1 RNA Copy Numbers >= 5,000 Copies/Ml|Completed||Phase 2|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.291093|2018-06-01 05:34:47.291093
NCT00002378|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients|A Randomized Phase IIIB Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) TID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) BID Regimen in Combination With Two NRTIs Versus Saquinavir Soft Gel Capsule (SGC) BID Plus Nelfinavir BID Plus a NRTI in HIV-1 Infected Patients|Completed||Phase 3|825||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.393371|2018-06-01 05:34:47.393371
NCT00002377|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2017-05-15|2001-08-30|2001-08-31|Estimate|||||||2017-05-15|2017-05-17|Actual|January 1997|Actual|1997-01-31|July 2005|2005-07-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes||Completed||Phase 3|||Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:34:47.699353|2018-06-01 05:34:47.699353
NCT00002376|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients|A Randomized Controlled Clinical Study to Determine If the Addition of HIV RNA Viral Load Is an Effective Tool in Determining Treatment Regimens for HIV-Infected Patients|Completed||Phase 4|540||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.797586|2018-06-01 05:34:47.797586
NCT00002375|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2000|2000-02-29||||||||Interventional|||Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients|A Multicenter, 24-Week Study of the Safety, Pharmacokinetics, and Activity of the Coadministration of Indinavir and Nelfinavir in HIV-1 Seropositive Patients|Completed||N/A|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.870672|2018-06-01 05:34:47.870672
NCT00002374|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients|A Phase IIIB Open-Label Trial Replacing Saquinavir HGC (Ro 31-8959) With Saquinavir SGC (Ro 31-8959) in Combination With Other Antiretroviral Drugs in Patients With HIV-1 Infection|Completed||Phase 3|120||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:47.941878|2018-06-01 05:34:47.941878
NCT00002286|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1989|1989-09-30||||||||Interventional|||A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients|Retrovir Capsules in the Treatment of Psoriasis in HIV Antibody Positive Patients: A Pilot Study|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.733868|2018-06-01 05:34:56.733868
NCT00002373|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients|A Phase I/II Trial to Evaluate the Tolerability, Anti-CMV Activity and Pharmacokinetics of 1263W94 Following Multiple Oral Administration of Escalating Doses in HIV-Infected Patients With Asymptomatic CMV Shedding|Completed||Phase 1|56||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.032407|2018-06-01 05:34:48.032407
NCT00002372|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of 141W94 in Combination With Other Anti-HIV Drugs|A Phase I/II Screening Trial to Identify Potential Partner Compounds to Use in Combination With 141W94|Completed||Phase 1|48||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.119846|2018-06-01 05:34:48.119846
NCT00002371|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02||2011-04-13|2011-04-28|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|June 1996||1996-06-30|April 2011|2011-04-30|December 1997|Actual|1997-12-31|December 1997|Actual|1997-12-31||Interventional|||The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine|A Randomized Double-Blind Study of Safety, Virologic and Immunological Effects of Stavudine Plus Lamivudine (3TC) Versus Zidovudine Plus Lamivudine in HIV-Infected Subjects Following At Least Six Months of Zidovudine Therapy|Completed||Phase 3|80||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:48.191012|2018-06-01 05:34:48.191012
NCT00002370|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||Study of Itraconazole in Patients With Advanced HIV Infection|Pharmacokinetics Study of Intravenous Itraconazole Followed by Oral Dosing at 200 Mg Twice Daily in Patients With Advanced HIV Infection|Completed||N/A|36||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.274664|2018-06-01 05:34:48.274664
NCT00002369|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|An Open Label, Randomized, Comparative Study of Zerit (d4T) + Epivir (3TC) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700 Cells/mm3 and HIV RNA Baseline Copy Number of >= 10,000 Copies/ml|Completed||N/A|200||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:48.341595|2018-06-01 05:34:48.341595
NCT00002368|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Interventional|||The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs|An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS Progression Events or Death When Used in Combination With Lamivudine (3TC) and Stable (>= 4 Weeks) Background Nucleoside Therapy|Completed||Phase 3|2000||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.452548|2018-06-01 05:34:48.452548
NCT00002367|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs|An Open-Label, Non-Comparative Study of Saquinavir-SGC in Combination With Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients With No Previous Anti-Retroviral Drug Therapy|Completed||Phase 3|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.584077|2018-06-01 05:34:48.584077
NCT00002366|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma|A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma|Completed||Phase 2|||Abbott|||||f||||||||||||||2018-06-01 05:34:48.645184|2018-06-01 05:34:48.645184
NCT00002365|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Study of LXR015-1 in HIV-Infected Patients|A Randomized, Parallel, Open-Label Phase I Study of LXR015-1 in HIV-Infected Patients|Completed||Phase 1|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.715708|2018-06-01 05:34:48.715708
NCT00002364|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1997|1997-04-30||||||||Interventional|||A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs|An Exploratory Study of the Antiretroviral Activity of 1592U89 When Administered in Combination With Other Specific Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in NRTI Experienced Patients|Completed||Phase 2|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.789576|2018-06-01 05:34:48.789576
NCT00002363|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients|Study of the Safety and Effects of Two Doses of SPC3, Administered Daily Intravenously in HIV-1 Seropositive Patients|Completed||Phase 1|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.847979|2018-06-01 05:34:48.847979
NCT00002362|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1999||1999-08-31|March 2000|2000-03-31||||||||Interventional|||A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients|Suspended||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.892288|2018-06-01 05:34:48.892288
NCT00002361|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2000|2000-02-29||||||||Interventional|||Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors|A Multicenter, Open-Label, 24-Week Study to Evaluate the Safety and Activity of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 200 Mg b.i.d. and Two NRTIs in HIV-1 Infected Patients Who Failed PI Therapy|Completed||Phase 2|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:48.954678|2018-06-01 05:34:48.954678
NCT00002360|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-04-13|2001-08-30|2001-08-31|Estimate|||||||2011-04-13|2011-04-14|Estimate|March 1999||1999-03-31|April 2011|2011-04-30|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||A Study Comparing Two Forms of Didanosine in HIV-infected Patients|Pivotal Bioequivalence Study of Videx Chewable/Dispersible Buffered Tablets and an Encapsulated Enteric Coated Bead Formulation of Didanosine in HIV-Infected Subjects|Completed||Phase 1|30||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:34:49.022008|2018-06-01 05:34:49.022008
NCT00002359|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1997|1997-06-30||||||||Interventional|||A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega|A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Regardless of Concomitant HIV Therapies|Completed||Phase 3|3000||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.076459|2018-06-01 05:34:49.076459
NCT00002358|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV|Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy|Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:49.266515|2018-06-01 05:34:49.266515
NCT00002357|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1997|1997-05-31||||||||Interventional|||The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms|A Multicenter, Randomized, Double-Blinded, Dose-Escalation Study Evaluating the Safety and Antiretroviral Activity of HBY 097 Versus HBY 097 Plus AZT in Patients With Asymptomatic or Mildly Symptomatic HIV Infection|Completed||Phase 2|144||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.333604|2018-06-01 05:34:49.333604
NCT00002356|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes|An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial)|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.40791|2018-06-01 05:34:49.40791
NCT00002355|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes|A Randomized Comparison of Immediate Versus Delayed Treatment With Intravitreal Injections of ISIS 2922 in Patients With Peripheral Cytomegalovirus (CMV) Retinitis|Completed||N/A|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.508|2018-06-01 05:34:49.508
NCT00002354|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1996|1996-01-31||||||||Interventional|||A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients|One Year Study in HIV-1 Seropositive, AZT-Experienced Patients to Evaluate the Safety and Efficacy of MK-639 Administered Concomitantly With Stavudine (d4T)|Completed||N/A|540||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.594928|2018-06-01 05:34:49.594928
NCT00002353|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.662444|2018-06-01 05:34:49.662444
NCT00002352|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Study of Lobucavir in Patients With AIDS|Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients|Completed||N/A|30||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:49.726942|2018-06-01 05:34:49.726942
NCT00002351|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1995|1995-10-31||||||||Interventional|||A Study of L-735,524 in HIV-Positive Children and Adolescents|An Open-Labeled, Multiple Dose, Multicenter Study to Investigate the Safety, Tolerability, and Plasma Concentration Profile of L-735,524 Capsules in HIV-Seropositive Older Children and Adolescent Patients|Completed||Phase 1|12||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.79636|2018-06-01 05:34:49.79636
NCT00002350|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients|A Phase I Trial of APL 400-003 Vaccine: Safety and Immune Response Evaluations of Multiple Injections at Escalating Doses in Asymptomatic HIV-Infected Patients|Completed||Phase 1|16||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:49.859238|2018-06-01 05:34:49.859238
NCT00002349|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-04-13|2001-08-30|2001-08-31|Estimate|||||||2011-04-13|2011-04-14|Estimate|January 1995||1995-01-31|April 2011|2011-04-30|May 1999|Actual|1999-05-31|May 1999|Actual|1999-05-31||Interventional|||A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.|A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.|Completed||N/A|40||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:34:49.938769|2018-06-01 05:34:49.938769
NCT00002348|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma|Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.016017|2018-06-01 05:34:50.016017
NCT00002347|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1995|1995-06-30||||||||Interventional|||The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection|A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection: Retrovir/HIVID/Nevirapine and Retrovir/HIVID/Invirase|Completed||Phase 2|225||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.078452|2018-06-01 05:34:50.078452
NCT00002346|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1995|1995-03-31||||||||Interventional|||The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients|A Phase I/II Study of Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) and Placebo in HIV-Infected Patients|Completed||Phase 1|36||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.138276|2018-06-01 05:34:50.138276
NCT00002343|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1997|1997-06-30||||||||Interventional|||A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS|An Open-Label Randomized Pharmacokinetic/Pharmacodynamic Study of Mycobutin (Rifabutin) or Rifabutin in Combination With Myambutol (Ethambutol) for Prophylaxis of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts <= 100 Cells/mm3|Completed||Phase 4|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.325577|2018-06-01 05:34:50.325577
NCT00002342|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Tecogalan Sodium|A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Twice Weekly for 21 Days|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.388851|2018-06-01 05:34:50.388851
NCT00002341|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole|An Open-Label Extension Study of Maintenance Therapy in HIV-Positive Subjects With Fluconazole-Refractory Oropharyngeal Candidiasis Who Have Responded to Itraconazole Oral Solution|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.442033|2018-06-01 05:34:50.442033
NCT00002340|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX|A Randomized, Open-Label Trial of High Dose Atovaquone Versus Low Dose Atovaquone Versus Aerosolized Pentamidine for Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With HIV Infection Who Are Intolerant of TMP/SMX|Completed||Phase 3|615||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.518442|2018-06-01 05:34:50.518442
NCT00002339|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems|An Open Multicenter Trial of Fluconazole Oral Suspension in the Treatment of Esophageal Candidiasis in Immunocompromised Patients|Completed||Phase 3|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.580842|2018-06-01 05:34:50.580842
NCT00002338|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||The Safety and Effectiveness of 935U83 in HIV-Infected Patients|A Phase I Trial to Evaluate the Safety, Tolerance, and Pharmacokinetics of 935U83 After Multiple Dosing in Patients With HIV Infection|Completed||Phase 1|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.637053|2018-06-01 05:34:50.637053
NCT00002337|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease|A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease|Completed||Phase 1|56||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.705312|2018-06-01 05:34:50.705312
NCT00002336|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-01-15|2001-08-30|2001-08-31|Estimate|||||||2015-01-15|2015-01-16|Estimate|November 1992||1992-11-30|February 2009|2009-02-28|November 1994|Actual|1994-11-30|November 1994|Actual|1994-11-30||Interventional|||The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients|A Prospective, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of Clarithromycin for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients With CD4 Counts <= 100 Cells/mm3|Completed||N/A|||Abbott|||||f||||||||||||||2018-06-01 05:34:50.759648|2018-06-01 05:34:50.759648
NCT00002335|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||The Safety and Effectiveness of 524W91|A Phase I, Randomized, Single-Dose, Placebo-Controlled Trial to Evaluate the Safety and Pharmacokinetics of 524W91|Completed||Phase 1|18||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.837669|2018-06-01 05:34:50.837669
NCT00002334|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1996|1996-09-30||||||||Interventional|||A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment|A Randomized, Multicenter, Double-Blind, Phase III, Parallel Study of Zidovudine (AZT) Alone Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus AZT Plus Saquinavir Mesylate (Ro 31-8959 ; HIV Proteinase Inhibitor) Versus AZT Plus ddC Plus Ro 31-8959 in Previously Untreated or Minimally Pretreated HIV-Infected Patients With CD4 Lymphocyte Counts From 50 to <= 350 Cells/mm3|Completed||Phase 3|3000||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.887423|2018-06-01 05:34:50.887423
NCT00002333|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine|A Randomized, Double-Blind, Multicenter, Parallel Study of Ro 31-8959 (Saquinavir; HIV Proteinase Inhibitor) Alone, HIVID (Dideoxycytidine; Zalcitabine, ddC) Alone, and Both in Combination, as Treatment for Advanced HIV Infection (CD4 50-300 Cells/mm3) in Patients Discontinuing or Unable to Take Retrovir (Zidovudine; AZT) Therapy|Completed||Phase 2|900||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:50.971411|2018-06-01 05:34:50.971411
NCT00002332|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1995|1995-12-31||||||||Interventional|||A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs|Double-Blind Study of the Effect of Timunox (Thymopentin) on Lymphoproliferative Responses and Virus Load in HIV-Infected Subjects Receiving Nucleoside Analog Antiretroviral Therapy|Completed||Phase 2|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.089913|2018-06-01 05:34:51.089913
NCT00002331|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-01-15|2001-08-30|2001-08-31|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 1994||1994-01-31|February 2009|2009-02-28|March 1995|Actual|1995-03-31|March 1995|Actual|1995-03-31||Interventional|||The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS|A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS|Completed||N/A|||Abbott|||||f||||||||||||||2018-06-01 05:34:51.149249|2018-06-01 05:34:51.149249
NCT00002232|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||A Study of GENEVAX-HIV, a Possible Vaccine|GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular or Intradermal Administration in HIV Seronegative Volunteers|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.346417|2018-06-01 05:35:02.346417
NCT00002330|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|A Randomized Study Comparing the Safety and Efficacy of Three Doses of Oral Ganciclovir to Intravenous Ganciclovir for the Maintenance Treatment of Cytomegalovirus Retinitis in People With AIDS|Completed||N/A|280||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.333802|2018-06-01 05:34:51.333802
NCT00002329|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1995|1995-05-31||||||||Interventional|||A Study of MDL 28,574A in HIV-Infected Patients|A Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Oral Dose-Tolerance Study of Oral MDL 28,574A Solution in HIV-Positive Patients|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.473847|2018-06-01 05:34:51.473847
NCT00002328|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs|Oral/Intravenous Azithromycin in the Treatment of Cryptosporidiosis in Patients Whose Disease Has Not Been Controlled by Conventional Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.539494|2018-06-01 05:34:51.539494
NCT00002327|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients|A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Condyloma Acuminatum in Patients With HIV Infection|Completed||Phase 1|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.608371|2018-06-01 05:34:51.608371
NCT00002326|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1995|1995-10-31||||||||Interventional|||The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients|A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of Combination Zidovudine (AZT) and 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA; Adefovir) Treatment in HIV-Infected Patients|Completed||Phase 1|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.715299|2018-06-01 05:34:51.715299
NCT00002325|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common|A Double-Blind, Placebo-Controlled Study of Fluconazole in the Prevention of Active Coccidioidomycosis and Other Systemic Fungal Infections in HIV-Infected Patients Living in the Coccidioidal Endemic Area|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.787058|2018-06-01 05:34:51.787058
NCT00002324|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Interventional|||The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease|A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety, and Tolerance of 1) 400 Mg Nevirapine in Combination With 500-600 Mg Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 3-24 Months of Prior Zidovudine Therapy and 200-500 CD4 Cells/mm3 and 2) 400 Mg Nevirapine Versus Nevirapine Placebo in Asymptomatic HIV-1 Nucleoside Naive Patients With 200-500 CD4 Cells/mm3|Completed||Phase 2|250||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.876701|2018-06-01 05:34:51.876701
NCT00002323|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Interventional|||A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell|A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cells/mm3|Completed||N/A|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:51.964738|2018-06-01 05:34:51.964738
NCT00002322|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1996|1996-11-30||||||||Interventional|||A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients|Randomized, Double-Blind, Placebo-Controlled Comparative Dose-Response Study of Two Doses of Atevirdine Mesylate (U-87201E) in Combination With Fixed Doses of Zidovudine (AZT) in HIV+ Patients|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.039106|2018-06-01 05:34:52.039106
NCT00002321|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1994|1994-10-31||||||||Interventional|||A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis|A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.113844|2018-06-01 05:34:52.113844
NCT00002320|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-12-08|2001-08-30|2001-08-31|Estimate|||||||2005-12-08|2005-12-12|Estimate||||May 1994|1994-05-31||||||||Interventional|||A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past|A Randomized, Double-Blind Multicenter Trial to Compare the Safety and Efficacy of Lamivudine (3TC; GR109714X) Monotherapy Versus Zidovudine (AZT) Monotherapy Versus 3TC Administered With AZT in the Treatment of HIV-1 Infected Patients Who Are AZT Naive (< 4 Weeks) With CD4 Cell Counts of 200-500 Cells/mm3|Completed||Phase 3|320||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.179101|2018-06-01 05:34:52.179101
NCT00002319|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1996|1996-01-31||||||||Interventional|||A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma|Open Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.289486|2018-06-01 05:34:52.289486
NCT00002318|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1996|1996-01-31||||||||Interventional|||A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma|Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Adriamycin, Bleomycin, and Vincristine (ABV) in the Treatment of Severe AIDS-Related Kaposi's Sarcoma|Unknown status|Active, not recruiting|Phase 3|225||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.39062|2018-06-01 05:34:52.39062
NCT00002316|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1994|1994-12-31||||||||Interventional|||The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis|Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.531379|2018-06-01 05:34:52.531379
NCT00002315|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1994|1994-05-31||||||||Interventional|||A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems|A Double-Blind, Multicenter Study Comparing Oral 882C87 With Oral Acyclovir for Treatment of Localized Herpes Zoster in Immunocompromised Patients|Completed||Phase 3|400||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.593082|2018-06-01 05:34:52.593082
NCT00002314|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1993|1993-12-31||||||||Interventional|||A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma|A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.69383|2018-06-01 05:34:52.69383
NCT00002313|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1994|1994-04-30||||||||Interventional|||A Study of Nystatin in HIV-Infected Patients|Extended Maintenance Protocol for Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection (NOTE: Continuation Study Intended Only for Patients Who Have Completed FDA 103B)|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.740967|2018-06-01 05:34:52.740967
NCT00002312|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1994|1994-04-30||||||||Interventional|||The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine|Open-Label Escalating Multiple-Dose Study of the Safety, Tolerance, and Pharmacokinetics of Oral U-90152 in HIV-1 Infected Males and Females With CD4 Counts of 200 - 500 Cells/mm3 Who Are Maintained on a Stable Dose of Zidovudine (AZT)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.789365|2018-06-01 05:34:52.789365
NCT00002311|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1993|1993-05-31||||||||Interventional|||The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients|A Phase I-II Dose Escalation Study to Examine the Safety of Four Doses of Wobenzym in HIV Seropositive Patients|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.838023|2018-06-01 05:34:52.838023
NCT00002310|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1993|1993-09-30||||||||Interventional|||SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir|A Pilot Study to Determine the Safety and Efficacy of Topically Applied SP-303T in Patients With Acquired Immunodeficiency Syndrome and Concomitant Herpes Simplex Virus (HSV) Infection Unresponsive to Acyclovir|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.900652|2018-06-01 05:34:52.900652
NCT00002309|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients|A Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Azithromycin as Prophylaxis Against the Development of Mycobacterium Avium Complex Disease in HIV-Infected People|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:52.952945|2018-06-01 05:34:52.952945
NCT00002308|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-08-04|2001-08-30|2001-08-31|Estimate|||||||2011-08-04|2011-08-05|Estimate||||August 2011|2011-08-31|November 1991|Actual|1991-11-30|||||Interventional|||A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs|A Randomized Blinded Evaluation of Two Doses of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; d4T) to Make Treatment Available to Severely Immunocompromised Patients With HIV Infection Who Have Failed or Are Intolerant of Alternative Antiretroviral Therapy|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:34:53.006001|2018-06-01 05:34:53.006001
NCT00002307|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-08-04|2001-08-30|2001-08-31|Estimate|||||||2011-08-04|2011-08-05|Estimate||||August 2011|2011-08-31|December 1994|Actual|1994-12-31|||||Interventional|||A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients|A Double-Blind Comparison of Zidovudine (AZT) Versus Stavudine (d4T; BMY 27857) for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between 50 and 500 Cells/mm3|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:34:53.083297|2018-06-01 05:34:53.083297
NCT00002306|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B|Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:54.152199|2018-06-01 05:34:54.152199
NCT00002305|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:54.233339|2018-06-01 05:34:54.233339
NCT00002304|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems|A Randomized Comparative Multicenter Trial of Fluconazole and Ketoconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:54.481103|2018-06-01 05:34:54.481103
NCT00002303|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in Patients With AIDS or Advanced ARC and Anemia|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:54.75235|2018-06-01 05:34:54.75235
NCT00002287|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus|A Placebo-Controlled Trial to Evaluate Retrovir in Preventing Infection With the Human Immunodeficiency Virus (HIV) in Health Care Workers After Accidental Exposure|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.57206|2018-06-01 05:34:56.57206
NCT00002302|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||The Safety and Effectiveness of r-HuEPO in Patients With AIDS and Anemia Caused by AIDS and Treatment With AZT|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:54.813966|2018-06-01 05:34:54.813966
NCT00002301|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1991|1991-03-31||||||||Interventional|||A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir|Foscarnet Treatment of Cytomegalovirus (CMV) Retinitis in AIDS Patients Not Eligible for Ganciclovir Therapy and Ganciclovir Treatment Failures|Unknown status|Active, not recruiting|N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:54.893223|2018-06-01 05:34:54.893223
NCT00002300|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition|Phase II-III Randomized Double-Blind Study Comparing Megestrol Acetate at 100, 400, and 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia|Completed||Phase 2|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:54.980553|2018-06-01 05:34:54.980553
NCT00002299|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1990|1990-04-30||||||||Interventional|||The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS|Combination Therapy With 9-(1,3-Dihydroxy-2-Propoxymethyl) Guanine (DHPG) and Interferon Beta for the Prevention of Relapse of Cytomegalovirus Retinitis in Patients With the Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:55.098813|2018-06-01 05:34:55.098813
NCT00002298|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1998|1998-03-31||||||||Interventional|||The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection|Long-Term Efficacy and Tolerance of Oral Ribavirin Compared to Placebo as a Preventative in Early Stages of Human Immunodeficiency Virus Infection - United States|Terminated||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:55.191368|2018-06-01 05:34:55.191368
NCT00002297|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1989|1989-06-30||||||||Interventional|||A Study of Isoprinosine in Patients With Lymph Node Disease|A Multi-Center Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Unexplained Generalized Lymphadenopathy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:55.32664|2018-06-01 05:34:55.32664
NCT00002296|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1989|1989-06-30||||||||Interventional|||The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease|A Multi-Center Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:55.383504|2018-06-01 05:34:55.383504
NCT00002295|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1989|1989-06-30||||||||Interventional|||A Study of Isoprinosine in Patients With Severe AIDS|A Double-Blind Placebo-Controlled Study to Investigate the Action of Isoprinosine (Inosiplex) in Patients With Severe Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:55.44143|2018-06-01 05:34:55.44143
NCT00002294|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS|Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:55.606129|2018-06-01 05:34:55.606129
NCT00002293|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes|Nystatin Pastille for the Prophylaxis of Oral Candidiasis in Patients With AIDS or AIDS Related Syndromes|Completed||N/A|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:55.722028|2018-06-01 05:34:55.722028
NCT00002292|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|Inhaled Versus Intravenous Pentamidine in Pneumocystis Carinii Pneumonia in the Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:55.839406|2018-06-01 05:34:55.839406
NCT00002291|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1989|1989-10-31||||||||Interventional|||The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP Before|A Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.080136|2018-06-01 05:34:56.080136
NCT00002290|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection|A Multi-Center, Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir (Zidovudine) and Zovirax (Acyclovir) Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus (HIV) Infection|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.165978|2018-06-01 05:34:56.165978
NCT00002289|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients|Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.376234|2018-06-01 05:34:56.376234
NCT00002288|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System|Safety and Efficacy of Retrovir in HIV Infected Patients Having Neuropsychological Impairments|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.454749|2018-06-01 05:34:56.454749
NCT00002285|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS|A Phase I/II Pilot Trial To Evaluate Zidovudine (AZT) and T Lymphocyte Transfer in the Treatment of Human Immunodeficiency Virus Type-III (HIV) Infection in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.816981|2018-06-01 05:34:56.816981
NCT00002284|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant|A Pilot Study To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients Receiving a Bone Marrow Transplant|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.886671|2018-06-01 05:34:56.886671
NCT00002283|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:56.964354|2018-06-01 05:34:56.964354
NCT00002282|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS|A Randomized Multicenter Study of the Efficacy, Safety, and Toleration of Fluconazole or Clotrimazole Troches in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:57.031309|2018-06-01 05:34:57.031309
NCT00002281|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex|An Open Label Phase I/II Study of Recombinant Granulocyte Colony-Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With AIDS or ARC|Completed||N/A|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:57.157104|2018-06-01 05:34:57.157104
NCT00002280|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-08-04|2001-08-30|2001-08-31|Estimate|||||||2011-08-04|2011-08-05|Estimate||||August 2011|2011-08-31|November 1994|Actual|1994-11-30|||||Interventional|||A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine|An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Children With Acquired Immunodeficiency Syndrome (AIDS) Who Have Demonstrated Significant Deterioration or Intolerance to Zidovudine (Retrovir)|Completed||N/A|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:57.367348|2018-06-01 05:34:57.367348
NCT00002279|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1991|1991-10-31||||||||Interventional|||A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)|Dideoxycytidine (Ro 24-2027). An Open-Label, Safety Study of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine (AZT) Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:57.429854|2018-06-01 05:34:57.429854
NCT00002278|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1990|1990-07-31||||||||Interventional|||A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS|28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:57.505426|2018-06-01 05:34:57.505426
NCT00002277|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1993|1993-12-31||||||||Interventional|||A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections|Fluconazole Versus Amphotericin B: A Prospective, Randomized, Multicenter Study for Therapy of Fungal Infection|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:57.566586|2018-06-01 05:34:57.566586
NCT00002276|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1990|1990-06-30||||||||Interventional|||The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia|Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:57.641723|2018-06-01 05:34:57.641723
NCT00002275|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)|Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations|Completed||N/A|||Abbott|||||f||||||||||||||2018-06-01 05:34:57.814603|2018-06-01 05:34:57.814603
NCT00002274|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine|An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:34:57.919956|2018-06-01 05:34:57.919956
NCT00002273|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1989|1989-09-30||||||||Interventional|||A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS|Double-Blind, Placebo-Controlled Study of Intravenous Ganciclovir (DHPG) for Cytomegalovirus Colitis in Patients With Acquired Immune Deficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.04381|2018-06-01 05:34:58.04381
NCT00002272|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1990|1990-09-30||||||||Interventional|||An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies|An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.143862|2018-06-01 05:34:58.143862
NCT00002130|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons|A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.786602|2018-06-01 05:35:14.786602
NCT00002271|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1991|1991-06-30||||||||Interventional|||An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects|An Ascending, Single Oral Dose Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.222712|2018-06-01 05:34:58.222712
NCT00002270|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1991|1991-03-31||||||||Interventional|||A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection|A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.327293|2018-06-01 05:34:58.327293
NCT00002269|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1991|1991-08-31||||||||Interventional|||A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen|A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.44031|2018-06-01 05:34:58.44031
NCT00002268|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1991|1991-12-31||||||||Interventional|||A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria|A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.517454|2018-06-01 05:34:58.517454
NCT00002267|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1992|1992-03-31||||||||Interventional|||Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial|Completed||N/A|750||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.590906|2018-06-01 05:34:58.590906
NCT00002266|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1990|1990-12-31||||||||Interventional|||An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients|An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.725973|2018-06-01 05:34:58.725973
NCT00002265|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1994|1994-02-28||||||||Interventional|||An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492|An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.789516|2018-06-01 05:34:58.789516
NCT00002264|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea|Efficacy of Cow's Milk Immune Globulin in the Treatment of Chronic Intestinal Cryptosporidiosis in Patients With AIDS|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.881207|2018-06-01 05:34:58.881207
NCT00002263|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine|A Pilot Study to Evaluate the Effects of Subcutaneously Administered Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Pediatric HIV-Infected Patients With Neutropenia Secondary to Azidothymidine|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:58.949193|2018-06-01 05:34:58.949193
NCT00002262|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1988|1988-12-31||||||||Interventional|||A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma|A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:59.369592|2018-06-01 05:34:59.369592
NCT00002261|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-09-24|2001-08-30|2001-08-31|Estimate|||||||2007-09-24|2007-09-26|Estimate||||September 2007|2007-09-30||||||||Interventional|||A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers|A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers|Completed||Phase 1|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:34:59.422458|2018-06-01 05:34:59.422458
NCT00002260|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1992|1992-03-31||||||||Interventional|||An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects|An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:59.517755|2018-06-01 05:34:59.517755
NCT00002259|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1991|1991-08-31||||||||Interventional|||Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma|Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:59.579951|2018-06-01 05:34:59.579951
NCT00002129|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3|A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3|Completed||Phase 1|36||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.847132|2018-06-01 05:35:14.847132
NCT00002258|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1992|1992-11-30||||||||Interventional|||A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia|A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:59.655636|2018-06-01 05:34:59.655636
NCT00002257|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1992|1992-07-31||||||||Interventional|||A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS|A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS|Completed||N/A|150||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:59.713933|2018-06-01 05:34:59.713933
NCT00002256|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1994|1994-08-31||||||||Interventional|||Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.|Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:34:59.946662|2018-06-01 05:34:59.946662
NCT00002255|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1991|1991-01-31||||||||Interventional|||An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)|An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:00.013591|2018-06-01 05:35:00.013591
NCT00002254|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1991|1991-05-31||||||||Interventional|||A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)|A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:00.094094|2018-06-01 05:35:00.094094
NCT00002253|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1992|1992-08-31||||||||Interventional|||"A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either Responders or Non-Responders in a Prior Placebo-Controlled Double-Blind Sandostatin Study."|"A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either Responders or Non-Responders in a Prior Placebo-Controlled Double-Blind Sandostatin Study."|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:00.282736|2018-06-01 05:35:00.282736
NCT00002252|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1992|1992-08-31||||||||Interventional|||A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea|A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:00.523197|2018-06-01 05:35:00.523197
NCT00002251|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1991|1991-05-31||||||||Interventional|||A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir|A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir|Completed||N/A|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:00.775759|2018-06-01 05:35:00.775759
NCT00002250|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1991|1991-08-31||||||||Interventional|||A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura|A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:00.929989|2018-06-01 05:35:00.929989
NCT00002249|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1991|1991-09-30||||||||Interventional|||A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection|A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:00.99552|2018-06-01 05:35:00.99552
NCT00002248|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1993|1993-04-30||||||||Interventional|||A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients|A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients|Completed||Phase 1|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:01.061881|2018-06-01 05:35:01.061881
NCT00002247|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1993|1993-03-31||||||||Interventional|||A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy|A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy|Completed||N/A|225||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:01.140051|2018-06-01 05:35:01.140051
NCT00002246|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02||2011-04-13|2011-04-28|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|October 1997||1997-10-31|April 2011|2011-04-30|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex|A Pilot Open Label, Multicenter Study to Evaluate the Role of Stavudine (d4T) in the Treatment of AIDS Dementia Complex|Completed||Phase 3|20||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:01.237166|2018-06-01 05:35:01.237166
NCT00002245|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1999||1999-04-30|August 2000|2000-08-31||||||||Interventional|||A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients|Effect of Amprenavir on Carbohydrate and Lipid Metabolism in Patients With HIV Infection|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:01.312204|2018-06-01 05:35:01.312204
NCT00002244|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2001|2001-03-31||||||||Interventional|||A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pivotal Clinical Study Evaluating the Safety and Efficacy of WF10 (TCDO) Intravenous Solution in the Management of Patients With Late-Stage HIV Disease|Completed||Phase 3|240||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:01.387563|2018-06-01 05:35:01.387563
NCT00002243|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2000|2000-07-31||||||||Interventional|||A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment|A Phase 1B Dose-Range Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-Calanolide A on Surrogate Markers in HIV-Positive Patients With No Previous Antiretroviral Therapy|Completed||Phase 1|32||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:01.498569|2018-06-01 05:35:01.498569
NCT00002241|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2001|2001-07-31||||||||Interventional|||Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily|A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 100 Mg/d4T/3TC b.i.d. in HIV-Infected Individuals|Unknown status|Active, not recruiting|Phase 2|80||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:01.573044|2018-06-01 05:35:01.573044
NCT00002240|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02||2011-04-13|2011-04-28|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-28|2011-05-04|Estimate|March 1999||1999-03-31|April 2011|2011-04-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs|Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen|Completed||Phase 2|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:01.679184|2018-06-01 05:35:01.679184
NCT00002239|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-11-14|2001-08-30|2001-08-31|Estimate|||||||2005-11-14|2005-11-15|Estimate|May 1999||1999-05-31|November 2005|2005-11-30||||||||Interventional|||A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults|A Controlled Phase 2 Trial Assessing Three Doses of T-20 in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz in HIV-1 Infected Adults|Completed||Phase 2|68||Hoffmann-La Roche|||||||||||||||||||2018-06-01 05:35:01.77805|2018-06-01 05:35:01.77805
NCT00002238|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1991|1991-04-30||||||||Interventional|||Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen|Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:01.883177|2018-06-01 05:35:01.883177
NCT00002237|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1999|1999-09-30||||||||Interventional|||A Study of Peldesine (BCX-34) in HIV-Infected Patients|Phase I Placebo-Controlled Study of Oral BCX-34 (Peldesine) in HIV-Infected Patients|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.032167|2018-06-01 05:35:02.032167
NCT00002236|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2000|2000-04-30||||||||Interventional|||A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients|An Open-Label, Parallel Group, Pilot Study of Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of BID and TID Regimens of Delavirdine Mesylate, Zidovudine, and Indinavir Sulfate in HIV-1 Infected Individuals|Completed||N/A|32||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.082764|2018-06-01 05:35:02.082764
NCT00002235|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2000|2000-03-31||||||||Interventional|||A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors|A Phase II, 48-Week, Open-Label Study Designed to Evaluate the Safety, Tolerability, and Efficacy of a Simplified Dosing Regimen of Viracept (Nelfinavir Mesylate) 1250 Mg BID, Crixivan (Indinavir Sulfate) 1200mg q12h, and Sustiva (Efavirenz; DMP-266) 600 Mg q24h for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Transcriptase Inhibitor and Protease Inhibitor Naive Patients|Completed||Phase 2|6||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.148012|2018-06-01 05:35:02.148012
NCT00002234|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-30|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2004|2004-11-30||||||||Interventional|||Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients|A Phase II, 48 Week, Open-Label Study Designed to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Simplified Dosing Regimen of Preveon (Adefovir Dipivoxil; bis-POM PMEA), Videx (Didanosine; ddI), Sustiva (Efavirenz; DMP-266), and Epivir (Lamivudine; 3TC) Administered Once Daily for the Treatment of HIV-1 Infection|Completed||Phase 2|25||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:02.210776|2018-06-01 05:35:02.210776
NCT00002233|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||A Study of a Combination of Four Drugs in Patients With Recent HIV Infection|A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Quadruple Antiretroviral Therapy (EPIVIR, Abacavir, Amprenavir, and Indinavir) in Subjects Acutely Infected With HIV-1|Completed||Phase 2|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.276776|2018-06-01 05:35:02.276776
NCT00002231|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 2000|2000-05-31||||||||Interventional|||Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers|GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.433822|2018-06-01 05:35:02.433822
NCT00002230|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients|A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients|Completed||Phase 3|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.49102|2018-06-01 05:35:02.49102
NCT00002229|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1999|1999-12-31||||||||Interventional|||Safety and Effectiveness of Adding Saquinavir (FORTOVASE) in Soft Gel Capsule Form to an Anti-HIV Drug Combination in HIV-Infected Patients|A Phase IV, Non-Comparative Study to Evaluate FORTOVASE (Saquinavir) Soft Gel Capsule (SGC) TID Regimen in Combination With Two NRTI's in HIV-1 Infected Women and Men|Completed||Phase 4|80||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.549527|2018-06-01 05:35:02.549527
NCT00002228|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of T-20 in HIV-Positive Adults|A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection|Completed||Phase 2|78||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:02.720478|2018-06-01 05:35:02.720478
NCT00002227|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs|A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Lamivudine in Antiretroviral Therapy-Naive HIV-Infected Patients|Completed||Phase 2|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:03.10996|2018-06-01 05:35:03.10996
NCT00002226|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2000|2000-06-30||||||||Interventional|||Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma|A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma|Completed||N/A|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:03.613025|2018-06-01 05:35:03.613025
NCT00002225|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of Efavirenz in Combination With Stavudine and Didanosine|A Phase II, Open-Label, Multicenter Study to Characterize the Effectiveness and Safety of Efavirenz in Combination With Stavudine and Didanosine in Antiretroviral Therapy-Naive HIV-Infected Patients|Completed||Phase 2|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:05.531605|2018-06-01 05:35:05.531605
NCT00002224|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02||2011-04-13|2011-04-13|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-13|2011-04-25|Estimate|March 1999||1999-03-31|April 2011|2011-04-30|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)|Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric Coated or Didanosine Formulations Each Administered Once Daily|Completed||Phase 3|120||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:35:05.637677|2018-06-01 05:35:05.637677
NCT00002223|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients|Ritonavir (ABT-538)/Indinavir Combination Treatment in HIV-Infected Patients Previously Receiving Indinavir 800 mg TID|Completed||N/A|||Abbott|||||f||||||||||||||2018-06-01 05:35:05.842003|2018-06-01 05:35:05.842003
NCT00002222|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS|An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS|Completed||N/A|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:05.958802|2018-06-01 05:35:05.958802
NCT00002221|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2003|2003-06-30||||||||Interventional|||Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma|High Dose Chemotherapy and Autologous Peripheral Stem Cell Transplantation for HIV Lymphomas: A Phase IIA Study of Comparative Marking Using a Ribozyme Gene and a Neutral Gene|Completed||Phase 2|5||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.069993|2018-06-01 05:35:06.069993
NCT00002220|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir|Multi-Center, Open-Label Study of the Effect of Indinavir, Efavirenz, and Adefovir Dipivoxil Combination Therapy in Patients Who Have Failed Nelfinavir|Completed||Phase 3|120||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.141087|2018-06-01 05:35:06.141087
NCT00002219|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||Safety and Effectiveness of Adding Adefovir Dipivoxil and Nelfinavir to the Anti-HIV Therapy of HIV-Infected Children|A Phase I/II, Open-Label, Multi-Center Study of the Pharmacokinetics, Safety, Tolerance and Activity of Two Dose Levels of Adefovir Dipivoxil (ADF) and Nelfinavir When Added to Antiretroviral Therapy for the Treatment of HIV-Infected Pediatric Patients|Unknown status|Active, not recruiting|Phase 2|36||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.278633|2018-06-01 05:35:06.278633
NCT00002218|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients|A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients|Completed||Phase 1|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.363978|2018-06-01 05:35:06.363978
NCT00002217|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs|Combivir, 1592U89, 141W94 Triple Antiretroviral, Experienced Patient Trial|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.455834|2018-06-01 05:35:06.455834
NCT00002216|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment|A Comparison of a Four-Drug Regimen Comprised of 141W94, 1592U89, and Combivir With a Three-Drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naive HIV-Infected Patients.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.521201|2018-06-01 05:35:06.521201
NCT00002215|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive|A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.60727|2018-06-01 05:35:06.60727
NCT00002214|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||Phase I Trial of S-1153 in Patients With HIV Infection|Phase I Trial of S-1153 in Patients With HIV Infection|Completed||Phase 1|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.672458|2018-06-01 05:35:06.672458
NCT00002213|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1998|1998-03-31||||||||Interventional|||The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors|A Phase II Study Evaluating the Safety and Antiviral Activity of Combination Therapy With 1592U89, 141W94 and DMP 266 in HIV-1 Infected Subjects With Detectable HIV-1 Plasma RNA Despite Treatment With a Protease Inhibitor Containing Regimen|Completed||Phase 2|80||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.840636|2018-06-01 05:35:06.840636
NCT00002212|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma|Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma|Completed||Phase 2|27||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.923137|2018-06-01 05:35:06.923137
NCT00002211|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2000|2000-04-30||||||||Interventional|||Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients|An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) Plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals|Completed||N/A|160||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:06.977792|2018-06-01 05:35:06.977792
NCT00002210|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1998|1998-01-31||||||||Interventional|||A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies|Phase II Study of the Safety, Tolerance, Pharmacokinetics, and Antiviral Effect of Delavirdine Mesylate (Rescriptor), in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1-Infected Neonates, Infants, and Children|Completed||Phase 2|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.032827|2018-06-01 05:35:07.032827
NCT00002209|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1999|1999-12-31||||||||Interventional|||Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy|Multiple Ascending Dose Pharmacokinetics of CPI-1189 (LU 02-584) in Fasted, HIV Infected, Male Volunteers on Combined Reverse Transcriptase and Protease Inhibitor Therapy|Completed||Phase 1|48||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.102317|2018-06-01 05:35:07.102317
NCT00002208|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2003|2003-02-28||||||||Interventional|||A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC|A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC|Completed||Phase 3|400||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.173639|2018-06-01 05:35:07.173639
NCT00002207|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02||2011-04-13|2011-04-13|2001-08-30|2001-08-31|Estimate||||2011-04-13|2011-04-25|Estimate|2011-04-13|2011-04-25|Estimate|February 2004||2004-02-29|April 2011|2011-04-30|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients|A Randomized, Double-Blind Study of the Antiviral Activity of Once-Daily and Twice-Daily Dosing of Didanosine in Combination With Twice-Daily Dosing of Stavudine in HIV-Infected Subjects|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:35:07.264248|2018-06-01 05:35:07.264248
NCT00002206|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs|A Phase I/II, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 60 Mg Daily Dose of Adefovir Dipivoxil in HIV-Infected Patients Naive to Anti-Retroviral Therapy|Completed||Phase 1|45||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.38282|2018-06-01 05:35:07.38282
NCT00002205|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen|An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.481526|2018-06-01 05:35:07.481526
NCT00002204|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults|A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults|Completed||Phase 1|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.582762|2018-06-01 05:35:07.582762
NCT00002203|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of Two Anti-HIV Drug Combinations|A Randomized, Multicenter Study of Epivir 150 Mg Bid, Retrovir 200 Mg Tid and a Protease Inhibitor Vs 3TC 150 Mg/ZDV 300 Mg Fixed Dose Tablet Given Bid With a Protease Inhibitor in HIV-Infected Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.680209|2018-06-01 05:35:07.680209
NCT00002202|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Comparison of 141W94 and Indinavir in HIV-Infected Patients|A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 With Indinavir in Combination With Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy, in NRTI-Experienced, Protease Inhibitor (PI)-Naive, HIV-1-Infected Patients.|Completed||Phase 3|460||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:07.822252|2018-06-01 05:35:07.822252
NCT00002201|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients|Safety and Efficacy of Ritonavir (ABT-538) in Combination With Nelfinavir in HIV-Infected Subjects.|Completed||N/A|||Abbott|||||f||||||||||||||2018-06-01 05:35:07.924213|2018-06-01 05:35:07.924213
NCT00002200|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||A Study of 1592U89 in HIV-Infected Adults|A 1592U89 Open-Label Protocol for Adult Patients With HIV-1 Infection.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.007423|2018-06-01 05:35:09.007423
NCT00002199|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.|A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.|Completed||Phase 3|550||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.065134|2018-06-01 05:35:09.065134
NCT00002198|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients|A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 1592U89 and Ethanol Following Their Co-Administration to HIV-Infected Subjects.|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.126419|2018-06-01 05:35:09.126419
NCT00002197|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||A Study of 1592U89 in HIV-Infected Children|1592U89 Open-Label Protocol for Pediatric Patients With HIV Infection.|Completed||N/A|250||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.177859|2018-06-01 05:35:09.177859
NCT00002196|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Study of CI-1012 in HIV-Infected Patients|A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers.|Completed||Phase 1|32||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.231298|2018-06-01 05:35:09.231298
NCT00002195|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients|A Phase III Trial to Evaluate the Safety and Antiviral Efficacy of 141W94 in Combination With Retrovir and Epivir Compared to Retrovir and Epivir Alone in Patients With HIV Infection.|Completed||Phase 3|290||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.308409|2018-06-01 05:35:09.308409
NCT00002194|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Interventional|||An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.|An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.|Completed||Phase 1|36||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.424873|2018-06-01 05:35:09.424873
NCT00002193|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors|A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of 141W94 Plus Current Nucleoside Therapy Versus Current Nucleoside Therapy Alone in Protease-Naive, HIV-Infected Children|Completed||Phase 3|210||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.527181|2018-06-01 05:35:09.527181
NCT00002192|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.|Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.679474|2018-06-01 05:35:09.679474
NCT00002191|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis|A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal Microsporidiosis|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.800774|2018-06-01 05:35:09.800774
NCT00002190|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients|A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients|Completed||Phase 2|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.873409|2018-06-01 05:35:09.873409
NCT00002189|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1998|1998-06-30||||||||Interventional|||Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals|Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:09.944982|2018-06-01 05:35:09.944982
NCT00002188|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma|Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.|Completed||Phase 2|27||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.027687|2018-06-01 05:35:10.027687
NCT00002187|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis|A Randomized Comparison of Two Dosage Schedules of Intravitreal ISIS 2922 for Patients With Advanced Cytomegalovirus Retinitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.102969|2018-06-01 05:35:10.102969
NCT00002186|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1998|1998-02-28||||||||Interventional|||Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)|Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)|Completed||N/A|400||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.204157|2018-06-01 05:35:10.204157
NCT00002185|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3|A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3|Completed||Phase 2|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.312678|2018-06-01 05:35:10.312678
NCT00002184|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1998|1998-10-31||||||||Interventional|||A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient|A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 100/mm3 and HIV-1 RNA Copy Numbers >= 5,000 Copies/Ml and Prior RTI Therapy But No Prior PI Therapy|Completed||Phase 2|120||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.386152|2018-06-01 05:35:10.386152
NCT00002183|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection|A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection|Completed||Phase 1|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.46991|2018-06-01 05:35:10.46991
NCT00002182|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Study of Megestrol Acetate in HIV-Infected Children|Megestrol Acetate For Failure To Thrive In Pediatric HIV|Completed||N/A|25||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.531829|2018-06-01 05:35:10.531829
NCT00002181|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1997|1997-11-30||||||||Interventional|||Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS|Open-Label Study of Cidofovir Gel for Acyclovir-Unresponsive Mucocutaneous Herpes Simplex Disease in Patients With AIDS.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.609549|2018-06-01 05:35:10.609549
NCT00002180|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1999|1999-09-30||||||||Interventional|||A Study of PMPA in HIV-Infected Patients|A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerance, and Pharmacokinetics, and Antiviral Activity of 9-[(R)-2-(Phosphonomethoxy)Propyl] Adenine (PMPA) in HIV-Infected Patients|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.773538|2018-06-01 05:35:10.773538
NCT00002179|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection|A Multiclinic, Open Study to Evaluate the Ability of the Combination of Indinavir, Zidovudine and Lamivudine to Result in Sustained Suppression of HIV-1 in Asymptomatic HIV-1 Seropositive Patients|Completed||Phase 4|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.84993|2018-06-01 05:35:10.84993
NCT00002178|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients|A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients|Completed||Phase 3|375||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:10.943049|2018-06-01 05:35:10.943049
NCT00002177|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-04-13|2001-08-30|2001-08-31|Estimate|||||||2011-04-13|2011-04-14|Estimate|May 1997||1997-05-31|April 2011|2011-04-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection|A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection|Completed||N/A|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:11.065671|2018-06-01 05:35:11.065671
NCT00002176|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-04-13|2001-08-30|2001-08-31|Estimate|||||||2011-04-13|2011-04-14|Estimate|May 1997||1997-05-31|April 2011|2011-04-30|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Interventional|||A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection|A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:35:11.139113|2018-06-01 05:35:11.139113
NCT00002175|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1999|1999-01-31||||||||Interventional|||Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.|Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.|Completed||Phase 1|46||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.208095|2018-06-01 05:35:11.208095
NCT00002174|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients|Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients|Completed||N/A|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.265073|2018-06-01 05:35:11.265073
NCT00000894|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-22|2001-08-30|2001-08-31|Estimate|||||||2011-02-22|2011-02-23|Estimate||||June 2003|2003-06-30||||June 2000|Actual|2000-06-30||Interventional|||Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis|Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)|Completed||Phase 4|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.67737|2018-06-01 05:36:00.67737
NCT00002173|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1998|1998-06-30||||||||Interventional|||An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.|An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.336355|2018-06-01 05:35:11.336355
NCT00002172|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1995|1995-06-30||||||||Interventional|||An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml|An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.387387|2018-06-01 05:35:11.387387
NCT00002171|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||A Study of Viracept in HIV-Positive Women|A Phase II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Viracept in Combination With Antiretroviral Therapy in HIV Positive Women With <= 1 Month of Prior Treatment With d4T and/or 3TC|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.440862|2018-06-01 05:35:11.440862
NCT00002170|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)|A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Disseminated Mycobacterium Avium Complex Disease (MAC) in AIDS Patients Who Are Receiving Standard Acute Treatment for This Opportunistic Infection|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.516612|2018-06-01 05:35:11.516612
NCT00002169|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis|A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.582642|2018-06-01 05:35:11.582642
NCT00002168|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients|An Open Label, Randomized, Comparative Study of Zerit (d4T) + Videx (ddI) + Crixivan Versus Retrovir (AZT) + Epivir (3TC) + Crixivan in HIV-Infected, Antiretroviral Naive Subjects With CD4 Cell Counts of 200 - 700/mm3 and HIV RNA Baseline Copy Number of >= 10,000 Copies/ml|Completed||N/A|200||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:11.651636|2018-06-01 05:35:11.651636
NCT00002167|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.|Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.|Completed||Phase 2|78||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.734363|2018-06-01 05:35:11.734363
NCT00002166|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Interventional|||An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease|An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.790128|2018-06-01 05:35:11.790128
NCT00002165|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1996|1996-10-31||||||||Interventional|||Viracept Expanded Access Program|Viracept Expanded Access Program|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.842453|2018-06-01 05:35:11.842453
NCT00002164|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants|Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants|Completed||Phase 1|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.903158|2018-06-01 05:35:11.903158
NCT00002163|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex|A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:11.961144|2018-06-01 05:35:11.961144
NCT00002162|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs|A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs|Completed||Phase 2|140||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.035988|2018-06-01 05:35:12.035988
NCT00002161|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1997|1997-05-31||||||||Interventional|||A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3|Completed||N/A|400||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.209463|2018-06-01 05:35:12.209463
NCT00002160|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1998|1998-03-31||||||||Interventional|||A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain|A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain|Completed||Phase 2|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.337413|2018-06-01 05:35:12.337413
NCT00002159|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1997|1997-12-31||||||||Interventional|||A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis|A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis|Completed||Phase 3|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.470767|2018-06-01 05:35:12.470767
NCT00002158|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-07-09|2001-08-30|2001-08-31|Estimate|||||||2007-07-09|2007-07-10|Estimate||||July 2007|2007-07-31||||||||Interventional|||A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis|Open-Label Compassionate Use of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients|Unknown status|Active, not recruiting|N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.555073|2018-06-01 05:35:12.555073
NCT00002157|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome|Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.639018|2018-06-01 05:35:12.639018
NCT00002156|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1998|1998-12-31||||||||Interventional|||A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )|A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )|Completed||Phase 2|194||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.710712|2018-06-01 05:35:12.710712
NCT00002155|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1996|1996-06-30||||||||Interventional|||A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC|A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC|Completed||N/A|600||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.800637|2018-06-01 05:35:12.800637
NCT00002154|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia|Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia|Completed||Phase 2|32||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.905508|2018-06-01 05:35:12.905508
NCT00002153|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1999|1999-05-31||||||||Interventional|||Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders|Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders|Completed||Phase 1|25||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:12.966535|2018-06-01 05:35:12.966535
NCT00002152|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Study of WF 10 IV Solution in Patients With Advanced HIV Disease|Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of WF 10 IV Solution ( TCDO ) in the Management of Patients With Advanced HIV Disease|Completed||Phase 2|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.045965|2018-06-01 05:35:13.045965
NCT00002151|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients|A Randomized, Double-Blind Active-Controlled, Dose-Ranging Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients|Completed||Phase 2|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.109308|2018-06-01 05:35:13.109308
NCT00002150|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients|A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients|Completed||Phase 2|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.207415|2018-06-01 05:35:13.207415
NCT00002149|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1997|1997-09-30||||||||Interventional|||Acupuncture and Herbal Treatment of Chronic HIV Sinusitis|Acupuncture and Herbal Treatment of Chronic HIV Sinusitis|Completed||N/A|40||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.287741|2018-06-01 05:35:13.287741
NCT00002148|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia|Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia|Completed||Phase 1|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.356672|2018-06-01 05:35:13.356672
NCT00002147|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1996|1996-01-31||||||||Interventional|||Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.|Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.41617|2018-06-01 05:35:13.41617
NCT00002146|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1997|1997-01-31||||||||Interventional|||Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study|Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study|Completed||Phase 4|12||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.481155|2018-06-01 05:35:13.481155
NCT00002145|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease|Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease|Completed||Phase 3|145||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.575868|2018-06-01 05:35:13.575868
NCT00002144|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment|The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment|Completed||Phase 1|12||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.672162|2018-06-01 05:35:13.672162
NCT00002143|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Interventional|||Treatment of Psoriasis Using Acitretin in HIV-Positive Patients|Treatment of Psoriasis Using Acitretin in HIV-Positive Patients|Completed||Phase 3|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.733932|2018-06-01 05:35:13.733932
NCT00002142|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1995|1995-10-31||||||||Interventional|||An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS|An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS|Completed||N/A|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.790285|2018-06-01 05:35:13.790285
NCT00002141|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1994||1994-07-31|October 1994|1994-10-31||||||||Interventional|||A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89|A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89|Completed||Phase 1|18||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.848998|2018-06-01 05:35:13.848998
NCT00002140|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients|A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:13.904155|2018-06-01 05:35:13.904155
NCT00002139|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.|Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.068964|2018-06-01 05:35:14.068964
NCT00002138|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.|A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.127556|2018-06-01 05:35:14.127556
NCT00002137|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4|A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.188089|2018-06-01 05:35:14.188089
NCT00002136|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days|A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.258692|2018-06-01 05:35:14.258692
NCT00002135|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1995|1995-11-30||||||||Interventional|||An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access|An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.337513|2018-06-01 05:35:14.337513
NCT00002134|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis|A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis|Completed||N/A|450||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.403538|2018-06-01 05:35:14.403538
NCT00002133|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.|An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.509989|2018-06-01 05:35:14.509989
NCT00002132|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.|Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.611922|2018-06-01 05:35:14.611922
NCT00002131|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma|A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma|Completed||Phase 2|28||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.722521|2018-06-01 05:35:14.722521
NCT00002128|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1994|1994-07-31||||||||Interventional|||Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients|Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients|Completed||Phase 1|15||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.903089|2018-06-01 05:35:14.903089
NCT00002127|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome|A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome|Completed||Phase 2|75||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:14.979131|2018-06-01 05:35:14.979131
NCT00002126|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.|A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection|Completed||Phase 2|250||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.058176|2018-06-01 05:35:15.058176
NCT00002125|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1997|1997-06-30||||||||Interventional|||A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)|A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)|Completed||Phase 4|112||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.149745|2018-06-01 05:35:15.149745
NCT00002124|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1997|1997-07-31||||||||Interventional|||A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3|A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3|Completed||Phase 3|1250||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.240094|2018-06-01 05:35:15.240094
NCT00002123|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1996|1996-11-30||||||||Interventional|||A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3|A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.415534|2018-06-01 05:35:15.415534
NCT00002122|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients|A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients|Completed||Phase 3|720||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.56703|2018-06-01 05:35:15.56703
NCT00002121|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea|Diethylhomospermine (DEHSPM) for Refractory AIDS-Related Diarrhea|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.632791|2018-06-01 05:35:15.632791
NCT00002120|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia|Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia|Completed||Phase 1|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.692311|2018-06-01 05:35:15.692311
NCT00002119|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection|A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.739794|2018-06-01 05:35:15.739794
NCT00002118|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1997|1997-08-31||||||||Interventional|||An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies|An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies|Completed||N/A|600||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.786363|2018-06-01 05:35:15.786363
NCT00002117|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection|A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection|Completed||Phase 3|528||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:15.846815|2018-06-01 05:35:15.846815
NCT00002102|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1994|1994-01-31||||||||Interventional|||A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.|A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.162178|2018-06-01 05:35:17.162178
NCT00002116|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1995|1995-12-31||||||||Interventional|||A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS|A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS|Completed||Phase 1|30||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.003449|2018-06-01 05:35:16.003449
NCT00002115|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1995|1995-11-30||||||||Interventional|||A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.|A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.|Completed||Phase 1|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.089567|2018-06-01 05:35:16.089567
NCT00002114|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1994|1994-01-31|January 1994||1994-01-31|||||Interventional|||A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides|A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides|Completed||Phase 2|125||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.16418|2018-06-01 05:35:16.16418
NCT00002113|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.|A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.|Completed||N/A|64||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.225667|2018-06-01 05:35:16.225667
NCT00002112|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome|Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.308807|2018-06-01 05:35:16.308807
NCT00002111|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1995|1995-05-31||||||||Interventional|||A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.|A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.|Completed||Phase 1|32||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.389732|2018-06-01 05:35:16.389732
NCT00002110|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1995|1995-10-31||||||||Interventional|||A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease|A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease|Completed||Phase 2|300||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.4556|2018-06-01 05:35:16.4556
NCT00002109|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy|Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.549602|2018-06-01 05:35:16.549602
NCT00002108|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1995|1995-11-30||||||||Interventional|||3TC (Lamivudine; GR109714X) Open-Label Program|3TC (Lamivudine; GR109714X) Open-Label Program|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.714528|2018-06-01 05:35:16.714528
NCT00002107|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1995|1995-03-31||||||||Interventional|||A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients|A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.779193|2018-06-01 05:35:16.779193
NCT00002106|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1994|1994-05-31||||||||Interventional|||A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3|A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3|Completed||Phase 2|104||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.846189|2018-06-01 05:35:16.846189
NCT00002105|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1996|1996-01-31||||||||Interventional|||Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma|Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma|Completed||Phase 3|220||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:16.929216|2018-06-01 05:35:16.929216
NCT00002104|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV|Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.035329|2018-06-01 05:35:17.035329
NCT00002103|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1994|1994-01-31||||||||Interventional|||A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia|A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.098747|2018-06-01 05:35:17.098747
NCT00002101|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1999|1999-06-30||||||||Interventional|||A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo|A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo|Completed||Phase 3|450||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.235831|2018-06-01 05:35:17.235831
NCT00002100|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1994|1994-04-30||||||||Interventional|||Phase I/II Study of Curdlan Sulfate|Phase I/II Study of Curdlan Sulfate|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.336945|2018-06-01 05:35:17.336945
NCT00002099|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1994|1994-07-31||||||||Interventional|||Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients|Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients|Unknown status|Active, not recruiting|Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.397003|2018-06-01 05:35:17.397003
NCT00002098|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1995|1995-03-31||||||||Interventional|||Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients|Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients|Completed||Phase 1|50||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.452683|2018-06-01 05:35:17.452683
NCT00002097|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1994|1994-04-30||||||||Interventional|||A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.|A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.511618|2018-06-01 05:35:17.511618
NCT00002096|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1993|1993-11-30||||||||Interventional|||A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine|A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine|Completed||Phase 1|24||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.566326|2018-06-01 05:35:17.566326
NCT00002095|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1993|1993-11-30||||||||Interventional|||A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus|A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus|Completed||N/A|700||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.654521|2018-06-01 05:35:17.654521
NCT00002094|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1993|1993-02-28||||||||Interventional|||Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E|Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.734402|2018-06-01 05:35:17.734402
NCT00002093|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.|A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.77945|2018-06-01 05:35:17.77945
NCT00002092|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection|A Study to Evaluate the Effect of Cimetidine on CD4 Lymphocyte Counts in HIV Infection|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.84953|2018-06-01 05:35:17.84953
NCT00002091|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1993|1993-10-31||||||||Interventional|||An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent|An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent|Completed||N/A|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.901899|2018-06-01 05:35:17.901899
NCT00002090|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)|An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:17.956058|2018-06-01 05:35:17.956058
NCT00002089|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy|An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:18.00933|2018-06-01 05:35:18.00933
NCT00002088|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1996|1996-03-31||||||||Interventional|||Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial|Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial|Completed||Phase 2|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.050345|2018-06-01 05:35:19.050345
NCT00002087|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1994|1994-04-30||||||||Interventional|||Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals|Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.11896|2018-06-01 05:35:19.11896
NCT00002086|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1993|1993-10-31||||||||Interventional|||A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection|A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection|Completed||Phase 2|256||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.175706|2018-06-01 05:35:19.175706
NCT00002085|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1998|1998-07-31||||||||Interventional|||A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy|A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.248401|2018-06-01 05:35:19.248401
NCT00002084|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients|A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.316244|2018-06-01 05:35:19.316244
NCT00002083|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1993|1993-03-31||||||||Interventional|||Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS|Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.523229|2018-06-01 05:35:19.523229
NCT00002082|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study|Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.5975|2018-06-01 05:35:19.5975
NCT00002081|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1992|1992-06-30||||||||Interventional|||Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease|Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.664032|2018-06-01 05:35:19.664032
NCT00002080|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2003|2003-04-30||||||||Interventional|||Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.73851|2018-06-01 05:35:19.73851
NCT00002079|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1993|1993-03-31||||||||Interventional|||Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)|Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.809879|2018-06-01 05:35:19.809879
NCT00002078|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1993|1993-11-30||||||||Interventional|||Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection|Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.903626|2018-06-01 05:35:19.903626
NCT00002077|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:19.980762|2018-06-01 05:35:19.980762
NCT00002076|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.045396|2018-06-01 05:35:20.045396
NCT00002075|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1989|1989-09-30||||||||Interventional|||Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.106285|2018-06-01 05:35:20.106285
NCT00002074|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1990|1990-05-31||||||||Interventional|||Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome|Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.17211|2018-06-01 05:35:20.17211
NCT00002073|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.270795|2018-06-01 05:35:20.270795
NCT00002072|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.319124|2018-06-01 05:35:20.319124
NCT00002071|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.455016|2018-06-01 05:35:20.455016
NCT00002070|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1991|1991-05-31||||||||Interventional|||Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis|Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis|Completed||Phase 3|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.535337|2018-06-01 05:35:20.535337
NCT00002069|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1989|1989-07-31||||||||Interventional|||A Study of DTC in Patients With AIDS and AIDS Related Complex|A Study of DTC in Patients With AIDS and AIDS Related Complex|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.641249|2018-06-01 05:35:20.641249
NCT00002068|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.715678|2018-06-01 05:35:20.715678
NCT00002067|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia|Phase III Randomized Double-Blind Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia|Completed||Phase 3|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:20.803747|2018-06-01 05:35:20.803747
NCT00002066|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1989|1989-11-30||||||||Interventional|||Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection|Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.889785|2018-06-01 05:35:20.889785
NCT00002065|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||Depot Disulfiram for AIDS and ARC|Depot Disulfiram for AIDS and ARC|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:20.962568|2018-06-01 05:35:20.962568
NCT00002064|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1989|1989-06-30||||||||Interventional|||Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse|Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.035328|2018-06-01 05:35:21.035328
NCT00002063|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)|Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.09899|2018-06-01 05:35:21.09899
NCT00002062|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1991|1991-10-31||||||||Interventional|||"Open-Label Compassionate Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients"|"Open-Label Compassionate Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients"|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.167429|2018-06-01 05:35:21.167429
NCT00002061|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1989|1989-06-30||||||||Interventional|||A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy|A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.233322|2018-06-01 05:35:21.233322
NCT00002060|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1989|1989-06-30||||||||Interventional|||A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)|A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.289579|2018-06-01 05:35:21.289579
NCT00002059|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1989|1989-06-30||||||||Interventional|||A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers|A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.342849|2018-06-01 05:35:21.342849
NCT00022789|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-14|||2014-03-12|2001-08-13|2001-08-14|Estimate|||||||2014-03-12|2014-03-13|Estimate|August 2001||2001-08-31|March 2014|2014-03-31|November 2006|Actual|2006-11-30|June 2006|Actual|2006-06-30||Observational|||Prevalence of Sleep-Disordered Breathing in Children|Prevalence of Sleep Disordered Breathing in Children|Completed|||700|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-06-01 05:36:43.132447|2018-06-01 05:36:43.132447
NCT00002058|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1990|1990-12-31||||||||Interventional|||A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease|A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.396159|2018-06-01 05:35:21.396159
NCT00002057|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC|Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC|Completed||N/A|||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:21.450584|2018-06-01 05:35:21.450584
NCT00002056|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS|A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.503731|2018-06-01 05:35:21.503731
NCT00002055|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP|A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.560857|2018-06-01 05:35:21.560857
NCT00002054|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1989|1989-10-31||||||||Interventional|||A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients|A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.615415|2018-06-01 05:35:21.615415
NCT00002053|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1989|1989-10-31||||||||Interventional|||A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP|A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.667942|2018-06-01 05:35:21.667942
NCT00002052|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients|Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.715807|2018-06-01 05:35:21.715807
NCT00002051|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1989|1989-11-30||||||||Interventional|||Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection|Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.787053|2018-06-01 05:35:21.787053
NCT00002050|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients|A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:21.949426|2018-06-01 05:35:21.949426
NCT00002049|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1989|1989-08-31||||||||Interventional|||Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients|Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.015626|2018-06-01 05:35:22.015626
NCT00002048|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1989|1989-09-30||||||||Interventional|||The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)|The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.083291|2018-06-01 05:35:22.083291
NCT00002047|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1990|1990-05-31||||||||Interventional|||Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure|Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.173659|2018-06-01 05:35:22.173659
NCT00002046|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1990|1990-05-31||||||||Interventional|||A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC|A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.238925|2018-06-01 05:35:22.238925
NCT00002045|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||A Prospective Double-Blind Study of Retrovir in Early HIV Infection|A Prospective Double-Blind Study of Retrovir in Early HIV Infection|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.351743|2018-06-01 05:35:22.351743
NCT00002044|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases|A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.4084|2018-06-01 05:35:22.4084
NCT00002043|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)|Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.4624|2018-06-01 05:35:22.4624
NCT00002042|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1989|1989-12-31||||||||Interventional|||A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia|A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.517837|2018-06-01 05:35:22.517837
NCT00002041|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-10-01|2001-08-30|2001-08-31|Estimate|||||||2007-10-01|2007-10-02|Estimate||||October 2007|2007-10-31||||||||Interventional|||Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients|Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:35:22.571187|2018-06-01 05:35:22.571187
NCT00002040|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.63123|2018-06-01 05:35:22.63123
NCT00002039|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1991|1991-03-31||||||||Interventional|||An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients|An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.699586|2018-06-01 05:35:22.699586
NCT00002038|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1996|1996-06-30||||||||Interventional|||Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy|Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.765151|2018-06-01 05:35:22.765151
NCT00002037|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1991|1991-05-31||||||||Interventional|||Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study|Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study|Completed||N/A|15||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:22.82633|2018-06-01 05:35:22.82633
NCT00002036|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)|Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)|Completed||Phase 1|12||Abbott|||||f||||||||||||||2018-06-01 05:35:22.881451|2018-06-01 05:35:22.881451
NCT00002035|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-08-04|2001-08-30|2001-08-31|Estimate|||||||2011-08-04|2011-08-05|Estimate||||August 2011|2011-08-31|April 1992|Actual|1992-04-30|||||Interventional|||Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine|Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine|Completed||N/A|300||Bristol-Myers Squibb|||||||||||||||||||2018-06-01 05:35:22.939992|2018-06-01 05:35:22.939992
NCT00002034|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1992|1992-01-31||||||||Interventional|||A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS|A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS|Completed||N/A|100||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.037916|2018-06-01 05:35:23.037916
NCT00002033|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1991|1991-02-28||||||||Interventional|||A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease|A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.104201|2018-06-01 05:35:23.104201
NCT00002032|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1992|1992-01-31||||||||Interventional|||Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial|Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial|Completed||N/A|750||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.165484|2018-06-01 05:35:23.165484
NCT00002031|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1990|1990-02-28||||||||Interventional|||Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)|Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.263183|2018-06-01 05:35:23.263183
NCT00002030|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1989|1989-11-30||||||||Interventional|||An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients|An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.306531|2018-06-01 05:35:23.306531
NCT00002029|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2009-02-19|2001-08-30|2001-08-31|Estimate|||||||2009-02-19|2009-02-20|Estimate||||February 2009|2009-02-28||||||||Interventional|||Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent|Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent|Completed||N/A|||Abbott|||||f||||||||||||||2018-06-01 05:35:23.351385|2018-06-01 05:35:23.351385
NCT00002028|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-08-15|2001-08-30|2001-08-31|Estimate|||||||2007-08-15|2007-08-16|Estimate||||August 2007|2007-08-31||||||||Interventional|||A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)|A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)|Completed||N/A|||Bristol-Myers Squibb|||||f||||||||||||||2018-06-01 05:35:23.400508|2018-06-01 05:35:23.400508
NCT00002027|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1990|1990-06-30||||||||Interventional|||Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)|Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)|Completed||N/A|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.450594|2018-06-01 05:35:23.450594
NCT00002026|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1990|1990-05-31||||||||Interventional|||Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)|Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.496801|2018-06-01 05:35:23.496801
NCT00002025|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1989|1989-09-30||||||||Interventional|||Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient|Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.560344|2018-06-01 05:35:23.560344
NCT00002024|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1989|1989-09-30||||||||Interventional|||Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections|Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.688947|2018-06-01 05:35:23.688947
NCT00002023|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2|An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.747453|2018-06-01 05:35:23.747453
NCT00002022|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1991|1991-02-28||||||||Interventional|||Treatment Program for Anemia in AIDS Patients|Treatment Program for Anemia in AIDS Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.806343|2018-06-01 05:35:23.806343
NCT00002021|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1990|1990-10-31||||||||Interventional|||An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies|An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.867626|2018-06-01 05:35:23.867626
NCT00002020|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1992|1992-02-29||||||||Interventional|||Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC|Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:23.950494|2018-06-01 05:35:23.950494
NCT00002019|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1999|1999-11-30||||||||Interventional|||Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome|Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.069526|2018-06-01 05:35:24.069526
NCT00002018|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1993|1993-03-31||||||||Interventional|||Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects|Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects|Completed||N/A|60||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.17259|2018-06-01 05:35:24.17259
NCT00002017|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1991|1991-08-31||||||||Interventional|||Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2|Immunomodulation of HIV-1 Infected Individuals With PEG-Interleukin-2|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.270762|2018-06-01 05:35:24.270762
NCT00002016|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1993|1993-04-30||||||||Interventional|||A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis|A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.359306|2018-06-01 05:35:24.359306
NCT00002015|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children|An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children|Completed||N/A|20||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.452322|2018-06-01 05:35:24.452322
NCT00001120|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-11|2001-08-30|2001-08-31|Estimate|||||||2008-09-11|2008-09-12|Estimate||||May 2006|2006-05-31||||||||Observational|||A Study of Patients With AIDS Syndrome|Oncogenic Viral Pathogenesis and Cancer Risk Factors Among Patients With the Acquired Immunodeficiency Syndrome: A Prospective Cohort Study|Completed|||5000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:28.416666|2018-06-01 05:35:28.416666
NCT00002014|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1991|1991-08-31||||||||Interventional|||A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)|A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.521749|2018-06-01 05:35:24.521749
NCT00002013|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1990|1990-12-31||||||||Interventional|||A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients|A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.582668|2018-06-01 05:35:24.582668
NCT00002012|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1993|1993-03-31||||||||Interventional|||Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients|Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients|Completed||N/A|45||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.640942|2018-06-01 05:35:24.640942
NCT00002011|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1990|1990-07-31||||||||Interventional|||The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex|The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.723026|2018-06-01 05:35:24.723026
NCT00002010|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1992|1992-02-29||||||||Interventional|||Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis|Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.779588|2018-06-01 05:35:24.779588
NCT00002009|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1988|1988-06-30||||||||Interventional|||A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia|A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.837034|2018-06-01 05:35:24.837034
NCT00002008|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1989|1989-01-31||||||||Interventional|||An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia|An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.893502|2018-06-01 05:35:24.893502
NCT00002007|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia|A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:24.964444|2018-06-01 05:35:24.964444
NCT00002006|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility|A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.048124|2018-06-01 05:35:25.048124
NCT00002005|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex|A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.103484|2018-06-01 05:35:25.103484
NCT00002004|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1990|1990-01-31||||||||Interventional|||A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.151751|2018-06-01 05:35:25.151751
NCT00002003|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1992|1992-03-31||||||||Interventional|||Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas|Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.198417|2018-06-01 05:35:25.198417
NCT00002002|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1992|1992-07-31||||||||Interventional|||A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome|A Randomized, Double-Blind, Placebo Controlled Study of l-Leucovorin in Combination With Trimethoprim / Sulfamethoxazole in the Therapy of Pneumocystis Carinii Pneumonia in Patients With the Acquired Immunodeficiency Syndrome|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.275646|2018-06-01 05:35:25.275646
NCT00002001|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 1991|1991-09-30||||||||Interventional|||The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease|The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.327612|2018-06-01 05:35:25.327612
NCT00000950|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-01|2001-08-30|2001-08-31|Estimate|||||||2011-03-01|2011-03-02|Estimate||||March 2011|2011-03-31||||May 2002|Actual|2002-05-31||Interventional|||Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis|Pharmacokinetics of Antituberculosis Agents in HIV-Infected Persons With Tuberculosis|Completed||N/A|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.270809|2018-06-01 05:35:51.270809
NCT00002000|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1996|1996-04-30||||||||Interventional|||A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients|A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.39268|2018-06-01 05:35:25.39268
NCT00001999|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1993|1993-04-30||||||||Interventional|||A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS|A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.470677|2018-06-01 05:35:25.470677
NCT00001998|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1992|1992-11-30||||||||Interventional|||Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)|Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.532316|2018-06-01 05:35:25.532316
NCT00001997|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1991|1991-07-31||||||||Interventional|||Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.580661|2018-06-01 05:35:25.580661
NCT00001996|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||May 1992|1992-05-31||||||||Interventional|||A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole|A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.630511|2018-06-01 05:35:25.630511
NCT00001995|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1992|1992-11-30||||||||Interventional|||A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS|A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS|Completed||N/A|200||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.701805|2018-06-01 05:35:25.701805
NCT00001994|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1992|1992-03-31||||||||Interventional|||A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine|A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.772831|2018-06-01 05:35:25.772831
NCT00001993|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1992|1992-02-29||||||||Interventional|||Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3|Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3|Completed||Phase 2|120||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.84123|2018-06-01 05:35:25.84123
NCT00001992|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 1992|1992-08-31||||||||Interventional|||A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers|A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers|Completed||Phase 1|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:25.984498|2018-06-01 05:35:25.984498
NCT00001991|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2003|2003-04-30||||||||Interventional|||A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia|A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:26.058273|2018-06-01 05:35:26.058273
NCT00001990|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1993|1993-04-30||||||||Interventional|||An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine|An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine|Completed||N/A|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:26.151537|2018-06-01 05:35:26.151537
NCT00001989|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1992|1992-10-31||||||||Interventional|||A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin|A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin|Completed||Phase 2|||NIH AIDS Clinical Trials Information Service|||||f||||||||||||||2018-06-01 05:35:26.22319|2018-06-01 05:35:26.22319
NCT00001137|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2013-12-05|2001-08-30|2001-08-31|Estimate|||||||2013-12-05|2013-12-06|Estimate|January 2000||2000-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Long-Term Data Collection From Participants in Adult AIDS Clinical Trials|Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) Protocol|Completed|||5982|Actual|AIDS Clinical Trials Group|||||f||||||||||||||2018-06-01 05:35:26.388018|2018-06-01 05:35:26.388018
NCT00001136|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-25|||2012-05-11|2001-08-30|2001-08-31|Estimate|||||||2012-05-11|2012-05-14|Estimate||||May 2012|2012-05-31|May 2001|Actual|2001-05-31|||||Interventional|||A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine|A Multi-Centered Phase 1 Trial to Evaluate the Memory Responses to a Single Boosting Vaccination With ALVAC-HIV vCP205 in Volunteers Who Have Previously Received Poxvirus-Based Vaccines|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:26.686877|2018-06-01 05:35:26.686877
NCT00001135|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-23|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|May 2001|Actual|2001-05-31|||||Interventional|||A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants|A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women|Completed||Phase 3|2009||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:26.791326|2018-06-01 05:35:26.791326
NCT00001133|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|August 2006|Actual|2006-08-31|||||Interventional|||Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir|A Phase I/II, Randomized, Open-Label Study of the Safety and Pharmacokinetics of Indinavir + Ritonavir Therapy in HIV-Infected Subjects Failing Amprenavir, Nelfinavir, Saquinavir, or Nelfinavir/Saquinavir Combination Therapy|Completed||Phase 1|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:35:26.928447|2018-06-01 05:35:26.928447
NCT00001132|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2008-09-08|2001-08-30|2001-08-31|Estimate|||||||2008-09-08|2008-09-09|Estimate|November 1999||1999-11-30|June 2003|2003-06-30|April 2001||2001-04-30|||||Interventional|||Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination|A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy|Completed||Phase 2|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:27.2333|2018-06-01 05:35:27.2333
NCT00001131|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2015-05-14|2001-08-30|2001-08-31|Estimate|||||||2015-05-14|2015-05-15|Estimate|May 2004||2004-05-31|September 2013|2013-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients|Procedure for Initiation, Administration, and Discontinuation of Interleukin-2 (IL-2) Therapy in Conjunction With Highly Active Antiretroviral Therapy|Completed||N/A|42|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:35:27.427127|2018-06-01 05:35:27.427127
NCT00001130|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2008-09-08|2001-08-30|2001-08-31|Estimate|||||||2008-09-08|2008-09-09|Estimate||||January 2005|2005-01-31||||||||Observational|||Identifying Emergency Room Patients Who Have Recently Been Infected With HIV|Increasing Identification of Patients With Primary HIV Infection (PHI) Through a Questionnaire Intervention in an Emergency Department (ED) Setting|Completed|||200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:27.55638|2018-06-01 05:35:27.55638
NCT00001129|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|June 2003|Actual|2003-06-30|||||Interventional|||A Study of Two Adherence Plans to Help HIV-Positive Patients Take Their Medications Correctly|Adherence Strategies Using a Medication Manager and an Electronic Medication Reminder System for HIV-Infected Patients Receiving HAART|Completed||N/A|1248||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:27.669496|2018-06-01 05:35:27.669496
NCT00001128|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2016-12-13|2001-08-30|2001-08-31|Estimate|||||||2016-12-13|2016-12-14|Estimate||||June 2003|2003-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Treatment of Chronic Cryptosporidiosis in AIDS Patients|A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS|Terminated||N/A|16||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:27.869495|2018-06-01 05:35:27.869495
NCT00001127|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Study of a Flu Vaccine in Children|Study of the Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in a Community-Based, Non-Randomized, Open-Label Trial in Children to Assess Safety and Herd Immunity for the Control of Epidemic Influenza|Completed||Phase 3|15000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:27.965717|2018-06-01 05:35:27.965717
NCT00001126|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)|A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:28.040731|2018-06-01 05:35:28.040731
NCT00001125|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2014-10-28|2001-08-30|2001-08-31|Estimate|||||||2014-10-28|2014-10-29|Estimate||||October 2014|2014-10-31|March 2004|Actual|2004-03-31|||||Interventional|||Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox|Use of a Live-Attenuated Varicella-Zoster Virus (VZV) Vaccine to Boost Immunity to VZV in HIV-Infected Children Previously Infected With Varicella|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:35:28.090031|2018-06-01 05:35:28.090031
NCT00001123|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome|A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome|Completed||N/A|130||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:28.19618|2018-06-01 05:35:28.19618
NCT00001122|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-01|2001-08-30|2001-08-31|Estimate|||||||2011-03-01|2011-03-02|Estimate||||January 2005|2005-01-31||||October 2003|Actual|2003-10-31||Interventional|||A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly|A Phase II, Randomized, Open-Label Study of Maximally Assisted Therapy (MAT) Compared to Self-Administered Therapy (SAT) for the Treatment of HIV Infection in Antiretroviral Naive Subjects With CD4 Greater Than or Equal to 200 Cells/mm3|Completed||Phase 2|74||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:28.241283|2018-06-01 05:35:28.241283
NCT00001121|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-11|2001-08-30|2001-08-31|Estimate|||||||2008-09-11|2008-09-12|Estimate|August 1999||1999-08-31|June 2003|2003-06-30||||||||Observational|||A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1|Evaluation of Virologic, Immunologic, and Clinical Parameters of Participants in HIVNET 014 Who Become Infected With HIV-1|Completed|||||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:28.354296|2018-06-01 05:35:28.354296
NCT00001119|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-01|2001-08-30|2001-08-31|Estimate|||||||2011-03-01|2011-03-02|Estimate|October 1999||1999-10-31|January 2005|2005-01-31||||June 2004|Actual|2004-06-30||Interventional|||Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV|A Study of the Effects of Combination Antiretroviral Therapy in Acute HIV-1 Infection With an Emphasis on Immunological Responses|Completed||N/A|288||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:28.493827|2018-06-01 05:35:28.493827
NCT00001118|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|December 2002|Actual|2002-12-31|||||Interventional|||Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children|A Phase I/II Study of T-20, a Fusion Inhibitor, in HIV-1 Infected Children|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:28.74838|2018-06-01 05:35:28.74838
NCT00001117|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-30|2001-08-30|2001-08-31|Estimate|||||||2008-07-30|2008-08-01|Estimate||||June 2003|2003-06-30||||||||Observational|||A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection|Dynamics of Hepatitis C Infection in Subjects With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Receiving Highly Active Antiretroviral Therapy (HAART)|Completed|||60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:29.767252|2018-06-01 05:35:29.767252
NCT00001116|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|June 2000|Actual|2000-06-30|||||Interventional|||A Study to Evaluate the Ability of TNFR:Fc to Decrease the Amount of IL-6 (Interleukin-6) and TNF-alpha (Tumor Necrosis Factor) in HIV-Infected Patients|Effect of Recombinant Human Soluble Tumor Necrosis Factor Receptor (TNFR:Fc) on Interleukin-6 (IL-6), Tumor Necrosis Factor-Alpha (TNF-alpha) and Markers of Immune Activation in HIV-Infected Subjects|Completed||N/A|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:30.532592|2018-06-01 05:35:30.532592
NCT00001115|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-10-27|2001-08-30|2001-08-31|Estimate|||||||2016-10-27|2016-10-31|Estimate||||June 1998|1998-06-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood|A Pilot Study to Determine the Effect of Acyclovir Treatment for Herpes Simplex Virus (HSV) Infection on Peripheral Blood HIV Viral Load.|Completed||N/A|75||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:30.661668|2018-06-01 05:35:30.661668
NCT00001114|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|March 2000|Actual|2000-03-31|||||Interventional|||The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma|A Randomized Phase II Trial to Determine the Safety, Tolerance, and Efficacy of Two Doses of Interferon Alfa-2b Combined With Didanosine in Patients With Kaposi's Sarcoma|Completed||Phase 2|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:30.798761|2018-06-01 05:35:30.798761
NCT00001113|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|March 1990|Actual|1990-03-31|||||Interventional|||A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma|A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:30.901749|2018-06-01 05:35:30.901749
NCT00001112|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|April 1993|Actual|1993-04-30|||||Interventional|||The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine|A Phase I Study To Determine the Safety of the Optimal Monocyte Activating Administration Schedule of Subcutaneous Human Recombinant Interferon-gamma in ZDV-Treated Patients With AIDS|Completed||Phase 1|5||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:31.120579|2018-06-01 05:35:31.120579
NCT00001111|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-28|2001-08-30|2001-08-31|Estimate|||||||2011-02-28|2011-03-01|Estimate||||February 2011|2011-02-28||||June 1995|Actual|1995-06-30||Interventional|||A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children|Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children|Completed||N/A|35||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:31.372443|2018-06-01 05:35:31.372443
NCT00001110|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate|August 1999||1999-08-31|July 2013|2013-07-31|April 2003|Actual|2003-04-30|||||Interventional|||Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients|Effect of Highly Active Antiretroviral Therapy (HAART) on Viral Burden and Immune Function in the Lungs of HIV-Infected Subjects|Completed||N/A|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:31.477733|2018-06-01 05:35:31.477733
NCT00001109|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||October 2004|2004-10-31||||||||Observational|||A Blood Test to Look at Cells of the Immune System in Healthy Children|Mononuclear Cell Phenotyping in Normal Children|Completed|||630||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:31.608396|2018-06-01 05:35:31.608396
NCT00001108|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|June 2000|Actual|2000-06-30|||||Interventional|||A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses|Multi-Drug Antiretroviral Therapy for Heavily Pretreated Pediatric AIDS Patients: A Phase I Proof of Concept Trial|Completed||Phase 1|6||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:31.967642|2018-06-01 05:35:31.967642
NCT00001107|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants|Invasive Fungal Infection in Liver Transplant Recipients: A Randomized Double-Blind Trial Comparing AmBisome and Fluconazole in the High Risk Group and an Observational Cohort Study in the Low Risk|Completed||Phase 4|500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:32.114343|2018-06-01 05:35:32.114343
NCT00001106|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-06-02|2001-08-30|2001-08-31|Estimate|||||||2015-06-02|2015-06-03|Estimate||||March 2012|2012-03-31|March 1994|Actual|1994-03-31|||||Interventional|||A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children|A Phase I Trial To Evaluate Zidovudine (ZDV) in HIV-1 Infected Pregnant Women and Their Offspring|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:32.19471|2018-06-01 05:35:32.19471
NCT00001105|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-08|2001-08-30|2001-08-31|Estimate|||||||2012-05-08|2012-05-09|Estimate||||May 2012|2012-05-31|March 1996|Actual|1996-03-31|||||Interventional|||The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV|A Phase I Clinical Trial to Study the Toxicity, Pharmacokinetics, and Efficacy of Human Monoclonal Antibody, F105, for Treating Human Immunodeficiency Virus Infection.|Completed||Phase 1|8||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:32.292957|2018-06-01 05:35:32.292957
NCT00001104|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1990|Actual|1990-02-28|||||Interventional|||A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia|A Placebo Controlled Trial To Evaluate Zidovudine (ZDV) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Hemophilic Patients|Completed||Phase 3|538||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:32.385809|2018-06-01 05:35:32.385809
NCT00001103|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-28|2001-08-30|2001-08-31|Estimate|||||||2008-07-28|2008-07-29|Estimate||||May 2006|2006-05-31||||||||Observational|||HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs|Cerebrospinal Fluid Human Immunodeficiency Virus-1 (HIV-1) and Cognitive Function in Individuals Receiving Potent Antiretroviral Therapy|Completed|||100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:32.730615|2018-06-01 05:35:32.730615
NCT00001102|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-04-16|2001-08-30|2001-08-31|Estimate|||||||2014-04-16|2014-04-17|Estimate||||April 2014|2014-04-30|June 2006|Actual|2006-06-30|||||Observational|||The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients|Metabolic Consequences of Highly Active Antiretroviral Therapy (HAART) in HIV-Positive Individuals|Completed|||460||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:32.841699|2018-06-01 05:35:32.841699
NCT00001101|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||March 2010|2010-03-31|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease|Completed||Phase 3|194||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:32.934714|2018-06-01 05:35:32.934714
NCT00001100|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.|A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.|Completed||Phase 3|130||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:33.000224|2018-06-01 05:35:33.000224
NCT00001097|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-04-23|2001-08-30|2001-08-31|Estimate|||||||2010-04-23|2010-04-26|Estimate|December 1997||1997-12-31|November 2005|2005-11-30||||||||Observational|||Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems|Establishment and Maintenance of Long-Term Undetectable Plasma HIV-1 RNA: Correlation With Immunologic Reconstitution and Viral Dynamics|Completed|||120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:33.132215|2018-06-01 05:35:33.132215
NCT00001096|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|March 2000|Actual|2000-03-31|||||Interventional|||A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:33.269646|2018-06-01 05:35:33.269646
NCT00001095|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|October 1999|Actual|1999-10-31|||||Interventional|||A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir|A Phase II Study of 1) Amprenavir (141W94/VX478) Plus 3TC Plus ZDV (or d4T) or 2) IDV Plus NVP Plus 3TC Plus d4T in Subjects Previously Treated With Amprenavir and 3) Other Treatment Regimens (Observational ARM) in Subjects Previously Treated With Amprenavir|Completed||Phase 2|94||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:33.35664|2018-06-01 05:35:33.35664
NCT00001094|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-03-05|2001-08-30|2001-08-31|Estimate|||||||2015-03-05|2015-03-09|Estimate||||March 2015|2015-03-31||||||||Interventional|||A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients|A Phase II, Randomized, Controlled, Open-Label Trial of Combination Therapy With Nelfinavir (NFV) and Saquinavir (SQV)Sgc With Delavirdine (DLV) or 3TC/ZDV Versus Nelfinavir (NFV) and 3TC/ZDV in Subjects With HIV Infection and > 5,000 HIV RNA Copies/ML|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:33.574228|2018-06-01 05:35:33.574228
NCT00001093|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-26|2001-08-30|2001-08-31|Estimate|||||||2012-10-26|2012-10-29|Estimate|October 1999||1999-10-31|October 2012|2012-10-31|June 2007|Actual|2007-06-30|||||Observational|||Outcomes of Anti-HIV Therapy During Early HIV Infection|Outcomes of Antiretroviral Therapy During Primary HIV Infection|Completed|||48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:33.694228|2018-06-01 05:35:33.694228
NCT00001092|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-10-21|2001-08-30|2001-08-31|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 1999||1999-10-31|October 2015|2015-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||The Biology of HIV Transmission|The Determinants of the Biology of HIV Transmission to Determine the Immunologic and Virologic Characteristics of Those Who May Have Transmitted HIV to Another Individual|Completed|||20|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||Samples With DNA|"~     Blood, genital fluids, and saliva collection~   "|||2018-06-01 05:35:33.755734|2018-06-01 05:35:33.755734
NCT00001091|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|October 2000|Actual|2000-10-31|||||Interventional|||Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens|A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs and an NNRTI|Completed||Phase 1|200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:33.832461|2018-06-01 05:35:33.832461
NCT00001090|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|October 1999|Actual|1999-10-31|||||Interventional|||A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers|A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205, Combined With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Healthy, HIV-1 Uninfected Volunteers|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.038809|2018-06-01 05:35:34.038809
NCT00001089|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2003|2003-02-28||||||||Observational|||A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients|Human Immunodeficiency Virus (HIV) and Cytomegalovirus (CMV) Viral Burden and Development of CMV End-Organ Disease: A Prospective Study in HIV-Infected Individuals.|Completed|||400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.133032|2018-06-01 05:35:34.133032
NCT00001088|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-26|2001-08-30|2001-08-31|Estimate|||||||2008-09-26|2008-09-29|Estimate|July 1997||1997-07-31|September 2008|2008-09-30|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.319342|2018-06-01 05:35:34.319342
NCT00001087|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|July 2000|Actual|2000-07-31|||||Interventional|||The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs|Comparison of the Virologic Efficacy of Nelfinavir and/or DMP 266 (Efavirenz, EFV) in Combination With One or Two New Nucleoside Analogs in Nucleoside Experienced Subjects: A Roll-Over Study to ACTG 302/303|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.414775|2018-06-01 05:35:34.414775
NCT00001086|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|September 1999|Actual|1999-09-30|||||Interventional|||A Study of Abacavir Plus Indinavir Sulfate Plus Efavirenz in HIV-Infected Patients|A Randomized, Phase II, Placebo Controlled Trial of Abacavir (ABC, 1592U89) in Combination With Open-Label Indinavir Sulfate (IDV) and Efavirenz (EFV, DMP-266) in HIV-Infected Subjects With Nucleoside Analog Experience: A Rollover Study for ACTG 320|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.542095|2018-06-01 05:35:34.542095
NCT00001085|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-14|2001-08-30|2001-08-31|Estimate|||||||2012-02-14|2012-02-16|Estimate||||February 2012|2012-02-29|September 1998|Actual|1998-09-30|||||Interventional|||A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients|A Randomized, Double-Blind, Phase II Study of 141W94 (VX-478) Monotherapy vs. 141W94 (VX-478) Plus ZDV Plus 3TC in HIV Infected Individuals|Completed||Phase 2|94||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.728979|2018-06-01 05:35:34.728979
NCT00001084|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|December 1997|Actual|1997-12-31|||||Interventional|||A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients|A Prospective Randomized Double-Blind Trial of Three Maintenance Regimens for HIV-Infected Subjects Receiving Induction Therapy With Zidovudine, Lamivudine and Indinavir|Completed||Phase 2|500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.840917|2018-06-01 05:35:34.840917
NCT00001083|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-14|2001-08-30|2001-08-31|Estimate|||||||2012-02-14|2012-02-16|Estimate||||February 2012|2012-02-29|June 2001|Actual|2001-06-30|||||Interventional|||Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs|A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV- Infected Children; PRAM-1: ZDV+3TC vs. d4T+Ritonavir vs. ZDV+3TC+Ritonavir; PRAM-1, Step 2: d4T+Nevirapine+Ritonavir; PRAM-1, Step 3: d4T+Indinavir vs. ZDV+3TC+Indinavir|Completed||Phase 2|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:34.99023|2018-06-01 05:35:34.99023
NCT00001082|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate|December 1996||1996-12-31|September 2013|2013-09-30|August 1999|Actual|1999-08-31|January 1999|Actual|1999-01-31||Interventional|||The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (Bis-POM PMEA) in Prolonging Survival of HIV-Infected Individuals With a CD4+ Cell Count of <= 100/mm3 or With a CD4+ Cell Count Both > 100 and <= 200/mm3 and a Nadir CD4+ Cell Count of <= 50/mm3|Completed||Phase 3|505|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:35:35.179358|2018-06-01 05:35:35.179358
NCT00001081|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-14|2001-08-30|2001-08-31|Estimate|||||||2012-02-14|2012-02-16|Estimate||||February 2012|2012-02-29|September 1998|Actual|1998-09-30|||||Interventional|||A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium|A Phase II/III Placebo-Controlled Study of Nitazoxanide (NTZ) For Persons With AIDS and Cryptosporidiosis|Completed||Phase 2|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:35.272324|2018-06-01 05:35:35.272324
NCT00001080|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31||||||||Interventional|||Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals|Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||||as of 4/23/97|f||||||||||||||2018-06-01 05:35:35.329552|2018-06-01 05:35:35.329552
NCT00001079|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|December 2002|Actual|2002-12-31|||||Interventional|||A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss|Double-Blind Randomized Comparison Phase II Trial of Megestrol Acetate and Testosterone Enanthate in Combination Versus Megestrol Acetate Plus Testosterone Enanthate Placebo in Human Immunodeficiency Virus (HIV)-Associated Wasting.|Completed||Phase 2|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:35.390958|2018-06-01 05:35:35.390958
NCT00001078|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-01|2001-08-30|2001-08-31|Estimate|||||||2011-03-01|2011-03-02|Estimate||||July 2005|2005-07-31||||May 2005|Actual|2005-05-31||Interventional|||A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications|An Observational Study of the Rate of Opportunistic Infection Events in HIV-Infected Children Who Have Demonstrated Immunologic Reconstitution and Who Have Discontinued OI Prophylaxis|Completed||N/A|200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:35.472991|2018-06-01 05:35:35.472991
NCT00001077|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate|June 1996||1996-06-30|September 2013|2013-09-30|April 1998|Actual|1998-04-30|April 1998|Actual|1998-04-30||Observational|||A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements|An Open-Label, Randomized, Three-Arm, Comparative Trial of a Caloric Supplement With Peptides and Medium-Chain Triglycerides Versus a Caloric Supplement With Whole Protein and Long-Chain Triglycerides Versus No Caloric Supplement for the Prevention of Weight Loss in Individuals With AIDS Who Take a Daily Multivitamin and Mineral Supplement|Completed|||536|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||||||||Samples With DNA|"~     Blood collection~   "|||2018-06-01 05:35:35.576984|2018-06-01 05:35:35.576984
NCT00001076|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|December 1997|Actual|1997-12-31|||||Interventional|||A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules|Completed||Phase 1|34||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:35.683565|2018-06-01 05:35:35.683565
NCT00001075|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-13|2001-08-30|2001-08-31|Estimate|||||||2012-02-13|2012-02-14|Estimate||||February 2012|2012-02-29|July 2007|Actual|2007-07-31|||||Interventional|||The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients|A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease|Completed||N/A|55||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:35.854002|2018-06-01 05:35:35.854002
NCT00001074|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|January 2000|Actual|2000-01-31|||||Interventional|||The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients|A Phase I/II Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone and in Combination With ddI Compared With ddI Alone in Subjects With HIV Infection|Completed||Phase 1|140||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:35.953567|2018-06-01 05:35:35.953567
NCT00001073|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|March 2001|Actual|2001-03-31|||||Interventional|||Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors|A Randomized Phase III Trial of Oral Isotretinoin Versus Observation for Low-Grade Squamous Intraepithelial Lesions in HIV-Infected Women|Completed||Phase 3|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.074423|2018-06-01 05:35:36.074423
NCT00001072|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|January 1999|Actual|1999-01-31|||||Interventional|||A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|140||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.205573|2018-06-01 05:35:36.205573
NCT00001071|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|October 1998|Actual|1998-10-31|||||Interventional|||A Study of Stem Cells and Filgrastim|A Pilot Study of Stem Cell Mobilization and Harvesting From the Peripheral Blood Using Filgrastim|Completed||N/A|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.279812|2018-06-01 05:35:36.279812
NCT00001070|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-12-28|2001-08-30|2001-08-31|Estimate|||||||2012-12-28|2012-12-31|Estimate||||December 2012|2012-12-31||||||||Interventional|||The Safety and Effectiveness of Different Doses of Vitamin C in HIV-Infected Patients|A Dose Escalation Study to Evaluate Tolerance and Antiviral Effect of Oral Vitamin C in Two Groups of HIV-Infected Adults|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.344949|2018-06-01 05:35:36.344949
NCT00001069|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2003|2003-01-31||||||||Observational|||A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment|A Randomized Study of the Clinical Effects of Initiating or Changing Antiretroviral Therapy Based on Plasma HIV RNA Quantitation Compared With Initiating or Changing Therapy Based on Current Clinical Practice Alone|Terminated|||1100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.397375|2018-06-01 05:35:36.397375
NCT00001068|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|October 1998|Actual|1998-10-31|||||Interventional|||A Study of Disease Progression and Anti-HIV Treatments|Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-up Study to ACTG 175|Completed||Phase 2|210||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.483597|2018-06-01 05:35:36.483597
NCT00001067|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|November 1997|Actual|1997-11-30|||||Interventional|||The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs|A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience|Completed||Phase 2|105||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.59402|2018-06-01 05:35:36.59402
NCT00001066|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-01|2001-08-30|2001-08-31|Estimate|||||||2011-03-01|2011-03-02|Estimate||||March 2011|2011-03-31||||January 2001|Actual|2001-01-31||Interventional|||A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children|A Randomized Comparative Study of Combined Zidovudine-Lamivudine (3TC) vs. the Better of ddI Monotherapy vs. Zidovudine Plus Ddl in Symptomatic HIV-1 Infected Children|Completed||Phase 2|740||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.721491|2018-06-01 05:35:36.721491
NCT00001065|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|April 1998|Actual|1998-04-30|||||Interventional|||A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole|A Phase II Trial of Amphotericin B Oral Suspension for Fluconazole-Resistant Oral Candidiasis in HIV-Infected Patients|Completed||Phase 2|70||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:36.918654|2018-06-01 05:35:36.918654
NCT00001064|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-12-13|2001-08-30|2001-08-31|Estimate|||||||2016-12-13|2016-12-14|Estimate||||April 1995|1995-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3|A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3|Terminated||N/A|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.137718|2018-06-01 05:35:37.137718
NCT00001063|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-13|2001-08-30|2001-08-31|Estimate|||||||2012-04-13|2012-04-17|Estimate||||April 2012|2012-04-30|November 1997|Actual|1997-11-30|||||Interventional|||The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks|A Phase II Randomized Study of the Virologic and Immunologic Effects of d4T vs Zidovudine Plus d4T vs Zidovudine Plus Ddl in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and Greater Than 12 Weeks Zidovudine Experience|Completed||Phase 2|200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.196334|2018-06-01 05:35:37.196334
NCT00001062|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|January 1998|Actual|1998-01-31|||||Interventional|||A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes|A Phase I Study of a Fixed-Schedule Regimen of Alternating Oral and Intravenous Ganciclovir for Treatment of Cytomegalovirus Retinitis|Completed||Phase 1|25||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.303555|2018-06-01 05:35:37.303555
NCT00001061|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-08|2001-08-30|2001-08-31|Estimate|||||||2012-05-08|2012-05-10|Estimate||||May 2012|2012-05-31|March 1998|Actual|1998-03-31|||||Interventional|||Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS|A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis|Completed||Phase 2|167||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.388919|2018-06-01 05:35:37.388919
NCT00001060|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-05-03|2001-08-30|2001-08-31|Estimate|||||||2013-05-03|2013-05-06|Estimate||||May 2013|2013-05-31|June 2002|Actual|2002-06-30|||||Interventional|||A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons|A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.477982|2018-06-01 05:35:37.477982
NCT00001059|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-13|2001-08-30|2001-08-31|Estimate|||||||2012-04-13|2012-04-17|Estimate||||April 2012|2012-04-30|August 1998|Actual|1998-08-31|||||Interventional|||Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS|Comparison Study of Liposomal Doxorubicin With or Without Bleomycin and Vincristine for the Treatment of Advanced AIDS-Associated Kaposi's Sarcoma|Completed||Phase 2|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.53296|2018-06-01 05:35:37.53296
NCT00001058|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|January 1999|Actual|1999-01-31|||||Interventional|||A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS|A Phase II/III Prospective, Multicenter, Randomized, Controlled Trial Comparing the Safety and Efficacy of Three Clarithromycin-Containing Combination Drug Regimens for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Disease in Persons With AIDS|Completed||Phase 2|246||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.614264|2018-06-01 05:35:37.614264
NCT00001057|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|May 1995|Actual|1995-05-31|||||Interventional|||The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of the Virologic Effect of Two Different Nucleoside Treatment Strategies (Zidovudine Versus Zidovudine in Combination With Didanosine) for HIV Infection in Subjects With CD4+ Counts >= 550 Cells/mm3|Completed||Phase 2|105||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.814669|2018-06-01 05:35:37.814669
NCT00001056|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|October 1994|Actual|1994-10-31|||||Interventional|||A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose|Completed||Phase 1|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:37.950456|2018-06-01 05:35:37.950456
NCT00001055|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|November 1997|Actual|1997-11-30|||||Interventional|||A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|76||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.066595|2018-06-01 05:35:38.066595
NCT00001054|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-04|Estimate||||April 2012|2012-04-30|January 2001|Actual|2001-01-31|||||Interventional|||The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children|A Phase I Trial to Evaluate the Pharmacokinetics, Safety, and Tolerance of Valacyclovir HCl in HIV-1 Infected Children With Herpes Simplex Infections or Varicella/Zoster Infections|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.170719|2018-06-01 05:35:38.170719
NCT00001053|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-08|2001-08-30|2001-08-31|Estimate|||||||2012-05-08|2012-05-09|Estimate||||May 2012|2012-05-31|March 1996|Actual|1996-03-31|||||Interventional|||A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects|A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects|Completed||Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.262829|2018-06-01 05:35:38.262829
NCT00001052|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|September 1997|Actual|1997-09-30|||||Interventional|||A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults|Completed||Phase 1|110|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.342648|2018-06-01 05:35:38.342648
NCT00001050|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1994|1994-03-31||||||||Observational|||Study of Women Who Have AIDS|Women's AIDS Cohort Study (WACS)|Terminated|||1250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.441068|2018-06-01 05:35:38.441068
NCT00001049|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|June 1998|Actual|1998-06-30|||||Interventional|||A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV|A Phase I Evaluation of the Safety and Toxicity of Zidovudine and Didanosine in Combination in HIV-Infected or Exposed Infants and a Phase II Study of the Effect of Didanosine vs. Combination Therapy With Zidovudine and Didanosine on HIV-1 RNA in Infants With HIV Infection|Completed||Phase 1|180||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.509822|2018-06-01 05:35:38.509822
NCT00001048|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|April 1997|Actual|1997-04-30|||||Interventional|||Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients|A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected Subjects|Completed||Phase 2|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.705255|2018-06-01 05:35:38.705255
NCT00001047|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|August 1996|Actual|1996-08-31|||||Interventional|||Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS|An Open-Label, Randomized Trial of Four Treatment Regimens for Patients With Disseminated Mycobacterium Avium Complex Disease and Acquired Immunodeficiency Syndrome (AIDS)|Completed||Phase 3|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.808651|2018-06-01 05:35:38.808651
NCT00001046|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31||||||||Interventional|||Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)|Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.902164|2018-06-01 05:35:38.902164
NCT00001045|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|October 1998|Actual|1998-10-31|||||Interventional|||Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease|A Double-Blinded, Randomized Trial Comparing Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus ddI Plus Nevirapine in Asymptomatic Patients on AZT Monotherapy Who Develop a Mutation at Codon 215 of HIV Reverse Transcriptase in Serum/Plasma Viral RNA|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:38.985909|2018-06-01 05:35:38.985909
NCT00001044|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-24|Estimate||||May 2012|2012-05-31|May 1995|Actual|1995-05-31|||||Interventional|||A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.|Completed||Phase 1|80|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.108833|2018-06-01 05:35:39.108833
NCT00001043|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|May 1997|Actual|1997-05-31|||||Interventional|||A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.189683|2018-06-01 05:35:39.189683
NCT00001042|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|March 1996|Actual|1996-03-31|||||Interventional|||A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals|Completed||Phase 1|112|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.245624|2018-06-01 05:35:39.245624
NCT00001041|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|July 1998|Actual|1998-07-31|||||Interventional|||Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)|Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.307315|2018-06-01 05:35:39.307315
NCT00000937|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Study and Treatment of Post Lyme Disease (STOP-LD)|Study and Treatment of Post Lyme Disease (STOP-LD)|Completed||Phase 3|55||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:53.790493|2018-06-01 05:35:53.790493
NCT00001040|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-28|2001-08-30|2001-08-31|Estimate|||||||2011-02-28|2011-03-01|Estimate||||February 2011|2011-02-28||||May 1994|Actual|1994-05-31||Interventional|||Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC|Double-Blind, Randomized, Phase II Study of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus Ro 31-8959 Plus AZT Plus ddC|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.382395|2018-06-01 05:35:39.382395
NCT00001039|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-29|2001-08-30|2001-08-31|Estimate|||||||2012-10-29|2012-10-31|Estimate||||October 2012|2012-10-31|June 2002|Actual|2002-06-30|||||Interventional|||Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients|The Effect of Therapy on the Tissue Burden of Disseminated MAC Infection as Measured by Quantitative Bone Marrow Culture and Correlation With Quantitative Blood Culture in HIV-Infected Patients|Completed||Phase 2|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.478172|2018-06-01 05:35:39.478172
NCT00001038|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-28|2001-08-30|2001-08-31|Estimate|||||||2011-02-28|2011-03-01|Estimate||||February 2011|2011-02-28||||May 1996|Actual|1996-05-31||Interventional|||A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients|A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)|Completed||Phase 3|1200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.548901|2018-06-01 05:35:39.548901
NCT00001037|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|May 1995|Actual|1995-05-31|||||Interventional|||A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules|A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules|Completed||Phase 1|22|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.635247|2018-06-01 05:35:39.635247
NCT00001036|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||October 1996|1996-10-31||||||||Interventional|||The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine and Thymosin Alpha 1 in HIV-Positive, Asymptomatic and Symptomatic Individuals|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.690825|2018-06-01 05:35:39.690825
NCT00001035|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-27|2001-08-30|2001-08-31|Estimate|||||||2012-04-27|2012-04-30|Estimate||||April 2012|2012-04-30|September 1996|Actual|1996-09-30|||||Interventional|||The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections|A Phase I Pilot Study of the Safety and Efficacy of Interferon Alfa-2b (IFN Alfa-2b) in Combination With Nucleoside Analog Therapy in Patients With Combined Hepatitis C (HCV) and Advanced Human Immunodeficiency Virus (HIV) Infections|Completed||Phase 1|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:39.744447|2018-06-01 05:35:39.744447
NCT00001034|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|August 1995|Actual|1995-08-31|||||Interventional|||The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV|A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression|Completed||Phase 2|850||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:40.728933|2018-06-01 05:35:40.728933
NCT00001033|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|July 1997|Actual|1997-07-31|||||Interventional|||The Treatment of Tuberculosis in HIV-Infected Patients|The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection|Completed||Phase 3|650||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:42.567737|2018-06-01 05:35:42.567737
NCT00001032|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|April 1995|Actual|1995-04-30|||||Interventional|||A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT|A Phase II Study to Evaluate Pharmacokinetics, Safety, Tolerance and Activity of Dideoxycytidine (ddC) Administered in Combination With Zidovudine (AZT) in Stable, AZT-Treated Pediatric Patients With HIV Infection|Completed||Phase 2|180||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:42.776457|2018-06-01 05:35:42.776457
NCT00001031|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|December 1997|Actual|1997-12-31|||||Interventional|||A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults|A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults|Completed||Phase 2|296|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:42.955612|2018-06-01 05:35:42.955612
NCT00001030|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-06-02|2001-08-30|2001-08-31|Estimate|||||||2015-06-02|2015-06-03|Estimate||||March 2012|2012-03-31|June 1996|Actual|1996-06-30|||||Interventional|||The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients|A Prospective, Randomized, Comparative Study of the Safety and Efficacy of Clarithromycin Versus Rifabutin Versus the Combination of Clarithromycin Plus Rifabutin for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia or Disseminated MAC Disease in HIV-Infected Patients With CD4 Lymphocyte Counts <= 100 Cells/mm3|Completed||Phase 3|1100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:43.151945|2018-06-01 05:35:43.151945
NCT00001029|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|May 1993|Actual|1993-05-31|||||Interventional|||A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past|A Randomized, Double-Blind, Three-Arm Study Comparing Combination to Monthly Alternating Nucleoside Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) With a Prior History of Nucleoside Therapy|Completed||Phase 2|654||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:43.43177|2018-06-01 05:35:43.43177
NCT00001028|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|June 1994|Actual|1994-06-30|||||Interventional|||A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides|A Randomized, Comparative, Prospective Study of Monthly Aerosolized Pentamidine and Thrice Weekly Dapsone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant to Trimethoprim and/or Sulfonamides|Completed||Phase 3|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:43.577995|2018-06-01 05:35:43.577995
NCT00001027|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Children Who Cannot Take Trimethoprim-Sulfamethoxazole|A Phase I/II Trial of Parenteral Pentamidine for PCP Prophylaxis in HIV-Infected Children Who Are Intolerant to Oral Trimethoprim-Sulfamethoxazole|Completed||Phase 1|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:43.676721|2018-06-01 05:35:43.676721
NCT00001026|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|December 1994|Actual|1994-12-31|||||Interventional|||A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals|Completed||Phase 1|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:43.791395|2018-06-01 05:35:43.791395
NCT00001025|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|May 1995|Actual|1995-05-31|||||Interventional|||Evaluation of Patients Who Have Not Had Success With Zidovudine|A Study to Evaluate the Short-Term Clinical and Virologic Significance of Zidovudine Resistance|Completed||Phase 2|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:43.979203|2018-06-01 05:35:43.979203
NCT00001024|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|June 2002|Actual|2002-06-30|||||Interventional|||The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS|A Multicenter, Open-Label Study of Viral Burden in Peripheral Blood Versus Lymphoid Tissue Before and After Antiretroviral Therapy in HIV-Infected Individuals Without AIDS (NOTE: One Arm Receives no Treatment)|Completed||N/A|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.064739|2018-06-01 05:35:44.064739
NCT00001023|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-29|2001-08-30|2001-08-31|Estimate|||||||2012-10-29|2012-10-31|Estimate||||October 2012|2012-10-31|July 1998|Actual|1998-07-31|||||Interventional|||The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients|Evaluation of the Safety, Tolerance and Pharmacokinetics of Rifabutin/Clarithromycin Combination and Rifabutin/Azithromycin Combination in HIV-Infected Patients|Completed||N/A|91||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.231154|2018-06-01 05:35:44.231154
NCT00001022|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|December 1995|Actual|1995-12-31|||||Interventional|||A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients|A Randomized, Comparative Trial of Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus Dideoxycytidine (ddC) in HIV-Infected Patients|Completed||Phase 3|1200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.412|2018-06-01 05:35:44.412
NCT00001021|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 2002|2002-10-31||||||||Interventional|||A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)|A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)|Completed||Phase 1|57||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.519125|2018-06-01 05:35:44.519125
NCT00001020|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|February 1995|Actual|1995-02-28|||||Interventional|||A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)|A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)|Completed||Phase 1|28||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.595431|2018-06-01 05:35:44.595431
NCT00001019|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-29|2001-08-30|2001-08-31|Estimate|||||||2012-10-29|2012-10-30|Estimate||||October 2012|2012-10-31||||||||Interventional|||Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant|A Phase I Clinical Trial to Evaluate:Part A. The Safety and Immunogenicity of Two Dose Levels of SF-2 gp120 (CHO) With or Without MTP-PE Adjuvant in the MF59 Emulsion Part B. The Safety and Immunogenicity of Five Monthly Doses of 50 mcg gp120 Protein in MF59 Emulsion (Without MTP-PE) Versus the Emulsion Control|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.738769|2018-06-01 05:35:44.738769
NCT00001018|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1992|1992-10-31||||||||Interventional|||A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea|Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics and Dose Escalation, Efficacy, and Safety Study of Letrazuril for AIDS-Related Cryptosporidial Diarrhea|Completed||Phase 1|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.805308|2018-06-01 05:35:44.805308
NCT00001017|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||September 2002|2002-09-30||||July 1991|Actual|1991-07-31||Interventional|||Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS|Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome|Completed||Phase 3|330||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:44.911456|2018-06-01 05:35:44.911456
NCT00001016|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-26|2001-08-30|2001-08-31|Estimate|||||||2008-09-26|2008-09-30|Estimate||||July 1993|1993-07-31|August 2007|Actual|2007-08-31|||||Interventional|||A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies|A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies|Completed||Phase 3|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.051502|2018-06-01 05:35:45.051502
NCT00001015|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|June 1990|Actual|1990-06-30|||||Interventional|||A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems|A Multicenter Phase I Clinical Trial of Ribavirin in the Treatment of Patients With AIDS and Advanced AIDS Related Illnesses|Completed||Phase 1|96||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.134629|2018-06-01 05:35:45.134629
NCT00001014|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-19|Estimate||||March 2012|2012-03-31|September 1991|Actual|1991-09-30|||||Interventional|||Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS|Completed||Phase 3|302||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.205119|2018-06-01 05:35:45.205119
NCT00001013|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-19|Estimate||||March 2012|2012-03-31|September 1991|Actual|1991-09-30|||||Interventional|||Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS|A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS|Completed||Phase 3|364||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.360164|2018-06-01 05:35:45.360164
NCT00001012|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 2002|2002-09-30||||||||Interventional|||A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes|An Open Label, Multiple Dose Ranging Trial of AL721 in Patients With Persistent Generalized Lymphadenopathy and Symptomatic HIV Infection|Completed||Phase 1|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.469864|2018-06-01 05:35:45.469864
NCT00001011|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1995|Actual|1995-02-28|||||Interventional|||The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex|The Safety and Efficacy of Zidovudine in the Treatment of Patients With Early AIDS Related Complex|Completed||Phase 3|538||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.567809|2018-06-01 05:35:45.567809
NCT00001010|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|October 1990|Actual|1990-10-31|||||Interventional|||A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients|An Uncontrolled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Zidovudine (AZT) and Acyclovir (ACV) Given Concomitantly to Patients With Human Immunodeficiency Virus Infection|Completed||Phase 1|72||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.677757|2018-06-01 05:35:45.677757
NCT00001009|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|April 1990|Actual|1990-04-30|||||Interventional|||A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC)|A Phase I/II Dose Ranging Trial of Oral Dextran Sulfate (UA001) in HIV Infected Individuals and in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS Related Complex (ARC)|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.750193|2018-06-01 05:35:45.750193
NCT00001008|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||August 1991|1991-08-31||||March 1991|Actual|1991-03-31||Interventional|||A Study of Azidothymidine Plus Methadone in Patients With AIDS and AIDS Related Complex (ARC)|Pharmacokinetic Study of the Interaction of Azidothymidine and Methadone in Patients With AIDS and ARC|Completed||N/A|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.811992|2018-06-01 05:35:45.811992
NCT00001007|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-11|2001-08-30|2001-08-31|Estimate|||||||2008-07-11|2008-07-15|Estimate||||January 2003|2003-01-31||||||||Interventional|||A Study of Zidovudine in Infants Exposed to the HIV Before or Soon After Birth|A Multicenter Phase I Trial To Evaluate the Safety and Pharmacokinetics of Intravenous and Oral Zidovudine in Infants With Perinatal Human Immunodeficiency Virus (HIV) Exposure|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:45.949555|2018-06-01 05:35:45.949555
NCT00001006|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|March 1993|Actual|1993-03-31|||||Interventional|||A Study of AS-101 in Patients With AIDS or AIDS Related Complex (ARC)|A Phase One Study of AS-101 in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.027364|2018-06-01 05:35:46.027364
NCT00001005|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-25|2001-08-30|2001-08-31|Estimate|||||||2012-04-25|2012-04-26|Estimate||||April 2012|2012-04-30|February 1995|Actual|1995-02-28|||||Interventional|||A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes|Interleukin-2 Augmentation of Specific Anti-HIV Immune Responses: Phase I Trial of the Combination of 3'-Azido-3'-Deoxythymidine (Zidovudine) and Recombinant Interleukin-2 in Patients With Asymptomatic HIV Infection Associated With Lymphadenopathy (Walter Reed Stage II)|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.124183|2018-06-01 05:35:46.124183
NCT00001004|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|February 1990|Actual|1990-02-28|||||Interventional|||A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex|A Randomized Multicenter Phase II Trial of Recombinant Tumor Necrosis Factor and Recombinant Human Interferon-gamma in Patients With AIDS Related Complex|Completed||Phase 2|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.248815|2018-06-01 05:35:46.248815
NCT00000881|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29||||||||Interventional|||A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease|A Phase I/II Study of Cidofovir for HIV-Infected Children With Invasive CMV (Cytomegalovirus) Disease|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:02.106918|2018-06-01 05:36:02.106918
NCT00001003|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|January 1992|Actual|1992-01-31|||||Interventional|||A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia|Aerosols in the Treatment of Pneumocystis Carinii Pneumonia: A Nested Study Quantitating the Delivery of Aerosolized Pentamidine for Prophylaxis of PCP in Protocols ACTG 021 and ACTG 081|Completed||N/A|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.335476|2018-06-01 05:35:46.335476
NCT00001002|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|June 1991|Actual|1991-06-30|||||Interventional|||A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time|Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.427437|2018-06-01 05:35:46.427437
NCT00001001|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|May 1990|Actual|1990-05-31|||||Interventional|||A Study of Zidovudine in HIV-Infected Patients With Liver Disease|A Clinical Study Examining the Pharmacokinetics and Bioavailability of Azidothymidine (AZT, Zidovudine) in Patients With Human Immunodeficiency Virus (HIV) Infection and Hepatic Disease|Completed||N/A|39||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.512625|2018-06-01 05:35:46.512625
NCT00001000|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-18|2001-08-30|2001-08-31|Estimate|||||||2012-10-18|2012-10-19|Estimate||||October 2012|2012-10-31|January 1990|Actual|1990-01-31|||||Interventional|||A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection|Immunologic Effect After Single Dose Atvogen in Healthy Volunteers and Asymptomatic HIV-Infected Patients|Completed||N/A|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.599134|2018-06-01 05:35:46.599134
NCT00000999|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|March 1989|Actual|1989-03-31|||||Interventional|||The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC|A Multicenter Uncontrolled Trial To Evaluate the Long Term Safety and Tolerance of Zidovudine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS and Advanced ARC|Completed||Phase 1|500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.685933|2018-06-01 05:35:46.685933
NCT00000998|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-12-17|2001-08-30|2001-08-31|Estimate|||||||2012-12-17|2012-12-18|Estimate||||December 2012|2012-12-31|April 1989|Actual|1989-04-30|||||Interventional|||A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP|Evaluation of Escalating Doses of Intravenous Trimetrexate as Therapy for Previously Untreated Pneumocystis Carinii Pneumonia in AIDS Patients With Subsequent Comparison of Intravenous and Oral Pharmacokinetics|Completed||Phase 1|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.781606|2018-06-01 05:35:46.781606
NCT00000997|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|December 1988|Actual|1988-12-31|||||Interventional|||A Study of Dideoxycytidine in HIV-Infected Patients|Pharmacokinetics and Bioavailability of Dideoxycytidine in Patients With Human Immunodeficiency Virus Infection|Completed||N/A|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.847565|2018-06-01 05:35:46.847565
NCT00000996|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|June 1990|Actual|1990-06-30|||||Interventional|||A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma|Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma|Completed||Phase 2|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.916807|2018-06-01 05:35:46.916807
NCT00000995|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-15|2001-08-30|2001-08-31|Estimate|||||||2012-02-15|2012-02-17|Estimate||||February 2012|2012-02-29|February 1990|Actual|1990-02-28|||||Interventional|||A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection|Phase I Studies of the Combination of AZT and DHPG (Ganciclovir) in Patients With AIDS and Cytomegalovirus Infection|Completed||N/A|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:46.995087|2018-06-01 05:35:46.995087
NCT00000994|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-15|2001-08-30|2001-08-31|Estimate|||||||2012-02-15|2012-02-17|Estimate||||February 2012|2012-02-29|May 1990|Actual|1990-05-31|||||Interventional|||A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma|A Placebo-Controlled Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS-Associated Kaposi's Sarcoma|Completed||Phase 3|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.114352|2018-06-01 05:35:47.114352
NCT00000993|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-11-04|2001-08-30|2001-08-31|Estimate|||||||2016-11-04|2016-11-07|Estimate||||April 1991|1991-04-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus|An Open Protocol for the Use of Zidovudine for Prophylactic Treatment of Individuals After Accidental Massive Exposure to the Human Immunodeficiency Virus (HIV)|Completed||N/A|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.202685|2018-06-01 05:35:47.202685
NCT00000992|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-05-15|2001-08-30|2001-08-31|Estimate|||||||2015-05-15|2015-05-18|Estimate||||March 2012|2012-03-31|June 1992|Actual|1992-06-30|||||Interventional|||A Study of Itraconazole in Preventing the Return of Histoplasmosis, a Fungal Infection, in Patients With AIDS|Pilot Study to Determine the Feasibility of Itraconazole for Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.260924|2018-06-01 05:35:47.260924
NCT00000991|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|April 1994|Actual|1994-04-30|||||Interventional|||A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients|A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection|Completed||Phase 3|600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.336378|2018-06-01 05:35:47.336378
NCT00000990|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|September 1992|Actual|1992-09-30|||||Interventional|||The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms|A Multicenter Placebo-Controlled Trial To Evaluate the Safety and Efficacy of Oral Zidovudine in the Treatment of Children Infected With Human Immunodeficiency Virus With Mild to Moderate Symptoms (Including LIP)|Completed||Phase 2|224||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.438295|2018-06-01 05:35:47.438295
NCT00000989|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|July 1992|Actual|1992-07-31|||||Interventional|||The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS|A Controlled, Randomized Phase II Study of the Safety and Efficacy of Combined Therapy With Ganciclovir and Granulocyte-Macrophage Colony Stimulating Factor Versus Ganciclovir Alone for the Treatment of Sight-Threatening Cytomegalovirus Retinitis in AIDS Patients|Completed||N/A|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.519817|2018-06-01 05:35:47.519817
NCT00000988|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-25|2001-08-30|2001-08-31|Estimate|||||||2008-08-25|2008-08-26|Estimate||||December 1994|1994-12-31||||||||Interventional|||A Study of BMY-27857 in Patients With AIDS or AIDS Related Complex|A Phase I Safety and Pharmacokinetics Study of BMY-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily to Patients With AIDS or AIDS Related Complex|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.577363|2018-06-01 05:35:47.577363
NCT00000987|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|April 1992|Actual|1992-04-30|||||Interventional|||A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS|A Phase I Study of Combination Chemotherapy (Adriamycin, Bleomycin, and Vincristine) and Azidothymidine in the Treatment of AIDS Related Kaposi's Sarcoma|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.643699|2018-06-01 05:35:47.643699
NCT00000986|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-25|2001-08-30|2001-08-31|Estimate|||||||2012-04-25|2012-04-27|Estimate||||April 2012|2012-04-30|January 1994|Actual|1994-01-31|||||Interventional|||The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex|A Safety, Tolerance, and Immunological Study of a Combination of Recombinant Interleukin 2 and Zidovudine in Patients With AIDS or AIDS Related Complex|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.700314|2018-06-01 05:35:47.700314
NCT00000985|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|October 1990|Actual|1990-10-31|||||Interventional|||Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir|Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine|Completed||Phase 3|26||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.846914|2018-06-01 05:35:47.846914
NCT00000984|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1996|1996-10-31||||||||Interventional|||A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:47.920714|2018-06-01 05:35:47.920714
NCT00000983|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|December 1994|Actual|1994-12-31|||||Interventional|||The Safety of Different Dose Levels of Zidovudine in HIV-Infected Children|A Randomized Blinded Trial To Evaluate the Safety and Tolerance of High Versus Low Dose Zidovudine Administered to Children With Human Immunodeficiency Virus|Completed||Phase 2|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.016289|2018-06-01 05:35:48.016289
NCT00000982|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||October 1996|1996-10-31||||September 1996|Actual|1996-09-30||Interventional|||A Study of Azidothymidine in HIV-Infected Children|A Randomized Trial To Evaluate the Impact of Maintaining Steady-State Concentrations of Azidothymidine (AZT) Versus an Intermittent Schedule of AZT Delivery in Children With Symptomatic HIV Infection|Completed||Phase 2|75||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.161042|2018-06-01 05:35:48.161042
NCT00000981|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-12-17|2001-08-30|2001-08-31|Estimate|||||||2012-12-17|2012-12-18|Estimate||||December 2012|2012-12-31|February 1993|Actual|1993-02-28|||||Interventional|||The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS|Efficacy and Safety of Oral FIAC in AIDS Patients With Cytomegalovirus Infection: A Dose Ranging Study|Completed||Phase 2|78||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.252945|2018-06-01 05:35:48.252945
NCT00000980|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1990|1990-10-31||||||||Interventional|||A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea|Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea|Completed||Phase 1|25||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.346898|2018-06-01 05:35:48.346898
NCT00000979|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||January 2003|2003-01-31||||October 1992|Actual|1992-10-31||Interventional|||Comparison of ddI Versus Zidovudine in HIV-Infected Patients|Comparison of 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine in Therapy of Patients With HIV Infection|Completed||Phase 2|1500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.453094|2018-06-01 05:35:48.453094
NCT00000978|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-06|2001-08-30|2001-08-31|Estimate|||||||2008-08-06|2008-08-08|Estimate||||August 1992|1992-08-31||||||||Interventional|||A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)|An Open-Label, Randomized, Dose-Finding, Multicenter Trial of Dideoxycytidine (ddC) Administered Concurrently With Zidovudine (AZT) in the Treatment of AIDS or Advanced ARC|Completed||Phase 1|68||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.612395|2018-06-01 05:35:48.612395
NCT00000977|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|May 1993|Actual|1993-05-31|||||Interventional|||Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity|Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity|Completed||Phase 1|52||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.696153|2018-06-01 05:35:48.696153
NCT00000921|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-22|2001-08-30|2001-08-31|Estimate|||||||2011-02-22|2011-02-23|Estimate|August 1996||1996-08-31|June 2003|2003-06-30||||June 2002|Actual|2002-06-30||Interventional|||The Effects of Prednisone on HIV Levels and the Immune System|A Phase II, Randomized, Placebo-Controlled Study of the Immunologic and Virologic Effects of Prednisone on HIV-1 Infection|Completed||Phase 2|118||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:57.254766|2018-06-01 05:35:57.254766
NCT00000976|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-05|2001-08-30|2001-08-31|Estimate|||||||2008-08-05|2008-08-06|Estimate||||December 1994|1994-12-31||||||||Interventional|||A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex|A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.758015|2018-06-01 05:35:48.758015
NCT00000975|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1994|Actual|1994-09-30|||||Interventional|||A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS|Pilot Study To Determine the Feasibility of Itraconazole for Primary Treatment and Suppression of Relapse of Disseminated Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome|Completed||Phase 2|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.823712|2018-06-01 05:35:48.823712
NCT00000974|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia|A Phase I Study of the Safety, Tolerance, and Study of the Pharmacokinetics of Aerosolized Pentamidine and Parenteral Pentamidine in Children With HIV Infection and Suspected Pneumocystis Carinii Pneumonia|Completed||Phase 1|16||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.899776|2018-06-01 05:35:48.899776
NCT00000973|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|March 1995|Actual|1995-03-31|||||Interventional|||A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients|Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii|Completed||Phase 1|26||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:48.989295|2018-06-01 05:35:48.989295
NCT00000972|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-27|2001-08-30|2001-08-31|Estimate|||||||2012-04-27|2012-04-30|Estimate||||April 2012|2012-04-30|April 1992|Actual|1992-04-30|||||Interventional|||A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59|A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59|Completed||Phase 1|64|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.068938|2018-06-01 05:35:49.068938
NCT00000971|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-31|2001-08-30|2001-08-31|Estimate|||||||2008-07-31|2008-08-04|Estimate||||October 1996|1996-10-31||||||||Interventional|||The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS|A Phase I/II Dose-Ranging, Pharmacokinetic, Drug Interaction, Safety and Preliminary Efficacy Study of Oral Clarithromycin Granules for Suspension, in Combination With Zidovudine or Dideoxyinosine, in the Treatment of Disseminated Mycobacterium Avium Complex Infections in Pediatric Patients With AIDS|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.137067|2018-06-01 05:35:49.137067
NCT00000970|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|June 1993|Actual|1993-06-30|||||Interventional|||A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir|A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.197705|2018-06-01 05:35:49.197705
NCT00000969|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|September 1992|Actual|1992-09-30|||||Interventional|||A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy|A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy|Completed||N/A|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.274821|2018-06-01 05:35:49.274821
NCT00000968|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|August 1993|Actual|1993-08-31|||||Interventional|||A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)|Completed||Phase 1|60|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.349519|2018-06-01 05:35:49.349519
NCT00000967|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children|Safety and Tolerance of Zidovudine and Interferon-Alpha in HIV-Infected Children|Completed||Phase 1|52||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.413472|2018-06-01 05:35:49.413472
NCT00000966|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-25|2001-08-30|2001-08-31|Estimate|||||||2008-08-25|2008-08-26|Estimate||||October 1994|1994-10-31||||||||Interventional|||A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS|A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS|Completed||Phase 1|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.479107|2018-06-01 05:35:49.479107
NCT00000965|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-25|2001-08-30|2001-08-31|Estimate|||||||2011-02-25|2011-03-01|Estimate||||February 2011|2011-02-28||||August 1993|Actual|1993-08-31||Interventional|||The Effects of Zidovudine on the Blood of HIV-Infected Patients|Pharmacokinetics of Total Phosphorylated Zidovudine in Mononuclear Cells From HIV-Infected Patients|Completed||N/A|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.542583|2018-06-01 05:35:49.542583
NCT00000964|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|October 1990|Actual|1990-10-31|||||Interventional|||The Effect of Stomach Acid on Foscarnet|The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet)|Completed||Phase 1|6||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.610285|2018-06-01 05:35:49.610285
NCT00000963|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1995|Actual|1995-09-30|||||Interventional|||A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine|A Randomized Comparative Trial of Two Doses of 2',3'-Dideoxyinosine (ddI) in Children With Symptomatic HIV Infection Who Are Either Unresponsive to Zidovudine and/or Who Are Intolerant to Zidovudine|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.672826|2018-06-01 05:35:49.672826
NCT00000962|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-01|2001-08-30|2001-08-31|Estimate|||||||2008-08-01|2008-08-04|Estimate||||December 1994|1994-12-31||||||||Interventional|||The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients|An Open Label, Staggered Rising Dose Cohort Study Assessing Safety, Tolerance, and Activity of BI-RG-587 in Patients With HIV Infection (CD4+ Cell Count < 400 Cells/mm3)|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.776373|2018-06-01 05:35:49.776373
NCT00000961|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||March 1998|1998-03-31||||May 1991|Actual|1991-05-31||Interventional|||The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants|A Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HIVIG) and of Zidovudine (ZDV) in Infants With Documented HIV Infections|Terminated||Phase 2|112||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:49.942257|2018-06-01 05:35:49.942257
NCT00000960|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-05-15|2001-08-30|2001-08-31|Estimate|||||||2015-05-15|2015-05-18|Estimate||||March 2012|2012-03-31|June 1994|Actual|1994-06-30|||||Interventional|||The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants|A Phase III Randomized Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerance of Oral Zidovudine (AZT) in Pregnant HIV Infected Women and Their Infants|Completed||Phase 3|1496||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:50.031926|2018-06-01 05:35:50.031926
NCT00000959|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|June 1996|Actual|1996-06-30|||||Interventional|||Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection|Completed||N/A|600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:50.240138|2018-06-01 05:35:50.240138
NCT00000958|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|September 1995|Actual|1995-09-30|||||Interventional|||A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)|A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)|Completed||Phase 1|8||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:50.343409|2018-06-01 05:35:50.343409
NCT00000957|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|August 1993|Actual|1993-08-31|||||Interventional|||A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:50.421666|2018-06-01 05:35:50.421666
NCT00000956|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|March 1993|Actual|1993-03-31|||||Interventional|||A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|Completed||Phase 1|25||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:50.505281|2018-06-01 05:35:50.505281
NCT00000955|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|December 1992|Actual|1992-12-31|December 1992|Actual|1992-12-31||Interventional|||Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection|Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection|Completed||N/A|864|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:35:50.579983|2018-06-01 05:35:50.579983
NCT00000954|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma|Phase I/II Study of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) and Dideoxyinosine (ddI) or Dideoxycytidine (ddC) in the Treatment of AIDS-Related Kaposi's Sarcoma|Completed||Phase 1|72||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:50.719292|2018-06-01 05:35:50.719292
NCT00000953|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-25|2001-08-30|2001-08-31|Estimate|||||||2011-02-25|2011-03-01|Estimate||||February 2011|2011-02-28||||September 1996|Actual|1996-09-30||Interventional|||Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients|Evaluation of Brovavir ( BV-ara-U; SQ 32,756 ) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV-Infected Patients|Completed||Phase 2|180||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:50.847639|2018-06-01 05:35:50.847639
NCT00000952|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-10-28|2001-08-30|2001-08-31|Estimate|||||||2014-10-28|2014-10-29|Estimate||||October 2014|2014-10-31|January 2004|Actual|2004-01-31|||||Interventional|||A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children|A Phase I/II Study of Ritonavir Therapy in HIV-1 Infected Infants and Children|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.052152|2018-06-01 05:35:51.052152
NCT00000951|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|May 2002|Actual|2002-05-31|||||Interventional|||A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush|A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis|Completed||Phase 4|948||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.156998|2018-06-01 05:35:51.156998
NCT00000949|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|July 2000|Actual|2000-07-31|||||Interventional|||A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3|A Randomized, Open-Label, Study of the Impact of Two Doses of Subcutaneous Recombinant IL-2 (Proleukin) on Viral Burden and CD4+ Cell Count in Patients With HIV-1 Infection and CD4+ Cell Counts Greater Than or Equal to 300/mm3|Completed||Phase 3|460||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.34141|2018-06-01 05:35:51.34141
NCT00000948|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-02-01|2001-08-30|2001-08-31|Estimate|||||||2013-02-01|2013-02-04|Estimate|February 1998||1998-02-28|February 2013|2013-02-28||||March 2000|Actual|2000-03-31||Interventional|||Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3|A Randomized, Open Label Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3|Completed||Phase 2|72||National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:35:51.455682|2018-06-01 05:35:51.455682
NCT00000947|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|July 2000|Actual|2000-07-31|||||Interventional|||A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients|A Randomized, Double-Blind, Placebo-Controlled Trial of Prophylaxis for Disseminated Mycobacterium Avium Complex Disease and Bacterial Pneumonia Versus Deferred Prophylaxis in HIV-Infected Patients Who Experience Rebound in CD4+ Cell Count Due to Active Antiretroviral Therapy|Completed||N/A|850||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.535239|2018-06-01 05:35:51.535239
NCT00000946|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|March 2001|Actual|2001-03-31|||||Interventional|||A Study to Test the Safety of Three Experimental HIV Vaccines|"A Phase I Trial to Evaluate the HIV-1 SF-2 Recombinant p24 Subunit Vaccine [Chiron Vaccines] Administered as a Novel Boost in Prime-Boost Vaccination Regimens With ALVAC-HIV vCP205 [Pasteur Merieux Connaught] and HIV-1 SF-2 rgp120 in MF59 [Chiron Vaccines]"|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.627451|2018-06-01 05:35:51.627451
NCT00000945|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|March 2001|Actual|2001-03-31|||||Interventional|||A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients|A Pilot Study of the Effect of Cidofovir for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Subjects With Acquired Immunodeficiency Syndrome (AIDS)|Completed||N/A|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.697954|2018-06-01 05:35:51.697954
NCT00000944|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|March 2003|Actual|2003-03-31|||||Interventional|||A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants|A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Indinavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women During Gestation and Post Partum, and in Their Infants Post Maternal Dosing|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:35:51.793388|2018-06-01 05:35:51.793388
NCT00000943|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|November 2005|Actual|2005-11-30|||||Interventional|||A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328|A Controlled, Pilot Study of the Immunogenicity of Remune in HIV-Infected Subjects Receiving Either Highly Active Antiretroviral Therapy (HAART) Alone or HAART and Interleukin-2 (IL-2): A Nested Substudy of ACTG 328|Completed||N/A|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:51.856673|2018-06-01 05:35:51.856673
NCT00000942|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|May 2001|Actual|2001-05-31|||||Interventional|||A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Babies|A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women|Completed||Phase 3|1244||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:52.82344|2018-06-01 05:35:52.82344
NCT00000941|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|March 2002|Actual|2002-03-31|||||Interventional|||A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood|Evaluation of Potential Pharmacokinetic Interactions Between Protease Inhibitors and Lipid Lowering Agents|Completed||Phase 1|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:52.909508|2018-06-01 05:35:52.909508
NCT00000940|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-01-05|2001-08-30|2001-08-31|Estimate|||||||2016-01-05|2016-01-07|Estimate|May 1999||1999-05-31|January 2016|2016-01-31|October 2006|Actual|2006-10-31|||||Interventional|||Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV|A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion|Completed||Phase 2|121|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:35:53.180001|2018-06-01 05:35:53.180001
NCT00000939|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|January 2000|Actual|2000-01-31|||||Interventional|||A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible|Phase II Randomized, Open-Label Study of Maintenance of HIV RNA Suppression After Switching to ddI/d4T/HU vs. ddI/d4T/EFV vs. Continuing the Pre-Entry Protease Inhibitor Regimen|Completed||Phase 2|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:53.43175|2018-06-01 05:35:53.43175
NCT00000938|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-08-26|2001-08-30|2001-08-31|Estimate|||||||2010-08-26|2010-08-27|Estimate||||November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease|Completed||Phase 3|66||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:53.625643|2018-06-01 05:35:53.625643
NCT00000936|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2017-01-10|2001-08-30|2001-08-31|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 1999||1999-11-30|January 2017|2017-01-31|March 2004|Actual|2004-03-31|||||Interventional|||A Study To Test An Anti-Rejection Therapy After Kidney Transplantation|Controlled Trial of Induction Therapy in Renal Transplantation|Terminated||Phase 3|292|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:35:54.411619|2018-06-01 05:35:54.411619
NCT00000935|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2017-01-10|2001-08-30|2001-08-31|Estimate|||||||2017-01-10|2017-01-11|Estimate||||January 2017|2017-01-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens|Evaluation of Intravenous Gamma Globulin (IVIG) As an Agent to Lower Allosensitization and Improve Allograft Survival in Highly-Sensitized Adult End-Stage Renal Disease (ESRD) Patients (IG02)|Completed||Phase 3|100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-06-01 05:35:54.740663|2018-06-01 05:35:54.740663
NCT00000933|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|July 2000|Actual|2000-07-31|||||Observational|||Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048|Effects of Prophylaxis for Disseminated Mycobacterium Avium Complex (MAC) Disease With Azithromycin Versus Deferred Prophylaxis on Carriage of Antibiotic-Resistant Streptococcus Pneumoniae: A Substudy of the CR-MAC Protocol (CPCRA 048)|Completed|||326||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:55.050281|2018-06-01 05:35:55.050281
NCT00000932|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-04-14|2001-08-30|2001-08-31|Estimate|||||||2014-04-14|2014-04-15|Estimate|March 1999||1999-03-31|April 2014|2014-04-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Observational|||A Study of the Long-Term Outcomes of HIV-Positive Patients|A Prospective Study of Long-Term Clinical, Virologic, and Immunologic Outcomes in HIV-Infected Individuals|Completed|||3669|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||||||||||||2018-06-01 05:35:55.341538|2018-06-01 05:35:55.341538
NCT00000931|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-08|2001-08-30|2001-08-31|Estimate|||||||2008-09-08|2008-09-09|Estimate||||November 2006|2006-11-30||||||||Interventional|||HIV Prevention Counseling for Men Who Have Sex With Men|A Randomized Clinical Trial of the Efficacy of a Behavioral Intervention to Prevent Acquisition of HIV Among Men Who Have Sex With Men|Completed||Phase 3|4350||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:55.792254|2018-06-01 05:35:55.792254
NCT00000930|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-11-04|2001-08-30|2001-08-31|Estimate|||||||2016-11-04|2016-11-07|Estimate||||October 2012|2012-10-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||A Study of HIV in Newly Infected Individuals|Infected Participants Protocol: Evaluation of Natural History of HIV Infection in Newly HIV-Infected Persons in HIVNET Target Populations|Completed|||||National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Specimens appropriate for clinical and laboratory assessments and necessary for evaluation of~     study outcome measures~   "|||2018-06-01 05:35:55.873568|2018-06-01 05:35:55.873568
NCT00000929|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|July 1999|Actual|1999-07-31|||||Interventional|||A Study of the Effects of Advantage 24 on the Rectum|Phase I Rectal Microbicide Study|Completed||Phase 1|70||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||||||2018-06-01 05:35:55.996238|2018-06-01 05:35:55.996238
NCT00000928|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-11-04|2001-08-30|2001-08-31|Estimate|||||||2016-11-04|2016-11-07|Estimate||||October 2012|2012-10-31|July 1999|Actual|1999-07-31|July 1999|Actual|1999-07-31||Interventional|||Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples|Phase I Trial of an Intervention to Increase Condom Use by HIV-Discordant Couples|Completed||Phase 1|90|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:35:56.175166|2018-06-01 05:35:56.175166
NCT00000927|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-01-08|2001-08-30|2001-08-31|Estimate|||||||2007-01-08|2007-01-09|Estimate||||March 1999|1999-03-31||||||||Interventional|||A Study of BufferGel in Women|Phase I Vaginal Microbicide Study of BufferGel|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:56.245783|2018-06-01 05:35:56.245783
NCT00000926|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|February 2001|Actual|2001-02-28|||||Interventional|||A Study of Nonoxynol-9 (N-9) and HIV Infection|Phase III Nonoxynol-9 and HIV Infection|Completed||Phase 3|4400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:56.394973|2018-06-01 05:35:56.394973
NCT00000925|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate|May 1999||1999-05-31|July 2013|2013-07-31||||June 2003|Actual|2003-06-30||Interventional|||A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss|Evaluation of High Protein Supplementation in HIV-1-Positive Subjects With Stable Weight Loss|Completed||Phase 2|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:56.553781|2018-06-01 05:35:56.553781
NCT00000924|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|June 2001|Actual|2001-06-30|||||Interventional|||A Study to Compare Two Different Anti-HIV Drug Regimens|A Phase II Randomized, Multicenter Protocol Evaluating Two Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs, and an NNRTI|Completed||Phase 2|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:56.685937|2018-06-01 05:35:56.685937
NCT00000923|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|August 2004|Actual|2004-08-31|||||Interventional|||Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328|Treatment Rollover for Subjects Formerly on ACTG 328 With Subcutaneous Interleukin-2 (IL-2) in Combination With Highly Active Antiretroviral Therapy (HAART)|Completed||N/A|110||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:56.907327|2018-06-01 05:35:56.907327
NCT00000922|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-04-16|2001-08-30|2001-08-31|Estimate|||||||2014-04-16|2014-04-17|Estimate||||April 2014|2014-04-30|June 2006|Actual|2006-06-30|January 2003|Actual|2003-01-31||Interventional|||A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)|A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons|Completed||N/A|1710||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:57.15253|2018-06-01 05:35:57.15253
NCT00000920|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|April 2003|Actual|2003-04-30|||||Interventional|||Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns|A Phase I Trial of the Safety and Pharmacokinetics of Fortovase (Saquinavir-SGC) Co-Administered With Low Dose (Ritonavir) RTV, ZDV and 3TC in HIV Seropositive Pregnant Women During Gestation and Postpartum, and in Their Infant's Post-Maternal Dosing|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:35:57.383491|2018-06-01 05:35:57.383491
NCT00000919|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-06-05|2001-08-30|2001-08-31|Estimate|||||||2012-06-05|2012-06-07|Estimate||||June 2012|2012-06-30|November 2002|Actual|2002-11-30|||||Interventional|||A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection|Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor With Dual Nucleosides in Initial Therapy of HIV Infection|Completed||N/A|900||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:57.484383|2018-06-01 05:35:57.484383
NCT00000918|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|February 2002|Actual|2002-02-28|||||Interventional|||A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure|A Phase II, Randomized, Open-Label Comparative Trial of Salvage Antiretroviral Therapies for HIV-Infected Individuals With Virological Evidence of Nelfinavir Treatment Failure as Reflected by Plasma HIV RNA Concentration of >= 1,000 Copies/ml|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:57.664004|2018-06-01 05:35:57.664004
NCT00000917|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-30|2001-08-30|2001-08-31|Estimate|||||||2008-07-30|2008-08-01|Estimate|September 1997||1997-09-30|June 2003|2003-06-30||||||||Observational|||Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants|Establishment of a Cord Blood Bank for Gene Therapy in HIV-Infected Infants|Terminated|||200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:57.976003|2018-06-01 05:35:57.976003
NCT00000916|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|August 2004|Actual|2004-08-31|||||Interventional|||A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood|A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma|Completed||Phase 2|399||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.075616|2018-06-01 05:35:58.075616
NCT00000915|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1999|1999-03-31||||||||Interventional|||An HIV Vaccine Preparedness Study|HIV Vaccine Preparedness Study|Completed||N/A|4892||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.220746|2018-06-01 05:35:58.220746
NCT00000914|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-26|2001-08-30|2001-08-31|Estimate|||||||2012-03-26|2012-03-27|Estimate||||March 2012|2012-03-31|June 2000|Actual|2000-06-30|||||Interventional|||A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks|A Randomized Study of the Virologic Efficacy of Different Antiretroviral (AR) Treatment Strategies in HIV-Infected Individuals With Detectable Plasma HIV RNA Measurements After at Least 16 Weeks on Their Initial Protease Inhibitor-Containing AR Regimens|Completed||N/A|800||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.30147|2018-06-01 05:35:58.30147
NCT00000913|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-26|2001-08-30|2001-08-31|Estimate|||||||2012-03-26|2012-03-27|Estimate||||March 2012|2012-03-31|April 2001|Actual|2001-04-30|||||Interventional|||A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children|A Randomized Trial of Two Saquinavir-Containing Combination Treatment Regimens in Children With HIV Infection|Completed||Phase 2|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.418115|2018-06-01 05:35:58.418115
NCT00000912|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-06-02|2001-08-30|2001-08-31|Estimate|||||||2015-06-02|2015-06-03|Estimate||||July 2013|2013-07-31|May 2000|Actual|2000-05-31|||||Interventional|||A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients|A Phase II, Randomized Trial of Amprenavir as Part of Dual Protease Inhibitor Regimens (Placebo-Controlled) in Combination With Abacavir, Efavirenz, and Adefovir Dipivoxil Versus Amprenavir Alone in HIV-Infected Subjects With Prior Exposure to Approved Protease Inhibitors and Loss of Virologic Suppression as Reflected by a Plasma HIV-1 RNA Concentration >= 1,000 Copies/ml|Completed||Phase 2|475||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.562872|2018-06-01 05:35:58.562872
NCT00000911|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-10-21|2001-08-30|2001-08-31|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 1999||1999-10-31|October 2015|2015-10-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||A Study to Monitor Patients With Primary or Early HIV Infection|An Observational Study of Subjects With Primary HIV Infection: A Study of the UCSD Acute/Early HIV Infection (AEHIV) Clinical Studies Unit|Completed|||1500|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||Samples With DNA|"~     Blood, lymph node tissue, CSF, and semen or vaginal secretion specimens~   "|||2018-06-01 05:35:58.728727|2018-06-01 05:35:58.728727
NCT00000910|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-10-04|2001-08-30|2001-08-31|Estimate|||||||2013-10-04|2013-10-07|Estimate||||October 2013|2013-10-31|June 2004|Actual|2004-06-30|||||Observational|||A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies|Medical Chart Abstraction of HIV-Infected Pregnant Women and Their Infants Receiving Care or Consultation at Study Sites|Completed|||2000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.78663|2018-06-01 05:35:58.78663
NCT00000909|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|June 2004|Actual|2004-06-30|||||Interventional|||A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy|A Randomized, Open Label Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Alone vs No Therapy in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3 Who Do Not Wish to Receive Treatment With Antiretroviral Therapy|Completed||Phase 2|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.842717|2018-06-01 05:35:58.842717
NCT00000908|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2003|2003-02-28||||||||Observational|||A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts|Impact of Discontinuing PCP Prophylaxis in Subjects Receiving Antiretroviral Therapies Who Have Had Increases in CD4 Counts to > 200 Cells/mm3|Completed|||250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:58.915532|2018-06-01 05:35:58.915532
NCT00000907|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||June 2003|2003-06-30||||||||Observational|||A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients|A Study of Discontinuing Maintenance Therapy in Subjects With Disseminated Mycobacterium Avium Complex (DMAC)|Completed|||50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:59.145412|2018-06-01 05:35:59.145412
NCT00000906|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|September 2000|Actual|2000-09-30|||||Interventional|||Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients|The Effect of HIV Protease Inhibitors on the Stereospecific Metabolism of Methadone in HIV-Infected Subjects|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:59.228099|2018-06-01 05:35:59.228099
NCT00000905|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-28|2001-08-30|2001-08-31|Estimate|||||||2008-07-28|2008-07-30|Estimate||||June 2003|2003-06-30||||||||Observational|||A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy|Discontinuation of Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Immune Reconstitution by Potent Antiretroviral Therapy: Safety, Virology, and Immunology Profiles|Completed|||75||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:59.288805|2018-06-01 05:35:59.288805
NCT00000904|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|August 1999|Actual|1999-08-31|||||Interventional|||Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults|A Phase I Trial to Compare the Safety and Immunogenicity of the Live Recombinant Canarypox ALVAC-HIV Vaccines, vCP205, vCP1433, and vCP1452, in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:59.463195|2018-06-01 05:35:59.463195
NCT00000903|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|July 2001|Actual|2001-07-31|||||Interventional|||Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen|A Phase III Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination With Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects With Less Than or Equal to 200 CD4 Cells/mm3 or Greater Than or Equal to 80,000 HIV RNA Copies/ml in Plasma|Completed||Phase 3|444||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:59.572987|2018-06-01 05:35:59.572987
NCT00000902|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-09-30|2001-08-30|2001-08-31|Estimate|||||||2014-09-30|2014-10-01|Estimate||||October 2012|2012-10-31|April 2002|Actual|2002-04-30|||||Interventional|||A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment|RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience|Completed||Phase 1|217||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:35:59.821593|2018-06-01 05:35:59.821593
NCT00000901|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|October 2000|Actual|2000-10-31|||||Interventional|||Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children|A Multicenter, Open-Labeled, 96-Week Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Indinavir in Combination With Stavudine and Lamivudine in Pediatric Patients With HIV-1 Infection|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.015742|2018-06-01 05:36:00.015742
NCT00000900|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1999|1999-04-30||||||||Observational|||The Effects of Illnesses on HIV Levels in the Body|The Impact of Intercurrent Illness on HIV Viral Load|Completed|||26||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.121221|2018-06-01 05:36:00.121221
NCT00000899|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|October 2001|Actual|2001-10-31|||||Interventional|||A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients|Effect of Cytoreductive Chemotherapy Combined With Highly Active Antiretroviral Therapy on Lymph Node HIV DNA in HIV-Infected Subjects|Completed||Phase 1|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.204685|2018-06-01 05:36:00.204685
NCT00000898|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|May 2000|Actual|2000-05-31|||||Interventional|||The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir|A Prototype Study to Test the Effect of Staggered Dosing on the Pharmacokinetic Interactions Between Paired Combinations of Nelfinavir (NFV), Ritonavir (RTV), and Soft Gelatin Capsule of Saquinavir (SQVsgc)|Completed||N/A|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.29888|2018-06-01 05:36:00.29888
NCT00000897|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-01|2001-08-30|2001-08-31|Estimate|||||||2011-03-01|2011-03-02|Estimate||||March 2011|2011-03-31||||October 2005|Actual|2005-10-31||Interventional|||A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women|The Effect of Oral and Injectable Contraceptives (Norethindrone/Ethinyl Estradiol, Medroxyprogesterone Acetate) and Gender on Plasma and Intracellular Zidovudine Pharmacokinetics|Completed||N/A|42||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.372827|2018-06-01 05:36:00.372827
NCT00000896|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|October 2000|Actual|2000-10-31|||||Interventional|||A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients|A Randomized Controlled Trial to Compare the Efficacy of a Four Drug Antiretroviral Regimen Alone or in Combination With GM-CSF or IL-12 Administered to HIV-1 Infected Subjects as Measured by the Characteristics of Viral Decay|Completed||N/A|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.442162|2018-06-01 05:36:00.442162
NCT00000895|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-16|2001-08-30|2001-08-31|Estimate|||||||2012-02-16|2012-02-17|Estimate||||February 2012|2012-02-29|August 2001|Actual|2001-08-31|||||Interventional|||A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection|Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections|Completed||N/A|85||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.524014|2018-06-01 05:36:00.524014
NCT00023049|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-21|||2018-05-18|2001-08-21|2001-08-22|Estimate|||||||2018-05-18|2018-05-21|Actual|August 20, 2001||2001-08-20|May 11, 2018|2018-05-11||||||||Observational|||Genetic Analysis of Hereditary Disorders of Hearing and Balance|Genetic Analysis of Hereditary Disorders of Hearing and Balance|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:34.724208|2018-06-01 05:36:34.724208
NCT00000893|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-06-02|2001-08-30|2001-08-31|Estimate|||||||2015-06-02|2015-06-04|Estimate|October 1997||1997-10-31|June 2015|2015-06-30|December 2002|Actual|2002-12-31|||||Interventional|||Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children|A Phase I/II, Open-Label, AUC-Controlled Study to Determine the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in Children|Completed||Phase 1|103|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:36:00.755428|2018-06-01 05:36:00.755428
NCT00000892|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|August 1999|Actual|1999-08-31|||||Interventional|||A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir|Activity of the Soft Gelatin Capsule of Saquinavir (SQVsgc) in Combination With Ritonavir or Nelfinavir and Combinations of Delavirdine and/or Adefovir Dipivoxil in HIV-Infected Subjects With Prior Indinavir Use and Viral Loads From 2,000 to 200,000 Copies HIV RNA/ml|Completed||N/A|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.866029|2018-06-01 05:36:00.866029
NCT00000891|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|May 2004|Actual|2004-05-31|||||Interventional|||Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315|Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315|Completed||Phase 2|34||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:00.987374|2018-06-01 05:36:00.987374
NCT00000890|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31||||||||Observational|||A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients|Effect of Highly Active Antiretroviral Therapy (HAART) on Lean Body Mass|Completed|||200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.05647|2018-06-01 05:36:01.05647
NCT00000889|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-11-07|2001-08-30|2001-08-31|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 1997||1997-10-31|April 2014|2014-04-30|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3|A Randomized, Open-Label, Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3|Completed||Phase 2|72||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.133585|2018-06-01 05:36:01.133585
NCT00000888|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|April 2001|Actual|2001-04-30|||||Interventional|||Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies|A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Ritonavir Co-Administered With Lamivudine (3TC) and Zidovudine (ZDV) in HIV-1-Infected Pregnant Women and Their Infants|Completed||Phase 1|14||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.18987|2018-06-01 05:36:01.18987
NCT00000887|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|July 2004|Actual|2004-07-31|||||Interventional|||A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants|A Phase I Trial of the Safety, Tolerance, and Pharmacokinetics of Oral Nelfinavir (Viracept) Co-Administered With Zidovudine (ZDV) and Lamivudine (3TC) in HIV Infected Pregnant Women and Their Infants|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.27133|2018-06-01 05:36:01.27133
NCT00000886|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-10|2001-08-30|2001-08-31|Estimate|||||||2012-05-10|2012-05-14|Estimate||||May 2012|2012-05-31|April 1999|Actual|1999-04-30|||||Interventional|||A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)|A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)|Completed||Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.34769|2018-06-01 05:36:01.34769
NCT00000885|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-08-15|2001-08-30|2001-08-31|Estimate|||||||2012-08-15|2012-08-16|Estimate||||August 2012|2012-08-31|June 2003|Actual|2003-06-30|||||Interventional|||Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320|A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320|Completed||Phase 2|440||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.410798|2018-06-01 05:36:01.410798
NCT00000884|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|October 2000|Actual|2000-10-31|||||Interventional|||A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers|A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|84|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-06-01 05:36:01.642907|2018-06-01 05:36:01.642907
NCT00000883|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-24|2001-08-30|2001-08-31|Estimate|||||||2012-10-24|2012-10-25|Estimate|October 1997||1997-10-31|October 2012|2012-10-31|April 2007|Actual|2007-04-30|||||Interventional|||Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy|Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Complications In Subjects With Past CD4 Cells/mm3 Below 50 Who Increased CD4 Cells/mm3 to Above 100 on HAART|Completed||N/A|636||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.787625|2018-06-01 05:36:01.787625
NCT00000882|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31||||May 1999|Actual|1999-05-31||Interventional|||Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects|Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:01.980115|2018-06-01 05:36:01.980115
NCT00000880|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-14|2001-08-30|2001-08-31|Estimate|||||||2012-02-14|2012-02-16|Estimate||||February 2012|2012-02-29|May 2000|Actual|2000-05-31|||||Interventional|||A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease|Phase II Study of Cyclosporin (Neoral) in Immune Activation and HIV Expression in Early HIV Disease|Completed||Phase 2|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:02.173166|2018-06-01 05:36:02.173166
NCT00000879|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|April 2005|Actual|2005-04-30|||||Interventional|||A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers|A Phase I/II Study to Evaluate the Safety and Immunogenicity of ALVAC HIV Vaccines Alone and With AIDSVAX B/B in Children Born to HIV-Infected Mothers|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:36:02.262857|2018-06-01 05:36:02.262857
NCT00000878|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|October 2001|Actual|2001-10-31|||||Interventional|||A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants|A Phase I/II, Open-Label Study to Evaluate the Safety, Tolerance and Pharmacokinetics of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Infected Pregnant Women and Their Infants|Completed||Phase 1|26||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:02.365142|2018-06-01 05:36:02.365142
NCT00000877|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|October 2000|Actual|2000-10-31|||||Interventional|||Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults|Steady-State Pharmacokinetic Interaction Study of Indinavir and Rifabutin|Completed||Phase 1|31||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:02.467705|2018-06-01 05:36:02.467705
NCT00000876|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|November 2006|Actual|2006-11-30|||||Interventional|||Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children|Phase I/II Trial of CD4-IgG2 in HIV-Infected Children|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:36:02.549555|2018-06-01 05:36:02.549555
NCT00000875|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-12-13|2001-08-30|2001-08-31|Estimate|||||||2016-12-13|2016-12-14|Estimate||||April 2003|2003-04-30|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection|Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection|Terminated||N/A|16||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:02.634428|2018-06-01 05:36:02.634428
NCT00000874|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate|August 1997||1997-08-31|September 2013|2013-09-30|March 1999|Actual|1999-03-31|January 1999|Actual|1999-01-31||Observational|||A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART|A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART|Completed|||148|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||||||||Samples With DNA|"~     Blood collection~   "|||2018-06-01 05:36:02.691851|2018-06-01 05:36:02.691851
NCT00000873|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-10-04|2001-08-30|2001-08-31|Estimate|||||||2013-10-04|2013-10-07|Estimate||||October 2013|2013-10-31|September 2005|Actual|2005-09-30|||||Interventional|||A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants|A Randomized, Double-Blind, Controlled Study of an Increased Caloric Density Infant Formula and Its Effect on Growth and Nutritional Status in HIV-Infected Infants|Completed||N/A|2400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:02.779955|2018-06-01 05:36:02.779955
NCT00000872|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|January 2005|Actual|2005-01-31|||||Interventional|||Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection|Early Intensive Antiretroviral Combination Therapy in HIV-1 Infected Infants and Children|Completed||Phase 2|55|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:02.928773|2018-06-01 05:36:02.928773
NCT00000871|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|January 2000|Actual|2000-01-31|||||Interventional|||A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers|A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers|Completed||Phase 2|420||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:03.007513|2018-06-01 05:36:03.007513
NCT00000870|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|March 2007|Actual|2007-03-31|||||Interventional|||A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone|A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone|Completed||Phase 2|200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:03.094249|2018-06-01 05:36:03.094249
NCT00000869|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|May 2001|Actual|2001-05-31|||||Interventional|||A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies|A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women|Completed||Phase 3|2009||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:03.189107|2018-06-01 05:36:03.189107
NCT00000868|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|May 2000|Actual|2000-05-31|||||Interventional|||A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers|A Phase I Safety and Immunogenicity Trial of Orally Administered Live Attenuated Recombinant Salmonella Typhi CVD 908 Delta-asd (pW57-asd+) Expressing HIV-1 LAI gp120 (VVG 203) and Parenterally Administered HIV-1 MN rgp120 in Alum in HIV-1-Uninfected Volunteers|Completed||Phase 1|27||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:04.231054|2018-06-01 05:36:04.231054
NCT00000867|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-06-07|2001-08-30|2001-08-31|Estimate|||||||2013-06-07|2013-06-10|Estimate|December 1996||1996-12-31|June 2013|2013-06-30|July 2001|Actual|2001-07-31|||||Interventional|||A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)|A Phase II, Randomized, Double Blind, Placebo-Controlled Trial of Memantine for AIDS Dementia Complex (ADC) as Concurrent Treatment With Antiretroviral Therapy|Completed||Phase 2|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:04.302824|2018-06-01 05:36:04.302824
NCT00000866|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|July 1999|Actual|1999-07-31|||||Interventional|||A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.|Completed||N/A|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:04.389046|2018-06-01 05:36:04.389046
NCT00000865|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-14|2001-08-30|2001-08-31|Estimate|||||||2012-02-14|2012-02-16|Estimate||||February 2012|2012-02-29|April 1998|Actual|1998-04-30|||||Interventional|||The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children|A Phase I Safety and Pharmacokinetic Study of 1592U89 Alone and In Combination With Other Antiretroviral Agents in Infants and Children With HIV Infection|Completed||Phase 1|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:04.505107|2018-06-01 05:36:04.505107
NCT00000864|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|January 2001|Actual|2001-01-31|||||Interventional|||A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women|Phase I Study of Safety, Tolerance, and Pharmacokinetics of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy In Neonates Born to HIV-1 Infected Women|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:36:04.660432|2018-06-01 05:36:04.660432
NCT00000863|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|July 1998|Actual|1998-07-31|||||Interventional|||A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients|A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection|Completed||Phase 2|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:04.749419|2018-06-01 05:36:04.749419
NCT00000862|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|November 2003|Actual|2003-11-30|||||Interventional|||A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women|A Phase I Trial of the Pharmacokinetics and Tolerance of Oral Zidovudine Administered to HIV-1 Infected Pregnant Women During Labor and Delivery|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:04.853813|2018-06-01 05:36:04.853813
NCT00000861|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|March 1997|Actual|1997-03-31|||||Interventional|||The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients|A Randomized Trial of Immediate Versus Deferred Indinavir in Addition to Background Antiretroviral Therapy in HIV-Infected Patients With CD4+ Cell Counts Between 200 and 500/mm3 and Plasma HIV RNA Levels >= 10,000 Copies/ml|Completed||N/A|1900||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:04.953262|2018-06-01 05:36:04.953262
NCT00000860|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 1999|1999-07-31||||||||Observational|||The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients|Effects of Treatment for MAC Infection on Cytokine Expression in HIV-Infected Persons.|Completed|||24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.0557|2018-06-01 05:36:05.0557
NCT00000859|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|December 2001|Actual|2001-12-31|||||Interventional|||A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3|A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3|Completed||N/A|1300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.141775|2018-06-01 05:36:05.141775
NCT00000858|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Observational|||Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections|Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections|Completed|||350||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.246566|2018-06-01 05:36:05.246566
NCT00000857|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-06-02|2001-08-30|2001-08-31|Estimate|||||||2015-06-02|2015-06-03|Estimate||||May 2012|2012-05-31|June 2001|Actual|2001-06-30|||||Interventional|||A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3|A Phase I, Double-Blind, Randomized, Placebo-Controlled Trial of Recombinant Human Interleukin-12 (rhIL-12) in HIV-Infected Subjects With Less Than 50 CD4+ T Cells and Subjects With 300-500 CD4+ T Cells|Completed||Phase 1|65||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.297488|2018-06-01 05:36:05.297488
NCT00000856|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-29|2001-08-30|2001-08-31|Estimate|||||||2012-05-29|2012-05-31|Estimate||||May 2012|2012-05-31||||||||Interventional|||A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.|A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.469478|2018-06-01 05:36:05.469478
NCT00000855|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 2000|Actual|2000-02-29|||||Interventional|||A Study to Evaluate the Safety and Tolerability of Zidovudine (ZDV) in Premature Infants Born to HIV-Positive Women.|The Safety, Tolerance, and Pharmacokinetics of Zidovudine in Premature Infants Exposed to HIV.|Completed||N/A|35||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.544467|2018-06-01 05:36:05.544467
NCT00000854|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-13|2001-08-30|2001-08-31|Estimate|||||||2012-02-13|2012-02-14|Estimate||||February 2012|2012-02-29|May 2003|Actual|2003-05-31|||||Interventional|||A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss|A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Trial of Nandrolone Decanoate in Women With HIV-Associated Weight Loss|Completed||Phase 1|38||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.691509|2018-06-01 05:36:05.691509
NCT00000853|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|January 1999|Actual|1999-01-31|||||Interventional|||A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults|Completed||Phase 1|37|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.831804|2018-06-01 05:36:05.831804
NCT00000852|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection|A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection|Completed||N/A|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.910252|2018-06-01 05:36:05.910252
NCT00000851|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|October 1998|Actual|1998-10-31|||||Interventional|||Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children|Trial of Stavudine (d4T) Plus Didanosine (ddI) in Children on Long-Term Stavudine Monotherapy, and Stavudine Versus Stavudine Plus Didanosine in Children on Long-Term Zidovudine Monotherapy: A Rollover Protocol for ACTG 240 Participants and Children Receiving Prescription Zidovudine|Completed||Phase 2|198||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:05.992935|2018-06-01 05:36:05.992935
NCT00000850|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|December 2003|Actual|2003-12-31|||||Interventional|||The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy|The Effects of GM-CSF on Plasma HIV-1 RNA and Chemokine Receptor Expression in HIV-1 Infected Subjects Receiving Concomitant Potent Antiretroviral Therapy|Completed||Phase 2|108||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.128255|2018-06-01 05:36:06.128255
NCT00000849|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|March 2001|Actual|2001-03-31|||||Interventional|||A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children|Phase I/II Trial of Recombinant Interleukin-2 In Symptomatic Human Immunodeficiency Virus-Infected Children|Completed||Phase 1|27||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.243907|2018-06-01 05:36:06.243907
NCT00000848|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-13|2001-08-30|2001-08-31|Estimate|||||||2012-02-13|2012-02-14|Estimate||||February 2012|2012-02-29|October 1998|Actual|1998-10-31|||||Interventional|||The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year|The Antiviral Effect of Switching From Hard Capsule Saquinavir (SQVhc) to the Soft Gelatin Capsule of Saquinavir (SQVsc) Versus Switching to Indinavir (IDV) After 1 Year of Saquinavir Use|Completed||Phase 2|144|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.321275|2018-06-01 05:36:06.321275
NCT00000847|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|May 1999|Actual|1999-05-31|||||Interventional|||A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.396622|2018-06-01 05:36:06.396622
NCT00000846|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 2002|2002-10-31||||||||Interventional|||A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.|A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.47352|2018-06-01 05:36:06.47352
NCT00000845|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 2002|2002-10-31||||||||Interventional|||A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.527093|2018-06-01 05:36:06.527093
NCT00000844|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-23|Estimate||||May 2012|2012-05-31|June 2002|Actual|2002-06-30|||||Interventional|||A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3|A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3|Completed||N/A|560||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.580332|2018-06-01 05:36:06.580332
NCT00000843|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 1998|1998-04-30||||||||Interventional|||The Safety and Effectiveness of Adefovir Dipivoxil in HIV-Infected Children|A Phase IA Single Dose Pharmacokinetics and Safety Study of the Oral Antiviral Compound, 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) (Adefovir Dipivoxil) in Children With HIV-1 Infection|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.774865|2018-06-01 05:36:06.774865
NCT00000842|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-09|2001-08-30|2001-08-31|Estimate|||||||2012-05-09|2012-05-10|Estimate||||May 2012|2012-05-31|February 1999|Actual|1999-02-28|||||Interventional|||A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy|A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy|Completed||Phase 2|270||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:06.880708|2018-06-01 05:36:06.880708
NCT00000841|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|June 1997|Actual|1997-06-30|||||Interventional|||A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months|A Randomized, Double-Blind, Phase III Study of Indinavir Sulfate With Open-Label Zidovudine (AZT) and Lamivudine (3TC) in Subjects With HIV Infection With CD4 Cell Counts <= 200 Cells/mm3 and >= 6 Months of Prior AZT Experience|Completed||Phase 3|1750||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.002244|2018-06-01 05:36:07.002244
NCT00000840|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2000|2000-04-30||||||||Observational|||A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA|A Multicenter, Exploratory Study to Evaluate the Effects of Antiretroviral Cessation on Plasma Associated HIV-1 RNA|Completed|||70||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.212247|2018-06-01 05:36:07.212247
NCT00000839|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||August 2004|2004-08-31|June 2001|Actual|2001-06-30|||||Interventional|||A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women|A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.280605|2018-06-01 05:36:07.280605
NCT00000838|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|March 1998|Actual|1998-03-31|||||Interventional|||Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine|A Phase II, Randomized Study of the Antiviral Activity and Resistance Interactions of Lamivudine (3TC) in Combination With Zidovudine (AZT), Stavudine (d4T), or Didanosine (ddI) Versus Monotherapy With ddI or d4T in HIV-Infected Individuals With 200 - 600 CD4+ Cells/mm3 and No Previous Nucleoside Experience|Completed||Phase 2|256||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.373632|2018-06-01 05:36:07.373632
NCT00000837|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-02-11|2001-08-30|2001-08-31|Estimate|||||||2015-02-11|2015-02-13|Estimate||||February 2015|2015-02-28|November 2005|Actual|2005-11-30|||||Interventional|||A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children|Phase I/II Study of the Safety and Immunogenicity of Live-Attenuated Varicella Vaccine (Varivax) in HIV-Infected Children|Completed||Phase 1|127||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:36:07.496352|2018-06-01 05:36:07.496352
NCT00000836|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-24|2001-08-30|2001-08-31|Estimate|||||||2012-10-24|2012-10-25|Estimate||||October 2012|2012-10-31|August 1998|Actual|1998-08-31|||||Interventional|||A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)|A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.595028|2018-06-01 05:36:07.595028
NCT00000835|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31||||||||Observational|||A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine|Withdrawn|||0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.658083|2018-06-01 05:36:07.658083
NCT00000834|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|June 2002|Actual|2002-06-30|||||Interventional|||A Phase I Study of Methotrexate for HIV Infection|A Phase I Study of Methotrexate for HIV Infection|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.702633|2018-06-01 05:36:07.702633
NCT00000833|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|July 1998|Actual|1998-07-31|||||Interventional|||A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.|A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.|Completed||Phase 1|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.793102|2018-06-01 05:36:07.793102
NCT00000832|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-24|Estimate||||May 2012|2012-05-31|January 1998|Actual|1998-01-31|||||Interventional|||A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers|A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.875259|2018-06-01 05:36:07.875259
NCT00000831|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|May 1998|Actual|1998-05-31|||||Interventional|||Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy|Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy|Completed||Phase 2|280||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:07.944705|2018-06-01 05:36:07.944705
NCT00000830|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 1998|1998-03-31||||||||Observational|||Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.|Intracellular Pharmacokinetics of Zidovudine Triphosphate in Maternal and Infant Cord Blood Mononuclear Cells.|Completed|||24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.063073|2018-06-01 05:36:08.063073
NCT00000829|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-08|2001-08-30|2001-08-31|Estimate|||||||2012-05-08|2012-05-10|Estimate||||May 2012|2012-05-31|October 1999|Actual|1999-10-31|||||Interventional|||A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants|A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:36:08.121345|2018-06-01 05:36:08.121345
NCT00000828|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1997|1997-10-31||||||||Observational|||Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine|Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine|Completed|||250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.331945|2018-06-01 05:36:08.331945
NCT00000827|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|April 1998|Actual|1998-04-30|||||Interventional|||A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children|A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children|Completed||Phase 1|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.45598|2018-06-01 05:36:08.45598
NCT00000826|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-01|2001-08-30|2001-08-31|Estimate|||||||2012-05-01|2012-05-02|Estimate||||May 2012|2012-05-31|May 1999|Actual|1999-05-31|||||Interventional|||Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites|Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.595876|2018-06-01 05:36:08.595876
NCT00000825|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-04-08|2001-08-30|2001-08-31|Estimate|||||||2014-04-08|2014-04-09|Estimate|May 1998||1998-05-31|April 2014|2014-04-30||||March 2000|Actual|2000-03-31||Interventional|||The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3|A Randomized, Open-Label Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3|Completed||Phase 2|72||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.687498|2018-06-01 05:36:08.687498
NCT00000824|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-12-13|2001-08-30|2001-08-31|Estimate|||||||2016-12-13|2016-12-14|Estimate||||April 1995|1995-04-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients|A Pilot Study of HIV Specific Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients With CD4+ T Cells 100-350 Cells/mm3|Terminated||N/A|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.74877|2018-06-01 05:36:08.74877
NCT00000823|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-07-26|2001-08-30|2001-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate||||July 2013|2013-07-31|February 2000|Actual|2000-02-29|||||Interventional|||A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection|A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection|Completed||Phase 2|85||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.819049|2018-06-01 05:36:08.819049
NCT00000822|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-08|2001-08-30|2001-08-31|Estimate|||||||2012-05-08|2012-05-10|Estimate||||May 2012|2012-05-31|May 1999|Actual|1999-05-31|||||Interventional|||A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells|A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells|Completed||Phase 1|46||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.918084|2018-06-01 05:36:08.918084
NCT00000821|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-11-01|2001-08-30|2001-08-31|Estimate|||||||2012-11-01|2012-11-02|Estimate||||October 2012|2012-10-31|March 2002|Actual|2002-03-31|||||Interventional|||Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients|Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients|Completed||Phase 1|78||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:08.989405|2018-06-01 05:36:08.989405
NCT00000820|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-24|2001-08-30|2001-08-31|Estimate|||||||2012-04-24|2012-04-26|Estimate||||April 2012|2012-04-30|March 2002|Actual|2002-03-31|||||Interventional|||A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy|A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy|Completed||Phase 2|104||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:09.064527|2018-06-01 05:36:09.064527
NCT00000819|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-13|2001-08-30|2001-08-31|Estimate|||||||2012-04-13|2012-04-17|Estimate||||April 2012|2012-04-30|September 1996|Actual|1996-09-30|||||Interventional|||A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)|A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)|Completed||Phase 2|54||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:09.143439|2018-06-01 05:36:09.143439
NCT00000818|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-28|2001-08-30|2001-08-31|Estimate|||||||2008-07-28|2008-07-29|Estimate||||May 1996|1996-05-31||||||||Interventional|||Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.|Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:09.233137|2018-06-01 05:36:09.233137
NCT00000817|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate|November 1994||1994-11-30|September 2013|2013-09-30|May 1997|Actual|1997-05-31|||||Interventional|||The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients|The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients|Completed||N/A|260|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-06-01 05:36:09.32493|2018-06-01 05:36:09.32493
NCT00000816|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-13|2001-08-30|2001-08-31|Estimate|||||||2012-04-13|2012-04-17|Estimate||||April 2012|2012-04-30|September 1996|Actual|1996-09-30|||||Interventional|||Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis|Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis|Completed||Phase 4|370||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:09.435373|2018-06-01 05:36:09.435373
NCT00023036|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-21|||2018-03-27|2001-08-21|2001-08-22|Estimate|||||||2018-03-27|2018-03-29|Actual|August 17, 2001||2001-08-17|March 13, 2018|2018-03-13||||||||Observational|||Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts|Clinical and Molecular Analysis of Enlarged Vestibular Aqueducts|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:38.856788|2018-06-01 05:36:38.856788
NCT00000815|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|August 2001|Actual|2001-08-31|||||Interventional|||A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group|A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group|Completed||Phase 2|270|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-06-01 05:36:09.563781|2018-06-01 05:36:09.563781
NCT00000814|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|November 1998|Actual|1998-11-30|||||Interventional|||A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease|A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease|Completed||Phase 1|390||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:09.699752|2018-06-01 05:36:09.699752
NCT00000813|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31|June 1995|Actual|1995-06-30|||||Interventional|||A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers|A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers|Completed||Phase 1|28||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:09.832793|2018-06-01 05:36:09.832793
NCT00000812|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-04|Estimate||||April 2012|2012-04-30|July 2000|Actual|2000-07-31|||||Interventional|||A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection|A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:09.888859|2018-06-01 05:36:09.888859
NCT00000811|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-04|Estimate||||April 2012|2012-04-30|November 2001|Actual|2001-11-30|||||Interventional|||A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children|A Randomized, Phase II/III, Double-Blind, Two-Armed Study of Micronized Atovaquone and Azithromycin (AT/AZ) as Compared to Trimethoprim-Sulfamethoxazole (TMP/SMX) in the Prevention of Serious Bacterial Infections When Used in Children Aged 3 Months to 19 Years With HIV Infection|Completed||Phase 2|690||National Institute of Allergy and Infectious Diseases (NIAID)|||||||||||||||||||2018-06-01 05:36:09.971928|2018-06-01 05:36:09.971928
NCT00000810|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|January 1996|Actual|1996-01-31|||||Interventional|||Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)|Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)|Completed||Phase 1|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:10.278312|2018-06-01 05:36:10.278312
NCT00000809|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-16|2001-08-30|2001-08-31|Estimate|||||||2012-05-16|2012-05-18|Estimate||||May 2012|2012-05-31||||||||Interventional|||Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women|A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:10.388558|2018-06-01 05:36:10.388558
NCT00000808|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|September 1998|Actual|1998-09-30|||||Interventional|||A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers|A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers|Completed||Phase 1|49||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:10.475767|2018-06-01 05:36:10.475767
NCT00000807|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|July 2000|Actual|2000-07-31|||||Interventional|||Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy|Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy|Completed||Phase 2|41||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:10.586239|2018-06-01 05:36:10.586239
NCT00000806|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 1995|1995-02-28||||||||Interventional|||A Phase I Randomized Dose/Formulation Comparison Study of SC-52151|A Phase I Randomized Dose/Formulation Comparison Study of SC-52151|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:10.694244|2018-06-01 05:36:10.694244
NCT00000805|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|March 1998|Actual|1998-03-31|||||Interventional|||A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease|A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease|Completed||Phase 1|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:10.79548|2018-06-01 05:36:10.79548
NCT00000804|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-12-13|2001-08-30|2001-08-31|Estimate|||||||2016-12-13|2016-12-14|Estimate||||April 2003|2003-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)|A Randomized Trial of L-735,524, An Inhibitor of the HIV Protease Enzyme, and Interleukin-2 in Persons Infected With HIV (NOTE: Only For Patients Who Previously Completed NIAID 93 CC-113)|Withdrawn||N/A|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:10.906985|2018-06-01 05:36:10.906985
NCT00000803|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-04|Estimate||||April 2012|2012-04-30|March 1997|Actual|1997-03-31|||||Interventional|||A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy|A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy|Completed||Phase 2|471||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:11.016858|2018-06-01 05:36:11.016858
NCT00000802|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|July 1997|Actual|1997-07-31|||||Interventional|||A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides|A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides|Completed||Phase 3|700||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:11.40954|2018-06-01 05:36:11.40954
NCT00000801|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-31|2001-08-30|2001-08-31|Estimate|||||||2012-10-31|2012-11-01|Estimate||||October 2012|2012-10-31|April 1998|Actual|1998-04-30|||||Interventional|||Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma|Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma|Completed||Phase 2|33||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:11.895344|2018-06-01 05:36:11.895344
NCT00000800|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|October 1998|Actual|1998-10-31|||||Interventional|||Methadone Effects on Zidovudine (ZDV, AZT) Disposition|Methadone Effects on Zidovudine (ZDV, AZT) Disposition|Completed||Phase 1|15||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:11.981503|2018-06-01 05:36:11.981503
NCT00000799|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-31|2001-08-30|2001-08-31|Estimate|||||||2012-10-31|2012-11-01|Estimate||||October 2012|2012-10-31|April 1996|Actual|1996-04-30|||||Interventional|||HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol|HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol|Completed||N/A|100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:12.146066|2018-06-01 05:36:12.146066
NCT00000798|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 2002|2002-10-31||||||||Interventional|||A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects|Completed||Phase 1|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:12.240633|2018-06-01 05:36:12.240633
NCT00000797|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2018-05-01|2001-08-30|2001-08-31|Estimate|||||||2018-05-01|2018-05-02|Actual|October 1994||1994-10-31|May 2018|2018-05-31||||April 2019|Anticipated|2019-04-30||Observational|||Women's Interagency HIV Study (WIHS)|Women's Interagency HIV Study (WIHS)|Active, not recruiting|||4982|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||f|f|f||||Samples With DNA|"~     Blood, bodily fluid, and hair collection~   "|No||2018-06-01 05:36:12.334399|2018-06-01 05:36:12.334399
NCT00000796|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|October 1998|Actual|1998-10-31|||||Interventional|||A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.|A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.|Completed||N/A|525||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:12.431479|2018-06-01 05:36:12.431479
NCT00000795|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-08|2001-08-30|2001-08-31|Estimate|||||||2008-09-08|2008-09-09|Estimate||||October 2002|2002-10-31||||||||Interventional|||A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects|A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects|Completed||Phase 1|28||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:12.645664|2018-06-01 05:36:12.645664
NCT00000794|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|April 1998|Actual|1998-04-30|||||Interventional|||Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis|Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis|Completed||Phase 2|100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:12.720498|2018-06-01 05:36:12.720498
NCT00000793|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|October 1997|Actual|1997-10-31|||||Interventional|||A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection|A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection|Completed||Phase 2|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:12.908052|2018-06-01 05:36:12.908052
NCT00000792|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|January 1995|Actual|1995-01-31|||||Interventional|||A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects|A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:13.046714|2018-06-01 05:36:13.046714
NCT00000791|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-02|2001-08-30|2001-08-31|Estimate|||||||2012-04-02|2012-04-03|Estimate||||April 2012|2012-04-30|July 1995|Actual|1995-07-31|||||Interventional|||A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV|A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV|Completed||Phase 2|210||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:14.005047|2018-06-01 05:36:14.005047
NCT00000790|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|October 1998|Actual|1998-10-31|||||Interventional|||Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection|Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection|Completed||Phase 2|164||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:14.300669|2018-06-01 05:36:14.300669
NCT00000789|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|July 1998|Actual|1998-07-31|||||Interventional|||A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection|A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection|Completed||Phase 2|230||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:14.448757|2018-06-01 05:36:14.448757
NCT00000788|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|June 1994|Actual|1994-06-30|||||Interventional|||A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone|A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:14.735161|2018-06-01 05:36:14.735161
NCT00000787|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2003|2003-04-30||||||||Interventional|||Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study|Heterosexual HIV Transmission Study (HATS). Prospective Cohort Study|Completed||N/A|1000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:14.852123|2018-06-01 05:36:14.852123
NCT00000785|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate|August 1992||1992-08-31|September 2013|2013-09-30|June 1994|Actual|1994-06-30|June 1994|Actual|1994-06-30||Observational|||A Registry of Tuberculosis Cases in the CPCRA|A Registry of Tuberculosis Cases in the CPCRA|Completed|||1509|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||Samples With DNA|"~     Any sample that can be used to test for M.tuberculosis~   "|||2018-06-01 05:36:14.943002|2018-06-01 05:36:14.943002
NCT00000784|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate|October 1994||1994-10-31|September 2013|2013-09-30|September 1996|Actual|1996-09-30|September 1996|Actual|1996-09-30||Observational|||A Study of Psychosocial and Behavioral Determinants of Differential Rates of Participant Compliance in CPCRA Protocols|A Study of Psychosocial and Behavioral Determinants of Differential Rates of Participant Compliance in CPCRA Protocols|Completed|||557|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||||||||||||2018-06-01 05:36:15.080784|2018-06-01 05:36:15.080784
NCT00000783|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-10-05|2001-08-30|2001-08-31|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 1994||1994-06-30|October 2012|2012-10-31||||November 1999|Actual|1999-11-30||Observational|||Heterosexual HIV Transmission Study (HATS)|Heterosexual HIV Transmission Study (HATS)|Completed|||||National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||Samples With DNA|"~     Seminal and cervico-vaginal fluids will be collected as well as blood and urine samples.~   "|||2018-06-01 05:36:15.286315|2018-06-01 05:36:15.286315
NCT00000782|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|October 1996|Actual|1996-10-31|||||Interventional|||A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen|A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen|Completed||Phase 1|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:15.424142|2018-06-01 05:36:15.424142
NCT00000781|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)|A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)|Completed||Phase 2|1292||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:15.549479|2018-06-01 05:36:15.549479
NCT00000780|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2003|2003-03-31||||||||Observational|||"A Pre-Enrollment Protocol for HIV-Infected Adolescents"|"A Pre-Enrollment Protocol for HIV-Infected Adolescents"|Completed|||250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:16.027592|2018-06-01 05:36:16.027592
NCT00000779|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|September 1996|Actual|1996-09-30|||||Interventional|||A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3|A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3|Completed||Phase 1|130||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:16.262132|2018-06-01 05:36:16.262132
NCT00000778|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-06|2001-08-30|2001-08-31|Estimate|||||||2008-08-06|2008-08-08|Estimate||||June 1995|1995-06-30||||||||Interventional|||A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin|A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin|Completed||Phase 1|44||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:16.415104|2018-06-01 05:36:16.415104
NCT00000777|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|July 1998|Actual|1998-07-31|||||Interventional|||Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)|Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:16.54964|2018-06-01 05:36:16.54964
NCT00000776|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||Dexamethasone in Cryptococcal Meningitis|Dexamethasone in Cryptococcal Meningitis|Completed||Phase 2|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:16.654901|2018-06-01 05:36:16.654901
NCT00000775|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 2002|2002-10-31||||||||Interventional|||A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)|A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:16.791453|2018-06-01 05:36:16.791453
NCT00000774|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|January 1999|Actual|1999-01-31|||||Interventional|||A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers|A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers|Completed||Phase 1|156|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-06-01 05:36:16.965267|2018-06-01 05:36:16.965267
NCT00023023|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-18|||2018-03-27|2001-08-18|2001-08-20|Estimate|||||||2018-03-27|2018-03-29|Actual|August 17, 2001||2001-08-17|February 27, 2018|2018-02-27||||||||Observational|||Study of Transfusion-Transmitted Infections|A Prospective Study of Transfusion-Transmitted Infections|Recruiting|||3200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:39.918563|2018-06-01 05:36:39.918563
NCT00000773|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children|Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.102738|2018-06-01 05:36:17.102738
NCT00000772|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|February 1995|Actual|1995-02-28|||||Interventional|||A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals|A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals|Completed||Phase 1|15||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.165586|2018-06-01 05:36:17.165586
NCT00000771|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3|A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3|Completed||Phase 2|68||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.250292|2018-06-01 05:36:17.250292
NCT00000770|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-03|Estimate||||March 2012|2012-03-31|November 1994|Actual|1994-11-30|||||Interventional|||A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine|A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine|Completed||Phase 2|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.339914|2018-06-01 05:36:17.339914
NCT00000769|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-27|2001-08-30|2001-08-31|Estimate|||||||2012-04-27|2012-05-01|Estimate||||April 2012|2012-04-30|April 1998|Actual|1998-04-30|||||Interventional|||A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma|A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.535282|2018-06-01 05:36:17.535282
NCT00000768|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|August 1998|Actual|1998-08-31|||||Interventional|||A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients|A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.616995|2018-06-01 05:36:17.616995
NCT00000767|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|July 1996|Actual|1996-07-31|||||Interventional|||A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.706682|2018-06-01 05:36:17.706682
NCT00000766|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-28|2001-08-30|2001-08-31|Estimate|||||||2011-02-28|2011-03-01|Estimate||||February 2011|2011-02-28||||September 1995|Actual|1995-09-30||Interventional|||CMV Retinitis Retreatment Trial|CMV Retinitis Retreatment Trial|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.783935|2018-06-01 05:36:17.783935
NCT00000765|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|June 2002|Actual|2002-06-30|||||Interventional|||Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)|Pilot Study to Evaluate the Efficacy of Zidovudine in Preventing CD4+ Lymphocyte Decline in Patients With Primary HIV Infection. (One Treatment Arm Receives Placebo)|Completed||N/A|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.8878|2018-06-01 05:36:17.8878
NCT00000764|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|July 1996|Actual|1996-07-31|||||Interventional|||Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.|Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.|Completed||Phase 1|98||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:17.969895|2018-06-01 05:36:17.969895
NCT00000763|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|February 1997|Actual|1997-02-28|||||Interventional|||A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma|A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma|Completed||Phase 1|42||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.06265|2018-06-01 05:36:18.06265
NCT00000762|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|February 1996|Actual|1996-02-29|||||Interventional|||A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection|A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection|Completed||Phase 1|72||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.165733|2018-06-01 05:36:18.165733
NCT00000761|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-27|2001-08-30|2001-08-31|Estimate|||||||2012-04-27|2012-04-30|Estimate||||April 2012|2012-04-30|October 1997|Actual|1997-10-31|||||Interventional|||Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children|Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children|Completed||Phase 1|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.350443|2018-06-01 05:36:18.350443
NCT00022750|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2010-01-14|2001-08-09|2001-08-10|Estimate|||||||2010-01-14|2010-01-15|Estimate|October 2000||2000-10-31|January 2010|2010-01-31|May 2005||2005-05-31|||||Interventional|||Randomized Trial of Health Events Costs in Diabetic Blacks|Project Sugar 2: Health Events Costs in Diabetic Blacks|Completed||N/A|800||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:36:43.19917|2018-06-01 05:36:43.19917
NCT00000760|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-31|2001-08-30|2001-08-31|Estimate|||||||2008-07-31|2008-08-04|Estimate||||November 1998|1998-11-30||||||||Interventional|||A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection|A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection|Completed||Phase 1|96||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.436962|2018-06-01 05:36:18.436962
NCT00000759|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 1998|1998-06-30||||||||Observational|||Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials|Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials|Completed|||675||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.508436|2018-06-01 05:36:18.508436
NCT00000758|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|April 1998|Actual|1998-04-30|||||Interventional|||A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women|A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women|Completed||Phase 3|158||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.56915|2018-06-01 05:36:18.56915
NCT00000757|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|October 1992|Actual|1992-10-31|||||Interventional|||A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.702817|2018-06-01 05:36:18.702817
NCT00000756|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|June 2002|Actual|2002-06-30|||||Interventional|||Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3|Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3|Completed||Phase 1|15||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.781153|2018-06-01 05:36:18.781153
NCT00000755|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|March 1993|Actual|1993-03-31|||||Interventional|||A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3|A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3|Completed||Phase 1|168||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.848627|2018-06-01 05:36:18.848627
NCT00000754|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|February 1995|Actual|1995-02-28|||||Interventional|||A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3|A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3|Completed||Phase 2|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.925435|2018-06-01 05:36:18.925435
NCT00000753|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|February 1995|Actual|1995-02-28|||||Interventional|||A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC|A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:18.998166|2018-06-01 05:36:18.998166
NCT00000752|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-05-14|2001-08-30|2001-08-31|Estimate|||||||2015-05-14|2015-05-18|Estimate||||October 2012|2012-10-31|February 1993|Actual|1993-02-28|||||Interventional|||Preventing Frequent Sinus Infections in HIV-Infected Patients|Management of HIV-Infected Patients at Risk of Recurrent Purulent Sinusitis: Role of Anti-Inflammatory, Antibacterial, and Decongestant Prophylaxis|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.076019|2018-06-01 05:36:19.076019
NCT00000751|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-26|2001-08-30|2001-08-31|Estimate|||||||2008-09-26|2008-09-30|Estimate||||May 2006|2006-05-31|August 2007|Actual|2007-08-31|||||Interventional|||A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)|A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)|Completed||Phase 3|1600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.163601|2018-06-01 05:36:19.163601
NCT00000750|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection|A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection|Completed||Phase 3|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.38877|2018-06-01 05:36:19.38877
NCT00000749|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-29|2001-08-30|2001-08-31|Estimate|||||||2012-10-29|2012-10-30|Estimate||||October 2012|2012-10-31||||||||Interventional|||A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months|Completed||Phase 1|14||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.514756|2018-06-01 05:36:19.514756
NCT00000748|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|November 1996|Actual|1996-11-30|||||Interventional|||A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients|A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients|Completed||Phase 3|2500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.577429|2018-06-01 05:36:19.577429
NCT00000747|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-28|2001-08-30|2001-08-31|Estimate|||||||2011-02-28|2011-03-01|Estimate||||February 2011|2011-02-28||||December 1994|Actual|1994-12-31||Interventional|||An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3|An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3|Completed||Phase 2|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.696234|2018-06-01 05:36:19.696234
NCT00000746|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|July 1994|Actual|1994-07-31|||||Interventional|||A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines|A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines|Completed||Phase 1|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.758675|2018-06-01 05:36:19.758675
NCT00000745|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-23|2001-08-30|2001-08-31|Estimate|||||||2012-05-23|2012-05-25|Estimate||||May 2012|2012-05-31|May 1991|Actual|1991-05-31|||||Interventional|||A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160|Completed||Phase 1|72||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.858396|2018-06-01 05:36:19.858396
NCT00000744|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|December 1995|Actual|1995-12-31|||||Interventional|||A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women|A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women|Completed||N/A|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:19.946314|2018-06-01 05:36:19.946314
NCT00000743|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-27|2001-08-30|2001-08-31|Estimate|||||||2012-04-27|2012-04-30|Estimate||||April 2012|2012-04-30|May 1995|Actual|1995-05-31|||||Interventional|||A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons|A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons|Completed||Phase 1|64||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.046457|2018-06-01 05:36:20.046457
NCT00000742|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|October 1993|Actual|1993-10-31|||||Interventional|||A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)|A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)|Completed||Phase 1|15||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.116308|2018-06-01 05:36:20.116308
NCT00000741|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-24|2001-08-30|2001-08-31|Estimate|||||||2012-10-24|2012-10-25|Estimate||||October 2012|2012-10-31||||||||Interventional|||The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS|A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients|Withdrawn||Phase 3|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.208957|2018-06-01 05:36:20.208957
NCT00000740|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|September 1993|Actual|1993-09-30|||||Interventional|||Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects|Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects|Completed||Phase 1|44||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.288645|2018-06-01 05:36:20.288645
NCT00000739|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|June 1998|Actual|1998-06-30|||||Interventional|||Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection|Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection|Completed||Phase 1|96||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.376451|2018-06-01 05:36:20.376451
NCT00000738|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|June 1994|Actual|1994-06-30|||||Interventional|||Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1|Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.498757|2018-06-01 05:36:20.498757
NCT00000737|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-22|2001-08-30|2001-08-31|Estimate|||||||2008-08-22|2008-08-25|Estimate||||January 1994|1994-01-31||||||||Interventional|||A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome|A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome|Completed||Phase 1|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.579361|2018-06-01 05:36:20.579361
NCT00000736|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1995|Actual|1995-02-28|||||Interventional|||Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals|Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals|Completed||Phase 3|3200||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.675267|2018-06-01 05:36:20.675267
NCT00000735|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|February 1990|Actual|1990-02-28|||||Interventional|||A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC|A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.787717|2018-06-01 05:36:20.787717
NCT00000734|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|May 1990|Actual|1990-05-31|||||Interventional|||Evaluation of the Interaction Between High Dose Sulfamethoxazole/Trimethoprim and Zidovudine|Evaluation of the Interaction Between High Dose Trimethoprim/Sulfamethoxazole and Zidovudine|Completed||N/A|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.849995|2018-06-01 05:36:20.849995
NCT00000733|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|October 1991|Actual|1991-10-31|||||Interventional|||Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients|Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients|Completed||Phase 1|42||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.907324|2018-06-01 05:36:20.907324
NCT00000732|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|May 1990|Actual|1990-05-31|||||Interventional|||Evaluation of the Interaction Between Low Dose Sulfamethoxazole-Trimethoprim and Zidovudine|Evaluation of the Interaction Between Low Dose Trimethoprim/Sulfamethoxazole and Zidovudine|Completed||N/A|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:20.967689|2018-06-01 05:36:20.967689
NCT00000731|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|May 1990|Actual|1990-05-31|||||Interventional|||Evaluation of the Interaction Between Acetaminophen and Zidovudine|Evaluation of the Interaction Between Acetaminophen and Zidovudine|Completed||N/A|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.046119|2018-06-01 05:36:21.046119
NCT00000730|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-29|2001-08-30|2001-08-31|Estimate|||||||2012-05-29|2012-05-30|Estimate||||May 2012|2012-05-31|March 1989|Actual|1989-03-31|||||Interventional|||Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients|A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to Conventional Drugs|Terminated||Phase 3|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.104424|2018-06-01 05:36:21.104424
NCT00000729|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|June 1992|Actual|1992-06-30|||||Interventional|||A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease|A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease|Completed||Phase 1|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.264081|2018-06-01 05:36:21.264081
NCT00000728|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-24|2001-08-30|2001-08-31|Estimate|||||||2012-04-24|2012-04-26|Estimate||||April 2012|2012-04-30|April 1990|Actual|1990-04-30|||||Interventional|||Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy|Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy|Completed||Phase 1|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.332263|2018-06-01 05:36:21.332263
NCT00000727|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|August 1991|Actual|1991-08-31|||||Interventional|||A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)|A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)|Completed||Phase 3|322||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.391996|2018-06-01 05:36:21.391996
NCT00000726|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|February 1992|Actual|1992-02-29|||||Interventional|||Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome|Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome|Completed||Phase 1|53||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.552077|2018-06-01 05:36:21.552077
NCT00000725|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1990|Actual|1990-02-28|||||Interventional|||A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma|A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma|Completed||Phase 1|56||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.648044|2018-06-01 05:36:21.648044
NCT00000724|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-12-18|2001-08-30|2001-08-31|Estimate|||||||2012-12-18|2012-12-19|Estimate||||December 2012|2012-12-31|July 2004|Actual|2004-07-31|||||Interventional|||A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia|A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia|Completed||Phase 3|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.740796|2018-06-01 05:36:21.740796
NCT00000723|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-29|2001-08-30|2001-08-31|Estimate|||||||2012-05-29|2012-05-30|Estimate||||May 2012|2012-05-31|March 1990|Actual|1990-03-31|||||Interventional|||The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer|Chemotherapy, Radiotherapy, and Azidothymidine for AIDS-Related Primary CNS Lymphoma|Terminated||N/A|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.837282|2018-06-01 05:36:21.837282
NCT00000722|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|June 1991|Actual|1991-06-30|||||Interventional|||Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy|Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy|Completed||N/A|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:21.932402|2018-06-01 05:36:21.932402
NCT00000721|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|March 1991|Actual|1991-03-31|||||Interventional|||An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive|An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive|Completed||Phase 1|85||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.010205|2018-06-01 05:36:22.010205
NCT00000720|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|April 1993|Actual|1993-04-30|||||Interventional|||A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine|A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine|Completed||Phase 3|250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.105435|2018-06-01 05:36:22.105435
NCT00000719|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|February 1995|Actual|1995-02-28|||||Interventional|||A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease|A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease|Completed||N/A|96||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.281608|2018-06-01 05:36:22.281608
NCT00000718|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1991|Actual|1991-09-30|||||Interventional|||A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC|A Clinical Trial of Alternating and Intermittent Regimens of 2',3'-Dideoxycytidine and 3'-Azido-3'-Deoxythymidine in the Treatment of Patients With AIDS and Advanced ARC|Completed||N/A|112||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.374207|2018-06-01 05:36:22.374207
NCT00000717|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-18|2001-08-30|2001-08-31|Estimate|||||||2012-10-18|2012-10-19|Estimate||||October 2012|2012-10-31|November 1991|Actual|1991-11-30|||||Interventional|||The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS|The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS|Completed||N/A|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.453589|2018-06-01 05:36:22.453589
NCT00000716|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||May 1990|1990-05-31||||January 1991|Actual|1991-01-31||Interventional|||A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection|A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection|Completed||Phase 2|70||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.549383|2018-06-01 05:36:22.549383
NCT00000715|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1991|Actual|1991-09-30|||||Interventional|||A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS|A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Pneumonia in AIDS|Completed||Phase 3|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.63066|2018-06-01 05:36:22.63066
NCT00000714|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|July 2004|Actual|2004-07-31|||||Interventional|||An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies|An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies|Completed||Phase 3|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.712564|2018-06-01 05:36:22.712564
NCT00000713|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|October 1992|Actual|1992-10-31|||||Interventional|||A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects|A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects|Completed||Phase 1|40||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.807243|2018-06-01 05:36:22.807243
NCT00000712|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|November 1994|Actual|1994-11-30|||||Interventional|||A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3|A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3|Completed||Phase 2|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.880304|2018-06-01 05:36:22.880304
NCT00000711|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-25|2001-08-30|2001-08-31|Estimate|||||||2012-04-25|2012-04-27|Estimate||||April 2012|2012-04-30|May 1990|Actual|1990-05-31|||||Interventional|||Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC|Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:22.949056|2018-06-01 05:36:22.949056
NCT00000710|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|May 1990|Actual|1990-05-31|||||Interventional|||A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex|A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex|Completed||Phase 1|42||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.025492|2018-06-01 05:36:23.025492
NCT00000709|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1990|Actual|1990-02-28|||||Interventional|||An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts|An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts|Completed||Phase 3|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.098228|2018-06-01 05:36:23.098228
NCT00000708|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||July 1991|1991-07-31||||July 1991|Actual|1991-07-31||Interventional|||Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis|Completed||N/A|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.166591|2018-06-01 05:36:23.166591
NCT00000707|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|June 1991|Actual|1991-06-30|||||Interventional|||Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms|Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms|Completed||N/A|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.259605|2018-06-01 05:36:23.259605
NCT00000706|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|December 1988|Actual|1988-12-31|||||Interventional|||Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine|Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine|Completed||N/A|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.321017|2018-06-01 05:36:23.321017
NCT00000705|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-08-04|2001-08-30|2001-08-31|Estimate|||||||2014-08-04|2014-08-05|Estimate||||August 2014|2014-08-31|March 1989|Actual|1989-03-31|||||Interventional|||Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia|A Phase I Trial to Evaluate Azidothymidine (AZT) in the Treatment of HIV Infections in Patients With Hemophilia|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.379069|2018-06-01 05:36:23.379069
NCT00000704|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|April 1990|Actual|1990-04-30|||||Interventional|||A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.|A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.|Completed||Phase 1|64||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.467277|2018-06-01 05:36:23.467277
NCT00000703|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|March 1990|Actual|1990-03-31|||||Interventional|||Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members|Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members|Completed||N/A|45||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.527661|2018-06-01 05:36:23.527661
NCT00000702|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-15|2001-08-30|2001-08-31|Estimate|||||||2012-02-15|2012-02-17|Estimate||||February 2012|2012-02-29|August 1990|Actual|1990-08-31|||||Interventional|||A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection|A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and Central Nervous System (CNS) Human Immunodeficiency Virus (HIV) Infection|Completed||Phase 3|315||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:23.617005|2018-06-01 05:36:23.617005
NCT00000701|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1990|Actual|1990-02-28|||||Interventional|||A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)|A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)|Completed||Phase 1|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:24.696917|2018-06-01 05:36:24.696917
NCT00000700|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-02-15|2001-08-30|2001-08-31|Estimate|||||||2012-02-15|2012-02-17|Estimate||||February 2012|2012-02-29|May 1990|Actual|1990-05-31|||||Interventional|||A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP|A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP|Completed||Phase 3|482||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:24.766693|2018-06-01 05:36:24.766693
NCT00000699|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-25|2001-08-30|2001-08-31|Estimate|||||||2008-08-25|2008-08-26|Estimate||||April 2003|2003-04-30||||||||Interventional|||A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients|A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients|Completed||Phase 1|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:24.868139|2018-06-01 05:36:24.868139
NCT00000698|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-09-26|2001-08-30|2001-08-31|Estimate|||||||2008-09-26|2008-09-30|Estimate||||April 1992|1992-04-30|August 2007|Actual|2007-08-31|||||Interventional|||A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis|A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis|Completed||Phase 3|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:24.941536|2018-06-01 05:36:24.941536
NCT00000697|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-29|2001-08-30|2001-08-31|Estimate|||||||2012-05-29|2012-05-30|Estimate||||May 2012|2012-05-31||||||||Interventional|||A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use Ganciclovir|A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.001654|2018-06-01 05:36:25.001654
NCT00000696|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|November 1993|Actual|1993-11-30|||||Interventional|||A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease|A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.071989|2018-06-01 05:36:25.071989
NCT00000695|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|July 1991|Actual|1991-07-31|||||Interventional|||Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma|Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma|Completed||Phase 1|36||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.243979|2018-06-01 05:36:25.243979
NCT00000694|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|August 1992|Actual|1992-08-31|||||Interventional|||A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma|A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.453736|2018-06-01 05:36:25.453736
NCT00000693|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|March 1992|Actual|1992-03-31|||||Interventional|||Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS|Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS|Completed||N/A|25||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.539789|2018-06-01 05:36:25.539789
NCT00000692|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2003|2003-03-31||||||||Interventional|||Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex|Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.682396|2018-06-01 05:36:25.682396
NCT00000691|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|August 1992|Actual|1992-08-31|||||Interventional|||A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure|A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure|Completed||Phase 2|156||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.794424|2018-06-01 05:36:25.794424
NCT00000690|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|October 1989|Actual|1989-10-31|||||Interventional|||Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers|Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers|Completed||Phase 1|6||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.903626|2018-06-01 05:36:25.903626
NCT00000689|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|March 1991|Actual|1991-03-31|||||Interventional|||Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma|Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:25.978383|2018-06-01 05:36:25.978383
NCT00000688|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||October 1990|1990-10-31||||February 1995|Actual|1995-02-28||Interventional|||A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS|A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS|Completed||Phase 3|180||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.081745|2018-06-01 05:36:26.081745
NCT00000687|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|July 1993|Actual|1993-07-31|||||Interventional|||Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma|Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma|Completed||Phase 2|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.17868|2018-06-01 05:36:26.17868
NCT00000686|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-25|2001-08-30|2001-08-31|Estimate|||||||2008-08-25|2008-08-26|Estimate||||May 1999|1999-05-31||||||||Interventional|||A Study of d4T in Patients With AIDS or AIDS-Related Complex Who Cannot Take AZT|A Phase I Safety Study of BMY-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [d4T]) Administered Four Times Daily to AZT-Intolerant Patients With AIDS or AIDS-Related Complex|Terminated||Phase 1|35||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.298317|2018-06-01 05:36:26.298317
NCT00000685|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1990|Actual|1990-02-28|||||Interventional|||A Study of Zidovudine in HIV-Infected Patients With Kidney Problems|Evaluation of Zidovudine Pharmacokinetics in Patients With Human Immunodeficiency Virus and Varying Degrees of Renal Insufficiency|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.380796|2018-06-01 05:36:26.380796
NCT00000684|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|April 1991|Actual|1991-04-30|||||Interventional|||Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals|Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals|Completed||N/A|10||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.449244|2018-06-01 05:36:26.449244
NCT00000683|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|June 1993|Actual|1993-06-30|||||Interventional|||A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus|A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus|Completed||Phase 1|54||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.619721|2018-06-01 05:36:26.619721
NCT00000682|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1992|Actual|1992-09-30|||||Interventional|||A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002|A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002|Completed||Phase 3|120||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.706206|2018-06-01 05:36:26.706206
NCT00000681|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|October 1993|Actual|1993-10-31|||||Interventional|||A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma|A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.792179|2018-06-01 05:36:26.792179
NCT00000680|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|April 1993|Actual|1993-04-30|||||Interventional|||A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC|A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC|Completed||Phase 1|6||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.893965|2018-06-01 05:36:26.893965
NCT00000679|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||December 1994|1994-12-31||||February 1994|Actual|1994-02-28||Interventional|||(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC|(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC|Completed||Phase 2|600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:26.982459|2018-06-01 05:36:26.982459
NCT00000678|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||September 1992|1992-09-30||||July 1992|Actual|1992-07-31||Interventional|||Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.|Dideoxycytidine ( Ro 24-2027 ) A Randomized, Open-Label, Comparative Study of Dideoxycytidine ( ddC ) Versus Zidovudine ( AZT ) in Patients With AIDS or Advanced ARC Who Have Received Long-Term AZT Therapy.|Completed||Phase 2|320||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.085958|2018-06-01 05:36:27.085958
NCT00000677|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 1994|1994-12-31||||||||Interventional|||SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy|SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy|Completed||Phase 1|50||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.224119|2018-06-01 05:36:27.224119
NCT00000676|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|November 1993|Actual|1993-11-30|||||Interventional|||Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)|Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)|Completed||Phase 3|500||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.340122|2018-06-01 05:36:27.340122
NCT00000675|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 1991|1991-01-31||||||||Interventional|||A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex|A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex|Completed||Phase 1|60||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.466975|2018-06-01 05:36:27.466975
NCT00000674|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31|August 1992|Actual|1992-08-31|||||Interventional|||A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS|A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS|Completed||N/A|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.555595|2018-06-01 05:36:27.555595
NCT00000673|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|May 1993|Actual|1993-05-31|||||Interventional|||A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy|A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy|Completed||Phase 1|38||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.641534|2018-06-01 05:36:27.641534
NCT00000672|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||October 1994|1994-10-31||||February 1993|Actual|1993-02-28||Interventional|||An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex|An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex|Completed||Phase 2|660||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.727226|2018-06-01 05:36:27.727226
NCT00000671|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||August 1992|1992-08-31||||March 1992|Actual|1992-03-31||Interventional|||A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment|A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment|Completed||Phase 2|750||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:27.877935|2018-06-01 05:36:27.877935
NCT00000670|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|July 1989|Actual|1989-07-31|||||Interventional|||Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks|Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks|Completed||N/A|16||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.151215|2018-06-01 05:36:28.151215
NCT00023010|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-18|||2017-06-30|2001-08-18|2001-08-20|Estimate|||||||2017-06-30|2017-07-02|Actual|August 15, 2001||2001-08-15|December 13, 2010|2010-12-13|December 13, 2010||2010-12-13|||||Observational|||Gene Therapy for Patients With Leukocyte Adherence Deficiency (Follow-Up of Phase 1 Trial)|Follow-Up of a Phase-I Gene Therapy Trial of Patients With Leukocyte Adherence Deficiency|Completed|||2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:40.038478|2018-06-01 05:36:40.038478
NCT00000669|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-25|2001-08-30|2001-08-31|Estimate|||||||2008-08-25|2008-08-26|Estimate||||October 1996|1996-10-31||||||||Interventional|||A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection|A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection|Completed||Phase 1|25||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.230299|2018-06-01 05:36:28.230299
NCT00000668|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-15|2001-08-30|2001-08-31|Estimate|||||||2012-03-15|2012-03-16|Estimate||||March 2012|2012-03-31|February 1995|Actual|1995-02-28|||||Interventional|||A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir|A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir|Completed||Phase 1|48||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.314799|2018-06-01 05:36:28.314799
NCT00000667|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-21|2001-08-30|2001-08-31|Estimate|||||||2012-05-21|2012-05-22|Estimate||||May 2012|2012-05-31|July 1993|Actual|1993-07-31|||||Interventional|||A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells|A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells|Completed||Phase 1|20||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.392275|2018-06-01 05:36:28.392275
NCT00000666|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-26|2001-08-30|2001-08-31|Estimate|||||||2012-10-26|2012-10-29|Estimate||||October 2012|2012-10-31|March 1992|Actual|1992-03-31|||||Interventional|||A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection|A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection|Completed||N/A|600||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.476238|2018-06-01 05:36:28.476238
NCT00000665|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||December 1994|1994-12-31||||April 1992|Actual|1992-04-30||Interventional|||Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component|Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component|Completed||N/A|240||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.584602|2018-06-01 05:36:28.584602
NCT00000664|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-01|2001-08-30|2001-08-31|Estimate|||||||2008-08-01|2008-08-04|Estimate||||December 1994|1994-12-31||||||||Interventional|||Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals|Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals|Completed||Phase 1|26||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.664022|2018-06-01 05:36:28.664022
NCT00000663|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 1996|1996-10-31||||||||Interventional|||A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection|Completed||Phase 1|18||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.734738|2018-06-01 05:36:28.734738
NCT00000662|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-10-27|2001-08-30|2001-08-31|Estimate|||||||2016-10-27|2016-10-31|Estimate||||April 1992|1992-04-30|May 1993|Actual|1993-05-31|May 1993|Actual|1993-05-31||Interventional|||A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease|A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease|Completed||N/A|||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.809192|2018-06-01 05:36:28.809192
NCT00000661|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-08-01|2001-08-30|2001-08-31|Estimate|||||||2008-08-01|2008-08-04|Estimate||||December 1994|1994-12-31||||||||Interventional|||The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient|The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient|Completed||Phase 1|8||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.866223|2018-06-01 05:36:28.866223
NCT00000660|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|July 1992|Actual|1992-07-31|||||Interventional|||Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma|Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma|Completed||Phase 1|24||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:28.943878|2018-06-01 05:36:28.943878
NCT00000659|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-03-11|2001-08-30|2001-08-31|Estimate|||||||2011-03-11|2011-03-14|Estimate||||July 1990|1990-07-31||||July 1990|Actual|1990-07-31||Interventional|||A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)|A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)|Terminated||Phase 2|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.018145|2018-06-01 05:36:29.018145
NCT00000658|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-26|2001-08-30|2001-08-31|Estimate|||||||2012-04-26|2012-04-30|Estimate||||April 2012|2012-04-30|February 1996|Actual|1996-02-29|||||Interventional|||A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma|A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma|Completed||Phase 3|250||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.113909|2018-06-01 05:36:29.113909
NCT00000657|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|September 1992|Actual|1992-09-30|||||Interventional|||Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex|Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex|Completed||Phase 2|80||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.218|2018-06-01 05:36:29.218
NCT00000656|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|November 1993|Actual|1993-11-30|||||Interventional|||A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease|A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease|Completed||Phase 1|116||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.293736|2018-06-01 05:36:29.293736
NCT00000655|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-25|2001-08-30|2001-08-31|Estimate|||||||2011-02-25|2011-03-01|Estimate||||February 2011|2011-02-28||||January 1992|Actual|1992-01-31||Interventional|||A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients|A Randomized, Double-Blind Study of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients|Completed||Phase 2|300||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.362084|2018-06-01 05:36:29.362084
NCT00000654|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-12-17|2001-08-30|2001-08-31|Estimate|||||||2012-12-17|2012-12-18|Estimate||||December 2012|2012-12-31|February 1993|Actual|1993-02-28|||||Interventional|||The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU|The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU|Completed||Phase 2|78||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.463634|2018-06-01 05:36:29.463634
NCT00000653|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|June 1995|Actual|1995-06-30|||||Interventional|||A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT|A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT|Completed||Phase 2|140||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.56394|2018-06-01 05:36:29.56394
NCT00000652|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-31|2001-08-30|2001-08-31|Estimate|||||||2012-10-31|2012-11-01|Estimate||||October 2012|2012-10-31|November 1995|Actual|1995-11-30|||||Interventional|||A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection|A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection|Completed||Phase 1|85||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:29.872046|2018-06-01 05:36:29.872046
NCT00000651|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-28|2001-08-30|2001-08-31|Estimate|||||||2012-03-28|2012-03-29|Estimate||||March 2012|2012-03-31|May 1993|Actual|1993-05-31|||||Interventional|||A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy|A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy|Completed||Phase 3|750||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.003592|2018-06-01 05:36:30.003592
NCT00000650|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients|An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients|Completed||N/A|12||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.160456|2018-06-01 05:36:30.160456
NCT00000649|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||June 1993|1993-06-30||||||||Interventional|||An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)|An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.235913|2018-06-01 05:36:30.235913
NCT00000648|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-10-24|2001-08-30|2001-08-31|Estimate|||||||2012-10-24|2012-10-25|Estimate||||October 2012|2012-10-31|February 1996|Actual|1996-02-29|||||Interventional|||A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals|A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals|Completed||N/A|100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.383488|2018-06-01 05:36:30.383488
NCT00000647|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|December 1994|Actual|1994-12-31|||||Interventional|||An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection|An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection|Completed||N/A|6||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.573001|2018-06-01 05:36:30.573001
NCT00000646|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|March 1993|Actual|1993-03-31|||||Interventional|||Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS|Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS|Completed||Phase 1|54||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.696154|2018-06-01 05:36:30.696154
NCT00000645|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|October 1994|Actual|1994-10-31|||||Interventional|||A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes|A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes|Completed||Phase 1|32||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.779198|2018-06-01 05:36:30.779198
NCT00000644|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-24|2001-08-30|2001-08-31|Estimate|||||||2011-02-24|2011-02-25|Estimate||||February 2011|2011-02-28||||November 1997|Actual|1997-11-30||Interventional|||A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS|A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS|Completed||Phase 2|100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.891859|2018-06-01 05:36:30.891859
NCT00000643|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|May 1994|Actual|1994-05-31|||||Interventional|||Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients|Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients|Completed||Phase 2|150||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:30.974085|2018-06-01 05:36:30.974085
NCT00000642|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|2001-08-30|2001-08-31|Estimate|||||||2005-06-23|2005-06-24|Estimate||||October 2003|2003-10-31||||||||Interventional|||A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns|A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns|Completed||Phase 1|30||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:31.083933|2018-06-01 05:36:31.083933
NCT00000641|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|December 1994|Actual|1994-12-31|||||Interventional|||A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.|A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.|Completed||Phase 2|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:31.159152|2018-06-01 05:36:31.159152
NCT00000640|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|September 1994|Actual|1994-09-30|||||Interventional|||A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS|A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS|Completed||Phase 3|290||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:31.283328|2018-06-01 05:36:31.283328
NCT00000639|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|September 1997|Actual|1997-09-30|||||Interventional|||A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis|A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis|Completed||N/A|400||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:31.426639|2018-06-01 05:36:31.426639
NCT00000638|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|September 1999|Actual|1999-09-30|||||Interventional|||Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection|Completed||N/A|2000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:31.557583|2018-06-01 05:36:31.557583
NCT00000637|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|September 1996|Actual|1996-09-30|||||Interventional|||A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children|A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children|Completed||Phase 3|819||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:31.724489|2018-06-01 05:36:31.724489
NCT00000636|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-09-28|2001-08-30|2001-08-31|Estimate|||||||2013-09-28|2013-10-01|Estimate||||September 2013|2013-09-30|October 1997|Actual|1997-10-31|||||Interventional|||Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection|Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection|Completed||N/A|2000||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:31.874423|2018-06-01 05:36:31.874423
NCT00000635|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-29|2001-08-30|2001-08-31|Estimate|||||||2012-03-29|2012-03-30|Estimate||||March 2012|2012-03-31|April 1992|Actual|1992-04-30|||||Interventional|||Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine|Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine|Completed||N/A|25||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.14861|2018-06-01 05:36:32.14861
NCT00000634|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-25|2001-08-30|2001-08-31|Estimate|||||||2011-02-25|2011-03-01|Estimate||||February 2011|2011-02-28||||June 1995|Actual|1995-06-30||Interventional|||A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children|A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children|Completed||N/A|6||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.241263|2018-06-01 05:36:32.241263
NCT00000633|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-17|2001-08-30|2001-08-31|Estimate|||||||2012-05-17|2012-05-21|Estimate||||May 2012|2012-05-31|October 1998|Actual|1998-10-31|||||Interventional|||A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals|A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals|Completed||Phase 1|55||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.336438|2018-06-01 05:36:32.336438
NCT00000632|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-04-27|2001-08-30|2001-08-31|Estimate|||||||2012-04-27|2012-04-30|Estimate||||April 2012|2012-04-30|May 1992|Actual|1992-05-31|||||Interventional|||A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59|Completed||Phase 1|14|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.429862|2018-06-01 05:36:32.429862
NCT00000631|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|December 1992|Actual|1992-12-31|||||Interventional|||A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)|A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)|Completed||Phase 1|13||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.521072|2018-06-01 05:36:32.521072
NCT00022997|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-17|||2018-05-26|2001-08-17|2001-08-20|Estimate|||||||2018-05-26|2018-05-30|Actual|August 16, 2001||2001-08-16|May 24, 2018|2018-05-24||||||||Observational|||Study of Taste Deficits|Studies of Deficits in the Sense of Taste|Completed|||450|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:40.335107|2018-06-01 05:36:40.335107
NCT00000630|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|December 1992|Actual|1992-12-31|||||Interventional|||Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)|Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)|Completed||Phase 1|35||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.603404|2018-06-01 05:36:32.603404
NCT00000629|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||October 2003|2003-10-31||||||||Interventional|||The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.|The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.|Completed||Phase 1|6||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.7253|2018-06-01 05:36:32.7253
NCT00000628|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-07-29|2001-08-30|2001-08-31|Estimate|||||||2008-07-29|2008-07-30|Estimate||||October 1994|1994-10-31||||||||Interventional|||A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine|A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine|Completed||Phase 1|27||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.808765|2018-06-01 05:36:32.808765
NCT00000627|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|November 1994|Actual|1994-11-30|||||Interventional|||Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome|Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome|Completed||N/A|90||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:32.905601|2018-06-01 05:36:32.905601
NCT00000626|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-05-22|2001-08-30|2001-08-31|Estimate|||||||2012-05-22|2012-05-23|Estimate||||May 2012|2012-05-31|February 1999|Actual|1999-02-28|||||Interventional|||Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease|Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease|Completed||Phase 2|27||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:33.016161|2018-06-01 05:36:33.016161
NCT00000625|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-03-30|2001-08-30|2001-08-31|Estimate|||||||2012-03-30|2012-04-02|Estimate||||March 2012|2012-03-31|November 1995|Actual|1995-11-30|||||Interventional|||A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3|A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3|Completed||Phase 2|2100||National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||||||||||||2018-06-01 05:36:33.140246|2018-06-01 05:36:33.140246
NCT00023192|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-29|||2008-03-03|2001-08-29|2001-08-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2001||2001-08-31|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care|Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care|Completed||Phase 3|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:33.306261|2018-06-01 05:36:33.306261
NCT00023166|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-24|||2005-06-23|2001-08-25|2001-08-27|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2001||2001-05-31|March 2004|2004-03-31|May 2002||2002-05-31|||||Interventional|||Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas|Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors and Lymphomas|Terminated||Phase 1|||Enzon Pharmaceuticals, Inc.|||||||||||||||||||2018-06-01 05:36:33.364369|2018-06-01 05:36:33.364369
NCT00023153|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-24|||2008-03-03|2001-08-24|2001-08-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2001||2001-08-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection|Studies of the Addition of Adefovir Dipivoxil to Lamivudine for the Treatment of Chronic Hepatitis B: A Randomized, Double-Blind, Placebo Controlled Study in HIV-Infected Patients and an Open-Label Study in HIV-Negative Subjects|Completed||Phase 3|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:33.420897|2018-06-01 05:36:33.420897
NCT00023140|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-22|||2015-04-13|2001-08-23|2001-08-24|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 1999||1999-07-31|April 2015|2015-04-30|June 2002|Actual|2002-06-30|May 2002|Actual|2002-05-31||Observational|||Collaborative Study of 1,3 Butadiene Biomarkers|Collaborative Study of 1,3 Butadiene Biomarkers|Completed|||80||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:33.482567|2018-06-01 05:36:33.482567
NCT00023127|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-22|||2006-03-22|2001-08-23|2001-08-24|Estimate|||||||2006-03-22|2006-03-23|Estimate||||March 2006|2006-03-31||||||||Interventional|||Reducing Indoor Allergen Exposures in Northern Manhattan and the South Bronx||Completed||N/A|40||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:33.525378|2018-06-01 05:36:33.525378
NCT00023114|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-22|||2006-09-01|2001-08-23|2001-08-24|Estimate|||||||2006-09-01|2006-09-04|Estimate|September 2000||2000-09-30|September 2006|2006-09-30|September 2001||2001-09-30|||||Observational|||p450 Mediated Lung Toxicity||Completed|||10||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:33.566239|2018-06-01 05:36:33.566239
NCT00023101|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-22|||2006-03-22|2001-08-23|2001-08-24|Estimate|||||||2006-03-22|2006-03-23|Estimate|August 1996||1996-08-31|March 2006|2006-03-31||||||||Observational|||Lead, Endocrine Disruption and Reproductive Outcomes||Completed|||800||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:33.611556|2018-06-01 05:36:33.611556
NCT00023088|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-22|||2017-06-30|2001-08-22|2001-08-23|Estimate|||||||2017-06-30|2017-07-02|Actual|April 13, 1994||1994-04-13|July 9, 2008|2008-07-09|July 9, 2008||2008-07-09|||||Observational|||Screening Study for the Department of Rehabilitation Medicine|Rehabilitation Medicine Screening Protocol|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:33.688474|2018-06-01 05:36:33.688474
NCT00023075|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-22|||2008-03-03|2001-08-22|2001-08-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2001||2001-08-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Observational|||Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis|Nuclear Magnetic Spectroscopy for the Evaluation of Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis|Completed|||55||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:33.754117|2018-06-01 05:36:33.754117
NCT00023062|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-22|||2008-03-03|2001-08-22|2001-08-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2001||2001-08-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Observational|||Transcranial Magnetic Stimulation in Parkinson's Disease|TMS Measures in Parkinson's Disease|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:34.134429|2018-06-01 05:36:34.134429
NCT00022984|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-17|||2008-03-03|2001-08-17|2001-08-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2001||2001-08-31|August 2004|2004-08-31|August 2004||2004-08-31|||||Observational|||Technology Dependency and Health-Related Quality of Life|Toward a Theory of Technology Dependency and Health Related Quality of Life (HRQL): A Test of a Model in Patients With an Implantable Cardioverter Defibrillator|Completed|||125||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:40.429909|2018-06-01 05:36:40.429909
NCT00022971|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-17|||2018-05-24|2001-08-17|2001-08-20|Estimate|||||||2018-05-24|2018-05-25|Actual|August 15, 2001||2001-08-15|March 17, 2017|2017-03-17|March 17, 2017|Actual|2017-03-17|January 22, 2010|Actual|2010-01-22||Interventional|||Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia|Combination Antibody Therapy With Apolizumab (1D10) and Rituximab (CD20) in Relapsed Lymphoma and CLL|Terminated||Phase 1|35|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:36:40.559822|2018-06-01 05:36:40.559822
NCT00022958|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-16|||2005-06-23|2001-08-17|2001-08-20|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1998||1998-09-30|August 2004|2004-08-31||||||||Interventional|||Expanded Access Study of Iodine-131 Anti-B1 Antibody|Expanded Access Study of Iodine-131 Anti-B1 Antibody for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma|Unknown status|Active, not recruiting|N/A|||Corixa Corporation|||||||||||||||||||2018-06-01 05:36:40.811448|2018-06-01 05:36:40.811448
NCT00022945|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-16|||2005-06-23|2001-08-17|2001-08-20|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2005|2005-01-31||||||||Interventional|||Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma|Phase II Study Of Iodine-131 Anti-B1 Antibody Plus CHOP For Patients With Previously Untreated Mantle Cell Lymphoma|Completed||Phase 2|||Corixa Corporation|||||||||||||||||||2018-06-01 05:36:41.051178|2018-06-01 05:36:41.051178
NCT00022932|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-16|||2005-06-23|2001-08-17|2001-08-20|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|September 2004|2004-09-30||||||||Interventional|||Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP|Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-Line CHOP|Unknown status|Active, not recruiting|Phase 2|||Corixa Corporation|||||||||||||||||||2018-06-01 05:36:42.065256|2018-06-01 05:36:42.065256
NCT00022919|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-16|||2008-03-03|2001-08-16|2001-08-17|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2001||2001-08-31|August 2004|2004-08-31|August 2004||2004-08-31|||||Observational|||Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods|Analysis of Prostate Cancer Short-Term Cultures Utilizing Molecular Cytogenetic Methods|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:42.150359|2018-06-01 05:36:42.150359
NCT00022906|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-15|||2005-06-23|2001-08-16|2001-08-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1999||1999-05-31|August 2004|2004-08-31||||||||Interventional|||Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement|Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody For Patients With Previously Treated Non-Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement|Unknown status|Active, not recruiting|Phase 1|24||Corixa Corporation|||||||||||||||||||2018-06-01 05:36:42.221197|2018-06-01 05:36:42.221197
NCT00022893|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-15|||2005-06-23|2001-08-16|2001-08-17|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2004|2004-08-31||||||||Interventional|||Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma|Retreatment Study of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti-B1 Antibody.|Unknown status|Active, not recruiting|N/A|||Corixa Corporation|||||||||||||||||||2018-06-01 05:36:42.291231|2018-06-01 05:36:42.291231
NCT00022880|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-15|||2005-06-23|2001-08-16|2001-08-17|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1999||1999-07-31|August 2004|2004-08-31||||||||Interventional|||Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia|A Phase I, Dose-Escalation, Open-Label, Multicenter Study of Iodine-131, Anti-B1 Antibody for Intermediate- and High-Risk B-Cell Chronic Lymphocytic Leukemia|Unknown status|Active, not recruiting|Phase 1|30||Corixa Corporation|||||||||||||||||||2018-06-01 05:36:42.362381|2018-06-01 05:36:42.362381
NCT00022867|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-14|||2015-07-23|2001-08-15|2001-08-16|Estimate|||||||2015-07-23|2015-07-24|Estimate|May 2001||2001-05-31|July 2015|2015-07-31|November 2006|Actual|2006-11-30|January 2005|Actual|2005-01-31||Interventional|||Encouraging Calcium Absorption and Bone Formation During Early Puberty|Optimization of Calcium Absorption and Bone Formation During Early Puberty|Completed||Phase 1/Phase 2|100||Baylor College of Medicine|||||f||||t||||||||||2018-06-01 05:36:42.439222|2018-06-01 05:36:42.439222
NCT00022854|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-14|||2013-05-02|2001-08-15|2001-08-16|Estimate|||||||2013-05-02|2013-05-03|Estimate|May 2001||2001-05-31|May 2013|2013-05-31|January 2005|Actual|2005-01-31|||||Interventional|||Pain Relief Results After Anterior Cruciate Ligament (ACL) Reconstruction|Outcomes After ACL Reconstruction: The Effect of Femoral Nerve Block Analgesia|Completed||Phase 4|270|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-06-01 05:36:42.506711|2018-06-01 05:36:42.506711
NCT00022841|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-14|||2007-12-14|2001-08-15|2001-08-16|Estimate|||||||2007-12-14|2007-12-19|Estimate||||December 2007|2007-12-31|September 2005|Actual|2005-09-30|||||Interventional|||Prevention of Steroid-Induced Osteoporosis in Children|Prevention of Steroid-Induced Osteoporosis in Children|Terminated||Phase 1/Phase 2|40||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||||Inadequate eligible subjects to expect sufficient numbers to analyse outcomes.|||||||||||||||2018-06-01 05:36:42.684134|2018-06-01 05:36:42.684134
NCT00022828|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-14|||2007-01-02|2001-08-15|2001-08-16|Estimate|||||||2007-01-02|2007-01-04|Estimate|January 2003||2003-01-31|October 2006|2006-10-31|January 2006||2006-01-31|||||Observational|||3-D Laser Imaging to Analyze Neck Movement|3-D Laser Imaging for Cervical Spine Motion Analysis|Unknown status|Active, not recruiting||134||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:36:42.781831|2018-06-01 05:36:42.781831
NCT00022815|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-14|||2008-04-11|2001-08-15|2001-08-16|Estimate|||||||2008-04-11|2008-04-14|Estimate|June 2002||2002-06-30|April 2008|2008-04-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Management of Compartment Syndrome With Ultrafiltration|Management of Compartment Syndrome With Ultrafiltration|Completed||Phase 1|10||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:36:42.874179|2018-06-01 05:36:42.874179
NCT00022802|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-14|||2009-04-07|2001-08-15|2001-08-16|Estimate|||||||2009-04-07|2009-04-09|Estimate|December 2002||2002-12-31|April 2009|2009-04-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Image Guided System for Orthopaedic Surgery|Image Guided Surgical System for Orthopaedic Trauma|Terminated||Phase 2|40||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||||Grant expired|f||||||||||||||2018-06-01 05:36:42.942337|2018-06-01 05:36:42.942337
NCT00022776|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-13|||2013-02-26|2001-08-14|2001-08-15|Estimate|||||||2013-02-26|2013-02-27|Estimate|September 2000||2000-09-30|February 2013|2013-02-28|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Surgical Versus Nonsurgical Treatment for Spinal Stenosis|Randomized Clinical Trial of Treatment for Spinal Stenosis|Completed||Phase 3|178|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-06-01 05:36:43.034678|2018-06-01 05:36:43.034678
NCT00021944|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-07-28|2001-08-09|2001-08-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2001||2001-04-30|January 2008|2008-01-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Non-Traditional Cardiovascular Risk Factors in Type 2 Diabetes Mellitus - Ancillary to VA Study of Glycemic Control||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:36:43.400248|2018-06-01 05:36:43.400248
NCT00021931|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-03-15|2001-08-09|2001-08-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 2001||2001-04-30|July 2005|2005-07-31|March 2005|Actual|2005-03-31|||||Observational|||Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:36:43.45059|2018-06-01 05:36:43.45059
NCT00021918|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-02-17|2001-08-09|2001-08-10|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2001||2001-04-30|October 2005|2005-10-31|June 2004|Actual|2004-06-30|||||Observational|||Serum Total Homocysteine and C-Reactive Protein - Ancillary to IDNT||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:36:43.498147|2018-06-01 05:36:43.498147
NCT00021905|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2008-07-23|2001-08-09|2001-08-10|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 2002||2002-07-31|July 2008|2008-07-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Atrial Fibrillation Incidence, Risk Factors and Genetics||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:36:43.590454|2018-06-01 05:36:43.590454
NCT00021892|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2014-02-20|2001-08-09|2001-08-10|Estimate|||||||2014-02-20|2014-02-21|Estimate|June 2001||2001-06-30|February 2014|2014-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Ventricular Matrix Remodeling: Correlates and Prognosis||Completed|||||Boston University|||||f||||||||||||||2018-06-01 05:36:43.745578|2018-06-01 05:36:43.745578
NCT00021879|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-10|||2016-02-17|2001-08-09|2001-08-10|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 2001||2001-03-31|January 2008|2008-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||Visceral Adiposity and CVD Risk in Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:36:43.785934|2018-06-01 05:36:43.785934
NCT00021866|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-08|||2013-11-08|2001-08-09|2001-08-10|Estimate|||||||2013-11-08|2013-11-11|Estimate|September 2000||2000-09-30|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2010|Actual|2010-08-31||Observational|||Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy|Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study|Completed|||331|Actual|Emory University|||4||f||||t||||||Samples With DNA|"~     Venous blood for AED levels Cord Blood for G6PD, Homocysteine Saliva for drug metabolizing~     enzymes, antioxidant enzymes, DNA repair enzymes, drug membrane transporter proteins and~     folate-related genes~   "|||2018-06-01 05:36:43.833051|2018-06-01 05:36:43.833051
NCT00021853|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-08|||2008-03-03|2001-08-08|2001-08-09|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2001||2001-08-31|August 2002|2002-08-31|August 2002||2002-08-31|||||Interventional|||Motor Training to Treat Hand Dystonia|Motor Training as Treatment of Focal Hand Dystonia|Completed||Phase 2|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:44.057626|2018-06-01 05:36:44.057626
NCT00021840|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-07|||2014-08-01|2001-08-06|2001-08-07|Estimate|||||||2014-08-01|2014-08-04|Estimate|July 2001||2001-07-31|August 2014|2014-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Genetic Epidemiology of Asthma in Costa Rica|Genetic Epidemiology of Asthma in Costa Rica|Completed|||4245|Actual|Brigham and Women's Hospital|||1||f||||f||||||Samples With DNA|"~     Blood (and its components, e.g., serum, WBC, etc.)~   "|||2018-06-01 05:36:44.125625|2018-06-01 05:36:44.125625
NCT00021827|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-04|||2010-03-01|2001-08-03|2001-08-06|Estimate|||||||2010-03-01|2010-03-02|Estimate|June 1999||1999-06-30|March 2010|2010-03-31|December 2001||2001-12-31|||||Interventional|||PTHrP and Osteoporosis|Pathophysiology of PTH-related Protein in Humans.|Completed||Phase 2|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:36:44.206043|2018-06-01 05:36:44.206043
NCT00021814|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-04|||2010-01-12|2001-08-03|2001-08-06|Estimate|||||||2010-01-12|2010-01-14|Estimate|December 1995||1995-12-31|January 2010|2010-01-31|March 1998||1998-03-31|||||Interventional|||Medical Therapy of Prostatic Symptoms (MTOPS)||Completed||Phase 3|2931||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 05:36:44.285944|2018-06-01 05:36:44.285944
NCT00021801|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-04|||2010-03-01|2001-08-03|2001-08-06|Estimate|||||||2010-03-01|2010-03-02|Estimate|March 2000||2000-03-31|March 2010|2010-03-31|September 2000||2000-09-30|||||Interventional|||Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen|Pathways to Tolerance in Human Islet Transplantation|Completed||Phase 2|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:36:44.417042|2018-06-01 05:36:44.417042
NCT00021788|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-04|||2010-07-07|2001-08-03|2001-08-06|Estimate|||||||2010-07-07|2010-07-09|Estimate|July 2000||2000-07-31|July 2010|2010-07-31|December 2001||2001-12-31|||||Interventional|||Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression|Immunomodulation for Islet Transplantation in Diabetes|Completed||Phase 2|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:36:44.494946|2018-06-01 05:36:44.494946
NCT00021749|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-03|||2009-11-10|2001-08-04|2001-08-06|Estimate|||||||2009-11-10|2009-11-13|Estimate|January 2001||2001-01-31|November 2009|2009-11-30||||January 2003|Actual|2003-01-31||Interventional|||Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia|Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia|Completed||Phase 1/Phase 2|40|Actual|Genta Incorporated|||||f||||f||||||||||2018-06-01 05:36:44.564816|2018-06-01 05:36:44.564816
NCT00021736|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-03|||2005-06-23|2001-08-04|2001-08-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2001||2001-07-31|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Phase II/III Study of Anti-VEGF in Neovascular AMD|Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD).|Completed||Phase 2/Phase 3|540||Eyetech Pharmaceuticals|||||||||||||||||||2018-06-01 05:36:44.702874|2018-06-01 05:36:44.702874
NCT00021723|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-02|||2009-09-22|2001-08-03|2001-08-06|Estimate|||||||2009-09-22|2009-09-24|Estimate|September 2001||2001-09-30|November 2001|2001-11-30|September 2003||2003-09-30|||||Interventional|||Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease||Terminated||Phase 2|375||JANSSEN Alzheimer Immunotherapy Research & Development, LLC|||||||||||||||||||2018-06-01 05:36:44.762877|2018-06-01 05:36:44.762877
NCT00021710|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-02|||2008-03-03|2001-08-02|2001-08-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2001||2001-07-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Motor Learning in Stroke Patients and Healthy Volunteers|Motor Learning: Behavioral and Physiologic Studies in Normal Volunteers and Stroke Patients|Completed|||78||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:44.835277|2018-06-01 05:36:44.835277
NCT00018317|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2000||2000-10-31|December 2004|2004-12-31|December 2005||2005-12-31|||||Interventional|||Resistance Training and Diet in Patients With Chronic Renal Failure|Resistance Training and Diet in Patients With Chronic Renal Failure|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.144658|2018-06-01 05:36:49.144658
NCT00021697|ClinicalTrials.gov processed this data on May 31, 2018|2001-08-01|||2016-07-13|2001-08-02|2001-08-03|Estimate|||||||2016-07-13|2016-07-14|Estimate|January 2001||2001-01-31|July 2016|2016-07-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS|A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis|Completed||Phase 3|100||Avanir Pharmaceuticals|||||||||||||||||||2018-06-01 05:36:44.896894|2018-06-01 05:36:44.896894
NCT00021658|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-30|||2014-09-26|2001-07-31|2001-08-01|Estimate|||||||2014-09-26|2014-09-29|Estimate|October 1999||1999-10-31|July 2014|2014-07-31|September 2003||2003-09-30|||||Interventional|||Effects of Pesticide Exposure on Neurodevelopment/Growth/Respiratory Health||Completed||N/A|550||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:44.990558|2018-06-01 05:36:44.990558
NCT00021645|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-26|||2008-03-03|2001-07-26|2001-07-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2001||2001-07-31|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||Vitamin E to Treat Uveitis-Associated Macular Edema|Randomized Masked Study to Evaluate the Use of Vitamin E in the Treatment of Uveitis-Associated Macular Edema|Completed||Phase 1|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:45.046714|2018-06-01 05:36:45.046714
NCT00021580|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-24|||2005-06-23|2001-07-25|2001-07-26|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2004|2004-04-30||||||||Interventional|||"Modification of the Edmonton Protocol to Allow for Successful Islet Transplantation From a Single Pancreas and Extension of the Edmonton Protocol to Kidney Transplant Recipients"|"Modification of the Edmonton Protocol to Allow for Successful Islet Transplantation From a Single Pancreas and Extension of the Edmonton Protocol to Kidney Transplant Recipients (Project 1 of JDFI Washington University Center for Islet Transplantation)"|Unknown status|Active, not recruiting|Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:45.101278|2018-06-01 05:36:45.101278
NCT00021567|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-24|||2008-03-03|2001-07-24|2001-07-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2001||2001-07-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections|A Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterial in Previously Treated or Moderate to Severe Pulmonary Mycobacterium Avium Complex (MAC) Infection|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:45.163608|2018-06-01 05:36:45.163608
NCT00021541|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-19|2012-03-30||2018-03-15|2001-07-21|2001-07-23|Estimate|2012-08-13|2012-09-17|Estimate||||2018-03-15|2018-04-17|Actual|July 17, 2001|Actual|2001-07-17|March 2018|2018-03-31|February 19, 2009|Actual|2009-02-19|February 19, 2009|Actual|2009-02-19||Interventional|||R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas|A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas|Completed||Phase 2|62|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f|||f|||No||2018-06-01 05:36:45.243165|2018-06-01 05:36:45.243165
NCT00021528|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-20|||2009-09-24|2001-07-21|2001-07-23|Estimate|||||||2009-09-24|2009-09-25|Estimate|July 2001||2001-07-31|September 2006|2006-09-30|September 2006||2006-09-30|||||Interventional|||Sequenced Treatment Alternatives to Relieve Depression (STAR*D)|Sequenced Treatment Alternatives to Relieve Depression|Completed||Phase 4|4000||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:36:45.818565|2018-06-01 05:36:45.818565
NCT00021502|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-18|||2009-08-13|2001-07-19|2001-07-20|Estimate|||||||2009-08-13|2009-08-14|Estimate|March 2001||2001-03-31|August 2009|2009-08-31|May 2004|Actual|2004-05-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)|A Phase 3, Multi-Center, Randomized, Placebo Controlled Study of PHP When Administered by Continuous Infusion in Patients With Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)|Completed||Phase 3|1000||Apex Bioscience|||||||||||||||||||2018-06-01 05:36:46.013144|2018-06-01 05:36:46.013144
NCT00021476|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-16|||2013-08-09|2001-07-17|2001-07-18|Estimate|||||||2013-08-09|2013-08-13|Estimate|May 2001||2001-05-31|August 2013|2013-08-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Preventing Chronic Whiplash Pain|Preventing Chronic Whiplash Pain: Biobehavioral Approach|Completed||Phase 3|300||University of Washington|||||f||||||||||||||2018-06-01 05:36:46.067657|2018-06-01 05:36:46.067657
NCT00021437|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-11|||2005-06-23|2001-07-12|2001-07-13|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Biological Significance of the Bloom's Syndrome Protein|Biological Significance of the Bloom's Syndrome Protein|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:46.175021|2018-06-01 05:36:46.175021
NCT00018902|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-10|||2014-03-11|2001-07-11|2001-07-12|Estimate|||||||2014-03-11|2014-03-12|Estimate|January 2001||2001-01-31|March 2014|2014-03-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|TORDIA||Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)|Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)|Completed||Phase 2/Phase 3|334|Actual|University of Pittsburgh||4|||||||t||||||||||2018-06-01 05:36:46.234085|2018-06-01 05:36:46.234085
NCT00018889|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-07|||2018-04-24|2001-07-07|2001-07-09|Estimate|||||||2018-04-24|2018-04-25|Actual|July 6, 2001||2001-07-06|April 11, 2018|2018-04-11||||||||Observational|||Phenotype/Genotype Correlations in Movement Disorders|Phenotype/Genotype Correlations in Movement Disorders|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:46.346874|2018-06-01 05:36:46.346874
NCT00018876|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-05|||2013-06-06|2001-07-06|2001-07-09|Estimate|||||||2013-06-06|2013-06-07|Estimate|October 2000||2000-10-31|March 2006|2006-03-31|October 2002||2002-10-31|||||Interventional|||Low-Dose Radiation to Prevent Complications of Back Surgery|Radiotherapy to Prevent Fibrosis After Lumbar Laminectomy|Completed||Phase 1|46||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:36:46.430866|2018-06-01 05:36:46.430866
NCT00018863|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-05|||2013-11-01|2001-07-06|2001-07-09|Estimate|||||||2013-11-01|2013-11-04|Estimate|April 2001||2001-04-30|October 2006|2006-10-31||||March 2006|Actual|2006-03-31||Interventional|||Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS)|Methylphenidate Efficacy and Safety in ADHD Preschoolers|Unknown status|Active, not recruiting|Phase 3|165||New York State Psychiatric Institute|||||||||||||||||||2018-06-01 05:36:46.500578|2018-06-01 05:36:46.500578
NCT00018850|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|June 1998||1998-06-30|December 2004|2004-12-31|June 2003||2003-06-30|||||Interventional|||5HT3 Antagonism and Auditory Gating in Schizophrenia|5HT3 Antagonism and Auditory Gating in Schizophrenia|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:46.601091|2018-06-01 05:36:46.601091
NCT00018837|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|December 2004|2004-12-31|March 2001||2001-03-31|||||Interventional|||Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome|Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:46.674882|2018-06-01 05:36:46.674882
NCT00018824|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-09-21|2001-07-04|2001-07-05|Estimate|||||||2009-09-21|2009-09-23|Estimate|October 1999||1999-10-31|September 2009|2009-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Treating Alcohol Use In Older Adults With Depression|The Treatment of Late Life Major Depression Complication by Alcohol|Completed||Phase 4|74|Actual|VA Office of Research and Development||2|||f||||||||||||||2018-06-01 05:36:46.732511|2018-06-01 05:36:46.732511
NCT00018811|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|December 2003|2003-12-31|March 2003||2003-03-31|||||Interventional|||Psychological Assessment and Treatment of Chronic Benign Headache|Psychological Assessment and Treatment of Chronic Benign Headache|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:46.795238|2018-06-01 05:36:46.795238
NCT00018798|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 2000||2000-04-30|December 2004|2004-12-31|April 2003||2003-04-30|||||Observational|||Post-Traumatic Stress Disorder (PTSD) Symptom Study|Longitudinal Evaluation of Chronic Combat-Related PTSD|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:46.856336|2018-06-01 05:36:46.856336
NCT00018785|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1998||1998-10-31|December 2004|2004-12-31|September 2003||2003-09-30|||||Interventional|||Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants|Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:46.905346|2018-06-01 05:36:46.905346
NCT00018772|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|December 2004|2004-12-31|April 2003||2003-04-30|||||Observational|||Risk Factors for Venous Thromboembolism|2779 Epidemiology of Genetic and Acquired Risk Factors for Venous Thrombosis|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:46.956187|2018-06-01 05:36:46.956187
NCT00018759|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2001||2001-03-31|December 2004|2004-12-31|October 2003||2003-10-31|||||Interventional|||Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients|Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.010072|2018-06-01 05:36:47.010072
NCT00018746|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|July 1999||1999-07-31|December 2004|2004-12-31|July 2001||2001-07-31|||||Interventional|||Transcranial Magnetic Stimulation in Depression|Efficacy of Threshold vs. Subthreshold TMS in the Treatment of Depression|Completed||Phase 1|||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:36:47.067197|2018-06-01 05:36:47.067197
NCT00018733|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|September 1996||1996-09-30|December 2004|2004-12-31|December 2001||2001-12-31|||||Interventional|||Biological Aspects of Depression and Antidepressant Drugs|Biological Aspects of Depression and Antidepressant Drugs|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.115518|2018-06-01 05:36:47.115518
NCT00018720|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1996||1996-04-30|December 2004|2004-12-31|December 2000||2000-12-31|||||Observational|||Regulation of Sterol Homeostasis|Regulation of Sterol Homeostasis|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.164543|2018-06-01 05:36:47.164543
NCT00018707|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|December 2004|2004-12-31|March 2003||2003-03-31|||||Observational|||Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress|Follow-up of Psychological and Neurocognitive Gulf War Outcome: Relation to Stress|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.209209|2018-06-01 05:36:47.209209
NCT00018694|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2013-10-11|2001-07-04|2001-07-05|Estimate|||||||2013-10-11|2013-10-14|Estimate|October 1999||1999-10-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Cholestanol in Humans|Biologic Significance of Cholestanol in Man|Withdrawn||N/A|0|Actual|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:36:47.254648|2018-06-01 05:36:47.254648
NCT00018681|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|December 2004|2004-12-31|January 2002||2002-01-31|||||Observational|||Regulation of Human Intestinal Bile Acid Transport in Health and Disease|Regulation of Human Intestinal Bile Acid Transport in Health and Disease|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.312057|2018-06-01 05:36:47.312057
NCT00018668|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2000||2000-10-31|December 2004|2004-12-31|September 2004||2004-09-30|||||Interventional|||Antipsychotic Response in Schizophrenia|Psychopharmacologic Aspects of Motor Slowing in Schizophrenia|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.380352|2018-06-01 05:36:47.380352
NCT00018655|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2014-12-09|2001-07-04|2001-07-05|Estimate|||||||2014-12-09|2014-12-10|Estimate|April 2000||2000-04-30|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2009|Actual|2009-09-30||Interventional|||Integrated Intervention for Substance Abusers With Depressive Disorders|Integrated Intervention for Substance Abusers With Depressive Disorders|Terminated||Phase 2|276|Actual|VA Office of Research and Development||2||"PI has been contacted numerous times for an update, with no response. ORD requested a close out~   of this project. 10/2011"|f||||t||||||||||2018-06-01 05:36:47.433145|2018-06-01 05:36:47.433145
NCT00018642|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1997||1997-04-30|December 2004|2004-12-31|March 2002||2002-03-31|||||Interventional|||Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder|Predicting the Optimal Pharmacotherapy for Outpatients With Schizophrenia|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.49968|2018-06-01 05:36:47.49968
NCT00018629|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-05|2001-07-04|2001-07-05|Estimate|||||||2009-01-05|2009-01-07|Estimate|May 2000||2000-05-31|September 2008|2008-09-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Cognitive - Behavioral Therapy|Rehabilitation of Older Patients With Schizophrenia|Completed||Phase 2|76|Actual|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.550445|2018-06-01 05:36:47.550445
NCT00018616|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-09-21|2001-07-04|2001-07-05|Estimate|||||||2009-09-21|2009-09-23|Estimate|October 1999||1999-10-31|September 2009|2009-09-30|January 2005|Actual|2005-01-31|January 2004|Actual|2004-01-31||Interventional|||Improving Compliance With Metformin|Improving Compliance With Metformin|Completed||Phase 2|79|Actual|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:36:47.688176|2018-06-01 05:36:47.688176
NCT00018603|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 1999||1999-11-30|December 2004|2004-12-31|October 2002||2002-10-31|||||Interventional|||Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)|Guanfacine for the Treatment of PTSD|Completed||Phase 1|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.763424|2018-06-01 05:36:47.763424
NCT00018577|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2008-04-02|2001-07-04|2001-07-05|Estimate|||||||2008-04-02|2008-04-04|Estimate|October 2000||2000-10-31|December 2004|2004-12-31|September 2002||2002-09-30|||||Observational|||The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men|The Association of Neurotoxin Exposure With Parkinson's Disease and Parkinsonism in World War II Veterans and Other Men|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.893872|2018-06-01 05:36:47.893872
NCT00018564|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2000||2000-10-31|December 2004|2004-12-31|September 2003||2003-09-30|||||Interventional|||Novel Therapies for Essential Tremor|Novel Therapies for Essential Tremor|Completed||Phase 3|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:47.987396|2018-06-01 05:36:47.987396
NCT00018551|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1998||1998-10-31|December 2004|2004-12-31|September 2003||2003-09-30|||||Interventional|||Chemoprevention With Folic Acid|3389 Colorectal Adenoma: Chemoprevention With Folic Acid|Completed||Phase 2|||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:36:48.076307|2018-06-01 05:36:48.076307
NCT00018538|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|December 2004|2004-12-31|September 2002||2002-09-30|||||Interventional|||Calcifidol Therapy in Men With Cancer|Calcifidol Therapy in Men With Cancer|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.135021|2018-06-01 05:36:48.135021
NCT00018525|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2000||2000-10-31|December 2004|2004-12-31|September 2002||2002-09-30|||||Interventional|||Lung Volume Reductions Surgery (LVRS) Study|Effects of Lung Volume Reduction Surgery in the Treatment of Severe Emphysema|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.203036|2018-06-01 05:36:48.203036
NCT00018512|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|December 2004|2004-12-31|September 2004||2004-09-30|||||Interventional|||Biological Specifications for Denture Designs|Biological Specifications for Denture Designs|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.267334|2018-06-01 05:36:48.267334
NCT00018499|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1998||1998-10-31|December 2004|2004-12-31|October 2001||2001-10-31|||||Observational|||Genotype Influence on Recovery After Traumatic Brain Injury|The Influence of APOE Genotype on Recovery After Traumatic Brain Injury|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.319011|2018-06-01 05:36:48.319011
NCT00018486|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|December 2004|2004-12-31|March 2004||2004-03-31|||||Observational|||Epidemiology of Hearing Loss in Diabetic and Non-Diabetic Veterans|Epidemiology of Hearing Loss in Diabetic and Non-Diabetic Veterans|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.370976|2018-06-01 05:36:48.370976
NCT00018473|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|December 2004|2004-12-31|March 2004||2004-03-31|||||Observational|||Gene-Environment Interactions in Alzheimer's Disease|Gene-Environment Interactions in Alzheimer's Disease|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.416899|2018-06-01 05:36:48.416899
NCT00018460|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|December 2004|2004-12-31|March 2002||2002-03-31|||||Interventional|||Anticoagulation, Vitamins, and Endothelial Function|Anticoagulation, Vitamins, and Endothelial Function|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.480225|2018-06-01 05:36:48.480225
NCT00018447|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 1998||1998-11-30|December 2004|2004-12-31|October 2003||2003-10-31|||||Interventional|||Combination Osteogenic Therapy in Established Osteoporosis|Combination Osteogenic Therapy in Established Osteoporosis|Completed||Phase 2|||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:36:48.53424|2018-06-01 05:36:48.53424
NCT00018434|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2015-06-25|2001-07-04|2001-07-05|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 1998||1998-07-31|June 2015|2015-06-30|June 2001||2001-06-30|||||Observational|||The Epidemiology of Infection With Vancomycin-Resistant Enterococci|The Epidemiology of Infection With Vancomycin-Resistant Enterococci|Completed|||||VA Office of Research and Development|||1||f||||||||||||||2018-06-01 05:36:48.59958|2018-06-01 05:36:48.59958
NCT00018421|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|July 1997||1997-07-31|December 2004|2004-12-31|June 2001||2001-06-30|||||Interventional|||Effects of Exercise on Patients With Hemiparetic Stroke|Effects of Exercise on Patients With Hemiparetic Stroke|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.656279|2018-06-01 05:36:48.656279
NCT00018408|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1998||1998-10-31|December 2004|2004-12-31|September 2001||2001-09-30|||||Observational|||Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)|Genetic Mechanisms of Chronic Obstructive Pulmonary Disease|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.722104|2018-06-01 05:36:48.722104
NCT00018395|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|August 1997||1997-08-31|December 2004|2004-12-31|June 2002||2002-06-30|||||Observational|||Cardiovascular Mortality Associated With Abnormal Calcium Metabolism|Cardiovascular Mortality Associated With Abnormal Calcium Metabolism|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.777623|2018-06-01 05:36:48.777623
NCT00018382|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|December 2004|2004-12-31|March 2003||2003-03-31|||||Interventional|||Insulin, Neurogenetics and Memory in Alzheimer's Disease|Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:48.828988|2018-06-01 05:36:48.828988
NCT00018369|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|December 2000||2000-12-31|December 2004|2004-12-31|April 2004||2004-04-30|||||Observational|||Age-Related Changes in Stress Hormone Regulation|Mechanism of Aging-Related Changes in (HPA) Hydrocortisone Corticotropin Feedback Function|Completed|||||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:36:48.883465|2018-06-01 05:36:48.883465
NCT00018356|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2011-06-22|2001-07-04|2001-07-05|Estimate|||||||2011-06-22|2011-06-23|Estimate|January 1999||1999-01-31|June 2011|2011-06-30|August 2006|Actual|2006-08-31|July 2006|Actual|2006-07-31||Interventional|||Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly|Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly|Completed||Phase 4|88|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:36:48.956605|2018-06-01 05:36:48.956605
NCT00018343|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|December 2004|2004-12-31|March 2001||2001-03-31|||||Interventional|||Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen|Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.023353|2018-06-01 05:36:49.023353
NCT00018278|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1998||1998-10-31|December 2004|2004-12-31|September 2001||2001-09-30|||||Interventional|||Electrophysiologic Measures of Treatment Response in Alzheimer Disease|Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease|Completed||Phase 4|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.318145|2018-06-01 05:36:49.318145
NCT00018265|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|December 2004|2004-12-31|September 2003||2003-09-30|||||Interventional|||Fitness and Daily Function in Adults|Oxygen Kinetics, Mobility Task Performance, and Task Training in Older Adults|Completed||Phase 3|140||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.373059|2018-06-01 05:36:49.373059
NCT00018252|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1997||1997-04-30|June 2001|2001-06-30|March 2000||2000-03-31|||||Interventional|||The Effect of Exercise Training on Mental Stress-Induced Silent Ischemia|The Effect of Exercise Training on Mental Stress-Induced Silent Ischemia|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.42427|2018-06-01 05:36:49.42427
NCT00018239|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|December 2004|2004-12-31|September 2002||2002-09-30|||||Interventional|||Aging and Cellular Mechanism for Insulin Action After Exercise Training|Aging and Cellular Mechanism for Insulin Action After Exercise Training|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.484009|2018-06-01 05:36:49.484009
NCT00018226|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|December 2004|2004-12-31|March 2001||2001-03-31|||||Interventional|||Effect Of Case Management Following Discharge From Methadone Treatment|Enhanced Outreach Counseling Following Methadone Treatment Discharge|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.541916|2018-06-01 05:36:49.541916
NCT00018213|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|September 2007|2007-09-30|March 2001||2001-03-31|||||Interventional|||Naltrexone and Patch for Smokers|Naltrexone and Nicotine Replacement Effects on Cue Reactivity of Smokers|Completed||N/A|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.592627|2018-06-01 05:36:49.592627
NCT00018200|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2012-06-04|2001-07-04|2001-07-05|Estimate|||||||2012-06-04|2012-06-05|Estimate|April 1999||1999-04-30|June 2012|2012-06-30|March 2004|Actual|2004-03-31|December 2003|Actual|2003-12-31||Interventional|||Effect of Antidepressants on Back Pain|Efficacy of Antidepressants in Chronic Back Pain|Completed||Phase 2|130|Actual|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 05:36:49.650392|2018-06-01 05:36:49.650392
NCT00018187|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 1998||1998-11-30|May 2007|2007-05-31|June 2001||2001-06-30|||||Interventional|||Combinations of Pharmacologic Smoking Cessation Treatments|Combinations of Pharmacologic Smoking Cessation Treatments|Completed||Phase 1|||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:36:49.733512|2018-06-01 05:36:49.733512
NCT00018174|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-02-26|2001-07-04|2001-07-05|Estimate|||||||2009-02-26|2009-03-02|Estimate|February 1998||1998-02-28|February 2009|2009-02-28|January 2005|Actual|2005-01-31|January 2003|Actual|2003-01-31||Interventional|||Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers|Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers|Completed||Phase 3|247|Actual|VA Office of Research and Development||2|||f||||||||||||||2018-06-01 05:36:49.782014|2018-06-01 05:36:49.782014
NCT00018161|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2009-01-20|2001-07-04|2001-07-05|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1997||1997-01-31|September 2007|2007-09-30|June 2001||2001-06-30|||||Interventional|||Treatment to Quit Smoking|Combined Pharmacologic/Behavioral Treatment for Smoking Cessation|Completed||Phase 2|||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:36:49.852394|2018-06-01 05:36:49.852394
NCT00018148|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2010-09-14|2001-07-04|2001-07-05|Estimate|||||||2010-09-14|2010-09-15|Estimate|April 1998||1998-04-30|September 2010|2010-09-30|January 2003|Actual|2003-01-31|December 2002|Actual|2002-12-31||Interventional|||Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation|Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation|Completed||Phase 2|158|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:36:49.905599|2018-06-01 05:36:49.905599
NCT00018135|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2005-06-23|2001-07-04|2001-07-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals|Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals|Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:49.990171|2018-06-01 05:36:49.990171
NCT00018122|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2005-06-27|2001-07-04|2001-07-05|Estimate|||||||2005-06-27|2005-06-28|Estimate||||December 2003|2003-12-31||||||||Observational|||Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls|Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls (Project 2 of JDFI Washington University Center for Islet Transplantation, KS Polonsky, PI)|Unknown status|Active, not recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:50.059185|2018-06-01 05:36:50.059185
NCT00018109|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-03|||2005-06-23|2001-07-04|2001-07-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)|A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)|Completed||Phase 3|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:50.110373|2018-06-01 05:36:50.110373
NCT00018096|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-02|||2008-05-05|2001-07-03|2001-07-04|Estimate|||||||2008-05-05|2008-05-06|Estimate|June 2001||2001-06-30|May 2008|2008-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Genetics of Environmental Asthma|The Genetics of Environmental Asthma|Completed||N/A|176|Actual|National Institute of Environmental Health Sciences (NIEHS)||1|||f||||f||||||||||2018-06-01 05:36:50.25709|2018-06-01 05:36:50.25709
NCT00018083|ClinicalTrials.gov processed this data on May 31, 2018|2001-07-02|||2005-06-23|2001-07-03|2001-07-04|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen|Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen|Unknown status|Recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:50.383937|2018-06-01 05:36:50.383937
NCT00018070|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-30|||2017-06-30|2001-06-30|2001-07-02|Estimate|||||||2017-06-30|2017-07-02|Actual|June 28, 2001||2001-06-28|August 30, 2006|2006-08-30|August 30, 2006||2006-08-30|||||Interventional|||Identification and Treatment of Feeder Vessels in Macular Degeneration|Feasibility Study of the Identification and Treatment of Feeder-Vessels of Choroidal Neovascularization in Age-Related Macular Degeneration|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:50.487546|2018-06-01 05:36:50.487546
NCT00018057|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-29|||2018-05-22|2001-06-29|2001-07-02|Estimate|||||||2018-05-22|2018-05-23|Actual|June 27, 2001||2001-06-27|May 7, 2018|2018-05-07||||||||Observational|||Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes|Fluoxetine's Effects on Attention and Emotional Memory in Anxious and Depressed Youth and Adults|Recruiting|||2530|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:50.606237|2018-06-01 05:36:50.606237
NCT00018044|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-28|||2018-04-03|2001-06-28|2001-06-29|Estimate|||||||2018-04-03|2018-04-04|Actual|June 27, 2001||2001-06-27|March 16, 2018|2018-03-16||||||||Observational|||Study of Mycobacterial Infections|Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections|Recruiting|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:50.719151|2018-06-01 05:36:50.719151
NCT00018031|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-27|2013-01-18||2014-09-25|2001-06-27|2001-06-28|Estimate|2014-09-25|2014-10-01|Estimate||||2014-09-25|2014-10-01|Estimate|June 2001||2001-06-30|September 2014|2014-09-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|HEPCPR||Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients|A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin|Completed||Phase 2|36|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:36:50.839878|2018-06-01 05:36:50.839878
NCT00018018|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-27|||2018-05-15|2001-06-27|2001-06-28|Estimate|||||||2018-05-15|2018-05-16|Actual|June 20, 2001||2001-06-20|September 17, 2014|2014-09-17|September 17, 2014|Actual|2014-09-17|||||Interventional|||Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency|Treatment of SCID Due to ADA Deficiency With Autologous Cord Blood or Bone Marrow CD34+ Cells Transduced With a Human ADA Gene|Completed||Phase 1|8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:51.079536|2018-06-01 05:36:51.079536
NCT00018005|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-26|||2012-10-19|2001-06-25|2001-06-26|Estimate|||||||2012-10-19|2012-10-22|Estimate|June 2001||2001-06-30|October 2012|2012-10-31|June 2007|Actual|2007-06-30|||||Interventional|HART||A Self-Management Intervention for Mild to Moderate Heart Failure|Heart Failure Adherence and Retention Trial (HART)|Completed||Phase 3|902|Actual|Rush University Medical Center|||||f||||t||||||||||2018-06-01 05:36:51.151599|2018-06-01 05:36:51.151599
NCT00017979|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-23|||2008-03-03|2001-06-23|2001-06-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2001||2001-06-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Study of Brain Control of Movement|Effect of Volitional Inhibition on Cortical Inhibitory Mechanisms|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:51.220371|2018-06-01 05:36:51.220371
NCT00017966|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-23|||2008-03-03|2001-06-23|2001-06-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2001||2001-06-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Brain Excitability During Self-Paced Voluntary Movements|Cortical Excitability During Self-Paced Voluntary Movements|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:51.284856|2018-06-01 05:36:51.284856
NCT00017940|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-20|||2009-12-10|2001-06-21|2001-06-22|Estimate|||||||2009-12-10|2009-12-11|Estimate||||July 2005|2005-07-31|November 2003|Actual|2003-11-30|November 2003|Actual|2003-11-30||Interventional|||Gene Therapy for Alzheimer's Disease Clinical Trial|A Phase I Study of Ex Vivo Nerve Growth Factor Gene Therapy for Alzheimer's Disease|Completed||Phase 1|8||National Institute on Aging (NIA)|||||||||||||||||||2018-06-01 05:36:51.34575|2018-06-01 05:36:51.34575
NCT00017953|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-21|||2018-03-06|2001-06-20|2001-06-21|Estimate|||||||2018-03-06|2018-03-08|Actual|June 2001|Actual|2001-06-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|September 2012|Actual|2012-09-30||Interventional|LookAHEAD||Look AHEAD: Action for Health in Diabetes|Look AHEAD: Action for Health in Diabetes|Active, not recruiting||N/A|5145|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||Yes|We plan to share data sets through the NIDDK repository, baseline data sets are currently available. Outcome data will be available approximately 1 year after the study is over.|2018-06-01 05:36:51.427613|2018-06-01 05:36:51.427613
NCT00017927|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-20|||2008-03-03|2001-06-20|2001-06-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2001||2001-06-30|June 2005|2005-06-30|June 2005||2005-06-30|||||Interventional|||A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome|A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome|Completed||Phase 3|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:51.598768|2018-06-01 05:36:51.598768
NCT00017914|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-19|||2018-05-17|2001-06-19|2001-06-20|Estimate|||||||2018-05-17|2018-05-18|Actual|June 8, 1994||1994-06-08|March 6, 2018|2018-03-06||||||||Observational|||Adult and Juvenile Myositis|Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies|Recruiting|||1200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:51.68947|2018-06-01 05:36:51.68947
NCT00017875|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-15|||2008-03-03|2001-06-15|2001-06-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2001||2001-06-30|July 2005|2005-07-31|July 2005||2005-07-31|||||Observational|||Transcranial Magnetic Stimulation (TMS) Studies of Dystonia|Neurophysiological Studies of Focal and Generalized Forms of Dystonia Using Transcranial Magnetic Stimulation (TMS)|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:51.79214|2018-06-01 05:36:51.79214
NCT00017836|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-15|||2014-05-28|2001-06-14|2001-06-15|Estimate|||||||2014-05-28|2014-05-29|Estimate|June 2001||2001-06-30|May 2014|2014-05-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Mechanisms Linking Depression to Cardiovascular Risk||Completed|||||Emory University|||||f||||||||||||||2018-06-01 05:36:51.841534|2018-06-01 05:36:51.841534
NCT00017823|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-13|||2010-04-20|2001-06-13|2001-06-14|Estimate|||||||2010-04-20|2010-04-21|Estimate||||April 2001|2001-04-30||||||||Interventional|||Acupressure to Treat Nausea and Vomiting in HIV/AIDS Patients|The Acupressure Study|Completed||Phase 1|||National Institute of Nursing Research (NINR)|||||f||||||||||||||2018-06-01 05:36:51.882443|2018-06-01 05:36:51.882443
NCT00017810|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-13|||2005-12-08|2001-06-13|2001-06-14|Estimate|||||||2005-12-08|2005-12-09|Estimate||||April 2001|2001-04-30||||||||Interventional|||The Healthy Life Choices Project in HIV-Positive Patients||Unknown status|Recruiting|Phase 1|||National Institute of Nursing Research (NINR)|||||f||||||||||||||2018-06-01 05:36:51.939584|2018-06-01 05:36:51.939584
NCT00017745|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-08|||2017-06-30|2001-06-08|2001-06-11|Estimate|||||||2017-06-30|2017-07-02|Actual|June 1, 2001||2001-06-01|May 10, 2007|2007-05-10|May 10, 2007||2007-05-10|||||Observational|||Phenotype/Genotype Correlations in Neuromuscular Disorders|Phenotype/Genotype Correlations in Inherited Myopathies|Completed|||1000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:51.989518|2018-06-01 05:36:51.989518
NCT00017732|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-08|||2008-03-03|2001-06-08|2001-06-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2001||2001-06-30|March 2003|2003-03-31|March 2003||2003-03-31|||||Observational|||Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans|Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans|Completed|||2000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:52.038991|2018-06-01 05:36:52.038991
NCT00017706|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-07|||2010-01-12|2001-06-06|2001-06-07|Estimate|||||||2010-01-12|2010-01-14|Estimate||||January 2010|2010-01-31|May 2001||2001-05-31|||||Interventional|||Effectiveness of Primary Care Physicians in Delivering Weight Control Counseling|Treatment of Obesity in the Primary Care Setting|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:36:52.084202|2018-06-01 05:36:52.084202
NCT00016848|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2008-03-03|2001-06-06|2001-06-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2001||2001-06-30|May 2003|2003-05-31|May 2003||2003-05-31|||||Observational|||Effects of Dietary Carbohydrate and Fat on Hormones|The Effects of Dietary Carbohydrate and Fat on Hormone Regulators of Body Composition and Reproduction|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:52.133842|2018-06-01 05:36:52.133842
NCT00016835|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-05|||2017-07-14|2001-06-06|2001-06-07|Estimate|||||||2017-07-14|2017-07-19|Actual|October 17, 2001|Actual|2001-10-17|July 2017|2017-07-31|September 3, 2004|Actual|2004-09-03|September 3, 2004|Actual|2004-09-03||Interventional|||Treating Periodontal Infection: Effects on Glycemic|Treating Periodontal Infection: Effects on Glycemic Control in People With Type 2 Diabetes|Completed||Phase 2|46|Actual|University of Michigan||3|||f||||t||||||||No|There is no current plan to share data with other researchers at this time|2018-06-01 05:36:52.185879|2018-06-01 05:36:52.185879
NCT00017680|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2008-06-06|2001-06-05|2001-06-06|Estimate|||||||2008-06-06|2008-06-09|Estimate|July 1999||1999-07-31|June 2008|2008-06-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis|Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in|Completed||Phase 2|25||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:36:52.277781|2018-06-01 05:36:52.277781
NCT00017654|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2005-06-23|2001-06-05|2001-06-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2001||2001-04-30|October 2003|2003-10-31||||||||Interventional|||Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia||Unknown status|Active, not recruiting|N/A|3||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:36:52.335917|2018-06-01 05:36:52.335917
NCT00017641|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2005-06-23|2001-06-05|2001-06-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2001||2001-04-30|November 2003|2003-11-30||||||||Interventional|||Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus||Unknown status|Active, not recruiting|Phase 1|10||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:36:52.395076|2018-06-01 05:36:52.395076
NCT00017628|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-06|||2005-06-23|2001-06-05|2001-06-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2001||2001-04-30|July 2004|2004-07-31||||||||Interventional|||Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis||Completed||Phase 1|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:36:52.450773|2018-06-01 05:36:52.450773
NCT00016796|ClinicalTrials.gov processed this data on May 31, 2018|2001-06-02|||2008-03-03|2001-06-02|2001-06-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2001||2001-05-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||Language Stimuli Screening in Children|Language Stimuli Screening in Children|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:52.521776|2018-06-01 05:36:52.521776
NCT00016744|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-31|||2009-01-08|2001-06-01|2001-06-04|Estimate|||||||2009-01-08|2009-01-09|Estimate|September 2001||2001-09-30|January 2009|2009-01-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)|A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous Cystic Fibrosis Patients|Completed||Phase 1/Phase 2|12|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-06-01 05:36:52.570506|2018-06-01 05:36:52.570506
NCT00016731|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-31|||2018-05-24|2001-05-31|2001-06-01|Estimate|||||||2018-05-24|2018-05-25|Actual|May 29, 2001||2001-05-29|October 18, 2017|2017-10-18|October 18, 2017||2017-10-18|||||Observational|||Adolescence, Puberty, and Emotion Regulation|Adolescence, Puberty, Hormones, and Emotion Regulation: An fMRI Study|Completed|||300|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:52.634329|2018-06-01 05:36:52.634329
NCT00016679|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-24|||2008-03-03|2001-05-24|2001-05-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2001||2001-05-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Interventional|||1-Octanol to Treat Essential Tremor|Dose Finding Study of 1-Octanol in Essential Tremor|Completed||Phase 1|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:52.684757|2018-06-01 05:36:52.684757
NCT00016666|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-23|||2017-06-30|2001-05-23|2001-05-24|Estimate|||||||2017-06-30|2017-07-02|Actual|May 21, 2001||2001-05-21|January 19, 2007|2007-01-19|January 19, 2007||2007-01-19|||||Interventional|||Clinical Trial of Propranolol for Seasonal Affective Disorder|Treatment of Winter Depression With Pharmacological Suppression of Melatonin Secretion|Completed||Phase 2|70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:53.648505|2018-06-01 05:36:53.648505
NCT00016653|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-21|||2011-10-26|2001-05-22|2001-05-23|Estimate|||||||2011-10-26|2011-10-27|Estimate|June 2000||2000-06-30|October 2011|2011-10-31|December 2006||2006-12-31|||||Interventional|||Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy|A Multicenter Randomized Placebo-controlled Double-blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy|Completed||Phase 2/Phase 3|48||Cooperative International Neuromuscular Research Group|||||||||||||||||||2018-06-01 05:36:53.715207|2018-06-01 05:36:53.715207
NCT00016627|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-19|||2016-02-17|2001-05-18|2001-05-21|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 2000||2000-08-31|November 2005|2005-11-30|July 2005|Actual|2005-07-31|||||Observational|||Linkage Study in Familial Pulmonary Fibrosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:36:53.78815|2018-06-01 05:36:53.78815
NCT00016562|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-16|||2017-06-30|2001-05-16|2001-05-17|Estimate|||||||2017-06-30|2017-07-02|Actual|May 13, 2001||2001-05-13|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||Cause and Pathogenesis of Neurometabolic Disorders|The Etiology and Pathogenesis of Neurometabolic Disorders|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:53.839854|2018-06-01 05:36:53.839854
NCT00016549|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-16|||2017-06-30|2001-05-16|2001-05-17|Estimate|||||||2017-06-30|2017-07-02|Actual|May 13, 2001||2001-05-13|April 6, 2012|2012-04-06|January 29, 2007|Actual|2007-01-29|January 29, 2007|Actual|2007-01-29||Interventional|||Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer|A Pilot Study to Evaluate Angiogenesis After Treatment With Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) in Previously Untreated Patients With Inflammatory Breast Cancer or Locally Advanced Breast Cancer|Completed||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:53.925182|2018-06-01 05:36:53.925182
NCT00016523|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-14|||2017-09-22|2001-05-15|2001-05-16|Estimate|||||||2017-09-22|2017-09-26|Actual|January 2001||2001-01-31|September 2017|2017-09-30|May 2006|Actual|2006-05-31|September 2003|Actual|2003-09-30||Interventional|Preemie iNO||Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure|Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure|Terminated||Phase 3|420|Actual|NICHD Neonatal Research Network||2||Preliminary results showed increased intraventricular hemorrhage (IVH) in experimental arm|f||||t||||||||||2018-06-01 05:36:54.046496|2018-06-01 05:36:54.046496
NCT00016510|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-12|||2008-03-03|2001-05-12|2001-05-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2001||2001-05-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Differences in Brain Processing of First and Second Languages (Korean and English)|Differences of Verbal Working Memory and Translation Systems Between First and Second Languages: a Functional MRI Study|Completed|||63||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:54.207092|2018-06-01 05:36:54.207092
NCT00016497|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-10|||2006-04-21|2001-05-11|2001-05-14|Estimate|||||||2006-04-21|2006-04-24|Estimate|February 1997||1997-02-28|April 2006|2006-04-30|January 2007||2007-01-31|||||Interventional|||Adenoidectomy for Otitis Media in 2-3 Year Old Children|Adenoidectomy for Otitis Media in 2-3 Year Old Children|Terminated||Phase 3|||National Institute on Deafness and Other Communication Disorders (NIDCD)|||||f||||||||||||||2018-06-01 05:36:54.366293|2018-06-01 05:36:54.366293
NCT00016471|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-07|||2005-06-23|2001-05-08|2001-05-09|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2001||2001-03-31|November 2003|2003-11-30|February 2002||2002-02-28|||||Observational|||A Genetic Analysis of Usher Syndrome in Ashkenazi Jews|A Genetic Analysis of Usher Syndrome in Ashkenazi Jews|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:54.570869|2018-06-01 05:36:54.570869
NCT00016458|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2008-09-02|2001-05-04|2001-05-07|Estimate|||||||2008-09-02|2008-09-03|Estimate|June 2000||2000-06-30|September 2008|2008-09-30||||||||Interventional|||Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis||Completed||Phase 2|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:36:54.694368|2018-06-01 05:36:54.694368
NCT00016445|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2008-09-08|2001-05-04|2001-05-07|Estimate|||||||2008-09-08|2008-09-09|Estimate|February 2001||2001-02-28|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Phase II Study of Growth Hormone in Children With Cystic Fibrosis||Completed||Phase 2|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:36:54.772416|2018-06-01 05:36:54.772416
NCT00015808|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-06|||2006-07-11|2001-05-05|2001-05-07|Estimate|||||||2006-07-11|2006-07-12|Estimate|May 2001||2001-05-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Safety Study of Idebenone to Treat Friedreich's Ataxia|Phase I Clinical Trial to Establish the Maximum Tolerated Dose of Idebenone in Children, Adolescents, and Adults With Friedreich's Ataxia|Completed||Phase 1|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:54.850365|2018-06-01 05:36:54.850365
NCT00015795|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-04|||2008-03-03|2001-05-04|2001-05-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2001||2001-05-31|June 2003|2003-06-30|June 2003||2003-06-30|||||Interventional|||Study of Air Stream in Voice Production|Laryngeal Resistance in Abductor Spasmodic Dysphonia|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:54.930474|2018-06-01 05:36:54.930474
NCT00015782|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-04|||2017-06-30|2001-05-04|2001-05-07|Estimate|||||||2017-06-30|2017-07-02|Actual|April 27, 2001||2001-04-27|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||The Natural History and Pathogenesis of Mucolipidosis Type IV|The Natural History and Pathogenesis of Mucolipidosis Type IV|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:55.003944|2018-06-01 05:36:55.003944
NCT00015769|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-04|||2008-03-03|2001-05-04|2001-05-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2001||2001-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness|Pilot Evaluation of Levetiracetam (Keppra® (Registered Trademark)) in Bipolar Illness|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:55.08599|2018-06-01 05:36:55.08599
NCT00015756|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-04|||2017-06-30|2001-05-04|2001-05-07|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2, 2001||2001-05-02|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Tissue Collection From People With Cystic Fibrosis|Tissue Collection Protocol for Individuals With Cystic Fibrosis|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:55.153072|2018-06-01 05:36:55.153072
NCT00015717|ClinicalTrials.gov processed this data on May 31, 2018|2001-05-02|||2008-03-03|2001-05-02|2001-05-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2001||2001-04-30|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Magnetic Resonance Imaging to Investigate Silent Strokes During Neck and Skull Angioplasty|Silent Cerebral Ischemia After Cervico-Cranial Angioplasty Detected by Diffusion-Weighted MRI|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:55.209974|2018-06-01 05:36:55.209974
NCT00015678|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-28|||2008-03-03|2001-04-28|2001-04-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2001||2001-04-30|April 2002|2002-04-30|April 2002||2002-04-30|||||Observational|||Effects of Flumazenil on Brain Excitability|Effects of Flumazenil on Cortical Excitability in Humans|Completed|||7||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:55.264272|2018-06-01 05:36:55.264272
NCT00015665|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-28|||2008-03-03|2001-04-28|2001-04-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2001||2001-04-30|March 2003|2003-03-31|March 2003||2003-03-31|||||Interventional|||Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections|Open-Label, Non-Comparative Protocol for the Emergency Use of Voriconazole in Patients With Life Threatening, Invasive Mycoses Who Are Failing on Currently Available Antifungal Agents|Completed||Phase 3|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:55.334991|2018-06-01 05:36:55.334991
NCT00015639|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-25|||2008-03-03|2001-04-25|2001-04-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2001||2001-04-30|February 2004|2004-02-29|February 2004||2004-02-29|||||Observational|||Identification of Donors of CD36-Deficient Platelets Among Japanese Individuals on the NIH Campus|Identification of Donors of CD36-Deficient Platelets Among Individuals on the NIH Campus|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:55.401301|2018-06-01 05:36:55.401301
NCT00015626|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-24|||2005-06-23|2001-04-25|2001-04-26|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)|A Clinical Trial to Prevent the Complications of Insulin Resistance (Including Type-2 Diabetes)|Completed||Phase 2|300||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:55.457678|2018-06-01 05:36:55.457678
NCT00015613|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-23|||2005-11-02|2001-04-24|2001-04-25|Estimate|||||||2005-11-02|2005-11-03|Estimate|August 1998||1998-08-31|September 2002|2002-09-30|September 2001||2001-09-30|||||Observational|||Farm Work & Preterm Low Birthweight Among Hispanic Women|Study of Hispanic Acculturation Reproduction and the Environment (SHARE)|Completed|||1500||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:55.509136|2018-06-01 05:36:55.509136
NCT00015600|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-23|||2006-03-22|2001-04-24|2001-04-25|Estimate|||||||2006-03-22|2006-03-23|Estimate|October 1997||1997-10-31|March 2006|2006-03-31|September 2002||2002-09-30|||||Interventional|||Community-Based Environmental Health Intervention|Community-Based Environmental Health Intervention|Completed||N/A|500||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:55.558104|2018-06-01 05:36:55.558104
NCT00013351|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|January 2001|2001-01-31|March 2001|Actual|2001-03-31|||||Observational|||Restricted Useful Field View as a Risk Factor in Older Adults|Restricted Useful Field View as a Risk Factor in Older Adults|Completed|||150||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.198653|2018-06-01 05:37:10.198653
NCT00015587|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-23|||2016-10-11|2001-04-24|2001-04-25|Estimate|||||||2016-10-11|2016-10-12|Estimate|April 1995||1995-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|CCLS||Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)|Chemical Exposures and Leukemia Risks and Childhood Leukemia and Environmental Exposure|Completed|||3523|Actual|National Institute of Environmental Health Sciences (NIEHS)|||||f||||f||||||Samples With DNA|"~     pre-treatment peripheral blood and bone marrow saliva~   "|||2018-06-01 05:36:55.715426|2018-06-01 05:36:55.715426
NCT00015574|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-20|||2006-09-01|2001-04-21|2001-04-23|Estimate|||||||2006-09-01|2006-09-04|Estimate|September 1998||1998-09-30|September 2006|2006-09-30|September 2004||2004-09-30|||||Observational|||Air Pollution and Implantable Cardioverter Defibrillators||Completed|||500||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:55.841803|2018-06-01 05:36:55.841803
NCT00015561|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-20|||2006-09-01|2001-04-21|2001-04-23|Estimate|||||||2006-09-01|2006-09-04|Estimate|September 1996||1996-09-30|September 2006|2006-09-30|August 2001||2001-08-31|||||Observational|||Pesticides--Health Fertility and Reproductive Risk||Completed|||1803||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:55.903883|2018-06-01 05:36:55.903883
NCT00015548|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-20|||2015-06-16|2001-04-21|2001-04-23|Estimate|||||||2015-06-16|2015-06-17|Estimate|March 2001||2001-03-31|February 2009|2009-02-28|October 2004||2004-10-31|||||Interventional|||CATIE-Alzheimer's Disease Trial|Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)|Completed||N/A|450||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:36:55.989836|2018-06-01 05:36:55.989836
NCT00015483|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-20|||2006-09-01|2001-04-20|2001-04-23|Estimate|||||||2006-09-01|2006-09-04|Estimate||||September 2006|2006-09-30||||||||Observational|||Hematotoxic Effects of Particulate Exposure|Hematotoxic Effects of Benzene and Doxorubicin|Completed|||||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:56.437851|2018-06-01 05:36:56.437851
NCT00015470|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-19|||2017-06-30|2001-04-19|2001-04-20|Estimate|||||||2017-06-30|2017-07-02|Actual|April 16, 2001||2001-04-16|May 10, 2007|2007-05-10|May 10, 2007||2007-05-10|||||Observational|||Diagnostic Evaluation of Patients With Neuromuscular Disease|Diagnostic Evaluation of Patients With Neuromuscular Diseases|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:56.509574|2018-06-01 05:36:56.509574
NCT00015457|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|2013-03-14||2013-03-14|2001-04-18|2001-04-19|Estimate|2013-03-14|2013-04-01|Estimate||||2013-03-14|2013-04-01|Estimate|April 2001||2001-04-30|March 2013|2013-03-31||||April 2009|Actual|2009-04-30||Interventional|||Amlodipine Plus Botulinum Toxin for Focal Dystonia|Trial of Amlodipine Combined With Botulinum Toxin Injections for Focal Dystonia|Completed||Phase 2|16|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:36:56.67259|2018-06-01 05:36:56.67259
NCT00015444|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2018-05-22|2001-04-18|2001-04-19|Estimate|||||||2018-05-22|2018-05-23|Actual|May 1, 2001||2001-05-01|May 7, 2018|2018-05-07||||||||Observational|||Screening and Natural History: Primary Lateral Sclerosis and Related Disorders|Screening and Natural History: Primary Lateral Sclerosis and Related Disorders|Active, not recruiting|||189|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:56.992143|2018-06-01 05:36:56.992143
NCT00015431|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2018-02-13|2001-04-18|2001-04-19|Estimate|||||||2018-02-13|2018-02-14|Actual|April 16, 2001||2001-04-16|July 10, 2013|2013-07-10|July 10, 2013||2013-07-10|||||Observational|||Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms|The Immune Basis for the Gastrointestinal Complications of Common Variable Immunodeficiency|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:57.132|2018-06-01 05:36:57.132
NCT00015015|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-17|||2006-09-01|2001-04-18|2001-04-19|Estimate|||||||2006-09-01|2006-09-04|Estimate|December 1994||1994-12-31|September 2006|2006-09-30|October 2002||2002-10-31|||||Observational|||Dichloroacetate Kinetics, Metabolism and Toxicology||Completed|||100||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:57.190122|2018-06-01 05:36:57.190122
NCT00015340|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1999||1999-08-31|August 2016|2016-08-31|September 2001|Actual|2001-09-30|August 2001|Actual|2001-08-31||Interventional|||Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14|Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study|Completed||Phase 4|582|Actual|National Institute on Drug Abuse (NIDA)||1|||f||||||||||||||2018-06-01 05:36:57.243556|2018-06-01 05:36:57.243556
NCT00015301|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-02-23|2001-04-17|2001-04-18|Estimate|||||||2017-02-23|2017-02-24|Actual|December 2003|Actual|2003-12-31|December 2002|2002-12-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11|Methylphenidate Raclopride PET Test|Completed||Phase 4|0||National Institute on Drug Abuse (NIDA)|||||f|||||t|f||||||||2018-06-01 05:36:57.349129|2018-06-01 05:36:57.349129
NCT00015288|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1996||1996-11-30|August 1998|1998-08-31||||||||Interventional|||Buprenorphine and Naloxone Combination Study - 10|PK0496 Pharmacokinetics of Buprenorphine|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:57.413533|2018-06-01 05:36:57.413533
NCT00015275|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate||||December 2002|2002-12-31||||||||Interventional|||Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9|Pathophysiological Subtyping of Abnormalities in Cocaine Dependence|Completed||Phase 4|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:57.468217|2018-06-01 05:36:57.468217
NCT00015249|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 1997||1997-02-28|June 1998|1998-06-30|May 1998|Actual|1998-05-31|April 1998|Actual|1998-04-30||Interventional|||Prepulse Inhibition of Startle in Cocaine Dependence - 7|Prepulse Inhibition of Startle in Cocaine Dependence (Human)|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:57.519653|2018-06-01 05:36:57.519653
NCT00015236|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 1997||1997-03-31|June 1998|1998-06-30||||||||Interventional|||Modeling Impaired Judgement in Cocaine Abusers - 6|Modeling Impaired Judgement in Cocaine Abusers|Completed||Phase 4|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:57.644651|2018-06-01 05:36:57.644651
NCT00015223|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-13|2001-04-17|2001-04-18|Estimate|||||||2017-01-13|2017-01-16|Estimate|June 1997||1997-06-30|October 2012|2012-10-31|August 1999|Actual|1999-08-31|July 1999|Actual|1999-07-31||Interventional|||Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5|Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:57.708154|2018-06-01 05:36:57.708154
NCT00015210|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2015-07-29|2001-04-17|2001-04-18|Estimate|||||||2015-07-29|2015-07-30|Estimate|February 1997||1997-02-28|July 2015|2015-07-31||||May 1999|Actual|1999-05-31||Interventional|||Nefazodone in the Treatment of Cocaine Dependence and Depression - 4|Efficacy of Nefazodone in Cocaine Dependent Subjects|Completed||Phase 2|69|Actual|Boston Medical Center||2|||f||||||||||||||2018-06-01 05:36:57.885366|2018-06-01 05:36:57.885366
NCT00015171|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-13|2001-04-17|2001-04-18|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 1996||1996-04-30|January 1999|1999-01-31|June 1997|Actual|1997-06-30|May 1997|Actual|1997-05-31||Interventional|||Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1|CS1008 A&B Eff/Safety Trial of BUP/NX for the Treatment of Opiate Dependence|Completed||Phase 3|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:57.994711|2018-06-01 05:36:57.994711
NCT00015132|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 1999||1999-03-31|March 1999|1999-03-31|November 2000|Actual|2000-11-30|September 2000|Actual|2000-09-30||Interventional|||Tiagabine, Sertraline, or Donepezil for the Treatment of Cocaine Dependence - 9|CREST-II: Tiagabine, Sertraline, or Donepezil vs. Unmatched Placebo|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:58.08797|2018-06-01 05:36:58.08797
NCT00015106|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1997||1997-11-30|February 1999|1999-02-28|February 1999|Actual|1999-02-28|January 1999|Actual|1999-01-31||Interventional|||Resperine, Gabapentin, or Lamotrigine for the Treatment of Cocaine Dependence: 2 - 7|CREST-I: Resperine, Gabapentin, or Lamotrigine vs. Placebo|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:58.169499|2018-06-01 05:36:58.169499
NCT00015080|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-13|2001-04-17|2001-04-18|Estimate|||||||2017-01-13|2017-01-16|Estimate|May 1995||1995-05-31|December 1996|1996-12-31|July 1996|Actual|1996-07-31|June 1996|Actual|1996-06-30||Interventional|||Naltrexone in Treatment of Cocaine Dependence - 5|Naltrexone in Treatment of Cocaine Dependence|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:58.253561|2018-06-01 05:36:58.253561
NCT00015067|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 1997||1997-12-31|October 1998|1998-10-31||||||||Interventional|||Cocaine-Methylphendidate Interaction Study - 4|Cocaine-Methylphendidate Interaction Study|Completed||Phase 1|8||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:58.473683|2018-06-01 05:36:58.473683
NCT00015054|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-13|2001-04-17|2001-04-18|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 1998||1998-09-30|February 1999|1999-02-28|November 1999|Actual|1999-11-30|October 1999|Actual|1999-10-31||Interventional|||Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3|MPD04961-Methylphendidate Treatment of Cocaine Dependent ADHD Patients|Completed||Phase 2|20||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:58.539592|2018-06-01 05:36:58.539592
NCT00015041|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-11|2001-04-17|2001-04-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1996||1996-11-30|July 1998|1998-07-31|July 1998|Actual|1998-07-31|June 1998|Actual|1998-06-30||Interventional|||Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2|PK 0396 - Buprenorphine Dose Escalation Trial|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:58.605924|2018-06-01 05:36:58.605924
NCT00015028|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-18|||2017-01-13|2001-04-17|2001-04-18|Estimate|||||||2017-01-13|2017-01-16|Estimate|November 1996||1996-11-30|November 1996|1996-11-30|January 1997|Actual|1997-01-31|December 1996|Actual|1996-12-31||Interventional|||Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1|CS1008A Efficacy/Safety Trial of Buprenorphine/Naloxone|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:36:58.706309|2018-06-01 05:36:58.706309
NCT00015002|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-17|||2016-09-29|2001-04-17|2001-04-18|Estimate|||||||2016-09-29|2016-10-03|Estimate|March 2000||2000-03-31|September 2016|2016-09-30|March 2007|Actual|2007-03-31|May 2006|Actual|2006-05-31||Interventional|BEARS||Repeat Antenatal Steroids Trial|A Randomized Placebo-Controlled Trial of Antenatal Corticosteroid Regimens|Terminated||Phase 3|486|Actual|The George Washington University Biostatistics Center||||Concerns regarding neonatal data|f||||t||||||||Yes|The data will be shared after completion and publication of the main analyses in accordance with NIH policy. The dataset can be obtained by emailing mfmudatasets@bsc.gwu.edu|2018-06-01 05:36:58.801206|2018-06-01 05:36:58.801206
NCT00014989|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-17|||2016-09-26|2001-04-17|2001-04-18|Estimate|||||||2016-09-26|2016-09-28|Estimate|December 1997||1997-12-31|September 2016|2016-09-30|June 2007|Actual|2007-06-30|February 2007|Actual|2007-02-28||Interventional|BEAM||Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)|Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)|Completed||Phase 3|2136|Actual|The George Washington University Biostatistics Center|||||f||||t||||||||Yes|The data will be shared after completion and publication of the main analyses in accordance with NIH policy. The dataset can be obtained by email at mfmudatasets@bsc.gwu.edu.|2018-06-01 05:36:58.938697|2018-06-01 05:36:58.938697
NCT00014976|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-17|||2017-06-30|2001-04-17|2001-04-18|Estimate|||||||2017-06-30|2017-07-02|Actual|April 13, 2001||2001-04-13|November 1, 2010|2010-11-01|November 1, 2010||2010-11-01|||||Observational|||Physiologic Studies of Spasticity|Spasticity: Physiologic Studies|Completed|||48|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:59.048594|2018-06-01 05:36:59.048594
NCT00014963|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-16|||2006-03-22|2001-04-17|2001-04-18|Estimate|||||||2006-03-22|2006-03-23|Estimate||||March 2006|2006-03-31||||||||Observational|||Biomarkers of Benzene Exposure in Inner City Residents||Completed|||90||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:59.116163|2018-06-01 05:36:59.116163
NCT00014950|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-14|||2010-03-01|2001-04-13|2001-04-16|Estimate|||||||2010-03-01|2010-03-02|Estimate||||March 2010|2010-03-31||||||||Interventional|||Benefits and Risks of Newborn Screening for Cystic Fibrosis|Pulmonary Benefits of Cystic Fibrosis Neonatal Screening|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:36:59.260504|2018-06-01 05:36:59.260504
NCT00014898|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-12|||2005-06-23|2001-04-12|2001-04-13|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|March 2001|2001-03-31|May 2002||2002-05-31|||||Observational|||Attention Deficit Disorder and Exposure to Lead||Completed|||500||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:59.320648|2018-06-01 05:36:59.320648
NCT00014885|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-12|||2006-03-22|2001-04-12|2001-04-13|Estimate|||||||2006-03-22|2006-03-23|Estimate|September 1998||1998-09-30|March 2006|2006-03-31|August 2001||2001-08-31|||||Observational|||Bone Lead Levels and College Achievement Scores||Completed|||750||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:59.380195|2018-06-01 05:36:59.380195
NCT00014872|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-11|||2014-01-09|2001-04-11|2001-04-12|Estimate|||||||2014-01-09|2014-01-10|Estimate|May 2001||2001-05-31|January 2014|2014-01-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Genetic Epidemiology and Energy Metabolism in Black Girls||Completed|||600|Actual|University of New Mexico|||||f||||||||||||||2018-06-01 05:36:59.434136|2018-06-01 05:36:59.434136
NCT00014859|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-11|||2018-04-30|2001-04-11|2001-04-12|Estimate|||||||2018-04-30|2018-05-03|Actual|June 2001|Actual|2001-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|4 Weeks|Observational [Patient Registry]|||Epidemiology of Surfactant Protein-B Deficiency|Epidemiology of Surfactant Protein-B Deficiency|Recruiting|||5000|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples With DNA|"~     DNA and tracheal aspirate samples~   "|||2018-06-01 05:36:59.484399|2018-06-01 05:36:59.484399
NCT00014833|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-11|||2016-04-09|2001-04-11|2001-04-12|Estimate|||||||2016-04-09|2016-04-12|Estimate|March 2001||2001-03-31|April 2016|2016-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Observational|||Life Course Socioeconomic Status, Social Context and Cardiovascular Disease||Completed|||15872|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||Yes|Data shared through LOINCC and directly by request to the PI|2018-06-01 05:36:59.589285|2018-06-01 05:36:59.589285
NCT00014820|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-11|||2015-12-17|2001-04-11|2001-04-12|Estimate|||||||2015-12-17|2015-12-18|Estimate|March 2001||2001-03-31|December 2015|2015-12-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Observational|||Occupation and Asthma in an Urban Low Income Population|Occupation and Asthma in an Urban Low Income Population|Completed|||800|Actual|New York University School of Medicine|||3||f||||||||||||||2018-06-01 05:36:59.645869|2018-06-01 05:36:59.645869
NCT00014807|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-11|||2006-09-01|2001-04-11|2001-04-12|Estimate|||||||2006-09-01|2006-09-04|Estimate|July 2000||2000-07-31|September 2006|2006-09-30|June 2005||2005-06-30|||||Interventional|||Reducing Pesticide Exposure in Minority Families|Reducing Pesticide Exposure in Minority Families|Completed||N/A|1000||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:36:59.693377|2018-06-01 05:36:59.693377
NCT00014794|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-11|||2008-03-03|2001-04-11|2001-04-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2001||2001-04-30|March 2003|2003-03-31|March 2003||2003-03-31|||||Interventional|||Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate Synovial Blood Flow in Rheumatoid Arthritis Patients|H215O Positron Emission Tomography (PET) in the Assessment of Synovial Blood Flow in Rheumatoid Arthritis Patients|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:36:59.746101|2018-06-01 05:36:59.746101
NCT00014781|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2009-03-10|2001-04-10|2001-04-11|Estimate|||||||2009-03-10|2009-03-12|Estimate|February 2001||2001-02-28|March 2009|2009-03-31||||||||Observational|||Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis||Completed|||39|Anticipated|Office of Rare Diseases (ORD)|||||f||||t||||||||||2018-06-01 05:36:59.856673|2018-06-01 05:36:59.856673
NCT00014768|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2005-06-23|2001-04-10|2001-04-11|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2001||2001-02-28|March 2002|2002-03-31||||||||Observational|||Study of Metabolic Effects of Pregnancy in Women With Cystic Fibrosis||Terminated|||36||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:36:59.904207|2018-06-01 05:36:59.904207
NCT00014755|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2005-06-23|2001-04-10|2001-04-11|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1997||1997-12-31|April 2001|2001-04-30||||||||Interventional|||Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis||Completed||Phase 1|35||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:36:59.956451|2018-06-01 05:36:59.956451
NCT00014742|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2015-03-24|2001-04-10|2001-04-11|Estimate|||||||2015-03-24|2015-03-25|Estimate||||April 2001|2001-04-30|April 2004||2004-04-30|||||Interventional|||Phase III Randomized Study of Collagenase in Patients With Residual Stage Dupuytren's Disease||Completed||Phase 3|72|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:37:00.110881|2018-06-01 05:37:00.110881
NCT00014729|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-10|||2015-03-24|2001-04-10|2001-04-11|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2000||2000-10-31|May 2001|2001-05-31|September 2002||2002-09-30|||||Interventional|||Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa||Completed||Phase 1|20||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:37:00.163807|2018-06-01 05:37:00.163807
NCT00014040|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-07|||2008-03-03|2001-04-07|2001-04-09|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2001||2001-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Nitric Oxide Inhalation Therapy to Relieve Chest Pain in Patients With Coronary Artery Disease|Nitric Oxide Inhalation Therapy for Myocardial Ischemia in Patients With Coronary Artery Disease|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:00.223138|2018-06-01 05:37:00.223138
NCT00014027|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-07|||2017-06-30|2001-04-07|2001-04-09|Estimate|||||||2017-06-30|2017-07-02|Actual|April 4, 2001||2001-04-04|July 13, 2010|2010-07-13|April 11, 2008|Actual|2008-04-11|April 11, 2008|Actual|2008-04-11||Interventional|||Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress|Polyunsaturated Fatty Acids and the Neurochemistry of Cardiovascular and Behavioral Responses in Aggressive Alcoholics|Completed||Phase 1|97|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:00.293256|2018-06-01 05:37:00.293256
NCT00014001|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-06|||2015-06-16|2001-04-07|2001-04-09|Estimate|||||||2015-06-16|2015-06-17|Estimate|December 2000||2000-12-31|October 2006|2006-10-31|December 2004||2004-12-31|||||Interventional|||CATIE- Schizophrenia Trial|Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)|Completed||Phase 4|1600||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:37:00.380237|2018-06-01 05:37:00.380237
NCT00013975|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-04|||2008-03-03|2001-04-04|2001-04-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|March 2003|2003-03-31|March 2003||2003-03-31|||||Observational|||Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease|Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:00.704164|2018-06-01 05:37:00.704164
NCT00013962|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-03|||2005-06-23|2001-04-04|2001-04-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Vitamin D Metabolism and the Williams Syndrome|Vitamin D Metabolism and the Williams Syndrome|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:00.792964|2018-06-01 05:37:00.792964
NCT00013949|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-03|||2006-09-01|2001-04-03|2001-04-04|Estimate|||||||2006-09-01|2006-09-04|Estimate|September 1998||1998-09-30|September 2006|2006-09-30|September 2004||2004-09-30|||||Observational|||Cardiovascular Vulnerability to Particulate Exposure|Active Elderly Study|Completed|||200||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:00.870612|2018-06-01 05:37:00.870612
NCT00013936|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-03|||2008-03-03|2001-04-03|2001-04-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Observational|||A Novel Acuity Testing Method|A Novel Acuity Testing Method|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:00.947662|2018-06-01 05:37:00.947662
NCT00013923|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-02|||2009-12-10|2001-04-02|2001-04-03|Estimate|||||||2009-12-10|2009-12-11|Estimate||||August 2003|2003-08-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease|A Nutritional Brain Metabolic Enhancer for Alzheimer Disease|Completed||Phase 2|40||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:37:01.007431|2018-06-01 05:37:01.007431
NCT00013910|ClinicalTrials.gov processed this data on May 31, 2018|2001-04-02|||2005-06-23|2001-04-02|2001-04-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes|NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes|Completed||Phase 1|30||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:01.086282|2018-06-01 05:37:01.086282
NCT00013884|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-31|||2008-03-03|2001-03-31|2001-04-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||HIV Maintenance Therapy With T-20 During HAART Interruption|A Pilot Study to Evaluate the Ability of Maintenance Therapy With the HIV Fusion Inhibitor T20 to Prevent Rebound of Plasma HIV RNA Following an Interruption of HAART|Completed||Phase 2|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:01.321243|2018-06-01 05:37:01.321243
NCT00013845|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-30|||2018-04-03|2001-03-30|2001-04-02|Estimate|||||||2018-04-03|2018-04-04|Actual|May 1, 2001||2001-05-01|March 16, 2018|2018-03-16||||||||Observational|||Evaluation and Treatment of Patients With Epilepsy|Evaluation and Treatment of Patients With Epilepsy|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:01.391396|2018-06-01 05:37:01.391396
NCT00013832|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-30|||2017-06-30|2001-03-30|2001-04-02|Estimate|||||||2017-06-30|2017-07-02|Actual|March 28, 2001||2001-03-28|April 11, 2007|2007-04-11|April 11, 2007||2007-04-11|||||Observational|||Study of Tongue Pressures|Effect of Task on Oral Pressure Dynamics During Swallowing|Completed|||160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:01.461987|2018-06-01 05:37:01.461987
NCT00013819|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-29|||2015-04-13|2001-03-29|2001-03-30|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 1997||1997-02-28|April 2015|2015-04-30|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Observational|||Exposure, Dose, Body Burden and Health Effects of Lead|Exposure, Dose, Body Burden and Health Effects of Lead|Completed|||944||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:01.518714|2018-06-01 05:37:01.518714
NCT00013806|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-29|||2005-06-23|2001-03-29|2001-03-30|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study|CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study|Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:01.560533|2018-06-01 05:37:01.560533
NCT00013793|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-29|||2005-06-23|2001-03-29|2001-03-30|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Ultrasound and Motivational Enhancement for Prenatal Smoking Cessation|Ultrasound and Motivational Enhancement for Prenatal Smoking Cessation|Completed||N/A|30||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:01.618473|2018-06-01 05:37:01.618473
NCT00013780|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-29|||2006-03-22|2001-03-29|2001-03-30|Estimate|||||||2006-03-22|2006-03-23|Estimate|July 1998||1998-07-31|March 2006|2006-03-31|June 2003||2003-06-30|||||Observational|||Ozone Exposure and Dose Delivered to Human Lungs||Completed|||50||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:01.713879|2018-06-01 05:37:01.713879
NCT00013767|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-29|||2015-04-13|2001-03-29|2001-03-30|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 1999||1999-06-30|April 2015|2015-04-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||Community Based Prevention/Control Project|Child Environmental Health Center--Reducing Pesticide Exposure in Children of Farmworkers|Completed||N/A|400||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:01.78565|2018-06-01 05:37:01.78565
NCT00013754|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-29|||2015-04-13|2001-03-29|2001-03-30|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2001||2001-03-31|April 2015|2015-04-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Observational|||Pesticide Exposure Pathways for Farmworker Children|Child Environmental Health Center--Reducing Pesticide Exposure in Children of Farmworkers (UW IRB 96-6567-C02, FENSKE, 6/15/00-6/14/01)|Completed|||40|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:01.829965|2018-06-01 05:37:01.829965
NCT00013741|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-28|||2012-05-23|2001-03-29|2001-03-30|Estimate|||||||2012-05-23|2012-05-24|Estimate||||February 2003|2003-02-28||||||||Interventional|||The MI-HEART Project||Completed||N/A|55||National Library of Medicine (NLM)|||||f||||||||||||||2018-06-01 05:37:01.883841|2018-06-01 05:37:01.883841
NCT00013728|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-28|||2006-03-22|2001-03-29|2001-03-30|Estimate|||||||2006-03-22|2006-03-23|Estimate|September 2000||2000-09-30|March 2006|2006-03-31|October 2003||2003-10-31|||||Observational|||Asthma & Exposure to Peaks in Particulate Air Pollution||Completed|||24||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:02.015683|2018-06-01 05:37:02.015683
NCT00013715|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-28|||2008-08-08|2001-03-29|2001-03-30|Estimate|||||||2008-08-08|2008-08-11|Estimate|September 1999||1999-09-30|August 2008|2008-08-31|August 2003||2003-08-31|||||Observational|||Ozone and Rhinovirus-Induced Disease in Asthmatics||Completed|||60|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:02.07227|2018-06-01 05:37:02.07227
NCT00013702|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-28|||2008-03-03|2001-03-28|2001-03-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients|Adefovir Dipivoxil for the Treatment of Hepatitis B in Human Immunodeficiency Virus Infected Patients With Decompensated Hepatitis B Liver Disease and a Hepatitis B Viral Load of at Least 1.0 X 10(6) (Copies/mL) Despite 52 Weeks of Lamivudine Therapy|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:02.116235|2018-06-01 05:37:02.116235
NCT00013689|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-28|||2008-03-03|2001-03-28|2001-03-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|March 2003|2003-03-31|March 2003||2003-03-31|||||Interventional|||Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome|Pilot Study of Pyrimethamine and Sulfadoxine (Fansidar) for the Treatment of Individuals With the Autoimmune Lymphoproliferative Syndrome (ALPS)|Completed||Phase 1|8||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:02.184935|2018-06-01 05:37:02.184935
NCT00013650|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-27|||2017-06-30|2001-03-27|2001-03-28|Estimate|||||||2017-06-30|2017-07-02|Actual|March 22, 2001||2001-03-22|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Interventional|||Effects of an Anti-Inflammatory Drug in Alzheimer's Disease|Pilot Study of Immunomodulatory Versus Antiinflammatory Therapy in Alzheimer's Disease|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:02.239608|2018-06-01 05:37:02.239608
NCT00013637|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-26|||2006-09-01|2001-03-27|2001-03-28|Estimate|||||||2006-09-01|2006-09-04|Estimate|September 1998||1998-09-30|September 2006|2006-09-30|August 2003||2003-08-31|||||Observational|||Lead Exposure, Genetics, and Osteoporosis Epidemiology||Completed|||650||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:02.296012|2018-06-01 05:37:02.296012
NCT00013624|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-24|||2008-03-03|2001-03-24|2001-03-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Riluzole to Treat Parkinson's Disease|Effect of Antiglutamatergic Treatment in Parkinson's Disease|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:02.336945|2018-06-01 05:37:02.336945
NCT00013338|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2000||2000-01-31|January 2001|2001-01-31|December 2002|Actual|2002-12-31|||||Interventional|||Supported Treadmill Ambulation Training After Spinal Cord Injury|Supported Treadmill Ambulation Training After Spinal Cord Injury|Completed||Phase 2|40||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.248895|2018-06-01 05:37:10.248895
NCT00013611|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-24|2010-11-08||2011-08-02|2001-03-24|2001-03-26|Estimate|2010-11-08|2010-12-13|Estimate||||2011-08-02|2011-08-08|Estimate|March 2001||2001-03-31|August 2011|2011-08-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|SILCAAT||Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)|A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)|Completed||Phase 3|1695|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-06-01 05:37:02.406724|2018-06-01 05:37:02.406724
NCT00013598|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-24|||2008-03-03|2001-03-24|2001-03-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Interventional|||Treatment of Nonalcoholic Steatohepatitis With Pioglitazone|Treatment of Nonalcoholic Steatohepatitis With Pioglitazone|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:03.405818|2018-06-01 05:37:03.405818
NCT00013559|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-20|||2018-05-26|2001-03-20|2001-03-21|Estimate|||||||2018-05-26|2018-05-30|Actual|March 19, 2001||2001-03-19|May 24, 2018|2018-05-24||||||||Observational|||Natural History Study of Smith-Magenis Syndrome|Natural History Study of the Clinical and Molecular Manifestations of Smith-Magenis Syndrome (SMS)|Recruiting|||700|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:03.651439|2018-06-01 05:37:03.651439
NCT00013546|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-20|||2008-03-03|2001-03-20|2001-03-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2001||2001-03-31|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Hormone Replacement Therapy to Treat Turner Syndrome|Turner Syndrome: Hormone Replacement Therapy|Completed||Phase 2|92||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:06.647165|2018-06-01 05:37:06.647165
NCT00013533|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-20|||2018-05-19|2001-03-20|2001-03-21|Estimate|||||||2018-05-19|2018-05-22|Actual|March 14, 2001||2001-03-14|May 7, 2015|2015-05-07|May 7, 2015|Actual|2015-05-07|March 1, 2008|Actual|2008-03-01||Interventional|||Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies|Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies|Completed||Early Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:37:08.107062|2018-06-01 05:37:08.107062
NCT00013507|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1999||1999-01-31|January 2001|2001-01-31|December 2002|Actual|2002-12-31|||||Interventional|||Effects of Functional Incidental Training in VA NHCU Residents|Effects of Functional Incidental Training in VA NHCU Residents|Completed||Phase 2|24|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:08.270708|2018-06-01 05:37:08.270708
NCT00013494|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|July 1999||1999-07-31|March 2006|2006-03-31|June 2003|Actual|2003-06-30|||||Interventional|||Video-Based Functional Performance and Assessment Following Stroke|Video-Based Functional Performance and Assessment Following Stroke|Completed||Phase 2|30||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:08.405929|2018-06-01 05:37:08.405929
NCT00013481|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-11-09|2001-03-15|2001-03-16|Estimate|||||||2009-11-09|2009-11-10|Estimate|January 2000||2000-01-31|November 2009|2009-11-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Coordination of Hemiparetic Movement After Post-Stroke Rehabilitation|Coordination of Hemiparetic Movement After Post-Stroke Rehabilitation|Completed||Phase 2|70|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:37:08.661575|2018-06-01 05:37:08.661575
NCT00013468|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|August 2000||2000-08-31|January 2001|2001-01-31|August 2003|Actual|2003-08-31|||||Observational|||Early Diagnosis of Steroid-Responsive & No-Responsive Hearing Loss|Early Diagnosis of Steroid-Responsive & No-Responsive Hearing Loss|Completed|||50|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:08.839367|2018-06-01 05:37:08.839367
NCT00013455|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|August 2000||2000-08-31|May 2002|2002-05-31|August 2003|Actual|2003-08-31|||||Interventional|||Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting|Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting|Completed||Phase 2|48|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:09.112537|2018-06-01 05:37:09.112537
NCT00013442|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2000||2000-01-31|January 2001|2001-01-31|December 2002|Actual|2002-12-31|||||Observational|||AERs in Aphasia: Severity and Improvement|AERs in Aphasia: Severity and Improvement|Completed|||20||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:09.237272|2018-06-01 05:37:09.237272
NCT00013429|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 2000||2000-01-31|January 2001|2001-01-31|September 2003|Actual|2003-09-30|||||Interventional|||Evaluation of Eye Movement Tracking Systems for Visual Rehabilitation|Evaluation of Eye Movement Tracking Systems for Visual Rehabilitation|Completed||Phase 2|100||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:09.309473|2018-06-01 05:37:09.309473
NCT00013416|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|January 2001|2001-01-31|September 2002|Actual|2002-09-30|||||Interventional|||Measurement and Prediction of Outcomes of Amplification|Measurement and Prediction of Outcomes of Amplification|Completed||Phase 2|120||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:09.567539|2018-06-01 05:37:09.567539
NCT00013403|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-06-25|2001-03-15|2001-03-16|Estimate|||||||2015-06-25|2015-06-26|Estimate|April 1999||1999-04-30|June 2015|2015-06-30|March 2002|Actual|2002-03-31|||||Interventional|||The Impact of Rehabilitation on Quality of Life in Visually Impaired|The Impact of Rehabilitation on Quality of Life in Visually Impaired|Completed||Phase 2|300||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:09.647554|2018-06-01 05:37:09.647554
NCT00013390|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2011-05-17|2001-03-15|2001-03-16|Estimate|||||||2011-05-17|2011-05-18|Estimate|October 1999||1999-10-31|May 2011|2011-05-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Evaluation of Treatment Methods for Clinically Significant Tinnitus|Evaluation of Treatment Methods for Clinically Significant Tinnitus|Completed||Phase 2|200|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:37:09.878783|2018-06-01 05:37:09.878783
NCT00013377|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|January 2001|2001-01-31|March 2002|Actual|2002-03-31|||||Interventional|||Predictors of Driving Performance and Successful Mobility - Rehabilitation in Patients With Medical Eye Condition|Predictors of Driving Performance and Successful Mobility - Rehabilitation in Patients With Medical Eye Condition|Completed||Phase 2|30||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.04805|2018-06-01 05:37:10.04805
NCT00013364|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|January 2001|2001-01-31|March 2001|Actual|2001-03-31|||||Observational|||Effects of Stimulus Validity on Speech Recognition|Effects of Stimulus Validity on Speech Recognition|Completed|||80||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.139853|2018-06-01 05:37:10.139853
NCT00013325|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|January 2001|2001-01-31|September 2002|Actual|2002-09-30|||||Observational|||Cardiac Disease and the Electrocardiogram in SCI Patients|Cardiac Disease and the Electrocardiogram in SCI Patients|Completed|||800||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.550661|2018-06-01 05:37:10.550661
NCT00013312|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1999||1999-04-30|January 2001|2001-01-31|March 2001|Actual|2001-03-31|||||Interventional|||Effects of Acute SCI on Colonic Motility & Tone|Effects of Acute SCI on Colonic Motility & Tone|Completed||Phase 2|12||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.63492|2018-06-01 05:37:10.63492
NCT00013299|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 2000||2000-10-31|January 2001|2001-01-31|April 2001|Actual|2001-04-30|||||Interventional|||Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3|Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3|Completed||Phase 2|427||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.706305|2018-06-01 05:37:10.706305
NCT00013286|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|October 1999||1999-10-31|January 2001|2001-01-31|September 2002|Actual|2002-09-30|||||Observational|||A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk|A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk|Completed|||750||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.783048|2018-06-01 05:37:10.783048
NCT00013273|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-01-20|2001-03-15|2001-03-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1999||1999-01-31|January 2001|2001-01-31|December 2001|Actual|2001-12-31|||||Interventional|||Physical Conditioning in Management of Chronic Venous Insufficiency|Physical Conditioning in Management of Chronic Venous Insufficiency|Completed||Phase 2|60||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:10.877952|2018-06-01 05:37:10.877952
NCT00013260|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|July 2000|Actual|2000-07-31|||||Interventional|||An Integrated Model of Primary Care in Mental Health|An Integrated Model of Primary Care in Mental Health|Completed||N/A|271|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:10.954709|2018-06-01 05:37:10.954709
NCT00013247|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|December 2002|Actual|2002-12-31|||||Interventional|||Facilitating Shared Decisionmaking About Prostate Cancer Screening|Facilitating Shared Decisionmaking About Prostate Cancer Screening|Completed||N/A|1152|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:11.069706|2018-06-01 05:37:11.069706
NCT00013234|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2003|Actual|2003-09-30|||||Interventional|||Health Services Implications of a Teledermatology Consult System|Health Services Implications of a Teledermatology Consult System|Completed||N/A|260|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:11.234528|2018-06-01 05:37:11.234528
NCT00013221|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2000|Actual|2000-03-31|||||Interventional|||Exercise Effect on Aerobic Capacity and QOL in Heart Failure|Exercise Effect on Aerobic Capacity and QOL in Heart Failure|Completed||Phase 4|84|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:11.384831|2018-06-01 05:37:11.384831
NCT00013208|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|August 2002|Actual|2002-08-31|||||Interventional|||Proactive Diabetes Case Management|Proactive Diabetes Case Management|Completed||N/A|260|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:11.523099|2018-06-01 05:37:11.523099
NCT00013195|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|June 2000|Actual|2000-06-30|||||Interventional|||Nurse Counseling for Physical Activity in Primary Care Patients|Nurse Counseling for Physical Activity in Primary Care Patients|Completed||N/A|210|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:11.589281|2018-06-01 05:37:11.589281
NCT00013182|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|June 2001|Actual|2001-06-30|||||Interventional|||Effect of Activity on Sleep of Cognitively-Impaired Veterans|Effect of Activity on Sleep of Cognitively-Impaired Veterans|Completed||N/A|90|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:11.678504|2018-06-01 05:37:11.678504
NCT00013169|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2002|Actual|2002-09-30|||||Interventional|||Patient-Centered Alternative to Psychiatric Hospitalization for Veterans|Patient-Centered Alternative to Psychiatric Hospitalization for Veterans|Completed||N/A|220|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:11.791864|2018-06-01 05:37:11.791864
NCT00013156|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2000|Actual|2000-03-31|||||Interventional|||Cost-Effectiveness of Lung Volume Reduction Surgery|Cost-Effectiveness of Lung Volume Reduction Surgery|Completed||Phase 2|92|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:12.925112|2018-06-01 05:37:12.925112
NCT00013143|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2001||2001-06-30|February 2007|2007-02-28|January 2003|Actual|2003-01-31|||||Interventional|||Patient Profiling and Provider Feedback to Reduce Adverse Drug Events|Patient Profiling and Provider Feedback to Reduce Adverse Drug Events|Completed||N/A|1200|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.005202|2018-06-01 05:37:13.005202
NCT00013130|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|February 2001|Actual|2001-02-28|||||Interventional|||Ambulatory Care Quality Improvement (ACQUIP)|Ambulatory Care Quality Improvement (ACQUIP)|Completed||Phase 2|62487|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.101584|2018-06-01 05:37:13.101584
NCT00013117|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||November 2007|2007-11-30|December 2002|Actual|2002-12-31|||||Interventional|||Computer-Assisted Access to Specialist Expertise|Computer-Assisted Access to Specialist Expertise|Completed||N/A|10000|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.264716|2018-06-01 05:37:13.264716
NCT00013104|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||January 2005|2005-01-31|September 2002|Actual|2002-09-30|||||Observational|||Implementation of Ischemic Heart Disease Clinical Practice Guidelines|Implementation of Ischemic Heart Disease Clinical Practice Guidelines|Completed|||50|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:13.334809|2018-06-01 05:37:13.334809
NCT00012623|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||April 2015|2015-04-30|March 2002|Actual|2002-03-31|||||Observational|||Improving Service Delivery Through Access Points|Improving Service Delivery Through Access Points|Completed|||39481|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:17.332965|2018-06-01 05:37:17.332965
NCT00013091|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 1997||1997-10-31|May 2009|2009-05-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Treatment of Depression in Patients With PTSD|Treatment of Depression in Patients With PTSD|Completed||N/A|120|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.3982|2018-06-01 05:37:13.3982
NCT00013078|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||June 2005|2005-06-30|June 2001|Actual|2001-06-30|||||Interventional|||Safe-Grip Fall/Injuries Intervention: A Randomized Trial|Safe-Grip Fall/Injuries Intervention: A Randomized Trial|Completed||N/A|210|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.460437|2018-06-01 05:37:13.460437
NCT00013065|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||January 2005|2005-01-31|December 2003|Actual|2003-12-31|||||Observational|||A Medication Adherence Intervention for HIV Infected Veterans|A Medication Adherence Intervention for HIV Infected Veterans|Completed|||210|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:13.693755|2018-06-01 05:37:13.693755
NCT00013052|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2002|Actual|2002-09-30|||||Interventional|||Improving Health Outcomes of Diabetic Veterans: A Diabetic Self-Management Program|Improving Health Outcomes of Diabetic Veterans: A Diabetic Self-Management Program|Completed||N/A|2068|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.778776|2018-06-01 05:37:13.778776
NCT00013039|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|February 2001|Actual|2001-02-28|||||Interventional|||Computerized Guidelines Enhanced by Symptoms and History: Clinical Effects|Computerized Guidelines Enhanced by Symptoms and History: Clinical Effects|Completed||N/A|1000|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.891557|2018-06-01 05:37:13.891557
NCT00013026|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2004|Actual|2004-03-31|||||Interventional|||Trial of a Tailored Message Program to Implement CHF Guidelines|Trial of a Tailored Message Program to Implement CHF Guidelines|Completed||N/A|700|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:13.99336|2018-06-01 05:37:13.99336
NCT00013013|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|August 2001|Actual|2001-08-31|||||Interventional|||A Randomized Trial to Implement the AHCPR Smoking Cessation Guideline|A Randomized Trial to Implement the AHCPR Smoking Cessation Guideline|Completed||Phase 4|4000|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.077359|2018-06-01 05:37:14.077359
NCT00013000|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2000|Actual|2000-09-30|||||Interventional|||A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines|A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines|Completed||N/A|400|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.176716|2018-06-01 05:37:14.176716
NCT00012987|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|December 2002|Actual|2002-12-31|||||Interventional|||Implementing Guidelines for Smoking Cessation: A Randomized Trial of Evidence-Based Quality Improvement|Implementing Guidelines for Smoking Cessation: A Randomized Trial of Evidence-Based Quality Improvement|Completed||N/A|2500|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.321612|2018-06-01 05:37:14.321612
NCT00012974|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate|November 2005||2005-11-30|December 2005|2005-12-31|May 2007|Actual|2007-05-31|||||Interventional|||Telephone Administered Psychotherapy for the Treatment of Depression for Veterans in Rural Areas|Innovative Strategies for Implementing New CHF Guideline Recommendations|Completed||Phase 1/Phase 2|60|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.43941|2018-06-01 05:37:14.43941
NCT00012961|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||January 2005|2005-01-31|March 2003|Actual|2003-03-31|||||Observational|||Improving Health Services for Veterans With Schizophrenia|Improving Health Services for Veterans With Schizophrenia|Completed|||300|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:14.514179|2018-06-01 05:37:14.514179
NCT00012948|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2004|Actual|2004-09-30|||||Interventional|||Centralized Telephone Outreach to Assist Smoking Cessation Among Veterans|Centralized Telephone Outreach to Assist Smoking Cessation Among Veterans|Completed||Phase 4|800|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.624991|2018-06-01 05:37:14.624991
NCT00012935|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|December 2001|Actual|2001-12-31|||||Interventional|||Treatment Decision Intervention for Veterans With Prostate Cancer|Treatment Decision Intervention for Veterans With Prostate Cancer|Completed||N/A|100|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.739024|2018-06-01 05:37:14.739024
NCT00012922|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|April 2003|Actual|2003-04-30|||||Interventional|||Low Literacy Intervention for Colorectal Cancer Screening|Low Literacy Intervention for Colorectal Cancer Screening|Completed||N/A|2400|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.828067|2018-06-01 05:37:14.828067
NCT00012909|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||November 2007|2007-11-30|March 2004|Actual|2004-03-31|||||Interventional|||Development and Evaluation of a Hormone Replacement Therapy Decision-Aid|Development and Evaluation of a Hormone Replacement Therapy Decision-Aid|Completed||N/A|150|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:14.944472|2018-06-01 05:37:14.944472
NCT00012896|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2004|Actual|2004-09-30|||||Interventional|||Improving Cancer Pain Management Using AHCPR Cancer Pain Guidelines|Improving Cancer Pain Management Using AHCPR Cancer Pain Guidelines|Completed||N/A|320|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.045159|2018-06-01 05:37:15.045159
NCT00012883|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|December 2001|Actual|2001-12-31|||||Interventional|||Home Walking Exercise Training in Advanced Heart Failure|Home Walking Exercise Training in Advanced Heart Failure|Completed||N/A|110|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.104061|2018-06-01 05:37:15.104061
NCT00012870|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2002|Actual|2002-03-31|||||Interventional|||Effect of Behavioral Management on Quality of Life in Heart Failure|Effect of Behavioral Management on Quality of Life in Heart Failure|Completed||N/A|116|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.256196|2018-06-01 05:37:15.256196
NCT00012857|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2001|Actual|2001-03-31|||||Interventional|||Pain Management and Behavioral Outcomes in Patients With Dementia|Pain Management and Behavioral Outcomes in Patients With Dementia|Completed||Phase 2|66|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.3464|2018-06-01 05:37:15.3464
NCT00012844|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|December 1999|Actual|1999-12-31|||||Interventional|||Redesigning Patient Handling Tasks to Prevent Nursing Back Injuries|Redesigning Patient Handling Tasks to Prevent Nursing Back Injuries|Completed||N/A|134|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.436426|2018-06-01 05:37:15.436426
NCT00012831|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||December 2005|2005-12-31|June 2001|Actual|2001-06-30|||||Observational|||Nurse Managed Clinic for Dementia Patients and Family Caregivers|Nurse Managed Clinic for Dementia Patients and Family Caregivers|Completed|||120|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:15.549541|2018-06-01 05:37:15.549541
NCT00012818|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2003|Actual|2003-09-30|||||Interventional|||Efficacy and Cost Effectiveness of Relaxation and Response to CHF|Efficacy and Cost Effectiveness of Relaxation and Response to CHF|Completed||N/A|90|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.700149|2018-06-01 05:37:15.700149
NCT00012805|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|March 2001|Actual|2001-03-31|||||Interventional|||Effectiveness and Cost Impact of a Telecommunications System in COPD|Effectiveness and Cost Impact of a Telecommunications System in COPD|Completed||Phase 4|300|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.843524|2018-06-01 05:37:15.843524
NCT00012792|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||December 2005|2005-12-31|December 2000|Actual|2000-12-31|||||Interventional|||Randomized Controlled Trial of Exercise Training in Patients With COPD|Randomized Controlled Trial of Exercise Training in Patients With COPD|Completed||Phase 3|130|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:15.928476|2018-06-01 05:37:15.928476
NCT00012779|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||June 2005|2005-06-30|March 2003|Actual|2003-03-31|||||Interventional|||Effectiveness of a Health Education Program in a Primary Care Setting|Effectiveness of a Health Education Program in a Primary Care Setting|Completed||Phase 2|288|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:16.008859|2018-06-01 05:37:16.008859
NCT00012766|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||December 2005|2005-12-31|March 2001|Actual|2001-03-31|||||Interventional|||Effectiveness of Team Treatment of Depression in Primary Care|Effectiveness of Team Treatment of Depression in Primary Care|Completed||Phase 2|360|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:16.149248|2018-06-01 05:37:16.149248
NCT00012753|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|December 1999|Actual|1999-12-31|||||Interventional|||Automated Calls With Nurse Follow-Up to Improve Diabetes Ambulatory Care|Automated Calls With Nurse Follow-Up to Improve Diabetes Ambulatory Care|Completed||Phase 3|272|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:16.217421|2018-06-01 05:37:16.217421
NCT00012740|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||December 2005|2005-12-31|September 2001|Actual|2001-09-30|||||Interventional|||A Casefinding and Referral System for Older Veterans Within Primary Care|A Casefinding and Referral System for Older Veterans Within Primary Care|Completed||N/A|792|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:16.397336|2018-06-01 05:37:16.397336
NCT00012727|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||July 2005|2005-07-31|August 2001|Actual|2001-08-31|||||Interventional|||Matching, Outcomes and Costs in Substance Abuse/Psychiatric Treatment|Matching, Outcomes and Costs in Substance Abuse/Psychiatric Treatment|Completed||Phase 2|236|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:16.504297|2018-06-01 05:37:16.504297
NCT00012714|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|June 2000|Actual|2000-06-30|||||Interventional|||Evaluation of Subacute Rehabilitative Care|Evaluation of Subacute Rehabilitative Care|Completed||Phase 2|180|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:16.601129|2018-06-01 05:37:16.601129
NCT00012701|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||July 2005|2005-07-31|June 2003|Actual|2003-06-30|||||Observational|||Measuring HIV Quality of Care|Measuring HIV Quality of Care|Completed|||1600|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:16.704874|2018-06-01 05:37:16.704874
NCT00012688|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2003|Actual|2003-09-30|||||Interventional|||Periodontal Care and Glycemic Control in Diabetes|Periodontal Care and Glycemic Control in Diabetes|Completed||N/A|300|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:16.823447|2018-06-01 05:37:16.823447
NCT00012675|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2012-05-23|2001-03-15|2001-03-16|Estimate|||||||2012-05-23|2012-05-24|Estimate||||May 2012|2012-05-31|December 2003|Actual|2003-12-31|||||Observational|||Developing and Implementing a Quality Measure for Glycemic Control|Developing and Implementing a Quality Measure for Glycemic Control|Withdrawn|||0|Actual|VA Office of Research and Development|||1|This study was withdrawn prior to enrollment.|f||||f||||||||||2018-06-01 05:37:16.908528|2018-06-01 05:37:16.908528
NCT00012662|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|December 2002|Actual|2002-12-31|||||Interventional|||Disease Management and Educational Intervention Outcomes in High-Risk Diabetics|Disease Management and Educational Intervention Outcomes in High-Risk Diabetics|Completed||N/A|1800|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:17.026335|2018-06-01 05:37:17.026335
NCT00012649|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||January 2005|2005-01-31|May 2003|Actual|2003-05-31|||||Observational|||Improving Diabetes Care Via Telephone Assessment and Patient Education|Improving Diabetes Care Via Telephone Assessment and Patient Education|Completed|||480|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:17.105252|2018-06-01 05:37:17.105252
NCT00012636|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2015-04-06|2001-03-15|2001-03-16|Estimate|||||||2015-04-06|2015-04-07|Estimate||||February 2007|2007-02-28|September 2000|Actual|2000-09-30|||||Interventional|||Guidelines for Drug Therapy of Hypertension: Closing the Loop|Guidelines for Drug Therapy of Hypertension: Closing the Loop|Completed||N/A|36|Anticipated|VA Office of Research and Development||1|||f||||f||||||||||2018-06-01 05:37:17.21236|2018-06-01 05:37:17.21236
NCT00012584|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-14|||2009-06-23|2001-03-15|2001-03-16|Estimate|||||||2009-06-23|2009-06-24|Estimate|November 2000||2000-11-30|June 2009|2009-06-30|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Treatment of Youth With ADHD and Anxiety|A Treatment Study of Youth With Comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Anxiety Disorders|Completed||N/A|120||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:37:17.660517|2018-06-01 05:37:17.660517
NCT00012558|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-13|||2007-05-03|2001-03-14|2001-03-15|Estimate|||||||2007-05-03|2007-05-04|Estimate|September 1998||1998-09-30|April 2007|2007-04-30|September 2005||2005-09-30|||||Interventional|||Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)|Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)|Completed||N/A|5000||National Institute of Mental Health (NIMH)|||||||||||||||||||2018-06-01 05:37:17.771848|2018-06-01 05:37:17.771848
NCT00012545|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-10|||2018-05-23|2001-03-10|2001-03-12|Estimate|||||||2018-05-23|2018-05-24|Actual|March 8, 2001||2001-03-08|December 21, 2017|2017-12-21||||||||Observational|||Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease|Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:17.943553|2018-06-01 05:37:17.943553
NCT00012506|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-10|||2005-06-23|2001-03-09|2001-03-12|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2001|2001-03-31||||||||Interventional|||The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis||Unknown status|Recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:37:18.042352|2018-06-01 05:37:18.042352
NCT00012493|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-09|||2006-09-01|2001-03-09|2001-03-12|Estimate|||||||2006-09-01|2006-09-04|Estimate|October 1999||1999-10-31|September 2006|2006-09-30|December 2002||2002-12-31|||||Observational|||Cardiac Vulnerability in Potentially Susceptible Patients||Completed|||100||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:18.136283|2018-06-01 05:37:18.136283
NCT00012480|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-09|||2015-04-14|2001-03-09|2001-03-12|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2002||2002-08-31|April 2015|2015-04-30|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Effect of Environmental Exposures on the Egg Fertilizing Ability of Human Sperm|Human Sperm Zona Acceptor: Environmental Effects|Completed|||400|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:18.211155|2018-06-01 05:37:18.211155
NCT00012441|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-06|||2005-06-23|2001-03-07|2001-03-08|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Comparison of Daily Nocturnal Hemodialysis With Daily Hemodialysis|Comparison of Daily Nocturnal Hemodialysis With Daily Hemodialysis|Unknown status|Recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:18.295487|2018-06-01 05:37:18.295487
NCT00012428|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-06|||2015-04-13|2001-03-07|2001-03-08|Estimate|||||||2015-04-13|2015-04-14|Estimate|September 1999||1999-09-30|April 2015|2015-04-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Prenatal PCB Exposure|Prenatal PCB Exposure and Cognitive Development|Completed|||224||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:18.38884|2018-06-01 05:37:18.38884
NCT00011908|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-03|||2008-03-03|2001-03-03|2001-03-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|January 2003|2003-01-31|January 2003||2003-01-31|||||Interventional|||Humanized LL2IGG to Treat Systemic Lupus Erythematosus|A Phase I Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Systemic Lupus Erythematosus|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:18.450784|2018-06-01 05:37:18.450784
NCT00011856|ClinicalTrials.gov processed this data on May 31, 2018|2001-03-01|||2008-03-03|2001-03-01|2001-03-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|March 2002|2002-03-31|March 2002||2002-03-31|||||Observational|||Genetic Analysis of Familial Brain Aneurysms|Linkage Analysis of Familial Intracranial Aneurysms|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:18.546768|2018-06-01 05:37:18.546768
NCT00011843|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2017-06-30|2001-02-28|2001-03-01|Estimate|||||||2017-06-30|2017-07-02|Actual|February 22, 2001||2001-02-22|February 4, 2009|2009-02-04|February 4, 2009||2009-02-04|||||Observational|||Molecular Analysis of Microphthalmia/Anophthalmia|Molecular Analysis of Microphthalmia/Anophthalmia and Related Disorders|Completed|||450||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:18.623236|2018-06-01 05:37:18.623236
NCT00011830|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2008-03-03|2001-02-28|2001-03-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|February 2006|2006-02-28|February 2006||2006-02-28|||||Interventional|||Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission|A Pilot Study of G-CSF Induced Stem Cell Mobilization Potential in Patients With Relapsed Severe Aplastic Anemia|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:18.736197|2018-06-01 05:37:18.736197
NCT00011817|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2017-06-30|2001-02-28|2001-03-01|Estimate|||||||2017-06-30|2017-07-02|Actual|February 21, 2001||2001-02-21|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Observational|||Evaluation and Treatment of Patients With Inherited Eye Diseases|Evaluation and Treatment Protocol for Potential Research Subjects With Inherited Ophthalmic Diseases|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:18.790854|2018-06-01 05:37:18.790854
NCT00011804|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2008-03-03|2001-02-28|2001-03-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|February 2005|2005-02-28|February 2005||2005-02-28|||||Interventional|||Topiramate in the Treatment of Sciatica|Topiramate in the Treatment of Sciatica|Completed||Phase 2|65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:18.841129|2018-06-01 05:37:18.841129
NCT00011791|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2017-06-30|2001-02-28|2001-03-01|Estimate|||||||2017-06-30|2017-07-02|Actual|February 22, 2001||2001-02-22|May 10, 2011|2011-05-10|May 10, 2011||2011-05-10|||||Observational|||Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia|Catecholamine Reserve and Exercise Tolerance in Subjects With Congenital Adrenal Hyperplasia and Healthy Controls|Completed|||61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:18.943496|2018-06-01 05:37:18.943496
NCT00011778|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2018-05-23|2001-02-28|2001-03-01|Estimate|||||||2018-05-23|2018-05-24|Actual|February 22, 2001||2001-02-22|February 8, 2013|2013-02-08|February 8, 2013|Actual|2013-02-08|August 26, 2010|Actual|2010-08-26||Interventional|||PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck|A Phase I Study of Concomitant Therapy With Proteasome Inhibitor PS-341 and Radiation in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:19.000974|2018-06-01 05:37:19.000974
NCT00011765|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2017-06-30|2001-02-28|2001-03-01|Estimate|||||||2017-06-30|2017-07-02|Actual|February 22, 2001||2001-02-22|June 2, 2010|2010-06-02|February 26, 2007|Actual|2007-02-26|February 26, 2007|Actual|2007-02-26||Interventional|||Effect of Fluoxetine (Prozac) on Domestic Violence|The Effect of Fluoxetine on Measures of Domestic Violence|Completed||Phase 2|104|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:19.105503|2018-06-01 05:37:19.105503
NCT00011752|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-28|||2008-03-03|2001-02-28|2001-03-01|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Serotonin in Alcoholism|Effects of Acute Plasma Tryptophan Depletion on Serotonin Receptor Occupancy and Binding Affinity Using PET in Healthy and Alcoholic Human Subjects|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:19.204078|2018-06-01 05:37:19.204078
NCT00011739|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-27|||2009-01-20|2001-02-28|2001-03-01|Estimate|||||||2009-01-20|2009-01-21|Estimate|November 1997||1997-11-30|February 2003|2003-02-28|September 2001||2001-09-30|||||Observational|||A Prospective Cohort Study of MR Abnormalities and Back Pain Risk|A Prospective Cohort Study of MR Abnormalities and Back Pain Risk|Completed|||150||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:19.26241|2018-06-01 05:37:19.26241
NCT00011726|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-27|||2006-03-22|2001-02-28|2001-03-01|Estimate|||||||2006-03-22|2006-03-23|Estimate|August 1996||1996-08-31|March 2006|2006-03-31|December 2002||2002-12-31|||||Observational|||Lead Mobilization & Bone Turnover in Pregnancy/Lactation||Completed|||1000||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:19.329022|2018-06-01 05:37:19.329022
NCT00011713|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-27|||2018-03-30|2001-02-28|2001-03-01|Estimate|||||||2018-03-30|2018-04-03|Actual|October 1999||1999-10-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|EARTH||Environment and Reproductive Health; Human Exposure to Bisphenol A, Phthalates and Fertility and Pregnancy Outcomes|Human Exposure to Bisphenol A, Phthalates and Fertility, Pregnancy Outcomes.|Recruiting|||2401|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||1||f||||f||||||Samples With DNA|"~     Whole blood, urine, semen, follicular fluid, amniotic fluid~   "|||2018-06-01 05:37:19.416221|2018-06-01 05:37:19.416221
NCT00011700|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-26|||2015-04-13|2001-02-27|2001-02-28|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 1999||1999-01-31|April 2015|2015-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Stachybotrys Induced Hemorrhage in the Developing Lung||Completed|||50|Anticipated|National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:19.569901|2018-06-01 05:37:19.569901
NCT00011687|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-26|||2006-03-22|2001-02-27|2001-02-28|Estimate|||||||2006-03-22|2006-03-23|Estimate|September 1999||1999-09-30|March 2006|2006-03-31|September 2003||2003-09-30|||||Observational|||Study for Future Families|US Study of Semen Quality in Partners of Pregnant Women|Completed|||2400||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:19.653478|2018-06-01 05:37:19.653478
NCT00011674|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-26|||2006-03-22|2001-02-27|2001-02-28|Estimate|||||||2006-03-22|2006-03-23|Estimate|May 1997||1997-05-31|March 2006|2006-03-31|May 2001||2001-05-31|||||Observational|||Early Exposure to Lead and Adolescent Development||Completed|||300||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:19.703692|2018-06-01 05:37:19.703692
NCT00011661|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-26|||2006-09-01|2001-02-27|2001-02-28|Estimate|||||||2006-09-01|2006-09-04|Estimate|June 2000||2000-06-30|September 2006|2006-09-30|August 2005||2005-08-31|||||Interventional|||Social Network Based Intervention to Reduce Lead Exposure Among Native American Children||Completed||N/A|400||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:19.781461|2018-06-01 05:37:19.781461
NCT00011648|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-24|||2018-05-26|2001-02-24|2001-02-26|Estimate|||||||2018-05-26|2018-05-30|Actual|February 22, 2001||2001-02-22|May 23, 2018|2018-05-23||||||||Observational|||Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia|Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients With Sickle Cell Anemia|Completed|||986|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:19.833575|2018-06-01 05:37:19.833575
NCT00011622|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2005-06-23|2001-02-23|2001-02-26|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Maternal Glucose Measurement in Pregnancy Using a Continuous Ambulatory Subcutaneous Monitor|Maternal Glucose Measurement in Pregnancy Using a Continuous Ambulatory Subcutaneous Monitor|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:19.91482|2018-06-01 05:37:19.91482
NCT00011609|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2009-01-20|2001-02-23|2001-02-26|Estimate|||||||2009-01-20|2009-01-21|Estimate|August 2000||2000-08-31|January 2001|2001-01-31|November 2001|Actual|2001-11-30|||||Interventional|||Clinical Evaluation of a Wheelchair Mounted Robotic Arm|Clinical Evaluation of a Wheelchair Mounted Robotic Arm|Completed||Phase 2|30||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:19.975677|2018-06-01 05:37:19.975677
NCT00011596|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2009-01-20|2001-02-23|2001-02-26|Estimate|||||||2009-01-20|2009-01-21|Estimate|August 2000||2000-08-31|January 2001|2001-01-31|August 2003|Actual|2003-08-31|||||Interventional|||FNS and Weight Support Treadmill Training for Gait Component Restoration|FNS and Weight Support Treadmill Training for Gait Component Restoration|Completed||Phase 2|36|Anticipated|VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:20.084333|2018-06-01 05:37:20.084333
NCT00011583|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2008-03-10|2001-02-23|2001-02-26|Estimate|||||||2008-03-10|2008-03-11|Estimate|January 2000||2000-01-31|March 2008|2008-03-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Robot Assisted Upper Limb Neuro-Rehabilitation|Robot Assisted Upper Limb Neuro-Rehabilitation|Completed||Phase 2|60|Anticipated|VA Office of Research and Development||2|||f||||||||||||||2018-06-01 05:37:20.142481|2018-06-01 05:37:20.142481
NCT00011570|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2008-04-25|2001-02-23|2001-02-26|Estimate|||||||2008-04-25|2008-04-28|Estimate|April 1998||1998-04-30|April 2008|2008-04-30|November 2007|Actual|2007-11-30|October 2005|Actual|2005-10-31||Interventional|||Electrical Control of Bladder in Spinal Cord Injury Patients|Electrical Control of Bladder in Spinal Cord Injury Patients|Completed||Phase 2|18|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:37:20.318332|2018-06-01 05:37:20.318332
NCT00011557|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2009-01-20|2001-02-23|2001-02-26|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1998||1998-01-31|January 2001|2001-01-31|December 2000|Actual|2000-12-31|||||Interventional|||Functional Magnetic Micturition in Patients w/SCI|Functional Magnetic Micturition in Patients w/SCI|Completed||Phase 2|36||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:20.437232|2018-06-01 05:37:20.437232
NCT00011544|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2009-01-20|2001-02-23|2001-02-26|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1998||1998-01-31|January 2001|2001-01-31|December 2000|Actual|2000-12-31|||||Interventional|||Physical Performance Measures for Manual Wheelchair Users|Physical Performance Measures for Manual Wheelchair Users|Completed||Phase 2|120||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:20.509817|2018-06-01 05:37:20.509817
NCT00011531|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2009-02-05|2001-02-23|2001-02-26|Estimate|||||||2009-02-05|2009-02-09|Estimate|January 2000||2000-01-31|January 2001|2001-01-31|December 2001|Actual|2001-12-31|||||Interventional|||Investigation of Subatmospheric Pressure Dressing on Pressure Ulcer Healing|Investigation of Subatmospheric Pressure Dressing on Pressure Ulcer Healing|Completed||Phase 2|120|Anticipated|VA Office of Research and Development||1|||f||||||||||||||2018-06-01 05:37:20.585991|2018-06-01 05:37:20.585991
NCT00011518|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2006-03-22|2001-02-23|2001-02-26|Estimate|||||||2006-03-22|2006-03-23|Estimate|October 1997||1997-10-31|March 2006|2006-03-31|July 2001||2001-07-31|||||Observational|||Bladder Cancer Case Control Study of Arsenic in Water||Completed|||600||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:20.716799|2018-06-01 05:37:20.716799
NCT00011505|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2008-03-03|2001-02-22|2001-02-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|April 2006|2006-04-30|April 2006||2006-04-30|||||Interventional|||Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia|Investigation of G-CSF-Induced Stem Cell Mobilization Potential in Patients With Diamond-Blackfan Anemia|Completed||Phase 2|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:20.779594|2018-06-01 05:37:20.779594
NCT00011492|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-22|||2018-05-24|2001-02-22|2001-02-23|Estimate|||||||2018-05-24|2018-05-25|Actual|February 21, 2001||2001-02-21|December 6, 2017|2017-12-06||||||||Observational|||Patient Evaluation for Head and Neck Surgery Branch Studies|Evaluation for NIDCD Head & Neck Surgery Branch Clinical Research Protocols|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:20.909604|2018-06-01 05:37:20.909604
NCT00011466|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-21|||2005-06-23|2001-02-22|2001-02-23|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Nutrient Intake in Children With Attention Deficit Hyperactivity Disorder|Nutrient Intake in Children With Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:21.013756|2018-06-01 05:37:21.013756
NCT00011453|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-21|||2005-06-23|2001-02-22|2001-02-23|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1998||1998-07-31|July 2002|2002-07-31|June 2001||2001-06-30|||||Observational|||Protection Against Benzene Toxicity|NQO1 in Protection Against Benzene Toxicity|Completed|||||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:21.100174|2018-06-01 05:37:21.100174
NCT00011440|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-20|||2006-03-22|2001-02-20|2001-02-21|Estimate|||||||2006-03-22|2006-03-23|Estimate|December 1998||1998-12-31|March 2006|2006-03-31|August 2002||2002-08-31|||||Observational|||Pollutant Altered Allergic Responses|Markers of Pollutant Altered Allergic Responses|Completed|||20||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:21.190374|2018-06-01 05:37:21.190374
NCT00011414|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-17|||2018-04-18|2001-02-17|2001-02-19|Estimate|||||||2018-04-18|2018-04-19|Actual|February 15, 2001||2001-02-15|January 13, 2016|2016-01-13|January 13, 2016|Actual|2016-01-13|November 28, 2007|Actual|2007-11-28||Interventional|||Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors|Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors|Completed||Phase 1|29|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:37:21.246025|2018-06-01 05:37:21.246025
NCT00011388|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-16|||2006-03-22|2001-02-17|2001-02-19|Estimate|||||||2006-03-22|2006-03-23|Estimate||||March 2006|2006-03-31||||||||Observational|||Reproductive Effects of Pesticide, PCB and Mercury Exposure in Laotian Immigrants|Organochlorine Compounds and Menstrual Cycle Function|Completed|||50||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:21.372906|2018-06-01 05:37:21.372906
NCT00011375|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-16|||2008-03-03|2001-02-16|2001-02-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|April 2004|2004-04-30|April 2004||2004-04-30|||||Interventional|||Rolipram to Treat Multiple Sclerosis|Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure|Completed||Phase 2|52||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:21.44818|2018-06-01 05:37:21.44818
NCT00011362|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-15|||2015-06-03|2001-02-16|2001-02-19|Estimate|||||||2015-06-03|2015-06-08|Estimate|September 1992||1992-09-30|June 2015|2015-06-30|April 1994|Actual|1994-04-30|January 1994|Actual|1994-01-31||Interventional|Dexamethasone||Dexamethasone Therapy in VLBW Infants at Risk of CLD|Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD)|Completed||Phase 3|371|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 05:37:21.530947|2018-06-01 05:37:21.530947
NCT00011349|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-15|||2013-04-11|2001-02-16|2001-02-19|Estimate|||||||2013-04-11|2013-04-15|Estimate|January 2001||2001-01-31|April 2013|2013-04-30|January 2010|Actual|2010-01-31|June 2006|Actual|2006-06-30||Observational|||Early Stage Prostate Cancer Cohort|CSP #719B - Prospective Cohort of Early Stage Prostate Cancer|Completed|||1116|Actual|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:21.699615|2018-06-01 05:37:21.699615
NCT00011336|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-15|||2009-01-20|2001-02-16|2001-02-19|Estimate|||||||2009-01-20|2009-01-21|Estimate|July 1998||1998-07-31|February 2003|2003-02-28|June 2002||2002-06-30|||||Observational|||Determine the Association Between the Level of SCI With Chronic Respiratory Symptoms, Measures of Pulmonary Function, and Respiratory Illness.|Prospective Cohort Study of Respiratory Function and Illness in Chronic SCI|Completed|||400||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:21.818767|2018-06-01 05:37:21.818767
NCT00011323|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-15|||2009-01-20|2001-02-16|2001-02-19|Estimate|||||||2009-01-20|2009-01-21|Estimate|June 1998||1998-06-30|February 2003|2003-02-28|January 2001||2001-01-31|||||Observational|||Determining the Risk Factors Such as Smoking, Alcohol, and Caffeine and Their Association With Osteoporosis in Men|Prevalence and Determinants of Osteoporosis in Male Veterans|Completed|||1000||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:21.885921|2018-06-01 05:37:21.885921
NCT00011310|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-15|||2006-09-01|2001-02-16|2001-02-19|Estimate|||||||2006-09-01|2006-09-04|Estimate|March 1999||1999-03-31|September 2006|2006-09-30|February 2002||2002-02-28|||||Observational|||Cardiopulmonary Effects of Particulate Exposure||Completed|||||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:21.936567|2018-06-01 05:37:21.936567
NCT00011297|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-15|||2006-10-20|2001-02-16|2001-02-19|Estimate|||||||2006-10-20|2006-10-23|Estimate||||October 2006|2006-10-31|December 2005||2005-12-31|||||Interventional|||Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal|Alcohol Research Center - Treatment and Implications|Completed||Phase 2|160||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:37:22.007268|2018-06-01 05:37:22.007268
NCT00011284|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-15|||2005-06-23|2001-02-16|2001-02-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 2002|2002-09-30|November 2001||2001-11-30|||||Observational|||Mechanisms of Inflammatory Liver Injury||Completed|||50||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:22.075724|2018-06-01 05:37:22.075724
NCT00011258|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-14|||2009-01-20|2001-02-15|2001-02-16|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 1997||1997-03-31|January 2004|2004-01-31|September 2003||2003-09-30|||||Observational|||Paraoxonase and LDL Oxidation in Carotid Artery Disease|Paraoxonase and LDL Oxidation in Carotid Artery Disease|Completed|||1000||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:22.132005|2018-06-01 05:37:22.132005
NCT00011245|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-14|||2017-06-30|2001-02-14|2001-02-15|Estimate|||||||2017-06-30|2017-07-02|Actual|February 8, 2001||2001-02-08|May 18, 2011|2011-05-18|May 18, 2011||2011-05-18|||||Observational|||Study and Surgical Treatment of Syringomyelia|Establishing the Pathophysiology of Primary Spinal Syringomyelia|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:22.222138|2018-06-01 05:37:22.222138
NCT00011154|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-12|||2006-03-22|2001-02-13|2001-02-14|Estimate|||||||2006-03-22|2006-03-23|Estimate|September 1996||1996-09-30|March 2006|2006-03-31|August 2002||2002-08-31|||||Observational|||Exogenous Toxicants and Genetic Susceptibility in ALS||Completed|||525||National Institute of Environmental Health Sciences (NIEHS)|||||f||||||||||||||2018-06-01 05:37:22.2958|2018-06-01 05:37:22.2958
NCT00011193|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-13|||2012-05-25|2001-02-12|2001-02-13|Estimate|||||||2012-05-25|2012-05-28|Estimate|January 2001||2001-01-31|May 2012|2012-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|DREW||Dose-Response to Exercise in Women Aged 45-75 Years (DREW)|Dose-response to Exercise in Women Aged 45-75 Years (DREW)|Completed|||464|Actual|Pennington Biomedical Research Center|||4||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-06-01 05:37:22.488592|2018-06-01 05:37:22.488592
NCT00011180|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-13|||2012-12-05|2001-02-12|2001-02-13|Estimate|||||||2012-12-05|2012-12-06|Estimate|April 2001||2001-04-30|December 2012|2012-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Risk Factors for Venous Thromboembolism in the Community|Subtherapeutic Heparin Anticoagulation as a Predictor of Recurrent Venous Thromboembolism: A Population-Based Cohort Study|Completed|||385|Actual|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     Plasma and genomic DNA~   "|||2018-06-01 05:37:22.625268|2018-06-01 05:37:22.625268
NCT00011167|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-13|||2016-02-05|2001-02-12|2001-02-13|Estimate|||||||2016-02-05|2016-02-08|Estimate|March 2001||2001-03-31|February 2016|2016-02-29|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Observational|||Retinal Arteriolar Abnormalities and CV Mortality||Completed|||1380|Actual|University of Wisconsin, Madison|||||f||||f||||||||||2018-06-01 05:37:22.704258|2018-06-01 05:37:22.704258
NCT00011076|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-09|||2008-03-03|2001-02-09|2001-02-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2001||2001-02-28|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Pirfenidone to Treat Hypertrophic Cardiomyopathy|Double-Blind Placebo-Controlled Study of Pirfenidone, A Novel Anti-Fibrotic Drug in Symptomatic Patients With Hypertrophic Cardiomyopathy (HCM) Associated With Left Ventricular Diastolic Function|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:22.783163|2018-06-01 05:37:22.783163
NCT00011115|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-09|||2010-01-12|2001-02-08|2001-02-09|Estimate|||||||2010-01-12|2010-01-14|Estimate|September 2001||2001-09-30|January 2010|2010-01-31|May 2003||2003-05-31|||||Interventional|||Motivations for Weight Loss|Weight Loss Motivations and Long-term Weight Loss|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:22.837815|2018-06-01 05:37:22.837815
NCT00011102|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-09|||2010-01-12|2001-02-08|2001-02-09|Estimate|||||||2010-01-12|2010-01-14|Estimate|February 2001||2001-02-28|January 2010|2010-01-31|December 2001||2001-12-31|||||Interventional|||Prevention of Weight Gain|Prevention of Weight Gain in Women Aged 25 Through 44|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:22.923959|2018-06-01 05:37:22.923959
NCT00011024|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-08|||2006-08-17|2001-02-08|2001-02-09|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1998||1998-09-30|August 2006|2006-08-31|June 2004||2004-06-30|||||Interventional|||Prospective Studies of the Use of Self Hypnosis, Acupuncture and Osteopathic Manipulation on Muscle Tension in Children With Spastic Cerebral Palsy|Prospective Studies of the Use of Self Hypnosis, Acupuncture and Osteopathic Manipulation on Muscle Tension in Children With Spastic Cerebral Palsy|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:22.967584|2018-06-01 05:37:22.967584
NCT00010998|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|December 2004||2004-12-31|||||Interventional|||Yoga: Effect on Attention in Aging & Multiple Sclerosis|Yoga: Effect on Attention in Aging & Multiple Sclerosis|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.066155|2018-06-01 05:37:23.066155
NCT00010985|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-05|2001-02-02|2001-02-05|Estimate|||||||2008-03-05|2008-03-07|Estimate|September 1999||1999-09-30|March 2008|2008-03-31|August 2003||2003-08-31|||||Interventional|||Usual Care Vs Choice of Alternative Rx: Low Back Pain|Usual Care Vs Choice of Alternative Rx: Low Back Pain|Completed||Phase 3|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.142496|2018-06-01 05:37:23.142496
NCT00010972|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate||||August 2006|2006-08-31||||||||Interventional|||Use of Acupuncture for Dental Pain: Testing a Model|Use of Acupuncture for Dental Pain: Testing a Model|Completed||Phase 3|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.195804|2018-06-01 05:37:23.195804
NCT00010959|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2007-03-01|2001-02-02|2001-02-05|Estimate|||||||2007-03-01|2007-03-02|Estimate|February 2001||2001-02-28|March 2007|2007-03-31|February 2002||2002-02-28|||||Interventional|||Single-Dose Study of Black Cohosh and Red Clover|A Phase I Single-Dose Pharmacokinetic Study of Black Cohosh and Red Clover in Healthy Menopausal Women 45-59 Years of Age|Completed||Phase 1|30||National Center for Complementary and Integrative Health (NCCIH)|||||f||||f||||||||||2018-06-01 05:37:23.23609|2018-06-01 05:37:23.23609
NCT00010946|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-05|2001-02-02|2001-02-05|Estimate|||||||2008-03-05|2008-03-07|Estimate|September 1998||1998-09-30|March 2008|2008-03-31|August 2003||2003-08-31|||||Interventional|||Acupuncture Safety/Efficacy in Knee Osteoarthritis|Acupuncture Safety/Efficacy in Knee Osteoarthritis|Completed||Phase 3|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.331411|2018-06-01 05:37:23.331411
NCT00010933|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-16|2001-02-02|2001-02-05|Estimate|||||||2006-08-16|2006-08-18|Estimate|September 1998||1998-09-30|August 2006|2006-08-31|June 2004||2004-06-30|||||Interventional|||Treatment of Functional Abdominal Pain in Children: Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities|Treatment of Functional Abdominal Pain in Children: Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities|Completed||N/A|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.381679|2018-06-01 05:37:23.381679
NCT00010920|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|December 2004||2004-12-31|||||Interventional|||Preventing Cognitive Decline With Alternative Therapies|Preventing Cognitive Decline With Alternative Therapies|Completed||Phase 3|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.548714|2018-06-01 05:37:23.548714
NCT00010907|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-03-21|2001-02-02|2001-02-05|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31||||||||Interventional|||Preliminary Human Trial of NPI-028||Withdrawn||Phase 2|0|Actual|National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.647468|2018-06-01 05:37:23.647468
NCT00010881|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|December 2004||2004-12-31|||||Interventional|||Oregon Center for Complementary and Alternative Medicine in Neurological Disorders|Oregon Center for Complementary and Alternative Medicine in Neurological Disorders|Completed||N/A|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.754976|2018-06-01 05:37:23.754976
NCT00010868|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|July 2000||2000-07-31|July 2006|2006-07-31|July 2004||2004-07-31|||||Interventional|||Omega-3 Fatty Acids in Bipolar Disorder|Omega-3 Fatty Acids in Bipolar Disorder Prophylaxis|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.848487|2018-06-01 05:37:23.848487
NCT00010855|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-08-04|2001-02-02|2001-02-05|Estimate|||||||2008-08-04|2008-08-06|Estimate|September 1997||1997-09-30|August 2008|2008-08-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Nonpharmacologic Analgesia for Invasive Procedures|Nonpharmacologic Analgesia for Invasive Procedures|Completed||Phase 2/Phase 3|390||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:23.93511|2018-06-01 05:37:23.93511
NCT00010842|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|December 2004||2004-12-31|||||Interventional|||Natural Antioxidants in the Treatment of Multiple Sclerosis|Natural Antioxidants in the Treatment of Multiple Sclerosis|Completed||Phase 1/Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:24.086153|2018-06-01 05:37:24.086153
NCT00010829|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|January 2001||2001-01-31|August 2006|2006-08-31|December 2005||2005-12-31|||||Interventional|||Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors|Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:24.207724|2018-06-01 05:37:24.207724
NCT00010816|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1998||1998-09-30|August 2006|2006-08-31|June 2003||2003-06-30|||||Interventional|||Herbal Treatment of Hepatitis C in Methadone Maintained Patients|Herbal Treatment of Hepatitis C in Methadone Maintained Patients|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:24.321388|2018-06-01 05:37:24.321388
NCT00010803|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|2009-03-27||2013-03-11|2001-02-02|2001-02-05|Estimate|2010-08-23|2010-09-16|Estimate||||2013-03-11|2013-03-14|Estimate|October 2000||2000-10-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|April 2008|Actual|2008-04-30||Interventional|||Ginkgo Biloba Prevention Trial in Older Individuals|Ginkgo Biloba Prevention Trial in Older Individuals|Completed||Phase 3|3069|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 05:37:24.41611|2018-06-01 05:37:24.41611
NCT00010777|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|March 2004||2004-03-31|||||Interventional|||Fibromyalgia: A Randomized Controlled Trial of a Mind/Body Intervention|Fibromyalgia: A Randomized Controlled Trial of a Mind/Body Intervention|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:24.801993|2018-06-01 05:37:24.801993
NCT00010764|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-05|2001-02-02|2001-02-05|Estimate|||||||2008-03-05|2008-03-07|Estimate|September 2000||2000-09-30|March 2008|2008-03-31|July 2002||2002-07-31|||||Interventional|||Efficacy of Acupuncture in the Treatment of Fibromyalgia|Efficacy of Acupuncture in the Treatment of Fibromyalgia|Completed||Phase 1|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:24.864366|2018-06-01 05:37:24.864366
NCT00010751|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1998||1998-09-30|August 2006|2006-08-31|June 2004||2004-06-30|||||Interventional|||Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors|Chronic Diabetic Painful Neuropathy and Cardiovascular Risk Factors in NIDDM: An Alternative Approach.|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:24.920804|2018-06-01 05:37:24.920804
NCT00010738|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|July 2006|2006-07-31|August 2002||2002-08-31|||||Interventional|||Effects of Meditation on Mechanism of Coronary Heart Disease|Effects of Meditation on Mechanism of Coronary Heart Disease|Completed||Phase 2|145||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:24.975594|2018-06-01 05:37:24.975594
NCT00010725|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2010-01-11|2001-02-02|2001-02-05|Estimate|||||||2010-01-11|2010-01-12|Estimate|September 1999||1999-09-30|January 2010|2010-01-31|August 2004|Actual|2004-08-31|||||Interventional|||Effects of Herbal Antioxidants on Cardiovascular Disease in Older Blacks|Effects of Herbal Antioxidants on Cardiovascular Disease in Older Blacks|Completed||Phase 2|138||National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:37:25.029195|2018-06-01 05:37:25.029195
NCT00010712|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|July 2005||2005-07-31|||||Interventional|||Effects of Black Cohosh on Menopausal Hot Flashes|Effects of Black Cohosh on Menopausal Hot Flashes|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.104993|2018-06-01 05:37:25.104993
NCT00010699|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-03-21|2001-02-02|2001-02-05|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31|April 2003|Actual|2003-04-30|April 2003|Actual|2003-04-30||Interventional|||Effect of High Dose Vitamin E on Carotid Atherosclerosis|Effect of High Dose Vitamin E on Carotid Atherosclerosis|Completed||Phase 2|120||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.162807|2018-06-01 05:37:25.162807
NCT00010686|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate||||August 2006|2006-08-31|December 2005||2005-12-31|||||Interventional|||Dietary Phytoestrogens and Bone Metabolism|Dietary Phytoestrogens and Bone Metabolism|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.215059|2018-06-01 05:37:25.215059
NCT00010634|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|July 2004||2004-07-31|||||Interventional|||Complementary Naturopathic Medicine for Periodontitis|Complementary Naturopathic Medicine for Periodontitis|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.264769|2018-06-01 05:37:25.264769
NCT00010621|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|July 2004||2004-07-31|||||Interventional|||Complementary Medicine Approaches to TMD Pain Management|Complementary Medicine Approaches to TMD Pain Management|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.317007|2018-06-01 05:37:25.317007
NCT00010608|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2009-12-04|2001-02-02|2001-02-05|Estimate|||||||2009-12-04|2009-12-07|Estimate|October 1999||1999-10-31|December 2009|2009-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Clinical Trial of Meditation for Cardiovascular Disease in Older Black Women|Clinical Trial of Meditation for Cardiovascular Disease in Older Black Women|Completed||Phase 2|196|Actual|National Center for Complementary and Integrative Health (NCCIH)||2|||f||||t||||||||||2018-06-01 05:37:25.365306|2018-06-01 05:37:25.365306
NCT00010530|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2009-12-04|2001-02-02|2001-02-05|Estimate|||||||2009-12-04|2009-12-07|Estimate|September 1999||1999-09-30|December 2009|2009-12-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Basic Mechanisms of Meditation and Cardiovascular Disease in Older Blacks|Basic Mechanisms of Meditation and Cardiovascular Disease in Older Blacks|Completed||Phase 1|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||t||||||||||2018-06-01 05:37:25.429863|2018-06-01 05:37:25.429863
NCT00010491|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-05|2001-02-02|2001-02-05|Estimate|||||||2008-03-05|2008-03-07|Estimate|September 1999||1999-09-30|March 2008|2008-03-31|August 2003||2003-08-31|||||Interventional|||Acupuncture and Moxa: A Randomized Clinical Trial for Chronic Diarrhea in HIV Patients|Acupuncture and Moxa: A Randomized Clinical Trial for Chronic Diarrhea in HIV Patients|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.635837|2018-06-01 05:37:25.635837
NCT00010478|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2006-08-17|2001-02-02|2001-02-05|Estimate|||||||2006-08-17|2006-08-18|Estimate||||July 2006|2006-07-31||||||||Interventional|||Acupuncture and Hypertension|Acupuncture and Hypertension-Efficacy and Mechanisms|Completed||N/A|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.68252|2018-06-01 05:37:25.68252
NCT00010465|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2013-03-21|2001-02-02|2001-02-05|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Nervous System Manipulation and Botanicals for the Treatment of Recurrent Ear Infections in Children|Osteopathic Manipulation and Echinacea for the Treatment of Recurrent Ear Infections in Children|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:25.725072|2018-06-01 05:37:25.725072
NCT00009685|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-03|2001-02-02|2001-02-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||HIV-1 Vaccine Test in Uninfected Adult Volunteers|Evaluation of an HIV-1 DNA Vaccine Encoding a Modified Gag-Pol Protein in Uninfected Adult Volunteers|Completed||Phase 1|21||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:25.768322|2018-06-01 05:37:25.768322
NCT00009672|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2017-06-30|2001-02-02|2001-02-05|Estimate|||||||2017-06-30|2017-07-02|Actual|January 30, 2001||2001-01-30|December 12, 2006|2006-12-12|December 12, 2006||2006-12-12|||||Interventional|||Pain Treatment for Sciatica|Morphine, Nortriptyline and Their Combination in Sciatica Treatment|Completed||Phase 2|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:25.81531|2018-06-01 05:37:25.81531
NCT00009659|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-03-03|2001-02-02|2001-02-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Interventional|||Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause|Biologic Activity of a Selective Progesterone Receptor Modulator, CDB-2914, in Post-Menopausal Women|Completed||Phase 2|58||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:25.869459|2018-06-01 05:37:25.869459
NCT00009646|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-01|||2015-06-03|2001-02-02|2001-02-05|Estimate|||||||2015-06-03|2015-06-08|Estimate|November 1993||1993-11-30|June 2015|2015-06-30|March 2001|Actual|2001-03-31|March 1999|Actual|1999-03-31||Interventional|TIPP||Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)|Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)|Completed||Phase 3|1202|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 05:37:26.793099|2018-06-01 05:37:26.793099
NCT00009633|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-01|||2017-11-07|2001-02-02|2001-02-05|Estimate|||||||2017-11-07|2017-11-09|Actual|January 1993||1993-01-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|FU||Follow-up Visit of High Risk Infants|Follow-up Visit of High Risk Infants|Recruiting|||68000|Anticipated|NICHD Neonatal Research Network|||||f||||f||||||||||2018-06-01 05:37:26.912979|2018-06-01 05:37:26.912979
NCT00009620|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-01|||2015-06-03|2001-02-02|2001-02-05|Estimate|||||||2015-06-03|2015-06-08|Estimate|February 1993||1993-02-28|June 2015|2015-06-30|February 1997|Actual|1997-02-28|February 1995|Actual|1995-02-28||Interventional|Phenobarbital||Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage|Randomized Clinical Trial of Antenatal Phenobarbital in the Prevention of Neonatal Intracranial Hemorrhage|Completed||Phase 3|610|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 05:37:27.134511|2018-06-01 05:37:27.134511
NCT00010452|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2015-03-24|2001-02-01|2001-02-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 2000||2000-04-30|January 2008|2008-01-31|November 2007|Actual|2007-11-30|June 2006|Actual|2006-06-30||Interventional|||Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations|Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial|Completed||Phase 2/Phase 3|150|Actual|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:37:27.234375|2018-06-01 05:37:27.234375
NCT00010439|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|2009-06-03||2010-10-21|2001-02-01|2001-02-02|Estimate|2010-08-25|2010-09-17|Estimate||||2010-10-21|2010-11-08|Estimate|September 2000||2000-09-30|October 2010|2010-10-31|November 2008|Actual|2008-11-30|October 2003|Actual|2003-10-31||Interventional|||Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis|A Non-Randomized, Open-Label, Prospective, Non-Controlled, 12-Month Clinical Trial to Determine the Effects of Alendronate 35 or 70 mg/Week Depending Upon Body Weight, in Children and Adolescent With IJO|Completed||Phase 2|10|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-06-01 05:37:27.438236|2018-06-01 05:37:27.438236
NCT00010426|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2015-03-24|2001-02-01|2001-02-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|December 1999||1999-12-31|April 2001|2001-04-30|February 2001||2001-02-28|||||Interventional|||Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis||Completed||N/A|30||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:37:27.615224|2018-06-01 05:37:27.615224
NCT00010413|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-10-01|2001-02-01|2001-02-02|Estimate|||||||2008-10-01|2008-10-02|Estimate|April 1999||1999-04-30|October 2008|2008-10-31||||August 2007|Actual|2007-08-31||Interventional|||Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus||Completed||Phase 2|35||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:27.673878|2018-06-01 05:37:27.673878
NCT00010400|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2005-06-23|2001-02-01|2001-02-02|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1997||1997-04-30|July 2004|2004-07-31||||||||Interventional|||Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome||Completed||N/A|35||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:27.735536|2018-06-01 05:37:27.735536
NCT00010387|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-09-08|2001-02-01|2001-02-02|Estimate|||||||2008-09-08|2008-09-10|Estimate|March 1999||1999-03-31|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease||Completed||Phase 2|32||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:27.945288|2018-06-01 05:37:27.945288
NCT00010374|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2008-09-15|2001-02-01|2001-02-02|Estimate|||||||2008-09-15|2008-09-16|Estimate|February 2000||2000-02-29|September 2008|2008-09-30|October 2008|Anticipated|2008-10-31|October 2008|Anticipated|2008-10-31||Interventional|||Electrical Activation of The Diaphragm for Ventilatory Assist|Multi-Center Pivotal Study of NeuRx RA/4 Ventilatory Assist Device|Unknown status|Active, not recruiting|N/A|50|Anticipated|Synapse Biomedical||2|||f||||||||||||||2018-06-01 05:37:28.060838|2018-06-01 05:37:28.060838
NCT00010361|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2014-12-08|2001-02-01|2001-02-02|Estimate|||||||2014-12-08|2014-12-09|Estimate|November 2000||2000-11-30|August 2006|2006-08-31||||April 2007|Actual|2007-04-30||Interventional|||Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders||Completed||N/A|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:28.167912|2018-06-01 05:37:28.167912
NCT00010335|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-02|||2015-03-04|2001-02-01|2001-02-02|Estimate|||||||2015-03-04|2015-03-06|Estimate|November 2000||2000-11-30|March 2015|2015-03-31|May 2011|Actual|2011-05-31|July 2010|Actual|2010-07-31||Interventional|||Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders|A Pilot Study of High-Dose Immunosuppression Followed by Infusion of CD34-Selected Autologous or Syngeneic Peripheral Blood Stem Cells for Treatment of Refractory Autoimmune Disorders|Completed||Phase 1|6|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:37:28.302764|2018-06-01 05:37:28.302764
NCT00009594|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-01|||2006-08-17|2001-02-01|2001-02-02|Estimate|||||||2006-08-17|2006-08-18|Estimate|September 1999||1999-09-30|August 2006|2006-08-31|July 2004||2004-07-31|||||Interventional|||Alternative Medicine Approaches for Women With Temporomandibular Disorders|Alternative Medicine Approaches for Women With Temporomandibular Disorders|Completed||Phase 2|||National Center for Complementary and Integrative Health (NCCIH)|||||f||||||||||||||2018-06-01 05:37:28.396407|2018-06-01 05:37:28.396407
NCT00009581|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-01|||2008-03-03|2001-02-01|2001-02-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|January 2003|2003-01-31|January 2003||2003-01-31|||||Interventional|||Nitric Oxide to Improve Blood Flow in Sickle Cell Disease|Targeted Delivery of Nitric Oxide by Hemoglobin to Improve Regional Blood Flow in Sickle Cell Disease|Completed||Phase 2|65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:28.446732|2018-06-01 05:37:28.446732
NCT00009568|ClinicalTrials.gov processed this data on May 31, 2018|2001-02-01|||2008-03-03|2001-02-01|2001-02-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Platelet Function in Patients Treated With SSRI and Non-SSRI Antidepressants|Platelet Dysfunction in Patients Treated With SSRI Versus Non-SSRI Antidepressants|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:28.49719|2018-06-01 05:37:28.49719
NCT00009529|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-27|||2009-10-15|2001-01-26|2001-01-29|Estimate|||||||2009-10-15|2009-10-16|Estimate||||October 2009|2009-10-31||||||||Observational|||The Contact Lens and Myopia Progression (CLAMP) Study||Completed|||||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:37:28.544265|2018-06-01 05:37:28.544265
NCT00009256|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-25|||2017-06-30|2001-01-25|2001-01-26|Estimate|||||||2017-06-30|2017-07-02|Actual|April 13, 2000||2000-04-13|March 3, 2009|2009-03-03|March 3, 2009||2009-03-03|||||Observational|||Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy|Analysis of HIV Genetic Variation in Patients Prior to Initiation of Highly Active Antiretroviral Therapy|Completed|||65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:28.587082|2018-06-01 05:37:28.587082
NCT00009243|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-24|||2018-05-22|2001-01-24|2001-01-25|Estimate|||||||2018-05-22|2018-05-23|Actual|January 22, 2001||2001-01-22|May 16, 2018|2018-05-16||||||||Observational|||Natural History of Stroke: Cause and Development|Evaluation, Pathogenesis, and Treatment of Patients With or at Risk for Cerebrovascular Disease (A Natural History/Disease Pathogenesis Protocol)|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:28.738573|2018-06-01 05:37:28.738573
NCT00009230|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2017-05-03|2001-01-23|2001-01-24|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2000|Actual|2000-06-30|May 2017|2017-05-31|August 2005|Actual|2005-08-31|June 2005|Actual|2005-06-30||Interventional|||Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial||Completed||Phase 3|||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:37:28.825047|2018-06-01 05:37:28.825047
NCT00009217|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2016-05-23|2001-01-23|2001-01-24|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 1999||1999-01-31|February 2012|2012-02-29|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Treatment of Behavioral Symptoms in Alzheimer's Disease|Treatment of Behavioral Symptoms in Alzheimer's Disease|Completed||Phase 4|44|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 05:37:28.924024|2018-06-01 05:37:28.924024
NCT00009204|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2017-06-14|2001-01-23|2001-01-24|Estimate|||||||2017-06-14|2017-06-16|Actual|September 1995||1995-09-30|June 2017|2017-06-30|April 2002|Actual|2002-04-30|April 2000|Actual|2000-04-30||Interventional|SPAD||Serotonergic Pharmacotherapy for Agitation of Dementia|Serotonergic Pharmacotherapy for Agitation of Dementia|Completed||Phase 3|||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:37:29.081204|2018-06-01 05:37:29.081204
NCT00009191|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2013-09-17|2001-01-23|2001-01-24|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2005||2005-11-30|September 2013|2013-09-30|November 2007|Actual|2007-11-30|November 2006|Actual|2006-11-30||Interventional|||The Depression in Alzheimer's Disease Study (DIADS)||Completed||Phase 4|||Johns Hopkins University|||||f||||||||||||||2018-06-01 05:37:29.174215|2018-06-01 05:37:29.174215
NCT00009048|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2008-03-03|2001-01-23|2001-01-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Interventional|||EMD 128130 for the Treatment of Parkinson's Disease|Effect of Serotoninergic Treatment in Parkinson's Disease|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:29.2368|2018-06-01 05:37:29.2368
NCT00009035|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2018-05-24|2001-01-23|2001-01-24|Estimate|||||||2018-05-24|2018-05-25|Actual|January 22, 2001||2001-01-22|November 24, 2017|2017-11-24||||||||Observational|||Natural History of Patients With Brain and Spinal Cord Tumors|Evaluation of the Natural History of Patients With Tumors of the Central Nervous System|Active, not recruiting|||3049|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:29.329458|2018-06-01 05:37:29.329458
NCT00009178|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-23|||2010-01-12|2001-01-22|2001-01-23|Estimate|||||||2010-01-12|2010-01-14|Estimate|March 1998||1998-03-31|January 2010|2010-01-31|December 2001||2001-12-31|||||Interventional|||Treatment of Bulimia Nervosa in a Primary Care Setting||Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:29.419526|2018-06-01 05:37:29.419526
NCT00009009|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-20|||2008-03-03|2001-01-20|2001-01-22|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Kidney Transplant for HIV-Infected Patients in Renal Failure|Renal Allotransplantation for Treatment of End Stage Renal Disease in the Setting of Human Immunodeficiency Virus (HIV) Infection|Completed||Phase 2|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:29.486643|2018-06-01 05:37:29.486643
NCT00008892|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-18|||2017-06-30|2001-01-18|2001-01-19|Estimate|||||||2017-06-30|2017-07-02|Actual|January 12, 2001||2001-01-12|January 31, 2007|2007-01-31|January 31, 2007||2007-01-31|||||Observational|||Brain Imaging in Children With AD/HD|Anatomic MRI Brain Imaging of White Matter in Children|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:29.567681|2018-06-01 05:37:29.567681
NCT00008814|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-16|||2005-06-23|2001-01-17|2001-01-18|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Functional Magnetic Resonance Imaging in Infants|Functional Magnetic Resonance Imaging (fMRI) in Infants|Unknown status|Recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:29.618762|2018-06-01 05:37:29.618762
NCT00006432|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2007-06-22|2000-11-03|2000-11-06|Estimate|||||||2007-06-22|2007-06-25|Estimate|January 2000||2000-01-31|June 2007|2007-06-30||||||||Interventional|||Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:45.136972|2018-06-01 05:37:45.136972
NCT00008801|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-16|||2005-10-31|2001-01-17|2001-01-18|Estimate|||||||2005-10-31|2005-11-01|Estimate||||December 2003|2003-12-31||||||||Interventional|||hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure|hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure|Unknown status|Active, not recruiting|Phase 1/Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:29.676837|2018-06-01 05:37:29.676837
NCT00008788|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-16|||2005-06-23|2001-01-17|2001-01-18|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Osteoporosis in Children and Adults Following Liver Transplantation|Osteoporosis in Children and Adults Following Liver Transplantation|Unknown status|Active, not recruiting||40||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:29.728817|2018-06-01 05:37:29.728817
NCT00008775|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-16|||2005-06-23|2001-01-17|2001-01-18|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Pressure Support Ventilation During CF Exacerbations|Pressure Support Ventilation During CF Exacerbations: A Randomized, Controlled Trial|Suspended||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:29.777681|2018-06-01 05:37:29.777681
NCT00008762|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-16|||2005-06-23|2001-01-17|2001-01-18|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Bone Health of People With Cystic Fibrosis|Bone Health of People With Cystic Fibrosis|Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:29.829283|2018-06-01 05:37:29.829283
NCT00008749|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-16|||2005-06-23|2001-01-17|2001-01-18|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus|Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus|Unknown status|Recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:29.878468|2018-06-01 05:37:29.878468
NCT00008736|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-16|||2005-06-23|2001-01-17|2001-01-18|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Electrogastrography (EGC) in Premature Infants With Feeding Intolerance|Electrogastrography (EGC) in Premature Infants With Feeding Intolerance: The Effect of Metoclopramide|Completed||Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:29.927177|2018-06-01 05:37:29.927177
NCT00008827|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-17|||2010-01-12|2001-01-16|2001-01-17|Estimate|||||||2010-01-12|2010-01-14|Estimate|September 2000||2000-09-30|January 2010|2010-01-31|April 2001||2001-04-30|||||Interventional|||The Use of the Internet to Facilitate Weight Loss and Maintenance.|The Use of the Internet to Facilitate Weight Loss and Maintenance.|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:29.974482|2018-06-01 05:37:29.974482
NCT00008541|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-13|||2017-06-30|2001-01-13|2001-01-15|Estimate|||||||2017-06-30|2017-07-02|Actual|January 2, 2001||2001-01-02|March 6, 2009|2009-03-06|March 6, 2009||2009-03-06|||||Observational|||Evaluation and Treatment of Patients With Corneal and External Diseases|Evaluation and Treatment of Corneal and External Diseases and Anterior Segment Disorders|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:30.029233|2018-06-01 05:37:30.029233
NCT00008515|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-12|||2008-03-03|2001-01-12|2001-01-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Interventional|||Fluocinolone Implant to Treat Macular Degeneration|A Randomized, Prospective Study of Sustained-Release Fluocinolone Acetonide Implant for Choroidal Neovascularization Associated With Age-Related Macular Degeneration|Completed||Phase 1|16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:30.088119|2018-06-01 05:37:30.088119
NCT00008502|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-12|||2018-03-27|2001-01-12|2001-01-15|Estimate|||||||2018-03-27|2018-03-29|Actual|January 10, 2001||2001-01-10|January 24, 2018|2018-01-24||||||||Observational|||Genetic Analysis of Familial Keloids|Genetic Analysis of Familial Keloids|Completed|||106|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:30.14657|2018-06-01 05:37:30.14657
NCT00008476|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-09|||2008-03-03|2001-01-09|2001-01-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2001||2001-01-31|January 2004|2004-01-31|January 2004||2004-01-31|||||Interventional|||Capsaicin to Control Pain Following Third Molar Extraction|Evaluation of Vanilloid Receptor Inactivation for Preemptive Analgesia|Completed||Phase 2|162||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:30.206156|2018-06-01 05:37:30.206156
NCT00008450|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-06|||2017-07-12|2001-01-05|2001-01-08|Estimate|||||||2017-07-12|2017-07-14|Actual|August 11, 1997|Actual|1997-08-11|July 2017|2017-07-31||||October 25, 2011|Actual|2011-10-25||Interventional|||Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant|Induction of Mixed Hematopoietic Chimerism in Patients With Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil|Active, not recruiting||Phase 1|6|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-06-01 05:37:30.268288|2018-06-01 05:37:30.268288
NCT00007800|ClinicalTrials.gov processed this data on May 31, 2018|2001-01-05|||2010-01-12|2001-01-04|2001-01-05|Estimate|||||||2010-01-12|2010-01-14|Estimate|May 2000||2000-05-31|January 2010|2010-01-31|May 2002||2002-05-31|||||Interventional|||NEW DAY: Nutrition, Exercise, Weight Loss, Diabetes And You|Obesity Treatment and NIDDM in Black and White Women|Completed||Phase 2|218||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:30.38109|2018-06-01 05:37:30.38109
NCT00007696|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2011-02-02|2001-01-03|2001-01-04|Estimate|||||||2011-02-02|2011-02-03|Estimate|April 1998||1998-04-30|February 2011|2011-02-28||||||||Observational|||Finding Diabetes Mellitus Among Veterans|CSP #705D - Screening for Diabetes Mellitus in Veterans|Completed|||1276|Anticipated|VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:30.533726|2018-06-01 05:37:30.533726
NCT00007670|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-01-20|2001-01-03|2001-01-04|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1998||1998-01-31|February 2007|2007-02-28|March 2003||2003-03-31|||||Interventional|||Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.|CSP #428 - Treatment of Seizures in the Elderly Population|Completed||Phase 3|720||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:30.598518|2018-06-01 05:37:30.598518
NCT00007657|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-06-12|2001-01-03|2001-01-04|Estimate|||||||2009-06-12|2009-06-15|Estimate|December 1998||1998-12-31|June 2009|2009-06-30|June 2006|Actual|2006-06-30|||||Interventional|||Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation|CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation|Completed||Phase 3|3260|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:37:30.697832|2018-06-01 05:37:30.697832
NCT00007774|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-02-03|2000-12-30|2001-01-01|Estimate|||||||2009-02-03|2009-02-04|Estimate|March 1998||1998-03-31|February 2009|2009-02-28||||June 2001|Actual|2001-06-30||Interventional|||To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia|CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia|Completed||Phase 4|600|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:37:30.853277|2018-06-01 05:37:30.853277
NCT00007761|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-09-22|2000-12-30|2001-01-01|Estimate|||||||2009-09-22|2009-09-24|Estimate|July 1997||1997-07-31|September 2009|2009-09-30||||December 2003|Actual|2003-12-31||Interventional|||Does Bipolar Disease Program (BDP) Intervention Improve Long Term Manic and Depressive Symptoms.|CSP #430 - Reducing The Efficacy-Effectiveness Gap In Bipolar Disorder|Completed||Phase 3|382|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:37:30.982509|2018-06-01 05:37:30.982509
NCT00007748|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2015-06-25|2000-12-30|2001-01-01|Estimate|||||||2015-06-25|2015-06-26|Estimate|March 1999||1999-03-31|June 2015|2015-06-30|August 2001||2001-08-31|||||Interventional|||Exercise and Behavioral Therapy Trial (EBT).|CSP#470 - A Randomized, Multi-Center, Controlled Trial of Multi-Modal Therapy in Veterans With Gulf War Illnesses|Completed||Phase 3|1064||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:31.098395|2018-06-01 05:37:31.098395
NCT00007735|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-01-20|2000-12-30|2001-01-01|Estimate|||||||2009-01-20|2009-01-21|Estimate|January 1999||1999-01-31|February 2007|2007-02-28|October 2001||2001-10-31|||||Interventional|||Antibiotic Treatment of Gulf War Veterans' Illnesses|CSP #475 - Persian Gulf - Antibiotic Treatment Trial of Gulf War Veterans' Illnesses|Completed||Phase 3|450||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:37:31.203018|2018-06-01 05:37:31.203018
NCT00007722|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-10-07|2000-12-30|2001-01-01|Estimate|||||||2009-10-07|2009-10-09|Estimate|July 2000||2000-07-31|October 2009|2009-10-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Observational|||Amyotrophic Lateral Sclerosis (ALS) Gulf War Study|CSP #500 - An Epidemiological Investigation Into the Occurrence of Amyotrophic Lateral Sclerosis (ALS) Among Gulf War Veterans|Completed|||135|Actual|VA Office of Research and Development|||1||f||||f||||||Samples With DNA|"~     DNA samples of blood or mouthwash were collected in veterans' homes by nurses.~   "|||2018-06-01 05:37:31.299349|2018-06-01 05:37:31.299349
NCT00007709|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2011-02-02|2000-12-30|2001-01-01|Estimate|||||||2011-02-02|2011-02-03|Estimate|January 1998||1998-01-31|February 2011|2011-02-28||||||||Observational|||To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI).|CSP #706D - HIV Seroprevalence and Risks in Veterans With Severe Mental Illness|Completed|||||VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:31.362763|2018-06-01 05:37:31.362763
NCT00007683|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2011-06-14|2000-12-30|2001-01-01|Estimate|||||||2011-06-14|2011-06-16|Estimate|October 1998||1998-10-31|June 2011|2011-06-30|December 2004|Actual|2004-12-31|July 2003|Actual|2003-07-31||Interventional|||Warfarin and Antiplatelet Therapy in Chronic Heart Failure|CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)|Completed||Phase 3|1587|Anticipated|VA Office of Research and Development||3|||f||||t||||||||||2018-06-01 05:37:31.463145|2018-06-01 05:37:31.463145
NCT00007644|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|2013-08-15||2014-04-24|2000-12-30|2001-01-01|Estimate|2013-11-21|2014-01-10|Estimate||||2014-04-24|2014-05-09|Estimate|November 1994||1994-11-30|April 2014|2014-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|PIVOT||Prostate Cancer Intervention Versus Observation Trial (PIVOT)|CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer|Completed||Phase 3|731|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:37:31.75862|2018-06-01 05:37:31.75862
NCT00007631|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-01-29|2000-12-30|2001-01-01|Estimate|||||||2009-01-29|2009-01-30|Estimate|March 1998||1998-03-31|January 2009|2009-01-31|July 2006|Actual|2006-07-31|November 2004|Actual|2004-11-30||Interventional|||Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer|CSP #402 - VA Topical Tretinoin Chemoprevention Trial|Completed||Phase 3|1131|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:37:32.034777|2018-06-01 05:37:32.034777
NCT00007618|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2011-02-02|2000-12-30|2001-01-01|Estimate|||||||2011-02-02|2011-02-03|Estimate|January 1998||1998-01-31|February 2011|2011-02-28||||||||Observational|||The Identification of Prognostic Factors of Late Stage Disease, Particularly Those That Are Modifiable, That Might Explain the Worsened Prognosis With Colorectal Cancer Among Veterans.|CSP #707D - Colorectal Cancer-Risk Factors for Advanced Disease|Completed|||||VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:32.109292|2018-06-01 05:37:32.109292
NCT00007605|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2011-06-13|2000-12-30|2001-01-01|Estimate|||||||2011-06-13|2011-06-15|Estimate|April 1998||1998-04-30|June 2011|2011-06-30|December 2003|Actual|2003-12-31|October 2002|Actual|2002-10-31||Interventional|||Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm|CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation|Completed||Phase 3|706|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-06-01 05:37:32.254455|2018-06-01 05:37:32.254455
NCT00007592|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-01-20|2000-12-30|2001-01-01|Estimate|||||||2009-01-20|2009-01-21|Estimate|June 1989||1989-06-30|February 2003|2003-02-28||||||||Observational|||Hypertension Screening and Treatment Program|VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY)|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:32.374283|2018-06-01 05:37:32.374283
NCT00007579|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2008-10-16|2000-12-30|2001-01-01|Estimate|||||||2008-10-16|2008-10-17|Estimate|February 1998||1998-02-28|February 2003|2003-02-28||||||||Observational|||To Explore Racial Differences in Potential Risk Factors for Developing Prostate Cancer in the VA Population.|Prostate Cancer Case-Control Study: Black Versus White: VA Versus Private Sector|Completed|||||VA Office of Research and Development|||1||f||||f||||||||||2018-06-01 05:37:32.449138|2018-06-01 05:37:32.449138
NCT00007540|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-01-20|2000-12-30|2001-01-01|Estimate|||||||2009-01-20|2009-01-21|Estimate|April 1998||1998-04-30|February 2003|2003-02-28|September 2000||2000-09-30|||||Observational|||Study of Prostate Cancer in Black and White U.S. Veterans|Study of Prostate Cancer in Black and White U.S. Veterans|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:32.542018|2018-06-01 05:37:32.542018
NCT00007527|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-01-20|2000-12-30|2001-01-01|Estimate|||||||2009-01-20|2009-01-21|Estimate|August 1999||1999-08-31|February 2003|2003-02-28|January 2002||2002-01-31|||||Interventional|||Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice|A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence|Completed||Phase 4|600||VA Office of Research and Development|||||||||||||||||||2018-06-01 05:37:32.707883|2018-06-01 05:37:32.707883
NCT00007514|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2009-01-20|2000-12-30|2001-01-01|Estimate|||||||2009-01-20|2009-01-21|Estimate|March 2000||2000-03-31|February 2003|2003-02-28|February 2001||2001-02-28|||||Observational|||Investigate Olfactory Functioning as a Possible Proxy for Neurotoxic Exposure in Cohorts of Deployed and Non-Deployed Gulf War-Era Veterans.|Olfactory Functioning in Gulf War Veterans|Completed|||||VA Office of Research and Development|||||f||||||||||||||2018-06-01 05:37:33.260627|2018-06-01 05:37:33.260627
NCT00007501|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-29|||2013-07-02|2000-12-30|2001-01-01|Estimate|||||||2013-07-02|2013-07-04|Estimate|November 1998||1998-11-30|July 2013|2013-07-31|February 2011|Actual|2011-02-28|April 2004|Actual|2004-04-30||Interventional|SPS||Shingles Prevention Study|CSP #403 - Trial of Varicella Zoster Vaccine for the Prevention of Herpes Zoster and Its Complications|Completed||Phase 3|38456|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-06-01 05:37:33.366564|2018-06-01 05:37:33.366564
NCT00007475|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-22|2015-06-19||2016-02-08|2000-12-22|2000-12-25|Estimate|2016-02-08|2016-02-10|Estimate||||2016-02-08|2016-02-10|Estimate|December 2000||2000-12-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Permeability Factor in Focal Segmental Glomerulosclerosis|Permeability Factor in Focal Segmental Glomerulosclerosis|Completed||Phase 1/Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)|Note: definitive FSGS Permeability Factor (FPF) assays still in development. Data/samples transferred to the NIH-CC Glomerulosclerosis Consolidation protocol: focus on cardiotrophin like cytokine 1 & antibodies to a panel of podocyte proteins as FPF.|1|||f||||f||||||||||2018-06-01 05:37:33.542912|2018-06-01 05:37:33.542912
NCT00007410|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2016-07-28|2000-12-18|2000-12-19|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2000||2000-09-30|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Genetic Architecture of Plasma T-PA and PAI-1||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:34.254411|2018-06-01 05:37:34.254411
NCT00007397|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2016-05-12|2000-12-18|2000-12-19|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 2000||2000-02-29|December 2005|2005-12-31|January 2004|Actual|2004-01-31|||||Observational|||Age, Risk Factors for CVD and Cognitive Functioning||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:34.309204|2018-06-01 05:37:34.309204
NCT00007384|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2016-02-17|2000-12-18|2000-12-19|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 2000||2000-07-31|January 2008|2008-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Longitudinal LDL-C Studies in Black and White Families||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:34.377192|2018-06-01 05:37:34.377192
NCT00007358|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2016-03-10|2000-12-16|2000-12-18|Estimate|||||||2016-03-10|2016-03-11|Estimate|October 2000||2000-10-31|March 2016|2016-03-31|October 2008|Actual|2008-10-31|April 2007|Actual|2007-04-30||Interventional|||Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus|Study of Dexamethasone in Neonatal Lupus Congenital Heart Block; PRIDE (PR Interval and Dexamethasone Evaluation) in Congenital Heart Block|Completed||N/A|150|Anticipated|New York University School of Medicine||1|||f||||||||||||||2018-06-01 05:37:34.43673|2018-06-01 05:37:34.43673
NCT00007345|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|2016-01-14||2017-04-13|2000-12-16|2000-12-18|Estimate|2016-01-14|2016-02-12|Estimate||||2017-04-13|2017-05-16|Actual|March 8, 2001|Actual|2001-03-08|April 2017|2017-04-30|July 27, 2015|Actual|2015-07-27|January 26, 2015|Actual|2015-01-26||Interventional||Although 7 cohorts were written in the protocol, the cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.|Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma|Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma|Completed||Phase 2|131|Actual|National Institutes of Health Clinical Center (CC)|7 cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.|2|||f||||f|t|f||||||No||2018-06-01 05:37:34.586518|2018-06-01 05:37:34.586518
NCT00007306|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2007-01-02|2000-12-16|2000-12-18|Estimate|||||||2007-01-02|2007-01-04|Estimate|January 2000||2000-01-31|March 2003|2003-03-31|April 2005||2005-04-30|||||Interventional|||Treatment of Psoriasis With Parathyroid Hormone|Evaluation of the Therapeutic Efficacy & Safety of Topical Administration of Parathyroid Hormone (PTH) in Psoriasis|Completed||Phase 1/Phase 2|40||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||||||||||||||||2018-06-01 05:37:35.422624|2018-06-01 05:37:35.422624
NCT00007293|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2007-01-02|2000-12-16|2000-12-18|Estimate|||||||2007-01-02|2007-01-04|Estimate|August 2000||2000-08-31|February 2003|2003-02-28|July 2002||2002-07-31|||||Interventional|||Scalp Psoriasis Treatment With a Fiber Optic Comb|Phototherapy of Psoriasis of the Scalp With a UV-B Emitting Fiber Optic Comb|Completed||Phase 1/Phase 2|30||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:37:35.482252|2018-06-01 05:37:35.482252
NCT00007280|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2013-08-01|2000-12-16|2000-12-18|Estimate|||||||2013-08-01|2013-08-02|Estimate|October 2000||2000-10-31|April 2008|2008-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Bioengineered Skin and Wound Healing|Mechanisms of Bioengineered Skin in Human Wounds|Completed||Phase 1|50|Actual|Roger Williams Medical Center|||||f||||||||||||||2018-06-01 05:37:35.55232|2018-06-01 05:37:35.55232
NCT00007267|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2017-08-08|2000-12-16|2000-12-18|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2001||2001-06-30|August 2017|2017-08-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Psychological Treatments for Scleroderma|Psychosocial Interventions for Scleroderma|Completed||Phase 2|89|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-06-01 05:37:35.711716|2018-06-01 05:37:35.711716
NCT00007254|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2013-05-17|2000-12-16|2000-12-18|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 2000||2000-03-31|May 2013|2013-05-31|February 2003||2003-02-28|||||Interventional|||Morphine Gel for Bedsores|Morphine-Infused Gel for Pressure Ulcer Analgesia|Completed||Phase 1/Phase 2|75||University of Kansas Medical Center|||||f||||||||||||||2018-06-01 05:37:35.796669|2018-06-01 05:37:35.796669
NCT00007241|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-16|||2007-01-02|2000-12-16|2000-12-18|Estimate|||||||2007-01-02|2007-01-04|Estimate|September 2001||2001-09-30|February 2003|2003-02-28|July 2002||2002-07-31|||||Interventional|||Muscle Strengthening Device for Knee Osteoarthritis|Osteoarthritic Knee Isometric Exerciser for Home Use|Completed||Phase 2|92||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:37:35.864881|2018-06-01 05:37:35.864881
NCT00007228|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-15|||2008-03-03|2000-12-15|2000-12-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2000||2000-12-31|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Heart and Skeletal Muscle Problems in Neuroacanthocytosis|Characterization of Cardiac and Skeletal Myopathy, Risk Evaluation, and Phenotype-Genotype Correlation in Patients With Neuroacanthocytosis|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:35.939356|2018-06-01 05:37:35.939356
NCT00007215|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-15|||2008-03-03|2000-12-15|2000-12-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2000||2000-12-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Observational|||Dynamic Light Scattering Device (DLS) Study of Age-Related Changes in the Lens and Cataracts|A Study of Age-Related Changes in the Human Lens and Cataracts In Vivo Using Dynamic Light Scattering Device (DLS) Combined With Keratoscopy|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:35.991931|2018-06-01 05:37:35.991931
NCT00007189|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-14|||2016-10-18|2000-12-13|2000-12-14|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2001||2001-01-31|October 2016|2016-10-31||||May 2007|Actual|2007-05-31||Interventional|||Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)|Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)|Completed||Phase 3|2625||Seattle Institute for Biomedical and Clinical Research|||||f||||||||||||||2018-06-01 05:37:36.073738|2018-06-01 05:37:36.073738
NCT00006434|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2005-06-23|2000-11-03|2000-11-06|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma||Completed||Phase 3|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:45.029205|2018-06-01 05:37:45.029205
NCT00007163|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-09|||2008-03-03|2000-12-09|2000-12-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2000||2000-12-31|November 2002|2002-11-30|November 2002||2002-11-30|||||Interventional|||Monoclonal Antibody Treatment of Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Levels of Subcutaneously Administered Human Monoclonal Antibody to Interleukin-12 (J695) in Patients With Active Crohn's Disease|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:36.17459|2018-06-01 05:37:36.17459
NCT00007150|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-09|||2018-05-17|2000-12-09|2000-12-11|Estimate|||||||2018-05-17|2018-05-18|Actual|December 7, 2000||2000-12-07|July 21, 2017|2017-07-21||||||||Observational|||Treatment of Hemochromatosis|Studies of Phlebotomy Therapy in Hereditary Hemochromatosis|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:36.238027|2018-06-01 05:37:36.238027
NCT00007137|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-09|||2017-06-30|2000-12-09|2000-12-11|Estimate|||||||2017-06-30|2017-07-02|Actual|December 5, 2000||2000-12-05|April 11, 2007|2007-04-11|April 11, 2007||2007-04-11|||||Observational|||Structure and Function of the Human Tongue|Task-Induced Physiological and Biomechanical Changes of the In Vivo Human Tongue|Completed|||165||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:36.313742|2018-06-01 05:37:36.313742
NCT00007124|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-07|||2008-03-03|2000-12-07|2000-12-08|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 2000||2000-12-31|November 2002|2002-11-30|November 2002||2002-11-30|||||Observational|||Ketogenic Diet in Lafora Disease|A Trial of Ketogenic Diet in Lafora Disease|Completed|||15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:36.377388|2018-06-01 05:37:36.377388
NCT00007111|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-07|||2015-12-21|2000-12-07|2000-12-08|Estimate|||||||2015-12-21|2015-12-23|Estimate|April 1992||1992-04-30|January 2005|2005-01-31|April 2002||2002-04-30|||||Observational|||Children's Activity and Nutrition III||Completed|||||Augusta University|||||f||||||||||||||2018-06-01 05:37:36.439389|2018-06-01 05:37:36.439389
NCT00007098|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-07|||2016-12-06|2000-12-07|2000-12-08|Estimate|||||||2016-12-06|2016-12-07|Estimate|May 1995||1995-05-31|December 2016|2016-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Influence of Insulin on BP Change During Adolescence||Completed|||2|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||Undecided||2018-06-01 05:37:36.50704|2018-06-01 05:37:36.50704
NCT00007085|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-07|||2016-07-28|2000-12-07|2000-12-08|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2000||2000-09-30|January 2008|2008-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED II)||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:36.553628|2018-06-01 05:37:36.553628
NCT00007059|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2005-06-23|2000-12-06|2000-12-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1998||1998-06-30|December 2003|2003-12-31||||||||Interventional|||Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation|Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation|Completed||N/A|20||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:36.610099|2018-06-01 05:37:36.610099
NCT00007046|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2005-06-23|2000-12-06|2000-12-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 2000||2000-08-31|December 2003|2003-12-31||||||||Observational|||Genetic Study of Patients and Families With Diaphyseal Medullary Stenosis With Malignant Fibrous Histiocytoma of the Bone||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:36.661648|2018-06-01 05:37:36.661648
NCT00007033|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06|||2009-01-21|2000-12-06|2000-12-07|Estimate|||||||2009-01-21|2009-01-22|Estimate|October 2000||2000-10-31|April 2002|2002-04-30||||||||Interventional|||Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease||Completed||N/A|25||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:36.70871|2018-06-01 05:37:36.70871
NCT00007020|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-06||2013-05-21|2015-04-15|2000-12-06|2000-12-07|Estimate||||2013-05-21|2013-05-29|Estimate|2015-04-15|2015-05-06|Estimate|January 1992||1992-01-31|April 2015|2015-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid|"Investigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid Metabolism. This Study Was Previously Registered by the NCRR and Identified as NCRR-M01RR08084-0009"|Completed||Phase 3|79|Actual|Retrophin, Inc.||1|||f||||f||||||||||2018-06-01 05:37:36.76931|2018-06-01 05:37:36.76931
NCT00006565|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-01|||2016-02-17|2000-11-30|2000-12-01|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2000||2000-09-30|October 2008|2008-10-31|April 2004|Actual|2004-04-30|March 2003|Actual|2003-03-31||Interventional|||Randomized Trial to Reduce Environmental Tobacco Smoke in Children With Asthma|Randomized Trial to Reduce Environmental Tobacco Smoke in Children With Asthma|Completed||Phase 3|225|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||f||||||||||2018-06-01 05:37:36.834728|2018-06-01 05:37:36.834728
NCT00007371|ClinicalTrials.gov processed this data on May 31, 2018|2000-12-19|||2016-09-22|2000-11-27|2000-11-28|Estimate|||||||2016-09-22|2016-09-26|Estimate|September 1999||1999-09-30|January 2005|2005-01-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Observational|||Hepatitis C in Clinically Discordant Hemophilic Siblings|Hepatitis C in Clinically Discordant Hemophilic Siblings|Completed|||||University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-06-01 05:37:36.903309|2018-06-01 05:37:36.903309
NCT00006552|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-28|||2016-03-15|2000-11-27|2000-11-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1999||1999-09-30|May 2005|2005-05-31|August 2002|Actual|2002-08-31|||||Observational|||Adherence to Antihypertensive Therapy--Data Analyses||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:36.956138|2018-06-01 05:37:36.956138
NCT00006539|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-28|||2016-03-15|2000-11-27|2000-11-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1999||1999-09-30|March 2005|2005-03-31|August 2004|Actual|2004-08-31|||||Observational|||Thrombotic, Inflammatory & Gene Markers of CVD in Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:37.002645|2018-06-01 05:37:37.002645
NCT00006526|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-28|||2016-03-15|2000-11-27|2000-11-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1999||1999-07-31|August 2004|2004-08-31|May 2003|Actual|2003-05-31|||||Observational|||Coronary Calcification Progression Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:37.055696|2018-06-01 05:37:37.055696
NCT00006519|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-23|||2006-07-10|2000-11-23|2000-11-24|Estimate|||||||2006-07-10|2006-07-11|Estimate|November 2000||2000-11-30|October 2004|2004-10-31|October 2004||2004-10-31|||||Interventional|||Capravirine to Treat Children With HIV Infection|A Phase I Study of Capravirine (AG 1549), a Novel Non-Nucleoside Reverse Transcriptase Inhibitor in Children With HIV Infection|Completed||Phase 1|96||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:37.110482|2018-06-01 05:37:37.110482
NCT00006518|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-22|||2018-05-16|2000-11-22|2000-11-23|Estimate|||||||2018-05-16|2018-05-17|Actual|November 21, 2000||2000-11-21|April 13, 2018|2018-04-13||||||||Observational|||Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer|Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer|Recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:37.173965|2018-06-01 05:37:37.173965
NCT00006517|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-22|||2015-06-02|2000-11-22|2000-11-23|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 1998||1998-09-30|November 2005|2005-11-30|April 2004|Actual|2004-04-30|June 2003|Actual|2003-06-30||Interventional|||Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)|Light and Ion Therapy for Seasonal Affective Disorder|Completed||N/A|150|Actual|New York State Psychiatric Institute||5|||f||||f||||||||||2018-06-01 05:37:37.397902|2018-06-01 05:37:37.397902
NCT00006516|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-21|||2016-09-23|2000-11-21|2000-11-22|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 1999||1999-09-30|May 2011|2011-05-31||||August 2004|Actual|2004-08-31||Interventional|||Home Stimulation for Brain-Asphyxiated Infants|Neuroplasticity of Brain-Asphyxiated Infants: Efficacy of Intervention|Completed||Phase 2|120|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:37.516268|2018-06-01 05:37:37.516268
NCT00006515|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-21|||2017-06-30|2000-11-21|2000-11-22|Estimate|||||||2017-06-30|2017-07-02|Actual|November 16, 2000||2000-11-16|November 18, 2011|2011-11-18|November 18, 2011||2011-11-18|||||Observational|||Late Effects of Treatment for Sarcomas in Children|Late Effects of Treatment in Survivors of Pediatric Sarcomas|Completed|||39|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:37.603478|2018-06-01 05:37:37.603478
NCT00006514|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-20|||2016-02-17|2000-11-20|2000-11-21|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2000||2000-09-30|July 2005|2005-07-31|August 2004|Actual|2004-08-31|||||Observational|||Multivariate Risk of CVD in Diverse Populations||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:38.083019|2018-06-01 05:37:38.083019
NCT00006513|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-20|||2016-03-15|2000-11-20|2000-11-21|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2000||2000-09-30|January 2006|2006-01-31|August 2004|Actual|2004-08-31|||||Observational|||Assessing the Occupation Burden in COPD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:38.431605|2018-06-01 05:37:38.431605
NCT00006512|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-20|||2016-01-19|2000-11-20|2000-11-21|Estimate|||||||2016-01-19|2016-01-21|Estimate|September 2000||2000-09-30|January 2016|2016-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Characterizing a 5P-Linked BHR Susceptibility Locus||Completed|||||University of Chicago|||||f||||||||||||||2018-06-01 05:37:38.493788|2018-06-01 05:37:38.493788
NCT00006511|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-20|||2016-02-17|2000-11-20|2000-11-21|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2000||2000-09-30|January 2006|2006-01-31|August 2005|Actual|2005-08-31|||||Observational|||Chromosome 5Q Gene Variants and Asthma-Related Traits||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:39.944817|2018-06-01 05:37:39.944817
NCT00006510|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-20|||2016-07-28|2000-11-20|2000-11-21|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2000||2000-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Identification of an Asthma Susceptibility Gene on 3P||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:41.62944|2018-06-01 05:37:41.62944
NCT00006508|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-18|||2005-06-23|2000-11-18|2000-11-20|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Disorders of Systemic Glucose Balance||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:42.150443|2018-06-01 05:37:42.150443
NCT00006505|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-17|||2018-05-18|2000-11-17|2000-11-20|Estimate|||||||2018-05-18|2018-05-21|Actual|November 16, 2000||2000-11-16|April 20, 2018|2018-04-20|June 1, 2020|Anticipated|2020-06-01|June 30, 2002|Actual|2002-06-30||Interventional|||Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression|Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression|Active, not recruiting||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:37:42.264663|2018-06-01 05:37:42.264663
NCT00006504|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2016-03-15|2000-11-16|2000-11-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2000||2000-08-31|August 2004|2004-08-31|July 2002|Actual|2002-07-31|||||Observational|||Flavonoids and Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:42.349553|2018-06-01 05:37:42.349553
NCT00006503|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2014-04-29|2000-11-16|2000-11-17|Estimate|||||||2014-04-29|2014-05-01|Estimate|August 2000||2000-08-31|April 2008|2008-04-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Prevalence & Progression of Subclinical Atherosclerosis||Completed|||||Rush University Medical Center|||||f||||||||||||||2018-06-01 05:37:42.473425|2018-06-01 05:37:42.473425
NCT00006502|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2016-02-26|2000-11-16|2000-11-17|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2000||2000-09-30|July 2005|2005-07-31|June 2005|Actual|2005-06-30|||||Observational|||Myocardial Perfusion, Risk Factors, and Coronary Calcium||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:42.550752|2018-06-01 05:37:42.550752
NCT00006501|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2015-12-21|2000-11-16|2000-11-17|Estimate|||||||2015-12-21|2015-12-23|Estimate|January 2003||2003-01-31|December 2015|2015-12-31|February 2012|Actual|2012-02-29|December 2009|Actual|2009-12-31||Observational|||Prognostic Significance of T Wave Alternans|The Prevalence and Prognostic Significance of T Wave Alternans in Patients With Severe Congestive Heart Failture|Completed|||549|Actual|Columbia University|||1||f||||f||||||||||2018-06-01 05:37:42.598938|2018-06-01 05:37:42.598938
NCT00006500|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2016-06-22|2000-11-16|2000-11-17|Estimate|||||||2016-06-22|2016-06-24|Estimate|April 2000||2000-04-30|June 2016|2016-06-30|March 2002||2002-03-31|||||Observational|||Trends in Trans-Fatty Acid Intake Between 1980 and 1997||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:37:42.765082|2018-06-01 05:37:42.765082
NCT00006499|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2016-03-15|2000-11-16|2000-11-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2000||2000-06-30|July 2004|2004-07-31|April 2004|Actual|2004-04-30|||||Observational|||Genetics of Hypertension and Its Intermediate Phenotypes||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:42.83122|2018-06-01 05:37:42.83122
NCT00006498|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2016-03-15|2000-11-16|2000-11-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2000||2000-09-30|January 2006|2006-01-31|August 2005|Actual|2005-08-31|||||Observational|||Chronic Life Stress and Incident Asthma in Adult Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:42.89582|2018-06-01 05:37:42.89582
NCT00006497|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2008-08-20|2000-11-16|2000-11-17|Estimate|||||||2008-08-20|2008-08-21|Estimate|September 2000||2000-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Long-Term Effects of Subclinical CAD on Cardiac Function||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:42.966231|2018-06-01 05:37:42.966231
NCT00006496|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-16|||2018-03-24|2000-11-16|2000-11-17|Estimate|||||||2018-03-24|2018-03-27|Actual|February 2000||2000-02-29|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||Molecular Epidemiology of ARDS|Molecular Epidemiology of Acute Respiratory Distress Syndrome|Recruiting|||4000|Anticipated|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     Blood will be collected for DNA extraction and plasma cytokine measurements~   "|No||2018-06-01 05:37:43.07671|2018-06-01 05:37:43.07671
NCT00006433|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2005-06-23|2000-11-03|2000-11-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|November 2001|2001-11-30||||||||Interventional|||Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer||Unknown status|Recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:45.080721|2018-06-01 05:37:45.080721
NCT00006494|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-14|||2017-06-30|2000-11-14|2000-11-15|Estimate|||||||2017-06-30|2017-07-02|Actual|November 7, 2000||2000-11-07|September 6, 2011|2011-09-06|September 6, 2011||2011-09-06|||||Observational|||Study of Tests to Evaluate Effectiveness of Anti-HIV Drugs|An Assessment of the Relationship Between Antiretroviral Drug Genotype/Phenotype (IC50) and Antiretroviral Activity in HIV-Infected, Drug-Experienced Patients With Suboptimal Suppression of Plasma Viral Load|Completed|||14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:43.170396|2018-06-01 05:37:43.170396
NCT00006493|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-14|||2005-06-23|2000-11-14|2000-11-15|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2004|2004-01-31||||||||Interventional|||Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia||Completed||Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:43.240234|2018-06-01 05:37:43.240234
NCT00006492|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-09|||2008-03-03|2000-11-09|2000-11-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2000||2000-11-30|December 2002|2002-12-31|December 2002||2002-12-31|||||Observational|||Gluten-Free Diet in Patients With Gluten Sensitivity and Cerebellar Ataxia|Open Label Controlled Trial of Gluten-Free Diet in Patients With Gluten-Sensitivity and Cerebellar Ataxia|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:43.300757|2018-06-01 05:37:43.300757
NCT00006489|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-08|2016-11-21||2017-03-10|2000-11-08|2000-11-09|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|December 2000||2000-12-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)|Naltrexone and Cognitive-Behavioral Therapy for Patients With Alcoholism and Post-Traumatic Stress Disorder|Completed||Phase 4|165|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-06-01 05:37:43.415138|2018-06-01 05:37:43.415138
NCT00006488|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-08|||2005-06-23|2000-11-08|2000-11-09|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2004|2004-01-31||||||||Interventional|||Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease||Completed||Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:44.122087|2018-06-01 05:37:44.122087
NCT00006450|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-07|||2008-03-03|2000-11-07|2000-11-08|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 2000||2000-11-30|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors|Phase II Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Progressive or Recurrent CNS Malignancy|Completed||Phase 2|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:44.191628|2018-06-01 05:37:44.191628
NCT00006449|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-06|||2010-05-11|2000-11-06|2000-11-07|Estimate|||||||2010-05-11|2010-05-12|Estimate|September 2000||2000-09-30|May 2010|2010-05-31|July 2006||2006-07-31|||||Interventional|||Post-Treatment Effects of Naltrexone|Post-Treatment Effects of Naltrexone|Completed||Phase 4|160||Indiana University|||||f||||||||||||||2018-06-01 05:37:44.290743|2018-06-01 05:37:44.290743
NCT00006507|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-04|||2007-01-16|2000-11-04|2000-11-06|Estimate|||||||2007-01-16|2007-01-17|Estimate|March 1999||1999-03-31|December 2004|2004-12-31|February 2002||2002-02-28|||||Interventional|||Occupational Therapy to Treat Children Who Over or Under React to Their Environment|Occupational Therapy (OT) Outcomes: Children With Sensory Modulation Disorders|Completed||Phase 2|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:44.34942|2018-06-01 05:37:44.34942
NCT00006448|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-04|||2016-09-23|2000-11-04|2000-11-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 1996||1996-08-31|March 2003|2003-03-31||||July 2001|Actual|2001-07-31||Interventional|||Treatment of Chronic Pain After Spinal Cord Injury (SCI) or Amputation|Spinal Cord Injury (SCI) and Amputation Pain Prevention and Treatment|Completed||N/A|400||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:44.407318|2018-06-01 05:37:44.407318
NCT00006447|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-04|||2016-09-23|2000-11-04|2000-11-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 1997||1997-09-30|May 2011|2011-05-31||||August 2002|Actual|2002-08-31||Interventional|||Supporting Traumatic Brain Injury (TBI) Caregivers||Completed||Phase 2|64||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:44.472662|2018-06-01 05:37:44.472662
NCT00006446|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-04|||2007-02-21|2000-11-04|2000-11-06|Estimate|||||||2007-02-21|2007-02-22|Estimate|July 1996||1996-07-31|April 2003|2003-04-30|June 2001||2001-06-30|||||Interventional|||Preventing Problems in Children's Social Behavior|John F. Kennedy Center for Mental Retardation at Vanderbilt University: Preventing Problems in Children's Social Behavior|Completed||N/A|180||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:44.52457|2018-06-01 05:37:44.52457
NCT00006445|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-04|||2007-02-21|2000-11-04|2000-11-06|Estimate|||||||2007-02-21|2007-02-22|Estimate||||March 2003|2003-03-31||||||||Interventional|||Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters|First and 2nd Trimester Evaluation of the Risk of Aneuploidy|Unknown status|Active, not recruiting|N/A|38000||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:44.579129|2018-06-01 05:37:44.579129
NCT00006439|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-04|||2005-06-23|2000-11-04|2000-11-06|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Effects of Home Visits on Medication Adherence in Children and Youth With HIV||Unknown status|Active, not recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:44.708964|2018-06-01 05:37:44.708964
NCT00006438|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2005-06-23|2000-11-03|2000-11-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1997||1997-01-31|March 2000|2000-03-31|December 1999||1999-12-31|||||Interventional|||How Shoes With Rocker Soles Affect Walking|Rocker Sole Kinetics and Kinematics|Completed||N/A|46||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:44.754168|2018-06-01 05:37:44.754168
NCT00006437|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2008-03-03|2000-11-03|2000-11-06|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2000||2000-10-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Observational|||Pathophysiology of Chronic Wounds|Pathophysiology of Chronic Wounds: Collection of Blood From Healthy Volunteers|Completed|||999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:44.802935|2018-06-01 05:37:44.802935
NCT00006436|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2018-05-26|2000-11-03|2000-11-06|Estimate|||||||2018-05-26|2018-05-30|Actual|November 1, 2000||2000-11-01|May 21, 2018|2018-05-21|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection|Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas|Recruiting||Phase 2|80|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:37:44.868646|2018-06-01 05:37:44.868646
NCT00006435|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2018-04-03|2000-11-03|2000-11-06|Estimate|||||||2018-04-03|2018-04-04|Actual|October 29, 2000||2000-10-29|June 19, 2017|2017-06-19||||||||Observational|||Study of Plexiform Neurofibromas in Neurofibromatosis Type 1|Natural History of Plexiform in Neurofibromatosis Type I|Completed|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:44.957267|2018-06-01 05:37:44.957267
NCT00006431|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2005-06-23|2000-11-03|2000-11-06|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA||Unknown status|Active, not recruiting|Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:45.197867|2018-06-01 05:37:45.197867
NCT00006430|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-03|||2005-06-23|2000-11-03|2000-11-06|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2002|2002-02-28||||||||Interventional|||A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA||Unknown status|Active, not recruiting|Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:45.253981|2018-06-01 05:37:45.253981
NCT00006429|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-01|||2016-09-23|2000-11-01|2000-11-02|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 1999||1999-03-31|May 2011|2011-05-31|February 2004||2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Treadmill Training for Spinal Cord Injury|Locomotor Therapy Trial for Spinal Cord Injury|Completed||Phase 2|200||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:45.308228|2018-06-01 05:37:45.308228
NCT00006428|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-01|||2012-12-14|2000-11-01|2000-11-02|Estimate|||||||2012-12-14|2012-12-18|Estimate|August 1996||1996-08-31|March 2003|2003-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Chronic Pain in Spinal Cord Injury|Management of Chronic Pain in Rehabilitation Project I - Management of Chronic Pain in Persons With Spinal Cord Injury|Completed||Phase 4|100||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:45.362024|2018-06-01 05:37:45.362024
NCT00006427|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-01|||2016-09-23|2000-11-01|2000-11-02|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 1996||1996-08-31|May 2011|2011-05-31||||July 2001|Actual|2001-07-31||Interventional|||Chronic Pain After Amputation|Management of Chronic Pain in Rehabilitation Project II Management of Chronic Pain in Persons With Amputation|Completed||Phase 4|125||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:45.435611|2018-06-01 05:37:45.435611
NCT00006426|ClinicalTrials.gov processed this data on May 31, 2018|2000-11-01|||2005-06-23|2000-11-01|2000-11-02|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1998||1998-08-31|March 2003|2003-03-31|May 2003||2003-05-31|||||Interventional|||Achilles Tendon Lengthening in Patients With Diabetes to Prevent Foot Ulcers|Controlled Clinical Trial Comparing the Effect of an Achilles Tendon Lengthening Procedure and Casting to Casting Alone for the Treatment of Neuropathic Forefoot Plantar Ulcers in Patients With Diabetes Mellitus|Completed||Phase 1|60||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:37:45.498518|2018-06-01 05:37:45.498518
NCT00006425|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-31|||2017-11-07|2000-10-31|2000-11-01|Estimate|||||||2017-11-07|2017-11-08|Actual|November 1, 2000||2000-11-01|October 30, 2017|2017-10-30||||||||Observational|||Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study|Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Pilot Study|Completed|||20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:45.563438|2018-06-01 05:37:45.563438
NCT00006424|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-28|||2008-03-03|2000-10-28|2000-10-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2000||2000-10-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Observational|||Study of Brain Changes Shaped by Experience|fMRI and Spectroscopy Studies of Cortical Plasticity at 1.5 and 3 Tesla|Completed|||153||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:46.577341|2018-06-01 05:37:46.577341
NCT00006422|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-27|||2008-03-03|2000-10-27|2000-10-30|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2000||2000-10-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Interventional|||Evaluation and Treatment of Pediatric Eye Diseases|Evaluation and Treatment Protocol for Patients With Pediatric Eye Diseases and Strabismus|Completed||N/A|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:46.655224|2018-06-01 05:37:46.655224
NCT00006421|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-27|||2017-10-18|2000-10-27|2000-10-30|Estimate|||||||2017-10-18|2017-10-19|Actual|November 1, 2000||2000-11-01|June 19, 2017|2017-06-19||||||||Observational|||Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study|Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study|Completed|||200|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:46.728616|2018-06-01 05:37:46.728616
NCT00006420|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-26|||2016-02-03|2000-10-26|2000-10-27|Estimate|||||||2016-02-03|2016-02-05|Estimate|August 2000||2000-08-31|February 2016|2016-02-29|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|MHS||Minnesota Heart Survey - Mortality and Morbidity|Study of Trends of Cardiovascular Disease in a Metropolitan Area.|Completed|||||University of Minnesota - Clinical and Translational Science Institute|||1||f||||||||||||||2018-06-01 05:37:46.796095|2018-06-01 05:37:46.796095
NCT00006419|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-26|||2016-03-15|2000-10-26|2000-10-27|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2000||2000-07-31|May 2005|2005-05-31|June 2004|Actual|2004-06-30|||||Observational|||Diet and Chronic Obstructive Pulmonary Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:46.85757|2018-06-01 05:37:46.85757
NCT00006418|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-25|||2014-04-01|2000-10-25|2000-10-26|Estimate|||||||2014-04-01|2014-04-02|Estimate|September 2003||2003-09-30|November 2005|2005-11-30|August 2007||2007-08-31|||||Observational|||Molecular Genetics of Schizophrenia||Completed|||10800|Anticipated|NorthShore University HealthSystem|||||f||||||||||||||2018-06-01 05:37:46.982839|2018-06-01 05:37:46.982839
NCT00006417|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-24|||2008-03-03|2000-10-24|2000-10-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2000||2000-10-31|November 2004|2004-11-30|November 2004||2004-11-30|||||Interventional|||Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease|HLA-Matched, Peripheral Blood Stem Cell Transplantation Using Low Intensity Conditioning to Treat Patients With Chronic Granulomatous Disease Who Are Actively Infected|Completed||Phase 2|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:47.075656|2018-06-01 05:37:47.075656
NCT00006414|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-17|||2008-03-03|2000-10-17|2000-10-18|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2000||2000-10-31|March 2006|2006-03-31|March 2006||2006-03-31|||||Observational|||Hand Exercise and Upper Arm Anesthesia to Improvements Hand Function in Chronic Stroke Patients|Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia|Completed|||12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:47.176993|2018-06-01 05:37:47.176993
NCT00006413|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-17|||2017-06-30|2000-10-17|2000-10-18|Estimate|||||||2017-06-30|2017-07-02|Actual|October 13, 2000||2000-10-13|December 14, 2006|2006-12-14|December 14, 2006||2006-12-14|||||Interventional|||Stem Cell Transplantation to Treat Systemic Mastocytosis|Low Intensity Preparative Regimen Followed by HLA-Matched, Mobilized Peripheral Blood Stem Cell Transplantation for Systemic Mastocytosis|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:47.333782|2018-06-01 05:37:47.333782
NCT00006411|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-13|||2010-03-23|2000-10-13|2000-10-16|Estimate|||||||2010-03-23|2010-03-24|Estimate|July 2002||2002-07-31|April 2008|2008-04-30|July 2013|Anticipated|2013-07-31|December 2007|Actual|2007-12-31||Interventional|CDS||Cornea Donor Study|Cornea Donor Study|Unknown status|Active, not recruiting|N/A|1101|Actual|National Eye Institute (NEI)||2|||f||||t||||||||||2018-06-01 05:37:47.399386|2018-06-01 05:37:47.399386
NCT00006409|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|2010-02-17||2015-06-29|2000-10-12|2000-10-13|Estimate|2010-04-26|2010-05-14|Estimate||||2015-06-29|2015-07-22|Estimate|September 2000||2000-09-30|June 2015|2015-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|TAAG||Trial of Activity for Adolescent Girls (TAAG)|Trial of Activity for Adolescent Girls (TAAG)|Completed||Phase 2|8727|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-06-01 05:37:47.524031|2018-06-01 05:37:47.524031
NCT00006408|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2014-03-27|2000-10-12|2000-10-13|Estimate|||||||2014-03-27|2014-03-28|Estimate|August 2000||2000-08-31|March 2014|2014-03-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Hypertension in Black Americans: A Life Course Approach||Completed|||||Duke University|||||f||||f||||||||||2018-06-01 05:37:48.030939|2018-06-01 05:37:48.030939
NCT00006407|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2016-03-15|2000-10-12|2000-10-13|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2000||2000-09-30|March 2005|2005-03-31|July 2004|Actual|2004-07-31|||||Observational|||Sex Steroid Hormones and Risk of CHD in Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:48.083068|2018-06-01 05:37:48.083068
NCT00006406|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2016-03-15|2000-10-12|2000-10-13|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2000||2000-08-31|December 2005|2005-12-31|July 2005|Actual|2005-07-31|||||Observational|||Amino Acids in Urine, Diet, and Blood Pressure: International Population Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:48.126672|2018-06-01 05:37:48.126672
NCT00006405|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2008-01-18|2000-10-12|2000-10-13|Estimate|||||||2008-01-18|2008-01-21|Estimate|April 2002||2002-04-30|January 2008|2008-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||APEX: Adiposity Prevention by Exercise in Black Girls||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:48.174407|2018-06-01 05:37:48.174407
NCT00006404|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2014-03-25|2000-10-12|2000-10-13|Estimate|||||||2014-03-25|2014-03-26|Estimate|September 2000||2000-09-30|May 2009|2009-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Nutrition in Pregnancy, Birth Weight, and Childhood Asthma||Completed|||||Harvard Pilgrim Health Care|||||f||||||||||||||2018-06-01 05:37:48.221569|2018-06-01 05:37:48.221569
NCT00006403|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2016-05-12|2000-10-12|2000-10-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2000||2000-07-31|March 2005|2005-03-31|June 2004|Actual|2004-06-30|||||Observational|||Inflammation: Correlates and Prognosis in Framingham||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:48.268297|2018-06-01 05:37:48.268297
NCT00006402|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2008-01-18|2000-10-12|2000-10-13|Estimate|||||||2008-01-18|2008-01-21|Estimate|August 2000||2000-08-31|January 2008|2008-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Observational|||Lifestyle, Adiposity and Cardiovascular Health in Youths||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:48.314982|2018-06-01 05:37:48.314982
NCT00006401|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12|||2015-10-05|2000-10-12|2000-10-13|Estimate|||||||2015-10-05|2015-10-06|Estimate|September 2000||2000-09-30|October 2015|2015-10-31|October 2007|Actual|2007-10-31|September 2005|Actual|2005-09-30||Interventional|||Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants|Inhaled NO for the Prevention of Chronic Lung Disease|Completed||Phase 3|793|Anticipated|University of Colorado, Denver||2|||f||||||||||||||2018-06-01 05:37:48.36239|2018-06-01 05:37:48.36239
NCT00006400|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-12||2011-04-07|2011-04-15|2000-10-12|2000-10-13|Estimate||||2011-04-07|2011-04-14|Estimate|2011-04-15|2011-04-27|Estimate|August 2000||2000-08-31|April 2011|2011-04-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia|Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)|Completed||Phase 3|191|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-06-01 05:37:48.557747|2018-06-01 05:37:48.557747
NCT00006398|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-05|||2017-05-30|2000-10-05|2000-10-06|Estimate|||||||2017-05-30|2017-06-01|Actual|August 1993|Actual|1993-08-31|May 2017|2017-05-31|September 2002|Actual|2002-09-30|September 2002|Actual|2002-09-30||Interventional|||Prevention of Esophageal Varices by Beta-Adrenergic Blockers|Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis|Completed||Phase 3|213|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||||2018-06-01 05:37:48.69201|2018-06-01 05:37:48.69201
NCT00006394|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2005-06-23|2000-10-04|2000-10-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1997||1997-04-30|December 2003|2003-12-31||||||||Interventional|||Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency||Completed||N/A|72||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:48.789421|2018-06-01 05:37:48.789421
NCT00006393|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2005-06-23|2000-10-04|2000-10-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1998||1998-07-31|December 2003|2003-12-31||||||||Observational|||Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis|Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis|Unknown status|Recruiting||80||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:48.862715|2018-06-01 05:37:48.862715
NCT00006337|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2008-03-03|2000-10-04|2000-10-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 2000||2000-10-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||KW-6002 to Treat Parkinson's Disease|Adenosine A2A Blockade With KW-6002 in Parkinson's Disease|Completed||Phase 2|16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:48.924719|2018-06-01 05:37:48.924719
NCT00006336|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2008-03-03|2000-10-04|2000-10-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2000||2000-09-30|November 2001|2001-11-30|November 2001||2001-11-30|||||Observational|||Sensory Training to Treat Focal Dystonia|Sensory Training for Treatment of Focal Dystonia|Completed|||22||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:48.980694|2018-06-01 05:37:48.980694
NCT00006335|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2017-06-30|2000-10-04|2000-10-05|Estimate|||||||2017-06-30|2017-07-02|Actual|September 26, 2000||2000-09-26|September 23, 2009|2009-09-23||||September 25, 2008|Actual|2008-09-25||Observational|||Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID|Decisions of Female Adolescents About Carrier Testing in Families With X-Linked Severe Combined Immunodeficiency (XSCID)|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:49.034986|2018-06-01 05:37:49.034986
NCT00006334|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2017-10-05|2000-10-04|2000-10-05|Estimate|||||||2017-10-05|2017-10-06|Actual|September 26, 2000||2000-09-26|July 8, 2014|2014-07-08|July 8, 2014||2014-07-08|||||Observational|||Turner Syndrome: Genotype and Phenotype|Turner Syndrome: Genotype and Phenotype|Completed|||1017|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:49.108963|2018-06-01 05:37:49.108963
NCT00006333|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2018-03-27|2000-10-04|2000-10-05|Estimate|||||||2018-03-27|2018-03-29|Actual|September 29, 2000||2000-09-29|March 8, 2018|2018-03-08||||||||Observational|||Study of Arthritis and Related Conditions|Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:49.174167|2018-06-01 05:37:49.174167
NCT00006332|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2005-06-23|2000-10-04|2000-10-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate||Completed||Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:49.252165|2018-06-01 05:37:49.252165
NCT00006331|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2005-06-27|2000-10-04|2000-10-05|Estimate|||||||2005-06-27|2005-06-28|Estimate||||December 2003|2003-12-31||||||||Observational|||Prospective Controlled Study of Posttransplant Diabetes||Unknown status|Recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:49.308154|2018-06-01 05:37:49.308154
NCT00006330|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2005-06-23|2000-10-04|2000-10-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Pharmacokinetic and Pharmacodynamic Interaction Study of Digoxin and Hawthorn||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:49.412035|2018-06-01 05:37:49.412035
NCT00006329|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2005-06-23|2000-10-04|2000-10-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Comparison of Two Methods of Parathyroidectomy for Primary Hyperparathyroidism||Completed||Phase 2/Phase 3|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:49.479592|2018-06-01 05:37:49.479592
NCT00006328|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-04|||2005-06-23|2000-10-04|2000-10-05|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Chronic Allograft Nephropathy||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:49.530847|2018-06-01 05:37:49.530847
NCT00006323|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-02|||2016-05-12|2000-10-02|2000-10-03|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1999||1999-09-30|March 2005|2005-03-31|July 2004|Actual|2004-07-31|||||Observational|||Neurobehavioral Consequences of Sleep Apnea in Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:49.578548|2018-06-01 05:37:49.578548
NCT00006322|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-02|||2016-03-15|2000-10-02|2000-10-03|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1999||1999-07-31|March 2005|2005-03-31|June 2003|Actual|2003-06-30|||||Observational|||Birth Weight Effect on Blood Pressure in Late Childhood||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:49.622162|2018-06-01 05:37:49.622162
NCT00006321|ClinicalTrials.gov processed this data on May 31, 2018|2000-10-02|||2017-04-06|2000-10-02|2000-10-03|Estimate|||||||2017-04-06|2017-04-10|Actual|September 1999|Actual|1999-09-30|April 2017|2017-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Neurocognitive Function in Snoring Children||Terminated|||40|Actual|University of Louisville||||PI left the university|f|||||f|f||||||Undecided||2018-06-01 05:37:49.69178|2018-06-01 05:37:49.69178
NCT00006320|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-30|||2008-03-03|2000-09-30|2000-10-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2000||2000-09-30|July 2004|2004-07-31|July 2004||2004-07-31|||||Interventional|||Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women|Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant Women|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:49.747356|2018-06-01 05:37:49.747356
NCT00006319|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-30|||2018-05-30|2000-09-30|2000-10-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 25, 2000||2000-09-25|February 28, 2018|2018-02-28||||||||Observational|||Molecular and Clinical Studies of Primary Immunodeficiency Diseases|Molecular and Clinical Studies of Primary Immunodeficiency Diseases|Enrolling by invitation|||266|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:49.798449|2018-06-01 05:37:49.798449
NCT00006318|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-30|||2008-03-03|2000-09-30|2000-10-02|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2000||2000-09-30|December 2003|2003-12-31|December 2003||2003-12-31|||||Observational|||Role of Prostaglandins in the Regulation of Brain Blood Flow|Role of Prostaglandins in the Control of Cerebral Blood Flow During Hypercapnia and Functional Activation in Humans|Completed|||125||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:49.96311|2018-06-01 05:37:49.96311
NCT00006315|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-05-12|2000-09-28|2000-09-29|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1999||1999-09-30|May 2005|2005-05-31|August 2004|Actual|2004-08-31|||||Observational|||Dose/Response of Exercise on Long Term Weight Loss||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:50.031854|2018-06-01 05:37:50.031854
NCT00006314|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-05-12|2000-09-28|2000-09-29|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1999||1999-07-31|January 2006|2006-01-31|June 2004|Actual|2004-06-30|||||Observational|||Cytomegalovirus Spread and Reactivation in Blood Cells||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:50.086425|2018-06-01 05:37:50.086425
NCT00006313|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-05-12|2000-09-28|2000-09-29|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 1999||1999-06-30|September 2002|2002-09-30|June 2000|Actual|2000-06-30|||||Observational|||Hormone Therapy Effects on CVD Risk Factors||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:50.145627|2018-06-01 05:37:50.145627
NCT00006312|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-01-14|2000-09-28|2000-09-29|Estimate|||||||2016-01-14|2016-01-15|Estimate|July 1999||1999-07-31|January 2016|2016-01-31|May 2003||2003-05-31|||||Observational|||Hemochromatosis--Genetic Prevalence and Penetrance||Completed|||||University of Rochester|||||f||||||||||||||2018-06-01 05:37:50.203695|2018-06-01 05:37:50.203695
NCT00006311|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-02-17|2000-09-28|2000-09-29|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 1999||1999-06-30|January 2006|2006-01-31|May 2004|Actual|2004-05-31|||||Observational|||Anxiety and Vagal Control of the Heart in Coronary Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:50.264035|2018-06-01 05:37:50.264035
NCT00006310|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-03-08|2000-09-28|2000-09-29|Estimate|||||||2016-03-08|2016-03-10|Estimate|April 1999||1999-04-30|March 2016|2016-03-31|March 2004||2004-03-31|||||Observational|||KSHV Infection in Blood Donors From Texas|KSHV Seroprevalence in Hospital Patients From San Antonio|Completed|||||The University of Texas Health Science Center at San Antonio|||||f||||f||||||||No||2018-06-01 05:37:50.316467|2018-06-01 05:37:50.316467
NCT00006309|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-02-17|2000-09-28|2000-09-29|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1999||1999-09-30|December 2004|2004-12-31|August 2002|Actual|2002-08-31|||||Observational|||Pooling of Cohort Studies on Diet & Coronary Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:50.387264|2018-06-01 05:37:50.387264
NCT00006308|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2014-05-07|2000-09-28|2000-09-29|Estimate|||||||2014-05-07|2014-05-08|Estimate|September 1999||1999-09-30|May 2014|2014-05-31|August 2004|Actual|2004-08-31|August 2004|Actual|2004-08-31||Observational|||Observational Cohort Study of Sodium, Weight and Cardiovascular Disease|Observational Cohort Study of Sodium, Weight and Cardiovascular Disease|Completed|||||Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 05:37:50.438352|2018-06-01 05:37:50.438352
NCT00006307|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-02-17|2000-09-28|2000-09-29|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 2000||2000-08-31|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Epidemiology of Body Mass Index Rebound||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:50.486046|2018-06-01 05:37:50.486046
NCT00006306|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|||2016-02-26|2000-09-28|2000-09-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 1999||1999-09-30|January 2006|2006-01-31|August 2004|Actual|2004-08-31|||||Observational|||Effects of Chronic Ozone Exposure on Lung Function||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:50.533151|2018-06-01 05:37:50.533151
NCT00006305|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-28|2011-01-27||2016-01-12|2000-09-28|2000-09-29|Estimate|2011-05-11|2011-05-12|Estimate||||2016-01-12|2016-02-08|Estimate|September 2000||2000-09-30|January 2016|2016-01-31|March 2009|Actual|2009-03-31|November 2008|Actual|2008-11-30||Interventional|BARI2D||Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes|Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes|Completed||Phase 3|2368|Actual|University of Pittsburgh||4|||f||||t||||||||||2018-06-01 05:37:50.606782|2018-06-01 05:37:50.606782
NCT00006301|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-27|||2018-05-19|2000-09-27|2000-09-28|Estimate|||||||2018-05-19|2018-05-22|Actual|September 24, 2000||2000-09-24|March 24, 2015|2015-03-24|March 24, 2015||2015-03-24|||||Observational|||Immune Response to Hepatitis C Virus|Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus|Completed|||89|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:51.128845|2018-06-01 05:37:51.128845
NCT00006300|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-27|||2008-03-03|2000-09-27|2000-09-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2000||2000-04-30|April 2002|2002-04-30|April 2002||2002-04-30|||||Observational|||Oral Manifestations of Aplastic Anemia|Oral Manifestations of Aplastic Anemia|Completed|||146||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:51.190747|2018-06-01 05:37:51.190747
NCT00006299|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-27|||2008-03-03|2000-09-27|2000-09-28|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Celebrex for Pain Relief After Oral Surgery|In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model|Completed||Phase 2|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:51.239204|2018-06-01 05:37:51.239204
NCT00006297|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-25|||2016-02-17|2000-09-25|2000-09-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2000||2000-09-30|October 2005|2005-10-31|July 2005|Actual|2005-07-31|||||Observational|||Risk Factors for CV Disease in a Dialysis Cohort||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:51.290593|2018-06-01 05:37:51.290593
NCT00006296|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-25|||2016-02-17|2000-09-25|2000-09-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2000||2000-09-30|April 2009|2009-04-30|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Observational|||CV Risk Factors at Age 25-64 & Long-Term Medicare Costs||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:51.338251|2018-06-01 05:37:51.338251
NCT00006295|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-25|||2016-08-19|2000-09-25|2000-09-26|Estimate|||||||2016-08-19|2016-08-23|Estimate|August 2000||2000-08-31|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Molecular & Clinical Evaluation of Low HDL Syndromes||Completed|||370|Anticipated|University of Maryland|||12||f||||||||||||||2018-06-01 05:37:51.382205|2018-06-01 05:37:51.382205
NCT00006294|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-25|||2018-04-04|2000-09-25|2000-09-26|Estimate|||||||2018-04-04|2018-04-06|Actual|September 1999||1999-09-30|April 2018|2018-04-30|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|GenHAT||Genetics of Hypertension Associated Treatments (GenHAT)|Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment|Completed|||37939|Actual|University of Kentucky|||4||f||||f|f|f||||||||2018-06-01 05:37:51.437528|2018-06-01 05:37:51.437528
NCT00006292|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-23|||2008-03-03|2000-09-23|2000-09-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2000||2000-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Infliximab for the Treatment of Early Rheumatoid Arthritis|Randomized Double Blind Active Treatment Controlled Trial of the Anti-TNF-Alpha Antibody Infliximab in Patients With Erosive Rheumatoid Arthritis|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:51.523988|2018-06-01 05:37:51.523988
NCT00006289|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-21|2013-06-04||2017-08-21|2000-09-21|2000-09-22|Estimate|2016-05-12|2016-06-21|Estimate||||2017-08-21|2017-08-22|Actual|September 2000||2000-09-30|August 2017|2017-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional||Clinical evaluation includes blood chemistries (acute care, hepatic panel, and mineral panel) as well as measurements of pain (including allodynia, hyperalgesia, and hyperpathia), edema, autonomic dysfunction (altered skin color, temperature, or sudomotor activity) and extent of movement disorders.|Neurotropin to Treat Chronic Neuropathic Pain|Neurotropin for Acute Dental Pain and for Chronic Neuropathic Pain|Terminated||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)|Because of the difficulty in patient recruitment, the interim analysis was performed for the first 16 patients (target was 30). The results are inconclusive due to large variations in pain scores associated with insufficient the number of patients.|2||difficulty in the recruitment of patients|f||||f||||||||||2018-06-01 05:37:51.585911|2018-06-01 05:37:51.585911
NCT00006285|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-16|||2017-06-30|2000-09-16|2000-09-18|Estimate|||||||2017-06-30|2017-07-02|Actual|September 14, 2000||2000-09-14|June 8, 2009|2009-06-08|April 1, 2002|Actual|2002-04-01|April 1, 2002|Actual|2002-04-01||Observational|||Use of Transcranial Magnetic Stimulation (TMS) and Magnetic Resonance Imaging (MRI) to Study Visual Attention|Transcranial Magnetic Stimulation Studies of Visual Attention|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:51.972587|2018-06-01 05:37:51.972587
NCT00006286|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-14|||2014-04-16|2000-09-14|2000-09-15|Estimate|||||||2014-04-16|2014-04-17|Estimate|September 1998||1998-09-30|November 2005|2005-11-30|March 2004||2004-03-31|||||Interventional|||Treatment for Adolescents With Depression Study (TADS)|Treatment for Adolescents With Depression Study (TADS)|Completed||Phase 3|432||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:37:52.039842|2018-06-01 05:37:52.039842
NCT00006278|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-14|||2008-03-03|2000-09-14|2000-09-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2000||2000-09-30|September 2002|2002-09-30|September 2002||2002-09-30|||||Observational|||Study of Cushing's Syndrome Not Related to ACTH Production|The Molecular and Cellular Etiology of ACTH-Independent Adrenal Disease|Completed|||18||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:52.161565|2018-06-01 05:37:52.161565
NCT00006276|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-14|||2008-03-03|2000-09-14|2000-09-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2000||2000-09-30|October 2002|2002-10-31|October 2002||2002-10-31|||||Interventional|||Micellar Paclitaxel to Treat Severe Psoriasis|A Pilot Open-Label Single-Dose Study Using Intravenous Micellar Paclitaxel for Patients With Severe Psoriasis|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:52.216397|2018-06-01 05:37:52.216397
NCT00006280|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2010-03-01|2000-09-11|2000-09-12|Estimate|||||||2010-03-01|2010-03-02|Estimate|February 2000||2000-02-29|March 2010|2010-03-31|February 2002||2002-02-28|||||Interventional|||A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis|A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis|Completed||Phase 2|98||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:52.291976|2018-06-01 05:37:52.291976
NCT00006275|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2000-09-11|2000-09-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 2000||2000-07-31|September 2000|2000-09-30|July 2000||2000-07-31|||||Interventional|||Study of Topical Calcitriol in Children With Psoriasis||Completed||N/A|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:52.360548|2018-06-01 05:37:52.360548
NCT00006274|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2000-09-11|2000-09-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1997||1997-03-31|December 2003|2003-12-31||||||||Observational|||Study of Energy Requirements in Critically Ill Newborns|Study of Energy Requirements in Critically Ill Newborns|Unknown status|Recruiting||60||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:52.417936|2018-06-01 05:37:52.417936
NCT00006273|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2000-09-11|2000-09-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1996||1996-06-30|December 2003|2003-12-31||||||||Observational|||Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis|Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis|Unknown status|Active, not recruiting||60||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:52.474292|2018-06-01 05:37:52.474292
NCT00006272|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2000-09-11|2000-09-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1994||1994-08-31|December 2003|2003-12-31||||||||Observational|||Study of Energy Expenditure in Infants With Ventricular Septal Defects|Study of Energy Expenditure in Infants With Ventricular Septal Defects|Unknown status|Recruiting||20||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:52.530346|2018-06-01 05:37:52.530346
NCT00006271|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2000-09-11|2000-09-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1997||1997-01-31|December 2003|2003-12-31||||||||Observational|||Phase I/II Study of Neuroendocrine Dysfunction in Patients With Closed Head Injuries||Unknown status|Active, not recruiting||100||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:52.584419|2018-06-01 05:37:52.584419
NCT00006270|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2005-06-23|2000-09-11|2000-09-12|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1998||1998-02-28|December 2003|2003-12-31||||||||Observational|||Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury||Unknown status|Active, not recruiting||32||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:52.633951|2018-06-01 05:37:52.633951
NCT00006206|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2010-04-30|2000-09-11|2000-09-12|Estimate|||||||2010-04-30|2010-05-03|Estimate|August 1997||1997-08-31|November 2007|2007-11-30|May 2006|Actual|2006-05-31|||||Interventional|||COMBINE (Acamprosate/Naltrexone)|COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions|Completed||Phase 3|1375||University of North Carolina, Chapel Hill|||||||||||||||||||2018-06-01 05:37:52.693398|2018-06-01 05:37:52.693398
NCT00006205|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2013-03-14|2000-09-11|2000-09-12|Estimate|||||||2013-03-14|2013-03-15|Estimate|March 2005||2005-03-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Alcohol Dependency Study: Combining Medication Treatment for Alcoholism|Combining Medications Treatment for Alcoholism|Unknown status|Recruiting|Phase 2|320|Anticipated|University of Virginia||4|||f||||t||||||||||2018-06-01 05:37:52.775811|2018-06-01 05:37:52.775811
NCT00006204|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2007-12-07|2000-09-11|2000-09-12|Estimate|||||||2007-12-07|2007-12-10|Estimate|March 2000||2000-03-31|December 2007|2007-12-31|January 2006|Actual|2006-01-31|||||Interventional|||Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)|Combined Pharmacotherapy in Depressed Alcoholics|Completed||Phase 4|106||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:37:52.883244|2018-06-01 05:37:52.883244
NCT00006203|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-11|||2006-10-20|2000-09-11|2000-09-12|Estimate|||||||2006-10-20|2006-10-23|Estimate||||October 2006|2006-10-31|May 2005||2005-05-31|||||Interventional|||Naltrexone, Craving, and Drinking|Naltrexone, Craving, and Drinking: Ecological Assessment|Completed||Phase 4|186||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:37:52.946213|2018-06-01 05:37:52.946213
NCT00006202|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-09|||2008-03-03|2000-09-09|2000-09-11|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 2000||2000-09-30|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||Lutein for Age-Related Macular Degeneration|Dose Ranging Study of Lutein Supplementation in Persons Over Age 60|Completed||Phase 2|45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:52.996367|2018-06-01 05:37:52.996367
NCT00006200|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-09|||2005-06-23|2000-09-09|2000-09-11|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2004|2004-01-31||||||||Interventional|||Thalidomide and Dacarbazine for Metastatic Melanoma||Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.069552|2018-06-01 05:37:53.069552
NCT00006199|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-09|||2005-06-23|2000-09-09|2000-09-11|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2004|2004-01-31||||||||Interventional|||Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)||Unknown status|Recruiting|Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.115849|2018-06-01 05:37:53.115849
NCT00006198|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-09|||2005-06-23|2000-09-09|2000-09-11|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2004|2004-01-31||||||||Interventional|||Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer||Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.20119|2018-06-01 05:37:53.20119
NCT00006196|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-07|||2005-06-23|2000-09-07|2000-09-08|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||The Relationship Between Vitamin D, Fingernail Thickness and Bone Density||Completed||Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.248871|2018-06-01 05:37:53.248871
NCT00006195|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-07|||2006-10-11|2000-09-07|2000-09-08|Estimate|||||||2006-10-11|2006-10-12|Estimate||||December 2003|2003-12-31||||||||Interventional|||Glucose Regulation During Risperidone and Olanzapine Treatment||Unknown status|Recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.294637|2018-06-01 05:37:53.294637
NCT00006194|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-07|||2005-06-23|2000-09-07|2000-09-08|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Effects of Exercise on Markers of Inflammation in Skeletal Muscle in Elderly Hip Fracture Patients||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.359813|2018-06-01 05:37:53.359813
NCT00006193|ClinicalTrials.gov processed this data on May 31, 2018|2000-09-07|||2005-06-23|2000-09-07|2000-09-08|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Effectiveness of Atkins Diet for Weight Loss||Unknown status|Active, not recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.40886|2018-06-01 05:37:53.40886
NCT00006192|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-31|||2016-07-28|2000-08-31|2000-09-01|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 2000||2000-08-31|May 2009|2009-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Genetics of Coronary Artery Disease in Alaskan Natives (GOCADAN)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:53.44793|2018-06-01 05:37:53.44793
NCT00006190|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-25|||2010-03-01|2000-08-25|2000-08-28|Estimate|||||||2010-03-01|2010-03-02|Estimate|November 2000||2000-11-30|March 2010|2010-03-31|November 2001||2001-11-30|||||Interventional|||A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy|The Study of Mechanisms of Lipodystrophy in HIV-Infected Patients|Completed||Phase 4|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:53.49191|2018-06-01 05:37:53.49191
NCT00006068|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-18|||2005-06-23|2000-07-18|2000-07-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Does Islet Transplantation Eliminate Hypoglycemia?||Unknown status|Not yet recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:59.503697|2018-06-01 05:37:59.503697
NCT00006188|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-26|||2017-06-30|2000-08-26|2000-08-28|Estimate|||||||2017-06-30|2017-07-02|Actual|August 19, 2000||2000-08-19|July 25, 2008|2008-07-25|July 25, 2008||2008-07-25|||||Observational|||Evaluation and Treatment of Patients With Inflammatory Eye Diseases|Evaluation and Treatment Protocol for Patients With Intraocular Inflammatory Disease (Uveitis)|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:53.544916|2018-06-01 05:37:53.544916
NCT00006187|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-25|||2009-12-10|2000-08-25|2000-08-28|Estimate|||||||2009-12-10|2009-12-11|Estimate||||October 2003|2003-10-31|June 2005|Anticipated|2005-06-30|June 2005|Anticipated|2005-06-30||Interventional|||The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease||Terminated||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:37:53.592736|2018-06-01 05:37:53.592736
NCT00006186|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-25|||2005-06-23|2000-08-25|2000-08-28|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Autologous Fresh Whole Blood and Coagulation Following Cardiopulmonary Bypass in Infants||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:53.752061|2018-06-01 05:37:53.752061
NCT00006184|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-23|2012-12-13||2017-09-19|2000-08-23|2000-08-24|Estimate|2012-12-13|2013-01-24|Estimate||||2017-09-19|2017-10-20|Actual|February 8, 2001|Actual|2001-02-08|September 2017|2017-09-30|January 12, 2008|Actual|2008-01-12|January 12, 2008|Actual|2008-01-12||Interventional|||Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma|Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation|Completed||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f||||||No||2018-06-01 05:37:53.818829|2018-06-01 05:37:53.818829
NCT00006185|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-22|||2010-03-01|2000-08-22|2000-08-23|Estimate|||||||2010-03-01|2010-03-02|Estimate|September 1999||1999-09-30|March 2010|2010-03-31|August 2003||2003-08-31|||||Interventional|||Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome|Cellular Mechanisms for Metabolic Dysfunction in HIV|Completed||Phase 1|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:54.631173|2018-06-01 05:37:54.631173
NCT00006183|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-21|||2016-07-28|2000-08-21|2000-08-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2000||2000-07-31|March 2008|2008-03-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Comparison of Hematocrit Levels in Infant Heart Surgery|Hematocrit Strategy in Infant Heart Surgery|Completed||Phase 3|120||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:54.713677|2018-06-01 05:37:54.713677
NCT00006182|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-21|||2016-02-17|2000-08-21|2000-08-22|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 2000||2000-07-31|October 2005|2005-10-31|February 2006|Actual|2006-02-28|||||Interventional|||Stroke Prevention in Sickle Cell Anemia (STOP 2)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:37:54.777461|2018-06-01 05:37:54.777461
NCT00006399|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-18|||2009-01-13|2000-08-18|2000-08-21|Estimate|||||||2009-01-13|2009-01-15|Estimate|September 1999||1999-09-30|January 2009|2009-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease|Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease|Completed||Phase 2|45||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:37:54.838896|2018-06-01 05:37:54.838896
NCT00006181|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-19|||2014-01-06|2000-08-19|2000-08-21|Estimate|||||||2014-01-06|2014-01-07|Estimate|April 1999||1999-04-30|March 2003|2003-03-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|PHLAME||Promoting Healthy Lifestyles Among Firefighters|PHLAME: Promoting Healthy Lifestyles: Alternative Models' Effects|Completed||Phase 2|600||Oregon Health and Science University|||||f||||||||||||||2018-06-01 05:37:54.931339|2018-06-01 05:37:54.931339
NCT00006180|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-17|||2017-06-30|2000-08-17|2000-08-18|Estimate|||||||2017-06-30|2017-07-02|Actual|August 10, 2000||2000-08-10|January 19, 2007|2007-01-19|January 19, 2007||2007-01-19|||||Interventional|||Bone Loss in Premenopausal Women With Depression|The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression)|Completed||Phase 4|220||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:55.005056|2018-06-01 05:37:55.005056
NCT00006178|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-15|2010-01-14||2010-06-16|2000-08-15|2000-08-16|Estimate|2010-01-15|2010-02-11|Estimate||||2010-06-16|2010-06-22|Estimate|August 2000||2000-08-31|June 2010|2010-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection|Sirolimus Monotherapy to Optimize Activation Induced Cell Death (AICD) in Renal Transplants Following Lymphocyte Depletion Induction With Thymoglobulin|Completed||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)|Optimal dose of RATG remains to be determined. Whether other depleting agents are as effective as RATG is unclear.||||f||||||||||||||2018-06-01 05:37:55.084793|2018-06-01 05:37:55.084793
NCT00006177|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-12|||2018-05-22|2000-08-12|2000-08-14|Estimate|||||||2018-05-22|2018-05-23|Actual|August 11, 2000||2000-08-11|May 7, 2018|2018-05-07||||||||Observational|||Child & Adolescent Bipolar Disorder Brain Imaging and Treatment Study|The Phenomenology and Neurophysiology of Affective Dysregulation in Children and Adolescents With Bipolar Disorder|Recruiting|||2300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:55.297416|2018-06-01 05:37:55.297416
NCT00006176|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-12|||2017-06-30|2000-08-12|2000-08-14|Estimate|||||||2017-06-30|2017-07-02|Actual|August 10, 2000||2000-08-10|August 4, 2009|2009-08-04|August 4, 2009|Actual|2009-08-04|August 4, 2009|Actual|2009-08-04||Observational|||Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies|Clinical, Molecular and Biochemical Characterization of Familial Encephalopathy With Neuroserpin Inclusion Bodies|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:55.381602|2018-06-01 05:37:55.381602
NCT00006175|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-12|||2008-03-03|2000-08-12|2000-08-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2000||2000-08-31|October 2005|2005-10-31|October 2005||2005-10-31|||||Observational|||Cyclooxygenase Levels Following Surgery to Remove Third Molars (Wisdom Teeth)|Cytokine Responses to Acute Inflammation in the Oral Surgery Model|Completed|||160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:55.438106|2018-06-01 05:37:55.438106
NCT00006174|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-11|||2017-06-30|2000-08-11|2000-08-14|Estimate|||||||2017-06-30|2017-07-02|Actual|August 3, 2000||2000-08-03|May 18, 2009|2009-05-18|May 18, 2009||2009-05-18|||||Interventional|||Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome|Effects of the Aromatase Inhibitor Letrozole on Pubertal Progression and Indices of Bone Turnover in Girls With Precocious Puberty and McCune-Albright Syndrome (MAS)|Completed||Phase 1|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:55.48836|2018-06-01 05:37:55.48836
NCT00006173|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-11|||2008-03-03|2000-08-11|2000-08-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2000||2000-08-31|January 2004|2004-01-31|January 2004||2004-01-31|||||Observational|||Magnetic Resonance Imaging for Evaluating Kidney Function|Assessment of Renal Artery Stenosis and Renovascular Hypertension by Contrast Enhanced Magnetic Resonance Imaging: A Pilot Study|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:55.552403|2018-06-01 05:37:55.552403
NCT00006172|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-11|||2014-09-30|2000-08-11|2000-08-14|Estimate|||||||2014-09-30|2014-10-01|Estimate|April 2000||2000-04-30|March 2008|2008-03-31|February 2004|Actual|2004-02-29|July 2003|Actual|2003-07-31||Interventional|||Clinical Trials of Two Non-drug Treatments for Chronic Depression|Light and Negative Ion Treatment for Chronic Depression|Completed||N/A|32|Actual|New York State Psychiatric Institute||3|||f||||f||||||||||2018-06-01 05:37:55.611746|2018-06-01 05:37:55.611746
NCT00006171|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-10|||2018-05-11|2000-08-10|2000-08-11|Estimate|||||||2018-05-11|2018-05-14|Actual|August 7, 2000||2000-08-07|June 29, 2012|2012-06-29|June 29, 2012||2012-06-29|||||Observational|||Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma|A Study of the Effects of Potent Anti-HIV Therapy on Parameters Hypothesized to be Related to the Pathogenesis of Kaposi's Sarcoma (KS) in HIV-Infected Individuals|Completed|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:55.703711|2018-06-01 05:37:55.703711
NCT00006170|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-09|2013-06-18||2016-06-22|2000-08-09|2000-08-10|Estimate|2013-09-06|2013-11-14|Estimate||||2016-06-22|2016-07-21|Estimate|September 2000||2000-09-30|June 2016|2016-06-30|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|||Bupropion and Weight Control for Smoking Cessation - 1|Bupropion and Weight Control for Smoking Cessation|Completed||Phase 4|349|Actual|University of Pittsburgh||4|||f||||f||||||||No||2018-06-01 05:37:55.786204|2018-06-01 05:37:55.786204
NCT00006156|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-09|2013-03-28||2013-03-28|2000-08-09|2000-08-10|Estimate|2013-03-28|2013-05-16|Estimate||||2013-03-28|2013-05-16|Estimate|August 2000||2000-08-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Feasibility Study for Development of an Early Test for Ovarian Failure|FSH-Stimulated Inhibin B as a Marker for Early Ovarian Insufficiency|Completed||N/A|49|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:37:56.274358|2018-06-01 05:37:56.274358
NCT00006169|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-03-01|2000-08-08|2000-08-09|Estimate|||||||2010-03-01|2010-03-02|Estimate|June 1996||1996-06-30|March 2010|2010-03-31|November 1999||1999-11-30|||||Interventional|||Behavioral Treatment of Weight Gain in CF|Behavioral Treatment of Weight Gain in CF|Completed||Phase 3|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:56.512712|2018-06-01 05:37:56.512712
NCT00006168|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-01-12|2000-08-08|2000-08-09|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 1994||1994-01-31|January 2010|2010-01-31|March 2004||2004-03-31|||||Interventional|||Ursodiol-Methotrexate for Primary Biliary Cirrhosis||Completed||Phase 3|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:56.557163|2018-06-01 05:37:56.557163
NCT00006167|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-01-12|2000-08-08|2000-08-09|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 1998||1998-01-31|January 2010|2010-01-31|August 2000||2000-08-31|||||Interventional|||Nutrition Intervention in AIDS Wasting||Completed||Phase 4|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:56.709465|2018-06-01 05:37:56.709465
NCT00006166|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-01-12|2000-08-08|2000-08-09|Estimate|||||||2010-01-12|2010-01-13|Estimate|March 1997||1997-03-31|January 2010|2010-01-31|October 2001||2001-10-31|||||Interventional|||North American Study for the Treatment of Refractory Ascites (NASTRA)|The North American Study for the Treatment of Refractory Ascites (NASTRA) Clinical Trial|Completed||Phase 3|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:56.767605|2018-06-01 05:37:56.767605
NCT00006165|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-03-01|2000-08-08|2000-08-09|Estimate|||||||2010-03-01|2010-03-02|Estimate||||March 2010|2010-03-31||||||||Interventional|||Native Hawaiian Diabetes Intervention Program|Cultural-based Diabetes Program for Native Hawaiians|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:56.823571|2018-06-01 05:37:56.823571
NCT00006164|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|2009-06-09||2018-04-11|2000-08-08|2000-08-09|Estimate|2009-07-30|2009-09-04|Estimate||||2018-04-11|2018-05-11|Actual|June 2000||2000-06-30|March 2018|2018-03-31|October 2009|Actual|2009-10-31|April 2007|Actual|2007-04-30||Interventional|HALT-C||Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment|Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)|Completed||Phase 3|1050|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||||2018-06-01 05:37:56.894459|2018-06-01 05:37:56.894459
NCT00006163|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-03-01|2000-08-08|2000-08-09|Estimate|||||||2010-03-01|2010-03-02|Estimate|September 1997||1997-09-30|March 2010|2010-03-31|June 1999||1999-06-30|||||Interventional|||Computer-assisted Diabetes Self-management Interventions||Completed||Phase 4|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:57.479771|2018-06-01 05:37:57.479771
NCT00006162|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-03-01|2000-08-08|2000-08-09|Estimate|||||||2010-03-01|2010-03-02|Estimate|October 1994||1994-10-31|March 2010|2010-03-31|April 1999||1999-04-30|||||Interventional|||Lifestyle Interventions to Reduce Diabetes Risk|Interventions to Reduce Diabetic Risk in Japanese Americans|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:57.54764|2018-06-01 05:37:57.54764
NCT00006161|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-01-12|2000-08-08|2000-08-09|Estimate|||||||2010-01-12|2010-01-13|Estimate|December 1996||1996-12-31|January 2010|2010-01-31|December 2003||2003-12-31|||||Interventional|||Decompression Intervention of Variceal Rebleeding Trial (DIVERT)|Decompression Intervention of Variceal Rebleeding Trial|Completed||Phase 3|140||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:57.611358|2018-06-01 05:37:57.611358
NCT00006160|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-02-12|2000-08-08|2000-08-09|Estimate|||||||2010-02-12|2010-02-15|Estimate||||February 2010|2010-02-28||||||||Interventional|||African-American Diabetes Intervention Project||Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:57.682238|2018-06-01 05:37:57.682238
NCT00006159|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-02-12|2000-08-08|2000-08-09|Estimate|||||||2010-02-12|2010-02-15|Estimate|March 1994||1994-03-31|February 2010|2010-02-28|January 2004|Actual|2004-01-31|||||Interventional|||Family-Centered Diabetes Project|Family-Centered Diabetes Project for Pueblo Native Americans|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:57.733577|2018-06-01 05:37:57.733577
NCT00006158|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-02-12|2000-08-08|2000-08-09|Estimate|||||||2010-02-12|2010-02-15|Estimate|September 1998||1998-09-30|February 2010|2010-02-28|December 2004|Actual|2004-12-31|||||Interventional|||AIDS Wasting in Women: Anabolic Effects of Testosterone||Completed||Phase 2|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:57.809282|2018-06-01 05:37:57.809282
NCT00006157|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2010-01-12|2000-08-08|2000-08-09|Estimate|||||||2010-01-12|2010-01-13|Estimate|July 1996||1996-07-31|January 2010|2010-01-31|March 2001||2001-03-31|||||Interventional|||Treatment of Functional Bowel Disorders|Multicenter Trial of Functional Bowel Disorders|Completed||Phase 3|300||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:37:57.869975|2018-06-01 05:37:57.869975
NCT00006151|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|2013-06-24||2015-12-01|2000-08-08|2000-08-09|Estimate|2013-11-15|2014-01-06|Estimate||||2015-12-01|2015-12-03|Estimate|May 1999||1999-05-31|December 2015|2015-12-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Combining a Smoke Ending Aid With Behavioral Treatment - 1|Combining a Smoke Ending Aid With Behavioral Treatment|Completed||N/A|60|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-06-01 05:37:57.945795|2018-06-01 05:37:57.945795
NCT00006150|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2018-03-27|2000-08-08|2000-08-09|Estimate|||||||2018-03-27|2018-03-29|Actual|August 7, 2000||2000-08-07|November 1, 2017|2017-11-01||||||||Observational|||Study of Clinical Features and Genetics of Hyperimmunoglobulin E Recurrent Infection|Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:58.2121|2018-06-01 05:37:58.2121
NCT00006148|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-08|||2008-03-03|2000-08-08|2000-08-09|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2000||2000-08-31|June 2004|2004-06-30|June 2004||2004-06-30|||||Observational|||Spleen Size in Peripheral Blood Stem Cell Donors|Spleen Size in Peripheral Blood Stem Cell Donors|Completed|||49||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:58.276441|2018-06-01 05:37:58.276441
NCT00006077|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-04|||2008-03-03|2000-08-04|2000-08-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 2000||2000-08-31|July 2003|2003-07-31|July 2003||2003-07-31|||||Interventional|||Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease|Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:58.325191|2018-06-01 05:37:58.325191
NCT00006142|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1983||1983-12-31|August 2000|2000-08-31||||||||Interventional|||Study of a Phenylalanine Restricted Diet During Pregnancy to Prevent Symptoms in Offspring of Patients With Phenylketonuria||Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:58.396651|2018-06-01 05:37:58.396651
NCT00006138|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1998||1998-06-30|October 2000|2000-10-31|August 2000||2000-08-31|||||Observational|||Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia Major||Completed|||35||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:58.44722|2018-06-01 05:37:58.44722
NCT00006137|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2000||2000-05-31|September 2000|2000-09-30||||||||Interventional|||Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy||Completed||N/A|43||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:58.488737|2018-06-01 05:37:58.488737
NCT00006136|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-11-04|2000-08-03|2000-08-04|Estimate|||||||2005-11-04|2005-11-08|Estimate|March 1999||1999-03-31|July 2004|2004-07-31||||||||Interventional|||Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia||Completed||Phase 2|15||Office of Rare Diseases (ORD)|||||||||||||||||||2018-06-01 05:37:58.537674|2018-06-01 05:37:58.537674
NCT00006135|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1997||1997-06-30|December 2003|2003-12-31||||||||Interventional|||Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth||Completed||Phase 3|66||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:58.603573|2018-06-01 05:37:58.603573
NCT00006134|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1993||1993-09-30|December 2003|2003-12-31||||||||Observational|||Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture||Completed|||300||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:58.69587|2018-06-01 05:37:58.69587
NCT00006133|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2000||2000-06-30|December 2003|2003-12-31||||||||Interventional|||Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus||Completed||N/A|970||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:58.745222|2018-06-01 05:37:58.745222
NCT00006132|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1997||1997-06-30|December 2003|2003-12-31||||||||Interventional|||Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System||Unknown status|Recruiting|Phase 3|132||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:58.818217|2018-06-01 05:37:58.818217
NCT00006131|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2007-05-22|2000-08-03|2000-08-04|Estimate|||||||2007-05-22|2007-05-24|Estimate|January 1997||1997-01-31|December 2003|2003-12-31||||||||Interventional|||Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster||Completed||N/A|66|Anticipated|National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:58.956803|2018-06-01 05:37:58.956803
NCT00006130|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2017-02-14|2000-08-03|2000-08-04|Estimate|||||||2017-02-14|2017-02-15|Actual|June 1999||1999-06-30|February 2017|2017-02-28||||||||Interventional|||Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease|Randomized Study of Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease|Completed||N/A|50||Children's Hospital & Research Center Oakland|||||f||||||||||||||2018-06-01 05:37:59.007565|2018-06-01 05:37:59.007565
NCT00006129|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2000||2000-06-30|December 2003|2003-12-31||||||||Interventional|||Randomized Study of Testosterone and Progressive Resistance Exercise in Men With Burn Injury||Unknown status|Recruiting|N/A|60||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:59.121792|2018-06-01 05:37:59.121792
NCT00006128|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1998||1998-07-31|December 2003|2003-12-31||||||||Observational|||Study of Neurobehavioral Outcome in Children or Adolescents With Closed Head Injuries||Unknown status|Recruiting||374||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:59.194567|2018-06-01 05:37:59.194567
NCT00006127|ClinicalTrials.gov processed this data on May 31, 2018|2000-08-03|||2005-06-23|2000-08-03|2000-08-04|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2000||2000-04-30|October 2003|2003-10-31||||||||Interventional|||Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia||Unknown status|Active, not recruiting|Phase 1|21||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:59.26065|2018-06-01 05:37:59.26065
NCT00006076|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-28|||2017-06-30|2000-07-28|2000-07-31|Estimate|||||||2017-06-30|2017-07-02|Actual|July 26, 2000||2000-07-26|June 29, 2010|2010-06-29|June 29, 2010||2010-06-29|||||Observational|||Genetic Studies of Tone Deafness|Genetic Studies of Tune Deafness|Completed|||968|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:59.319843|2018-06-01 05:37:59.319843
NCT00006072|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-25|||2005-06-23|2000-07-25|2000-07-26|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2000|2000-07-31||||||||Interventional|||A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies||Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:37:59.391105|2018-06-01 05:37:59.391105
NCT00006070|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-18|||2008-03-03|2000-07-18|2000-07-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 2000||2000-07-31|May 2004|2004-05-31|May 2004||2004-05-31|||||Interventional|||Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction|Safety and Efficacy of a TNF Receptor Fusion Protein for Injury-Induced Inflammation and Sequelae|Completed||Phase 2|86||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:59.443508|2018-06-01 05:37:59.443508
NCT00005937|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-06|2010-04-02||2014-10-20|2000-07-06|2000-07-07|Estimate|2014-10-20|2014-10-23|Estimate||||2014-10-20|2014-10-23|Estimate|June 2000||2000-06-30|October 2014|2014-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia|A Phase II Study of Antithymocyte Globulin (ATG) and Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)|Completed||Phase 2|42|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 05:37:59.561469|2018-06-01 05:37:59.561469
NCT00005936|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-06|||2008-03-03|2000-07-06|2000-07-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|March 2002|2002-03-31|March 2002||2002-03-31|||||Observational|||Collection of Liver Tissue for Virologic Studies|Collection of Liver Tissue for Virologic Studies|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:59.773761|2018-06-01 05:37:59.773761
NCT00005935|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-06|||2008-03-03|2000-07-06|2000-07-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|March 2002|2002-03-31|March 2002||2002-03-31|||||Interventional|||Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia|A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA)|Completed||Phase 2|130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:59.835843|2018-06-01 05:37:59.835843
NCT00005934|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-06|||2008-03-03|2000-07-06|2000-07-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|June 2003|2003-06-30|June 2003||2003-06-30|||||Interventional|||5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia|A Pilot Study of 5-Azacytidine and Oral Sodium Phenylbutyrate in Severe Thalassemia|Completed||Phase 2|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:37:59.909764|2018-06-01 05:37:59.909764
NCT00006063|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2005-06-23|2000-07-05|2000-07-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1999||1999-07-31|July 2000|2000-07-31|August 1999||1999-08-31|||||Interventional|||Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis||Completed||N/A|24||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:37:59.987806|2018-06-01 05:37:59.987806
NCT00006061|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2005-06-23|2000-07-05|2000-07-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|July 2000|2000-07-31|January 2000||2000-01-31|||||Interventional|||Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency||Completed||N/A|1||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:00.058132|2018-06-01 05:38:00.058132
NCT00006060|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2009-03-10|2000-07-05|2000-07-06|Estimate|||||||2009-03-10|2009-03-12|Estimate|April 1999||1999-04-30|March 2009|2009-03-31||||||||Observational|||Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis||Unknown status|Recruiting||100||Office of Rare Diseases (ORD)|||||f||||t||||||||||2018-06-01 05:38:00.115387|2018-06-01 05:38:00.115387
NCT00006059|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2005-06-23|2000-07-05|2000-07-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1997||1997-01-31|December 2003|2003-12-31||||||||Observational|||Genetic Study of Familial Epilepsy||Completed|||898||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:00.199268|2018-06-01 05:38:00.199268
NCT00006058|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2005-06-23|2000-07-05|2000-07-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1996||1996-09-30|December 2003|2003-12-31||||||||Observational|||Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns|Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns|Completed|||200||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:00.253374|2018-06-01 05:38:00.253374
NCT00006057|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2005-06-23|2000-07-05|2000-07-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1999||1999-12-31|April 2002|2002-04-30||||||||Observational|||Diagnostic and Screening Study of Genetic Disorders||Completed|||50||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:00.31107|2018-06-01 05:38:00.31107
NCT00006056|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2005-06-23|2000-07-05|2000-07-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2000||2000-03-31|October 2003|2003-10-31||||||||Interventional|||Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders||Unknown status|Active, not recruiting|N/A|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:00.366128|2018-06-01 05:38:00.366128
NCT00006055|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2005-06-23|2000-07-05|2000-07-06|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2000||2000-03-31|October 2003|2003-10-31||||||||Interventional|||Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases||Unknown status|Active, not recruiting|N/A|10||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:00.447373|2018-06-01 05:38:00.447373
NCT00006054|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-05|||2009-10-14|2000-07-05|2000-07-06|Estimate|||||||2009-10-14|2009-10-15|Estimate|March 2000||2000-03-31|October 2003|2003-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies||Terminated||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:00.533387|2018-06-01 05:38:00.533387
NCT00005933|ClinicalTrials.gov processed this data on May 31, 2018|2000-07-04|||2008-03-03|2000-07-04|2000-07-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|July 2005|2005-07-31|July 2005||2005-07-31|||||Observational|||Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders|Cognitive Function in Leukocyte Disorders|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:00.598338|2018-06-01 05:38:00.598338
NCT00005928|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-28|||2008-03-03|2000-06-28|2000-06-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|February 2002|2002-02-28|February 2002||2002-02-28|||||Interventional|||Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation|Effects of Angiotensin Converting Enzyme Inhibitor Therapy on Vascular Inflammation and Compliance|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:00.653429|2018-06-01 05:38:00.653429
NCT00005927|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-28|||2018-05-18|2000-06-28|2000-06-29|Estimate|||||||2018-05-18|2018-05-21|Actual|July 1, 2000||2000-07-01|March 29, 2018|2018-03-29||||||||Observational|||Study of Adrenal Gland Tumors|Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:00.702186|2018-06-01 05:38:00.702186
NCT00005925|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-24|||2017-10-05|2000-06-24|2000-06-26|Estimate|||||||2017-10-05|2017-10-06|Actual|June 23, 2000||2000-06-23|December 24, 2014|2014-12-24|December 24, 2014|Actual|2014-12-24|||||Interventional|||Brain Infusion of Muscimol to Treat Epilepsy|Trial of Intracerebral Infusion in Patients With Medically Intractable Epilepsy|Terminated||Phase 1|3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:00.760475|2018-06-01 05:38:00.760475
NCT00005924|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-24|||2017-06-30|2000-06-24|2000-06-26|Estimate|||||||2017-06-30|2017-07-02|Actual|June 23, 2000||2000-06-23|February 2, 2010|2010-02-02|February 2, 2010||2010-02-02|||||Observational|||Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr Virus|Persistence of Epstein-Barr Virus in Vivo|Completed|||41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:00.814773|2018-06-01 05:38:00.814773
NCT00005923|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-23|||2005-06-23|2000-06-23|2000-06-26|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Observational|||The Effect of Estrogen and Progesterone Levels on Knee and Ankle Joint Laxity||Unknown status|Active, not recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:00.856509|2018-06-01 05:38:00.856509
NCT00005922|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-22|||2013-09-20|2000-06-22|2000-06-23|Estimate|||||||2013-09-20|2013-09-24|Estimate|August 2000||2000-08-31|September 2013|2013-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Conditioning, the Placebo Effect, and Psoriasis|Role of Conditioning in the Pharmacotherapy of Psoriasis|Completed||N/A|138|Actual|University of Rochester||3|||f||||t||||||||||2018-06-01 05:38:00.894214|2018-06-01 05:38:00.894214
NCT00005919|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-17|||2008-03-03|2000-06-17|2000-06-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|August 2003|2003-08-31|August 2003||2003-08-31|||||Observational|||Cause of Pigment Dispersion Syndrome|Etiology of Pigment Dispersion Syndrome (PDS)|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:00.999619|2018-06-01 05:38:00.999619
NCT00005917|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-16|||2018-03-27|2000-06-16|2000-06-19|Estimate|||||||2018-03-27|2018-03-29|Actual|June 14, 2000||2000-06-14|October 4, 2017|2017-10-04||||||||Observational|||Study of Chediak-Higashi Syndrome|Investigations Into Chediak-Higashi Syndrome and Related Disorders|Recruiting|||60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:01.053907|2018-06-01 05:38:01.053907
NCT00005916|ClinicalTrials.gov processed this data on May 31, 2018|2006-06-30|||2017-06-30|2000-06-16|2000-06-19|Estimate|||||||2017-06-30|2017-07-02|Actual|June 13, 2000||2000-06-13|December 22, 2005|2005-12-22|December 22, 2005|Actual|2005-12-22|||||Interventional|||PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer|A Randomized Phase II Study of a PSA-Based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy|Completed||Phase 2|48|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:01.110985|2018-06-01 05:38:01.110985
NCT00005914|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-15|||2009-12-16|2000-06-15|2000-06-16|Estimate|||||||2009-12-16|2009-12-17|Estimate|October 1999||1999-10-31|February 2009|2009-02-28|September 2003||2003-09-30|||||Observational|||Genetics of Recurrent Early-Onset Depression||Completed|||||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:38:01.185355|2018-06-01 05:38:01.185355
NCT00005911|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-13|||2008-03-03|2000-06-13|2000-06-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||Magnetic Resonance Imaging to Study the Normal Eye|Refinement of the Magnetic Resonance Imaging Technique for the Study of the Normal Eye, Particularly the Lens and Cataract|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:01.237412|2018-06-01 05:38:01.237412
NCT00005910|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-13|||2008-03-03|2000-06-13|2000-06-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|May 2006|2006-05-31|May 2006||2006-05-31|||||Interventional|||Laparoscopy to Remove Pancreatic Tumors (Insulinomas)|Use of Laparoscopy for Localization and Resection of Insulinomas of the Pancreas|Completed||N/A|23||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:01.282074|2018-06-01 05:38:01.282074
NCT00005909|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-13|||2018-05-12|2000-06-13|2000-06-14|Estimate|||||||2018-05-12|2018-05-15|Actual|June 12, 2000||2000-06-12|April 12, 2018|2018-04-12||||||||Observational|||Study of Alkaptonuria|Clinical, Biochemical, and Molecular Investigations Into Alkaptonuria|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:01.333368|2018-06-01 05:38:01.333368
NCT00005908|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-13|2012-02-14||2013-03-13|2000-06-13|2000-06-14|Estimate|2012-07-23|2012-08-27|Estimate||||2013-03-13|2013-03-19|Estimate|June 2000||2000-06-30|March 2013|2013-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer|A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression|Completed||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:38:01.40256|2018-06-01 05:38:01.40256
NCT00005907|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-09|||2008-03-03|2000-06-09|2000-06-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers|Evaluation of Hepatitis B Surface Antigen-Specific and Tetanus Toxoid-Specific Lymphocytes|Completed|||55||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:02.637618|2018-06-01 05:38:02.637618
NCT00005906|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-09|2010-02-26||2010-04-29|2000-06-09|2000-06-12|Estimate|2010-04-29|2010-04-30|Estimate||||2010-04-29|2010-04-30|Estimate|June 2000||2000-06-30|April 2010|2010-04-30||||April 2008|Actual|2008-04-30||Interventional|||Treatment With Octreotide in Patients With Lymphangioleiomyomatosis|Treatment With Octreotide in Patients With Lymphangioleiomyomatosis|Completed||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 05:38:02.700233|2018-06-01 05:38:02.700233
NCT00005905|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-09|||2008-03-03|2000-06-09|2000-06-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Leptin to Treat Lipodystrophy|Efficacy of Leptin Replacement in Treatment of Lipodystrophy|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:02.857592|2018-06-01 05:38:02.857592
NCT00005903|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-07|||2008-03-03|2000-06-07|2000-06-08|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 2000||2000-06-30|May 2005|2005-05-31|May 2005||2005-05-31|||||Interventional|||Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy|Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP|Completed||Phase 2|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:02.914045|2018-06-01 05:38:02.914045
NCT00005902|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-06|||2018-05-23|2000-06-06|2000-06-07|Estimate|||||||2018-05-23|2018-05-24|Actual|June 5, 2000||2000-06-05|March 11, 2018|2018-03-11||||||||Observational|||Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease|A Prospective Natural History Study of VHL Patients With CNS Hemangioblastomas|Active, not recruiting|||250|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:02.974548|2018-06-01 05:38:02.974548
NCT00005901|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-06|2015-11-24||2016-02-01|2000-06-06|2000-06-07|Estimate|2016-02-01|2016-03-01|Estimate||||2016-02-01|2016-03-01|Estimate|June 2000||2000-06-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||Pamidronate to Treat Osteogenesis Imperfecta in Children|A Trial of Pamidronate in Children With Osteogenesis Imperfecta|Completed||Phase 3|34|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:38:03.153457|2018-06-01 05:38:03.153457
NCT00005900|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1999||1999-08-31|October 2003|2003-10-31||||||||Observational|||Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation||Unknown status|Active, not recruiting||10||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:03.581206|2018-06-01 05:38:03.581206
NCT00005898|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2000||2000-02-29|July 2004|2004-07-31||||||||Interventional|||Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia||Completed||Phase 1/Phase 2|30||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:03.663291|2018-06-01 05:38:03.663291
NCT00005896|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2000||2000-03-31|March 2001|2001-03-31||||||||Interventional|||Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia||Unknown status|Active, not recruiting|Phase 1|6||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:03.759384|2018-06-01 05:38:03.759384
NCT00005893|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 2000||2000-06-30|July 2004|2004-07-31||||||||Interventional|||Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders||Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:03.814306|2018-06-01 05:38:03.814306
NCT00005892|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2000||2000-03-31|July 2004|2004-07-31||||||||Interventional|||Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia||Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:03.898564|2018-06-01 05:38:03.898564
NCT00005891|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 2000||2000-03-31|July 2004|2004-07-31||||||||Interventional|||Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia||Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:03.961778|2018-06-01 05:38:03.961778
NCT00005890|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1996||1996-03-31|December 2003|2003-12-31||||||||Interventional|||Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock||Completed||N/A|56||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:04.015506|2018-06-01 05:38:04.015506
NCT00005889|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|December 2003|2003-12-31||||||||Interventional|||Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion|Study of Gluconeogenesis in Very Low Birth Weight Infants Receiving Total Parenteral Nutrition|Unknown status|Recruiting|N/A|96||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:04.073044|2018-06-01 05:38:04.073044
NCT00005888|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-02|||2005-06-23|2000-06-02|2000-06-05|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1997||1997-01-31|April 2002|2002-04-30||||||||Interventional|||Study of the Relationship Between Feeding and Late Onset Sepsis and/or Necrotizing Enterocolitis in Low Birth Weight Infants||Completed||N/A|300||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:04.142541|2018-06-01 05:38:04.142541
NCT00005785|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2008-03-03|2000-06-03|2000-06-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1999||1999-09-30|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer|Low Intensity Non-Myeloablative Preparative Conditioning Followed by Transplantation of Genetically Modified HLA-Matched Peripheral Blood Hematopoietic Precursor Cells (PBPC) for Hematologic Malignancies in HIV Positive Adults|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:04.197658|2018-06-01 05:38:04.197658
NCT00005784|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2017-06-30|2000-06-03|2000-06-05|Estimate|||||||2017-06-30|2017-07-02|Actual|May 31, 2000||2000-05-31|August 8, 2008|2008-08-08|August 8, 2008||2008-08-08|||||Observational|||Evaluation and Treatment of Patients With Retinal Disease|Evaluation and Treatment Protocol for Patients With Retinal Disease|Completed|||1000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:04.247876|2018-06-01 05:38:04.247876
NCT00005782|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2008-03-03|2000-06-03|2000-06-05|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait|Leukapheresis of Volunteers With Sickle Cell Trait to Evaluate Mobilization of Stem Cells With Granulocyte Colony-Stimulating Factor and Stem Cell Collection and Storage for Allogeneic Transplantation|Completed||Phase 3|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:04.333827|2018-06-01 05:38:04.333827
NCT00005780|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2018-05-23|2000-06-03|2000-06-05|Estimate|||||||2018-05-23|2018-05-24|Actual|June 1, 2000||2000-06-01|October 4, 2017|2017-10-04|June 1, 2019|Anticipated|2019-06-01|August 31, 2005|Actual|2005-08-31||Interventional|||Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma|Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma|Active, not recruiting||Phase 2|26|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:38:04.453778|2018-06-01 05:38:04.453778
NCT00005778|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-03|||2008-11-05|2000-06-03|2000-06-05|Estimate|||||||2008-11-05|2008-11-06|Estimate|January 2000||2000-01-31|November 2008|2008-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide|Randomized Trial of High-Dose IV Cyclophosphamide Versus Monthly IV Cyclophosphamide|Completed||Phase 3|100|Anticipated|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:38:04.532985|2018-06-01 05:38:04.532985
NCT00005777|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2015-06-03|2000-06-01|2000-06-02|Estimate|||||||2015-06-03|2015-06-08|Estimate|February 1998||1998-02-28|June 2015|2015-06-30|September 2002|Actual|2002-09-30|September 1998|Actual|1998-09-30||Interventional|SAVE||Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)|Randomized Trial of Minimal Ventilator Support and Early Corticosteroid Therapy to Increase Survival Without Chronic Lung Disease in Extremely-Low-Birth-Weight Infants|Terminated||Phase 3|220|Actual|NICHD Neonatal Research Network||4||"The trial was halted because of unanticipated nonrespiratory adverse events related to~   dexamethasone therapy."|f||||t||||||||||2018-06-01 05:38:04.61311|2018-06-01 05:38:04.61311
NCT00005776|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2017-09-22|2000-06-01|2000-06-02|Estimate|||||||2017-09-22|2017-09-26|Actual|October 1995||1995-10-31|September 2017|2017-09-30|May 1998|Actual|1998-05-31|May 1996|Actual|1996-05-31||Interventional|NINOS||Inhaled Nitric Oxide Study for Respiratory Failure in Newborns|The Randomized Inhaled Nitric Oxide Study (NINOS) in Full-Term and Nearly Full-Term Infants With Hypoxic Respiratory Failure|Terminated||Phase 3|235|Actual|NICHD Neonatal Research Network||2||Results showed statistically significant benefit in the experimental group|f||||t||||||||||2018-06-01 05:38:04.765636|2018-06-01 05:38:04.765636
NCT00005775|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2015-06-03|2000-06-01|2000-06-02|Estimate|||||||2015-06-03|2015-06-08|Estimate|July 1999||1999-07-31|June 2015|2015-06-30|August 2001|Actual|2001-08-31|December 2000|Actual|2000-12-31||Interventional|Glutamine||Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants|Randomized Controlled Trial of Parenteral Glutamine Supplementation for Extremely-Low-Birth-Weight (ELBW) Infants|Completed||Phase 3|1433|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 05:38:04.923703|2018-06-01 05:38:04.923703
NCT00005753|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 1997||1997-06-30|February 2005|2005-02-28|May 2002|Actual|2002-05-31|||||Observational|||Pharmacological and Behavioral Treatment of Insomnia||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.527405|2018-06-01 05:38:06.527405
NCT00005774|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2015-06-03|2000-06-01|2000-06-02|Estimate|||||||2015-06-03|2015-06-08|Estimate|May 2000||2000-05-31|June 2015|2015-06-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|Surfactant 2||Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants|Early Surfactant Followed by Nasal CPAP to Reduce the Use of Mechanical Ventilation Without Additional Morbidity in Infants 1250- 2000 Grams With RDS|Terminated||Phase 3|61|Actual|NICHD Neonatal Research Network||2||The trial was stopped after 7 months for lack of recruitment.|f||||t||||||||||2018-06-01 05:38:05.06971|2018-06-01 05:38:05.06971
NCT00005773|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2017-09-22|2000-06-01|2000-06-02|Estimate|||||||2017-09-22|2017-09-26|Actual|August 1998||1998-08-31|September 2017|2017-09-30|August 2003|Actual|2003-08-31|May 2001|Actual|2001-05-31||Interventional|Early iNO||Early Inhaled Nitric Oxide for Respiratory Failure in Newborns|Early Inhaled Nitric Oxide Therapy in Term and Near Term Infants With Respiratory Failure|Terminated||Phase 3|302|Actual|NICHD Neonatal Research Network||2||Halted after 3 years because of a persistent decline in enrollment|f||||t||||||||||2018-06-01 05:38:05.205526|2018-06-01 05:38:05.205526
NCT00005772|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2017-09-22|2000-06-01|2000-06-02|Estimate|||||||2017-09-22|2017-09-26|Actual|October 1999||1999-10-31|September 2017|2017-09-30|July 2010|Actual|2010-07-31|May 2003|Actual|2003-05-31||Interventional|||Whole-Body Cooling for Birth Asphyxia in Term Infants|Randomized Controlled Trial of Hypothermia for Hypoxic-Ischemic Encephalopathy in Term Infants|Completed||Phase 3|208|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-06-01 05:38:05.356508|2018-06-01 05:38:05.356508
NCT00005771|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2005-06-23|2000-06-01|2000-06-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||The Use of Real Time Ultrasound Feedback in Teaching Abdominal Hollowing Exercises||Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:05.460647|2018-06-01 05:38:05.460647
NCT00005770|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2005-06-23|2000-06-01|2000-06-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Observational|||Investigation of the Effect of Acupuncture Needling on Connective Tissue Using Ultrasound Elastography||Unknown status|Active, not recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:05.500988|2018-06-01 05:38:05.500988
NCT00005769|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2005-06-23|2000-06-01|2000-06-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women||Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:05.537907|2018-06-01 05:38:05.537907
NCT00005768|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2005-06-23|2000-06-01|2000-06-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Estrogen Modulation of Mood and Cognition Following Monoaminergic Depletion in Post-Menopausal Women||Unknown status|Recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:05.575997|2018-06-01 05:38:05.575997
NCT00005767|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2005-06-23|2000-06-01|2000-06-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Dynamic Aspects of Amino Acid Metabolism||Unknown status|Recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:05.621343|2018-06-01 05:38:05.621343
NCT00005766|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2005-06-23|2000-06-01|2000-06-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis||Completed||Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:05.665717|2018-06-01 05:38:05.665717
NCT00005765|ClinicalTrials.gov processed this data on May 31, 2018|2000-06-01|||2005-06-23|2000-06-01|2000-06-02|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Behavioral Economics of Human Drug Self-Administration||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:05.799469|2018-06-01 05:38:05.799469
NCT00005761|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-26|||2017-06-30|2000-05-26|2000-05-29|Estimate|||||||2017-06-30|2017-07-02|Actual|May 23, 2000||2000-05-23|December 7, 2010|2010-12-07|December 7, 2010||2010-12-07|||||Observational|||Blood Factors and Diabetic Retinopathy|Study of Association of Serum Factors With Diabetic Retinopathy|Completed|||173|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:05.85882|2018-06-01 05:38:05.85882
NCT00005760|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-26|||2008-03-03|2000-05-26|2000-05-29|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2000||2000-05-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Observational|||Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes|A Pilot Study of the Metabolic Effects of Large Volume Liposuction in Overweight Women With Hyperinsulinemia, Impaired Glucose Tolerance and/or Type 2 Diabetes|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:05.912423|2018-06-01 05:38:05.912423
NCT00005675|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-26|||2010-05-24|2000-05-26|2000-05-29|Estimate|||||||2010-05-24|2010-05-25|Estimate|April 2000||2000-04-30|March 2008|2008-03-31||||May 2005|Actual|2005-05-31||Interventional|||Oral Type I Collagen for Relieving Scleroderma|Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma|Completed||Phase 2|168|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||2|||t||||t||||||||||2018-06-01 05:38:05.973344|2018-06-01 05:38:05.973344
NCT00005674|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-26|||2005-06-23|2000-05-26|2000-05-29|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]||Completed||Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:06.099732|2018-06-01 05:38:06.099732
NCT00005763|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 1984||1984-12-31|June 2000|2000-06-30|April 1997|Actual|1997-04-30|||||Observational|||INTERSALT: International Study of Sodium, Potassium, and Blood Pressure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.154731|2018-06-01 05:38:06.154731
NCT00005757|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-11-23|2000-05-25|2000-05-26|Estimate|||||||2016-11-23|2016-11-28|Estimate|September 1997||1997-09-30|November 2016|2016-11-30|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Observational|||Racial Variation in ACE--Genetic and Physiologic Bases||Completed|||293|Actual|Vanderbilt University|||||f||||||||||||||2018-06-01 05:38:06.219223|2018-06-01 05:38:06.219223
NCT00005756|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-12|2000-05-25|2000-05-26|Estimate|||||||2016-01-12|2016-01-13|Estimate|August 1999||1999-08-31|January 2016|2016-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Epidemiology of Coronary Calcification in the Elderly||Completed|||||University of Pittsburgh|||||f||||t||||||||Yes||2018-06-01 05:38:06.285845|2018-06-01 05:38:06.285845
NCT00005755|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 1999||1999-05-31|January 2006|2006-01-31|April 2003|Actual|2003-04-30|||||Observational|||Community Based Study on Occupational Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.372694|2018-06-01 05:38:06.372694
NCT00005754|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-06-08|2000-05-25|2000-05-26|Estimate|||||||2015-06-08|2015-06-10|Estimate|September 1999||1999-09-30|June 2015|2015-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Coronary Artery Calcification in Type 1 Diabetes||Completed|||1420|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-06-01 05:38:06.462824|2018-06-01 05:38:06.462824
NCT00005752|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-08|2000-05-25|2000-05-26|Estimate|||||||2016-01-08|2016-01-12|Estimate|April 1999||1999-04-30|August 2004|2004-08-31|March 2002||2002-03-31|||||Observational|||Overweight Adults--Ethnic, SES and Behavioral Influences||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:38:06.593701|2018-06-01 05:38:06.593701
NCT00005751|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 1998||1998-12-31|July 2004|2004-07-31|November 2003|Actual|2003-11-30|||||Observational|||Endothelial Vasomotor Function in the Framingham Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.674388|2018-06-01 05:38:06.674388
NCT00005750|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-08|2000-05-25|2000-05-26|Estimate|||||||2016-01-08|2016-01-12|Estimate|April 1996||1996-04-30|July 2001|2001-07-31|March 2001||2001-03-31|||||Observational|||School and Family-Based Obesity Prevention for Children||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:38:06.722911|2018-06-01 05:38:06.722911
NCT00005749|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-11|2000-05-25|2000-05-26|Estimate|||||||2016-01-11|2016-01-12|Estimate|July 1996||1996-07-31|August 2004|2004-08-31|December 2002||2002-12-31|||||Observational|||Project Andale--Increasing Exercise in Hispanic Women||Completed|||||San Diego State University|||||f||||||||||||||2018-06-01 05:38:06.795866|2018-06-01 05:38:06.795866
NCT00005748|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 1998||1998-05-31|March 2005|2005-03-31|April 2004|Actual|2004-04-30|||||Observational|||Stress Reduction and Prevention of Hypertension in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.851226|2018-06-01 05:38:06.851226
NCT00005746|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1998||1998-04-30|May 2005|2005-05-31|March 2003|Actual|2003-03-31|||||Observational|||Community Site Coronary Risk Control in Black Families||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.895114|2018-06-01 05:38:06.895114
NCT00005745|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 1998||1998-01-31|September 2004|2004-09-30|December 2002|Actual|2002-12-31|||||Observational|||Consequences and Correlates of Weight Fluctuations||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.948152|2018-06-01 05:38:06.948152
NCT00005744|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1996||1996-09-30|August 2004|2004-08-31|August 2001|Actual|2001-08-31|||||Observational|||Increased Physical Activity in African-American Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:06.993932|2018-06-01 05:38:06.993932
NCT00005743|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 1996||1996-05-31|August 2004|2004-08-31|April 2001|Actual|2001-04-30|||||Interventional|||Exercise Adherence in a Behavioral Weight Loss Program||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.038522|2018-06-01 05:38:07.038522
NCT00005742|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 1995||1995-09-30|May 2005|2005-05-31|August 2001|Actual|2001-08-31|||||Observational|||Behavioral Interventions for Control of Tuberculosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.090299|2018-06-01 05:38:07.090299
NCT00005741|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1995||1995-09-30|May 2002|2002-05-31|August 2001|Actual|2001-08-31|||||Observational|||Indigenous Outreach Among Injection Drug Users to Treat and Control TB||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.135771|2018-06-01 05:38:07.135771
NCT00005740|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1995||1995-09-30|May 2002|2002-05-31|August 2000|Actual|2000-08-31|||||Observational|||TB Contact Investigation: Behavioral Intervention||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.172274|2018-06-01 05:38:07.172274
NCT00005739|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-21|2000-05-25|2000-05-26|Estimate|||||||2015-12-21|2015-12-23|Estimate|September 1995||1995-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2004|Actual|2004-12-31||Observational|||Behavioral Interventions for Control of TB|Behavioral Interventions for Control of Tuberculosis|Completed|||145|Actual|Columbia University|||2||f||||f||||||||||2018-06-01 05:38:07.213512|2018-06-01 05:38:07.213512
NCT00005738|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-11|2000-05-25|2000-05-26|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 1995||1995-09-30|May 2002|2002-05-31|August 2001||2001-08-31|||||Observational|||Promoting Adherence to TB Regimens in Latino Adolescents||Completed|||||San Diego State University|||||f||||||||||||||2018-06-01 05:38:07.293691|2018-06-01 05:38:07.293691
NCT00005737|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1995||1995-09-30|April 2004|2004-04-30|August 1999|Actual|1999-08-31|||||Observational|||Tuberculosis Prophylaxis in the Homeless--A Controlled Trial||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.333016|2018-06-01 05:38:07.333016
NCT00005736|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|July 2004|2004-07-31|September 2002||2002-09-30|||||Observational|||Interventions to Improve Asthma Management/Prevention at School||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.376141|2018-06-01 05:38:07.376141
NCT00005735|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1995||1995-09-30|July 2004|2004-07-31|October 2002|Actual|2002-10-31|||||Observational|||Controlling Asthma at School||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.414579|2018-06-01 05:38:07.414579
NCT00005734|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|March 2005|2005-03-31|September 2002||2002-09-30|||||Observational|||Intervention to Improve Asthma Management/Prevention||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.45802|2018-06-01 05:38:07.45802
NCT00005733|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1993||1993-09-30|September 2002|2002-09-30|March 1997||1997-03-31|||||Observational|||Develop and Implement Asthma Controlling Strategies (2)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.507913|2018-06-01 05:38:07.507913
NCT00005732|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1993||1993-09-30|August 2000|2000-08-31|January 1997||1997-01-31|||||Observational|||Develop and Implement Asthma Controlling Strategies (1)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.544372|2018-06-01 05:38:07.544372
NCT00005731|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1993||1993-09-30|April 2001|2001-04-30|May 1997||1997-05-31|||||Observational|||Develop and Implement Asthma Controlling Strategies||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.579177|2018-06-01 05:38:07.579177
NCT00005730|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1989||1989-01-31|March 2005|2005-03-31|December 1995||1995-12-31|||||Observational|||National Marrow Donor Program (NMDP)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.616199|2018-06-01 05:38:07.616199
NCT00005729|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-11|2000-05-25|2000-05-26|Estimate|||||||2016-01-11|2016-01-12|Estimate|August 1992||1992-08-31|July 2000|2000-07-31|December 1996||1996-12-31|||||Observational|||CVD Nutrition Education for Low Literacy ESL Students||Completed|||||San Diego State University|||||f||||||||||||||2018-06-01 05:38:07.670005|2018-06-01 05:38:07.670005
NCT00005728|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 1992||1992-05-31|July 2000|2000-07-31|April 1996|Actual|1996-04-30|||||Observational|||Nutrition Education||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.801066|2018-06-01 05:38:07.801066
NCT00005727|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-08-23|2000-05-25|2000-05-26|Estimate|||||||2016-08-23|2016-08-24|Estimate|August 1991||1991-08-31|August 2016|2016-08-31|January 2000|Actual|2000-01-31|December 1995|Actual|1995-12-31||Interventional|||CVD Nutrition Education||Completed||N/A|351|Actual|Stanford University||2|||f||||f||||||||No||2018-06-01 05:38:07.851543|2018-06-01 05:38:07.851543
NCT00005726|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|August 1991||1991-08-31|May 2000|2000-05-31|May 1995|Actual|1995-05-31|||||Observational|||Evaluation of Low Literacy CVD Nutrition Education||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.906732|2018-06-01 05:38:07.906732
NCT00005725|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1991||1991-08-31|May 2000|2000-05-31|May 1996|Actual|1996-05-31|||||Observational|||Low Literacy CVD Diet Education for Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:07.961443|2018-06-01 05:38:07.961443
NCT00005724|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-04-17|2000-05-25|2000-05-26|Estimate|||||||2017-04-17|2017-04-18|Actual|August 1991|Actual|1991-08-31|April 2017|2017-04-30|July 31, 1996|Actual|1996-07-31|July 1995|Actual|1995-07-31||Interventional|||CVD Nutrition Modules Tailored to Low Literacy Skills|CVD Nutrition Modules Tailored to Low Literacy Skills|Completed||N/A|369|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||No||2018-06-01 05:38:08.02925|2018-06-01 05:38:08.02925
NCT00005723|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-28|2000-05-25|2000-05-26|Estimate|||||||2016-03-28|2016-03-30|Estimate|January 1991||1991-01-31|March 2016|2016-03-31|September 1996|Actual|1996-09-30|January 1996|Actual|1996-01-31||Observational|||Worksite Issues in Organizational Health Promotion (Take Heart)||Completed|||||Oregon Research Institute|||||f||||f||||||||Undecided||2018-06-01 05:38:08.110146|2018-06-01 05:38:08.110146
NCT00005722|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1990||1990-09-30|May 2000|2000-05-31|September 1996||1996-09-30|||||Observational|||Stroke Belt Initiative||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.157926|2018-06-01 05:38:08.157926
NCT00005721|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-08|2000-05-25|2000-05-26|Estimate|||||||2016-04-08|2016-04-11|Estimate|September 1990||1990-09-30|April 2016|2016-04-30|December 1994||1994-12-31|December 1993|Actual|1993-12-31||Observational|||Retaining Donors and Increasing Donation Frequency||Completed|||||Bloodworks (Puget Sound Blood Center)|||||f||||||||||||||2018-06-01 05:38:08.21083|2018-06-01 05:38:08.21083
NCT00005720|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1990||1990-09-30|April 2001|2001-04-30|August 1996||1996-08-31|||||Observational|||Lay-Led Smoking Cessation Approach for Southeast Asian Men||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.257653|2018-06-01 05:38:08.257653
NCT00005719|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1990||1990-07-31|July 2000|2000-07-31|June 1996||1996-06-30|||||Observational|||Sustaining Women's Smoking Cessation Postpartum||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.324857|2018-06-01 05:38:08.324857
NCT00005718|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1990||1990-04-30|July 2000|2000-07-31|March 1993|Actual|1993-03-31|||||Observational|||Evaluation of Cholesterol Education for At-Risk Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.376074|2018-06-01 05:38:08.376074
NCT00005717|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1990||1990-08-31|June 2001|2001-06-30|July 1995|Actual|1995-07-31|||||Observational|||Medication Adherence in COPD--A Self-Regulation Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.431767|2018-06-01 05:38:08.431767
NCT00005716|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1994||1994-08-31|May 2002|2002-05-31|July 1999|Actual|1999-07-31|||||Observational|||Asthma Partnership for Minority Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.475294|2018-06-01 05:38:08.475294
NCT00005715|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1990||1990-08-31|May 2000|2000-05-31|July 1995|Actual|1995-07-31|||||Observational|||Community Intervention for Minority Children With Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.526072|2018-06-01 05:38:08.526072
NCT00005714|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1990||1990-08-31|August 2004|2004-08-31|July 1996|Actual|1996-07-31|||||Observational|||Development and Evaluation of Community Asthma Program||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.574468|2018-06-01 05:38:08.574468
NCT00005713|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-22|2000-05-25|2000-05-26|Estimate|||||||2015-12-22|2015-12-23|Estimate|August 1990||1990-08-31|December 2015|2015-12-31|February 1997|Actual|1997-02-28|February 1997|Actual|1997-02-28||Observational|||Childhood Asthma Program in NYC Health Department Clinics|Improving Care for Minority Children With Asthma: Professional Education in Public Health Clinics|Completed|||1000|Actual|Columbia University|||1||f||||f||||||||||2018-06-01 05:38:08.624771|2018-06-01 05:38:08.624771
NCT00005712|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|August 1990||1990-08-31|January 2016|2016-01-31|July 1996||1996-07-31|||||Observational|||Self Management Education Asthma||Completed|||||University of New Mexico|||||f||||||||||||||2018-06-01 05:38:08.688215|2018-06-01 05:38:08.688215
NCT00005711|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-06|2000-05-25|2000-05-26|Estimate|||||||2016-05-06|2016-05-10|Estimate|August 1990||1990-08-31|May 2016|2016-05-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||Intervention for Hispanic Children With Asthma|Intervention for Hispanic Children With Asthma|Completed||N/A|145|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||No||2018-06-01 05:38:08.734519|2018-06-01 05:38:08.734519
NCT00005710|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-06-22|2000-05-25|2000-05-26|Estimate|||||||2016-06-22|2016-06-24|Estimate|July 1990||1990-07-31|June 2016|2016-06-30|June 1995||1995-06-30|||||Observational|||Recycling of Chronic Smokers to Sustained Abstinence||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:08.797229|2018-06-01 05:38:08.797229
NCT00005709|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1993||1993-09-30|June 2001|2001-06-30|August 1998|Actual|1998-08-31|||||Observational|||Lipoprotein Metabolism in Hypertensive African-Americans||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.840303|2018-06-01 05:38:08.840303
NCT00005708|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|July 2000|2000-07-31|August 1997|Actual|1997-08-31|||||Observational|||Improving Adherence to Interventions for Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.900046|2018-06-01 05:38:08.900046
NCT00005707|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-08|2000-05-25|2000-05-26|Estimate|||||||2015-12-08|2015-12-10|Estimate|September 1993||1993-09-30|December 2015|2015-12-31|August 1998||1998-08-31|||||Observational|||Improving Hypertension Care for Inner City Minorities||Completed|||||Baylor College of Medicine|||||f||||||||||||||2018-06-01 05:38:08.942966|2018-06-01 05:38:08.942966
NCT00005706|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|May 2002|2002-05-31|August 1998|Actual|1998-08-31|||||Observational|||Urban African-American Community Hypertension Control||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:08.984484|2018-06-01 05:38:08.984484
NCT00005705|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1992||1992-09-30|September 2002|2002-09-30|June 1996|Actual|1996-06-30|||||Observational|||Adherence in the Childhood Asthma Management Program||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.023984|2018-06-01 05:38:09.023984
NCT00005704|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-26|2000-05-25|2000-05-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|July 1991||1991-07-31|July 2000|2000-07-31|June 1997||1997-06-30|||||Observational|||Pharmacologic Intervention for Postcessation Weight Gain||Completed|||||University of Memphis|||||f||||||||||||||2018-06-01 05:38:09.064087|2018-06-01 05:38:09.064087
NCT00005703|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1995||1995-07-31|March 2005|2005-03-31|July 1998|Actual|1998-07-31|||||Observational|||Hemostasis in Sickle Cell Disease--Infancy to Adulthood||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.106455|2018-06-01 05:38:09.106455
NCT00005702|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-29|2000-05-25|2000-05-26|Estimate|||||||2016-02-29|2016-03-01|Estimate|May 1996||1996-05-31|February 2016|2016-02-29|April 2000||2000-04-30|||||Observational|||Promoting Smoking Cessation in Hospital Patients||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:09.145857|2018-06-01 05:38:09.145857
NCT00005701|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1994||1994-07-31|April 2000|2000-04-30|June 1997|Actual|1997-06-30|||||Observational|||Acute Cardiac Ischemia in Women in the ACI/TIPI Trial||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.186701|2018-06-01 05:38:09.186701
NCT00005700|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|May 2001|2001-05-31|August 1998|Actual|1998-08-31|||||Observational|||Fat Reduction Intervention Trial in African-Americans||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.226754|2018-06-01 05:38:09.226754
NCT00005699|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-10|2000-05-25|2000-05-26|Estimate|||||||2016-02-10|2016-02-11|Estimate|September 1993||1993-09-30|February 2016|2016-02-29|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Observational|||Improving Hypertension Control in the Inner City|Improving Hypertension Control in the Inner City|Completed|||2000|Actual|Medical College of Wisconsin|||2||f||||f||||||||Undecided|to be published|2018-06-01 05:38:09.266304|2018-06-01 05:38:09.266304
NCT00005698|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|July 2000|2000-07-31|August 1997|Actual|1997-08-31|||||Observational|||IN CONTROL--Hypertension Reduction in Inner City Seattle||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.314881|2018-06-01 05:38:09.314881
NCT00005697|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1993||1993-01-31|April 2001|2001-04-30|December 1996||1996-12-31|||||Observational|||Intervention for Resistant Pregnant Smokers||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.352908|2018-06-01 05:38:09.352908
NCT00005696|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 1994||1994-01-31|May 2005|2005-05-31|December 1996|Actual|1996-12-31|||||Observational|||Early Atherosclerosis Change in Two Clinical Trials||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.392193|2018-06-01 05:38:09.392193
NCT00005695|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-21|2000-05-25|2000-05-26|Estimate|||||||2015-12-21|2015-12-23|Estimate|January 1995||1995-01-31|April 2002|2002-04-30|December 1997||1997-12-31|||||Observational|||Physical Training and Blood Pressure in High Risk Youths||Completed|||||Augusta University|||||f||||||||||||||2018-06-01 05:38:09.439876|2018-06-01 05:38:09.439876
NCT00005694|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1992||1992-07-31|July 2000|2000-07-31|June 1996|Actual|1996-06-30|||||Observational|||Worksites, Occupational Nurses and Cholesterol Change||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.479062|2018-06-01 05:38:09.479062
NCT00005693|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1992||1992-04-30|July 2000|2000-07-31|March 1995|Actual|1995-03-31|||||Observational|||Computer Assisted Instruction Weight Management for Low Literacy Populations||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.518465|2018-06-01 05:38:09.518465
NCT00005692|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1992||1992-04-30|March 2005|2005-03-31|November 2002|Actual|2002-11-30|||||Observational|||Inflammation Markers Over Time in Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.557641|2018-06-01 05:38:09.557641
NCT00005691|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1992||1992-09-30|July 2001|2001-07-31|August 1996|Actual|1996-08-31|||||Observational|||Psychosocial Risk Factors for Coronary Heart Disease in Swedish Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.603367|2018-06-01 05:38:09.603367
NCT00005690|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1991||1991-08-31|January 2005|2005-01-31|November 2000|Actual|2000-11-30|||||Observational|||Improving Outcomes and Quality of Life After CABG||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.644282|2018-06-01 05:38:09.644282
NCT00005689|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1991||1991-07-31|March 2001|2001-03-31|June 1995||1995-06-30|||||Observational|||Trial of Smoking Cessation Programs in Black Churches||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.690779|2018-06-01 05:38:09.690779
NCT00005688|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1989||1989-07-31|July 2000|2000-07-31|February 1997|Actual|1997-02-28|||||Observational|||Cardiac Arrhythmias and the Perception of Symptoms||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.735731|2018-06-01 05:38:09.735731
NCT00005687|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 1989||1989-04-30|July 2000|2000-07-31|April 1999|Actual|1999-04-30|||||Observational|||Recycling Attempters and Relapsers in Smoking Cessation||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.774061|2018-06-01 05:38:09.774061
NCT00005686|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-29|2000-05-25|2000-05-26|Estimate|||||||2016-02-29|2016-03-01|Estimate|April 1989||1989-04-30|February 2016|2016-02-29|April 2003||2003-04-30|||||Observational|||Dietary Intervention Methods for Clinical Trials||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:09.900135|2018-06-01 05:38:09.900135
NCT00005685|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1983||1983-09-30|January 2006|2006-01-31|July 2002|Actual|2002-07-31|||||Observational|||Blood Pressure Control--Racial and Psychosocial Influences||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:09.974453|2018-06-01 05:38:09.974453
NCT00005684|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 1996||1996-03-31|February 2005|2005-02-28|January 2001|Actual|2001-01-31|||||Observational|||Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.04116|2018-06-01 05:38:10.04116
NCT00005683|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|December 1986||1986-12-31|January 2016|2016-01-31|November 1997||1997-11-30|||||Observational|||Clinical Interventions in Respiratory Distress Syndrome and Neonatal Lung Injury - SCOR in Lung Biology and Diseases in Infants and Children||Completed|||||University of Rochester|||||f||||||||||||||2018-06-01 05:38:10.108528|2018-06-01 05:38:10.108528
NCT00005682|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1988||1988-09-30|May 2000|2000-05-31|August 1994|Actual|1994-08-31|||||Observational|||Aplastic Anemia Epidemiology: Incidence and Case-control||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.167783|2018-06-01 05:38:10.167783
NCT00005681|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1989||1989-08-31|October 2005|2005-10-31|July 2001|Actual|2001-07-31|||||Observational|||Vascular Basis for the Treatment of Ischemia||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.228572|2018-06-01 05:38:10.228572
NCT00005680|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 1993||1993-09-30|January 2008|2008-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Whitehall II - Social and Occupational Influences On Health and Illness||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.301012|2018-06-01 05:38:10.301012
NCT00005679|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 1985||1985-06-30|January 2008|2008-01-31|July 1993|Actual|1993-07-31|July 1993|Actual|1993-07-31||Observational|||Pathobiological Determinants of Atherosclerosis in Youth (PDAY)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.422361|2018-06-01 05:38:10.422361
NCT00005678|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1984||1984-07-31|May 2000|2000-05-31|April 1996||1996-04-30|||||Observational|||Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.528091|2018-06-01 05:38:10.528091
NCT00005677|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-12|2000-05-25|2000-05-26|Estimate|||||||2016-01-12|2016-01-13|Estimate|August 1980||1980-08-31|January 2016|2016-01-31|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Observational|||Percutaneous Transluminal Coronary Angioplasty (PTCA) Registries I, II, and III and the Dynamic Registry|Dynamic Evaluation of Coronary Intervention|Completed|||4290|Actual|University of Pittsburgh|||||f||||t||||||||||2018-06-01 05:38:10.588238|2018-06-01 05:38:10.588238
NCT00005676|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-03-03|2000-05-25|2000-05-26|Estimate|||||||2014-03-03|2014-03-04|Estimate|April 2000||2000-04-30|March 2014|2014-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||High Density Lipoprotein Subspecies and Coronary Disease|High Density Lipoprotein Subspecies and Coronary Disease|Completed|||2700|Actual|Tufts University|||1||f||||f||||||||||2018-06-01 05:38:10.691817|2018-06-01 05:38:10.691817
NCT00005565|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 1997||1997-08-31|January 2008|2008-01-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Observational|||Mechanisms of Low Levels of Apolipoprotein B||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.754439|2018-06-01 05:38:10.754439
NCT00005564|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1997||1997-07-31|July 2004|2004-07-31|June 2002|Actual|2002-06-30|||||Observational|||Impact of Adult Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.802504|2018-06-01 05:38:10.802504
NCT00005563|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1999||1999-07-31|September 2002|2002-09-30|June 2001|Actual|2001-06-30|||||Observational|||Multicenter Asthma Research Collaboration||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.854774|2018-06-01 05:38:10.854774
NCT00005562|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-03-12|2000-05-25|2000-05-26|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 1999||1999-09-30|March 2014|2014-03-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Coronary Artery Calcium, Exercise Tests, and CHD Outcome||Completed|||||The Cooper Institute|||||f||||||||||||||2018-06-01 05:38:10.899242|2018-06-01 05:38:10.899242
NCT00005560|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 1999||1999-08-31|January 2008|2008-01-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Observational|||Prevalence and Correlates of Childhood Sleep Apnea||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:10.966195|2018-06-01 05:38:10.966195
NCT00005559|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1997||1997-07-31|March 2004|2004-03-31|June 2000|Actual|2000-06-30|||||Observational|||Statistical Basis for Hemochromatosis Screening||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.015951|2018-06-01 05:38:11.015951
NCT00005557|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-10-31|2000-05-25|2000-05-26|Estimate|||||||2016-10-31|2016-11-01|Estimate|April 1999||1999-04-30|October 2016|2016-10-31|April 2023|Anticipated|2023-04-30|April 2022|Anticipated|2022-04-30||Observational|||Epidemiology of Sleep-Disordered Breathing in Adults|Epidemiology of Sleep-Disordered Breathing in Adults|Enrolling by invitation|||1545|Actual|University of Wisconsin, Madison|||||f||||f||||||Samples With DNA|"~     Blood~   "|Undecided||2018-06-01 05:38:11.064706|2018-06-01 05:38:11.064706
NCT00005556|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1997||1997-05-31|August 2004|2004-08-31|April 2003|Actual|2003-04-30|||||Observational|||Retention of Bone Marrow Donors in a National Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.12295|2018-06-01 05:38:11.12295
NCT00005555|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-07|2000-05-25|2000-05-26|Estimate|||||||2016-01-07|2016-01-08|Estimate|May 1998||1998-05-31|January 2016|2016-01-31|April 2003||2003-04-30|||||Interventional|||Dose Response to Exercise and Cardiovascular Health||Completed||N/A|||University of Florida|||||f||||||||||||||2018-06-01 05:38:11.16332|2018-06-01 05:38:11.16332
NCT00005554|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 1999||1999-02-28|December 2004|2004-12-31|January 2004|Actual|2004-01-31|||||Observational|||Biobehavioral Predictors of Coronary Angioplasty Outcome||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.205944|2018-06-01 05:38:11.205944
NCT00005553|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-08|2000-05-25|2000-05-26|Estimate|||||||2016-01-08|2016-01-12|Estimate|May 1998||1998-05-31|October 2005|2005-10-31|April 2004||2004-04-30|||||Observational|||Prospective Assessment After Pediatric Cardiac Ablation (PAPCA)||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:38:11.245466|2018-06-01 05:38:11.245466
NCT00005552|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1999||1999-01-31|August 2004|2004-08-31|December 2001|Actual|2001-12-31|||||Observational|||Isocyanate Dermal Exposures in Autobody Shops||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.285803|2018-06-01 05:38:11.285803
NCT00005551|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1999||1999-04-30|August 2004|2004-08-31|March 2002|Actual|2002-03-31|||||Observational|||Sleep Apnea in a Non-Clinical Population||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.323253|2018-06-01 05:38:11.323253
NCT00005550|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-08-08|2000-05-25|2000-05-26|Estimate|||||||2014-08-08|2014-08-11|Estimate|January 1999||1999-01-31|August 2014|2014-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|||Endotoxin and Bronchial Inflammation in Asthma||Completed|||||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 05:38:11.364343|2018-06-01 05:38:11.364343
NCT00005549|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-03-13|2000-05-25|2000-05-26|Estimate|||||||2014-03-13|2014-03-14|Estimate|January 1999||1999-01-31|March 2014|2014-03-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Isocyanate Antigens and T Cells That Cause Asthma||Completed|||||Yale University|||||f||||||||||||||2018-06-01 05:38:11.406581|2018-06-01 05:38:11.406581
NCT00005548|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1999||1999-04-30|January 2005|2005-01-31|March 2001|Actual|2001-03-31|||||Observational|||Green Tea Consumption and Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.476813|2018-06-01 05:38:11.476813
NCT00005547|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1999||1999-04-30|January 2005|2005-01-31|June 2003|Actual|2003-06-30|||||Observational|||Infection and Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.518584|2018-06-01 05:38:11.518584
NCT00005546|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1999||1999-01-31|December 2004|2004-12-31|December 2004|Actual|2004-12-31|||||Observational|||Molecular Genetic Epidemiology of Three Cardiac Defects -SCOR in Pediatric Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.560807|2018-06-01 05:38:11.560807
NCT00005545|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-12-10|2000-05-25|2000-05-26|Estimate|||||||2013-12-10|2013-12-12|Estimate|December 1998||1998-12-31|December 2013|2013-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Arterial Endothelial Function--An Epidemiologic Study|Arterial Endothelial Function--An Epidemiologic Study|Completed|||600|Actual|University of Iowa|||||f||||||||||Samples With DNA|"~     Stored plasma and DNA samples~   "|||2018-06-01 05:38:11.597906|2018-06-01 05:38:11.597906
NCT00005544|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 1999||1999-02-28|May 2005|2005-05-31|January 2005|Actual|2005-01-31|||||Observational|||Community Based Study of Adult Onset Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.640564|2018-06-01 05:38:11.640564
NCT00005543|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-29|2000-05-25|2000-05-26|Estimate|||||||2015-12-29|2015-12-30|Estimate|April 1999||1999-04-30|December 2015|2015-12-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Observational|||Genetic Epidemiology of Venous Thromboembolism||Completed|||3135|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 05:38:11.693203|2018-06-01 05:38:11.693203
NCT00005542|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 1999||1999-05-31|October 2005|2005-10-31|April 2005|Actual|2005-04-30|||||Observational|||Sarcoid Genetic Analysis (SAGA)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.737446|2018-06-01 05:38:11.737446
NCT00005541|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-13|2000-05-25|2000-05-26|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2000||2000-01-31|April 2009|2009-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Hemochromatosis and Iron Overload Screening Study (HEIRS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:11.780773|2018-06-01 05:38:11.780773
NCT00005540|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-03-29|2000-05-25|2000-05-26|Estimate|||||||2017-03-29|2017-03-31|Actual|July 1999||1999-07-31|March 2017|2017-03-31|May 2002||2002-05-31|||||Observational|||Physical Fitness and Cardiovascular Mortality in Firefighters||Completed|||3403|Actual|University of Southern California|||||f||||f|f|f||||||No||2018-06-01 05:38:11.828661|2018-06-01 05:38:11.828661
NCT00005539|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-05|2000-05-25|2000-05-26|Estimate|||||||2016-02-05|2016-02-08|Estimate|February 1999||1999-02-28|February 2016|2016-02-29|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Observational|WESCID||Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes|Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes|Completed|||||University of Wisconsin, Madison|||||f||||||||||||||2018-06-01 05:38:12.730868|2018-06-01 05:38:12.730868
NCT00005538|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1987||1987-07-31|August 2004|2004-08-31|June 2000|Actual|2000-06-30|||||Observational|||CHD Risk, Behavioral Stress and Reproductive Hormones||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:12.783997|2018-06-01 05:38:12.783997
NCT00005537|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1997||1997-07-31|August 2004|2004-08-31|June 2002|Actual|2002-06-30|||||Observational|||Genetics of Airway Responsiveness and Lung Function||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:12.835097|2018-06-01 05:38:12.835097
NCT00005536|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1997||1997-07-31|March 2005|2005-03-31|June 2003|Actual|2003-06-30|||||Observational|||Genetic Analysis of Human Hypertensive End Stage Renal Disease (H-ESRD)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:12.876229|2018-06-01 05:38:12.876229
NCT00005535|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1995||1995-09-30|October 2002|2002-10-31|August 2000|Actual|2000-08-31|||||Observational|||Gene Mapping for Quantitative Traits||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:12.922401|2018-06-01 05:38:12.922401
NCT00005534|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-03-05|2000-05-25|2000-05-26|Estimate|||||||2014-03-05|2014-03-07|Estimate|January 1997||1997-01-31|March 2014|2014-03-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||Prevalence of Asymptomatic Ventricular Dysfunction||Completed|||||Mayo Clinic|||||f||||||||||||||2018-06-01 05:38:12.97219|2018-06-01 05:38:12.97219
NCT00005533|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-07-14|2000-05-25|2000-05-26|Estimate|||||||2014-07-14|2014-07-15|Estimate|February 1997||1997-02-28|February 2013|2013-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Hostility, Depression, Social Environment and CHD Risk|Hostility, Depression, Social Environment and CHD Risk|Completed|||592|Actual|Duke University|||1||f||||||||||||||2018-06-01 05:38:13.035934|2018-06-01 05:38:13.035934
NCT00005532|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-06|2000-05-25|2000-05-26|Estimate|||||||2016-01-06|2016-01-08|Estimate|May 1996||1996-05-31|January 2016|2016-01-31|August 2005||2005-08-31|||||Observational|||Dietary Fat, Plasma Lipids, and Other CHD Risk Factors||Completed|||||Tufts University|||||f||||||||||||||2018-06-01 05:38:13.089149|2018-06-01 05:38:13.089149
NCT00005531|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 1996||1996-12-31|August 2004|2004-08-31|November 2000|Actual|2000-11-30|||||Observational|||Genetic Epidemiology of Sarcoidosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:13.222652|2018-06-01 05:38:13.222652
NCT00005530|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-10|2000-05-25|2000-05-26|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 1994||1994-05-31|May 2016|2016-05-31|April 2000||2000-04-30|||||Observational|||Diet, Insulin Resistance, and Cardiovascular Risk||Completed|||||University of South Carolina|||||f||||||||||||||2018-06-01 05:38:13.28304|2018-06-01 05:38:13.28304
NCT00005529|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1995||1995-09-30|November 2001|2001-11-30|August 2000|Actual|2000-08-31|||||Observational|||Self-Scored Cardiovascular Disease Risk Appraisal||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:13.397676|2018-06-01 05:38:13.397676
NCT00005528|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1995||1995-04-30|August 2004|2004-08-31|February 2000|Actual|2000-02-29|||||Observational|||Genetics of CVD Risk Factors in Samoans||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:13.534216|2018-06-01 05:38:13.534216
NCT00005526|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1991||1991-08-31|August 2004|2004-08-31|November 2001|Actual|2001-11-30|||||Observational|||Genetic Basis of Abdominal Aortic Aneurysm||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:13.746947|2018-06-01 05:38:13.746947
NCT00005525|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1998||1998-08-31|March 2005|2005-03-31|July 2002|Actual|2002-07-31|||||Observational|||Sleep Apnea in Elderly Male Twins||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:13.834808|2018-06-01 05:38:13.834808
NCT00005524|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-08|2000-05-25|2000-05-26|Estimate|||||||2016-01-08|2016-01-12|Estimate|September 1998||1998-09-30|July 2005|2005-07-31|August 2003||2003-08-31|||||Observational|||Mental Stress, Autonomic Function, and Heart Disease||Completed|||||Hebrew Rehabilitation Center, Boston|||||f||||||||||||||2018-06-01 05:38:13.933927|2018-06-01 05:38:13.933927
NCT00005523|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1998||1998-08-31|January 2006|2006-01-31|December 2003|Actual|2003-12-31|||||Observational|||Home Based Environmental Adherence Trial||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:14.503073|2018-06-01 05:38:14.503073
NCT00005522|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1998||1998-05-31|October 2005|2005-10-31|April 2004|Actual|2004-04-30|||||Observational|||Social Dominance, Gender, and Cardiovascular Reactivity||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:14.646717|2018-06-01 05:38:14.646717
NCT00005521|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 1998||1998-06-30|December 2004|2004-12-31|July 2004|Actual|2004-07-31|||||Observational|||Exercise and Blood Pressure in Children: A Meta-Analysis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:15.05361|2018-06-01 05:38:15.05361
NCT00005520|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-01-15|2000-05-25|2000-05-26|Estimate|||||||2013-01-15|2013-01-17|Estimate|February 1997||1997-02-28|January 2013|2013-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|GERA||Genetic Epidemiology of Responses to Antihypertensives|Genetic Epidemiology of Responses to Antihypertensives|Completed|||1200|Actual|Mayo Clinic|||4||f||||f||||||Samples With DNA|"~     Serum, plasma, buffy coat, urine.~   "|||2018-06-01 05:38:15.190145|2018-06-01 05:38:15.190145
NCT00005519|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1998||1998-09-30|August 2004|2004-08-31|August 2001|Actual|2001-08-31|||||Observational|||Prospective Study of Diet and Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:15.382607|2018-06-01 05:38:15.382607
NCT00005518|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 1998||1998-06-30|August 2004|2004-08-31|August 2003|Actual|2003-08-31|||||Observational|||Epidemiology and Immunology of Hemophilia A Inhibitors||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:15.710534|2018-06-01 05:38:15.710534
NCT00005517|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|August 1998||1998-08-31|November 2005|2005-11-30|June 2004|Actual|2004-06-30|||||Observational|||Community Surveillance of Congestive Heart Failure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:15.941871|2018-06-01 05:38:15.941871
NCT00005516|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1998||1998-07-31|March 2005|2005-03-31|June 2002|Actual|2002-06-30|||||Observational|||Epidemiology of Sleep Disordered Breathing in Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:16.164731|2018-06-01 05:38:16.164731
NCT00005515|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|September 1998||1998-09-30|July 2005|2005-07-31|August 2003||2003-08-31|||||Observational|||Mutations, Hormone Therapy (HRT) and Venous Thromboembolism||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:16.228012|2018-06-01 05:38:16.228012
NCT00005514|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-03-18|2000-05-25|2000-05-26|Estimate|||||||2013-03-18|2013-03-20|Estimate|August 1998||1998-08-31|March 2013|2013-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Dietary Patterns and Risk of Cardiovascular Disease||Completed|||120000|Actual|Harvard School of Public Health|||||f||||||||||Samples With DNA|"~     Plasma and buffy coat~   "|||2018-06-01 05:38:16.420076|2018-06-01 05:38:16.420076
NCT00005513|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1998||1998-09-30|August 2004|2004-08-31|July 2002|Actual|2002-07-31|||||Observational|||Framingham Nutrition Studies||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:16.648052|2018-06-01 05:38:16.648052
NCT00005512|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-29|2000-05-25|2000-05-26|Estimate|||||||2016-02-29|2016-03-01|Estimate|August 1998||1998-08-31|February 2016|2016-02-29|July 2002||2002-07-31|||||Observational|||Genetic Epidemiology--Development of Cardiovascular Risk||Completed|||||Virginia Commonwealth University|||||f||||||||||||||2018-06-01 05:38:16.819166|2018-06-01 05:38:16.819166
NCT00005511|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-19|2000-05-25|2000-05-26|Estimate|||||||2016-01-19|2016-01-20|Estimate|September 1998||1998-09-30|January 2016|2016-01-31||||August 2003|Actual|2003-08-31||Observational|||SCOR in Neurobiology of Sleep--Intermediate Traits for Sleep Apnea||Completed|||||University of Pennsylvania|||||f||||||||||||||2018-06-01 05:38:16.964376|2018-06-01 05:38:16.964376
NCT00005510|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1998||1998-04-30|November 2001|2001-11-30|March 1999|Actual|1999-03-31|||||Observational|||Strong Heart Study Analyses Obesity and Lipoproteins||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:17.261419|2018-06-01 05:38:17.261419
NCT00005509|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1998||1998-04-30|December 2004|2004-12-31|March 2002|Actual|2002-03-31|||||Observational|||Cardiovascular Risk Factors in a Cohort of Latina Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:17.378205|2018-06-01 05:38:17.378205
NCT00005508|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1998||1998-08-31|August 2004|2004-08-31|June 2003|Actual|2003-06-30|||||Observational|||Determinants of Coronary Disease in High Risk Families||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:17.605509|2018-06-01 05:38:17.605509
NCT00005507|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 1998||1998-03-31|April 2002|2002-04-30|March 2000|Actual|2000-03-31|||||Observational|||Race and the Use of Cardiovascular Surgical Procedures||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:17.856068|2018-06-01 05:38:17.856068
NCT00005506|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 1998||1998-01-31|April 2004|2004-04-30|June 2000|Actual|2000-06-30|||||Observational|||Vascular Disease--Structure/Function||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:17.926914|2018-06-01 05:38:17.926914
NCT00005505|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 1997||1997-12-31|August 2004|2004-08-31|November 2002|Actual|2002-11-30|||||Observational|||Neighborhood Environments and Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:17.998717|2018-06-01 05:38:17.998717
NCT00005504|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-05-23|2000-05-25|2000-05-26|Estimate|||||||2017-05-23|2017-05-25|Actual|February 1998|Actual|1998-02-28|May 2017|2017-05-31|April 2030|Anticipated|2030-04-30|April 2030|Anticipated|2030-04-30||Observational|LITE||Epidemiology of Venous Thrombosis and Pulmonary Embolism|Longitudinal Investigation of Thromboembolism Etiology|Active, not recruiting|||21680|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples With DNA|"~     DNA, serum, plasma~   "|No||2018-06-01 05:38:18.080698|2018-06-01 05:38:18.080698
NCT00005503|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1997||1997-09-30|October 2002|2002-10-31|August 1999|Actual|1999-08-31|||||Observational|||Epidemiology of Cardiac Development in Youth||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:18.550694|2018-06-01 05:38:18.550694
NCT00005502|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-05-13|2000-05-25|2000-05-26|Estimate|||||||2013-05-13|2013-05-14|Estimate|October 2002||2002-10-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Coronary Disease Morbidity and Mortality in a Population|Coronary Disease Morbidity and Mortality in a Population|Completed|||5476|Actual|Mayo Clinic|||1||f||||f||||||Samples Without DNA|"~     plasma, serum and white blood cells are stored for future research projects~   "|||2018-06-01 05:38:18.647544|2018-06-01 05:38:18.647544
NCT00005501|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1998||1998-09-30|December 2000|2000-12-31|August 2000|Actual|2000-08-31|||||Observational|||Hypertensive Treatment and Epidemiological Analyses||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:18.878646|2018-06-01 05:38:18.878646
NCT00005500|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-10-20|2000-05-25|2000-05-26|Estimate|||||||2017-10-20|2017-10-24|Actual|September 1992||1992-09-30|October 2017|2017-10-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Observational|||Collaborative Studies on the Genetics of Asthma (CSGA)||Completed|||50|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:18.933364|2018-06-01 05:38:18.933364
NCT00005499|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1998||1998-07-31|August 2004|2004-08-31|June 2001|Actual|2001-06-30|||||Observational|||Congestive Heart Failure Trends in the Elderly 1970-94||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.119644|2018-06-01 05:38:19.119644
NCT00005498|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1998||1998-05-31|August 2004|2004-08-31|October 2001|Actual|2001-10-31|||||Observational|||Do Hostility and Stress Predict Cardiovascular Mortality in MRFIT?||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.21555|2018-06-01 05:38:19.21555
NCT00005497|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1998||1998-04-30|October 2005|2005-10-31|March 2004|Actual|2004-03-31|||||Observational|||Risk Factors for Pulmonary Hypertension of the Newborn||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.265022|2018-06-01 05:38:19.265022
NCT00005496|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1998||1998-09-30|February 2005|2005-02-28|August 2002|Actual|2002-08-31|||||Observational|||Inflammation, Infection, and Future Cardiovascular Risk||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.342133|2018-06-01 05:38:19.342133
NCT00005495|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1998||1998-07-31|November 2002|2002-11-30|June 1999|Actual|1999-06-30|||||Observational|||Primary Prevention of CHD Risk Factors Occurring in US||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.413398|2018-06-01 05:38:19.413398
NCT00005494|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|June 1998||1998-06-30|July 2005|2005-07-31|May 2004|Actual|2004-05-31|||||Observational|||Prospective Study of Health in Runners and Walkers||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.479898|2018-06-01 05:38:19.479898
NCT00005493|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1998||1998-04-30|August 2004|2004-08-31|March 2001|Actual|2001-03-31|||||Observational|||Observational Aspirin Use and CVD in the Physicians' Health Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.531838|2018-06-01 05:38:19.531838
NCT00005492|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1997||1997-08-31|March 2005|2005-03-31|July 2000|Actual|2000-07-31|||||Observational|||Pooled Analysis of NHANES I/II--Race, Gender, and CHD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.580767|2018-06-01 05:38:19.580767
NCT00005490|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-11-04|2000-05-25|2000-05-26|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 1997||1997-08-31|February 2005|2005-02-28|June 2003|Actual|2003-06-30|||||Observational|||Modeling DNA Diversity in Cardiovascular Health/Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.648835|2018-06-01 05:38:19.648835
NCT00005489|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-28|2000-05-25|2000-05-26|Estimate|||||||2015-12-28|2015-12-30|Estimate|January 1998||1998-01-31|December 2015|2015-12-31|December 2001||2001-12-31|||||Observational|||Salt Sensitivity, Cardiovascular and Metabolic Disease||Completed|||||Indiana University|||||f||||||||||||||2018-06-01 05:38:19.725222|2018-06-01 05:38:19.725222
NCT00005488|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|July 1998||1998-07-31|January 2005|2005-01-31|August 2002||2002-08-31|||||Observational|||Common Variants in Candidate Genes and Premature MI Risk||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:19.781021|2018-06-01 05:38:19.781021
NCT00005487|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 1999||1999-01-31|April 2012|2012-04-30|June 2009|Actual|2009-06-30|August 2015|Anticipated|2015-08-31||Observational|||Multi-Ethnic Study of Atherosclerosis (MESA)|Multi-Ethnic Study of Atherosclerosis (MESA)|Unknown status|Active, not recruiting||6000|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:19.840824|2018-06-01 05:38:19.840824
NCT00005486|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1997||1997-07-31|December 2005|2005-12-31|June 2003|Actual|2003-06-30|||||Observational|||Lymphangioleiomyomatosis (LAM) Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:20.093799|2018-06-01 05:38:20.093799
NCT00005464|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 1991||1991-02-28|May 2000|2000-05-31|January 1993|Actual|1993-01-31|||||Observational|||DISH Data Analysis Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.705199|2018-06-01 05:38:21.705199
NCT00005485|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-27|2000-05-25|2000-05-26|Estimate|||||||2016-04-27|2016-04-28|Estimate|September 2000||2000-09-30|April 2016|2016-04-30||||||||Observational|JHS||Jackson Heart Study (JHS) of Cardiovascular Diseases in African Americans|Environmental and Genetic Factors That Influence Cardiovascular Disease in African Americans|Unknown status|Active, not recruiting||5306|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||t||||||Samples With DNA|"~     Serum, plasma, urine, DNA~   "|Yes||2018-06-01 05:38:20.146153|2018-06-01 05:38:20.146153
NCT00005484|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1992||1992-04-30|March 2004|2004-03-31|March 1997|Actual|1997-03-31|||||Observational|||Predictors of Hospital-Based Care in Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:20.29106|2018-06-01 05:38:20.29106
NCT00005483|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-06|2000-05-25|2000-05-26|Estimate|||||||2016-01-06|2016-01-08|Estimate|December 1994||1994-12-31|January 2016|2016-01-31|July 1999||1999-07-31|||||Observational|||Plasma Homocysteine Distribution in the United States||Completed|||||Tufts University|||||f||||||||||||||2018-06-01 05:38:20.358755|2018-06-01 05:38:20.358755
NCT00005482|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|September 1995||1995-09-30|June 2000|2000-06-30|March 1999||1999-03-31|||||Observational|||Homocyst(e)Ine, Vitamin Status, and CVD Risk||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:20.411136|2018-06-01 05:38:20.411136
NCT00005481|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1996||1996-09-30|July 2004|2004-07-31|July 2002|Actual|2002-07-31|||||Observational|||Epidemiology of Impaired Coagulant Balance in Diabetes||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:20.481941|2018-06-01 05:38:20.481941
NCT00005480|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1996||1996-09-30|October 2001|2001-10-31|August 1998|Actual|1998-08-31|||||Observational|||Cardiovascular Disease Knowledge/Morbidity--Socioeconomic Cohort Outcomes||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:20.641383|2018-06-01 05:38:20.641383
NCT00005479|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-23|2000-05-25|2000-05-26|Estimate|||||||2015-12-23|2015-12-28|Estimate|September 1996||1996-09-30|December 2015|2015-12-31|September 2009|Actual|2009-09-30|August 2001|Actual|2001-08-31||Observational|||Diabetes, Lipoproteins and Accelerated Vascular Disease|Measures of Postprandial Lipoproteins Are Not Associated With Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus|Completed|||164|Actual|Columbia University|||||f||||f||||||||||2018-06-01 05:38:20.703504|2018-06-01 05:38:20.703504
NCT00005478|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1996||1996-09-30|March 2004|2004-03-31|September 1998|Actual|1998-09-30|||||Observational|||Precursors of CVD Risk Factors--Project Heartbeat||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:20.781094|2018-06-01 05:38:20.781094
NCT00005477|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-08|2000-05-25|2000-05-26|Estimate|||||||2016-01-08|2016-01-12|Estimate|September 1996||1996-09-30|April 2002|2002-04-30|August 1998||1998-08-31|||||Observational|||Hispanic and White Women's Cardiovascular Health||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:38:20.861478|2018-06-01 05:38:20.861478
NCT00005476|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 1996||1996-09-30|May 2009|2009-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Observational|||Sociodemographic Regulation of Cardiovascular Function and Structure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:20.90462|2018-06-01 05:38:20.90462
NCT00005475|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 1996||1996-08-31|May 2009|2009-05-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Longitudinal Study of Asthma From Birth to Adulthood||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:20.957904|2018-06-01 05:38:20.957904
NCT00005474|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-04-13|2000-05-25|2000-05-26|Estimate|||||||2015-04-13|2015-04-14|Estimate|September 1996||1996-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Markers and Mechanisms of Macrovascular Disease in IDDM||Completed|||1063|Actual|Medical University of South Carolina|||||f||||||||||Samples Without DNA|"~     Both DNA samples as well as plasma, serum and urine samples were collected from the DCCT/EDIC~     cohort.~   "|||2018-06-01 05:38:21.078175|2018-06-01 05:38:21.078175
NCT00005473|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1996||1996-07-31|September 2002|2002-09-30|June 2001|Actual|2001-06-30|||||Observational|||Cardiovascular Disease Trends 1980-91--A Gender Specific Perspective||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.144686|2018-06-01 05:38:21.144686
NCT00005472|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1996||1996-09-30|August 2004|2004-08-31|August 1998|Actual|1998-08-31|||||Observational|||Job Strain, Ambulatory Blood Pressure and Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.190645|2018-06-01 05:38:21.190645
NCT00005471|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1996||1996-09-30|March 2005|2005-03-31|January 2001|Actual|2001-01-31|||||Observational|||Anxiety and Cardiovascular Autonomic Control||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.284973|2018-06-01 05:38:21.284973
NCT00005470|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1996||1996-09-30|August 2004|2004-08-31|August 2002|Actual|2002-08-31|||||Observational|||Divergence of Blood Pressure By Race in Adolescent Girls||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.33228|2018-06-01 05:38:21.33228
NCT00005469|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1990||1990-09-30|May 2000|2000-05-31|November 1996|Actual|1996-11-30|||||Observational|||Maturational Changes in Cardiac Structures -- Blood Pressure Relationship -- SCOR in Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.37938|2018-06-01 05:38:21.37938
NCT00005468|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1990||1990-07-31|June 2000|2000-06-30|December 1992|Actual|1992-12-31|||||Observational|||Lipid Variability--Influence of Stress||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.438825|2018-06-01 05:38:21.438825
NCT00005467|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 1990||1990-01-31|May 2000|2000-05-31|December 1992|Actual|1992-12-31|||||Observational|||Indices of Severity and Prognosis for Sickle Cell Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.514365|2018-06-01 05:38:21.514365
NCT00005466|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1991||1991-08-31|May 2000|2000-05-31|July 1995|Actual|1995-07-31|||||Observational|||Stroke and MI in Users of Estrogen/Progestogen||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.58088|2018-06-01 05:38:21.58088
NCT00005465|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|August 1991||1991-08-31|May 2001|2001-05-31|July 1996||1996-07-31|||||Observational|||Genetic Mapping of Atherogenic Lipoprotein Phenotypes||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:21.642557|2018-06-01 05:38:21.642557
NCT00005463|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1991||1991-08-31|September 2002|2002-09-30|May 1993|Actual|1993-05-31|||||Observational|||Population-Based Modeling of Cholesterol Lowering in the United States||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.754269|2018-06-01 05:38:21.754269
NCT00005462|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-11|2000-05-25|2000-05-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1991||1991-09-30|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Genetics of Atherosclerosis in Mexican Americans||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.805112|2018-06-01 05:38:21.805112
NCT00005461|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1991||1991-04-30|July 2004|2004-07-31|June 2002|Actual|2002-06-30|||||Observational|||Epidemiology of Symptom Perception in Childhood Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.903583|2018-06-01 05:38:21.903583
NCT00005460|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 1991||1991-01-31|May 2000|2000-05-31|December 1992|Actual|1992-12-31|||||Observational|||Predictors of Cardiovascular Disease in the Elderly||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:21.984104|2018-06-01 05:38:21.984104
NCT00005459|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2000||2000-09-30|January 2008|2008-01-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Observational|||Risk of Coronary Heart Disease in Women With Polycystic Ovary Syndrome||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.021084|2018-06-01 05:38:22.021084
NCT00005458|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1991||1991-01-31|May 2000|2000-05-31|December 1991|Actual|1991-12-31|||||Observational|||Suppressed Anger, Blood Pressure and Mortality Follow-up||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.062604|2018-06-01 05:38:22.062604
NCT00005457|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 1991||1991-01-31|June 2000|2000-06-30|June 1994|Actual|1994-06-30|||||Observational|||Model-Free Time Curves for Longitudinal Data Analysis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.113581|2018-06-01 05:38:22.113581
NCT00005456|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 1990||1990-12-31|March 2005|2005-03-31|November 1995|Actual|1995-11-30|||||Observational|||Hypertensive and Normal Pregnancy--Calcium Metabolism and Renin-Angiotensin - SCOR in Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.151126|2018-06-01 05:38:22.151126
NCT00005455|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-14|2000-05-25|2000-05-26|Estimate|||||||2016-07-14|2016-07-15|Estimate|January 1993||1993-01-31|November 2001|2001-11-30|December 1993|Actual|1993-12-31|||||Observational|||Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.221873|2018-06-01 05:38:22.221873
NCT00005453|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1992||1992-09-30|September 2002|2002-09-30|June 1997|Actual|1997-06-30|||||Observational|||Adherence in Clinical Trials-Induction Strategies||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.339422|2018-06-01 05:38:22.339422
NCT00005452|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1991||1991-09-30|June 2000|2000-06-30|April 1996|Actual|1996-04-30|||||Observational|||Ti PC Software for Analyzing Longitudinal Data||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.382002|2018-06-01 05:38:22.382002
NCT00005451|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1995||1995-09-30|July 2000|2000-07-31|July 1999||1999-07-31|||||Observational|||WINCATI Software Tool for Survey Research||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.420635|2018-06-01 05:38:22.420635
NCT00005450|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1991||1991-05-31|July 2000|2000-07-31|November 1991|Actual|1991-11-30|||||Observational|||Health Promotion in the Elderly--Prevention of Cardiovascular Disorders||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.473192|2018-06-01 05:38:22.473192
NCT00005449|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-07|2000-05-25|2000-05-26|Estimate|||||||2016-01-07|2016-01-08|Estimate|August 1996||1996-08-31|January 2016|2016-01-31|June 2001||2001-06-30|||||Observational|||Social Support and Myocardial Ischemia||Completed|||||University of Florida|||||f||||||||||||||2018-06-01 05:38:22.535683|2018-06-01 05:38:22.535683
NCT00005448|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-09-07|2000-05-25|2000-05-26|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 1996||1996-07-31|August 2016|2016-08-31|June 2002|Anticipated|2002-06-30|June 2002|Anticipated|2002-06-30||Observational|||Adverse Events With Magnesium Sulfate||Withdrawn|||0|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.609057|2018-06-01 05:38:22.609057
NCT00005447|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1995||1995-08-31|April 2002|2002-04-30|July 2001|Actual|2001-07-31|||||Observational|||Physical Activity and Cardiovascular Disease Prevention||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.67019|2018-06-01 05:38:22.67019
NCT00005446|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-30|2000-05-25|2000-05-26|Estimate|||||||2015-12-30|2015-12-31|Estimate|April 1994||1994-04-30|December 2015|2015-12-31||||March 1999|Actual|1999-03-31||Observational|||Endogenous Estrogen and Coronary Heart Disease in Women||Completed|||||New York University School of Medicine|||2||f||||||||||||||2018-06-01 05:38:22.751035|2018-06-01 05:38:22.751035
NCT00005445|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-05|2000-05-25|2000-05-26|Estimate|||||||2016-01-05|2016-01-06|Estimate|April 1994||1994-04-30|January 2016|2016-01-31|February 1999||1999-02-28|||||Observational|||Epidemiology of Pediatric Asthma Hospitalization||Completed|||||Dartmouth-Hitchcock Medical Center|||||f||||||||||||||2018-06-01 05:38:22.808126|2018-06-01 05:38:22.808126
NCT00005444|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1995||1995-08-31|July 2004|2004-07-31|July 2001|Actual|2001-07-31|||||Observational|||Hypertension in Families of African Origin||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.857095|2018-06-01 05:38:22.857095
NCT00005443|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 1994||1994-01-31|July 2000|2000-07-31|December 1997|Actual|1997-12-31|||||Observational|||Race, Class, and Gender--Studies of Health Effects||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.917062|2018-06-01 05:38:22.917062
NCT00005442|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 1994||1994-06-30|March 2005|2005-03-31|May 2000|Actual|2000-05-31|||||Observational|||Re-evaluating Triglycerides in Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:22.964162|2018-06-01 05:38:22.964162
NCT00005441|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-04|2000-05-25|2000-05-26|Estimate|||||||2016-02-04|2016-02-08|Estimate|April 1993||1993-04-30|February 2016|2016-02-29|March 1998|Actual|1998-03-31|October 1997|Actual|1997-10-31||Observational|||Lifestyle Management for Women With CHD and NIDDM||Completed|||||Oregon Research Institute|||||f||||f||||||||Undecided||2018-06-01 05:38:23.046057|2018-06-01 05:38:23.046057
NCT00005440|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1992||1992-09-30|May 2000|2000-05-31|January 1997|Actual|1997-01-31|||||Observational|||Disability Among Adults With Asthma||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.092174|2018-06-01 05:38:23.092174
NCT00005439|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1992||1992-04-30|May 2000|2000-05-31|March 1997|Actual|1997-03-31|||||Observational|||Evaluation of Childhood Blood Pressure and Lipid Screening||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.173661|2018-06-01 05:38:23.173661
NCT00005438|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 1993||1993-02-28|November 2001|2001-11-30|January 1998|Actual|1998-01-31|||||Observational|||Neuropsychological Studies of Children With Sickle Cell||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.249304|2018-06-01 05:38:23.249304
NCT00005437|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1992||1992-02-29|August 2004|2004-08-31|January 1998||1998-01-31|||||Observational|||Physical Activity and Cardiovascular Risk in Black Girls||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.322367|2018-06-01 05:38:23.322367
NCT00005436|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1991||1991-09-30|May 2000|2000-05-31|August 1996|Actual|1996-08-31|||||Observational|||Lupus Cohort--Thrombotic Events and Coronary Artery Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.371858|2018-06-01 05:38:23.371858
NCT00005435|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1991||1991-07-31|June 2000|2000-06-30|June 1997|Actual|1997-06-30|||||Observational|||Hostility and Pathogenic Mechanisms of Coronary Heart Disease in Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.429617|2018-06-01 05:38:23.429617
NCT00005434|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1992||1992-04-30|May 2000|2000-05-31|March 1997|Actual|1997-03-31|||||Observational|||Opioid Compromise in Hypertension--Modulating Factors||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.480618|2018-06-01 05:38:23.480618
NCT00005433|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-04-20|2000-05-25|2000-05-26|Estimate|||||||2017-04-20|2017-04-24|Actual|April 1996||1996-04-30|April 2017|2017-04-30|April 1997|Actual|1997-04-30|April 1997|Actual|1997-04-30||Observational|||Correlates of Angiographic Changes and Coronary Events|Correlates of Angiographic Changes and Coronary Events: The Cholesterol-Lowering Atherosclerosis Study (CLAS)|Completed|||188|Actual|University of Southern California|||||f|||||f|f||||||No||2018-06-01 05:38:23.523672|2018-06-01 05:38:23.523672
NCT00005432|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 1995||1995-05-31|November 2001|2001-11-30|December 1997|Actual|1997-12-31|||||Observational|||Impact of Surfactant's Availability on Newborns||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.58754|2018-06-01 05:38:23.58754
NCT00005431|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1994||1994-09-30|April 2001|2001-04-30|February 1996|Actual|1996-02-29|||||Observational|||Coronary Heart Disease Risk Factors in Blacks Vs Whites||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.645591|2018-06-01 05:38:23.645591
NCT00005430|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|November 2001|2001-11-30|September 1995|Actual|1995-09-30|||||Observational|||Low Cholesterol and Mortality in Blacks and Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.709732|2018-06-01 05:38:23.709732
NCT00005429|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|November 2001|2001-11-30|March 1996|Actual|1996-03-31|||||Observational|||Clinical Cardiovascular Outcomes of African-Americans||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.748768|2018-06-01 05:38:23.748768
NCT00005428|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1993||1993-08-31|May 2000|2000-05-31|July 1995|Actual|1995-07-31|||||Observational|||Familial Aggregation of Stress Response||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.784336|2018-06-01 05:38:23.784336
NCT00005427|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|March 1993||1993-03-31|January 2016|2016-01-31|February 1995||1995-02-28|||||Observational|||Cohort Study of Respiratory Illness in Early Childhood||Completed|||||University of New Mexico|||||f||||||||||||||2018-06-01 05:38:23.824946|2018-06-01 05:38:23.824946
NCT00005426|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|May 1993||1993-05-31|December 2000|2000-12-31|December 1994|Actual|1994-12-31|||||Observational|||Effects of CHD Prevention on Lipoprotein Subclasses||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.864641|2018-06-01 05:38:23.864641
NCT00005425|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1992||1992-09-30|April 2001|2001-04-30|February 1995|Actual|1995-02-28|||||Observational|||Statistical Analysis of Vlagtwedde-Vlaardingen Data Set||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:23.912905|2018-06-01 05:38:23.912905
NCT00005424|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1993||1993-09-30|November 2001|2001-11-30|February 1996|Actual|1996-02-29|||||Observational|||Prospective Analysis of the Effect of Widowhood on CVD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.015854|2018-06-01 05:38:24.015854
NCT00005423|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1992||1992-07-31|April 2002|2002-04-30|December 1994|Actual|1994-12-31|||||Observational|||Dietary Quality and Subsequent Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.05865|2018-06-01 05:38:24.05865
NCT00005422|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1992||1992-04-30|June 2000|2000-06-30|March 1995|Actual|1995-03-31|||||Observational|||Longitudinal Analysis of Spirometry in Black Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.097022|2018-06-01 05:38:24.097022
NCT00005421|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1992||1992-09-30|March 2005|2005-03-31|March 1995|Actual|1995-03-31|||||Observational|||Blood Pressure Tracking--Childhood to Young Adulthood||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.14917|2018-06-01 05:38:24.14917
NCT00005420|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-13|2000-05-25|2000-05-26|Estimate|||||||2016-01-13|2016-01-14|Estimate|April 1992||1992-04-30|January 2016|2016-01-31|March 1995||1995-03-31|||||Observational|||Prediction of Quality of Life in Cardiovascular Disease||Completed|||||University of Texas at Austin|||||f||||||||||||||2018-06-01 05:38:24.213268|2018-06-01 05:38:24.213268
NCT00005419|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-08|2000-05-25|2000-05-26|Estimate|||||||2016-01-08|2016-01-12|Estimate|March 1992||1992-03-31|January 2016|2016-01-31|February 1994||1994-02-28|||||Observational|||Physical Activity, Hypertension, Diabetes, and Coronary Heart Disease||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:38:24.257457|2018-06-01 05:38:24.257457
NCT00005418|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1992||1992-04-30|September 2001|2001-09-30|March 1994|Actual|1994-03-31|||||Observational|||Epidemiology of Cardiotoxicity in Children With Cancer||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.302584|2018-06-01 05:38:24.302584
NCT00005417|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1991||1991-09-30|May 2000|2000-05-31|September 1993|Actual|1993-09-30|||||Observational|||Fifteen Year Follow-up of 5,500 Black and 5,500 Other Hypertensives||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.366853|2018-06-01 05:38:24.366853
NCT00005416|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-21|2000-05-25|2000-05-26|Estimate|||||||2015-12-21|2015-12-23|Estimate|July 1992||1992-07-31|April 2002|2002-04-30|June 1995||1995-06-30|||||Observational|||Diet, Exercise, and Cardiovascular Health Among Ethnic Children||Completed|||||Augusta University|||||f||||||||||||||2018-06-01 05:38:24.405426|2018-06-01 05:38:24.405426
NCT00005415|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1992||1992-09-30|June 2000|2000-06-30|September 1993|Actual|1993-09-30|||||Observational|||Physical Activity Effects on Health Care Utilization||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.453997|2018-06-01 05:38:24.453997
NCT00005414|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1991||1991-09-30|July 2000|2000-07-31|September 1993|Actual|1993-09-30|||||Observational|||Validation of a Historical Physical Activity Survey||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.495834|2018-06-01 05:38:24.495834
NCT00005413|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1991||1991-09-30|March 2005|2005-03-31|September 1993|Actual|1993-09-30|||||Observational|||Stroke Risk in the NAS-NRC Twin Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.538335|2018-06-01 05:38:24.538335
NCT00005412|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1992||1992-07-31|June 2000|2000-06-30|June 1995|Actual|1995-06-30|||||Observational|||Dietary Antioxidants and Atherosclerosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.5846|2018-06-01 05:38:24.5846
NCT00005411|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1991||1991-09-30|March 2005|2005-03-31|September 1993|Actual|1993-09-30|||||Observational|||Study of Children's Activity and Nutrition (SCAN)--Extended Analyses||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.621093|2018-06-01 05:38:24.621093
NCT00005410|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 1991||1991-06-30|May 2000|2000-05-31|May 1993|Actual|1993-05-31|||||Observational|||Epidemiology of Coronary Heart Disease in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.659517|2018-06-01 05:38:24.659517
NCT00005409|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 1991||1991-05-31|June 2000|2000-06-30|April 1993|Actual|1993-04-30|||||Observational|||Longitudinal Studies of Blood Pressure in the Elderly||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.703838|2018-06-01 05:38:24.703838
NCT00005408|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1992||1992-07-31|May 2000|2000-05-31|April 1994|Actual|1994-04-30|||||Observational|||Reanalysis of CVD Risk Factors Via Likelihood Methods||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.738198|2018-06-01 05:38:24.738198
NCT00005407|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 1991||1991-02-28|May 2000|2000-05-31|January 1993|Actual|1993-01-31|||||Observational|||Statistical Analysis of Pediatric Task Force Data Base||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.857262|2018-06-01 05:38:24.857262
NCT00005406|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1991||1991-05-31|April 2000|2000-04-30|April 1992|Actual|1992-04-30|||||Observational|||Change in Coronary Heart Disease Risk Factors in Young Adults||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:24.916195|2018-06-01 05:38:24.916195
NCT00005405|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-19|2000-05-25|2000-05-26|Estimate|||||||2016-01-19|2016-01-20|Estimate|September 1991||1991-09-30|January 2016|2016-01-31|September 1993|Actual|1993-09-30|September 1993|Actual|1993-09-30||Observational|||Parity and Serum Lipids in White and Hispanic Women||Completed|||||University of Pennsylvania|||||f||||||||||||||2018-06-01 05:38:24.982572|2018-06-01 05:38:24.982572
NCT00005404|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 1991||1991-02-28|May 2000|2000-05-31|January 1993|Actual|1993-01-31|||||Observational|||Compliance in the Physicians' Health Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.039812|2018-06-01 05:38:25.039812
NCT00005403|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 1991||1991-02-28|June 2000|2000-06-30|January 1993|Actual|1993-01-31|||||Observational|||Heart Disease and the Black Health Disadvantage||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.094025|2018-06-01 05:38:25.094025
NCT00005402|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-16|2000-05-25|2000-05-26|Estimate|||||||2015-12-16|2015-12-17|Estimate|May 1996||1996-05-31|April 2002|2002-04-30|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Observational|||Transfusion Associated HCV in a Pediatric Population||Completed|||||Children's Research Institute|||||f||||||||||||||2018-06-01 05:38:25.153351|2018-06-01 05:38:25.153351
NCT00005401|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|August 1995||1995-08-31|July 2000|2000-07-31|July 1999||1999-07-31|||||Observational|||Validation and Exploration of Sleep and Mood Predictors||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.202265|2018-06-01 05:38:25.202265
NCT00005400|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-19|2000-05-25|2000-05-26|Estimate|||||||2016-01-19|2016-01-21|Estimate|August 1995||1995-08-31|January 2016|2016-01-31|July 2003||2003-07-31|||||Observational|||Angiotensinogen Variants and Adverse Pregnancy Outcomes||Completed|||||University of Utah|||||f||||||||||||||2018-06-01 05:38:25.264424|2018-06-01 05:38:25.264424
NCT00005399|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-11|2000-05-25|2000-05-26|Estimate|||||||2016-04-11|2016-04-12|Estimate|August 1996||1996-08-31|April 2016|2016-04-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Observational|||Cohort Study of Heart Rate Variability|Cohort Study of Heart Rate Variability|Completed|||111654|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-06-01 05:38:25.324478|2018-06-01 05:38:25.324478
NCT00005398|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-04-23|2000-05-25|2000-05-26|Estimate|||||||2018-04-23|2018-04-24|Actual|May 1996||1996-05-31|April 2018|2018-04-30||||May 2026|Anticipated|2026-05-31||Observational|||University of North Carolina Alumni Heart Study|University of North Carolina Alumni Heart Study|Active, not recruiting|||6340|Actual|Duke University|||1||f||||f||||||||||2018-06-01 05:38:25.394276|2018-06-01 05:38:25.394276
NCT00005397|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-06-09|2000-05-25|2000-05-26|Estimate|||||||2017-06-09|2017-06-12|Actual|September 1995||1995-09-30|June 2017|2017-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Epidemiology of Carotid Artery Atherosclerosis in Youth||Completed|||1360|Actual|University of Iowa|||||f||||||||||Samples With DNA|"~     Blood~   "|||2018-06-01 05:38:25.476243|2018-06-01 05:38:25.476243
NCT00005396|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1994||1994-09-30|April 2002|2002-04-30|August 1999|Actual|1999-08-31|||||Observational|||Motivating Smokers--Reduce Child Environmental Tobacco Smoke Exposure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.546802|2018-06-01 05:38:25.546802
NCT00005395|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1995||1995-09-30|February 2005|2005-02-28|July 2000|Actual|2000-07-31|||||Observational|||Honolulu Heart Program-Study of Stroke and Dementia||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.601134|2018-06-01 05:38:25.601134
NCT00005394|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1995||1995-08-31|August 2004|2004-08-31|July 2000|Actual|2000-07-31|||||Observational|||Diagnosis/Pathophysiology of Glucocorticoid Remediable Aldosteronism Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.655456|2018-06-01 05:38:25.655456
NCT00005393|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-05-23|2000-05-25|2000-05-26|Estimate|||||||2017-05-23|2017-05-24|Actual|August 1996||1996-08-31|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Epidemiology: Oxidative Stress and Early Atherosclerosis|Epidemiology: Oxidative Stress and Early Atherosclerosis|Active, not recruiting|||5115|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples With DNA|"~     blood and urine samples and DNA~   "|||2018-06-01 05:38:25.707708|2018-06-01 05:38:25.707708
NCT00005392|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 1995||1995-09-30|July 2005|2005-07-31|July 2000|Actual|2000-07-31|||||Observational|||Epidemiology of Venous Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.764136|2018-06-01 05:38:25.764136
NCT00005391|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-08-05|2000-05-25|2000-05-26|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 1995||1995-09-30|January 2014|2014-01-31|May 2010|Actual|2010-05-31|||||Observational|||Pediatric Cardiomyopathy Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.811285|2018-06-01 05:38:25.811285
NCT00005390|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1996||1996-08-31|August 2004|2004-08-31|July 2001|Actual|2001-07-31|||||Observational|||Family Process, Adherence, and Child Asthma Outcome||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.876603|2018-06-01 05:38:25.876603
NCT00005389|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|September 1995||1995-09-30|April 2001|2001-04-30|August 1998||1998-08-31|||||Observational|||Effect of Drug Therapy on Reinfarction Risk in Women||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:25.932251|2018-06-01 05:38:25.932251
NCT00005388|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1995||1995-09-30|April 2004|2004-04-30|March 2004|Actual|2004-03-31|||||Observational|||Visceral Fat, Metabolic Rate, and CHD Risk in Young Adults||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:25.989476|2018-06-01 05:38:25.989476
NCT00005387|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-11|2000-05-25|2000-05-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1995||1995-09-30|December 2008|2008-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Genetics of Hypertension in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.043171|2018-06-01 05:38:26.043171
NCT00005386|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-26|2000-05-25|2000-05-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|September 1995||1995-09-30|August 2004|2004-08-31|August 1998||1998-08-31|||||Observational|||Biobehavioral Determinants of Obesity in Black Women||Completed|||||University of Memphis|||||f||||||||||||||2018-06-01 05:38:26.092402|2018-06-01 05:38:26.092402
NCT00005385|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1994||1994-09-30|October 2005|2005-10-31|July 1999|Actual|1999-07-31|||||Observational|||Seasonal Variation of Blood Cholesterol Levels||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.157626|2018-06-01 05:38:26.157626
NCT00005384|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 1995||1995-01-31|August 2004|2004-08-31|December 2002|Actual|2002-12-31|||||Observational|||Diet/Activity of Mexican American and Anglo Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.198029|2018-06-01 05:38:26.198029
NCT00005383|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 1995||1995-01-31|September 2002|2002-09-30|December 1999|Actual|1999-12-31|||||Observational|||Anger and Cardiovascular Risk in Urban Youth||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.27053|2018-06-01 05:38:26.27053
NCT00005382|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1995||1995-07-31|November 2001|2001-11-30|May 1998|Actual|1998-05-31|||||Observational|||Sources of Variability in Peak Expiratory Flow||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.307406|2018-06-01 05:38:26.307406
NCT00005381|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-04-13|2000-05-25|2000-05-26|Estimate|||||||2018-04-13|2018-04-17|Actual|October 29, 1995|Actual|1995-10-29|April 2018|2018-04-30||||August 2, 1998|Actual|1998-08-02||Observational|||Prevalence of Sleep Apnea in Women|Prevalence of Sleep Apnea in Women|Active, not recruiting|||1000|Actual|Milton S. Hershey Medical Center|||||f||||f|f|f||||||No||2018-06-01 05:38:26.343149|2018-06-01 05:38:26.343149
NCT00005380|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1993||1993-09-30|March 2005|2005-03-31|August 1998|Actual|1998-08-31|||||Observational|||Insulin, Androgen, and Risk in African-American Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.391154|2018-06-01 05:38:26.391154
NCT00005379|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-28|2000-05-25|2000-05-26|Estimate|||||||2015-12-28|2015-12-29|Estimate|August 1994||1994-08-31|December 2015|2015-12-31|July 1999|Actual|1999-07-31|July 1999|Actual|1999-07-31||Observational|||Tuberculosis in a Multiethnic Inner City Population|Tuberculosis in a Multiethnic Inner City Population|Completed|||||New York University School of Medicine|||3||f||||||||||||||2018-06-01 05:38:26.436511|2018-06-01 05:38:26.436511
NCT00005378|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1994||1994-07-31|November 2001|2001-11-30|May 1998|Actual|1998-05-31|||||Observational|||Impact of Sleep Disordered Breathing in Older Adults||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.483042|2018-06-01 05:38:26.483042
NCT00005377|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2009-05-01|2000-05-25|2000-05-26|Estimate|||||||2009-05-01|2009-05-04|Estimate|July 1994||1994-07-31|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Molecular Epidemiology of Essential Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.552032|2018-06-01 05:38:26.552032
NCT00005376|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|November 2001|2001-11-30|August 1998|Actual|1998-08-31|||||Observational|||Premature Birth and Its Sequelae in Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.606739|2018-06-01 05:38:26.606739
NCT00005375|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2008-01-25|2000-05-25|2000-05-26|Estimate|||||||2008-01-25|2008-01-29|Estimate|September 1993||1993-09-30|January 2008|2008-01-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Observational|||Smoking Onset in a Biethnic Population||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.646216|2018-06-01 05:38:26.646216
NCT00005374|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|January 1994||1994-01-31|March 2005|2005-03-31|May 2004||2004-05-31|||||Observational|||Genetics of the Metabolic Syndrome in Japanese Americans||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:26.700328|2018-06-01 05:38:26.700328
NCT00005373|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1992||1992-09-30|July 2000|2000-07-31|August 1998|Actual|1998-08-31|||||Observational|||Racial Differences in the Coronary Microcirculation||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.756396|2018-06-01 05:38:26.756396
NCT00005372|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-15|2000-05-25|2000-05-26|Estimate|||||||2016-01-15|2016-01-20|Estimate|January 1994||1994-01-31|January 2016|2016-01-31|February 2005||2005-02-28|||||Observational|||Intimal Thickening and Antioxidants in Hispanics and Anglos (Los Angeles Atherosclerosis Study)||Completed|||||University of Southern California|||||f||||||||||||||2018-06-01 05:38:26.801473|2018-06-01 05:38:26.801473
NCT00005371|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1993||1993-04-30|March 2005|2005-03-31|March 1995|Actual|1995-03-31|||||Observational|||Epidemiology of Acute Phase Protein and CHD||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.842853|2018-06-01 05:38:26.842853
NCT00005370|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1993||1993-04-30|November 2001|2001-11-30|March 1999|Actual|1999-03-31|||||Observational|||Longitudinal Study of Cortisol and Pulmonary Function||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.887461|2018-06-01 05:38:26.887461
NCT00005369|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1992||1992-09-30|April 2002|2002-04-30|August 1996|Actual|1996-08-31|||||Observational|||Coronary Artery Disease Mechanisms in High Risk Families--Racial Difference||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:26.944332|2018-06-01 05:38:26.944332
NCT00005368|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|July 1993||1993-07-31|January 2005|2005-01-31|August 2003||2003-08-31|||||Observational|||Genetic Epidemiology of Hypertriglyceridemia||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:26.983764|2018-06-01 05:38:26.983764
NCT00005367|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1993||1993-02-28|March 2005|2005-03-31|January 1995||1995-01-31|||||Observational|||Epidemiology of Long QTand Asian Sudden Death in Sleep||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:27.931136|2018-06-01 05:38:27.931136
NCT00005366|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1993||1993-09-30|April 2001|2001-04-30|August 1998|Actual|1998-08-31|||||Observational|||Biobehavioral Mechanisms of Blood Pressure Regulation||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:27.975438|2018-06-01 05:38:27.975438
NCT00005365|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|February 1993||1993-02-28|August 2004|2004-08-31|January 1998||1998-01-31|||||Observational|||Central Obesity and Disease Risk in Japanese Americans||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:28.034112|2018-06-01 05:38:28.034112
NCT00005364|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1994||1994-04-30|June 2000|2000-06-30|March 1999|Actual|1999-03-31|||||Observational|||Genetic Epidemiology of CHD Risk Factors in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.09503|2018-06-01 05:38:28.09503
NCT00005363|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1992||1992-08-31|April 2000|2000-04-30|July 1994|Actual|1994-07-31|||||Observational|||Ambulatory Blood Pressure and Prognosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.147766|2018-06-01 05:38:28.147766
NCT00005362|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1992||1992-09-30|May 2000|2000-05-31|August 1995|Actual|1995-08-31|||||Observational|||Dose Estimation for Studies of Acute Respiratory Effects||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.191963|2018-06-01 05:38:28.191963
NCT00005361|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1993||1993-04-30|June 2000|2000-06-30|March 1998|Actual|1998-03-31|||||Observational|||Determinants of Respiratory Health in Young Adults||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.232354|2018-06-01 05:38:28.232354
NCT00005360|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1992||1992-08-31|December 2001|2001-12-31|July 1997|Actual|1997-07-31|||||Observational|||HIV Diversity and Pathogenesis in Donor-Recipient Clusters||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.294572|2018-06-01 05:38:28.294572
NCT00005359|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-11|2000-05-25|2000-05-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 1994||1994-07-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Genetics of Asthma and Bronchial Hyperresponsiveness||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.365994|2018-06-01 05:38:28.365994
NCT00005358|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 1994||1994-04-30|January 2016|2016-01-31|March 1999||1999-03-31|||||Observational|||Thrombogenic Factors and Recurrent Coronary Events||Completed|||||University of Rochester|||||f||||||||||||||2018-06-01 05:38:28.511642|2018-06-01 05:38:28.511642
NCT00005357|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-09|2000-05-25|2000-05-26|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 1994||1994-04-30|February 2016|2016-02-29|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Observational|||Pulmonary Hypertension--Mechanisms and Family Registry|Pulmonary Hypertension--Mechanisms and Family Registry|Completed|||||Vanderbilt University|||||f||||||||||||||2018-06-01 05:38:28.566166|2018-06-01 05:38:28.566166
NCT00005356|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1994||1994-07-31|March 2005|2005-03-31|May 1998|Actual|1998-05-31|||||Observational|||Novel Hemostatic Cardiac Risk Factors in Framingham||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.667176|2018-06-01 05:38:28.667176
NCT00005355|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-29|2000-05-25|2000-05-26|Estimate|||||||2016-02-29|2016-03-02|Estimate|February 1993||1993-02-28|February 2016|2016-02-29|January 1996||1996-01-31|||||Observational|||Gender Differences in Familial Risk||Completed|||||Virginia Commonwealth University|||||f||||||||||||||2018-06-01 05:38:28.731004|2018-06-01 05:38:28.731004
NCT00005354|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-03-26|2000-05-25|2000-05-26|Estimate|||||||2014-03-26|2014-03-27|Estimate|April 1992||1992-04-30|January 2008|2008-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Computed Tomography (CT)--An Epidemiologic Study in the Young||Completed|||||University of Iowa|||||f||||||||||||||2018-06-01 05:38:28.781027|2018-06-01 05:38:28.781027
NCT00005353|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 1992||1992-06-30|May 2000|2000-05-31|May 1995|Actual|1995-05-31|||||Observational|||Cardiac Autonomic Control in Children of HIV Positive Mothers||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.83616|2018-06-01 05:38:28.83616
NCT00005309|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-05|2000-05-25|2000-05-26|Estimate|||||||2016-02-05|2016-02-09|Estimate|July 1990||1990-07-31|February 2016|2016-02-29|March 1995||1995-03-31|||||Observational|||Prospective Study of HIV Infection in Hemophiliacs||Completed|||||Bloodworks (Puget Sound Blood Center)|||||f||||||||||||||2018-06-01 05:38:31.471108|2018-06-01 05:38:31.471108
NCT00005352|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1992||1992-09-30|August 2004|2004-08-31|August 1996|Actual|1996-08-31|||||Observational|||Chronic Stress as a Risk Factor in the Etiology of Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.887087|2018-06-01 05:38:28.887087
NCT00005351|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1991||1991-08-31|September 2002|2002-09-30|July 1994|Actual|1994-07-31|||||Observational|||Incidence and Outcomes of Venous Thromboembolism||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:28.939662|2018-06-01 05:38:28.939662
NCT00005350|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-21|2000-05-25|2000-05-26|Estimate|||||||2015-12-21|2015-12-23|Estimate|April 1991||1991-04-30|December 2015|2015-12-31|January 1993||1993-01-31|||||Observational|||Evaluating Strategies to Control Hypercholesterolemia||Completed|||||National Bureau of Economic Research, Inc.|||||f||||||||||||||2018-06-01 05:38:29.025376|2018-06-01 05:38:29.025376
NCT00005349|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-06-18|2000-05-25|2000-05-26|Estimate|||||||2013-06-18|2013-06-19|Estimate|April 1991||1991-04-30|June 2013|2013-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Observational|ECAC||Epidemiology of Coronary Artery Calcification||Completed|||1736|Actual|University of Michigan|||||f||||||||||||||2018-06-01 05:38:29.080812|2018-06-01 05:38:29.080812
NCT00005348|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1991||1991-04-30|April 2000|2000-04-30|March 1993|Actual|1993-03-31|||||Observational|||Adipose Distribution and Atherosclerosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.148383|2018-06-01 05:38:29.148383
NCT00005347|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 1992||1992-02-29|May 2000|2000-05-31|January 1997|Actual|1997-01-31|||||Observational|||Framingham Cycle V Offspring-Spouse Nutrition Studies||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.191079|2018-06-01 05:38:29.191079
NCT00005346|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1993||1993-01-31|November 2001|2001-11-30|December 1995|Actual|1995-12-31|||||Observational|||Mechanisms Underlying Abnormal Ambulatory BP Patterns||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.233556|2018-06-01 05:38:29.233556
NCT00005345|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1993||1993-01-31|August 2004|2004-08-31|July 2000|Actual|2000-07-31|||||Observational|||Genetic Epidemiology of Blood Lipids and Obesity - Ancillary to NGHS||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.271721|2018-06-01 05:38:29.271721
NCT00005344|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 1992||1992-05-31|August 2004|2004-08-31|April 1998|Actual|1998-04-30|||||Observational|||Mediators of Social Support in Coronary Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.320289|2018-06-01 05:38:29.320289
NCT00005343|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1993||1993-01-31|May 2000|2000-05-31|December 1995||1995-12-31|||||Observational|||Social Support and CHD Risk Factors--A Community Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.382782|2018-06-01 05:38:29.382782
NCT00005342|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|May 1993||1993-05-31|July 2000|2000-07-31|April 1997|Actual|1997-04-30|||||Observational|||Weight Set-Point and HDL Concentration in Runners||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.425769|2018-06-01 05:38:29.425769
NCT00005341|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|February 1992||1992-02-29|January 2016|2016-01-31|January 1997||1997-01-31|||||Observational|||Blood Donation--Immune Sequelae and Recruitment||Completed|||||University of New Mexico|||||f||||||||||||||2018-06-01 05:38:29.552608|2018-06-01 05:38:29.552608
NCT00005340|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 1991||1991-09-30|January 2008|2008-01-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Hypertension in Blacks of West African Origin||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.610703|2018-06-01 05:38:29.610703
NCT00005339|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 1992||1992-02-29|June 2000|2000-06-30|April 2004|Actual|2004-04-30|||||Observational|||Risk of Post Transfusion Hepatitis C Virus Infection||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.693312|2018-06-01 05:38:29.693312
NCT00005338|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1991||1991-08-31|December 2004|2004-12-31|August 2004|Actual|2004-08-31|||||Observational|||Homocysteine and Progression of Atherosclerosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.742556|2018-06-01 05:38:29.742556
NCT00005337|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1991||1991-04-30|March 2005|2005-03-31|March 1995|Actual|1995-03-31|||||Observational|||Hostility and Coronary Risk--Role of Weak Vagal Function||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.813592|2018-06-01 05:38:29.813592
NCT00005336|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|April 1991||1991-04-30|April 2000|2000-04-30|September 1996||1996-09-30|||||Observational|||Dietary Treatment of Hyperlipidemia in Women vs. Men||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:29.869574|2018-06-01 05:38:29.869574
NCT00005335|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1991||1991-05-31|July 2004|2004-07-31|March 2002|Actual|2002-03-31|||||Observational|||Genetic Epidemiology of Lipoprotein-Lipid Levels||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:29.940594|2018-06-01 05:38:29.940594
NCT00005334|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1991||1991-07-31|June 2000|2000-06-30|June 1995|Actual|1995-06-30|||||Observational|||Effects of Personality and Context on Recovery From Coronary Artery Bypass||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.000701|2018-06-01 05:38:30.000701
NCT00005333|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1991||1991-01-31|August 2004|2004-08-31|August 2001|Actual|2001-08-31|||||Observational|||Epidemic Hypertension in Nigerian Workers||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.052606|2018-06-01 05:38:30.052606
NCT00005332|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-05-01|2000-05-25|2000-05-26|Estimate|||||||2018-05-01|2018-05-07|Actual|September 1991||1991-09-30|May 2018|2018-05-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Antihypertensive Drug/Gene Interactions and CV Events||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:30.107994|2018-06-01 05:38:30.107994
NCT00005331|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1988||1988-09-30|July 2000|2000-07-31|February 1995|Actual|1995-02-28|||||Observational|||Providers for Smoking Prevention Programs||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.170199|2018-06-01 05:38:30.170199
NCT00005286|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 1986||1986-04-30|January 2016|2016-01-31|March 1989||1989-03-31|||||Observational|||Epidemiology of Sleep Apnea Syndrome||Completed|||||University of New Mexico|||||f||||||||||||||2018-06-01 05:38:32.694033|2018-06-01 05:38:32.694033
NCT00005330|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1985||1985-09-30|April 2002|2002-04-30|April 2001|Actual|2001-04-30|||||Observational|||Framingham Children's Study - Food and Exercise Habits in Framingham Study Descendents||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.219974|2018-06-01 05:38:30.219974
NCT00005329|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1992||1992-05-31|March 2005|2005-03-31|March 1997|Actual|1997-03-31|||||Observational|||Protein S and Myocardial Infarction||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.268635|2018-06-01 05:38:30.268635
NCT00005328|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-01-16|2000-05-25|2000-05-26|Estimate|||||||2013-01-16|2013-01-17|Estimate|April 1980||1980-04-30|January 2013|2013-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Antecedents of the Type A Behavior Pattern||Completed|||184|Actual|University of Pittsburgh|||||f||||||||||||||2018-06-01 05:38:30.340231|2018-06-01 05:38:30.340231
NCT00005327|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-03-22|2000-05-25|2000-05-26|Estimate|||||||2017-03-22|2017-03-24|Actual|April 1993||1993-04-30|March 2017|2017-03-31|March 1998||1998-03-31|||||Observational|||Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center||Completed|||||University of Southern California|||||f||||||||||||||2018-06-01 05:38:30.41658|2018-06-01 05:38:30.41658
NCT00005326|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 1988||1988-01-31|December 2004|2004-12-31|March 2004|Actual|2004-03-31|||||Observational|||Cerebrovascular Involvement in Sickle Cell Disease - Comprehensive Sickle Cell Center||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.4677|2018-06-01 05:38:30.4677
NCT00005325|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-07-15|2000-05-25|2000-05-26|Estimate|||||||2014-07-15|2014-07-16|Estimate|February 1996||1996-02-29|July 2014|2014-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Identifying Genes Involved in Abnormal Blood Pressure - Hypertension SCOR||Completed|||||Boston University|||||f||||||||||||||2018-06-01 05:38:30.510949|2018-06-01 05:38:30.510949
NCT00005324|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-09-27|2000-05-25|2000-05-26|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 1992||1992-01-31|May 2000|2000-05-31|November 1996|Actual|1996-11-30|||||Observational|||Genetic and Epidemiologic Studies of Premature Coronary Artery Disease - SCOR in Arteriosclerosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.556734|2018-06-01 05:38:30.556734
NCT00005323|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 1991||1991-12-31|October 2001|2001-10-31|November 1996|Actual|1996-11-30|||||Observational|||Epidemiology of Persistent Pulmonary Hypertension of the Newborn - SCOR in Lung Biology and Diseases in Infants and Children||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.600127|2018-06-01 05:38:30.600127
NCT00005322|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-09-27|2000-05-25|2000-05-26|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 1990||1990-01-31|August 2004|2004-08-31|December 1998|Actual|1998-12-31|||||Observational|||Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.642055|2018-06-01 05:38:30.642055
NCT00005321|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-11|2000-05-25|2000-05-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1988||1988-09-30|August 2000|2000-08-31|August 1999|Actual|1999-08-31|||||Observational|||Epidemiology of Sleep Disordered Breathing - SCOR in Cardiopulmonary Disorders of Sleep||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.684683|2018-06-01 05:38:30.684683
NCT00005320|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-09-27|2000-05-25|2000-05-26|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 1988||1988-09-30|March 2005|2005-03-31|August 1998|Actual|1998-08-31|||||Observational|||Regulation of Pharyngeal Muscle Contraction - SCOR in Cardiopulmonary Disorders of Sleep||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.722713|2018-06-01 05:38:30.722713
NCT00005319|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1985||1985-09-30|May 2002|2002-05-31|December 1996|Actual|1996-12-31|||||Observational|||Epidemiologic Studies of Blood Use in the United States - SCOR in Transfusion Medicine||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.774219|2018-06-01 05:38:30.774219
NCT00005318|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-06-22|2000-05-25|2000-05-26|Estimate|||||||2016-06-22|2016-06-24|Estimate|January 1994||1994-01-31|June 2016|2016-06-30|November 2004||2004-11-30|||||Observational|||ARDS - Clinical Epidemiology and the Role of the Inflammatory Response - SCOR in Acute Lung Injury||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:30.814386|2018-06-01 05:38:30.814386
NCT00005317|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-11|2000-05-25|2000-05-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 1986||1986-12-31|May 2000|2000-05-31|November 1996|Actual|1996-11-30|||||Observational|||Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:30.950523|2018-06-01 05:38:30.950523
NCT00005316|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 1985||1985-12-31|August 2001|2001-08-31|November 1995|Actual|1995-11-30|||||Observational|||White Coat Hypertension and Antihypertensive Treatment Effect - SCOR in Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.015977|2018-06-01 05:38:31.015977
NCT00005315|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-03-07|2000-05-25|2000-05-26|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 1993||1993-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Psychosocial Factors and Cardiovascular Disease|Psychosocial Factors and Cardiovascular Disease|Completed|||||Columbia University|||||f||||f||||||||||2018-06-01 05:38:31.077008|2018-06-01 05:38:31.077008
NCT00005314|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-03-12|2000-05-25|2000-05-26|Estimate|||||||2015-03-12|2015-03-13|Estimate|July 1986||1986-07-31|February 2015|2015-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Behavioral Factors in Coronary Heart Disease||Completed|||694|Actual|Duke University|||||f||||f||||||Samples With DNA|"~     Urine and plasma samples and extracted DNA are retained~   "|||2018-06-01 05:38:31.161898|2018-06-01 05:38:31.161898
NCT00005313|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-12-09|2000-05-25|2000-05-26|Estimate|||||||2014-12-09|2014-12-11|Estimate|April 2001||2001-04-30|December 2014|2014-12-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Observational|||Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia|Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia|Completed|||450|Actual|University of Washington|||||f||||f||||||||||2018-06-01 05:38:31.263735|2018-06-01 05:38:31.263735
NCT00005312|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1990||1990-01-31|July 2004|2004-07-31|August 2002||2002-08-31|||||Observational|||International Programs Collaborative Studies Coordinating Center||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.358988|2018-06-01 05:38:31.358988
NCT00005311|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1993||1993-09-30|June 2000|2000-06-30|March 1996||1996-03-31|||||Observational|||Hypertension in Minorities Database-Workshop and Publication||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.416448|2018-06-01 05:38:31.416448
NCT00005308|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1990||1990-04-30|November 2001|2001-11-30|March 1995|Actual|1995-03-31|||||Observational|||Anemia and Surgery: Indications For Transfusion||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.520057|2018-06-01 05:38:31.520057
NCT00005307|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1989||1989-04-30|May 2000|2000-05-31|March 1991|Actual|1991-03-31|||||Observational|||Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.57296|2018-06-01 05:38:31.57296
NCT00005306|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-13|2000-05-25|2000-05-26|Estimate|||||||2016-04-13|2016-04-14|Estimate|March 1988||1988-03-31|August 2004|2004-08-31|September 2001||2001-09-30|||||Observational|||Natural History of Post-transfusion Non-A, Non-B Hepatitis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.618189|2018-06-01 05:38:31.618189
NCT00005305|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-06-13|2000-05-25|2000-05-26|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 1987||1987-09-30|June 2016|2016-06-30|September 1991|Actual|1991-09-30|September 1991|Actual|1991-09-30||Observational|||Hepatitis Delta Infections in Hemophiliacs|Prevalence and Consequences of Hepatitis Delta Virus Infection in Hemophiliacs|Completed|||61|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||No||2018-06-01 05:38:31.688108|2018-06-01 05:38:31.688108
NCT00005304|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-08|2000-05-25|2000-05-26|Estimate|||||||2015-12-08|2015-12-10|Estimate|September 1986||1986-09-30|December 2015|2015-12-31|September 1991||1991-09-30|||||Observational|||Delta Hepatitis and Liver Disease in Hemophiliacs||Completed|||||Baylor College of Medicine|||||f||||||||||||||2018-06-01 05:38:31.759021|2018-06-01 05:38:31.759021
NCT00005303|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1986||1986-09-30|December 2001|2001-12-31|September 1995||1995-09-30|||||Observational|||Effectiveness of AIDS Antibody Screening||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.804464|2018-06-01 05:38:31.804464
NCT00005302|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1985||1985-04-30|May 2000|2000-05-31|June 1992|Actual|1992-06-30|||||Observational|||Drug Etiology of Aplastic Anemia and Related Dyscrasias||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.854099|2018-06-01 05:38:31.854099
NCT00005301|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-14|2000-05-25|2000-05-26|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 1984||1984-09-30|August 2001|2001-08-31|February 1998||1998-02-28|||||Observational|||Transfusion Safety Study (TSS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.921272|2018-06-01 05:38:31.921272
NCT00005300|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-12|2000-05-25|2000-05-26|Estimate|||||||2016-04-12|2016-04-14|Estimate|October 1988||1988-10-31|May 2000|2000-05-31|June 1995||1995-06-30|||||Observational|||Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:31.992273|2018-06-01 05:38:31.992273
NCT00005299|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-10-26|2000-05-25|2000-05-26|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 1990||1990-08-31|October 2016|2016-10-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||Familial Aggregation and Natural History of Sleep Apnea||Completed|||726|Actual|Brigham and Women's Hospital|||||f||||||||||Samples With DNA|"~     Samples stored deidentified~   "|||2018-06-01 05:38:32.041745|2018-06-01 05:38:32.041745
NCT00005298|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1990||1990-07-31|June 2000|2000-06-30|June 1993|Actual|1993-06-30|||||Observational|||Inflammation, Autonomic Dysfunction and Airway Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.100065|2018-06-01 05:38:32.100065
NCT00005297|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 1990||1990-04-30|March 2005|2005-03-31|June 1997|Actual|1997-06-30|||||Observational|||Age-related Prevalence of Sleep Respiratory Disturbances||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.143972|2018-06-01 05:38:32.143972
NCT00005296|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-04-13|2000-05-25|2000-05-26|Estimate|||||||2018-04-13|2018-04-17|Actual|January 1990|Actual|1990-01-31|April 2018|2018-04-30||||January 18, 1995|Actual|1995-01-18||Observational|||Sleep Apnea: Age Effects On Prevalence and Natural History|Sleep Apnea: Age Effects On Prevalence and Natural History|Active, not recruiting|||741|Actual|Milton S. Hershey Medical Center|||||f||||f|f|f||||||||2018-06-01 05:38:32.189712|2018-06-01 05:38:32.189712
NCT00005295|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|July 1989||1989-07-31|January 2016|2016-01-31|June 1995||1995-06-30|||||Observational|||Idiopathic Pulmonary Fibrosis: a Case-control Study||Completed|||||University of New Mexico|||||f||||||||||||||2018-06-01 05:38:32.236474|2018-06-01 05:38:32.236474
NCT00005294|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1989||1989-07-31|April 2000|2000-04-30|June 1995|Actual|1995-06-30|||||Observational|||Developmental Sequelae of Severe Chronic Lung Disorders||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.282791|2018-06-01 05:38:32.282791
NCT00005293|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 1988||1988-12-31|April 2000|2000-04-30|November 1990|Actual|1990-11-30|||||Observational|||Antecedents of Bronchopulmonary Dysplasia||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.3213|2018-06-01 05:38:32.3213
NCT00005292|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-24|2000-05-25|2000-05-26|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 1988||1988-09-30|August 2004|2004-08-31|November 1999||1999-11-30|||||Observational|||Alpha1-antitrypsin Deficiency Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.364688|2018-06-01 05:38:32.364688
NCT00005291|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1988||1988-07-31|June 2000|2000-06-30|April 2003|Actual|2003-04-30|||||Observational|||Clinical Epidemiology of Asthma in An HMO||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.409531|2018-06-01 05:38:32.409531
NCT00005290|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 1988||1988-04-30|January 2016|2016-01-31|June 1997||1997-06-30|||||Observational|||Epidemiology of Interstitial Lung Disease||Completed|||||University of New Mexico|||||f||||||||||||||2018-06-01 05:38:32.445204|2018-06-01 05:38:32.445204
NCT00005289|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2008-07-23|2000-05-25|2000-05-26|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 1987||1987-07-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|||Risk Factors in Bronchopulmonary Dysplasia (Newborn Lung Project)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.508725|2018-06-01 05:38:32.508725
NCT00005288|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-01-13|2000-05-25|2000-05-26|Estimate|||||||2017-01-13|2017-01-16|Estimate|December 1986||1986-12-31|April 2001|2001-04-30|November 1991|Actual|1991-11-30|||||Observational|||Epidemiology and Pulmonary Response To Organic Dust Exposure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.572244|2018-06-01 05:38:32.572244
NCT00005287|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-08|2000-05-25|2000-05-26|Estimate|||||||2016-01-08|2016-01-12|Estimate|July 1986||1986-07-31|January 2016|2016-01-31|June 1989||1989-06-30|||||Observational|||Late Sequelae of Bronchopulmonary Dysplasia||Completed|||||Stanford University|||||f||||||||||||||2018-06-01 05:38:32.618968|2018-06-01 05:38:32.618968
NCT00005285|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1985||1985-07-31|April 2001|2001-04-30|November 1996|Actual|1996-11-30|||||Observational|||Effect of Maternal Smoking On Neonatal Lung Function||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.865952|2018-06-01 05:38:32.865952
NCT00005284|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 1985||1985-01-31|August 2004|2004-08-31|March 2002|Actual|2002-03-31|||||Observational|||Epidemiology of Airway Responsiveness||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:32.933377|2018-06-01 05:38:32.933377
NCT00005283|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1983||1983-07-31|May 2000|2000-05-31|June 1990|Actual|1990-06-30|||||Observational|||Risk Factors For Asthma in Laboratory Animal Allergy||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.031938|2018-06-01 05:38:33.031938
NCT00005282|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 1981||1981-12-31|April 2001|2001-04-30|November 1997|Actual|1997-11-30|||||Observational|||Prospective Evaluation of Airways Reactivity||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.132273|2018-06-01 05:38:33.132273
NCT00005281|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1977||1977-09-30|April 2001|2001-04-30|November 1998|Actual|1998-11-30|||||Observational|||Early Risk Predictors For Chronic Pulmonary Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.238562|2018-06-01 05:38:33.238562
NCT00005280|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 1972||1972-06-30|March 2005|2005-03-31|November 1991|Actual|1991-11-30|||||Observational|||Specialized Center of Research in Occupational and Immunologic Lung Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.321761|2018-06-01 05:38:33.321761
NCT00005279|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|June 1971||1971-06-30|May 2002|2002-05-31|November 1997|Actual|1997-11-30|||||Observational|||Tucson Epidemiology Study of Chronic Obstructive Lung Diseases||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.508983|2018-06-01 05:38:33.508983
NCT00005278|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-14|2000-05-25|2000-05-26|Estimate|||||||2016-04-14|2016-04-15|Estimate|July 1989||1989-07-31|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Observational|||Retrovirus Epidemiology Donor Study I (REDS I)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.708436|2018-06-01 05:38:33.708436
NCT00005277|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1977||1977-09-30|August 2004|2004-08-31|December 2000||2000-12-31|||||Observational|||Cooperative Study of The Clinical Course of Sickle Cell Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.805774|2018-06-01 05:38:33.805774
NCT00005276|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-24|2000-05-25|2000-05-26|Estimate|||||||2016-03-24|2016-03-25|Estimate|June 1995||1995-06-30|December 2005|2005-12-31|March 2003||2003-03-31|||||Observational|||A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:33.873621|2018-06-01 05:38:33.873621
NCT00005275|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2013-05-19|2000-05-25|2000-05-26|Estimate|||||||2013-05-19|2013-05-21|Estimate|September 1994||1994-09-30|May 2013|2013-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|SHHS||Sleep Heart Health Study (SHHS) Data Coordinating Center|The Sleep Heart Health Study (SHHS) Was a Multi-site Prospective Cohort Study to Investigate Obstructive Sleep Apnea (OSA) and Other Sleep-disordered Breathing (SDB) as Risk Factors for Cardiovascular Diseases and Hypertension|Completed|||6441|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||f||||||||||2018-06-01 05:38:33.958858|2018-06-01 05:38:33.958858
NCT00005274|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-13|2000-05-25|2000-05-26|Estimate|||||||2016-04-13|2016-04-14|Estimate|May 1989||1989-05-31|October 2005|2005-10-31|March 2003||2003-03-31|||||Observational|||Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.055971|2018-06-01 05:38:34.055971
NCT00005273|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1987||1987-09-30|March 2005|2005-03-31|May 1997|Actual|1997-05-31|||||Observational|||Pulmonary Complications of HIV Infection Study (PACS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.137019|2018-06-01 05:38:34.137019
NCT00005272|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-26|2000-05-25|2000-05-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|September 1990||1990-09-30|May 2000|2000-05-31|September 1992||1992-09-30|||||Observational|||Smoking and Body Weight: Analysis of HHANES||Completed|||||University of Memphis|||||f||||||||||||||2018-06-01 05:38:34.196152|2018-06-01 05:38:34.196152
NCT00005271|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-11|2000-05-25|2000-05-26|Estimate|||||||2016-01-11|2016-01-12|Estimate|July 1995||1995-07-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|August 2009|Actual|2009-08-31||Observational|||INTERMAP: International Population Study on Macronutrients and BP|INTERMAP: International Population Study on Macronutrients and BP|Completed|||4680|Actual|Northwestern University|||||f||||f||||||Samples Without DNA|"~     24 hour urine collection among all participants~   "|||2018-06-01 05:38:34.245667|2018-06-01 05:38:34.245667
NCT00005270|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-09-01|2000-05-25|2000-05-26|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 1995||1995-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Family Blood Pressure Program - SAPPHIRe Network||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.310339|2018-06-01 05:38:34.310339
NCT00005269|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2008-08-20|2000-05-25|2000-05-26|Estimate|||||||2008-08-20|2008-08-21|Estimate|September 1995||1995-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Family Blood Pressure Program - GENOA||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.369963|2018-06-01 05:38:34.369963
NCT00005268|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-08-05|2000-05-25|2000-05-26|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 1995||1995-09-30|August 2008|2008-08-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Family Blood Pressure Program - GenNet Network||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.442136|2018-06-01 05:38:34.442136
NCT00005267|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-10-06|2000-05-25|2000-05-26|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 1995||1995-09-30|June 2012|2012-06-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Family Blood Pressure Program - HyperGEN||Completed|||3604|Actual|University of Alabama at Birmingham|||||f||||||||||Samples With DNA|"~     Tissue suitable for DNA extraction~   "|||2018-06-01 05:38:34.5085|2018-06-01 05:38:34.5085
NCT00005266|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1990||1990-09-30|May 2000|2000-05-31|September 1992|Actual|1992-09-30|||||Observational|||Cardiovascular Disease Mortality in The NAS-NRC Twin Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.576766|2018-06-01 05:38:34.576766
NCT00005265|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1990||1990-09-30|November 2001|2001-11-30|May 1992|Actual|1992-05-31|||||Observational|||Natural History of Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.625367|2018-06-01 05:38:34.625367
NCT00005264|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1990||1990-09-30|October 2002|2002-10-31|September 1996|Actual|1996-09-30|||||Observational|||Pediatric Epidemiology of Cardiovascular Disease Risk Factors (Project Heartbeat)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.660928|2018-06-01 05:38:34.660928
NCT00005263|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-22|2000-05-25|2000-05-26|Estimate|||||||2015-12-22|2015-12-24|Estimate|July 1990||1990-07-31|December 2015|2015-12-31|November 1995|Actual|1995-11-30|November 1995|Actual|1995-11-30||Observational|||Postprandial Lipoproteins and Atherosclerosis|Association of Postprandial Triglyceride and Retinyl Palmitate Responses With Newly Diagnosed Exercise-induced Myocardial Ischemia in Middle-aged Men and Women|Completed|||205|Actual|Columbia University|||||f||||f||||||||||2018-06-01 05:38:34.700138|2018-06-01 05:38:34.700138
NCT00005262|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1990||1990-07-31|May 2000|2000-05-31|June 1996|Actual|1996-06-30|||||Observational|||Epidemiology of Idiopathic Dilated Cardiomyopathy (Washington, DC Dilated Cardiomyopathy Study)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.751192|2018-06-01 05:38:34.751192
NCT00005261|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-19|2000-05-25|2000-05-26|Estimate|||||||2016-01-19|2016-01-21|Estimate|July 1990||1990-07-31|January 2016|2016-01-31|June 1993||1993-06-30|||||Observational|||Urinary Kallikrein and Hypertension: A Prospective Study||Completed|||||University of Utah|||||f||||||||||||||2018-06-01 05:38:34.801659|2018-06-01 05:38:34.801659
NCT00005260|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1990||1990-07-31|July 2005|2005-07-31|August 2002|Actual|2002-08-31|||||Observational|||Mechanisms Underlying Psychosocial Associations With Ischemic Heart Disease (Kuopio)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.84215|2018-06-01 05:38:34.84215
NCT00005259|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-10-28|2000-05-25|2000-05-26|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 1990||1990-07-31|October 2016|2016-10-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Observational|||Polyunsaturated Fats and Risk of Primary Cardiac Arrest||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:34.904192|2018-06-01 05:38:34.904192
NCT00005258|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|June 1990||1990-06-30|November 2001|2001-11-30|May 1993|Actual|1993-05-31|||||Observational|||Family Study of Congenital Cardiovascular Malformations||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:34.965642|2018-06-01 05:38:34.965642
NCT00005257|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1990||1990-05-31|March 2005|2005-03-31|April 1992|Actual|1992-04-30|||||Observational|||Diet and Plasma Cholesterol - Secular Trend Analysis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.089745|2018-06-01 05:38:35.089745
NCT00005256|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 1990||1990-05-31|April 2000|2000-04-30|August 1996|Actual|1996-08-31|||||Observational|||Coronary Screening in a High Risk Subset||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.145228|2018-06-01 05:38:35.145228
NCT00005255|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 1990||1990-05-31|May 2000|2000-05-31|April 1995|Actual|1995-04-30|||||Observational|||Ischemic Heart Disease Incidence and Indices of Body-fat Distribution||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.227758|2018-06-01 05:38:35.227758
NCT00005254|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 1990||1990-04-30|June 2000|2000-06-30|March 1995|Actual|1995-03-31|||||Observational|||Natural History of Peripheral Arterial Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.290734|2018-06-01 05:38:35.290734
NCT00005253|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|January 1990||1990-01-31|January 2006|2006-01-31|January 2000||2000-01-31|||||Observational|||Proarrhythmic Medicines and Primary Cardiac Arrest||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:35.3512|2018-06-01 05:38:35.3512
NCT00005252|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 1990||1990-01-31|August 2004|2004-08-31|December 1992|Actual|1992-12-31|||||Observational|||Physicians' Health Study: Study of Low Cardiovascular Disease Mortality||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.408789|2018-06-01 05:38:35.408789
NCT00005251|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 1990||1990-01-31|June 2000|2000-06-30|March 1995|Actual|1995-03-31|||||Observational|||Genetic Analysis of Familial Hypertrophic Cardiomyopathy||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.478929|2018-06-01 05:38:35.478929
NCT00005250|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1990||1990-01-31|November 2001|2001-11-30|December 1992|Actual|1992-12-31|||||Observational|||Linkage Study of Long QT Syndrome In An Amish Kindred||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.533043|2018-06-01 05:38:35.533043
NCT00005249|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1989||1989-09-30|April 2000|2000-04-30|August 1991|Actual|1991-08-31|||||Observational|||Epidemiology of Blood Pressure, Insulin, Salt Transport||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.585923|2018-06-01 05:38:35.585923
NCT00005248|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1989||1989-08-31|May 2002|2002-05-31|July 1992|Actual|1992-07-31|||||Observational|||Adiposity and Fat Patterning in Black Americans||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.634736|2018-06-01 05:38:35.634736
NCT00005247|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1989||1989-08-31|May 2000|2000-05-31|July 1992|Actual|1992-07-31|||||Observational|||Nutritional Determinants of Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.685027|2018-06-01 05:38:35.685027
NCT00005246|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1989||1989-08-31|May 2000|2000-05-31|July 1991|Actual|1991-07-31|||||Observational|||Epidemiology of Insulin and Dehydroepiandrosterone Sulfate and Coronary Heart Disease Mortality||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.735153|2018-06-01 05:38:35.735153
NCT00005245|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-04|2000-05-25|2000-05-26|Estimate|||||||2016-02-04|2016-02-05|Estimate|June 1989||1989-06-30|February 2016|2016-02-29|May 1993|Actual|1993-05-31|May 1993|Actual|1993-05-31||Observational|||Community Structure and Cardiovascular Mortality Trends|Community Structure and Cardiovascular Mortality Trends|Completed|||||University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 05:38:35.788178|2018-06-01 05:38:35.788178
NCT00005244|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1989||1989-04-30|March 2005|2005-03-31|March 1991|Actual|1991-03-31|||||Observational|||Anger Expression, Self-focus and Coronary Heart Disease Risk Factors||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.8762|2018-06-01 05:38:35.8762
NCT00005243|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1989||1989-04-30|December 2005|2005-12-31|August 2004|Actual|2004-08-31|||||Observational|||Triggers of Ventricular Arrhythmias (TOVA) Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:35.951458|2018-06-01 05:38:35.951458
NCT00005242|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 1989||1989-04-30|February 2016|2016-02-29|June 1994||1994-06-30|||||Observational|||Childhood Passive Smoking: Cohort Study of Cardiac Risk||Completed|||||Virginia Commonwealth University|||||f||||||||||||||2018-06-01 05:38:36.012036|2018-06-01 05:38:36.012036
NCT00005241|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1989||1989-04-30|June 2001|2001-06-30|December 1999|Actual|1999-12-31|||||Observational|||Myocardial Infarction and Current Oral Contraceptive Use||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.060579|2018-06-01 05:38:36.060579
NCT00005240|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-22|2000-05-25|2000-05-26|Estimate|||||||2015-12-22|2015-12-24|Estimate|October 1989||1989-10-31|December 2015|2015-12-31|December 1992|Actual|1992-12-31|June 1991|Actual|1991-06-30||Observational|||Epidemiology of Hypertensive Emergency|Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population|Completed|||210|Actual|Columbia University|||||f||||f||||||||||2018-06-01 05:38:36.110759|2018-06-01 05:38:36.110759
NCT00005239|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 1989||1989-01-31|June 2004|2004-06-30|December 1991|Actual|1991-12-31|||||Observational|||Genetic Epidemiology of Coronary Heart Disease Risk in Women Twins||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.168736|2018-06-01 05:38:36.168736
NCT00005238|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-21|2000-05-25|2000-05-26|Estimate|||||||2015-12-21|2015-12-23|Estimate|December 1988||1988-12-31|December 2004|2004-12-31|December 2001||2001-12-31|||||Observational|||Antecedents of Hypertension: Role of Race and Stress||Completed|||||Augusta University|||||f||||||||||||||2018-06-01 05:38:36.22187|2018-06-01 05:38:36.22187
NCT00005237|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 1988||1988-12-31|May 2000|2000-05-31|November 1993|Actual|1993-11-30|||||Observational|||Epidemiology of Symptomatic Arrhythmias||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.294568|2018-06-01 05:38:36.294568
NCT00005236|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 1988||1988-12-31|April 2000|2000-04-30|November 1994|Actual|1994-11-30|||||Observational|||Atherosclerosis and Omega-3 Fatty Acids in Alaskan Natives||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.348984|2018-06-01 05:38:36.348984
NCT00005235|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-22|2000-05-25|2000-05-26|Estimate|||||||2015-12-22|2015-12-24|Estimate|December 1988||1988-12-31|December 2015|2015-12-31|September 1993|Actual|1993-09-30|September 1993|Actual|1993-09-30||Observational|||Heart Rate Variability and Sudden Cardiac Death|The Ability of Several Short-term Measures of RR Variability to Predict Mortality After Myocardial Infarction|Completed|||715|Actual|Columbia University|||||f||||f||||||||||2018-06-01 05:38:36.394739|2018-06-01 05:38:36.394739
NCT00005234|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1988||1988-09-30|April 2000|2000-04-30|August 1993|Actual|1993-08-31|||||Observational|||Cardiovascular Disease in Black Versus White Physicians||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.458262|2018-06-01 05:38:36.458262
NCT00005233|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1988||1988-09-30|July 2002|2002-07-31|August 1992|Actual|1992-08-31|||||Observational|||Patterns of Fatty Acids in Framingham Offspring||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.497412|2018-06-01 05:38:36.497412
NCT00005232|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1988||1988-08-31|June 2000|2000-06-30|July 1993|Actual|1993-07-31|||||Observational|||Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.548136|2018-06-01 05:38:36.548136
NCT00005231|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1988||1988-07-31|June 2000|2000-06-30|June 1991|Actual|1991-06-30|||||Observational|||Development, Testing, and Validation of A Protocol To Assess Cardiovascular Reactivity in Human Populations||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.601854|2018-06-01 05:38:36.601854
NCT00005230|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1988||1988-07-31|December 2004|2004-12-31|June 2003|Actual|2003-06-30|||||Observational|||Epidemiology of Carotid Disease in Elderly Adults||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.644466|2018-06-01 05:38:36.644466
NCT00005229|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1988||1988-07-31|December 2001|2001-12-31|June 1993|Actual|1993-06-30|||||Observational|||HIV-Associated Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.697782|2018-06-01 05:38:36.697782
NCT00005228|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1988||1988-07-31|December 2001|2001-12-31|June 1993|Actual|1993-06-30|||||Observational|||AIDS-Associated Heart Disease -- Incidence and Etiology||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.737259|2018-06-01 05:38:36.737259
NCT00005227|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1988||1988-07-31|March 2005|2005-03-31|June 1993|Actual|1993-06-30|||||Observational|||AIDS-Associated Cardiomyopathy||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.810403|2018-06-01 05:38:36.810403
NCT00005226|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-24|2000-05-25|2000-05-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 1988||1988-07-31|February 2016|2016-02-29|June 1992||1992-06-30|||||Observational|||Epidemiology of Plasma Fatty Acids and Atherosclerosis||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:36.86315|2018-06-01 05:38:36.86315
NCT00005225|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-19|2000-05-25|2000-05-26|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 1988||1988-04-30|January 2016|2016-01-31|March 1991||1991-03-31|||||Observational|||Apolipoprotein Polymorphisms and Risk of Coronary Heart Disease||Completed|||||University of Utah|||||f||||||||||||||2018-06-01 05:38:36.904796|2018-06-01 05:38:36.904796
NCT00005224|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1988||1988-04-30|March 2005|2005-03-31|March 1990|Actual|1990-03-31|||||Observational|||Gender Response To Coronary Risk||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.94568|2018-06-01 05:38:36.94568
NCT00005223|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1988||1988-04-30|April 2001|2001-04-30|March 1993|Actual|1993-03-31|||||Observational|||Epidemiology of APO- and Lipoproteins in Elderly Women||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:36.997097|2018-06-01 05:38:36.997097
NCT00005222|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1988||1988-04-30|April 2000|2000-04-30|March 1996|Actual|1996-03-31|||||Observational|||Decline in Cardiovascular Mortality: Framingham 1950-1984||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:37.053556|2018-06-01 05:38:37.053556
NCT00005221|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2012-05-15|2000-05-25|2000-05-26|Estimate|||||||2012-05-15|2012-05-17|Estimate|April 1988||1988-04-30|May 2012|2012-05-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Analysis of Longitudinal Cardiopulmonary Data||Completed|||60000|Actual|Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:38:37.097605|2018-06-01 05:38:37.097605
NCT00005220|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|April 1988||1988-04-30|June 2000|2000-06-30|January 1999||1999-01-31|||||Observational|||Postmenopausal Progestins, MI and Stroke||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:38.162764|2018-06-01 05:38:38.162764
NCT00005219|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-04-16|2000-05-25|2000-05-26|Estimate|||||||2018-04-16|2018-04-18|Actual|April 1988|Actual|1988-04-30|April 2018|2018-04-30|April 1991|Actual|1991-04-30|April 1990|Actual|1990-04-30||Observational|||Predicting Physical Activity Change: an Epidemiologic Study|Predicting Physical Activity Change: an Epidemiologic Study|Completed|||75|Actual|San Diego State University|||1||f||||f|f|f||||||No||2018-06-01 05:38:38.208459|2018-06-01 05:38:38.208459
NCT00005218|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1988||1988-04-30|April 2002|2002-04-30|March 1990|Actual|1990-03-31|||||Observational|||Epidemiological Tool To Detect Angina Pectoris in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.258157|2018-06-01 05:38:38.258157
NCT00005217|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-27|2000-05-25|2000-05-26|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 1988||1988-04-30|January 2016|2016-01-31|March 1991||1991-03-31|||||Observational|||Intermittent ST Depression and Prognosis After Myocardial Infarction||Completed|||||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:38:38.297574|2018-06-01 05:38:38.297574
NCT00005216|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 1988||1988-04-30|January 2016|2016-01-31|December 1994||1994-12-31|||||Observational|||Multicenter Study of Silent Myocardial Ischemia (MSSMI)||Completed|||||University of Rochester|||||f||||||||||||||2018-06-01 05:38:38.343108|2018-06-01 05:38:38.343108
NCT00005215|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 1988||1988-04-30|May 2000|2000-05-31|March 1992|Actual|1992-03-31|||||Observational|||Lipoprotein Subfractions and Coronary Heart Disease During 25 Year Follow-up||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.391493|2018-06-01 05:38:38.391493
NCT00005214|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1988||1988-04-30|May 2000|2000-05-31|March 1993||1993-03-31|||||Observational|||Epidemiology of Genetic Factors in Lipid Metabolism||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.431974|2018-06-01 05:38:38.431974
NCT00005213|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|March 1988||1988-03-31|June 2000|2000-06-30|February 1990|Actual|1990-02-28|||||Observational|||Lithium Countertransport and Blood Pressure In CARDIA and TOMHS||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.482051|2018-06-01 05:38:38.482051
NCT00005212|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 1988||1988-03-31|May 2000|2000-05-31|February 1993|Actual|1993-02-28|||||Observational|||Work Organization and Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.520604|2018-06-01 05:38:38.520604
NCT00005211|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-11|2000-05-25|2000-05-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|October 1987||1987-10-31|November 2001|2001-11-30|September 1990|Actual|1990-09-30|||||Observational|||Cardiovascular Mortality Among Tunnel and Bridge Workers Exposed To Carbon Monoxide||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.6628|2018-06-01 05:38:38.6628
NCT00005210|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 1987||1987-09-30|June 2000|2000-06-30|September 1992|Actual|1992-09-30|||||Observational|||Sex Steroids, Obesity and Lipids in Adolescent Females||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.731837|2018-06-01 05:38:38.731837
NCT00005209|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 1987||1987-08-31|January 2008|2008-01-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Observational|||Genetic Epidemiology of Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.805159|2018-06-01 05:38:38.805159
NCT00005208|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 1987||1987-09-30|May 2000|2000-05-31|July 1992|Actual|1992-07-31|||||Observational|||Regulation of Placental Vascular Reactivity in Pregnancy-induced Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:38.916102|2018-06-01 05:38:38.916102
NCT00005207|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1987||1987-09-30|May 2000|2000-05-31|July 1992|Actual|1992-07-31|||||Observational|||Renin and Prorenin in Pregnancy||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:39.097758|2018-06-01 05:38:39.097758
NCT00005206|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1987||1987-09-30|April 2002|2002-04-30|August 1991|Actual|1991-08-31|||||Observational|||Calcium Intake, Metabolism, and Gestational Blood Pressure||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:39.206253|2018-06-01 05:38:39.206253
NCT00005205|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-07|2000-05-25|2000-05-26|Estimate|||||||2016-03-07|2016-03-08|Estimate|August 1987||1987-08-31|March 2016|2016-03-31|July 2003||2003-07-31|||||Observational|||Incidence of Diabetes and Cardiovascular Disease in Mexican Americans|Incidence of Diabetes and Cardiovascular Disease in Mexican Americans|Completed|||||The University of Texas Health Science Center at San Antonio|||||f||||f||||||||No||2018-06-01 05:38:39.53541|2018-06-01 05:38:39.53541
NCT00005204|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1987||1987-08-31|November 2001|2001-11-30|July 1989|Actual|1989-07-31|||||Observational|||Blood Pressure and Diurnal Variation in Sodium, Potassium, and Water Excretion||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:39.703869|2018-06-01 05:38:39.703869
NCT00005203|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-08|2000-05-25|2000-05-26|Estimate|||||||2016-02-08|2016-02-10|Estimate|July 1987||1987-07-31|August 2004|2004-08-31|June 1992||1992-06-30|||||Observational|||Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia||Completed|||||University of Washington|||||f||||||||||||||2018-06-01 05:38:39.742924|2018-06-01 05:38:39.742924
NCT00005202|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1987||1987-07-31|May 2000|2000-05-31|June 1992|Actual|1992-06-30|||||Observational|||Identifying High Risk Patients With Syncope||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:39.795766|2018-06-01 05:38:39.795766
NCT00005201|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1987||1987-07-31|May 2000|2000-05-31|June 1992|Actual|1992-06-30|||||Observational|||Idiopathic Dilated Cardiomyopathy||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:39.994853|2018-06-01 05:38:39.994853
NCT00005200|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1987||1987-07-31|April 2000|2000-04-30|June 1991|Actual|1991-06-30|||||Observational|||Adolescent Blood Pressure Variation and Ventricular Mass||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:40.500762|2018-06-01 05:38:40.500762
NCT00005199|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1987||1987-06-30|May 2000|2000-05-31|November 1994||1994-11-30|||||Observational|||Balloon Valvuloplasty Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:42.022861|2018-06-01 05:38:42.022861
NCT00005198|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1987||1987-04-30|August 2001|2001-08-31|March 1998|Actual|1998-03-31|||||Observational|||Survival After Myocardial Infarction in A Biethnic Texas Community (Corpus Christi Heart Project)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:44.276082|2018-06-01 05:38:44.276082
NCT00005197|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 1986||1986-12-31|May 2000|2000-05-31|November 1991|Actual|1991-11-30|||||Observational|||Predictors of Perioperative Cardiac Morbidity||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:44.415018|2018-06-01 05:38:44.415018
NCT00005196|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 1986||1986-12-31|May 2009|2009-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Observational|||Worcester Heart Attack Community Surveillance Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:44.661479|2018-06-01 05:38:44.661479
NCT00005195|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1986||1986-09-30|September 2002|2002-09-30|August 1991|Actual|1991-08-31|||||Observational|||Catheter Ablation Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:44.800155|2018-06-01 05:38:44.800155
NCT00005194|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1986||1986-09-30|June 2000|2000-06-30|August 1991|Actual|1991-08-31|||||Observational|||Insulin and Biogenic Amines in Cardiovascular Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:44.857954|2018-06-01 05:38:44.857954
NCT00005193|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1986||1986-09-30|September 2002|2002-09-30|August 1990|Actual|1990-08-31|||||Observational|||Prospective Study of Diabetes-related Vascular Disease in Oklahoma Indians||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:44.946631|2018-06-01 05:38:44.946631
NCT00005192|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-14|2000-05-25|2000-05-26|Estimate|||||||2016-01-14|2016-01-15|Estimate|July 1986||1986-07-31|January 2016|2016-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||Psychophysiology of Cardiovascular Reactivity||Completed|||||University of Miami|||||f||||||||||||||2018-06-01 05:38:45.027503|2018-06-01 05:38:45.027503
NCT00005191|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1986||1986-07-31|April 2002|2002-04-30|March 2001|Actual|2001-03-31|||||Observational|||Clinical Course of Coronary Artery Disease Among Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.137242|2018-06-01 05:38:45.137242
NCT00005190|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1986||1986-07-31|October 2001|2001-10-31|December 1998|Actual|1998-12-31|||||Observational|||Reproduction and Survival After Cardiac Defect Repair||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.271431|2018-06-01 05:38:45.271431
NCT00005189|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1986||1986-07-31|November 2002|2002-11-30|April 1999|Actual|1999-04-30|||||Observational|||Carotid Atherosclerosis Follow-up Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.365718|2018-06-01 05:38:45.365718
NCT00005188|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 1986||1986-07-31|August 2004|2004-08-31|June 1991|Actual|1991-06-30|||||Observational|||Quantitative Genetic Analysis of Lipid Research Clinic Family Data||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.433063|2018-06-01 05:38:45.433063
NCT00005187|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1986||1986-04-30|April 2000|2000-04-30|March 1991||1991-03-31|||||Observational|||Cardiovascular Risk Profile Among Mexican-Americans||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.539274|2018-06-01 05:38:45.539274
NCT00005186|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1986||1986-04-30|March 2005|2005-03-31|June 1992|Actual|1992-06-30|||||Observational|||Epidemiology of Cardiovascular Diseases in The Elderly||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.630652|2018-06-01 05:38:45.630652
NCT00005185|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1986||1986-04-30|May 2000|2000-05-31|March 1990|Actual|1990-03-31|||||Observational|||Myocardial Infarction and Non-contraceptive Estrogen Use||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.70517|2018-06-01 05:38:45.70517
NCT00005184|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 1985||1985-12-31|May 2000|2000-05-31|November 1989|Actual|1989-11-30|||||Observational|||Immunogenetic Factors of Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:45.796022|2018-06-01 05:38:45.796022
NCT00005183|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2017-12-19|2000-05-25|2000-05-26|Estimate|||||||2017-12-19|2017-12-21|Actual|December 1985||1985-12-31|December 2017|2017-12-31|November 1988||1988-11-30|||||Observational|||Apolipoprotein A-I Gene Polymorphism and Atherosclerosis|Apolipoprotein A-I Gene Polymorphism and Atherosclerosis|Completed|||||Tufts University|||||f|||||f|f||||||||2018-06-01 05:38:45.879122|2018-06-01 05:38:45.879122
NCT00005182|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-02-27|2000-05-25|2000-05-26|Estimate|||||||2018-02-27|2018-02-28|Actual|December 1985||1985-12-31|February 2018|2018-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Health Professionals Follow-up Study||Completed|||50000|Actual|Harvard School of Public Health|||||f||||||||||Samples With DNA|"~     plasma, RBC, WBC~   "|||2018-06-01 05:38:46.010713|2018-06-01 05:38:46.010713
NCT00005181|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-02-24|2000-05-25|2000-05-26|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2000||2000-07-31|February 2014|2014-02-28|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Observational|||Blood Pressure Control in Juveniles - Longitudinal Study||Completed|||||Indiana University|||||f||||||||||||||2018-06-01 05:38:46.157847|2018-06-01 05:38:46.157847
NCT00005180|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1985||1985-09-30|May 2000|2000-05-31|June 1995|Actual|1995-06-30|||||Observational|||End-organ Pathology in Childhood Essential Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:46.217127|2018-06-01 05:38:46.217127
NCT00005179|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-21|2000-05-25|2000-05-26|Estimate|||||||2015-12-21|2015-12-23|Estimate|September 1985||1985-09-30|April 2000|2000-04-30|June 1990||1990-06-30|||||Observational|||Diet, Exercise and Cardiovascular Health Among Ethnic Children||Completed|||||Augusta University|||||f||||||||||||||2018-06-01 05:38:46.267766|2018-06-01 05:38:46.267766
NCT00005178|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-12-21|2000-05-25|2000-05-26|Estimate|||||||2015-12-21|2015-12-23|Estimate|September 1985||1985-09-30|December 2000|2000-12-31|August 1991||1991-08-31|||||Observational|||Study of Children's Activity and Nutrition (SCAN)||Completed|||||Augusta University|||||f||||||||||||||2018-06-01 05:38:46.324514|2018-06-01 05:38:46.324514
NCT00005177|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1985||1985-09-30|June 2000|2000-06-30|November 1996|Actual|1996-11-30|||||Observational|||Reno Diet Heart Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:46.388718|2018-06-01 05:38:46.388718
NCT00005176|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-10-20|2000-05-25|2000-05-26|Estimate|||||||2015-10-20|2015-10-22|Estimate|August 1985||1985-08-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|LQTS||Long QT Syndrome-Population Genetics and Cardiac Studies|Long QT Syndrome-Population Genetics and Cardiac Studies|Completed|||2125|Actual|University of Rochester|||||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-06-01 05:38:46.452521|2018-06-01 05:38:46.452521
NCT00005175|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1985||1985-07-31|May 2000|2000-05-31|June 1990|Actual|1990-06-30|||||Observational|||Coronary Heart Disease Risk Factors in Upwardly Mobile Blacks and Whites||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:46.678055|2018-06-01 05:38:46.678055
NCT00005174|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1985||1985-07-31|July 2000|2000-07-31|June 1990|Actual|1990-06-30|||||Observational|||Western Collaborative Group Study (WCGS): 25-Year Follow-up of Cardiovascular Disease Morbidity and Mortality||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:46.815449|2018-06-01 05:38:46.815449
NCT00005173|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1985||1985-04-30|July 2000|2000-07-31|April 1989|Actual|1989-04-30|||||Observational|||Myocardial Infarction and Past Oral Contraceptive Use||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:46.897083|2018-06-01 05:38:46.897083
NCT00005172|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 1984||1984-12-31|August 2004|2004-08-31|April 1997|Actual|1997-04-30|||||Observational|||Socioeconomic Status, John Henryism and Hypertension Risk in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:46.966077|2018-06-01 05:38:46.966077
NCT00005171|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 1984||1984-12-31|June 2000|2000-06-30|March 1993|Actual|1993-03-31|||||Observational|||Cardiovascular Risk Factors in United States Adolescents and Adults||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.039943|2018-06-01 05:38:47.039943
NCT00005170|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 1984||1984-12-31|April 2000|2000-04-30|February 1993|Actual|1993-02-28|||||Observational|||Ambulatory Blood Pressure and Behavior||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.122091|2018-06-01 05:38:47.122091
NCT00005169|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1984||1984-09-30|October 2002|2002-10-31|June 2000||2000-06-30|||||Observational|||Lifestyle and Chronic Disease in College Alumni (Harvard Alumni Health Study)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.216413|2018-06-01 05:38:47.216413
NCT00005168|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1984||1984-08-31|May 2000|2000-05-31|December 1991|Actual|1991-12-31|||||Observational|||Hyperapo B and Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.297222|2018-06-01 05:38:47.297222
NCT00005167|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1984||1984-07-31|April 2000|2000-04-30|December 1991|Actual|1991-12-31|||||Observational|||Diet Modification and Blood Pressure in Young People||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.381451|2018-06-01 05:38:47.381451
NCT00005166|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1984||1984-04-30|May 2000|2000-05-31|March 1996|Actual|1996-03-31|||||Observational|||Sodium Transport: Genetics and Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.460448|2018-06-01 05:38:47.460448
NCT00005165|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 1984||1984-01-31|April 2000|2000-04-30|March 1995|Actual|1995-03-31|||||Observational|||Charleston Heart Study - Predictors of Coronary Disease in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.553596|2018-06-01 05:38:47.553596
NCT00005164|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1983||1983-09-30|June 2000|2000-06-30|August 1991|Actual|1991-08-31|||||Observational|||Insulin Resistance and Blood Pressure Regulation in Blacks||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.622444|2018-06-01 05:38:47.622444
NCT00005163|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1983||1983-09-30|May 2000|2000-05-31|May 1989|Actual|1989-05-31|||||Observational|||Validation and Field Test for Risk Appraisal Instruments||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.698593|2018-06-01 05:38:47.698593
NCT00005162|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1983||1983-08-31|May 2000|2000-05-31|November 1996|Actual|1996-11-30|||||Observational|||Epidemiology of Decline in Heart Disease Mortality||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:47.763022|2018-06-01 05:38:47.763022
NCT00005161|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-04|2000-05-25|2000-05-26|Estimate|||||||2016-03-04|2016-03-08|Estimate|August 1983||1983-08-31|March 2016|2016-03-31|July 1993||1993-07-31|||||Observational|||Longitudinal Twin Study - Cohort Study of Blood Pressure||Completed|||||Virginia Commonwealth University|||||f||||||||||||||2018-06-01 05:38:47.822582|2018-06-01 05:38:47.822582
NCT00005160|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-12|2000-05-25|2000-05-26|Estimate|||||||2016-01-12|2016-01-13|Estimate|April 1983||1983-04-30|January 2016|2016-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Epidemiology of Cardiovascular Risk Factors in Women (Healthy Women Study)|Epidemiology of Cardiovascular Risk Factors in Women (Healthy Women Study)|Completed|||532|Actual|University of Pittsburgh|||||f||||t||||||Samples Without DNA|"~     Plasma and serum samples from baseline and follow up exams stored at -80 degrees Celsius in~     the Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh.~   "|||2018-06-01 05:38:47.911206|2018-06-01 05:38:47.911206
NCT00005159|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-08-05|2000-05-25|2000-05-26|Estimate|||||||2016-08-05|2016-08-08|Estimate|July 1983||1983-07-31|April 2012|2012-04-30|December 2009|Actual|2009-12-31|||||Observational|||National Longitudinal Mortality Study (NLMS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:48.040216|2018-06-01 05:38:48.040216
NCT00005158|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1982||1982-07-31|June 2000|2000-06-30|June 1991|Actual|1991-06-30|||||Observational|||Segregation/Linkage Analysis for Hypertension||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:48.103902|2018-06-01 05:38:48.103902
NCT00005157|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1982||1982-07-31|May 2000|2000-05-31|November 1989|Actual|1989-11-30|||||Observational|||Speech Characteristics in Coronary Heart Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:48.15644|2018-06-01 05:38:48.15644
NCT00005156|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-29|2000-05-25|2000-05-26|Estimate|||||||2016-02-29|2016-03-01|Estimate|April 1982||1982-04-30|February 2016|2016-02-29|July 1996||1996-07-31|||||Observational|||Mortality Surveillance of MRFIT Screenees||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:48.232742|2018-06-01 05:38:48.232742
NCT00005155|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 1982||1982-02-28|May 2000|2000-05-31|January 1989|Actual|1989-01-31|||||Observational|||Physiological and Psychosocial Correlates of Type A Behavior||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:48.322838|2018-06-01 05:38:48.322838
NCT00005154|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2009-04-13|2000-05-25|2000-05-26|Estimate|||||||2009-04-13|2009-04-14|Estimate|July 1981||1981-07-31|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||National Health and Nutrition Examination Survey IV (NHANES (IV)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:48.37071|2018-06-01 05:38:48.37071
NCT00005153|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|December 1980||1980-12-31|October 2001|2001-10-31|November 1998|Actual|1998-11-30|||||Observational|||Etiologic Risk Factors of Cardiovascular Malformations||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:48.426966|2018-06-01 05:38:48.426966
NCT00005152|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-01-18|2000-05-25|2000-05-26|Estimate|||||||2018-01-18|2018-01-23|Actual|August 1980||1980-08-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Nurses' Health Study (Cardiovascular Component)|Nurses' Health Study (Cardiovascular Component)|Active, not recruiting|||121700|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-06-01 05:38:48.506969|2018-06-01 05:38:48.506969
NCT00005151|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1980||1980-08-31|July 2000|2000-07-31|July 1997|Actual|1997-07-31|||||Observational|||Pawtucket Heart Health Program||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:48.639327|2018-06-01 05:38:48.639327
NCT00005150|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-24|2000-05-25|2000-05-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 1980||1980-07-31|February 2016|2016-02-29|June 1993||1993-06-30|||||Observational|||Minnesota Heart Health Program||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:48.723829|2018-06-01 05:38:48.723829
NCT00005149|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-19|2000-05-25|2000-05-26|Estimate|||||||2016-01-19|2016-01-21|Estimate|February 1980||1980-02-29|January 2016|2016-01-31|November 1992||1992-11-30|||||Observational|||Genetic and Environmental Determinants of Hypertension||Completed|||||University of Utah|||||f||||||||||||||2018-06-01 05:38:48.904702|2018-06-01 05:38:48.904702
NCT00005148|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1979||1979-09-30|April 2000|2000-04-30|August 1991|Actual|1991-08-31|||||Observational|||Coronary Heart Disease Incidence, Mortality, and Risk Factor Relationships||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:49.018149|2018-06-01 05:38:49.018149
NCT00005147|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1979||1979-09-30|April 2000|2000-04-30|June 1991|Actual|1991-06-30|||||Observational|||Epidemiology of Atherosclerosis||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:49.110627|2018-06-01 05:38:49.110627
NCT00005146|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-07|2000-05-25|2000-05-26|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 1979||1979-05-31|March 2016|2016-03-31|August 2002|Actual|2002-08-31|||||Observational|||Diabetes and Cardiovascular Risk In Mexico City (San Antonio Heart Study)|Diabetes and Cardiovascular Risk In Mexico City (San Antonio Heart Study)|Completed|||||The University of Texas Health Science Center at San Antonio|||||f||||f||||||||No||2018-06-01 05:38:49.204397|2018-06-01 05:38:49.204397
NCT00005145|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-03|2000-05-25|2000-05-26|Estimate|||||||2016-02-03|2016-02-05|Estimate|April 1979||1979-04-30|February 2016|2016-02-29|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Observational|MHS||Minnesota Heart Survey - Risk Factor Survey|Study of Trends in Cardiovascular Risk Factors in an Urban Population.|Completed|||||University of Minnesota - Clinical and Translational Science Institute|||1||f||||||||||||||2018-06-01 05:38:49.378349|2018-06-01 05:38:49.378349
NCT00005144|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|August 1978||1978-08-31|April 2000|2000-04-30|June 1991|Actual|1991-06-30|||||Observational|||Coronary-Prone Behavior and Cardiovascular Reactivity||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:49.504877|2018-06-01 05:38:49.504877
NCT00005143|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2005-06-23|2000-05-25|2000-05-26|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1978||1978-07-31|March 2005|2005-03-31|February 1998||1998-02-28|||||Observational|||Stanford Five-City Multifactor Risk Reduction Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:49.607235|2018-06-01 05:38:49.607235
NCT00005142|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-26|2000-05-25|2000-05-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 1978||1978-07-31|June 2000|2000-06-30|March 1990|Actual|1990-03-31|||||Observational|||Etiology and Prevalence of Peripheral Arterial Disease||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:49.697767|2018-06-01 05:38:49.697767
NCT00005141|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1977||1977-09-30|June 2000|2000-06-30|May 1997|Actual|1997-05-31|||||Observational|||Minneapolis Children's Blood Pressure Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:49.771417|2018-06-01 05:38:49.771417
NCT00005140|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-02-17|2000-05-25|2000-05-26|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1977||1977-09-30|January 2008|2008-01-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Observational|||Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:49.856631|2018-06-01 05:38:49.856631
NCT00005139|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-01-19|2000-05-25|2000-05-26|Estimate|||||||2016-01-19|2016-01-21|Estimate|July 1977||1977-07-31|January 2016|2016-01-31|December 1991||1991-12-31|||||Observational|||Characterization Of Coronary Prone Pedigrees||Completed|||||University of Utah|||||f||||||||||||||2018-06-01 05:38:49.997328|2018-06-01 05:38:49.997328
NCT00005138|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 1976||1976-06-30|May 2000|2000-05-31|June 1989|Actual|1989-06-30|||||Observational|||High Blood Pressure in the Young||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:50.085354|2018-06-01 05:38:50.085354
NCT00005137|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-05-27|2000-05-25|2000-05-26|Estimate|||||||2014-05-27|2014-05-29|Estimate|July 1992||1992-07-31|May 2014|2014-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|HERITAGE||Heritage Study--Genetics, Exercise and Risk Factors|Health, Risk Factors, Exercise Training, and Genetics|Completed||N/A|||Washington University School of Medicine|||||f||||||||||||||2018-06-01 05:38:50.155827|2018-06-01 05:38:50.155827
NCT00005136|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2014-03-14|2000-05-25|2000-05-26|Estimate|||||||2014-03-14|2014-03-17|Estimate|June 1992||1992-06-30|March 2014|2014-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Observational|||Family Heart Study (FHS)||Completed|||||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:38:50.277667|2018-06-01 05:38:50.277667
NCT00005135|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-08-05|2000-05-25|2000-05-26|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 1991||1991-09-30|April 2009|2009-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Insulin Resistance Atherosclerosis Study (IRAS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:50.389098|2018-06-01 05:38:50.389098
NCT00005134|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-28|2000-05-25|2000-05-26|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 1988||1988-09-30|May 2009|2009-05-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|||Strong Heart Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:50.465436|2018-06-01 05:38:50.465436
NCT00005133|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-10-24|2000-05-25|2000-05-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 1988||1988-06-30|May 2009|2009-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Cardiovascular Health Study (CHS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:50.562279|2018-06-01 05:38:50.562279
NCT00005132|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-13|2000-05-25|2000-05-26|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 1985||1985-09-30|January 2006|2006-01-31|March 2000||2000-03-31|||||Observational|||National Growth and Health Study (NGHS)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:50.62979|2018-06-01 05:38:50.62979
NCT00005131|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-12|2000-05-25|2000-05-26|Estimate|||||||2016-04-12|2016-04-14|Estimate|July 1985||1985-07-31|April 2009|2009-04-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Observational|||Atherosclerosis Risk in Communities (ARIC)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:50.704358|2018-06-01 05:38:50.704358
NCT00005130|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-12|2000-05-25|2000-05-26|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 1984||1984-01-31|April 2009|2009-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Coronary Artery Risk Development in Young Adults (CARDIA)||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:50.827166|2018-06-01 05:38:50.827166
NCT00005129|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2018-04-25|2000-05-25|2000-05-26|Estimate|||||||2018-04-25|2018-04-27|Actual|June 1972||1972-06-30|April 2018|2018-04-30|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Observational|||Bogalusa Heart Study||Active, not recruiting|||12000|Actual|Tulane University|||||f||||f|f|f||||Samples With DNA|"~     Blood samples collected at screening for biochemical cardiovascular risk factors, as well as~     genomic and DNA methylation analyses.~   "|Yes|Biolink|2018-06-01 05:38:50.978797|2018-06-01 05:38:50.978797
NCT00005128|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-13|2000-05-25|2000-05-26|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 1972||1972-07-31|April 2004|2004-04-30|December 1994||1994-12-31|||||Observational|||Lipid Research Clinics Population Studies||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:51.222951|2018-06-01 05:38:51.222951
NCT00005127|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-05-12|2000-05-25|2000-05-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 1971||1971-06-30|July 2000|2000-07-31|November 1991|Actual|1991-11-30|||||Observational|||Muscatine Heart Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:51.427845|2018-06-01 05:38:51.427845
NCT00005126|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-07-11|2000-05-25|2000-05-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 1989||1989-04-30|May 2000|2000-05-31|March 1991|Actual|1991-03-31|||||Observational|||Vietnam Era Twin (VET) Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:51.548026|2018-06-01 05:38:51.548026
NCT00005125|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2015-06-02|2000-05-25|2000-05-26|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 1970||1970-07-31|June 2001|2001-06-30|September 1988||1988-09-30|||||Observational|||NAS-NRC Twin Registry||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:51.647502|2018-06-01 05:38:51.647502
NCT00005124|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1969||1969-07-31|May 2000|2000-05-31|November 1998|Actual|1998-11-30|||||Observational|||National Heart, Lung, and Blood Institute Twin Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:51.768813|2018-06-01 05:38:51.768813
NCT00005123|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-13|2000-05-25|2000-05-26|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 1965||1965-07-31|September 2004|2004-09-30|September 2002||2002-09-30|||||Observational|||Honolulu Heart Program||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:51.907214|2018-06-01 05:38:51.907214
NCT00005122|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-03-15|2000-05-25|2000-05-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 1958||1958-07-31|June 2000|2000-06-30|August 1995|Actual|1995-08-31|||||Observational|||Evans County Studies||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:52.118227|2018-06-01 05:38:52.118227
NCT00005121|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-25|||2016-04-13|2000-05-25|2000-05-26|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 1948||1948-07-31|April 2009|2009-04-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Framingham Heart Study||Completed|||||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:38:52.25711|2018-06-01 05:38:52.25711
NCT00005673|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-24|||2008-03-03|2000-05-24|2000-05-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2000||2000-05-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Interventional|||Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs|Safety and Pharmacokinetic Study of Capravirine. Part I. Pharmacokinetics of Capravirine in HIV-Negative Volunteers. Part II. Antiviral Activity of Capravirine, Efavirenz, and Abacavir in HIV-Infected Patients|Completed||Phase 1|46||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:52.354452|2018-06-01 05:38:52.354452
NCT00005671|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-24|||2008-03-03|2000-05-24|2000-05-25|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2000||2000-05-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Quality of Life in Patients With Chronic Ischemic Heart Disease|Quality of Life in Chronic Ischemic Heart Disease With Left Ventricular Dysfunction|Completed|||105||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:52.425904|2018-06-01 05:38:52.425904
NCT00005669|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-19|2010-04-07||2015-04-21|2000-05-19|2000-05-22|Estimate|2011-03-07|2011-04-07|Estimate||||2015-04-21|2015-05-08|Estimate|May 2000||2000-05-31|April 2015|2015-04-30|May 2011|Actual|2011-05-31|August 2009|Actual|2009-08-31||Interventional|||Metformin to Treat Obesity in Children With Insulin Resistance|Effects of Metformin on Energy Intake, Energy Expenditure, and Body Weight in Overweight Children With Insulin Resistance|Completed||Phase 2|100|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:38:52.587453|2018-06-01 05:38:52.587453
NCT00005667|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-19|||2005-06-23|2000-05-19|2000-05-22|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Observational|||Vancomycin Resistant Enterococci in Patients Awaiting Liver Transplantation at the University of Michigan: Prevalence, Risk Factors, Natural History and Outcome of Colonization||Unknown status|Active, not recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:52.976354|2018-06-01 05:38:52.976354
NCT00005666|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-19|||2005-06-23|2000-05-19|2000-05-22|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Utility of Anatometabolic Imaging for Radiation Treatment Planning for Lung Cancer||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:53.040454|2018-06-01 05:38:53.040454
NCT00005665|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-19|||2005-06-23|2000-05-19|2000-05-22|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||"Ingested Interferon Alpha: Prolongation or Permanence of the Honeymoon Phase in Newly Diagnosed Type 1 Diabetes Mellitus"||Unknown status|Active, not recruiting|Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:53.104212|2018-06-01 05:38:53.104212
NCT00005664|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-17|||2018-03-27|2000-05-17|2000-05-18|Estimate|||||||2018-03-27|2018-03-29|Actual|May 16, 2000||2000-05-16|January 16, 2018|2018-01-16||||||||Observational|||Evaluation of Patients With Endocrine-Related Conditions|Evaluation of Patients With Endocrine-Related Conditions|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:53.226091|2018-06-01 05:38:53.226091
NCT00005660|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-12|||2008-03-03|2000-05-12|2000-05-15|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1977||1977-10-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Observational|||The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases|The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases|Completed|||130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:53.334347|2018-06-01 05:38:53.334347
NCT00005658|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-09|||2008-03-03|2000-05-09|2000-05-10|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 2000||2000-05-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Glycine to Treat Psychotic Disorders in Children|Childhood Onset Psychotic Disorders: An Open Trial With the Amino Acid Glycine|Completed||Phase 2|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:53.592548|2018-06-01 05:38:53.592548
NCT00005657|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-06|||2017-06-30|2000-05-06|2000-05-08|Estimate|||||||2017-06-30|2017-07-02|Actual|May 4, 2000||2000-05-04|April 19, 2011|2011-04-19|April 19, 2011||2011-04-19|||||Observational|||Genetics of Hepatitis C Virus Infection|Immunogenetics of Hepatitis C Virus Infection|Completed|||870|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:53.685482|2018-06-01 05:38:53.685482
NCT00005655|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-04|||2018-05-23|2000-05-04|2000-05-05|Estimate|||||||2018-05-23|2018-05-24|Actual|April 28, 2000||2000-04-28|March 2, 2017|2017-03-02|March 2, 2017|Actual|2017-03-02|October 6, 2010|Actual|2010-10-06||Interventional|||Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer|A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors|Terminated||Phase 1|39|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:38:53.794558|2018-06-01 05:38:53.794558
NCT00005654|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2005-06-23|2000-05-02|2000-05-03|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|April 2000|2000-04-30||||||||Interventional|||Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome||Completed||N/A|88||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:53.937733|2018-06-01 05:38:53.937733
NCT00005652|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2008-09-08|2000-05-02|2000-05-03|Estimate|||||||2008-09-08|2008-09-09|Estimate|December 2000||2000-12-31|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura||Completed||Phase 2|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:38:54.171485|2018-06-01 05:38:54.171485
NCT00005650|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-02|||2005-06-23|2000-05-02|2000-05-03|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 2000||2000-02-29|December 2003|2003-12-31||||||||Observational|||Genetic Study of Patients With Primary Ciliary Dyskinesia|Genetic Study of Patients With Primary Ciliary Dyskinesia|Completed|||180||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:54.314255|2018-06-01 05:38:54.314255
NCT00005575|ClinicalTrials.gov processed this data on May 31, 2018|2000-05-01|||2010-01-12|2000-05-01|2000-05-02|Estimate|||||||2010-01-12|2010-01-13|Estimate|January 1999||1999-01-31|January 2010|2010-01-31|December 2002||2002-12-31|||||Interventional|||Treatment of Non-Cardiac Chest Pain With Imipramine or Cognitive-Behavioral Therapy|Psychophysiological Interactions in Non-Cardiac Chest Pain|Completed||Phase 3|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:38:54.357968|2018-06-01 05:38:54.357968
NCT00005571|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-25|||2008-03-03|2000-04-25|2000-04-26|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2000||2000-04-30|December 2001|2001-12-31|December 2001||2001-12-31|||||Interventional|||Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis|A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients|Completed||Phase 2|17||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:54.445279|2018-06-01 05:38:54.445279
NCT00005569|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-22|||2008-03-03|2000-04-22|2000-04-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2000||2000-04-30|July 2003|2003-07-31|July 2003||2003-07-31|||||Interventional|||Effects of Topical SLPI on Skin Wounds|Effects of Topical Anti-Inflammatory Agents on Cutaneous Wound Healing|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:54.516361|2018-06-01 05:38:54.516361
NCT00005567|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-22|||2005-06-23|2000-04-22|2000-04-24|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2000|2000-04-30||||||||Interventional|||Parental Knowledge and Beliefs About Infant Sleep Position||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:54.568506|2018-06-01 05:38:54.568506
NCT00005566|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-22|||2005-06-23|2000-04-22|2000-04-24|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Cognitive Aspects of Adolescent Suicide||Unknown status|Active, not recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:54.614828|2018-06-01 05:38:54.614828
NCT00005119|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-19|||2010-03-01|2000-04-19|2000-04-20|Estimate|||||||2010-03-01|2010-03-02|Estimate|May 2000||2000-05-31|March 2010|2010-03-31|October 2003||2003-10-31|||||Interventional|||Altered Calcium and Vitamin D in PMDD or Severe PMS|Altered Calcium And Vitamin D Metabolism in PMDD|Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:38:54.659641|2018-06-01 05:38:54.659641
NCT00005117|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-18|||2005-06-23|2000-04-18|2000-04-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Effect of Pravastatin on Endothelial Dysfunction Following a Single High Fat Meal||Unknown status|Active, not recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:55.812297|2018-06-01 05:38:55.812297
NCT00005112|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-15|||2005-06-23|2000-04-15|2000-04-17|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Growth Hormone Use in Cystic Fibrosis - a Multicenter Study||Completed||Phase 3|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:55.934293|2018-06-01 05:38:55.934293
NCT00005116|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-13|||2010-03-01|2000-04-13|2000-04-14|Estimate|||||||2010-03-01|2010-03-02|Estimate||||March 2010|2010-03-31||||||||Interventional|||Depression In Juvenile Diabetics||Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:38:56.02816|2018-06-01 05:38:56.02816
NCT00005110|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-13|||2005-06-23|2000-04-13|2000-04-14|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis||Suspended||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:56.083564|2018-06-01 05:38:56.083564
NCT00005108|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-11|||2008-03-03|2000-04-11|2000-04-12|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 2000||2000-04-30|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls|Effects of Hormone Therapy on Vascular Inflammation and Compliance|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:56.17166|2018-06-01 05:38:56.17166
NCT00005107|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-11|||2005-06-23|2000-04-11|2000-04-12|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia||Unknown status|Recruiting|Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:56.340502|2018-06-01 05:38:56.340502
NCT00005105|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2000-04-06|2000-04-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1997||1997-01-31|December 2003|2003-12-31||||||||Observational|||Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation||Unknown status|Recruiting||75||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:56.410176|2018-06-01 05:38:56.410176
NCT00005104|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2000-04-06|2000-04-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 2000||2000-01-31|December 2003|2003-12-31||||||||Interventional|||Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome||Completed||N/A|99||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:56.515706|2018-06-01 05:38:56.515706
NCT00005103|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2000-04-06|2000-04-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 2000||2000-11-30|December 2003|2003-12-31||||||||Observational|||Study of the Pathogenesis of Porphyria Cutanea Tarda||Completed|||120||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:56.67213|2018-06-01 05:38:56.67213
NCT00005102|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2000-04-06|2000-04-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1995||1995-01-31|December 2003|2003-12-31||||||||Observational|||Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome|Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome|Unknown status|Recruiting||11||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:56.769862|2018-06-01 05:38:56.769862
NCT00005101|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2000-04-06|2000-04-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1998||1998-02-28|December 2003|2003-12-31||||||||Observational|||Study of Low Bone Mass in Premenopausal or Perimenopausal Women||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:56.916456|2018-06-01 05:38:56.916456
NCT00005100|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2000-04-06|2000-04-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1999||1999-09-30|December 2003|2003-12-31||||||||Observational|||Measurement of Outcome of Surgical Treatment in Patients With Acromegaly||Unknown status|Recruiting||165||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:57.068668|2018-06-01 05:38:57.068668
NCT00005098|ClinicalTrials.gov processed this data on May 31, 2018|2000-04-06|||2005-06-23|2000-04-06|2000-04-07|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1999||1999-03-31|May 2002|2002-05-31||||||||Observational|||Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency||Terminated|||160||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:38:57.251863|2018-06-01 05:38:57.251863
NCT00005015|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-31|||2005-11-17|2000-03-31|2000-04-03|Estimate|||||||2005-11-17|2005-11-21|Estimate||||November 2000|2000-11-30|September 2000||2000-09-30|||||Interventional|||Treatment of Depression in Youth With Bipolar Disorders|Fluoxetine for the Treatment of Major Depression in Youth With Bipolar Disorder _|Terminated||Phase 3|||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:38:57.317172|2018-06-01 05:38:57.317172
NCT00005014|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-31|||2014-04-16|2000-03-31|2000-04-03|Estimate|||||||2014-04-16|2014-04-17|Estimate|October 1997||1997-10-31|August 2010|2010-08-31|February 2001||2001-02-28|||||Interventional|||Treatment of Autism in Children and Adolescents|Placebo-Controlled Study of Risperidone for the Treatment of Children and Adolescents With Autism and Negative Behavioral Symptoms|Completed||Phase 3|101|Actual|National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:38:57.401839|2018-06-01 05:38:57.401839
NCT00005013|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-31|||2014-04-07|2000-03-31|2000-04-03|Estimate|||||||2014-04-07|2014-04-08|Estimate|December 1998||1998-12-31|March 2006|2006-03-31|July 2001|Actual|2001-07-31|||||Interventional|||Treatment of Major Depression With St. John's Wort (Hypericum)|A Placebo Controlled Clinical Trial of a Standardized Extract of Hypericum Perforatum in Major Depressive Disorder|Completed||N/A|||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:38:57.550046|2018-06-01 05:38:57.550046
NCT00005011|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-29|||2018-05-16|2000-03-29|2000-03-30|Estimate|||||||2018-05-16|2018-05-17|Actual|March 28, 2000||2000-03-28|October 28, 2016|2016-10-28|October 28, 2016||2016-10-28|||||Observational|||Combined Hormone Replacement in Menstrually-Related Mood Disorders|The Treatment of Menstrually-Related Mood Disorders With Continuous Gonadal Steroid Replacement|Completed|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:57.709163|2018-06-01 05:38:57.709163
NCT00005007|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-24|||2007-12-19|2000-03-24|2000-03-27|Estimate|||||||2007-12-19|2007-12-28|Estimate|June 2000||2000-06-30|December 2007|2007-12-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Etanercept for Wegener's Granulomatosis|Wegener's Granulomatosis Etanercept Trial (WGET)|Completed||Phase 2/Phase 3|181||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||||||||||||||||2018-06-01 05:38:57.785457|2018-06-01 05:38:57.785457
NCT00005006|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-24|||2015-08-17|2000-03-24|2000-03-27|Estimate|||||||2015-08-17|2015-08-19|Estimate|September 1987||1987-09-30|August 2015|2015-08-31|December 2006|Actual|2006-12-31|February 2003|Actual|2003-02-28||Interventional|||Parathyroid Hormone (PTH) With Alendronate for Osteoporosis|Cyclical vs Daily Continuous PTH in Combination With Alendronate vs Alendronate Alone|Completed||Phase 2|140|Actual|Helen Hayes Hospital||3|||f||||f||||||||||2018-06-01 05:38:57.884816|2018-06-01 05:38:57.884816
NCT00005005|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-24|||2013-02-04|2000-03-24|2000-03-27|Estimate|||||||2013-02-04|2013-02-05|Estimate|October 1999||1999-10-31|February 2013|2013-02-28|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis|Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis|Completed||Phase 2|238|Actual|University of California, San Francisco||4|||f||||||||||||||2018-06-01 05:38:58.009632|2018-06-01 05:38:58.009632
NCT00005004|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-23|||2008-03-03|2000-03-23|2000-03-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2000||2000-03-31|March 2005|2005-03-31|March 2005||2005-03-31|||||Observational|||Brain Processing of Language Meanings|Investigations in Discourse Processes|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:58.337918|2018-06-01 05:38:58.337918
NCT00005003|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-23|||2008-03-03|2000-03-23|2000-03-24|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2000||2000-03-31|April 2006|2006-04-30|April 2006||2006-04-30|||||Observational|||Genetic Component of Handedness|Mapping the Genetic Component of Hand-Use Preference|Completed|||1400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:58.473528|2018-06-01 05:38:58.473528
NCT00004739|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-29|||2005-06-23|2000-02-29|2000-03-01|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||The Metabolic Effects of Protease Inhibitors in HIV Infected Children||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:05.185485|2018-06-01 05:39:05.185485
NCT00004997|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-22|||2008-03-03|2000-03-22|2000-03-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Leucovorin for the Treatment of 5 q Minus Syndrome|The Experimental Treatment of Transfusion Dependent 5q Minus Syndrome With Leucovorin|Completed||Phase 2|14||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:58.679642|2018-06-01 05:38:58.679642
NCT00004996|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-22|||2018-05-15|2000-03-22|2000-03-23|Estimate|||||||2018-05-15|2018-05-16|Actual|March 20, 2000||2000-03-20|April 22, 2015|2015-04-22|April 22, 2015||2015-04-22|||||Observational|||Comparison of Immune Response in Normal Volunteers and Patients With Helminth Infections|Langherhans' Cell Function and Inflammatory Responses in Skin of Volunteers Using the Suction Blister Technique|Completed|||90|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:58.865998|2018-06-01 05:38:58.865998
NCT00004994|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-22|||2008-03-03|2000-03-22|2000-03-23|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1999||1999-10-31|October 2004|2004-10-31|October 2004||2004-10-31|||||Observational|||Comparison of Quality of Life in Patients Undergoing More Intensive Versus Less Intensive Chemotherapy and Radiation Preceding a Bone Marrow Transplant|A Study Comparing Quality of Life in Patients Undergoing a Non-Myeloablative Versus a Myeloablative Peripheral Blood Stem Cell Transplant for Hematological Diseases|Completed|||106||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:58.961227|2018-06-01 05:38:58.961227
NCT00004993|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-17|||2010-03-01|2000-03-17|2000-03-20|Estimate|||||||2010-03-01|2010-03-02|Estimate|August 1999||1999-08-31|March 2010|2010-03-31|August 2001||2001-08-31|||||Interventional|||Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis|Can PTH Reverse Glucocorticoid-induced Osteoporosis|Completed||Phase 2|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:38:59.068967|2018-06-01 05:38:59.068967
NCT00004992|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-17|||2018-02-28|2000-03-17|2000-03-20|Estimate|||||||2018-02-28|2018-03-02|Actual|July 1996||1996-07-31|February 2018|2018-02-28|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Diabetes Prevention Program||Completed||Phase 3|3234|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t|t|f||||||||2018-06-01 05:38:59.162347|2018-06-01 05:38:59.162347
NCT00004991|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-18|||2017-06-30|2000-03-18|2000-03-20|Estimate|||||||2017-06-30|2017-07-02|Actual|March 14, 2000||2000-03-14|August 31, 2009|2009-08-31||||August 31, 2009|Actual|2009-08-31||Observational|||Study of Brain Activity During Speech Production and Speech Perception|Brain Activation During Developmental Speech Production and Speech Perception|Completed|||411||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:59.260993|2018-06-01 05:38:59.260993
NCT00004990|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-18|||2008-03-03|2000-03-18|2000-03-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2000||2000-03-31|December 2004|2004-12-31|December 2004||2004-12-31|||||Interventional|||Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis|Pulse Dexamethasone in Focal Segmental Glomerulosclerosis|Completed||Phase 2|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:59.33078|2018-06-01 05:38:59.33078
NCT00004988|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-18|||2008-03-03|2000-03-18|2000-03-20|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 2000||2000-03-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Interventional|||Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria|A Phase I Trial of a Live, Genetically Modified Salmonella Typhimurium (VNP20009) for the Treatment of Cancer by Intravenous Administration|Completed||Phase 1|45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:38:59.437905|2018-06-01 05:38:59.437905
NCT00004984|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-13|||2010-01-14|2000-03-13|2000-03-14|Estimate|||||||2010-01-14|2010-01-15|Estimate|February 1994||1994-02-28|January 2010|2010-01-31|June 2003||2003-06-30|||||Interventional|||The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)||Completed||Phase 3|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||||||||||||||||2018-06-01 05:38:59.535586|2018-06-01 05:38:59.535586
NCT00004983|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-13|||2010-02-12|2000-03-13|2000-03-14|Estimate|||||||2010-02-12|2010-02-15|Estimate|September 1999||1999-09-30|February 2010|2010-02-28|December 2006|Actual|2006-12-31|November 2006|Actual|2006-11-30||Interventional|||Education and Group Support for Diabetic Hispanics||Completed||N/A|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:38:59.689168|2018-06-01 05:38:59.689168
NCT00004982|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-13|||2010-01-12|2000-03-13|2000-03-14|Estimate|||||||2010-01-12|2010-01-14|Estimate|December 1998||1998-12-31|January 2010|2010-01-31|November 2002||2002-11-30|||||Interventional|||Combination Iron Chelation Therapy||Completed||Phase 1|||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:38:59.773023|2018-06-01 05:38:59.773023
NCT00004980|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-10|2008-11-25||2013-08-05|2000-03-10|2000-03-13|Estimate|2012-06-05|2012-07-09|Estimate||||2013-08-05|2013-08-07|Estimate|December 1999||1999-12-31|August 2013|2013-08-31|June 2005|Actual|2005-06-30|January 2005|Actual|2005-01-31||Interventional|||"Repetitive Transcranial Magnetic Stimulation for Voices"|"Repetitive Transcranial Magnetic Stimulation of Speech Processing Brain Areas in Schizophrenic Patients Who Hear Voices"|Completed||Phase 2|50|Actual|Yale University||2|||f||||t||||||||||2018-06-01 05:38:59.924865|2018-06-01 05:38:59.924865
NCT00004854|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-08|||2005-06-23|2000-03-08|2000-03-09|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure||Completed||Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:02.693443|2018-06-01 05:39:02.693443
NCT00004853|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-04|||2018-05-22|2000-03-04|2000-03-06|Estimate|||||||2018-05-22|2018-05-23|Actual|March 3, 2000||2000-03-03|January 27, 2016|2016-01-27|May 20, 2009|Actual|2009-05-20|May 20, 2009|Actual|2009-05-20||Interventional|||Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy|A Randomized Trial of Filgrastim-SD/01 vs. Filgrastim in Newly Diagnosed Children and Young Adults With Sarcoma Treated With Dose-Intensive Chemotherapy|Completed||Phase 1|34|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:39:03.215403|2018-06-01 05:39:03.215403
NCT00004850|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-02|||2018-05-17|2000-03-02|2000-03-03|Estimate|||||||2018-05-17|2018-05-18|Actual|April 26, 1991||1991-04-26|October 25, 2017|2017-10-25||||||||Observational|||Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection|Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:03.40062|2018-06-01 05:39:03.40062
NCT00004847|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-02|||2018-05-03|2000-03-02|2000-03-03|Estimate|||||||2018-05-03|2018-05-04|Actual|March 1, 2000||2000-03-01|May 2, 2018|2018-05-02||||||||Observational|||Diagnosis of Pheochromocytoma|Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma|Recruiting|||2400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:03.983301|2018-06-01 05:39:03.983301
NCT00004846|ClinicalTrials.gov processed this data on May 31, 2018|2000-03-02|||2008-03-03|2000-03-02|2000-03-03|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Observational|||Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV|Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV|Completed|||30000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:04.929098|2018-06-01 05:39:04.929098
NCT00004845|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-28|||2009-12-10|2000-02-28|2000-02-29|Estimate|||||||2009-12-10|2009-12-11|Estimate||||June 2009|2009-06-30|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)|A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease|Completed||Phase 2/Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:39:05.267008|2018-06-01 05:39:05.267008
NCT00004738|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-26|||2018-05-24|2000-02-26|2000-02-28|Estimate|||||||2018-05-24|2018-05-25|Actual|February 25, 2000||2000-02-25|September 12, 2017|2017-09-12||||||||Observational|||Genetic Analysis of the Chiari I Malformation|Genetic Analysis of the Chiari I Malformation|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:05.690175|2018-06-01 05:39:05.690175
NCT00004734|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2005-06-23|2000-02-25|2000-02-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1996||1996-09-30|April 2004|2004-04-30|February 2004||2004-02-29|||||Interventional|||Vitamin Therapy for Prevention of Stroke|Vitamin Intervention for Stroke Prevention|Completed||Phase 3|||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:39:05.803316|2018-06-01 05:39:05.803316
NCT00004733|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2005-06-23|2000-02-25|2000-02-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1998||1998-01-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Timing of Levodopa Treatment in Parkinson's Disease|Earlier Versus Later L-Dopa in Parkinson's Disease|Completed||Phase 3|||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:39:06.011603|2018-06-01 05:39:06.011603
NCT00004732|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|2013-09-26||2017-04-13|2000-02-25|2000-02-28|Estimate|2013-09-26|2013-12-10|Estimate||||2017-04-13|2017-05-17|Actual|December 2000||2000-12-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|February 2011|Actual|2011-02-28||Interventional|CREST||Carotid Revascularization Endarterectomy Versus Stenting Trial|Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)|Completed||N/A|2502|Actual|Rutgers, The State University of New Jersey||2|||f||||t|f|t|f|||||No||2018-06-01 05:39:06.226516|2018-06-01 05:39:06.226516
NCT00004731|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2005-06-23|2000-02-25|2000-02-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1998||1998-09-30|December 2003|2003-12-31|October 2003||2003-10-31|||||Interventional|||Parkinson's Disease Treatment With Coenzyme Q10|Effects of Coenzyme Q10 in Early Parkinson's Disease|Completed||Phase 2|||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:39:07.456051|2018-06-01 05:39:07.456051
NCT00004730|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2011-10-26|2000-02-25|2000-02-28|Estimate|||||||2011-10-26|2011-10-28|Estimate|August 1998||1998-08-31|October 2011|2011-10-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Magnesium Sulfate For Brain Injury|Magnesium Sulfate for Neuroprotection After Brain Trauma|Completed||Phase 3|||University of Washington|||||f||||t||||||||||2018-06-01 05:39:07.569484|2018-06-01 05:39:07.569484
NCT00004729|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2006-12-21|2000-02-25|2000-02-28|Estimate|||||||2006-12-21|2006-12-22|Estimate|July 1997||1997-07-31|December 2006|2006-12-31||||||||Interventional|||Ketogenic Diet for Child Epilepsy and Seizure Control|Efficacy of the Ketogenic Diet -- a Blinded Study|Completed||N/A|||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:39:07.677861|2018-06-01 05:39:07.677861
NCT00004728|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2006-06-05|2000-02-25|2000-02-28|Estimate|||||||2006-06-05|2006-06-06|Estimate||||June 2006|2006-06-30|July 2003||2003-07-31|||||Interventional|||Aspirin Or Warfarin To Prevent Stroke|Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study|Terminated||Phase 3|||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:39:07.772303|2018-06-01 05:39:07.772303
NCT00004727|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-25|||2005-06-23|2000-02-25|2000-02-28|Estimate|||||||2005-06-23|2005-06-24|Estimate||||June 2003|2003-06-30||||||||Interventional|||Antiplatelet Therapy to Prevent Stroke in African Americans|African American Antiplatelet Stroke Prevention Study|Completed||Phase 4|||National Institute of Neurological Disorders and Stroke (NINDS)|||||f||||||||||||||2018-06-01 05:39:07.859591|2018-06-01 05:39:07.859591
NCT00004941|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 1996||1996-07-31|April 2000|2000-04-30|July 1996||1996-07-31|||||Interventional|||Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease||Completed||Phase 3|94||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:07.986161|2018-06-01 05:39:07.986161
NCT00004940|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 1996||1996-05-31|April 2000|2000-04-30|September 2001||2001-09-30|||||Interventional|||Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria||Completed||Phase 3|50||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:08.13745|2018-06-01 05:39:08.13745
NCT00004939|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1996||1996-08-31|December 2001|2001-12-31|August 1996||1996-08-31|||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy||Completed||Phase 3|34||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:08.206759|2018-06-01 05:39:08.206759
NCT00004938|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2006-06-08|2000-02-24|2000-02-25|Estimate|||||||2006-06-08|2006-06-09|Estimate|August 1996||1996-08-31|April 2000|2000-04-30|August 1996||1996-08-31|||||Interventional|||Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis||Completed||Phase 2|30||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:08.339174|2018-06-01 05:39:08.339174
NCT00004844|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1998||1998-07-31|January 1999|1999-01-31||||||||Interventional|||Randomized Study of Fetal Neurotransplantation for the Treatment of Parkinson's Disease||Unknown status|Active, not recruiting|N/A|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:08.448696|2018-06-01 05:39:08.448696
NCT00004843|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2017-05-25|2000-02-24|2000-02-25|Estimate|||||||2017-05-25|2017-05-30|Actual|April 1997|Actual|1997-04-30|May 2017|2017-05-31|March 30, 1999|Actual|1999-03-30|March 30, 1999|Actual|1999-03-30||Interventional|||A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic Primary Hyperparathyroidism|A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic|Completed||N/A|53|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f|||||f|f||||||||2018-06-01 05:39:08.518994|2018-06-01 05:39:08.518994
NCT00004842|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2017-05-30|2000-02-24|2000-02-25|Estimate|||||||2017-05-30|2017-05-31|Actual|May 1997|Actual|1997-05-31|May 2017|2017-05-31|April 1999|Actual|1999-04-30|April 1999|Actual|1999-04-30||Interventional|||Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis|Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis|Completed||Phase 1|22|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f|||||t|f||||||||2018-06-01 05:39:08.644865|2018-06-01 05:39:08.644865
NCT00004840|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1998||1998-05-31|October 1998|1998-10-31|June 1998||1998-06-30|||||Interventional|||Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants||Completed||N/A|996||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:08.753567|2018-06-01 05:39:08.753567
NCT00000154|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1976||1976-10-31|October 1999|1999-10-31||||||||Interventional|||Diabetic Retinopathy Vitrectomy Study (DRVS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.33332|2018-06-01 05:40:53.33332
NCT00004838|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1997||1997-09-30|September 1998|1998-09-30|July 1998||1998-07-31|||||Interventional|||Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children||Completed||N/A|175||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:08.938289|2018-06-01 05:39:08.938289
NCT00004834|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2013-02-20|2000-02-24|2000-02-25|Estimate|||||||2013-02-20|2013-02-21|Estimate|May 1998||1998-05-31|February 2013|2013-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder||Completed||N/A|326||Northwell Health|||||f||||||||||||||2018-06-01 05:39:09.036628|2018-06-01 05:39:09.036628
NCT00004833|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-04-06|2000-02-24|2000-02-25|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 1995||1995-07-31|September 2002|2002-09-30|November 2002||2002-11-30|||||Interventional|||Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome||Terminated||N/A|170||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.124036|2018-06-01 05:39:09.124036
NCT00004832|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1994||1994-08-31|July 1998|1998-07-31|June 1998||1998-06-30|||||Interventional|||Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome||Completed||N/A|26||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.192114|2018-06-01 05:39:09.192114
NCT00004831|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1996||1996-10-31|August 1998|1998-08-31|July 1998||1998-07-31|||||Interventional|||Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria||Completed||N/A|20||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.254271|2018-06-01 05:39:09.254271
NCT00004829|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 1995||1995-06-30|June 1998|1998-06-30|May 1998||1998-05-31|||||Interventional|||Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis||Completed||Phase 3|200||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.343402|2018-06-01 05:39:09.343402
NCT00004828|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|December 1994||1994-12-31|June 1998|1998-06-30|December 1997||1997-12-31|||||Interventional|||Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure||Completed||Phase 1|28||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.44353|2018-06-01 05:39:09.44353
NCT00004827|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 1996||1996-03-31|May 1998|1998-05-31|June 2002||2002-06-30|||||Interventional|||Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa||Completed||N/A|46||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.510009|2018-06-01 05:39:09.510009
NCT00004826|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1993||1993-10-31|May 1998|1998-05-31|November 1997||1997-11-30|||||Interventional|||Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease||Completed||N/A|60||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.586968|2018-06-01 05:39:09.586968
NCT00004825|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 1998||1998-05-31|July 1998|1998-07-31|May 1998||1998-05-31|||||Interventional|||Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism||Completed||N/A|10||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:09.645082|2018-06-01 05:39:09.645082
NCT00004817|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1991||1991-02-28|December 2001|2001-12-31||||||||Interventional|||Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures||Completed||Phase 3|385||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:09.728015|2018-06-01 05:39:09.728015
NCT00004816|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1995||1995-07-31|December 2001|2001-12-31||||||||Interventional|||A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis||Completed||Phase 1|25||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:09.800139|2018-06-01 05:39:09.800139
NCT00004815|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1992||1992-05-31|July 2004|2004-07-31||||||||Interventional|||Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome||Completed||N/A|1||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:09.897511|2018-06-01 05:39:09.897511
NCT00004814|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1991||1991-10-31|January 1997|1997-01-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis||Completed||Phase 3|250||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:09.971895|2018-06-01 05:39:09.971895
NCT00004812|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1995||1995-07-31|December 2001|2001-12-31||||||||Interventional|||Phase II Randomized Pilot Study of Body Weight Support and Treadmill Training for Chronic Thoracic Spinal Cord Injury||Completed||Phase 2|26||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.032508|2018-06-01 05:39:10.032508
NCT00004811|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2006-06-08|2000-02-24|2000-02-25|Estimate|||||||2006-06-08|2006-06-09|Estimate|March 1985||1985-03-31|December 2001|2001-12-31||||||||Interventional|||Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis||Completed||Phase 1/Phase 2|7||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.10498|2018-06-01 05:39:10.10498
NCT00004810|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1996||1996-06-30|December 2001|2001-12-31||||||||Interventional|||Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis||Completed||Phase 2|30||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.170288|2018-06-01 05:39:10.170288
NCT00004809|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1992||1992-06-30|December 2001|2001-12-31||||||||Interventional|||Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia||Completed||Phase 1|5||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.252399|2018-06-01 05:39:10.252399
NCT00004808|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2006-06-08|2000-02-24|2000-02-25|Estimate|||||||2006-06-08|2006-06-09|Estimate|September 1991||1991-09-30|December 2001|2001-12-31||||||||Interventional|||Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis||Completed||Phase 2|78||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.33088|2018-06-01 05:39:10.33088
NCT00004807|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1995||1995-01-31|December 1998|1998-12-31||||||||Interventional|||Study of the Pathogenesis of Rett Syndrome||Completed||N/A|120||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.40202|2018-06-01 05:39:10.40202
NCT00004806|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2011-03-29|2000-02-24|2000-02-25|Estimate|||||||2011-03-29|2011-03-30|Estimate|June 1995||1995-06-30|March 2011|2011-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis||Completed||Phase 1|9||University of Alabama at Birmingham|||||f||||f||||||||||2018-06-01 05:39:10.471953|2018-06-01 05:39:10.471953
NCT00004805|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1991||1991-09-30|February 2001|2001-02-28|August 1997||1997-08-31|||||Interventional|||Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death||Completed||N/A|500||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.577231|2018-06-01 05:39:10.577231
NCT00004804|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1993||1993-08-31|February 1997|1997-02-28||||||||Interventional|||Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C||Completed||Phase 3|57||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.649146|2018-06-01 05:39:10.649146
NCT00004802|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1992||1992-06-30|January 1998|1998-01-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders||Completed||Phase 3|64||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.710609|2018-06-01 05:39:10.710609
NCT00004801|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1992||1992-03-31|January 1998|1998-01-31||||||||Interventional|||Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency||Completed||Phase 1/Phase 2|3||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.794569|2018-06-01 05:39:10.794569
NCT00004800|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1992||1992-09-30|February 1998|1998-02-28||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines||Completed||Phase 3|13250||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.873751|2018-06-01 05:39:10.873751
NCT00004799|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1991||1991-04-30|January 1997|1997-01-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines||Completed||Phase 3|10000||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.941904|2018-06-01 05:39:10.941904
NCT00004797|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1995||1995-08-31|December 2001|2001-12-31||||||||Interventional|||Pilot Study of Fructose for Sickle Cell Crisis||Completed||N/A|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:10.993016|2018-06-01 05:39:10.993016
NCT00004796|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1994||1994-11-30|February 1998|1998-02-28|February 1997||1997-02-28|||||Interventional|||Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis||Completed||Phase 2|16||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.07913|2018-06-01 05:39:11.07913
NCT00004795|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1994||1994-08-31|December 2001|2001-12-31||||||||Interventional|||Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus||Completed||Phase 2/Phase 3|190||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.131216|2018-06-01 05:39:11.131216
NCT00004794|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1995||1995-03-31|January 1998|1998-01-31||||||||Interventional|||Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis||Completed||Phase 2|90||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.198409|2018-06-01 05:39:11.198409
NCT00004793|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1995||1995-06-30|December 2001|2001-12-31||||||||Observational|||Pilot Study of the Effect of Baclofen and Bromocriptine on Luteinizing Hormone Secretion in Pubertal Children||Completed|||4||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.253808|2018-06-01 05:39:11.253808
NCT00004791|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1995||1995-08-31|December 2001|2001-12-31||||||||Observational|||Study of the Nutritional, Metabolic, and Body Composition Profile in Children and Adolescents With Epidermolysis Bullosa||Completed|||15||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.31048|2018-06-01 05:39:11.31048
NCT00004789|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1993||1993-07-31|December 2001|2001-12-31||||||||Interventional|||Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria||Completed||Phase 1/Phase 2|59||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.364438|2018-06-01 05:39:11.364438
NCT00004788|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1988||1988-05-31|December 2001|2001-12-31||||||||Observational|||Study of Nutritional Factors in Porphyria||Completed|||30||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.417218|2018-06-01 05:39:11.417218
NCT00004787|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1994||1994-12-31|December 2001|2001-12-31||||||||Interventional|||Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes||Completed||Phase 2|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.463122|2018-06-01 05:39:11.463122
NCT00004786|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1995||1995-12-31|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis||Completed||Phase 3|200||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.529078|2018-06-01 05:39:11.529078
NCT00004785|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1995||1995-11-30|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia||Completed||Phase 3|54||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.589839|2018-06-01 05:39:11.589839
NCT00004784|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1994||1994-01-31|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis||Completed||Phase 3|315||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.74532|2018-06-01 05:39:11.74532
NCT00004781|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1989||1989-09-30|February 1997|1997-02-28||||||||Observational|||Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups||Completed|||250||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.816146|2018-06-01 05:39:11.816146
NCT00004779|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1993||1993-01-31|December 2001|2001-12-31||||||||Interventional|||Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis||Completed||Phase 1|12||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.888449|2018-06-01 05:39:11.888449
NCT00004667|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1993||1993-10-31|December 2001|2001-12-31||||||||Interventional|||Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease||Completed||Phase 1|10||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:16.962882|2018-06-01 05:39:16.962882
NCT00004778|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1993||1993-08-31|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery||Completed||Phase 3|1090||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:11.985133|2018-06-01 05:39:11.985133
NCT00004776|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1993||1993-11-30|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome||Completed||Phase 3|10||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.16227|2018-06-01 05:39:12.16227
NCT00004773|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1995||1995-08-31|January 1997|1997-01-31|June 1997||1997-06-30|||||Observational|||Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome||Completed|||95||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.299022|2018-06-01 05:39:12.299022
NCT00004772|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1992||1992-09-30|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy||Completed||Phase 3|90||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.376492|2018-06-01 05:39:12.376492
NCT00004771|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1992||1992-10-31|December 2001|2001-12-31||||||||Interventional|||Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease||Completed||Phase 2|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.461787|2018-06-01 05:39:12.461787
NCT00004770|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1995||1995-10-31|December 2001|2001-12-31||||||||Interventional|||Pilot Compassionate Use Study of Thioctic Acid Treatment in Mitochondrial Myopathy||Completed||N/A|1||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.542088|2018-06-01 05:39:12.542088
NCT00004769|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2013-01-25|2000-02-24|2000-02-25|Estimate|||||||2013-01-25|2013-01-28|Estimate|December 1993||1993-12-31|January 2013|2013-01-31|March 2000|Actual|2000-03-31|March 2000|Actual|2000-03-31||Observational|||Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy|Myotonic Dystrophy:Muscle Wasting and Altered Metabolism|Completed|||130|Actual|University of Rochester|||4||f||||f||||||||||2018-06-01 05:39:12.640578|2018-06-01 05:39:12.640578
NCT00004767|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1985||1985-01-31|December 2001|2001-12-31||||||||Interventional|||Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders||Completed||Phase 2|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.730672|2018-06-01 05:39:12.730672
NCT00004763|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1993||1993-01-31|December 2001|2001-12-31||||||||Interventional|||Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism||Completed||Phase 2|45||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.830274|2018-06-01 05:39:12.830274
NCT00004762|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1994||1994-12-31|December 2001|2001-12-31||||||||Interventional|||Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis||Completed||Phase 2|5||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:12.934544|2018-06-01 05:39:12.934544
NCT00004761|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1986||1986-09-30|July 2004|2004-07-31||||||||Observational|||Establishment of the National Epidermolysis Bullosa Registry||Completed|||||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.00759|2018-06-01 05:39:13.00759
NCT00004760|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1995||1995-05-31|April 1998|1998-04-30|December 1997||1997-12-31|||||Interventional|||Study of Axial Mobility Exercises in Parkinson Disease||Completed||N/A|80||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.074828|2018-06-01 05:39:13.074828
NCT00004759|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2008-09-08|2000-02-24|2000-02-25|Estimate|||||||2008-09-08|2008-09-10|Estimate|December 1991||1991-12-31|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Methylprednisolone Given by 24-Hour or 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury|Phase III Randomized, Double-Blind Study of Methylprednisolone by 24- Versus 48-Hour Infusion Versus Tirilazad for Acute Spinal Cord Injury|Completed||Phase 3|497||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.156308|2018-06-01 05:39:13.156308
NCT00004758|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1993||1993-11-30|December 2001|2001-12-31||||||||Interventional|||Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment||Completed||Phase 2|30||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.234311|2018-06-01 05:39:13.234311
NCT00004757|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1992||1992-08-31|January 1998|1998-01-31||||||||Interventional|||Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth||Completed||Phase 3|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.328823|2018-06-01 05:39:13.328823
NCT00004756|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1994||1994-12-31|December 2001|2001-12-31||||||||Interventional|||Study of Individualized Instruction Versus Pamphlet in Systemic Lupus Erythematosus|Randomized Study of Individualized Instruction Versus Pamphlet in Systemic Lupus Erythematosus|Completed||N/A|150||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.413935|2018-06-01 05:39:13.413935
NCT00004755|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|January 1998|1998-01-31||||||||Interventional|||Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil|Phase II Randomized Study of Allopurinol Versus Glucantime Versus Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil|Completed||Phase 2|375||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.49936|2018-06-01 05:39:13.49936
NCT00004754|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1993||1993-08-31|December 2001|2001-12-31||||||||Interventional|||Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension||Completed||Phase 4|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.577625|2018-06-01 05:39:13.577625
NCT00004753|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1993||1993-08-31|December 2001|2001-12-31||||||||Observational|||Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease||Completed|||90||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.688616|2018-06-01 05:39:13.688616
NCT00004751|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1991||1991-10-31|February 1997|1997-02-28||||||||Interventional|||Phase II Randomized Study of Selective Dorsal Rhizotomy and Physiotherapy Vs Physiotherapy Alone for Spastic Diplegia||Unknown status|Active, not recruiting|Phase 2|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:13.886097|2018-06-01 05:39:13.886097
NCT00004748|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1989||1989-11-30|December 2001|2001-12-31||||||||Interventional|||Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis|Phase III Randomized, Double-Blind, Placebo-Controlled Study of Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis|Completed||Phase 3|90||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:14.108748|2018-06-01 05:39:14.108748
NCT00004747|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1995||1995-07-31|December 2001|2001-12-31||||||||Interventional|||Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis||Completed||Phase 2|170||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:14.321257|2018-06-01 05:39:14.321257
NCT00004744|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2008-09-08|2000-02-24|2000-02-25|Estimate|||||||2008-09-08|2008-09-09|Estimate|February 1993||1993-02-28|September 2008|2008-09-30||||September 1998|Actual|1998-09-30||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis||Completed||Phase 3|76||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:14.547487|2018-06-01 05:39:14.547487
NCT00004740|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1995||1995-02-28|January 1998|1998-01-31||||||||Interventional|||Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users||Unknown status|Active, not recruiting|N/A|300||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:14.755652|2018-06-01 05:39:14.755652
NCT00004705|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1996||1996-09-30|March 1999|1999-03-31|January 1999||1999-01-31|||||Interventional|||Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis||Completed||N/A|||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:14.850802|2018-06-01 05:39:14.850802
NCT00004700|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1995||1995-08-31|March 1999|1999-03-31|January 1999||1999-01-31|||||Interventional|||Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism||Completed||Phase 2|16||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:14.949613|2018-06-01 05:39:14.949613
NCT00004699|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1995||1995-08-31|March 1999|1999-03-31|January 1999||1999-01-31|||||Interventional|||Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism||Completed||N/A|8||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.036725|2018-06-01 05:39:15.036725
NCT00004697|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 1997||1997-11-30|March 1999|1999-03-31|March 1999||1999-03-31|||||Interventional|||Randomized Study of the Use of Intravenous Choline Supplementation in Long Term Total Parenteral Nutrition||Completed||N/A|15||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.1142|2018-06-01 05:39:15.1142
NCT00004696|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1994||1994-08-31|May 1999|1999-05-31|July 1998||1998-07-31|||||Interventional|||Study of Morphine in Postoperative Infants to Allow Normal Ventilation||Completed||N/A|100||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.175054|2018-06-01 05:39:15.175054
NCT00004695|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1997||1997-09-30|May 1999|1999-05-31|March 2000||2000-03-31|||||Interventional|||Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency||Completed||N/A|48||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.252725|2018-06-01 05:39:15.252725
NCT00004694|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 1994||1994-01-31|April 1999|1999-04-30|September 1998||1998-09-30|||||Interventional|||Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations||Completed||N/A|24||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.319104|2018-06-01 05:39:15.319104
NCT00004690|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1996||1996-09-30|March 1999|1999-03-31|September 1998||1998-09-30|||||Interventional|||Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis||Completed||Phase 3|90||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.394451|2018-06-01 05:39:15.394451
NCT00004689|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 1991||1991-01-31|February 1999|1999-02-28|September 1998||1998-09-30|||||Interventional|||Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease||Completed||Phase 2|50||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.439155|2018-06-01 05:39:15.439155
NCT00004688|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1996||1996-08-31|March 1999|1999-03-31|July 1998||1998-07-31|||||Interventional|||Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms||Completed||Phase 2|35||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:15.551426|2018-06-01 05:39:15.551426
NCT00004686|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|February 1994||1994-02-28|March 1999|1999-03-31|September 1999||1999-09-30|||||Interventional|||Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis||Completed||Phase 2|300||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:16.610641|2018-06-01 05:39:16.610641
NCT00004685|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 1998||1998-01-31|March 1999|1999-03-31|September 2000||2000-09-30|||||Interventional|||Randomized Study of Albuterol in Patients With Facioscapulohumeral Muscular Dystrophy||Completed||N/A|90||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:16.678096|2018-06-01 05:39:16.678096
NCT00004682|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2015-03-24|2000-02-24|2000-02-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 1995||1995-03-31|March 1999|1999-03-31|March 1999||1999-03-31|||||Interventional|||Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis||Terminated||N/A|100||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:39:16.755372|2018-06-01 05:39:16.755372
NCT00004670|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1994||1994-10-31|December 2001|2001-12-31||||||||Interventional|||Phase II Study of Pallidotomy for Parkinson Disease||Completed||Phase 2|60||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:16.833871|2018-06-01 05:39:16.833871
NCT00004669|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1996||1996-06-30|December 2001|2001-12-31||||||||Interventional|||Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia||Completed||Phase 2|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:16.90925|2018-06-01 05:39:16.90925
NCT00004665|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1995||1995-06-30|December 2001|2001-12-31||||||||Interventional|||Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus||Completed||Phase 2|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.066505|2018-06-01 05:39:17.066505
NCT00004664|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1995||1995-06-30|December 2001|2001-12-31||||||||Interventional|||Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting||Completed||N/A|69||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.152106|2018-06-01 05:39:17.152106
NCT00004663|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1994||1994-02-28|July 2004|2004-07-31||||||||Observational|||Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus Erythematosus||Completed|||480||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.346829|2018-06-01 05:39:17.346829
NCT00004662|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1996||1996-03-31|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus||Completed||Phase 3|300||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.43097|2018-06-01 05:39:17.43097
NCT00004661|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1993||1993-05-31|December 2001|2001-12-31||||||||Observational|||Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism||Completed|||20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.51045|2018-06-01 05:39:17.51045
NCT00004660|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2017-05-25|2000-02-24|2000-02-25|Estimate|||||||2017-05-25|2017-05-30|Actual|June 1993||1993-06-30|May 2017|2017-05-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy|Phase II Randomized Controlled Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy|Completed||N/A|42|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f|||||f|f||||||||2018-06-01 05:39:17.579353|2018-06-01 05:39:17.579353
NCT00004659|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1994||1994-11-30|March 1999|1999-03-31||||||||Interventional|||Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors||Unknown status|Active, not recruiting|Phase 2|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.693978|2018-06-01 05:39:17.693978
NCT00004658|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1995||1995-03-31|December 2001|2001-12-31||||||||Interventional|||Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity||Completed||Phase 2|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.790261|2018-06-01 05:39:17.790261
NCT00004656|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1993||1993-05-31|February 1999|1999-02-28||||||||Interventional|||Nutritional Aspects of Rett Syndrome||Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.870172|2018-06-01 05:39:17.870172
NCT00004654|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1996||1996-01-31|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia||Completed||Phase 3|60||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:17.980513|2018-06-01 05:39:17.980513
NCT00004652|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1993||1993-02-28|December 2001|2001-12-31||||||||Interventional|||Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome||Completed||Phase 2|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.093534|2018-06-01 05:39:18.093534
NCT00004650|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1993||1993-08-31|June 1999|1999-06-30||||||||Interventional|||Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss||Completed||Phase 3|150||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.167148|2018-06-01 05:39:18.167148
NCT00004649|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1995||1995-05-31|December 2001|2001-12-31||||||||Observational|||Study of the Natural History and Genotype-Phenotype Correlations of Hereditary Hemorrhagic Telangiectasia Patients||Completed|||||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.221549|2018-06-01 05:39:18.221549
NCT00004648|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1996||1996-05-31|December 2001|2001-12-31||||||||Observational|||Studies of Hereditary Hemorrhagic Telangiectasia|Studies of Hereditary Hemorrhagic Telangiectasia: Screening Methods for Pulmonary Arteriovenous Malformations; Prevalence of Pulmonary and Cerebral Arteriovenous Malformations; Prevalence of Cardiac Valve Abnormalities; and Identification of Modifier Genes|Completed|||65||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.30976|2018-06-01 05:39:18.30976
NCT00004647|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1993||1993-03-31|March 1999|1999-03-31|February 1999||1999-02-28|||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy||Completed||Phase 3|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.481959|2018-06-01 05:39:18.481959
NCT00004646|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1995||1995-04-30|December 2001|2001-12-31||||||||Interventional|||Phase III Randomized, Double-Blind Study of Prednisone for Duchenne Muscular Dystrophy||Completed||Phase 3|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.577131|2018-06-01 05:39:18.577131
NCT00004645|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1995||1995-01-31|March 1999|1999-03-31||||||||Interventional|||Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone||Unknown status|Active, not recruiting|Phase 3|22||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.675089|2018-06-01 05:39:18.675089
NCT00004644|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1995||1995-02-28|March 1999|1999-03-31||||||||Interventional|||Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection||Completed||Phase 1/Phase 2|25||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.7961|2018-06-01 05:39:18.7961
NCT00004643|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1995||1995-02-28|March 1999|1999-03-31||||||||Interventional|||Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus||Completed||Phase 2|10||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.844653|2018-06-01 05:39:18.844653
NCT00000452|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2004|2004-11-30|January 2003||2003-01-31|||||Interventional|||Naltrexone Treatment of Alcohol Dependence||Completed||Phase 4|240||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:15.68508|2018-06-01 05:40:15.68508
NCT00004642|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-24|||2005-06-23|2000-02-24|2000-02-25|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1995||1995-02-28|March 1999|1999-03-31||||||||Interventional|||Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease|Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease|Completed||Phase 1/Phase 2|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:39:18.975737|2018-06-01 05:39:18.975737
NCT00004638|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-23|||2005-06-23|2000-02-23|2000-02-24|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:19.032741|2018-06-01 05:39:19.032741
NCT00004637|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-23|||2005-06-23|2000-02-23|2000-02-24|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy||Completed||Phase 4|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:19.095144|2018-06-01 05:39:19.095144
NCT00004635|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-19|2012-03-30||2018-04-13|2000-02-19|2000-02-21|Estimate|2012-08-13|2012-09-12|Estimate||||2018-04-13|2018-05-22|Actual|March 1, 2000|Actual|2000-03-01|April 2018|2018-04-30|March 30, 2010|Actual|2010-03-30|January 30, 2005|Actual|2005-01-30||Interventional|||Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer|A Double Blinded Randomized Crossover Phase III Study of Oral Thalidomide Versus Placebo in Patients With Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation|Completed||Phase 3|159|Actual|National Institutes of Health Clinical Center (CC)|A total of 159 participants were accrued beginning in March 2000 until January 2005. Accrual rates were less than anticipated and the study was closed to further entry by the Independent Data Safety and Monitoring Board for the NCI CCR.|2|||f||||f|t|f|||f|||No||2018-06-01 05:39:19.221403|2018-06-01 05:39:19.221403
NCT00004577|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-18|||2018-03-27|2000-02-18|2000-02-21|Estimate|||||||2018-03-27|2018-03-29|Actual|February 17, 2000||2000-02-17|August 23, 2017|2017-08-23||||||||Observational|||Study of New Magnetic Resonance Imaging Methods of the Brain|Characterization of Brain Morphology and Activity Using Functional and Anatomical MRI Contrast|Recruiting|||650|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:20.589223|2018-06-01 05:39:20.589223
NCT00004573|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-18|||2005-06-23|2000-02-18|2000-02-21|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2001|2001-11-30||||||||Interventional|||Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR||Unknown status|Active, not recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:20.66711|2018-06-01 05:39:20.66711
NCT00004572|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-16|||2005-06-23|2000-02-16|2000-02-17|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2000|2000-04-30||||||||Observational|||Identification and Therapy Efficacy of Type 2 Diabetes in Hispanic Patients||Unknown status|Active, not recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:20.81234|2018-06-01 05:39:20.81234
NCT00004571|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-15|||2018-04-24|2000-02-15|2000-02-16|Estimate|||||||2018-04-24|2018-04-25|Actual|February 14, 2000||2000-02-14|April 9, 2018|2018-04-09||||||||Observational|||Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers|Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 3.0 Tesla MRI and Magnetoencephalography|Recruiting|||2920|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:20.874168|2018-06-01 05:39:20.874168
NCT00004570|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-14|||2018-05-17|2000-02-14|2000-02-15|Estimate|||||||2018-05-17|2018-05-18|Actual|February 11, 2000||2000-02-11|September 7, 2017|2017-09-07||||||||Observational|||Hereditary Deficits in Auditory Processing Leading to Language Impairment|Identification of Hereditary Auditory Temporal Processing Deficits|Completed|||875|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:20.939305|2018-06-01 05:39:20.939305
NCT00004569|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-12|||2005-06-23|2000-02-12|2000-02-14|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2004|2004-01-31||||||||Interventional|||Incorporating Flow Limitation Into the Diagnosis and Quantification of Sleep Disordered Breathing||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:21.044421|2018-06-01 05:39:21.044421
NCT00004568|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-11|||2018-05-23|2000-02-11|2000-02-14|Estimate|||||||2018-05-23|2018-05-24|Actual|February 8, 2000||2000-02-08|March 12, 2018|2018-03-12||||||||Observational|||Study of Inherited Neurological Disorders|Clinical and Molecular Manifestations of Inherited Neurological Disorders|Recruiting|||2500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:21.090822|2018-06-01 05:39:21.090822
NCT00004567|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-11|||2008-03-03|2000-02-11|2000-02-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2000||2000-02-29|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes|A Randomized Trial Comparing Methotrexate Versus Mycophenolate Mofetil for Remission Maintenance in Wegener's Granulomatosis and Related Vasculitides|Completed||Phase 2|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:21.173623|2018-06-01 05:39:21.173623
NCT00004566|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-11|||2008-03-03|2000-02-11|2000-02-14|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2000||2000-02-29|May 2004|2004-05-31|May 2004||2004-05-31|||||Observational|||Study of Fetal Swallowing|Pilot Study: Ultrasonic Evaluation of the Development of the Fetal Upper Aerodigestive Tract: Establishing Clinical Indicators of Deglutitive Function|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:21.272649|2018-06-01 05:39:21.272649
NCT00004565|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-11|||2018-05-18|2000-02-11|2000-02-14|Estimate|||||||2018-05-18|2018-05-21|Actual|February 8, 2000||2000-02-08|May 4, 2012|2012-05-04|May 4, 2012||2012-05-04|||||Observational|||Susceptibility to Breast Cancer|Susceptibility to Breast Cancer|Completed|||737|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:21.324408|2018-06-01 05:39:21.324408
NCT00004564|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-11|||2005-06-23|2000-02-11|2000-02-14|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A||Unknown status|Recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:21.392925|2018-06-01 05:39:21.392925
NCT00004563|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-09|2015-02-19||2015-03-05|2000-02-09|2000-02-10|Estimate|2015-02-19|2015-03-06|Estimate||||2015-03-05|2015-03-27|Estimate|August 1999||1999-08-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SLS||Scleroderma Lung Disease|Cyclophosphamide Versus Placebo in Scleroderma Lung Study|Completed||Phase 3|158|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-06-01 05:39:21.459878|2018-06-01 05:39:21.459878
NCT00004562|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-09|2010-05-07||2014-04-03|2000-02-09|2000-02-10|Estimate|2013-01-04|2013-02-11|Estimate||||2014-04-03|2014-04-21|Estimate|September 1999||1999-09-30|April 2014|2014-04-30|June 2011|Actual|2011-06-30|March 2010|Actual|2010-03-31||Interventional|OAT||Occluded Artery Trial (OAT)|Occluded Artery Trial (OAT) - Randomized Comparative Effectiveness Trial of PCI and Medical Therapy Only Post MI|Completed||Phase 3|2201|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-06-01 05:39:21.703256|2018-06-01 05:39:21.703256
NCT00004561|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-09|||2016-05-12|2000-02-09|2000-02-10|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 1997||1997-06-30|August 2004|2004-08-31|May 2003|Actual|2003-05-31|||||Interventional|||Treatment of Hypertension With Two Exercise Intensities||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:39:22.143063|2018-06-01 05:39:22.143063
NCT00004560|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-09|||2016-04-13|2000-02-09|2000-02-10|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 1999||1999-09-30|November 2005|2005-11-30|February 2004||2004-02-29|||||Interventional|||Public Access Defibrillation (PAD) Community Trial||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:39:22.187878|2018-06-01 05:39:22.187878
NCT00004559|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-09|||2016-03-15|2000-02-09|2000-02-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|March 1999||1999-03-31|November 2005|2005-11-30|February 2002|Actual|2002-02-28|||||Interventional|||Fatty Acid Antiarrhythmia Trial (FAAT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:39:22.249603|2018-06-01 05:39:22.249603
NCT00004558|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-09|||2016-02-17|2000-02-09|2000-02-10|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 1999||1999-02-28|December 2005|2005-12-31|January 2004|Actual|2004-01-31|||||Interventional|||Antiarrhythmic Effects of N-3 Fatty Acids||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:39:22.300863|2018-06-01 05:39:22.300863
NCT00004556|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-08|||2018-03-27|2000-02-08|2000-02-09|Estimate|||||||2018-03-27|2018-03-29|Actual|September 30, 1991||1991-09-30|June 2, 2017|2017-06-02||||||||Observational|||The Effects of Dextroamphetamine on Brain Function|Mechanisms of Individual Variation of Dextroamphetamine Effects in Normal Human Subjects|Completed|||108|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:22.414607|2018-06-01 05:39:22.414607
NCT00004554|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-04|||2015-10-02|2000-02-04|2000-02-07|Estimate|||||||2015-10-02|2015-10-06|Estimate|January 2000||2000-01-31|September 2013|2013-09-30|February 2006|Actual|2006-02-28|August 2005|Actual|2005-08-31||Interventional|||Sertraline for Alcohol Dependence and Depression|Sertraline for Alcohol Dependence and Depression|Completed||Phase 4|171|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-06-01 05:39:22.472542|2018-06-01 05:39:22.472542
NCT00004553|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-04|||2008-03-03|2000-02-04|2000-02-07|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 2000||2000-02-29|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Electromyography to Diagnose Neuromuscular Disorders|Diagnosis of Neuromuscular Disorders With Specialized Electromyographic Studies|Completed||N/A|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:22.544913|2018-06-01 05:39:22.544913
NCT00004552|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-03|||2015-06-30|2000-02-03|2000-02-04|Estimate|||||||2015-06-30|2015-07-02|Estimate||||June 2015|2015-06-30|December 2002||2002-12-31|||||Interventional|||Acamprosate Treatment: Mechanisms of Action|Etiology and Treatment of Alcohol Dependence|Completed||Phase 2|120||Yale University|||||f||||||||||||||2018-06-01 05:39:22.606564|2018-06-01 05:39:22.606564
NCT00004551|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-03|||2010-09-28|2000-02-03|2000-02-04|Estimate|||||||2010-09-28|2010-09-29|Estimate|February 1999||1999-02-28|September 2010|2010-09-30|January 2003|Actual|2003-01-31|January 2003|Actual|2003-01-31||Interventional|||Behavioral Counseling for Alcohol Dependent Smokers (Nicotine Patch)|Mood Management Training for Alcohol Dependent Smokers|Completed||Phase 4|144|Actual|Mayo Clinic|||||f||||||||||||||2018-06-01 05:39:22.660152|2018-06-01 05:39:22.660152
NCT00004550|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-03|||2017-06-30|2000-02-03|2000-02-04|Estimate|||||||2017-06-30|2017-07-02|Actual|January 28, 2000||2000-01-28|April 21, 2008|2008-04-21|April 21, 2008||2008-04-21|||||Observational|||Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions|The Evaluation and Follow-up of Patients With Obsessive-Compulsive Disorder and OC Spectrum Disorders|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:22.765795|2018-06-01 05:39:22.765795
NCT00004549|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-03|||2008-03-03|2000-02-03|2000-02-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Magnetic Resonance Imaging to Detect Blood Vessel Inflammation in Patients Undergoing Peripheral Balloon Angioplasty|MRI Detection of Vascular Inflammation in Patients Undergoing Peripheral Angioplasty|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:22.817349|2018-06-01 05:39:22.817349
NCT00004547|ClinicalTrials.gov processed this data on May 31, 2018|2000-02-03|2011-08-30||2015-10-19|2000-02-03|2000-02-04|Estimate|2011-10-13|2011-11-22|Estimate||||2015-10-19|2015-11-18|Estimate|January 2000||2000-01-31|September 2015|2015-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy|Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis|Completed||Phase 2|188|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||f||||||||||2018-06-01 05:39:22.891029|2018-06-01 05:39:22.891029
NCT00004533|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2017-05-30|2000-01-28|2000-01-31|Estimate|||||||2017-05-30|2017-06-01|Actual|August 1999||1999-08-31|May 2017|2017-05-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis|Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis|Completed||Phase 1|19||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||||||||||||2018-06-01 05:39:23.359969|2018-06-01 05:39:23.359969
NCT00001987|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-28|||2018-05-18|2000-01-28|2000-01-31|Estimate|||||||2018-05-18|2018-05-21|Actual|January 30, 1976||1976-01-30|April 12, 2018|2018-04-12||||||||Observational|||Genetic Studies of Insulin and Diabetes|Natural History of Disorders of Insulin Resistance|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:23.428755|2018-06-01 05:39:23.428755
NCT00000436|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-29|||2007-01-02|2000-01-29|2000-01-31|Estimate|||||||2007-01-02|2007-01-04|Estimate|July 1993||1993-07-31|March 2001|2001-03-31|June 2000||2000-06-30|||||Interventional|||Improving Functional Recovery After Hip Fracture|Self-Efficacy and High-Intensity Strength Training to Improve Postoperative Rehabilitation of Hip Fracture Patients|Completed||Phase 3|200||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:39:23.502774|2018-06-01 05:39:23.502774
NCT00001985|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-26|||2008-03-04|2000-01-26|2000-01-27|Estimate|||||||2008-03-04|2008-03-05|Estimate|January 2000||2000-01-31|February 2003|2003-02-28|February 2003||2003-02-28|||||Observational|||Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus|Multi-Center Study to Determine Whether CD 152 Gene Polymorphisms Associated With Susceptibility to Type-1-Diabetes Mellitus (T1DM) Correspond With Abnormalities in T Cell Function|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:23.563074|2018-06-01 05:39:23.563074
NCT00001984|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-26|2010-09-13||2016-09-22|2000-01-26|2000-01-27|Estimate|2010-09-13|2010-10-05|Estimate||||2016-09-22|2016-10-27|Estimate|November 1999||1999-11-30|September 2016|2016-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys|Tolerance Induction Following Human Renal Transplantation Using Treatment With a Humanized Monoclonal Antibody Against CD52 (Campath-1H)|Completed||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 05:39:23.639786|2018-06-01 05:39:23.639786
NCT00001983|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-26|||2008-03-03|2000-01-26|2000-01-27|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Observational|||Eligibility Screening for National Institute of Dental and Craniofacial Research Studies|Screening Protocol to Evaluate Patients for Approved Studies|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:23.894393|2018-06-01 05:39:23.894393
NCT00001981|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2018-05-23|2000-01-21|2000-01-24|Estimate|||||||2018-05-23|2018-05-24|Actual|April 15, 1985||1985-04-15|April 26, 2018|2018-04-26||||||||Observational|||The Treatment and Natural History of Acromegaly|Acromegaly Treatment and Natural History|Active, not recruiting|||117|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:23.945097|2018-06-01 05:39:23.945097
NCT00000435|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2007-07-30|2000-01-21|2000-01-24|Estimate|||||||2007-07-30|2007-07-31|Estimate|September 1999||1999-09-30|July 2007|2007-07-31|September 2004||2004-09-30|||||Interventional|||dnaJ Peptide for Relieving Rheumatoid Arthritis|A Clinical Trial of Shared Epitope Peptides in Rheumatoid Arthritis (RA)|Completed||Phase 2|160|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||2|||||||||||||||||2018-06-01 05:39:24.029057|2018-06-01 05:39:24.029057
NCT00000434|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-21|||2007-12-20|2000-01-21|2000-01-24|Estimate|||||||2007-12-20|2007-12-28|Estimate|December 1983||1983-12-31|December 2007|2007-12-31|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Impact of Exercise on Older Persons With Osteoarthritis|Impact of Exercise on Older Persons With Osteoarthritis (OA)|Completed||Phase 2|217|Actual|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)||1|||f||||f||||||||||2018-06-01 05:39:24.10983|2018-06-01 05:39:24.10983
NCT00001979|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-20|||2018-03-27|2000-01-20|2000-01-21|Estimate|||||||2018-03-27|2018-03-29|Actual|April 14, 1992||1992-04-14|July 24, 2017|2017-07-24||||||||Observational|||Immune System Related Kidney Disease|Studies of Immunologically-Mediated Kidney Diseases|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.1885|2018-06-01 05:39:24.1885
NCT00001978|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-20|||2018-05-16|2000-01-20|2000-01-21|Estimate|||||||2018-05-16|2018-05-17|Actual|August 24, 1989||1989-08-24|December 28, 2017|2017-12-28||||||||Observational|||Determination of Kidney Function|Determination of Glomerular Filtration Rate, Effective Renal Plasma Flow and Glomerular Capillary Wall Permselectivity|Recruiting|||9999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.265915|2018-06-01 05:39:24.265915
NCT00001976|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-20|||2008-03-03|2000-01-20|2000-01-21|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 2000||2000-01-31|February 2003|2003-02-28|February 2003||2003-02-28|||||Observational|||Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection|CMV Real-Time PCR Versus PP65 Antigenemia in Diagnosing Cytomegalovirus Disease in Hematopoietic Stem Cell Transplant Patients|Completed|||180||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.322155|2018-06-01 05:39:24.322155
NCT00001975|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-20|||2018-05-24|2000-01-20|2000-01-21|Estimate|||||||2018-05-24|2018-05-25|Actual|January 19, 2000||2000-01-19|December 20, 2017|2017-12-20||||||||Observational|||Study of Skin Tumors in Tuberous Sclerosis|Cutaneous Tumorigenesis in Patients With Tuberous Sclerosis|Recruiting|||130|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.375607|2018-06-01 05:39:24.375607
NCT00001973|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2017-06-30|2000-01-18|2000-01-19|Estimate|||||||2017-06-30|2017-07-02|Actual|December 18, 1996||1996-12-18|December 12, 2008|2008-12-12|December 12, 2008||2008-12-12|||||Observational|||Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome|Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.433548|2018-06-01 05:39:24.433548
NCT00001972|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1994||1994-09-30|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||PET Scan of Brain Metabolism in Relation to Age and Disease|Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and Disease|Completed|||123||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.536415|2018-06-01 05:39:24.536415
NCT00001971|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2018-05-02|2000-01-18|2000-01-19|Estimate|||||||2018-05-02|2018-05-03|Actual|September 10, 1991||1991-09-10|May 1, 2018|2018-05-01||||||||Observational|||Evaluation of Patients With Liver Disease|Evaluation of Patients With Liver Disease|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.594079|2018-06-01 05:39:24.594079
NCT00001969|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2017-06-30|2000-01-18|2000-01-19|Estimate|||||||2017-06-30|2017-07-02|Actual|December 30, 1999||1999-12-30|January 19, 2007|2007-01-19|January 19, 2007||2007-01-19|||||Observational|||Heart Disease Risk Factors in Major Depression|Factors in Susceptibility to Ischemic Heart Disease in Major Depression: Documentation of Insulin Resistance in Patients With Major Depression Utilizing the Hyperinsulinemic Euglycemic Glucose Clamp|Completed|||160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.671764|2018-06-01 05:39:24.671764
NCT00001967|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1999||1999-11-30|November 2004|2004-11-30|November 2004||2004-11-30|||||Interventional|||Intermittent Versus Continuous Medication in the Treatment of HIV|Immunologic and Virologic Studies of Intermittent Versus Continuous HAART in the Treatment of HIV Disease|Completed||Phase 4|123||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.722295|2018-06-01 05:39:24.722295
NCT00001964|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2018-04-24|2000-01-18|2000-01-19|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2, 1999||1999-12-02|April 18, 2018|2018-04-18|May 12, 2015|Actual|2015-05-12|December 9, 2003|Actual|2003-12-09||Interventional|||Combination Therapy of Severe Aplastic Anemia|Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)|Completed||Phase 2|104|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:24.797638|2018-06-01 05:39:24.797638
NCT00001962|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|2011-04-20||2015-04-28|2000-01-18|2000-01-19|Estimate|2015-04-28|2015-05-14|Estimate||||2015-04-28|2015-05-14|Estimate|November 1999||1999-11-30|April 2015|2015-04-30|September 2010|Actual|2010-09-30|August 2009|Actual|2009-08-31||Interventional|||A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure|A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia|Terminated||Phase 2|100|Actual|National Institutes of Health Clinical Center (CC)||1||DSMB recommended closing the study and publishing the results|f||||t||||||||||2018-06-01 05:39:24.930561|2018-06-01 05:39:24.930561
NCT00001961|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Interventional|||MRI Evaluation of Chest Pain|MRI Evaluation of Chest Pain Compatible With Myocardial Ischemia|Completed||Phase 2|360||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.200781|2018-06-01 05:39:25.200781
NCT00001960|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1999||1999-11-30|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle|Controlled Cross-Over Study of DDD Pacemaker Therapy in Symptomatic Children With Obstructive Hypertrophic Cardiomyopathy|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.253398|2018-06-01 05:39:25.253398
NCT00001959|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|2010-06-16||2014-05-16|2000-01-18|2000-01-19|Estimate|2012-04-25|2012-06-01|Estimate||||2014-05-16|2014-05-26|Estimate|December 1999||1999-12-31|April 2012|2012-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)|Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study|Completed||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)|No control group, measurement imprecision, results may not applicable to all patients with FSGS, needs histologic evidence to support our findings, Optimal dosage needs to be identified.||||f||||f||||||||||2018-06-01 05:39:25.313854|2018-06-01 05:39:25.313854
NCT00001958|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|February 2002|2002-02-28|February 2002||2002-02-28|||||Interventional|||Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)|Effect of Hydroxyurea on the Level of Ineffective Erythropoiesis, Transfusion Requirement, and Fetal Hemoglobin Synthesis in Patients With Beta-Thalassemia-Intermedia|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.558655|2018-06-01 05:39:25.558655
NCT00001957|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1999||1999-11-30|November 2003|2003-11-30|November 2003||2003-11-30|||||Observational|||Testing a Possible Cause of Reduced Ability of Children to Process Speech in Noise|TEOAE Suppression in Children With Auditory Processing Difficulty|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.626577|2018-06-01 05:39:25.626577
NCT00001956|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2006-06-29|2000-01-18|2000-01-19|Estimate|||||||2006-06-29|2006-06-30|Estimate|January 2000||2000-01-31|February 2005|2005-02-28|February 2005||2005-02-28|||||Interventional|||Influence of Genetics in Pain Sensitivity||Completed||Phase 2|800||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.693163|2018-06-01 05:39:25.693163
NCT00001955|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)|The Role of Cytokines as Inflammatory Mediators in Painful Temporomandibular Joints|Completed||Phase 2|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.76631|2018-06-01 05:39:25.76631
NCT00001954|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||Etanercept Therapy for Sjogren's Syndrome|Etanercept Therapy for Sjogren's Syndrome|Completed||Phase 2|28||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.836038|2018-06-01 05:39:25.836038
NCT00001953|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1999||1999-11-30|December 2001|2001-12-31|December 2001||2001-12-31|||||Observational|||The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers|Basal and Stimulated Somatostatin Plasma Levels in Patients With Primary Sjogren's Syndrome and in Control Subjects|Completed|||32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.910004|2018-06-01 05:39:25.910004
NCT00001952|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1999||1999-11-30|December 2002|2002-12-31|December 2002||2002-12-31|||||Observational|||Using a Narcotic to Enhance the Numbing Effect of the Local Anesthetic Lidocaine on Inflamed Molar Teeth|Analgesic Effects of Peripherally Administered Opioids in a Clinical Model of Chronic Inflammation|Completed|||275||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:25.985005|2018-06-01 05:39:25.985005
NCT00001951|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2007-02-24|2000-01-18|2000-01-19|Estimate|||||||2007-02-24|2007-02-27|Estimate|December 1999||1999-12-31|October 2006|2006-10-31|October 2006||2006-10-31|||||Interventional|||Hormone Replacement in Young Women With Premature Ovarian Failure|Hormone Replacement in Young Women With Premature Ovarian Failure|Completed||Phase 2|250||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:26.034953|2018-06-01 05:39:26.034953
NCT00001950|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2018-02-13|2000-01-18|2000-01-19|Estimate|||||||2018-02-13|2018-02-14|Actual|December 14, 1999||1999-12-14|May 23, 2012|2012-05-23|May 23, 2012||2012-05-23|||||Observational|||The Development of Categorization|The Development of Categorization|Completed|||219|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:26.105822|2018-06-01 05:39:26.105822
NCT00001948|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|February 2002|2002-02-28|February 2002||2002-02-28|||||Observational|||A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy|A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:26.159182|2018-06-01 05:39:26.159182
NCT00001946|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2008-03-03|2000-01-18|2000-01-19|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1999||1999-12-31|September 2002|2002-09-30|September 2002||2002-09-30|||||Interventional|||Comparison of Magnetic Resonance Angiography and Standard Angiography in Diagnosing Atherosclerosis|A Comparison of Contrast Enhanced Magnetic Resonance Angiography (MRA) and Conventional Angiography in the Diagnosis of Atherosclerotic Disease: A Pilot Study|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:26.216639|2018-06-01 05:39:26.216639
NCT00001941|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|2012-04-23||2012-08-13|2000-01-18|2000-01-19|Estimate|2012-07-02|2012-08-09|Estimate||||2012-08-13|2012-08-20|Estimate|December 1999||1999-12-31|August 2012|2012-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Anti-Tac for Treatment of Leukemia|A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia|Completed||Phase 1/Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)|Study was closed to accrual since the cessation of the production of daclizumab.|5|||f||||f||||||||||2018-06-01 05:39:26.300368|2018-06-01 05:39:26.300368
NCT00001938|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2018-05-22|2000-01-18|2000-01-19|Estimate|||||||2018-05-22|2018-05-23|Actual|November 17, 1999||1999-11-17|May 4, 2018|2018-05-04||||||||Observational|||A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)|A Pilot Study of Proteomic Evaluation of Epithelial Ovarian Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile Associated With Relapse|Completed|||26|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:26.620713|2018-06-01 05:39:26.620713
NCT00000433|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2007-01-02|2000-01-18|2000-01-19|Estimate|||||||2007-01-02|2007-01-04|Estimate|October 1999||1999-10-31|February 2003|2003-02-28|March 2002||2002-03-31|||||Interventional|||Blocking Tumor Necrosis Factor in Ankylosing Spondylitis|Anti-Tumor Necrosis Factor (TNFR:Fc) in Ankylosing Spondylitis|Completed||Phase 2|42||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:39:26.683291|2018-06-01 05:39:26.683291
NCT00000432|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2013-12-23|2000-01-18|2000-01-19|Estimate|||||||2013-12-23|2013-12-24|Estimate|April 1997||1997-04-30|December 2013|2013-12-31|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Lyme Disease Prevention Program|A Controlled Trial of a Primary and Secondary Program for Lyme Disease|Completed||Phase 3|20000||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:39:26.753656|2018-06-01 05:39:26.753656
NCT00000431|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2013-05-08|2000-01-18|2000-01-19|Estimate|||||||2013-05-08|2013-05-13|Estimate|January 2005||2005-01-31|March 2009|2009-03-31|March 2011|Actual|2011-03-31|July 2008|Actual|2008-07-31||Interventional|||Preliminary Testing of New Treatment for Chronic Leg Wounds|Phase I Trial to Evaluate the Safety of Platelet Derived Growth Factor B (PDGF-B) and a Limb Compression Bandage in Venous Leg Ulcers|Completed||Phase 1|24|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-06-01 05:39:26.803577|2018-06-01 05:39:26.803577
NCT00000430|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2007-01-02|2000-01-18|2000-01-19|Estimate|||||||2007-01-02|2007-01-04|Estimate|October 1999||1999-10-31|February 2004|2004-02-29|September 2004||2004-09-30|||||Interventional|||Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis|Clinical Trial of Continuous Low-Dose Hormone Replacement Therapy Combined With Alendronate in Postmenopausal Women With Low Bone Density|Terminated||Phase 3|240||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:39:26.859911|2018-06-01 05:39:26.859911
NCT00000429|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2013-07-31|2000-01-18|2000-01-19|Estimate|||||||2013-07-31|2013-08-01|Estimate|June 1996||1996-06-30|July 2013|2013-07-31|May 2001||2001-05-31|||||Interventional|||Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis|Calcium Supplementation for Bone Mineralization in Juvenile Rheumatoid Arthritis (JRA)|Completed||Phase 2|192||Children's Hospital Medical Center, Cincinnati|||||f||||||||||||||2018-06-01 05:39:26.922054|2018-06-01 05:39:26.922054
NCT00000428|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2013-07-31|2000-01-18|2000-01-19|Estimate|||||||2013-07-31|2013-08-01|Estimate|September 2000||2000-09-30|July 2013|2013-07-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Combining N-of-1 Trials to Assess Fibromyalgia Treatments|Combining N-of-1 Trials to Assess Fibromyalgia Therapies|Completed||Phase 4|58|Actual|Tufts Medical Center||1|||f||||t||||||||||2018-06-01 05:39:26.969048|2018-06-01 05:39:26.969048
NCT00000427|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2013-12-06|2000-01-18|2000-01-19|Estimate|||||||2013-12-06|2013-12-09|Estimate|September 1999||1999-09-30|December 2013|2013-12-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Effects of Parathyroid Hormone in Men With Osteoporosis|Anabolic Actions of Parathyroid Hormone in Osteoporotic Men|Completed||Phase 3|81||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 05:39:27.180942|2018-06-01 05:39:27.180942
NCT00000112|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2005-06-23|2000-01-18|2000-01-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Prevalence of Carbohydrate Intolerance in Lean and Obese Children||Unknown status|Recruiting||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:27.241409|2018-06-01 05:39:27.241409
NCT00000111|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2005-06-23|2000-01-18|2000-01-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||September 2000|2000-09-30||||||||Interventional|||Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites||Unknown status|Active, not recruiting|Phase 1|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:27.288249|2018-06-01 05:39:27.288249
NCT00000110|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2005-06-23|2000-01-18|2000-01-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:27.327272|2018-06-01 05:39:27.327272
NCT00000108|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2005-06-23|2000-01-18|2000-01-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Interventional|||Effects of Training Intensity on the CHD Risk Factors in Postmenopausal Women||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:27.387212|2018-06-01 05:39:27.387212
NCT00000107|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2005-06-23|2000-01-18|2000-01-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Body Water Content in Cyanotic Congenital Heart Disease||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:27.432627|2018-06-01 05:39:27.432627
NCT00000106|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-18|||2005-06-23|2000-01-18|2000-01-19|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2000|2000-11-30||||||||Interventional|||41.8 Degree Centigrade Whole Body Hyperthermia for the Treatment of Rheumatoid Diseases||Unknown status|Active, not recruiting|N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:39:27.545866|2018-06-01 05:39:27.545866
NCT00000393|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2015-02-26|2000-01-17|2000-01-18|Estimate|||||||2015-02-26|2015-03-02|Estimate|January 1988||1988-01-31|April 2002|2002-04-30||||January 1990|Actual|1990-01-31||Interventional|||A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).||Completed||Phase 1|6|Actual|National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:39:27.605774|2018-06-01 05:39:27.605774
NCT00000392|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|2015-07-17||2017-02-27|2000-01-17|2000-01-18|Estimate|2015-07-29|2015-08-04|Estimate||||2017-02-27|2017-02-28|Actual|January 1990||1990-01-31|October 2013|2013-10-31|August 1996|Actual|1996-08-31|August 1996|Actual|1996-08-31||Interventional|||Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.|Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.|Completed||Phase 2|215|Actual|National Institute of Mental Health (NIMH)||2|||f||||||||||||||2018-06-01 05:39:27.680362|2018-06-01 05:39:27.680362
NCT00000391|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2015-03-02|2000-01-17|2000-01-18|Estimate|||||||2015-03-02|2015-03-03|Estimate|January 1988||1988-01-31|April 2002|2002-04-30||||January 1990|Actual|1990-01-31||Interventional|||A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.||Completed||Phase 1|30|Actual|National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:39:28.068023|2018-06-01 05:39:28.068023
NCT00000390|ClinicalTrials.gov processed this data on May 31, 2018|2000-01-17|||2015-04-22|2000-01-17|2000-01-18|Estimate|||||||2015-04-22|2015-04-23|Estimate||||April 2000|2000-04-30||||||||Interventional|||Antidepressant Treatment of AIDS Related Depression.||Completed||Phase 2|||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:39:28.144261|2018-06-01 05:39:28.144261
NCT00001936|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|September 28, 1999||1999-09-28|August 18, 2009|2009-08-18||||August 18, 2009|Actual|2009-08-18||Observational|||Electrical Muscle Stimulation to Aid Swallowing in Dysphagia|Feasibility of Neuromuscular Stimulation for Laryngeal Elevation During Swallowing|Completed|||155||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.211471|2018-06-01 05:39:28.211471
NCT00001905|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|March 2002|2002-03-31|March 2002||2002-03-31|||||Interventional|||Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I|Interferon Gamma Administration in Leukocyte Adhesion Deficiency Type I|Completed||Phase 2|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.408377|2018-06-01 05:39:29.408377
NCT00001934|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2011-08-04|1999-11-03|1999-11-04|Estimate|||||||2011-08-04|2011-08-05|Estimate|September 1999||1999-09-30|August 2011|2011-08-31|September 2008|Actual|2008-09-30|August 2005|Actual|2005-08-31||Interventional|||Zenapax to Treat Multiple Sclerosis|Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II Trial|Completed||Phase 2|22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.307189|2018-06-01 05:39:28.307189
NCT00001933|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1999||1999-07-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Nefiracetam in the Treatment of Alzheimer's Disease|Nefiracetam Therapy of Alzheimer's Type Dementia|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.384655|2018-06-01 05:39:28.384655
NCT00001932|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|June 21, 1999||1999-06-21|August 15, 2007|2007-08-15|August 15, 2007||2007-08-15|||||Observational|||Serotonin Receptors in Seizure Disorders|PET Imaging of Serotonin Receptors in Seizure Disorders|Completed|||95||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.458615|2018-06-01 05:39:28.458615
NCT00001927|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|February 22, 1999||1999-02-22|May 4, 2011|2011-05-04|May 4, 2011||2011-05-04|||||Observational|||Study of Abnormal Blood Clotting in Children With Stroke|Study of Abnormal Acquired and Genetic Coagulation Factors in Children With Porencephaly and Stroke|Completed|||130|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.527926|2018-06-01 05:39:28.527926
NCT00001926|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|November 2003|2003-11-30|November 2003||2003-11-30|||||Observational|||The Connection Between Areas in the Brain of Blind Patients|Connectivity of Occipital and Somatosensory Cortical Areas in Blind Subjects|Completed|||45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.611033|2018-06-01 05:39:28.611033
NCT00001925|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1999||1999-01-31|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Effect of Alcohol on Tremors|Effect of Alcohol on Physiologic and Pathologic Tremors|Completed||Phase 2|23||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.68988|2018-06-01 05:39:28.68988
NCT00001923|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1998||1998-12-31|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Transcranial Magnetic Stimulation for the Treatment of Phantom Pain|Phantom Pain: A Therapeutic Trial Using Transcranial Magnetic Stimulation|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.753486|2018-06-01 05:39:28.753486
NCT00001922|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|November 5, 1998||1998-11-05|September 14, 2009|2009-09-14||||September 14, 2009|Actual|2009-09-14||Observational|||Sensory Function in Idiopathic Voice Disorders|Sensory Function in Idiopathic Voice Disorders|Completed|||370||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.82317|2018-06-01 05:39:28.82317
NCT00001921|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-16|1999-11-03|1999-11-04|Estimate|||||||2018-05-16|2018-05-17|Actual|September 21, 1999||1999-09-21|January 9, 2018|2018-01-09||||||||Observational|||Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings|Integrating EEG/MEG and fMRI: Activity Correlation Between Frontal and Temporal Lobe Structures in Schizophrenic Patients, Their Siblings and Unrelated Normal Volunteers|Enrolling by invitation|||1376|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.878069|2018-06-01 05:39:28.878069
NCT00001920|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 30, 1999||1999-08-30|June 2, 2010|2010-06-02|June 2, 2010||2010-06-02|||||Observational|||Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia|Investigation of Brain Function During Eyeblink Responding in Normal Volunteers and Patients With Schizophrenia (A Study of Behavior and Evoked Potentials)|Completed|||112|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.935796|2018-06-01 05:39:28.935796
NCT00001919|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1999||1999-09-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects|Serotonin Transporter Availability and Mood State in Normal Volunteers Taking Hypericum Perforatum (St. John's Wort)|Completed|||13||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:28.990416|2018-06-01 05:39:28.990416
NCT00001917|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1999||1999-04-30|April 2005|2005-04-30|April 2005||2005-04-30|||||Observational|||Brain Imaging in Elderly People and Individuals With Alzheimer's Disease|M2 Receptor Measurements in Aging and in Alzheimer's Disease|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.040169|2018-06-01 05:39:29.040169
NCT00001915|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1999||1999-01-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Observational|||Study of Attention Deficit/Hyperactivity Disorder Using Transcranial Magnetic Stimulation|Cortical Correlates of Subtle Motor Signs in Attention-Deficit/Hyperactivity Disorder and Healthy Controls|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.090226|2018-06-01 05:39:29.090226
NCT00001913|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1998||1998-10-31|October 2003|2003-10-31|October 2003||2003-10-31|||||Observational|||The Impact of Familiarity and Emotional Attachment on the Visual Processing of Faces|The Impact of Familiarity and Emotional Attachment on the Visual Processing of Faces|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.135043|2018-06-01 05:39:29.135043
NCT00001912|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 10, 1999||1999-08-10|April 4, 2012|2012-04-04|April 4, 2012||2012-04-04|||||Observational|||Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis|Analysis of the Occurrence of Perilesional Edema and Seizures in Patients With Inactive Cysticercosis|Completed|||6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.175858|2018-06-01 05:39:29.175858
NCT00001911|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1999||1999-07-31|July 2003|2003-07-31|July 2003||2003-07-31|||||Interventional|||Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections|Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.224036|2018-06-01 05:39:29.224036
NCT00001910|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1999||1999-07-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Observational|||Mechanisms of Allergen Immunotherapy|Immunologic Mechanism of Allergen Immunotherapy|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.35978|2018-06-01 05:39:29.35978
NCT00001901|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1999||1999-02-28|March 2005|2005-03-31|March 2005||2005-03-31|||||Interventional|||Etanercept to Treat Wegener's Granulomatosis|Phase I/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatosis|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.466752|2018-06-01 05:39:29.466752
NCT00001899|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|December 16, 1998||1998-12-16|April 8, 2013|2013-04-08|April 8, 2013||2013-04-08|||||Observational|||Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy|Immunologic and Virologic Characterization of HIV-Infected Patients After Cessation of Highly Active Antiretroviral Therapy (HAART)|Completed|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.518393|2018-06-01 05:39:29.518393
NCT00001898|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|June 29, 1999||1999-06-29|May 20, 2008|2008-05-20|May 20, 2008||2008-05-20|||||Observational|||Microarray Analysis for Human Genetic Disease|Microarray Analysis for Human Genetic Disease|Completed|||1500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.573085|2018-06-01 05:39:29.573085
NCT00001895|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1999||1999-08-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Interventional|||Electromechanical Mapping to Evaluate Heart Muscle|Evaluation of Electromechanical Endocardial Mapping for Assessment of Myocardial Ischemia and Viability|Completed||Phase 3|71||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.640034|2018-06-01 05:39:29.640034
NCT00001894|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-07-03|1999-11-03|1999-11-04|Estimate|||||||2006-07-03|2006-07-04|Estimate|August 1999||1999-08-31|September 2002|2002-09-30|September 2002||2002-09-30|||||Interventional|||A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy|A Randomized Prospective Comparison of DDD Chamber Pacing and Percutaneous Transluminal Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Associated With Severe Drug-Refractory Symptoms|Completed||Phase 2|70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.703001|2018-06-01 05:39:29.703001
NCT00001893|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 17, 1999||1999-08-17|June 13, 2008|2008-06-13||||December 31, 2002|Actual|2002-12-31||Interventional|||Study of TNFR:Fc (Enbrel) in the Treatment of Asthma|A Clinical Trial of TNFR:Fc in a Segmental Allergen Challenge Model of Asthma|Completed||Phase 2|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.773596|2018-06-01 05:39:29.773596
NCT00001888|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|April 1, 1999||1999-04-01|April 13, 2018|2018-04-13||||||||Observational|||Sample Collections From the Airways of Asthmatic Patients|Asthma Sample Collection Protocol|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.841203|2018-06-01 05:39:29.841203
NCT00001885|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 21, 1999||1999-03-21|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Observational|||Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis|Pulmonary Fibrosis Associated With Rheumatoid Arthritis: Identification of Genetic Polymorphisms|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.902451|2018-06-01 05:39:29.902451
NCT00001884|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 21, 1999||1999-03-21|December 28, 2007|2007-12-28|December 28, 2007||2007-12-28|||||Observational|||Specimen Collection for Individuals With Lung Disease Associated With Rheumatoid Arthritis|Specimen Procurement for Individuals With Pulmonary Fibrosis Associated With Rheumatoid Arthritis|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.951965|2018-06-01 05:39:29.951965
NCT00001883|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|1999-11-03|1999-11-04|Estimate|||||||2008-03-04|2008-03-05|Estimate|March 1999||1999-03-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Observational|||Quality Control of Cardiopulmonary Exercise Equipment|Quality Control of P-CCMB Cardiopulmonary Exercise Equipment|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:29.994504|2018-06-01 05:39:29.994504
NCT00001880|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|March 12, 1999||1999-03-12|August 18, 2017|2017-08-18||||||||Observational|||Stem Cell Transplantation for Metastatic Solid Tumors|Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy|Completed|||84|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:30.037073|2018-06-01 05:39:30.037073
NCT00001878|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1999||1999-02-28|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts|Contribution of Insulin-Like Growth Factor-I (IGF-I) and Its Binding Protein (IGFBP3) to Increased Left Ventricular Mass in Familial Hypertrophic Cardiomyopathy Caused by Distinct Sarcomeric Mutations|Completed|||175||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:30.090108|2018-06-01 05:39:30.090108
NCT00001877|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1999||1999-02-28|May 2004|2004-05-31|May 2004||2004-05-31|||||Interventional|||Treatment of Pulmonary Sarcoidosis With Pentoxifylline|Treatment of Pulmonary Sarcoidosis With Pentoxifylline|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.077327|2018-06-01 05:39:31.077327
NCT00001876|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-26|1999-11-03|1999-11-04|Estimate|||||||2018-05-26|2018-05-30|Actual|March 1, 1999||1999-03-01|May 23, 2018|2018-05-23||||||||Observational|||Lung Disease Associated With Rheumatoid Arthritis|Pulmonary Fibrosis Associated With Rheumatoid Arthritis: Definition of the Natural History of Disease|Completed|||132|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.132918|2018-06-01 05:39:31.132918
NCT00001874|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|February 22, 1999||1999-02-22|August 3, 2009|2009-08-03|August 3, 2009|Actual|2009-08-03|August 3, 2009|Actual|2009-08-03||Observational|||Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy|Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.191489|2018-06-01 05:39:31.191489
NCT00001873|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|February 22, 1999||1999-02-22|June 13, 2017|2017-06-13|June 13, 2017|Actual|2017-06-13|December 28, 2007|Actual|2007-12-28||Interventional|||The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers|Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine|Completed||Phase 2|102|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.24095|2018-06-01 05:39:31.24095
NCT00001872|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-24|1999-11-03|1999-11-04|Estimate|||||||2018-05-24|2018-05-25|Actual|February 2, 1999||1999-02-02|March 2, 2018|2018-03-02|March 2, 2018||2018-03-02|||||Observational|||Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease|Apheresis of Family Members of Patients Undergoing Allogeneic Bone Marrow Transplantation. A Pre-Clinical Study of Selective Depletion of Donor Lymphocytes to Prevent Acute Graft-Versus-Host Disease|Completed|||14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.321053|2018-06-01 05:39:31.321053
NCT00001870|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1999||1999-01-31|December 2004|2004-12-31|December 2004||2004-12-31|||||Interventional|||Study of the Effects of Vitamin C on Patients With Type 2 Diabetes|An Exploratory Study of the Effects of Oral Vitamin C Administration on Insulin Sensitivity and Vascular Reactivity in Subjects With Type 2 Diabetes|Completed||Phase 2|150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.394073|2018-06-01 05:39:31.394073
NCT00001869|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1998||1998-12-31|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)|Lymphangioleiomyomatosis (LAM) Registry|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.487368|2018-06-01 05:39:31.487368
NCT00001865|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1999||1999-07-31|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||HAT in Eye Complications of Behcet's Disease|A Study to Investigate the Safety and Efficacy of HAT to Treat the Ocular Complications Related to Behcet's Disease|Completed||Phase 2|26||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.554198|2018-06-01 05:39:31.554198
NCT00001863|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|February 2003|2003-02-28|February 2003||2003-02-28|||||Interventional|||Leflunomide to Treat Uveitis|Pilot Study of Leflunomide for the Treatment of Uveitis|Completed||Phase 2|16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.718668|2018-06-01 05:39:31.718668
NCT00001862|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1999||1999-02-28|March 2003|2003-03-31|March 2003||2003-03-31|||||Interventional|||TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis|The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis|Completed||Phase 2|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.786987|2018-06-01 05:39:31.786987
NCT00001861|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|January 29, 1999||1999-01-29|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Screening for Studies on Nystagmus and Strabismus|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Nystagmus or Strabismus|Completed|||1500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.847546|2018-06-01 05:39:31.847546
NCT00001860|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1999||1999-08-31|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Sandostatin LAR Depot vs. Surgery for Treating Acromegaly|Sandostatin LAR vs. Surgery in Acromegalics With Macroadenoma|Completed||Phase 2|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.9357|2018-06-01 05:39:31.9357
NCT00001859|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|June 4, 1999||1999-06-04|May 30, 2014|2014-05-30|May 30, 2014||2014-05-30|||||Observational|||Screening for Patients Needing Kidney, Kidney-Pancreas, or Islet-Cell Transplant|Screening Protocol for Patients Needing a Kidney, Kidney-Pancreas, or Islet Cell Transplant|Completed|||621|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:31.995547|2018-06-01 05:39:31.995547
NCT00001858|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-16|1999-11-03|1999-11-04|Estimate|||||||2018-05-16|2018-05-17|Actual|June 8, 1999||1999-06-08|May 30, 2014|2014-05-30|May 30, 2014||2014-05-30|||||Observational|||Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants|Monitoring for Donor-Specific Hyporesponsiveness Following Renal and Pancreatic Allotransplantation|Completed|||294|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:32.054477|2018-06-01 05:39:32.054477
NCT00001856|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|May 17, 1999||1999-05-17|May 30, 2014|2014-05-30|May 30, 2014||2014-05-30|||||Observational|||Live Donors for Kidney Transplants|Live Donor Renal Donation for Allotransplantation|Completed|||260|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:32.137134|2018-06-01 05:39:32.137134
NCT00001854|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|February 12, 1999||1999-02-12|January 15, 2008|2008-01-15|January 15, 2008|Actual|2008-01-15|October 10, 2007|Actual|2007-10-10||Interventional|||Long-Term Therapy With Ribavirin for Chronic Hepatitis C|Long-Term Therapy With Ribavirin for Chronic Hepatitis C|Completed||Phase 4|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:32.275196|2018-06-01 05:39:32.275196
NCT00001853|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|October 9, 1998||1998-10-09|November 29, 2017|2017-11-29||||||||Observational|||Diabetes and Heart Disease Risk in Blacks|Diabetes and Heart Disease Risk in Blacks|Recruiting|||1132|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:33.202138|2018-06-01 05:39:33.202138
NCT00001852|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-24|1999-11-03|1999-11-04|Estimate|||||||2018-05-24|2018-05-25|Actual|April 9, 1999||1999-04-09|November 29, 2017|2017-11-29|November 29, 2017||2017-11-29|||||Observational|||Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome|Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome|Completed|||560|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:33.479345|2018-06-01 05:39:33.479345
NCT00001851|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|December 15, 1998||1998-12-15|June 26, 2009|2009-06-26|April 30, 2002|Actual|2002-04-30|April 30, 2002|Actual|2002-04-30||Observational|||Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome|Evaluation and Treatment to Improve Bone Quality and Prevent Fractures by the Percutaneous Replacement of Diseased Tissue in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:33.955383|2018-06-01 05:39:33.955383
NCT00001850|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-08|1999-11-03|1999-11-04|Estimate|||||||2018-05-08|2018-05-09|Actual|May 5, 1999||1999-05-05|May 2, 2018|2018-05-02||||||||Observational|||Evaluation of Women With Endocrine and Reproductive-Related Conditions|Evaluation of Women and Men With Endocrine and Reproductive-Related Conditions|Recruiting|||900|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.051511|2018-06-01 05:39:34.051511
NCT00001726|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|June 19, 1998||1998-06-19|August 3, 2009|2009-08-03|August 3, 2009|Actual|2009-08-03|August 3, 2009|Actual|2009-08-03||Observational|||Study of the Composition of Dental Plaque|Spatial Organization of Viridans Streptococci in Oral Biofilms|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.293364|2018-06-01 05:39:40.293364
NCT00001849|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|February 26, 1999||1999-02-26|April 16, 2018|2018-04-16|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome|New Imaging Modalities in the Evaluation of Patients With Ectopic Cushing's Syndrome|Recruiting||Phase 1/Phase 2|202|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.130739|2018-06-01 05:39:34.130739
NCT00001848|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2016-09-21|1999-11-03|1999-11-04|Estimate|||||||2016-09-21|2016-09-22|Estimate|November 1998||1998-11-30|September 2016|2016-09-30|January 2006||2006-01-31|||||Interventional|||The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis|The Safety and Effectiveness of Surgery With or Without Raloxifene (Evista (Trademark), Lilly) for the Treatment of Pelvic Pain Caused by Endometriosis|Completed||Phase 2|612||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.219381|2018-06-01 05:39:34.219381
NCT00001846|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-11|1999-11-03|1999-11-04|Estimate|||||||2018-04-11|2018-04-12|Actual|August 27, 1999||1999-08-27|April 10, 2018|2018-04-10||||||||Observational|||Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use|Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.393706|2018-06-01 05:39:34.393706
NCT00001845|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1999||1999-09-30|August 2004|2004-08-31|August 2004||2004-08-31|||||Observational|||Study of Brain Blood Flow During Induced Hypercapnia (Excess Blood Carbon Dioxide)|MR Perfusion Imaging in Hypercapnia: Development of Technical Protocols|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.455451|2018-06-01 05:39:34.455451
NCT00001844|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|September 8, 1999||1999-09-08|September 7, 2012|2012-09-07|September 7, 2012||2012-09-07|||||Observational|||Study of New Magnetic Resonance Methods|Functional and Metabolic Imaging Using Magnetic Resonance at 3.0 Tesla|Terminated|||99|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.512536|2018-06-01 05:39:34.512536
NCT00001842|ClinicalTrials.gov processed this data on May 31, 2018|2007-07-31|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1999||1999-07-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||G-CSF for Granulocyte Donation|Kinetics of Intravenous G-CSF-Induced Granulocyte Mobilization in Healthy Apheresis Donors|Completed||Phase 1|16||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.653056|2018-06-01 05:39:34.653056
NCT00001841|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1999||1999-03-31|December 2004|2004-12-31|December 2004||2004-12-31|||||Observational|||Magnetic Resonance Angiography (MRA) for the Diagnosis of Atherosclerosis|Contrast Enhanced Resonance Angiography (MRA) in the Diagnosis of Atherosclerotic Disease: A Pilot Technical Development Study|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.738361|2018-06-01 05:39:34.738361
NCT00001837|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1998||1998-11-30|October 2005|2005-10-31|October 2005||2005-10-31|||||Observational|||Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients|Sonographic Evaluation of the Effects of Raloxifene on the Uterus and Ovaries in Premenopausal Patients at High Risk for Developing Breast Cancer|Completed|||60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.803595|2018-06-01 05:39:34.803595
NCT00001836|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1998||1998-10-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Observational|||Detection of Coronary Artery Calcification: Comparison of Volumetric and Electron Beam Computed Tomography|Detection of Coronary Artery Calcification: Comparison of Volumetric and Electron Beam Computed Tomography|Completed|||213||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.866702|2018-06-01 05:39:34.866702
NCT00001835|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1999||1999-09-30|December 2001|2001-12-31|December 2001||2001-12-31|||||Interventional|||Oxaliplatin in Cancer Patients With Impaired Kidney Function|A Phase I Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:34.921018|2018-06-01 05:39:34.921018
NCT00001832|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2012-11-07||2012-12-19|1999-11-03|1999-11-04|Estimate|2012-12-19|2012-12-21|Estimate||||2012-12-19|2012-12-21|Estimate|August 1999||1999-08-31|December 2012|2012-12-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma|Treatment of Patients With Metastatic Melanoma Using Cloned Lymphocytes Following the Administration of a Non-Myeloablative But Lymphocyte Depleting Regimen|Completed||Phase 2|170|Actual|National Institutes of Health Clinical Center (CC)||15|||f||||t||||||||||2018-06-01 05:39:35.070792|2018-06-01 05:39:35.070792
NCT00001830|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|July 20, 1999||1999-07-20|May 19, 2015|2015-05-19|May 19, 2015|Actual|2015-05-19|||||Interventional|||Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants|Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation|Completed||Phase 1|110|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:37.671214|2018-06-01 05:39:37.671214
NCT00001827|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|July 26, 1999||1999-07-26|January 25, 2013|2013-01-25|January 25, 2013|Actual|2013-01-25|December 17, 2007|Actual|2007-12-17||Interventional|||p53 Vaccine for Ovarian Cancer|Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary|Terminated||Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:37.740665|2018-06-01 05:39:37.740665
NCT00001826|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1999||1999-07-31|May 2006|2006-05-31|May 2006||2006-05-31|||||Observational|||Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor|A Long-Term Observational Study of Immunologic Reconstitution in HIV-1 Infected Children Who Are Receiving Combination Protease Inhibitor and Reverse Transcriptase Inhibitors|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:37.829586|2018-06-01 05:39:37.829586
NCT00001823|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-25|1999-11-03|1999-11-04|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 1, 1999||1999-07-01|May 24, 2018|2018-05-24||||||||Observational|||Evaluation for NCI Surgery Branch Clinical Studies|Evaluation for NCI Surgery Branch Clinical Research Protocols|Recruiting|||6000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:37.906036|2018-06-01 05:39:37.906036
NCT00000367|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-10-25|1999-11-02|1999-11-03|Estimate|||||||2013-10-25|2013-10-29|Estimate|September 1998||1998-09-30|October 2013|2013-10-31|August 2003||2003-08-31|||||Interventional|||Prevention of Suicide in the Elderly||Completed||N/A|||Weill Medical College of Cornell University|||||f||||||||||||||2018-06-01 05:40:19.930962|2018-06-01 05:40:19.930962
NCT00001813|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-30|1999-11-03|1999-11-04|Estimate|||||||2018-03-30|2018-04-02|Actual|April 27, 1999||1999-04-27|December 15, 2017|2017-12-15||||||||Observational|||Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy|Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy|Recruiting|||700|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:37.978134|2018-06-01 05:39:37.978134
NCT00001807|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|April 16, 1999||1999-04-16|September 1, 2017|2017-09-01||||||||Observational|||(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy|(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy|Active, not recruiting|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.065123|2018-06-01 05:39:38.065123
NCT00001806|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-24|1999-11-03|1999-11-04|Estimate|||||||2018-05-24|2018-05-25|Actual|April 6, 1999||1999-04-06|December 6, 2017|2017-12-06|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Methods in Education for Breast Cancer Genetics|Methods in Education for Breast Cancer Genetics|Completed||Phase 3|170|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:39:38.16475|2018-06-01 05:39:38.16475
NCT00001803|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-02-22|1999-11-03|1999-11-04|Estimate|||||||2018-02-22|2018-02-23|Actual|February 26, 1999||1999-02-26|September 28, 2017|2017-09-28||||||||Observational|||Von Hippel-Lindau Disease Genetic Epidemiology Study|Von Hippel-Lindau (VHL) Disease Genetic Epidemiology Study|Active, not recruiting|||546|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.267632|2018-06-01 05:39:38.267632
NCT00001788|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|October 13, 1998||1998-10-13|February 8, 2018|2018-02-08||||||||Observational|||Genetic Basis of Primary Immunodeficiencies|Molecular Basis of Primary Immunodeficiencies|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.321997|2018-06-01 05:39:38.321997
NCT00001785|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1998||1998-09-30|September 2004|2004-09-30|September 2004||2004-09-30|||||Interventional|||Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)|Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a|Completed||Phase 2|12||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.382097|2018-06-01 05:39:38.382097
NCT00001784|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1998||1998-07-31|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Mexiletine for the Treatment of Focal Dystonia|Mexiletine for the Treatment of Focal Dystonia|Completed||Phase 2|24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.43598|2018-06-01 05:39:38.43598
NCT00001783|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy|Neuroanatomical and Neurophysiological Basis of Motor Recovery Associated With Treatment of Recent Stroke Using Amphetamine and Physical Therapy|Completed||Phase 2|34||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.492267|2018-06-01 05:39:38.492267
NCT00001781|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1998||1998-02-28|March 2002|2002-03-31|March 2002||2002-03-31|||||Interventional|||Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)|Open-Label Baseline vs. Treatment Trial Evaluating the Safety, Tolerability and Effect on MRI Lesion and Immunology Parameters of CGP 77116 in Patients With Multiple Sclerosis Mark|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.545954|2018-06-01 05:39:38.545954
NCT00001780|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1998||1998-02-28|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Magnetic Stimulation of the Human Nervous System|Stimulation of the Human Central and Peripheral Nervous System With a Magnetic Stimulator|Completed|||450||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.601324|2018-06-01 05:39:38.601324
NCT00001778|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-22|1999-11-03|1999-11-04|Estimate|||||||2018-05-22|2018-05-23|Actual|December 31, 1997||1997-12-31|August 2, 2017|2017-08-02||||||||Observational|||Evaluation of Patients With HAM/TSP|Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.813629|2018-06-01 05:39:38.813629
NCT00001776|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|December 2003|2003-12-31|December 2003||2003-12-31|||||Observational|||Effects of Brain Stimulation on Learning and Reasoning|Can Stimulation of Frontal Cortical Regions Facilitate Performance on Tests of Procedural Implicit Learning and Analogical Reasoning?|Completed|||122||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.885332|2018-06-01 05:39:38.885332
NCT00001771|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1998||1998-05-31|May 2003|2003-05-31|May 2003||2003-05-31|||||Observational|||I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers|I-123 Beta-CIT SPECT Studies of Dopamine and Serotonin Transporters in Neuropsychiatric Patients and Normal Volunteers|Completed|||112||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.942079|2018-06-01 05:39:38.942079
NCT00001770|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1998||1998-03-31|March 2003|2003-03-31|March 2003||2003-03-31|||||Observational|||Progestin (Progesterone-Like Hormones) Induced Dysphoria (Depressed Mood, Irritability, Anxiety)|The Phenomenology and Biophysiology of Progestin-Induced Dysphoria|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:38.997533|2018-06-01 05:39:38.997533
NCT00001766|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1998||1998-08-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||Drug Interactions Among Anti-HIV Agents|Pharmacokinetic Interactions Between Ritonavir, Amprenavir and Efavirenz and Nelfinavir, Amprenavir, and Efavirenz in People Infected With HIV|Completed||Phase 1|22||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.077494|2018-06-01 05:39:39.077494
NCT00001765|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|February 2005|2005-02-28|February 2005||2005-02-28|||||Interventional|||Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease|Low Intensity Preparative Regimen Followed by HLA-Matched, Mobilized Peripheral Blood Stem Cell Transplantation for Chronic Granulomatous Disease|Completed||Phase 1|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.13252|2018-06-01 05:39:39.13252
NCT00001764|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions|Mycophenolate Mofetil in the Treatment of Wegener's Granulomatosis and Related Vasculitides|Completed||Phase 1|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.192669|2018-06-01 05:39:39.192669
NCT00001762|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|February 23, 1998||1998-02-23|July 26, 2013|2013-07-26|July 26, 2013||2013-07-26|||||Observational|||Magnetic Resonance Imaging of the Face and Bones|Magnetic Resonance Imaging to Study Avascular Necrosis in HIV-Infected Subjects|Completed|||532|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.314541|2018-06-01 05:39:39.314541
NCT00001760|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2007-12-12|1999-11-03|1999-11-04|Estimate|||||||2007-12-12|2007-12-13|Estimate|January 1998||1998-01-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Observational|||Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals|Determination of Cytokine Production Patterns in the Skin of Patients With Systemic Mastocytosis and Atopic Dermatitis Using the Suction Blister Technique|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.36972|2018-06-01 05:39:39.36972
NCT00001758|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1997||1997-11-30|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz|Continued Salvage Anti-Retroviral Therapy With Abacavir, Amprenavir, and Efavirenz|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.428246|2018-06-01 05:39:39.428246
NCT00001756|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|November 12, 1997||1997-11-12|August 8, 2017|2017-08-08||||||||Observational|||Study of Mast Cell Precursors|The Characterization of CD34+ Derived Mast Cell Precursors Mobilized by Administration of Granulocyte Colony Stimulating Factor and Plerixafor|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.511835|2018-06-01 05:39:39.511835
NCT00001750|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1998||1998-09-30|August 2002|2002-08-31|August 2002||2002-08-31|||||Interventional|||Comparing Treatments for Multiple Myeloma|Randomized Trial of Autologous Transplantation With Filgrastim Versus Stem Cell Factor/Filgrastim-Primed CD34-Enriched Peripheral Blood Cells for Multiple Myeloma|Completed||Phase 2|32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.597233|2018-06-01 05:39:39.597233
NCT00001749|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1998||1998-07-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Interventional|||Medical Treatment for Diamond Blackfan Anemia|Treatment of Diamond Blackfan Anemia With Antithymocyte Globulin and Cyclosporine A|Completed||Phase 2|25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.670427|2018-06-01 05:39:39.670427
NCT00001746|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|1999-11-03|1999-11-04|Estimate|||||||2008-03-04|2008-03-05|Estimate|April 1998||1998-04-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Screening for Inherited Heart Disease|Evaluation of Patients With Known or Suspected Inherited Heart Disease (Screening Protocol)|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.738944|2018-06-01 05:39:39.738944
NCT00001741|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1997||1997-11-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Interventional|||Study of Inherited Changes of Receptors Located on Blood Vessels|Study of Vascular Responsiveness in Subjects With Polymorphisms of the Angiotensin II Type I Receptor Gene|Completed||Phase 1|200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.795068|2018-06-01 05:39:39.795068
NCT00001737|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1998||1998-05-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Interventional|||Cyclosporin Implant to Treat Uveitis|A Pilot Study of a Sustained-Release Cyclosporine A Implant for Uveitis|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.859127|2018-06-01 05:39:39.859127
NCT00001734|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 23, 1998||1998-03-23|October 3, 2008|2008-10-03|October 3, 2008||2008-10-03|||||Observational|||Screening for NEI Clinical Studies|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Ocular Inflammatory or Immunologic Diseases|Completed|||3000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.925169|2018-06-01 05:39:39.925169
NCT00001733|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 6, 1998||1998-03-06|July 2, 2008|2008-07-02|July 2, 2008||2008-07-02|||||Observational|||Screening for Studies on Retinovascular Diseases|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Retinovascular Diseases|Completed|||2000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:39.97937|2018-06-01 05:39:39.97937
NCT00001732|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|February 25, 1998||1998-02-25|May 20, 2008|2008-05-20|May 20, 2008||2008-05-20|||||Observational|||Screening for Studies on Inherited Eye Diseases|Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Inherited Ophthalmic Diseases|Completed|||800||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.03546|2018-06-01 05:39:40.03546
NCT00001729|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|September 2002|2002-09-30|September 2002||2002-09-30|||||Interventional|||Combination Drug Therapy for Patients With Hepatitis C|Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C|Completed||Phase 3|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.088725|2018-06-01 05:39:40.088725
NCT00001728|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 24, 1998||1998-08-24|May 2, 2011|2011-05-02|May 2, 2011|Actual|2011-05-02|August 19, 2007|Actual|2007-08-19||Interventional|||Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome|A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome|Completed||Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.157011|2018-06-01 05:39:40.157011
NCT00001727|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-26|1999-11-03|1999-11-04|Estimate|||||||2018-05-26|2018-05-30|Actual|August 25, 1998||1998-08-25|May 21, 2018|2018-05-21||||||||Observational|||Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome|Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.220382|2018-06-01 05:39:40.220382
NCT00000571|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-12-28|1999-10-27|1999-10-28|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 1986||1986-02-28|April 2001|2001-04-30||||||||Interventional|||Trial of Inspiratory Muscle Rest and Exercise in Chronic Obstructive Lung Disease||Completed||Phase 3|||McGill University|||||f||||||||||||||2018-06-01 05:40:27.093487|2018-06-01 05:40:27.093487
NCT00001725|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1997||1997-12-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Studies of Dextromethorphan and Topiramate to Treat Oral and Facial Pain|Clinical Trials in Orofacial Neuralgias|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.341967|2018-06-01 05:39:40.341967
NCT00001724|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1997||1997-11-30|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction|Evaluation of the Analgesic Effects of Locally Applied Flurbiprofen and Bupivacaine in the Oral Surgery Model|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.407835|2018-06-01 05:39:40.407835
NCT00001723|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2012-10-11||2012-11-15|1999-11-03|1999-11-04|Estimate|2012-11-15|2012-12-18|Estimate||||2012-11-15|2012-12-18|Estimate|May 1998||1998-05-31|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases|Safety and Efficacy of Orlistat (Xenical, Hoffmann LaRoche) in African American and Caucasian Children and Adolescents With Obesity-Related Comorbid Conditions|Completed||Phase 2|200|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||||2018-06-01 05:39:40.474912|2018-06-01 05:39:40.474912
NCT00001722|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|July 2003|2003-07-31|July 2003||2003-07-31|||||Observational|||Fat Tissue Microperfusion to Measure Leptin Secretion and Its Relations With Fat Breakdown in Humans|Adipose Tissue Microperfusion to Assess Leptin Secretion and Its Relations With Lipolysis in Humans|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:40.845309|2018-06-01 05:39:40.845309
NCT00001721|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|March 23, 1998||1998-03-23|October 2, 2017|2017-10-02||||||||Observational|||Study of Smith-Lemli-Opitz Syndrome|Clinical and Basic Investigations Into Smith-Lemli-Opitz Syndrome|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.028846|2018-06-01 05:39:41.028846
NCT00001720|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2016-09-21|1999-11-03|1999-11-04|Estimate|||||||2016-09-21|2016-09-22|Estimate|March 1998||1998-03-31|September 2016|2016-09-30|June 2003||2003-06-30|||||Interventional|||Treatment of Childhood Osteoporosis With Alendronate (Fosamax)|Alendronate Versus Placebo for Idiopathic Juvenile Osteoporosis|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.100551|2018-06-01 05:39:41.100551
NCT00001719|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1998||1998-08-31|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||Magnetic Resonance Imaging of Blood Flow in the Liver and Abdomen|Examination of the Hemodynamics of the Portal Venous System in Normal Volunteers Using Magnetic Resonance Imaging|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.158455|2018-06-01 05:39:41.158455
NCT00001716|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1998||1998-07-31|July 2003|2003-07-31|July 2003||2003-07-31|||||Interventional|||Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia|Physiologic Effects of Inhaled Nitric Oxide, Nitroglycerin, and Placebo in Study Subjects With Sickle Cell Anemia|Completed||Phase 2|58||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.224373|2018-06-01 05:39:41.224373
NCT00001715|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 21, 1998||1998-04-21|August 23, 2017|2017-08-23|August 23, 2017||2017-08-23|||||Observational|||Evaluation of Patients With Blood Disorders|Evaluation of Hematologic Patients - Training Protocol|Completed|||898|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.280906|2018-06-01 05:39:41.280906
NCT00001713|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1998||1998-02-28|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||Treatment for Blood Clots in the Veins of the Legs|Treatment of Acute Deep Vein Thrombosis of the Lower Extremity With Intraclot, Pulse-Sprayed Recombinant Tissue Plasminogen Activator, Plus Heparin and Warfarin: A Pilot Study|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.345906|2018-06-01 05:39:41.345906
NCT00001712|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1998||1998-02-28|October 2005|2005-10-31|October 2005||2005-10-31|||||Observational|||Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan|Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan|Completed|||3400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.408111|2018-06-01 05:39:41.408111
NCT00001711|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|October 29, 1997||1997-10-29|September 26, 2017|2017-09-26||||||||Observational|||Magnetic Resonance Imaging (MRI) Ofl Volunteers|Volunteer Scanning on MR|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.456378|2018-06-01 05:39:41.456378
NCT00001703|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2011-05-17||2014-07-16|1999-11-03|1999-11-04|Estimate|2012-05-11|2012-06-14|Estimate||||2014-07-16|2014-07-25|Estimate|August 1998||1998-08-31|July 2014|2014-07-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma|Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)|Patients were enrolled to Arm A only due to poor accrual and the lack of peptide vaccine.|1||Due to poor accrual and lack of peptide vaccine|f||||f||||||||||2018-06-01 05:39:41.523978|2018-06-01 05:39:41.523978
NCT00001702|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|July 29, 1998||1998-07-29|October 6, 2009|2009-10-06||||June 6, 2007|Actual|2007-06-06||Observational|||Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection|Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.801468|2018-06-01 05:39:41.801468
NCT00001659|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Consequences of Conjugal Bereavement in Adults|Conjugal Bereavement in Older Adults: Biological, Functional, and Psychological Consequences|Completed|||210||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.970785|2018-06-01 05:39:42.970785
NCT00001701|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|July 29, 1998||1998-07-29|October 6, 2009|2009-10-06||||June 21, 2007|Actual|2007-06-21||Observational|||Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection|Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.860142|2018-06-01 05:39:41.860142
NCT00001698|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1998||1998-06-30|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR|Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR|Completed||Phase 2|57||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:41.924443|2018-06-01 05:39:41.924443
NCT00001695|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1998||1998-04-30|January 2002|2002-01-31|January 2002||2002-01-31|||||Observational|||Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trials|Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trials|Completed|||125||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.034705|2018-06-01 05:39:42.034705
NCT00001693|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1998||1998-03-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers|Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.087264|2018-06-01 05:39:42.087264
NCT00001689|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1998||1998-01-31|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia|A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia|Completed||Phase 1|90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.145971|2018-06-01 05:39:42.145971
NCT00001686|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|December 3, 1997||1997-12-03|March 28, 2018|2018-03-28||||||||Observational|||Evaluation, Treatment, and Natural History of Children With Cancer|Treatment of Children With Cancer|Enrolling by invitation|||408|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-06-01 05:39:42.218247|2018-06-01 05:39:42.218247
NCT00001683|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1997||1997-10-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer|A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer|Completed||Phase 1|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.304045|2018-06-01 05:39:42.304045
NCT00001678|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|July 7, 1998||1998-07-07|June 20, 2014|2014-06-20|June 20, 2014||2014-06-20|||||Observational|||Genetics of Rheumatoid Arthritis|Genetics of Rheumatoid Arthritis: The North American Rheumatoid Arthritis Consortium|Completed|||39|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.384493|2018-06-01 05:39:42.384493
NCT00001676|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1998||1998-01-31|November 2002|2002-11-30|November 2002||2002-11-30|||||Interventional|||Cyclophosphamide and Fludarabine to Treat Lupus Nephritis|Combination of Cyclophosphamide and Fludarabine for Lupus Nephritis: Tolerance, Toxicity, Efficacy and Effects on B and T Lymphocyte Regeneration|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.462116|2018-06-01 05:39:42.462116
NCT00001671|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|September 9, 1997||1997-09-09|December 15, 2008|2008-12-15|December 15, 2008||2008-12-15|||||Observational|||The Classification and Cause of Leukodystrophies of Unknown Cause|The Nosology and Etiology of Leukodystrophies of Unknown Cause|Completed|||400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.537713|2018-06-01 05:39:42.537713
NCT00001666|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1997||1997-03-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy|Drug Refractory Partial Epilepsy, A Therapeutic Trial With Transcranial Magnetic Stimulation|Completed|||32||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.612407|2018-06-01 05:39:42.612407
NCT00001664|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|December 4, 1996||1996-12-04|September 7, 2011|2011-09-07|September 7, 2011||2011-09-07|||||Observational|||Sleep Disorders of Patients With Diseases of the Nervous System|Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders|Completed|||83|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.671499|2018-06-01 05:39:42.671499
NCT00001663|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1997||1997-01-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation|Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation|Completed||Phase 1|10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.727786|2018-06-01 05:39:42.727786
NCT00001662|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1996||1996-12-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Interventional|||Treatment of Alzheimer's Disease With CX516 (Ampalex)|Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease|Completed||Phase 2|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.798363|2018-06-01 05:39:42.798363
NCT00001661|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1996||1996-12-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Observational|||Mechanisms of Human Plasticity in the Human System|Mechanisms of Plasticity in the Human Motor System|Completed|||260||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:42.915365|2018-06-01 05:39:42.915365
NCT00001656|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2011-03-02||2011-03-11|1999-11-03|1999-11-04|Estimate|2011-03-11|2011-04-12|Estimate||||2011-03-11|2011-04-12|Estimate|June 1997||1997-06-30|March 2011|2011-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders|Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics|Completed||Phase 4|25|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:39:43.056999|2018-06-01 05:39:43.056999
NCT00001654|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1997||1997-05-31|May 2003|2003-05-31|May 2003||2003-05-31|||||Observational|||The Role of Emotion in the Development of Psychopathology|The Role of Emotion in the Development of Psychopathology|Completed|||1200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:43.556773|2018-06-01 05:39:43.556773
NCT00001652|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1996||1996-12-31|December 2002|2002-12-31|December 2002||2002-12-31|||||Observational|||The Evaluation and Follow-up of Patients With Bipolar Disorder|The Evaluation and Naturalistic Follow-up of Patients With Bipolar Disorder|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:43.599743|2018-06-01 05:39:43.599743
NCT00001651|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|September 19, 1997||1997-09-19|September 8, 2017|2017-09-08||||||||Observational|||Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients|Studies of Lymphocyte Kinetics Using Stable Isotopes|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:43.643559|2018-06-01 05:39:43.643559
NCT00001650|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|September 19, 1997||1997-09-19|May 13, 2011|2011-05-13|May 13, 2011||2011-05-13|||||Observational|||Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients|Studies of Lymphocyte Kinetics Using Bromodeoxyuridine|Completed|||56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:43.704155|2018-06-01 05:39:43.704155
NCT00001649|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1997||1997-08-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||Valaciclovir to Prevent Transmission of Herpes Simplex Virus|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples|Completed||Phase 3|180||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:43.758338|2018-06-01 05:39:43.758338
NCT00001648|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 20, 1997||1997-08-20|April 13, 2010|2010-04-13|April 13, 2010||2010-04-13|||||Observational|||Structure of the Herpes Simplex Virus Receptor|Polymorphism of the Herpes Simplex Virus Receptor|Completed|||60|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:43.807321|2018-06-01 05:39:43.807321
NCT00001647|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1997||1997-08-31|August 2002|2002-08-31|August 2002||2002-08-31|||||Interventional|||White Blood Cell Infusions to Treat HIV Infection|Effects of Repeated Infusions of Adoptively Transferred Syngeneic Lymphocytes on the Immune Systems of HIV-1 Infected Identical Twins|Completed||Phase 1|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:43.865938|2018-06-01 05:39:43.865938
NCT00001645|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-30|1999-11-03|1999-11-04|Estimate|||||||2018-03-30|2018-04-02|Actual|March 24, 1997||1997-03-24|August 9, 2017|2017-08-09||||||||Observational|||Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection|Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.030586|2018-06-01 05:39:44.030586
NCT00001644|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 3, 1997||1997-03-03|February 17, 2010|2010-02-17|February 17, 2010|Actual|2010-02-17|February 17, 2010|Actual|2010-02-17||Interventional|||Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection|Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication|Completed||Phase 1|42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.102852|2018-06-01 05:39:44.102852
NCT00001643|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 29, 1997||1997-08-29|August 31, 2009|2009-08-31||||August 31, 2009|Actual|2009-08-31||Observational|||Gene Analysis of Parkinson's Disease|Gene Analysis in Parkinson's Disease|Completed|||320||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.171089|2018-06-01 05:39:44.171089
NCT00001641|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1997||1997-03-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Study of Heritable Connective Tissue Disorders|Clinical and Molecular Manifestations of Heritable Connective Tissue Disorders|Completed|||900||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.247572|2018-06-01 05:39:44.247572
NCT00001640|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|February 11, 1997||1997-02-11|February 10, 2009|2009-02-10|February 10, 2009||2009-02-10|||||Observational|||Genetic Analysis of Parkinson's Disease|Genetic Analysis of Parkinson's Disease|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.331154|2018-06-01 05:39:44.331154
NCT00001638|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|September 29, 1997||1997-09-29|August 4, 2009|2009-08-04|August 3, 2009|Actual|2009-08-03|August 3, 2009|Actual|2009-08-03||Observational|||Magnetic Resonance Imaging of the Blood Vessels of the Heart|Cardiovascular Magnetic Resonance Imaging|Completed|||99999999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.378109|2018-06-01 05:39:44.378109
NCT00001637|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-22|1999-11-03|1999-11-04|Estimate|||||||2018-05-22|2018-05-23|Actual|September 29, 1997||1997-09-29|December 28, 2016|2016-12-28|December 28, 2016|Actual|2016-12-28|July 28, 2008|Actual|2008-07-28||Interventional|||Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults|Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults|Completed||Phase 2|28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.440631|2018-06-01 05:39:44.440631
NCT00001632|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1997||1997-09-30|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease|Myocardial Ultrasonic Tissue Characterization in Patients With a Genetic Predisposition for the Development of Hypertrophic Cardiomyopathy|Completed|||195||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.498829|2018-06-01 05:39:44.498829
NCT00000528|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-15|1999-10-27|1999-10-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1986||1986-09-30|December 2005|2005-12-31|June 1998|Actual|1998-06-30|||||Interventional|||Trials of Hypertension Prevention (TOHP)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.736987|2018-06-01 05:40:31.736987
NCT00001631|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1997||1997-08-31|January 2003|2003-01-31|January 2003||2003-01-31|||||Interventional|||Study of Blood Flow in Heart Muscle|Study of Myocardial Perfusion by MRI|Completed||Phase 2|249||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.678741|2018-06-01 05:39:44.678741
NCT00001630|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|July 21, 1997||1997-07-21|March 21, 2011|2011-03-21|June 11, 2009|Actual|2009-06-11|||||Interventional|||Treatment of Autoimmune Thrombocytopenia (AITP)|High-Dose Cyclophosphamide With CD34+ Selected Autologous Hematopoietic Cell Support for Treatment of Refractory Chronic Autoimmune Thrombocytopenia|Completed||Phase 1|29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.75145|2018-06-01 05:39:44.75145
NCT00001627|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-26|1999-11-03|1999-11-04|Estimate|||||||2018-05-26|2018-05-30|Actual|June 5, 1997||1997-06-05|May 22, 2018|2018-05-22||||||||Observational|||Collection of Blood and Bone Marrow From Healthy Volunteers and Patients for Research Purposes|Collection of Blood and Bone Marrow From Healthy Volunteers and Patients for Research Purposes|Completed|||154|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:44.823548|2018-06-01 05:39:44.823548
NCT00001626|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|May 5, 1997||1997-05-05|September 29, 2017|2017-09-29|March 3, 2008|Actual|2008-03-03|September 30, 2002|Actual|2002-09-30||Interventional|||Comparing Therapies for the Treatment of Severe Aplastic Anemia|A Randomized Trial of Antithymocyte Globulin and Cyclosporine Versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia|Completed||Phase 3|33|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:39:44.903769|2018-06-01 05:39:44.903769
NCT00001625|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|April 3, 1997||1997-04-03|April 11, 2007|2007-04-11|April 11, 2007||2007-04-11|||||Observational|||Methods for Measuring Insulin Sensitivity|Methods for Assessing Insulin Sensitivity In Vivo|Completed|||480||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.020549|2018-06-01 05:39:45.020549
NCT00001623|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-11|1999-11-03|1999-11-04|Estimate|||||||2018-05-11|2018-05-14|Actual|March 27, 1997||1997-03-27|August 3, 2017|2017-08-03|August 3, 2017|Actual|2017-08-03|January 31, 2008|Actual|2008-01-31||Interventional|||Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia|HLA-Matched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T Cell Add-Back for Hematological Malignancies|Completed||N/A|41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.093523|2018-06-01 05:39:45.093523
NCT00001621|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|January 9, 1997||1997-01-09|November 27, 2017|2017-11-27||||||||Observational|||Evaluation and Treatment of Patients With Lung Disease Not Participating in Research|Evaluation and Treatment of Pulmonary Patients Not Participating in Research (Training Protocol)|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.170661|2018-06-01 05:39:45.170661
NCT00001620|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-22|1999-11-03|1999-11-04|Estimate|||||||2018-05-22|2018-05-23|Actual|December 10, 1996||1996-12-10|May 8, 2018|2018-05-08||||||||Observational|||Screening for Hematology Branch Protocols|Screening Protocol for Subjects Being Evaluated for Hematology Branch Protocols|Recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.251363|2018-06-01 05:39:45.251363
NCT00001619|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|November 5, 1996||1996-11-05|July 20, 2011|2011-07-20|July 20, 2011||2011-07-20|||||Observational|||Magnetic Resonance Imaging at Different Levels of Magnetic Intensity|Magnetic Resonance at 1.5 and 3 Tesla|Completed|||497|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.329589|2018-06-01 05:39:45.329589
NCT00001618|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|November 18, 1996||1996-11-18|November 27, 2017|2017-11-27||||||||Observational|||Segmental Bronchoalveolar Lavage|Bronchoscopy in Patients With Pulmonary Diseases and Research Volunteers|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.433606|2018-06-01 05:39:45.433606
NCT00001613|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1997||1997-05-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Cataract Surgery to Obtain Human Lens Material for the Study of Nuclear Cataracts|Use of Human Lens Material for the Study of Nuclear Cataracts|Completed|||96||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.500531|2018-06-01 05:39:45.500531
NCT00001611|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1997||1997-02-28|April 2004|2004-04-30|April 2004||2004-04-30|||||Observational|||Immune Activity Against CVM Retinitis|Efficacy of Elevated CD4 Cell Counts on CMV Retinitis|Completed|||15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.554125|2018-06-01 05:39:45.554125
NCT00001610|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1997||1997-02-28|March 2003|2003-03-31|March 2003||2003-03-31|||||Observational|||Normal Human Electro-Oculogram|Normal Human Electro-Oculogram|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.630533|2018-06-01 05:39:45.630533
NCT00001609|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1996||1996-10-31|March 2003|2003-03-31|March 2003||2003-03-31|||||Observational|||Studies of Families With Hereditary Cataracts|Clinical and Molecular Studies in Families With Congenital or Hereditary Cataracts|Completed|||1200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.699497|2018-06-01 05:39:45.699497
NCT00001606|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|September 8, 1997||1997-09-08|April 7, 2015|2015-04-07|April 7, 2015||2015-04-07|||||Observational|||Genetic Analysis of Human Hereditary Hearing Impairment|Genetic Analysis of Human Hereditary Hearing Impairment|Terminated|||404|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.753049|2018-06-01 05:39:45.753049
NCT00001604|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|January 8, 1997||1997-01-08|June 8, 2017|2017-06-08||||||||Observational|||Genetic Linkage Studies of Stuttering|Genetic Studies of Stuttering|Recruiting|||4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.807021|2018-06-01 05:39:45.807021
NCT00001603|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1996||1996-12-31|December 2004|2004-12-31|December 2004||2004-12-31|||||Observational|||The Effects of Upper Airway and Digestive Tract Tumors on the Immune System|A Pilot Study of Immunoregulatory Factor Expression and Immune Responses in Patients With Squamous Cell Carcinoma or Papilloma of the Upper Aerodigestive Tract|Completed|||93||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.885458|2018-06-01 05:39:45.885458
NCT00000363|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2006-04-21|1999-11-02|1999-11-03|Estimate|||||||2006-04-21|2006-04-24|Estimate||||April 2006|2006-04-30|June 2001||2001-06-30|||||Interventional|||Acute Otitis Media: Adjuvant Therapy to Improve Outcome||Completed||Phase 3|||National Institute on Deafness and Other Communication Disorders (NIDCD)|||||f||||||||||||||2018-06-01 05:40:20.014464|2018-06-01 05:40:20.014464
NCT00001602|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1996||1996-10-31|February 2005|2005-02-28|February 2005||2005-02-28|||||Observational|||Genetic Factors Related to Stuttering|Genetic Linkage Analysis in Developmental Stuttering: Gene Mapping in Extended Kindreds and Candidate Gene Analyses|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:45.944023|2018-06-01 05:39:45.944023
NCT00001601|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1997||1997-08-31|August 2002|2002-08-31|August 2002||2002-08-31|||||Interventional|||Evaluation and Treatment of Oral Soft Tissue Diseases|Patient Evaluation and Treatment of Oral Soft Tissue Diseases According to Generally Available, Standard Procedures and Therapeutic Modalities|Completed||N/A|999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.022538|2018-06-01 05:39:46.022538
NCT00001600|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1997||1997-08-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Diagnosis and Evaluation of Patients Needing Third Molar (Wisdom Tooth) Extraction and Patients With Chronic Facial Pain|Diagnosis and Evaluation of Patients in Need of Third Molar Removal or Suffering From Chronic Facial Pain|Completed|||4000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.077189|2018-06-01 05:39:46.077189
NCT00001599|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1997||1997-05-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||Pilot Study of Thalidomide to Treat Sjogren's Syndrome|Pilot Study of Thalidomide for Sjogren's Syndrome|Completed||Phase 2|28||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.137573|2018-06-01 05:39:46.137573
NCT00001598|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1997||1997-05-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||DHEA Treatment for Sjogren's Syndrome|Dehydroepiandrosterone (DHEA) Treatment for Sjogren's Syndrome|Completed||Phase 2|28||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.186598|2018-06-01 05:39:46.186598
NCT00001597|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1997||1997-03-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Pain Measurement in Healthy Volunteers|Pain Measurement in Healthy Volunteers|Completed|||40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.241544|2018-06-01 05:39:46.241544
NCT00001596|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2011-12-12||2017-09-14|1999-11-03|1999-11-04|Estimate|2012-01-24|2012-01-26|Estimate||||2017-09-14|2017-10-16|Actual|September 2005||2005-09-30|September 2017|2017-09-30|May 9, 2016|Actual|2016-05-09|September 2009|Actual|2009-09-30||Interventional|||Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome|Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome|Completed||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)|Study enrollment progressed more slowly than anticipated (spanning >3 years instead of one). The Data Safety and Monitoring Board performed an interim analysis one year after 30 subjects enrolled and directed the study to stop due to futility.|2|||f||||t||||||||||2018-06-01 05:39:46.299642|2018-06-01 05:39:46.299642
NCT00001595|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|February 13, 1997||1997-02-13|February 21, 2018|2018-02-21||||||||Observational|||An Investigation of Pituitary Tumors and Related Hypothalmic Disorders|A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.761175|2018-06-01 05:39:46.761175
NCT00001594|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-03|1999-11-03|1999-11-04|Estimate|||||||2018-04-03|2018-04-04|Actual|January 21, 1997||1997-01-21|March 20, 2018|2018-03-20||||||||Observational|||Evaluation and Intervention for the Effects of Osteogenesis Imperfecta|Evaluation and Intervention for Ambulation, Growth, and Basilar Invagination in Osteogenesis Imperfecta|Active, not recruiting|||88|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.833386|2018-06-01 05:39:46.833386
NCT00001591|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|July 2003|2003-07-31|July 2003||2003-07-31|||||Observational|||Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy|Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy|Completed|||450||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.896301|2018-06-01 05:39:46.896301
NCT00001589|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1997||1997-04-30|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors|Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:46.954237|2018-06-01 05:39:46.954237
NCT00001586|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2012-12-18||2013-03-19|1999-11-03|1999-11-04|Estimate|2013-03-19|2013-05-15|Estimate||||2013-03-19|2013-05-15|Estimate|September 1997||1997-09-30|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis|Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis|Completed||Phase 2|105|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-06-01 05:39:47.031388|2018-06-01 05:39:47.031388
NCT00001582|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-01-09|1999-11-03|1999-11-04|Estimate|||||||2018-01-09|2018-01-10|Actual|July 10, 1997||1997-07-10|December 24, 2017|2017-12-24||||||||Observational|||Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer|Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:47.463618|2018-06-01 05:39:47.463618
NCT00001580|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1997||1997-06-30|March 2003|2003-03-31|March 2003||2003-03-31|||||Observational|||Tissue Acquisition for Molecular Diagnostics|Tissue Acquisition for Molecular Diagnostics|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:47.526636|2018-06-01 05:39:47.526636
NCT00001576|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1997||1997-07-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Interventional|||A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver|A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver|Completed||Phase 1|28||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:47.63502|2018-06-01 05:39:47.63502
NCT00000593|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 1994||1994-11-30|December 2005|2005-12-31|March 2001|Actual|2001-03-31|||||Interventional|||Viral Activation Transfusion Study (VATS)||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.113514|2018-06-01 05:40:25.113514
NCT00001575|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2015-05-14||2015-10-30|1999-11-03|1999-11-04|Estimate|2015-10-30|2015-12-07|Estimate||||2015-10-30|2015-12-07|Estimate|April 1997||1997-04-30|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia||Completed||Phase 1/Phase 2|87|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:39:47.698254|2018-06-01 05:39:47.698254
NCT00001574|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-03|1999-11-03|1999-11-04|Estimate|||||||2018-04-03|2018-04-04|Actual|March 14, 1997||1997-03-14|July 15, 2017|2017-07-15||||||||Observational|||A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors|A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors|Completed|||40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:49.071827|2018-06-01 05:39:49.071827
NCT00001572|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|January 30, 1997||1997-01-30|November 2, 2010|2010-11-02|November 2, 2010|Actual|2010-11-02|July 31, 1999|Actual|1999-07-31||Interventional|||Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype|Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype|Completed||Phase 1|21|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:49.15251|2018-06-01 05:39:49.15251
NCT00001569|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1997||1997-01-31|December 2002|2002-12-31|December 2002||2002-12-31|||||Interventional|||Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis|Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis|Completed||Phase 1|74||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:49.248562|2018-06-01 05:39:49.248562
NCT00001568|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1997||1997-02-28|October 2002|2002-10-31|October 2002||2002-10-31|||||Interventional|||Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities|Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities|Completed||Phase 2|200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:49.358528|2018-06-01 05:39:49.358528
NCT00001567|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1997||1997-01-31|April 2002|2002-04-30|April 2002||2002-04-30|||||Interventional|||A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia|A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia|Completed||Phase 2|56||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:49.4352|2018-06-01 05:39:49.4352
NCT00001566|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2012-03-28||2012-06-12|1999-11-03|1999-11-04|Estimate|2012-05-08|2012-06-12|Estimate||||2012-06-12|2012-06-15|Estimate|December 1996||1996-12-31|June 2012|2012-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas|A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas|Completed||Phase 2|42|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-06-01 05:39:49.555439|2018-06-01 05:39:49.555439
NCT00001564|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|December 23, 1996||1996-12-23|September 4, 2014|2014-09-04|October 25, 2007|Actual|2007-10-25|October 25, 2007|Actual|2007-10-25||Interventional|||A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas|A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas|Completed||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:50.772445|2018-06-01 05:39:50.772445
NCT00001563|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|December 12, 1996||1996-12-12|July 15, 2017|2017-07-15|May 5, 2005|Actual|2005-05-05|May 5, 2005|Actual|2005-05-05||Interventional|||EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma|EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma|Completed||Phase 2|39|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:39:50.848603|2018-06-01 05:39:50.848603
NCT00001561|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2007-09-21|1999-11-03|1999-11-04|Estimate|||||||2007-09-21|2007-09-24|Estimate|November 1996||1996-11-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation|Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation|Completed||Phase 3|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.028622|2018-06-01 05:39:51.028622
NCT00001560|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|December 24, 1996||1996-12-24|October 31, 2011|2011-10-31|October 31, 2011||2011-10-31|||||Observational|||Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers|Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers|Completed|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.092367|2018-06-01 05:39:51.092367
NCT00001552|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|May 22, 1996||1996-05-22|November 13, 2009|2009-11-13||||November 13, 2009|Actual|2009-11-13||Observational|||Characteristics of Idiopathic Familial Voice Disorders|Characteristics of Idiopathic Familial Voice Disorders|Completed|||270||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.149717|2018-06-01 05:39:51.149717
NCT00001551|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|May 22, 1996||1996-05-22|November 13, 2009|2009-11-13||||November 13, 2009|Actual|2009-11-13||Observational|||Characteristics of Idiopathic Familial Speech Disorders|Characteristics of Idiopathic Familial Speech Disorders|Completed|||375||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.221325|2018-06-01 05:39:51.221325
NCT00001550|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-07-13|1999-11-03|1999-11-04|Estimate|||||||2006-07-13|2006-07-14|Estimate|April 1996||1996-04-30|May 2002|2002-05-31|May 2002||2002-05-31|||||Interventional|||Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)|The Efficacy of High-Dose Intravenous Immunoglobulin Therapy in Patients With Stiff-Man Syndrome: A Double-Blind, Placebo-Controlled Trial|Completed||Phase 1|20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.28327|2018-06-01 05:39:51.28327
NCT00001549|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1995||1995-10-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Diagnosis and Natural History Study of Patients With Neurological Conditions|Diagnosis and Natural History Protocol for Patients With Neurological Conditions|Completed|||600||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.358227|2018-06-01 05:39:51.358227
NCT00001548|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|August 22, 1996||1996-08-22|September 29, 2015|2015-09-29|September 29, 2015||2015-09-29|||||Observational|||Genetics of Obsessive-Compulsive Disorder|Genetics of Obsessive-Compulsive Disorder: A Collaborative Study|Completed|||1067|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.421112|2018-06-01 05:39:51.421112
NCT00001547|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1996||1996-06-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Neuropsychiatric Effects of Interferon-Alpha and Ribavirin|A Magnetic Resonance Spectroscopy Study of Neuropsychiatric Effects Associated With Cytokines|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.50029|2018-06-01 05:39:51.50029
NCT00001545|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-07-12|1999-11-03|1999-11-04|Estimate|||||||2006-07-12|2006-07-13|Estimate|May 1996||1996-05-31|July 2006|2006-07-31|July 2006||2006-07-31|||||Interventional|||Evaluation of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Mood Disorders|Evaluation of rTMS in the Treatment of Mood Disorders|Completed||Phase 2|91||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.560073|2018-06-01 05:39:51.560073
NCT00001544|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1996||1996-04-30|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Genetic Aspects of Neurologic and Psychiatric Disorders|Genetic Aspects of Neurologic and Psychiatric Disorders|Completed|||1227||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.611142|2018-06-01 05:39:51.611142
NCT00001543|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1996||1996-03-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Dynamics of Leptin and Endocrine Function|Dynamics of Leptin and Endocrine Function|Completed|||230||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.681037|2018-06-01 05:39:51.681037
NCT00001541|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1996||1996-04-30|January 2003|2003-01-31|January 2003||2003-01-31|||||Observational|||Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis|Analysis of Bronchial and Bronchoalveolar Lavage Fluid and Bronchial Mucosal Biopsies in Patients With Wegener's Granulomatosis|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.736637|2018-06-01 05:39:51.736637
NCT00001539|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|March 25, 1996||1996-03-25|March 15, 2018|2018-03-15||||||||Observational|||A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations|A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.789971|2018-06-01 05:39:51.789971
NCT00001535|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-02-07|1999-11-03|1999-11-04|Estimate|||||||2008-02-07|2008-02-08|Estimate|March 1996||1996-03-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Interventional|||Twins Study of Gene Therapy for HIV Infection|Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Anti-Sense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV-1 Infected Identical Twins|Completed||Phase 1|48||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.885995|2018-06-01 05:39:51.885995
NCT00001534|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1996||1996-09-30|April 2003|2003-04-30|April 2003||2003-04-30|||||Observational|||Long Term Effects of Enalapril and Losartan on Genetic Heart Disease|Double-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCM|Completed|||112||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.944322|2018-06-01 05:39:51.944322
NCT00001532|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-08|1999-11-03|1999-11-04|Estimate|||||||2018-05-08|2018-05-09|Actual|June 6, 1996||1996-06-06|April 25, 2018|2018-04-25||||||||Observational|||Role of Genetic Factors in the Development of Lung Disease|Role of Genetic Factors in the Pathogenesis of Lung Disease|Recruiting|||3600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:51.997784|2018-06-01 05:39:51.997784
NCT00001529|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|March 14, 1996||1996-03-14|April 11, 2018|2018-04-11|May 1, 2030|Anticipated|2030-05-01|May 1, 2030|Anticipated|2030-05-01||Interventional|||Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives|Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections From Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation|Recruiting||Phase 1|99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.06822|2018-06-01 05:39:52.06822
NCT00001526|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|June 4, 1996||1996-06-04|September 6, 2007|2007-09-06|September 6, 2007||2007-09-06|||||Interventional|||ANTI-TAC THERAPY FOR UVEITIS|Trial of Treatment of Non-Infectious Intermediate and Posterior Uveitis With Humanized Anti-Tac Antibody Therapy|Completed||Phase 1|15||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.249289|2018-06-01 05:39:52.249289
NCT00001524|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1996||1996-06-30|December 2004|2004-12-31|December 2004||2004-12-31|||||Interventional|||Thalidomide to Treat Oral Lesions in HIV-Infected Patients|Evaluation of a TNF-Alpha Modulator for the Treatment of Oral Lesions in HIV/AIDS Patients|Completed||Phase 2|110||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.316625|2018-06-01 05:39:52.316625
NCT00001522|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|June 6, 1996||1996-06-06|April 12, 2018|2018-04-12|April 12, 2018||2018-04-12|||||Observational|||Metabolic Differences of Overweight Children and Children of Overweight Parents|Population Differences in the Insulin Sensitivity, Resting Energy Expenditure, and Body Composition of Overweight Children and Children of Overweight Parents|Completed|||246|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.39203|2018-06-01 05:39:52.39203
NCT00001480|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 21, 1995||1995-03-21|March 31, 2007|2007-03-31|March 31, 2007||2007-03-31|||||Observational|||The Evaluation and Follow-up of Individuals With Memory Disorder|The Evaluation and Follow-up of Patients With Memory Disorder and Normal Controls|Completed|||750||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.526491|2018-06-01 05:39:53.526491
NCT00001521|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|February 2, 1996||1996-02-02|January 17, 2018|2018-01-17|January 11, 2017|Actual|2017-01-11|||||Interventional|||Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia|An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia|Completed||Phase 1|62|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.458991|2018-06-01 05:39:52.458991
NCT00001516|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1996||1996-01-31|May 2003|2003-05-31|May 2003||2003-05-31|||||Observational|||Evaluating the Personal Computer as a Treatment Activity in Occupational Therapy|Linking Occupational Therapy Process and Patient Performance: The Personal Computer Activity in Occupational Interventions|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.534532|2018-06-01 05:39:52.534532
NCT00001515|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1995||1995-12-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Interventional|||Diagnostic Effectiveness of Virtual Bronchoscopy|Diagnostic Efficacy of Virtual Bronchoscopy|Completed||Phase 1|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.591523|2018-06-01 05:39:52.591523
NCT00001512|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|September 9, 1996||1996-09-09|March 5, 2010|2010-03-05|March 5, 2010|Actual|2010-03-05|March 5, 2010|Actual|2010-03-05||Interventional|||Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines|Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines|Completed||Phase 1|42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.655222|2018-06-01 05:39:52.655222
NCT00001507|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|July 12, 1996||1996-07-12|June 20, 2014|2014-06-20|June 20, 2014|Actual|2014-06-20|June 30, 1998|Actual|1998-06-30||Interventional|||Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer|A Multi-Center Study of Paclitaxel/Cyclophosphamide and High Dose Melphalan/Etoposide With Autologous Progenitor Cell Transplantation for the Treatment of Inflammatory Breast Cancer|Completed||Phase 1|107|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.721988|2018-06-01 05:39:52.721988
NCT00001506|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-24|1999-11-03|1999-11-04|Estimate|||||||2018-03-24|2018-03-27|Actual|June 11, 1996||1996-06-11|November 20, 2017|2017-11-20||||||||Observational|||Evaluation and Treatment of Patients With Dermatologic Diseases|Evaluation and Treatment of Subjects With Dermatologic Diseases|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.797697|2018-06-01 05:39:52.797697
NCT00001505|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-11-21|1999-11-03|1999-11-04|Estimate|||||||2017-11-21|2017-11-22|Actual|June 4, 1996||1996-06-04|November 20, 2017|2017-11-20||||||||Observational|||The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic Diseases|The Acquisition of Blood and Skin Samples From Patient Volunteers to Support Research Activities on Dermatologic and Other Diseases|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.871806|2018-06-01 05:39:52.871806
NCT00001504|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1996||1996-05-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients|A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients|Completed||Phase 1|18||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:52.94153|2018-06-01 05:39:52.94153
NCT00001503|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-11-07|1999-11-03|1999-11-04|Estimate|||||||2017-11-07|2017-11-08|Actual|May 2, 1996||1996-05-02|October 27, 2017|2017-10-27||||||||Observational|||Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease|Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols|Enrolling by invitation|||990|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.011268|2018-06-01 05:39:53.011268
NCT00001500|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1996||1996-04-30|July 2004|2004-07-31|July 2004||2004-07-31|||||Observational|||Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits|Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits|Completed|||4500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.091373|2018-06-01 05:39:53.091373
NCT00001496|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1996||1996-01-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Observational|||Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer|Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.157478|2018-06-01 05:39:53.157478
NCT00001491|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|May 11, 1995||1995-05-11|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||Analysis of the Nervous System in Patients With Fabry's Disease|The Natural History and Pathogenesis of Fabry Disease|Completed|||325||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.209286|2018-06-01 05:39:53.209286
NCT00001487|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|April 2004|2004-04-30|April 2004||2004-04-30|||||Interventional|||Treatment of Mid-Life-Related Mood Disorders|Dehydroepiandrosterone Treatment of Mid-Life-Related Mood Disorders in Women and Men|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.260571|2018-06-01 05:39:53.260571
NCT00001486|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-18|1999-11-03|1999-11-04|Estimate|||||||2017-10-18|2017-10-19|Actual|July 6, 1995||1995-07-06|July 27, 2017|2017-07-27||||||||Observational|||Genetic Study of Schizophrenia|A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings|Recruiting|||6150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.338836|2018-06-01 05:39:53.338836
NCT00001483|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|May 2002|2002-05-31|May 2002||2002-05-31|||||Interventional|||Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression|Acute Efficacy of Bupropion, Sertraline, and Venlafaxine as Adjuvant Treatment to Mood Stabilizers in Bipolar Depression: A Randomized, Double-Blind, Comparative Study|Completed||Phase 2|75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.407843|2018-06-01 05:39:53.407843
NCT00001481|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|April 4, 1995||1995-04-04|October 16, 2017|2017-10-16||||||||Observational|||The Role of Hormones in Postpartum Mood Disorders|An Endocrine Model for Postpartum Mood Disorders|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.464284|2018-06-01 05:39:53.464284
NCT00001476|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|June 1, 1995||1995-06-01|December 13, 2010|2010-12-13|December 13, 2010|Actual|2010-12-13|December 13, 2010|Actual|2010-12-13||Interventional|||Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up|Gene Therapy Approach for Chronic Granulomatous Disease|Completed||Phase 1|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.5762|2018-06-01 05:39:53.5762
NCT00001475|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1995||1995-06-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist|A Randomized Trial of Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist in Patients With HIV-1 Infection|Completed||Phase 2|85||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.627561|2018-06-01 05:39:53.627561
NCT00001474|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1995||1995-05-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Interventional|||Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients|Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients|Completed||Phase 2|36||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.691741|2018-06-01 05:39:53.691741
NCT00001473|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1995||1995-03-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides|A Staged Therapeutic Approach Using Cyclophosphamide and Methotrexate in the Treatment of Wegener's Granulomatosis and Related Vasculitides|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.747169|2018-06-01 05:39:53.747169
NCT00001471|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|November 22, 1994||1994-11-22|October 11, 2017|2017-10-11||||||||Observational|||Tissue Biopsy and Imaging Studies in HIV-Infected Patients|Virologic and Immunologic Evaluation of Lymph Node, Tonsillar, and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid|Recruiting|||635|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.885666|2018-06-01 05:39:53.885666
NCT00001469|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|July 14, 1995||1995-07-14|April 11, 2018|2018-04-11||||||||Observational|||Genetic Analysis of Hereditary Prostate Cancer|Genetic Analysis of Hereditary Prostate Cancer|Completed|||7776|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:53.960136|2018-06-01 05:39:53.960136
NCT00001467|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|February 3, 1995||1995-02-03|March 6, 2018|2018-03-06||||||||Observational|||Genetic Analysis of Immune Disorders|Genetic Analysis of Immune Disorders|Enrolling by invitation|||3546|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.054771|2018-06-01 05:39:54.054771
NCT00001465|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-08|1999-11-03|1999-11-04|Estimate|||||||2018-05-08|2018-05-09|Actual|September 25, 1995||1995-09-25|April 26, 2018|2018-04-26||||||||Observational|||Study of the Disease Process of Lymphangioleiomyomatosis|Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.121063|2018-06-01 05:39:54.121063
NCT00001464|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|August 1, 1995||1995-08-01|October 24, 2017|2017-10-24|July 10, 2007|Actual|2007-07-10|July 10, 2007|Actual|2007-07-10||Interventional|||Effect of High Levels of Oxygen and Smoking on the Lungs in Human Volunteers|Effect of Hypoxia and Smoking on Oxidation of Proteins and Nucleic Acids in Human Volunteers|Completed||Phase 1|77|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.193337|2018-06-01 05:39:54.193337
NCT00001460|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|1999-11-03|1999-11-04|Estimate|||||||2008-03-04|2008-03-05|Estimate|January 1995||1995-01-31|April 2002|2002-04-30|April 2002||2002-04-30|||||Interventional|||Evaluation and Treatment of Heart Disease in Patients Not Participating in Research|Evaluation and Therapy of Heart Disease in Patients Not Participating in Research (Teaching Protocol)|Completed||N/A|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.344823|2018-06-01 05:39:54.344823
NCT00001458|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|January 9, 1995||1995-01-09|February 23, 2018|2018-02-23||||||||Observational|||Evaluation of Patients With Heart Disease Not Eligible for Research Protocols|Diagnosis and Treatment of Patients With Heart and Vascular Disease (Training Protocol)|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.462871|2018-06-01 05:39:54.462871
NCT00001457|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1995||1995-09-30|September 2005|2005-09-30|September 2005||2005-09-30|||||Interventional|||Lamivudine for Chronic Hepatitis B|Lamivudine for Chronic Hepatitis B|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.565071|2018-06-01 05:39:54.565071
NCT00001456|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|September 22, 1995||1995-09-22|March 6, 2018|2018-03-06||||||||Observational|||Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome|Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.627591|2018-06-01 05:39:54.627591
NCT00001454|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 21, 1995||1995-04-21|July 27, 2015|2015-07-27|July 27, 2015||2015-07-27|||||Observational|||Hormonal Effects on the Uterus and Endometrium|Endometrial Mediators of Gonadal Steroid Action|Completed|||129|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.779765|2018-06-01 05:39:54.779765
NCT00001453|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|April 10, 1995||1995-04-10|October 20, 2014|2014-10-20|October 20, 2014||2014-10-20|||||Observational|||Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome|Internal Jugular Vein Sampling for ACTH Levels for the Differential Diagnosis of Cushing Syndrome|Completed|||98|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:54.955019|2018-06-01 05:39:54.955019
NCT00001452|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|January 24, 1995||1995-01-24|January 23, 2018|2018-01-23||||||||Observational|||Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex|Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:55.110758|2018-06-01 05:39:55.110758
NCT00001451|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 14, 1995||1995-03-14|February 1, 2011|2011-02-01|February 1, 2011||2011-02-01|||||Observational|||Evaluation of Healthy Volunteer Marrow Donors Participating in the National Marrow Donor Program (NMDP)|Evaluation of Healthy Volunteer Marrow Donors Participating in the National Marrow Donor Program (NMDP)|Completed|||57|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:55.567236|2018-06-01 05:39:55.567236
NCT00001444|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1995||1995-08-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Interventional|||A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms|A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms|Completed||Phase 1|51||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:55.741235|2018-06-01 05:39:55.741235
NCT00001442|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1995||1995-07-31|June 2004|2004-06-30|June 2004||2004-06-30|||||Interventional|||A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer|A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer|Completed||Phase 1|35||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:55.813844|2018-06-01 05:39:55.813844
NCT00001440|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-13|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1995||1995-07-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy|Pilot Study of Autologous T Cells and/or IL-2 for the Enhancement of Immune Reconstitution After Dose-Intensive Chemotherapy for Breast Cancer|Completed||Phase 1|51||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:55.919769|2018-06-01 05:39:55.919769
NCT00001432|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1995||1995-03-31|November 2003|2003-11-30|November 2003||2003-11-30|||||Observational|||The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies|The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies|Completed|||75||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.075628|2018-06-01 05:39:56.075628
NCT00001430|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1995||1995-02-28|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas|A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas|Completed||Phase 2|49||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.178733|2018-06-01 05:39:56.178733
NCT00001426|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-04|1999-11-03|1999-11-04|Estimate|||||||2018-04-04|2018-04-05|Actual|February 3, 1995||1995-02-03|November 7, 2013|2013-11-07|November 7, 2013|Actual|2013-11-07|October 15, 2007|Actual|2007-10-15||Interventional|||A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer|A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer|Completed||Phase 2|66|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.239112|2018-06-01 05:39:56.239112
NCT00001420|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1995||1995-03-31|January 2006|2006-01-31|January 2006||2006-01-31|||||Observational|||Study of Psoriatic Arthritis|Studies of the Pathogenesis and Natural History of Psoriatic Arthritis|Completed|||999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.382246|2018-06-01 05:39:56.382246
NCT00001418|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1994||1994-07-31|August 2004|2004-08-31|August 2004||2004-08-31|||||Observational|||PET Scan in Patients With Neurocardiologic Disorders|Positron Emission Tomographic (PET) Scanning of Sympathetic Innervation and Function in Patients With Neurocardiologic Disorders|Completed|||335||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.436245|2018-06-01 05:39:56.436245
NCT00001417|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1994||1994-06-30|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Direct Injection of Alcohol for the Treatment of Spinal Tumors|Study of the Efficacy of Direct Intratumoral Injection of Absolute Ethanol in Treating Symptomatic Spinal Tumors|Completed|||30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.498816|2018-06-01 05:39:56.498816
NCT00001414|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1994||1994-04-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Observational|||Mapping Personality Traits to Genes|Mapping Personality Traits to Genes|Completed|||2400||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.770592|2018-06-01 05:39:56.770592
NCT00001413|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|April 6, 1994||1994-04-06|January 19, 2007|2007-01-19|January 19, 2007||2007-01-19|||||Observational|||Bone Mineral Density in Women With Major Depression|Bone Mineral Density in Patients With Major Depression With Melancholic and Atypical Features: Relation to Stress-System Neurohormonal Function|Completed|||585||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.916971|2018-06-01 05:39:56.916971
NCT00001412|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1993||1993-12-31|November 2001|2001-11-30|November 2001||2001-11-30|||||Observational|||Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement|The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:56.968088|2018-06-01 05:39:56.968088
NCT00001410|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1993||1993-10-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Interventional|||PEG-Glucocerebrosidase for the Treatment of Gaucher Disease|A Phase I and II Study of PEG-Glucocerebrosidase in Patients With Type 1 or Type 3 Gaucher Disease|Completed||Phase 1|18||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.056828|2018-06-01 05:39:57.056828
NCT00001409|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1994||1994-09-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications|A Phase I/II Pilot Study of the Safety of the Adoptive Transfer of Syngeneic Gene-Modified Cytotoxic T Lymphocytes in HIV Infected Identical Twins|Completed||Phase 1|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.143151|2018-06-01 05:39:57.143151
NCT00001408|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|September 14, 1994||1994-09-14|June 25, 2009|2009-06-25|October 1, 1995|Actual|1995-10-01|October 1, 1995|Actual|1995-10-01||Observational|||Role of T-Cells in Asthma|Cytokine Expression in Allergic Asthma|Completed|||250||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.197141|2018-06-01 05:39:57.197141
NCT00001235|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1988||1988-02-29|February 2004|2004-02-29|February 2004||2004-02-29|||||Observational|||Genetic Studies in Alzheimer's Disease|Biochemical and Genetic Studies in Familial Alzheimer's Disease|Completed|||1500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.356757|2018-06-01 05:40:06.356757
NCT00001407|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1994||1994-05-31|May 2003|2003-05-31|May 2003||2003-05-31|||||Interventional|||Interferon Gamma for Drug Resistant Tuberculosis|Treatment of Multiply Drug Resistant Tuberculosis With Interferon Gamma: A Phase I/II Dose Escalation Trial|Completed||Phase 2|30||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.255331|2018-06-01 05:39:57.255331
NCT00001406|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|February 11, 1994||1994-02-11|April 17, 2018|2018-04-17||||||||Observational|||Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia|Eosinophil Activation and Function in Parasitic Infections and Other Conditions With Increased Tissue or Peripheral Blood Eosinophilia in Humans|Recruiting|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.359019|2018-06-01 05:39:57.359019
NCT00001405|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|February 9, 1994||1994-02-09|December 18, 2017|2017-12-18||||||||Observational|||Use of G-CSF to Obtain Blood Cell Precursors|Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells,Mononuclear Cells and Granulocytes|Recruiting|||450|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.429294|2018-06-01 05:39:57.429294
NCT00001404|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-02|1999-11-03|1999-11-04|Estimate|||||||2018-05-02|2018-05-03|Actual|August 18, 1994||1994-08-18|January 7, 2016|2016-01-07|January 7, 2016||2016-01-07|||||Observational|||Phenotype and Etiology of Pallister-Hall Syndrome|Genetic and Clinical Studies of Congenital Anomaly Syndromes|Completed|||1170|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.514433|2018-06-01 05:39:57.514433
NCT00001403|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|April 19, 1994||1994-04-19|July 24, 2017|2017-07-24||||||||Observational|||Study of Proteus Syndrome and Related Congenital Disorders|The Phenotype and Etiology of Proteus Syndrome and Related Overgrowth Disorders|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.704518|2018-06-01 05:39:57.704518
NCT00001400|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|1999-11-03|1999-11-04|Estimate|||||||2008-03-04|2008-03-05|Estimate|December 1993||1993-12-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Observational|||Outpatient Evaluation of Patients With Known or Suspected Heart Disease|Outpatient Evaluation of Patients With Known or Suspected Heart Disease (Screening Protocol)|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.781039|2018-06-01 05:39:57.781039
NCT00001399|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|December 3, 1993||1993-12-03|February 11, 2009|2009-02-11|February 11, 2009||2009-02-11|||||Interventional|||Gene Therapy for the Treatment of Fanconi's Anemia Type C|Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients|Completed||Phase 1|9||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.835336|2018-06-01 05:39:57.835336
NCT00001398|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1993||1993-10-31|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||Stem Cell Factor Medication for Aplastic Anemia|A Phase I/II Trial of Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) in Patients Diagnosed With Acquired Aplastic Anemia|Completed||Phase 1|40||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.894474|2018-06-01 05:39:57.894474
NCT00001397|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|October 20, 1993||1993-10-20|May 15, 2018|2018-05-15||||||||Observational|||Evaluation, Treatment, and Training for Patients With Blood Disorders|Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:57.960345|2018-06-01 05:39:57.960345
NCT00001396|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|October 6, 1993||1993-10-06|July 23, 2008|2008-07-23|July 23, 2008||2008-07-23|||||Interventional|||Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...|Obstructive Hypertrophic Cardiomyopathy (HCM) in Children: Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy|Completed||Phase 1|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.056123|2018-06-01 05:39:58.056123
NCT00001394|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1994||1994-08-31|July 2005|2005-07-31|July 2005||2005-07-31|||||Observational|||Using X-Ray Dye to Locate Hidden Parathyroid Tumors|Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.133549|2018-06-01 05:39:58.133549
NCT00001393|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|April 19, 1994||1994-04-19|April 27, 2018|2018-04-27||||||||Observational|||Genetic Markers for Focal Segmental Glomerulosclerosis|Genetic Markers for Focal Segmental Glomerulosclerosis|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.191801|2018-06-01 05:39:58.191801
NCT00001392|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-16|1999-11-03|1999-11-04|Estimate|||||||2018-05-16|2018-05-17|Actual|April 11, 1994||1994-04-11|April 5, 2018|2018-04-05||||||||Observational|||Pathogenesis of Glomerulosclerosis|Pathogenesis of Glomerulosclerosis|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.275974|2018-06-01 05:39:58.275974
NCT00001391|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 3, 1994||1994-08-03|October 4, 2010|2010-10-04|October 4, 2010||2010-10-04|||||Observational|||Bone Regeneration Using Bone Marrow Stromal Cells|Bone Regeneration Using Bone Marrow Stromal Cells|Completed|||54|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.386399|2018-06-01 05:39:58.386399
NCT00001390|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|October 26, 1993||1993-10-26|May 8, 2018|2018-05-08||||||||Observational|||Salivary Evaluation in Healthy Volunteers|Salivary Evaluation in Healthy Volunteers|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.444119|2018-06-01 05:39:58.444119
NCT00001386|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1994||1994-06-30|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection|Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection|Completed||Phase 1|31||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.523317|2018-06-01 05:39:58.523317
NCT00001160|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|May 31, 1977||1977-05-31|April 18, 2018|2018-04-18||||||||Observational|||Studies on Tumors of the Thyroid|Studies on Thyroid Nodules and Thyroid Cancer|Recruiting|||99999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.222522|2018-06-01 05:40:10.222522
NCT00001379|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-02-16|1999-11-03|1999-11-04|Estimate|||||||2018-02-16|2018-02-19|Actual|February 9, 1994||1994-02-09|September 1, 2017|2017-09-01|February 1, 2022|Anticipated|2022-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Treatment and Natural History Study of Lymphomatoid Granulomatosis|Treatment and Natural History Study of Lymphomatoid Granulomatosis|Recruiting||Phase 2|90|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-06-01 05:39:58.599661|2018-06-01 05:39:58.599661
NCT00001373|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-26|1999-11-03|1999-11-04|Estimate|||||||2018-05-26|2018-05-30|Actual|March 10, 1994||1994-03-10|May 24, 2018|2018-05-24||||||||Observational|||Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics|Genetics and Pathophysiology of Autoinflammatory Disorders.|Recruiting|||199998|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.703391|2018-06-01 05:39:58.703391
NCT00001372|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|February 2, 1994||1994-02-02|April 30, 2018|2018-04-30||||||||Observational|||Study of Systemic Lupus Erythematosus|Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.779575|2018-06-01 05:39:58.779575
NCT00001368|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1993||1993-10-31|November 2002|2002-11-30|November 2002||2002-11-30|||||Interventional|||Potential Risk Factors for Stroke|Cytokine and Leukocyte Activation Profile as a Risk Factor for Cerebral Vascular Disease and Stroke|Completed||Phase 1|500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.85571|2018-06-01 05:39:58.85571
NCT00001367|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|September 1, 1993||1993-09-01|April 12, 2018|2018-04-12||||||||Observational|||Diagnosis and History Study of Patients With Different Neurological Conditions|Diagnosis and Natural History Protocol for Patients With Different Neurological Conditions|Recruiting|||4100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:58.918193|2018-06-01 05:39:58.918193
NCT00001366|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1993||1993-08-31|September 2002|2002-09-30|September 2002||2002-09-30|||||Observational|||Mapping the Areas of the Brain Associated With Language in Children With Epilepsy|MRI-Based Functional Language Mapping in Children With Epilepsy|Completed|||230||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.01519|2018-06-01 05:39:59.01519
NCT00001364|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2, 1993||1993-06-02|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Evaluation and Treatment of Patients Spinal Blood Vessel Abnormalities|Evaluation and Treatment of Patients With Spinal Vascular Abnormalities|Completed|||120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.07136|2018-06-01 05:39:59.07136
NCT00001362|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1992||1992-12-31|July 2003|2003-07-31|July 2003||2003-07-31|||||Observational|||Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders|Structural and Functional Imaging of Neurologically Impaired Patients and Normal Volunteers With 1.5 and 3.0 Tesla MRI|Completed|||830||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.13425|2018-06-01 05:39:59.13425
NCT00001361|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1992||1992-10-31|January 2002|2002-01-31|January 2002||2002-01-31|||||Observational|||Magnetic Resonance Imaging Studies of Motor and Thought Processes|Central Nervous System Motor and Cognitive Processes: Nuclear Magnetic Resonance Imaging at 1.5 to 4 Tesla|Completed|||610||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.191392|2018-06-01 05:39:59.191392
NCT00001360|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2, 1993||1993-07-02|March 14, 2018|2018-03-14||||||||Observational|||Studies of Blood Flow to the Brain During Thought|Regional Cerebral Blood Flow Studies of Object Perception, Identification, Localization, and Memory|Recruiting|||4100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.247418|2018-06-01 05:39:59.247418
NCT00001359|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1993||1993-04-30|January 2006|2006-01-31|January 2006||2006-01-31|||||Interventional|||Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)|A Trial of Prophylaxis for the PANDAS Subgroup|Completed||Phase 2|90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.309911|2018-06-01 05:39:59.309911
NCT00001357|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1993||1993-08-31|April 2002|2002-04-30|April 2002||2002-04-30|||||Interventional|||Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients|Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients|Completed||Phase 2|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.37975|2018-06-01 05:39:59.37975
NCT00001356|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1993||1993-05-31|May 2002|2002-05-31|May 2002||2002-05-31|||||Observational|||Characteristics of Mast Cells in Mastocytosis|Culture and Characteristics of Mastocytosis Mast Cells|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.431399|2018-06-01 05:39:59.431399
NCT00001355|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-22|1999-11-03|1999-11-04|Estimate|||||||2018-05-22|2018-05-23|Actual|April 12, 1993||1993-04-12|May 11, 2018|2018-05-11||||||||Observational|||Detection and Characterization of Host Defense Defects|Detection and Characterization of Host Defense Defects|Enrolling by invitation|||2085|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.477838|2018-06-01 05:39:59.477838
NCT00001354|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1993||1993-03-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Interventional|||Interleukin-2 Therapy for HIV Infection - Supplemental Procedures|A Randomized Trial of Interleukin-2 Therapy in HIV-Infected Patients|Completed||Phase 2|60||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.560927|2018-06-01 05:39:59.560927
NCT00001353|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1993||1993-03-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Observational|||Safety and Survival of Genetically Modified White Blood Cells in HIV-Infected Persons - A Study in Identical Twin Pairs|A Study of the Safety and Survival of the Adoptive Transfer of Genetically Marked Syngeneic Lymphocytes in HIV-Infected Identical Twins|Completed|||24||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.613244|2018-06-01 05:39:59.613244
NCT00001352|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-26|1999-11-03|1999-11-04|Estimate|||||||2018-05-26|2018-05-30|Actual|March 11, 1993||1993-03-11|May 21, 2018|2018-05-21||||||||Observational|||Evaluation and Follow-up of Patients With Cryptococcosis|Cryptococcosis in Previously Healthy Adults|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.664065|2018-06-01 05:39:59.664065
NCT00001351|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-12|||2018-05-11|1999-11-03|1999-11-04|Estimate|||||||2018-05-11|2018-05-14|Actual|February 5, 1993||1993-02-05|September 1, 2017|2017-09-01||||||||Observational|||Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders|Evaluation and Long Term Follow Up of Patients With Acute or Chronic Inflammatory Disorders|Enrolling by invitation|||292|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.73303|2018-06-01 05:39:59.73303
NCT00001350|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|December 21, 1992||1992-12-21|January 12, 2018|2018-01-12||||||||Observational|||Study of Autoimmune Lymphoproliferative Syndrome (ALPS)|Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated With an Expansion of CD4-8-/TCR Alpha/Beta+ T Cells|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.796072|2018-06-01 05:39:59.796072
NCT00001349|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|December 16, 1992||1992-12-16|January 5, 2018|2018-01-05||||||||Observational|||Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies|Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.855015|2018-06-01 05:39:59.855015
NCT00001347|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1993||1993-06-30|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||Study of Usher Syndromes, Type 1 and Type 2|Usher Syndrome - Clinical and Molecular Studies|Completed|||200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.911924|2018-06-01 05:39:59.911924
NCT00001345|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-22|1999-11-03|1999-11-04|Estimate|||||||2018-05-22|2018-05-23|Actual|April 21, 1993||1993-04-21|May 9, 2018|2018-05-09||||||||Observational|||Studies of Inherited Diseases of Metabolism|Family Studies in Metabolic Diseases and Mineral Metabolism|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:39:59.970239|2018-06-01 05:39:59.970239
NCT00001343|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|December 11, 1992||1992-12-11|October 10, 2007|2007-10-10|October 10, 2007||2007-10-10|||||Interventional|||The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome|The Relative Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate, GH Binding Protein, IGF-I, and Cognitive Function in Growth Hormone-Treated Girls With Turner Syndrome|Completed||Phase 2|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.040145|2018-06-01 05:40:00.040145
NCT00001339|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1993||1993-08-31|August 2002|2002-08-31|August 2002||2002-08-31|||||Interventional|||A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection|A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection|Completed||Phase 2|42||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.093881|2018-06-01 05:40:00.093881
NCT00001337|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-12-13|1999-11-03|1999-11-04|Estimate|||||||2017-12-13|2017-12-14|Actual|May 3, 1993||1993-05-03|December 7, 2017|2017-12-07|March 31, 2022|Anticipated|2022-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma|Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma|Recruiting||Phase 2|348|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-06-01 05:40:00.168333|2018-06-01 05:40:00.168333
NCT00001336|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1993||1993-04-30|February 2003|2003-02-28|February 2003||2003-02-28|||||Observational|||In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients|In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients|Completed|||1000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.252413|2018-06-01 05:40:00.252413
NCT00001335|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1993||1993-04-30|January 2002|2002-01-31|January 2002||2002-01-31|||||Interventional|||New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma|New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma|Completed||Phase 2|90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.306577|2018-06-01 05:40:00.306577
NCT00001331|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|1999-11-03|1999-11-04|Estimate|||||||2008-03-04|2008-03-05|Estimate|May 1993||1993-05-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Observational|||Genetic and Family Studies of Inherited Muscle Diseases|Genetic and Family Studies of Inherited Muscle Diseases|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.364113|2018-06-01 05:40:00.364113
NCT00001329|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1992||1992-09-30|September 2002|2002-09-30|September 2002||2002-09-30|||||Observational|||Study of Norepinephrine Levels and Sympathetic Nervous System Activity|Plasma Catecholamine Kinetics|Completed|||50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.493109|2018-06-01 05:40:00.493109
NCT00001328|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 21, 1992||1992-08-21|April 30, 2010|2010-04-30|April 30, 2010|Actual|2010-04-30|April 30, 2010|Actual|2010-04-30||Interventional|||Gene Therapy for the Treatment of Brain Tumors|Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction With the Thymidine Kinase Gene and Intravenous Ganciclovir|Completed||Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.5578|2018-06-01 05:40:00.5578
NCT00001327|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|July 29, 1992||1992-07-29|March 31, 2011|2011-03-31|March 31, 2011||2011-03-31|||||Observational|||Establishing the Physiology of Syringomyelia|Establishing the Physiology of Syringomyelia|Completed|||120|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.633677|2018-06-01 05:40:00.633677
NCT00001325|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1992||1992-04-30|June 2004|2004-06-30|June 2004||2004-06-30|||||Observational|||Metabolic Abnormalities in Children With Epilepsy|Natural History of Metabolic Abnormalities in Children With Epilepsy|Completed|||80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.736131|2018-06-01 05:40:00.736131
NCT00001323|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1992||1992-08-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia|Neuropsychiatric Evaluation of Normal Subjects and Psychiatric and Neurologic Contrast Groups|Completed|||810||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.809791|2018-06-01 05:40:00.809791
NCT00001322|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 25, 1992||1992-04-25|May 8, 2018|2018-05-08||||||||Observational|||The Effects of Reproductive Hormones on Mood and Behavior|The Central Nervous System Effects of Pharmacologically Induced Hypogonadotropic Hypogonadism With and Without Estrogen and Progesterone Replacement|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.892818|2018-06-01 05:40:00.892818
NCT00001320|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1991||1991-10-31|July 2003|2003-07-31|July 2003||2003-07-31|||||Observational|||Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients|I-123 Iodobenzamide (IBZM) SPECT Studies of D2 Receptor Distribution and Function in Patients With Schizophrenia and Normal Volunteers|Completed|||265||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:00.976477|2018-06-01 05:40:00.976477
NCT00001319|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1992||1992-09-30|July 2003|2003-07-31|July 2003||2003-07-31|||||Observational|||Evaluation of HIV-Negative Patients With Low CD4+ T Lymphocyte Counts|Evaluation of the Epidemiology, Clinical Manifestations, Etiologies, and Immunology of Human Immunodeficiency Virus (HIV) Negative CD4 T Lymphocyte Deficient Patients|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.044275|2018-06-01 05:40:01.044275
NCT00001316|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|March 18, 1992||1992-03-18|July 12, 2017|2017-07-12||||||||Observational|||Viral Load in Blood and Lymph Tissues of HIV-Infected Individuals|A Study of Viral Burden in Peripheral Blood Versus Lymphoid and Bone Marrow Tissue in HIV-Infected Individuals|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.115287|2018-06-01 05:40:01.115287
NCT00001313|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|May 10, 1992||1992-05-10|January 6, 2009|2009-01-06|January 6, 2009||2009-01-06|||||Observational|||Evaluation of Patients With Known or Suspected Heart Disease|Evaluation of Patients With Known or Suspected Heart Disease (Screening Protocol)|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.200108|2018-06-01 05:40:01.200108
NCT00001310|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|March 5, 1992||1992-03-05|September 16, 2015|2015-09-16|September 16, 2015||2015-09-16|||||Observational|||Tissue Studies of Human Eye Diseases|Immunopathology and Molecular Pathology of Ocular Diseases in Humans|Terminated|||3833|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.276102|2018-06-01 05:40:01.276102
NCT00001309|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|October 25, 1991||1991-10-25|March 14, 2018|2018-03-14||||||||Observational|||The Body's Affect on Vitamin C|Pharmacokinetics and Biodistribution of Ascorbic Acid in Healthy Human Subjects|Recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.350509|2018-06-01 05:40:01.350509
NCT00001308|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|April 28, 1992||1992-04-28|October 6, 2016|2016-10-06|October 6, 2016||2016-10-06|||||Observational|||Central Mechanisms in Speech Motor Control Studied With H215O PET|Multimodal Studies of Language Production and Comprehension in Normal Volunteers and Patients With Neurologically-Based Language Impairments|Terminated|||1163|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.438993|2018-06-01 05:40:01.438993
NCT00001307|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1992||1992-08-31|August 2005|2005-08-31|August 2005||2005-08-31|||||Observational|||Positron Emission Tomography to Measure Pain and Pain Control|Somatosensory Studies of Pain and Pain Control Measured With Oxygen-15 Water Positron Emission Tomography and Functional MRI in Normals and Patients With Neuropathic or Chronic Pain Conditions|Completed|||273||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.518553|2018-06-01 05:40:01.518553
NCT00001306|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|July 10, 1992||1992-07-10|December 12, 2011|2011-12-12|December 12, 2011||2011-12-12|||||Observational|||Steroid Therapy in Autoimmune Premature Ovarian Failure|Autoimmune Premature Ovarian Failure: A Controlled Trial of Alternate-Day Prednisone Therapy|Completed|||33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.610737|2018-06-01 05:40:01.610737
NCT00001305|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|November 5, 1991||1991-11-05|May 19, 2017|2017-05-19|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||Growth Hormone Therapy in Osteogenesis Imperfecta|Studies of Growth Deficiency and Growth Hormone Treatment in Children With Osteogenesis Imperfecta Types III and IV|Completed||Phase 3|52|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:01.711228|2018-06-01 05:40:01.711228
NCT00001304|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2015-03-12||2015-11-10|1999-11-03|1999-11-04|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|October 1991||1991-10-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34|Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34|Completed||Phase 2|27|Actual|National Institutes of Health Clinical Center (CC)|Study reported here was the primary long-term study for adults with hypoparathyroidism. Subsequent studies included additional patients.|2|||f||||t||||||||||2018-06-01 05:40:01.803802|2018-06-01 05:40:01.803802
NCT00001303|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|April 6, 1992||1992-04-06|May 17, 2018|2018-05-17|May 17, 2018|Actual|2018-05-17|March 21, 2007|Actual|2007-03-21||Interventional|||Effects of Endotoxin in Normal Human Volunteers|The Cardiopulmonary Effects of Endotoxin in Normal Human Volunteers|Completed||Phase 1|198|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.387044|2018-06-01 05:40:02.387044
NCT00001302|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1992||1992-09-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833|A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833|Completed||Phase 1|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.448054|2018-06-01 05:40:02.448054
NCT00001295|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|January 29, 1992||1992-01-29|August 23, 2016|2016-08-23|August 23, 2016||2016-08-23|||||Observational|||Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease|Continuing Treatment for Children and Adults in the Center for Cancer Research|Completed|||2145|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.50984|2018-06-01 05:40:02.50984
NCT00001257|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 24, 1990||1990-04-24|July 12, 2017|2017-07-12||||||||Observational|||Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses|Comparison of Inflammatory Responses in Normal Volunteers and Patients With Abnormal Phagocyte Function Using the Suction Blister Technique|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:04.992148|2018-06-01 05:40:04.992148
NCT00001294|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1992||1992-01-31|April 2005|2005-04-30|April 2005||2005-04-30|||||Observational|||Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens|Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens|Completed|||2000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.559501|2018-06-01 05:40:02.559501
NCT00001289|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|September 23, 1991||1991-09-23|March 3, 2008|2008-03-03|March 3, 2008||2008-03-03|||||Observational|||Effects of Enzyme Replacement in Gaucher's Disease|Clinical and Biochemical Effects of Macrophage-Targeted Glucocerebrosidase on Neurological Involvement in Neuronopathic Gaucher's Disease|Completed|||70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.60735|2018-06-01 05:40:02.60735
NCT00001288|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1991||1991-05-31|June 2003|2003-06-30|June 2003||2003-06-30|||||Observational|||Brain Blood Flow Studies of Language and Memory|Cerebral Blood Flow Studies of Language and Memory|Completed|||303||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.654667|2018-06-01 05:40:02.654667
NCT00001284|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|May 10, 1991||1991-05-10|March 8, 2018|2018-03-08||||||||Observational|||Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers|Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 1.5 Tesla MRI|Completed|||2802|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.708195|2018-06-01 05:40:02.708195
NCT00001282|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1991||1991-07-31|April 2002|2002-04-30|April 2002||2002-04-30|||||Interventional|||A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients|A Phase I/II Study of the Combination of Azidothymidine and Interleukin-2 (IL-2) in the Treatment of HIV-Infected Patients|Completed||Phase 2|73||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.791487|2018-06-01 05:40:02.791487
NCT00001281|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|May 21, 1991||1991-05-21|December 7, 2017|2017-12-07||||||||Observational|||Studies of Blood and Reproductive Fluids in HIV-Infected and Non-HIV-Infected Persons|Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Reproductive Fluids in HIV-Infected and HIV-Uninfected Volunteers|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.846515|2018-06-01 05:40:02.846515
NCT00001277|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-22|1999-11-03|1999-11-04|Estimate|||||||2018-05-22|2018-05-23|Actual|March 31, 1991||1991-03-31|May 9, 2018|2018-05-09||||||||Observational|||Studies of Elevated Parathyroid Activity|Studies of Hyperparathyroidism and Related Disorders|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.914029|2018-06-01 05:40:02.914029
NCT00001276|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|January 29, 1991||1991-01-29|April 24, 2018|2018-04-24||||||||Observational|||Diagnosing and Treating Low Blood Sugar Levels|Fasting Hypoglycemia: Diagnosis and Treatment|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:02.980847|2018-06-01 05:40:02.980847
NCT00001275|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|May 12, 1991||1991-05-12|February 8, 2017|2017-02-08|February 8, 2017||2017-02-08|||||Observational|||Ovarian Follicle Function in Patients With Primary Ovarian Failure|Ovarian Follicle Function in Patients With Primary Ovarian Insufficiency|Completed|||1134|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:03.078227|2018-06-01 05:40:03.078227
NCT00001266|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1990||1990-10-31|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma|A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma|Completed||Phase 2|70||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:03.133865|2018-06-01 05:40:03.133865
NCT00001265|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|August 8, 1991||1991-08-08|September 25, 2017|2017-09-25||||||||Observational|||Study and Treatment of Inflammatory Muscle Diseases|Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:03.192666|2018-06-01 05:40:03.192666
NCT00001262|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2014-08-05||2015-09-29|1999-11-03|1999-11-04|Estimate|2015-09-29|2015-10-30|Estimate||||2015-09-29|2015-10-30|Estimate|June 1990||1990-06-30|September 2015|2015-09-30|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Copper Histidine Therapy for Menkes Diseases|Early Copper Histidine Therapy in Menkes Disease|Completed||Phase 1/Phase 2|60|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||||2018-06-01 05:40:03.2612|2018-06-01 05:40:03.2612
NCT00001261|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1990||1990-05-31|July 2002|2002-07-31|July 2002||2002-07-31|||||Interventional|||Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies|The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over|Completed||Phase 2|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:04.73153|2018-06-01 05:40:04.73153
NCT00001260|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|May 29, 1990||1990-05-29|June 16, 2017|2017-06-16|June 16, 2017||2017-06-16|||||Observational|||Brain Tissue Collection for Neuropathological Studies|Brain Procurement for the Human Brain Collection Core|Terminated|||2161|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:04.790349|2018-06-01 05:40:04.790349
NCT00001259|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|March 9, 1990||1990-03-09|March 19, 2018|2018-03-19||||||||Observational|||A Treatment Study for Premenstrual Syndrome (PMS)|The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:04.85546|2018-06-01 05:40:04.85546
NCT00001258|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|October 26, 1989||1989-10-26|September 6, 2017|2017-09-06||||||||Observational|||Studies of Frontal Lobe Brain Functioning in Schizophrenia|Studies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders|Completed|||1039|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:04.929824|2018-06-01 05:40:04.929824
NCT00001256|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1990||1990-03-31|February 2004|2004-02-29|February 2004||2004-02-29|||||Interventional|||Steroids and Methotrexate to Treat Systemic Vasculitis|An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.061125|2018-06-01 05:40:05.061125
NCT00001255|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1990||1990-09-30|July 2002|2002-07-31|July 2002||2002-07-31|||||Observational|||Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study|Treatment of Severe Combined Immunodeficiency Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency With Autologous Lymphocytes of CD34+ Cells Transduced With a Human ADA Gene: A Natural History Study|Completed|||10||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.216153|2018-06-01 05:40:05.216153
NCT00001254|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|May 22, 1990||1990-05-22|February 21, 2018|2018-02-21||||||||Observational|||Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome|Evaluation of the Gastrinoma in Patients With Zollinger-Ellison Syndrome|Completed|||273|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.282031|2018-06-01 05:40:05.282031
NCT00001253|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1990||1990-05-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Interventional|||The Effects of Estrogen on Cognition in Girls With Turner Syndrome|Estrogen Effects on Cognition in Girls With Turner Syndrome|Completed||Phase 2|950||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.339719|2018-06-01 05:40:05.339719
NCT00001252|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|July 5, 1990||1990-07-05|December 10, 2017|2017-12-10||||||||Observational|||Human Movement Database|A Rigid Body Database on Human Movement|Recruiting|||999999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.403797|2018-06-01 05:40:05.403797
NCT00001251|ClinicalTrials.gov processed this data on May 31, 2018|2006-07-07|||2013-08-16|1999-11-03|1999-11-04|Estimate|||||||2013-08-16|2013-08-19|Estimate|November 1989||1989-11-30|November 2003|2003-11-30|November 2003||2003-11-30|||||Interventional|||Phase I Study of Intrathecal Mafosfamide|Phase I Study of Intrathecal Mafosfamide|Completed||Phase 1|65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.473057|2018-06-01 05:40:05.473057
NCT00001250|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1989||1989-12-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Interventional|||Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial|Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial|Completed||Phase 2|130||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.535335|2018-06-01 05:40:05.535335
NCT00001248|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|March 13, 1989||1989-03-13|March 9, 2018|2018-03-09||||||||Observational|||Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)|Evaluation of Progression in Multiple Sclerosis by Magnetic Resonance Imaging (MRI)|Recruiting|||1100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.596622|2018-06-01 05:40:05.596622
NCT00001247|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|September 13, 1989||1989-09-13|March 28, 2018|2018-03-28||||||||Observational|||Inpatient Evaluation of Adults With Schizophrenia|Inpatient Evaluation of Neuropsychiatric Patients|Recruiting|||700|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.677268|2018-06-01 05:40:05.677268
NCT00001246|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-30|1999-11-03|1999-11-04|Estimate|||||||2018-03-30|2018-04-02|Actual|January 10, 1989||1989-01-10|December 3, 2017|2017-12-03||||||||Observational|||Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers|Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers|Recruiting|||6000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.746736|2018-06-01 05:40:05.746736
NCT00001245|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2009-08-24|1999-11-03|1999-11-04|Estimate|||||||2009-08-24|2009-08-25|Estimate|August 1989||1989-08-31|May 2009|2009-05-31||||May 2009|Actual|2009-05-31||Observational|||Study of Patients With Strongyloides Stercoralis Infection|Study of Patients With Known or Suspected Infection With Strongyloides Stercoralis|Completed|||650||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.833467|2018-06-01 05:40:05.833467
NCT00001244|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|September 14, 1989||1989-09-14|November 1, 2017|2017-11-01||||||||Observational|||Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes|Studies of Immune Regulation in Patients With Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.903013|2018-06-01 05:40:05.903013
NCT00001243|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1989||1989-02-28|December 2005|2005-12-31|December 2005||2005-12-31|||||Observational|||Effects of HIV on the Development and Function of Bone Marrow Cells|Effects of Infection With the Human Immunodeficiency Virus on the Development and Function of Bone Marrow Cells|Completed|||300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:05.985055|2018-06-01 05:40:05.985055
NCT00001242|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|September 29, 1989||1989-09-29|January 4, 2018|2018-01-04||||||||Observational|||Resistance to Vitamin D or Parathyroid Hormone|Studies of States With Resistance to Vitamin D and Parathyroid Hormone|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.031705|2018-06-01 05:40:06.031705
NCT00001241|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|January 27, 1989||1989-01-27|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Observational|||Treatment of Zollinger-Ellison Syndrome|Medical Therapy of Zollinger-Ellison Syndrome|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.100046|2018-06-01 05:40:06.100046
NCT00001240|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-04|1999-11-03|1999-11-04|Estimate|||||||2008-03-04|2008-03-05|Estimate|January 1989||1989-01-31|January 2004|2004-01-31|January 2004||2004-01-31|||||Observational|||Evaluating Patients With Abnormal Levels of Gastric Acid|Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion|Completed|||||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.150515|2018-06-01 05:40:06.150515
NCT00001238|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 20, 1989||1989-04-20|January 23, 2018|2018-01-23||||||||Observational|||Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders|Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-06-01 05:40:06.199166|2018-06-01 05:40:06.199166
NCT00001234|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1988||1988-01-31|April 2002|2002-04-30|April 2002||2002-04-30|||||Interventional|||Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells|Retroviral-Mediated Transfer and Expression of Glucocerebrosidase and Ceramidtrihexosidase (a-Galactosidase A) cDNA's in Human Hematopoietic Progenitor Cells|Completed||Phase 1|120||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.411306|2018-06-01 05:40:06.411306
NCT00001231|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|July 12, 1988||1988-07-12|April 2, 2018|2018-04-02||||||||Observational|||Perimenopause-Related Mood and Behavioral Disorders|The Evaluation of Women With Perimenopause-Related Mood and Behavioral Disorders|Recruiting|||1900|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.466287|2018-06-01 05:40:06.466287
NCT00001230|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|May 6, 1988||1988-05-06|August 8, 2017|2017-08-08||||||||Observational|||Host Response to Infection and Treatment in Filarial Diseases|Host Response to Infection and Treatment in the Filarial Diseases of Humans|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.537516|2018-06-01 05:40:06.537516
NCT00001228|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|October 25, 1988||1988-10-25|September 6, 2007|2007-09-06|September 6, 2007||2007-09-06|||||Interventional|||Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer|Evaluation of Treatment With Interferon, Octreotide, or Their Combination in Patients With Zollinger-Ellison Syndrome and Progressive Metastatic Non-B Islet Cell Neoplasm|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.604206|2018-06-01 05:40:06.604206
NCT00001226|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|December 1987||1987-12-31|March 2002|2002-03-31|March 2002||2002-03-31|||||Observational|||Lipoprotein Metabolism in Normal Volunteers and Patients With Abnormal Levels of Lipoproteins|Lipoprotein Metabolism in Normal Volunteers and Dyslipoproteinemic Patients (Stable Isotopes)|Completed|||90||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.662768|2018-06-01 05:40:06.662768
NCT00001225|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1987||1987-04-30|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||Family Studies of Inherited Heart Disease|Family Studies of Hypertrophic Cardiomyopathy|Completed|||5880||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.730253|2018-06-01 05:40:06.730253
NCT00001224|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1987||1987-07-31|September 2002|2002-09-30|September 2002||2002-09-30|||||Observational|||Analysis of Eye Tissue|Immunologic Analysis of Intra-Ocular Tissue|Completed|||150||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.794252|2018-06-01 05:40:06.794252
NCT00001223|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-03|1999-11-03|1999-11-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 18, 1987||1987-02-18|March 29, 2018|2018-03-29||||||||Observational|||Studying Patients With Cystic Fibrosis and Other Pulmonary and Pancreatic Disorders|Diagnosis and Treatment of Patients With Cystic Fibrosis and Other Disorders of the Respiratory System and Pancreas|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.871903|2018-06-01 05:40:06.871903
NCT00001221|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1987||1987-09-30|September 2003|2003-09-30|September 2003||2003-09-30|||||Interventional|||Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome|A Double-Blind, Randomized, Placebo-Controlled Trial of the Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome|Completed||Phase 2|160||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:06.942984|2018-06-01 05:40:06.942984
NCT00001220|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1987||1987-10-31|November 2005|2005-11-30|November 2005||2005-11-30|||||Observational|||Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders|Comparison of Ultrasound and Videofluoroscopic Imaging Techniques in Diagnosing Oropharyngeal Dysphagia in Neurologically Impaired Subjects|Completed|||750||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.002126|2018-06-01 05:40:07.002126
NCT00001219|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|June 18, 1987||1987-06-18|April 12, 2018|2018-04-12||||||||Observational|||Comparing Magnetic Resonance Imaging/Spectroscopy Techniques|Magnetic Resonance Imaging at 1.5 and 3.0 Tesla|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.058287|2018-06-01 05:40:07.058287
NCT00001215|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|May 16, 1986||1986-05-16|March 1, 2018|2018-03-01||||||||Observational|||Genetic Studies of Lysosomal Storage Disorders|Studies of Genetic Heterogeneity in Patients With Lysosomal Storage Disorders|Enrolling by invitation|||494|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.125717|2018-06-01 05:40:07.125717
NCT00001214|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-17|1999-11-03|1999-11-04|Estimate|||||||2018-05-17|2018-05-18|Actual|April 30, 1986||1986-04-30|August 16, 2017|2017-08-16||||||||Observational|||Collection of Blood From Patients With Pancytopenia|Lymphocytapheresis of Patients With Pancytopenia|Completed|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.189685|2018-06-01 05:40:07.189685
NCT00001213|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2014-06-20||2014-06-20|1999-11-03|1999-11-04|Estimate|2014-06-20|2014-07-22|Estimate||||2014-06-20|2014-07-22|Estimate|April 1986||1986-04-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis|Trial of Topical Cysteamine in the Treatment of Corneal Cystine Crystal Accumulation in Cystinosis|Completed||Phase 2|328|Actual|National Institutes of Health Clinical Center (CC)|Due to the progressive nature of the drug's development, this protocol reflects the culmination of cysteamine studies performed at NIH. The combined analyses of the data is presented and not the data or analyses of one individual protocol.|1|||f||||f||||||||||2018-06-01 05:40:07.264448|2018-06-01 05:40:07.264448
NCT00001212|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-04-08|1999-11-03|1999-11-04|Estimate|||||||2008-04-08|2008-04-09|Estimate|November 1986||1986-11-30|April 2008|2008-04-30|September 2004||2004-09-30|||||Interventional|||Drug Therapy in Lupus Nephropathy|Immunosuppressive Drug Therapy in Membranous Lupus Nephropathy|Completed||Phase 2|45||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.458974|2018-06-01 05:40:07.458974
NCT00001208|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|November 21, 1985||1985-11-21|March 8, 2018|2018-03-08|October 30, 2019|Anticipated|2019-10-30|||||Interventional|||Botulinum Toxin for the Treatment of Involuntary Movement Disorders|A Training Protocol for the Use of Botulinum Toxin in the Treatment of Neurological Disorders|Recruiting||N/A|2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.521713|2018-06-01 05:40:07.521713
NCT00001206|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-24|1999-11-03|1999-11-04|Estimate|||||||2018-05-24|2018-05-25|Actual|June 5, 1985||1985-06-05|May 15, 2017|2017-05-15|May 15, 2017||2017-05-15|||||Observational|||Biological Markers in Attention Deficit/Hyperactivity Disorder (ADHD)|Biological Markers in Childhood Psychiatric Disorders|Completed|||347|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.58555|2018-06-01 05:40:07.58555
NCT00001205|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-11|1999-11-03|1999-11-04|Estimate|||||||2018-05-11|2018-05-14|Actual|July 22, 1985||1985-07-22|March 26, 2018|2018-03-26||||||||Observational|||Treatment of Patients With Cysticercosis With Praziquantel or Albendazole|Treatment of Cysticercosis Including Neurocysticercosis With Praziquantel, Albendazole and Other Novel Treatment Modalities|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.643158|2018-06-01 05:40:07.643158
NCT00001204|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|May 28, 1985||1985-05-28|February 8, 2018|2018-02-08||||||||Observational|||Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers|Cardiovascular Evaluation of Homozygous Familial Hypercholesterolemia|Completed|||73|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.706501|2018-06-01 05:40:07.706501
NCT00001203|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 22, 1985||1985-04-22|November 9, 2015|2015-11-09|November 9, 2015||2015-11-09|||||Observational|||Deferoxamine for the Treatment of Hemochromatosis|Clinical Course of Patients With Transfusional Hemochromatosis on Deferoxamine|Completed|||151|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.764333|2018-06-01 05:40:07.764333
NCT00001202|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1985||1985-01-31|January 2004|2004-01-31|January 2004||2004-01-31|||||Interventional|||Treatment of Boys With Precocious Puberty|Spironolactone and Testolactone Treatment of Boys With Familial Isosexual Precocious Puberty|Completed||Phase 2|80||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.819372|2018-06-01 05:40:07.819372
NCT00001201|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1984||1984-10-31|November 2002|2002-11-30|November 2002||2002-11-30|||||Observational|||Evaluation of Neuromuscular Disease|Evaluation of Neuromuscular Diseases|Completed|||1500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:07.870835|2018-06-01 05:40:07.870835
NCT00001198|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-11|1999-11-03|1999-11-04|Estimate|||||||2017-10-11|2017-10-12|Actual|March 19, 1984||1984-03-19|October 10, 2017|2017-10-10|October 10, 2017||2017-10-10|||||Observational|||Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia|Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients|Terminated|||1556|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.032845|2018-06-01 05:40:08.032845
NCT00001197|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-15|1999-11-03|1999-11-04|Estimate|||||||2018-05-15|2018-05-16|Actual|February 7, 1984||1984-02-07|May 18, 2015|2015-05-18|May 18, 2015|Actual|2015-05-18|December 21, 2003|Actual|2003-12-21||Interventional|||Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia|Effect of Hydroxyurea on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia|Completed||Phase 2|41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.093733|2018-06-01 05:40:08.093733
NCT00001196|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|March 23, 1984||1984-03-23|September 29, 2015|2015-09-29|September 29, 2015||2015-09-29|||||Observational|||Evaluation of Salivary Gland Dysfunction|Evaluation of Salivary Gland Dysfunction|Terminated|||1740|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.183595|2018-06-01 05:40:08.183595
NCT00001195|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-10-05|1999-11-03|1999-11-04|Estimate|||||||2017-10-05|2017-10-06|Actual|August 28, 1984||1984-08-28|October 20, 2014|2014-10-20|October 20, 2014||2014-10-20|||||Observational|||Endocrine Studies of Healthy Children|Endocrine Studies of Healthy Children|Completed|||1247|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.296611|2018-06-01 05:40:08.296611
NCT00001192|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|October 18, 1983||1983-10-18|December 20, 2006|2006-12-20|December 20, 2006||2006-12-20|||||Observational|||Neuropsychological Evaluation of Psychiatric and Neurological Patients|Neuropsychological Evaluation of Psychiatric and Neurological Patients|Completed|||4300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.353835|2018-06-01 05:40:08.353835
NCT00001191|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|February 3, 1983||1983-02-03|December 10, 2007|2007-12-10|December 10, 2007||2007-12-10|||||Interventional|||The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid|The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid|Completed||Phase 2|||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.415838|2018-06-01 05:40:08.415838
NCT00001186|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-18|1999-11-03|1999-11-04|Estimate|||||||2018-05-18|2018-05-21|Actual|February 8, 1983||1983-02-08|May 17, 2018|2018-05-17||||||||Observational|||Psychological Benefits of a Normalized Camping Experience for Children With Cancer|Psychological Benefits of a Normalized Camping Experience for Children With Cancer|Recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-06-01 05:40:08.481789|2018-06-01 05:40:08.481789
NCT00001185|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|June 1982||1982-06-30|May 2003|2003-05-31|May 2003||2003-05-31|||||Observational|||"Study of Post-Polio Syndrome"|Post-Polio Motor Neuron Disease: Clinical, Virological, and Immunological Studies|Completed|||360||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.563212|2018-06-01 05:40:08.563212
NCT00001184|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|November 12, 1982||1982-11-12|November 29, 2017|2017-11-29||||||||Observational|||Immune Regulation in Ulcerative Colitis or Crohn s Disease|Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.64014|2018-06-01 05:40:08.64014
NCT00001183|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|March 11, 1982||1982-03-11|January 12, 2018|2018-01-12||||||||Observational|||Evaluation of the Causes and Disease Processes of Chronic Lung Disease|Comprehensive Evaluation of the Etiology and Pathogenesis of Chronic Lung Disease (Screening Protocol)|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.744895|2018-06-01 05:40:08.744895
NCT00001182|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|April 1982||1982-04-30|June 2002|2002-06-30|June 2002||2002-06-30|||||Interventional|||Evaluation of Patients With Unusual Diagnostic or Treatment Considerations|General Dental Diagnostic and Therapeutic Study: A Pilot Program for Evaluating the Research Potential of Referred Subjects|Completed||N/A|300||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.820178|2018-06-01 05:40:08.820178
NCT00001181|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1982||1982-10-31|May 2003|2003-05-31|May 2003||2003-05-31|||||Interventional|||Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty|Testolactone Treatment of Girls With LHRH Analog-Resistant Precocious Puberty Due to Autonomous, Non-Neoplastic Ovarian Estrogen Secretion|Completed||Phase 2|100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.875527|2018-06-01 05:40:08.875527
NCT00001180|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|March 1982||1982-03-31|June 2005|2005-06-30|June 2005||2005-06-30|||||Observational|||Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency|Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency|Completed|||2250||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:08.936219|2018-06-01 05:40:08.936219
NCT00001178|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-19|1999-11-03|1999-11-04|Estimate|||||||2018-05-19|2018-05-22|Actual|January 19, 1981||1981-01-19|December 17, 2012|2012-12-17|December 17, 2012||2012-12-17|||||Observational|||Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders|Regional Cerebral Utilization of Glucose in Patients With a Diagnosis of Frontal Lobe Dementia, Atypical Parkinsonian Disorder, and Other Basal Ganglia Disorders|Terminated|||597|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.017371|2018-06-01 05:40:09.017371
NCT00001177|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-04-24|1999-11-03|1999-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|August 24, 1981||1981-08-24|March 29, 2018|2018-03-29||||||||Observational|||Study of Premenstrual Syndrome and Premenstrual Dysphoria|The Evaluation of Women With Menstrually Regulated Mood and Behavioral Disorders|Recruiting|||1600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.073463|2018-06-01 05:40:09.073463
NCT00001176|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|May 1981||1981-05-31|December 2001|2001-12-31|December 2001||2001-12-31|||||Observational|||Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure|The Function of Dopaminergic and Noradrenergic Systems in Salt-Sensitive Hypertension: The Effects of Changes in Sodium Intake|Completed|||110||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.184006|2018-06-01 05:40:09.184006
NCT00001174|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-16|1999-11-03|1999-11-04|Estimate|||||||2018-05-16|2018-05-17|Actual|August 4, 1980||1980-08-04|March 12, 2018|2018-03-12||||||||Observational|||Evaluation of the Genetics of Bipolar Disorder|Bipolar Genetics: A Collaborative Study|Recruiting|||4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.23837|2018-06-01 05:40:09.23837
NCT00001172|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|August 26, 1980||1980-08-26|August 6, 2008|2008-08-06|August 6, 2008||2008-08-06|||||Observational|||Visual Stimulus and Eye Movement|Visual Motor Coordination in Man|Completed|||225||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.308205|2018-06-01 05:40:09.308205
NCT00001171|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1979||1979-07-31|September 2005|2005-09-30|September 2005||2005-09-30|||||Observational|||Evaluation of Factors in Human Brain Tumors|Evaluation of Biological, Immunological and Therapeutic Parameters in Brain Tumor Patients|Completed|||800||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.360612|2018-06-01 05:40:09.360612
NCT00001170|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1979||1979-10-31|February 2005|2005-02-28|February 2005||2005-02-28|||||Observational|||Study of the Psychological Development of Children of Parents With and Without Affective Disorders|Affective Disorders and Affective Development: A Study of Child Rearing and Child Development in Normal Families and Families With Affective Disorders|Completed|||1045||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.413215|2018-06-01 05:40:09.413215
NCT00001168|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-27|1999-11-03|1999-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|August 6, 1979||1979-08-06|February 7, 2018|2018-02-07||||||||Observational|||Evaluation of Lipoproteins|Teaching Protocol for the Evaluation of Plasma Lipoproteins|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.463847|2018-06-01 05:40:09.463847
NCT00001167|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|August 1979||1979-08-31|November 2004|2004-11-30|November 2004||2004-11-30|||||Observational|||Ultrasound Evaluation of Tongue Movements in Speech and Swallowing|Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx|Completed|||570||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.574468|2018-06-01 05:40:09.574468
NCT00001166|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|January 1978||1978-01-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Gyrate Atrophy of the Choroid and Retina|The Diagnosis, Pathogenesis and Treatment of Gyrate Atrophy of the Choroid and Retina|Completed|||65||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.629782|2018-06-01 05:40:09.629782
NCT00001165|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|September 1978||1978-09-30|August 2003|2003-08-31|August 2003||2003-08-31|||||Interventional|||Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas|Evaluation of Chemotherapy With Streptozotocin Combined With 5-Fluorouracil and Adriamycin in Patients With Zollinger-Ellison Syndrome and Metastatic Non-Beta-Islet Cell Neoplasm|Completed||Phase 2|999||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.749374|2018-06-01 05:40:09.749374
NCT00001163|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-03-20|1999-11-03|1999-11-04|Estimate|||||||2018-03-20|2018-03-21|Actual|March 20, 1978||1978-03-20|February 21, 2018|2018-02-21||||||||Observational|||Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer|Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer|Recruiting|||7500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:09.954712|2018-06-01 05:40:09.954712
NCT00001162|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|May 23, 1977||1977-05-23|May 31, 2017|2017-05-31|May 31, 2017||2017-05-31|||||Observational|||Parasitic Infections of the Gastrointestinal Tract|Study of Patients With Parasitic Infections of the Gastrointestinal Tract|Terminated|||150|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.019664|2018-06-01 05:40:10.019664
NCT00001161|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|July 1977||1977-07-31|August 2002|2002-08-31|August 2002||2002-08-31|||||Observational|||Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens|Anomalies of the Anterior Chamber, Angle, Iris, Cornea and Lens With or Without Glaucoma or Ocular Hypertension|Completed|||100||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.17077|2018-06-01 05:40:10.17077
NCT00000454|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-05-18|1999-11-02|1999-11-03|Estimate|||||||2010-05-18|2010-05-19|Estimate||||May 2010|2010-05-31|August 2002||2002-08-31|||||Interventional|||Smoking Cessation in Alcoholism Treatment|Field Study of Smoking Cessation in Alcoholism Treatment|Completed||Phase 4|112||Yale University|||||f||||f||||||||||2018-06-01 05:40:15.627602|2018-06-01 05:40:15.627602
NCT00001159|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|January 14, 1977||1977-01-14|May 3, 2018|2018-05-03||||||||Observational|||Evaluation of Patients With Thyroid Disorders|Evaluation of Patients With Thyroid Function Disorders|Recruiting|||99999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.304152|2018-06-01 05:40:10.304152
NCT00001156|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-06-30|1999-11-03|1999-11-04|Estimate|||||||2017-06-30|2017-07-02|Actual|January 23, 1976||1976-01-23|February 1, 2010|2010-02-01|February 1, 2010||2010-02-01|||||Observational|||Assessment of Patients With Multiple Sclerosis (MS)|Combined Clinical, Immunological and Virological Assessment of Patients With Multiple Sclerosis (MS)|Completed|||1388|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.39126|2018-06-01 05:40:10.39126
NCT00001155|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|February 1976||1976-02-29|February 2002|2002-02-28|February 2002||2002-02-28|||||Interventional|||Treatment of Wegener's Granulomatosis With Cyclophosphamide|Treatment of Wegener's Granulomatosis With Cyclophosphamide|Completed||Phase 2|200||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.438602|2018-06-01 05:40:10.438602
NCT00001154|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2018-05-23|1999-11-03|1999-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual|March 3, 1976||1976-03-03|November 27, 2017|2017-11-27||||||||Observational|||Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins|Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients|Recruiting|||900|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.522656|2018-06-01 05:40:10.522656
NCT00001151|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|2010-11-12||2013-11-21|1999-11-03|1999-11-04|Estimate|2013-11-21|2013-11-25|Estimate||||2013-11-21|2013-11-25|Estimate|March 1976||1976-03-31|June 2013|2013-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Studies With 1,25-Dihydroxycholecalciferol|Studies With 1,25-Dihydroxycholecalciferol|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1||Terminated because of lack of drug supply|f||||f||||||||||2018-06-01 05:40:10.679845|2018-06-01 05:40:10.679845
NCT00001150|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1976||1976-10-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers|Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers|Completed|||2000||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.843705|2018-06-01 05:40:10.843705
NCT00001149|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|November 1975||1975-11-30|January 2002|2002-01-31|January 2002||2002-01-31|||||Observational|||Monitoring Patients With Uncontrolled Epilepsy|Monitoring of Seizures, EEG and Serum Antiepileptic Drug Concentrations in Patients With Uncontrolled Epilepsy|Completed|||900||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:10.978455|2018-06-01 05:40:10.978455
NCT00001148|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1999||1999-10-31|January 2005|2005-01-31|January 2005||2005-01-31|||||Observational|||Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor|Detection of Glioblastoma or Anaplastic Astrocytoma Cells in the Circulation During Surgical Resection|Completed|||25||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:11.047042|2018-06-01 05:40:11.047042
NCT00001147|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1999||1999-10-31|March 2004|2004-03-31|March 2004||2004-03-31|||||Observational|||Blood Sampling for Neurochemical and Genetic Testing|Blood Sampling for Neurochemical and Genetic Testing|Completed|||500||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:11.107549|2018-06-01 05:40:11.107549
NCT00001146|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1999||1999-10-31|August 2002|2002-08-31|August 2002||2002-08-31|||||Interventional|||Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial|Omega-3 Fatty Acids in the Treatment of Major Depression and Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial|Completed||Phase 2|240||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:11.195735|2018-06-01 05:40:11.195735
NCT00001145|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1999||1999-10-31|October 2003|2003-10-31|October 2003||2003-10-31|||||Interventional|||Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome|Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome|Completed||Phase 2|5||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:11.278782|2018-06-01 05:40:11.278782
NCT00001144|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-10-06|1999-11-03|1999-11-04|Estimate|||||||2008-10-06|2008-10-07|Estimate|October 1999||1999-10-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Interventional|||Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia|Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML|Completed||Phase 2|50||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:11.359038|2018-06-01 05:40:11.359038
NCT00001143|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2008-03-03|1999-11-03|1999-11-04|Estimate|||||||2008-03-03|2008-03-04|Estimate|October 1999||1999-10-31|October 2002|2002-10-31|October 2002||2002-10-31|||||Observational|||Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye|Ocular Motor Development During the First Seven Months of Life in Infants With and Without a Family History of Strabismus|Completed|||20||National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-06-01 05:40:11.443668|2018-06-01 05:40:11.443668
NCT00000426|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-06-27|1999-11-03|1999-11-04|Estimate|||||||2013-06-27|2013-06-28|Estimate|January 1995||1995-01-31|June 2013|2013-06-30|June 2000||2000-06-30|||||Interventional|||Treatment of Calcium Deficiency in Young Women|Treatment of Calcium Deficiency in Young Women|Completed||Phase 2|150||Creighton University|||||f||||||||||||||2018-06-01 05:40:11.50675|2018-06-01 05:40:11.50675
NCT00000425|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-04-30|1999-11-03|1999-11-04|Estimate|||||||2013-04-30|2013-05-03|Estimate|July 1996||1996-07-31|April 2013|2013-04-30|April 2001||2001-04-30|||||Interventional|||Toward Better Outcomes in Osteoarthritis|Toward Better Outcomes in Osteoarthritis (OA): Finding the Appropriate Role for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)|Completed||Phase 3|900||Stanford University|||||f||||||||||||||2018-06-01 05:40:11.658707|2018-06-01 05:40:11.658707
NCT00000424|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-12-28|1999-11-03|1999-11-04|Estimate|||||||2006-12-28|2007-01-01|Estimate|July 1995||1995-07-31|March 2001|2001-03-31|June 2001||2001-06-30|||||Interventional|||Tidal Lavage in Knee Osteoarthritis|Tidal Lavage vs. Sham Lavage in Knee Osteoarthritis (OA)|Completed||Phase 2|180||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:40:11.755849|2018-06-01 05:40:11.755849
NCT00000423|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-12-03|1999-11-03|1999-11-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 1996||1996-09-30|March 2001|2001-03-31|February 2001||2001-02-28|||||Interventional|||Support, Health, and Fibromyalgia|Social Support and Health in Fibromyalgia|Completed||Phase 2|600||San Diego State University|||||f||||||||||||||2018-06-01 05:40:11.885249|2018-06-01 05:40:11.885249
NCT00000422|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-10-29|1999-11-03|1999-11-04|Estimate|||||||2013-10-29|2013-10-30|Estimate|July 1998||1998-07-31|October 2013|2013-10-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Tailored Treatments of Fibromyalgia|Subgroups of FMS: Symptoms, Beliefs and Tailored Treatments|Completed||Phase 2/Phase 3|312||University of Washington|||||f||||||||||||||2018-06-01 05:40:11.99563|2018-06-01 05:40:11.99563
NCT00000421|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2016-03-02|1999-11-03|1999-11-04|Estimate|||||||2016-03-02|2016-03-04|Estimate|September 1997||1997-09-30|March 2016|2016-03-31|August 2003|Actual|2003-08-31|August 2002|Actual|2002-08-31||Interventional|SACS-SLE||Serologically Active, Clinically Stable Systemic Lupus Erythematosus|Serologically Active, Clinically Stable Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|154|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-06-01 05:40:12.092108|2018-06-01 05:40:12.092108
NCT00000420|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-05-01|1999-11-03|1999-11-04|Estimate|||||||2013-05-01|2013-05-03|Estimate|June 1997||1997-06-30|May 2013|2013-05-31|August 2003||2003-08-31|||||Interventional|||Safety of Estrogens in Lupus: Birth Control Pills|Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Oral Contraceptives|Completed||Phase 3|350||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:40:12.186277|2018-06-01 05:40:12.186277
NCT00000419|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-05-01|1999-11-03|1999-11-04|Estimate|||||||2013-05-01|2013-05-03|Estimate|April 1996||1996-04-30|May 2013|2013-05-31|August 2002||2002-08-31|||||Interventional|||Safety of Estrogens in Lupus: Hormone Replacement Therapy|Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA): Hormone Replacement Therapy|Terminated||Phase 3|350||New York University School of Medicine|||||||||||||||||||2018-06-01 05:40:12.296718|2018-06-01 05:40:12.296718
NCT00000418|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-06-04|1999-11-03|1999-11-04|Estimate|||||||2013-06-04|2013-06-06|Estimate|September 1977||1977-09-30|June 1999|1999-06-30|March 2001||2001-03-31|||||Interventional|||Psychosocial Treatment for Acute Low Back Pain|Psychosocial Intervention for Acute Low Back Pain (ALBP)|Completed||Phase 2|211||Indiana University|||||f||||||||||||||2018-06-01 05:40:12.39535|2018-06-01 05:40:12.39535
NCT00000417|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-12-23|1999-11-03|1999-11-04|Estimate|||||||2013-12-23|2013-12-24|Estimate|April 1997||1997-04-30|December 2013|2013-12-31|March 2001|Actual|2001-03-31|March 2001|Actual|2001-03-31||Interventional|||Psychoeducational Approach to Improve Health in Lupus|A Randomized Controlled Trial of a Psychoeducational Intervention to Improve Outcomes in Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|150||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:40:12.463752|2018-06-01 05:40:12.463752
NCT00000416|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-07-24|1999-11-03|1999-11-04|Estimate|||||||2017-07-24|2017-07-26|Actual|September 1997||1997-09-30|July 2017|2017-07-31|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Prevention of Arthritis-Related Work Disability|Prevention of Arthritis-Related Work Disability: A Trial of Job Retention Services Provided to Employed Persons With Arthritis|Completed||N/A|242|Actual|Boston University Charles River Campus||2|||f||||f||||||||||2018-06-01 05:40:12.524103|2018-06-01 05:40:12.524103
NCT00000415|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-06-03|1999-11-03|1999-11-04|Estimate|||||||2013-06-03|2013-06-04|Estimate|April 1998||1998-04-30|June 2013|2013-06-30|March 2003|Actual|2003-03-31|February 2003|Actual|2003-02-28||Interventional|||Physical Activity, Calcium, and Bone in Children|Calcium Modifies Bone Response to Activity in Children|Completed||Phase 2|224||South Dakota State University|||||f||||||||||||||2018-06-01 05:40:12.59828|2018-06-01 05:40:12.59828
NCT00000414|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-06-19|1999-11-03|1999-11-04|Estimate|||||||2013-06-19|2013-06-21|Estimate|July 1996||1996-07-31|November 2004|2004-11-30|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Patient Education in Rheumatoid Arthritis and Osteoarthritis|Patient Education Strategies for Better Outcomes in Rheumatoid Arthritis (RA) and Osteoarthritis (OA)|Completed||N/A|1200|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 05:40:12.671493|2018-06-01 05:40:12.671493
NCT00000413|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2006-12-28|1999-11-03|1999-11-04|Estimate|||||||2006-12-28|2006-12-29|Estimate|July 1998||1998-07-31|February 2003|2003-02-28|June 2002||2002-06-30|||||Interventional|||Osteoporosis Prevention in Preadolescent Girls|Osteoporosis Prevention in Preadolescent Girls|Completed||Phase 2|340||National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|||||f||||||||||||||2018-06-01 05:40:12.768385|2018-06-01 05:40:12.768385
NCT00000412|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2015-07-02|1999-11-03|1999-11-04|Estimate|||||||2015-07-02|2015-07-07|Estimate|September 1997||1997-09-30|July 2015|2015-07-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Osteoporosis Prevention After Heart Transplant|Prevention of Osteoporosis After Cardiac Transplantation|Completed||Phase 3|149|Actual|Columbia University||2|||f||||||||||||||2018-06-01 05:40:12.826502|2018-06-01 05:40:12.826502
NCT00000411|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2015-08-03|1999-11-03|1999-11-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|March 2000||2000-03-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Spine Patient Outcomes Research Trial (SPORT): Spinal Stenosis|Spine Patient Outcomes Research Trial (SPORT): A Multicenter Trial for Spinal Stenosis (SpS)|Completed||Phase 4|289|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 05:40:12.905973|2018-06-01 05:40:12.905973
NCT00000410|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2015-08-03|1999-11-03|1999-11-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|March 2000||2000-03-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SPORT||Spine Patient Outcomes Research Trial (SPORT) - Intervertebral Disc Herniation|Spine Patient Outcomes Research Trial (SPORT): A Multicenter Randomized Trial for Intervertebral Disc Herniation (IDH)|Completed||Phase 4|501|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 05:40:13.001186|2018-06-01 05:40:13.001186
NCT00000409|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2015-08-03|1999-11-03|1999-11-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|March 2000||2000-03-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SPORT||Spine Patient Outcomes Research Trial (SPORT): Degenerative Spondylolisthesis With Spinal Stenosis|Spine Patient Outcomes Research Trial (SPORT): A Multicenter Randomized Trial for Degenerative Spondylolisthesis (DS) With Spinal Stenosis (SpS) at L4/L5 Level.|Completed||Phase 4|304|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-06-01 05:40:13.112972|2018-06-01 05:40:13.112972
NCT00000408|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-04-30|1999-11-03|1999-11-04|Estimate|||||||2013-04-30|2013-05-03|Estimate|February 1998||1998-02-28|February 2003|2003-02-28|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||Low Back Pain Patient Education Evaluation|Evaluation of a Low Back Pain Patient Education Program|Completed||N/A|580|Actual|Stanford University||2|||f||||f||||||||||2018-06-01 05:40:13.200617|2018-06-01 05:40:13.200617
NCT00000407|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2016-01-05|1999-11-03|1999-11-04|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 1997||1997-01-31|September 2015|2015-09-30|December 2001||2001-12-31|||||Interventional|||Improving Vocational Outcomes in Arthritis|Improving Vocational Outcomes in Arthritis|Completed||Phase 2|326|Actual|University of Alabama at Birmingham||2|||f||||||||||||||2018-06-01 05:40:13.26799|2018-06-01 05:40:13.26799
NCT00000406|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-04-29|1999-11-03|1999-11-04|Estimate|||||||2013-04-29|2013-04-30|Estimate|September 1977||1977-09-30|April 2013|2013-04-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Effects of Strength Training on Knee Osteoarthritis|Effects of Strength Training on Knee Osteoarthritis (OA)|Completed||Phase 2|280||Indiana University|||||f||||||||||||||2018-06-01 05:40:13.330304|2018-06-01 05:40:13.330304
NCT00000405|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2016-06-07|1999-11-03|1999-11-04|Estimate|||||||2016-06-07|2016-06-09|Estimate|September 1998||1998-09-30|June 2016|2016-06-30|November 2008|Actual|2008-11-30|June 2008|Actual|2008-06-30||Interventional|||Effects of Jumping on Growing Bones|The Effects of Jumping on Growing Bones|Completed||Phase 2|200||Oregon State University|||||f||||||||||||||2018-06-01 05:40:13.408017|2018-06-01 05:40:13.408017
NCT00000404|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-04-29|1999-11-03|1999-11-04|Estimate|||||||2013-04-29|2013-04-30|Estimate|April 1997||1997-04-30|April 2013|2013-04-30|March 2001||2001-03-31|||||Interventional|||Effects of Comprehensive Care for Knee OA|Effects of Comprehensive Care for Knee Osteoarthritis (OA)|Completed||Phase 2|300||Indiana University|||||f||||||||||||||2018-06-01 05:40:13.46254|2018-06-01 05:40:13.46254
NCT00000403|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-04-29|1999-11-03|1999-11-04|Estimate|||||||2013-04-29|2013-04-30|Estimate|September 1996||1996-09-30|April 2013|2013-04-30|July 2001||2001-07-31|||||Interventional|||Doxycycline and OA Progression|Effect of Doxycycline on Osteoarthritis (OA) Progression|Completed||Phase 3|432||Indiana University|||||||||||||||||||2018-06-01 05:40:13.517827|2018-06-01 05:40:13.517827
NCT00000402|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-05-21|1999-11-03|1999-11-04|Estimate|||||||2013-05-21|2013-05-22|Estimate|August 1991||1991-08-31|May 2013|2013-05-31|December 2001||2001-12-31|||||Interventional|||Calcium and Bone Mass in Young Females|Long Term Effects of Calcium on Bone Mass in Young Females|Completed||Phase 2|354||Ohio State University|||||f||||||||||||||2018-06-01 05:40:13.675434|2018-06-01 05:40:13.675434
NCT00000401|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-05-28|1999-11-03|1999-11-04|Estimate|||||||2013-05-28|2013-05-29|Estimate|July 1999||1999-07-31|May 2013|2013-05-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Oral Collagen for Rheumatoid Arthritis|Open Label Multicenter Induction of CII Tolerance in Patients With Rheumatoid Arthritis|Completed||Phase 2|110|Actual|University of Tennessee||2|||t||||t||||||||||2018-06-01 05:40:13.748968|2018-06-01 05:40:13.748968
NCT00000400|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-12-06|1999-11-03|1999-11-04|Estimate|||||||2013-12-06|2013-12-09|Estimate|August 1999||1999-08-31|December 2013|2013-12-31|June 2006|Actual|2006-06-30|April 2006|Actual|2006-04-30||Interventional|||Alendronate and/or Parathyroid Hormone for Osteoporosis|Bone Formation-Resorption Coupling and Osteoporosis|Completed||Phase 2|176|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-06-01 05:40:13.861239|2018-06-01 05:40:13.861239
NCT00000399|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-05-17|1999-11-03|1999-11-04|Estimate|||||||2013-05-17|2013-05-20|Estimate|August 1995||1995-08-31|May 2013|2013-05-31|January 2001||2001-01-31|||||Interventional|||Bone Estrogen Strength Training|Bone Estrogen Strength Training (BEST)|Completed||Phase 2|300||University of Arizona|||||f||||||||||||||2018-06-01 05:40:13.976846|2018-06-01 05:40:13.976846
NCT00000398|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-11-26|1999-11-03|1999-11-04|Estimate|||||||2013-11-26|2013-11-27|Estimate|July 1996||1996-07-31|June 2000|2000-06-30|June 2000||2000-06-30|||||Interventional|||Behavioral Treatment of Fibromyalgia|Behavioral Treatment of Fibromyalgia|Completed||Phase 2|180||Ohio University|||||f||||||||||||||2018-06-01 05:40:14.224513|2018-06-01 05:40:14.224513
NCT00000397|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2014-07-18|1999-11-03|1999-11-04|Estimate|||||||2014-07-18|2014-07-21|Estimate|July 1999||1999-07-31|December 2005|2005-12-31|September 2004|Actual|2004-09-30|||||Interventional|||Behavioral Insomnia Therapy for Fibromyalgia|Behavioral Insomnia Therapy for Fibromyalgia Patients|Completed||N/A|106|Actual|Duke University|||||f||||||||||||||2018-06-01 05:40:14.460971|2018-06-01 05:40:14.460971
NCT00000396|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-06-08|1999-11-03|1999-11-04|Estimate|||||||2013-06-08|2013-06-11|Estimate|September 1997||1997-09-30|June 2013|2013-06-30|October 2002|Actual|2002-10-31|March 2001|Actual|2001-03-31||Interventional|||Arthritis Patient Education for Urban African Americans|Evaluating/Reinforcing Arthritis Patient Education for Urban African Americans|Completed||N/A|90|Actual|University of Michigan||1|||f||||f||||||||||2018-06-01 05:40:14.698016|2018-06-01 05:40:14.698016
NCT00000395|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2016-12-14|1999-11-03|1999-11-04|Estimate|||||||2016-12-14|2016-12-16|Estimate|September 1996||1996-09-30|June 2013|2013-06-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Antifolate Effectiveness in Arthritis|Mechanisms of Antifolate Efficacy in Arthritis|Completed||Phase 2|40|Actual|University of Alabama at Birmingham||2|||f||||||||||||||2018-06-01 05:40:14.851163|2018-06-01 05:40:14.851163
NCT00000394|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2013-05-14|1999-11-03|1999-11-04|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 1999||1999-05-31|June 2000|2000-06-30|January 2002||2002-01-31|||||Interventional|||Acupuncture for Carpal Tunnel Syndrome|A Controlled Trial of Acupuncture for Carpal Tunnel Syndrome|Completed||Phase 2|144||George Washington University|||||f||||||||||||||2018-06-01 05:40:14.995154|2018-06-01 05:40:14.995154
NCT00000105|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2017-11-27|1999-11-03|1999-11-04|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2002||2002-07-31|November 2017|2017-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Vaccination With Tetanus and KLH to Assess Immune Responses.|Vaccination With Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses|Terminated|||112|Actual|Masonic Cancer Center, University of Minnesota|||3|Replaced by another study.|f||||t||||||Samples With DNA|"~     analysis of blood samples before and 4 weeks postvaccination~   "|||2018-06-01 05:40:15.084838|2018-06-01 05:40:15.084838
NCT00000104|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2005-06-23|1999-11-03|1999-11-04|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2003|2003-12-31||||||||Observational|||Does Lead Burden Alter Neuropsychological Development?||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:15.163805|2018-06-01 05:40:15.163805
NCT00000102|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-03|||2005-06-23|1999-11-03|1999-11-04|Estimate|||||||2005-06-23|2005-06-24|Estimate||||January 2004|2004-01-31||||||||Interventional|||Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets||Completed||Phase 1/Phase 2|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:15.225625|2018-06-01 05:40:15.225625
NCT00000458|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31|January 2002||2002-01-31|||||Interventional|||Sertraline and Cognitive Therapy in Depressed Alcoholics|Sertraline and Cognitive Therapy in Depressed Alcoholics|Completed||Phase 2|100||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:15.288377|2018-06-01 05:40:15.288377
NCT00000457|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-10-18|1999-11-02|1999-11-03|Estimate|||||||2013-10-18|2013-10-21|Estimate|June 1998||1998-06-30|October 2013|2013-10-31|August 2007|Actual|2007-08-31|April 2002|Actual|2002-04-30||Interventional|||Pharmacologic Relapse Prevention for Alcoholic Smokers|Pharmacologic Relapse Prevention for Alcoholic Smokers|Completed||Phase 2|195|Actual|Mayo Clinic||2|||f||||f||||||||||2018-06-01 05:40:15.367745|2018-06-01 05:40:15.367745
NCT00000456|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-10-01|1999-11-02|1999-11-03|Estimate|||||||2010-10-01|2010-10-04|Estimate|September 1992||1992-09-30|October 2010|2010-10-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Behavioral Therapy Plus Naltrexone for Alcoholism|Comparison of Cognitive Behavioral Therapy and Motivational Enhancement Therapy Plus Naltrexone for Alcoholism|Completed||Phase 4|160|Actual|Medical University of South Carolina|||||f||||||||||||||2018-06-01 05:40:15.488547|2018-06-01 05:40:15.488547
NCT00000455|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-06-17|1999-11-02|1999-11-03|Estimate|||||||2011-06-17|2011-06-20|Estimate||||June 2011|2011-06-30|September 2002||2002-09-30|||||Interventional|||Naltrexone for Early Problem Drinkers|Targeted Naltrexone for Early Problem Drinkers|Completed||Phase 4|160||UConn Health|||||f||||f||||||||||2018-06-01 05:40:15.574185|2018-06-01 05:40:15.574185
NCT00000592|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-12-21|1999-10-27|1999-10-28|Estimate|||||||2015-12-21|2015-12-23|Estimate|July 1994||1994-07-31|November 2005|2005-11-30|August 2000||2000-08-31|||||Interventional|||Stroke Prevention in Sickle Cell Anemia (STOP 1)||Completed||Phase 3|||Augusta University|||||f||||||||||||||2018-06-01 05:40:25.170015|2018-06-01 05:40:25.170015
NCT00000451|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-01-28|1999-11-02|1999-11-03|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2003||2003-01-31|January 2013|2013-01-31|November 2005|Actual|2005-11-30|August 2005|Actual|2005-08-31||Interventional|||Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)|Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives|Completed||Phase 2|198|Actual|Yale University||2|||f||||||||||||||2018-06-01 05:40:15.750862|2018-06-01 05:40:15.750862
NCT00000450|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2017-04-18|1999-11-02|1999-11-03|Estimate|||||||2017-04-18|2017-04-20|Actual|April 10, 1997|Actual|1997-04-10|April 2017|2017-04-30|February 13, 2002|Actual|2002-02-13|February 13, 2002|Actual|2002-02-13||Interventional|||Naltrexone Maintenance Treatment of Alcoholism|Nalmefene Maintenance Treatment of Alcoholism|Completed||Phase 4|159|Actual|The Scripps Research Institute||2|||f||||f|t|f||||||No||2018-06-01 05:40:15.817737|2018-06-01 05:40:15.817737
NCT00000449|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31|March 2000||2000-03-31|||||Interventional|||Behavior and Naltrexone Treatment for Alcoholics|Coping, Exposure, and Naltrexone Treatment With Alcoholics|Completed||Phase 4|160||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:15.882826|2018-06-01 05:40:15.882826
NCT00000448|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-05-06|1999-11-02|1999-11-03|Estimate|||||||2014-05-06|2014-05-07|Estimate|October 1995||1995-10-31|May 2014|2014-05-31|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Naltrexone Treatment for Alcoholic Women|Naltrexone: Consummatory Behaviors in Alcoholic Women|Completed||Phase 4|160|Actual|Yale University||2|||f||||f||||||||||2018-06-01 05:40:15.929849|2018-06-01 05:40:15.929849
NCT00000447|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-09-30|1999-11-02|1999-11-03|Estimate|||||||2010-09-30|2010-10-01|Estimate|September 1998||1998-09-30|September 2010|2010-09-30|May 2003|Actual|2003-05-31|||||Interventional|||Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch)|Behavioral/Pharmacological Treatments for Alcohol-Nicotine Dependence|Completed||Phase 4|200||The University of Texas Health Science Center, Houston|||||f||||||||||||||2018-06-01 05:40:16.006185|2018-06-01 05:40:16.006185
NCT00000446|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||April 2004|2004-04-30|December 2000||2000-12-31|||||Interventional|||Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder|Sertraline Treatment in Comorbid Post-Traumatic Stress Disorder and Alcoholism|Completed||Phase 2|||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:16.052151|2018-06-01 05:40:16.052151
NCT00000445|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||July 2003|2003-07-31|September 2002||2002-09-30|||||Interventional|||Use of Naltrexone in a Clinical Setting|Effectiveness of Naltrexone in a Community Setting|Completed||Phase 4|300||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:16.137224|2018-06-01 05:40:16.137224
NCT00000444|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-02-10|1999-11-02|1999-11-03|Estimate|||||||2011-02-10|2011-02-11|Estimate|September 1997||1997-09-30|January 2008|2008-01-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)|Timing of Smoking Intervention in Alcohol Treatment|Completed||Phase 4|500||Minneapolis Veterans Affairs Medical Center|||||f||||||||||||||2018-06-01 05:40:16.179706|2018-06-01 05:40:16.179706
NCT00000443|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31|April 2000||2000-04-30|||||Interventional|||Ondansetron Treatment for Alcoholism|Pharmacological Treatment for Alcoholism|Completed||Phase 2|||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:16.222158|2018-06-01 05:40:16.222158
NCT00000442|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2011-06-17|1999-11-02|1999-11-03|Estimate|||||||2011-06-17|2011-06-20|Estimate||||June 2011|2011-06-30|December 2002||2002-12-31|||||Interventional|||Naltrexone for Relapse Prevention|Etiology and Treatment of Alcohol Dependence|Completed||Phase 4|57||UConn Health|||||f||||||||||||||2018-06-01 05:40:16.293965|2018-06-01 05:40:16.293965
NCT00000441|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||August 2002|2002-08-31|December 2000||2000-12-31|||||Interventional|||Drug Therapy for Alcohol Detoxification|Carbamazepine and Lorazepam in Outpatient Detoxification|Completed||Phase 4|||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:16.347055|2018-06-01 05:40:16.347055
NCT00000440|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-06-23|1999-11-02|1999-11-03|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2004|2004-11-30|September 2002||2002-09-30|||||Interventional|||Sertraline and Naltrexone for Alcohol Dependence|Sertraline and Naltrexone for Alcohol Dependents|Completed||Phase 2|124||National Institute on Alcohol Abuse and Alcoholism (NIAAA)|||||f||||||||||||||2018-06-01 05:40:16.391623|2018-06-01 05:40:16.391623
NCT00000439|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2018-01-16|1999-11-02|1999-11-03|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2000||2000-10-31|January 2018|2018-01-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Drug Treatment for Alcoholics With Bipolar Disorder|Efficacy of Valproate Maintenance in Bipolar Alcoholics|Completed||Phase 2|72|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||f||||||||No||2018-06-01 05:40:16.444969|2018-06-01 05:40:16.444969
NCT00000438|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2010-05-13|1999-11-02|1999-11-03|Estimate|||||||2010-05-13|2010-05-14|Estimate||||May 2010|2010-05-31|March 2003||2003-03-31|||||Interventional|||Naltrexone Treatment for Alcoholism|Naltrexone Treatment for Alcoholism: Predicting Outcome|Completed||Phase 4|192||Johns Hopkins University|||||f||||f||||||||||2018-06-01 05:40:16.503966|2018-06-01 05:40:16.503966
NCT00000437|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2017-04-18|1999-11-02|1999-11-03|Estimate|||||||2017-04-18|2017-04-20|Actual|September 26, 1997|Actual|1997-09-26|April 2017|2017-04-30|September 15, 2005|Actual|2005-09-15|September 15, 2005|Actual|2005-09-15||Interventional|||Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)|Nalmefene in Nicotine and Alcohol Dependence|Completed||Phase 4|60|Actual|The Scripps Research Institute||4|||f||||f|t|f|||f|||No||2018-06-01 05:40:16.549269|2018-06-01 05:40:16.549269
NCT00000389|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-06-13|1999-11-02|1999-11-03|Estimate|||||||2007-06-13|2007-06-14|Estimate|October 1996||1996-10-31|November 2005|2005-11-30|November 1999||1999-11-30|||||Interventional|||Treatment for Anxiety in Children|Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study|Completed||Phase 3|||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:40:16.636532|2018-06-01 05:40:16.636532
NCT00000388|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-09-28|1999-11-02|1999-11-03|Estimate|||||||2015-09-28|2015-09-29|Estimate|September 1998||1998-09-30|September 2015|2015-09-30|November 1999||1999-11-30|||||Interventional|MTA||Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)|Multimodal Treatment Study of Children With ADHD|Completed||Phase 4|||New York University School of Medicine|||||f||||||||||||||2018-06-01 05:40:16.694212|2018-06-01 05:40:16.694212
NCT00000387|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2007-12-26|1999-11-02|1999-11-03|Estimate|||||||2007-12-26|2007-12-28|Estimate|April 1998||1998-04-30|December 2007|2007-12-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|FamCent||Self-Management Therapy for Youth With Schizophrenia|Self-Management Therapy for Youth With Schizophrenia|Completed||Phase 3|40|Actual|National Institute of Mental Health (NIMH)||2|||f||||f||||||||||2018-06-01 05:40:17.734038|2018-06-01 05:40:17.734038
NCT00000386|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2008-02-08|1999-11-02|1999-11-03|Estimate|||||||2008-02-08|2008-02-12|Estimate|December 1998||1998-12-31|February 2008|2008-02-29|November 2003||2003-11-30|||||Interventional|||Behavior Therapy for Children and Adolescents With Obsessive-Compulsive Disorder (OCD)|Behavior Therapy for Childhood OCD|Completed||Phase 3|||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:40:17.827647|2018-06-01 05:40:17.827647
NCT00000385|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-11-25|1999-11-02|1999-11-03|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 1997||1997-09-30|November 2013|2013-11-30|June 2005|Actual|2005-06-30|December 2003|Actual|2003-12-31||Interventional|||Long-Term Lithium Treatment for Aggressive Conduct Disorder|Long-Term Lithium for Aggressive Conduct Disorder|Completed||Phase 3|59|Actual|Drexel University||2|||f||||f||||||||||2018-06-01 05:40:17.895701|2018-06-01 05:40:17.895701
NCT00000384|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2016-08-19|1999-11-02|1999-11-03|Estimate|||||||2016-08-19|2016-08-22|Estimate|May 1997||1997-05-31|November 2005|2005-11-30|April 2002||2002-04-30|||||Interventional|||Treatment of Obsessive-Compulsive Disorder (OCD) in Children|Treatment of Pediatric Obsessive-Compulsive Disorder|Completed||Phase 3|||University of Pennsylvania|||||f||||||||||||||2018-06-01 05:40:17.998251|2018-06-01 05:40:17.998251
NCT00000383|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-03-27|1999-11-02|1999-11-03|Estimate|||||||2015-03-27|2015-03-30|Estimate|September 1997||1997-09-30|March 2015|2015-03-31|September 2002|Actual|2002-09-30|September 2001|Actual|2001-09-30||Interventional|||Treatment of Post-Traumatic Stress Disorder (PTSD) in Sexually Abused Children|Treatment of PTSD in Sexually Abused Children|Completed||N/A|229|Actual|Allegheny Singer Research Institute||2|||f||||t||||||||||2018-06-01 05:40:18.115977|2018-06-01 05:40:18.115977
NCT00000382|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-11-05|1999-11-02|1999-11-03|Estimate|||||||2013-11-05|2013-11-06|Estimate|July 1998||1998-07-31|November 2013|2013-11-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Preventing Child Abuse in Infants|Preventive Intervention for Maltreated Infants|Completed||Phase 3|||University of Rochester|||||f||||t||||||||||2018-06-01 05:40:18.210212|2018-06-01 05:40:18.210212
NCT00000381|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-01-07|1999-11-02|1999-11-03|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 1997||1997-06-30|December 2005|2005-12-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Fluoxetine for Anxious Children||Completed||Phase 3|||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:40:18.259541|2018-06-01 05:40:18.259541
NCT00000380|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-12-01|1999-11-02|1999-11-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 1996||1996-06-30|December 2015|2015-12-31|July 2007||2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances|Age-Related Sleep Impairment - Treatment w/GHRH|Completed||N/A|||University of Washington||2|||f||||||||||||||2018-06-01 05:40:18.406748|2018-06-01 05:40:18.406748
NCT00000379|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-02-19|1999-11-02|1999-11-03|Estimate|||||||2014-02-19|2014-02-20|Estimate|January 1999||1999-01-31|February 2014|2014-02-28|December 2003||2003-12-31|||||Interventional|||Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)|Treatment of Outcomes of Fluoxetine vs EMDR in PTSD|Completed||Phase 3|||Boston University|||||f||||||||||||||2018-06-01 05:40:18.489265|2018-06-01 05:40:18.489265
NCT00000378|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|2015-04-02||2015-10-06|1999-11-02|1999-11-03|Estimate|2015-04-17|2015-04-21|Estimate||||2015-10-06|2015-10-07|Estimate|July 1997||1997-07-31|September 2008|2008-09-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Antidepressant Treatment of Melancholia in Late Life|Antidepressant Treatment of Melancholia in Late :Ife|Completed||Phase 4|110|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-06-01 05:40:18.576798|2018-06-01 05:40:18.576798
NCT00000377|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-06-20|1999-11-02|1999-11-03|Estimate|||||||2013-06-20|2013-06-21|Estimate|March 1989||1989-03-31|June 2013|2013-06-30|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||Preventing the Return of Depression in Elderly Patients|Maintenance Therapies in Late-Life Depression|Completed||N/A|||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:40:18.86913|2018-06-01 05:40:18.86913
NCT00000376|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2015-10-09|1999-11-02|1999-11-03|Estimate|||||||2015-10-09|2015-10-12|Estimate|March 1996||1996-03-31|December 2005|2005-12-31|February 1999||1999-02-28|||||Interventional|||Cognitive and Drug Therapy for Drug-Resistant Depression||Completed||N/A|||University of Pennsylvania|||||f||||||||||||||2018-06-01 05:40:18.955173|2018-06-01 05:40:18.955173
NCT00000375|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2005-12-19|1999-11-02|1999-11-03|Estimate|||||||2005-12-19|2005-12-20|Estimate|February 1997||1997-02-28|December 2005|2005-12-31||||||||Interventional|||Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder|Continuation ECT Vs Pharmacotherapy--Efficacy And Safety|Completed||Phase 4|||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:40:19.035753|2018-06-01 05:40:19.035753
NCT00000374|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-01-12|1999-11-02|1999-11-03|Estimate|||||||2012-01-12|2012-01-13|Estimate|September 1998||1998-09-30|January 2012|2012-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Treatment for First-Episode Schizophrenia|Preventing Morbidity in First-Episode Schizophrenia|Completed||Phase 4|125|Actual|Northwell Health|||||f||||t||||||||||2018-06-01 05:40:19.121917|2018-06-01 05:40:19.121917
NCT00000373|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-11-26|1999-11-02|1999-11-03|Estimate|||||||2013-11-26|2013-11-27|Estimate|September 1992||1992-09-30|November 2013|2013-11-30|July 2003|Actual|2003-07-31|January 2003|Actual|2003-01-31||Interventional|||Treatment of Obsessive-Compulsive Disorder|Neurobiology/Treatment of Obsessive-Compulsive Disorder|Completed||Phase 4|74|Actual|University of Florida||2|||f||||f||||||||||2018-06-01 05:40:19.198166|2018-06-01 05:40:19.198166
NCT00000372|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-06-11|1999-11-02|1999-11-03|Estimate|||||||2014-06-11|2014-06-12|Estimate|March 1998||1998-03-31|June 2014|2014-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Glycine and D-Cycloserine in Schizophrenia|A Placebo Controlled Trial of Glycine Added to Clozapine in Schizophrenia|Withdrawn||Phase 3|0|Actual|Massachusetts General Hospital||3||"Pairing D-Cycloserine with Clozapine was found to worsen negative side effects in patients with~   Schizophrenia, so the study was suspended."|f||||||||||||||2018-06-01 05:40:19.294768|2018-06-01 05:40:19.294768
NCT00000371|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|2014-08-11||2014-09-03|1999-11-02|1999-11-03|Estimate|2014-09-03|2014-09-10|Estimate||||2014-09-03|2014-09-10|Estimate|August 1996||1996-08-31|September 2014|2014-09-30|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Trial of D-Cycloserine in Schizophrenia|A Six Month, Placebo-Controlled Trial of D-Cycloserine Co-Administered With Conventional Antipsychotics in Schizophrenia Patients|Completed||Phase 3|60|Actual|Massachusetts General Hospital|A biased sample may have been produced by restricting the analysis to patients with prominent negative symptoms receiving conventional agents (less compliant with study medication). Additionally, Adverse Event data was lost for the study.|2|||f||||||||||||||2018-06-01 05:40:19.371806|2018-06-01 05:40:19.371806
NCT00000370|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2018-01-16|1999-11-02|1999-11-03|Estimate|||||||2018-01-16|2018-01-18|Actual|May 1998||1998-05-31|January 2018|2018-01-31|February 2003||2003-02-28|||||Interventional|||Treatment of Social Phobia|Treatment of Social Phobia: Mediators And Moderators|Completed||N/A|||Boston University Charles River Campus|||||f||||||||||||||2018-06-01 05:40:19.57927|2018-06-01 05:40:19.57927
NCT00000369|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2013-06-21|1999-11-02|1999-11-03|Estimate|||||||2013-06-21|2013-06-25|Estimate|June 1997||1997-06-30|February 2008|2008-02-29|December 2002|Actual|2002-12-31|||||Interventional|||Maintenance Therapies in Bipolar Disorders||Completed||Phase 3|||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:40:19.640351|2018-06-01 05:40:19.640351
NCT00000368|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2014-03-17|1999-11-02|1999-11-03|Estimate|||||||2014-03-17|2014-03-18|Estimate|February 1999||1999-02-28|March 2014|2014-03-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Treatment of Panic Disorder: Long Term Strategies|Treatment of Panic Disorder: Long Term Strategies|Completed||Phase 3|379|Actual|New York State Psychiatric Institute|||||f||||t||||||||||2018-06-01 05:40:19.812525|2018-06-01 05:40:19.812525
NCT00000362|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2006-04-21|1999-11-02|1999-11-03|Estimate|||||||2006-04-21|2006-04-24|Estimate||||April 2006|2006-04-30|January 2006||2006-01-31|||||Interventional|||Randomized Study of Two Interventions for Liquid Aspiration: Short-Term and Long-Term Effects||Terminated||Phase 3|600||National Institute on Deafness and Other Communication Disorders (NIDCD)|||||f||||||||||||||2018-06-01 05:40:20.075528|2018-06-01 05:40:20.075528
NCT00000361|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2006-04-21|1999-11-02|1999-11-03|Estimate|||||||2006-04-21|2006-04-24|Estimate|March 1998||1998-03-31|April 2006|2006-04-30|November 2002||2002-11-30|||||Interventional|||Autoimmunity in Inner Ear Disease||Terminated||Phase 3|||National Institute on Deafness and Other Communication Disorders (NIDCD)|||||f||||||||||||||2018-06-01 05:40:20.130283|2018-06-01 05:40:20.130283
NCT00000359|ClinicalTrials.gov processed this data on May 31, 2018|1999-11-02|||2012-07-25|1999-11-02|1999-11-03|Estimate|||||||2012-07-25|2012-07-26|Estimate|October 1998||1998-10-31|July 2012|2012-07-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Treatments for Benign Paroxysmal Positional Vertigo (BPPV)|Treatments for Benign Paroxysmal Positional Vertigo (BPPV)|Completed||Phase 2|150|Actual|Baylor College of Medicine||5|||f||||f||||||||||2018-06-01 05:40:20.223596|2018-06-01 05:40:20.223596
NCT00000180|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2009-12-10|1999-10-29|1999-11-01|Estimate|||||||2009-12-10|2009-12-11|Estimate||||February 2005|2005-02-28|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||AIT-082 Phase 1B Study||Completed||Phase 1|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:20.366939|2018-06-01 05:40:20.366939
NCT00000179|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2005-06-23|1999-10-29|1999-11-01|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2005|2005-03-31||||||||Interventional|||Agitation in Alzheimer's Disease||Completed||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:20.508979|2018-06-01 05:40:20.508979
NCT00000178|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2005-06-23|1999-10-29|1999-11-01|Estimate|||||||2005-06-23|2005-06-24|Estimate||||February 2005|2005-02-28||||||||Interventional|||Multicenter Trial of Prednisone in Alzheimer's Disease|Multicenter Trial of Prednisone in Alzheimer's Disease|Completed||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:20.638564|2018-06-01 05:40:20.638564
NCT00000177|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2009-12-10|1999-10-29|1999-11-01|Estimate|||||||2009-12-10|2009-12-11|Estimate|October 1995||1995-10-31|September 2009|2009-09-30|January 1999|Actual|1999-01-31|January 1999|Actual|1999-01-31||Interventional|||Estrogen Hormone Protocol||Completed||Phase 3|120||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:20.755387|2018-06-01 05:40:20.755387
NCT00000176|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2010-11-03|1999-10-29|1999-11-01|Estimate|||||||2010-11-03|2010-11-05|Estimate||||November 2010|2010-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Alzheimer's Disease Prevention Trial|Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.|Completed||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:21.195771|2018-06-01 05:40:21.195771
NCT00000175|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2009-12-10|1999-10-29|1999-11-01|Estimate|||||||2009-12-10|2009-12-11|Estimate||||March 2004|2004-03-31|June 2005|Anticipated|2005-06-30|June 2005|Anticipated|2005-06-30||Interventional|||The Effects of Sex Hormones on Cognition and Mood in Older Adults||Terminated||N/A|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:21.364455|2018-06-01 05:40:21.364455
NCT00000174|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2005-12-08|1999-10-29|1999-11-01|Estimate|||||||2005-12-08|2005-12-09|Estimate||||January 2000|2000-01-31||||||||Interventional|||Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)||Completed||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:21.437865|2018-06-01 05:40:21.437865
NCT00000173|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2009-12-10|1999-10-29|1999-11-01|Estimate|||||||2009-12-10|2009-12-11|Estimate|March 1999||1999-03-31|June 2009|2009-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Memory Impairment Study (Mild Cognitive Impairment Study)|A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)|Completed||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:21.531094|2018-06-01 05:40:21.531094
NCT00000172|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2005-06-23|1999-10-29|1999-11-01|Estimate|||||||2005-06-23|2005-06-24|Estimate||||November 2002|2002-11-30||||||||Interventional|||Evaluation of Galantamine in the Treatment of Alzheimer's Disease|Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration Regimen|Completed||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:21.909509|2018-06-01 05:40:21.909509
NCT00000171|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-29|||2005-06-23|1999-10-29|1999-11-01|Estimate|||||||2005-06-23|2005-06-24|Estimate||||March 2005|2005-03-31||||||||Interventional|||Study of Melatonin: Sleep Problems in Alzheimer's Disease||Completed||Phase 3|||National Institute on Aging (NIA)|||||f||||||||||||||2018-06-01 05:40:22.102061|2018-06-01 05:40:22.102061
NCT00000623|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-03-03|1999-10-27|1999-10-28|Estimate|||||||2014-03-03|2014-03-04|Estimate|July 2000||2000-07-31|July 2006|2006-07-31|July 2006|Actual|2006-07-31|||||Observational|||Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)|Thalassemia Clinical Research Network (TCRN)|Completed|||1000|Anticipated|New England Research Institutes|||||f||||||||||||||2018-06-01 05:40:22.251832|2018-06-01 05:40:22.251832
NCT00000621|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2008-01-15|1999-10-27|1999-10-28|Estimate|||||||2008-01-15|2008-01-16|Estimate|September 1999||1999-09-30|January 2008|2008-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:22.373067|2018-06-01 05:40:22.373067
NCT00000620|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|2014-09-05||2016-11-21|1999-10-27|1999-10-28|Estimate|2014-09-05|2014-09-15|Estimate||||2016-11-21|2016-11-22|Estimate|September 1999||1999-09-30|November 2014|2014-11-30|December 2012|Actual|2012-12-31|June 2009|Actual|2009-06-30||Interventional|ACCORD||Action to Control Cardiovascular Risk in Diabetes (ACCORD)|Action to Control Cardiovascular Risk in Diabetes (ACCORD)|Completed||Phase 3|10251|Actual|National Heart, Lung, and Blood Institute (NHLBI)||6|||f||||t||||||||||2018-06-01 05:40:22.464664|2018-06-01 05:40:22.464664
NCT00000619|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2001||2001-04-30|January 2008|2008-01-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.227209|2018-06-01 05:40:23.227209
NCT00000617|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-11-04|1999-10-27|1999-10-28|Estimate|||||||2016-11-04|2016-11-07|Estimate|September 1998||1998-09-30|May 2005|2005-05-31|November 2005|Actual|2005-11-30|||||Interventional|||Azithromycin and Coronary Events Study (ACES)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.277869|2018-06-01 05:40:23.277869
NCT00000616|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1998||1998-09-30|November 2005|2005-11-30|August 2004|Actual|2004-08-31|||||Interventional|||PREMIER: Lifestyle Interventions for Blood Pressure Control||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.33982|2018-06-01 05:40:23.33982
NCT00000615|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2006-10-02|1999-10-27|1999-10-28|Estimate|||||||2006-10-02|2006-10-04|Estimate|August 1999||1999-08-31|April 2005|2005-04-30|November 2006||2006-11-30|||||Interventional|||Girls Health Enrichment Multi-Site Studies (GEMS)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.394688|2018-06-01 05:40:23.394688
NCT00000614|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-15|1999-10-27|1999-10-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 1998||1998-09-30|September 2005|2005-09-30|August 2004|Actual|2004-08-31|||||Interventional|||Prevention of Recurrent Venous Thromboembolism (PREVENT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.446192|2018-06-01 05:40:23.446192
NCT00000613|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-26|1999-10-27|1999-10-28|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 1997||1997-04-30|December 2005|2005-12-31|December 2004|Actual|2004-12-31|||||Interventional|||CVD Risk and Health in Postmenopausal Phytoestrogen Users||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.525577|2018-06-01 05:40:23.525577
NCT00000612|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1996||1996-01-31|November 2000|2000-11-30|December 1998|Actual|1998-12-31|||||Interventional|||Soy Estrogen Alternative Study (SEA)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.631582|2018-06-01 05:40:23.631582
NCT00000611|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-14|1999-10-27|1999-10-28|Estimate|||||||2016-04-14|2016-04-15|Estimate||||January 2006|2006-01-31||||March 2005|Actual|2005-03-31||Interventional|||Women's Health Initiative (WHI)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.769096|2018-06-01 05:40:23.769096
NCT00000610|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 1998||1998-04-30|March 2005|2005-03-31|November 2003||2003-11-30|||||Interventional|||Magnesium in Coronaries (MAGIC)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:23.921576|2018-06-01 05:40:23.921576
NCT00000609|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1997||1997-05-31|November 2005|2005-11-30|April 2005|Actual|2005-04-30|||||Interventional|||Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.019931|2018-06-01 05:40:24.019931
NCT00000608|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-28|1999-10-27|1999-10-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 1997||1997-02-28|January 2008|2008-01-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.091124|2018-06-01 05:40:24.091124
NCT00000607|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-12-22|1999-10-27|1999-10-28|Estimate|||||||2015-12-22|2015-12-23|Estimate|October 1997||1997-10-31|December 2015|2015-12-31|March 1999|Actual|1999-03-31|March 1999|Actual|1999-03-31||Interventional|||Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)|The REMATCH Trial: Rationale, Design, and End Points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure|Completed||Phase 3|129|Actual|Columbia University||2|||f||||f||||||||||2018-06-01 05:40:24.167619|2018-06-01 05:40:24.167619
NCT00000606|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|December 1996||1996-12-31|April 2009|2009-04-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||National Emphysema Treatment Trial (NETT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.279383|2018-06-01 05:40:24.279383
NCT00000605|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 1996||1996-08-31|April 2005|2005-04-30|July 2002|Actual|2002-07-31|||||Interventional|||Estrogen and Graft Atherosclerosis Research Trial (EAGER)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.371143|2018-06-01 05:40:24.371143
NCT00000604|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-12-11|1999-10-27|1999-10-28|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 1994||1994-01-31|December 2015|2015-12-31|December 1996||1996-12-31|||||Interventional|||Influence of CPB Temperature on CABG Morbidity||Completed||Phase 2|||Baystate Medical Center|||||f||||||||||||||2018-06-01 05:40:24.451929|2018-06-01 05:40:24.451929
NCT00000603|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-12|1999-10-27|1999-10-28|Estimate|||||||2016-04-12|2016-04-14|Estimate|September 1996||1996-09-30|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Cord Blood Stem Cell Transplantation Study (COBLT)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.510467|2018-06-01 05:40:24.510467
NCT00000602|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-09-15|1999-10-27|1999-10-28|Estimate|||||||2016-09-15|2016-09-16|Estimate|April 1994||1994-04-30|October 2005|2005-10-31|March 1997|Actual|1997-03-31|||||Interventional|||Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.579301|2018-06-01 05:40:24.579301
NCT00000601|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1995||1995-07-31|February 2005|2005-02-28|June 2000|Actual|2000-06-30|||||Interventional|||Postmenopausal Hormone Therapy in Unstable Angina||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.633629|2018-06-01 05:40:24.633629
NCT00000600|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|June 1995||1995-06-30|October 2006|2006-10-31|May 2000|Actual|2000-05-31|||||Interventional|||Vitamin E and C to Slow Progression of Common Carotid Artery Plaque Build-Up|Antioxidants and Prevention of Early Atherosclerosis|Terminated||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.704719|2018-06-01 05:40:24.704719
NCT00000599|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|June 1980||1980-06-30|May 2000|2000-05-31|November 1994|Actual|1994-11-30|||||Interventional|||Cholesterol-Lowering Atherosclerosis Study (CLAS)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.766979|2018-06-01 05:40:24.766979
NCT00000598|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-01-08|1999-10-27|1999-10-28|Estimate|||||||2016-01-08|2016-01-12|Estimate|August 1991||1991-08-31|March 2005|2005-03-31|August 1996||1996-08-31|||||Interventional|||Diet and Exercise for Elevated Risk (DEER)||Completed||Phase 3|||Stanford University|||||f||||||||||||||2018-06-01 05:40:24.853437|2018-06-01 05:40:24.853437
NCT00000597|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|March 1982||1982-03-31|May 2000|2000-05-31|December 1988|Actual|1988-12-31|||||Interventional|||Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.907835|2018-06-01 05:40:24.907835
NCT00000596|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|June 1978||1978-06-30|February 2002|2002-02-28|January 1983|Actual|1983-01-31|||||Interventional|||Diffuse Fibrotic Lung Disease||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:24.963137|2018-06-01 05:40:24.963137
NCT00000595|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|January 1978||1978-01-31|May 2000|2000-05-31|September 1994|Actual|1994-09-30|||||Interventional|||Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.015935|2018-06-01 05:40:25.015935
NCT00000594|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2012-04-26|1999-10-27|1999-10-28|Estimate|||||||2012-04-26|2012-04-27|Estimate|November 1971||1971-11-30|April 2012|2012-04-30|November 1976|Actual|1976-11-30|||||Interventional|||NHLBI Type II Coronary Intervention Study||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.062424|2018-06-01 05:40:25.062424
NCT00000591|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-14|1999-10-27|1999-10-28|Estimate|||||||2016-04-14|2016-04-15|Estimate|November 1993||1993-11-30|November 2005|2005-11-30|February 2005||2005-02-28|||||Interventional|||T-Cell Depletion in Unrelated Donor Marrow Transplantation||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.231398|2018-06-01 05:40:25.231398
NCT00000590|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 1991||1991-09-30|March 2005|2005-03-31|December 1996||1996-12-31|||||Interventional|||Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.290228|2018-06-01 05:40:25.290228
NCT00000589|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-11-04|1999-10-27|1999-10-28|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 1989||1989-08-31|May 2000|2000-05-31|July 1997|Actual|1997-07-31|||||Interventional|||Trial to Reduce Alloimmunization to Platelets (TRAP)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.357976|2018-06-01 05:40:25.357976
NCT00000588|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-02-10|1999-10-27|1999-10-28|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 1989||1989-06-30|February 2002|2002-02-28||||||||Interventional|||Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone||Completed||Phase 2|||Case Western Reserve University|||||f||||||||||||||2018-06-01 05:40:25.416068|2018-06-01 05:40:25.416068
NCT00000587|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2006-01-03|1999-10-27|1999-10-28|Estimate|||||||2006-01-03|2006-01-06|Estimate|September 1988||1988-09-30|December 2005|2005-12-31||||||||Interventional|||Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.470685|2018-06-01 05:40:25.470685
NCT00000586|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 1992||1992-01-31|January 2009|2009-01-31|June 1994|Actual|1994-06-30|June 1994|Actual|1994-06-30||Interventional|||Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)|Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)|Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.52556|2018-06-01 05:40:25.52556
NCT00000585|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-24|1999-10-27|1999-10-28|Estimate|||||||2016-03-24|2016-03-25|Estimate|August 1983||1983-08-31|October 1994|1994-10-31|October 1994||1994-10-31|||||Interventional|||Penicillin Prophylaxis in Sickle Cell Disease (PROPS)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.590987|2018-06-01 05:40:25.590987
NCT00000584|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|July 1983||1983-07-31|December 2005|2005-12-31|June 1988|Actual|1988-06-30|||||Interventional|||Transfusion-Transmitted Cytomegalovirus Prevention in Neonates||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.651518|2018-06-01 05:40:25.651518
NCT00000583|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|November 1978||1978-11-30|April 2012|2012-04-30|June 1980|Actual|1980-06-30|||||Interventional|||Hepatitis B Vaccine Clinical Trial||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.696775|2018-06-01 05:40:25.696775
NCT00000582|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2012-04-26|1999-10-27|1999-10-28|Estimate|||||||2012-04-26|2012-04-27|Estimate|July 1978||1978-07-31|April 2012|2012-04-30|July 1979|Actual|1979-07-31|||||Interventional|||Cooperative Study of Factor VIII Inhibitors||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.827368|2018-06-01 05:40:25.827368
NCT00000581|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 1976||1976-09-30|January 2000|2000-01-31|September 1981|Actual|1981-09-30|||||Interventional|||Granulocyte Transfusion Study||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.881525|2018-06-01 05:40:25.881525
NCT00000580|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|November 1975||1975-11-30|January 2000|2000-01-31|June 1986|Actual|1986-06-30|||||Interventional|||Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:25.931342|2018-06-01 05:40:25.931342
NCT00000579|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-22|1999-10-27|1999-10-28|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 1994||1994-09-30|August 2006|2006-08-31|July 2004|Actual|2004-07-31|||||Interventional|||Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)|Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)|Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:26.000648|2018-06-01 05:40:26.000648
NCT00000578|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 1994||1994-04-30|February 2005|2005-02-28|October 2000|Actual|2000-10-31|||||Interventional|||NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:26.169798|2018-06-01 05:40:26.169798
NCT00000577|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2017-01-12|1999-10-27|1999-10-28|Estimate|||||||2017-01-12|2017-01-16|Estimate|September 1993||1993-09-30|August 2006|2006-08-31|July 2008||2008-07-31|||||Interventional|||Asthma Clinical Research Network (ACRN)|Asthma Clinical Research Network (ACRN)|Withdrawn||Phase 3|0|Actual|Milton S. Hershey Medical Center||||"Record is an ACRN grant summary & not reflective of an individual trial. All ACTs conducted by~   ACRN were individually registered on the PRS."|f||||||||||||||2018-06-01 05:40:26.252764|2018-06-01 05:40:26.252764
NCT00000576|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 1993||1993-06-30|May 2001|2001-05-31|April 1999|Actual|1999-04-30|||||Interventional|||Inhaled Beclomethasone to Prevent Chronic Lung Disease||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:26.351632|2018-06-01 05:40:26.351632
NCT00000575|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|2013-10-16||2014-02-20|1999-10-27|1999-10-28|Estimate|2014-02-20|2014-04-03|Estimate||||2014-02-20|2014-04-03|Estimate|September 1991||1991-09-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|October 1999|Actual|1999-10-31||Interventional|CAMP||Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)|Childhood Asthma Management Program|Completed||Phase 3|1041|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-06-01 05:40:26.429141|2018-06-01 05:40:26.429141
NCT00000574|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-01-28|1999-10-27|1999-10-28|Estimate|||||||2016-01-28|2016-02-01|Estimate|September 1990||1990-09-30|January 2016|2016-01-31|July 1995||1995-07-31|||||Interventional|||Ibuprofen in Sepsis Study||Completed||Phase 3|||Vanderbilt University|||||f||||||||||||||2018-06-01 05:40:26.895703|2018-06-01 05:40:26.895703
NCT00000573|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 1990||1990-01-31|April 2002|2002-04-30|November 2005|Actual|2005-11-30|||||Interventional|||Emphysema: Physiologic Effects of Nutritional Support||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:26.947955|2018-06-01 05:40:26.947955
NCT00000572|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2018-03-04|1999-10-27|1999-10-28|Estimate|||||||2018-03-04|2018-03-06|Actual|June 1987||1987-06-30|March 2018|2018-03-31|January 1993|Actual|1993-01-31|April 1991|Actual|1991-04-30||Interventional|||Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome|Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome|Completed||Phase 3|40|Actual|Intermountain Health Care, Inc.||2|||f||||f||||||||||2018-06-01 05:40:27.022528|2018-06-01 05:40:27.022528
NCT00000570|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|January 1986||1986-01-31|January 2000|2000-01-31|June 1990|Actual|1990-06-30|||||Interventional|||Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.178645|2018-06-01 05:40:27.178645
NCT00000569|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-10-25|1999-10-27|1999-10-28|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 1993||1993-09-30|October 2016|2016-10-31|May 1999|Actual|1999-05-31|May 1999|Actual|1999-05-31||Interventional|LHSII||Lung Health Study II|The Chronic Obstructive Pulmonary Disease Early Intervention Trial|Completed||Phase 3|1116|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-06-01 05:40:27.22859|2018-06-01 05:40:27.22859
NCT00000568|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 1984||1984-09-30|August 2005|2005-08-31|January 2005||2005-01-31|||||Interventional|||Lung Health Study (LHS) I and III||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.327404|2018-06-01 05:40:27.327404
NCT00000567|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 1984||1984-08-31|December 2005|2005-12-31||||||||Interventional|||High Frequency Ventilation in Premature Infants (HIFI)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.428016|2018-06-01 05:40:27.428016
NCT00000566|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-14|1999-10-27|1999-10-28|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 1983||1983-09-30|June 2002|2002-06-30|December 1989||1989-12-31|||||Interventional|||Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.487587|2018-06-01 05:40:27.487587
NCT00000565|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 1976||1976-11-30|May 2002|2002-05-31||||||||Interventional|||Clinical Study of Intermittent Positive Pressure Breathing (IPPB)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.550009|2018-06-01 05:40:27.550009
NCT00000564|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2005-06-23|1999-10-27|1999-10-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1976||1976-07-31|May 2002|2002-05-31||||||||Interventional|||Nocturnal Oxygen Therapy||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.609247|2018-06-01 05:40:27.609247
NCT00000563|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2012-04-26|1999-10-27|1999-10-28|Estimate|||||||2012-04-26|2012-04-27|Estimate|June 1976||1976-06-30|April 2012|2012-04-30|August 1983|Actual|1983-08-31|||||Interventional|||Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.663502|2018-06-01 05:40:27.663502
NCT00000562|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|June 1974||1974-06-30|January 2000|2000-01-31|November 1979|Actual|1979-11-30|||||Interventional|||Extracorporeal Support for Respiratory Insufficiency (ECMO)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.715263|2018-06-01 05:40:27.715263
NCT00000561|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-22|1999-10-27|1999-10-28|Estimate|||||||2016-02-22|2016-02-23|Estimate|June 1995||1995-06-30|May 2005|2005-05-31|May 2002||2002-05-31|||||Interventional|||Mode Selection Trial in Sinus Node Dysfunction (MOST)||Completed||Phase 3|||Mt. Sinai Medical Center, Miami|||||f||||||||||||||2018-06-01 05:40:27.763691|2018-06-01 05:40:27.763691
NCT00000560|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-12|1999-10-27|1999-10-28|Estimate|||||||2016-04-12|2016-04-14|Estimate|June 1994||1994-06-30|April 2005|2005-04-30|September 1999||1999-09-30|||||Interventional|||Beta-Blocker Evaluation in Survival Trial (BEST)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.812409|2018-06-01 05:40:27.812409
NCT00000559|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 1995||1995-03-31|May 2005|2005-05-31|August 2001|Actual|2001-08-31|||||Interventional|||Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.868899|2018-06-01 05:40:27.868899
NCT00000558|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-15|Estimate|November 1995||1995-11-30|January 2008|2008-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:27.949531|2018-06-01 05:40:27.949531
NCT00000557|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-12|1999-10-27|1999-10-28|Estimate|||||||2016-04-12|2016-04-14|Estimate|September 1995||1995-09-30|January 2008|2008-01-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Enhancing Recovery in Coronary Heart Disease (ENRICHD) Patients||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:28.071229|2018-06-01 05:40:28.071229
NCT00000556|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-24|1999-10-27|1999-10-28|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 1995||1995-03-31|November 2005|2005-11-30|September 2002||2002-09-30|||||Interventional|||Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:28.16978|2018-06-01 05:40:28.16978
NCT00000555|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 1996||1996-08-31|August 2005|2005-08-31|May 2003|Actual|2003-05-31|||||Interventional|||Women's Angiographic Vitamin and Estrogen Trial (WAVE)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:28.620727|2018-06-01 05:40:28.620727
NCT00000554|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-04-03|1999-10-27|1999-10-28|Estimate|||||||2014-04-03|2014-04-04|Estimate|May 2001||2001-05-31|April 2014|2014-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Women's Ischemia Syndrome Evaluation (WISE)||Completed||Phase 3|||University of Pittsburgh|||||f||||||||||||||2018-06-01 05:40:28.959251|2018-06-01 05:40:28.959251
NCT00000553|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-08|1999-10-27|1999-10-28|Estimate|||||||2016-02-08|2016-02-10|Estimate|September 1994||1994-09-30|March 2005|2005-03-31|February 2001||2001-02-28|||||Interventional|||HDL-Atherosclerosis Treatment Study (HATS)||Completed||Phase 3|||University of Washington|||||f||||||||||||||2018-06-01 05:40:29.071437|2018-06-01 05:40:29.071437
NCT00000552|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-03-03|1999-10-27|1999-10-28|Estimate|||||||2014-03-03|2014-03-04|Estimate|September 1994||1994-09-30|March 2014|2014-03-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.||Completed||Phase 3|||New England Research Institutes|||||f||||||||||||||2018-06-01 05:40:29.407441|2018-06-01 05:40:29.407441
NCT00000551|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-24|1999-10-27|1999-10-28|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 1994||1994-09-30|August 2007|2007-08-31|September 2002||2002-09-30|||||Interventional|||Activity Counseling Trial (ACT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:29.569482|2018-06-01 05:40:29.569482
NCT00000550|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-03-03|1999-10-27|1999-10-28|Estimate|||||||2014-03-03|2014-03-04|Estimate|August 1994||1994-08-31|March 2014|2014-03-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Rapid Early Action for Coronary Treatment (REACT)||Completed||Phase 3|||New England Research Institutes|||||f||||||||||||||2018-06-01 05:40:29.71655|2018-06-01 05:40:29.71655
NCT00000549|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-15|1999-10-27|1999-10-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 1994||1994-08-31|December 2005|2005-12-31|July 2000|Actual|2000-07-31|||||Interventional|||Estrogen Replacement and Atherosclerosis (ERA) in Older Women||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:29.822821|2018-06-01 05:40:29.822821
NCT00000548|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-03-03|1999-10-27|1999-10-28|Estimate|||||||2015-03-03|2015-03-05|Estimate|March 2000||2000-03-31|March 2015|2015-03-31|February 2006|Actual|2006-02-28|||||Interventional|||Inhaled NO in Prevention of Chronic Lung Disease||Completed||Phase 3|||University of California, San Francisco|||||f||||||||||||||2018-06-01 05:40:29.887981|2018-06-01 05:40:29.887981
NCT00000547|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 1994||1994-04-30|December 2005|2005-12-31|February 2001|Actual|2001-02-28|||||Interventional|||Enalapril After Anthracycline Cardiotoxicity||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:29.969397|2018-06-01 05:40:29.969397
NCT00000546|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 1994||1994-03-31|October 2005|2005-10-31|May 2005|Actual|2005-05-31|||||Interventional|||Stress Reduction and Atherosclerotic CVD in Blacks||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:30.08255|2018-06-01 05:40:30.08255
NCT00000545|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-28|1999-10-27|1999-10-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 1993||1993-09-30|December 2005|2005-12-31|July 2002|Actual|2002-07-31|||||Interventional|||PATHWAYS--FULL SCALE STUDY|PATHWAYS--FULL SCALE STUDY|Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:30.168407|2018-06-01 05:40:30.168407
NCT00000544|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-11-04|1999-10-27|1999-10-28|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 1993||1993-08-31|October 2005|2005-10-31|July 1997|Actual|1997-07-31|||||Interventional|||Dietary Approaches to Stop Hypertension (DASH)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:30.262797|2018-06-01 05:40:30.262797
NCT00000543|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 1993||1993-08-31|April 2002|2002-04-30|July 1999|Actual|1999-07-31|||||Interventional|||Oral Calcium in Pregnant Women With Hypertension||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:30.381502|2018-06-01 05:40:30.381502
NCT00000542|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-28|1999-10-27|1999-10-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 1993||1993-08-31|February 2009|2009-02-28|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:30.520989|2018-06-01 05:40:30.520989
NCT00000541|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2018-05-11|1999-10-27|1999-10-28|Estimate|||||||2018-05-11|2018-05-14|Actual|May 1993||1993-05-31|May 2018|2018-05-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|WAFACS||Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)|Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)|Completed||Phase 2|||Brigham and Women's Hospital|||||f||||t||||||||||2018-06-01 05:40:30.683052|2018-06-01 05:40:30.683052
NCT00000540|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-11-04|1999-10-27|1999-10-28|Estimate|||||||2016-11-04|2016-11-07|Estimate|December 1992||1992-12-31|August 2004|2004-08-31|December 1998|Actual|1998-12-31|||||Interventional|||Coronary Artery Bypass Graft (CABG) Patch Trial||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:30.827542|2018-06-01 05:40:30.827542
NCT00000539|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1992||1992-09-30|January 2006|2006-01-31|March 1999|Actual|1999-03-31|||||Interventional|||Arterial Disease Multifactorial Intervention Trial (ADMIT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:30.911592|2018-06-01 05:40:30.911592
NCT00000538|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-08-11|1999-10-27|1999-10-28|Estimate|||||||2014-08-11|2014-08-13|Estimate|September 1992||1992-09-30|August 2014|2014-08-31|May 1995|Actual|1995-05-31|May 1995|Actual|1995-05-31||Interventional|||Dietary Effects on Lipoproteins and Thrombogenic Activity (DELTA)||Completed||Phase 3|189|Actual|University of North Carolina, Chapel Hill|||||f||||||||||||||2018-06-01 05:40:31.000828|2018-06-01 05:40:31.000828
NCT00000537|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2008-07-23|1999-10-27|1999-10-28|Estimate|||||||2008-07-23|2008-07-24|Estimate|July 1992||1992-07-31|July 2008|2008-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Stress Reduction & CVD Morbidity and Mortality in Blacks||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.056466|2018-06-01 05:40:31.056466
NCT00000536|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-24|1999-10-27|1999-10-28|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 1992||1992-07-31|February 2016|2016-02-29|June 1997||1997-06-30|||||Interventional|||Sodium Sensitivity in African Americans||Completed||Phase 2|||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:40:31.118708|2018-06-01 05:40:31.118708
NCT00000535|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-11-04|1999-10-27|1999-10-28|Estimate|||||||2016-11-04|2016-11-07|Estimate|April 1992||1992-04-30|October 2002|2002-10-31|March 1997|Actual|1997-03-31|||||Interventional|||Trial of Nonpharmacologic Interventions in Elderly (TONE)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.201027|2018-06-01 05:40:31.201027
NCT00000534|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2017-03-09|1999-10-27|1999-10-28|Estimate|||||||2017-03-09|2017-03-13|Actual|March 1991||1991-03-31|March 2017|2017-03-31|June 2000||2000-06-30|||||Interventional|||Calcium for Pre-Eclampsia Prevention (CPEP)||Completed||Phase 3|||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||||||||||||2018-06-01 05:40:31.284939|2018-06-01 05:40:31.284939
NCT00000533|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-12-28|1999-10-27|1999-10-28|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 1992||1992-02-29|March 2005|2005-03-31|December 1996||1996-12-31|||||Interventional|||Montreal Heart Attack Readjustment Trial (M-HART)|Montreal Heart Attack Readjustment Trial (M-HART)|Completed||Phase 3|||McGill University|||||f||||||||||||||2018-06-01 05:40:31.35577|2018-06-01 05:40:31.35577
NCT00000532|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 1992||1992-02-29|April 2002|2002-04-30|January 2000|Actual|2000-01-31|||||Interventional|||Women's Healthy Lifestyle Project: Cardiovascular Risk Factors and Menopause||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.416995|2018-06-01 05:40:31.416995
NCT00000531|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-12|1999-10-27|1999-10-28|Estimate|||||||2016-04-12|2016-04-14|Estimate|September 1992||1992-09-30|May 2005|2005-05-31|August 2002||2002-08-31|||||Interventional|||Antiarrhythmics Versus Implantable Defibrillators (AVID)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.482373|2018-06-01 05:40:31.482373
NCT00000530|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-14|1999-10-27|1999-10-28|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 1992||1992-09-30|August 2004|2004-08-31|June 1998||1998-06-30|||||Interventional|||Raynaud's Treatment Study (RTS)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.603227|2018-06-01 05:40:31.603227
NCT00000529|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-11-01|1999-10-27|1999-10-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 1992||1992-05-31|August 2001|2001-08-31|November 1995||1995-11-30|||||Interventional|||Tamoxifen Study||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.686225|2018-06-01 05:40:31.686225
NCT00000527|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-09|1999-10-27|1999-10-28|Estimate|||||||2013-12-09|2013-12-11|Estimate|August 1986||1986-08-31|December 2013|2013-12-31|November 1998|Actual|1998-11-30|November 1998|Actual|1998-11-30||Interventional|||Recurrent Carotid Stenosis||Completed||Phase 2|||Emory University|||||f||||||||||||||2018-06-01 05:40:31.789947|2018-06-01 05:40:31.789947
NCT00000526|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-05|1999-10-27|1999-10-28|Estimate|||||||2016-05-05|2016-05-06|Estimate|August 1986||1986-08-31|August 2004|2004-08-31|March 1998||1998-03-31|||||Interventional|||Cardiac Arrhythmia Suppression Trial (CAST)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:31.901917|2018-06-01 05:40:31.901917
NCT00000525|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-09-18|1999-10-27|1999-10-28|Estimate|||||||2013-09-18|2013-09-19|Estimate|July 1986||1986-07-31|September 2013|2013-09-30||||September 1989|Actual|1989-09-30||Interventional|||Diuretics, Hypertension, and Arrhythmias Clinical Trial||Completed||Phase 3|233|Actual|University of California, San Francisco|||||f||||||||||||||2018-06-01 05:40:32.094593|2018-06-01 05:40:32.094593
NCT00000524|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-27|Estimate|July 1986||1986-07-31|November 2013|2013-11-30|March 1994|Actual|1994-03-31|||||Interventional|||Myocarditis Treatment Trial||Completed||Phase 2|||University of Utah|||||f||||||||||||||2018-06-01 05:40:32.149534|2018-06-01 05:40:32.149534
NCT00000523|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2005-06-23|1999-10-27|1999-10-28|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1986||1986-04-30|January 2000|2000-01-31||||||||Interventional|||Optimal Exercise Regimens for Persons at Increased Risk||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:33.162685|2018-06-01 05:40:33.162685
NCT00000522|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-24|1999-10-27|1999-10-28|Estimate|||||||2016-02-24|2016-02-25|Estimate|August 1985||1985-08-31|February 2016|2016-02-29|May 1994||1994-05-31|||||Interventional|||Treatment of Mild Hypertension Study (TOMHS)||Completed||Phase 2|||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:40:33.232356|2018-06-01 05:40:33.232356
NCT00000521|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-05-27|1999-10-27|1999-10-28|Estimate|||||||2014-05-27|2014-05-29|Estimate|August 1985||1985-08-31|May 2014|2014-05-31|December 1990|Actual|1990-12-31|July 1990|Actual|1990-07-31||Interventional|||Sodium-Potassium Blood Pressure Trial in Children|Sodium-Potassium Blood Pressure Trial in Children|Completed||Phase 4|285|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:40:33.296184|2018-06-01 05:40:33.296184
NCT00000520|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|July 1985||1985-07-31|April 2012|2012-04-30|November 1989|Actual|1989-11-30|||||Interventional|||Prevention of Coronary Aneurysms in Kawasaki Syndrome||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:33.360912|2018-06-01 05:40:33.360912
NCT00000519|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-06-25|1999-10-27|1999-10-28|Estimate|||||||2013-06-25|2013-06-26|Estimate|July 1982||1982-07-31|June 2013|2013-06-30||||||||Interventional|||Exercise Training and Plasma Lipoproteins in Man||Completed||Phase 3|||Stanford University|||||f||||||||||||||2018-06-01 05:40:33.456043|2018-06-01 05:40:33.456043
NCT00000518|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-01-19|1999-10-27|1999-10-28|Estimate|||||||2016-01-19|2016-01-21|Estimate|July 1985||1985-07-31|January 2016|2016-01-31|December 1992||1992-12-31|||||Interventional|||Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)||Completed||Phase 3|||University of Utah|||||f||||||||||||||2018-06-01 05:40:33.523626|2018-06-01 05:40:33.523626
NCT00000517|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-04-09|1999-10-27|1999-10-28|Estimate|||||||2014-04-09|2014-04-10|Estimate|July 1985||1985-07-31|April 2014|2014-04-30|June 1991|Actual|1991-06-30|June 1991|Actual|1991-06-30||Interventional|||Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)||Completed||Phase 3|||Massachusetts General Hospital|||||f||||||||||||||2018-06-01 05:40:33.598311|2018-06-01 05:40:33.598311
NCT00000516|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-14|1999-10-27|1999-10-28|Estimate|||||||2016-04-14|2016-04-15|Estimate|July 1985||1985-07-31|April 2012|2012-04-30|May 1990|Actual|1990-05-31|||||Interventional|||Studies of Left Ventricular Dysfunction (SOLVD)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:33.758828|2018-06-01 05:40:33.758828
NCT00000515|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|July 1984||1984-07-31|February 2005|2005-02-28|September 1992|Actual|1992-09-30|||||Interventional|||Randomized Trial of Dietary Intervention Therapy in Obese Hypertensives (DITOH)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:33.855319|2018-06-01 05:40:33.855319
NCT00000514|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-14|1999-10-27|1999-10-28|Estimate|||||||2016-04-14|2016-04-15|Estimate|June 1984||1984-06-30|January 2005|2005-01-31|October 1996||1996-10-31|||||Interventional|||Systolic Hypertension in the Elderly Program (SHEP)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:33.909297|2018-06-01 05:40:33.909297
NCT00000513|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|April 1984||1984-04-30|April 2012|2012-04-30|November 1994|Actual|1994-11-30|||||Interventional|||Trial of Antihypertensive Intervention Management||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.009788|2018-06-01 05:40:34.009788
NCT00000512|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-12-01|1999-10-27|1999-10-28|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 1984||1984-01-31|December 2015|2015-12-31|August 1989|Actual|1989-08-31|August 1989|Actual|1989-08-31||Interventional|FATS||Familial Atherosclerosis Treatment Study|Familial Atherosclerosis Treatment Study|Completed||Phase 3|146|Actual|University of Washington||3|||f||||t||||||||||2018-06-01 05:40:34.092242|2018-06-01 05:40:34.092242
NCT00000511|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|December 1983||1983-12-31|December 2013|2013-12-31|November 1994|Actual|1994-11-30|November 1994|Actual|1994-11-30||Interventional|||Polyunsaturates and KCL to Control Mild Hypertension||Completed||Phase 2|||Brigham and Women's Hospital||1|||f||||||||||||||2018-06-01 05:40:34.232651|2018-06-01 05:40:34.232651
NCT00000510|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 1983||1983-09-30|March 2005|2005-03-31|September 1988|Actual|1988-09-30|||||Interventional|||Platelet-Inhibitor Drug Trial in Coronary Angioplasty||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.299687|2018-06-01 05:40:34.299687
NCT00000509|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2017-03-14|1999-10-27|1999-10-28|Estimate|||||||2017-03-14|2017-03-16|Actual|September 1983||1983-09-30|March 2017|2017-03-31|September 2003||2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Potassium and Sodium to Control Blood Pressure in Hypertensives||Completed||Phase 3|||University of Minnesota - Clinical and Translational Science Institute|||||f||||f|f|f||||||No||2018-06-01 05:40:34.353965|2018-06-01 05:40:34.353965
NCT00000508|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-01-08|1999-10-27|1999-10-28|Estimate|||||||2016-01-08|2016-01-12|Estimate|September 1983||1983-09-30|March 1993|1993-03-31|March 1993||1993-03-31|||||Interventional|||Stanford Coronary Risk Intervention Project (SCRIP)||Completed||Phase 3|||Stanford University|||||f||||||||||||||2018-06-01 05:40:34.406513|2018-06-01 05:40:34.406513
NCT00000507|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-08|1999-10-27|1999-10-28|Estimate|||||||2016-02-08|2016-02-10|Estimate|August 1983||1983-08-31|October 1994|1994-10-31|October 1994||1994-10-31|||||Interventional|||Intravenous Streptokinase in Acute Myocardial Infarction||Completed||Phase 3|||University of Washington|||||f||||||||||||||2018-06-01 05:40:34.455072|2018-06-01 05:40:34.455072
NCT00000506|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|May 1983||1983-05-31|January 2000|2000-01-31|April 1988|Actual|1988-04-30|||||Interventional|||Cardiovascular System in Obesity: Effect of Treatment||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.51138|2018-06-01 05:40:34.51138
NCT00000505|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-15|1999-10-27|1999-10-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1983||1983-04-30|July 2000|2000-07-31|December 1990|Actual|1990-12-31|||||Interventional|||Thrombolysis in Myocardial Infarction (TIMI)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.580754|2018-06-01 05:40:34.580754
NCT00000504|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2012-04-26|1999-10-27|1999-10-28|Estimate|||||||2012-04-26|2012-04-27|Estimate|September 1982||1982-09-30|April 2012|2012-04-30|September 1985|Actual|1985-09-30|||||Interventional|||Cardiac Arrhythmia Pilot Study (CAPS)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.664841|2018-06-01 05:40:34.664841
NCT00000503|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|August 1982||1982-08-31|January 2000|2000-01-31|October 1987|Actual|1987-10-31|||||Interventional|||Randomized Clinical Trial of Non-Surgical Reperfusion of the Coronary Arteries||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.809431|2018-06-01 05:40:34.809431
NCT00000502|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 1981||1981-09-30|May 2000|2000-05-31|June 1985|Actual|1985-06-30|||||Interventional|||Evaluation of SC-V Versus Conventional CPR||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.863977|2018-06-01 05:40:34.863977
NCT00000501|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 1981||1981-09-30|April 2012|2012-04-30|August 1986|Actual|1986-08-31|||||Interventional|||Hypertension Prevention Trial (HPT) Feasibility Study||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:34.915711|2018-06-01 05:40:34.915711
NCT00000500|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-01-24|1999-10-27|1999-10-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|September 1981||1981-09-30|January 2014|2014-01-31|December 1996|Actual|1996-12-31|December 1995|Actual|1995-12-31||Interventional|||Physicians' Health Study||Completed||Phase 3|||Brigham and Women's Hospital|||||f||||||||||||||2018-06-01 05:40:34.995973|2018-06-01 05:40:34.995973
NCT00000499|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 1980||1980-09-30|April 2012|2012-04-30|May 1983|Actual|1983-05-31|||||Interventional|||Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.104108|2018-06-01 05:40:35.104108
NCT00000498|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-25|1999-10-27|1999-10-28|Estimate|||||||2016-07-25|2016-07-26|Estimate|April 1980||1980-04-30|January 2000|2000-01-31|March 1983|Actual|1983-03-31|||||Interventional|||Control of Hypertension by Non-Pharmacologic Means||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.172796|2018-06-01 05:40:35.172796
NCT00000497|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2015-04-14|1999-10-27|1999-10-28|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 1980||1980-01-31|January 2000|2000-01-31|September 1994|Actual|1994-09-30|||||Interventional|||Dietary Intervention Study for Hypertension (DISH)||Completed||Phase 3|||University of Mississippi Medical Center|||||f||||||||||||||2018-06-01 05:40:35.235421|2018-06-01 05:40:35.235421
NCT00000496|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|December 1979||1979-12-31|April 2012|2012-04-30|December 1982|Actual|1982-12-31|||||Interventional|||Platelet Drug Trial in Coronary Disease Progression||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.315843|2018-06-01 05:40:35.315843
NCT00000495|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2014-11-21|1999-10-27|1999-10-28|Estimate|||||||2014-11-21|2014-11-24|Estimate|December 1978||1978-12-31|January 2000|2000-01-31||||||||Interventional|||Prevention of Hypertension: A Randomized Trial||Completed||Phase 3|||Northwestern University|||||f||||||||||||||2018-06-01 05:40:35.372622|2018-06-01 05:40:35.372622
NCT00000494|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|September 1978||1978-09-30|April 2012|2012-04-30|March 1982|Actual|1982-03-31|||||Interventional|||Management of Patent Ductus in Premature Infants||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.433318|2018-06-01 05:40:35.433318
NCT00000493|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1977||1977-09-30|December 1985|1985-12-31|December 1985|Actual|1985-12-31|||||Interventional|||Multicenter Investigation of Limitation of Infarct Size (MILIS)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.49923|2018-06-01 05:40:35.49923
NCT00000492|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1977||1977-09-30|October 1981|1981-10-31|October 1981|Actual|1981-10-31|||||Interventional|||Beta-Blocker Heart Attack Trial (BHAT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.638384|2018-06-01 05:40:35.638384
NCT00000491|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-24|1999-10-27|1999-10-28|Estimate|||||||2016-03-24|2016-03-25|Estimate|October 1974||1974-10-31|April 2012|2012-04-30|August 1979|Actual|1979-08-31|||||Interventional|||Aspirin-Myocardial Infarction Study (AMIS)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.733972|2018-06-01 05:40:35.733972
NCT00000490|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-24|1999-10-27|1999-10-28|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 1973||1973-06-30|February 2016|2016-02-29|December 1997||1997-12-31|||||Interventional|||Program on Surgical Control of Hyperlipidemias (POSCH)||Completed||Phase 3|||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:40:35.812471|2018-06-01 05:40:35.812471
NCT00000489|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-16|1999-10-27|1999-10-28|Estimate|||||||2016-02-16|2016-02-18|Estimate|June 1973||1973-06-30|December 2005|2005-12-31|December 1996||1996-12-31|||||Interventional|||Coronary Artery Surgery Study (CASS)||Completed||Phase 3|||University of Washington|||||f||||||||||||||2018-06-01 05:40:35.890734|2018-06-01 05:40:35.890734
NCT00000488|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-13|1999-10-27|1999-10-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 1973||1973-06-30|April 2012|2012-04-30|October 1989|Actual|1989-10-31|||||Interventional|||Lipid Research Clinics Coronary Primary Prevention Trial (CPPT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:35.968438|2018-06-01 05:40:35.968438
NCT00000487|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-24|1999-10-27|1999-10-28|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 1972||1972-06-30|February 2016|2016-02-29|July 1998||1998-07-31|||||Interventional|||Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)||Completed||Phase 3|||University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-06-01 05:40:36.051904|2018-06-01 05:40:36.051904
NCT00000486|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|January 1972||1972-01-31|January 2000|2000-01-31|January 1980|Actual|1980-01-31|||||Interventional|||Unstable Angina Pectoris Trial||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:36.151056|2018-06-01 05:40:36.151056
NCT00000485|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 1971||1971-05-31|December 2005|2005-12-31|May 1982|Actual|1982-05-31|||||Interventional|||Hypertension Detection and Follow-up Program (HDFP)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:36.304287|2018-06-01 05:40:36.304287
NCT00000484|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|April 1966||1966-04-30|January 2000|2000-01-31|January 1979|Actual|1979-01-31|||||Interventional|||Treatment of Hypertension||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:36.408203|2018-06-01 05:40:36.408203
NCT00000483|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|June 1981||1981-06-30|April 2004|2004-04-30|March 1985|Actual|1985-03-31|||||Interventional|||Coronary Drug Project Mortality Surveillance||Completed||N/A|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:36.475026|2018-06-01 05:40:36.475026
NCT00000482|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-11-25|1999-10-27|1999-10-28|Estimate|||||||2013-11-25|2013-11-26|Estimate|April 1965||1965-04-30|July 2004|2004-07-31|March 1985|Actual|1985-03-31|||||Interventional|||Coronary Drug Project||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:36.538032|2018-06-01 05:40:36.538032
NCT00000481|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2017-02-13|1999-10-27|1999-10-28|Estimate|||||||2017-02-13|2017-02-14|Actual|September 1991||1991-09-30|February 2017|2017-02-28|January 1996||1996-01-31|||||Interventional|||Women's Health Trial: Feasibility Study in Minority Populations||Completed||Phase 3|||National Cancer Institute (NCI)|||||f||||||||||||||2018-06-01 05:40:36.6161|2018-06-01 05:40:36.6161
NCT00000480|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2017-01-13|1999-10-27|1999-10-28|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 1991||1991-09-30|August 2004|2004-08-31|September 1996|Actual|1996-09-30|||||Interventional|||Multicenter Unsustained Tachycardia Trial (MUSTT)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:36.702446|2018-06-01 05:40:36.702446
NCT00000479|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|2011-12-05||2012-06-12|1999-10-27|1999-10-28|Estimate|2012-05-02|2012-06-13|Estimate||||2012-06-12|2012-06-15|Estimate|September 1992||1992-09-30|June 2012|2012-06-30|February 2005|Actual|2005-02-28|March 2004|Actual|2004-03-31||Interventional|WHS||Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer|Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women|Completed||Phase 3|39876|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-06-01 05:40:36.794513|2018-06-01 05:40:36.794513
NCT00000478|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-24|1999-10-27|1999-10-28|Estimate|||||||2016-03-24|2016-03-25|Estimate|November 1990||1990-11-30|February 2002|2002-02-28|June 1997||1997-06-30|||||Interventional|||Asymptomatic Cardiac Ischemia Pilot (ACIP) Study||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.183565|2018-06-01 05:40:37.183565
NCT00000477|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 1990||1990-07-31|June 1992|1992-06-30|June 1992|Actual|1992-06-30|||||Interventional|||Cholesterol Reduction in Seniors Program (CRISP)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.263252|2018-06-01 05:40:37.263252
NCT00000476|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 1990||1990-06-30|November 2005|2005-11-30|June 1998|Actual|1998-06-30|||||Interventional|||Digitalis Investigation Group (DIG)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.318073|2018-06-01 05:40:37.318073
NCT00000475|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 1990||1990-04-30|December 2005|2005-12-31|March 1995|Actual|1995-03-31|||||Interventional|||Prevention of Early Readmission in Elderly Congestive Heart Failure Patients||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.409226|2018-06-01 05:40:37.409226
NCT00000474|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-11|1999-10-27|1999-10-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 1989||1989-09-30|June 2001|2001-06-30|September 1994|Actual|1994-09-30|||||Interventional|||Prevention and Treatment of Hypertension Study (PATHS)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.46453|2018-06-01 05:40:37.46453
NCT00000473|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|July 1989||1989-07-31|April 2012|2012-04-30|June 1994|Actual|1994-06-30|||||Interventional|||Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty?||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.521376|2018-06-01 05:40:37.521376
NCT00000472|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-15|1999-10-27|1999-10-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 1989||1989-04-30|July 2000|2000-07-31|June 1995|Actual|1995-06-30|||||Interventional|||Thrombolysis in Myocardial Ischemia Trial (TIMI III)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.573881|2018-06-01 05:40:37.573881
NCT00000471|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-12-12|1999-10-27|1999-10-28|Estimate|||||||2013-12-12|2013-12-13|Estimate|April 1989||1989-04-30|January 2000|2000-01-31|March 1993|Actual|1993-03-31|||||Interventional|||Lifestyle Heart Trial||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.641632|2018-06-01 05:40:37.641632
NCT00000470|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-07-28|1999-10-27|1999-10-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 1988||1988-12-31|July 2016|2016-07-31|October 1993|Actual|1993-10-31|February 1992|Actual|1992-02-29||Interventional|BCAS||Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest|Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest|Completed||Phase 3|171|Actual|Boston Children’s Hospital|||||f||||t||||||||No|Not required when trial was performed in 1988-92|2018-06-01 05:40:37.703881|2018-06-01 05:40:37.703881
NCT00000469|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 1988||1988-05-31|April 2000|2000-04-30|August 1998|Actual|1998-08-31|||||Interventional|||Asymptomatic Carotid Artery Plaque Study (ACAPS)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.768094|2018-06-01 05:40:37.768094
NCT00000468|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-08|1999-10-27|1999-10-28|Estimate|||||||2016-02-08|2016-02-09|Estimate|April 1988||1988-04-30|June 2001|2001-06-30|March 1992||1992-03-31|||||Interventional|||Myocardial Infarction Triage and Intervention Project (MITI)||Completed||Phase 3|||University of Washington|||||f||||||||||||||2018-06-01 05:40:37.827606|2018-06-01 05:40:37.827606
NCT00000467|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 1987||1987-09-30|January 2008|2008-01-31|March 1991|Actual|1991-03-31|March 1991|Actual|1991-03-31||Interventional|||Child and Adolescent Trial for Cardiovascular Health (CATCH)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.898917|2018-06-01 05:40:37.898917
NCT00000466|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 1987||1987-09-30|July 2005|2005-07-31|October 2000|Actual|2000-10-31|||||Interventional|||Postmenopausal Estrogen/Progestin Interventions (PEPI)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:37.985061|2018-06-01 05:40:37.985061
NCT00000465|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-02-17|1999-10-27|1999-10-28|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 1987||1987-06-30|September 2002|2002-09-30|August 1998|Actual|1998-08-31|||||Interventional|||Emory Angioplasty Versus Surgery Trial (EAST)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:38.162357|2018-06-01 05:40:38.162357
NCT00000464|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2013-07-26|1999-10-27|1999-10-28|Estimate|||||||2013-07-26|2013-07-29|Estimate|April 1987||1987-04-30|July 2013|2013-07-31||||December 1992|Actual|1992-12-31||Interventional|||Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)||Completed||Phase 3|||University of Washington|||||f||||||||||||||2018-06-01 05:40:38.216554|2018-06-01 05:40:38.216554
NCT00000463|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-04-12|1999-10-27|1999-10-28|Estimate|||||||2016-04-12|2016-04-14|Estimate|April 1987||1987-04-30|August 2004|2004-08-31|December 1998||1998-12-31|||||Interventional|||Post Coronary Artery Bypass Graft (CABG) Study||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:38.298653|2018-06-01 05:40:38.298653
NCT00000462|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-12|1999-10-27|1999-10-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 1987||1987-04-30|March 2005|2005-03-31|November 2004||2004-11-30|||||Interventional|||Bypass Angioplasty Revascularization Investigation (BARI)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:38.38036|2018-06-01 05:40:38.38036
NCT00000461|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-03-15|1999-10-27|1999-10-28|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 1986||1986-12-31|March 2005|2005-03-31|November 1992|Actual|1992-11-30|||||Interventional|||Harvard Atherosclerosis Reversibility Project (HARP)||Completed||Phase 2|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:38.483256|2018-06-01 05:40:38.483256
NCT00000460|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-01-05|1999-10-27|1999-10-28|Estimate|||||||2016-01-05|2016-01-06|Estimate|December 1986||1986-12-31|November 2013|2013-11-30|March 1991|Actual|1991-03-31|March 1991|Actual|1991-03-31||Observational|||Training Levels Comparison Trial|Training Levels Comparison (TLC) Trial in Patients With Coronary Heart Disease|Withdrawn|||0|Actual|University of Alabama at Birmingham|||2|due to lack of enrollment|f||||||||||||||2018-06-01 05:40:38.553311|2018-06-01 05:40:38.553311
NCT00000459|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-27|||2016-05-04|1999-10-27|1999-10-28|Estimate|||||||2016-05-04|2016-05-05|Estimate|December 1986||1986-12-31|March 2005|2005-03-31|January 1999|Actual|1999-01-31|||||Interventional|||Dietary Intervention Study in Children (DISC)||Completed||Phase 3|||National Heart, Lung, and Blood Institute (NHLBI)|||||f||||||||||||||2018-06-01 05:40:38.637072|2018-06-01 05:40:38.637072
NCT00004500|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|2012-04-02||2012-05-01|1999-10-18|1999-10-19|Estimate|2012-04-02|2012-05-01|Estimate||||2012-05-01|2012-05-03|Estimate|March 2000||2000-03-31|May 2012|2012-05-31|November 2004|Actual|2004-11-30|November 2002|Actual|2002-11-30||Interventional|||Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome|A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of Bronchoalveolar Lavage With Lucinactant to Standard Care for the Treatment of the Meconium Aspriation Syndrome (MAS) in Newborn Infants|Terminated||Phase 3|69|Actual|Windtree Therapeutics|Early termination led to a small number of subjects analyzed. Results should be interpreted with caution.|2||Slow enrollment and administrative reasons|f||||t||||||||||2018-06-01 05:40:38.722381|2018-06-01 05:40:38.722381
NCT00004498|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 1998||1998-07-31|February 2000|2000-02-29|September 2000||2000-09-30|||||Interventional|||Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency||Terminated||Phase 1|21||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.178718|2018-06-01 05:40:39.178718
NCT00004497|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1998||1998-10-31|September 1999|1999-09-30|September 2000||2000-09-30|||||Interventional|||Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension||Completed||Phase 3|||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.235977|2018-06-01 05:40:39.235977
NCT00004496|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|February 1999||1999-02-28|August 1999|1999-08-31|September 2003||2003-09-30|||||Interventional|||Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure||Completed||Phase 1|45|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.303917|2018-06-01 05:40:39.303917
NCT00004495|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 1999||1999-06-30|August 1999|1999-08-31|September 2000||2000-09-30|||||Interventional|||Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis||Completed||N/A|84|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.366668|2018-06-01 05:40:39.366668
NCT00004494|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2013-03-07|1999-10-18|1999-10-19|Estimate|||||||2013-03-07|2013-03-08|Estimate|September 1998||1998-09-30|August 1999|1999-08-31||||||||Interventional|||Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis||Unknown status|Recruiting|Phase 1|18|Anticipated|Stony Brook University|||||f||||||||||||||2018-06-01 05:40:39.429444|2018-06-01 05:40:39.429444
NCT00004493|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1998||1998-09-30|May 2000|2000-05-31|September 2003||2003-09-30|||||Interventional|||Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia||Completed||Phase 2|75|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.556577|2018-06-01 05:40:39.556577
NCT00004492|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1999||1999-10-31|January 2001|2001-01-31|September 2001||2001-09-30|||||Interventional|||Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia||Completed||Phase 1/Phase 2|20|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.650514|2018-06-01 05:40:39.650514
NCT00004490|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1998||1998-10-31|April 2000|2000-04-30|September 2002||2002-09-30|||||Interventional|||Phase III Randomized Study of Sodium Dichloroacetate in Children With Congenital Lactic Acidosis||Completed||Phase 3|45||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.71306|2018-06-01 05:40:39.71306
NCT00004489|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1998||1998-10-31|January 2000|2000-01-31|September 2002||2002-09-30|||||Interventional|||Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis||Completed||N/A|60|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.766673|2018-06-01 05:40:39.766673
NCT00004488|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1998||1998-10-31|March 2000|2000-03-31|September 2002||2002-09-30|||||Interventional|||Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease||Completed||Phase 2|82|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.852755|2018-06-01 05:40:39.852755
NCT00004487|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 1999||1999-05-31|April 2001|2001-04-30||||||||Interventional|||Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux||Unknown status|Active, not recruiting|Phase 3|60||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.922416|2018-06-01 05:40:39.922416
NCT00004486|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1998||1998-09-30|December 2000|2000-12-31|December 2002||2002-12-31|||||Interventional|||Randomized Study of Fluoxetine in Children and Adolescents With Autism||Completed||N/A|45||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:39.973484|2018-06-01 05:40:39.973484
NCT00004485|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2008-09-08|1999-10-18|1999-10-19|Estimate|||||||2008-09-08|2008-09-10|Estimate|December 1999||1999-12-31|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Bone Marrow Transplantation in Treating Children With Sickle Cell Disease|Phase I/II Study of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation From HLA-Identical Donors in Children With Sickle Cell Disease|Completed||Phase 1/Phase 2|50||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:40.056695|2018-06-01 05:40:40.056695
NCT00004483|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-09-27|1999-10-18|1999-10-19|Estimate|||||||2005-09-27|2005-09-29|Estimate|January 2002||2002-01-31|September 2005|2005-09-30||||||||Observational|||NF2 Natural History Consortium||Unknown status|Active, not recruiting||100||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:40.138648|2018-06-01 05:40:40.138648
NCT00004482|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2010-09-08|1999-10-18|1999-10-19|Estimate|||||||2010-09-08|2010-09-09|Estimate|December 1999||1999-12-31|September 2010|2010-09-30|July 2006|Actual|2006-07-31|July 2005|Actual|2005-07-31||Interventional|||Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis||Completed||Phase 2|40||Mayo Clinic|||||f||||t||||||||||2018-06-01 05:40:40.213486|2018-06-01 05:40:40.213486
NCT00004481|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1999||1999-11-30|January 2004|2004-01-31||||||||Observational|||Genetic Study of Sitosterolemia||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:40.315269|2018-06-01 05:40:40.315269
NCT00004480|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1999||1999-07-31|July 2004|2004-07-31||||||||Interventional|||Study of Botulinum Toxin in Patients With Primary Hyperhidrosis||Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:40.390905|2018-06-01 05:40:40.390905
NCT00004479|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1999||1999-03-31|July 2004|2004-07-31||||||||Interventional|||Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope||Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:40.440496|2018-06-01 05:40:40.440496
NCT00004478|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2008-09-17|1999-10-18|1999-10-19|Estimate|||||||2008-09-17|2008-09-18|Estimate|March 1999||1999-03-31|September 2008|2008-09-30|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Droxidopa in Treating Patients With Neurogenic Hypotension|Study of Droxidopa in Patients With Neurologic Hypotension|Completed||N/A|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:40.492167|2018-06-01 05:40:40.492167
NCT00004475|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2018-05-09|1999-10-18|1999-10-19|Estimate|||||||2018-05-09|2018-05-15|Actual|December 1998|Actual|1998-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|||Genetic Linkage Study for Hereditary Pancreatitis|Molecular Genetics of Hereditary Pancreatitis|Recruiting|||1000|Anticipated|University of Pittsburgh|||||f||||f|f|f||||Samples With DNA|"~     Blood or saliva samples are collected from patients and family members. DNA is extracted and~     used for genotypic analysis.~   "|||2018-06-01 05:40:40.562136|2018-06-01 05:40:40.562136
NCT00004474|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2018-03-09|1999-10-18|1999-10-19|Estimate|||||||2018-03-09|2018-03-12|Actual|September 1998||1998-09-30|October 2008|2008-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia|Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia|Completed||Phase 3|224||Office of Rare Diseases (ORD)||2|||f||||t||||||||||2018-06-01 05:40:40.617003|2018-06-01 05:40:40.617003
NCT00004471|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2011-03-28|1999-10-18|1999-10-19|Estimate|||||||2011-03-28|2011-03-29|Estimate|August 1995||1995-08-31|March 2011|2011-03-31||||May 2001|Actual|2001-05-31||Interventional|||Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer||Completed||Phase 1|9||University of Alabama at Birmingham|||||f||||||||||||||2018-06-01 05:40:40.730953|2018-06-01 05:40:40.730953
NCT00004468|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2018-02-28|1999-10-18|1999-10-19|Estimate|||||||2018-02-28|2018-03-02|Actual|October 1998||1998-10-31|February 2018|2018-02-28||||||||Interventional|||Study of Topical Calcitriol or Oral Calcitriol in Patients With Psoriasis||Withdrawn||N/A|0|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||||Lack of funds|f||||||||||||||2018-06-01 05:40:40.772071|2018-06-01 05:40:40.772071
NCT00004467|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2017-10-11|1999-10-18|1999-10-19|Estimate|||||||2017-10-11|2017-10-13|Actual|June 1998||1998-06-30|October 2017|2017-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen||Completed||Phase 3|173|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||t||||t|t|f||||||||2018-06-01 05:40:40.913479|2018-06-01 05:40:40.913479
NCT00004466|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2017-09-14|1999-10-18|1999-10-19|Estimate|||||||2017-09-14|2017-09-15|Actual|October 1998|Actual|1998-10-31|September 2017|2017-09-30|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome||Terminated||Phase 2|5|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||Very poor enrollment|f|||||t|f||||||||2018-06-01 05:40:41.07384|2018-06-01 05:40:41.07384
NCT00004465|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2017-05-30|1999-10-18|1999-10-19|Estimate|||||||2017-05-30|2017-06-01|Actual|July 27, 1997|Actual|1997-07-27|May 2017|2017-05-31|April 14, 2001|Actual|2001-04-14|April 14, 2001|Actual|2001-04-14||Interventional|||Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome|Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated|Terminated||Phase 3|145|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2||Lack of efficacy at review by DSMB using pre-specified monitoring criteria|f||||t|t|f||||||No||2018-06-01 05:40:41.176246|2018-06-01 05:40:41.176246
NCT00004464|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2007-03-28|1999-10-18|1999-10-19|Estimate|||||||2007-03-28|2007-03-30|Estimate|February 1996||1996-02-29|March 2007|2007-03-31||||||||Interventional|||Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria||Unknown status|Active, not recruiting|N/A|25||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:41.310758|2018-06-01 05:40:41.310758
NCT00004458|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1997||1997-05-31|October 2003|2003-10-31||||||||Observational|||Longitudinal and Biological Study of Childhood Disintegrative Disorder||Terminated|||220||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:41.403014|2018-06-01 05:40:41.403014
NCT00004457|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1998||1998-03-31|January 2001|2001-01-31||||||||Observational|||Determinants of Disease Severity in Amyotrophic Lateral Sclerosis||Unknown status|Active, not recruiting||75||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:41.46966|2018-06-01 05:40:41.46966
NCT00004454|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1996||1996-10-31|October 2003|2003-10-31||||||||Interventional|||Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)||Completed||Phase 1/Phase 2|2||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:41.524612|2018-06-01 05:40:41.524612
NCT00004451|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-11-29|1999-10-18|1999-10-19|Estimate|||||||2005-11-29|2005-12-01|Estimate|March 1998||1998-03-31|November 2005|2005-11-30||||||||Interventional|||Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients||Completed||N/A|120||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:40:41.585461|2018-06-01 05:40:41.585461
NCT00004450|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1998||1998-08-31|January 2001|2001-01-31|November 2000||2000-11-30|||||Interventional|||Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy||Completed||N/A|60||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:41.64887|2018-06-01 05:40:41.64887
NCT00004449|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-05-26|1999-10-18|1999-10-19|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 1998||1998-05-31|May 2015|2015-05-31|April 2006|Actual|2006-04-30|September 2004|Actual|2004-09-30||Interventional|||Randomized Study of Intensive One-on-one Behavioral Treatment for Preschool Aged Children With Autism|Randomized Study of Intensive One-on-one Behavioral Treatment Versus Individualized Parent Training in Preschool Aged Children With Autism|Completed||N/A|102|Actual|University of California, Los Angeles|||||f||||f||||||||||2018-06-01 05:40:41.720315|2018-06-01 05:40:41.720315
NCT00004448|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2008-09-08|1999-10-18|1999-10-19|Estimate|||||||2008-09-08|2008-09-10|Estimate|November 1997||1997-11-30|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy||Completed||Phase 2|123||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:41.788001|2018-06-01 05:40:41.788001
NCT00004446|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1998||1998-04-30|March 2005|2005-03-31||||||||Interventional|||Study of Fluoxetine in Patients With Depersonalization Disorder||Completed||N/A|80||National Institute of Mental Health (NIMH)|||||f||||||||||||||2018-06-01 05:40:41.860121|2018-06-01 05:40:41.860121
NCT00004445|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2013-07-31|1999-10-18|1999-10-19|Estimate|||||||2013-07-31|2013-08-01|Estimate|September 1996||1996-09-30|July 2013|2013-07-31||||September 2009|Actual|2009-09-30||Interventional|||Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord Injuries||Completed||N/A|17|Actual|Case Western Reserve University||1|||f||||||||||||||2018-06-01 05:40:41.944681|2018-06-01 05:40:41.944681
NCT00004444|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 1994||1994-11-30|February 2001|2001-02-28|January 2001||2001-01-31|||||Interventional|||Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis||Completed||N/A|24||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.043645|2018-06-01 05:40:42.043645
NCT00004443|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1998||1998-10-31|April 2000|2000-04-30|September 2006||2006-09-30|||||Interventional|||Study of NTBC for Tyrosinemia I||Completed||N/A|20|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.129501|2018-06-01 05:40:42.129501
NCT00004442|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate||||November 2000|2000-11-30|April 1999||1999-04-30|||||Interventional|||Study of Bile Acids in Patients With Peroxisomal Disorders||Terminated||N/A|25|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.192986|2018-06-01 05:40:42.192986
NCT00004441|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1997||1997-09-30|July 1998|1998-07-31|September 2001||2001-09-30|||||Interventional|||Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis||Completed||N/A|39|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.262503|2018-06-01 05:40:42.262503
NCT00004440|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1996||1996-08-31|April 2000|2000-04-30|June 1999||1999-06-30|||||Interventional|||Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis||Completed||N/A|75||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.325598|2018-06-01 05:40:42.325598
NCT00004438|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1997||1997-09-30|June 1998|1998-06-30|September 2002||2002-09-30|||||Interventional|||Leuprolide in Treating Adults With Hypogonadotropism|Study of Leuprolide in Adults With Hypogonadotropism|Completed||N/A|45|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.392707|2018-06-01 05:40:42.392707
NCT00004437|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1999||1999-10-31|January 2001|2001-01-31|October 2000||2000-10-31|||||Interventional|||Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2||Completed||Phase 2|||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.445456|2018-06-01 05:40:42.445456
NCT00004436|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 1993||1993-07-31|August 2000|2000-08-31|June 2000||2000-06-30|||||Interventional|||Randomized Study of Hormonal Regulation of Infantile Hemangioma||Completed||N/A|30||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.489704|2018-06-01 05:40:42.489704
NCT00004433|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|December 1994||1994-12-31|March 2000|2000-03-31|September 2002||2002-09-30|||||Interventional|||Randomized Study of Pergolide in Children With Tourette Syndrome||Completed||N/A|74||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.552158|2018-06-01 05:40:42.552158
NCT00004431|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 1998||1998-06-30|April 2000|2000-04-30|September 1999||1999-09-30|||||Interventional|||Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia||Completed||N/A|30|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.616973|2018-06-01 05:40:42.616973
NCT00004430|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1994||1994-09-30|August 2000|2000-08-31|September 1998||1998-09-30|||||Interventional|||Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization||Completed||N/A|150|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.710502|2018-06-01 05:40:42.710502
NCT00004429|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|December 1999||1999-12-31|October 2007|2007-10-31|February 2005|Actual|2005-02-28|||||Interventional|||Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis||Completed||N/A|25|Actual|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.77824|2018-06-01 05:40:42.77824
NCT00004428|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1997||1997-09-30|January 2000|2000-01-31|October 1999||1999-10-31|||||Interventional|||Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis||Completed||Phase 1|35||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.858774|2018-06-01 05:40:42.858774
NCT00004426|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-25|1999-10-18|1999-10-19|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 1994||1994-08-31|January 2000|2000-01-31|September 1998||1998-09-30|||||Interventional|||Leuprolide in Determining the Cause of Gonadotropin Deficiency|Study of Gonadotropin Releasing Hormone Agonist Test Using Leuprolide Acetate in Patients With Gonadotropin Deficiency|Completed||N/A|90|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.904312|2018-06-01 05:40:42.904312
NCT00004342|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1994||1994-06-30|December 2003|2003-12-31||||||||Observational|||International Registry for Severe Chronic Neutropenia||Unknown status|Recruiting||1000||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.21126|2018-06-01 05:40:48.21126
NCT00004424|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 1996||1996-07-31|April 2000|2000-04-30|March 2000||2000-03-31|||||Interventional|||Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy||Completed||N/A|120||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:42.958351|2018-06-01 05:40:42.958351
NCT00004423|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|December 1995||1995-12-31|January 2000|2000-01-31|March 1998||1998-03-31|||||Interventional|||Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease||Completed||N/A|80||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:43.004818|2018-06-01 05:40:43.004818
NCT00004422|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1997||1997-08-31|June 2000|2000-06-30|September 2002||2002-09-30|||||Interventional|||Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection||Completed||Phase 3|174||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:43.071586|2018-06-01 05:40:43.071586
NCT00004421|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1997||1997-09-30|March 2000|2000-03-31|September 2000||2000-09-30|||||Interventional|||Deep Brain Stimulation in Treating Patients With Dystonia|Phase II/III Study of Deep Brain Stimulation in Patients With Dystonia|Completed||Phase 2/Phase 3|15|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:43.11914|2018-06-01 05:40:43.11914
NCT00004420|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1994||1994-09-30|January 2000|2000-01-31|August 1999||1999-08-31|||||Interventional|||Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis||Completed||N/A|50||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:43.171947|2018-06-01 05:40:43.171947
NCT00004419|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 1998||1998-04-30|June 1999|1999-06-30|September 2000||2000-09-30|||||Interventional|||Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance||Completed||N/A|18|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:43.217939|2018-06-01 05:40:43.217939
NCT00004418|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2014-09-17|1999-10-18|1999-10-19|Estimate|||||||2014-09-17|2014-09-18|Estimate|April 1998||1998-04-30|September 2014|2014-09-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy|Study of Glyceryl Trierucate and Glyceryl Trioleate (Lorenzo's Oil) Therapy in Male Children With Adrenoleukodystrophy|Suspended||Phase 2/Phase 3|30|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1||No funding and moved to expanded access|f||||t||||||||||2018-06-01 05:40:44.181491|2018-06-01 05:40:44.181491
NCT00004416|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 1997||1997-01-31|April 2001|2001-04-30|March 2002||2002-03-31|||||Interventional|||Randomized Study of Botulinum Toxin Type A for Achalasia||Completed||N/A|56||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:44.284484|2018-06-01 05:40:44.284484
NCT00004415|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-04-06|1999-10-18|1999-10-19|Estimate|||||||2015-04-06|2015-04-07|Estimate|May 1991||1991-05-31|September 2002|2002-09-30|September 2000||2000-09-30|||||Interventional|||Study of Combined Intercostal and Diaphragm Pacing for Artificial Respiration in Quadriplegic Patients||Terminated||N/A|5||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:44.362599|2018-06-01 05:40:44.362599
NCT00004414|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1997||1997-09-30|May 1999|1999-05-31|June 2002||2002-06-30|||||Interventional|||Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis||Completed||N/A|252||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:44.440081|2018-06-01 05:40:44.440081
NCT00004412|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|2013-07-22||2015-03-18|1999-10-18|1999-10-19|Estimate|2015-03-18|2015-03-31|Estimate||||2015-03-18|2015-03-31|Estimate|September 1997||1997-09-30|March 2015|2015-03-31|February 2005|Actual|2005-02-28|December 2002|Actual|2002-12-31||Interventional|||Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers|Phase II Trial of Arginine Butyrate for Treatment of Refractory Leg Ulcers in Sickle Cell Disease or Beta Thalassemia|Completed||Phase 2|23|Actual|Boston University||3|||f||||f||||||||||2018-06-01 05:40:44.520029|2018-06-01 05:40:44.520029
NCT00004410|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 1998||1998-06-30|August 1998|1998-08-31|March 2002||2002-03-31|||||Interventional|||Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants||Completed||N/A|50|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:44.904033|2018-06-01 05:40:44.904033
NCT00004409|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 1995||1995-08-31|May 2001|2001-05-31|April 2004||2004-04-30|||||Interventional|||Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease||Completed||Phase 2|36|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.067284|2018-06-01 05:40:45.067284
NCT00004408|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2012-03-05|1999-10-18|1999-10-19|Estimate|||||||2012-03-05|2012-03-06|Estimate|November 1997||1997-11-30|March 2012|2012-03-31|November 1999|Actual|1999-11-30|||||Interventional|||Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease||Completed||Phase 3|300||Mast Therapeutics, Inc.|||||f||||||||||||||2018-06-01 05:40:45.151848|2018-06-01 05:40:45.151848
NCT00004407|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|February 1998||1998-02-28|January 2001|2001-01-31|March 2000||2000-03-31|||||Interventional|||Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy||Terminated||N/A|75||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.283101|2018-06-01 05:40:45.283101
NCT00004406|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 1999||1999-10-31|January 2000|2000-01-31|July 2004||2004-07-31|||||Interventional|||Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis||Completed||N/A|36|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.345851|2018-06-01 05:40:45.345851
NCT00004404|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 1997||1997-04-30|May 1998|1998-05-31|September 2002||2002-09-30|||||Interventional|||Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes||Completed||N/A|20|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.412158|2018-06-01 05:40:45.412158
NCT00004403|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2000||2000-05-31|January 2001|2001-01-31|March 2002||2002-03-31|||||Interventional|||Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis||Completed||N/A|120||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.487821|2018-06-01 05:40:45.487821
NCT00004402|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 1999||1999-11-30|January 2001|2001-01-31|June 2000||2000-06-30|||||Interventional|||Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis||Completed||Phase 3|30||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.544359|2018-06-01 05:40:45.544359
NCT00004401|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 1998||1998-01-31|March 2000|2000-03-31|June 1998||1998-06-30|||||Interventional|||Study of Human Botulism Immunoglobulin in Infants With Botulism||Completed||N/A|120|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.640787|2018-06-01 05:40:45.640787
NCT00004400|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 1997||1997-04-30|May 1998|1998-05-31|September 2001||2001-09-30|||||Interventional|||Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women||Completed||Phase 2|56|Anticipated|FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.723624|2018-06-01 05:40:45.723624
NCT00004399|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2015-03-24|1999-10-18|1999-10-19|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 1995||1995-09-30|January 2001|2001-01-31|August 2000||2000-08-31|||||Interventional|||Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia||Completed||N/A|2000||FDA Office of Orphan Products Development|||||f||||||||||||||2018-06-01 05:40:45.785713|2018-06-01 05:40:45.785713
NCT00004398|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1998||1998-01-31|June 2000|2000-06-30|May 2000||2000-05-31|||||Interventional|||Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria||Completed||Phase 1|24||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:45.842255|2018-06-01 05:40:45.842255
NCT00004397|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1998||1998-01-31|June 2000|2000-06-30|May 2000||2000-05-31|||||Interventional|||Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria||Completed||Phase 1|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:45.893573|2018-06-01 05:40:45.893573
NCT00004396|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1997||1997-09-30|December 2003|2003-12-31||||||||Interventional|||Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias||Completed||Phase 2|32||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:45.9439|2018-06-01 05:40:45.9439
NCT00004393|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1997||1997-07-31|March 2001|2001-03-31|September 2000||2000-09-30|||||Interventional|||Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome||Completed||Phase 2|50||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:45.998833|2018-06-01 05:40:45.998833
NCT00004392|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1994||1994-05-31|January 2000|2000-01-31|August 1999||1999-08-31|||||Observational|||Incidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for Sudden Infant Death Syndrome (SIDS)||Completed|||900||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.05454|2018-06-01 05:40:46.05454
NCT00004390|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1995||1995-02-28|February 2000|2000-02-29||||||||Interventional|||Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia||Completed||Phase 3|120||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.111282|2018-06-01 05:40:46.111282
NCT00004387|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1996||1996-01-31|July 2000|2000-07-31||||||||Interventional|||Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease||Completed||Phase 2|34||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.268394|2018-06-01 05:40:46.268394
NCT00004386|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1995||1995-10-31|January 2000|2000-01-31||||||||Interventional|||Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency||Terminated||Phase 1|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.318881|2018-06-01 05:40:46.318881
NCT00004382|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2008-09-08|1999-10-18|1999-10-19|Estimate|||||||2008-09-08|2008-09-09|Estimate|December 1999||1999-12-31|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns||Completed||Phase 2|80||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.372118|2018-06-01 05:40:46.372118
NCT00004381|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1999||1999-12-31|October 2003|2003-10-31||||||||Interventional|||Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia||Completed||Phase 2|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.427369|2018-06-01 05:40:46.427369
NCT00004380|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1991||1991-12-31|July 2004|2004-07-31|December 1997||1997-12-31|||||Interventional|||Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis||Completed||Phase 2|1||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.490061|2018-06-01 05:40:46.490061
NCT00004378|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1995||1995-01-31|April 2002|2002-04-30||||||||Interventional|||Stem Cell Transplantation (SCT) for Genetic Diseases||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:46.543421|2018-06-01 05:40:46.543421
NCT00004376|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1994||1994-09-30|March 2001|2001-03-31|June 2000||2000-06-30|||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder||Completed||Phase 3|35||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.610999|2018-06-01 05:40:46.610999
NCT00004375|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1991||1991-09-30|January 2004|2004-01-31||||||||Interventional|||Ultraviolet Light Therapy for Systemic Lupus Erythematosus||Unknown status|Recruiting|Phase 2|20||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:46.660746|2018-06-01 05:40:46.660746
NCT00004374|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1979||1979-01-31|December 2003|2003-12-31||||||||Observational|||Study of Systemic Amyloidosis Presentation and Prognosis|Study of Systemic Amyloidosis Presentation and Prognosis|Unknown status|Recruiting||100||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:46.724607|2018-06-01 05:40:46.724607
NCT00004373|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1997||1997-03-31|May 2003|2003-05-31|March 2001||2001-03-31|||||Interventional|||Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety||Completed||Phase 2|80||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.782657|2018-06-01 05:40:46.782657
NCT00004368|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1990||1990-05-31|October 2003|2003-10-31||||||||Interventional|||Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis||Unknown status|Active, not recruiting|Phase 1|15||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.864256|2018-06-01 05:40:46.864256
NCT00004367|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 2000||2000-05-31|December 2003|2003-12-31||||||||Interventional|||Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia||Completed||N/A|165||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:46.917402|2018-06-01 05:40:46.917402
NCT00004366|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1995||1995-08-31|June 2000|2000-06-30|May 2000||2000-05-31|||||Interventional|||Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction||Completed||N/A|20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:46.976212|2018-06-01 05:40:46.976212
NCT00004365|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|December 2003|2003-12-31|February 2000||2000-02-29|||||Observational|||Study of Pituitary Size and Function in Familial Dwarfism of Sindh||Completed|||4||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.026058|2018-06-01 05:40:47.026058
NCT00004364|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2006-02-21|1999-10-18|1999-10-19|Estimate|||||||2006-02-21|2006-02-22|Estimate|December 1995||1995-12-31|February 2006|2006-02-28||||||||Observational|||Study of Novel Types of Familial Diabetes Insipidus||Unknown status|Active, not recruiting||5||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.088473|2018-06-01 05:40:47.088473
NCT00004363|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1995||1995-12-31|December 2003|2003-12-31||||||||Observational|||Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:47.144143|2018-06-01 05:40:47.144143
NCT00004361|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1995||1995-07-31|January 2001|2001-01-31||||||||Observational|||Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects||Completed|||150||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.209639|2018-06-01 05:40:47.209639
NCT00004360|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|December 1999|1999-12-31||||||||Observational|||Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus||Completed|||||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.260749|2018-06-01 05:40:47.260749
NCT00004359|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1996||1996-02-29|January 2000|2000-01-31||||||||Interventional|||Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita||Completed||Phase 2|10||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.307814|2018-06-01 05:40:47.307814
NCT00004358|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1992||1992-11-30|December 2003|2003-12-31||||||||Interventional|||Phase II Study of Calcitonin for Tumoral Calcinosis||Completed||Phase 2|9||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:47.353935|2018-06-01 05:40:47.353935
NCT00004357|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2011-07-20|1999-10-18|1999-10-19|Estimate|||||||2011-07-20|2011-07-22|Estimate|September 1997||1997-09-30|July 2011|2011-07-31|February 2008|Actual|2008-02-29|December 2005|Actual|2005-12-31||Interventional|||Absorption of Corticosteroids in Children With Juvenile Dermatomyositis|Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis|Completed||Phase 2|6|Actual|Northwestern University|||||f||||f||||||||||2018-06-01 05:40:47.416314|2018-06-01 05:40:47.416314
NCT00004356|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1995||1995-02-28|December 2001|2001-12-31|October 2000||2000-10-31|||||Observational|||Study of Homocysteine Metabolism in Homocystinuria||Completed|||60||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.474692|2018-06-01 05:40:47.474692
NCT00004354|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1999||1999-06-30|May 2002|2002-05-31||||||||Observational|||Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:47.518178|2018-06-01 05:40:47.518178
NCT00004353|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2008-07-09|1999-10-18|1999-10-19|Estimate|||||||2008-07-09|2008-07-10|Estimate|December 1978||1978-12-31|April 2002|2002-04-30||||||||Observational|||Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia||Completed|||35|Anticipated|National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:47.56081|2018-06-01 05:40:47.56081
NCT00004351|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1999||1999-09-30|October 2003|2003-10-31||||||||Observational|||Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes||Completed|||20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.61317|2018-06-01 05:40:47.61317
NCT00004350|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|December 1999|1999-12-31||||||||Observational|||Evaluation of Fanconi Syndrome and Cystinosis||Completed|||12||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.744484|2018-06-01 05:40:47.744484
NCT00004348|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|January 2000|2000-01-31||||||||Observational|||Study of Protein Translocation in Patients With Beta-Oxidation Disorders||Unknown status|Active, not recruiting||20||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:47.796765|2018-06-01 05:40:47.796765
NCT00004347|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1995||1995-11-30|December 2003|2003-12-31||||||||Interventional|||Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome|The Effects of Dietary Cholesterol in the Smith-Lemli-Opitz Syndrome|Unknown status|Recruiting|Phase 2|5||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:47.858589|2018-06-01 05:40:47.858589
NCT00004346|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1996||1996-01-31|December 2003|2003-12-31||||||||Interventional|||Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis|Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)|Unknown status|Recruiting|Phase 2|5||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:47.917604|2018-06-01 05:40:47.917604
NCT00004345|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|July 2002|2002-07-31||||||||Observational|||Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome||Terminated|||100||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:47.986506|2018-06-01 05:40:47.986506
NCT00004344|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1997||1997-01-31|February 2000|2000-02-29||||||||Observational|||Purification of Testis-Stimulating Factor in Precocious Puberty||Completed|||4||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:48.061288|2018-06-01 05:40:48.061288
NCT00004343|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|December 2003|2003-12-31||||||||Observational|||Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome||Unknown status|Active, not recruiting||40||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.130735|2018-06-01 05:40:48.130735
NCT00004341|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1995||1995-07-31|October 2003|2003-10-31||||||||Observational|||Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders||Unknown status|Active, not recruiting||||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:48.290223|2018-06-01 05:40:48.290223
NCT00004340|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1995||1995-06-30|April 2002|2002-04-30||||||||Interventional|||Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis||Completed||Phase 2|109||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.375704|2018-06-01 05:40:48.375704
NCT00004339|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2006-05-08|1999-10-18|1999-10-19|Estimate|||||||2006-05-08|2006-05-09|Estimate|January 1994||1994-01-31|December 2003|2003-12-31||||||||Interventional|||Study of Tetrathiomolybdate in Patients With Wilson Disease||Completed||Phase 3|90||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.439844|2018-06-01 05:40:48.439844
NCT00004338|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1993||1993-10-31|December 2003|2003-12-31||||||||Interventional|||Study of Zinc for Wilson Disease||Completed||Phase 4|300||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.502479|2018-06-01 05:40:48.502479
NCT00004336|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1995||1995-10-31|April 2002|2002-04-30||||||||Observational|||Pilot Study of Familial Nonsyndromal Mondini Dysplasia||Completed|||2||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.617625|2018-06-01 05:40:48.617625
NCT00004335|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1993||1993-04-30|December 2003|2003-12-31||||||||Observational|||Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle||Completed|||||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.686806|2018-06-01 05:40:48.686806
NCT00004334|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1994||1994-07-31|December 2003|2003-12-31||||||||Observational|||Study of Depression, Peptides, and Steroids in Cushing's Syndrome||Unknown status|Recruiting||8||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.745971|2018-06-01 05:40:48.745971
NCT00004333|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1994||1994-11-30|July 2000|2000-07-31||||||||Interventional|||Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I||Completed||Phase 2|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:48.80591|2018-06-01 05:40:48.80591
NCT00004332|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1993||1993-05-31|January 2000|2000-01-31||||||||Observational|||Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly||Completed|||148||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:48.857877|2018-06-01 05:40:48.857877
NCT00004331|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1992||1992-11-30|December 2003|2003-12-31||||||||Observational|||Studies in Porphyria I: Characterization of Enzyme Defects||Unknown status|Recruiting||25||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.920271|2018-06-01 05:40:48.920271
NCT00004330|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1987||1987-03-31|December 2003|2003-12-31||||||||Interventional|||Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks||Completed||N/A|||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:48.994742|2018-06-01 05:40:48.994742
NCT00004329|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1999||1999-11-30|December 2003|2003-12-31||||||||Observational|||Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy||Completed|||12||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:49.047289|2018-06-01 05:40:49.047289
NCT00004328|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1992||1992-12-31|May 2000|2000-05-31||||||||Interventional|||Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I||Completed||Phase 2|1||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:49.121857|2018-06-01 05:40:49.121857
NCT00004327|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1995||1995-01-31|June 2000|2000-06-30||||||||Interventional|||Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia||Completed||Phase 2|8||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:49.298121|2018-06-01 05:40:49.298121
NCT00004326|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1994||1994-08-31|April 2002|2002-04-30||||||||Observational|||Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome||Completed|||12||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:49.422198|2018-06-01 05:40:49.422198
NCT00004325|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1988||1988-12-31|January 2004|2004-01-31||||||||Observational|||Study of the Neurobiology of Tourette Syndrome and Related Disorders||Completed|||200||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:49.541971|2018-06-01 05:40:49.541971
NCT00004324|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1989||1989-12-31|January 2004|2004-01-31||||||||Observational|||Developmental Phenomenology of Obsessive Compulsive Disorder and Tourette Syndrome in Children and Adolescents||Completed|||90||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:49.628082|2018-06-01 05:40:49.628082
NCT00004323|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1995||1995-02-28|April 2002|2002-04-30||||||||Interventional|||Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia||Completed||Phase 2|10||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:49.732842|2018-06-01 05:40:49.732842
NCT00004317|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2009-05-13|1999-10-18|1999-10-19|Estimate|||||||2009-05-13|2009-05-14|Estimate|July 2000||2000-07-31|May 2009|2009-05-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Interventional|||Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis|Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis|Recruiting||Phase 4|600|Anticipated|Office of Rare Diseases (ORD)||2|||f||||t||||||||||2018-06-01 05:40:49.962219|2018-06-01 05:40:49.962219
NCT00004316|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2008-09-08|1999-10-18|1999-10-19|Estimate|||||||2008-09-08|2008-09-09|Estimate|June 1995||1995-06-30|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis||Completed||Phase 1/Phase 2|139||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:50.131782|2018-06-01 05:40:50.131782
NCT00004284|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1995||1995-04-30|June 2000|2000-06-30||||||||Interventional|||Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria||Completed||Phase 3|300||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:52.01483|2018-06-01 05:40:52.01483
NCT00004315|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1995||1995-11-30|April 2002|2002-04-30||||||||Interventional|||Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease||Unknown status|Active, not recruiting|Phase 2|20||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:50.35842|2018-06-01 05:40:50.35842
NCT00004314|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1996||1996-02-29|January 2000|2000-01-31||||||||Interventional|||Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease||Completed||Phase 2|2||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:50.520556|2018-06-01 05:40:50.520556
NCT00004313|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1995||1995-08-31|January 2000|2000-01-31||||||||Interventional|||Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency||Completed||Phase 3|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:50.588248|2018-06-01 05:40:50.588248
NCT00004312|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|December 2003|2003-12-31||||||||Observational|||Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis||Completed|||400||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:50.64525|2018-06-01 05:40:50.64525
NCT00004311|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1989||1989-07-31|May 2000|2000-05-31|January 1996||1996-01-31|||||Interventional|||Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome||Completed||Phase 2|||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:50.801184|2018-06-01 05:40:50.801184
NCT00004310|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1999||1999-10-31|December 2003|2003-12-31||||||||Interventional|||Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder||Unknown status|Active, not recruiting|Phase 2|76||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:50.906709|2018-06-01 05:40:50.906709
NCT00004307|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1999||1999-12-31|December 2003|2003-12-31||||||||Interventional|||Study of Treatment and Metabolism in Patients With Urea Cycle Disorders|Therapeutic and Metabolic Studies of Urea Cycle Disorders: Part A: Nitrogen Flux and Ureagenesis; Part B (Closed): Phase I Adenovirus Vector-Mediated Gene Therapy for Ornithine Transcarbamylase Deficiency|Unknown status|Recruiting|Phase 1|66||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:50.97095|2018-06-01 05:40:50.97095
NCT00004306|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2012-03-05|1999-10-18|1999-10-19|Estimate|||||||2012-03-05|2012-03-06|Estimate|November 1999||1999-11-30|March 2012|2012-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)|Pathogenic Mechanism of Spinocerebellar Ataxia Type 10 (SCA10)|Completed|||18|Actual|Office of Rare Diseases (ORD)|||||f||||f||||||Samples With DNA|"~     DNA from blood and skin and muscle biopsy samples.~   "|||2018-06-01 05:40:51.042415|2018-06-01 05:40:51.042415
NCT00004305|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|January 1998||1998-01-31|April 2002|2002-04-30||||||||Observational|||Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis||Completed|||105||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:51.181777|2018-06-01 05:40:51.181777
NCT00004300|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2010-10-05|1999-10-18|1999-10-19|Estimate|||||||2010-10-05|2010-10-06|Estimate||||March 2006|2006-03-31||||||||Interventional|||Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis|Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis|Suspended||Phase 2|40||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:51.279422|2018-06-01 05:40:51.279422
NCT00004297|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1995||1995-11-30|December 2001|2001-12-31|February 1999||1999-02-28|||||Interventional|||Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus||Completed||Phase 3|210||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:51.393539|2018-06-01 05:40:51.393539
NCT00004296|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1995||1995-09-30|January 2000|2000-01-31||||||||Observational|||Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients||Completed|||1000||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:51.508722|2018-06-01 05:40:51.508722
NCT00004294|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1999||1999-11-30|December 2003|2003-12-31||||||||Interventional|||Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease||Completed||Phase 1|15||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:51.652027|2018-06-01 05:40:51.652027
NCT00004293|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1999||1999-11-30|December 2003|2003-12-31||||||||Interventional|||Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease||Unknown status|Recruiting|Phase 2|24||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:51.711556|2018-06-01 05:40:51.711556
NCT00004288|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|May 1996||1996-05-31|January 2000|2000-01-31|December 1999||1999-12-31|||||Interventional|||Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis||Completed||Phase 2|4||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:51.768898|2018-06-01 05:40:51.768898
NCT00004287|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1995||1995-11-30|January 2000|2000-01-31||||||||Interventional|||Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis||Completed||Phase 1|14||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:51.819384|2018-06-01 05:40:51.819384
NCT00004286|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1996||1996-02-29|January 2000|2000-01-31|November 1999||1999-11-30|||||Interventional|||Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy||Completed||Phase 3|120||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:51.869029|2018-06-01 05:40:51.869029
NCT00004285|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2017-09-13|1999-10-18|1999-10-19|Estimate|||||||2017-09-13|2017-09-14|Actual|March 1995|Actual|1995-03-31|September 2017|2017-09-30|December 31, 2001|Actual|2001-12-31|December 31, 2001|Actual|2001-12-31||Interventional|HEMO||Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis|Randomized Study of Standard vs High Amount of Hemodialysis Using Low vs High Flux Dialyzer Membranes for End Stage Renal Disease|Completed||N/A|1846|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||t|f|t|f|f||||Yes|Data and samples are available at the NIDDK central repository|2018-06-01 05:40:51.920234|2018-06-01 05:40:51.920234
NCT00004278|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1991||1991-12-31|July 2000|2000-07-31||||||||Interventional|||Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection||Completed||Phase 3|130||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:52.067605|2018-06-01 05:40:52.067605
NCT00004276|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1990||1990-09-30|December 2001|2001-12-31|June 1999||1999-06-30|||||Interventional|||Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections||Completed||Phase 2|50||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:52.11723|2018-06-01 05:40:52.11723
NCT00004275|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2008-09-08|1999-10-18|1999-10-19|Estimate|||||||2008-09-08|2008-09-10|Estimate|October 1999||1999-10-31|September 2008|2008-09-30||||August 2007|Actual|2007-08-31||Interventional|||Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome|Phase II Randomized Study of Oxandrolone vs Placebo for Growth Hormone-Treated Girls With Turner's Syndrome|Completed||Phase 2|80||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:52.204923|2018-06-01 05:40:52.204923
NCT00004274|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1990||1990-02-28|October 2003|2003-10-31||||||||Interventional|||Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome|Controlled Study of Estrogen Effects on Cognitive and Social Function in Girls With Turner's Syndrome|Completed||N/A|260||Office of Rare Diseases (ORD)|||||f||||||||||||||2018-06-01 05:40:52.258859|2018-06-01 05:40:52.258859
NCT00004268|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2005-06-23|1999-10-18|1999-10-19|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 2001||2001-04-30|April 2002|2002-04-30||||||||Interventional|||Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension||Completed||Phase 2|300||National Center for Research Resources (NCRR)|||||f||||||||||||||2018-06-01 05:40:52.319899|2018-06-01 05:40:52.319899
NCT00004266|ClinicalTrials.gov processed this data on May 31, 2018|1999-10-18|||2018-03-05|1999-10-18|1999-10-19|Estimate|||||||2018-03-05|2018-03-07|Actual|August 1993|Actual|1993-08-31|March 2018|2018-03-31|July 1999|Actual|1999-07-31|July 1999|Actual|1999-07-31||Interventional|||Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes|Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease|Completed||Phase 3|160|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f|||||t|f||||||||2018-06-01 05:40:52.376255|2018-06-01 05:40:52.376255
NCT00000170|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2014-03-05|1999-09-23|1999-09-24|Estimate|||||||2014-03-05|2014-03-06|Estimate|April 1999||1999-04-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|November 2001|Actual|2001-11-30||Interventional|||Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia|Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia|Completed||Phase 3|419|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-06-01 05:40:52.457099|2018-06-01 05:40:52.457099
NCT00000169|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1999||1999-04-30|June 2001|2001-06-30||||||||Observational|||The Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study||Unknown status|Recruiting||||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:52.543035|2018-06-01 05:40:52.543035
NCT00000168|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2015-06-10|1999-09-23|1999-09-24|Estimate|||||||2015-06-10|2015-06-12|Estimate|August 1998||1998-08-31|June 2015|2015-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|LSOCA||Longitudinal Study of Ocular Complications of AIDS (LSOCA)|Studies of Ocular Complications of AIDS (SOCA)|Completed|||2392|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||t||||||Samples With DNA|"~     Laboratory studies will include hematology serum chemistry and lymphocyte subset analysis for~     all patients. The amount of blood for hematology, serum chemistry, and lymphocyte subset~     analysis is restricted to no more than a total of 17 mL per draw. Data existing on HIV viral~     load analysis at the clinic will be collected. If HIV data are not available from medical~     records within the visit time window, blood should be collected for local HIV viral load~     determination.~   "|||2018-06-01 05:40:52.635806|2018-06-01 05:40:52.635806
NCT00000167|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2010-03-23|1999-09-23|1999-09-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|May 1999||1999-05-31|December 2007|2007-12-31|June 2006|Actual|2006-06-30|||||Interventional|CAPT||Complications of Age-Related Macular Degeneration Prevention Trial|Complications of Age-Related Macular Degeneration Prevention Trial (CAPT)|Completed||Phase 3|1052|Actual|National Eye Institute (NEI)||1|||f||||t||||||||||2018-06-01 05:40:52.760085|2018-06-01 05:40:52.760085
NCT00000163|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|December 1997||1997-12-31|September 2009|2009-09-30|July 2000||2000-07-31|||||Observational|||Congenital Esotropia Observational Study (CEOS)||Completed|||||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:52.870157|2018-06-01 05:40:52.870157
NCT00000162|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1977||1977-07-31|October 1999|1999-10-31||||||||Interventional|||Branch Vein Occlusion Study||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:52.92568|2018-06-01 05:40:52.92568
NCT00000161|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1993||1993-08-31|September 2001|2001-09-30||||||||Interventional|||Randomized Trials of Vitamin Supplements and Eye Disease||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:52.969383|2018-06-01 05:40:52.969383
NCT00000160|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-06-01|1999-09-23|1999-09-24|Estimate|||||||2006-06-01|2006-06-02|Estimate|January 1972||1972-01-31|October 2003|2003-10-31||||||||Interventional|||Diabetic Retinopathy Study (DRS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.030401|2018-06-01 05:40:53.030401
NCT00000159|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|August 1983||1983-08-31|October 1999|1999-10-31||||||||Interventional|||Sorbinil Retinopathy Trial (SRT)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.090193|2018-06-01 05:40:53.090193
NCT00000158|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1979||1979-02-28|June 2002|2002-06-30||||||||Interventional|||Macular Photocoagulation Study (MPS)||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.131096|2018-06-01 05:40:53.131096
NCT00000157|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|April 1982||1982-04-30|September 2009|2009-09-30|January 1988|Actual|1988-01-31|||||Interventional|||Randomized Trial of Aspirin and Cataracts in U.S. Physicians||Terminated||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.186757|2018-06-01 05:40:53.186757
NCT00000156|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-06-02|1999-09-23|1999-09-24|Estimate|||||||2006-06-02|2006-06-05|Estimate|July 1995||1995-07-31|October 2003|2003-10-31||||||||Interventional|||The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.228167|2018-06-01 05:40:53.228167
NCT00000155|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1995||1995-06-30|November 2001|2001-11-30||||||||Observational|||The Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study||Unknown status|Active, not recruiting||||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.278347|2018-06-01 05:40:53.278347
NCT00000153|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1984||1984-12-31|October 1999|1999-10-31||||||||Interventional|||Krypton-Argon Regression of Neovascularization Study (KARNS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.455924|2018-06-01 05:40:53.455924
NCT00000152|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1982||1982-04-30|September 2001|2001-09-30||||||||Interventional|||Randomized Trial of Beta-Carotene and Macular Degeneration||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.516247|2018-06-01 05:40:53.516247
NCT00000151|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-09-01|1999-09-23|1999-09-24|Estimate|||||||2006-09-01|2006-09-04|Estimate|December 1979||1979-12-31|October 2003|2003-10-31||||||||Interventional|||Early Treatment Diabetic Retinopathy Study (ETDRS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.579758|2018-06-01 05:40:53.579758
NCT00000150|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 1999||1999-01-31|September 2009|2009-09-30|September 2001||2001-09-30|||||Interventional|||Submacular Surgery Trials (SST)|Submacular Surgery Trials (SST)|Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.651584|2018-06-01 05:40:53.651584
NCT00000149|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1993||1993-10-31|June 2002|2002-06-30||||||||Interventional|||Collaborative Initial Glaucoma Treatment Study (CIGTS)||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.705802|2018-06-01 05:40:53.705802
NCT00000148|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-06-02|1999-09-23|1999-09-24|Estimate|||||||2006-06-02|2006-06-05|Estimate|April 1988||1988-04-30|October 2003|2003-10-31||||||||Interventional|||Advanced Glaucoma Intervention Study (AGIS)||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.774259|2018-06-01 05:40:53.774259
NCT00000147|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-05-26|1999-09-23|1999-09-24|Estimate|||||||2006-05-26|2006-05-29|Estimate|July 1988||1988-07-31|October 1999|1999-10-31||||||||Interventional|||Longitudinal Optic Neuritis Study (LONS)||Unknown status|Active, not recruiting|N/A|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.87191|2018-06-01 05:40:53.87191
NCT00000146|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-06-02|1999-09-23|1999-09-24|Estimate|||||||2006-06-02|2006-06-05|Estimate|July 1988||1988-07-31|October 2003|2003-10-31||||||||Interventional|||Optic Neuritis Treatment Trial (ONTT)||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:53.99226|2018-06-01 05:40:53.99226
NCT00000145|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-01-21|1999-09-23|1999-09-24|Estimate|||||||2009-01-21|2009-01-23|Estimate|September 1990||1990-09-30|January 2009|2009-01-31|December 2006|Actual|2006-12-31|October 2001|Actual|2001-10-31||Interventional|||Age-Related Eye Disease Study (AREDS)|Age-Related Eye Disease Study (AREDS)|Completed||Phase 3|4757|Actual|National Eye Institute (NEI)||4|||f||||t||||||||||2018-06-01 05:40:54.114079|2018-06-01 05:40:54.114079
NCT00000144|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-06-02|1999-09-23|1999-09-24|Estimate|||||||2006-06-02|2006-06-05|Estimate|January 1984||1984-01-31|October 2003|2003-10-31||||||||Interventional|||Glaucoma Laser Trial (GLT) Glaucoma Laser Trial Followup Study (GLTFS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:54.218702|2018-06-01 05:40:54.218702
NCT00000143|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|2015-07-01||2016-02-18|1999-09-23|1999-09-24|Estimate|2016-02-18|2016-03-14|Estimate||||2016-02-18|2016-03-14|Estimate|May 1997||1997-05-31|July 2015|2015-07-31|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|GCCRT||Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)|Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)|Completed||Phase 3|61|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||Yes||2018-06-01 05:40:54.445132|2018-06-01 05:40:54.445132
NCT00000142|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|2015-06-02||2015-10-14|1999-09-23|1999-09-24|Estimate|2015-10-14|2015-11-17|Estimate||||2015-10-14|2015-11-17|Estimate|April 1994||1994-04-30|July 2015|2015-07-31|February 1996|Actual|1996-02-29|February 1996|Actual|1996-02-29||Interventional|HPCRT||Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)|Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)|Completed||Phase 2/Phase 3|64|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-06-01 05:40:54.715761|2018-06-01 05:40:54.715761
NCT00000140|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|September 1985||1985-09-30|October 1999|1999-10-31||||||||Interventional|||The Silicone Study||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:54.937858|2018-06-01 05:40:54.937858
NCT00000139|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2010-03-23|1999-09-23|1999-09-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|October 1992||1992-10-31|September 2009|2009-09-30||||||||Interventional|||Herpetic Eye Disease Study (HEDS) II||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:54.984353|2018-06-01 05:40:54.984353
NCT00000138|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|May 1989||1989-05-31|September 2009|2009-09-30||||||||Interventional|||Herpetic Eye Disease Study (HEDS) I||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:55.055487|2018-06-01 05:40:55.055487
NCT00000137|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|May 1986||1986-05-31|September 2009|2009-09-30|September 1989|Actual|1989-09-30|||||Interventional|||Collaborative Corneal Transplantation Studies (CCTS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:55.108387|2018-06-01 05:40:55.108387
NCT00000136|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|2015-06-22||2015-09-22|1999-09-23|1999-09-24|Estimate|2015-09-22|2015-10-22|Estimate||||2015-09-22|2015-10-22|Estimate|March 1990||1990-03-31|July 2015|2015-07-31|October 1991|Actual|1991-10-31|October 1991|Actual|1991-10-31||Interventional|FGCRT||Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)|Foscarnet-Ganciclovir CMV Retinitis Trial|Completed||Phase 3|234|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-06-01 05:40:55.164376|2018-06-01 05:40:55.164376
NCT00000135|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|2015-06-12||2015-10-14|1999-09-23|1999-09-24|Estimate|2015-10-14|2015-11-17|Estimate||||2015-10-14|2015-11-17|Estimate|September 1995||1995-09-30|July 2015|2015-07-31|August 1996|Actual|1996-08-31|August 1996|Actual|1996-08-31||Interventional|MACRT||Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)|Monoclonal Antibody CMV Retinitis Trial (MACRT)|Completed||Phase 2/Phase 3|209|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-06-01 05:40:55.355438|2018-06-01 05:40:55.355438
NCT00000134|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|2015-06-15||2015-08-11|1999-09-23|1999-09-24|Estimate|2015-08-11|2015-09-14|Estimate||||2015-08-11|2015-09-14|Estimate|December 1992||1992-12-31|August 2015|2015-08-31|March 1995|Actual|1995-03-31|March 1995|Actual|1995-03-31||Interventional|CRRT||Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)|Cytomegalovirus Retinitis Retreatment Trial|Completed||Phase 3|279|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-06-01 05:40:55.562645|2018-06-01 05:40:55.562645
NCT00000133|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2014-02-03|1999-09-23|1999-09-24|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 1986||1986-01-31|October 2003|2003-10-31|August 2003|Actual|2003-08-31|||||Interventional|||Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity||Completed||N/A|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:55.777355|2018-06-01 05:40:55.777355
NCT00000132|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|October 1992||1992-10-31|October 2001|2001-10-31||||||||Interventional|||Early Manifest Glaucoma Trial (EMGT)||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:55.853835|2018-06-01 05:40:55.853835
NCT00000131|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|August 1988||1988-08-31|September 2009|2009-09-30|February 1994|Actual|1994-02-28|||||Interventional|||Central Vein Occlusion Study (CVOS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:55.902641|2018-06-01 05:40:55.902641
NCT00000130|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|February 1990||1990-02-28|September 2009|2009-09-30|January 1995|Actual|1995-01-31|||||Interventional|||Endophthalmitis Vitrectomy Study (EVS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:55.949333|2018-06-01 05:40:55.949333
NCT00000129|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|April 1981||1981-04-30|September 2009|2009-09-30|October 1983|Actual|1983-10-31|||||Interventional|||Prospective Evaluation of Radial Keratotomy (PERK) Study||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:57.567698|2018-06-01 05:40:57.567698
NCT00000128|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1996||1996-06-30|June 2002|2002-06-30||||||||Interventional|||A Trial of Bifocals in Myopic Children With Esophoria||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:59.13985|2018-06-01 05:40:59.13985
NCT00000127|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2010-03-23|1999-09-23|1999-09-24|Estimate|||||||2010-03-23|2010-03-24|Estimate|October 1992||1992-10-31|September 2009|2009-09-30|October 1994|Actual|1994-10-31|||||Interventional|||Ischemic Optic Neuropathy Decompression Trial (IONDT)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:40:59.832999|2018-06-01 05:40:59.832999
NCT00000126|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-05-25|1999-09-23|1999-09-24|Estimate|||||||2006-05-25|2006-05-26|Estimate|October 1994||1994-10-31|October 2003|2003-10-31||||||||Observational|||Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)||Unknown status|Active, not recruiting||||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:00.260474|2018-06-01 05:41:00.260474
NCT00000125|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|2015-03-06||2016-12-15|1999-09-23|1999-09-24|Estimate|2015-03-06|2015-03-19|Estimate||||2016-12-15|2016-12-16|Estimate|February 1994||1994-02-28|December 2016|2016-12-31|March 2020|Anticipated|2020-03-31|June 2002|Actual|2002-06-30||Interventional|OHTS|1636 ocular hypertensive patients were randomized to either close observation or ocular hypertensive medication.|Ocular Hypertension Treatment Study (OHTS)|Ocular Hypertension Treatment Study (OHTS)|Active, not recruiting||Phase 3|1636|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-06-01 05:41:00.541723|2018-06-01 05:41:00.541723
NCT00000124|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2006-06-01|1999-09-23|1999-09-24|Estimate|||||||2006-06-01|2006-06-02|Estimate|November 1986||1986-11-30|June 2002|2002-06-30||||||||Interventional|||Collaborative Ocular Melanoma Study (COMS)||Unknown status|Active, not recruiting|Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.130227|2018-06-01 05:41:01.130227
NCT00000123|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 1978||1978-01-31|September 2009|2009-09-30|February 1979|Actual|1979-02-28|||||Interventional|||The Berkeley Orthokeratology Study||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.310949|2018-06-01 05:41:01.310949
NCT00000122|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|September 1985||1985-09-30|September 2009|2009-09-30|June 1988|Actual|1988-06-30|||||Interventional|||Fluorouracil Filtering Surgery Study (FFSS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.395072|2018-06-01 05:41:01.395072
NCT00000121|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|March 1984||1984-03-31|September 2009|2009-09-30|May 1989|Actual|1989-05-31|||||Interventional|||The Prism Adaptation Study (PAS)||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.53838|2018-06-01 05:41:01.53838
NCT00000120|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|January 1985||1985-01-31|September 2009|2009-09-30||||||||Interventional|||Clinical Trial of Eye Prophylaxis in the Newborn||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.612358|2018-06-01 05:41:01.612358
NCT00000119|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2005-06-23|1999-09-23|1999-09-24|Estimate|||||||2005-06-23|2005-06-24|Estimate|March 1994||1994-03-31|September 1999|1999-09-30||||||||Interventional|||Safety and Efficacy of a Heparin-Coated Intraocular Lens in Uveitis||Unknown status|Active, not recruiting|Phase 2|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.685014|2018-06-01 05:41:01.685014
NCT00000118|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|October 1992||1992-10-31|September 2009|2009-09-30|December 1993|Actual|1993-12-31|||||Interventional|||Ganciclovir Implant Study for Cytomegalovirus Retinitis||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.747127|2018-06-01 05:41:01.747127
NCT00000117|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|August 1995||1995-08-31|September 2009|2009-09-30|December 1997|Actual|1997-12-31|||||Interventional|||Intravenous Immunoglobulin Therapy in Optic Neuritis||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.797345|2018-06-01 05:41:01.797345
NCT00000116|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|May 1996||1996-05-31|September 2009|2009-09-30|September 1997||1997-09-30|||||Interventional|||Randomized Trial for Retinitis Pigmentosa|Randomized Trial for Retinitis Pigmentosa|Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.879569|2018-06-01 05:41:01.879569
NCT00000115|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|December 1990||1990-12-31|September 2009|2009-09-30|June 1994|Actual|1994-06-30|||||Interventional|||Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema||Completed||Phase 2|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.946794|2018-06-01 05:41:01.946794
NCT00000114|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2009-09-16|1999-09-23|1999-09-24|Estimate|||||||2009-09-16|2009-09-17|Estimate|May 1984||1984-05-31|September 2009|2009-09-30|June 1987|Actual|1987-06-30|||||Interventional|||Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa||Completed||Phase 3|||National Eye Institute (NEI)|||||f||||||||||||||2018-06-01 05:41:01.995144|2018-06-01 05:41:01.995144
NCT00000113|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-23|||2016-04-14|1999-09-23|1999-09-24|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 1997||1997-09-30|April 2016|2016-04-30|September 2013|Actual|2013-09-30|October 2001|Actual|2001-10-31||Interventional|||Correction of Myopia Evaluation Trial (COMET)|Correction of Myopia Evaluation Trial (COMET)|Completed||Phase 3|469|Actual|Stony Brook University||2|||f||||t||||||||||2018-06-01 05:41:02.077726|2018-06-01 05:41:02.077726
NCT00000358|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||December 2002|2002-12-31||||||||Interventional|||Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7|Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.155598|2018-06-01 05:41:02.155598
NCT00000357|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 1992||1992-06-30|December 1993|1993-12-31|October 1993|Actual|1993-10-31|August 1993|Actual|1993-08-31||Interventional|||Buprenorphine Maintenance for Opiate Dependence - 6|Buprenorphine Maintenance for Opiate Dependence|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.199836|2018-06-01 05:41:02.199836
NCT00000356|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 1991||1991-06-30|February 1992|1992-02-29|October 1992|Actual|1992-10-31|August 1992|Actual|1992-08-31||Interventional|||Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5|Pharmacokinetics of LAAM in Methadone Patients|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.269171|2018-06-01 05:41:02.269171
NCT00000355|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1994||1994-11-30|May 1995|1995-05-31|March 1996|Actual|1996-03-31|January 1996|Actual|1996-01-31||Interventional|||Effects of Buprenorphine and Naloxone in Opiate Addicts - 4|Effects of Buprenophine and Naloxone in Opiate Addicts|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.374406|2018-06-01 05:41:02.374406
NCT00000354|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 1996||1996-07-31|July 1996|1996-07-31|December 1997|Actual|1997-12-31|September 1997|Actual|1997-09-30||Interventional|||Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3|Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.552875|2018-06-01 05:41:02.552875
NCT00000353|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-17|1999-09-20|1999-09-21|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 1996||1996-10-31|December 2002|2002-12-31|October 1997|Actual|1997-10-31|September 1997|Actual|1997-09-30||Interventional|||Trial of Buprenorphine/Naloxone for Opiate Dependence - 2|Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.618661|2018-06-01 05:41:02.618661
NCT00000352|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 1996||1996-12-31|August 1997|1997-08-31|April 1998|Actual|1998-04-30|February 1998|Actual|1998-02-28||Interventional|||Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1|Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.710528|2018-06-01 05:41:02.710528
NCT00000351|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-10|1999-09-20|1999-09-21|Estimate|||||||2017-01-10|2017-01-11|Estimate||||December 2002|2002-12-31||||||||Observational|||Cognitive Correlates of Substance Abuse, Part 2 - 16|Cognitive Correlates of Substance Abuse, Part 2|Unknown status|Active, not recruiting||43||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.773407|2018-06-01 05:41:02.773407
NCT00000350|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-10|1999-09-20|1999-09-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 1999||1999-03-31|March 1999|1999-03-31||||||||Interventional|||Effects of Stimulant Dependence on Human Striatal Dopamine System - 15|Effects of Stimulant Dependence on Human Striatal Dopamine System|Unknown status|Active, not recruiting|Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.826094|2018-06-01 05:41:02.826094
NCT00000349|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-10|1999-09-20|1999-09-21|Estimate|||||||2017-01-10|2017-01-11|Estimate||||December 2002|2002-12-31||||||||Interventional|||Infusion Laboratory: Protocol 5 (Flupenthixol) - 14|Infusion Laboratory: Protocol 5 (Flupenthixol)|Unknown status|Active, not recruiting|Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.89118|2018-06-01 05:41:02.89118
NCT00000348|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-10|1999-09-20|1999-09-21|Estimate|||||||2017-01-10|2017-01-11|Estimate||||December 2002|2002-12-31||||||||Interventional|||Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13|Infusion Laboratory: Protocol 4 (Dihydrexidine)|Unknown status|Active, not recruiting|Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:02.964061|2018-06-01 05:41:02.964061
NCT00000347|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 1997||1997-07-31|March 1998|1998-03-31|September 1998|Actual|1998-09-30|August 1998|Actual|1998-08-31||Interventional|||Risperidone for Treatment of Cocaine Dependence in Outpatients - 12|Risperidone for Treatment of Cocaine Dependence in Outpatients|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.04727|2018-06-01 05:41:03.04727
NCT00000346|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-10|1999-09-20|1999-09-21|Estimate|||||||2017-01-10|2017-01-11|Estimate||||December 2002|2002-12-31||||||||Interventional|||Cognitive Correlates of Substance Abuse - 11|Cognitive Correlates of Substance Abuse, Part 1|Unknown status|Active, not recruiting|Phase 4|80||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.120126|2018-06-01 05:41:03.120126
NCT00000345|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 1996||1996-04-30|September 1997|1997-09-30||||||||Interventional|||Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10|Evaluation of Lofexidine for Treatment of Opiate Withdrawal|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.187042|2018-06-01 05:41:03.187042
NCT00000344|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||August 2008|2008-08-31|August 2000|Actual|2000-08-31|||||Interventional|||Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9|Trial of Buprenorphine/Naloxone for Treatment of Opiate Dependence|Completed||Phase 2|40||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.295287|2018-06-01 05:41:03.295287
NCT00000343|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 1996||1996-04-30|April 1996|1996-04-30||||||||Interventional|||Brain Changes in Stimulant Dependent Subjects - 8|Brain Changes in Stimulant Dependent Subjects|Completed||Phase 4|90||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.374362|2018-06-01 05:41:03.374362
NCT00000342|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-13|1999-09-20|1999-09-21|Estimate|||||||2017-01-13|2017-01-16|Estimate|July 1996||1996-07-31|June 1997|1997-06-30|September 1997|Actual|1997-09-30|August 1997|Actual|1997-08-31||Interventional|||Risperidone for the Treatment of Cocaine Dependence - 7|Risperidone for the Treatment of Cocaine Dependence|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.445008|2018-06-01 05:41:03.445008
NCT00000341|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1996||1996-08-31|August 2008|2008-08-31|August 2000|Actual|2000-08-31|||||Interventional|||Evaluation of Liquid vs. Tablet Buprenorphine - 6|Pharmacokinetics and Bioavailability of Liquid vs Tablet Buprenorphine|Completed||Phase 2|1||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.519416|2018-06-01 05:41:03.519416
NCT00000340|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 1996||1996-06-30|August 2008|2008-08-31||||||||Interventional|||Pemoline in the Treatment of Stimulant Dependence - 5|Pemoline in the Treatment of Stimulant Dependence|Withdrawn||Phase 2|0|Actual|National Institute on Drug Abuse (NIDA)||||Study was never funded.|f||||||||||||||2018-06-01 05:41:03.578586|2018-06-01 05:41:03.578586
NCT00000339|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-10|1999-09-20|1999-09-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 1996||1996-06-30|June 1996|1996-06-30||||||||Interventional|||Infusion Laboratory: Protocol 3 (Risperidone) - 4|Infusion Laboratory: Protocol 3 (Risperidone)|Unknown status|Active, not recruiting|Phase 1|13||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.653662|2018-06-01 05:41:03.653662
NCT00000338|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-10|1999-09-20|1999-09-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 1996||1996-03-31|March 1996|1996-03-31||||||||Interventional|||Infusion Laboratory: Protocol 2 (Lisuride) - 3|Infusion Laboratory: Protocol 2 (Lisuride)|Unknown status|Active, not recruiting|Phase 1|2||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.711431|2018-06-01 05:41:03.711431
NCT00000337|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1994||1994-11-30|August 1996|1996-08-31||||||||Interventional|||Infusion Laboratory: Protocol 1 - Selegeline - 2|Infusion Laboratory: Protocol 1 - Selegeline|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.769641|2018-06-01 05:41:03.769641
NCT00000336|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-13|1999-09-20|1999-09-21|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 1995||1995-01-31|January 1996|1996-01-31|March 1996|Actual|1996-03-31|February 1996|Actual|1996-02-29||Interventional|||Selegiline in Outpatient Treatment for Cocaine Dependence - 1|Safety and Efficacy of Selegiline in Outpatient Treatment for Cocaine|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.830351|2018-06-01 05:41:03.830351
NCT00000335|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-30|1999-09-20|1999-09-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 30, 1995|Actual|1995-09-30|December 2002|2002-12-31|May 20, 1996|Actual|1996-05-20|March 20, 1996|Actual|1996-03-20||Interventional|||Activity Monitoring Assessment of Opiate Withdrawal - 4|Activity Monitoring Assessment of Opiate Withdrawal|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.894725|2018-06-01 05:41:03.894725
NCT00000334|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-30|1999-09-20|1999-09-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 1, 2002|Actual|2002-12-01|December 2002|2002-12-31|January 15, 2005|Actual|2005-01-15|November 1, 2004|Actual|2004-11-01||Interventional|||Comparison of Buprenorphine and Methadone - 3|Pharmacological Comparison of Buprenorphine and Methadone|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:03.949698|2018-06-01 05:41:03.949698
NCT00000333|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-02-23|1999-09-20|1999-09-21|Estimate|||||||2017-02-23|2017-02-24|Actual|May 2001|Actual|2001-05-31|December 2002|2002-12-31|April 2003|Actual|2003-04-30|January 2003|Actual|2003-01-31||Interventional|||Evaluation of Benztropine for Cocaine Craving - 2|Evaluation of Efficacy of Benztropine for Cocaine Craving|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f|||||t|||||||||2018-06-01 05:41:03.996034|2018-06-01 05:41:03.996034
NCT00000332|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-02-23|1999-09-20|1999-09-21|Estimate|||||||2017-02-23|2017-02-24|Actual|May 1998|Actual|1998-05-31|December 2002|2002-12-31|April 2000|Actual|2000-04-30|January 2000|Actual|2000-01-31||Interventional|||High Dose Nimodipine Treatment Adjunct - 1|High Dose Nimodipine Pharmacotherapy Adjunct|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f|||||t|f||||||||2018-06-01 05:41:04.043601|2018-06-01 05:41:04.043601
NCT00000331|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-05-02|1999-09-20|1999-09-21|Estimate|||||||2017-05-02|2017-05-04|Actual|December 2002||2002-12-31|May 2017|2017-05-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver||2|||f||||||||||||||2018-06-01 05:41:04.177009|2018-06-01 05:41:04.177009
NCT00000330|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-05-02|1999-09-20|1999-09-21|Estimate|||||||2017-05-02|2017-05-04|Actual|October 1999||1999-10-31|May 2017|2017-05-31|November 1999|Actual|1999-11-30|November 1999|Actual|1999-11-30||Interventional|||Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver|||||f||||||||||||||2018-06-01 05:41:04.252812|2018-06-01 05:41:04.252812
NCT00000329|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-05-02|1999-09-20|1999-09-21|Estimate|||||||2017-05-02|2017-05-04|Actual|April 1999||1999-04-30|May 2017|2017-05-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver|||||f||||||||||||||2018-06-01 05:41:04.331784|2018-06-01 05:41:04.331784
NCT00000328|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-05-02|1999-09-20|1999-09-21|Estimate|||||||2017-05-02|2017-05-04|Actual|July 1997||1997-07-31|May 2017|2017-05-31|August 1997|Actual|1997-08-31|August 1997|Actual|1997-08-31||Interventional|||Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver|||||f|||||f|f||||||||2018-06-01 05:41:04.410467|2018-06-01 05:41:04.410467
NCT00000327|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-05-02|1999-09-20|1999-09-21|Estimate|||||||2017-05-02|2017-05-04|Actual|June 1997||1997-06-30|May 2017|2017-05-31|August 1997|Actual|1997-08-31|August 1997|Actual|1997-08-31||Interventional|||Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2)|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver|||||f||||||||||||||2018-06-01 05:41:04.492265|2018-06-01 05:41:04.492265
NCT00000326|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-05-02|1999-09-20|1999-09-21|Estimate|||||||2017-05-02|2017-05-04|Actual|April 1997||1997-04-30|May 2017|2017-05-31|August 1997|Actual|1997-08-31|August 1997|Actual|1997-08-31||Interventional|||Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1|Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1(1)|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver|||||f||||||||||||||2018-06-01 05:41:04.564447|2018-06-01 05:41:04.564447
NCT00000325|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||December 2002|2002-12-31|December 2001||2001-12-31|||||Interventional|||Psychostimulant Abuse - Novel Treatment Approaches - 1|Psychostimulant Abuse - Novel Treatment Approaches|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:04.637752|2018-06-01 05:41:04.637752
NCT00000324|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 1997||1997-03-31|August 2005|2005-08-31|April 2001||2001-04-30|||||Interventional|||Tryptophan and Behavior Therapy for Cocaine Abuse - 1|Tryptophan and Behavior Therapy for Cocaine Abuse|Completed||Phase 2|200||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:41:04.697425|2018-06-01 05:41:04.697425
NCT00000323|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 1996||1996-07-31|May 2004|2004-05-31|December 1998||1998-12-31|||||Observational|||Therapeutic Potential of Kappa-Opioids Against Cocaine - 1|Therapeutic Potential of Kappa-Opioids Against Cocaine|Completed|||10||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:04.766667|2018-06-01 05:41:04.766667
NCT00000322|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 1997||1997-04-30|April 1997|1997-04-30|December 2001||2001-12-31|||||Interventional|||Tyrosine for Methamphetamine Dependence - 1|Tyrosine for Methamphetamine Dependence|Completed||Phase 2|89||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:04.838761|2018-06-01 05:41:04.838761
NCT00000321|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 1996||1996-10-31|October 1996|1996-10-31|December 2001||2001-12-31|||||Interventional|||Methamphetamine Abuse Treatment in Patients With AIDS - 1|Methamphetamine Abuse Pharmacology in Patients With AIDS|Completed||Phase 4|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:04.904329|2018-06-01 05:41:04.904329
NCT00000320|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 1997||1997-10-31|January 2009|2009-01-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1|Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution|Completed||Phase 1/Phase 2|120|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 05:41:04.968959|2018-06-01 05:41:04.968959
NCT00000319|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|June 1996||1996-06-30|June 1996|1996-06-30||||||||Interventional|||Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2|Buprenorphine Maintenance Dose Schedule and Treatment Setting|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.058499|2018-06-01 05:41:05.058499
NCT00000318|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 1994||1994-12-31|December 2008|2008-12-31|August 2007|Actual|2007-08-31|March 2004|Actual|2004-03-31||Interventional|||Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1|Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot|Completed||Phase 2|202|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-06-01 05:41:05.116321|2018-06-01 05:41:05.116321
NCT00000317|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-06-22|1999-09-20|1999-09-21|Estimate|||||||2017-06-22|2017-06-26|Actual|August 1996|Actual|1996-08-31|June 2017|2017-06-30|July 1999|Actual|1999-07-31|July 1999|Actual|1999-07-31||Interventional|||Early Phase II Trials for Cocaine Medication Development - 1|Early Phase II Trials for Cocaine Medication Development|Completed||Phase 2|31|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-06-01 05:41:05.190064|2018-06-01 05:41:05.190064
NCT00000316|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1996||1996-08-31|August 1996|1996-08-31|December 2001||2001-12-31|||||Interventional|||Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2|Human Dopamine Transported Imaging in Cocaine Abuse: 2|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.291337|2018-06-01 05:41:05.291337
NCT00000315|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1996||1996-11-30|November 1996|1996-11-30|December 2001||2001-12-31|||||Interventional|||Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1|Human Dopamine Transported Imaging in Cocaine Abuse: 1|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.354195|2018-06-01 05:41:05.354195
NCT00000314|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-17|1999-09-20|1999-09-21|Estimate|||||||2017-01-17|2017-01-18|Estimate|September 1994||1994-09-30|December 2002|2002-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||M-CPP and Fenfluramine in Cocaine Addicts - 3|To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.468823|2018-06-01 05:41:05.468823
NCT00000313|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||December 2002|2002-12-31||||||||Interventional|||Predictive Values of Serotonergic Alterations for Outcome - 2|Predictive Values of Serotonergic Alterations for Outcome|Terminated||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.521636|2018-06-01 05:41:05.521636
NCT00000312|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate||||December 2002|2002-12-31||||||||Interventional|||Alterations in Serotonergic Functions in Cocaine Addicts - 1|Alterations in Serotonergic Functions in Cocaine Addicts|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.577981|2018-06-01 05:41:05.577981
NCT00000311|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2018-01-12|1999-09-20|1999-09-21|Estimate|||||||2018-01-12|2018-01-17|Actual|February 1995||1995-02-28|January 2018|2018-01-31|February 1999|Actual|1999-02-28|February 1999|Actual|1999-02-28||Interventional|||Combining Behavioral Treatment With Agonist Maintenance - 1|Combining Behavioral Treatment With Agonist Maintenance|Completed||Phase 3|168|Actual|Yale University||4|||f|||||f|f||||||||2018-06-01 05:41:05.63383|2018-06-01 05:41:05.63383
NCT00000310|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-13|1999-09-20|1999-09-21|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 1996||1996-01-31|January 1996|1996-01-31|March 1996|Actual|1996-03-31|March 1996|Actual|1996-03-31||Interventional|||Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2|Serotonin/Dopamine Antagonism of Cocaine Effect|Terminated||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.704767|2018-06-01 05:41:05.704767
NCT00000309|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-07-23|1999-09-20|1999-09-21|Estimate|||||||2015-07-23|2015-07-24|Estimate|August 1994||1994-08-31|July 2015|2015-07-31|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1|Serotonin/Dopamine Antagonism of Cocaine Effect|Terminated||Phase 2|0||Butler Hospital||||Unable to recruit adequate number of subjects|f||||||||||||||2018-06-01 05:41:05.756876|2018-06-01 05:41:05.756876
NCT00000308|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 1995||1995-09-30|October 2016|2016-10-31|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Dextroamphetamine-Cocaine Behavioral Intervention - 5|D-amphetamine-Cocaine Behavioral Intervention|Completed||Phase 2|54|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 05:41:05.826242|2018-06-01 05:41:05.826242
NCT00000307|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2003||2003-04-30|October 2016|2016-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4|Naltrexone as an Adjunct in Alcoholic Cocaine Dependent Patients|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:41:05.88244|2018-06-01 05:41:05.88244
NCT00000306|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 1994||1994-09-30|October 2016|2016-10-31|September 2001||2001-09-30|||||Interventional|||Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3|Dextroamphetamine as an Adjunct in Cocaine/Opiate Dependent Patients|Completed||Phase 2|140||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:05.930844|2018-06-01 05:41:05.930844
NCT00000305|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2012-05-17|1999-09-20|1999-09-21|Estimate|||||||2012-05-17|2012-05-18|Estimate||||May 2012|2012-05-31||||||||Interventional|||Amphetamine Cocaine Interaction Study - 2|Amphetamine Cocaine Interaction Study|Terminated||Phase 1|0||The University of Texas Health Science Center, Houston||||Original P.I. left the institution|f||||t||||||||||2018-06-01 05:41:05.984638|2018-06-01 05:41:05.984638
NCT00000304|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1997||1997-08-31|October 2016|2016-10-31|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Dextroamphetamine as an Adjunct in Cocaine Treatment - 1|Dextroamphetamine as an Adjunct in Cocaine Treatment|Completed||Phase 2|120|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-06-01 05:41:06.033458|2018-06-01 05:41:06.033458
NCT00000303|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-07-07|1999-09-20|1999-09-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 1997||1997-10-31|July 2016|2016-07-31||||May 1999|Actual|1999-05-31||Interventional|||Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6|Rapid Evaluation of Cocaine Pharmacotherapies (Baclofen)|Completed||Phase 2|0||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:41:06.184431|2018-06-01 05:41:06.184431
NCT00000302|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-11-03|1999-09-20|1999-09-21|Estimate|||||||2005-11-03|2005-11-07|Estimate||||December 2002|2002-12-31||||||||Interventional|||Study Comparing Liquid and Tablet Buprenorphine Formulations - 5|Expanded Steady-State Pharmacokinetic Study, Comparing Liquid and Tablet Buprenorphine Formulations|Completed||Phase 3|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.246409|2018-06-01 05:41:06.246409
NCT00000301|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-07-07|1999-09-20|1999-09-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|March 1996||1996-03-31|July 2016|2016-07-31||||June 1998|Actual|1998-06-30||Interventional|||Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4|Rapid Evaluation of Cocaine Pharmacotherapies (Amantadine)|Completed||Phase 2|0||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:41:06.308066|2018-06-01 05:41:06.308066
NCT00000300|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-10-31|1999-09-20|1999-09-21|Estimate|||||||2017-10-31|2017-11-01|Actual|March 1995||1995-03-31|March 1995|1995-03-31||||||||Interventional|||Feasibility Study of Take-Home LAAM Medication - 3|Feasibility Study of Take-Home LAAM Medication|Completed||Phase 4|0||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:41:06.376322|2018-06-01 05:41:06.376322
NCT00000299|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-01-27|1999-09-20|1999-09-21|Estimate|||||||2016-01-27|2016-01-29|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2|Rapid Opiate Detoxification & Naltrexone Induction Using Bup.|Completed||Phase 2|12|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-06-01 05:41:06.442256|2018-06-01 05:41:06.442256
NCT00000298|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|August 1995||1995-08-31|January 1996|1996-01-31||||||||Interventional|||Buprenorphine Combination Tablet Feasibility - 1|Buprenorphine Combination Tablet Feasibility|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.514211|2018-06-01 05:41:06.514211
NCT00000297|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 1998||1998-10-31|October 1998|1998-10-31|December 2001||2001-12-31|||||Interventional|||Effects of Labetalol on Nicotine Administration in Humans - 14|Effects of Labetalol on Nicotine Administration in Humans|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.577257|2018-06-01 05:41:06.577257
NCT00000296|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1997||1997-11-30|February 1999|1999-02-28|December 2001||2001-12-31|||||Interventional|||Role of Metabolites in Nicotine Dependence (4) - 13|Role of Metabolites in Nicotine Dependence (4)|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.641292|2018-06-01 05:41:06.641292
NCT00000295|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 1999||1999-04-30|April 1999|1999-04-30|December 2001||2001-12-31|||||Interventional|||Progesterone Treatment in Female Smokers - 12|Progesterone Treatment in Female Smokers|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.71618|2018-06-01 05:41:06.71618
NCT00000294|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 1998||1998-09-30|March 1999|1999-03-31|December 2001||2001-12-31|||||Interventional|||Effects of Carvedilol on Cocaine Use in Humans - 11|Effects of Carvedilol on Cocaine Use in Humans|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.778102|2018-06-01 05:41:06.778102
NCT00000293|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 1999||1999-01-31|November 2016|2016-11-30|December 2001||2001-12-31|||||Interventional|||Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10|Effect of Nefazodone on Relapse in Females With Cocaine Abuse|Completed||Phase 3|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.846049|2018-06-01 05:41:06.846049
NCT00000292|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 1996||1996-04-30|April 1996|1996-04-30|December 2001||2001-12-31|||||Interventional|||Acute Withdrawal From Smoked Cocaine - 9|Acute Withdrawal From Smoked Cocaine|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.916851|2018-06-01 05:41:06.916851
NCT00000291|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 1997||1997-10-31|November 2016|2016-11-30|December 2001||2001-12-31|||||Interventional|||Effects of Labetalol on Human Cocaine Use - 8|Effects of Labetalol on Human Cocaine Use|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:06.978932|2018-06-01 05:41:06.978932
NCT00000290|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 1997||1997-05-31|November 2016|2016-11-30|December 2001||2001-12-31|||||Interventional|||Stress Hormones and Human Cocaine Use - 7|Stress Hormones and Human Cocaine Use|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.041066|2018-06-01 05:41:07.041066
NCT00000289|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 1998||1998-05-31|December 1998|1998-12-31|December 2001||2001-12-31|||||Interventional|||Role of Metabolites in Nicotine Dependence (3) - 6|Role of Metabolites in Nicotine Dependence (3)|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.110183|2018-06-01 05:41:07.110183
NCT00000288|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 1995||1995-12-31|November 2016|2016-11-30|December 2002||2002-12-31|||||Interventional|||Role of Metabolites in Nicotine Dependence (2) - 5|Role of Metabolites in Nicotine Dependence (2)|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.167796|2018-06-01 05:41:07.167796
NCT00000287|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 1995||1995-02-28|October 2016|2016-10-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Observational|||Relapse Patterns in Female Cocaine Users - 4|Relapse Patterns in Female Cocaine Users|Completed|||0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.229701|2018-06-01 05:41:07.229701
NCT00000286|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 1996||1996-12-31|October 2016|2016-10-31|December 2001||2001-12-31|||||Interventional|||Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3|Effects of Nefazodone on Treatment of Female Cocaine Abusers|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.290087|2018-06-01 05:41:07.290087
NCT00000285|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 1996||1996-05-31|November 2016|2016-11-30|December 2001||2001-12-31|||||Interventional|||Effects of Phenytoin on Cocaine Use in Humans - 2|Effects of Phenytoin on Cocaine Use in Humans|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.349575|2018-06-01 05:41:07.349575
NCT00000284|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 1995||1995-02-28|November 2016|2016-11-30|December 2001||2001-12-31|||||Interventional|||Role of Metabolites in Nicotine Dependence (1) - 1|Role of Metabolites in Nicotine Dependence (1)|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.411347|2018-06-01 05:41:07.411347
NCT00000282|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-12-13|1999-09-20|1999-09-21|Estimate|||||||2016-12-13|2016-12-15|Estimate|September 1994||1994-09-30|December 2016|2016-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Pemoline for Cocaine Abuse - 7|Pemoline for Cocaine Abuse|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:07.478245|2018-06-01 05:41:07.478245
NCT00000281|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-12-13|1999-09-20|1999-09-21|Estimate|||||||2016-12-13|2016-12-15|Estimate|September 1994||1994-09-30|December 2016|2016-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Pharmacotherapy for Schizophrenic Drug Users - 6|Pharmacotherapy for Schizophrenic Drug Users|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:07.544466|2018-06-01 05:41:07.544466
NCT00000280|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-04-21|1999-09-20|1999-09-21|Estimate|||||||2017-04-21|2017-04-25|Actual|September 1994||1994-09-30|December 2002|2002-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Glutaminergic Agents for Cocaine Abuse - 5|Glutaminergic Agents for Cocaine Abuse|Completed||Phase 1|0||Yale University|||||f||||||||||||||2018-06-01 05:41:07.614545|2018-06-01 05:41:07.614545
NCT00000279|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2013-07-24|1999-09-20|1999-09-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 1994||1994-09-30|December 2002|2002-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Novel Medications for Opiate Detoxification - 4|Novel Medications for Opiate Detoxification|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:07.677792|2018-06-01 05:41:07.677792
NCT00000278|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2013-07-24|1999-09-20|1999-09-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 1994||1994-09-30|December 2002|2002-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Disulfiram for Cocaine-Alcohol Abuse - 3|Disulfiram for Cocaine-Alcohol Abuse|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:07.768617|2018-06-01 05:41:07.768617
NCT00000277|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2013-07-24|1999-09-20|1999-09-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 1994||1994-09-30|December 2002|2002-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Mazindol for Cocaine Abuse - 2|Mazindol for Cocaine Abuse|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:07.830949|2018-06-01 05:41:07.830949
NCT00000276|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2013-07-24|1999-09-20|1999-09-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 1994||1994-09-30|December 2008|2008-12-31|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Dopamine Reuptake Inhibitors of Cocaine Abuse - 1|Dopamine Reuptake Inhibitors of Cocaine Abuse|Terminated||Phase 1|0||Yale University|||||f||||||||||||||2018-06-01 05:41:07.896454|2018-06-01 05:41:07.896454
NCT00000275|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 1996||1996-11-30|November 2016|2016-11-30|March 1998||1998-03-31|||||Interventional|||Cocaine Abuse and ADHD - 10|Cocaine Abuse and ADHD|Completed||Phase 2|16||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:07.954837|2018-06-01 05:41:07.954837
NCT00000274|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 1997||1997-03-31|November 2016|2016-11-30|May 1999||1999-05-31|||||Interventional|||Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9|Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics|Completed||Phase 2|60||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:08.010971|2018-06-01 05:41:08.010971
NCT00000273|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-07-03|1999-09-20|1999-09-21|Estimate|||||||2017-07-03|2017-07-05|Actual|August 1995||1995-08-31|June 2017|2017-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Laboratory Model for Heroin Abuse Medications - 8|A Laboratory Model for Heroin Abuse Medications|Completed||Phase 2|8|Actual|New York State Psychiatric Institute||1|||f||||t|t|f||||||No||2018-06-01 05:41:08.082824|2018-06-01 05:41:08.082824
NCT00000271|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-07-03|1999-09-20|1999-09-21|Estimate|||||||2017-07-03|2017-07-05|Actual|January 1995|Actual|1995-01-31|June 2017|2017-06-30|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||New Approaches to Cocaine Abuse Medications (A) - 6|New Approaches to Cocaine Abuse Medications (A)|Completed||Phase 2|111|Actual|New York State Psychiatric Institute||2|||f||||f|t|f|||f|||No||2018-06-01 05:41:08.158671|2018-06-01 05:41:08.158671
NCT00000270|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-08-01|1999-09-20|1999-09-21|Estimate|||||||2017-08-01|2017-08-02|Actual|December 30, 1995|Actual|1995-12-30|July 2017|2017-07-31|December 30, 1995|Actual|1995-12-30|December 30, 1995|Actual|1995-12-30||Interventional|||Brain Imaging: Cocaine Effects & Medication Development - 5|Brain Imaging: Cocaine Effects & Medication Development|Withdrawn||Phase 4|0|Actual|New York State Psychiatric Institute||||Study never opened; never enrolled participants|f|||||f|f||||||||2018-06-01 05:41:08.225585|2018-06-01 05:41:08.225585
NCT00000269|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 1995||1995-10-31|November 2016|2016-11-30|December 2001||2001-12-31|||||Interventional|||Pergolide Treatment for Substance Abusers - 4|Pergolide Treatment for Substance Abusers|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:08.281334|2018-06-01 05:41:08.281334
NCT00000268|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 1995||1995-05-31|November 2016|2016-11-30|November 1998||1998-11-30|||||Interventional|||Cocaine Abuse and Attention Deficit Disorder - 3|Cocaine Abuse and Attention Deficit Disorder|Completed||N/A|32||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:41:08.332902|2018-06-01 05:41:08.332902
NCT00000267|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||October 2016|2016-10-31|December 2001||2001-12-31|||||Interventional|||Risperidone Treatment in Dually-Diagnosed Individuals - 2|Risperidone Treatment in Dually-Diagnosed Individuals|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:08.383972|2018-06-01 05:41:08.383972
NCT00000266|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|August 1994||1994-08-31|October 2016|2016-10-31|December 2001||2001-12-31|||||Interventional|||Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1|Flupenthixol Treatment in Schizophrenic Cocaine Abusers|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:08.4311|2018-06-01 05:41:08.4311
NCT00000265|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 1997||1997-07-31|May 2015|2015-05-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Observational|||Subjective Effects of Nitrous Oxide in Dental Patients - 17|Subjective Effects of Nitrous Oxide in Dental Patients|Completed|||46|Actual|University of Chicago|||3||f||||||||||||||2018-06-01 05:41:08.482301|2018-06-01 05:41:08.482301
NCT00000264|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 1997||1997-09-30|May 2015|2015-05-31|October 1999|Actual|1999-10-31|October 1999|Actual|1999-10-31||Interventional|||Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16|Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide|Completed||N/A|8|Actual|University of Chicago||3|||f||||||||||||||2018-06-01 05:41:08.617311|2018-06-01 05:41:08.617311
NCT00000263|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 1997||1997-01-31|May 2015|2015-05-31|October 1998|Actual|1998-10-31|October 1998|Actual|1998-10-31||Interventional|||Effects of Combined Alcohol and Nitrous Oxide Intake - 15|Effects of Combined Alcohol and Nitrous Oxide Intake|Completed||N/A|11|Actual|University of Chicago||3|||f||||||||||||||2018-06-01 05:41:08.720765|2018-06-01 05:41:08.720765
NCT00000262|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 1996||1996-11-30|May 2015|2015-05-31|February 1999|Actual|1999-02-28|February 1999|Actual|1999-02-28||Interventional|||Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14|Effects of Combined Sevoflurane and Nitrous Oxide Inhalation|Completed||N/A|20|Actual|University of Chicago||3|||f||||||||||||||2018-06-01 05:41:08.818479|2018-06-01 05:41:08.818479
NCT00000261|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 1997||1997-11-30|May 2015|2015-05-31|October 1998|Actual|1998-10-31|October 1998|Actual|1998-10-31||Interventional|||Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13|Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide|Completed||Phase 2|14|Actual|University of Chicago||1|||f||||||||||||||2018-06-01 05:41:08.928835|2018-06-01 05:41:08.928835
NCT00000260|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 1997||1997-06-30|May 2015|2015-05-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12|Effects of Behavioral Contingencies on Effects of Nitrous Oxide|Completed||N/A|18|Actual|University of Chicago|||||f||||||||||||||2018-06-01 05:41:09.023949|2018-06-01 05:41:09.023949
NCT00000259|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|August 1996||1996-08-31|May 2015|2015-05-31|November 1997|Actual|1997-11-30|November 1997|Actual|1997-11-30||Interventional|||Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11|Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations|Completed||N/A|12|Actual|University of Chicago||5|||f||||||||||||||2018-06-01 05:41:09.096182|2018-06-01 05:41:09.096182
NCT00000258|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 1996||1996-04-30|May 2015|2015-05-31|November 1997|Actual|1997-11-30|November 1997|Actual|1997-11-30||Interventional|||Role of Instructions in Nitrous Oxide Effects and Choice - 10|Role of Instructions in Nitrous Oxide Effects and Choice|Completed||N/A|22|Actual|University of Chicago||2|||f||||||||||||||2018-06-01 05:41:09.185012|2018-06-01 05:41:09.185012
NCT00000257|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|September 1995||1995-09-30|May 2015|2015-05-31|April 1997|Actual|1997-04-30|April 1997|Actual|1997-04-30||Interventional|||Effects of Alcohol History on Effects of Nitrous Oxide - 9|Effects of Alcohol History on Effects of Nitrous Oxide|Completed||N/A|19|Actual|University of Chicago||2|||f||||||||||||||2018-06-01 05:41:09.295026|2018-06-01 05:41:09.295026
NCT00000256|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|August 1995||1995-08-31|May 2015|2015-05-31|November 1996|Actual|1996-11-30|November 1996|Actual|1996-11-30||Interventional|||Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8|Reinforcing Effects of Brief Exposures to Nitrous Oxide|Completed||N/A|11|Actual|University of Chicago||4|||f||||||||||||||2018-06-01 05:41:09.38253|2018-06-01 05:41:09.38253
NCT00000255|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 1995||1995-04-30|May 2015|2015-05-31|May 1996|Actual|1996-05-31|May 1996|Actual|1996-05-31||Interventional|||Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7|Differential Acute Tolerance Development to Effects of Nitrous Oxide|Completed||Phase 2|10|Actual|University of Chicago||5|||f||||||||||||||2018-06-01 05:41:09.46223|2018-06-01 05:41:09.46223
NCT00000254|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 1995||1995-01-31|May 2015|2015-05-31|September 1995|Actual|1995-09-30|September 1995|Actual|1995-09-30||Interventional|||Isoflurane at Subanesthetic Concentrations - 6|Isoflurane at Subanesthetic Concentrations|Completed||Phase 2|10|Actual|University of Chicago||4|||f||||||||||||||2018-06-01 05:41:09.548417|2018-06-01 05:41:09.548417
NCT00000253|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|November 1994||1994-11-30|May 2015|2015-05-31|March 1996|Actual|1996-03-31|March 1996|Actual|1996-03-31||Interventional|||Effects of Nitrous Oxide: A Dose-Response Analysis - 5|Effects of Nitrous Oxide: A Dose-Response Analysis|Completed||N/A|16|Actual|University of Chicago||4|||f||||||||||||||2018-06-01 05:41:09.636607|2018-06-01 05:41:09.636607
NCT00000252|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|June 1994||1994-06-30|May 2015|2015-05-31|June 1996|Actual|1996-06-30|June 1996|Actual|1996-06-30||Interventional|||Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4|Lack of Acute Tolerance Development to Effects of Nitrous Oxide|Completed||Phase 2|11|Actual|University of Chicago||5|||f||||||||||||||2018-06-01 05:41:09.720523|2018-06-01 05:41:09.720523
NCT00000251|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-11-30|1999-09-20|1999-09-21|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 1994||1994-04-30|November 2015|2015-11-30|January 1996|Actual|1996-01-31|January 1996|Actual|1996-01-31||Interventional|||Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3|Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide|Completed||Phase 2|10|Actual|University of Chicago||6|||f||||||||||||||2018-06-01 05:41:09.805152|2018-06-01 05:41:09.805152
NCT00000250|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|December 1993||1993-12-31|May 2015|2015-05-31|May 1995|Actual|1995-05-31|May 1995|Actual|1995-05-31||Interventional|||Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2|Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide|Completed||Phase 2|12|Actual|University of Chicago||2|||f||||||||||||||2018-06-01 05:41:09.88859|2018-06-01 05:41:09.88859
NCT00000249|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|September 1993||1993-09-30|May 2015|2015-05-31|June 1995|Actual|1995-06-30|June 1995|Actual|1995-06-30||Interventional|||Effects of Subanesthetic Concentrations of Nitrous Oxide - 1|Effects of Subanesthetic Concentrations of Nitrous Oxide|Completed||Phase 2|10|Actual|University of Chicago||4|||f||||||||||||||2018-06-01 05:41:09.959096|2018-06-01 05:41:09.959096
NCT00000248|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2018-05-15|1999-09-20|1999-09-21|Estimate|||||||2018-05-15|2018-05-16|Actual|February 1996||1996-02-29|May 1997|1997-05-31||||||||Interventional|||Dose Response Trial of Pergolide for Cocaine Dependence - 1|Dose Response Trial of Pergolide for Cocaine Dependence|Completed||Phase 3|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:10.027462|2018-06-01 05:41:10.027462
NCT00000246|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-09-06|1999-09-20|1999-09-21|Estimate|||||||2016-09-06|2016-09-08|Estimate|January 1993||1993-01-31|September 2016|2016-09-30|December 1994|Actual|1994-12-31|December 1994|Actual|1994-12-31||Interventional|||Rapid Benzodiazepine Detoxification Using Flumazenil - 1|Rapid Benzodiazepine Detoxification Using Flumazenil|Completed||Phase 2|10|Actual|Yale University|||||f||||||||||||||2018-06-01 05:41:10.089454|2018-06-01 05:41:10.089454
NCT00000245|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 1994||1994-05-31|November 2016|2016-11-30|December 2001||2001-12-31|||||Interventional|||Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1|Evaluation of a Desipramine Ceiling in Cocaine Abuse|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:10.176796|2018-06-01 05:41:10.176796
NCT00000244|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 1994||1994-08-31|May 2015|2015-05-31|March 1997|Actual|1997-03-31|March 1997|Actual|1997-03-31||Interventional|||Effects of Dynorphin 1-13 on Heroin Addiction - 1|Effects of Dynorphin 1-13 on Heroin Addiction|Completed||Phase 2|0||University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-06-01 05:41:10.259897|2018-06-01 05:41:10.259897
NCT00000243|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2002||2002-09-30|November 2016|2016-11-30|January 2004||2004-01-31|||||Interventional|||Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone|Transitioning Patients From Methadone to Buprenorphine/Naloxone for Treating Opioid Dependence|Terminated||N/A|16||National Institute on Drug Abuse (NIDA)|||||||||||||||||||2018-06-01 05:41:10.43562|2018-06-01 05:41:10.43562
NCT00000242|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-04-06|1999-09-20|1999-09-21|Estimate|||||||2017-04-06|2017-04-07|Actual|October 1, 1992|Actual|1992-10-01|July 1996|1996-07-31|January 25, 1997|Actual|1997-01-25|January 25, 1997|Actual|1997-01-25||Interventional|||Carbamazepine Treatment of Cocaine Dependence - 1|Carbamazepine Treatment of Cocaine Dependence|Completed||Phase 2|0||Medical University of South Carolina|||||f||||||||||||||2018-06-01 05:41:10.545709|2018-06-01 05:41:10.545709
NCT00000241|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 1994||1994-02-28|October 2016|2016-10-31|May 1996||1996-05-31|||||Interventional|||Flupenthixol Decanoate in Methamphetamine Smoking - 1|Flupenthixol Decanoate in Methamphetamine Smoking|Completed||Phase 2|58||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:10.634344|2018-06-01 05:41:10.634344
NCT00000240|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-06-02|1999-09-20|1999-09-21|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 1999||1999-04-30|April 1999|1999-04-30||||||||Interventional|||Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22|Combined Buprenorphine and Behavioral Treatment Without Contingent Reinforcement|Completed||Phase 2|0||University of Vermont|||||f||||||||||||||2018-06-01 05:41:10.75502|2018-06-01 05:41:10.75502
NCT00000239|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate||||December 2002|2002-12-31||||||||Interventional|||Buprenorphine Pharmacology Related to Addiction Treatment - 21|Buprenorphine Pharmacology Related to Addiction Treatment|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:10.836996|2018-06-01 05:41:10.836996
NCT00000238|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2008-11-19|1999-09-20|1999-09-21|Estimate|||||||2008-11-19|2008-11-20|Estimate|August 1997||1997-08-31|November 2008|2008-11-30||||||||Interventional|||Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20|Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:10.918583|2018-06-01 05:41:10.918583
NCT00000237|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|May 1997||1997-05-31|May 1997|1997-05-31||||||||Interventional|||Buprenorphine Detoxification - BBDVI - 19|Buprenorphine Detoxification - BBDVI|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:11.04153|2018-06-01 05:41:11.04153
NCT00000236|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate||||December 2002|2002-12-31||||||||Interventional|||Buprenorphine Pharmacology Related to Addiction Treatment - 18|Buprenorphine Pharmacology Related to Addiction Treatment|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:11.111986|2018-06-01 05:41:11.111986
NCT00000235|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate||||December 2002|2002-12-31||||||||Interventional|||Alternate Day Buprenorphine Administration, Phase XII - 17|Alternate Day Buprenorphine Administration, Phase XII|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:11.221026|2018-06-01 05:41:11.221026
NCT00000234|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate||||December 2002|2002-12-31||||||||Interventional|||Alternate Day Buprenorphine Administration, Phase XI - 16|Alternate Day Buprenorphine Administration, Phase XI|Completed||Phase 2|0||University of Vermont|||||f||||||||||||||2018-06-01 05:41:11.339098|2018-06-01 05:41:11.339098
NCT00000233|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|May 1993||1993-05-31|September 1995|1995-09-30||||||||Interventional|||Alternate Day Buprenorphine Administration, Phase X - 15|Alternate Day Buprenorphine Administration, Phase X|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:11.392291|2018-06-01 05:41:11.392291
NCT00000232|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 1992||1992-03-31|April 1994|1994-04-30||||||||Interventional|||Alternate Day Buprenorphine Administration, Phase IX - 14|Alternate Day Buprenorphine Administration, Phase IX|Completed||Phase 2|0||University of Vermont|||||f||||||||||||||2018-06-01 05:41:12.359267|2018-06-01 05:41:12.359267
NCT00000231|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|February 1992||1992-02-29|March 1994|1994-03-31||||||||Interventional|||Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13|Buprenorphine Detoxification With Two Types of Treatment. BBD IV|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:12.422857|2018-06-01 05:41:12.422857
NCT00000230|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 1995||1995-01-31|August 1996|1996-08-31||||||||Interventional|||Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12|Buprenorphine Detoxification With Two Types of Treatment. BBD III|Completed||Phase 2|0||University of Vermont|||||f||||||||||||||2018-06-01 05:41:12.489953|2018-06-01 05:41:12.489953
NCT00000229|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|October 1995||1995-10-31|September 1996|1996-09-30||||||||Interventional|||Buprenorphine Detox With Two Types of Treatment. BBD II - 11|Buprenorphine Detox With Two Types of Treatment. BBD II|Completed||Phase 2|0||University of Vermont|||||f||||||||||||||2018-06-01 05:41:12.541815|2018-06-01 05:41:12.541815
NCT00000228|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|August 1994||1994-08-31|July 1996|1996-07-31||||||||Interventional|||Buprenorphine Detox With Two Types of Treatment. BBD I - 10|Buprenorphine Detox With Two Types of Treatment. BBD I|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:12.620841|2018-06-01 05:41:12.620841
NCT00000227|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|August 1994||1994-08-31|July 1996|1996-07-31||||||||Interventional|||Alternate-Day Buprenorphine Administration. Phase VIII - 9|Alternate-Day Buprenorphine Administration. Phase VIII|Completed||Phase 2|0||University of Vermont|||||f||||||||||||||2018-06-01 05:41:12.681898|2018-06-01 05:41:12.681898
NCT00000226|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|November 1994||1994-11-30|July 1996|1996-07-31||||||||Interventional|||Alternate-Day Buprenorphine Administration. Phase VII - 8|Alternate-Day Buprenorphine Administration. Phase VII|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:12.774357|2018-06-01 05:41:12.774357
NCT00000225|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|December 1992||1992-12-31|June 2004|2004-06-30||||||||Interventional|||Alternate-Day Buprenorphine Administration. Phase VI - 7|Alternate-Day Buprenorphine Administration. Phase VI|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:12.838289|2018-06-01 05:41:12.838289
NCT00000224|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|February 1993||1993-02-28|April 1996|1996-04-30||||||||Interventional|||Alternate-Day Buprenorphine. Phase V - 6|Alternate-Day Buprenorphine. Phase V|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:12.999199|2018-06-01 05:41:12.999199
NCT00000223|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1993||1993-06-30|September 1994|1994-09-30||||||||Interventional|||Alternate-Day Buprenorphine Administration. Phase IV - 5|Alternate-Day Buprenorphine Administration. Phase IV|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.083396|2018-06-01 05:41:13.083396
NCT00000222|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|July 1992||1992-07-31|December 1993|1993-12-31||||||||Interventional|||Alternate-Day Buprenorphine Administration. Phase II - 4|Alternate-Day Buprenorphine Administration. Phase II|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.148214|2018-06-01 05:41:13.148214
NCT00000221|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|April 1992||1992-04-30|November 1993|1993-11-30||||||||Interventional|||Alternate-Day Buprenorphine Administration. Phase I - 3|Alternate-Day Buprenorphine Administration. Phase I|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.215511|2018-06-01 05:41:13.215511
NCT00000220|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-06-23|1999-09-20|1999-09-21|Estimate|||||||2005-06-23|2005-06-24|Estimate|June 1991||1991-06-30|September 1991|1991-09-30|July 2001||2001-07-31|||||Interventional|||Gradual Vs. Rapid Buprenorphine Detoxification - 2|Gradual Vs. Rapid Buprenorphine Detoxification|Completed||Phase 1|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.288238|2018-06-01 05:41:13.288238
NCT00000219|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|December 1991||1991-12-31|April 1992|1992-04-30|July 2001||2001-07-31|||||Interventional|||Buprenorphine Dose Alteration Study - 1|Buprenorphine Dose Alteration Study|Completed||Phase 1|0||University of Vermont|||||f||||||||||||||2018-06-01 05:41:13.353795|2018-06-01 05:41:13.353795
NCT00000218|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||October 2016|2016-10-31|June 2005|Actual|2005-06-30|||||Interventional|||Pharmacotherapy and Intensive Treatment - 2|Pharmacotherapy and Intensive Treatment|Completed||Phase 4|353||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.422185|2018-06-01 05:41:13.422185
NCT00000217|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-04-15|1999-09-20|1999-09-21|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 1990||1990-09-30|April 2015|2015-04-30||||October 1996|Actual|1996-10-31||Interventional|||Pharmacotherapy and Intensive Treatment of Drug Abuse - 1|Pharmacotherapy and Intensive Treatment of Drug Abuse|Completed||Phase 2|||University of Kansas Medical Center|||||f||||||||||||||2018-06-01 05:41:13.491909|2018-06-01 05:41:13.491909
NCT00000216|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate||||December 2002|2002-12-31||||||||Interventional|||Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1|Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts|Completed||Phase 3|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.56175|2018-06-01 05:41:13.56175
NCT00000215|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||October 2016|2016-10-31|December 2001||2001-12-31|||||Interventional|||IV Cocaine Abuse: A Laboratory Model - 4|IV Cocaine Abuse: A Laboratory Model|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.614813|2018-06-01 05:41:13.614813
NCT00000214|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-08-27|1999-09-20|1999-09-21|Estimate|||||||2015-08-27|2015-08-31|Estimate|January 1992||1992-01-31|December 2012|2012-12-31|January 1993|Actual|1993-01-31|January 1993|Actual|1993-01-31||Interventional|||IV Cocaine Abuse: A Laboratory Model - 3|IV Cocaine Abuse: A Laboratory Model|Completed||Phase 2|0||New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 05:41:13.684777|2018-06-01 05:41:13.684777
NCT00000213|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-08-27|1999-09-20|1999-09-21|Estimate|||||||2015-08-27|2015-08-28|Estimate|April 1990||1990-04-30|December 2012|2012-12-31|April 1991|Actual|1991-04-30|April 1991|Actual|1991-04-30||Interventional|||IV Cocaine Abuse: A Laboratory Model - 2|IV Cocaine Abuse: A Laboratory Model|Completed||Phase 2|0||New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 05:41:13.742578|2018-06-01 05:41:13.742578
NCT00000212|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-08-27|1999-09-20|1999-09-21|Estimate|||||||2015-08-27|2015-08-31|Estimate|July 1987||1987-07-31|December 2012|2012-12-31|July 1988|Actual|1988-07-31|July 1988|Actual|1988-07-31||Interventional|||IV Cocaine Abuse: A Laboratory Model - 1|IV Cocaine Abuse: A Laboratory Model|Completed||Phase 2|0||New York State Psychiatric Institute|||||f||||||||||||||2018-06-01 05:41:13.797603|2018-06-01 05:41:13.797603
NCT00000211|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 1989||1989-09-30|December 2002|2002-12-31|February 1996|Actual|1996-02-29|February 1996|Actual|1996-02-29||Interventional|||Treatment Efficacy for Drug Abuse and AIDS Prevention - 2|Treatment Efficacy for Drug Abuse and AIDS Prevention|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.859467|2018-06-01 05:41:13.859467
NCT00000210|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 1989||1989-09-30|December 2002|2002-12-31|February 1996|Actual|1996-02-29|February 1996|Actual|1996-02-29||Interventional|||Treatment Efficacy for Drug Abuse and AIDS Prevention - 1|Treatment Efficacy for Drug Abuse and AIDS Prevention|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:13.909551|2018-06-01 05:41:13.909551
NCT00000209|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|November 1992||1992-11-30|September 1994|1994-09-30||||||||Interventional|||Buprenorphine Dosing Interval - 5|Buprenorphine Dosing Interval|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:14.058186|2018-06-01 05:41:14.058186
NCT00000208|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2005-08-16|1999-09-20|1999-09-21|Estimate|||||||2005-08-16|2005-08-17|Estimate|February 1992||1992-02-29|September 1993|1993-09-30||||||||Interventional|||Methadone/Buprenorphine Cross-Over Study - 4|Methadone/Buprenorphine Cross-Over Study|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:14.115631|2018-06-01 05:41:14.115631
NCT00000207|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-07-07|1999-09-20|1999-09-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 1992||1992-05-31|July 2016|2016-07-31||||April 1997|Actual|1997-04-30||Interventional|||Multicenter Clinical Trial of Buprenorphine - 3|Multicenter Clinical Trial of Buprenorphine|Completed||Phase 3|0||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:41:14.175943|2018-06-01 05:41:14.175943
NCT00000206|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-11-03|1999-09-20|1999-09-21|Estimate|||||||2016-11-03|2016-11-07|Estimate|April 1991||1991-04-30|November 2016|2016-11-30||||August 2005|Actual|2005-08-31||Interventional|||Clinical Rescue Protocol - 2|Clinical Rescue Protocol|Completed||Phase 2|0||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:41:14.249006|2018-06-01 05:41:14.249006
NCT00000205|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-07-07|1999-09-20|1999-09-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 1990||1990-10-31|July 2016|2016-07-31|September 1993|Actual|1993-09-30|March 1993|Actual|1993-03-31||Interventional|||Buprenorphine Maintenance Protocol - 1|Buprenorphine Maintenance Protocol|Completed||Phase 3|0||University of California, Los Angeles|||||f||||||||||||||2018-06-01 05:41:14.320086|2018-06-01 05:41:14.320086
NCT00000204|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2013-07-24|1999-09-20|1999-09-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|August 1988||1988-08-31|August 2005|2005-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Buprenorphine Maintenance for Opioid Addicts - 3|Buprenorphine Maintenance for Opioid Addicts|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:14.396794|2018-06-01 05:41:14.396794
NCT00000203|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2013-07-24|1999-09-20|1999-09-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|August 1988||1988-08-31|August 2005|2005-08-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Buprenorphine Maintenance for Opioid Addicts - 2|Buprenorphine Maintenance for Opioid Addicts|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:14.464865|2018-06-01 05:41:14.464865
NCT00000202|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2013-07-24|1999-09-20|1999-09-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|August 1988||1988-08-31|December 2002|2002-12-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Buprenorphine Maintenance for Opioid Addicts - 1|Buprenorphine Maintenance for Opioid Addicts|Completed||Phase 2|0||Yale University|||||f||||||||||||||2018-06-01 05:41:14.529109|2018-06-01 05:41:14.529109
NCT00000201|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate||||October 2016|2016-10-31|December 2001||2001-12-31|||||Interventional|||Pharmacological Modulation of Cocaine Effects - 1|Pharmacological Modulation of Cocaine Effects|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||||||||||||2018-06-01 05:41:14.596139|2018-06-01 05:41:14.596139
NCT00000200|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 1997||1997-01-31|October 2016|2016-10-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Cocaine Effects in Humans: Physiology and Behavior - 1|Cocaine Effects in Humans: Physiology and Behavior|Completed||Phase 2|19|Actual|National Institute on Drug Abuse (NIDA)|||||f||||t||||||||||2018-06-01 05:41:14.670472|2018-06-01 05:41:14.670472
NCT00000199|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-03-28|1999-09-20|1999-09-21|Estimate|||||||2017-03-28|2017-03-30|Actual||||March 2017|2017-03-31||||||||Interventional|||Piracetam for Treatment of Cocaine Addiction, Phase II - 4|Piracetam for Treatment of Cocaine Addiction, Phase II|Withdrawn||Phase 1|0|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 05:41:14.745364|2018-06-01 05:41:14.745364
NCT00000198|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-10-05|1999-09-20|1999-09-21|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 1996||1996-10-31|December 2013|2013-12-31|October 1997|Actual|1997-10-31|October 1997|Actual|1997-10-31||Interventional|||Piracetam for Treatment of Cocaine Addiction - 3|Piracetam for Treatment of Cocaine Addiction|Completed||Phase 1|0||University of Pennsylvania|||||||||||||||||||2018-06-01 05:41:14.80539|2018-06-01 05:41:14.80539
NCT00000197|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2017-01-11|1999-09-20|1999-09-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 1987||1987-01-31|October 2016|2016-10-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Interventional|||Propranolol for Treatment of Cocaine Addiction - 2|Propranolol for Treatment of Cocaine Addiction|Completed||Phase 2|0||National Institute on Drug Abuse (NIDA)|||||f||||f||||||||||2018-06-01 05:41:14.864605|2018-06-01 05:41:14.864605
NCT00000196|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-06-02|1999-09-20|1999-09-21|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 1993||1993-01-31|September 2013|2013-09-30|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Neurobiology of Opioid Dependence: 5 - 5|Neurobiology of Opioid Dependence: 5|Withdrawn||Phase 2|0|Actual|Yale University|||||f||||||||||||||2018-06-01 05:41:14.932854|2018-06-01 05:41:14.932854
NCT00000195|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 1993||1993-01-31|August 2015|2015-08-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Neurobiology of Opioid Dependence: 4 - 4|Neurobiology of Opioid Dependence: 4|Withdrawn||Phase 2|0|Actual|Yale University|||||f||||||||||||||2018-06-01 05:41:15.00255|2018-06-01 05:41:15.00255
NCT00000194|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2016-05-05|1999-09-20|1999-09-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 1993||1993-01-31|August 2015|2015-08-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Neurobiology of Opioid Dependence: 3 - 3|Neurobiology of Opioid Dependence: 3|Withdrawn||Phase 2|0|Actual|Yale University|||||f||||||||||||||2018-06-01 05:41:15.063989|2018-06-01 05:41:15.063989
NCT00000193|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-08-05|1999-09-20|1999-09-21|Estimate|||||||2015-08-05|2015-08-07|Estimate|January 1993||1993-01-31|August 2015|2015-08-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Neurobiology of Opioid Dependence: 2 - 2|Neurobiology of Opioid Dependence: 2|Withdrawn||Phase 2|0|Actual|Yale University|||||f||||||||||||||2018-06-01 05:41:15.131305|2018-06-01 05:41:15.131305
NCT00000192|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-08-05|1999-09-20|1999-09-21|Estimate|||||||2015-08-05|2015-08-07|Estimate|January 1993||1993-01-31|August 2015|2015-08-31|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Neurobiology of Opioid Dependence: 1 - 1|Neurobiology of Opioid Dependence: 1|Withdrawn||Phase 2|0|Actual|Yale University|||||f||||||||||||||2018-06-01 05:41:15.217597|2018-06-01 05:41:15.217597
NCT00000191|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 1991||1991-01-31|May 2015|2015-05-31|February 1994|Actual|1994-02-28|February 1994|Actual|1994-02-28||Interventional|||Carbamazepine Treatment for Cocaine Dependence - 5|Carbamazepine Treatment for Cocaine Dependence|Completed||Phase 2|0||University of Pennsylvania|||||f||||||||||||||2018-06-01 05:41:15.315365|2018-06-01 05:41:15.315365
NCT00000190|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 1991||1991-01-31|May 2015|2015-05-31|February 1992|Actual|1992-02-29|February 1992|Actual|1992-02-29||Interventional|||Cocaine in Parotid Saliva, Blood and Urine - 4|Cocaine in Parotid Saliva, Blood and Urine|Completed||Phase 1|0||University of Pennsylvania|||||f||||||||||||||2018-06-01 05:41:15.407569|2018-06-01 05:41:15.407569
NCT00000189|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 1990||1990-01-31|May 2015|2015-05-31|February 1991|Actual|1991-02-28|February 1991|Actual|1991-02-28||Interventional|||Gepirone vs Placebo in Treatment of Cocaine Dependence - 3|Gepirone vs Placebo in Treatment of Cocaine Dependence|Completed||Phase 2|41|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 05:41:15.484919|2018-06-01 05:41:15.484919
NCT00000188|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|September 1994||1994-09-30|May 2015|2015-05-31|October 1995|Actual|1995-10-31|October 1995|Actual|1995-10-31||Interventional|||Selegiline in Treatment of Cocaine Dependence - 2|Selegiline in Treatment of Cocaine Dependence|Completed||Phase 2|50|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 05:41:15.540549|2018-06-01 05:41:15.540549
NCT00000187|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-20|||2015-05-26|1999-09-20|1999-09-21|Estimate|||||||2015-05-26|2015-05-28|Estimate|July 1992||1992-07-31|May 2015|2015-05-31||||June 1994|Actual|1994-06-30||Interventional|||Ritanserin in Treatment of Cocaine Dependence - 1|Ritanserin in Treatment of Cocaine Dependence|Completed||Phase 2|80|Actual|University of Pennsylvania|||||f||||||||||||||2018-06-01 05:41:15.594274|2018-06-01 05:41:15.594274
NCT00004640|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-17|||2012-06-19|1999-09-17|1999-09-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|May 1998||1998-05-31|June 2012|2012-06-30|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional|||"Clinical Trials to Enhance Elders' Oral Health (TEETH)"|Trials to Enhance Elders' Teeth and Oral Health|Completed||Phase 3|1101|Anticipated|University of Washington|||||f||||t||||||||||2018-06-01 05:41:15.765339|2018-06-01 05:41:15.765339
NCT00004639|ClinicalTrials.gov processed this data on May 31, 2018|1999-09-17|||2011-09-16|1999-09-17|1999-09-20|Estimate|||||||2011-09-16|2011-09-20|Estimate|February 1996||1996-02-29|June 2011|2011-06-30|April 2007|Actual|2007-04-30|March 2006|Actual|2006-03-31||Interventional|||Cleft Palate Surgery and Speech Development|Velopharyngeal Function for Speech After Palatal Surgery|Completed||Phase 2|475|Actual|University of Florida|||||f||||t||||||||||2018-06-01 05:41:15.838042|2018-06-01 05:41:15.838042
